{"columns":["record_id","title","first_author","year","journal","design_class","record_type","doi","pmid","pmcid","registry_ids","study_ids","sources","is_open_access","fulltext_status","tier","is_retracted","publication_types"],"rows":[["R0000001","Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting System","Eduardo I","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9818062/v3",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0000002","Adjunctive GLP1 Receptor Agonists in Patients With Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.","Yeh KH","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","nonrandomized_study","article","10.1016/j.cgh.2026.06.008","42309434",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000003","Drugs are not cutting it: Patient motivations for metabolic and bariatric surgery despite glucagon-like peptide-1 use.","Dass A","2026","Surgery","other","article","10.1016/j.surg.2026.110492","42623901",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000004","Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions.","Elgindi D","2026","Clinics in dermatology","nonrandomized_study","article","10.1016/j.clindermatol.2026.08.012","42692277",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000005","High Prevalence and Low Incidence of Constipation Among Glucagon-Like Peptide-1 Receptor Agonist Users.","Chang M","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2026.05.018","42235870","PMC13570802",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000006","Ethical considerations of cosmetic glucagon-like peptide-1 receptor agonist prescribing in dermatology.","Jonnalagadda A","2026","Clinics in dermatology","other","article","10.1016/j.clindermatol.2026.09.002","42710721",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000007","Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis.","Zhong X","2026","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","systematic_review","article","10.1055/a-2923-3830","42600634",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0000008","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.","Moiz A","2026","Annals of internal medicine","systematic_review","article","10.7326/annals-25-05519","42673585",null,"PROSPERO:CRD42024505558",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; article"],["R0000009","Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies.","Bijoch J","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15145358","42513271","PMC13410358",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000010","Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure.","Loblundo C","2026","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","randomized_trial","article","10.1002/ohn.70407","42611692",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0000011","Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes.","Lin CL","2026","Nature communications","randomized_trial","article","10.1038/s41467-026-77047-5","42778559","PMC13601590",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0000012","Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?","Medeiros R","2026","Cureus","nonrandomized_study","article","10.7759/cureus.112724","42602910","PMC13475472",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000013","Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans.","Grigson PS","2026","Biological psychiatry","nonrandomized_study","article","10.1016/j.biopsych.2026.06.033","42480803",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0000014","Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials.","Abomohsen M","2026","Canadian journal of diabetes","systematic_review","article","10.1016/j.jcjd.2026.04.001","41967797",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; review"],["R0000015","Investigating the Relationship Between Glucagon-Like Peptide-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis: A Propensity-Matched Analysis.","Stump K","2026","Clinical spine surgery","nonrandomized_study","article","10.1097/bsd.0000000000002145","42683541",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000016","Glucagon-Like Peptide-1 Receptor Agonist-Based Agents and Body Composition: Filling More Gaps.","Dubin RL","2026","Obesity (Silver Spring, Md.)","narrative_review","article","10.1002/oby.70212","42415595","PMC13535704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000017","Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.","Puspitasari IM","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s626279","42812898","PMC13623077",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000018","Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics.","Kwaśny A","2026","Advances in clinical and experimental medicine : official organ Wroclaw Medical University","other","article","10.17219/acem/235937","42823936",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000019","GLP-1 receptor agonist exposure and non-arteritic anterior ischaemic optic neuropathy: an illustrative case.","Devebacak A","2026","Clinical & experimental optometry","other","article","10.1080/08164622.2026.2725047","42680170",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000020","Knowledge, Prescribing Practices, and Perceived Barriers Regarding Novel Glucose-Lowering Medications Among Community Physicians: A Cross-Sectional Survey Across 36 Primary Healthcare Institutions in Pudong, Shanghai","Liu Y","2026","Research Square","other","preprint","10.21203/rs.3.rs-10889636/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0000021","Adaptations of glucagon-like peptide-1 receptor agonist-induced weight loss, drivers of weight regain and future directions of therapeutics.","Piguet CEM","2026","The Journal of physiology","narrative_review","article","10.1113/jp291081","42574696",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000022","Pneumatosis intestinalis in a patient treated with a glucagon-like peptide-1 receptor agonist and prednisone.","Sutton S","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag019","41743176","PMC12930473",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000023","Association Between Baseline Glucagon-like Peptide-1 Receptor Agonist Use and Newly Documented Depression Diagnosis in Adults with Type 2 Diabetes: A Multi-State Medicaid Cohort Study.","Ndiulor M","2026","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare14182971","42793510","PMC13606689",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000024","From Gila Monster Venom to Dermatology: The History of GLP-1 Receptor Agonists.","Dyson S","2026","Clinics in dermatology","other","article","10.1016/j.clindermatol.2026.09.011","42749027",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000025","Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","Kamrul-Hasan ABM","2026","Obesity science & practice","systematic_review","article","10.1002/osp4.70181","42564827","PMC13445785",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0000026","Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents.","Ghanim H","2026","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2026.04.009","42527003",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000027","Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.","Tong LH","2026","Journal of chromatography. A","other_trial","article","10.1016/j.chroma.2026.467288","42603384",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; preprint; article"],["R0000028","Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).","Ammendolia I","2026","Naunyn-Schmiedeberg's archives of pharmacology","nonrandomized_study","article","10.1007/s00210-026-05813-9","42629417",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000029","Glucagon-like peptide-1 receptor agonist and post-operative opioid consumption in gynecologic surgery.","Mateo-Kubach P","2026","International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","nonrandomized_study","article","10.1016/j.ijgc.2026.104803","42447684",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000030","Suggested improvements to clarity of glucagon-like peptide-1 receptor agonist publications.","Heymsfield SB","2026","Cell metabolism","other","article","10.1016/j.cmet.2026.01.018","41780501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000031","Abdominoplasty After Bariatric Surgery and GLP-1 Receptor Agonists: Independent vs Combined Complication Risks.","Boukind A","2026","Aesthetic surgery journal","nonrandomized_study","article","10.1093/asj/sjaf244","41403207",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000032","Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES Database","Bai L","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.08.04.26359670",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0000033","Suitability of the ICH S1B(R1) weight-of-evidence framework to evaluate glucagon-like protein-1 receptor agonist (GLP-1RA) carcinogenicity risk.","Roach KA","2026","Regulatory toxicology and pharmacology : RTP","preclinical","article","10.1016/j.yrtph.2026.106252","42800499",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000034","A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction.","Wu JY","2026","Communications medicine","nonrandomized_study","article","10.1038/s43856-026-01618-2","42045526","PMC13324032",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000035","Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.","Alfonso Arvez MJ","2026","Clinical pharmacology and therapeutics","nonrandomized_study","article","10.1002/cpt.70414","42533561","PMC13424737",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000036","Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology.","Li M","2026","Frontiers in cardiovascular medicine","randomized_trial","article","10.3389/fcvm.2026.1926629","42819943","PMC13625624",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000037","Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity.","Chen H","2026","Journal of the neurological sciences","nonrandomized_study","article","10.1016/j.jns.2026.126106","42492143","PMC13452011",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000038","Anti-Obesity Medications in Longevity and Aesthetic Medicine.","Bijoch J","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15156026","42590128","PMC13467233",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000039","Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With Obesity.","Liu TH","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71353","42736027",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000040","Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant.","Manolas MI","2026","Gastroenterology & hepatology","other","article",null,"42713454","PMC13552437",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0000041","Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study.","Matsuo Y","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71189","42572004","PMC13646363",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000042","Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report.","Chong AC","2026","The journal of allergy and clinical immunology. Global","case_report","article","10.1016/j.jacig.2026.100751","42405354","PMC13331987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000043","Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity.","Mollero ELM","2026","Nutrients","randomized_trial","article","10.3390/nu18162654","42654234","PMC13516410",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000044","Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.","Guo J","2026","Frontiers in pharmacology","other_trial","article","10.3389/fphar.2026.1933018","42729683","PMC13562903",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000045","Patients With Ileal Pouch-Anal Anastomosis Have Decreased Bowel Frequency on Glucagon-Like Peptide-1 Receptor Agonist Therapy.","Chaudhry E","2026","Clinical and translational gastroenterology","nonrandomized_study","article","10.14309/ctg.0000000000001070","42384913","PMC13502744",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0000046","Complex clinical encounter series: glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?","Ambrogini E","2026","Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","case_report","article","10.1093/jbmr/zjag069","41989133",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0000047","A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.","Chen Q","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s585436","41710707","PMC12912087",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000048","Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.","Singhani V","2026","Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition","randomized_trial","article","10.1002/ncp.70180","42808923","PMC13622393",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000049","Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.","Au HCT","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70120","41792979","PMC13371786",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0000050","The Expanding Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Dermatology: From Immunometabolism to Clinical Practice.","Giorgio CM","2026","Dermatology and therapy","narrative_review","article","10.1007/s13555-026-01916-6","42728528","PMC13650102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000051","Glucagon-like peptide-1 receptor agonists and related incretin therapies in dermatology: Patient selection and shared decision-making.","Ndubisi S","2026","Clinics in dermatology","other","article","10.1016/j.clindermatol.2026.08.005","42571802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000052","Successful Use of Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis.","Guralwar C","2025","ACG case reports journal","case_report","article","10.14309/crj.0000000000001890","41267906","PMC12626758",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000053","Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.","Miller LB","2026","Military medicine","nonrandomized_study","article","10.1093/milmed/usag316","42424303",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000054","Editorial Commentary: Preoperative Glucagon-Like Peptide-1 Receptor Agonist Use May Improve Outcomes After Arthroscopic Rotator Cuff Repair but Beneficial Effects May Vary Across Patient Subgroups.","Moran J","2026","Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association","commentary","article","10.1002/arj.70372","42314082",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0000055","Specialty-based variation in glucagon-like Peptide-1 receptor agonist prescribing practices for adolescent obesity in Saudi Arabia.","Kalagi F","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100331","42733817","PMC13571590",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000056","Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.","Almukhadeb E","2026","International journal of dermatology","nonrandomized_study","article","10.1111/ijd.70346","41729201",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; review"],["R0000057","Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.","De Filippo O","2026","Journal of cardiovascular pharmacology","randomized_trial","article","10.1097/fjc.0000000000001862","42520399",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0000058","Adjuvant Glucagon-like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis.","Cross-Najafi AA","2026","The Journal of surgical research","nonrandomized_study","article","10.1016/j.jss.2026.08.047","42767161",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000059","Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies.","Li R","2026","Preventive medicine reports","systematic_review","article","10.1016/j.pmedr.2026.103548","42381894","PMC13316655",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0000060","Glucagon-Like Peptide-1 Receptor Agonist Use and Postoperative Outcomes After Distal Radius Fracture Fixation in Adults With Type 2 Diabetes.","Choudhury A","2026","Hand (New York, N.Y.)","nonrandomized_study","article","10.1177/15589447261451445","42251480","PMC13243302",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000061","The Effect of Glucagon-like Peptide-1 Receptor Agonists in Total Joint Arthroplasty: Implications, Complications, and Considerations.","Barton KI","2026","The Journal of the American Academy of Orthopaedic Surgeons","other","article","10.5435/jaaos-d-25-00892","42678766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000062","Keeping the weight off: can oral orforglipron maintain all the weight loss following glucagon-like peptide-1 receptor agonist (GLP-1 RA) discontinuation?","Alhazmi A","2026","Expert review of clinical pharmacology","commentary","article","10.1080/17512433.2026.2731087","42706941",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000063","Glucagon-like Peptide-1 Receptor Agonists and Dual Incretin Therapies Across HFpEF and Cardiovascular Outcomes Trials in Patients with Obesity.","Belančić A","2026","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina62081446","42654343","PMC13514512",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000064","Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases.","Kwiek B","2026","Dermatology and therapy","other_trial","article","10.1007/s13555-025-01640-7","41535531","PMC12936331",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0000065","A clinical and experimental investigation of liraglutide effects on the brain-kidney axis.","Greenwood MP","2026","Science advances","other_trial","article","10.1126/sciadv.aef4951","42555711","PMC13440386",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0000066","Glucagon-like Peptide-1 Receptor Agonist Use May Reduce Disease Activity and Progression in Osteoarthritis and Inflammatory Arthritis.","Trudeau M","2026","The Orthopedic clinics of North America","randomized_trial","article","10.1016/j.ocl.2026.05.004","42692567",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000067","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study.","Kim C","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70985","42380063","PMC13448862",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0000068","Pulmonary response to glucagon-like peptide-1 receptor agonist therapy in adults with cystic fibrosis-related diabetes: factors associated with improvement in FEV1.","Mirfakhraee S","2026","Respiratory medicine","nonrandomized_study","article","10.1016/j.rmed.2026.109137","42685881",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000069","Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis.","Kamel-Abusalha L","2026","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-026-01929-0","41867417","PMC13000040",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000070","Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials.","Parker CH","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16437","40329607","PMC12232371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000071","Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report.","Sato M","2026","Journal of clinical medicine research","nonrandomized_study","article","10.14740/jocmr6532","42327970","PMC13278717",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000072","Integrating glucagon-like peptide-1 receptor agonists into dermatology practice: Safety and monitoring strategies.","Narla S","2026","Clinics in dermatology","other_trial","article","10.1016/j.clindermatol.2026.07.030","42562129",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0000073","Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation.","Fallot LB","2026","Journal of the American Chemical Society","other","article","10.1021/jacs.6c01289","42133988","PMC13220265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0000074","Glucagon-Like Peptide-1 Receptor Agonists in Obesity: Evidence for Dose Reduction and Durable Weight Loss Maintenance","Fain MM","2026","Preprints.org","other","preprint","10.20944/preprints202610.0658.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0000075","Glucagon-like peptide-1 receptor agonist treatment is associated with lower frequency of diabetic peripheral neuropathy and neuropathic pain in type 2 diabetes.","Falco P","2026","Pain","other","article","10.1097/j.pain.0000000000004104","42663556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000076","Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.","Pisani D","2026","Endocrine","systematic_review","article","10.1007/s12020-026-04701-9","42536323","PMC13427886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0000077","The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study.","Israel A","2026","Therapeutic advances in musculoskeletal disease","nonrandomized_study","article","10.1177/1759720x261425441","41773280","PMC12949789",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000078","Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.","Alvina","2026","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-026-10017-5","42207410",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Preprint; article; preprint"],["R0000079","A retrospective cohort study on the comparative safety of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on the onset of gallbladder disease in type II diabetes.","Carlson K","2026","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2026.2726017","42712138",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0000080","Metformin-Associated Lactic Acidosis and Relative Euglycemic Ketoacidosis Precipitated by a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report and Literature Review.","Adnani H","2026","Kidney360","case_report","article","10.34067/kid.0000001379","42696402",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000081","Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Kanbay M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71106","42449480","PMC13538776","PROSPERO:CRD420261321430",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0000082","Beyond Weight Loss: Gut Microenvironment Modulation to Enhance Cardiometabolic Outcomes and Long-Term Adherence During Incretin-Based Therapy.","Geraci C","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15155909","42590012","PMC13467095",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000083","Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications-A Narrative Review.","La Vignera S","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27146116","42511463","PMC13411830",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0000084","Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With and May Lead to Esophageal Motility Abnormalities.","Gala K","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2025.11.003","41213390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000085","Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.","Evans B","2026","Behavioural pharmacology","preclinical","article","10.1097/fbp.0000000000000880","42228850","PMC13573658",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000086","Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes.","Olubodun T","2026","PloS one","systematic_review","article","10.1371/journal.pone.0354497","42594084","PMC13472420",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; review"],["R0000087","Incretin-based therapies and altered myocardial metabolism in a swine model of ischemic heart disease in the setting of metabolic syndrome.","Zheng C","2026","Surgery","randomized_trial","article","10.1016/j.surg.2026.110369","42386418",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0000088","Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026.","Orandi BJ","2026","Pediatrics","nonrandomized_study","article","10.1542/peds.2026-077048","42692477",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000089","A Case of GLP-1 Receptor Agonist-Induced Dysphoria and Aggression in a Patient With Underlying Major Depressive Disorder.","Hofstad M","2026","Journal of psychiatric practice","case_report","article","10.1097/pra.0000000000000920","42095721",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0000090","Boerhaave's syndrome associated with glucagon-like peptide-1 receptor agonist use: a case report.","Aubrey JM","2026","Journal of cardiothoracic surgery","case_report","article","10.1186/s13019-026-04214-6","42286576","PMC13505130",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0000091","Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.","Paceana MA","2026","Pharmaceutics","randomized_trial","article","10.3390/pharmaceutics18050620","42198313","PMC13210960",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000092","Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes.","Eldesouki MH","2026","United European gastroenterology journal","nonrandomized_study","article","10.1002/ueg2.70238","42247589","PMC13240991",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000093","Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.","Chen SC","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71088","42420795","PMC13538802",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000094","Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: a bibliometric analysis of global research trends and research hotspots from 2006 to 2025.","Bi Q","2026","Naunyn-Schmiedeberg's archives of pharmacology","narrative_review","article","10.1007/s00210-026-05635-9","42384167",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000095","Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting System","Eduardo I","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9818000/v3",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0000096","Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.","Sun H","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71358","42768849",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","4","FALSE","Journal Article; article"],["R0000097","Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention.","Kruglikov IL","2025","Journal of cosmetic dermatology","other","article","10.1111/jocd.70584","41316800","PMC12663710",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000098","Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study.","Keshen A","2026","World psychiatry : official journal of the World Psychiatric Association (WPA)","other","article","10.1002/wps.70096","42742590","PMC13576927",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000099","Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot.","Ortiz Romero M","2026","Biomedicines","nonrandomized_study","article","10.3390/biomedicines14020406","41751305","PMC12938257",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000100","Class-Wide Impaired Gastric Emptying Signal Across Nine GLP-1 Receptor Agonist Agents: Indication-Stratified Pharmacovigilance Analysis of 6,868 Cases in FDA FAERS (2004-2024) with Cross-National Validation","Eduardo I","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9818062/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0000101","Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.","Mohseni Y","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","narrative_review","article","10.1097/dss.0000000000005172","42210892",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000102","Psychiatric Adverse Events Associated with GLP-1 Receptor Agonists: Evidence of Intraclass Heterogeneity in the WHO VigiBase Global Database","Zavaleta-Monestel E","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202606.2007.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint; article"],["R0000103","Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.","Kakkar AK","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70952","42259643",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0000104","Implications of GLP-1 receptor agonists for the fertility of women with polyendocrine metabolic ovarian syndrome.","Kordowitzki P","2026","Cell metabolism","other","article","10.1016/j.cmet.2026.08.013","42710489",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000105","Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies.","Kim JY","2026","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2026.0702","42722378","PMC13561646",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000106","Combining Sodium-Glucose Co-Transporter-2 Inhibitor Plus Glucagon-Like Peptide-1 Receptor Agonist for Glucose-Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real-World Clinical Practice (CombiKid Study).","Hinton W","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70946","42300258","PMC13448856",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000107","GLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period.","Mills AM","2026","Appetite","narrative_review","article","10.1016/j.appet.2026.108729","42508693",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000108","Use of fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Asians with type 2 diabetes.","Kong AP","2026","Primary care diabetes","randomized_trial","article","10.1016/j.pcd.2026.08.005","42697752",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000109","Effects of Glucagon-Like Peptide-1 Receptor Agonist Use After Transient Ischemic Attack on Risks of Subsequent Ischemic Stroke and Mortality.","Kakadiya J","2026","Journal of clinical neurology (Seoul, Korea)","nonrandomized_study","article","10.3988/jcn.2026.0073","42683794","PMC13553170",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000110","Trends in utilization of glucagon-like peptide‑1 receptor agonists, sodium-glucose cotransporter‑2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity.","Wartko PD","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113504","42624330",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000111","Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes.","Piraccini BM","2026","Dermatology and therapy","nonrandomized_study","article","10.1007/s13555-026-01792-0","42249225","PMC13280097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000112","GLP-1 receptor agonists in psoriasis management.","Cutrona M","2026","Clinics in dermatology","randomized_trial","article","10.1016/j.clindermatol.2026.09.037","42822650",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0000113","Current Concepts in Perioperative Guidance and Outcomes in Hand Surgery Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.","Song EY","2026","The Journal of hand surgery","narrative_review","article","10.1016/j.jhsa.2026.05.008","42397318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000114","Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis.","Ailawadi S","2026","Cancers","nonrandomized_study","article","10.3390/cancers18020179","41595103","PMC12839127",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000115","Glucagon-Like Peptide-1 Receptor Agonists in Chronic Migraine: A Convergent Disease-Modification Hypothesis","Sulter GA","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202605.0916.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0000116","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.","Zarabian N","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","narrative_review","article","10.1097/dss.0000000000005176","42210891",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000117","GLP-1 Receptor Agonist-Associated Weight Loss and Aesthetic Breast Surgery: A Narrative Review and Experience-Based Recommendations for Plastic and Reconstructive Surgeons.","Nahabedian MY","2026","Aesthetic surgery journal. Open forum","narrative_review","article","10.1093/asjof/ojag054","41978571","PMC13070687",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; review"],["R0000118","Neonatal and obstetric outcomes following periconceptional exposure to glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","Hakim J","2026","American journal of obstetrics and gynecology","systematic_review","article","10.1016/j.ajog.2026.04.037","42061782",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article; review"],["R0000119","Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis.","Rai P","2026","Neurology international","nonrandomized_study","article","10.3390/neurolint18050098","42188698","PMC13210162",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000120","Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use.","Wang AL","2026","Journal of clinical gastroenterology","nonrandomized_study","article","10.1097/mcg.0000000000002395","42133868",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000121","GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions-A Systematic Review.","Myśliwczyk D","2026","Nutrients","systematic_review","article","10.3390/nu18111662","42280306","PMC13258732",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0000122","Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With Decreased Incidence of Carpal Tunnel Syndrome in Patients With Type 2 Diabetes: A Propensity-Matched Analysis.","Stump K","2026","Hand (New York, N.Y.)","nonrandomized_study","article","10.1177/15589447261422503","41719026","PMC12923368",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000123","GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.","Ahmed F","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15134992","42452454","PMC13362885",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000124","Do GLP-1 Receptor Agonists Sabotage Fat Grafts? : A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.","Chalhoub X","2026","Aesthetic surgery journal","narrative_review","article","10.1093/asj/sjag108","42219269",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000125","Decoding the hallmarks of GLP-1RA weight-loss super-responders.","Venkatakrishnan AJ","2026","Biology methods & protocols","nonrandomized_study","article","10.1093/biomethods/bpag021","42147968","PMC13176449",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000126","Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization.","Zhang T","2026","The international journal of lower extremity wounds","nonrandomized_study","article","10.1177/15347346261487722","42726083",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000127","Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information.","Brown JP","2026","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-25-04820","42258827","PMC13430612",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0000128","Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.","Dziewierz A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71017","42297761","PMC13448982",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000129","Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts.","Haberman RH","2026","Arthritis & rheumatology (Hoboken, N.J.)","nonrandomized_study","article","10.1002/art.70170","41940492","PMC13154331",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000130","Association of glucagon-like peptide-1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes.","Yu YT","2026","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70281","41793207","PMC13137280",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000131","Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society.","Sánchez-Prieto M","2026","Maturitas","narrative_review","article","10.1016/j.maturitas.2026.109101","42664617",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Consensus Statement; article"],["R0000132","The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review.","Weber L","2026","Stem cell reviews and reports","systematic_review","article","10.1007/s12015-025-11002-7","41129073","PMC12795975",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0000133","The Potential Role of Topical Skincare Approaches After Glucagon-like Peptide-1 Receptor Agonist Use and Rapid Weight Loss.","Shridharani SM","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","narrative_review","article","10.1097/dss.0000000000005151","42210880",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000134","Glucagon-like Peptide-1 receptor agonist use is associated with decreased risk of periprosthetic joint infection following total knee arthroplasty: A laterality-verified propensity matched comparison.","Bowers CJ","2026","Journal of orthopaedic surgery (Hong Kong)","nonrandomized_study","article","10.1177/10225536261488188","42702012",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0000135","Target Trial Emulation: Glucagon-Like Peptide-1 Receptor Agonist, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors for Kidney Outcome Prevention.","Hung A","2026","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000001033","41885954","PMC13268379",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000136","Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.","Rosen CB","2026","Advances in surgery","narrative_review","article","10.1016/j.yasu.2026.03.011","42556958",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000137","Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.","Horváth L","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16645","40719033","PMC12308273",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0000138","Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.","Engström A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70760","41994910","PMC13243990",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000139","Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy.","Ruan F","2026","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvag224","42857401","PMC13650476",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000140","Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review.","Desai A","2026","Gastro hep advances","randomized_trial","article","10.1016/j.gastha.2026.101023","42405289","PMC13331968",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0000141","Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?","La Vignera S","2026","Journal of the Endocrine Society","narrative_review","article","10.1210/jendso/bvag149","42487666","PMC13389710",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000142","Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Hidradenitis Suppurativa: A Narrative Review of Emerging Evidence.","Silberzweig A","2026","Clinics in dermatology","randomized_trial","article","10.1016/j.clindermatol.2026.09.029","42790605",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; review"],["R0000143","Association Between Continuous Glucose Monitoring Utilization and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Type 2 Diabetes: A Real-World Study.","Wright EE","2026","Diabetes technology & therapeutics","nonrandomized_study","article","10.1177/15209156261489904","42762166",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000144","698. Glucagon-like peptide-1 receptor agonists and eating disorders",null,"2026","The international journal of neuropsychopharmacology","other","article",null,null,"PMC13556763",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0000145","Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives.","Patel D","2026","Cureus","nonrandomized_study","article","10.7759/cureus.107202","42153087","PMC13180026",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000146","Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025.","Kildegaard H","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70234","42252120","PMC13422664",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000147","Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024.","Taipale H","2026","Acta psychiatrica Scandinavica","randomized_trial","article","10.1111/acps.70120","42324672","PMC13532777",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000148","Potential oral and maxillofacial adverse events associated with glucagon-like peptide-1 receptor agonist administration: a narrative review.","Brooks JK","2026","Quintessence international (Berlin, Germany : 1985)","nonrandomized_study","article","10.3290/j.qi.b7034788","42334501",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; review"],["R0000149","Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot study.","Carafa A","2026","Acta diabetologica","preclinical","article","10.1007/s00592-026-02778-2","42766134",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000150","Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.","Anatriello A","2026","Pharmacological reports : PR","nonrandomized_study","article","10.1007/s43440-026-00864-4","42207473",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000151","Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.","Zhang Y","2026","European journal of medical research","systematic_review","article","10.1186/s40001-026-03933-9","41582189","PMC12918571",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000152","Lean Mass Reduction During Glucagon-like Peptide-1 Receptor Agonists-Induced Weight Loss: Rethinking Its Clinical Significance.","Moscucci F","2026","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","narrative_review","article","10.1007/s40292-026-00819-z","42701941",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000153","Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.","Patel KS","2026","Intestinal research","nonrandomized_study","article","10.5217/ir.2026.00152","42717572",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000154","Glucagon-like peptide-1 receptor agonists as adjunctive therapy in refractory hypertriglyceridemia following recurrent pancreatitis.","Miura D","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag274","42750924","PMC13579051",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000155","Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists After Bowel Obstruction or Ileus: A Nationwide, Real-World, Database Study.","Matsuo Y","2026","Journal of evidence-based medicine","nonrandomized_study","article","10.1111/jebm.70164","42439225","PMC13613258",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000156","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review.","Soares LA","2025","Current epidemiology reports","narrative_review","article","10.1007/s40471-025-00375-5","41230336","PMC12602557",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000157","Are Glucagon-Like Peptide-1 Receptor Agonists Suitable for Secondary Stroke Prevention?","Kwon HS","2026","Journal of clinical neurology (Seoul, Korea)","commentary","article","10.3988/jcn.2026.0463","42683789","PMC13553161",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0000158","A Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Reducing the Incidence of Tuberculosis and Mortality in Patients with Diabetes","Hsu C","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202609.0818.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0000159","Renal Effects of Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Disease: A Narrative Review of Mechanisms and Clinical Evidence.","Braha A","2026","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina62081509","42654406","PMC13514747",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0000160","Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy.","Huang SC","2026","Frontiers in urology","nonrandomized_study","article","10.3389/fruro.2026.1855180","42630726","PMC13494580",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000161","GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review.","Malluhi M","2026","Biomolecules & biomedicine","narrative_review","article","10.17305/bb.2026.14701","42770962",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000162","Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated with Increased Peripheral Nerve Compression after Bariatric Surgery","Biaggi Ondina A","2026","Plastic and reconstructive surgery. Global open","other","article",null,null,"PMC13652008",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0000163","Overscreening of patients on glucagon-like peptide-1 receptor agonists: A second \"epidemic\" of thyroid cancer overdiagnosis?","Raghunathan R","2026","Surgery","nonrandomized_study","article","10.1016/j.surg.2025.109868","41371825",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000164","Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.","Panou T","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-026-01865-5","41984373","PMC13156392",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000165","Can glucagon-like peptide-1 receptor agonists affect outcomes after spine surgery? A systematic review and meta-analysis.","Muthu S","2026","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","systematic_review","article","10.1007/s00586-026-10205-x","42471496",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0000166","AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice.","d'Ávila M","2026","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.2614476123","42550908","PMC13462369",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000167","Adipocytes as a Mechanistic Link Between Incretin-Based Therapies and Hair Loss.","Gupta AK","2026","Biology","narrative_review","article","10.3390/biology15181642","42792587","PMC13604800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000168","Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety.","Lee N","2026","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.70163","41886296","PMC13020769",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000169","Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.","Kopp KL","2026","Pharmaceutical research","other","article","10.1007/s11095-026-04146-9","42533250","PMC13593678",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000170","Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.","Wu JY","2026","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.125.047018","42466510","PMC13477337",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0000171","Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis.","Shokravi A","2026","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-026-03113-3","41761267","PMC13049956",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; research-article; review; other"],["R0000172","The GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity Era","Hungund S","2026","Qeios","systematic_review","preprint","10.32388/i85yu1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0000173","Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes.","Kansakar U","2026","International journal of molecular sciences","other_trial","article","10.3390/ijms27031409","41683830","PMC12898445",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000174","Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.","Xu Y","2025","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2025.112954","42618994",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; Review; review"],["R0000175","Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients.","Kutler RB","2026","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","nonrandomized_study","article","10.1002/ohn.70231","41979383",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000176","Changes in HbA1c With Glucagon-Like Peptide-1 Receptor Agonist Therapy Alone and Followed by Initiation of Continuous Glucose Monitoring: A Retrospective Analysis of U.S. Medical Claims Data.","McGonigle J","2026","Journal of diabetes science and technology","nonrandomized_study","article","10.1177/19322968261450596","42289934","PMC13269114",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000177","Effect of GLP-1 Receptor Agonists and Tirzepatide on Obstructive Sleep Apnea Severity: A Systematic Literature Review","Daut UN","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202606.0065.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0000178","Glucagon-Like Peptide-1 Receptor Agonists Improve Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction, Independent of Diabetes: A Systematic Review and Meta-Analysis.","Shokravi A","2026","CJC open","systematic_review","article","10.1016/j.cjco.2026.02.008","42327438","PMC13282519",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000179","Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.","Sørensen KK","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70581","41741950","PMC13071185",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0000180","Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.","Pendrey AG","2026","Advances in therapy","narrative_review","article","10.1007/s12325-026-03702-4","42423951","PMC13619721",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000181","Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence.","Altami IK","2026","Journal of clinical medicine","systematic_review","article","10.3390/jcm15124781","42355949","PMC13300848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000182","Altered eating experience during GLP-1 receptor agonist therapy: a sensory-liking-wanting framework for food preference and nutritional behaviour.","Du J","2026","Frontiers in nutrition","narrative_review","article","10.3389/fnut.2026.1870484","42539396","PMC13423643",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000183","Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.","Ali Akbar U","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.05.004","42103200",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0000184","Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.","Testelmans D","2026","Pulmonology","nonrandomized_study","article","10.1080/25310429.2026.2722795","42639925",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; article"],["R0000185","GLP-1 receptor agonists in hip, knee and shoulder arthroplasty: Implications for obesity, osteoarthritis, metabolic optimisation and complications.","Avram GM","2026","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA","nonrandomized_study","article","10.1002/ksa.70557","42546112",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; editorial"],["R0000186","Long-Term Glucagon-Like Peptide 1 Receptor Agonist Use Is Not Associated With Increased Risk of Thyroid Cancer in Adults With Type 2 Diabetes.","Pollack R","2025","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.70104","41182904","PMC12582397",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000187","Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist.","Kim AR","2026","Nutrients","preclinical","article","10.3390/nu18071050","41978101","PMC13074448",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000188","Glucagon-like Peptide-1 Receptor Agonists and the Perioperative Patient.","Fischer L","2026","AORN journal","other","article","10.1002/aorn.70127","42517192","PMC13408904",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0000189","[Value and benefit of basic insulin/GLP-1RA weekly preparation in clinical treatment of type 2 diabetes in adults].","Zhang SC","2026","Zhonghua yi xue za zhi","other_trial","article","10.3760/cma.j.cn112137-20260325-00802","42161872",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","English Abstract; Journal Article; other"],["R0000190","Glucagon-like Peptide-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: Insights From a Pilot Implementation Program.","Gerges M","2026","Canadian journal of diabetes","other","article","10.1016/j.jcjd.2026.06.001","42331284",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000191","Peri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort study.","Potter TE","2026","Anaesthesia","nonrandomized_study","article","10.1111/anae.70380","42748560",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000192","Effect of two-week perioperative glucagon-like peptide-1 receptor agonist interruption on retained gastric contents during esophagogastroduodenoscopy: a retrospective, observational study.","Dong Z","2026","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-026-13121-9","42426387",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0000193","Risk of Diabetic Ketoacidosis with Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis","Alkhushaym N","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-10216709/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0000194","Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis.","Singh V","2026","Journal of clinical gastroenterology","nonrandomized_study","article","10.1097/mcg.0000000000002396","42183591",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000195","Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.","Lipska KJ","2026","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-25-05216","42441965",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0000196","Effects of the glucagon-like peptide-1 receptor agonist PEG-Loxe on diabetic osteoporosis: A mechanistic study.","Zhang L","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2026.102390","42229580","PMC13276415",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000197","Real-World Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Combination Therapy on Weight Management Within a Digital-Supported Shared Care Model for Type 2 Diabetes.","Wang M","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.05.033","42250764",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000198","Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.","Yang Q","2026","BMC ophthalmology","systematic_review","article","10.1186/s12886-026-05036-9","42380920","PMC13591686","PROSPERO:CRD420251007882",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0000199","Switching from glucagon-like peptide-1 receptor agonists to tirzepatide in type 2 diabetes: does therapeutic sequencing matter for metabolic dysfunction-associated steatotic liver disease?","Patoulias D","2026","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2026.109418","42772979",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000200","Clinical Guidance on the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in Adults with Type 1 Diabetes.","Saeed ZI","2026","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2026.04.006","42527001",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000201","Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.","Frey C","2026","Obstetrics and gynecology","nonrandomized_study","article","10.1097/aog.0000000000006367","42424619",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000202","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Hung TH","2026","Human psychopharmacology","systematic_review","article","10.1002/hup.70041","41914576",null,"PROSPERO:CRD42024566217",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0000203","Coming full circle: could glucagon-like peptide-1 receptor agonists confer a net perioperative benefit?","Hobai IA","2026","British journal of anaesthesia","nonrandomized_study","article","10.1016/j.bja.2025.10.003","41162254",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0000204","Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study.","Choi JG","2026","Gut and liver","nonrandomized_study","article","10.5009/gnl260189","42682267",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000205","Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.","Qi H","2026","PeerJ","systematic_review","article","10.7717/peerj.21713","42729958","PMC13564392",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0000206","Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.","Wachiraphansakul N","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70884","42209204",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Network Meta-Analysis; Journal Article; Comparative Study; review"],["R0000207","Incretin-based therapies: Effects on plasma lipids and potential mechanisms.","Syed-Abdul MM","2026","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2026.109057","42250734",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000208","Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study.","Tu CY","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113573","42764072",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000209","Glucagon-like peptide-1 receptor agonist use for type 2 diabetes and risk of upper extremity fragility fracture.","Cathey JM","2026","Injury","nonrandomized_study","article","10.1016/j.injury.2026.113456","42314528",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000210","Use of Glucagon-Like Peptide-1 Receptor Agonists in Women with Type 2 Diabetes Before Pregnancy: Addressing the Dilemma in A Real-World Setting.","Amiri A","2026","Current diabetes reports","nonrandomized_study","article","10.1007/s11892-026-01632-7","42262435",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0000211","758. Use of glucagon-like peptide 1 receptor agonists and the associated outcomes in bipolar disorder, from a nationwide cohort, 2009-2024",null,"2026","The international journal of neuropsychopharmacology","nonrandomized_study","article",null,null,"PMC13556412",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0000212","Use of glucagon-like peptide-1 receptor agonists is associated with inadequate bowel preparation for colonoscopy in patients with diabetes.","Ogawa O","2026","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70426","42635465","PMC13502145",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000213","[GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects].","Klotz T","2026","Zentralblatt fur Chirurgie","other","article","10.1055/a-2943-1080","42748969",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0000214","Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes: What We Know So Far and Future Trials.","Stein A","2026","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2026.04.003","42526995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000215","Perioperative Desaturation and Postoperative Nausea or Vomiting Requiring Antiemetic Administration in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Ambulatory Ophthalmic Surgery Under Mild-To-Moderate Sedation: A Large Retrospective Cohort Study.","Hyung B","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70955","42259623",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0000216","Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.","Patil S","2026","Addictive behaviors reports","systematic_review","article","10.1016/j.abrep.2026.100671","41696398","PMC12906085","OSF:osf.io/x58ne",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; brief-report; review"],["R0000217","Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery.","Huerta Díaz LA","2026","Cureus","randomized_trial","article","10.7759/cureus.113460","42661796","PMC13518602",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000218","Preoperative Use of Glucagon-Like Peptide-1 Receptor Agonists Is Not Protective Against Pseudoarthrosis Following Small Joint Hand Arthrodesis: A Propensity-Matched Analysis.","Stump K","2026","Hand (New York, N.Y.)","nonrandomized_study","article","10.1177/15589447261415646","41620384","PMC12861399",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000219","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Age-Related Macular Degeneration at a Tertiary Ophthalmology Center.","Joo JH","2026","Ophthalmology. Retina","nonrandomized_study","article","10.1016/j.oret.2025.12.014","41443408",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000220","Advances in Cardiovascular Pharmacotherapy. IX. Protection Against Major Adverse Cardiovascular Events by Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Obesity.","Pagel PS","2026","Journal of cardiothoracic and vascular anesthesia","narrative_review","article","10.1053/j.jvca.2026.07.032","42580924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000221","GLP-1 Receptor Agonist Use and A1 Pulley Release After Corticosteroid Injection for Trigger Finger in Type 2 Diabetes.","Khan AA","2026","Hand (New York, N.Y.)","nonrandomized_study","article","10.1177/15589447261480181","42678052","PMC13534347",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000222","Differences in Prescribing Rates of Glucagon-Like Peptide-1 Receptor Agonists Between Spinal Cord Injured and Non-Spinal Cord Injured Individuals: A Retrospective Study.","Thatte S","2026","Topics in spinal cord injury rehabilitation","nonrandomized_study","article","10.46292/sci25-00066","42583213","PMC13460120",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000223","Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study.","Frier K","2026","ACR open rheumatology","other","article","10.1002/acr2.90070","42310946","PMC13275997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000224","[SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes].","Scheen A","2026","Revue medicale de Liege","other_trial","article",null,"41815032",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","5","FALSE","English Abstract; Equivalence Trial; Journal Article; other"],["R0000225","Treatment of Bile Acid Diarrhea With Glucagon-Like Peptide 1 Receptor Agonists: A Promising Yet Understudied Approach.","Ellegaard AM","2025","Clinical and translational gastroenterology","randomized_trial","article","10.14309/ctg.0000000000000815","39807780","PMC11932613",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000226","Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity.","Palmer M","2026","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2026.09.002","42791090",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0000227","Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review.","Bihelek N","2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","systematic_review","article","10.1093/ajhp/zxag121","42033237",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; review"],["R0000228","Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications.","Odeleye V","2026","Current cardiology reports","randomized_trial","article","10.1007/s11886-026-02357-5","41870800","PMC13009101",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000229","Obesity and Female Reproductive Health; Is There a Role for Glucagon-Like Peptide-1 Receptor Agonists?","Roberts R","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.70015","41077659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000230","Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum - Mechanisms, evidence, and future directions.","Dahshan A","2026","Clinical parkinsonism & related disorders","randomized_trial","article","10.1016/j.prdoa.2026.100461","42328044","PMC13279746",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000231","GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.","Gupta AK","2026","Science progress","systematic_review","article","10.1177/00368504261444578","41998799","PMC13100445","PROSPERO:CRD420261297384",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0000232","Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Eisa N","2026","AACE endocrinology and diabetes","systematic_review","article","10.1016/j.aed.2026.03.003","42221413","PMC13221932",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000233","Real-World Effectiveness, Safety, and Use Patterns of GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Nationwide Multicentre Community Pharmacy Study","Vergniory-Trueba O","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202608.0314.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0000234","Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment.","Wietholter JP","2026","The Annals of pharmacotherapy","other_trial","article","10.1177/10600280261486055","42760621",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0000235","Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie.","Busti M","2026","Heart failure reviews","nonrandomized_study","article","10.1007/s10741-026-10627-1","41984352",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0000236","Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved and mildly reduced ejection fraction - a meta-analysis of randomized controlled trials.","Ravikulan R","2025","European journal of heart failure","systematic_review","article","10.1002/ejhf.70085","41216984",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0000237","The gut microbiota as a potential determinant of response to GLP-1 receptor agonists: a narrative review.","De La Motte LR","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1858420","42518541","PMC13381830",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0000238","GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide)/GLP-1 Receptor Agonists for Antipsychotic-Induced Weight Gain: A Narrative Review.","Buczkowska A","2026","Cureus","randomized_trial","article","10.7759/cureus.114435","42730175","PMC13568719",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0000239","Glucagon-like peptide-1 receptor agonist use and clinical outcomes after posterior cervical spinal fusion for degenerative pathologies: A large cohort retrospective analysis.","Rajkovic C","2026","North American Spine Society journal","nonrandomized_study","article","10.1016/j.xnsj.2026.100873","41938705","PMC13049663",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000240","Glucagon-like peptide-1 receptor agonists and the risk of Parkinson's disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data.","Chen Y","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1849318","42661791","PMC13518207",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0000241","Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.","Guo M","2026","Naunyn-Schmiedeberg's archives of pharmacology","nonrandomized_study","article","10.1007/s00210-026-05113-2","41748946",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0000242","A fuel partitioning perspective on appetite suppression by GLP-1 receptor agonists.","Friedman MI","2026","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2026.03.013","41991393",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000243","Worsening vasomotor symptoms in the setting of estradiol and semaglutide: a case report.","Parker AE","2025","Menopause (New York, N.Y.)","case_report","article","10.1097/gme.0000000000002621","40729307",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0000244","Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs.","Bitar ER","2026","Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract","nonrandomized_study","article","10.1016/j.gassur.2026.102497","42447648",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0000245","Pulmonary aspiration during upper endoscopy in a patient prescribed semaglutide.","Dong T","2026","Revista espanola de enfermedades digestivas","case_report","article","10.17235/reed.2024.10844/2024","39421913",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0000246","[Association between the initiation of glucagon-like peptide-1 receptor agonist use and the risk of incident diabetic retinopathy in patients with type 2 diabetes mellitus].","Zheng YQ","2026","Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi","nonrandomized_study","article","10.3760/cma.j.cn112338-20260105-00013","42618485",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","English Abstract; Journal Article; other"],["R0000247","Time-restricted eating in adults with type 2 diabetes mellitus on concomitant glucagon-like peptide-1 receptor agonists: case report.","Laing KL","2026","Frontiers in clinical diabetes and healthcare","other_trial","article","10.3389/fcdhc.2026.1725278","42416288","PMC13337375","ClinicalTrials.gov:NCT05365529",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0000248","Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.","Castro-Gamboa J","2026","Cureus","nonrandomized_study","article","10.7759/cureus.110178","42403733","PMC13330733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0000249","Readability of AI-Generated Patient Information on Glucagon-Like Peptide-1 Receptor Agonists.","Williams T","2026","JMIR bioinformatics and biotechnology","commentary","article","10.2196/90572","42085653","PMC13143154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0000250","Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity.","Fernandes MT","2026","Life (Basel, Switzerland)","narrative_review","article","10.3390/life16091486","42795351","PMC13608023",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000251","Pre-operative gastric volume measurement and glucagon-like peptide-1 receptor agonists.","Lim ZJ","2026","Anaesthesia","commentary","article","10.1111/anae.70293","42429195","PMC13551147",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0000252","Orofacial adverse events associated with glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study.","Oyewole SO","2026","Oral surgery, oral medicine, oral pathology and oral radiology","nonrandomized_study","article","10.1016/j.oooo.2026.06.002","42463344",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0000253","Unanticipated Residual Gastric Contents in an Appropriately Fasted Pediatric Patient on Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Case Report and Review of Perioperative Considerations.","Lookabaugh M","2025","Cureus","case_report","article","10.7759/cureus.99731","41573454","PMC12822851",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000254","Glucagon-like peptide-1 receptor agonists and venous thromboembolism: an unresolved question for Australian prescribers.","Kamel KS","2026","Internal medicine journal","commentary","article","10.1111/imj.70522","42444392","PMC13458209",null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0000255","Age-related macular degeneration associated with glucagon-like peptide-1 receptor agonist use: a systematic review.","Al-Burak SA","2026","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","systematic_review","article","10.1016/j.jcjo.2026.05.010","42242290",null,"PROSPERO:CRD420251183938",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0000256","GLP-1 receptor agonists and alcohol use disorder: a systematic review.","Patel S","2025","Alcohol and alcoholism (Oxford, Oxfordshire)","systematic_review","article","10.1093/alcalc/agaf069","41273789",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; review"],["R0000257","GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.","Alqinai B","2026","Inflammatory bowel diseases","nonrandomized_study","article","10.1093/ibd/izag167","42627215",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000258","Do Patients Receiving GLP-1 Receptor Agonists for Weight Loss Require Structured Dietetic Care? Lessons from Metabolic and Bariatric Surgery (MBS) Pathways.","Balasubaramaniam V","2026","Nutrients","narrative_review","article","10.3390/nu18162643","42654223","PMC13516109",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000259","Glucagon-like peptide-1 receptor agonists in dermatology: ethical considerations.","Deitelzweig C","2026","Clinics in dermatology","other","article","10.1016/j.clindermatol.2026.08.016","42710719",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000260","GLP-1 receptor agonists in pediatric obesity.","Abodi M","2026","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","narrative_review","article","10.1016/j.dld.2026.06.010","42401514",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000261","Evaluating Glucagon-Like Peptide-1 Receptor Agonist Safety Before Upper Endoscopy: A Systematic Review and Meta-Analysis.","Ahmed Z","2026","Gastroenterology research","systematic_review","article","10.14740/gr2108","42137745","PMC13171266",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0000262","Comparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists.","Bea S","2026","Diabetes care","nonrandomized_study","article","10.2337/dc26-0757","42684335",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; other; article"],["R0000263","Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.","Rouse M","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","randomized_trial","article","10.1016/j.soard.2026.05.027","42342489",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0000264","Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement.","Grewal US","2026","Cancer","nonrandomized_study","article","10.1002/cncr.70586","42606162","PMC13479761",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Consensus Statement; Journal Article; other; article"],["R0000265","Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Periconception Exposure and Perinatal Outcomes.","Lau KGY","2026","BJOG : an international journal of obstetrics and gynaecology","other","article","10.1111/1471-0528.70339","42830218",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; IM; article"],["R0000266","Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis.","Carter V","2026","Regional anesthesia and pain medicine","nonrandomized_study","article","10.1136/rapm-2026-107658","42229941",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000267","Impact of glucagon-like peptide-1 receptor agonists on outcomes following anterior cervical discectomy and fusion: a systematic review and meta-analysis.","Duru DO","2026","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","systematic_review","article","10.1007/s00586-026-10258-y","42570103",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0000268","Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance.","Zambrano-Villacres R","2026","Nutrients","nonrandomized_study","article","10.3390/nu18111751","42280393","PMC13258902",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000269","GLP-1 receptor agonists: The good, the bad, and the ugly-A comprehensive guide for NPs.","Rodriguez ME","2026","The Nurse practitioner","narrative_review","article","10.1097/01.npr.0000000000000430","42021007",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000270","Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.","Temperley HC","2026","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","narrative_review","article","10.1200/jco-26-00062","42372204","PMC13475729",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000271","Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study.","Nielsen VW","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","nonrandomized_study","article","10.1111/jdv.70769","42828450",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000272","Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review.","van Maren SJF","2026","Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation","other_trial","article","10.1007/s12471-026-02073-3","42733032","PMC13615203",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000273","Semaglutide-Induced Ischemic Colitis in A Middle-Aged Female Without Vascular Risk Factors.","Joma M","2026","European journal of case reports in internal medicine","other","article","10.12890/2026_006649","42466220","PMC13374836",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000274","Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.","Hwang I","2026","Drug design, development and therapy","nonrandomized_study","article","10.2147/dddt.s604247","42518911","PMC13381347",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0000275","Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.","Gupta M","2026","The Indian journal of medical research","nonrandomized_study","article","10.25259/ijmr_2041_2025","42165732","PMC13224277",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000276","Glucagon-Like Peptide-1 Receptor Agonists and Reproductive Health: A Narrative Review for Obstetrician-Gynecologists.","Almaradweh S","2026","Cureus","narrative_review","article","10.7759/cureus.111915","42544159","PMC13428985",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0000277","GLP-1R agonists: recent advances, current gaps, and future challenges.","Saran A","2026","Molecular diversity","narrative_review","article","10.1007/s11030-025-11195-6","40301134",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000278","Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide.","Vilsbøll T","2026","The British journal of ophthalmology","randomized_trial","article","10.1136/bjo-2025-328729","42049287",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0000279","Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.","Kwan ATH","2026","Clinical nutrition (Edinburgh, Scotland)","nonrandomized_study","article","10.1016/j.clnu.2026.106620","41864088",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0000280","Metabolic and Bariatric Surgery Utilization in the Era of Glucagon-Like Peptide-1 Receptor Agonists among Adolescents versus Adults.","Messiah SE","2025","The Journal of pediatrics","other","article","10.1016/j.jpeds.2025.114564","40132747","PMC12184987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; Research Support, U.S. Gov't, P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0000281","Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs).","Li J","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-026-01872-6","42012593","PMC13253940",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000282","The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Peri- and Postmenopausal Breast Cancer Outcomes.","Den J","2026","Journal of surgical oncology","nonrandomized_study","article","10.1002/jso.70411","42813380",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000283","Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.","Vieira FT","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.70116","41782395","PMC13371857",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Scoping Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0000284","Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?","Cowart K","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16502","40497353","PMC12308271",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Video-Audio Media; research-article; article"],["R0000285","Glucagon-Like Peptide-1 Receptor Agonists in Dialysis: The Evidence Grows, but Trials Must Follow.","Kovesdy CP","2026","Clinical journal of the American Society of Nephrology : CJASN","other","article","10.2215/cjn.0000001256","42821340",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000286","Interactions of Glucagon-Like Peptide-1 Receptor Agonists With GLP-1R-Gs Complex: Insights From Gaussian-Accelerated Molecular Dynamics.","Zhou X","2026","Proteins","other","article","10.1002/prot.70186","42823625",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000287","Receipt of glucagon-like peptide-1 receptor agonists among rural patients with obstructive sleep apnea and excess weight.","Leonhard AG","2026","Annals of the American Thoracic Society","nonrandomized_study","article","10.1093/annalsats/aaoag047","41776791","PMC13307129",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; research-article; article"],["R0000288","Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control.","Hemdev V","2026","Cureus","systematic_review","article","10.7759/cureus.109953","42382865","PMC13315952",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000289","Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes.","Žaliukaitė G","2026","Journal of clinical medicine","narrative_review","article","10.3390/jcm15082944","42074746","PMC13116968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000290","Effects of GLP-1 Receptor Agonists on Psoriasis: An \"Agent-Specific\" Systematic Review of the Literature.","Marani A","2026","Journal of clinical medicine","systematic_review","article","10.3390/jcm15135126","42452586","PMC13362826",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000291","Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists.","Kerr KW","2026","Childhood obesity (Print)","nonrandomized_study","article","10.1177/21532176261486979","42751742",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000292","From Glycemic Control to Gut Telescoping: Intussusception in a Patient on a Glucagon-Like Peptide-1 Receptor Agonist.","Thakkar B","2025","ACG case reports journal","case_report","article","10.14309/crj.0000000000001679","40291604","PMC12026376",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000294","Assessing Awareness, Confidence and Utilization of Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists Among Healthcare Clinicians and Pharmacists: A Comprehensive Survey Study.","Umbreit A","2026","Journal of primary care & community health","nonrandomized_study","article","10.1177/21501319261484772","42670579","PMC13530456",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0000295","Smell and Taste Disturbances Among Glucagon-Like Peptide-1 Receptor Agonist Users.","Zontag J","2026","JAMA otolaryngology-- head & neck surgery","nonrandomized_study","article","10.1001/jamaoto.2026.1498","42348217","PMC13306484",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0000296","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health: A Systematic Review of Psychiatric Safety and Antidepressant Potential.","Quadir A","2026","Cureus","systematic_review","article","10.7759/cureus.115703","42829595","PMC13633565",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000297","Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.","Alicic RZ","2025","Cardiology clinics","narrative_review","article","10.1016/j.ccl.2024.12.003","40582734",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000298","Glucagon-like peptide-1 receptor agonists across anti-inflammation.","Chen D","2026","Molecular aspects of medicine","narrative_review","article","10.1016/j.mam.2026.101474","41996973",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000299","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.","Chan TH","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70878","42150748","PMC13341386",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0000300","Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.","Haidar L","2026","Current opinion in HIV and AIDS","nonrandomized_study","article","10.1097/coh.0000000000001059","42467949",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0000301","Beyond metabolic control: the potential role of antidiabetic therapies in modulating male reproductive function and spermatogenesis.","Paternò V","2026","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-026-10090-1","42821207",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0000302","Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review.","West J","2025","Neurology and therapy","nonrandomized_study","article","10.1007/s40120-025-00724-y","40172827","PMC12255637",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0000303","Exploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review.","Baldwin K","2026","Journal of dual diagnosis","randomized_trial","article","10.1080/15504263.2026.2720402","42636272",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000304","GLP-1 receptor agonist targets an AMPKα1-HIF1α-PFKFB3 metabolic vulnerability and enhances Lenvatinib response in hepatocellular carcinoma.","Noma T","2026","NPJ precision oncology","other","article","10.1038/s41698-026-01584-x","42373728",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000305","Glucagon-like peptide-1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta-analysis.","Purcell AR","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70188","41334580","PMC12673429",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0000306","Glucagon-like peptide-1 receptor agonist-induced lipidome remodelling is associated with improved liver, kidney and inflammatory markers in type 2 diabetes","Lipska D","2026","medRxiv","randomized_trial","preprint","10.64898/2026.07.22.26358565",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0000307","Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework.","Kaczynski MM","2026","Biomedicines","randomized_trial","article","10.3390/biomedicines14091957","42792699","PMC13604614",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0000308","GLP-1 Receptor Agonists in the Male Aesthetic Practice: Opportunities for the Dermatologic Surgeon.","Badalian H","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","nonrandomized_study","article","10.1097/dss.0000000000005158","42210890",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0000309","Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Clinical evidence and insights.","Maideen NMP","2026","Indian journal of ophthalmology","randomized_trial","article","10.4103/ijo.ijo_2659_25","41817564","PMC13422913",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000310","Novel pharmacotherapies for opioid use disorder and opioid withdrawal.","Shen MR","2026","Frontiers in psychiatry","randomized_trial","article","10.3389/fpsyt.2026.1909149","42755825","PMC13581858",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000311","Glucagon-like peptide-1 receptor agonists and cognitive function: beyond the metabolic effects.","Polyzos SA","2026","Hormones (Athens, Greece)","other","article","10.1007/s42000-026-00827-7","42736531",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000312","Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes.","Lee JJ","2026","Ophthalmology. Retina","nonrandomized_study","article","10.1016/j.oret.2026.08.029","42692107",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000313","Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.","Sobral MVS","2026","Schizophrenia research","systematic_review","article","10.1016/j.schres.2026.06.025","42497473",null,"PROSPERO:CRD420251177261",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0000314","Exenatide Is Associated with Superior Gastrointestinal Motility Slowing Among GLP-1 Receptor Agonists","Murugadoss K","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202607.1605.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0000315","Current Challenges in Monitoring the Safety and Utilisation of the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A UK Perspective.","Davies M","2026","Drug safety","commentary","article","10.1007/s40264-026-01676-4","42086849",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0000316","Glucagon-like peptide-1 receptor agonists reduce experimental atherosclerosis progression, inflammatory biomarkers and cardiovascular events, irrespective of hyperglycaemia and obesity.","Kassab MB","2026","European heart journal","nonrandomized_study","article","10.1093/eurheartj/ehag060","41926331","PMC13384727",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000317","Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.","Fat MN","2026","Journal of drugs in dermatology : JDD","nonrandomized_study","article","10.36849/jdd.9448","41493256",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000318","Photodistributed exfoliative dermatitis associated with semaglutide: Expanding the spectrum of glucagon-like peptide-1 receptor agonist-associated cutaneous reactions.","Kann R","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.03.062","42183100","PMC13191260",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000319","Concurrent metformin-associated lactic acidosis and euglycemic diabetic ketoacidosis from tirzepatide starvation ketosis.","Epitropoulos F","2026","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-26-0025","42789768","PMC13640942",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0000320","Comparison of Cardiac Adverse Event Signal Profiles for GLP-1 Receptor Agonists: An Analysis of the FAERS Database","Yildirim BO","2026","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.177438465.59859376/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint; article"],["R0000321","The Therapeutic Opportunity of Glucagon-Like Peptide-1 Receptor Agonists in Pediatric Psychiatry.","McIntyre RS","2026","Journal of child and adolescent psychopharmacology","commentary","article","10.1177/10445463261484023","42702877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000322","Association Between Dermatologic Diseases and Glucagon-Like Peptide-1 Receptor Agonist Among Patients with Type 2 Diabetes","Chiang Y","2026","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.176821399.98169583/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0000323","Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy.","Bakheet M","2026","Cureus","case_report","article","10.7759/cureus.102472","41769577","PMC12947803",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000324","Clinical effects of glucagon-like peptide-1 receptor agonist in type 2 diabetes with low body mass index: findings from large-scale emulated target trials.","Tsai MH","2026","International journal of medical sciences","nonrandomized_study","article","10.7150/ijms.130295","42080079","PMC13133889",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000325","Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes.","Zhou R","2026","Journal of virology","preclinical","article","10.1128/jvi.00401-26","42423377","PMC13483299",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000326","Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis.","Elkin J","2025","Anaesthesia","systematic_review","article","10.1111/anae.16601","40230298","PMC12171790",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0000327","The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials.","Pilśniak J","2025","Life (Basel, Switzerland)","nonrandomized_study","article","10.3390/life15121893","41465832","PMC12735111",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000328","Glucagon-like peptide-1 receptor agonists and pulmonary aspiration. Comment on Br J Anaesth 2026; 137: 628-30.","Vlaeminck N","2026","British journal of anaesthesia","commentary","article","10.1016/j.bja.2026.07.075","42805889",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0000329","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Melanoma and Nonmelanoma Skin Cancer: A Propensity Score-Matched Cohort Study.","Bahar F","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71394","42802295",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000330","Perioperative Nutrition and Surgical Outcomes in Patients Receiving Glucagon-like Peptide-1 Receptor Agonists: A Scoping Review.","Sandha TS","2026","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina62081434","42654331","PMC13514910",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Scoping Review; review-article; article"],["R0000331","Prehospital glucagon-like peptide-1 receptor agonists are not associated with reduced inpatient opioid exposure but with shorter hospital length of stay after total joint arthroplasty.","Vaknin N","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1918370","42698481","PMC13541510",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000332","Reappraisal of GLP-1 receptor agonists in older adults.","Maltese G","2026","Trends in endocrinology and metabolism: TEM","other","article","10.1016/j.tem.2026.07.009","42567819",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000333","Preoperative Glucagon-like Peptide-1 Receptor Agonists and Postoperative Outcomes: An Observational Analysis.","Choi UE","2026","Anesthesiology","nonrandomized_study","article","10.1097/aln.0000000000006326","42585629",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000334","Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms.","Rajan LT","2026","European journal of endocrinology","randomized_trial","article","10.1093/ejendo/lvag135","42541759",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0000335","Glucagon-like peptide-1 receptor agonists for weight loss in end-stage heart failure patients considered for heart transplantation.","Jeyakumar S","2026","JHLT open","nonrandomized_study","article","10.1016/j.jhlto.2026.100559","42165084","PMC13186067",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0000336","Engineering Marker-Free Lettuce Chloroplast Genome to Express Functional Glucagon-Like Peptide-1 Receptor Agonists Exenatide and Lixisenatide.","Singh R","2026","Plant biotechnology journal","other","article","10.1111/pbi.70554","41578882","PMC13110178",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000337","The Ethics of Ozempic and Wegovy.","Ryan N","2026","Journal of medical ethics","other","article","10.1136/jme-2024-110374","39848681","PMC13018845",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000338","Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.","Abdelrahman RM","2025","Journal of obesity","other_trial","article","10.1155/jobe/9919810","41333115","PMC12668848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000339","Exploring actions of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond glucose and obesity control: bone health and osteoporosis.","Kasotas A","2026","Expert review of endocrinology & metabolism","commentary","article","10.1080/17446651.2026.2652305","41947390",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0000340","Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.","Dhivagaran T","2026","Neurology","systematic_review","article","10.1212/wnl.0000000000214864","42060879",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0000341","Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.","Ramadurgum P","2026","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2026.1917800","42582425","PMC13457703",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0000342","Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence.","Hallaj S","2026","Ophthalmology. Retina","nonrandomized_study","article","10.1016/j.oret.2026.05.016","42229850","PMC13629172",null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0000343","International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.","Mironova M","2026","Gut","other_trial","article","10.1136/gutjnl-2026-340031","42728029",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0000344","Integrating metabolic rehabilitation with incretin-based anti-obesity therapy: a narrative review of a multimodal strategy for sustainable weight loss.","Olumuyide E","2026","International journal of obesity (2005)","other_trial","article","10.1038/s41366-026-02143-x","42365122",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0000345","GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.","Bruna-Mejias A","2026","Nutrients","systematic_review","article","10.3390/nu18111781","42280424","PMC13259188","PROSPERO:CRD420261360837",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0000346","Symptom evaluation cannot exclude retained gastric content in patients taking glucagon-like peptide-1 receptor agonists.","Zavos C","2026","Anaesthesia","commentary","article","10.1111/anae.70409","42740460",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0000347","Glucagon-like Peptide-1 Receptor Agonists and Upper Gastrointestinal Endoscopy: A Narrative Review of Residual Gastric Contents Aspiration Risk and Periprocedural Management.","Bandaranaike R","2026","Euroasian journal of hepato-gastroenterology","randomized_trial","article","10.5005/jp-journals-10018-1502","42798680","PMC13612733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0000348","Glucagon-like peptide-1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study.","Hisada H","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70194","41069284","PMC12673464",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000349","Assessing the impact of pharmacist-led interventions on glucagon-like peptide 1 receptor agonist access and treatment outcomes.","Huddleston H","2026","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2026.32.6.651","42166307","PMC13193319",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000350","Advances in Cardiovascular Pharmacotherapy. X. Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure and Mechanisms of Protection.","Pagel PS","2026","Journal of cardiothoracic and vascular anesthesia","narrative_review","article","10.1053/j.jvca.2026.07.030","42580921",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000351","Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy.","Belančić A","2026","Journal of clinical medicine","narrative_review","article","10.3390/jcm15155870","42589975","PMC13466772",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000352","Incretin-Based Therapies: A Novel Pathway in Addiction Treatment.","Dawid R","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15041613","41753300","PMC12941627",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000353","Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know.","Bala S","2026","Survey of ophthalmology","randomized_trial","article","10.1016/j.survophthal.2025.12.007","41482136",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000354","GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease.","Gandhi A","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27062853","41898712","PMC13026677",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Preprint; review-article; preprint; article"],["R0000355","Trends in Glucagon-Like Peptide-1 Receptor Agonist Prescriptions in Heart Failure With Reduced Ejection Fraction.","Zingano CP","2026","JACC. Heart failure","other","article","10.1016/j.jchf.2026.103318","42758062",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000356","Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.","Ciconte G","2026","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","nonrandomized_study","article","10.1093/europace/euag018","41666150","PMC12910615",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000357","Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","Behers BJ","2026","Journal of cardiovascular development and disease","systematic_review","article","10.3390/jcdd13020103","41745350","PMC12942127",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000358","GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence.","Yu X","2026","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","systematic_review","article","10.1007/s00586-026-10293-9","42635669",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0000359","Symptom evaluation cannot exclude retained gastric content in patients taking glucagon-like peptide-1 receptor agonists: a reply.","Vlaeminck N","2026","Anaesthesia","nonrandomized_study","article","10.1111/anae.70413","42740688",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0000360","GLP-1 receptor agonists-a potential therapy for chronic kidney disease?","Boeckhaus J","2026","Clinical science (London, England : 1979)","narrative_review","article","10.1042/cs20261312","42820470","PMC13642989",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000361","Association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and neurogenesis: a systematic review.","Au HCT","2025","Acta neuropsychiatrica","systematic_review","article","10.1017/neu.2025.4","39950609","PMC13130299",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0000362","GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.","Al-Ali D","2026","Experimental gerontology","randomized_trial","article","10.1016/j.exger.2026.113325","42735804",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0000363","Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists.","Melnikov I","2026","Cells","other_trial","article","10.3390/cells15171578","42738873","PMC13565109",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000364","Glucagon-like peptide-1 receptor agonists and new-onset atrial fibrillation in adults with diabetes or obesity: a multinational cohort study.","Weng CH","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113454","42480717",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; article"],["R0000365","The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations.","Lampsas S","2026","Biomedicines","randomized_trial","article","10.3390/biomedicines14051057","42193383","PMC13204196",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000366","Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial.","Lau LCM","2026","Bone & joint open","protocol","article","10.1302/2633-1462.77.bjo-2025-0359.r1","42402343","PMC13333214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0000367","Lumbar Discectomy Outcomes and Preoperative Glucagon-like Peptide-1 Receptor Agonist Exposure: A Retrospective, Comparative Cohort Study.","Wang JE","2026","HSS journal : the musculoskeletal journal of Hospital for Special Surgery","nonrandomized_study","article","10.1177/15563316261455872","42261452","PMC13242363",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000368","Glucagon-like peptide-1 receptor agonists and bowel preparation: methodological and clinical considerations for meta-analysis.","Yang N","2026","Gastrointestinal endoscopy","systematic_review","article","10.1016/j.gie.2026.03.005","42601135",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; article"],["R0000369","Glucagon-Like Peptide-1 Receptor Agonists Therapy: The Biological Bridge Across Comorbidities in Behavioral Health.","Haass-Koffler CL","2026","Rhode Island medical journal (2013)","other","article",null,"42647832",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000370","Direct Coronary Vascular and Lipidomic Remodeling by Low-Dose GLP-1 Agonist Therapy in Cardiometabolic HFpEF.","Lefer D","2026","Research square","preclinical","article","10.21203/rs.3.rs-10630296/v1","42845643","PMC13640906",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; preprint"],["R0000371","Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists.","Lixi F","2026","Vision (Basel, Switzerland)","narrative_review","article","10.3390/vision10020029","42201157","PMC13214628",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000372","Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma.","Chen H","2026","Neurosurgery","randomized_trial","article","10.1227/neu.0000000000004193","42599090",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0000373","Glucagon-like peptide-1 receptor agonist-based regimens compared with metformin-based regimens for preventing cardiovascular disease in adults with type 2 diabetes mellitus.","Ahmed S","2026","The Cochrane database of systematic reviews","narrative_review","article","10.1002/14651858.cd016380","42573030","PMC13455057",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; systematic-review; article"],["R0000374","Sodium homeostatic reserve in people with epilepsy receiving glucagon-like peptide-1 receptor agonists.","Cotrik E","2026","Seizure","commentary","article","10.1016/j.seizure.2026.08.022","42722577",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0000375","A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.","Amirthalingam P","2026","Current drug safety","other","article","10.2174/0115748863367086250420011411","40337971",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000376","Do glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysis.","Alves MLM","2026","North American Spine Society journal","systematic_review","article","10.1016/j.xnsj.2026.100938","42740823","PMC13572007",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000377","Trends in glucagon-like peptide 1 receptor agonist prescribing patterns.","Ukhanova M","2025","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2025.89778","40829097",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0000378","Cardiovascular Risk Reduction With GLP-1 RA Drugs.","Pigeyre M","2026","Circulation","randomized_trial","article","10.1161/circulationaha.126.079319","42406865",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000379","Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk.","Kafol J","2026","Cells","narrative_review","article","10.3390/cells15141293","42505402","PMC13406431",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000380","Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study.","Basri T","2026","Mayo Clinic proceedings","nonrandomized_study","article","10.1016/j.mayocp.2026.07.014","42486225",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000381","Where the future lies: GLP-1 receptor agonists as therapeutics for dermatologic comorbidities.","DeCoster M","2026","Clinics in dermatology","nonrandomized_study","article","10.1016/j.clindermatol.2026.08.013","42685919",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000382","Semaglutide promotes intramuscular fat formation after injury","Noble C","2026","bioRxiv","other","preprint","10.64898/2026.06.16.732451",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0000383","Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.","Old V","2026","Journal of cachexia, sarcopenia and muscle","other","article","10.1002/jcsm.70254","41852165","PMC13140976",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000384","Beyond Weight Loss: Association Between Glucagon-like peptide-1 Receptor Agonist Therapy and Incidence of Facial and Oculoplastic Procedures.","Lishinsky-Fischer N","2026","Plastic and reconstructive surgery","nonrandomized_study","article","10.1097/prs.0000000000013108","41945654",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000385","Musculoskeletal Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults.","Wu JS","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70218","42225263","PMC13535762",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000386","Glucagon-like Peptide-1 Receptor Agonists and Chronic Pain: Preclinical Antinociceptive Mechanisms, Indirect Metabolic-Functional Effects, and Clinical Considerations-A Narrative Review.","Hyung SW","2026","Journal of clinical medicine","narrative_review","article","10.3390/jcm15155932","42590035","PMC13466897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0000387","Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis.","Jorge A","2026","Arthritis & rheumatology (Hoboken, N.J.)","nonrandomized_study","article","10.1002/art.43403","40994310","PMC13501418",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0000388","GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles.","Li Y","2026","Pharmacological research","systematic_review","article","10.1016/j.phrs.2026.108333","42401410",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0000389","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Allergic Inflammation and Asthma: A Mechanistic Review.","Alvarez-Perea A","2026","Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","narrative_review","article","10.1111/cea.70442","42806728",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000390","Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.","Weng J","2025","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-025-09344-w","40830314",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000391","Prevention of Vascular Aging as a Novel Paradigm for GLP-1 Receptor Agonist-Mediated Cardioprotection.","Dennis CJ","2026","Circulation research","narrative_review","article","10.1161/circresaha.126.327425","42461988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000392","Targeting the Metabolic-Inflammatory Axis in Psoriasis and Psoriatic Arthritis: Evidence From Diet, Glucagon-like Peptide-1 Receptor Agonists, and Patient Perspectives.","Marchionni G","2026","The Journal of rheumatology","narrative_review","article","10.3899/jrheum.2026-0589","42414047",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000393","Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials.","Joy B","2026","Endocrine","systematic_review","article","10.1007/s12020-025-04494-3","41489846",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Meta-Analysis; review"],["R0000394","A Novel Approach to Managing \"Double Diabetes\" in a Pediatric Patient on Insulin Pump Therapy: An Off-Label Use of a Fixed-Ratio Insulin Degludec/Liraglutide Combination.","Almoallem B","2026","Cureus","case_report","article","10.7759/cureus.114782","42761866","PMC13587759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000395","Glucagon-Like Peptide 1 Receptor Agonists and Early Colorectal Neoplasia: A Colonoscopy-Anchored Target Trial Emulation","Kwan AT","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9727823/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0000396","Effects of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Endometriosis Symptoms Management and Quality of Life: An International Survey Study","Gholiof M","2026","Authorea Preprints","other","preprint","10.22541/au.177194722.27223197/v1",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0000397","Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis.","Basile C","2026","European journal of preventive cardiology","systematic_review","article","10.1093/eurjpc/zwaf560","40899050",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; other; review"],["R0000398","Association of GLP-1RA discontinuation and risk of depressive and anxiety disorders in people with type 2 diabetes: a cohort study.","Zhang T","2026","Nature metabolism","nonrandomized_study","article","10.1038/s42255-026-01567-z","42426287",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000399","Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder: A Narrative Review of Available Clinical Evidence.","Klausen MK","2026","Biological psychiatry","randomized_trial","article","10.1016/j.biopsych.2026.07.010","42486217",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; review"],["R0000400","Glucagon-Like Peptide-1 Receptor Agonists: Considerations for Treating Preconception Obesity.","Berube LT","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70210","42083106","PMC13535735",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; other; article"],["R0000401","Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease.","Weng J","2026","Gastroenterology research","nonrandomized_study","article","10.14740/gr2136","42325216","PMC13278702",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000402","Association of Peri-procedural Glucagon-Like Peptide-1 Receptor Agonist Exposure with Long-Term Outcomes After Carotid Artery Revascularization Procedures: A Propensity Score-Matched Analysis.","Rai P","2026","AJNR. American journal of neuroradiology","nonrandomized_study","article","10.3174/ajnr.a9592","42595461",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000403","Association of glucagon-like peptide-1 receptor agonists with risk of gastrointestinal adverse events: evidence from a drug target Mendelian randomization.","Huang H","2026","European heart journal. Cardiovascular pharmacotherapy","narrative_review","article","10.1093/ehjcvp/pvaf065","40874865","PMC12862966",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0000404","Glucagon-Like Peptide-1 Receptor Agonist and Hyponatremia: A Potential Association.","Yeo YH","2026","JACC. Case reports","case_report","article","10.1016/j.jaccas.2026.108258","42149072","PMC13326193",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000405","Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.","Khatami S","2026","Cardiovascular toxicology","systematic_review","article","10.1007/s12012-026-10119-6","42455418","PMC13372915",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0000406","Highlights from JAAD Reviews: Skin in the Game: Dermatologic and Medicolegal Aspects of Glucagon-Like Peptide-1 Receptor Agonists.","Lipner SR","2026","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2026.08.072","42637047",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000407","Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study.","Pan SY","2026","Ophthalmology science","nonrandomized_study","article","10.1016/j.xops.2026.101245","42383218","PMC13314882",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000408","Standardising gastric ultrasound planes in patients receiving glucagon-like peptide-1 receptor agonists.","Zhong X","2026","Anaesthesia","commentary","article","10.1111/anae.70324","42604762",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0000409","Central nervous system effects of GLP-1 receptor agonists: A systematic review of human neuroimaging studies.","Brucar LR","2026","Neuroscience and biobehavioral reviews","systematic_review","article","10.1016/j.neubiorev.2026.106990","42762879",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Review; review"],["R0000410","Reframing obesity-related HFpEF as a multiorgan syndrome: incretin-based therapies and imaging endpoints.","Mahmod M","2026","Heart failure reviews","narrative_review","article","10.1007/s10741-026-10629-z","41968220","PMC13070973",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000411","Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review.","Bawadi H","2026","Endocrinology, diabetes & metabolism","randomized_trial","article","10.1002/edm2.70338","42747132","PMC13580159",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; Comparative Study; review-article; review"],["R0000412","Do Patients on Glucagon-Like Peptide-1 Receptor Agonists Require Longer Fasting Before Vibration Controlled Transient Elastography?","Sandhu S","2026","The American journal of gastroenterology","other","article","10.14309/ajg.0000000000004191","42678758",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000413","Visual and Neurological Outcomes Following Glucagon-Like Peptide-1 Receptor Agonist Therapy and Bariatric Surgery in Idiopathic Intracranial Hypertension: A Network Meta-Analysis.","Phutinart S","2026","Metabolic syndrome and related disorders","systematic_review","article","10.1177/15578518261442833","41973746",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Review; article"],["R0000414","Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis-Related Diabetes.","Ephraums LA","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71312","42712101",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0000415","GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.","Sajjad M","2026","Multiple sclerosis and related disorders","systematic_review","article","10.1016/j.msard.2026.107388","42470876",null,"PROSPERO:CRD420261385854",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0000416","Glucagon-like-peptide-1 receptor agonists in the intensive care unit: practical implications for the intensivists.","Bianchini L","2026","Critical care science","commentary","article","10.62675/2965-2774.20260166","42615745","PMC13518016",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0000417","Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications.","Awadalla L","2026","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2025-0248","42013575",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000418","Reply to Comment on: \"Glucagon-like peptide-1 receptor agonists and risk of systemic and ocular vascular complications in patients with type 2 diabetes and diabetic retinopathy\".","Ramsey DJ","2026","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2026.08.025","42636995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0000419","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases.","Ho MJ","2026","Expert review of clinical immunology","narrative_review","article","10.1080/1744666x.2026.2665732","42043978",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000420","GLP-1 Receptor Agonists in Diabetic Lower Extremity Peripheral Artery Disease: From Mechanisms to Clinical Practice.","Pan J","2026","British journal of hospital medicine (London, England : 2005)","nonrandomized_study","article","10.31083/bjhm55884","42812078",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0000421","Exendin-4 as a multi-target therapy for Fetal Inflammatory Response Syndrome-induced brain injury.","Li S","2026","Frontiers in neurology","narrative_review","article","10.3389/fneur.2026.1848474","42661740","PMC13518335",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000422","Glucagon-like peptide-1 receptor agonists in pediatrics: The pancreatology perspective.","Bass R","2026","Journal of pediatric gastroenterology and nutrition","other","article","10.1002/jpn3.70512","42535519",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000423","Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.","Cheng PL","2026","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2026.113333","42155605",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0000424","GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective review.","Said J","2026","Journal of pediatric endocrinology & metabolism : JPEM","nonrandomized_study","article","10.1515/jpem-2026-0227","42732089",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000425","Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patients.","Hwang SY","2026","European journal of gastroenterology & hepatology","nonrandomized_study","article","10.1097/meg.0000000000003162","41784422",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000426","Glucagon-Like Peptide-1 Receptor Agonist Use Does Not Impact Spine Surgery Outcomes: A Systematic Review and Meta-Analysis.","Ibrahim S","2026","Global spine journal","systematic_review","article","10.1177/21925682251415347","41483457","PMC12764418","PROSPERO:CRD420251061447",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000427","GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.","Soliman AT","2026","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2026.113400","42365860",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Review; review"],["R0000428","Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.","Pedagogos E","2026","Internal medicine journal","other_trial","article","10.1111/imj.70647","42813318",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0000429","Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: Balancing reassurance and vigilance.","Li J","2026","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","commentary","article","10.1016/j.pan.2026.08.009","42586878",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000430","Evolving incretin-based therapies in Japan: optimizing treatment strategies for diverse clinical and socioeconomical profiles in type 2 diabetes.","Seno Y","2025","Diabetology international","nonrandomized_study","article","10.1007/s13340-025-00818-w","40607140","PMC12209093",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000431","Liver benefits of early initiation of low-dose GLP-1 receptor agonists in newly diagnosed type 2 diabetes - A case report.","Lee JY","2026","Journal of family medicine and primary care","case_report","article","10.4103/jfmpc.jfmpc_1596_25","42023337","PMC13098808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000432","Orforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects.","Li Y","2026","Cells","preclinical","article","10.3390/cells15141301","42505410","PMC13406627",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000433","Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study.","Hung CT","2026","Journal of asthma and allergy","randomized_trial","article","10.2147/jaa.s637738","42730051","PMC13565390",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000434","The GLP-1 Nutritional Paradox: A Structured Review with Novel Quantitative Frameworks for Sarcopenic Risk and Micronutrient Adequacy in GLP-1 Receptor Agonist Pharmacotherapy","Hungund S","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-10929531/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0000435","GLP-1 Receptor Agonists: Clinical Considerations and Risk Management for Patients Undergoing Ophthalmic Surgery.","Baumal CR","2026","Ophthalmic surgery, lasers & imaging retina","narrative_review","article","10.3928/23258160-20260310-01","41891915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000436","Nutritional Care for Adults With Obesity Treated With Glucagon-Like Peptide (GLP)-1 and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications.","McGuane C","2026","Cureus","randomized_trial","article","10.7759/cureus.109731","42367464","PMC13307047",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; article"],["R0000437","Evaluating the Impact of Glucagon-Like Peptide-1 Receptor Agonist Receptor Agonists on Postoperative Pain Management in Patients Undergoing Cancer Surgery: A Retrospective Study.","Pennycuff JE","2026","Anesthesia and analgesia","nonrandomized_study","article","10.1213/ane.0000000000007967","41698178",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000438","Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions.","He WT","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1889594","42683151","PMC13531409",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000439","Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying.","Friedman MI","2026","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.70255","42392577","PMC13422674","ClinicalTrials.gov:NCT02647944","S001045","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; brief-report; article"],["R0000440","Associations Between Glucagon-like Peptide-1 Receptor Agonists and Respiratory Outcomes in Chronic Obstructive pulmonary disease and Diabetes.","Liao KM","2026","QJM : monthly journal of the Association of Physicians","nonrandomized_study","article","10.1093/qjmed/hcag217","42606949",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000441","Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.","Pillai AA","2025","Cardiology in review","other_trial","article","10.1097/crd.0000000000001139","41398455",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0000442","Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.","Khalil W","2026","Cureus","systematic_review","article","10.7759/cureus.110952","42465136","PMC13374084",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000443","Use of Glucagon-Like Peptide-1 Receptor Agonists Across the Liver Transplant Continuum.","Lichtenstein GR","2026","Gastroenterology & hepatology","commentary","article",null,"42713392","PMC13552393",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0000444","Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis.","Uysal N","2026","Scientific reports","systematic_review","article","10.1038/s41598-026-61582-8","42420519",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; review"],["R0000445","Institutional survey of gastric ultrasound usage in patients receiving glucagon-like peptide-1 receptor agonists.","Michell E","2026","Anaesthesia","commentary","article","10.1111/anae.70220","42093223","PMC13446823",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0000446","Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study.","Brouer IC","2026","Frontiers in medicine","nonrandomized_study","article","10.3389/fmed.2026.1909537","42741157","PMC13572214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000447","Could Patients Using Glucagon-like Peptide-1 Receptor Agonists Be Experiencing Less Postoperative Pain?","Hobai IA","2026","Anesthesia and analgesia","other","article","10.1213/ane.0000000000008227","42575485",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000448","Combination treatment for the management of chronic kidney disease and type 2 diabetes: a review and practical guidance.","Mohsen M","2026","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgag163","41973867","PMC13271800",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; article"],["R0000449","Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes.","Neumiller JJ","2026","American journal of kidney diseases : the official journal of the National Kidney Foundation","randomized_trial","article","10.1053/j.ajkd.2026.04.007","42302979",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Observational Study; Comparative Study; article"],["R0000450","Patients on Long-Term Preoperative Glucagon-Like Peptide-1 Receptor Agonist Therapy Show Significant Reductions in Postoperative Complications After Elective Laminectomy in Overweight Adults: A Propensity-Matched Study.","Wahid M","2026","International journal of spine surgery","nonrandomized_study","article","10.14444/8856","41672939","PMC13153957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000451","Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts.","Dennard E","2026","JMIR infodemiology","other","article","10.2196/89732","42099097","PMC13153451",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000452","Esophageal high-resolution manometry can be safely and effectively performed with concurrent glucagon-like peptide-1 receptor agonist use.","Gala K","2025","Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus","nonrandomized_study","article","10.1093/dote/doaf109","41343723",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000453","Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.","Vilsbøll T","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70291","41287564","PMC12803555",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000454","New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.","Panou T","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-026-01921-0","42803913",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0000455","Role of glucagon-like peptide-1 receptor agonists in pediatric obesity and metabolic dysfunction associated steatotic liver disease.","Rehman R","2025","World journal of clinical pediatrics","narrative_review","article","10.5409/wjcp.v14.i3.105731","40881096","PMC12305094",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000456","Glucagon-like peptide-1 receptor agonists in neoplastic diseases.","Ji L","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1465881","39371922","PMC11449759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000457","The effects of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior.","Rutigliani G","2026","Physiology & behavior","nonrandomized_study","article","10.1016/j.physbeh.2026.115486","42641845",null,"ClinicalTrials.gov:NCT07611201","S002684","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0000458","Are Pediatric GLP-1 Receptor Agonist Cutaneous Adverse Events Being Overlooked? Emerging Age-Specific Patterns and Their Implications for Dermatologists.","Cote MF","2026","Pediatric dermatology","narrative_review","article","10.1111/pde.70340","42661567",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000459","Annals Video Summary - Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes.",null,"2026","Annals of internal medicine","other","article","10.7326/annals-26-03114-vs","42673591",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000460","Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes.","Liao KM","2026","Nature communications","nonrandomized_study","article","10.1038/s41467-026-77068-0","42768061","PMC13594082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; research-article; article"],["R0000461","Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.","DeParis SW","2026","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2026.04.008","42132708",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Consensus Statement; Journal Article; article"],["R0000462","Glucagon-like peptide-1 receptor agonists for heart failure with reduced ejection fraction: Is it the next step?","Biegus J","2026","ESC heart failure","commentary","article","10.1093/eschf/xvag131","42095270","PMC13187925",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0000463","Glucagon-Like Peptide-1 Receptor Agonists and Aortic Stenosis: An Emerging Cardiometabolic Opportunity.","Boulet J","2026","The Canadian journal of cardiology","commentary","article","10.1016/j.cjca.2026.07.369","42508686",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000464","Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.","Lee HM","2026","International journal of obesity (2005)","preclinical","article","10.1038/s41366-026-02161-9","42457940",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000465","The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity.","Koyanagi Y","2026","Hypertension research : official journal of the Japanese Society of Hypertension","preclinical","article","10.1038/s41440-026-02633-5","41963534","PMC13236593",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000466","Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.","Marshall LZ","2026","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2026.32.3.281","41760566","PMC12948759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000467","Glucagon-Like Peptide-1 Receptor Agonists Use Among Reproductive-Aged Women with Type 2 Diabetes.","Bailey SC","2026","Journal of women's health (2002)","other_trial","article","10.1177/15409996261478007","42576647",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0000468","Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types.","Ungvari Z","2025","GeroScience","nonrandomized_study","article","10.1007/s11357-024-01494-5","39777709","PMC12181560",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0000469","GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.","Chikatimalla R","2026","Annals of medicine","other_trial","article","10.1080/07853890.2026.2660386","41999297","PMC13094292",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0000470","Impact of glucagon-like-peptide-1 receptor agonist therapy on pulmonary function in people with cystic fibrosis who achieve normal body mass index.","Horvit A","2026","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","nonrandomized_study","article","10.1016/j.jcf.2025.10.006","41109836",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000471","The emerging implications of GLP-1 receptor agonists in radiation therapy.","Reinicke T","2026","The oncologist","narrative_review","article","10.1093/oncolo/oyag073","41776829","PMC13000109",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article-commentary; article"],["R0000472","Real world, retrospective experience of glucagon-like peptide-1 receptor agonists in kidney transplant recipients: A single-center case series.","Singh P","2026","Clinical nephrology","randomized_trial","article","10.5414/cn111893","41841288",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0000473","Glucagon-Like Peptide-1 Receptor Agonists, Readmission, and Postoperative Complications in Arthroplasty: A Systematic Review and Meta-Analysis.","Chan YC","2026","The Journal of arthroplasty","systematic_review","article","10.1016/j.arth.2025.11.036","41276236",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0000474","Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus: a nationwide propensity-score matched study.","Wu HL","2026","British journal of anaesthesia","nonrandomized_study","article","10.1016/j.bja.2025.08.003","40940281","PMC12851884",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000475","Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists.","Chen KE","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70975","42259622","PMC13341374",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000476","Glucagon-like peptide-1 receptor agonists and risk of diabetic retinopathy in type 2 diabetes: A systematic review and network meta-analysis of randomized clinical trials.","Ortiz-Seller A","2026","Survey of ophthalmology","systematic_review","article","10.1016/j.survophthal.2026.08.007","42612754",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Review; review"],["R0000477","GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.","Dhupati P","2026","Annals of plastic surgery","case_report","article","10.1097/sap.0000000000004570","41417708",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0000478","The glucagon-like peptide-1 receptor agonist, Ex4, reduces intromission in sexually experienced male mice.","Shevchouk O","2026","Psychoneuroendocrinology","preclinical","article","10.1016/j.psyneuen.2026.107893","42166808",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000479","Rapid uptake of glucagon-like peptide-1 receptor agonists among adults with obstructive sleep apnea.","Lin A","2026","Sleep","other","article","10.1093/sleep/zsag147","42189915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000480","Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction.","Kassab J","2026","ESC heart failure","randomized_trial","article","10.1093/eschf/xvag111","41991158","PMC13220942",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; brief-report; article"],["R0000481","Comment on: \"Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy\".","Wang J","2026","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2026.07.063","42632508",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0000482","Glucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study.","Divya A","2026","ASAIO journal (American Society for Artificial Internal Organs : 1992)","nonrandomized_study","article","10.1097/mat.0000000000002804","42497207",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000483","Glucagon-like peptide-1 receptor agonists for primary cardiovascular disease prevention in type 2 diabetes, a systematic review.","Grenet G","2026","BMJ open diabetes research & care","systematic_review","article","10.1136/bmjdrc-2026-006225","42618306","PMC13504861",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; review"],["R0000484","Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia.","Kang D","2026","The Korean journal of internal medicine","narrative_review","article","10.3904/kjim.2025.277","42128379","PMC13172807",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000485","Semaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and Mechanisms","Barseghyan L","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202609.0561.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0000486","Novel Compounds as Glucagon-Like Peptide‑1 Receptor Agonists for Treating Diabetes.","Sabnis RW","2026","ACS medicinal chemistry letters","commentary","article","10.1021/acsmedchemlett.6c00025","41704387","PMC12907960",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0000487","GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes.","Gregory JM","2026","Endocrinology and metabolism clinics of North America","randomized_trial","article","10.1016/j.ecl.2026.04.010","42526996",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000488","Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.","Lim M","2026","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.70169","41936548",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Systematic Review; Network Meta-Analysis; Journal Article; Review; review"],["R0000489","Benefits of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide-1 receptor agonists in older patients with type 2 diabetes.","Mortada I","2026","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/14791641261495569","42808164",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0000490","The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.","Madsbad S","2025","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2025.2472408","40022548",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0000491","Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.","Repetti GG","2026","Circulation research","narrative_review","article","10.1161/circresaha.126.328680","42241516","PMC13339430",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0000492","Decoding the hallmarks of GLP-1RA weight-loss super responders","Venkatakrishnan A","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.11.15.25340314",null,null,null,null,"europepmc","FALSE","free_to_read","4",null,"Preprint"],["R0000493","Re: Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Thyroid Eye Disease.","Nitzan I","2026","Ophthalmic plastic and reconstructive surgery","commentary","article","10.1097/iop.0000000000003248","42475244",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; letter"],["R0000494","The Influence of Glucagon-like Peptide-1 Receptor Agonists on Outcomes Following Trigger Finger Release.","Dameron LS","2026","Journal of hand surgery global online","nonrandomized_study","article","10.1016/j.jhsg.2025.100923","41657744","PMC12878631",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000495","Effects of Incretin-Based Therapies on Testosterone Levels and Incretin Response in Men with Hypogonadism: A Systematic Literature Review Following PRISMA 2020 Guidelines.","La Vignera S","2026","Pharmaceuticals (Basel, Switzerland)","randomized_trial","article","10.3390/ph19081321","42653816","PMC13516258",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0000496","Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis.","Raza H","2026","Brain and behavior","systematic_review","article","10.1002/brb3.71344","41880197","PMC13109035",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0000497","Summary for Patients: An Updated Systematic Review on Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes.",null,"2026","Annals of internal medicine","systematic_review","article","10.7326/annals-25-05519-ps","42673597",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0000498","Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.","Bu F","2026","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2026.02.5123","41984016","PMC13191718",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; Multicenter Study; research-article; Preprint; article; preprint"],["R0000499","Glucagon like peptide-1 receptor agonist (Ozempic): Revolutionising chronic kidney disease management in diabetes.","Nazar QUA","2026","JPMA. The Journal of the Pakistan Medical Association","other_trial","article","10.47391/jpma.30655","42160574",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0000500","Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia.","Prokopidis K","2026","Advances in therapy","randomized_trial","article","10.1007/s12325-026-03750-w","42631799",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0000501","Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.","Son JW","2026","Endocrine reviews","narrative_review","article","10.1210/endrev/bnaf036","41054801",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000502","Reply.","Jorge A","2026","Arthritis & rheumatology (Hoboken, N.J.)","commentary","article","10.1002/art.70298","42598740","PMC13552633",null,null,"europepmc","FALSE",null,null,null,"Letter; article-commentary"],["R0000503","Use of semaglutide and tirzepatide among people with multiple sclerosis.","Salter A","2026","Multiple sclerosis (Houndmills, Basingstoke, England)","nonrandomized_study","article","10.1177/13524585261442033","42053291",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000504","GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes.","Amorim Moreira Alves G","2026","Chronic diseases and translational medicine","randomized_trial","article","10.1002/cdt3.70048","42254823","PMC13238930",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000505","A Case of GLP-1 Receptor Agonist-Induced Lithium Neurotoxicity.","Kotta A","2026","Journal of psychiatric practice","case_report","article","10.1097/pra.0000000000000921","42095722",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0000506","Tirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study.","Sawamura T","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.06.008","42379268",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000507","A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists.","Virk A","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15062464","41899386","PMC13027927",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000508","Glucagon-like Peptide-1 Receptor Agonists Are Not Associated with Increased Risk of Acute Pancreatitis or Pancreatic Complications, Including Pancreatic Cancer, in Type 2 Diabetes: A Global Propensity-Matched Cohort Study.","Sun Y","2026","Journal of personalized medicine","nonrandomized_study","article","10.3390/jpm16090478","42783509","PMC13608214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000509","Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Disease: Redefining Therapy Through Cardiometabolic Substrate Modification.","Ramadan A","2026","Cardiology in review","randomized_trial","article","10.1097/crd.0000000000001322","42307757",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0000510","Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.","Lempesis IG","2026","Metabolism open","narrative_review","article","10.1016/j.metop.2026.100463","41948476","PMC13051938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000511","Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review.","Barone M","2026","Aesthetic plastic surgery","systematic_review","article","10.1007/s00266-026-05820-4","42162206",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0000512","Increased Allergy Susceptibility Associated with Semaglutide, a Glucagon-like Peptide-1 Receptor Agonist.","Tashiro A","2026","Journal of emergencies, trauma, and shock","commentary","article","10.4103/jets.jets_188_25","42852130","PMC13649209",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0000513","Glucagon Like Peptide -1 Receptor Agonists for Weight Loss: A Primary Care Perspective.","Mohr K","2024","Missouri medicine","narrative_review","article",null,"39697577","PMC11651266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0000514","Signal thresholds and causal inference in pharmacovigilance studies of glucagon-like Peptide-1 receptor agonists.","Li L","2026","Clinical nutrition (Edinburgh, Scotland)","nonrandomized_study","article","10.1016/j.clnu.2026.106731","42520369",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0000515","How Negative Controls Are Used in Pharmacoepidemiology: A Methodological Scoping Review of Real-World Observational Studies of Glucagon-Like Peptide-1 Receptor Agonists.","Li Z","2026","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.70420","42432825","PMC13354716",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; review-article; article"],["R0000516","Periorbital Changes Following Glucagon-Like Peptide-1 Receptor Agonist Use: A Retrospective Cohort Study of Oculofacial Complications and Interventions.","Saffari PS","2026","Ophthalmic plastic and reconstructive surgery","nonrandomized_study","article","10.1097/iop.0000000000003129","41251628","PMC12743635",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000517","Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice.","Bridges AG","2026","Clinics in dermatology","nonrandomized_study","article","10.1016/j.clindermatol.2026.09.017","42767469",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000518","Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map.","Jensterle M","2026","Drugs","narrative_review","article","10.1007/s40265-026-02325-x","42106472",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0000519","Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study.","Takiyama T","2026","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2026.109391","42618422",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0000520","Novel GLP-1RA-like effects of Bafetinib: a preliminary study integrated in vitro screening and in vivo validation.","Zheng X","2026","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2026.117866","42128231",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000521","GLP-1 receptor agonists in dermatology: Prescribing frameworks, access, and the emerging pipeline.","Bridges AG","2026","Clinics in dermatology","nonrandomized_study","article","10.1016/j.clindermatol.2026.09.018","42777891",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000522","Perioperative Management of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter 2 Inhibitors.","Lozada GA","2026","Anesthesiology clinics","narrative_review","article","10.1016/j.anclin.2026.02.002","42069389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000523","The potential role for GLP-1 receptor agonists in cancer survivorship: a narrative review.","Hatzis G","2026","Postgraduate medical journal","randomized_trial","article","10.1093/postmj/qgag044","42059880",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; review"],["R0000524","Tirzepatide (Mounjaro): Indication: For once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus: Reimbursement Recommendation",null,"2026","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","randomized_trial","article",null,"42771745",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0000525","Body Composition Considerations in Glucagon-Like Peptide-1 Receptor Agonists Treatment.","Zydel DS","2026","Mayo Clinic proceedings","other","article","10.1016/j.mayocp.2026.07.002","42425305",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000526","Glucagon-Like Peptide-1 Receptor Agonists Are Not Associated With Increased Pulmonary Aspiration During Endoscopy and Colonoscopy.","Yang JY","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2026.07.010","42486393",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000527","M4 drug discovery: Human drug predictions from integrated preclinical insights exemplified with a GLP-1R agonist.","Silfvergren O","2026","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","nonrandomized_study","article","10.1016/j.ejps.2026.107648","42669385",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000528","Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes.","Ahmad O","2026","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2025.134042","41297711",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000529","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis.","Hattler E","2026","Obstetrics and gynecology","systematic_review","article","10.1097/aog.0000000000006363","42391628","PMC13489104",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; article"],["R0000530","Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes.","Xu Y","2026","Nature medicine","nonrandomized_study","article","10.1038/s41591-026-04274-0","41857198","PMC13190255",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000531","Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study.","Kapan A","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1864209","42388883","PMC13318717",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000532","Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.","Morse BL","2026","Clinical pharmacology and therapeutics","other_trial","article","10.1002/cpt.70377","42399716","PMC13337131",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0000533","[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?].","Himmerich H","2025","Der Nervenarzt","narrative_review","article","10.1007/s00115-025-01813-x","40042613","PMC12058874",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Review; review-article; article"],["R0000534","Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in dialysis patients with type 2 diabetes: a real-world propensity score-matched study.","Chen JJ","2026","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfag188","42436945","PMC13355531",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000535","Real-World and Randomized Controlled Trial Evidence Converge: Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Safety.","Wang T","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.1016/j.eprac.2026.07.001","42413660",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0000536","Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials.","Moubarak ES","2026","Journal of psychopharmacology (Oxford, England)","systematic_review","article","10.1177/02698811261478625","42746999",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0000537","Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms.","Fernando S","2026","Frontiers in gastroenterology (Lausanne, Switzerland)","narrative_review","article","10.3389/fgstr.2026.1864456","42699172","PMC13542812",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000538","Is There a Better Day of the Week to Administer Semaglutide or Tirzepatide? A Systematic Literature Review.","La Vignera S","2026","Medicina (Kaunas, Lithuania)","systematic_review","article","10.3390/medicina62081536","42654433","PMC13515371",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; Review; review"],["R0000539","Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China.","Fu W","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16581","40613325",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0000540","Relationship Between GLP-1-Based Therapies and Periodontal Health: A Systematic Review of Current Evidence and Future Perspectives.","Nijakowski K","2026","International journal of molecular sciences","systematic_review","article","10.3390/ijms27146447","42511792","PMC13411477",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0000541","Role of glucagon-like peptide-1 receptor agonists in type 2 diabetes-associated atherosclerosis: from vascular mechanism to omics-based biomarkers and imaging.","Al-Taweel R","2026","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2026.1813873","42222104","PMC13215906",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000542","Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study.","Sheashaa H","2026","Transplantation direct","nonrandomized_study","article","10.1097/txd.0000000000001932","41884702","PMC13012210",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000543","Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis.","Ahmed M","2026","European heart journal. Quality of care & clinical outcomes","systematic_review","article","10.1093/ehjqcco/qcag079","42142362",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0000544","Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes.","Alsayed O","2026","Cureus","systematic_review","article","10.7759/cureus.113777","42677221","PMC13528408",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000545","Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials.","de Paulo RS","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70779","42037117","PMC13244000","PROSPERO:CRD420251181076",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0000546","Incretin-Based Therapy in Patients with Malignancy and Obesity or Type 2 Diabetes. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF), and Italian Society of Obesity (SIO) Position Paper.","Faggiano A","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.70231","42823599",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000547","Glucagon-Like Peptide-1 Receptor Agonist and Age-related Macular Degeneration: Adding to the Story.","Maguire MG","2026","Ophthalmology","commentary","article","10.1016/j.ophtha.2026.06.025","42501021",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000548","The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Jobanputra R","2026","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.70194","42319968","PMC13282017",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review-article; review"],["R0000549","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy.","Shah J","2026","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2026.04.021","42025665",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000550","GLP-1 receptor agonists and podocyte senescence in diabetic kidney disease: structural pharmacology, mechanistic evidence, and multi-receptor agonism.","Yue H","2026","Biochemical pharmacology","narrative_review","article","10.1016/j.bcp.2026.118495","42777788",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000551","Glucagon-like peptide-1 receptor agonists in India: Psychiatric considerations and the case for integrated metabo-psychiatry care.","Alam A","2026","Indian journal of psychiatry","commentary","article","10.4103/indianjpsychiatry_450_26","42495031","PMC13395204",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0000552","Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.","Eiden C","2026","Fundamental & clinical pharmacology","narrative_review","article","10.1111/fcp.70103","42380081","PMC13318852",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0000553","Glucagon-Like Peptide-1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.","Maier GA","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71023","42331736","PMC13449085",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000554","Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model.","Martinez JM","2026","Kidney360","other_trial","article","10.34067/kid.0000001067","41945470","PMC13134791",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0000555","Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes.","Park CM","2026","Diabetes care","other","article","10.2337/dc25-1031","41232081","PMC12643794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; other; article"],["R0000556","Effect of Glucagon-Like Peptide-1 Receptor Agonist Use on Fusion Outcomes After First Metatarsophalangeal Arthrodesis in Patients With Type 2 Diabetes Mellitus.","Kayali H","2026","The Journal of the American Academy of Orthopaedic Surgeons","nonrandomized_study","article","10.5435/jaaos-d-26-00153","42200664",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000557","Glucagon-Like Peptide-1 Receptor Agonists and Heart Failure Hospitalization in a Real-World Cardiometabolic Population.","Issaka Y","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.03.055","41895359",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000558","An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists.","Dani SS","2025","JACC. Advances","randomized_trial","article","10.1016/j.jacadv.2025.101740","40447342","PMC12235410",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000559","Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.","Alsuwailem OA","2025","Cureus","systematic_review","article","10.7759/cureus.92454","41111833","PMC12530271",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000560","Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.","Kanbay M","2026","Clinical kidney journal","systematic_review","article","10.1093/ckj/sfag105","42017027","PMC13092978","PROSPERO:CRD420251153352",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000561","Glucagon-like Peptide-1 Receptor Agonist Therapy and Risk of Pulmonary and Systemic Infections in Diabetic Gastroparesis: A Propensity-Matched Cohort Study.","Kazi MAI","2026","Advances in respiratory medicine","nonrandomized_study","article","10.3390/arm94020020","42041268","PMC13113843",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000562","Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies.","Caruso P","2026","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-026-03283-0","42410649","PMC13617921",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review-article; Review; review"],["R0000563","Glucagon-Like Peptide-1 Receptor Agonists: A Novel Indication for Substance Use Disorders?","Ftiha F","2025","Cardiology in review","other","article","10.1097/crd.0000000000001145","41398454",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000564","Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.","Wong K","2026","Case reports in women's health","case_report","article","10.1016/j.crwh.2026.e00831","42376629","PMC13310638",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000565","GLP-1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation.","Tang H","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71142","42521622","PMC13538745",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000566","Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.","Ciancio G","2026","Frontiers in immunology","other_trial","article","10.3389/fimmu.2026.1744308","42131335","PMC13161150","ClinicalTrials.gov:NCT06588296; ClinicalTrials.gov:NCT06864026","S001069; S001889","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000567","Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia.","Belančić A","2026","The Journal of international medical research","nonrandomized_study","article","10.1177/03000605261470651","42570295","PMC13474226",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000568","Care of Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists.","Laine C","2026","Annals of internal medicine","other","article","10.7326/annals-26-02496","42330495",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000569","Glucagon-Like Peptide-1 Agonists and the Incidence of Atrial Fibrillation in Obese Patients With Heart Failure With Preserved Ejection Fraction and No Diabetes.","Rassam F","2026","Journal of arrhythmia","nonrandomized_study","article","10.1002/joa3.70455","42774613","PMC13595020",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0000570","Evidence on glucagon-like peptide-1 receptor agonists around conception: cautious interpretation (reply to letter to the editor).","Rajesh D","2026","American journal of obstetrics and gynecology","commentary","article","10.1016/j.ajog.2026.07.012","42462797",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0000571","Effect of glucagon-like peptide-1 receptor agonists on prostate cancer: A review.","Yu X","2024","Medicine","narrative_review","article","10.1097/md.0000000000039956","39465848","PMC11479428",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0000572","GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review.","Woo S","2026","Alcohol, clinical & experimental research","randomized_trial","article","10.1111/acer.70312","42144979","PMC13181353",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000573","Dramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report.","Fougerousse AC","2026","Clinical, cosmetic and investigational dermatology","case_report","article","10.2147/ccid.s606727","42683449","PMC13532928",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000574","GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.","Park J","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71065","42410329","PMC13449008",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0000575","Do Preoperative Glucagon-Like Peptide-1 Receptor Agonists Influence Lumbar Fusion Outcomes? A Systematic Review and Meta-Analysis.","Alves MLM","2026","International journal of spine surgery","systematic_review","article","10.14444/8954","42754392",null,"PROSPERO:CRD420261414637",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; review"],["R0000576","Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.","Berg S","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13929","40186344",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0000577","Decreased Risk of Mental Illness Worsening: Comment on \"Glucagon-like Peptide-1 Receptor Agonists in Individuals With Severe Mental Illness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials\".","Wajid MA","2026","International journal of psychiatry in medicine","systematic_review","article","10.1177/00912174261479866","42628005",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0000578","GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence.","Frey C","2026","Future oncology (London, England)","nonrandomized_study","article","10.1080/14796694.2026.2654735","41930781","PMC13089914",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review"],["R0000579","Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.","Gillikin A","2026","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2026.104033","42382138","PMC13316231",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000580","Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations.","Li Z","2026","Journal of diabetes research","nonrandomized_study","article","10.1155/jdr/8893769","41861108","PMC13140801",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000581","Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP‑1 receptor agonist use.","Porterfield LR","2026","Current atherosclerosis reports","randomized_trial","article","10.1007/s11883-026-01448-6","42470502","PMC13380630",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000582","Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.","Fuentes-Mendoza JM","2026","World journal of clinical pediatrics","randomized_trial","article","10.5409/wjcp.118730","42625929","PMC13491103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000583","State-level variation in the use of glucagon-like peptide-1 receptor agonists for weight loss and diabetes: a real-world analysis.","Do S","2026","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2026.32.5.625","42043919","PMC13119483",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000584","Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population.","Schrage B","2026","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2026.01.055","41811277",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0000585","GLP-1 Receptor Agonists in Eating Disorder Recovery","Cunanan ALP","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202609.2026.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0000586","The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.","Micha JP","2026","Expert review of anticancer therapy","randomized_trial","article","10.1080/14737140.2026.2691887","42308159",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000587","Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis.","Massay R","2026","Current opinion in rheumatology","randomized_trial","article","10.1097/bor.0000000000001153","41782546",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000588","Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study.","Khouri C","2026","American journal of respiratory and critical care medicine","nonrandomized_study","article","10.1093/ajrccm/aamag474","42745463",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000589","Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure.","Fioretti F","2026","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2026.02.5086","42017554",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0000590","Association between glucagon-like peptide-1 receptor agonist therapy and respiratory illness in patients with type 2 diabetes: a retrospective observational cohort study.","Ho LT","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-19657-5","41083699","PMC12518849",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0000591","Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.","Wang Y","2026","Renal failure","systematic_review","article","10.1080/0886022x.2026.2620155","41644273","PMC12879500",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; Review; article; review"],["R0000592","Exercise and glucagon-like peptide 1 receptor agonists in cardiovascular disease beyond weight loss.","Jordan AJ","2026","Nature metabolism","other","article","10.1038/s42255-026-01560-6","42342868",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000593","Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease.","Yau K","2025","Diabetes care","nonrandomized_study","article","10.2337/dc24-2811","40569823",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0000594","Glucagon-Like Peptide-1 Receptor Agonists for Binge Eating Disorder and Bulimia Nervosa in Children and Adolescents: The Impulsivity Measurement Gap","Klein J","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202609.1626.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0000595","Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.","Mahoon D","2026","International journal of molecular sciences","systematic_review","article","10.3390/ijms27125618","42353331","PMC13299499","PROSPERO:CRD420261337353",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0000596","Improving Medication Classification in GLP-1RA Research: Feasibility of a Photo-Review Protocol.","Katz JM","2026","Obesity science & practice","protocol","article","10.1002/osp4.70200","42774636","PMC13595039",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0000597","Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies.","Scannell C","2026","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2026.89983","42640207",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0000598","Body composition in glucagon-like peptide-1 receptor agonist therapy: Absolute loss, relative changes, and outcomes.","Chen S","2026","Hepatology forum","commentary","article","10.14744/hf.2026.84986","42601996","PMC13473246",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0000599","Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials.","Chiappa GR","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70572","41725443",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Network Meta-Analysis; Journal Article; Comparative Study; Review; article"],["R0000600","Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study.","Khan SA","2026","Medicine","nonrandomized_study","article","10.1097/md.0000000000050733","42736811","PMC13574452",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0000601","Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.","Kuryłowicz A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71226","42634284",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0000602","Impact of Glucagon-like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy: A Large, Matched Regional Cohort.","Cole JL","2026","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/10600280251349583","40583805",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; article"],["R0000603","Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease: systematic review and meta-analysis of randomised trials.","Montenegro-Avila A","2026","Cardiovascular endocrinology & metabolism","systematic_review","article","10.1097/xce.0000000000000360","42376130","PMC13313748","PROSPERO:CRD420251034652",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000604","Metabolic Reversal of Functional Hypogonadism? GLP-1 Receptor Agonists and Male Reproductive Endocrinology-A Systematic Review.","Zafrani Z","2026","Cells","systematic_review","article","10.3390/cells15151319","42587729","PMC13464801",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0000605","Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report.","Itsathitpaisarn R","2025","The American journal of case reports","case_report","article","10.12659/ajcr.949913","41353763","PMC12750940",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0000606","Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database.","Tao C","2025","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1557691","40697657","PMC12279493",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000607","Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study.","Allan KC","2026","Ophthalmology. Retina","nonrandomized_study","article","10.1016/j.oret.2025.10.020","41197713",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0000608","Immediate allergy against glucagon-like peptide-1 receptor agonist liraglutide.","Özdemir Ö","2026","Asia Pacific allergy","commentary","article","10.5415/apallergy.0000000000000196","42182607","PMC13193258",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0000609","Glucagon-Like Peptide-1 Receptor Agonists in Psychiatry: A Pharmacoepidemiological Scoping Review.","Volkow ND","2026","Biological psychiatry","randomized_trial","article","10.1016/j.biopsych.2026.03.1002","41932372","PMC13080939",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Scoping Review; Research Support, Non-U.S. Gov't; article"],["R0000610","Glucagon-like peptide-1 receptor agonists are associated with cardiac, cancer- and mortality-related benefits in diabetic patients treated with anthracyclines.","Chen ST","2026","European heart journal open","nonrandomized_study","article","10.1093/ehjopen/oeag109","42518325","PMC13384431",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000611","Glucagon-like Peptide-1 Receptor Agonists and Risk for Anterior Ischemic Optic Neuropathy : A Nationwide Cohort Study.","Ueda P","2026","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-25-02096","42441962",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000612","Expanding the dermatological horizon of glucagon-like peptide-1 receptor agonists: response to 'Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study'.","Potluru A","2026","Clinical and experimental dermatology","randomized_trial","article","10.1093/ced/llag025","41549421",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0000613","Safety and Efficacy of GLP-1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes.","Son H","2026","Annals of clinical and translational neurology","nonrandomized_study","article","10.1002/acn3.70505","42563258","PMC13447792",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000614","Modernizing perioperative fasting: Liberal clear liquids, glucagon-like peptide-1 receptor agonists, and point-of-care gastric ultrasound.","Dost B","2026","Saudi journal of anaesthesia","narrative_review","article","10.4103/sja.sja_91_26","42553740","PMC13436883",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000615","Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for incident dementia: A retrospective multicohort study.","Anagnostakis F","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70336","41309383","PMC12803637",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0000616","The effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents.","Sioufi MC","2026","Acta neuropsychiatrica","systematic_review","article","10.1017/neu.2026.10060","41684077","PMC13130272",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0000617","Current Insights and Future Directions on the Role of GLP-1 Receptor Agonists in Chronic Kidney Disease.","Rajan K","2026","International journal of nephrology and renovascular disease","narrative_review","article","10.2147/ijnrd.s522424","41908557","PMC13023396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000618","GLP-1 Receptor Agonist Associated Unmasking of Insulinoma.","Simonov E","2026","European journal of case reports in internal medicine","other","article","10.12890/2026_006552","42130933","PMC13166994",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000619","Interpreting Glucagon-Like Peptide-1 Receptor Agonist-Associated Cough in Observational Data.","Lu DH","2026","JAMA otolaryngology-- head & neck surgery","other","article","10.1001/jamaoto.2026.0941","42133308",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000620","Glucagon-like Peptide-1 Receptor Agonists: An Alternative for Dysglycemia in Hospitalized Patients?","Kligman M","2026","The Surgical clinics of North America","narrative_review","article","10.1016/j.suc.2025.12.011","41997638",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000621","Response to Letter to the Editor: Decreased Risk of Mental Illness Worsening: Comment on \"Glucagon-like Peptide-1 Receptor Agonists in Individuals With Severe Mental Illness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials\".","Srisurapanont M","2026","International journal of psychiatry in medicine","systematic_review","article","10.1177/00912174261480243","42633966",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0000622","Interpreting Glucagon-Like Peptide-1 Receptor Agonist-Associated Cough in Observational Data.","Ragozzino G","2026","JAMA otolaryngology-- head & neck surgery","other","article","10.1001/jamaoto.2026.0938","42133340",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000623","Combining GLP-1 Receptor Agonists and Health-Behaviour and Lifestyle Therapy Yields Higher Adherence and Reduces Session Needs for Successful Weight Management in Adolescence: An Observational Real-World Single-Center Study.","Lischka J","2026","Pediatric obesity","nonrandomized_study","article","10.1111/ijpo.70122","42222894",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0000624","Beyond weight loss: Patient-reported psychosocial and behavioral outcomes of glucagon-like peptide-1 receptor agonists in real-world use","Griffiths K","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-10353500/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0000625","Best in Class? The Comparative Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists in Preventing Incident CKD Stage 3 or Higher.","Reaves AC","2026","American journal of kidney diseases : the official journal of the National Kidney Foundation","commentary","article","10.1053/j.ajkd.2026.07.001","42431574",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000626","Differential effects of glucagon-like peptide-1 receptor agonist classes on blood pressure: a systematic review and network meta-analysis of randomised controlled trials with meta-regression","Chou OHI","2025","medRxiv","systematic_review","preprint","10.1101/2025.07.05.25330933",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0000627","Glucagon-like peptide-1 receptor agonists and retained gastric contents on endoscopy: a prospective observational study.","Wilson PR","2026","Canadian journal of anaesthesia = Journal canadien d'anesthesie","nonrandomized_study","article","10.1007/s12630-026-03186-4","42618723",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000628","GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.","Kennedy KP","2026","The Journal of clinical psychiatry","randomized_trial","article","10.4088/jcp.25m16212","42474323","PMC13527612",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000629","Hepatic portal venous gas in a patient with diabetes on GLP-1 receptor agonist and alpha-glucosidase inhibitor.","Noguchi T","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag070","42093866","PMC13142154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000630","Weekly Journal Scan: Genetic insights into glucagon-like peptide 1 receptor agonist response, toward precision obesity therapy.","Pedicino D","2026","European heart journal","other","article","10.1093/eurheartj/ehag550","42478858",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000631","Depression following the initiation of glucagon-like-peptide-1 receptor agonist therapy: A multinational self-controlled case series study.","Yan VKC","2026","Journal of internal medicine","nonrandomized_study","article","10.1111/joim.70098","41988822","PMC13137393",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0000632","Inadvertent glucagon-like peptide-1 receptor agonist exposure in pregnancy: reassuring data, unresolved safety (letter to the editor).","Singh R","2026","American journal of obstetrics and gynecology","commentary","article","10.1016/j.ajog.2026.07.011","42462798",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0000633","Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.","Chen JJ","2025","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph18050735","40430553","PMC12115298",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000634","Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes.","Lu Y","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24366","40841345","PMC12906048",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000635","Association of GLP-1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort.","Tyndall B","2026","medRxiv : the preprint server for health sciences","randomized_trial","article","10.64898/2026.01.15.26344218","41646707","PMC12870566",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Preprint; research-article; article; preprint"],["R0000636","Beyond weight loss: multisystem benefits of obesity medications.","Savas M","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00100-2","42208956",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0000637","Interpreting Glucagon-Like Peptide-1 Receptor Agonist-Associated Cough in Observational Data-Reply.","Gallagher TJ","2026","JAMA otolaryngology-- head & neck surgery","other","article","10.1001/jamaoto.2026.0944","42133320",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000638","Evaluating the indirect interaction between glucagon-like peptide-1 receptor agonists and warfarin using real-world data.","Gilbert SJ","2026","Journal of thrombosis and thrombolysis","nonrandomized_study","article","10.1007/s11239-026-03310-7","42115581","PMC13344373",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000639","A new tool requires a new approach: glucagon-like peptide-1 receptor agonists and the scope of fertility care.","Vitek WS","2026","F&S reports","commentary","article","10.1016/j.xfre.2026.06.005","42630779","PMC13494593",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0000640","Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Incident Atrial Fibrillation in Type 2 Diabetes: A Population-Based Target Trial Emulation.","Ostrovsky D","2026","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwag478","42700963",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000641","Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.","Ali A","2025","Clinical obesity","systematic_review","article","10.1111/cob.70012","40265328","PMC12289403",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; research-article; review"],["R0000642","Vagal activity related events and glucagon-like peptide-1 receptor agonists.","Al-Ansary L","2026","European heart journal. Cardiovascular pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvag072","42709513",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000643","Impact of GLP-1 Receptor Agonists on Bone Metabolism.","Vadini V","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag323","42563411",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000644","Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications.","Burke OM","2025","Skin appendage disorders","narrative_review","article","10.1159/000544023","41058954","PMC12500303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000645","Pre-stroke glucagon-like peptide-1 receptor agonist use and outcomes after acute ischemic stroke: a propensity score-matched retrospective cohort study","Negida Y","2026","medRxiv","randomized_trial","preprint","10.64898/2026.04.29.26352109",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0000646","Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes.","Kokura Y","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113404","42385946",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000647","Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States.","Akpan N","2026","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2026.32.1.14","41439383","PMC12728810",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000648","[GLP-1 agonists : indications and pancreatic and endoscopic safety considerations].","Cuénoud S","2026","Revue medicale suisse","narrative_review","article","10.53738/revmed.2026.22.954.48466","41855031",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; English Abstract; Review; article"],["R0000649","Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis.","Liu X","2026","Endocrine connections","systematic_review","article","10.1530/ec-26-0280","42447044","PMC13386145",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; systematic-review; review"],["R0000650","The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.","Alkhouri N","2025","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2025.2473062","40016997",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0000651","Semaglutide attenuates neuroinflammation in male mice.","Belmont-Rausch DM","2026","Nature communications","preclinical","article","10.1038/s41467-026-74038-4","42265098","PMC13402617",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000652","Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.","Wang Y","2025","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgaf336","40489581",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; other; review"],["R0000653","Impact of Incretin-Based Therapy on Skeletal Muscle Health.","Koceva A","2025","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina61091691","41011082","PMC12471476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000654","Is There a Causal Link Between GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence.","Danesh-Meyer HV","2026","Clinical & experimental ophthalmology","randomized_trial","article","10.1111/ceo.70096","42020100",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0000655","Weight Loss and Body Image Are Not Synonymous: Divergent Effects of Glucagon-Like Peptide-1 Receptor Agonist Therapy and Behavioural Intervention in a Young Adult With Type 1 Diabetes-A Case Report.","Patience N","2026","Canadian journal of diabetes","case_report","article","10.1016/j.jcjd.2026.08.002","42600932",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0000656","Outcomes of GLP-1 Receptor Agonist Therapy after Liver Transplantation in Patients with Type 2 Diabetes: A Real-World Cohort Study.","Nguefang GL","2026","Journal of gastrointestinal and liver diseases : JGLD","nonrandomized_study","article","10.15403/jgld-6863","42803248",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000657","Trends in Usage and Payments for Glucagon-Like Peptide-1 Receptor Agonists in the United States, 2017 to 2022: A Nationally Representative Repeated Cross-Sectional Study.","Hammond MM","2026","Journal of the American Heart Association","other","article","10.1161/jaha.125.046302","42464889",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000658","Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.","Alibilli AS","2025","JMIR infodemiology","nonrandomized_study","article","10.2196/73619","40706081","PMC12289294",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, N.I.H., Intramural; research-article; article"],["R0000659","Glucagon-Like Peptide-1 Receptor Agonist Treatment and Risk of Esophageal Cancer.","Hardvik Åkerström J","2026","The American journal of gastroenterology","randomized_trial","article","10.14309/ajg.0000000000003885","41384845",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; article"],["R0000660","Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders.","Russjan E","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27135803","42450077","PMC13361537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000661","Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review.","Deameh MG","2026","The journal of sexual medicine","systematic_review","article","10.1093/jsxmed/qdaf381","41498523",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0000662","Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Wen J","2025","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70113","40988099","PMC12457091",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0000663","Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection.","Singh N","2026","ACG case reports journal","case_report","article","10.14309/crj.0000000000002168","42326458","PMC13282047",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000664","ABSTRACT NUMBER: ESOC2026A1557 EFFICACY AND SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON STROKE RISK AND CEREBROVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A NETWORK META-ANALYSIS",null,"2026","European stroke journal","systematic_review","article",null,null,"PMC13145756",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0000665","An Integrated Analysis of GLP-1R Agonist Mechanisms: Addressing Study Variations in Heterogeneous Cell Systems","Silfvergren O","2026","bioRxiv","preclinical","preprint","10.64898/2026.03.25.714139",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0000666","GLP-1 receptor agonists at the crossroads of diabetes, hepatic steatosis, and hepatocellular carcinoma.","Vozza A","2026","Internal and emergency medicine","nonrandomized_study","article","10.1007/s11739-026-04456-1","42521944",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0000667","\"Ozempic Limb\": Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals With Lower Limb Amputation.","Bykowski J","2026","American journal of physical medicine & rehabilitation","case_report","article","10.1097/phm.0000000000002989","41955540",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0000668","Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity.","Wada Y","2026","Clinical and experimental nephrology","nonrandomized_study","article","10.1007/s10157-026-02845-6","41838277",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0000669","Hemodynamic Compromise Due to Semaglutide-Associated Abdominal Distension.","Amdahl MB","2026","JACC. Case reports","case_report","article","10.1016/j.jaccas.2026.110452","42820899",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0000670","Estimating eligibility for GLP-1 receptor agonists for chronic weight management and cardiovascular disease in Australia","Castrillon J","2026","medRxiv","other","preprint","10.64898/2026.03.17.26348659",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0000671","Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review.","Lev D","2026","Clinical nutrition (Edinburgh, Scotland)","nonrandomized_study","article","10.1016/j.clnu.2025.106571","41534460",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0000672","Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis.","Alqinai B","2026","ACG case reports journal","case_report","article","10.14309/crj.0000000000002070","41959596","PMC13061526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000673","Residual Gastric Contents in Glucagon-Like Peptide-1 Receptor Agonist Users: The Potential Confounding Role of Diabetes-Related Gastric Dysmotility.","Dajie S","2026","Anesthesia and analgesia","other","article","10.1213/ane.0000000000008151","42385730",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000674","Glucagon-Like Peptide-1 Receptor Agonists as a Potential Mitochondrial Modulation Therapy for Hidradenitis Suppurativa.","Hosseini A","2026","Acta dermato-venereologica","other","article","10.2340/actadv.v106.adv-2025-0093","42257526","PMC13244553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000675","Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.","Bhat S","2025","World journal of cardiology","narrative_review","article","10.4330/wjc.v17.i8.107991","40949933","PMC12426997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000676","Adjunctive use of glucagon-like peptide-1 receptor agonists after bariatric surgery: updated systematic review and meta-analysis of randomized controlled trials.","Arora S","2026","Acta diabetologica","systematic_review","article","10.1007/s00592-026-02730-4","42334596",null,"PROSPERO:CRD420251251321",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Review; review"],["R0000677","Medications for Obstructive Sleep Apnea.","Macanian J","2025","Cardiology in review","other","article","10.1097/crd.0000000000001148","41403009",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000678","The Quiet Window–Challenge Window Framework: A Conceptual Framework for Habit Formation During GLP-1 Receptor Agonist Therapy","Hull HR","2026","PsyArXiv","other","preprint","10.31234/osf.io/xt23e_v2",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0000679","Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.","Davila Diaz R","2025","Cureus","randomized_trial","article","10.7759/cureus.99865","41445996","PMC12724355",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000680","GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.","Myśliwczyk D","2026","International journal of molecular sciences","randomized_trial","article","10.3390/ijms27188191","42794619","PMC13607036",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000681","GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics.","Samuels JM","2026","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.71320","42712125","PMC13646343","ClinicalTrials.gov:NCT06162715","S002348","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; methods-article; article"],["R0000682","Association of GLP-1 Receptor Agonist Use With Cardiovascular Outcomes and Mortality in Japanese Patients With Type 2 Diabetes: A Real-World Claims Database Study.","Koshizaka M","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71209","42581431",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000683","Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes.","Imbroane MR","2025","American journal of obstetrics and gynecology","nonrandomized_study","article","10.1016/j.ajog.2025.01.019","39848396",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000684","Effects of GLP-1 receptor agonists on periodontal tissue: An interdisciplinary evidence mapping - scoping review.","Henriques JP","2026","Annales pharmaceutiques francaises","other_trial","article","10.1016/j.pharma.2026.06.008","42349781",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0000685","Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document.","Monzo L","2025","European journal of heart failure","narrative_review","article","10.1002/ejhf.70082","41309245","PMC12765371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Consensus Statement; review-article; article"],["R0000686","Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","Eze ED","2026","Frontiers in oncology","systematic_review","article","10.3389/fonc.2026.1859759","42523690","PMC13407199",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0000687","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta-Analysis.","Bilal AR","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70102","41721616","PMC12928090",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0000688","Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.","Iglesias P","2026","Endocrine","nonrandomized_study","article","10.1007/s12020-026-04587-7","41803337",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0000689","Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.","Sattar N","2026","Diabetes care","nonrandomized_study","article","10.2337/dc26-0298","41940793","PMC13594787",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Randomized Controlled Trial; research-article; other; article"],["R0000690","Semaglutide-induced transient intestinal ischemia: A case report.","Kalluru PKR","2026","International journal of clinical pharmacology and therapeutics","case_report","article","10.5414/cp204861","41467632",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000691","Mosapride as a Pre-Endoscopy Preparation in a Patient Receiving GLP-1 Receptor Agonist Therapy.","Inoue K","2026","Internal medicine (Tokyo, Japan)","other","article","10.2169/internalmedicine.6983-25","41922235",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000692","Neuroprotective Effects of Glucagon-like Peptide-1/glucagon-like Peptide-1 Receptor Agonists on Neurodegenerative Eye Diseases and their Molecular Mechanisms: A Recent Update.","Liu S","2026","Current neuropharmacology","other","article","10.2174/011570159x446766260311123827","42163661",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000693","Effect of glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors alone and in combination on AF recurrence and cardiovascular outcomes after catheter ablation for atrial fibrillation.","Ramadan A","2026","Heart rhythm","nonrandomized_study","article","10.1016/j.hrthm.2026.09.018","42753998",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000694","GLP-1 Receptor Agonist Coverage for Obesity in Medicaid and Total GLP-1 Receptor Agonist Utilization.","Khanna R","2026","JAMA health forum","other","article","10.1001/jamahealthforum.2026.3353","42789287","PMC13615463",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000695","Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey.","DiStefano MJ","2026","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2026.32.8.903","42504813","PMC13403254",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000696","Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.","Song BG","2026","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2026.101776","42349715",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000697","Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases.","Karacabeyli D","2026","Rheumatology (Oxford, England)","randomized_trial","article","10.1093/rheumatology/keag147","41912427","PMC13105841",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000698","Case Report: Acute biliary pancreatitis after semaglutide dose escalation in an adolescent with obesity and cholelithiasis.","Alanizi AH","2026","Frontiers in pediatrics","case_report","article","10.3389/fped.2026.1959617","42769395","PMC13590710",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000699","Real-World Effectiveness and Safety of GLP-1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery.","Yuce T","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70280","42642900",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000700","Perioperative Glucagon-Like Peptide-1 Receptor Agonist Therapy and Postoperative Outcomes in Adult Foot and Ankle Surgery: A Scoping Review.","Zahed M","2026","Cureus","nonrandomized_study","article","10.7759/cureus.101653","41700259","PMC12906652",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000701","GLP-1RA pharmacokinetics and clinical effects: focus on cardiac, vascular, and glomerular structures.","Barnaba I","2026","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1080/17425255.2026.2714849","42552669",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000702","Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study.","Kazi MAI","2026","PloS one","nonrandomized_study","article","10.1371/journal.pone.0358659","42784582","PMC13606989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000703","The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases.","Beniwal-Patel P","2026","Inflammatory bowel diseases","randomized_trial","article","10.1093/ibd/izag151","42593078",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0000704","Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis.","Kellner DA","2025","ACR open rheumatology","nonrandomized_study","article","10.1002/acr2.70103","40932015","PMC12423941",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0000705","Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection.","Mohanty SS","2026","Indian journal of pharmacology","narrative_review","article","10.4103/ijp.ijp_1384_25","42583965","PMC13412501",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000706","A rapid review of the effects of GLP-1 receptor agonists on opioid and stimulant use-related outcomes.","Leach M","2026","Drug and alcohol dependence reports","narrative_review","article","10.1016/j.dadr.2026.100440","42111969","PMC13156756",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000707","Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.","Giraldi LV","2026","BMJ open","protocol","article","10.1136/bmjopen-2026-123779","42754274","PMC13599909",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0000708","Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase.","Cheng X","2026","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-025-02712-3","41021211",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000709","Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk.","McIntyre RS","2026","Biological psychiatry","narrative_review","article","10.1016/j.biopsych.2026.04.019","42069105",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000710","Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis.","Lauri G","2026","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","systematic_review","article","10.1016/j.pan.2026.04.005","41991368",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0000711","Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes.","Abbasi M","2026","Acta pharmaceutica Sinica. B","narrative_review","article","10.1016/j.apsb.2026.01.035","42180536","PMC13198345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000712","GLP-1 Receptor Agonists and Oral-Facial Aesthetics: The Intersection of Dentistry and Dermatologic Surgery.","Motamedi S","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","nonrandomized_study","article","10.1097/dss.0000000000005161","42210894",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0000713","Fasting Considerations for Patients on Glucagon-Like Peptide-1 Receptor Agonists for Electroconvulsive Therapy.","Fitzmartin K","2026","The journal of ECT","other","article","10.1097/yct.0000000000001272","42183589",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000714","Glucagon-Like Peptide-1 Receptor Agonists Versus Bariatric Surgery in Patients With Obesity and Heart Failure With Preserved Ejection Fraction.","Ibrahim R","2025","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.125.044577","41378487","PMC12826936",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0000715","The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.","Lopez J","2025","US cardiology","narrative_review","article","10.15420/usc.2024.44","40458830","PMC12127966",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000716","Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases.","Karacabeyli D","2026","Arthritis & rheumatology (Hoboken, N.J.)","nonrandomized_study","article","10.1002/art.70044","41466578","PMC12991922",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000717","Association between GLP-1 receptor agonist use and neurosurgical intervention in patients with idiopathic intracranial hypertension and obesity: a propensity-matched, multi-institutional, cohort study.","Debiec JC","2026","Journal of neurointerventional surgery","nonrandomized_study","article","10.1136/jnis-2025-024139","40987589",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0000718","Relationship between glucagon-like peptide-1 receptor agonist use and incidence of trigger finger in patients with type 2 diabetes.","Stump K","2026","Hand surgery & rehabilitation","nonrandomized_study","article","10.1016/j.hansur.2026.102589","41619807",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000719","GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.","Bair H","2026","Ophthalmology and therapy","nonrandomized_study","article","10.1007/s40123-026-01425-x","42366332","PMC13424029",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0000720","Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective.","Ros-Madrid I","2025","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2025-0148","41086442",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000721","Glucagon-like peptide-1 receptor agonists in patients with moyamoya disease and type 2 diabetes mellitus.","Roy JM","2026","Journal of neurosurgery","randomized_trial","article","10.3171/2025.12.jns251072","41962156",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0000722","Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.","Karam L","2025","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","preclinical","article","10.1007/s00198-025-07664-1","40920189","PMC12628458",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000723","Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.","Rodriguez PJ","2026","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2025-109259","42481079","PMC13410697",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000724","Lifestyle First and Lifestyle Always, Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care in the Era of GLP-1 Receptor Agonists.","Joy E","2026","American journal of lifestyle medicine","other","article","10.1177/15598276261450530","42206250","PMC13201374",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000725","GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.","Beaudart C","2026","Drugs","systematic_review","article","10.1007/s40265-026-02365-3","42730869","PMC13615104","PROSPERO:CRD420251024082",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0000726","Commentary on the Risks of Prescription GLP-1 Agonists in Patients on Psychiatric Medications.","Garakani A","2026","Journal of psychiatric practice","commentary","article","10.1097/pra.0000000000000931","42095723",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0000727","Glucagon-Like Peptide-1 Receptor Agonists: Are We Swapping One Public Health Crisis for Another?","Ní Chróinín D","2026","Australasian journal on ageing","commentary","article","10.1111/ajag.70180","42159343",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000728","Oral Incretin-Based Therapies for Weight Management.","Cheng HE","2026","Current atherosclerosis reports","other_trial","article","10.1007/s11883-026-01456-6","42696191",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0000729","Glucagon-like peptide-1 receptor agonists and advanced liver outcomes in type 2 diabetes: a systematic review and exploratory meta-analysis.","Hu JH","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1874720","42312204","PMC13268877","PROSPERO:CRD420261299499",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0000730","Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes.","Khadija HA","2026","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2026.101794","42785671",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000731","Glucagon-like peptide-1 receptor agonists and oral health.","Dler D","2026","British dental journal","commentary","article","10.1038/s41415-026-9842-0","42104053",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0000732","Glucagon-like peptide-1 receptor agonists in orthopaedics.","Mavrogenis AF","2026","SICOT-J","commentary","article","10.1051/sicotj/2025067","41789832","PMC12965058",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article; editorial"],["R0000733","Risk management of cardiovascular disease in older patients with diabetes.","Sawami K","2025","Hypertension research : official journal of the Japanese Society of Hypertension","narrative_review","article","10.1038/s41440-025-02424-4","41102421","PMC12678176",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0000734","A house divided cannot stand: Conflicting guidelines on GLP-1R agonists in peri-operative care - a reply to Glucagon-like peptide-1 receptor agonists in peri-operative care by Paggers et al.","Willingshofer MP","2026","European journal of anaesthesiology","other","article","10.1097/eja.0000000000002219","41340140",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0000735","Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction.","Ming Q","2026","Frontiers in nutrition","randomized_trial","article","10.3389/fnut.2026.1914155","42666197","PMC13521789",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000736","Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System.","Chen H","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-01206-9","40413246","PMC12103604",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000737","Glucagon-Like Peptide-1 Receptor Agonists in Asthma and Obesity-Associated Asthma: A Systematic Review of Clinical Outcomes and Translational Mechanisms.","Saadat S","2026","The journal of allergy and clinical immunology. In practice","systematic_review","article","10.1016/j.jaip.2026.05.010","42167405",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0000738","Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.","DiStefano MJ","2026","JAMA health forum","other","article","10.1001/jamahealthforum.2026.2207","42467450",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000739","Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes.","Liu PY","2026","Nature communications","randomized_trial","article","10.1038/s41467-026-76083-5","42669711","PMC13526834",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0000740","Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.","Chan WK","2026","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes26005","42421259","PMC13429816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000741","Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.","Alexander GC","2026","JAMA internal medicine","systematic_review","article","10.1001/jamainternmed.2025.8222","41770554","PMC12954602",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0000742","Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with ESKD.","Karpinski S","2026","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.0000001208","42640716",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0000743","Perioperative risks of glucagon-like peptide-1 receptor agonists and their implications in airway management using supraglottic airway devices.","Oh CS","2026","Anesthesia and pain medicine","narrative_review","article","10.17085/apm.26589","42135216","PMC13175902",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000744","Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes.","Wójcik-Sosnowska E","2026","International journal of molecular sciences","systematic_review","article","10.3390/ijms27093882","42123472","PMC13164057",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0000745","Comment on Puga et al. : Effect of glucagon-like peptide-1 receptor agonist on outcomes after elective total hip arthroplasty: A retrospective cohort study.","Singh N","2026","Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association","nonrandomized_study","article","10.1016/j.jos.2026.03.010","42431801",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0000746","[Glucagon-like peptide-1 agonists and heart failure].","Soborun N","2026","Revue medicale suisse","narrative_review","article","10.53738/revmed.2026.22.963.48693","42169518",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0000747","Response to the correspondence by Dr. Liu: Comment on \"The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity\".","Koyanagi Y","2026","Hypertension research : official journal of the Japanese Society of Hypertension","commentary","article","10.1038/s41440-026-02701-w","42243293",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0000748","Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review.","Duru DO","2026","BMC musculoskeletal disorders","nonrandomized_study","article","10.1186/s12891-026-10092-9","42298552","PMC13295517",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; review-article; other; article"],["R0000749","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients With Obesity and Without Type 2 Diabetes.","Kotecha P","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70904","42244137",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0000750","GLP-1RAs Use and Postoperative Outcomes in T2DM Patients Undergoing Radical Nephrectomy.","Kwon S","2026","Clinical genitourinary cancer","nonrandomized_study","article","10.1016/j.clgc.2026.102630","42613293",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000751","GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials.","Gupta P","2026","Journal of neuroendocrinology","narrative_review","article","10.1111/jne.70246","42580680","PMC13461250",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000752","GLP-1 receptor agonist therapy and skeletal muscle: A narrative review synthesizing adult evidence with implications for older adults.","Jagasia K","2026","JAR life","narrative_review","article","10.1016/j.jarlif.2026.100083","42633386","PMC13499509",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0000753","Weight Changes From Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study.","Alexander GC","2026","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.70076","41271442","PMC13463575",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000754","Impact of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors on Post-liver Transplant New-onset Major Adverse Cardiovascular Events, Graft Failure, Renal Outcome, and Mortality.","Kosako Yost KC","2026","Transplantation direct","nonrandomized_study","article","10.1097/txd.0000000000001935","42158034","PMC13183107",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000755","Putting a Glucagon-Like Peptide-1 Receptor Agonist Trial for Type 2 Diabetes in Context.","Cohen RM","2026","JAMA network open","other_trial","article","10.1001/jamanetworkopen.2026.15634","42234432",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0000756","Glucagon-like Peptide-1 Receptor Agonists and Risk of Pneumonia and Postprocedure Hospitalization Among Patients Undergoing Gastrointestinal Endoscopy.","Qiu C","2026","Gastro hep advances","nonrandomized_study","article","10.1016/j.gastha.2025.100869","41660373","PMC12878672",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000757","Long-Term Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Peripheral Artery Disease and Type 2 Diabetes.","Rosenzveig A","2026","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.125.045664","42383806",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000758","Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?","Ihle-Hansen H","2026","Frontiers in stroke","other","article","10.3389/fstro.2026.1918465","42712498","PMC13549906",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0000759","Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials","Hassan A","2026","F1000Res","systematic_review","preprint","10.12688/f1000research.186847.1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; review"],["R0000760","Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health.","Tariq A","2026","Urology case reports","case_report","article","10.1016/j.eucr.2026.103368","41716526","PMC12914309",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000761","The Trojan horse of off-label glucagon-like peptide-1 receptor agonist use: Protecting patients through responsible practice.","Belančić A","2026","The Journal of international medical research","other","article","10.1177/03000605261458168","42315330","PMC13291563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000762","Impact of the injectable weight-loss medications, glucagon-like peptide-1 receptor agonists, on reproductive health in non-polycystic ovary syndrome state.","Merhi Z","2025","Current opinion in obstetrics & gynecology","preclinical","article","10.1097/gco.0000000000001044","40459435",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000763","Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.","Taj S","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70382","41395692","PMC12890775",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0000764","Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.","Leikin JB","2026","Disease-a-month : DM","commentary","article","10.1016/j.disamonth.2026.102149","42173778",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0000765","Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation.","Reynolds KR","2026","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-25-00860","42441967",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0000766","Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice.","Dalpiaz H","2026","Heart (British Cardiac Society)","randomized_trial","article","10.1136/heartjnl-2024-324847","40664497",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0000767","Comment on \"The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity\".","Liu Y","2026","Hypertension research : official journal of the Japanese Society of Hypertension","commentary","article","10.1038/s41440-026-02681-x","42120776",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0000768","Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.","Chen SC","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71266","42642357","PMC13646335",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000769","Corrigendum to: The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.","Batista JL","2026","US cardiology","notice","article","10.15420/usc.2024.44.co1","41859185","PMC12997237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0000770","Molecular evidence associating GLP-1 receptor agonists and brain-derived neurotrophic factors in neurodegenerative and psychiatric disorders: A systematic review.","Xu T","2026","Asian journal of psychiatry","systematic_review","article","10.1016/j.ajp.2026.104870","41619567",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Systematic Review; Journal Article; Review; review"],["R0000771","Immunometabolic reprogramming via GLP-1 receptor agonists in people with HIV: A multidimensional systemic framework.","Sun L","2026","Bioscience trends","randomized_trial","article","10.5582/bst.2026.01148","42633920",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0000772","Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial.","Yen FS","2026","Metabolism: clinical and experimental","nonrandomized_study","article","10.1016/j.metabol.2026.156790","42810614",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000773","2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists.","Hocking SL","2025","Anaesthesia and intensive care","other","article","10.1177/0310057x251355288","40814081","PMC12420935",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; research-article; article"],["R0000774","Prescribing of GLP-1 Receptor Agonists for Adolescents with Obesity and Associated Disparities.","Kim C","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.10.06.25337411","41282921","PMC12632649",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0000775","GLP-1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri-Procedural Guidance.","Beig J","2026","Chronic diseases and translational medicine","nonrandomized_study","article","10.1002/cdt3.70059","42494946","PMC13393514",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000776","The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists.","Lee H","2026","Diabetes care","nonrandomized_study","article","10.2337/dc26-0662","42561183",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; other; article"],["R0000777","Efficacy of GLP-1 receptor agonists in Parkinson's disease: a systematic review and exploratory network meta-analysis of randomized controlled trials.","Ali M","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","systematic_review","article","10.1007/s10072-026-08929-1","41995965","PMC13090280",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; review-article; review"],["R0000778","Do GLP-1 receptor agonists improve insulin sensitivity and reduce lipid accumulation in skeletal muscles and the liver independent of weight loss?","Kołakowski A","2026","Endokrynologia Polska","narrative_review","article","10.5603/ep.107227","42112562",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000779","Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.","Aboukaoud M","2026","Journal of affective disorders","nonrandomized_study","article","10.1016/j.jad.2026.121802","42002107",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000780","Risk of peripheral vestibular disorders and hearing impairment among users of glucagon-like peptide-1 receptor agonists.","Huang JY","2026","International journal of medical sciences","nonrandomized_study","article","10.7150/ijms.131397","41938526","PMC13048892",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000781","GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.","Hsu AH","2026","Annals of oncology : official journal of the European Society for Medical Oncology","nonrandomized_study","article","10.1016/j.annonc.2026.04.013","42252247",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000782","Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System.","Bhattacharyya M","2024","Cureus","nonrandomized_study","article","10.7759/cureus.65989","39221363","PMC11366408",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000783","For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?","Giang C","2026","Biology","other_trial","article","10.3390/biology15161395","42651699","PMC13509466",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000784","Risk of Retinal Vein Occlusion between Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Retrospective Cohort Study.","Pan SY","2025","Ophthalmology science","nonrandomized_study","article","10.1016/j.xops.2025.100734","40206263","PMC11979394",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000785","Immunometabolic Modulation in Obese Asthma: How GLP-1 Receptor Agonists Could Influence Systemic and Pulmonary Immune Phenotypes.","O'Brien H","2026","Pulmonary therapy","nonrandomized_study","article","10.1007/s41030-026-00380-z","42690609","PMC13569773",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000786","Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?","Renehan AG","2026","Cancer prevention research (Philadelphia, Pa.)","randomized_trial","article","10.1158/1940-6207.capr-26-0018","41918364",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000787","Patterns of GLP-1 Receptor Agonist Initiation Compared With Other Glucose-Lowering and Anti-Obesity Therapies Among Older Adults","Brooks JD","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.09.29.26364340",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","4","FALSE","Preprint; preprint"],["R0000788","A multi-scale quantitative systems pharmacology model of the Pharmaco-Nutritional Kinetic Paradox: GLP-1 receptor agonists, colonic fibre fermentation and endogenous GLP-1 signalling","Choudhary AK","2026","Research Square","other","preprint","10.21203/rs.3.rs-10780569/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0000789","Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.","Tongta S","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms262210974","41303457","PMC12652136",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0000790","The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives.","Dilbaz B","2026","The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception","narrative_review","article","10.1080/13625187.2026.2644895","41860479",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000791","Dietary Fiber and Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Converging Mechanisms, Interactions, and Strategies for Durable Weight Control.","Wang Y","2026","Advances in nutrition (Bethesda, Md.)","narrative_review","article","10.1016/j.advnut.2026.100647","42106160","PMC13234238",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000792","Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production.","Hansell L","2026","BMJ open","other","article","10.1136/bmjopen-2026-124968","42785932","PMC13630073",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0000793","Association between Glucagon-like Peptide-1 Receptor Agonist Use and Nonarteritic Anterior Ischemic Optic Neuropathy with Optic Disc Drusen.","Abboud I","2026","Ophthalmology","other","article","10.1016/j.ophtha.2026.06.014","42302889",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000794","Glucagon-Like Peptide-1 Receptor Agonists and Ocular Outcomes: Metabolic Transition, Retinal Vulnerability, and Risk-Stratified Monitoring.","Song SJ","2026","Journal of obesity & metabolic syndrome","randomized_trial","article","10.7570/jomes26012","42059115","PMC13158027",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000795","Glucagon-like peptide-1 receptor agonist use and clinical outcomes after lung transplantation: A single-center cohort study.","Miyashita Y","2026","JHLT open","nonrandomized_study","article","10.1016/j.jhlto.2026.100513","41798058","PMC12966907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000796","Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus: target trial emulation with active comparators. Response to Br J Anaesth 2026; 137: 877-8.","Wu HL","2026","British journal of anaesthesia","nonrandomized_study","article","10.1016/j.bja.2026.06.055","42601296",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0000797","Commentary: Glucagon-Like Peptide-1 Receptor Agonists and Outcomes After Intracerebral Hemorrhage in Patients With Type 2 Diabetes: A Propensity-Matched Cohort Study.","Essibayi MA","2026","Neurosurgery","nonrandomized_study","article","10.1227/neu.0000000000004122","42283470",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; editorial"],["R0000798","The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.","Hertzer LA","2026","Childhood obesity (Print)","systematic_review","article","10.1177/21532176251413898","41715277","PMC13191177",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0000799","Emerging Evidence for Cardiorenal Protection with Sodium-Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes.","Fernandes S","2026","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2026.04.007","42526998",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000800","Case report: Tirzepatide-responsive refractory diabetes mellitus in an adult female with prader-willi syndrome.","Li S","2026","Medicine","case_report","article","10.1097/md.0000000000050605","42700085","PMC13549606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0000801","Beyond Weight Loss: Metabolic and Immunologic Power of GLP-1 Agonists in Plastic Surgery.","Patel NK","2026","Aesthetic surgery journal","narrative_review","article","10.1093/asj/sjag064","41913544",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000802","Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.","Su YJ","2026","Clinical pharmacology and therapeutics","nonrandomized_study","article","10.1002/cpt.70440","42572932","PMC13454975",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000803","Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs).","Li J","2026","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s579419","41908941","PMC13021384",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000804","Correction: Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis.","Omarion A","2026","Frontiers in endocrinology","notice","article","10.3389/fendo.2026.1932302","42549142","PMC13430553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0000805","The interplay of GLP-1 receptor agonist use, chronic kidney disease and fracture risk in obese pAtients: a retrospective cohort study.","Eubanks A","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70566","41995433","PMC13421053",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000806","GLP-1 Receptor Agonists in Neuropathic Pain and Neurodegenerative Diseases: Mechanisms, Therapeutic Potentials, and Future Perspectives.","Grasso M","2026","Current neuropharmacology","other","article","10.2174/011570159x450007260305034049","42227394",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000807","Traditional Chinese medicine acupoint pasting for preventing and treating gastrointestinal reactions in type II diabetes mellitus patients undergoing glucagon-like peptide-1 receptor agonist therapy: A clinical study.","Zheng S","2025","Journal of medical biochemistry","randomized_trial","article","10.5937/jomb0-55092","41054590","PMC12497455",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000808","Pavlovian conditioned approach with different reward magnitudes reveals opposing effects of acute and chronic semaglutide treatment","Desrochers SS","2026","bioRxiv","preclinical","preprint","10.64898/2026.09.08.750149",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0000809","Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE).","Facciorusso A","2026","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","narrative_review","article","10.1016/j.dld.2026.02.018","41850932",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Consensus Statement; Journal Article; Practice Guideline; Review; article"],["R0000810","The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Pain Management in Chronic Pancreatitis: A Real-World Cohort Study.","Dhali A","2026","Gastro hep advances","nonrandomized_study","article","10.1016/j.gastha.2026.101028","42405290","PMC13330660",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000811","Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon-Like Peptide-1 Receptor Agonists.","Zawadzki M","2026","Cardiovascular therapeutics","narrative_review","article","10.1155/cdr/8388511","42130151","PMC13172615",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000812","Rapid gastric emptying rate in postbariatric hypoglycemia and effect of glucagon-like peptide-1 receptor agonist on postprandial hypoglycemia.","Turk N","2026","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgag376","42784533",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000813","Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine","Sulter GA","2026","Preprints.org","other_trial","preprint","10.20944/preprints202607.1279.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","5","FALSE","Preprint; preprint"],["R0000814","Molecular insights into GLP-1 receptor agonists and emerging metabolic-inflammatory targets in hidradenitis suppurativa.","Brogaard E","2026","Expert opinion on therapeutic targets","randomized_trial","article","10.1080/14728222.2026.2738341","42779274",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000815","Effects of GLP-1 receptor agonists on aesthetic surgery practice: A contemporary review.","Ersan M","2026","Turkish journal of surgery","nonrandomized_study","article","10.47717/turkjsurg.2026.2026-4-35","42830623",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000816","Evaluation of GLP-1 receptor agonist therapy in the management of steroid-induced diabetes: a narrative review.","Jędrasek A","2026","Frontiers in clinical diabetes and healthcare","narrative_review","article","10.3389/fcdhc.2026.1772391","42038034","PMC13105962",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0000817","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Prompting a Meaningful Improvement in Alcohol Use Disorder.","Meilinger A","2026","Journal of primary care & community health","case_report","article","10.1177/21501319261437615","41914511","PMC13039557",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0000818","Weight maintenance after discontinuation of GLP-1 therapies.","Moiz A","2026","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2026.103992","42256676","PMC13240724",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000819","The combination of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis.","Avogaro A","2026","Acta diabetologica","systematic_review","article","10.1007/s00592-026-02666-9","41706180","PMC13468739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000820","The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.","Nunns M","2026","Health technology assessment (Winchester, England)","systematic_review","article","10.3310/skht8119","40580049","PMC12336958",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Scoping Review; article"],["R0000821","Glucagon-like peptide-1 receptor agonists and gastric emptying time: a systematic review and meta-analysis of prospective studies.","Chen A","2026","Canadian journal of anaesthesia = Journal canadien d'anesthesie","systematic_review","article","10.1007/s12630-026-03114-6","42087044","PMC13249630","PROSPERO:CRD42023461665",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0000822","Medication Safety and Perioperative Risk Management of GLP-1 Receptor Agonists: A Pharmacist-Led Framework for Individualized Care.","Shen N","2026","Therapeutics and clinical risk management","nonrandomized_study","article","10.2147/tcrm.s623743","42666740","PMC13523872",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000823","Reassessing the role of GLP-1 receptor agonists in colorectal cancer Care.","Wang B","2026","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2026.101742","41698477",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0000824","ABSTRACT NUMBER: ESOC2026LT58 LT58 - GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN ACUTE LARGE VESSEL OCCLUSION STROKE TREATED BY REPERFUSION THERAPIES (GALLOP-2) – A MULTICENTER, RANDOMIZED, OPEN-LABEL, BLINDED END-POINT TRIAL",null,"2026","European stroke journal","randomized_trial","article",null,null,"PMC13144785",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0000825","Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials.","Zou M","2026","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-026-02179-z","42121292","PMC13343907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000826","Advances in weight-loss-independent cardiovascular protective mechanisms of GLP-1 receptor agonists.","Ma J","2026","Peptides","narrative_review","article","10.1016/j.peptides.2026.171519","42778024",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000827","Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus.","Alqifari SF","2024","World journal of diabetes","narrative_review","article","10.4239/wjd.v15.i3.331","38591071","PMC10999055",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000828","Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes.","Noh Y","2026","Diabetes care","nonrandomized_study","article","10.2337/dc25-2577","41701611",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; other; article"],["R0000829","Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.","Ismaiel A","2025","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-025-01859-6","40804463","PMC12532569",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review-article; review"],["R0000830","Glucagon-Like Peptide-1 Receptor Agonist Use in Obese Patients Is Associated With Decreased Risk of Revision and Retears After Arthroscopic Rotator Cuff Repair.","Omurzakov A","2026","Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association","nonrandomized_study","article","10.1002/arj.70370","42314072",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000831","GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials.","Sun SP","2026","Hepatology international","systematic_review","article","10.1007/s12072-026-11132-1","42509395",null,"PROSPERO:CRD420261287573",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0000832","Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2.","Shao Q","2025","Frontiers in molecular biosciences","narrative_review","article","10.3389/fmolb.2025.1729904","41573745","PMC12819216",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000833","Obesity Management: Pharmacotherapy.","Rhodes MA","2026","FP essentials","narrative_review","article",null,"42101582",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000834","Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA.","Tian Z","2026","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2026.104176","42701458","PMC13545350",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000835","The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism.","Shantaram D","2025","Diabetes","other","article","10.2337/db24-0861","40663700","PMC12365420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0000836","Eating Disorder Risk and Screening in Patients Using GLP-1RAs: Lessons Learned From Metabolic and Bariatric Surgery.","Herb Neff KM","2026","The International journal of eating disorders","other","article","10.1002/eat.70180","42502918",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000837","Improvement in chronic lymphedema in a gynecologic cancer survivor after starting GLP-1 receptor agonist therapy: A case report.","Fromson A","2026","Gynecologic oncology reports","case_report","article","10.1016/j.gore.2026.102132","42305902","PMC13267697",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0000838","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Adverse Events in Patients Receiving Platinum Analog-Based Chemotherapy.","Vemulapalli V","2026","American journal of clinical oncology","nonrandomized_study","article","10.1097/coc.0000000000001358","42574286",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000839","An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs.","Zayed MF","2026","Current pharmaceutical design","nonrandomized_study","article","10.2174/0113816128375766250720234005","40798976",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0000840","Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis.","Nogueira A","2026","Diabetes care","systematic_review","article","10.2337/dc25-1238","41498755",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; other; article"],["R0000841","Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes Mellitus: A Population-Based Longitudinal Cohort Study.","Cheng HW","2025","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.70058","40481813","PMC12145076",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0000842","Combined Glucagon-like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Use and Survival.","Reule S","2026","AACE endocrinology and diabetes","nonrandomized_study","article","10.1016/j.aed.2025.12.001","41938315","PMC13043450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000843","Wound Healing Effects of Polyethylene Glycol Loxenatide via PI3K/AKT Pathway: In Vitro Evaluation in Human Keratinocytes.","Zhao Z","2026","Journal of diabetes research","preclinical","article","10.1155/jdr/6683809","42017759","PMC13101450",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000844","Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.","Anderson BJ","2026","The Annals of otology, rhinology, and laryngology","narrative_review","article","10.1177/00034894261450724","42126155",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000845","Glucagon-like peptide-1 receptor agonist dulaglutide attenuates liver injury in metabolic dysfunction-associated steatotic liver disease with diabetic mice.","Wang Y","2026","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2026.179251","42607855",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000846","Interpretable machine learning for rare events: an inverse probability weighted application to understanding glucagon-like peptide-1 receptor agonists use and incident alcohol-related disorder.","Gautam R","2026","Alcohol and alcoholism (Oxford, Oxfordshire)","nonrandomized_study","article","10.1093/alcalc/agag045","42322639",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000847","Post Weight Loss Body Contouring Surgery: Complication Rates Following Bariatric Surgery, Injectable Glucagon-like Peptide-1 Receptor Agonist Pharmacotherapy, Combination Therapy, and Lifestyle Modification.","Abbott EN","2026","Aesthetic surgery journal","nonrandomized_study","article","10.1093/asj/sjag049","41742366","PMC13481096",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0000848","GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease.","Zarei M","2026","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-026-02196-y","42271434","PMC13479717",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000849","EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.","European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu","2026","Journal of hepatology","other","article","10.1016/j.jhep.2026.08.028","42805503",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0000850","GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Diabetes and Chronic Pancreatitis: A Real World Cohort Study of Pancreatic Outcomes","Dhali A","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-10331792/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0000851","The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.","Kornelius E","2024","Scientific reports","nonrandomized_study","article","10.1038/s41598-024-75965-2","39424950","PMC11489776",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000852","Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity-A Meta-Analysis.","Rego de Figueiredo I","2026","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.70098","41640092","PMC13535706","PROSPERO:CRD420251074381",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; Review; article"],["R0000853","The Association Between Glucagon-like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Thoracic Aortic Aneurysm.","Raslan MA","2026","Diagnostics (Basel, Switzerland)","nonrandomized_study","article","10.3390/diagnostics16111742","42279609","PMC13257157",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000854","Reply to letter to the editor by Singh et al.","Puga T","2026","Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association","nonrandomized_study","article","10.1016/j.jos.2026.06.008","42420094",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Letter"],["R0000855","Glucagon-like peptide-1 receptor agonists and healthcare use in older adults with heart failure and obesity","Acheampong C","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.07.24.26358897",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0000856","Glucagon-like Peptide-1 Receptor Agonists in Rheumatoid Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects.","Buonanno S","2026","Journal of personalized medicine","randomized_trial","article","10.3390/jpm16060284","42346595","PMC13300951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000857","GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.","Conforti A","2026","Drug discovery today","narrative_review","article","10.1016/j.drudis.2026.104786","42637139",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000858","Effect of glucagon-like peptide-1 receptor agonist on paclitaxel induced neurotoxicity in dorsal root ganglion neuronal cells in vitro.","Jung Y","2025","The Korean journal of pain","preclinical","article","10.3344/kjp.24419","40485178","PMC12221959",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000859","Efficacy of GLP-1 Receptor agonists in treating Obstructive sleep apnea: A systematic review and meta-analysis of cardiometabolic and respiratory outcomes.","Dandamudi M","2026","Sleep & breathing = Schlaf & Atmung","systematic_review","article","10.1007/s11325-026-03681-4","42029967","PMC13109165",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0000860","A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.","Alali S","2025","Frontiers in nutrition","other","article","10.3389/fnut.2025.1590379","40458827","PMC12127183",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000861","The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?","Seyed Jafari SM","2026","American journal of clinical dermatology","narrative_review","article","10.1007/s40257-026-01021-6","41957308",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000862","GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease.","Hölscher C","2026","Frontiers in neuroscience","other_trial","article","10.3389/fnins.2026.1906426","42666495","PMC13522209",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000863","Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic Review.","Alsanosi ZY","2026","Cureus","systematic_review","article","10.7759/cureus.114350","42725235","PMC13561143",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000864","Commentary: Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.","Hanke CW","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","nonrandomized_study","article","10.1097/dss.0000000000005173","42210893",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; editorial"],["R0000865","The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management.","Johnson A","2026","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2025-0219","41818791",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000866","Widespread exposure to GLP-1RAs and weight loss-related discourse: Considering potential public health implications.","Côté M","2026","Canadian journal of public health = Revue canadienne de sante publique","other","article","10.17269/s41997-026-01197-8","41986775",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000867","Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use.","Kelly A","2026","Irish medical journal","case_report","article",null,"41589628",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0000868","Comment on Park et al. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes. Diabetes Care 2026;49:147-151.","Maltese G","2026","Diabetes care","commentary","article","10.2337/dc25-2930","41861131","PMC13006810",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0000869","Perioperative Management of Patients on GLP-1 Receptor Agonists: Clinical Implications and Best Practices","Jones B","2025","Preprints.org","other","preprint","10.20944/preprints202506.0860.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0000870","Transforming Care: Implications of Glucagon Like Peptide-1 Receptor Agonists on Physical Therapist Practice.","Mulcahy J","2025","Physical therapy","narrative_review","article","10.1093/ptj/pzaf061","40305684","PMC12203058",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0000871","How Bioethics and Reproductive Justice Ought to Inform Glucagon-Like Peptide-1 Receptor Agonists, Research, and Pregnancy.","Pondugula N","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.70047","41271564",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0000872","Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States.","Ofili SC","2026","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2026.32.2.166","41636679","PMC12871523",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; research-article; article"],["R0000873","Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation study.","Xiang YJ","2026","Gut","nonrandomized_study","article","10.1136/gutjnl-2026-338462","42399086",null,"ChiCTR:ChiCTR2600118495",null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000874","Preoperative GLP-1 receptor agonist use and outcomes after total hip arthroplasty: a matched cohort study.","Diab AR","2026","Hip international : the journal of clinical and experimental research on hip pathology and therapy","nonrandomized_study","article","10.1177/11207000261476202","42725550",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000875","Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis.","Ateiwi YA","2026","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2026.113158","41722869",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0000876","Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.","Alansari AO","2025","Medicine","systematic_review","article","10.1097/md.0000000000046173","41366934","PMC12688971",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0000877","Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.","He D","2026","Frontiers in cardiovascular medicine","systematic_review","article","10.3389/fcvm.2026.1868320","42723815","PMC13557988",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0000878","Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports.","Di Stefano R","2025","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2025.103238","40388845",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0000879","The emerging role of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: Therapeutic potential and challenges.","Thandampallayam M","2026","Indian journal of ophthalmology","narrative_review","article","10.4103/ijo.ijo_1125_25","42535806","PMC13485101",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000880","Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities","Sehgal NKR","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.03.12.26348253",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint; article"],["R0000881","The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Psoriasis and Hidradenitis Suppurativa.","Morales JK","2026","The Journal of clinical and aesthetic dermatology","randomized_trial","article",null,"41890772","PMC13016449",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000882","Glucagon-like peptide-1 receptor agonists and risk of depression: a systematic review and meta-analysis.","Bi Z","2026","BMC psychiatry","systematic_review","article","10.1186/s12888-026-08016-x","41904417","PMC13151306",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review-article; review"],["R0000883","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obesity.","Huang SC","2026","Drug design, development and therapy","randomized_trial","article","10.2147/dddt.s609054","42292155","PMC13263172",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000884","Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Metabolism and the Expression of Insulin Receptor Substrate 1 in an Osteoporotic Rat Model.","Ye Y","2026","International journal of endocrinology","randomized_trial","article","10.1155/ije/4418640","41788539","PMC12957885",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000885","Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses.","Ramzy D","2026","Cureus","systematic_review","article","10.7759/cureus.113641","42668799","PMC13525620",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0000886","Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.","Cannon EJ","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70711","42464447",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000887","Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.","Xie Z","2024","Risk management and healthcare policy","nonrandomized_study","article","10.2147/rmhp.s455897","38680477","PMC11055556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000888","Endoscopy and anesthesia outcomes associated with glucagon-like peptide-1 receptor agonist use in patients undergoing outpatient upper endoscopy.","Panchal S","2025","Gastrointestinal endoscopy","nonrandomized_study","article","10.1016/j.gie.2025.01.004","39824444","PMC12260032",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0000889","Real-World Adherence Trajectories of GLP-1 Receptor Agonists Among Adults and Paediatric Patients With Obesity.","Huang W","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71299","42755139",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000890","Beyond Weight Loss: Glucagon-Like Peptide-1 Receptor Agonists and Antipsychotic Adherence in Schizophrenia.","López-Ibor I","2026","Cureus","randomized_trial","article","10.7759/cureus.114933","42765077","PMC13590060",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0000891","GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease.","Alicic RZ","2026","Nature reviews. Nephrology","narrative_review","article","10.1038/s41581-025-01036-y","41507425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0000892","Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.","Rosenstock J","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04476-6","42249138","PMC13472849","ClinicalTrials.gov:NCT06693843","S000899","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0000893","Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program.","Jennings I","2026","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwag279","42165511",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000894","Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies","Saldívar-Cerón HI","2025","Preprints.org","other_trial","preprint","10.20944/preprints202505.0972.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; article; preprint"],["R0000895","Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.","Srisurapanont M","2026","International journal of psychiatry in medicine","systematic_review","article","10.1177/00912174261422822","41618880",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0000896","Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan.","Chou YC","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70334","41346258","PMC12803572",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000897","Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies.","Caimi E","2026","Aesthetic plastic surgery","other","article","10.1007/s00266-026-06155-w","42477152",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000898","Reduced Epidermal p21 Expression Is Identified in Some Subjects on Systemic GLP-1 Receptor Agonists: A Hypothesis-Generating Pilot Study of Metabolic Modulation in Human Skin Senescence.","Wyles S","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","nonrandomized_study","article","10.1097/dss.0000000000005186","42210884",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0000899","Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis.","Lv L","2025","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","nonrandomized_study","article","10.1016/j.jval.2025.01.018","39947393",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0000900","The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant.","Abbas MT","2026","The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","nonrandomized_study","article","10.1016/j.healun.2026.01.003","41520801",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0000901","GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions.","Gandhi A","2025","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2025.1708565","41356006","PMC12675206",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000902","Prevalence and Clinical Characteristics of Patients With Heart Failure With Preserved Ejection Fraction Who Meet the Obesity-Related Eligibility Criteria for Subcutaneous Incretin Receptor Agonists in Japan　- Insights From the PARACLETE Study.","Nishikawa K","2026","Circulation journal : official journal of the Japanese Circulation Society","other","article","10.1253/circj.cj-25-1120","41967967",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000903","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortality.","McIntyre RS","2026","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2026.2621191","41565481",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0000904","Efficacy and Safety of GLP-1RAs including Tirzepatide, in the Management of Obesity in Nondiabetic Patients: A Systematic Review","Ndubuisi J","2024","Preprints.org","systematic_review","preprint","10.20944/preprints202407.2397.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0000905","An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes.","Bolli GB","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16616","40678871","PMC12308269",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0000906","Glucagon-like peptide 1 receptor agonists switching patterns in type two diabetes: A retrospective real-world study.","Kassem S","2025","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v16.i11.112999","41278443","PMC12635781",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000907","Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis.","Pham TP","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70635","41804851",null,"PROSPERO:CRD42024592825",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Network Meta-Analysis; Journal Article; Systematic Review; article"],["R0000908","GLP-1 receptor agonists beyond glycemic control: integrated cardio-renal-metabolic protection across the cardiovascular kidney metabolic continuum.","Elsayed A","2026","Cardiovascular diabetology. Endocrinology reports","nonrandomized_study","article","10.1186/s40842-026-00322-3","42702727","PMC13548558",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0000909","Comments on the reduced risk of psoriatic arthritis in patients with psoriasis treated with glucagon-like peptide-1 receptor agonists.","Chang TH","2026","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2026.03.111","42036016",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0000910","GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes.","Tawfik F","2026","Journal of neurology","nonrandomized_study","article","10.1007/s00415-026-14127-y","42704495",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0000911","Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework.","Dalbeni A","2025","Cancer medicine","systematic_review","article","10.1002/cam4.71434","41388641","PMC12701129",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review-article; article"],["R0000912","Comparison of Perioperative Glycemic Control in Patients Continuing Versus Temporarily Holding Glucagon-Like Peptide-1 Receptor Agonists or Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists Preoperatively.","Trykall CC","2026","AACE endocrinology and diabetes","nonrandomized_study","article","10.1016/j.aed.2026.02.002","42221394","PMC13221920",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000913","Risk of Dementia after initiation of GLP-1 RA versus long-acting insulin in patients with type 2 Diabetes mellitus.","Lin CH","2026","The journal of prevention of Alzheimer's disease","randomized_trial","article","10.1016/j.tjpad.2026.100645","42570467","PMC13476480",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000914","Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.","Lake JE","2026","HIV medicine","other_trial","article","10.1111/hiv.70292","42517548","PMC13631692",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial, Phase II; research-article; article"],["R0000915","Weight Loss-Independent Mechanisms of Kidney Protection With Glucagon-Like Peptide 1 Receptor Agonists and Implications for Clinical Practice.","Friedman AN","2026","American journal of kidney diseases : the official journal of the National Kidney Foundation","randomized_trial","article","10.1053/j.ajkd.2026.03.037","42140342",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000916","Comment on \"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","M A","2026","Journal of the neurological sciences","systematic_review","article","10.1016/j.jns.2026.125953","42176522",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0000917","Glucagon-like Peptide-1 Receptor Agonists and Colorectal Cancer Risk.","Winkelman JW","2026","AACE endocrinology and diabetes","randomized_trial","article","10.1016/j.aed.2026.02.013","42221415","PMC13221934",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000918","Targeting Metainflammation in Hidradenitis Suppurativa: The Emerging Role of GLP-1 Receptor Agonists and Metabolic Pharmacotherapies","Brogaard E","2026","Preprints.org","other","preprint","10.20944/preprints202608.1275.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint; article"],["R0000919","Economic evaluation of sodium-glucose transporter 2 inhibitors compared with glucagon-like peptide 1 receptor agonist for the treatment of type 2 diabetes: a systematic review.","Wang L","2026","European journal of clinical pharmacology","systematic_review","article","10.1007/s00228-026-04015-9","41811375",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Comparative Study; Review; review"],["R0000920","Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy.","AbuAlrob MA","2026","Epilepsia","nonrandomized_study","article","10.1111/epi.70022","41251033",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0000921","Effects of glucagon-like peptide-1 receptor agonists on anthropometric and adiposity measures in patients with antipsychotic-induced weight gain: A systematic review and meta-analysis.","Lee S","2026","Journal of psychopharmacology (Oxford, England)","systematic_review","article","10.1177/02698811261456190","42312633",null,"PROSPERO:CRD420251118829",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; review"],["R0000922","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Cutaneous Biology: Implications for Skin Disease and Longevity.","Vyas K","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","randomized_trial","article","10.1097/dss.0000000000005187","42210887",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000923","Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-Analysis.","Lalani I","2026","Cancer control : journal of the Moffitt Cancer Center","systematic_review","article","10.1177/10732748261483767","42677883","PMC13535051",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; Review; review"],["R0000924","Clinical Knowns and Mechanistic Unknowns: Cardioprotection and Inflammation Modulation of GLP-1 Receptor Agonists and SGLT2 Inhibitors.","Kim EY","2026","The Canadian journal of cardiology","narrative_review","article","10.1016/j.cjca.2026.02.024","41722857","PMC12971158",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0000925","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Mediating Myocardial Resilience in Cardiac Surgery.","Venkatesan A","2026","Cardiology in review","other","article","10.1097/crd.0000000000001330","42190075",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000926","Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network.","Kazi MAI","2026","Journal of gastrointestinal cancer","nonrandomized_study","article","10.1007/s12029-026-01523-w","42745130",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000927","Glucagon-Like Peptide-1 Receptor Agonist Therapy and Neurocognitive Outcomes in Medically Managed Idiopathic Intracranial Hypertension: A Propensity Score-Matched Cohort Study.","Ahmed S","2026","AJNR. American journal of neuroradiology","nonrandomized_study","article","10.3174/ajnr.a9559","42527309",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0000928","Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain","Jackson SE","2025","medRxiv","other","preprint","10.1101/2025.06.06.25329114",null,null,"OSF:osf.io/r2whq",null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0000929","Exendin-4, a glucagon-like peptide-1 receptor agonist, alleviates muscular dysfunction and wasting in a streptozotocin-induced diabetic mouse model compared to metformin.","Chan DC","2024","Tissue & cell","preclinical","article","10.1016/j.tice.2024.102479","39018713",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0000930","Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study.","Jeon M","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113091","41513044",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000931","Clinical Effectiveness and Safety of Oral Semaglutide in a Real-World Cohort of Patients with Heart Failure with Reduced Ejection Fraction, Type 2 Diabetes and Obesity: A Propensity Score-Matched Analysis.","Trenas-Calero A","2026","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19060894","42356512","PMC13305021",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0000932","Utilization and Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients.","Metoyer G","2025","Clinical transplantation","nonrandomized_study","article","10.1111/ctr.70354","41123471",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000933","Expanding Evidence for Glucagon-Like Peptide-1 Receptor Agonists in Those with Diabetes and Kidney Disease.","Holliday MW","2026","Clinical journal of the American Society of Nephrology : CJASN","commentary","article","10.2215/cjn.0000001072","41960971","PMC13143466",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0000934","Dementia progression with GLP-1 receptor agonists in people with mild cognitive impairment and type 2 diabetes: target-trial emulation study.","Schechter M","2026","Alzheimer's & dementia (New York, N. Y.)","randomized_trial","article","10.1002/trc2.70315","42769274","PMC13590930",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0000935","Impact of glucagon-like peptide-1 receptor agonists on colonoscopy outcomes: a systematic review and meta-analysis.","Abdulraheem A","2026","Clinical endoscopy","systematic_review","article","10.5946/ce.2025.137","41943648","PMC13058711",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0000936","Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis.","Greenblatt ZL","2026","Metabolism open","systematic_review","article","10.1016/j.metop.2026.100484","42434480","PMC13351396",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0000937","Effects of GLP-1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review.","Santos Dantas R","2026","The FEBS journal","systematic_review","article","10.1111/febs.70656","42625391",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Review; review"],["R0000938","Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Postmastectomy Lymphedema in Breast Cancer Survivors: A Multicenter Real-World Cohort Study","Yesho DH","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-10121512/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0000939","Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.","Silva JPMRJ","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71051","42410309","PMC13449074","PROSPERO:CRD420261354941",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Comparative Study; research-article; review"],["R0000940","Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events in Adults With Obesity and Autoimmune Disease: A Target Trial Emulation.","Dai H","2026","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.125.047893","42250252",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0000941","Reply to \"Impact of Glucagon-like Peptide-1 Receptor Agonists on Metabolic Health in Liver Transplant Recipients\".","Kochunny A","2026","Transplantation","commentary","article","10.1097/tp.0000000000005708","41984759",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; letter"],["R0000942","Comment on \"Glucagon like peptide-1 receptor agonist therapy and long-term renal outcomes after radical nephrectomy: a propensity-matched cohort analysis\".","Tribhuvan M","2026","International urology and nephrology","nonrandomized_study","article","10.1007/s11255-026-05217-x","42189463",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0000943","Efficacy and safety of GLP-1RA on cardio-metabolic outcomes in overweight or obese Chinese adults: a systematic review and meta-analysis.","Bilal AR","2026","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-026-02000-8","42422116","PMC13341986",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review"],["R0000944","Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity.","Kavarian PN","2024","Current opinion in pediatrics","narrative_review","article","10.1097/mop.0000000000001379","39254757",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0000945","GLP-1 Receptor Agonists in Adolescents: Emerging Endocrine, Reproductive, and Psychosocial Concerns.","Haider MA","2026","Journal of pediatric and adolescent gynecology","other","article","10.1016/j.jpag.2026.06.017","42364709",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000946","Effects of GLP-1 analogs on metabolic alterations including male sexual function, hypogonadism and erectile dysfunction: a narrative review.","Olivares A","2026","Translational andrology and urology","nonrandomized_study","article","10.21037/tau-2026-0285","42582759","PMC13458544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0000947","Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.","Harris A","2026","JAMA otolaryngology-- head & neck surgery","other_trial","article","10.1001/jamaoto.2026.2266","42690639",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0000948","GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity.","Simsek H","2026","Current nutrition reports","narrative_review","article","10.1007/s13668-026-00777-x","42303931","PMC13272609",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Scoping Review; review-article; article"],["R0000949","GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates.","Mastaitis JW","2025","Nature communications","preclinical","article","10.1038/s41467-025-59485-9","40360507","PMC12075787",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000950","Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.","White RT","2026","Pharmacotherapy","systematic_review","article","10.1002/phar.70135","41947645",null,"PROSPERO:CRD42024615851",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; review"],["R0000951","Return on investment of SGLT2 inhibitors and GLP-1 receptor agonists: Implications of real-world use for managed care.","Rapp H","2026","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2026.32.10.1167","42808548",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000952","Changes in Body Composition Assessed by Bioelectrical Impedance Analysis in Patients Treated With Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Experience.","Atencia Goñi J","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.09.005","42762981",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000953","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap-Informed Umbrella Review.","Lee O","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71325","42723273",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; article"],["R0000954","Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.","Salim H","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71375","42802242",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0000955","PD53 Glucagon-Like Peptide-1 Receptor Agonists And Polyagonists For Severe Obesity: Rapid Overview Of Outcomes Measurement",null,"2025","International journal of technology assessment in health care","other","article",null,null,"PMC12768723",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0000956","Comment on \"The combination of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis\".","Cao B","2026","Acta diabetologica","systematic_review","article","10.1007/s00592-026-02700-w","42089955",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0000957","Facelift Demand Among Patients Using Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss-Associated Facial Changes.","Harsinay A","2026","Facial plastic surgery & aesthetic medicine","other","article","10.1177/26893614261448298","42068024",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0000958","Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities.","Mukim RD","2026","Molecular biology reports","other_trial","article","10.1007/s11033-026-12549-5","42573665",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0000959","The impact of glucagon-like peptide-1 receptor agonists on objective physical activity in adults: a systematic review and exploratory meta-analysis.","Kim H","2026","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-026-02141-z","42399550","PMC13649565",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review-article; review"],["R0000960","Risk of perioperative cardiorespiratory complications and mortality associated with preoperative glucagon-like peptide-1 receptor agonist use in type 2 diabetes mellitus. Comment on Br J Anaesth 2026; 136: 86-97.","Ciardi F","2026","British journal of anaesthesia","commentary","article","10.1016/j.bja.2026.04.069","42342495",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0000961","The Effect of Submaximal Doses of Semaglutide on the Expression of Microribonucleic Acid in Patients with Obesity: A Pilot Study.","Jurica J","2026","Obesity facts","other","article","10.1159/ofa/adzag002","42821500",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0000962","Indications, efficacy, and safety of glucagon-like peptide-1 receptor agonists in respiratory diseases: A systematic review.","Esmaeel MN","2026","Journal of family medicine and primary care","systematic_review","article","10.4103/jfmpc.jfmpc_1811_25","42257115","PMC13241106",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0000963","Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation.","Xie Y","2026","BMJ medicine","nonrandomized_study","article","10.1136/bmjmed-2025-002150","41877758","PMC13007077",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000964","Real-World Evidence of the GLP-1RA/SGLT2-i Therapy versus Standard Care: A Retrospective Cohort Study.","Mahmoud NM","2026","Clinical medicine insights. Endocrinology and diabetes","nonrandomized_study","article","10.1177/11795514261471399","42643762","PMC13504133",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000965","Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial.","Sklepinski SM","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112910","40983112",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0000966","Efficacy and safety of glucagon-like peptide-1 receptor agonists for diabetic cardiomyopathy: a protocol for systematic review and meta-analysis.","Tang B","2026","BMJ open","systematic_review","article","10.1136/bmjopen-2026-121200","42642087","PMC13536143","PROSPERO:CRD420261360886",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0000967","Recent advances in the treatment of chronic liver diseases: focus on MASLD/MASH-related fibrosis.","Jędrysik M","2026","Clinical and experimental hepatology","other_trial","article","10.5114/ceh.2026.161043","42724836","PMC13559701",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0000968","Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.","McIntyre RS","2026","JAMA psychiatry","randomized_trial","article","10.1001/jamapsychiatry.2026.2574","42647034",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0000969","Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.","Lee S","2025","Therapeutic advances in psychopharmacology","systematic_review","article","10.1177/20451253251396304","41445693","PMC12722685",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000970","Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters.","Abuetabh Y","2026","JCI insight","preclinical","article","10.1172/jci.insight.201810","42262870","PMC13464422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0000971","Pharmacokinetics of novel drugs for the treatment of diabetic nephropathy.","Mousavi T","2026","Expert opinion on drug metabolism & toxicology","nonrandomized_study","article","10.1080/17425255.2026.2729203","42709045",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0000972","Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.","Panou T","2026","Advances in therapy","narrative_review","article","10.1007/s12325-026-03599-z","41991874","PMC13290921",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000973","Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease.","Obi MF","2026","Cureus","narrative_review","article","10.7759/cureus.106266","42078285","PMC13134359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000974","Chilean Multidisciplinary Consensus on the Use of GLP-1 Receptor Agonists: Recommendations Based on the GRADE Methodology.","Cabrera S","2026","Revista medica de Chile","randomized_trial","article","10.4067/s0034-98872026000701070","42809786",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Consensus Statement; Journal Article; article"],["R0000975","The association between genetically proxied GLP-1 receptor agonists and cancer risks.","Zhou F","2026","Annals of medicine and surgery (2012)","other","article","10.1097/ms9.0000000000005253","42433766","PMC13354389",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000976","Comparative Cardiovascular Outcomes and Safety Profiles of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Trials.","Mohamed Abdalla SA","2026","Cureus","systematic_review","article","10.7759/cureus.111723","42529614","PMC13418259",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0000977","Sepsis risk in patients with COPD and type 2 diabetes mellitus: influence of emerging antihyperglycemic therapies.","Kuo KC","2026","Expert review of respiratory medicine","nonrandomized_study","article","10.1080/17476348.2026.2713233","42543031",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; Comparative Study; other; article"],["R0000978","Comment on \"Prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study\".","Salman M","2026","European journal of clinical pharmacology","commentary","article","10.1007/s00228-026-04055-1","42036491",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0000979","Genetic evidence for a causal protective effect of GLP-1 receptor agonists on paralytic ileus but not on other gastrointestinal events.","Yuan B","2026","Medicine","other","article","10.1097/md.0000000000048089","41861181","PMC13008193",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000980","Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control.","Xanthopoulou M","2026","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph19030462","41901309","PMC13029718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000981","GLP-1 Receptor Agonists in Cardiac Surgery: From Metabolic Drug to Potential Perioperative Cardioprotective Agent.","Androutsopoulou V","2026","Journal of cardiovascular development and disease","randomized_trial","article","10.3390/jcdd13070305","42505882","PMC13409872",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0000982","GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction.","Javaid SS","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.06.008","42264283",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000983","Diabetes-type-specific thyroid safety of GLP-1 receptor agonists: evidence from a large real-world cohort.","Hsieh HI","2026","Therapeutic advances in endocrinology and metabolism","nonrandomized_study","article","10.1177/20420188261460619","42389160","PMC13319793",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000984","Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives.","Meier M","2026","Kidney medicine","narrative_review","article","10.1016/j.xkme.2026.101282","41808780","PMC12969668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0000985","Correction to \"Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review\".",null,"2026","Journal of obesity","notice","article","10.1155/jobe/9821679","41641176","PMC12867086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0000986","GLP-1 receptor agonists and conscious sedation.","Holder EK","2026","Interventional pain medicine","other","article","10.1016/j.inpm.2025.100734","41585429","PMC12828509",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0000987","GLP-1 Receptor Agonists and Obesity Related Cancers: What We Know So Far.","Raja NP","2026","Current oncology reports","randomized_trial","article","10.1007/s11912-026-01825-z","42645635",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0000988","Association Between GLP-1 Receptor Agonist Use and Postpartum Pelvic Complications: A Global Matched Cohort Study","Hammad MAM","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-10580243/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0000989","Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders.","Sabbagh MN","2026","Nature aging","narrative_review","article","10.1038/s43587-025-01029-3","41419667","PMC13528608",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0000990","Perioperative and Renal Outcomes After Nephrectomy in Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists: A Pilot Study.","Weitzner AS","2026","Urology practice","nonrandomized_study","article","10.1097/upj.0000000000001007","41886402",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000991","GLP-1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis.","Malka RE","2026","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","nonrandomized_study","article","10.1002/ohn.70327","42405847",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000992","Glucagon-Like Peptide-1 Receptor Agonists in Hip and Knee Arthroplasty: A Comprehensive Systematic Review and Meta-Analysis of Perioperative and Postoperative Outcomes.","Wajda B","2026","Arthroplasty today","systematic_review","article","10.1016/j.artd.2026.102043","42182892","PMC13197706",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0000993","One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.","Donnelly LA","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70269","41189335","PMC12803620",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0000994","GLP-1 Receptor Agonist Exposure and Malignancy Risk in Patients With Endogenous Cushing's Syndrome.","Dotan I","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag223","42233686",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0000995","Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists.","Batty JA","2026","BMJ medicine","commentary","article","10.1136/bmjmed-2026-002704","41877757","PMC13007122",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0000996","Changes in Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Exposures Following Recent Demand for Weight Management: A Retrospective Review of California Poison Control System Data.","Ho RY","2025","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","nonrandomized_study","article","10.1177/87551225251332212","40371098","PMC12069307",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0000997","Glucagon-Like Peptide-1 Receptor Agonists and Cirrhosis.","Janardhan S","2026","Gastroenterology & hepatology","other","article",null,"41884641","PMC13011860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0000998","Commentary on 'effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity'.","Liang Y","2026","European journal of heart failure","randomized_trial","article","10.1093/ejhf/xuaf022","41771083",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Editorial; Comment; editorial"],["R0000999","Glucagon-like peptide-1 receptor agonists ameliorate polycystic ovarian syndrome in mice by regulating the irisin level and activating the BMP4-Smad signaling pathway†.","Yang Y","2026","Biology of reproduction","preclinical","article","10.1093/biolre/ioag065","41892800",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001000","From metformin to glucagon-like peptide-1 receptor agonists: can metabolic modulation enhance progestin therapy for endometrial cancer?","Martins JC","2026","International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","commentary","article","10.1016/j.ijgc.2026.104705","42105616",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0001001","Glucagon-like peptide-1 receptor agonists & thyroid cancer: What thyroid surgeons should know.","Yuan L","2026","American journal of surgery","commentary","article","10.1016/j.amjsurg.2026.116975","41990629",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0001002","Duration of GLP-1 Receptor Agonist Therapy and Nephrolithiasis Risk in Type 2 Diabetes: A Multicenter Retrospective Cohort Study","Othman L","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-10951421/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001003","Association of Glucagon-Like Peptide-1 Receptor Agonist with Incident Atrial Fibrillation.","Khalil S","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","nonrandomized_study","article","10.1007/s40256-025-00751-y","40682632",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001004","A systematic review and meta-analyses of glucagon-like peptide-1 receptor agonists in acute myocardial infarction.","Bhullar JK","2026","The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology","systematic_review","article","10.1186/s43044-026-00767-y","42479368","PMC13388624",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; other; review"],["R0001005","Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus.","Park MJ","2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxag086","41870187",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001006","GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes.","Ko CS","2026","Journal of metabolic and bariatric surgery","narrative_review","article","10.17476/jmbs.2026.15.1.28","42124784","PMC13158175",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001007","Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations.","Kim MK","2026","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes25081","41819567","PMC13158034",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001008","Gastric ultrasound to assess the prokinetic efficacy of erythromycin in a patient taking glucagon-like peptide-1 receptor agonists.","Sidhu NS","2025","Anaesthesia reports","other","article","10.1002/anr3.70008","40236817","PMC11998948",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0001009","Adult Annular Pancreas Presenting With Gastric Outlet Obstruction Following Semaglutide Initiation: A Case Report.","Gamaleldin F","2026","Cureus","case_report","article","10.7759/cureus.111636","42523990","PMC13408417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001010","Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes.","Schwarz CR","2026","Pediatrics","case_report","article","10.1542/peds.2025-074286","42097623",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0001011","Exploring Glucagon-Like Peptide-1 Receptor Agonists Usage Among Non-Diabetic Healthcare Providers: A Cross-Sectional Multi-Country Study.","Nashwan AJ","2025","Health science reports","other","article","10.1002/hsr2.70638","40276133","PMC12018279",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001012","Integrating GLP-1 Receptor Agonists into Modern Stroke Prevention: Evidence, Mechanisms, and Clinical Consideration-A Narrative Review.","Khan S","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14040743","42072284","PMC13113324",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0001013","GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD.","Lee WT","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","nonrandomized_study","article","10.1093/ndt/gfag032","41697144",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001014","Association of GLP-1 receptor agonist use with long-term outcomes in patients with opioid use disorder.","Lakhani DA","2026","Journal of addictive diseases","nonrandomized_study","article","10.1080/10550887.2026.2653228","42116696",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001015","The dual role of GLP-1 receptor agonists in weight management and eating disorders: Potential benefits and risks.","Leziak A","2026","Journal of psychiatric research","narrative_review","article","10.1016/j.jpsychires.2026.03.008","41806782",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001016","Low dose systemic AAV-exendin-4 gene therapy for Prader-Willi syndrome and dietary obesity.","Huang W","2026","Molecular therapy. Advances","preclinical","article","10.1016/j.omta.2026.201718","42137604","PMC13148920",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001017","GLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023.","Chu PY","2026","Pediatrics","nonrandomized_study","article","10.1542/peds.2025-071971","41765350","PMC13374117",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001018","Glucagon‐like peptide‐1 receptor agonists for neurological disorders: a systematic review and meta‐analysis","Manolopoulos A","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","systematic_review","article","10.1002/alz70859_098720","41447172","PMC12739814",null,null,"europepmc; openalex","TRUE","open_europepmc","3","FALSE","Abstract; review"],["R0001019","The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis.","Emptage I","2026","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2026.104007","42666688","PMC13523834","PROSPERO:CRD42024570728",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001020","Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation.","Glaser K","2025","World journal of cardiology","nonrandomized_study","article","10.4330/wjc.v17.i7.107510","40741027","PMC12304861",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001021","The effect of GLP-1 receptor agonists on anxiety: A systematic review.","Yi YT","2026","Psychoneuroendocrinology","systematic_review","article","10.1016/j.psyneuen.2026.107844","41931929",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0001022","Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation.","Tobaiqy M","2026","Drug design, development and therapy","randomized_trial","article","10.2147/dddt.s622972","42544311","PMC13429114",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0001023","GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study.","Mahmoud AK","2026","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2026.134588","42203003",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0001024","Reply to commentary on 'effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular kidney-metabolic comorbidity'.","Siddiqi TJ","2026","European journal of heart failure","randomized_trial","article","10.1093/ejhf/xuaf004","41771103",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Editorial; Comment; letter"],["R0001025","GLP-1 receptor agonists in obesity-related knee osteoarthritis: from weight loss to therapeutic pathway reconstruction.","Wu J","2026","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2026.1856307","42389272","PMC13318696",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001026","Dietary Intake as an Undermeasured Potential Mediator: The Ethical Case for Complete and Transparent Dietary Reporting in GLP-1 Receptor Agonist Trials.","Strosahl JN","2026","Nutrients","nonrandomized_study","article","10.3390/nu18162722","42654302","PMC13516648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; other; article"],["R0001027","GLP-1 receptor agonists and surgical care: implications for bariatric Procedures, perioperative Outcomes, and nutritional optimization.","Elawa Z","2026","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2026.113332","42155603",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001028","Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review.","Wu H","2026","Frontiers in medicine","systematic_review","article","10.3389/fmed.2026.1783429","42292219","PMC13253451",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0001029","GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies.","Alourfi NM","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s584052","41907109","PMC13022896",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001030","Diabetic Ketoacidosis Risk in Sodium-Glucose Cotransporter 2 Inhibitors versus Glucagon-Like Peptide-1 Receptor Agonists Initiators with CKD Stages 3-4 and Type 2 Diabetes.","Hansrivijit P","2026","Kidney360","nonrandomized_study","article","10.34067/kid.0000001144","41627917","PMC13337201",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001031","Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?","Gogineni P","2024","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2024.2356254","38753454","PMC11195668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0001032","The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis.","Sinha B","2025","Addiction science & clinical practice","systematic_review","article","10.1186/s13722-025-00637-z","41350683","PMC12805745","PROSPERO:CRD420251045294",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0001033","Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review.","Urbina J","2026","Clinical obesity","nonrandomized_study","article","10.1111/cob.70070","41549912",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; review"],["R0001034","Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes: What we've Learned and What Comes Next.","Innes R","2026","Endocrinology and metabolism clinics of North America","other_trial","article","10.1016/j.ecl.2026.04.002","42526994",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0001035","Safety, tolerability and efficacy of GLP-1 receptor agonists (GLP-1 RA) in the management of post-liver transplant weight gain: A multicenter, observational study.","Khan MQ","2026","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","randomized_trial","article","10.1097/lvt.0000000000000917","42208060",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0001036","Glucagon-Like Peptide-1 Receptor Agonists in Orthopedics: A Scoping Review of Emerging Applications.","Regmi A","2026","Indian journal of orthopaedics","nonrandomized_study","article","10.1007/s43465-025-01614-z","42483241","PMC13385562",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; article"],["R0001037","Therapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal.","Ziegler D","2026","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-026-02241-w","42533340","PMC13425879",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001038","Assessing the efficacy of large language models in data extraction for a meta-analysis on the role of glucagon-like peptide-1 receptor agonists in heart failure",null,"2026","European heart journal. Digital health","systematic_review","article",null,null,"PMC12794896",null,null,"europepmc","TRUE","open_europepmc","3",null,"research-article; Journal Article"],["R0001039","Gut-Derived GLP-1 Released by Rare Sugar d-Allulose Cooperates With Insulin to Activate Left-Sided Vagal Afferents and Enhance Insulin Sensitivity.","Ohbayashi K","2026","Diabetes","preclinical","article","10.2337/db25-1134","42062836",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Preprint; other; article; preprint"],["R0001040","Aesthetic Considerations for Preventing and Managing GLP-1 Receptor Agonist-Related Facial Aging.","Bommareddy K","2026","The Journal of clinical and aesthetic dermatology","other","article",null,"42761689","PMC13588480",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Other; article"],["R0001041","Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling.","Shah PP","2026","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2026.101418","41608676","PMC12834930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0001042","Glucagon-Like Peptide-1 Receptor Agonists and Outcomes After Intracerebral Hemorrhage in Patients With Type 2 Diabetes: A Propensity-Matched Cohort Study.","Ruchika F","2026","Neurosurgery","nonrandomized_study","article","10.1227/neu.0000000000004079","42084373",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001043","A Text Messaging-Based Program to Transition From Basal Insulin to Glucagon-Like Peptide-1 Receptor Agonists in Safety-Net Diabetes Care: Pilot Quality Improvement Intervention Study.","Levy N","2026","JMIR formative research","other_trial","article","10.2196/76993","41955563","PMC13065235",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0001044","Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review.","Graczyk NA","2026","Cureus","narrative_review","article","10.7759/cureus.101693","41704988","PMC12908505",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001045","Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon-Like Peptide-1 Receptor Agonist Versus a Fixed-Ratio Combination Therapy: A Japanese Database Study.","Miyatsuka T","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70812","42086460","PMC13243944",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0001046","WITHDRAWN: Can glucagon like peptide-1 receptor agonists be beneficial for brain health?","Ballabio G","2026","medRxiv","other","preprint","10.64898/2026.05.13.26353120",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Preprint-withdrawal; preprint"],["R0001047","Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes.","Lee CM","2026","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","narrative_review","article","10.1055/a-2928-5204","42697206",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001048","Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists.","West L","2026","Reviews in cardiovascular medicine","other_trial","article","10.31083/rcm44528","41659089","PMC12873696",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0001049","Semaglutide and Liraglutide Modulate Oxidative Stress and Wound Repair in Normal Human Skin Cells Exposed to an In Vitro Diabetic-like Environment.","Anastasiou IA","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27156981","42589634","PMC13467259",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001050","GLP-1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation.","Hurtado RL","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70609","41796096","PMC13071213",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001051","Medication holds and extended fasting in patients on glucagon-like peptide-1 receptor agonists: interpreting evidence when practice is already ahead of data.","Kruthof J","2026","Canadian journal of anaesthesia = Journal canadien d'anesthesie","commentary","article","10.1007/s12630-026-03185-5","42618721",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0001052","The ethics of Wegovy: promoting autonomy in pediatric care.","Ryan N","2026","Medicine, health care, and philosophy","narrative_review","article","10.1007/s11019-025-10300-8","41065944","PMC12960309",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001053","GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Diabetic Nephropathy: A Comparative Study.","Alghadeer SG","2026","Saudi medical journal","nonrandomized_study","article","10.15537/1658-3175.8828","42445750","PMC13360869",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001054","The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes.","Sheth K","2025","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-025-01319-6","40736924","PMC12590185",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0001055","Are patient factors associated with adverse perioperative outcomes in GLP-1 receptor agonist users? A retrospective cohort study.","Fanizza JD","2026","Journal of clinical anesthesia","nonrandomized_study","article","10.1016/j.jclinane.2026.112192","41895163",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001056","Perioperative GLP-1 Receptor Agonist Use and 30-Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study.","Alsaleh N","2026","World journal of surgery","nonrandomized_study","article","10.1002/wjs.70487","42444315","PMC13576591",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001057","The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?","Kounatidis D","2025","Biomolecules","narrative_review","article","10.3390/biom15091284","41008590","PMC12467596",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001058","Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis.","Eshraghi R","2025","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2025.103645","41324012","PMC12663662","PROSPERO:CRD420251009075",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001059","Glucagon-like Peptide-1 Receptor Agonists and Ocular Disease: Mechanisms, Evidence and Therapeutic Perspectives.","Gong X","2026","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms27031432","41683853","PMC12897703",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0001060","Polyethylene glycol loxenatide reduces NETosis and immunofluorescence hyperactivation in Behçet's disease.","Jia F","2025","European journal of medical research","preclinical","article","10.1186/s40001-025-03442-1","41299760","PMC12659052",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001061","Secondary Ocular Complications Associated with GLP-1 Receptor Agonist Use for Weight Loss: A Large Retrospective Cohort Study","Juran TM","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9960273/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001062","Roux-en-Y Gastric Bypass Compared to Glucagon-like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity","Thiyagarajan S","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-7623447/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001063","Glucagon-like peptide-1 receptor agonist use in endoscopy: risk stratification beyond gastric residue.","Bhandari R","2026","Gastrointestinal endoscopy","commentary","article","10.1016/j.gie.2025.09.025","41862243",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001064","GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes.","Pan JY","2026","Journal of general internal medicine","randomized_trial","article","10.1007/s11606-026-10515-2","42151525",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0001065","Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.","Anthony MS","2024","Diabetes care","nonrandomized_study","article","10.2337/dc23-1911","38363873","PMC10973896",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0001066","GLP-1 receptor agonists and risk of suicide or suicide attempts - A nationwide cohort and self-controlled case series study.","Stanislaus C","2026","Molecular psychiatry","nonrandomized_study","article","10.1038/s41380-026-03619-y","42000905","PMC13441866",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001067","Combined Exendin-4 and Rituximab Treatment Improves β-Cell Function and Delays Disease Progression in NOD Mice.","Wang Y","2026","Biology","preclinical","article","10.3390/biology15171472","42737905","PMC13565562",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001068","Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis.","Lu D","2026","Clinical obesity","systematic_review","article","10.1111/cob.70112","42733128","PMC13572569",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Review; review-article; article"],["R0001069","Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis.","Nashwan AJ","2025","Cureus","commentary","article","10.7759/cureus.93373","41164064","PMC12559017",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0001070","Effect of glucagon-like peptide-1 receptor agonists on histologic MASH: A meta-analysis of randomized controlled trials.","Siranart N","2026","Hepatology communications","systematic_review","article","10.1097/hc9.0000000000000871","41543478",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0001071","Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis.","Rai A","2025","Cureus","systematic_review","article","10.7759/cureus.96162","41367446","PMC12683079",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0001072","GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential.","Luo Y","2026","BMC ophthalmology","systematic_review","article","10.1186/s12886-025-04559-x","41501669","PMC12781364",null,"S002534","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; Review; article"],["R0001073","Tracking Bone Loss in GLP-1RA Therapy: The Potential of the Deoxypyridinoline Urine Test.","Margoni A","2026","Diagnostics (Basel, Switzerland)","other","article","10.3390/diagnostics16132128","42449909","PMC13360158",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0001074","Novel cutaneous adverse effects of the increasingly prevalent glucagon-like peptide 1 agonists.","Carson L","2026","Skin health and disease","case_report","article","10.1093/skinhd/vzag090","42813201","PMC13623448",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001075","Glucagon-Like Peptide-1 Receptor Agonists in Obesity-Induced Respiratory Pathophysiology.","Ruiz MA","2026","Acta physiologica (Oxford, England)","other","article","10.1111/apha.70171","41636090","PMC12906307",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001076","Effects of GLP-1 Receptor Agonists on Breast Reconstruction Outcomes: A Large-Database Retrospective Study.","Hamzeh BF","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15135042","42452504","PMC13362899",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001077","Prior GLP-1RA or tirzepatide use and early cardiorenal outcomes after metabolic and bariatric surgery.","Tseng TC","2026","The American journal of medicine","nonrandomized_study","article","10.1016/j.amjmed.2026.09.010","42735883",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001078","Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series.","Chakrabarti MP","2026","The American journal of case reports","nonrandomized_study","article","10.12659/ajcr.952158","42101979","PMC13170763",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Case Reports; research-article; article"],["R0001079","40-week repeat-dose toxicity, toxicokinetics, and immunogenicity of efsubaglutide alfa following subcutaneous administration in cynomolgus monkeys.","Wang Y","2026","Regulatory toxicology and pharmacology : RTP","randomized_trial","article","10.1016/j.yrtph.2026.106192","42532462",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0001080","[Glucagon-like peptide-1 receptor agonists: from metabolic regulation to rheumatic disease therapy].","Xie WH","2026","Zhonghua yi xue za zhi","randomized_trial","article","10.3760/cma.j.cn112137-20260312-00692","42706128",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; English Abstract; article"],["R0001081","Airway Management in the Age of GLP-1 Receptor Agonists: New Challenges and Solutions.","Valkeniers K","2026","Anesthesiology clinics","narrative_review","article","10.1016/j.anclin.2025.10.010","41781102",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001082","Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system.","Chen JH","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1844057","42232176","PMC13223089",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001083","Fixed BMI eligibility criteria for GLP-1 receptor agonist trials and estimated trial-eligible proportions in Asian and non-Asian populations: A cross-sectional analysis.","Huh KY","2026","PloS one","other_trial","article","10.1371/journal.pone.0351415","42348574","PMC13298741",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0001084","Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy.","Qiu L","2026","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2026.1870649","42466348","PMC13372633",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0001085","GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?","Angelopoulos A","2026","Rheumatology international","randomized_trial","article","10.1007/s00296-026-06258-2","42484659","PMC13391457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001086","Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.","Ren X","2025","Scientific reports","systematic_review","article","10.1038/s41598-025-09807-0","40619508","PMC12230154",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; research-article; review"],["R0001087","A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.","Goldenberg RM","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15381","38016705",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0001088","Trends in Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024.","Zhang DS","2026","AACE endocrinology and diabetes","nonrandomized_study","article","10.1016/j.aed.2026.03.012","42491541","PMC13377882",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001089","Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.","Albanese R","2026","Aesthetic plastic surgery","nonrandomized_study","article","10.1007/s00266-026-06232-0","42716982",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001090","Glucagon-Like Peptide-1 Receptor Agonists in Breast Cancer: Metabolic, Clinical, and Survivorship Implications.","Hundal J","2026","JCO oncology practice","nonrandomized_study","article","10.1200/op-26-00061","42385128",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001091","Clinical Considerations in the Use of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management.","Phan V","2026","Nursing for women's health","other","article","10.1016/j.nwh.2025.09.003","41453400",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001092","Impact of monotherapy and combination therapy with glucagon-like peptide-1 receptor agonists on exosomal and non-exosomal MicroRNA signatures in type 2 diabetes mellitus: a systematic review.","Yu H","2025","Journal of translational medicine","systematic_review","article","10.1186/s12967-025-06461-y","40281607","PMC12032824","PROSPERO:CRD42024586000",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0001093","Glucagon-like peptide-1 receptor agonist use in pregnancy: a review.","Drummond RF","2025","American journal of obstetrics and gynecology","nonrandomized_study","article","10.1016/j.ajog.2024.08.024","39181497",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0001094","Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)","Latif W","2024","StatPearls Publishing, Treasure Island (FL)","other","article",null,"34283517",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0001095","Impact of hypoglycemic agents on glycemic control and cognitive decline in older adults with type 2 diabetes: real-world evidence on glucagon like peptide 1 receptor agonists.","DI Marzio B","2026","Minerva endocrinology","nonrandomized_study","article","10.23736/s2724-6507.26.04501-x","41925713",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001096","Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Promises, Pitfalls, and the Path Forward.","Eke AC","2026","Obstetrics and gynecology","other","article","10.1097/aog.0000000000006021","41712943","PMC12922484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001097","GLP-1 Receptor Agonist Initiation Is Associated With Excess Skeletal Muscle Loss in Adults With Diabetes: A Prospective Population-Based MRI Study","Stambollxhiu E","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.09.15.26363157",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001098","The pancreatic signal of GLP-1 receptor agonists: A biliary phenomenon rather than direct toxicity.","Koren A","2026","British journal of clinical pharmacology","randomized_trial","article","10.1002/bcp.70512","41786617",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0001099","Glucagon Like Peptide-1 Receptor Agonist Use Not Related With Gastric Volume After Preoperative Fasting: A Prospective Observational Study.","Oates PL","2026","Military medicine","nonrandomized_study","article","10.1093/milmed/usaf510","41168658",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0001100","The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review.","Huang JXF","2026","Cureus","narrative_review","article","10.7759/cureus.103234","41822624","PMC12977824",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0001101","Perioperative management of GLP-1 receptor agonists: a structured narrative review with considerations relevant to neurosurgical patients.","Topçu U","2026","Journal of endocrinological investigation","narrative_review","article","10.1007/s40618-026-03004-0","42573674",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0001102","Integrating Precision Nutrition with GLP-1 Receptor Agonist Therapy: Mechanisms, Clinical Outcomes, and Pharmacoeconomic Implications.","Ruga S","2026","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19081230","42653727","PMC13516115",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001103","Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes.","Hughes MS","2026","Endocrinology and metabolism clinics of North America","other_trial","article","10.1016/j.ecl.2026.04.015","42526999",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0001104","Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic Burden","Marwaha A","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202607.2217.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0001105","Comment on \"efficacy of glucagon-like Peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","Srinivasan N","2026","Journal of the neurological sciences","systematic_review","article","10.1016/j.jns.2026.125877","41955853",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0001106","AANA Journal Course-GLP-1 Receptor Agonists: What CRNAs Need to Know About Their Expanding Role.","Davies A","2026","AANA journal","narrative_review","article","10.70278/aanaj/.0000001093","42213027",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001107","Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Ghafoury R","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-026-01911-2","42678648","PMC13620032","PROSPERO:CRD420261320374",null,"pubmed; europepmc","TRUE","open_europepmc","3",null,"Journal Article; Systematic Review; review-article"],["R0001108","Anaesthesia's Hobson's choice: The brave new world of glucagon-like peptide-1 receptor agonists (GLP-1RAs).","Hacking DF","2025","Anaesthesia and intensive care","commentary","article","10.1177/0310057x251355289","40814080",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0001109","Pharmacological Management of Diabesity: Current and Emerging Therapies.","Galasso M","2026","Current obesity reports","narrative_review","article","10.1007/s13679-025-00681-5","41528611",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0001110","GLP-1 receptor agonists and acute pancreatitis: fact or overstated risk?","Domínguez Muñoz JE","2026","Revista espanola de enfermedades digestivas","narrative_review","article","10.17235/reed.2025.11499/2025","41020937",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001111","GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes.","Kasher Meron M","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag056","41665888",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001112","Weight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report.","Garg DK","2026","Cureus","case_report","article","10.7759/cureus.111313","42488278","PMC13391223",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001113","Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit.","Thomas J","2026","Circulation. Heart failure","narrative_review","article","10.1161/circheartfailure.125.013279","41878820","PMC13182810",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001114","Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates.","Abdelhamid M","2025","Cardiac failure review","narrative_review","article","10.15420/cfr.2025.17","41234532","PMC12606456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001115","Blamed but not at fault: anti-obesity medication adverse effects misidentified as perioperative complications - a comprehensive review and medicolegal warning for anesthesiologists.","Kwak HJ","2026","Korean journal of anesthesiology","nonrandomized_study","article","10.4097/kja.26375","42046446","PMC13439146",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0001116","Safety of glucagon-like peptide-1 receptor agonists and other new-generation glucose-lowering agents for the management of type 2 diabetes in pregnancy: a French nationwide population-based study.","Collier M","2026","Diabetologia","nonrandomized_study","article","10.1007/s00125-026-06882-4","42809004",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001117","Patulous Eustachian tube dysfunction following rapid weight loss associated with semaglutide use: A case report.","Burmeister JR","2026","SAGE open medical case reports","case_report","article","10.1177/2050313x261486164","42694263","PMC13538991",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001118","Cup-To-Disc Ratio in Glucagon-Like Peptide 1 Receptor Agonist-Associated Nonarteritic Anterior Ischemic Optic Neuropathy.","Robertson CM","2026","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2026.07.036","42556433",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001119","The Impact of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular-Kidney-Metabolic Health in Romanian Patients with Type 2 Diabetes: A Retrospective Study.","Lixandru N","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15010152","41517401","PMC12787240",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001120","A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.","Min JS","2025","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s506957","40330819","PMC12052016",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review; article"],["R0001121","Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial.","Ji L","2026","Signal transduction and targeted therapy","randomized_trial","article","10.1038/s41392-026-02859-2","42595749","PMC13473623","ClinicalTrials.gov:NCT06569355","S002553","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0001122","Evidence-Based Positioning of Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Management of Chronic Kidney Disease with Type 2 Diabetes and Overweight or Obesity: A Systematic Literature Review.","Handelsman Y","2026","Advances in therapy","systematic_review","article","10.1007/s12325-026-03559-7","41874854","PMC13156165","PROSPERO:CRD420251053598",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0001123","Glucagon-like Peptide-1 Receptor Agonists as a Dual-target Strategy for Depression and Metabolic Health: A Narrative Review.","Kumar V","2026","Annals of African medicine","randomized_trial","article","10.4103/aam.aam_546_25","41568621",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; review"],["R0001124","Is GLP-1 receptor agonist therapy safe for patients with intraductal papillary mucinous neoplasm?","Lagger M","2025","Swiss medical weekly","narrative_review","article","10.57187/s.4850","41100817",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001125","The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on Clinical Outcomes After Total Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of 346,899 Patients.","Lee S","2026","The Journal of arthroplasty","systematic_review","article","10.1016/j.arth.2025.09.054","41072556",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0001126","Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic review.","Hullon D","2025","Cardiovascular endocrinology & metabolism","systematic_review","article","10.1097/xce.0000000000000344","40978810","PMC12445413",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001127","Glucagon-Like Peptide-1 Receptor Agonists and Cancer.","Harris M","2026","JAMA oncology","other","article","10.1001/jamaoncol.2025.5367","41410932",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001128","Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis.","Muller Ferreira V","2026","Cureus","systematic_review","article","10.7759/cureus.110621","42292722","PMC13254196",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; Preprint; review; preprint"],["R0001129","Glucagon-Like Peptide-1 Receptor Agonists and Cancer.","Etminan M","2026","JAMA oncology","other","article","10.1001/jamaoncol.2025.5364","41411009",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001130","Correction: Tongta et al. Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review. Int. J. Mol. Sci. 2025, 26, 10974.","Tongta S","2026","International journal of molecular sciences","notice","article","10.3390/ijms27052365","41828741","PMC12985315",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0001131","Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study.","Lin CM","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16191","39806559","PMC11885080",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001132","Effect of glucagon-like peptide-1 receptor agonists on cigarette smoking consumption in type 2 diabetes patients: study protocol of a randomized, parallel -controlled clinical trial.","Chen D","2026","Frontiers in clinical diabetes and healthcare","protocol","article","10.3389/fcdhc.2026.1665837","41704542","PMC12907205","ClinicalTrials.gov:NCT06924697","S000317","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; methods-article; article"],["R0001133","Review Article: The Evolving Role of GLP-1 Receptor Agonists in Gastroenterology Practice.","Pomenti S","2026","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.70450","41215723",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0001134","Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States.","Xu Y","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16300","40028670","PMC12049267",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001135","Glucagon-like peptide receptor agonists (GLP-1RAs) as cardiovascular risk modifiers in obstructive sleep apnea and obesity: a real-world study.","Ahn J","2026","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","nonrandomized_study","article","10.1007/s44470-026-00110-x","42387223","PMC13323676",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001136","GLP-1 Analogues and Long-Term Outcomes in Adults With Obesity and Elevated CRP: A Real-World Matched Cohort Study.","Shah S","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.09.016","42767411",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; article"],["R0001137","Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules.","Yang B","2026","International journal of pharmaceutics","other","article","10.1016/j.ijpharm.2026.127394","42764083",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0001138","Exposure-adjusted safety and efficacy of GLP-I and GLP-1/GIP receptor agonists compared with non-GLP-I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects.","Prasad A","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70515","41902330",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001139","From Venom-to-Vial-to-Pill: The Translational Journey of GLP-1 Peptides and the Evolving Landscape of Biopharmaceutics Modeling.","Madny MA","2026","Journal of peptide science : an official publication of the European Peptide Society","narrative_review","article","10.1002/psc.70092","41734819",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001140","Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown.","Mannucci E","2026","Nature reviews. Clinical oncology","randomized_trial","article","10.1038/s41571-026-01135-0","41803464",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0001141","Comment on \"Exploratory real-world experience with glucagon-like peptide 1 receptor agonists vs. metformin in youth with new-onset type 2 diabetes: a single-center retrospective study\".","Sundar Sah S","2026","Journal of pediatric endocrinology & metabolism : JPEM","nonrandomized_study","article","10.1515/jpem-2025-0664","42034966",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0001142","Reply to the Letter to the Editor on \"The Association Between Glucagon-like Peptide-1 Receptor Agonists and Postoperative Complications after Arthroplasty: A Systematic Review and Meta-Analysis\".","Chan YC","2026","The Journal of arthroplasty","systematic_review","article","10.1016/j.arth.2025.12.010","41881605",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0001143","GLP-1 receptor agonists in kidney transplant recipients with post-transplant diabetes: efficacy and safety outcomes from a retrospective cohort study.","Navarrete RET","2026","Archives of endocrinology and metabolism","nonrandomized_study","article","10.20945/2359-4292-2026-0076","42485571","PMC13397952",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001144","Psychiatric Outcomes after GLP-1 Receptor Agonists versus Metformin in Hidradenitis Suppurativa.","Shrestha R","2026","Skin appendage disorders","nonrandomized_study","article","10.1159/000551916","42344960","PMC13290251",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0001145","Comment on \"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","Zhang M","2026","Journal of the neurological sciences","systematic_review","article","10.1016/j.jns.2026.125867","41826174",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0001146","Perioperative management of glucagon-like peptide-1 receptor agonists: international guidance and variability in recommendations.","Lam C","2026","British journal of anaesthesia","commentary","article","10.1016/j.bja.2026.01.028","41741283",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001147","Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.","Galli M","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2025.08.027","40892610",null,"PROSPERO:CRD420251032222",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0001148","Association between glucagon-like peptide-1 receptor agonists and femur fracture risk in type 2 diabetes: A large-scale target trial emulation.","Chang YJ","2026","Bone","nonrandomized_study","article","10.1016/j.bone.2026.117851","41819195",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001149","GLP-1 and the brain's powerhouse: a new perspective on the role of mitochondria in neuroprotection.","Dasgupta T","2026","Metabolic brain disease","narrative_review","article","10.1007/s11011-026-01839-3","41920344",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0001150","Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.","Nanah MH","2026","Crohn's & colitis 360","nonrandomized_study","article","10.1093/crocol/otag027","42117113","PMC13157343",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001151","Comparative Outcomes of Metabolic and Bariatric Surgery Versus GLP-1 Receptor Agonists: An Updated Systematic Review and Meta-Analysis of 14,548 Patients.","Rivero-Moreno Y","2026","Journal of laparoendoscopic & advanced surgical techniques. Part A","systematic_review","article","10.1177/10926429261469272","42452903",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0001152","Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.","Falcão L","2026","Headache","systematic_review","article","10.1111/head.70131","42619634",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0001153","Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study.","Kapan A","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16548","40552449","PMC12326916",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001154","Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making.","Moiz A","2026","EClinicalMedicine","narrative_review","article","10.1016/j.eclinm.2026.103991","42238011","PMC13227224",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001155","Glucagon-Like Peptide-1 Receptor Agonists and Cancer-Reply.","Dai H","2026","JAMA oncology","other","article","10.1001/jamaoncol.2025.5370","41410912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001156","Effectiveness of GLP-1 Receptor Agonists and SGLT-2 Inhibitors Combination Therapy in Type 2 Diabetes: A Real-World Experience.","Milluzzo A","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.06.006","42362054",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001157","Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study.","Dhali A","2026","BMC gastroenterology","nonrandomized_study","article","10.1186/s12876-026-05125-5","42458277","PMC13393884",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0001158","Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons.","Lessard C","2026","Obstetrics and gynecology","nonrandomized_study","article","10.1097/aog.0000000000006161","41505759","PMC12788792",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001159","Diabetic macular edema and GLP-1 receptor agonist use: a systematic review and meta-analysis.","Al-Burak SA","2026","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","systematic_review","article","10.1016/j.jcjo.2026.05.004","42242293",null,"PROSPERO:CRD420251176164",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001160","Association between glucagon-like peptide-1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation.","Zhou T","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70384","41424236","PMC12890729",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001161","Effects of Renin-Angiotensin Inhibitors, Sodium-Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon-Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta-Analysis.","Perry F","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71337","42733137",null,"PROSPERO:CRD420261352699",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; review"],["R0001162","GLP-1 receptor agonist use and aspiration pneumonia risk following endovascular thrombectomy.","Sardana S","2026","Journal of neurointerventional surgery","nonrandomized_study","article","10.1136/jnis-2026-025486","42248677",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001163","Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists.","Miao X","2025","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-025-01581-3","39794819","PMC11724456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001164","Glucagon-like peptide-1 receptor agonism and end-organ protection.","Daniels S","2025","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2025.01.002","39934020",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0001165","Pharmacological intersections between type 2 diabetes and cancer: Metabolic crosstalk, antidiabetic therapies and clinical implications.","Liu D","2026","Pharmacological research","randomized_trial","article","10.1016/j.phrs.2026.108456","42753877",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0001166","The promise of GLP-1 receptor agonists for neurodegenerative diseases.","Athauda D","2026","The Journal of clinical investigation","narrative_review","article","10.1172/jci194745","41697753","PMC12904716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001167","Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes.","Hamad CD","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2026.25141","42496972","PMC13401206",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001168","Effects of glucagon-like PEPTIDE-1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: A systematic review and META-analysis.","Pasta A","2025","European journal of clinical investigation","systematic_review","article","10.1111/eci.70000","39937048","PMC12066890",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; brief-report; review"],["R0001169","Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Retrospective Study.","Yuan D","2025","Journal of diabetes research","nonrandomized_study","article","10.1155/jdr/2663671","41246137","PMC12614731",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001170","GLP-1 receptor agonists and psychiatric outcomes: a bibliometric analysis of research trends, thematic evolution, and collaboration networks.","Roca Mora MM","2026","Frontiers in psychiatry","systematic_review","article","10.3389/fpsyt.2026.1857078","42553449","PMC13433608",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0001171","The physiologic and psychologic effects of glucagon-like peptide-1 receptor agonists.","Browne-Bradwisch SA","2025","Nursing","narrative_review","article","10.1097/nsg.0000000000000223","40851184",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001172","GLP-1 Receptor Agonists, Stroke, and Cognitive Outcomes: Systematic Review and Meta-Regression","Danielli M","2026","medRxiv","systematic_review","preprint","10.64898/2026.09.18.26363449",null,null,"PROSPERO:CRD420261305938",null,"europepmc; openalex","FALSE","free_to_read","3","FALSE","Preprint; preprint"],["R0001173","Adjunctive GLP-1 Receptor Agonist Therapy Lowers Incident Pulmonary Hypertension and All-cause Mortality in Obese Patients with Obstructive Sleep Apnea Treated with PAP","Governor SB","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.01.20.26344489",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0001174","The role of glucagon-like peptide-1 receptor agonists in cancer therapy-related cardiovascular disease: a meta-analysis.","Farmakis D","2026","European journal of preventive cardiology","systematic_review","article","10.1093/eurjpc/zwaf730","41253686",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; other; article"],["R0001175","Response to \"Comment on 'efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis'\".","Ahmed W","2026","Journal of the neurological sciences","systematic_review","article","10.1016/j.jns.2026.125866","41833129",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Letter; review"],["R0001176","The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.","Sheth S","2026","JAMA dermatology","randomized_trial","article","10.1001/jamadermatol.2026.0859","42054048",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001177","Response to comment by Srinivasan et al. on \"Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis\".","Ahmed W","2026","Journal of the neurological sciences","systematic_review","article","10.1016/j.jns.2026.125876","41916123",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Letter; review"],["R0001178","Glucagon-like peptide-1 receptor agonists as metabolic adjuncts in immune-mediated skin disease.","Lazarowitz R","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.02.047","41713583",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001179","GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects.","Cardoso P","2026","The Journal of clinical investigation","narrative_review","article","10.1172/jci194742","41542765","PMC12807466",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001180","Metabolic effects of GLP-1 receptor agonists in rheumatology patients and inflammatory outcomes: a single-centre retrospective cohort.","Retuerto-Guerrero M","2026","RMD open","nonrandomized_study","article","10.1136/rmdopen-2026-007122","42642078","PMC13536120",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0001181","Benefits of Incretin Therapy on Ovarian Function: A Scientific Literature Review.","La Vignera S","2026","International journal of molecular sciences","randomized_trial","article","10.3390/ijms27114752","42278283","PMC13257354",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001182","Postoperative Outcomes in Body Contouring Procedures Following Glucagon-Like Peptide-1 Receptor Agonist Use: A 10-Year Analysis.","Liang J","2025","Aesthetic surgery journal","nonrandomized_study","article","10.1093/asj/sjaf029","39960861",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001183","Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.","Gougol A","2026","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.70596","41813606",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0001184","Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry.","McCormick NP","2026","ACR open rheumatology","nonrandomized_study","article","10.1002/acr2.90068","42101387","PMC13155138",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001185","Community pharmacists' experiences and perspectives on GLP-1 receptor agonists for obesity management: a cross-sectional study in Ireland.","Demmel J","2026","The International journal of pharmacy practice","other","article","10.1093/ijpp/riag090","42439264",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001186","Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes.","Xie L","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2026.1272","41805958","PMC12976791",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001187","Sustained metabolic control in latent autoimmune diabetes in adults (LADA) with semaglutide therapy in a patient with multiple autoimmune comorbidities: a case report and literature review.","D'Andrea S","2026","Acta diabetologica","case_report","article","10.1007/s00592-026-02739-9","42440093",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001188","Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.","Chao AM","2026","PLoS medicine","other","article","10.1371/journal.pmed.1004871","41533690","PMC12803457",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0001189","Comment on: Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","Zheng X","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","systematic_review","article","10.1016/j.soard.2025.12.009","41946634",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0001190","Oral Antidiabetic Medications","Regalla DKR","2026","StatPearls Publishing, Treasure Island (FL)","other","article",null,"29494008",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0001191","Glucagon-like peptide-1 receptor agonists (GLP-1RA) and acute pancreatitis.","Whitcomb DC","2025","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","commentary","article","10.1016/j.pan.2025.07.005","40695709",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0001192","Anti-inflammatory effects of GLP1-RA drugs.","Quintana L","2026","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgag218","42219869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001193","GLP-1 receptor agonists for kidney transplant recipients.","Schmitz SH","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfaf199","41026089",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0001194","Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy.","Lopez A","2026","Acta paediatrica (Oslo, Norway : 1992)","nonrandomized_study","article","10.1111/apa.70554","42011014","PMC13371817",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001195","Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025).","Makkena HB","2026","Cureus","nonrandomized_study","article","10.7759/cureus.101738","41704984","PMC12908611",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001196","GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.","Santiago JA","2026","Trends in molecular medicine","narrative_review","article","10.1016/j.molmed.2025.12.001","41444101","PMC13005735",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; review"],["R0001197","Glucagon-like Peptide-1 Receptor Agonists and Reproductive Health: Current Evidence and Clinical Implications.","Kettner J","2026","Journal of pharmacy practice","narrative_review","article","10.1177/08971900251376795","40906565",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001198","Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation.","Chiang YL","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1801203","42051453","PMC13111083",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0001199","What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.","Frias JP","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16593","40637050","PMC12308270",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0001200","Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes.","Miramontes-González JP","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-025-01829-1","41489681","PMC13000015",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001201","Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.","Møller AL","2026","American journal of physiology. Cell physiology","other","article","10.1152/ajpcell.00526.2025","42605988",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001202","GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review.","Wang X","2026","Journal of endocrinological investigation","narrative_review","article","10.1007/s40618-026-02891-7","42171681",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001203","The ethics of wegovy for children: the argument from too many unknowns.","Ryan N","2026","Monash bioethics review","other","article","10.1007/s40592-025-00280-z","41546795",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001204","Evaluating the Ocular Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists","Khan Z","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-8371495/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001205","Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis.","Desai A","2026","Inflammatory bowel diseases","nonrandomized_study","article","10.1093/ibd/izaf301","41365321",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001206","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients.","Shabanowitz S","2026","Pharmacotherapy","nonrandomized_study","article","10.1002/phar.70123","41800749",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001207","The access and use of GLP-1 receptor agonists in people with eating disorders in the UK: A mixed method study","Pickard A","2026","PsyArXiv","other","preprint","10.31234/osf.io/5w4mc_v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0001208","Unraveling the obesity-asthma link: A new horizon with glucagon-like peptide-1 receptor agonists in a complex intersection of metabolism and airway disease.","Menzella F","2025","The Journal of international medical research","narrative_review","article","10.1177/03000605251392717","41193498","PMC12589782",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0001209","Effect of GLP-1 receptor agonists on upper gastrointestinal endoscopy outcomes: a systematic review and meta-analysis.","Malandris K","2026","Annals of gastroenterology","systematic_review","article","10.20524/aog.2026.1067","42434158","PMC13352199",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001210","Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes.","Francisco C","2026","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","systematic_review","article","10.1007/s00417-026-07430-x","42541561",null,"PROSPERO:CRD420251237987",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0001211","Glucagon-Like Peptide-1 Receptor Agonists in the Prevention of Ischemic Stroke: Therapeutic Potential and Mechanisms.","Lin Z","2025","Journal of stroke","randomized_trial","article","10.5853/jos.2025.00584","41084286","PMC12527581",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001212","Impact of GLP-1 receptor agonists on stroke, subarachnoid hemorrhage, and intracerebral hemorrhage: a propensity-matched multi-institutional cohort study.","Costa M","2026","Journal of neurosurgery","nonrandomized_study","article","10.3171/2025.5.jns25786","41043189",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0001213","Changes in metabolic and pulmonary outcomes after discontinuation of glucagon-like-peptide-1 receptor agonist therapy in people with cystic fibrosis.","Singh A","2026","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","nonrandomized_study","article","10.1016/j.jcf.2026.05.009","42151007",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001214","Bidirectional interplay between the gut microbiota and GLP-1 receptor agonists: towards Microbiome-Mediated therapeutics in type 2 diabetes mellitus.","Ganamurali N","2026","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-025-01834-y","41613163","PMC12847532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001215","Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs.","Flanary SM","2026","Current opinion in physiology","nonrandomized_study","article","10.1016/j.cophys.2026.100956","42272808","PMC13249376",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; review"],["R0001216","Obesity, diabetes and glucagon-like peptide-1 receptor agonists.","BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health","2026","Archives of disease in childhood","other","article","10.1136/archdischild-2025-330241","41554557",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001217","Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement.","Dobbie LJ","2026","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(26)00122-1","42419343",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Consensus Statement; Review; article"],["R0001218","Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review.","Au HCT","2025","Acta neuropsychiatrica","systematic_review","article","10.1017/neu.2025.10038","40899147","PMC13130282",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0001219","Nutrition Considerations in Youth with Type 2 Diabetes Using Glucagon-Like Peptide-1 Receptor Agonists: A Commentary.","Diaz ME","2026","Journal of the Academy of Nutrition and Dietetics","nonrandomized_study","article","10.1016/j.jand.2026.156317","41724352",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001220","GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape.","Ahmed MM","2026","Therapeutic advances in endocrinology and metabolism","nonrandomized_study","article","10.1177/20420188261472587","42523902","PMC13408070",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001221","Psychotropic effects of GLP-1R agonists.","Bucciarelli L","2025","Pharmacological research","randomized_trial","article","10.1016/j.phrs.2025.108036","41253199",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0001222","GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.","Parekh RS","2026","Disease-a-month : DM","systematic_review","article","10.1016/j.disamonth.2026.102150","42215399",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0001223","GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischemic Optic Neuropathy: What an Endocrinologist Needs to Know.","Liu L","2025","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgaf541","41022666",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0001224","Evaluating the impact of GLP-1 receptor agonists in combination with total neoadjuvant therapy for locally advanced rectal cancer.","Temperley HC","2026","The British journal of surgery","narrative_review","article","10.1093/bjs/znag029","41806363","PMC13175531","ClinicalTrials.gov:NCT07314528","S002389","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0001225","Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.","Cronenberger C","2026","Journal of clinical pharmacology","other_trial","article","10.1002/jcph.70158","42053447","PMC13127352","ClinicalTrials.gov:NCT05671653; ClinicalTrials.gov:NCT05788328","S000950; S001778","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial, Phase I; research-article; article"],["R0001226","Perioperative glucagon-like peptide-1 receptor agonist use and surgical outcomes in patients with morbid obesity (BMI > 35) undergoing robotic urologic surgery: A propensity score-matched analysis.","Gallagher M","2026","Journal of robotic surgery","nonrandomized_study","article","10.1007/s11701-026-03454-x","42213238",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001227","Perioperative glucagon-like Peptide-1 receptor agonist use and clinical outcomes following lower extremity fracture fixation: A large retrospective cohort study with two year follow up.","Pereira DE","2025","Injury","nonrandomized_study","article","10.1016/j.injury.2025.112746","40915058",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; article"],["R0001228","Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract Development.","Ahuja AS","2026","American journal of ophthalmology","randomized_trial","article","10.1016/j.ajo.2025.10.021","41130371",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0001229","GLP-1 Receptor Agonists and Risk of Age-Related Macular Degeneration in Older Adults With Obesity: A Target Trial Emulation.","Chang TW","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70910","42186202","PMC13341406",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001230","Pharmacovigilance Assessment of Thrombotic Adverse Events Linked to GLP-1 Receptor Agonists: Analysis of FAERS Reports from 2020-2025.","Mansory EM","2026","Current drug safety","nonrandomized_study","article","10.2174/0115748863468899260323094036","42227478",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001231","Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trials.","Mendonça MF","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","systematic_review","article","10.1007/s10072-026-09084-3","42105060","PMC13157460",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review-article; review"],["R0001232","Authors response to the comments by Muhammad Salman, Muhammad Hammad Chola and Muhammad Hasan on our paper \"prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study\".","Fors A","2026","European journal of clinical pharmacology","commentary","article","10.1007/s00228-026-04056-0","42036553",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0001233","Effect of GLP-1 Receptor Agonists on Post-Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis.","Shubietah A","2026","Pacing and clinical electrophysiology : PACE","systematic_review","article","10.1111/pace.70262","42033283","PMC13456437",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; article"],["R0001234","Heart transplantation in the GLP-1 Era: Time to catch up? Invited commentary for \"The association between glucagon-like peptide 1 receptor agonist therapy and outcomes after heart transplant\".","Dhingra NK","2026","The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","commentary","article","10.1016/j.healun.2026.04.017","42001918",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0001235","Assessing the Impact of GLP-1R Agonists in Post-sinus Surgery Management.","Hoying D","2026","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","nonrandomized_study","article","10.1002/ohn.70072","41353729",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001236","Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study.","Trenas-Calero A","2026","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19040583","42075839","PMC13119513",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001237","The Liraglutide-Induced Pemphigus Vulgaris: A First Case Report Highlighting Autoimmune Risks of GLP-1 Receptor Agonists.","Cai S","2026","Endocrine, metabolic & immune disorders drug targets","case_report","article","10.2174/0118715303361089250320050246","40264312",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0001238","Risk of Glaucoma in Patients without Diabetes Using a Glucagon-Like Peptide 1 Receptor Agonist.","Vasu P","2025","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2025.02.011","39978437","PMC12626175",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; research-article; article"],["R0001239","Semaglutide Prevents Aortic Rupture and Dissection in the Angiotensin II Mouse Model.","Balboa Ramilo A","2026","Biomedicines","other_trial","article","10.3390/biomedicines14040933","42072473","PMC13113176",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0001240","Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes and atrial fibrillation: a multicenter comparative effectiveness cohort study of cardiovascular and arrhythmic outcomes.","Islam MM","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113346","42214559",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Comparative Study; article"],["R0001241","Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists.","Siddiqi AK","2025","Current hypertension reports","narrative_review","article","10.1007/s11906-025-01342-7","41324724",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001242","Estimating Eligibility for GLP-1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross-Sectional Analysis of National Health Survey Data.","Castrillon J","2026","The Medical journal of Australia","other","article","10.5694/mja2.70253","42604458","PMC13477643",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001243","GLP-1 RAs in Substance Use Disorders: Emerging Evidence and Future Directions.","Macanian J","2026","Cardiology in review","randomized_trial","article","10.1097/crd.0000000000001319","42219586",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0001244","Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations.","Wu TE","2026","Journal of the Chinese Medical Association : JCMA","nonrandomized_study","article","10.1097/jcma.0000000000001370","41857480","PMC13286313",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001245","Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment.","González-Luis A","2025","European journal of endocrinology","narrative_review","article","10.1093/ejendo/lvaf223","41166543",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001246","Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records.","Varma G","2026","Biology methods & protocols","nonrandomized_study","article","10.1093/biomethods/bpag035","42433615","PMC13353216",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001247","Beyond GLP-1 Monotherapy: Novel Multi-Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes.","Khachaturov M","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70822","42098899",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0001248","Optimising obesity management: integrating continuous glucose monitoring with GLP-1 receptor agonists.","Gupta P","2025","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2025.112434","40849048",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001249","Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan®: a systematic review and meta-analysis.","Berardicurti A","2026","Internal and emergency medicine","systematic_review","article","10.1007/s11739-026-04384-0","42141180",null,"PROSPERO:CRD420251162316",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001250","GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.","Hu Y","2026","European heart journal","other","article","10.1093/eurheartj/ehaf1066","41609518",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001251","Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials.","Stefanou MI","2026","Therapeutic advances in neurological disorders","systematic_review","article","10.1177/17562864251408269","41631108","PMC12861370","PROSPERO:CRD420251008703",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001252","Glucagon-like Peptide-1 Receptor Agonists Improve Liver and Metabolic Health Outcomes in Type 2 Diabetes and Obesity Regardless of Prior Liver Disease","Sanyal A","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-8342646/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001253","Impact of GLP-1 receptor agonists on gastrointestinal function and symptoms.","Frazier RD","2025","Expert review of gastroenterology & hepatology","nonrandomized_study","article","10.1080/17474124.2025.2579117","41138239",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0001254","Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists.","Sciscent BY","2026","OTO open","nonrandomized_study","article","10.1002/oto2.70188","41523888","PMC12780965",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001255","Counting days: Cardiovascular and kidney event postponement with glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes.","Schmidt S","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70589","41733076",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0001256","Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?","Chrysavgis L","2025","Biomedicines","other","article","10.3390/biomedicines13071516","40722592","PMC12292612",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0001257","Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty.","Almeida VFA","2026","Research square","nonrandomized_study","article","10.21203/rs.3.rs-9665910/v1","42245794","PMC13232417",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; research-article; preprint"],["R0001258","Pro-Con: Antiobesity Drugs Such as Glucagon-Like Peptide-1 Receptor Agonists Should Be a First-Line Treatment in Idiopathic Intracranial Hypertension.","Lange MG","2026","Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society","other","article","10.1097/wno.0000000000002431","41701180",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001259","Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review.","Rojas Lopez RF","2025","Cureus","randomized_trial","article","10.7759/cureus.90021","40951222","PMC12431796",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001260","Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.","Wu Y","2026","BMC pulmonary medicine","nonrandomized_study","article","10.1186/s12890-026-04469-8","42401898","PMC13621701","ChiCTR:ChiCTR2500110394",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001261","Cross-Sectional Survey Results of Registered Dietitians of the Weight Management and Diabetes Dietetic Practice Groups of the Academy, Providing Medical Nutrition Therapy to People Using Glucagon-like Peptide-1 Receptor Agonist-Based Therapy.","Cardamone K","2026","Journal of the Academy of Nutrition and Dietetics","other","article","10.1016/j.jand.2026.156432","42556638",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001262","Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.","Au HCT","2025","Neuroscience and biobehavioral reviews","nonrandomized_study","article","10.1016/j.neubiorev.2025.106159","40252880",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0001263","Preoperative Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery Outcomes: A Systematic Review.","Esparham A","2025","Obesity surgery","systematic_review","article","10.1007/s11695-025-08137-4","40782272",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0001264","The neuroendocrine-appetite-mental health triangle in PMOS: Implications for GLP-1 receptor agonist therapy.","Xu W","2026","Neuroscience and biobehavioral reviews","narrative_review","article","10.1016/j.neubiorev.2026.106846","42419462",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001265","Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database.","Zhou J","2025","Endocrine","nonrandomized_study","article","10.1007/s12020-024-04112-8","39578328",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001266","Effects of patient age on the therapeutic effects of GIP/GLP-1 receptor agonists (tirzepatide).","Ishimura A","2025","Drug discoveries & therapeutics","other","article","10.5582/ddt.2025.01012","40301081",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001267","A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity.","Quddos F","2025","Scientific reports","randomized_trial","article","10.1038/s41598-025-17927-w","41093891","PMC12528724",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0001268","Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada.","McNally ES","2026","CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","randomized_trial","article","10.1503/cmaj.250591","41730540","PMC12959951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0001269","Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis.","Tapper EB","2025","Journal of comparative effectiveness research","nonrandomized_study","article","10.57264/cer-2024-0223","41047964","PMC12580915",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0001270","Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions.","Prokopidis K","2026","British journal of pharmacology","randomized_trial","article","10.1111/bph.70355","41577337",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0001271","Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System.","Ohyama K","2026","International journal of clinical pharmacology and therapeutics","nonrandomized_study","article","10.5414/cp204789","41122011",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001272","Comparative Safety of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1-RAs) in Type 2 Diabetes and Chronic Weight Management: A Real-World Data Study.","Hurwitz SR","2025","Pharmacoepidemiology and drug safety","randomized_trial","article","10.1002/pds.70214","40947139","PMC12433752","OSF:osf.io/psy74",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001273","Glucagon-like peptide-1 receptor agonists linked to a reduced risk of developing asthma among patients with type 2 diabetes.","Cheng YS","2025","Therapeutic advances in endocrinology and metabolism","nonrandomized_study","article","10.1177/20420188251400536","41425689","PMC12712316",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001274","Assessment of Gastric Content Using Gastric Ultrasound in Patients on Glucagon-Like Peptide-1 Receptor Agonists: Selection Matters.","Neuner M","2026","Anesthesia and analgesia","other","article","10.1213/ane.0000000000007988","41698213",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001275","Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis.","Jia A","2025","Frontiers in cardiovascular medicine","systematic_review","article","10.3389/fcvm.2025.1633114","41112222","PMC12533278",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0001276","Body Mass Index-Dependent Effect of Glucagon-Like Peptide 1 Receptor Agonist Therapy on Bowel Preparation Quality.","Vikash FNU","2026","Clinical and translational gastroenterology","nonrandomized_study","article","10.14309/ctg.0000000000001037","41972405","PMC13400046",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001277","Semaglutide-associated agranulocytosis requiring hospitalisation and granulocyte colony-stimulating factor: a case report.","Calvo Arbeloa M","2026","European journal of hospital pharmacy : science and practice","nonrandomized_study","article","10.1136/ejhpharm-2026-005049","42638077",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001278","Letter Regarding \"The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis (Chan et al., J Arthroplasty, 2025)\".","Guevel B","2026","The Journal of arthroplasty","systematic_review","article","10.1016/j.arth.2025.11.050","41881604",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0001279","CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.","Gadelmawla AF","2026","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2026.02.030","41759565",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0001280","Impact Of Glucagon-like Peptide-1 Receptor Agonists Utilization on Outcomes of Midfoot and Hindfoot Fusions",null,"2025","Foot & ankle orthopaedics","other","article",null,null,"PMC12743865",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0001281","Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.","Hong AT","2026","Ophthalmology. Retina","nonrandomized_study","article","10.1016/j.oret.2026.02.002","41655764",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0001282","GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives.","Andrzejczak K","2026","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics18050605","42198298","PMC13210952",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001283","Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis.","Hindi A","2026","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19030365","41901212","PMC13028733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001284","Combined Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Therapy to Restore Fertility in Patients With Obesity, Polycystic Ovary Syndrome, and Incident Type 2 Diabetes.","Banerjee M","2026","Cureus","case_report","article","10.7759/cureus.102358","41769480","PMC12936452",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001285","A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus.","Joshi S","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s570273","41836360","PMC12982893",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001286","GLP-1 receptor agonists and aneurysm rupture risk in type 2 diabetes: a multicenter retrospective study.","Li SY","2026","Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","nonrandomized_study","article","10.1016/j.jocn.2026.111905","41671787",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0001287","Comparative cardiovascular outcomes of GLP-1 receptor agonists vs. SGLT2 inhibitors in type 2 diabetes: a large-scale real-world cohort analysis.","Ukita K","2026","Clinical research in cardiology : official journal of the German Cardiac Society","nonrandomized_study","article","10.1007/s00392-026-02970-y","42307748",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001288","Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis.","Kandalam S","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-026-01847-7","41762380","PMC13103177",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001289","HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.","Gu W","2026","Nature communications","randomized_trial","article","10.1038/s41467-026-73018-y","42331800","PMC13443196","ClinicalTrials.gov:NCT06250946","S002275","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; research-article; article"],["R0001290","Angiogenic T cells and cognitive function in older adults with type 2 diabetes treated with GLP-1 receptor agonists.","Longo M","2026","Aging clinical and experimental research","nonrandomized_study","article","10.1007/s40520-026-03417-0","42177747","PMC13415266",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0001291","Pancreatic Mucinous Cystic Neoplasms Following GLP-1 Receptor Agonists Use: A Report of Two Cases with Literature Review.","Alsaleh NM","2026","Journal of gastrointestinal cancer","case_report","article","10.1007/s12029-025-01377-8","41609941","PMC12855357",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; Review; case-report; article"],["R0001292","Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.","Yang Y","2025","Journal of diabetes","systematic_review","article","10.1111/1753-0407.70063","40040445","PMC11880690","PROSPERO:CRD42023480167",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0001293","Glucagon-like peptide-1 receptor agonists and the risk of surgical intervention in idiopathic intracranial hypertension: A propensity-matched cohort study.","Kelleher S","2026","Clinical neurology and neurosurgery","nonrandomized_study","article","10.1016/j.clineuro.2026.109372","41832796",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001294","Efficacy of a fixed-ratio combination of glucagon-like peptide-1 receptor agonist and basal insulin therapy for the treatment of type 2 diabetes: a protocol for systematic review and meta-analysis of randomized clinical trials","Ramalan MA","2024","medRxiv","systematic_review","preprint","10.1101/2024.07.18.24310630",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0001295","GLP-1 receptor agonists and weight-loss strategies for individuals with obesity and hip or knee osteoarthritis: a scoping review.","McCann CJ","2026","British journal of sports medicine","randomized_trial","article","10.1136/bjsports-2025-111225","42321007",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Scoping Review; article"],["R0001296","GLP-1 Receptor Agonists and Cardiovascular Events During Androgen Receptor Pathway Inhibitor Therapy.","Atkins KM","2026","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.64898/2026.05.26.26353962","42282196","PMC13252489",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0001297","Ethical Approaches to Limiting Overall Costs for Glucagon-Like Peptide-1 Receptor Agonists for Weight Management.","Dellgren J","2026","Annals of internal medicine","commentary","article","10.7326/annals-25-03474","41698227",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001298","Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with glucagon-like peptide-1 receptor agonists: A population cohort study from the TriNetX collaborative network.","Feng AS","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.03.023","41833917",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001299","Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles.","Ghusn W","2026","Annals of surgery","nonrandomized_study","article","10.1097/sla.0000000000007064","42002851",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001300","Preventing GLP-1-Associated Facial Aging: An Anatomy-Driven Risk Stratification Model and Prevention Algorithm in the \"Ozempic Face\" Era.","Castrellon R","2026","Aesthetic plastic surgery","other","article","10.1007/s00266-026-05953-6","42260145",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001301","Early Weight Regain After GLP-1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De-Escalation Strategies.","Damhof MA","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71075","42396734","PMC13538768",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001302","Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis.","Liang CS","2026","International journal of molecular sciences","systematic_review","article","10.3390/ijms27094137","42123715","PMC13164542",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; article"],["R0001303","Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.","Verma R","2026","Current opinion in cardiology","randomized_trial","article","10.1097/hco.0000000000001323","42388102",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001304","Research progress on the molecular mechanism and clinical evidence of glucagon-like peptide-1 receptor agonists in improving sarcopenia.","Yang Q","2026","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-026-02133-z","41749352","PMC13214370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001305","Editor's Highlights-June 2026.","Kemény L","2026","International journal of dermatology","commentary","article","10.1111/ijd.70463","42068165",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0001306","Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer.","Muscogiuri G","2026","Internal and emergency medicine","randomized_trial","article","10.1007/s11739-026-04458-z","42414781",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0001307","Glucagon-Like Peptide-1 Receptor Agonist Mediated Weight Loss and Diabetes Mellitus Benefits: A Narrative Review.","Kaye AD","2024","Cureus","narrative_review","article","10.7759/cureus.76101","39840162","PMC11745841",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0001308","Glucagon-Like Peptide-1 Receptor Agonists Reduce Surgeries and Hospitalizations in Hidradenitis Suppurativa: A Multicenter TriNetX Cohort Study.","Gupta N","2025","Journal of drugs in dermatology : JDD","nonrandomized_study","article","10.36849/jdd.8926","40911751",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0001309","Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-Analysis.","Shirmohammadi E","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70311","42700367","PMC13546078",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Comparative Study; review-article; Review; review"],["R0001310","Community Pharmacists' Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Türkiye: A Cross-Sectional Study.","Bayram-Ozgur D","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s587750","41804360","PMC12967530",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001311","Semaglutide alleviates ovarian ferroptosis in polycystic ovary syndrome and is associated with reduced GPX4 promoter hypermethylation.","Zhang Y","2026","Journal of molecular histology","preclinical","article","10.1007/s10735-026-10764-9","41803302",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001312","SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.","Singh B","2026","Journal of affective disorders","randomized_trial","article","10.1016/j.jad.2026.122407","42632571","PMC13561641",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001313","Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes.","Dziewierz A","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113493","42575344",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; article"],["R0001314","Preoperative Use of GLP-1 Receptor Agonists Is Associated With Reduced Risk of Postoperative DVT and Mortality in Patients Undergoing Lumbar Laminectomy.","Marzook FA","2026","Clinical spine surgery","nonrandomized_study","article","10.1097/bsd.0000000000002113","42397280",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001315","Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.","Dubin RL","2024","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15913","39344838",null,null,"S002373","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0001316","Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis.","Huang R","2026","The Journal of international medical research","systematic_review","article","10.1177/03000605261458641","42424036","PMC13351244",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0001317","Can Glucagon-Like Peptide-1 Receptor Agonists or Sodium-Glucose Cotransporter 2 Inhibitors Be Considered New Treatment Options for Male Hypogonadism and Sexual Dysfunction?","Corona G","2026","The world journal of men's health","narrative_review","article","10.5534/wjmh.260045","42608153",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001318","Wolfram syndrome and diabetes mellitus in Aotearoa, New Zealand: Phenotype and response to GLP-1 receptor agonist therapy.","L'Amie A","2026","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.70405","42324630","PMC13380341",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001319","Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures.","Liu Y","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag052","41655226",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001320","Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes.","Sklepinski SM","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113503","42607727",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001321","Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury.","Charatsi E","2026","Cureus","narrative_review","article","10.7759/cureus.107715","42205663","PMC13201981",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001322","A Case of Euglycemic Diabetic Ketoacidosis With Tirzepatide Use and Severe Calorie Restriction.","Raptis D","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luaf324","41613297","PMC12851108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001323","Apelin/APJ Signalling as a Potential Complementary Target for Glucagon-like Peptide-1 Receptor Agonist Therapy in Heart Failure.","Alfonso DM","2026","Cardiac failure review","commentary","article","10.15420/cfr.2025.54","41837114","PMC12983138",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0001324","Beyond the prescription: Global observations on the social implications of GLP-1 receptor agonists for weight loss.","Jensen SD","2025","PLOS global public health","narrative_review","article","10.1371/journal.pgph.0005516","41452858","PMC12742762",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0001325","Association of Glucagon-like Peptide-1 Receptor Agonists with Mortality and Aspiration Pneumonia in Patients with Type 2 Diabetes After Gastrostomy: A Target Trial Emulation Study.","Tseng YT","2026","International journal of medical sciences","nonrandomized_study","article","10.7150/ijms.128956","41938505","PMC13048897",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001326","Modulation of the Incretin Axis (GLP-1/GIP) in Behavioral Compulsions: A New Neuropsychopharmacology Frontier","Andrade LJdO","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9238201/v1",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0001327","Unconventional Applications of Semaglutide and Tirzepatide: From Oncology to Human Reproduction.","La Vignera S","2026","Biomedicines","randomized_trial","article","10.3390/biomedicines14071644","42512116","PMC13406544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001328","Efficacy and Safety of Tirzepatide in Refractory Hypoglycemia Associated with Esophagojejunostomy.","Caporusso M","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf249","41140513","PMC12547409",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001329","Use and Potential Misuse of Glucagon-Like Peptide-1 Receptor Agonists in France: A Nationwide Cohort Study.","du Soulier N","2025","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","nonrandomized_study","article","10.1016/j.jval.2025.06.001","40562309",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0001330","Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.","Tang H","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70054","40874398","PMC12515787",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001331","Effects of GLP-1 receptor agonists on the incidence of contrast-induced acute kidney injury in patients with Type 2 diabetes mellitus undergoing coronary interventions.","Oksen D","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1930088","42723898","PMC13557935",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001332","The Interplay of GLP-1 Receptor Agonist Use, Chronic Kidney Disease, and Fracture Risk in Obese Patients: A Retrospective Cohort Study","Eubanks A","2025","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.176706936.68195055/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001333","Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study.","Wu JY","2026","Frontiers in medicine","nonrandomized_study","article","10.3389/fmed.2026.1820366","42239959","PMC13226182",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001334","Annals Consult Guys - Preoperative Management of Glucagon-Like Peptide-1 Receptor Agonist Therapy.","Weitz HH","2026","Annals of internal medicine","other","article","10.7326/annals-26-00505-cg","41698226",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Video-Audio Media; article"],["R0001335","Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers.","DePietro R","2026","Healthcare (Basel, Switzerland)","other","article","10.3390/healthcare14020186","41595322","PMC12841317",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001336","Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation.","Tang H","2026","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2026-100077","42486607",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001337","Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.","Nejat C","2026","Clinical case reports","case_report","article","10.1002/ccr3.73183","42487660","PMC13389892",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0001338","Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.","He L","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1416985","39040467","PMC11260617",null,"S002529","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001339","Sequential Intragastric Balloon Followed By GLP-1 Receptor Agonist Therapy in Obesity: A Comparative Study of 12-Month Weight Loss Outcomes.","Teke E","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08698-y","42026424",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0001340","Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape.","Mondoh A","2025","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2025.2601060","41351384",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; Comparative Study; article"],["R0001341","The hidden advantage: colonoscopy preparation mitigates gastric content risk associated with glucagon-like peptide-1 receptor agonists.","Shi Y","2026","Gastrointestinal endoscopy","commentary","article","10.1016/j.gie.2025.07.032","41565429",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001342","Evaluating the Use of GLP-1 Receptor Agonists in Wolfram syndrome Patients.","Lee L","2026","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.64898/2026.03.31.26349885","41959758","PMC13060457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0001343","Glucagon-like peptide-1 receptor agonists to modulate neuroinflammation and neurogenesis.","Elvira R","2026","Neural regeneration research","other_trial","article","10.4103/nrr.nrr-d-25-01144","41467435","PMC13557675",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; other; article"],["R0001344","Association of GLP-1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program.","Hwang I","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70668","41847743","PMC13146207",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001345","Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.","Banerjee M","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70853","42098901",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0001346","Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes.","Wu J","2025","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2025.31.10.1029","41004212","PMC12467763",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001347","Combined GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy for Adults with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease: A Large-Scale Target Trial Emulation","Bai H","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-10427939/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001348","Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists.","Idowu TO","2026","Journal of applied genetics","narrative_review","article","10.1007/s13353-026-01084-5","42298277",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001349","Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.","Myers WK","2026","Ophthalmology. Retina","nonrandomized_study","article","10.1016/j.oret.2025.12.016","41453515","PMC12768466",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0001350","The Impact of GLP-1 Receptor Agonists on Esophagogastroduodenoscopy Outcomes: A Retrospective Cohort Study in a Predominantly African American Population.","El Sabagh A","2026","JGH open : an open access journal of gastroenterology and hepatology","nonrandomized_study","article","10.1002/jgh3.70370","41798306","PMC12966880",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001351","The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review.","Völker KM","2025","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2025.1702448","41552827","PMC12808432","PROSPERO:CRD42024571356",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0001352","Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey.","Sundell I","2026","BMC primary care","other","article","10.1186/s12875-026-03488-y","42557543","PMC13445834",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0001353","Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?","Dreher L","2025","Hypertension (Dallas, Tex. : 1979)","other_trial","article","10.1161/hypertensionaha.125.25112","40406862",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0001354","Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).","Seijas-Amigo J","2026","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2026.03.012","42103575",null,"ClinicalTrials.gov:NCT05136287","S001352","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; article"],["R0001355","Obesity hypoventilation syndrome in the era of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: limitations of serum bicarbonate as a screening tool.","Manuel A","2026","Sleep","other","article","10.1093/sleep/zsaf297","41014194",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001356","GLP-1 Receptor Agonists Versus Bariatric Surgery: Effects of Weight Loss and BMI on Subsequent General Surgical Procedures.","Zindani S","2026","Clinical obesity","nonrandomized_study","article","10.1111/cob.70075","41804113","PMC12972600",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001357","Glucagon-Like Peptide 1 Receptor Agonist Use and Vertebral Fracture Risk in Type 2 Diabetes.","Khor WT","2026","JAMA surgery","nonrandomized_study","article","10.1001/jamasurg.2025.5372","41369924","PMC12696653",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0001358","Patient Experiences With GLP-1 Receptor Agonists.","de Vere Hunt I","2026","JAMA network open","other","article","10.1001/jamanetworkopen.2026.16951","42247231","PMC13241945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0001359","GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia.","Bhaduri G","2026","Endocrine","systematic_review","article","10.1007/s12020-026-04559-x","41697556",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0001360","Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson's disease: a bibliometric analysis.","Yu T","2026","Frontiers in neuroscience","systematic_review","article","10.3389/fnins.2026.1894856","42591537","PMC13462061","OSF:osf.io/u7wdy",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0001361","GLP-1 receptor agonists in people with epilepsy: A scoping review of clinical data, safety, and therapeutic implications.","Pinto LF","2026","Seizure","nonrandomized_study","article","10.1016/j.seizure.2026.05.013","42202441",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Scoping Review; article"],["R0001362","Nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy: a case report.","Cho CH","2026","Korean journal of family medicine","case_report","article","10.4082/kjfm.26.0135","42773534","PMC13617292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001363","Glucagon-like peptide-1 receptor agonists in alcohol use disorder: Multi-system effects, early clinical promise and uncertain long-term use.","Haass-Koffler CL","2026","Addiction (Abingdon, England)","commentary","article","10.1111/add.70374","41715992",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0001364","Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study.","Takashima S","2026","Diabetology international","nonrandomized_study","article","10.1007/s13340-026-00903-8","42078492","PMC13133284",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0001365","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®).","McIntyre RS","2025","Journal of affective disorders","nonrandomized_study","article","10.1016/j.jad.2024.10.062","39433133",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001366","SGLT2 Inhibitors and GLP-1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta-Analysis.","Barreto EF","2026","Pharmacotherapy","systematic_review","article","10.1002/phar.70137","41947629",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001367","Preoperative GLP-1 receptor agonist use is not associated with increased risk of pseudoarthrosis following midfoot fusion: a propensity-matched analysis.","Baur AJ","2026","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","nonrandomized_study","article","10.1053/j.jfas.2026.05.015","42217565",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001368","Potential additional benefits of glucagon-like peptide-1 receptor agonists in psoriasis.","Svedbom A","2026","The British journal of dermatology","commentary","article","10.1093/bjd/ljaf382","41037492",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0001369","GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight.","Patel TA","2026","Circulation research","other_trial","article","10.1161/circresaha.126.327683","42461990",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0001370","An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review.","Wen J","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16110","39654073",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001371","Rates of repeat EGD in nondiabetic adults with glucagon-like peptide-1 receptor agonist prescription: a retrospective matched cohort study.","Elangovan A","2025","Gastrointestinal endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.10.004","39389433",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001372","Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of GLP-1 receptor agonist efficacy and safety.","Jan A","2026","Obesity pillars","systematic_review","article","10.1016/j.obpill.2026.100272","42095067","PMC13141732",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001373","Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.","Belančić A","2026","British journal of clinical pharmacology","systematic_review","article","10.1002/bcp.70492","41703425",null,"PROSPERO:CRD42024609736",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; article"],["R0001374","A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease.","Xie Z","2022","Therapeutics and clinical risk management","nonrandomized_study","article","10.2147/tcrm.s375067","36065167","PMC9440721",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001375","From adiposity to multisystem morbidity: the case for weight loss as disease modification.","Sattar N","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00186-5","42660161",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Review"],["R0001376","Response to Comment on Park et al. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes. Diabetes Care 2026;49:147-151.","Park CM","2026","Diabetes care","commentary","article","10.2337/dci26-0008","41861128",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0001377","New onset diabetic retinopathy with glucagon-like peptide-1 receptor agonists: A case report.","Ko J","2025","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2025.102475","40609682",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0001378","Benefits of glucagon-like peptide-1 receptor agonists versus pioglitazone for cardio-hepatic outcomes: a territory-wide target trial emulation.","Li L","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02973-5","41174643","PMC12577280",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001379","Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.","Armentaro G","2026","Internal and emergency medicine","other","article","10.1007/s11739-026-04499-4","42622752",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001380","Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL Trial.","Hasebe M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71035","42348164","PMC13449011",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0001381","Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue†.","Zhang Y","2023","Biology of reproduction","randomized_trial","article","10.1093/biolre/ioad032","36930063","PMC10266951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0001382","Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions.","Dao MQ","2026","Burns : journal of the International Society for Burn Injuries","nonrandomized_study","article","10.1016/j.burns.2025.107848","41581262",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001383","Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria.","Ozturk S","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15135049","42452511","PMC13362839",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001384","Exendin-4 protects brain endothelial cell damage against hyperammonemic condition.","Ahn SY","2026","Biochemistry and biophysics reports","preclinical","article","10.1016/j.bbrep.2026.102644","42222506","PMC13217415",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001385","Efficacy and safety of glucagon-like peptide-1 receptor agonist liraglutide in new-onset diabetes after kidney transplantation: An open-label, parallel-group, randomized controlled trial.","Cao H","2025","Chinese medical journal","randomized_trial","article","10.1097/cm9.0000000000003880","41267184",null,"ChiCTR:ChiCTR2300078600",null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0001386","Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists on Diabetic Foot Disease : An Emulated Target Trial.","Kristensen FPB","2026","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-25-01262","41490509",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0001387","Blood Pressure Control Among U.S. Adults With Hypertension, Stratified by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use: Evidence From the National Health and Nutrition Examination Survey, 2017-2020.","Elfezzani N","2026","Cureus","other","article","10.7759/cureus.113504","42662789","PMC13520756",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001388","GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis.","Rai P","2026","Respiratory medicine","nonrandomized_study","article","10.1016/j.rmed.2026.109001","42362122","PMC13349367",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0001389","Glucagon-like peptide-1 receptor agonists in pediatric metabolic dysfunction-associated steatotic liver disease.","Tou AM","2026","Journal of pediatric gastroenterology and nutrition","nonrandomized_study","article","10.1002/jpn3.70242","41144868",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0001390","Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression.","Abenavoli L","2026","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina62050986","42195239","PMC13208855",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001391","Unraveling the safety profile of GLP-1 receptor agonists: Mechanistic insights with a focus on semaglutide.","He X","2025","European journal of medicinal chemistry","randomized_trial","article","10.1016/j.ejmech.2025.118163","40975962",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001392","Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression.","Khalil I","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2025.06.005","40553959",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Comparative Study; Network Meta-Analysis; article"],["R0001393","Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials.","Chen J","2025","Journal of diabetes","systematic_review","article","10.1111/1753-0407.70151","40887719","PMC12399406",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0001394","Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence.","Ștefănescu C","2025","Healthcare (Basel, Switzerland)","systematic_review","article","10.3390/healthcare13222958","41302345","PMC12652309",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0001395","Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients.","El Khatib O","2026","Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","nonrandomized_study","article","10.6002/ect.2025.0180","41808646",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Comparative Study"],["R0001396","GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.","Gonzalez F","2026","Journal of pediatric endocrinology & metabolism : JPEM","nonrandomized_study","article","10.1515/jpem-2025-0568","41353583",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0001397","Safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes mellitus fasting during Ramadan: a systematic review and meta-analysis.","Kamrul-Hasan ABM","2025","World journal of methodology","systematic_review","article","10.5662/wjm.v15.i4.105478","40900863","PMC12400322",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001398","Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies.","Anatriello A","2026","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2026.1808359","42311413","PMC13269103","PROSPERO:CRD420251080120",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0001399","Atypical retrobulbar optic neuropathy after semaglutide escalation.","Channabasappa S","2026","JCEM case reports","nonrandomized_study","article","10.1210/jcemcr/luag108","42220603","PMC13220016",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0001400","Improved cardiovascular outcomes with glucagon-like peptide-1 receptor agonists - what is the role of weight reduction?","Jacob S","2025","Cardiovascular endocrinology & metabolism","randomized_trial","article","10.1097/xce.0000000000000346","40950532","PMC12431743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0001401","Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.","Bhaduri G","2026","Clinical obesity","systematic_review","article","10.1111/cob.70105","42584177","PMC13464048",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0001402","Glaucoma Risk Reduction as a Secondary Benefit of Glucagon-like Peptide-1 Receptor Agonists: A Review of Emerging Evidence.","Lang MV","2025","Journal of current glaucoma practice","randomized_trial","article","10.5005/jp-journals-10078-1501","41523168","PMC12780357",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001403","Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.","Khademi R","2026","Cardiovascular diabetology. Endocrinology reports","randomized_trial","article","10.1186/s40842-026-00319-y","42487144","PMC13393864",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001404","Predicting GLP-1 Discontinuation From Pharmacy Claims.","Sisodia A","2026","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2026.89993","42663544",null,"ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001405","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Ankle Fracture Open Reduction and Internal Fixation",null,"2025","Foot & ankle orthopaedics","other","article",null,null,"PMC12743929",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0001406","Orforglipron in type 2 diabetes mellitus and obesity: an overview.","Panou T","2025","Expert review of clinical pharmacology","nonrandomized_study","article","10.1080/17512433.2025.2594493","41275408",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0001407","GLP-1 Receptor Agonists Are Associated with Reduced Ascending Aorta Dilatation in Patients with Type 2 Diabetes: A Prospective Study.","Sardu C","2025","International journal of molecular sciences","other","article","10.3390/ijms26209977","41155271","PMC12563610",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0001408","A Case of Slowly Progressive Type 1 Diabetes Mellitus (SPIDDM, Probable) Successfully Managed With Oral Semaglutide for Glycemic Control and Weight Management Accompanied by Changes in Eating Behavior.","Hirai T","2025","Cureus","case_report","article","10.7759/cureus.96335","41367443","PMC12682503",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001409","GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1-40 in diabetes.","Ikonomidis I","2026","American journal of physiology. Heart and circulatory physiology","nonrandomized_study","article","10.1152/ajpheart.00996.2025","41579346",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0001410","Glucagon-like peptide-1 receptor agonists and periprocedural pulmonary aspiration: where are we now?","Hobai IA","2026","Canadian journal of anaesthesia = Journal canadien d'anesthesie","commentary","article","10.1007/s12630-026-03113-7","42087043",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0001411","Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment-A Single Center Case Series.","Magnatta A","2026","Life (Basel, Switzerland)","nonrandomized_study","article","10.3390/life16040582","42073391","PMC13117391",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001412","Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept.","Briere DA","2026","Molecular metabolism","other_trial","article","10.1016/j.molmet.2026.102452","42829171",null,"ClinicalTrials.gov:NCT04641312","S000553","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0001413","Clinical Presentation of a Child With a Novel ALMS1 Variant Associated With Alström Syndrome and Favorable Response to GLP-1 Receptor Agonist Therapy.","Alvarez G","2026","American journal of medical genetics. Part A","case_report","article","10.1002/ajmga.70055","41549937",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0001414","15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.","Nalbandian M","2026","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.2606533123","42228536","PMC13250539",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001415","Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis.","AbdelMagid AM","2026","Pharmacotherapy","systematic_review","article","10.1002/phar.70142","41947610",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0001416","NLRP3 inflammasome as a central target for the pleiotropic effects of GLP-1 receptor agonists.","Mahmoudi A","2026","International immunopharmacology","narrative_review","article","10.1016/j.intimp.2026.117063","42348985",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001417","Exploration of the Effects of SGLT-2 Inhibitors and GLP-1 Receptor Agonists on Coronary Inflammation in Type 2 Diabetes Patients Based on the Peri-Coronary Fat Attenuation Index.","Wang T","2026","Reviews in cardiovascular medicine","nonrandomized_study","article","10.31083/rcm47415","42238645","PMC13227378",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001418","A Retrospective Analysis of Glucagon-like Peptide-1 Receptor Agonists on Bowel Preparation Efficacy in Colonoscopies.","Zaher A","2026","American journal of therapeutics","nonrandomized_study","article","10.1097/mjt.0000000000001964","41505167",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001419","Managing patients taking glucagon-like peptide-1 receptor agonists: proceed with caution.","Ovsak GG","2026","British journal of anaesthesia","nonrandomized_study","article","10.1016/j.bja.2025.10.004","41162256",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0001420","Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.","Ko A","2026","Annals of internal medicine","systematic_review","article","10.7326/annals-25-02237","41359966",null,"PROSPERO:CRD42024608365","S002468","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; article"],["R0001421","GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications.","Ramírez-Mejía MM","2025","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/20420188251406456","41459016","PMC12739101",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001422","Semaglutide Attenuates Neuroinflammation in Mice","Rausch DM","2026","bioRxiv","preclinical","preprint","10.64898/2026.01.10.698763",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0001423","Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review.","Johnson BVB","2025","Obesity pillars","narrative_review","article","10.1016/j.obpill.2025.100209","41368199","PMC12685510",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0001424","Suspected liraglutide (glucagon-like peptide-1 receptor agonist)-induced hyperthyroidism: A case report.","Md Sabudin SNS","2025","Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia","case_report","article","10.51866/cr.886","40949169","PMC12432342",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001425","Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.","Teli B","2026","Cureus","randomized_trial","article","10.7759/cureus.111322","42495454","PMC13394655",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001426","Aesthetic, muscle, and dermatologic effects of medical weight management: patient-reported outcomes shape a holistic preventive procedural approach.","Santiago Mangual KP","2026","International journal of women's dermatology","other","article","10.1097/jw9.0000000000000283","42639588","PMC13502791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001427","Glucagon-Like Peptide-1 Receptor Agonists and Decreased Subarachnoid Hemorrhage Risk in Patients With Intracranial Aneurysm.","Feghali J","2026","Stroke","nonrandomized_study","article","10.1161/strokeaha.125.053599","41492776",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001428","Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.","Salvatore M","2026","Nature communications","nonrandomized_study","article","10.1038/s41467-026-72947-y","42185271","PMC13388941",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001429","Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis.","Dos Santos Borges R","2026","JHEP reports : innovation in hepatology","systematic_review","article","10.1016/j.jhepr.2025.101708","41810433","PMC12969438",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001430","Preserving musculoskeletal health through resistance training in individuals undergoing Glucagon-like Peptide-1 Receptor Agonist Therapy: a controlled interrupted time-series analysis (Stage 1 Registered Report)","Steele J","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.06.24.25330195",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001431","Outcomes of primary rotator cuff repair in non-diabetic patients using glucagon-like peptide-1 (GLP-1) receptor agonists: A propensity-matched analysis.","Ambrose Martino J","2026","Shoulder & elbow","nonrandomized_study","article","10.1177/17585732261434004","41869012","PMC13004713",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0001432","A noninvasive 13C-mannitol breath test to monitor semaglutide treatment-induced delayed oral-cecal transit in mice.","Vieira DE","2026","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00113.2026","42623313","PMC13615566",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001433","GLP-1 receptor agonists in neurological diseases: mechanisms and therapeutic prospects from metabolism to neuroprotection.","Yang M","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1839620","42416049","PMC13337448",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001434","Beyond lifestyle modification: the role of GLP-1 receptor agonists in treating pediatric obesity.","Wen H","2025","Frontiers in pediatrics","narrative_review","article","10.3389/fped.2025.1684485","41641128","PMC12864059",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001435","Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease.","Hong AT","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112982","41177308","PMC12645714",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001436","The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.","Qeadan F","2025","Addiction (Abingdon, England)","nonrandomized_study","article","10.1111/add.16679","39415416","PMC11707322",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001437","Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.","Thiyagarajan S","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-08467-3","41484761","PMC12957123",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001438","Glucagon-Like Peptide-1 Receptor Agonists in Managing High Stoma Output: A Scoping Review.","Mao C","2026","The Journal of surgical research","randomized_trial","article","10.1016/j.jss.2026.03.080","41990642",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Scoping Review; article"],["R0001439","GLP‑1 receptor agonist therapy and 2‑year structural outcomes after arthroscopic rotator cuff repair in type 2 diabetes.","Yang MY","2026","BMC musculoskeletal disorders","nonrandomized_study","article","10.1186/s12891-026-10059-w","42265675","PMC13474731",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001440","Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration.","Ahuja AS","2025","JAMA ophthalmology","randomized_trial","article","10.1001/jamaophthalmol.2025.3821","41129133","PMC12550735",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0001441","Angioedema After Accidental Semaglutide Dosing Error: A Case Report.","Kraft BD","2026","Journal of clinical medicine","case_report","article","10.3390/jcm15103705","42194666","PMC13207423",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001442","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Knee Arthroplasty Outcomes.","Zaffar H","2026","Indian journal of orthopaedics","nonrandomized_study","article","10.1007/s43465-025-01646-5","41909003","PMC13031487",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001443","Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?","Kylies D","2026","Current hypertension reports","narrative_review","article","10.1007/s11906-026-01374-7","42091772","PMC13149630",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001444","GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research.","Merhi Z","2026","Sexual medicine reviews","randomized_trial","article","10.1093/sxmrev/qeag015","41870138",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0001445","The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.","Lingyu Z","2026","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2026.1825379","42165019","PMC13183531",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0001446","Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report.","Quarenghi M","2026","Journal of the American College of Emergency Physicians open","other_trial","article","10.1016/j.acepjo.2026.100427","42256775","PMC13241993",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0001447","Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.","Sidrak WR","2024","Indian journal of endocrinology and metabolism","randomized_trial","article","10.4103/ijem.ijem_442_23","39676791","PMC11642516",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001448","History of glucagon-like peptide-1 receptor agonists.","Darwish R","2025","Pharmacological research","commentary","article","10.1016/j.phrs.2025.108045","41314319",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0001449","GLP-1 Receptor Agonists versus Bariatric Surgery in Breast Cancer: A Comparative Study of Oncologic Outcomes.","Den J","2026","Annals of surgery","nonrandomized_study","article","10.1097/sla.0000000000007121","42298328",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0001450","Combination of GLP-1 receptor agonist and Akkermansia muciniphila Akk11 reduces adiposity and ameliorates MASLD in T2D mice.","Gao K","2026","Cell & bioscience","preclinical","article","10.1186/s13578-025-01525-4","41526984","PMC12888585",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001451","Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity.","Park J","2026","Scientific reports","nonrandomized_study","article","10.1038/s41598-026-56002-w","42286047","PMC13507221",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001452","Pleiotropy of glucagon-like peptide-1 receptor agonists: too much of a good thing?","Sili Scavalli A","2025","Minerva cardiology and angiology","other","article","10.23736/s2724-5683.25.07174-1","41414924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001453","The Efficacy of Glucagon-like Peptide-1 Receptor Agonists on Different Cognitive Domains: A Meta-analysis of Randomized Controlled Trials.","Xu H","2026","Current neuropharmacology","systematic_review","article","10.2174/011570159x439787260312090015","42163663",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0001454","From Prescription to Understanding: Medil AI, a Multilingual Mobile Platform for Medication Information, Pill Reminders, Adherence Support, and Between-Visit Communication","Israel A","2026","Preprints.org","other","preprint","10.20944/preprints202609.0448.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0001455","Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.","Sørensen KK","2026","JAMA network open","other","article","10.1001/jamanetworkopen.2025.55449","41587033","PMC12836129",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001456","Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease-A Danish Nationwide Cohort Study.","Nielsen J","2025","Inflammatory bowel diseases","nonrandomized_study","article","10.1093/ibd/izae276","39603814",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001457","Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists.","Rashid Z","2026","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-026-10300-1","41749007","PMC13176436",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001458","Liraglutide and renal mitochondrial homeostasis: targeting the \"metabolism-inflammation-lithogenesis\" axis in metabolic syndrome.","Wang F","2026","Frontiers in pharmacology","other_trial","article","10.3389/fphar.2026.1903973","42761830","PMC13587710",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0001459","Timing and duration of glucagon-like peptide-1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy.","Niazi S","2026","Acta ophthalmologica","nonrandomized_study","article","10.1111/aos.70168","42126975",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001460","GLP-1RA may open a new era for MASLD treatment: Editorial on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Feng Y","2026","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2025.0628","40551542","PMC13129799",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; Comment; article"],["R0001461","GLP-1 Receptor Agonists in the Rehabilitation of Patients with Heart Failure: Mechanisms, Clinical Evidence, and Future Perspectives.","Suastika LOS","2026","Nutrients","narrative_review","article","10.3390/nu18111688","42280332","PMC13259458",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001462","Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease.","Ibe T","2026","Annual review of medicine","narrative_review","article","10.1146/annurev-med-043024-011141","41160742",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0001463","Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.","Patrizio A","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag051","41693146","PMC13404424",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0001464","Glucagon like peptide-1 receptor agonist therapy and long-term renal outcomes after radical nephrectomy: a propensity-matched cohort analysis.","Ahmad NB","2026","International urology and nephrology","nonrandomized_study","article","10.1007/s11255-026-05177-2","42128993","PMC13586004",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001465","Semaglutide and diabetic retinopathy: an OHDSI network study.","Cai CX","2025","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2025-005424","41192935","PMC12587949",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0001466","Summary of Research: Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis.","Hassanein M","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-025-01827-3","41697523","PMC13000099",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0001467","GLP-1 receptor agonist exposure in the periconceptional period and adverse obstetric outcomes: A systematic review and meta-analysis.","D'Antonio F","2026","Med (New York, N.Y.)","systematic_review","article","10.1016/j.medj.2026.101267","42810337",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001468","Erratum to \"Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions\" [Burns 52/2 (2026) 107848].","Dao MQ","2026","Burns : journal of the International Society for Burn Injuries","notice","article","10.1016/j.burns.2026.107909","41707539",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0001469","Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.","Crabtree TSJ","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14701","35322528","PMC9322019",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0001470","Comment on: Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Cataract Development.","Yu HN","2026","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2025.11.050","41475442",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0001471","GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.","Ramadurgum P","2026","Current cardiology reports","randomized_trial","article","10.1007/s11886-026-02356-6","41880122",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001472","Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure.","Llongueras-Espí P","2025","Biomolecules","narrative_review","article","10.3390/biom15091342","41008649","PMC12466965",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0001473","Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.","Barkmeier AJ","2026","Ophthalmology. Retina","nonrandomized_study","article","10.1016/j.oret.2025.07.019","40774571",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Comparative Study; Multicenter Study; article"],["R0001474","Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough.","Gallagher TJ","2026","JAMA otolaryngology-- head & neck surgery","nonrandomized_study","article","10.1001/jamaoto.2025.4181","41296333","PMC12658766",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; article"],["R0001475","A Target Trial Emulation Study of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Combination Therapy in Preventing Kidney Failure in Type 2 Diabetes.","Blum MF","2026","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000000902","41400456","PMC12959744",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001476","ICER report demonstrates both the value and challenges in financing of weight loss medications.","Ramachandran S","2026","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2026.32.6.753","42166309","PMC13193314",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; research-article; Journal Article; article"],["R0001477","Clarifying the Guidelines and Decoding the Enigma: Strategies for Anesthetic Management of Patients on Glucagon-Like Peptide-1 Receptor Agonists.","Joshi GP","2026","Anesthesia and analgesia","other","article","10.1213/ane.0000000000007921","41468591",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001478","GLP-1 Receptor Agonist Use Is Associated With Lower Risk of Intracranial Aneurysm Rupture and Rupture Severity.","Chen H","2026","Stroke","nonrandomized_study","article","10.1161/strokeaha.126.055692","42165144","PMC13196425",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001479","Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease.","Sedrak P","2025","The Canadian journal of cardiology","narrative_review","article","10.1016/j.cjca.2025.03.037","40311673",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001480","Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices.","Marques P","2025","JACC. Heart failure","nonrandomized_study","article","10.1016/j.jchf.2025.102573","40992090",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0001481","History of GLP-1 receptor agonists confer no improvement for Achilles tendon repairs: A national, propensity-matched comparison.","Rajan T","2026","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","nonrandomized_study","article","10.1053/j.jfas.2026.05.005","42128170",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Multicenter Study; article"],["R0001482","Co-prescription of metformin and glucagon-like peptide-1 receptor agonists and metformin-associated lactic acidosis: A case series.","Hussain H","2026","Clinical nephrology. Case studies","case_report","article","10.5414/cncs111965","42164410","PMC13185473",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001483","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Treatment After Liver Transplantation: A Hypothesis-Generating Case Report.","Yurukova NN","2026","Cureus","case_report","article","10.7759/cureus.108793","42291858","PMC13262899",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001484","GLP1 Mimetics and Stem Cells: An Intersection of Metabolic and Regenerative Medicine.","Kolonin MG","2026","Stem cell reviews and reports","commentary","article","10.1007/s12015-026-11194-6","42470527",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0001485","GLP1 receptor agonists attenuate systemic inflammation through microbiota mediated enrichment of Faecalibacterium prausnitzii and Roseburia spp","Tanaka H","2025","bioRxiv","other","preprint","10.1101/2025.09.07.674712",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0001486","Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential.","Colwill M","2025","Journal of Crohn's & colitis","nonrandomized_study","article","10.1093/ecco-jcc/jjaf167","40972535","PMC12558716",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001487","Metabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.","Hageen AW","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70275","42487237","PMC13392217",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; review-article; article"],["R0001488","Glucagon Like Peptide-1 Receptor Agonists for Sarcopenia and Muscle Wasting Disorders: A Systematic Review of Efficacy and Mechanisms.","Maihemuti A","2025","Aging and disease","systematic_review","article","10.14336/ad.2025.1165","41400575",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Review; review"],["R0001489","Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.","Bloomgarden Z","2026","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.70248","42417199","PMC13343302",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0001490","Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.","Lee S","2025","CNS spectrums","other_trial","article","10.1017/s109285292510031x","40485141","PMC13064770",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0001491","Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study.","Koide Y","2025","Frontiers in clinical diabetes and healthcare","other_trial","article","10.3389/fcdhc.2025.1638681","41040428","PMC12483915","UMIN:UMIN000045362",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0001492","Efficacy of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.","Ahmed W","2026","Journal of the neurological sciences","systematic_review","article","10.1016/j.jns.2025.125711","41468715",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001493","Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP-1 Receptor Agonists: A Meta-Analysis and Meta-Regression of Randomised Controlled Trials.","Hasebe M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70749","41969171","PMC13243948",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0001494","Reply to Comment on Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Cataract Development.","Ahuja AS","2026","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2025.12.021","41478534",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0001495","Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.","Wright EE","2025","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2025.24253","39823185","PMC11852799",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001496","Advancing Physical Function Outcomes in Glucagon-Like Peptide-1 Receptor Agonist Trials.","Karregat JHM","2026","Annals of internal medicine","commentary","article","10.7326/annals-25-03519","41429019",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0001497","Retatrutide in type 2 diabetes mellitus and obesity: an overview.","Panou T","2026","Expert review of clinical pharmacology","nonrandomized_study","article","10.1080/17512433.2026.2642415","41785010",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0001498","Risk of periprocedural regurgitation of gastric contents in patients on glucagon-like peptide-1 receptor agonists: a two-centre nested case-control study.","van Klei WA","2026","British journal of anaesthesia","nonrandomized_study","article","10.1016/j.bja.2025.12.033","41547617",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0001499","Glucagon-like peptide-1 receptor agonists may decrease biologic initiation in hidradenitis suppurativa: A TriNetX retrospective analysis.","Kasheri E","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.12.092","41478501",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001500","The role of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in chronic obstructive pulmonary disease.","Mah JSY","2026","Expert review of clinical immunology","randomized_trial","article","10.1080/1744666x.2026.2625967","41640042",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0001501","Suboptimal protein intake for hypocaloric diet needs while using glucagon-like peptide-1 receptor agonists","Johnson B","2025","Journal of the International Society of Sports Nutrition","other","article","10.1080/15502783.2025.2550139",null,"PMC12419545",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0001502","Early Signal Detection in GLP-1 Receptor Agonists in Spain: A Comparative Bayesian Disproportionality Analysis in 2024 and 2025","Jimenez-Serrania M","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-7574712/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001503","Effect of Glucagon-Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea.","Qian BB","2025","Obesity science & practice","other","article","10.1002/osp4.70090","40860896","PMC12371556",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001504","Effects of neoadjuvant glucagon-like-peptide 1 receptor agonists on weight loss after bariatric surgery.","Benavidez MC","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2025.09.010","41162242",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001505","Beyond Weight Loss: Tirzepatide as a Metabolic Disease-Modifying Strategy for Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.","Ahmed Z","2026","Health science reports","other_trial","article","10.1002/hsr2.73044","42597512","PMC13469756",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; review"],["R0001506","Design, Structure-Activity Relationships, and Computational Modeling Studies of a Series of α-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists.","Sawyer JR","2024","Molecules (Basel, Switzerland)","other","article","10.3390/molecules30010012","39795070","PMC11721672",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001507","Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II.","Siamashvili M","2025","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2024.2436593","39629799",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Comparative Study; other; article"],["R0001508","The mechanisms of GLP-1 receptor agonists in liver diseases: their multifaceted impact on immune response and metabolic regulation.","Hu Z","2026","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2026.1754721","41939830","PMC13044122",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001509","Glucagon-like peptide-1 receptor agonists and muscle mass effects.","Ceasovschih A","2025","Pharmacological research","narrative_review","article","10.1016/j.phrs.2025.107927","40858197",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001510","Glucagon-like peptide-1 receptor agonists: an emerging hope against nephrolithiasis risk reduction via body weight reduction.","Kanbay M","2026","International urology and nephrology","commentary","article","10.1007/s11255-025-04997-y","41484515",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001511","Some Risks of Gastrointestinal Adverse Events Associated With Glucagon-Like PEPTIDE-1 Receptor Agonists Are Likely Explained by BMI.","Liu BD","2025","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.70190","40356540",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0001512","Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort.","AbuAlrob MA","2025","Journal of Alzheimer's disease reports","nonrandomized_study","article","10.1177/25424823251388650","41122341","PMC12536097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001513","Protease-Resistant Azapeptide GLP-1 Analogue Improves Metabolic Control in Diet-Induced Obesity.","He M","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.05.09.653092","41278761","PMC12632547",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0001514","Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study.","Wu JY","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1877392","42601938","PMC13472920",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001515","Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes.","Ozbek L","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70699","41885132",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; review"],["R0001516","Analysis of NHANES: Nutrient, Food, and Beverage Intake of Glucagon-Like Peptide-1 Receptor Agonist Users with Type 2 Diabetes, 2007-2020.","Frankenfeld CL","2026","The Journal of nutrition","other","article","10.1016/j.tjnut.2026.101685","42331063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001517","Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.","Kishi T","2026","Translational psychiatry","systematic_review","article","10.1038/s41398-026-04253-6","42420255","PMC13631319",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; Systematic Review; review-article; article"],["R0001518","Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study.","Khogalee M","2026","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2026.08.004","42711176",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001519","Perioperative anesthesia management of GLP-1 receptor agonists: a systematic review of potential risks.","Merhavy ZI","2026","Perioperative medicine (London, England)","systematic_review","article","10.1186/s13741-026-00662-9","41723539","PMC13032261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001520","Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists.","Wang R","2026","Spine","nonrandomized_study","article","10.1097/brs.0000000000005773","42348793",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001521","Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists.","Barrett TS","2025","JAMA surgery","nonrandomized_study","article","10.1001/jamasurg.2025.3590","40960852","PMC12444648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Comment; research-article; article"],["R0001522","Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges.","Westermeier F","2025","Cardiovascular diabetology","commentary","article","10.1186/s12933-025-02608-9","39881322","PMC11781064",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Historical Article; editorial"],["R0001523","Glucagon-Like Peptide-1 Receptor Agonist Exposure and Long-Term Outcomes in Patients with Asymptomatic Carotid Stenosis: A Propensity Score-Matched Real-World Analysis.","Rai P","2026","AJNR. American journal of neuroradiology","nonrandomized_study","article","10.3174/ajnr.a9443","42229997",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001524","Social Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis.","Stallion C","2026","JMIR diabetes","nonrandomized_study","article","10.2196/87590","42684325","PMC13515349",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001525","Residual gastric content after holding of glucagon-like peptide-1 receptor agonists before elective surgery: a cross-sectional study - the RESIDUAL study.","Boudreau C","2026","BMC anesthesiology","nonrandomized_study","article","10.1186/s12871-026-03999-2","42265610","PMC13491755","ClinicalTrials.gov:NCT06500143","S001411","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0001526","Do Incretin-Based Therapies Influence the Risk of Cholangiocarcinoma in Type 2 Diabetes Patients? Insights from a Systematic Review and Meta-Analysis.","Yonatan ER","2025","Journal of gastrointestinal cancer","systematic_review","article","10.1007/s12029-025-01330-9","41075111",null,"PROSPERO:CRD42025641616",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001527","GLP-1 and GLP-1/GIP receptor agonist medication use and self-reported outcomes in individuals with lipedema: Results from a large online survey.","Srinivasan A","2026","Obesity pillars","other","article","10.1016/j.obpill.2026.100316","42656629","PMC13507742",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001528","Hemodynamic changes in response to GLP-1 treatment in ICD and CRT patients: insights from HeartLogic sensor data.","Fussing FH","2026","European journal of heart failure","nonrandomized_study","article","10.1093/ejhf/xuag114","41990363",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001529","Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors combination therapy for adults with type 2 diabetes mellitus: a network meta-analysis.","Osman AA","2025","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd015952","40237224","PMC12001318",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; systematic-review; article"],["R0001530","Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.","Chen D","2026","BMJ medicine","systematic_review","article","10.1136/bmjmed-2026-003026","42688617","PMC13536023","PROSPERO:CRD420261279841",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001531","GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.","Schifano F","2026","Current psychiatry reports","randomized_trial","article","10.1007/s11920-026-01709-w","42624955","PMC13493456",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001532","Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis.","Guo M","2026","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.70134","41668634",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0001533","Advances in Incretin-Based Therapies for MAFLD: Mechanisms and Clinical Evidence.","Dong W","2026","Clinical pharmacology and therapeutics","randomized_trial","article","10.1002/cpt.70131","41243582",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0001534","Exploring Dietary Intake in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists: A Cross-Sectional Analysis.","Ponzo V","2025","Nutrients","nonrandomized_study","article","10.3390/nu17213318","41228390","PMC12610383",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001535","GLP-1 Receptor Agonists in Ear, Nose and Throat: A Review of Clinical Implications, Side Effects and High-Risk Airway Surgery Considerations.","Somasundaram S","2026","Ear, nose, & throat journal","narrative_review","article","10.1177/01455613261445013","42089506",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001536","Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of \"Ozempic Face\".","Rao S","2026","Dermatology and therapy","other","article","10.1007/s13555-026-01882-z","42579223","PMC13558510",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0001537","Newer and novel antidiabetic drug classes across the cardiovascular-kidney-metabolic continuum.","Stefanakis K","2026","Endocrine reviews","other","article","10.1210/endrev/bnag022","42440116",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001538","Glucagon-like Peptide-1 Receptor Agonist Use and Outcomes in Peripartum Cardiomyopathy: A Propensity-Score Matched Analysis.","Jain H","2026","The Canadian journal of cardiology","nonrandomized_study","article","10.1016/j.cjca.2025.12.047","41482149",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0001539","GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization.","Mahadevan A","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgaf703","41482652","PMC13183429",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0001540","Muscle loss and GLP-1R agonists use.","Rossi G","2026","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-025-02611-2","41201615","PMC12957034",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001541","GLP-1 Receptor Agonists as a Potential Fifth Pillar of GDMT in HFrEF (NYHA II–IV): A Multicenter Real-World Propensity-Matched Analysis","Yousafzai O","2026","medRxiv","randomized_trial","preprint","10.64898/2026.04.13.26350824",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0001542","Impact of Glucagon-Like Peptide-1 Agonists on Hepatocellular Carcinoma Risk and Management in Type 2 Diabetes Mellitus: A Scoping Review.","Tungekar B","2025","Cureus","randomized_trial","article","10.7759/cureus.100252","41607999","PMC12840817",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001543","Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.","Kateel R","2026","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2026.113270","42105869",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0001544","Glucagon-like peptide-1 receptor agonists and kidney outcomes.","MacIsaac RJ","2024","Journal of diabetes","other_trial","article","10.1111/1753-0407.13609","39364792","PMC11450654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0001545","Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.","Celsa C","2025","Gut","systematic_review","article","10.1136/gutjnl-2024-334591","40015951",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0001546","Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.","Bruno A","2026","Aesthetic plastic surgery","randomized_trial","article","10.1007/s00266-026-05805-3","41944875",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Observational Study; article"],["R0001547","Pharmacotherapy for obesity management-Emphasizing the role of GLP-1 receptor agonist-based therapeutics.","Warden BA","2026","Journal of clinical lipidology","narrative_review","article","10.1016/j.jacl.2025.11.013","41708216",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001548","The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review.","Corcoran E","2026","Molecular and cellular neurosciences","systematic_review","article","10.1016/j.mcn.2026.104091","42014236",null,"PROSPERO:CRD420251029748",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0001549","Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis.","Osumili B","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-025-01728-5","40214900","PMC12085526",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0001550","Prepregnancy GLP-1RA Exposure and Risk of Hypertensive Disorders of Pregnancy Among Women With Obesity and Diabetes.","Lemas DJ","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70221","42120704",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001551","Weight-loss dynamics with tirzepatide versus semaglutide.","Venkatakrishnan AJ","2026","PNAS nexus","nonrandomized_study","article","10.1093/pnasnexus/pgag171","42311474","PMC13270487",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001552","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias.","Jaiswal V","2025","Journal of arrhythmia","nonrandomized_study","article","10.1002/joa3.70242","41404443","PMC12704023",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001553","GLP-1 Receptor Agonists and Fertility: What Is Known So Far?","Becker AS","2026","JBRA assisted reproduction","randomized_trial","article","10.5935/1518-0557.20260028","42441883","PMC13544260",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001554","Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study.","Cai CX","2026","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2026.05.034","42229813","PMC13318194",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0001555","GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework.","Kaltsas A","2026","Journal of clinical medicine","narrative_review","article","10.3390/jcm15187313","42796084","PMC13607358",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0001556","Acute pancreatitis following semaglutide therapy: a case report.","Alduraibi RK","2026","Annals of medicine and surgery (2012)","case_report","article","10.1097/ms9.0000000000005389","42725314","PMC13561303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001557","Impact of Sleeping Habits on the Weight Loss Effect of Oral Glucagon-Like Peptide-1 Receptor Agonists Among Obese Patients: An Observational Study in Japan.","Takakura K","2025","Cureus","nonrandomized_study","article","10.7759/cureus.87823","40655063","PMC12256015",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001558","Use of Second-line Diabetes Mellitus Medications and Adverse Events Among Older Adults After the Introduction of Glucagon-like Peptide-1 Receptor Agonists in Ontario, Canada: A Retrospective Cohort Study.","Chu C","2026","Canadian journal of diabetes","nonrandomized_study","article","10.1016/j.jcjd.2025.12.009","41418910",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001559","Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review.","Kunutsor SK","2026","Drugs","randomized_trial","article","10.1007/s40265-025-02263-0","41351656",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0001560","Early cancer risk reduction after GLP-1RA use: Signal or bias?: Letter to the editor on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Jean SS","2026","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2025.0583","40485099","PMC13129741",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comment; Letter; letter"],["R0001561","Comparative Effectiveness of Liraglutide versus Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Multicenter Propensity Score-Matched Real-World Study.","Khalil I","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.03.009","41895690",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Comparative Study; article"],["R0001562","Glucagon-Like Peptide-1 Receptor Agonists and Alcohol Use: A Real-Word Observational Study in a Large, Integrated Health Care System.","Palzes VA","2026","Biological psychiatry global open science","nonrandomized_study","article","10.1016/j.bpsgos.2025.100659","41552778","PMC12803901",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001563","GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection.","Wang X","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1614726","41158620","PMC12554446",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001564","An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.","Thorne AK","2026","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.2618845123","42789307","PMC13643317",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001565","Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: implementation of complex fasting recommendations. Response to Br J Anaesth 2025; 136: 375-6.","Hepner DL","2026","British journal of anaesthesia","commentary","article","10.1016/j.bja.2025.12.022","41577608",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001566","The systems medicine view of semaglutide: from clinical trials to molecular mechanisms.","Vitorino R","2026","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2026.2695172","42339860",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001567","GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.","Parekh DS","2026","Disease-a-month : DM","systematic_review","article","10.1016/j.disamonth.2026.102151","42285803",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0001568","Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework.","Alhowail AH","2026","Frontiers in aging neuroscience","other_trial","article","10.3389/fnagi.2026.1851072","42325226","PMC13279212",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0001569","Exploring the Therapeutic Potential of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review.","Al Rashid S","2026","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","narrative_review","article","10.1055/a-2787-1205","41643685",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0001570","Perceptions, attitudes, and experiences of GLP-1 receptor agonists for weight management in the United Kingdom: a cross-sectional survey study.","Tallis J","2026","BMC public health","nonrandomized_study","article","10.1186/s12889-026-27975-0","42231269","PMC13445760",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001571","Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring.","Colorado M","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf195","40895495","PMC12395549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001572","Glucagon-Like Peptide-1 Receptor Agonist Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes in the All of Us Research Program.","Almazan E","2026","The American journal of gastroenterology","randomized_trial","article","10.14309/ajg.0000000000004048","42117589","PMC13428635",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0001573","Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.","Fountoulakis N","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70481","41705420","PMC12992176","ISRCTN:ISRCTN97699312; EudraCT:2016-001758-17",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0001574","Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease.","Dunn TJ","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112162","40220796",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001575","GLP-1-based therapeutics for cardiorenal protection in metabolic diseases.","Apperloo EM","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","nonrandomized_study","article","10.1093/ndt/gfaf110","40560166","PMC12855604",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001576","Preoperative Glucagon-Like Peptide-1 Receptor Agonist Treatment to Allow Safe Laparoscopic Left Pancreatectomy in Extreme Obesity: The First Report.","Canali G","2026","Case reports in surgery","other","article","10.1155/cris/9201182","41522658","PMC12779918",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0001577","The effect of GLP-1 receptor agonists on osteoarthritis risk in individuals with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized controlled trials.","Zhou L","2026","Acta diabetologica","systematic_review","article","10.1007/s00592-026-02697-2","42101662",null,"PROSPERO:CRD420251034203",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0001578","Genetic Insights Into Protective Effects of GLP-1 Receptor Agonists on Stroke and Alzheimer Disease Across Ancestries.","Caro-Châtelier I","2026","Neurology. Genetics","other","article","10.1212/nxg.0000000000200425","42812740","PMC13621555",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001579","Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Thyroid Eye Disease.","Muayad J","2026","Ophthalmic plastic and reconstructive surgery","nonrandomized_study","article","10.1097/iop.0000000000003222","41949435",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001580","Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.","Karakasis P","2025","Metabolism: clinical and experimental","systematic_review","article","10.1016/j.metabol.2024.156113","39719170",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0001581","Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report.","Alsermani M","2026","Cureus","nonrandomized_study","article","10.7759/cureus.100836","41646548","PMC12871440",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0001582","Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.","Ahmad M","2025","Cureus","systematic_review","article","10.7759/cureus.89514","40918811","PMC12413470",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001583","Glucagon-Like Peptide-1 Receptor Agonists Reduce Liver Stiffness in a Pediatric Metabolic Dysfunction-Associated Liver Disease Cohort and Normalize Disease-Associated Core Gene Expression in an Experimental Model.","Findling E","2026","Cureus","nonrandomized_study","article","10.7759/cureus.106280","42078303","PMC13134759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001584","GLP-1 receptor agonists and age-related macular degeneration risk in diabetes or non-diabetic obesity: A retrospective cohort study.","Pan SY","2026","The American journal of medicine","nonrandomized_study","article","10.1016/j.amjmed.2026.06.023","42379510",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001585","Trends in preoperative weight loss modalities among patients receiving body contouring surgery.","Liang J","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2026.08.008","42686475",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0001586","Insulin requirements after switching from GLP-1 receptor agonist to dual GIP/GLP-1 receptor agonist in patients with type 2 diabetes mellitus.","Lahey AM","2025","Pharmacotherapy","nonrandomized_study","article","10.1002/phar.70009","40108854",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001587","Glucagon-like peptide-1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect.","Scheen AJ","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16453","40364515",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0001588","Potential therapeutic role of GLP-1 receptor agonists in Idiopathic intracranial hypertension: a systematic review and meta-analysis.","Song J","2026","Neurological research","systematic_review","article","10.1080/01616412.2026.2640121","41776834",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; article; review"],["R0001589","Cardiovascular outcomes and mortality of bariatric surgery versus glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis.","Cordova F","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","systematic_review","article","10.1016/j.soard.2025.11.024","41506923",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; review"],["R0001590","Aesthetic Use of Poly-L-Lactic Acid and Hyaluronic Acid Fillers in Medication-Driven Weight Loss Due to GLP-1 Receptor Agonists: Real-World Case Series from Latin America.","Avelar LET","2026","Clinical, cosmetic and investigational dermatology","nonrandomized_study","article","10.2147/ccid.s620566","42328491","PMC13280651",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001591","Glucagon-Like Peptide-1 Receptor Agonists in the Management of Mitochondrial Diabetes in an Adolescent: A Case Report.","Hayes E","2026","Hormone research in paediatrics","case_report","article","10.1159/000552014","41999618",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0001592","Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review.","Liang Y","2024","Journal of Alzheimer's disease reports","systematic_review","article","10.3233/adr-230181","38746639","PMC11091751",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0001593","Oral Nutritional Supplements and Body Composition Outcomes Among GLP-1 Receptor Agonist Users: Real-World Evidence.","Hong K","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s574765","42117035","PMC13157696",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001594","Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk.","Neumiller JJ","2025","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000000587","39729347","PMC11835155","ClinicalTrials.gov:NCT05214573","S002708","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0001595","Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral center.","Avenatti E","2026","American journal of preventive cardiology","nonrandomized_study","article","10.1016/j.ajpc.2026.101733","42827863","PMC13632139",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0001596","Repurposing GLP-1 receptor agonists and SGLT-2 inhibitors in neurodegeneration and metabolically at-risk populations: Myth or reality? An overview of randomized clinical trials.","Mourtzos MA","2026","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2026.113345","42208664",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001597","GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review.","Saad Alfaiz A","2025","Annals of medicine and surgery (2012)","narrative_review","article","10.1097/ms9.0000000000004189","41377305","PMC12688977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0001598","SUN-075 Efficacy of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Diabetes Management in Patients with Cushing’s Disease",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545494",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0001599","GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction.","Ha J","2026","Journal of reconstructive microsurgery","nonrandomized_study","article","10.1055/a-2858-3774","42013898",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001600","Impact of GLP-1 Receptor Agonists on Chronic Low Back Pain in Patients with Obesity: A Prospective Pilot Cohort Study.","Benedict B","2026","medRxiv : the preprint server for health sciences","randomized_trial","article","10.64898/2026.05.20.26353666","42238413","PMC13228689",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Preprint; article; preprint"],["R0001601","Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonist on Outcomes Following Major Surgery.","Rashid Z","2025","World journal of surgery","nonrandomized_study","article","10.1002/wjs.12484","39788883","PMC11903251",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001602","GLP-1 receptor agonist utilization is associated with a low risk of Anesthesia-related complications prior to total joint arthroplasty.","C Palmer R","2025","European journal of orthopaedic surgery & traumatology : orthopedie traumatologie","nonrandomized_study","article","10.1007/s00590-025-04604-x","41351714",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001603","Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review.","Kavibharathi V","2026","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","narrative_review","article","10.1016/j.jchromb.2026.125267","42664897",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001604","Effectiveness of GLP-1RA vs metformin for diabetes prevention in antipsychotic-treated patients.","Liu TH","2026","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","nonrandomized_study","article","10.1016/j.euroneuro.2026.112853","42068648",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0001605","The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials.","Cao M","2026","Therapeutic advances in musculoskeletal disease","systematic_review","article","10.1177/1759720x261428147","41782908","PMC12953953",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001606","Comparative cardiovascular effectiveness of GLP-1RAs versus DPP-4is in dialysis patients with type 2 diabetes: a target trial emulation.","Shimada H","2026","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2026.101760","41974347",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Comparative Study; article"],["R0001607","Glucagon-like peptide-1 receptor agonists are associated with reduced abdominal aortic aneurysm-related events.","Ahn H","2026","Journal of vascular surgery","nonrandomized_study","article","10.1016/j.jvs.2025.11.021","41276093","PMC13395541",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0001608","Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Reduced Disease Severity and Pain in Hidradenitis Suppurativa: A Retrospective Study.","Islam Z","2026","International journal of dermatology","nonrandomized_study","article","10.1111/ijd.70191","41366828",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001609","Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.","Sayed MS","2026","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000002069","41656069",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0001610","Mirtazapine for gastrointestinal side effects of glucagon-like peptide-1 receptor agonist therapy in older adults.","Khan AR","2025","Endocrine regulations","case_report","article","10.2478/enr-2025-0030","41388533",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0001611","Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk.","Hartsell SE","2026","Journal of the American Society of Nephrology : JASN","nonrandomized_study","article","10.1681/asn.0000001016","41563358","PMC12924663",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001612","Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials.","Mantovani A","2025","Liver international : official journal of the International Association for the Study of the Liver","systematic_review","article","10.1111/liv.70256","40736113","PMC12309150",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; article"],["R0001613","The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review.","Liu Z","2025","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s559919","41312047","PMC12653004",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001614","Patterns of prescription and discontinuation of glucagon-like peptide-1 receptor agonists among patients with irritable bowel syndrome.","Gautam M","2025","Annals of gastroenterology","nonrandomized_study","article","10.20524/aog.2025.0971","40697433","PMC12277515",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001615","A restrictive fasting regimen is not necessary in patients taking glucagon-like peptide-1 receptor agonists. Response to Br J Anaesth 2025; 135: 1816-8.","Oprea AD","2026","British journal of anaesthesia","commentary","article","10.1016/j.bja.2025.11.022","41491545",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001616","Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials.","Yeo D","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70298","41255131","PMC12803684","PROSPERO:CRD420251112823",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; article"],["R0001617","Intraductal Papillary Mucinous Neoplasms and GLP-1 Receptor Agonists: Navigating Therapeutic Uncertainty in Diabetes Management.","Tassone F","2025","Biomedicines","nonrandomized_study","article","10.3390/biomedicines13102326","41153613","PMC12561726",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; other; article"],["R0001618","Redox-Driven Blood-Nerve Barrier Dysfunction in Diabetic Peripheral Neuropathy: Mechanisms and Therapeutic Opportunities.","Huang WH","2026","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox15060670","42351976","PMC13295332",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Preprint; preprint; article"],["R0001619","Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study.","Olbrich H","2026","The British journal of dermatology","nonrandomized_study","article","10.1093/bjd/ljaf346","40897378",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001620","Glucagon-like peptide-1 receptor agonists in neuropathic pain: hype or hope?","Choi JI","2025","The Korean journal of pain","commentary","article","10.3344/kjp.25214","40589055","PMC12221951",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0001621","GLP-1 Receptor Agonists and Long-Term Survival after Spontaneous Intracerebral Hemorrhage in Type 2 Diabetes.","Chen CM","2026","World neurosurgery","nonrandomized_study","article","10.1016/j.wneu.2026.124932","41895521",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001622","Time-to-First Clinical Benefit of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure.","Basile C","2026","Journal of cardiac failure","commentary","article","10.1016/j.cardfail.2025.11.489","41274487",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001623","Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.","Gaytan G","2026","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2026.103069","41794178",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0001624","Addressing the Growing Epidemic of Obesity: Bariatric Surgery or Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease?","Khataniar H","2025","Gastro hep advances","narrative_review","article","10.1016/j.gastha.2025.100791","41142532","PMC12550770",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001625","GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study.","Nelson RA","2026","The oncologist","nonrandomized_study","article","10.1093/oncolo/oyag268","42434976","PMC13395082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0001626","Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions.","Karacabeyli D","2025","Nature reviews. Rheumatology","preclinical","article","10.1038/s41584-025-01302-0","41034339",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0001627","Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.","Wali AF","2026","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2026.1736380","41743116","PMC12929497","OSF:osf.io/3rv6d",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0001628","Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus: a systematic review and meta-analysis.","Rebelos E","2025","Hormones (Athens, Greece)","systematic_review","article","10.1007/s42000-025-00704-9","40760325","PMC12678461",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0001629","GLP-1 Receptor Agonists Reduce Aortic Dissection and Hypertensive Crisis in Diabetic Patients with Aortic Aneurysm: A Retrospective Cohort Study.","Tsai YF","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s612622","42221150","PMC13217444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001630","Cannabis use and cardiovascular, renal, and mortality outcomes in patients with type 2 diabetes receiving GLP-1 receptor agonists: A propensity score-matched cohort study.","Salameh A","2026","Drug and alcohol dependence","nonrandomized_study","article","10.1016/j.drugalcdep.2026.113296","42546368",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001631","Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.","Martínez-Castelao A","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14238326","41375628","PMC12693365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0001632","Effect of GLP-1 receptor agonists on body composition.","Bhandarkar A","2025","Current opinion in endocrinology, diabetes, and obesity","preclinical","article","10.1097/med.0000000000000934","41076575",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001633","Bridging Innovation and Practice in Type 2 Diabetes Mellitus: Novel Antidiabetic Therapies and the Expanding Role of Community Pharmacists.","Spanakis M","2026","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19020271","41754812","PMC12944600",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001634","Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.","Schechter M","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02962-8","41204243","PMC12595915",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0001635","Weighing In: The Use of Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.","Sahyoun LC","2026","Digestive diseases and sciences","commentary","article","10.1007/s10620-025-09515-9","41217593",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0001636","GLP-1 Receptor Agonist Semaglutide and SGLT2 Inhibitors after Acute Coronary Syndrome in Patients with Diabetes: Real-World Comparative Outcomes from an Observational Registry.","Jurin I","2026","Cardiology","nonrandomized_study","article","10.1159/000551964","41979990",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001637","Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis.","Elliott B","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-026-01843-x","41697522","PMC13000097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001638","The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms.","Davies I","2026","Annual review of nutrition","narrative_review","article","10.1146/annurev-nutr-061824-043740","42166683",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0001639","Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study.","Chen SY","2025","European heart journal. Cardiovascular pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvaf014","39963713","PMC12231126",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0001640","Glucagon-Like Peptide 1 Receptor Agonist Is Associated With Improved Survival in Overweight Heart Failure Patients.","Karlström P","2025","JACC. Heart failure","nonrandomized_study","article","10.1016/j.jchf.2024.12.004","40088230",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0001641","Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study.","Wang M","2025","Gynecologic oncology","nonrandomized_study","article","10.1016/j.ygyno.2025.06.012","40554181",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0001642","Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research.","Lu X","2026","Frontiers in medicine","narrative_review","article","10.3389/fmed.2026.1763185","41767516","PMC12935680",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001643","GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.","Abid M","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s566414","42318576","PMC13271900",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0001644","Semaglutide versus other GLP-1 receptor agonists in patients with MASLD.","Kuo CC","2025","Hepatology communications","nonrandomized_study","article","10.1097/hc9.0000000000000747","40536520","PMC12180814",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001645","Drug-induced liver injury secondary to tirzepatide.","Cao CY","2026","BMJ case reports","case_report","article","10.1136/bcr-2025-269172","41932719",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0001646","Advances in Pharmacotherapies for Obesity-Related HFpEF: A Comprehensive Review.","Wu Y","2025","Current heart failure reports","randomized_trial","article","10.1007/s11897-025-00722-z","41160296",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0001647","Glucagon-like peptide-1 receptor agonist and lupus nephritis in systemic lupus erythematosus with type 2 diabetes.","Hanif M","2026","The American journal of medicine","nonrandomized_study","article","10.1016/j.amjmed.2026.02.016","41812723",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001648","Sodium-Glucose Cotransporter 2 Inhibitors Prevent Nephrolithiasis in Patients with Diabetes: A TriNetX-Based Real-World Global Comparison.","Liu CM","2026","Kidney360","nonrandomized_study","article","10.34067/kid.0000000981","41117521","PMC13065125",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Multicenter Study; research-article; article"],["R0001649","Divergent Risks of Endocrine and Nonendocrine Malignancies in GLP-1 Receptor Agonist Users: A Propensity-Matched Real-World Analysis of Over 140 000 Patients.","Hung CH","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.05.010","42142623",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001650","Methodological and statistical errors distort the effects of glucagon-like peptide-1 receptor agonist drugs on body composition in patients with type 2 diabetes mellitus.","Trexler ET","2026","Diabetology & metabolic syndrome","commentary","article","10.1186/s13098-025-02051-6","41559806","PMC12821924",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0001651","Effect of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility during upper endoscopy in Asian patients with diabetes.","Oh YE","2025","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v16.i12.112694","41480609","PMC12754130",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001652","GLP-1 receptor agonists are associated with lower kidney cancer risk after metabolic bariatric surgery.","Hernández-Pérez JG","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","nonrandomized_study","article","10.1093/ndt/gfag197","42644757",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001653","Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Obesity: A Systematic Review and Meta-Analysis.","Tom-Ayegunle K","2026","Cureus","systematic_review","article","10.7759/cureus.100947","41658748","PMC12875684",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001654","GLP-1 receptor agonists during chemotherapy and radiotherapy: a supportive care call for nutrition-centred monitoring in the era of widespread prescribing.","Alati A","2026","Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer","other","article","10.1007/s00520-026-10691-1","42008149",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001655","Impact of GLP-1 Receptor Agonist on Atrial Fibrillation Recurrence After Catheter Ablation in Non-Obese Patients.","Abughazaleh S","2026","Pacing and clinical electrophysiology : PACE","nonrandomized_study","article","10.1111/pace.70317","42261786",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001656","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Hip Arthroplasty Outcomes: A Systematic Review and Meta-Analysis.","Zaffar H","2025","Cureus","systematic_review","article","10.7759/cureus.96279","41362522","PMC12681965",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001657","Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.","Sun WT","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71094","42426564",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Network Meta-Analysis; Journal Article; Systematic Review; Review; article"],["R0001658","Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy.","Joshi S","2026","The Journal of the Association of Physicians of India","narrative_review","article","10.59556/japi.74.1302","41818055",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001659","Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines.","Ulrich FS","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70548","41741822","PMC13071226",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001660","Knowledge, attitudes, and practices of Saudi physicians toward the use of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus: a nationwide cross-sectional study.","Alrasheed MA","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1929125","42724767","PMC13559532",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001661","Letter to Editor on: Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery: A Study Among Over 15,000 Patients.","Lu C","2026","Spine","commentary","article","10.1097/brs.0000000000005611","41510659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001662","Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations.","Yılmaz N","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s584175","41884101","PMC13012139",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001663","Muscle Health in the Era of Incretin-Based Weight Loss: Implications for Patients with Cardiovascular-Kidney-Metabolic Syndrome.","Nobakht N","2026","Cardiorenal medicine","nonrandomized_study","article","10.1159/000553166","42560932",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0001664","Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review.","Gruzmark FS","2025","Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society","systematic_review","article","10.1111/wrr.70085","40888511","PMC12400791",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0001665","Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial.","Šiarnik P","2026","Neurology and therapy","randomized_trial","article","10.1007/s40120-026-00982-4","42321509","PMC13396319","EudraCT:2019-003001-94",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0001666","Annals Video Summary - Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis.",null,"2026","Annals of internal medicine","systematic_review","article","10.7326/annals-25-04736-vs","41359969",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Video-Audio Media; article"],["R0001667","Glucagon-like Peptide-1 receptor agonists rarely cause de novo acute pancreatitis but often result in serum lipase elevations of unclear clinical significance.","Li J","2026","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","other","article","10.1016/j.pan.2025.12.021","41521121",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001668","GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation.","Tang H","2026","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2026.103857","42005929","PMC13084313",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001669","Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.","Corso H","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1834580","42488012","PMC13388208",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001670","Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes.","Teunis CJ","2026","European heart journal","other","article","10.1093/eurheartj/ehag627","42806711",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001671","Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists for Smoking Cessation.","Hendershot CS","2026","Biological psychiatry","randomized_trial","article","10.1016/j.biopsych.2026.04.002","41967661",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; article"],["R0001672","State-Level Variation in Glucagon-Like Peptide-1 Receptor Agonists Fills and Spending by Obesity Prevalence, 2023.","Khan T","2025","Journal of the American Heart Association","other","article","10.1161/jaha.125.043137","40673513","PMC12449911",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0001673","GLP-1 receptor agonist protects glucose-stimulated insulin secretion in pancreatic β-cells against lipotoxicity via PPARδ/UCP2 pathway.","Liu Z","2025","Cellular and molecular life sciences : CMLS","preclinical","article","10.1007/s00018-025-05844-0","41165809","PMC12575910",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001674","Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study.","Vozza A","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1674308","41079186","PMC12507565",null,"S002095","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0001675","Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction.","Scalia IG","2025","Cardio-oncology (London, England)","nonrandomized_study","article","10.1186/s40959-025-00381-y","40999487","PMC12465527",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001676","Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A Mendelian Randomization Study.","Remala S","2026","Circulation. Genomic and precision medicine","other","article","10.1161/circgen.125.005535","42028610","PMC13120722",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001677","Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.","Ognard J","2025","The journal of headache and pain","systematic_review","article","10.1186/s10194-025-02148-3","41057780","PMC12502165",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; Review; review"],["R0001678","Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists.","Shah E","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70713","41889156",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001679","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinsonian Disorders in Patients with Obesity","Kotecha P","2025","medRxiv","nonrandomized_study","preprint","10.64898/2025.11.24.25340763",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001680","GLP-1 receptor agonists at the crossroads of obesity and addiction: A review of shared neurobiology and translational evidence.","Lista S","2026","Pharmacology, biochemistry, and behavior","narrative_review","article","10.1016/j.pbb.2026.174217","42184906",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001681","The impact of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) on anesthetic risk in patients undergoing surgery or esophagogastroduodenoscopy: A systematic review and meta-Analysis","Chen X","2025","Authorea Preprints","systematic_review","preprint","10.22541/au.176719154.49976277/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0001682","Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues.","Popa Ilie IR","2026","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2026-120507","42823110","PMC13630132",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001683","A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass.","Moscucci F","2026","Nutrients","nonrandomized_study","article","10.3390/nu18040632","41754149","PMC12943638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0001684","Correction: Exploring the Therapeutic Potential of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis in Patients with Type 2 Diabetes: A Narrative Review.","Al Rashid S","2026","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","notice","article","10.1055/a-2811-1672","41702547",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0001685","Biomarkers and Endothelial Damage in Obesity: An Insight into the Pharmacological Modulation.","Bojórquez-González AY","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27083694","42074331","PMC13116177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001686","Glucagon-like peptide 1 receptor agonists and venous thromboembolism: putting the evidence on the scale.","Verlaan JPL","2025","Journal of thrombosis and haemostasis : JTH","other","article","10.1016/j.jtha.2025.07.035","41139078",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001687","Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists.","Klebanoff MJ","2025","JAMA","other","article","10.1001/jama.2025.15841","40991250","PMC12461600",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001688","Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning.","McCarthy AD","2026","Journal of cosmetic dermatology","commentary","article","10.1111/jocd.70670","41521763","PMC12793942",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0001689","Effects of Reimbursement Policy Change on Utilization of Injectable Semaglutide for Type 2 Diabetes and on Glycemic Control Among Discontinuers: A Danish Nationwide Cohort Study","Simonsen E","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.09.23.26363640",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001690","Tirzepatide Attenuates Wire Injury-Induced Arterial Remodeling in Non-Diabetic and Diabetic Mice: Comparison with Semaglutide.","Mori Y","2026","Biomedicines","preclinical","article","10.3390/biomedicines14071554","42512027","PMC13405626",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0001691","Improved Survival With Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Heart Failure With Preserved Ejection Fraction and Metabolic Dysfunction-Associated Steatotic Liver Disease.","Tepetes NI","2026","American journal of therapeutics","nonrandomized_study","article","10.1097/mjt.0000000000002139","42090713",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001692","Utilization of thyroid ultrasound and surgery after glucagon-like peptide-1 receptor agonist prescription.","Delaney LD","2026","Surgery","other","article","10.1016/j.surg.2025.110042","41520572","PMC13210382",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001693","Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era.","Pohlman N","2025","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgaf295","40388382","PMC12823194",null,"S002726","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, U.S. Gov't, P.H.S.; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0001694","Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes.","Hsiao FC","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.55952","41604151","PMC12853205",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0001695","Inflammatory optic neuritis and scleritis following commencement of semaglutide: a case report.","Maher CB","2025","Journal of surgical case reports","nonrandomized_study","article","10.1093/jscr/rjaf937","41306396","PMC12646242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0001696","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Outcomes Based on Race and Sex Among Patients With and Without Diabetes Mellitus: A Meta-Analysis of Nine Randomized Controlled Trials.","Jaiswal V","2026","Reviews in cardiovascular medicine","systematic_review","article","10.31083/rcm45797","41659090","PMC12873659",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001697","Metabolic Bariatric Surgery versus GLP-1 Receptor Agonists for Obesity Management: A Systematic Review and Meta-Analysis.","Delgado LM","2026","Obesity surgery","systematic_review","article","10.1007/s11695-026-08551-2","41826529",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Comparative Study; review"],["R0001698","The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","Hageen AW","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70222","42116665","PMC13161550",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review-article; article"],["R0001699","Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions.","Shirani A","2025","Expert opinion on investigational drugs","randomized_trial","article","10.1080/13543784.2025.2587277","41196232",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001700","\"Examining the impact of perioperative glucagon-like-peptide-1 use within foot and ankle surgery: A systematic review of comparative studies\".","Anaspure OS","2026","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","systematic_review","article","10.1053/j.jfas.2026.07.011","42508720",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; review"],["R0001701","Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery?","Sibal R","2025","Nutrients","narrative_review","article","10.3390/nu17233659","41373949","PMC12693348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001702","Comparative effects of SGLT2 inhibitors and GLP-1 receptor agonists on osteoarthritis risk in patients with type 2 diabetes mellitus: A multi-institutional cohort study.","Jao WY","2026","PloS one","nonrandomized_study","article","10.1371/journal.pone.0353956","42475344","PMC13384269",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Multicenter Study; research-article; article"],["R0001703","Glucagon-like peptide-1 receptor agonists: reshaping the surgical paradigm in obesity and gastrointestinal disease.","Yagnik VD","2026","Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract","other","article","10.1016/j.gassur.2025.102276","41203194",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001704","Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence.","Yang CC","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113206","41802676",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001705","GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways.","Lucente D","2025","Genes","preclinical","article","10.3390/genes16111352","41300804","PMC12652922",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001706","Incretin analogues as cardiovascular agents: a state-of-the-art review.","Araiza-Garaygordobil D","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1898812","42568490","PMC13447287",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001707","The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis.","Peter K","2026","Cardiovascular diabetology. Endocrinology reports","systematic_review","article","10.1186/s40842-026-00295-3","42063138","PMC13134098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; Preprint; review; other; preprint"],["R0001708","Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.","Koca N","2026","Cardiovascular diabetology","other_trial","article","10.1186/s12933-026-03346-2","42649514","PMC13520461",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; letter; article"],["R0001709","National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss.","Miller J","2026","Journal of medical toxicology : official journal of the American College of Medical Toxicology","other","article","10.1007/s13181-026-01121-z","41634285","PMC13076849",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001710","New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.","Pardali EC","2026","Nutrients","nonrandomized_study","article","10.3390/nu18060962","41901137","PMC13029618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001711","Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice.","Oh EY","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2026.119042","41633255",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001712","Association of GLP-1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes.","Fan Y","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71313","42712110",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001713","Glucagon-like peptide 1 receptor agonists: anti-inflammatory effects in cardiovascular diseases.","Bajic Z","2026","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2026-0021","42132521",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001714","Is there still room for pioglitazone in contemporary type 2 diabetes management?","Caruso I","2026","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-026-03093-4","41840391","PMC12990594",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0001715","Impact of Glucagon-Like Peptide-1 Receptor Agonist Exposure on Gastrointestinal Outcomes Among ICU Patients: A Multicenter Matched Cohort Study.","Gmehlin CG","2025","Critical care explorations","nonrandomized_study","article","10.1097/cce.0000000000001263","40366278","PMC12080681",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0001716","Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit?","Walker T","2026","The Medical journal of Australia","other","article","10.5694/mja2.70246","42429319","PMC13353042",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0001717","The Potential Utility of GLP-1 Receptor Agonist Medications for Addiction Treatment: A Narrative Review of Clinical and Epidemiological Evidence.","Yammine L","2025","Current addiction reports","randomized_trial","article","10.1007/s40429-025-00657-4","41347181","PMC12674624",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; review"],["R0001718","The Glucagon-like Peptide-1 Receptor Agonist Era and Its Influence on Body-Contouring Referrals After Weight Loss in Appalachia.","Rahimpour A","2026","Plastic and reconstructive surgery. Global open","nonrandomized_study","article","10.1097/gox.0000000000007620","41907071","PMC13023714",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001719","The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report.","Abdulraheem A","2025","Cureus","case_report","article","10.7759/cureus.79105","40104488","PMC11919247",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001720","Glucagon-like peptide-1 receptor agonists: a review of the literature from a dental perspective.","O Driscoll J","2026","British dental journal","narrative_review","article","10.1038/s41415-025-9345-4","41688699",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001721","THR-β Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty.","Alzaki AA","2026","Cureus","systematic_review","article","10.7759/cureus.106038","42051839","PMC13120833","PROSPERO:CRD420251230032",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001722","Weight loss interventions and sexual function in midlife women: the emerging role of glucagon-like peptide-1 receptor agonists.","Castaneda R","2026","Menopause (New York, N.Y.)","other","article","10.1097/gme.0000000000002854","42517362",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001723","Comparative Risk of Psoriatic Arthritis in Type 2 Diabetes: An Emulated Target Trial of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists.","Yen FS","2026","Drug design, development and therapy","randomized_trial","article","10.2147/dddt.s614222","42473649","PMC13380918",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001724","Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes.","Yen FS","2025","Journal of autoimmunity","nonrandomized_study","article","10.1016/j.jaut.2025.103493","41110425",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; preprint; article"],["R0001725","GLP-1 receptor agonists in systemic lupus erythematosus: a scoping review.","Sia R","2026","RMD open","nonrandomized_study","article","10.1136/rmdopen-2026-007037","42463280","PMC13384179",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; research-article; article"],["R0001726","Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis.","Shokravi A","2025","Cardiovascular diabetology. Endocrinology reports","systematic_review","article","10.1186/s40842-025-00248-2","41354946","PMC12683810",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; other; review"],["R0001727","Glucagon-Like Peptide-1 Receptor Agonist Use and Age-Related Macular Degeneration-Where Do We Stand?","Talcott KE","2025","JAMA ophthalmology","commentary","article","10.1001/jamaophthalmol.2025.4090","41129138",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0001728","Shifting obesity treatment paradigms: Trends of glucagon-like peptide-1 receptor agonists and bariatric surgery in the United States.","Dawwas GK","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16600","40654206","PMC12409213",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0001729","Potential application of mono-, dual-, and triple-target GLP-1 receptor agonists in improving the prognosis of patients with diabetic foot ulcers.","Li Z","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1754925","41647111","PMC12867866",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001730","Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?","Brennan DJ","2025","Cancer discovery","other","article","10.1158/2159-8290.cd-25-0991","41178350",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001731","GLP-1R Agonists Improve Ocular Surface Parameters in Type 2 Diabetes Mellitus.","Ottonelli G","2025","Clinical ophthalmology (Auckland, N.Z.)","nonrandomized_study","article","10.2147/opth.s547776","41116973","PMC12535700",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001732","Citrus Changshan Huyou extracts as natural GLP-1R agonists attenuate atherosclerosis via the GLP-1R/PKA/CREB pathway: a functional food perspective.","Fang YY","2026","Frontiers in nutrition","preclinical","article","10.3389/fnut.2026.1899085","42620584","PMC13486218",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001733","Combined Use of Glp-1 Receptor Agonists and Sglt2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Observational Cohort Studies","ÇİFTÇİOĞLU M","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-10332369/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0001734","Primary Care Providers Perspectives of GLP-1 Receptor Agonists to Manage Recurrent Weight Gain after Metabolic Bariatric Surgery - a Qualitative Study.","Tolvanen L","2026","Obesity surgery","other","article","10.1007/s11695-025-08408-0","41299124","PMC12852154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001735","Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.","Hsu YH","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112995","41218687",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001736","The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea.","Mifsud CS","2025","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2025.2574848","41114602",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0001737","Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study.","Miertová Z","2026","Scientific reports","nonrandomized_study","article","10.1038/s41598-026-56147-8","42236900","PMC13473473",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0001738","Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data.","Chabassier A","2026","Mayo Clinic proceedings. Digital health","nonrandomized_study","article","10.1016/j.mcpdig.2026.100375","42746268","PMC13576509",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001739","Trends, Demographics, and Outcomes for Glucagon-Like Peptide-1 Receptor Agonist Use in Total Knee Arthroplasty: An 11-Year Perspective.","Katzman JL","2025","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2025.02.042","40087066",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001740","Tirzepatide in type 1 diabetes: beyond mere weight loss.","Panou T","2026","Expert review of clinical pharmacology","randomized_trial","article","10.1080/17512433.2026.2685653","42240053",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001741","Medicaid Coverage and Prior Authorization for Antiobesity Glucagon-Like Peptide-1 Receptor Agonists: A Cross-Sectional Study of State Policies.","Klebanoff MJ","2026","Journal of general internal medicine","commentary","article","10.1007/s11606-025-10012-y","41269509","PMC13176405",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0001742","The Beneficial Effects of Combination Therapy With SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.","Kalogeris A","2026","Current diabetes reviews","narrative_review","article","10.2174/0115733998419380251126073540","41572751",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001743","Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance.","Marin RC","2026","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms27072988","41977175","PMC13073578",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001744","Glucagon-like Peptide-1 Receptor Agonists Are Associated With a Lower Risk of Peptic Ulcer Disease: A Nationwide Cohort Study.","Seika P","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","nonrandomized_study","article","10.1016/j.cgh.2025.08.015","40865627",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001745","Obesity, Weight Loss, and Rhinology and Allergy.","Kahn C","2026","Otolaryngologic clinics of North America","narrative_review","article","10.1016/j.otc.2026.06.001","42425811",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0001746","Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV.","Nguyen Q","2024","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","nonrandomized_study","article","10.1093/cid/ciae151","38501237",null,null,"S001029","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0001747","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in MASH Resolution and Fibrosis Reduction: A Meta-Analysis.",null,"2025","Gastroenterology & hepatology","systematic_review","article",null,"41658349","PMC12879061",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; other; article"],["R0001748","The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials.","Trott M","2026","BJPsych open","systematic_review","article","10.1192/bjo.2026.12001","42179170","PMC13202607",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001749","Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword?","Kałas M","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14093122","40364152","PMC12072339",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001750","GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.","Atiquzzaman N","2025","European journal of clinical pharmacology","randomized_trial","article","10.1007/s00228-025-03898-4","40835981",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001751","Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment.","Stenberg E","2024","The British journal of surgery","nonrandomized_study","article","10.1093/bjs/znae221","39235379","PMC11375857",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0001752","Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review.","Lubo C","2026","Brain sciences","systematic_review","article","10.3390/brainsci16090926","42793351","PMC13604221",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001753","Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis.","Lampsas S","2026","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","systematic_review","article","10.1007/s00417-026-07291-4","42201355",null,"PROSPERO:CRD420251155026",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001754","Efsubaglutide Alfa attenuates metabolic dysfunction-associated steatohepatitis in mice with improvements in second harmonic generation-derived fibrosis features.","Wang Y","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70495","41555840",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0001755","Comment on: \"Effects of neoadjuvant glucagon-like-peptide 1 receptor agonists on weight loss after bariatric surgery\".","O'Neill SM","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","commentary","article","10.1016/j.soard.2025.11.001","41309436",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; letter"],["R0001756","Glucagon-like Peptide 1 Receptor Agonist use and the effect on diabetic retinopathy: An uncertain relationship.","Hui BTK","2024","Peptides","narrative_review","article","10.1016/j.peptides.2024.171240","38705472",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001757","Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials.","Chiang CH","2025","Journal of thrombosis and haemostasis : JTH","systematic_review","article","10.1016/j.jtha.2025.06.020","40602613",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001758","Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.","Rosenstock J","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70022","40808573",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; article"],["R0001759","Rapidly changing landscape of diabetic kidney disease management: recent advances and the road ahead.","Wang SSY","2026","Singapore medical journal","randomized_trial","article","10.4103/singaporemedj.smj-2025-240","42496362",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0001760","Glucagon-like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?","Giugliano D","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70246","41178790",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001761","Lean Mass Loss in Glucagon-Like Peptide-1/GIP Therapy: Clinical Implications for Obesity and Cardiovascular Care.","Haner Wasserstein D","2026","Cardiology in review","other_trial","article","10.1097/crd.0000000000001178","41636548",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0001762","Comment on: \"Effects of neoadjuvant glucagon-like-peptide 1 receptor agonists on weight loss after bariatric surgery\".","Faler B","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","commentary","article","10.1016/j.soard.2025.11.003","41271460",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; letter"],["R0001763","The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses.","Zamanian N","2025","European journal of pharmacology","systematic_review","article","10.1016/j.ejphar.2025.177966","40680981",null,"PROSPERO:CRD42024603661",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0001764","Correction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges.","Westermeier F","2025","Cardiovascular diabetology","notice","article","10.1186/s12933-025-02647-2","40075386","PMC11905680",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0001765","Polish healthcare professionals' perceptions of GLP-1 receptor agonists in cardiometabolic risk reduction: a cross-sectional online survey in Poland.","Pucek WF","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1906959","42614226","PMC13481303",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001766","Effect of Beta-Cell Function on Glucose Variability When Switching From Insulin Degludec Plus a Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide: Preliminary Results From a Pilot Study.","Oe Y","2025","International journal of endocrinology","nonrandomized_study","article","10.1155/ije/3911323","41376852","PMC12688642",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001767","Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.","Guo H","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1461398","39605914","PMC11600108",null,"S002474","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001768","Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes.","Teli B","2026","Cureus","nonrandomized_study","article","10.7759/cureus.108999","42311743","PMC13269946",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001769","Korean consensus-based recommendations for preanesthetic gastric ultrasound and anesthetic considerations for GLP-1 receptor agonist-based therapy: a consensus statement from Clinical Practice Guideline Committee of the Korean Society of Anesthesiologists.","Bang YJ","2026","Korean journal of anesthesiology","narrative_review","article","10.4097/kja.26655","42529794","PMC13624820",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Consensus Statement; Journal Article; Review; Research Support, Non-U.S. Gov't; research-article; article"],["R0001770","To be, or not to be, on insulin for simultaneous kidney-pancreas transplant: Is that the question?","Stratta RJ","2026","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","other","article","10.1016/j.ajt.2026.05.2291","42190915",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0001771","GLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management.","Xande JG","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26167744","40869064","PMC12386789",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001772","GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives.","Marquez-Meneses JD","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26115338","40508146","PMC12155186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001773","Glucagon-Like Peptide-1 Receptor Agonists in Gynecologic Surgery.","Hsu R","2025","Obstetrics and gynecology","narrative_review","article","10.1097/aog.0000000000006035","40811820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001774","Association of GLP-1 receptor agonists with post-operative outcomes after achilles tendon repair in obese patients.","Rai C","2026","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","nonrandomized_study","article","10.1053/j.jfas.2026.02.007","41690504",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001775","Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes.","Cozma D","2025","Biomedicines","randomized_trial","article","10.3390/biomedicines13123079","41463089","PMC12730251",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001776","Low Rates of Aborted Endoscopy Due to Gastric Food Retention in Patients on Glucagon-Like-Peptide-1 Receptor Agonists.","Dev B","2025","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-025-08915-1","40021603",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0001777","Corrigendum to \"Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R\" [Biomed. Pharmacother. 130 (2020) 110523].","Li Z","2025","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","notice","article","10.1016/j.biopha.2025.118545","40935758",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0001778","HIF-1 plays a dual regulatory role in hippocampal neuronal PANoptosis in Alzheimer's disease via the HK2/VDAC1/NLRP3 axis and RIPK3 signaling.","Wang S","2026","Pharmacological research","preclinical","article","10.1016/j.phrs.2026.108440","42702341",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001779","Real-world Evidence for Improvements in Inflammation and Anemia Biomarkers After the Initiation of GLP-1RA in Patients Receiving Hemodialysis.","Lama S","2026","Kidney medicine","nonrandomized_study","article","10.1016/j.xkme.2026.101476","42787930","PMC13602310",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001780","Preclinical development of an extended half-life anti-myostatin monoclonal antibody.","Hsu T","2026","Scientific reports","preclinical","article","10.1038/s41598-026-59882-0","42380199",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001781","Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.","Zhang S","2025","Diabetes technology & therapeutics","systematic_review","article","10.1089/dia.2024.0533","39911047",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; Research Support, Non-U.S. Gov't; review"],["R0001782","Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and Mounjaro","Kannan S","2026","Preprints.org","other","preprint","10.20944/preprints202604.1175.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0001783","Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia.","Alharbi S","2026","Skin appendage disorders","nonrandomized_study","article","10.1159/000550540","41799300","PMC12965749",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0001784","All-cause mortality and cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and heart failure with reduced ejection fraction.","Vignarajah A","2025","American heart journal plus : cardiology research and practice","nonrandomized_study","article","10.1016/j.ahjo.2025.100676","41323510","PMC12664052",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001785","Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce.",null,"2025","Cleveland Clinic journal of medicine","notice","article",null,"41033851",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Published Erratum; article"],["R0001786","Systematic Review Evaluating the Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use on the Postoperative Outcomes of Patients Undergoing Arthroplasty Procedures.","Tabor H","2026","Cureus","systematic_review","article","10.7759/cureus.105269","41988613","PMC13077518",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001787","Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.","Niu C","2026","The American journal of gastroenterology","nonrandomized_study","article","10.14309/ajg.0000000000003760","40900093",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001788","Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk.","Ho CN","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf088","40893948","PMC12391755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001789","GLP-1 receptor agonists and the risk of acute pancreatitis: a living systematic review and meta-analysis","Bakker L","2026","medRxiv","systematic_review","preprint","10.64898/2026.03.19.26348844",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0001790","Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.","Raza SS","2025","Cureus","nonrandomized_study","article","10.7759/cureus.96739","41393574","PMC12701534",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001791","Effects of Body Weight on Middle Ear Disease.","Cole CL","2026","Otolaryngologic clinics of North America","narrative_review","article","10.1016/j.otc.2026.05.004","42532732",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0001792","Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) on Increased Residual Gastric Content in Patients With and Without Concurrent Colonoscopy: A Retrospective Case-Control Study.","Chang S","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15062121","41899046","PMC13027199",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001793","Machine learning algorithms for predicting glycemic control and weight loss outcomes in GLP-1 receptor agonist users.","Abegaz TM","2026","Frontiers in artificial intelligence","nonrandomized_study","article","10.3389/frai.2026.1861563","42529241","PMC13416677",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001794","The Impact of Semaglutide on Metabolic Syndrome: A Case Report.","Joseph J","2025","Cureus","case_report","article","10.7759/cureus.87223","40755669","PMC12317596",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001795","Association of GLP-1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation.","Hussain T","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70867","42150869",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001796","Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients.","Kohler J","2026","Urologic oncology","nonrandomized_study","article","10.1016/j.urolonc.2026.05.010","42224918",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001797","Poly-l-Lactic Acid as a Regenerative Treatment for the Glucagon-like Peptide-1 Receptor Agonist User Population.","Franco J","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","nonrandomized_study","article","10.1097/dss.0000000000005171","42210881",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0001798","Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery.","New RRC","2024","Frontiers in drug delivery","other","article","10.3389/fddev.2024.1456654","40836975","PMC12363265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001799","The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.","Zhou J","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1646956","41450584","PMC12727569",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0001800","GLP-1 RAs for Treating Metabolic Dysfunction-Associated Steatosis Liver Disease: From GLP-1 Discovery to FDA Approval: A Comprehensive Narrative Review.","Khalifa O","2026","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph19030408","41901255","PMC13029481",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0001801","Endogenous Incretin Secretagogue Compositions as a Mechanistic Class Versus Pharmacological Incretin Receptor Agonists for Weight Reduction in Overweight Adults: A Real-World Observational Cohort Analysis of a Nutraceutical Composition (Trimsulin) and Comparison with Published Outcomes for Semaglutide and Tirzepatide","Kaufman RC","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-9657897/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0001802","Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study.","Gandhi A","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14217678","41227073","PMC12610529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001803","Oral Semaglutide Preserves Islet of Langerhans Structure and Cellular Integrity in a Type 2 Diabetes Mellitus Rat Model: Histological, Immunohistochemical, and Biochemical Study","Hassan SM","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-10712752/v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0001804","Glucagon-Like Peptide-1 Receptor Agonists and Dementia Risk Reduction in Older Adults With Type 2 Diabetes: A Retrospective Cohort Study.","Wu JY","2025","Journal of the American Medical Directors Association","randomized_trial","article","10.1016/j.jamda.2025.105901","41075815",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0001805","Blood pressure effects of SGLT2 inhibitors and GLP-1 receptor agonists: Mechanisms, trial evidence and Real-world data.","Belančić A","2025","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70378","41344902",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0001806","[Insulin intoxications caused by falsified semaglutide].","Stammers J","2026","Nederlands tijdschrift voor geneeskunde","case_report","article",null,"42390457",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; English Abstract; article"],["R0001807","Adherence Patterns of Oral vs Injectable GLP-1 Receptor Agonists: A National Real-World Analysis of Commercial Claims Data, 2010–2021","Wang Y","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-6586064/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001808","Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents.","Shevchouk O","2026","Behavioural brain research","preclinical","article","10.1016/j.bbr.2026.116085","41653988",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001809","Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study.","Al-Moussally F","2025","Drugs","nonrandomized_study","article","10.1007/s40265-025-02177-x","40223043",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001810","Impact of the Four Pillars on Electrolyte Derangements during State-of-the-Art Therapy for Diabetic Kidney Disease.","Yoo MJ","2026","Electrolyte & blood pressure : E & BP","narrative_review","article","10.5049/ebp.2026.24.e13","42812713","PMC13620187",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001811","Combination therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in heart failure patients with type 2 diabetes.","Kishimori T","2025","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2025-005364","41192940","PMC12588009",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0001812","Risk of Depression With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Compared to Other Antidiabetic Medications in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Ferrer Zavala GM","2026","Cureus","systematic_review","article","10.7759/cureus.106972","42137703","PMC13170771",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001813","Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database.","Murray M","2026","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2025.12.015","41429246",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001814","Preoperative fasting status and retained gastric contents in patients undergoing endoscopy who are using glucagon-like peptide type 1 receptor agonists: a multicentre retrospective study.","Mendez-Pino L","2026","Canadian journal of anaesthesia = Journal canadien d'anesthesie","nonrandomized_study","article","10.1007/s12630-026-03187-3","42618722",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0001815","Cardiovascular Outcomes among New Users of GLP-1 Receptor Agonists Compared with DPP-4 Inhibitors and Sulfonylureas in Kidney Failure.","Catanese B","2026","Journal of the American Society of Nephrology : JASN","nonrandomized_study","article","10.1681/asn.0000001061","41817629","PMC13240616",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001816","Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?","Resnick O","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1520313","39906033","PMC11790463",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001817","Navigating the clinical benefits, risks, and emerging controversies with glucagon-like peptide-1 receptor agonists.","Sen S","2025","Current opinion in anaesthesiology","narrative_review","article","10.1097/aco.0000000000001522","40493797",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001818","Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors as Adjunctive Therapy to Automated Insulin Delivery System in Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","Zhou Y","2026","Diabetes technology & therapeutics","systematic_review","article","10.1177/15209156261420209","41640116",null,"PROSPERO:CRD420251107996",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0001819","Semaglutide ameliorates neuroinflammation and cognitive impairment in APP/PS1 mice.","Yuan Y","2026","Molecular and cellular biochemistry","preclinical","article","10.1007/s11010-026-05568-0","42126676",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001820","The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Fracture Risk in Overweight or Obese, Nondiabetic Patients.","Constantine E","2026","The Journal of the American Academy of Orthopaedic Surgeons","nonrandomized_study","article","10.5435/jaaos-d-24-01505","41429015",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001821","Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women.","Mohammed A","2026","AACE endocrinology and diabetes","case_report","article","10.1016/j.aed.2025.09.012","41641313","PMC12866074",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0001822","GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications.","Moiz A","2026","American journal of hypertension","narrative_review","article","10.1093/ajh/hpaf205","41128495","PMC13080269",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0001823","Glucagon-like peptide-1 receptor agonist therapy in patients with psoriasis is associated with a decreased risk of psoriatic arthritis: A retrospective cohort study using the TriNetX database.","Hsiao YW","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.12.035","41390127",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001824","The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol.","Moiz A","2026","Systematic reviews","systematic_review","article","10.1186/s13643-026-03153-6","41808133","PMC13088735","PROSPERO:CRD420251009368",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; review"],["R0001825","Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review.","Dang V","2026","bioRxiv : the preprint server for biology","systematic_review","article","10.64898/2026.01.31.702984","41676468","PMC12889473",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Preprint; preprint"],["R0001826","Contextual Factors Affecting SGLT2 Inhibitors and GLP-1 Receptor Agonists Prescribing in Primary Care: An Application of the Consolidated Framework for Implementation Research.","Salgado TM","2026","Journal of the American College of Clinical Pharmacy : JACCP","other","article","10.1002/jac5.70263","42522049",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001827","Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association.","Neumiller JJ","2025","Diabetes care","narrative_review","article","10.2337/dci24-0091","39620926",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001828","Real-World Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Weight Recurrence After Bariatric Surgery","Yuce T","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.11.21.25340747",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001829","GLP-1 receptor agonists and pulmonary hypertension in diabetes: A promising therapeutic strategy.","Albulushi A","2025","American heart journal plus : cardiology research and practice","nonrandomized_study","article","10.1016/j.ahjo.2025.100555","40510546","PMC12162050",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001830","Perioperative Glucagon-like Peptide-1 Receptor Agonist Use Is Associated With Lower Pseudoarthrosis Rates Following Long-Segment Spinal Deformity Correction: A Propensity-Matched Analysis.","Stump K","2026","Global spine journal","nonrandomized_study","article","10.1177/21925682251396965","41217855","PMC12611751",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001831","Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review.","Ibrahim R","2025","Cureus","narrative_review","article","10.7759/cureus.92441","40964464","PMC12440237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001832","Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.","Horn DB","2026","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2026.100301","42577069","PMC13453602","ClinicalTrials.gov:NCT05869903; ClinicalTrials.gov:NCT05872620","S000754; S001722","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0001833","Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.","Mirghani H","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1777907","41798193","PMC12960479",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0001834","Dapagliflozin associates with heart rate variability decline in T2DM patients on GLP-1 receptor agonist therapy: a prospective observational study.","Wang Y","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1809146","42199788","PMC13198993",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0001835","Glucagon-Like Peptide-1 Receptor Agonists for People With Chronic Kidney Disease and Diabetes.","Elliott J","2025","American family physician","other","article",null,"41118180",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001836","Should glucagon-like peptide 1 receptor agonists be withheld during the preoperative period?",null,"2025","Cleveland Clinic journal of medicine","notice","article",null,"41033850",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Published Erratum; article"],["R0001837","Cardiovascular Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes or Obesity Undergoing Surgical Aortic Valve Replacement","Lum J","2026","medRxiv","randomized_trial","preprint","10.64898/2026.06.02.26354773",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0001838","Glucagon-like peptide-1 receptor agonists in total joint arthroplasty: a comprehensive systematic review of what orthopaedic surgeons should know.","Abdelaziz O","2026","Arthroplasty (London, England)","systematic_review","article","10.1186/s42836-026-00375-w","41872949","PMC13007374",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001839","Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: a nested case-control study in the All of Us research program.","Abegaz TM","2026","Frontiers in psychiatry","nonrandomized_study","article","10.3389/fpsyt.2026.1766770","41883728","PMC13008929",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001840","GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects.","Barać M","2025","Biology","nonrandomized_study","article","10.3390/biology14121650","41463424","PMC12729639",null,"S001428","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0001841","Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials.","Banerjee M","2026","Endocrine","systematic_review","article","10.1007/s12020-026-04752-y","42616235",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0001842","Glucagon-like peptide-1 receptor agonists and hair loss: An emerging clinical concern.","Camino-Salvador JM","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","commentary","article","10.1111/jdv.70088","41025593",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001843","Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor Agonists","Al-Nusair M","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.09.21.26363576",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0001844","Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation.","Hernández-Pérez JG","2026","Hepatology international","nonrandomized_study","article","10.1007/s12072-026-11138-9","42584814",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0001845","GLP-1 Receptor Agonists Versus DPP-4 Inhibitors and Incident Dementia Risk in COVID-19 Survivors with Type 2 Diabetes: A Target Trial Emulation Study.","Hung KC","2026","Drug design, development and therapy","nonrandomized_study","article","10.2147/dddt.s638249","42831108","PMC13634317",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; IM; research-article; article"],["R0001846","Glucagon-like peptide-1 receptor agonists in adults with cystic fibrosis-related diabetes: Rationale and emerging evidence.","Assalia Naffa M","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16516","40490408","PMC12326930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0001847","Nurse-led supportive care interventions for adults with type 2 diabetes and/or obesity receiving glucagon-like peptide-1 receptor agonists: a scoping review","Dong H","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-9794498/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0001848","GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review.","Pantazopoulos D","2025","Advances in therapy","narrative_review","article","10.1007/s12325-025-03257-w","40473906","PMC12313732",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0001849","Patterns of TSH test after GLP-1 RAs initiation in patients on levothyroxine: a trial emulation study.","Chen Y","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag131","41902399","PMC13466952",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0001850","In silico investigations of albumin-GLP-1 receptor agonist complexes for diabetes drug delivery applications.","Murphy G","2025","Computational and structural biotechnology journal","preclinical","article","10.1016/j.csbj.2025.11.007","41321995","PMC12657752",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001851","Emerging and Established Pharmacotherapies for Smoking Cessation: A Review.","Huhulea EN","2026","Cardiology in review","narrative_review","article","10.1097/crd.0000000000001171","41697002",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001852","Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents.","Wang SY","2025","Diabetes & metabolism journal","commentary","article","10.4093/dmj.2025.0666","41243299","PMC12620693",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0001853","Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.","Stefanakis K","2026","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2026.156493","41513169",null,"ClinicalTrials.gov:NCT02944500","S001466","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0001854","SGLT2 inhibitors and GLP-1 receptor agonists in atrial fibrillation treatment: Clinical evidence and mechanistic insights.","Fan Y","2026","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2026.156678","42289243",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0001855","Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP-1 Receptor Agonists.","Al-Harbi FA","2026","Annals of clinical and translational neurology","nonrandomized_study","article","10.1002/acn3.70406","41994958","PMC13395034",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001856","Glucagon-Like Peptide-1 Receptor Agonists in Cognitive and Mental Health Disorders: A Comprehensive Review of Pre-Clinical and Clinical Evidence","Ghenciulescu A","2025","BJPsych open","randomized_trial","article","10.1192/bjo.2025.10793",null,"PMC12260759",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0001857","Preoperative GLP-1 Receptor Agonist Use Is Not Associated With Complications in Non-Obese Patients Undergoing Total Shoulder Arthroplasty: A Propensity Score Matched Large Database Analysis.","White AE","2026","HSS journal : the musculoskeletal journal of Hospital for Special Surgery","nonrandomized_study","article","10.1177/15563316261439127","41958521","PMC13056801",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0001858","Understanding the Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Heart Failure.","Bonfioli GB","2025","Cardiac failure review","narrative_review","article","10.15420/cfr.2025.10","40901556","PMC12400177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001859","Glucagon-Like Peptide-1 Receptor Agonists: Have We Found the Holy Grail for Total Joint Arthroplasty?","Scuderi GR","2025","The Journal of arthroplasty","commentary","article","10.1016/j.arth.2025.10.027","41101567",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0001860","Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence.","Llach CD","2026","Molecular psychiatry","nonrandomized_study","article","10.1038/s41380-025-03261-0","40940560",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0001861","Glucagon-Like Peptide-1 Receptor Agonists and Pay-Per-Click Direct-to-Consumer Advertising.","Eisenkraft Klein D","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.38718","41171279","PMC12579337",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001862","Association Between Glucagon-like Peptide-1 Receptor Agonist Use and Perioperative Aspiration: A Systematic Review and Meta-Analysis","Elkin J","2024","medRxiv","systematic_review","preprint","10.1101/2024.11.10.24317070",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0001863","Glucagon-like peptide-1 receptor agonists for improving quality of life and mortality in adults with heart failure with preserved ejection fraction: A systematic review and meta-analysis of efficacy and safety.","Ahmad B","2025","Semergen","systematic_review","article","10.1016/j.semerg.2025.102628","41223488",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001864","The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome.","Kumar S","2026","JACC. Advances","other","article","10.1016/j.jacadv.2025.102465","41609289","PMC12869889",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001865","Population-Level Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Using Google Trends Statistics in a 12-Month Retrospective Analysis: An Infodemiology and Infoveillance Study.","Shareef LG","2024","Cureus","nonrandomized_study","article","10.7759/cureus.71569","39553073","PMC11564366",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001866","Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study.","Wu JY","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113273","42009260",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0001867","Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma.","Trakoonsenathong R","2024","World journal of gastroenterology","nonrandomized_study","article","10.3748/wjg.v30.i34.3862","39350782","PMC11438652",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; editorial"],["R0001868","Implications of Glucagon-like Peptide-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study.","Zhang Z","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2025.07.013","40706753",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001869","Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity.","Li P","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.40890","41171277","PMC12579341",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001870","Fat and lean mass changes during incretin-based therapy with structured exercise and nutritional support: A retrospective real-world pilot study.","Kucuk Yetgin M","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100335","42820241","PMC13626787",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0001871","Cardiovascular outcomes of SGLT2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes and a history of myocardial infarction: a systematic review and network meta-analysis of randomized controlled trials.","Ren Y","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1902802","42591121","PMC13461399","PROSPERO:CRD420261299756",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Comparative Study; systematic-review; review"],["R0001872","Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection.","Battistoni A","2025","Frontiers in medicine","narrative_review","article","10.3389/fmed.2025.1669685","40995089","PMC12454090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001873","Development of an electrochemiluminescence immunoassay for quantitative determination of semaglutide in human serum.","Luo Y","2026","Analytical biochemistry","other","article","10.1016/j.ab.2026.116115","41871707",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001874","Fiber Supplementation during and after Glucagon-Like Peptide-1 Receptor Agonists Treatment: A Perspective on Clinical Benefits.","Johnson BV","2026","The Journal of nutrition","narrative_review","article","10.1016/j.tjnut.2026.101436","41730476",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001875","Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment?","Kaufmann D","2025","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics17070865","40733074","PMC12300928",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001876","Discovery of New Difluorocyclobutyl Derivatives as Effective Glucagon-Like Peptide-1 Receptor Agonists with Reduced hERG Inhibitory Activities.","Miao L","2025","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.5c00231","40167442",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001877","GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence.","Mikdachi H","2025","Current opinion in obstetrics & gynecology","narrative_review","article","10.1097/gco.0000000000001015","39970049",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001878","Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children.","Zaitoon H","2025","Children (Basel, Switzerland)","randomized_trial","article","10.3390/children12111427","41300545","PMC12651817",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0001879","Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.","Xu Y","2026","Circulation","nonrandomized_study","article","10.1161/circulationaha.125.075157","41732861",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0001880","Nanocomplexes Integrated into a Polymeric Bilayer Film Enhance Buccal Permeation of a GLP-1 Peptide Analogue.","Karki S","2026","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.6c06607","42377081",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001881","Peri-Procedural Fasting and Gastric Ultrasound Strategies in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Users: A Systematic Review With Qualitative Synthesis.","Abdallah OW","2026","Cureus","systematic_review","article","10.7759/cureus.108216","42245865","PMC13231299",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001882","Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression.","Budini B","2026","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2026.103796","41938838","PMC13043475","PROSPERO:CRD420250631751",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; Preprint; review; preprint"],["R0001883","The association of GLP-1 receptor agonists and outcomes following midfoot arthrodesis.","Bank NC","2026","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","nonrandomized_study","article","10.1053/j.jfas.2026.01.011","41565054",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001884","Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis.","Beran A","2025","The American journal of gastroenterology","systematic_review","article","10.14309/ajg.0000000000003362","39933910",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article; review"],["R0001885","The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care.","Mazza AD","2025","Cureus","narrative_review","article","10.7759/cureus.98153","41479489","PMC12754808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001886","Real-world trends in glucagon-like peptide-1 receptor agonists prescribing in acute kidney disease: a global federated-network study of dialysis-requiring acute kidney injury survivors.","Pan HC","2025","Kidney research and clinical practice","nonrandomized_study","article","10.23876/j.krcp.25.104","42298987",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0001887","Endocrinology: What You May Have Missed in 2025.","Escudero C","2026","Annals of internal medicine","narrative_review","article","10.7326/annals-26-00925","41974004",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001888","Glucagon-Like Peptide-1 Receptor Agonists and Youth Obesity.","Edmondson EK","2025","JAMA pediatrics","other","article","10.1001/jamapediatrics.2025.2077","40690232",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001889","Characteristics and outcomes of cubital tunnel decompression in diabetic patients receiving glucagon-like peptide-1 receptor agonists.","Shabbir R","2025","Clinics in shoulder and elbow","nonrandomized_study","article","10.5397/cise.2025.00801","41376436","PMC12698356",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001890","Impact of glucagon-like peptide-1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes.","Yen FS","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70034","40859767",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001891","Should We Stop Glucagon-Like Peptide-1 Receptor Agonists Before Surgical or Endoscopic Procedures? Balancing Limited Evidence With Clinical Judgment.","Umpierrez G","2025","Journal of diabetes science and technology","narrative_review","article","10.1177/19322968241231565","38465586","PMC11571478",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article-commentary; editorial"],["R0001892","Massive Weight Loss with Bariatric Surgery and GLP-1RA Therapy Predicts Postoperative Complications Following Abdominal Body Contouring.","Liang J","2026","Plastic and reconstructive surgery","nonrandomized_study","article","10.1097/prs.0000000000013015","42054101",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001893","JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology.","Narla S","2026","Journal of the American Academy of Dermatology","randomized_trial","article","10.1016/j.jaad.2025.12.116","41698604",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001894","Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT.","Fadini GP","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-025-01784-x","40886230","PMC12474826",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0001895","AMPK/USP10 loop activation of ACE2: implications for pulmonary hypertension.","Chen Z","2026","European heart journal","preclinical","article","10.1093/eurheartj/ehag568","42517561",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001896","Cardiovascular outcome of Glucagon-Like Peptide-1 Receptor Agonists vs Dipeptidyl Peptidase-4 Inhibitor on End-stage Renal Disease patients with Heart Failure: An Emulated Target Trial in Patients with Diabetes","Yu C","2025","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-7722921/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0001897","Perioperative Management of Patients using GLP-1 Receptor Agonists Current Evidence, Risks, and Practical Recommendations-A Narrative Review.","Çitilcioğlu US","2026","Turkish journal of anaesthesiology and reanimation","narrative_review","article","10.4274/tjar.2026.262459","42332931","PMC13308581",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review"],["R0001898","Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data.","Alourfi NM","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s575375","42158845","PMC13182737",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001899","Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study.","McIntyre RS","2026","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2024.2430306","39552465",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; preprint; article"],["R0001900","The GLP-1 Receptor Agonist Liraglutide Promotes Anticancer Activities in MCF7 Breast and PC-3 Prostate Cancer Cells by Modulating Glycolysis, Oxidative Stress and Adipokines.","Refaat B","2026","Journal of biochemical and molecular toxicology","other","article","10.1002/jbt.70913","42152582",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001901","Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?","Kumar S","2025","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-025-01347-2","41205002",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001902","Efficiency of fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin in type 2 diabetes on different therapeutic regimen","Risovic I","2023","Research Square","other","preprint","10.21203/rs.3.rs-3340824/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0001903","GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies.","Jerlhag E","2026","Biological psychiatry","preclinical","article","10.1016/j.biopsych.2026.04.022","42461204",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001904","Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study.","Cetiner S","2026","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-026-02232-y","41832437","PMC13020155",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001905","Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes.","Ikonomidis I","2026","Journal of hypertension","nonrandomized_study","article","10.1097/hjh.0000000000004311","42201656",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001906","Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes.","Fang YE","2025","Diabetes care","nonrandomized_study","article","10.2337/dc25-1840","41144235","PMC12718078",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0001907","Orforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling.","Deng Y","2026","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2026.118294","42508653",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001908","Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study.","Dosda A","2026","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2026.101734","41547436",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001909","Effects of lifestyle and glucagon-like Peptide-1 receptor agonist-based therapies on waist circumference: A systematic review and meta-analysis.","Ghosal S","2026","Obesity pillars","systematic_review","article","10.1016/j.obpill.2026.100281","42318161","PMC13272577",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0001910","Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes.","Matsushita T","2026","Hypertension research : official journal of the Japanese Society of Hypertension","nonrandomized_study","article","10.1038/s41440-026-02695-5","42243292",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0001911","Hyperdilute Radiesse Preserves Facial Volume in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Rapid Weight Loss.","Durairaj KK","2025","Aesthetic surgery journal. Open forum","nonrandomized_study","article","10.1093/asjof/ojaf088","41127050","PMC12538281",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0001912","Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events.","Reges O","2026","Obesity facts","nonrandomized_study","article","10.1159/000551805","42160228","PMC13387749",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001913","Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.","Hong AT","2026","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2025.12.003","41360342",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0001914","Beyond Single-Class Therapy: Real-World Combined Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.","Vournas G","2026","Advances in therapy","nonrandomized_study","article","10.1007/s12325-026-03699-w","42423950","PMC13619674",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; case-report; article"],["R0001915","Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery.","Villelabeitia IK","2026","Heart (British Cardiac Society)","narrative_review","article","10.1136/heartjnl-2025-326812","41730547",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001916","Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists.","Llinares-Arvelo V","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26168096","40869417","PMC12386527",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001917","GLP-1 Receptor Agonists and Cardiovascular Events in Adults with Obesity and Autoimmune Disease: A Target Trial Emulation.","Dai H","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.11.10.25339912","41292651","PMC12642734",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0001918","Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications.","Davis JW","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.30969","40920387",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001919","Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","Asif M","2025","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70059","40509955","PMC12163345",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0001920","The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study.","Alcázar-Navarrete B","2026","Pragmatic and observational research","randomized_trial","article","10.2147/por.s550543","41889676","PMC13015956",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0001921","Spending and Affordability of Glucagon-Like Peptide-1 Receptor Agonists and Other Incretin Mimetics in the United States, 2013-2023.","Zhu DT","2026","Journal of general internal medicine","other","article","10.1007/s11606-026-10658-2","42533264",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0001922","Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide.","Bernardi JC","2026","Journal of diabetes","systematic_review","article","10.1111/1753-0407.70192","41664890","PMC12887578",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Comparative Study; Review; review-article; article"],["R0001923","Evidence-Based Cardiovascular-Kidney-Metabolic Therapies in Kidney Transplant Recipients.","Shroff GR","2026","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.0000001195","42522128",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0001924","Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot.","Kaya E","2025","Current opinion in gastroenterology","narrative_review","article","10.1097/mog.0000000000001083","39998880",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001925","GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study.","Thomas O","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70335","41204831","PMC12746371",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; brief-report; article"],["R0001926","Peptide GLP-1 receptor agonists: From injection to oral delivery strategies.","Ke Z","2024","Biochemical pharmacology","narrative_review","article","10.1016/j.bcp.2024.116471","39127152",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0001927","From association to action: why causal estimands matter in perioperative studies of glucagon-like peptide-1 receptor agonist outcomes.","Messinger CJ","2026","British journal of anaesthesia","commentary","article","10.1016/j.bja.2025.10.007","41162255",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0001928","Obesity and Cardio-Metabolic Health in Kidney Disease: Implications for Kidney Health, Risk Stratification, and Management.","Mathew RO","2026","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000001233","42726513",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001929","Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis.","Sedenho-Prado LG","2025","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-025-01790-w","40269110",null,"PROSPERO:CRD42024532845",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0001930","Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy.","Kennedy S","2026","Frontiers in oncology","preclinical","article","10.3389/fonc.2026.1834606","42294299","PMC13253391",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001931","Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials.","Hasebe M","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70121","40926380","PMC12587236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0001932","Glucagon-Like Peptide-1 Receptor Agonists among Pregnancies with Pregestational Diabetes and Its Relationship with Congenital Malformations.","Lewin Z","2026","American journal of perinatology","nonrandomized_study","article","10.1055/a-2716-1639","41052622",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001933","Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae.","Hsu J","2026","Journal of vascular surgery","nonrandomized_study","article","10.1016/j.jvs.2026.02.003","41654037",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0001934","Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022.","Watanabe JH","2024","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2023.10.002","37821008",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0001935","Protective Impact of GLP-1 Therapy on Post-ERCP Outcomes: A TriNetX Retrospective Cohort Analysis.","Kazi MAI","2026","Journal of clinical gastroenterology","nonrandomized_study","article","10.1097/mcg.0000000000002374","42084951",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001936","Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications.","Rahman E","2026","Toxicon : official journal of the International Society on Toxinology","randomized_trial","article","10.1016/j.toxicon.2025.108638","41173332",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0001937","Clinical outcomes associated with prior glucagon-like peptide-1 receptor agonist exposure in burned patients.","Boukind A","2026","The British journal of surgery","nonrandomized_study","article","10.1093/bjs/znag048","42003114",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001938","GLP-1 receptor agonist initiation and risk of colorectal cancer and colonic polyps.","Moh'd Mari AA","2026","The American journal of the medical sciences","nonrandomized_study","article","10.1016/j.amjms.2026.02.002","41698506",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Letter; article"],["R0001939","Obesity, Weight Loss, and Knee Osteoarthritis: The Role of Glucagon-Like Peptide-1 Receptor Agonists.","Felson DT","2025","Annals of internal medicine","other","article","10.7326/annals-25-03113","40953448",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001940","Computable longitudinal patient journeys from structured and unstructured EHR data.","Kim E","2026","Nature medicine","nonrandomized_study","article","10.1038/s41591-026-04695-x","42742184",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0001941","The GLP-1-Mitochondria Axis in Metabolic Aging.","Chang R","2026","Aging cell","other_trial","article","10.1111/acel.70676","42608657","PMC13481478",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0001942","Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on \"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis\".","Ren TY","2024","Clinical and molecular hepatology","systematic_review","article","10.3350/cmh.2024.0558","39038961","PMC11540406",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Editorial; Comment; article"],["R0001943","Glucagon-Like Peptide-1 Receptor Agonist Eligibility Among US Adolescents and Young Adults.","Chetty AK","2025","JAMA pediatrics","commentary","article","10.1001/jamapediatrics.2025.2308","40758363","PMC12322816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; research-article; article"],["R0001944","GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity.","Stefater-Richards MA","2025","Pediatrics","narrative_review","article","10.1542/peds.2024-068119","40031990",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0001945","Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study.","Mavromatis LA","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16445","40450698","PMC12227298",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; research-article; conference-abstract; article"],["R0001946","GLP-1 Receptor Agonists and Cancer: Interpreting a Wave of Real-World Signals From the 2026 ASCO Annual Meeting","Starasvetskaya N","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-10368790/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0001947","Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders.","De Giorgi R","2025","Journal of neurology, neurosurgery, and psychiatry","preclinical","article","10.1136/jnnp-2024-335593","40210453","PMC12418562",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001948","Effectiveness of GLP-1 RAs in Restoring Normoglycemia in Patients With Prediabetes: An Updated Systematic Review and Meta-Analysis.","Tsironikos GI","2026","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.70114","41398448",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0001949","Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.","Samuels JM","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15737","38934217","PMC12223922",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, N.I.H., Extramural; research-article; article"],["R0001950","Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol.","Freet CS","2025","Addiction science & clinical practice","protocol","article","10.1186/s13722-025-00618-2","41168808","PMC12573902","ClinicalTrials.gov:NCT06548490","S001579","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0001951","Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence.","Sa B","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70198","41126551","PMC12673456",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0001952","[Treatment of Morbid Obesity in Israel: GLP-1 Agonists Versus Bariatric Surgery - Clinical and Economic Aspects].","Boaz E","2026","Harefuah","narrative_review","article",null,"42345248",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Comparative Study; English Abstract; article"],["R0001953","The Risk of Hypothyroidism With the Use of GLP-1 Receptor Agonists in Saudi Arabia.","Alfakhri A","2026","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.70315","41490610",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0001954","Utilization of Glucagon-Like Peptide-1 Receptor Agonist and Dipeptidyl Peptidase-4 Inhibitors at the Veterans Health Administration.","Krishnan A","2024","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","other_trial","article","10.1177/87551225241266773","39391328","PMC11462932",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0001955","Glucagon-Like Peptide-1 Receptor Agonists: Friend or Foe of Aesthetic Medicine?","Rosenbloom AJ","2025","Aesthetic surgery journal. Open forum","commentary","article","10.1093/asjof/ojaf022","40351555","PMC12062882",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0001956","Antihyperglycemic Drugs and Risk of Asthma Exacerbation in Patients With Asthma and Type 2 Diabetes: A Multinational Retrospective Cohort Study.","Hung CT","2026","Pharmacotherapy","randomized_trial","article","10.1002/phar.70194","42618217","PMC13489788",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0001957","Guidelines in Action: The Role of GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists in Primary Stroke Prevention.","Inikori E","2025","Stroke","other","article","10.1161/strokeaha.125.051441","40982602",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001958","Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases.","Deng S","2025","Cell & bioscience","preclinical","article","10.1186/s13578-025-01486-8","41074143","PMC12512578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001959","Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study.","Wu JY","2026","BMC cardiovascular disorders","nonrandomized_study","article","10.1186/s12872-026-06269-8","42426654","PMC13632370",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Comparative Study; research-article; article"],["R0001960","The Real-World Clinical Benefits of GLP-1 Receptor Agonist Treatment","Coetzer H","2025","medRxiv","randomized_trial","preprint","10.1101/2025.10.24.25338256",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0001961","IL-27, a metabolic regulator secreted by astrocytes in response to GLP-1RA OHP2, modulates microglial reprogramming in Alzheimer's disease by regulating cGAS lactylation.","Du Y","2026","Journal of neuroinflammation","preclinical","article","10.1186/s12974-025-03683-1","41527082","PMC12888396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001962","A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD.","Wu JY","2025","Nature communications","nonrandomized_study","article","10.1038/s41467-025-62891-8","40796776","PMC12343782",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0001963","Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa.","Gouvrion L","2025","JAMA dermatology","nonrandomized_study","article","10.1001/jamadermatol.2025.2723","40802272","PMC12351460",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001964","M4 drug discovery: human drug predictions from integrated preclinical insights exemplified with a GLP-1R agonist","Silfvergren O","2025","bioRxiv","nonrandomized_study","preprint","10.1101/2025.11.03.686224",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0001965","Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes.","Acheampong CO","2025","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2025-005090","41057208","PMC12506239",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001966","15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist-Induced Weight Loss.","Nalbandian M","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.02.26.708119","42124647","PMC13160160",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0001967","Gestational Weight Gain and Hypertensive Disorders of Pregnancy With Prepregnancy and Early Pregnancy Glucagon-Like Peptide-1 Receptor Agonist Exposure.","Pondugula N","2026","Obstetrics and gynecology","nonrandomized_study","article","10.1097/aog.0000000000005995","40609095","PMC12233158",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001968","Lesson for the clinical nephrologist: glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a patient with obesity and diabetic kidney disease on peritoneal dialysis.","Yavorskiy P","2025","Journal of nephrology","other","article","10.1007/s40620-025-02247-z","40082391",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001969","Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome.","Afrin LB","2025","The American journal of the medical sciences","randomized_trial","article","10.1016/j.amjms.2025.07.006","40675372",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0001970","Adenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists.","Garg S","2025","Clinical and translational gastroenterology","nonrandomized_study","article","10.14309/ctg.0000000000000913","40874603","PMC12637316",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001972","Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication.","Sarpatwari A","2025","JAMA health forum","nonrandomized_study","article","10.1001/jamahealthforum.2025.4258","41071563","PMC12514621",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001973","Impact of GLP-1 Receptor Agonist Use on Total Knee Arthroplasty Outcomes in Metformin-Treated Diabetic Patients With and Without Comorbid Obesity: A Propensity-Matched Analysis.","Lee S","2026","The Journal of the American Academy of Orthopaedic Surgeons","nonrandomized_study","article","10.5435/jaaos-d-25-00982","41805656",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0001974","Association of SGLT2 inhibitors and GLP-1 receptor agonists with the risk of Parkinson's disease in patients with type 2 diabetes: A propensity score-matched cohort study with meta-analysis.","Yeh JA","2025","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2025.112914","40976497",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0001975","Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action.","Bykova A","2024","Cardiac failure review","narrative_review","article","10.15420/cfr.2024.06","39507374","PMC11539042",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0001976","Association of GLP-1 Receptor Agonist Use With Chronic Kidney Disease Risk in Type 2 Diabetes: Multicenter Emulated Target Trials.","Yen FS","2026","Mayo Clinic proceedings","nonrandomized_study","article","10.1016/j.mayocp.2026.01.035","42012433",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0001977","GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device: A Real-World Study.","Holmager P","2025","Journal of diabetes science and technology","nonrandomized_study","article","10.1177/19322968241289438","39417493","PMC11571627",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; meeting-report; conference-abstract"],["R0001978","Glucagon-Like Peptide-1 Analogs Associated with a Reduced Risk of Legal Blindness in Type 2 Diabetics with Cardiovascular Risks.","Jarrett E","2026","Clinical ophthalmology (Auckland, N.Z.)","nonrandomized_study","article","10.2147/opth.s581826","41907810","PMC13022916",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001979","Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease.","Maracle B","2026","Alimentary pharmacology & therapeutics","systematic_review","article","10.1111/apt.70485","41319219","PMC12690230","PROSPERO:CRD42025628850",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0001980","GLP-1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation.","Dai H","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70024","40954547","PMC12701773",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; research-article; article"],["R0001981","Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.","Tantoush M","2026","Cureus","systematic_review","article","10.7759/cureus.102018","41728423","PMC12923295",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001982","Worth the Weight? The Challenges of Administering the Glucagon-Like Peptide 1 Receptor Agonist Semaglutide With Long-Term Olanzapine Use in a Patient With Schizophrenia.","Ricciardi FL","2025","The Journal of clinical psychiatry","other","article","10.4088/jcp.25cr15857","40488719",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0001983","Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region-a register-based cross-sectional study.","Fors A","2025","European journal of clinical pharmacology","other","article","10.1007/s00228-025-03823-9","40074942","PMC12003583",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0001984","Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes.","Nomoto H","2023","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v14.i3.188","37035222","PMC10075027",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0001985","Glucagon-like Peptide-1 Receptor Agonist Use in Hospital: A Multicentre Observational Study.","Ray P","2025","Canadian journal of diabetes","nonrandomized_study","article","10.1016/j.jcjd.2024.10.011","39486576",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Multicenter Study; Preprint; preprint; article"],["R0001986","Dulaglutide vs insulin in adolescents with thalassaemia-induced diabetes: effect on metabolism and atherogenesis (DIADEMA).","Adly AAM","2026","Diabetologia","randomized_trial","article","10.1007/s00125-026-06835-x","42618811","PMC13627196","ClinicalTrials.gov:NCT07370922","S001897","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; research-article; article"],["R0001987","Glycated hemoglobin and body mass index as mediators of GLP-1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes.","Tang H","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","nonrandomized_study","article","10.1002/alz.70161","40207412","PMC11982930",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0001988","[Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine].","Seidel DU","2025","HNO","narrative_review","article","10.1007/s00106-025-01653-w","40767957",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0001989","GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review.","Abedi MM","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15093204","42122936","PMC13164487",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0001990","Adapting Glucagon-Like Peptide-1 Receptor Agonists for Innovative Psoriasis Therapy.","Tanquilut E","2026","Journal of cutaneous medicine and surgery","randomized_trial","article","10.1177/12034754261428062","41847997",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0001991","Glucagon-Like Peptide-1 Receptor Agonists in the Peri-Operative Period.","Narasimhan P","2025","British journal of hospital medicine (London, England : 2005)","narrative_review","article","10.12968/hmed.2024.0566","39862040",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0001992","Letter to the editor on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Wang C","2026","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2025.0676","40825722","PMC13129761",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comment; Letter; letter"],["R0001993","Reply to correspondence on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Yao X","2026","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2025.0892","40825717","PMC13129742",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comment; reply; letter"],["R0001994","GLP-1 Receptor Agonist Therapy and Surgical Procedure Rates in Hidradenitis Suppurativa","Sidhu KS","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-7603854/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0001995","Causal association between glucagon-like peptide-1 receptor agonists and mental disorders: insight from genetic and real-world evidence.","Ouyang C","2026","Journal of affective disorders","systematic_review","article","10.1016/j.jad.2026.121452","41713610",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0001996","Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.","Liu L","2024","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph17070828","39065679","PMC11279917",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0001997","GLP-1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi-site cohort of patients with type 2 diabetes.","Nance N","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","nonrandomized_study","article","10.1002/alz.70621","40952016","PMC12434700",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0001998","Letter to the Editor Regarding \"Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease\": A BMI-Stratified Retrospective Study.","Liu L","2026","Spine","nonrandomized_study","article","10.1097/brs.0000000000005577","41284919",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0001999","Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.","An X","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16228","39910752",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; Systematic Review; article"],["R0002000","The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials.","O'Mara A","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","systematic_review","article","10.1007/s10072-025-08602-z","41524953",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0002001","Physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity: a pilot study","Quddos F","2025","medRxiv","randomized_trial","preprint","10.1101/2025.04.25.25326413",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0002002","Timing and Duration of Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy","Niazi S","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.02.01.26345315",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002003","Glucagon-Like Peptide-1 Receptor Agonists vs Dipeptidyl Peptidase-4 Inhibitor Use on Risk of Asthma Exacerbation Among Diabetic Patients with Co-Morbid Asthma in Hong Kong.","Kwok WC","2026","Journal of asthma and allergy","nonrandomized_study","article","10.2147/jaa.s622748","42516533","PMC13402093",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002004","Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity.","Wu B","2026","Journal of medicinal chemistry","other_trial","article","10.1021/acs.jmedchem.6c00032","41941715","PMC13126679",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0002005","The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials.","Hoteit BH","2025","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/20420188251383064","41069706","PMC12504844",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002006","Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: implementation of complex fasting recommendations. Comment on Br J Anaesth 2025; 135: 48-78.","Frank C","2026","British journal of anaesthesia","commentary","article","10.1016/j.bja.2025.09.028","41162252",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002007","Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database.","Lu W","2025","European psychiatry : the journal of the Association of European Psychiatrists","nonrandomized_study","article","10.1192/j.eurpsy.2024.1803","39901452","PMC11823005",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002008","Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis.","Choudhury I","2026","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2026.02.010","41862354",null,"PROSPERO:CRD420251025534",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Review; review"],["R0002009","GLP-1RA based therapies in the young and old.","Rigas G","2025","Current opinion in endocrinology, diabetes, and obesity","other_trial","article","10.1097/med.0000000000000900","39692102",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0002010","Variability in the management of GLP-1 agonists and endoscopic procedures: an opportunity for standardization.","Crespo J","2025","Revista espanola de enfermedades digestivas","commentary","article","10.17235/reed.2025.11011/2024","39812010",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0002011","Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss.","Mariam-Smith A","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16612","40677145","PMC12409233",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002012","GLP-1 receptor agonists for the treatment of alcohol use disorder.","Petrie GN","2025","The Journal of clinical investigation","preclinical","article","10.1172/jci192414","40309769","PMC12043078",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article-commentary; article"],["R0002013","Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system.","Huang H","2025","British journal of anaesthesia","nonrandomized_study","article","10.1016/j.bja.2024.10.013","39578156",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002014","Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes.","Kuo CC","2025","Diabetologia","nonrandomized_study","article","10.1007/s00125-025-06453-z","40471238",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002015","The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition.","Chrysavgis L","2025","International journal of molecular sciences","randomized_trial","article","10.3390/ijms262412130","41465555","PMC12733374",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0002016","Stroke risk in diabetic patients with concomitant cardiovascular disease the CARDIAB-Stroke study.","Arow Z","2026","Annales d'endocrinologie","nonrandomized_study","article","10.1016/j.ando.2026.103058","42607995",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article"],["R0002017","Research on the effects of GLP-1 receptor agonists in treating cognitive dysfunction and gait disorders in elderly patients with diabetes.","Yang Y","2025","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2025.1607443","40630129","PMC12234456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002018","Considerations for Dietary Supplements after GLP-1RA Treatment: A Narrative Review.","Johnson BV","2026","The Journal of nutrition","narrative_review","article","10.1016/j.tjnut.2026.101695","42398916",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0002019","The comparative effectiveness of bariatric operations versus GLP-1 RAs: a systematic review and meta-analysis.","Campbell C","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","systematic_review","article","10.1016/j.soard.2026.07.012","42660781",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Review; review"],["R0002020","Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes.","Wang L","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.26327","40788646","PMC12340659",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002021","Care of dental patients on glucagon-like peptide-1 receptor agonists or tirzepatide requiring sedation.","Khan I","2025","British dental journal","commentary","article","10.1038/s41415-025-8563-0","40148608",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0002022","What Clinicians Need to Know About Glucagon-like Peptide 1 Agonists.","da Silva DLF","2025","The Journal of rheumatology","narrative_review","article","10.3899/jrheum.2025-0531","40816736",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002023","Clinical Insights on \"Tolerability and Effectiveness of Glucagon‑Like Peptide‑1 Receptor Agonists in Patients with Inflammatory Bowel Disease\".","Yang X","2026","Digestive diseases and sciences","commentary","article","10.1007/s10620-025-09349-5","40913722",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002024","Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum.","Mahalingam S","2026","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2026.1752204","42222167","PMC13218907",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002025","Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective.","Turkistani Y","2025","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2025.1535134","40342976","PMC12060260",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002026","Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.","Gibble TH","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71064","42575714","PMC13646385",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0002027","Correspondence to letter to the editor 2 on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Mao X","2026","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2025.0884","40825718","PMC13129776",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comment; Letter; letter"],["R0002028","Responses to GLP-1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data.","Mallette JH","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70180","41919489","PMC13191755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002029","AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists.","Wei T","2025","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.202507044","40787887","PMC12561408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002030","Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review.","Tassavor B","2025","Cureus","systematic_review","article","10.7759/cureus.93282","41020015","PMC12466318",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002031","Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis.","Stefanou MI","2026","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2026.109271","41619622",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0002032","Glucagon-like peptide-1 receptor agonists across the cardiovascular-kidney-metabolic spectrum: One size does not fit all.","Ferreira JP","2025","European journal of heart failure","commentary","article","10.1002/ejhf.70055","40961122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0002033","Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities.","Škudar S","2026","The International journal of eating disorders","systematic_review","article","10.1002/eat.70145","42223191",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0002034","Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: a restrictive fasting regimen is not necessary. Comment on Br J Anaesth 2025; 135: 48-78.","Khandaker R","2025","British journal of anaesthesia","commentary","article","10.1016/j.bja.2025.09.027","41125490",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002035","GLP-1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta-analysis including the SOUL trial.","Hasebe M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70458","41565576","PMC12992182",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0002036","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Liver-Related Outcomes, Laboratory and Physiologic Parameters in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis.","Wang MJ","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s565093","41710713","PMC12912157","PROSPERO:CRD420251090801",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0002037","Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce.","Mehta AE","2025","Cleveland Clinic journal of medicine","other_trial","article","10.3949/ccjm.92a.24113","40750324",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0002038","GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance.","Ngabea MA","2025","Biochemical and biophysical research communications","narrative_review","article","10.1016/j.bbrc.2025.152822","41161090",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002039","Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: Association Versus Causation and the Need for Ongoing Surveillance.","McIntyre RS","2025","The American journal of psychiatry","other","article","10.1176/appi.ajp.20241087","40859700",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002040","Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.","Bailey CJ","2025","Peptides","randomized_trial","article","10.1016/j.peptides.2025.171380","40081498",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0002041","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.","Velji-Ibrahim J","2025","Journal of obesity","systematic_review","article","10.1155/jobe/3897161","41211586","PMC12591819",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; review"],["R0002042","Association of glucagon-like peptide-1 receptor agonist use with anxiety disorders, depression, self-harm, and suicidality: a large cohort study.","Anagnostakis F","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113104","41592697",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0002043","Assessment of cardiovascular event reduction with SGLT2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes mellitus.","Prasad Vudathaneni VK","2025","Bioinformation","nonrandomized_study","article","10.6026/973206300213000","41466638","PMC12744504",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002044","Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS).","Arumugam S","2024","POCUS journal","case_report","article","10.24908/pocus.v9i2.17700","39640084","PMC11619776",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002045","Investigating the impact of Glucagon-like peptide-1 therapy on total shoulder arthroplasty outcomes.","Chebi P","2026","International orthopaedics","nonrandomized_study","article","10.1007/s00264-026-06984-z","42622874","PMC13619677",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002046","Contemporary medical therapy for heart failure with mildly reduced or preserved ejection fraction.","Beavers CJ","2026","Heart failure reviews","randomized_trial","article","10.1007/s10741-026-10656-w","42565898","PMC13451241",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0002047","Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.","Wen J","2024","Cureus","systematic_review","article","10.7759/cureus.69008","39385875","PMC11463578",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002048","Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes.","Henney AE","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70267","41178701","PMC12803636",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002049","The MUSCLE-GLP1-CKD study: design and rationale of a prospective real-world cohort evaluating muscle health during GLP-1 receptor agonist therapy in chronic kidney disease and type 2 diabetes","Macía-Heras M","2026","Research Square","protocol","preprint","10.21203/rs.3.rs-10372706/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0002050","Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis.","Nie Y","2025","Obesity surgery","systematic_review","article","10.1007/s11695-025-07733-8","39948306",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0002051","Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea.","D'Annibale DA","2025","Current opinion in pulmonary medicine","randomized_trial","article","10.1097/mcp.0000000000001208","40855981","PMC12538296",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; research-article; article"],["R0002052","Real-World Weight Loss and Telehealth Platform Utilization Patterns of Long-Term GLP-1 Receptor Agonist Treatment of self pay patients : A Retrospective Analysis","Patil P","2026","medRxiv","randomized_trial","preprint","10.64898/2026.03.27.26349009",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0002053","Enhanced cardioprotective effects of resveratrol and liraglutide against isoproterenol-induced myocardial injury: role of oxidative stress, inflammation, and mitochondrial function","El-Deen AEN","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-9302185/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0002054","Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022.","Gaw CE","2024","Journal of medical toxicology : official journal of the American College of Medical Toxicology","other","article","10.1007/s13181-024-00999-x","38421490","PMC10959851",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002055","Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions.","Al-Rashid AH","2026","Cureus","nonrandomized_study","article","10.7759/cureus.113910","42694337","PMC13539018",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0002056","Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.","Sohn M","2024","BMC medicine","nonrandomized_study","article","10.1186/s12916-024-03483-z","38956548","PMC11218058",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0002057","GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.","Dhippayom T","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70322","41365841","PMC12803668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0002058","Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Buragohain S","2026","Cureus","systematic_review","article","10.7759/cureus.106751","42116999","PMC13157524",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002059","Sex and Socioeconomic Differences in the Initiation of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Nationwide Cohort Study.","Calderon E","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71334","42764409",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002060","Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis.","Argobi Y","2026","Journal of cosmetic dermatology","other","article","10.1111/jocd.70835","41914454","PMC13036819",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002061","Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative.","Maier GA","2025","Diabetologia","commentary","article","10.1007/s00125-025-06538-9","40924113","PMC12534233",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0002062","Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer’s disease–type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning","Schröder J","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.08.21.26361012",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002063","GLP-1 Receptor Agonists - Good for Body Weight, Bad for Micronutrient Status?","Kerlikowsky F","2025","Current developments in nutrition","nonrandomized_study","article","10.1016/j.cdnut.2025.107587","41328178","PMC12664951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0002064","The Silent Weight of Nutrition Data in Glucagon-Like Peptide-1 Receptor Agonists Clinical Trials.","Dashti HS","2025","Advances in nutrition (Bethesda, Md.)","commentary","article","10.1016/j.advnut.2025.100498","40825502","PMC12592230",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002065","Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis.","Li L","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1854779","42483679","PMC13385192",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0002066","Liraglutide affects mitochondrial function and histone acetylation through the NQO1/SIRT3 pathway in diabetic kidney disease.","Gao J","2026","Molecular and cellular biochemistry","preclinical","article","10.1007/s11010-026-05670-3","42545560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002067","Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.","Arterburn D","2026","Annals of internal medicine","randomized_trial","article","10.7326/annals-25-05468","42372278",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0002068","GLP-1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study.","Kwon S","2026","BJUI compass","nonrandomized_study","article","10.1002/bco2.70169","41641338","PMC12863992",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002069","GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders.","Seijas-Amigo J","2026","Progress in neuro-psychopharmacology & biological psychiatry","randomized_trial","article","10.1016/j.pnpbp.2026.111802","42364723",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0002070","Time to approve glucagon-like peptide-1 receptor agonists for MASLD: a rational step based on robust evidence.","Arredouani A","2025","Diabetologia","commentary","article","10.1007/s00125-025-06527-y","40866732",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002071","GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies.","Luo Y","2025","Food & function","other_trial","article","10.1039/d5fo03273c","41160511",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0002072","Sex-Specific and Reproductive Status-Dependent Effects of Liraglutide on Metabolic Disorders Associated with Prediabetes.","Lebertová L","2026","Antioxidants (Basel, Switzerland)","preclinical","article","10.3390/antiox15060729","42352035","PMC13295372",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002073","Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.","Comisi JC","2026","Clinical oral investigations","nonrandomized_study","article","10.1007/s00784-026-07135-9","42734711",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0002074","The Impact of Glucagon-Like Peptide 1 Receptor Agonists Versus Diabetes Mellitus on Endoscopic Procedures: A Case-Control Study From a Large Tertiary Care Health System.","Bahdi F","2026","Journal of clinical gastroenterology","nonrandomized_study","article","10.1097/mcg.0000000000002414","42348290",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0002075","Glucagon-like peptide-1 receptor agonists reduce major adverse cardiovascular events and worsening heart failure in patients with heart failure: an umbrella meta-analysis.","Sun C","2026","BMC endocrine disorders","systematic_review","article","10.1186/s12902-026-02246-6","41928191","PMC13169775",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002076","The Real-World Costs of GLP-1 Receptor Agonist Treatment","Wennberg D","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.10.24.25338255",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002077","Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement.","Oprea AD","2025","British journal of anaesthesia","systematic_review","article","10.1016/j.bja.2025.04.001","40379536","PMC12597468","PROSPERO:CRD42023438624",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Consensus Statement; Journal Article; Systematic Review; research-article; article"],["R0002078","Reduced Complications and Improved Survival With Postoperative GLP-1 Receptor Agonist Use Following Lumbar Arthrodesis.","Proffitt EB","2026","Global spine journal","nonrandomized_study","article","10.1177/21925682261442187","41974096","PMC13076474",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002079","Diabetic lumbosacral radiculoplexus neuropathy after glucagon-like peptide 1 receptor agonist use: A case series.","Chandrashekhar S","2026","Journal of the neurological sciences","case_report","article","10.1016/j.jns.2026.125755","41534440",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0002080","GLP-1 Receptor Agonist Exposure and Diabetic Retinopathy Progression: An American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) Analysis","Ross C","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-11063573/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002081","Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.","Cassataro G","2026","Internal and emergency medicine","randomized_trial","article","10.1007/s11739-026-04468-x","42493728",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002082","Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.","Hölscher C","2025","CNS drugs","other_trial","article","10.1007/s40263-025-01226-z","40938528","PMC12602575",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0002083","The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Pharmacokinetics and Toxicokinetics: Is a New Diagnostic and Therapeutic Framework Needed?","Whitledge JD","2025","Journal of medical toxicology : official journal of the American College of Medical Toxicology","commentary","article","10.1007/s13181-025-01075-8","40216700","PMC12204967",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002084","Semaglutide in postmenopausal women: Clinical implications for weight loss, muscle health, and sleep-disordered breathing.","Pereira NRM","2026","Maturitas","narrative_review","article","10.1016/j.maturitas.2026.109129","42772087",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002085","Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes.","Temporelli PL","2025","European heart journal supplements : journal of the European Society of Cardiology","other","article","10.1093/eurheartjsupp/suae086","39980783","PMC11836705",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002086","GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy.","Gong B","2025","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2025.1675552","41019986","PMC12461214",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002087","GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials.","Li HY","2026","Diabetes care","systematic_review","article","10.2337/dc25-1929","41587563",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0002088","Combination Disease-Modifying Therapy for Neurodegenerative Diseases Using Repurposed Drugs.","Shtilbans A","2026","Annals of neurology","narrative_review","article","10.1002/ana.78190","41925063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002089","Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria.","Checa-Ros A","2026","Journal of personalized medicine","narrative_review","article","10.3390/jpm16020097","41745389","PMC12941783",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002090","Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions.","Ismail A","2025","World journal of gastrointestinal pharmacology and therapeutics","narrative_review","article","10.4292/wjgpt.v16.i3.107148","40937289","PMC12421399",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002091","Interest in Facial Volume Restorative Procedures With the Rise in \"Ozempic Face\": A Google Trends Analysis.","Mnajjed L","2025","Plastic and reconstructive surgery. Global open","other","article","10.1097/gox.0000000000007282","41255744","PMC12622603",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002092","Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.","Quarenghi M","2025","Journal of clinical medicine","randomized_trial","article","10.3390/jcm14113791","40507553","PMC12155999",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0002093","Informed Decision-Making for Glucagon-like Peptide-1 Receptor Agonists Use in Adolescents: A Call for Robust Evidence Related to Healthy Growth and Development.","Caouette JL","2025","The Journal of adolescent health : official publication of the Society for Adolescent Medicine","other","article","10.1016/j.jadohealth.2025.08.020","40956268",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002094","Real-World Sex Differences in Response to Treatment with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Single-Center Outpatient Case Series.","Inceu GV","2025","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina61081343","40870388","PMC12388165",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0002095","Real-World Insulin Deintensification and Discontinuation with GLP-1 Incretin Therapies Versus SGLT2 Inhibitors in Type 2 Diabetes","Matson R","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202607.2282.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0002096","Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.","Song K","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1695075","41234238","PMC12605505","PROSPERO:CRD42024567890; PROSPERO:CRD420251037959",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; systematic-review; review"],["R0002097","Chronic kidney disease, atrial fibrillation, and stroke: risk scores in the era of SGLT2i, non-steroidal MRA, and GLP-1 RA, and presence of high competing mortality.","Zoccali C","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other","article","10.1093/ndt/gfag191","42622348",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002098","Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond.","Faruque L","2025","Current opinion in nephrology and hypertension","other_trial","article","10.1097/mnh.0000000000001066","40047207",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0002099","Glucagon-like peptide-1 receptor agonists and its possible nephroprotective role: a systematic review.","Perencin A","2025","Minerva medica","systematic_review","article","10.23736/s0026-4806.25.09709-5","40932602",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0002100","Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic Surgery.","Wolff Sagy Y","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2026.21305","42384380","PMC13324868",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Comparative Study; research-article; article"],["R0002101","HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.","Guo L","2026","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2026.15622","42234428","PMC13234685","ClinicalTrials.gov:NCT05759897","S000877","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; research-article; article"],["R0002102","Glucagon-Like Peptide 1 Receptor Agonists and the Deepening Health Equity Divide in America.","Spinelli KJ","2025","American journal of health promotion : AJHP","other","article","10.1177/08901171251335507b","40340524",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002103","Semaglutide Exposure During Pregnancy: Results from the FAERS Database.","Zinzi A","2026","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19081249","42653746","PMC13516160",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002104","Effect of the glucagon-like peptide-1 receptor agonists dulaglutide on kidney outcomes in db/db mice.","Deng F","2025","Cellular signalling","preclinical","article","10.1016/j.cellsig.2025.111603","39805329",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002105","Glucagon-Like Peptide-1-Receptor Agonist Treatment of Obesity: Is It Cost-Effective and Equitable?","Hertzer L","2025","The Journal of pediatrics","other","article","10.1016/j.jpeds.2025.114779","40835048",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002106","Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Multicenter Cohort Analysis.","Sun Y","2025","Diagnostics (Basel, Switzerland)","nonrandomized_study","article","10.3390/diagnostics15172264","40941750","PMC12427755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002107","Defining the Roles of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Management of Chronic Kidney Disease in Adults with Type 2 Diabetes With or Without Overweight/Obesity: An International Delphi Consensus.","Handelsman Y","2026","Advances in therapy","other","article","10.1007/s12325-026-03618-z","42217111","PMC13499768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Consensus Statement; research-article; article"],["R0002108","Association of GLP-1 receptor agonists with risk of intestinal obstruction in patients with type 2 diabetes mellitus: a retrospective cohort study.","Gao Z","2025","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-025-02525-z","40471297","PMC12640328",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002109","Treating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges.","Chen AS","2025","Diabetes","other_trial","article","10.2337/dbi25-0004","40644314","PMC12645253",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002110","Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults.","Prentice L","2026","Drug and therapeutics bulletin","narrative_review","article","10.1136/dtb.2022.000065","42386393",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002111","Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review","Thomas M","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.07.23.25332036",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0002112","Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases.","Kong F","2026","Nature communications","systematic_review","article","10.1038/s41467-025-67701-9","41501059","PMC12847739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; article"],["R0002113","No Mid-Term Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Total Joint Arthroplasty: A Systematic Review.","Leggieri F","2026","The Journal of bone and joint surgery. American volume","systematic_review","article","10.2106/jbjs.25.00879","41921052","PMC13127733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0002114","Letter to the Editor: Glucagon-like peptide-1 receptor agonists improve outcomes in individuals with type 2 diabetes with and without heart failure.","Umar M","2026","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133871","40921276",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0002115","Maternal cardiometabolic health and the role of GLP-1 receptor agonists from preconception to postpartum: A review of evidence and opportunities.","Vardhan S","2026","American journal of preventive cardiology","narrative_review","article","10.1016/j.ajpc.2026.101471","42291049","PMC13261203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002116","Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial.","Noureddin M","2025","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/apt.70382","41127972","PMC12646629","ClinicalTrials.gov:NCT03900429",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0002117","GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Translational Perspective on Mechanisms and Clinical Implications.","Gómez-Maldonado I","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27167108","42653112","PMC13513034",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002118","Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements.","Sullivan SD","2026","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2026.01.016","41651376",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002119","Renal and urothelial cancer risks with SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes: a target trial emulation.","Huang CW","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","nonrandomized_study","article","10.1093/ndt/gfag028","41665869",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0002120","Postpartum GLP-1 receptor agonists and SGLT-2 therapies in women with prior gestational diabetes: current evidence and uncertainties.","Vanlaer Y","2026","BMC medicine","randomized_trial","article","10.1186/s12916-026-05182-3","42717332","PMC13560376",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; brief-report; article"],["R0002121","Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia.","Alharajin R","2026","Journal of the ASEAN Federation of Endocrine Societies","randomized_trial","article","10.15605/jafes.041.02.6171","42802824","PMC13616068",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0002122","Glucagon-like-peptide 1 receptor agonist for metabolic dysfunction-associated steatotic liver disease: hype or hope?","Wong YJ","2025","Singapore medical journal","randomized_trial","article","10.4103/singaporemedj.smj-2025-051","40258233","PMC12063942",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article-commentary; article"],["R0002123","Current antiretrovirals, hyperglycemia, and type 2 diabetes in people with HIV.","Farminer M","2026","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2026.09.001","42786007",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002124","Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom.","Ferreira ET","2025","Arquivos de neuro-psiquiatria","narrative_review","article","10.1055/s-0045-1812303","41145149","PMC12558699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002125","The use of GLP-1: receptor agonist medications for benign gynecology.","Howard MD","2025","Current opinion in obstetrics & gynecology","narrative_review","article","10.1097/gco.0000000000001028","40183300",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002126","Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.","Tang H","2025","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-24-01347","39993315","PMC12132804",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0002127","Tirzepatide-associated interstitial kidney injury.","Eldib M","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag125","42093865","PMC13142148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002128","Strategies to Enhance the Therapeutic Efficacy of GLP-1 Receptor Agonists through Structural Modification and Carrier Delivery.","Zhang T","2025","Chembiochem : a European journal of chemical biology","narrative_review","article","10.1002/cbic.202400962","39744852",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002129","[Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications].","Scheen A","2025","Revue medicale de Liege","randomized_trial","article",null,"41069298",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","2","FALSE","Journal Article; Review; English Abstract; article"],["R0002130","Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue.","Li X","2026","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-026-07958-4","42758273",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002131","Incretin therapy and transplant readiness: Distinguishing BMI-based access from physiologic reserve in solid organ transplantation.","Corrêa LMA","2026","Transplantation reviews (Orlando, Fla.)","narrative_review","article","10.1016/j.trre.2026.101037","42251798",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002132","Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis.","Nasrollahizadeh A","2026","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-02006-x","41508124","PMC12825243",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0002133","GLP-1 Receptor Agonist Prescription Patterns in the All of Us Research Program.","Gasdaska A","2026","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.64898/2026.01.13.26344022","41742942","PMC12930450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0002134","Optimizing Weight Loss in the GLP-1 Era: Preserving Muscle Mass, Function and Metabolic Health Through Precision Nutrition and Resistance Training.","Sancho-Haro E","2026","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph19060897","42356514","PMC13305067",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002135","Incretin Mimetics in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review.","Leong D","2026","JACC. CardioOncology","randomized_trial","article","10.1016/j.jaccao.2025.12.003","41705747","PMC12922619",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0002136","Letter to the editor on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Yao X","2026","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2025.0620","40690958","PMC13129789",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comment; Letter; letter"],["R0002137","7018 Improved Tolerability After Transitioning from Glucagon-like Peptide-1 Receptor Agonists to Tirzepatide",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453673",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0002138","Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning.","Kim JA","2025","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2025.0242","40631457","PMC12270588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002139","Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.","McCall KL","2026","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2025.2499670","40285721",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0002140","Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.","Nong K","2026","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj-2026-372161","42419792",null,"PROSPERO:CRD42024507993",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Network Meta-Analysis; Journal Article; Comparative Study; review"],["R0002141","Comparative Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Composite Surrogate Markers of Insulin Resistance: A Real-World Study Using METS-IR and SPISE.","Voziki D","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15124403","42355570","PMC13302001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002142","GLP-1 Receptor Agonists as Emerging Modulators of Inflammation and Angiogenesis in Chronic Cutaneous Wound Healing.","Ghebrehiwet-Kuflom J","2025","The Journal of investigative dermatology","preclinical","article","10.1016/j.jid.2025.08.045","41081666",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002143","The expanding role of peptides in cardiovascular care.","Pabón Romero AF","2026","Diabetes & vascular disease research","narrative_review","article","10.1177/14791641261476328","42559749","PMC13451712",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002144","Ocular Effects of GLP-1 Receptor Agonists: A Systematic Review of Current Evidence and Safety Concerns","Albanese GM","2025","Preprints.org","systematic_review","preprint","10.20944/preprints202508.0031.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0002145","Effect of Glucagon-like Peptide-1 Receptor Agonists on Outcomes and Complications Following Arthroscopic Rotator Cuff Repair: A Matched-Cohort Analysis.","Lauck BJ","2026","Orthopaedic journal of sports medicine","nonrandomized_study","article","10.1177/23259671251412408","41660290","PMC12873108",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002146","GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.","Müller Alves K","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf150","41230025","PMC12602866",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002147","GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations.","Alkuwaiti MA","2026","Journal of gastroenterology and hepatology","nonrandomized_study","article","10.1111/jgh.70589","42442720","PMC13534337",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0002148","Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017-2023: Demographic, Income, and Insurance Associations.","Jacobs M","2026","Journal of general internal medicine","other","article","10.1007/s11606-026-10408-4","41984414","PMC13421679",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002149","Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease.","Allen MR","2026","Bone","preclinical","article","10.1016/j.bone.2026.117933","42128321",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article; preprint"],["R0002150","Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.","Li M","2025","Sleep","systematic_review","article","10.1093/sleep/zsae280","39626095",null,null,"S002208","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; review"],["R0002151","Diabetic ketoacidosis induced by liraglutide overdose for weight loss in a type 2 diabetes patient: A case report.","Xu H","2026","Medicine","case_report","article","10.1097/md.0000000000046197","41578502","PMC12851697",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0002152","Artificial Intelligence for Precision Allocation of Cardiometabolic Therapies in Diabetes and Metabolic Disease: From Risk Prediction to Treatment Response","Labate AM","2026","Research Square","other","preprint","10.21203/rs.3.rs-10257059/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0002153","Instrumental variable analysis applied to randomised controlled trials of glucagon-like-peptide-1 receptor agonists and bariatric surgery: A study protocol","Gatua W","2026","Wellcome Open Res","protocol","preprint","10.12688/wellcomeopenres.26912.1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","5","FALSE","Preprint; article"],["R0002154","Glucagon-like peptide-1 receptor agonists and mental health: a narrative review of emerging benefits and risks.","Kim J","2025","Journal of Yeungnam medical science","randomized_trial","article","10.12701/jyms.2025.42.61","41025359","PMC12824553",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; review"],["R0002155","Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.","Shabil M","2024","BMC endocrine disorders","systematic_review","article","10.1186/s12902-024-01775-2","39551761","PMC11571652",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002156","Medication use for patients with obesity: trends and characteristics for US employees.","Good CB","2026","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2026.89920","42044422",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002157","Comprehensive pharmacovigilance assessment of pairwise drug-drug interactions and acute pancreatitis in the FDA adverse event reporting system: focus on incretin-based drugs.","Kazume I","2026","Frontiers in drug safety and regulation","nonrandomized_study","article","10.3389/fdsfr.2026.1827098","42359103","PMC13291152",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002158","New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching","Marwaha A","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202607.1370.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0002159","Exploring the Pleiotropic Cardioprotective Effects of GLP-1 Receptor Agonists in Preventing Anthracycline-Induced Cardiotoxicity: A Theoretical Proposal for Future Research.","Repp ML","2026","Medicines (Basel, Switzerland)","narrative_review","article","10.3390/medicines13010010","41893369","PMC13027766",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002160","Achieving equitable access to incretin-based therapies in cardiovascular care.","Reddy TK","2024","American heart journal plus : cardiology research and practice","other","article","10.1016/j.ahjo.2024.100455","39315291","PMC11417191",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0002161","Semaglutide-Induced Small Bowel Pseudo-Obstruction and Ileitis in a Patient With Type 2 Diabetes: A Case Report.","Javed F","2025","Cureus","case_report","article","10.7759/cureus.88350","40687404","PMC12276633",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002162","Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review.","Luna Ceron E","2025","Journal of Brown hospital medicine","systematic_review","article","10.56305/001c.132255","40191699","PMC11966775",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0002163","Weight loss from glucagon-like peptide-1 receptor agonists by genetic factors in adults with type 2 diabetes.","Zheng Y","2026","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2025.113041","41349614",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002164","Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.","Curtis LH","2026","Annals of internal medicine","randomized_trial","article","10.7326/annals-26-00202","42372277",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002165","GLP-1RAs: antidiabetic drug crossover-new hope for chronic inflammatory airway diseases.","Chen Y","2026","Respiratory research","randomized_trial","article","10.1186/s12931-026-03569-7","41699622","PMC13014972",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0002166","Comparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists.","Almohammed OA","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1847755","42741141","PMC13572232",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0002167","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Obese or Diabetic Patients With Obstructive Sleep Apnea Syndrome: A Meta-Analysis.","Xu S","2026","Nutrition reviews","systematic_review","article","10.1093/nutrit/nuaf115","40700548",null,"PROSPERO:CRD42024599675",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0002168","In Silico Exploration of Therapeutics for GLP-1 Receptor Agonist-Induced Nausea and Their in Vivo Validation in Mice.","Shibui N","2025","Biological & pharmaceutical bulletin","nonrandomized_study","article","10.1248/bpb.b25-00077","40866246",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002169","Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease.","Wu JY","2026","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2026.1838392","42244870","PMC13231402",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0002170","Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve indices of atrial cardiomyopathy: a systematic review and meta-analysis",null,"2025","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","systematic_review","article",null,null,"PMC12100276",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0002171","Prevalence Patterns of Body Contouring Procedures Among Injectable Glucagon-like Peptide-1 Receptor Agonist Users.","Toms JA","2024","Aesthetic surgery journal","nonrandomized_study","article","10.1093/asj/sjae085","38620005",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002172","Next-generation therapeutics for diabetic kidney disease.","Yi TW","2026","Nature reviews. Nephrology","narrative_review","article","10.1038/s41581-025-01042-0","41526484",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002173","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Perioperative Outcomes in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis","Brady A","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-9197869/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0002174","Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.","Timmons JG","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71076","42473259","PMC13538731","ClinicalTrials.gov:NCT03899402","S001603","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0002175","Use of glucagon-like peptide 1 receptor agonist to sustain patients off basal-bolus insulin regimens.","Blumenfeld L","2025","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2024.102288","39527981",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002176","Bariatric Surgery Versus GLP-1RAs in Idiopathic Intracranial Hypertension: A Propensity Matched Multi-Institutional Cohort.","Maroufi SF","2026","Neurosurgery","nonrandomized_study","article","10.1227/neu.0000000000004099","42159383",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002177","Impact of semaglutide introduction on the use of triptans: an interrupted-time series.","Roland N","2026","The journal of headache and pain","nonrandomized_study","article","10.1186/s10194-026-02462-4","42557547","PMC13445726",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002178","The Ethics of Wegovy in Pediatric Mental Health.","Ryan N","2026","Bioethics","other","article","10.1111/bioe.70087","41614219",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002179","GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes.","Choi J","2026","Hepatology communications","nonrandomized_study","article","10.1097/hc9.0000000000000949","41974037","PMC13075898",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002180","Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future.","Caruso I","2024","Endocrine","narrative_review","article","10.1007/s12020-024-03757-9","38472620","PMC11208186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002181","Cardiovascular risk management in the elderly: a dilemma in daily clinical practice.","Dacquino GM","2026","European journal of preventive cardiology","narrative_review","article","10.1093/eurjpc/zwag316","42648728",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002182","Research on epicardial adipose tissue as a metabolic therapeutic target in AF: focus on GLP-1 receptor agonists.","Liu L","2026","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2026.1708109","41869522","PMC12999421",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002183","GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease.","Sardà H","2025","Medicina clinica","narrative_review","article","10.1016/j.medcli.2025.106951","40378625",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002184","Body-wide multi-omic counteraction of aging with GLP-1R agonism.","Huang J","2025","Cell metabolism","preclinical","article","10.1016/j.cmet.2025.10.014","41265449",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002185","Research Progress on the Association Between GLP-1 Receptor Agonists and Cardiomyopathy.","Yang X","2025","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm37180","40927090","PMC12415761",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002186","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis.","Mohan N","2025","JAMA ophthalmology","nonrandomized_study","article","10.1001/jamaophthalmol.2025.2822","40875223","PMC12395358",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0002187","Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) Improve Periodontal and Peri-Implant Health in Type 2 Diabetes Mellitus.","Ahmad P","2025","Journal of periodontal research","nonrandomized_study","article","10.1111/jre.13410","40348599",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0002188","Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting-Expert Group Recommendations from Kuwait.","Aldahi WA","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-025-01838-0","41678007","PMC13000071",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002189","Glucagon-like peptide-1 receptor activation, inflammation and heart failure: Insights from genetic analysis.","Tian Y","2026","Heart & lung : the journal of critical care","other","article","10.1016/j.hrtlng.2026.102943","42727531",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0002190","GLP-1 agonists: a game changer in pain treatment and addiction.","Bade S","2025","Pain management","narrative_review","article","10.1080/17581869.2025.2536998","40726115","PMC12691565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002191","Selecting Pharmacologic Interventions for MASH.","Pan JJ","2026","Digestive diseases and sciences","narrative_review","article","10.1007/s10620-026-10003-x","42307712",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002192","Combination GLP-1 receptor agonist and SGLT2 inhibitor therapy versus GLP-1 receptor agonist monotherapy on arrhythmia outcomes in non-diabetic obese patients: A real-world time-dependent analysis.","Blankson GA","2026","International journal of cardiology. Cardiovascular risk and prevention","nonrandomized_study","article","10.1016/j.ijcrp.2026.200681","42500549","PMC13396740",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002193","Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance.","Patrizio A","2026","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf182","41376649","PMC12686943",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002194","Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes.","Hundal J","2025","NPJ breast cancer","nonrandomized_study","article","10.1038/s41523-025-00844-6","41290666","PMC12647897",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002195","Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis.","Gunawan B","2025","TouchREVIEWS in endocrinology","systematic_review","article","10.17925/ee.2025.21.2.5","41246119","PMC12616672",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002196","Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery: A Study Among Over 15,000 Patients.","Wiener JM","2025","Spine","nonrandomized_study","article","10.1097/brs.0000000000005283","39895110",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0002197","Perioperative management of patients on GLP-1 receptor agonists: Risks, recommendations, and future directions-A narrative review.","Li XY","2025","Journal of clinical anesthesia","narrative_review","article","10.1016/j.jclinane.2025.111871","40378603",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0002198","Preoperative GLP-1 Receptor Agonist (GLP-1 RA) Exposure Is Associated With Postoperative Initiation of GLP-1 RA Following Metabolic Bariatric Surgery: A Multicenter Cohort Study.","Hung KC","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08671-9","41965452",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0002199","Problematic Pharmacokinetics: A Case of Recurrent Pancreatitis Post Discontinuation of a Glucagon-Like Peptide 1 Receptor Agonists.","Morehouse ZP","2025","Journal of pharmacy practice","case_report","article","10.1177/08971900241273188","39109559",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0002200","Efficacy and Safety of Tirzepatide  for the Management of Obesity: A Systematic Review and Meta-analysis of Randomized  Controlled Trials (RCTs)            ","Ghose K","2025","Authorea Preprints","systematic_review","preprint","10.22541/au.176402391.10613553/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0002201","Preoperative Weight Loss Intervention With Glucagon-Like Peptides 1 Receptor Agonists Is Associated With Lower Complication Rates Following Primary Total Knee Arthroplasty Than Preoperative Bariatric Surgery.","Bcharah G","2026","Arthroplasty today","nonrandomized_study","article","10.1016/j.artd.2026.102033","42205466","PMC13206731",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002202","The Anti-Inflammatory Role of GLP-1 RAs in Acute Lung Injury and Acute Respiratory Distress Syndrome.","Dumitrescu P","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27072922","41977112","PMC13073149",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002203","Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes.","La Vignera S","2026","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph19081236","42653733","PMC13516247",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002204","GLP-1 receptor agonists and obstructive lung disease: Beyond metabolic control to respiratory outcomes.","Georgakopoulou VE","2026","Metabolism open","randomized_trial","article","10.1016/j.metop.2026.100449","41717504","PMC12914190",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0002205","Correspondence to editorial on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Mao X","2026","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2025.0705","40625070","PMC13129787",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comment; Letter; letter"],["R0002206","Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.","Wu X","2026","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2026.1846714","42394981","PMC13322860","PROSPERO:CRD420251152746",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0002207","Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.","Madsbad S","2023","Cardiovascular research","other","article","10.1093/cvr/cvac112","35925683",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002208","The potential adverse effects of hypodermic glucagon-like peptide -1 receptor agonist on patients with type 2 diabetes: A population-based study.","Cheng Z","2024","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.70013","39435881","PMC11494487",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002209","A brain reward circuit inhibited by next-generation weight-loss drugs in mice.","Godschall EN","2026","Nature","preclinical","article","10.1038/s41586-026-10444-4","42092139","PMC13293854",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002210","Incretin-based therapies for the treatment of obesity-related diseases.","Caruso I","2024","npj metabolic health and disease","randomized_trial","article","10.1038/s44324-024-00030-5","40604322","PMC12118674",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0002211","Microneedle patches deliver targeted GLP-1RAs-loaded nanoparticles for the treatment of rheumatoid arthritis.","Zhang H","2026","Journal of nanobiotechnology","other","article","10.1186/s12951-026-04261-0","41840375","PMC13020363",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002212","Incretin signaling at the crossroads of metabolism, inflammation, and tumorigenesis: implications for obesity patients.","Wawrzak-Pienkowska K","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.178290","41138841",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002213","Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.","Omeh Z","2026","Expert review of endocrinology & metabolism","systematic_review","article","10.1080/17446651.2026.2656247","41968780",null,"PROSPERO:CRD420251016726",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Comparative Study; review"],["R0002214","Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.","Jiao X","2023","Clinical drug investigation","systematic_review","article","10.1007/s40261-023-01319-x","37938535",null,"PROSPERO:CRD42023413199",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0002215","Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration.","Sadashivaiah K","2026","Aging","other","article","10.18632/aging.206376","42095816","PMC13632846",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002216","Glucagon-like Peptide-1 Receptor Agonists in Asthma Exacerbations: An Application of High-Dimensional Iterative Causal Forest to Identify Subgroups.","Wang T","2025","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.70192","40717037","PMC12831167",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0002217","APPETITIVE TRAITS AND QUALITY OF LIFE IN WOMEN WITH OBESITY USING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: INSIGHTS FROM A PCOS-ENRICHED SAMPLE.","Aldewachi A","2025","Georgian medical news","other","article",null,"41072526",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002218","Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.","Liu M","2026","Annals of internal medicine","randomized_trial","article","10.7326/annals-25-04623","42372276",null,"ClinicalTrials.gov:NCT06256549","S001220","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Comparative Study; article"],["R0002219","Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial.","McCoy RG","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.01.012","41638310",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002220","Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan.","Nagayama D","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100291","42388688","PMC13320546",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002221","Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.","Tsukamoto S","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15312","37828829",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0002222","Glucagon-like peptide-1 receptor agonists in the adjunctive treatment of patients with hidradenitis suppurativa: A systematic review.","Sánchez-Feliciano A","2025","Journal of the American Academy of Dermatology","systematic_review","article","10.1016/j.jaad.2025.06.077","40706684",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0002223","GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.","Yuan Y","2026","Drugs","systematic_review","article","10.1007/s40265-026-02380-4","42791433",null,"PROSPERO:CRD420251079970",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0002224","Potential Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Diabetes and High Risk for Dementia.","Plascencia-Villa G","2025","Annals of internal medicine","commentary","article","10.7326/annals-25-02362","40690776",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0002225","Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence.","Haddadin J","2026","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-026-00801-3","42350760",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002226","GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential.","Ahmed GU","2026","Annals of medicine and surgery (2012)","randomized_trial","article","10.1097/ms9.0000000000004725","41789246","PMC12959817",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; review"],["R0002227","Plant- and Microalgae-Based Biotechnological Strategies for Affordable and Non-Invasive Delivery of Antidiabetic Peptides.","Boscart T","2026","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics18020223","41754966","PMC12944287",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002228","A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.","Le TTB","2024","Cureus","case_report","article","10.7759/cureus.51460","38298324","PMC10829695",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002229","Beyond weight loss: Integrating GLP-1 RA therapies into psychological and behavioral care for obesity and binge eating disorder.","Mack I","2026","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-026-10047-4","42068458",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002230","Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity.","Siddiqi TJ","2025","European journal of heart failure","nonrandomized_study","article","10.1002/ejhf.70048","40977256",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002231","Should We Be Concerned About Glucagon-Like Peptide-1 Receptor Agonists?","VanderBeek BL","2025","JAMA ophthalmology","commentary","article","10.1001/jamaophthalmol.2025.1599","40471633",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0002232","Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: a network meta-analysis.","Chuang MH","2026","CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","systematic_review","article","10.1503/cmaj.250369","42442791","PMC13374707","PROSPERO:CRD42024605727",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; research-article; article"],["R0002233","Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?","Ezhilarasan D","2025","Journal of gastroenterology and hepatology","other_trial","article","10.1111/jgh.17037","40538007",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0002234","Correspondence to letter to the editor 1 on \"Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study\".","Mao X","2026","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2025.0704","40625069","PMC13129730",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comment; Letter; letter"],["R0002235","Contemporary Initial Glucose-Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta-Analysis.","Cavalcante Lima Chagas G","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71397","42811398",null,"PROSPERO:CRD420251178714",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; review"],["R0002236","Weight Management in Menopause: Diet, Physical Activity, Medication, and Surgery.","Lu V","2026","Obstetrics and gynecology clinics of North America","narrative_review","article","10.1016/j.ogc.2026.04.002","42508875",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002237","Effects of the glucagon-like peptide-1 receptor agonist liraglutide on retinal endothelial function and oxidative stress during sepsis.","Böhm EW","2026","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2026.1778848","42375616","PMC13312418",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002238","Efficacy of glucagon-like peptide-1 receptor agonists for prevention of stroke among patients with and without diabetes: A meta-analysis with the SELECT and FLOW trails.","Gera A","2025","International journal of cardiology. Heart & vasculature","systematic_review","article","10.1016/j.ijcha.2025.101638","40165866","PMC11957674",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0002239","GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities.","Maher S","2025","Journal of drugs in dermatology : JDD","randomized_trial","article","10.36849/jdd.9062","41329148",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0002240","Glucagon suppression under GLP-1RA therapy: hidden trade-offs for muscle and resilience.","Tippairote T","2026","Diabetology international","commentary","article","10.1007/s13340-025-00856-4","41311515","PMC12647404",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Preprint; article; preprint"],["R0002241","Glucose-Lowering Therapies and Cognitive Decline: From Molecular Mechanisms to Clinical Evidence and Future Perspectives.","Grasso M","2026","Advances in therapy","randomized_trial","article","10.1007/s12325-026-03760-8","42631802",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0002242","Diabetes-Associated Heart Failure After Percutaneous Coronary Intervention: Molecular Mechanisms and Prospects for Early Multi-Targeted Intervention.","Hu H","2026","Journal of visualized experiments : JoVE","narrative_review","article","10.3791/72255","42631574",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Video-Audio Media; Review; Research Support, Non-U.S. Gov't; article"],["R0002243","Glucagon-Like Peptide-1 Receptor Agonists: What's the Optimizing Policies for Obesity-Related Metabolic Diseases?","Park TS","2025","Diabetes & metabolism journal","commentary","article","10.4093/dmj.2025.0047","40073904","PMC11960206",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002244","Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.","Santos P","2026","Pharmaceutics","systematic_review","article","10.3390/pharmaceutics18010069","41599176","PMC12844791","PROSPERO:CRD420251143171",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002245","In vivo functional profiling and structural characterization of the human GLP1R A316T variant.","El Eid L","2026","Science advances","preclinical","article","10.1126/sciadv.adw0899","41637494","PMC13267291",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002246","Digital multicriteria evaluation of negotiated medicines using Chinese mini-HTA: application of structured methodologies in assessing once-weekly GLP-1 RAs for improved clinical decision-making.","Li X","2025","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1588056","41041641","PMC12483912",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002247","Glucagon-Like Peptide-1 Receptor agonists: A magic bullet or a double-edged sword?","Mandelbaum RS","2025","F&S reports","commentary","article","10.1016/j.xfre.2025.02.007","40201101","PMC11973741",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0002248","Interaction of Glucagon-Like Peptide 1 and Its Analogues with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity","Litus EA","2025","Preprints.org","other","preprint","10.20944/preprints202504.2038.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0002249","Severe reflux oesophagitis caused by repeated vomiting due to glucagon-like peptide-1 receptor agonist.","Kashima S","2025","BMJ case reports","other","article","10.1136/bcr-2025-266368","40759494","PMC12322966",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0002250","Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.","Azzam AY","2026","JACC. Advances","nonrandomized_study","article","10.1016/j.jacadv.2026.102917","42489387","PMC13400122",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002251","If the evidence is there, why are GLP-1 receptor agonists not on-label for hip and knee osteoarthritis in overweight patients?","Ursini F","2025","RMD open","nonrandomized_study","article","10.1136/rmdopen-2025-006025","40992788","PMC12458797","ClinicalTrials.gov:NCT06191848","S001724","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Clinical Trial; discussion; article"],["R0002252","Association of GLP-1 receptor agonists with intentional self-harm in patients with type 2 diabetes: a Sentinel Distributed Database study.","Kuzucan A","2026","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2025-005840","41850718","PMC13007165",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002253","Mitochondrial control of fuel switching via carnitine biosynthesis.","Auger C","2026","Science (New York, N.Y.)","preclinical","article","10.1126/science.ady5532","41505503",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002254","Are GLP-1 Receptor Agonists Safe in Spine Surgery: A Systematic Review.","Younus I","2025","Spine","systematic_review","article","10.1097/brs.0000000000005466","40719010",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0002255","Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes.","Braun N","2025","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2025.08.019","40835131",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002256","GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation.","Li P","2026","Drug design, development and therapy","other_trial","article","10.2147/dddt.s613616","42311464","PMC13271144",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002257","Impact of GLP-1 receptor agonists on cardiovascular outcomes in patients with peripheral artery disease without diabetes: A propensity score-matched analysis.","Daniel E","2026","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","randomized_trial","article","10.1177/10815589251393978","41137196",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002258","Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulation.","Chen YR","2026","GeroScience","nonrandomized_study","article","10.1007/s11357-026-02300-0","42101745",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002259","A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan.","Chiu CF","2026","Obesity research & clinical practice","nonrandomized_study","article","10.1016/j.orcp.2026.09.001","42744726",null,"ClinicalTrials.gov:NCT06283641","S001445","pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0002260","A Novel Cosmetic Anti-inflammatory Peptide With Firming and Lifting Benefits: The Potential for Adjunctive Care for Skin Laxity Associated With Weight Loss.","Lisante TA","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","randomized_trial","article","10.1097/dss.0000000000005181","42210882",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0002261","Hypoglycaemic coma induced by a falsified semaglutide product: a case report.","Antonacci G","2026","European journal of hospital pharmacy : science and practice","case_report","article","10.1136/ejhpharm-2025-004656","41125326",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0002262","Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.","Cedirian S","2025","Dermatology and therapy","narrative_review","article","10.1007/s13555-025-01537-5","40924351","PMC12549488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002263","Promising Real-World Data on Glucagon-Like Peptide-1 Receptor Agonists in Dialysis.","Shin JI","2025","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000000791","40608867","PMC12342062",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; editorial; article"],["R0002264","Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: A propensity-score matched analysis.","Goldman SN","2025","North American Spine Society journal","nonrandomized_study","article","10.1016/j.xnsj.2025.100612","40470002","PMC12136921",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002265","New therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review.","Doroba O","2025","Anaesthesiology intensive therapy","narrative_review","article","10.5114/ait/208895","40995652","PMC12793977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002266","Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.","Sundararaman L","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14061978","40142784","PMC11943310",null,"S000630","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002267","1-Minute Pearls/Pitfalls for the Clinician.","Gulla V","2026","Journal of Brown hospital medicine","other","article","10.56305/001c.158387","41940220","PMC13048396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0002268","Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Gamal I","2026","Cardiology in review","systematic_review","article","10.1097/crd.0000000000001465","42693519",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0002269","Endobariatrics in the era of glucagon-like peptide-1 receptor agonists: evolving roles, evidence, and integration.","Vahedi F","2025","Current opinion in gastroenterology","narrative_review","article","10.1097/mog.0000000000001134","41025685",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002270","GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection.","Jiang W","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27188378","42794805","PMC13607562",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002271","Making Modern Diabetes Medications Affordable and Accessible: Lessons From India for Other Countries.","Mohan V","2026","Diabetes care","narrative_review","article","10.2337/dci26-0054","42747945",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002272","Identifying Provider Prescribing Practices for GLP-1RAs and SGLT-2is in Patients With Type 2 Diabetes to Address Pharmacoinequity.","Wongsirisakul P","2026","Journal of diabetes research","nonrandomized_study","article","10.1155/jdr/7439681","41767554","PMC12943470",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002273","Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials.","Mohammadi D","2026","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-026-02226-9","42365335","PMC13573484",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0002274","Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial.","Lu L","2026","Stroke","randomized_trial","article","10.1161/strokeaha.125.056010","42145088","PMC13281981","ClinicalTrials.gov:NCT03948347","S001659","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0002275","Reply of the authors: Refining glucagon-like peptide-1 receptor agonist therapy in polycystic ovary syndrome: addressing phenotypic, racial, and pharmacologic heterogeneity.","Gleason E","2025","Fertility and sterility","commentary","article","10.1016/j.fertnstert.2025.07.014","40930624",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0002276","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Liu Y","2025","Journal of the American Heart Association","systematic_review","article","10.1161/jaha.124.039446","40314346","PMC12184242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0002277","Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.","Xie Z","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1244432","37701904","PMC10493284",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review-article; review"],["R0002278","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonist Use During the First Trimester in Pregnant Women With Type 2 Diabetes.","Hanif M","2025","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2025.03.013","40107335",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002279","Reframing glucagon-like peptide-1 receptor agonist research for psychiatric care: Gaps in evidence and translation.","Toor MAW","2025","Psychoneuroendocrinology","commentary","article","10.1016/j.psyneuen.2025.107562","40752464",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002280","Trends in Glucagon-Like Peptide-1 Receptor Agonist Social Media Posts Using Artificial Intelligence.","Javaid A","2024","JACC. Advances","other","article","10.1016/j.jacadv.2024.101182","39372460","PMC11450939",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002281","Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes.","Salvatore M","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.06.03.25328908","40502555","PMC12155001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0002282","Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes: A Real-World Data Cohort Study.","Chuang CH","2025","Oncology research","nonrandomized_study","article","10.32604/or.2025.072875","41502515","PMC12774574",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002283","Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release.","Bank NC","2025","Journal of hand surgery global online","nonrandomized_study","article","10.1016/j.jhsg.2025.100746","40497273","PMC12148469",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002284","Semaglutide-Associated Sequential Unilateral Transient Osteoporosis of The Hip: A Case Report.","Keles A","2026","American journal of physical medicine & rehabilitation","case_report","article","10.1097/phm.0000000000003003","41961511",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002285","Systemic semaglutide provides a mild vasoprotective and antineuroinflammatory effect in a rat model of ocular hypertensive glaucoma.","Mouhammad ZA","2025","Molecular brain","preclinical","article","10.1186/s13041-025-01224-8","40597179","PMC12211916",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0002286","Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis.","Wang X","2026","Journal of diabetes investigation","systematic_review","article","10.1111/jdi.70293","41902544","PMC13238613",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Comparative Study; Systematic Review; research-article; article"],["R0002287","The Role and Mechanism of Incretins in Gynaecologic Diseases.","Yan J","2026","Endocrinology, diabetes & metabolism","narrative_review","article","10.1002/edm2.70340","42789930","PMC13614832",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002288","Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight.","Tanaka M","2025","Hypertension research : official journal of the Japanese Society of Hypertension","narrative_review","article","10.1038/s41440-025-02418-2","41102420",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002289","All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium-Glucose Cotransporter-2 Inhibitors.","Garg S","2025","Gastro hep advances","nonrandomized_study","article","10.1016/j.gastha.2025.100736","40917760","PMC12410549",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002290","GLP-1 Receptor Agonist Use Is Associated with Venous Ulcer Healing and Fewer Wound Infections.","Go CC","2026","Annals of vascular surgery","nonrandomized_study","article","10.1016/j.avsg.2026.03.023","41895589",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0002291","Association of GLP-1 receptor agonist use with outcomes after surgical fixation of femoral neck fracture in patients with type 2 diabetes: a propensity score-matched analysis.","Box M","2026","European journal of orthopaedic surgery & traumatology : orthopedie traumatologie","nonrandomized_study","article","10.1007/s00590-026-04720-2","41870668",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002292","Combination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In Vivo.","Thome AD","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27177855","42737751","PMC13566286",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002293","Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.","Seetharaman S","2025","Journal of diabetes science and technology","nonrandomized_study","article","10.1177/19322968241305641","39707844","PMC11662345",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Case Reports; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0002294","Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis.","Abdelrahman RM","2026","Inquiry : a journal of medical care organization, provision and financing","nonrandomized_study","article","10.1177/00469580261441498","42033296","PMC13129305",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002295","GLP-1 Receptor Agonists in Diabetes and Obesity: A Case Report and Review of Bowel Obstruction Risks and Management.","Jones M","2025","Cureus","case_report","article","10.7759/cureus.81891","40342457","PMC12060997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002296","Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer.","Cornelio CK","2026","Pharmacotherapy","randomized_trial","article","10.1002/phar.70130","41801847",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002297","GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness.","Jacobson S","2026","Canadian journal of psychiatry. Revue canadienne de psychiatrie","narrative_review","article","10.1177/07067437251386626","41091899","PMC12528064",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0002298","Association of Glucagon-Like Peptide-1 Receptor Agonists With Liver-Related Outcomes and All-Cause Mortality in Patients With Harmful Alcohol Use: A Target Trial Emulation Study.","John BV","2026","The American journal of gastroenterology","nonrandomized_study","article","10.14309/ajg.0000000000003585","40488647","PMC12354218",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0002299","Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.","Nadolsky S","2026","Obesity pillars","case_report","article","10.1016/j.obpill.2026.100302","42518361","PMC13382402",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002300","Heterogeneous treatment effects of GLP-1RAs and SGLT2is on risk of Alzheimer's disease and related dementia in patients with type 2 diabetes: Insights from a real-world target trial emulation.","Tang H","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","nonrandomized_study","article","10.1002/alz.70313","40448382","PMC12125485",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002301","Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.","Lakhani M","2025","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2025.05.007","40383360",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0002302","The Effect of GLP-1 Receptor Agonists on Reoperation Following Anterior Cervical Discectomy and Fusion.","Bank NC","2026","World neurosurgery","nonrandomized_study","article","10.1016/j.wneu.2025.124751","41422925",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0002303","Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer.","Tatum KL","2026","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2026.12133","42113513","PMC13162077",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0002304","Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort.","Aldhaleei WA","2024","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph17020199","38399414","PMC10891568",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002305","Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?","Mademlis C","2025","Expert review of clinical pharmacology","other_trial","article","10.1080/17512433.2025.2573785","41070406",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0002306","Causal Machine Learning for Comparative Effectiveness of GLP-1 RA versus SGLT2i in Heart Failure Using Real-World EHR Data","Han GY","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.04.06.26350259",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002307","Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis.","Elghanam Y","2026","Archives of pharmacal research","systematic_review","article","10.1007/s12272-026-01615-y","42098470","PMC13222307","PROSPERO:CRD420261277032",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002308","Generalizability of glucagon-like peptide 1 receptor agonist clinical trial results to product labeling and the real world.","Dal-Ré R","2025","Annals of the New York Academy of Sciences","randomized_trial","article","10.1111/nyas.70025","40760786",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002309","A single-center retrospective review of food retention during upper endoscopy following GLP-1 receptor agonist usage and introduction of the Tampa Intraluminal Gastric Residue (TiGR) grading scale.","Patel Y","2026","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-026-12640-9","41772229",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002310","Cutaneous hypersensitivity reaction to dulaglutide: A case report of an allergic reaction.","Samhani C","2024","Diabetes & metabolism","case_report","article","10.1016/j.diabet.2024.101552","38942076",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0002311","Liraglutide-Induced Acute Hepatocellular Injury With Positive Rechallenge: A Case Report and Literature Review.","Adi M","2026","Clinical medicine insights. Case reports","nonrandomized_study","article","10.1177/11795476261461221","42311917","PMC13269733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0002312","Advances in the management of obesity and heart failure: latest evidence from clinical trials.","Costa TA","2025","Current opinion in cardiology","randomized_trial","article","10.1097/hco.0000000000001214","39998461",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0002313","Ocular safety of glucagon-like peptide-1 receptor agonists: insights and unanswered questions.","Dziewierz A","2025","Polish archives of internal medicine","other","article","10.20452/pamw.17045","40552472",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002314","The Obesity Drug Revolution: New Frontiers in Pharmacotherapy.","Manoria PC","2025","Cureus","narrative_review","article","10.7759/cureus.96713","41393538","PMC12700842",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002315","Male Sexual and Reproductive Health in Diabetes and Obesity Pharmacotherapy: A Source-Triangulated Counseling Map.","Broul M","2026","Andrology","other_trial","article","10.1111/andr.70366","42661473",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0002316","Global trends and focuses of GLP-1RA in obesity: a bibliometric analysis and visualization from 2014 to 2024","Abdelrahman RM","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-6509163/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint; article"],["R0002317","Headline: Fracture Risk in Type 2 Diabetes: Systematic Review of Cardiovascular Outcome Trials with Glucagon Like Peptide Receptor Agonists.","Mahalingasivam AA","2025","Current osteoporosis reports","systematic_review","article","10.1007/s11914-025-00937-y","41026248",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0002318","Chronotropic Responses to GLP-1 Receptor Agonists and Sitagliptin in Atria From Diabetic Rats.","Akcabag E","2024","Journal of cardiovascular pharmacology","preclinical","article","10.1097/fjc.0000000000001564","38547520",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002319","[Regional Trends in Antidiabetic Drug Prescribing in Portugal: Eight Years of Nationwide Real-World Evidence (2017 - 2024) (TREND-8 REGIONS Study)].","Leite AR","2026","Acta medica portuguesa","nonrandomized_study","article","10.20344/amp.24706","42697864",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","English Abstract; Journal Article; article"],["R0002320","GLP-1 Agonist Use Is Not Associated With a Reduction of Paraspinal Muscle Quality in Diabetic Patients With Low Back Pain: A Retrospective Cohort Study.","Zadeh AT","2026","HSS journal : the musculoskeletal journal of Hospital for Special Surgery","nonrandomized_study","article","10.1177/15563316261446300","42147420","PMC13176119",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0002321","Glucagon-like Peptide 1 Receptor Agonists and Risk of Pulmonary Hypertension.","Garry JD","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.09.18.25336100","41001493","PMC12458527",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0002322","Glucagon-Like Peptide-1 Receptor Agonists During Electroconvulsive Therapy: Case Report With Evolving Concerns and Management Considerations.","Espinoza RT","2024","The journal of ECT","case_report","article","10.1097/yct.0000000000000992","38315827",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002323","Disproportionality analysis of semaglutide-associated bile-duct cancer: A vigibase study.","Kaur RJ","2026","Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","randomized_trial","article","10.1007/s12664-025-01891-4","41639322",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002324","Fat, muscle, and anti-obesity medications in cardiovascular disease prevention.","Khan MS","2026","European heart journal","other_trial","article","10.1093/eurheartj/ehag201","41914150",null,null,"S002095","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0002325","Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.","Crisafulli S","2026","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-25-01724","41183330","PMC12718079",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, N.I.H., Extramural; research-article; article"],["R0002326","[Progression inhibition in chronic kidney disease].","Weinmann-Menke J","2026","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-026-02145-x","42397586",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0002327","Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy.","Smith WA","2026","Childhood obesity (Print)","other","article","10.1177/21532176261475103","42544560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002328","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes in Arthroplasty: A Systematic Review.","Lee V","2025","The Journal of arthroplasty","systematic_review","article","10.1016/j.arth.2025.07.015","40675511",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0002329","Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017-2024.","Senthilkumar A","2026","Journal of medical toxicology : official journal of the American College of Medical Toxicology","nonrandomized_study","article","10.1007/s13181-026-01128-6","41784916","PMC13076819",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0002330","Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder.","Oesterle TS","2025","Brain sciences","randomized_trial","article","10.3390/brainsci15070702","40722294","PMC12293269",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; Preprint; review-article; preprint; article"],["R0002331","Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta-analysis of observational studies.","Goldenberg RM","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70013","40757429",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0002332","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Retained Gastric Contents During Esophagogastroduodenoscopy: A Propensity Score-Matched Study.","Hisada H","2025","Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society","nonrandomized_study","article","10.1111/den.70016","40819843",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002333","Effect of liraglutide on the dysglycemia, inflammation, and gut microbiota in prediabetic KKay mice.","Zhang Y","2025","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2025.1714859","41394123","PMC12698571",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002334","Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.","Derington CG","2025","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2025.37297","41082229","PMC12519307",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; Research Support, N.I.H., Extramural; research-article; article"],["R0002335","Association of semaglutide use with depressive symptoms and suicidal behavior in a patient with type 2 diabetes: A case report.","Stojkovska A","2025","The Journal of international medical research","case_report","article","10.1177/03000605251349393","40652323","PMC12255853",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0002336","A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms.","Voros C","2026","International journal of molecular sciences","systematic_review","article","10.3390/ijms27020759","41596408","PMC12841515",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; Review; review"],["R0002337","Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction.","Vignarajah A","2025","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.125.040919","41195790","PMC12887215",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002338","Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus.","Toffoli B","2026","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms27114694","42278227","PMC13256121",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0002339","Beyond diabetes and obesity: GLP-1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation.","Spezani R","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70400","41417476","PMC12890747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002340","Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative. Reply to Maier GA, Rathmann W, Kuß O [letter].","Kuo CC","2025","Diabetologia","commentary","article","10.1007/s00125-025-06526-z","40905997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002341","Association of Baseline Comorbidities With First-Year Adherence to GLP-1 Receptor Agonists in Patients With Diabetes or Obesity: A Retrospective Cohort Study.","Mai Z","2026","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/10600280251384637","41355396","PMC13332170",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002342","Real-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study.","Yu Z","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1756581","41953701","PMC13053266",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0002343","Glucagon-Like Peptide-1-Based Therapies in Cardiovascular Disease: Evidence, Mechanisms, and Emerging Clinical Applications.","Mazzone PM","2026","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwag430","42612171",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002344","Neoadjuvant Glucagon-Like Peptide-1 Receptor Agonists in Abdominal Wall Hernia Surgery: A Narrative Review.","Prabhakaran S","2026","World journal of surgery","randomized_trial","article","10.1002/wjs.70260","41653161",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0002345","GLP-1 receptor agonists and hospitalization due to infections in patients with type 2 diabetes: A nationwide cohort study.","Wang JL","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112324","40505816",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002346","Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review.","Rico-Fontalvo J","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-026-01854-8","41848820","PMC13103125","OSF:osf.io/sz87j",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0002347","The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: a systematic review and meta-analysis.","Mousavi A","2025","Eating and weight disorders : EWD","systematic_review","article","10.1007/s40519-025-01770-z","40877612","PMC12394290",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002348","Correction to: The Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists on 24-Hour Urine Parameters: A Retrospective Cohort Study.","Schaub JA","2025","Kidney360","notice","article","10.34067/kid.0000000956","40788684","PMC12483035",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0002349","Euglycaemic ketoacidosis associated with dual-acting GLP-1/GIP receptor agonist treatment following bariatric surgery.","Green D","2026","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-26-0059","42766383","PMC13617635",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0002350","Glucagon-like peptide-1 receptor agonists and acute pancreatitis.","Liao KF","2025","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2025.101666","40419239",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002351","The Cardiovascular Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-level Outcomes to Micro-level Mechanisms","Mansoor M","2025","Preprints.org","other","preprint","10.20944/preprints202507.1487.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint; article"],["R0002352","Great Debates: Undergoing the Knife versus Pill-Popping-The Comparative Efficacy and Cost-Effectiveness of Bariatric Surgery and GLP-1 Receptor Agonists in the Management of Obesity.","Brosnihan P","2025","The American surgeon","narrative_review","article","10.1177/00031348251337145","40285863",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Comparative Study; article"],["R0002353","Benefits of glucagon-like peptide (GLP)-1 receptor agonists on 5-year risk of major amputation, all-cause mortality, myocardial infarction, and ischemic stroke in patients with chronic limb-threatening ischemia.","Yahyavi A","2026","Vascular medicine (London, England)","nonrandomized_study","article","10.1177/1358863x251393107","41410071",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002354","Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.","Abdulraheem A","2025","Surgical endoscopy","systematic_review","article","10.1007/s00464-025-11962-4","40634731",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; article; review"],["R0002355","Comparative outcomes of adding SGLT2 inhibitors versus incretin-based therapies to insulin in type 2 diabetes.","Yen FS","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112328","40532767",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0002356","Efficacy of preoperative GLP-1 receptor agonists on the perioperative outcomes of bariatric surgery: a systematic review and meta-analysis.","Liu C","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","systematic_review","article","10.1016/j.soard.2026.02.019","41887957",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002357","Treatment of obesity with GLP-1 receptor agonist after bariatric surgery: Real-world evidence.","Milad C","2025","Medicina clinica","nonrandomized_study","article","10.1016/j.medcli.2025.107153","40865274",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002358","Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease.","Chng WQ","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1831174","42327723","PMC13280206",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002359","The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review.","Gala D","2025","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm45204","41524068","PMC12780994",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002360","The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review.","Buonanno S","2025","Inflammation research : official journal of the European Histamine Research Society ... [et al.]","narrative_review","article","10.1007/s00011-025-02140-2","41266905","PMC12634801",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Scoping Review; review-article; article"],["R0002361","A Novel Presentation of Euglycemic Diabetic Ketoacidosis Associated with SGLT2 Inhibitor and Weekly GLP-1 Agonist: Case Report.","Lyu YS","2025","Healthcare (Basel, Switzerland)","case_report","article","10.3390/healthcare13172245","40941597","PMC12427735",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Preprint; case-report; preprint; article"],["R0002362","GLP-1 Receptor Agonists in Acute Ischemic Stroke and Secondary Stroke Prevention: A Narrative Review of Preclinical and Clinical Evidence.","Samanidou V","2026","Journal of central nervous system disease","randomized_trial","article","10.1177/11795735261444425","42006939","PMC13087331",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0002363","Ocular safety of glucagon-like peptide-1 receptor agonists: insights and unanswered questions. Authors' reply.","Bahit MC","2025","Polish archives of internal medicine","other","article","10.20452/pamw.17046","40552471",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002364","From indirect regulation to multi-layered metabolic control in MASLD: Multi-receptor agonism and microbiota-metabolite functional convergence.","Zhou S","2026","Pharmacological research","narrative_review","article","10.1016/j.phrs.2026.108369","42570767",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002365","Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy.","Moradi A","2026","Dermatology and therapy","randomized_trial","article","10.1007/s13555-026-01699-w","41781778","PMC13047010",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0002366","Expanding the discussion on airway management with glucagon-like peptide-1 receptor agonist use.","Pennycuff JE","2025","Anaesthesia","commentary","article","10.1111/anae.16676","40576070",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0002367","A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia.","Vetrugno L","2025","Journal of anesthesia, analgesia and critical care","narrative_review","article","10.1186/s44158-025-00237-y","40156058","PMC11951578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002368","GLP-1 receptor agonist use and surgical outcomes following diabetic foot reconstruction: A propensity score-matched retrospective cohort study.","Zhang JZ","2026","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","nonrandomized_study","article","10.1016/j.bjps.2026.03.001","41880708",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002369","Geroprotective potential of anti-diabetic medications: Bridging type 2 diabetes and accelerated aging.","Cui H","2026","Pharmacological research","randomized_trial","article","10.1016/j.phrs.2026.108443","42710703",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0002370","An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders.","De Giorgi R","2025","Nature. Mental health","other","article","10.1038/s44220-025-00390-x","42239616","PMC7619120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002371","GLP-1R agonist therapy and vaccine response: Neglected implications.","van Niekerk G","2024","Cytokine & growth factor reviews","narrative_review","article","10.1016/j.cytogfr.2024.07.006","39025754",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0002372","The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis.","Lomeli LD","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111806","39111552",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002373","Glucagon-Like Peptide-1 Receptor Agonist Therapy Associated With Fewer Diagnoses of Carpal Tunnel Syndrome Within 2 Years of Treatment.","Hiredesai AN","2026","Hand (New York, N.Y.)","nonrandomized_study","article","10.1177/15589447251366676","40899869","PMC12408536",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002374","Mitochondrial Alterations and CKD: A Review.","Pinzon-Cortes JA","2026","American journal of kidney diseases : the official journal of the National Kidney Foundation","narrative_review","article","10.1053/j.ajkd.2026.01.021","42331132",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002375","Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease.","Hong CT","2024","Journal of biomedical science","other_trial","article","10.1186/s12929-024-01090-x","39501255","PMC11539687",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002376","Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.","Chen H","2023","Medicine","systematic_review","article","10.1097/md.0000000000034122","37417602","PMC10328610","PROSPERO:CRD42022342241",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; article"],["R0002377","Effects of semaglutide, a GLP-1 receptor agonist, on food preferences in Japanese subjects with type 2 diabetes and visceral fat accumulation.","Hara T","2026","Endocrine journal","nonrandomized_study","article","10.1507/endocrj.ej25-0402","41605684","PMC13195457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0002378","Semaglutide-Induced Sarcopenia via GLP-1R-mTOR-Satellite Cells Axis and Muscle-Glucose Feedback Loop Potentially Leading to Refractory Hyperglycemia in Type 2 Diabetes: A Case-Driven Hypothesis.","Ahmed A","2026","Problemy endokrinologii","case_report","article","10.14341/probl13660","42545324","PMC13474366",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; review-article; article"],["R0002379","The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective.","Scagliusi FB","2026","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70069","41221797","PMC13535755",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0002380","Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: Shared Mechanisms and Therapeutic Opportunities.","Basta D","2026","Cardiology in review","other","article","10.1097/crd.0000000000001298","42121355",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002381","Relative Impact of GLP-1 Agonist Use on Microvascular Versus Macrovascular Complications.","Okorigba EM","2025","Cureus","other","article","10.7759/cureus.93925","41147020","PMC12554327",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002382","Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease.","Saadeh M","2025","Crohn's & colitis 360","narrative_review","article","10.1093/crocol/otaf056","40919598","PMC12409399",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002383","Association of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score-matched Cohort Study.","Chang Y","2026","Global spine journal","nonrandomized_study","article","10.1177/21925682251383170","40988481","PMC12460268",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002384","GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: target trial emulation.","Xie Y","2026","BMJ medicine","nonrandomized_study","article","10.1136/bmjmed-2025-002183","42046647","PMC13110570",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002385","Comparison of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide-1 Receptor Agonists and Risks of Osteoarthritis and Arthroplasty in Patients With Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohorts Retrospective Study.","Su YC","2025","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.70051","40478380",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0002386","Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.","Ruggiero R","2024","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph17020147","38399362","PMC10892952",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002387","Beyond Glycemic Control: GLP-1RA-Based Therapies and Emerging Targets Beyond the Metabolic Axis.","Matuszewski W","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15072786","41977086","PMC13073043",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0002388","A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.","Visan MA","2026","American journal of clinical dermatology","systematic_review","article","10.1007/s40257-026-01049-8","42295612",null,"PROSPERO:CRD420251110220",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0002389","Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis.","Xie X","2025","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2025.1613610","41050409","PMC12491879","PROSPERO:CRD42024592308",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0002390","Cardiovascular and Kidney Outcomes of Glucagon-Like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.","Felix N","2025","Cardiorenal medicine","systematic_review","article","10.1159/000543149","39746343","PMC11844710",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002391","The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials.","Mendonça L","2025","Clinical journal of the American Society of Nephrology : CJASN","systematic_review","article","10.2215/cjn.0000000584","39480988","PMC11835157","ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT04865770","S000395; S000716; S000953","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0002392","Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists.","Kelly CA","2025","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgae722","39400117",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0002393","Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.","Nieto LM","2026","The American journal of gastroenterology","nonrandomized_study","article","10.14309/ajg.0000000000003525","40358430",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0002394","Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist.","Qi W","2025","The Journal of pharmacology and experimental therapeutics","other_trial","article","10.1016/j.jpet.2025.103683","41015846",null,"ClinicalTrials.gov:NCT05694741","S002413","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; article"],["R0002395","Factors Associated with GLP-1 Receptor Agonist Use in Patients with Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Retrospective Propensity-Score Matched Analysis.","Vournas G","2026","Diseases (Basel, Switzerland)","nonrandomized_study","article","10.3390/diseases14020075","41745113","PMC12939290",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002396","Exploring new therapeutic drugs for osteoarthritis and osteoporosis: Glucagon-like peptide-1 receptor agonists: A review.","Zheng M","2025","Medicine","narrative_review","article","10.1097/md.0000000000043239","40696619","PMC12282812",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0002397","A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure.","Gul U","2024","Cureus","narrative_review","article","10.7759/cureus.76519","39872560","PMC11771532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002398","Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study.","Hong AT","2025","Diabetes care","nonrandomized_study","article","10.2337/dc25-0292","40560644","PMC12451831",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0002399","Peripheral artery disease: advances in medical therapy.","Garagoli F","2026","European heart journal","other","article","10.1093/eurheartj/ehag516","42466921",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002400","A cross-sectional study of prescribing rates for SGLT2 inhibitors and GLP-1 receptor agonists among primary care clinics with and without embedded pharmacists.","Dixon DL","2026","Journal of the American Pharmacists Association : JAPhA","other","article","10.1016/j.japh.2026.103106","41905685","PMC13137380",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002401","Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report.","Lo SC","2026","Cureus","randomized_trial","article","10.7759/cureus.101908","41728571","PMC12919507",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Case Reports; Journal Article; case-report; article"],["R0002402","Glucagon-Like Peptide-1 Use and Healthcare Resource Utilization for Depression and Anxiety Among Adults with Type 2 Diabetes: 2019 to 2023.","Do D","2026","The journal of behavioral health services & research","nonrandomized_study","article","10.1007/s11414-025-09950-6","40439835",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0002403","How do GLP-1 receptor agonists influence the progression of shoulder pathology? A matched cohort analysis.","Davis WR","2026","JSES reviews, reports, and techniques","nonrandomized_study","article","10.1016/j.xrrt.2025.100613","41458332","PMC12743434",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002404","The Integration of Lifestyle Modification Advice and Diet and Physical Exercise Interventions: Cornerstones in the Management of Obesity with Incretin Mimetics.","Minnetti M","2026","Obesity facts","narrative_review","article","10.1159/000548370","41252315","PMC12707955",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002405","Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF.","Sauer AJ","2026","ESC heart failure","other_trial","article","10.1093/eschf/xvag056","41711220","PMC12988776",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002406","Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease.","Verma A","2024","Chemical biology & drug design","narrative_review","article","10.1111/cbdd.14426","38230775",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002407","Recent advances in incretin-based therapy for the treatment of cognitive impairment associated to the type 2 diabetes mellitus: preclinical and clinical studies - a narrative review.","Giofrè F","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1696419","41480353","PMC12753325",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002408","Trajectory-Oriented Brain Vulnerability Framework for Cognitive Decline in Type 2 Diabetes.","Komel J","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27188342","42794768","PMC13607053",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002409","Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.","Ji L","2026","Signal transduction and targeted therapy","randomized_trial","article","10.1038/s41392-026-02586-8","41760612","PMC12948953","ClinicalTrials.gov:NCT06256562","S002790","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0002410","Glucagon-like peptide-1 receptor agonists associated with improved clinical outcomes in patients with inflammatory bowel disease: a retrospective cohort study.","Aksan F","2026","Naunyn-Schmiedeberg's archives of pharmacology","nonrandomized_study","article","10.1007/s00210-025-04745-0","41143957",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002411","Titration of Basal and Prandial Insulin Doses With the Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy.","Hill AC","2024","Cureus","nonrandomized_study","article","10.7759/cureus.59899","38854306","PMC11160513",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0002412","Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease.","Economos H","2025","World journal of nephrology","other_trial","article","10.5527/wjn.v14.i4.109457","41479840","PMC12754405",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002413","SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Ahmed AAO","2025","BMC cardiovascular disorders","systematic_review","article","10.1186/s12872-025-05455-4","41454299","PMC12849425","PROSPERO:CRD420251168485",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002414","Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.","Abreu ES","2026","Clinics in liver disease","narrative_review","article","10.1016/j.cld.2026.01.004","42142900",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002415","Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetes.","Gobaru M","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1924744","42723833","PMC13557946","UMIN:UMIN000048469; UMIN:UMIN000048471",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0002416","Semaglutide Induces Oxidative Stress and Differentially Modulates mTOR-Dependent Growth and Invasion in Human Trophoblast Cell Models: Implications for Placental Function.","Thurmond E","2026","Current issues in molecular biology","other","article","10.3390/cimb48050524","42193128","PMC13204696",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002417","Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure.","Wang W","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13051108","40426935","PMC12109496",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002418","Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care.","Samajdar SS","2026","Diabetology international","nonrandomized_study","article","10.1007/s13340-026-00910-9","42256584","PMC13241372",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; article"],["R0002419","Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.","Htoo PT","2026","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-026-03287-w","42437918","PMC13644152",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0002420","Glucagon-like peptide-1 receptor agonist and adverse obstetrical outcomes.","Regens A","2025","American journal of obstetrics and gynecology","commentary","article","10.1016/j.ajog.2025.05.028","40466898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002421","Perioperative Optimization Strategies in Major Genitourinary Cancer Surgery.","Yellu A","2026","Cancers","nonrandomized_study","article","10.3390/cancers18162588","42649902","PMC13510800",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0002422","Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients.","Kim HSJ","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70938","42259626","PMC13341327",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002423","Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis.","Wang MJ","2025","Systematic reviews","systematic_review","article","10.1186/s13643-025-03011-x","41373001","PMC12817519","PROSPERO:CRD420251090801",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; review"],["R0002424","Weekly Journal Scan: a large observational study unravels the wide-ranging effects of glucagon-like peptide-1 receptor agonists.","Pedicino D","2025","European heart journal","other","article","10.1093/eurheartj/ehaf277","40256867",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002425","Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity.","Lee MMY","2025","Diabetes care","systematic_review","article","10.2337/dc24-1533","39977628","PMC12081317",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0002426","Comparative Exposure-Adjusted Adverse Reaction Reporting Rates for GLP-1-Based Therapies: An Analysis of UK MHRA Yellow Card Data and NHS Prescribing Data for England","Asiri A","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202608.1213.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0002427","Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.","Damen JAA","2026","Annals of internal medicine","systematic_review","article","10.7326/annals-24-03764","42296503",null,"PROSPERO:CRD42023491646",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Review; review"],["R0002428","Annals On Call - Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in the Absence of Diabetes.","Centor RM","2025","Annals of internal medicine","other","article","10.7326/annals-25-02205-oc","40456160",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002429","Periconceptional Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation.","Khan SS","2025","JAMA cardiology","other","article","10.1001/jamacardio.2025.0637","40238124",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002430","GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer.","Srinivasan NM","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf141","41081017","PMC12509273",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002431","Glucagon-like peptide-1 receptor agonist, semaglutide, attenuates intravenous self-administration of fentanyl in female rats.","Rojas KE","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.05.19.726324","42239073","PMC13228359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0002432","Beyond weight loss: a narrative review of tirzepatide's impact on muscle and lean mass in people with overweight and obesity.","Wilkinson T","2026","Current medical research and opinion","randomized_trial","article","10.1080/03007995.2026.2734645","42806732",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; review"],["R0002433","Perioperative bronchoaspiration in a semaglutide user on a residue-free diet: a case report and insights from a complication.","Barbosa Santos L","2025","Perioperative medicine (London, England)","case_report","article","10.1186/s13741-025-00603-y","41137050","PMC12551300",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002434","Oral Semaglutide Therapy Reduces Cardiovascular Events in Patients with Type 2 Diabetes: Deciphering the Soul of the Study.","Jialal I","2025","Journal of clinical medicine","commentary","article","10.3390/jcm14103335","40429331","PMC12112023",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002435","Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease.","King A","2025","American journal of preventive cardiology","nonrandomized_study","article","10.1016/j.ajpc.2024.100922","39896054","PMC11786665",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002436","Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists.","Beauregard N","2024","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000001064","39150432",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002437","Preoperative fasting guidelines: A narrative review.","De Meyer M","2026","European journal of anaesthesiology and intensive care","narrative_review","article","10.1097/ea9.0000000000000120","42730097","PMC13568165",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002438","Skeletal Muscle Mass Loss and Glucagon-Like Peptide-1 Receptor Agonists: Are Older Patients at Risk?","Kakkar AP","2025","Annals of internal medicine","commentary","article","10.7326/annals-24-03950","40489783",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0002439","Dual GIP/GLP-1 Receptor Agonist Versus Selective GLP-1 Receptor Agonist in Patients Undergoing Primary Total Knee or Hip Arthroplasty","Davis SC","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-10744245/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002440","Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants.","Alhowiti A","2025","Frontiers in pharmacology","other","article","10.3389/fphar.2025.1510554","40822483","PMC12350480",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002441","Testosterone Replacement Therapy as a Potential Strategy to Preserve Lean Mass in Men With Persistently Low Serum Testosterone Receiving GLP-1 Receptor Agonists: A Narrative Review.","Canal de Velasco LM","2026","Cureus","randomized_trial","article","10.7759/cureus.105734","42037905","PMC13103340",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0002442","GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly.","Pérez López G","2025","Medicina clinica","nonrandomized_study","article","10.1016/j.medcli.2025.107122","40716192",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0002443","Clinician Guidance on the Benefits of Healthy Nutrition and Increased Physical Activity for People With Type 2 Diabetes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation.","Kushner P","2025","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd25-0037","41438314","PMC12719322",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002444","Weight Management in a Patient With Smith-Magenis Syndrome: The Role of GLP-1 Receptor Agonists.","Correia JC","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf094","40443456","PMC12119458",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002445","Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes.","Ramos S","2026","Clinical lymphoma, myeloma & leukemia","nonrandomized_study","article","10.1016/j.clml.2026.06.007","42471299",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002446","Beyond Weight Loss: Skeletal Considerations in Obesity Treatment.","Kim MJ","2026","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2026.2986","41951103","PMC13172636",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002447","Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.","Shah VN","2025","Journal of diabetes science and technology","randomized_trial","article","10.1177/19322968241291512","39517127","PMC11571606",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Consensus Statement; Review; Research Support, N.I.H., Extramural; review-article; article"],["R0002448","Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.","Burson JR","2026","The mental health clinician","case_report","article","10.9740/mhc.2026.02.034","41646202","PMC12872343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002449","SGLT-2 inhibitors and GLP-1 receptor agonists in primary care pharmacotherapy of type 2 diabetes in people living with HIV versus HIV-negative controls: Findings from a multicenter study in Germany.","Hilgefort L","2026","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2026.01.005","41547635",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Comparative Study; article"],["R0002450","MON-535 Glucagon-Like-Peptide-1 Receptor Agonists Are Effective in Patients with Cystic Fibrosis",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544486",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0002451","Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data.","Jullien A","2024","Diabetes care","systematic_review","article","10.2337/dca24-0034","39190488",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0002452","Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System.","Makhmutov A","2026","Cureus","nonrandomized_study","article","10.7759/cureus.108868","42299163","PMC13264684",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002453","Individualizing pharmacologic and non-pharmacologic therapy for CKD associated with diabetes.","Zhang Z","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfag179","42570222",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002454","One step closer to solving the mystery of the anti-inflammatory effects of glucagon-like peptide-1 receptor agonists.","Watada H","2025","Journal of diabetes investigation","commentary","article","10.1111/jdi.14346","39535352","PMC11786165",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0002455","We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.","Agewall S","2025","European heart journal. Cardiovascular pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvaf039","40574526","PMC12231122",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; editorial; article"],["R0002456","Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis.","Yang R","2025","Journal of translational medicine","systematic_review","article","10.1186/s12967-025-06302-y","40181368","PMC11967144","PROSPERO:CRD42024558287",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002457","Bariatric Surgery in the Era of GLP1RA: A Narrative Review.","Muhundan M","2026","Advances in therapy","randomized_trial","article","10.1007/s12325-026-03494-7","41627368","PMC12999599",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0002458","The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation.","Sola-Leyva A","2025","Acta obstetricia et gynecologica Scandinavica","narrative_review","article","10.1111/aogs.15010","39696822","PMC11782050",null,"S000630","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002459","GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes.","Chen JC","2026","Journal of the American Geriatrics Society","nonrandomized_study","article","10.1111/jgs.70187","41132144","PMC12774297",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002460","Meta-analysis of sodium glucose transport 2 inhibitors versus other glucose-lowering agents on the progression of diabetic retinopathy and diabetic macular edema.","Akande R","2026","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2026.113429","42425328",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0002461","Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic.","Samuels JM","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70004","40762026","PMC12515774",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002462","Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.","Amjad MM","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71400","42811393",null,"PROSPERO:CRD420261456447",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; review"],["R0002463","GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score-matched population-based cohort study.","Chen WM","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112407","40803507",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002464","Renal Function Improvement With Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Type 2 Diabetes.","Yanai H","2024","Journal of medical cases","case_report","article","10.14740/jmc4189","38646419","PMC11027764",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002465","Endoscopic gastric remodeling and its histologic impact on metabolic dysfunction-associated steatohepatitis: a 12-month prospective study.","Jirapinyo P","2026","Gastrointestinal endoscopy","other","article","10.1016/j.gie.2026.02.042","41786151",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0002466","Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes : A Target Trial Emulation.","Inoue K","2025","Annals of internal medicine","randomized_trial","article","10.7326/annals-24-02648","40690769",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002467","Correction to: Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging.",null,"2025","Aesthetic surgery journal","notice","article","10.1093/asj/sjaf039","40116692",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0002468","Effect of Glucagon-like Peptide-1 Receptor Agonists on Outcomes After Hip Hemiarthroplasty for Femoral Neck Fractures in Patients With Type 2 Diabetes.","Box MW","2025","Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews","nonrandomized_study","article","10.5435/jaaosglobal-d-25-00312","41118557","PMC12543238",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; review-article; article"],["R0002469","The impact of glucagon-like peptide-1 receptor agonists on the quality indicators of colonoscopy - a systematic review and meta-analysis.","Chiu YT","2025","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","systematic_review","article","10.1016/j.dld.2025.03.004","40121157",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002470","Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis.","Ayoub M","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14030944","39941615","PMC11818918",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002471","GLP-1 receptor agonists in patients with MGUS: A real-world propensity-matched study.","Tentolouris A","2026","European journal of clinical investigation","nonrandomized_study","article","10.1111/eci.70140","41123105",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002472","Assessment of Gastric Content Using Gastric Ultrasound in Patients on Glucagon-Like Peptide-1 Receptor Agonists Before Anesthesia.","Pai SL","2026","Anesthesia and analgesia","nonrandomized_study","article","10.1213/ane.0000000000007764","41032460",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0002473","Interaction Between Glucagon-like Peptide 1 and Its Analogs with Amyloid-β Peptide Affects Its Fibrillation and Cytotoxicity.","Litus EA","2025","International journal of molecular sciences","other","article","10.3390/ijms26094095","40362335","PMC12071944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002474","GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial.","Fragozo-Ramos MC","2025","PloS one","protocol","article","10.1371/journal.pone.0335060","41124171","PMC12543135",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0002475","Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Weight Loss Following Bariatric Treatment.","Kramer CK","2024","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgae176","38488042",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0002476","Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.","Liu M","2026","Cell reports. Medicine","randomized_trial","article","10.1016/j.xcrm.2026.102874","42320483","PMC13400172","ClinicalTrials.gov:NCT06256523","S002776","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; research-article; article"],["R0002477","GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies.","Wang X","2026","Pharmacological research","narrative_review","article","10.1016/j.phrs.2026.108331","42379432",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002478","Association of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults.","Shah P","2026","The Laryngoscope","nonrandomized_study","article","10.1002/lary.70808","42584027",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002479","Media Coverage of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) After Semaglutide Use: A Content Analysis of News Reporting Accuracy and Framing.","Mahiny D","2026","Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society","nonrandomized_study","article","10.1097/wno.0000000000002454","41870413",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002480","Rejuvenation of senescent microglia using glucagon-like peptide-1 receptor agonist attenuates Alzheimer’s disease-like pathologies and behavioral deficits in aged 5xFAD mice model","Lee Y","2025","Research Square","preclinical","preprint","10.21203/rs.3.rs-6546219/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0002481","Diet quality and nutrient distribution while using glucagon-like-peptide-1 receptor agonist: A secondary cross-sectional analysis.","Johnson BVB","2025","Obesity pillars","other","article","10.1016/j.obpill.2025.100195","40852562","PMC12369429",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002482","Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes.","Guo W","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1865769","42318205","PMC13271928",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0002483","GLP-1 receptor agonist suppresses fatty infiltration while improving range of motion and electromyographic function in a chronic rotator cuff tear rat model.","Yoon JP","2026","Journal of shoulder and elbow surgery","randomized_trial","article","10.1016/j.jse.2025.12.019","41644032",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002484","SAT-560 Glucagon Like Peptide 1 Receptor Agonists as a Potential Treatment of Post Bariatric Hypoglycemia",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12543860",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0002485","Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review.","Tantawy D","2025","Cureus","systematic_review","article","10.7759/cureus.96218","41211260","PMC12591504",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002486","The Role of Incretins in Obstructive Sleep Apnea \"GLP1RAs and GLP1RA/GIPRAs in OSA\".","Fuentes AL","2025","Journal of diabetes","commentary","article","10.1111/1753-0407.70170","41265850","PMC12634136",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article-commentary; article"],["R0002487","Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis.","Chiang CH","2025","Gastroenterology","systematic_review","article","10.1053/j.gastro.2025.06.003","40499738",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002488","Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System.","Estler B","2026","PharmacoEconomics","nonrandomized_study","article","10.1007/s40273-026-01621-4","42228345","PMC13499734",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002490","The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review.","Valentino K","2025","Journal of psychiatric research","systematic_review","article","10.1016/j.jpsychires.2025.02.008","39956093",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0002491","Fall Reporting with GLP-1 Receptor Agonists in Older Adults: A FDA Adverse Event Reporting System (FAERS) Disproportionality Analysis","Gedik TE","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-10419901/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002492","Outcomes of Maternal Periconceptional Exposure to Glucagon-Like Peptide-1 Receptor Agonists: A Scoping Review of Evidence and Reporting Trends.","Lee IO","2026","Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC","nonrandomized_study","article","10.1016/j.jogc.2025.103191","41319953",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Scoping Review; article"],["R0002493","Kidney Protective Effects of Glucagon-Like Peptide-1 Receptor Agonists Versus Sodium/Glucose Cotransporter 2 Inhibitors in Persons With Diabetes and CKD: Implications for Personalized Medicine.","Taal MW","2025","American journal of kidney diseases : the official journal of the National Kidney Foundation","commentary","article","10.1053/j.ajkd.2025.05.005","40673858",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0002494","Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.","Subedi L","2026","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2026.115297","42636888",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002495","Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.","Büyükcavlak M","2026","Journal of anesthesia","randomized_trial","article","10.1007/s00540-026-03813-w","42377486",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002496","Weight management treatment in obesity.","Rubio-Herrera MA","2025","Medicina clinica","narrative_review","article","10.1016/j.medcli.2025.107152","40865172",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002497","Phenome-Wide Risk Evaluation of GLP-1 Receptor Agonist Use in Type 2 Diabetes with Real-World Data Across Multiple Healthcare Systems.","Vashisht R","2025","medRxiv : the preprint server for health sciences","randomized_trial","article","10.1101/2025.08.13.25333579","40832397","PMC12363721",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Preprint; preprint"],["R0002498","Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients.","Patel R","2025","Current heart failure reports","other_trial","article","10.1007/s11897-025-00704-1","40366488",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0002499","Glucagon-like peptide-1 receptor agonist use is associated with reduced risk of out-of-hospital cardiac arrest in women with type 2 diabetes: A nationwide nested case-control study.","Eroglu TE","2024","Resuscitation plus","nonrandomized_study","article","10.1016/j.resplu.2024.100821","39569410","PMC11577171",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002500","GLP-1 Signalling as a Therapeutic Avenue in Parkinson's Disease: A Comprehensive Review.","Orozco MP","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms262412163","41465588","PMC12733648",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002501","Effect of Tirzepatide on Cardiovascular Outcomes.","Huston J","2026","American journal of cardiovascular drugs : drugs, devices, and other interventions","narrative_review","article","10.1007/s40256-025-00767-4","41032189",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002502","Comparative Effectiveness of Metformin versus GLP-1 Receptor Agonists in Treating Antipsychotic-Induced Metabolic Disturbances: A Systematic Review and Network Meta-Analysis","Chen Y","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-9317100/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0002503","Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis.","Baig MU","2025","Gastrointestinal endoscopy","systematic_review","article","10.1016/j.gie.2024.12.019","39694296",null,"PROSPERO:CRD42024556732",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0002504","Comparative Effectiveness of Bariatric Surgery Versus GLP-1 Receptor Agonists in Reducing the Risk of New-Onset of NASH: A Retrospective Multinational Cohort Study From North America and Europe.","Hussein A","2025","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70075","40650867","PMC12255231",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Multicenter Study; research-article; article"],["R0002505","Sociodemographic and Socioeconomic Disparities in Incretin Therapy Utilization Among Hospitalized Adults in the United States: A Nationwide Inpatient Sample Analysis","Sachdeva S","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9800110/v1",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0002506","All-Cause Mortality and Health Care Resource Utilization in Patients with Type 1 Diabetes Treated with Glucagon-like Peptide 1 Receptor Agonists/Glucose-Dependent Insulinotropic Polypeptide.","Garg S","2026","Diabetes technology & therapeutics","nonrandomized_study","article","10.1177/15209156251403555","41468099",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002507","HFpEF in Asia-Clinical Characterization and Therapeutic Strategies.","Tromp J","2026","JACC. Asia","narrative_review","article","10.1016/j.jacasi.2026.08.009","42762207",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002508","Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.","Jabbour S","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.1016/j.eprac.2024.05.005","38723893",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002509","Association of Periprocedural GLP-1 Receptor Agonist Therapy With 1-Year Major Adverse Cardiovascular Events After Carotid Artery Stenting: A Propensity-Matched Analysis.","Ghuman A","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.105387","42516849","PMC13404038",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002510","Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.","Cho YK","2026","Clinical and molecular hepatology","narrative_review","article","10.3350/cmh.2025.0744","41297910","PMC13129745",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002511","Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.","Wang H","2025","Nature communications","randomized_trial","article","10.1038/s41467-025-66167-z","41392086","PMC12717234","ClinicalTrials.gov:NCT05920889","S001115; S002078","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; research-article; Preprint; article; preprint"],["R0002512","Impact of Adjuvant GLP-1RA Treatment on the Adherence of Second-Generation Antipsychotics in Nondiabetic Adults.","Daggolu J","2026","Journal of clinical psychopharmacology","nonrandomized_study","article","10.1097/jcp.0000000000002145","41676872",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002513","Benefits of Supplementing a GLP-1 Type Medication With Physical Activity.","Ablah E","2025","American journal of health promotion : AJHP","other","article","10.1177/08901171251357130","40671361",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002514","Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP-1 receptor agonists: A prospective observational study.","Li XY","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70537","41635113",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0002515","Real-World Comparisons Between Glucagon-Like Peptide-1 Receptor Agonists and Other Glucose-Lowering Agents in Type 2 Diabetes: Retrospective Analyses of Cardiovascular and Economic Outcomes in England.","Connolly D","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01715-w","40117087","PMC12006603",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002516","Exendin-4(1-32)K-Capric Acid, a Glucagon-Like Peptide-1 Receptor Agonist, Suppresses Food Intake via Arcuate Pro-Opiomelanocortin Neurons.","Yoo S","2025","Endocrinology and metabolism (Seoul, Korea)","preclinical","article","10.3803/enm.2024.2185","40223290","PMC12230261",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002517","GLP-1 receptor agonist indications and prescriptions among adults who do and do not smoke.","Leavens ELS","2025","medRxiv : the preprint server for health sciences","commentary","article","10.1101/2025.08.12.25331941","40832400","PMC12363733",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; Letter; article; preprint"],["R0002518","GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases.","Yen TT","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.58205","41665904","PMC12892152",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002519","Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart.","Neumann J","2026","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics18040447","42076099","PMC13118858",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002520","Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease.","Go CC","2025","Journal of vascular surgery","nonrandomized_study","article","10.1016/j.jvs.2025.05.037","40484062",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0002521","The Effects of GLP-1 Receptor Agonists on Alzheimer's Pathophysiology: A Systematic Review","Corcoran E","2025","Research Square","systematic_review","preprint","10.21203/rs.3.rs-7631508/v1",null,null,"PROSPERO:CRD420251029748",null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0002522","Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function.","Ishimura A","2024","Drug discoveries & therapeutics","case_report","article","10.5582/ddt.2024.01061","39462543",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0002523","Accuracy of Large Language Model Responses Versus Internet Searches for Common Questions About Glucagon-Like Peptide-1 Receptor Agonist Therapy: Exploratory Simulation Study.","Tan SYT","2025","JMIR formative research","other","article","10.2196/78289","41284989","PMC12643393",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002524","Repurposing GLP-1 Receptor Agonists: A Perspective on Epigenetic Strategies to Combat Fibrosis and Hepatocellular Carcinoma in the Aged Liver.","Hanna S","2025","Cancers","other","article","10.3390/cancers17162600","40867230","PMC12384729",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0002525","Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network.","Conover MM","2025","Pharmacoepidemiology and drug safety","systematic_review","article","10.1002/pds.70087","39805811","PMC11730806",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0002526","GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review.","Pantazopoulos D","2025","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2025.112924","41022269",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0002527","SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome.","Gajjar A","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13081924","40868177","PMC12383900",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002528","Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis.","Orra SH","2025","BMC urology","systematic_review","article","10.1186/s12894-025-02005-0","41291666","PMC12752444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0002529","Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications.","Kofman K","2026","Canadian journal of diabetes","narrative_review","article","10.1016/j.jcjd.2026.03.008","41967795",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002530","Therapeutic Mechanisms of Resmetirom and Semaglutide in MASLD/MASH: A Review of Inflammatory and Fibrotic Metabolites.","Toshikuni N","2026","Metabolites","narrative_review","article","10.3390/metabo16080586","42646322","PMC13515630",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002531","Glucagon-Like Peptide-1 Receptor Agonists as a Non-surgical Alternative to Bariatric Surgery for Weight Loss: A Review.","Steven C","2026","Cureus","narrative_review","article","10.7759/cureus.100704","41635371","PMC12863638",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002532","Trends in Glucagon-like peptide-1 Receptor Agonists for Weight Loss Prior to Total Joint Arthroplasty","Playter K","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-7490872/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002533","The Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists on 24-Hour Urine Parameters: A Retrospective Cohort Study.","Schaub JA","2025","Kidney360","nonrandomized_study","article","10.34067/kid.0000000728","39918878","PMC12136646",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002534","Evaluating the Evolving Real-World Adverse Events of GLP-1RAs Using FDA Adverse Event Reporting System (FAERS).","Stone D","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70176","41797511","PMC13535732",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002535","The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis.","Xu Y","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-01633-8","40165263","PMC11959866",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0002536","Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.","Dhanapalaratnam R","2025","Journal of neurophysiology","other","article","10.1152/jn.00228.2024","39584713",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002537","Effectiveness of Pre-Transplant Dual GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy on All-Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target-Trial Emulation.","Huang YN","2026","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","nonrandomized_study","article","10.1002/advs.202518813","41387113","PMC12931237",null,"S002468","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002538","Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis.","Shokravi A","2025","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-025-02900-8","41029853","PMC12487346",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; other; review"],["R0002539","SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplantation: A Systematic Review and Meta-Analysis.","Lee SA","2026","Transplantation","systematic_review","article","10.1097/tp.0000000000005496","40702593",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002540","Safety and efficacy of glucagon-like peptide 1 receptor agonists in solid organ transplant recipients with diabetes mellitus: a systematic review and meta-analysis.","Usman M","2025","Kidney research and clinical practice","systematic_review","article","10.23876/j.krcp.24.271","40905039","PMC12611633",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review-article; review"],["R0002541","Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes.","Mahajan A","2026","ACR open rheumatology","nonrandomized_study","article","10.1002/acr2.90046","42415363","PMC13341954",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0002542","Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists in patients without obesity: a systematic review and meta-analysis of randomized controlled trials.","Waqas SA","2026","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-026-01969-6","42299230","PMC13264643",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review"],["R0002543","Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations.","Xu D","2022","Cardiovascular therapeutics","narrative_review","article","10.1155/2022/6820377","36474714","PMC9683988",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002544","Glucagon-Like Peptide-1 Receptor Agonists and Anesthesia-Are We Clearer on the Correct Approach?","Bloomgarden Z","2024","Journal of diabetes","commentary","article","10.1111/1753-0407.70041","39697053","PMC11656029",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002545","Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database.","Cazzola M","2024","The Journal of asthma : official journal of the Association for the Care of Asthma","nonrandomized_study","article","10.1080/02770903.2024.2372600","38913778",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002546","Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.","Laroche ML","2026","European journal of clinical pharmacology","nonrandomized_study","article","10.1007/s00228-026-04079-7","42168638","PMC13194321",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0002547","18 F-FDG PET/CT Five Days Post First Administration of Semaglutide : Side Effects in One Shot.","Triumbari EKA","2026","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000006360","41650160",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0002548","Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes.","Hoog MM","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01794-9","41066072","PMC12579026",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002549","Preoperative Glucagon-Like Peptide-1 Receptor Agonist Utilization and Association with Bariatric Surgery Outcomes.","AbuHasan Q","2025","Obesity surgery","other","article","10.1007/s11695-024-07651-1","39810030","PMC11835518",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; research-article; article"],["R0002550","Retrospective case-control study of pre-diagnosis observational and prescription data in Parkinson's disease.","Doherty P","2026","Scientific reports","nonrandomized_study","article","10.1038/s41598-026-55378-z","42286088","PMC13529696",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; Preprint; article"],["R0002551","GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation.","Chan SH","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.113073","41453566",null,null,"S002468","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002552","Liraglutide Causing Pancreatitis in an Indian Obese Female: A Case Report and Review of the Literature.","Singh J","2026","Current drug safety","case_report","article","10.2174/0115748863418018251111133620","42136236",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0002553","Implementation and evaluation of a pharmacist-led glucagon-like peptide-1 receptor agonist titration service in two primary care clinics.","Miller K","2025","Journal of the American Pharmacists Association : JAPhA","other","article","10.1016/j.japh.2025.102385","40044076",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002554","Sodium-Glucose Cotransporter 2 Inhibitors and Cancer Risk in Patients With Type 2 Diabetes Mellitus: An Active Comparator, New-User Cohort Study.","Li Y","2026","International journal of cancer","nonrandomized_study","article","10.1002/ijc.70642","42538609",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002555","Effectiveness of GLP-1 RAs and SGLT2 inhibitors in preventing T2DM in high-risk patients: an updated systematic review and meta-analysis.","Tsironikos GI","2025","Frontiers in clinical diabetes and healthcare","systematic_review","article","10.3389/fcdhc.2025.1694808","41451292","PMC12727544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0002556","Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.","Iwamoto Y","2026","Endocrine journal","case_report","article","10.1507/endocrj.ej26-0396","42732962",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002557","GLP-1 receptor agonists in the context of cancer: the road ahead.","Miousse IR","2025","American journal of physiology. Cell physiology","narrative_review","article","10.1152/ajpcell.00245.2025","40285503","PMC12109175",null,"S002389","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; research-article; article"],["R0002558","Racial/ethnic differences in the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for atherosclerotic cardiovascular disease (ASCVD) benefit in patients with type 2 diabetes.","Ahmed F","2025","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2025.2606551","41427774",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002559","Psyllium and Glucomannan as Viscous Fiber Modulators of the Gut-Microbiome-Incretin Axis: Molecular Links to Metabolic Inflammation, Barrier Function, and GLP-1 Receptor Agonist Therapy.","Yoon Y","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27146287","42511630","PMC13410363",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002560","Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies.","Zhong Y","2025","BMC gastroenterology","systematic_review","article","10.1186/s12876-025-04211-4","40847331","PMC12372225",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0002561","Glucagon-like peptide-1 receptor agonists and risk for cardiovascular events in older adults treated with levothyroxine: a target trial emulation.","Du F","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02971-7","41444586","PMC12729143",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Comparative Study; research-article; article"],["R0002562","Nonarteritic anterior ischemic optic neuropathy and glucagon-like peptide-1 receptor agonists: Evaluating a potential association.","Özbek L","2025","European journal of internal medicine","commentary","article","10.1016/j.ejim.2025.05.011","40404514",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002563","GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms.","Mullur N","2024","The Journal of endocrinology","narrative_review","article","10.1530/joe-24-0046","39145614","PMC11466209",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002564","Safety and effectiveness of GLP-1 receptor agonists and SGLT-2 inhibitors in liver transplant recipients with diabetes.","Mazzola A","2026","Clinics and research in hepatology and gastroenterology","nonrandomized_study","article","10.1016/j.clinre.2026.102899","42562072",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002565","GLP-1 Receptor Agonists in Heart Failure.","Rahmani AR","2025","Biomolecules","narrative_review","article","10.3390/biom15101403","41154632","PMC12562493",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002566","Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage.","Sa B","2026","Journal of psychiatric research","nonrandomized_study","article","10.1016/j.jpsychires.2026.01.042","41616750",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002567","Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.","Quan AT","2026","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2026.103466","42508090",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0002568","GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practice.","Gutiérrez-Medina S","2026","Obesity research & clinical practice","nonrandomized_study","article","10.1016/j.orcp.2026.05.007","42191517",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0002569","Modulation of the tumor microenvironment by incretins and glucagon: Metabolic and immune mechanisms (Review).","Hu M","2026","Experimental and therapeutic medicine","narrative_review","article","10.3892/etm.2026.13178","42199348","PMC13200260",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002570","Bimagrumab: Novel Medical Therapy for Inclusion Body Myositis, Sarcopenia, and Medication-Induced Lean Body Mass Loss.","Kaiser M","2025","Cardiology in review","other_trial","article","10.1097/crd.0000000000001113","41248895",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0002571","Evidence-based ranking of diabetes prevention in prediabetes: A comprehensive network meta-analysis of 378 randomised controlled trials.","Maria B","2026","Clinical and translational medicine","systematic_review","article","10.1002/ctm2.70829","42711998","PMC13554713","PROSPERO:CRD42023473875",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0002572","Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cataract.","Lin BH","2026","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2025.12.025","41456709",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002573","Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.","Lee YC","2025","American journal of kidney diseases : the official journal of the National Kidney Foundation","nonrandomized_study","article","10.1053/j.ajkd.2025.03.016","40311668",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0002574","Incretin-based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta-analysis of randomized controlled trials.","Costa TA","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16512","40497333",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Meta-Analysis; Journal Article; review"],["R0002575","GLP-1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation.","Wu H","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70847","42098911",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; article"],["R0002576","Pros and Cons of Early Treatment with GLP-1 Receptor Agonist and SGLT-2 Inhibitors for Youth with Type 2 Diabetes: A Narrative Review.","DeLacey SE","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-025-01823-7","41252112","PMC12847589",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002577","Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis.","de Faria Moraes B","2025","Drug and alcohol dependence","systematic_review","article","10.1016/j.drugalcdep.2025.112840","40845737",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002578","Real-World Utilisation, Efficacy, and Safety of Injectable GLP-1 Receptor Agonists: A Drug Use Evaluation in Singapore’s Largest Healthcare Cluster","Lene LJ","2024","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.173535301.14921524/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002579","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.","Tang H","2024","Movement disorders : official journal of the Movement Disorder Society","nonrandomized_study","article","10.1002/mds.29992","39189078","PMC11568939",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002580","Are All Incretin Therapies Equal for the Kidney? Comparative FAERS Analysis of Tirzepatide and Semaglutide","Gandhi A","2025","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202510.0154.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002581","Social Determinants of Health and GLP-1 RA Use Among Patients with Type 2 Diabetes and Stage 2 CKM: Insights from NHANES 2005–2020","Jian Q","2026","medRxiv","other","preprint","10.64898/2026.08.18.26360763",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0002582","Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.","Alfehaid L","2026","Expert opinion on drug safety","systematic_review","article","10.1080/14740338.2025.2465870","39964295",null,"PROSPERO:CRD42024585971",null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article; review"],["R0002583","Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes.","Krug I","2025","Nutrients","nonrandomized_study","article","10.3390/nu17233735","41374025","PMC12694361",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0002584","Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.","Kim Y","2026","Kidney research and clinical practice","other_trial","article","10.23876/j.krcp.26.272","42682157",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0002585","Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology.","Luo ZY","2025","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2024.2419989","39425661",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002586","What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs)? A Scoping Review.","Febrey S","2025","Health expectations : an international journal of public participation in health care and health policy","nonrandomized_study","article","10.1111/hex.70251","40227008","PMC11995417",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0002587","Efficacy of Metabolic and Bariatric Surgery Compared with GLP-1 Receptor Agonist Treatment in Preventing Mortality and Major Adverse Cardiac Events Among Individuals with Obesity and Type 2 Diabetes: A Systematic Review and Meta-analysis.","Chadwick J","2026","Obesity surgery","systematic_review","article","10.1007/s11695-026-08508-5","41697578","PMC13038674",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0002588","Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity.","O'Connor R","2026","Drug and therapeutics bulletin","narrative_review","article","10.1136/dtb.2025.000039","41513440",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002589","Heterogeneous treatment effects of GLP-1RA on kidney outcomes in patients with type 2 diabetes.","Xu Y","2026","Kidney international","nonrandomized_study","article","10.1016/j.kint.2026.06.041","42498061",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002590","Risk of depression with GLP-1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new-user, active-comparator cohort study.","Chang Y","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70175","41017578","PMC12673450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002591","MON-527 Association of Acute kidney injury with commonly prescribed glucagon-like peptide 1 receptor Agonists: A Pharmacovigilance Analysis",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12545745",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0002592","Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma.","Taşkaldıran I","2026","Acta diabetologica","case_report","article","10.1007/s00592-026-02702-8","42171706",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0002593","Effects of Glucagon-Like Peptide-1 Receptor Agonists After Treatment Withdrawal: A Systematic Review and Meta-Analysis.","Zhou L","2026","Journal of general internal medicine","systematic_review","article","10.1007/s11606-025-09950-4","41249646","PMC12960891",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0002594","Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database.","Osei SP","2024","Diagnostics (Basel, Switzerland)","nonrandomized_study","article","10.3390/diagnostics14242829","39767190","PMC11675942",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002595","GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.","King AC","2026","Journal of addiction medicine","randomized_trial","article","10.1097/adm.0000000000001565","40792626",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Observational Study; article"],["R0002596","Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence.","Krishnan S","2025","Journal of cardiovascular development and disease","other_trial","article","10.3390/jcdd12010019","39852297","PMC11766028",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0002597","Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.","Alkhezi OS","2023","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13543","36579723",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Network Meta-Analysis; article"],["R0002598","Glucagon-like peptide-1 agonists in Parkinson's disease: a meta-analysis.","Abdallah AK","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","systematic_review","article","10.1007/s10072-026-09238-3","42432163",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0002599","Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India.","Saxena A","2026","The Journal of the Association of Physicians of India","nonrandomized_study","article","10.59556/japi.74.1507","42543940",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0002600","Exenatide through PPARδ improved hepatic insulin resistance in patients of type 2 diabetes mellitus via suppressing pyroptosis.","Li X","2026","International immunopharmacology","preclinical","article","10.1016/j.intimp.2026.116416","41723896",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002601","Comment on Pradhan et al. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. Diabetes Care 2025;48:444-454.","Kornelius E","2025","Diabetes care","commentary","article","10.2337/dc25-0451","40690648",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0002602","Risk of thyroid cancer related to glucagon-like peptide-1 receptor agonists: A systematic review with meta-analysis of harms of randomized controlled trials.","Duchemin L","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16504","40468864",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0002603","Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling.","Yang B","2026","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/clinem/dgag383","42764204",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0002604","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes mellitus: friends or foes to bone health? a narrative review of clinical studies.","Al Refaie A","2025","Endocrine","preclinical","article","10.1007/s12020-025-04253-4","40342008","PMC12227486",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002605","Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.","Samanta A","2025","International ophthalmology clinics","randomized_trial","article","10.1097/iio.0000000000000541","39710901",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0002606","Commentary: association of glucagon-like peptide-1 receptor agonists with risk of cancers evidence from a drug target Mendelian randomization and clinical trials.","Yang Z","2025","International journal of surgery (London, England)","commentary","article","10.1097/js9.0000000000002617","40474819",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial"],["R0002607","Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review.","Wang L","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-01927-x","40859274","PMC12382109",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0002608","GLP-1 receptor agonists: Bridging diabetes, obesity, and periodontitis-A scoping review of emerging evidence.","Polymeri A","2026","Journal of periodontology","other_trial","article","10.1002/jper.70092","41711341","PMC13350402",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Scoping Review; review-article; article"],["R0002609","Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction.","Valente V","2026","International journal of heart failure","other_trial","article","10.36628/ijhf.2025.0111","41696054","PMC12901533",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002610","Glucagon-like peptide-1 receptor agonists and suicide risk in individuals with diabetes and Cannabis use disorder.","Dhruva Y","2025","Preventive medicine reports","nonrandomized_study","article","10.1016/j.pmedr.2025.103244","41050856","PMC12491714",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0002611","Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review.","De Oliveira-Gomes D","2025","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000001225","40305149",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0002612","Trends in nephrology: from \"supportive care\" to CKD combination therapy.","He K","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","narrative_review","article","10.1093/ndt/gfag003","41533660",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002613","Protecting the endocrine axis in immuno-oncology: GLP-1 receptor agonists as host-directed modulators in colorectal cancer.","Saghafi S","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","nonrandomized_study","article","10.1016/j.biopha.2025.118948","41496347",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0002614","Effects of GLP-1 receptor agonists on neurological complications of diabetes.","García-Casares N","2023","Reviews in endocrine & metabolic disorders","systematic_review","article","10.1007/s11154-023-09807-3","37231200","PMC10404567",null,"S000497","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review-article; article"],["R0002615","Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care.","Gupta N","2025","Cardiology and therapy","narrative_review","article","10.1007/s40119-025-00426-4","40643886","PMC12378854",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002616","The GLP-1 Agonist Exenatide Is Associated with Improved Adherence to Health Behavior and Lifestyle Treatment in Adolescents with Obesity: A Randomized Controlled Trial.","Stenlid R","2026","Obesity facts","randomized_trial","article","10.1159/000552826","42228680","PMC13395467",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0002617","Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.","Nishida K","2025","Clinical nutrition (Edinburgh, Scotland)","nonrandomized_study","article","10.1016/j.clnu.2025.06.011","40617160",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0002618","The fasting and the furious: reconciling fasting guidelines with glucagon-like peptide-1 receptor agonists, 'Sip-til-Send' policies and gastric ultrasound.","Sidhu NS","2025","Anaesthesia reports","commentary","article","10.1002/anr3.70015","40502386","PMC12150242",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002619","A Hypothesis That Glucagon-like Peptide-1 Receptor Agonists Exert Immediate and Multifaceted Effects by Activating Adenosine Monophosphate-Activate Protein Kinase (AMPK).","Schooling CM","2025","Life (Basel, Switzerland)","randomized_trial","article","10.3390/life15020253","40003662","PMC11857512",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; other; article"],["R0002620","Comparing Out-of-Pocket Costs and Health-Related Quality of Life Between Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.","Hu S","2025","Drug, healthcare and patient safety","nonrandomized_study","article","10.2147/dhps.s496619","40302900","PMC12039827",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002621","GLP-1 Receptor Agonists versus Bariatric Surgery: A Global Health Network Analysis of Panniculectomy Outcomes.","Braud SC","2026","Plastic and reconstructive surgery","nonrandomized_study","article","10.1097/prs.0000000000012955","41729134",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0002622","Racial and Ethnic Disparities in Medication Adherence Among Medicare Advantage Enrollees With Diabetes.","Essien UR","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2026.34846","42804695","PMC13595183",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002623","GLP-1 Receptor Agonists for the Prevention of New-Onset Heart Failure: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials.","Neves JS","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70043","41287923","PMC13008604",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review-article; review"],["R0002624","SAT-147 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Erectile Dysfunction and Testosterone Levels: A Systematic Review and Meta-Analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12545469",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0002625","Comparison of non-insulin glucose-lowering therapies on coronary atherosclerotic plaque progression in diabetes.","Liu R","2026","La Radiologia medica","nonrandomized_study","article","10.1007/s11547-026-02237-6","42496918",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Comparative Study"],["R0002626","Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.","Wang L","2025","Journal of the National Cancer Institute","nonrandomized_study","article","10.1093/jnci/djae260","39418202","PMC11884861",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002627","A Framework for Risk-Based Implementation of Combination Therapy in CKD: Who, Why, When, and How?","Yeung EK","2026","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.0000001158","42335037",null,"ClinicalTrials.gov:NCT06058585; ClinicalTrials.gov:NCT06268873; ClinicalTrials.gov:NCT06742723","S001518","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0002628","Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.","Shamim MA","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15777","39044306",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0002629","Systemic Metabolic and Skeletal Muscle-Related Profiles Associated with Annual Axial Elongation Across Optical Myopia-Control Strategies in Adolescents: A Retrospective Cohort Study.","Wang X","2026","Ophthalmology and therapy","nonrandomized_study","article","10.1007/s40123-026-01505-y","42771327",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002630","Response to Comment on Pradhan et al. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. Diabetes Care 2025;48:444-454.","Pradhan R","2025","Diabetes care","commentary","article","10.2337/dci25-0052","40690649",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0002631","The current and changing role of glucagon-like peptide-1 receptor agonists in knee osteoarthritis.","Holleman AD","2025","Osteoarthritis and cartilage open","commentary","article","10.1016/j.ocarto.2025.100611","40487803","PMC12139491",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002632","Glucagon-like peptide-1 receptor agonist use in patients with psoriasis is associated with lower incidence of atherosclerotic cardiovascular disease: A retrospective cohort study using TriNetX.","Sontam T","2025","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.06.022","40513888",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002633","Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study.","Lin CP","2025","Medicine","nonrandomized_study","article","10.1097/md.0000000000041243","39928811","PMC11813052",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0002634","Mechanism of action: Glucagon-like peptide-1 receptors in skin biology.","Mehta S","2026","Clinics in dermatology","other","article","10.1016/j.clindermatol.2026.08.004","42570708",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0002635","GLP-1 Receptor Agonists vs Alternatives for Alcohol Use Disorder: A Multi-Target Trial Emulation","Rodriguez PJ","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.06.07.25329184",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002636","Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes.","Kishimori T","2025","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.124.037510","39921523","PMC12074738",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0002637","Aspiration risk and strategic approach for patients receiving GLP-1 receptor agonists undergoing elective surgery.","Li J","2025","Current medical research and opinion","narrative_review","article","10.1080/03007995.2025.2494646","40241295",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002638","Efficacy of semaglutide in IgA nephropathy with obesity: a case report.","Li H","2026","BMC nephrology","case_report","article","10.1186/s12882-026-04784-6","41629851","PMC12955259",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002639","Impact of Glucagon-Like Peptide 1 Receptor Agonists on Tacrolimus Dose-to-Concentration Ratios in Solid Organ Transplantation.","Sweiss H","2025","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds25-0031","41522279","PMC12784424",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002640","Danuglipron and orforglipron engage GLP-1R through materially different interfaces: an unbiased molecular dynamics study","Oztekin A","2026","bioRxiv","other","preprint","10.64898/2026.09.30.754652",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0002641","Sustained Effects of Glucagon-Like Peptide-1 (GLP-1) Agonists on Blood Pressure in Obesity and Type 2 Diabetes: A Longitudinal Case Study.","Joseph J","2025","Cureus","case_report","article","10.7759/cureus.88893","40777719","PMC12329614",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002642","Exploring the effects of glucagon-like peptide-1 receptor agonists on ventricular arrhythmias: a propensity score-matched analysis.","Tan MC","2025","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","nonrandomized_study","article","10.1093/europace/euaf090","40314211","PMC12096155",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002643","Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.","Ostrominski JW","2026","JAMA cardiology","randomized_trial","article","10.1001/jamacardio.2026.3566","42747817","PMC13583892","ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; article"],["R0002644","Discovery and optimization of novel indolecarboxylic acid derivative as potent glucagon-like peptide‑1 receptor agonists.","Zhao W","2026","Molecular diversity","other","article","10.1007/s11030-025-11213-7","40366550",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002645","Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights.","Bin Dayel FF","2025","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare13222922","41302309","PMC12652781",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0002646","Metformin as a Cardioprotective Agent: New Life for an Old Drug?","Duran R","2026","Cardiology in review","other","article","10.1097/crd.0000000000001279","42048623",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002647","Efficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.","Pérez-Velasco MA","2025","Medicina clinica","nonrandomized_study","article","10.1016/j.medcli.2025.107019","40466271",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0002648","Spending on Glucagon-Like Peptide-1 Receptor Agonists Among US Adults.","Tsipas S","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.2964","40172891","PMC11966331",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002649","Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure.","Mortada I","2026","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/14791641261467888","42420805","PMC13346706",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0002650","SUN-665 Meta-Analysis of Psychiatric and Quality of Life Outcomes in Patients With Obesity and Diabetes Treated With Glucagon-Like Peptide 1 Receptor Agonists",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12543558",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0002651","Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence.","Stachteas P","2025","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm39691","40776973","PMC12326405",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002652","State of the Art Review: Glucagon-Like Peptide-1 in Obesity-Related Asthma.","Gomez DR","2025","Lung","narrative_review","article","10.1007/s00408-025-00861-z","41359186","PMC13379408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0002653","Glucagon-like Peptide-1 Receptor Agonists Are Associated With Improved Survival and Reduced Liver-Related Events in Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Liver Disease: A Large Real-World Retrospective Study.","Liu BD","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2025.04.017","40306364",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002654","GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study.","Faour O","2025","American journal of medicine open","nonrandomized_study","article","10.1016/j.ajmo.2025.100114","41473903","PMC12745096",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002655","Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland.","Łupina K","2026","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-026-02709-1","42142150","PMC13395827",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002656","Comprehensive drug safety assessment of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors: A Danish population-based active comparator new user cohort study.","Lund LC","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113341","42202888",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0002657","Use of GLP-1 receptor agonists and risks of suicide attempts or self-harm in patients with type 2 diabetes: a multicountry self-control case series study.","Peng ZY","2025","BMJ mental health","nonrandomized_study","article","10.1136/bmjment-2025-301635","40571427","PMC12207151",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0002658","Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach.","Henney AE","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70169","41058240","PMC12673470",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0002659","GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation.","Migliorisi G","2025","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2025.1610368","40735319","PMC12306662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002660","Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity.","Lin HT","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.21016","40663350",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002661","Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.","Garagoli F","2025","Endocrinologia, diabetes y nutricion","systematic_review","article","10.1016/j.endien.2025.501562","40413013",null,"PROSPERO:CRD42024565567",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002662","Author's response to the Letter to the Editor \"Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy\".","Agarwal S","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2025.109143","40721363",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0002663","Beyond Appetite: An MBM-Based Hypothesis for Dual-Action Anti-Obesity Pharmacotherapy Targeting Both Sides of the Mass Balance Equation","Manninen AH","2026","Preprints.org","other_trial","preprint","10.20944/preprints202606.0369.v2",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","5","FALSE","Preprint; preprint"],["R0002664","Efficacy of SGLT2i and GLP-1RA in Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials.","Zhao H","2026","Current medicinal chemistry","systematic_review","article","10.2174/0109298673349221251203101854","42099143",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0002665","Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial.","Del Prato S","2026","Annals of internal medicine","randomized_trial","article","10.7326/annals-25-05602","42184419",null,"ClinicalTrials.gov:NCT05433584","S000778","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Comparative Study; Equivalence Trial; article"],["R0002666","Expanded discussion of limitations for impact of glucagon-like peptide-1 receptor agonist use association with decreased risk of adverse obstetrical outcomes.","Imbroane MR","2025","American journal of obstetrics and gynecology","commentary","article","10.1016/j.ajog.2025.05.029","40466896",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002667","Glucagon-like peptide-1 receptor agonist versus sodium-glucose cotransporter-2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity.","Bowe A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70219","41165079",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0002668","Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.","Nauck MA","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70613","41757397","PMC13071187",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0002669","GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review.","Jarade C","2024","EClinicalMedicine","narrative_review","article","10.1016/j.eclinm.2024.102789","39246720","PMC11377134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002670","Personalizing cardiovascular prevention in chronic kidney disease: an operational framework for risk-treatment mapping.","Zoccali C","2026","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2026.107117","42580908",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002671","Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review.","Vekic J","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01828-2","41493731","PMC13000107",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0002672","Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.","Khan BW","2026","Naunyn-Schmiedeberg's archives of pharmacology","systematic_review","article","10.1007/s00210-026-05809-5","42608559",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0002673","Influence of Combination Therapy with Dulaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP Study.","Muta Y","2025","The Tokai journal of experimental and clinical medicine","other","article",null,"40105226",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002674","Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.","Wang Z","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.53323","41511769","PMC12789952",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0002675","Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity.","Correra A","2026","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph19020297","41754837","PMC12943345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002676","Refining glucagon-like peptide-1 receptor agonist therapy in polycystic ovary syndrome: addressing phenotypic, racial, and pharmacologic heterogeneity.","Jin S","2025","Fertility and sterility","commentary","article","10.1016/j.fertnstert.2025.05.160","40414482",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0002677","Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","Jaradat JH","2025","Cureus","systematic_review","article","10.7759/cureus.96071","41356998","PMC12676983",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002678","Should glucagon-like peptide 1 receptor agonists be withheld during the preoperative period?","Mishra S","2025","Cleveland Clinic journal of medicine","other","article","10.3949/ccjm.92a.24110","40169221",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002679","Letter to the Editor \"Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy\".","Borrás-Blasco J","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2025.109134","40750509",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0002680","8707 Are We Adequately Prescribing Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) Or Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) In Patients With Type 2 Diabetes Mellitus (T2DM) And Established Atherosclerotic Cardiovascular Disease (ASCVD) Or Chronic Kidney Disease (CKD) In An Outpatient Setting: A Community Center Experience",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455273",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0002681","Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.","Psaltis JP","2025","Medicinal research reviews","other_trial","article","10.1002/med.22070","39139038","PMC11638809",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0002682","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration.","Shor R","2025","JAMA ophthalmology","nonrandomized_study","article","10.1001/jamaophthalmol.2025.1455","40471562","PMC12142475",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002683","Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations.","Shen B","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-01878-3","40830891","PMC12366118",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0002684","SUN-114 Comparative Analysis of Glucagon-Like Peptide-1 Receptor Agonists, Metformin, and Inositol in Managing Polycystic Ovary Syndrome: A Network Meta-Analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12545136",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0002685","Temporally Phenotyping GLP-1RA Case Reports with Large Language Models: A Textual Time Series Corpus and Risk Modeling.","Kumar S","2026","medRxiv : the preprint server for health sciences","case_report","article","10.64898/2026.04.05.26350197","42006776","PMC13086104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; article; preprint"],["R0002686","Healthcare Cost Trends in New Users of SGLT-2i, DPP-4i and GLP-1 RA for Type 2 Diabetes: An Observational Longitudinal Study.","Durand CP","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70923","42289317","PMC13449046",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0002687","Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.","Malhotra A","2026","Contemporary clinical trials communications","protocol","article","10.1016/j.conctc.2026.101660","42383207","PMC13316212","ClinicalTrials.gov:NCT06649045","S000603","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0002688","Reframing the role of glucagon-like peptide 1 receptor agonists in cardiovascular medicine.","Inciardi RM","2025","ESC heart failure","commentary","article","10.1002/ehf2.15123","39410712","PMC11911606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002689","Weight Loss Dynamics and Health Burden Changes with Tirzepatide versus Semaglutide","Venkatakrishnan A","2025","medRxiv","nonrandomized_study","preprint","10.64898/2025.11.30.25341294",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002690","Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.","Almeida OP","2025","Current opinion in psychiatry","nonrandomized_study","article","10.1097/yco.0000000000001001","40009763",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0002691","Gastrointestinal Motility Effects of GLP-1 Receptor Agonists.","Bellavance D","2025","Current gastroenterology reports","narrative_review","article","10.1007/s11894-025-00995-3","40622491",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002692","Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.","Rivera FB","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15529","38505997",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Preprint; preprint; article"],["R0002693","Gastric ultrasound: a consistent tool for anesthesiologists amid the shifting sands of perioperative glucagon-like peptide-1 receptor agonist management.","Girón-Arango L","2025","Canadian journal of anaesthesia = Journal canadien d'anesthesie","commentary","article","10.1007/s12630-025-03047-6","41493753",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002694","Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.","Chou OH","2025","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.123.034175","40401622","PMC12229098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0002695","Primary cilia regulate GLP-1 signaling in pancreatic β cells.","Melena I","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.02.22.707280","41757129","PMC12934674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0002696","Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration.","Allan KC","2025","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2025.01.016","39863057",null,null,"S002229","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002697","Novel Use of Glucagon-Like Peptide-1 (GLP-1) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists in Maturity-Onset Diabetes of the Young (MODY).","Hilal A","2025","Cureus","nonrandomized_study","article","10.7759/cureus.94882","41262822","PMC12624097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002698","Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap.","Quimbayo-Cifuentes AF","2026","Cureus","randomized_trial","article","10.7759/cureus.104259","41909366","PMC13031337",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; editorial"],["R0002699","Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy.","Abu-Freha N","2025","Endoscopy","nonrandomized_study","article","10.1055/a-2419-3875","39389565",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0002700","Can GLP-1RAs redefine transplantation standard of care?","Almalki BA","2025","Trends in pharmacological sciences","narrative_review","article","10.1016/j.tips.2025.08.013","40973569",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0002701","Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.","Liang Y","2024","Endocrine connections","nonrandomized_study","article","10.1530/ec-24-0404","39404734","PMC11623261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002702","Should glucagon-like peptide 1 receptor agonists be recommended for routine use before metabolic and bariatric surgery in adolescents?","Ng NBH","2025","The Journal of pediatrics","commentary","article","10.1016/j.jpeds.2025.114617","40286842",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002703","Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care 2025;48:489-493.","Chang YT","2025","Diabetes care","systematic_review","article","10.2337/dc25-0896","40834250",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; review"],["R0002704","Correction: Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Atrial Fibrillation in Adults with Diabetes: A Real-World Study.","Xu Y","2025","Journal of general internal medicine","notice","article","10.1007/s11606-025-09417-6","40281278",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0002705","Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes.","Kanbay M","2025","Clinical kidney journal","narrative_review","article","10.1093/ckj/sfaf351","41409228","PMC12706267",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002706","Diet Quality and Micronutrient Intake among United States Adults Eligible for GLP-1 Receptor Agonist Antiobesity Medications: A Nationally Representative Analysis.","Babazadeh D","2026","The Journal of nutrition","other","article","10.1016/j.tjnut.2026.101753","42520970",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002707","Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.","Noh Y","2025","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-24-03420","40658955",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002708","Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists.","Tanasescu MD","2026","Life (Basel, Switzerland)","randomized_trial","article","10.3390/life16050756","42195313","PMC13208886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0002709","Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis.","Wen Z","2025","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2025.111999","39828025",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0002710","Glucagon-like peptide-1 receptor agonists and the eye.","Zhang DL","2025","Current opinion in ophthalmology","narrative_review","article","10.1097/icu.0000000000001137","40145579",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002711","Suppressing appetites, doping virtue?","Jesudason E","2026","Journal of medical ethics","other","article","10.1136/jme-2026-111799","41781266",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002712","Glucagon-like peptide-1 receptor agonists for weight loss: Consider the case for selective pharmacotherapy.","Li YR","2025","Australian journal of general practice","other","article","10.31128/ajgp-06-23-6877","40174616",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002713","Effects of Glucagon-Like Peptide-1 Receptor Agonist on Facial Landmarks.","Chen TH","2026","Ophthalmic plastic and reconstructive surgery","nonrandomized_study","article","10.1097/iop.0000000000003070","41022041",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002714","Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis.","Zheng H","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1942151","42745769","PMC13574646","PROSPERO:CRD420251231137",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0002715","The Therapeutic Potential of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Peripheral Neuropathy.","Panou T","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-025-01712-z","40153231","PMC12085435",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002717","Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis.","Siranart N","2025","Journal of Crohn's & colitis","systematic_review","article","10.1093/ecco-jcc/jjaf193","41212197",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0002718","Information pharmacists assist in the construction of GLP-1RA prescription review rules in a tertiary hospital in China.","Zhou L","2025","BMC health services research","nonrandomized_study","article","10.1186/s12913-025-13377-2","41034888","PMC12487512",null,"S002468","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002719","Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Gao W","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s580095","41907103","PMC13023393","PROSPERO:CRD42024582164",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002720","Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.","Oya J","2025","Journal of diabetes investigation","other","article","10.1111/jdi.14391","39707717","PMC11970300",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002721","Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.","Berman C","2023","TouchREVIEWS in endocrinology","other_trial","article","10.17925/ee.2023.19.1.38","37313232","PMC10258616",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002722","GLP-1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity.","Bucci T","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16238","39930557",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002723","Liraglutide upregulates the Cftr gene and regulates the mucus transcriptome profile in Brunner's glands in mice.","Voetmann LM","2025","Clinical and translational medicine","preclinical","article","10.1002/ctm2.70510","41146523","PMC12559683",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002724","Impact of GLP-1 receptor agonist-induced weight loss on 22 cancers in the next ten years using a Markov state-transition model - A UK weight and wellness cancer landscape analysis.","Dong J","2025","Cancer epidemiology","nonrandomized_study","article","10.1016/j.canep.2025.102837","40413897",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0002725","Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.","Khan SA","2026","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-026-10171-w","42570075",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002726","Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes.","Cheng CY","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000214509","41370744",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002727","Long-acting management of diabetes and associated complications using an injectable thermosensitive hydrogel incorporating IgG-conjugated GLP-1RA.","Wang H","2026","Theranostics","preclinical","article","10.7150/thno.120844","41356183","PMC12680532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002728","Identification and functional characterization of a novel mutation in the NEUROD1 gene in a Chinese family with maturity-onset diabetes of the young.","Li J","2026","Acta diabetologica","case_report","article","10.1007/s00592-026-02731-3","42329280","PMC13534152",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0002729","Response to Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care 2025;48:489-493.","Lee MMY","2025","Diabetes care","systematic_review","article","10.2337/dci25-0060","40834256",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; review"],["R0002730","Glucagon-like peptide-1 receptor agonists inhibit the progression of malignant pleural effusion in obese mice by regulating the metabolism of pleural effusion.","Shao MM","2025","Journal of translational medicine","preclinical","article","10.1186/s12967-025-06875-8","40781724","PMC12333053",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002731","Insomnia, Sleep, and the Use of Sedative-Hypnotic Drugs: Practical Notes.","Andrade C","2026","The Journal of clinical psychiatry","other","article","10.4088/jcp.26f16467","42207990",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002732","Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: A meta-analysis of eleven cardiovascular outcome trials.","Kang YM","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16424","40342232",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; article"],["R0002733","The future of glucagon-like peptide-1 receptor agonists in cardiovascular-kidney-metabolic diseases considerations from the ERA Diabesity Working Group.","Trillini M","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other","article","10.1093/ndt/gfaf008","39799384",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002734","Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study.","Trenas A","2025","European journal of internal medicine","nonrandomized_study","article","10.1016/j.ejim.2025.06.007","40518344",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002735","A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.","Hu EH","2024","Medicina (Kaunas, Lithuania)","systematic_review","article","10.3390/medicina60030357","38541083","PMC10972401",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Review; review-article; review"],["R0002736","The importance of treatment sequencing with SGLT2 inhibitors and GLP-1 receptor agonists combination for kidney function preservation in type 2 diabetes.","Morieri ML","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70445","41480667",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002737","GLP-1 receptor agonist treatment in women with polycystic ovary syndrome-a systematic review and meta-analysis.","Forslund M","2026","European journal of endocrinology","systematic_review","article","10.1093/ejendo/lvag033","41701618",null,"PROSPERO:CRD42024535096",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002738","Standard of Care for Chronic Kidney Disease: The Four Pillars of Pharmacotherapy - Implications for Nephrology Nursing Practice.","Laub MR","2026","Nephrology nursing journal : journal of the American Nephrology Nurses' Association","nonrandomized_study","article",null,"42742304",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; Review; article"],["R0002739","Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.","Kishimori T","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-06245-w","40594279","PMC12217050",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Comparative Study; research-article; article"],["R0002740","Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful?","Bahit MC","2025","Polish archives of internal medicine","other","article","10.20452/pamw.16987","40196964",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002741","Correction: Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.","Khatami S","2026","Cardiovascular toxicology","notice","article","10.1007/s12012-026-10183-y","42747619","PMC13582104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0002742","Navigating compounded semaglutide: what health care providers need to know.","Liu G","2025","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2025.89787","40966636",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0002743","Glucagon-Like Peptide-1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes.","Kuo CC","2025","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.18502","39791391",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002744","Searching for New Pharmacological Treatments of Alcohol Use Disorder (AUD): Focus on GLP-1 Receptor Agonists.","Zawilska JB","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27104502","42196481","PMC13206968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002745","The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study.","Gameil MA","2024","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-024-01526-2","39633496","PMC11616335",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002746","Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study.","Karacabeyli D","2024","PloS one","nonrandomized_study","article","10.1371/journal.pone.0308533","39116084","PMC11309412",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002747","Comparing Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Metabolic Bariatric Surgery: A Systematic Review and Meta-Analysis.","Shekouh D","2026","Obesity surgery","systematic_review","article","10.1007/s11695-026-08500-z","41644868",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; Review; review"],["R0002748","Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials.","Hung CM","2026","International journal of molecular sciences","systematic_review","article","10.3390/ijms27062619","41898482","PMC13026302","PROSPERO:CRD420261282728",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; research-article; review"],["R0002749","Anti-obesity medications in children and adolescents: blood pressure and chronic kidney disease implications.","Clement MA","2026","Pediatric nephrology (Berlin, Germany)","narrative_review","article","10.1007/s00467-026-07293-8","42033464",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002750","Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists.","Chen J","2025","Diabetes & metabolism","other_trial","article","10.1016/j.diabet.2025.101641","40127835",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0002751","Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability.","Cook G","2026","Journal of medical Internet research","randomized_trial","article","10.2196/104227","42709474","PMC13598464",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0002752","Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease.","Zaher A","2025","Przeglad gastroenterologiczny","narrative_review","article","10.5114/pg.2025.151891","40620309","PMC12224265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002753","Utilization of Glucagon-Like Peptide-1 Receptor Agonist at the Time of Total Hip Arthroplasty for Patients Who Have Morbid Obesity.","Kim BI","2025","The Journal of arthroplasty","randomized_trial","article","10.1016/j.arth.2024.12.008","39662850",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002754","From insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals.","Teofilović B","2026","Current medical research and opinion","narrative_review","article","10.1080/03007995.2026.2727202","42690722",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002755","Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.","Alawad AO","2026","Therapeutic advances in endocrinology and metabolism","other_trial","article","10.1177/20420188261469947","42534427","PMC13420054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; review"],["R0002756","Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers.","Zhang J","2026","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2026.178921","42070764",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002757","Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis.","Alrasheed T","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1734549","41625236","PMC12852008","PROSPERO:CRD420251157476",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0002758","Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes in Orthopaedic Surgery: A Scoping Review of Perioperative and Recovery Outcomes.","Strickler I","2026","The Journal of the American Academy of Orthopaedic Surgeons","nonrandomized_study","article","10.5435/jaaos-d-25-01571","41930687",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Scoping Review; article"],["R0002759","Semaglutide Decreases Risk of Non-Arteritic Anterior Ischemic Optic Neuroapthy in Type 2 Diabetic Patients.","Lieberman RA","2026","Military medicine","nonrandomized_study","article","10.1093/milmed/usaf522","41217382",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0002760","Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database.","Kim TH","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16376","40176478",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002761","Echocardiographic evaluation and clinical implications of cardiac remodeling in obesity.","Okushi Y","2026","Journal of echocardiography","narrative_review","article","10.1007/s12574-026-00721-6","41701436",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002762","Assessment of community awareness and attitude about the use of GLP 1 agonists as a treatment for obesity in Saudi Arabia: Cross-sectional study.","Abualhommos AK","2026","Medicine","other","article","10.1097/md.0000000000046957","41517730","PMC12795086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002763","Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study.","Younis A","2026","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2026.113083","41544899",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0002764","Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions.","Hajibandeh S","2026","Journal of the American Pharmacists Association : JAPhA","randomized_trial","article","10.1016/j.japh.2026.103117","42025961",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0002765","An overview of the role of platelets in vascular disease associated with diabetes mellitus.","Panou T","2026","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-026-00760-9","41926072",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002766","GLP1R expression and Parkinson's disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes.","Woo KA","2026","Brain : a journal of neurology","nonrandomized_study","article","10.1093/brain/awag130","41967915",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002767","Med14 phosphorylation shapes genomic response to GLP-1 agonists.","Van de Velde S","2026","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.2536772123","41779793","PMC12974444",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002768","Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals.","Ahuja A","2026","Cardiovascular diabetology. Endocrinology reports","systematic_review","article","10.1186/s40842-026-00311-6","42316363","PMC13281493","PROSPERO:CRD420261305875",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002769","Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes.","Hoog MM","2026","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2026.32.10.1173","42808550","PMC13621902",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002770","Combination pharmacotherapy in type 2 diabetes and chronic kidney disease: translating evidence into clinical practice.","Lovshin JA","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","narrative_review","article","10.1093/ndt/gfag136","42611042","PMC13655459",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; article"],["R0002771","Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study.","Titus J","2025","Drug safety","nonrandomized_study","article","10.1007/s40264-025-01558-1","40587039",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002772","Efficacy and Safety of Semaglutide in Patients with Polycystic Ovary Syndrome: A Scoping Review.","La Vignera S","2026","Biomedicines","nonrandomized_study","article","10.3390/biomedicines14081845","42652226","PMC13510204",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0002773","Semaglutide exerts anti-pulmonary fibrosis effects by inhibiting cellular senescence through activation of the Sirt1/HSF1/HSPs pathway.","Qian Z","2026","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2026.118172","42315078",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002774","Ferroptosis and pyroptosis in diabetes mellitus: emerging therapeutic potential of GLP-1 receptor agonists.","Panou T","2025","Frontiers in clinical diabetes and healthcare","narrative_review","article","10.3389/fcdhc.2025.1657710","41244507","PMC12614075",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002775","Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review.","Stretton B","2023","Internal medicine journal","systematic_review","article","10.1111/imj.16126","37189293",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Meta-Analysis; Journal Article; review"],["R0002776","The GLP-1 analog, exendin-4, improves bone material properties and strength through a central relay in ovariectomized mice.","Mermet M","2025","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00086.2025","40789661","PMC7618104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002777","Promising results but caution needed in GLP-1RA large scale epidemiology.","Deo SV","2025","Trends in endocrinology and metabolism: TEM","randomized_trial","article","10.1016/j.tem.2025.03.015","40280862",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0002778","Response to: \"Comment on: Association between Glucagon-Like Peptide 1 Receptor Agonists Exposure and Intraocular Pressure Change\".","Hallaj S","2025","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2024.10.021","39486630","PMC11960104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article-commentary; article"],["R0002779","Impact of glucagon-like peptide-1 receptor agonists on postoperative outcomes following ankle fracture open reduction and internal fixation.","Morningstar J","2025","The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons","nonrandomized_study","article","10.1053/j.jfas.2025.05.002","40345639",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0002780","GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.","Zhang J","2026","Metabolism: clinical and experimental","systematic_review","article","10.1016/j.metabol.2025.156433","41207615",null,"PROSPERO:CRD420251088042",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0002781","[Diabetes mellitus: new insights and developments].","Jagroep ST","2026","Nederlands tijdschrift voor tandheelkunde","narrative_review","article","10.5177/ntvt.2026.06.25097","42267501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0002782","Phyllanthus niruri niosomes ameliorate obesity-induced hepatic steatosis in rats via modulating MALAT1/miR-206/GLP-1R signaling and hepatic lipid metabolism.","Khater SI","2026","Biological research","preclinical","article","10.1186/s40659-026-00682-1","42045980","PMC13130705",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002783","Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review.","El-Solh AA","2025","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2024.2437525","39621418",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0002784","SGLT2 inhibitors, GLP-1 RAs, and DPP4 inhibitors and the risk of hypomagnesemia in type 2 diabetes: A target trial emulation.","Shao SC","2026","PLoS medicine","nonrandomized_study","article","10.1371/journal.pmed.1004968","41790761","PMC12987583",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0002785","Time to Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists Versus Comparators in People with Type 2 Diabetes Treated with Metformin.","Ostrominski JW","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01751-6","40402403","PMC12182540",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002786","GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.","Boccatonda A","2026","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2026.113271","42009258",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002787","The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial.","Lehenbauer KS","2025","Heart failure reviews","randomized_trial","article","10.1007/s10741-025-10579-y","41370018",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0002788","Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study.","Oe Y","2025","Therapeutic advances in endocrinology and metabolism","other_trial","article","10.1177/20420188251378216","40979838","PMC12444058",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0002789","Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review.","Joshi N","2024","Annals of medicine and surgery (2012)","narrative_review","article","10.1097/ms9.0000000000002712","39649934","PMC11623894",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002790","Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta-analysis.","Chen SH","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70503","41588709","PMC12992183",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; Comparative Study; research-article; review"],["R0002791","Cost-Effectiveness of Obesity Treatments: Glucagon-Like Peptide-1 Receptor Agonists, Endoscopic Sleeve Gastroplasty, and Metabolic/Bariatric Surgery.","Huh YJ","2025","Journal of metabolic and bariatric surgery","other_trial","article","10.17476/jmbs.2025.14.2.97","40917206","PMC12411144",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002792","Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome and Alström Syndrome.","Dauleh H","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf266","41312179","PMC12647937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002793","Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model.","Bosch R","2024","CPT: pharmacometrics & systems pharmacology","other","article","10.1002/psp4.13183","38867373","PMC11533103",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002794","Potential Benefits of Thiazolidinediones in Combination With Glucagon-Like Peptide-1 Receptor Agonists.","Florez H","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.2587","40163124",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002795","Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study.","Alkhezi O","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1805015","41970978","PMC13061728",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0002796","The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025","Falster MO","2025","medRxiv","other","preprint","10.1101/2025.10.30.25339120",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0002797","Primary Prevention of CKD for Heart and Kidney Health: Ready for Primetime?","Dorjee T","2026","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.0000001170","42545745",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0002798","The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity.","Scragg J","2025","Med (New York, N.Y.)","narrative_review","article","10.1016/j.medj.2025.100805","40834863",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0002799","Distributional Diagnosis and Calibration with Negative Controls for Outcome-wide Real-world Evidence.","Wang H","2026","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.64898/2026.07.08.26357550","42528508","PMC13409211",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0002800","To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists.","Hunter Guevara LR","2024","Journal of neurosurgical anesthesiology","narrative_review","article","10.1097/ana.0000000000000985","39082303",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002801","The Role of Exenatide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, in Idiopathic Intracranial Hypertension and Polycystic Ovary Syndrome: A Case Report.","Nicolaou D","2025","Cureus","case_report","article","10.7759/cureus.93846","41054431","PMC12496463",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002802","Impact of GLP-1 Agonist on Surgical Wound Complications after Plastic and Reconstructive Surgery: A Propensity-Matched Cohort Large Database Analysis.","Lee CC","2026","Plastic and reconstructive surgery","nonrandomized_study","article","10.1097/prs.0000000000012703","41364427",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002803","Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence.","Bidesie J","2026","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.70256","42399213","PMC13535703",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; Review; article"],["R0002804","Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists.","Spinelli KJ","2025","American journal of medicine open","nonrandomized_study","article","10.1016/j.ajmo.2025.100100","40496649","PMC12151216",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002805","The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.","Roskoski R","2026","Pharmacological research","narrative_review","article","10.1016/j.phrs.2026.108365","42556625",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002806","Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.","Drucker DJ","2024","Diabetes care","narrative_review","article","10.2337/dci24-0003","38843460",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0002807","A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder.","Zheng YJ","2025","Acta neuropsychiatrica","systematic_review","article","10.1017/neu.2025.6","39969054","PMC13130248",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0002808","Enrollment of Females in Randomized Trials for Glucagon-Like Peptide 1 Receptor Agonists: A Systematic Review.","Rivera FB","2024","JACC. Advances","systematic_review","article","10.1016/j.jacadv.2024.101386","39583870","PMC11585747",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0002809","GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 Diabetes","Tirumalasetty MB","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.07.29.26359248",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002810","Liraglutide","Cerillo JL","2024","StatPearls Publishing, Treasure Island (FL)","other","article",null,"39383283",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0002811","Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future.","O'Neill ES","2024","Plastic and reconstructive surgery. Global open","other","article","10.1097/gox.0000000000005516","38268718","PMC10807879",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002812","Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Han S","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70692","41852258",null,"PROSPERO:CRD42024546896",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0002813","Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis.","Bayoumy AB","2025","Journal of Crohn's & colitis","systematic_review","article","10.1093/ecco-jcc/jjaf181","41071055","PMC12668684",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002814","Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes.","Sun M","2025","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2025-004902","40695613","PMC12306345",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; research-article; article"],["R0002815","<span data-teams=\"true\">Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs","Labate AM","2026","Preprints.org","systematic_review","preprint","10.20944/preprints202609.1706.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0002816","Are we at risk of increasing sarcopenia? Implications for osteoarthritis and osteoporosis.","Pan F","2026","Best practice & research. Clinical rheumatology","narrative_review","article","10.1016/j.berh.2026.102204","42827061",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002817","Exendin-4, a glucagon-like peptide-1 receptor agonist, regulates ductus arteriosus by vasodilation and anti-remodeling through the PKA pathway.","Liu YC","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.177106","39515563",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002818","GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial.","Ji L","2026","Cell reports. Medicine","randomized_trial","article","10.1016/j.xcrm.2026.102743","41956096","PMC13130691","ClinicalTrials.gov:NCT06256536","S002782","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0002819","Obstructive Sleep Apnoea and Atrial Fibrillation: Current Evidence and Emerging Research Directions.","Basiukiewicz P","2026","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm50804","42694604","PMC13540011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002820","Association of glucagon-like peptide-1 receptor agonists and seven common mental disorders: A drug target and mediation Mendelian randomization.","Zhang Z","2025","Journal of affective disorders","systematic_review","article","10.1016/j.jad.2025.119509","40447157",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0002821","Targeting the cardiohepatic-metabolic axis: GLP-1-based and incretin multi-agonist therapies in MASH.","Zhang YW","2026","British journal of clinical pharmacology","other_trial","article","10.1002/bcp.70828","42755225",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0002822","Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.","British Medical Journal Publishing Group","2025","BMJ (Clinical research ed.)","notice","article","10.1136/bmj.r845","40294951","PMC12036536",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; article"],["R0002823","Choice of Insulin Coformulations: Biphasic Insulin Versus Insulin-GlP1RA.","Kalra S","2025","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.24-61","40500836",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002824","Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes.","Graham TE","2025","Diabetes care","randomized_trial","article","10.2337/dc25-1753","41264828","PMC12635876",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; other; article"],["R0002825","Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.","Feng Z","2023","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2023.1226778","37621313","PMC10445164",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002826","GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites.","Gong B","2026","Nutrients","nonrandomized_study","article","10.3390/nu18030531","41683353","PMC12899774",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002827","Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management.","Carlson TL","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102287","41270831","PMC12719563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0002828","GLP1-RAs: long-term use versus discontinuation events of an emerging therapy for obesity and cardiovascular diseases.","Salerno ENM","2026","Current problems in cardiology","narrative_review","article","10.1016/j.cpcardiol.2025.103213","41297647",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002829","Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on \"time in range\" in patients with type 2 diabetes.","Chen Y","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1370594","38515845","PMC10955089","ChiCTR:ChiCTR2300073697",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002830","Obesity and Glucagon-Like Peptide-1 Receptor Agonists.","Celletti F","2025","JAMA","other","article","10.1001/jama.2024.25872","39693101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002831","Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis.","Chen W","2025","Clinical nutrition (Edinburgh, Scotland)","systematic_review","article","10.1016/j.clnu.2025.10.006","41187492",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0002832","Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland.","Nowak K","2025","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare13222874","41302262","PMC12652702",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002833","Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning.","Zaman W","2026","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2026.2676109","42138103",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0002834","Short-Term Complications of Preoperative Weight Loss Strategies in Total Knee Arthroplasty: Bariatric Surgery Versus Glucagon-Like Peptide-1 Receptor Agonists.","Sharma A","2026","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2025.08.073","40912337",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0002835","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Nontraumatic Intracerebral Hemorrhage in Patients With Type 2 Diabetes.","Pasi M","2025","Stroke","nonrandomized_study","article","10.1161/strokeaha.125.050972","40469023",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002836","Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review.","Ciarloni A","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14040778","42072319","PMC13114086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002837","GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity.","Abasheva D","2024","Clinical kidney journal","other_trial","article","10.1093/ckj/sfae296","39583142","PMC11581768",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0002838","GYG1 as a Dual Biomarker of Glucagon-Like Peptide-1 Receptor Agonist Weight-Loss Response: Findings from an Integrative Multi-Omics Substudy of a Phase II Trial.","Li L","2026","Endocrinology and metabolism (Seoul, Korea)","other_trial","article","10.3803/enm.2025.2641","41634531",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0002839","Neuroprotective strategies for cognitive decline in type 2 diabetes.","Cimini FA","2026","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2026.04.003","42055924",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002840","Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol.","Freet CS","2025","Research square","protocol","article","10.21203/rs.3.rs-6666196/v1","40502777","PMC12154142","ClinicalTrials.gov:NCT06548490","S001579","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Preprint; preprint"],["R0002841","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.","Moiz A","2025","Annals of internal medicine","systematic_review","article","10.7326/annals-24-01590","39761578",null,"PROSPERO:CRD42024505558",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0002842","Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.","Al-Badri M","2025","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.70054","39853913","PMC11757277",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002843","Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.","Rudofsky G","2025","Advances in therapy","nonrandomized_study","article","10.1007/s12325-024-03000-x","39636564","PMC11787244",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0002844","Association Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Atrial Fibrillation Adverse Events: A Systematic Review and Meta-Analysis of Randomized Trials.","Aiwuyo HO","2026","Cureus","systematic_review","article","10.7759/cureus.107195","42153045","PMC13180454",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002845","The Rise in Glucagon-Like Peptide-1 Receptor Agonist Related Calls to United States Poison Centers",null,"2024","European journal of public health","other","article",null,null,"PMC11516913",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0002846","Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: systematic review and meta-analysis.","Singh S","2025","Gastrointestinal endoscopy","systematic_review","article","10.1016/j.gie.2024.10.011","39401599",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0002847","Characterizing Geographic Variation in GLP-1 Receptor Agonist Prescribing Using Interpretable Machine Learning","Chu Z","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-8803134/v1",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0002848","Effect of glucagon-like peptide 1 receptor agonist medications on weight loss in patients with and without polycystic ovary syndrome.","Gleason E","2025","Fertility and sterility","other","article","10.1016/j.fertnstert.2025.04.009","40239888",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002849","Benefits of Glucagon-like Peptide-1 Receptor Agonists After Kidney Transplantation.","Sahi SS","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2025.02.020","40054529",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002850","Association of preoperative GLP‑1 receptor agonist use with outcomes after primary total knee arthroplasty.","Box MW","2026","The Knee","nonrandomized_study","article","10.1016/j.knee.2025.10.026","41241648",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002851","Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists.","Jiang H","2025","ESC heart failure","nonrandomized_study","article","10.1002/ehf2.15308","40289068","PMC12287838",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0002852","Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.","Zhou J","2024","BMC medicine","nonrandomized_study","article","10.1186/s12916-024-03274-6","38355513","PMC10865629",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article; other"],["R0002853","Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus.","Terui S","2026","Journal of lipid and atherosclerosis","other_trial","article","10.12997/jla.2026.15.2.249","42211143","PMC13213236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002854","Tirzepatide engages a brain-brown adipose tissue axis to promote body weight loss independent of appetite suppression","Sun J","2026","Research Square","preclinical","preprint","10.21203/rs.3.rs-10163129/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0002855","Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study.","Morales DR","2025","Diabetes care","nonrandomized_study","article","10.2337/dc25-0154","40465422","PMC12281980",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0002856","Combination pharmacotherapy for MASH: Potential synergistic approaches.","Meije DA","2026","Biochemical pharmacology","other_trial","article","10.1016/j.bcp.2026.118492","42767573",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0002857","Glucagon-Like Peptide-1 Receptor Agonists: Multifaceted Roles in Immune and Inflammatory Regulation, Glycemic Control, and Synergistic Therapeutic Applications.","Hsu CC","2025","International journal of rheumatic diseases","commentary","article","10.1111/1756-185x.70199","40213996",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0002858","Combination of GLP-1 receptor agonists and SGLT2 inhibitors in cardiometabolic disease: synergistic, additive, or non-additive effects? A narrative review.","Stamouli E","2026","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-026-03239-4","42252454","PMC13466521",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0002859","Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome.","Ravic M","2024","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph17040525","38675485","PMC11053642",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002860","GLP-1 Receptor Agonist Use in Patients Undergoing Distal Radius Fracture Surgery: A Retrospective Review of Perioperative Considerations.","Khak M","2025","Cureus","nonrandomized_study","article","10.7759/cureus.89183","40895987","PMC12399179",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002861","Effects of GLP-1 receptor agonists on cardiometabolic outcomes in heart transplant recipients: A systematic review and meta-analysis of observational studies.","Dalal N","2026","JHLT open","systematic_review","article","10.1016/j.jhlto.2026.100565","42088447","PMC13137046","PROSPERO:CRD420251243172",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0002862","Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity.","Michos ED","2023","Journal of the American Heart Association","narrative_review","article","10.1161/jaha.122.029282","37278394","PMC10381974",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002863","Sex-specific changes in GLP-1RA trends (2019-2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States.","Daggolu J","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70555","41669827",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002864","Adverse Event Comparison between Glucagon-like Peptide-1 Receptor Agonists and Other Anti-Obesity Medications Following Bariatric Surgery","Samuels JM","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.04.21.24306138",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002865","Clinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study.","Dhali A","2026","Journal of personalized medicine","nonrandomized_study","article","10.3390/jpm16080437","42645931","PMC13514437",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002866","Muscle health in the modern era of incretin-based therapies.","De Girolamo G","2026","European journal of clinical investigation","randomized_trial","article","10.1111/eci.70155","41328795","PMC12825403",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0002867","GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence.","Varughese MS","2025","Clinical medicine (London, England)","other","article","10.1016/j.clinme.2025.100298","39993530","PMC11929868",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0002868","Immunomodulatory effects of anti-diabetic therapies: Cytokine and chemokine modulation by metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists (2013-2025).","Ullah A","2025","European journal of medicinal chemistry","narrative_review","article","10.1016/j.ejmech.2025.118065","40829258",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002869","Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.","Gutierrez de Piñeres V","2026","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2026.113113","41571048",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0002870","Patient characteristics and early experiences with anti-obesity medications: the CAMP study.","Tewksbury C","2026","Frontiers in nutrition","nonrandomized_study","article","10.3389/fnut.2026.1931188","42774137","PMC13593473",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002871","GPs' perspectives on GLP-1RAs for obesity management: a qualitative study in England.","Keating S","2025","The British journal of general practice : the journal of the Royal College of General Practitioners","other","article","10.3399/bjgp.2025.0065","40628416","PMC12745643",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002872","Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study.","Lago Garma J","2026","Endocrinologia, diabetes y nutricion","nonrandomized_study","article","10.1016/j.endien.2026.501713","41651756",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0002873","Perioperative Use of GLP-1 Receptor Agonists in Patients Undergoing Cardiac Procedures: A Scoping Review.","Wookey O","2025","Heart, lung & circulation","narrative_review","article","10.1016/j.hlc.2024.11.025","39824665",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Scoping Review; article"],["R0002874","Heart-liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.","Zhou XD","2026","Nature reviews. Gastroenterology & hepatology","narrative_review","article","10.1038/s41575-026-01255-z","42717057",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0002875","Bowel preparation quality in patients using glucagon-like peptide-1 agonists: a systematic review and meta-analysis.","Ahmed Z","2026","Gastrointestinal endoscopy","systematic_review","article","10.1016/j.gie.2025.08.027","40846241",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002876","Corrigendum to \"Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System\".","Shah, Viral N.","2025","Journal of diabetes science and technology","notice","article","10.1177/19322968241305079","39614712","PMC11607703",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0002877","The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Agonists for Polycystic Ovary Syndrome.","Rahim S","2025","Cureus","other_trial","article","10.7759/cureus.77998","40007927","PMC11852098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002878","Implementation of an Integrated Cardiology/Pharmacy GLP-1 Receptor Antagonist Prescribing to Improve Utilization and Cardiovascular Risk","Pollmann DL","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.08.01.25332846",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002879","Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis.","Shirmard FO","2025","BMC gastroenterology","systematic_review","article","10.1186/s12876-025-04496-5","41275083","PMC12752087","PROSPERO:CRD420251063158",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002880","Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.","Gunasekaran P","2026","Disease-a-month : DM","systematic_review","article","10.1016/j.disamonth.2026.102113","41991422",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0002881","GLP-1 Receptor Agonists in Periodontology: Mechanisms, Clinical Evidence, and Implications for Care.","Sufaru IG","2026","Biomolecules","nonrandomized_study","article","10.3390/biom16060857","42352323","PMC13297429",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0002882","National Trends in Glucagon-Like Peptide-1 Receptor Agonist Use in Adults Without Diabetes, 2018 to 2022.","Shadbolt C","2025","Annals of internal medicine","other","article","10.7326/annals-24-02878","40163864",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002883","Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials.","Dai M","2024","Journal of clinical research in pediatric endocrinology","systematic_review","article","10.4274/jcrpe.galenos.2024.2024-1-5","38828884","PMC11590762",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0002884","Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data.","Fishkin A","2025","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.70066","40698871","PMC12285216","PROSPERO:CRD42023405356",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0002885","Personalized Combination of a Ketogenic Diet and Low-Dose Semaglutide for Cardiometabolic Health: A Retrospective Case Series.","Parker G","2026","Journal of personalized medicine","nonrandomized_study","article","10.3390/jpm16060313","42346624","PMC13300755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002886","Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.","Jensen SBK","2026","Sports medicine (Auckland, N.Z.)","randomized_trial","article","10.1007/s40279-025-02386-0","41579235","PMC13388483","ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32","S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; research-article; article"],["R0002887","Drugs to Slow Progression of Chronic Kidney Disease: It Is a Whole New World!","Schoonmaker JA","2026","Kidney & blood pressure research","narrative_review","article","10.1159/000552776","42268775","PMC13399940",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002888","A Case of Pulmonary Hemorrhage, Supratherapeutic International Normalized Ratio (INR), and Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Unmasking a Potential Link to Tirzepatide.","Shakour H","2025","Cureus","case_report","article","10.7759/cureus.80539","40225446","PMC11993429",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002889","Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives.","Cadena-Ullauri S","2026","Frontiers in microbiology","narrative_review","article","10.3389/fmicb.2026.1901528","42499664","PMC13395659",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002891","Exploratory Assessment of Preoperative GLP-1 Receptor Agonists Before Sleeve Gastrectomy: A Retrospective Matched Analysis.","Luc G","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-08258-w","40931278",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002892","Insights into the Mechanism of Action of Tirzepatide: A Narrative Review.","Galindo RJ","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-025-01804-w","41196501","PMC12847476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002893","Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss.","Rahman E","2026","Aesthetic plastic surgery","randomized_trial","article","10.1007/s00266-026-05990-1","42414642",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0002894","Real-world effectiveness of GLP-1RAs on Time in Range in pati ents with type 2 diabetes: A retrospective study","Chen Y","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3290924/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002895","Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study.","Scott Butsch W","2025","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2025.100186","40584822","PMC12205620",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002896","Clinical efficacy of GLP-1 receptor agonists in the treatment of Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","Zhang Y","2025","Journal of neurology","systematic_review","article","10.1007/s00415-025-13301-y","40760123",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002897","GLP-1 receptor agonist-induced diabetic ketoacidosis: A case report.","Zhang J","2024","Medicine","case_report","article","10.1097/md.0000000000039799","39331877","PMC11441871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0002898","Semaglutide Therapy and Cardiorenal Risk Management in Type 2 Diabetes: hsCRP as a Biomarker of Risk","Kostadinov NK","2025","Preprints.org","other","preprint","10.20944/preprints202508.1768.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint; article"],["R0002899","Comparative effectiveness of GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors on liver outcomes in metabolic dysfunction-associated steatotic liver disease: A retrospective cohort study.","Sarker J","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70505","41560595",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0002900","GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions","Cao K","2025","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202506.1838.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002901","Network meta-analysis of the risk of dyspepsia and anorexia in patients with type 2 diabetes mellitus induced by glucagon-like peptide 1 receptor agonist hypoglycemic drugs.","Jiao BL","2024","European review for medical and pharmacological sciences","systematic_review","article","10.26355/eurrev_202404_36023","38708466",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; review"],["R0002902","Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety.","Tang ASP","2025","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-025-02840-3","40652242","PMC12255114","OSF:osf.io/7vxn5",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0002903","Quality Assessment of Medical Institutions' Websites Regarding Prescription Drug Misuse of Glucagon-Like Peptide-1 Receptor Agonists by Off-Label Use for Weight Loss: Website Evaluation Study.","Oyama R","2025","JMIR formative research","other","article","10.2196/68792","39742456","PMC11736224",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002904","The Impact of Glucagon-Like Peptide-1 (GLP-1) Agonists on Acne, Hidradenitis, and Sebaceous Activity.","Jabin A","2026","Cureus","other_trial","article","10.7759/cureus.101212","41669596","PMC12884193",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0002905","GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer.","Shen S","2025","Oncology (Williston Park, N.Y.)","other","article","10.46883/2025.25921046","40834286",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002906","Childhood Obesity: Epidemiology, Risk Factors, Prevention, and Emerging Treatment Strategies.","Hadid S","2026","Cardiology in review","other","article","10.1097/crd.0000000000001359","42269007",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002907","Efficacy of Dual Glucagon and GLP-1 Agonists as New Treatments for Type II Diabetes.","Vats J","2026","Mini reviews in medicinal chemistry","narrative_review","article","10.2174/0113895575419389251118100027","41735212",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002908","Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome.","Ahmed S","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1881392","42755517","PMC13581520",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; research-article; Preprint; article"],["R0002909","Approach to the Patient: Ethics Cases in Pediatric Endocrinology and Their Management.","Ladd JM","2026","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgag354","42657774",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002910","The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions.","Moiz A","2025","EClinicalMedicine","narrative_review","article","10.1016/j.eclinm.2025.103363","40727007","PMC12303005",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002911","Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors: Systematic Review and Meta-Analysis.","Corona G","2026","Andrology","systematic_review","article","10.1111/andr.70238","42011503",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002912","Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.","Yovera-Aldana M","2026","JCEM case reports","other_trial","article","10.1210/jcemcr/luag260","42751099","PMC13579046",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0002913","Localized Semaglutide Injection for Hyperinsulinemia-Induced Lymphatic Dysfunction: A Narrative Review Proposing a Promising Metabolic Perspective for Lymphedema Therapy.","Akl MM","2025","Advanced pharmaceutical bulletin","narrative_review","article","10.34172/apb.025.43911","41403736","PMC12703388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002914","Metabolite Profiling and Identification of Semaglutide in Liver S9 Across Species and Rat Plasma.","Cong Y","2026","Biomedical chromatography : BMC","preclinical","article","10.1002/bmc.70415","41787929",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002915","Minimal Change Podocytopathy with Coexistent Thin Glomerular Basement Membrane following Exposure to Semaglutide.","Kovvuru K","2025","Glomerular diseases","other","article","10.1159/000543357","40035048","PMC11875556",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0002916","Effects of glucagon-like peptide-1 receptor agonists in HFpEF and obesity without diabetes mellitus.","Vignarajah A","2025","Journal of cardiology","commentary","article","10.1016/j.jjcc.2025.02.017","39988084",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0002917","Exploring the Putative Involvement of MALAT1 in Mediating the Beneficial Effect of Exendin-4 on Oleic Acid-Induced Lipid Accumulation in HepG2 Cells.","Khalifa O","2025","Biomedicines","other","article","10.3390/biomedicines13020370","40002783","PMC11853215",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002918","Mapping the effectiveness and risks of GLP-1 receptor agonists.","Xie Y","2025","Nature medicine","nonrandomized_study","article","10.1038/s41591-024-03412-w","39833406",null,null,"S000353","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002919","Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD.","Chapman MB","2024","Gastrointestinal endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.05.012","38759761",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002920","Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Lung Transplant Recipients: A Single Center Report.","Fishman CE","2025","Transplantation proceedings","other","article","10.1016/j.transproceed.2024.11.016","39648063","PMC11867881",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002921","Single-cell RNA sequencing reveals beneficial mechanisms of Exendin-4 in autoimmune uveitis.","Wu D","2026","Biochemical pharmacology","other","article","10.1016/j.bcp.2025.117483","41173056",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002922","Glucagon-like Peptide-1 and Dual GIP/GLP-1 Receptor Agonists in Brain: Exploring the Expanding Role and Safety in Neuropsychiatry.","Tudosie AC","2026","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms27083628","42074266","PMC13115786",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0002923","Is There a Role for Pentoxifylline in Diabetic Kidney Disease? A Mini Review.","Leehey DJ","2026","American journal of kidney diseases : the official journal of the National Kidney Foundation","randomized_trial","article","10.1053/j.ajkd.2025.09.030","41866016",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0002924","Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity.","Raveendra K","2026","ESC heart failure","systematic_review","article","10.1093/eschf/xvag091","41883191","PMC13064920","PROSPERO:CRD420251074882",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; article"],["R0002925","Glucagon-like Peptide-1 Receptor Agonists Reduce Surgical Complications in Diabetic Patients","Zhang A","2024","Plastic and reconstructive surgery. Global open","other","article","10.1097/01.gox.0001064004.58065.80",null,"PMC11411987",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0002926","Weight loss therapy and addiction: Increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists.","Scheen AJ","2025","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2025.101612","39818408",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0002927","Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence.","Lin A","2025","Biomarker research","narrative_review","article","10.1186/s40364-025-00765-3","40140925","PMC11948983",null,"S002389","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0002928","Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapy.","Chen JY","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112339","40581158",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002929","Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.","Saglietto A","2024","European journal of clinical investigation","systematic_review","article","10.1111/eci.14292","39058274",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0002930","Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.","Kitsunai H","2026","Endocrine journal","nonrandomized_study","article","10.1507/endocrj.ej26-0246","42457543",null,"UMIN:UMIN000056962",null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002931","Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.","Robles Cabanillas C","2025","Gaceta sanitaria","nonrandomized_study","article","10.1016/j.gaceta.2024.102444","39818039",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002932","Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review.","Nybo PF","2026","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.70346","42036870",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Review; review"],["R0002933","Effect of Semaglutide on Body Weight, Blood Lipid Profile, and Adipokine Status in Obese Patients.","Tyurina AV","2026","Kardiologiia","other","article","10.18087/cardio.2026.2.n3116","41925173",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0002934","Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.","Wang TY","2025","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2025.1725782","41476792","PMC12747910",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0002935","Semaglutide-associated drug-induced liver injury: a case report and review of the literature.","Kempster I","2025","Oxford medical case reports","case_report","article","10.1093/omcr/omaf177","41025030","PMC12476543",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0002936","[An historical overview of GLP-1/GIP incretins. From hormone to \"swiss-army knife\" medications].","Portha B","2026","Biologie aujourd'hui","narrative_review","article","10.1051/jbio/2026005","42536830",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Historical Article; English Abstract; article"],["R0002937","GLP-1 agonists are protective against postoperative complications following total knee arthroplasty.","Ranson R","2025","The Knee","nonrandomized_study","article","10.1016/j.knee.2025.08.007","40834675",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0002938","Glucagon-like peptide-1 receptor agonists in conjunction with bariatric surgery: an alert regarding the less commonly perceived nonarteritic anterior ischemic optic neuropathy (NAION).","Varughese MS","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","commentary","article","10.1016/j.soard.2025.03.013","40340119",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0002939","Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations.","Li S","2025","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","systematic_review","article","10.1016/j.euroneuro.2025.08.002","40925272",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0002940","How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis.","Anyiam O","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13916","40181228","PMC12137041",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0002941","Hypothalamic RASA1/Ras/AKT/GnRH axis reprogramming mediates GLP-1RA's central rescue of PCOS HPG dysfunction.","Yang L","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70256","41208497",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002942","Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization.","Zhang X","2025","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-025-01712-w","40442813","PMC12123724",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0002943","Obesity, anti-obesity medications, and atrial fibrillation: Recent advances.","Siaravas KC","2026","Kardiologia polska","randomized_trial","article","10.33963/v.phj.111856","41891549",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0002944","Exploring real-world user experiences of GLP-1 receptor agonist therapy for obesity treatment, and barriers and motivators to adherence","Griffiths A","2025","medRxiv","nonrandomized_study","preprint","10.64898/2025.12.11.25342052",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0002945","Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis.","Lee SH","2026","Journal of global health","systematic_review","article","10.7189/jogh.16.04187","42626880","PMC13494846","PROSPERO:CRD420251130232",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Comparative Study; research-article; article"],["R0002946","Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?","Alnima T","2024","Current opinion in lipidology","narrative_review","article","10.1097/mol.0000000000000949","39082103",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0002947","The combination of SGLT2 inhibitors and glucagon-like peptide 1 receptor agonists: are 2 drugs better than 1?","Ikizler TA","2025","Kidney international","other","article","10.1016/j.kint.2024.11.032","39984249",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002948","Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes.","Choe HJ","2025","Endocrinology and metabolism (Seoul, Korea)","other","article","10.3803/enm.2024.2150","39582250","PMC11898308",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002949","Exploring the clinical effectiveness of glucagon-like peptide-1 receptor agonists in managing cardiovascular complications: an updated comprehensive review and future directives.","Joshi N","2024","Annals of medicine and surgery (2012)","nonrandomized_study","article","10.1097/ms9.0000000000002494","39359798","PMC11444620",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0002950","Efficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.","Aljulajil FA","2026","Cureus","systematic_review","article","10.7759/cureus.111363","42495484","PMC13394370",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0002951","GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity.","Dai H","2025","JAMA oncology","nonrandomized_study","article","10.1001/jamaoncol.2025.2681","40839273","PMC12371547",null,"S002362; S002468","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0002952","Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor use: A post hoc analysis of ONWARDS 1-5.","Vilsbøll T","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16328","40098267","PMC12046478",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; research-article; article"],["R0002953","Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice.","Xi L","2025","Peptides","preclinical","article","10.1016/j.peptides.2025.171366","39954860",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002954","Impact-Factor Concentration and Citation Disparities: GLP-1 Literature Outperforms Bariatric Surgery Through Preferential Placement in High-Impact Journals","Prado R","2026","Research Square","other","preprint","10.21203/rs.3.rs-9882907/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0002955","The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.","Hsieh WC","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70907","42162578","PMC13341395",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; research-article; review"],["R0002956","GLP-1 receptor agonist medications for weight loss: Sociodemographic patterns of awareness, use, and access in a U.S. national cohort.","Sanborn J","2026","Annals of epidemiology","nonrandomized_study","article","10.1016/j.annepidem.2026.110151","42349695","PMC13401313",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002957","Non arteritic ischemic optic neuropathy in a patient taking semaglutide: Is there a relation? A case report and a review of the literature.","Maceroni M","2025","European journal of ophthalmology","nonrandomized_study","article","10.1177/11206721251331655","40183385",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Case Reports; Review; article"],["R0002958","Geroprotective Agents, Including Glucagon-Like Peptide-1 Receptor Agonists, for Ocular Health.","Nguyen A","2026","Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","narrative_review","article","10.1177/10807683261456222","42281177",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0002959","Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity.","Wang J","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16552","40629903",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0002960","Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial.","Wexler DJ","2026","American heart journal","randomized_trial","article","10.1016/j.ahj.2025.107332","41456635",null,"ClinicalTrials.gov:NCT05390892","S002011","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Pragmatic Clinical Trial; Randomized Controlled Trial; Multicenter Study; article"],["R0002961","Metabolic Improvement Mediates the Causal Relationship Between GLP-1 Receptor Agonists and Myocardial Infarction: A Mendelian Randomization and Mediation Analysis Study.","Tong J","2026","Diabetes care","other","article","10.2337/dc25-1822","41259721","PMC12719715",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0002962","Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review.","Raza FA","2024","Medicine","narrative_review","article","10.1097/md.0000000000040364","39496023","PMC11537668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0002963","Reduction of Cerebrospinal Fluid Leaks in Idiopathic Intracranial Hypertension with Glucagon-like Peptide-1 Receptor Agonist Use.","Vesole AS","2026","Journal of neurological surgery. Part B, Skull base","randomized_trial","article","10.1055/a-2678-8331","42404189","PMC13331668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; conference-paper; article"],["R0002964","Oral Wegovy Broadens Care Continuum Across First-Time GLP-Starters, High Cardiometabolic Burden GLP-Switchers, and Medicare-Age Patients","Murugadoss K","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202607.0935.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0002965","Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.","de Oliveira Costa J","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15597","38618983",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0002966","Using large language models to assess public perceptions around glucagon-like peptide-1 receptor agonists on social media.","Somani S","2024","Communications medicine","randomized_trial","article","10.1038/s43856-024-00566-z","38987347","PMC11237093",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0002967","Polycystic ovary syndrome and insulin resistance: A focus on pathogenesis, risk factors, and therapeutic strategies.","Singla J","2026","Journal of reproductive immunology","narrative_review","article","10.1016/j.jri.2026.104943","42531755",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0002968","Re: Vasu et al.: Risk of glaucoma in patients without diabetes using a glucagon-like peptide 1 receptor agonist (Ophthalmology. 2025;132:859-868).","Zaidi Z","2025","Ophthalmology","commentary","article","10.1016/j.ophtha.2025.03.021","40272339",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0002969","Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study.","Lee YJ","2025","Journal of autoimmunity","nonrandomized_study","article","10.1016/j.jaut.2025.103453","40544585",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0002970","Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes.","Ikonomidis I","2025","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.124.039129","40008510","PMC12132653","ClinicalTrials.gov:NCT03878706","S000665","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0002971","Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists.","Khan SS","2025","JAMA","other","article","10.1001/jama.2024.22284","39535741",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0002972","Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice.","Sawada M","2026","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70295","42552642","PMC13437943",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0002973","Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines.","Chan JCN","2026","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2026.113173","41722868",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0002974","Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-Like Peptide-1 Receptor Agonists in Reducing Cardiovascular Events in Patients With Type 2 Diabetes.","Khan HU","2025","Cureus","nonrandomized_study","article","10.7759/cureus.84137","40524985","PMC12168791",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0002975","Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis.","Li Z","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s539822","41019499","PMC12476180",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0002976","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation.","Satti DI","2024","JACC. Clinical electrophysiology","nonrandomized_study","article","10.1016/j.jacep.2024.03.031","38795099",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0002977","Glucagon-Like Peptide-1 Receptor Agonists Compared to Insulin for Post-Transplant Diabetes Mellitus After Solid Organ Transplant.","Gordon R","2025","Transplantation proceedings","nonrandomized_study","article","10.1016/j.transproceed.2025.02.031","40140314",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; Observational Study; article"],["R0002978","Real-world outcomes of hybrid obesity care using digital coaching and GLP-1 therapy in a multi-ethnic Asian setting.","Ali SH","2026","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-026-02062-x","41957114","PMC13286992",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002979","Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.","Yin Y","2025","Journal of diabetes","systematic_review","article","10.1111/1753-0407.70082","40207414","PMC11982705",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0002980","Body image in the age of GLP-1s: Emerging questions for research and practice.","Craddock N","2026","Body image","narrative_review","article","10.1016/j.bodyim.2026.102095","42030632",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0002981","Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.","Wen J","2025","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70045","40184508","PMC11970626",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; review-article; review"],["R0002982","Endocrinology: What You May Have Missed in 2024.","Aman M","2025","Annals of internal medicine","narrative_review","article","10.7326/annals-25-00990","40163884","PMC13322357",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0002983","Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis.","Venier S","2026","Circulation. Arrhythmia and electrophysiology","nonrandomized_study","article","10.1161/circep.125.014101","41446932","PMC12822759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; Preprint; article; preprint"],["R0002984","GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes.","Ramsey DJ","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.26321","40788647","PMC12340654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002985","Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study.","Xiang L","2025","International journal of molecular sciences","systematic_review","article","10.3390/ijms26062741","40141382","PMC11942543",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0002986","New Contours, Different Risks: A 9-Year Comparison of Trends and Postoperative Complications in Patients Undergoing Aesthetic Surgery With Previous Bariatric Surgery Vs Glucagon-Like Peptide 1 Receptor Agonist Use.","Khong J","2025","Aesthetic surgery journal","nonrandomized_study","article","10.1093/asj/sjaf131","40692274",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0002987","Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.","Mehetre KN","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1933913","42769318","PMC13591101",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0002988","Semaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's Missing.","Chirapongsathorn S","2026","Digestion","other_trial","article","10.1159/dig/acmag014","42715139",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0002989","Impact of GLP-1 and GLP-1/GIP receptor agonists before, during, and after pregnancy: a narrative review.","Zajdenverg L","2026","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-026-02235-8","42754900","PMC13584491",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0002990","The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort.","Toraih EA","2025","Biomedicines","nonrandomized_study","article","10.3390/biomedicines13051049","40426877","PMC12109458",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0002991","Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials.","Karakasis P","2026","Metabolism: clinical and experimental","systematic_review","article","10.1016/j.metabol.2025.156463","41349790",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0002992","Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial.","Miyake T","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71233","42605535","PMC13646358","jRCT:jRCTs061210009; UMIN:UMIN000045003",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0002993","Adherence to GLP-1 receptor agonists and SGLT2 inhibitors by out-of-pocket spending among Medicare beneficiaries with diabetes.","Klepser NS","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16619","40667705","PMC12313199",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0002994","Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.","Al Refaie A","2024","Calcified tissue international","preclinical","article","10.1007/s00223-024-01240-1","38864922","PMC11246279",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0002995","Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis.","Wang Y","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1486655","40933374","PMC12417164","PROSPERO:CRD42024518348",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Comparative Study; systematic-review; review"],["R0002996","Cardiometabolic and RAAS-Targeted Therapy in Thoracic Aortic Aneurysm: Propensity-Matched Associations with Survival and Major Cardiovascular Events.","Abdul Nabi H","2026","Medical sciences (Basel, Switzerland)","nonrandomized_study","article","10.3390/medsci14020329","42346868","PMC13303541",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0002997","GLP-1 Receptor Agonists for Secondary Prevention After Myocardial Infarction and Stroke in Type 2 Diabetes: Nationwide Real-World Evidence.","Sedova P","2026","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwag002","41499432",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0002998","Effect of GLP-1 receptor agonists on idiopathic intracranial hypertension: A systematic review.","de Oliveira HM","2026","Headache","systematic_review","article","10.1111/head.70005","41246926",null,"PROSPERO:CRD420251058602",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; review"],["R0002999","Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists.","Cosentino N","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18081202","40872593","PMC12388946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003000","Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies.","Park JS","2025","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2025.0106","40367985","PMC12086555",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003001","Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.","Park B","2026","European heart journal","randomized_trial","article","10.1093/eurheartj/ehaf690","40886061","PMC13016833",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0003002","Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.","Nielsen MJF","2026","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-026-01654-0","42228334","PMC13356073","ClinicalTrials.gov:NCT04209049; ClinicalTrials.gov:NCT05564104","S000141; S002770","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0003003","The impact of GLP-1 receptor agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic.","Nanayakkara N","2024","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2024.111740","38852625",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003004","Metabolic and bariatric surgery versus glucagon-like peptide-1 receptor agonist therapy: A comparison of cardiovascular outcomes in patients with obesity.","Maan S","2025","American journal of surgery","other","article","10.1016/j.amjsurg.2025.116242","39965476",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0003005","Alcoholic Use Disorder Outcomes After Roux-en-Y Gastric Bypass in Patients Taking GLP-1 RAs: A Multicenter Analysis.","Adeniran O","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70001","40855971",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0003006","Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.","Jiménez-Mausbach M","2026","Alzheimer's & dementia (Amsterdam, Netherlands)","randomized_trial","article","10.1002/dad2.70432","42571323","PMC13452022",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0003007","Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus.","Kim M","2025","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2024.0105","39443282","PMC11788542",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003008","Preoperative weight loss by noninvasive approach in patients with obesity scheduled for bariatric and metabolic surgery: an update narrative review of indications and results available until 2024.","Grandone I","2025","Updates in surgery","randomized_trial","article","10.1007/s13304-025-02198-x","40220081","PMC12540583",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0003009","Tirzepatide-Associated Severe Hepatocellular Injury: A Case Report and Diagnostic Considerations.","Kim DG","2026","Diagnostics (Basel, Switzerland)","case_report","article","10.3390/diagnostics16152359","42587596","PMC13465100",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003010","Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensus.","Carter P","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.70160","41058255",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Consensus Statement; article"],["R0003011","Glucagon-like peptide-1 receptor agonists improve outcomes in individuals with type 2 diabetes with and without heart failure.","Horiuchi Y","2025","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2024.132611","39393444","PMC12107941",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0003012","Drug failure in diabetic kidney disease: translational barriers, target validation and trial de-risking strategies.","Hu H","2026","Biochemical pharmacology","other_trial","article","10.1016/j.bcp.2026.118405","42667964",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0003013","Neighborhood-Level Material Resources and Risk of Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.","Sheth MS","2026","The Canadian journal of cardiology","nonrandomized_study","article","10.1016/j.cjca.2026.06.027","42398733",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0003014","Effects of Combined Therapy with SGLT2i and GLP-1RAs on Atrial Fibrillation Recurrence After Catheter Ablation in Diabetic Cohorts: One-Year Outcomes from Continuous Monitoring.","Sardu C","2025","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms26199285","41096554","PMC12524772",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0003015","Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.","Guirguis A","2024","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","nonrandomized_study","article","10.1016/j.euroneuro.2024.02.003","38508100",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003016","Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study.","Fawzy MS","2025","Cancers","nonrandomized_study","article","10.3390/cancers17091593","40361517","PMC12072167",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003017","Preferences for benefit and harm outcomes of GLP-1 receptor agonists in adults with overweight or obesity: a multinational best–worst scaling study","Moll H","2025","medRxiv","other","preprint","10.64898/2025.12.15.25342259",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003018","Semaglutide in Metabolic Medicine: A Review on Clinical Applications and Emerging Therapeutics.","Aljabri AA","2026","Saudi medical journal","narrative_review","article","10.15537/1658-3175.1060","42237968","PMC13227446",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003019","Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy.","Finkle J","2025","Obstetrics and gynecology","narrative_review","article","10.1097/aog.0000000000005825","39847778",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003020","Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study.","Zeng H","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-17574-1","40883386","PMC12397294",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003021","Availability, treatment costs and affordability of SGLT-2 inhibitors and GLP-1 RAs for diabetes in 10 countries: a cross-sectional study.","Li Z","2026","BMJ open","other","article","10.1136/bmjopen-2026-120259","42498467","PMC13404856",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003022","Association Between GLP-1RAs and Postoperative Complications Following Operative Ankle Fracture Fixation: A Retrospective Cohort Study.","Monteiro SK","2026","Foot & ankle orthopaedics","nonrandomized_study","article","10.1177/24730114261453350","42358523","PMC13291453",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003023","A pullulan-based bilayer film for buccal delivery of a GLP-1 peptide analogue.","Karki S","2026","Carbohydrate polymers","preclinical","article","10.1016/j.carbpol.2026.125064","41831981",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003024","Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks.","Carminati M","2026","International clinical psychopharmacology","systematic_review","article","10.1097/yic.0000000000000595","40577093",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0003025","Glucagon-like peptide-1 receptor agonist for patients with heart failure with preserved ejection fraction and obesity.","Fu L","2025","European journal of internal medicine","commentary","article","10.1016/j.ejim.2025.02.022","40000362",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0003026","Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.","Sinha B","2025","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.24360","40685589",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; article"],["R0003027","GLP-1 Receptor Agonists as Pharmacologic Treatment for Obesity After Spinal Cord Injury: Clinical Considerations.","Farkas GJ","2026","Archives of physical medicine and rehabilitation","other","article","10.1016/j.apmr.2026.02.498","41825707",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003028","Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.","Jiang Y","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1347684","38524632","PMC10958196",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003029","GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges.","Kupnicka P","2024","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph17111470","39598383","PMC11597758",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0003030","Alterations in Cardiac and Systemic Metabolism in Heart Failure.","Bertero E","2026","Circulation. Heart failure","narrative_review","article","10.1161/circheartfailure.125.013766","42305084",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003031","Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults.","Toma L","2026","The Senior care pharmacist","case_report","article","10.4140/tcp.n.2026.78","41966038",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0003032","GLP-1 Receptor Agonists and SGLT2 Inhibitors in Stable Kidney Transplantation: Clinical Outcomes from a Cohort of Patients with Post-Transplant Diabetes Mellitus.","Navarrete RET","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15010181","41517430","PMC12787301",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003033","Semaglutide alters the human embryo-endometrium interface","Apostolov A","2026","medRxiv","other","preprint","10.64898/2026.03.03.26347354",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint; article"],["R0003034","The role of GLP-1 in the pathophysiology and treatment of sepsis: a narrative review.","Dimic N","2025","Frontiers in medicine","narrative_review","article","10.3389/fmed.2025.1612034","41357527","PMC12678266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003035","Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis.","Lin YM","2025","European heart journal. Cardiovascular pharmacotherapy","systematic_review","article","10.1093/ehjcvp/pvae093","39923808","PMC11905764",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0003036","Perioperative glucagon-like peptide-1 receptor agonists-induced gastroparesis - Is gastric ultrasound the answer?","Narayanasamy S","2024","Indian journal of anaesthesia","randomized_trial","article","10.4103/ija.ija_609_24","39386414","PMC11460805",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0003037","Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists.","Chetty AK","2025","JAMA health forum","other","article","10.1001/jamahealthforum.2024.5018","39820389","PMC11742527",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003038","Real-World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in FAERS.","Liu X","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71373","42768828",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","4","FALSE","Journal Article; article"],["R0003039","Secondary Prevention of Cardiovascular Events in Patients with Overweight/Obesity in Routine Clinical Practice.","Guo W","2026","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.64898/2026.02.18.26346594","41757166","PMC12934895",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0003040","AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework.","Barakat G","2026","JMIR AI","systematic_review","article","10.2196/86960","41802231","PMC13010075",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003041","Clinical Decision Support for Digital Dietary Counseling Under GLP-1 Receptor Agonist Therapy: Convergent Mixed Methods Usability and Treatment Satisfaction Pilot Study of the Personalized Nutrition Advisor.","Orban F","2026","JMIR formative research","other","article","10.2196/81112","42522425","PMC13423961","ClinicalTrials.gov:NCT05997771",null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0003042","Exploring the link between GLP-1 receptor agonists and dementia: A comprehensive review.","Chuansangeam M","2025","Journal of Alzheimer's disease reports","randomized_trial","article","10.1177/25424823251342182","40370762","PMC12075970",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003043","New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes.","Heberer K","2026","JAMA ophthalmology","nonrandomized_study","article","10.1001/jamaophthalmol.2025.6262","41678180","PMC12902922",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0003044","Exendin-4 improves cerebral ischemia by relaxing microvessels, rapidly increasing cerebral blood flow after reperfusion.","Chen Y","2025","Basic research in cardiology","preclinical","article","10.1007/s00395-025-01096-y","40121575",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003045","In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy.","Nadeem N","2025","Canadian journal of diabetes","randomized_trial","article","10.1016/j.jcjd.2025.07.002","40712696",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0003046","GLP-1 Agonism for Kidney Transplant Recipients: A Narrative Review of Current Evidence and Future Directions Across the Research Spectrum.","Riehl-Tonn VJ","2024","Canadian journal of kidney health and disease","randomized_trial","article","10.1177/20543581241290317","39492845","PMC11528610",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0003047","Management of Obesity in Psoriasis Consultations.","Nicolau J","2026","Dermatology and therapy","randomized_trial","article","10.1007/s13555-026-01664-7","41627722","PMC12936324",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0003048","Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis.","Mostafa MEA","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1548346","40134805","PMC11932899","PROSPERO:CRD42024613545",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0003049","Glucagon-like peptide-1 receptor agonists are associated with improved 90-day outcomes after total hip and knee arthroplasty : a systematic review and meta-analysis.","Rudran B","2026","The bone & joint journal","systematic_review","article","10.1302/0301-620x.108b8.bjj-2025-1486.r2","42538001",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0003050","A Multicenter, Open-Label Study of Combined Poly-L-Lactic Acid and Hyaluronic Midface Filler Regimen Enhances Facial Harmony and Skin Quality in GLP-1 Medication Users.","Lorenc ZP","2026","Aesthetic surgery journal","other_trial","article","10.1093/asj/sjaf240","41243519","PMC13064655",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0003051","The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Postoperative Complications After Arthroplasty: A Systematic Review and Meta-Analysis.","Chan YC","2025","The Journal of arthroplasty","systematic_review","article","10.1016/j.arth.2025.06.083","40617546",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0003052","RE: Glucagon-like peptide 1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.","Liu X","2025","Journal of the National Cancer Institute","randomized_trial","article","10.1093/jnci/djae324","39658267",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; letter"],["R0003053","Polyethylene Glycol Loxenatide Accelerates Diabetic Wound Healing by Downregulating Systemic Inflammation and Improving Endothelial Progenitor Cell Functions.","Ding Z","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms26052367","40076985","PMC11901084",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003054","Metabolic dysfunction-associated steatotic liver disease in people living with HIV: a framework for integrated screening and care.","Sebastiani G","2026","The lancet. HIV","narrative_review","article","10.1016/s2352-3018(26)00172-4","42710522",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003055","Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.","Kahkedjian F","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1885961","42460324","PMC13368568",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0003056","Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study.","Thompson W","2025","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2024-004677","40780839","PMC12336545",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003057","A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity.","Ojinna BT","2026","Cureus","nonrandomized_study","article","10.7759/cureus.107970","42220771","PMC13220851",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0003058","The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome.","Sultana R","2022","Life (Basel, Switzerland)","other","article","10.3390/life12081222","36013401","PMC9410036",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0003059","Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation.","Joshi SR","2026","Obesity pillars","narrative_review","article","10.1016/j.obpill.2026.100296","42529748","PMC13418229",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003060","Impact of Adding GLP-1 Receptor Agonists to Insulin Therapy on Cardiovascular and Microvascular Outcomes in Type 2 Diabetes: A Nationwide Cohort Study from Taiwan.","Yen FS","2025","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph18091368","41011236","PMC12472429",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003061","Temporal changes in mediation effects on cardiovascular and microvascular outcomes with glucagon-like peptide-1 receptor agonist therapy: a post-hoc analysis of the LEADER trial.","Peng ZY","2025","Cardiovascular research","other_trial","article","10.1093/cvr/cvae237","39498852",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0003062","Anesthesiologists' Perspectives on GLP-1 Receptor Agonists in Elective Surgeries: A Qualitative Survey Analysis of National Data.","Boudreau B","2025","Cureus","other","article","10.7759/cureus.95986","41346889","PMC12673413",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003063","Comparison of Effects of Glucagon-Like Peptide-1 Receptor Agonists Compared to Long-Acting Insulin, Added to Oral Anti-Diabetic Agents on Self-Management Behaviors, Anxiety, and Sleep Quality in Patients with Type 2 Diabetes.","Song X","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s502475","40124098","PMC11929419",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003064","Combination Therapy of GLP-1 RA and SGLT2i in Patients with Established Heart Failure: A Systematic Review and Meta-Analysis of Observational Studies.","Tristan CD","2026","American journal of cardiovascular drugs : drugs, devices, and other interventions","systematic_review","article","10.1007/s40256-026-00812-w","42429894",null,"PROSPERO:CRD420261320840",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003065","Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes.","Shen J","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16207","39887855","PMC11885103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0003066","GLP-1 Demand Shock: Work Reallocation, Productivity Decline, and Training Implications Across General and Bariatric Surgery.","Dallal RM","2026","Annals of surgery","other","article","10.1097/sla.0000000000007039","41766061",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003067","A Case of Intussusception With Bowel Obstruction in a Gastric Roux-en-Y Patient Prescribed Semaglutide.","Pavuluri SK","2025","Journal of the American College of Emergency Physicians open","case_report","article","10.1016/j.acepjo.2025.100045","39959551","PMC11830288",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003068","Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis.","He L","2025","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1509561","40041492","PMC11878242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003069","Treatment of Youth-Onset Type 2 Diabetes: Focus on SGLT-2 Inhibitor Use.","Arslanian S","2026","Pediatric diabetes","narrative_review","article","10.1155/pedi/4555805","41930239","PMC13042356",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003070","Ocular Complications of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in T2DM Treatments: A Retrospective Real-World Cohort Study.","Lin LY","2026","Clinical pharmacology and therapeutics","nonrandomized_study","article","10.1002/cpt.70087","41074575",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0003071","Provider perspectives of clinical decision support for chronic kidney disease management: a cross-sectional study.","Goldberg R","2026","BMC medical informatics and decision making","other","article","10.1186/s12911-026-03721-9","42482200",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003072","Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective.","Wang MW","2025","Journal of clinical and translational hepatology","other_trial","article","10.14218/jcth.2024.00271","39801787","PMC11712088",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0003073","Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD.","Ortega-Montiel J","2026","American journal of kidney diseases : the official journal of the National Kidney Foundation","nonrandomized_study","article","10.1053/j.ajkd.2026.06.013","42767321",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003074","Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.","Alharbi SH","2024","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/20420188231222367","38288136","PMC10823863",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003075","Sex differences in the efficacy of GLP-1 receptor agonists: A systematic review and meta-analysis of cardiovascular and renal outcome trials.","Siddiqui HF","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70123","40932012","PMC12587241",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0003076","Exercise maintains LEAP2 levels after weight loss in females with obesity.","Holt J","2026","iScience","randomized_trial","article","10.1016/j.isci.2025.114288","41503208","PMC12768860",null,null,"pubmed; europepmc","TRUE","open_europepmc","2",null,"Journal Article; research-article"],["R0003077","Pleural and Pericardial Effusions Associated with Semaglutide: A Case Report.","Stark M","2026","Clinical practice and cases in emergency medicine","case_report","article","10.5811/cpcem.48864","41666880","PMC12890333",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003078","Comparative Effectiveness of Current Glucose-lowering Medications in Type 2 Diabetes Mellitus: Emulation of a Modified GRADE Trial.","Ray A","2026","Journal of general internal medicine","randomized_trial","article","10.1007/s11606-026-10170-7","41566094",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0003079","Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.","Lee MMY","2025","Diabetes care","systematic_review","article","10.2337/dc25-0241","40156846",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003080","Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives.","Sawami K","2024","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-024-02500-y","39548500","PMC11568621",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003081","Anti-Inflammatory Effects of Glucagon-Like Peptide-1 Receptor Agonists via the Neuroimmune Axis.","Fang S","2024","DNA and cell biology","narrative_review","article","10.1089/dna.2024.0057","38579130",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003082","Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity.","Li J","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.178133","40935112",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003083","Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk.","Inia JA","2026","Diabetes & metabolism journal","preclinical","article","10.4093/dmj.2025.1060","42449565",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003084","Comparative Clinical and Metabolic Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 1 Diabetes: A Retrospective Cohort Study from Saudi Arabia.","Al Hayek A","2026","Current diabetes reviews","nonrandomized_study","article","10.2174/0115733998428827251223081042","41691684",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0003085","Tirzepatide, a novel, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist for the ongoing diabesity epidemic: the dawn of a new era?","Rangraze I","2024","Expert review of clinical pharmacology","commentary","article","10.1080/17512433.2024.2408753","39364766",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0003086","Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly.","Bianchettin RG","2026","American journal of cardiovascular drugs : drugs, devices, and other interventions","narrative_review","article","10.1007/s40256-025-00777-2","41247648",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003087","Severe lumbosacral polyradiculopathy secondary to micronutrient deficiencies in a patient on semaglutide therapy following bariatric surgery.","Donigan EC","2025","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-25-0072","40956288","PMC12558415",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0003088","Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists.","Jensen EL","2024","Hepatology communications","narrative_review","article","10.1097/hc9.0000000000000561","39392766","PMC11469819","ClinicalTrials.gov:NCT04822181","S000511","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0003089","GLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement.","Chen Y","2026","Frontiers in neurology","systematic_review","article","10.3389/fneur.2026.1858507","42490867","PMC13375474","PROSPERO:CRD420251170531",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0003090","Delayed gastric emptying in adolescent patients on GLP-1 receptor agonists with standard preoperative fasting guidelines: a prospective cohort study.","O'Brien EM","2026","British journal of anaesthesia","nonrandomized_study","article","10.1016/j.bja.2026.07.016","42711215",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003091","Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.","Badulescu S","2026","Med (New York, N.Y.)","randomized_trial","article","10.1016/j.medj.2025.100916","41218611",null,"ClinicalTrials.gov:NCT04466345","S001015","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0003092","Reply to correspondence on \"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis\".","Ren TY","2024","Clinical and molecular hepatology","systematic_review","article","10.3350/cmh.2024.0801","39314134","PMC11540347",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; reply; Journal Article; letter"],["R0003093","Long-Term Impact of GLP-1 Receptor Agonists on AF Recurrence After Ablation in Obese Patients.","Patel H","2025","Journal of cardiovascular electrophysiology","nonrandomized_study","article","10.1111/jce.16737","40406931",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003094","Emerging Cardiorenal Protective Therapies in Lupus Nephritis.","Capon IM","2026","Drugs","randomized_trial","article","10.1007/s40265-026-02337-7","42133281",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0003095","Use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with ischaemic heart disease and type 2 diabetes in Swedish primary care: a cross-sectional analysis of regional primary care registry data (QregPV).","Andersson T","2026","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2025-110395","41628920","PMC12878446",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0003096","Targeting Oxidative Stress and Mitochondrial Dysfunction in Diabetic Neuropathy: Mechanisms and Therapeutic Opportunities.","Sztanek F","2026","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox15030367","41897513","PMC13024170",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003097","Oral GLP-1-Based Therapeutics in the Obesity-Metabolic Syndrome-Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies.","Rabbani SA","2026","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph19050732","42198407","PMC13209388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003098","Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.","Schacht JP","2026","The American journal of psychiatry","randomized_trial","article","10.1176/appi.ajp.20260003","42522065","PMC13567346",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0003099","Subcutaneous injection of semaglutide causes increased muscle uptake of 18F-FDG and reduces the imaging quality of PET/CT: a case report.","Hong DC","2026","EJNMMI research","case_report","article","10.1186/s13550-026-01373-4","42118195","PMC13338111",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0003100","Comparative Post-Marketing Pharmacovigilance of Five GLP-1 Receptor Agonists: A Disproportionality Analysis of 412,643 FDA Adverse Event Reports (2004-2024)","Eduardo I","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9818000/v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0003101","Impact of Tirzepatide on FIB-4 in Patients with Type 2 Diabetes: A Comparison between GLP-1RA-naïve and GLP-1RA Switch Initiation in a Retrospective Cohort.","Ito H","2026","Internal medicine (Tokyo, Japan)","nonrandomized_study","article","10.2169/internalmedicine.6886-25","42055675",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003102","Treatment Strategies for Weight Loss Insufficiency and Weight Regain After Sleeve Gastrectomy: A Network Meta-Analysis and Systematic Review","Min Y","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-10121806/v1",null,null,null,null,"europepmc","FALSE","open_pdf","3",null,"Preprint"],["R0003103","Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.","Stefanou MI","2024","Therapeutic advances in neurological disorders","systematic_review","article","10.1177/17562864241281903","39345822","PMC11437580","PROSPERO:CRD42024515966",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; other; review"],["R0003104","The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).","McIntyre RS","2024","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2023.2295397","38087976",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003105","Efficacy of GLP-1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomised controlled trials.","Talavera A","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70102","40937512",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003106","Paediatric proteomic signatures of cardiometabolic disease-associated traits predict adult disease outcomes.","Landman JM","2026","Nature metabolism","other","article","10.1038/s42255-026-01589-7","42728365","PMC13597307",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003107","Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: challenges and opportunities.","Halimi JM","2026","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf426","40660809",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0003108","A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists.","Wu Q","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1532587","40182628","PMC11966957","PROSPERO:CRD42024543945",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; systematic-review; review"],["R0003109","Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.","Abdel-Rahman SM","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70506","41605813",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003110","Therapeutic Modulation of Nitric Oxide Pathways to Address Insulin Resistance in Cardiovascular-Kidney-Metabolic Syndrome.","Ceteraș LM","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27177701","42737598","PMC13566844",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003111","Glucagon-Like Peptide-1 Receptor Agonists: A New Era in Cardiometabolic and Cardiovascular Care.","Tajdini M","2025","Research in heart yield and translational medicine","commentary","article","10.18502/jthc.v20i3.20107","42781493","PMC13599719",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0003112","Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Inflammatory Bowel Disease.","Boumitri C","2025","Gastroenterology & hepatology","other","article",null,"39897342","PMC11784567",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0003113","Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation.","Maya J","2025","JAMA","nonrandomized_study","article","10.1001/jama.2025.20951","41284263","PMC12645404",null,"S002591","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; article-commentary; article"],["R0003114","Glucagon-like Peptide 1 Receptor Agonists and Asthma Exacerbations: Which Patients Benefit Most?","Wang T","2024","Annals of the American Thoracic Society","nonrandomized_study","article","10.1513/annalsats.202309-836oc","39012183","PMC11568508",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003115","Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort.","Lu DF","2025","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v16.i2.98552","39959283","PMC11718473",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003116","Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.","Wu Y","2026","BMC medicine","systematic_review","article","10.1186/s12916-026-04705-2","41715123","PMC13020221","PROSPERO:CRD42025636991",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; article"],["R0003117","Cardiometabolic Comorbidities in COPD: Focus on Diabetes, GLP-1 Receptor Agonists, SGLT-2 Inhibitors and Antidiabetic Drugs.","Kallieri M","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15052082","41827498","PMC12986202",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003118","Beyond Skin Laxity: GLP-1 Receptor Agonist-Induced Lean Mass Depletion and Surgical Tissue Quality in Aesthetic Surgery: A Narrative Review.","Cuggy C","2026","Aesthetic surgery journal. Open forum","nonrandomized_study","article","10.1093/asjof/ojag163","42820120","PMC13626246",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0003119","Hip and Knee Arthroplasty in Patients with Obesity.","Koh CK","2025","The Journal of bone and joint surgery. American volume","narrative_review","article","10.2106/jbjs.25.00131","40938955",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003120","Glucagon-like peptide-1 receptor agonists during pregnancy and lactation.","Zipursky JS","2024","CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","other","article","10.1503/cmaj.240768","39681363","PMC11649328",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0003121","Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomization.","Zhang L","2025","BMC psychiatry","randomized_trial","article","10.1186/s12888-025-06914-0","40369498","PMC12079933",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0003122","Glucagon-Like Peptide-1 Receptor Agonists Lead to Gastrointestinal Benefits in Patients with Type 2 Diabetes: A Real-World Study.","Hsu JH","2025","Medical science monitor : international medical journal of experimental and clinical research","nonrandomized_study","article","10.12659/msm.946935","40424213","PMC12125961",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003123","Papillary Thyroid Carcinoma Following Semaglutide Therapy for Metabolic Syndrome: A Case Presentation and Review of Current Evidence","Haddadin J","2026","Research Square","narrative_review","preprint","10.21203/rs.3.rs-8344892/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003124","Glucagon-like peptide-1 receptor agonists and capsule endoscopy in patients with diabetes: a matched cohort study.","Odah T","2025","Gastrointestinal endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.07.014","39094916",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003125","Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.","Brown A","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70246","42345739","PMC13422669",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; preprint; article"],["R0003126","Use of continuous glucose monitoring when initiating glucagon-like peptide-1 receptor agonist therapy in insulin-treated diabetes.","Hirsch IB","2024","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15883","39193839",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003127","Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.","Ding M","2026","iScience","preclinical","article","10.1016/j.isci.2026.117174","42630988","PMC13495082",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003128","Glucagon-like peptide-1 receptor agonists: Exploring the mechanisms from glycemic control to treatment of multisystemic diseases.","Kong MW","2024","World journal of gastroenterology","commentary","article","10.3748/wjg.v30.i36.4036","39351253","PMC11439120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0003129","Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review.","Birda CL","2026","Autoimmunity reviews","systematic_review","article","10.1016/j.autrev.2025.103936","41077375",null,"OSF:osf.io/jvmz6",null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; other; review"],["R0003130","Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease.","Nakhleh A","2025","Journal of clinical medicine","randomized_trial","article","10.3390/jcm14228209","41303244","PMC12653522",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0003131","Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study.","Burke O","2025","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.01.046","39863171",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003132","The Effect of Weight Loss and Metabolic Interventions on Recurrence After Atrial Fibrillation Ablation.","Fu S","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15166493","42652896","PMC13514514",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003133","Multifactorial Mechanisms and Therapeutic Role of the Gut Microbiota in Sarcopenic Obesity: Role of Lifestyle and Gut Microbiota-Derived Metabolites.","Tao Y","2026","Nutrition reviews","other","article","10.1093/nutrit/nuaf274","41528387",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003134","GLP-1 receptor agonists in kidney transplant recipients with type 2 diabetes mellitus: a systematic review and meta-analysis on mortality and major adverse kidney events.","Aliyeva T","2026","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-025-01801-7","41522206","PMC12783420",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review"],["R0003135","Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c.","German J","2026","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2025-005546","42020116","PMC13110560",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003136","Multiomics insight into the role of glucagon-like peptide-1 receptor agonists in heart failure.","Tao Y","2025","ESC heart failure","other","article","10.1002/ehf2.15310","40290076","PMC12287862",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003137","Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.","Lamothe S","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16175","39829337","PMC11885082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003138","Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.","Lassen MCH","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15872","39215626",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003139","GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.","Tan YW","2025","Langenbeck's archives of surgery","systematic_review","article","10.1007/s00423-025-03831-4","41071360","PMC12513976",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0003140","The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity.","Betensky DJ","2025","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-24-03609","40953447","PMC13229537",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0003141","Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact.","Xie Z","2025","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2025.1618079","40777992","PMC12328412",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003142","GLP-1 Receptor Agonists Are Associated With Reduced Mortality Following Diabetic Foot Ulcers: A Nationwide Observational Study.","Bonnet JB","2026","Diabetes care","nonrandomized_study","article","10.2337/dc25-2120","41615296",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; Observational Study; other; article"],["R0003143","Perioperative Implications of Glucagon-like Peptide-1 Receptor Agonists.","Wolfe RC","2024","Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses","other","article","10.1016/j.jopan.2024.09.022","39617519",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003144","Preoperative GLP-1 Receptor Agonists Exposure and Risk of Postoperative Acute Kidney Injury after Metabolic and Bariatric Surgery: A Retrospective Study.","Hung KC","2026","Obesity surgery","randomized_trial","article","10.1007/s11695-025-08436-w","41405672",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0003145","A Rare Case of Dulaglutide-Associated Angioedema in a Male Patient.","Karakousis N","2021","Cureus","case_report","article","10.7759/cureus.20041","34987924","PMC8717822",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003146","Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.","Tan X","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70440","41508706","PMC12992163",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0003147","GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis.","Hooper L","2025","Pharmacotherapy","nonrandomized_study","article","10.1002/phar.70007","39989027","PMC11998891",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003148","[GLP-1 receptor agonists : impact on diabetic kidney disease].","Wéra M","2024","Revue medicale suisse","other","article","10.53738/revmed.2024.20.884.1488","39219391",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0003149","Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study.","Sardu C","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112452","40912462",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0003150","Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists.","Song R","2022","Journal of diabetes research","narrative_review","article","10.1155/2022/4554996","35434139","PMC9012640",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003151","Racial and ethnic disparities in early uptake of GLP-1 receptor agonists in patients with and without MASLD","Boateng S","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-6926160/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003152","Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide.","Al Ozairi E","2026","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.70213","42555627","PMC13440749",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0003153","Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum.","Jalleh RJ","2024","World journal of diabetes","commentary","article","10.4239/wjd.v15.i10.2036","39493561","PMC11525724",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0003154","Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.","Branigan P","2026","Cureus","systematic_review","article","10.7759/cureus.116039","42724505","PMC13559776",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003155","Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.","Targher G","2025","Gut","randomized_trial","article","10.1136/gutjnl-2024-334023","39592207",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0003156","Endothelial Dysfunction and Obesity: New Diagnostic and Therapeutic Strategies.","Giglio RV","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27177552","42737456","PMC13565607",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003157","Potential kidney protective effects of glucagon-like peptide-1 receptor agonists.","Trevella P","2024","Nephrology (Carlton, Vic.)","other_trial","article","10.1111/nep.14336","39030739",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0003158","Trends in the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists among ischemic stroke patients.","Ding Q","2026","Cardiovascular diabetology. Endocrinology reports","nonrandomized_study","article","10.1186/s40842-026-00280-w","41803896","PMC12973876","ClinicalTrials.gov:NCT04322162",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003159","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease.","Wang W","2023","International journal of chronic obstructive pulmonary disease","narrative_review","article","10.2147/copd.s393323","36815056","PMC9939668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003160","Cardiometabolic and renal complications of obesity: an updated comprehensive overview by SIO - Campania region.","Bracale R","2026","Minerva endocrinology","other","article","10.23736/s2724-6507.26.04454-4","42383929",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003161","GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With Diabetes and Peripheral Artery Disease: An Updated Systematic Review and Meta-Analysis.","Shuja SH","2026","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2025.09.039","41022246",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003162","GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms.","Viquez Burboa GU","2026","Skin appendage disorders","systematic_review","article","10.1159/000553070","42621629","PMC13489628","PROSPERO:CRD420261335458",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review"],["R0003163","Sex-Based Differences in SGLT2i and GLP-1RA Use and Mortality in T2DM with Atherosclerotic Cardiovascular Disease.","Vaknin-Assa H","2026","Biomedicines","nonrandomized_study","article","10.3390/biomedicines14020404","41751303","PMC12937676",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003164","GLP-1 Receptor Agonists in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis on Mortality and Major Adverse Kidney Events","Aliyeva T","2025","Research Square","systematic_review","preprint","10.21203/rs.3.rs-7859743/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0003165","Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.","Ayoub M","2024","Cancers","nonrandomized_study","article","10.3390/cancers16183224","39335195","PMC11430483",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003166","Current Updates on Pharmacotherapy for Obstructive Sleep Apnea.","Kim SW","2026","Journal of rhinology : official journal of the Korean Rhinologic Society","narrative_review","article","10.18787/jr.2026.00003","42548223","PMC13434379",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003167","GLP-1 and the cardiovascular system.","Kahles F","2026","The Journal of clinical investigation","narrative_review","article","10.1172/jci194748","41697744","PMC12904707",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003168","Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.","Thomsen RW","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16364","40196933","PMC12000858",null,"S002092; S002095","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0003169","A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.","Aristizábal-Colorado D","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1605746","40692593","PMC12277171",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003170","With Great Statistical Power Comes Great Responsibility: Pitfalls of Claims Database Research on the Periprocedural Glucagon-like Peptide 1 Receptor Agonist Management Debate.","Hiramoto B","2025","Gastroenterology","nonrandomized_study","article","10.1053/j.gastro.2024.05.039","39245412","PMC11663097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; research-article; article"],["R0003171","Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin.","Pavlidis G","2026","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina62020254","41752654","PMC12941497",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0003172","Real-world Associations Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Accounting for Longitudinal Glycemic Control.","Talebi R","2025","Retina (Philadelphia, Pa.)","nonrandomized_study","article","10.1097/iae.0000000000004507","40334190",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003173","Weight Loss Outcomes Between GLP-1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta-Analysis and Meta-Regression.","Tahir M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70676","41873009",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review"],["R0003174","Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.","Arduino I","2026","International journal of pharmaceutics","other","article","10.1016/j.ijpharm.2026.127291","42570682",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003175","Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category.","Navas A","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-026-01875-3","42105046","PMC13253911","ClinicalTrials.gov:NCT01720446","S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0003176","Glucagon-like Peptide-1 Receptor Agonists: Additional Improvement of Erectile Dysfunction in Type 2 Diabetes.","Popovic DS","2025","Current vascular pharmacology","commentary","article","10.2174/0115701611415013250616111421","40600541",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0003177","GLP-1 Receptor Agonist Initiation and Anti-VEGF Treatment Frequency in Diabetic Macular Edema: an IRIS  <sup>®<\/sup>  Registry Cohort Study","Nagalamadaka P","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.08.29.26361426",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0003178","Longitudinal Analysis of Obesity Drug Use and Public Awareness.","Berning P","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2024.57232","39878977","PMC11780480",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0003179","GLP-1 Receptor Agonists and Acute Diabetes Complications in Adults with Type 1 Diabetes: A Target Trial Emulation.","Dai H","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.11.10.25339908","41292646","PMC12642713",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0003180","Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity.","Innocent B","2025","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","case_report","article","10.1093/ajhp/zxaf088","40220283",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0003181","Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging.","Ridha Z","2024","Aesthetic surgery journal","narrative_review","article","10.1093/asj/sjae132","38874170",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003182","Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?","Mansur RB","2024","CNS spectrums","narrative_review","article","10.1017/s109285292400244x","39801083",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0003183","A commentary on 'Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials'.","Zhang G","2024","International journal of surgery (London, England)","other","article","10.1097/js9.0000000000001725","38814292","PMC11392142",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003184","The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.","Wen J","2025","Journal of diabetes","narrative_review","article","10.1111/1753-0407.70119","40739991","PMC12311314",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003185","The essential role of the physiotherapy profession in incretin-based weight loss.","Sampford J","2026","Physiotherapy","other","article","10.1016/j.physio.2025.101840","41273939",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0003186","The Liraglutide Effects in Atrial Fibrillation (LEAF) Study.","Goldberger JJ","2026","JACC. Clinical electrophysiology","randomized_trial","article","10.1016/j.jacep.2026.03.026","42159524",null,"ClinicalTrials.gov:NCT03856632","S000737","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0003187","8007 The Effect of Glucagon-Like Peptide-1 Receptor Agonists in Reducing Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC11453410",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0003188","Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.","Zhu X","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1750615","41987895","PMC13076170","PROSPERO:CRD420251146144",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; systematic-review; article"],["R0003189","Semaglutide-Induced Liver Injury.","Kalsi H","2025","ACG case reports journal","case_report","article","10.14309/crj.0000000000001776","40761336","PMC12321452",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003190","Treatment Intensification Strategies and Metabolic Outcomes in Individuals With Type 2 Diabetes on GLP-1 RA Therapy.","Falcetta P","2025","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgaf229","40199481",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003191","From Oxyntomodulin to Retatrutide: Engineering Metabolic Polyagonism","Saldívar-Cerón HI","2026","Preprints.org","other_trial","preprint","10.20944/preprints202610.0201.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","5","FALSE","Preprint; preprint"],["R0003192","Allodynia (skin tenderness) associated with semaglutide: A case series.","Stark J","2025","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","case_report","article","10.1093/ajhp/zxaf008","39862389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0003193","Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).","Choi E","2024","Children (Basel, Switzerland)","nonrandomized_study","article","10.3390/children11030275","38539310","PMC10969291",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0003194","Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.","Riester MR","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15682","38779879","PMC11233240",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; Research Support, N.I.H., Extramural; research-article; article"],["R0003195","Emerging therapeutic potential of glucagon-like Peptide-1 receptor agonists in knee osteoarthritis: a systematic review.","Li Y","2025","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2025.1627691","41158135","PMC12554640","PROSPERO:CRD420250656321",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003196","A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.","Bader S","2024","Women's health (London, England)","systematic_review","article","10.1177/17455057241234530","38444070","PMC10916466",null,"S000630","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; other; review"],["R0003197","Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study.","Montaser E","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71287","42675550","PMC13646344",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0003198","Beyond Glycemic Control: Glucagon-Like Peptide-1 Receptor Agonists as Potential Modifiers of Aortic Disease.","Singh K","2025","Cardiology in review","preclinical","article","10.1097/crd.0000000000001045","40963159",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003199","Overcoming therapeutic inertia in primary care: a multisite quality initiative to increase guideline-based prescribing for patients with diabetes.","Latreille MW","2025","BMJ open quality","other","article","10.1136/bmjoq-2025-003499","41125367","PMC12548601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; brief-report; article"],["R0003200","Correspondence to editorial on \"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis\".","Kim H","2024","Clinical and molecular hepatology","systematic_review","article","10.3350/cmh.2024.0705","39188227","PMC11540367",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; letter; Journal Article"],["R0003201","Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?","Liu K","2025","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2025.101696","40834980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003202","Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis.","Nassar M","2025","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2025.101613","39826595",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003203","Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study.","Karanxha J","2026","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2026.134773","42710812",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Observational Study; article"],["R0003204","The Use of Semaglutide in Patients Undergoing Lumbar Fusion Does not Increase 90-Day Medical or 1-Year Implant Complications.","Ghali A","2025","Clinical spine surgery","nonrandomized_study","article","10.1097/bsd.0000000000001800","40096579",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003205","Reduced risks of colorectal cancer with GLP-1RAs in type 2 diabetes: A nationwide cohort study using a target trial emulation framework.","Wu CC","2025","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2025.101695","40796052",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003206","Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.","Hegaz MG","2026","BMC endocrine disorders","systematic_review","article","10.1186/s12902-026-02538-x","42750018","PMC13579720",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0003207","Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.","Passos PRC","2026","Diabetes care","systematic_review","article","10.2337/dc26-0336","41973508",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Review; article"],["R0003208","The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Abusedera O","2025","Journal of clinical medicine","systematic_review","article","10.3390/jcm14248734","41464636","PMC12733705","PROSPERO:CRD420251034071",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003209","Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.","Haluzík M","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15811","39245809",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003210","Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.","Takeshita Y","2022","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13749","35034428","PMC9153847",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0003211","Oral Semaglutide: A Step Forward in Cardiovascular Risk Management for Type 2 Diabetes.","Luna-Ceron E","2025","Cardiovascular & hematological disorders drug targets","nonrandomized_study","article","10.2174/011871529x421551250801194823","40798974",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0003212","Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.","Xie Z","2024","Metabolism: clinical and experimental","systematic_review","article","10.1016/j.metabol.2024.156038","39305981",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0003213","An investigation into adsorption process of biologically- fermented semaglutide precursor peptide on macroporous resins","Zhang Z","2025","Food and Bioproducts Processing.","other","article","10.1016/j.fbp.2025.06.006",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003214","Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice.","Takubo M","2024","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","preclinical","article","10.1055/a-2307-8036","38626913",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003215","When the Transition Goes Wrong: A Rare Case of Diabetic Ketoalkalosis After Transitioning to Tirzepatide in Insulin-dependent Type 2 Diabetes.","Sultan W","2025","Cureus","case_report","article","10.7759/cureus.87031","40746803","PMC12310415",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003216","Model-based network meta-analysis: Joint estimation of dose-response and time-course relationships.","Strathe A","2026","Research synthesis methods","systematic_review","article","10.1017/rsm.2026.10098","42230565",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; article"],["R0003217","Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation.","Choi J","2025","JHEP reports : innovation in hepatology","nonrandomized_study","article","10.1016/j.jhepr.2025.101624","41362712","PMC12682120",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003218","One-year weight loss and metabolic outcomes after laparoscopic sleeve gastrectomy in adolescents compared with young adults: A propensity score-matched cohort study.","Taki-Eldin A","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100315","42643169","PMC13503128",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003219","Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes.","Alghamdi FA","2024","Cureus","narrative_review","article","10.7759/cureus.74345","39720384","PMC11668125",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003220","Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.","Wong HJ","2025","Journal of hypertension","systematic_review","article","10.1097/hjh.0000000000003903","39445607",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0003221","Risk of Aspiration Pneumonitis After Elective Esophagogastroduodenoscopy in Patients on Glucagon-Like Peptide-1 Receptor Agonists.","Al Sakka Amini R","2024","Cureus","nonrandomized_study","article","10.7759/cureus.66311","39238749","PMC11376965",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003222","Weight Loss Therapies and Hypertension Benefits.","Katsi V","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12102293","39457606","PMC11504410",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003223","Potential protective role of GLP-1 receptor agonists for lithium-induced nephrotoxicity: a population-based observational study.","McIntyre RS","2025","CNS spectrums","nonrandomized_study","article","10.1017/s1092852925100709","41220244","PMC13076073",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0003224","GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysis","Triozzi JL","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.10.13.25337903",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003225","Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.","Hitaka K","2026","International journal of obesity (2005)","preclinical","article","10.1038/s41366-026-02025-2","41723268","PMC13056526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0003226","Glucagon-Like Peptide-1 Receptor Agonists are Not Associated with an Increased Risk of Progressing to Vision-Threatening Diabetic Retinopathy.","Tauqeer Z","2025","Ophthalmic epidemiology","nonrandomized_study","article","10.1080/09286586.2024.2399764","39389007","PMC11982348",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0003227","Exploring Glucagon-Like Peptide-1 Receptor Agonist Use in Inflammatory Bowel Disease Patients.","Lichtenstein GR","2025","Gastroenterology & hepatology","other","article",null,"39897337","PMC11784568",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0003228","Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis.","Li Y","2026","Biomedical reports","systematic_review","article","10.3892/br.2026.2165","42339050","PMC13284603",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0003229","Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes.","Grosicki GJ","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16151","39743934",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0003230","Patients With Severe Obesity Are Made Eligible for Complex Abdominal Wall Repair After Preoptimization With GLP-1 Agonists: Results of a Bicentric Pilot Study.","Romain B","2025","World journal of surgery","nonrandomized_study","article","10.1002/wjs.12547","40088135","PMC11994139",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0003231","Response to Milder et al. \"Letter to the editor regarding multisociety clinical practice guidance- safe use of glucagon-like peptide-1 receptor agonists in perioperative period\".","Kindel TL","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","commentary","article","10.1016/j.soard.2025.01.012","40055129",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0003232","The Cardiovascular Benefits of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.","Kallash M","2025","Cardiology in review","other_trial","article","10.1097/crd.0000000000000970","40539787",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0003233","Beyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity.","Boroghină SC","2026","Medicines (Basel, Switzerland)","nonrandomized_study","article","10.3390/medicines13030021","42496290","PMC13398316",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003234","Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.","Ruggiero R","2025","European journal of pharmacology","nonrandomized_study","article","10.1016/j.ejphar.2025.178004","40716637",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0003235","Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.","Jung I","2026","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2025.0681","41277001","PMC13175701",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0003236","Factors Associated With Initiation of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonists in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the Kidney CHAMP Trial.","Lavenburg LU","2025","Diabetes spectrum : a publication of the American Diabetes Association","randomized_trial","article","10.2337/ds25-0046","41257235","PMC12620743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0003237","Impact of Antidiabetic Medications on IgG and Plasma Protein N-Glycosylation in Type 2 Diabetes Patients","Mraz N","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.06.17.26355850",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003238","Reversibility and indefinite treatment: implications for consent and widening inequalities - a response to Ryan and Savulescu.","Carter P","2026","Journal of medical ethics","other","article","10.1136/jme-2026-111965","41895820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003239","Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome.","Liao XC","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag152","42245471","PMC13231163",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003240","New pharmacological agents and emerging therapeutic targets for painful diabetic neuropathy.","Panou T","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1788702","41987888","PMC13076184",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003241","Summary for Patients: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.",null,"2025","Annals of internal medicine","other","article","10.7326/annals-24-01590-ps","39761585",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003242","Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial post hoc analysis.","Dinkla L","2025","Frontiers in aging","randomized_trial","article","10.3389/fragi.2025.1691007","41393101","PMC12695752","ClinicalTrials.gov:NCT05786521","S000230","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; brief-report; article"],["R0003243","Effect of Semaglutide on Recurrence of Intracranial Hypertension After Venous Sinus Stenting: A Two-Phase Cohort Study","Lu C","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-10482089/v1",null,null,"ClinicalTrials.gov:NCT06361823","S000276","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0003244","Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side.","Abdelrahman AM","2024","Journal of clinical medicine","narrative_review","article","10.3390/jcm13247732","39768655","PMC11677827",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Preprint; review-article; preprint; article"],["R0003245","The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials.","Yu M","2023","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-023-01118-6","37491292","PMC10369734","PROSPERO:CRD42023396138",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0003246","Glucagon-like peptide-1 agonists alleviate adenine-induced nephrotoxicity in rats: interaction with the renin-angiotensin system and role of NLRP-3 inflammasome, nephrin and KIM-1.","Nematalla HA","2025","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2025.117431","41110489",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003247","Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes Following Operative Ankle Fracture Repair in Patients With Type 2 Diabetes: A National Database Study.","White CJK","2025","Foot & ankle international","nonrandomized_study","article","10.1177/10711007251364187","40923457",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003248","Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care.","Gigliotti L","2025","Journal of the Academy of Nutrition and Dietetics","narrative_review","article","10.1016/j.jand.2024.10.023","39521378",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003249","Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification.","Lee J","2024","Diabetes & metabolism journal","other","article","10.4093/dmj.2022.0363","38173373","PMC10850275",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0003250","Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases.","Li Y","2026","Drug metabolism and disposition: the biological fate of chemicals","nonrandomized_study","article","10.1016/j.dmd.2026.100346","42418948",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0003251","Glucagon-Like Peptide-1 Receptor Agonists for Abdominal Aortic Aneurysm?","Birnbaum Y","2025","Cardiovascular drugs and therapy","commentary","article","10.1007/s10557-024-07647-0","39531113",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0003252","Effectiveness of adding glucagon-like peptide-1 receptor agonist on diabetes complications and mortality among basal insulin-treated people with type 2 diabetes: A real-world Korean study.","Ha KH","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2025.108983","40117955",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003253","Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).","Agarwal R","2025","Diabetes care","randomized_trial","article","10.2337/dc25-1673","40968755","PMC12583382",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; other; article"],["R0003254","Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study.","Ferician AC","2026","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina62091816","42796421","PMC13609424",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003255","SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.","Arow Z","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02874-7","40887578","PMC12400556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; Comparative Study; research-article; article"],["R0003256","The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: A meta-analysis of randomized controlled trials.","Lu J","2025","European journal of pharmacology","systematic_review","article","10.1016/j.ejphar.2025.177885","40615102",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0003257","Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control.","Pachimatla AG","2025","JCI insight","nonrandomized_study","article","10.1172/jci.insight.195484","40857107","PMC12513478",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0003258","The Effects of New Antidiabetic Drugs on the Course of Peripheral Arterial Occlusive Disease.","Kröger K","2026","Deutsches Arzteblatt international","randomized_trial","article","10.3238/arztebl.m2026.0055","42059101","PMC13330741",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003259","Do GLP-1 agonists affect perioperative risk in spine surgery? A systematic review and meta-analysis.","Ononogbu-Uche FC","2026","North American Spine Society journal","systematic_review","article","10.1016/j.xnsj.2025.100835","41551027","PMC12811479","PROSPERO:CRD420251111692",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003260","Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.","Milder DA","2024","Anaesthesia","nonrandomized_study","article","10.1111/anae.16306","38740566",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0003261","American Society for Gastrointestinal Endoscopy position statement on periendoscopic management of patients on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.","Sharaiha RZ","2025","Gastrointestinal endoscopy","other","article","10.1016/j.gie.2024.10.057","39892967",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0003262","Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy.","Sidra FNU","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2024.108925","39644537",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; Research Support, N.I.H., Extramural; article"],["R0003263","Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status.","Ulrich FS","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70535","41703773","PMC12992168",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003264","Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman.","Abdelshafey EE","2026","The American journal of case reports","case_report","article","10.12659/ajcr.952750","42381258","PMC13334994",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0003265","Influence of glucagon-like peptide-1 receptor agonists on renal parameters: a meta-analysis of randomized controlled trials.","Li W","2025","BMC endocrine disorders","systematic_review","article","10.1186/s12902-025-01948-7","40336001","PMC12056997",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0003266","Acetonemic vomiting: a potential complication of treatment with glucagon-like peptide-1 receptor agonists especially in lean type 2 diabetes patients.","Fujishiro M","2025","Diabetology international","case_report","article","10.1007/s13340-024-00758-x","39877456","PMC11769917",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003267","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas.","McIntyre RS","2024","Expert opinion on drug safety","commentary","article","10.1080/14740338.2024.2335215","38520274",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0003268","Pharmacokinetic Characteristics of a Once-Weekly Combination Therapy of Insulin Icodec and Semaglutide Versus Its Separate Components in Chinese Individuals with Type 2 Diabetes.","Wang F","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-025-01803-x","41051695","PMC12579042","ClinicalTrials.gov:NCT05435677","S001682","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0003269","Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients.","Nadeem D","2024","Gastrointestinal endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.04.2900","38692518",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003270","The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.","Ng VWW","2024","Clinical obesity","systematic_review","article","10.1111/cob.12642","38273176",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Journal Article; review"],["R0003271","Gallbladder Outcomes With Prokinetic Agents and Semaglutide in Adults With Type 2 Diabetes","Chan H","2025","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.176551396.60769594/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003272","Changes in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition.","Gizdović I","2026","Cells","preclinical","article","10.3390/cells15141258","42505368","PMC13406854",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003273","Skeletal Muscle Mass Loss with Use of Dual GLP-1/GIP Receptor Agonist Tirzepatide: CaseReport and Review of Literature","Zinn J","2024","Research Square","narrative_review","preprint","10.21203/rs.3.rs-4022269/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003274","Noninsulin Therapies in Management of Type 1 Diabetes.","Saeed ZI","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.1016/j.eprac.2025.06.027","40618954",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0003275","Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity.","Roth CL","2026","Drugs","narrative_review","article","10.1007/s40265-025-02280-z","41678022",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003276","Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation.","Khan TTS","2026","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2026.127363","42669320",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003277","Novel antidiabetic agents and the risk of respiratory diseases: a systematic review and meta-analysis of 27 randomized controlled trials.","Yu Z","2025","Frontiers in medicine","systematic_review","article","10.3389/fmed.2025.1721311","41567683","PMC12815760","PROSPERO:CRD420251158592",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0003278","Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.","Tang H","2024","Annals of internal medicine","nonrandomized_study","article","10.7326/m24-0329","39008852","PMC12132802",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0003279","Weekly Liraglutide for the Management of Intractable Polydipsia and Interdialytic Weight Gain in a Patient on Hemodialysis: A Case Report.","Mora-Bravo F","2026","Cureus","case_report","article","10.7759/cureus.102197","41585614","PMC12831222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003280","Routine peri-operative cessation of glucagon-like peptide-1 receptor agonists has unintended consequences.","Levy NA","2025","Anaesthesia","commentary","article","10.1111/anae.16509","39638371",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0003281","Weight loss mediates improvement in proinsulin processing during GLP-1 receptor agonist treatment.","Liu R","2025","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-025-01765-x","40682186","PMC12275330",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0003282","Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease.","Clarke L","2025","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-025-08964-6","40069510",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003283","The Interplay of Diabetes, Glucose Variability, and Antidiabetic Therapy in Preventing Periprosthetic Joint Infection Following Hip and Knee Arthroplasty: A Review.","Askari A","2026","JBJS reviews","narrative_review","article","10.2106/jbjs.rvw.26.00049","42339956",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003284","Novel Glucagon-like Peptide 1 Receptor Agonists for Treating Type II Diabetes.","Sabnis RW","2024","ACS medicinal chemistry letters","commentary","article","10.1021/acsmedchemlett.4c00303","39140072","PMC11318100",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0003285","Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis.","Omarion A","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1833904","42490840","PMC13375489","OSF:osf.io/zyhws",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Network Meta-Analysis; Journal Article; Systematic Review; Comparative Study; systematic-review; article"],["R0003286","GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.","Inamine S","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71190","42552238","PMC13538759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003287","Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.","Ali MAS","2025","Patient preference and adherence","nonrandomized_study","article","10.2147/ppa.s569096","41446509","PMC12724230",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003288","The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care.","Gatto A","2025","Current reviews in musculoskeletal medicine","narrative_review","article","10.1007/s12178-025-09978-3","40372699","PMC12325148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003289","Incretin signaling suppresses high glucose-induced β-cell hypoxia through a cAMP/PKA-dependent mechanism.","Saranaruk P","2026","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2026.154627","42790025",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003290","Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database.","Kim TH","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15864","39161072",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003291","Preprocedure Care of Patients on Glucagon-like Peptide-1 Receptor Agonists: A Multisociety Clinical Practice Guidance.","Joshi GP","2024","Anesthesiology","other","article","10.1097/aln.0000000000005231","39471342",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003292","Glucagon-like peptide-1 receptor agonists and aspiration risk.","McIsaac DI","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1986","39438049",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0003293","Confounding Factors in the Association Between Glucagon-Like Peptide-1 Receptor Agonist Use and Retained Gastric Contents in Asymptomatic Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Study.","Elimihele TA","2024","Cureus","nonrandomized_study","article","10.7759/cureus.69152","39398811","PMC11467768",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003294","Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.","Al-Jarshawi M","2026","Cardiovascular diabetology. Endocrinology reports","other_trial","article","10.1186/s40842-026-00299-z","42169198","PMC13196176",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0003295","Flash Glucose Monitoring System Enhances Glycemic Control and Metabolic Health in People with Type 2 Diabetes on GLP-1RA-Based Therapy: Real-World Evidence.","Al Hayek A","2026","Advances in therapy","nonrandomized_study","article","10.1007/s12325-026-03495-6","41718943",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003296","Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges.","Zhou ZD","2025","Pharmacological research","preclinical","article","10.1016/j.phrs.2025.107770","40344943",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003297","Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.","Abulehia A","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70187","41787737","PMC12963462",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Comparative Study; Review; review-article; article"],["R0003298","Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.","Leiter LA","2026","Diabetes care","randomized_trial","article","10.2337/dc26-0847","42251764",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; other; article"],["R0003299","GLP-1 Receptor Agonists and Clinical Outcomes after Endovascular Treatment of Unruptured Aneurysms in Type 2 Diabetes.","Perng PS","2025","Stroke (Hoboken, N.J.)","nonrandomized_study","article","10.1161/svin.125.001933","41608727","PMC12697656",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003300","GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes","Ditchfield C","2026","bioRxiv","other","preprint","10.64898/2026.07.20.739515",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003301","Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVD.","Tan X","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112473","40934962",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Comparative Study; article"],["R0003302","Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors.","Wiener BG","2024","Clinical toxicology (Philadelphia, Pa.)","case_report","article","10.1080/15563650.2024.2322049","38470137",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0003303","Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study.","Wolff Sagy Y","2025","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2025.103213","40599584","PMC12208935",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0003304","Measuring Food Noise in Hispanic Persons: Spanish Translation of the Ro Allison Indiana Dhurandhar Food Noise (RAID-FN) Inventory","Jimenez-Garcia JA","2025","PsyArXiv","other","preprint","10.31234/osf.io/4sgj7_v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003305","Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Atherosclerotic Cardiovascular Risk Among Patients With Type 2 Diabetes in Primary Health Care Settings in Jeddah, Saudi Arabia.","A Ljohani R","2026","Cureus","nonrandomized_study","article","10.7759/cureus.103507","41846669","PMC12989733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003306","Advances in GLP-1 receptor agonists for pain treatment and their future potential.","He Y","2025","The journal of headache and pain","narrative_review","article","10.1186/s10194-025-01979-4","40016636","PMC11869436",null,"S000353","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0003307","Complementary neuroprotective effects of semaglutide and papaya in diabetic encephalopathy via antioxidant and insulin-signaling pathways.","Zeweil MM","2026","Scientific reports","preclinical","article","10.1038/s41598-026-42791-7","41792420","PMC13035831",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003308","Glucagon-like peptide-1 receptor agonist use is associated with increased rates of acne vulgaris diagnosis in nondiabetic obese women but not men: A retrospective cohort study.","Cho SW","2025","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.02.009","39923849",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003309","Incretin-Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency.","Falahee B","2026","Obesity (Silver Spring, Md.)","narrative_review","article","10.1002/oby.70294","42782166",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003310","Differential Therapeutic Modulations of Adiponectin: Beneficial, Adverse, and Context-Dependent Effects in Chronic Coronary Syndromes.","Stojanović S","2026","Medical principles and practice : international journal of the Kuwait University, Health Science Centre","narrative_review","article","10.1159/000552748","42213633","PMC13412414",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003311","The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.","Jalleh RJ","2026","The Journal of clinical investigation","nonrandomized_study","article","10.1172/jci194740","41697736","PMC12904723",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0003312","Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.","Hendershot CS","2026","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2026.14898","42189538","PMC13213524","ClinicalTrials.gov:NCT05530577","S001126","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Research Support, N.I.H., Extramural; research-article; article"],["R0003313","Ethical Approaches to Limiting Overall Costs for Glucagon-Like Peptide-1 Receptor Agonists for Weight Management.","Dellgren J","2025","Annals of internal medicine","commentary","article","10.7326/annals-24-01317","39586102",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0003314","Metabolic health in severe mental illness: bridging the mortality gap - a narrative review.","Ishaq K","2026","Current opinion in psychiatry","narrative_review","article","10.1097/yco.0000000000001121","42742988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; review"],["R0003315","Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.","Samuels SL","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15430","38229444",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Multicenter Study; Journal Article; article"],["R0003316","A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity.","Xie J","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70794","42010360",null,"ClinicalTrials.gov:NCT06547775",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; article"],["R0003317","Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies.","Varra FN","2026","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina62081445","42654342","PMC13515260",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003318","Evidence for reduced migraine reporting with GLP-1 receptor agonists","Chen H","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-9854054/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0003319","GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis.","Rai P","2026","Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","nonrandomized_study","article","10.1016/j.jocn.2026.112089","42217849","PMC13354290",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; article"],["R0003320","[Hair loss during treatment of obesity: current state of the problem and potential solutions].","Troshina EA","2026","Problemy endokrinologii","narrative_review","article","10.14341/probl13817","42733368","PMC13585292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; review-article; article"],["R0003321","Cardiovascular effects of incretin receptor agonists: beyond glycemic control.","Ravic M","2026","Canadian journal of physiology and pharmacology","other_trial","article","10.1139/cjpp-2026-0184","42721492",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0003322","Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials.","Won H","2025","Translational and clinical pharmacology","other_trial","article","10.12793/tcp.2025.33.e3","40206874","PMC11976150",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0003323","GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?","Arredouani A","2025","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2025.108824","39983843",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0003324","GLP-1 Receptor Agonists as Treatment of Nondiabetic Ischemic Stroke: A Systematic Review and Meta-Analysis.","Michaelsen MK","2026","Stroke","systematic_review","article","10.1161/strokeaha.125.053075","41263069",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003325","Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice.","Oprea AD","2024","Anesthesiology","other","article","10.1097/aln.0000000000005204","39471345",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003326","Pulmonary hypertension related to sleep-disordered breathing.","LaCavera M","2026","Current opinion in pulmonary medicine","narrative_review","article","10.1097/mcp.0000000000001307","42713788",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003327","Pharma-cise in the Glucagon-like Peptide-1 Receptor Agonists Era: A Concept Whose Time Has Come.","Arena R","2024","Mayo Clinic proceedings","other","article","10.1016/j.mayocp.2024.07.007","39631985",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003328","Preoperative Strategies for Patients on Glucagon-like Peptide-1 Receptor Agonists Navigating Current Controversies and Future Directions.","Joshi GP","2024","Anesthesiology","nonrandomized_study","article","10.1097/aln.0000000000005222","39471348",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003329","Efficacy and Safety of Efpeglenatide in Patients With Type 2 Diabetes and Obesity: A Systematic Review.","Narayan N","2025","Cureus","systematic_review","article","10.7759/cureus.77089","39917155","PMC11801804",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003330","GLP-1 receptor agonists-another promising therapy for Alport syndrome?","Boeckhaus J","2025","Journal of rare diseases (Berlin, Germany)","narrative_review","article","10.1007/s44162-024-00065-8","40026358","PMC11870915",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003331","The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence.","Owczarczyk-Durma AC","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-026-01913-0","42667546","PMC13619989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0003332","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention.","Xiong C","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s451129","38406269","PMC10894520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003333","Effects of preoperative glucagon-like peptide-1 receptor agonist therapy on weight loss following bariatric surgery.","Friesch M","2025","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-025-11838-7","40490579",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003334","Monitoring Report: GLP-1 RA Prescribing Trends – March 2026 Data","Gratzl S","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.03.06.25323524",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003335","Increased Risk of New Onset NAION for Initiators of Semaglutide with Type 2 Diabetes in the U.S. Veterans Health Administration","Heberer K","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.09.15.25335753",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003336","Metabolic sarcopenia in the era of incretin-based therapy: a narrative review of mitochondrial determinants of muscle quality and emerging therapeutic strategies.","Park CH","2026","Journal of Yeungnam medical science","narrative_review","article","10.12701/jyms.2026.43.61","42680135",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review"],["R0003337","GLP-1 RA initiation versus metformin and risk of cardiomyopathy in patients with cancer and diabetes treated with chemotherapy, radiation, or immunotherapy: a target trial emulation.","Hernández-Pérez JG","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113119","41605300","PMC13525917",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003338","Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.","Pratt E","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15150","37264711",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Letter; article"],["R0003339","Advances in incretin therapies for targeting cardiovascular disease in diabetes.","Roberts TD","2025","Journal of molecular and cellular cardiology","narrative_review","article","10.1016/j.yjmcc.2025.03.007","40086589",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003340","Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.","Heisey HD","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70913","42244474","PMC13341420",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0003341","Association of glucagon-like peptide-1 receptor agonist use with patient-reported outcomes after lumbar decompression or fusion.","Parker J","2026","North American Spine Society journal","nonrandomized_study","article","10.1016/j.xnsj.2026.100882","42183111","PMC13191625",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003342","Beyond fat: Does semaglutide affect lean mass?","Jamialahmadi T","2025","Clinical nutrition (Edinburgh, Scotland)","narrative_review","article","10.1016/j.clnu.2024.12.004","39647240",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003343","Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.","Klonoff DC","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15636","38742898","PMC12051400",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0003344","Corrigendum to \"Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product\" [Obesity Pillars 12C (2024) 100138].","Bacus C","2024","Obesity pillars","notice","article","10.1016/j.obpill.2024.100144","39734694","PMC11681361",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0003345","Letter to the editor regarding multisociety clinical practice guidance - safe use of glucagon-like peptide-1 receptor agonists in perioperative period.","Milder TY","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","commentary","article","10.1016/j.soard.2024.12.014","39809624",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0003346","The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review.","Paschou IA","2025","Journal of the European Academy of Dermatology and Venereology : JEADV","narrative_review","article","10.1111/jdv.20694","40298469","PMC12645182",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003347","Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.","Chung CW","2026","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes25085","41549439","PMC12884623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003348","Acute Functional Gastric Outlet Obstruction Associated With Low-Dose Tirzepatide.","Iskander M","2025","Cureus","case_report","article","10.7759/cureus.78090","40026949","PMC11867769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003349","The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health.","Al Qassab M","2025","Current issues in molecular biology","narrative_review","article","10.3390/cimb47040285","40699685","PMC12025658",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003350","Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study.","Johannes CB","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01825-5","41364416","PMC12909696","ClinicalTrials.gov:NCT05526157","S002732","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003351","Agonizing GABABR suppresses GLP-1RA's chronotropic effect and reduces post-myocardial infarction arrhythmogenesis.","Qi R","2025","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2025.1616181","41244817","PMC12616031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003352","Update on Perioperative Medication Management for the Hand Surgeon: A Focus on Diabetes, Weight Loss, Rheumatologic, and Antithrombotic Medications.","Xu W","2024","The Journal of hand surgery","narrative_review","article","10.1016/j.jhsa.2024.05.018","39093237",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003353","The Optimal Treatments for Type 2 Diabetes from The Perspective of Anti-Aging Medicine","Yanai H","2025","Preprints.org","other","preprint","10.20944/preprints202508.0997.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003354","Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.","Al-Soleiti M","2025","Journal of clinical psychopharmacology","case_report","article","10.1097/jcp.0000000000002090","40999647","PMC12541346",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; Review; research-article; article"],["R0003355","Weight Loss in Primary Total Hip and Knee Arthroplasty: A Comparative Study of Glucagon-Like Peptide-1 Receptor Agonists and Bariatric Surgery.","Ledford CK","2026","Arthroplasty today","nonrandomized_study","article","10.1016/j.artd.2026.101988","41853803","PMC12995498",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003356","Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis of randomized controlled trials.","Emara A","2026","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-026-02218-9","42363271","PMC13563702",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003357","Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis.","Felson DT","2024","The New England journal of medicine","commentary","article","10.1056/nejme2409972","39476345",null,null,"S000353","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; article"],["R0003358","Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials.","Rivera FB","2025","Current medical research and opinion","systematic_review","article","10.1080/03007995.2024.2442027","39666879",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0003359","Glucagon-like peptide-1 receptor agonists are associated with fewer venous thromboembolic events and limb complications in obese patients with chronic venous insufficiency.","Micalo L","2026","Journal of vascular surgery. Venous and lymphatic disorders","nonrandomized_study","article","10.1016/j.jvsv.2026.102557","42323127","PMC13383999",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0003360","Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.","Tuttle KR","2026","Nature reviews. Nephrology","narrative_review","article","10.1038/s41581-026-01117-6","42697978",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003361","Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.","Herrou J","2024","Calcified tissue international","preclinical","article","10.1007/s00223-023-01150-8","37999750",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0003362","Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","Waqas SA","2025","Journal of cardiac failure","systematic_review","article","10.1016/j.cardfail.2025.01.022","39993464",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003363","Vitreous hemorrhage in a patient on tirzepatide: Coincidence or drug induced?","Azeem S","2026","Oman journal of ophthalmology","case_report","article","10.4103/ojo.ojo_437_25","41929995","PMC13043162",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003364","Evaluation of clinical decision support to improve guideline directed medical therapy in patients with type 2 diabetes.","Ernst K","2026","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2026.103081","41866125",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0003365","Glucagon-like peptide-1 receptor agonists and the risk of erectile dysfunction: a drug target Mendelian randomization study.","An H","2024","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2024.1448394","39605940","PMC11600104",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0003366","Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis.","Bushi G","2025","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.70037","39945396","PMC11823376",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0003367","Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.","Jankauskas SS","2026","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-026-03177-1","42057054","PMC13274062",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0003368","The Potential of Using Glucagon-Like Peptide-1 Receptor Agonists in Sepsis.","Tomy N","2025","Cardiology in review","other","article","10.1097/crd.0000000000000998","40745623",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003369","Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation.","Arslan S","2026","Clinical nutrition ESPEN","randomized_trial","article","10.1016/j.clnesp.2026.103305","42036071",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0003370","Impact of Obesity, Sarcopenia, and Nutritional Status on Spine Surgery Patients.","Daniels AH","2026","The Journal of the American Academy of Orthopaedic Surgeons","narrative_review","article","10.5435/jaaos-d-25-01362","42171350",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003371","Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.","Orandi BJ","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70301","42768905",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","4","FALSE","Journal Article; article"],["R0003372","Evidence Report on the Safety of Gastrointestinal Endoscopy in Patients on Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","Tarar ZI","2025","Diagnostics (Basel, Switzerland)","systematic_review","article","10.3390/diagnostics15060770","40150111","PMC11941505",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003373","Glucagon-like peptide-1 receptor agonists for treating chronic kidney disease in patients with type 2 diabetes.","Khan I","2024","CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","randomized_trial","article","10.1503/cmaj.240469","39586604","PMC11588397",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; other; article"],["R0003374","Updates in management of cardiorenal syndrome.","Chung I","2026","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000001209","42411248",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003375","Long-Acting Lipid-Lowering Injectables and Behavioral Moral Hazard: A Systematic Review of Adherence, Lifestyle Measurement, and Structural Evidence Gaps.","Cumpăt CM","2026","Healthcare (Basel, Switzerland)","systematic_review","article","10.3390/healthcare14101319","42194410","PMC13206233",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003376","Glucagon-like peptide-1 receptor agonists and upper endoscopy: a real-world experience.","Jirapinyo P","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24190","39763285",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003377","Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.","Cimino G","2024","ESC heart failure","narrative_review","article","10.1002/ehf2.14560","38093506","PMC10966224",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003378","Anemia risk and mitigation strategies in type 2 diabetic patients: The role of novel antidiabetic agents.","Meliš P","2025","World journal of diabetes","narrative_review","article","10.4239/wjd.v16.i5.105549","40487613","PMC12142205",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003379","Quality of bowel preparation for colonoscopy in patients on glucagon-like peptide-1 receptor agonists.","Gala K","2025","Gastrointestinal endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.11.024","39557200",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003380","Glucagon-like receptor-1 agonists and impotence: A meta-analysis.","Mirghani HO","2026","World journal of methodology","systematic_review","article","10.5662/wjm.119385","42626264","PMC13491145",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0003381","Peri-Procedural Safety of GLP-1 Receptor Agonists in Elective Endoscopy: A Multicenter Retrospective Cohort Study.","Kalsi H","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14176147","40943907","PMC12429542",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003382","ABSTRACT NUMBER: ESOC2026A2308 GLP-1 OR DUAL GIP/GLP-1 RECEPTOR AGONIST IN ACUTE ISCHAEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PRE-CLINICAL STUDIES",null,"2026","European stroke journal","systematic_review","article",null,null,"PMC13145916",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0003383","Optimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM.","Ghosal S","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s575790","41328392","PMC12665223",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0003384","Correction to \"Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study\".",null,"2025","Diabetes, obesity & metabolism","notice","article","10.1111/dom.16204","39803719",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0003385","A Closer Look at the Dermatological Profile of GLP-1 Agonists.","Persson C","2025","Diseases (Basel, Switzerland)","preclinical","article","10.3390/diseases13050127","40422559","PMC12110338",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003386","GLP-1RA and the possible skin aging.","Paschou IA","2025","Endocrine","narrative_review","article","10.1007/s12020-025-04293-w","40498168","PMC12370548",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003387","Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis.","Ebrahimi P","2025","JAMA psychiatry","systematic_review","article","10.1001/jamapsychiatry.2025.0091","40105856","PMC11923776",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; article"],["R0003388","Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta-Analysis.","Kim HJ","2024","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.3843","39311048",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; report; article"],["R0003389","Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction – real world outcomes","Hammer Y","2025","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-6768681/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0003390","Short-Term Semaglutide Improves Safety in High Body Weight Recipients Undergoing Living Donor Liver Transplant: A Case Report.","Cheng SM","2025","Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","case_report","article","10.6002/ect.2025.0244","41578754",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0003391","Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.","Meshkat S","2025","Brain and behavior","systematic_review","article","10.1002/brb3.70661","40635383","PMC12241715",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; review"],["R0003392","Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.","Ren L","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71303","42687799",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003393","What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK.","Auerbach N","2025","BMJ public health","other","article","10.1136/bmjph-2024-002519","40734969","PMC12306312",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003394","Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes.","Pradhan R","2025","Diabetes care","nonrandomized_study","article","10.2337/dc24-1903","39774820",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; other; article"],["R0003395","The Nutrition Landscape in Chronic Liver Disease.","McNally BB","2026","Digestive diseases and sciences","narrative_review","article","10.1007/s10620-026-09929-z","42096022",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003396","Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study.","Chen M","2025","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2025.1586589","40469447","PMC12133453",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0003397","Repurposing glucose-lowering drugs for cancer therapy.","Luconi M","2025","Trends in cancer","preclinical","article","10.1016/j.trecan.2025.04.010","40374399",null,null,"S002468","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; review"],["R0003398","Effect of the glucagon-like peptide-1 receptor agonists on diabetic peripheral neuropathy: A meta-analysis.","Fan S","2025","Journal of neurochemistry","systematic_review","article","10.1111/jnc.16242","39453834",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Review; Research Support, Non-U.S. Gov't; article"],["R0003399","Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.","Yahya R","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfag154","42397155",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0003400","A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy.","Cheng AYY","2024","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2024.111871","39343145",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003401","Beyond Weight Loss: A Comprehensive Review of Integrated Pharmacotherapy and Metabolic Bariatric Surgery in Endometrial Cancer Care.","Innocenzi C","2026","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina62081571","42654468","PMC13515252",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003402","Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials.","Chen Q","2026","BMC endocrine disorders","systematic_review","article","10.1186/s12902-026-02248-4","41913139","PMC13159308",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0003403","Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism-A Narrative Review.","Szekeres Z","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25158214","39125786","PMC11311305",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003404","GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study.","Tesfaye H","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70200","41104517","PMC12718077",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003405","Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?","Hölscher C","2024","Neuropharmacology","other_trial","article","10.1016/j.neuropharm.2024.109952","38677445",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0003406","Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.","Gallwitz B","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.1004044","36313764","PMC9606350",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003407","Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial.","Ji L","2026","Med (New York, N.Y.)","randomized_trial","article","10.1016/j.medj.2026.101063","41875890",null,"ClinicalTrials.gov:NCT01904913; ClinicalTrials.gov:NCT04904913","S001183","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; article"],["R0003408","Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report.","Liekens L","2025","BJPsych open","case_report","article","10.1192/bjo.2025.10909","41320187","PMC12835689",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003409","GLP-1 Receptor Agonist Exposures Are Increasingly Common and Generally Associated with Mild Symptoms: A Single Poison Center Experience.","Marshall S","2024","Journal of medical toxicology : official journal of the American College of Medical Toxicology","nonrandomized_study","article","10.1007/s13181-024-01008-x","38861153","PMC11288212",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003410","Enhanced renoprotective effects of combined glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real-world evidence.","Jhu JY","2025","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14361","39569871","PMC11786168",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003411","Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer's Disease.","Urkon M","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18050614","40430434","PMC12114801",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003412","A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.","Menon T","2024","CNS spectrums","systematic_review","article","10.1017/s1092852924000531","39582175",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Review; review"],["R0003413","Treating Reproductive-Aged Women With Glucagon-Like Peptide-1 Receptor Agonists: What Are the Clinical Considerations?","Sharma G","2024","Circulation","commentary","article","10.1161/circulationaha.124.070766","39495836",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0003414","Sodium-Glucose Cotransporter 2 Inhibitors and Reduced Fibromyalgia Risk in Patients With Diabetes: A Target Trial Emulation Study.","Jhang YS","2026","In vivo (Athens, Greece)","nonrandomized_study","article","10.21873/invivo.14229","41482395","PMC12764255",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003415","Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management.","Postlethwaite R","2025","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","nonrandomized_study","article","10.1016/j.pan.2025.06.018","40695708",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003416","GLP-1 receptor agonists may enhance the effects of desmopressin in individuals with AVP deficiency: a case series and proposed mechanism.","Nakhleh A","2024","Pituitary","case_report","article","10.1007/s11102-024-01451-7","39240512","PMC11513766",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0003417","GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Across Myocardial Infarction-Defined Populations: A Systematic Review and Meta-Analysis.","Batista PG","2026","American journal of cardiovascular drugs : drugs, devices, and other interventions","systematic_review","article","10.1007/s40256-026-00809-5","42387250",null,"PROSPERO:CRD420251270326",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003418","In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.","Maher M","2024","Annals of internal medicine","randomized_trial","article","10.7326/annals-24-02849-jc","39496174",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; editorial"],["R0003419","The glucagon-like peptide-1 receptor agonist semaglutide in diabetic kidney disease: A new kid on the block to afford maximal kidney protection.","Georgianos PI","2024","European journal of clinical investigation","randomized_trial","article","10.1111/eci.14284","38979836",null,"ClinicalTrials.gov:NCT04865770","S000395","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; article"],["R0003420","Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses.","Jun JE","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1843595","42388875","PMC13318618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; research-article; article"],["R0003421","Semaglutide Attenuates Type 2 Diabetes-Induced Neurotoxicity by Modulating Neuroinflammation, Oxidative Stress, and Neuroapoptosis.","Alharbi AS","2026","Life (Basel, Switzerland)","preclinical","article","10.3390/life16081317","42653006","PMC13514282",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003422","Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide.","Tan X","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01741-8","40377834","PMC12182539",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003423","The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems.","Antonič KG","2025","The aging male : the official journal of the International Society for the Study of the Aging Male","narrative_review","article","10.1080/13685538.2025.2601423","41399135",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003424","Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies.","Cheng J","2025","Osteoarthritis and cartilage open","systematic_review","article","10.1016/j.ocarto.2025.100567","39995585","PMC11849622","PROSPERO:CRD42024522782; PROSPERO:CRD42024522787",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0003425","Glucagon-Like Peptide-1 Receptor Agonists and Suicidality-Two Important Pieces of Data but an Incomplete Puzzle.","Anderson TS","2024","JAMA internal medicine","commentary","article","10.1001/jamainternmed.2024.4320","39226047",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0003426","Effects of 6-month treatment with the GLP-1 receptor agonist liraglutide on 24-hour energy metabolism and body composition in adults with obesity.","Basolo A","2025","Journal of endocrinological investigation","other","article","10.1007/s40618-025-02717-y","41060519",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003427","Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study.","Heni M","2025","Diabetologia","nonrandomized_study","article","10.1007/s00125-025-06448-w","40404820","PMC12245949",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0003428","Colonoscopy preparation adequacy in glucagon-like peptide-1 receptor agonist users: the jury is still out.","Burke CA","2025","Endoscopy","nonrandomized_study","article","10.1055/a-2461-3899","39577846",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003429","Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.","Tan S","2025","Frontiers in cardiovascular medicine","systematic_review","article","10.3389/fcvm.2025.1731127","41472878","PMC12745249","PROSPERO:CRD420251147337",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0003430","Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.","Yammine L","2026","BMJ open","protocol","article","10.1136/bmjopen-2025-115675","42161545","PMC13202040","ClinicalTrials.gov:NCT07227948","S001647","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0003431","Correction: Sodium-Glucose Cotransporter-2 Inhibitors versus Glucagon-Like Peptide 1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes.","Morello CM","2025","Kidney360","notice","article","10.34067/kid.0000000667","39625786","PMC11793168",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0003432","Therapies for Cardiovascular-Kidney-Liver-Metabolic Syndrome: Reappraisal of Fibrates.","Anagnostopoulou V","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71230","42608342",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0003433","Retrospective real-world database study to examine the prevalence and incidence of cardiovascular diseases and medication prescription in Japanese patients with type 2 diabetes.","Komatsu M","2026","Diabetology international","nonrandomized_study","article","10.1007/s13340-026-00877-7","41852486","PMC12992755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003434","Targeting cardiometabolic risk in type 1 diabetes through incretin physiology.","Frampton R","2026","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2025.06.004","40610267",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003435","Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Banerjee I","2026","Cureus","systematic_review","article","10.7759/cureus.115758","42830876","PMC13634180","PROSPERO:CRD420261435182",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003436","Association between Glucagon-like Peptide-1 Receptor Agonists and Aspiration Pneumonia during Endoscopic Procedures.","Peng CY","2024","Anesthesiology","nonrandomized_study","article","10.1097/aln.0000000000005174","39240542",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003437","Exploring the role of glucagon-like peptide-1 receptor agonists in critical illness: mechanisms, benefits, and clinical implications.","Jogani VG","2025","Current opinion in critical care","narrative_review","article","10.1097/mcc.0000000000001294","40512576",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003438","Semaglutide attenuates autistic-like behaviors in BTBR mice through the shaping of gut microbiota.","Liu J","2026","Pharmacological research","preclinical","article","10.1016/j.phrs.2026.108149","41724218",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003439","Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria.","Stefano GB","2025","Frontiers in neuroendocrinology","narrative_review","article","10.1016/j.yfrne.2025.101217","41047006",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0003440","Case Series: Exposure to Glucagon-like Peptide-1 Receptor Agonist in the First Trimester of Pregnancy in Two Siblings.","Doğan ŞE","2024","Endocrine, metabolic & immune disorders drug targets","randomized_trial","article","10.2174/0118715303252109231023115112","37937565",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Case Reports; Journal Article; article"],["R0003441","6923 Case Report: Long Standing Type 2 Diabetes with TOFI Phenotype Successfully Weaned Off One Hundred Units of Basal-Bolus Insulin Therapy With Glucagon-Like Peptide 1 Receptor Agonist Therapy",null,"2024","Journal of the Endocrine Society","case_report","article",null,null,"PMC11453539",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0003442","Immunological effects of GLP-1 analogs on female reproduction: Therapeutic perspectives for infertility and recurrent pregnancy loss.","Tavares ACM","2025","Journal of reproductive immunology","narrative_review","article","10.1016/j.jri.2025.104538","40359784",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003443","Psychosocial aspects and mental health burden of pediatric MASLD.","Ganakumar V","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1916057","42707585","PMC13548502",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003444","Comment on: Association Between Glucagon-Like Peptide 1 Receptor Agonists Exposure and Intraocular Pressure Change.","Tang WZ","2025","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2024.09.038","39481672",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0003445","Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.","Al-Abdulkarim HA","2025","Frontiers in clinical diabetes and healthcare","nonrandomized_study","article","10.3389/fcdhc.2025.1677695","41676233","PMC12886416",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003446","Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors.","Król M","2025","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms26146777","40725024","PMC12295648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0003447","Asymptomatic Subcutaneous Semaglutide Overdose: A Case Report and Literature Review.","Diec CB","2026","Journal of pharmacy practice","case_report","article","10.1177/08971900251335111","40232990",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; Review; article"],["R0003448","The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF.","Withaar C","2023","JACC. Basic to translational science","preclinical","article","10.1016/j.jacbts.2023.05.012","38094687","PMC10714176",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003449","GLP-1 Receptor Agonists in Pulmonary Hypertension: Mechanistic Rationale, Preclinical Evidence, and Clinical Knowledge Gaps.","Allaham L","2026","Lung","nonrandomized_study","article","10.1007/s00408-026-00939-2","42747605",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0003450","Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes.","Triplitt C","2025","Diabetes care","other_trial","article","10.2337/dc25-0490","40627548","PMC12368385",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; research-article; article; other"],["R0003451","Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.","Visolyi GÁ","2023","Canadian journal of diabetes","systematic_review","article","10.1016/j.jcjd.2023.03.002","36963632",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; article"],["R0003452","Impact of GLP-1 dose intensity on perioperative and long-term fusion outcomes following ACDF.","Stirpe C","2026","The spine journal : official journal of the North American Spine Society","nonrandomized_study","article","10.1016/j.spinee.2026.08.009","42705550",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0003453","GLP-1 receptor agonist increase retained gastric contents on EGD and same-day colonoscopy reduces this risk.","Ukwade D","2025","Frontiers in medicine","nonrandomized_study","article","10.3389/fmed.2025.1638981","41001395","PMC12457285",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003454","Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial.","Cao Y","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s472968","39108611","PMC11300556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003455","Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?","Lisco G","2023","Endocrine connections","nonrandomized_study","article","10.1530/ec-23-0257","37656509","PMC10563602",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0003456","Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes.","Htoo PT","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70195","41090391",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0003457","Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (GLP-1/GIP RA) Exposures Presenting to the Emergency Department.","Gartner HT","2025","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/10600280251334642","40269635",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Clinical Study; Journal Article; Multicenter Study; article"],["R0003458","GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.","Sawicka-Gutaj N","2026","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-026-02088-1","42034831","PMC13461353","PROSPERO:CRD420251002447",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0003459","Severe Small-Bowel Obstruction in a High-Risk Patient on Long-Term Tirzepatide Therapy: A Case Report.","Nahar S","2025","Cureus","case_report","article","10.7759/cureus.98935","41523550","PMC12789710",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003460","Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors.","Poonawalla IB","2025","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2025.31.7.627","40577036","PMC12204329",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0003461","Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity?","Prokopidis K","2025","The journal of nutrition, health & aging","narrative_review","article","10.1016/j.jnha.2025.100652","40819408","PMC12391595",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; brief-report; article"],["R0003462","SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in diabetic cardiomyopathy: A prospective cohort study.","Zhang A","2025","Kardiologia polska","nonrandomized_study","article","10.33963/v.phj.106152","40365883",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003463","The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review.","Old VJ","2025","Journal of cachexia, sarcopenia and muscle","systematic_review","article","10.1002/jcsm.13677","39815782","PMC11735953",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0003464","Impact of GLP-1 Receptor Agonists on Alcohol-Related Liver Disease Development and Progression in Alcohol Use Disorder.","Kuo CC","2025","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.70007","39891379",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003465","Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists.","Moore KT","2025","Journal of clinical pharmacology","other","article","10.1002/jcph.6136","39297583",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003466","Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period.","Kindel TL","2025","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","narrative_review","article","10.1016/j.cgh.2024.10.003","39480373",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; Review; article"],["R0003467","Dementia in type 2 diabetes: risk factors, disease processes and opportunities for prevention across the lifespan.","de Leijer JF","2026","Diabetologia","narrative_review","article","10.1007/s00125-026-06795-2","42440082","PMC13541823",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003468","The Use of Glucagon-Like Peptide 1 Agonists Among Non-Diabetics: Evidence From Medicare Part D.","Kim M","2026","Health services research","other","article","10.1111/1475-6773.70098","41813593","PMC13077783",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003469","On the front lines of cardiovascular-kidney-metabolic syndrome: Review of GLP-1 and Dual GLP-1/GIP receptor agonists in CV and kidney health.","Salama L","2025","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","randomized_trial","article","10.1093/ajhp/zxaf053","40197714",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0003470","The 'Obesity First' approach: Redefining the future of healthcare.","Mulder CJJ","2026","Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","narrative_review","article","10.1007/s12664-025-01882-5","41152558","PMC12920710",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003472","Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.","Rakhsha SS","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70957","42304171","PMC13449080",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Network Meta-Analysis; Journal Article; Comparative Study; review-article; review"],["R0003473","Efficacy and Safety of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in the Treatment of Diabetes Mellitus and Obesity in Liver Transplant Recipients: A Systematic Review.","Garlatti Costa E","2025","Journal of clinical medicine","systematic_review","article","10.3390/jcm14134619","40648992","PMC12251260",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003474","Effect of GLP-1 receptor agonist on nutrient intake: A narrative review.","Fujioka K","2026","Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition","narrative_review","article","10.1002/ncp.70172","42754546","PMC13622391",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003475","Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Chen Y","2026","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.70111","41331723",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0003476","Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study.","Maier GA","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70523","41725345","PMC12992157",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0003477","Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.","Suzuki Y","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15561","38528820",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0003478","Glucagon-like peptide-1 receptor agonist and new-onset diabetes in overweight/obese individuals with prediabetes: A systematic review and meta-analysis of randomized trials.","Yanto TA","2024","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2024.103069","38963997",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0003479","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis.","Facciorusso A","2025","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","systematic_review","article","10.1016/j.cgh.2024.07.021","39142543",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0003480","Genetically proxied glucagon-like peptide-1 receptor agonist is associated with risk of tubulo-interstitial nephritis: A network Mendelian randomization study.","Xu XC","2025","Medicine","other","article","10.1097/md.0000000000044742","40988251","PMC12459490",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003481","Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control.","Ábel T","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27031186","41683613","PMC12898281",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003482","Cardiovascular Outcomes in Diabetic Patients Treated with Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist: A Systematic Review and Meta-Analysis.","Marino G","2026","Cardiology","systematic_review","article","10.1159/000551686","41979993",null,"PROSPERO:CRD420261306111",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0003483","Improving Patient Outcomes by Bridging Bariatric and Body Contouring Surgery with Comprehensive Prehabilitation.","Campbell CA","2026","Plastic and reconstructive surgery. Global open","other","article","10.1097/gox.0000000000008073","42781681","PMC13600585",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003484","Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.","Yao H","2024","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj-2023-076410","38286487","PMC10823535","PROSPERO:CRD42022342845","S002511","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; research-article; review"],["R0003485","Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials.","Lin S","2025","Scientific reports","systematic_review","article","10.1038/s41598-025-99622-4","40360648","PMC12075827",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0003486","Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis.","Salvio G","2025","Andrology","systematic_review","article","10.1111/andr.70022","40105090","PMC12569732",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0003487","Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study.","Jensen AB","2025","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-025-01913-4","40197361","PMC11974010",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0003488","Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients: A nationwide cohort study.","Sørensen KK","2024","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.70000","39364788","PMC11450598",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0003489","Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis.","Akbari A","2024","Journal of diabetes research","systematic_review","article","10.1155/2024/3212795","38529046","PMC10963118",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review-article; review"],["R0003490","Molecular Connectomics Reveals a Glucagon-Like Peptide 1 Sensitive Neural Circuit for Satiety.","Webster AN","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2023.10.31.564990","37961449","PMC10635031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; other; preprint"],["R0003491","Real‑World Safety Signals of Tirzepatide Versus GLP‑1RAs: A Machine Learning Analysis of FDA FAERS Data","Wang SY","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-8546087/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003492","Novel Small Molecule GLP-1R Agonists Based on 1H-Benzo[d]imidazole-5-Carboxylic Acid Scaffold.","Tolkacheva EV","2026","Molecules (Basel, Switzerland)","preclinical","article","10.3390/molecules31071129","41976172","PMC13075017",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003493","Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon-like peptide-1 receptor agonist therapy in UK primary care: A retrospective, real-world study.","Gulati K","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16201","39840515","PMC11885099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003494","Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.","Ceravolo R","2026","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2026.06.015","42342009",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0003495","Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period.","Kindel TL","2025","Surgical endoscopy","other","article","10.1007/s00464-024-11263-2","39370500","PMC11666732",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003496","The time-varying cardiovascular benefits of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials.","Deo SV","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14738","35491516","PMC9540124",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0003497","Efficacy of GLP-1 receptor agonists in obese patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis of randomized trials and propensity score-matched cohorts.","Caldeira Gaelzer G","2026","Current problems in cardiology","systematic_review","article","10.1016/j.cpcardiol.2025.103194","41173128",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003498","Synthesis, Characterization, and Antidiabetic Evaluation of Sequence-Modified Liraglutide Analogs in a Drosophila melanogaster Model.","Ravi T","2026","Biopolymers","preclinical","article","10.1002/bip.70113","42394279",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003499","Mapping GLP-1 receptor agonist research across the MASLD-MASH-HCC continuum: a bibliometric and translational analysis.","Xie Y","2026","Frontiers in medicine","systematic_review","article","10.3389/fmed.2026.1913929","42666665","PMC13522774",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0003500","Effects of Hypoglycemic Agents on The Musculoskeletal System: A Comprehensive Review.","Zhao J","2025","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s517101","40727922","PMC12301114",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003501","Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.","Subhani M","2024","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2024.102920","39764544","PMC11701477","PROSPERO:CRD42024531982",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0003502","A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus.","Kalra S","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00894-y","32725484","PMC7434819",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0003503","SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes.","Jensen SK","2026","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2025.7409","41557360","PMC12820778",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0003504","Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association.","El-Boghdadly K","2025","Anaesthesia","other","article","10.1111/anae.16541","39781571","PMC11885194",null,"S002511","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Practice Guideline; Consensus Statement; Research Support, Non-U.S. Gov't; other; article"],["R0003505","Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.","Yuan S","2023","Frontiers in public health","systematic_review","article","10.3389/fpubh.2023.1201818","37744474","PMC10513082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; research-article; article"],["R0003506","Acute onset of neovascular age-related macular degeneration after initiation of tirzepatide.","Takebayashi K","2026","Diabetology international","nonrandomized_study","article","10.1007/s13340-026-00885-7","41948417","PMC13050665",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0003507","Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review.","Meftah A","2026","Cureus","randomized_trial","article","10.7759/cureus.109089","42317925","PMC13273784",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003508","SAT-631 Glucagon-Like Peptide-1 Receptor Agonist Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-Analysis",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12047309",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0003509","Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials.","Peng ZY","2025","Cardiovascular diabetology","other_trial","article","10.1186/s12933-025-03007-w","41286734","PMC12751512",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0003510","Total Knee Arthroplasty and Morbid Obesity: Is There a Glimmer of Hope?: Commentary on an article by Billy I. Kim, MD, et al.: \"Glucagon-Like Peptide-1 Receptor Agonists Decrease Medical and Surgical Complications in Morbidly Obese Patients Undergoing Primary TKA\".","Roberts DW","2025","The Journal of bone and joint surgery. American volume","nonrandomized_study","article","10.2106/jbjs.24.01050","39969496",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003511","Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings.","Ugur F","2025","Journal of orthopaedic surgery and research","preclinical","article","10.1186/s13018-025-06300-2","41063270","PMC12509403",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003512","Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study.","Liu BD","2024","Gut","nonrandomized_study","article","10.1136/gutjnl-2023-329651","37739778",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003513","Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients.","Levy S","2024","Cancers","nonrandomized_study","article","10.3390/cancers17010078","39796706","PMC11720624",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003514","Food Retention at Endoscopy Among Adults Using Glucagon-Like Peptide-1 Receptor Agonists.","Nasser J","2024","JAMA network open","other","article","10.1001/jamanetworkopen.2024.36783","39352703","PMC11445686",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003515","Molecular mechanisms and novel therapeutic targets of diabetic kidney disease.","Xu Z","2026","Chinese medical journal","narrative_review","article","10.1097/cm9.0000000000004025","42050936","PMC13236292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003516","Re: Muayad et al.: Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes (Ophthalmology. 2025;132:271-279).","Bai WH","2025","Ophthalmology","commentary","article","10.1016/j.ophtha.2024.11.018","39718522",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0003517","Semaglutide Overdose in a Diabetic Patient: Suicidal Behavior and Multiorgan Failure.","Zamir D","2025","The American journal of case reports","case_report","article","10.12659/ajcr.947682","40849680","PMC12396086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0003518","Durable insulin elimination after duodenal re-cellularization via electroporation therapy combined with glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes.","Busch CBE","2025","iGIE : innovation, investigation and insights","other","article","10.1016/j.igie.2025.03.012","41646459","PMC12850761",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003519","Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.","Ceasovschih A","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27188317","42794744","PMC13607339",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003520","Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.","Kalathiya UN","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2025.09.004","40945659",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0003521","Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With MASLD in a Real-World Setting Is Associated With Slower Disease Progression and Lower All-Cause Mortality.",null,"2024","Gastroenterology & hepatology","nonrandomized_study","article",null,"39896970","PMC11784558",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; other; article"],["R0003522","Effects of weight-loss interventions on bone health in people living with obesity.","Paccou J","2025","Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","randomized_trial","article","10.1093/jbmr/zjaf135","41042228",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0003523","Liraglutide-Induced Liver Injury: A Case Report and Review.","Lai M","2025","Case reports in gastroenterology","case_report","article","10.1159/000547634","41064547","PMC12503594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0003524","Socioeconomic aspects of incretin-based therapy.","Karagiannis T","2023","Diabetologia","nonrandomized_study","article","10.1007/s00125-023-05962-z","37433896","PMC10474181",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0003525","Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.","Panlilio MA","2026","Cureus","narrative_review","article","10.7759/cureus.113635","42668762","PMC13525501",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003526","Real-world Physical Activity and Sedentary Time Trends in Patients Undergoing Obesity Treatment: Insights From the All of Us Research Program.","Butensky SD","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08645-x","41912836",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0003527","FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide.","Sánchez-López D","2026","Journal of molecular and cellular cardiology","other","article","10.1016/j.yjmcc.2025.10.009","41183609",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003528","Impact of Semaglutide on Limb Events: A Meta-Analysis of Randomized Controlled Trials.","Cesaro A","2026","European journal of preventive cardiology","systematic_review","article","10.1093/eurjpc/zwag077","41662383",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0003529","Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis.","Johnson CE","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15809","39044308",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Systematic Review; Comparative Study; article"],["R0003530","Association of sodium-glucose cotransporter 2 inhibitors with the risk of incident anxiety and insomnia: a retrospective cohort study using the TriNetX database.","Chang CI","2026","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2025.103373","41477924",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Multicenter Study"],["R0003531","Preliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study.","Yugueros A","2026","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina62020386","41752784","PMC12942463",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0003532","GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women.","McDonald ES","2026","JCO oncology practice","nonrandomized_study","article","10.1200/op-26-00485","42227662",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003533","Brain Amylin Signaling, Feeding, and Reward.","Mietlicki-Baase EG","2026","Comprehensive physiology","narrative_review","article","10.1002/cph4.70120","41793055","PMC13001112",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0003534","Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide.","Sigalov A","2026","Cardiology in review","other_trial","article","10.1097/crd.0000000000001468","42745233",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0003535","The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis.","Yugar LBT","2024","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-024-01337-5","38659064","PMC11044464","PROSPERO:CRD42023393020",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; other; review"],["R0003536","Potential role of postbiotics in supporting lean mass preservation and weight-loss sustainability during GLP-1-based anti-obesity therapy.","Cengiz Kaynakcı E","2026","Frontiers in nutrition","narrative_review","article","10.3389/fnut.2026.1794882","41953539","PMC13053641",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003537","Contractile effects of dulaglutide in the human atrium.","Neumann J","2026","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-026-05647-5","42380521","PMC13593670",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003538","Long-Term Effects of Bariatric Surgery on Type 2 Diabetes: Mechanisms, Outcomes, and Clinical Implications: A Focused Review.","Xia YY","2026","Journal of visualized experiments : JoVE","narrative_review","article","10.3791/74093","42747104",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Video-Audio Media; Review; article"],["R0003539","Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.","Sergi CM","2026","Contemporary clinical trials","other_trial","article","10.1016/j.cct.2026.108493","42822760",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0003540","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use and Inflammatory Markers Among U.S. Adults: A National Health and Nutrition Examination Survey (NHANES)-Based Analysis.","Youkhana S","2025","Cureus","nonrandomized_study","article","10.7759/cureus.90964","41001317","PMC12459877",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003541","GLP-1 Agonists as Potential Neuromodulators in Development of Parkinson's Disease: A Nationwide Cohort Study.","Gamborg M","2025","European journal of neurology","nonrandomized_study","article","10.1111/ene.70075","39927573","PMC11808555",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0003542","Acute Heart Failure in Heart Failure with Preserved Ejection Fraction: A State-of-the-art Review from an International Expert Group.","Radu RI","2026","Cardiac failure review","narrative_review","article","10.15420/cfr.2025.56","42488703","PMC13389318",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003543","Long-term risk of total joint replacement associated with second-line glucose-lowering therapies in type 2 diabetes: A population-based retrospective cohort study.","Liu CY","2026","Seminars in arthritis and rheumatism","nonrandomized_study","article","10.1016/j.semarthrit.2026.152995","42139974",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0003544","[Multiple effects: potential new strategies of glucagon-like peptide-1 receptor agonists in treating obesity-related obstructive sleep apnea].","Wang LX","2024","Zhonghua nei ke za zhi","other","article","10.3760/cma.j.cn112138-20240731-00487","39482066",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003545","Glucagon-like peptide 1 receptor agonists outperform basal insulin in cardiovascular and renal outcomes for type 2 diabetes mellitus: a retrospective cohort study.","Chen TH","2025","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-024-02443-6","39812791",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003546","Risk of Urogenital Infections in People With Type 2 Diabetes Initiating SGLT2is Versus GLP-1RAs in Routine Clinical Care: A Danish Cohort Study.","Ljungberg C","2025","Diabetes care","nonrandomized_study","article","10.2337/dc24-2169","40173095",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0003547","Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.","Lakhani M","2026","The British journal of ophthalmology","nonrandomized_study","article","10.1136/bjo-2025-328483","41807083",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0003548","Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists: A One-Two Punch?","Harrington J","2024","JACC. Heart failure","commentary","article","10.1016/j.jchf.2024.08.013","39387772",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0003549","Erratum to \"Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity\".","Klein, Matthew P.","2026","Journal of diabetes science and technology","notice","article","10.1177/19322968241256557","38747372","PMC11571299",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0003550","Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications.","Baba AH","2026","Nepal journal of epidemiology","systematic_review","article","10.3126/nje.v16i1.92323","42211533","PMC13215652",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003551","Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort.","Chen JW","2026","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2026.101740","41687959",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0003552","Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.","Umapathysivam MM","2026","Genome medicine","other_trial","article","10.1186/s13073-026-01630-0","41906117","PMC13072570","ClinicalTrials.gov:NCT02723110; ClinicalTrials.gov:NCT02465515; ClinicalTrials.gov:NCT01144338","S000905; S001074","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0003553","Risk Assessability and Recorded Organ-Protective Therapy Gaps in Type 2 Diabetes: A Five-Center Cross-Sectional Study","li w","2026","Research Square","other","preprint","10.21203/rs.3.rs-10749649/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0003554","Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025).","Patel S","2025","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics17081036","40871057","PMC12389369",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003555","Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro).","Bhandari P","2026","Cureus","case_report","article","10.7759/cureus.110692","42438627","PMC13355954",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003556","Improvement of Kidney Function Following Unilateral Nephrectomy in a Patient With Cardiovascular-Kidney-Metabolic (CKM) Syndrome.","Asopa M","2025","Cureus","case_report","article","10.7759/cureus.83263","40453308","PMC12124764",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003557","Semaglutide exposure in early pregnancy and pregnancy outcomes: A case report and review of literature.","Jin YC","2026","Journal of gynecology obstetrics and human reproduction","case_report","article","10.1016/j.jogoh.2026.103133","41654227",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; Review; article"],["R0003558","Glucagon-Like Peptide-1 Receptor Agonists for Bile Acid Diarrhea: Emerging Evidence and Clinical Implications.","Omeludike EK","2026","Cureus","randomized_trial","article","10.7759/cureus.105789","42037908","PMC13105829",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003559","Baseline metabolite profiles predict the glucose-lowering efficacy of exenatide in patients with type 2 diabetes.","Le Y","2026","Metabolism open","other","article","10.1016/j.metop.2026.100453","41799733","PMC12964271",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003560","Glucagon-like-peptide-1 and Mental Health: The Unexpected Outcomes.","O'Connor MA","2026","The Nursing clinics of North America","narrative_review","article","10.1016/j.cnur.2025.09.005","41581971",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003561","Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Prescriptions in Type 2 Diabetes by Kidney and Cardiovascular Disease.","Mehta SS","2025","Journal of the American Society of Nephrology : JASN","other","article","10.1681/asn.0000000585","39688374","PMC11801770",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003562","The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis.","Yang M","2025","Frontiers in medicine","systematic_review","article","10.3389/fmed.2025.1621958","40917833","PMC12408605","PROSPERO:CRD420251015882",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0003563","Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.","Ghusn W","2024","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2024.100127","39286601","PMC11404059",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003564","The Impact of Contemporary Glucagon-like Peptide-1 Receptor Agonists on the Onset, Severity, and Conversion to Arthroplasty in Hip and Knee Osteoarthritis.","Porto JR","2025","Orthopaedic journal of sports medicine","nonrandomized_study","article","10.1177/23259671241297157","39811151","PMC11729447",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003565","Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system.","Xiao Y","2025","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-024-02415-w","39556224",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003566","The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.","Ganamurali N","2026","Clinical pharmacology in drug development","other_trial","article","10.1002/cpdd.70001","41545327",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0003567","Re: The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.","Wang Y","2025","Addiction (Abingdon, England)","nonrandomized_study","article","10.1111/add.16779","39856534",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; letter"],["R0003568","Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare Advantage beneficiaries with T2D and ASCVD.","Tan X","2025","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2025.2577762","41122783",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Comparative Study; article"],["R0003569","Semaglutide-associated kidney injury.","Begum F","2024","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfae250","39258261","PMC11384876",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0003570","Complex interrelationship and therapeutic advances in diabetic patients with atrial fibrillation.","Karanikola AE","2025","World journal of cardiology","narrative_review","article","10.4330/wjc.v17.i12.114575","41479997","PMC12754075",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003571","GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes.","Gitto M","2026","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-025-02606-z","41186740","PMC12957045",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003572","Liraglutide Attenuates FFA-Induced Retinal Pigment Epithelium Dysfunction via AMPK Activation and Lipid Homeostasis Regulation in ARPE-19 Cells.","Tsou SH","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms26083704","40332323","PMC12027664",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003573","Advances in antidepressant pharmacotherapy: phase 3 evidence and clinical perspectives.","Cuomo A","2026","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2026.2634195","41701518",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0003574","Analysis of the current status of SGLT-2i and GLP-1RA in patients with diabetes complicated with coronary heart disease","Wang F","2026","Research Square","other","preprint","10.21203/rs.3.rs-8349890/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003575","Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure.","Wolff Sagy Y","2024","Nature medicine","nonrandomized_study","article","10.1038/s41591-024-03052-0","38749475",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Comparative Study; article"],["R0003576","Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia.","Memel Z","2025","Current nutrition reports","narrative_review","article","10.1007/s13668-025-00649-w","40289060",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003577","Pharmacologic Treatment for Obstructive Sleep Apnea in Older Adults.","Jaganathan N","2026","Drugs & aging","narrative_review","article","10.1007/s40266-026-01311-y","42435144",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003578","Incidence of Barrett's esophagus and esophageal cancer following sleeve gastrectomy versus liraglutide therapy.","Butt E","2026","Annals of gastroenterology","nonrandomized_study","article","10.20524/aog.2026.1058","42164611","PMC13184147",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003579","Blood pressure lowering effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).","Toyoda S","2024","Hypertension research : official journal of the Japanese Society of Hypertension","commentary","article","10.1038/s41440-023-01569-4","38182906",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0003580","Immunometabolism in Obesity-Associated Type 2 Diabetes: Molecular Mechanisms and Emerging Therapeutic Targets.","Acierno C","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27188063","42794492","PMC13606635",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003581","Emerging and Off-Label Uses Of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) and Dual GIP/GLP1-RAs.","Morello CM","2026","Journal of the American Board of Family Medicine : JABFM","randomized_trial","article","10.3122/jabfm.2025.250158r1","42049507","PMC13197145",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0003582","Cellulite as a Possible Biomarker of Metabolic Dysfunction: Redefining Body Remodeling in the Glucagon-Like Peptide-1 Era Through the Cellulite Removal Medical Protocol-G21 Concept.","Adamidis N","2026","Cureus","protocol","article","10.7759/cureus.110805","42453843","PMC13367778",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Editorial; editorial"],["R0003583","The menopause-obesity axis in MASH progression: from estrogen decline to liver fibrosis.","Ntikoudi A","2026","Frontiers in gastroenterology (Lausanne, Switzerland)","narrative_review","article","10.3389/fgstr.2026.1889458","42662108","PMC13519902",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003584","Prescribing Patterns and Adverse Effects of Semaglutide: A Real-World Comparative Evaluation.","Whorton A","2025","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare14010035","41516966","PMC12785528",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003585","Chronic Kidney Disease and Its Role in Cardiovascular Disease.","Swamynathan R","2026","Cardiology in review","other","article","10.1097/crd.0000000000001309","42115832",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003586","Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.","Harbi MH","2026","Frontiers in medicine","systematic_review","article","10.3389/fmed.2026.1764664","42100257","PMC13143735",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0003587","Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatment.","Kim SE","2025","The Korean journal of internal medicine","narrative_review","article","10.3904/kjim.2024.387","40360219","PMC12081111",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0003588","Effects of Incretin-Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat-Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.","Busk-Cirera L","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71006","42324178","PMC13449088",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review-article; review"],["R0003589","Preoperative optimization of obese spine patients with GLP-1 receptor agonists: enhancing surgery and improving outcomes.","Barkyoumb D","2025","Journal of spine surgery (Hong Kong)","narrative_review","article","10.21037/jss-24-152","40621386","PMC12226182",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003590","Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?","Lecis D","2023","Biomolecules","narrative_review","article","10.3390/biom13121695","38136567","PMC10741698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003591","Re: Muayad et al.: Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in type 2 diabetes (Ophthalmology. 2025;132:271-279).","Chuang SH","2025","Ophthalmology","commentary","article","10.1016/j.ophtha.2024.10.027","39614848",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0003592","An Overview of Nonalcoholic Fatty Liver Disease With Current Treatment Strategies.","Glover G","2026","Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates","narrative_review","article","10.1097/sga.0000000000000923","41875334",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003593","Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management?","Scilletta S","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","other","article","10.1016/j.numecd.2026.104860","42469142",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0003594","Effect of Submaximal Doses of Semaglutide in Patients with Obesity on Metabolic Profile and Serum Levels of Adipocytokines.","Péč MJ","2025","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph18091364","41011232","PMC12472706",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003595","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.","Lee S","2024","Annals of general psychiatry","systematic_review","article","10.1186/s12991-024-00527-9","39529123","PMC11552190",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003596","Correction to: Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists.","Lai HW","2024","Cardiovascular diabetology","notice","article","10.1186/s12933-024-02452-3","39402518","PMC11472640",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0003597","The Physiologic Basis of Acute Glomerular Filtration Rate Decline With Renoprotective Therapies.","Ayub F","2026","Mayo Clinic proceedings","narrative_review","article","10.1016/j.mayocp.2026.06.015","42336099",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003598","The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?","Karakasis P","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12092112","39335625","PMC11429383",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003599","Heart matters: How glucose- and lipid-modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning.","Heuboeck E","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70324","41309293","PMC12803631",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003600","GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials.","Tsai WW","2025","Therapeutic advances in neurological disorders","systematic_review","article","10.1177/17562864251372747","40951542","PMC12426393",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0003601","Considerations for Perioperative Management Guidance Regarding GLP-1 Receptor Agonists: Evaluation of Current Practices and Future Directions.","Knuf KM","2025","Military medicine","other","article","10.1093/milmed/usaf029","39869102",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003602","Correction to: Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.",null,"2024","Anaesthesia","notice","article","10.1111/anae.16427","39277875",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0003603","Injectable drugs for weight management.","Yates N","2025","Australian prescriber","narrative_review","article","10.18773/austprescr.2025.052","41416056","PMC12711348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003604","Protective effects of SGLT2 inhibitors and GLP-1 receptor agonists on infection-related implant failure following ankle fracture ORIF: A global big data analysis.","Yang MY","2026","Journal of orthopaedic surgery (Hong Kong)","nonrandomized_study","article","10.1177/10225536261447739","42037563",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0003605","Optimizing Breast Cancer Survivorship: Addressing Lifestyle, Weight Management, and Psychological Health.","Hundal J","2026","American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","nonrandomized_study","article","10.1200/edbk-26-517396","42127339",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0003606","Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.","Stefanou MI","2025","European journal of neurology","systematic_review","article","10.1111/ene.70358","40937960","PMC12426903","PROSPERO:CRD42025650082",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0003607","Combining Glucagon-Like Peptide-1 Receptor agonists and Sodium-Glucose Cotransporter-2 Inhibitors in the management of Type 2 Diabetes Mellitus: A protocol for a scoping review","Builes-Montaño CE","2025","F1000Res","protocol","preprint","10.12688/f1000research.159628.1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","5","FALSE","Preprint; article"],["R0003608","Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.","Riedinger CJ","2024","Gynecologic oncology","narrative_review","article","10.1016/j.ygyno.2024.07.008","39116625",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0003609","Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications.","Goudra B","2024","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18010004","39861067","PMC11768320",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003610","Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence.","Jena S","2026","TouchREVIEWS in endocrinology","systematic_review","article","10.17925/ee.2026.22.1.8","42272996","PMC13249221",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003611","Glucagon-Like Peptide 1 Receptor Agonist Use Before Surgery.","Jones PM","2024","JAMA surgery","other","article","10.1001/jamasurg.2024.2304","39018079",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003612","Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets.","Feng X","2026","Chinese medical journal","narrative_review","article","10.1097/cm9.0000000000003919","41396202","PMC12815558",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003613","Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.","Kang YM","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16398","40212008","PMC12146062",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Comparative Study; Systematic Review; Meta-Analysis; research-article; article"],["R0003614","Recent progress of remission in type 2 diabetes.","Zhao Z","2025","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/20420188251408210","41459017","PMC12739105",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003615","Surgical Options in the Treatment of Severe Obesity","Kannan U","2026","StatPearls Publishing, Treasure Island (FL)","other","article",null,"35015397",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0003616","Nonhormonal Pharmacological Interventions in Adolescent Polycystic Ovary Syndrome (PCOS): A Systematic Review.","Sibal R","2026","Journal of pediatric and adolescent gynecology","systematic_review","article","10.1016/j.jpag.2026.01.001","41506442",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0003617","Targeting Inflammation in Chronic Kidney Disease: Pathophysiological Insights and Emerging Therapeutic Strategies.","Tsalouchos A","2026","Journal of clinical medicine","other_trial","article","10.3390/jcm15176550","42739556","PMC13566433",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Preprint; review-article; article"],["R0003618","Editorial Comment: A New Chapter for Obesity-Glucagon-Like Peptide-1 Receptor Agonists and Body Composition Imaging.","Boutin RD","2024","AJR. American journal of roentgenology","commentary","article","10.2214/ajr.24.32045","39291948",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Editorial; Journal Article; editorial"],["R0003619","The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?","Mizdrak M","2026","Medical sciences (Basel, Switzerland)","narrative_review","article","10.3390/medsci14050577","42783450","PMC13609229",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003620","Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real-world retrospective cohort study of adults with type 2 diabetes.","Zhang Q","2025","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14415","39899440","PMC12057371",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003621","Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.","Laffin L","2026","American journal of preventive cardiology","protocol","article","10.1016/j.ajpc.2026.101783","42830762","PMC13633904","ClinicalTrials.gov:NCT06948422","S000533","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0003622","Glucagon-like Peptide-1 Receptor Agonists: New Evidence of Kidney and Cardiovascular Protection From the FLOW and SELECT Trials.","Taal MW","2025","American journal of kidney diseases : the official journal of the National Kidney Foundation","commentary","article","10.1053/j.ajkd.2024.08.002","39341543",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0003623","Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials.","Kow CS","2025","Sleep medicine","systematic_review","article","10.1016/j.sleep.2025.02.010","39978242",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003624","Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.","Postema A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70251","41243611","PMC12803591",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0003625","The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis.","Ren Y","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16366","40230207",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0003626","Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26-Week Prospective Observational Real-Life Study.","Vozza A","2025","Journal of diabetes research","nonrandomized_study","article","10.1155/jdr/8182211","39963363","PMC11832268",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0003627","Optimising Access to Care for Patients with Heart and Kidney Diseases: A World Heart Federation and International Society of Nephrology White Paper.","Narula J","2025","Global heart","narrative_review","article","10.5334/gh.1460","41079057","PMC12513359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Consensus Statement; research-article; article"],["R0003628","Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial.","Fang W","2025","Frontiers in endocrinology","protocol","article","10.3389/fendo.2025.1629157","41647109","PMC12867914",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; methods-article; article"],["R0003629","Exploring the therapeutic potential of GLP-1 receptor agonists in the management of obstructive sleep apnea: a comprehensive review.","Alluri AA","2025","Journal of basic and clinical physiology and pharmacology","narrative_review","article","10.1515/jbcpp-2024-0193","39804718",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003630","GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus.","Crespo J","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14155597","40807216","PMC12347859",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003631","The impact of preoperative antiobesity medications on weight loss in adolescents undergoing metabolic and bariatric surgery - a COSMIC study.","Chinn JO","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2025.10.014","41353013",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S."],["R0003632","Comparative Effectiveness of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in Reducing Adverse Cardiovascular Events in Type 2 Diabetes.","Shah SZ","2025","Cureus","nonrandomized_study","article","10.7759/cureus.92048","41080335","PMC12514854",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003633","Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis.","Li L","2026","JHEP reports : innovation in hepatology","systematic_review","article","10.1016/j.jhepr.2025.101661","41503569","PMC12771308",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0003634","Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease Risk: Findings from Real-World Data using AI-Powered Outcomes","Prakash S","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.09.17.24313797",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003635","GLP-1 Receptor Agonist Utilization for Obesity Among Medicaid Beneficiaries in Rural vs. Urban U.S. States, 2020–2024","Moka AO","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-9795190/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0003636","Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure.","Ferreira JP","2023","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgad398","37409733",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003637","Emerging strategies in drug repurposing for decreasing the risk of age-related macular degeneration.","Zhou B","2026","Expert opinion on drug discovery","nonrandomized_study","article","10.1080/17460441.2026.2635492","41805144",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0003638","Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.","Huang YN","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15869","39171569",null,null,"S002468; S002726","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0003639","Effect of glucagon-like peptide-1 receptor agonist on insulin secretion index and serum Wnt5a protein in patients with new-onset type 2 diabetes mellitus.","Xu W","2023","Journal of diabetes and metabolic disorders","other","article","10.1007/s40200-022-01175-0","37255814","PMC10225441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003640","Heart failure with preserved ejection fraction (HFpEF): translational mechanisms, diagnostic evolution and therapeutic frontiers.","Gao L","2026","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2026.113116","41580149",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003641","GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses.","Yang K","2026","JAMA network open","systematic_review","article","10.1001/jamanetworkopen.2026.4722","41915388","PMC13040404",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; research-article; article"],["R0003642","Glucagon-Like Peptide 1 Receptor Agonist Use Before Surgery-Reply.","Potnuru PP","2024","JAMA surgery","other","article","10.1001/jamasurg.2024.2307","39018041",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003643","The Cardiovascular Outcomes Between Liraglutide and Dulaglutide Among Different Chronic Kidney Disease Stages in Patients With Type 2 Diabetes.","Cai YX","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2024.11.016","39689782",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003644","Impact of Exendin-4 on the Differentiation and Function of Transplanted Porcine Neonatal Pancreatic Cell Clusters in Diabetic Nude Mice.","Juang JH","2025","Journal of diabetes research","preclinical","article","10.1155/jdr/5847576","41140368","PMC12552079",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003645","Tirzepatide-Induced Liver Injury: A Rare Complication.","Spaeth LD","2026","AACE endocrinology and diabetes","case_report","article","10.1016/j.aed.2025.11.009","41938310","PMC13043485",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003646","GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.","Rea N","2025","Frontiers in clinical diabetes and healthcare","systematic_review","article","10.3389/fcdhc.2025.1579961","40937349","PMC12420244","PROSPERO:CRD42024516313",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0003647","Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review.","Corrêa LMA","2026","Transplantation reviews (Orlando, Fla.)","nonrandomized_study","article","10.1016/j.trre.2026.101003","41707409",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; review"],["R0003648","Glucagon-like peptide-1 receptor agonists in peri-operative care: Dispelling myths and unveiling insights with essential considerations for anaesthesiologists.","Paggers L","2025","European journal of anaesthesiology","narrative_review","article","10.1097/eja.0000000000002103","39620622",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003649","Hormonal modulation, mitochondria and Alzheimer's prevention: the role of GLP-1 agonists and estrogens.","Lizcano F","2025","Frontiers in molecular biosciences","narrative_review","article","10.3389/fmolb.2025.1622186","40642529","PMC12240769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003650","Predictors of Perioperative Major Adverse Cardiovascular Events After Bariatric Surgery.","Bcharah H","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.08.035","42727630",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0003651","Impact of GLP-1 Receptor Agonists in Gastrointestinal Endoscopy: An Updated Review.","Singh S","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13185627","39337114","PMC11432656",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0003652","The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review.","Laurence A","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.1016/j.eprac.2026.02.011","41720343",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003653","Diabetic kidney disease: integrating multi-omics insights, artificial intelligence, and novel therapeutics for precision medicine.","Li T","2026","Frontiers in genetics","narrative_review","article","10.3389/fgene.2026.1760654","41635803","PMC12863704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003654","GLP-1 RAs vs. SGLT2is: Divergent pathways of cardiovascular inflammation control in obesity-associated diabetes.","Samuel AH","2026","Annales d'endocrinologie","randomized_trial","article","10.1016/j.ando.2026.102494","41713726",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0003655","Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder.","Hammad MAM","2025","Toxins","nonrandomized_study","article","10.3390/toxins17110542","41295856","PMC12656553",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003656","Reply to 'Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure?'.","Ferreira JP","2024","European journal of heart failure","commentary","article","10.1002/ejhf.3415","39143853",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0003657","Postoperative Aspiration Pneumonia Among Adults Using GLP-1 Receptor Agonists.","Chen YH","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.0081","40036031","PMC11880946",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003658","A Single-Center, Blinded, Placebo-Controlled Study Evaluating Cosmetic Efficacy and Safety of a Novel Topical GLPSGLT in Glucagon-Like Peptide-1 Analog-Treated Patients.","Semersky A","2025","Aesthetic surgery journal. Open forum","randomized_trial","article","10.1093/asjof/ojaf030","40401118","PMC12094012",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Case Reports; Journal Article; case-report; article"],["R0003659","Glucagon-like peptide-1 receptor agonists in the perioperative period: Implications for the anaesthesiologist.","Gariani K","2024","European journal of anaesthesiology","randomized_trial","article","10.1097/eja.0000000000001914","38298102","PMC10842663",null,"S002511","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; letter; article"],["R0003660","Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting.","Weng J","2025","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-025-01722-8","40380308","PMC12083176",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003661","AI Patient Support and 6-Month Medication Adherence in a Digital Obesity Program: A Retrospective Analysis.","Talay L","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71181","42575845",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003662","Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Ahmed A","2025","Cureus","systematic_review","article","10.7759/cureus.92175","41084648","PMC12515520",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003663","Structure-Based Discovery of Orthosteric Non-Peptide GLP-1R Agonists via Integrated Virtual Screening and Molecular Dynamics.","Alturki MS","2025","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms26136131","40649923","PMC12249819",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; research-article; article; preprint"],["R0003664","Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?","Ling J","2024","Med (New York, N.Y.)","randomized_trial","article","10.1016/j.medj.2024.06.010","39127031",null,null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article"],["R0003665","Increased risk of hypereosinophilia following initiation of glucagon-like peptide 1 receptor agonist: A symmetry analysis using the Danish health registries.","Rahbek MT","2024","Journal of internal medicine","commentary","article","10.1111/joim.20025","39440625",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0003666","Letter to \"Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists\".","Merhi Z","2025","Fertility and sterility","commentary","article","10.1016/j.fertnstert.2024.08.314","39128670",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0003667","Emerging treatment strategies for polycystic ovary syndrome women with obesity: Focus on glucagon-like peptide-1 receptor agonists.","Jensterle M","2024","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2024.108872","39299029",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003668","Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta-analysis.","Alammari N","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16476","40390279",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0003669","Oral Semaglutide as an Opportunity for an Appropriate Therapeutic Switch in People with Type 2 Diabetes: A Delphi Consensus.","Bruglia M","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-025-01762-3","40542226","PMC12317931",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003670","Impact of Glucagon-like Peptide-1 Receptor Agonists on Metabolic Health in Liver Transplant Recipients.","Yakubu I","2025","Transplantation","nonrandomized_study","article","10.1097/tp.0000000000005361","40128152",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003671","Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2).","Malighetti ME","2026","Minerva endocrinology","nonrandomized_study","article","10.23736/s2724-6507.25.04376-3","41307513",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0003672","Reply of the authors: a call for metabolic stratification within obesity research and an urgent need for human, reproductive translational research with glucagon-like peptide 1 receptor agonists.","Boots CE","2025","Fertility and sterility","commentary","article","10.1016/j.fertnstert.2024.10.031","39454711",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0003673","Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet.","Ma T","2025","Frontiers in nutrition","randomized_trial","article","10.3389/fnut.2025.1659233","41019552","PMC12460090",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0003674","Lipoedema and Obesity Misclassification: A Phenotype Based Approach to Cardiometabolic Risk Beyond Body Mass Index.","Varghese RT","2026","Clinical obesity","narrative_review","article","10.1111/cob.70115","42767624","PMC13593362",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003675","The Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction","Vignarajah A","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.01.02.25319923",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003676","Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients.","Lin LC","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02649-0","39984953","PMC11846168",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0003677","Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review.","Badulescu S","2024","Physiology & behavior","systematic_review","article","10.1016/j.physbeh.2024.114622","38945189",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0003678","Advancements in the management of obesity: a review of current evidence and emerging therapies.","Abdalla Ahmed MA","2024","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2024.2347258","38685693",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0003679","Withholding or continuing glucose-lowering drugs for elective surgery in patients with type 2 diabetes mellitus: a secondary analysis of the MOPED international, prospective, observational study.","Buggy DJ","2026","British journal of anaesthesia","nonrandomized_study","article","10.1016/j.bja.2026.03.068","42191528","PMC13494077",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0003680","Assessing the Stabilizing Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atherosclerotic Plaque: An Interventional Study Investigating Cytokine Profiles in Diabetic Individuals","Hachula M","2024","Authorea Preprints","other","preprint","10.22541/au.171229916.65668662/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003681","The Potential Target Value of ADP-Ribosylation Factor 6 in Insulin Secretion Regulation and the Treatment of Metabolic Disorders.","Wang Y","2026","Metabolites","narrative_review","article","10.3390/metabo16070508","42506459","PMC13414401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003682","Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis.","Siriyotha S","2024","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2024-086424","39581734","PMC11590856",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003683","Upcoming drug targets for kidney protective effects in chronic kidney disease.","Nardone M","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other_trial","article","10.1093/ndt/gfae216","39907540","PMC11852282",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Review; Journal Article; review-article; article"],["R0003684","Effect of glucagon-like peptide-1 receptor agonist on outcomes after elective total hip arthroplasty: A retrospective cohort study.","Puga T","2026","Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association","nonrandomized_study","article","10.1016/j.jos.2026.02.002","41735126",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003685","Chasing the FoxO in Metabolic Disorders: Novel Considerations for Oxidative Stress, Programmed Cell Death, Wnt, and the Gut Microbiome.","Maiese K","2026","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox15070895","42510625","PMC13405709",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003686","Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.","Silverii GA","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15382","38018310",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0003687","Temporal trends and clinical factors associated with hypoglycemia-related hospitalization of patients with type 2 diabetes: a large-scale claims database study in Japan.","Kageyama M","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113539","42660202",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0003688","Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.","Gilbert MP","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15479","38317618",null,"ClinicalTrials.gov:NCT02465515","S001074","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003689","Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study.","Mai T","2026","Medicine","nonrandomized_study","article","10.1097/md.0000000000047562","41686569","PMC12908829",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; research-article; article"],["R0003690","GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction.","Bonfioli GB","2025","Heart failure reviews","narrative_review","article","10.1007/s10741-024-10450-6","39425816","PMC11646221",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0003691","Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-A systematic review and network meta-analysis.","Bramlage P","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70010","40798873",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Comparative Study; Network Meta-Analysis; review"],["R0003692","Combination of Glucagon-Like Peptide 1 Receptor Agonist and Thiazolidinedione for Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes.","Li JX","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.2577","40163115","PMC11959443",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0003693","Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial.","Atieh O","2026","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","randomized_trial","article","10.1093/cid/ciaf577","41098140","PMC13189676","ClinicalTrials.gov:NCT04019197","S001425","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Research Support, N.I.H., Extramural; article"],["R0003694","The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Katole NT","2024","Cureus","systematic_review","article","10.7759/cureus.66280","39238716","PMC11376316",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003695","A Scoping Review of GLP-1 Receptor Agonists: Are They Associated with Increased Gastric Contents, Regurgitation, and Aspiration Events?","Chang MG","2024","Journal of clinical medicine","randomized_trial","article","10.3390/jcm13216336","39518474","PMC11546377",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Scoping Review; review-article; article"],["R0003696","Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes.","Niazi S","2024","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2024.03.004","38490274",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003697","Beyond weight loss: How metabolism in human adipocytes is shaped by GLP-1R agonists and dual GIPR/GLP-1R agonists.","Curto R","2026","Pharmacological research","preclinical","article","10.1016/j.phrs.2026.108278","42229677",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003698","Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.","Hachuła M","2024","Medicina (Kaunas, Lithuania)","other","article","10.3390/medicina60060908","38929525","PMC11205508",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003699","The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atherosclerotic Plaque: Cytokine Profile in Diabetic Individuals","Hachula M","2024","Authorea Preprints","other","preprint","10.22541/au.171167452.25360247/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003700","Palmitic acid reprograms neutrophils to compromise vascular integrity and promote breast cancer lung metastasis.","Qian P","2026","Immunity","other","article","10.1016/j.immuni.2026.03.026","42034064",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0003701","Semaglutide-Associated Gastric Pneumatosis.","Turunen AM","2025","ACG case reports journal","case_report","article","10.14309/crj.0000000000001579","39734391","PMC11671069",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003702","Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter Protein-2 Inhibitors on Treating Metabolic Dysfunction-Associated Steatotic Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.","Xu R","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2024.11.017","39701283",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0003703","The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.","Abdelmalek MF","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15524","38511418",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0003705","The First Report of Tirzepatide-Induced Diabetic Ketoacidosis in Latent Autoimmune Diabetes in Adults","Shapoo N","2026","Preprints.org","other","preprint","10.20944/preprints202606.1343.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003706","Comparative Analysis of the Anti-Inflammatory Effects of Liraglutide and Dulaglutide.","Hou Y","2024","International heart journal","other","article","10.1536/ihj.23-576","38749748",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0003707","GLP-1 receptor agonist use in elective lumbar spine surgery: Reduced pseudarthrosis rates and favorable safety profile.","Tummala S","2025","Journal of orthopaedics","nonrandomized_study","article","10.1016/j.jor.2025.05.018","40502373","PMC12148742",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003708","Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus.","An XD","2025","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v16.i11.111280","41278452","PMC12635768",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003709","Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study.","Chen TP","2026","Science progress","nonrandomized_study","article","10.1177/00368504261484176","42648283","PMC13519180",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003710","A rationally designed 18-amino acid peptide with potential as GLP-1 receptor agonist.","Singh A","2026","Frontiers in pharmacology","other","article","10.3389/fphar.2026.1789257","42244872","PMC13229714",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003711","Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey.","Arnaut T","2026","Advances in therapy","nonrandomized_study","article","10.1007/s12325-026-03636-x","42217114","PMC13415491",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; article"],["R0003712","Comparative safety of glucose-lowering medications on depression in adults with type 2 diabetes.","Hooker SA","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70415","41479367",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Clinical Trial; Comparative Study; Journal Article; article"],["R0003713","Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis.","Kalayci A","2025","European heart journal. Cardiovascular pharmacotherapy","systematic_review","article","10.1093/ehjcvp/pvaf037","40886073","PMC12450594",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0003714","Accessible Type 2 diabetes medication through stable expression of Exendin-4 in Saccharomyces cerevisiae.","Balius G","2024","Frontiers in systems biology","other","article","10.3389/fsysb.2024.1283371","40809148","PMC12342014",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003715","Does the Carbohydrate-Insulin Model Explain Obesity? Evidence from Mechanistic and Clinical Studies: A Critical Review.","Ashtary-Larky D","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00751-2","42616211",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003716","Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular-Kidney-Metabolic Syndrome.","Zeitler E","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70781","42010373","PMC13135858",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003717","Effects of glucagon-like peptide-1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.","Karakasis P","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15979","39344842",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0003718","Reply to the Letter to the Editor: Why Did the \"Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists\" Differ From the Previous Randomized Controlled Study?","Lavu MS","2024","The Journal of arthroplasty","randomized_trial","article","10.1016/j.arth.2024.08.036","39523050",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; letter"],["R0003719","Weight Loss From Combination Anti-Obesity Medication Regimens Can Approach that Achieved From Bariatric Surgery.","Patel PN","2023","JCEM case reports","case_report","article","10.1210/jcemcr/luac038","37908264","PMC10578411",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003720","Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.","McCormick N","2026","Diabetes care","nonrandomized_study","article","10.2337/dc25-1713","41615420","PMC12925992",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003721","Incidence of Gastrointestinal Adverse Events and Healthcare Resource Utilization in Patients Using Glucagon-Like Peptide-1 Analogs: A Real-World Study.","Nathani P","2026","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-026-10112-7","42418075","PMC13585874",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003722","Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.","Buckeridge C","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15643","38751362",null,"ClinicalTrials.gov:NCT04305587; ClinicalTrials.gov:NCT05158244","S000290; S001483","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0003723","Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis.","Wang Y","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-01877-4","40770817","PMC12326795","PROSPERO:CRD42023473528",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003724","Interconnection between polycystic ovary syndrome, immune disorders, and reproductive outcomes.","Romero TB","2026","Reproduction & fertility","narrative_review","article","10.1530/raf-25-0186","41961878","PMC13130874",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003725","From Prescription to Predicament: A Case of Semaglutide-Induced Discoid Lupus Erythematosus in an Adult Male Patient.","Nazzicone K","2025","Cureus","case_report","article","10.7759/cureus.81663","40330408","PMC12051072",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003726","Comparative Weight Change With Initiation and Adherence to Common Medications for Type 2 Diabetes.","Sneed NM","2025","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.70022","41102137","PMC12559777",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Comparative Study; research-article; article"],["R0003727","Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.","Almeida OP","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15616","38650544",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003728","Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review protocol","Thomas M","2024","medRxiv","protocol","preprint","10.1101/2024.12.04.24318321",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0003729","Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction","Varra F","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202605.1774.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0003730","Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile.","Scheen AJ","2024","Expert opinion on drug safety","randomized_trial","article","10.1080/14740338.2024.2354885","38738549",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0003731","Improving Prescribing Rates of Glucagon-Like Peptide 1 Receptor Agonists in Youth With Type 2 Diabetes.","Huang A","2025","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd24-0070","40741462","PMC12304563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0003732","Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.","Stefanou MI","2024","European stroke journal","systematic_review","article","10.1177/23969873241234238","38400569","PMC11418422",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; other; review"],["R0003733","Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.","Giannakogeorgou A","2024","Alimentary pharmacology & therapeutics","narrative_review","article","10.1111/apt.17848","38813830",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0003734","The Association of Diabetes and Atherosclerosis: Understanding the Molecular Mechanism of the Double Burden.","Tripathy M","2026","Current medicinal chemistry","nonrandomized_study","article","10.2174/0109298673435173260213113630","42316498",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0003735","Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies.","Zheng W","2025","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-025-01917-z","40826119","PMC12359955",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003736","Glucagon-Like Peptide 1 Receptor Agonists: A Role in Glaucoma?","Johnson C","2024","Ophthalmology. Glaucoma","commentary","article","10.1016/j.ogla.2024.03.005","38944802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0003737","Traditional and Modern Predictors of Atherosclerotic Cardiovascular Disease in Patients with T2D and MASLD.","Vulpescu Diaconu CT","2026","Diagnostics (Basel, Switzerland)","nonrandomized_study","article","10.3390/diagnostics16111607","42279474","PMC13256716",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003738","Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial.","Gamborg M","2025","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2025.101346","40950945","PMC12426824",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003739","Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study.","Yen Y","2026","BMC medicine","randomized_trial","article","10.1186/s12916-026-04648-8","41572274","PMC12910975","ChiCTR:ChiCTR2300070632; ChiCTR:ChiCTR-2300070632",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; Clinical Trial; research-article; article"],["R0003740","Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.","Ciudin A","2026","Advances in therapy","systematic_review","article","10.1007/s12325-026-03523-5","41820778","PMC13156185",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Comparative Study; Systematic Review; research-article; review"],["R0003741","A Multidisciplinary Perspective on Semaglutide Treatment and Medical Nutrition Therapy in Obesity Management.","Barrea L","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00667-3","41129057","PMC12549762",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003742","Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review","Fattahi A","2025","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.175521972.20484170/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003743","Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.","Morse BL","2026","Clinical pharmacology in drug development","other_trial","article","10.1002/cpdd.1594","40888509",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; article"],["R0003744","Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.","Xu S","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71138","42481928","PMC13538726",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003745","Sodium-Glucose Cotransporter-2 Inhibitors versus Glucagon-Like Peptide 1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes.","Morello CM","2024","Kidney360","nonrandomized_study","article","10.34067/kid.0000000597","39361784","PMC12282624",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003746","Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Syndrome Management: A Narrative Review.","Dragonieri S","2024","Diseases (Basel, Switzerland)","narrative_review","article","10.3390/diseases12090224","39329893","PMC11431450",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003747","Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis.","De la Flor JC","2022","Case reports in nephrology and dialysis","case_report","article","10.1159/000527919","36465574","PMC9710441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003748","Semaglutide attenuates diabetic vascular calcification by enhancing autophagy and lysosomal function via targeting CPNE1.","Xiao S","2026","Apoptosis : an international journal on programmed cell death","preclinical","article","10.1007/s10495-026-02269-3","41793524",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003749","Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial).","Li J","2025","MedComm","nonrandomized_study","article","10.1002/mco2.70094","39949982","PMC11822460",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003750","Screening and Treatment Using a Risk-Based Approach With NT-proBNP Guidance in Diabetes Mellitus: The STRONG-DM Pilot Study.","Subramanian V","2026","JACC. Heart failure","randomized_trial","article","10.1016/j.jchf.2026.103153","42233896",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0003751","Exacerbation of Postural Orthostatic Tachycardia Syndrome With Tirzepatide Prescribed for Weight Loss.","Hedge ET","2025","JACC. Case reports","case_report","article","10.1016/j.jaccas.2025.105430","40944681","PMC12793844",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003752","Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.","Beach R","2026","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","case_report","article","10.1093/cid/ciag121","42139091",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; Research Support, Non-U.S. Gov't; article"],["R0003753","A small molecule PTER-selective inhibitor reduces food intake and body weight.","Fu S","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.01.26.701829","41659642","PMC12873775",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0003754","The Effectiveness of an Electronic Decision Support Algorithm to Optimize Recommendations of SGLT2i and GLP-1RA in Patients with Type 2 Diabetes upon Discharge from Internal Medicine Wards.","Ayalon-Dangur I","2025","Journal of clinical medicine","other","article","10.3390/jcm14072170","40217621","PMC11989524",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003755","Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.","Khare S","2025","Advances in therapy","nonrandomized_study","article","10.1007/s12325-024-03002-9","39487881","PMC11782337",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0003756","Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions.","Pahulu I","2026","JNCI cancer spectrum","systematic_review","article","10.1093/jncics/pkag014","41703670","PMC12972670",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0003757","Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: A meta-analysis of clinical studies emphasising retinal changes as a primary outcome.","Kapoor I","2025","Clinical & experimental ophthalmology","systematic_review","article","10.1111/ceo.14445","39327045",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0003758","Glucagon-like Peptide 1 Receptor Agonists and Risk of Adverse Anesthesia Events: Caution Warranted When Interpreting Associations With Pulmonary Aspiration.","Zandvakili I","2025","Gastroenterology","commentary","article","10.1053/j.gastro.2024.06.040","39245411",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0003759","Diabetic retinopathy as a sentinel of systemic vascular dysfunction: Shared molecular mechanisms with cardiovascular disease.","Wang T","2025","Experimental eye research","narrative_review","article","10.1016/j.exer.2025.110644","40972855",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003760","Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms","Murugadoss K","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202608.1193.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0003761","Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.","Yang W","2024","Medicine","randomized_trial","article","10.1097/md.0000000000038879","39121301","PMC11315522",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0003762","Disease modifying therapies in heart failure: an update.","Tanaka A","2025","QJM : monthly journal of the Association of Physicians","narrative_review","article","10.1093/qjmed/hcaf060","40036960",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003763","Nephroprotective Effect of GLP-1 Receptor Agonists (GLP-1 RAs) in Patients Receiving Lithium Therapy: A Population-Based Study Using the TriNetX Network","McIntyre RS","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.02.09.26345925",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0003764","Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review.","Gravina AG","2025","Current issues in molecular biology","narrative_review","article","10.3390/cimb47050383","40699782","PMC12109805",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003765","Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes.","Saeed ZI","2025","Clinical diabetes : a publication of the American Diabetes Association","narrative_review","article","10.2337/cd24-0067","39829697","PMC11739354",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003766","The Proteomic Analysis of Intermittent Fasting Alone or with GLP-1RA in NAFLD Rats.","Shao Y","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s550262","41215755","PMC12596835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003767","Exploration of factors associated with eGFR slope improvement before and after intensive treatment of patients with diabetic nephropathy at high risk of disease progression: a retrospective cohort study.","Kiku M","2026","Journal of rural medicine : JRM","nonrandomized_study","article","10.2185/jrm.2025-039","42006693","PMC13087666","UMIN:UMIN000050610",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003768","Evolving Role of GLP-1 Therapies in Liver Disease.","Lindsay M","2025","Current gastroenterology reports","other_trial","article","10.1007/s11894-025-00988-2","40478351",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0003769","FRONTIER: FReeStyle Libre system use in Ontario among people with diabetes in the IC/ES database-Evidence from real-world practice: Patients on basal insulin, glucagon-like peptide 1 receptor agonist or oral therapies.","Ratzki-Leewing A","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16266","40117297",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003770","Anti-diabetic effects of GLP-1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review.","Wong HJ","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16136","39726212",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0003771","Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.","Allahwala MA","2025","Heart, lung & circulation","nonrandomized_study","article","10.1016/j.hlc.2025.07.005","40914712",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0003772","GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials.","Duhan S","2025","International journal of cardiology","systematic_review","article","10.1016/j.ijcard.2025.133604","40623630",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; review"],["R0003773","From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.","Badran AS","2025","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","systematic_review","article","10.1007/s10072-025-08411-4","40835782",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003774","Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.","Ghazanfar H","2024","World journal of gastroenterology","nonrandomized_study","article","10.3748/wjg.v30.i26.3221","39086638","PMC11287410",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003775","Artificial intelligence in anti-obesity drug discovery: unlocking next-generation therapeutics.","Gangwal A","2025","Drug discovery today","narrative_review","article","10.1016/j.drudis.2025.104333","40107411",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003776","Discontinuation of oral semaglutide due to adverse effects: a database study on Japanese individuals with type 2 diabetes.","Ishiguro M","2026","Diabetology international","nonrandomized_study","article","10.1007/s13340-025-00868-0","41509889","PMC12775246",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0003777","Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study.","Madsen JM","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-024-02548-w","39755640","PMC11700455",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0003778","Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.","Wang C","2025","Journal of cancer research and clinical oncology","preclinical","article","10.1007/s00432-025-06154-5","40055197","PMC11889073",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003779","A review of recent research and development on GLP-1 receptor agonists-sustained-release microspheres.","Gao Z","2023","Journal of materials chemistry. B","narrative_review","article","10.1039/d3tb02207b","37975420",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0003780","Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study.","Wu YC","2026","Reproductive biology and endocrinology : RB&E","nonrandomized_study","article","10.1186/s12958-026-01549-6","42001071","PMC13224514",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0003781","Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction.","Ni D","2024","Military medicine","randomized_trial","article","10.1093/milmed/usae311","38870042",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0003782","The Treatment of Obesity in the Context of the Obesity Paradox in Patients with Heart Failure: A Narrative Review.","Alebna PL","2025","Current cardiology reports","narrative_review","article","10.1007/s11886-025-02333-5","41400711","PMC12708749",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003783","Self-medication with GLP-1 receptor agonists among Brazilian Adults: findings from a web-based survey.","de Carvalho TR","2026","International journal of obesity (2005)","other","article","10.1038/s41366-026-02186-0","42618598",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003784","Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes.","Yamada T","2023","Diabetology international","case_report","article","10.1007/s13340-023-00621-5","37397904","PMC10307741",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003785","Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy.","Dhanapalaratnam R","2024","Diabetologia","nonrandomized_study","article","10.1007/s00125-023-06072-6","38189936",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003786","Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.","Cautela D","2026","International journal of molecular sciences","randomized_trial","article","10.3390/ijms27188057","42794486","PMC13607671",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0003787","Beyond current standards: combination therapy and emerging targets in diabetic kidney disease.","Lee J","2026","Kidney research and clinical practice","other","article","10.23876/j.krcp.26.234","42595707",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003788","Emerging Treatments for Obesity: the Role of GLP1 Receptor Agonists on Stroke.","Mariscal M","2025","Current neurology and neuroscience reports","randomized_trial","article","10.1007/s11910-025-01423-9","40397216","PMC12095380",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003789","A machine learning model for optimizing treatment of patients with poorly controlled type 2 diabetes.","Shi J","2026","Communications medicine","nonrandomized_study","article","10.1038/s43856-026-01442-8","41703087","PMC13022273",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003790","GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.","Alfaris N","2024","EClinicalMedicine","narrative_review","article","10.1016/j.eclinm.2024.102782","39281096","PMC11402415",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003791","GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.","Vu M","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","nonrandomized_study","article","10.1097/dss.0000000000005162","42210885",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0003792","GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?","Doumani G","2024","Life (Basel, Switzerland)","other_trial","article","10.3390/life14111478","39598276","PMC11595976",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0003793","GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias.","Tang H","2025","JAMA neurology","nonrandomized_study","article","10.1001/jamaneurol.2025.0353","40193118","PMC11976648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003794","Comparative efficacy and safety of Glucagon-like pepetide-1 receptor agonists with metformin in Asian versus non-Asian patients with type 2 diabetes: A systematic review and meta-analysis.","Li W","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70084","40936218",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Comparative Study; review"],["R0003795","Acute Pancreatitis Likely Due to Semaglutide.","Hughes K","2024","Cureus","case_report","article","10.7759/cureus.69844","39308839","PMC11416045",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003796","Antiobesity medications in rheumatology. Quo vadis?","Kyriazi N","2026","Annals of the rheumatic diseases","randomized_trial","article","10.1016/j.ard.2025.08.013","40946026",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0003797","Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass.","Mera-Carreiro S","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08954-1","42802300",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003798","Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.","Giorgino F","2026","JAMA","randomized_trial","article","10.1001/jama.2026.9512","42251769","PMC13244277","ClinicalTrials.gov:NCT06109311","S001044","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; article"],["R0003799","Preoperative Glucagon-Like Peptide-1 Agonist Use Is Associated With Decreased Complications Compared to Bariatric Surgery Following Primary Total Hip Arthroplasty.","Bcharah G","2026","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2026.04.032","42001909",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0003800","Use of oral Semaglutide after Acute Coronary Syndrome - Design and rationale of a prospective observational study","Biasin M","2025","medRxiv","protocol","preprint","10.1101/2025.08.03.25332910",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0003801","Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD.","Gregg LP","2025","Journal of the American Society of Nephrology : JASN","other","article","10.1681/asn.0000000000000477","39186372","PMC11706553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003802","GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?","Hayat J","2024","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-024-01214-6","38809399",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003803","Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials.","Hosseinpour A","2024","Clinical cardiology","systematic_review","article","10.1002/clc.24314","38953365","PMC11217813",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; article"],["R0003804","Peer Review for \"Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis\".","Anonymous","2024","JMIRx med","nonrandomized_study","article","10.2196/59120","38738851","PMC11090021",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; reviewer-report; article"],["R0003805","Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs.","Theodorakis N","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13010135","39857719","PMC11760485",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003806","Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.","Wolsing SK","2026","Clinical obesity","randomized_trial","article","10.1111/cob.70079","41871584","PMC13008477",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; research-article; article"],["R0003807","Impact of GLP-1 receptor agonists on idiopathic intracranial hypertension clinical and neurosurgical outcomes: a propensity-matched multi-institutional cohort study.","O'Leary S","2025","Journal of neurosurgery","randomized_trial","article","10.3171/2025.1.jns242357","40344770",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; article"],["R0003808","Glucagon-Like Peptide-1 Receptor Agonists and Atrial Fibrillation Recurrence After Ablation: A Fire Without the Smoke?","Karakasis P","2024","JACC. Clinical electrophysiology","commentary","article","10.1016/j.jacep.2024.07.004","39197973",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0003809","Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models.","Zhang M","2025","International journal of medical sciences","preclinical","article","10.7150/ijms.112264","40765557","PMC12320650",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003810","Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients.","Zheng K","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15769","39056216",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003811","Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea.","Noreña JA","2026","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000949","41405280",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003812","GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy.","Scheen AJ","2024","Drugs","randomized_trial","article","10.1007/s40265-024-02090-9","39342059",null,null,"S002726","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0003813","Sleeve gastrectomy versus GLP-1 agonist to improve kidney transplant access in end-stage renal disease patients with obesity: a decision analysis.","Di Napoli M","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","other","article","10.1016/j.soard.2025.04.001","40320319",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003814","Medication adherence and persistence of newly initiated medications in older adults with diabetes.","Dombrowski SK","2026","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2026.103075","41850681",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0003815","Antidiabetic drug effects on gastrointestinal health: convergent evidence from a longitudinal cohort and Mendelian randomization study.","Li X","2026","Journal of advanced research","nonrandomized_study","article","10.1016/j.jare.2026.04.014","41951048",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0003816","Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.","Sattar N","2026","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2026.04.044","42233927",null,"ClinicalTrials.gov:NCT04184622","S001077","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0003817","Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report.","Wilcox L","2024","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2024.102185","38992739",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0003818","Active GLP-1 RA Use Is Associated With Lower Rates of Surgical Complications Across Diabetic BMI Cohorts: A Retrospective Analysis of 72,578 Surgical Encounters.","Salingaros S","2026","Annals of plastic surgery","nonrandomized_study","article","10.1097/sap.0000000000004657","41687055",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0003819","Effects of beinaglutide on visceral fat area and gut microbiota in obesity.","Liu T","2025","European journal of medical research","other","article","10.1186/s40001-025-02585-5","40462210","PMC12135259",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0003820","Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?","Linge J","2024","Circulation","narrative_review","article","10.1161/circulationaha.124.067676","39401279",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003821","GLP-1R agonist semaglutide protects human forebrain organoids from cholesterol-induced neurotoxicity.","Yu F","2026","Alzheimer's & dementia : the journal of the Alzheimer's Association","other","article","10.1002/alz.71888","42805933","PMC13619743",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003822","Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.","Hamarsheh S","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70248","42207966","PMC13239642",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Comparative Study; research-article; article"],["R0003823","Perioperative management of patients on glucagon-like peptide-1 receptor agonists.","Mizubuti GB","2024","Current opinion in anaesthesiology","nonrandomized_study","article","10.1097/aco.0000000000001348","38390914",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0003824","Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G).","Ohsugi M","2023","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2023.110841","37481115",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003825","A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Efficacy and Adverse Events.","Radparvar I","2025","Archives of clinical and medical case reports","other","article","10.26502/acmcr.96550740","41835241","PMC12981728",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003826","Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).","Strojek K","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.71049","42387310","PMC13449048","ClinicalTrials.gov:NCT05813912","S000429","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0003827","Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence.","Moore J","2025","Pharmacy (Basel, Switzerland)","nonrandomized_study","article","10.3390/pharmacy13020046","40126319","PMC11932303",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0003828","Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.","Arun AJ","2025","Cardiology in review","other_trial","article","10.1097/crd.0000000000001062","40963161",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0003829","Semaglutide Initiation and Treatment Duration On Suicidality Risk in US Veterans With Type 2 Diabetes","Maldonado AI","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.04.17.26351118",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0003830","Role of Incretin Mimetics in Cardiovascular Outcomes and Other Classical Cardiovascular Risk Factors beyond Obesity and Diabetes Mellitus in Nondiabetic Adults with Obesity: a Meta-analysis of Randomized Controlled Trials.","Kamarullah W","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","systematic_review","article","10.1007/s40256-024-00695-9","39616304",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0003831","Correction to: Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.","Ahmad A","2024","Cardiovascular diabetology","notice","article","10.1186/s12933-024-02283-2","38824524","PMC11144318",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0003832","Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure with Reduced Ejection Fraction: Time for a Trial.","Ostrominski JW","2025","Journal of cardiac failure","other_trial","article","10.1016/j.cardfail.2024.07.002","39032688",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0003833","Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions.","Bilgin E","2025","Autoimmunity reviews","randomized_trial","article","10.1016/j.autrev.2025.103864","40617296",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0003834","A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD.","Singh AK","2026","Kidney international reports","other","article","10.1016/j.ekir.2025.10.032","41630895","PMC12860910",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003835","Epigenetic Aging and Treatment Response to Semaglutide in the SLIM LIVER Study.","Corley M","2025","Research square","other_trial","article","10.21203/rs.3.rs-7697256/v1","41256006","PMC12622174","ClinicalTrials.gov:NCT04216589","S001796","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Preprint; preprint"],["R0003836","Trends and Disparities in Newer GLP1 Receptor Agonist Initiation among Real-World Adult Patients Eligible for Obesity Treatment.","Radwan RM","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.01.20.25320839","39974110","PMC11839001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0003837","Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.","Scheen AJ","2023","Annales d'endocrinologie","narrative_review","article","10.1016/j.ando.2022.12.423","36639119",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003838","Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment.","Radwan RM","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16318","40035205","PMC12049259",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003839","GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension.","Sioutas GS","2025","JAMA neurology","nonrandomized_study","article","10.1001/jamaneurol.2025.2020","40658395","PMC12261113",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003840","Fasting Duration, Not Timing of Last GLP-1 Dose, Predicts Aspiration Risk Indicators: A Prospective Point-of-Care Gastric Ultrasound Study.","Shahidifar E","2026","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-025-09570-2","41266825","PMC13201273",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0003841","Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease.","Tirandi A","2024","Polish archives of internal medicine","narrative_review","article","10.20452/pamw.16658","38226456",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003842","Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials.","Wong HJ","2025","Diabetes care","systematic_review","article","10.2337/dc24-1678","39841962",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003843","The Heart-Kidney Axis in Heart Failure and Chronic Kidney Disease: Mechanisms, Mediators, and Therapeutic Implications.","Fan A","2026","Biomolecules","randomized_trial","article","10.3390/biom16091241","42793073","PMC13604364",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003844","A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes.","Ohwaki K","2026","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.70157","41325139","PMC12863000",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0003845","Safety and efficacy of semaglutide for non-alcoholic fatty liver disease: A meta-analysis of clinical outcomes","Faheem MSB","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-9176897/v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0003846","Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review.","Mady R","2026","Cureus","randomized_trial","article","10.7759/cureus.111445","42388957","PMC13319496",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0003847","Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland.","Hoffmann K","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s531697","40792001","PMC12338098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003848","Searching the Crystal Ball for Tailored GLP-1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity.","Saturnino A","2025","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.70017","39673731",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0003849","Reply: Glucagon-Like Peptide-1 Receptor Agonists and Atrial Fibrillation Recurrence After Ablation: A Fire Without the Smoke?","Satti DI","2024","JACC. Clinical electrophysiology","commentary","article","10.1016/j.jacep.2024.07.005","39197974",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter; Comment"],["R0003850","The Neural Impact Score benchmarks drugs in Multi-Region Brain Organoids","Pantula A","2026","bioRxiv","preclinical","preprint","10.64898/2026.08.26.746777",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003851","Use of glucagon-like peptide-1 receptor agonists in patients with left ventricular assist devices.","Ibrahim R","2025","ESC heart failure","nonrandomized_study","article","10.1002/ehf2.15379","41078121","PMC12719829",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0003852","A scoping review of obesity policies and reimbursement landscape: global insights and lessons for Thailand.","Rawdaree P","2026","Implementation science communications","nonrandomized_study","article","10.1186/s43058-026-00985-0","42321875","PMC13551807",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003853","[Fixed ratio combinations GLP-1RA and basal insulin: literature review].","Kurkin DV","2024","Problemy endokrinologii","randomized_trial","article","10.14341/probl13312","38433545","PMC10926250",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Review; English Abstract; Journal Article; research-article; article"],["R0003854","Liraglutide enhances bone regeneration in a critical-size calvarial defect model in male rats: A comparative study with autogenous grafts, allografts, and xenografts.","Zavrak N","2026","Archives of oral biology","preclinical","article","10.1016/j.archoralbio.2026.106519","41579495",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0003855","Nutritional Counseling Is Independently Associated with Greater Knowledge of Drug-Food Interactions in Patients with Type 2 Diabetes.","Korbela J","2026","Nutrients","other","article","10.3390/nu18050742","41829912","PMC12987031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003856","Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity.","Avogaro A","2026","European journal of clinical investigation","nonrandomized_study","article","10.1111/eci.70184","41653035",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0003857","Glucagon-like Peptide 1 Receptor Agonist: Balancing Alarm and Caution.","Ziemssen F","2024","Klinische Monatsblatter fur Augenheilkunde","commentary","article","10.1055/a-2369-9085","39284357",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0003858","Improved quality of life with semaglutide in schizophrenia: Secondary analyses from a randomized controlled trial.","Uhrenholt N","2026","Schizophrenia research","randomized_trial","article","10.1016/j.schres.2026.02.009","41702353",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0003859","Gastric Motility Assays May Not Capture the Entire Clinical Picture in Patients Using Glucagon-Like Peptide-1 Receptor Agonists.","Hobai IA","2025","The American journal of gastroenterology","other","article","10.14309/ajg.0000000000002949","39120044",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003860","Obesity as a modifiable risk factor in patients with chronic kidney disease.","Morales E","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","narrative_review","article","10.1093/ndt/gfaf231","41165722",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003861","GLP-1 prescribing for individuals with schizophrenia-spectrum disorders in a safety net hospital.","Khan S","2026","General hospital psychiatry","nonrandomized_study","article","10.1016/j.genhosppsych.2026.08.002","42594759",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0003862","Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis.","Lei D","2026","Urologic oncology","systematic_review","article","10.1016/j.urolonc.2026.05.024","42314323",null,"PROSPERO:CRD420251149266",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0003863","Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.","Plutzky J","2026","Circulation","randomized_trial","article","10.1161/circulationaha.125.074482","42610271","PMC13574348","ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0003864","Gastric ultrasound and mitigating risk of glucagon-like peptide-1 receptor agonists.","Hurley C","2024","Anaesthesia","nonrandomized_study","article","10.1111/anae.16362","38894670",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0003865","Impact of glucagon-like peptide-1 receptor agonists on postoperative complications after total joint arthroplasty: A systematic review and meta-analysis.","Mashayekhi Y","2025","Journal of orthopaedic surgery (Hong Kong)","systematic_review","article","10.1177/10225536251391959","41233973",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003866","Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.","Chang LS","2026","American heart journal","randomized_trial","article","10.1016/j.ahj.2026.107359","41610902",null,"ClinicalTrials.gov:NCT06046560","S002701","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase IV; Journal Article; Pragmatic Clinical Trial; Randomized Controlled Trial; article"],["R0003867","Gastric ultrasound and mitigating risk of glucagon-like peptide-1 receptor agonists: a reply.","Kam PC","2024","Anaesthesia","commentary","article","10.1111/anae.16369","38924034",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0003868","Comparative Effectiveness of SGLT2i and GLP-1RA on Blood Pressure in Hypertensive Patients with Type 2 Diabetes: A Saudi Multicenter Retrospective Study.","Alshehri G","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14207428","41156303","PMC12564954",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003869","Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide.","Fareed A","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.1016/j.eprac.2024.09.004","39278353",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003870","Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.","Candido R","2024","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2024.03.023","38693036",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0003871","Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study.","Abutaima R","2024","PloS one","other","article","10.1371/journal.pone.0314407","39636914","PMC11620468",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0003872","Hyperglycemia following pancreas transplantation: Rethinking graft function and metabolic control.","Singh N","2026","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","narrative_review","article","10.1016/j.ajt.2026.05.714","42144113",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003873","GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective.","Carmellini P","2025","Life (Basel, Switzerland)","randomized_trial","article","10.3390/life15091422","41010364","PMC12471315",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003874","[Effects of semaglutide on mental health].","Rozhdestvenskaya VA","2025","Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","narrative_review","article","10.17116/jnevro202512509128","41051803",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0003875","A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists.","Pierret ACS","2025","Acta diabetologica","other","article","10.1007/s00592-024-02392-0","39520512","PMC12116896",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003876","Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes.","Raven LM","2023","JCEM case reports","other_trial","article","10.1210/jcemcr/luac017","37908242","PMC10578374",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0003877","Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists.","Ahmed M","2025","Innovations in pharmacy","nonrandomized_study","article","10.24926/iip.v16i1.6450","41080834","PMC12509713",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003878","Antidiabetic drug and chronic respiratory disease in type 2 diabetes: a network meta-analysis and Mendelian randomization analysis.","Patel I","2026","Therapeutic advances in endocrinology and metabolism","systematic_review","article","10.1177/20420188261437346","41969412","PMC13069171","PROSPERO:CRD42024542379",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0003879","Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-κb pathways.","Zhang L","2025","Scientific reports","preclinical","article","10.1038/s41598-025-12715-y","40715315","PMC12297628",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003880","Real-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes.","Zhang J","2026","Metabolism open","nonrandomized_study","article","10.1016/j.metop.2026.100497","42857180","PMC13651640",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003881","Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life.","Shchendrygina A","2024","Cardiac failure review","narrative_review","article","10.15420/cfr.2024.05","39309521","PMC11413987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003882","Pharmacological management of obesity: Current landscape and emerging therapies.","Atal S","2026","Indian journal of pharmacology","narrative_review","article","10.4103/ijp.ijp_37_26","42683980","PMC13610767",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003883","Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis.","Yeo YH","2024","Annals of internal medicine","nonrandomized_study","article","10.7326/m24-0019","39038291",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0003884","GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation.","Zhong J","2024","Journal of pharmaceutical analysis","other_trial","article","10.1016/j.jpha.2023.12.007","38799233","PMC11127228",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0003885","Impact of co-administration of proton pump inhibitors on efficacy and safety of oral semaglutide in patients with type 2 diabetes: a single-center retrospective study","Yokoyama T","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9444720/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint; article"],["R0003886","GLP-1 receptor agonists and the risk of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a single-center, retrospective cohort study.","Shan X","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2024.09.013","39482214",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003887","Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.","Bailey CJ","2026","Peptides","preclinical","article","10.1016/j.peptides.2026.171480","41747885",null,"ClinicalTrials.gov:NCT07022977; ClinicalTrials.gov:NCT06924320","S003345","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0003888","GLP-1 receptor agonist attenuates tubular cell ferroptosis in diabetes via enhancing AMPK-fatty acid metabolism pathway through macropinocytosis.","Shen R","2024","Biochimica et biophysica acta. Molecular basis of disease","other","article","10.1016/j.bbadis.2024.167060","38354757",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003889","Comparative Use Human Factors Study of a Manual vs. A Partially Automated Pen Injector for GLP-1 Receptor Agonist Delivery.","Natarajan K","2026","Clinical pharmacology and therapeutics","randomized_trial","article","10.1002/cpt.70295","41997744",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comparative Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0003890","Authors' Response to Peer Reviews of \"Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis\".","Makunts T","2024","JMIRx med","nonrandomized_study","article","10.2196/58273","38738852","PMC11090022",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; author-comment; article"],["R0003891","Case Report: Gastric Retention Induced by Tirzepatide in a Patient Undergoing Gastroscopy","Zhao Y","2026","Research Square","case_report","preprint","10.21203/rs.3.rs-8818962/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0003892","Glucagon-Like Peptide-1 (GLP-1a) Receptor Agonist Use in Patients Presenting for Gastroenterology Procedures: A Review of Concerns.","Wunder L","2025","Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates","narrative_review","article","10.1097/sga.0000000000000891","40986735",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003893","Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort study.","Lagger M","2026","PloS one","protocol","article","10.1371/journal.pone.0357577","42715243","PMC13557380","ClinicalTrials.gov:NCT07014709","S002615","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0003894","Obesity Epidemic and Its Impact on Female Fertility: Current Understanding and Future Directions.","Malhotra R","2025","Cureus","narrative_review","article","10.7759/cureus.87283","40755647","PMC12318484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003895","Cardiometabolic Heart Failure with Preserved Ejection Fraction (HFpEF): Epidemiology, Mechanisms, and the Role of Lifestyle Modification.","Yang DG","2026","Journal of cardiovascular development and disease","narrative_review","article","10.3390/jcdd13070291","42505868","PMC13409762",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003896","The perioperative use of GLP-1 receptor agonists in patients undergoing hip and knee arthroplasty: a scoping review.","Dworsky-Fried J","2026","Annals of joint","nonrandomized_study","article","10.21037/aoj-2025-1-93","42591481","PMC13462197",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0003897","Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.","Chrzanowski J","2026","PLoS medicine","systematic_review","article","10.1371/journal.pmed.1005064","42166479","PMC13221145",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0003898","Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications.","Liu H","2023","European review for medical and pharmacological sciences","narrative_review","article","10.26355/eurrev_202303_31768","37013752",null,null,"S002229","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Review; Journal Article; review"],["R0003899","Cardiomyocyte calcium homeostasis remodeling in diabetes-related HFpEF: mechanisms and therapeutic perspectives.","Zhang K","2026","Pharmacological research","narrative_review","article","10.1016/j.phrs.2026.108434","42697419",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003900","Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations.","Fatima N","2024","Cureus","randomized_trial","article","10.7759/cureus.68786","39376859","PMC11456416",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003901","Cellular signaling crosstalk between osteoporosis and diabetes: Common mechanisms and therapeutic targets (Review).","Cheng Y","2026","Biomedical reports","narrative_review","article","10.3892/br.2026.2157","42199525","PMC13199948",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003902","[Managing the discontinuation of GLP-1 agonists : how to insure a smooth transition].","Correia JC","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.910.527","40111294",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0003903","Weight maintenance on cost-effective antiobesity medications after 1 year of GLP-1 receptor agonist therapy: a real-world study.","Paddu NU","2024","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24177","39558626","PMC11589535",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003904","Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States.","Kovesdy CP","2026","Journal of clinical & translational endocrinology","nonrandomized_study","article","10.1016/j.jcte.2026.100435","41810084","PMC12969326","ClinicalTrials.gov:NCT05526157","S002732","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003905","Prepregnancy GLP-1RA use improves maternal lipid metabolism via liver-secreted FGF21 during pregnancy in HFD-fed dams.","Guo H","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24328","40635195",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003906","Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes.","Yen FS","2024","BMC medicine","nonrandomized_study","article","10.1186/s12916-023-03228-4","38172833","PMC10765623",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0003907","Impact of ADA Guidelines and Medication Shortage on GLP-1 Receptor Agonists Prescribing Trends in the UK: A Time-Series Analysis with Country-Specific Insights.","Ibrahim ARN","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13206256","39458206","PMC11508750",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0003908","SGLT2 inhibition attenuates γδ T cell–mediated meta-inflammation associated with cardiometabolic risk in type 2 diabetes","Cuculić MT","2026","Research Square","other","preprint","10.21203/rs.3.rs-9020037/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0003909","Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok.","Li H","2026","Frontiers in public health","other","article","10.3389/fpubh.2026.1826485","42620396","PMC13485863",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003910","Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.","Naz F","2026","Medicine","systematic_review","article","10.1097/md.0000000000049986","42536519","PMC13433015",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; research-article; review"],["R0003911","Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice.","Chen M","2025","Cardiovascular research","preclinical","article","10.1093/cvr/cvaf005","39928435",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003912","Beyond metformin: The promise of glucagon-like peptide-1 receptor agonists for neuroprotection in Parkinson's disease.","Kow CS","2024","Clinical nutrition ESPEN","commentary","article","10.1016/j.clnesp.2024.06.034","38959105",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0003913","Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report.","Palmisano T","2026","European journal of clinical nutrition","case_report","article","10.1038/s41430-026-01749-8","41998348","PMC13341316",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003914","Time to Benefit of Incretin-Based Therapies in Adiposity-Related Heart Failure With Mildly Reduced or Preserved Ejection Fraction: a Systematic Review and Meta-Analysis.","Spiazzi BF","2026","Journal of cardiac failure","systematic_review","article","10.1016/j.cardfail.2026.06.025","42401228",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; review"],["R0003915","Perioperative glucagon-like peptide-1 receptor agonist use and retained gastric contents: A retrospective analysis of patients undergoing elective upper endoscopy.","Quinn JA","2025","Journal of clinical anesthesia","nonrandomized_study","article","10.1016/j.jclinane.2025.111776","39951938",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003916","Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis.","Fatima H","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s439587","37954886","PMC10638946",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0003917","Acute Pancreatitis in a Patient Taking Semaglutide.","Patel F","2023","Cureus","other_trial","article","10.7759/cureus.43773","37731423","PMC10506915",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0003918","Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.","Zacharia GS","2025","Cureus","narrative_review","article","10.7759/cureus.95632","41322896","PMC12660513",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0003919","Quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and MRA in heart failure with preserved ejection fraction patients with type 2 diabetes mellitus: A prospective and observational cohort study.","Ke J","2026","Kardiologia polska","nonrandomized_study","article","10.33963/v.phj.109920","41496625",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0003920","GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies.","Palani A","2026","Cardiovascular drugs and therapy","narrative_review","article","10.1007/s10557-025-07744-8","40637950","PMC12992454",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003921","GLP-1 receptor agonists significantly impair taste function.","Khan R","2025","Physiology & behavior","other","article","10.1016/j.physbeh.2024.114793","39722367",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; preprint; article"],["R0003922","Sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease.","Kim DW","2026","Kidney research and clinical practice","randomized_trial","article","10.23876/j.krcp.26.139","42521293",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0003923","Role of mitochondria-associated ER membranes in lipid metabolism: implications for renal lipotoxicity.","Gao Y","2026","Bioscience reports","narrative_review","article","10.1042/bsr20260413","42693812","PMC13542912",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003924","Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes.","Agarwal S","2025","Frontiers in cardiovascular medicine","nonrandomized_study","article","10.3389/fcvm.2025.1606198","40486825","PMC12141205",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0003925","Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.","Windram M","2026","Psychopharmacology","other_trial","article","10.1007/s00213-025-06854-3","40699363","PMC13242451",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0003926","Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.","Yen FS","2026","Epilepsia","nonrandomized_study","article","10.1002/epi.70369","42397685",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003927","Ethical considerations for semaglutide use in children.","Ryan N","2026","Archives of disease in childhood","narrative_review","article","10.1136/archdischild-2025-329747","41494820",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0003928","Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.","Mishra NK","2026","Clinical nutrition ESPEN","nonrandomized_study","article","10.1016/j.clnesp.2026.103260","41933725",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0003929","Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies.","Colombijn JMT","2026","Diabetologia","systematic_review","article","10.1007/s00125-025-06565-6","41117973","PMC12686040","PROSPERO:CRD42024532383",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0003930","Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.","Auth R","2025","AACE endocrinology and diabetes","case_report","article","10.1016/j.aed.2025.03.011","40786988","PMC12332434",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003931","Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study.","Dacon C","2026","Journal of pharmacy practice","nonrandomized_study","article","10.1177/08971900261449175","42084545",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003932","Is polyethylene glycol loxenatide 100 μg the preferred glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus? A meta-analysis and trial sequential analysis.","Liu P","2024","European review for medical and pharmacological sciences","systematic_review","article","10.26355/eurrev_202403_35731","38567590",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; review"],["R0003933","Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.","Tuccinardi D","2025","Journal of endocrinological investigation","randomized_trial","article","10.1007/s40618-025-02700-7","41212412","PMC12640352",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0003934","Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.","Nigam A","2024","The Journal of the Association of Physicians of India","nonrandomized_study","article","10.59556/japi.72.0644","39291515",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003935","Polycystic Ovary Syndrome and Cardiovascular Risk: Mechanisms, Clinical Evidence, and Prevention Strategies.","Moore M","2026","Cardiology in review","other","article","10.1097/crd.0000000000001453","42673534",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003936","Vascular regeneration: a new mechanism of glucagon-like peptide-1 receptor agonist-mediated cardioprotection?","Chan JSF","2024","American journal of physiology. Heart and circulatory physiology","commentary","article","10.1152/ajpheart.00446.2024","38995213",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; article"],["R0003937","Comparative Effectiveness of Bariatric Metabolic Surgery Versus Glucagon-Like Peptide-1 Receptor Agonists on Cardiovascular Outcomes and Mortality: A Meta-Analysis.","Saeed L","2024","Cureus","systematic_review","article","10.7759/cureus.71684","39552962","PMC11568484",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0003938","Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis.","Njei B","2026","Cost effectiveness and resource allocation : C/E","nonrandomized_study","article","10.1186/s12962-026-00741-0","41862906","PMC13126990",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003939","Modulation of Endoplasmic Reticulum Stress via CEBPB: A Potential Molecular Link to Therapeutic Action in Substance Use Disorders.","Zhang C","2026","CNS neuroscience & therapeutics","other","article","10.1002/cns.71183","42808816","PMC13621937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003940","Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes.","Liao KM","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1928877","42712413","PMC13549827",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003941","Oral Delivery of Semaglutide and Tirzepatide Using Milk-Derived Small Extracellular Vesicles.","Zhang Y","2025","Journal of extracellular biology","preclinical","article","10.1002/jex2.70099","41293773","PMC12640765",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003942","Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial.","Novodvorský P","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70362","41395661","PMC12890759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; research-article; article"],["R0003943","Fatty Kidney Disease: Current Understanding in 2025.","Aung HM","2025","Cardiology in review","other","article","10.1097/crd.0000000000001060","41004791",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003944","Outcomes of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1A) and Patients Undergoing Total Hip Arthroplasty (THA): A Systematic Review and Meta-Analysis.","Puga TB","2026","The Iowa orthopaedic journal","systematic_review","article",null,"42488294","PMC13389273",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0003945","Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study.","Díaz-Cerezo S","2025","Patient preference and adherence","nonrandomized_study","article","10.2147/ppa.s509483","40330535","PMC12053930",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003946","Single-Administration Self-Boosting Microneedle Patch for The Treatment of Obesity.","Singh P","2024","Advanced therapeutics","other","article","10.1002/adtp.202400028","39429250","PMC11486425",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003947","A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy.","Knop FK","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15875","39188238",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0003948","Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.","Bea S","2025","Gut","nonrandomized_study","article","10.1136/gutjnl-2024-332687","39242193","PMC11874371",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0003949","GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction.","Khadke S","2025","Journal of cardiac failure","nonrandomized_study","article","10.1016/j.cardfail.2024.10.448","39667523",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0003950","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).","Brown S","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1457363","39318780","PMC11420520",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003951","Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.","Song R","2025","Postgraduate medical journal","systematic_review","article","10.1093/postmj/qgae148","39487697",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0003952","Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.","Sharma N","2025","International urology and nephrology","systematic_review","article","10.1007/s11255-024-04266-4","39495435",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003953","Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?","Locatelli JC","2024","Diabetes care","randomized_trial","article","10.2337/dci23-0100","38687506",null,null,"S002674","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; other; article"],["R0003954","Glucagon-like peptide 1 (GLP-1) receptor agonists and asthma and COPD exacerbations in adults with diabetes: A systematic review.","Cooper DH","2025","Respiratory medicine","systematic_review","article","10.1016/j.rmed.2025.108197","40480531",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0003955","The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.","Witkowski M","2026","Acta biochimica Polonica","narrative_review","article","10.3389/abp.2026.16436","42568471","PMC13447232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003956","Mitochondrial Function and Dysfunction in Female Fertility: Biological Mechanisms, Genetic Determinants, and Therapeutic Opportunities - A Review.","Nagaraju S","2026","Reproductive sciences (Thousand Oaks, Calif.)","narrative_review","article","10.1007/s43032-026-02113-8","42082824",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0003957","Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome.","Nzobokela J","2025","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2025.1661563","41235339","PMC12605086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003958","Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review.","Teague M","2023","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2023.02.003","36872170",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0003959","Critical discourse analysis of social media advertisements for GLP-1 receptor agonist weight loss drugs: implications for public perceptions and health communication.","Rad J","2025","BMC public health","other","article","10.1186/s12889-025-24197-8","40890660","PMC12400570",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0003960","Efficacy, adherence and persistence of various glucagon-like peptide-1 agonists: nationwide real-life data.","Kassem S","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15828","39109455",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0003961","SGLT2 Inhibitors and Nephrolithiasis Risk in Adults With Type 2 Diabetes: A Systematic Review and Meta-analysis.","Abreu M","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2026.09.007","42810621",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Review"],["R0003962","Appendicitis: A Hidden Danger of GLP-1 Receptor Agonists?","Casella S","2024","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","nonrandomized_study","article","10.1177/87551225231216638","38525095","PMC10959081",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0003963","The use of GLP-1 receptor agonists and subsequent risk of nicotine-related events: a cross- sectional study.","Alsaleh NA","2026","BMC public health","other","article","10.1186/s12889-026-26474-6","41673636","PMC12998102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003964","Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis.","Safwan M","2025","Annals of Saudi medicine","systematic_review","article","10.5144/0256-4947.2025.129","40189856","PMC12542916",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0003965","No dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study.","Chen Z","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1816593","42137314","PMC13168755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0003966","Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.","Rosenstock J","2021","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14345","33565209","PMC8252076",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0003967","Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.","Mostafa MEA","2024","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2024.1410883","39464183","PMC11502341","PROSPERO:CRD42023448720",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; systematic-review; review"],["R0003968","Beyond intraocular pressure: vascular and metabolic modifiers of optic nerve vulnerability in glaucoma.","Lakavath B","2026","International ophthalmology","nonrandomized_study","article","10.1007/s10792-026-04189-2","42484773",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0003969","Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis.","Passos PRC","2025","Journal of gastroenterology and hepatology","systematic_review","article","10.1111/jgh.16752","39322970",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0003970","Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study.","Kravos Tramšek NA","2025","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2025.1715800","41268167","PMC12626799",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0003971","Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study.","Kaneto H","2025","Advances in therapy","nonrandomized_study","article","10.1007/s12325-025-03135-5","40056372","PMC12006214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0003972","Semaglutide-Induced Acute Pancreatitis Leading to Death After Four Years of Use.","Dagher C","2024","Cureus","case_report","article","10.7759/cureus.69704","39429379","PMC11489890",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003973","Cardiovascular effects of chronic GIPR and GLP-1R agonism in lean and diet-induced obese mice: sex differences and dose-dependent remodeling.","Göktaş SŞ","2026","American journal of physiology. Heart and circulatory physiology","preclinical","article","10.1152/ajpheart.00204.2026","42734425",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0003974","Pharmacogenetics of incretin-based therapies.","Yaluri AS","2025","Postgraduate medical journal","other","article","10.1093/postmj/qgaf232","41474140",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003975","Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial.","Bai S","2026","BMJ open","protocol","article","10.1136/bmjopen-2025-110759","41692523","PMC12911792","ChiCTR:ChiCTR2500106943",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0003976","Sex differences in trial representation and the cardiovascular effectiveness of newer glucose-lowering agents in patients with and without type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.","Zawadka M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70411","41504379","PMC12890774",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0003977","Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD.","Yen FS","2024","Thorax","nonrandomized_study","article","10.1136/thorax-2023-221040","39353727",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0003978","Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus.","Yang J","2026","Hepatology (Baltimore, Md.)","systematic_review","article","10.1097/hep.0000000000001695","41609749",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0003979","Weight Loss and Its Impact on Soft Tissue.","Fathizadeh S","2026","Journal of drugs in dermatology : JDD","narrative_review","article","10.36849/jdd.9532","42081631",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003980","Mechanisms of efficacy of drug therapy in type 2 diabetes: the role of microbiomes.","Li Y","2026","Minerva endocrinology","narrative_review","article","10.23736/s2724-6507.25.04306-4","40587084",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0003981","GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease.","Pan HC","2024","Nature communications","nonrandomized_study","article","10.1038/s41467-024-50199-y","39003287","PMC11246471",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0003982","Weighing in on glucagon-like peptide-1 receptor agonists in dermatology.","Heymann WR","2024","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2024.04.044","38692437",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0003983","Naturopathic Management to Taper Off Glucagon-Like Peptide-1 Receptor Agonist Therapy in Type 2 Diabetes: A Case Report.","Linder L","2025","Integrative medicine (Encinitas, Calif.)","case_report","article",null,"39896831","PMC11778319",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0003984","Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study.","Ljungberg C","2025","Diabetes care","nonrandomized_study","article","10.2337/dc25-0693","40737110",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; other; article"],["R0003985","Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.","Rayner CK","2021","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14202","32991041","PMC7756611",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; article"],["R0003986","Irisin may be involved in exendin-4 mitochondrial action in human adipocytes.","Dziewońska A","2026","Archives of medical science : AMS","preclinical","article","10.5114/aoms/214730","42305296","PMC13266781",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0003987","Phase I study of the oral GLP-1 receptor agonist DA-302168S: Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults.","Zheng L","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70159","40994059",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; article"],["R0003988","Association between semaglutide use and thyroid eye disease-related outcomes in autoimmune thyroiditis with type II diabetes.","Shlomov T","2026","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","nonrandomized_study","article","10.1016/j.jcjo.2026.01.010","41620207",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0003989","Inflammatory mechanisms in diabetic nephropathy: emerging insights and targeted therapeutics.","Lin S","2025","Frontiers in medicine","narrative_review","article","10.3389/fmed.2025.1722159","41625744","PMC12857186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003990","Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large.","Minerva F","2026","Bioethics","other","article","10.1111/bioe.70068","41353657",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003991","Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.","Evola V","2026","Inflammation research : official journal of the European Histamine Research Society ... [et al.]","nonrandomized_study","article","10.1007/s00011-025-02166-6","41504939",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0003992","Reply to \"Glucagon-Like Peptide-1 Receptor Agonists During Electroconvulsive Therapy: Case Report With Evolving Concerns and Management Considerations\".","Jacobi D","2024","The journal of ECT","case_report","article","10.1097/yct.0000000000001053","38984842",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0003993","Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease.","Wang T","2024","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2024.1396656","38720777","PMC11076696",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003994","Pro-healing impact of liraglutide on skin wounds in normoglycemic mice.","Yue H","2025","International immunopharmacology","preclinical","article","10.1016/j.intimp.2025.114050","39798474",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0003995","Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure.","Crispino SP","2025","Biomolecules","narrative_review","article","10.3390/biom15111574","41301492","PMC12650310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0003996","Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry.","Himmerich H","2024","Journal of clinical psychopharmacology","commentary","article","10.1097/jcp.0000000000001869","38635918",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0003997","Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.","Ostrominski JW","2024","European heart journal","other","article","10.1093/eurheartj/ehae414","38982938",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0003998","Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends.","Castellana E","2026","Hospital pharmacy","nonrandomized_study","article","10.1177/00185787251403040","41509894","PMC12774802",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0003999","Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States.","Liu L","2025","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2025.31.5.441","40298310","PMC12039506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0004000","Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process.","Hachuła M","2024","International journal of molecular sciences","other","article","10.3390/ijms25031854","38339133","PMC10855444",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004001","Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.","Garza K","2024","The American journal of gastroenterology","nonrandomized_study","article","10.14309/ajg.0000000000002777","38534127",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004002","Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease: Effect, Safety, and Outcomes.","Thapa R","2025","JACC. Advances","nonrandomized_study","article","10.1016/j.jacadv.2025.101674","40132346","PMC11985053",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004003","Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.","Kintzoglanakis K","2024","Diabetes & vascular disease research","narrative_review","article","10.1177/14791641241269743","39139128","PMC11325323",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0004004","GLP-1 Receptor Agonists vs SGLT2 Inhibitors for Alzheimer’s Disease Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis","Silva LL","2026","medRxiv","systematic_review","preprint","10.64898/2026.07.22.26358702",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0004005","Lead-guided prodrug development of small molecules as GLP-1R agonists.","Lentschat H","2026","Bioorganic chemistry","preclinical","article","10.1016/j.bioorg.2026.110210","42424921",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004006","Perceptions of GLP-1 RA Use for Children With Obesity Among Caregivers With Food Insecurity: A Qualitative Study.","Stephenson KM","2026","JAMA network open","other","article","10.1001/jamanetworkopen.2025.52825","41499114","PMC12780928",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004007","Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.","Patel JP","2025","Cureus","systematic_review","article","10.7759/cureus.80321","40206909","PMC11979670",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004008","Effects of SGLT2 inhibitors and GLP-1 receptor agonists on glycemic variability, islet cell function, and insulin resistance in patients with type 2 diabetes mellitus and renal cell carcinoma.","Zhang A","2025","American journal of cancer research","nonrandomized_study","article","10.62347/olur1927","40226468","PMC11982740",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004009","Contractile effects of albiglutide in the human and mouse atrium.","Neumann J","2026","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2026.1831742","42490806","PMC13375485",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004010","Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023.","Lee JM","2024","JAMA","other","article","10.1001/jama.2024.7112","38776113","PMC11112492",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0004011","From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.","Tian X","2026","Translational research : the journal of laboratory and clinical medicine","other_trial","article","10.1016/j.trsl.2026.07.008","42480913",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0004012","Physio-Friendly Remission-Facilitating Pharmacotherapy (PRP) in Type 2 Diabetes.","Kalra S","2024","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.24-89","39548626",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004013","An overview of insulin resistance: from molecular mechanisms to medical interventions.","Dey S","2026","Minerva endocrinology","narrative_review","article","10.23736/s2724-6507.25.04390-8","41416384",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004014","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Alcohol Use Disorder.","Khan S","2025","The primary care companion for CNS disorders","narrative_review","article","10.4088/pcc.24nr03855","40392538",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004015","GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.","Zhang Z","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1149328","37484944","PMC10359616","PROSPERO:CRD42022359346",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Research Support, Non-U.S. Gov't; Systematic Review; Journal Article; Network Meta-Analysis; systematic-review; article"],["R0004016","Glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and advanced CKD: kidney and cardiovascular outcomes in a real-world setting.","Hsiao CC","2025","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfaf172","40510690","PMC12160804",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004017","The potential role of GLP-1 receptor agonists in osteoarthritis.","Ryan M","2025","Pharmacotherapy","other_trial","article","10.1002/phar.70005","39980227",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0004018","Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes.","Grandhi N","2024","JNCI cancer spectrum","nonrandomized_study","article","10.1093/jncics/pkae095","39514091","PMC11643351",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004019","Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.","Jara M","2025","Nature medicine","nonrandomized_study","article","10.1038/s41591-025-03799-0","40691365","PMC12443624",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004020","Real-World Evidence of Long-Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years.","Kim HS","2026","Clinical endocrinology","nonrandomized_study","article","10.1111/cen.70078","41387176",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004021","Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial.","Krychtiuk KA","2026","European journal of preventive cardiology","randomized_trial","article","10.1093/eurjpc/zwae379","39602568",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0004022","Incretin and glucagon receptor polypharmacology in chronic kidney disease.","McFarlin BE","2024","American journal of physiology. Endocrinology and metabolism","narrative_review","article","10.1152/ajpendo.00374.2023","38477666","PMC11551006",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004023","Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide.","Israel A","2026","Frontiers in nutrition","nonrandomized_study","article","10.3389/fnut.2026.1833045","42125318","PMC13159200",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004024","A System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks.","Fadel LP","2025","Cureus","narrative_review","article","10.7759/cureus.78575","40062098","PMC11888820",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004025","Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists.","Firkins SA","2025","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2024.03.013","38574832",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004026","The clinical relevance of obesity and glucagon-like peptide-1-based therapies for chronic weight management in patients treated by obstetrician-gynecologists and gynecologists: A non-systematic narrative review.","Mackey S","2026","Therapeutic advances in reproductive health","randomized_trial","article","10.1177/26334941261481473","42756737","PMC13583316",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0004027","SGLT2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes: A cohort study and meta-analysis.","Yeh JA","2025","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2025.112088","40057043",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis"],["R0004028","Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone.","Ferrara F","2025","Naunyn-Schmiedeberg's archives of pharmacology","nonrandomized_study","article","10.1007/s00210-025-04319-0","40515833",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0004029","Summary for Patients: Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes.",null,"2024","Annals of internal medicine","other","article","10.7326/p24-0004","39008851",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Patient Education Handout; article"],["R0004030","GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies: A Case-Control Evaluation.","Triplett JD","2025","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000213916","40694751",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004031","Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis.","Ku SC","2024","Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","systematic_review","article","10.1111/ddg.15431","38824670",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Meta-Analysis; Letter; review"],["R0004032","Comparative Pharmacological and Pharmaceutical Perspectives on Antidiabetic Therapies in Humans, Dogs, and Cats.","Kim I","2025","Pharmaceutics","nonrandomized_study","article","10.3390/pharmaceutics17091098","41012437","PMC12472474",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004033","Diastolic Dysfunction in Acute and Critical Illness: Acute Pathophysiology to Chronic Heart Failure.","Fisher T","2026","JACC. Advances","narrative_review","article","10.1016/j.jacadv.2025.102532","41534382","PMC12830123",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004034","Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?","Burmeister MA","2026","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2026.1925534","42602523","PMC13474148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004035","Novel glucose-lowering agents that benefit diabetic foot: icing on the cake.","Li Q","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1581403","40671916","PMC12263376",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004036","Patient-reported endometriosis symptom change during GLP-1 receptor agonist use, and its relationship to weight loss: an international cross-sectional survey (GLEAM)","Baudoin B","2026","Research Square","other_trial","preprint","10.21203/rs.3.rs-10323555/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0004037","Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity.","Koceva A","2026","Nutrients","narrative_review","article","10.3390/nu18040677","41754194","PMC12943190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004038","Spinal Cord Stimulation - Device Revision After Weight Loss in a Patient on Chronic Semaglutide - A Case Report.","Hoffmann C","2025","International medical case reports journal","case_report","article","10.2147/imcrj.s513630","40395634","PMC12091066",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004039","GLP-1 Receptor Agonist Add-On at Immune Checkpoint Inhibitor Initiation and Fewer Wasting-Related Diagnoses and Acute-Care Episodes in People with Cancer and Obesity without Diabetes: A Target Trial Emulation","Lin Y","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9412701/v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0004040","Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).","Tan X","2024","Clinical drug investigation","nonrandomized_study","article","10.1007/s40261-024-01354-2","38507188","PMC10980663",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; article"],["R0004041","Long-term delirium and survival outcomes in patients treated with GLP-1 receptor agonists versus metformin in type 2 diabetes: A population-based cohort study.","Sun M","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16434","40331425",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0004042","Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.","Wu J","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15383","38100147",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; article"],["R0004043","SEMA-RENAL: Real-World Effects of Subcutaneous Semaglutide on Kidney Outcomes","Poon KV","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9609547/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0004044","The critical role of gut-brain signalling in eating behaviour and obesity.","de Lartigue G","2026","Nature reviews. Gastroenterology & hepatology","narrative_review","article","10.1038/s41575-026-01203-x","42014861",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004045","Glucagon-like Peptide-1 receptor agonist use is not associated with increased reoperation risk following rotator cuff repair.","Rasmussen ST","2025","Journal of orthopaedics","nonrandomized_study","article","10.1016/j.jor.2025.08.016","40895356","PMC12391505",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0004046","[Comparison of the effects of intensified lifestyle and glucagon-like peptide-1 receptor agonist combined with lifestyle intervention on body composition in adult patients with overweight or obesity].","Chen YT","2025","Zhonghua yi xue za zhi","nonrandomized_study","article","10.3760/cma.j.cn112137-20250305-00530","41083404",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; English Abstract; article"],["R0004047","Treatment intensification following glucagon-like peptide-1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE-G real-world study.","Napoli R","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15697","38853712",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0004048","The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists.","Lavu MS","2024","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2024.06.008","38857711",null,null,"S001275","pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0004049","Mechanisms of ferroptosis and glucagon-like peptide-1 receptor agonist in post-percutaneous coronary intervention restenosis.","Wang M","2025","Molecular and cellular biochemistry","narrative_review","article","10.1007/s11010-024-05118-6","39283562",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004050","Obesity Management in End-Stage Kidney Disease: Pathways to Improve Kidney Transplant Access.","Budhiraja P","2026","American journal of kidney diseases : the official journal of the National Kidney Foundation","narrative_review","article","10.1053/j.ajkd.2025.11.019","41905619",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004051","Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective.","Alkhatib NS","2022","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","other","article","10.1016/j.jsps.2022.01.018","35527835","PMC9068523",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004052","Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis.","Li M","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1681965","41133230","PMC12540095","PROSPERO:CRD42025640318",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; systematic-review; review"],["R0004053","[Therapeutic advances in metabolic dysfunction-associated steatotic liver disease].","Canivet CM","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.928.47553","40928398",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0004054","Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis.","Kelkar R","2024","Frontiers in cardiovascular medicine","systematic_review","article","10.3389/fcvm.2024.1453297","39323759","PMC11422096","PROSPERO:CRD42024553048",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0004055","Post-transplant metabolic dysregulation: Insights and implications for kidney graft survival.","Elahi T","2026","World journal of nephrology","narrative_review","article","10.5527/wjn.v15.i2.118270","42395658","PMC13324431",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004056","Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.","Wong C","2021","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2021.609110","33897616","PMC8063104",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; systematic-review; review"],["R0004057","Current Treatment of Heart Failure with Preserved Ejection Fraction.","Riccardi M","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14155406","40807027","PMC12347804",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004058","Starvation ketoacidosis associated with tirzepatide use for weight loss in a non-diabetic East Asian woman: a case report.","Minoda Y","2026","International journal of emergency medicine","case_report","article","10.1186/s12245-026-01170-9","41840480","PMC13104288",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0004059","Inflammation-induced promoter hypermethylation of GLP-1R limits the protective effect of GLP-1R agonists against acute lung injury.","Deng G","2026","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2026.118112","42214767",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004060","Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.","Yen FS","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","nonrandomized_study","article","10.1016/j.cgh.2023.06.004","37331413",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004061","Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?","Karakasis P","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12112503","39595069","PMC11591904",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004062","Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.","Bardóczi A","2025","Sleep medicine reviews","systematic_review","article","10.1016/j.smrv.2025.102119","40633481",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0004063","Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors.","Liu J","2024","Scientific reports","nonrandomized_study","article","10.1038/s41598-024-69016-z","39112571","PMC11306237",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004064","Effect of treatment duration on the associations between three modern antidiabetic drugs and survival outcomes of lung cancer in China.","Chen Z","2025","Frontiers in molecular biosciences","nonrandomized_study","article","10.3389/fmolb.2025.1701515","41573744","PMC12819283",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004065","A Nationwide Danish Comparative Effectiveness Study of GLP-1 RA, SGLT2i and DPP-4i Treatment on Risk of Stroke, Myocardial Infarction and Mortality in Type 2 Diabetes.","Hastrup S","2026","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70165","41578841","PMC12831120",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0004066","Insulin resistance in cerebral small vessel disease: a mini review.","Su C","2026","Frontiers in neuroscience","narrative_review","article","10.3389/fnins.2026.1760558","41710155","PMC12909493",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004067","Insulin resistance and hyperinsulinaemia in kidney disease: mechanisms and metabolic effects.","Zaitoon H","2026","Nature reviews. Nephrology","narrative_review","article","10.1038/s41581-026-01066-0","41882295",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0004068","Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.","Sztanek F","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.71277","42681751",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004069","Suicidal Thoughts and Self-injurious Behavior Associated With Glucagon- Like Peptide-1 Receptor Agonists - A Review.","Maideen NMP","2025","Current drug safety","nonrandomized_study","article","10.2174/0115748863301925240507044637","38766830",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0004070","GLP-1 Refractory Obesity Is Associated with Inferior Weight Loss After Bariatric Surgery and a Distinct Hepatic Mitochondrial Phenotype","Pratap A","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.08.04.26359613",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","4","FALSE","Preprint; preprint"],["R0004071","GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways.","Lindquist P","2026","Cell chemical biology","other","article","10.1016/j.chembiol.2026.06.003","42419304",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004072","Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy.","Kobori T","2023","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14005","36919944","PMC10204182",null,"S002295","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004073","Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network.","Murugadoss K","2026","Biology methods & protocols","nonrandomized_study","article","10.1093/biomethods/bpag020","42163990","PMC13186195",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0004074","The complexity of malnutrition in people living with excess body weight.","Mwala NN","2026","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000001227","42013005",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004075","Semaglutide Adherence and Cardiovascular Diseases in Patients With Type 2 Diabetes: Evidence From Real-World Data in Japan.","Masudo C","2025","Cureus","nonrandomized_study","article","10.7759/cureus.80511","40225492","PMC11992962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004076","Comparative Efficacy of Semaglutide Versus Liraglutide or Efinopegdutide on Weight Loss in Obese Patients: A Systematic Review and Meta-Analysis.","Wen J","2024","Cureus","systematic_review","article","10.7759/cureus.75304","39776746","PMC11704649",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004077","Harnessing adiponectin for sepsis: current knowledge, clinical insights and future therapies.","Gianoli S","2025","Critical care (London, England)","narrative_review","article","10.1186/s13054-025-05516-2","40652274","PMC12255986",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004078","Racial and ethnic disparities in GLP-1 prescriptions among veterans with obesity across direct and community care settings.","Stein RI","2026","Health affairs scholar","other","article","10.1093/haschl/qxag130","42305721","PMC13268760",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004079","Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Rao Y","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2025.11.017","41419174",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0004080","Use of glucagon-like peptide-1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review.","Zupec J","2025","Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition","narrative_review","article","10.1002/ncp.11279","39961620",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0004081","Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study.","Johnson B","2025","Frontiers in nutrition","other","article","10.3389/fnut.2025.1566498","40352260","PMC12062175",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004082","Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference.","Grosicki GJ","2025","American journal of physiology. Heart and circulatory physiology","nonrandomized_study","article","10.1152/ajpheart.00809.2024","39705534",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004083","The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.","De R","2026","Schizophrenia bulletin","randomized_trial","article","10.1093/schbul/sbaf236","42297449","PMC13267902",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004084","Otolaryngologic Side Effects of GLP-1 Receptor Agonists.","Khan FI","2025","The Laryngoscope","nonrandomized_study","article","10.1002/lary.32061","39936458",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004085","[Pharmacological post-acute treatment of alcohol use disorder: Established strategies and innovative approaches].","Roser P","2026","Therapeutische Umschau. Revue therapeutique","narrative_review","article","10.23785/tu.2026.01.006","41878754",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0004086","Differential effects of GLP-1 receptor agonists on diabetic osteopathy in type 2 diabetes: a patient-stratified network meta-analysis.","Alalwani YJ","2025","BMC musculoskeletal disorders","systematic_review","article","10.1186/s12891-025-09022-y","40751153","PMC12315457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; research-article; article"],["R0004087","Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.","Kan M","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15219","37529870",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0004088","Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights.","Amorim Moreira Alves G","2025","Medical sciences (Basel, Switzerland)","narrative_review","article","10.3390/medsci13030136","40843757","PMC12372146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004089","Efficacy of Initiation of Semaglutide versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study.","Khalil I","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.06.004","42320716",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004090","Bidirectional relationship between metabolic and thrombotic disease mechanisms.","Jameson AT","2026","Current opinion in hematology","narrative_review","article","10.1097/moh.0000000000000929","42307608",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004091","Review of Acetazolamide and Novel Medical Paradigms for Idiopathic Intracranial Hypertension Treatment.","Lee Y","2025","Ear, nose, & throat journal","randomized_trial","article","10.1177/01455613251358629","40801435",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0004092","Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.","Akhverdyan N","2024","Metabolic syndrome and related disorders","nonrandomized_study","article","10.1089/met.2024.0115","38868900",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004093","Phenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic Disorders","Lalwani R","2026","Preprints.org","other","preprint","10.20944/preprints202607.0236.v2",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004094","Risk of Neuroendocrine Neoplasms with Glucagon-Like-Petide-1 Receptor Agonist Use in Patients with Type 2 Diabetes Mellitus","Hong G","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.07.18.25331594",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0004095","The incretin-joint axis: weight-independent mechanisms and disease-modifying potential in chronic arthropathies.","Papastathopoulou NS","2026","Rheumatology advances in practice","narrative_review","article","10.1093/rap/rkag105","42774139","PMC13593563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004096","Sex Differences in Comparative Effectiveness and Safety of Second-line Antidiabetic Agents: Real-world Evidence from Large-scale Multinational Study","Ding X","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.04.10.26350252",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","4","FALSE","Preprint; preprint"],["R0004097","Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes.","Neugebauer R","2025","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2025.36100","41091469","PMC12529185",null,"S000248","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004098","Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.","Biasin M","2026","Journal of cardiovascular medicine (Hagerstown, Md.)","nonrandomized_study","article","10.2459/jcm.0000000000001837","41703411",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0004099","Temporal trends in patient demographics and postoperative outcomes in metabolic and bariatric surgery: a longitudinal analysis of the MBSAQIP database in the GLP-1 era.","Airhart AE","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2026.05.029","42336702",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0004100","Glucagon-like peptide-1 receptor agonists use for type 2 diabetes mellitus in end-stage renal disease.","Thomas AM","2023","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2023.06.003","37301509",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004101","Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.","Risovic I","2023","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-023-01282-w","36726134","PMC9890870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0004102","An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database.","Butuca A","2024","Biomedicines","nonrandomized_study","article","10.3390/biomedicines12051124","38791086","PMC11117978",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0004103","Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network","Conover M","2024","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.171119334.40228546/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0004104","Risk-Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling.","Ghosal S","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-025-01817-5","41201574","PMC12847540","PROSPERO:CRD420251146788",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004105","SGLT2 Inhibitors and External Genital Infection in Male Patients With Type 2 Diabetes.","Cheng TH","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.34485","41021225","PMC12481227",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004106","Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.","Amin NB","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16005","39415344","PMC11618248","ClinicalTrials.gov:NCT05579977","S000448","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0004107","Obesity-Related Tendon Pathology: Cardiometabolic Mechanisms, Clinical Implications, and Management.","Zhao H","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00759-8","42726433",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004108","Prevalence and Factors Associated with GLP-1 Receptor Agonist Use for Weight Management Among Overweight and Obese Adults in the Eastern Province of Saudi Arabia.","Alhussain K","2026","Healthcare (Basel, Switzerland)","other","article","10.3390/healthcare14030345","41682196","PMC12897281",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004109","Perioperative anesthesia care for patients with diabetes mellitus: a review of current literature with focus on oral antidiabetic medication.","Riesemann S","2026","Current opinion in anaesthesiology","nonrandomized_study","article","10.1097/aco.0000000000001644","41885293",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0004110","Beyond Glycemic Control: Semaglutide Use in Non-Diabetic Female Patients with Overactive Bladder Receiving BOTOX is Associated with Improved Urinary Outcome","Hammad MAM","2025","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202508.0545.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0004111","Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease.","Santos GL","2025","World journal of diabetes","narrative_review","article","10.4239/wjd.v16.i6.104706","40548289","PMC12179897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004112","Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study.","Nassar M","2024","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2024.103116","39332263",null,null,"S000313","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004113","A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies.","Daniel S","2025","Journal of drugs in dermatology : JDD","nonrandomized_study","article","10.36849/jdd.8605","40196945",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0004114","MON-301 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12047111",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0004115","Guideline-Directed Medical Therapy for Diabetic Kidney Disease: Advances in Primary and Secondary Prevention.","Verma S","2026","Cureus","randomized_trial","article","10.7759/cureus.101867","41717165","PMC12916118",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0004116","The expanding role of semaglutide: beyond glycemic control.","Zarei M","2025","Journal of diabetes and metabolic disorders","other_trial","article","10.1007/s40200-025-01663-z","40620322","PMC12227398",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0004117","Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiovascular, and Kidney Disease: Triple Challenges.","Tsai SY","2026","Clinical journal of the American Society of Nephrology : CJASN","other","article","10.2215/cjn.0000001209","42566259",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004118","The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review.","Rahman A","2023","Cardiology research","systematic_review","article","10.14740/cr1523","37559715","PMC10409547",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004119","Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain.","Jackson SE","2026","BMC medicine","other","article","10.1186/s12916-025-04528-7","41501776","PMC12781702",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0004120","Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review.","Irfan H","2023","Cureus","systematic_review","article","10.7759/cureus.40448","37456411","PMC10349654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004121","The role of tanycytes in the regulation of energy balance.","Martinez-Martinez S","2026","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-025-10010-9","41460475",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0004122","Systemic pathways linking subcutaneous therapies to gastrointestinal adverse effects: A Narrative review of mechanisms and mitigation strategies.","Singh A","2026","Indian journal of pharmacology","randomized_trial","article","10.4103/ijp.ijp_1343_25","42583966","PMC13412434",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0004123","Coincidence of Autoimmune Diabetes Mellitus and Familial Partial Lipodystrophy.","Krienke M","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf265","41221014","PMC12598280",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004124","Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.","Wang W","2025","Molecular neurobiology","preclinical","article","10.1007/s12035-025-05253-1","40748430",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004125","Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study.","Alzahrani M","2026","Cureus","nonrandomized_study","article","10.7759/cureus.112523","42583162","PMC13459852",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004126","MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome.","Zhou XD","2026","Science China. Life sciences","narrative_review","article","10.1007/s11427-025-3193-9","41854965",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004127","Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes.","Aschen SZ","2025","Annals of surgery","nonrandomized_study","article","10.1097/sla.0000000000006614","39704067","PMC12014183",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; Research Support, N.I.H., Extramural; research-article; article"],["R0004128","The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Alcohol Use Disorder: Current Evidence and Future Directions.","Tanguturi Yella SS","2025","Journal of clinical psychopharmacology","narrative_review","article","10.1097/jcp.0000000000002010","40184516",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004129","Novel Therapeutic Strategies for Obesity-Related Glomerulopathy.","Liu Y","2025","Current hypertension reports","narrative_review","article","10.1007/s11906-025-01357-0","41455033","PMC12865782",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0004130","Quantifying the Basal Insulin Treatment Preferences of People Living in Canada With Type 2 Diabetes When Glycemic Management and Cost Are Held Constant: A Discrete Choice Experiment.","Hallworth P","2026","Canadian journal of diabetes","other","article","10.1016/j.jcjd.2026.01.006","41638420",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004131","Diabetic kidney disease within the framework of cardio-kidney-metabolic health: a paradigm shift.","Braga JR","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1907928","42774501","PMC13594706",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004132","Sleep and obesity-known interactions and open questions.","Schmickl CN","2026","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","other_trial","article","10.1007/s44470-026-00130-7","42547676","PMC13433679",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0004133","Glucagon-Like Peptide 1 Receptor Agonist Stimulation Inhibits Laser-Induced Choroidal Neovascularization by Suppressing Intraocular Inflammation.","Machida A","2025","Investigative ophthalmology & visual science","preclinical","article","10.1167/iovs.66.5.15","40332908","PMC12061060",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004134","Combined Insulin and GLP-1 Receptor Agonists: Simplifying Treatment or Adding Obstacles?","Yang T","2019","Journal of pharmacy practice","narrative_review","article","10.1177/0897190017753041","30270723",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004135","Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes.","Wang L","2024","Gastroenterology","nonrandomized_study","article","10.1053/j.gastro.2024.04.029","38692395","PMC12294230",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0004136","First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context.","Rajput R","2022","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/ijem.ijem_217_22","36618518","PMC9815186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004137","The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes-A Scientometric Investigation and Visualization Study.","Pantea I","2024","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina60111761","39596946","PMC11596011",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004138","Could Glucagon-Like Peptide-1 (GLP-1) receptor antagonists be used to treat obstructive sleep apnoea in children and adolescents with obesity?","Silva D","2026","Paediatric respiratory reviews","nonrandomized_study","article","10.1016/j.prrv.2025.08.001","40887408",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0004139","Characterizing Prescribing Patterns of Diabetes Medications at an Adult Medicine Clinic: A Focus on Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.","Shtoyko AN","2024","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds22-0095","38756431","PMC11093767",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0004140","Repurposed Systemic Pharmacologic Agents in Chronic Pain: Emerging Mechanistic and Clinical Insights.","McKenzie A","2026","Journal of clinical medicine","narrative_review","article","10.3390/jcm15041572","41753258","PMC12942416",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004141","Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany.","Auzanneau M","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15741","38982585",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; other; article"],["R0004142","Glucagon-like peptide-1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism.","Lin K","2023","MedComm","preclinical","article","10.1002/mco2.416","38020719","PMC10661313",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004143","Glucagon-Like Peptide-1 Receptor Agonists Decrease Medical and Surgical Complications in Morbidly Obese Patients Undergoing Primary TKA.","Kim BI","2025","The Journal of bone and joint surgery. American volume","randomized_trial","article","10.2106/jbjs.24.00468","39719003",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0004144","Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.","Cao M","2023","International journal of clinical pharmacy","nonrandomized_study","article","10.1007/s11096-023-01556-2","36977858",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","4","FALSE","Journal Article; article"],["R0004145","GLP-1 Receptor Agonists in Aesthetic Surgery: A Narrative Review on Perioperative Safety, Sarcopenic Morphologies, and Adapted Body Contouring Strategies.","Venza M","2026","Aesthetic plastic surgery","narrative_review","article","10.1007/s00266-026-05980-3","42298156",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0004146","Preferences for basal insulin treatments in adults with type 2 diabetes: A discrete choice experiment in France and Spain.","Jones AM","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70422","41555588","PMC12890752",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004147","Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions.","Wallentowitz L","2026","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-026-10053-6","42154164","PMC13388769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004148","Obesity-Driven Hypertension: Exploring the Mechanisms and Modern Treatment Strategies.","Sindhwani N","2026","Cardiology in review","other","article","10.1097/crd.0000000000001193","41622529",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004149","New potential therapeutic targets of metabolic disorder-associated kidney disease and diabetic kidney disease.","Li X","2026","Kidney international","narrative_review","article","10.1016/j.kint.2025.09.023","41139023","PMC13470854",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0004150","Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence.","Acucella GA","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70225","42007544","PMC13093900","PROSPERO:CRD420261335230",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0004151","Disease-Modifying Therapies for Metabolic Dysfunction–Associated Steatohepatitis: Health Systems",null,"2026","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"42485471",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0004152","Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications.","Lee J","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00709-4","41920466","PMC13043608",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004153","Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes.","Al-Sadawi MA","2023","International journal of cardiology. Heart & vasculature","randomized_trial","article","10.1016/j.ijcha.2023.101218","37252197","PMC10209701",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0004154","Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies.","Wei M","2024","Frontiers in sleep","narrative_review","article","10.3389/frsle.2024.1524593","41424495","PMC12713997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004155","Novel pharmacotherapies and breakthroughs in psoriatic arthritis treatment.","Arraf A","2025","Expert opinion on pharmacotherapy","randomized_trial","article","10.1080/14656566.2025.2601050","41406130",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0004156","Three-Dimensional Atomic-Level Structure of an Amorphous Glucagon-Like Peptide-1 Receptor Agonist.","Torodii D","2025","Journal of the American Chemical Society","other","article","10.1021/jacs.5c01925","40331906",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004157","Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials.","Rivera FB","2024","Journal of clinical lipidology","systematic_review","article","10.1016/j.jacl.2024.03.011","38906751",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0004158","Real-World Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Mild-to-Moderate Diabetic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective, Single-Arm Clinical Trial [Letter].","Aguilar Castañeda RD","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s489805","39220802","PMC11366235",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0004159","Structural basis for chemotype diversity in small molecule GLP-1 receptor agonist drug discovery","Wu F","2025","Research Square","other","preprint","10.21203/rs.3.rs-7597307/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004160","Clinical Practice Guidelines for Adult MASLD in Bosnia and Herzegovina: National Recommendations for Diagnosis, Risk Stratification, and Treatment.","Zerem E","2026","Acta medica academica","other","article","10.5644/ama2006-124.515","42578551","PMC13641016",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; research-article; article"],["R0004161","Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.","Shao C","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s616418","42763732","PMC13589532",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004162","Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells.","Khalifa O","2023","International journal of molecular sciences","preclinical","article","10.3390/ijms241411606","37511368","PMC10380891",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0004163","Getting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure.","Jones KL","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15631","38706104",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; article"],["R0004164","The central amygdala gates exogenous glucagon-like peptide 1 signals.","Duran M","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2026.102403","42314903","PMC13332456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004165","Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation.","Yammine L","2025","Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","randomized_trial","article","10.1093/ntr/ntaf005","39780397",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0004166","Anti-inflammatory and anabolic effects of liraglutide on 3D inflammatory osteoarthritic spheroid and scaffold models of human chondrocytes.","Ciftci E","2026","Osteoarthritis and cartilage","other","article","10.1016/j.joca.2026.04.018","42107583",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004167","Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.","Xiao D","2025","PloS one","nonrandomized_study","article","10.1371/journal.pone.0310497","39913436","PMC11801598",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0004168","Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD.","Yau K","2026","American journal of kidney diseases : the official journal of the National Kidney Foundation","nonrandomized_study","article","10.1053/j.ajkd.2025.09.010","41238166",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0004169","Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product.","Bacus C","2024","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2024.100138","39416284","PMC11480229",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0004170","Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice.","Pantanetti P","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13164752","39200893","PMC11355440",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004171","Efficacy of Incretin-Based Therapies in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Liu L","2025","Journal of gastroenterology and hepatology","systematic_review","article","10.1111/jgh.70084","41025363",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0004172","Tirzepatide-Associated Euglycemic Diabetic Ketoacidosis in the Absence of Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.","Campana C","2026","The Journal of emergency medicine","case_report","article","10.1016/j.jemermed.2026.01.002","41747466",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0004173","Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.","Sass MR","2026","JAMA psychiatry","randomized_trial","article","10.1001/jamapsychiatry.2025.3639","41335431","PMC12676471","ClinicalTrials.gov:NCT04892199","S001916","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0004174","Clinical progress note: Glucagon-like peptide-1 receptor agonists and hospitalized patients.","Ravee A","2024","Journal of hospital medicine","narrative_review","article","10.1002/jhm.13357","38572574",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004175","Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.","Górriz JL","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-021-01198-5","35175551","PMC8934828",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0004176","Editorial: Are glucagon-like peptide-1 receptor agonists the functional cure for patients with metabolic dysfunction-associated cirrhosis?","Dajti E","2024","Alimentary pharmacology & therapeutics","commentary","article","10.1111/apt.17943","38652786",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; editorial"],["R0004177","Correlation Study of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Diabetic Patients with Hypertension.","Chang Y","2024","Iranian journal of public health","other","article","10.18502/ijph.v53i7.16050","39086405","PMC11287599",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004178","Empagliflozin and glucagon-like peptide-1 receptor agonists: The brothers for heart failure? Letter regarding the article 'Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE'.","Hu Y","2024","European journal of heart failure","commentary","article","10.1002/ejhf.3419","39155567",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0004179","Do Glucagon-like Peptide 1 Receptor Agonists Cause Postendoscopic Aspiration Pneumonia?","Hartmann P","2025","Gastroenterology","commentary","article","10.1053/j.gastro.2024.04.002","38580130",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0004180","Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials.","Sattar N","2026","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2026.101454","42006438","PMC13084130",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004181","Associations between thyroid axis changes and glycemic improvement after weight loss in type 2 diabetes: a mediation analysis.","Li P","2026","American journal of translational research","nonrandomized_study","article","10.62347/ropj5775","42631139","PMC13495636",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004182","Gallstones and acute cholecystitis in CKD and dialysis: an underrecognized biliary burden in nephrology.","Furuto Y","2026","Clinical and experimental nephrology","narrative_review","article","10.1007/s10157-026-02933-7","42573957",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004183","Fibrosis-Driven Cardiovascular Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease: Emerging Links With Atherosclerotic Cardiovascular Disease.","Mahajan N","2026","Cureus","narrative_review","article","10.7759/cureus.115501","42819336","PMC13625605",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004184","Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.","Bonaca MP","2025","European heart journal. Cardiovascular pharmacotherapy","protocol","article","10.1093/ehjcvp/pvae071","39424598","PMC11724141","ClinicalTrials.gov:NCT04560998","S001363","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; article"],["R0004185","Now and the Future: Medications Changing the Landscape of Cardiovascular Disease and Heart Failure Management.","Oswald T","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14113948","40507711","PMC12156302",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004186","How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA.","Morales E","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other_trial","article","10.1093/ndt/gfaf069","40359159","PMC12548029",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0004187","Effects of Weekly Semaglutide and Tirzepatide Therapy on APRI and FIB-4 Scores in Adults with Obesity: A Real-World 12-Month Study","Kotan R","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9928068/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0004188","Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.","Abdelaal A","2026","Ophthalmology","systematic_review","article","10.1016/j.ophtha.2026.02.013","41692115",null,"PROSPERO:CRD420251107346",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; article"],["R0004189","Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake.","Farokhnia M","2025","The Journal of clinical investigation","nonrandomized_study","article","10.1172/jci188314","40048376","PMC12043080",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004190","GLP-1 RA Prescribing Errors in a Multidisciplinary Digital Weight-Loss Service: A Retrospective Quantitative Analysis.","Talay L","2024","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare12202093","39451508","PMC11507644",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004191","GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know.","Abdulrazeq H","2024","Neurosurgery practice","nonrandomized_study","article","10.1227/neuprac.0000000000000098","39959894","PMC11783641",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004192","Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog.","Bian L","2026","Cell host & microbe","preclinical","article","10.1016/j.chom.2026.05.003","42269582",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004193","Liraglutide Promoted Osteogenic Differentiation of Dental Pulp Stem Cells via H3K18 Lactylation-Dependent DSPP Activation.","Li R","2026","Tissue engineering and regenerative medicine","other","article","10.1007/s13770-026-00801-9","41849034","PMC13212838",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004194","Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study.","Caruso I","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70005","40785519","PMC12515759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004195","What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional study in the UK","Auerbach N","2024","Research Square","other","preprint","10.21203/rs.3.rs-5689779/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004196","Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus: Growing Evidence But Not Yet There.","Ginès P","2024","Gastroenterology","commentary","article","10.1053/j.gastro.2024.05.030","38823653",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0004197","Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.","DiStefano MJ","2025","Journal of pharmaceutical policy and practice","other","article","10.1080/20523211.2024.2441220","39776466","PMC11703442",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004198","MON-030 Effective Use of Low-dose Glucagon-like Peptide-1 Receptor Agonist for Hypothalamic Obesity in a Patient with Type 1 Diabetes Mellitus",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC12047126",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0004199","Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.","Guo X","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71025","42443144","PMC13538822",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004200","Gambling Disorder as a Behaviorally Driven Systemic Medical Condition: From Reward Circuitry to Multi-System Morbidity.","Ballerio M","2026","Clinics and practice","other_trial","article","10.3390/clinpract16080137","42645133","PMC13510928",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0004201","Research on TCM Comprehensive Treatment of DKD Based on Pathophysiological Mechanism.","Piao L","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s523094","40687906","PMC12276746",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004202","REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide.","Pruijm M","2026","Kidney international","protocol","article","10.1016/j.kint.2025.10.005","41207620",null,"ClinicalTrials.gov:NCT04865770; ClinicalTrials.gov:NCT03819153","S000395; S000953","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Clinical Trial Protocol; Research Support, N.I.H., Extramural; article"],["R0004203","GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage.","Park B","2024","American journal of physiology. Heart and circulatory physiology","narrative_review","article","10.1152/ajpheart.00574.2023","38426865",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0004204","GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.","Kapoor I","2023","Survey of ophthalmology","systematic_review","article","10.1016/j.survophthal.2023.07.002","37454782",null,null,"S002229; S002534","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0004205","GLP-1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis.","Wu J","2025","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.202501605r","40815122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004206","A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists.","Ogunremi OO","2024","International journal of women's dermatology","systematic_review","article","10.1097/jw9.0000000000000143","38586157","PMC10997314",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004207","Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors combination therapy versus monotherapy and major adverse cardiovascular events: Do the benefits add up?","Karakasis P","2024","European journal of internal medicine","commentary","article","10.1016/j.ejim.2024.07.002","38981766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0004208","Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema.","Phu A","2024","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2024.108808","39018897","PMC11315198",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0004209","Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6.","Klein KR","2024","Diabetes care","other_trial","article","10.2337/dc23-1791","38048543","PMC10834386",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; other; article"],["R0004210","Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain.","Botana López M","2024","Advances in therapy","other","article","10.1007/s12325-024-02938-2","39039388","PMC11349830",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Consensus Statement; research-article; article"],["R0004211","Perceived Competence and GLP-1RA Weight Management Engagement: Mixed-Methods Insights From Six Patient Groups.","McElroy JA","2026","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70275","42572911","PMC13511413",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004212","New Names, New Drugs, Better Outcomes in Steatotic Liver Disease.","Peverelle M","2025","British journal of hospital medicine (London, England : 2005)","narrative_review","article","10.12968/hmed.2024.0655","40847981",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004213","The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation.","Albor C","2026","Current obesity reports","nonrandomized_study","article","10.1007/s13679-026-00707-6","41922811",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0004214","Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration.","Koureta E","2024","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2024.1343587","38464718","PMC10920271",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004215","Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a randomised, double-blind, placebo-controlled, phase 3 trial","Bing s","2025","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-6342890/v1",null,null,"ClinicalTrials.gov:NCT05680155","S001967","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0004216","SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia.","Ramírez-Rincón A","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01593-8","38717577","PMC11211291","ClinicalTrials.gov:NCT05324462","S000109","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004217","Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population.","van Kleef LA","2026","Gastro hep advances","nonrandomized_study","article","10.1016/j.gastha.2026.100912","41953380","PMC13054597",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004218","Epidemiology of cardiovascular-kidney-metabolic syndrome.","Mavromatis LA","2026","Nature reviews. Nephrology","narrative_review","article","10.1038/s41581-026-01078-w","42098477",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004219","New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity.","Dira LM","2025","International journal of molecular sciences","systematic_review","article","10.3390/ijms26136143","40649920","PMC12249713",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0004220","Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide.","Choi W","2025","Nature medicine","case_report","article","10.1038/s41591-025-04035-5","41249493","PMC12705427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0004221","Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.","Seighali N","2026","BMC pharmacology & toxicology","systematic_review","article","10.1186/s40360-026-01149-5","42163419","PMC13371186",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0004222","Effects of GLP-1 Receptor Agonists on Major Cardiovascular Events Among Patients with Atopic Dermatitis: A Population-Based Study.","Katz A","2026","Dermatitis : contact, atopic, occupational, drug","nonrandomized_study","article","10.1177/17103568251410211","41649183",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004223","Contemporary Type 2 Diabetes Guidelines: Converging Evidence, Diverging Strategies, and the Position of the Korean Diabetes Association Framework.","Kim SK","2026","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2026.3080","42298756","PMC13341183",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004224","Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study.","Taipale H","2026","The lancet. Psychiatry","randomized_trial","article","10.1016/s2215-0366(26)00014-3","41862258",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0004225","Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.","Tesoro NA","2026","American journal of preventive cardiology","randomized_trial","article","10.1016/j.ajpc.2026.101623","42395062","PMC13326075",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004226","Adipose Tissue Memory and Why Patients Regain Weight after Weight Loss: Understanding the Immunologic Basis for Recurrent Cardiovascular Risk.","Sami N","2026","Cardiology in review","other","article","10.1097/crd.0000000000001345","42296333",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004227","Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.","Ravussin E","2025","Cell metabolism","other_trial","article","10.1016/j.cmet.2025.03.011","40203836",null,"ClinicalTrials.gov:NCT04081337","S000078","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; article"],["R0004228","Association of glucagon-like peptide-1 receptor agonist use with risk of infections: A systematic review and meta-analysis.","Han S","2025","The Journal of infection","systematic_review","article","10.1016/j.jinf.2025.106645","41173399",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0004229","Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series.","Barakat S","2024","Hospital pharmacy","nonrandomized_study","article","10.1177/00185787241266803","39449861","PMC11497530",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0004230","GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients.","Yehualashet E","2025","Annals of vascular surgery","nonrandomized_study","article","10.1016/j.avsg.2025.08.013","40825437","PMC13065351",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0004231","Managing Bone Fragility in Older Adults with Diabetes: Pathophysiology, Assessment, and Therapeutic Considerations.","Bahat G","2026","Drugs & aging","narrative_review","article","10.1007/s40266-026-01290-0","41854838","PMC13038465",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004232","Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon.","Nassar M","2024","World journal of diabetes","commentary","article","10.4239/wjd.v15.i2.133","38464377","PMC10921167",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0004233","Glucagon-like Peptide 1 Receptor Agonists and Postendoscopic Aspiration Pneumonia: What Plays a Role in Clinical Practice?","Xu H","2025","Gastroenterology","commentary","article","10.1053/j.gastro.2024.04.007","38631416",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0004234","Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support-A Narrative Review.","Dziewierz A","2026","Nutrients","randomized_trial","article","10.3390/nu18111761","42280404","PMC13259006",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0004235","Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.","Aroda VR","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00126-9","42251860",null,"ClinicalTrials.gov:NCT06323174","S000273","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0004236","Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.","Pałka W","2026","Journal of endocrinological investigation","systematic_review","article","10.1007/s40618-026-03006-y","42560457","PMC13627233","PROSPERO:CRD420251014401",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; review"],["R0004237","Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes: A Retrospective Observational Multicenter Study (ORIGAMI Study).","Iwata Y","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01790-z","41249746","PMC12847525","UMIN:UMIN000050499",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004238","SAT085 Oral Glucagon-like Peptide-1 Receptor Agonist As Adjuvant Treatment In HNF1A-MODY",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10554658",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0004239","Remission of polycystic ovary syndrome based on the recovery of ovarian morphology identified by three-dimensional ultrasonography: a retrospective study.","Su K","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1877873","42597837","PMC13469636","ClinicalTrials.gov:NCT05063383",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004240","GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease.","Morrison L","2024","Journal of the American Board of Family Medicine : JABFM","narrative_review","article","10.3122/jabfm.2023.230455r1","39142859",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004241","Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.","Anson M","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15576","38558280",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0004242","Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.","Malik RA","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16591","40785322","PMC12409210",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0004243","Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.","Khan S","2026","Medicine","systematic_review","article","10.1097/md.0000000000049916","42499082","PMC13406235",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0004244","Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with psoriasis and comorbid type 2 diabetes: A population-based target trial emulation.","Cheng D","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.02.008","41655841",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0004245","Measuring the Quality and Safety of Upper Endoscopy in Patients Taking Glucagon-like Peptide 1 Receptor Agonists.","Bansal R","2025","Gastroenterology","commentary","article","10.1053/j.gastro.2024.04.001","38580131",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0004246","Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: The Impact GLP-1 CKD study.","Chu L","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15834","39113258",null,"ClinicalTrials.gov:NCT06236672","S002409","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0004247","Genetic evidence for repurposing of glucagon-like peptide-1 receptor agonists to prevent chronic liver diseases.","Liu B","2024","Gut","commentary","article","10.1136/gutjnl-2024-332254","38490731",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0004248","[A new era for glucagon-like peptide-1 receptor agonists].","Neuville MF","2023","Revue medicale de Liege","other","article",null,"36634066",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0004249","Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: A propensity based cohort study.","Yen FS","2024","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2024.103099","39128378",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004250","Coronary Artery Calcium as a Biological Staging Marker for Atherosclerosis: Aligning Preventive Therapies With Plaque Evolution.","Arun AJ","2026","Cardiology in review","other","article","10.1097/crd.0000000000001240","41854510",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004251","GLP-1 guidelines amid an obesity epidemic: a poor fit for the Global South.","Shrisunder R","2026","Archives of public health = Archives belges de sante publique","nonrandomized_study","article","10.1186/s13690-026-01883-6","41851786","PMC13001263",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0004252","Treatment Options for Improving The Semen Quality in Obese Men: A Scoping Review.","Wang H","2026","Journal of multidisciplinary healthcare","narrative_review","article","10.2147/jmdh.s582182","41883587","PMC13012178",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004253","GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus.","Borissov Borissov M","2026","Sleep & breathing = Schlaf & Atmung","nonrandomized_study","article","10.1007/s11325-026-03748-2","42363996",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004254","Remission in diabetic kidney disease: current evidence and future directions.","Reaume M","2026","Current opinion in nephrology and hypertension","randomized_trial","article","10.1097/mnh.0000000000001197","42077164",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0004255","Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change: GLP-1 Receptor Agonists and Intraocular Pressure Change.","Hallaj S","2025","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2024.08.030","39237049","PMC11634659",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004256","Incretin-Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists.","Lisco G","2025","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.70073","40914967","PMC12414530",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004257","Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.","Espinosa De Ycaza AE","2024","Thyroid : official journal of the American Thyroid Association","systematic_review","article","10.1089/thy.2023.0530","38343381","PMC10998705",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; review"],["R0004258","Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.","Zhuo C","2021","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2021.759262","35002700","PMC8741261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0004259","Effect of acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, and estrus phase on cue- and drug-induced fentanyl seeking in female rats.","Urbanik LA","2025","Behavioural pharmacology","preclinical","article","10.1097/fbp.0000000000000805","39718042","PMC12013456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0004260","Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease-Current Background, Hopes, and Perspectives.","Cazac GD","2023","Metabolites","narrative_review","article","10.3390/metabo13050581","37233622","PMC10221116",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004261","Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Chen X","2024","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-024-01497-4","39456002","PMC11515276",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004262","Nitric oxide redox signaling as a convergent mechanism in aging and fibrosis.","Guo X","2026","Ageing research reviews","narrative_review","article","10.1016/j.arr.2026.103156","42070665",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004263","Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro.","Cheng X","2025","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70107","40931416",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004264","Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.","Frías JP","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16214","39905643","PMC11885071","ClinicalTrials.gov:NCT05114590","S002030","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase IV; Journal Article; Multicenter Study; research-article; article"],["R0004265","Effects of glucagon‑like peptide‑1 receptor agonists on fracture healing in a rat osteoporotic model.","Wang R","2023","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2023.12111","37559934","PMC10407998",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004266","Diabetes Medication Regimen Complexity and Glycemic Outcomes among Medically Underserved Latino Adults: Implications for Pharmacoequity.","Wisseh C","2026","Journal of immigrant and minority health","nonrandomized_study","article","10.1007/s10903-026-01999-5","42766184",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004267","Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.","Buse JB","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00125-7","42251859",null,"ClinicalTrials.gov:NCT06065540","S001612","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0004268","Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes.","Wang YH","2026","Drug safety","nonrandomized_study","article","10.1007/s40264-025-01623-9","41123870",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0004269","Obesity and Atrial Fibrillation: Epidemiology, Mechanisms, and Therapeutic Implications in the Era of Metabolic Therapies.","Zine-Eddine H","2026","Cardiology in review","randomized_trial","article","10.1097/crd.0000000000001332","42269002",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0004270","Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes.","Yeh JJ","2024","Biomedicines","nonrandomized_study","article","10.3390/biomedicines12030488","38540106","PMC10968458",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004271","58 risk and 34 protective effects of  <i>GLP1R<\/i>  on disease phenome and adverse neonatal health","Campbell RH","2026","medRxiv","other","preprint","10.64898/2026.01.24.26344404",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004272","Endothelial Dysfunction and Therapeutic Advances in Chronic Kidney Disease.","Liang F","2025","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.70086","40914977",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0004273","Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity?","Suissa S","2024","Gut","nonrandomized_study","article","10.1136/gutjnl-2024-331976","38499341",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comment; article"],["R0004274","Semaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trials","Campos-Garcia F","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-10976576/v1",null,null,"PROSPERO:CRD420251059430",null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0004275","Prescribing trends of cardioprotective medications among patients with diabetes and ASCVD in primary care setting in Qatar.","Jaam M","2025","Journal of pharmaceutical policy and practice","nonrandomized_study","article","10.1080/20523211.2025.2594824","41377695","PMC12687906",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004276","Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network : Author list.","Nassar M","2025","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-024-02466-4","39302577",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0004277","GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model.","Zhang MW","2025","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2025.110659","40882702",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004278","Liraglutide alleviates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by enhancing mitophagy mediated by the AMPK-Parkin signaling pathway.","Zhu YX","2025","World journal of diabetes","preclinical","article","10.4239/wjd.v16.i12.112423","41480600","PMC12754102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004279","Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.","Ayoub NR","2026","Clinical interventions in aging","other_trial","article","10.2147/cia.s620882","42781074","PMC13599794",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; review"],["R0004280","Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Case Study","Talay L","2024","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202407.0092.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0004281","Emerging pharmacotherapies for obesity: A systematic review.","Kokkorakis M","2025","Pharmacological reviews","systematic_review","article","10.1124/pharmrev.123.001045","39952695",null,"ClinicalTrials.gov:NCT01351753; ClinicalTrials.gov:NCT05579977; ClinicalTrials.gov:NCT01540864; ClinicalTrials.gov:NCT03051451","S000448","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0004282","Hypersensitivity to liraglutide: A case report.","Marino-Fernández AG","2025","Asia Pacific allergy","case_report","article","10.5415/apallergy.0000000000000149","40718123","PMC12289086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004283","Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists.","Ghosh P","2023","Theranostics","narrative_review","article","10.7150/thno.86831","37771773","PMC10526673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0004284","Comparative Effectiveness of GLP-1 Receptor Agonists Versus Metformin in Reducing Dementia Risk Among Adults ≥65 Years with Type 2 Diabetes Mellitus and Delirium: A 20-Year Real-World Data Analysis (2005–2025)","Mercado F","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202601.2404.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint; article"],["R0004285","GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.","Lin YJ","2026","Cancer immunology, immunotherapy : CII","nonrandomized_study","article","10.1007/s00262-026-04488-8","42400648","PMC13612769",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004286","Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.","Weng J","2024","Journal of evidence-based medicine","systematic_review","article","10.1111/jebm.12620","38858300",null,"PROSPERO:CRD42023409585",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Comparative Study; Network Meta-Analysis; review"],["R0004287","Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes.","Shah VN","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16251","39950217","PMC11965002",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Clinical Trial, Phase IV; research-article; article"],["R0004288","Heart failure with preserved ejection fraction: current insights and emerging therapeutic directions.","Kim J","2026","The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology","other_trial","article","10.4196/kjpp.25.250","41340488","PMC13124746",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0004289","Editor's Roundup: ECT for Pediatric Depression and Catatonia - It Works and Is Safe; Maintenance Strategies and Impact on Long-Term Outcomes; and What to Do About Glucagon-Like Peptide-1 Receptor Agonists and ECT.","Espinoza RT","2024","The journal of ECT","commentary","article","10.1097/yct.0000000000001065","39190368",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0004290","Association of Sodium-Glucose Cotransporter-2 Inhibitors With Reduced Hepatocellular Carcinoma Risk in Patients With Type 2 Diabetes.","Choi J","2026","The American journal of gastroenterology","nonrandomized_study","article","10.14309/ajg.0000000000003889","41400268",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004291","Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.","Hsieh TYJ","2026","Gynecologic oncology","nonrandomized_study","article","10.1016/j.ygyno.2026.03.010","42000371",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004292","Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist.","Anazco D","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2023.11.024","38043694",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004293","A Case Series on the Efficacy of the Pharmacological Treatment of Lipedema: The Italian Experience with Exenatide.","Patton L","2025","Clinics and practice","case_report","article","10.3390/clinpract15070128","40710038","PMC12293800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004294","Neuroprotective effects of semaglutide targeting the left temporal lobe in adults with overweight or obesity: A 24-week multimodal neuroimaging study.","Meng F","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70524","41657113",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0004295","Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.","Wharton S","2025","Cardiovascular diabetology","other_trial","article","10.1186/s12933-025-02781-x","40481478","PMC12142847","ClinicalTrials.gov:NCT05048719; ClinicalTrials.gov:NCT05051579","S002265; S002337","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0004296","The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.","Hudanich M","2025","Cureus","narrative_review","article","10.7759/cureus.93104","41141001","PMC12551431",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004297","Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy.","Guney-Coskun M","2024","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v30.i43.4682","39575401","PMC11572635",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; letter; article"],["R0004298","Obesity and Heart Failure: Introducing the Theme.","Monitillo F","2026","Journal of cardiovascular development and disease","narrative_review","article","10.3390/jcdd13040153","42041979","PMC13116647",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004299","Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation.","Wade FG","2025","Clinical transplantation","nonrandomized_study","article","10.1111/ctr.70344","41075262",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004300","Liraglutide-associated depression in a patient with type 2 diabetes: A case report and discussion.","He Y","2024","Medicine","case_report","article","10.1097/md.0000000000037928","38701264","PMC11062733",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; research-article; article"],["R0004301","Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery.","Abdallah H","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-08210-y","40913138","PMC12540538",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004302","Glucagon-like peptide-1 receptor agonist use and perioperative outcomes after anterior cervical discectomy and fusion: a propensity-matched cohort study.","Heo KY","2026","The spine journal : official journal of the North American Spine Society","nonrandomized_study","article","10.1016/j.spinee.2025.12.019","41482188",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004303","Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases.","Yang Y","2025","Journal of autoimmunity","systematic_review","article","10.1016/j.jaut.2025.103414","40174283",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0004304","Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.","Garvey WT","2026","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.70271","42528333","PMC13511289","ClinicalTrials.gov:NCT06854952","S002590","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; research-article; article"],["R0004305","GLP-1 RA-Exacerbated Gut Microbiome Dysbiosis in Obesity Mediates Post-Cessation Weight Regain","Song D","2026","medRxiv","randomized_trial","preprint","10.64898/2026.05.02.26352300",null,null,"ChiCTR:ChiCTR2200066014",null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0004306","Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients.","Singh S","2024","Current problems in cardiology","systematic_review","article","10.1016/j.cpcardiol.2024.102403","38237815",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Review; article"],["R0004307","Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea.","Kårhus ML","2023","JCEM case reports","case_report","article","10.1210/jcemcr/luac004","37908253","PMC10578406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004308","Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease.","Desai A","2024","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.18138","38938071",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004309","Leucine supplementation modulates body composition and early weight rebound during GLP-1 receptor agonist therapy in diet-induced obese mice.","Zhao ZW","2026","Journal of endocrinological investigation","preclinical","article","10.1007/s40618-026-02896-2","42002672",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004310","Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.","Barkmeier AJ","2024","Ophthalmology. Retina","nonrandomized_study","article","10.1016/j.oret.2024.05.003","38735641","PMC12233001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Comparative Study; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0004311","Hypertriglyceridemia in chronic kidney disease: pathophysiological mechanisms, cardiovascular risk, and emerging therapeutics.","Li D","2026","Lipids in health and disease","narrative_review","article","10.1186/s12944-026-02862-0","41559781","PMC12906056",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004312","Pharmacological therapy in the obese patient: is it only a matter of fat loss?","Borghi C","2026","European heart journal supplements : journal of the European Society of Cardiology","randomized_trial","article","10.1093/eurheartjsupp/suag029","42099474","PMC13147263",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004313","Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.","Soresi M","2024","World journal of gastroenterology","commentary","article","10.3748/wjg.v30.i30.3541","39193573","PMC11346152",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0004314","Should glucagon-like peptide-1 receptor agonist treatment be withheld in preoperative management?","Bloomgarden Z","2023","Journal of diabetes","commentary","article","10.1111/1753-0407.13469","37727016","PMC10509509",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0004315","Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease.","Lee HA","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms24119324","37298276","PMC10253495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004316","The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications.","Duan X","2025","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-025-02750-4","40295996","PMC12038999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0004317","Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics.","Liu X","2025","ACS nano","other","article","10.1021/acsnano.5c05745","40490304",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004318","Incretin receptor agonism during pregnancy: implications for mother and baby.","Dearden L","2025","Clinical science (London, England : 1979)","preclinical","article","10.1042/cs20258493","41359794","PMC12794308",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0004319","In vivo functional profiling and structural characterisation of the human Glp1r A316T variant.","El Eid L","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.10.19.619191","39484598","PMC11527029",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0004320","Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.","Park MJ","2023","Clinical and molecular hepatology","systematic_review","article","10.3350/cmh.2022.0330","36907574","PMC10366812",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; research-article; article"],["R0004321","Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China.","Deng X","2025","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2025-106126","41448677","PMC12742173",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004323","From diet to hypothalamic dysfunction: Neuroanatomical and hormonal integration of the microbiota-hypothalamus-adipose tissue axis.","de Freitas Queiroz Barros HD","2026","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-026-10038-5","42012618","PMC13246865",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0004324","The Metabolic Revolution in Dermatology: Obesity, Insulin Resistance, and Ultra-Processed Diets as Drivers of Skin Inflammation.","Khalaf R","2026","Journal of cutaneous medicine and surgery","narrative_review","article","10.1177/12034754261467034","42590998",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004325","ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum.","De Luca L","2025","European heart journal supplements : journal of the European Society of Cardiology","other","article","10.1093/eurheartjsupp/suaf071","40385470","PMC12078771",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004326","Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.","Price SAL","2025","Archives of gynecology and obstetrics","nonrandomized_study","article","10.1007/s00404-024-07849-9","39762582","PMC12033171",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0004327","Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.","Guo H","2025","Obesity pillars","systematic_review","article","10.1016/j.obpill.2025.100162","39980735","PMC11840199",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004328","Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients.","Ali S","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15398","38151964",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004329","First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss.","Sudhoff H","2025","European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery","nonrandomized_study","article","10.1007/s00405-025-09604-5","40721956",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Case Reports; article"],["R0004330","RAAS blockade in the kidney life-cycle-treatment standard.","Moriconi D","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","narrative_review","article","10.1093/ndt/gfag090","42008148","PMC13314374",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004331","Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.","Borlaug BA","2026","JACC. Heart failure","randomized_trial","article","10.1016/j.jchf.2026.103218","42417681","PMC13398731","ClinicalTrials.gov:NCT04847557","S000047","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0004332","Glucagon-like peptide agonists: A prospective review.","Mariam Z","2024","Endocrinology, diabetes & metabolism","narrative_review","article","10.1002/edm2.462","38093651","PMC10782143",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004333","Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.","British Medical Journal Publishing Group","2024","BMJ (Clinical research ed.)","notice","article","10.1136/bmj.q1094","38754911","PMC11097967",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; article"],["R0004334","The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.","Yamanouchi D","2025","International journal of molecular sciences","other_trial","article","10.3390/ijms27010027","41515907","PMC12785922",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0004335","The potential biomarker value of soluble CD36 in the treatment of diabetic kidney disease: evidence from GLP-1 and insulin interventions.","Li W","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1605631","40496556","PMC12148844",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0004336","Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization.","Singh V","2025","Advances in therapy","narrative_review","article","10.1007/s12325-025-03352-y","40911213","PMC12579698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0004337","GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.","Pak KY","2025","Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology","systematic_review","article","10.1097/mao.0000000000004373","39666743",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0004338","Impact of a pharmacist-led weight management service in a cardiology clinic.","Yates M","2024","Journal of the American Pharmacists Association : JAPhA","other","article","10.1016/j.japh.2023.11.011","37944862",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0004339","Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries.","Wallner M","2024","European heart journal. Cardiovascular pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvae026","38632048","PMC11250228",null,"S000913","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0004340","Beyond Cardiology's Pillars: A Network Meta-Analysis Comparing the Recombinant Zoster Vaccine (Shingrix/RZV) with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Prevention of Major Adverse Cardiovascular Events and Dementia in Adults Aged ≥50 Years","Ahmed A","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-9727771/v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0004341","Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight (LIGHT 1): A randomized, double-blind, placebo-controlled, ascending-dose phase 2a trial.","Gao F","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70429","41492234",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; article"],["R0004342","Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review.","Sreenivasan C","2024","Cureus","systematic_review","article","10.7759/cureus.66697","39262558","PMC11390157",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004343","A novel GIPR/GLP-1R dual agonist improves systemic metabolism through differentially regulating inflammation and lipid metabolism in obesity.","Zhang F","2026","Journal of advanced research","preclinical","article","10.1016/j.jare.2026.02.006","41690462",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004344","Differential Modulation of Postprandial Glycemic, Incretin, and Satiety Responses by Low-Digestible Carbohydrates in Humans: An Exploratory Investigation.","Noh J","2026","Nutrients","other","article","10.3390/nu18111742","42280385","PMC13258582",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0004345","Total care strategies in atrial fibrillation practice: Lifestyle intervention and risk factor management.","Tokuda M","2026","Journal of cardiology","narrative_review","article","10.1016/j.jjcc.2026.06.018","42402270",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004346","Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice.","Marassi M","2025","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2024.11.005","39616020",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; review"],["R0004347","Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials.","Silverii GA","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15538","38449004",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0004348","Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases.","Steven S","2025","Pharmacological reviews","narrative_review","article","10.1016/j.pharmr.2025.100082","40803202","PMC12799437",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004349","Improvement of Quality of Life by Switching from Oral Semaglutide to Tirzepatide in Patients with Type 2 Diabetes.","Fukaishi T","2025","JMA journal","nonrandomized_study","article","10.31662/jmaj.2025-0011","40786468","PMC12328484",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004350","Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling.","He X","2024","Acta pharmaceutica Sinica. B","nonrandomized_study","article","10.1016/j.apsb.2024.03.011","38828140","PMC11143538",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004351","Leptin for Obesity: Previous Failures, Promising Future.","Marcucci A","2025","Cardiology in review","preclinical","article","10.1097/crd.0000000000000979","40536347",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004352","Semaglutide Alleviates Ovarian Oxidative Stress and Autophagy via the PI3K/AKT/mTOR Pathway in Mice with Polycystic Ovary Syndrome.","Guo S","2025","Drug design, development and therapy","preclinical","article","10.2147/dddt.s522730","40433568","PMC12109608",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004353","Nutrient-Stimulated Hormone Therapies in Heart Failure: Targeting Cardiometabolic Burden Beyond Weight Reduction.","Cho DH","2026","International journal of heart failure","narrative_review","article","10.36628/ijhf.2026.0002","42110706","PMC13150458",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004354","TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends.","Günaltay MM","2026","Journal of the American Pharmacists Association : JAPhA","other","article","10.1016/j.japh.2026.103082","41866128",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004355","Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial.","Lv R","2026","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2026.104045","42472282","PMC13380094","ClinicalTrials.gov:NCT06415214","S001370","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0004356","Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.","Bucheit JD","2020","Diabetes technology & therapeutics","other_trial","article","10.1089/dia.2019.0185","31436480",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0004357","Socioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study.","Pazzagli L","2025","Obesity facts","nonrandomized_study","article","10.1159/000542682","39591946","PMC12017747",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004358","Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs.","Gao R","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1502050","39717105","PMC11664219",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004359","Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.","Pratt E","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15184","37344954",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; article"],["R0004360","GLP-1 Receptor Agonists and Risk of Paralytic Ileus: A drug-target Mendelian Randomization Study.","Ding P","2024","medRxiv : the preprint server for health sciences","other","article","10.1101/2024.10.17.24315627","39484277","PMC11527067",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0004361","Genetic evidence for repurposing GLP-1 receptor agonists in chronic kidney disease and IgA nephropathy: Metabolic and anti-inflammatory pathways beyond glycaemic control.","Yang X","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70144","40994081",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004362","Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Njei B","2024","Cureus","systematic_review","article","10.7759/cureus.71366","39534801","PMC11556413",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004363","Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis.","Dutta D","2023","Indian journal of endocrinology and metabolism","systematic_review","article","10.4103/ijem.ijem_162_23","38107730","PMC10723608",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; other; review"],["R0004364","A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.","Goldenberg RM","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15588","38576082",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; Comment; review"],["R0004365","Glucagon-Like Peptide-1 Receptor Agonists in Patients With Cirrhosis: Answering the Unanswered Questions?","Mahgoub S","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","commentary","article","10.1016/j.cgh.2024.01.041","38342276",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0004366","Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study).","Moreno-Pérez O","2025","Seminars in arthritis and rheumatism","nonrandomized_study","article","10.1016/j.semarthrit.2025.152807","40816061",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0004367","From Weight Loss to Organ-Specific Disease Modification: A Narrative Review of Incretin-Based Therapies in Obesity-Related Cardiometabolic Disease, Chronic Kidney Disease, Metabolic Dysfunction-Associated Steatohepatitis, and Obstructive Sleep Apnoea.","Joshi D","2026","Cureus","nonrandomized_study","article","10.7759/cureus.112135","42559252","PMC13440212",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0004368","The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice.","Martens P","2023","Acta cardiologica","other_trial","article","10.1080/00015385.2022.2076307","35575294",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Review; Journal Article; article"],["R0004369","Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.","Alper A","2026","Cardiovascular diabetology. Endocrinology reports","systematic_review","article","10.1186/s40842-025-00270-4","41715239","PMC12922244","PROSPERO:CRD420251229397",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review; other"],["R0004370","Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!","Patoulias D","2023","Expert opinion on drug safety","commentary","article","10.1080/14740338.2023.2247984","37584280",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0004371","Functional and Aesthetic Periorbital, Ocular Adnexal and Ocular Surface Changes Linked to GLP-1 Receptor Agonists.","Kapantais D","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14248792","41464694","PMC12733712",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004372","Comments on \"Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation\" [Letter].","Hou Y","2026","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s644959","42787185","PMC13600973",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; review"],["R0004373","Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.","Taal MW","2026","Seminars in nephrology","narrative_review","article","10.1016/j.semnephrol.2026.151692","41760475",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004374","Comparative risks of dementia and Parkinson's disease with GLP-1 RAs versus other oral glucose-lowering medications in obese patients with type 2 diabetes: a large real-world cohort study.","Abu Ahmad W","2026","European journal of internal medicine","nonrandomized_study","article","10.1016/j.ejim.2026.107164","42629262",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0004375","Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.","Tamayo-Trujillo R","2024","Frontiers in nutrition","other_trial","article","10.3389/fnut.2024.1398059","38742021","PMC11090168",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0004376","Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.","Freet CS","2024","Addiction science & clinical practice","protocol","article","10.1186/s13722-024-00481-7","39061093","PMC11282646","ClinicalTrials.gov:NCT04199728","S001339","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0004377","Semaglutide protects against diabetes-associated cardiac inflammation via Sirt3-dependent RKIP pathway.","Lin K","2025","British journal of pharmacology","preclinical","article","10.1111/bph.17327","39710830",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004378","Therapeutic advances in obesity management: an overview of the therapeutic interventions.","Roomy MA","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1364503","38715796","PMC11074390",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; review-article; article"],["R0004379","Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.","Iwamoto H","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15784","39039725",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0004380","Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome.","Diakosavvas M","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00614-2","40045077","PMC11882674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004381","Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.","Abiola JO","2024","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph17060736","38931402","PMC11206448",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004382","Patient initiation and maintenance of GLP-1 RAs for treatment of obesity.","Patel D","2021","Expert review of clinical pharmacology","nonrandomized_study","article","10.1080/17512433.2021.1947796","34231442",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0004383","Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.","Dash S","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15829","39157881",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0004384","Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies.","Suresh MG","2026","World journal of diabetes","narrative_review","article","10.4239/wjd.v17.i2.113149","41696109","PMC12897526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004385","Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.","Wong SY","2024","Cardiovascular drugs and therapy","systematic_review","article","10.1007/s10557-022-07360-w","35819544",null,"PROSPERO:CRD42021259661",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0004386","Pharmacological strategies to prevent cancer therapy-related cardiovascular toxicity: the road to personalised cardioprotection.","Camilli M","2026","Heart (British Cardiac Society)","narrative_review","article","10.1136/heartjnl-2025-326656","41748200",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004387","Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes.","Dániel E","2025","International journal of molecular sciences","other","article","10.3390/ijms262110404","41226444","PMC12609315",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004388","Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis.","Yeh TL","2023","PloS one","systematic_review","article","10.1371/journal.pone.0278685","36696429","PMC9876280",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; research-article; article"],["R0004389","Indigenous Leadership and Advocacy in Pro-Equity Eligibility Criteria for New Diabetes Medicines in Aotearoa New Zealand [Policy Report].","Tamatea J","2025","Health systems and reform","other","article","10.1080/23288604.2025.2592386","41360052",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004390","Glucagon-Like Peptide-1 Receptor Agonists vs. Bariatric Endoscopy: A Systematic Review and Meta Analysis of Efficacy, Safety, and Metabolic Outcomes.","Khan S","2026","Obesity surgery","systematic_review","article","10.1007/s11695-026-08588-3","41954719",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; Review; review"],["R0004391","What do I need to know about liraglutide (Saxenda), the glucagon-like peptide 1 receptor agonist for weight management in children with obesity?","Ryan PM","2022","Paediatrics & child health","other","article","10.1093/pch/pxac026","35859679","PMC9291360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004392","Half the genome, half the story? Paternal metabolic health and offspring outcomes in the era of modern obesity pharmacotherapy.","Koufakis T","2026","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2026.101743","41748068",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0004393","Role of Gastric Point-of-Care Ultrasound in Perioperative Management of Semaglutide.","Muranaka MO","2025","Cureus","other","article","10.7759/cureus.85791","40656422","PMC12254052",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004394","Use of Glucose-Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents.","Harbi H","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71308","42687767",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004395","Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.","Arora G","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15020541","41598480","PMC12842597",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0004396","Modern Hypoglycemic Agents and Their Perioperative Implications","Goudra B","2024","Preprints.org","other","preprint","10.20944/preprints202411.0253.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004397","Novel Therapeutic Targets in the Management of Psoriatic Disease.","Childs BA","2025","Rheumatic diseases clinics of North America","narrative_review","article","10.1016/j.rdc.2025.05.005","40681281",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004398","Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists.","Goldberg AS","2024","Fertility and sterility","narrative_review","article","10.1016/j.fertnstert.2024.05.154","38810863",null,null,"S000630","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0004399","GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?","Menghini R","2023","Acta diabetologica","narrative_review","article","10.1007/s00592-023-02124-w","37401947","PMC10520195",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004400","The GLP-1 analogue, exendin-4, improves bone material properties and strength through a central relay in ovariectomized mice","Mermet M","2024","bioRxiv","preclinical","preprint","10.1101/2024.10.05.616809",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004401","Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.","Fang L","2024","Primary care diabetes","systematic_review","article","10.1016/j.pcd.2024.03.005","38555202",null,"PROSPERO:CRD42023390735",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0004402","Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study.","Hennies N","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15931","39300717",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004403","Rates of glucagon-like peptide-1 receptor agonist use and aspiration events associated with anesthesia at a Canadian academic teaching centre.","Milne AD","2024","Canadian journal of anaesthesia = Journal canadien d'anesthesie","commentary","article","10.1007/s12630-024-02761-x","38589738",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0004404","The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis.","Siddiqui HF","2025","Heart failure reviews","systematic_review","article","10.1007/s10741-025-10523-0","40399552",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0004405","The Emerging Role of Pharmacotherapy in Obstructive Sleep Apnea.","Jaganathan N","2024","Journal of otorhinolaryngology, hearing and balance medicine","other","article","10.3390/ohbm5020012","39588209","PMC11585974",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004406","Sleep apnea and diabetes.","Ding S","2025","Chinese medical journal","narrative_review","article","10.1097/cm9.0000000000003862","41342166","PMC12721765",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004407","hESCs-derived Organoids Achieve Liver Zonation Features through LSEC Modulation.","Zhang Y","2025","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.202411667","40277442","PMC12120767",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004408","Therapeutic tailored approach in patients with diabetes, cardiovascular and renal comorbidities: A cardiologist's view.","Nardi E","2025","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2025.104033","40610294",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004409","Not Just for Diabetes: The Next Frontier for GLP-1 Agonists.","Colangelo H","2026","Journal of the American Board of Family Medicine : JABFM","other","article","10.3122/jabfm.2025.250473r1","42624784",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004410","Renoprotective effect of dulaglutide in L-NAME-induced hypertensive nephropathy in rats: insight into the roles of PPAR-gamma and VEGF.","Bastawy N","2026","Hypertension research : official journal of the Japanese Society of Hypertension","preclinical","article","10.1038/s41440-025-02403-9","41145714","PMC12960213",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004411","Teratogenic risks of treated and untreated maternal obesity.","Jones RE","2025","Seminars in perinatology","narrative_review","article","10.1016/j.semperi.2025.152081","40251041",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004412","Semaglutide ameliorates retinal vascular permeability destruction in diabetic retinopathy by AnxA2-mediated MMP-9 activation and basement membrane remodeling.","Xu C","2025","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2025.118409","40749340",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004413","Impact of GAD-65 antibody detection on antihyperglycemic therapy in T2D.","Halliburton S","2026","Endocrine connections","nonrandomized_study","article","10.1530/ec-25-0785","42598998","PMC13545754",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004414","Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease.","Tsiampali C","2024","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-024-00541-2","38472647","PMC11519281",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004415","Exenatide Attenuates Doxorubicin-Induced Acute Hepatic Injury Through Modulation of SIRT1-HMGB1 Signaling and Oxidative Stress.","Karakullukcu HK","2026","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph19071086","42515767","PMC13415849",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004416","Adjuvant Role of Glucagon-Like Peptide-1 Receptor Agonist-Based Therapies for Sustained Weight Loss in Post-bariatric Surgery Patients.","Dutta D","2024","Obesity surgery","commentary","article","10.1007/s11695-024-07230-4","38616240",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0004417","A real-world study of tirzepatide for weight loss in adults without diabetes mellitus.","Angelopoulos N","2026","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-025-01986-0","41354867",null,"ANZCTR:ACTRN12625000071426",null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0004418","Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin Treatment.","Obagi ZE","2026","Journal of drugs in dermatology : JDD","other_trial","article","10.36849/jdd.10086","42696340",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Clinical Trial; article"],["R0004419","Incretin based therapy and pancreatic cancer: Realising the reality.","Suryadevara V","2022","World journal of gastroenterology","nonrandomized_study","article","10.3748/wjg.v28.i25.2881","35978867","PMC9280733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004420","Polycystic ovary syndrome and type 1 diabetes - the current state of knowledge.","Cichocka E","2024","Endokrynologia Polska","narrative_review","article","10.5603/ep.101392","39376174",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004421","Diuretic resistance in cardiorenal syndrome: mechanisms, monitoring and phenotype-tailored management.","Aletras G","2025","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2025.1731305","41561121","PMC12813186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004422","Lifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success.","Mallardo M","2026","Nutrients","narrative_review","article","10.3390/nu18172748","42738922","PMC13566978",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004423","Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.","Almansour AH","2025","The American journal of case reports","case_report","article","10.12659/ajcr.950781","41351866","PMC12746690",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0004424","Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials.","Salamah HM","2024","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-024-01371-3","38877565","PMC11177512",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004425","Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs.","Le R","2024","Journal of clinical medicine","randomized_trial","article","10.3390/jcm13164674","39200816","PMC11355214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0004426","Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes.","Zhang D","2025","Diabetes care","nonrandomized_study","article","10.2337/dc24-2746","40202527","PMC13053885",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004427","Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease: A BMI-Stratified Retrospective Study.","Kishan A","2026","Spine","nonrandomized_study","article","10.1097/brs.0000000000005494","40905270",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004428","Characterization of treatment intensified (add-on to metformin) adults with type 2 diabetes in Thailand: A cross-sectional real-world study (CONVERGE).","Sriphrapradang C","2025","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14409","40077899","PMC12131932",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004429","Nonanticoagulant Strategies for Venous Thromboembolism Prophylaxis.","Gurumurthy G","2026","Seminars in thrombosis and hemostasis","randomized_trial","article","10.1055/a-2712-3534","41092960",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0004430","Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.","Mather KJ","2024","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgae319","38795393",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0004431","Formulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: Environmental Scan",null,"2024","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"38648306",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0004432","Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.","Katz G","2025","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","systematic_review","article","10.1055/a-2569-7315","40409279",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0004433","Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.","Concepción-Zavaleta MJ","2025","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v31.i37.111435","41025003","PMC12476660",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004434","Understanding of Evidence and Molecular Mechanisms for the Four Pillars of Treatments for Diabetic Kidney Disease, and Its Promising Optional Treatments","Yanai H","2026","Preprints.org","other","preprint","10.20944/preprints202602.1265.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004435","The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.","Seetharaman S","2025","Journal of diabetes science and technology","nonrandomized_study","article","10.1177/19322968241309896","40022528","PMC11686489",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; meeting-report; conference-abstract"],["R0004436","Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.","Htoo PT","2024","Cardiovascular diabetology","notice","article","10.1186/s12933-024-02190-6","38500096","PMC10949568",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0004437","The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review.","Luca SA","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14196877","41095961","PMC12524434",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0004438","Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review.","Mandal L","2026","European journal of obstetrics, gynecology, and reproductive biology","systematic_review","article","10.1016/j.ejogrb.2025.114836","41313865",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0004439","Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration.","Khawaji A","2025","Journal of obesity","systematic_review","article","10.1155/jobe/3442754","40746703","PMC12313391","ClinicalTrials.gov:NCT04255433","S002212","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0004440","The central amygdala integrates exogenous glucagon-like peptide 1 signals","Duran M","2026","bioRxiv","preclinical","preprint","10.64898/2026.04.06.716705",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004441","Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.","Quast DR","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14477","34189834",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0004442","PYY3-36 potentiates semaglutide-mediated mitochondrial modulation in MASLD.","Geiger N","2026","American journal of physiology. Endocrinology and metabolism","randomized_trial","article","10.1152/ajpendo.00036.2026","42526426",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004443","Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis.","Wang W","2023","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.3680","37356073",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0004444","Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials.","Watkins AR","2023","Future cardiology","systematic_review","article","10.2217/fca-2022-0093","36975720",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0004445","A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.","Yammine L","2025","Contemporary clinical trials","protocol","article","10.1016/j.cct.2025.107989","40554081",null,"ClinicalTrials.gov:NCT06173778","S001493","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Clinical Trial Protocol; Research Support, Non-U.S. Gov't; article"],["R0004446","Reduction of New Onset of Atrial Fibrillation in Patients Treated with Semaglutide: An updated systematic review and meta regression analysis of randomized controlled trials.","Cesaro A","2025","European journal of preventive cardiology","systematic_review","article","10.1093/eurjpc/zwaf257","40294206",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; review"],["R0004447","Maturity-Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report.","Sue M","2025","Clinical case reports","case_report","article","10.1002/ccr3.70173","39902194","PMC11790339",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0004448","Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.","Gofron KK","2025","Nutrients","systematic_review","article","10.3390/nu17081303","40284168","PMC12029897",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0004449","Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4/MyD88/NF-κB pathway in diabetic kidney disease.","Huang L","2024","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00083.2024","39133777","PMC11483077",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004450","Comparative Cardiovascular and Renal Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review.","Khan HK","2025","Cureus","systematic_review","article","10.7759/cureus.80932","40255755","PMC12009492",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004451","Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?","Lau D","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15459","38229461",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0004452","Incretins for type 2 diabetes.","Min E","2026","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2025-0142","42250284",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004453","Increased Risk of Aspiration Pneumonia Associated With Endoscopic Procedures Among Patients With Glucagon-like Peptide 1 Receptor Agonist Use.","Yeo YH","2024","Gastroenterology","other","article","10.1053/j.gastro.2024.03.015","38552724",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004454","Combined SGLT2i and GLP1ra therapy reduces all-cause mortality in people with diabetes, with greater benefit in women.","Garcia-Vega D","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2025.104483","41484025",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Comparative Study; article"],["R0004455","Comparative Efficacy of Tirzepatide Versus GLP-1 Receptor Agonists on Glycaemic Control and Body Weight in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Head-to-Head Randomised Controlled Trials","Khan OO","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-9079798/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0004456","Familial partial lipodystrophy type 2 associated with a novel LMNA variant (c.604G>C; p.Glu202Gln): a Colombian family case series.","Mendoza C","2026","Frontiers in endocrinology","case_report","article","10.3389/fendo.2026.1788846","42039119","PMC13106280",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004457","Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials.","Adamou A","2024","International journal of stroke : official journal of the International Stroke Society","systematic_review","article","10.1177/17474930241253988","38676552",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0004458","ASA Consensus-based Guidance on Preoperative Management of Patients on Glucagon-like Peptide-1 Receptor Agonists.","Ushakumari DS","2024","Anesthesiology","nonrandomized_study","article","10.1097/aln.0000000000004776","37982170",null,null,"S002511","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0004459","Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study.","Su YC","2024","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2024.101545","38777141",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004460","Food noise: Conceptual, methodological, and ethical considerations.","Brewis A","2026","Appetite","narrative_review","article","10.1016/j.appet.2026.108700","42392316",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004461","Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.","Aronne LJ","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04386-7","42120723","PMC13375559","ClinicalTrials.gov:NCT06584916","S001469","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; research-article; article"],["R0004462","Comparative effectiveness of combining antidiabetic medications to treat renal impairment in patients with type 2 diabetes mellitus.","Mo Q","2025","Scientific reports","other","article","10.1038/s41598-025-10299-1","40670474","PMC12267706",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0004463","Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.","Ciudin A","2026","International journal of obesity (2005)","other_trial","article","10.1038/s41366-026-02229-6","42806056",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0004464","Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes.","Sarwal A","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16642","40735916","PMC12409243",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004465","[Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea].","Wang LX","2025","Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","narrative_review","article","10.3760/cma.j.cn112147-20250718-00418","41218868",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0004466","Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials.","Zhang Y","2025","Bone","systematic_review","article","10.1016/j.bone.2024.117338","39603373",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; Research Support, Non-U.S. Gov't; review"],["R0004467","A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists.","Yacawych WT","2026","The Journal of clinical investigation","other","article","10.1172/jci193743","42742987",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004468","Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.","Rochoń J","2024","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v30.i23.2964","38946874","PMC11212696",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004469","Peptide mapping analysis of synthetic semaglutide and liraglutide for generic development of drugs originating from recombinant DNA technology.","Kim SH","2025","Journal of pharmaceutical and biomedical analysis","other","article","10.1016/j.jpba.2025.116682","39847923",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004470","Cardiovascular Outcomes of Tirzepatide vs Semaglutide in Obesity Without Type 2 Diabetes: A Matched Cohort Study","Chen S","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-9855917/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0004471","Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.","Xie W","2024","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2024.108743","38688179",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0004472","Glucagon-like peptide-1 receptor (GLP-1R) agonists prevent tributyltin-induced muscle atrophy/wasting via restoring GLP-1R signaling in vitro and in mice.","Yang RS","2026","Ecotoxicology and environmental safety","preclinical","article","10.1016/j.ecoenv.2025.119523","41352264",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004473","Diabetes Mellitus in Kidney Transplant Recipients and New Hypoglycemic Agent Options.","Bartoli G","2025","International journal of molecular sciences","other_trial","article","10.3390/ijms26135952","40649730","PMC12250267",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0004474","Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Orthopedic Shoulder Surgery: A Comparative Analysis.","Mahatme RJ","2026","Cureus","nonrandomized_study","article","10.7759/cureus.110874","42460175","PMC13370761",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004475","Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study.","Nicolau J","2026","Clinical and experimental dermatology","nonrandomized_study","article","10.1093/ced/llaf473","41137591",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004476","Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched control study.","Vlaeminck N","2026","Anaesthesia","nonrandomized_study","article","10.1111/anae.70129","41631344",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0004477","Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases.","Pugliese N","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","narrative_review","article","10.1016/j.cgh.2025.10.018","41284511",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004478","Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists.","Lai HW","2024","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-024-02364-2","39080745","PMC11287940",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Comparative Study; Multicenter Study; research-article; other; article"],["R0004479","Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity.","Klein MP","2025","Journal of diabetes science and technology","nonrandomized_study","article","10.1177/19322968241245680","38629877","PMC11571401",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; meeting-report; other; article"],["R0004480","Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials.","Giorgino F","2024","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2024.111604","38447911",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0004481","Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis.","Abbas N","2026","Journal of clinical psychopharmacology","systematic_review","article","10.1097/jcp.0000000000002234","42503999",null,"PROSPERO:CRD420251248437",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0004482","Predictors of Use of Individual Insulin and GLP-1 RA Products Versus Fixed Ratio Insulin/GLP-1 RA Combinations in Medicare Beneficiaries.","Jeter AF","2025","The Senior care pharmacist","nonrandomized_study","article","10.4140/tcp.n.2025.97","39891325",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0004483","Comparison of the Effects of SGLT-2i Versus GLP-1RA on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes, Based on Baseline Renal Function.","Wang Y","2025","Diabetes","systematic_review","article","10.2337/db24-0688","39932725",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Comparative Study; Systematic Review; Network Meta-Analysis; other; article"],["R0004484","Comparative Weight-Loss Outcomes Following Initiation of GLP-1 Receptor Agonists versus SGLT2 Inhibitors: A Real-World Active Comparator Study.","Milanov V","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.09.013","42810620",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004485","Acute Kidney and Liver Injury Associated With Low-Dose Liraglutide in an Obese Adolescent Patient.","Komargodski R","2024","Pediatrics","case_report","article","10.1542/peds.2023-063719","38864114",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0004486","Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies.","Ahmad A","2024","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-024-02192-4","38500154","PMC10949729",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0004487","Semaglutide alleviates age-related dry eye disease by restoring lacrimal gland structure and function.","Zuo X","2026","Free radical biology & medicine","preclinical","article","10.1016/j.freeradbiomed.2026.03.019","41812831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004488","Frailty-stratified effectiveness of SGLT2 inhibitors versus DPP-4 inhibitors and GLP-1 receptor agonists on pulmonary outcomes in type 2 diabetes: a nationwide cohort study.","Meng LC","2025","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2025.103332","40686688","PMC12270711",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004489","Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.","Harrison SA","2025","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","randomized_trial","article","10.1016/j.cgh.2024.02.022","38447814",null,"ClinicalTrials.gov:NCT05039450","S002626","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0004490","GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.","Chen TH","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.30952","40920377","PMC12418133",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004491","Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.","Liu L","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.1043789","36568085","PMC9770009",null,"S000313; S002529","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004492","Evaluation of bone health and fracture risk in type 2 diabetes: a network meta-analysis of anti-diabetic treatments versus placebo.","Oh S","2025","Archives of pharmacal research","systematic_review","article","10.1007/s12272-025-01552-2","40542285","PMC12241289","PROSPERO:CRD42024538789",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; review"],["R0004493","Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review.","Wen J","2025","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2025.104213","40685266",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004494","Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis.","Chu J","2025","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2025.103464","40926900","PMC12414836","PROSPERO:CRD42024600250",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004495","Pharmacotherapy for Obstructive Sleep Apnea: From Pathophysiology to Emerging Treatments.","Zhou R","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15166473","42652875","PMC13513462",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0004496","Multimodal Strategies for Obesity Management: Integration and Combination of GLP-1/GIP Therapies, Bariatric Endoscopy, and Metabolic Surgery: A Scoping Review","Rodríguez-Velásquez F","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202607.2380.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0004497","GLP-1RAs attenuated obesity and reversed leptin resistance partly via activating the microbiome-derived inosine/A2A pathway.","Dong C","2025","Acta pharmaceutica Sinica. B","preclinical","article","10.1016/j.apsb.2024.12.006","40177547","PMC11959926",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004498","HIF-1α exerts a double-edged sword regulatory role in hippocampal neuronal PANoptosis of Alzheimer's disease through HK2/VDAC1/NLRP3 axis and RIPK3 signal","Chao YL","2025","Research Square","other_trial","preprint","10.21203/rs.3.rs-7239681/v1",null,null,null,null,"europepmc","FALSE","open_pdf","5",null,"Preprint"],["R0004499","Unexpected Residual Gastric Contents in a Patient After Holding Semaglutide After Standard Fasting Guidelines: A Case Report.","Ando K","2026","A&A practice","case_report","article","10.1213/xaa.0000000000002161","41705849",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0004500","A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.","Grennan KN","2026","AACE endocrinology and diabetes","case_report","article","10.1016/j.aed.2025.12.002","41938282","PMC13043482",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004501","Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL.","Kittipibul V","2026","American heart journal","randomized_trial","article","10.1016/j.ahj.2026.107475","42102896",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0004502","Swiss obesity clinical practice guidance.","Gerber PA","2026","Swiss medical weekly","other","article","10.57187/5415","42312974",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0004503","Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.","Chuang MH","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.27258","39133485","PMC11320168",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004504","GLP-1 receptor agonists and acute diabetes complications in adults with type 1 diabetes.","Dai H","2026","iScience","nonrandomized_study","article","10.1016/j.isci.2026.115700","42080136","PMC13133957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004505","Evaluating biased agonism of glucagon-like peptide-1 (GLP-1) receptors to improve cellular bioenergetics: A systematic review.","Wong S","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16660","40726453","PMC12515783",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0004506","Glucagon-like peptide-1 receptor agonist use is associated with increased risk of perioperative complication and readmission following shoulder arthroplasty.","Lawand JJ","2025","Journal of shoulder and elbow surgery","nonrandomized_study","article","10.1016/j.jse.2024.09.012","39528042",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004507","The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents.","Malas K","2025","Expert opinion on pharmacotherapy","randomized_trial","article","10.1080/14656566.2025.2504702","40340589",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0004508","Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study.","Wood M","2024","Journal of pharmacy practice","nonrandomized_study","article","10.1177/08971900241253661","38720191",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004509","Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i.","Simanenkova A","2024","Frontiers in bioscience (Landmark edition)","preclinical","article","10.31083/j.fbl2907265","39082364",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004510","The effect of Semaglutide on mitochondrial function and insulin sensitivity in a myotube model of insulin resistance.","Spry ER","2025","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2025.112629","40752656",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004511","Correction to \"Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes\".",null,"2023","JCEM case reports","notice","article","10.1210/jcemcr/luac027","37908271","PMC10578375",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; Journal Article; correction; erratum"],["R0004512","Short-Term Associations Between Fat-Free Mass Preservation and Glycaemic Markers During Tirzepatide Therapy: A Secondary Exploratory Analysis.","Schiavo L","2026","Nutrients","randomized_trial","article","10.3390/nu18071092","41978142","PMC13074557",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004513","The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension.","Lee HY","2024","Clinical hypertension","narrative_review","article","10.1186/s40885-024-00279-4","39217384","PMC11366170",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004514","Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial.","Lam CSP","2025","Obesity (Silver Spring, Md.)","protocol","article","10.1002/oby.24332","40545827",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Clinical Trial Protocol; article"],["R0004515","Does Preoperative GLP-1 Therapy Improve Postoperative Bariatric Surgery Outcomes? A Single-Centre Retrospective Observational Study.","Mushtaq M","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08525-4","41686318",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0004516","Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management.","Riccioni G","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms27010354","41516231","PMC12785618",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004517","Sociodemographic Disparities in Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Prescription Patterns Among Patients With Poorly Controlled Diabetes.","Antwi-Amoabeng D","2024","Cureus","nonrandomized_study","article","10.7759/cureus.56845","38659524","PMC11039430",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004518","Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning.","Moon S","2026","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19060953","42356570","PMC13304840",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0004519","New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States.","Bozick R","2025","Rand health quarterly","other","article","10.7249/rhq-13-01-03","41415116","PMC12711338",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004520","GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach.","Arillotta D","2023","Brain sciences","other","article","10.3390/brainsci13111503","38002464","PMC10669484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004521","Case report: GLP1RA for the treatment of diabetes in liver transplanted people. Do they increase the risk of pancreatitis?","Grancini V","2024","Frontiers in endocrinology","case_report","article","10.3389/fendo.2024.1392371","38779453","PMC11109377",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004522","Aspiration under anesthesia: what happens after we sound the glucagon-like peptide-1 receptor agonist alarm?","Bartoszko J","2024","Canadian journal of anaesthesia = Journal canadien d'anesthesie","commentary","article","10.1007/s12630-024-02809-y","39187640",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0004523","Diabetes in Older Adults","Mitchell LM","2023","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)","narrative_review","article",null,"42160656",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0004524","An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation.","Standen EC","2026","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-026-02061-y","41933207","PMC13391369",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0004525","Linking pediatric obesity to youth-onset type 2 diabetes: integrated longitudinal and cross-sectional evidence from population-based studies worldwide.","Soliman AT","2026","Clinical and experimental pediatrics","nonrandomized_study","article","10.3345/cep.2026.01228","42503624","PMC13434514",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; review-article; article"],["R0004526","Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits.","Dixon DL","2025","Mayo Clinic proceedings","other","article","10.1016/j.mayocp.2024.08.026","40057872","PMC13094883",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004527","Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.","Mattingly TJ","2026","Health affairs scholar","nonrandomized_study","article","10.1093/haschl/qxag023","41737498","PMC12927500",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004528","GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells.","Sun H","2024","Immunology","preclinical","article","10.1111/imm.13784","38544428",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004529","Reprogramming immunity at the metabolic-epidermal interface in obesity-associated psoriasis.","Jang J","2026","Cytokine & growth factor reviews","narrative_review","article","10.1016/j.cytogfr.2026.01.003","41534195",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0004530","Targeting ER Stress of GLP-1 Receptor Agonist in Diabetic Retinopathy.","Huang H","2026","Biochemical pharmacology","narrative_review","article","10.1016/j.bcp.2025.117623","41380802",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0004531","Mitigating heart failure risk in patients with diabetes and chronic kidney disease.","Kowalczyk NS","2025","Current opinion in cardiology","randomized_trial","article","10.1097/hco.0000000000001208","39998480","PMC13528586",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0004532","Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies.","Scheen AJ","2025","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2024.101594","39608670",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0004533","Activin Actions in Adipocytes.","Ongaro L","2025","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgaf233","40208114","PMC12192441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004534","Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Qazi S","2026","Healthcare (Basel, Switzerland)","systematic_review","article","10.3390/healthcare14070850","41975852","PMC13073533","PROSPERO:CRD420251276594",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004535","Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes-So Why Is Their Uptake So Low?","King A","2023","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd22-0027","37092151","PMC10115618",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004536","Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes.","Forst T","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16247","39931897",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004537","Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.","Webb J","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14580","34668637","PMC9299650",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004538","The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.","Richardson KM","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16395","40259488","PMC12146451",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0004539","Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists.","Feng J","2025","Journal of translational internal medicine","other","article","10.1515/jtim-2025-0026","40896289","PMC12392083",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004540","A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.","Ono R","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14928","36433713","PMC10107991",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004541","Possible Attenuation of Early Weight Loss During Tirzepatide Therapy in a Patient Treated With Levosulpiride: A Case Report and Mechanistic Hypothesis.","Carducci A","2026","Cureus","case_report","article","10.7759/cureus.111508","42502530","PMC13401505",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004542","Obesity in Adults with Type 1 Diabetes Mellitus.","Batman A","2026","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes26001","42421260","PMC13429850",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004543","Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review).","Tilinca MC","2021","Experimental and therapeutic medicine","narrative_review","article","10.3892/etm.2021.10601","34504612","PMC8394024",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004544","Efficacy and Safety of Oral Antidiabetic Drugs in People with Diabetes and Chronic Kidney Disease: A Systematic Review.","Borooghani H","2025","Iranian journal of kidney diseases","systematic_review","article","10.61882/zwq4sh57","42234904",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0004545","Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis.","Kamrul-Hasan ABM","2025","World journal of diabetes","systematic_review","article","10.4239/wjd.v16.i4.101731","40236848","PMC11947928",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004546","Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo.","Bharaj IS","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13092192","41007755","PMC12467412",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0004547","Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic Perspectives.","Yanai H","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27062757","41898617","PMC13026646",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004548","Hemorrhoid risk among people with diabetes mellitus using glucose lowering agents.","Hu WS","2025","Naunyn-Schmiedeberg's archives of pharmacology","other","article","10.1007/s00210-025-04272-y","40504374",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0004549","Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.","Heerspink HJL","2026","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.0000001051","42308057","PMC13379112","ClinicalTrials.gov:NCT04889183","S002054","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0004550","Effects of antidiabetic medications on the relationship between type 2 diabetes mellitus and cognitive impairment.","Cozza A","2025","Ageing research reviews","narrative_review","article","10.1016/j.arr.2025.102834","40659290",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004551","Therapeutic approaches in the management of chronic kidney disease: the past, the present, and the future.","Doumani G","2025","Minerva medica","narrative_review","article","10.23736/s0026-4806.25.09747-2","41051293",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004552","Association Between GLP1 RAs Use and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis.","Bushi G","2025","Health science reports","systematic_review","article","10.1002/hsr2.70490","39980820","PMC11839483",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004553","Implications of GLP-1 Receptor Agonist on Thyroid Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality and TSH Levels.","Capuccio S","2024","Biomolecules","narrative_review","article","10.3390/biom14060687","38927090","PMC11202033",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004554","Modulation of metabolic syndrome components by oral semaglutide in hypothyroid-T2DM patients: a retrospective analysis.","Tilici DM","2025","Journal of medicine and life","nonrandomized_study","article","10.25122/jml-2025-0144","41635458","PMC12863099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004555","Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study.","Lin DS","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15788","39030922",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0004556","Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.","Kawaguchi Y","2024","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.14151","38258482","PMC11060164",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; research-article; article"],["R0004557","Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes.","Wang G","2025","Saudi medical journal","narrative_review","article","10.15537/smj.2025.46.3.20240920","40096971","PMC11918663",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004558","Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis.","Jarso G","2026","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/ijem.ijem_1085_25","42238558","PMC13229245",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004559","Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose-escalation phase 1 study.","Wang Q","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16452","40470753",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; article"],["R0004560","Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson's disease.","Yu HY","2023","Neural regeneration research","preclinical","article","10.4103/1673-5374.360242","36751811","PMC10154509",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004561","Across Clinical Profiles of Cardiorenal-Metabolic (CKM) Syndrome: A Phenotype-Driven Therapeutic Approach.","Carlino I","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14061289","42351717","PMC13296698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004562","Synergistic Effect of Liraglutide and Strength-Endurance Exercise Training on Hepatic Oxidative Stress and Lipid Metabolism in Middle-Aged Male Rats.","Vlahović D","2025","Antioxidants (Basel, Switzerland)","preclinical","article","10.3390/antiox14121492","41462691","PMC12730097",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004563","GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk.","Jebeile H","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","nonrandomized_study","article","10.1111/obr.70049","41340366",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0004564","Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management.","Wojtara M","2023","Advances in medicine","narrative_review","article","10.1155/2023/9946924","37771634","PMC10533252",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004565","Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.","Henney AE","2025","Annals of the American Thoracic Society","randomized_trial","article","10.1513/annalsats.202409-923oc","40590655",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comparative Study; article"],["R0004566","Comprehensive obesity care: Leveraging lifestyle modifications, obesity medications, and bariatric procedures to improve clinical and nutrition outcomes.","Ezenekwe L","2026","Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition","narrative_review","article","10.1002/ncp.70074","41351318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004567","Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.","Horii T","2024","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14265","39243175","PMC11527826",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; brief-report; article"],["R0004568","Diabetic Kidney Disease in Type 2 Diabetes: A Comprehensive Review of Epidemiology, Pathophysiology, and Therapeutic Advances.","Uma A","2025","Journal of pharmacy & bioallied sciences","narrative_review","article","10.4103/jpbs.jpbs_1059_25","40860001","PMC12373389",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004569","Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials.","Kreiner FF","2023","Aging cell","commentary","article","10.1111/acel.13818","37191234","PMC10186594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0004570","Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.","Layton JB","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01750-7","40465145","PMC12317948",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004571","Epicardial Adipose Tissue as a Cardiometabolic Target in Atrial Fibrillation: Implications for Ablation Strategies and Emerging Metabolic Therapies.","Cacciapuoti F","2026","Medical sciences (Basel, Switzerland)","nonrandomized_study","article","10.3390/medsci14010127","41892842","PMC13027828",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0004572","Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program.","Makam AN","2025","Annals of internal medicine","other","article","10.7326/annals-24-01449","40258281",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004573","Semaglutide Use Is Associated With Decreased Length of Stay and Hospital Costs in Patients Undergoing Anterior Lumbar Interbody Fusion: A Retrospective Cohort Study.","Ng MK","2026","Orthopedics","nonrandomized_study","article","10.3928/01477447-20251219-01","41636429",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004574","Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.","Thomas TS","2024","Topics in antiviral medicine","narrative_review","article",null,"39765237","PMC11737811",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0004575","The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review.","Dinkov B","2026","Biomedicines","other_trial","article","10.3390/biomedicines14040806","42072347","PMC13113392",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; review"],["R0004576","Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists.","Wu Q","2022","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2022.113517","36076602",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004577","Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction.","Wang TY","2025","Heart failure reviews","other_trial","article","10.1007/s10741-024-10438-2","39269643",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0004578","Semaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta‑analysis.","Xia L","2025","Biomedical reports","systematic_review","article","10.3892/br.2024.1913","39781043","PMC11704830",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004579","Extensive Deep Vein Thrombosis in a Young Man Taking Tirzepatide for Weight Loss.","Farooqi MF","2024","AACE clinical case reports","case_report","article","10.1016/j.aace.2024.08.011","39734498","PMC11680757",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004580","Glucagon-like peptide-1 receptor agonists in the perioperative period: to cease or not to cease?","Martis WR","2024","ANZ journal of surgery","other","article","10.1111/ans.18804","38012089",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004581","Systemic inflammation from the brain.","Foley JF","2024","Science signaling","commentary","article","10.1126/scisignal.adn9627","38227685",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0004582","A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency.","Wang X","2024","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2024.117761","38795571",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004583","GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report.","Crowley F","2024","Frontiers in oncology","case_report","article","10.3389/fonc.2024.1392375","38699640","PMC11063291",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004584","A melanocortin 4- and glucagon-like peptide 1 receptor multiple agonist for the treatment of diabetes and obesity.","Ashlaw EF","2026","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2025.156414","41093057","PMC13286047",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0004585","Discovery of Small-Molecule GLP‑1 Receptor Agonists with Improved Oral Pharmacokinetics Based on Orforglipron.","Li M","2026","ACS medicinal chemistry letters","preclinical","article","10.1021/acsmedchemlett.6c00077","42305200","PMC13266644",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004586","Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis.","Lin S","2026","Andrology","nonrandomized_study","article","10.1111/andr.70222","41883294","PMC13432634",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004587","Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.","Quagliariello V","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms252011299","39457081","PMC11508560",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004588","Anesthetic Considerations in Adult Patients on Glucagon-Like Peptide-1 Receptor Agonists: Gastrointestinal Focus.","Joshi GP","2024","Anesthesia and analgesia","other","article","10.1213/ane.0000000000006810","37874648",null,null,"S002511","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0004589","Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.","Hu S","2026","Clinical journal of the American Society of Nephrology : CJASN","other_trial","article","10.2215/cjn.0000001053","41805697",null,"ClinicalTrials.gov:NCT05570305; ClinicalTrials.gov:NCT06150924; ClinicalTrials.gov:NCT00287183; ClinicalTrials.gov:NCT02010242; ClinicalTrials.gov:NCT00044421; ClinicalTrials.gov:NCT03926117; ClinicalTrials.gov:NCT01683409; ClinicalTrials.gov:NCT05314231; ClinicalTrials.gov:NCT00913393",null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0004590","Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.","Yeh JG","2024","Hepatology (Baltimore, Md.)","randomized_trial","article","10.1097/hep.0000000000000768","38345826",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; article"],["R0004591","Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data.","Henney AE","2024","Thorax","randomized_trial","article","10.1136/thorax-2024-221906","39645259","PMC11671942",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; research-article; article"],["R0004592","Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.","Hurtado I","2024","Diabetologia","nonrandomized_study","article","10.1007/s00125-024-06243-z","39103719","PMC11519213",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004593","Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.","Tartaglia E","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02986-0","41257737","PMC12628983",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; other; article"],["R0004594","Comparison chart: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.",null,"2025","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2025.1742c","41259102",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004595","Outcomes of Body Contouring Surgery After Bariatric Surgery vs. GLP-1 Receptor Agonist-Induced Weight Loss: A Propensity Score Matched Analysis.","Smith JE","2026","Aesthetic plastic surgery","nonrandomized_study","article","10.1007/s00266-026-05861-9","41991800",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0004596","Trust the Gold Standard: All Glucagon-like Peptide-1 Receptor Agonists Can Delay Gastric Emptying.","Weber MM","2024","Anesthesiology","other","article","10.1097/aln.0000000000004752","37934577",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004597","Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline.","Qi L","2025","Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","preclinical","article","10.1016/j.neurot.2025.e00615","40413074","PMC12491809",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004598","Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications.","Cherney DZI","2026","Mayo Clinic proceedings","randomized_trial","article","10.1016/j.mayocp.2026.01.010","42017862",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0004599","The dual incretin agonist tirzepatide blunts nicotine-induced behaviours and neurochemistry in male mice.","Edvardsson CE","2026","British journal of pharmacology","preclinical","article","10.1111/bph.70678","42805610",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004600","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Metabolism in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Li X","2024","International journal of endocrinology","systematic_review","article","10.1155/2024/1785321","39309475","PMC11416174","PROSPERO:CRD42023418166",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004601","Presentation of Acute Pancreatitis After Initiation of Phentermine/Topiramate for Weight Loss: An Adverse Drug Event Case Report.","Balli M","2026","Journal of pharmacy practice","case_report","article","10.1177/08971900261416787","41557742",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0004602","Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.","Lam CSP","2022","Circulation","randomized_trial","article","10.1161/circulationaha.121.057934","34775781",null,"ClinicalTrials.gov:NCT03496298","S000755","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0004603","Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams.","Alexopoulos AS","2026","Diabetes care","narrative_review","article","10.2337/dci26-0019","42008105",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004604","The hidden link between diabetes and dementia: Findings from recent epidemiological studies.","Tseng CH","2026","Biomedical journal","nonrandomized_study","article","10.1016/j.bj.2026.100985","42019901","PMC13452960",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004605","Effects of pharmacological blood pressure lowering in heart failure with mildly reduced or preserved ejection fraction: a meta-analysis.","Pack SJJ","2026","Heart (British Cardiac Society)","systematic_review","article","10.1136/heartjnl-2026-327872","42571647",null,"PROSPERO:CRD42025631539",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0004606","Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article.","Ghazanfar H","2021","Cureus","narrative_review","article","10.7759/cureus.15141","34164242","PMC8214471",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004607","The estrous cycle moderates the food and body weight suppressive effects of glucagon-like peptide-1 receptor agonism.","Applebey SV","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70177","41017581","PMC12673426",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0004608","Glucagon-Like Peptide-1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices.","Elad B","2025","Artificial organs","nonrandomized_study","article","10.1111/aor.14942","39835590",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004609","[A meta-analysis of efficacy and safety of anti-obesity medications in the treatment of childhood obesity].","Zhou XL","2025","Zhonghua yi xue za zhi","systematic_review","article","10.3760/cma.j.cn112137-20250416-00945","41218895",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; English Abstract; review"],["R0004610","Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes.","Tong Y","2023","Frontiers in pharmacology","other_trial","article","10.3389/fphar.2023.1176206","37089939","PMC10115949","ChiCTR:ChiCTR2200056148",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0004611","Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE).","Ng CD","2025","Advances in therapy","nonrandomized_study","article","10.1007/s12325-025-03340-2","40875186","PMC12579654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004612","Absolute Benefits From Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.","Bancks MP","2023","Diabetes care","commentary","article","10.2337/dci23-0023","37220264","PMC10234736",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment; article-commentary; article"],["R0004613","Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity.","Maynard S","2026","The International journal of eating disorders","nonrandomized_study","article","10.1002/eat.24575","41139846",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0004614","Current Status of Delay in Injectable Therapy among Type 2 Diabetes Mellitus Patients in South Korea: Multicenter Retrospective Study (2015-2021).","Choi JH","2025","Endocrinology and metabolism (Seoul, Korea)","nonrandomized_study","article","10.3803/enm.2024.2280","40437795","PMC12602008",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0004615","Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials.","Figlioli G","2024","Pharmacological research","systematic_review","article","10.1016/j.phrs.2024.107401","39251099",null,"PROSPERO:CRD42023476762",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0004616","Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.","Nong K","2025","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj-2024-083039","40813122",null,"PROSPERO:CRD42022325948",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0004617","Glucagon-Like Peptide-1 (GLP-1) Agents and Cardiovascular Risk in Non-diabetic Patients: A Descriptive Analysis of National Health and Nutrition Examination Survey (NHANES), 2011-2018.","Disu F","2025","Cureus","nonrandomized_study","article","10.7759/cureus.94373","41230299","PMC12603435",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004618","Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.","Kuwata H","2021","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.13598","34022121","PMC8668059",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0004619","Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.","Hashmi TM","2025","Clinical and translational science","systematic_review","article","10.1111/cts.70127","39930946","PMC11811509",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Comparative Study; Research Support, Non-U.S. Gov't; review-article; article"],["R0004620","Automatic processing of gastrointestinal endoscopy referrals and patient instructions using large language models.","Gorelik Y","2026","BMC gastroenterology","other","article","10.1186/s12876-026-04636-5","41634585","PMC12958611",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004621","Renal Lipotoxicity: Mechanisms and Therapeutic Perspectives.","Zaitoon H","2026","Diabetes care","other","article","10.2337/dci26-0036","42201307",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0004622","Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis.","Potter KJ","2025","Journal of the Canadian Association of Gastroenterology","systematic_review","article","10.1093/jcag/gwae057","40224572","PMC11991874","PROSPERO:CRD42023472186",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004623","Exenatide administration time determines the effects on blood pressure dipping in db/db mice via modulation of food intake and sympathetic activity.","Chacon AN","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.07.02.601700","39005289","PMC11245019",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0004624","Therapeutic Advances in Diabetic Kidney Disease: 30 Years of Evidence and the Rise of the \"Fantastic Four\" in Nephrology.","Husain-Syed F","2026","Cardiorenal medicine","other_trial","article","10.1159/000550423","41528949","PMC12923249",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0004625","Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes.","Havranek B","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-89408-z","39930071","PMC11811119",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004626","Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence.","Rasalam R","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14953","36541153",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0004627","From Gut to Metabolism: Exploring the Intersection of Inflammatory Bowel Disease and Systemic Metabolic Dysfunction.","Tariq R","2026","Journal of clinical gastroenterology","narrative_review","article","10.1097/mcg.0000000000002359","41805835",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004628","Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With T2DM and ASCVD in South Korea.","Eom YR","2025","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.70183","40589143","PMC12209748",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004629","Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review.","Wang Y","2024","Endocrine journal","systematic_review","article","10.1507/endocrj.ej23-0384","38644220",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Journal Article; review"],["R0004630","Effectiveness and care continuity in an app-based, glucagon-like peptide-1 receptor agonist-supported weight-loss service for women with overweight and obesity in the UK: A real-world retrospective cohort analysis.","Talay L","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15607","38623616",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0004631","Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty?","Katzman J","2026","Archives of orthopaedic and trauma surgery","nonrandomized_study","article","10.1007/s00402-025-06167-2","41718773",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0004632","Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review.","Prentza V","2024","Journal of clinical medicine","systematic_review","article","10.3390/jcm13195786","39407846","PMC11476433",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004633","Diabetic kidney disease macrophage cholesterol efflux: a revolution from metabolism to immune.","Wang J","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1714167","41282283","PMC12629929",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004634","Efficacy and Safety of Semaglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Bacha Z","2025","Cardiology in review","systematic_review","article","10.1097/crd.0000000000001057","40968407",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0004635","GLP-1 receptor agonist exendin-4 suppresses food intake by inhibiting hindbrain orexigenic NPY neurons.","Shen J","2025","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00528.2024","40126941",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004636","Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.","Tinsley GM","2025","SAGE open medical case reports","case_report","article","10.1177/2050313x251388724","41122508","PMC12536186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; preprint; article"],["R0004637","Newer Outpatient Diabetes Therapies and Technologies.","Kamal N","2024","The Medical clinics of North America","narrative_review","article","10.1016/j.mcna.2024.03.002","39084842",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004638","Therapeutic potential of GLP-1RAs in sleep apnea with genetic associations to type 2 diabetes.","Cheng F","2025","Diabetology & metabolic syndrome","other","article","10.1186/s13098-025-01699-4","40296043","PMC12036185",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004639","Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity.","Hwang JH","2025","JAMA health forum","nonrandomized_study","article","10.1001/jamahealthforum.2025.0905","40279111","PMC12032556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004640","Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis.","Pierret ACS","2025","JAMA psychiatry","systematic_review","article","10.1001/jamapsychiatry.2025.0679","40366681","PMC12079569",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review; article"],["R0004641","Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study.","Krishnan A","2024","Journal of clinical & translational endocrinology","nonrandomized_study","article","10.1016/j.jcte.2024.100370","39386155","PMC11460491",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004642","Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation.","Malik F","2026","European heart journal. Cardiovascular pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvag044","42334436","PMC13588637",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004643","Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis.","Makunts T","2024","JMIRx med","nonrandomized_study","article","10.2196/55976","38738836","PMC11090023",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004644","Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets.","Song S","2025","Brain and behavior","preclinical","article","10.1002/brb3.71074","41251049","PMC12623454",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004645","Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes.","Guo X","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15043","36864658",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004646","Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a Department of Veterans Affairs quality improvement intervention.","Yun S","2025","BMC primary care","other","article","10.1186/s12875-025-02709-0","40119283","PMC11927310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0004647","Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes.","Luo Y","2026","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2026.113474","42543082",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004648","The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System.","Zhou J","2025","British journal of clinical pharmacology","nonrandomized_study","article","10.1111/bcp.16354","39658840",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004649","The effects of glucagon-like peptide-1 receptor agonists on adipose tissues in patients with type 2 diabetes: A meta-analysis of randomised controlled trials.","Liu F","2022","PloS one","systematic_review","article","10.1371/journal.pone.0270899","35797355","PMC9262225",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0004650","Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Eisa N","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70666","41877354",null,null,"S002095; S002747","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Comparative Study; review"],["R0004651","The change in Fibrosis-4 index in Japanese patients with type 2 diabetes treated by a fixed-ratio combination therapy of insulin degludec and liraglutide: A retrospective observational study.","Ito H","2024","Hepatology research : the official journal of the Japan Society of Hepatology","nonrandomized_study","article","10.1111/hepr.14002","38141029",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004652","Adherence and Effectiveness of Liraglutide in Adolescents with Obesity.","Yaron S","2025","Childhood obesity (Print)","randomized_trial","article","10.1177/21532176251385715","41047941",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0004653","Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group.","Janez A","2022","International journal of cardiology","other","article","10.1016/j.ijcard.2022.07.017","35905827",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004654","Gallstone Occurrence Versus Clinically Significant Biliary Disease With GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Propensity-Matched Cohort Study With Phenotype and Quantitative-Bias Analysis","Onwuzo C","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-10321029/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0004655","Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.","Goldenberg RM","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","other_trial","article","10.1111/obr.13663","37968541",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0004656","The correlation between novel antidiabetic agents utilization and hepatocellular carcinoma incidence in type 2 diabetes patients: a network meta-analysis.","Lin J","2025","European journal of clinical pharmacology","systematic_review","article","10.1007/s00228-025-03899-3","40788386",null,"PROSPERO:CRD420251068833",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis; Systematic Review"],["R0004657","Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA.","King A","2024","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2024-004431","39366717","PMC11459310",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0004658","Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.","Okuma H","2025","Cureus","nonrandomized_study","article","10.7759/cureus.83712","40486301","PMC12145500",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004659","Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.","Chen SD","2023","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2022.175439","36470445",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004660","Glucagon like peptide-1 receptor agonists in type 1 diabetes.","Deng C","2023","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2023.101487","37884124",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0004661","Preventing Cardiovascular-Kidney-Metabolic Syndrome Progression: Pharmacologic Approaches and Pharmacists' Contributions.","Nguyen T","2026","Cardiorenal medicine","narrative_review","article","10.1159/000552517","42118699","PMC13368018",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004662","\"Next-in-class\" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024).","Tolkacheva EV","2025","Current medicinal chemistry","nonrandomized_study","article","10.2174/0109298673366258250710101146","40873282",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004663","Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.","Alkabbani W","2024","BMJ (Clinical research ed.)","randomized_trial","article","10.1136/bmj-2024-080340","39438043","PMC11494456",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004664","Letter to Editor From Banerjee et al: \"Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure\".","Banerjee M","2024","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/clinem/dgad506","37623277",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Comment; Letter; article"],["R0004665","Utilization patterns of glucagon like Peptide-1 receptor agonists prior to bariatric and metabolic surgery: a multicenter study.","Rayman S","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2024.09.010","39516068",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0004666","IMPACT OF GLP-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES MELLITUS ON THE DEVELOPMENT AND PROGRESSION OF AGE-RELATED MACULAR DEGENERATION.","McLaughlin SA","2025","Retina (Philadelphia, Pa.)","nonrandomized_study","article","10.1097/iae.0000000000004616","40712124",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0004667","Med14 phosphorylation shapes genomic response to GLP-1 Agonist.","Van de Velde S","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.06.17.660196","40667025","PMC12262311",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0004668","Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.","Dutta D","2024","Obesity surgery","systematic_review","article","10.1007/s11695-024-07175-8","38502519",null,"PROSPERO:CRD42023473991",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0004669","The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.","Liu Y","2023","The American journal of clinical nutrition","systematic_review","article","10.1016/j.ajcnut.2023.04.017","37661106",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0004670","iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China.","Yu M","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70192","41116700","PMC12590520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0004671","Glucagon-like peptide-1 and atrial fibrillation incidence: Associations independent of weight loss.","Palmisano T","2026","Heart rhythm","nonrandomized_study","article","10.1016/j.hrthm.2026.03.1940","42029362",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0004672","The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Lipid Profile of Diabetic Patients Using Statins: A Retrospective Cohort Study in the Diabetic Center of King Salman Bin Abdulaziz Hospital, Saudi Arabia.","Albahli OM","2024","Cureus","nonrandomized_study","article","10.7759/cureus.65521","39188504","PMC11346815",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004673","Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Patoulias D","2023","Biomedicines","systematic_review","article","10.3390/biomedicines11030669","36979648","PMC10045529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004674","Therapeutic potential of liraglutide in rheumatoid arthritis: Modulation of inflammation, apoptosis, and metabolic dysfunction in a rat model.","Nematalla HA","2026","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1016/j.jpet.2026.104310","41863197",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004675","Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management.","Chen D","2025","Journal of molecular and cellular cardiology","narrative_review","article","10.1016/j.yjmcc.2025.06.013","40623544",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004676","Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.","Dong S","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.1032199","36583004","PMC9792852",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004677","THU338 Risks Of Stroke, Its Subtypes And Atrial Fibrillation Associated With Glucagon-like Peptide 1 Receptor Agonists Versus Sodium-glucose Cotransporter 2 Inhibitors: A Real-world Population-based Study In Hong Kong",null,"2023","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC10555345",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0004678","Semaglutide and GLP-1 Agonists: Forensic and Medicolegal Implications.","Fagiola M","2025","The American journal of forensic medicine and pathology","narrative_review","article","10.1097/paf.0000000000001044","40261091",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004679","GLP Medications and Severe Post-COVID-19 Outcomes Among Individuals with Type 2 Diabetes Mellitus.","Butzin-Dozier Z","2026","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.64898/2026.07.03.26357246","42465874","PMC13370558",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0004680","Glucagon-like peptide-1 receptor agonists increase the risk of residual gastric content and pulmonary aspiration on upper endoscopy: A meta-analysis.","Tan Y","2025","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","systematic_review","article","10.1016/j.dld.2025.03.002","40133086",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0004681","Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice.","Lv F","2024","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph17121655","39770498","PMC11728704",null,"S000828","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0004682","Preventing Type 2 Diabetes in At-Risk Cardiorenal Populations.","de Silva D","2026","Cureus","nonrandomized_study","article","10.7759/cureus.113529","42662961","PMC13521482",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004683","Capturing the Additional Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists Beyond the Control of Traditional Risk Factors in People With Diabetes.","Niu S","2025","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2025.01.015","39922304","PMC12147311",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0004684","Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists.","Sawami K","2022","Cardiovascular diabetology","commentary","article","10.1186/s12933-022-01611-8","36068534","PMC9450447",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0004685","Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study.","Pascu BM","2026","Metabolites","nonrandomized_study","article","10.3390/metabo16070460","42506413","PMC13414465",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; research-article; article; preprint"],["R0004686","Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis.","Pan XH","2024","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.24002","38413012",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; Review; article"],["R0004687","New Therapies for the Management of Chronic Kidney Disease.","Treihaft AM","2025","Cureus","narrative_review","article","10.7759/cureus.81824","40337581","PMC12057290",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004688","Association of GLP1-Receptor Agonists With Diabetic Retinopathy.","Gonzalez A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71267","42660856",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004689","Comparative Effectiveness of Combination Therapy in Patients with Chronic Kidney Disease and Diabetes mellitus Type 2 using Real World Data.","Casper J","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","nonrandomized_study","article","10.1093/ndt/gfag198","42658186",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004690","Glucagon-like peptide receptor agonists and risk for depression.","Tagliapietra GA","2024","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2024.05.005","38852027",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S."],["R0004691","Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a real-world pharmacovigilance study of post-marketing surveillance data","Cao M","2022","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-2020035/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0004692","Obesity and Chronic Kidney Disease: The Dual Epidemic in Cardiovascular Health.","Grant CH","2025","European cardiology","narrative_review","article","10.15420/ecr.2025.33","41210917","PMC12590400",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004693","Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.","Mousavi A","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-01635-6","39994802","PMC11849334",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004694","Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors: Agent Comparison With Implications for Clinical Practice and Trial Design.","Ferreira JP","2026","Journal of cardiac failure","other_trial","article","10.1016/j.cardfail.2025.05.002","40389106",null,null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Comparative Study; Review"],["R0004695","Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists.","Raven LM","2024","The Medical journal of Australia","randomized_trial","article","10.5694/mja2.52170","38009941",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004696","A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients.","Carlucci PM","2025","Rheumatology (Oxford, England)","nonrandomized_study","article","10.1093/rheumatology/keae547","39388251","PMC12048073",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; brief-report; article"],["R0004697","Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.","da Silva AMP","2026","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2026.109306","41825212",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comparative Study; article"],["R0004698","Metformin and Tirzepatide in Lipedema: Targeting Fibrosis and Inflammation Through Complementary Pathways. A Mechanistic, Translational and Therapeutic Perspective","Fernandes Lima M","2026","Preprints.org","other","preprint","10.20944/preprints202604.1715.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004699","Response to Letter to Editor From Banerjee et al: \"Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure\".","Ferreira JP","2024","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgad507","37623824",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Comment; Letter; article"],["R0004700","Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.","Gajos G","2025","Polish archives of internal medicine","other_trial","article","10.20452/pamw.16983","40126003",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0004701","The Potential Indirect Impact of GLP-1 Receptor Agonists in the Management of Fibromyalgia.","Quodling N","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15093330","42123062","PMC13163736",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Preprint; review-article; article; preprint"],["R0004702","Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).","Gourdy P","2023","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-023-01798-4","37005640","PMC10067319",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0004703","Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.","De Block CEM","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14640","34984793",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0004704","Adult Overweight and Obesity Management: Updates From the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines.","Corrado RL","2026","Annals of internal medicine","other","article","10.7326/annals-26-00676","42636450",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0004705","Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.","Patoulias D","2023","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2023.108529","37301063",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0004706","Efficacy and Safety of Dulaglutide for Weight Reduction Among Diabetic Patients in Saudi Arabia: A Retrospective Cohort Study.","Alonazi GK","2025","Cureus","nonrandomized_study","article","10.7759/cureus.88424","40842739","PMC12366480",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004707","A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.","Richards R","2025","JMIR formative research","nonrandomized_study","article","10.2196/72577","40434299","PMC12260464",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004708","Superior cardiovascular protection with GLP-1 RAs over SGLT2 inhibitors in DM and HFpEF: A propensity score matching study.","Li AC","2025","PloS one","randomized_trial","article","10.1371/journal.pone.0326534","40570020","PMC12200838",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004709","Concurrent diabetes and heart failure: revisiting epidemiological and clinicopathological interplay.","Balagopalan JP","2026","Diabetology international","narrative_review","article","10.1007/s13340-025-00855-5","41476907","PMC12748482",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004710","Beyond Glycemic Control: GLP-1 Receptor Agonists and Their Impact on Calcium Homeostasis in Real-World Patients.","Alenezi BT","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13164896","39201039","PMC11355112",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004711","Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study.","Hirotsu T","2025","Frontiers in clinical diabetes and healthcare","randomized_trial","article","10.3389/fcdhc.2025.1520389","40196376","PMC11973326",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004712","Letter to the Editor: Endocrine determinants of diabetic ketoacidosis outcomes in type 2 diabetes and insights into Gymnema sylvestre actions.","Milionis C","2026","World journal of experimental medicine","commentary","article","10.5493/wjem.v16.i2.121192","42394775","PMC13323856",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0004713","Point-of-Care Gastric Ultrasound to Identify a Full Stomach on a Diabetic Patient Taking a Glucagon-Like Peptide 1 Receptor Agonist.","Girón-Arango L","2024","A&A practice","case_report","article","10.1213/xaa.0000000000001751","38305719",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0004714","A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes.","Selvarajan R","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s385196","37312901","PMC10259523",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004715","MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians.","Kumar A","2025","The Journal of the Association of Physicians of India","nonrandomized_study","article","10.59556/japi.73.1058","40836732",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0004716","DIVINE-pilot trial: a phase 2 multicentre, randomised pilot trial of pharmacotherapy and physical activity monitoring conducted in women with recent gestational diabetes and increased risk of type 2 diabetes recruited from tertiary referral hospitals in Australia.","Chen AX","2025","BMJ open","protocol","article","10.1136/bmjopen-2025-107551","41386999","PMC12706213","ANZCTR:ACTRN12624001253594",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0004717","Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weigh Gain After Primary Bariatric Surgery?","Rivero-Moreno Y","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08627-z","41906069",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0004718","A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.","Rahman E","2026","Aesthetic plastic surgery","randomized_trial","article","10.1007/s00266-026-05973-2","42310090",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0004719","Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials.","McManus KR","2026","Expert review of clinical pharmacology","nonrandomized_study","article","10.1080/17512433.2026.2625341","41611606","PMC13132032",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0004720","Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: Role of non-invasive diagnostics and early pharmacological intervention.","Ng NB","2026","World journal of hepatology","narrative_review","article","10.4254/wjh.v18.i1.111211","41640966","PMC12865443",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004721","[Type 2 diabetes in patients with coronary artery disease: from an overlooked diagnosis to treatments with new glucose-lowering drugs].","Guido V","2026","Giornale italiano di cardiologia (2006)","narrative_review","article","10.1714/4618.46269","41441832",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0004722","Weight to go!-Glucagon-like peptide 1 receptor agonists in liver transplant recipients.","Shenoy A","2024","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","commentary","article","10.1097/lvt.0000000000000291","37903064",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; article"],["R0004723","Preoperative GLP-1 Receptor Agonist Use and Weight Loss Outcomes Following Bariatric Surgery.","Holler E","2026","Annals of surgery","nonrandomized_study","article","10.1097/sla.0000000000007042","41772757",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004724","Statistical declarations versus scientific inferences and clinical judgments: the association of Glucagon-like peptide-1 receptor agonist use with the risk of biliary disease.","Most DE","2024","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2024.1367158","38390213","PMC10882269",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; discussion; article"],["R0004725","Perivascular adipose tissue in cardiovascular disease: From mechanisms to therapeutic targets.","Ueda K","2026","Journal of cardiology","narrative_review","article","10.1016/j.jjcc.2025.08.001","40789455",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0004726","[Research status of glucagon-like peptide-1 receptor agonists on obstructive sleep apnea].","Zhou BN","2024","Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","other","article","10.3760/cma.j.cn112147-20230913-00155","38448183",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0004727","A convergence of global epidemics: diabetes as a modulator of neurodegenerative and neuro-inflammatory disorders.","Leone L","2026","Frontiers in neurology","narrative_review","article","10.3389/fneur.2026.1824840","42394935","PMC13322903",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004728","Tirzepatide attenuates estrogen deficiency-induced metabolic dysfunction-associated steatotic liver disease progression by reducing steatosis, inflammation, and fibrosis in obese-diabetic mice.","Marcondes-de-Castro IA","2026","Menopause (New York, N.Y.)","preclinical","article","10.1097/gme.0000000000002683","41217893",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004729","Effects of Combination Treatment with Leptin and Liraglutide on Glucose Metabolism in Insulin-Dependent Diabetic Mice.","Fu L","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms26104595","40429740","PMC12111290",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004730","SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation.","Chan YH","2024","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgae157","38466894",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0004731","Cardiac MRI in diabetic cardiomyopathy: translating imaging biomarkers into clinical practice.","Huang S","2025","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-025-03019-6","41345656","PMC12781312",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004732","Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study.","Bezin J","2025","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2024.103029","39844933","PMC11751538",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004733","Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage.","DesRochers P","2025","Cureus","case_report","article","10.7759/cureus.97851","41458667","PMC12742330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004734","From progression to remission: a new paradigm for success in chronic kidney disease.","Tangri N","2026","Kidney international","nonrandomized_study","article","10.1016/j.kint.2025.10.004","41205673",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0004735","[Patient with type 2 diabetes and progressive chronic kidney disease].","Scheen A","2025","Revue medicale de Liege","case_report","article",null,"39815707",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; English Abstract; Journal Article; article"],["R0004736","Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review.","Lommer C","2026","Frontiers in oncology","systematic_review","article","10.3389/fonc.2026.1751628","41858365","PMC12995638","PROSPERO:CRD420251055134",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0004737","Local administration of exendin-4 ameliorates wear-particle-induced periprosthetic osteolysis by rebalancing bone remodeling.","Ma B","2026","Acta biomaterialia","preclinical","article","10.1016/j.actbio.2026.09.014","42700783",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004738","Appetite Dysregulation as a Driver of Weight Regain After GLP-1 Receptor Agonist-Induced Weight Loss: A Systematic Review","Mısırlıoğlu PE","2026","Preprints.org","systematic_review","preprint","10.20944/preprints202604.1938.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0004739","Liraglutide modulates ALCAT1-Mediated cardiolipin remodeling to improve cardiac function in obese mice.","Wang L","2025","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2025.151583","40054063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004740","The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.","Brenisin K","2025","JMIR research protocols","protocol","article","10.2196/76013","41364787","PMC12688052","ClinicalTrials.gov:NCT06754163","S001293","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0004741","Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.","Ma X","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-024-01554-1","38402332","PMC10951152","ClinicalTrials.gov:NCT03929744; ClinicalTrials.gov:NCT05110794","S001347; S002049","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0004742","Efficacy of Liraglutide on Metabolic and Reproductive Outcomes in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis","Lu Y","2025","Authorea Preprints","systematic_review","preprint","10.22541/au.174919687.75586804/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0004743","Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system.","Bolden DM","2025","American journal of preventive cardiology","nonrandomized_study","article","10.1016/j.ajpc.2025.100966","40275941","PMC12018204",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004744","Suboptimal physician adherence to evidence-based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single-center study in Taiwan.","Shen ZY","2025","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70090","40445189","PMC12315241",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0004745","Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.","Saeed A","2025","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-24-00775","40523289",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Observational Study; article"],["R0004746","A Comprehensive Review of Emerging Therapies for Type 2 Diabetes and Their Cardiovascular Effects.","Acosta G AJ","2024","Cureus","narrative_review","article","10.7759/cureus.65707","39211720","PMC11358602",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004747","The benefits of oral glucose-lowering agents: GLP-1 receptor agonists, DPP-4 and SGLT-2 inhibitors on myocardial ischaemia/reperfusion injury.","Huang XD","2024","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2024.176698","38821168",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004748","Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes.","Elsaid MI","2024","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.17925","38538967",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0004749","Abolishing β-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists.","Hinds CE","2024","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.15288","37795639",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004750","A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.","Eijsvogel PPNM","2026","Clinical pharmacology and therapeutics","systematic_review","article","10.1002/cpt.70315","42104724","PMC13339527",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review-article; review"],["R0004751","Initial Pharmacological Strategies in People with Early Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.","Choi JH","2025","Diabetes & metabolism journal","systematic_review","article","10.4093/dmj.2024.0660","40300775","PMC12620703",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; review"],["R0004752","Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials.","Sabatella L","2026","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.70100","41326176","PMC13032060",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Comparative Study; Review; review-article; article"],["R0004753","Tirzepatide for fertility-sparing treatment in obese/overweight patients with endometrial cancer and atypical hyperplasia: a phase II single-arm clinical trial protocol.","Zheng J","2025","BMJ open","protocol","article","10.1136/bmjopen-2025-105429","41198197","PMC12593436","ChiCTR:ChiCTR2500102009",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0004754","GLP-1 receptor agonists and their role in managing type 2 diabetes.","Nazarko L","2024","British journal of community nursing","other","article","10.12968/bjcn.2024.0089","39072740",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004755","Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.","Chen JJ","2024","Kidney international","nonrandomized_study","article","10.1016/j.kint.2024.01.002","38388145",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comment; article"],["R0004756","Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression.","Chang Y","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70927","42209408","PMC13341328",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004757","Obesity in Cardiorenal syndrome: Management Opportunities and Challenges.","Reaves A","2025","Current hypertension reports","narrative_review","article","10.1007/s11906-025-01352-5","41455079","PMC12977100",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0004758","New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report.","Purvez A","2025","Cureus","case_report","article","10.7759/cureus.99651","41425685","PMC12716871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004759","Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection.","Yau K","2023","The Canadian journal of cardiology","narrative_review","article","10.1016/j.cjca.2023.07.007","37429523",null,null,"S002662","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0004760","Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists.","Jalleh RJ","2023","Annals of internal medicine","randomized_trial","article","10.7326/m23-2019","37931267",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Editorial; article"],["R0004761","Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults.","Katsura M","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70721","41891334",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0004762","The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease.","Lin Y","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-01793-9","36932379","PMC10024371",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Preprint; research-article; preprint; article"],["R0004763","Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium-glucose cotransporter 2 inhibitor users.","Le H","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70558","41981780","PMC13421048",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004764","Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3).","Xie Y","2023","BMJ open","protocol","article","10.1136/bmjopen-2022-069080","37192802","PMC10193081","ChiCTR:ChiCTR2200056410",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004765","Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect.","Carris NW","2024","Canadian journal of physiology and pharmacology","case_report","article","10.1139/cjpp-2023-0464","38587178",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0004766","Metabolic syndrome in youth - A fresh look at an old problem.","Wilson DP","2025","Journal of clinical lipidology","narrative_review","article","10.1016/j.jacl.2025.03.005","40975568",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0004767","[An elderly patient with type 2 diabetes who developed a hyperglycemic emergency and showed a marked decline in insulin secretion, but she was able to be weaned off insulin by alleviating glucose toxicity and adjusting her medication: A case report].","Ohashi Y","2026","Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics","case_report","article","10.3143/geriatrics.63.237","42749671",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; English Abstract; article"],["R0004768","Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART.","Thompson W","2025","CJC open","nonrandomized_study","article","10.1016/j.cjco.2025.02.008","40894837","PMC12399144",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004769","GHRH and GLP-1 receptor agonism promote human β-cell survival and improve glucose homeostasis in diabetic mice.","Louzada RA","2026","Endocrinology","preclinical","article","10.1210/endocr/bqag104","42811814","PMC13624276",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0004770","Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.","Campos C","2021","Postgraduate medicine","nonrandomized_study","article","10.1080/00325481.2021.1971461","34416133",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Comparative Study; Journal Article; article"],["R0004771","Association of GLP-1 receptor agonists versus bariatric surgery with outcomes in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis.","Mahmoud AK","2026","European heart journal. Quality of care & clinical outcomes","nonrandomized_study","article","10.1093/ehjqcco/qcag051","41910632",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0004772","Glucagon-like Peptide-1 Receptor Agonist Therapy Is Associated With Fewer Medical Complications After Carpal Tunnel Release in Diabetic Patients.","Hiredesai AN","2026","Hand (New York, N.Y.)","nonrandomized_study","article","10.1177/15589447251350181","40667672","PMC12267201",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004773","Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study.","Yan Y","2023","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2023.1170127","37383395","PMC10293789",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004774","Glucagon-like peptide-1 analogues in the management of high output stoma in adult patients: A narrative review.","Tuttle Z","2026","JPEN. Journal of parenteral and enteral nutrition","randomized_trial","article","10.1002/jpen.70131","42533381",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0004775","Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.","Sodhi M","2023","JAMA","nonrandomized_study","article","10.1001/jama.2023.19574","37796527","PMC10557026",null,"S000313","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004776","Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.","Taha MB","2022","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-022-01041-7","35624390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004777","Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.","Nauck MA","2026","Lancet (London, England)","narrative_review","article","10.1016/s0140-6736(25)02105-1","41547366",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; article"],["R0004778","Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss.","Durell N","2022","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","nonrandomized_study","article","10.1177/87551225221110850","36046348","PMC9420918",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004779","Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials.","Musso G","2026","Med (New York, N.Y.)","systematic_review","article","10.1016/j.medj.2025.100959","41610839",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; review"],["R0004780","Cardiovascular Disease and Obesity Medications in Older Women by Obesity-Related Cancers Status: SEER-Medicare 2007-2015.","Lopez DS","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70211","42083112",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0004781","Corticosteroid insensitivity in obese asthma: potential mechanisms and therapeutic perspectives.","To M","2025","Frontiers in allergy","narrative_review","article","10.3389/falgy.2025.1719900","41376865","PMC12685837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004782","The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia.","Novodvorský P","2022","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-022-00982-3","35080714",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0004783","A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies.","Tipa RO","2024","International journal of molecular sciences","systematic_review","article","10.3390/ijms25094972","38732190","PMC11084700",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0004784","Glucose-lowering in type 2 diabetes may be mediated by improved proinsulin processing without better β-cell compensation.","Retnakaran R","2026","American journal of physiology. Endocrinology and metabolism","randomized_trial","article","10.1152/ajpendo.00163.2026","42721371",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Randomized Controlled Trial"],["R0004785","The ocular surface in type 2 diabetes: pathophysiology and impact of anti-diabetic drugs.","Singh I","2026","Progress in retinal and eye research","narrative_review","article","10.1016/j.preteyeres.2025.101417","41297876",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004786","Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.","Rosenstock J","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)01022-6","42251856",null,"ClinicalTrials.gov:NCT06323161","S000718","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0004787","Exendin-4 averts all-trans-retinal-driven damage to photoreceptors and the retina via the GLP-1R/PKA/CREB1 signaling axis.","He B","2026","Cellular & molecular biology letters","nonrandomized_study","article","10.1186/s11658-026-00952-6","42226100","PMC13435657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004788","Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists.","Boianelli A","2024","Pharmaceutics","other_trial","article","10.3390/pharmaceutics16101310","39458639","PMC11510446",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0004789","A worldwide perspective on clinical characteristics and treatment of youth with monogenic diabetes in the SWEET registry.","Deng L","2026","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvag064","41958866","PMC13058832",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004790","Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study.","Cetiner S","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s594898","41938643","PMC13050166",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004791","Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.","Yuan X","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1170881","37342259","PMC10277636",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Systematic Review; Journal Article; Network Meta-Analysis; systematic-review; article"],["R0004792","Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP-1RA in CHB and T2DM Patients.","Yun B","2025","Liver international : official journal of the International Association for the Study of the Liver","nonrandomized_study","article","10.1111/liv.70060","40257422",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0004793","Incretin-Based Drugs and the Incidence of Endometrial Cancer Among People with Type 2 Diabetes: Active Comparator New-User Design.","Rothman SM","2025","Drug safety","nonrandomized_study","article","10.1007/s40264-025-01551-8","40347221",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0004794","R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 17.","Arora P","2025","Journal of comparative effectiveness research","nonrandomized_study","article","10.57264/cer-2024-0212","39601215","PMC11650383",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; editorial; article"],["R0004795","Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.","Chai S","2024","Journal of diabetes research","systematic_review","article","10.1155/2024/8145388","39072050","PMC11283333","PROSPERO:CRD42023410345",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Comparative Study; Systematic Review; review-article; article"],["R0004796","Diabetes and Cardiometabolic Care, Pharmacotherapy, and Patient Outcomes in Two Regional Aboriginal Primary Care Health Centres: Lessons to be Learnt.","Hayes AG","2025","Heart, lung & circulation","nonrandomized_study","article","10.1016/j.hlc.2025.06.1019","40885604",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; article"],["R0004797","Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.","Tóth LI","2025","International journal of molecular sciences","randomized_trial","article","10.3390/ijms26135951","40649729","PMC12250273",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0004798","Update on Obesity and Its Relationship to Atherosclerotic Cardiovascular Disease and Associated Risk Factors.","Ahmad Y","2026","Journal of clinical medicine","narrative_review","article","10.3390/jcm15124430","42355597","PMC13301890",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004799","Advancing Obstructive Sleep Apnea Management: Recent Trends from Conventional to Innovative Therapies.","Park SK","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14217586","41226983","PMC12608792",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004800","Medicare Should Cover Weight Loss Drugs as Long as the Prices are Affordable.","Hwang CS","2024","The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics","other","article","10.1017/jme.2024.56","38818585",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004801","Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions.","Pan HC","2026","Kidney research and clinical practice","nonrandomized_study","article","10.23876/j.krcp.25.126","41644266","PMC13176909",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; review-article; article"],["R0004802","How Ozempic is Changing Dating: GLP-1 Weight Loss Medications Are Reshaping Body Confidence, Desire, and Stigma","Balzarini RN","2026","PsyArXiv","other","preprint","10.31234/osf.io/ucxv5_v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004803","Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.","Urva S","2024","Current medical research and opinion","other_trial","article","10.1080/03007995.2024.2322072","38407177",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0004804","Gradually, then Suddenly: Nutrition in an Era of Medically Induced Weight Loss.","Bergia RE","2025","The Journal of nutrition","other","article","10.1016/j.tjnut.2025.09.033","41016550",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0004805","Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Huixing L","2023","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2022.12.006","36604209",null,"PROSPERO:CRD42021226231",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0004806","New kidneys, old risks: cardiovascular challenges after transplantation.","Van Craenenbroeck AH","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfaf239","41206563","PMC13270328",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0004807","Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus.","Westergaard L","2024","Clinical drug investigation","randomized_trial","article","10.1007/s40261-024-01405-8","39488821","PMC11564230","ClinicalTrials.gov:NCT03789578","S000284","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; research-article; article"],["R0004808","Efficacy of glucagon-like peptide 1 analogues in psoriasis: A cohort study.","Bar D","2026","JAAD international","nonrandomized_study","article","10.1016/j.jdin.2026.04.004","42164833","PMC13185915",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004809","Impact of GLP-1 Agonists on Male Reproductive Health-A Narrative Review.","Varnum AA","2023","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina60010050","38256311","PMC10820247",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0004810","Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.","Rabbani SA","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18081130","40872522","PMC12389137",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004811","Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.","Kaur R","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71031","42337824","PMC13448877",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; research-article; review"],["R0004812","Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.","Katsuyama H","2024","Biomedicines","nonrandomized_study","article","10.3390/biomedicines12051001","38790963","PMC11118092",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004813","Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors.","Sukumar JS","2026","Cancer research communications","nonrandomized_study","article","10.1158/2767-9764.crc-25-0554","41677473","PMC13043164",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004814","Consensus on the management of hypertension in individuals with diabetes by Asian-Pacific Society of hypertension (APSH) & Diabetes Asia Study Group (DASG).","Maheshwari A","2026","Journal of human hypertension","randomized_trial","article","10.1038/s41371-026-01150-9","42056284",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Consensus Statement; Journal Article"],["R0004815","Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes.","Vale C","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16077","39604324",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004816","Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease.","Tan X","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-02051-8","37985992","PMC10662529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004817","Sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists treatment: variable observations of sequelae on diabetic retinopathy.","Varughese GI","2023","Journal of the Royal Society of Medicine","commentary","article","10.1177/01410768231215999","38054392","PMC10850872",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0004818","GLP-1 agonist liraglutide decreases operant methamphetamine intake in rats under conditions of short- but not extended-access to the drug.","Hrickova M","2026","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2026.1791206","42147332","PMC13176170",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004819","Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement.","Correia JC","2026","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2026.101840","42733510","PMC13571449",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004820","Defining Weight-Loss-Independent Hepatic Effects of Incretin-Based Therapies.","Zhang M","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.71391","42786132",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004821","Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: A real-world study.","Su YC","2024","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2024.101522","38341131",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004822","GLP-1 Receptor Agonists in Hidradenitis Suppurativa: Time to Treat the Whole Patient.","Viquez Burboa GU","2026","Skin appendage disorders","randomized_trial","article","10.1159/000552598","42454220","PMC13368244",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; article"],["R0004823","Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments.","Tinsley GM","2024","Journal of the Endocrine Society","narrative_review","article","10.1210/jendso/bvae164","39372917","PMC11450469",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004824","Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of polycystic ovary syndrome-A systematic review and meta-analysis.","Tong X","2024","Archives of physiology and biochemistry","systematic_review","article","10.1080/13813455.2024.2380422","39084250",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article; review"],["R0004825","SIRT2 in Diabetic Kidney Disease: Multifaceted Regulatory Roles and Therapeutic Challenges.","Zhang F","2026","Journal of inflammation research","narrative_review","article","10.2147/jir.s588949","41907207","PMC13021380",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004826","Epicardial adipose tissue in coronary microvascular disease.","Gašpárková V","2026","American heart journal plus : cardiology research and practice","narrative_review","article","10.1016/j.ahjo.2026.100734","41694543","PMC12906140",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004827","The Efficacy of Various Weight Loss Strategies in Alleviating Polycystic Ovary Syndrome.","Yang S","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00649-5","40580384",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004828","Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population.","Palecek EJ","2024","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","randomized_trial","article","10.1177/10815589241270427","39075666","PMC11581925",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0004829","Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.","Pourabhari Langroudi A","2025","International journal of impotence research","nonrandomized_study","article","10.1038/s41443-025-01061-2","40240532",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004830","What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives.","Sabouret P","2023","European heart journal","randomized_trial","article","10.1093/eurheartj/ehad632","37793139",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0004831","Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta-analysis based on randomized controlled trials.","Wan S","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70201","41104525",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","TRUE","Journal Article; Systematic Review; Meta-Analysis; Retracted Publication; review"],["R0004832","Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.","Abusnana S","2023","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2022.110183","36436550",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Multicenter Study; Journal Article; article"],["R0004833","[Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice].","Karásek D","2022","Vnitrni lekarstvi","other_trial","article","10.36290/vnl.2022.018","36208922",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0004834","The effect of glucagon like peptide-1 receptor agonist on behavioral despair and anxiety-like behavior in ovariectomized rats: Modulation of BDNF/CREB, Nrf2 and lipocalin 2.","Sağlam C","2022","Behavioural brain research","preclinical","article","10.1016/j.bbr.2022.114053","35961539",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004835","Obesity, Metabolic Syndrome, Diabetes and Kidney Stones: Strengthening Links Over Time?","Colin IM","2026","TouchREVIEWS in endocrinology","nonrandomized_study","article","10.17925/ee.2026.22.1.7","42272999","PMC13249147",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004836","GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region: Results from the PACT-MEA studys.","Al-Dahi WA","2025","Saudi medical journal","nonrandomized_study","article","10.15537/smj.2025.46.2.20240620","39933762","PMC11822930",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004837","Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards.","Horowitz M","2024","World journal of diabetes","commentary","article","10.4239/wjd.v15.i3.326","38591090","PMC10999054",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0004838","Characterize Disease Progression Subphenotypes in Real World Populations with Overweight and Obesity using a Graph-based Neural Network Framework.","Lee YA","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.11.10.25339913","41292627","PMC12642739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0004839","Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.","Chen HY","2026","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","nonrandomized_study","article","10.1007/s00198-026-08134-y","42435064",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004840","Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.","Seijas-Amigo J","2025","Diabetes & metabolic syndrome","randomized_trial","article","10.1016/j.dsx.2025.103312","41129847",null,"ClinicalTrials.gov:NCT05136287","S001352","pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0004841","Are glucagon-like peptide 1 receptor agonists effective in decreasing body weight and body mass index in people living with diabetes and HIV?","Bottanelli M","2024","HIV medicine","nonrandomized_study","article","10.1111/hiv.13587","37990373",null,"ClinicalTrials.gov:NCT04174755; ClinicalTrials.gov:NCT04019197","S001425; S001849","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0004842","Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.","Edmonston D","2024","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2024.06.016","39142723",null,"ClinicalTrials.gov:NCT05465317","S002603","pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0004843","Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.","Nomoto H","2023","Pharmaceutics","randomized_trial","article","10.3390/pharmaceutics15082163","37631377","PMC10459529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004844","Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study.","Hu Y","2025","Advances in therapy","nonrandomized_study","article","10.1007/s12325-024-03082-7","39680313",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0004845","Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry.","García-Vega D","2025","Revista espanola de cardiologia (English ed.)","nonrandomized_study","article","10.1016/j.rec.2024.07.003","39033874",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0004846","[GLP-1 receptor agonists in type 2 diabetes : paradoxical real-life underuse in patients with atherosclerotic cardiovascular disease].","Scheen A","2024","Revue medicale de Liege","randomized_trial","article",null,"38487908",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","2","FALSE","English Abstract; Journal Article; Observational Study; other"],["R0004847","Functional and multi-omic aging rejuvenation with GLP-1R agonism","Huang J","2024","bioRxiv","preclinical","preprint","10.1101/2024.05.06.592653",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004848","Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies.","Chai S","2023","Journal of diabetes investigation","systematic_review","article","10.1111/jdi.14015","37147888","PMC10286783",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0004849","Perioperative Nutritional Optimization in Total Joint Arthroplasty: From Screening to Supplementation.","Siddiqi A","2026","The Journal of arthroplasty","randomized_trial","article","10.1016/j.arth.2026.03.088","41951067",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0004850","Mechanistic Insights Into the Cardioprotective Effects of Modern Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review.","Ratnala M","2025","Cureus","systematic_review","article","10.7759/cureus.93284","41146812","PMC12554296",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004851","The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists.","Fang H","2024","Current medicinal chemistry","narrative_review","article","10.2174/0929867330666230416153301","37062063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004852","Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.","Li F","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70880","42310888","PMC13449077",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial, Phase I; research-article; article"],["R0004853","Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide.","Vaduganathan M","2023","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2023.09.812","37993202",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; article"],["R0004854","A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity.","Abdullah Bin Ahmed I","2024","Journal of obesity","narrative_review","article","10.1155/2024/8056440","38765635","PMC11101251",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004855","Pharmacological strategies for slowing the rise of creatinine and urea nitrogen in diabetic kidney disease: A scoping review.","Xia D","2026","Pakistan journal of pharmaceutical sciences","narrative_review","article","10.36721/pjps.2026.39.10.288.1","42474167",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Scoping Review; article"],["R0004856","Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD.","Moolla A","2025","JHEP reports : innovation in hepatology","randomized_trial","article","10.1016/j.jhepr.2025.101363","40342635","PMC12060445","EudraCT:2016-002045-36",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004857","The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects.","Krajewski PK","2024","Journal of clinical medicine","systematic_review","article","10.3390/jcm13216292","39518431","PMC11547001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004858","Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options.","Koullias E","2025","Cureus","narrative_review","article","10.7759/cureus.76716","39897209","PMC11783198",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004859","Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.","Huang X","2025","Frontiers in medicine","systematic_review","article","10.3389/fmed.2025.1509947","40051726","PMC11882565",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0004860","Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats.","Klotsman M","2024","BMC veterinary research","preclinical","article","10.1186/s12917-024-04051-6","38762728","PMC11102179",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0004861","Utilization Trends of Glucose-Lowering Medications Among Adult Kidney Transplant Recipients with Type 2 Diabetes in the United States.","Hansrivijit P","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14020651","39860655","PMC11766230",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004862","Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.","Chou HW","2022","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph15121569","36559020","PMC9787187",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004863","Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.","Builes-Montaño CE","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-026-01886-0","42252377","PMC13388875",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0004864","Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association.","Ahmadi H","2025","BMC ophthalmology","case_report","article","10.1186/s12886-025-03958-4","40087651","PMC11908077",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0004865","Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review.","Kalyani RR","2025","JAMA","randomized_trial","article","10.1001/jama.2025.5956","40549398","PMC13014273",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0004866","Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi.","Qasim SF","2023","Pakistan journal of medical sciences","nonrandomized_study","article","10.12669/pjms.39.4.7353","37492314","PMC10364304",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004867","A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs.","Godschall EN","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.12.12.628169","39763823","PMC11702550",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0004868","Pulse of Progress: A Systematic Review of Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular Health.","Sabina M","2024","Cardiology research","systematic_review","article","10.14740/cr1600","38464707","PMC10923257",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004869","GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers.","Heinla K","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-023-01381-w","36800161","PMC10064408","ClinicalTrials.gov:NCT02089256; ClinicalTrials.gov:NCT03160261","S000175; S000403","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; case-report; article"],["R0004870","What the diabetologist needs to know about the risk of non-arteritic anterior ischaemic optic neuropathy and GLP-1 receptor agonist use in patients with type 2 diabetes.","Feldman-Billard S","2025","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2025.101664","40383371",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0004871","A primary care guide to the screening and pharmacologic management of chronic kidney disease in people living with type 2 diabetes.","Wright EE","2025","Primary care diabetes","other","article","10.1016/j.pcd.2025.05.005","40903105","PMC12549410",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Consensus Statement; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0004872","GLP-1 analogs restore inflammatory, mitochondrial and intercellular signaling networks in the  <i>  Snca  <sup>G51D/G51D<\/sup>  <\/i>  knock-in mouse model of Parkinson’s disease","Vaidya B","2026","bioRxiv","preclinical","preprint","10.64898/2026.05.18.726024",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004873","Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation.","Chiang CH","2025","Blood advances","nonrandomized_study","article","10.1182/bloodadvances.2025015871","39908569","PMC12142527",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004874","Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.","Petersen J","2026","Nature metabolism","preclinical","article","10.1038/s42255-026-01603-y","42744908",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0004875","Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study.","Pladevall-Vila M","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01717-8","40106222","PMC12006594","ClinicalTrials.gov:NCT05526157","S002732","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004876","Association between variants in TCF7L2, CTRB1/2, and GLP-1R genes and response to therapy with glucagon-like peptide-1 receptor agonists.","Kyriakidou A","2024","Postgraduate medicine","other","article","10.1080/00325481.2024.2328513","38453649",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004877","Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.","Jiang Y","2021","Advances in therapy","systematic_review","article","10.1007/s12325-021-01637-6","33582976","PMC7932945",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; Network Meta-Analysis; review-article; other; article"],["R0004878","Sex in CKD trials: representation and treatment effects of cardiorenoprotective therapies.","Bellos I","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfag199","42671242",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0004879","Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease.","Wallace R","2024","Nephrology (Carlton, Vic.)","nonrandomized_study","article","10.1111/nep.14277","38369756",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Case Reports; Journal Article; article"],["R0004880","Knowledge, Counseling Practice, Perceived Barriers, and Clinical Decision-Making of Community Pharmacists in Saudi Arabia Regarding Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.","Alhomoud IS","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s552287","40919568","PMC12409477",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004881","Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020.","Jacobs JA","2024","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2023.100624","38125205","PMC10730337",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0004882","Can Unmet Needs Be Addressed by Adjunctive Therapies? Findings from a Patient Perspectives Survey in Adults with Type 1 Diabetes.","Lamaro BD","2024","Journal of patient experience","other","article","10.1177/23743735241257811","38799027","PMC11128168",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0004883","Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).","Lin J","2023","European journal of clinical pharmacology","other","article","10.1007/s00228-023-03539-8","37449993","PMC10427543",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004884","GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis.","Li X","2024","Acta diabetologica","preclinical","article","10.1007/s00592-023-02184-y","37847379",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004885","Trends in the utilization, expenditure and costs of noninsulin glucose-lowering drugs in the Medicaid population: Steady increases in glucagon-like peptide-1 receptor agonist and sodium-glucose transporter-2 inhibitor use, prices and expenditure.","Almadfaa RO","2025","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70162","40630025",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004886","Ketosis-Prone Type 2 Diabetes Mellitus: 3 Decades of Clinical, Pathophysiologic, and Therapeutic Insights.","Umpierrez G","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.1016/j.eprac.2026.03.007","42002040",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004887","Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","Lam CSP","2026","Kidney international","other","article","10.1016/j.kint.2025.10.011","41791738","PMC13092174",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; research-article; article"],["R0004888","Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD.","Shi Y","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","nonrandomized_study","article","10.1016/j.cgh.2025.06.001","40490148",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0004889","Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?","Steenackers N","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1569468","40607226","PMC12214899",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004890","Comparison of semaglutide and lifestyle counseling for weight loss using electronic health records","Powell W","2025","medRxiv","randomized_trial","preprint","10.64898/2025.12.01.25341393",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0004891","Mitigating Lipotoxicity: A Potential Mechanism to Delay Chronic Kidney Disease Progression Using Current Pharmacological Therapies.","Anumas S","2025","Nephrology (Carlton, Vic.)","narrative_review","article","10.1111/nep.70098","40665557",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0004892","Glucagon-Like Peptide-1 Receptor Agonists: Best Choice for Patients With Cirrhosis and Diabetes?","Li Y","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","commentary","article","10.1016/j.cgh.2023.08.012","37660768",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0004893","Peptide-functionalized nanoemulsions with exendin-4 as a model ligand.","Holler N","2026","International journal of pharmaceutics: X","other","article","10.1016/j.ijpx.2026.100598","42472074","PMC13380532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004894","Anti-atherosclerotic effect of incretin receptor agonists.","Wang X","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1463547","39493783","PMC11527663",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004895","Updates in chronic kidney disease management: A systematic review.","Ammar A","2025","Pharmacotherapy","systematic_review","article","10.1002/phar.70014","40152479",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0004896","Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.","Mody R","2024","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2024.30.2.153","38308628","PMC10839462",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004897","Associations Between Common Hip and Knee Osteoarthritis Treatments and All-Cause Mortality.","Orchard JW","2025","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare13172229","40941581","PMC12428238",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004898","The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.","Abushamat LA","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","narrative_review","article","10.1016/j.cgh.2024.01.032","38367743",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0004899","Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.","Yang Y","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15342","37860884",null,"PROSPERO:CRD42023418551",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0004900","Expert meeting report: epidemiology and management of acquired hypothalamic obesity.","Müller HL","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1798619","42064767","PMC13124477",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; brief-report; article"],["R0004901","Liraglutide Treatment Reverses Unconventional Cellular Defects in Induced Pluripotent Stem Cell-Derived β-Cells Harboring a Partially Functional WFS1 Variant.","Torchio S","2025","Diabetes","other","article","10.2337/db24-0720","40202504","PMC12185971",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article; other"],["R0004902","Alterations in glucose and insulin resistance following stress and alcohol cues predict alcohol craving in those with AUD and obesity: A preliminary study.","Harvanek ZM","2026","Alcohol, clinical & experimental research","other_trial","article","10.1111/acer.70283","42101823","PMC13651010",null,"S000275","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; research-article; article"],["R0004903","Effects of GLP-1 receptor agonists on copeptin in euvolemic participants.","Leibnitz S","2026","European journal of endocrinology","randomized_trial","article","10.1093/ejendo/lvag005","41525326",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0004904","Glucagon-Like Peptide-1 Receptor Agonist Treatment in Liver Cirrhosis.","Han Ng C","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","commentary","article","10.1016/j.cgh.2023.08.024","37683880",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0004905","GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.","Giugliano D","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70454","41508745",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0004906","The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD.","Petrovic A","2023","Current issues in molecular biology","preclinical","article","10.3390/cimb45060288","37367037","PMC10296833",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004907","The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review.","McGill JB","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-024-01569-8","38573469","PMC11043311",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0004908","Cardiorenal interactions in heart failure: insights from recent therapeutic advances.","Damman K","2024","Cardiovascular research","narrative_review","article","10.1093/cvr/cvad096","37364186","PMC11472538",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004909","The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.","Norlin J","2025","PloS one","preclinical","article","10.1371/journal.pone.0331665","41150667","PMC12561900",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004910","Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis.","Sillassen CDB","2025","BMJ open","systematic_review","article","10.1136/bmjopen-2024-098205","41371743","PMC12699605","PROSPERO:CRD42024623312",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004911","Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus.","Wang Q","2025","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-025-01570-9","41107649",null,"ClinicalTrials.gov:NCT04994288","S001511","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0004912","Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway.","Tian Y","2025","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2025.1539411","40129942","PMC11931165",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004913","Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.","Henney AE","2025","Liver international : official journal of the International Association for the Study of the Liver","randomized_trial","article","10.1111/liv.70367","40980971","PMC12452214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; research-article; article"],["R0004914","Adipose tissue distribution in metabolic disease: depot-specific biology, clinical assessment, and therapeutic remodeling.","LiuLi A","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1822659","42422426","PMC13341497",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004915","A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients.","Spasovski G","2024","Metabolic syndrome and related disorders","other","article","10.1089/met.2023.0227","38386800",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004916","Successful Reversal of Tamoxifen-Associated Weight Gain and Metabolic Dysfunction with Liraglutide in a Breast Cancer Survivor: A Case Report.","Anvarbek M","2026","Clinical medicine insights. Case reports","case_report","article","10.1177/11795476261485623","42668751","PMC13525322",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004917","Glucagon-like-peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association.","Nguyen A","2024","Clinical obesity","randomized_trial","article","10.1111/cob.12676","38778795",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0004918","The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial-Study Design and Protocol.","Novodvorský P","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","protocol","article","10.1007/s13300-024-01582-x","38653903","PMC11096133","ClinicalTrials.gov:NCT04945070","S002272","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0004919","Correction: Response by Sharp to: \"Ozempic Face\" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions\" by Daneshgaran et al.",null,"2026","Aesthetic surgery journal. Open forum","notice","article","10.1093/asjof/ojag174","42757249","PMC13584834",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0004920","The effects of incretin-based therapies on weight reduction and metabolic parameters in children with obesity: A systematic review and meta-analysis.","Wang JY","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13686","38204284",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0004921","Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway.","Xu Q","2025","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2025.108975","39987624",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004922","Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study.","Chang KC","2024","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-024-02461-2","39420429","PMC11487834",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0004923","Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden.","Svensson AM","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14276","33289287","PMC7953897",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004924","Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.","Dutta D","2024","Obesity science & practice","systematic_review","article","10.1002/osp4.743","38414573","PMC10896246",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004925","The Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Cohort Study.","Talay L","2024","Pharmacy (Basel, Switzerland)","nonrandomized_study","article","10.3390/pharmacy12050135","39311126","PMC11417943",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004926","Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction.","Elbatreek MH","2026","European heart journal","preclinical","article","10.1093/eurheartj/ehag732","42830666",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; IM; article"],["R0004927","Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide.","Oe Y","2025","Frontiers in endocrinology","case_report","article","10.3389/fendo.2025.1501984","40491599","PMC12146166",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004928","Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.","Rodriguez PJ","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.57349","39888616","PMC11786232",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0004929","The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.","Zhang Y","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15557","38528818",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0004930","[Advantages of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus: A review].","Demidova TY","2023","Terapevticheskii arkhiv","narrative_review","article","10.26442/00403660.2023.10.202425","38159021",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; English Abstract; Journal Article; article"],["R0004931","Digital engagement enhances dual GIP/GLP-1 receptor agonist and GLP-1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety.","Johnson H","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70244","41145379","PMC12673462",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004932","Comparative Effects of Glucagon-like Peptide 1 Receptor Agonists and Metformin on Glaucoma Risk in Patients with Type 2 Diabetes.","Muayad J","2025","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2024.08.023","39182626",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Multicenter Study; article"],["R0004933","Current and Future Implications of Weight Loss Drugs on Liver Disease.","Bussetty A","2025","Clinics in liver disease","randomized_trial","article","10.1016/j.cld.2025.06.005","41109700",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0004934","The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review.","Le KDR","2024","Pharmacy (Basel, Switzerland)","randomized_trial","article","10.3390/pharmacy12010011","38251405","PMC10801460",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Scoping Review; review-article; article"],["R0004935","Bias in the Composite Outcomes of Kidney-Cardio Protective Trials in Chronic Kidney Disease: A Meta-Epidemiological Study.","Bellos I","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15124840","42356008","PMC13301691",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article"],["R0004936","Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations.","Brubaker J","2026","Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents","other","article","10.1007/s00044-026-03579-6","42507153",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0004937","Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report.","Gandecka-Pempera A","2025","Frontiers in endocrinology","case_report","article","10.3389/fendo.2025.1649270","41127515","PMC12537370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0004938","Depression and Anxiety Among Individuals Receiving Incretin Mimetic Medications: A Saudi Cross-Sectional Study.","Bahathig AM","2026","Healthcare (Basel, Switzerland)","other","article","10.3390/healthcare14081049","42072949","PMC13115962",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004939","Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review.","Clemens KK","2023","Nutrition, metabolism, and cardiovascular diseases : NMCD","randomized_trial","article","10.1016/j.numecd.2023.03.023","37100640",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0004940","Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN.","Ni J","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.71036","42387313","PMC13449076",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; research-article; article"],["R0004941","Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.","Villegas Meza AD","2026","JBJS reviews","randomized_trial","article","10.2106/jbjs.rvw.26.00027","42160466",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0004942","Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.","RECAP study group","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15652","38764356",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004943","Correction to \"Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes\" (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017).",null,"2023","JCEM case reports","notice","article","10.1210/jcemcr/luad005","37908263","PMC10578365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; Journal Article; correction; erratum"],["R0004944","Basal insulin in the age of innovation: are diamonds still forever?","Koufakis T","2025","Expert review of endocrinology & metabolism","narrative_review","article","10.1080/17446651.2025.2580629","41139150",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0004945","The Hidden Costs of GLP-1 Agonists: A Meta-Analysis of Sarcopenia, Psychiatric Risks, and Long-Term Health Implications","Chtatbi A","2025","Authorea Preprints","systematic_review","preprint","10.22541/au.175641359.91480737/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0004946","Eating Disorder Screen Results and GLP-1 Awareness, Interest, and Use in a Nationally Representative Sample of Adults in U.S. Households.","Siegel JA","2026","The International journal of eating disorders","other","article","10.1002/eat.70103","42319160",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004947","Semaglutide Activates the Orexin/Hypocretin and Basal Forebrain Cholinergic Systems and Increases Acetylcholine Levels in the Hippocampus of Young and Aged Rats","Wohlfeld C","2026","bioRxiv","preclinical","preprint","10.64898/2026.08.03.742612",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004948","The Effects of Incretin Mimetic Therapies on Muscle and Bone Health in Older Adults: A Narrative Review.","Saavedra JM","2026","Obesity (Silver Spring, Md.)","narrative_review","article","10.1002/oby.70203","42438123","PMC13367407",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0004949","Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.","Dicker D","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.15392","38848064","PMC11161844",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Comparative Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0004950","GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series.","Mehdi AZ","2025","BMJ open diabetes research & care","case_report","article","10.1136/bmjdrc-2024-004885","40274278","PMC12020758",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004951","Starvation ketosis following self-administered tirzepatide obtained via online services in a young woman later diagnosed with anorexia nervosa: a case report.","Yasui-Furukori N","2026","Journal of eating disorders","case_report","article","10.1186/s40337-026-01666-y","42243968","PMC13621499",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; Preprint; article; preprint"],["R0004952","Guideline for the Management of Obesity in Adult Patients With Obstructive Sleep Apnea.","Park SK","2026","Clinical and experimental otorhinolaryngology","nonrandomized_study","article","10.21053/ceo.2025-00396","41725293","PMC13256478",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Guideline; Journal Article; research-article; article"],["R0004953","Mitochondrial Quality Control in Macrophages During Cardiovascular Disease.","Falconer RC","2026","The Canadian journal of cardiology","narrative_review","article","10.1016/j.cjca.2026.02.034","41740845",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004954","Obesity Management for Patients with Coronary Artery Disease and Heart Failure.","Syed AA","2025","Heart failure clinics","narrative_review","article","10.1016/j.hfc.2024.12.006","40107803",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004955","Definition, Classification, Diagnosis, and Management of an Emerging Threat: Cardio-Renal-Metabolic Syndrome.","Koufakis T","2026","American journal of cardiovascular drugs : drugs, devices, and other interventions","narrative_review","article","10.1007/s40256-025-00761-w","40858968",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0004956","Which heart failure phenotypes benefit from GLP-1 receptor agonists?","Deng J","2026","Cardiovascular diabetology. Endocrinology reports","commentary","article","10.1186/s40842-026-00328-x","42669668","PMC13527946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0004957","Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.","Ciudin A","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70773","42050884","PMC13243967",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Comparative Study; Network Meta-Analysis; research-article; article"],["R0004958","Semaglutide and High-Intensity Interval Exercise Attenuate Cognitive Impairment in Type 2 Diabetic Mice via BDNF Modulation.","Lai S","2025","Brain sciences","preclinical","article","10.3390/brainsci15050480","40426650","PMC12109977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004959","Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis.","Bhattarai HB","2025","Medicine","systematic_review","article","10.1097/md.0000000000046671","41465949","PMC12746972",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0004960","Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Kotecha P","2025","JAMA pediatrics","systematic_review","article","10.1001/jamapediatrics.2025.3243","40952752","PMC12439189",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; article"],["R0004961","Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials.","Sridharan K","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-01730-8","40410888","PMC12102854",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0004962","A Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders.","Sarma I","2026","Cureus","systematic_review","article","10.7759/cureus.111641","42524101","PMC13409016",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004963","The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity.","Kaplan A","2025","Advances in therapy","nonrandomized_study","article","10.1007/s12325-025-03175-x","40198520","PMC12085370",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; article"],["R0004964","The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials.","Kan R","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-01995-z","41286982","PMC12642090",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0004965","Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists.","Raven LM","2023","The American journal of medicine","case_report","article","10.1016/j.amjmed.2023.07.016","37567375",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0004966","Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care.","Caturano A","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12092039","39335551","PMC11429233",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004967","Mitohormesis linking metabolic dysfunction and neurodegeneration: implications for dementia and therapeutic strategies.","Otoda T","2026","Frontiers in molecular neuroscience","narrative_review","article","10.3389/fnmol.2026.1892506","42812893","PMC13621133",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004968","Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy.","McCrimmon RJ","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-021-01156-1","34714524","PMC8586382",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0004969","Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.","Powell J","2024","Clinical therapeutics","other","article","10.1016/j.clinthera.2023.12.014","38310052",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004970","Risk of Allodynia with GLP-1 Agonists","Frey C","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.01.07.26343603",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0004971","Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study.","Buckley AJ","2025","Diabetologia","nonrandomized_study","article","10.1007/s00125-025-06466-8","40637847","PMC12361273",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004972","IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy.","Mi B","2026","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.6c00218","42216891",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004973","Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysis.","Wu KA","2026","The Knee","nonrandomized_study","article","10.1016/j.knee.2026.104639","42727208",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004974","Real-World Impact of Weekly Dulaglutide and Semaglutide on Hba1c and Weight in a Predominantly Underrepresented Demographic.","Deas C","2026","Journal of health care for the poor and underserved","nonrandomized_study","article","10.1353/hpu.2026.a982969","42766517",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004975","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review.","Hamed K","2024","Cureus","nonrandomized_study","article","10.7759/cureus.68390","39355484","PMC11444311",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0004976","Effects of glucagon-like peptide-1 on systemic hemodynamics, kidney function, and intrarenal oxygenation in sheep with sepsis-associated acute kidney injury.","Hulst AH","2025","Scientific reports","randomized_trial","article","10.1038/s41598-025-33109-0","41444417","PMC12830701",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; Preprint; article"],["R0004977","Association of GLP1RAs with risk of chronic obstructive pulmonary disease: evidence from drug target Mendelian randomization.","Lai S","2025","Diabetology & metabolic syndrome","other","article","10.1186/s13098-025-01866-7","40722198","PMC12302747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0004978","Adjunctive Treatment with GLP-1 and Dual GLP-1/GIP Receptor Agonists for People with Type 1 Diabetes: Consensus Report and Practical Guidelines for Safe Use.","Garg SK","2026","Diabetes technology & therapeutics","randomized_trial","article","10.1177/15209156261449879","42246488",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0004979","Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.","Spitery A","2026","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2026.89952","42335260",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0004980","Patient and physician factors driving the gaps in use of drugs with cardiovascular and kidney benefits by medicare beneficiaries with type 2 diabetes treated by endocrinologists, nephrologists, and cardiologists: Population-based cohort study.","McCoy RG","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112039","39923965",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0004981","The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.","Kobayashi K","2023","Cardiovascular endocrinology & metabolism","nonrandomized_study","article","10.1097/xce.0000000000000292","37779602","PMC10540913",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004982","Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.","Zhu D","2026","Diabetologia","randomized_trial","article","10.1007/s00125-025-06593-2","41272211",null,"ClinicalTrials.gov:NCT04994288","S001511","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; article"],["R0004983","Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease.","Rroji M","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12030657","38540270","PMC10967743",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004984","A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit.","Addad F","2026","Cardiology and therapy","narrative_review","article","10.1007/s40119-026-00451-x","42171985","PMC13221515",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004985","Questioning the kidney-protective effects of tolvaptan: a testable hypothesis to revisit the current narrative.","Groothof D","2025","Open research Europe","nonrandomized_study","article","10.12688/openreseurope.20428.2","42661607","PMC13507848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Preprint; article"],["R0004986","Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study.","Yammine L","2023","Journal of addiction medicine","randomized_trial","article","10.1097/adm.0000000000001147","37579116",null,"ClinicalTrials.gov:NCT04941521","S001473","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0004987","Short-term effect of tirzepatide on serum calcitonin in adults with obesity.","Angelopoulos N","2026","Endocrine","nonrandomized_study","article","10.1007/s12020-026-04655-y","42081121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0004988","Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study.","Tournayre S","2026","Journal of medical Internet research","nonrandomized_study","article","10.2196/80119","42684246","PMC13515347",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0004989","Increases but pronounced state-level disparities in semaglutide prescribing to Medicaid patients from 2018 to 2022","Hsiao AL","2025","medRxiv","other","preprint","10.1101/2025.07.31.25332171",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0004990","Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.","Yuan X","2023","Medicine","systematic_review","article","10.1097/md.0000000000035739","37904378","PMC10615555",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; research-article; article"],["R0004991","Semaglutide in Heart Failure With Preserved Ejection Fraction: Emerging Evidence and Clinical Implications.","Arty F","2025","Cureus","randomized_trial","article","10.7759/cureus.87605","40786355","PMC12333672",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0004992","Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes.","Ray A","2025","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2024.7811","39928303","PMC11811870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0004993","High-Sensitivity C-Reactive Protein and Residual Inflammatory Risk in Coronary Artery Disease: The Pathophysiology, Prognosis, and Emerging Therapies.","Katamine M","2026","Journal of atherosclerosis and thrombosis","narrative_review","article","10.5551/jat.rv22044","40967771","PMC12782873",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0004994","Metabolic Dysfunction-Associated Steatotic Liver Disease and Atherosclerotic Cardiovascular Disease: Shared Pathophysiology, Biomarkers, and Emerging Therapeutic Strategies.","Drogy MS","2026","Cardiology in review","other","article","10.1097/crd.0000000000001259","41913294",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0004995","Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study.","Haddy N","2025","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","nonrandomized_study","article","10.1007/s40259-024-00699-6","39930059",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004996","Evaluating the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Metabolic Changes in Patients With Type 2 Diabetes on High-Dose Insulin.","Rentsch T","2022","American journal of therapeutics","nonrandomized_study","article","10.1097/mjt.0000000000001283","33416240",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0004997","Glucagon-like peptide-1 agonists: Role of the gut in hypoglycemia unawareness, and the rationale in type 1 diabetes.","Mirghani HO","2024","World journal of diabetes","commentary","article","10.4239/wjd.v15.i11.2167","39582561","PMC11580574",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0004998","Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.","Shapiro SB","2025","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2024-080679","40010803","PMC11863255",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0004999","Approach to obesity in the elderly population: a consensus report from the Diabetes, Obesity and Nutrition Working Group of SEMI (Spanish Society of Internal Medicine).","Pérez Martínez P","2023","Revista clinica espanola","other","article","10.1016/j.rceng.2023.07.005","37468094",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Consensus Statement"],["R0005000","Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.","Milenkovikj T","2023","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2023.111018","37972857",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005001","Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society.","Lambadiari V","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.02.014","41713690",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Consensus Statement; Journal Article; Review"],["R0005002","Trends in first-line glucose-lowering medication use among US adults with type 2 diabetes from 2019 to 2023.","Do D","2025","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2025.31.5.520","40298309","PMC12039499",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005003","Lifestyle management approaches for obesity.","Landry MJ","2026","Journal of clinical lipidology","narrative_review","article","10.1016/j.jacl.2025.08.022","41708214",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0005004","Obesity in China: current progress and future prospects.","Pan XF","2026","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(25)00357-2","41389801",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005005","SGLT2 inhibitors for primary prevention of macrovascular and major microvascular complications in type 2 diabetes: an island-wide cohort study.","Cheng WY","2025","Journal of the Royal Society of Medicine","nonrandomized_study","article","10.1177/01410768251375906","41182046","PMC12583002",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005006","Dual metformin and glucagon-like peptide-1 receptor agonist therapy reduces mortality and hepatic complications in cirrhotic patients with diabetes mellitus.","Huynh DJ","2023","Annals of gastroenterology","nonrandomized_study","article","10.20524/aog.2023.0814","37664227","PMC10433257",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005007","Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: A call to action.","Cooper DM","2023","Journal of clinical and translational science","commentary","article","10.1017/cts.2023.612","37706005","PMC10495825",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0005008","Nephroprotective effects of GLP-1 receptor agonists in patients receiving lithium treatment: a multinational cohort study using the TriNetX network.","McIntyre RS","2026","CNS spectrums","nonrandomized_study","article","10.1017/s1092852926101023","42261766",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; article"],["R0005009","From Metabolic Syndrome to Cardiovascular-Kidney-Metabolic Syndrome and Systemic Metabolic Disorder: A Call to Recognize the Progressive Multisystemic Dysfunction.","Özyüncü N","2025","Anatolian journal of cardiology","narrative_review","article","10.14744/anatoljcardiol.2025.5602","40771113","PMC12336713",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005010","Advancing Heart Failure Care: Breakthroughs and Emerging Strategies.","Tedeschi A","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14207253","41156123","PMC12565679",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0005011","The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.","Guo X","2022","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","systematic_review","article","10.1055/a-1844-1176","35512849",null,"PROSPERO:CRD42020173199",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0005012","Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data.","Wang M","2025","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2025.103385","40777864","PMC12329256",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005013","Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.","Karakasis P","2023","Metabolism: clinical and experimental","systematic_review","article","10.1016/j.metabol.2023.155710","37852529",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0005014","Novel evidence for tirzepatide, a dual GLP-1/GIP receptor agonist, to reduce the motivation for cocaine in rodents.","Knackstedt LA","2026","EBioMedicine","preclinical","article","10.1016/j.ebiom.2026.106257","41980479","PMC13092657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0005015","Diabetic Kidney Disease.","Gaddy A","2025","Disease-a-month : DM","narrative_review","article","10.1016/j.disamonth.2024.101848","39753456",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005016","Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report.","Li Y","2025","BMC pediatrics","case_report","article","10.1186/s12887-025-05886-0","40619352","PMC12232629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0005017","Comments on Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation [Response To Letter].","Tobaiqy M","2026","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s655784","42801167","PMC13615825",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; reply; review"],["R0005018","The Effect of Glucagon-like-Peptide-1 Receptor Agonists on Diabetic Retinopathy Progression, Central Subfield Thickness, and Response to Intravitreal Injections.","Michaeli T","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13206269","39458219","PMC11508636",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005019","Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.","Agrawal PK","2026","Journal of mid-life health","randomized_trial","article","10.4103/jmh.jmh_373_25","42124821","PMC13160545",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005020","Interplay of childhood metabolic dysfunction-associated steatotic liver disease and obesity in the development of youth-onset type 2 diabetes.","Parizad R","2026","World journal of clinical pediatrics","other","article","10.5409/wjcp.v15.i1.111030","41884030","PMC13010889",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005021","Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus.","Diker Cohen T","2025","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2025.101624","39961479",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0005022","Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review.","Iorra F","2026","Liver international : official journal of the International Association for the Study of the Liver","systematic_review","article","10.1111/liv.70643","41999054","PMC13090617",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; research-article; review"],["R0005023","Hypokalemia Requiring Hospitalization After Taking Semaglutide Injections.","Grennan KN","2025","Cureus","case_report","article","10.7759/cureus.87382","40772190","PMC12326210",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005024","Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery.","Wang A","2025","Life (Basel, Switzerland)","narrative_review","article","10.3390/life15030427","40141772","PMC11944163",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005025","Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin.","Gavin KL","2025","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2025.31.12.1311","41296314","PMC12653633",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; research-article; article"],["R0005026","Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder.","Klausen MK","2025","Basic & clinical pharmacology & toxicology","nonrandomized_study","article","10.1111/bcpt.70004","39891507","PMC11786240",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0005027","Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: A propensity score-matched cohort study.","Liu T","2025","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2025.133229","40187657",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005028","Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.","Silverii GA","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71128","42530338","PMC13538750",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Network Meta-Analysis; Journal Article; research-article; article"],["R0005029","Polyethylene glycol loxenatide improves cognitive and emotional performance in patients with type 2 diabetes: a 12-week multicenter clinical observational study.","Yin X","2026","Journal of endocrinological investigation","other","article","10.1007/s40618-026-02831-5","41661444",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005030","Semaglutide outperforms insulin in restoring neutrophil function against implant-related infection in diabetic and obese mice: experimental research.","Liu T","2025","International journal of surgery (London, England)","preclinical","article","10.1097/js9.0000000000001896","38935106","PMC11745711",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005031","Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample.","Tang S","2023","Annals of internal medicine","nonrandomized_study","article","10.7326/m22-3051","36848654","PMC10422868",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005032","Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management.","Zargar AH","2025","Cureus","narrative_review","article","10.7759/cureus.88561","40861717","PMC12371295",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005033","Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.","Calvarysky B","2024","Drug safety","systematic_review","article","10.1007/s40264-023-01392-3","38273155","PMC11018670","PROSPERO:CRD42022332339",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0005034","Correction to: Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.","Blüher M","2024","Diabetologia","notice","article","10.1007/s00125-024-06095-7","38349400","PMC10904490",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0005035","Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants.","Wu X","2025","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-025-01541-0","40587051",null,"ClinicalTrials.gov:NCT05694221","S002010","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Clinical Trial; Research Support, Non-U.S. Gov't; article"],["R0005036","Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis.","Le Y","2026","Foot & ankle specialist","nonrandomized_study","article","10.1177/19386400261471652","42609010",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005037","Clinical and Metabolic Effects of Incretin-Based Pharmacotherapy in Normal-Weight Patients With Type 2 Diabetes: A Real-World Analysis.","Carson E","2025","Cureus","nonrandomized_study","article","10.7759/cureus.88898","40881557","PMC12382426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005038","Dose-Response Relationship of Glucagon-like Peptide-1 Receptor Agonists on HbA1c and Body Weight in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis.","Chen QQ","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2024.11.013","39638244",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0005039","Knowledge, attitudes, and practices in obesity among trained and in-training primary care providers in an urban safety-net hospital system.","Campos A","2025","Obesity pillars","other","article","10.1016/j.obpill.2025.100185","40546447","PMC12182768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005040","GLP-1 receptor agonists: A review of glycemic benefits and beyond.","Clark L","2024","JAAPA : official journal of the American Academy of Physician Assistants","narrative_review","article","10.1097/01.jaa.0001007388.97793.41","38531038",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0005041","Use of glucagon-like peptide-1 receptor agonists in eating disorder populations.","Bartel S","2024","The International journal of eating disorders","narrative_review","article","10.1002/eat.24109","38135891",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; article"],["R0005042","Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy.","Chen X","2025","Peptides","preclinical","article","10.1016/j.peptides.2025.171429","40680859",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005043","Kidney Transplant and Cardiovascular-Kidney-Metabolic Health.","Jittirat A","2025","Cardiology clinics","narrative_review","article","10.1016/j.ccl.2024.12.004","40582736",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005044","Missed Doses, Missed Opportunities: Readmission Due to GLP-1RA Interruption Inspires Algorithms to Improve Reinitiation of Therapy at Discharge.","Michelet A","2026","Hospital pharmacy","nonrandomized_study","article","10.1177/00185787251372054","41017792","PMC12463868",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0005045","Severe Hypomagnesemia and Hypocalcemia Linked to Semaglutide in Type 2 Diabetes: A Case Report.","Davis TME","2025","The American journal of case reports","case_report","article","10.12659/ajcr.946539","39757501","PMC11717150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; research-article; article"],["R0005046","Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.","Altobaishat O","2025","European clinical respiratory journal","systematic_review","article","10.1080/20018525.2025.2484048","40144943","PMC11938315","PROSPERO:CRD42024562853",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005047","Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence.","Yang XH","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1868198","42494867","PMC13391339",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0005048","The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases.","Cheng D","2022","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s348055","35340338","PMC8943601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005049","Data mining study on adverse events of tirzepatide based on FAERS database.","Huo Y","2025","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2024.2376686","39007672",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005050","A narrative review on tirzepatide's therapeutic potential in glycemic control and cardioprotection.","Thiriveedi M","2026","Annals of medicine and surgery (2012)","nonrandomized_study","article","10.1097/ms9.0000000000004055","41496949","PMC12768080",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0005051","Identifying High-Risk Obese Individuals Without Diabetes for GLP-1RA Therapy Using Coronary CTA.","Blair CV","2025","JACC. Advances","other_trial","article","10.1016/j.jacadv.2025.101995","40682896","PMC12301774",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0005052","From the SELECT study to SOUL: different administration methods of semaglutide but same efficacy?","Gatto L","2025","European heart journal supplements : journal of the European Society of Cardiology","randomized_trial","article","10.1093/eurheartjsupp/suaf024","40248301","PMC12001787",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005053","Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.","Szczesnowicz A","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm12185915","37762856","PMC10532286",null,"S000630","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005054","Ischemic Colitis Associated With Tirzepatide Therapy in a Young Female Patient: A Case Report.","Sekhon S","2026","Cureus","case_report","article","10.7759/cureus.101437","41694961","PMC12896725",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005055","Clinical Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Meta-analysis.","Shi L","2023","Cellular and molecular biology (Noisy-le-Grand, France)","systematic_review","article","10.14715/cmb/2023.69.4.13","37329543",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Journal Article; review"],["R0005056","Engagement With a Breath-Based Metabolic Device Is Associated with Greater Weight Loss in Self-Reported Real-World GLP-1RA Users","Ben David G","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.02.22.26346841",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0005057","Beneficial Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Asthma: A Literature Review.","Kanwar MK","2022","Cureus","narrative_review","article","10.7759/cureus.30812","36457601","PMC9705051",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005058","The Impact of Obesity on Airway Inflammation, Lung Function and Biologic Treatment in Asthma: A Narrative Review.","Hadžić B","2026","Journal of inflammation research","narrative_review","article","10.2147/jir.s554138","42273223","PMC13248980",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0005059","Exploratory real-world experience with GLP-1 receptor agonists vs. metformin in youth with new-onset type 2 diabetes: a single-center retrospective study.","Tejeji I","2026","Journal of pediatric endocrinology & metabolism : JPEM","nonrandomized_study","article","10.1515/jpem-2025-0493","41204644","PMC12780941",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0005060","The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.","Li C","2022","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2022.838277","35185588","PMC8854770",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005061","Integrated Genetic and Protein Mechanisms Underlying Glucagon-like Peptide-1 Receptor Agonists in Treating Diabetes Mellitus and Weight Loss.","Francis L","2025","Current issues in molecular biology","nonrandomized_study","article","10.3390/cimb47121007","41614771","PMC12732264",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; other; article"],["R0005062","GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study.","Ganju N","2026","Scientific reports","nonrandomized_study","article","10.1038/s41598-026-58181-y","42321339","PMC13554153",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005063","Utility of glucagon-like peptide 1 receptor agonists as anti-obesity medications in liver transplant recipients.","Richardson SH","2024","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","other","article","10.1097/lvt.0000000000000233","37530854",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0005064","Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions.","Zhu JJ","2024","World journal of diabetes","systematic_review","article","10.4239/wjd.v15.i10.2135","39493569","PMC11525725",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0005065","Portal vein thrombosis in a patient on semaglutide.","Farooqi MF","2025","Qatar medical journal","other","article","10.5339/qmj.2025.57","40792243","PMC12338108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005066","Incretin-based therapy: a new horizon in diabetes management.","Zarei M","2024","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-024-01479-3","39610543","PMC11599551",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005067","Pancreas Transplantation for Recipients with Type 2 Diabetes Mellitus: Results of an International Survey.","Fridell JA","2026","Transplantation direct","other","article","10.1097/txd.0000000000001963","42256091","PMC13236245",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005068","Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.","Nreu B","2023","Minerva endocrinology","systematic_review","article","10.23736/s2724-6507.20.03219-8","32720500",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0005069","Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.","Malik RA","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15599","38637981",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0005070","Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World Study.","Bonora BM","2025","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.70045","40277315","PMC12023824",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0005071","Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis.","Raveendra K","2026","European heart journal","systematic_review","article","10.1093/eurheartj/ehag021","41603358","PMC13268693",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; review-article; article"],["R0005072","[Innovative therapeutic drug combination for type 2 diabetes at cardiorenal risk].","Scheen AJ","2024","Revue medicale suisse","nonrandomized_study","article","10.53738/revmed.2024.20.884.1492","39219392",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","English Abstract; Journal Article; article"],["R0005073","Insulin resistance induced by obesity: Mechanisms, metabolic implications and therapeutic approaches.","Choo YN","2026","Molecular biology reports","narrative_review","article","10.1007/s11033-026-11509-3","41636917","PMC12872655",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005074","Anatomical evidence links the stomach to the central amygdala, a region responsive to local GLP-1R agonist induced feeding and nausea-like behaviors in male mice.","Yang H","2026","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2026.1740052","41685252","PMC12890699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005075","The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis.","Sasaki T","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","systematic_review","article","10.1093/ndt/gfaf193","40982219","PMC13037467",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0005076","Incretin-Based Therapies in Alzheimer's and Parkinson's Disease: Advancing Neuroprotection With Dual and Triple Agonists-A Review.","Mohammed O","2025","Health science reports","narrative_review","article","10.1002/hsr2.71065","40671844","PMC12264087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005077","Mechanistic insights and emerging therapeutic strategies targeting endothelial dysfunction in cardiovascular diseases.","Heo KS","2025","Archives of pharmacal research","narrative_review","article","10.1007/s12272-025-01542-4","40301174",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005078","Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.","Gallo G","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25052484","38473732","PMC10931718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005079","Rationale for DPP-4 Inhibitors as Bridge or Dose-Sparing Therapy in Patients Using GLP-1 Receptor Agonists or Tirzepatide: A Conceptual Framework","M","2025","Authorea Preprints","randomized_trial","preprint","10.22541/au.175762014.42205498/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0005080","The potential of glucagon-like peptide-1 receptor agonists in heart failure.","Kreiner FF","2022","Frontiers in physiology","narrative_review","article","10.3389/fphys.2022.983961","36203939","PMC9531309",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005081","Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus.","Qaisar R","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70253","40855709",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0005082","Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study.","Busch CBE","2024","Gastrointestinal endoscopy","other","article","10.1016/j.gie.2024.04.2904","38692517",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005083","The Role of Combining Exercise with Pharmacologic Management of Chronic Kidney disease: From Sodium-Glucose Co-Transporter-2 and Glucagon-Like Peptide-1 to Broader Therapeutic Strategies.","Wilkinson TJ","2026","Nephron","narrative_review","article","10.1159/000551510","41843705",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005084","Sepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2 Diabetes.","Tseng YY","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","nonrandomized_study","article","10.1093/ndt/gfag175","42566276",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005085","Chronic kidney disease for the primary care provider.","Doak W","2026","Disease-a-month : DM","narrative_review","article","10.1016/j.disamonth.2025.102027","41152063","PMC12616483",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005086","Association between sarcopenia and the presence of diarrhea or constipation in individuals with type 2 diabetes: a cross-sectional study.","Kobayashi G","2026","Diabetology international","other","article","10.1007/s13340-026-00887-5","41852485","PMC12992780",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0005087","[ANMCO Statement: semaglutide in cardio-nephro-metabolic disorders].","De Luca L","2024","Giornale italiano di cardiologia (2006)","narrative_review","article","10.1714/4372.43702","39588627",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0005088","Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes.","Sato T","2023","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgad177","36974363",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005089","Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.","Neves JS","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70750","42027097","PMC13243951","ClinicalTrials.gov:NCT02540993; ClinicalTrials.gov:NCT02545049",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; research-article; article"],["R0005090","Rapid Improvement in Weight, Body Composition, and Glucose Variability With Semaglutide in Type 1 Diabetes.","Gad H","2024","Cureus","case_report","article","10.7759/cureus.61577","38962634","PMC11221340",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005091","Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.","Arrowaili A","2025","Obesity surgery","systematic_review","article","10.1007/s11695-025-07856-y","40237975",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0005092","Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.","Cai M","2026","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2025-086886","41781010","PMC12958796",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005093","Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.","Rossing P","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14883","36193847","PMC10092103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005094","GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.","Huang T","2024","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2024.3806","39133509","PMC11320332",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, N.I.H., Extramural; research-article; article"],["R0005095","Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.","Yaseen M","2026","Annals of medicine and surgery (2012)","systematic_review","article","10.1097/ms9.0000000000005353","42583410","PMC13461105",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0005096","Hypercalcemia Induced by Tirzepatide and Calcium Supplementation: A Case Report.","Nguyen E","2026","Cureus","case_report","article","10.7759/cureus.108061","42226819","PMC13222126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005097","Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.","Kozato A","2026","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-026-13147-z","42467193",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005098","Activation of the HPA Axis Does Not Explain Nonresponsiveness to GLP-1R Agonist Treatment in Individuals With Type 2 Diabetes.","Tokgöz S","2025","Diabetes","other","article","10.2337/db24-0463","39561332","PMC11755685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005099","[Expert consensus on the clinical application of nutrient-stimulated hormone receptor agonist in the treatment of type 2 diabetes mellitus (2026 edition)].","Endocrinology and Metabolism Professional Committee, National Association of Health Industry and Enterprise Management","2026","Zhonghua yi xue za zhi","other","article","10.3760/cma.j.cn112137-20260527-01398","42618499",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Consensus Statement; English Abstract"],["R0005100","Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.","Lin TK","2021","Frontiers in molecular neuroscience","other_trial","article","10.3389/fnmol.2021.697440","34305527","PMC8292641",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0005101","Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists.","Grenet G","2025","The Cochrane database of systematic reviews","narrative_review","article","10.1002/14651858.cd016144","40237182","PMC12001313",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; systematic-review; article"],["R0005102","Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth?","Nesti L","2024","World journal of diabetes","other_trial","article","10.4239/wjd.v15.i5.818","38766425","PMC11099368",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Editorial; article"],["R0005103","A novel dual CCK/ GLP-1 receptor agonist ameliorates cognitive impairment in 5 × FAD mice by modulating mitophagy via the PINK1/Parkin pathway.","Luo R","2025","International immunopharmacology","preclinical","article","10.1016/j.intimp.2025.114612","40184808",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; preprint; article"],["R0005104","Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment.","Sanchez-Baya M","2025","Journal of clinical medicine","randomized_trial","article","10.3390/jcm14041048","40004579","PMC11856796",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005105","Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study.","Hong B","2024","Annals of internal medicine","nonrandomized_study","article","10.7326/m23-3220","39186787",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005106","Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study.","Lengsfeld S","2024","EBioMedicine","randomized_trial","article","10.1016/j.ebiom.2024.105284","39232425","PMC11404067",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0005107","Novel oral agents in anti-obesity pharmacotherapy: A narrative review.","Buch A","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16618","40662383",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0005108","Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia.","Sen S","2024","JAMA surgery","nonrandomized_study","article","10.1001/jamasurg.2024.0111","38446466","PMC10918573",null,"S002511","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005109","A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.","Zhang Y","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70967","42410323","PMC13448884",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005110","Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?","Thotamgari SR","2022","Cardiovascular endocrinology & metabolism","nonrandomized_study","article","10.1097/xce.0000000000000265","35702660","PMC9187195",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005111","Polycystic ovary syndrome (PCOS): current insights, emerging therapeutics, and future treatment strategies.","Panchpuri M","2026","Inflammopharmacology","narrative_review","article","10.1007/s10787-026-02117-5","41615570",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005112","G protein-coupled receptors and obesity.","Pocai A","2023","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2023.1301017","38161982","PMC10757641",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005113","Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.","Anderson SR","2025","The American journal of gastroenterology","nonrandomized_study","article","10.14309/ajg.0000000000003208","39717004",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005114","Hemoglobin A1c and Weight Changes Associated With Grocery Delivery and Low-Carbohydrate Education in Adults With Type 2 Diabetes and Food Insecurity: Observational Quality Improvement Cohort Study.","Waselewski M","2026","JMIR formative research","nonrandomized_study","article","10.2196/89459","42766389","PMC13592385",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0005115","Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.","Gutierrez de Piñeres V","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70313","41287185",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0005116","Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review.","Xie Z","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s537229","40821754","PMC12357579","PROSPERO:CRD42024576314",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005117","Treatable Traits-Based Pharmacologic Treatment of Sleep Apnea.","Lisik D","2025","Sleep medicine clinics","randomized_trial","article","10.1016/j.jsmc.2024.10.002","39894591",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0005118","Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?","Singh AK","2024","The Journal of the Association of Physicians of India","nonrandomized_study","article","10.59556/japi.72.0621","39163055",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0005119","An overview of GLP-1 agonists and recent cardiovascular outcomes trials.","Sheahan KH","2020","Postgraduate medical journal","narrative_review","article","10.1136/postgradmedj-2019-137186","31801807","PMC7042958",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005120","Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.","Pradhan R","2024","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.15248","37876318",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005121","One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.","Zhang M","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16078","39568391",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Comparative Study; Meta-Analysis; Systematic Review; article"],["R0005122","Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies.","Sango K","2022","Frontiers in cell and developmental biology","preclinical","article","10.3389/fcell.2022.950623","35874814","PMC9298969",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005123","Association of GLP-1 Agonists With Postoperative Complications Following Knee Extensor Mechanism Repair:An Analysis of 1,092 Patients.","Forst E","2026","Orthopedics","nonrandomized_study","article","10.3928/01477447-20260811-01","42673608",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005124","[New Therapeutic Approaches for MASH: Mechanisms and Clinical Promise].","Barton A","2026","Zeitschrift fur Gastroenterologie","nonrandomized_study","article","10.1055/a-2894-7716","42777699",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; English Abstract; article"],["R0005125","DXA-Measured Body Composition Effects of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adults with Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis of Phase 3 Randomized Trials","Alaycı B","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-9973131/v1",null,null,"PROSPERO:CRD420261323497",null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0005126","Liquid Chromatography Evaluation of a Novel Graphitic Carbon Stationary Phase Using Glucagon-Like Peptide‑1 Analogs.","Parente MJ","2025","ACS omega","other","article","10.1021/acsomega.5c02172","40852274","PMC12368705",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005127","Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion.","Ehrhardt NM","2024","Clinical diabetes : a publication of the American Diabetes Association","case_report","article","10.2337/cd23-0047","38666194","PMC11040021",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005128","Clinical Significance of Cardio-Ankle Vascular Index in Stage A/B Heart Failure Patients With Type 2 Diabetes Mellitus.","Hitsumoto T","2026","Journal of clinical medicine research","other","article","10.14740/jocmr6680","42730413","PMC13568742",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005129","Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.","Billings LK","2025","Annals of internal medicine","randomized_trial","article","10.7326/annals-24-03849","40183678",null,"ClinicalTrials.gov:NCT05564039","S001940","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; Comparative Study; article"],["R0005130","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.","Ansari HUH","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2023.11.007","38029929",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0005131","Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?","Sawami K","2023","Hypertension research : official journal of the Japanese Society of Hypertension","other_trial","article","10.1038/s41440-023-01324-9","37258623",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0005132","Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.","Barritt AS","2022","Alimentary pharmacology & therapeutics","other_trial","article","10.1111/apt.16794","35266164","PMC9310586",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005133","Heterogeneity of treatment effects of glucose-lowering drug classes for type 2 diabetes: LEGEND-T2DM network real-world evidence.","Dávila-García DM","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2025.109114","40582069",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Preprint; preprint; article"],["R0005134","Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity.","Rajamoorthi A","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.06.07.730723","42327337","PMC13278011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0005135","In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist.","Jones B","2022","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14794","35676825","PMC9796023",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005136","Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.","Kwon J","2025","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2025.2462100","39921267",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0005137","Particulate Gastric Contents in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists After Appropriate Perioperative Fasting: A Report of 2 Cases.","Wilson PR","2023","A&A practice","case_report","article","10.1213/xaa.0000000000001712","37616174",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0005138","Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.","Rossing P","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-03002-1","41422027","PMC12862915","ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0005139","Economic burden of type 2 diabetes management in France according to clinical characteristics.","Guerci B","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70586","41804199","PMC13071239",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005140","Breakthrough drugs in the treatment of hypertension-related disease.","Hoshide S","2026","Hypertension research : official journal of the Japanese Society of Hypertension","narrative_review","article","10.1038/s41440-026-02725-2","42443375",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005141","Corrigendum to \"Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4\" [Eur. J. Pharmacol. 1011 (2026) 178445].","Jung JE","2026","European journal of pharmacology","notice","article","10.1016/j.ejphar.2025.178495","41423407",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0005142","Initiation of Type 2 Diabetes Mellitus Medications in the NGHA Healthcare System in Saudi Arabia: Contemporary Trends.","Alyabsi MS","2025","Current therapeutic research, clinical and experimental","other","article","10.1016/j.curtheres.2025.100809","40894464","PMC12395078",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005143","The potential of GLP-1 RAs in treating Tobacco use dependence and Obesity","Tan KK","2023","Qeios","other","preprint","10.32388/k171wv",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005144","Is Semaglutide a Safer Weight-Management Option Than Bariatric Surgery for Patients Undergoing Total Hip Arthroplasty (THA)?","Alpert Z","2026","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2025.08.068","40907673",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0005145","[Advances in the diagnosis and poor prognosis of diabetic hyperfiltration].","Ma RX","2024","Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]","narrative_review","article","10.3760/cma.j.cn112150-20240108-00027","39142898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005146","The Risk of GLP-1 Receptor Agonist (GLP-1 RA) Exposure in Early Pregnancy. A Call to Action: Quantifying the Impact on Pregnancy Outcomes in the United Kingdom.","Stedman M","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70791","42017293","PMC13243965",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0005147","Barriers in prescribing antidiabetic medications with cardiovascular benefits: practice, experience, and attitudes of GPs in Croatia.","Kurevija T","2025","BMC primary care","nonrandomized_study","article","10.1186/s12875-025-02837-7","40316896","PMC12046718",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005148","Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report.","Dinoi E","2025","Frontiers in endocrinology","case_report","article","10.3389/fendo.2025.1533209","39996062","PMC11847660",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005149","Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.","Parlati AL","2026","Clinical Medicine Insights. Cardiology","narrative_review","article","10.1177/11795468261460202","42317617","PMC13272863",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005150","Diabetic retinopathy severity is associated with renal function deterioration in patients with diabetic kidney disease: a retrospective cohort study.","Yu L","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1757296","41837122","PMC12980877",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005151","An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits.","Subedi L","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2024.12.039","39709071",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005152","The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study.","Ayoub M","2024","Cancers","nonrandomized_study","article","10.3390/cancers16091625","38730578","PMC11082986",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005153","Trends in diabetes medication prescribing from 2018 to 2021: A cross-sectional analysis.","Riad J","2024","PloS one","nonrandomized_study","article","10.1371/journal.pone.0307451","39146274","PMC11326546",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005154","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.","Mohamed Ali Elbashir R","2025","Cureus","systematic_review","article","10.7759/cureus.95938","41341350","PMC12670982",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005155","Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use.","Menkü Özdemir FD","2026","Annals of plastic surgery","other","article","10.1097/sap.0000000000004673","41687026",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0005156","Artificial intelligence in obesity management: clinical evidence, translational gaps, and implementation priorities-a structured narrative review.","Liu W","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1955223","42755727","PMC13581758",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0005157","What is the association between insulin dependence and the incidence of postoperative complications, perioperative glucose control, and five-year reoperation rates after total joint replacement?","Wong J","2026","Bone & joint open","nonrandomized_study","article","10.1302/2633-1462.79.bjo-2026-0056.r1","42686200","PMC13537884",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005158","GLP-1 Agonist Use Leads to Earlier Return of Bowel Function Following Lumbar Fusion.","Fano A","2025","Spine","nonrandomized_study","article","10.1097/brs.0000000000005598","41400023",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005159","Liraglutide Ameliorates Renal Endothelial Dysfunction in Diabetic Rats Through the Inhibition of the Dll4/Notch2 Pathway.","Li Y","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s492252","39492960","PMC11531755",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005160","The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care.","Cortinovis M","2026","Clinical journal of the American Society of Nephrology : CJASN","narrative_review","article","10.2215/cjn.0000000975","41348481","PMC13493017","ClinicalTrials.gov:NCT04939935; ClinicalTrials.gov:NCT06582875; ClinicalTrials.gov:NCT06902558; ClinicalTrials.gov:NCT06345755; ClinicalTrials.gov:NCT04907799","S000493","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005161","Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities.","Podder V","2026","Clinical cancer research : an official journal of the American Association for Cancer Research","nonrandomized_study","article","10.1158/1078-0432.ccr-25-2819","41329840",null,null,"S002362","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0005162","Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.","Rodriguez LA","2024","Lancet regional health. Americas","nonrandomized_study","article","10.1016/j.lana.2024.100759","38745886","PMC11091531",null,"S000248","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005163","Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.","Ahmed M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70667","41834765",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; review"],["R0005164","Evaluation of safety of preoperative GLP-1 receptor agonists in patients undergoing elective surgery: a systematic review, meta-analysis and meta-regression.","Kamarajah SK","2025","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2025.103408","41054439","PMC12496209","PROSPERO:CRD420251027809",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0005165","Updates on paediatric MASLD: insights from an endocrine lens.","Segev N","2026","Diabetologia","narrative_review","article","10.1007/s00125-026-06724-3","41973196",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005166","Effect of anti-diabetic agent on interstitial lung disease in patients with diabetes mellitus.","Hu WS","2025","Naunyn-Schmiedeberg's archives of pharmacology","nonrandomized_study","article","10.1007/s00210-024-03296-0","39031184",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0005167","Global perspectives on monogenic forms of diabetes.","Russ-Silsby J","2025","Diabetologia","narrative_review","article","10.1007/s00125-025-06495-3","40668408","PMC12534271",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005168","Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1.","Yin YH","2023","World journal of gastroenterology","other_trial","article","10.3748/wjg.v29.i48.6235","38186863","PMC10768396",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; letter; article"],["R0005169","Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes.","Lewis M","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.17086","40549381","PMC12186121",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005170","Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.","Kobayashi K","2022","Scientific reports","nonrandomized_study","article","10.1038/s41598-022-20313-5","36167964","PMC9515152",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005171","Liraglutide inhibits the development of colorectal cancer by regulating TGF-β/Smad3 signaling pathway and affecting epithelial-mesenchymal transition.","Li X","2025","Discover oncology","preclinical","article","10.1007/s12672-025-03223-6","40681775","PMC12274191",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005172","Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis.","Krisanapan P","2024","Clinical kidney journal","systematic_review","article","10.1093/ckj/sfae018","38410684","PMC10896177","PROSPERO:CRD42023426190",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article; review"],["R0005173","Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.","Rosenstock J","2026","Nature medicine","notice","article","10.1038/s41591-026-04532-1","42343118","PMC13472946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0005174","From Control to Cure: Insights into the Synergy of Glycemic and Antibiotic Management in Modulating the Severity and Outcomes of Diabetic Foot Ulcers.","Omotosho IA","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26146909","40725154","PMC12295755",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005175","Implementation of guideline-recommended organ-protective therapy in people with type 2 diabetes and cardiovascular disease, heart failure, or kidney disease: real-world evidence from a German University Hospital.","Suliman K","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1736984","41567800","PMC12816769",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005176","GLP-1 receptor agonist therapy for obesity via direct-to-consumer telemedicine: Clinical characteristics and treatment outcomes.","Gratzke M","2025","Digital health","nonrandomized_study","article","10.1177/20552076251382040","41000573","PMC12457751",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005177","First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis.","Deng R","2024","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2024.1289643","38348420","PMC10860745","PROSPERO:CRD42022347233",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; systematic-review; review"],["R0005178","Mortality and persistence in therapy in elderly subjects with type 2 diabetes receiving gliflozins or incretins.","Del Zoppo A","2026","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-026-02994-1","42484967",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005179","Identifying predictors of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist use in hospital among adults with diabetes.","Raudanskis A","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2024.108945","39740304",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0005180","Addressing the dual challenge: Managing smoking cessation in patients with diabetes.","Russo C","2025","World journal of diabetes","narrative_review","article","10.4239/wjd.v16.i12.105241","41480599","PMC12754108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005181","Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review.","Fernando K","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01116-9","34309808","PMC8312211",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0005182","Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes.","Ng E","2022","Australian journal of general practice","narrative_review","article","10.31128/ajgp-07-21-6057","35773162",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005183","Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.","Vergès B","2022","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-022-01686-3","36380358","PMC9667639",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005184","GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?","Pedrosa MR","2022","Current atherosclerosis reports","other_trial","article","10.1007/s11883-022-01062-2","36044100",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0005185","Unmasking Euglycemic Diabetic Ketoacidosis: The Interplay of Pregnancy, Sepsis, and Glucagon-Like Peptide 1 Analog.","Huang A","2025","Cureus","case_report","article","10.7759/cureus.78193","40026933","PMC11870146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005186","Disproportionality analysis of infection associated with antidiabetic drug use patterns.","Kim TH","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-18723-2","41023271","PMC12479883",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005187","Tirzepatide: A Breakthrough Therapy for Obstructive Sleep Apnea and Metabolic Dysfunction.","Singh G","2026","Current hypertension reviews","narrative_review","article","10.2174/0115734021398680251001102514","41140212",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005188","Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.","Popoviciu MS","2025","Biomedicines","nonrandomized_study","article","10.3390/biomedicines13092174","41007739","PMC12467173",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005189","Consequences of weight cycling in patients with obesity and the potential impact of high protein diet: a health economic assessment from a US societal perspective.","Schwander B","2025","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2025-101058","40829826","PMC12366568",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005190","Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Idiopathic Inflammatory Myopathy: From Mechanisms of Action to Clinical Applications.","Rajagopal S","2023","Cureus","randomized_trial","article","10.7759/cureus.51352","38292961","PMC10824603",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005191","The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy.","Oezer K","2023","Acta diabetologica","preclinical","article","10.1007/s00592-023-02135-7","37423944","PMC10520173",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005192","GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.","Singh A","2024","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v30.i48.5205","39735270","PMC11612699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; letter; article"],["R0005193","Addressing screams for evidence on renoprotection by GLP-1 receptor agonists.","Sasako T","2022","Kidney international","nonrandomized_study","article","10.1016/j.kint.2021.11.021","35065690",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comment; article"],["R0005194","Glucagon-Like Peptide-1 Receptor Agonist Use is Not Associated With Increased Complications After Total Knee Arthroplasty in Patients With Type-2 Diabetes.","Heo KY","2024","Arthroplasty today","nonrandomized_study","article","10.1016/j.artd.2024.101506","39959369","PMC11827009",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005195","Therapeutic effects of finerenone and exenatide on diabetes-induced heart failure: A combined approach targeting inflammation and oxidative stress.","Koçak A","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.177826","40494432",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005196","An updated patent review of GLP-1 receptor agonists (2020-present).","Lu W","2023","Expert opinion on therapeutic patents","nonrandomized_study","article","10.1080/13543776.2023.2274905","37870067",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0005197","Insulin Resistance as a Systemic Metabolic Risk State for Cancer: Mechanisms, Biomarkers, and Prevention.","Matek Sarić M","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27125495","42353211","PMC13299947",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005198","Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.","Wan KW","2026","JAMA pediatrics","systematic_review","article","10.1001/jamapediatrics.2026.2248","42329656","PMC13288192",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; article"],["R0005199","Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists.","Hernández C","2022","Acta diabetologica","other","article","10.1007/s00592-022-01928-6","35925404",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005200","Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review.","Tuttle KR","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70180","41054018","PMC12673433",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005201","Examining the association of dipeptidyl peptidase-4 inhibitors with autoimmune blistering disorders in the U.S. Military veterans.","Saad-Omer S","2026","Cutaneous and ocular toxicology","nonrandomized_study","article","10.1080/15569527.2026.2672618","42189844",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0005202","GLP-1 Receptor Agonism Exacerbates Activity-Based Anorexia in Mice.","Thakar A","2026","The International journal of eating disorders","preclinical","article","10.1002/eat.70169","42420812",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005203","Glucagon-Like Peptide-1 Receptor Agonists","Collins L","2024","StatPearls Publishing, Treasure Island (FL)","other","article",null,"31855395",null,null,"S000532; S002418","europepmc","TRUE","free_to_read","5",null,"Study Guide"],["R0005204","Clinical studies on anti-obesity medications in Arab countries.","AlOtaibi HF","2025","Saudi medical journal","randomized_trial","article","10.15537/smj.2025.46.5.20250126","40335111","PMC12074045",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; systematic-review; article"],["R0005205","Editorial: Incretin-based therapies: economic sustainability and health impact in the global management of metabolic syndrome.","Provenzani A","2026","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2026.1954325","42676583","PMC13526936",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; editorial"],["R0005206","Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Literature Review on Pathophysiology and Treatment.","Romanos M","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70659","41937581","PMC13094683",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005207","Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.","Kushner PR","2026","Journal of the American Heart Association","other_trial","article","10.1161/jaha.126.049727","42535526",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0005208","Comparative Efficacy of GLP-1 Receptor Agonists, Exercise, and Their Combination on Body Composition and Glucolipid Metabolism in Adults With Overweight or Obesity: A Network Meta-Analysis of Randomized Controlled Trials.","Vandoni M","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70189","42444070","PMC13460723",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Review; review-article; article"],["R0005209","Influence of Common Medications on Diabetic Macular Edema in Type 2 Diabetes Mellitus.","Muayad J","2025","Ophthalmology. Retina","nonrandomized_study","article","10.1016/j.oret.2024.12.006","39644923",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Multicenter Study"],["R0005210","Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy.","Liu C","2023","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2023.1268619","38313844","PMC10836428",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005211","Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies.","Kong F","2023","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2023.1205207","37771725","PMC10525376",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0005212","Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials.","Tang H","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16147","39723481","PMC12135018",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; research-article; review"],["R0005213","Erythrocytosis and thromboembolic risks associated with SGLT2 inhibitors in type 2 diabetes.","Chen YH","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-31726-3","41372397","PMC12808242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005214","Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).","Kimura T","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15258","37646192",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0005215","Enteroendocrine hormones and gut microbiota in obesity: a systematic review from mechanistic insight to precision metabolic care.","Jayathilaka NS","2026","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-026-01887-7","41743894","PMC12929769",null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Review"],["R0005216","The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function.","Kantreva K","2025","Endocrine","narrative_review","article","10.1007/s12020-024-04033-6","39289244",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005217","Declining Bariatric Surgery Volumes and Shifting Practice Patterns: A Five-Year Analysis of Over One Million Procedures.","Wills MV","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08795-y","42458201","PMC13429527",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005218","Obesity and Cancer: Mechanisms, Epidemiological Evidence, and Potential Risk Reduction.","Lim JS","2026","Journal of obesity & metabolic syndrome","randomized_trial","article","10.7570/jomes25088","41506747","PMC12884606",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005219","CROI 2025: Metabolic and Other Complications of HIV Infection.","Sarkar S","2025","Topics in antiviral medicine","randomized_trial","article",null,"40802984","PMC12324710",null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Review; research-article"],["R0005220","Treating class 2-3 obesity with glucagon-like peptide-1 agonists: A 2-year real-world cohort study.","Abdel-Bary M","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16331","40104874",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005221","Effect of GLP-1RA Treatment on Adhesion Molecules and Monocyte Chemoattractant Protein-1 in Diabetic Patients with Atherosclerosis.","Hachuła M","2024","Life (Basel, Switzerland)","other","article","10.3390/life14060690","38929672","PMC11204864",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005222","The Potential of Antidiabetic Medications in the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Subjects with Type 2 Diabetes Mellitus.","Panou T","2025","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","narrative_review","article","10.1055/a-2567-7542","40139217",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005223","New Perspectives on Obesity-Associated Nephropathy from Pathophysiology to Therapeutics: Revealing the Promise of GLP-1 RA Therapy.","Ren L","2024","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s476815","39347536","PMC11437658",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005224","Pharmacological management of pediatric metabolic dysfunction-associated steatotic liver disease.","Abou Jaoudeh RAR","2025","Journal of pediatric gastroenterology and nutrition","narrative_review","article","10.1002/jpn3.12402","39526564",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005225","A Mitochondrion-Targeting Piezoelectric Nanosystem for the Treatment of Erectile Dysfunction via Autophagy Regulation.","Wang S","2025","Advanced materials (Deerfield Beach, Fla.)","other","article","10.1002/adma.202413287","39686789",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005226","The Impact of Antidiabetic Therapy on Liver Injury, Steatosis, and Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.","Albai O","2025","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina61101850","41155837","PMC12566187",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0005227","Obesity Medications: Evidence-Based Management","Chamarthi VS","2025","StatPearls Publishing, Treasure Island (FL)","nonrandomized_study","article",null,"40991762",null,null,null,"europepmc","TRUE","free_to_read","4",null,"Study Guide"],["R0005228","Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review.","Zhang H","2025","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.70077","40847599",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0005229","Semaglutide for Refractory Reactive Hypoglycaemia: A Case Report.","Kalimuthu H","2026","Cureus","case_report","article","10.7759/cureus.112861","42605357","PMC13477730",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005230","Acute Pancreatitis Caused by Tirzepatide.","Mando N","2024","Cureus","case_report","article","10.7759/cureus.76007","39834977","PMC11743417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005231","Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.","Buse JB","2025","Diabetes care","nonrandomized_study","article","10.2337/dc24-2841","40249765","PMC12635953",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; other; article"],["R0005232","Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice.","Hedin KA","2023","ACS synthetic biology","preclinical","article","10.1021/acssynbio.3c00455","37827516","PMC10661039",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005233","Semaglutide is associated with improved breast cancer survival, lower metastatic burden, and a dose–survival relationship uncoupled from weight-loss magnitude","Murugadoss K","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.04.23.26351609",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0005234","Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population.","Meyer KB","2026","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2026.32.3.271","41760563","PMC12948758",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005235","The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.","Abbass NJ","2025","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2025.02.025","40015592","PMC13110070",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0005236","Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table.","Cosentino F","2023","European heart journal","narrative_review","article","10.1093/eurheartj/ehad445","37448181",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005237","SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Reducing Heart Failure Hospitalizations in Type-2 Diabetes. A Systematic Review and Meta-Analysis","Asifa F","2024","Preprints.org","systematic_review","preprint","10.20944/preprints202410.0929.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0005238","Impact of Semaglutide Exposure on Neonatal Outcomes in Pregnant Women: A Systematic Review","Hansen LMH","2025","Authorea Preprints","systematic_review","preprint","10.22541/au.175023393.36965849/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0005239","Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study).","Feher M","2022","JMIR research protocols","protocol","article","10.2196/34206","35852840","PMC9346560",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0005240","Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide.","Beshay LH","2026","Cureus","case_report","article","10.7759/cureus.107836","42220693","PMC13215789",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005241","Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults.","Hashemi A","2025","Drugs & aging","narrative_review","article","10.1007/s40266-024-01165-2","39826050","PMC12576600",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0005242","\"Ozempic Face\" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.","Daneshgaran G","2025","Aesthetic surgery journal. Open forum","systematic_review","article","10.1093/asjof/ojaf056","40626110","PMC12232544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0005243","The Influence of GLP-1 Receptor Agonists on Five-Year Mortality in Colon Cancer Patients.","Cuomo RE","2025","Cancer investigation","other","article","10.1080/07357907.2025.2585512","41216819",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005244","Acute Unilateral NAION following Tirzepatide Therapy: A Case Report.","Valášková J","2026","Case reports in ophthalmology","nonrandomized_study","article","10.1159/000552569","42569780","PMC13450988",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0005245","Semaglutide-Associated Acute Interstitial Nephritis: A Case Report.","Borkum M","2022","Kidney medicine","case_report","article","10.1016/j.xkme.2022.100561","36471818","PMC9719074",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005246","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.","Boye KS","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15145","37712754",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0005247","GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","Kanwal F","2024","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2024.4661","39283612","PMC11406452",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005248","A very rare cause of markedly elevated CA 19-9: Glucagon-like peptide-1 receptor agonists.","Liang R","2024","Diabetes & metabolism","case_report","article","10.1016/j.diabet.2024.101578","39271004",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005249","Tirzepatide and semaglutide: different twins?","Cesaro A","2026","European heart journal supplements : journal of the European Society of Cardiology","other","article","10.1093/eurheartjsupp/suag028","42099488","PMC13147262",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005250","Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis.","Xiao Z","2025","European journal of medical research","systematic_review","article","10.1186/s40001-025-03445-y","41287008","PMC12642067","PROSPERO:CRD42024532600",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Comparative Study; Systematic Review; Network Meta-Analysis; review-article; article"],["R0005251","Exercise as a Cornerstone Therapy for Cardiovascular-Kidney-Metabolic Syndrome: A Stage-Informed, Mechanistic, and Integrative Framework.","Papadakis Z","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.03.103","41921667",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0005252","Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin.","Fanshier AV","2023","Clinical diabetes : a publication of the American Diabetes Association","other_trial","article","10.2337/cd22-0060","37456095","PMC10338280",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0005253","Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy.","Shiina K","2024","Hypertension research : official journal of the Japanese Society of Hypertension","narrative_review","article","10.1038/s41440-024-01852-y","39210083","PMC11534699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005254","Experiences of GPs with incretin mimetics: a qualitative study in Germany.","Ege A","2026","BJGP open","other","article","10.3399/bjgpo.2025.0135","41238383",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005255","Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life.","Gjersdal E","2025","Pituitary","other","article","10.1007/s11102-025-01564-7","40830718","PMC12364737",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005256","Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.","Kitsios K","2026","Diabetes technology & therapeutics","randomized_trial","article","10.1177/15209156261486127","42695140",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0005257","Recent advances in preconception care.","Black KI","2025","Current opinion in obstetrics & gynecology","narrative_review","article","10.1097/gco.0000000000001060","40889154",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005258","Implementation Barriers to Evidence-Based Cardiovascular-Kidney-Metabolic Syndrome Management.","Davis G","2025","Heart, lung & circulation","narrative_review","article","10.1016/j.hlc.2025.05.095","40866167",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005259","An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review.","Dagli N","2023","Cureus","nonrandomized_study","article","10.7759/cureus.46510","37808605","PMC10552354",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0005260","Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study.","Yang F","2025","International journal of surgery (London, England)","randomized_trial","article","10.1097/js9.0000000000003156","40788007","PMC12695207",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; research-article; article"],["R0005261","Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.","Chen W","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1330936","38390214","PMC10882716",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005262","Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.","Qadeer A","2026","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/14791641261465360","42376874","PMC13319829",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Observational Study; research-article; article"],["R0005263","GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential.","Moaket OS","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms262110743","41226780","PMC12608514",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005264","Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data.","Singh H","2025","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2025.2459720","39873334",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005265","Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?","Kim HS","2021","International journal of molecular sciences","other_trial","article","10.3390/ijms22189936","34576096","PMC8470357",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005266","Effects of GLP-1 on ovarian dysfunction in polycystic ovary syndrome: A protocol for systematic review and meta-analysis.","Zhang C","2023","Medicine","systematic_review","article","10.1097/md.0000000000032312","36637917","PMC9839209","PROSPERO:CRD42020188247",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0005267","The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.","Barrett A","2024","Journal of medical economics","nonrandomized_study","article","10.1080/13696998.2024.2367919","38963346",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0005268","Body mass index as a determinant of surgical outcomes in total hip arthroplasty.","Leja W","2026","Wiadomosci lekarskie (Warsaw, Poland : 1960)","narrative_review","article","10.36740/wlek/218174","41962097",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005269","The Synergistic Treatment of Heart and Kidney Disease.","Mahfoud F","2026","Deutsches Arzteblatt international","narrative_review","article","10.3238/arztebl.m2025.0131","40801823","PMC12980813",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0005270","SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease.","Wang MJ","2023","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2023.115515","37742607",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005271","National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.","Adhikari R","2022","Journal of the American Heart Association","other","article","10.1161/jaha.121.023811","35475341","PMC9238581",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005272","Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEF.","Elbatreek MH","2026","Redox biology","preclinical","article","10.1016/j.redox.2026.104394","42743759","PMC13595013",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005273","Exenatide increases CTRP3 gene expression in adipose cells by inhibiting adipogenesis and induces apoptosis.","Koldemir Gündüz M","2022","Toxicology in vitro : an international journal published in association with BIBRA","preclinical","article","10.1016/j.tiv.2022.105479","36152787",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005274","GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors.","Patel R","2024","JACC. Heart failure","nonrandomized_study","article","10.1016/j.jchf.2024.07.006","39207323",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0005275","Pharmacological treatment patterns, factors associated with glycemic control, and renal function parameters in a real-world cohort of Hispanic adults with type 2 diabetes.","Diaz-Martinez J","2026","Biomedical reports","nonrandomized_study","article","10.3892/br.2026.2140","41987878","PMC13077263",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005276","Semaglutide showed limited improvements in patients with Alzheimer's disease: Revisiting the evoke and evoke + clinical trials.","Hölscher C","2026","Journal of Alzheimer's disease : JAD","other_trial","article","10.1177/13872877261458402","42261705",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005277","Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma.","Müller HL","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1768254","42325616","PMC13278930",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005278","Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.","Kubota M","2023","Cureus","randomized_trial","article","10.7759/cureus.46490","37800161","PMC10550307",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005279","Glucagon-like peptide-1 receptor agonist exendin 4 ameliorates diabetes-associated vascular calcification by regulating mitophagy through the AMPK signaling pathway.","Chen K","2024","Molecular medicine (Cambridge, Mass.)","preclinical","article","10.1186/s10020-024-00817-8","38720283","PMC11080124",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005280","Gender-Specific Differences in Diastolic Dysfunction and HFpEF: Pathophysiology, Diagnosis, and Therapeutic Strategies.","Coppi F","2025","Journal of cardiovascular development and disease","narrative_review","article","10.3390/jcdd12060213","40558648","PMC12194537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005281","The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Retinopathy at a Tertiary Care Center.","Joo JH","2024","Ophthalmology science","nonrandomized_study","article","10.1016/j.xops.2024.100547","39139548","PMC11321299",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005282","The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis.","Dichtel LE","2021","Hepatology (Baltimore, Md.)","other","article","10.1002/hep.31886","33960005","PMC8463414",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0005283","Lower respiratory infections in diabetes: which hypoglycemic agents help and which harm? A drug-target Mendelian randomization study","Wu Z","2026","Research Square","other","preprint","10.21203/rs.3.rs-10008003/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0005284","Comparative cardiovascular outcomes and safety of hypoglycemic drug classes in patients with type 2 diabetes and hypertension: a multicenter cohort analysis.","Wei Z","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02892-5","40836299","PMC12369064",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0005285","GLP-1 agonists: A review for emergency clinicians.","Long B","2024","The American journal of emergency medicine","narrative_review","article","10.1016/j.ajem.2024.01.010","38241775",null,null,"S000313","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0005286","Effect of common diabetes medications on metabolic dysfunction-associated steatotic liver disease as measured by transient elastography and other metabolic parameters: A systematic review.","Thompson K","2026","Clinics and research in hepatology and gastroenterology","systematic_review","article","10.1016/j.clinre.2026.102784","41679467",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0005287","Activation of GLP-1R modulates the spontaneous discharge of nigral dopaminergic neurons and motor behavior in mice with chronic MPTP Parkinson's disease.","Liu WH","2025","Frontiers in aging neuroscience","preclinical","article","10.3389/fnagi.2025.1529919","40353061","PMC12062123",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005288","Formulation and characterization of exenatide-loaded PLGA microspheres prepared by coacervation.","White C","2026","Drug delivery and translational research","preclinical","article","10.1007/s13346-025-02008-2","41364402","PMC13346254",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; dissertation; article"],["R0005289","Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.","Xu Y","2024","Journal of general internal medicine","randomized_trial","article","10.1007/s11606-023-08589-3","38191976","PMC11116290",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005290","Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk.","Emanuelsson F","2026","European heart journal","other","article","10.1093/eurheartj/ehaf779","41056187","PMC13247186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005291","Semaglutide Versus Dulaglutide and Liraglutide in Chinese Patients With T2DM: A Multicenter Real-World Study.","Xie Z","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70065","41266832",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Comparative Study; article"],["R0005292","Glucagon-Like Peptide-1 Receptor Agonists Combined With Personalized Digital Health Care for the Treatment of Metabolic Syndrome in Adults With Obesity: Retrospective Observational Study.","Zakaria H","2025","Interactive journal of medical research","nonrandomized_study","article","10.2196/63079","40146920","PMC11967752",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005293","Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet-induced obesity.","Sequeira V","2025","ESC heart failure","randomized_trial","article","10.1002/ehf2.15152","39482267","PMC11911617",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005294","Exploring Cardiometabolic Health, Physical Activity, and Quality of Life in Patients with Obesity and Multimorbidity during an Intensive Weight Loss Program: A Protocol for a Real-Life Prospective Cohort Study","Brødsgaard RH","2025","medRxiv","protocol","preprint","10.1101/2025.10.20.25337060",null,null,"ClinicalTrials.gov:NCT06234111","S001937","europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0005295","[Obesity: novel pharmacological treatments].","Seufert J","2026","Deutsche medizinische Wochenschrift (1946)","other_trial","article","10.1055/a-2610-3294","41802423",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review; English Abstract"],["R0005296","Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review.","Tariq S","2024","Cureus","systematic_review","article","10.7759/cureus.73705","39568487","PMC11578637",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005297","What is known about the use of weight loss medication in women with overweight/obesity on fertility and reproductive health outcomes? A scoping review.","Maslin K","2024","Clinical obesity","nonrandomized_study","article","10.1111/cob.12690","38951960",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Scoping Review; article"],["R0005298","The mechanism of liraglutide on promoting osteogenesis via macrophages polarization under the inflammatory and oxidative stress in osteoporosis.","Zhu S","2025","Life sciences","preclinical","article","10.1016/j.lfs.2025.123717","40436107",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005299","Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4.","Jung JE","2026","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.178445","41354295",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005300","CROI 2025: neuropsychiatric complications in people with HIV.","Corley MJ","2025","Topics in antiviral medicine","narrative_review","article",null,"40472384",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005301","Type 2 diabetes in the US managed care setting: the burden of disease and rationale for an oral glucagon-like peptide-1 receptor agonist.","Dougherty T","2020","The American journal of managed care","narrative_review","article","10.37765/ajmc.2020.88552","33439581",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0005302","Comparative Efficacy and Safety of GLP-1 Receptor Agonists in Neurological and Nephrological Outcomes of Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","Ramteke HD","2025","medRxiv","systematic_review","preprint","10.1101/2025.09.01.25334855",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0005303","A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction.","Qian P","2020","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2020.114209","32860826",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005304","Incretin-based therapy and the risk of diabetic foot ulcers and related events.","Werkman NCC","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15721","38951877",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0005305","Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks.","Rajab AM","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16332","40130476","PMC12046473",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005306","[Bariatric surgery versus GLP-1 and dual GIP/GLP-1 receptor agonists : Effects on weight, risk factors and prognosis].","Ordemann J","2025","Herz","narrative_review","article","10.1007/s00059-025-05319-9","40514456",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Comparative Study; English Abstract"],["R0005307","AI-enabled chest x-ray potentially detects subclinical diastolic dysfunction in diabesity and monitors its functional responses to GLP-1 or GLP-1/GIP receptor agonists: initial exploration and proof-of-concept.","White RD","2026","Cardiovascular diabetology. Endocrinology reports","other","article","10.1186/s40842-026-00312-5","42542549","PMC13429017",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005308","Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting.","Hu Y","2022","Annals of translational medicine","other","article","10.21037/atm-22-200","35284548","PMC8904982",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005309","Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.","Mohamed Abdalla SA","2026","Cureus","systematic_review","article","10.7759/cureus.114454","42732434","PMC13570719",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005310","Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity.","Stanisavljevic I","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2024.117668","39536536",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005311","Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014-2019 from a US database: prescriber and patient characteristics.","Lingvay I","2023","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.13363","36796312","PMC9934953",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0005312","Mechanisms of diabetic kidney disease and established and emerging treatments.","Martinez Leon V","2026","Nature reviews. Endocrinology","other_trial","article","10.1038/s41574-025-01171-3","40935879",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0005313","Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).","Lin TY","2023","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2023.0188","37533200","PMC10404523",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Comment; reply; article"],["R0005314","Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404).","Ko J","2023","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2023.0164","37533199","PMC10404527",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Comment; article"],["R0005315","Acute GLP-1 Agonism Induces Arrhythmogenic Electrical Activity in Aged Mice Heart Through Impaired Cellular Na+ and Ca2+ Handlings: The Role of CK2 Hyperphosphorylation.","Olgar Y","2025","Anatolian journal of cardiology","preclinical","article","10.14744/anatoljcardiol.2024.4719","39655941","PMC11793800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005316","Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide.","Huang R","2025","Theranostics","other","article","10.7150/thno.104523","39990223","PMC11840739",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005317","Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.","Bailey TS","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14739","35491520","PMC10286657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005318","Post Hoc Analyses of DKD Clinical Trials in Ethnic Minorities (Asian, Hispanic, Black) Narrative Review.","Hsiao LL","2025","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2025.09.003","41027828",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; review"],["R0005319","Future of Stroke Prevention: 7 Updates in the 2024 AHA/ASA Primary Prevention of Stroke Guideline.","Razavi AC","2025","JACC. Advances","randomized_trial","article","10.1016/j.jacadv.2025.101724","40338758","PMC12277621",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005320","FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue.","Oldan JD","2024","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000005318","38914020",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0005321","Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists.","Piccini S","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111689","38697297",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005322","Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.","Harrington J","2024","Current cardiology reports","randomized_trial","article","10.1007/s11886-023-02016-z","38551786",null,null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Review"],["R0005323","The Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis.","Woźniak M","2026","Journal of clinical medicine","systematic_review","article","10.3390/jcm15176818","42739822","PMC13566191","PROSPERO:CRD42025645378",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005324","Clinical and mechanistic effects of GLP-1 receptor agonists in hidradenitis suppurativa and comorbidities.","Brogaard E","2026","Science progress","narrative_review","article","10.1177/00368504261464855","42389771","PMC13329101",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005325","The role of cost-effectiveness in the use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.","Liu M","2023","European journal of preventive cardiology","randomized_trial","article","10.1093/eurjpc/zwad032","36740456",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Editorial; Comment; editorial"],["R0005326","Association of GLP-1 Receptor Agonists with Chronic Obstructive Pulmonary Disease Exacerbations among Patients with Type 2 Diabetes.","Foer D","2023","American journal of respiratory and critical care medicine","nonrandomized_study","article","10.1164/rccm.202303-0491oc","37647574","PMC10867930",null,"S001679","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0005327","A Biweekly GLP-1R Agonist Designed With Drug-Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability.","Ding W","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.71304","42712076",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005328","Dorsomedial striatal GABA dynamics organize palatable reward consumption and are reshaped by GLP-1 receptor agonism.","Copling AN","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.09.03.749293","42818528","PMC13622482",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0005329","Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US.","Pearson SD","2025","Journal of comparative effectiveness research","other","article","10.57264/cer-2025-0083","40641455","PMC12403326",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; discussion; article"],["R0005330","Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives.","Albini A","2025","Seminars in cancer biology","randomized_trial","article","10.1016/j.semcancer.2025.07.008","40701453",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0005331","The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis.","Conroy LJ","2024","American journal of physiology. Cell physiology","narrative_review","article","10.1152/ajpcell.00695.2023","38525540",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0005332","Comparison of the blood pressure management between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists","Kobayashi K","2022","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-1728274/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0005333","GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases, a Systematic Review of the Literature.","Thin L","2025","Biomedicines","systematic_review","article","10.3390/biomedicines13051128","40426955","PMC12108654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005334","The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment.","Pililis S","2024","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina60101656","39459443","PMC11509436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005335","Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.","Barrett A","2023","Advances in therapy","nonrandomized_study","article","10.1007/s12325-023-02540-y","37286889","PMC10246869",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005336","Case Report: Semaglutide-associated depression: a report of two cases.","Li JR","2023","Frontiers in psychiatry","case_report","article","10.3389/fpsyt.2023.1238353","37706035","PMC10495976",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005337","Synergistic Effects of SGLT2 Inhibitors and GLP-1R Agonists on Inflammation-Associated Oxidative Stress in Atrial Fibrillation.","Fakih W","2026","JACC. Basic to translational science","other","article","10.1016/j.jacbts.2026.101587","42247826","PMC13266112",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005338","Effects of Liraglutide on Mitigation of Hearing Loss After Repeated Blast Exposures: A Summary of Studies in Animal Model of Chinchilla.","Jiang S","2025","Military medicine","preclinical","article","10.1093/milmed/usaf255","40984095",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005339","Tirzepatide and Intermittent Cold Exposure Independently Improve Glucose Homeostasis in DIO Mice Housed at Thermoneutrality","Bellucci A","2026","bioRxiv","preclinical","preprint","10.64898/2026.05.21.727027",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005340","The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.","Caruso I","2024","Journal of endocrinological investigation","randomized_trial","article","10.1007/s40618-024-02441-z","39141075","PMC11473560",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005341","GLP-1 Receptor Agonists for Treatment of Pediatric Obesity: Behavioral Health Considerations.","Jhe GB","2025","Childhood obesity (Print)","narrative_review","article","10.1089/chi.2024.0418","40306953","PMC13622971",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0005342","GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Banerjee M","2023","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgad076","36800286",null,"PROSPERO:CRD42022331547",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0005343","Economic evaluation of weight loss and transplantation strategies for kidney transplant candidates with obesity.","Puttarajappa CM","2024","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","other","article","10.1016/j.ajt.2024.07.024","39084464",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005344","Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.","Nreu B","2020","Nutrition, metabolism, and cardiovascular diseases : NMCD","systematic_review","article","10.1016/j.numecd.2020.03.013","32448716",null,"PROSPERO:CRD42018115577",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0005345","Beyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management.","Vasile A","2026","Nutrients","randomized_trial","article","10.3390/nu18142266","42514335","PMC13415615",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005346","Review of Organ Collaborative Protection Strategies Based on CKM Staging: A Multidisciplinary Intervention Model Centered on Dysfunctional Adipose Tissue","Wang J","2025","Preprints.org","narrative_review","preprint","10.20944/preprints202509.0325.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005347","Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis.","Solpari K","2026","Liver international : official journal of the International Association for the Study of the Liver","nonrandomized_study","article","10.1111/liv.70580","41823026",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0005348","Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures.","Shah I","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf261","41179268","PMC12576406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005349","GLP-1 receptor agonists and weight loss in schizophrenia - past, present, and future.","Trott M","2024","Current opinion in psychiatry","narrative_review","article","10.1097/yco.0000000000000952","38847529",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005350","Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists- preliminary study.","Korus S","2026","Journal of translational medicine","nonrandomized_study","article","10.1186/s12967-026-07702-4","41965670","PMC13088576",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005351","Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?","Mouhammad ZA","2022","Frontiers in neuroscience","narrative_review","article","10.3389/fnins.2022.824054","35264926","PMC8899005",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005352","Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study.","Hviid KVR","2026","Human reproduction open","nonrandomized_study","article","10.1093/hropen/hoag015","41852577","PMC12995393",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005353","Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm.","Chaudhry A","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70240","41145374","PMC12803549",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005354","Glucose metabolism impairment in major depressive disorder.","Meng F","2025","Brain research bulletin","narrative_review","article","10.1016/j.brainresbull.2025.111191","39788458",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0005355","Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients.","Yen FS","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112174","40228671",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0005356","Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity.","Hropot T","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms24108592","37239935","PMC10218520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005357","The long-term cardiovascular benefits of metabolic and bariatric surgery versus pharmacological therapies in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.","Tong J","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","systematic_review","article","10.1016/j.soard.2026.06.012","42442963",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article"],["R0005358","Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards.","Abaalkhail F","2026","Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","other","article","10.4103/sjg.sjg_199_25","40888069","PMC13016600",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0005359","Preclinical and Emerging Clinical Evidence Supporting the Translational Potential of GLP-1 Receptor Agonists for Treating Psychostimulant and Nicotine Use Disorders.","Herman RJ","2026","Biological psychiatry","narrative_review","article","10.1016/j.biopsych.2026.05.002","42142797",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005360","High Dose of Liraglutide Impairs Renal Function in Female Hypertensive Rats.","Tonon Firmino F","2025","Journal of cardiovascular pharmacology","preclinical","article","10.1097/fjc.0000000000001649","39514188",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005361","Glucagon Stimulation Test and Insulin Secretory Capacity in the Clinical Assessment of Incretin-Based Therapy for Diabetes.","Haraguchi T","2024","Diabetes","nonrandomized_study","article","10.2337/db24-0518","39196369",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005362","Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study.","Mao X","2025","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2024.1096","40268291","PMC12260620",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005363","Semaglutide and heart failure: Updated meta-analysis.","Barbagelata L","2024","Current problems in cardiology","systematic_review","article","10.1016/j.cpcardiol.2024.102721","38908729",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0005364","Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting.","Lv L","2024","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2024.06.013","38991896",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0005365","Beyond GLP-1R: Dynamic Glucagon Receptor Family Signalling May Determine Antifibrotic Responses to Incretin-Based Therapies.","Andrés-Rozas M","2026","Liver international : official journal of the International Association for the Study of the Liver","other","article","10.1111/liv.70794","42415336",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005366","Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes.","Sørensen KK","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02915-1","41053738","PMC12502128",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0005367","Metabolic dysfunction-associated steatotic liver disease (MASLD): definition, diagnosis, natural history, and treatment.","Tamaki N","2026","Japanese journal of radiology","narrative_review","article","10.1007/s11604-025-01930-2","41591640",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005368","Advances in Oral Biomacromolecule Therapies for Metabolic Diseases.","Jiao Q","2025","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics17020238","40006605","PMC11859201",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005369","Incretin-based therapeutics for the treatment of neurodegenerative diseases.","Vear A","2025","Nature metabolism","narrative_review","article","10.1038/s42255-025-01263-4","40211045",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005370","Oral GLP-1 Super-Responders are Characterized by Greater Pretreatment Weight Gain, Faster Early Dose Escalation, and Larger On-Treatment Blood Pressure Reductions","Murugadoss K","2026","Preprints.org","other","preprint","10.20944/preprints202609.1730.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005371","Cagrilintide–Semaglutide Combination Therapy Versus Monotherapy or Placebo: A Systematic Review and Meta-Analysis","Laguna MAS","2025","Authorea Preprints","systematic_review","preprint","10.22541/au.176361875.58584436/v1",null,null,"PROSPERO:CRD420251128528",null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0005372","Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025.","Jiang R","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1883559","42558249","PMC13437389",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0005373","Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database.","Alenzi KA","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1364110","38860168","PMC11163090",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005374","GLP-1 receptor agonists: an updated review of head-to-head clinical studies.","Trujillo JM","2021","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018821997320","33767808","PMC7953228",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005375","Cardiovascular Disease Update: Heart Failure Update.","Bobeck KA","2025","FP essentials","narrative_review","article",null,"40829047",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005376","Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 Diabetes.","Wang J","2026","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.64898/2026.09.04.26362304","42818421","PMC13622739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0005377","Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies.","Trapanese V","2025","Life (Basel, Switzerland)","preclinical","article","10.3390/life15060843","40566497","PMC12193786",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005378","Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk.","Deng Y","2025","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.124.040217","40673553","PMC12449908",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005379","Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.","Zhou XY","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","systematic_review","article","10.1016/j.numecd.2026.104859","42469143",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0005380","Triple Agonism Based Therapies for Obesity.","Goldney J","2025","Current cardiovascular risk reports","other_trial","article","10.1007/s12170-025-00770-z","40741227","PMC12304053",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005381","Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity.","Kim SQ","2023","Biochemical and biophysical research communications","randomized_trial","article","10.1016/j.bbrc.2023.149164","37951155",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005382","Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis.","Huang X","2024","Medicine","systematic_review","article","10.1097/md.0000000000038236","38787986","PMC11124640",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0005383","Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease.","Vear A","2026","Cell reports. Medicine","preclinical","article","10.1016/j.xcrm.2026.102906","42413499","PMC13400174",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005384","Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients.","Mahmoud T","2023","Clinical transplantation","randomized_trial","article","10.1111/ctr.15144","37755118",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0005385","Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis.","Yang L","2026","The journal of sexual medicine","systematic_review","article","10.1093/jsxmed/qdag272","42704281",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0005386","Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.","Ostrominski JW","2026","Diabetes care","nonrandomized_study","article","10.2337/dc25-3063","41778928","PMC13241951",null,"S002366","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005387","Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study.","Skriver C","2023","Diabetologia","nonrandomized_study","article","10.1007/s00125-023-05972-x","37532786",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005388","Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.","Otsuka E","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1362242","38873429","PMC11169618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005389","Influence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X).","AlHazmi S","2026","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","other","article","10.1007/s44446-026-00097-9","42429876","PMC13354737",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005390","Analysis of Psychiatric Adverse Events for Semaglutide, Liraglutide, and Tirzepatide Reported to the EudraVigilance Database","Tobaiqy M","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3419258/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0005391","Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.","Hendershot CS","2025","JAMA psychiatry","randomized_trial","article","10.1001/jamapsychiatry.2024.4789","39937469","PMC11822619","ClinicalTrials.gov:NCT05520775","S000123; S000951","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0005392","Neuroprotective Role of the Novel GLP-1R Agonist Semaglutide.","Kenzheshova A","2025","Current medicinal chemistry","other","article","10.2174/0109298673359635250401051339","40277068",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005393","A New Age for Secondary Prevention: Optimal Medical Therapy for Stable Ischemic Heart Disease Among Patients with Diabetes and/or Obesity.","Osude N","2024","The Medical clinics of North America","narrative_review","article","10.1016/j.mcna.2023.11.003","38548458",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005394","Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012-2021.","Steiger K","2026","Journal of general internal medicine","other","article","10.1007/s11606-025-09784-0","40760383","PMC12855668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; Periodical Index; article"],["R0005395","Transpupillary in vivo two-photon imaging reveals enhanced surveillance of retinal microglia in diabetic mice.","Sotani N","2025","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.2426241122","41060759","PMC12541322",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005396","Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.","Tzang CC","2025","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2025.103680","41399474","PMC12702299","PROSPERO:CRD42025646185",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0005397","Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review.","Vasiliu O","2023","Experimental and therapeutic medicine","systematic_review","article","10.3892/etm.2023.12054","37324512","PMC10265718",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0005398","GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.","Vienghirun J","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70698","41872986",null,"PROSPERO:CRD42024539634",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Network Meta-Analysis; Journal Article; review"],["R0005399","Ketotic Hypoglycaemia Following Sleeve Gastrectomy.","He J","2025","Clinical endocrinology","case_report","article","10.1111/cen.15232","40129270","PMC12134454",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; letter; article"],["R0005400","Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors.","Grancini V","2025","Frontiers in endocrinology","other","article","10.3389/fendo.2025.1586941","40496570","PMC12148859",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005401","Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes.","Kumar S","2026","Clinics in liver disease","narrative_review","article","10.1016/j.cld.2026.01.003","42142899",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005402","Guidelines for treating heart failure.","Kittleson MM","2025","Trends in cardiovascular medicine","narrative_review","article","10.1016/j.tcm.2024.10.002","39442740",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005403","[The pathogenesis and effects of glucagon-like peptide-1 receptor agonist on diabetic cardiomyopathy].","Zhou LQ","2023","Zhonghua xin xue guan bing za zhi","other","article","10.3760/cma.j.cn112148-20230112-00025","37057334",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005404","Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle.","Choi RH","2025","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.24274","40254778","PMC12015655",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005405","The Emerging Role of Injectable Weight Loss Medications in Plastic Surgery: A Systematic Review.","Shridharani SM","2023","Aesthetic surgery journal","systematic_review","article","10.1093/asj/sjad240","37493261",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; review"],["R0005406","Efficacy and safety of beinaglutide with continuous subcutaneous infusion in newly diagnosed patients with type 2 diabetes: a randomized, control, open-labeled clinical trial.","Luo Y","2025","Journal of endocrinological investigation","randomized_trial","article","10.1007/s40618-025-02665-7","40719951",null,"ChiCTR:ChiCTR1800015914",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0005407","Diabetic Kidney Disease: From Pathophysiology to Regression of Albuminuria and Kidney Damage: Is It Possible?","Doumani G","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26178224","40943149","PMC12427747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005408","Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways.","Piątkowska-Chmiel I","2025","Cellular and molecular neurobiology","preclinical","article","10.1007/s10571-025-01534-4","40059125","PMC11891103",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005409","Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial.","Zehra A","2026","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.125.046238","42132163","PMC13279346",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0005410","Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes.","Fediuk DJ","2024","Journal of clinical pharmacology","other_trial","article","10.1002/jcph.2371","37840155",null,"ClinicalTrials.gov:NCT04616027","S001891","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005411","Adverse Liver and Renal Outcomes After Initiating SGLT-2i and GLP-1RA Therapy Among Patients With Diabetes and MASLD.","Krishnan A","2025","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.70069","40289065","PMC12034490",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005412","Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus.","Prakash V","2025","Journal of pharmacy & bioallied sciences","other_trial","article","10.4103/jpbs.jpbs_1334_25","41522902","PMC12788593",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0005413","Intramuscular Fat as a Biomarker of Muscle Health: Strengths, Limitations and Open Challenges.","Spence C","2026","Journal of cachexia, sarcopenia and muscle","narrative_review","article","10.1002/jcsm.70389","42816429","PMC13626970",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005414","Diabetes and its complications: molecular mechanisms, prevention and treatment.","Zhao L","2026","Signal transduction and targeted therapy","narrative_review","article","10.1038/s41392-025-02401-w","41549124","PMC12812840",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005415","GLP-1 medications: use and interest in a representative survey of Finns.","Jallinoja PT","2026","International journal of obesity (2005)","other","article","10.1038/s41366-026-02149-5","42414609",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005416","Machine Learning-Based Plasma Metabolomics in Liraglutide-Treated Type 2 Diabetes Mellitus Patients and Diet-Induced Obese Mice.","Park S","2024","Metabolites","preclinical","article","10.3390/metabo14090483","39330490","PMC11434292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005417","Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.","Seksaria S","2024","Current diabetes reviews","narrative_review","article","10.2174/1573399820666230809152148","37559236",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005418","Obesity Medications and Their Impact on Cardiovascular Health: A Narrative Review.","Islam KN","2024","Cureus","narrative_review","article","10.7759/cureus.71875","39559664","PMC11573306",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0005419","Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.","Seijas-Amigo J","2023","Primary care diabetes","randomized_trial","article","10.1016/j.pcd.2023.05.004","37230813",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Observational Study; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005420","The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury.","Harej Hrkać A","2024","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph17101313","39458954","PMC11510130",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005421","Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis.","Lin RT","2024","Metabolism: clinical and experimental","systematic_review","article","10.1016/j.metabol.2024.156043","39357599",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Comparative Study; Network Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0005422","Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss.","Castellana E","2026","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","nonrandomized_study","article","10.1177/87551225261422610","41743493","PMC12929087",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; article"],["R0005423","The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials.","Wen S","2025","BMC endocrine disorders","systematic_review","article","10.1186/s12902-025-01985-2","40665260","PMC12265122",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0005424","The role of weight control in the management of type 2 diabetes mellitus: Perspectives on semaglutide.","Kurtzhals P","2023","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2023.110881","37591343",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005425","Adenosine Monophosphate-Activated Protein Kinase Activation and Mammalian Target of Rapamycin Complex 1 Inhibition: A Mechanistic Rationale for Anti-Aging Therapy in Type 2 Diabetes.","Yanai H","2025","Journal of clinical medicine research","narrative_review","article","10.14740/jocmr6370","41132242","PMC12542718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005426","Differences in signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide","Pickford P","2019","bioRxiv","preclinical","preprint","10.1101/803833",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005427","Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.","Bea S","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15292","37735822",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005428","Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA.","Inzucchi SE","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01678-4","39688779","PMC11794941",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005429","Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-A hospital-based cohort study in Japan.","Yano Y","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16394","40259482","PMC12146464",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005430","No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.","Liu Y","2018","Diabetes/metabolism research and reviews","other","article","10.1002/dmrr.3061","30109766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005431","Correction: Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.",null,"2023","Annals of internal medicine","notice","article","10.7326/l23-0249","37459619",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0005432","Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists.","Choe HJ","2021","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2021.102","33677922","PMC7937847",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005433","Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset.","Hendrix N","2025","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.70227","41024632",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Preprint; article; preprint"],["R0005434","Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.","Schneck K","2024","CPT: pharmacometrics & systems pharmacology","nonrandomized_study","article","10.1002/psp4.13099","38356317","PMC10962491",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005435","Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study.","Gisondi P","2026","Dermatology and therapy","nonrandomized_study","article","10.1007/s13555-026-01812-z","42240733","PMC13280319",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0005436","Appropriate Use of SGLT2s and GLP-1 RAs With Insulin to Reduce CVD Risk in Patients With Diabetes (Archived)","Patel R","2023","StatPearls Publishing, Treasure Island (FL)","other","article",null,"35015463",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0005437","Managing hypertension in a patient with diabetic kidney disease: A clinical case.","Benenson I","2025","Journal of the American Association of Nurse Practitioners","case_report","article","10.1097/jxx.0000000000001133","41342772",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0005438","Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy.","Mehta M","2026","Plastic and reconstructive surgery","narrative_review","article","10.1097/prs.0000000000012672","41329155",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005439","Current Approaches and Therapeutic Strategies for Hypothalamic Syndrome in Patients with Childhood-onset Craniopharyngioma.","Müller HL","2026","Journal of clinical research in pediatric endocrinology","narrative_review","article","10.4274/jcrpe.galenos.2025.2025-12-12","41537273","PMC13325933",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005440","Metabolic Dysfunction-Associated Steatotic Liver Disease and Peripheral Arterial Disease: Associations and Treatment Considerations.","Polyzos SA","2026","Current vascular pharmacology","nonrandomized_study","article","10.2174/0115701611414052251127074106","41582340",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005441","Effect of Semaglutide in Individuals With Obesity or Overweight Without Diabetes.","Alanazi M","2024","Cureus","narrative_review","article","10.7759/cureus.67889","39328692","PMC11425063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005442","Semaglutide and obesity: beyond the nutritional and lifestyle intervention?","Basile L","2024","Minerva endocrinology","nonrandomized_study","article","10.23736/s2724-6507.23.04103-9","39028209",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0005443","Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP-1 Receptor Agonists: A Machine Learning-Based Analysis of a Large Real World Cohort.","Falcetta P","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70648","41804217",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005444","Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.","Parizad R","2026","Vascular health and risk management","systematic_review","article","10.2147/vhrm.s578698","41953528","PMC13054715",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0005445","Exploring beyond numeric weight loss: The metabolic effects of semaglutide.","Sokary S","2025","Clinical nutrition ESPEN","narrative_review","article","10.1016/j.clnesp.2025.03.010","40107359",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005446","Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.","Honigberg MC","2020","JAMA cardiology","randomized_trial","article","10.1001/jamacardio.2020.1966","32584928","PMC7744318",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0005447","Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.","Fadini GP","2024","Diabetologia","nonrandomized_study","article","10.1007/s00125-024-06251-z","39177691","PMC11519175",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; Comparative Study; research-article; article"],["R0005448","Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats.","Bajic Z","2023","Canadian journal of physiology and pharmacology","preclinical","article","10.1139/cjpp-2022-0534","36848640",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005449","Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients.","Huang XM","2023","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v14.i8.1280","37664475","PMC10473942",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005450","Patients' Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.","Banjara B","2022","Patient preference and adherence","other","article","10.2147/ppa.s391719","36597550","PMC9805720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005451","An eye on long-duration spaceflight: Controversies, countermeasures and challenges.","Ng VWS","2026","Experimental physiology","narrative_review","article","10.1113/ep091561","40607685","PMC13394971",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005452","GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease.","Dhamelia P","2026","Cardiovascular drugs and therapy","nonrandomized_study","article","10.1007/s10557-026-07897-0","42397479",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005453","Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.","Jepsen MM","2021","Expert opinion on emerging drugs","narrative_review","article","10.1080/14728214.2021.1947240","34176426",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005454","Exploring novel protective role of semaglutide in 5-fluorouracil-induced hepatotoxicity: Insights into phosphorylated CREB, PINK1/Parkin-mediated mitophagy, and NF-κB/NLRP3 pathways.","El Sayed NF","2025","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1016/j.jpet.2025.103629","40609293",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005455","Auditable LLM Curation of Clinical Notes Refines GLP-1 Initiation, Persistence Ascertainment and Compounding Use Beyond Prescription Records","Varma G","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202606.0682.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0005456","Differential Effects of GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-on Therapy on Outcomes Following Cardiac Surgery: A Propensity Score-Matched Analysis.","Biswas S","2026","Cardiology in review","nonrandomized_study","article","10.1097/crd.0000000000001393","42487161",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005457","Real-World Study of Cardiac Remodeling on Semaglutide and Tirzepatide Therapy Using Longitudinal Echocardiography","Rajendran PS","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202607.1606.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0005458","Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping","Murugadoss K","2026","Research Square","other_trial","preprint","10.21203/rs.3.rs-9407186/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0005459","Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.","Scheltens P","2026","Alzheimer's & dementia (New York, N. Y.)","randomized_trial","article","10.1002/trc2.70200","41522368","PMC12789876","ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0005460","Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists.","Garvey WT","2024","Obesity science & practice","other","article","10.1002/osp4.756","38708040","PMC11069397",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005461","National Trends in Expenditures on Glucose-Lowering Medications in U.S. Adults With Diabetes: 2000-2022.","Wang Y","2026","Diabetes care","other","article","10.2337/dc25-2016","41701609",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0005462","Glucagon-like-peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study.","Zareini B","2024","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.13560","38751369","PMC11096807",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0005463","Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease.","Alicic RZ","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","narrative_review","article","10.1093/ndt/gfae212","39907543","PMC11795665",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005464","Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and Mendelian randomization study.","Xu B","2025","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2025.2595727","41283794",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005465","Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.","Rao H","2026","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-026-01942-3","42180166","PMC13190888",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review"],["R0005466","Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes.","Zhang X","2024","BMC musculoskeletal disorders","preclinical","article","10.1186/s12891-024-07640-6","39080620","PMC11287913",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0005467","Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution!","Jones PM","2023","Canadian journal of anaesthesia = Journal canadien d'anesthesie","commentary","article","10.1007/s12630-023-02550-y","37466910",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0005468","Non-diabetic Kidney Disease in Type 2 Diabetes: From Kidney Biopsy to Precision Medicine.","Sreedharan S","2026","Cureus","randomized_trial","article","10.7759/cureus.100716","41646563","PMC12869812",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005469","SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum.","Preston FG","2024","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2024.06.021","39068059",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005470","REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.","Cárdenas-Salas JJ","2024","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2024.108874","39442257",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0005471","Venous thromboembolism with modern glucose-lowering agents in diabetes: active-comparator evidence beyond placebo-based meta-analyses.","Boccatonda A","2026","Internal and emergency medicine","systematic_review","article","10.1007/s11739-026-04363-5","42091826","PMC13263266",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; article"],["R0005472","Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","Yuan D","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14776","35589615","PMC9541913",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0005473","Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future.","Fernando K","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-025-01738-3","40272772","PMC12085743",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0005474","Effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on podocytes, inflammation, and oxidative stress in patients with diabetic nephropathy (DN).","Liu J","2022","Pakistan journal of medical sciences","randomized_trial","article","10.12669/pjms.38.5.4719","35799717","PMC9247776",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005475","A Real-World Cohort Study on the Association of the Use of Sodium-Glucose Cotransporter-2 Inhibitor With the Incidence of Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus Without CKD Using the SingHealth Diabetes Registry.","Ong YL","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71137","42476952","PMC13538739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005476","Use of Semaglutide After Acute Coronary Syndrome - Design and rationale of a retrospective observational study","Biasin M","2025","medRxiv","protocol","preprint","10.1101/2025.07.31.25332452",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0005477","Lipidated interleukin-22 reduces body weight and spares lean mass in mice by a novel gut-acting mechanism additive to GLP-1 agonism.","Hass D","2026","Molecular therapy : the journal of the American Society of Gene Therapy","preclinical","article","10.1016/j.ymthe.2026.02.041","41764072","PMC13246301",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0005478","Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims.","Wang X","2024","JMIR diabetes","randomized_trial","article","10.2196/58137","39436276","PMC11520261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005479","Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i.","Zhu Y","2025","Renal failure","other_trial","article","10.1080/0886022x.2025.2575921","41285492","PMC12646099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005480","Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes.","Heo KY","2025","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2024.10.099","39486470",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005481","Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.","Zhao Z","2021","Annals of translational medicine","nonrandomized_study","article","10.21037/atm-21-4162","34734034","PMC8506728",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005482","GLP-1 Receptor Agonists Reduce Liver Stiffness in a Pediatric MASLD Cohort and Normalize Disease-associated Core Gene Expression in a MASLD Model","Findling E","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202603.0905.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0005483","Prior Use of GLP-1 Receptor Agonists versus SGLT2 Inhibitors and Clinical Outcomes After Sepsis in Patients with Type 2 Diabetes: A Propensity Score-Matched Cohort Study.","Liu HH","2026","Drug design, development and therapy","nonrandomized_study","article","10.2147/dddt.s642220","42829714","PMC13633727",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0005484","Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice.","Iwai S","2023","Biochimica et biophysica acta. Molecular basis of disease","preclinical","article","10.1016/j.bbadis.2023.166770","37276988",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005485","Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes.","Barlowe TS","2025","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","nonrandomized_study","article","10.1016/j.cgh.2024.04.038","38759826","PMC11564414",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005486","Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.","Ahern S","2025","Cureus","case_report","article","10.7759/cureus.94126","41210042","PMC12594042",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005487","Impact of GLP-1 receptor agonist-based therapies on cardiovascular and renal outcomes in diabetic and non-diabetic patients with CKD.","Siniukovich A","2025","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-025-01831-4","40605083","PMC12220177",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005488","PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis.","Zhang ZY","2023","The Journal of international medical research","systematic_review","article","10.1177/03000605231177191","37317834","PMC10278420",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; other; article; report"],["R0005489","Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials.","Rivera FB","2024","American journal of preventive cardiology","systematic_review","article","10.1016/j.ajpc.2024.100679","38779187","PMC11108827",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0005490","Emerging role of antidiabetic drugs in cardiorenal protection.","Fu WJ","2024","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2024.1349069","38384297","PMC10880452",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005491","Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.","Klein KR","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)01865-9","42815506",null,"ClinicalTrials.gov:NCT05803421","S001090","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0005492","Investigating the functional connectivity between central glucagon-like peptide-1 (GLP-1) and glutamatergic signaling: a systematic review.","Wong S","2026","CNS spectrums","systematic_review","article","10.1017/s1092852926100844","41607204","PMC13076071",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0005493","Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026.","Bays HE","2026","Obesity pillars","narrative_review","article","10.1016/j.obpill.2026.100283","42729919","PMC13564139",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005494","Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions.","Jalleh RJ","2024","The lancet. Gastroenterology & hepatology","nonrandomized_study","article","10.1016/s2468-1253(24)00188-2","39096914",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0005495","Role of Point-of-Care Gastric Ultrasound in Advancing Perioperative Fasting Guidelines.","Razak A","2024","Diagnostics (Basel, Switzerland)","narrative_review","article","10.3390/diagnostics14212366","39518332","PMC11545054",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005496","First-Time Prescribing of GLP-1 Receptor Agonists from 2018-2023: A Descriptive Analysis","Rodriguez PJ","2023","medRxiv","other","preprint","10.1101/2023.08.22.23294277",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005497","GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes.","Sun M","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70459","41582696",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0005498","Glucagon-like peptide-1 receptor agonists, weight loss, and gastric emptying: have I gut news for you.","Jalleh RJ","2022","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23525","35894084","PMC9544962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comment; article-commentary; article"],["R0005499","The weight reduction mediated by anti-obesity medication and the cardiovascular outcome.","Guo Y","2024","iScience","randomized_trial","article","10.1016/j.isci.2024.110867","39319264","PMC11419803",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005500","The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care.","Wojeck BS","2026","Biomedical journal","narrative_review","article","10.1016/j.bj.2026.101038","42735880",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005501","Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019.","Kim JH","2024","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2024.0275","39610135","PMC11621650",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005502","Management of Obesity in Menopausal Women: Implications for Metabolic Health and Minimally Invasive Surgery.","Huang HW","2025","Gynecology and minimally invasive therapy","randomized_trial","article","10.4103/gmit.gmit-d-25-00082","41262087","PMC12626142",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005503","Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide.","Bracha P","2024","American journal of ophthalmology case reports","case_report","article","10.1016/j.ajoc.2024.102121","39175932","PMC11338990",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005504","Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists.","Chen L","2023","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.3c00320","37286364",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005505","Pain mechanisms in osteoarthritis: recent discoveries and opportunities ahead.","Hoffman DB","2025","Connective tissue research","narrative_review","article","10.1080/03008207.2025.2531414","40778733","PMC12392683",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0005506","Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency.","Infante M","2026","Nutrients","narrative_review","article","10.3390/nu18132038","42451041","PMC13362726",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0005507","A hypothesis-driven perspective on GLP-1R-β-catenin pathway crosstalk in astrocyte plasticity and endogenous neural repair.","Tamrakar S","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2026.119946","42762604",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005508","The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.","Bendotti G","2022","Pharmacological research","preclinical","article","10.1016/j.phrs.2022.106320","35738455",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005509","Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases.","Katranski J","2025","International journal of clinical pharmacy","nonrandomized_study","article","10.1007/s11096-025-01943-x","40522403","PMC12630159",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005510","High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.","Aroda VR","2025","Diabetes care","randomized_trial","article","10.2337/dc24-2425","40279144","PMC12094194",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0005511","Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023.","Hamblin PS","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15893","39219539",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005512","The Anti-Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models.","Scheike AS","2025","Journal of orthopaedic research : official publication of the Orthopaedic Research Society","preclinical","article","10.1002/jor.26050","39904754","PMC11982606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005513","[Cardio- and neuroprotective role of glucagon-like receptor-1 agonists in reducing the incidence of ischemic stroke accompanying type 2 diabetes].","Winkler G","2024","Orvosi hetilap","other","article","10.1556/650.2024.33012","38555568",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005514","Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice.","Petersen J","2024","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.102027","39265725","PMC11424796",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0005515","Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials.","Miranda S","2025","European journal of pharmacology","systematic_review","article","10.1016/j.ejphar.2025.177953","40675357",null,"PROSPERO:CRD42025100858",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0005516","Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies.","Ullah MI","2025","Medicines (Basel, Switzerland)","narrative_review","article","10.3390/medicines12030019","40843857","PMC12372088",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005517","Modulation of Endoplasmic Reticulum Stress via CEBPB: a Novel Therapeutic Target in Opioid Use Disorder","Zhang C","2026","Preprints.org","other","preprint","10.20944/preprints202603.0093.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005518","Assessing the Growing Impact of Oral GLP-1 Agonists on National Obesity Policies of the United Kingdom.","Mathew A","2026","Cureus","commentary","article","10.7759/cureus.116274","42746314","PMC13576665",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0005519","Effects of Glucagon-Like Peptide 1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-analysis.","Karakasis P","2024","Advances in therapy","systematic_review","article","10.1007/s12325-024-02959-x","39141282",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0005520","Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery.","Nguefang GL","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08864-2","42471527",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005521","Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data.","Yang CT","2023","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2023.110625","36924833",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005522","How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma.","Arvanitakis K","2022","Cancers","narrative_review","article","10.3390/cancers14194651","36230573","PMC9562923",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005523","Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis.","Lee B","2025","Clinical and molecular hepatology","other_trial","article","10.3350/cmh.2025.0337","40755009","PMC12538144",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005524","[Guidelines for the basic management of chronic kidney disease].","Delanaye P","2025","Revue medicale de Liege","other","article",null,"40518893",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Guideline; Journal Article; other"],["R0005525","Long-term effects of duodenal mucosal resurfacing and liraglutide on glycaemic control in patients with type 2 diabetes.","Busch CBE","2025","BMJ nutrition, prevention & health","nonrandomized_study","article","10.1136/bmjnph-2024-001006","40771521","PMC12322534",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005526","Exploring the Potential Effect of GLP1R Agonism on Common Aging-Related Diseases via Glucose Reduction: A Mendelian Randomization Study.","Jiang W","2025","The journals of gerontology. Series A, Biological sciences and medical sciences","other","article","10.1093/gerona/glaf007","39797952",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005527","New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.","Alshehri FS","2025","Medicine","systematic_review","article","10.1097/md.0000000000044917","41054173","PMC12499737",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; review"],["R0005528","Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension.","Krajnc N","2023","The journal of headache and pain","nonrandomized_study","article","10.1186/s10194-023-01631-z","37460968","PMC10353241",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; other; preprint; article"],["R0005529","Emerging natural products against obesity and metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Direct target discovery and mechanistic insights.","Hu W","2026","Pharmacological reviews","other_trial","article","10.1016/j.pharmr.2026.100125","41950803",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0005530","Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies.","Caparrotta TM","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-021-01021-1","33635502","PMC7994483","PROSPERO:CRD42020165720",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005531","Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.","Mody R","2022","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2022.01.017","35264311",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0005532","GLP-1 receptor agonist properties of a chimeric peptide derived by hybridization of Latrodectus αLatrotoxin and Heloderma Exendin-4.","Chepurny OG","2025","General and comparative endocrinology","preclinical","article","10.1016/j.ygcen.2025.114745","40347985","PMC13231408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005533","Cardiovascular Disease Update: Peripheral Artery Disease.","Smith DK","2025","FP essentials","narrative_review","article",null,"40829044",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005534","Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice.","Dan K","2026","Scientific reports","preclinical","article","10.1038/s41598-026-42437-8","41946762","PMC13223216",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005535","Tirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE-/- mice.","Gómez-Martín Á","2026","Pharmacological research","preclinical","article","10.1016/j.phrs.2026.108321","42342001",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005536","Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.","Home PD","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14136","32627297",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0005537","Kidney Disease: The Forgotten Legacy of Type 1 Diabetes.","Thomas MC","2025","Diabetes care","narrative_review","article","10.2337/dci25-0028","40478448",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005538","Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention.","Nusca A","2025","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2025.01.007","39805357",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0005539","Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.","Wahi G","2024","Pediatric obesity","systematic_review","article","10.1111/ijpo.13169","39238400",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0005540","The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.","Tsiampali C","2023","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2023.2274536","37864548",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005541","Correction: Effcacy of Polyethylene Glycol Loxenatide in Combination with Basal Insulin in Patients with Type 2 Diabetes Mellitus: A Retrospective Real-World Study.","Liu X","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-025-01757-0","40531277","PMC12317940",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0005542","Tirzepatide attenuates neurotoxicity by suppressing inflammation, apoptosis and restoring neurotrophin expression in an Alzheimer's disease-like rat model.","Attia MSM","2026","Metabolic brain disease","preclinical","article","10.1007/s11011-026-01870-4","42154338",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005543","Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.","Dong YH","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14741","35491533",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005544","The Weight of Cardiovascular Diseases: Addressing the Global Cardiovascular Crisis Associated with Obesity.","Lopez-Jimenez F","2025","Global heart","nonrandomized_study","article","10.5334/gh.1451","40860963","PMC12372701",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005545","Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities.","Vacca A","2025","Heart failure reviews","narrative_review","article","10.1007/s10741-024-10439-1","39283525","PMC12166027",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005546","2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Primary Care Management of Chronic Kidney Disease.","Schwartz AR","2026","Annals of internal medicine","other","article","10.7326/annals-25-03499","41461086",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0005547","Combination of cardioprotective glucose-lowering drugs and statins on cardiovascular mortality in diabetes: a nationwide cohort study.","Ternhamar T","2026","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwag085","41733203",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005548","Intranasal delivery of glucagon-like peptide-1 to the brain for obesity treatment: opportunities and challenges.","Khan TTS","2024","Expert opinion on drug delivery","narrative_review","article","10.1080/17425247.2024.2387110","39086086",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005549","Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.","He L","2022","JAMA internal medicine","systematic_review","article","10.1001/jamainternmed.2022.0338","35344001","PMC8961394","PROSPERO:CRD42021271599","S000313; S002095","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; article"],["R0005550","Comparison of societal guidance on perioperative management of glucagon-like peptide-1 receptor agonists: implications for clinical practice and future investigations.","Chang MG","2024","Canadian journal of anaesthesia = Journal canadien d'anesthesie","narrative_review","article","10.1007/s12630-024-02810-5","39187641",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; Review; article"],["R0005551","First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.","Carriazo S","2023","Annals of internal medicine","randomized_trial","article","10.7326/l23-0005","37068289",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Comment; article"],["R0005552","Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.","Kamrul-Hasan ABM","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70247","42175595","PMC13240113","PROSPERO:CRD420261340457",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Review; review-article; article"],["R0005553","Impact of treatment with GLP-1RAs on suicide attempts in adults persons with type 2 diabetes: A retrospective comparative effectiveness study based on a global TriNetX health research database.","Nassar M","2024","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.13547","38501220","PMC10949079",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005554","Amylin analogs for the treatment of obesity without diabetes: present and future.","Panou T","2024","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2024.2409403","39317404",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005555","First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.","Hanna C","2023","Annals of internal medicine","randomized_trial","article","10.7326/l23-0006","37068293",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Comment; article"],["R0005556","Type 2 Diabetes Mellitus Exacerbates Pathological Processes of Parkinson's Disease: Insights from Signaling Pathways Mediated by Insulin Receptors.","Liu S","2025","Neuroscience bulletin","narrative_review","article","10.1007/s12264-024-01342-8","39754628","PMC11978575",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0005557","The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus.","Salmen T","2023","Life (Basel, Switzerland)","nonrandomized_study","article","10.3390/life13030839","36983994","PMC10051290",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005558","Implementation of Established Global Guidelines in the Management of CKD in Patients with Type 2 Diabetes in Asia.","Agarwal R","2025","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000000909","40986470","PMC13143481",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; review-article; article"],["R0005559","Systemic medications and dementia risk: a systematic umbrella review.","Belessiotis-Richards C","2025","Molecular psychiatry","systematic_review","article","10.1038/s41380-025-03129-3","40707785","PMC12532590","PROSPERO:CRD42021226307",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005560","First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.","Laiteerapong N","2023","Annals of internal medicine","commentary","article","10.7326/l23-0007","37068291",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0005561","Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease.","Chen R","2026","Kidney & blood pressure research","systematic_review","article","10.1159/000552201","42030206","PMC13313621",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review-article; article"],["R0005562","Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.","Inaishi J","2022","Clinical pharmacology : advances and applications","other_trial","article","10.2147/cpaa.s288846","35422660","PMC9004502",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005563","Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes.","Gavigan C","2023","Journal of diabetes research","nonrandomized_study","article","10.1155/2023/9972132","37589043","PMC10427225",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005564","Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.","Dutta D","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2026.07.018","42551699",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0005565","Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.","Schoretsanitis G","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.23385","39163046","PMC11337067",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005566","Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies.","Fadini GP","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-021-01012-2","33550569","PMC7947045",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005567","Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.","Goldenberg RM","2021","Canadian journal of diabetes","narrative_review","article","10.1016/j.jcjd.2020.09.005","33189580",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005568","SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review.","Cruz AM","2026","European journal of clinical pharmacology","systematic_review","article","10.1007/s00228-026-04095-7","42265474","PMC13249686",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0005569","Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.","Hankosky ER","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16290","39996368","PMC11964993",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0005570","Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study.","Peng ZY","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-01991-5","37794465","PMC10552437",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005571","Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis.","Wang Y","2023","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2023.175730","37062504",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005572","Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis.","Pereira M","2024","Obesity surgery","systematic_review","article","10.1007/s11695-024-07486-w","39215779",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0005573","Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes.","Sharma A","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15896","39192531",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0005574","The molecular mechanisms of incretin resistance in Type 2 Diabetes Mellitus (T2DM).","Albaghlany RM","2026","Nutrition & diabetes","narrative_review","article","10.1038/s41387-026-00426-w","42091853","PMC13315620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005575","Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.","Candido R","2023","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2023.07.025","37679243",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0005576","What should the doctor prescribe-formula diet or antidiabetics? Effectiveness of formula diet-based lifestyle intervention vs. pharmacological antiglycemic therapy on weight loss and HbA1c reduction in type 2 diabetes patients-a systematic review.","Kempf K","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1644442","41113714","PMC12527879",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0005577","hESCs-derived organoids achieve liver zonation by LSEC modulation","Zhang Y","2024","bioRxiv","preclinical","preprint","10.1101/2024.05.05.592562",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0005578","Type 5 diabetes mellitus: nutritional-imprinted β-cell insufficiency, diagnostic gaps, and emerging therapeutic strategies.","Chen S","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1739521","41918975","PMC13033534",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005579","Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes.","Wettergreen SA","2023","Diabetes spectrum : a publication of the American Diabetes Association","other_trial","article","10.2337/ds21-0108","36818408","PMC9935291",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0005580","Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation.","Qin J","2026","Frontiers in public health","nonrandomized_study","article","10.3389/fpubh.2026.1787562","42273622","PMC13246638","ClinicalTrials.gov:NCT05413369","S000073","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0005581","Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment.","Yamada H","2023","Journal of clinical medicine research","nonrandomized_study","article","10.14740/jocmr4995","37822852","PMC10563818",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005582","Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States.","Zhao JZ","2023","Kidney medicine","nonrandomized_study","article","10.1016/j.xkme.2022.100564","36593878","PMC9803841",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005583","Role of β-cell autophagy in β-cell physiology and the development of diabetes.","Yasasilka XR","2024","Journal of diabetes investigation","narrative_review","article","10.1111/jdi.14184","38470018","PMC11143416",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005584","Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Abdullah A","2025","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70136","41276951","PMC12640882","PROSPERO:CRD420251019235",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0005585","Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.","Blitshteyn S","2026","Immunopharmacology and immunotoxicology","randomized_trial","article","10.1080/08923973.2026.2731357","42703003",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0005586","Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study.","Bain SC","2023","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2022-003300","37328273","PMC10277078",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0005587","Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study.","Yang YS","2024","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2023.0225","38273793","PMC10995487",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005588","Cardiovascular Implications in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.","Suresh MG","2026","Korean circulation journal","narrative_review","article","10.4070/kcj.2025.0212","41371916","PMC12929038",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005589","Perceptions and Attitudes Toward Oral Semaglutide Among Japanese Physicians and Individuals with Type 2 Diabetes: A Web-Based Survey.","Suzuki R","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-025-01739-2","40434552","PMC12182544",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005590","[New outcome studies with injectable semaglutide in different at risk populations].","Scheen A","2024","Revue medicale de Liege","randomized_trial","article",null,"39397557",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","2","FALSE","Journal Article; Review; English Abstract; article"],["R0005591","Development and Validation of a Liquid Chromatography/Tandem Mass Spectrometry Method for the Quantification of the GLP-1 Analog Semaglutide in Rat Plasma, and Its Application in a Pharmacokinetic Study.","Kim JM","2026","Pharmaceutics","preclinical","article","10.3390/pharmaceutics18070770","42514852","PMC13415238",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005592","Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.","Malandris K","2026","Current diabetes reports","other_trial","article","10.1007/s11892-026-01621-w","41831086","PMC12989002",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005593","Adipose tissue ageing: implications for metabolic health and lifespan.","Wang G","2025","Nature reviews. Endocrinology","narrative_review","article","10.1038/s41574-025-01142-8","40550948",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005594","Exploratory associations between co-occurring opioid and alcohol use disorders and GIP/GLP-1 receptor agonist treatment.","Qeadan F","2026","Communications medicine","nonrandomized_study","article","10.1038/s43856-026-01685-5","42265341","PMC13646277",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005595","The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders.","Si J","2025","Therapeutic advances in neurological disorders","narrative_review","article","10.1177/17562864251332035","40291753","PMC12033604",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005596","Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes.","McKone DB","2025","Diabetes spectrum : a publication of the American Diabetes Association","nonrandomized_study","article","10.2337/ds24-0035","40823594","PMC12357194",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005597","Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists.","Gill L","2021","Journal of women's health (2002)","nonrandomized_study","article","10.1089/jwh.2020.8683","33626287","PMC8290308",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0005598","Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.","Trautmann ME","2018","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.13610","29478255","PMC5969085",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0005599","Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art.","Theodorakis N","2025","Heart failure reviews","other_trial","article","10.1007/s10741-025-10506-1","40163257",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0005600","Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.","Mann JFE","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00134-8","42567173",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0005601","Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus: A Narrative Review.","Tiwari RK","2025","Current diabetes reviews","nonrandomized_study","article","10.2174/0115733998294919240506044544","38766831",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; review"],["R0005602","Incretin-based therapies and craving: a clinical signal pointing to reward reprogramming.","Monami M","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","other","article","10.1016/j.numecd.2026.104818","42386466",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005603","Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs.","Cigrovski Berkovic M","2025","World journal of diabetes","narrative_review","article","10.4239/wjd.v16.i9.109123","40980310","PMC12444289",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005604","Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.","Ceriello A","2023","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-023-01993-3","37833776","PMC10576408",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0005605","Trends in Newly Filled GLP-1 Receptor Agonist Prescriptions for US Patients With Versus Without Comorbid Alcohol Use Disorder, 2016-2024.","Wallach JD","2026","Journal of addiction medicine","nonrandomized_study","article","10.1097/adm.0000000000001575","41036780","PMC12636227",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; research-article; article"],["R0005606","[Gastrointestinal hormones: their increasing pharmacotherapeutic relevance in metabolic diseases].","Gallwitz B","2023","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-022-01447-0","36598526",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0005607","Synthesis of scarless circular RNAs expressing long-acting GLP-1RAs for type 2 diabetes therapy.","Lin Y","2026","Journal of advanced research","preclinical","article","10.1016/j.jare.2026.05.028","42150718",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005608","MetALD: A narrative review of the clinical and molecular landscape of reclassifying steatotic liver disease.","Fakhoury B","2026","Alcohol, clinical & experimental research","narrative_review","article","10.1111/acer.70259","41736181",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0005609","Sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of chronic kidney disease-mineral and bone disorders in patients with type 2 diabetes mellitus and stage 1-3 chronic kidney disease.","Tsai DH","2025","CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","nonrandomized_study","article","10.1503/cmaj.240922","39993818","PMC11867598",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005610","Heart failure with preserved ejection fraction and metabolic dysfunction-associated steatotic liver disease: Twin challenges, one metabolic solution.","Lian LY","2025","World journal of cardiology","commentary","article","10.4330/wjc.v17.i2.103845","40061276","PMC11886398",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0005611","SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation.","Lopes AC","2024","Expert review of clinical pharmacology","other","article","10.1080/17512433.2024.2421872","39450504",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005612","Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension.","Aguado B","2026","ERJ open research","randomized_trial","article","10.1183/23120541.01479-2025","42232566","PMC13224206",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005613","The Management of Obesity Before Catheter Ablation of AF: The Missing Piece?","Win KZ","2025","Arrhythmia & electrophysiology review","narrative_review","article","10.15420/aer.2024.45","40458371","PMC12127968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005614","Thyroid function and liver fibrosis: FT3 levels are inversely and independently correlated with enhanced liver fibrosis score in solid organ transplant patients with dysglycemia.","Leanza C","2025","Frontiers in immunology","other","article","10.3389/fimmu.2025.1726617","41583490","PMC12823537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005615","GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials.","Beavers KM","2025","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.24172","39710882","PMC11774015",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Review; research-article; article"],["R0005616","Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report.","Gulak MA","2023","Canadian journal of anaesthesia = Journal canadien d'anesthesie","case_report","article","10.1007/s12630-023-02521-3","37280458",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0005617","Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.","Del Prato S","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14068","32323437","PMC7754453",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0005618","Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation.","Huang CH","2025","BMC medicine","nonrandomized_study","article","10.1186/s12916-025-04606-w","41469686","PMC12964619",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0005619","SGLT2 Inhibitor and GLP-1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross-Sectional Study.","Müller F","2025","Journal of diabetes research","nonrandomized_study","article","10.1155/jdr/6656982","41220901","PMC12602036",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005620","Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.","Wu CC","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24302","40415172","PMC12210098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Case Reports; brief-report; article"],["R0005621","Sex-Based Gaps in the Prescription of Cardio-Nephroprotective Medications in CKD","Balafa O","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202603.0884.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; article; preprint"],["R0005622","Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database.","Scavone C","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1882225","42723821","PMC13558095",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005623","Physiology and clinical applications of GIP.","Yamane S","2025","Endocrine journal","narrative_review","article","10.1507/endocrj.ej25-0087","40175127","PMC12260194",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005624","Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.","Jensterle M","2023","Hormone research in paediatrics","other_trial","article","10.1159/000521264","34852347",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0005625","Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.","Koychev I","2024","BMJ open","protocol","article","10.1136/bmjopen-2023-081401","38908839","PMC11328662","ISRCTN:ISRCTN71283871",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005626","Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy.","Feng Y","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1934027","42798476","PMC13612292","PROSPERO:CRD420261327235",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0005627","Dapagliflozin effect on pericardial fat deposition: lessons from the DAPA EAT.","Palazzuoli A","2026","Heart failure reviews","randomized_trial","article","10.1007/s10741-026-10607-5","41806003",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0005628","Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.","Edelman SV","2017","The Journal of family practice","other","article",null,"28991932",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005629","Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.","Xiong S","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01594-7","38776037","PMC11263519",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005630","EVIDENCE OF THE INFLUENCE OF GLUCAGON-LIKE PEPTIDE ANALOGS IN INFLAMMATORY BOWEL DISEASE: A SCOPING REVIEW.","Rezende LDA","2026","Arquivos de gastroenterologia","randomized_trial","article","10.1590/s0004-2803.24612026-028","42615757","PMC13475708",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Scoping Review; review-article; article"],["R0005631","Secondary stroke prevention beyond antiplatelets: The role of colchicine and GLP-1RA - an ounce of prevention is worth a pound of cure.","Mijajlović MD","2025","Therapeutic advances in neurological disorders","narrative_review","article","10.1177/17562864251326769","40291758","PMC12033550",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005632","Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.","Goldney J","2023","Diabetologia","other_trial","article","10.1007/s00125-023-05988-3","37597048","PMC10474214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0005633","Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials.","Simental-Mendía LE","2021","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2021.108899","34098057",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0005634","Exendin-4 Increases Scavenger Receptor Class BI Expression via Activation of AMPK/FoxO1 in Human Vascular Endothelial Cells.","Lyu J","2022","Current issues in molecular biology","other","article","10.3390/cimb44110370","36354682","PMC9689235",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005635","Outcomes of retained gastrointestinal debris during upper endoscopy.","Jacob JS","2025","Endoscopy international open","nonrandomized_study","article","10.1055/a-2544-2468","40230565","PMC11996021",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005636","Calculating Glucagon-Like Pepide-1 Receptor Agonist-Associated Medullary Thyroid Cancer Risk: A Novel Integration of the Surveillance, Epidemiology and End Results Cancer Registry and the FDA Adverse Event Reporting System.","D'Arcy SJ","2026","Head & neck","nonrandomized_study","article","10.1002/hed.70286","42003032",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005637","Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China.","Ruan Z","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s483065","39386037","PMC11463179",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005638","Impact on Metabolism Generated by Surgical and Pharmacological Interventions for Weight Loss in Women with Infertility.","Gete Palacios PC","2025","Metabolites","narrative_review","article","10.3390/metabo15040260","40278389","PMC12029110",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005639","Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.","Jalleh RJ","2024","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgae719","39418085","PMC11651700",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005640","Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.","Al Ozairi E","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70172","41048008","PMC12673458",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0005641","Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects.","Riemma MA","2024","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2024.1422740","38948473","PMC11212466",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005642","Outcomes of GLP-1 receptor agonist use following ischemic stroke: a propensity score-matched real-world analysis.","Rai P","2025","Journal of neurology","nonrandomized_study","article","10.1007/s00415-025-13470-w","41118000",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005643","Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.","Pan Y","2026","BMC gastroenterology","randomized_trial","article","10.1186/s12876-026-04986-0","42249304","PMC13459454",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005644","Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.","Deng S","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1369908","38803473","PMC11128627",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005645","Hypoglycemic drugs, circulating inflammatory proteins, and gallbladder diseases: A mediation mendelian randomization study.","Wang ZQ","2024","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2024.111882","39366640",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005646","Glucagon-like peptide-1 analog, liraglutide, alters blood-testis barrier permeability in juvenile healthy rats.","Dasso ME","2026","Environmental toxicology and pharmacology","preclinical","article","10.1016/j.etap.2026.104998","41856344",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005647","Structural Biophysics-Guided Computational Design of Semaglutide Analogues to Enhance GLP-1R Activation","Li W","2025","Qeios","other_trial","preprint","10.32388/fgtlkf",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0005648","Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction.","Ohkuma T","2026","Journal of diabetes investigation","case_report","article","10.1111/jdi.70300","41914136","PMC13238849",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-study; article"],["R0005649","Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach.","Arillotta D","2024","Brain sciences","other","article","10.3390/brainsci14060617","38928616","PMC11202225",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005650","From the Incretin System to the Entero–Pancreatico–Hepatico–Systemic Polyhormonal Metabolic Homeostasis Network","Lalwani R","2026","Preprints.org","other","preprint","10.20944/preprints202607.2008.v2",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005651","Tirzepatide improves extracellular matrix integrity and vascularization in pancreatic islets of a mouse model of obesity, diabetes, and menopause.","Reis-Barbosa PH","2025","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2025.152913","41191986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005652","Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.","Alavi SE","2026","European journal of medicinal chemistry","narrative_review","article","10.1016/j.ejmech.2026.118587","41547240",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005653","Effects of glucagon-like peptide-1 receptor agonists on patients with heart failure: a meta-analysis of randomized controlled trials.","Obata S","2023","Journal of cardiovascular medicine (Hagerstown, Md.)","systematic_review","article","10.2459/jcm.0000000000001430","36583981",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; review"],["R0005654","Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.","Long F","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70359","41388343","PMC12890723",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0005655","Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials.","Wang A","2024","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2024.04.013","38796335",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Systematic Review; Network Meta-Analysis"],["R0005656","Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson's disease (PD)? Does the clinical trial with lixisenatide add anything?","Doggrell SA","2025","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2025.2459409","39864104",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0005657","Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance.","Cersosimo A","2024","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-024-02181-7","38468245","PMC10926589",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005658","Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus.","Dhatariya K","2024","British journal of anaesthesia","commentary","article","10.1016/j.bja.2023.12.015","38290906",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0005659","Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP.","Fang P","2023","Drug design, development and therapy","preclinical","article","10.2147/dddt.s400249","36936522","PMC10019346",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005660","Is Oral Semaglutide a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective.","Dahan AE","2026","Pharmaceutics","other","article","10.3390/pharmaceutics18040466","42076118","PMC13118332",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0005661","The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","Zhao F","2026","PeerJ","systematic_review","article","10.7717/peerj.20710","41660088","PMC12880101",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0005662","Glucagon-like peptide-1 receptor agonist use is associated with lower serum periostin.","Foer D","2023","Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","commentary","article","10.1111/cea.14284","36648098","PMC10106378",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0005663","Diabetes mellitus therapy in the light of oxidative stress and cardiovascular complications.","Osman AAM","2025","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2024.108941","39671854",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0005664","MetALD: Does it require a different therapeutic option?","Marek GW","2024","Hepatology (Baltimore, Md.)","narrative_review","article","10.1097/hep.0000000000000935","38820071","PMC12172020",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0005665","Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials.","Zhang Y","2025","European journal of medical research","systematic_review","article","10.1186/s40001-024-02241-4","39773332","PMC11706166",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Comparative Study; review-article; review"],["R0005666","Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS.","Jaiswal A","2026","Journal of pharmaceutical and biomedical analysis","other_trial","article","10.1016/j.jpba.2025.117128","40865303",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0005667","Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach.","Schechter M","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14675","35212443","PMC9313801",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0005668","Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study.","Sharma A","2023","The Lancet regional health. Western Pacific","nonrandomized_study","article","10.1016/j.lanwpc.2023.100692","37181530","PMC10166999",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005669","Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?","Popovic DS","2023","Endocrine","commentary","article","10.1007/s12020-022-03294-3","36607508",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0005670","Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!","Popovic DS","2024","Expert review of clinical pharmacology","randomized_trial","article","10.1080/17512433.2024.2418398","39429118",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0005671","Evaluation of a nurse-led chronic kidney disease clinic: a single-centre cohort study.","Wallace H","2026","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfag084","42111240","PMC13153467",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005672","Weight loss with glucagon-like peptide-1 receptor agonists in Bardet-Biedl syndrome.","Ganawa S","2022","Clinical obesity","case_report","article","10.1111/cob.12546","35932204","PMC9539684",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005673","GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss.","Della Pepa G","2024","Diabetes","other","article","10.2337/db23-0972","38976482",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005674","Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus.","Ken-Opurum J","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01477-3","37801225","PMC10597971",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005675","Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets.","Le TDV","2023","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2023.01.03.522509","36711605","PMC9881863",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0005676","Effect of Polyethylene Glycol Loxenatide Treatment on Body Weight in Patients With Type 2 Diabetes With Different Body Mass Index: A Retrospective Real-World Study.","Xu P","2026","International journal of endocrinology","nonrandomized_study","article","10.1155/ije/7060233","42112153","PMC13150479","ChiCTR:ChiCTR2400087532",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005677","Discovery of a Novel Glucagon-like Peptide-1 (GLP-1) Analogue from Bullfrog and Investigation of Its Potential for Designing GLP-1-Based Multiagonists.","Jiang N","2024","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.3c01049","38117235",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005678","[GLP-1 agonists - new kid on the block in nephrology].","Kraft L","2025","Deutsche medizinische Wochenschrift (1946)","narrative_review","article","10.1055/a-2420-6176","40388980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; Research Support, Non-U.S. Gov't; article"],["R0005679","Abdominoplasty Outcomes after GLP-1 Agonist-Induced versus Postbariatric Massive Weight Loss: A Retrospective Comparative Case Series.","Friedman O","2026","Plastic and reconstructive surgery","nonrandomized_study","article","10.1097/prs.0000000000012523","41118524",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0005680","SELECT: Glucagon-like peptide-1 receptor agonist in obese patients with cardiovascular disease in the absence of diabetes.","Kotit S","2024","Global cardiology science & practice","randomized_trial","article","10.21542/gcsp.2024.26","39351469","PMC11439431",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; discussion; article"],["R0005681","Change on glycosylated hemoglob with glucagon-like peptide-1 receptor agonists affecting the progress of diabetes retinopathy in type 2 diabetes– A systematic review and meta-analysis","Wang w","2024","Research Square","systematic_review","preprint","10.21203/rs.3.rs-3834867/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0005682","Mapping the continuum of procedural bariatric care: real-world weight loss after endoscopic and surgical interventions.","Ghusn W","2026","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-026-12933-z","42277424",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0005683","GLP-1 Receptor Agonists in the Management of Post-bariatric Weight Regain and Dysglycemia: A Systematic Review and Meta-Analysis.","Natche J","2026","Cureus","systematic_review","article","10.7759/cureus.102516","41769499","PMC12949042",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005684","Incretin-Based Therapies and Cardiovascular Outcomes: Beyond Weight Loss.","Després JP","2026","Circulation","commentary","article","10.1161/circulationaha.126.079488","42149995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0005685","No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study.","Bodini S","2024","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2024.04.009","38964935",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Comparative Study; article"],["R0005686","Safe use of a once-a-week glucagon-like peptide-1 receptor agonist in a 16-year-old girl with type 2 diabetes when approved therapy options fail.","van den Boom L","2021","Clinical case reports","case_report","article","10.1002/ccr3.4811","34567554","PMC8449226",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005687","Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world.","Franch-Nadal J","2022","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2022.10.005","36336605",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005688","Orforglipron","Hoofnagle JH","2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"42391415",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0005689","Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.","Zhu H","2026","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2025.5684","41182740","PMC12584062","ClinicalTrials.gov:NCT03948347","S001659","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0005690","Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial.","Jensen SBK","2024","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2024.16775","38916894","PMC11200146","EudraCT:2015-005585-32","S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0005691","Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management.","Fahim SA","2025","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2025.118731","41177120",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Comparative Study; article"],["R0005692","Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.","Dong YH","2022","Pharmacotherapy","nonrandomized_study","article","10.1002/phar.2688","35508702",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005693","GABA and GLP-1 receptor agonist combination therapy modifies diabetes and Langerhans islet cytoarchitecture in a rat model of Wolfram syndrome.","Jagomäe T","2025","Diabetology & metabolic syndrome","preclinical","article","10.1186/s13098-025-01651-6","40050934","PMC11887366",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005694","Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.","Zhang Y","2026","Diabetes care","other_trial","article","10.2337/dc26-1171","42623541","PMC13493337",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0005695","Effects of liraglutide on gut bacterial community dynamics.","Bull J","2026","Microbiology spectrum","preclinical","article","10.1128/spectrum.00343-26","42545022","PMC13532357",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0005696","Semaglutide in Patients with Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-analysis of Randomized Controlled Trials.","Otmani Z","2025","Cardiology in review","systematic_review","article","10.1097/crd.0000000000000925","40310127",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0005697","Are we standing on the shifting sands of post-transplant metabolic-associated steatotic liver disease?","Zatta R","2025","World journal of hepatology","narrative_review","article","10.4254/wjh.v17.i7.107837","40747227","PMC12308607",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005698","Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management.","Kalra S","2022","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.22-64","35713074",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005699","Utilization of glucagon-like peptide-1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database.","Hirose N","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14600","34779098","PMC9300085",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0005700","AI-Enabled Chest X-Ray Detects Subclinical Diastolic Dysfunction in Diabesity and its Therapeutic Responses to GLP-1 or GLP-1/GIP Receptor Agonists","White RD","2026","Research Square","other","preprint","10.21203/rs.3.rs-9272120/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005701","DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits.","Razavi M","2022","Military Medical Research","narrative_review","article","10.1186/s40779-022-00410-2","35986429","PMC9392232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005702","Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus.","Tan X","2023","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2023.975880","38249345","PMC10797415","PROSPERO:CRD42020199840",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; article"],["R0005703","Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.","von Arx LB","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14985","36692268",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005704","Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis.","Shou X","2023","Current problems in cardiology","randomized_trial","article","10.1016/j.cpcardiol.2022.101194","35395332",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0005705","The role of weight management in sleep disordered breathing.","Griffin W","2025","Breathe (Sheffield, England)","narrative_review","article","10.1183/20734735.0182-2025","40964177","PMC12439296",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005706","Breaking the diabetes-depression cycle: Exploring shared mechanisms, neuroinflammation, and emerging interventions for metabolic-mood comorbidities.","Luo C","2025","World journal of diabetes","commentary","article","10.4239/wjd.v16.i7.107406","40697597","PMC12278072",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0005707","Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database.","Aoyama K","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70255","41177923","PMC12673422",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005708","Ecnoglutide: First Approvals.","Shirley M","2026","Drugs","narrative_review","article","10.1007/s40265-026-02350-w","42412371",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005709","GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads.","O'Brien H","2026","Current opinion in pulmonary medicine","randomized_trial","article","10.1097/mcp.0000000000001249","41664500",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0005710","Quantifying Patient Preferences for Basal Insulin Treatments in Adults Living with Type 2 Diabetes: A Discrete Choice Experiment in Canada, Spain, France, and Japan.","Jones AM","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-025-01779-8","40833702","PMC12474790",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005711","Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.","Kyriakidou A","2021","Current pharmaceutical design","nonrandomized_study","article","10.2174/1381612826666201203145654","33272167",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0005712","Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series.","Richards JR","2023","The Journal of clinical psychiatry","randomized_trial","article","10.4088/jcp.23m15068","38019594",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; Case Reports; article"],["R0005713","Response to Letter to the Editor regarding \"Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists\".","Wang R","2026","Spine","commentary","article","10.1097/brs.0000000000005876","42773902",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0005714","Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes.","Longo M","2023","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2023.110688","37116797",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005715","Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes: protocol for a nationwide observational comparative study in routine care.","Danchin N","2025","BMJ open","protocol","article","10.1136/bmjopen-2024-087790","39788759","PMC11751855",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Comparative Study; research-article; article"],["R0005716","Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis.","Khaity A","2023","Frontiers in psychiatry","systematic_review","article","10.3389/fpsyt.2023.1153648","37215670","PMC10196269","PROSPERO:CRD42022333040",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; article; review"],["R0005717","Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.","Bensignor MO","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14681","35491535","PMC9177669",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; letter; article"],["R0005718","Emerging Strategies for Drug-Based Cancer Risk Reduction.","Daca-Álvarez M","2025","American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","narrative_review","article","10.1200/edbk-25-473708","40435434",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005719","As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes.","Seddio AE","2025","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2025.08.003","40784425",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005720","A Physiological Model of Incretin-Based Therapies and Hierarchical Energy Allocation Across Metabolic Phenotypes.","Stier C","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70890","42209293",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0005721","Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy.","Foss-Freitas MC","2024","Diabetes care","nonrandomized_study","article","10.2337/dc23-1614","38300898","PMC10973902",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0005722","The role of incretin receptor agonists in the treatment of obesity.","Forst T","2024","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15796","39072877",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0005723","Expert Opinion on Optimising Type 2 Diabetes Treatment Using Fixed-Ratio Combination of Basal Insulin and GLP-1 RA for Treatment Intensification and Simplification.","Haluzik M","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-024-01610-w","38935189","PMC11263442",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005724","Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies.","Scheen AJ","2023","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2023.101474","37678760",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; Network Meta-Analysis; article"],["R0005725","Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2025","Endocrinology and metabolism (Seoul, Korea)","systematic_review","article","10.3803/enm.2024.2164","39814031","PMC11898313",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0005726","Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study.","Baxter SM","2025","Thyroid : official journal of the American Thyroid Association","systematic_review","article","10.1089/thy.2024.0387","39772758",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Multicenter Study; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0005727","Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy.","Vaughan EM","2024","American family physician","narrative_review","article",null,"38648832",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005728","Clinical Data Mega-Collection of Obesity and Obesity-Related Trials: Primary Inclusion Criteria from All Studies and Highlights of Clinical Efficacy Analysis of GLP-1 Drugs.","Nguyen TT","2025","Journal of clinical medicine","other","article","10.3390/jcm14030812","39941484","PMC11818846",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005729","Once-Monthly Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines","Saldívar-Cerón HI","2025","Preprints.org","other_trial","preprint","10.20944/preprints202512.1726.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0005730","Podocyte Metabolic Reprogramming and Targeted Therapy.","Hu H","2026","Journal of the American Society of Nephrology : JASN","narrative_review","article","10.1681/asn.0000000917","41082318","PMC12935371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005731","Gastroparesis: A Review.","Camilleri M","2026","JAMA","nonrandomized_study","article","10.1001/jama.2026.12181","42485161",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0005732","Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists.","Goldenberg RM","2022","Stroke","narrative_review","article","10.1161/strokeaha.121.038151","35259929",null,null,"S001115","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0005733","Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.","Gleason PP","2024","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2024.23332","38717042","PMC11293763",null,"S002095; S002621","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005734","Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus.","Pelle MC","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms241411301","37511061","PMC10379573",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005735","Exendin-4 improves neurodevelopmental outcome after neonatal germinal matrix hemorrhage.","Jonsdotter A","2026","Cell death & disease","preclinical","article","10.1038/s41419-026-09189-9","42618557","PMC13490559",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005736","Comparative risk of infections with GLP-1 receptor agonists versus SGLT2 inhibitors in patients with advanced chronic kidney disease and type 2 diabetes.","Hsiao CC","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113115","41611096",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0005737","Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight Loss.","Elbatreek MH","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.09.26.678829","41256540","PMC12621885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0005738","Translating trial results into interpretable risk estimates: Systematic analysis of cardiorenal outcome trials of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.","Rizzi A","2024","Nutrition, metabolism, and cardiovascular diseases : NMCD","randomized_trial","article","10.1016/j.numecd.2023.12.012","38336546",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0005739","Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.","Siamashvili M","2021","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2021.1933433","34015974",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005740","Evaluation of GLP-1 Receptor Agonists in Combination With Multiple Daily Insulin Injections for Type 2 Diabetes.","Sassenrath K","2022","Journal of pharmacy practice","randomized_trial","article","10.1177/08971900211010678","33926305",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0005741","Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus.","Zhang J","2023","Diabetes & metabolic syndrome","randomized_trial","article","10.1016/j.dsx.2023.102804","37315473",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0005742","Exploring Liraglutide in Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy Model in Rats: Impact on Inflammation, Mitochondrial Function, and Behavior.","Antmen FM","2024","Biomedicines","preclinical","article","10.3390/biomedicines12102205","39457518","PMC11505538",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005743","Type 2 Diabetes and Vascular Complications: Current Perspectives on Pathophysiology and Management Strategies.","Singh H","2026","Current pharmaceutical design","nonrandomized_study","article","10.2174/0113816128415070251009170250","41735213",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005744","Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.","Parker VER","2023","Nature metabolism","randomized_trial","article","10.1038/s42255-023-00938-0","38066113","PMC10730390","ClinicalTrials.gov:NCT03555994","S000670","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0005745","A Dose of Perspective: A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD.","Shah NA","2026","Kidney360","nonrandomized_study","article","10.34067/kid.0000001227","42228487","PMC13567879","ClinicalTrials.gov:NCT06058585","S001518","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0005746","Nonadherence to GLP-1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Shegena EA","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70200","42503568",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0005747","The effect of combining surgical or endoscopic bariatric interventions with anti-obesity medication or probiotics on weight loss: a narrative review.","de Waal JR","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1680182","41717546","PMC12913063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0005748","Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report From Palestine.","Nasser A","2025","Case reports in gastrointestinal medicine","case_report","article","10.1155/crgm/9918202","41355891","PMC12680473",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005749","Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes.","Hansrivijit P","2025","Kidney medicine","nonrandomized_study","article","10.1016/j.xkme.2025.101013","40510603","PMC12152630",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005750","Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study.","Azzam AY","2025","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70019","39949069","PMC11825589",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005751","A mini review on glucagon-like peptide-1 receptor agonists and its role in blood pressure regulation","Alharbi NHJ","2024","Preprints.org","narrative_review","preprint","10.20944/preprints202402.0005.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005752","Exploring Combined Use of Continuous Glucose Monitoring and Anti-Diabetes Medications on Glycaemic Control for People With Type 2 Diabetes Not Using Insulin.","Nemlekar PM","2025","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70089","40851538","PMC12375899",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0005753","Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.","Richardson TL","2023","Annals of internal medicine","nonrandomized_study","article","10.7326/m22-2751","37155984","PMC10367222",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0005754","Novel strategies for medical management of obesity: mechanisms, clinical implications, and societal impacts-a report from the 25th Annual Harvard Nutrition Obesity Symposium.","Srivastava G","2025","The American journal of clinical nutrition","other","article","10.1016/j.ajcnut.2025.06.015","40550419","PMC12489366",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005755","Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.","Alhazmi A","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.71074","42452898","PMC13588232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0005756","Orthobiologics and Peptide Therapy for Central Nervous System Repair in Neurodegenerative Conditions.","de Oliveira CAA","2025","Cells","narrative_review","article","10.3390/cells14231853","41369342","PMC12691428",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005757","GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis.","Banerjee M","2024","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2024.102943","38211482",null,"PROSPERO:CRD42022337559",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Review; review"],["R0005758","Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease.","Mahalingam S","2023","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2023.115613","37209859","PMC10351880",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005759","Beyond Standard Echocardiography: Strain Imaging as the AI-Powered Key to Comprehensive Cardiac Function Evaluation","Saha S","2024","Authorea Preprints","other","preprint","10.22541/au.171231754.48906447/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005760","Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials.","Gomes DA","2025","Cardiovascular drugs and therapy","systematic_review","article","10.1007/s10557-024-07547-3","38214869",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0005761","OR18-07 Weight Reduction, Body Composition, and Cardiometabolic Changes in Patients with Adrenal Adenomas Treated with GLP-1 or GIP/GLP-1 Receptor Agonists",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12543637",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0005762","GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling.","Kooij KL","2024","Neuroscience applied","preclinical","article","10.1016/j.nsa.2023.103925","40656110","PMC12244221",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005763","The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.","AlAraibi AJ","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","systematic_review","article","10.1016/j.numecd.2026.104994","42772984",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0005764","Effect of GLP1 Agonists on Reproduction.","Couldwell M","2025","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgaf401","40658801",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005765","Monitoring Report: GLP-1 RA Prescribing Trends - September 2024 Data","Gratzl S","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.01.18.24301500",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0005766","Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease.","Ostrominski JW","2025","Diabetes care","other_trial","article","10.2337/dc24-1873","40019856",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0005767","Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.","Ekinci EI","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70861","42331726","PMC13448873","ClinicalTrials.gov:NCT04153929; ClinicalTrials.gov:NCT04667377; EudraCT:2019-002390-60; EudraCT:2020-002479-37","S000172; S002375","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0005768","Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.","Ji L","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00136-1","42594928",null,"ClinicalTrials.gov:NCT06269107","S001494","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0005769","Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy.","Mac Curtain BM","2024","Gastroenterology and hepatology from bed to bench","nonrandomized_study","article","10.22037/ghfbb.v17i1.2899","38737926","PMC11080689",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; review-article; article"],["R0005770","Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials.","Rasouli N","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-025-01711-0","40016573","PMC11925828",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005771","GLP-1 agonism alters local field potential in the lateral septum and alters operant behavior in rats","Culshaw IR","2026","bioRxiv","preclinical","preprint","10.64898/2026.04.19.719508",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005772","Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials.","Kunutsor SK","2024","Scandinavian cardiovascular journal : SCJ","systematic_review","article","10.1080/14017431.2024.2418086","39425977",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0005773","Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States.","Nicholas SB","2023","Kidney medicine","commentary","article","10.1016/j.xkme.2022.100590","36605084","PMC9807823",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0005774","Targeting Metabolic Dysfunction in Parkinson's Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection.","Aviles-Olmos I","2025","Current diabetes reports","narrative_review","article","10.1007/s11892-025-01606-1","41003884","PMC12474678",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005775","Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.","Costa A","2022","Molecular metabolism","preclinical","article","10.1016/j.molmet.2021.101407","34844019","PMC8689241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0005776","Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.","Abi Zeid Daou C","2025","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70038","40055991","PMC11889434",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0005777","Reminders embedded in PCI reports to optimize discharge diabetes mellitus care (REMIND-DM): Rationale, design, and baseline characteristics.","Chatur S","2025","American heart journal","protocol","article","10.1016/j.ahj.2025.01.020","39988205",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Clinical Trial Protocol; Journal Article"],["R0005778","An Injection Leading to Oesophageal Perforation: A Rare Case of Contained Boerhaave's Syndrome Following Unsupervised GLP-1/GIP Receptor Agonist Dose Escalation.","Syed NS","2026","Cureus","case_report","article","10.7759/cureus.101811","41717183","PMC12914087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005779","GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway.","Xiang J","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s425642","37602204","PMC10439806",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005780","Ethnic/Racial and Geographic Disparities on Major Cardiovascular Events in Glucagon Like Peptide-1 receptor Agonists Trials: A Meta-Analysis.","Lavalle Cobo A","2023","Current problems in cardiology","systematic_review","article","10.1016/j.cpcardiol.2023.101940","37422042",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Review; review"],["R0005781","Glucagon-like peptide-1 receptor agonists and safety in the preconception period.","Minis E","2023","Current opinion in endocrinology, diabetes, and obesity","randomized_trial","article","10.1097/med.0000000000000835","37678163","PMC10615799",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Review; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005782","[Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].","Scheen A","2025","Revue medicale de Liege","narrative_review","article",null,"40931739",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0005783","Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.","Widiarti W","2021","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2021.04.005","33866119",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0005784","GLP-1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels.","Schulz ME","2026","Microcirculation (New York, N.Y. : 1994)","preclinical","article","10.1111/micc.70070","42231627","PMC13436613",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005785","Plant-Based Nutrition Alleviates Gastrointestinal Symptoms and Enhances Protein Intake during GLP-1 Therapy.","Withrow NA","2026","Current developments in nutrition","other_trial","article","10.1016/j.cdnut.2026.109393","42388893","PMC13319671","ClinicalTrials.gov:NCT07096739","S001802","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0005786","Development and validation of an LC-MS/MS method for Tirzepatide, a dual GIP/GLP-1 receptor agonist, in rat plasma for application to a pharmacokinetic study.","Choi HI","2026","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","preclinical","article","10.1016/j.jchromb.2025.124836","41197390",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005787","Treatment and Monitoring of Idiopathic Intracranial Hypertension.","Chen JJ","2025","Continuum (Minneapolis, Minn.)","randomized_trial","article","10.1212/cont.0000000000001586","40459312",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; Case Reports; article"],["R0005788","Cost-effectiveness and budget-impact analysis of tirzepatide in heart failure with preserved ejection fraction and obesity in the German health-care system.","Estler B","2026","International journal of cardiology","other","article","10.1016/j.ijcard.2026.134560","42155673",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005789","Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States.","Kosaraju SA","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s473319","39376661","PMC11457783",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005790","Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia.","Al-Omar HA","2024","Journal of medical economics","nonrandomized_study","article","10.1080/13696998.2024.2319458","38420695",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005791","Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.","Mosenzon O","2021","Advances in chronic kidney disease","nonrandomized_study","article","10.1053/j.ackd.2021.04.005","34922691",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0005792","Glucagon-Like Peptide-1 Agonist vs. Placebo and Pulmonary Decline After Open-Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial.","Mikkelsen AD","2026","Acta anaesthesiologica Scandinavica","randomized_trial","article","10.1111/aas.70282","42318973","PMC13281132",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0005793","A novel high dimensional approach to assess heterogeneous treatment effect in claims data.","Wang T","2025","American journal of epidemiology","nonrandomized_study","article","10.1093/aje/kwaf127","40512658","PMC12527247",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0005794","Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.","Murakami T","2020","Journal of diabetes investigation","preclinical","article","10.1111/jdi.13281","32323451","PMC7610126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005795","The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis.","Chen X","2024","The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry","systematic_review","article","10.1016/j.jagp.2023.08.010","37684186",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0005796","Clinical Impact of Tirzepatide on Patients With OSA and Obesity.","Wu JY","2025","Chest","nonrandomized_study","article","10.1016/j.chest.2025.03.030","40254150",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005797","Cardiac Damage in Hypertension: From Molecular Mechanisms to Novel Therapeutic Approaches.","Gallo G","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26125610","40565074","PMC12192565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005798","Adverse event reporting of combining SGLT2 inhibitor and GLP1 receptor agonist: A real-world study from FAERS.","Tian C","2025","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2024.09.028","39571323",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0005799","Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease.","Zhang P","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","randomized_trial","article","10.1002/alz.70639","40898408","PMC12404899",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005800","Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Reinstatement of Cocaine-Mediated Conditioned Place Preference in Mice.","Zhu C","2021","Frontiers in behavioral neuroscience","preclinical","article","10.3389/fnbeh.2021.769664","35069139","PMC8766416",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005801","Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study.","Katragadda R","2026","The Laryngoscope","nonrandomized_study","article","10.1002/lary.70810","42647098",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005802","Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on time to outcome in type 2 diabetes cardiorenal outcome trials.","Rizzi A","2024","Diabetes & metabolic syndrome","randomized_trial","article","10.1016/j.dsx.2024.102945","38262118",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0005803","GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes.","Wilbon SS","2023","Cells","narrative_review","article","10.3390/cells13010065","38201269","PMC10778154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; review-article; article"],["R0005804","Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis.","Bilal A","2024","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2024.108783","38870731",null,"PROSPERO:CRD42021260167",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Preprint; preprint"],["R0005805","Retinal perfusion delay associated with GLP-1 receptor agonists: A possible role of intracranial pressure?","Lee YK","2025","medRxiv","preclinical","preprint","10.1101/2025.09.25.25336128",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005806","Efficacy of three modern anti-diabetic drugs on survival outcomes of lung cancer patients with type 2 diabetes in China.","Chen Z","2025","Frontiers in oncology","nonrandomized_study","article","10.3389/fonc.2025.1498927","40040724","PMC11876025",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005807","Portal vein thrombosis in a patient on semaglutide.","Farooqi MF","2024","Qatar medical journal","other","article","10.5339/qmj.2024.75","39925824","PMC11806721",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005808","Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial.","Poulsen AS","2025","Osteoarthritis and cartilage open","randomized_trial","article","10.1016/j.ocarto.2024.100562","39877802","PMC11773487","ClinicalTrials.gov:NCT02905864","S001734","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0005809","GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning.","Wang J","2023","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2023.04.012","37167707",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005810","Comment on: \"Relative Effectiveness and Safety of the GLP-1 Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics\" [Letter].","Zhu H","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","commentary","article","10.2147/dmso.s560523","40919564","PMC12413826",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0005811","GLP-1RA Use and Thyroid Cancer Risk.","Brito JP","2025","JAMA otolaryngology-- head & neck surgery","nonrandomized_study","article","10.1001/jamaoto.2024.4852","39847346","PMC11907303","ClinicalTrials.gov:NCT05214573","S002708","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005812","GLP-1 Receptor Agonists and Dual GIP/GLP-1 and Reduction in Major Cardiovascular Events: A Systematic Review and Network Meta-Analysis","Campos García FJ","2026","Preprints.org","systematic_review","preprint","10.20944/preprints202610.0314.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0005813","Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery.","Preda V","2023","BJS open","nonrandomized_study","article","10.1093/bjsopen/zrac169","36723995","PMC9891341",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; letter; article"],["R0005814","Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study.","Bakken IJ","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70827","42086462",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Preprint; preprint; article"],["R0005815","Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.","Kutz A","2023","Diabetes care","nonrandomized_study","article","10.2337/dc23-0671","37677118","PMC10620535",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; other; article"],["R0005816","Cardiorenal interactions: an update and review of treatment options","Wei L","2025","Authorea Preprints","randomized_trial","preprint","10.22541/au.174072853.34697252/v1",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","2","FALSE","Preprint; preprint"],["R0005817","The impact of sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on insulin utilisation and costs in Australia: a national retrospective observational cross-sectional study.","Hamblin PS","2024","The Lancet regional health. Western Pacific","nonrandomized_study","article","10.1016/j.lanwpc.2024.101207","39381086","PMC11460498",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005818","Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus.","Cai X","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-021-01079-x","34047959","PMC8266933","ClinicalTrials.gov:NCT01128205",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0005819","Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.","Ciardullo S","2024","Gastroenterology report","randomized_trial","article","10.1093/gastro/goae029","38681750","PMC11052658",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005820","Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.","Edelman S","2022","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2022.28.9.958","36001104","PMC10373043",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005821","The 2024 top 10 list of endoscopy topics in medical publishing: an annual review by the American Society for Gastrointestinal Endoscopy Editorial Board.","Martinez M","2025","Gastrointestinal endoscopy","narrative_review","article","10.1016/j.gie.2025.04.004","40402124",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0005822","Comparing demographic/clinical characteristics, health care resource utilization, and costs among patients with type 2 diabetes and established atherosclerotic cardiovascular disease with and without the use of cardioprotective medications.","Dunn TJ","2025","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2025.24251","39823186","PMC11852797",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0005823","Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.","Urquhart S","2020","JAAPA : official journal of the American Academy of Physician Assistants","narrative_review","article","10.1097/01.jaa.0000669452.63883.45","32740122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005824","Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?","Kaplan JM","2024","Current cardiology reports","other_trial","article","10.1007/s11886-024-02097-4","39031282",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0005825","Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status.","Chen AS","2026","Journal of general internal medicine","other","article","10.1007/s11606-025-09691-4","40588707","PMC12894581",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0005826","Oral Semaglutide: Dosage in Special Situations.","Kalra S","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-022-01265-5","35532859","PMC9174361",null,"S000298","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0005827","The effect of sex and endurance exercise training on the incretin signaling pathway in 17 rat tissues.","Jin C","2026","Physiological genomics","preclinical","article","10.1152/physiolgenomics.00171.2026","42636194",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005828","Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management.","Jayathilaka NS","2026","Clinical pharmacology in drug development","systematic_review","article","10.1002/cpdd.1624","41238444",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Review; article"],["R0005829","Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.","Wharton S","2022","Postgraduate medicine","other","article","10.1080/00325481.2021.2002616","34775881",null,null,"S001600","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0005830","Cerebral microcirculation disorders after recanalization in acute ischemic stroke: A narrative review.","Li Z","2026","Brain circulation","narrative_review","article","10.4103/bc.bc_3_25","42667050","PMC13524409",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0005831","Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes.","Wong G","2023","JCEM case reports","case_report","article","10.1210/jcemcr/luad040","37908483","PMC10580416",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005832","Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.","Rosenstock J","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)00202-3","41765029",null,"ClinicalTrials.gov:NCT06045221","S000438","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Clinical Trial, Phase III; Randomized Controlled Trial; Comparative Study; Equivalence Trial; article"],["R0005833","GLP-1 receptor agonists and cardiovascular outcome trials: An update.","Andrikou E","2019","Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese","randomized_trial","article","10.1016/j.hjc.2018.11.008","30528435",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0005834","Real-world study of the concomitant use of biphasic insulin aspart 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.","Davies M","2024","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.15267","38088483",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005835","Periodontitis and GLP-1 pathways: a new frontier in oral-systemic health connections -a scoping review.","Jeong N","2025","Frontiers in clinical diabetes and healthcare","preclinical","article","10.3389/fcdhc.2025.1679511","41307071","PMC12643841",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005836","Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis.","Koenig ZA","2026","Plastic and reconstructive surgery","nonrandomized_study","article","10.1097/prs.0000000000012405","40875227",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005837","Assessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic.","Peng G","2026","Therapeutic advances in endocrinology and metabolism","other_trial","article","10.1177/20420188261467887","42756349","PMC13583291",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0005838","Mazdutide versus placebo in Chinese adults with type 2 diabetes.","Zhu D","2026","Nature","randomized_trial","article","10.1038/s41586-025-10026-w","41407859",null,null,"S000578","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0005839","Multi-target Mechanisms and Clinical Evidence for Ganzaoning Granule in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.","Zhao H","2026","Cureus","randomized_trial","article","10.7759/cureus.110011","42388541","PMC13319940",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0005840","Structural Overview of GLP-1 Analogs.","van der Velden WJC","2026","Biomedical journal","narrative_review","article","10.1016/j.bj.2026.101037","42727920",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0005841","An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning.","Rameshrad M","2020","Iranian journal of basic medical sciences","narrative_review","article","10.22038/ijbms.2020.41638.9832","32742592","PMC7374997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005842","Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.","Mehta R","2022","Diabetic medicine : a journal of the British Diabetic Association","other_trial","article","10.1111/dme.14901","35708737","PMC9542161",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0005843","GLP-1, Pancreatic β-Cells, and Insulin Secretion: What We Know and Where We Need to Go.","Vogt ÉL","2026","Diabetes","narrative_review","article","10.2337/db25-0695","41525103",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005844","Association of glucagon-like peptide-1 agonist therapy with postsurgical outcomes following multilevel correction for adult spinal deformity: a propensity score-matched analysis.","D'Amico C","2026","Asian spine journal","nonrandomized_study","article","10.31616/asj.2025.0407","41490720","PMC13329249",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005845","Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs).","Anam M","2022","Cureus","systematic_review","article","10.7759/cureus.32610","36654602","PMC9840940",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005846","Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update.","Tomlinson B","2024","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1080/17425255.2024.2341882","38594810",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005847","Pharmacotherapy for Obesity: Recent Updates.","Fredrick TW","2025","Clinical pharmacology : advances and applications","other_trial","article","10.2147/cpaa.s497904","40995421","PMC12456317",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005848","Pillar Risk-Based Treatment for Chronic Kidney Disease in People With Type 2 Diabetes: A Narrative Review.","Cheng AYY","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-025-01796-7","40971126","PMC12579093",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; review"],["R0005849","Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.","Sanchez-Navarro MJ","2026","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2026.115478","42603595",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005850","Glucagon-like peptide 1 receptor agonists in heart failure: the need for a rewind.","Ferreira JP","2022","European journal of heart failure","commentary","article","10.1002/ejhf.2693","36102183",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0005851","Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.","Lingvay I","2025","Diabetologia","randomized_trial","article","10.1007/s00125-024-06348-5","39820580","PMC11950020","ClinicalTrials.gov:NCT05259033","S000155","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; research-article; article"],["R0005852","Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs).","Kalra S","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-021-01113-y","34268675","PMC8342688",null,"S000944","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005853","Missing Opportunity for Nephroprotective Therapy in Patients With Non-Dialysis CKD Under Stable Nephrology Care.","De Nicola L","2026","Kidney international reports","nonrandomized_study","article","10.1016/j.ekir.2026.106541","42179812","PMC13194180",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005854","Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes.","Vázquez LA","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-023-01467-5","37713104","PMC10570244",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0005855","Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.","Iwamoto Y","2024","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.15972","39344853",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005856","The Multifaceted Nature of GLP-1: Molecular Mechanisms and Signaling Pathways in Metabolic and Neurodegenerative Diseases.","Kowalska MK","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27041886","41752021","PMC12941302",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005857","Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.","Pai YW","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15918","39248211",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005858","Effects of Dulaglutide on Ectopic Fat Deposition in Chronic Kidney Disease (CKD): A Pilot and Feasibility Study (GLIMP).","Dilaver RG","2025","medRxiv : the preprint server for health sciences","other","article","10.1101/2025.03.19.25324266","40166561","PMC11957094",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0005859","Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.","Leite AR","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14707","35373878",null,"ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Meta-Analysis; Journal Article; article"],["R0005860","Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide.","Pickford P","2020","British journal of pharmacology","preclinical","article","10.1111/bph.15134","32436216","PMC7429481",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005861","Pulsatile liraglutide on a biased tirzepatide background: a hypothesis.","Kopitovic I","2026","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2026.1922908","42787169","PMC13600978",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0005862","Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5/NR4a1 axis.","Ma YL","2024","Nature communications","preclinical","article","10.1038/s41467-024-48970-2","38834564","PMC11150406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005863","Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.","Aroda VR","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15079","37013892",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0005864","Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?","Lam B","2026","BMJ case reports","case_report","article","10.1136/bcr-2025-269690","41786442","PMC12969776",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0005865","Glucagon-like peptide-1 mimotopes screened from an Fv-antibody library.","Bae HE","2026","Journal of materials chemistry. B","other","article","10.1039/d5tb02128f","41978477",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005866","Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.","Chae Y","2024","Expert review of clinical pharmacology","systematic_review","article","10.1080/17512433.2024.2363838","38832475",null,"PROSPERO:CRD42021282668",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; article; review"],["R0005867","Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity.","Bensignor MO","2024","Pediatric obesity","randomized_trial","article","10.1111/ijpo.13105","38339799","PMC11006569",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0005868","Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists.","Yassine HN","2022","Alzheimer's & dementia : the journal of the Alzheimer's Association","narrative_review","article","10.1002/alz.12474","34647685","PMC8940606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0005869","Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.","Nørgaard CH","2022","Alzheimer's & dementia (New York, N. Y.)","randomized_trial","article","10.1002/trc2.12268","35229024","PMC8864443",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005870","Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique.","Yepes-Cortés CA","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-025-01722-x","40126829","PMC12006584",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005871","Examining the Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Human Gut Microbiome: A Systematic Review","Au H","2024","Authorea Preprints","systematic_review","preprint","10.22541/au.173199831.11097717/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0005872","Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery.","Wright JD","2025","International journal of surgery (London, England)","nonrandomized_study","article","10.1097/js9.0000000000002425","40359555","PMC12165584",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005873","Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.","Zufry H","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70073","40859897",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0005874","Medication Adherence to Semaglutide Once-Weekly Injection Among Type-2 Diabetes Patients in Tabuk, Saudi Arabia - A Cross-Sectional Study.","Amirthalingam P","2025","Patient preference and adherence","other","article","10.2147/ppa.s534534","40860604","PMC12375302",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005875","Liraglutide Enhances Cell Viability and Reduces Oxidative Stress in Hyperglycemic H9c2 Cardiomyocytes.","Durmus S","2025","Medicina (Kaunas, Lithuania)","preclinical","article","10.3390/medicina61101754","41155741","PMC12566514",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005876","Semaglutide in Heart Failure With Preserved Ejection Fraction: Exploring Recent Evidence in Therapeutic Potential for the Obese Population.","Kusayev J","2026","Cardiology in review","narrative_review","article","10.1097/crd.0000000000000726","38757954",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005877","Incretin-Based Therapies and Cancer: What's New?","Medenica S","2025","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina61040678","40282969","PMC12028497",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005878","Liraglutide alleviates sepsis-induced encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis","Yi H","2025","Research Square","preclinical","preprint","10.21203/rs.3.rs-7340017/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005879","Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus.","Rodríguez Jiménez B","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1386542","38894744","PMC11182984",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005880","Unmasking an insulinoma: recurrent Hypoglycemia in a young patient following GLP-1 receptor agonist therapy -A case report.","Baldera-Rodriguez N","2026","Oxford medical case reports","case_report","article","10.1093/omcr/omaf283","41589102","PMC12832021",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005881","Does glucose lowering restore GIP effects on insulin secretion?","Grespan E","2023","Nutrition, metabolism, and cardiovascular diseases : NMCD","other","article","10.1016/j.numecd.2022.12.021","36710118",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0005882","Tirzepatide retention in iWAT with mesoporous polydopamine encapsulation enhances weight loss through leptin receptor signaling.","Mi L","2026","Journal of advanced research","preclinical","article","10.1016/j.jare.2025.09.009","40945849","PMC13227263",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005883","GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study.","Koutouratsas T","2026","Age and ageing","randomized_trial","article","10.1093/ageing/afag281","42765724",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0005884","Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome.","Premji R","2022","Metabolic syndrome and related disorders","narrative_review","article","10.1089/met.2022.0004","35452324",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005885","Burden of long-term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT-O study.","Khunti K","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70345","41408076","PMC12890748",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005886","GLP-1 agonist use and lower rates of pseudarthrosis and dysphagia following anterior cervical discectomy and fusion surgery, with time-dependent effects.","Mehta MKS","2026","Journal of neurosurgery. Spine","nonrandomized_study","article","10.3171/2026.4.spine26216","42664518",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005887","Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Hematological Malignancies: A Narrative Review of Current and Emerging Evidence.","Krishnan Nair H","2026","Cureus","randomized_trial","article","10.7759/cureus.114008","42565010","PMC13445956",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0005888","Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis.","Qiu M","2021","Journal of cardiovascular pharmacology","systematic_review","article","10.1097/fjc.0000000000000916","33136765",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; Network Meta-Analysis; article"],["R0005889","Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study.","Bach P","2026","The lancet. Psychiatry","nonrandomized_study","article","10.1016/s2215-0366(26)00172-0","42456704",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0005890","Sleeve gastrectomy versus dual GLP-1/GIP receptor agonist to improve access to kidney transplantation in patients with end-stage renal disease and obesity: A decision analysis.","Di Napoli M","2025","American journal of surgery","other","article","10.1016/j.amjsurg.2025.116475","40540976",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0005891","Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors.","Khalil A","2025","EBioMedicine","preclinical","article","10.1016/j.ebiom.2025.106033","41274021","PMC12682123",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005892","Assessment of Glucagon-like Peptide-1 Receptor Agonists in Veterans Taking Basal/Bolus Insulin Regimens.","Castek SL","2022","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article","10.12788/fp.0317","36923548","PMC10010496",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005893","Risk of Suicidal Ideation and Behaviors, Depression, and Anxiety with GLP-1 Receptor Agonist Use in Children and Adolescents: A Target Trial Emulation Study.","Kotecha P","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.11.11.25339931","41292652","PMC12642753",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0005894","Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States.","Gibble TH","2025","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2025.05.003","40480878",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0005895","The GLP-1R Agonist Semaglutide Reduces Motivated Running and Alters Dopamine Dynamics in the Nucleus Accumbens.","Foscue EP","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.10.08.681212","41279988","PMC12632335",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0005896","Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats.","Douton JE","2021","Behavioural pharmacology","preclinical","article","10.1097/fbp.0000000000000609","33229892","PMC8119287",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0005897","From incretin discovery to anti-obesity blockbuster drugs. One hundred years of research to move from shadow to spotlight","Portha B","2025","Cahiers de Nutrition et de Diététique","other","article","10.1016/j.cnd.2025.05.006",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005898","Safety and Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients: Synthesis of Evidence.","Bellos I","2024","Journal of clinical medicine","randomized_trial","article","10.3390/jcm13206181","39458136","PMC11508237",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005899","Tirzepatide alters oncogenic signaling pathways in colorectal cancer cells in vitro.","Fadhil NM","2025","Cellular and molecular biology (Noisy-le-Grand, France)","preclinical","article","10.14715/cmb/2025.71.11.15","41351362",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0005900","Association of GLP-1 Receptor Agonist and SGLT2 Inhibitor With Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement.","Fahoury AM","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.02.043","41765256",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005901","Venous Congestion in Metabolic Heart Disease: Potential Indirect Role of Dual Incretin Agonists.","Senapati SG","2026","Cardiovascular & hematological disorders drug targets","other","article","10.2174/011871529x502187260803101832","42634315",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005902","Aspiration Risk During Endoscopic Procedures While on GLP-1 Agonist Therapy.","Stryelkina M","2026","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-025-09307-1","40783459",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005903","Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature.","Sonego B","2023","Dermatology reports","case_report","article","10.4081/dr.2023.9676","37822982","PMC10563024",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005904","Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.","Nakhla M","2025","Cardiovascular drugs and therapy","nonrandomized_study","article","10.1007/s10557-024-07613-w","39264502",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0005905","Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice.","Zhang Y","2025","Nature aging","preclinical","article","10.1038/s43587-025-00869-3","40394225",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005906","Benchmarking weight loss and survival benefits after gastric bypass: a long-term cohort study.","Dallal RM","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2025.12.007","41672790",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0005907","GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Patients With Versus Without Cardiovascular Disease: A Systematic Review, Meta-analysis, and Trial Sequential Analysis.","Kilickap M","2024","Angiology","systematic_review","article","10.1177/00033197231183229","37326223",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; other; review"],["R0005908","Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.","Giorgino F","2020","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2020.108478","33002548",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0005909","Association between intra-pancreatic fat deposition and diseases of the exocrine pancreas: A narrative review.","Ye J","2025","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v31.i2.101180","39811515","PMC11684206",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0005910","Prediabetes and diabetes mellitus type II after ischemic stroke.","Moelgg K","2025","European stroke journal","nonrandomized_study","article","10.1177/23969873241304301","39763481","PMC11705302",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005911","Real-World Incretin-Based Therapy for Obesity After Solid Organ Transplantation: A Single-Centre Retrospective Study From Poland.","Kędzierska-Kapuza K","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71222","42634580",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0005912","Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies.","Corraliza-Gomez M","2025","Molecular neurodegeneration","systematic_review","article","10.1186/s13024-025-00894-1","41146261","PMC12560610",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review-article; other; review"],["R0005913","Effects of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and nonalcoholic fatty liver disease: A cohort study.","Naguib R","2025","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","nonrandomized_study","article","10.1007/s44446-025-00044-0","41145880","PMC12559501",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005914","Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study.","Singh P","2020","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13964","31943645","PMC9292640",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0005915","Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways.","Botros SR","2024","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2024.1353029","38440177","PMC10910313",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005916","An approach to insulin tapering and discontinuation after glucagon-like peptide-1 receptor agonist initiation.","Crossey CD","2022","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxac230","35981331",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0005917","Semaglutide-induced weight loss improves mitochondrial energy efficiency in skeletal muscle.","Choi RH","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.11.13.623431","39605484","PMC11601453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0005918","GLP-1 Receptor Agonists Alleviate Diabetic Kidney Injury via β-Klotho-Mediated Ferroptosis Inhibition.","Tian S","2025","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","other","article","10.1002/advs.202409781","39630101","PMC11775532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005919","Virtual shared medical appointments for obesity and GLP-1 medications: A scalable method for optimizing care delivery.","Mirsky J","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100277","42254478","PMC13235319",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0005920","Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.","Chunduri S","2026","Cardiovascular drugs and therapy","nonrandomized_study","article","10.1007/s10557-025-07757-3","40938549",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; Preprint; preprint; article"],["R0005921","Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.","Buckeridge C","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16534","40539310","PMC12326921","ClinicalTrials.gov:NCT04707313","S000279","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; research-article; article"],["R0005922","Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists: Report",null,"2022","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"38696623",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0005923","Anabolic androgenic steroid use and risk of diabetes mellitus in males.","Esmann FVL","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70283","41208464",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005924","Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation.","Wong CK","2024","Cell metabolism","other","article","10.1016/j.cmet.2023.11.009","38113888",null,null,"S002468","pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0005925","Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis.","Vatsia SK","2025","Clinical spine surgery","nonrandomized_study","article","10.1097/bsd.0000000000001775","40042198",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005926","Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.","Seijas-Amigo J","2026","International journal of clinical pharmacy","nonrandomized_study","article","10.1007/s11096-026-02099-y","41739406","PMC13176177",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0005927","Localized Injection of Semaglutide, a GLP-1 Agonist, for Hyperinsulinemia-Induced Lymphatic Dysfunction A Novel Therapeutic Strategy for Lymphedema Treatment","Akl MM","2024","Qeios","other","preprint","10.32388/l6amnd",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005928","Polyethylene Glycol Loxenatide Selectively Reduces Adiposity While Preserving Lean Body Mass in Type 2 Diabetes: A 12-Week Clinical Study.","Gu R","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","other_trial","article","10.2147/dmso.s592044","42453280","PMC13368281","ClinicalTrials.gov:NCT05611684",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Clinical Trial; Journal Article; case-report; article"],["R0005929","6989 Novel Use of Dual GIP/GLP-1 Receptor Agonist in HNF4A-MODY",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455316",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0005930","Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications.","Marshall WR","2026","Current opinion in nephrology and hypertension","nonrandomized_study","article","10.1097/mnh.0000000000001225","42683763",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0005931","Safety of Drugs in Breastfeeding Women With CKD.","Parnizari P","2025","Kidney international reports","nonrandomized_study","article","10.1016/j.ekir.2025.04.038","40677356","PMC12266210",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005932","Effect of glucagon-like peptide-1 receptor agonists on fat distribution in patients with type 2 diabetes: A systematic review and meta-analysis.","Duan K","2022","Journal of diabetes investigation","systematic_review","article","10.1111/jdi.13775","35191185","PMC9248433",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0005933","Obesity and Cancer: A Translational Science Review.","Shen S","2026","JAMA","narrative_review","article","10.1001/jama.2026.1114","41801209",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005934","Combined effect of continuous glucose monitoring and semaglutide: analysis of administrative claims.","Nemlekar PM","2025","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2025.89719","40227398",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005935","Prolonged Semaglutide Treatment Reveals Stage-Dependent Changes to Feeding Behavior and Metabolic Adaptations in Male Mice.","Shah H","2026","Diabetes","preclinical","article","10.2337/db25-0678","41329075","PMC12823338",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0005936","The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis.","Alhindi Y","2022","Contemporary clinical trials communications","systematic_review","article","10.1016/j.conctc.2022.100944","35812819","PMC9260263",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005937","Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease.","Barber T","2025","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.1093/ajhp/zxaf045","40197743",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005938","The effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysis.","Mavridis A","2026","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2026.104220","42831062","PMC13634272",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0005939","Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system.","Qi L","2024","Nature communications","preclinical","article","10.1038/s41467-024-52258-w","39266553","PMC11393072",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0005940","What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?-A Mini Review.","Berndt J","2021","Molecules (Basel, Switzerland)","narrative_review","article","10.3390/molecules26164822","34443410","PMC8400553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005941","Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.","Iqbal J","2022","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13435","35194917",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0005942","Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.","Duan XY","2021","Medicine","systematic_review","article","10.1097/md.0000000000026431","34397684","PMC8322563",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review-article; article"],["R0005943","GLP-1 receptor agonists show no detrimental effect on sperm quality in mouse models and cell lines.","Yin D","2025","Endocrine","preclinical","article","10.1007/s12020-025-04245-4","40347306","PMC12289847",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005944","Investigating the association between GLP-1 receptor agonists and mood disorders: A study integrating real-world data and Mendelian randomization.","Zheng X","2025","European psychiatry : the journal of the Association of European Psychiatrists","nonrandomized_study","article","10.1192/j.eurpsy.2025.10125","41331950","PMC12816927",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005945","Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.","Kaneto H","2020","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14095","32436323",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0005946","Five-Year Incidence of Progression to Ankle Osteoarthritis in Patients with and without Glucagon-like Peptide-1 Receptor Agonist Therapy.","Le Y","2026","Foot & ankle specialist","nonrandomized_study","article","10.1177/19386400261427898","41805465",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005947","Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Using Four Pillars of Therapy: The Time to Act is Now.","Georgianos PI","2024","Drugs","randomized_trial","article","10.1007/s40265-024-02091-8","39259460",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0005948","Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.","Wei XB","2021","Primary care diabetes","systematic_review","article","10.1016/j.pcd.2020.08.017","32912710",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; review"],["R0005949","Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta-analysis.","Kato S","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70182","41126557",null,"UMIN:UMIN000042499",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0005950","Response to \"An approach to insulin tapering and discontinuation after glucagon-like peptide-1 receptor agonist initiation\".","George J","2022","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxac231","35977884",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comment; article"],["R0005951","Tirzepatide for type 2 diabetes.","Anderson SL","2023","Drugs in context","other_trial","article","10.7573/dic.2023-6-1","37664792","PMC10470858",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0005952","Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.","Lin YH","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2024.01.016","38325629",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comparative Study; article"],["R0005953","Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics.","Inokuchi T","2024","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14225","38700282","PMC11363112",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005954","Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.",null,"2026","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2026.1755a","42139026",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0005955","Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.","Tanaka K","2022","Scientific reports","nonrandomized_study","article","10.1038/s41598-021-04149-z","34997102","PMC8742102",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0005956","Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy.","Yao R","2024","The American journal of gastroenterology","nonrandomized_study","article","10.14309/ajg.0000000000002564","37856247",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005957","Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.","Wang J","2025","Annals of medicine","systematic_review","article","10.1080/07853890.2025.2455539","39834076","PMC11753015",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; research-article; review"],["R0005958","Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.","Katayama S","2026","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2025.109213","41289823",null,"ClinicalTrials.gov:NCT02540993; ClinicalTrials.gov:NCT02545049",null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0005959","Efficacy and Safety of Tirzepatide and Semaglutide for Obesity Management: A Real-World Comparison.","Shil KK","2025","Cureus","nonrandomized_study","article","10.7759/cureus.98858","41523559","PMC12783929",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005960","The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs.","Douros JD","2025","Journal of clinical medicine","preclinical","article","10.3390/jcm14113812","40507574","PMC12155807",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005961","Efficacy and safety of semaglutide for weight management: evidence from the STEP program.","Amaro A","2022","Postgraduate medicine","other_trial","article","10.1080/00325481.2022.2147326","36691309",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0005962","Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions.","Zhang H","2025","Frontiers in medicine","narrative_review","article","10.3389/fmed.2025.1631053","40861214","PMC12370670",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005963","Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer's Disease.","Colin IM","2023","TouchREVIEWS in endocrinology","randomized_trial","article","10.17925/ee.2023.19.1.16","37313236","PMC10258618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005964","Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension.","Samaranayake CB","2026","JCI insight","preclinical","article","10.1172/jci.insight.202660","42171611","PMC13232712",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005965","GLP-1 Receptor Agonist-Based Prandial Insulin De-Intensification in Outpatients With Type 2 Diabetes Receiving Basal-Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","Yang H","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71359","42736042",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0005966","GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.","Mao X","2026","Hepatology (Baltimore, Md.)","nonrandomized_study","article","10.1097/hep.0000000000001771","42029657",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005967","Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials.","Wu S","2022","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-022-00970-2","36572913","PMC9791739","PROSPERO:CRD42022339389",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005968","Kidney disease in patients with HIV.","Mejia SM","2025","Current opinion in HIV and AIDS","narrative_review","article","10.1097/coh.0000000000000941","40184511",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0005969","Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.","Gadde KM","2026","JAMA","commentary","article","10.1001/jama.2026.10443","42251768",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0005970","Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice.","Zhao L","2024","Endocrine","preclinical","article","10.1007/s12020-024-03734-2","38378894",null,null,"S000128","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0005971","Proximal Jejunal Bypass with Sleeve Gastrectomy for Severe Obesity and Type 2 Diabetes: First Case Report in Japan.","Nabekura T","2025","Surgical case reports","case_report","article","10.70352/scrj.cr.25-0392","41122449","PMC12536066",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0005972","IDegLira for type 2 diabetes: a systematic review and meta-analysis.","Liu Y","2024","Endocrine","systematic_review","article","10.1007/s12020-023-03543-z","37768513",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0005973","Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.","Luo Y","2026","Contemporary clinical trials","protocol","article","10.1016/j.cct.2025.108150","41260459",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Clinical Trial Protocol; article"],["R0005974","Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?","Mihălțan FD","2026","Life (Basel, Switzerland)","randomized_trial","article","10.3390/life16050802","42195357","PMC13208907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005975","Severe Diabetic Ketoacidosis Triggered by Premature Insulin Reduction After Tirzepatide Initiation","Hussein K","2026","Research Square","other","preprint","10.21203/rs.3.rs-9669421/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0005976","Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.","Falcon B","2026","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","randomized_trial","article","10.1007/s44470-026-00162-z","42675225","PMC13530102","ClinicalTrials.gov:NCT05412004","S000156","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; research-article; article"],["R0005977","Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists.","Shah MY","2025","Cureus","randomized_trial","article","10.7759/cureus.88334","40837892","PMC12361690",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0005978","Liraglutide, a GLP-1 Receptor Agonist, Mitigates LPS-Induced Osteoclastogenesis and Bone Loss by Downregulating Macrophage TNF-α Expression.","Murakami K","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27125624","42353338","PMC13299069",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0005979","Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.","Munawar N","2025","Cureus","systematic_review","article","10.7759/cureus.86080","40666599","PMC12263181",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0005980","Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.","Seminer A","2025","JAMA neurology","systematic_review","article","10.1001/jamaneurol.2025.0360","40193122","PMC11976645",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; article"],["R0005981","GLP-1 physiology and pharmacology along the gut-brain axis.","Beutler LR","2026","The Journal of clinical investigation","narrative_review","article","10.1172/jci194744","41542773","PMC12807470",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005982","Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?","Gouveri E","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-023-01506-1","37950798","PMC10786794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0005983","Comparative Effects of Dulaglutide and Semaglutide on Renal Function Decline and Proteinuria Reduction in Diabetic Patients: A Retrospective Cohort Study.","Sue YM","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14124287","40566032","PMC12193715",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005984","Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.","Wester A","2024","Gut","randomized_trial","article","10.1136/gutjnl-2023-330962","38253482","PMC11041618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0005985","Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Antipsychotic-Induced Weight Gain.","Pascale S","2026","The Annals of pharmacotherapy","systematic_review","article","10.1177/10600280251414107","41723102",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0005986","Relevance of GLP-1 receptor agonists or SGLT-2 inhibitors on the recruitment for clinical studies in patients with NAFLD.","Holzhey M","2024","European journal of gastroenterology & hepatology","nonrandomized_study","article","10.1097/meg.0000000000002656","37823453",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0005987","Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.","Taylor SI","2023","medRxiv : the preprint server for health sciences","other","article","10.1101/2023.03.15.23287166","36993363","PMC10055582","ClinicalTrials.gov:NCT05071898; ClinicalTrials.gov:NCT02462421; ClinicalTrials.gov:NCT05762744","S000444; S000519","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Preprint; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; preprint; article"],["R0005988","The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.","Skelley JW","2024","Journal of the American Pharmacists Association : JAPhA","other_trial","article","10.1016/j.japh.2023.10.037","37940101",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0005989","Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.","Sun Y","2026","Endocrine","randomized_trial","article","10.1007/s12020-026-04699-0","42439957",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; Preprint; preprint; article"],["R0005990","Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.","Dankner R","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2023.50408","38175642","PMC10767614","ClinicalTrials.gov:NCT02072902",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0005991","A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice.","Douros JD","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102124","40157531","PMC12398856",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0005992","Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).","Ishigaki Y","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00977-w","33300091","PMC7843848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0005993","Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation.","Turchin A","2026","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2026-100574","42778221",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0005994","CORRECTION: Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide?","British Medical Journal Publishing Group","2025","BMJ (Clinical research ed.)","notice","article","10.1136/bmj.r269","39919809",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0005995","Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review.","Nikolaidou A","2024","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina60060912","38929529","PMC11205945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0005996","The prevention and management of chronic kidney disease among patients with metabolic syndrome.","Zhu D","2025","Kidney international","randomized_trial","article","10.1016/j.kint.2024.12.021","39986466",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0005997","The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes.","Bolli GB","2025","Diabetes care","narrative_review","article","10.2337/dci24-0104","40116796","PMC12034903",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0005998","A review of the latest real-world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?","Bonnet F","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15710","38899425",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0005999","Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis.","Yang B","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s503216","39990178","PMC11844210",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006000","Incretin effect is sufficient for glucose control in developing rats.","Motokura K","2026","The Journal of endocrinology","preclinical","article","10.1530/joe-25-0146","41503805",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006001","A Plethora of GLP-1 Agonists: Decisions About What to Use and When.","Samson SL","2016","Current diabetes reports","other_trial","article","10.1007/s11892-016-0823-6","27766579",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0006002","COVID-19 and Diabetes: Persistent Cardiovascular and Renal Risks in the Post-Pandemic Landscape.","Huang TS","2025","Life (Basel, Switzerland)","narrative_review","article","10.3390/life15050726","40430154","PMC12112973",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006003","[Relationship Between Dementia and Lifestyle Diseases].","Shimasaki R","2024","No shinkei geka. Neurological surgery","narrative_review","article","10.11477/mf.1436205028","39622317",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0006004","Roflumilast Enhances Liraglutide's Atrial Natriuretic Peptide-Dependent Suppression of Adrenal Aldosterone Secretion.","Hosseini A","2026","International journal of molecular sciences","other","article","10.3390/ijms27094098","42123676","PMC13164327",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006005","Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.","Katsuyama H","2023","Biomedicines","nonrandomized_study","article","10.3390/biomedicines11030869","36979848","PMC10046001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006006","Prescribing Patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Patients with T2DM and ASCVD in South Korea","Je NK","2024","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.171065778.86745224/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006007","GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.","Coke LA","2022","Journal of the American Association of Nurse Practitioners","other","article","10.1097/jxx.0000000000000661","35120085",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006008","Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration.","Woronow D","2022","JAMA internal medicine","other","article","10.1001/jamainternmed.2022.3810","36036939","PMC9425280",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006009","Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice.","Yeung MHY","2021","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2021.777395","35299724","PMC8921774",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006010","Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.","Stenberg E","2023","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-023-01254-z","36670155","PMC10113141",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006011","[Not Available].","Kårhus ML","2023","Ugeskrift for laeger","other","article",null,"37264870",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0006012","Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.","Mantovani A","2021","Metabolites","systematic_review","article","10.3390/metabo11020073","33513761","PMC7911747",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006013","Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.","Apperloo EM","2024","The lancet. Diabetes & endocrinology","systematic_review","article","10.1016/s2213-8587(24)00155-4","38991584",null,null,"S002662","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0006014","Skeletal Muscle Mass and Body Weight Fall Proportionally With Use of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Tirzepatide: Case Report and Review of Literature.","Zinn J","2025","AACE clinical case reports","case_report","article","10.1016/j.aace.2024.12.001","40201455","PMC11973593",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006015","Chronic semaglutide alters ingestive behavior without impairing taste function in mice.","Acosta AA","2026","Molecular metabolism","other_trial","article","10.1016/j.molmet.2026.102410","42364710","PMC13382136",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0006016","Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus.","Du J","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.1097612","36686441","PMC9846071",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006017","Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework.","Yang CT","2024","Journal of internal medicine","nonrandomized_study","article","10.1111/joim.13751","37994187",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006018","[Effects of antidiabetic medications on metabolic-associated fatty liver disease].","Scheen AJ","2023","Revue medicale suisse","other","article","10.53738/revmed.2023.19.838.1498","37610193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0006019","Second-line antidiabetic drugs: friend or foe of the liver.","Yang J","2025","Journal of liver cancer","narrative_review","article","10.17998/jlc.2025.06.25","40567201","PMC12518991",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0006020","Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence.","Kong Y","2025","European journal of medical research","randomized_trial","article","10.1186/s40001-025-02738-6","40506769","PMC12160363",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0006021","Semaglutide-Associated Acute Pancreatitis in a Patient With Type 2 Diabetes Mellitus: A Case Report.","Puri P","2026","Cureus","case_report","article","10.7759/cureus.105591","42017101","PMC13094300",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006022","The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.","Patel Chavez C","2022","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgab578","34406410","PMC8684453",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0006023","Informing Hospital Formulary Decisions in China: A Multi-Criteria Value Framework for GLP-1 Receptor Agonists.","Jiang Y","2026","Risk management and healthcare policy","other","article","10.2147/rmhp.s564791","41755903","PMC12935510",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006024","Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.","Trakoonsenathong R","2024","Scientific reports","preclinical","article","10.1038/s41598-024-64774-2","38877189","PMC11178799",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006025","Unmasking Aspiration Risks: A Propensity-Matched Odyssey of GLP-1 Receptor Agonists and Colonoscopy.","Chhabra P","2025","Journal of gastroenterology and hepatology","nonrandomized_study","article","10.1111/jgh.70071","40954421",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006026","Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.","Sanyal AJ","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2413258","40305708",null,"ClinicalTrials.gov:NCT04822181","S000511; S002481","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; article"],["R0006027","Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.","Hankosky ER","2025","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2025.101636","40057019",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0006028","Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review.","Mahé G","2024","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-024-02325-9","38926722","PMC11210102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; other; article"],["R0006029","Prevention of cardiovascular events in heart failure with mildly reduced or preserved ejection fraction: a comprehensive network meta-analysis of eight randomized controlled trials using reconstructed individual patient's data.","Diallo A","2025","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2025.103506","41181824","PMC12572806","PROSPERO:CRD420251007431",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0006030","Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats.","Douton JE","2022","Behavioural pharmacology","preclinical","article","10.1097/fbp.0000000000000685","35695511","PMC9308649",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006031","RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.","Mashayekhi M","2025","The Journal of endocrinology","randomized_trial","article","10.1530/joe-25-0174","41042549","PMC12556785",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0006032","Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?","Janić M","2024","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina60122030","39768911","PMC11728110",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006033","Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.","Dhas Y","2024","Molecular biomedicine","narrative_review","article","10.1186/s43556-024-00204-z","39333445","PMC11436690",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006034","Current clinical application of incretin therapy for obesity management.","Skinner K","2026","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2025-0152","41420876",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006035","Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.","Wu T","2022","Clinical drug investigation","nonrandomized_study","article","10.1007/s40261-022-01202-1","36175609",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006036","Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort.","Zhu H","2023","Annals of the rheumatic diseases","nonrandomized_study","article","10.1136/ard-2023-223845","37258065","PMC10423473",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0006037","The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.","Najafi S","2022","British journal of clinical pharmacology","systematic_review","article","10.1111/bcp.15344","35384008",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0006038","Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations.","Zaki MK","2024","Journal of bone metabolism","narrative_review","article","10.11005/jbm.2024.31.3.169","39307518","PMC11416877",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0006039","Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model.","Bredum SK","2026","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00480.2024","41671030",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006040","Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care data.","Jansz TT","2026","The Lancet. Primary care","randomized_trial","article","10.1016/j.lanprc.2026.100139","42109572","PMC13153036",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006041","Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis.","Khasawneh O","2026","Digestive diseases (Basel, Switzerland)","systematic_review","article","10.1159/000553479","42611799","PMC13485284",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; other; review"],["R0006042","What obgyns need to know about GLP-1 receptor agonists.","Chauhan I","2026","Current opinion in obstetrics & gynecology","nonrandomized_study","article","10.1097/gco.0000000000001116","42108205",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0006043","Changes in Type 2 Diabetes Medications Among Primary Care Patients After California's 2022 Medicaid Expansion.","Ro AE","2026","Diabetes care","other","article","10.2337/dc25-0787","41191813","PMC12719703",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0006044","Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.","Mittman BG","2024","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2024.2303413","38193509","PMC10947468",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0006045","National Utilization and Expenditure Trends of GLP-1 Receptor Agonists and Dual GLP-1/GIP Agonist in Croatia, 2017-2024.","Car M","2025","Medicina (Kaunas, Lithuania)","other","article","10.3390/medicina61122210","41470212","PMC12734843",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006046","Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review.","Hammad BF","2025","Frontiers in clinical diabetes and healthcare","narrative_review","article","10.3389/fcdhc.2025.1590530","40708853","PMC12286811",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006047","Assessing the Effects of Childhood and Adult Body Mass Index on Diabetic Retinopathy Risk: A Mendelian Randomization Study.","Gao L","2026","Endocrine, metabolic & immune disorders drug targets","other","article","10.2174/0118715303487103260827072037","42725617",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006048","Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review.","Scheen AJ","2024","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2023.101508","38158077",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0006049","The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review.","Kwiendacz H","2023","Advances in therapy","randomized_trial","article","10.1007/s12325-023-02567-1","37326901","PMC10329951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0006050","First-in-Human Study of a Long-Acting GLP-1 Receptor Agonist (TE-8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus.","Chuang YS","2026","Journal of clinical pharmacology","other_trial","article","10.1002/jcph.70224","42530137","PMC13421993",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial, Phase I; research-article; article"],["R0006051","Associations between GLP 1 receptor agonist therapy and surgical wound healing in a high-risk cohort","Pullmann D","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.04.21.26351321",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","4","FALSE","Preprint; preprint"],["R0006052","A meta-analytic review of the safety and efficacy of semaglutide in type 2 diabetes mellitus and chronic kidney disease patients.","Ashraf T","2025","Annals of medicine and surgery (2012)","randomized_trial","article","10.1097/ms9.0000000000003126","40212218","PMC11981399",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006053","The interplay between heart failure and chronic kidney disease.","Lala A","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16371","40259497","PMC12146472",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006054","Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4.","Carmichael C","2025","The patient","other_trial","article","10.1007/s40271-025-00730-0","39987302","PMC11985590",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0006055","Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.","Busetto L","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71134","42503495","PMC13538786",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0006056","Oral Wegovy Is Associated with Greater Early Weight Loss Than Foundayo in Propensity Matched Adult GLP-1 Users","Murugadoss K","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202609.2359.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006057","Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist.","Patel KV","2020","Current cardiology reports","narrative_review","article","10.1007/s11886-020-01355-5","32770420",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; article"],["R0006058","Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system.","Niu K","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1414268","38887555","PMC11180901",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006059","Metabolic breakdown: Linking insulin resistance and mitochondrial dysfunction to neurodegeneration in Alzheimer's disease.","Lanzillotta S","2026","Neural regeneration research","narrative_review","article","10.4103/nrr.nrr-d-25-00144","40536952","PMC13211837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0006060","Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Cai CX","2025","JAMA ophthalmology","randomized_trial","article","10.1001/jamaophthalmol.2024.6555","39976940","PMC11843465",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0006061","The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis.","do Nascimento TS","2024","Perioperative medicine (London, England)","systematic_review","article","10.1186/s13741-024-00439-y","39039540","PMC11264430",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; other; review"],["R0006062","Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy.","Cengiz A","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16229","39950222","PMC11885104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006063","Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62).","Kim HS","2022","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2022.0166","35929176","PMC9353569",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Comment; article"],["R0006064","Divergent Efficacy of GLP-1 Receptor Agonists in HFpEF Versus HFrEF: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Ahmed HM","2026","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2026.04.046","42069283",null,"PROSPERO:CRD420251138529",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0006065","Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome.","Hao Y","2022","Bioengineered","preclinical","article","10.1080/21655979.2022.2031418","35184645","PMC8975272",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006066","MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management-A Narrative Review.","Ştefan AG","2026","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina62020325","41752724","PMC12942444",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0006067","Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials.","Salamah HM","2023","Scientific reports","systematic_review","article","10.1038/s41598-023-46274-x","37923756","PMC10624877",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; research-article; review"],["R0006068","The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients.","Huang CF","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s389964","36760582","PMC9843232",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; letter; article"],["R0006069","The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis.","Ali MU","2024","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-024-02154-w","38360604","PMC10870515",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review-article; other; review"],["R0006070","Semaglutide Protects Retinal Ganglion Cells Against Rotenone-Induced Degeneration via Improved Glucose Metabolism.","Mouhammad ZA","2026","Investigative ophthalmology & visual science","preclinical","article","10.1167/iovs.67.2.25","41665299","PMC12898937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0006071","GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use.","Arvanitakis K","2023","Current obesity reports","narrative_review","article","10.1007/s13679-023-00506-3","37081371",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006072","Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62).","Kawada T","2022","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2022.0131","35929175","PMC9353571",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Comment; article"],["R0006073","Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.","Newsome PN","2023","Journal of hepatology","other_trial","article","10.1016/j.jhep.2023.07.033","37562748",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0006074","Association of 14-day continuous glucose monitoring-derived postprandial hyperglycemic area with 6-month change in urinary albumin-to-creatinine ratio in patients with newly diagnosed type 2 diabetes mellitus.","Yu T","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1890463","42688121","PMC13533769",null,null,"pubmed; europepmc","TRUE","open_europepmc","4",null,"Journal Article; research-article"],["R0006075","Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.","Lee J","2023","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2023.07.006","37541792",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006076","Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials.","Vargas-Uricoechea H","2023","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2023.19.14","37185053","PMC10082333",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; review-article; article"],["R0006077","GLP-1 Receptor Agonist Use in Cancer Survivors-Challenges and Opportunities: A Narrative Review.","Agurs-Collins T","2026","Cancers","randomized_trial","article","10.3390/cancers18162714","42650025","PMC13510418",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0006078","Comparative effectiveness of metabolic bariatric surgery versus incretin-based and medical therapies for weight loss and glycemic outcomes: a systematic review and meta-analysis","Alshahrani SD","2026","F1000Res","systematic_review","preprint","10.12688/f1000research.185053.1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; review; preprint"],["R0006079","What is the pipeline for future medications for obesity?","Melson E","2025","International journal of obesity (2005)","other_trial","article","10.1038/s41366-024-01473-y","38302593","PMC11971045",null,"S002621","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0006080","Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.","Nissen SE","2026","JAMA cardiology","randomized_trial","article","10.1001/jamacardio.2026.0767","41903177","PMC13033170","ClinicalTrials.gov:NCT04255433","S002212","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study; research-article; article"],["R0006081","Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment.","Chen S","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s443631","38505539","PMC10949166",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006082","Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.","Silver HJ","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15113","37188932","PMC10544709",null,"S001745","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0006083","The impact of glucagon-like peptide-1 (GLP-1) receptor agonists on postoperative outcomes following rotator cuff repair.","Choudhury A","2026","Shoulder & elbow","nonrandomized_study","article","10.1177/17585732261486333","42712738","PMC13550227",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0006084","Semaglutide for adults living with obesity.","Bracchiglione J","2025","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd015092.pub2","41161683","PMC12571522","PROSPERO:CRD420250654193",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0006085","Recent Advances on Therapy of Slowing Progression of Dia-betic Kidney Disease","Wang N","2024","Preprints.org","other","preprint","10.20944/preprints202401.0454.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006086","Comment on '2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists'.","Frei D","2026","Anaesthesia and intensive care","commentary","article","10.1177/0310057x261460073","42598987",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; editorial"],["R0006087","Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.","Ard J","2021","Advances in therapy","narrative_review","article","10.1007/s12325-021-01710-0","33977495","PMC8189979",null,"S000313; S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0006088","Depression and suicide/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database.","Wang M","2025","Journal of affective disorders","nonrandomized_study","article","10.1016/j.jad.2025.119670","40523410",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006089","New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics.","Jastreboff AM","2023","Annual review of medicine","narrative_review","article","10.1146/annurev-med-043021-014919","36706749",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; review"],["R0006090","Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity.","Gasoyan H","2025","Nature medicine","other","article","10.1038/s41591-025-03893-3","40957960",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006091","GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.","Silverii GA","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16489","40437949","PMC12232360",null,"S002389; S002468","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0006092","Exenatide at mealtimes in type 1 diabetes-no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists.","Doggrell SA","2020","Annals of translational medicine","commentary","article","10.21037/atm-20-3702","33437809","PMC7791265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0006093","Knowledge of Primary Health Care Physicians About the Novel Class of Type 2 Diabetes Medication in Qassim Province, Saudi Arabia.","Alghofaili R","2025","Cureus","other","article","10.7759/cureus.86638","40718234","PMC12289452",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006094","Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review.","Liarakos AL","2023","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2022.108390","36610322",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0006095","Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.","Saxena AR","2023","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2023.14493","37213102","PMC10203889","ClinicalTrials.gov:NCT03985293","S001191","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006096","Gastric ultrasound: Enhancing preoperative risk assessment and patient safety.","Kar Man Chan L","2025","Journal of perioperative practice","nonrandomized_study","article","10.1177/17504589241302220","39663603","PMC12547038",null,"S002462","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006097","Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies.","Pottegård A","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15912","39284788",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006098","Epigenetic determinants of GLP-1 responsiveness: Integrating dietary modulation beyond genetics.","Shin HR","2026","Obesity research & clinical practice","narrative_review","article","10.1016/j.orcp.2026.09.004","42760157",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006099","Assessing the Safety of Semaglutide and Tirzepatide in Black and Asian Populations: A Narrative Review.","Iftikhar P","2025","Cureus","narrative_review","article","10.7759/cureus.87188","40755607","PMC12316492",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0006100","Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs).","Al Rifai M","2022","The American journal of cardiology","other","article","10.1016/j.amjcard.2022.02.013","35305783","PMC13056013",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0006101","Effect of video conferencing between primary and secondary care specialists on type 2 diabetes medication.","Prætorius T","2025","NPJ digital medicine","randomized_trial","article","10.1038/s41746-025-01570-w","40148532","PMC11950227","ClinicalTrials.gov:NCT05268081","S002665","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0006102","Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.","Simms-Williams N","2024","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2023-078242","38663919","PMC11043905",null,"S002421; S002481; S002726","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006103","Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.","Thomsen RW","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01323-y","36315384","PMC9663772","ClinicalTrials.gov:NCT03993132","S001461","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006104","Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.","Banerjee M","2024","Cardiovascular drugs and therapy","systematic_review","article","10.1007/s10557-023-07432-5","36696050",null,"PROSPERO:CRD42022367633",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0006105","Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.","Dejgaard TF","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15889","39192527",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0006106","The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms.","Ribeiro-Silva JC","2023","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2023.102355","36857807",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0006107","Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk.","McCoy RG","2024","Nature cardiovascular research","nonrandomized_study","article","10.1038/s44161-024-00453-9","38846711","PMC11156225","ClinicalTrials.gov:NCT05214573","S002708","pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; research-article"],["R0006108","Exposure to GLP-1 Receptor Agonist and Bariatric Surgery Use on Obesity Policy Support.","Post SM","2024","Annals of behavioral medicine : a publication of the Society of Behavioral Medicine","randomized_trial","article","10.1093/abm/kaae063","39427238","PMC11568355",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; brief-report; article"],["R0006109","Raised intracranial pressure alters cortical vascular function and cephalic allodynia.","Grech O","2025","Brain : a journal of neurology","preclinical","article","10.1093/brain/awae415","40056451","PMC12129729",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006110","Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative Database.","Anson M","2024","Journal of diabetes research","nonrandomized_study","article","10.1155/2024/3470654","38846063","PMC11156508",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006111","GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes.","Park B","2024","American journal of physiology. Heart and circulatory physiology","randomized_trial","article","10.1152/ajpheart.00257.2024","38874618",null,"ClinicalTrials.gov:NCT05253521",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0006112","[Non-arteritic anterior ischemic optic neuropathy associated with tirzepatide (Mounjaro®): A case report documented by multimodal imaging].","Guenoun JM","2026","Journal francais d'ophtalmologie","case_report","article","10.1016/j.jfo.2026.104990","42810270",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0006113","Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform.","Feldman WB","2025","The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics","other","article","10.1017/jme.2025.54","40197405",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006114","Pharmacogenomics of GLP-1 receptor agonists: Focus on pharmacological profile.","Jakhar K","2022","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2022.175356","36330902",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006115","The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis.","Merza N","2023","Current problems in cardiology","systematic_review","article","10.1016/j.cpcardiol.2023.101602","36682393",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0006116","Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.","Edwards K","2023","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgac618","36268825",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006117","Holistic Management of Obesity in Patients with Incidental Cancer After Unprovoked Deep Vein Thrombosis: A Cardiometabolic and Antithrombotic Framework.","Geraci C","2026","Cancers","randomized_trial","article","10.3390/cancers18142212","42512277","PMC13406728",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0006118","Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know.","Skolnik N","2018","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd17-0048","29686457","PMC5898172",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006119","Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications.","Kuthati Y","2025","Biomolecules","narrative_review","article","10.3390/biom15050622","40427515","PMC12108864",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0006120","Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.","Yale JF","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01353-6","36574199","PMC9943797","ClinicalTrials.gov:NCT03767543","S001367","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006121","Clinical Factors Associated with Body-weight Reduction Induced by Semaglutide 1.0 mg Weekly in Patients with Type 2 Diabetes Mellitus.","Kurinami N","2025","JMA journal","nonrandomized_study","article","10.31662/jmaj.2024-0366","40416014","PMC12095099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006122","Response to comment on '2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists'.","Olesnicky BL","2026","Anaesthesia and intensive care","other","article","10.1177/0310057x261460074","42598995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006123","Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries.","Imam A","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad129","37942291","PMC10628815",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006124","Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies.","Zheng D","2023","BMC medicine","nonrandomized_study","article","10.1186/s12916-023-02753-6","36737746","PMC9898966",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0006125","A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.","Xie P","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15624","38808476",null,"ClinicalTrials.gov:NCT04016974","S000976","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; article"],["R0006126","The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis.","Patoulias D","2021","Blood pressure monitoring","systematic_review","article","10.1097/mbp.0000000000000537","33741774",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0006127","Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure.","Costa TA","2026","Current opinion in cardiology","randomized_trial","article","10.1097/hco.0000000000001284","41802118",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0006128","Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70291","42487213","PMC13392206","PROSPERO:CRD420261361351",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Comparative Study; review-article; review"],["R0006129","GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease.","Yang YS","2022","Diabetes care","nonrandomized_study","article","10.2337/dc21-1993","35275992",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0006130","Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland.","Noordam C","2025","Children (Basel, Switzerland)","nonrandomized_study","article","10.3390/children12121716","41462856","PMC12732185",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006131","Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist","Quadri H","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.748",null,"PMC8090007",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0006132","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.","Guerci B","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14823","35876235","PMC9804517",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006133","Letter to the Editor Regarding \"Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists\".","Wang J","2026","Spine","commentary","article","10.1097/brs.0000000000005792","42531456",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0006134","Discovery and Evaluation of DA-302168S as an Efficacious Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist.","Dong G","2025","Journal of medicinal chemistry","other_trial","article","10.1021/acs.jmedchem.5c00242","40257122",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0006135","Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide?","Lang K","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.q2636","39900371",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006136","Alternative Perspectives on Obesity and Hypertension.","Schulhof A","2024","Cardiology in review","other","article","10.1097/crd.0000000000000802","39436088",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006137","Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis.","Han SH","2023","Aesthetic surgery journal","other","article","10.1093/asj/sjad211","37402640",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006138","Systemic Pharmacokinetic Principles of Therapeutic Peptides.","Nordell P","2026","Clinical pharmacokinetics","other","article","10.1007/s40262-025-01615-z","41661442","PMC13038672",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006139","Integrated approaches to preventing macrovascular complications in type 2 diabetes mellitus: Advances in secondary prevention.","Qian F","2026","Pakistan journal of pharmaceutical sciences","randomized_trial","article","10.36721/pjps.2026.39.3.reg.15014.1","41620898",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0006140","The Obesity Paradox in Heart Failure With Preserved Ejection Fraction: Untangling Body Composition, Inflammation, and Outcomes.","Tannous L","2025","Cardiology in review","other_trial","article","10.1097/crd.0000000000001106","41198097",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0006141","CROI 2024: Metabolic and Other Complications of HIV Infection.","Sarkar S","2024","Topics in antiviral medicine","randomized_trial","article",null,"39142292","PMC11293603",null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Review; research-article"],["R0006142","Cardioprotective Actions of a Glucagon-like Peptide-1 Receptor Agonist on Hearts Donated After Circulatory Death.","Kadowaki S","2023","Journal of the American Heart Association","preclinical","article","10.1161/jaha.122.027163","36695313","PMC9973624",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006143","Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.","Marx N","2025","Circulation","randomized_trial","article","10.1161/circulationaha.125.074545","40156843","PMC12144549","ClinicalTrials.gov:NCT03914326","S002179","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0006144","Obesity, incretin-based therapies, and cardiovascular disease in women.","Salih M","2026","Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation","narrative_review","article","10.1007/s12471-026-02084-0","42747778","PMC13615230",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006145","Cardiovascular benefits of early sodium-glucose cotransporter 2 inhibitor use for diabetics with acute myocardial infarction: A nationwide cohort study.","Wang SF","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70416","41392024",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006146","Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Receptor Agonist) Therapy.","Nelson LW","2024","AJR. American journal of roentgenology","nonrandomized_study","article","10.2214/ajr.24.31805","39230989",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0006147","Concurrent diabetic ketoacidosis, acute pancreatitis, and subsequent ruptured acalculous cholecystitis in a patient receiving semaglutide: A case report.","Chiu CT","2026","SAGE open medical case reports","case_report","article","10.1177/2050313x261463142","42395841","PMC13323645",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006148","Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Knee Osteoarthritis: A Systematic Review and Meta-Analysis","Singh MP","2025","Research Square","systematic_review","preprint","10.21203/rs.3.rs-6482330/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; review; preprint"],["R0006149","Exendin-4-induced reduction of steatosis in HepG2 cells implicates upregulation of essential lipid metabolism genes via modulation of MALAT1","Khalifa O","2024","Research Square","preclinical","preprint","10.21203/rs.3.rs-3996681/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006150","Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease.","Chen CY","2026","Kidney360","other_trial","article","10.34067/kid.0000001109","41385299","PMC13450959","ClinicalTrials.gov:NCT05521191; ClinicalTrials.gov:NCT06902558; ClinicalTrials.gov:NCT07161037; ClinicalTrials.gov:NCT04939935; ClinicalTrials.gov:NCT06582875; ClinicalTrials.gov:NCT04907799; ClinicalTrials.gov:NCT03203642; ClinicalTrials.gov:NCT04578548","S000493","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006151","Diabetes and Heart Failure: A Literature Review, Reflection and Outlook.","Li X","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12071572","39062145","PMC11274420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006152","Body Mass Index, Comorbidities, and the New Lancet Obesity Definition: Implications for Risk Analysis in Plastic and Reconstructive Surgery.","Tobin MJ","2026","Plastic and reconstructive surgery","nonrandomized_study","article","10.1097/prs.0000000000012830","41557524",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006153","Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial.","Ruff CT","2022","Nature medicine","randomized_trial","article","10.1038/s41591-021-01584-3","34873344",null,"ClinicalTrials.gov:NCT01455896","S000677","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; article"],["R0006154","Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.","Verma S","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14160","32744418","PMC7754406","ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446","S001496; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; brief-report; article"],["R0006155","Exendin-4 induced retching-like behavior mediated by postsynaptic effect via AMPA receptors in the area postrema of mice.","Ding H","2025","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00174.2025","40622911",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006156","Liraglutide for adults living with obesity.","Meza N","2025","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd016017","41161684","PMC12571521","PROSPERO:CRD420250654193",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0006157","Anisotropic Electrostatics in the Instability of GLP‑1 Analog Micelles: Effects of Electrolytes, Denaturants, pH, and Temperature.","Jarand CW","2026","ACS omega","other","article","10.1021/acsomega.6c02639","42662384","PMC13520545",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006158","Emerging Role of Weight-Loss Medications in the Management of Heart Failure: Current Evidence and Future Perspectives.","Maryam","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","narrative_review","article","10.1007/s40256-025-00735-y","40434553",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006159","The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review","Tempia Valenta S","2025","European psychiatry : the journal of the Association of European Psychiatrists","systematic_review","article",null,null,"PMC12438424",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0006160","Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.","Aneke-Nash C","2025","BMJ open gastroenterology","nonrandomized_study","article","10.1136/bmjgast-2024-001704","40175094","PMC11966946",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0006161","Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A.","Li Y","2025","Genes & diseases","preclinical","article","10.1016/j.gendis.2025.101761","40837406","PMC12361993",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006162","Lifestyle Modification and Incretin-Based Therapy for Obesity.","Kushner RF","2026","JAMA","other","article","10.1001/jama.2026.4106","42160059",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006163","Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication Opportunities","Venkatakrishnan A","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202609.0311.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0006164","Impact of dramatic weight loss with the new injectable medications on reproduction in healthy non-polycystic ovary syndrome obese women.","Merhi Z","2025","F&S reports","other","article","10.1016/j.xfre.2024.12.003","40201092","PMC11973803",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0006165","Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.","Nguyen BN","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15009","36751968",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Comparative Study; Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0006166","Targeting the GLP-1 receptor pathways for dual management of obesity and depression.","Keswani R","2026","Drug discovery today","narrative_review","article","10.1016/j.drudis.2026.104727","42361966",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006167","Weighing your options-intragastric balloon versus semaglutide.","Choy K","2024","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-024-11169-z","39138683",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0006168","Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.","Nauck MA","2021","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2021.645566","33854484","PMC8039387","ClinicalTrials.gov:NCT03914326","S002179","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0006169","Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis","gong x","2024","Research Square","systematic_review","preprint","10.21203/rs.3.rs-4159026/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0006170","From needles to pills: oral GLP-1 therapy enters the obesity arena.","Santulli G","2025","Cardiovascular diabetology. Endocrinology reports","nonrandomized_study","article","10.1186/s40842-025-00245-5","41053816","PMC12498447",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; article"],["R0006171","Emerging Role of Dual Glucagon-Like Peptide-1 (GLP-1)/Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Cardiovascular Prevention.","Contreras Figueroa N","2026","Cureus","other_trial","article","10.7759/cureus.104567","41930072","PMC13043246",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006172","Effectiveness, safety, and treatment patterns of GLP-1 receptor agonists in adolescents with obesity: a multicenter retrospective study from Saudi Arabia.","Kalagi F","2026","Frontiers in nutrition","nonrandomized_study","article","10.3389/fnut.2026.1902763","42577813","PMC13455499",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006173","Glucagon-Like Peptide-1 Receptor Agonists-How Safe Are They?","Haider S","2022","JAMA internal medicine","commentary","article","10.1001/jamainternmed.2022.0335","35344015",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0006174","Semaglutide (Ozempic®) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss.","Mailhac A","2024","Clinical epidemiology","nonrandomized_study","article","10.2147/clep.s456170","38685990","PMC11057509",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006175","Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review.","Lopez Delgado DS","2026","Frontiers in medicine","randomized_trial","article","10.3389/fmed.2026.1803474","42519802","PMC13382510",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0006176","Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide.","Lu Y","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.26013","40779264","PMC12334959",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; research-article; article"],["R0006177","Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.","Yoshida Y","2022","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2022.108255","35817678",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0006178","GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.","Marfella R","2024","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-02118-6","38184582","PMC10771648","ClinicalTrials.gov:NCT06017544","S002594","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0006179","Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease.","Zhang S","2024","Nature communications","nonrandomized_study","article","10.1038/s41467-024-54009-3","39639039","PMC11621321",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006180","Mechanisms and clinical implications of gut-brain interactions.","Lorsch ZS","2026","The Journal of clinical investigation","narrative_review","article","10.1172/jci196346","41480755","PMC12721889",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0006181","Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.","Hamilton A","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.71387","42823075",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006182","Metabolic dysfunction-associated steatotic liver disease in people with HIV.","Gattu AK","2025","Current opinion in HIV and AIDS","narrative_review","article","10.1097/coh.0000000000000952","40397552","PMC12314779",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0006183","Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.","Kadowaki T","2025","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2025.3599","40758358","PMC12322823","ClinicalTrials.gov:NCT05132088","S000582","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0006184","Acute Cholesterol-Lowering Effect of Exendin-4 in Ldlr-/- and C57BL/6J Mice.","Hori M","2023","Journal of atherosclerosis and thrombosis","preclinical","article","10.5551/jat.60921","35314564","PMC9899697",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006185","Obesity pharmacotherapy in older adults: a narrative review of evidence.","Henney AE","2025","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-024-01529-z","38710803","PMC11971046",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0006186","Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.","Hathaway JT","2024","JAMA ophthalmology","nonrandomized_study","article","10.1001/jamaophthalmol.2024.2296","38958939","PMC11223051",null,"S002229","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006187","The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.","Wilson JM","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14553","34542221","PMC9292792",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0006188","Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.","Pabon MA","2026","European heart journal","other_trial","article","10.1093/eurheartj/ehag162","41884984",null,"PROSPERO:CRD42024570467",null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0006189","Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.","Goldenberg RM","2022","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2022.108285","35998555",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Comment; review"],["R0006190","Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches.","Althoff MD","2024","American journal of respiratory and critical care medicine","nonrandomized_study","article","10.1164/rccm.202406-1166so","39311907","PMC11568442",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; research-article; article"],["R0006191","Compounded Tirzepatide Therapy for Weight Loss: A Health Economics & Outcomes Research (HEOR) Analysis.","Guth MA","2025","International journal of pharmaceutical compounding","nonrandomized_study","article","10.5281/zenodo.22017427","39921911",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0006192","Semaglutide and major adverse cardiovascular events in patients with and without DM: a systematic review and meta-analysis","Li Y","2024","Research Square","systematic_review","preprint","10.21203/rs.3.rs-5687083/v1",null,null,null,null,"europepmc","FALSE","open_pdf","3",null,"Preprint"],["R0006193","Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.","Gerstein HC","2023","Circulation","randomized_trial","article","10.1161/circulationaha.122.063716","36802715",null,"ClinicalTrials.gov:NCT03496298","S000755","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006194","Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.","Lui DTW","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-01772-0","36829226","PMC9960638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006195","Metabolic and renal effects of combined SGLT-2 inhibitors and GLP1-R agonists therapy in type 2 diabetes: a real-world analysis across DKD and non-DKD patients.","Mazzeo L","2026","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-025-02756-5","41452441",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0006196","Incretin Mimetics (GLP-1 Agonists) as an Addition to the Psychopharmacology Armamentarium.","Alenezi HFF","2025","Psychopharmacology bulletin","narrative_review","article","10.64719/pb.4531","40223913","PMC11983476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006197","GLP-1 RA treatment improves the secretory function and proliferation of pancreatic β-cells with ABCC8 dysfunction","Zhang Y","2023","Research Square","preclinical","preprint","10.21203/rs.3.rs-3007917/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006198","Vitreous hemorrhage during GLP-1 receptor agonist treatment.","Kim DS","2023","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2023.02.018","36966088",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0006199","Lifestyle interventions for hypertension management in primary care: a narrative review.","Han B","2025","Ewha medical journal","narrative_review","article","10.12771/emj.2025.00850","41223885","PMC12611427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; review"],["R0006200","Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.","Solis-Herrera C","2024","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd22-0118","38230324","PMC10788673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006201","Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity.","Matias I","2024","Journal of endocrinological investigation","other","article","10.1007/s40618-023-02228-8","37924474",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006202","Incretin mimetics for weight loss forgive nonadherence.","Cengiz A","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16438","40364508","PMC12232367",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0006203","Prescribing Patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Patients with T2DM and ASCVD in South Korea","Eom YR","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3890662/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006204","Exendin-4 induces extracellular-superoxide dismutase through histone H3 acetylation in human retinal endothelial cells.","Yasuda H","2016","Journal of clinical biochemistry and nutrition","other","article","10.3164/jcbn.16-26","27895384","PMC5110938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006205","Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.","Hu M","2020","Journal of the American Heart Association","systematic_review","article","10.1161/jaha.119.015323","32223390","PMC7428598",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review-article; article"],["R0006206","Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.","Martinelli S","2024","Drug and alcohol dependence","systematic_review","article","10.1016/j.drugalcdep.2024.112424","39288591",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Systematic Review; Journal Article; review"],["R0006207","Non-Arteritic Anterior Ischemic Optic Neuropathy in an Otherwise Healthy Young Adult Patient Treated with Liraglutide and Semaglutide for Weight Loss: A Cautionary Tale.","Lixi F","2025","International medical case reports journal","case_report","article","10.2147/imcrj.s531930","40800673","PMC12339668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006208","Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes.","Perreault L","2019","Advances in therapy","narrative_review","article","10.1007/s12325-018-0868-9","30610613","PMC6824345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0006209","Cardiovascular-Kidney-Metabolic Disease Burden in Children and Adults Following Heart Transplantation.","Huang S","2025","JACC. Heart failure","nonrandomized_study","article","10.1016/j.jchf.2025.102710","41117724","PMC12984543",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; Preprint; preprint; article"],["R0006210","GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders.","Guo J","2025","The Journal of neuroscience : the official journal of the Society for Neuroscience","nonrandomized_study","article","10.1523/jneurosci.1375-25.2025","41224657","PMC12614067","ClinicalTrials.gov:NCT05897398","S000252","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, N.I.H., Intramural; research-article; article"],["R0006211","Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.","He Y","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00196-2","40854315",null,"ClinicalTrials.gov:NCT05680129","S001941","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III; Equivalence Trial; Research Support, Non-U.S. Gov't; article"],["R0006212","Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs.","Christensen S","2024","Obesity pillars","narrative_review","article","10.1016/j.obpill.2024.100121","39175746","PMC11340591",null,"S002529; S002624","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; review"],["R0006213","2025 ISOBS OBA emergency manual: new drugs, devices, diversions, and dysfunction.","Talluto J","2025","Current opinion in anaesthesiology","narrative_review","article","10.1097/aco.0000000000001518","40492872",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006214","Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.","Vukajlovic T","2022","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgac063","35134170",null,"ClinicalTrials.gov:NCT03141632; ClinicalTrials.gov:NCT02770885","S000001; S002343","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0006215","Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems.","Shokr H","2026","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19010136","41599734","PMC12845133",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006216","Oral GLP-1 Receptor Agonists for Weight Loss.","Krinsky D","2024","Cardiology in review","other","article","10.1097/crd.0000000000000833","39688941",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006217","Epicardial adipose tissue as target of the incretin-based therapies in cardio-metabolic pathologies: a narrative review.","Pop A","2025","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2024-0384","40048723",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0006218","Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies.","Abburi K","2025","Panminerva medica","other_trial","article","10.23736/s0031-0808.25.05339-x","40728225",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0006219","Effect of GLP-1RA on diabetes retinopathy with blood glucose variation at different levels of baseline HbAlc– A systematic review and meta-analysis","Wang W","2024","Research Square","systematic_review","preprint","10.21203/rs.3.rs-4098611/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0006220","Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.","Apperloo EM","2025","Diabetes care","randomized_trial","article","10.2337/dc24-1773","39746157","PMC11870291",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; other; article"],["R0006221","Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study.","Takahashi N","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-026-01877-1","42217105","PMC13388600",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006222","Response by Sharp to \"\"Ozempic Face\": Construct, Consequence, or Clinical Entity?\" by Daneshgaran et al.","Sharp G","2026","Aesthetic surgery journal. Open forum","narrative_review","article","10.1093/asjof/ojag080","42232108","PMC13225259",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; review"],["R0006223","Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.","Huang X","2024","The Journal of endocrinology","narrative_review","article","10.1530/joe-23-0404","38916409",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0006224","Characteristics of Youth Treated With GLP-1RAs at an Integrated Weight Management Clinic.","Gregory EF","2026","Pediatrics","nonrandomized_study","article","10.1542/peds.2025-074094","41765353",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006225","Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors.","Sachinidis A","2020","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2020.154343","32810485",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006226","Clinical characteristics, treatment patterns, and healthcare utilization among children, adolescents, and young adults with obesity in the United States.","Gibble TH","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100252","41777814","PMC12950411",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006227","Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.","Wang W","2024","Molecular psychiatry","randomized_trial","article","10.1038/s41380-024-02498-5","38486046","PMC11412894",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0006228","Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders.","Cortés-Martín A","2025","World journal of gastroenterology","commentary","article","10.3748/wjg.v31.i4.101436","39877709","PMC11718636",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0006229","Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients.","Wu JY","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112083","40049522",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0006230","Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.","McCrimmon RJ","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-021-01159-y","34714523","PMC8586275",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006231","Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series.","Cymbal M","2025","ACG case reports journal","nonrandomized_study","article","10.14309/crj.0000000000001789","40761333","PMC12321443",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0006232","Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.","Rehman A","2024","Clinical cardiology","nonrandomized_study","article","10.1002/clc.24283","38767042","PMC11103635",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006233","Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.","Goldenberg RM","2023","Current opinion in cardiology","other_trial","article","10.1097/hco.0000000000001084","37792556",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Review; Journal Article; article"],["R0006234","Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability.","Chen H","2022","Pharmaceutical research","preclinical","article","10.1007/s11095-022-03265-3","35698011",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006235","[Obesity as a chronic disease: the key role of new therapies].","Nicolucci A","2025","Assistenza infermieristica e ricerca : AIR","other","article","10.1702/4616.46253","41384400",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0006236","Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish.","Bertelli PR","2021","Progress in neuro-psychopharmacology & biological psychiatry","preclinical","article","10.1016/j.pnpbp.2021.110388","34147534",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Preprint; preprint; article"],["R0006237","Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes.","Yanai H","2023","Cardiology research","other_trial","article","10.14740/cr1459","36896226","PMC9990545",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006238","The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.","Lunati ME","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag072","41729594","PMC13271783",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006239","Assessing the Renal Outcomes of Semaglutide in Diabetic Kidney Disease: A Systematic Review.","Rehman SU","2024","Cureus","systematic_review","article","10.7759/cureus.64038","39114239","PMC11303570",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006240","Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.","Wharton S","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71032","42338042","PMC13448879",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Clinical Trial, Phase III; research-article; article"],["R0006241","Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.","Karimi MA","2025","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2025.1438318","40444045","PMC12120964",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0006242","Long-acting hydrogel-based depot formulations of tirzepatide and semaglutide for the management of type 2 diabetes and weight.","d'Aquino AI","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.07.02.662867","40631235","PMC12236481",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0006243","Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.","Munshi M","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15377","38082473",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0006244","Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study.","Roy Chowdhury S","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01551-4","38427165","PMC10951141",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; article"],["R0006245","Comparative Risk of Stroke Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors in Veterans with Type 2 Diabetes","Sun SC","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.05.13.26353028",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0006246","Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?","Belančić A","2021","Clinical obesity","narrative_review","article","10.1111/cob.12439","33423388","PMC7995087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006247","Metabolic-Hormonal Interplay and the Case for a Reproductive-Metabolic Framework in the Glucagon-Like Peptide-1 (GLP-1) Era.","Lakhani A","2026","Cureus","commentary","article","10.7759/cureus.111478","42502525","PMC13401353",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0006248","Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide.","Olson TE","2026","JOR spine","preclinical","article","10.1002/jsp2.70196","42253285","PMC13239351",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006249","Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.","Ferrannini E","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14688","35257461","PMC9314929","ClinicalTrials.gov:NCT02787551","S001125","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0006250","Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof-of-concept results from the DECIDE-CV clinical programme.","Marques P","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15691","38831564",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006251","Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.","Cardoso P","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16470","40375735","PMC12232322",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0006252","Tirzepatide (Zepbound): Indication: For once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial body mass index of: 30 kg/m2 or greater (obesity), or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease): Reimbursement Recommendation",null,"2026","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","randomized_trial","article",null,"42771753",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0006253","Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?","Scheen AJ","2023","Expert review of clinical pharmacology","randomized_trial","article","10.1080/17512433.2023.2279193","37919944",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0006254","Long-acting glucagon-like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: A retrospective cohort study.","Lisco G","2024","Andrology","randomized_trial","article","10.1111/andr.13519","37615353",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0006255","The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","Furth SL","2026","Kidney international","other","article","10.1016/j.kint.2025.09.019","41176308",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; article"],["R0006256","Clinical pharmacology of antidiabetic drugs: What can be expected of their use?","Scheen AJ","2023","Presse medicale (Paris, France : 1983)","randomized_trial","article","10.1016/j.lpm.2022.104158","36565754",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0006257","Prevalence, treatment patterns, burden, and factors related to treatment failure with sodium-glucose cotransporter 2 inhibitor in adults with type 2 diabetes in the United States.","Tan X","2025","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2025.103281","40819425",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0006258","Anorgasmia following initiation of GLP-1 agonist.","Visvabharathy V","2025","Sexual medicine","case_report","article","10.1093/sexmed/qfaf047","40666108","PMC12260840",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006259","Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.","Foresta A","2023","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2023.02.007","36933975","PMC9974363",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006260","Comparative Efficacy of GLP-1 RAs Versus SGLT2 Inhibitors in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Multicenter Propensity Score-Matched Real-World Study.","Khalil I","2026","Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions","randomized_trial","article","10.1002/ccd.70668","42219874","PMC13432452",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Comparative Study; Observational Study; research-article; article"],["R0006261","Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes.","Rashid AM","2025","Journal of the American Society of Nephrology : JASN","nonrandomized_study","article","10.1681/asn.0000000752","40327845","PMC12499624",null,"S000018","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0006262","Structural Biophysics-Guided Computational Design of Semaglutide Analogues to Enhance GLP-1R Activation","Li W","2024","bioRxiv","other_trial","preprint","10.1101/2024.11.29.625980",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0006263","Bile Acids in Pancreatic Carcinogenesis.","Sharma B","2024","Metabolites","narrative_review","article","10.3390/metabo14070348","39057671","PMC11278541",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006264","The role of multimodality imaging in diabetic cardiomyopathy: a brief review.","Adel FW","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1405031","39764242","PMC11700833",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006265","The effect of GLP-1RA exenatide on Idiopathic Intracranial Hypertension: Randomised Clinical Trial","Mitchell JL","2022","medRxiv","randomized_trial","preprint","10.1101/2022.05.24.22275518",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0006266","Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.","Kelly MS","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15934","39248221",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0006267","Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study.","Nguyen XT","2026","The lancet. Diabetes & endocrinology","nonrandomized_study","article","10.1016/s2213-8587(25)00395-x","41763234",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006268","The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.","Kuang Z","2023","International urology and nephrology","narrative_review","article","10.1007/s11255-022-03355-6","36036316",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006269","Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide.","Itoh Y","2024","Diabetology international","case_report","article","10.1007/s13340-024-00751-4","39469548","PMC11512937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006270","Perioperative GLP-1 Receptor Agonist Use is Associated With Reduced Revisions and Complications Following ACDF: A Propensity-Matched Analysis.","Kim MT","2026","Global spine journal","nonrandomized_study","article","10.1177/21925682261419753","41607363","PMC12854998",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006271","Efficacy, Tolerability, and Safety of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) in Kidney Transplant Recipients With Diabetes.","Zelada H","2025","Clinical transplantation","nonrandomized_study","article","10.1111/ctr.70144","40230336",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0006272","The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review.","Bica IC","2023","International journal of molecular sciences","systematic_review","article","10.3390/ijms24087184","37108347","PMC10138454",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0006273","New generation agents for glycemic control and diabetic retinopathy progression: what we need to know?","Vujosevic S","2025","Acta diabetologica","narrative_review","article","10.1007/s00592-025-02552-w","40586870",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006274","Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.","Sloan LA","2019","Journal of diabetes","narrative_review","article","10.1111/1753-0407.12969","31318152","PMC6900024",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006275","Assessment of Exenatide Extended-Release for Maintenance of Diabetic Remission in Cats.","Gilor C","2025","Journal of veterinary internal medicine","randomized_trial","article","10.1111/jvim.70069","40105430","PMC11921135",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006276","GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification.","Gorgul YA","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27188036","42794466","PMC13607823",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006277","Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.","Kim MK","2021","Journal of diabetes investigation","narrative_review","article","10.1111/jdi.13552","33759351","PMC8169368",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article-commentary; article"],["R0006278","Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.","Eleftheriadou A","2024","Diabetologia","nonrandomized_study","article","10.1007/s00125-024-06132-5","38584180","PMC11153282",null,"S002534","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006279","Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials.","Li Z","2024","Alzheimer's research & therapy","systematic_review","article","10.1186/s13195-024-01645-y","39716328","PMC11668108",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0006280","Uptake of Goal-Directed Therapies in a Multidisciplinary and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Research Letter.","Ouimet JP","2025","Canadian journal of kidney health and disease","nonrandomized_study","article","10.1177/20543581251380509","41058979","PMC12497978",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0006281","Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.","Norrbacka K","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01039-5","33860927","PMC8099971",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006282","A longitudinal case report illustrating diagnostic complexity among overlapping sleep-wake phenotypes.","Martirosyan Z","2026","Sleep medicine","case_report","article","10.1016/j.sleep.2026.109254","42759347",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Case Reports"],["R0006283","Impact of perioperative GLP-1 agonist use on pseudarthrosis rates following single-level anterior cervical discectomy and fusion: a propensity-matched cohort study.","Amasa S","2026","Journal of spine surgery (Hong Kong)","nonrandomized_study","article","10.21037/jss-25-142","41810399","PMC12968910",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006284","SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease.","Moon JS","2022","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2022.03.005","35491295",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review"],["R0006285","The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required.","Sinclair AJ","2025","Metabolites","narrative_review","article","10.3390/metabo15010049","39852391","PMC11767933",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006286","Update on eating disorders and disordered eating behaviors in metabolic bariatric surgery patients.","Conceição E","2024","Current opinion in psychiatry","narrative_review","article","10.1097/yco.0000000000000962","39239873",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006287","Adipose Tissue Remodeling Beyond Weight Loss: New Insights Into Incretin-Based Therapies and Bariatric Surgery.","Abud GF","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00756-x","42720874","PMC13562211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006288","Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance","Mendias CL","2026","Preprints.org","other","preprint","10.20944/preprints202604.1748.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006289","GLP-1 receptor agonists in older people with type 2 diabetes: safety evidence from the real world.","Marassi M","2026","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2026.2640982","41773040",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0006290","Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.","Xue H","2023","Drug design, development and therapy","nonrandomized_study","article","10.2147/dddt.s404055","37197367","PMC10184894",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006291","Semaglutide","Kommu S","2024","StatPearls Publishing, Treasure Island (FL)","other","article",null,"38753931",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0006292","Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits.","Salem AM","2022","Atherosclerosis","commentary","article","10.1016/j.atherosclerosis.2022.05.010","35662526",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0006293","Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.","Hachuła M","2023","Pharmaceuticals (Basel, Switzerland)","other","article","10.3390/ph16091190","37764998","PMC10534491",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006294","Serum uric acid lowering mediated by glucagon-like peptide-1 receptor agonists: Emerging considerations.","Patoulias D","2022","British journal of clinical pharmacology","commentary","article","10.1111/bcp.15382","35574903",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0006295","A comprehensive meta-analysis on the association of SGLT2is and GLP-1RAs with vascular diseases, digestive diseases and fractures.","Wang DH","2024","Acta diabetologica","systematic_review","article","10.1007/s00592-024-02289-y","38714558",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0006296","Insulinoma Unmasked By Tirzepatide: A Rare Case of Postprandial Hypoglycemia In a Nondiabetic Patient.","Polisky M","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luaf290","41356535","PMC12676122",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006297","The hypothalamus as the central regulator of energy balance and its impact on current and future obesity treatments.","Bombassaro B","2024","Archives of endocrinology and metabolism","narrative_review","article","10.20945/2359-4292-2024-0082","39876968","PMC11771753",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006298","Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.","Wysham CH","2018","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd17-0064","29686454","PMC5898162",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006299","Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.","Risebrough NA","2021","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2021.08.015","34728099",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0006300","GLP-1 Agonist Use Among Men With Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials.","Fang A","2025","Urology","other_trial","article","10.1016/j.urology.2025.04.056","40348027","PMC13036752",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; preprint; review"],["R0006301","Incidence of GLP-1 receptor agonist use by women of reproductive age attending general practices in Australia, 2011-2022: a retrospective open cohort study.","Thapaliya K","2025","The Medical journal of Australia","nonrandomized_study","article","10.5694/mja2.70026","40888243","PMC12502889",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006302","Association Between Preoperative GLP-1 Receptor Agonists Use and Perioperative Complications in Metabolic Bariatric Surgery: A Meta-Analysis.","Zhu C","2026","Obesity surgery","systematic_review","article","10.1007/s11695-026-08629-x","41951956",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0006303","Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies.","Wang S","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-023-01520-3","38175486","PMC10838895",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0006304","Off-label GLP-1 receptor agonist and tirzepatide use for weight loss: patient safety and regulatory oversight.","Maqsood A","2026","Annals of medicine and surgery (2012)","randomized_trial","article","10.1097/ms9.0000000000005191","42433852","PMC13354365",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0006305","A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.","Véniant MM","2024","Nature metabolism","randomized_trial","article","10.1038/s42255-023-00966-w","38316982","PMC10896721","ClinicalTrials.gov:NCT04478708","S001178","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; research-article; article"],["R0006306","Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1.","Ji S","2024","Reproductive sciences (Thousand Oaks, Calif.)","preclinical","article","10.1007/s43032-024-01503-0","38441776",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006307","Type 2 diabetes in South Asians.","Misra A","2025","BMJ (Clinical research ed.)","narrative_review","article","10.1136/bmj-2024-079801","40796264",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006308","Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study.","Sinha B","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-024-01635-1","39115619","PMC11411018",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006309","High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist.","Ma B","2023","BMC cancer","nonrandomized_study","article","10.1186/s12885-023-11077-w","37370018","PMC10304216",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0006310","GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents","Mahajan Y","2025","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202510.1849.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006311","Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.","James S","2025","American heart journal","randomized_trial","article","10.1016/j.ahj.2025.05.001","40345413",null,"ClinicalTrials.gov:NCT04032197","S002019","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0006312","The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis.","Zhang MQ","2024","Biomedical and environmental sciences : BES","systematic_review","article","10.3967/bes2024.067","38988111",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0006313","Clinical pharmacology of glucagon-like peptide-1 receptor agonists.","Sfairopoulos D","2018","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-018-0038-0","29949126",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006314","Preoperative liraglutide modulates control of fat and glucose metabolism during cardiopulmonary bypass surgery.","van Wilpe R","2025","Endocrine connections","randomized_trial","article","10.1530/ec-24-0427","39927559","PMC11896647","NTR:NTR6323",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006315","Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial.","Borlaug BA","2025","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2025.04.059","40701669",null,"ClinicalTrials.gov:NCT04847557","S000047","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0006316","Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?","Patoulias D","2021","Kidney medicine","commentary","article","10.1016/j.xkme.2021.02.014","34401735","PMC8350837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0006317","Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","Ortiz A","2025","Kidney international","other","article","10.1016/j.kint.2025.04.005","40536455","PMC12646115",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006318","The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.","Sloop KW","2024","Science translational medicine","preclinical","article","10.1126/scitranslmed.adp5765","39693407",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006319","Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone.","Wright EE","2024","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2024.0015","38669474",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0006320","[The glucagon-like peptide-1 receptor-agonist semaglutide].","Boje AD","2019","Ugeskrift for laeger","narrative_review","article",null,"31610830",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006321","Effects of Lipoproteins on Metabolic Health.","Albitar O","2024","Nutrients","narrative_review","article","10.3390/nu16132156","38999903","PMC11243180",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006322","GLP-1 RAs May Prevent Metastatic Progression.",null,"2026","Cancer discovery","commentary","article","10.1158/2159-8290.cd-nw2026-0059","42175743",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0006323","2025 Update on resistant hypertension in CKD: where do we stand and where do we go?","Schmieder RE","2025","Clinical kidney journal","other","article","10.1093/ckj/sfaf285","41393860","PMC12699690",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006324","Perioperative GLP1-RA management and risk of aspiration in patients with diabetes undergoing fast-track hip and knee arthroplasty.","Mahmoud LI","2025","Danish medical journal","nonrandomized_study","article","10.61409/a09240629","40407287",null,"ClinicalTrials.gov:NCT05613439",null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0006325","Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.","Maselli DB","2024","Obesity surgery","nonrandomized_study","article","10.1007/s11695-024-07278-2","38753265",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0006326","Cardiovascular protection conferred by glucagon-like peptide-1 receptor agonists: A role for serum uric acid reduction?","Najafi S","2022","British journal of clinical pharmacology","nonrandomized_study","article","10.1111/bcp.15381","35574902",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Letter; Comment; article"],["R0006327","Combination therapy with kidney protective therapies: optimizing the benefits?","Kotwal S","2024","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000000929","37767945",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006328","Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.","Lyu B","2022","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2021.11.013","34937658","PMC8766913",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0006329","Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes.","Gundapaneni SRC","2025","Cureus","systematic_review","article","10.7759/cureus.78555","40062102","PMC11887937",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006330","Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series.","Kolker A","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag284","42756500","PMC13583620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006331","Rethinking the Diabetes-Cardiovascular Disease Continuum: Toward Integrated Care.","Caturano A","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14186678","41010881","PMC12471255",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; other; article"],["R0006332","Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.","Le TDV","2023","Molecular metabolism","preclinical","article","10.1016/j.molmet.2023.101718","37030441","PMC10131131",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0006333","Effects of glucagon-like peptide-1 receptor agonists on spermatogenesis-related gene expression in mouse testis and testis-derived cell lines.","Iida M","2024","The Journal of veterinary medical science","preclinical","article","10.1292/jvms.24-0042","38556323","PMC11144540",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006334","Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta-analysis.","Al-Qudah AA","2025","The journal of obstetrics and gynaecology research","systematic_review","article","10.1111/jog.16296","40301112",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0006335","Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity.","Terenzi DC","2024","Cardiovascular research","other","article","10.1093/cvr/cvae016","38367275",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006336","Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus.","Onoviran OF","2019","Therapeutic advances in chronic disease","narrative_review","article","10.1177/2040622319862691","31321014","PMC6628533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006337","A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.","Jansson AK","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70077","41491340",null,"OSF:osf.io/xpngy",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Research Support, U.S. Gov't, Non-P.H.S.; article; review"],["R0006338","GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.","Ashraf T","2026","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2026.113369","42269776",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006339","Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery.","German J","2025","Nature medicine","other","article","10.1038/s41591-025-03645-3","40251273","PMC12283387",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006340","Heme oxygenase, biliverdin reductase, and bilirubin pathways regulate oxidative stress and insulin resistance: a focus on diabetes and therapeutics.","Lee WH","2025","Clinical science (London, England : 1979)","narrative_review","article","10.1042/cs20242825","39873298","PMC12204025",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; review-article; article"],["R0006341","Are recent decreases in adult obesity trends in the United States encouraging or alarming?","Peiper NC","2025","Preventive medicine","nonrandomized_study","article","10.1016/j.ypmed.2025.108297","40334816","PMC13162329",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; research-article"],["R0006342","Use of pre-procedure electronic questionnaire to enhance scheduling and safety in interventional radiology procedures with anesthesia care.","Serafin J","2026","Current problems in diagnostic radiology","other","article","10.1067/j.cpradiol.2025.04.008","40287283","PMC13012651",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0006343","Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide.","Mantovani A","2021","Hepatobiliary surgery and nutrition","commentary","article","10.21037/hbsn-2021-13","34430533","PMC8350997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0006344","The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes.","Shami D","2023","Cureus","narrative_review","article","10.7759/cureus.33484","36751181","PMC9901266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006345","Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study.","Lee CH","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16049","39497579",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0006346","Exposure to glucagon-like peptide 1 receptor (GLP-1R) agonists reduces glaucoma risk","Sterling JK","2021","medRxiv","nonrandomized_study","preprint","10.1101/2021.01.16.21249949",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006347","Real-World Effectiveness of Liraglutide Versus Dulaglutide In Japanese Patients With Type 2 Diabetes: A Retrospective Study","Tanaka K","2021","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-795616/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006348","Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management.","Rabbani SA","2024","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2024.2395540","39194153",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0006349","Global trends and focuses of GLP-1RA in renal disease: a bibliometric analysis and visualization from 2005 to 2022.","Meng Y","2023","Naunyn-Schmiedeberg's archives of pharmacology","nonrandomized_study","article","10.1007/s00210-023-02575-6","37389601",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0006350","The effect of glucagon-like peptide-1 receptor agonist (GLP1RA) on hypertensive-induced heart failure with preserved ejection fraction and hypertensive cardiomyopathy","Zhang ZY","2023","bioRxiv","preclinical","preprint","10.1101/2023.02.12.528171",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006351","Challenges in mitigating weight regain with incretin-based therapy.","Scheen AJ","2026","Lancet (London, England)","other","article","10.1016/s0140-6736(26)00871-8","42119589",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006352","Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.","Jung H","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15038","36855221",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006353","Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?","Scheen AJ","2022","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2022.101325","35121148",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0006354","Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist-based therapies.","Morissette A","2025","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2024.07.012","39127552",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0006355","Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks.","Chai S","2022","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2022.825417","35847027","PMC9285982",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0006356","Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature.","Pavli P","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25031909","38339186","PMC10856238",null,"S000630","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006357","Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset","Chiappini S","2023","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202309.1300.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006358","New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies.","Hsiao FC","2022","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgac402","35776065",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0006359","Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial.","Haff N","2025","American heart journal","protocol","article","10.1016/j.ahj.2025.02.007","39986337","PMC11981828","ClinicalTrials.gov:NCT05463705","S002730","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; article"],["R0006360","Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.","Iijima T","2023","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.14000","36871272","PMC10204181",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0006361","The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.","Dong M","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s375559","36035518","PMC9417299",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006362","Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review.","El-Amawy HS","2026","Anais brasileiros de dermatologia","nonrandomized_study","article","10.1016/j.abd.2025.501255","41483501","PMC12800350",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0006363","Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.","Htike ZZ","2017","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12849","27981757",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0006364","Semaglutide and cancer: A systematic review and meta-analysis.","Nagendra L","2023","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2023.102834","37531876",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0006365","Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus.","Chuang CC","2024","International journal of medical sciences","nonrandomized_study","article","10.7150/ijms.90273","38250602","PMC10797676",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006366","Recent Trends in the Prevention and Management of Obesity Among Adults: A Systematic Review.","Shankar G","2025","Cureus","systematic_review","article","10.7759/cureus.89207","40895654","PMC12399046",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006367","GLP1R Gene Expression and Kidney Disease Progression.","Triozzi JL","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.40286","39453656","PMC11581634",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0006368","Additive Effects of Dorzagliatin and Glucagon-Like Peptide 1 Receptor Agonism in a Novel Mouse Model of GCK-MODY and in Obese db/db Mice.","Salazar S","2026","Diabetes","preclinical","article","10.2337/db25-0520","41196662","PMC12716621",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0006369","Cardiovascular effectiveness of newer glucose-lowering agents, with and without baseline lipid-lowering therapy in type 2 diabetes: A systematic meta-analysis of cardiovascular outcome trials and real-world evidence.","Kunutsor SK","2024","Primary care diabetes","systematic_review","article","10.1016/j.pcd.2024.09.007","39366881",null,"PROSPERO:CRD42024498939",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0006370","[The early use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and high cardiovascular risk].","Nardi F","2023","Giornale italiano di cardiologia (2006)","narrative_review","article","10.1714/4004.39819","36971172",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; English Abstract; Journal Article; article"],["R0006371","Erratum to \"Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs\" [Obesity Pillars 11C (2024)100121].","Christensen S","2024","Obesity pillars","notice","article","10.1016/j.obpill.2024.100136","39734697","PMC11681360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0006372","Patient-Reported Continuity of GLP-1 Receptor Agonist Therapy.","Chen Y","2026","Obesity science & practice","other","article","10.1002/osp4.70189","42683049","PMC13531010",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006373","Comparing the Impact of GLP-1 Agonists vs. Lifestyle Interventions and Weight Controllability Information on Stigma and Weight-Related Cognitions.","Post SM","2025","International journal of behavioral medicine","other","article","10.1007/s12529-025-10353-2","39934611",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0006374","Feasibility of Endoscopic Conversion of Sleeve Gastrectomy to Single Anastomosis Sleeve-Ileal bypass for Refractory Gastroesophageal Reflux Disease or Non-responder: First-in-human Study","Lim CH","2026","Research Square","other","preprint","10.21203/rs.3.rs-10102615/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0006375","Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence.","Kaplan AG","2022","Pulmonary therapy","narrative_review","article","10.1007/s41030-022-00203-x","36417159","PMC9727043",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0006376","Safe and Appropriate Use of GLP-1 RAs in Treating Adult Patients With Type 2 Diabetes and Macrovascular Disease.","LaSalle J","2022","The Journal of family practice","other_trial","article","10.12788/jfp.0442","36178698",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Video-Audio Media; article"],["R0006377","Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.","van Dalem J","2021","Hepatology (Baltimore, Md.)","nonrandomized_study","article","10.1002/hep.32012","34129693","PMC8596626",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0006378","GLP-1 receptor agonists in the treatment of polycystic ovary syndrome.","Lamos EM","2017","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2017.1292125","28276778",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006379","Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.","Lim LL","2023","Nature reviews. Endocrinology","randomized_trial","article","10.1038/s41574-022-00776-2","36446898",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0006380","Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system.","Dailey KA","2025","microPublication biology","other","article","10.17912/micropub.biology.001690","40838124","PMC12364531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0006381","Exendin-4 Caused Growth Arrest by Regulating Sugar Metabolism in Hyphantria cunea (Lepidoptera: Erebidae) Larvae.","Shi W","2024","Insects","other","article","10.3390/insects15070503","39057236","PMC11276936",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006382","Tirzepatide for Weight Loss: Can Medical Therapy \"Outweigh\" Bariatric Surgery?","Novograd J","2023","Cardiology in review","other_trial","article","10.1097/crd.0000000000000515","36688833",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Review; Journal Article; article"],["R0006383","Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent","Akl MM","2023","Qeios","other","preprint","10.32388/l9aqqc",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006384","Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population.","Natale F","2024","Journal of cardiovascular development and disease","narrative_review","article","10.3390/jcdd11050145","38786967","PMC11122593",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006385","Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis.","Armstrong BBS","2025","Journal of gynecology obstetrics and human reproduction","systematic_review","article","10.1016/j.jogoh.2025.103046","41052543",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0006386","Pharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans.","Langer HT","2025","medRxiv : the preprint server for health sciences","other_trial","article","10.1101/2025.07.28.25332295","40766140","PMC12324625",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Preprint; preprint"],["R0006387","Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia.","Buenaventura-Collazos DC","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1372992","38982987","PMC11231389",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0006388","[Anti-obesity drugs : from previous disappointments to new hopes].","Scheen A","2023","Revue medicale de Liege","other","article",null,"36924152",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0006389","In Reply to 'Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?'.","Leehey DJ","2021","Kidney medicine","randomized_trial","article","10.1016/j.xkme.2021.03.017","34401736","PMC8350822",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; letter"],["R0006390","Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes.","Hirose J","2025","Communications medicine","preclinical","article","10.1038/s43856-025-00959-8","40634590","PMC12241343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006391","Can we effectively manage binge eating disorder with pharmacotherapy?","Hay P","2024","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2024.2428371","39568427",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006392","A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes.","Romera I","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-018-0535-9","30506340","PMC6349277",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0006393","Risk-directed management of chronic kidney disease.","Blum MF","2025","Nature reviews. Nephrology","randomized_trial","article","10.1038/s41581-025-00931-8","39885336",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0006394","Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.","Uzoigwe C","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01053-7","33837922","PMC8099966",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006395","Tirzepatide counteracts brown adipose tissue whitening, inflammation, and mitochondrial dysfunction in estrogen-deficient obese diabetic mice.","Bittencourt JOA","2026","Life sciences","preclinical","article","10.1016/j.lfs.2025.124155","41412277",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006396","Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials.","Alper A","2026","Cardiovascular diabetology. Endocrinology reports","systematic_review","article","10.1186/s40842-026-00333-0","42681675","PMC13536828",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review"],["R0006397","Association of GLP-1 receptor agonist use with psychiatric outcomes in adults with type 2 diabetes: a target trial emulation.","Tang H","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.113038","41386528","PMC13082438",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006398","Orforglipron: First Approval.","Shirley M","2026","Drugs","narrative_review","article","10.1007/s40265-026-02363-5","42479349",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006399","Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.","Babazadeh D","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100292","42440974","PMC13334816","ClinicalTrials.gov:NCT06467604","S001530","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006400","Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs.","Cherney DZI","2022","Kidney international reports","other_trial","article","10.1016/j.ekir.2022.07.167","36531884","PMC9751689",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0006401","Hidden Malnutrition in the GLP-1 Era: Micronutrient Status, Protein Adequacy, and Lean Mass as Emerging Nutritional Considerations-A Narrative Review.","Sorić T","2026","Nutrients","narrative_review","article","10.3390/nu18172757","42738931","PMC13567228",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0006402","Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease.","Gay HC","2023","The American journal of cardiology","other","article","10.1016/j.amjcard.2022.10.041","36424193","PMC9908071",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0006403","Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials.","Pan SY","2024","Age and ageing","systematic_review","article","10.1093/ageing/afae175","39137064",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0006404","Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.","Mahapatra MK","2022","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-021-09699-1","34993760","PMC8736331",null,"S001914","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006405","The difference in type 2 diabetes care between the National Health Insurance beneficiaries and public assistance recipients in Japan: A retrospective cohort study based on claims data in a municipality.","Yamaoka T","2026","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70213","41342345","PMC12863007",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0006406","Obesity and the Gut-Brain Axis in Type 1 Diabetes Mellitus: Terra Incognita?","Argyrakopoulou G","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00654-8","40707821","PMC12289725",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006407","Clinical trial designs of emerging therapies for diabetic kidney disease (DKD).","Singh AK","2024","Postgraduate medicine","randomized_trial","article","10.1080/00325481.2024.2377529","39045637",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0006408","Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study.","Engström A","2024","Hepatology (Baltimore, Md.)","nonrandomized_study","article","10.1097/hep.0000000000000712","38085855",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006409","New perspectives in the management of diabetic nephropathy.","Psyllaki A","2024","World journal of diabetes","randomized_trial","article","10.4239/wjd.v15.i6.1086","38983809","PMC11229954",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0006410","Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.","Htoo PT","2022","Journal of the American Heart Association","randomized_trial","article","10.1161/jaha.121.022376","35132865","PMC9245812",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006411","Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Kumar M","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70217","41937314","PMC13052322",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; review-article; review"],["R0006412","Impact of Glucagon-Like Peptide 1 Receptor Agonists in Patients with Hemoglobin A1c of 9% or Greater.","Tran V","2023","Journal of pharmacy practice","nonrandomized_study","article","10.1177/08971900221087933","35427194",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006413","Dual GIPR and GLP-1R Agonist Tirzepatide Is Associated With Fewer Asthma Exacerbations in Adults With Obesity.","Mehta S","2026","Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","other","article","10.1111/cea.70245","41708478",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006414","Obesity hypoventilation syndrome: Current status and future directions for optimizing care of a complex and diverse condition (a narrative review).","Pépin JL","2025","Sleep medicine","narrative_review","article","10.1016/j.sleep.2025.106491","40203613",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0006415","How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.","Burns RB","2024","Annals of internal medicine","other","article","10.7326/annals-24-01740","39374523",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Clinical Conference; Journal Article; article"],["R0006416","Advances in GLP-1 treatment: focus on oral semaglutide.","Eliaschewitz FG","2021","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-021-00713-9","34526121","PMC8442336",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006417","Glucagon-like peptide-1 receptor agonist attenuates diabetic neuropathic pain via inhibition of NOD-like receptor protein 3 inflammasome in brain microglia.","Zhang Q","2022","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2022.109806","35240228",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006418","Recent advances in understanding the mechanisms in skeletal muscle of interaction between exercise and frontline antihyperglycemic drugs.","Newsom SA","2024","Physiological reports","narrative_review","article","10.14814/phy2.16093","38845596","PMC11157199",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; review-article; article"],["R0006419","Bariatric surgery vs. GLP-1 receptor agonists among primarily medicare and medicaid patients with diabetes: a 3-year analysis.","Brown A","2026","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-025-12403-y","41326727",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Multicenter Study; Research Support, N.I.H., Extramural; article"],["R0006420","Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.","Blonde L","2021","Diabetes care","randomized_trial","article","10.2337/dc20-2023","33468520","PMC7896258","ClinicalTrials.gov:NCT02787551","S001125","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0006421","Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.","McGuire DK","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2501006","40162642",null,"ClinicalTrials.gov:NCT03914326","S002179","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Equivalence Trial; article"],["R0006422","The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study.","Alenzi S","2024","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2024.1395651","39205685","PMC11349510",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006423","Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.","Shah J","2026","American journal of nephrology","other_trial","article","10.1159/ajn/ablag011","42715144",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0006424","CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.","Verma S","2026","Hypertension (Dallas, Tex. : 1979)","randomized_trial","article","10.1161/hypertensionaha.125.26055","41328546","PMC12822771","ClinicalTrials.gov:NCT05567796","S001154","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0006425","Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China.","Li C","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.987081","36277697","PMC9585197",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006426","A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study.","Meiring S","2022","Frontiers in clinical diabetes and healthcare","other","article","10.3389/fcdhc.2022.856661","36992788","PMC10012157",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006427","An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is).","Wen S","2021","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s312527","34234493","PMC8254548",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006428","Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms.","Kato S","2021","Scientific reports","preclinical","article","10.1038/s41598-021-88612-x","33911125","PMC8080802",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006429","Cardioprotective glucose-lowering drugs, statins, and secondary major adverse cardiovascular events: a nationwide cohort study of individuals with type 2 diabetes and cardiovascular disease.","Ternhamar T","2026","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-026-03242-9","42304446","PMC13501814",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006430","Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis.","Caruso I","2023","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2023.102181","37719418","PMC10500557","PROSPERO:CRD42022329878",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0006431","Oral GLP-1 receptor agonist promotes astrocyte-neuron lactate and lipid transfer with neuroprotective effects.","Du Y","2026","Cell metabolism","other","article","10.1016/j.cmet.2026.05.014","42330959",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006432","The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study.","Kvist AV","2026","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","nonrandomized_study","article","10.1007/s00198-026-07950-6","41851446",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0006433","A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form.","Kalra S","2022","Indian journal of endocrinology and metabolism","other_trial","article","10.4103/ijem.ijem_522_21","35873937","PMC9302409",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006434","Semaglutide-induced Hyperemesis Gravidarum.","Okeke IG","2024","JCEM case reports","case_report","article","10.1210/jcemcr/luad167","38249445","PMC10798820",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006435","Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia.","Tobaiqy MA","2026","Saudi medical journal","other","article","10.15537/1658-3175.8842","42598160","PMC13471477",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006436","The complementary effects of GLP-1 receptor agonists and SGLT2 inhibitors in transthyretin cardiac amyloidosis patients: A retrospective multicenter cohort study.","Mahmoud AK","2025","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2025.133567","40592407",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Multicenter Study; Journal Article; article"],["R0006437","A Case Report of Bezoar-Induced Small Bowel Obstruction: A Potential Surgical Complication of Semaglutide.","Keng C","2025","Cureus","case_report","article","10.7759/cureus.99664","41431486","PMC12718217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006438","Reducing Ischemic Stroke in Diabetes: The Role of GLP-1 RAs.","Anderson JE","2023","The Journal of family practice","other","article","10.12788/jfp.0624","37549420",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006439","Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.","Gulisano W","2026","Journal of diabetes science and technology","other","article","10.1177/19322968261461530","42366647","PMC13314649",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006440","Exocrine Pancreatic Insufficiency During the Use of Semaglutide: A Case Report.","Agra de Melo Junior C","2024","Cureus","case_report","article","10.7759/cureus.55549","38576650","PMC10993639",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006441","Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence.","Karakasis P","2024","Current pharmaceutical design","narrative_review","article","10.2174/0113816128304097240529053538","38910481","PMC11475097",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006442","Incretin-based investigational therapies for the treatment of MASLD/MASH.","Brouwers B","2024","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2024.111675","38636848",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006443","Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.","Grech O","2024","Eye (London, England)","other_trial","article","10.1038/s41433-023-02908-y","38212401","PMC11076535",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0006444","Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.","Koychev I","2024","Alzheimer's research & therapy","randomized_trial","article","10.1186/s13195-024-01573-x","39358806","PMC11448378","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0006445","GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors.","Shilyansky JS","2025","Surgery","preclinical","article","10.1016/j.surg.2024.09.052","39665969",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006446","Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.","Xia L","2021","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2021.108904","34102249",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; Network Meta-Analysis; article"],["R0006447","GLP-1 receptor agonists: trend, necessity, or blessing?","Shoaib N","2025","The American journal of managed care","commentary","article","10.37765/ajmc.2025.89854","41512269",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0006448","Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice.","Morieri ML","2020","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s216054","33204129","PMC7665457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0006449","Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy.","Miller E","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01619-1","39008235","PMC11330431",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006450","Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies.","Alkhezi OS","2021","Primary care diabetes","systematic_review","article","10.1016/j.pcd.2021.04.005","33926837",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0006451","Economic evaluations of antiobesity medications: A systematic literature review.","Jurković M","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70825","42764443",null,"PROSPERO:CRD420251139475",null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; review"],["R0006452","Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study.","Volpe S","2023","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2023.1240263","37780624","PMC10534984",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006453","Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity.","Desai A","2025","Inflammatory bowel diseases","nonrandomized_study","article","10.1093/ibd/izae090","38642103",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; article"],["R0006454","Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.","Candido R","2026","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-025-02626-9","41307691","PMC12957030",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006455","Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?","Wołos-Kłosowicz K","2022","Journal of clinical medicine","narrative_review","article","10.3390/jcm11206183","36294503","PMC9604821",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006456","Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach.","Șeremet OC","2025","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina61111902","41303737","PMC12654632",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006457","Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes.","Cardiovascular Subcommittee of Chinese International Exchange and Promotion Association for Medical and Healthcare","2024","Journal of geriatric cardiology : JGC","other","article","10.26599/1671-5411.2024.07.007","39183955","PMC11341531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006458","Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.","Branine N","2026","Cureus","case_report","article","10.7759/cureus.115260","42669023","PMC13525912",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006459","Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.","Benny O","2026","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","systematic_review","article","10.1016/j.pan.2026.03.021","41927408",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0006460","Public Awareness, Perceptions, and Treatment Preferences Regarding Metabolic (Bariatric) Surgery and Injectable Pharmacotherapies for Type 2 Diabetes in Jeddah, Saudi Arabia: A Cross-Sectional Analysis.","Albog YH","2026","Cureus","other","article","10.7759/cureus.103354","41835756","PMC12981280",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006461","New drug therapies for metabolic dysfunction-associated steatohepatitis.","Chiang JYL","2025","Liver research (Beijing, China)","narrative_review","article","10.1016/j.livres.2025.01.001","40620497","PMC12226798",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006462","Antidiabetic Drug Associations With Heart Failure Outcomes: Real-World Evidence Study Using Electronic Health Records.","Jodlowska-Siewert E","2026","JMIR diabetes","nonrandomized_study","article","10.2196/85083","41985055","PMC13082573",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006463","Glucagon-Like Peptide-1 (GLP-1) Analogues",null,"2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"31643819",null,null,null,"europepmc","TRUE",null,null,null,"Book; Review"],["R0006464","Glucagon-like peptide-1 improves vascular endothelial dysfunction in hypertensive mice via CREB-driven transcriptional regulation of long non-coding RNA 155383.","Zhang Y","2026","British journal of pharmacology","preclinical","article","10.1111/bph.70560","42400305",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006465","Sequential Biologic, Small-Molecule, and GLP-1 Analogue Therapy in Postcolectomy Enteritis With High Output Stoma.","Tuttle Z","2026","ACG case reports journal","case_report","article","10.14309/crj.0000000000002233","42441220","PMC13337088",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006466","The Effect of GLP-1 Receptor Agonists on Hidradenitis Suppurativa: A Comprehensive Systematic Review.","Kassira NR","2026","Cutis","systematic_review","article","10.12788/cutis.1385","42411880",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Review; article"],["R0006467","Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.","Wu R","2025","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","systematic_review","article","10.1007/s10072-025-08680-z","41402646",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0006468","[Effectiveness of GLP-1 receptor agonists in managing patients with type 2 diabetes].","Bejarano Romero F","2025","Atencion primaria","nonrandomized_study","article","10.1016/j.aprim.2025.103354","40925137","PMC12454283",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","English Abstract; Journal Article; research-article; article"],["R0006469","Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study.","Piccini S","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-01800-z","36966321","PMC10039680",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; article; preprint"],["R0006470","Endothelial-Fibroblast Organoids Generated in Hydrogel Microchamber Arrays: A Translational Model of Vascular Dysfunction in Cardio-Kidney-Metabolic Disease.","Zitman-Gal T","2026","Journal of vascular research","other","article","10.1159/jvr/adiag003","42814650",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006471","Exendin-4 enhances insulin-positive phenotype of human pluripotent stem cell-derived β cells during transplantation.","Crumley KM","2025","Molecular therapy : the journal of the American Society of Gene Therapy","other","article","10.1016/j.ymthe.2025.07.015","40676832","PMC12324850",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006472","Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort.","Zhang J","2025","Journal of orthopaedic surgery and research","randomized_trial","article","10.1186/s13018-025-05664-9","40050929","PMC11884071",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0006473","Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum.","Shahid I","2025","Heart failure reviews","narrative_review","article","10.1007/s10741-025-10481-7","39815071",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006474","Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.","Ji L","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70895","42557064","PMC13538793","ClinicalTrials.gov:NCT05352815; ClinicalTrials.gov:NCT05259033; ClinicalTrials.gov:NCT05013229","S000155; S000458; S001633","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; research-article; article"],["R0006475","The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.","Rossing P","2023","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","protocol","article","10.1093/ndt/gfad009","36651820","PMC10469096","ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; research-article; article"],["R0006476","Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation.","Moiz A","2025","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2025.01.021","39892489",null,null,"S002529; S002619","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0006477","Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.","Zafer M","2025","Alimentary pharmacology & therapeutics","other_trial","article","10.1111/apt.70196","40364529","PMC12323726",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0006478","Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.","Lin PY","2026","Journal of hematology & oncology","systematic_review","article","10.1186/s13045-026-01788-5","41957612","PMC13063595","PROSPERO:CRD420251151419",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Network Meta-Analysis; Letter; review"],["R0006479","Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial.","Holdt-Caspersen NS","2025","JMIR research protocols","protocol","article","10.2196/64899","40986866","PMC12504889","ClinicalTrials.gov:NCT06333080","S001277","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; Research Support, Non-U.S. Gov't; research-article; article"],["R0006480","Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.","Muzurović EM","2022","Journal of cardiovascular pharmacology and therapeutics","narrative_review","article","10.1177/10742484221146371","36546652",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006481","Cutaneous Variations in Stem-Cell Population in Those on GLP1-Receptor Agonists: A Comparative Controlled Study.","Firsowicz M","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","other","article","10.1097/dss.0000000000005175","42210886",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0006482","Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.","Zhu D","2024","Nature communications","randomized_trial","article","10.1038/s41467-024-52353-y","39333121","PMC11437099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; research-article; article"],["R0006483","A systematic review of the use of GLP-1 receptor agonists in surgery.","Ihnat JMH","2025","American journal of surgery","systematic_review","article","10.1016/j.amjsurg.2024.116119","39615284",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0006484","New insights into the treatment of obesity.","Blüher M","2023","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15077","37055715",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0006485","Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management.","Alhomoud IS","2024","Pharmacotherapy","narrative_review","article","10.1002/phar.4607","39225417",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006486","Doctor who prescribed Ozempic and Wegovy to her partner has suspension extended.","Dyer C","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-100590","42608058",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0006487","Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study.","Pardo Lozano F","2025","Endocrinologia, diabetes y nutricion","nonrandomized_study","article","10.1016/j.endien.2025.501574","40450456",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006488","GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice.","Romera I","2023","Advances in therapy","nonrandomized_study","article","10.1007/s12325-023-02442-z","36821026","PMC10070220",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0006489","Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.","Ganeshalingam AA","2025","JAMA psychiatry","randomized_trial","article","10.1001/jamapsychiatry.2025.2332","40900607","PMC12409653","ClinicalTrials.gov:NCT05193578","S001361","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; research-article; article"],["R0006490","Treatment options for heart failure in individuals with overweight or obesity: a review.","Nasoufidou A","2025","Future cardiology","narrative_review","article","10.1080/14796678.2025.2479378","40098467","PMC11980494",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006491","Metabolic effects of a GLP-1 analog combined with aerobic training in ovariectomized rats.","Selau B","2026","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2026.112917","42727623",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006492","Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis.","Lavalle-Cobo A","2021","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","systematic_review","article","10.1007/s40292-021-00479-1","34705249",null,"PROSPERO:CRD42021260040",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0006493","Retrospective Analysis of Hospitalized Patients with Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide 1 Receptor Agonist Therapy.","San K","2023","Southern medical journal","nonrandomized_study","article","10.14423/smj.0000000000001511","36724541",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006494","Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.","Gonzales-Uribe A","2026","Clinical research in cardiology : official journal of the German Cardiac Society","systematic_review","article","10.1007/s00392-025-02710-8","40637782",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0006495","Innovative Glucagon-like Peptide 1 Receptor Agonists: Exploring the Therapeutic Potential of Specific Modified Monomer, Dimer, and Tetramer in Type 2 Diabetes Treatment.","Du Y","2025","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.5c00261","40679854",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006496","Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.","Corley MJ","2026","npj aging","other_trial","article","10.1038/s41514-026-00383-9","42014432","PMC13287572","ClinicalTrials.gov:NCT04216589","S001796","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0006497","GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway.","Mazzieri A","2023","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2023.1163288","38053992","PMC10694219",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0006498","GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study.","Almuammar SA","2025","Saudi medical journal","nonrandomized_study","article","10.15537/smj.2025.46.8.20240100","40840939","PMC12376157",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006499","The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes.","Yin WL","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-020-00798-x","32185624","PMC7136364",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0006500","Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials.","Simental-Mendía LE","2021","British journal of clinical pharmacology","systematic_review","article","10.1111/bcp.14855","33835520",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0006501","Exendin-4 Prevents oxLDL-Induced upregulation of TREM2 and attenuates foam cell formation and inflammation in Macrophages.","Wang X","2025","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2025.117306","40914218",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006502","Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.","Weeda ER","2021","International journal of clinical practice","systematic_review","article","10.1111/ijcp.14060","33527605",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0006503","Factors Influencing the Choice of Glucose-Lowering Medications Among Physicians Treating Patients With Type 2 Diabetes.","AlSofiani ME","2024","Cureus","nonrandomized_study","article","10.7759/cureus.53844","38465107","PMC10924471",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006504","PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.","Saravanan P","2024","Advances in therapy","nonrandomized_study","article","10.1007/s12325-024-02973-z","39316289","PMC11480173","ClinicalTrials.gov:NCT04862923","S001151; S001914","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0006505","The Obesity-OSA-Arrhythmia Axis: Pathophysiological Mechanisms and Translational Therapeutic Targets.","Cacciapuoti F","2026","Life (Basel, Switzerland)","narrative_review","article","10.3390/life16050737","42195293","PMC13208216",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006506","Cardiovascular Disease in Patients with Chronic Kidney Disease: Current Understanding, Preventative Strategies, and Future Directions.","Naami R","2024","Cardiology in review","other","article","10.1097/crd.0000000000000746","39629994",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006507","Innovative therapeutics for renoprotection: Where we are.","Cortinovis M","2025","Pharmacological reviews","narrative_review","article","10.1016/j.pharmr.2025.100060","40382796",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006508","Comparing Glucagon-Like Peptide-1 Receptor Agonists to Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review.","Al-Shudifat M","2025","Cureus","systematic_review","article","10.7759/cureus.78570","40062142","PMC11888795",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006509","Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.","Ferrari F","2022","American journal of cardiovascular drugs : drugs, devices, and other interventions","systematic_review","article","10.1007/s40256-021-00515-4","34958423",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0006510","The glucagon-like peptide 1 receptor agonist Exendin-4 induces tenogenesis in human mesenchymal stem cells.","Abdulmalik S","2021","Differentiation; research in biological diversity","other","article","10.1016/j.diff.2021.05.001","34062407","PMC13074720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0006511","Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.","Iepsen EW","2018","Cell metabolism","other_trial","article","10.1016/j.cmet.2018.05.008","29861388",null,null,"S001692","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Controlled Clinical Trial; Journal Article; article"],["R0006512","Allergic Reaction to Exenatide and Lixisenatide but Not to Liraglutide: Unveiling Anaphylaxis to Glucagon-Like Peptide 1 Receptor Agonists.","Shamriz O","2019","Diabetes care","commentary","article","10.2337/dc19-0720","31296642",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0006513","The central role of IL-6 in the differential effects of GLP-1 receptor agonists and metformin across multiple health conditions.","Elkoshi Z","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1864104","42553087","PMC13433303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0006514","Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis.","Tuccinardi D","2025","Cardiovascular diabetology. Endocrinology reports","nonrandomized_study","article","10.1186/s40842-025-00251-7","41366491","PMC12690812",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006515","Incretin-based therapies in patients with pituitary disorders: clinical opportunity or premature enthusiasm? A balanced perspective.","Iglesias P","2026","Journal of endocrinological investigation","other","article","10.1007/s40618-026-02828-0","41636997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006516","Glucagon-like peptide-1 receptor agonist stimulates mitochondrial bioenergetics in human adipocytes.","Góralska J","2017","Acta biochimica Polonica","other","article","10.18388/abp.2017_1634","28822994",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006517","Tracking the Dynamic Trajectories: A Global-to-Local Pharmacovigilance Analysis of GLP-1 Receptor Agonists","Lu S","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.05.28.26354401",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006518","One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.","Gao SX","2026","Appetite","narrative_review","article","10.1016/j.appet.2026.108723","42492687",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006519","Design of a novel long-acting dual GLP-1/GIP receptor agonist.","Dong Y","2024","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2024.117630","38330849",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006520","Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes.","Kugathasan L","2024","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2024.155785","38215965",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; article"],["R0006521","Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients.","Vigara LA","2022","Clinical transplantation","nonrandomized_study","article","10.1111/ctr.14633","35258121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0006522","Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model.","Chung YW","2022","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2022.175269","36103932",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006523","GLP-1 receptor agonists alleviate inflammatory responses and endothelial dysfunction in atherosclerosis by activating the Sema3A/NRP1 pathway.","Hu L","2026","Frontiers in cardiovascular medicine","preclinical","article","10.3389/fcvm.2026.1836833","42205784","PMC13201246",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006524","The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis.","Zeng BS","2026","Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","systematic_review","article","10.1016/j.cmi.2026.01.014","41610949",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Network Meta-Analysis; Review; article"],["R0006525","Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.","Tilg H","2026","JAMA","narrative_review","article","10.1001/jama.2025.19615","41212550",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006526","A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.","Bucheit J","2022","Journal of cardiovascular pharmacology","other_trial","article","10.1097/fjc.0000000000001299","35767712",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0006527","Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.","Alfayez OM","2020","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-020-01070-z","32571416","PMC7310317",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; research-article; other; article"],["R0006528","Strategies to address diabetic kidney disease burden in Mexico: a narrative review by the Mexican College of Nephrologists.","Palomo-Piñón S","2024","Frontiers in medicine","narrative_review","article","10.3389/fmed.2024.1376115","38962740","PMC11219582",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0006529","Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.","Meier JJ","2021","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2021.645617","34248838","PMC8269445",null,"S002311","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0006530","An Investigation on the Efficacy of Glucagon-Like Peptide 1 Receptor Agonists Drugs in Reducing Urine Albumin-to-Creatinine Ratio in Patients With Type 2 Diabetes: A Potential Treatment for Diabetic Nephropathy.","Yarlagadda C","2023","Cureus","narrative_review","article","10.7759/cureus.36438","37090383","PMC10115595",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006531","Coronary atherosclerotic plaque modification: the present and the future.","Theofilis P","2025","Expert review of cardiovascular therapy","narrative_review","article","10.1080/14779072.2025.2476132","40040242",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006532","Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.","Tuttle KR","2024","Kidney international reports","other_trial","article","10.1016/j.ekir.2024.04.028","39081763","PMC11284422","ClinicalTrials.gov:NCT01720446","S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0006533","Enhanced Oral Efficacy of Semaglutide via an Ionic Nanocomplex with Organometallic Phyllosilicate in Type 2 Diabetic Rats.","Kim GL","2024","Pharmaceutics","preclinical","article","10.3390/pharmaceutics16070886","39065583","PMC11280289",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006534","Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.","Jensen AB","2023","Obesity surgery","randomized_trial","article","10.1007/s11695-023-06484-8","36765019","PMC9918402",null,"S001448","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Observational Study; Journal Article; research-article; article"],["R0006535","Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study.","Kurozumi A","2023","Diabetology international","other","article","10.1007/s13340-023-00640-2","37781464","PMC10533751",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006536","Evaluating the neuroprotective effect of GLP-1 receptor agonists in parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","Pessoa-Gonçalves YM","2025","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","systematic_review","article","10.1007/s10072-025-08568-y","41077616",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0006537","Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.","Wharton S","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2511774","40960239",null,"ClinicalTrials.gov:NCT05869903","S001722","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; article"],["R0006538","Computational assessment of the dimeric incretin GLP-1cpGLP-1 reveals the structural bases for its activity.","Mariam Z","2025","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2025.152525","40865282",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006539","Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: A post hoc analysis of three randomized controlled trials.","Rubino D","2024","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.24042","38932728",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006540","Conceptualizing Treatment Strategies for Diabetic Kidney Disease: the Importance of Early Diagnosis and Treatment.","Gohda T","2024","Juntendo Iji zasshi = Juntendo medical journal","other","article","10.14789/ejmj.jmj24-0031-p","39840000","PMC11745826",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0006541","The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment.","Xie B","2021","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2021.697442","34220521","PMC8243369",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006542","Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.","Rejili M","2026","Vascular pharmacology","narrative_review","article","10.1016/j.vph.2025.107563","41344603",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006543","The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.","Korayem GB","2022","Frontiers in public health","nonrandomized_study","article","10.3389/fpubh.2022.1031306","36408008","PMC9673169",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006544","Long-Term Effects of Incretin-Based Drugs on Glycemic Control in Permanent Neonatal Diabetes.","Oshiro A","2024","JCEM case reports","case_report","article","10.1210/jcemcr/luae188","39430732","PMC11487289",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006545","Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.","Feraco A","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00695-7","41733759",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006546","In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.","Kelsey MD","2022","Annals of internal medicine","nonrandomized_study","article","10.7326/j22-0003","35226528",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comment; article"],["R0006547","Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.","El-Sheikh M","2025","BMJ open","systematic_review","article","10.1136/bmjopen-2025-103668","40976663","PMC12458674","PROSPERO:CRD420251003374",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0006548","Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?","Bai S","2023","European journal of internal medicine","randomized_trial","article","10.1016/j.ejim.2023.01.008","36628824",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0006549","A Review of Glucagon-like Peptide-1 in Dermatology.","Patino W","2025","The Journal of clinical and aesthetic dermatology","nonrandomized_study","article",null,"40135183","PMC11932103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0006550","The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes.","Tee SA","2023","Clinical endocrinology","other","article","10.1111/cen.14901","36843143",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006551","The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients.","Tanashat M","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","systematic_review","article","10.1007/s40256-025-00726-z","40246808",null,"PROSPERO:CRD42024498538",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0006552","Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus.","Gorgojo-Martínez JJ","2022","Journal of clinical medicine","other","article","10.3390/jcm12010145","36614945","PMC9821052",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0006553","Incretin-based therapies for obesity and disordered eating: optimising care in general practice.","Atlantis E","2026","Family medicine and community health","commentary","article","10.1136/fmch-2025-003622","41545054","PMC12815131",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; conference-abstract"],["R0006554","Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1-based therapies: a retrospective observational study in the United Arab Emirates.","Almemari S","2026","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-026-02273-3","41968307","PMC13181871",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0006555","Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?","Moreira RO","2018","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-018-0327-4","29636825","PMC5883417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006556","The Effects of NLY01, a Novel Glucagon-Like Peptide-1 Receptor Agonist, on Cuprizone-Induced Demyelination and Remyelination: Challenges and Future Perspectives.","Gharagozloo M","2023","Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","preclinical","article","10.1007/s13311-023-01390-4","37296356","PMC10457267",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0006557","Advances in small-molecule insulin secretagogues for diabetes treatment.","Su J","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2024.117179","39059347",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006558","Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study.","Omachi T","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-023-01493-3","37880502","PMC10786762","UMIN:UMIN000042670",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006559","The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.","Wu W","2024","Endocrine","systematic_review","article","10.1007/s12020-023-03636-9","38097902","PMC10902041",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0006560","Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management.","Abdul-Hafez HA","2026","Endocrinology, diabetes & metabolism","randomized_trial","article","10.1002/edm2.70152","41566974","PMC12824524",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0006561","GLP-1 receptor agonists on WHO-EML 2025 list: major breakthrough bounded by persistent challenge.","Mani K","2025","Journal of diabetes and metabolic disorders","commentary","article","10.1007/s40200-025-01810-6","41358329","PMC12678662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0006562","Repositioning dual GLP-1/GIP receptor agonists for the treatment of colitis and colitis-associated tumourigenesis.","Islam BN","2026","Gut","commentary","article","10.1136/gutjnl-2025-337537","41605614","PMC13528585",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; research-article; article"],["R0006563","Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses.","Lai HW","2025","Cardiovascular diabetology","commentary","article","10.1186/s12933-024-02543-1","40057763","PMC11890503",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0006564","Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus.","Zou Y","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16080","39618170",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; article"],["R0006565","Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019-2024).","Dos Santos Barbosa LA","2026","Therapeutic innovation & regulatory science","systematic_review","article","10.1007/s43441-025-00875-y","40993341",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0006566","The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.","Potts JE","2015","PloS one","systematic_review","article","10.1371/journal.pone.0126769","26121478","PMC4487255",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; research-article; review"],["R0006567","Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.","Rodriguez PJ","2024","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2024.2525","38976257","PMC11231910",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0006568","Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.","Foer D","2021","American journal of respiratory and critical care medicine","nonrandomized_study","article","10.1164/rccm.202004-0993oc","33052715","PMC8017590",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0006569","Schisandrin B, a potential GLP-1R agonist, exerts anti-diabetic effects by stimulating insulin secretion.","Shang J","2023","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2023.112029","37495090",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006570","Administrative costs of prior authorizations for glucagon-like peptide-1 agonists.","Pham D","2026","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2026.32.3.292","41760565","PMC12948749",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0006571","Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia/reperfusion in rats.","Mi R","2024","Brain circulation","preclinical","article","10.4103/bc.bc_38_24","40012598","PMC11850941",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006572","Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function.","Katogiannis K","2024","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina60030395","38541121","PMC10971983",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0006573","Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis.","Qian W","2021","Journal of clinical pharmacy and therapeutics","systematic_review","article","10.1111/jcpt.13502","34355405",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; article"],["R0006574","[Potentiation of weight reduction with GLP-1 receptor agonists].","Scheen AJ","2021","Revue medicale suisse","other","article",null,"34431633",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006575","Pharmacological Research Progress of Novel Antihypertensive Drugs.","Huang L","2024","Discovery medicine","narrative_review","article","10.24976/discov.med.202436184.83","38798249",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006576","Genetic associations between SGLT2 inhibition, DPP4 inhibition or GLP1R agonism and prostate cancer risk: a two-sample Mendelian randomisation study","Shen L","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.09.15.24313695",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006577","Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study.","Nersessian RSF","2024","Anaesthesia","nonrandomized_study","article","10.1111/anae.16454","39435967",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0006578","Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity.","Zaffina I","2023","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2023.1095753","36909312","PMC9992880",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006579","Exploring Adults' Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study.","Adam S","2025","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare13233102","41373319","PMC12691977",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006580","New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada.","Bodoarca R","2022","Canadian journal of diabetes","other","article","10.1016/j.jcjd.2022.04.004","35940961",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006581","Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications.","Wu H","2025","BMC medicine","systematic_review","article","10.1186/s12916-025-04200-0","40691794","PMC12281790",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; article"],["R0006582","A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","Meng Z","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1121387","37051199","PMC10084319",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0006583","Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.","Gaborit B","2020","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgz069","31589290",null,"ClinicalTrials.gov:NCT02686177; ClinicalTrials.gov:NCT02671864","S000549; S002542","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0006584","Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK.","Weiss T","2022","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2021-002517","35101924","PMC8804648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006585","Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.","Ogunsanmi DO","2023","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2023.29.6.699","37276038","PMC10387916",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006586","Effect of Dual Glucagon-Like Peptide 1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (Tirzepatide) versus Bariatric Surgery on Weight Loss and Nonalcoholic Fatty Liver Disease.","Al-Sabah S","2024","Medical principles and practice : international journal of the Kuwait University, Health Science Centre","preclinical","article","10.1159/000540534","39047721","PMC11460980",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006587","Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).","Scavo MP","2024","International journal of molecular sciences","other","article","10.3390/ijms25031493","38338770","PMC10855465",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006588","GLP-1 agonists reduce right ventricular mitochondrial dysfunction by inhibiting the GSK3β-Drp1 signalling in pulmonary hypertension.","Zhao L","2026","European journal of medical research","preclinical","article","10.1186/s40001-025-03815-6","41520117","PMC12882202",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006589","PPARG activation by pioglitazone promotes mitophagy and inhibits the NLRP3 inflammasome to alleviate arthritic joint inflammation and bone damage.","Fu T","2026","Autophagy","preclinical","article","10.1080/15548627.2026.2676071","42144710","PMC13502046",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0006590","The Effect of Liraglutide on Axon Regeneration and Functional Recovery after Peripheral Nerve Lesion.","Yalçın MB","2024","Current issues in molecular biology","preclinical","article","10.3390/cimb46010021","38248323","PMC10814355",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006591","Optimizing Type 2 Diabetes Management in Iraq: Expert Consensus on Initiation and Intensification of Insulin-Based Treatment Options.","Saab C","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-026-01861-9","41984372","PMC13156370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006592","Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?","Gentilella R","2019","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.3070","30156747",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0006593","PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9624642",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0006595","Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes.","Gomez-Peralta F","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14365","33651460","PMC8252507",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0006596","Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis.","Osorio Manyari AA","2025","Obesity surgery","systematic_review","article","10.1007/s11695-025-08414-2","41313431",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0006597","Evidence that tirzepatide protects against diabetes-related cardiac damages.","Taktaz F","2024","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-024-02203-4","38555463","PMC10981817",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0006598","M14 substitutions in exanatide modulate alpha-synuclein aggregation.","Panuganti V","2026","The FEBS journal","preclinical","article","10.1111/febs.70321","41206637",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006599","Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.","Lambert F","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70216","41153084","PMC12673446",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0006600","Optimizing SGLT2 inhibitor and GLP-1 RA Prescribing in High-Risk Patients with Diabetes: A Department of Veterans Affairs Quality Improvement Intervention","Yun S","2024","Research Square","other","preprint","10.21203/rs.3.rs-4025186/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006601","Real-World Patterns of Basal Insulin Use with Other Diabetes Medications Among People with Type 2 Diabetes Between 2014 and 2020.","Schapiro D","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01414-4","37184630","PMC10241716",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006602","The cardioprotective effect of human glucagon-like peptide-1 receptor agonist (semaglutide) on cisplatin-induced cardiotoxicity in rats: Targeting mitochondrial functions, dynamics, biogenesis, and redox status pathways.","Atef MM","2023","Cell biochemistry and function","preclinical","article","10.1002/cbf.3795","37051656",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006603","Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006).","Atasoy O","2025","Current radiopharmaceuticals","preclinical","article","10.2174/0118744710381356250429045716","40329735",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006604","Reconsidering the role of depression and common psychiatric disorders as partners in the type 2 diabetes epidemic.","Claro AE","2024","World journal of diabetes","commentary","article","10.4239/wjd.v15.i6.1374","38983820","PMC11229977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0006605","Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.","Al-Nusair M","2026","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-026-02087-z","42840232","PMC13638953",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint; article"],["R0006606","Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction.","Shoji S","2024","Heart failure reviews","narrative_review","article","10.1007/s10741-024-10432-8","39187605",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006607","Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.","Lingvay I","2020","BMJ open diabetes research & care","other_trial","article","10.1136/bmjdrc-2020-001706","33115821","PMC7594204",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006608","Ethnic Variations in Cardiovascular and Renal Outcomes From Newer Glucose-Lowering Drugs: A Meta-Analysis of Randomized Outcome Trials.","Tang H","2023","Journal of the American Heart Association","systematic_review","article","10.1161/jaha.122.026791","37158069","PMC10227303",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; brief-report; article"],["R0006609","Type 2 diabetes disease and management patterns across a large, diverse healthcare system: Issues and opportunities for guideline-directed therapies.","Blood AJ","2025","American heart journal","other","article","10.1016/j.ahj.2025.01.003","39778759",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0006610","Exendin-4 improves high glucose-induced mitochondrial dysfunction of pancreatic β-cells via PKA/Drp1 signaling.","Zhao J","2026","The Journal of endocrinology","preclinical","article","10.1530/joe-26-0023","42454501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006611","A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.","Bikou A","2024","Expert opinion on pharmacotherapy","systematic_review","article","10.1080/14656566.2024.2343092","38629387",null,null,"S000067","pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Systematic Review; Journal Article; article; preprint; review"],["R0006612","Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?","Aroda VR","2018","Clinical diabetes : a publication of the American Diabetes Association","randomized_trial","article","10.2337/cd17-0065","29686453","PMC5898167",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006613","pH-temperature Responsive Hydrogel-Mediated Delivery of Exendin-4 Encapsulated Chitosan Nanospheres for Sustained Therapeutic Efficacy in Type 2 Diabetes Mellitus.","Trinh TA","2023","Macromolecular bioscience","other","article","10.1002/mabi.202300221","37365122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006614","Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.","Zimner Rapuch S","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01055-5","33864629","PMC8099988",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006615","Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives.","Gourgari E","2021","Pediatric diabetes","other","article","10.1111/pedi.13234","34018306",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006616","Structural dynamics underlying agonist activation of a GLP-1R-Gs precoupled complex","Sýs J","2026","bioRxiv","other","preprint","10.64898/2026.08.03.742488",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006618","Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D).","Raja UY","2025","Pakistan journal of medical sciences","nonrandomized_study","article","10.12669/pjms.41.5.11002","40469149","PMC12130946",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006619","How glucagon-like peptide 1 receptor agonists work.","Andreasen CR","2021","Endocrine connections","narrative_review","article","10.1530/ec-21-0130","34137731","PMC8346189",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006620","Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics","Delgado A","2021","European psychiatry : the journal of the Association of European Psychiatrists","other","article","10.1192/j.eurpsy.2021.2050",null,"PMC9479982",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0006621","Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.","Krisanapan P","2024","Diseases (Basel, Switzerland)","systematic_review","article","10.3390/diseases12010014","38248365","PMC10814593","PROSPERO:CRD42023398452",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006622","The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes.","Inman TR","2018","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018818763698","29796245","PMC5958427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006623","Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.","Hardin M","2023","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article","10.12788/fp.0413","38812588","PMC11132191",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006624","Subocclusive ileus following off-label high-dose semaglutide use.","Nikolaeva A","2025","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-25-0081","41294925","PMC12666770",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0006625","The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.","Ali MU","2022","The Canadian journal of cardiology","systematic_review","article","10.1016/j.cjca.2022.05.011","35961756",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0006626","Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.","Miyoshi H","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01373-w","36809494","PMC10064399","UMIN:UMIN000044126",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006627","High-intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus.","Wu B","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70032","40826958","PMC12515762",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006628","Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.","Madsbad S","2016","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12596","26511102","PMC5064617",null,"S000204; S001448","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Journal Article; Review; review-article; article"],["R0006629","Lixisenatide ameliorated lipopolysaccharide (LPS)-induced expression of mucin and inflammation in bronchial epithelial cells.","Xu L","2024","Journal of biochemical and molecular toxicology","other","article","10.1002/jbt.23618","38229325",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006630","Is global interest in fasting, intermittent fasting and the liver shifting?","Tselebis A","2025","World journal of hepatology","commentary","article","10.4254/wjh.v17.i4.101910","40308823","PMC12038410",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0006631","Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518.","Marathe CS","2021","Diabetes care","randomized_trial","article","10.2337/dc20-2987","34670789",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Letter; Comment; article"],["R0006632","A Systematic Review Supporting the Clinical Practice Guidelines on the Management of Preexisting Diabetes and Pregnancy.","Al Nofal A","2025","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgaf289","40652449",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0006633","Disproportionality analysis of GLP-1 receptor agonists combined with metformin based on the FAERS database.","Liu B","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-02394-0","41053152","PMC12500926",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006634","Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.","Ligumsky H","2024","Medical oncology (Northwood, London, England)","other","article","10.1007/s12032-024-02390-w","38705935",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006635","Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials.","Yang W","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13725","38346789",null,null,"S000313; S002095","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0006636","Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.","Rudofsky G","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01668-6","39535683","PMC11760389","ClinicalTrials.gov:NCT04559815; ClinicalTrials.gov:NCT04537637; ClinicalTrials.gov:NCT05230615; ClinicalTrials.gov:NCT04601740; ClinicalTrials.gov:NCT04601753; ClinicalTrials.gov:NCT04537624; ClinicalTrials.gov:NCT04862923","S000069; S000278; S000621; S001039; S001151; S001499; S001519","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006637","Evaluating the Impact of SGLT-2 Inhibitors on Frailty in Older Adults: A Clinical Review.","Al Rashid S","2026","Current drug safety","randomized_trial","article","10.2174/0115748863365749250519051710","40454499",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0006638","Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary.","Anderson J","2022","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd22-0020","35983422","PMC9331622",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006639","Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review.","Li D","2026","Clinical drug investigation","systematic_review","article","10.1007/s40261-026-01530-6","41811592","PMC12999595",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0006640","Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies.","Genua I","2024","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/dsi23-0012","38385098","PMC10877217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006641","Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform.","Eshak N","2026","Rheumatology (Oxford, England)","nonrandomized_study","article","10.1093/rheumatology/keag033","41578948",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0006642","TAAR1 as a Potential Alternate Molecular Target to GLP-1 for Novel Anti-diabetic, Anti-obesity Medications.","Lenham RK","2026","Handbook of experimental pharmacology","other","article","10.1007/164_2026_821","42432129",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0006643","Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States.","Zhao JZ","2022","Kidney medicine","nonrandomized_study","article","10.1016/j.xkme.2022.100510","35898692","PMC9310119",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006644","Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.","Januzzi JL","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.03.380","38597864",null,"ClinicalTrials.gov:NCT04083339",null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't"],["R0006645","Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Małyszczak A","2024","Journal of clinical medicine","systematic_review","article","10.3390/jcm13061797","38542021","PMC10971133",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006646","Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care.","Nogueira JP","2024","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/dsi23-0013","38385099","PMC10877218",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006647","A Bibliometric Analysis Review of the Top 50 Most Cited Articles on Incretin-Based Therapy for Weight Reduction and Diabetes Management.","Alsaygh EF","2026","Cureus","nonrandomized_study","article","10.7759/cureus.102500","41769631","PMC12948323",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0006648","Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: A comparison of study designs, populations and results.","Pantalone KM","2020","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.14165","32744372","PMC7754368",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0006649","Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide.","McLean BA","2021","JCI insight","preclinical","article","10.1172/jci.insight.153732","34673572","PMC8663785",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006650","Obesity: Next game changer of allergic airway diseases?","Li W","2025","Clinical and translational medicine","narrative_review","article","10.1002/ctm2.70316","40329860","PMC12056501",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; review-article; article"],["R0006651","Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats.","Evans B","2022","Brain research bulletin","preclinical","article","10.1016/j.brainresbull.2022.08.022","36038016","PMC10757750",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006652","Glucagon-Like Peptide 1 Receptor Agonist Improves Renal Tubular Damage in Mice with Diabetic Kidney Disease.","Li R","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s353717","35519661","PMC9064072",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006653","Glucagon-like peptide-1 receptor agonist Exendin-4 improves neurological outcomes by attenuating TBI- induced inflammatory responses and MAPK activation in rats.","Zhang J","2020","International immunopharmacology","preclinical","article","10.1016/j.intimp.2020.106715","32570036",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006654","Management of the T2D Patient With High A1C.","Frias JP","2019","The Journal of family practice","other","article",null,"32735306",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Video-Audio Media; conference-abstract"],["R0006655","Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes: Part 2.","Hao S","2023","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2022.07.004","36754496","PMC10158502",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0006656","Akkermansia muciniphila and GLP-1-Based Therapies: Bidirectional Interactions and Implications for Type 2 Diabetes and MASLD/MASH.","Dinkov B","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14061235","42351662","PMC13297378",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006657","Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.","Diallo A","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14859","36057779","PMC10087851","PROSPERO:CRD42022299690",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; research-article; article"],["R0006658","Counseling Patients on Bariatric Surgery for Obesity","Wilson C","2026","StatPearls Publishing, Treasure Island (FL)","other","article",null,"34283422",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0006659","GLP-1 receptor agonist-induced transient retinal perfusion delay and its potential mediation by intracranial pressure.","Lee YK","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","nonrandomized_study","article","10.1016/j.biopha.2026.119635","42335513",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0006660","Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus.","Anyiam O","2024","Clinical nutrition (Edinburgh, Scotland)","randomized_trial","article","10.1016/j.clnu.2024.06.034","38996661",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0006661","Oral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic Interventions","Marwaha A","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202608.1618.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0006662","Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.","Dutta D","2024","Indian journal of endocrinology and metabolism","systematic_review","article","10.4103/ijem.ijem_45_24","39676787","PMC11642503",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006663","Cardiovascular effects of tirzepatide.","Sumithran P","2025","The Journal of endocrinology","narrative_review","article","10.1530/joe-24-0259","39751188",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006664","Narrative literature review of antidiabetic drugs' effect on hyperuricemia: elaborating actual data and mechanisms.","Liu Z","2024","Endocrine connections","narrative_review","article","10.1530/ec-24-0070","38579756","PMC11103759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006665","Surface-mediated spontaneous emulsification of the acylated peptide, semaglutide.","Li Q","2024","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.2305770121","38227645","PMC10835113",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006666","Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.","Kamrul-Hasan ABM","2024","Medicine","systematic_review","article","10.1097/md.0000000000038568","38905435","PMC11192004",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0006667","Glucagon-Like Peptide-1 Receptor Agonists-Use in Clinical Practice.","Tricò D","2021","Advances in chronic kidney disease","narrative_review","article","10.1053/j.ackd.2021.04.002","34922689",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006668","GLP-1 Receptor Agonist Use Across Preconception, Pregnancy, and the Postpartum Periods.","Porterfield F","2026","Paediatric drugs","narrative_review","article","10.1007/s40272-026-00746-5","41926051",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006669","Tirzepatide ameliorates cisplatin-induced acute kidney injury by restoring NAMPT/NAD + homeostasis and enhancing Pink1-Parkin-mediated mitophagy.","Han C","2026","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2026.118040","42114682",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006670","Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease.","Nowak K","2025","The Annals of pharmacotherapy","narrative_review","article","10.1177/10600280251322002","40072011",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006671","Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists","Stachowska Es","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-7640335/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006672","Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson's Disease.","Jeong SH","2025","Journal of movement disorders","other_trial","article","10.14802/jmd.25008","39914809","PMC12061612",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0006673","Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.","Patorno E","2021","Annals of internal medicine","randomized_trial","article","10.7326/m21-0893","34570599","PMC8969214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006674","Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential.","Arvanitakis K","2024","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2023.102935","38163417",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0006675","Tirzepatide prevents neurodegeneration through multiple molecular pathways.","Fontanella RA","2024","Journal of translational medicine","preclinical","article","10.1186/s12967-024-04927-z","38287296","PMC10823712",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0006676","Metabolomic Effects of Liraglutide Therapy on the Plasma Metabolomic Profile of Patients with Obesity.","Alfadda AA","2024","Metabolites","other","article","10.3390/metabo14090500","39330507","PMC11433991",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006677","Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.","Rentzeperi E","2022","Journal of personalized medicine","narrative_review","article","10.3390/jpm12030454","35330453","PMC8950819",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006678","Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM.","Khera R","2023","BMJ medicine","nonrandomized_study","article","10.1136/bmjmed-2023-000651","37829182","PMC10565313",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006679","Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements.","Taha MME","2026","Naunyn-Schmiedeberg's archives of pharmacology","nonrandomized_study","article","10.1007/s00210-025-04574-1","40900331",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006680","Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.","Rajab I","2026","Naunyn-Schmiedeberg's archives of pharmacology","systematic_review","article","10.1007/s00210-026-05257-1","41879841",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0006681","Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.","Upadhyay N","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71250","42638166","PMC13646331",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006682","Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518.","Rosenstock J","2021","Diabetes care","randomized_trial","article","10.2337/dci21-0004","34670790",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Letter; Comment; article"],["R0006683","Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.","Lyseng-Williamson KA","2019","Clinical drug investigation","narrative_review","article","10.1007/s40261-019-00826-0","31317516","PMC6746674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0006684","Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials' meta-analysis studies.","Khashayar P","2024","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-024-01518-2","39716250","PMC11665059",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006685","Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials.","Yates T","2022","Diabetes care","randomized_trial","article","10.2337/dc22-0888","35984425",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006686","GLP-1 Receptor Agonist Improves Mitochondrial Energy Status and Attenuates Nephrotoxicity In Vivo and In Vitro.","Wang L","2023","Metabolites","preclinical","article","10.3390/metabo13111121","37999218","PMC10672795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006687","Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.","Israelsen SB","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14329","33502076","PMC8014019",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0006688","Implications of Generic Semaglutide Availability on the Cost-Effectiveness of GLP-1RA for Guideline-Indicated Patients With Type 2 Diabetes.","McNally E","2026","The Canadian journal of cardiology","commentary","article","10.1016/j.cjca.2026.05.013","42484591",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0006689","The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.","Kitsunai H","2025","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph18010129","39861190","PMC11769496",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006690","Global Landscape and Thematic Evolution of Selective GLP-1 Receptor Agonists and GLP-1-Based Multi-Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis.","Wang Y","2026","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70351","42817068","PMC13627873",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0006691","How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?","Izumida T","2025","International journal of heart failure","narrative_review","article","10.36628/ijhf.2025.0004","40519717","PMC12160049",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006692","A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome.","Ye L","2026","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s581491","41908934","PMC13032732",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006693","GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.","Roumane A","2024","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2024.1379228","38745956","PMC11091257",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006694","Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.","Zhang HD","2024","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2024.103067","38955095",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0006695","KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease in Children and Adults: a commentary from the European Renal Best Practice (ERBP).","Iatridi F","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfae209","39299913","PMC11792658",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; article"],["R0006696","Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?","Updike WH","2021","Drugs","systematic_review","article","10.1007/s40265-021-01525-x","33929717",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0006697","Weight and mortality in people living with HIV and heart failure: Obesity paradox in the era of glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.","Nazarenko N","2025","HIV medicine","nonrandomized_study","article","10.1111/hiv.13760","39948235",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006698","Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes.","Choi S","2025","Frontiers in pharmacology","other","article","10.3389/fphar.2025.1715585","41403449","PMC12702981",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006699","Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.","McGuire DK","2022","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-022-01601-w","36002856","PMC9400320",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; other; article"],["R0006700","Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta-Regression Analysis.","Rodriguez-Valadez JM","2024","Journal of the American Heart Association","systematic_review","article","10.1161/jaha.123.032463","38362889","PMC11010086",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006701","Effects and safety of dulaglutide treatment on glucocorticoid-induced hyperglycemia in patients treated with CHOP therapy","Suyama T","2024","Research Square","other","preprint","10.21203/rs.3.rs-4216351/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006702","Weight regain after bariatric surgery: A framework for management.","Niedbala CG","2026","JAAPA : official journal of the American Academy of Physician Assistants","narrative_review","article","10.1097/01.jaa.0000000000000322","41733456",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006703","Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.","Guja C","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-021-01180-1","34894329","PMC8776928","ClinicalTrials.gov:NCT02787551","S001125","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; article"],["R0006704","Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.","Gudzune KA","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16046","39497468","PMC11701187","ClinicalTrials.gov:NCT04184622","S001077","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; research-article; article"],["R0006705","Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy.","See XY","2025","ERJ open research","nonrandomized_study","article","10.1183/23120541.00803-2024","40230429","PMC11995278",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006706","Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): Consensus on Obesity and Cardiometabolic Comorbidities in Inflammatory Bowel Disease using Evidence Synthesis and the RAND/UCLA Appropriateness Method","Devi J","2025","medRxiv","other","article","10.64898/2025.12.20.25342738","41480017",null,"PROSPERO:CRD420251178843; PROSPERO:CRD420251178799; PROSPERO:CRD420251174653",null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006707","Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo.","Dong Y","2021","Molecular metabolism","preclinical","article","10.1016/j.molmet.2021.101352","34626854","PMC8590079",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006708","Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.","Neeland IJ","2024","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15728","38937282",null,null,"S000067; S001795","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0006709","Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review).","Iorga RA","2020","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2020.8714","32765722","PMC7401476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006710","Obesity management in the pediatric patient.","Matson KL","2025","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.1093/ajhp/zxae236","39150883",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006711","[Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic].","Patoulias D","2022","Revista clinica espanola","systematic_review","article","10.1016/j.rce.2021.04.001","33935292","PMC8075844",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Case Reports; English Abstract; Journal Article; Meta-Analysis; case-report; article"],["R0006712","The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.","Arici M","2024","Frontiers in medicine","other_trial","article","10.3389/fmed.2024.1384454","38947237","PMC11214281",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Scoping Review; article"],["R0006713","A GLP-1 receptor agonist enhances islet microvascular flow through nitric oxide-dependent mechanisms in a diabetic mouse model: investigation using intravital two-photon imaging.","Kimura T","2026","Diabetologia","preclinical","article","10.1007/s00125-026-06825-z","42565824",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006714","Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying.","Fujino E","2023","Cureus","case_report","article","10.7759/cureus.42153","37602101","PMC10438952",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006715","Updates of incretin-related drugs for the treatment of type 2 diabetes.","Araki H","2023","Journal of diabetes investigation","other","article","10.1111/jdi.13945","36373430","PMC9889679",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006716","Are Semaglutide and Tirzepatide Cost-Effective for Weight Management? A Systematic Review and Meta-analysis","Xu Y","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-9709510/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0006717","Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.","Goldman JD","2020","Journal of clinical pharmacy and therapeutics","other_trial","article","10.1111/jcpt.13226","32910492","PMC7540076",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006718","Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.","McCormick TA","2024","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2023-003792","38719507","PMC11085886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006719","[Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].","Scheen AJ","2022","Revue medicale suisse","other","article","10.53738/revmed.2022.18.792.1539","36004653",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0006720","Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.","Abdul Fasi M","2026","Expert opinion on therapeutic patents","nonrandomized_study","article","10.1080/13543776.2026.2645812","41820018",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0006721","Letter to the Editor: The Gut Microbiome-Endocrine Axis in Obesity: Mechanisms and Therapeutics.","Su JB","2026","Journal of gastroenterology and hepatology","commentary","article","10.1111/jgh.70772","42767274",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0006722","Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases.","Peng W","2022","Aging and disease","narrative_review","article","10.14336/ad.2021.0928","35371594","PMC8947838",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006723","Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.","Lim CE","2023","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwac315","36582120",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006724","Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study.","Morieri ML","2021","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2021.08.049","34629258",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0006725","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap.","Salama S","2026","Cureus","systematic_review","article","10.7759/cureus.108005","42220875","PMC13221614",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006726","Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD.","Jirapinyo P","2024","Obesity surgery","nonrandomized_study","article","10.1007/s11695-024-07178-5","38512644",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006727","Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?","Veneti S","2020","World journal of diabetes","randomized_trial","article","10.4239/wjd.v11.i9.370","32994865","PMC7503505",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0006728","Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.","Tan B","2023","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-023-01321-5","37253796",null,null,"S000817","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0006729","Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.","Patel D","2020","Journal of clinical pharmacy and therapeutics","other_trial","article","10.1111/jcpt.13224","32910489","PMC7540306",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006730","The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes.","Koirala S","2024","Current cardiology reports","narrative_review","article","10.1007/s11886-024-02129-z","39235729",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006731","Impact of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) on Food Content During Esophagogastroduodenoscopy (EGD).","Stark JE","2022","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/10600280211055804","34726082",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006732","Preoperative GLP-1 receptor agonist use and postoperative respiratory complications in patients undergoing elective surgeries: a target trial emulation study.","Kotecha P","2026","American journal of respiratory and critical care medicine","nonrandomized_study","article","10.1164/rccm.202503-0775rl","41072397","PMC12688471",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006733","Exploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome.","Akel M","2024","Cureus","randomized_trial","article","10.7759/cureus.73687","39677183","PMC11646169",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0006734","The cardiovascular effects of novel weight loss therapies.","Usman MS","2023","European heart journal","narrative_review","article","10.1093/eurheartj/ehad664","37966486",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; article"],["R0006735","GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis.","Silva CFXCA","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70864","42115753",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0006736","Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.","Ida S","2021","Heart failure reviews","systematic_review","article","10.1007/s10741-020-09936-w","32080782",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0006737","Emerging Pharmacological Approaches for the Treatment of Arterial Hypertension.","Schinzari F","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13040790","40299361","PMC12024671",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006738","The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease.","Ren R","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2024.108932","39700591",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006739","Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease.","Chui ZSW","2024","Medical review (2021)","narrative_review","article","10.1515/mr-2024-0007","38680683","PMC11046571",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; review"],["R0006740","Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder.","Fakhoury B","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.49086","41632137","PMC12723548",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006741","Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease.","Seko Y","2025","Liver international : official journal of the International Association for the Study of the Liver","narrative_review","article","10.1111/liv.16164","39540675",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0006742","Reply to Watchorn et al.: Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes.","Foer D","2021","American journal of respiratory and critical care medicine","commentary","article","10.1164/rccm.202012-4511le","33508207","PMC8017586",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0006743","Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population.","Rana KB","2023","Journal of pharmacy practice","nonrandomized_study","article","10.1177/08971900221087127","35414304",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006744","GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.","Ahmad N","2026","Medicine","systematic_review","article","10.1097/md.0000000000047994","41824845","PMC12991648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; research-article; review"],["R0006745","Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.","Li Q","2021","Journal of the American Heart Association","other_trial","article","10.1161/jaha.120.020734","34250817","PMC8483500","ClinicalTrials.gov:NCT03707171","S001477","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0006746","Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group.","Janez A","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-024-01615-5","38990471","PMC11330437",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006747","Summary of the 2024 Professionals in Nutrition for Exercise and Sport \"10 Questions/10 Experts\" Session-Hot Topics for the Paris Olympic Games.","Wardenaar FC","2025","International journal of sport nutrition and exercise metabolism","other","article","10.1123/ijsnem.2024-0167","39560956",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006748","Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.","Krishnan A","2024","Diabetologia","nonrandomized_study","article","10.1007/s00125-023-06057-5","38117293","PMC10844347",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006749","Tirzepatide: A Review in Type 2 Diabetes.","France NL","2024","Drugs","other_trial","article","10.1007/s40265-023-01992-4","38388874",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; other; article"],["R0006750","Comparison of Safety Profile of Semaglutide, Tirzepatide, and Liraglutide in Obese Patients: FAERS Database Investigation",null,null,"Spartan medical research journal","nonrandomized_study","article",null,null,"PMC12399039",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0006751","Use of a Dual GIP/GLP-1 Receptor Agonist in HNF1A-MODY and HNF4A-MODY.","Broome DT","2024","Diabetes care","case_report","article","10.2337/dc24-0730","39008714","PMC11362115",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Case Reports; Research Support, N.I.H., Extramural; article"],["R0006752","A Case Report of a Pregnant Woman With Type 2 Diabetes Mellitus Using Dulaglutide During the First Trimester of Pregnancy.","Alghamdi A","2023","Cureus","case_report","article","10.7759/cureus.44644","37809127","PMC10552061",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006753","Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes.","Lou YR","2025","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-025-01475-7","39961992",null,"ClinicalTrials.gov:NCT03745885; ClinicalTrials.gov:NCT04314622; ClinicalTrials.gov:NCT04994288; ClinicalTrials.gov:NCT04998032","S000651; S001446; S001511; S002121","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0006754","Obesity Management in Youth with Duchenne Muscular Dystrophy: A Review of Metformin and Alternative Pharmacotherapies.","Goldman V","2025","Childhood obesity (Print)","nonrandomized_study","article","10.1089/chi.2024.0297","39392010",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0006755","Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel.","Tabak AG","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01556-z","38472626","PMC11043254",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0006756","Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases.","Murray-Thomas T","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16393","40292833","PMC12146475",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006757","Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis.","Wei J","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.1007980","36545339","PMC9760859",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006758","IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective.","Seetharaman R","2024","Journal of basic and clinical physiology and pharmacology","narrative_review","article","10.1515/jbcpp-2024-0058","38856001",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006759","Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study.","Cromer SJ","2026","Diabetes care","nonrandomized_study","article","10.2337/dca26-0039","42765974",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article; other"],["R0006760","Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia.","AlRuthia Y","2024","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","nonrandomized_study","article","10.1016/j.jsps.2024.102057","38601976","PMC11004995",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006761","Incretin-based therapies and PPARγ agonists as regulators of adipokines-Nrf2 axis in diabetic cardiovascular disease.","Kashmoola IO","2026","Global cardiology science & practice","narrative_review","article","10.21542/gcsp.2026.20","42544277","PMC13429184",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006762","Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.","Patoulias D","2022","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2021.12.040","35045931",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Meta-Analysis; article"],["R0006763","Table: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.",null,"2024","The Medical letter on drugs and therapeutics","narrative_review","article","10.58347/tml.2024.1708c","39137181",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006764","A glucose-responsive dual-nanoparticle-hydrogel-based microneedle patch for co-delivery of insulin and exendin-4.","Zhang T","2026","Biomaterials science","preclinical","article","10.1039/d6bm00181e","42148925",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006765","Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management.",null,"2024","The Medical letter on drugs and therapeutics","narrative_review","article","10.58347/tml.2024.1708d","39137182",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006766","Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development.","Sonne N","2026","EBioMedicine","preclinical","article","10.1016/j.ebiom.2026.106121","41547115","PMC12855590",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006767","No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.","Sherman SI","2018","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/dme.13437","28755389","PMC5838554","ClinicalTrials.gov:NCT00734474","S001242","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Research Support, Non-U.S. Gov't; Journal Article; case-report; article"],["R0006768","Role of incretin-based therapies in pain management.","Alcántara Montero A","2026","Medicina clinica","commentary","article","10.1016/j.medcli.2025.107263","41505943",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0006769","GLP-1 Receptor Agonist Improves Metabolic Disease in a Pre-clinical Model of Lipodystrophy","Roumane A","2023","bioRxiv","preclinical","preprint","10.1101/2023.09.01.555852",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006770","Operational and financial implications of GLP-1 agonist reimbursement among independent community pharmacies.","Pile T","2026","Journal of the American Pharmacists Association : JAPhA","other","article","10.1016/j.japh.2026.103135","42105864",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006771","GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art.","Granata A","2022","Clinical kidney journal","narrative_review","article","10.1093/ckj/sfac069","36003669","PMC9394722",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006772","De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test.","Pavlikova B","2024","Life (Basel, Switzerland)","nonrandomized_study","article","10.3390/life14050568","38792590","PMC11122184",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006773","Leptin and heart failure: the chicken or the egg?","Theodorakis N","2025","Heart failure reviews","narrative_review","article","10.1007/s10741-025-10501-6","40090991",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006774","Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series.","Prasad F","2023","Therapeutic advances in psychopharmacology","randomized_trial","article","10.1177/20451253231165169","37113745","PMC10126648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Case Reports; Journal Article; case-report; article"],["R0006775","Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer?","Katsiki N","2021","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2021.108075","34656423",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Research Support, N.I.H., Extramural; Comment; article"],["R0006776","Hunting for heroes: Brain neurons mediating GLP-1R agonists in obesity treatment.","Cao Y","2024","Obesity medicine","other","article","10.1016/j.obmed.2024.100569","39831282","PMC11741184",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006777","Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352.","Foer D","2021","Diabetes care","commentary","article","10.2337/dc21-0904","34285099","PMC8385467",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; Comment; article"],["R0006778","Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients With Type 2 Diabetes Without Baseline Metformin: An Update Meta-analysis","Cobo AL","2021","Research Square","systematic_review","preprint","10.21203/rs.3.rs-664920/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0006779","Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.","Valentine WJ","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14979","36655340",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006780","Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials.","Tamilwanan S","2025","BMC gastroenterology","systematic_review","article","10.1186/s12876-025-04358-0","41146009","PMC12560356",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0006781","Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node.","Lubberding AF","2024","Cardiovascular research","preclinical","article","10.1093/cvr/cvae120","38832935","PMC11472427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006782","Outcomes and Management of Re-Establishing Bariatric Patients.","Medhati P","2024","Journal of the American College of Surgeons","nonrandomized_study","article","10.1097/xcs.0000000000001062","38421026",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006783","Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients With Cirrhosis.","Morris SM","2022","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","commentary","article","10.1016/j.cgh.2021.09.023","34560279",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; article"],["R0006784","Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005-2019.","Alshehri A","2024","Primary care diabetes","other","article","10.1016/j.pcd.2024.07.003","39095227","PMC11616792",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0006785","Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.","Chiappini S","2023","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph16070994","37513906","PMC10384093",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006786","Human trials exploring anti-aging medicines.","Guarente L","2024","Cell metabolism","narrative_review","article","10.1016/j.cmet.2023.12.007","38181790",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0006787","Understanding the erectile dysfunction-cardiovascular disease connection: clinical and pathophysiological insights.","An J","2025","Sexual medicine reviews","nonrandomized_study","article","10.1093/sxmrev/qeaf014","40153594",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0006788","The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia.","Ajabnoor GMA","2023","Diseases (Basel, Switzerland)","nonrandomized_study","article","10.3390/diseases11010050","36975599","PMC10046996",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006789","Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascularization in patients with type 2 diabetes.","Patoulias D","2022","Coronary artery disease","other","article","10.1097/mca.0000000000001111","34845145",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006790","Renoprotective Effects of Metabolic Surgery Versus GLP1 Receptor Agonists on Progression of Kidney Impairment in Patients with Established Kidney Disease.","Aminian A","2024","Annals of surgery","other","article","10.1097/sla.0000000000006379","38860374",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0006791","May Patients Receiving GLP-1 Agonists Be at Lower Risk of Prostate Cancer Aggressiveness and Progression?","Drewa J","2025","Cancers","narrative_review","article","10.3390/cancers17091576","40361502","PMC12071316",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006792","Metabolic inflammation at the adipose-brain axis.","Mateus-Gomes S","2026","Frontiers in physiology","narrative_review","article","10.3389/fphys.2026.1795058","42037991","PMC13107480",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006793","Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis.","Lin PY","2025","Biomolecules","systematic_review","article","10.3390/biom15111622","41301540","PMC12650725",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Research Support, Non-U.S. Gov't; review-article; article"],["R0006794","Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma.","Cheraghpour M","2025","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","narrative_review","article","10.1016/j.cgh.2024.09.041","39800201",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006795","GLP-1 Receptor: A New Target for Sepsis.","Yang F","2021","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2021.706908","34335269","PMC8316682",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006796","Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022.","Milder TY","2025","British journal of clinical pharmacology","other","article","10.1111/bcp.16231","39224963","PMC11671323",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006797","Comparison of amylase and lipase levels of patients with Type 2 diabetes under different treatment modalities.","Cakmak R","2022","Biomarkers in medicine","other","article","10.2217/bmm-2021-0318","34856813",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006798","Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).","Almansour HA","2025","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare13182259","41008391","PMC12469573",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006799","Treatment of Hypothalamic Obesity With GLP-1 Analogs.","Dimitri P","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae200","39703362","PMC11655849",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0006800","Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study.","Yamada H","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-022-01313-0","36006593","PMC9500122",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006801","Is Semaglutide Linked to NAION? A Case Report on a Rare Ocular Complication.","Lešin Gaćina D","2025","Reports (MDPI)","case_report","article","10.3390/reports8030149","40843891","PMC12372079",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006802","GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications.","Restrepo Mejia M","2026","HSS journal : the musculoskeletal journal of Hospital for Special Surgery","narrative_review","article","10.1177/15563316261438492","42147422","PMC13176104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0006803","Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study.","Xie P","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-023-01434-0","37329393","PMC10299984",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0006804","Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?","Doggrell SA","2023","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2023.2206560","37086147",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; article"],["R0006805","Revisiting food addiction in the era of GLP-1-based obesity pharmacotherapy via neural reward pathways linking feeding and substance use.","O'Connor RM","2026","Frontiers in behavioral neuroscience","narrative_review","article","10.3389/fnbeh.2026.1805953","42051627","PMC13111218",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006806","Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis.","Malandris K","2024","Journal of gastroenterology and hepatology","systematic_review","article","10.1111/jgh.16559","38627972",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0006807","Evaluating the Efficacy of ChatGPT vs. Google Gemini in Generating Patient Education Materials for GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Tirzepatide): A Cross-Sectional Study.","Karnan N","2025","Cureus","other","article","10.7759/cureus.81993","40351930","PMC12065961",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006808","Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity.","Pilkington AW","2024","Current allergy and asthma reports","narrative_review","article","10.1007/s11882-024-01153-x","38878250","PMC11233394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0006809","Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy","Cengiz A","2024","medRxiv","other","preprint","10.1101/2024.11.27.24318093",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006810","Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?","Kobayati A","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14637","34989070",null,null,"S000485","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Review; article"],["R0006811","Investigating Potential GLP-1 Receptor Agonists in Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and Peptides Derived from Heterophyllin B for the Treatment of Type 2 Diabetes: An In Silico Study.","Liao HJ","2022","Metabolites","other","article","10.3390/metabo12060549","35736482","PMC9227353",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006812","The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.","Leiter LA","2020","Diabetes, obesity & metabolism","other","article","10.1111/dom.14079","32372454","PMC7496251","ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446","S001496; S001933; S002638","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0006813","Safety and Efficacy of Efpeglenatide in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.","Escobar J","2023","Cureus","systematic_review","article","10.7759/cureus.45927","37885518","PMC10599090",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006814","Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide.","Kamm DR","2021","The Journal of biological chemistry","preclinical","article","10.1016/j.jbc.2021.100807","34022222","PMC8192871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006815","Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials.","Chen JJ","2026","International journal of molecular sciences","systematic_review","article","10.3390/ijms27020608","41596262","PMC12841245",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; review"],["R0006816","Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.","Nagaoka T","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2515117","41337725",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0006817","Drug Therapies for Diabetes.","Weinberg Sibony R","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms242417147","38138975","PMC10742594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006818","[Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes].","Andersen A","2019","Ugeskrift for laeger","narrative_review","article",null,"30931886",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006819","Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity.","Bae JH","2025","Journal of diabetes investigation","other","article","10.1111/jdi.14336","39460581","PMC11786174",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0006820","Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.","Newsome PN","2024","Alimentary pharmacology & therapeutics","protocol","article","10.1111/apt.18331","39412509","PMC11599791","ClinicalTrials.gov:NCT04822181","S000511","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006821","Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study.","Kim HS","2022","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2021.0232","34743486","PMC9353570",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006822","Neuroendocrine tumors and diabetes mellitus: which treatment and which effect.","Mazzilli R","2025","Endocrine","nonrandomized_study","article","10.1007/s12020-024-04149-9","39752043",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0006823","Genetic Assessment of Oesophageal Safety of GLP-1 and GIP Receptor Perturbation: A Drug-Target Mendelian Randomisation Study.","Lee H","2026","Biomedicines","nonrandomized_study","article","10.3390/biomedicines14091887","42792631","PMC13604261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006824","Medical and surgical treatment of postbariatric hypoglycaemia: Retrospective data from daily practice.","de Heide LJM","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14920","36377811",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0006825","Molecular Therapeutics for Diabetic Kidney Disease: An Update.","Guo M","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms251810051","39337537","PMC11431964",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006826","Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.","Mazzieri A","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25073969","38612779","PMC11012439",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006827","Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy.","Muir KC","2026","American journal of physiology. Heart and circulatory physiology","randomized_trial","article","10.1152/ajpheart.00828.2025","41553720","PMC12931278",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006828","Obesity in Heart Failure: Mechanistic, Diagnostic and Therapeutic Considerations.","Pathan F","2026","Cardiac failure review","narrative_review","article","10.15420/cfr.2026.05","42774757","PMC13595267",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006829","Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.","Zhao S","2026","Internal and emergency medicine","systematic_review","article","10.1007/s11739-026-04326-w","41917519",null,"ClinicalTrials.gov:NCT04166773; ClinicalTrials.gov:NCT04849728; ClinicalTrials.gov:NCT03900429; ClinicalTrials.gov:NCT04197479; ClinicalTrials.gov:NCT04951219; PROSPERO:CRD42025637054","S000031","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Review; review"],["R0006830","Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials.","Wang R","2024","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.3752","38013215",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0006831","Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus.","Dotan I","2024","Transplantation","randomized_trial","article","10.1097/tp.0000000000004945","38361246",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0006832","[Patient with type 2 diabetes and coronary heart disease developing heart failure].","Scheen A","2024","Revue medicale de Liege","other","article",null,"38602215",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0006833","Discontinuation of incretin-based therapies in obesity: the complexity of a breakup.","Avogaro A","2026","European journal of internal medicine","randomized_trial","article","10.1016/j.ejim.2026.106833","41833473",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0006834","The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.","Ma R","2021","Medicine","systematic_review","article","10.1097/md.0000000000026295","34115034","PMC8202615",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review-article; article"],["R0006835","Exploring the risk of depression and suicide/self-injury in patients receiving GLP-1RAs combined with metformin versus GLP-1RA monotherapy: a real-word analysis of the FAERS database.","Ji W","2026","Endocrine connections","nonrandomized_study","article","10.1530/ec-25-0403","41670433","PMC12961268",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006836","Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.","Cherney DZI","2021","Med (New York, N.Y.)","narrative_review","article","10.1016/j.medj.2021.10.004","35590197",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006837","Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV.","Butale B","2022","Sexual health","nonrandomized_study","article","10.1071/sh22070","35995175",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Review; Journal Article; article"],["R0006838","The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients.","Fadah K","2022","Current cardiology reports","nonrandomized_study","article","10.1007/s11886-021-01619-8","35000149",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0006839","Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy.","O'Keefe JH","2025","Progress in cardiovascular diseases","narrative_review","article","10.1016/j.pcad.2024.12.010","39743126","PMC12103286",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0006840","Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches.","Heidarpour M","2024","International journal of endocrinology","systematic_review","article","10.1155/2024/9900213","38500709","PMC10948218",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006841","Cardiovascular Outcomes With GLP-1 Receptor Agonists in Patients With Diabetes or Obesity Undergoing Transcatheter Aortic Valve Replacement.","Goyal A","2026","The Canadian journal of cardiology","nonrandomized_study","article","10.1016/j.cjca.2026.04.003","42019817",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006842","Thyroid Cancer Risk and the Next Generation of Diabetes Drugs: What Can We Learn from Incretin-Based Therapies?","Son H","2025","Endocrinology and metabolism (Seoul, Korea)","nonrandomized_study","article","10.3803/enm.2025.2581","40898926","PMC12409154",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; article"],["R0006843","[Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases].","Gilarevsky SR","2021","Kardiologiia","other","article","10.18087/cardio.2021.4.n1549","33998411",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006844","Effects of Semaglutide in Doxorubicin-Induced Cardiac Toxicity in Wistar Albino Rats.","HamaSalih RM","2024","Cancer management and research","preclinical","article","10.2147/cmar.s468453","38952352","PMC11216551",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006845","Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus.","Eghbali M","2024","Advances in therapy","randomized_trial","article","10.1007/s12325-023-02761-1","38172377",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Equivalence Trial; Journal Article; Randomized Controlled Trial; article"],["R0006846","Assessing the proportion of patients with type 2 diabetes in tertiary care eligible for combination therapy with GLP-1 receptor agonist and SGLT2 inhibitors.","Jensen AB","2026","European journal of internal medicine","other","article","10.1016/j.ejim.2026.106787","41735082",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006847","Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.","Lee YC","2022","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2022.869804","36176438","PMC9513310",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006848","GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians.","Saha B","2025","Mayo Clinic proceedings","other_trial","article","10.1016/j.mayocp.2025.09.017","41324524",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0006849","Direct Comparison Two Fixed-ratio Combination Glucagon-like Peptide Receptor Agonist and Basal Insulin on Glycemic and Non Glycemic Parameters in Type 2 Diabetes","Risovic I","2022","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-1592081/v2",null,null,null,null,"europepmc","FALSE","free_to_read","4",null,"Preprint"],["R0006850","A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders.","Au HCT","2025","Journal of affective disorders","systematic_review","article","10.1016/j.jad.2024.11.019","39515485",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0006851","GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events.","Pahud de Mortanges A","2022","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2022.856111","35370744","PMC8964343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006852","Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.","Salvador R","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18030399","40143174","PMC11944337",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006853","Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance.","Harrington J","2024","Circulation. Heart failure","narrative_review","article","10.1161/circheartfailure.124.011518","39087359",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006854","Postmenopausal bleeding associated with semaglutide: a diagnostic challenge.","Prasad S","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag261","42751094","PMC13579060",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006855","Targeting Persistent Neuroinflammation after Hypoxic-Ischemic Encephalopathy-Is Exendin-4 the Answer?","Zhou KQ","2022","International journal of molecular sciences","preclinical","article","10.3390/ijms231710191","36077587","PMC9456443",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006856","Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.","Shirani A","2024","Therapeutic advances in neurological disorders","nonrandomized_study","article","10.1177/17562864241241383","38566910","PMC10986166",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0006857","Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison.","Jung HN","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.870722","35669682","PMC9165059",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0006858","Long-term adherence to glucose-lowering medications in adults with diabetes: A data linkage study.","Lee CMY","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16408","40264387","PMC12146459",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006859","Comparison of the Completeness of Spontaneously Reported Adverse Drug Reactions by Consumers, Healthcare Professionals, and Pharmaceutical Companies: An Evaluation of Databases From Two High-Income Countries.","Dedefo MG","2025","Pharmacology research & perspectives","nonrandomized_study","article","10.1002/prp2.70164","40778745","PMC12332888",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0006860","Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.","Kimura T","2024","Journal of diabetes research","nonrandomized_study","article","10.1155/2024/5880589","38223524","PMC10783983",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; article"],["R0006861","Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.","Richards R","2025","JMIR formative research","nonrandomized_study","article","10.2196/81912","40838489","PMC12475876",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0006862","Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.","Dong W","2025","EBioMedicine","preclinical","article","10.1016/j.ebiom.2025.105791","40479843","PMC12205698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006863","Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.","Yang XY","2023","European review for medical and pharmacological sciences","systematic_review","article","10.26355/eurrev_202308_33290","37606127",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; review"],["R0006864","GLP-1 receptor agonist use does not increase risk of respiratory complications post-endoscopy.","Velji-Ibrahim J","2025","Endoscopy international open","nonrandomized_study","article","10.1055/a-2487-2937","39958662","PMC11827728",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006865","Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.","Hviid MEB","2025","Alcohol, clinical & experimental research","randomized_trial","article","10.1111/acer.70110","40630018","PMC12365570",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0006866","One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients.","Kim MJ","2024","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2024.06.024","39069432",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0006867","Twelve-month analysis of real-world evidence from a telehealth obesity-treatment provider using antiobesity medications.","Ard JD","2024","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24169","39478294","PMC11589532",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0006868","GLP-1 receptor agonists or SGLT2-inhibitors? Evaluation of a personalized treatment algorithm for individuals with type 2 diabetes: a registry-based cohort study.","Mori T","2026","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","nonrandomized_study","article","10.1055/a-2798-6496","41881006","PMC13016828",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0006869","Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.","Vilsbøll T","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15031","36809678",null,null,"S001790","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006870","Corrigendum: Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study.","Tsai WH","2022","Frontiers in pharmacology","notice","article","10.3389/fphar.2022.886343","35392555","PMC8980915",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0006871","Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments.","Nabi-Afjadi M","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2024.116808","38805967",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0006872","Association of GLP1-receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes.","Al Ashi S","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16657","40735942",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006873","Are Incretin-Based Therapies Associated With Decreased Risk of Alcohol Use Disorder After Bariatric Surgery?","Cotes RO","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.49006","41632140",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006874","Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction-associated steatotic liver disease.","Kehar M","2024","Journal of pediatric gastroenterology and nutrition","other","article","10.1002/jpn3.12236","38698664",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006875","Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice.","Mosqueira A","2026","Molecular brain","preclinical","article","10.1186/s13041-026-01329-8","42436546","PMC13640180",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006876","Delayed gastric emptying and antiseizure medication absorption: a potential pharmacokinetic consideration for GLP-1/GIP receptor agonists.","João RB","2026","European journal of clinical pharmacology","commentary","article","10.1007/s00228-026-04042-6","41944888",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0006877","[Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.].","Belleudi V","2024","Recenti progressi in medicina","other","article","10.1701/4392.43917","39688041",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0006878","Steatotic liver disease and cancer: from pathogenesis to therapeutic targets.","Yang Z","2025","eGastroenterology","narrative_review","article","10.1136/egastro-2025-100218","41098801","PMC12519389",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006879","Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial.","Frampton R","2024","Diabetic medicine : a journal of the British Diabetic Association","protocol","article","10.1111/dme.15377","38853340",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial Protocol; Journal Article; article"],["R0006880","Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss.","Fabi S","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","nonrandomized_study","article","10.1097/dss.0000000000005166","42210883",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006881","Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis.","Kamrul-Hasan A","2025","World journal of diabetes","systematic_review","article","10.4239/wjd.v16.i2.101282","39959269","PMC11718474",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0006882","Optimizing Obesity Management With GLP-1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and Progressive Strength Training: A Retrospective Program Review.","Edens ES","2026","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.70140","41947826","PMC13052065",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006883","GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling.","Samaranayake CB","2026","European heart journal open","randomized_trial","article","10.1093/ehjopen/oeaf170","41536961","PMC12798715","ClinicalTrials.gov:NCT06118203","S000111","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0006884","Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma.","Sterling J","2023","The British journal of ophthalmology","nonrandomized_study","article","10.1136/bjophthalmol-2021-319232","34413054","PMC8857286",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006885","Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations.","Sagar G","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.71015","42297758","PMC13448860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006886","Risk of Alzheimer's Disease and Alzheimer's Disease‐Related Dementias with liraglutide compared to semaglutide and dulaglutide in veterans with type 2 diabetes: An emulated clinical trial observational study","Sarwal A","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","nonrandomized_study","article","10.1002/alz70857_101831","41447030","PMC12739614",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0006887","Semaglutide and Tirzepatide Suppress Hepatic Fatty Acid Uptake and Fatty Acid β‑Oxidation in High-Fat Diet-Induced Obesity Mice","Patel D",null,"Journal of proteome research","preclinical","article",null,null,"PMC13640507",null,null,"europepmc","TRUE",null,null,null,"research-article; Journal Article"],["R0006888","The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes.","Rasmussen MF","2020","Diabetology international","other_trial","article","10.1007/s13340-019-00423-8","32206477","PMC7082439",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006889","Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review.","Herascu A","2024","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina60122067","39768947","PMC11678706",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0006890","GLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America Study","Chaturvedi R","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.08.28.26361368",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0006891","Estimating the lives that could be saved by expanded access to weight-loss drugs.","Pandey A","2024","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.2412872121","39405358","PMC11513960",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Preprint; research-article; preprint; article"],["R0006892","Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus.","Koullias E","2024","Cureus","other","article","10.7759/cureus.53813","38465109","PMC10924185",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006893","Association of GLP1R locus with mental ill-health endophenotypes and cardiometabolic traits: A trans-ancestry study in UK Biobank.","Hayman MME","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16178","39838854","PMC11885074",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006894","Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation.","Abrignani MG","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14093083","40364115","PMC12072322",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006895","Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.","Ma H","2023","BMJ open","systematic_review","article","10.1136/bmjopen-2022-061807","36882248","PMC10008474","PROSPERO:CRD42021258103",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; systematic-review; review"],["R0006896","Sociodemographic disparities in semaglutide and tirzepatide prescription for obesity treatment.","Le MT","2026","Health affairs scholar","nonrandomized_study","article","10.1093/haschl/qxag255","42852064","PMC13648207",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006897","Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.","Wang L","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.21305","38967919","PMC11227080",null,"S002362; S002389; S002468","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006898","Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods.","Morieri ML","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02952-w","41107882","PMC12535053",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0006899","Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.","Wright AK","2022","Diabetes care","systematic_review","article","10.2337/dc21-1113","35100355",null,null,"S002421; S002481","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article; other"],["R0006900","Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.","Salahuddin T","2021","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14193","32902128",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0006901","Reliable localization of insulinomas with [68Ga]Ga-NODAGA-Lys40-Exendin-4: a preliminary evaluation and clinical illustration.","Menon SR","2026","EJNMMI research","other","article","10.1186/s13550-025-01365-w","42018102","PMC13269569",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0006902","Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder.","Zhu C","2022","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2022.819470","35300299","PMC8921771",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006903","Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs.","Kolli RT","2025","Cureus","systematic_review","article","10.7759/cureus.94926","41116804","PMC12535773",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006904","Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study.","Pradhan R","2022","American journal of epidemiology","nonrandomized_study","article","10.1093/aje/kwac021","35136902","PMC9989345",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006905","The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis.","Kennedy C","2023","Journal of clinical medicine","systematic_review","article","10.3390/jcm12030772","36769420","PMC9917722",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article; conference-abstract; review"],["R0006906","\"Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both?\".","Patoulias D","2022","European journal of internal medicine","commentary","article","10.1016/j.ejim.2021.12.010","34969593",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0006907","Unmasking the risk: euglycemic diabetic ketoacidosis induced by GLP-1 agonist in type 2 diabetes.","Adrejiya P","2026","Proceedings (Baylor University. Medical Center)","case_report","article","10.1080/08998280.2025.2555778","41487555","PMC12758207",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006908","Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings.","Yamada H","2023","Journal of cardiovascular development and disease","nonrandomized_study","article","10.3390/jcdd10040176","37103055","PMC10141082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006909","Pasireotide-induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment.","Shikata M","2020","Clinical case reports","case_report","article","10.1002/ccr3.3230","33363790","PMC7752440",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006910","Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2.","Yang L","2024","Drug design, development and therapy","preclinical","article","10.2147/dddt.s495659","39634723","PMC11616417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; article; preprint"],["R0006911","A Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonist in Kidney Transplant Recipients With Type 2 Diabetes","Sato T","2021","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvab048.826",null,"PMC8090345",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0006912","68Ga-DOTA-exendin-4 PET/CT for Insulinoma Localization in Patients with Negative or Inconclusive Conventional Imaging.","Fricke JG","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag214","42168767",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0006913","The effects of incretins as a double-edged sword on cancer.","Mavaddat H","2025","Molecular biology reports","nonrandomized_study","article","10.1007/s11033-025-11062-5","41023473",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0006914","Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what's new?","Ning X","2024","Expert opinion on investigational drugs","narrative_review","article","10.1080/13543784.2024.2439501","39645243",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006915","Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.","Orsini Federici M","2021","Diabetes/metabolism research and reviews","other_trial","article","10.1002/dmrr.3434","33900667","PMC8519155",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006916","Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report.","Elliott DC","2026","Cureus","case_report","article","10.7759/cureus.101016","41658769","PMC12880732",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006917","Potential Therapeutic Effects of a GLP-1 Analogue on Blood Pressure in Morbidly Obese Patient: A Case Report","Gul R","2026","Research Square","case_report","preprint","10.21203/rs.3.rs-10856515/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006918","Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes.","Bilal A","2023","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2022.10.010","36948784",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0006919","Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection.","Bea S","2024","Clinical pharmacology and therapeutics","nonrandomized_study","article","10.1002/cpt.3182","38284421","PMC11023771",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006920","Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections versus Glucagon like peptide 1 Receptor Agonist in weight loss. A Prospective randomized study","Gameel A","2023","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-3196471/v1",null,null,"ClinicalTrials.gov:NCT05268627","S000104","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0006921","Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.","Lim S","2018","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2018.01.011","29463450",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review"],["R0006922","Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.","Simancas-Racines D","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100290","42382663","PMC13316283",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0006923","Exposure-Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies.","Pan Q","2022","Frontiers in endocrinology","other","article","10.3389/fendo.2022.893971","35721733","PMC9204533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006924","Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis.","Borodavkin P","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14565","34605124",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0006925","Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.","Vanek L","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15967","39375862",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0006926","Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network.","García-Vega D","2024","Cardiovascular diabetology","other","article","10.1186/s12933-023-02096-9","38172989","PMC10765851",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0006927","Comparative Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Agonists on Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Alqurain AA","2026","Cureus","systematic_review","article","10.7759/cureus.100927","41523725","PMC12781563",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0006928","Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus.","Markoutsaki V","2026","Hormones (Athens, Greece)","nonrandomized_study","article","10.1007/s42000-025-00743-2","41417204",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0006929","Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?","Lehmann EW","2021","Cardiovascular research","randomized_trial","article","10.1093/cvr/cvab249","34448813",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006930","Advances in Diabetes Medications and Patient Preparation for Oncologic FDG PET: AJR Expert Panel Narrative Review.","Mulugeta PG","2026","AJR. American journal of roentgenology","narrative_review","article","10.2214/ajr.26.34744","42417652",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0006931","New approach to optimize therapy in type 2 diabetes mellitus: the importance of subclassification.","Reyes-Medina MJ","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1710511","41255523","PMC12620229",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006932","The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.","Giorgino F","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15244","37700627",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0006933","Late Allograft Loss and Contemporary Cardiorenal Metabolic Therapies.","Vinson AJ","2025","Journal of the American Society of Nephrology : JASN","narrative_review","article","10.1681/asn.0000000726","40193211","PMC12342079","ClinicalTrials.gov:NCT06059664",null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006934","3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy.","El Sanadi CE","2020","Annals of translational medicine","nonrandomized_study","article","10.21037/atm-20-4063","33313090","PMC7723528",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006935","Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study.","Niu S","2025","Frontiers in endocrinology","other","article","10.3389/fendo.2025.1650729","41103643","PMC12521249",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006936","Interactions between antidiabetes medications and heart-brain axis.","Ong LT","2025","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000896","39639832",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0006937","Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review.","Domingues C","2026","Cureus","randomized_trial","article","10.7759/cureus.110038","42388962","PMC13322461",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0006938","Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.","Soto-Catalán M","2024","International journal of molecular sciences","preclinical","article","10.3390/ijms25052961","38474208","PMC10932050",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006939","Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh.","Rahman MH","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70343","41342185","PMC12803531",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0006940","Update on the Present and Future Pharmacologic Treatment of Parkinson's Disease.","Müller T","2025","Neurology and therapy","other_trial","article","10.1007/s40120-025-00800-3","40679671","PMC12450148",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006941","Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients.","Masaki T","2022","Metabolites","other","article","10.3390/metabo12020147","35208221","PMC8878247",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006942","Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.","Kunutsor SK","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15500","38379094",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0006943","Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.","Mann JFE","2024","Nature medicine","randomized_trial","article","10.1038/s41591-024-03133-0","38914124","PMC11485243","ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0006944","Gut microbiota in MAFLD: therapeutic and diagnostic implications.","Alghamdi W","2024","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/20420188241242937","38628492","PMC11020731",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006945","Quantitative analysis of the efficacy characteristics and influencing factors of weight loss drugs in children and adolescents.","Wang Y","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16599","40642833",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0006946","Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.","Liu L","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01336-7","36414806","PMC9880095",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006947","Access to Anti-Obesity GLP-1s for Medicare-Aged Adults","Rodriguez PJ","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.03.26.24304923",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0006948","JNK3 regulates β cell responses to incretins in human islets and mouse models.","Louzada RA","2026","The Journal of clinical investigation","preclinical","article","10.1172/jci185707","41480766","PMC12721909",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0006949","Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review.","Maskery MP","2021","Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","nonrandomized_study","article","10.1177/0271678x20952011","32954901","PMC7747170",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; review-article; article"],["R0006950","An Overview of the Burden of Illness and the Role of Once-Weekly Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.","Brunton SA","2018","The Journal of family practice","other_trial","article",null,"29912995",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0006951","Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative Review.","Wanner C","2025","Advances in therapy","nonrandomized_study","article","10.1007/s12325-025-03228-1","40434618","PMC12182529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0006952","Web Exclusive. Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?","Centor RM","2026","Annals of internal medicine","other","article","10.7326/annals-26-00135-oc","41554140",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Video-Audio Media; article"],["R0006953","Treatment Patterns and Glycaemic Control Between 2015 and 2019 in Tianjin, China: A Real-World Study of Adults with Type 2 Diabetes.","Zhang Q","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01661-z","39487283","PMC11759750",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006954","Employing an Artificial Intelligence Platform to Enhance Treatment Responses to GLP-1 Agonists by Utilizing Metabolic Variability Signatures Based on the Constrained Disorder Principle.","Landau J","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13112645","41301738","PMC12650194",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006955","Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.","Harashima SI","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13267","29473709","PMC6033027",null,"S002709","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; brief-report; article"],["R0006956","Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.","Essien UR","2023","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2023.16290","37261826","PMC10236237",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006957","Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact.","Lee AA","2025","Medical sciences (Basel, Switzerland)","narrative_review","article","10.3390/medsci13040269","41283270","PMC12641833",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0006958","Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.","Patorno E","2022","Annals of internal medicine","commentary","article","10.7326/l21-0709","35038404",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0006959","Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.","Liu QK","2024","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2024.1431292","39114288","PMC11304055",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006960","Meta-Inflammation and New Anti-Diabetic Drugs: A New Chance to Knock Down Residual Cardiovascular Risk.","d'Aiello A","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms24108643","37239990","PMC10217924",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006961","Dose-dependent pancreatitis risk associated with GLP-1 agonists.","Gu JH","2025","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-024-01552-x","39758806","PMC11695654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006962","The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes.","Alhowiti A","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1550938","40852189","PMC12367517",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; systematic-review; article"],["R0006963","Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.","Bepo L","2022","Annals of internal medicine","commentary","article","10.7326/l21-0707","35038403",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0006964","Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.","Qiu M","2022","Annals of internal medicine","nonrandomized_study","article","10.7326/l21-0706","35038402",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0006965","Obesity Management in Female Adolescents.","Roth LP","2025","Clinical endocrinology","narrative_review","article","10.1111/cen.15238","40255106","PMC12928152",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0006966","Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial.","Sandsdal RM","2026","Nature metabolism","randomized_trial","article","10.1038/s42255-026-01554-4","42342869","PMC13400309","ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32","S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0006967","Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis.","Guimarães GNF","2026","Case reports in medicine","other","article","10.1155/carm/3016596","42211780","PMC13213196",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0006968","Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials.","Sohn M","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15251","37649320",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0006969","Bile acids and incretins as modulators of obesity-associated atherosclerosis.","Kirsch A","2024","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2024.1510148","39834741","PMC11743266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0006970","Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.","Cowart K","2020","The Annals of pharmacotherapy","other_trial","article","10.1177/1060028019889064","31744308",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0006971","Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma.","Gjersdal E","2024","Pituitary","case_report","article","10.1007/s11102-024-01426-8","39088138","PMC11513775",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0006972","Saudi Healthcare Providers' Perspectives and Clinical Practice of Anti-Obesity Medications: A National Survey.","AlOtaibi HF","2025","Saudi journal of medicine & medical sciences","other","article","10.4103/sjmms.sjmms_672_24","40843226","PMC12366907",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006973","Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.","Storgaard H","2017","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12885","28105738",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0006974","The results are in: Cardiovascular benefits of glucagon-like peptide-1 receptor agonists - a trial sequential analysis.","Chan JSK","2021","European journal of preventive cardiology","other_trial","article","10.1177/2047487320918722","33611393",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0006975","Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).","Jia W","2026","Nature communications","randomized_trial","article","10.1038/s41467-026-72574-7","42103705","PMC13369722","ClinicalTrials.gov:NCT04998032","S002121","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Adaptive Clinical Trial; research-article; article"],["R0006976","Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.","Keskin U","2026","Behavioural brain research","preclinical","article","10.1016/j.bbr.2026.116343","42385950",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; article; preprint"],["R0006977","Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.","Eberly LA","2021","JAMA health forum","randomized_trial","article","10.1001/jamahealthforum.2021.4182","35977298","PMC8796881",null,"S001795","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0006978","Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease.","Altintas Dogan AD","2022","International journal of chronic obstructive pulmonary disease","randomized_trial","article","10.2147/copd.s350133","35237033","PMC8882670",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0006979","Role and impact of a specialized cardiometabolic clinic in managing high-risk patients with type 2 diabetes and atherosclerotic cardiovascular disease.","Modarressi T","2024","American journal of preventive cardiology","nonrandomized_study","article","10.1016/j.ajpc.2024.100706","39070023","PMC11278552",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0006980","Effects of tryptophan-selective lipidated glucagon-like peptide 1 (GLP-1) peptides on the GLP-1 receptor.","Lu X","2025","The Journal of endocrinology","preclinical","article","10.1530/joe-24-0026","39807656",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006981","GLP-1 agonists to slow down Parkinson's progression? The quest continues.","Bloem BR","2025","Med (New York, N.Y.)","other_trial","article","10.1016/j.medj.2025.100645","40220748",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0006982","Effects of Combination of SGLT-2 Inhibitor and GLP-1 Receptor Agonist on Renal Outcome in T2D with GFR below 30 and Macroalbuminuria : A Case Series","Kuhadiya N","2020","Authorea Preprints","case_report","preprint","10.22541/au.160638319.95190343/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0006983","Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.","Ni XY","2024","Acta pharmacologica Sinica","preclinical","article","10.1038/s41401-024-01265-0","38589689","PMC11272793",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0006984","Weighing the Risks: Small Bowel Obstruction Associated With Semaglutide Use in the Postoperative Abdomen.","Nagib N","2025","Cureus","case_report","article","10.7759/cureus.88589","40861748","PMC12372858",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0006985","Multiple analysis based on dual-mode anion-exchange chromatography strategy reveals significant impact of charge heterogeneity on structure and function of dulaglutide.","Gong F","2025","International journal of biological macromolecules","other","article","10.1016/j.ijbiomac.2025.147808","40976302",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0006986","[Individualizing antihypertensive therapy in diabetes mellitus. Guidelines of the Austrian Diabetes Association (Update 2026)].","Saely CH","2026","Wiener klinische Wochenschrift","narrative_review","article","10.1007/s00508-026-02719-7","42162470","PMC13190778",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Practice Guideline; English Abstract; research-article; article"],["R0006987","Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin Deintensification, Cardiovascular Outcomes and Safety Assessment","Matson R","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202606.0638.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0006988","Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance.","Jain AB","2021","International journal of clinical practice","other","article","10.1111/ijcp.13731","32975890","PMC7900946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Consensus Statement; research-article; article"],["R0006989","Prevalence of Obesity Medications in the Military Health System: An Update from 2022.","Corrado RL","2026","Military medicine","nonrandomized_study","article","10.1093/milmed/usag142","41894608",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0006990","CURRENT TREATMENT APPROACHES AND GLYCEMIC CONTROL IN TURKISH PATIENTS WITH TYPE 2 DIABETES MELLITUS: A REAL-WORLD EVIDENCE FROM A TERTIARY HOSPITAL IN TURKEY.","Demir SB","2024","Acta endocrinologica (Bucharest, Romania : 2005)","nonrandomized_study","article","10.4183/aeb.2024.324","40530092","PMC12169838",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006991","Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.","Hansen BB","2020","Journal of medical economics","other_trial","article","10.1080/13696998.2020.1722678","31990244",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0006992","Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study.","Wheeler DC","2025","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfaf305","41220896","PMC12598660","ClinicalTrials.gov:NCT05348733",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0006993","Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists.","Patoulias D","2021","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2021.08.009","34497008",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Meta-Analysis; review"],["R0006994","Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management.","Eleftheriadou A","2024","Diabetologia","other_trial","article","10.1007/s00125-024-06242-0","39120767","PMC11604676",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0006995","Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions.","Song S","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2026.119345","41966799",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0006996","Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: A meta-analysis and meta-regression analysis.","Yoshiji S","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14666","35137511",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; article"],["R0006997","Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.","Zhou L","2023","BMC endocrine disorders","systematic_review","article","10.1186/s12902-023-01500-5","37940910","PMC10631119",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0006998","Macrovascular Complications.","McRae M","2022","Primary care","narrative_review","article","10.1016/j.pop.2021.11.012","35595481",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0006999","The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis.","Lucero KS","2023","JMIR medical education","nonrandomized_study","article","10.2196/48586","37642994","PMC10498312",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007000","Wegovy: GPs are told not to prescribe GLP semaglutide for heart health without funding guarantee.","Iacobucci G","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-100816","42722400",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0007001","The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes.","Kroopnick JM","2022","Expert opinion on pharmacotherapy","other","article","10.1080/14656566.2022.2089021","35765193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007002","Potential Implications of Body Mass Composition Changes in Heart Failure Patients in the Era of SGLT2i, GLP-1 RA, and GIP/GLP-1 RA.","Gryglewska-Wawrzak K","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18111726","41304969","PMC12655702",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007003","Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","Bril F","2025","Journal of lipid and atherosclerosis","narrative_review","article","10.12997/jla.2025.14.1.5","39911965","PMC11791423",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007004","Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.","Brunetti VC","2022","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-022-01140-1","36175881","PMC9520836",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0007005","Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.","Lin TY","2023","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2022.0221","36872060","PMC10244193",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007006","Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study.","Lim CE","2026","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2026.101729","42306189","PMC13265897",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007007","A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment.","Lee CY","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.748477","34616367","PMC8489573",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; discussion; article"],["R0007008","A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis.","Shah N","2025","The American journal of gastroenterology","narrative_review","article","10.14309/ajg.0000000000003215","39569874",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; article"],["R0007009","Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.","Liakopoulou P","2017","Endocrine","systematic_review","article","10.1007/s12020-017-1293-6","28401444",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007010","Discovery of non-peptide GLP-1r natural agonists for enhancing coronary safety in type 2 diabetes patients.","Shakour N","2025","Journal of biomolecular structure & dynamics","other","article","10.1080/07391102.2023.2298734","38165453",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007011","Options for patients with out-of-control blood pressure: after all avenues have been exhausted.","Zeng W","2024","Expert review of cardiovascular therapy","narrative_review","article","10.1080/14779072.2024.2401875","39258872",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007012","Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.","Sun Y","2024","International journal of surgery (London, England)","systematic_review","article","10.1097/js9.0000000000001514","38701500","PMC11325911",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0007013","Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus.","Albert SG","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other_trial","article","10.1016/j.eprac.2023.12.007","38097111",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Review; Journal Article"],["R0007014","Health Beliefs and Obesity Bias as Determinants of Attitudes Toward the Rising Tides of GLP-1 Medications: Mounjaro and Ozempic.","Al-Mahzoum K","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s518994","40343227","PMC12059217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007015","Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.","Santos Solis R","2026","Cureus","systematic_review","article","10.7759/cureus.111728","42529769","PMC13418920",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007016","Effect of Liraglutide on Osteoporosis in a Rat Model of Type 2 Diabetes Mellitus: A Histological, Immunohistochemical, and Biochemical Study.","Fathy MA","2023","Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada","preclinical","article","10.1093/micmic/ozad102","37832035",null,null,"S000828","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0007017","Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study.","Sato G","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01631-5","39110375","PMC11330422",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007018","Efficacy and Safety of Injectable Dulaglutide 1.5 mg Among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia.","Albargawi MS","2024","Journal of epidemiology and global health","nonrandomized_study","article","10.1007/s44197-024-00207-7","38753098","PMC11442716",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007019","Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement.","Störmann S","2024","Frontiers in endocrinology","other","article","10.3389/fendo.2024.1348990","38405148","PMC10884330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Consensus Statement; research-article; article"],["R0007020","Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A retrospective multi-institutional study.","Hsiao FC","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.109076","34599973",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0007021","Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis.","Greco C","2022","Diabetes & metabolism journal","systematic_review","article","10.4093/dmj.2021.0314","35410110","PMC9723196",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0007022","Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome.","Carmina E","2026","Journal of clinical medicine","other","article","10.3390/jcm15135165","42452625","PMC13362893",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007023","Cardio-Renal-Metabolic Outcomes Associated With the Use of GLP-1 Receptor Agonists After Heart Transplantation.","Donald EM","2024","Clinical transplantation","nonrandomized_study","article","10.1111/ctr.15401","39023081","PMC11634378",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007024","A Review on the Efficacy and Safety of Oral Semaglutide.","Niman S","2021","Drugs in R&D","other_trial","article","10.1007/s40268-021-00341-8","33772451","PMC8206300",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007025","Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages.","Lu C","2019","International immunopharmacology","preclinical","article","10.1016/j.intimp.2019.105969","31685436",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007026","Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial.","Gómez-Medina AM","2025","Diabetologia","randomized_trial","article","10.1007/s00125-025-06446-y","40760249","PMC12361261","ClinicalTrials.gov:NCT05767255","S002117","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0007027","CORRIGENDUM FOR \"Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM\".",null,"2020","Journal of the Endocrine Society","notice","article","10.1210/jendso/bvaa134","33241168","PMC7672806",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0007028","Evolutionary History of the Comorbidity-Driven Coronary Microvascular Endothelial Inflammation Hypothesis and Its Metamorphosis to the Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction.","Packer M","2026","JACC. Heart failure","narrative_review","article","10.1016/j.jchf.2025.102822","41269201",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0007029","KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD.","Navaneethan SD","2025","American journal of kidney diseases : the official journal of the National Kidney Foundation","narrative_review","article","10.1053/j.ajkd.2024.08.003","39556063",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007030","Antidiabetic Medication and Asthma Attacks.","Lee B","2025","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2024.5982","39556360","PMC11574725",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007031","Amyloidogenicity of peptides targeting diabetes and obesity.","Lima LMTR","2022","Colloids and surfaces. B, Biointerfaces","narrative_review","article","10.1016/j.colsurfb.2021.112157","34715595",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007032","Oral Adverse Effects of Semaglutide Therapy: A Narrative Review.","Al-Zawawi AS","2024","Journal of International Society of Preventive & Community Dentistry","nonrandomized_study","article","10.4103/jispcd.jispcd_5_26","42730115","PMC13568709",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0007033","Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.","Kobayashi K","2022","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2022.109231","35131376",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0007034","Effect of polyethylene glycol loxenatide on weight loss in super-obese patients with type 2 diabetes: a randomized controlled trial.","Liu Z","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1689040","41694563","PMC12900763","ChiCTR:ChiCTR2100052922",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0007035","A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.","Romera I","2022","Advances in therapy","nonrandomized_study","article","10.1007/s12325-022-02196-0","35689162",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0007036","Role of GLP-1 Agonists in Obesity: A Comprehensive Review","Thirukonda Jegadeesh Babu KS","2024","Preprints.org","narrative_review","preprint","10.20944/preprints202410.1829.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007037","Dulaglutide and pregnancy: a comprehensive safety assessment using the ex vivo placenta perfusion and in vitro models.","Kuoni S","2025","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2025.1765815","41640683","PMC12865208",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007038","Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists.","Lucey M","2020","Molecular metabolism","preclinical","article","10.1016/j.molmet.2020.100991","32278079","PMC7262448",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0007039","Insulin release from isolated cat islets of Langerhans.","Strage EM","2024","Domestic animal endocrinology","other","article","10.1016/j.domaniend.2023.106836","38141375",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007040","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Diabetes and Obesity: Implications for Periodontology and Family Dentistry.","Almohammad AA","2025","Cureus","randomized_trial","article","10.7759/cureus.95792","41328144","PMC12665121",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0007041","Colonic Ischemia Following Semaglutide Use: A Case Report","Kosel L","2026","Research Square","case_report","preprint","10.21203/rs.3.rs-8816823/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; article; preprint"],["R0007042","IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.","Elmendorf AJ","2026","Pharmacological research","preclinical","article","10.1016/j.phrs.2025.108077","41478576","PMC12910462",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0007043","From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics.","Roy A","2025","Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","other_trial","article","10.1016/j.neurot.2025.e00712","40738791","PMC12491786",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007044","Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.","Monda VM","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01472-8","37801224","PMC10597965",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007045","The interactions between energy homeostasis and neurovascular plasticity.","Chen B","2024","Nature reviews. Endocrinology","narrative_review","article","10.1038/s41574-024-01021-8","39054359",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007046","Using a Combination Amino Acid, Carbohydrate, and Micronutrient Beverage for Preoperative Nutrition Allows Safe Gastric Emptying for Anesthesia Provision in a Prospective, Single-Group Intervention.","Bowden JA","2026","Journal of the Academy of Nutrition and Dietetics","other","article","10.1016/j.jand.2025.156223","41192763",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0007047","Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice.","Toki S","2021","Allergy","preclinical","article","10.1111/all.14879","33955007","PMC8597133",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0007048","Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.","Neves JS","2025","European journal of heart failure","other_trial","article","10.1002/ejhf.3478","39381950",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0007049","A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction.","Liu Z","2022","Frontiers in cardiovascular medicine","systematic_review","article","10.3389/fcvm.2022.1019120","36277800","PMC9581215",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0007050","The new evidence on cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: one step closer to their use in this setting?","Popovic DS","2023","Expert review of clinical pharmacology","randomized_trial","article","10.1080/17512433.2023.2274988","37864783",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0007051","Risk Factors for New-Onset Atrial Fibrillation in Thai Adults with Hypertension","Limpijankit V","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.05.07.25327197",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0007052","Unlocking the Potential: Semaglutide's Impact on Alzheimer's and Parkinson's Disease in Animal Models.","Meca AD","2024","Current issues in molecular biology","narrative_review","article","10.3390/cimb46060354","38921025","PMC11202139",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007053","Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.","Schechter M","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-01829-0","37244998","PMC10225085",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007054","Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.","Fischer SL","2026","Pharmacological research","narrative_review","article","10.1016/j.phrs.2026.108382","42586227",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007055","Preserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy.","Sanchis-Gomar F","2025","Current cardiology reports","narrative_review","article","10.1007/s11886-025-02334-4","41400708",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007056","Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.","Albulushi A","2024","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-024-02415-8","39217337","PMC11366143",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Systematic Review; research-article; review"],["R0007057","Optimizing care for chronic kidney disease: Considerations from A to Z.","Chen FY","2025","Journal of the Chinese Medical Association : JCMA","narrative_review","article","10.1097/jcma.0000000000001280","40790782","PMC12718738",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0007058","Duodenal mucosal ablation with irreversible electroporation reduces liver lipids in rats with non-alcoholic fatty liver disease.","Yu JW","2025","World journal of gastroenterology","preclinical","article","10.3748/wjg.v31.i16.105188","40308802","PMC12038522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007059","Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Meta-Analysis and Meta-Regression Analysis","Yoshiji S","2021","medRxiv","systematic_review","preprint","10.1101/2021.10.14.21264803",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0007060","Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus.","Patoulias D","2022","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2021.12.001","34974899",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Meta-Analysis; review"],["R0007061","Exploration of metformin-based drug combination for mitigating diabetes-associated atherosclerotic diseases.","Qu B","2025","World journal of diabetes","commentary","article","10.4239/wjd.v16.i4.100533","40236872","PMC11947926",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0007062","Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Neuen BL","2024","Circulation","systematic_review","article","10.1161/circulationaha.124.071689","39210781",null,"PROSPERO:CRD42024565765","S002481; S002662","pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0007063","Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes.","Marquis-Gravel G","2021","Diabetes care","randomized_trial","article","10.2337/dci20-0076","34016611","PMC8247522",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comment; article-commentary; article"],["R0007064","Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.","Giugliano D","2019","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13743","30969018",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0007065","GLP-1 agonists for smoking cessation and post-cessation weight management: A systematic review and meta-analysis of randomized trials.","Heshmati J","2026","Tobacco induced diseases","systematic_review","article","10.18332/tid/219815","42529623","PMC13417961",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007066","In brief: Rybelsus R2 rebranded as Ozempic.",null,"2026","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2026.1752f","41961538",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007067","Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice","Yang H","2026","medRxiv","randomized_trial","preprint","10.64898/2026.10.04.26364715",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0007068","A diabetes registrar assisted workflow intervention in general practice for systematic initiation of cardiorenal medications for patients with type 2 diabetes and albuminuria in Aotearoa New Zealand.","Niyagama A","2023","The New Zealand medical journal","other","article","10.26635/6965.6297","38096435",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007069","Do relationships between ambient temperature and serious adverse health outcomes vary among users of different antidiabetes drugs? A retrospective cohort study of US Medicaid beneficiaries with type 2 diabetes.","Leonard CE","2024","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2024-085139","39433419","PMC11499775",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0007070","All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.","Riley DR","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15185","37385958",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007071","A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes.","Volpe M","2021","European heart journal","randomized_trial","article","10.1093/eurheartj/ehab550","34355764",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0007072","The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.","Kim GS","2019","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2019.34.2.106","31099200","PMC6599901",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0007073","Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.","Sass MR","2024","Acta psychiatrica Scandinavica","other_trial","article","10.1111/acps.13690","38631670",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007074","Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.","Blonde L","2019","Current medical research and opinion","narrative_review","article","10.1080/03007995.2018.1541790","30370783",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007075","Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report.","Lechner B","2026","Cardiovascular diabetology. Endocrinology reports","case_report","article","10.1186/s40842-026-00318-z","42538551","PMC13428413",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0007076","PSUN188 Evaluating Response to GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Managed at a Veterans Affairs Hospital",null,"2022","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC9624607",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0007077","Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.","Borlaug BA","2025","Nature medicine","randomized_trial","article","10.1038/s41591-024-03374-z","39551891","PMC11835708","ClinicalTrials.gov:NCT04847557","S000047; S000913","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0007078","The role of GLP-1 receptor in pain disorders and its pharmacological properties.","Jing F","2025","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2025.178345","41207354",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007079","Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues.","Iqbal AM","2021","Current drug safety","randomized_trial","article","10.2174/1574886315999201208212356","33292155",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0007080","Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.","Thirugnanam AM","2026","Cardiovascular revascularization medicine : including molecular interventions","randomized_trial","article","10.1016/j.carrev.2026.03.011","42000295",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Review; article"],["R0007081","Comparative effects of glucose-lowering agents on endothelial function and arterial stiffness in patients with type 2 diabetes: A network meta-analysis.","Kim H","2024","Atherosclerosis","systematic_review","article","10.1016/j.atherosclerosis.2024.117490","38452432",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis"],["R0007082","Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension.","Lee JH","2022","Medical hypotheses","preclinical","article","10.1016/j.mehy.2021.110739","34916733","PMC8654461",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007083","The multifaceted role of GLP-1 in metabolic disorders, chronic inflammation, and aging: Mechanisms and therapeutic potential.","Li M","2026","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2026.156547","41672302",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0007084","Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism.","Model JFA","2024","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2024.116623","39542180",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0007085","GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","Ahmed M","2025","Clinical cardiology","systematic_review","article","10.1002/clc.70234","41388927","PMC12701558",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; Meta-Analysis; Systematic Review; review"],["R0007086","The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight.","Post SM","2024","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-024-01516-4","38561488","PMC12439114","OSF:osf.io/xme4w",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0007087","The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis.","Avogaro A","2022","International journal of cardiology","systematic_review","article","10.1016/j.ijcard.2022.03.032","35306033",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Scoping Review; article"],["R0007088","Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.","Newsome PN","2025","The Journal of clinical investigation","other_trial","article","10.1172/jci186425","40590228","PMC12208534",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0007089","Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.","Burcelin R","2017","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.12465","27636208",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0007090","Oral GLP1 Analog: Where Does the Tide Go?","Gardner H","2020","Clinical medicine insights. Endocrinology and diabetes","narrative_review","article","10.1177/1179551420984130","33447122","PMC7780176",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007091","Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients.","Frontino G","2021","Frontiers in pediatrics","case_report","article","10.3389/fped.2021.755365","34970515","PMC8712700",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007092","Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression.","Naaman SC","2023","Diabetes care","narrative_review","article","10.2337/dci23-0030","37625003","PMC10547606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, N.I.H., Extramural; review-article; article"],["R0007093","In silico prediction of optimal multifactorial intervention in chronic kidney disease.","Latosinska A","2025","Journal of translational medicine","nonrandomized_study","article","10.1186/s12967-025-06977-3","40842026","PMC12372250",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0007094","Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?","Scheen AJ","2025","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(25)00219-0","40854316",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007095","Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society.","Napoli R","2021","Nutrition, metabolism, and cardiovascular diseases : NMCD","other","article","10.1016/j.numecd.2021.08.039","34627692",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007096","Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice.","Rakhat Y","2023","Nutrients","preclinical","article","10.3390/nu15173765","37686797","PMC10489807",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007097","Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review.","Dréant A","2024","Obesity surgery","systematic_review","article","10.1007/s11695-024-07127-2","38436920",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0007098","Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions-A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data.","Popa Ilie IR","2026","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19060876","42356493","PMC13305957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0007099","Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.","Mantovani A","2022","The lancet. Gastroenterology & hepatology","systematic_review","article","10.1016/s2468-1253(21)00261-2","35030323",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0007100","12-Month Weight Loss and Adherence in a Real-World Tirzepatide-Supported Digital Obesity Service","Talay L","2025","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202511.2177.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0007101","Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.","Piccoli GF","2021","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgaa891","33248445","PMC8089886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; Abstract; review"],["R0007102","Larotrectinib-associated withdrawal symptoms resolved following initiation of GLP-1 receptor agonist: a case report.","Patel R","2025","Cancer chemotherapy and pharmacology","case_report","article","10.1007/s00280-025-04829-x","41125972",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0007103","Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.","Targher G","2023","The lancet. Gastroenterology & hepatology","randomized_trial","article","10.1016/s2468-1253(22)00338-7","36620987",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0007104","A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.","Yazawa R","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15064","36974349",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase I; Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007105","The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution.","Zhao L","2019","The Journal of endocrinology","preclinical","article","10.1530/joe-18-0374","30530905",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007106","Effects of GLP-1 Receptor Agonists vs Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.","Almubaddil K","2026","Cureus","systematic_review","article","10.7759/cureus.103927","41873309","PMC13006129",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007107","The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.","Joshi SR","2022","Diabetes & metabolic syndrome","randomized_trial","article","10.1016/j.dsx.2022.102508","35653929",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0007108","Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.","Paccola GP","2026","Clinical obesity","systematic_review","article","10.1111/cob.70111","42670242","PMC13527552",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; research-article; review"],["R0007109","Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis.","Bellos I","2024","Biomolecules","systematic_review","article","10.3390/biom15010039","39858434","PMC11764242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0007110","Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.","Takrori E","2025","Medicina (Kaunas, Lithuania)","systematic_review","article","10.3390/medicina61111987","41303824","PMC12654588",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0007111","Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.","Chen GL","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15441","38287130",null,"ChiCTR:ChiCTR2100049732",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; article"],["R0007112","Variant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor-orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics.","Mohammad A","2026","International journal of biological macromolecules","other_trial","article","10.1016/j.ijbiomac.2026.153525","42437645",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0007113","Ethical Considerations in the Use of Weight Loss Medications.","Savla R","2026","Journal of general internal medicine","commentary","article","10.1007/s11606-025-10026-6","41219651","PMC12960898",null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0007114","Cardio-renal outcomes in type 2 diabetes patients with advanced chronic kidney disease on SGLT2 inhibitors or GLP-1 receptor agonists.","Chen JJ","2026","The American journal of medicine","randomized_trial","article","10.1016/j.amjmed.2025.12.011","41419094",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0007115","A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.","Johansen P","2020","Advances in therapy","other","article","10.1007/s12325-020-01242-z","32048148","PMC7089718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0007116","Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.","Frias JP","2018","The Journal of family practice","other_trial","article",null,"29912998",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0007117","Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.","Wittbrodt ET","2018","The American journal of managed care","nonrandomized_study","article",null,"29693361",null,"ClinicalTrials.gov:NCT01147250; ClinicalTrials.gov:NCT01144338; ClinicalTrials.gov:NCT01455896; ClinicalTrials.gov:NCT02465515; ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01394952; ClinicalTrials.gov:NCT01720446","S000147; S000677; S000905; S001074; S001496; S001933; S001991","pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; article"],["R0007118","Targeting metabolic dysfunction in amyotrophic lateral sclerosis: therapeutic potential of GLP-1 receptor agonists.","Helal MM","2026","Amyotrophic lateral sclerosis & frontotemporal degeneration","narrative_review","article","10.1080/21678421.2026.2627901","41678537",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007119","Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control.","Ito H","2022","Diabetology international","other","article","10.1007/s13340-021-00508-3","35059245","PMC8733088",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007120","Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.","Rhee JJ","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15427","38186297","PMC10932840",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0007121","Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Zhao H","2023","Drugs","systematic_review","article","10.1007/s40265-023-01932-2","37639180",null,"PROSPERO:CRD42022357886",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0007122","Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.","Yamada T","2021","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-020-01197-z","33413348","PMC7792332",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; research-article; other; review"],["R0007123","Associations of taste intensity changes with appetite during incretin-based therapy in obesity",null,"2025","European journal of public health","other","article",null,null,"PMC12556604",null,null,"europepmc","TRUE",null,null,null,"Other"],["R0007124","Liraglutide Attenuates Glucolipotoxicity-Induced RSC96 Schwann Cells' Inflammation and Dysfunction.","Kornelius E","2022","Biomolecules","other","article","10.3390/biom12101338","36291547","PMC9599544",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007125","Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis.","Wu Y","2021","The Journal of international medical research","systematic_review","article","10.1177/03000605211066306","34939442","PMC8721710",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; other; review"],["R0007126","Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?","Melo M","2021","Diabetology & metabolic syndrome","other_trial","article","10.1186/s13098-021-00698-5","34315528","PMC8317280",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007127","Optimizing kidney and cardiovascular protection in an era of multiple effective treatments.","Taal MW","2024","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000001019","39137040",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007128","The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.","Giugliano D","2022","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-022-01474-z","35296336","PMC8925229",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; Preprint; review; preprint"],["R0007129","Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.","Terakawa A","2020","Medicine","case_report","article","10.1097/md.0000000000021939","32871938","PMC7458169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007130","Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction.","Ridker PM","2026","JAMA cardiology","protocol","article","10.1001/jamacardio.2025.4491","41369941",null,"ClinicalTrials.gov:NCT05021835",null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007131","Beyond Public Health and Medicine: The Potential Impact of GLP-1s and Other Incretin Mimetic Medications on Greenhouse Gas Emissions.","Mann DM","2026","Journal of public health management and practice : JPHMP","other","article","10.1097/phh.0000000000002387","42284491","PMC13359041",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007132","GLP-1 receptor agonist liraglutide facilitates rotator cuff healing by reducing tendon cell inflammation and endoplasmic reticulum stress through the GLP-1R-AMPK/SIRT1 pathway.","Zhang X","2026","International immunopharmacology","preclinical","article","10.1016/j.intimp.2025.116010","41386184",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007133","A Predictive Mathematical Model of Nutrient-Stimulated Hormone Dynamics (NUSH) and Their Impact on Body Weight Regulation","de Oliveira Andrade LJ","2025","medRxiv","other","preprint","10.1101/2025.07.06.25330959",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007134","Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-analysis","Yamada T","2020","Research Square","systematic_review","preprint","10.21203/rs.3.rs-58029/v3",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0007135","Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database.","Zhang Z","2025","Endocrine connections","nonrandomized_study","article","10.1530/ec-25-0205","40631601","PMC12291155",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007136","Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.","Frias JP","2022","Diabetes care","randomized_trial","article","10.2337/dc21-2656","35671039","PMC9274225","ClinicalTrials.gov:NCT03353350","S002081","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; research-article; other; article"],["R0007137","GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease-a KDIGO commentary.","de Boer IH","2025","Kidney international","commentary","article","10.1016/j.kint.2024.12.019","40254354",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0007138","Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes.","Lebbar M","2021","Acta diabetologica","other","article","10.1007/s00592-021-01729-3","33954848",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007139","A beneficial role of GLP-1 receptor agonist therapy in ABCC8-MODY (MODY 12).","Nakhleh A","2023","Journal of diabetes and its complications","case_report","article","10.1016/j.jdiacomp.2023.108566","37536118",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0007140","Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.","Hofer F","2021","Cardiovascular drugs and therapy","nonrandomized_study","article","10.1007/s10557-021-07160-8","33666822",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007141","Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials.","Wachiraphansakul N","2024","PloS one","systematic_review","article","10.1371/journal.pone.0297488","38408098","PMC10896528","PROSPERO:CRD42023458228",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; research-article; review"],["R0007142","The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects-A Family Doctor Perspective.","Kurevija T","2024","Journal of clinical medicine","narrative_review","article","10.3390/jcm13061617","38541843","PMC10970784",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007143","Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.","Husain M","2022","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-022-01489-6","35484580","PMC9052629","ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0007144","Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.","Khan Z","2023","Cureus","systematic_review","article","10.7759/cureus.44314","37779743","PMC10536403",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007145","Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.","Taki Y","2025","Endocrine journal","case_report","article","10.1507/endocrj.ej24-0548","39842795","PMC11997266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; Review; case-report; article"],["R0007146","Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial.","Liao M","2024","Endocrine","randomized_trial","article","10.1007/s12020-023-03487-4","37653215","PMC10806039","ClinicalTrials.gov:NCT03151005","S001582","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0007147","Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis.","Meurot C","2022","Scientific reports","preclinical","article","10.1038/s41598-022-05323-7","35091584","PMC8799666",null,"S002286","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007148","Meta-Analysis of the Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Patients With Polycystic Ovary Syndrome.","Li L","2021","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000001418","34224428",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0007149","Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records.","Irons EE","2026","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2025.103749","41583363","PMC12830215",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007150","Causal relationship between novel antidiabetic drugs and ischemic stroke: a drug-targeted Mendelian randomization study.","Yu Z","2024","Frontiers in cardiovascular medicine","nonrandomized_study","article","10.3389/fcvm.2024.1449185","39380626","PMC11458414",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007151","Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide.","Tang CC","2024","Journal of clinical pharmacology","other","article","10.1002/jcph.2373","37853524",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007152","Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials.","Ahmad E","2023","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.15083","36905324",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0007153","Correlation between intestinal flora and GLP-1 receptor agonist dulaglutide in type 2 diabetes mellitus treatment-A preliminary longitudinal study.","Liang L","2024","iScience","other","article","10.1016/j.isci.2024.109784","38711446","PMC11070333",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007154","The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Lv X","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s443396","38371390","PMC10873148",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007155","Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future.","Kalra S","2016","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/2230-8210.176351","27042424","PMC4792029",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007156","Thyroid cancer and insulin resistance.","Brenta G","2024","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-023-09849-7","37957487",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007157","Expert Opinion on Diabetes Management Challenges and Role of Basal Insulin/GLP-1 RA Fixed-Ratio Combination in People with Type 2 Diabetes from Indonesia.","Suastika K","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","commentary","article","10.2147/dmso.s367153","36193540","PMC9526452",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0007158","Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Bae J","2025","Endocrinology and metabolism (Seoul, Korea)","systematic_review","article","10.3803/enm.2024.2120","39805574","PMC12061750",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0007159","Decoding incretin resistance: a mechanistic framework to reclassify therapeutic variability for GLP-1 receptor agonist therapy.","Fajkić A","2025","Amino acids","narrative_review","article","10.1007/s00726-025-03488-9","41236578","PMC12618332",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007160","Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov.","Alorfi NM","2023","Journal of multidisciplinary healthcare","narrative_review","article","10.2147/jmdh.s419245","37547806","PMC10402718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007161","SUN-602 Weight Loss After Glucagon-Like Peptide-1 Receptor Agonist Treatment in Childhood Obesity with Diabetes and Cirrhosis Associated with a Homozygous MC4R Mutation","Klee P","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.611",null,"PMC7208598",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0007162","Digital Microsteps as Scalable Adjuncts for Adults Using GLP-1 Receptor Agonists: A Randomized Clinical Trial.","Adam M","2026","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2026.0577","41801203","PMC12973101","ClinicalTrials.gov:NCT06967337","S002525","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0007163","Cardioprotective glucose-lowering drugs, statins, and risk of first-time atherosclerotic cardiovascular disease in Denmark: a nationwide cohort study.","Ternhamar T","2025","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2025.101490","41158416","PMC12557563",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007164","Genetic variants show link to patients losing more weight when taking Wegovy and Mounjaro.","Wise J","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.s693","41974493",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007165","Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.","Karagiannis T","2022","Diabetologia","systematic_review","article","10.1007/s00125-022-05715-4","35579691","PMC9112245","PROSPERO:CRD42021283449",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0007166","Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.","Lewis JE","2026","Nature metabolism","preclinical","article","10.1038/s42255-026-01575-z","42498824","PMC13489937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007167","GLP-1 medications: Use and Intention in a Representative Survey of Finns","Jallinoja P","2025","Research Square","other","preprint","10.21203/rs.3.rs-8016813/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0007168","The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.","Chan YH","2022","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-022-01549-x","35765074","PMC9241240",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0007169","Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.","Wisniewski B","2024","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2024.30.1.34","38153863","PMC10775775",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007170","Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.","Carneiro GRA","2026","Rapid communications in mass spectrometry : RCM","other","article","10.1002/rcm.70179","42745421","PMC13578828",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007171","ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia",null,"2022","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC9624564",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0007172","Longitudinal 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) Findings in Korsakoff Syndrome After Rapid Weight Loss During Tirzepatide Therapy: A Case Report.","Crelier VT","2026","Cureus","case_report","article","10.7759/cureus.110101","42395251","PMC13325681",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007173","Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization Study","Remala S","2025","medRxiv","other","preprint","10.1101/2025.07.15.25331531",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007174","Real-world effectiveness of tirzepatide among youth with type 2 diabetes and/or obesity: a multicenter analysis.","Valdez Y","2026","Journal of pediatric endocrinology & metabolism : JPEM","nonrandomized_study","article","10.1515/jpem-2026-0335","42576608",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0007175","Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization.","Yao YX","2025","Renal failure","systematic_review","article","10.1080/0886022x.2025.2478488","40230199","PMC12001840",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0007176","Optimising renal risk parameters in type 2 diabetes mellitus: Perspectives from a retinal viewpoint.","Jacob S","2024","Clinical medicine (London, England)","other","article","10.1016/j.clinme.2024.100031","38369127","PMC11091439",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0007177","Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus.","Vieira IH","2024","Biomedicines","nonrandomized_study","article","10.3390/biomedicines12051102","38791064","PMC11117787",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007178","GLP-1R associates with VAPB and SPHKAP at ERMCSs to regulate β-cell mitochondrial remodelling and function.","Austin G","2025","bioRxiv : the preprint server for biology","other","article","10.1101/2024.04.28.591531","40791518","PMC12338517",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0007179","Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.","Pérez-Belmonte LM","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.851035","35813629","PMC9263111",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0007180","Binding sites and design strategies for small molecule GLP-1R agonists.","Zhang H","2024","European journal of medicinal chemistry","narrative_review","article","10.1016/j.ejmech.2024.116632","38959726",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007181","Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice.","Díaz-Megido C","2023","Psychopharmacology","preclinical","article","10.1007/s00213-023-06367-x","37106129","PMC10172234",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007182","Metformin-Enhanced Digital Therapeutics for the Affordable Primary Prevention of Diabetes and Cardiovascular Diseases: Advancing Low-Cost Solutions for Lifestyle-Related Chronic Disorders.","Farley B","2025","Healthcare (Basel, Switzerland)","other","article","10.3390/healthcare13243220","41464289","PMC12732773",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0007183","Correction to: \"Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide\".",null,"2025","The Journal of clinical endocrinology and metabolism","notice","article","10.1210/clinem/dgaf387","40638456","PMC12539352",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0007184","Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review.","Karacabeyli D","2024","Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases","randomized_trial","article","10.1097/rhu.0000000000001949","36870080",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Scoping Review; article"],["R0007185","Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.","Pradhan R","2022","Diabetes care","nonrandomized_study","article","10.2337/dc21-1953","35104330",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0007186","Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.","Zhang YS","2018","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","systematic_review","article","10.1007/s00198-018-4649-8","30083774",null,"PROSPERO:CRD42018094433",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; review"],["R0007187","Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function.","Begic E","2021","Heart, lung & circulation","narrative_review","article","10.1016/j.hlc.2021.07.024","34479819",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007188","Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.","Guyton J","2019","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.1093/ajhp/zxz179","31612934",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007189","Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?","Lee B","2023","American journal of physiology. Cell physiology","narrative_review","article","10.1152/ajpcell.00147.2023","37273240",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0007190","End-stage renal diseases associated with SGLT2 inhibitors versus GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease.","Ko HY","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112921","40998218",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0007191","Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias.","Boulmpou A","2023","Acta cardiologica","systematic_review","article","10.1080/00015385.2022.2087839","35699112",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Review; review"],["R0007192","Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.","Khera R","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.05.069","39197980","PMC12045554",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; Multicenter Study; research-article; article"],["R0007193","GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients.","Pablo A","2021","Current hypertension reviews","other","article","10.2174/1573402116999201124123549","33238857",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007194","Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.","Xuan Y","2024","Renal failure","preclinical","article","10.1080/0886022x.2024.2351473","38915241","PMC11207906",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007195","Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.","Franchi M","2024","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2023-003991","38802266","PMC11131106",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0007196","Dronedarone hydrochloride reverses obesity-related metabolic syndrome while preserving skeletal muscle mass","Lei J","2026","bioRxiv","preclinical","preprint","10.64898/2026.07.20.739085",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007197","Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes.","Andraos J","2024","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-024-01406-6","38932889","PMC11196467",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0007198","Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.","Mody R","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14195","32945083","PMC7756843",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007199","Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies.","Ear PH","2025","Endocrine oncology (Bristol, England)","preclinical","article","10.1530/eo-25-0051","41312422","PMC12648204",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0007200","Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.","Mannucci E","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14888","36205446",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Journal Article; article"],["R0007201","evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.","Cummings JL","2025","Alzheimer's research & therapy","randomized_trial","article","10.1186/s13195-024-01666-7","39780249","PMC11708093","ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; research-article; article"],["R0007202","Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study.","Tesfaye H","2024","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-024-08793-9","38710868","PMC11282041",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Comparative Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0007203","Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes.","Skolnik N","2021","Advances in therapy","randomized_trial","article","10.1007/s12325-020-01614-5","33620694","PMC8004501",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0007204","Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis.","Kamiya M","2022","Journal of cachexia, sarcopenia and muscle","preclinical","article","10.1002/jcsm.13025","35775116","PMC9397554",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007205","Safety and cardiometabolic efficacy of novel antidiabetic drugs.","Michaud L","2023","Expert opinion on drug safety","randomized_trial","article","10.1080/14740338.2023.2188190","36877138",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Review; Journal Article; article"],["R0007206","The Effect of Fructose and FTO Gene Polymorphism on the Efficacy of GLP-1 and GIP Combination Therapies: A Narrative Review.","Larner DS","2026","Cureus","narrative_review","article","10.7759/cureus.110199","42403816","PMC13331727",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0007207","GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology.","De Fano M","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70888","42209267","PMC13341370",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007208","Redox-Driven Blood-Nerve Barrier Dysfunction in Diabetic Peripheral Neuropathy: The Peripheral Nerve Neurovascular Unit and Incretin-Based Therapeutic Opportunities","Huang W","2026","Preprints.org","other","preprint","10.20944/preprints202603.1003.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007209","Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization.","Shepard BD","2021","Seminars in nephrology","narrative_review","article","10.1016/j.semnephrol.2021.06.005","34715963",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; article"],["R0007210","An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review.","Bandyopadhyay S","2024","Hospital practice (1995)","nonrandomized_study","article","10.1080/21548331.2024.2412513","39356238",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0007211","Mind the Plateau: A Mathematical Modeling Analysis of Long-Term GLP-1 Receptor Agonist Treatment.","Hubert PA","2026","Journal of the Academy of Nutrition and Dietetics","other_trial","article","10.1016/j.jand.2026.156366","42055215",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0007212","A GLP-1 Receptor Agonist Inhibits Aldosterone Release in Healthy Volunteers.","Heinla K","2021","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","randomized_trial","article","10.1055/a-1498-7098","34154031",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0007213","Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.","Wallace H","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16608","40667713","PMC12409226",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007214","Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.","Frías JP","2024","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/clinem/dgad495","37602701","PMC10795909",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0007215","Collaboration to transition members to preferred formulary dipeptidyl-peptidase-4 inhibitor.","Ernst K","2025","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2025.89661","39847784",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007216","Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study.","Johnson H","2025","Journal of medical Internet research","nonrandomized_study","article","10.2196/69466","40164173","PMC11997532",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007217","Facial aging after GLP-1 receptor agonist-induced weight loss: the emerging Ozempic face phenomenon.","Kılıç S","2025","Journal of diabetes and metabolic disorders","commentary","article","10.1007/s40200-025-01778-3","41210112","PMC12592601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0007218","Semaglutide",null,"2006","National Institute of Child Health and Human Development, Bethesda (MD)","narrative_review","article",null,"30000039",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0007219","Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study.","Wu CY","2025","Alzheimer's research & therapy","nonrandomized_study","article","10.1186/s13195-025-01929-x","41420258","PMC12751920",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; other; article"],["R0007220","Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes.","Zannad F","2025","Journal of internal medicine","narrative_review","article","10.1111/joim.20050","39739537","PMC12033002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0007221","Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.","Piazza MJ","2025","JBRA assisted reproduction","narrative_review","article","10.5935/1518-0557.20250162","41165218","PMC12694975",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007222","Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.","Sebastian SA","2026","Disease-a-month : DM","systematic_review","article","10.1016/j.disamonth.2026.102099","41862384",null,"PROSPERO:CRD420251170117",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0007223","Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits.","Chandra KP","2026","Cureus","randomized_trial","article","10.7759/cureus.102866","41798487","PMC12961357",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0007224","Successful Implementation of a Multidisciplinary Weight Loss Program Including GLP1 Receptor Agonists for Liver Transplant Candidates With High Body Mass Index.","Gonzalez HC","2024","Transplantation","other","article","10.1097/tp.0000000000005070","39466197",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007225","Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors.","Vafeidou K","2025","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph18060807","40573204","PMC12195917",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007226","Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.","Klen J","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms23073451","35408810","PMC8998939",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007227","Development of an automated radiosynthesis for [68Ga]Ga-NODAGA[40Lys]-Exendin-4 in sodium acetate buffer.","Ragot M","2026","EJNMMI radiopharmacy and chemistry","other","article","10.1186/s41181-026-00452-0","42223859","PMC13437812",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0007228","Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.","Paik JM","2024","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2023.7660","38285598","PMC10825784",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; article"],["R0007229","Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis.","Hui EK","2025","Journal of Alzheimer's disease : JAD","systematic_review","article","10.1177/13872877251319054","40017057","PMC12231844",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review-article; review"],["R0007230","Crosstalk Between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger- 1 and 3 in Cardiometabolic Diseases","Al-Shamasi A","2024","Authorea Preprints","other","preprint","10.22541/au.170667104.47477358/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007231","Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study.","Tramunt B","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01327-8","36331712","PMC9663793",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007232","Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth.","Tanaka Y","2022","Diabetology international","preclinical","article","10.1007/s13340-021-00560-z","35693999","PMC9174406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007233","Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.","Kunutsor SK","2024","Journal of the Royal Society of Medicine","systematic_review","article","10.1177/01410768231198442","37734450","PMC11450921","PROSPERO:CRD42023401734",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; research-article; review"],["R0007234","Scalable hypothalamic neuron differentiation from human pluripotent stem cells suitable for modeling metabolic disorders.","Jovanovic VM","2026","Stem cell reports","other","article","10.1016/j.stemcr.2026.102958","42276059","PMC13385436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007235","Visceral Adiposity and Renal Health: From Pathophysiological Mechanisms to Novel Therapeutic Strategies.","Marques Vidas M","2026","Journal of clinical medicine","other_trial","article","10.3390/jcm15187201","42795973","PMC13607204",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007236","Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy.","Allocca S","2025","Healthcare (Basel, Switzerland)","narrative_review","article","10.3390/healthcare13121437","40565464","PMC12193533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007237","Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.","Wharton S","2026","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2607219","42820639",null,"ClinicalTrials.gov:NCT06066528","S002304","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0007238","Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.","Saxena AR","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15168","37311722",null,"ClinicalTrials.gov:NCT04617275","S001063","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007239","Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.","Blüher M","2024","Diabetologia","randomized_trial","article","10.1007/s00125-023-06053-9","38095657","PMC10844353","ClinicalTrials.gov:NCT04153929; EudraCT:2019-002390-60","S000172","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007240","Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.","Lau DCW","2022","Expert review of clinical pharmacology","other","article","10.1080/17512433.2022.2070473","35466848",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007241","Septal GLP-1 receptors control alcohol taking and seeking.","D'Ottavio G","2026","Neuron","preclinical","article","10.1016/j.neuron.2026.05.006","42385677",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0007242","Effectiveness of Oral Versus Injectable Semaglutide in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia","Klobučar S","2023","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202309.0030.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0007243","Critical Evaluation of \"GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis\".","Bibi Z","2025","Clinical cardiology","systematic_review","article","10.1002/clc.70249","41450071","PMC12741511",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; review"],["R0007244","Study protocol for the investigator-initiated Danish pragmatic randomised STENO INTEN-CT trial: does screening and intervention for subclinical coronary artery disease in type 2 diabetes reduce cardiovascular events?","Funck KL","2025","BMJ open","protocol","article","10.1136/bmjopen-2025-106018","41401988","PMC12706207","ClinicalTrials.gov:NCT05700877","S000808","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0007245","Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes.","Kuhadiya ND","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13609","30536789",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007246","The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy.","Liu JS","2023","Medicine","other_trial","article","10.1097/md.0000000000033167","36897731","PMC9997828",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007247","Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression.","Detka J","2021","Pharmacological reports : PR","narrative_review","article","10.1007/s43440-021-00274-8","34003475","PMC8413152",null,"S000532","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007248","GLP-1 RA semaglutide for alcohol use disorder: a potential multi-target therapy.","Maimone S","2026","Acta diabetologica","commentary","article","10.1007/s00592-026-02708-2","42142149",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0007249","Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program.","Devineni D","2024","Cardiovascular drugs and therapy","nonrandomized_study","article","10.1007/s10557-022-07403-2","36378394","PMC10959811",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007250","Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis.","Cignarelli A","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.846903","35265043","PMC8899086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007251","Warfarin pharmacokinetics and pharmacodynamics are not affected by concomitant administration of the long-acting GLP-1 receptor agonist polyethylene glycol loxenatide.","Zhou H","2025","International journal of clinical pharmacology and therapeutics","other_trial","article","10.5414/cp204510","39607179",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0007252","Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.","Xu L","2022","Primary care diabetes","systematic_review","article","10.1016/j.pcd.2021.11.006","34953749",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0007253","Semaglutide in patients with hidradenitis suppurativa and obesity.","Nicolau J","2026","Medicina clinica","nonrandomized_study","article","10.1016/j.medcli.2026.107405","41832804",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007254","Incretin-based therapy and atrial fibrillation risk in overweight or obesity.","Karakasis P","2026","Metabolism: clinical and experimental","commentary","article","10.1016/j.metabol.2025.156491","41478557",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0007255","Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management.","Elangovan H","2026","Clinical and molecular hepatology","narrative_review","article","10.3350/cmh.2025.0857","41146519","PMC12835728",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007256","Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.","An XD","2025","World journal of diabetes","systematic_review","article","10.4239/wjd.v16.i10.110174","41113488","PMC12531691",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0007257","Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity.","Klein KR","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01562-1","38536629","PMC11043305",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007258","GLP-1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms.","Rutigliani G","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.70148","42083883","PMC13655938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007259","Liraglutide Protects Pancreatic Islet From Ischemic Injury by Reducing Oxidative Stress and Activating Akt Signaling During Cold Preservation to Improve Islet Transplantation Outcomes.","Cai X","2024","Transplantation","preclinical","article","10.1097/tp.0000000000004949","38578708",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007260","Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes.","Watchorn D","2021","American journal of respiratory and critical care medicine","commentary","article","10.1164/rccm.202011-4162le","33508209","PMC8017582",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0007261","Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility.","Zhang X","2026","Nature and science of sleep","randomized_trial","article","10.2147/nss.s611573","42591103","PMC13461384",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0007262","Oral Treatment of Obesity by GLP-1 and Its Analogs.","Holler N","2025","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics17121596","41471111","PMC12736778",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007263","Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.","Blonde L","2019","Diabetes care","randomized_trial","article","10.2337/dc19-1357","31530665",null,"ClinicalTrials.gov:NCT02787551","S001125","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0007264","Glucagon-Like Peptide-1 Signaling in Learning and Memory: Evidence, Mechanisms, and Therapeutic Implications.","Bashaw AG","2026","Biological psychiatry","preclinical","article","10.1016/j.biopsych.2026.06.006","42320781","PMC13587819",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0007265","Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:real-world evidence from a Mediterranean area.","Mata-Cases M","2019","Current medical research and opinion","randomized_trial","article","10.1080/03007995.2019.1618806","31081693",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007266","Mood Disorders, Metabolic Bariatric Surgery, and Weight Loss Pharmacotherapy: a Research Update.","Barbuti M","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00674-4","41313528",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007267","Semaglutide Enhances Cellular Regeneration in Skin and Retinal Cells In Vitro.","Anastasiou IA","2025","Pharmaceutics","preclinical","article","10.3390/pharmaceutics17091115","41012453","PMC12473120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007268","Obesity and heart failure-the role of GLP-1 receptor agonists.","Simonis G","2025","Herz","narrative_review","article","10.1007/s00059-025-05312-2","40172656",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007269","Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Glaucoma in Patients With Type 2 Diabetes: A Target Trial Emulation.","Eng K","2025","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2024.10.029","39515454",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study; Multicenter Study"],["R0007270","GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis.","Amaral DC","2025","American journal of ophthalmology","systematic_review","article","10.1016/j.ajo.2024.12.024","39732312",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007271","Renal protection with glucagon-like peptide-1 receptor agonists.","Vitale M","2020","Current opinion in pharmacology","other_trial","article","10.1016/j.coph.2020.08.018","33027748",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; review"],["R0007272","GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI.","Xu L","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1355540","38559688","PMC10978586",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007273","Semaglutide-eye-catching results.","Cigrovski Berkovic M","2023","World journal of diabetes","other_trial","article","10.4239/wjd.v14.i4.424","37122431","PMC10130900",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007274","Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study","Simonsen E","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.12.09.24318574",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0007275","Incretin-Based Therapies: Cardiovascular Benefit With and Beyond Weight Loss.","Bozkurt B","2025","JACC. Heart failure","commentary","article","10.1016/j.jchf.2025.102631","40908081",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0007276","Effects of Blood-Glucose Lowering Therapies on Body Composition and Muscle Outcomes in Type 2 Diabetes: A Narrative Review.","Bujdei-Tebeică I","2025","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina61081399","40870444","PMC12387884",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0007277","EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.","Mora PF","2019","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep-2018-0615","31241362",null,"ClinicalTrials.gov:NCT02058160; ClinicalTrials.gov:NCT02058147","S001199; S001409","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0007278","Game changers: do new medications make lifestyle-based treatment of obesity obsolete?","Lewis KH","2024","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.23962","38044481",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007279","Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database.","Cabral Lopes A","2023","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2023.2172159","36695099",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0007280","Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease.","Alicic RZ","2023","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000000894","37195250","PMC10241427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; research-article; article"],["R0007281","Injectable thermosensitive hydrogel-based sustained delivery system for anti-diabetic peptides in type 2 diabetes mellitus therapy: A review.","Vu LQ","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2026.119249","41875502",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007282","Medical Treatments for Obesity: What Does the Future Have in Store?","Bassatne A","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag274","42444567",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007283","evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease","Cummings JL","2024","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-5043179/v1",null,null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0007284","Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.","Deng M","2023","BMC medicine","systematic_review","article","10.1186/s12916-023-03129-6","37974258","PMC10655371","PROSPERO:CRD42022342373",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; research-article; review"],["R0007285","Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.","Kim HJ","2017","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2017.41.6.423","29272081","PMC5741550",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0007286","Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression.","Marassi M","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","systematic_review","article","10.1016/j.numecd.2026.104714","41997798",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; article"],["R0007287","Food noise: A theoretical review.","Wylie F","2026","Appetite","narrative_review","article","10.1016/j.appet.2026.108791","42772688",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007288","Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia.","Siskind D","2025","The lancet. Psychiatry","randomized_trial","article","10.1016/s2215-0366(25)00129-4","40506208",null,"ANZCTR:ACTRN12621001539820",null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; article"],["R0007289","Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease.","Kazi MAI","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14248882","41464784","PMC12733479",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007290","Sex Differences in [ 68Ga]Ga-NODAGA-Exendin-4 Uptake in the Pituitary of Individuals With Type 2 Diabetes.","Tokgöz S","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70600","41766452","PMC13071207","ClinicalTrials.gov:NCT03923114; ClinicalTrials.gov:NCT03182231; ClinicalTrials.gov:NCT05418907","S000130; S001350; S001829","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0007291","The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.","Thomas L","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15551","38560764",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007292","Trends in antidiabetes medication use among hospitalised patients with type 2 diabetes: a retrospective single-centre cohort study.","Meier N","2024","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2024-084526","38950998","PMC11328642",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007293","Multi-modal neo-adjuvant anti-obesity medications may be more effective than medically supervised weight loss or GLP-1 therapy alone in preparing BMI≥70 patients for metabolic surgery.","Kachmar M","2025","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-025-01798-2","40456879","PMC12396963",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007294","Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis.","Malandris K","2023","Hormones (Athens, Greece)","systematic_review","article","10.1007/s42000-023-00493-z","37770761","PMC10651545",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; research-article; review"],["R0007295","[Consensus recommendations on utilizing glucagon-like peptide-1(GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus].","Chinese Society of Endocrinology","2020","Zhonghua nei ke za zhi","other","article","10.3760/cma.j.cn112138-20200704-00646","33120487",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Consensus Statement; article"],["R0007296","Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.","Tang EHM","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.109071","34592391",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007297","Use of Tirzepatide in the Management of Obesity and Overweight: Feasibility Analysis for Incorporation into the Public Health System of Mato Grosso, Brazil","Pereira P","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-9180565/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0007298","Fixing the food environment: beyond weight-loss drugs.","Pineda E","2026","Public health nutrition","commentary","article","10.1017/s1368980026101839","41645430","PMC12979011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0007299","Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and SGLT2 Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature.","Malik M","2026","Clinical case reports","case_report","article","10.1002/ccr3.71929","41584389","PMC12827052",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0007300","GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD.","Levine I","2025","Inflammatory bowel diseases","other","article","10.1093/ibd/izae250","39438251","PMC12476976",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0007301","Prescribing of evidence-based diabetes pharmacotherapy in patients with metabolic dysfunction-associated steatohepatitis.","Alexopoulos AS","2023","BMJ open diabetes research & care","other","article","10.1136/bmjdrc-2023-003763","38030391","PMC10689360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007302","Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.","Mantsiou C","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14108","32476254",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007303","Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy.","Van Dril E","2022","American heart journal plus : cardiology research and practice","other","article","10.1016/j.ahjo.2022.100163","38559880","PMC10978364",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007304","Danuglipron Ameliorates Pressure Overload-Induced Cardiac Remodelling Through the AMPK Pathway.","Wang P","2025","Journal of cellular and molecular medicine","preclinical","article","10.1111/jcmm.70488","40070049","PMC11897056",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007305","Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues","Douros JD","2025","bioRxiv","preclinical","preprint","10.1101/2025.04.01.646483",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007306","Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy.","Dauner DG","2021","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2021.1887136","33554677",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0007307","Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.","Gallwitz B","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.645507","34267725","PMC8276717",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0007308","Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.","Harris S","2020","Drugs","nonrandomized_study","article","10.1007/s40265-019-01245-3","31960258","PMC7007423",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007309","Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.","Xue X","2016","International journal of clinical practice","systematic_review","article","10.1111/ijcp.12847","27456750",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Comparative Study; Journal Article; Systematic Review; article"],["R0007310","Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.","Igweokpala S","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15367","38031234",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0007311","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis.","Jianping W","2021","Journal of clinical gastroenterology","systematic_review","article","10.1097/mcg.0000000000001556","34039937",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0007312","Mediterranean diet adherence and tirzepatide: real-world evidence on adiposity indices and insulin resistance beyond weight loss.","Paternò V","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1700894","41613958","PMC12846957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007313","Evidence of metabolic memory-induced neurodegeneration and the therapeutic effects of glucagon-like peptide-1 receptor agonists via Forkhead box class O.","Chen S","2019","Biochimica et biophysica acta. Molecular basis of disease","preclinical","article","10.1016/j.bbadis.2018.11.012","30465895",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007314","Role of GLP‑1 receptor agonists in sepsis and their therapeutic potential in sepsis‑induced muscle atrophy (Review).","Zhao X","2025","International journal of molecular medicine","narrative_review","article","10.3892/ijmm.2025.5515","40052580","PMC11936484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007315","2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults.","Mancini GBJ","2022","The Canadian journal of cardiology","other_trial","article","10.1016/j.cjca.2022.04.029","35961754",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Practice Guideline; article"],["R0007316","Semaglutide for the treatment of obesity.","Chao AM","2023","Trends in cardiovascular medicine","narrative_review","article","10.1016/j.tcm.2021.12.008","34942372","PMC9209591",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; research-article; article"],["R0007317","Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.","Wretlind A","2023","Lipids in health and disease","randomized_trial","article","10.1186/s12944-023-01922-z","37752566","PMC10521385","ClinicalTrials.gov:NCT02545738; ClinicalTrials.gov:NCT03449654","S001417; S001895","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0007318","Liraglutide Preserves CD34 + Stem Cells from Dysfunction Induced by High Glucose Exposure","Sforza A","2021","Research Square","other","preprint","10.21203/rs.3.rs-1093380/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007319","Loxenatide attenuates ROS-mediated vascular endothelial progenitor cell damage and mitochondrial dysfunction via SIRT3/Foxo3 signaling pathway.","Yuan J","2023","Journal of biochemical and molecular toxicology","other","article","10.1002/jbt.23452","37417536",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007320","Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.","Gu X","2024","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-023-01251-2","38212831","PMC10782753",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; other; review"],["R0007321","A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.","Fu EL","2024","Kidney international","nonrandomized_study","article","10.1016/j.kint.2023.11.025","38101515","PMC10922914",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0007322","Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.","Tsai HR","2024","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.3739","37862117",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; article"],["R0007323","Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.","Overgaard RV","2021","Cell reports. Medicine","other_trial","article","10.1016/j.xcrm.2021.100387","34622228","PMC8484505",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007324","Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.","Chen KY","2026","Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)","systematic_review","article","10.1016/j.apjo.2025.100245","40962119",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0007325","Recent developments in adjunct therapies for type 1 diabetes.","Timmons JG","2022","Expert opinion on investigational drugs","narrative_review","article","10.1080/13543784.2022.2159806","36655950",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; article"],["R0007326","The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-α Expression in Macrophages.","Shen WR","2018","Journal of immunology research","preclinical","article","10.1155/2018/5783639","29725604","PMC5872659",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007327","Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.","He K","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71218","42764407",null,"ClinicalTrials.gov:NCT05152277","S000819","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0007328","Refining the Bariatric Journey: A Proposed Neoadjuvant and Adjuvant Framework for GLP-1 Receptor Agonists Inspired by Oncology.","Song K","2026","Current obesity reports","randomized_trial","article","10.1007/s13679-026-00726-3","42274840",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0007329","Federated target trial emulation for time-to-event outcomes via POLARIS: Pooled-equivalent One-shot Likelihood Aggregation for Real-world Inference in Survival.","Wang T","2026","Research square","nonrandomized_study","article","10.21203/rs.3.rs-9613167/v1","42239773","PMC13228815",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Preprint"],["R0007330","Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.","Cai TT","2021","BioMed research international","randomized_trial","article","10.1155/2021/3361309","34580638","PMC8464416","ClinicalTrials.gov:NCT01648582","S001404","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0007331","A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: 2026 Update","Ciudin A","2026","medRxiv","systematic_review","preprint","10.64898/2026.04.19.26351196",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","3","FALSE","Preprint; preprint"],["R0007332","Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment.","Edwards K","2023","Therapeutic advances in endocrinology and metabolism","nonrandomized_study","article","10.1177/20420188231180987","37440840","PMC10334016",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007333","The roles of exercise stress echocardiography for the evaluation of heart failure with preserved ejection fraction in the heart failure pandemic era.","Yuasa N","2024","Journal of medical ultrasonics (2001)","narrative_review","article","10.1007/s10396-024-01468-2","38926301","PMC11923037",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007334","Plasma Proteomic Analysis of APOE ε4 Homozygotes Identifies Preclinical Alzheimer's Disease Alterations Potentially Treatable with Semaglutide.","Dammer EB","2026","medRxiv : the preprint server for health sciences","other","article","10.64898/2026.02.14.26346321","41757216","PMC12934836",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0007335","Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.","Guo L","2026","Nature","randomized_trial","article","10.1038/s41586-025-10031-z","41407860",null,"ClinicalTrials.gov:NCT05606913","S000578; S001537","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0007336","Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists.","Song E","2026","Frontiers in nutrition","randomized_trial","article","10.3389/fnut.2026.1809416","42311951","PMC13269364",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0007337","GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.","Giugliano D","2021","Cardiovascular diabetology","commentary","article","10.1186/s12933-021-01400-9","34641876","PMC8513211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0007338","Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States.","Nargesi AA","2023","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2023.03.002","37012183","PMC11007258",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0007339","Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure.","Sforza A","2022","Cardiovascular diabetology","other","article","10.1186/s12933-022-01486-9","35397526","PMC8994898",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0007340","Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.","Prattichizzo F","2019","European journal of preventive cardiology","other_trial","article","10.1177/2047487319880040","31766918",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0007341","In vivo mapping of hemodynamic responses mediated by tubuloglomerular feedback in hypertensive kidneys.","Lee B","2023","Scientific reports","preclinical","article","10.1038/s41598-023-49327-3","38081921","PMC10713540",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007342","Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.","Kassem S","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71293","42736522","PMC13588235",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0007343","The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment.","Sun H","2025","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2025.1525623","40134421","PMC11932860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007344","GLP-1 Receptor Agonist Use Among Adults With Diabetes and Cancer History.","Linares-Perdomo O","2026","JAMA network open","other","article","10.1001/jamanetworkopen.2026.37813","42842252","PMC13647141",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007345","Pattern of Antidiabetic Drug Prescription in Older Persons With Type 2 Diabetes: Results From the German DPV Registry.","Zeyfang A","2025","Journal of the American Medical Directors Association","nonrandomized_study","article","10.1016/j.jamda.2025.105724","40553729",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study; Research Support, Non-U.S. Gov't"],["R0007346","Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets.","Im S","2026","Pharmaceutics","preclinical","article","10.3390/pharmaceutics18070826","42514904","PMC13415043",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007347","Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction.","Li Q","2024","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.13517","38173120","PMC11212302",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0007348","The Gut-Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications.","Menozzi E","2025","Movement disorders clinical practice","narrative_review","article","10.1002/mdc3.70029","40079755","PMC12275011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007349","Incretin-Based Therapies and Heart Failure Outcomes: Benefit Beyond Weight Loss?","Savarese G","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2025.07.022","40903132",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0007350","Knowledge, Attitudes, and Practices of Libyan Healthcare Providers Regarding GLP-1 RA FDA Safety Warnings","Alsherif E","2025","Research Square","other","preprint","10.21203/rs.3.rs-7410889/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007351","Reply: The ethics of Ozempic and Wegovy.","Ryan N","2026","Journal of medical ethics","commentary","article","10.1136/jme-2025-111420","41083199",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter"],["R0007352","Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression.","Wang N","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25063086","38542060","PMC10970506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007353","Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis.","Qiu M","2020","Medicine","systematic_review","article","10.1097/md.0000000000023489","33285754","PMC7717767",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; review-article; article"],["R0007354","Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.","Maruyama F","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70734","41944182",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0007355","[Weight reduction with incretin mimetics-Opportunities and risks].","Zech TJ","2025","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-025-01918-0","40514554",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0007356","Effectiveness and use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease.","Tian JQ","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1637035","41030848","PMC12477034",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0007357","Cost-utility analysis of loxenatide versus DPP-4 inhibitors in Chinese patients with type 2 diabetes at high cardiovascular risk.","Lai L","2026","Frontiers in public health","other","article","10.3389/fpubh.2026.1929706","42729196","PMC13561895",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0007358","Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.","Chubb B","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-021-01034-w","33723769","PMC8099977",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0007359","From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists.","Dave BP","2024","Molecular biology reports","nonrandomized_study","article","10.1007/s11033-024-09793-y","39042283",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0007360","The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study.","Ozeki Y","2022","Medicines (Basel, Switzerland)","other","article","10.3390/medicines9090047","36135828","PMC9502467",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007361","Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.","Fitch A","2021","Postgraduate medicine","systematic_review","article","10.1080/00325481.2020.1845534","33151791",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0007362","GLP-1 receptor agonists in atherosclerotic cardiovascular disease and diabetes mellitus or obesity: investigation of the potential role in a German inpatient dataset.","Oettinger V","2026","Clinical research in cardiology : official journal of the German Cardiac Society","nonrandomized_study","article","10.1007/s00392-025-02735-z","40839017","PMC13346366",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007363","Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.","Bi Y","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-024-01561-2","38494574","PMC11043231","ClinicalTrials.gov:NCT04093752","S000909","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007364","Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.","Wright EE","2020","Postgraduate medicine","narrative_review","article","10.1080/00325481.2020.1798127","32815423",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Video-Audio Media; article"],["R0007365","SAT-528 Real-world Treatment Patterns Of Tirzepatide Versus Semaglutide In GLP-1 RA-naive Patients With T2D",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12544560",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0007366","Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.","Lunati ME","2024","Pharmacological research","nonrandomized_study","article","10.1016/j.phrs.2023.107040","38128857",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Journal Article; article"],["R0007367","Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.","Guan R","2022","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2022.998816","36313305","PMC9613929",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; article"],["R0007368","Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation.","Ertuglu LA","2021","Transplant international : official journal of the European Society for Organ Transplantation","randomized_trial","article","10.1111/tri.13883","33880815",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0007369","Tirzepatide for adults living with obesity.","Franco JV","2025","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd016018","41161687","PMC12571520","PROSPERO:CRD420250654193",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0007370","SAT-529 Real-world Treatment Patterns Of Tirzepatide Versus Semaglutide In GLP-1 RA-experienced Patients With T2D",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12544543",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0007371","GLP-1RA in JBMMSCs promoted osteogenic differentiation via modulating CREB and BRD4 signaling mediated proliferation and stemness.","Liu H","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-24633-0","41258401","PMC12630770",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007372","Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.","Bliddal H","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2403664","39476339",null,"ClinicalTrials.gov:NCT05064735","S000353; S000629","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; article"],["R0007373","Euglycemic Diabetic Ketoacidosis in the Setting of Dulaglutide Use.","Patel N","2025","Cureus","case_report","article","10.7759/cureus.82143","40357083","PMC12068660",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007374","Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?","Li Y","2018","Current cardiology reports","other_trial","article","10.1007/s11886-018-1051-2","30259238",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0007375","IcoSema and the evolution of fixed-ratio insulin-GLP-1 receptor agonist therapies.","Umpierrez G","2025","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(25)00162-7","40482672",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007376","New Long-Acting [89Zr]Zr-DFO GLP-1 PET Tracers with Increased Molar Activity and Reduced Kidney Accumulation.","Wilbs J","2023","Journal of medicinal chemistry","other","article","10.1021/acs.jmedchem.2c02073","36995126","PMC10292199",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007377","De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes.","Falcetta P","2023","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-022-01974-0","36166172",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007378","New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide","Al-Nusair M","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.09.21.26363546",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0007379","Novel neural pathways targeted by GLP-1R agonists and bariatric surgery.","Hankir MK","2025","Pflugers Archiv : European journal of physiology","narrative_review","article","10.1007/s00424-024-03047-3","39644359","PMC11761532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0007380","Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review.","Mady R","2026","Cureus","notice","article","10.7759/cureus.c457","42388932","PMC13319495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; Journal Article; correction; review"],["R0007381","Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.","Tuttle KR","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04674-2","42823485",null,"ClinicalTrials.gov:NCT04865770","S000395","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0007382","Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials.","Rosenstock J","2023","Diabetes care","other_trial","article","10.2337/dc23-0872","37673061","PMC10620542",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article; other"],["R0007383","Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.","Gras C","2025","European journal of clinical nutrition","nonrandomized_study","article","10.1038/s41430-025-01653-7","40908328",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Case Reports; article"],["R0007384","A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.","Baxter M","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00836-8","32445125","PMC7324466",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007385","SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review.","Caturano A","2025","Journal of clinical medicine","randomized_trial","article","10.3390/jcm14155549","40807170","PMC12347938",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0007386","Association Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use and Blood Pressure Levels in Nondiabetic Obese Adults: A Cross-Sectional Analysis.","Odoeke MC","2026","Cureus","other","article","10.7759/cureus.108646","42281713","PMC13251654",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007387","Antidiabetic Molecule Efficacy in Patients with Type 2 Diabetes Mellitus-A Real-Life Clinical Practice Study.","Salmen T","2023","Biomedicines","nonrandomized_study","article","10.3390/biomedicines11092455","37760896","PMC10525559",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007388","Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases.","Sun Y","2025","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2025.103186","39793280",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0007389","Protocol for a randomised, double-blinded, controlled trial of youth with childhood-onset obesity treated with semaglutide 2.4 mg/week: the RESETTLE trial.","Byberg S","2024","BMJ open","protocol","article","10.1136/bmjopen-2023-082446","39551589","PMC11574404","EudraCT:2019-002274-31","S001692","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; Research Support, Non-U.S. Gov't; research-article; article"],["R0007390","Therapeutic Function of Liraglutide for Mitigation of Blast-Induced Hearing Damage: An Initial Investigation in Animal Model of Chinchilla.","Jiang S","2024","Military medicine","preclinical","article","10.1093/milmed/usae142","39160824",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0007391","Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.","Lisco G","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.920541","36157450","PMC9494570",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; systematic-review; article"],["R0007392","Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies.","Jensterle M","2025","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2025.2554668","40888044",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Editorial; editorial"],["R0007393","Exendin-4, a GLP-1 receptor agonist, suppresses diabetic retinopathy in vivo and in vitro.","Liu J","2025","Archives of physiology and biochemistry","preclinical","article","10.1080/13813455.2023.2274279","37920998",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007394","Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes.","Uchiyama S","2023","Journal of clinical medicine research","nonrandomized_study","article","10.14740/jocmr4987","37575352","PMC10416191",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007395","Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.","Al Lawati A","2025","Diseases (Basel, Switzerland)","narrative_review","article","10.3390/diseases13050129","40422561","PMC12110573",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0007396","Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.","Scheen AJ","2017","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2017.03.009","28402902",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0007397","Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist In Patients with Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study.","Azzam AY","2024","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2024.11.12.24317193","39677436","PMC11643283",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0007398","An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents.","Edvardsson CE","2025","EBioMedicine","preclinical","article","10.1016/j.ebiom.2025.105684","40245495","PMC12044336",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007399","Beyond Weight Loss: Holistic Impacts of a Digital Weight Management Programme Integrating Tirzepatide.","Sikorska LM","2026","Cureus","nonrandomized_study","article","10.7759/cureus.102817","41788104","PMC12958089",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007400","Prescribing Trajectories in Type 2 Diabetes in the United States, 2019-2024.","Lux TS","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71013","42310901","PMC13448853",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007401","Evaluating video capsule endoscopy in diabetes mellitus: transit times, preparation adequacy, and the influence of insulin and GLP-1 receptor agonist use.","Akerman N","2025","Therapeutic advances in gastrointestinal endoscopy","nonrandomized_study","article","10.1177/26317745251359459","40777749","PMC12329204",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007402","Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center.","Robalino Gonzaga E","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13185403","39336890","PMC11432687",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007403","Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial.","Butt JH","2026","European heart journal","randomized_trial","article","10.1093/eurheartj/ehaf635","40888808",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0007404","Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.","Klausen MK","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)00305-3","42070571",null,"ClinicalTrials.gov:NCT05895643","S002359","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; article"],["R0007405","Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.","Wadden TA","2023","Nature medicine","randomized_trial","article","10.1038/s41591-023-02597-w","37840095","PMC10667099","ClinicalTrials.gov:NCT04657016","S001026; S001795; S002157","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007406","Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.","Corley MJ","2026","Nature communications","randomized_trial","article","10.1038/s41467-026-72861-3","42156721","PMC13381876","ClinicalTrials.gov:NCT04019197","S001425","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0007407","Optimizing GLP-1R Agonist: A Computational Semaglutide Analogue with 112-fold Enhanced Binding Affinity to GLP-1R","Li W","2024","Preprints.org","other","preprint","10.20944/preprints202406.1032.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007408","LBSUN206 Provider Prescribing Habits And Use Of Newer Agents For Type 2 Diabetes In A Large Multicenter Health Care System",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9624648",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0007409","Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study.","Prado BS","2026","Annals of the American Thoracic Society","nonrandomized_study","article","10.1093/annalsats/aaoaf071","41915565",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007410","The glucagon-like peptide-1 receptor agonist, exendin-4, reduces sexual interaction behaviors in a brain site-specific manner in sexually naïve male mice.","Vestlund J","2020","Hormones and behavior","preclinical","article","10.1016/j.yhbeh.2020.104778","32450068",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007411","Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.","Fadini GP","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15554","38477183",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; Comparative Study; article"],["R0007412","Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India.","RoyChaudhuri S","2023","Cureus","nonrandomized_study","article","10.7759/cureus.40179","37431351","PMC10329815",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007413","Patient Knowledge of GLP-1 Receptor Agonists for Obesity and Exploration of Potential Household-Level Effects in an Urban Health System.","Schumacher LM","2026","Obesity science & practice","other","article","10.1002/osp4.70199","42851870","PMC13646696",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007414","GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015.","Gallwitz B","2015","European endocrinology","narrative_review","article","10.17925/ee.2015.11.01.21","29632562","PMC5819057",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007415","Prescribing Trends of Glucose-Lowering Medications Near End of Life Among Adults With Type 2 Diabetes: A Cohort Study.","Kutz A","2025","Diabetes care","nonrandomized_study","article","10.2337/dc24-1795","39746144","PMC11870286",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0007416","Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.","Monami M","2017","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12926","28244632",null,null,"S000313; S002474","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0007417","The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.","Heimbürger SM","2019","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2019.1571040","30730773",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0007418","Efficacy and safety of GLP1-ras compared to SGLT2is and DPP-4is in individuals with schizophrenia and diabetes: A Danish nationwide target-trial emulation study.","Jacobsen SL","2025","Psychiatry research","nonrandomized_study","article","10.1016/j.psychres.2025.116592","40526989",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; article"],["R0007419","Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.","Jungnik A","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14948","36527386",null,"ClinicalTrials.gov:NCT03175211; ClinicalTrials.gov:NCT03591718","S000226; S000327","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007420","Probable tirzepatide-associated limbic encephalitis with status epilepticus in a patient with extreme obesity: a case report.","Mazzeo A","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","case_report","article","10.1007/s10072-026-08977-7","41882230",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0007421","Treatment of acromegaly-induced diabetes: an updated proposal.","Biagetti B","2024","Pituitary","narrative_review","article","10.1007/s11102-024-01477-x","39738706",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007422","Efficacy of 12-week treatment with polyethylene glycol loxenatide in obesity or overweight patients with type 2 diabetes: a multicenter, prospective cohort study based on the flash glucose monitoring system.","Zhu L","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1810786","42238245","PMC13226117","ClinicalTrials.gov:NCT05611684",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Clinical Trial; research-article; article"],["R0007423","Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism.","Zou S","2023","Cureus","case_report","article","10.7759/cureus.33384","36751230","PMC9898871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007424","Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study.","Bepo L","2024","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-024-08961-x","39085578","PMC11576692",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0007425","Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.","Courtney H","2017","Diabetes, metabolic syndrome and obesity : targets and therapy","other_trial","article","10.2147/dmso.s126763","28331351","PMC5357070",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007426","Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?","Colin IM","2022","TouchREVIEWS in endocrinology","other_trial","article","10.17925/ee.2022.18.1.35","35949360","PMC9354513",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007427","The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes.","Sivalingam S","2021","Scientific reports","randomized_trial","article","10.1038/s41598-021-90191-w","34012064","PMC8134438",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0007428","MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.","Perez FA","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14366","33651438","PMC8353597",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0007429","Glucagon-Like Peptide-1 Agonists: A Practical Overview for Plastic and Reconstructive Surgeons.","Stanton EW","2025","Annals of plastic surgery","narrative_review","article","10.1097/sap.0000000000004089","39293069",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0007430","Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy.","Sacre JW","2022","Diabetes care","other_trial","article","10.2337/dc21-1929","35775451",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0007431","Effect of different hypoglycemic drugs and insulin on the risk of new-onset atrial fibrillation in people with diabetes: a network meta-analysis.","Lv Q","2024","European journal of medical research","systematic_review","article","10.1186/s40001-024-01954-w","39085898","PMC11290211",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; article"],["R0007432","Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.","Zhu D","2026","Nature communications","randomized_trial","article","10.1038/s41467-025-68165-7","41501026","PMC12881390","ClinicalTrials.gov:NCT05680155","S001967","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; research-article; article"],["R0007433","Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review.","Ali M","2025","The primary care companion for CNS disorders","narrative_review","article","10.4088/pcc.24nr03828","40505607",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Scoping Review; article"],["R0007434","[Use of antidiabetic medications in the course of bariatric/metabolic surgery].","Scheen AJ","2023","Revue medicale suisse","other","article","10.53738/revmed.2023.19.838.1492","37610192",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0007435","Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.","Shaefer CF","2016","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/diaclin.34.2.81","27092017","PMC4833487",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007436","The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies.","Song ZH","2024","Therapeutic innovation & regulatory science","systematic_review","article","10.1007/s43441-024-00633-6","38683419",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't"],["R0007437","Perspectives in weight control in diabetes - Survodutide.","Klein T","2024","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2023.110779","37330144",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0007438","Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.","Sandsdal RM","2023","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-023-01765-z","36841762","PMC9960425","ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32","S000067; S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0007439","Pharmacokinetic Study of SKL-18287, a Novel Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, in Rats, Monkeys and Mini-Pigs.","Takeuchi M","2019","Drug research","preclinical","article","10.1055/a-0885-1429","31083740",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007440","Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.","Shah T","2026","Headache","case_report","article","10.1111/head.70152","42403198","PMC13571063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; brief-report; article"],["R0007441","Contemporary Management of Obesity: A Comparison of Bariatric Metabolic Surgery and Novel Incretin Mimetic Drugs.","Singh A","2024","Diabetes technology & therapeutics","narrative_review","article","10.1089/dia.2024.0122","38669473",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007442","Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Moiz A","2024","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2024.04.041","38679221",null,null,"S002092","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0007443","High-yield, standardised automated radiosynthesis process for routine clinical insulinoma PET with [⁶⁸Ga]Ga-NODAGA-exendin-4.","Duray E","2026","EJNMMI radiopharmacy and chemistry","other","article","10.1186/s41181-026-00470-y","42380410","PMC13373115",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0007444","Possible Mechanisms and Molecular Signaling of Incretins against the Development of Type 2 Diabetes Mellitus.","Salami R","2023","Current molecular pharmacology","narrative_review","article","10.2174/1874467215666220829102020","36043753",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Review; Journal Article"],["R0007445","Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study.","Ojeda-Fernández L","2026","Clinical research in cardiology : official journal of the German Cardiac Society","randomized_trial","article","10.1007/s00392-025-02674-9","40358690",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0007446","Severe Gastrointestinal Intolerance After Resuming Maintenance-Dose Semaglutide Following Ramadan-Related Treatment Interruption: A Case Report.","Valizada H","2026","Cureus","case_report","article","10.7759/cureus.113026","42622003","PMC13489215",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007447","An Integrated Computational–Experimental Strategy For the Prediction of Small Molecules as GLP-1R Agonists","García EM","2026","bioRxiv","preclinical","preprint","10.64898/2026.03.30.715288",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; article; preprint"],["R0007448","Short-term effects of liraglutide and semaglutide on weight gain and adiposity by rats fed a Western diet.","Airosus C","2025","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2025.114955","40389050",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007449","The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.","Elnaggar M","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01691-1","39969755","PMC11926313",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007450","[Glucagon-like peptide-1 receptor agonists].","Mashimo Y","2015","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"25812369",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0007451","The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials.","Rizos EC","2024","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2024.108781","38833853",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007452","Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study.","Júlíusdóttir YK","2023","European heart journal. Cardiovascular pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvad033","37173284",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0007453","Evaluating the effects of glucagon-like peptide-1 receptor agonists on cognitive function in Alzheimer's disease: A systematic review and meta-analysis.","Bi Z","2023","Advances in clinical and experimental medicine : official organ Wroclaw Medical University","systematic_review","article","10.17219/acem/161734","37077141",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0007454","COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes.","Popovic DS","2025","Expert review of clinical pharmacology","other_trial","article","10.1080/17512433.2025.2516784","40464480",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Review; Journal Article; Comparative Study; article"],["R0007455","Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease.","Chianetta R","2026","Biomolecules","narrative_review","article","10.3390/biom16060797","42352264","PMC13297077",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007456","Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4.","Errafii K","2021","Journal of translational medicine","preclinical","article","10.1186/s12967-021-02885-4","34078383","PMC8173795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0007457","GLP-1 Receptor Agonists in Addiction: From Observational Signals to Research Priorities","Okoro A",null,"BJPsych open","other","article",null,null,"PMC13328913",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0007458","Glucagon-Like Peptide-1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications.","Alharbi NHJ","2026","Pharmacology research & perspectives","narrative_review","article","10.1002/prp2.70329","42830469","PMC13635475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; IM; review-article; article"],["R0007459","[The Evolution of Diabetes Treatment: Combining Innovative Pharmacological Therapies and Advanced Devices toward Remission].","Choi JH","2024","Jugan geon-gang gwa jilbyeong","narrative_review","article","10.56786/phwr.2024.17.44.4","41334420","PMC12480074",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Review; review-article; article"],["R0007460","Effect of Ozempic on Diabetic Nephropathy: A Case Report.","Joseph J","2025","Cureus","case_report","article","10.7759/cureus.87416","40772213","PMC12326341",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007461","Sodium-Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies.","Mantovani A","2025","Diabetes care","systematic_review","article","10.2337/dc25-0282","40392994",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0007462","Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.","Sattar N","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16549","40555920","PMC12409218",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007463","[Uncertainties in cardiovascular risk factors: sodium-glucose cotransporter 2 inhibitors for all diabetic patients with high cardiovascular risk and in all patients with renal insufficiency, regardless of albuminuria? Glucagon-like peptide-1 receptor agonists as a weapon against obesity?].","Avogaro A","2023","Giornale italiano di cardiologia (2006)","other","article","10.1714/4026.40007","37102346",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0007464","Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease.","Chen JN","2026","BMC gastroenterology","nonrandomized_study","article","10.1186/s12876-026-04626-7","41742068","PMC13040818",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; other; article"],["R0007465","Non-inferiority and clinical superiority of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes.","Zaccardi F","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14735","35491523","PMC9543971",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; research-article; article"],["R0007466","Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study.","Kakegawa T","2024","Medicine","nonrandomized_study","article","10.1097/md.0000000000038444","38847728","PMC11155541",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0007467","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.","García-Pérez LE","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01076-0","34097244","PMC8266969",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; conference-paper; article"],["R0007468","The Mitochondrion: A Promising Target for Kidney Disease.","Tanriover C","2023","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics15020570","36839892","PMC9960839",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007469","Ex vivo lung perfusion with GLP-1R agonist mitigates ischemia/reperfusion injury through pyroptosis modulation in lung transplantation- an experimental study.","Zhang Y","2025","International journal of surgery (London, England)","preclinical","article","10.1097/js9.0000000000002438","40387728","PMC12165588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007470","Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET).","Evans M","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14703","35504854","PMC9324926",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007471","Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist.","Lee SH","2020","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2020.06.022","32619744",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007472","Change in cT1 Following Interventions in MASLD: A Systematic Review and Meta-Analysis.","Andersson A","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","systematic_review","article","10.1016/j.cgh.2025.03.003","40220846",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0007473","Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.","Sacco S","2024","Diabetologia","narrative_review","article","10.1007/s00125-024-06146-z","38625582","PMC11153285",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007474","The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model.","Thornton P","2025","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.24305","40304241","PMC12210099",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007475","Physiological effects of biased glucagon-like peptide-1 receptor agonists","Lucey MA","2019","Imperial College London","other","article","10.25560/88958",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0007476","Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.","Michos ED","2023","American journal of preventive cardiology","other_trial","article","10.1016/j.ajpc.2023.100502","37313358","PMC10258236","ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT04865770; ClinicalTrials.gov:NCT03914326; ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT04255433","S000395; S000716; S000953; S002179; S002212","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007477","SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.","Fu EL","2024","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2023-078483","38925801","PMC11200155",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0007478","[Chinese expert consensus on metformin in clinical practice: 2023 update].","Expert Group for Updating Chinese Expert Consensus on Metformin in Clinical Practice","2023","Zhonghua nei ke za zhi","other","article","10.3760/cma.j.cn112138-20230305-00131","37263945",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Consensus Statement"],["R0007479","Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.","Tobaiqy M","2024","International journal of clinical pharmacy","nonrandomized_study","article","10.1007/s11096-023-01694-7","38265519","PMC10960895",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007480","Electrochemical Sensing of the Peptide Drug Exendin-4 Using a Versatile Nucleic Acid Nanostructure.","Khuda N","2022","ACS sensors","other","article","10.1021/acssensors.1c02336","35180342","PMC8985241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007481","Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation.","Nissaisorakarn P","2021","Advances in chronic kidney disease","narrative_review","article","10.1053/j.ackd.2021.03.001","34922692",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007482","Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.","Htoo PT","2024","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-024-02150-0","38331813","PMC10854040",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; other; article"],["R0007483","Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC).","Volpe M","2023","Frontiers in cardiovascular medicine","other","article","10.3389/fcvm.2023.1136340","36993998","PMC10040794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0007484","GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.","Iepsen EW","2020","Cell reports. Medicine","case_report","article","10.1016/j.xcrm.2020.100006","33205056","PMC7659505",null,"S000945","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0007485","Role of Renal Sympathetic Nerves in GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Exendin-4-Mediated Diuresis and Natriuresis in Diet-Induced Obese Rats.","Liu X","2021","Journal of the American Heart Association","preclinical","article","10.1161/jaha.121.022542","34713714","PMC8751817",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0007486","Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352.","Albogami Y","2021","Diabetes care","commentary","article","10.2337/dci21-0024","34285101",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0007487","Glucagon-Like Peptide-1 Receptor Agonism and Muscle Health: Vascular and Myocellular Effects on Glucose and Protein Metabolism.","Katsanos CS","2026","Comprehensive physiology","narrative_review","article","10.1002/cph4.70126","41839621",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007488","Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.","Cai W","2024","Frontiers in public health","systematic_review","article","10.3389/fpubh.2024.1277113","38356942","PMC10864442",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; systematic-review; review"],["R0007489","Off-Trial: Real-World Weight Loss on Tirzepatide and Semaglutide","Erly B","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.07.14.26357502",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0007490","Safety and Efficacy of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Veterans With Type 2 Diabetes.","McCulley L","2022","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article","10.12788/fp.0319","36923546","PMC10010498",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007491","Semaglutide exposure and its association with adverse outcomes in diabetic patients undergoing transforaminal lumbar interbody fusion for lumbar degenerative disc disease.","Khalid SI","2025","Journal of neurosurgery. Spine","nonrandomized_study","article","10.3171/2024.6.spine24141","39366019",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007492","Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities.","Bettadapura S","2025","International journal of obesity (2005)","narrative_review","article","10.1038/s41366-024-01500-y","38454010","PMC11971042",null,"S002529","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0007493","Mental health outcomes in obesity interventions with GLP-1 receptor agonists: is it similar to other obesity interventions? A narrative review with systematic evidence synthesis.","Osborne D","2026","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-025-02002-1","41491273",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Review; review"],["R0007494","Effects of Weight-Loss Interventions on Kidney, Cardiometabolic and Anthropometric Outcomes in Adults With CKD and Overweight or Obesity: A Systematic Review and Meta-Analysis.","Stamatiou A","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70997","42331714","PMC13448983",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; research-article; review"],["R0007495","Histological concordance of medial arterial calcification between tibial and peroneal arteries in advanced peripheral arterial disease.","Adler S","2026","JVS-vascular science","nonrandomized_study","article","10.1016/j.jvssci.2026.100426","42326615","PMC13280337",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007496","Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.","Sohn M","2023","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-023-01877-6","37381019","PMC10303335",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; research-article; other; review"],["R0007497","A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.","Battise DM","2021","Journal of the American Association of Nurse Practitioners","nonrandomized_study","article","10.1097/jxx.0000000000000516","33105320",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0007498","Association between glucagon-like peptide-1 receptor agonists and nonfusion risk after single-level anterior cervical discectomy and fusion.","Chang Y","2026","The spine journal : official journal of the North American Spine Society","nonrandomized_study","article","10.1016/j.spinee.2025.07.010","40633588",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007499","Management of Obesity: Office-Based Strategies.","Keating MK","2024","American family physician","narrative_review","article",null,"39172672",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007500","Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults.","Dadwani RS","2023","MDM policy & practice","randomized_trial","article","10.1177/23814683231187566","37492502","PMC10363885",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0007501","The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis.","Tseng PT","2026","Journal of the Royal Society of Medicine","systematic_review","article","10.1177/01410768251395877","41359407","PMC12685696","PROSPERO:CRD42024601021",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0007502","Effects of GLP-1 Receptor Agonists on Paediatric Population in a Real World Setting.","Barajas AG","2025","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70053","40260650","PMC12012572",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007503","INDIVIDUAL ARTICLE: Psoriasis and Obesity: Optimizing Pharmacologic Treatment and Lifestyle Interventions.","Guo L","2025","Journal of drugs in dermatology : JDD","nonrandomized_study","article",null,"39761151",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; article"],["R0007504","Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes.","Chaiyakunapruk N","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02737-1","40275332","PMC12023599",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0007505","Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.","Patoulias D","2020","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2020.04.001","32437914",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review"],["R0007506","Increased A1 astrocyte activation-driven hippocampal neural network abnormality mediates delirium-like behavior in aged mice undergoing cardiac surgery.","Liu W","2024","Aging cell","preclinical","article","10.1111/acel.14074","38155547","PMC10928578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007507","DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model.","Zhang L","2022","Parkinson's disease","other_trial","article","10.1155/2022/1428817","36419409","PMC9678466",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007508","Shared pathophysiology and therapeutic repurposing in Alzheimer's disease and type 2 diabetes: a critical review of convergent mechanisms and clinical challenges.","Fu W","2026","Bioorganic chemistry","narrative_review","article","10.1016/j.bioorg.2026.110044","42247872",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007509","PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.","Al-Kawas F","2019","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other_trial","article","10.4158/ep-2018-0507","30865522",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0007510","Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.","Martínez-Montoro JI","2022","Frontiers in endocrinology","case_report","article","10.3389/fendo.2022.838887","35498407","PMC9046779",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007511","Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.","Li H","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","systematic_review","article","10.1016/j.biopha.2024.116150","38242040",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0007512","Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.","Diallo A","2023","Acta diabetologica","systematic_review","article","10.1007/s00592-023-02154-4","37439858",null,"PROSPERO:CRD42023400899",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0007513","GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.","Aoun L","2024","Journal of clinical & translational endocrinology","systematic_review","article","10.1016/j.jcte.2024.100333","38449772","PMC10915596",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007514","Noninsulin antidiabetic prescription patterns in Colombia: a cross-sectional study.","Machado-Alba JE","2024","Therapeutic advances in endocrinology and metabolism","nonrandomized_study","article","10.1177/20420188241271806","39483171","PMC11526234",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007515","GLP-1 Agonist Attenuates Nicotine Reward-Related Behavior by Regulating the Prepro-Orexin in the Hypothalamus and Prepro-Glucagon in the Nucleus Tractus Solitarius.","Rahmadi M","2026","Behavioural neurology","preclinical","article","10.1155/bn/1193259","42310968","PMC13275999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007516","Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight Loss.","Modestino EJ","2024","Acta scientific neurology","other","article","10.31080/asne.2024.07.0731","39118673","PMC11309767",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007517","Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update.","Sofogianni A","2020","World journal of hepatology","narrative_review","article","10.4254/wjh.v12.i8.493","32952876","PMC7475780",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007518","The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.","Reis-Barbosa PH","2024","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.15820","39113264",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007519","An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis.","Balogh DB","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms24097789","37175496","PMC10177821",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007520","Mutagenic and genotoxic in silico QSAR prediction of dimer impurity of gliflozins; canagliflozin, dapaglifozin, and emphagliflozin and in vitro evaluation by Ames and micronucleus test.","Rane R","2025","Drug and chemical toxicology","preclinical","article","10.1080/01480545.2024.2378768","39072496",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007521","Preoperative management of diabetes mellitus: A comparative narrative review of the recommendations of three professional organizations with Hamad Medical Corporation guidelines.","Fahda M Jamiu F","2025","Qatar medical journal","narrative_review","article","10.5339/qmj.2025.23","40432987","PMC12109678",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; review"],["R0007522","GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study.","Brahmbhatt S","2026","HSS journal : the musculoskeletal journal of Hospital for Special Surgery","nonrandomized_study","article","10.1177/15563316261492267","42856761","PMC13650054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007523","Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated Weight Loss in Medicare-Age Patients","Marwaha A","2026","Preprints.org","other","preprint","10.20944/preprints202607.0809.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007524","Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.","Dave CV","2020","Diabetes care","nonrandomized_study","article","10.2337/dc19-1943","32041899","PMC7519473",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Historical Article; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; brief-report; article"],["R0007525","GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder.","Lira MC","2025","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-025-09498-3","40272681","PMC12463799",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; article"],["R0007526","How Does Diabetes Affect Daily Life? A Beyond-A1C Perspective on Unmet Needs.","Gopisetty D","2018","Clinical diabetes : a publication of the American Diabetes Association","randomized_trial","article","10.2337/cd17-0093","29686452","PMC5898173",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0007527","Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential.","Flintoff J","2021","Expert opinion on investigational drugs","preclinical","article","10.1080/13543784.2021.1951702","34213981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007528","GLP-1 Receptor Agonists in Fibromyalgia: Opioid Sparing Signals from Real World Data","Verma A",null,"European psychiatry : the journal of the Association of European Psychiatrists","nonrandomized_study","article",null,null,"PMC13444893",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0007529","The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials.","Liu L","2025","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph18050668","40430487","PMC12114739","PROSPERO:CRD42021283449",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007530","Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.","Yamauchi T","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00402-4","42009015",null,"ClinicalTrials.gov:NCT05813925","S001089","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0007531","Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.","Boye KS","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-023-01451-z","37526908","PMC10570242","ClinicalTrials.gov:NCT03954834; ClinicalTrials.gov:NCT03987919; ClinicalTrials.gov:NCT03882970; ClinicalTrials.gov:NCT03730662; ClinicalTrials.gov:NCT04039503","S000095; S000407; S001287; S001591; S001608","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007532","Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.","Dicembrini I","2017","Acta diabetologica","systematic_review","article","10.1007/s00592-017-1031-9","28748377",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0007533","Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.","de Mesquita YLL","2023","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-023-01337-x","37460681",null,"PROSPERO:CRD42022348576",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Review; Research Support, N.I.H., Extramural; review"],["R0007534","Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.","Scheen AJ","2026","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(26)00129-4","42251858",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007535","From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease.","Maggioni AP","2026","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2026.134646","42361988",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0007536","Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review.","Lv X","2020","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.163","32704576","PMC7375121",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007537","Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management.","Zhang K","2025","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2025.1676718","40895624","PMC12394033",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; editorial"],["R0007538","Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus.","Hulst AH","2021","British journal of anaesthesia","commentary","article","10.1016/j.bja.2020.10.023","33341227",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0007539","Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy.","Sun X","2024","Peptides","preclinical","article","10.1016/j.peptides.2024.171203","38582303",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007540","Pediatric metabolic and bariatric surgery: When is the right time to operate?","Shacker M","2025","Current problems in pediatric and adolescent health care","narrative_review","article","10.1016/j.cppeds.2025.101882","41344950",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007541","Treatment modification after initiating second-line medication for type 2 diabetes.","Liss DT","2023","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2023.89466","38170483",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007542","Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases.","Wang J","2022","Endocrine research","nonrandomized_study","article","10.1080/07435800.2021.1955255","34459679",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0007543","An update on peptide-based therapies for type 2 diabetes and obesity.","Bailey CJ","2023","Peptides","narrative_review","article","10.1016/j.peptides.2023.170939","36608818",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007544","GLP-1 AND CIRRHOSIS: EFFECTS ON MORTALITY AND LIVER-RELATED COMPLICATIONS.","Onwuzo CN","2026","Arquivos de gastroenterologia","nonrandomized_study","article","10.1590/s0004-2803.24612025-130","42267984","PMC13249180",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007545","Emerging Topics In Obesity Treatment in the Setting of Organ Transplantation.","Maahs E","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00749-w","42690550",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007546","Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial.","Bladin CF","2023","Stroke","randomized_trial","article","10.1161/strokeaha.123.044568","38011235","PMC10664794","ClinicalTrials.gov:NCT03287076; ANZCTR:ACTRN12617000409370","S000310","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Multicenter Study; Journal Article; research-article; article"],["R0007547","<span class=\"word\">Glucagon-<span class=\"word\"><span class=\"changedDisabled\">Like <span class=\"word\"><span class=\"changedDisabled\">Peptide-<span class=\"word\">1 <span class=\"word\"><span class=\"changedDisabled\">Receptor <span class=\"word\"><span class=\"changedDisabled\">Agonists <span class=\"word\">in <span class=\"word\">the <span class=\"word\"><span class=\"changedDisabled\">Real <span class=\"word\"><span class=\"changedDisabled\">World: <span class=\"word\"><span class=\"changedDisabled\">Are <span class=\"word\"><span class=\"changedDisabled\">Clinical <span class=\"word\"><span class=\"changedDisabled\">Trials <span class=\"word\"><span class=\"changedDisabled\">Reproducible? <span class=\"word\">A <span class=\"word\">Spanish <span class=\"word\"><span class=\"changedDisabled\">Pilot <span class=\"word\"><span class=\"changedDisabled\">Study","Vergniory-Trueba O","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202605.0987.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint; article"],["R0007548","Acute Systemic Complications Following High-Dose Semaglutide Reinitiation in an Elderly Patient.","Mehta J","2026","Clinical case reports","other","article","10.1002/ccr3.72356","42038657","PMC13106220",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0007549","Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.","Stewart KD","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-026-01907-y","42754765",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0007550","Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.","Krüger N","2026","Nature medicine","randomized_trial","article","10.1038/s41591-025-04102-x","41207920","PMC12823426","ClinicalTrials.gov:NCT06659744; ClinicalTrials.gov:NCT07088718; ClinicalTrials.gov:NCT07096063","S000666; S001860; S002323","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0007551","Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.","Evans M","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-021-01201-z","35044569","PMC8767360",null,"S000298","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0007552","Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.","Drab SR","2016","Current diabetes reviews","narrative_review","article","10.2174/1573399812666151223093841","26694823","PMC5101635",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0007553","Comparative Effectiveness of SGLT2 Inhibitors and Semaglutide in Diabetic Nephropathy: A Retrospective Observational Study.","Joseph J","2025","Cureus","randomized_trial","article","10.7759/cureus.87399","40772215","PMC12326033",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0007554","Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis.","Alsugair HA","2021","Healthcare (Basel, Switzerland)","systematic_review","article","10.3390/healthcare9091125","34574899","PMC8466858","PROSPERO:CRD42018091598",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0007555","Association of tirzepatide with erectile dysfunction in people with type 2 diabetes.","Cowart K","2025","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2025.109116","40614622",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0007556","The impact of glucagon-like peptide-1 receptor agonist on the gastric residue in upper endoscopy.","Abu-Freha N","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111900","39433216",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0007557","Effect of glucagon-like peptide-1 agonists on deep inferior epigastric perforator flap breast reconstruction outcomes in obese patients: A study of 5618 patients.","Sidhu AS","2026","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","nonrandomized_study","article","10.1016/j.bjps.2025.11.048","41308379",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0007558","Medical Therapy for Peripheral Artery Disease.","Canonico ME","2024","Current cardiology reports","narrative_review","article","10.1007/s11886-024-02065-y","38696099",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007559","Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies.","Caruso I","2022","Metabolites","systematic_review","article","10.3390/metabo12020183","35208256","PMC8879165",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007560","Efficacy and safety of glucagon-like peptide-1 receptor agonist combined with sodium-glucose co-transporter-2 inhibitor in the treatment of type 2 diabetes mellitus patients with obesity: a retrospective analysis study.","Wang J","2023","American journal of translational research","nonrandomized_study","article",null,"37193156","PMC10182534",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007561","New Horizons: Emerging Antidiabetic Medications.","Mingrone G","2022","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgac499","36106900",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; article"],["R0007562","Iterative Causal Forest: A Novel Algorithm for Subgroup Identification.","Wang T","2024","American journal of epidemiology","nonrandomized_study","article","10.1093/aje/kwad219","37943684","PMC11485278",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007563","The effect of GLP-1 agonist on idiopathic intracranial hypertension: a systematic review and meta-analysis.","Ahmad J","2025","Therapeutic advances in neurological disorders","systematic_review","article","10.1177/17562864251378845","41180125","PMC12575947","PROSPERO:CRD420251008614",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0007564","Role of incretin-based therapy in hospitalized patients with type 2 diabetes.","Gracia-Ramos AE","2020","Journal of diabetes investigation","commentary","article","10.1111/jdi.13130","31529777","PMC7078129",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0007565","Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.","Gonzalez J","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-01784-w","36899387","PMC9999503",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0007566","Exploring the Impact of Diabetes on Kidney Transplant: Patient Outcomes and Management Strategies.","Eltayeb HHH","2025","Cureus","narrative_review","article","10.7759/cureus.80843","40255815","PMC12007845",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007567","YN1548: A novel small-molecule agonist of human glucagon-like peptide-1 receptor for the treatment of type 2 diabetes mellitus and obesity.","Je IG","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.178143","40945896",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0007568","Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.","Lorenz M","2017","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-016-0490-6","28086882","PMC5237337",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0007569","Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.","Alatorre C","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12902","28181725","PMC5485056",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; research-article; article"],["R0007570","The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.","Nowrouzi-Sohrabi P","2021","European journal of pharmacology","systematic_review","article","10.1016/j.ejphar.2020.173823","33352183",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007571","Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity.","Chow EW","2026","Lancet (London, England)","other","article","10.1016/s0140-6736(25)02381-5","41421831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007572","Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.","Sadraei S","2025","BMC cardiovascular disorders","systematic_review","article","10.1186/s12872-025-05278-3","41272444","PMC12752371","PROSPERO:CRD42024538847",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0007573","Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes.","Olowo-Oribi BA","2025","Academic emergency medicine : official journal of the Society for Academic Emergency Medicine","narrative_review","article","10.1111/acem.70088","40583149",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007574","Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study.","Fadini GP","2025","The Lancet regional health. Europe","other","article","10.1016/j.lanepe.2025.101499","41142657","PMC12550164",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007575","Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer's disease by suppressing NLRP2 activation in astrocytes.","Zhang M","2022","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2021.111529","34906628",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007576","Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.","Jain AB","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00984-x","33367981","PMC7846659",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007577","Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.","Qin L","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-017-0230-2","28155131","PMC5380493",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007578","Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review.","Solmi M","2024","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2024.2396396","39225182",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0007579","Approach to weight management in patients with advanced chronic kidney disease in a real-life clinical setting.","Lockhart Pastor P","2024","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.755","38711815","PMC11070438",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007580","SGLT-2 Inhibitors' and GLP-1 Receptor Agonists' Influence on Neuronal and Glial Damage in Experimental Stroke.","Murasheva A","2024","Biomedicines","preclinical","article","10.3390/biomedicines12122797","39767704","PMC11673681",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007581","The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial.","Liu X","2023","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.13483","37864379","PMC10850920","ClinicalTrials.gov:NCT03829891","S000676","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0007582","Natural Weight Loss or \"Ozempic Face\": Demystifying A Social Media Phenomenon.","Carboni A","2024","Journal of drugs in dermatology : JDD","other","article","10.36849/jdd.7613","38206146",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007583","Antipsychotic-induced weight gain: exploring the role of psychiatrists in managing patients' physical health - challenges, current options and direction for future care.","Lee K","2024","BJPsych bulletin","commentary","article","10.1192/bjb.2023.29","37165776","PMC10801410",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0007584","EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.","Lingvay I","2019","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep-2018-0284","30383495",null,null,"S001328; S001654; S002285","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0007585","Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis.","Balata M","2024","BMC cardiovascular disorders","randomized_trial","article","10.1186/s12872-024-04275-2","39462311","PMC11515153",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0007586","Frequency of GLP-1 receptor agonists use in diabetic patients diagnosed with delayed gastric emptying and their demographic profile.","Kalas MA","2023","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","nonrandomized_study","article","10.1136/jim-2022-002480","36198436",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007587","Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.","Infante M","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14041303","40004833","PMC11856673",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007588","Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial.","Cai H","2023","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2023.1106868","36777344","PMC9909427","ChiCTR:ChiCTR2200057800",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007589","Revision Medialization Thyroplasty for Glottic Insufficiency Amid Rapid Weight Loss on Semaglutide.","Xu K","2026","The Laryngoscope","case_report","article","10.1002/lary.70732","42439301",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0007590","Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention.","Mannucci E","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15226","37529868",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Journal Article; Review; article"],["R0007591","Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?","Koufakis T","2023","Drugs","other","article","10.1007/s40265-023-01852-1","36941489",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0007592","Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.","Koike M","2021","International journal of molecular sciences","preclinical","article","10.3390/ijms222111463","34768897","PMC8583813",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007593","Motility-mediated drug interactions with GLP-1 receptor agonists: labeled evidence and a framework for quantitative assessment.","Chung JY","2026","Translational and clinical pharmacology","preclinical","article","10.12793/tcp.2026.34.e13","42846711","PMC13645479",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; Brief Report; article"],["R0007594","The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis.","Alexander JT","2022","Journal of general internal medicine","systematic_review","article","10.1007/s11606-021-07105-9","34508290","PMC8810987","PROSPERO:CRD42018090506",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review; Journal Article; review-article; review"],["R0007595","GLP-1RA partially alleviates obesity-induced reproductive dysfunction driven by the interplay mechanisms of inflammation and metabolic dysregulation via the SIRT-associated pathway.","Matiki TW","2026","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.178459","41380824",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007596","Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system - A disproportionality analysis.","Azab M","2025","Obesity research & clinical practice","nonrandomized_study","article","10.1016/j.orcp.2025.01.011","39922760",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007597","Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review.","Rangraze IR","2026","Current drug safety","systematic_review","article","10.2174/0115748863330434241015125302","39484756",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; article"],["R0007598","Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.","Esparham A","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13811","39134066",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007599","Long-acting amylin analogues for the management of obesity.","Mathiesen DS","2022","Current opinion in endocrinology, diabetes, and obesity","other_trial","article","10.1097/med.0000000000000716","35066542",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0007600","Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014-2019.","Neilson LM","2021","Medical care","nonrandomized_study","article","10.1097/mlr.0000000000001597","34183622",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007601","Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.","Rosenstock J","2020","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14154","32729183","PMC7818416",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007602","The GLP-1 receptor agonist exendin-4 reduces taurine and glycine in nucleus accumbens of male rats, an effect tentatively involving the nucleus tractus solitarius.","Edvardsson CE","2024","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2024.1439203","39221138","PMC11362053",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007603","Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.","Rashid M","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70198","42483841",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Review; article"],["R0007604","The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.","Yang S","2022","Drugs","systematic_review","article","10.1007/s40265-022-01779-z","36129662",null,"PROSPERO:CRD42021248314",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Systematic Review; Journal Article; Network Meta-Analysis"],["R0007605","Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.","Trujillo J","2020","Journal of clinical pharmacy and therapeutics","other_trial","article","10.1111/jcpt.13225","32910487","PMC7540535",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007606","Pharmacotherapy in obstructive sleep apnoea: a clinical guide.","Shastry S","2026","Sleep & breathing = Schlaf & Atmung","other_trial","article","10.1007/s11325-026-03724-w","42557390",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0007607","Morphotype-resolved 3D morphometry reveals a structure-density-location coupling in mitochondrial networks.","Singh A","2026","Structure (London, England : 1993)","preclinical","article","10.1016/j.str.2026.07.014","42624104",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Preprint"],["R0007608","Diabetic kidney disease treatment: new perspectives.","Tong LL","2022","Kidney research and clinical practice","other","article","10.23876/j.krcp.21.288","36239062","PMC9590300",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007609","GLP-1R agonists activate human hypothalamic neurons","Mazzaferro S","2024","bioRxiv","other","preprint","10.1101/2024.04.02.587825",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007610","Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.","Isakov V","2025","World journal of gastroenterology","commentary","article","10.3748/wjg.v31.i20.105346","40495947","PMC12146937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0007611","Adherence and persistence rates of major antidiabetic medications: a review.","Lee DSU","2022","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-022-00785-1","35033161","PMC8761325",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007612","GLP-1 receptor agonist use is associated with shorter survival in patients with amyotrophic lateral sclerosis and diabetes mellitus","Lee I","2025","medRxiv","other","preprint","10.1101/2025.05.05.25326993",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007613","New Hypoglycemic Drugs: Combination Drugs and Targets Discovery.","Ni X","2022","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2022.877797","35865956","PMC9295075",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007614","Technology advances in diabetes pregnancy: right technology, right person, right time.","McLean A","2024","Diabetologia","narrative_review","article","10.1007/s00125-024-06216-2","38967667","PMC11447080",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007615","Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies.","Pramanik S","2024","World journal of methodology","narrative_review","article","10.5662/wjm.v14.i2.91319","38983664","PMC11229880",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007616","An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus.","Tao J","2026","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.5c24385","42066004",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007617","The Effects of pH and Excipients on Exenatide Stability in Solution.","Benet A","2021","Pharmaceutics","other","article","10.3390/pharmaceutics13081263","34452224","PMC8398870",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007618","Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.","Zeng L","2026","Annals of the American Thoracic Society","systematic_review","article","10.1093/annalsats/aaoag177","42479131",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0007619","Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD.","Varghese P","2026","Cardiology in the young","nonrandomized_study","article","10.1017/s1047951126113109","42290594",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0007620","Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective.","Shenker MN","2025","Hormone research in paediatrics","randomized_trial","article","10.1159/000541228","39222618","PMC12324803",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0007621","Safety of Semaglutide.","Smits MM","2021","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2021.645563","34305810","PMC8294388",null,"S000313; S000766","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0007622","Association of Social Determinants of Health with Utilization of SGLT2 Inhibitors and GLP1 Receptor Agonists: A Systematic Review and Meta-Analysis.","Shah N","2026","Journal of general internal medicine","systematic_review","article","10.1007/s11606-026-10178-z","41838266","PMC13421548",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0007623","Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis.","Lui DTW","2022","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2022.101510","35784442","PMC9241106",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007624","Practical guidance for use of oral semaglutide in primary care: a narrative review.","Morales J","2020","Postgraduate medicine","systematic_review","article","10.1080/00325481.2020.1788340","32643514",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0007625","Is there a role for glucagon-like peptide-1 receptor agonists in the treatment of male infertility?","Cannarella R","2021","Andrology","randomized_trial","article","10.1111/andr.13015","33818920","PMC8596505",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article-commentary; article"],["R0007626","Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review.","Frangie Machado M","2024","Cureus","narrative_review","article","10.7759/cureus.66691","39262529","PMC11389649",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Scoping Review; review-article; article"],["R0007627","Advances in the management of chronic kidney disease.","Chen TK","2023","BMJ (Clinical research ed.)","narrative_review","article","10.1136/bmj-2022-074216","38052474",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007628","Posttransplant Diabetes Mellitus: Recent Developments in Pharmacological Management of Hyperglycemia.","Munoz Pena JM","2023","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgad395","37410930",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Review; Journal Article; article"],["R0007629","Association of Glucose-Lowering Therapy with Myocardial Work Recovery and Reverse Remodeling After STEMI.","Buz BF","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15134891","42452353","PMC13361639",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007630","Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.","Terauchi Y","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14036","32291880",null,"ClinicalTrials.gov:NCT02752828","S002305","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0007631","Qualitative and Quantitative Analyses of Noninvasive Diagnosis of Insulinoma Using [18F]FB(ePEG12)12-Exendin-4 PET/CT.","Murakami T","2025","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/clinem/dgaf253","40391925",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; article"],["R0007632","Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance.","Almandoz JP","2020","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd19-0100","33132510","PMC7566932",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007633","Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists.","Poudwal S","2021","Journal of drug targeting","narrative_review","article","10.1080/1061186x.2021.1894434","33620269",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007634","Predictors of treatment response to semaglutide for weight management.","Tzoulis P","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1893511","42824923","PMC13628350",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007635","Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.","Morton JI","2023","Diabetologia","nonrandomized_study","article","10.1007/s00125-022-05832-0","36404375","PMC9947091",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007636","Experimental drugs for the treatment of idiopathic intracranial hypertension (IIH): shedding light on phase I and II trials.","Khatkar P","2023","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2023.2288073","38006580",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0007637","[The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy].","Shestakova MV","2025","Terapevticheskii arkhiv","narrative_review","article","10.26442/00403660.2025.10.203366","41235513",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0007638","Cardiovascular risk reduction in older people with type 2 diabetes mellitus-a comprehensive narrative review.","Si PEH","2024","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2024.111662","38599285",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007639","Unveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach.","Pan SY","2024","Kidney research and clinical practice","other","article","10.23876/j.krcp.23.289","38934037","PMC11237330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007640","Effects of GLP-1 Receptor Agonist Exenatide on Mitochondrial Dysfunction After Spinal Cord Injury.","Kishi T","2026","Neurotrauma reports","preclinical","article","10.1177/2689288x261454812","42539351","PMC13422609",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007641","Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats.","Urbanik LA","2022","Brain research bulletin","preclinical","article","10.1016/j.brainresbull.2022.08.023","36031011",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; article"],["R0007642","High-dimensional Iterative Causal Forest (hdiCF) for Subgroup Identification Using Health Care Claims Data.","Wang T","2024","American journal of epidemiology","nonrandomized_study","article","10.1093/aje/kwae322","39245674","PMC12234226",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007643","Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes.","Pradhan R","2022","Diabetes care","nonrandomized_study","article","10.2337/dc22-0712","35866685",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007644","Potential underutilisation of weight loss medications in obese patients with knee osteoarthritis.","Badhe N","2026","Annals of the Royal College of Surgeons of England","other","article","10.1308/rcsann.2026.0063","42558015",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007645","GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide).","Manoharan SVRR","2024","Innovations in clinical neuroscience","case_report","article",null,"38938530","PMC11208009",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007646","Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities.","Sarzani R","2024","Frontiers in medicine","narrative_review","article","10.3389/fmed.2024.1365183","38654832","PMC11037084",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007647","Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin.","MacIsaac RJ","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-023-01475-5","37824027","PMC10597955",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007648","AI-Driven Efficient  <i>De Novo<\/i>  design of GLP-1RAs with Extended Half-Life and Enhanced Efficacy","Wei T","2025","bioRxiv","preclinical","preprint","10.1101/2025.03.26.645438",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0007649","Integration of Glucagon-Like Peptide 1 Receptor Actions Through the Central Amygdala.","Duran M","2025","Endocrinology","narrative_review","article","10.1210/endocr/bqaf019","39888375","PMC11850305",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007650","Unanticipated Effects of GLP-1 Receptor Agonists: A Net Positive.","Gilden AH","2026","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.70288","42532552","PMC13535716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0007651","One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial.","Vedtofte L","2020","Journal of clinical medicine","randomized_trial","article","10.3390/jcm9103213","33036179","PMC7601647",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0007652","Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.","Horn DB","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(25)02165-8","41275875",null,"ClinicalTrials.gov:NCT05872620","S000754","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0007653","Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.","Welch M","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)00800-7","42259339",null,"ClinicalTrials.gov:NCT06192108","S001651","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III; Equivalence Trial; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0007654","GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies.","Yang HM","2025","Journal of clinical medicine","other_trial","article","10.3390/jcm14196758","41095837","PMC12525426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007655","Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying.","Horowitz M","2020","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.14166","32749029",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0007656","Perspectives on weight control in diabetes - Tirzepatide.","Várkonyi TT","2023","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2023.110770","37279858",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007657","Impact of GLP-1 Receptor Agonists on Male Fertility: Emerging Evidence and Future Directions.","Kuchakulla M","2026","Urology","preclinical","article","10.1016/j.urology.2025.09.038","41016449",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007658","Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans.","Deo SV","2022","Diabetes care","nonrandomized_study","article","10.2337/dc22-0570","36256925",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007659","The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system.","Yang Z","2022","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2021.10.003","34895802",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007660","Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.","Viljoen A","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-023-01398-1","37000390","PMC10126190","ClinicalTrials.gov:NCT03987919; ClinicalTrials.gov:NCT03882970","S000095; S001591","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; article"],["R0007661","Semaglutide as a potential therapeutic adjunct for reducing flare-ups in Sjögren's syndrome: A case report.","Jung J","2025","SAGE open medical case reports","case_report","article","10.1177/2050313x251372813","40900762","PMC12399809",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007662","Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update.","Giglio RV","2023","Biomedicines","narrative_review","article","10.3390/biomedicines11020291","36830828","PMC9953496",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007663","Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats.","Yamada S","2022","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2021.111472","34606964",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007664","Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.","Cao J","2025","Nature communications","other_trial","article","10.1038/s41467-025-58680-y","40204768","PMC11982234",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007665","Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes.","Santella C","2020","Epidemiology (Cambridge, Mass.)","nonrandomized_study","article","10.1097/ede.0000000000001196","32282437",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007666","Retinopathy risk factors in patients with type 2 diabetes on liraglutide.","Mahzari MM","2024","Medicine","nonrandomized_study","article","10.1097/md.0000000000039026","39029073","PMC11398743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0007667","Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study.","Narasaki Y","2024","Lancet regional health. Americas","nonrandomized_study","article","10.1016/j.lana.2024.100814","38993538","PMC11237921",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007668","Combination therapy for kidney disease in people with diabetes mellitus.","van Raalte DH","2024","Nature reviews. Nephrology","narrative_review","article","10.1038/s41581-024-00827-z","38570632",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, U.S. Gov't, P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural"],["R0007669","Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue.","Chandrashekar C","2024","Journal of medicinal chemistry","other","article","10.1021/acs.jmedchem.4c00093","38465973",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007670","Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP-1, GIP, and Glucagon Agonists.","Khan MS","2026","Journal of peptide science : an official publication of the European Peptide Society","narrative_review","article","10.1002/psc.70083","41518129",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007671","GLP-1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models.","Baumer-Harrison C","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70427","41508705","PMC12981003",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007672","Specialty Visits and Real-world Initiation of Cardioprotective Anti-hyperglycemic Medications Among US Adults with Type 2 Diabetes","Nargesi AA","2022","medRxiv","nonrandomized_study","preprint","10.1101/2022.05.17.22275232",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0007673","Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.","Patorno E","2021","Diabetes care","randomized_trial","article","10.2337/dc20-1464","33495295","PMC7896266",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0007674","Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.","Pöhlmann J","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-019-0569-7","30706364","PMC6437226",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0007675","GLP-1 RAs: The newest powerhouse in metabolic medicine.","Drake ES","2024","The Nurse practitioner","narrative_review","article","10.1097/01.npr.0000000000000216","39049152",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007676","Low C-Reactive Protein Alleles in Hepatocyte Nuclear Factor 1A Are Associated With an Increased Risk of Cardiovascular Disease.","Yang C","2025","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgae602","39210612",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; article"],["R0007677","No Heavy Drinking Days and Percentage of Days Abstinent in a Randomized Trial of Adjunctive Ketamine for Alcohol Use Disorder: Secondary Analysis of the KARE Trial","Morgan CJ","2026","medRxiv","randomized_trial","preprint","10.64898/2026.09.26.26363761",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0007678","Effectiveness and Safety of Antidiabetic Medications in Hidradenitis Suppurativa: A Systematic Review.","Almukhadeb E","2026","Clinical, cosmetic and investigational dermatology","systematic_review","article","10.2147/ccid.s591676","41869434","PMC13005274",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007679","Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.","Quast DR","2020","Diabetes care","randomized_trial","article","10.2337/dc20-0720","32647054",null,"ClinicalTrials.gov:NCT02231658","S001412","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article; other"],["R0007680","Number needed to treat in cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists: A systematic review with temporal analysis.","Davies MJ","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14066","32372425",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0007681","Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli.","Cheney C","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s488806","40336809","PMC12056664",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007682","Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease.","Kim H","2026","Electrolyte & blood pressure : E & BP","narrative_review","article","10.5049/ebp.2026.24.e6","42415738","PMC13338641",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007683","Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review.","Liu Z","2025","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgaf335","40488294","PMC12448640",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; review-article; review"],["R0007684","Diabetic Kidney Disease Back in Focus: Management Field Guide for Health Care Professionals in the 21st Century.","Alicic R","2022","Mayo Clinic proceedings","narrative_review","article","10.1016/j.mayocp.2022.05.003","36202498",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007685","GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research.","Valencia-Rincón E","2025","The Journal of clinical investigation","narrative_review","article","10.1172/jci194743","41178720","PMC12578377",null,"S002468","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0007686","Safety of injectable semaglutide for type 2 diabetes.","Peter R","2020","Expert opinion on drug safety","other_trial","article","10.1080/14740338.2020.1772230","32428416",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0007687","Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes.","Gronroos NN","2024","Journal of health economics and outcomes research","nonrandomized_study","article","10.36469/001c.124111","39507603","PMC11539928",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007688","Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study.","Yaseen A","2023","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd22-0100","37849520","PMC10577502",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0007689","GLP-1 receptor agonist for the management of metabolic syndrome in an adolescent with bipolar disorder on atypical antipsychotic treatment","Ruiz Martínez M",null,"European psychiatry : the journal of the Association of European Psychiatrists","other","article",null,null,"PMC13443686",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0007690","Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis.","Khalil I","2026","Clinical cardiology","nonrandomized_study","article","10.1002/clc.70441","42573026","PMC13455117",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0007691","A Review of First-Generation Obesity Medications.","Schmitz SH","2026","Current atherosclerosis reports","other_trial","article","10.1007/s11883-026-01389-0","41569475",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0007692","Efficacy and Safety of Injectable Dulaglutide 1.5 mg among Type 2 Diabetes Patients in Clinics at King Saud Medical City, Riyadh, Saudi Arabia","Albargawi MS","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3593071/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0007693","Stratified analysis in comparative effectiveness studies that emulate randomized trials.","Htoo PT","2024","Pharmacoepidemiology and drug safety","randomized_trial","article","10.1002/pds.5716","37876341",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007694","The influence of insulin and incretin-based therapies on renal tubular transport.","Rosati E","2024","Journal of nephrology","narrative_review","article","10.1007/s40620-024-02048-w","39167349","PMC11649737",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0007695","Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome.","Kourtidou C","2023","Biomedicines","other","article","10.3390/biomedicines11020496","36831032","PMC9953739",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007696","Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","Li J","2021","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2021.108656","33434602",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007697","Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.","Peterson SC","2018","Current diabetes reviews","systematic_review","article","10.2174/1573399813666170414101450","28413990",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0007698","Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.","Tran KL","2017","American health & drug benefits","other_trial","article",null,"28794822","PMC5536194",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007699","Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes.","Nørgaard CH","2022","European heart journal. Cardiovascular pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvab053","34215881",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007700","Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.",null,"2021","Journal of the Endocrine Society","notice","article","10.1210/jendso/bvaa201","33506162","PMC7819509",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0007701","729. From metabolic dysregulation and shared genetic etiology to suicidality: the psychiatric promise and safety debate of GLP-1 receptor agonists",null,"2026","The international journal of neuropsychopharmacology","other","article",null,null,"PMC13556478",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0007702","Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.","North EJ","2019","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000000673","31436559","PMC6876849",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0007703","Cardiometabolic Profiles of Oral and Subcutaneous Glucagon-Like Peptide-1 Receptor Mono-Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta-Analysis.","Lu Y","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70742","41992023","PMC13243969",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Network Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0007704","Twelve-month analysis of real-world evidence from a commercial telehealth obesity treatment provider","Ard J","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3959336/v1",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0007705","Metabolic-associated enthesitis: a review on pathophysiology, clinical relevance, diagnostic challenges, and perspective on target treatments.","Lisco G","2025","Immunologic research","narrative_review","article","10.1007/s12026-025-09655-0","40646307",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007706","GLP-1 Receptor Agonists and Suicide Risk in Adults With Chronic Pain: A New User Cohort Across Multi-System EHR data","Verma A",null,"European psychiatry : the journal of the Association of European Psychiatrists","nonrandomized_study","article",null,null,"PMC13445118",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0007707","Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.","Zaccardi F","2016","Annals of internal medicine","systematic_review","article","10.7326/m15-1432","26642233",null,null,"S000235","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; article"],["R0007708","Adverse Events Related to Tirzepatide.","Mishra R","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad016","36789109","PMC9915969",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007709","Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.","Tang H","2022","Diabetes care","systematic_review","article","10.2337/dc21-1722","35349656",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0007710","Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.","Yagyu H","2022","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13859","35638331","PMC9434581",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0007711","Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L.","Blonde L","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00797-y","32166620","PMC7136373",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; other; article"],["R0007712","Comparing the anorexigenic effects and mechanisms of gut-derived GLP-1 and its receptor agonists: insights into incretin-based therapies for obesity.","Masuda Y","2025","Diabetology international","narrative_review","article","10.1007/s13340-025-00819-9","40607142","PMC12209052",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007713","Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).","Singla A","2026","Cureus","nonrandomized_study","article","10.7759/cureus.113371","42639326","PMC13503022",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007714","Therapeutic Potential of the Novel GLP-1 Receptor Agonist Semaglutide in Alcohol Use Disorder.","Liu T","2025","Pharmacopsychiatry","preclinical","article","10.1055/a-2550-6470","40228539",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007715","Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.","Evans M","2024","Advances in therapy","randomized_trial","article","10.1007/s12325-023-02750-4","38340253","PMC11052848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007716","Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.","Shetty R","2022","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2022.102427","35217468",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Case Reports; Journal Article; Systematic Review; review"],["R0007717","GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms.","Kawanami D","2020","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2020.00967","32694999","PMC7338581",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007718","The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses.","Ballum H","2026","Journal of affective disorders","systematic_review","article","10.1016/j.jad.2026.121310","41621451",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0007719","New Antidiabetes Medications and Their Cardiovascular and Renal Benefits.","Ferro EG","2021","Cardiology clinics","narrative_review","article","10.1016/j.ccl.2021.04.007","34247748",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007720","Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.","Ghusn W","2026","Mayo Clinic proceedings","nonrandomized_study","article","10.1016/j.mayocp.2026.02.006","42383938",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007721","Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials.","Bray JJH","2021","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14399","33830637",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007722","The new bridge to hernia surgery: achieving preoperative weight optimization with GLP-1 receptor agonists for abdominal wall hernia repair.","Spurzem GJ","2025","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-025-11921-z","40603614","PMC12287229",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007723","Septic Shock and Glucagon-Like Peptide-1 Analog Association in Real World: A Propensity Score Matched Analysis.","Yadav Y","2026","Chest","nonrandomized_study","article","10.1016/j.chest.2026.06.016","42320668",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007724","Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes.","Aimelet V","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70229","41178728","PMC12803604",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007725","Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy.","Hong Y","2019","Journal of cachexia, sarcopenia and muscle","preclinical","article","10.1002/jcsm.12434","31020810","PMC6711418",null,"S001679","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007726","Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors.","Lin DS","2022","Diabetologia","nonrandomized_study","article","10.1007/s00125-022-05772-9","35945333",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007727","Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796.","Thornton P","2024","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.123.002013","38336379",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007728","Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia.","Aronson R","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13580","30421545","PMC6587752",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; brief-report; article"],["R0007729","Obstructive Sleep Apnea: An Evolving Therapeutic Landscape with an Emerging Role for Incretin-Based Therapies.","Xu B","2025","Advances in therapy","narrative_review","article","10.1007/s12325-025-03312-6","40699277","PMC12305468",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007730","Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes.","Lee BW","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-023-01515-0","38236431","PMC10838861","ClinicalTrials.gov:NCT03061214","S001311","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007731","Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study.","Khalil I","2026","Hepatology international","randomized_trial","article","10.1007/s12072-026-11122-3","42397506",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; article"],["R0007732","A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.","Rahbek MT","2024","Pharmacoepidemiology and drug safety","randomized_trial","article","10.1002/pds.5673","37559355",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0007733","The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension.","Younes ST","2020","American journal of physiology. Heart and circulatory physiology","preclinical","article","10.1152/ajpheart.00486.2019","31729903","PMC6985807",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0007734","Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.","Home PD","2023","Diabetes, obesity & metabolism","other","article","10.1111/dom.14907","36309941","PMC10099981","EudraCT:2017-003370-13",null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007735","Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial.","Pasquel FJ","2025","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2024.59348","39951268","PMC11829226","ClinicalTrials.gov:NCT05815342",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Clinical Trial; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0007736","Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care.","Lingvay I","2020","The American journal of managed care","other_trial","article","10.37765/ajmc.2020.88555","33439583",null,"ClinicalTrials.gov:NCT03914326","S002179","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007737","Effects of GLP-1R agonist or co-cyprindiol, in combination with metformin, on polycystic ovary syndrome in overweight women: A Randomized Clinical Trial","Liao M","2021","Authorea Preprints","randomized_trial","preprint","10.22541/au.163570984.48793962/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0007738","Alpha-cell glucagon is essential for maintaining β-cell function and identity in adult mice.","Prasadan K","2026","The Journal of biological chemistry","preclinical","article","10.1016/j.jbc.2026.113145","42134544","PMC13264239",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007739","Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.","Banerjee M","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70277","42618523",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007740","Trial of Lixisenatide in Early Parkinson's Disease.","Meissner WG","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2312323","38598572",null,"ClinicalTrials.gov:NCT03439943","S001960; S002208","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007741","Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes.","Baragetti A","2026","British journal of pharmacology","narrative_review","article","10.1111/bph.70483","42185046",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Preprint; preprint; article"],["R0007742","Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity.","Parums DV","2024","Medical science monitor : international medical journal of experimental and clinical research","commentary","article","10.12659/msm.946675","39350608","PMC11453121",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0007743","Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.","Vernstrøm L","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15464","38240066",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0007744","Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.","Santos-Pereira M","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1870008","42718598","PMC13553220","PROSPERO:CRD42022371697",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0007745","A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.","You Z","2026","Frontiers in pharmacology","other_trial","article","10.3389/fphar.2026.1815576","42741482","PMC13572791",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0007746","The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways.","Rakipovski G","2018","JACC. Basic to translational science","preclinical","article","10.1016/j.jacbts.2018.09.004","30623143","PMC6314963",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007747","Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.","He L","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-020-00882-2","32734559","PMC7434822",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0007748","A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity.","Hasanzad M","2020","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-020-00619-9","33520865","PMC7843728",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0007749","Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.","Wadden TA","2026","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.70122","41537305","PMC12933222","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657003; ClinicalTrials.gov:NCT04657016","S001077; S001712; S002157","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0007750","Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.","D'Ascanio AM","2024","Cardiology in review","other","article","10.1097/crd.0000000000000513","36883831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007751","The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer.","Ibrahim SS","2024","Cancer metastasis reviews","narrative_review","article","10.1007/s10555-024-10192-9","38801466","PMC11554930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0007752","Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes.","Lambadiari V","2021","Antioxidants (Basel, Switzerland)","other","article","10.3390/antiox10091379","34573011","PMC8468804",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007753","Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility.","Jalleh RJ","2024","Endocrinology","narrative_review","article","10.1210/endocr/bqae155","39568409","PMC11630531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007754","GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials.","Romariz LM","2026","Pediatric research","systematic_review","article","10.1038/s41390-025-04228-1","40588554",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007755","Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.","Østergaard HB","2023","Diabetes, obesity & metabolism","other","article","10.1111/dom.14887","36199242","PMC10092227",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007756","Generalizability of kidney and cardiovascular protection by finerenone to the real world in Italy: insights from Fidelio and Figaro studies.","De Cosmo S","2025","Journal of nephrology","nonrandomized_study","article","10.1007/s40620-024-02171-8","39676127",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007757","Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study.","Miyake T","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-022-01239-7","35312970","PMC9076799","jRCT:jRCTs061210009; UMIN:UMIN000045003",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0007758","Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.","Müllertz ALO","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13717","38463003",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0007759","Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study.","Terui S","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01557-y","38494572","PMC11043256",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007760","Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?","Razzaki TS","2022","Therapeutics and clinical risk management","narrative_review","article","10.2147/tcrm.s328056","36199834","PMC9527616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007761","Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type 2 diabetes mellitus : Systematic review of real-world observational studies.","Alam A","2026","Wiener medizinische Wochenschrift (1946)","systematic_review","article","10.1007/s10354-025-01108-5","40900212",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0007762","Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up.","Grigorescu ED","2023","Diagnostics (Basel, Switzerland)","other","article","10.3390/diagnostics13172817","37685355","PMC10487011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007763","Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis.","Bellastella G","2020","Stroke","systematic_review","article","10.1161/strokeaha.119.027557","31813360",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007764","Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.","Federici MO","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0396-2","29525885","PMC6104260",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0007765","Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese mice","Krah NM","2026","bioRxiv","preclinical","preprint","10.64898/2026.09.01.748392",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007766","Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health.","Ghaleb J","2025","International journal of endocrinology","narrative_review","article","10.1155/ije/2876156","41069980","PMC12507501",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007767","Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules.","Balachandra S","2025","The Journal of surgical research","nonrandomized_study","article","10.1016/j.jss.2025.05.016","40578060",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0007768","Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.","Nguyen H","2017","Advances in therapy","nonrandomized_study","article","10.1007/s12325-016-0470-y","28078541","PMC5350190",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007769","Impact of tirzepatide in a patient with type 1 diabetes and obesity: A case report.","Mendoza F","2023","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2023.08.012","37604405",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0007770","Effect of metabolic status on response to SIV infection and antiretroviral therapy in nonhuman primates.","Webb GM","2024","JCI insight","nonrandomized_study","article","10.1172/jci.insight.181968","39115937","PMC11457846",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007771","Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.","Kuate Defo A","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15331","37869901",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0007772","Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks' treatment with semaglutide.","Ganeshalingam AA","2026","Cardiovascular diabetology. Endocrinology reports","randomized_trial","article","10.1186/s40842-025-00258-0","41555458","PMC12817643","ClinicalTrials.gov:NCT05193578","S001361","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0007773","Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.","Chen QX","2026","Endocrine","systematic_review","article","10.1007/s12020-026-04757-7","42603240",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0007774","Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.","Katsiki N","2022","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2022.2143263","36322877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0007775","A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist.","Bosch R","2022","CPT: pharmacometrics & systems pharmacology","other","article","10.1002/psp4.12752","34889083","PMC8923724",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007776","The Therapeutic Effects of Semaglutide in Congenital Linear Scleroderma.","Chen H","2025","Cureus","case_report","article","10.7759/cureus.88725","40861533","PMC12376079",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007777","Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists.","Tanday N","2022","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14821","35848461","PMC9804730",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007778","The unseen risk of Ozempic: NAION and vision damage.","Saleem NUA","2025","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000004149","41377330","PMC12688804",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0007779","Myocardial deformation links combined liraglutide-empagliflozin therapy with improved cardiovascular and economic outcomes in type 2 diabetes: a 6-year study.","Thymis J","2026","European heart journal. Imaging methods and practice","other","article","10.1093/ehjimp/qyag080","42226732","PMC13222642","ClinicalTrials.gov:NCT03878706","S000665","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0007780","[Obesity and type 2 diabetes mellitus (Update 2026)].","Brix JM","2026","Wiener klinische Wochenschrift","narrative_review","article","10.1007/s00508-026-02706-y","42162469","PMC13190753",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; research-article; article"],["R0007781","Redefining Cystic Fibrosis-Related Diabetes Management With Tirzepatide: A Case Report.","Suresh Babu Y","2025","Cureus","case_report","article","10.7759/cureus.97448","41439084","PMC12719532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007782","Acute Pancreatitis-Induced Euglycemic Diabetic Ketoacidosis.","Chaudhry A","2021","Cureus","case_report","article","10.7759/cureus.15949","34336446","PMC8312994",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007783","Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes.","Longato E","2021","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaa081","33624059",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007784","Change in circulating irisin level and its association with lipid metabolism after exenatide treatment in patients with type 2 diabetes mellitus.","Gao Y","2026","Journal of clinical & translational endocrinology","other_trial","article","10.1016/j.jcte.2026.100447","42381981","PMC13315098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007785","Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis.","Li X","2026","European journal of medical research","preclinical","article","10.1186/s40001-026-03974-0","41622219","PMC12952193",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007786","Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.","Sani E","2022","Endocrine, metabolic & immune disorders drug targets","case_report","article","10.2174/1871530322666220509225637","35538810",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; conference-abstract; article"],["R0007787","GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.","Nauck MA","2021","Molecular metabolism","narrative_review","article","10.1016/j.molmet.2020.101102","33068776","PMC8085572",null,"S000918; S002311","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007788","Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Gonzalez JS","2024","Diabetes care","randomized_trial","article","10.2337/dc23-2459","38416773","PMC10973899",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007789","Psychometric Validation of the Simplicity of Diabetes Treatment Questionnaire (Sim-Q) for Type 2 Diabetes.","Boye KS","2026","Advances in therapy","other","article","10.1007/s12325-025-03448-5","41678136","PMC13065586",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Validation Study; Multicenter Study; research-article; article"],["R0007790","Oral TIX100 protects against obesity-associated glucose intolerance and diet-induced adiposity.","Jo S","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16223","39895486","PMC11885086",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0007791","A practical review of diabetes mellitus type 2 treatment in primary care.","Call JT","2022","Romanian journal of internal medicine = Revue roumaine de medecine interne","narrative_review","article","10.2478/rjim-2021-0031","34333891",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007792","GLP-1 drugs: New eyesight warning for Ozempic/Wegovy.","Iacobucci G","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.s252","41651549",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007793","GLP-1 agonists and exercise: the future of lifestyle prioritization.","Codella R","2025","Frontiers in clinical diabetes and healthcare","narrative_review","article","10.3389/fcdhc.2025.1720794","41367404","PMC12683586",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007794","Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice.","Xu Q","2022","Molecular medicine (Cambridge, Mass.)","preclinical","article","10.1186/s10020-022-00574-6","36463128","PMC9719171",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Preprint; research-article; preprint; article"],["R0007795","Prescription Fills Among Patients With Type 2 Diabetes After Hospitalization for Acute Coronary Syndrome.","Kelsey MD","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.47102","39602121","PMC12520711",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007796","Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.","Haggag AZ","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16047","39495140","PMC11701199","ClinicalTrials.gov:NCT05654831","S002988","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0007797","The Role of Bariatric Surgery in the Era of GLP-1 Receptor Agonists.","Koeller E","2025","Rhode Island medical journal (2013)","narrative_review","article",null,"41284403",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007798","Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.","Lingvay I","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01010-4","33594582","PMC7947062",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0007799","Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology.","Dwibedi C","2024","Nature metabolism","randomized_trial","article","10.1038/s42255-023-00943-3","38177805","PMC10822775","ClinicalTrials.gov:NCT04451837","S001033","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0007800","Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).","Polonsky WH","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01189-6","34918213","PMC8776963",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007801","Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.","Eissing T","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15387","38037539",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0007802","Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats.","Chang SE","2026","Psychopharmacology","preclinical","article","10.1007/s00213-026-07045-4","41870532",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007803","The Horizon Ahead: Emerging Adjunctive Therapies for Type 1 Diabetes.","Hamidi V","2026","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2026.04.012","42527005",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0007804","Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis.","Li X","2022","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2022.101366","35760374",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007805","Metabolic disorders in prediabetes: From mechanisms to therapeutic management.","Ping WX","2024","World journal of diabetes","narrative_review","article","10.4239/wjd.v15.i3.361","38591088","PMC10999048",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007806","The Impact of Liraglutide, a GLP-1 Receptor Agonist, on High Glucose-Induced Inflammation, Apoptosis, Oxidative Stress, and NLRP3 Signaling.","Gokce M","2025","Cell biochemistry and biophysics","other","article","10.1007/s12013-025-01742-1","40216698",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007807","Periconceptional GLP-1 Receptor Agonist Exposure: Lower Observed Risk or Lower Certainty?","Singh R","2026","JACC. Advances","commentary","article","10.1016/j.jacadv.2026.103152","42585855","PMC13482208",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0007808","Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.","Pirro V","2022","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgab722","34608929",null,"ClinicalTrials.gov:NCT03131687","S000010","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0007809","Muscle and Bone Implications of GLP-1 Receptor Agonists and Fragility Fractures in Older Adults With Diabetes.","Abraham JD","2026","Journal of cachexia, sarcopenia and muscle","commentary","article","10.1002/jcsm.70371","42634141","PMC13500797",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0007810","Oral delivery of GLP-1R agonist by an engineered probiotic yeast strain has anti-obesity effects in mice","Hedin KA","2022","bioRxiv","preclinical","preprint","10.1101/2022.12.21.521368",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007811","Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.","Kim YJ","2020","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2020.00553","32973680","PMC7466678",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; systematic-review; article"],["R0007812","Risk factor obesity: treatment standard.","Mashayekhi M","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","narrative_review","article","10.1093/ndt/gfag164","42446420","PMC13518094",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; review-article; article"],["R0007813","Clinical Efficacy of Polyethylene Glycol Loxenatide in the Treatment of Obese or Overweight Patients with Type 2 Diabetes Mellitus.","Song X","2023","Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","randomized_trial","article","10.29271/jcpsp.2023.12.1390","38062594",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0007814","Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.","Colosimo S","2021","Liver international : official journal of the International Association for the Study of the Liver","nonrandomized_study","article","10.1111/liv.14799","33497019","PMC8248247",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007815","High Salt Intake Affects Visceral Adipose Tissue Homeostasis: Beneficial Effects of GLP-1 Agonists.","Touceda V","2025","Biology","preclinical","article","10.3390/biology14091171","41007316","PMC12467069",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007816","Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.","Batsis JA","2026","Annals of internal medicine","systematic_review","article","10.7326/annals-25-00478","41996180",null,"OSF:osf.io/s3a5e",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0007817","Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study.","Iwamoto T","2026","Endocrine journal","nonrandomized_study","article","10.1507/endocrj.ej26-0274","42816319",null,"UMIN:UMIN000053671",null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0007818","Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes.","Anderson JE","2020","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds19-0031","32425454","PMC7228816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007819","Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis.","Tuersun A","2024","The American journal of the medical sciences","systematic_review","article","10.1016/j.amjms.2024.07.011","38977245",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007820","Anti-inflammatory effects of GLP-1 in patients with COVID-19.","Sazgarnejad S","2022","Expert review of anti-infective therapy","nonrandomized_study","article","10.1080/14787210.2021.1964955","34348067","PMC8425436",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007821","Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression.","Rodriguez-Valadez JM","2023","Diabetes care","systematic_review","article","10.2337/dc22-0772","37220263","PMC10234755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; review-article; review; other"],["R0007822","Mechanistic insights into GLP-1 receptor agonist-induced weight loss through ceRNA network analysis.","Li W","2025","Genomics","preclinical","article","10.1016/j.ygeno.2025.110988","39761765",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007823","Mazdutide: First Approval.","Shirley M","2025","Drugs","narrative_review","article","10.1007/s40265-025-02249-y","41028652",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007824","Oral semaglutide in type 2 diabetes.","Anderson SL","2020","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2019.107520","31952996",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007825","Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: Initial report from a cardiometabolic center of excellence.","Sammour Y","2021","The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","nonrandomized_study","article","10.1016/j.healun.2021.02.012","33745782",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0007826","Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.","Garvey WT","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2502081","40544433",null,"ClinicalTrials.gov:NCT05567796","S001154","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; article"],["R0007827","Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models.","Borner T","2025","Science advances","preclinical","article","10.1126/sciadv.adu1589","40532005","PMC12175907",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007828","1-year patient-reported outcomes in patients with a documented GLP-1 agonist prescription history prior to total hip arthroplasty: a retrospective cohort study.","Benyamini B","2026","Hip international : the journal of clinical and experimental research on hip pathology and therapy","nonrandomized_study","article","10.1177/11207000261450078","42274387",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007829","Diabetes of Unclear Type in an Adolescent Boy With Multiple Islet-cell Autoantibody Positivity Successfully Managed With Glucagon-like Peptide-1 Receptor Agonist Alone: A Case Report.","Ginnard OZB","2023","Canadian journal of diabetes","case_report","article","10.1016/j.jcjd.2022.07.006","36075851","PMC10024250",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; research-article; article"],["R0007830","[Semaglutide-induced acute-on-chronic liver failure: A case report and literature review].","Fu R","2026","Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences","case_report","article","10.11817/j.issn.1672-7347.2026.250330","42244313","PMC13229664",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; Review; English Abstract; research-article; article"],["R0007831","Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications.","Katamine A","2026","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70407","42499272","PMC13401126",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0007832","Erratum to: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.","Geloneze B","2017","Drugs","notice","article","10.1007/s40265-017-0766-5","28523587","PMC6828282",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0007833","Incretin-induced changes in the transcriptome of skeletal muscles of fa/fa Zucker rat (ZFR) with obesity, without diabetes.","Colin IM","2022","International journal of obesity (2005)","preclinical","article","10.1038/s41366-022-01114-2","35383269",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0007834","GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases.","Vilarrasa N","2025","Medicina clinica","narrative_review","article","10.1016/j.medcli.2025.107184","41016281",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007835","Exenatide implant therapy in diabetes.","Kalra S","2018","JPMA. The Journal of the Pakistan Medical Association","narrative_review","article",null,"30317359",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007836","Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review.","Liu G","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-023-01391-8","36913143","PMC10126195",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007837","The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.","Jakubowska A","2024","Endocrinology and metabolism (Seoul, Korea)","randomized_trial","article","10.3803/enm.2024.1942","38356208","PMC10901658",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Review; Journal Article; review-article; article"],["R0007838","Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.","Hussein H","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14008","32077218",null,"PROSPERO:CRD42018091306",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0007839","Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence.","Goshe M","2026","Cureus","systematic_review","article","10.7759/cureus.114404","42729808","PMC13564011",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007840","Cardioprotective antihyperglycemic drugs ameliorate endoplasmic reticulum stress.","Mooradian AD","2024","American journal of physiology. Cell physiology","narrative_review","article","10.1152/ajpcell.00470.2023","38009197",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0007841","Effects of incretin-based therapies on renal function.","Tsimihodimos V","2018","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2017.10.049","29066413",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007842","[Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide].","Troshina EA","2026","Problemy endokrinologii","nonrandomized_study","article","10.14341/probl13784","42545321","PMC13474367",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Consensus Statement; English Abstract; review-article; article"],["R0007843","DUAL GIP/GLP-1Ra reduces residual proteinuria in non-diabetic fabry disease.","Riccio E","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other","article","10.1093/ndt/gfag115","42159298",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007844","Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.","Krychtiuk KA","2024","European heart journal. Cardiovascular pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvae006","38271596","PMC13031111",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0007845","Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.","Baviera M","2021","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14361","33606897",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0007846","Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.","Simon TG","2022","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","nonrandomized_study","article","10.1016/j.cgh.2021.07.010","34256144","PMC8743301",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0007847","Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model.","Horska K","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2024.116763","38805968",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007848","The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review.","Daniilopoulou I","2022","Medicina (Kaunas, Lithuania)","systematic_review","article","10.3390/medicina58020224","35208548","PMC8878541",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0007849","Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2024","Obesity science & practice","systematic_review","article","10.1002/osp4.70032","39720158","PMC11667760",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0007850","Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s.","Etrusco A","2024","Biomedicines","nonrandomized_study","article","10.3390/biomedicines12030653","38540265","PMC10967775",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007851","Detection of pancreatic beta cell mass in vivo in humans: studies in individuals with long-standing type 1 diabetes and in individuals with obesity","Cas AD","2026","medRxiv","other","preprint","10.64898/2026.03.12.26348138",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007852","Association between Glucose-lowering Treatments and Risk of Diabetic Retinopathy in People with Type 2 Diabetes: A Nationwide Cohort Study.","Hasselstrøm Jensen J","2024","Current drug safety","nonrandomized_study","article","10.2174/1574886318666230420084701","37078347",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007853","Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.","Cortes TM","2024","JMIR research protocols","protocol","article","10.2196/62667","39269759","PMC11437224","ClinicalTrials.gov:NCT05786521","S000230","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007854","Analysis of long noncoding RNA-associated competing endogenous RNA network in glucagon-like peptide-1 receptor agonist-mediated protection in β cells.","Cui LJ","2020","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v11.i9.374","32994866","PMC7503504",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007855","Synergistic SGLT2 and GLP-1R targeting alleviates systemic inflammation-induced and M1 monocyte-driven endothelial dysfunction in coronary artery disease.","Mroueh A","2026","Cardiovascular diabetology","other","article","10.1186/s12933-026-03267-0","42401896","PMC13617697",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007856","Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.","Yu D","2023","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2023.06.008","37455226",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0007857","Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial.","Chen C","2025","Life metabolism","nonrandomized_study","article","10.1093/lifemeta/loaf024","42058132","PMC13122358","ClinicalTrials.gov:NCT05024032","S001086","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007858","Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats.","Vallöf D","2020","Translational psychiatry","preclinical","article","10.1038/s41398-020-00923-1","32678077","PMC7367312",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007859","Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.","Kosiborod MN","2024","JACC. Heart failure","protocol","article","10.1016/j.jchf.2024.09.004","39453356",null,"ClinicalTrials.gov:NCT06077864","S000475","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, N.I.H., Extramural; article"],["R0007860","The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism.","Zhang Y","2025","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.202411980","40125821","PMC12097124",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007861","Chronic Kidney Disease in the Older Adult Patient with Diabetes.","Ravender R","2024","Journal of clinical medicine","narrative_review","article","10.3390/jcm13020348","38256482","PMC10816477",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007862","Unexpected Insulinoma in Type 2 Diabetes During Long-term Dulaglutide Therapy: A Case Report and Literature Review","Limiroli M","2026","Research Square","case_report","preprint","10.21203/rs.3.rs-9440682/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007863","Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective.","Torre E","2026","ClinicoEconomics and outcomes research : CEOR","other","article","10.2147/ceor.s585328","42099530","PMC13144296",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007864","SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality.","Qiu M","2021","Frontiers in cardiovascular medicine","nonrandomized_study","article","10.3389/fcvm.2021.791311","34950720","PMC8688798",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0007865","Use of Diabetes Medications before and after a Heart Failure-Related Hospitalization among Nursing Home Residents.","Zhang T","2024","Journal of the American Medical Directors Association","nonrandomized_study","article","10.1016/j.jamda.2023.06.033","37553080","PMC10839110",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0007866","Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions.","Ruggeri RM","2025","Reviews in endocrine & metabolic disorders","nonrandomized_study","article","10.1007/s11154-025-09958-5","40175622","PMC12316766",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0007867","Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.","Pratley RE","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.08.004","39217553",null,"ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0007868","Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.","Davies MJ","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2502082","40544432",null,"ClinicalTrials.gov:NCT05394519","S001912","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; article"],["R0007869","Reasons for and Outcomes of Medicare Part D Appeals for Denied GLP-1 Receptor Agonist Claims.","Klebanoff MJ","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71201","42575866","PMC13646333",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0007870","A single dorsal vagal complex circuit mediates the aversive and anorectic responses to GLP1R agonists.","Yacawych WT","2025","bioRxiv : the preprint server for biology","other","article","10.1101/2025.01.21.634167","39896596","PMC11785067",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0007871","GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2/HO-1 and MAPK/NF-κB signaling pathways.","Lv R","2024","International immunopharmacology","preclinical","article","10.1016/j.intimp.2024.113222","39321702",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007872","Correction: Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway.","Kang X","2026","Molecular medicine (Cambridge, Mass.)","notice","article","10.1186/s10020-026-01448-x","41913098","PMC13034588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0007873","High-fat diet alters fluid intake without reducing sensitivity to glucagon-like peptide-1 receptor agonist effects.","Volcko KL","2020","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2020.112910","32283107","PMC7266080",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007874","Downstream Treatment Burden and Health-Care Utilization Following Initiation of GLP-1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes.","Alhamdan Y","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70718","41913529","PMC13146132",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0007875","Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.","Ayesh H","2024","Metabolism open","systematic_review","article","10.1016/j.metop.2024.100284","38699397","PMC11064603","OSF:osf.io/gd67x",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0007876","Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists.","Tommerdahl KL","2021","Advances in chronic kidney disease","narrative_review","article","10.1053/j.ackd.2021.06.001","34922690","PMC9119551",null,"S002311","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0007877","Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19.","Salmen T","2022","Biomedicines","nonrandomized_study","article","10.3390/biomedicines10102624","36289885","PMC9599217",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007878","Fatty acid amide hydrolase (FAAH) and the endocannabinoid system in obesity: Mechanistic insights and pharmacological opportunities beyond incretin-based therapies.","Serra I","2026","British journal of pharmacology","narrative_review","article","10.1111/bph.70511","42144898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007879","Advances in the Insulin-Heart Axis: Current Therapies and Future Directions.","Caturano A","2024","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms251810173","39337658","PMC11432093",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007880","GLP-1 receptor agonists for Alzheimer's disease: Lessons from trials and translational challenges.","Stringhi R","2026","Cell reports. Medicine","randomized_trial","article","10.1016/j.xcrm.2026.102918","42612619","PMC13522798",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; news; article"],["R0007881","Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes.","Albogami Y","2021","Diabetes care","randomized_trial","article","10.2337/dc20-1794","33875487","PMC8247488",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0007882","A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.","Goryanin I","2026","CPT: pharmacometrics & systems pharmacology","other_trial","article","10.1002/psp4.70322","42572918","PMC13454951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0007883","Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review.","Haran K","2024","Psoriasis (Auckland, N.Z.)","randomized_trial","article","10.2147/ptt.s485061","39564576","PMC11575455",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0007884","Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.","Cardoso P","2024","Diabetologia","nonrandomized_study","article","10.1007/s00125-024-06099-3","38388753","PMC10955037",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007885","Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.","Mayne KJ","2024","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15625","38699995",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007886","Reduced Risk in Melanoma and Nonmelanoma Skin Cancers in Obese Patients on Semaglutide and Tirzepatide.","Alameddine R","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","other","article","10.1097/dss.0000000000005339","42714323",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007887","Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021.","Salahuddin T","2024","American heart journal","nonrandomized_study","article","10.1016/j.ahj.2023.11.009","37956920",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0007888","JAAD CME Part 1: Mechanism of Action of GLP-1 Receptor Agonists and Potential Pathways in Skin Health.","Narla S","2026","Journal of the American Academy of Dermatology","narrative_review","article","10.1016/j.jaad.2026.01.088","41707707",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007889","Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin.","Yuen KCJ","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1456195","39665021","PMC11632222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007890","An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.","Lin CH","2020","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2019.1695779","31790314",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007891","A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.","Tilinca MC","2021","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina57070669","34209532","PMC8307742",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0007892","Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.","Fadini GP","2018","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2017-000475","29449951","PMC5808638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007893","Tirzepatide improves neutrophilic inflammation in obese asthmatic mice by downregulating Th17 cell differentiation.","Sun L","2025","Molecular biology reports","preclinical","article","10.1007/s11033-025-11366-6","41389087",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007894","SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.","Anson M","2023","Diabetologia","nonrandomized_study","article","10.1007/s00125-023-05975-8","37505282","PMC10473989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007895","Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.","Xie C","2024","World journal of hepatology","nonrandomized_study","article","10.4254/wjh.v16.i5.731","38818288","PMC11135259",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0007896","CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.","Jacobsen JM","2025","Nature metabolism","preclinical","article","10.1038/s42255-025-01324-8","40629149","PMC12286864",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007897","Sedation for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Guideline.","Triantafyllou K","2026","Endoscopy","other","article","10.1055/a-2898-6540","42480549",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Practice Guideline; Journal Article; article"],["R0007898","Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists.","Boshchenko AA","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25094900","38732142","PMC11084666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007899","Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis.","Kawai Y","2022","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2021.109146","34780865",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0007900","The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis.","Lin J","2026","Journal of ovarian research","systematic_review","article","10.1186/s13048-026-02078-x","41862977","PMC13126963","PROSPERO:CRD420251045700",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; article"],["R0007901","[Efficacy and safety of SGLT-2 inhibitors and GLP-1 receptor agonists in the elderly].","Gölz S","2025","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-025-4842-6","40312642",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007902","Liraglutide ameliorates intrauterine adhesion by inhibiting NF-κb phosphorylation and reducing epithelial-mesenchymal transition.","Shi J","2025","Experimental cell research","nonrandomized_study","article","10.1016/j.yexcr.2025.114708","40784419",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007903","Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.","Iacobellis G","2022","Journal of endocrinological investigation","narrative_review","article","10.1007/s40618-021-01687-1","34643917",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007904","Severe Euglycemic Ketoacidosis Secondary to Tirzepatide Use for Weight Loss.","Hassan A","2026","Cureus","case_report","article","10.7759/cureus.107028","42147686","PMC13175126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007905","The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.","Jung CH","2019","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes.2019.28.1.18","31089576","PMC6484938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007906","Equitable Access to GLP-1 Receptor Agonists-Essential but Not Accessible.","Abdool Karim S","2026","JAMA","other","article","10.1001/jama.2026.15762","42821279",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007907","Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.","Wu Z","2024","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2024.1378291","38868747","PMC11167098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0007908","Safety and Efficacy of Biosimilar Insulin Glargine (Basaglar) in Indian Patients with Type 2 Diabetes Mellitus: Results from a Multicenter, Open-Label, Single-Arm, Phase 4 Trial (ABEX).","Saboo B","2025","The Journal of the Association of Physicians of India","other_trial","article","10.59556/japi.73.0842","39927997",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Multicenter Study; Clinical Trial, Phase IV; article"],["R0007909","Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.","Blumer I","2018","Postgraduate medicine","narrative_review","article","10.1080/00325481.2018.1450058","29521173",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007910","The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.","Meece J","2017","Advances in therapy","narrative_review","article","10.1007/s12325-017-0491-1","28210986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007911","Efficacy and safety of employing an intragastric balloon to manage super obesity, either as a standalone treatment or in combination with GLP-1 receptor agonists.","Jeske P","2026","Research Square","other","preprint","10.21203/rs.3.rs-9910074/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007912","Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden.","Eliasson B","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00872-4","32617849","PMC7376998",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0007913","Layer-by-Layer Polymeric Films: A Novel Approach to Buccal GLP-1 Delivery","Pantazoglou E","2026","bioRxiv","preclinical","preprint","10.64898/2026.01.19.700335",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007914","Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.","Patoulias D","2019","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2019.107927","31733280",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0007915","Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.","Kow CS","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70325","42673571","PMC13529306",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0007916","Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.","Petrie MC","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.04.022","38819334",null,null,"S000913","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0007917","Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?","Lee MMY","2024","Current heart failure reports","randomized_trial","article","10.1007/s11897-023-00637-7","38133864","PMC10827951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0007918","Rewriting Heart Health: Epigenetic Drugs in Cardiovascular Medicine.","Atzemian N","2026","European heart journal. Cardiovascular pharmacotherapy","other_trial","article","10.1093/ehjcvp/pvag075","42781940",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0007919","Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.","Yandrapalli S","2020","Cardiology in review","randomized_trial","article","10.1097/crd.0000000000000308","32282393",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0007920","Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study.","Abrahami D","2022","Diabetes care","randomized_trial","article","10.2337/dc22-1174","36170656","PMC9998845",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0007921","Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies.","Soliman S","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18101519","41155633","PMC12567493",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007922","Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis","Kanie T","2020","The Cochrane database of systematic reviews","narrative_review","article","10.1002/14651858.cd013650",null,"PMC7387055",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","systematic-review; Review; article"],["R0007923","[Non-Insulin Antidiabetic Agents in the Management of Hyperglycaemia of Non-Critical Hospitalized Patients].","Monteiro Lopes S","2024","Acta medica portuguesa","narrative_review","article","10.20344/amp.20858","38316163",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Review; article"],["R0007924","Identification of a pathogenic founder variant in the WFS1 gene that causes Wolfram syndrome in the Druze population.","Halabi I","2025","Frontiers in pediatrics","nonrandomized_study","article","10.3389/fped.2025.1525846","39944315","PMC11814454",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007925","Evaluation of a pharmacist's impact on the use of glucagon-like peptide-1 receptor agonists for weight management in a family medicine setting.","Crocetta N","2023","Family practice","nonrandomized_study","article","10.1093/fampra/cmac110","36200484",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007926","Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial.","Takase T","2019","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12906","30076787","PMC6497607",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0007927","Kidney fat by magnetic resonance spectroscopy in type 2 diabetes with chronic kidney disease.","Heinrich NS","2025","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2024.108923","39647261",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0007928","Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells.","Wang Y","2021","Frontiers in endocrinology","other","article","10.3389/fendo.2021.622737","34434166","PMC8380782",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007929","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.","Lu JM","2019","Advances in therapy","narrative_review","article","10.1007/s12325-019-00914-9","30859500",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0007930","Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists.","Forner P","2023","Internal medicine journal","other","article","10.1111/imj.16312","38158765",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007931","Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial.","Corley MJ","2025","medRxiv : the preprint server for health sciences","randomized_trial","article","10.1101/2025.07.09.25331038","40791720","PMC12338914",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Preprint; preprint"],["R0007932","Methyl Proton Spin Relaxation (R2/R1) Enables Sensitive Detection of pH-Dependent Oligomerization in GLP-1 Analogs.","Lu J","2026","Analytical chemistry","other","article","10.1021/acs.analchem.6c01281","42131979","PMC13283412",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007933","Hypertension management in patients with cardiovascular comorbidities.","Lauder L","2023","European heart journal","narrative_review","article","10.1093/eurheartj/ehac395","36342266",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; article"],["R0007934","Differences in brain spindle density during sleep between patients with and without type 2 diabetes.","Yeung D","2025","Computers in biology and medicine","nonrandomized_study","article","10.1016/j.compbiomed.2024.109484","39622099","PMC11663128",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Intramural; research-article; article"],["R0007935","Weight loss, bariatric surgery, and novel antidiabetic drugs effects on diabetic retinopathy: a review.","Perez AM","2024","Current opinion in ophthalmology","narrative_review","article","10.1097/icu.0000000000001038","38295156",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0007936","RF28 | PSUN182 Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9625460",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0007937","Combination therapies in nonalcoholic fatty liver disease using antidiabetic and disease-specific drugs.","Koureta E","2023","Annals of gastroenterology","narrative_review","article","10.20524/aog.2023.0806","37396007","PMC10304532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007938","Comments on 'BAF60a-dependent chromatin remodeling preserves β-cell function and contributes to the therapeutic benefits of GLP-1R agonists'.","Wu Q","2026","Journal of molecular cell biology","other","article","10.1093/jmcb/mjaf044","41288317","PMC13049365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007939","Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?","MacIsaac RJ","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-020-00863-5","32564337","PMC7376989",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; other; article"],["R0007940","Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD.","Hu JC","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.0946","38436955","PMC10912959",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007941","Modern glucose-lowering drugs in liver transplant recipients: improvement in weight, glycemic control, and potentially allograft steatosis.","Atthota S","2023","Frontiers in transplantation","nonrandomized_study","article","10.3389/frtra.2023.1223169","38993868","PMC11235220",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0007942","The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF).","Hullon D","2025","Cardiovascular diabetology","other_trial","article","10.1186/s12933-025-02607-w","39920668","PMC11806760",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0007943","Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge.","Prasad S","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag121","42027588","PMC13100657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007944","Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials.","Ng CH","2022","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2021.09.013","34606980",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis; Review"],["R0007945","Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.","Mody R","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16372","40181696",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0007946","Slowing the Progression of Diabetic Kidney Disease.","Blazek O","2023","Cells","narrative_review","article","10.3390/cells12151975","37566054","PMC10417620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007947","Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients.","Du L","2022","Frontiers in physiology","systematic_review","article","10.3389/fphys.2022.1028486","36419835","PMC9676496",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; discussion; article"],["R0007948","Peptide Hormones in Appetite Regulation: A Complex Network.","Abdollahi S","2026","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph19070989","42515672","PMC13415584",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007949","[Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].","Li ZX","2016","Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences","systematic_review","article",null,"27318907",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; article"],["R0007950","From Potency Ratios to Target Engagement: Translational Identifiability of Multi-Incretin Receptor Balance","Fouda A","2026","Authorea Preprints","other","preprint","10.22541/authorea.15008173/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007951","Ventricular-arterial coupling as a potential therapeutic target in diabetes.","Saeed S","2021","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.01279","34783749",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007952","Evaluating Weight Loss Associated with Bariatric Surgery After Liraglutide Use: A Matched Population-Level Retrospective Cohort Study.","Faran M","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-08054-6","40711700",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0007953","Vertical sleeve gastrectomy and semaglutide have distinct effects on skeletal health and heart function in obese male mice.","Picoli CC","2025","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00521.2024","40072928","PMC12121371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007954","Effects of acute GLP-1 analogue infusion on the glycemic and neurohormonal responses to meal test in non- hypoglycemic subjects after gastric bypass.","Almby KE","2025","Endocrine","randomized_trial","article","10.1007/s12020-025-04446-x","41071533","PMC12708692",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0007955","GLP‐1 Receptor Agonists and Facial Aging: Two Overlooked Mechanisms","Feng M","2026","Journal of cosmetic dermatology","commentary","article","10.1111/jocd.71077",null,"PMC13385476",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0007956","Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu.","Yaribeygi H","2020","Life sciences","narrative_review","article","10.1016/j.lfs.2020.117916","32534034",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007957","Use of incretin-based therapies in women using hormone replacement therapy (HRT).","Mukherjee A","2025","Post reproductive health","other","article","10.1177/20533691251343069","40378270",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007958","Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.","Michalak W","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70919","42225305","PMC13341387",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0007959","New advances in type 1 diabetes.","Subramanian S","2024","BMJ (Clinical research ed.)","narrative_review","article","10.1136/bmj-2023-075681","38278529",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0007960","Cardio-protective Effects of Glucagon-like Peptide-1 Receptor Agonists: An Overview of Systematic Reviews and Publication Overlap.","Zafeiropoulos S","2021","Current pharmaceutical design","systematic_review","article","10.2174/1381612827666210119103153","33463455",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0007961","Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus.","Clements JN","2021","Clinical pharmacokinetics","randomized_trial","article","10.1007/s40262-020-00951-6","33108617",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0007962","Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials.","Vetter ML","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-019-0627-1","31077072","PMC6612359",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0007963","Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control.","Bonga KN","2026","Rambam Maimonides medical journal","narrative_review","article","10.5041/rmmj.10565","41605830","PMC12857648",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007964","Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study.","Peng XV","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00783-4","32112204","PMC7136385",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; other; article"],["R0007965","The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research.","Violette CJ","2023","Expert review of anticancer therapy","other","article","10.1080/14737140.2023.2194636","36944434",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007966","The Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Stimulates Mechanistic Target of Rapamycin (mTOR) Signaling via PKA And Akt","Le T","2021","Journal of the Endocrine Society","other","article",null,null,"PMC8090693",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0007967","Extensive Arteriovenous Fistula Thrombosis With Glucagon-Like Peptide-1 Agonist.","Muneeb M","2025","Cureus","case_report","article","10.7759/cureus.88015","40821211","PMC12352808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007968","Exendin-4 alleviates anxiety-like behaviors in chronic restraint stress mice via regulating BLA GLP-1R/BDNF signaling.","Wei K","2026","Acta pharmaceutica Sinica. B","preclinical","article","10.1016/j.apsb.2026.05.031","42592101","PMC13464066",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007969","GLP-1R Agonism Directly Improves the Pumping Capacity of Murine Collecting Lymphatic Vessels.","Schulz ME","2025","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2025.12.26.696603","41509291","PMC12776126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0007970","Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats.","Inoue K","2022","BMC ophthalmology","randomized_trial","article","10.1186/s12886-022-02413-y","35524186","PMC9074190",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0007971","Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.","Thethi TK","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14054","32267058","PMC7384149","ClinicalTrials.gov:NCT02906930; ClinicalTrials.gov:NCT02863328; ClinicalTrials.gov:NCT02607865; ClinicalTrials.gov:NCT02863419; ClinicalTrials.gov:NCT02827708; ClinicalTrials.gov:NCT02692716; ClinicalTrials.gov:NCT02849080; ClinicalTrials.gov:NCT03021187; ClinicalTrials.gov:NCT03018028; ClinicalTrials.gov:NCT03015220","S000133; S000234; S000251; S001153; S001381; S001741; S001943; S002025; S002267; S002369","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0007972","Persistent disparities in diabetes medication receipt by socio-economic disadvantage in Australia.","Morton JI","2022","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.14898","35694847","PMC9545050",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007973","Preclinical Evaluation of a Novel Dual-Targeting Probe, [68Ga]Ga-DOTA-exendin-4-TOC, for Neuroendocrine Tumor Imaging","Ruan C","2026","Research Square","preclinical","preprint","10.21203/rs.3.rs-9669031/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0007974","Correction to 'GLP-1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation'.",null,"2026","Diabetes, obesity & metabolism","notice","article","10.1111/dom.71179","42543252","PMC13538780",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0007975","The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.","Serowik TC","2024","Journal of osteopathic medicine","other_trial","article","10.1515/jom-2023-0179","37921061",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Review; Journal Article; article"],["R0007976","Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it.","Gelfand ST","2026","Obesity pillars","narrative_review","article","10.1016/j.obpill.2025.100233","41404471","PMC12704374",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007977","Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care.","Rodbard HW","2020","The American journal of managed care","other_trial","article","10.37765/ajmc.2020.88554","33439582",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007978","GLP-1 Agonists and Cardiovascular Risk Markers in U.S. Adults: National Health and Nutrition Examination Survey (NHANES) 2011-2018.","Telakeng Tekengne BO","2025","Cureus","nonrandomized_study","article","10.7759/cureus.91722","41058804","PMC12498555",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007979","A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment.","Consoli A","2018","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2018.1428305","29334278",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0007980","Clinical Efficacy of Once-weekly Glucagonlike Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.","Bailey TS","2018","The Journal of family practice","narrative_review","article",null,"29912997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0007981","The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.","Lu C","2024","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina61010017","39858999","PMC11767243",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0007982","Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs.","Yu YH","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71182","42563367","PMC13538751",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007983","Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile.","Muzurović E","2020","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2020.1795132","32697112",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0007984","Mimicking natural cholesterol assimilation to elevate the oral delivery of liraglutide for type II diabetes therapy.","Wu R","2022","Asian journal of pharmaceutical sciences","preclinical","article","10.1016/j.ajps.2022.08.002","36382301","PMC9640699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0007985","Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction.","Trombara F","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-01758-y","36747186","PMC9903538",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0007986","Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report.","Zahir A","2025","BMC neurology","case_report","article","10.1186/s12883-025-04540-7","41299410","PMC12764084",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0007987","Clinicians' self-reported efficacy in cardiovascular prevention practice in the southeastern United States.","Caldarera T","2023","Future cardiology","other","article","10.2217/fca-2023-0040","37916575",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0007988","GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study.","Orandi BJ","2025","The lancet. Diabetes & endocrinology","nonrandomized_study","article","10.1016/s2213-8587(24)00371-1","40056927","PMC12171561",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007989","Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss.","Haseeb M","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.6221","38607627","PMC11015347",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Clinical Study; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0007990","Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.","Weiss T","2020","Patient preference and adherence","nonrandomized_study","article","10.2147/ppa.s277676","33273810","PMC7708309",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0007991","Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.","Chakravarthy MV","2026","Molecular metabolism","randomized_trial","article","10.1016/j.molmet.2025.102291","41319798","PMC12771327","ClinicalTrials.gov:NCT04838405","S002824","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0007992","Net prices of new antiobesity medications.","Hernandez I","2024","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.23973","38228492",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0007993","The Use of Semaglutide in Patients With Renal Failure-A Retrospective Cohort Study.","Long JJ","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.1016/j.eprac.2024.07.008","39025300",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0007994","GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study.","Moll H","2024","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2024.102661","38846069","PMC11154119",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0007995","Anti-diabetic drugs and NASH: from current options to promising perspectives.","Smati S","2021","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2021.1951701","34214406",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0007996","Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.","Guo X","2016","Clinical drug investigation","systematic_review","article","10.1007/s40261-016-0389-8","26979594",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0007997","Exendin-4 protects against high glucose-induced mitochondrial dysfunction and oxidative stress in SH-SY5Y neuroblastoma cells through GLP-1 receptor/Epac/Akt signaling.","Pandey S","2023","European journal of pharmacology","other","article","10.1016/j.ejphar.2023.175896","37391007",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0007998","Mitigation of Hearing Damage With Liraglutide Treatment in Chinchillas After Repeated Blast Exposures at Mild-TBI.","Jiang S","2023","Military medicine","other","article","10.1093/milmed/usad235","37948240",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0007999","Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes.","Tan Y","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.935180","36034438","PMC9399467",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008000","Novel Antidiabetic Drug Approvals in 2025: Clinical Evidence, Regulatory Milestones, and Global Market Implications","HAIT A","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-8265802/v1",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0008001","GLP-1 Receptor Agonists and the Dermatologist: Promise, Pitfalls, and Responsibility (Part I).","Petronic-Rosic V","2026","Clinics in dermatology","commentary","article","10.1016/j.clindermatol.2026.09.034","42805320",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0008002","Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction.","Trevisan M","2021","European heart journal. Cardiovascular pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvaa004","31999317","PMC7957901",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0008003","Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials.","Qie S","2020","Endocrine","systematic_review","article","10.1007/s12020-020-02193-9","31927749",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008004","Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol.","Yevusiak T","2026","PloS one","protocol","article","10.1371/journal.pone.0354237","42507673","PMC13405095","ClinicalTrials.gov:NCT07294950","S001541","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0008005","Exendin-4 alleviates diabetic retinopathy by activating autophagy via regulation of the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway.","Liu J","2025","Journal of molecular histology","preclinical","article","10.1007/s10735-025-10405-7","40580219",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008006","Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial.","Kataoka Y","2024","Atherosclerosis plus","randomized_trial","article","10.1016/j.athplu.2024.03.001","38617596","PMC11015340","jRCT:jRCT1052180152; UMIN:UMIN000036721",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008007","Delayed Type Hypersensitivity Reaction Induced By Liraglutide With Tolerance to Semaglutide.","Moreno-Borque R","2024","JCEM case reports","case_report","article","10.1210/jcemcr/luae105","38911363","PMC11191647",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008008","GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.","Dahiya L","2020","Current diabetes reviews","narrative_review","article","10.2174/1573399815666190502114924","31057118",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008009","Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients.","Patoulias D","2020","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2020.10.004","33045202",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0008010","Re: \"Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer\".","Harborg S","2026","Epidemiology (Cambridge, Mass.)","commentary","article","10.1097/ede.0000000000002037","42555912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; letter"],["R0008011","Re: Survival and \"Recurrence With GLP-1 Receptor Agonists in Breast Cancer\".","Maliniak ML","2026","Epidemiology (Cambridge, Mass.)","commentary","article","10.1097/ede.0000000000002036","42555906",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; letter"],["R0008012","Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice.","Inia JA","2023","International journal of molecular sciences","preclinical","article","10.3390/ijms24108494","37239841","PMC10218334",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008013","Atrial fibrillation reporting with semaglutide versus tirzepatide in eudravigilance: a comparative disproportionality analysis",null,"2026","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","nonrandomized_study","article",null,null,"PMC13300923",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0008014","Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.","Ryszkiewicz P","2026","Pharmacological reports : PR","nonrandomized_study","article","10.1007/s43440-026-00879-x","42484993","PMC13437604",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008015","Ninerafaxstat in the Treatment of Diabetic Cardiomyopathy and Nonobstructive Hypertrophic Cardiomyopathy.","Feldman JM","2024","Cardiology in review","randomized_trial","article","10.1097/crd.0000000000000776","39194232",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0008016","Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.","Waldrop G","2016","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2015.12.058","27012410","PMC4861061",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0008017","HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.","Vilsbøll T","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16592","40746012","PMC12409195",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008018","Exploring the underlying mechanisms of obesity and diabetes and the potential of Traditional Chinese Medicine: an overview of the literature.","Chen YK","2023","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2023.1218880","37600709","PMC10433171",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0008019","The Risk of Aspiration Is Low With Continuing Semaglutide During Elective Eye Surgery When Patients Receive Only Moderate Sedation.","Zapp C","2026","Cureus","nonrandomized_study","article","10.7759/cureus.102921","41798554","PMC12965188",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008020","Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial.","Luchsinger JA","2025","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2025.1189","40388190","PMC12090067","ClinicalTrials.gov:NCT01794143","S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0008021","Postpartum Initiation of GLP-1 Receptor Agonists Among Commercially Insured Women in the US.","Cai ST","2026","JAMA","other","article","10.1001/jama.2026.16841","42821286","PMC13631791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008022","Effects of the Short-Acting GLP-1 Analogue Beinaglutide on Liver Fat and Visceral Adiposity in T2DM with MASLD: A 24-Week Single-Arm Exploratory Pilot Study","Fang E","2026","Authorea Preprints","randomized_trial","preprint","10.22541/au.177036320.04416099/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0008023","Liraglutide, a glucagon-like peptide-1 receptor agonist, induces ADAM10-dependent ectodomain shedding of RAGE via AMPK activation in human aortic endothelial cells.","Baek CH","2022","Life sciences","other","article","10.1016/j.lfs.2022.120331","35041837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008024","Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.","Bouzas C","2023","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","other_trial","article","10.1016/j.biopha.2023.114561","36934556",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0008025","Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial.","Yammine L","2023","BMJ open","protocol","article","10.1136/bmjopen-2023-072707","37316311","PMC10277057","ClinicalTrials.gov:NCT05610800","S001464","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0008026","Discovery and identification of semaphorin 4D as a bioindicator of high fracture incidence in type 2 diabetic mice with glucose control.","Liu X","2026","Journal of advanced research","preclinical","article","10.1016/j.jare.2025.03.014","40073972","PMC12766207",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008027","Recent advances in peptide-based therapies for obesity and type 2 diabetes.","Bailey CJ","2024","Peptides","other","article","10.1016/j.peptides.2024.171149","38184193",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008028","Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.","Luo J","2020","JAMA network open","other","article","10.1001/jamanetworkopen.2020.20969","33057641","PMC7563069",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0008029","The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study.","Kim M","2023","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2021.0373","35487507","PMC9925144",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008030","Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?","Cigrovski Berkovic M","2022","World journal of clinical cases","narrative_review","article","10.12998/wjcc.v10.i20.6759","36051145","PMC9297405",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008031","Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study.","Guo L","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15252","37612876",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008032","Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.","Lingvay I","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14943","36514843",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008033","Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week.","Morales J","2023","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2023.04.052","37407115",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008034","Efficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials.","Waqas SA","2025","Archives of gerontology and geriatrics","systematic_review","article","10.1016/j.archger.2025.105981","40812084",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008035","Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial.","Lee MMY","2022","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2021.102382","35030451",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0008036","Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.","Sakaki K","2026","Diabetes","other","article","10.2337/db25-1127","41814494","PMC13097202",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0008037","GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.","Giugliano D","2021","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-021-01366-8","34526024","PMC8442438",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0008038","Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes.","Hinnen D","2017","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds16-0026","28848315","PMC5556578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008039","Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study.","Patil T","2023","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2023.06.016","37393731",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Observational Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S."],["R0008040","Weight Loss Agents","Hoofnagle JH","2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"31644235",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0008041","Chronic Kidney Disease in the Elderly Patient with Diabetes","Ravender R","2023","Preprints.org","other","preprint","10.20944/preprints202310.0551.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008042","Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China.","Guo L","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16139","39703112","PMC11802397",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008043","COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.","Levin P","2017","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep171769.or","28816532",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; article"],["R0008044","ASRA pain medicine narrative review and expert practice recommendations for gastric point-of-care ultrasound to assess aspiration risk in medically complex patients undergoing regional anesthesia and pain procedures.","Haskins SC","2026","Regional anesthesia and pain medicine","narrative_review","article","10.1136/rapm-2024-106346","40250977",null,"PROSPERO:CRD42023445927",null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0008045","Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome.","Ravić MP","2026","Medical sciences (Basel, Switzerland)","preclinical","article","10.3390/medsci14050590","42783463","PMC13609326",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008046","Bioinspired pullulan-based adhesive coacervate films for targeted buccal delivery of peptides.","Sacramento MMA","2026","Carbohydrate polymers","other","article","10.1016/j.carbpol.2026.125612","42586641",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008047","Current trends in semaglutide therapy and strategies to improve its bioavailability.","Nayak S","2026","Expert opinion on drug delivery","nonrandomized_study","article","10.1080/17425247.2026.2688990","42288971",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0008048","Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.","Humphrey CD","2023","Facial plastic surgery : FPS","other","article","10.1055/a-2148-6321","37541662",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008049","Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes.","Jha KK","2022","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-022-01066-y","36422789",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008050","The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study.","Werkman NCC","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-01897-2","37386427","PMC10311702",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008051","Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds.","Wilke T","2022","ClinicoEconomics and outcomes research : CEOR","nonrandomized_study","article","10.2147/ceor.s357540","35531480","PMC9075907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008052","Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.","Neuen BL","2024","Circulation","other","article","10.1161/circulationaha.123.067584","37952217",null,null,"S000018","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0008053","Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.","Kelly AS","2023","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23808","37196421",null,"ClinicalTrials.gov:NCT04102189","S001529","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008054","Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing-Impaired Patients With Type 2 Diabetes.","Martines F","2026","Pharmacology research & perspectives","nonrandomized_study","article","10.1002/prp2.70316","42717744","PMC13559470",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0008055","Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities-Quo Vadis?: A Review.","Farokhnia M","2026","JAMA psychiatry","randomized_trial","article","10.1001/jamapsychiatry.2025.4308","41563749",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0008056","Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).","Nomoto H","2022","BMJ open","protocol","article","10.1136/bmjopen-2021-056885","35584872","PMC9119155","jRCT:jRCT1011210032; UMIN:UMIN000045270",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; article"],["R0008057","Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.","Ikonomidis I","2020","Journal of the American Heart Association","randomized_trial","article","10.1161/jaha.119.015716","32326806","PMC7428590","ClinicalTrials.gov:NCT03878706","S000665","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0008058","Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.","Mishriky BM","2019","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2018.09.002","30243806",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review"],["R0008059","Effect of Benaglutide on Gut Microbiota and Fecal Metabolites in Patients with Type 2 Diabetes Mellitus.","Han CY","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s418757","37577040","PMC10416789",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008060","Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.","Jendle J","2021","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-021-01431-2","34920733","PMC8684205","ClinicalTrials.gov:NCT01425580","S001448; S002231","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0008061","Glucagon-like peptide-1 receptor analog use is associated with reduced thromboembolic events compared with dipeptidyl peptidase-4 inhibitors in rheumatoid arthritis patients: A global retrospective cohort study.","Wang Q","2025","Clinical rheumatology","nonrandomized_study","article","10.1007/s10067-025-07709-0","41015607","PMC12568834",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; brief-report; article"],["R0008062","Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.","Luo J","2023","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2023.17886","37307000","PMC10261995",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0008063","Diabetes Mellitus in Acute Coronary Syndrome.","Stampouloglou PK","2023","Life (Basel, Switzerland)","randomized_trial","article","10.3390/life13112226","38004366","PMC10671950",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; article"],["R0008064","Association between circulating sex hormone levels and diabetic kidney disease in men and postmenopausal women with type 2 diabetes mellitus.","Shi Y","2025","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v16.i11.111366","41278451","PMC12635756",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008065","Effects of Incretin-Based Therapies on Diabetic Microvascular Complications.","Kang YM","2017","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2017.32.3.316","28956360","PMC5620027",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008066","Predictors of efficacy of Sodium-GLucose Transporter-2 inhibitors and Glucagon-Like Peptide 1 receptor agonists: A retrospective cohort study.","Scoccimarro D","2024","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.3727","37776322",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0008067","Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.","Siskind D","2019","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13522","30187620",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0008068","Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.","Lincoff AM","2023","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2307563","37952131",null,"ClinicalTrials.gov:NCT03574597","S000716; S001115; S001467; S002208; S002234; S002481","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0008069","Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review.","Zhu J","2023","Advances in therapy","systematic_review","article","10.1007/s12325-023-02612-z","37515713","PMC10499965",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review-article; review"],["R0008070","GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.","Corrêa LMA","2026","Translational research : the journal of laboratory and clinical medicine","other_trial","article","10.1016/j.trsl.2026.07.001","42398811",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0008071","Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery.","Connelly JW","2026","Clinical spine surgery","narrative_review","article","10.1097/bsd.0000000000001888","40673583",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0008072","Localization of Benign Insulinomas With a Radionuclide Tracer Targeting the GLP-1 Receptor With Pegylated Exendin-4.","Nauck MA","2026","The Journal of clinical endocrinology and metabolism","commentary","article","10.1210/clinem/dgaf297","40388377",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0008073","Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.","le Roux CW","2023","Obesity (Silver Spring, Md.)","protocol","article","10.1002/oby.23612","36478180","PMC10107501","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657003; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT04660643","S000242; S001077; S001712; S002157","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; research-article; article"],["R0008074","Epidemiological, Pathophysiological, and Clinical Considerations on the Interplay between Thyroid Disorders and Type 2 Diabetes Mellitus.","Grigoriadis G","2023","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina59112013","38004062","PMC10673571",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0008075","Effects of repeated developmental GLP-1R agonist exposure on young adult behavior and hippocampal structure in mice.","Cerroni C","2023","Neuroscience letters","preclinical","article","10.1016/j.neulet.2023.137299","37196974","PMC10330515",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0008076","Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.","Gaspari T","2016","Diabetes & vascular disease research","preclinical","article","10.1177/1479164115605000","26408644",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008077","Intestinal-related substances in obesity regulation: A comprehensive review.","Wang SY","2025","World journal of gastrointestinal pharmacology and therapeutics","narrative_review","article","10.4292/wjgpt.v16.i4.111082","41378072","PMC12686998",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008078","Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis.","Kukhareva PV","2024","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2024.10.28.24316312","39574878","PMC11581057",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0008079","In brief: Wegovy HD - high-dose injectable semaglutide for weight loss.",null,"2026","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2026.1754c","42068314",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008080","Same Result, Different Price: Compounded versus Branded Tirzepatide","Erly B","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.07.14.26357505",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0008081","A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus.","Botfield HF","2017","Science translational medicine","preclinical","article","10.1126/scitranslmed.aan0972","28835515",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008082","Liraglutide Potently Protects Against Streptozotocin-Induced Islet Injury Associated with Inhibition of HMGB1 Release.","Shi Y","2026","Cells","preclinical","article","10.3390/cells15131203","42439677","PMC13359402",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008083","Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Gao L","2019","Aging and disease","systematic_review","article","10.14336/ad.2019.0303","31788342","PMC6844583",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0008084","Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.","Sivalingam S","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15287","37722966",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008085","Cardio-Protective Effect of GLP-1 Agonists in OSA Patients: A Study of Cardiovascular Risk.","Lane M","2026","Laryngoscope investigative otolaryngology","nonrandomized_study","article","10.1002/lio2.70495","42453328","PMC13364540",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008086","Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes.","Reppo I","2023","International journal of molecular sciences","randomized_trial","article","10.3390/ijms24065714","36982786","PMC10054691",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008087","Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin.","Alexopoulos AS","2019","Metabolism: clinical and experimental","nonrandomized_study","article","10.1016/j.metabol.2019.06.012","31255662","PMC6690751",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0008088","COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.","Agarwal R","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfaf022","39916475","PMC12315800","ClinicalTrials.gov:NCT05254002; EudraCT:2021-003037-11","S000018","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; research-article; article"],["R0008089","Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.","Rosenstock J","2020","Diabetes care","randomized_trial","article","10.2337/dc19-2316","32694215","PMC7510023","ClinicalTrials.gov:NCT02229227","S001887","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0008090","Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.","Briand F","2026","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.70155","41741376","PMC13250738",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008091","Corrigendum to \"Exendin-4 alleviates Aβ1-40-induced apoptosis and calcium dysregulation in RPE cells through the CHP1/NHE1 complex\" [Biochem. Pharmacol. 247 (2026) 117789].","Shu Q","2026","Biochemical pharmacology","notice","article","10.1016/j.bcp.2026.117880","41833145",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0008092","Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People.","Sood A","2019","Metabolic syndrome and related disorders","narrative_review","article","10.1089/met.2018.0134","31145029",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008093","A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.","Dougherty JA","2021","The Annals of pharmacotherapy","systematic_review","article","10.1177/1060028020935105","32571083",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0008094","The Welander TIA1 mutation dedifferentiates insulin-producing cells: Reversal by a GLP-1 receptor agonist.","Zhao T","2026","The Journal of biological chemistry","other","article","10.1016/j.jbc.2026.111336","41786146","PMC13054421",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008095","2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part II.","Chao TH","2024","Acta Cardiologica Sinica","randomized_trial","article","10.6515/acs.202411_40(6).20240724b","39582845","PMC11579689",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008096","The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.","Fan S","2020","Revista espanola de enfermedades digestivas","systematic_review","article","10.17235/reed.2020.6392/2019","32496108",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008097","Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study.","Houbachi L","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112017","39900263",null,null,"S001666","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0008098","Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.","Monami M","2014","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2014.01.010","24485345",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; review"],["R0008099","The impact of GLP-1 and incretin-based therapies on counterregulatory responses to hypoglycemia in diabetes mellitus: mechanisms and clinical implications.","Balakumar P","2026","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2026.113155","41692324",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008100","Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials.","Monami M","2017","Journal of endocrinological investigation","systematic_review","article","10.1007/s40618-017-0698-7","28569363",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008101","Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report.","Sano H","2020","Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology","case_report","article","10.1297/cpe.29.81","32313377","PMC7160459",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008102","Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.","Kawanami D","2016","International journal of molecular sciences","narrative_review","article","10.3390/ijms17081223","27483245","PMC5000621",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008103","Association between hemoglobin glycation index and carotid plaques in non-dialysis CKD stage 3-5 patients: a retrospective cross-sectional study.","Wang L","2026","International urology and nephrology","nonrandomized_study","article","10.1007/s11255-025-04728-3","40813550",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0008104","GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.","Neves JS","2023","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2023.05.048","37532422",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0008105","Semaglutide, the first approved GLP-1 receptor agonist for the management of metabolic dysfunction-associated steatohepatitis.","Boutari C","2026","Metabolism: clinical and experimental","commentary","article","10.1016/j.metabol.2025.156397","41047002",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0008106","Endotypic Trait Responses to 12-Month Tirzepatide Treatment for an Obese Patient with Obstructive Sleep Apnea: A Case Report.","Hsu Y","2026","Obesity facts","other_trial","article","10.1159/000553125","42378200","PMC13451026",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0008107","SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Managing Metabolic Syndrome Among Patients with Type 2 Diabetes Mellitus - A Narrative Review.","Ahamed HZR","2026","Cardiovascular & hematological disorders drug targets","narrative_review","article","10.2174/011871529x480529260812061106","42708338",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; review"],["R0008108","In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA1c and SBP and may reduce body weight.","Tanner M","2020","Annals of internal medicine","commentary","article","10.7326/acpj202011170-052","33197349",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; editorial"],["R0008109","A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models.","Borner T","2020","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14089","32410372","PMC7927944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0008110","Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.","Ferreira JP","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14997","36722252",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008111","Glucagon-like peptide-1 receptor agonist treatment of high carbohydrate intake-induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction.","Durak A","2022","Clinical and experimental pharmacology & physiology","preclinical","article","10.1111/1440-1681.13590","34519087",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008112","Tirzepatide but not Semaglutide Ameliorates Hepatic Steatosis and Inflammatory Infiltration in a Mouse Model of MASLD via Inhibition of the CCL2/CCR2-PI3K-Akt Pathway","Pan Y","2025","Research Square","preclinical","preprint","10.21203/rs.3.rs-7562588/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008113","Assessing Type 2 Diabetes and GLP-1 agonist response trajectories with a proteomic atlas of glycemic stages","Tangirala S","2025","medRxiv","other_trial","preprint","10.1101/2025.09.26.25336579",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0008114","Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes.","Almohareb SN","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13216532","39518671","PMC11546400",null,"S000685","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008115","Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?","Valenzuela-Vallejo L","2022","Metabolism: clinical and experimental","commentary","article","10.1016/j.metabol.2022.155248","35803320",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0008116","KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD.","Mottl AK","2024","American journal of kidney diseases : the official journal of the National Kidney Foundation","other","article","10.1053/j.ajkd.2023.09.003","38142396",null,null,"S000018","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article"],["R0008117","Obesity and Pancreatic Diseases: From Inflammation to Oncogenesis and the Impact of Weight Loss Interventions.","Souto M","2025","Nutrients","narrative_review","article","10.3390/nu17142310","40732935","PMC12299513",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008118","Epicardial Adipose Tissue: A Precise Biomarker for Cardiovascular Risk, Metabolic Diseases, and Target for Therapeutic Interventions.","Bogdański A","2026","Cardiology in review","narrative_review","article","10.1097/crd.0000000000000670","38477580",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008119","Glucagon-like Peptide-1 Receptor Dependent Signaling in Cardiovascular Health and Disease: A Mini-review.","Lin MP","2026","Journal of cardiovascular translational research","narrative_review","article","10.1007/s12265-026-10759-7","41724871",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0008120","Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.","Uneda K","2021","Scientific reports","systematic_review","article","10.1038/s41598-021-89620-7","33986377","PMC8119733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; research-article; review"],["R0008121","Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury.","Yang T","2023","Ageing research reviews","narrative_review","article","10.1016/j.arr.2023.101884","36801379",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0008122","Newer pharmacological interventions directed at gut hormones for obesity.","Camilleri M","2024","British journal of pharmacology","narrative_review","article","10.1111/bph.16278","37917871","PMC10947960",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; research-article; article"],["R0008123","GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?","Muzurović E","2023","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2023.108647","37952274",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0008124","Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists.","Myasoedova VA","2023","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox13010016","38275636","PMC10812629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008125","Combination therapy of glucagon-like peptide-1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy.","Kitazawa T","2016","Journal of diabetes investigation","other","article","10.1111/jdi.12423","27330725","PMC4847893",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008126","Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.","Heuvelman VD","2020","Cardiovascular research","narrative_review","article","10.1093/cvr/cvz323","31825468",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008127","in vivo mapping of hemodynamic responses mediated by tubuloglomerular feedback in healthy and hypertensive rat kidneys","Lee BS","2023","Research Square","preclinical","preprint","10.21203/rs.3.rs-2882192/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008128","Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital.","Hossain A","2025","Cureus","nonrandomized_study","article","10.7759/cureus.96974","41409973","PMC12707267",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008129","Incidence of dementia in patients with type 2 diabetes using SGLT2 inhibitors versus GLP-1 receptor agonists or DPP-4 inhibitors: A systematic review and meta-analysis of cohort studies.","Milori PH","2026","Journal of Alzheimer's disease : JAD","systematic_review","article","10.1177/13872877251395086","41252314",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0008130","Exendin-4 protects the dopaminergic neurons by attenuating inflammatory responses of microglial cells via activation of AMPK.","Rimal N","2025","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2025.110643","40825494",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008131","Effects of weight control interventions on cardiovascular outcomes: an umbrella review of systematic reviews and meta-analyses.","Chen X","2025","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-025-01860-z","40715579","PMC12532613","PROSPERO:CRD42024573542",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0008132","Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway.","Kang X","2023","Molecular medicine (Cambridge, Mass.)","preclinical","article","10.1186/s10020-023-00718-2","37667187","PMC10478475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0008133","Dermatological, Trichological and Quality of Life Consequences of GLP‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey","Olivero J","2026","Journal of cosmetic dermatology","other","article",null,null,"PMC13494060",null,null,"europepmc","TRUE",null,null,null,"research-article; Journal Article"],["R0008134","Metabolic-Dysfunction Associated Steatotic Liver Disease -Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Ideal Treatments","Yanai H","2023","Preprints.org","other","preprint","10.20944/preprints202309.1062.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008135","Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction.","Turan B","2022","Molecular and cellular biochemistry","narrative_review","article","10.1007/s11010-022-04474-5","35598217",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008136","Rational design of dual-agonist peptides targeting GLP-1 and NPY2 receptors for regulating glucose homeostasis and body weight with minimal nausea and emesis.","Liu J","2025","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2025.117320","39892093",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008137","Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis.","Guo N","2023","European journal of clinical pharmacology","systematic_review","article","10.1007/s00228-023-03561-w","37682287",null,"PROSPERO:CRD42023429701",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Systematic Review; Journal Article"],["R0008138","Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report.","Lee ATM","2025","Lung Cancer (Auckland, N.Z.)","other_trial","article","10.2147/lctt.s549011","41477303","PMC12747890",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0008139","Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.","Silva-Nunes J","2022","Metabolites","nonrandomized_study","article","10.3390/metabo12111121","36422260","PMC9694138",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008140","Acute Nutritional Axonal Neuropathy in the Setting of Semaglutide-Associated Gastrointestinal Intolerance: A Case Report.","Cohan CJ","2026","Case reports in neurology","case_report","article","10.1159/000552961","42549476","PMC13432944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008141","Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis.","Sarma S","2022","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.23563","36321278",null,null,"S001448","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0008142","Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.","Gerstein HC","2021","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.14223","33026143",null,"ClinicalTrials.gov:NCT03496298","S000755","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Clinical Trial Protocol; article"],["R0008143","Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation.","Abu-Nejim H","2025","Current atherosclerosis reports","other_trial","article","10.1007/s11883-025-01350-7","41065947","PMC12511252",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0008144","Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.","Uccellatore A","2015","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-015-0127-x","26271795","PMC4575308",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0008145","GLP-1 receptor agonists at the crossroads of metabolic and gut inflammation: Implications for people with type 2 diabetes and inflammatory bowel disease.","Dardari D","2026","Therapeutic advances in endocrinology and metabolism","commentary","article","10.1177/20420188261478400","42662155","PMC13519219",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0008146","Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.","Filchenko I","2018","Diabetes & vascular disease research","preclinical","article","10.1177/1479164118788079","30024276",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0008147","[Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].","Scheen AJ","2019","Revue medicale suisse","narrative_review","article",null,"31436058",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008148","ASO Visual Abstract: GLP-1 Receptor Agonists and Colorectal Cancer Outcomes: Hype, Hope, or Hidden Confounding?","Murthy SS","2026","Annals of surgical oncology","other","article","10.1245/s10434-026-20345-5","42545419",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008149","Real-world experience with GLP-1 receptor agonists in adults with epilepsy following a modified atkins diet.","El Zibaoui R","2026","Epilepsy research","nonrandomized_study","article","10.1016/j.eplepsyres.2026.107896","42617503",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008150","Ozempic and Wegovy Meet Congress: Political Economy Without Critique and Sociology Without Society.","Loeppky R","2026","International journal of social determinants of health and health services","other","article","10.1177/27551938261425193","41744415","PMC13269720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008151","Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide.","Saito C","2026","Internal medicine (Tokyo, Japan)","other","article","10.2169/internalmedicine.7502-26","42543696",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008152","A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.","Roth CL","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14224","33026160","PMC7821019",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0008153","Broad glucagon-like peptide-1 (GLP-1) receptor distribution enhances glutamatergic transmission throughout the mouse cerebellar cortex.","Ritchey CR","2026","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2026.110993","42034161",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008154","Therapeutic landscape evolution for steatotic liver disease: from lifestyle interventions to precision pharmacotherapy.","Bong SHS","2026","Clinical and molecular hepatology","nonrandomized_study","article","10.3350/cmh.2026.0125","41928627","PMC13641670",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008155","Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.","Muller DRP","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1215356","37881498","PMC10597691",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0008156","Association of sodium-glucose cotransporter 2 inhibitor use with risk of osteoporotic fracture among older women: A nationwide, population-based cohort study.","Lee S","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111712","38768867",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0008157","Cardiovascular Disease in Patients With Type 2 Diabetes: A Qualitative Analysis of Knowledge, Attitudes, and Beliefs of Health Care Professionals.","Ciemins EL","2021","The Journal of ambulatory care management","other","article","10.1097/jac.0000000000000379","34009833",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008158","GLP-1 Receptor Agonists and Muscle Loss in Chronic Kidney Disease.","Sawaira F","2026","American journal of therapeutics","other","article","10.1097/mjt.0000000000002218","42711767",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008159","Cosmetic use of GLP-1 receptor agonists: Ethical concerns amid drug shortages.","Arfan A","2026","British journal of clinical pharmacology","commentary","article","10.1002/bcp.70652","42304554","PMC13519772",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0008160","Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons.","Dalsgaard NB","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13128","29024408","PMC5836903",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; review"],["R0008161","Impact of Smartphone-Enabled Home Urinary Albumin-Creatinine Ratio Testing on Albuminuria Screening and Management.","Zafar W","2026","American journal of kidney diseases : the official journal of the National Kidney Foundation","randomized_trial","article","10.1053/j.ajkd.2025.09.019","41360254",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Clinical Trial; article"],["R0008162","Retatrutide-A Game Changer in Obesity Pharmacotherapy.","Katsi V","2025","Biomolecules","other_trial","article","10.3390/biom15060796","40563436","PMC12190491",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0008163","[Unmet needs in the therapy of type 2 diabetes mellitus. How can barriers to insulin therapy be overcome?].","Aberle J","2023","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-023-2432-z","37415032",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0008164","[Obesity, type 2 diabetes, metabolic syndrome and depression : a two-way relationship].","Scheen A","2023","Revue medicale de Liege","other","article",null,"37067836",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0008165","Perioperative Use of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Lower Readmission Rates After Coronary Artery Bypass Grafting (CABG) in Adults With Congenital Heart Disease.","Yan JH","2025","Cureus","nonrandomized_study","article","10.7759/cureus.95767","41322791","PMC12664678",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008166","[SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?].","Scheen AJ","2018","Revue medicale suisse","other","article",null,"30136462",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008167","Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.","Huang YN","2026","Communications medicine","other","article","10.1038/s43856-026-01750-z","42373755",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008168","O-SEMA-FAST: A Prospective, Non-interventional Study Investigating Oral Semaglutide Use in Adults with Type 2 Diabetes Mellitus During Ramadan.","Hassanein M","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-025-01702-1","40016571","PMC11926314","ClinicalTrials.gov:NCT05716724","S002182","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0008169","Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.","Nicholls SJ","2024","American heart journal","protocol","article","10.1016/j.ahj.2023.09.007","37758044",null,null,"S002366","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; article"],["R0008170","Tirzepatide non-response with subsequent semaglutide response in class 2 obesity.","La Vignera S","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag245","42670558","PMC13526503",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008171","Impact of GLP-1 receptor agonists on cranial nerve palsies in type 2 diabetes: a retrospective cohort study.","Bhatia R","2025","Journal of neurology","nonrandomized_study","article","10.1007/s00415-025-13560-9","41361010",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Preprint; article; preprint"],["R0008172","Lessons from incretin-based therapy in MASH and obesity.","Tilg H","2025","Nature reviews. Gastroenterology & hepatology","other","article","10.1038/s41575-025-01096-2","40579476",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008173","Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents.","Vekic J","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms222212409","34830295","PMC8622770",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008174","Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications.","Cummings JL","2026","The journal of prevention of Alzheimer's disease","nonrandomized_study","article","10.1016/j.tjpad.2026.100677","42785112","PMC13634738",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008175","Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus.","Grewal S","2021","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2021.05.043","34266665",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0008176","Late-life semaglutide treatment slows ageing and extends lifespan in female mice.","Feng Y","2026","Nature","preclinical","article","10.1038/s41586-026-10940-7","42686906","PMC13558073",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008177","Up and down waves of glycemic control and lower-extremity amputation in diabetes.","Caruso P","2021","Cardiovascular diabetology","other_trial","article","10.1186/s12933-021-01325-3","34229673","PMC8261935",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; editorial; article"],["R0008178","GLP-1 Receptor Agonists: Informing Mechanistic Models and Innovative Targets in the Treatment and Prevention of Mental and Substance Use Disorders.","McIntyre RS","2026","Biological psychiatry","other","article","10.1016/j.biopsych.2026.08.002","42749380",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008179","GLP-1 Receptor Agonists in CKD: A Case-Based Discussion of Translating Evidence into Practice.","Cheung DS","2026","Clinical journal of the American Society of Nephrology : CJASN","other","article","10.2215/cjn.0000001252","42747893",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008180","GLP-1R R131Q links long-range conformational remodeling to cellular stress phenotypes.","Kato T","2026","Journal of molecular graphics & modelling","other","article","10.1016/j.jmgm.2026.109445","42167066",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0008181","Effects of repeated developmental GLP-1R agonist exposure on adult behavior and hippocampal structure in mice.","Cerroni C","2023","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2023.04.21.537724","37131808","PMC10153236",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0008182","[Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].","Fiorentino TV","2016","Giornale italiano di cardiologia (2006)","other","article","10.1714/2616.26911","28151517",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008183","Survodutide Once Weekly for the Treatment of Adults with Obesity.","le Roux CW","2026","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2600751","42253238",null,"ClinicalTrials.gov:NCT06066515","S000367","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; article"],["R0008184","Effect of GLP-1 RA and SGLT2I on Biomarkers of Oxidative Stress in T2DM: A Systematic Review and Meta-analysis.","Wei H","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf075","40607042","PMC12214030",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0008185","Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care.","Colling C","2021","Diabetes care","nonrandomized_study","article","10.2337/dc21-0013","34016618","PMC8247510",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article; other"],["R0008186","A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer.","Hidayat K","2023","Pharmacoepidemiology and drug safety","systematic_review","article","10.1002/pds.5550","36224724",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0008187","Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.","Yanai H","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms242015473","37895151","PMC10607514",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008188","A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis.","Rallabandi S","2026","Cureus","case_report","article","10.7759/cureus.104376","41913883","PMC13033244",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008189","IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists.","Zhang L","2026","Science advances","preclinical","article","10.1126/sciadv.aeh4670","42647645","PMC13510684",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008190","Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.","Kuckuck S","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70393","41491619","PMC12890760",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0008191","Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.","Ferdinand KC","2023","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-023-01775-x","36894938","PMC9999488","ClinicalTrials.gov:NCT01064687; ClinicalTrials.gov:NCT00734474; ClinicalTrials.gov:NCT01769378; ClinicalTrials.gov:NCT02597049; ClinicalTrials.gov:NCT01149421; ClinicalTrials.gov:NCT03495102","S000046; S000305; S000784; S001068; S001242; S002153","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0008192","Exploring a novel long-acting glucagon-like peptide-1 receptor agonist built on the albumin-binding domain and XTEN scaffolds.","Zhou Y","2024","Heliyon","preclinical","article","10.1016/j.heliyon.2024.e24340","38293540","PMC10826136",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008193","Harmine Plus Exendin-4 Enhances Remission of Recent-Onset Type 1 Diabetes Following Anti-CD3 Therapy.","Lu G","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.09.21.753317","42818192","PMC13622117",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0008194","Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.","Khan MS","2020","Circulation","randomized_trial","article","10.1161/circulationaha.120.045888","32955939",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0008195","Vascular regenerative cells in cardiometabolic disease.","Bakbak E","2023","Current opinion in cardiology","other","article","10.1097/hco.0000000000001089","37668181",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008196","Exenatide improves hypogonadism and attenuates inflammation in diabetic mice by modulating gut microbiota.","Chen Y","2023","International immunopharmacology","preclinical","article","10.1016/j.intimp.2023.110339","37210914",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008197","Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.","Herrera Comoglio R","2020","International journal of clinical practice","systematic_review","article","10.1111/ijcp.13553","32452094",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0008198","Interaction among GLP-1 signaling-related genetic variants suggests contribution to the control of appetitive traits among preadolescents.","Renier TJ","2026","Appetite","other","article","10.1016/j.appet.2026.108759","42628573",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008199","Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.","Zafar Y","2022","Clinics and research in hepatology and gastroenterology","systematic_review","article","10.1016/j.clinre.2022.101970","35659603",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0008200","A Retrospective Study of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Diabetes After Transplantation.","Thangavelu T","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00786-1","32072430","PMC7136376",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; case-report; other; article"],["R0008201","The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease.","Elangovan H","2025","Hepatology international","nonrandomized_study","article","10.1007/s12072-025-10795-6","40140191","PMC12003568",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008202","GLP-1 Receptor Agonists, Lithium, and the Kidneys: A Tale of Two Signals.","Leung JG","2026","Journal of clinical psychopharmacology","other","article","10.1097/jcp.0000000000002253","42690023",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008203","Factors Associated with Response to SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes Mellitus.","Arora G","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14124092","40565841","PMC12194277",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008204","Complete radiologic and clinical reversal of lumbar spinal epidural lipomatosis via GLP-1 agonist.","Wurm LM","2026","Journal of surgical case reports","case_report","article","10.1093/jscr/rjag052","41694436","PMC12900073",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008205","Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?","van Raalte DH","2016","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2016.04.009","27160799",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0008206","GLP-1 receptor agonists and their impact on knee surgery.","Hing CB","2026","The Knee","commentary","article","10.1016/j.knee.2026.104619","42641214",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0008207","Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.","Htoo PT","2023","The journals of gerontology. Series A, Biological sciences and medical sciences","nonrandomized_study","article","10.1093/gerona/glad075","36866496","PMC10692415",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0008208","Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy.","Fantasia KL","2019","Journal of the Endocrine Society","case_report","article","10.1210/js.2019-00278","31737858","PMC6846329",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008209","Cardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Roessler J","2026","Diabetes care","systematic_review","article","10.2337/dc26-1127","42627353",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0008210","Interpreting Real-World Cardiovascular Outcomes With GLP-1 Receptor Agonists.","Akbar UA","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.08.028","42686051",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0008211","Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?","Patoulias D","2021","International journal of cardiology","commentary","article","10.1016/j.ijcard.2020.08.049","32810546",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0008212","Predictors of weight reduction effectiveness with liraglutide in diabetes mellitus type 2 patients: a retrospective cohort study.","Wangpattanamongkol P","2025","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-025-02066-0","41131486","PMC12548173",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008213","Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design.","Nelson AJ","2023","American heart journal","protocol","article","10.1016/j.ahj.2022.10.079","36279931",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Clinical Trial Protocol"],["R0008214","Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management.","Goodarzi MO","2023","Drugs","other","article","10.1007/s40265-023-01913-5","37410209","PMC10361873",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008215","Genetic Evidence for Repurposing of GLP1R (Glucagon-Like Peptide-1 Receptor) Agonists to Prevent Heart Failure.","Daghlas I","2021","Journal of the American Heart Association","other","article","10.1161/jaha.120.020331","34184541","PMC8403330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; brief-report; article"],["R0008216","Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy.","Pöhlmann J","2019","ClinicoEconomics and outcomes research : CEOR","other","article","10.2147/ceor.s218746","31632108","PMC6789179",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008217","Tirzepatide enhances liver structural integrity by promoting mitochondrial dynamics and mitophagy via PINK1/PRKN and SIRT3/NRF2 pathways in an obese-diabetic-menopausal mouse model.","Marcondes-de-Castro IA","2026","Tissue & cell","preclinical","article","10.1016/j.tice.2025.103146","40974707",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008218","Semaglutide-the \"new kid on the block\" in the field of glucagon-like peptide-1 receptor agonists?","Guja C","2017","Annals of translational medicine","commentary","article","10.21037/atm.2017.10.09","29285508","PMC5733318",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; editorial"],["R0008219","Long-acting glucagon-like peptide-1 receptor agonist-status December 2018.","Holst JJ","2019","Annals of translational medicine","commentary","article","10.21037/atm.2019.01.09","31019933","PMC6462657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0008220","Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.","Chen C","2023","European psychiatry : the journal of the Association of European Psychiatrists","nonrandomized_study","article","10.1192/j.eurpsy.2023.2474","38031404","PMC10755578",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008221","GLP-1 Receptor Agonists and Pediatric Dermatology: An Emerging Clinical Intersection.","Kumar S","2026","Pediatric dermatology","other","article","10.1111/pde.70353","42679800",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008222","GLP-1 Receptor Agonists as Potential Treatments for Alcohol Use Disorder.","Kranzler HR","2026","The American journal of psychiatry","commentary","article","10.1176/appi.ajp.20260651","42675560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0008223","Opioid Toxicity Associated With Tirzepatide in a Patient on Chronic Oral Morphine.","Mataraarachchi NE","2026","Cureus","case_report","article","10.7759/cureus.115380","42807130","PMC13617212",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008224","GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes.","Del Olmo-Garcia MI","2018","Journal of diabetes research","narrative_review","article","10.1155/2018/4020492","29805980","PMC5902002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008225","ODP222 Liragluitde Increased IL-1RA Concentrations in Obese Type 2 Diabetes: A Small Randomized Controlled Trial",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9624849",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0008226","Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.","Morieri ML","2020","Metabolism: clinical and experimental","systematic_review","article","10.1016/j.metabol.2020.154190","32109448",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Multicenter Study; Research Support, Non-U.S. Gov't; review"],["R0008227","GLP-1 Agonists in Aesthetic Surgery: Implications for Perioperative Outcomes and Body Contouring Procedures.","Albanese R","2025","Aesthetic plastic surgery","nonrandomized_study","article","10.1007/s00266-025-05015-3","40603775",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0008228","Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists.","Ahmed S","2023","Cureus","case_report","article","10.7759/cureus.35102","36945294","PMC10024922",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008229","The role of GIP in carbohydrate metabolism: Implications in the development of therapies for T2DM, a narrative review.","Almorza-Gomar D","2026","Histology and histopathology","narrative_review","article","10.14670/hh-18-967","40755350",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0008230","2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.","Godoy-Matos AF","2024","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-024-01259-2","38238868","PMC10797995",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0008231","Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.","Kopp KO","2024","Biomolecules","preclinical","article","10.3390/biom14070872","39062586","PMC11275108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; research-article; article"],["R0008232","Glucose-lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types.","Isaksen AA","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15230","37550891",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008233","iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP-L trial.","Yabe D","2021","Journal of diabetes investigation","other_trial","article","10.1111/jdi.13563","33945227","PMC8565419","ClinicalTrials.gov:NCT02752412","S000356","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; research-article; article"],["R0008234","Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.","Ericsson Å","2019","Journal of medical economics","nonrandomized_study","article","10.1080/13696998.2019.1614009","31044636",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0008235","The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes.","Boye KS","2020","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2020.06.019","32741645",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0008236","The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.","Ye ZR","2023","Reproductive sciences (Thousand Oaks, Calif.)","systematic_review","article","10.1007/s43032-023-01222-y","37002532","PMC10354168",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0008237","Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study.","Yao Z","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s607678","42610030","PMC13480159",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008238","The Skinny on the Use of GLP-1 Receptor Agonists in Peripheral Artery Disease.","Beckman JA","2026","Journal of the American Heart Association","commentary","article","10.1161/jaha.126.052332","42669900",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0008239","Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.","Christensen RM","2019","Drug safety","other_trial","article","10.1007/s40264-019-00812-7","30972641",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0008240","Updates on RPE cell damage in diabetic retinopathy (Review).","Li M","2023","Molecular medicine reports","preclinical","article","10.3892/mmr.2023.13072","37594078",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008241","GLP-1 Receptor Agonists and Breast Cancer Surgery: Is 30-Day Morbidity Enough to Define Surgical Safety?","Tambasco D","2026","World journal of surgery","commentary","article","10.1002/wjs.70579","42764534",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008242","Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation.","Mert I","2022","Inflammopharmacology","preclinical","article","10.1007/s10787-022-00978-0","35412166",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008243","Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis.","Park S","2025","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","other","article","10.1016/j.jcf.2024.08.005","39214747",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008244","GLP-1 receptor agonists are changing the treatment of type 2 diabetes mellitus.","Hill B","2026","British journal of nursing (Mark Allen Publishing)","other","article","10.12968/bjon.2026.0350","42689741",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008245","Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings.","Guerci B","2019","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2019.01.006","30677504",null,null,"S002638","pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0008246","Use of diabetes medications in adults with T2D and CVD in Japan: secondary analysis of the CAPTURE study.","Onishi Y","2023","Diabetology international","nonrandomized_study","article","10.1007/s13340-023-00638-w","37781463","PMC10533472","ClinicalTrials.gov:NCT03786406; ClinicalTrials.gov:NCT03811288",null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article"],["R0008247","Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.","Scheen AJ","2018","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2018.06.008","29944969",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008248","A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.","Ludwig MQ","2026","Nature metabolism","preclinical","article","10.1038/s42255-026-01539-3","42260119","PMC13303089",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008249","Clinical Phenotypes May be Able to Identify Populations With Nonalcoholic Fatty Liver-Spectrum Disease.","Geyer BM","2025","Gastro hep advances","nonrandomized_study","article","10.1016/j.gastha.2024.100611","40256316","PMC12008565",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008250","Semaglutide treatment reverses HFD induced hippocampal microglia activation and improves cognitive dysfunction.","Gong H","2026","Tissue & cell","preclinical","article","10.1016/j.tice.2026.103495","41916100",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008251","GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection.","Bertoccini L","2021","Advances in experimental medicine and biology","narrative_review","article","10.1007/5584_2020_494","32034729",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; book-chapter"],["R0008252","12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis.","Talay L","2025","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare14010060","41516991","PMC12786109",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008253","Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.","Foghsgaard S","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15306","37846555",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008254","GLP-1 Receptor Agonists, Gastric Emptying, and Mechanisms of Weight Loss.","Ludwig DS","2026","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.70299","42663424",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0008255","Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide.","Kårhus ML","2019","Gastroenterology","case_report","article","10.1053/j.gastro.2019.04.002","30965026",null,null,"S001709","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Case Reports; Journal Article; article"],["R0008256","MASLD: Established Knowledge and Emerging Directions - Guideline Updates.","Roeb E","2026","Zeitschrift fur Gastroenterologie","narrative_review","article","10.1055/a-2894-7628","42777696",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008257","Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.","Kang YM","2019","Diabetes & metabolism journal","systematic_review","article","10.4093/dmj.2018.0070","30604598","PMC6712219",null,"S000298","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0008258","Breaking the weight of therapeutic inertia: obesity management in cardiology practice.","Garagoli F","2025","Medicina","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3778","41109278",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008259","Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.","Ding L","2020","International journal of endocrinology","systematic_review","article","10.1155/2020/1626484","33061964","PMC7539133",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0008260","GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans.","Kim KS","2024","Science (New York, N.Y.)","preclinical","article","10.1126/science.adj2537","38935778","PMC11961025",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0008261","Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Substance Use Disorders.","Bremmer MP","2024","Journal of studies on alcohol and drugs","nonrandomized_study","article","10.15288/jsad.23-00318","37917019","PMC10846600",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0008262","Beauty standards and reproductive health: increasing use of GLP-1 receptor agonists despite limited evidence.","de Matos SMS","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1911235","42812212","PMC13619372",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; discussion; article"],["R0008263","Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.","Yie J","2026","Antibody therapeutics","narrative_review","article","10.1093/abt/tbag029","42592044","PMC13463644",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008264","Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.","Violante-Ortiz R","2026","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2025-005711","41912265","PMC13052782","ClinicalTrials.gov:NCT05564039","S001940","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0008265","Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes.","Yesildag B","2022","Clinical immunology (Orlando, Fla.)","other","article","10.1016/j.clim.2022.109118","36084852",null,null,"S001320","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008266","Channeling by Phenotype: Does the Obesity Paradox in COPD Confound the Respiratory Benefits Attributed to GLP-1 Receptor Agonists?","Cardenas-Duran E","2026","QJM : monthly journal of the Association of Physicians","other","article","10.1093/qjmed/hcag250","42755054",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008267","Trump strikes deal with Ozempic and Mounjaro makers to cut prices of obesity injections.","Brown C","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r2361","41203407",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0008268","GLP-1 agonists and the gut microbiome: A bidirectional relationship.","Kamath S","2026","British journal of clinical pharmacology","narrative_review","article","10.1002/bcp.70487","41703894","PMC13122291",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008269","Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.","Mannucci E","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13888","31595657",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0008270","Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.","Huthmacher JA","2020","Diabetes care","systematic_review","article","10.2337/dc20-0498","32910778",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; other; review"],["R0008271","Glucagon-like peptide-1 receptor PET in indolent and aggressive insulinoma: Diagnostic performance, quantitative differences, and clinical implications.","Xu J","2026","European journal of nuclear medicine and molecular imaging","other","article","10.1007/s00259-026-08039-2","42400625",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0008272","[18F]FB(ePEG12)12-Exendin-4 positron emission tomography/magnetic resonance imaging for precise preoperative localization of a pancreatic-head insulinoma: a case report with review of literature.","Yoshida H","2026","Endocrine journal","case_report","article","10.1507/endocrj.ej25-0591","41833398","PMC13271857",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; Review; case-report; article"],["R0008273","A High-Potency Protein That Normalizes Body Weight in DIO Mice through Triple Agonism at FGF21, GLP1, and GIP Receptors.","Brunel FM","2026","Biochemistry","preclinical","article","10.1021/acs.biochem.5c00820","41861089",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008274","Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure.","Cromer SJ","2023","Diabetes care","other","article","10.2337/dc22-0383","36383481","PMC9797651",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0008275","Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.","Boye KS","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0377-5","29460259","PMC6104268",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008276","Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.","Varin EM","2020","Canadian journal of diabetes","narrative_review","article","10.1016/j.jcjd.2019.08.011","31699625",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008277","Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.","Qin J","2022","BMC endocrine disorders","systematic_review","article","10.1186/s12902-022-01036-0","35546664","PMC9097124",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0008278","Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs.","Stanciu S","2023","Metabolites","narrative_review","article","10.3390/metabo13010087","36677012","PMC9863091",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008279","Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non-Diabetic Adults: A Narrative Review.","Laraib A","2026","Health science reports","randomized_trial","article","10.1002/hsr2.72144","42005640","PMC13087639",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; review"],["R0008280","Tirzepatide data: safety first is safety always!","Janić M","2026","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2026.2681511","42201797",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0008281","GLP-1 receptor agonists versus DPP-4 inhibitors after curative resection of hepatocellular carcinoma in patients with type 2 diabetes.","Chen CL","2026","Gut","other","article","10.1136/gutjnl-2026-339889","42810850",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008282","A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use.","Nduma B","2025","Endocrinology, diabetes & metabolism case reports","nonrandomized_study","article","10.1530/edm-25-0067","40911613","PMC12423746",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; article"],["R0008283","Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?","Tsankof A","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.984041","36120448","PMC9478023",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008284","Development of a Long-Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP-1R Agonists for the Treatment of Obesity.","Zhou Y","2026","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.5c00558","41429154",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008285","Type 2 diabetes and cardiovascular disease: risk reduction and early intervention.","Hinnen D","2023","Postgraduate medicine","narrative_review","article","10.1080/00325481.2022.2126235","36154802",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0008286","Antihyperglycemic treatment patterns for chronic kidney disease and type 2 diabetes.","Betts KA","2024","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2024.89599","39302264",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008287","L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.","Elabi OF","2021","International journal of molecular sciences","preclinical","article","10.3390/ijms222212346","34830228","PMC8618072",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008288","Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists.","Chen X","2025","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.4c02616","39824521",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008289","Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes.","Patti AM","2023","Biomedicines","nonrandomized_study","article","10.3390/biomedicines11051362","37239033","PMC10216597",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008290","The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials.","Hung CM","2026","International journal of surgery (London, England)","systematic_review","article","10.1097/js9.0000000000003450","40990658","PMC12825905",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; review"],["R0008291","Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities.","Vahora S","2026","Pharmaceutical research","narrative_review","article","10.1007/s11095-026-04185-2","42687069",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008292","Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management.","Alluri AA","2025","Journal of basic and clinical physiology and pharmacology","nonrandomized_study","article","10.1515/jbcpp-2025-0031","40150960",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0008293","Determinants Influencing Glycaemic Control in Elderly Chinese Patients Diagnosed with Type 2 Diabetes: A Cross-sectional Study","Cao L","2024","Authorea Preprints","other","preprint","10.22541/au.172514313.39465631/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008294","Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.","Lin R","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70224","41147324","PMC12673457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Comparative Study; Network Meta-Analysis; research-article; review"],["R0008295","Discussions About Binge Eating and Type 2 Diabetes in a Facebook Group: A Qualitative Analysis.","Lindgreen P","2024","The International journal of eating disorders","other","article","10.1002/eat.24242","38934575",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008296","Assessment of lixisenatide-induced nephropathy in chick embryos: Implications for prevention of diabetic kidney disease.","Srivastava AK","2025","Bioinformation","other","article","10.6026/973206300213926","41623754","PMC12859325",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008297","GLP-1R mediates idebenone-reduced blood glucose in mice.","Zhao X","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","nonrandomized_study","article","10.1016/j.biopha.2024.117202","39053424",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0008298","Incretin mimetics and acute pancreatitis: enemy or innocent bystander?","Pratley R","2024","Current opinion in gastroenterology","randomized_trial","article","10.1097/mog.0000000000001057","38967917",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0008299","Influence of GLP-1 receptor agonist on insulin dosage and blood glucose control of patients with type 2 diabetes mellitus.","Shen Y","2021","American journal of translational research","other","article",null,"34786110","PMC8581930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008300","No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes.","Svane MS","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14106","32495988",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008301","The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression.","Liu Y","2024","DNA and cell biology","other","article","10.1089/dna.2024.0052","38923881",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008302","Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.","Al-Horani RA","2024","Current diabetes reviews","narrative_review","article","10.2174/0115733998276832231124170324","38275036","PMC11452264",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0008303","Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study.","Hepşen S","2026","Obesity facts","nonrandomized_study","article","10.1159/000552104","42030208","PMC13318359",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008304","Practical Considerations for Use of Insulin/Glucagon-Like Peptide 1 Receptor Agonist Combinations in Older Adults With Type 2 Diabetes.","Champlain JM","2022","The Journal of family practice","other","article","10.12788/jfp.0394","35960944",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008305","Medical Weight Optimization for Arthroplasty Patients: A Primer of Emerging Therapies for the Joint Arthroplasty Surgeon.","Mayfield CK","2024","The Journal of arthroplasty","narrative_review","article","10.1016/j.arth.2023.07.017","37531983",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Review; Journal Article"],["R0008306","[Effects of \"new\" antidiabetic drugs on management of anesthesia].","Rupprecht B","2025","Die Anaesthesiologie","narrative_review","article","10.1007/s00101-025-01521-w","40164842",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0008307","Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis.","Myasoedova VA","2023","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-023-01738-2","36721184","PMC9890718",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; research-article; review"],["R0008308","Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec-Liraglutide (Ideglira).","Zenari L","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00945-4","33104959","PMC7843811",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0008309","Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin Secretion From Rat Islets.","Yang X","2021","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2021.664802","33995091","PMC8116734",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008310","Outcomes of Beinaglutide on Weight Loss in Patients With Diabetes or Obesity: A Systematic Review and Meta-Analysis.","Wen J","2025","Cureus","systematic_review","article","10.7759/cureus.100224","41607973","PMC12835569",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0008311","Candidate composite biomarker to inform drug treatments for diabetic kidney disease.","Jones RD","2023","Frontiers in medicine","other","article","10.3389/fmed.2023.1271407","38020124","PMC10646536",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008312","Response to \"GLP-1 Receptor Agonists, Gastric Emptying, and Mechanisms of Weight Loss\".","Friedman MI","2026","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.70300","42665869",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0008313","GLP-1 receptor agonists: a role in the treatment of neuropathic pain?","Moisset X","2026","Pain","other","article","10.1097/j.pain.0000000000004103","42663525",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008314","Patient-Reported Outcomes in People With Type 2 Diabetes Escalating Dulaglutide or Switching From Dulaglutide to Tirzepatide.","Boye KS","2026","Annals of internal medicine","other","article","10.7326/annals-25-03219","41911554",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008315","Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?","Mc Namara KP","2022","The Medical journal of Australia","randomized_trial","article","10.5694/mja2.51701","36183318","PMC9828708",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0008316","Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats.","Douton JE","2022","Addiction biology","preclinical","article","10.1111/adb.13117","34802173","PMC10825889",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0008317","Ambulatory blood pressure monitoring strengthens the cardiovascular signal of GLP-1RA: a meta-analysis of blood pressure and weight mediation.","Renna NF","2026","Journal of hypertension","systematic_review","article","10.1097/hjh.0000000000004158","41230897",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008318","Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome.","Ferch M","2025","The Journal of clinical endocrinology and metabolism","case_report","article","10.1210/clinem/dgaf258","40302276","PMC12623033",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0008319","Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption.","Jensen ME","2025","Alcohol, clinical & experimental research","randomized_trial","article","10.1111/acer.70041","40123107","PMC12098802","ClinicalTrials.gov:NCT05895643","S002359","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0008320","Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.","Makri E","2020","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2020.09.030","33011499",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; article"],["R0008321","Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.","Cirnigliaro CM","2024","The journal of spinal cord medicine","randomized_trial","article","10.1080/10790268.2023.2207064","37158751","PMC11218576","ClinicalTrials.gov:NCT03292315","S000243","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0008322","The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis.","Abo-Elenin MHH","2025","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-024-03378-z","39254876","PMC11920005",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008323","The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study.","Al-Mashhadi ZK","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.882998","36299454","PMC9589410",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008324","Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues.","Douros JD","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2026.102327","41654015","PMC12926979",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0008325","Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?","Doggrell SA","2018","Expert opinion on drug metabolism & toxicology","other_trial","article","10.1080/17425255.2018.1441286","29439603",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0008326","Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.","Choi YJ","2024","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00158.2023","38014444","PMC11208022",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008327","Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.","Hach M","2024","Pharmaceutical research","other","article","10.1007/s11095-024-03771-6","39379664",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0008328","Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.","Yale JF","2022","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2021-002619","35383100","PMC8984040","ClinicalTrials.gov:NCT03457012; ClinicalTrials.gov:NCT03631186; ClinicalTrials.gov:NCT03648281; ClinicalTrials.gov:NCT03876015","S000084; S000303; S000510; S000917; S001761","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008329","The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.","Linjawi S","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-016-0218-3","27943107","PMC5306117","ClinicalTrials.gov:NCT01676116","S001654","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0008330","Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.","Gibble TH","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100300","42491427","PMC13377426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0008331","All GLP-1 Agonists Should, Theoretically, Cure Alzheimer's Dementia but Dulaglutide Might Be More Effective Than the Others.","Fessel J","2024","Journal of clinical medicine","randomized_trial","article","10.3390/jcm13133729","38999294","PMC11242057",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0008332","Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial.","Yammine L","2021","Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","randomized_trial","article","10.1093/ntr/ntab066","33831213","PMC8517504","ClinicalTrials.gov:NCT02975297","S000617","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0008333","Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.","Lovshin JA","2017","Canadian journal of diabetes","other_trial","article","10.1016/j.jcjd.2017.08.242","28942790",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0008334","Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis.","Gharagozloo M","2021","Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","other_trial","article","10.1007/s13311-021-01088-5","34260042","PMC8608955",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0008335","Potential Associations Between GLP-1 Receptor Agonists and Polyendocrine Metabolic Ovarian Syndrome: Triangulation of Genetic and Pharmacovigilance Evidence.","Feng Z","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71348","42736040",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0008336","Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.","Xu L","2020","Biomedical and environmental sciences : BES","systematic_review","article","10.3967/bes2020.005","32029057",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0008337","A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.","An IB","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14058","32314505","PMC7383507",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008338","Decoupling weight loss from organoprotective benefits in GLP-1RA, dual agonists, and SGLT2I therapy: A narrative review.","Bhaduri G","2026","Acta diabetologica","randomized_trial","article","10.1007/s00592-025-02636-7","41504921",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0008339","GLP-1 receptor agonists: from glycaemic control to cardio-reno-metabolic disease modification.","Farmakis D","2026","European heart journal. Quality of care & clinical outcomes","commentary","article","10.1093/ehjqcco/qcag096","42237895",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0008340","The Ageing Adipose Paradox: Implications for Metabolic Health.","Matar DB","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.71037","42366180","PMC13449016",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008341","Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice.","Allingbjerg ML","2023","Experimental and clinical psychopharmacology","nonrandomized_study","article","10.1037/pha0000620","36480394","PMC10198891",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008342","Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy.","Courtney LA","2025","Diabetes & metabolic syndrome","narrative_review","article","10.1016/j.dsx.2025.103314","41176849",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008343","Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.","Monami M","2017","Acta diabetologica","systematic_review","article","10.1007/s00592-017-1054-2","28932989",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008344","Contractile Effects of Semaglutide in the Human Atrium.","Neumann J","2024","Pharmaceutics","preclinical","article","10.3390/pharmaceutics16091139","39339176","PMC11435389",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008345","GLP-1RA improves diabetic renal injury by alleviating glomerular endothelial cells pyrotosis via RXRα/circ8411/miR-23a-5p/ABCA1 pathway.","Wu W","2024","PloS one","preclinical","article","10.1371/journal.pone.0314628","39621727","PMC11611192",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008346","Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.","Hompesch M","2021","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2021-002208","34172436","PMC8237726","ClinicalTrials.gov:NCT02059564","S001369","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0008347","Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.","Mashayekhi M","2024","Diabetes","randomized_trial","article","10.2337/db23-0356","37874653","PMC10784656",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0008348","Tirzepatide-Induced Injection Site Reaction.","Mizumoto J","2023","Cureus","case_report","article","10.7759/cureus.45181","37842452","PMC10575762",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008349","Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.","Mann JFE","2021","Diabetes, obesity & metabolism","other","article","10.1111/dom.14443","34009708","PMC8453827",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0008350","Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival.","Wang J","2026","Urologic oncology","commentary","article","10.1016/j.urolonc.2026.08.019","42722558",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0008351","Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications.","Satheesan A","2024","Inflammopharmacology","narrative_review","article","10.1007/s10787-024-01556-2","39160391",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008352","Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.","Trang NN","2021","International journal of molecular sciences","preclinical","article","10.3390/ijms22031177","33503985","PMC7865477",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008353","Current management of chronic kidney disease in type-2 diabetes-A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelines.","Dasgupta I","2025","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.15450","39415639","PMC11733655",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; review-article; article"],["R0008354","Semaglutide 2.4-mg injection as a novel approach for chronic weight management.","Kyrillos J","2022","The American journal of managed care","other_trial","article","10.37765/ajmc.2022.89293","36525677",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008355","Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).","Liakos CI","2021","American journal of cardiovascular drugs : drugs, devices, and other interventions","narrative_review","article","10.1007/s40256-020-00423-z","32780214",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008356","Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care.","O'Hara DV","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111745","38876274",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0008357","Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.","Awad AA","2025","Proceedings (Baylor University. Medical Center)","systematic_review","article","10.1080/08998280.2025.2480512","40557198","PMC12184113",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0008358","Comparative Effects of Exercise and GLP-1 RAs on Type 2 Diabetic Rat Model: A Systematic Review.","Afzal S","2025","International journal of exercise science","systematic_review","article","10.70252/fhzh8622","40190743","PMC11970413",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0008359","The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.","Wilson JM","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14174","33462955","PMC7756479",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0008360","Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.","Li XY","2022","European review for medical and pharmacological sciences","randomized_trial","article","10.26355/eurrev_202211_30153","36394750",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0008361","Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.","Matsuhisa M","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01333-w","36422802","PMC9880089","UMIN:UMIN000044126",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008362","Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?","Albert SG","2023","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2022.102696","36596264",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Meta-Analysis; Journal Article; article"],["R0008363","Comparative cardiovascular effectiveness of newer glucose-lowering drugs in elderly with type 2 diabetes: a target trial emulation cohort study.","Kosjerina V","2025","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2025.103162","40201798","PMC11976231",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008364","Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy.","Xu X","2026","Analytical chemistry","other","article","10.1021/acs.analchem.5c07959","42708757",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008365","Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes.","Liuzzo G","2026","European heart journal","other_trial","article","10.1093/eurheartj/ehag194","41879154",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0008366","Potential Suppression of HSV-1 Outbreaks During GLP-1 (Semaglutide)   Therapy: A Self-Observed Case Report","Georgakopoulos A","2025","ScienceOpen Preprints","case_report","preprint","10.14293/pr2199.001770.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008367","GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models.","Gorgogietas V","2023","Diabetologia","preclinical","article","10.1007/s00125-023-05905-8","36995380","PMC10244297",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0008368","Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists.","Sun L","2022","Pharmaceuticals (Basel, Switzerland)","other","article","10.3390/ph15060740","35745659","PMC9230455",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0008369","Comment on: GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes.","Smith H","2026","International journal of impotence research","nonrandomized_study","article","10.1038/s41443-026-01337-1","42697915",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; letter"],["R0008370","Medullary Carcinoma of Thyroid Due to GLP-1 Receptor Agonist","Vemula H","2021","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvab048.1823",null,"PMC8089522",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0008371","Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment.","Acharya M","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71199","42575862",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008372","Glucagon-Like Peptide-1 Receptor Agonist Protects Dorsal Root Ganglion Neurons against Oxidative Insult.","Mohiuddin MS","2019","Journal of diabetes research","preclinical","article","10.1155/2019/9426014","30918901","PMC6408997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008373","Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.","Ulrich FS","2026","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2026.101738","42294355","PMC13262276",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008374","Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.","Suzuki T","2024","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2024.108779","38833854",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Clinical Study; Journal Article; article"],["R0008375","A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.","Kayaniyil S","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-016-0155-1","26886440","PMC4801811",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0008376","Guidance on Preoperative Management of Hand Surgery Patients Taking GLP-1 Receptor Agonists.","Kisiel SC","2026","Hand (New York, N.Y.)","narrative_review","article","10.1177/15589447241300712","39663564","PMC11635785",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0008377","Total parenteral nutrition impairs glucose metabolism by modifying the gut microbiome.","Wang P","2023","Nature metabolism","nonrandomized_study","article","10.1038/s42255-023-00744-8","36782071",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0008378","One small molecule for man, one giant leap for mankind with obesity.","Novikoff A","2025","Med (New York, N.Y.)","other_trial","article","10.1016/j.medj.2025.100924","41389711",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0008379","Semaglutide as a promising antiobesity drug.","Christou GA","2019","Obesity reviews : an official journal of the International Association for the Study of Obesity","other_trial","article","10.1111/obr.12839","30768766",null,null,"S001427","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0008380","Tirzepatide Attenuates Diabetes-Associated Testicular Inflammation and Sperm DNA Fragmentation in Obese Diabetic Mice: Potential Pleiotropic Effects Beyond Glycemic Control","Mori Y","2026","Research Square","preclinical","preprint","10.21203/rs.3.rs-10208764/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008381","GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials.","Cao C","2020","Endocrine","systematic_review","article","10.1007/s12020-020-02223-6","32103407",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0008382","GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis.","Elmati PR","2025","The open respiratory medicine journal","systematic_review","article","10.2174/0118743064372550250603061720","41036293","PMC12481593","PROSPERO:CRD42024595241",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0008383","Neglected GLP-1 receptors in the eyes and nose: possible correlation with regulation of appetite.","Saturnino A","2026","Endocrine","narrative_review","article","10.1007/s12020-026-04581-z","41925981",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008384","Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis.","Pradhan R","2020","The lancet. Diabetes & endocrinology","nonrandomized_study","article","10.1016/s2213-8587(19)30382-1","31806579",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0008385","Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health.","Chiang CE","2025","Journal of the Chinese Medical Association : JCMA","narrative_review","article","10.1097/jcma.0000000000001263","40605133","PMC12637135",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008386","Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.","Wolffenbuttel BHR","2023","Advances in therapy","nonrandomized_study","article","10.1007/s12325-022-02385-x","36542260","PMC9768392","ClinicalTrials.gov:NCT03929679","S000683","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008387","Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.","Chen H","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1937754","42775225","PMC13595571","PROSPERO:CRD420251150683",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; systematic-review; review"],["R0008388","A Pair of Siblings With Wolfram Syndrome: A Review of the Literature and Treatment Options.","Png D","2023","Journal of investigative medicine high impact case reports","case_report","article","10.1177/23247096221150631","36644884","PMC9846294",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Review; Research Support, Non-U.S. Gov't; case-report; article"],["R0008389","Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease.","Tang H","2023","Movement disorders clinical practice","systematic_review","article","10.1002/mdc3.13893","37982117","PMC10654811",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; brief-report; article"],["R0008390","Glucagon-like peptide-1 analogs: Miracle drugs are blooming?","Gong B","2024","European journal of medicinal chemistry","narrative_review","article","10.1016/j.ejmech.2024.116342","38531211",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008391","Association of GLP-1 Receptor Agonists With Gastrointestinal and Liver Outcomes in Adults With Type 2 Diabetes: A Target Trial Emulation Study.","Zhang D","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71352","42736029",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Letter; article"],["R0008392","What Do Sugar, Gila Monsters, and the Therapeutic Dance Have in Common With GLP-1RA, Stroke, and Dementia?","Worrall BB","2026","Neurology. Genetics","nonrandomized_study","article","10.1212/nxg.0000000000200450","42812718","PMC13621552",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; editorial"],["R0008393","Correction to: Glucagon‑like peptide‑1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.","Ligumsky H","2026","Medical oncology (Northwood, London, England)","notice","article","10.1007/s12032-026-03285-8","41894100",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0008394","Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2",null,"2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article",null,null,"PMC9067827","ClinicalTrials.gov:NCT02863328","S000251","europepmc","TRUE","open_europepmc","1",null,"Abstract"],["R0008395","The first successful desensitization protocol in exenatide allergy: a case report.","Yeğit OO","2023","Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology","protocol","article","10.1186/s13223-023-00761-y","36639791","PMC9838064",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; article"],["R0008396","National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation.","Chopra HK","2026","The Journal of the Association of Physicians of India","randomized_trial","article","10.59556/japi.74.1375","41818087",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0008397","Effect of liraglutide on expression of inflammatory genes in type 2 diabetes.","Zobel EH","2021","Scientific reports","randomized_trial","article","10.1038/s41598-021-97967-0","34535716","PMC8448739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0008398","Online Prescribing of GLP-1 Receptor Agonists.","Chetty AK","2026","JAMA","other","article","10.1001/jama.2026.9131","42406378","PMC13338841",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008399","Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.","van Ruiten CC","2022","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgac043","35134184","PMC9113812","ClinicalTrials.gov:NCT03361098","S000930","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0008400","Practice Patterns of Glucagon-Like Peptide-1 Agonist Use Among Pediatric Bariatric Surgeons: A National Survey.","Kochis M","2024","The Journal of surgical research","other","article","10.1016/j.jss.2024.05.045","38941713",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008401","Corrigendum to \"Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway\".",null,"2025","BioMed research international","notice","article","10.1155/bmri/9793841","40900906","PMC12401594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0008402","Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression.","Pan X","2024","Molecular and cellular biochemistry","preclinical","article","10.1007/s11010-023-04784-2","37318712",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008403","Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes.","Lim CE","2025","Diabetologia","nonrandomized_study","article","10.1007/s00125-025-06439-x","40316732","PMC12246030",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008404","Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.","Zhang X","2023","Journal of managed care & specialty pharmacy","other_trial","article","10.18553/jmcp.2023.29.3.276","36840958","PMC10388019",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0008405","Response To \"Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data\".","Hussein MH","2026","Cardiovascular drugs and therapy","nonrandomized_study","article","10.1007/s10557-025-07820-z","41317265",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0008406","A rheumatological reading of GLP-1 receptor agonists: from muscle loss to musculoskeletal gain.","Ciaffi J","2026","International journal of obesity (2005)","other","article","10.1038/s41366-026-02204-1","42625000",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008407","Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71058","42410325","PMC13538747",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review-article; review"],["R0008408","Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.","Kaneko M","2018","The Annals of pharmacotherapy","randomized_trial","article","10.1177/1060028018757407","29424239",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; other; article"],["R0008409","PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients.","Liu X","2023","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2023.1088670","37781697","PMC10539604",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008410","Brainstem BDNF neurons are downstream of GFRAL/GLP1R signalling.","Feetham CH","2024","Nature communications","preclinical","article","10.1038/s41467-024-54367-y","39737892","PMC11685588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008411","Sustained Low-Dose Semaglutide Is Linked to Broad-Spectrum Cardiometabolic Benefits, and Better Tolerability Profile over Low-Dose Tirzepatide, Motivating Semaglutide Microdosing Studies","Murugadoss K","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202606.0636.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0008412","Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lost","Murugadoss K","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.04.16.26351060",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0008413","Increasing skeletal muscle mass and strength during incretin-based weight loss.","Mendias CL","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100317","42620560","PMC13486323",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0008414","High-yield recombinant production of the semaglutide main chain P29 intermediate using SNAC-tagged enterokinase-cleavable fusion peptides.","Qi Q","2026","PloS one","other","article","10.1371/journal.pone.0348509","42361026","PMC13308793",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008415","Complementary and antagonistic effects of combined glucagon-like peptide-2 and glucagon-like peptide-1 receptor agonist administration on parameters relevant to short bowel syndrome.","Srikrishnaraj A","2022","JPEN. Journal of parenteral and enteral nutrition","preclinical","article","10.1002/jpen.2307","34826336",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008416","Nephroprotective Properties of Antidiabetic Drugs.","Gerdes C","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm12103377","37240483","PMC10219007",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008417","The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.","Zhang L","2020","Journal of Parkinson's disease","other_trial","article","10.3233/jpd-191768","31958096",null,"ClinicalTrials.gov:NCT02953665","S001357","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008418","Cystic Fibrosis and Hemochromatosis Carriers May Be Prone to Glucagon-like Peptide-1 Agonist Pancreatitis: 3 Cases.","Sydney GI","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf104","40384889","PMC12078934",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008419","Cardiorenal syndrome and diabetes: an evil pairing.","Méndez Fernández AB","2023","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2023.1185707","37234376","PMC10206318",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008420","[New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus® tablets), an oral GLP-1 receptor agonist].","Miyasaka K","2022","Nihon yakurigaku zasshi. Folia pharmacologica Japonica","other","article","10.1254/fpj.21052","35228448",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008421","Characteristics of subjects with type 2 diabetes enrolled in randomized controlled trials and non-randomized controlled trials in Japan: A systematic review.","Kadowaki T","2023","Journal of diabetes investigation","systematic_review","article","10.1111/jdi.13872","35726690","PMC9889671",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; review"],["R0008422","Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).","Laverde LP","2026","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-026-02118-y","42321502","PMC13461373",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review-article; review"],["R0008423","The global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD): current status and future prospects.","Sun J","2025","International journal of surgery (London, England)","nonrandomized_study","article","10.1097/js9.0000000000002654","40474833","PMC12430730",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008424","Changes in the use of glucose-lowering drugs: A Danish nationwide study.","Pottegård A","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14947","36514856",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0008425","Biliary Events and GLP-1 Receptor Agonist Therapy in Adolescents and Young Adults.","Rodrigues de Oliveira Filho J","2026","JAMA pediatrics","nonrandomized_study","article","10.1001/jamapediatrics.2026.3918","42671848","PMC13531382",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0008426","Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis.","Ferrannini G","2022","European heart journal. Cardiovascular pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvac044","35963647","PMC9384777",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008427","Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes.","Vargas-Uricoechea H","2022","Journal of clinical medicine research","narrative_review","article","10.14740/jocmr4660","35211212","PMC8827224",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008428","Clinical assessment of liraglutide use in prediabetic and obese schizophrenic patients: A systematic literature review and meta-analysis","Abbas A","2023","Research Square","systematic_review","preprint","10.21203/rs.3.rs-3150409/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0008429","Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP-1 Receptor Agonist.","Kelly H","2026","Movement disorders clinical practice","case_report","article","10.1002/mdc3.70704","42260955","PMC13338974",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-study; article"],["R0008430","The Ozempic Generation: What the Interventional Radiologist Needs to Know About GLP-1 Agonists.","Wani S","2025","Journal of medical imaging and radiation oncology","narrative_review","article","10.1111/1754-9485.70045","41239945",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008431","The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.","Jin Y","2020","Acta diabetologica","systematic_review","article","10.1007/s00592-020-01529-1","32300876",null,"PROSPERO:CRD42019138777",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008432","Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials.","Guo J","2025","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2025.1517272","40213686","PMC11983143","PROSPERO:CRD42024571544",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0008433","Implications of GLP-1 Agonists on Office-Based Sedation and General Anesthesia for Dentistry.","McKenzie C","2025","Anesthesia progress","narrative_review","article","10.2344/anpr-72-1-anpr_agonists","40657828","PMC11922517",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0008434","GLP-1 receptor agonists: A paradigm shift for psychiatry?","Guillaume S","2026","L'Encephale","commentary","article","10.1016/j.encep.2026.05.001","42468980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0008435","Corrigendum to \"Inflammation-induced promoter hypermethylation of GLP-1R limits the protective effect of GLP-1R agonists against acute lung injury\" [Biochem. Pharmacol. 251 (2026) 118112].","Deng G","2026","Biochemical pharmacology","notice","article","10.1016/j.bcp.2026.118155","42287946",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0008436","Beyond pressure: Reframing idiopathic intracranial hypertension in the era of GLP-1 receptor agonists.","Krajnc N","2026","Headache","other","article","10.1111/head.70150","42619235",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008437","Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.","Mozaffarian D","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24336","40445127","PMC12304835",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Review; research-article; review-article; article"],["R0008438","Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.","Natali A","2021","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-021-01385-5","34583699","PMC8479881",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0008439","Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations.","Jia IT","2026","Surgical endoscopy","systematic_review","article","10.1007/s00464-026-12940-0","42260171",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0008440","The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice.","Forny Germano L","2024","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.102019","39216535","PMC11408156",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008441","Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes.","Suganuma Y","2020","Journal of diabetes investigation","other_trial","article","10.1111/jdi.13115","31301103","PMC7078094",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0008442","Reconsidering the Association Between GLP-1 Receptor Agonists and Atrial Fibrillation Risk in Chronic Kidney Disease.","Chen W","2026","Cardiovascular drugs and therapy","commentary","article","10.1007/s10557-026-07939-7","42658385",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008443","Association of dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy with colon cancer risk in post-polypectomy patients with diabetes: a target trial emulation.","Wang CH","2026","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-026-02151-x","41906175","PMC13154574",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0008444","A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada.","Qureshy K","2022","Cardiovascular endocrinology & metabolism","other","article","10.1097/xce.0000000000000260","35350598","PMC8955057",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008445","Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.","Levin PA","2017","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s130834","28435305","PMC5389657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0008446","Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide.","Wang C","2025","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2025.118266","40499315",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0008447","Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.","Chen JH","2014","Journal of medical case reports","case_report","article","10.1186/1752-1947-8-304","25213589","PMC4164326",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; case-report; article"],["R0008448","A Probable Case of Tirzepatide-Induced Acute Pancreatitis.","Sumaruth Y","2025","Cureus","case_report","article","10.7759/cureus.85291","40612832","PMC12225653",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008449","PT320, a GLP-1 receptor agonist, mitigates nucleus accumbens-associated depression- and anxiety-like behaviors in MitoPark mice of Parkinson's disease.","Tseng KY","2026","Journal of Parkinson's disease","preclinical","article","10.1177/1877718x261477621","42585299","PMC13473357",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008450","Reappraising obesity management in the GLP-1 receptor agonist era.","Christmas T","2026","npj metabolic health and disease","commentary","article","10.1038/s44324-026-00126-0","42624962","PMC13493817",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0008451","GLP-1 Receptor Agonist Prescriptions Among People With and Without Serious Mental Illness.","McGinty EE","2026","JAMA psychiatry","other","article","10.1001/jamapsychiatry.2026.2667","42684696","PMC13539436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008452","Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.","Qin L","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-017-0237-8","28236271","PMC5380499",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008453","Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.","Wilding JP","2016","Diabetic medicine : a journal of the British Diabetic Association","other_trial","article","10.1111/dme.13021","26525806",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0008454","Blinded by the drug? A vigilyze signal linking semaglutide to NAION.","Suresh J","2025","International ophthalmology","nonrandomized_study","article","10.1007/s10792-025-03760-7","41026313",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0008455","Maternal Weight Management to Prevent the Developmental Programming of MAFLD in Offspring of Obese Mothers.","Purcell AR","2023","Nutrients","narrative_review","article","10.3390/nu15092155","37432265","PMC10180876",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008456","Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists.","Icart LP","2021","Journal of microencapsulation","narrative_review","article","10.1080/02652048.2021.1889059","33586588",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008457","Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.","Kasagga A","2025","Cureus","systematic_review","article","10.7759/cureus.90335","40978842","PMC12444735",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0008458","Alopecia Risk With GLP‐1 Receptor Agonists: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS)","Gupta A","2026","Journal of cosmetic dermatology","nonrandomized_study","article","10.1111/jocd.70967",null,"PMC13243728",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","research-article; Journal Article; article"],["R0008459","Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Li Z","2016","PloS one","systematic_review","article","10.1371/journal.pone.0154206","27158818","PMC4861281",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; review"],["R0008460","Bariatric Surgery and GLP-1/GIP Medications for the Treatment of Obstructive Sleep Apnoea: A Comprehensive Review.","Alnagar A","2025","Current obesity reports","randomized_trial","article","10.1007/s13679-025-00640-0","40407960",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0008461","Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.","Morales J","2024","Postgraduate medicine","narrative_review","article","10.1080/00325481.2024.2316572","38344772",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0008462","GLP-1 Receptor Agonists and Eating Disorders - Cause for Concern.",null,"2026","The New England journal of medicine","notice","article","10.1056/nejmx260022","42585662",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; article"],["R0008463","Oral semaglutide (Wegovy) for weight loss.",null,"2026","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2026.1747a","41575765",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008464","SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus","Fazeli S","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-sun-164",null,"PMC6553273",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0008465","Exendin-4 enhances GLP-1 signaling and reduces anxiety-like behaviors in male heroin withdrawal mice.","Xiang Y","2026","PloS one","preclinical","article","10.1371/journal.pone.0343995","41818251","PMC12981496",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008466","Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.","Hagemann AR","2025","Cancers","other","article","10.3390/cancers17040598","40002193","PMC11853405",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008467","Progress in the management of patients with diabetes and chronic kidney disease.","Pozo Garcia L","2022","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000000811","35894280","PMC9377049",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0008468","Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis.","Wei J","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.910256","36034440","PMC9403613",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; Journal Article; systematic-review; review"],["R0008469","Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","Ma H","2022","medRxiv","systematic_review","preprint","10.1101/2022.02.06.22270446",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0008470","Cardiovascular outcome trials in obesity: A review.","Wilding JPH","2021","Obesity reviews : an official journal of the International Association for the Study of Obesity","other_trial","article","10.1111/obr.13112","32893459",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0008471","Retatrutide showing promise in obesity (and type 2 diabetes).","Doggrell SA","2023","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2023.2283020","37947489",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0008472","New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists.","Sztanek F","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12061320","38927527","PMC11201978",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008473","Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.","Kimura Y","2025","BMJ open","protocol","article","10.1136/bmjopen-2025-112318","41448692","PMC12742159","jRCT:jRCT2051230090",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0008474","Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.","Cui J","2021","Journal of managed care & specialty pharmacy","other_trial","article","10.18553/jmcp.2021.27.7.840","34185562","PMC10391238",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Journal Article; brief-report; article"],["R0008475","Role of metformin in the management of type 2 diabetes: recent advances.","Gonzalez-Lopez C","2023","Polish archives of internal medicine","other","article","10.20452/pamw.16511","37317976",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008476","Glucagon-Like Peptide-1 Receptor Agonist, Liraglutide, Attenuated Diabetic Retinal Edema in Spontaneously Diabetic Torii Fatty Rats","Inoue K","2021","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-1069652/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0008477","Impact of GLP-1 receptor agonists on gastric residuals in patients receiving gastrointestinal endoscopic procedures.","Le K","2026","Proceedings (Baylor University. Medical Center)","nonrandomized_study","article","10.1080/08998280.2025.2583025","41487538","PMC12758203",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008478","Comparative study on anorexigenic effect of glucagon-like peptide-1 receptor agonists in rats.","Wen S","2019","Sheng li xue bao : [Acta physiologica Sinica]","randomized_trial","article",null,"31440748",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Comparative Study; Journal Article; article"],["R0008479","Erratum for the Research Article \"Exendin-4 gene modification and microscaffold encapsulation promote self-persistence and antidiabetic activity of MSCs\" by Y. Zhang et al.",null,"2025","Science advances","notice","article","10.1126/sciadv.aea8045","41042889","PMC12494002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0008480","Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia.","Alnaser RI","2024","Journal of bone metabolism","nonrandomized_study","article","10.11005/jbm.24.739","39496297","PMC11658841",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; review-article; article"],["R0008481","Authors' reply to \"Comment on generalizability of GLP-1 RA CVOTs in US T2D population\".","Wittbrodt ET","2019","The American journal of managed care","commentary","article",null,"30986013",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0008482","Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.","Peng H","2016","Current diabetes reports","other_trial","article","10.1007/s11892-016-0728-4","27037706",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0008483","Oral delivery of GLP-1 analogues by recombinant Lactococcus lactis restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice.","Huang Y","2026","EBioMedicine","preclinical","article","10.1016/j.ebiom.2026.106141","41637938","PMC12887662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008484","Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson's Disease Rat Model.","Delvadia P","2025","ACS chemical neuroscience","preclinical","article","10.1021/acschemneuro.4c00729","39964252",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008485","Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.","Chen JJ","2022","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2022.1169","35254430","PMC8902651",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008486","Exendin-4 imaging based on gastrointestinal GLP-1R targets for IBD diagnosis and efficacy assessment.","Li X","2025","European journal of nuclear medicine and molecular imaging","preclinical","article","10.1007/s00259-025-07197-z","40178570",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008487","Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease.","Nelson AJ","2021","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.120.016835","33432843","PMC7955303",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0008488","SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes.","Nonomura K","2020","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.4323-19","32188813","PMC7364240",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008489","Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis.","Chen Q","2026","PloS one","nonrandomized_study","article","10.1371/journal.pone.0351059","42268869","PMC13252742",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008490","Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations.","Agarwal PN","2025","In silico pharmacology","other","article","10.1007/s40203-025-00393-7","40686549","PMC12267729",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008491","A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents.","Cornell S","2020","Journal of clinical pharmacy and therapeutics","narrative_review","article","10.1111/jcpt.13230","32910490","PMC7540167",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008492","Novel and ultra-rare damaging variants in neuropeptide signaling are associated with disordered eating behaviors.","Lutter M","2017","PloS one","preclinical","article","10.1371/journal.pone.0181556","28846695","PMC5573281",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008493","Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors.","Chan ATP","2022","Kidney research and clinical practice","narrative_review","article","10.23876/j.krcp.21.285","35977903","PMC9731775",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0008494","Findings Interpretation Concerns Regarding the Emulated Target Trial of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Psoriatic Arthritis [Response to Letter].","Yen FS","2026","Drug design, development and therapy","other_trial","article","10.2147/dddt.s650968","42757044","PMC13584087",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comment; Letter; reply; article"],["R0008495","Acute Mesenteric Ischemia as a Severe Complication Associated With Tirzepatide: A Case Report and Safety Alert.","Brooks S","2025","Cureus","case_report","article","10.7759/cureus.97035","41416326","PMC12709405",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008496","GLP-1 Receptor Agonist Paradox in Hair Biology: A Biphasic dWAT-Follicle Signaling Hypothesis.","Kahn MA","2026","Journal of drugs in dermatology : JDD","other","article","10.36849/jdd.9868","42696329",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008497","Metabolic dysfunction and the use of adjunct medications in type 1 diabetes.","Luk A","2026","Current opinion in endocrinology, diabetes, and obesity","nonrandomized_study","article","10.1097/med.0000000000000956","41889083","PMC13152071",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0008498","GLP-1 receptor agonists and colorectal neoplasia: Interpreting the evidence.","Khan AN","2026","The American journal of the medical sciences","commentary","article","10.1016/j.amjms.2026.07.011","42608207",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008499","Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.","Aminorroaya A","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2025.03.516","40368575","PMC12186526",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0008500","Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities.","Han J","2018","British journal of pharmacology","preclinical","article","10.1111/bph.14107","29171021","PMC5773971",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008501","Body Composition in Paediatric GLP-1 Receptor Agonist Therapy. Comment on Zaitoon et al. Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children. Children 2025, 12, 1427.","Improda N","2026","Children (Basel, Switzerland)","commentary","article","10.3390/children13050607","42194133","PMC13205057",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Journal Article; letter; article"],["R0008502","Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.","Zhang S","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71057","42473266","PMC13538735",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study; research-article; article"],["R0008503","Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease.","Limonte CP","2024","Seminars in nephrology","narrative_review","article","10.1016/j.semnephrol.2024.151520","38705774","PMC11283968",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; research-article"],["R0008504","Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.","Rouette J","2020","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.14287","32124472",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008505","Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet.","Jin M","2020","Open medicine (Warsaw, Poland)","preclinical","article","10.1515/med-2020-0212","33336025","PMC7712363",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008506","It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.","Oberle MM","2019","Frontiers in endocrinology","other","article","10.3389/fendo.2019.00738","31736876","PMC6828818",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0008507","Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study.","Guan Z","2022","European journal of clinical pharmacology","nonrandomized_study","article","10.1007/s00228-021-03249-z","35079845",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008508","Low-Carbohydrate Nutrition Counseling With Continuous Glucose Monitoring to Improve Metabolic Health Among Veterans With Type 2 Diabetes: Pilot Quality Improvement Initiative Study.","Turner CD","2025","JMIR diabetes","nonrandomized_study","article","10.2196/75672","41397294","PMC12705128",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008509","GLP-1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching.","Choi J","2025","Liver international : official journal of the International Association for the Study of the Liver","nonrandomized_study","article","10.1111/liv.70447","41250965","PMC12625798",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0008510","The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review.","Biondi F","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14082705","40283534","PMC12027986",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008511","Making sense of newer treatment options for type 2 diabetes.","Lee PC","2018","Internal medicine journal","narrative_review","article","10.1111/imj.13947","29984503",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008512","Central nervous system pathways targeted by amylin in the regulation of food intake.","Hankir MK","2025","Biochimie","narrative_review","article","10.1016/j.biochi.2024.10.012","39426704",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008513","Benefits of intensified reductions in blood glucose and in blood pressure for patients with type 2 diabetes.","Wang N","2023","Presse medicale (Paris, France : 1983)","randomized_trial","article","10.1016/j.lpm.2022.104160","36565752",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Review; Journal Article"],["R0008514","The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review.","Chen C","2020","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","systematic_review","article","10.1080/09513590.2019.1703943","31858859",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0008515","Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.","Bea S","2023","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2023.49856","38153732","PMC10755620",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008516","A Glucagon-like Peptide 1 Analog Protects Mitochondria and Attenuates Hypoxia-Reoxygenation Injury in Cultured Cardiomyocytes.","Kobara M","2022","Journal of cardiovascular pharmacology","preclinical","article","10.1097/fjc.0000000000001218","34983916",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008517","Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes.","Wilkinson TJ","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","nonrandomized_study","article","10.1093/ndt/gfaf258","41344888","PMC13314376",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008518","Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor.","Medak KD","2026","JCI insight","preclinical","article","10.1172/jci.insight.201148","41774502","PMC13135390",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0008519","Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.","Cheng L","2019","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.3168","30974033",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0008520","Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis.","Liu Y","2019","Journal of diabetes research","systematic_review","article","10.1155/2019/1534365","31396537","PMC6664552",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0008521","Exendin-4 improves mitochondrial integrity against cisplatin-induced cardiac damage: Targeting p53 and NF-κB pathways.","Khine HEE","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.178233","41075914",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008522","GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives.","Fang Q","2026","Frontiers in medicine","narrative_review","article","10.3389/fmed.2026.1752341","42136855","PMC13167927",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008523","Do Fasting GLP-1 and GIP Levels Predict the Initial Pharmacological Response to Semaglutide and Tirzepatide?","La Vignera S","2026","Diagnostics (Basel, Switzerland)","randomized_trial","article","10.3390/diagnostics16131979","42449760","PMC13360020",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008524","Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.","Gullaksen S","2023","Diabetologia","randomized_trial","article","10.1007/s00125-023-05876-w","36746803",null,"EudraCT:2019-000781-38",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008525","Dangers of Injectable Peptides and Other Unregulated \"Biohacking\" Drugs.","Moiz A","2026","Missouri medicine","narrative_review","article",null,"42757290","PMC13585006",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0008526","GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes.","Karakasis P","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26073050","40243679","PMC11988964",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008527","The evolving landscape of obesity pharmacotherapy.","Petersen J","2026","Nature reviews. Drug discovery","narrative_review","article","10.1038/s41573-026-01427-1","42129460",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008528","Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).","Shin S","2023","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes23054","38049180","PMC10786205",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008529","Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.","Ramos Belinchón C","2024","Revista espanola de enfermedades digestivas","nonrandomized_study","article","10.17235/reed.2024.10305/2024","38767015",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008530","Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists.","Sciannameo V","2020","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13962","31943710",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008531","Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience.","Janić M","2023","The Journal of international medical research","nonrandomized_study","article","10.1177/03000605231211402","37987649","PMC10664446",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008532","Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes.","Akturk HK","2026","Diabetes technology & therapeutics","nonrandomized_study","article","10.1177/15209156261423903","41804758",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008533","Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study.","Aoki K","2020","Endocrine journal","other","article","10.1507/endocrj.ej19-0464","32554954",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008534","Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study.","Tsai WH","2022","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2022.765446","35281896","PMC8904427",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008535","Outcomes of Unicompartmental Knee Arthroplasty in Patients Receiving Glucagon-like Peptide 1 Agonist Therapy: A Matched Cohort Study.","Heo KY","2026","Arthroplasty today","nonrandomized_study","article","10.1016/j.artd.2026.101958","41704638","PMC12907661",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008536","Design and Biosynthesis of Ornithine 8-Containing Semaglutide Variants with a Click Chemistry-Modifiable Position 26.","Xu Y","2025","ACS synthetic biology","other","article","10.1021/acssynbio.5c00132","40305415","PMC12090216",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008537","MC4R-related monogenic obesity in children: insights from 2 cases.","Shanmugam D","2026","Annals of pediatric endocrinology & metabolism","case_report","article","10.6065/apem.2550160.080","42099117","PMC13153791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008538","Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan.","Kalafati IP","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.70220","42683734",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008539","Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.","Bzowyckyj A","2020","Journal of clinical pharmacy and therapeutics","narrative_review","article","10.1111/jcpt.13229","32910488","PMC7540468",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008540","Gastric point-of-care ultrasound in patients on GLP-1 receptor agonists: additional evidence for residual gastric content but not for pulmonary aspiration.","Vlaeminck N","2026","Regional anesthesia and pain medicine","commentary","article","10.1136/rapm-2026-108307","42665315",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008541","Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial.","Zobel EH","2021","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2021-002395","34518158","PMC8451300","ClinicalTrials.gov:NCT03449654","S001895","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0008542","Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.","Gough SC","2016","Expert review of endocrinology & metabolism","other_trial","article","10.1586/17446651.2016.1113129","27335581","PMC4894076",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0008543","GLP-1 Receptor Agonists for Clozapine-Induced Weight Gain: A Case Report With the Dual GLP-1/GIP Agonist Tirzepatide.","Lim C","2025","The primary care companion for CNS disorders","case_report","article","10.4088/pcc.25cr03952","40650875",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008544","Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study.","Siddeeque N","2024","International immunopharmacology","nonrandomized_study","article","10.1016/j.intimp.2024.113537","39486172",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0008545","Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.","Rubino D","2026","Postgraduate medicine","other_trial","article","10.1080/00325481.2026.2686467","42286992",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0008546","Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function.","Jensen SBK","2023","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23715","36942420",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008547","Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity.","Dai S","2021","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.1c00032","33825469",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008548","Considerations on the Weight Loss-Associated Glucagon-like Peptide-1 Receptor Agonists for Older People.","Watanabe JH","2023","The Senior care pharmacist","other","article","10.4140/tcp.n.2023.493","38041227",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008549","Glucagon Can Increase Force of Contraction via Glucagon Receptors in the Isolated Human Atrium.","Neumann J","2025","International journal of molecular sciences","other","article","10.3390/ijms26020698","39859412","PMC11765814",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008550","Interpreting reduced biologic initiation after GLP-1 receptor agonist exposure in hidradenitis suppurativa: Efficacy versus access bias.","Islam RK","2026","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2026.07.140","42731700",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0008551","Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.","Yan K","2025","Acta diabetologica","systematic_review","article","10.1007/s00592-025-02534-y","40471293","PMC12433336","PROSPERO:CRD42024532368",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review-article; review"],["R0008552","Use and Misuse of GLP-1 Receptor Agonists Among People With Eating Disorders.","Peiper NC","2026","JAMA psychiatry","other","article","10.1001/jamapsychiatry.2026.1716","42340738","PMC13294816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008553","Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review.","Malakar S","2026","World journal of gastrointestinal pharmacology and therapeutics","other_trial","article","10.4292/wjgpt.120122","42707862","PMC13548203",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; review"],["R0008554","GLP-1 receptor agonists after liver transplant: Early reassurance, unanswered questions.","Albhaisi S","2026","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","other","article","10.1097/lvt.0000000000000978","42560050",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008555","Soaring GLP-1 receptor agonist use.","The Lancet Diabetes Endocrinology","2026","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(26)00194-4","42526475",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0008556","GLP-1 receptor agonists and breast cancer: emerging evidence from prevention to treatment.","de Alencar EBA","2026","The American journal of medicine","commentary","article","10.1016/j.amjmed.2026.07.042","42551775",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0008557","GLP-1 Receptor Agonists in Hidradenitis Suppurativa-Emerging Opportunities for Comorbidity Management?","Naik HB","2026","JAMA dermatology","commentary","article","10.1001/jamadermatol.2026.1882","42384420",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0008558","Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression.","Ahmed A","2024","Advanced pharmaceutical bulletin","nonrandomized_study","article","10.34172/apb.2024.040","39206389","PMC11347740","ClinicalTrials.gov:NCT06057077","S001485","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; article"],["R0008559","Obesity in the GLP-1 Era: Clinical Characteristics and Prescribing Patterns in a Large Integrated Health System.","Wells BJ","2026","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.64898/2026.09.04.26361064","42818435","PMC13622720",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0008560","Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study.","Waki H","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-026-01916-x","42709397",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0008561","Myoprotective Fat-Loss Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study of Metformin-Based Treatment Regimens.","Bujdei-Tebeică I","2026","Clinics and practice","nonrandomized_study","article","10.3390/clinpract16080141","42645137","PMC13510956",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008562","GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.","Giugliano D","2019","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13847","31373167",null,null,"S000128","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0008563","A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease.","Koufakis T","2022","American journal of cardiovascular drugs : drugs, devices, and other interventions","other","article","10.1007/s40256-022-00527-8","35292920",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0008564","The Fatty Kidney and Beyond: A Silent Epidemic.","Hti Lar Seng NS","2023","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2023.06.025","37451390",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008565","Insulinoma diagnosis and characterization with intratumoral heterogeneity employing [18F]FB(ePEG12)12-exendin-4 PET/MRI.","Yoshida H","2026","European journal of nuclear medicine and molecular imaging","other","article","10.1007/s00259-025-07513-7","40839308","PMC13013310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0008566","GLP-1 Receptor Agonists for Stroke Prevention in Type 2 Diabetes or Obesity.","Keister D","2026","American family physician","other","article",null,"42789653",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008567","A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans.","Sargeant JA","2019","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2019.34.3.247","31565876","PMC6769337",null,"S001745; S002042; S002529; S002633","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0008568","The impact of the glucagon-like peptide 1 receptor agonist liraglutide on the streptozotocin-induced diabetic mouse kidney proteome.","Liljedahl L","2019","Physiological reports","preclinical","article","10.14814/phy2.13994","30806030","PMC6389751",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008569","Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.","Anderson SL","2025","Drugs in context","nonrandomized_study","article","10.7573/dic.2025-4-8","40734920","PMC12306892",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008570","A cardiovascular indication for oral semaglutide (Rybelsus).",null,"2025","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2025.1743b","41575833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008571","Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs.","Goodarzi G","2023","Metabolic brain disease","preclinical","article","10.1007/s11011-023-01225-3","37335453",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0008572","Obesity burden among heart failure patients in an urban safety net hospital: Implications for GLP-1 agonist therapy.","Yee T","2026","American heart journal plus : cardiology research and practice","nonrandomized_study","article","10.1016/j.ahjo.2025.100688","41439268","PMC12720304",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0008573","Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes.","Papazafiropoulou AK","2021","Current pharmaceutical design","randomized_trial","article","10.2174/1381612826666200909142126","32912116",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0008574","The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.","Chuang SM","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70915","42219271","PMC13341365",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Network Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0008575","Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients.","Vigara LA","2024","Nefrologia","nonrandomized_study","article","10.1016/j.nefroe.2024.11.007","39645509",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; article"],["R0008576","Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide.","MacIsaac RJ","2021","Future cardiology","other","article","10.2217/fca-2020-0210","33820430",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008577","The Impact and Safety of GLP-1 Agents and Breast Cancer.","Parsons K","2025","Cancer medicine","nonrandomized_study","article","10.1002/cam4.70932","40552446","PMC12186097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008578","Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.","Kalra S","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-019-0669-4","31359367","PMC6778554",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; other; article"],["R0008579","Weight loss differences seen between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for treatment of type 2 diabetes.","Frieling K","2021","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2021.06.015","34266747",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008580","GLP-1 Receptor Agonists in Aesthetic Surgery: An Expert Video Roundtable Discussion.","Austin RE","2026","Aesthetic surgery journal. Open forum","other","article","10.1093/asjof/ojag152","42774607","PMC13594978",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0008581","Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Simental-Mendía LE","2026","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","systematic_review","article","10.1007/s40292-026-00812-6","42371360",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008582","SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.","Singh AK","2019","Indian journal of endocrinology and metabolism","randomized_trial","article","10.4103/ijem.ijem_12_19","31161099","PMC6540886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0008583","Comment on: \"Impact of GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus on the Development and Progression of Age-Related Macular Degeneration\".","Hung CH","2026","Retina (Philadelphia, Pa.)","commentary","article","10.1097/iae.0000000000004994","42640665",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; letter"],["R0008584","Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population.","Basu A","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15878","39223846","PMC11479577",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008585","Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide.","Odigwe C","2025","American heart journal plus : cardiology research and practice","other_trial","article","10.1016/j.ahjo.2025.100518","40115122","PMC11923757",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0008586","Clarifying cohort design in a study of GLP-1 receptor agonist use and metabolic outcomes following radical cystectomy.","Yu CC","2026","Urologic oncology","nonrandomized_study","article","10.1016/j.urolonc.2026.05.008","42618167",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0008587","Medication-overuse headache in migraine: could GLP-1 receptor agonists treat the addiction-like phenotype?","Pellesi L","2026","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2026.2716375","42565625",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0008588","A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.","Aroda VR","2022","Reviews in endocrine & metabolic disorders","other_trial","article","10.1007/s11154-022-09735-8","35838946","PMC9515042",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0008589","Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research.","Yang X","2022","Frontiers in neurology","narrative_review","article","10.3389/fneur.2022.844697","35370875","PMC8964641",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008590","Erratum: GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.","Mao X","2026","Hepatology (Baltimore, Md.)","notice","article","10.1097/hep.0000000000001846","42782120",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; erratum"],["R0008591","GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.","Karagiannis T","2021","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2021.108737","33705820",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008592","Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.","Monami M","2012","Experimental diabetes research","systematic_review","article","10.1155/2012/672658","22675341","PMC3362858",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0008593","Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.","Liu L","2019","Endocrine connections","systematic_review","article","10.1530/ec-18-0546","30694794","PMC6410765",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0008594","Unaddressed Sources of Exposure and Detection Bias in the TriNetX Analysis of GLP-1 Receptor Agonists and Atrial Fibrillation in CKD.","Baloch MSA","2026","Cardiovascular drugs and therapy","commentary","article","10.1007/s10557-026-07935-x","42595939",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008595","Youth Perspectives on the Use of Medications for Weight Loss.","Peyyety V","2025","The Journal of adolescent health : official publication of the Society for Adolescent Medicine","nonrandomized_study","article","10.1016/j.jadohealth.2025.02.011","40266162",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0008596","The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes.","Yaribeygi H","2021","Journal of diabetes research","narrative_review","article","10.1155/2021/6518221","34258291","PMC8263148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008597","Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.","Nelson AJ","2021","Circulation","narrative_review","article","10.1161/circulationaha.121.053766","34228476",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; article"],["R0008598","Correction: Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review.","Barone M","2026","Aesthetic plastic surgery","notice","article","10.1007/s00266-026-05948-3","42474489",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0008599","GLP-1 Receptor Agonists.","Rosen CJ","2026","The New England journal of medicine","randomized_trial","article","10.1056/nejmra2500106","41931049",null,null,"S002095","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0008600","Incretin therapy in feline diabetes mellitus - A review of the current state of research.","Haller N","2024","Domestic animal endocrinology","preclinical","article","10.1016/j.domaniend.2024.106869","38870560",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008601","Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats.","Chang SE","2025","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2025.12.06.692775","41415399","PMC12710968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0008602","Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease.","Aldrich S","2019","The Nurse practitioner","other","article","10.1097/01.npr.0000553396.65976.bb","30695005",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008603","A Rare Case of Tirzepatide-Associated Immune Thrombocytopenia.","Rojas K","2026","Cureus","case_report","article","10.7759/cureus.104281","41909371","PMC13032196",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008604","Diagnostic and Management Pitfalls of SGLT2 Inhibitor-Associated Ketoacidosis in the ICU: Lessons Following Cardiac Surgery and GLP-1 Agonist Interaction.","Pérez APG","2026","Case reports in critical care","other","article","10.1155/crcc/4896065","42564745","PMC13444720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0008605","Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management.","Rinella ME","2026","Nature reviews. Gastroenterology & hepatology","narrative_review","article","10.1038/s41575-026-01187-8","41851447",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008606","Adjunct therapies in treatment of type 1 diabetes.","Goyal I","2020","Journal of diabetes","narrative_review","article","10.1111/1753-0407.13078","32567125",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008607","Clozapine and GLP-1 receptor agonists: an underrated gastrointestinal safety risk.","Cotrik E","2026","The lancet. Psychiatry","other","article","10.1016/s2215-0366(26)00223-3","42492564",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008608","A Review of Weight Loss With Glucagon-Like Peptide 1 Agonist Therapy: Is There a Role for Its Preoperative Use in Gynecology?","Sinha A","2025","Cureus","randomized_trial","article","10.7759/cureus.90764","40984942","PMC12450455",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0008609","MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","Nauck MA","2019","European journal of endocrinology","narrative_review","article","10.1530/eje-19-0566","31600725",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008610","Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US.","Kim M","2025","JAMA surgery","randomized_trial","article","10.1001/jamasurg.2025.3089","40864458","PMC12392147",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0008611","Fat Quality, Not Just Quantity: Incretin-Based Therapy and Fat Composition in Type 2 Diabetes.","Nakatani A","2025","Clinical diabetes : a publication of the American Diabetes Association","case_report","article","10.2337/cd25-0014","41140726","PMC12547040",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008612","Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.","Gerstein HC","2023","Diabetes care","randomized_trial","article","10.2337/dc22-2397","36897834",null,"ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","paywalled","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article; other"],["R0008613","Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients.","Lu Y","2023","Therapeutic advances in drug safety","systematic_review","article","10.1177/20420986231178126","37332886","PMC10272677",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0008614","Semaglutide Attenuates Inflammatory Macrophage Polarization and Promotes Changes Associated with Mitochondrial Biogenesis Through cAMP-Dependent Signaling.","Pavshintsev VV","2026","Biomedicines","preclinical","article","10.3390/biomedicines14091987","42792729","PMC13604756",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008615","Prediabetes: To Be Treated or Not?","Agrawal R","2025","The Journal of the Association of Physicians of India","narrative_review","article","10.59556/japi.73.1172","41100339",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008616","Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration.","Wilhite K","2024","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/10600280231205490","37881914",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0008617","Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.","Ruotolo G","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71200","42608321","PMC13646367","ClinicalTrials.gov:NCT04881760; ClinicalTrials.gov:NCT04867785","S000489; S001653","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0008618","Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.","Frias JP","2023","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(23)01163-7","37364590",null,"ClinicalTrials.gov:NCT04982575","S002064","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008619","Comparison of low-dose liraglutide use versus other GLP-1 receptor agonists in patients without type 2 diabetes.","Wittbrodt ET","2018","The American journal of managed care","nonrandomized_study","article",null,"29693362",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Comparative Study; Journal Article; article"],["R0008620","Findings Interpretation Concerns Regarding the Emulated Target Trial of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Psoriatic Arthritis [Letter].","Lymperopoulos A","2026","Drug design, development and therapy","other_trial","article","10.2147/dddt.s647018","42668988","PMC13525794",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0008621","RE: Comment on: \"Impact of GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus on the Development and Progression of Age-Related Macular Degeneration.","McLaughlin SA","2026","Retina (Philadelphia, Pa.)","commentary","article","10.1097/iae.0000000000004995","42640660",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; letter"],["R0008622","Recent advances in incretin biology and therapeutics: From glucose-dependent insulinotropic polypeptide reappraisal to next-generation agonists.","Kubota S","2026","Journal of diabetes investigation","narrative_review","article","10.1111/jdi.70299","41928613","PMC13238638",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; other; article"],["R0008623","Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.","Lyseng-Williamson KA","2020","Clinical drug investigation","notice","article","10.1007/s40261-020-00892-9","32040760","PMC7035237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0008624","Corrigendum to \"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study\" eClinicalMedicine 2024;73:102661.","Moll H","2026","EClinicalMedicine","notice","article","10.1016/j.eclinm.2026.104022","42389463","PMC13320438",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0008625","Reply: Metabolic Heterogeneity of Obesity and Outcome-Specific Effects of GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome.","Kumar S","2026","JACC. Advances","commentary","article","10.1016/j.jacadv.2026.102806","42134061","PMC13202266",null,null,"pubmed; europepmc","TRUE",null,null,null,"Letter"],["R0008626","Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond.","Kloecker DE","2021","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14384","33764645",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008627","Use of Glucose-Lowering Agents in Diabetes and CKD.","Alicic RZ","2022","Kidney international reports","narrative_review","article","10.1016/j.ekir.2022.09.018","36506243","PMC9727535",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008628","Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.","Veronese N","2025","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2025.103303","41151201",null,"PROSPERO:CRD42025649619",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0008629","New Drug: Tirzepatide (Mounjaro™).","Gettman L","2023","The Senior care pharmacist","other","article","10.4140/tcp.n.2023.50","36751934",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008630","Case study of semaglutide and cardiovascular outcomes: An application of the Causal Roadmap to a hybrid design for augmenting an RCT control arm with real-world data.","Dang LE","2023","Journal of clinical and translational science","randomized_trial","article","10.1017/cts.2023.656","38028337","PMC10643919",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008631","Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.","Jordy AB","2021","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-020-00976-x","33782832","PMC8416862","ClinicalTrials.gov:NCT02845219; ClinicalTrials.gov:NCT03010475","S000727; S001553","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008632","275 Patient perspectives on GLP-1 receptor agonists for weight loss: A mixed-methods study to inform translational obesity care","McElroy J",null,"Journal of clinical and translational science","other","article",null,null,"PMC13172905",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0008634","SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.","Zhuo M","2022","American journal of kidney diseases : the official journal of the National Kidney Foundation","nonrandomized_study","article","10.1053/j.ajkd.2021.09.015","34762974","PMC9079190",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0008635","The Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Perioperative Period: A Case Study.","Anderson TR","2025","Cureus","case_report","article","10.7759/cureus.77106","39917093","PMC11802257",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008636","Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.","Yaribeygi H","2019","Life sciences","narrative_review","article","10.1016/j.lfs.2019.116776","31425698",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008637","Comprehensive assessment of the causal effects and metabolite mediators of glucose-lowering drug targets on cardio-renal-liver-metabolic health.","Huang H","2025","Metabolism: clinical and experimental","other","article","10.1016/j.metabol.2025.156276","40320164",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0008638","Quantitative analysis of Tr1 lymphocytes in patients with type 2 diabetes mellitus.","Knott-Torcal C","2024","Journal of endocrinological investigation","other","article","10.1007/s40618-023-02250-w","38183564","PMC11142976",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008639","Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease.","Neuen BL","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfae258","39907542","PMC11795647",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0008640","Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice.","Tonin G","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1547920","40692597","PMC12277154","DRKS:DRKS00034478",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008641","Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.","Son JW","2024","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2024.1940","38626909","PMC11066441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0008642","Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients.","Mosenzon O","2020","Postgraduate medicine","other_trial","article","10.1080/00325481.2020.1800286","32815439",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; Video-Audio Media; article"],["R0008643","Attitudes Toward Injectable GLP-1 Drugs for Obesity Treatment: A Qualitative Interview Study With Healthcare Professionals.","Capaian RC","2026","Obesity science & practice","other","article","10.1002/osp4.70130","42630863","PMC13494737",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008644","Emerging trends in managed care pharmacy: A mixed-method study.","Mattingly TJ","2025","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2025.31.2-a.s2","39888855","PMC11785360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008645","Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.","Lajara R","2019","Postgraduate medicine","nonrandomized_study","article","10.1080/00325481.2019.1670017","31580737",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0008646","The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease.","Teil M","2026","Current opinion in neurobiology","narrative_review","article","10.1016/j.conb.2025.103164","41570740",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0008647","Cost-Consequence Analysis of Semaglutide vs. Liraglutide for Managing Obese Prediabetic and Diabetic Patients in Saudi Arabia: A Single-Center Study.","Bawazeer N","2025","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare13141755","40724780","PMC12294622",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008648","Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.","van Ruiten CC","2022","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-022-01492-x","35484607","PMC9052512","ClinicalTrials.gov:NCT03361098","S000930","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0008649","Acupuncture for patients with glucagon-like peptide-1 receptor agonists-induced nausea and vomiting: A systematic review protocol.","Ding N","2020","Medicine","systematic_review","article","10.1097/md.0000000000020343","32481324","PMC7249859","OSF:osf.io/3fgu8",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review-article; article"],["R0008650","Reply to Improda, N.; Ballarin, G. Body Composition in Paediatric GLP-1 Receptor Agonist Therapy. Comment on \"Zaitoon et al. Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children. Children 2025, 12, 1427\".","Zaitoon H","2026","Children (Basel, Switzerland)","commentary","article","10.3390/children13050608","42194134","PMC13205087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Journal Article; reply; letter"],["R0008651","Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription.","Sedensky A","2026","Public health reports (Washington, D.C. : 1974)","other","article","10.1177/00333549261464876","42541373","PMC13428802",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008652","GLP-1 Receptor Agonist Use and Risk of Suicide Death.","Ueda P","2024","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2024.4369","39226030","PMC11372654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008653","Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy.","Davis KN","2022","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd21-0090","35983418","PMC9331620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008654","Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus.","Kim CH","2022","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2022.06.027","35716949",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","4","FALSE","Journal Article; article"],["R0008655","Prevention of type 2 diabetes in India and China.","Unnikrishnan R","2026","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2026.156761","42705413",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008656","Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.","Hammad N","2026","Diabetes technology & therapeutics","systematic_review","article","10.1177/15209156261420404","41640110",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0008657","Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomes.","Gupta K","2026","Pituitary","randomized_trial","article","10.1007/s11102-026-01760-z","42801380","PMC13616847",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0008658","American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).","Cusi K","2022","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.1016/j.eprac.2022.03.010","35569886",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Practice Guideline; Review; Journal Article"],["R0008659","Sociodemographic disparities in the use of GLP-1 receptor agonists and SGLT-2 inhibitors among US adults with type 2 diabetes: NHANES 2005-March 2020","Mittman BG","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.03.30.23287965",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0008660","Small intestine-permeable cyclic peptide-mediated enhancement of Fc-fusion protein absorption in mice.","Chikamatsu S","2026","Journal of pharmaceutical sciences","preclinical","article","10.1016/j.xphs.2026.104335","42162694",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0008661","Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Response to Letter].","Huang SC","2026","Drug design, development and therapy","commentary","article","10.2147/dddt.s644716","42605364","PMC13477665",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Letter; reply; article"],["R0008662","Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.","Garvey WT","2023","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(23)01200-x","37385275",null,"ClinicalTrials.gov:NCT04657003","S000353; S001709; S001712; S002674","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008663","Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats.","Rossetti CL","2024","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2024.112374","39306226",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008664","Semaglutide treatment attenuates vessel remodelling in ApoE-/- mice following vascular injury and blood flow perturbation.","Jensen DM","2022","Atherosclerosis plus","randomized_trial","article","10.1016/j.athplu.2022.05.004","36644202","PMC9833261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; preprint; article"],["R0008665","Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide.","Azizi Z","2024","Circulation","narrative_review","article","10.1161/circulationaha.124.069680","39008562","PMC11254327",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; editorial"],["R0008666","Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index.","Shiomi M","2020","JGH open : an open access journal of gastroenterology and hepatology","nonrandomized_study","article","10.1002/jgh3.12384","33102775","PMC7578289",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008667","Cardiovascular Outcomes Trials of Incretin-Based Therapies.","Thethi TK","2021","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds20-0072","34511847","PMC8387616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0008668","GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.","Alonso SP","2025","Medicina clinica","narrative_review","article","10.1016/j.medcli.2025.107042","40513367",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0008669","Trends in GLP-1 Receptor Agonist Prescribing Without Documented Indications.","Kim C","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71153","42547885",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008670","SGLT2 Inhibitor and GLP-1 Receptor Agonist Co-Treatment: Liver Function Effects in Patients with Type 2 Diabetes Mellitus","Tsuriya D","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-4444467/v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0008671","Dumping Syndrome: Pragmatic Treatment Options and Experimental Approaches for Improving Clinical Outcomes.","Masclee GMC","2023","Clinical and experimental gastroenterology","narrative_review","article","10.2147/ceg.s392265","37954129","PMC10637186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008672","Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.","Zhao Z","2026","Biomedicines","other_trial","article","10.3390/biomedicines14091884","42792628","PMC13604765",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0008673","Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus.","Billings LK","2018","Journal of managed care & specialty pharmacy","narrative_review","article","10.18553/jmcp.2018.24.9-a.s30","30156447","PMC10408424",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0008674","Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes.","Seo YG","2021","Journal of obesity & metabolic syndrome","nonrandomized_study","article","10.7570/jomes20059","33071241","PMC8017323",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008675","Changes over time in the cardiovascular risk profile of type 2 diabetes from 2007 to 2020: A community-based study.","Williams BA","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14686","35257457",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008676","Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis.","Cui H","2022","Pharmacological research","systematic_review","article","10.1016/j.phrs.2022.106094","35074527",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review"],["R0008677","A potent novel small molecule GLP-1R agonist identified by rational design and CADD.","Chen J","2026","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2026.118578","41650553",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008678","Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease.","Alicic RZ","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm13010201","38202209","PMC10779638",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008679","Comment on 'Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data'.","Choudhry MA","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70882","42855911",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","4","FALSE","Letter; Preprint; preprint"],["R0008680","Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound Healing.","Liu X","2026","Investigative ophthalmology & visual science","preclinical","article","10.1167/iovs.67.11.52","42808829","PMC13641211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008681","Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.","Hsu AY","2025","JAMA ophthalmology","nonrandomized_study","article","10.1001/jamaophthalmol.2025.0349","40146102","PMC11950975",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008682","Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH).","Van Kleef LA","2026","Drug design, development and therapy","nonrandomized_study","article","10.2147/dddt.s559331","41868171","PMC13005583",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008683","Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.","Mahtta D","2022","Diabetes care","nonrandomized_study","article","10.2337/dc21-1815","35015080","PMC8914426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; other; article"],["R0008684","A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor.","Griffith DA","2022","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.1c01856","35647711","PMC9234956","ClinicalTrials.gov:NCT03309241","S002228","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008685","GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis.","Ghobar F","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1627909","41210503","PMC12588854","PROSPERO:CRD42024565439",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0008686","Prior GLP-1 agonist use is not associated with adverse inpatient critical care outcomes: A propensity-matched analysis.","Park AK","2026","Journal of hospital medicine","nonrandomized_study","article","10.1002/jhm.70228","41286572",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0008687","Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.","Packer M","2025","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2025.06.058","40903131",null,"ClinicalTrials.gov:NCT04847557","S000047; S001989","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0008688","The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study.","Kravetz L","2025","Eye (London, England)","nonrandomized_study","article","10.1038/s41433-025-03807-0","40301667","PMC12209418",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008689","The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysis.","Kellett J","2025","Obesity surgery","systematic_review","article","10.1007/s11695-025-07723-w","39910018",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0008690","Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan.","Tu ST","2026","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70333","42762462","PMC13589615","ClinicalTrials.gov:NCT06283641","S001445","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0008691","Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes.","Kis JT","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-021-01128-5","34357560","PMC8385086",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008692","GLP-1 receptor agonists and heart failure in diabetes.","Scheen AJ","2017","Diabetes & metabolism","other_trial","article","10.1016/s1262-3636(17)30068-x","28431666",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0008693","Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers.","Winzeler B","2020","Endocrine","randomized_trial","article","10.1007/s12020-020-02394-2","32623637",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0008694","Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.","Rossing P","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14558","34580995","PMC9293162","ClinicalTrials.gov:NCT02540993",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0008695","Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials.","Wang A","2022","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2021.109080","34626677",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis"],["R0008696","Preoperative GLP-1 Receptor Agonist Use and Weight Loss Outcomes After Bariatric Surgery.","Huynh RL","2026","JAMA surgery","nonrandomized_study","article","10.1001/jamasurg.2026.3327","42584884","PMC13470424",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0008697","Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.","Kojima M","2020","International journal of molecular sciences","preclinical","article","10.3390/ijms21165722","32785012","PMC7460814",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008698","Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis.","Squire P","2025","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2024-089477","39819958","PMC11751938",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008699","Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.","Kim DL","2023","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2022.1629","36891650","PMC10008664",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; review-article; article"],["R0008700","Beta-cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?","Sayyed Kassem L","2023","Journal of diabetes","narrative_review","article","10.1111/1753-0407.13446","37522521","PMC10590683",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008701","HbA1c and beyond.","Rossing P","2023","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other","article","10.1093/ndt/gfab243","34383945",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008702","Regulatory cycles of orexin and glucagon-Like peptide-1 in postviral syndromes.","Ruhrländer J","2026","Endocrine reviews","narrative_review","article","10.1210/endrev/bnag009","42037238",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008703","Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study.","Bellido V","2022","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm11174938","36078869","PMC9456474",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008704","Effect of glucagon-like peptide-1 receptor agonists on renal function: A meta-analysis of randomized controlled trials.","Simental-Mendía M","2022","British journal of clinical pharmacology","systematic_review","article","10.1111/bcp.15304","35277985",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0008705","GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine.","Merhi Z","2025","PloS one","narrative_review","article","10.1371/journal.pone.0326210","40601607","PMC12221084",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0008706","Diabetes mellitus and presentation, care and outcomes of patients with NSTEMI: the Association for Acute Cardiovascular Care-European Association of Percutaneous Cardiovascular Interventions EURObservational Research Programme NSTEMI Registry of the European Society of Cardiology.","Nadarajah R","2024","European heart journal. Quality of care & clinical outcomes","nonrandomized_study","article","10.1093/ehjqcco/qcae002","38192034",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0008707","Should we enlarge the indication for kidney biopsy in diabetics? The con part.","Ortiz A","2024","Clinical kidney journal","narrative_review","article","10.1093/ckj/sfad267","38186897","PMC10768755",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008708","Association between Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Exposure and Intraocular Pressure Change.","Hallaj S","2024","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2024.05.06.24306943","38765972","PMC11100841",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Preprint; Journal Article; preprint"],["R0008709","Efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise for moderate-to-severe obstructive sleep apnea in overweight or obese patients: a network meta-analysis.","Zheng J","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1869479","42676363","PMC13526671",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; systematic-review; article"],["R0008710","iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study.","Morea N","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14077","32363634","PMC7497103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0008711","Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist.","Shoemaker AH","2022","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-021-01043-6","34975146","PMC8881399",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0008712","Disruptions in Aesthetic Medicine: A Global Analysis of GLP-1 Agonists Using Punctuated Equilibrium Framework.","Rahman E","2026","Plastic and reconstructive surgery","other","article","10.1097/prs.0000000000012307","40690352",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0008713","Biopharma Evaluation of Anti-Obesity Vaccines in Global Trials by Dr. Slim™","Ghalamghash R","2025","Preprints.org","other_trial","preprint","10.20944/preprints202506.0907.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0008714","Ultrasound assessment of preoperative gastric volume in fasted diabetic surgical patients: A prospective observational cohort study on the effects of glucagon-like peptide-1 agonists on gastric emptying.","Wolla CD","2025","Journal of clinical anesthesia","nonrandomized_study","article","10.1016/j.jclinane.2025.111853","40324318","PMC12797078",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0008715","Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).","Sass MR","2023","BMJ open","protocol","article","10.1136/bmjopen-2022-068652","36720576","PMC9890830","ClinicalTrials.gov:NCT04892199","S001916","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008716","Novel insights into the augmented effect of curcumin and liraglutide in ameliorating cisplatin-induced nephrotoxicity in rats: Effects on oxidative stress, inflammation, apoptosis and pyroptosis via GSK-3β.","El-Gohary RM","2023","Archives of biochemistry and biophysics","preclinical","article","10.1016/j.abb.2023.109801","37884117",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008717","[The weight-loss injection : An orthopaedic overview].","Al Basri S","2025","Orthopadie (Heidelberg, Germany)","nonrandomized_study","article","10.1007/s00132-025-04609-8","39900779",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"English Abstract; Journal Article; Review"],["R0008718","Letter to the editor: GLP‑1RAs for pouchitis in obesity: what the current study does not tell us.","Zhu Z","2026","Inflammatory bowel diseases","commentary","article","10.1093/ibd/izag133","42424362",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; letter"],["R0008719","Regulation of feeding and therapeutic application of bioactive peptides.","Ueno H","2022","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2022.108187","35430293",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0008720","Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?","Salman L","2023","Kidney360","narrative_review","article","10.34067/kid.0000000000000126","37055910","PMC10371374","ClinicalTrials.gov:NCT00225537; ClinicalTrials.gov:NCT05386420; ClinicalTrials.gov:NCT05295680; ClinicalTrials.gov:NCT05128929; ClinicalTrials.gov:NCT02780752",null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; review-article; article"],["R0008721","Impact of GLP-1 Receptor Agonists on Hidradenitis Suppurativa: A Cross-Sectional Survey.","Javaheri ED","2026","International journal of dermatology","commentary","article","10.1111/ijd.70586","42461155",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008722","Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes.","Hirsch IB","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.39278","41171276","PMC12579344",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008723","GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa.","Jastrzab-Miskiewicz B","2026","JAMA dermatology","nonrandomized_study","article","10.1001/jamadermatol.2026.1907","42384412","PMC13324938",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0008724","Aortic Risk Stratification in the GLP-1 Receptor Agonist Era: It's Time to Retire BSA Indexing for Good.","Ma J","2026","Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography","commentary","article","10.1016/j.echo.2026.08.010","42617822",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008725","Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.","le Roux CW","2026","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-025-02792-1","41661445","PMC12924827",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0008726","GLP-1 receptor agonists in type 1 diabetes: expanding the therapeutic landscape beyond insulin.","Dimitriadis GD","2026","The Lancet regional health. Europe","other","article","10.1016/j.lanepe.2026.101782","42529222","PMC13416622",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0008727","Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway.","Lee J","2022","Endocrinology and metabolism (Seoul, Korea)","other","article","10.3803/enm.2021.1293","35144334","PMC8901965",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008728","Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.","Nauck M","2016","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12591","26489970","PMC4785614",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0008729","Real-World Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes and Cardiometabolic Disease.","Alhomoud IS","2025","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph19010009","41599611","PMC12845426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008730","Engineering single-dose plasmid DNA for sustained in vivo delivery of designer incretins.","Gary EN","2026","Trends in biotechnology","preclinical","article","10.1016/j.tibtech.2026.05.023","42321077","PMC13380232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; review"],["R0008731","Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.","Sun XY","2026","Journal of translational medicine","systematic_review","article","10.1186/s12967-026-08219-6","42192439","PMC13386775","OSF:osf.io/dm2nc",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Network Meta-Analysis; Journal Article; Systematic Review; research-article; review"],["R0008732","Semaglutide and tirzepatide for obesity: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.","Agboola F","2026","Journal of managed care & specialty pharmacy","narrative_review","article","10.18553/jmcp.2026.32.5.631","42043926","PMC13119487",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008733","Comparing Machine Learning and Advanced Methods with Traditional Methods to Generate Weights in Inverse Probability of Treatment Weighting: The INFORM Study.","Kwak D","2024","Pragmatic and observational research","nonrandomized_study","article","10.2147/por.s466505","39386162","PMC11462432",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; methods-article; article"],["R0008734","Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.","Gill H","2026","JAMA psychiatry","randomized_trial","article","10.1001/jamapsychiatry.2026.0594","42054055","PMC13130066","ClinicalTrials.gov:NCT04466345","S001015","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0008735","[Severe gastroparesia associated with the use of GLP-1 receptor agonists for weight loss].","Chávez-Sánchez SA","2024","Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","case_report","article",null,"38734915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; English Abstract; article"],["R0008736","Liraglutide ameliorates diabetic cardiomyopathy via activating Cav3/eNOS/NO signaling and enhancing interaction of Cav3 with RyR2","Li X","2022","Research Square","preclinical","preprint","10.21203/rs.3.rs-1647971/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008737","The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.","Arnott C","2020","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2020.06.011","32569700",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0008738","Clinical review of subcutaneous semaglutide for obesity.","Phillips A","2022","Journal of clinical pharmacy and therapeutics","randomized_trial","article","10.1111/jcpt.13574","34964141",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0008739","Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.","Chun JH","2020","JAAPA : official journal of the American Academy of Physician Assistants","other_trial","article","10.1097/01.jaa.0000669456.13763.bd","32740121",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0008740","Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population-Based Study.","Hamblin PS","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71047","42373540","PMC13449010",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008741","American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery.","Vosburg RW","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2026.04.002","42150970",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review; Practice Guideline"],["R0008742","Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?","Borner T","2022","British journal of pharmacology","narrative_review","article","10.1111/bph.15647","34363224","PMC8810668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0008743","Levodopa Efficacy and GLP-1 Receptor Agonists.","Martinez C","2026","Movement disorders clinical practice","other_trial","article","10.1002/mdc3.70591","41821320","PMC13339658",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0008744","Effects of Treatment with Liraglutide on Health-Related Quality of Life and Obstructive Sleep Apnea in People with Obesity and Chronic Obstructive Pulmonary Disease","Dogan ADA","2022","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-1665063/v1",null,null,"ClinicalTrials.gov:NCT03466021; EudraCT:2017-003551-32","S002322","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0008745","GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice.","Furber EC","2024","Diabetes","preclinical","article","10.2337/db23-0172","37934926","PMC10796301",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article; other"],["R0008746","Authors' Reply: SGLT2 Inhibitors vs GLP-1 Receptor Agonists Type 2 Diabetes, the Kidney Conundrum.","Blum MF","2026","Clinical journal of the American Society of Nephrology : CJASN","commentary","article","10.2215/cjn.0000001074","42030092","PMC13493025",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0008747","7765 Exploring the Synergistic Effect of GHRH Receptor Agonist MR-409 and Incretin-based Therapies in Type 1 Diabetes Using a Low-dose Streptozotocin Model",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455139",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0008748","Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study.","Sawamura T","2024","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-024-01472-w","39610482","PMC11599550",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008749","Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.","Monami M","2017","International journal of cardiology","systematic_review","article","10.1016/j.ijcard.2017.03.163","28501352",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0008750","Comment on \"Reduced Complications and Improved Survival With Postoperative GLP-1 Receptor Agonist Use Following Lumbar Arthrodesis\".","Wang J","2026","Global spine journal","commentary","article","10.1177/21925682261452221","42130291","PMC13176118",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0008751","A Point-of-Care Interactive Decision Tool Reveals Variance Between Clinicians and Experts in Selecting Among GLP-1 RAs in T2D","Schwartz Z","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.949",null,"PMC8089797",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0008752","Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: A population-based cohort study.","Chou OHI","2025","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2024.101571","39182669",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Comparative Study"],["R0008753","Response to letter to the editor: \"GLP-1RAs for pouchitis in obesity: what the current study does not tell us\".","Habib H","2026","Inflammatory bowel diseases","nonrandomized_study","article","10.1093/ibd/izag128","42424310",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; Comment; letter"],["R0008754","Cardiovascular Prevention and the Implementation Gap in GLP-1 Receptor Agonist Therapies: After the Trials.","Erhabor J","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.06.024","42583991",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008755","Efficacy and tolerance of GLP-1 analogues in the treatment of adolescent obesity: analysis of a French population.","Bouhmouch S","2026","Archives de pediatrie : organe officiel de la Societe francaise de pediatrie","other","article","10.1016/j.arcped.2026.105545","42348955",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008756","SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence.","D'Marco L","2021","Journal of diabetes research","narrative_review","article","10.1155/2021/9032378","34790827","PMC8592766",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008757","GLP-1 receptor agonists in type 1 diabetes: a new frontier for cardiovascular prevention?","Chen Q","2026","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwag371","42460801",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008758","An Orthogonal Framework for Higher-Order Structural and In Vitro Functional Comparability of Chemically Synthesized Liraglutide Relative to an rDNA-Origin Reference Product.","Tang Y","2026","Pharmaceutical research","nonrandomized_study","article","10.1007/s11095-026-04178-1","42687068",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008759","Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis.","Ahmed F","2026","Biomedicines","nonrandomized_study","article","10.3390/biomedicines14061368","42351796","PMC13296858",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008760","Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.","Gæde P","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-019-0630-6","31098942","PMC6612343",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0008761","Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.","Altés A","2026","Advances in therapy","nonrandomized_study","article","10.1007/s12325-026-03644-x","42250076","PMC13499823",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008762","Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease.","Neumiller JJ","2023","Seminars in nephrology","narrative_review","article","10.1016/j.semnephrol.2023.151427","37857231",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008763","Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.","Murugadoss K","2026","npj metabolic health and disease","nonrandomized_study","article","10.1038/s44324-026-00131-3","42680805","PMC13534496",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008764","Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.","Vaduganathan M","2019","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2019.01.029","30922481","PMC6764415",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0008765","Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management.","d'Aquino AI","2023","Cell reports. Medicine","preclinical","article","10.1016/j.xcrm.2023.101292","37992687","PMC10694761",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0008766","Mechanistic Links between Central Obesity and Cardiorenal Metabolic Diseases.","Al-Chalabi S","2024","Cardiorenal medicine","nonrandomized_study","article","10.1159/000535772","38171343",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0008767","Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.","Al-Harbi FA","2025","Metabolism open","randomized_trial","article","10.1016/j.metop.2025.100414","41255585","PMC12621565",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008768","GLP-1 Receptor Agonists and Colorectal Cancer Outcomes: Hype, Hope, or Hidden Confounding?","Murthy SS","2026","Annals of surgical oncology","commentary","article","10.1245/s10434-026-20206-1","42455483",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0008769","The importance of patient-reported outcomes in type 2 diabetes: insight from the PIONEER program with oral semaglutide.","Schneider D","2020","The American journal of managed care","other","article","10.37765/ajmc.2020.88556","33439584",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008770","[New guideline on diabetes management in chronic kidney disease].","Wanner C","2023","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-023-01485-2","36745249","PMC9941257",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Review; Practice Guideline; review-article; article"],["R0008771","Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.","Xu B","2023","Molecular biology reports","narrative_review","article","10.1007/s11033-023-08836-0","37819499",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008772","Are GLP-1 receptor agonists gerotherapeutics or just treatments for obesity?","Peyer JG","2026","Nature aging","commentary","article","10.1038/s43587-026-01165-4","42332275",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008773","Metabolic Syndrome: An Updated Review on Diagnosis and Treatment for Primary Care Clinicians.","Peterseim CM","2024","Journal of primary care & community health","nonrandomized_study","article","10.1177/21501319241309168","39714021","PMC11672556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008774","O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE, NON-DIABETIC, ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS","Eriksson R","2019","Schizophrenia bulletin","randomized_trial","article","10.1093/schbul/sbz021.268",null,"PMC6455238",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0008775","Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review.","Koceva A","2024","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2024.1528457","39906041","PMC11790462",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Case Reports; Review; case-report; article"],["R0008776","Subjective Olfactory Impairment in a Patient Undergoing Anti-Obesity Pharmacotherapy: A Case of Symptom-Test Discrepancy.","Lee HJ","2025","Life (Basel, Switzerland)","case_report","article","10.3390/life15091349","41010291","PMC12471383",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008777","State-Level Variation in GLP-1 Receptor Agonist Use Among Medicaid Beneficiaries Without Diabetes by State Obesity Coverage Policy.","Dun C","2026","Diabetes care","commentary","article","10.2337/dc26-1511","42635563",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; other; article"],["R0008778","Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.","Sridhar VS","2024","Diabetologia","narrative_review","article","10.1007/s00125-023-06015-1","37801140",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0008779","Glucagon-like peptide-1 receptor agonists and fracture risk-limitations to current knowledge.","Hygum K","2019","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","commentary","article","10.1007/s00198-019-05013-7","31119314",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0008780","Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence.","Li C","2026","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2026.1859388","42453588","PMC13365254",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0008781","A comparison of virtual and in person delivery of a full meal replacement program for obesity.","Skeldon M","2024","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.718","38259352","PMC10801667",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008782","Hypersensitivity Reactions to the GLP-1 Receptor Agonists Liraglutide and Semaglutide: A Case Series.","Barroso B","2024","Journal of investigational allergology & clinical immunology","case_report","article","10.18176/jiaci.0932","38639450",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0008783","The effect of metformin combined with liraglutide on gut microbiota of Chinese patients with type 2 diabetes.","Niu X","2024","International microbiology : the official journal of the Spanish Society for Microbiology","other","article","10.1007/s10123-023-00380-y","37316616",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008784","Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.","García de Lucas MD","2023","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2023.1240279","37955013","PMC10634592",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008785","The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.","Urva S","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14110","32519795","PMC7539915",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0008786","Severe Perioperative Lactic Acidosis and Hyperglycemia Responsive to Thiamine in a Patient With Prior Semaglutide Use and Restrictive Dieting: A Case Report.","Kataria S","2026","A&A practice","case_report","article","10.1213/xaa.0000000000002253","42439433",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0008787","GLP-1 Receptor Agonist Use for Diabetes Mellitus is Associated With Reduced Psoriasis Disease Severity.","Vu TN","2026","Journal of drugs in dermatology : JDD","other","article","10.36849/jdd.10057","42555070",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008788","Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points.","Yabe D","2015","Current medical research and opinion","other","article","10.1185/03007995.2015.1045471","25916903",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008789","[Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines].","Kobalava ZD","2020","Kardiologiia","narrative_review","article","10.18087/cardio.2020.9.n1274","33131483",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0008790","'For me, it didn't seem as drastic a step as being controlled by insulin': A qualitative investigation of expectations and experiences of non-insulin injectable therapy among adults with type 2 diabetes.","Holmes-Truscott E","2022","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.14681","34465005",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008791","An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.","Pratley RE","2021","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14497","34286894","PMC9291551",null,"S002311","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008792","Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards: Systematic review and meta-analysis.","Soto-Chávez MJ","2022","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2022.110019","35931222",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008793","Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.","Zhou XY","2026","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-026-02163-7","42316327","PMC13523518","PROSPERO:CRD420251008819",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0008794","New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs.","Katsenos AP","2022","Expert opinion on investigational drugs","narrative_review","article","10.1080/13543784.2022.2022122","34941464",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008795","Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.","Mashayekhi M","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14903","36306151","PMC10306232",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0008796","Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial.","Romero-Gómez M","2023","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/apt.17598","37328931",null,"ClinicalTrials.gov:NCT02970942","S000922","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008797","Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.","Tuchscherer RM","2018","The Annals of pharmacotherapy","narrative_review","article","10.1177/1060028018784583","29932006",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008798","In T2D inadequately controlled with metformin, orforglipron reduced HbA1c more than oral semaglutide at 52 wk.","Lau D","2026","Annals of internal medicine","other","article","10.7326/annals-26-01781-jc","42224699",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008799","Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center.","Hamid A","2020","Journal of cardiovascular pharmacology","nonrandomized_study","article","10.1097/fjc.0000000000000864","32569016",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0008800","Cardiorenal Protection in Diabetic Kidney Disease.","Lee JF","2021","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2021.987","33873265","PMC8090466",null,"S002662","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0008801","Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.","Belcourt J","2026","The Annals of pharmacotherapy","commentary","article","10.1177/10600280261421979","41689811",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0008802","Assessing the impact of the Inflation Reduction Act on Medicare prescription drug coverage.","Zhang YW","2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxag083","41805901",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","4","FALSE","Journal Article; article"],["R0008803","Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.","Li J","2020","Clinical journal of the American Society of Nephrology : CJASN","narrative_review","article","10.2215/cjn.02690320","32518100","PMC7646234",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0008804","Diagnostic Performance of Exendin-4 PET/CT in Localizing Insulinomas: A Systematic Review and Meta-analysis.","Qi-Chang W","2025","Academic radiology","systematic_review","article","10.1016/j.acra.2025.09.020","41033966",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0008805","Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.","Johansen P","2020","Advances in therapy","other_trial","article","10.1007/s12325-020-01337-7","32306244","PMC7467468",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0008806","iGlarlixi for the simplification of more complex insulin regimens in type 2 diabetes patients with good glycaemic control.","Taybani ZJ","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1906632","42698423","PMC13541476",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0008807","GLP-1 receptor agonists and atherosclerosis: a metabolic treatment for a cardiometabolic disease.","Georgiopoulos G","2026","European heart journal","commentary","article","10.1093/eurheartj/ehag075","41955046",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0008808","FGF21 analogue PF-05231023 on alcohol consumption and neuronal activity in the nucleus accumbens.","Cooley BJ","2026","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/s41386-025-02133-z","40419727","PMC12708781",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008809","Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update.","Scheen AJ","2023","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1080/17425255.2023.2252333","37620287",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008810","Effect of Glucagon-like peptide-1 agonist (liriglutide) on weight and glycemic control among adults with type 2 diabetes mellitus attending primary care center at security forces hospital in Riyadh, Saudi Arabia.","Alanazi NK","2020","Journal of family medicine and primary care","randomized_trial","article","10.4103/jfmpc.jfmpc_361_20","33110789","PMC7586614",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008811","Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?","Holst JJ","2019","Lancet (London, England)","commentary","article","10.1016/s0140-6736(19)31350-9","31186119",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0008812","Effect of Different Types of Hypoglycemic Medications on Psoriasis: An Analysis of Current Evidence.","Sun X","2023","Dermatology (Basel, Switzerland)","systematic_review","article","10.1159/000528026","36623489",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Meta-Analysis; Journal Article; article"],["R0008813","Semaglutide - properties, action and chromatographic analysis.","Wasilewska B","2025","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-025-01711-8","40937273","PMC12420565",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008814","Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.","Rajani A","2020","Diabetic medicine : a journal of the British Diabetic Association","other_trial","article","10.1111/dme.14262","32012347",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0008815","BDNF dynamics and NETosis risk during GLP-1 receptor agonist therapy in schizophrenia: A gut microbiota-based hypothesis.","Nagamine T","2026","Asian journal of psychiatry","commentary","article","10.1016/j.ajp.2026.105121","42617333",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008816","Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment.","Milani I","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1819337","42582375","PMC13457613",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008817","The Common Single Cause of Chronic Multi-Hormonal Resistance in Oxidative Stress.","Wittmann I","2022","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox12010075","36670938","PMC9854708",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008818","Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Letter].","Hong Y","2026","Drug design, development and therapy","commentary","article","10.2147/dddt.s640490","42504204","PMC13401917",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0008819","Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems.","Alhomoud IS","2025","Canadian journal of physiology and pharmacology","other_trial","article","10.1139/cjpp-2025-0038","40367521",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; review"],["R0008820","Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists.","Patoulias D","2019","Polish archives of internal medicine","commentary","article","10.20452/pamw.14998","31566590",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0008821","A GLP-1 receptor agonist semaglutide attenuates cardiac microvascular injury in HFD/STZ-induced diabetic mice.","Wang X","2026","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.178429","41344533",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008822","Negative Consequences of Removing GLP-1 RA Obesity Coverage: A Cross-Sectional Cohort Comparison Study.","Francis JM","2026","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.70123","41783650","PMC12955695",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0008823","Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.","Ma J","2025","Endocrine","preclinical","article","10.1007/s12020-024-03998-8","39212900",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0008824","Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model.","Goodman AZ","2026","PloS one","preclinical","article","10.1371/journal.pone.0358225","42758714","PMC13588371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008825","Pharmacogenetics of new classes of antidiabetic drugs.","Imamovic Kadric S","2021","Bosnian journal of basic medical sciences","narrative_review","article","10.17305/bjbms.2021.5646","33974529","PMC8554705",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008826","Measuring Cardiac Autonomic Function Directly in GLP-1 Receptor Agonist Users: Heart Rate Variability Beyond Composite Allostatic Load.","Ozdemir O","2026","Metabolic syndrome and related disorders","commentary","article","10.1177/15578518261481089","42615129",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0008827","Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.","Tang H","2023","Journal of the American Geriatrics Society","systematic_review","article","10.1111/jgs.18306","36821780","PMC10363181",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, N.I.H., Extramural; research-article; review"],["R0008828","Disrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease.","Corrao S","2026","Journal of translational medicine","other_trial","article","10.1186/s12967-026-08564-6","42421032","PMC13632275",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; editorial; article"],["R0008829","Response to the Letter Regarding \"Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study\".","Bruno A","2026","Aesthetic plastic surgery","commentary","article","10.1007/s00266-026-06176-5","42525274",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008830","Heart failure evidence update 2026.","Liori S","2026","Heart failure reviews","narrative_review","article","10.1007/s10741-026-10609-3","41811612","PMC12979370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0008831","Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studies.","Yang CY","2022","Scientific reports","nonrandomized_study","article","10.1038/s41598-021-04014-z","34997053","PMC8741962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008832","Post-transplant diabetes mellitus following heart transplantation.","Newman JD","2022","The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","narrative_review","article","10.1016/j.healun.2022.07.011","35970647",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Review; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural"],["R0008833","GLP-1 Receptor Agonists to Reduce Mortality in Patients with Diabetic Foot Ulcers: Insights from a Recent Nationwide Observational Study.","Pantazopoulos D","2026","The international journal of lower extremity wounds","nonrandomized_study","article","10.1177/15347346261474199","42523126",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; editorial"],["R0008834","Cardiovascular autonomic neuropathy and the risk of diabetic kidney disease.","Cho I","2024","Frontiers in endocrinology","other","article","10.3389/fendo.2024.1462610","39329106","PMC11424464",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008835","Beyond drug discontinuation and prolonged fasting: gastric ultrasound as a third option for patients taking GLP-1 receptor agonists.","Vetrugno L","2026","Journal of ultrasound","commentary","article","10.1007/s40477-026-01198-w","42502140",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008836","Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?","Brunton SA","2020","Postgraduate medicine","other_trial","article","10.1080/00325481.2020.1798162","32815453",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; Video-Audio Media; article"],["R0008837","Improved leptin sensitivity and increased soluble leptin receptor concentrations may underlie the additive effects of combining PYY [, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ] and exendin-4 on body weight lowering in diet-induced obese mice.","Wulff BS","2024","Heliyon","preclinical","article","10.1016/j.heliyon.2024.e32009","39183855","PMC11341243",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008838","Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta-regression analysis of 120 randomized controlled trials.","Vargas KG","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15519","38425176",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; article"],["R0008839","Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.","Kitamoto T","2026","Current medical research and opinion","other_trial","article","10.1080/03007995.2026.2695047","42434924",null,"ClinicalTrials.gov:NCT05822830","S000093","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0008840","Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.","Johansson E","2026","Journal of medical economics","other_trial","article","10.1080/13696998.2026.2646078","42012820",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Clinical Trial, Phase III; Comparative Study; article"],["R0008841","Future Directions in the Medical Treatment of Obesity: A Narrative Review.","Bassatne A","2026","Advances in therapy","narrative_review","article","10.1007/s12325-026-03576-6","41954863","PMC13222310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0008842","Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys.","Martin JA","2024","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","other_trial","article","10.1016/j.ejps.2024.106895","39243911",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial, Phase I; Journal Article; article"],["R0008843","Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes.","Ko HY","2023","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2023.35797","37751205","PMC10523172",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008844","Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis.","Oh S","2022","Diabetes & vascular disease research","systematic_review","article","10.1177/14791641221106866","35686694","PMC9189550","PROSPERO:CRD42021256363",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; other; review"],["R0008845","Genetically Simulated GLP-1 Receptor Agonism and Cerebral Small Vessel Disease.","Zangas P","2026","Neurology. Genetics","other","article","10.1212/nxg.0000000000200359","41773243","PMC12947837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008846","Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes.","Berg DD","2021","Current diabetes reports","other_trial","article","10.1007/s11892-021-01417-0","34741199",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0008847","Semaglutide-Induced Silent Aspiration: An Unrecognised Cause of Organising Pneumonia.","Essilfie-Quaye K","2025","Respirology case reports","other","article","10.1002/rcr2.70249","40625884","PMC12231217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0008848","GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.","Triplitt C","2015","The Diabetes educator","narrative_review","article","10.1177/0145721715607981","26450217",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0008849","Variation in peri-operative management of GLP-1 receptor agonists among UK anaesthetists.","Burton ZA","2026","Anaesthesia","commentary","article","10.1111/anae.70289","42410300",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008850","Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.","Faillie JL","2022","Clinical pharmacology and therapeutics","nonrandomized_study","article","10.1002/cpt.2430","34587280",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008851","Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.","Alper A","2026","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","systematic_review","article","10.1007/s40292-026-00814-4","42458197",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008852","The mechanism and related research progress of GLP-1 receptor agonists in treating Alzheimer's disease.","Zhu XC","2024","Yi chuan = Hereditas","narrative_review","article","10.16288/j.yczz.24-178","39658957",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008853","Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.","Singh S","2017","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12805","27717130","PMC5299485",null,"S000691","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0008854","Current and future pharmacotherapies for obesity in children and adolescents.","Kelly AS","2023","Nature reviews. Endocrinology","narrative_review","article","10.1038/s41574-023-00858-9","37337008",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008855","Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.","Vernstrøm L","2024","Diabetologia","randomized_trial","article","10.1007/s00125-024-06228-y","39078489","PMC11447057","EudraCT:2019-000781-38",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0008856","Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.","Volpe S","2022","Nutrients","other","article","10.3390/nu14214673","36364937","PMC9657108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008857","Efficacy and Safety of Basal Insulin/GLP-1 Receptor Agonist Used in Combination for Type 2 Diabetes Management.","McCarty D","2019","Journal of pharmacy practice","other","article","10.1177/0897190018764984","29566586",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008858","The oral-systemic frontier: navigating the dental implications of GLP-1 receptor agonists.","Donaldson M","2026","General dentistry","other","article",null,"42329607",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008859","Early Promise, Persistent Gaps: Do GLP-1 Receptor Agonists Have a Role in Substance Use Disorder Treatment?","Abram MD","2026","International journal of addiction nursing","other","article","10.1097/jan.0000000000000713","42734570",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008860","Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double‑blind, randomized controlled clinical trial.","Sun L","2023","Experimental and therapeutic medicine","randomized_trial","article","10.3892/etm.2023.11948","37153886","PMC10160922","ChiCTR:ChiCTR2200063693",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008861","Euglycemic Ketoacidosis Following the Use of Counterfeit Semaglutide for Weight Loss.","Sterckx M","2026","Cureus","case_report","article","10.7759/cureus.102627","41773123","PMC12950111",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0008862","Two Doses to ICU or When Lactate Equals Glucose: Life-Threatening Lactic Acidosis due to Metformin After Initiation of Semaglutide.","Albany Z","2026","Case reports in critical care","other","article","10.1155/crcc/3478800","42147805","PMC13179746",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0008863","Effects of GLP-1RA Treatment on Long-Term Post-PCI Prognosis in T2DM Patients: A Propensity Score Matching Study.","Fang B","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s535325","40894807","PMC12396521",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008864","Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program",null,"2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article",null,null,"PMC9067771",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0008865","Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.","Yang X","2022","Expert opinion on therapeutic targets","other","article","10.1080/14728222.2022.2079492","35584372",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008866","[Obesity : what's new in 2025].","Boudjaoui FN","2026","Revue medicale suisse","other","article","10.53738/revmed.2026.22.945.48035","41540867",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0008867","[Analysis of cardiovascular safety of novel glucose-lowering medications].","Mkrtumyan AM","2019","Kardiologiia","other_trial","article","10.18087/cardio.2019.7.10267","31322093",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0008868","Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.","Caparrotta TM","2020","Diabetes care","nonrandomized_study","article","10.2337/dc20-0120","32581068",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Historical Article; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008869","D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice.","Rakhat Y","2026","Nutrients","preclinical","article","10.3390/nu18040707","41754224","PMC12943764",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008870","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS.","Blonde L","2018","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.4158/ep-2018-0293","30084684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Practice Guideline; Review; article"],["R0008871","Peer-to-Peer Referral Networks and Six-Month Outcomes in a Tirzepatide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study","Talay T","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202607.0060.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0008872","Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations.","Cotrik E","2026","International clinical psychopharmacology","nonrandomized_study","article","10.1097/yic.0000000000000636","42542974",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0008873","Glucagon-like peptide-1 analogues and prevention of atrial fibrillation: clinical and mechanistic insights.","Ren QW","2026","European journal of preventive cardiology","other_trial","article","10.1093/eurjpc/zwaf242","40300803",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; Comment; editorial"],["R0008874","Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States.","Mody R","2022","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2022.2085962","35758147",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008875","Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.","Bojer AS","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14480","34189832",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0008876","GLP-1 Receptor Agonist and Bariatric Surgery Utilization Among Adolescents and Young Adults.","Messiah SE","2026","JAMA pediatrics","other","article","10.1001/jamapediatrics.2026.2828","42475086","PMC13386303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008877","Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.","Smits MM","2017","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/dme.13160","27278095","PMC5363237",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0008878","Saying no to weight-loss drugs: The paradox of the ideal patient-consumer and stratified biomedicalization.","Jackson N","2025","Social science & medicine (1982)","other","article","10.1016/j.socscimed.2025.118429","40961640",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0008879","Semaglutide in Cystic Fibrosis-Related Diabetes.","Gnanapragasam H","2020","The Journal of clinical endocrinology and metabolism","case_report","article","10.1210/clinem/dgaa167","32232400",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0008880","Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.","Stogios N","2026","JAMA psychiatry","systematic_review","article","10.1001/jamapsychiatry.2026.1814","42418179","PMC13347271",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; article"],["R0008881","Tirzepatide (Mounjaro®, Zepbound®)",null,"1994","Organization of Teratology Information Specialists (OTIS), Brentwood (TN)","narrative_review","article",null,"39038307",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0008882","Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes.","Ferreira JP","2022","European journal of heart failure","randomized_trial","article","10.1002/ejhf.2660","36053803",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008883","Inactivation of Pancreatic Stellate Cells by Exendin-4 Inhibits the Migration and Invasion of Pancreatic Cancer Cells.","Yan M","2020","OncoTargets and therapy","preclinical","article","10.2147/ott.s259853","33061431","PMC7522302",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008884","Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.","Johansen NJ","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14568","34617375",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0008885","Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.","Souza M","2025","Hepatology (Baltimore, Md.)","systematic_review","article","10.1097/hep.0000000000001254","39903735","PMC12614381",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Comparative Study; Network Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; review"],["R0008886","Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.","Brown JD","2018","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00459.2017","29949410","PMC6230892",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0008887","Polyethylene glycol loxenatide protects diabetic kidneys by inhibiting GRP78/PERK/eIF2α pathway, and improves cardiac injury by suppressing TLR4/NF-κB inflammatory pathway.","Shi C","2024","BMC cardiovascular disorders","preclinical","article","10.1186/s12872-024-04427-4","39695387","PMC11658142",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008888","Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.","Plotkin M","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70911","42225300","PMC13341388",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; Randomized Controlled Trial; research-article; article"],["R0008889","Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DM.","Kim C","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.05.08.25327248","40385382","PMC12083636",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0008890","Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review.","Comșa AD","2026","In vivo (Athens, Greece)","narrative_review","article","10.21873/invivo.14224","41482411","PMC12764261",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008891","Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.","Chen W","2025","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","systematic_review","article","10.1080/09513590.2025.2553052","40960939",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; review"],["R0008892","Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis.","Vosoughi K","2021","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2021.101213","34877513","PMC8633575",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; preprint; review"],["R0008893","Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?","Strong J","2025","American journal of clinical dermatology","narrative_review","article","10.1007/s40257-024-00911-x","39690371",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008894","Genotype-phenotype discrepancy among family members carrying a novel glucokinase mutation: insights into the interplay of GCK-MODY and insulin resistance","Ji S","2024","medRxiv","preclinical","preprint","10.1101/2024.08.13.24311668",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008895","Treatment Approaches for Obesity in Children With Heterozygous MC4R Variants.","Salama M","2026","Clinical obesity","case_report","article","10.1111/cob.70069","41489233",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0008896","A Case of Dulaglutide-Induced Vaginal Bleed.","Vaccaro CJ","2023","Cureus","case_report","article","10.7759/cureus.38774","37303364","PMC10249759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0008897","Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.","Frias JP","2023","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(23)01302-8","37369232",null,"ClinicalTrials.gov:NCT05048719","S002265","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008898","Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.","Yau K","2022","Kidney international reports","other_trial","article","10.1016/j.ekir.2022.04.094","35812300","PMC9263228",null,"S002662","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0008899","Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide.","Knudsen JS","2018","Diabetes care","randomized_trial","article","10.2337/dc18-0999","30002200",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0008900","Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus.","Milicevic Z","2016","Clinical therapeutics","other","article","10.1016/j.clinthera.2016.07.013","27673601",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008901","Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes.","Kahkoska AR","2021","Diabetes care","nonrandomized_study","article","10.2337/dc21-0065","34135013","PMC8323175",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; research-article; article; other"],["R0008902","Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Authors' reply.","Waluś-Miarka M","2019","Polish archives of internal medicine","commentary","article","10.20452/pamw.14999","31566589",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; letter"],["R0008903","Exendin-4 exhibits cardioprotective effects against high glucose-induced mitochondrial abnormalities: Potential role of GLP-1 receptor and mTOR signaling.","Parichatikanond W","2024","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2024.116552","39307319",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008904","Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication.","Sivakumar PM","2021","Mini reviews in medicinal chemistry","narrative_review","article","10.2174/1389557521666210422114909","33888049",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008905","Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement.","Giorgino F","2018","Patient preference and adherence","nonrandomized_study","article","10.2147/ppa.s151736","29765207","PMC5944456",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0008906","Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.","Dawwas GK","2018","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-018-0746-4","30016946","PMC6048850",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0008907","Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role intreatment; from the past to future.","Dogruel H","2019","World journal of diabetes","narrative_review","article","10.4239/wjd.v10.i8.446","31523380","PMC6715574",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008908","Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Davies MJ","2022","Diabetes care","narrative_review","article","10.2337/dci22-0034","36148880","PMC10008140",null,"S000018","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; Consensus Statement; review-article; article"],["R0008909","Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis.","Sawada N","2020","Journal of diabetes research","preclinical","article","10.1155/2020/8843310","33274238","PMC7695495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008910","Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology.","Grimolizzi F","2026","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2026.04.2020","42398782",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0008911","GLP-1 Receptor Agonists in the Asia-Pacific: Confronting the Cardiovascular Equity Gap and Cost-Benefit Analysis.","Ochani S","2026","Asia-Pacific journal of public health","commentary","article","10.1177/10105395261465730","42411413",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008912","Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.","Aroda VR","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14990","36700417",null,null,"S001745; S002229","pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008913","GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Hypertrophic Cardiomyopathy With Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis.","Hafez A","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.07.025","42526673",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008914","Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes.","Chowdhary A","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.04.064","39084829","PMC11296502","ClinicalTrials.gov:NCT04657939","S000883","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; research-article; article"],["R0008915","Prepregnancy GLP-1 Receptor Agonist Use: Unaccounted Pretreatment BMI May Distort Obstetric Outcome Signals in Real-World Studies.","Banerjee M","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70286","42575725",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0008916","Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial.","Zhang J","2022","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","randomized_trial","article","10.1136/jim-2021-002237","35725020",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0008917","Study of Metformin and GLP-1 Receptor Agonist Use in Hidradenitis Suppurativa Using the NIH All of Us Research Program.","Shrestha R","2026","Diabetes care","commentary","article","10.2337/dc26-0165","42283704",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008918","The Periprocedural Safety of Continued GLP-1 Receptor Agonist Prior to Cardiac Catheterization.","Chi KY","2026","The American journal of cardiology","other","article","10.1016/j.amjcard.2026.06.029","42435980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008919","GLP-1 Receptor Agonists and THRIVE-Assisted Airway Surgery: The Need for Procedure-specific Evidence.","Özbuğday Y","2026","Ear, nose, & throat journal","commentary","article","10.1177/01455613261466048","42396668",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0008920","Effects of water-sodium balance and regulation of electrolytes associated with antidiabetic drugs.","Zhang J","2023","European review for medical and pharmacological sciences","narrative_review","article","10.26355/eurrev_202306_32817","37401315",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; review"],["R0008921","Transthyretin gates GLP-1R-mediated affect by metabolic stat","Liu S","2026","Research Square","preclinical","preprint","10.21203/rs.3.rs-8322552/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0008922","The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials.","Tseng PT","2025","Journal of hematology & oncology","systematic_review","article","10.1186/s13045-025-01750-x","41310711","PMC12661836","PROSPERO:CRD420251003016",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; review"],["R0008923","Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment.","Brooks A","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-019-0591-9","30847838","PMC6437254",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008924","GLP-1 Receptor Agonists in Reproductive Medicine: A Narrative Review and Investigational Pilot Survey of Patient Perspectives in Academic Reproductive Endocrinology.","Vlasak AL","2026","Reproductive sciences (Thousand Oaks, Calif.)","narrative_review","article","10.1007/s43032-026-02136-1","42310245",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0008925","Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.","Bettge K","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12824","27860132",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0008926","The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.","Guo XH","2016","Current medical research and opinion","narrative_review","article","10.1185/03007995.2015.1103214","26439329",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0008927","Could GLP-1RAs improve outcomes for patients with chronic migraine?","Hou TW","2026","Expert review of clinical pharmacology","nonrandomized_study","article","10.1080/17512433.2026.2710153","42494252",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Editorial; editorial"],["R0008928","The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.","Ehlers LH","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01221-3","35187628","PMC8934846",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008929","Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.","Cao H","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14702","35665989","PMC9541855",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; Network Meta-Analysis; research-article; review"],["R0008930","Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin seeking behavior in rats","Douton JE","2019","bioRxiv","other_trial","preprint","10.1101/730408",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0008931","Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.","Dejgaard TF","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14532","34463425","PMC9292057","ClinicalTrials.gov:NCT02098395; ClinicalTrials.gov:NCT01836523","S001732; S002341","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0008932","Activation of GLP-1R ameliorates alcohol withdrawal induced anxiety-like behavior by regulating neuronal mitochondrial quality control.","Wang Z","2026","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2026.1820128","42292814","PMC13260387",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0008933","Improving incretin-mediated body weight loss via energy expenditure.","Elmendorf AJ","2026","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2025.12.004","41904104","PMC13098988",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; review"],["R0008934","Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy.","Watanabe S","2025","Diabetology international","other_trial","article","10.1007/s13340-025-00799-w","40166440","PMC11954779",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0008935","Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.","Bhagavathula AS","2021","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph14100991","34681215","PMC8537322",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0008936","Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism.","Qin H","2026","Cell metabolism","randomized_trial","article","10.1016/j.cmet.2026.01.008","41666927",null,"ChiCTR:ChiCTR2200066291","S001989","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0008937","Oral delivery of semaglutide and tirzepatide using milk-derived small extracellular vesicles","Zhang Y","2024","bioRxiv","preclinical","preprint","10.1101/2024.12.28.630566",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0008938","Weight Management With Semaglutide and Tirzepatide in U.S. Adults: Projected Impact on Obesity Prevalence and Heart Failure Risk.","Choi H","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70903","42209262",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0008939","Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review.","González-González JG","2021","BMJ open","systematic_review","article","10.1136/bmjopen-2021-049130","34244276","PMC8273479","PROSPERO:CRD42020159284",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0008940","Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment.","Ciardullo S","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm12175597","37685664","PMC10488336",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008941","Response to \"Prepregnancy GLP-1 Receptor Agonist Use: Unaccounted Pretreatment BMI May Distort Obstetric Outcome Signals in Real-World Studies\".","Lemas DJ","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70287","42578724",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0008942","Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.","Hoog M","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01473-7","37740872","PMC10570245",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008943","Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.","Pearson MJ","2026","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgag201","42135195",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0008944","Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.","Ren H","2023","BMJ open","other_trial","article","10.1136/bmjopen-2022-070473","37775297","PMC10546165","ClinicalTrials.gov:NCT02863419","S000133","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008945","Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.","Powell J","2020","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2020.07.017","32873415",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0008946","Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet.","Hiraide T","2025","Journal of health, population, and nutrition","nonrandomized_study","article","10.1186/s41043-025-01161-1","41462404","PMC12750934",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008947","Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.","Kuritzky L","2014","Postgraduate medicine","other_trial","article","10.3810/pgm.2014.10.2821","25414935",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0008948","Multidisciplinary cardiac rehabilitation-an indispensable therapeutic intervention when starting a GLP-1 receptor agonist therapy?","Rauch B","2026","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwag351","42479608",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008949","Decreased Risk of Readmission and Complications With Preoperative GLP-1 Analog Use in Patients Undergoing Primary Total Joint Arthroplasty.","Buddhiraju A","2024","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2024.05.079","38823516",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008950","Ambulatory BP and Weight Reduction as Predictors of GLP-1RA CV Benefit","Renna NF","2025","medRxiv","randomized_trial","preprint","10.1101/2025.06.12.25329536",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0008951","Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study.","Li X","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70902","42186210","PMC13341321",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0008952","Combined effect of GABA and glucagon-like peptide-1 receptor agonist on cytokine-induced apoptosis in pancreatic β-cell line and isolated human islets.","Son DO","2019","Journal of diabetes","preclinical","article","10.1111/1753-0407.12881","30520247",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008953","[Profile of glucose lowering drug use in outpatients with type 2 diabetes mellitus].","Grassi BA","2022","Revista medica de Chile","other","article","10.4067/s0034-98872022001001334","37358092",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0008954","GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.","Górriz JL","2020","Journal of clinical medicine","narrative_review","article","10.3390/jcm9040947","32235471","PMC7231090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008955","Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches.","Morissette A","2024","Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques","narrative_review","article","10.3389/jpps.2024.13065","38903652","PMC11186996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0008956","PHARMACOVIGILANCE SIGNALS OF SEMAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS: AN ANALYSIS OF THE FOOD AND DRUG ADMINISTRATION (FDA) ADVERSE EVENTS REPORTING SYSTEM (FAERS) DATASET",null,"2025","The international journal of neuropsychopharmacology","nonrandomized_study","article",null,null,"PMC11815027",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0008957","Time trends and regional variation in utilization of antidiabetic medicines in China, 2015-2022.","Zhang J","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15594","38618979",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008958","MON-LB032 Real World Evidence Data on the Role of Sodium/Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist in Chronic Kidney Disease Stage 3 Patients beyond Glycemic Control, at Glycemia Clinic- Kuwait","Shaghouli A","2019","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/js.2019-mon-lb032",null,"PMC6550959",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0008959","Anti-Diabetic Agents and Heart Failure　- Response to the CARMELINA Study.","Sano M","2018","Circulation reports","narrative_review","article","10.1253/circrep.cr-18-0011","33693068","PMC7925121",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008960","Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review.","Alorfi NM","2022","Clinical pharmacology : advances and applications","narrative_review","article","10.2147/cpaa.s374741","35958046","PMC9357557",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008961","Response to comment on: GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes.","Noakes J","2026","International journal of impotence research","other","article","10.1038/s41443-026-01319-3","42410064",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008962","FGF21 Analogue PF-05231023 on Alcohol Consumption and Neuronal Activity in the Nucleus Accumbens","Cooley BJ","2024","bioRxiv","preclinical","preprint","10.1101/2024.12.22.629996",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0008963","Corrigendum to \"GLP-1 Receptor Agonists and Long-Term Survival after Spontaneous Intracerebral Hemorrhage in Type 2 Diabetes [World Neurosurgery, Volume 210 (2026) 124932]\".","Chen CM","2026","World neurosurgery","notice","article","10.1016/j.wneu.2026.125199","42567099",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0008964","Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.","Handelsman Y","2018","Journal of managed care & specialty pharmacy","narrative_review","article","10.18553/jmcp.2018.24.9-a.s14","30156445","PMC10408429",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0008965","GLP-1 agonists versus bariatric surgery: Which management carries heavier weight prior to total knee arthroplasty?","Zickler CL","2026","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA","nonrandomized_study","article","10.1002/ksa.70473","42240558",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0008966","The outcome of frailty in older people with diabetes as a function of glycaemic control and hypoglycaemic therapy: a review.","Keegan GL","2023","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2023.2239907","37489773",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0008967","Exenatide attenuates neuroinflammation and rescues sepsis-induced depressive behavior and cognitive dysfunction in a mouse model.","Liu S","2026","Neuroscience","preclinical","article","10.1016/j.neuroscience.2026.02.033","41747818",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008968","Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial.","Caruso P","2024","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2024.1545","38470420","PMC10933706","ClinicalTrials.gov:NCT04881110","S000264","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0008969","The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.","Nielsen R","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14135","32627271",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0008970","GLP-1 Receptor Agonists and Hepatic Encephalopathy in Cirrhosis: A Protective Signal Requiring Cancer and Nutritional Phenotyping.","Wang H","2026","Journal of clinical gastroenterology","other","article","10.1097/mcg.0000000000002421","42383842",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008971","Current therapeutic landscape and future treatment perspectives of MASH.","Gallage S","2026","Nature","narrative_review","article","10.1038/s41586-026-10672-8","42687024",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008972","Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.","Marty VN","2020","Frontiers in neuroscience","preclinical","article","10.3389/fnins.2020.599646","33424537","PMC7785877",null,"S000504","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0008973","Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics.","Pitocco D","2026","European cardiology","narrative_review","article","10.15420/ecr.2025.99","42338975","PMC13284786",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008974","GLP-1 Receptor Agonists for Non-obese Asian Patients With Schizophrenia: Beyond the Body Mass Index Paradigm.","Nagamine T","2026","The Journal of clinical psychiatry","other","article","10.4088/jcp.26lr16549","42447265",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0008975","A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico.","Garnica-Cuellar JC","2023","PharmacoEconomics - open","other_trial","article","10.1007/s41669-023-00421-2","37452964","PMC10471528",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0008976","Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study.","Wium-Andersen IK","2022","Basic & clinical pharmacology & toxicology","nonrandomized_study","article","10.1111/bcpt.13776","35968738","PMC9804689",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008977","Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.","Hall S","2018","Clinical pharmacokinetics","narrative_review","article","10.1007/s40262-018-0668-z","29915923",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0008978","Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.","Yabe D","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00138-5","42607698",null,"ClinicalTrials.gov:NCT06010004","S002128","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0008979","Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States.","Abdeen AA","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71020","42348222","PMC13449014",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008980","Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis.","Janjusevic M","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms23042336","35216451","PMC8878509",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0008981","Risk of Suicidal Ideation or Attempts in Adolescents With Obesity Treated With GLP1 Receptor Agonists.","Kerem L","2024","JAMA pediatrics","nonrandomized_study","article","10.1001/jamapediatrics.2024.3812","39401009","PMC11581746",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0008982","Albuminuria and cardiorenal risk.","Georgianos PI","2023","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000001055","37016948",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0008983","Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus.","Zhu J","2023","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2023.110568","36738836",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Consensus Statement; article"],["R0008984","Visual demonstration of weight loss and health risk improvement with a dual GIP and GLP-1 receptor agonist.","Ramirez S","2025","International journal of obesity (2005)","other_trial","article","10.1038/s41366-025-01842-1","40659850","PMC12532576","ClinicalTrials.gov:NCT04184622","S001077","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0008985","Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence.","Narcisse DI","2022","Current cardiology reports","narrative_review","article","10.1007/s11886-022-01677-6","35201560",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0008986","Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.","Hasegawa Y","2018","Journal of clinical lipidology","nonrandomized_study","article","10.1016/j.jacl.2017.11.006","29217412",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0008987","Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.","AlTaweel MO","2026","Expert review of cardiovascular therapy","nonrandomized_study","article","10.1080/14779072.2026.2713476","42535667",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0008988","The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis.","Maciel MG","2018","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2018.05.034","29857094",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0008989","Evaluation of Metastatic Insulinoma With Severe Hypoglycemia Using 68 Ga-Exendin-4 PET/CT.","Gao J","2025","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000006008","40590104",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0008990","Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.","McCarty D","2017","The Annals of pharmacotherapy","other_trial","article","10.1177/1060028017689878","28133970",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0008991","Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.","Bramante CT","2020","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2020.09.01.20185850","32909011","PMC7480063",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Preprint; Journal Article; preprint"],["R0008992","A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes.","Corey KM","2026","JCI insight","randomized_trial","article","10.1172/jci.insight.204463","42390946","PMC13502179",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0008993","Interpreting Pregnancy Risk After GLP-1 Receptor Agonists Discontinuation.","Scairati R","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70615","41749408","PMC13071202",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article-commentary; article"],["R0008994","Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Spinal Fusion Outcomes: A Comprehensive Meta-Analysis.","Zahed M","2025","Cureus","systematic_review","article","10.7759/cureus.93065","41141191","PMC12549411",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0008995","Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience.","Piazzolla G","2022","Open medicine (Warsaw, Poland)","randomized_trial","article","10.1515/med-2022-0504","35859794","PMC9263895",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0008996","Identification of a novel oral potential multiple agonist for obesity treatment: multi-target in silico study.","Galiano Á","2026","Journal of computer-aided molecular design","preclinical","article","10.1007/s10822-026-00836-z","42162325",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0008997","Visualizing subcellular rearrangements in intact β cells using soft x-ray tomography.","White KL","2020","Science advances","other","article","10.1126/sciadv.abc8262","33298443","PMC7725475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0008998","A 2-Years Comparative Analysis of Tirzepatide, Semaglutide, Qsymia, Contrave, and Phentermine on Ocular Health in Individuals with Obesity: A Propensity-Score Matched Cohort Study","Su P","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-5493930/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0008999","Refractory Dysmenorrhea Managed With a Glucagon-Like Peptide-1 Agonist: A Case Report.","Tran M","2025","Cureus","other_trial","article","10.7759/cureus.77387","39944451","PMC11821293",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0009000","Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists.","Shiomi M","2019","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.12900","30033675","PMC6400150",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009001","Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus.","Liu W","2022","Frontiers in cellular and infection microbiology","narrative_review","article","10.3389/fcimb.2022.853771","35711668","PMC9194476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0009002","Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study.","Al Hayek A","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2025.109064","40318459",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009003","Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment.","Xing C","2022","International journal of women's health","narrative_review","article","10.2147/ijwh.s344542","35140526","PMC8818772",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009004","Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.","Tavaglione F","2026","Cell reports. Medicine","other_trial","article","10.1016/j.xcrm.2026.103023","42697203","PMC13589479",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0009005","Comparative Effectiveness of GLP-1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study.","Zhang B","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71244","42660859",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0009006","iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies.","Song L","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16260","40013432","PMC11964995",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0009007","Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.","Mohammedi K","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15045","36869853",null,null,"S001244","pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Multicenter Study; Observational Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009008","How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.","Lee MMY","2020","Arteriosclerosis, thrombosis, and vascular biology","other_trial","article","10.1161/atvbaha.119.311904","31996025",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0009009","Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients.","Dai JW","2024","Scientific reports","nonrandomized_study","article","10.1038/s41598-024-79255-9","39528690","PMC11555252",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0009010","Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.","Iacobellis G","2022","Handbook of experimental pharmacology","other","article","10.1007/164_2021_577","35156138",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0009011","A septal inhibitory circuit constrains alcohol reward and mediates liraglutide's suppressive effects on alcohol intake in mice.","Tian Y","2026","Neuron","preclinical","article","10.1016/j.neuron.2026.02.019","41903537",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009012","Understanding the Work of the Pharmacovigilance Risk Assessment Committee (PRAC): A Quantitative Review of the Post-Authorisation Safety Evaluation of Antidiabetic Drugs from 2012 to 2022.","Le H","2025","Drug safety","nonrandomized_study","article","10.1007/s40264-025-01536-7","40024970","PMC12174291",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0009013","The Preventive Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cancer Metastasis: A Network Meta-Analysis of 67 Randomized Controlled Trials.","Hsu CW","2025","International journal of molecular sciences","systematic_review","article","10.3390/ijms26178202","40943127","PMC12428495",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; review"],["R0009014","Transdermal Semaglutide Administration in Mice: Reduces Body Weight by Suppressing Appetite and Enhancing Metabolic Rate.","Li W","2025","Biology","preclinical","article","10.3390/biology14050575","40427764","PMC12109181",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009015","Pneumatosis intestinalis associated with α-glucosidase inhibitors: a pharmacovigilance study of the FDA adverse event reporting system from 2004 to 2022.","Chen Y","2023","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2023.2278708","37929311",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0009016","Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.","Nargesi AA","2021","Journal of the American Heart Association","other","article","10.1161/jaha.121.021084","33998258","PMC8403287",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0009017","GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.","Yan H","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.923606","35909522","PMC9325993","PROSPERO:CRD42021251704",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; systematic-review; review"],["R0009018","Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.","Svane MS","2022","International journal of obesity (2005)","other_trial","article","10.1038/s41366-022-01207-y","35982119",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009019","Postprandial glucose-management strategies in type 1 diabetes: Current approaches and prospects with precision medicine and artificial intelligence.","Jafar A","2024","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15463","38263540",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009020","Exploring the potential impact of GLP-1 receptor agonists in cancer therapy.","Aslam B","2025","Minerva endocrinology","randomized_trial","article","10.23736/s2724-6507.23.04101-5","38127407",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0009021","The changing trajectory of diabetic kidney disease.","Mistry N","2023","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000000844","36250469",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0009022","Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study.","Tsai CY","2021","Frontiers in endocrinology","other","article","10.3389/fendo.2021.814770","35095773","PMC8793908",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009023","Lipid effects of glucagon-like peptide 1 receptor analogs.","Berberich AJ","2021","Current opinion in lipidology","narrative_review","article","10.1097/mol.0000000000000750","33900276",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0009024","Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel.","Lyu B","2022","Diabetes care","nonrandomized_study","article","10.2337/dc22-1253","36282149","PMC9763031",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0009025","Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.","Lähteenvuo M","2025","JAMA psychiatry","nonrandomized_study","article","10.1001/jamapsychiatry.2024.3599","39535805","PMC11561716",null,"S000817","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; brief-report; article"],["R0009026","Treatment potential of oral small-molecule GLP-1 receptor agonists.","Blüher M","2026","Lancet (London, England)","other","article","10.1016/s0140-6736(26)01135-9","42259335",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009027","Insulin resistance: The role in comorbid type 2 diabetes mellitus and depression.","Yao J","2025","Neuroscience and biobehavioral reviews","narrative_review","article","10.1016/j.neubiorev.2025.106218","40403856",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009028","Cagrilintide-Semaglutide in Adults with Overweight or Obesity.","Fogacci F","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2513141","41259764",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0009029","[Effect of glucagon-like peptide 1 receptor agonists on body fat redistribution and muscle mass in overweight and obese type 2 diabetic patients].","Zhang Y","2019","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","nonrandomized_study","article","10.12122/j.issn.1673-4254.2019.04.11","31068289","PMC6743999",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009030","Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.","Mousa SA","2019","Neural regeneration research","preclinical","article","10.4103/1673-5374.249217","30688255","PMC6375047",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009031","GLP-1 Receptor Agonists and the Kidney: Progress With Important Caveats.","Kunutsor SK","2026","Mayo Clinic proceedings","commentary","article","10.1016/j.mayocp.2026.04.010","42223393",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009032","A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.","McGowan B","2025","Nature medicine","systematic_review","article","10.1038/s41591-025-03978-z","41039116","PMC12532627",null,"S001978","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; review"],["R0009033","Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus.","Dou X","2025","Frontiers in neuroscience","narrative_review","article","10.3389/fnins.2025.1537898","40171533","PMC11959055",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009034","GLP-1 receptor agonists in neuroinflammation: a novel therapeutic target?","Brielle Pontes Silva P","2026","Nutritional neuroscience","other","article","10.1080/1028415x.2026.2680999","42234798",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009035","Liraglutide Treatment in a Morbidly Obese Adolescent with a MC4R Gene Variant: Side Effects Reduce Success.","Çamtosun E","2023","Journal of clinical research in pediatric endocrinology","other","article","10.4274/jcrpe.galenos.2021.2021.0158","34584129","PMC10234058",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0009036","Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.","Lian J","2026","Liver international : official journal of the International Association for the Study of the Liver","narrative_review","article","10.1111/liv.70576","41823054","PMC12983196",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009037","GLP-1 Receptor Analogs: Evidence Linking to Effect on Metabolic and Reproductive Functions in Patients with PCOS and Obesity.","Celik O","2026","Obesity facts","systematic_review","article","10.1159/000547055","40743996","PMC12503748",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; Review; article"],["R0009038","Depression, cognition, and GLP-1 receptors: Heterogeneity and therapeutic prospects.","Chen MH","2026","Med (New York, N.Y.)","randomized_trial","article","10.1016/j.medj.2025.100954","41519115",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Comment"],["R0009039","Impact of chemical structure, lipidation and formulation on luminal stability and intestinal absorption of GLP-1 analogues.","Emeh P","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.114144","40840601",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009040","Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE.","Zobel EH","2021","Diagnostics (Basel, Switzerland)","randomized_trial","article","10.3390/diagnostics11081431","34441365","PMC8391433",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0009041","Time to unshackle the medical treatment of obesity in the NHS.","Ansari S","2024","Clinical medicine (London, England)","other","article","10.1016/j.clinme.2024.100206","38643826","PMC11091500",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009042","Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon.","Jeon E","2023","Journal of obesity & metabolic syndrome","other_trial","article","10.7570/jomes23032","37349257","PMC10327684",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0009043","Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic.","Gonikman D","2023","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina59101810","37893528","PMC10608676",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0009044","Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Davies MJ","2022","Diabetologia","narrative_review","article","10.1007/s00125-022-05787-2","36151309","PMC9510507",null,"S000298","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Consensus Statement; review-article; other"],["R0009045","Comment on: GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes.","Grimolizzi F","2026","International journal of impotence research","commentary","article","10.1038/s41443-026-01312-w","42342928",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; letter"],["R0009046","Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis.","Ghosal S","2026","European heart journal open","randomized_trial","article","10.1093/ehjopen/oeag071","42131512","PMC13167074",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comment; brief-report; article"],["R0009047","THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON PATIENTS WITH DIABETES ON INSULIN THERAPY.","Gyorffy JB","2019","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep-2019-0023","31170363",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0009048","A systematic review of the safety of incretin-based therapies in type 2 diabetes.","Evans M","2016","Expert review of endocrinology & metabolism","systematic_review","article","10.1586/17446651.2015.1057502","30058866",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; other; article; review"],["R0009049","Semaglutide Hype or Hope: Evidence-based Review in Diabesity.","Gupta S","2026","The Journal of the Association of Physicians of India","narrative_review","article","10.59556/japi.74.1439","41818107",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009050","Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis.","Tan L","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1303238","38239984","PMC10795175","PROSPERO:CRD42022332052",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; systematic-review; article"],["R0009051","Comment on Hong et al. Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes Care 2025;48:1728-1736.","García de Lucas MD","2026","Diabetes care","nonrandomized_study","article","10.2337/dc25-2996","42160599","PMC13191411",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0009052","Applicability of multiple quantitative ultrasound liver biomarkers in children and adolescents with severe obesity.","Cetinic I","2025","BMC pediatrics","other","article","10.1186/s12887-025-05750-1","40380181","PMC12083147",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009053","Early Access to GLP-1 Receptor Agonists for Weight Management in Medicare: The GLP-1 Bridge Demonstration.","Sullivan SD","2026","Annals of internal medicine","commentary","article","10.7326/annals-26-01469","42330504",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0009054","Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review.","Halloum W","2024","The journal of headache and pain","systematic_review","article","10.1186/s10194-024-01821-3","38997662","PMC11241973",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0009055","Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction-associated steatohepatitis (MASH): A real-world data analysis.","Beyene E","2026","Clinics and research in hepatology and gastroenterology","nonrandomized_study","article","10.1016/j.clinre.2026.102760","41500355",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Comparative Study"],["R0009056","Effects of semaglutide on subclinical cardiovascular health in people with HIV.","Daher J","2026","AIDS (London, England)","randomized_trial","article","10.1097/qad.0000000000004624","42752515",null,"ClinicalTrials.gov:NCT04019197","S001425","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; article"],["R0009057","Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?","RoyChaudhuri S","2023","Cureus","nonrandomized_study","article","10.7759/cureus.37065","37153287","PMC10155755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009058","Polyethylene glycol loxenatide modulates lipid metabolism and insulin resistance through lncRNA steroid receptor RNA activator/cellular nucleic acid binding protein/Rho-associated coiled-coil kinase 2 axis in type 2 diabetes mellitus.","Chen Z","2025","Journal of diabetes investigation","preclinical","article","10.1111/jdi.14373","39651712","PMC11970291",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009059","An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.","Acosta-Madiedo AS","2025","Journal of drugs in dermatology : JDD","randomized_trial","article","10.36849/jdd.9569","41329144",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0009060","Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.","Yang Q","2023","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2023.110592","36842477",null,"PROSPERO:CRD42022343601",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Systematic Review; Journal Article; Network Meta-Analysis"],["R0009061","Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes.","Marusic S","2026","International journal of clinical pharmacology and therapeutics","case_report","article","10.5414/cp204985","42087771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009062","Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,","Zou CY","2023","Clinics and research in hepatology and gastroenterology","systematic_review","article","10.1016/j.clinre.2022.102053","36403941",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0009063","Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.","Nuhoho S","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-019-00706-y","31599391","PMC6848399",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; other; review"],["R0009064","Brca1 heterozygosity leads to hepatic steatosis in male and female mice despite sexually dimorphic effects on systemic metabolism.","Palikhe S","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.02.25.708005","42124628","PMC13160122",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; article"],["R0009065","Adherence to Treatment Guidelines Among Patients With Type 2 Diabetes Attending a Tertiary Hospital in Jeddah, Saudi Arabia.","Radi S","2024","Cureus","nonrandomized_study","article","10.7759/cureus.73850","39563693","PMC11576062",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009066","Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment.","Florentin M","2022","World journal of diabetes","narrative_review","article","10.4239/wjd.v13.i2.85","35211246","PMC8855136",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009067","Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA).","Kalra S","2016","JPMA. The Journal of the Pakistan Medical Association","narrative_review","article",null,"26968296",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009068","Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs - The CAPISCO International Expert Panel.","Popovic DS","2023","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","randomized_trial","article","10.1055/a-2019-1111","36693416",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Review; Journal Article; article"],["R0009069","Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Cancer Prevention: Methodological Pitfalls in Observational Studies.","Harris M","2025","Cancers","other","article","10.3390/cancers17091451","40361378","PMC12070977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0009070","A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.","Romero-Gómez M","2023","Journal of hepatology","randomized_trial","article","10.1016/j.jhep.2023.05.013","37355043",null,"ClinicalTrials.gov:NCT04944992; EudraCT:2020-005136-30","S000186; S001747","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009071","Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction.","Yang Z","2022","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2022.1120085","36712249","PMC9877359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009072","GLP-1 Agonists in Plastic Surgery: Impact on Aesthetic Outcomes-Two Case Reports.","Taraschi F","2025","Aesthetic plastic surgery","case_report","article","10.1007/s00266-025-04703-4","39843868",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0009073","The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials.","Wu S","2019","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13613","30536884",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0009074","Emerging Therapeutic Strategies for Infantile Obesity: A Narrative Review","Tomaso O","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202609.0649.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0009075","Can oral GLP-1 receptor agonists ACHIEVE the same as SGLT2 inhibitors?","Heerspink HJL","2026","Lancet (London, England)","other","article","10.1016/s0140-6736(26)01040-8","42259333",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009076","The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany.","Hille H","2026","Cost effectiveness and resource allocation : C/E","nonrandomized_study","article","10.1186/s12962-026-00801-5","42509550","PMC13404957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0009077","Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add?","Ferdinand KC","2017","Annals of translational medicine","commentary","article","10.21037/atm.2017.10.24","29285509","PMC5733310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0009078","Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial.","Ahmad E","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14343","33565691",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009079","Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysis.","Song J","2024","BMJ open","other","article","10.1136/bmjopen-2024-088318","39627122","PMC11624754",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009080","The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome.","O'Brien R","2020","Neurogastroenterology and motility","preclinical","article","10.1111/nmo.13738","31602785",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009081","A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues.","Koshy RM","2021","Current drug safety","narrative_review","article","10.2174/1574886315999201105153852","33153424",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009082","Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.","Ellenbroek JH","2013","Diabetologia","preclinical","article","10.1007/s00125-013-2957-2","23771206",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009083","Infectious complications of newer agents in the fight against diabetes.","Stover KR","2020","The Nurse practitioner","narrative_review","article","10.1097/01.npr.0000718508.65708.a1","33093391",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009084","GLP-1 receptor agonists for the management of obesity in individuals treated with antipsychotics.","Patoulias D","2026","European journal of internal medicine","commentary","article","10.1016/j.ejim.2026.106977","42230187",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009085","Acute esophageal necrosis as a complication of diabetic ketoacidosis: A case report.","Moss K","2021","World journal of clinical cases","case_report","article","10.12998/wjcc.v9.i31.9571","34877292","PMC8610878",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009086","Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis.","Shen P","2026","PloS one","nonrandomized_study","article","10.1371/journal.pone.0344289","41894422","PMC13028446",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009087","Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease.","Neumiller JJ","2024","Clinical kidney journal","narrative_review","article","10.1093/ckj/sfad285","38213492","PMC10783256",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009088","Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.","Bulum T","2022","Biomedicines","narrative_review","article","10.3390/biomedicines10102586","36289848","PMC9599125",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009089","Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.","Lyseng-Williamson KA","2019","Clinical drug investigation","notice","article","10.1007/s40261-019-00839-9","31422551","PMC6765691",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0009090","Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.","Loomba R","2026","The lancet. Gastroenterology & hepatology","randomized_trial","article","10.1016/s2468-1253(26)00123-8","42456707",null,"ClinicalTrials.gov:NCT05016882","S001202","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0009091","Exposure-driven tolerance modeling of efpeglenatide-induced nausea or vomiting using repeated time-to-event analysis: implications for dose-escalation strategies.","Seo J","2026","Frontiers in pharmacology","other","article","10.3389/fphar.2026.1846164","42840589","PMC13639893",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009092","GLP-1 receptor agonists in patients with Type 2 diabetes: cardiorenal protection versus ocular safety.","Stougaard EB","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other","article","10.1093/ndt/gfag131","42314070",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009093","GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance.","Chi KY","2025","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2025.17541","40587132","PMC12210086",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0009094","Diabetes Therapeutics Beyond Hyperglycaemia: Toward Biological Systems Redesign.","Habtemariam S","2026","Biomedicines","other","article","10.3390/biomedicines14061336","42351764","PMC13297353",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009095","The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats.","Arslan HE","2025","Acta cirurgica brasileira","preclinical","article","10.1590/acb407325","41036937","PMC12487549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009096","Anti-Proliferative Activity of Glucagon-Like Peptide-1 Receptor Agonist on Obesity-Associated Breast Cancer: The Impact on Modulating Adipokines' Expression in Adipocytes and Cancer Cells.","Alanteet AA","2021","Dose-response : a publication of International Hormesis Society","other","article","10.1177/1559325821995651","33746653","PMC7903831",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009097","Mechanism of preventive effects of exendin-4 and des-fluoro-sitagliptin in a murine model of fructose-induced prediabetes.","Castro MC","2023","Biochimica et biophysica acta. Molecular and cell biology of lipids","preclinical","article","10.1016/j.bbalip.2023.159363","37429413",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009098","Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.","Kanumilli N","2026","Journal of medical economics","other_trial","article","10.1080/13696998.2026.2631920","41771166",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0009099","The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.","Sillassen CDB","2026","BMC medicine","systematic_review","article","10.1186/s12916-026-04824-w","41896878","PMC13147618","PROSPERO:CRD42024599035",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; research-article; review"],["R0009100","Obesity: a gender-view.","Muscogiuri G","2024","Journal of endocrinological investigation","other_trial","article","10.1007/s40618-023-02196-z","37740888","PMC10859324",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0009101","Anti-Inflammatory Potential of Liraglutide, a Glucagon-like peptide-1 receptor agonist, in Rats with Peripheral Acute Inflammation","Mert İ","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-1003623/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009102","Prescriptions for Glucagon-Like Peptide 1 Agonists (GLP-1RAs) Before Bariatric Surgery in the United States.","Zion A","2026","Annals of surgery","other","article","10.1097/sla.0000000000007069","42002848","PMC13258227",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009103","Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review.","Skeik N","2023","Vascular medicine (London, England)","narrative_review","article","10.1177/1358863x221143811","36593757",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009104","Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study.","Hao R","2022","BMC primary care","other","article","10.1186/s12875-022-01731-w","35606699","PMC9128222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0009105","Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries.","Ueda P","2019","Diabetes care","nonrandomized_study","article","10.2337/dc18-2532","31010872",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Letter; article"],["R0009106","Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database.","Uzoigwe C","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01322-z","36239850","PMC9663787",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009107","Cardiovascular Benefits of GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight: A Meta-analysis of Randomized Controlled Trials.","de Oliveira Almeida G","2024","American journal of cardiovascular drugs : drugs, devices, and other interventions","systematic_review","article","10.1007/s40256-024-00647-3","38734847",null,"PROSPERO:CRD42023475226",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0009108","Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications.","Zhang X","2026","Cardiovascular drugs and therapy","narrative_review","article","10.1007/s10557-025-07670-9","39832069","PMC12872670",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0009109","Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.","Tall Bull S","2022","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2022.108332","36375235",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0009110","Exendin‑4 promotes osteogenic differentiation of adipose‑derived stem cells and facilitates bone repair.","Deng B","2019","Molecular medicine reports","preclinical","article","10.3892/mmr.2019.10764","31661134","PMC6854547",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009111","Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Prevention: Evidence From Randomized Outcomes Trials.","Gerstein HC","2026","JACC. Advances","randomized_trial","article","10.1016/j.jacadv.2026.102645","41819677","PMC12997211",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; editorial"],["R0009112","Extending our understanding of exenatide: a rare case of angio-oedema.","Mahfooz F","2021","BMJ case reports","case_report","article","10.1136/bcr-2020-235663","33461993","PMC7813304",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009113","The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence.","Abdalla MA","2021","Therapeutic advances in endocrinology and metabolism","nonrandomized_study","article","10.1177/2042018821989238","33552465","PMC7844452",null,"S002080","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0009114","Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.","Gamble JM","2018","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2018-023830","30297350","PMC6194463",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009115","Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice.","Chen CJ","2026","International journal of pharmaceutics","other_trial","article","10.1016/j.ijpharm.2026.126752","41819389",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0009116","The Weight of the Matter in Diabetes Care.","Bhattacharyya S","2025","The Journal of the Association of Physicians of India","nonrandomized_study","article","10.59556/japi.73.1201","41277213",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0009117","The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome.","Bednarz K","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms23084334","35457152","PMC9029608",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009118","Poster Session I - A100 IMPACT OF GLP-1 RECEPTOR AGONISTS ON THE QUALITY OF BOWEL PREPARATION IN SCREENING COLONOSCOPIES",null,"2026","Journal of the Canadian Association of Gastroenterology","other","article",null,null,"PMC12900921",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0009119","GLP-1 Receptor Agonists in Body Contouring Surgery: Beyond Weight Loss Timing and Bleeding Risk.","Bruno A","2026","Aesthetic plastic surgery","commentary","article","10.1007/s00266-026-06094-6","42298162",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009120","Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits.","Hwang E","2025","Endocrinology","narrative_review","article","10.1210/endocr/bqaf125","40911609","PMC12641536",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009121","Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network.","Monzo L","2026","ESC heart failure","randomized_trial","article","10.1093/eschf/xvag042","41711744","PMC13108322",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; Comparative Study; Multicenter Study; brief-report; article"],["R0009122","Sex differences in the weight response to GLP-1RA in people with type 2 diabetes. A long-term longitudinal real-world study.","Marassi M","2025","Pharmacological research","nonrandomized_study","article","10.1016/j.phrs.2025.107866","40706779",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; article"],["R0009123","Clinical spotlight intervention to accelerate translation of evidence-based practices in primary care.","Chawla K","2022","BMJ open quality","other","article","10.1136/bmjoq-2022-002032","36581350","PMC9806053",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009124","Comparative Renal Effectiveness of GLP-1RA and SGLT2i in US Veterans with Type 2 Diabetes and CKD.","Htoo PT","2026","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000001244","42809365",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009125","1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.","Leslie DB","2026","The lancet. Diabetes & endocrinology","nonrandomized_study","article","10.1016/s2213-8587(26)00030-6","42309121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009126","Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.","Bonnesen K","2025","Pharmacoepidemiology and drug safety","randomized_trial","article","10.1002/pds.70276","41334697",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0009127","Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.","Wysham CH","2017","Postgraduate medicine","systematic_review","article","10.1080/00325481.2017.1297669","28294702",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article; review"],["R0009128","Pharmacoeconomic Review Report: Insulin degludec and liraglutide injection (Xultophy): (Novo Nordisk Canada Inc.): Indication: An adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 U daily) or liraglutide (less than or equal to 1.8 mg daily) do not provide adequate glycemic control",null,"2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"32182000",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0009129","Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice.","Aviles Bueno B","2022","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfac096","35892023","PMC9308087",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009130","Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes.","Kyriakidou A","2022","Journal of personalized medicine","other","article","10.3390/jpm12030424","35330424","PMC8955617",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009131","Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.","Hsiao FY","2024","The lancet. Healthy longevity","randomized_trial","article","10.1016/j.lanhl.2024.07.004","39284334",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0009132","GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.","Villaschi A","2024","Clinical research in cardiology : official journal of the German Cardiac Society","systematic_review","article","10.1007/s00392-023-02362-6","38252145",null,"PROSPERO:CRD42022371264",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Systematic Review; review"],["R0009133","Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.","Pratley RE","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04440-4","42260100","PMC13375528","ClinicalTrials.gov:NCT06445075","S002002","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0009134","Associations between income/employment status and diabetes care processes, health behaviors, and health outcomes in Japan: A cross-sectional study using claims data linked to a questionnaire survey.","Yamaoka T","2024","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14301","39264346","PMC11527804",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009135","Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs.","Zhou Y","2023","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2023.115669","37820568",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009136","Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.","Geloneze B","2017","Drugs","preclinical","article","10.1007/s40265-017-0706-4","28233273","PMC5357258",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0009137","Use of Fixed Ratio Combinations to Improve Glycemic Control in Individuals with Type 2 Diabetes: Experts' Opinion from the Gulf Region.","Hassanein M","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-025-01824-6","41379370","PMC12909634",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009138","Response to multiple glucose-lowering agents in a sib-pair with a novel HNF1α (MODY3) variant.","Tan CSH","2020","European journal of human genetics : EJHG","case_report","article","10.1038/s41431-019-0561-8","31844173","PMC7080716",null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0009139","Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study.","Pasternak B","2020","Diabetes care","nonrandomized_study","article","10.2337/dc19-2088","32295809",null,null,"S002638","pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0009140","Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.","Marathe SJ","2025","npj metabolic health and disease","preclinical","article","10.1038/s44324-025-00054-5","40094000","PMC11908972",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009141","Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.","Kanu C","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70097","40916752","PMC12587234",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; research-article; article"],["R0009142","Acute Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Prevents Drug-Induced Heroin Seeking in Rats","Douton JE","2021","bioRxiv","preclinical","preprint","10.1101/2021.09.15.460527",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009143","A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?","Docimo S","2024","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-024-11191-1","39285034",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0009144","Research progress in precision medicine for type 2 diabetes based on the GLP-1.","Wang S","2025","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2025.1721842","41561058","PMC12813692",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0009145","Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes.","Oya J","2024","Diabetology international","other","article","10.1007/s13340-023-00681-7","38524940","PMC10959845",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009146","Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026).","Qaseem A","2026","Annals of internal medicine","other","article","10.7326/annals-25-02714","42296496",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0009147","Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use.","Ayo-Ajibola O","2026","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf204","41476725","PMC12749571",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009148","Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial.","Gao F","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14163","32744358",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009149","Pharmacological treatment for metabolic dysfunction-associated steatotic liver disease and related disorders: Current and emerging therapeutic options.","Zhang X","2025","Pharmacological reviews","narrative_review","article","10.1016/j.pharmr.2024.100018","40148030",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009150","In Reply to the Letter to the Editor Regarding \"The Effect of GLP-1 Receptor Agonists on Reoperation Following Anterior Cervical Discectomy and Fusion\".","Bank NC","2026","World neurosurgery","commentary","article","10.1016/j.wneu.2026.125149","42331146",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0009151","Quantitative analysis of free polyethylene glycols in PEGylated peptides using reverse-phase high-performance liquid chromatography and charged aerosol detection.","Sun Y","2026","PloS one","other","article","10.1371/journal.pone.0357292","42691081","PMC13541174",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009152","GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective.","Rasalam R","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-019-0642-2","31183762","PMC6612351",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0009153","Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.","Rea F","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.109035","34487757",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Comparative Study; Journal Article; article"],["R0009154","Hypoglycemia Reporting in GLP-1RA Trials for Type 1 Diabetes: A Critical Gap That Needs To Be Addressed.","Ishtiaq S","2026","Endocrinology, diabetes & metabolism","commentary","article","10.1002/edm2.70256","42246515","PMC13238602",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0009155","GLP-1 receptor agonists: a review of head-to-head clinical studies.","Trujillo JM","2015","Therapeutic advances in endocrinology and metabolism","other_trial","article","10.1177/2042018814559725","25678953","PMC4321870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0009156","Real-World Prescribing of Renal and Cardiovascular Protective Drugs in Patients With Type 2 Diabetes and Chronic Kidney Disease: Analysis of Data From a Western Australian Quaternary Hospital.","Lan NSR","2025","Heart, lung & circulation","nonrandomized_study","article","10.1016/j.hlc.2025.07.007","40912924",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0009157","Liraglutide alleviates postoperative cognitive impairment via NRF2/NLRP3 signal pathway in aged mice.","Sun H","2026","Neuroscience letters","preclinical","article","10.1016/j.neulet.2026.138621","42102962",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009158","Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.","Gu S","2022","Journal of clinical medicine","systematic_review","article","10.3390/jcm11237094","36498669","PMC9740076",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0009159","Social determinants of health and newer glucose-lowering drugs adoption among US Medicare beneficiaries with type 2 diabetes.","Chen WH","2024","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2024.30.11.1298","39471265","PMC11522454",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009160","Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study.","Hsu HY","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113186","41740927",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009161","Sex Differences in Renal Outcomes and Metabolic Markers by Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Individuals with Type 2 Diabetes: A Post-Hoc Analysis of the RECAP Study.","Muta Y","2025","JMA journal","nonrandomized_study","article","10.31662/jmaj.2025-0224","41220513","PMC12598152",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009162","Trends in Metabolic and Bariatric Surgery and GLP-1 Receptor Agonist Use Among Adolescents with Severe Obesity.","Collins RA","2026","Annals of surgery","other","article","10.1097/sla.0000000000007146","42374648",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009163","Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.","Christensen RM","2019","Drug safety","notice","article","10.1007/s40264-019-00830-5","31041671",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0009164","Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.","Allam MM","2018","Archives of physiology and biochemistry","preclinical","article","10.1080/13813455.2017.1348362","28696785",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009165","Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP-1 Drug.","Harrison DB","2025","The Laryngoscope","case_report","article","10.1002/lary.31815","39370986","PMC11729570",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; research-article; article"],["R0009166","Diabetes and the kidney.","Chowdhury TA","2021","Clinical medicine (London, England)","randomized_trial","article","10.7861/clinmed.2021-0144","35192470","PMC8313217",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; other; article"],["R0009167","Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease.","Dihoum A","2023","Expert opinion on investigational drugs","randomized_trial","article","10.1080/13543784.2023.2196010","36972373",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Review; Journal Article; article"],["R0009168","Clinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin.","Hopton OM","2022","Pharmacotherapy","nonrandomized_study","article","10.1002/phar.2648","34807465",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0009169","Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes.","Pawaskar M","2021","The American journal of managed care","randomized_trial","article","10.37765/ajmc.2021.88728","34460181",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009170","Efficacy of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Moderate-to-Severe COPD Exacerbations Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Pirera E","2025","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph18091337","41011208","PMC12472923",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0009171","Measuring Facial Appearance in GLP-1 Agonist Use with the FACE-Q Aesthetics Item Library.","Klassen AF","2026","Aesthetic surgery journal","other","article","10.1093/asj/sjag095","42140744",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009172","Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.","Hoekx CA","2024","Experimental physiology","other","article","10.1113/ep091815","38965822","PMC11291866","ClinicalTrials.gov:NCT01761318; ClinicalTrials.gov:NCT02660047","S000142; S000566","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0009173","A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products.","Nuffer W","2018","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018817752315","29492243","PMC5813858",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009174","GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes.","Bailey J","2022","Diabetologia","preclinical","article","10.1007/s00125-022-05730-5","35687178","PMC11973880",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0009175","Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.","Rosenstock J","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13462","29974618","PMC6282993","ClinicalTrials.gov:NCT00975286; ClinicalTrials.gov:NCT01768559; ClinicalTrials.gov:NCT02058160; ClinicalTrials.gov:NCT02058147","S000792; S001199; S001409; S001630","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009176","Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.","Overgaard RV","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13479","30047216","PMC6585654",null,"S000329; S000878","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0009177","Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study.","Basile P","2023","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm12041586","36836121","PMC9962489",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009178","Time in uncontrolled hyperglycemia before insulin initiation in people living with type 2 diabetes: A systematic literature review.","Harris S","2023","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2023.10.008","39492047",null,"PROSPERO:CRD42022327974",null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; review"],["R0009179","Computer-Aided Design of Novel Acrylamido Derivatives as Potential Oral Antidiabetic Agents.","Şentürk AM","2026","Medicinal chemistry (Shariqah (United Arab Emirates))","other","article","10.2174/0115734064513164260828103027","42736679",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009180","The cardiovascular benefits of glucagon-like peptide-1 receptor agonists as novel diabetes drugs are mediated via the suppression of miR-203a-3p and miR-429 expression","Liu Y","2023","Research Square","other","preprint","10.21203/rs.3.rs-3756107/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009181","Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.","Ferreira EVM","2025","Infectious disease reports","nonrandomized_study","article","10.3390/idr17010005","39846709","PMC11755651",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009182","[Management of patients with type 2 diabetes during cardiac prevention and rehabilitation. An expert opinion from the Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P)].","Ambrosetti M","2023","Giornale italiano di cardiologia (2006)","other","article","10.1714/4100.40985","37767837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Practice Guideline; English Abstract; article"],["R0009183","Considering Real-World Effectiveness of GLP-1RA Persistence and Outcomes for Weight loss regimes.","Rizwan MR","2025","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.175565534.46206657/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0009184","A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.","Barrientos-Pérez M","2022","Pediatric diabetes","randomized_trial","article","10.1111/pedi.13343","35411611","PMC9790255","ClinicalTrials.gov:NCT02803918","S000673","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0009185","Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide.","Murugadoss K","2026","Biology methods & protocols","nonrandomized_study","article","10.1093/biomethods/bpag048","42857675","PMC13651699",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009186","A case of type 2 diabetes with spinal and bulbar muscular atrophy treated with oral semaglutide while sparing muscle reduction for two years: a case report with literature review.","Nakano Y","2026","Diabetology international","case_report","article","10.1007/s13340-026-00882-w","41815887","PMC12972491",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009187","Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists.","Sharma RK","2025","Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","nonrandomized_study","article","10.1002/ohn.1209","40407186",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009188","Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.","Yale JF","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14468","34142429","PMC9291287",null,"S000084","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0009189","Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis.","Zhao Y","2025","Reproductive sciences (Thousand Oaks, Calif.)","systematic_review","article","10.1007/s43032-025-01788-9","39881036",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; article"],["R0009190","Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet.","Zhao L","2022","Frontiers in nutrition","preclinical","article","10.3389/fnut.2022.1048693","36643973","PMC9835552",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009191","Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis.","Huang YL","2023","BMC cardiovascular disorders","systematic_review","article","10.1186/s12872-023-03324-6","37296380","PMC10251583",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; research-article; Preprint; preprint; review"],["R0009192","Evolving medicolegal liability patterns in GLP-1 receptor agonist prescribing.","Barnawi G","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.06.018","42264371",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009193","Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern.","Koufakis T","2026","Advances in therapy","commentary","article","10.1007/s12325-026-03804-z","42804080",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009194","Cardiovascular disease management in Australian adults with type 2 diabetes: insights from the CAPTURE study.","Davis TME","2023","Internal medicine journal","other","article","10.1111/imj.15929","36112472",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009195","The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.","Tornea DA","2026","Pharmaceutics","systematic_review","article","10.3390/pharmaceutics18010086","41599194","PMC12844962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0009196","Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register.","Eliasson B","2023","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwac308","36567502",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009197","Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.","Ussher JR","2023","Nature reviews. Cardiology","other_trial","article","10.1038/s41569-023-00849-3","36977782",null,null,"S002418","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0009198","Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.","Massy M","2025","BMC medicine","nonrandomized_study","article","10.1186/s12916-025-04031-z","40189538","PMC11974072",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009199","The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma.","Lehman C","2025","Exploration of asthma & allergy","other","article","10.37349/eaa.2025.100967","40474934","PMC12140623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009200","Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.","Di Dalmazi G","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.892702","35909534","PMC9335857",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009201","Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study).","Tsuriya D","2025","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70066","40331745","PMC12209503",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009202","Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.","Nicholls SJ","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2505928","41406444",null,"ClinicalTrials.gov:NCT04255433","S001989; S002212","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; article"],["R0009203","Summary for Patients: Continuing Use of GLP-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes.",null,"2026","Annals of internal medicine","other","article","10.7326/annals-25-04820-ps","42258824",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009204","Obesity, sleep apnea and cancer revisited.","Sánchez-de-la-Torre M","2026","International journal of obesity (2005)","narrative_review","article","10.1038/s41366-026-02230-z","42823495",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009205","Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China.","McEwan P","2023","The European journal of health economics : HEPAC : health economics in prevention and care","other","article","10.1007/s10198-022-01470-w","35526173","PMC9080344",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009206","CGM-derived postprandial glucose with IcoSema versus other insulin regimens: a post hoc analysis of COMBINE 1 and 3.","De Block C","2026","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2026.103985","42306490","PMC13266221","ClinicalTrials.gov:NCT05352815; ClinicalTrials.gov:NCT05013229","S000458; S001633","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0009207","The impact of oral semaglutide on glycemic control and weight reduction: a database analysis of dosing effects in Japanese individuals with type 2 diabetes.","Ishiguro M","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1615516","40933382","PMC12417148",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009208","GLP-1 receptor agonists modulate blood glucose levels in T2DM by affecting Faecalibacterium prausnitzii abundance in the intestine.","Liang L","2023","Medicine","other","article","10.1097/md.0000000000034978","37657059","PMC10476738",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009209","GLP-1 Receptor Agonists in Orthopedic Surgery: Friend or Foe?","Cornell CN","2026","HSS journal : the musculoskeletal journal of Hospital for Special Surgery","commentary","article","10.1177/15563316261451263","42147421","PMC13179288",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009210","The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.","Retnakaran R","2023","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-023-01781-z","36894921","PMC9998007","ClinicalTrials.gov:NCT02194595","S000693","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009211","The effects of SGLT2 inhibitors and GLP-1 receptor agonists on the triglyceride to HDL cholesterol ratio and the triglyceride-glucose index in patients with type 2 diabetes.","Voziki D","2025","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2025.109044","40253725",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009212","The Role of GLP-1 Agonists in Esthetic Medicine: Exploring the Impact of Semaglutide on Body Contouring and Skin Health.","Haykal D","2025","Journal of cosmetic dermatology","narrative_review","article","10.1111/jocd.16716","39645647","PMC11845967",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article-commentary; article"],["R0009213","Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.","Liu F","2021","Journal of diabetes investigation","other_trial","article","10.1111/jdi.13504","33475222","PMC8354505",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0009214","Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post-authorization safety study.","Fazeli Farsani S","2024","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.5800","38719731",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; Comparative Study; article"],["R0009215","Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic Review.","Olaniyi AO","2026","Cureus","systematic_review","article","10.7759/cureus.114962","42769739","PMC13591238",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0009216","Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.","Zhang Y","2022","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-022-01676-5","36335326","PMC9637313",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; Preprint; research-article; other; preprint; article"],["R0009217","Poster Session I - A159 IMPACT OF GLP-1 RECEPTOR AGONISTS ON BOWEL PREPARATION QUALITY IN PATIENTS UNDERGOING ELECTIVE COLONOSCOPY",null,"2026","Journal of the Canadian Association of Gastroenterology","other","article",null,null,"PMC12901539",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0009218","Mechanotransduction of Collagen Biostimulators: Comparative Signaling and Implications for GLP‐1 RA–Associated Facial Aging","Cho C","2026","Journal of cosmetic dermatology","narrative_review","article",null,null,"PMC13438120",null,null,"europepmc","TRUE",null,null,null,"review-article; Review; Journal Article"],["R0009219","Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity.","Babenko AY","2019","Journal of diabetes research","other","article","10.1155/2019/1365162","30944827","PMC6421820",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009220","Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan-A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform.","Sato A","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13175107","39274317","PMC11396164","ClinicalTrials.gov:NCT06278207","S002414","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009221","Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.","Ciardullo S","2024","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.3791","38549238",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009222","68 Ga-Exendin-4 PET/CT Enables Identification of Multiple and Ectopic Insulinoma in a Patient With Multiple Endocrine Neoplasia 1.","Zhang H","2025","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000006032","40523237",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0009223","HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity.","Mohanan PP","2023","Indian heart journal","narrative_review","article","10.1016/j.ihj.2022.11.010","36435205","PMC9986737",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009224","Semaglutide injection for the treatment of adults with type 2 diabetes.","Chudleigh RA","2020","Expert review of clinical pharmacology","other_trial","article","10.1080/17512433.2020.1776108","32476529",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0009225","Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease.","Jiang D","2025","International journal of clinical pharmacology and therapeutics","other","article","10.5414/cp204632","39790030",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009226","Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese ‎Individuals: A Narrative Review","Sallam M","2025","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202503.0430.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; review; preprint"],["R0009227","Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Gu S","2022","Journal of clinical medicine","systematic_review","article","10.3390/jcm11185435","36143082","PMC9504435",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0009228","Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.","Reed J","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15608","38680050",null,"ClinicalTrials.gov:NCT05523362",null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Clinical Trial; Research Support, Non-U.S. Gov't; article"],["R0009229","IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.","Hughes E","2016","Primary care diabetes","narrative_review","article","10.1016/j.pcd.2015.12.005","26776758",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0009230","Prescribing GLP-1 Receptor Agonists for Persons With Mental Disorders: Evidence-Based and Aspirational Targets.","McIntyre RS","2026","The Journal of clinical psychiatry","other","article","10.4088/jcp.26com16484","42247271",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009231","Drug utilisation study of antidiabetic medication during 2012-2019 in Romania.","Bucsa C","2021","International journal of clinical practice","nonrandomized_study","article","10.1111/ijcp.14770","34473890",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009232","Secondary diabetes mellitus in pheochromocytomas and paragangliomas.","Moustaki M","2023","Endocrine","narrative_review","article","10.1007/s12020-023-03492-7","37731140","PMC10618385",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009233","Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.","Boye KS","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13649","30714309","PMC6593714",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009234","Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.","Waldrop G","2018","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2016.08.018","29074120",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Systematic Review; review"],["R0009235","Semaglutide and pioglitazone restore airway mucosal homeostasis by resolving Pseudomonas aeruginosa pyocyanin-induced mucus hypersecretion, ciliostasis, and type 2 airway inflammation.","Wu C","2026","Frontiers in immunology","preclinical","article","10.3389/fimmu.2026.1877061","42769032","PMC13590329",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009236","Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.","Ambulkar KS","2025","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","nonrandomized_study","article","10.1055/a-2620-2931","40409292",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009237","Obesity and GLP-1.","Perez-Montes DE Oca A","2021","Minerva endocrinology","narrative_review","article","10.23736/s2724-6507.20.03369-6","33213122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009238","Timing of GLP-1RA exposure in real-world cardiovascular risk analyses.","Sarıoğlu G","2026","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","nonrandomized_study","article","10.1007/s44470-026-00188-3","42717185","PMC13558490",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0009239","Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis.","Avgerinos I","2019","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13484","30058208",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0009240","Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.","Tuttle KR","2023","Kidney international","other_trial","article","10.1016/j.kint.2022.12.028","36738891",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009241","Immortal Time Bias and the Association Between GLP-1R Agonist Use and Peripartum Cardiomyopathy Outcomes.","Wang J","2026","The Canadian journal of cardiology","commentary","article","10.1016/j.cjca.2026.01.056","41651215",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009242","Persistence of GLP-1 RA in combination with basal insulin among adults with type 2 diabetes in Canada.","Abitbol A","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.108920","34139288",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009243","The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era.","Lieberman DE","2026","JAMA","other","article","10.1001/jama.2026.5537","42081217",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009244","GLP-1 Receptor Agonist Therapy in Patients With Extragenital Lichen Sclerosus.","Prenner J","2026","JAMA dermatology","other","article","10.1001/jamadermatol.2026.0476","42054011",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009245","Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19: A Systematic Review and Network Meta-analysis.","Zhu Z","2022","JAMA network open","systematic_review","article","10.1001/jamanetworkopen.2022.44652","36472874","PMC9856231",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; research-article; article"],["R0009246","Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discovery.","Papadakos SP","2025","Expert opinion on drug discovery","narrative_review","article","10.1080/17460441.2025.2579124","41131939",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009247","Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm.","Marzolla V","2026","Reports (MDPI)","nonrandomized_study","article","10.3390/reports9010075","41893436","PMC13030616",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0009248","Deinsulinisation in type 2 Diabetes: Evidence-based strategies for safe treatment simplification \"Approaches to reducing insulin in type 2 diabetes\".","Giorda CB","2026","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2025.113056","41390000",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009249","Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling.","Huang L","2020","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00128.2020","32715762",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009250","Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease.","Chien CT","2014","Thrombosis and haemostasis","preclinical","article","10.1160/th14-03-0258","25030617",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009251","Severe Adverse Effects of Tirzepatide Overdose Requiring Intensive Care Unit Admission and Complex Rehabilitation.","Sharafeldin M","2025","Cureus","case_report","article","10.7759/cureus.98681","41368024","PMC12683422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009252","Peripheral neuropathic symptoms with GLP-1 receptor agonists: Insights from a large real-world cohort.","Cestari M","2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxag077","41824639",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; Comment; article"],["R0009253","Differentiating monogenic and syndromic obesities from polygenic obesity: Assessment, diagnosis, and management.","Fitch AK","2024","Obesity pillars","narrative_review","article","10.1016/j.obpill.2024.100110","38766314","PMC11101890",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009254","Response to: From Glycaemic Response to Clinical Trajectories: Extending Phenotyping in GLP-1RA-SGLT2 Inhibitor Combination Therapy.","Milluzzo A","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","commentary","article","10.1016/j.eprac.2026.09.012","42805391",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009255","Clarifying Analysis Inconsistencies in a Study of GLP-1RAs and Cardiovascular Outcomes in Nondiabetic Patients With Atherosclerotic Disease and Obesity.","Wang J","2026","The American journal of cardiology","commentary","article","10.1016/j.amjcard.2026.06.028","42437619",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009256","MON-701 A case which GLP 1 receptor agonist semaglutide enabled the management of both obesity and diabetes mellitus, suggesting the potential for diabetes remission",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544328",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0009257","IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target.","Bruns Vi N","2024","Pharmacological research","narrative_review","article","10.1016/j.phrs.2024.107312","39032839","PMC11467891",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0009258","Tirzepatide Versus Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes With Established Cardiovascular Disease: An Indirect Treatment Comparison Meta-Analysis.","Goldenberg RM","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70859","42115707",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; article"],["R0009259","Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.","Bajaj HS","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)00967-0","42250575",null,"ClinicalTrials.gov:NCT06354660","S001500","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0009260","Approach to the Patient: Youth-Onset Type 2 Diabetes.","Hitt TA","2023","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgad482","37584397",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009261","GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review.","Gholami M","2025","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-025-01604-w","40182581","PMC11961817",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0009262","Exosomal miR-450b-5p Secreted from Exendin-4-Stimulated Endothelial Cells Protects Retinal Ganglion Cells Against Ischemia Reperfusion Injury.","Sun Y","2025","International journal of nanomedicine","other","article","10.2147/ijn.s525339","41030574","PMC12478217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009263","Weight Recidivism After Bariatric Surgery: A Narrative Review.","Cao Q","2025","The American surgeon","narrative_review","article","10.1177/00031348251337161","40252043",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0009264","Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.","Foer D","2023","Journal of immunology (Baltimore, Md. : 1950)","nonrandomized_study","article","10.4049/jimmunol.2300102","37870292","PMC10842986",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0009265","The Pharmacokinetic Properties of Glucagon-like Peptide-1 Receptor Agonists and Their Mode and Mechanism of Action in Patients with Type 2 Diabetes.","Anderson J","2018","The Journal of family practice","narrative_review","article",null,"29912996",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0009266","Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.","Holliday MW","2024","Current opinion in nephrology and hypertension","randomized_trial","article","10.1097/mnh.0000000000000976","38411162","PMC11126299",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Review; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0009267","The inhibitor VB-87531 synergizes with tirzepatide and semaglutide for greater weight loss in DIO mice.","Corbalan JJ","2025","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2025.152360","40694906",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009268","Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post-transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation.","Lawrence SE","2023","Clinical transplantation","nonrandomized_study","article","10.1111/ctr.14922","36708369",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0009269","Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.","Scheen AJ","2022","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2022.101390","36170946",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0009270","GLP-1 physiology informs the pharmacotherapy of obesity.","Drucker DJ","2022","Molecular metabolism","nonrandomized_study","article","10.1016/j.molmet.2021.101351","34626851","PMC8859548",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0009271","Efficacy and Cardiovascular Safety of SGLT2 Inhibitors.","Fernandez CJ","2021","Current drug safety","narrative_review","article","10.2174/1574886315666201002154640","33006538",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009272","Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.","Nowak M","2022","Endokrynologia Polska","other_trial","article","10.5603/ep.a2022.0029","35593668",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0009273","The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.","Gonzalez-Rellan MJ","2026","Cell metabolism","preclinical","article","10.1016/j.cmet.2026.03.011","41985454",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009274","Editorial: Optimizing GLP-1 receptor agonist use: mechanisms, clinical applications, and safety profiles.","Rasineni K","2026","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2026.1887751","42367279","PMC13303595",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; editorial"],["R0009275","Comments on \"Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study\" by Bruno et al., 2026.","Abroumand Gholami A","2026","Aesthetic plastic surgery","commentary","article","10.1007/s00266-026-06121-6","42323759",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009276","GLP-1 agonists-induced autoimmune pancreatitis.","Mahajne J","2025","BMJ case reports","case_report","article","10.1136/bcr-2025-267811","40992778",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0009277","GLP-1 Receptor Agonists and Cancer-The Promise Is Real.","Wender RC","2026","JAMA network open","other","article","10.1001/jamanetworkopen.2026.12143","42113519",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009278","Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.","Østergaard L","2017","Expert review of clinical pharmacology","other_trial","article","10.1080/17512433.2017.1313109","28349716",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0009279","Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action.","Czupryniak L","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15789","39140231",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0009280","The Dipeptidyl Peptidase-4 Inhibitor Saxagliptin as a Candidate Treatment for Disorders of Consciousness: A Deep Learning and Retrospective Clinical Analysis.","Toker D","2025","Neurocritical care","nonrandomized_study","article","10.1007/s12028-025-02217-0","39904872","PMC12321933",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009281","Suicidality as a potential risk and therapeutic target during widespread GLP-1 receptor agonists use: implications of inflammation.","Borovcanin MM","2026","Frontiers in synaptic neuroscience","other","article","10.3389/fnsyn.2026.1869086","42325838","PMC13275439",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0009282","Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats.","Ono Y","2026","Hypertension research : official journal of the Japanese Society of Hypertension","preclinical","article","10.1038/s41440-026-02632-6","41992025",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009283","Patient perspectives on incretin-based weight loss medications and relationship with demographic factors.","McVay MA","2024","Obesity science & practice","other","article","10.1002/osp4.783","39109182","PMC11302371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0009284","Impact of antidiabetic agents on COPD exacerbations in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.","Shabil M","2026","Diabetes & vascular disease research","systematic_review","article","10.1177/14791641261487590","42821775",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; Review; review"],["R0009285","Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes.","Cipriani C","2023","Journal of clinical medicine","randomized_trial","article","10.3390/jcm12237260","38068310","PMC10707671",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0009286","Semaglutide (Wegovy) for MASH.",null,"2025","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2025.1739a","41060673",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009287","Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","Ji L","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00141-x","40555243",null,"ClinicalTrials.gov:NCT05813795","S001629","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0009288","Brachial Plexopathy Following Rapid Weight Loss from Tirzepatide: A Case Report.","Wen J","2026","Pain medicine case reports","case_report","article",null,"42263282",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009289","Interpreting Post-Discontinuation Trajectories After Semaglutide or Tirzepatide.","Sun M","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70710","41873004",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009290","Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.","Galasso M","2026","Journal of translational medicine","nonrandomized_study","article","10.1186/s12967-026-08558-4","42464302",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0009291","Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials.","Lim S","2020","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13850","31379119",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0009292","Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity.","Dong S","2026","Medicinal research reviews","randomized_trial","article","10.1002/med.70049","41923370",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0009293","Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance.","Hirota Y","2019","Endocrine","other","article","10.1007/s12020-018-1808-9","30406884",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009294","Opportunities and Risks of Integrating Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Heart Failure Management.","Davidson PM","2026","Heart, lung & circulation","commentary","article","10.1016/j.hlc.2026.05.004","42252146",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0009295","Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study.","Dzaye O","2022","Frontiers in cardiovascular medicine","other","article","10.3389/fcvm.2022.936651","35966558","PMC9372305",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009296","Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Treated with Metformin.","Wang Q","2025","Clinical pharmacokinetics","randomized_trial","article","10.1007/s40262-025-01569-2","40991141",null,"ClinicalTrials.gov:NCT04998032","S002121","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009297","A Single-dose, Two-Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects.","Feng S","2023","Clinical pharmacology in drug development","randomized_trial","article","10.1002/cpdd.1187","36648126",null,"ChiCTR:ChiCTR2100043348",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Equivalence Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009298","Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.","Xu J","2021","Journal of clinical pharmacy and therapeutics","systematic_review","article","10.1111/jcpt.13398","33675117",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0009299","Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis.","Zhou Z","2024","ESC heart failure","systematic_review","article","10.1002/ehf2.14726","38419382","PMC11098653",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Comparative Study; research-article; review"],["R0009300","SAT-291 Impact of the Incretin Mimetic Drug Tirzepatide on Obesity-Associated Breast Cancer Growth: Findings from a Preclinical Model",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12543766",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0009301","Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Karagiannis T","2015","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12541","26395850",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0009302","A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).","Ghosal S","2021","Scientific reports","systematic_review","article","10.1038/s41598-021-01663-y","34764398","PMC8586228","PROSPERO:CRD42021228824",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; Preprint; preprint; review"],["R0009303","Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.","Li W","2022","Journal of cardiovascular pharmacology","systematic_review","article","10.1097/fjc.0000000000001197","34935705",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0009304","The GLP-1 Receptor Agonist Paradox in Dermatology: Why We Cannot Afford the Knowledge Gap.","Awadalla R","2026","International journal of dermatology","randomized_trial","article","10.1111/ijd.70348","41736171","PMC13238367",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article-commentary; article"],["R0009305","Oral versus injectable GLP-1 receptor agonists in clinical practice!","Curovic VR","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other","article","10.1093/ndt/gfag101","42089458",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009306","Gravity as a key player for the preservation of muscle mass and function in the era of anti-obesity therapies?","Boirie Y","2026","Clinical nutrition ESPEN","narrative_review","article","10.1016/j.clnesp.2026.103278","41956156",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009307","Hyperglycemia promotes maladaptive Dectin-1 signaling and impairs skin antifungal host defense.","Reyna DE","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.02.11.705431","41726973","PMC12918998",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0009308","The critical role of GLP-1 signaling pathways in the pathology of Parkinson's disease and diabetes.","Chen J","2025","Pathology, research and practice","narrative_review","article","10.1016/j.prp.2025.155985","40279852",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009309","GLP-1 Receptor Agonists and NAION: A Risk Worth Taking?","Grossman SN","2026","Neurology","commentary","article","10.1212/wnl.0000000000218088","42060885",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0009310","Proteomics of Mouse Heart Ventricles Reveals Mitochondria and Metabolism as Major Targets of a Post-Infarction Short-Acting GLP1Ra-Therapy.","de Freitas Germano J","2021","International journal of molecular sciences","preclinical","article","10.3390/ijms22168711","34445425","PMC8395861",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009311","Comparison of Exendin-4 and Its Single Amino Acid Substitutions as Parent Peptides for GLP-1 Receptor Imaging Probes.","Kondo N","2025","Molecules (Basel, Switzerland)","preclinical","article","10.3390/molecules30051011","40076236","PMC11901735",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0009312","Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease.","Domingues I","2024","Drug delivery and translational research","preclinical","article","10.1007/s13346-024-01576-z","38615156","PMC11385015",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009313","Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.","Fadini GP","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13747","30985052","PMC6767088",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Evaluation Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0009314","In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y.","Karagiannis T","2026","Annals of internal medicine","commentary","article","10.7326/annals-26-00991-jc","42081805",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0009315","From Satiety to Substance Use: Neural Mechanisms of Glucagon-Like Peptide-1 Signaling in Appetite and Reward.","Baumer-Harrison C","2026","Biological psychiatry","narrative_review","article","10.1016/j.biopsych.2026.06.015","42349741",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009316","Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain.","Diz-Chaves Y","2024","Neural regeneration research","narrative_review","article","10.4103/1673-5374.389626","38103230","PMC10960307",null,"S002208","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0009317","Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity.","Soni H","2016","Medical hypotheses","preclinical","article","10.1016/j.mehy.2016.08.005","27692167",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009318","Exogenous oral application of PYY and exendin-4 impacts upon taste-related behavior and taste perception in wild-type mice.","Iyer S","2025","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2025.110408","40086622","PMC12042652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0009319","Acute liver injury associated with tirzepatide: An unexpected adverse event warranting clinical attention.","Alqarni B","2026","Annales d'endocrinologie","case_report","article","10.1016/j.ando.2026.102485","41519257",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009320","Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.","Du Y","2022","Primary care diabetes","systematic_review","article","10.1016/j.pcd.2021.12.007","34930687",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0009321","Glucagon-Like Peptide-1 Agonist Exendin-4 Facilitates the Extinction of Cocaine-Induced Condition Place Preference.","Zhu C","2021","Frontiers in systems neuroscience","preclinical","article","10.3389/fnsys.2021.711750","35024034","PMC8744468",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009322","Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1).","Lee CJ","2023","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvad056","37153701","PMC10157777",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0009323","Are GLP-1 receptor agonists a 'magic bullet' for cancer?","Hebert JR","2026","Nature reviews. Cancer","other","article","10.1038/s41568-025-00874-z","40931125","PMC13291921",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009324","Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.","Heile M","2018","Journal of managed care & specialty pharmacy","other_trial","article","10.18553/jmcp.2018.24.9-a.s42","30156446","PMC10408396",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0009325","Multinational Patterns of Second-line Anti-hyperglycemic Drug Initiation Across Cardiovascular Risk Groups: A Federated Pharmacoepidemiologic Evaluation in LEGEND-T2DM","Khera R","2022","medRxiv","nonrandomized_study","preprint","10.1101/2022.12.27.22283968",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0009326","GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction.","Verma S","2025","Cell metabolism","other_trial","article","10.1016/j.cmet.2025.05.001","40466625",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0009327","Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype.","Jagomäe T","2021","Cells","preclinical","article","10.3390/cells10113193","34831417","PMC8623088",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; preprint; article"],["R0009328","GLP-1 Receptor Agonists and Upper Endoscopy: Guidance for Periprocedural Management.","Khan R","2026","Gastroenterology","other","article","10.1053/j.gastro.2026.04.031","42092595",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009329","Novel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review.","Valencia-Morales ND","2023","Life (Basel, Switzerland)","narrative_review","article","10.3390/life13061265","37374048","PMC10304316",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009330","Safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of the novel oral bofanglutide in healthy Chinese participants.","Hao X","2026","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2026.113437","42442555",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0009331","Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports.","Ouellette S","2023","Journal of drugs in dermatology : JDD","case_report","article","10.36849/jdd.6550","37026881",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009332","Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.","Kelly M","2022","Pharmacotherapy","systematic_review","article","10.1002/phar.2737","36271706","PMC10099849","PROSPERO:CRD42022320157",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review-article; review"],["R0009333","Why do patients with obesity discontinue glucagon-like peptide 1 analogues?","Almohaileb FI","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16531","40521761","PMC12326882",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0009334","Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy.","Nagai Y","2019","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.1585-18","30568127","PMC6478970",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009335","Semaglutide and Alcohol use Disorder: Breaking Free of Addiction?","Papaetis GS","2026","Current pharmaceutical design","other","article","10.2174/0113816128443199260115135518","41937527",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009336","Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison.","Kelsey MD","2022","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2022.02.046","35512864","PMC8972581",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Review; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; abstract"],["R0009337","Long-Term Activation of Glucagon-like peptide-1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes.","Xie S","2022","Journal of the American Heart Association","preclinical","article","10.1161/jaha.122.026728","36172969","PMC9673690",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009338","Impact of CVOTs in primary and secondary prevention of kidney disease.","De Cosmo S","2019","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2019.107907","31676332",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0009339","Real-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk.","Mariscal Vázquez S","2026","Revista clinica espanola","nonrandomized_study","article","10.1016/j.rceng.2026.502562","42061608",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0009340","A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.","Jiang H","2022","Nature communications","randomized_trial","article","10.1038/s41467-022-31328-x","35750681","PMC9232612","ClinicalTrials.gov:NCT04466904","S002331","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0009341","Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update.","Vandemark C","2023","Molecules (Basel, Switzerland)","narrative_review","article","10.3390/molecules28031369","36771035","PMC9921762",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009342","Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.","Boye KS","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-023-01457-7","37668888","PMC10570229","ClinicalTrials.gov:NCT03954834; ClinicalTrials.gov:NCT03987919; ClinicalTrials.gov:NCT03882970; ClinicalTrials.gov:NCT03730662; ClinicalTrials.gov:NCT04039503","S000095; S000407; S001287; S001591; S001608","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0009343","Incretin-based therapies for liver disease.","Kotsiliti E","2024","Nature reviews. Gastroenterology & hepatology","other","article","10.1038/s41575-024-00961-w","38977817",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009344","Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection.","Tentolouris A","2026","Primary care diabetes","randomized_trial","article","10.1016/j.pcd.2026.01.003","41565568",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0009345","GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.","Musa EYA","2026","BMC cardiovascular disorders","systematic_review","article","10.1186/s12872-026-05808-7","41906074","PMC13154893","PROSPERO:CRD420251237462",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0009346","Efficacy and Cardiovascular Safety of Thiazolidinediones.","Raveendran AV","2021","Current drug safety","narrative_review","article","10.2174/1574886315666201026125530","33106148",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009347","Metabolic Impact of Frailty Changes Diabetes Trajectory.","Sinclair AJ","2023","Metabolites","narrative_review","article","10.3390/metabo13020295","36837914","PMC9960364",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009348","Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.","Koceva A","2025","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2025.102038","41015723",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009349","Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System.","Makunts T","2023","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2023.11.19.23298750","38045343","PMC10690345",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Preprint; Journal Article; Comment; preprint"],["R0009350","GLP-1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study.","Ma EJ","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","randomized_trial","article","10.1111/jdv.70376","41785915","PMC13425446",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0009351","ONE MONTH WEIGHT LOSS PREDICTS THE EFFICACY OF LIRAGLUTIDE IN OBESE PATIENTS: DATA FROM A SINGLE CENTER.","Maccora C","2020","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep-2019-0169","31682516",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009352","Comment on: The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study.","Chen G","2026","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","nonrandomized_study","article","10.1007/s00198-026-08070-x","42201386",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; letter"],["R0009353","Uncovering CNS access of lipidated exendin-4 analogues by quantitative whole-brain 3D light sheet imaging.","Skovbjerg G","2023","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2023.109637","37391028",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009354","Disparities in Adolescent and Young Adult Obesity Medication Dispensing: A Retrospective Linked EHR-Pharmacy Cohort, 2020-2025.","Granados I","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70128","41612871","PMC13540985",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009355","Semaglutide Inhibits Osteoblast Ferroptosis Induced by Diabetic Periodontitis via Modulating the Wnt5a/Ror2/p38 MAPK Signaling Pathway.","Zhang Z","2026","Drug design, development and therapy","preclinical","article","10.2147/dddt.s599539","42206237","PMC13209148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009356","The role of dulaglutide in the treatment of alcohol use disorder: a case report.","Hill O","2025","Frontiers in psychiatry","case_report","article","10.3389/fpsyt.2025.1420316","40375882","PMC12078295",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009357","Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Early Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression","Ahmed A","2023","Qeios","nonrandomized_study","preprint","10.32388/g6uisp.2",null,null,"ClinicalTrials.gov:NCT06057077","S001485","europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0009358","GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.","Divino V","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-019-0615-5","31028689","PMC6531601",null,"S002638","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0009359","The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists.","Mahoon DA","2026","International journal of molecular sciences","systematic_review","article","10.3390/ijms27093967","42123553","PMC13163320",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0009360","Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review.","Ruan Z","2022","Expert review of pharmacoeconomics & outcomes research","systematic_review","article","10.1080/14737167.2022.2042255","35152812",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0009361","Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.","Alfayez OM","2019","Canadian journal of diabetes","systematic_review","article","10.1016/j.jcjd.2019.04.003","31175007",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Review; review"],["R0009362","Elective semaglutide prescription enabled waitlisting and transplantation of otherwise ineligible obese renal transplant candidates.","Navaux E","2025","Frontiers in transplantation","other","article","10.3389/frtra.2025.1623096","41234778","PMC12606581",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0009363","Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications.","Staszewsky L","2022","BMJ open diabetes research & care","systematic_review","article","10.1136/bmjdrc-2021-002708","35351688","PMC8966566",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0009364","Exploring the aetiology of pre-motor Parkinson's disease and the efficacy of potential neuroprotective therapies","Sancandi M","2021","University College London (University of London)","preclinical","article",null,null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Dissertation; dissertation"],["R0009365","Priorities and practicalities of prescribing diabetes medicines with cardiovascular and renal protective effects: an Australian perspective.","Hitchen SA","2020","Internal medicine journal","other","article","10.1111/imj.15055","33215837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009366","Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment.","Zhang Y","2026","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2026.115167","42349668",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009367","Cardiorenal outcomes of tirzepatide versus semaglutide in adults with type 2 diabetes and chronic kidney disease: a target trial emulation in the TriNetX Global Collaborative Network","Chiang P","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-9573853/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0009368","Risk of postoperative respiratory complications in adults treated with GLP-1 receptor agonists: a propensity-matched population-based study.","Talmy T","2026","British journal of anaesthesia","nonrandomized_study","article","10.1016/j.bja.2026.04.051","42215372",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0009369","Controlled Release of Pyrimidine Compound Using Polymeric Coated ZIF-8 Metal-Organic Framework as Glucagon-Like Peptide-1 Receptor Agonist Carrier.","AlNeyadi SS","2020","Molecules (Basel, Switzerland)","other","article","10.3390/molecules25184313","32962260","PMC7570959",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009370","Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.","Russell S","2013","International journal of clinical pharmacy","nonrandomized_study","article","10.1007/s11096-012-9729-9","23263796",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0009371","Newer GLP-1 receptor agonists and obesity-diabetes.","Brown E","2018","Peptides","narrative_review","article","10.1016/j.peptides.2017.12.009","29412833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009372","Semaglutide ameliorates traumatic sepsis-induced cardiac injury by activating the March5-ACSL4 axis to suppress ferroptosis.","Sun B","2026","Free radical biology & medicine","preclinical","article","10.1016/j.freeradbiomed.2026.08.002","42542232",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009373","GLP-1 Receptor Agonist Use and Long-Term Outcomes in Hypertrophic Cardiomyopathy With Obstructive Sleep Apnea: A Real-World Cohort Analysis.","Shah S","2026","JACC. Advances","nonrandomized_study","article","10.1016/j.jacadv.2026.102955","42663372",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0009374","GLP-1 Receptor Agonists, Gestational Weight Gain, and Pregnancy Outcomes.","Boujenah J","2026","JAMA","nonrandomized_study","article","10.1001/jama.2026.2648","42008281",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009375","GLP-1 Receptor Agonists, Gestational Weight Gain, and Pregnancy Outcomes.","Hnid K","2026","JAMA","other","article","10.1001/jama.2026.2651","42008263",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009376","Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.","Saxena AR","2021","Nature medicine","randomized_trial","article","10.1038/s41591-021-01391-w","34127852",null,"ClinicalTrials.gov:NCT03538743","S001420","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009377","AlfaDAX-Derived ActRIIA/B Antibody with Semaglutide Enhances Fat Loss and Improves Weight-Loss Quality in DIO Mice","Zhang N","2026","bioRxiv","preclinical","preprint","10.64898/2026.07.09.737400",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0009378","Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia.","Alluhidan M","2023","Journal of medical economics","other","article","10.1080/13696998.2023.2277056","37933169",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009379","Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.","Himmerich H","2024","CNS drugs","narrative_review","article","10.1007/s40263-024-01111-1","39096466",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0009380","Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.","He L","2022","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj-2021-068882","35764326","PMC9237836","PROSPERO:CRD42021271647",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; research-article; review"],["R0009381","GLP-1 Agonist As Adjunct To Antidepressants In Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.","Saad A",null,"European psychiatry : the journal of the Association of European Psychiatrists","randomized_trial","article",null,null,"PMC13443858",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0009382","Acanthosis nigricans independently predicts hepatic fibrosis in people with type 2 diabetes in North India.","Dutta K","2024","Primary care diabetes","other","article","10.1016/j.pcd.2024.01.003","38245384",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0009383","Prevalence of GLP-1 Receptor Agonist Use Among Privately Insured Individuals With Mood Disorders.","Breitzig MT","2026","The Journal of clinical psychiatry","other","article","10.4088/jcp.26br16352","42247272",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009384","Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.","Galindo RJ","2026","Journal of endocrinological investigation","other","article","10.1007/s40618-026-02895-3","42002673","PMC13451520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009385","GLP-1 receptor agonists as adjunct therapy in hidradenitis suppurativa: A hypothesis.","Feily A","2026","International journal of clinical pharmacology and therapeutics","other","article","10.5414/cp204935","41582649",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009386","Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases.","Hölscher C","2022","Frontiers in synaptic neuroscience","narrative_review","article","10.3389/fnsyn.2022.955258","35965783","PMC9363704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009387","Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.","López-Cano C","2022","Diabetes","randomized_trial","article","10.2337/db21-0688","34737187",null,"ClinicalTrials.gov:NCT02889510","S000332","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009388","Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.","Horowitz M","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12872","28058769","PMC5412849",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0009389","Lessons Learned From a Patient-Centered, Team-Based Intervention for Patients With Type 2 Diabetes at High Cardiovascular Risk: Year 1 Results From the CINEMA Program.","Neeland IJ","2022","Journal of the American Heart Association","other","article","10.1161/jaha.120.024482","35904203","PMC9375496",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009390","Prevalence of Obesity and Related Conditions and GLP-1 Use in Medicare Fee-for-Service Beneficiaries.","Kim S","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71033","42348175","PMC13449082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009391","Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study.","Volpe S","2022","Nutrients","other","article","10.3390/nu14122414","35745144","PMC9227575",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009392","Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis.","Song Y","2021","International journal of molecular sciences","preclinical","article","10.3390/ijms23010437","35008865","PMC8745294",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009393","Obesity and its management in primary care setting.","Ibrahim M","2025","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2025.109045","40305970","PMC12233002",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; research-article"],["R0009394","Exendin-4 attenuates pain-induced cognitive impairment by alleviating hippocampal neuroinflammation in a rat model of spinal nerve ligation.","Cui SS","2020","Neural regeneration research","preclinical","article","10.4103/1673-5374.272620","31960821","PMC7047783",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009395","GLP-1 Receptor Agonists and Eating Disorders - Cause for Concern.","Banks A","2026","The New England journal of medicine","other","article","10.1056/nejmp2600300","42041223",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009396","Development of a sensitive LC-MS/MS assay to support human microdose study for an oral agonist of the GLP-1 receptor.","Kadar EP","2024","Bioanalysis","other","article","10.1080/17576180.2024.2349421","39088035","PMC11299791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009397","Injectable combination therapies for the management of diabetes: an Indian perspective.","Dutta D","2020","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1080/17425255.2020.1735351","32098522",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009398","Tirzepatide attenuates doxorubicin-induced cardiotoxicity via mitochondrial function improvement.","Li Z","2026","Translational cancer research","preclinical","article","10.21037/tcr-2025-1-2801","42180982","PMC13190704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009399","Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials.","Ussher JR","2022","Diabetes","narrative_review","article","10.2337/dbi20-0049","35050311","PMC8914293",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; discussion; article"],["R0009400","Psychotropic Drug-Related Weight Gain and Its Treatment.","McIntyre RS","2024","The American journal of psychiatry","narrative_review","article","10.1176/appi.ajp.20230922","38161305",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0009401","Letter to the Editor from Bhaduri et al.: \"GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia\".","Cannarella R","2026","Endocrine","commentary","article","10.1007/s12020-026-04682-9","42228018",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0009402","Insulin resistance as a driver of neuroinflammation and oxidative stress in Alzheimer's disease: Mechanistic links and therapeutic approaches.","Hajeforoosh P","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2026.119760","42561602",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009403","Influence of Trp-Cage on the Function and Stability of GLP-1R Agonist Exenatide Derivatives.","Horváth D","2024","Journal of medicinal chemistry","other","article","10.1021/acs.jmedchem.4c01553","39254428","PMC11440607",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009404","Liraglutide innovations: a comprehensive review of patents (2014-2024).","Pandey A","2024","Pharmaceutical patent analyst","narrative_review","article","10.1080/20468954.2024.2366693","39316579","PMC11449036",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009405","Corrigendum to 'Breast implant explantation with mastopexy in patients using GLP-1 receptor agonists: A retrospective comparative analysis' [J Plast, Reconstr & Aesthet Surg 111 (2025) 76-85].","Friedman O","2026","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","notice","article","10.1016/j.bjps.2026.07.005","42419169",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0009406","Beyond Weight Loss: Comparative Effects of Tirzepatide Plus Low-Energy Ketogenic Versus Low-Calorie Diet on Hepatic Steatosis and Stiffness in MASLD.","Schiavo L","2025","Nutrients","other_trial","article","10.3390/nu17152409","40805994","PMC12348380",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Controlled Clinical Trial; Journal Article; research-article; article"],["R0009407","Activation of the Vascular Smooth Muscle GLP-1/NCX1 Pathway Regulates Cytoplasmic Ca2+ Homeostasis and Improves Blood Pressure Variability in Hypertension.","Xu Y","2023","Gerontology","preclinical","article","10.1159/000527675","36882028",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009408","Are Women Living With Obesity More Responsive to GLP-1 Receptor Agonists? A Potential Signal From Trial-Level and Within-Trial Analyses.","Monami M","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70956","42244476",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0009409","Trends in add-on medications following metformin monotherapy for type 2 diabetes.","Swart EC","2022","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2022.28.11.1253","36282929","PMC10373027",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009410","Incretin Analogs for Weight Management in Adults Without Diabetes.","Lobkovich A","2024","The Annals of pharmacotherapy","randomized_trial","article","10.1177/10600280231190089","37522468",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0009411","Exploring the off-label use of liraglutide in the treatment of obesity: a review.","Braga CBA","2026","Molecular and cellular biochemistry","nonrandomized_study","article","10.1007/s11010-026-05560-8","42060040",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0009412","GLP-1 receptor agonists are a transformative prehabilitation tool for weight loss in obese patients undergoing elective hernia repair.","Spurzem GJ","2025","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-024-11308-6","39369100","PMC11666797",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009413","Comparative Effectiveness of Liraglutide versus Dulaglutide in Asian Patients with Type 2 Diabetes: A Retrospective Study","Dai J","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-4920008/v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0009414","Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.","Davies MJ","2022","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-022-01575-9","35927730","PMC9351217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0009415","14-3-3-zeta mediates GLP-1 receptor agonist action to alter α cell proglucagon processing.","Holter MM","2022","Science advances","preclinical","article","10.1126/sciadv.abn3773","35867787","PMC9307243",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009416","The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy.","Pang B","2018","Peptides","narrative_review","article","10.1016/j.peptides.2017.08.003","28807775",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009417","Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.","Aronne LJ","2026","The American journal of medicine","other_trial","article","10.1016/j.amjmed.2026.03.010","41865857",null,"ClinicalTrials.gov:NCT05822830","S000093","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0009418","GLP-1/GLP-1R Signaling Regulates Ovarian PCOS-Associated Granulosa Cells Proliferation and Antiapoptosis by Modification of Forkhead Box Protein O1 Phosphorylation Sites.","Sun Z","2020","International journal of endocrinology","preclinical","article","10.1155/2020/1484321","32655632","PMC7321515",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009419","GLP-1 Receptor Agonists, Gestational Weight Gain, and Pregnancy Outcomes-Reply.","Maya J","2026","JAMA","other","article","10.1001/jama.2026.2654","42008261",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009420","Obesity-related glomerulopathy: Current approaches and future perspectives.","Martínez-Montoro JI","2022","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.13450","35362662","PMC9286698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0009421","Oppositely biased glucagon-like peptide-1 receptor agonism does not differentially affect lipid metabolism in APOE*3-Leiden CETP mice.","Modder M","2025","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.16374","40176480","PMC12046449",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009422","Exendin-4 intervention attenuates atherosclerosis severity by modulating myeloid-derived suppressor cells and inflammatory cytokines in ApoE-/- mice.","Fu M","2024","International immunopharmacology","preclinical","article","10.1016/j.intimp.2024.112844","39094363",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009423","A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.","Zhang Z","2023","Parkinson's disease","other_trial","article","10.1155/2023/7427136","37791037","PMC10545468",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0009424","An Atypical Presentation of Dulaglutide-Induced Pancreatitis Complicated by Superior Mesenteric Vein Thrombosis.","Manuel SL","2023","Cureus","case_report","article","10.7759/cureus.50051","38186519","PMC10768942",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009425","Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.","Blonde L","2019","Advances in therapy","other_trial","article","10.1007/s12325-019-01033-1","31359368","PMC6822975","ClinicalTrials.gov:NCT02058160","S001409","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0009426","Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors.","Lin DS","2021","Diabetologia","randomized_trial","article","10.1007/s00125-021-05497-1","34195865",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0009427","GLP-1 receptor agonists and heart failure: insights from human genetics.","Emanuelsson F","2026","European heart journal","commentary","article","10.1093/eurheartj/ehaf1058","41609561",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0009428","The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review.","Scheen AJ","2023","Expert review of endocrinology & metabolism","narrative_review","article","10.1080/17446651.2023.2210673","37154218",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0009429","Incretins beyond type 2 diabetes.","Mathieu C","2023","Diabetologia","randomized_trial","article","10.1007/s00125-023-05980-x","37552238",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Review"],["R0009430","Use of second-generation incretin analogs (GLP-1 and GIP receptor agonists) in type 1 diabetes and latent autoimmune diabetes in adults: A systematic review.","Horne MP","2026","Journal of the American Association of Nurse Practitioners","systematic_review","article","10.1097/jxx.0000000000001303","42250233",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0009431","A Fluorescent Probe-Based Platform for Precise Pharmaceutical Analysis and Quality Assessment of Tirzepatide.","Al-Refaey SM","2026","Luminescence : the journal of biological and chemical luminescence","other","article","10.1002/bio.70442","41649304",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009432","Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study.","Cai X","2024","The Lancet regional health. Western Pacific","randomized_trial","article","10.1016/j.lanwpc.2024.101197","39430684","PMC11488426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0009433","Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).","Morales J","2015","Advances in therapy","narrative_review","article","10.1007/s12325-015-0208-2","25962992","PMC4449377",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0009434","Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis.","Ryan PM","2021","The Journal of pediatrics","systematic_review","article","10.1016/j.jpeds.2021.05.009","33984333",null,"PROSPERO:CRD42020195869",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0009435","Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus.","He X","2024","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2024.1483792","39902077","PMC11788294",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009436","Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study.","Galasso M","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1855886","42518535","PMC13381489",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0009437","Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.","Lin L","2022","The Journal of dermatological treatment","randomized_trial","article","10.1080/09546634.2020.1826392","32962477",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0009438","Letter to the Editor regarding \"The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study\".","Zhang Y","2026","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","nonrandomized_study","article","10.1007/s00198-026-08068-5","42201384",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0009439","Letter to \"Perioperative GLP-1 Receptor Agonist Use Is Associated With Reduced Revisions and Complications Following ACDF: A Propensity-Matched Analysis\".","Zhou Y","2026","Global spine journal","nonrandomized_study","article","10.1177/21925682261431790","41786644","PMC12965889",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0009440","Semaglutide Ameliorates Neuroinflammation Caused by Enterogenous Pyrogen in APP/PS1 Mice","Yuan Y","2025","Research Square","preclinical","preprint","10.21203/rs.3.rs-6098406/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009441","Emerging therapies for diabetic kidney disease: beyond SGLT2 inhibitors.","Ni H","2026","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2026.2723583","42638087",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0009442","Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.","Angelidi AM","2023","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2022.155346","36375643",null,"ClinicalTrials.gov:NCT03851874; ClinicalTrials.gov:NCT01562678; ClinicalTrials.gov:NCT02944500","S001397; S001466","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009443","Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.","Thompson AM","2015","The Annals of pharmacotherapy","narrative_review","article","10.1177/1060028014564180","25565404",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009444","GLP-1 receptor agonists in NAFLD.","Petit JM","2017","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(17)30070-8","28431668",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009445","Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist.","Gentinetta S","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","commentary","article","10.2147/dmso.s494919","39722834","PMC11668918",null,"S002529","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; article-commentary; article"],["R0009446","Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.","Tsapas A","2020","Annals of internal medicine","systematic_review","article","10.7326/m20-0864","32598218",null,"PROSPERO:CRD42019122043",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; article"],["R0009447","Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.","Torekov SS","2018","Cardiovascular research","other","article","10.1093/cvr/cvy124","30052921",null,null,"S000371","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; article"],["R0009448","Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients.","Coleman CI","2019","Journal of comparative effectiveness research","nonrandomized_study","article","10.2217/cer-2019-0002","31167554",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0009449","Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6.","Hammerman A","2022","Postgraduate medicine","other","article","10.1080/00325481.2022.2090794","35701876",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009450","Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.","Pineda ED","2020","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2020.26.5.610","32347181","PMC10391160",null,"S002638","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009451","Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort-the DIABET-IC study.","Gonzalez-Manzanares R","2024","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-024-02358-0","39014420","PMC11253346",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0009452","The change of Testosterone after weight intervention in obese men","Ghelani D","2022","Authorea Preprints","other","preprint","10.22541/au.166490958.88965013/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009453","Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform.","Ciaffi J","2026","Rheumatology (Oxford, England)","nonrandomized_study","article","10.1093/rheumatology/keag350","42384173",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; Comment; letter"],["R0009454","Inter-relationships between gastric emptying and glycaemia: Implications for clinical practice.","Arunachala Murthy T","2023","World journal of diabetes","narrative_review","article","10.4239/wjd.v14.i5.447","37273253","PMC10236995",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009455","Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.","Zhang J","2022","International journal of clinical practice","randomized_trial","article","10.1155/2022/7128859","37214201","PMC10199797","ChiCTR:ChiCTR-1800015658",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0009456","Clinical Trials in Prader-Willi Syndrome: A Review.","Mahmoud R","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms24032150","36768472","PMC9916985",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009457","Liraglutide improves cognitive function by reducing amyloid-beta peptide accumulation and inhibiting inflammation in 5 × FAD mice.","Qi L","2026","The journals of gerontology. Series A, Biological sciences and medical sciences","preclinical","article","10.1093/gerona/glaf265","41349262",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009458","Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.","Rosenstock J","2019","Diabetes care","randomized_trial","article","10.2337/dc18-2648","31320446",null,"ClinicalTrials.gov:NCT02057172","S001626","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009459","GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.","Murugadoss K","2026","Biology methods & protocols","randomized_trial","article","10.1093/biomethods/bpag043","42602880","PMC13475380",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0009460","The GLP-1 Receptor Agonist Liraglutide Decreases Primary Bile Acids and Serotonin in the Colon Independently of Feeding in Mice.","Nonogaki K","2024","International journal of molecular sciences","preclinical","article","10.3390/ijms25147784","39063026","PMC11277076",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0009461","Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review.","Monney M","2025","Endocrine connections","narrative_review","article","10.1530/ec-24-0529","40066975","PMC11949528",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0009462","Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.","Shubrook JH","2022","Advances in therapy","other","article","10.1007/s12325-022-02181-7","35797004","PMC9402769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009463","Impact of Preoperative Semaglutide Discontinuation Timing on Postoperative Outcomes in Aesthetic Abdominoplasty: A Retrospective Comparative Study.","Bruno A","2026","Aesthetic plastic surgery","nonrandomized_study","article","10.1007/s00266-026-05978-x","42286330",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0009464","Comment on \"Association of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study\".","Li X","2026","Global spine journal","nonrandomized_study","article","10.1177/21925682261442913","41937267","PMC13053403",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0009465","Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis.","Dutta D","2024","TouchREVIEWS in endocrinology","systematic_review","article","10.17925/ee.2024.20.2.10","39526060","PMC11548363",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0009466","The change of Testosterone after weight intervention in obese men","H D","2022","Authorea Preprints","other","preprint","10.22541/au.166455371.11870912/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009467","An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism.","Ren Q","2022","Drug design, development and therapy","preclinical","article","10.2147/dddt.s381546","36304787","PMC9594960",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009468","Efficacy and Cardiovascular Safety of Insulins.","Fernandez CJ","2021","Current drug safety","narrative_review","article","10.2174/1574886315999201105153458","33153425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009469","First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.","Choi JG","2022","Annals of internal medicine","randomized_trial","article","10.7326/m21-2941","36191315","PMC10155215",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009470","Novel Therapeutical Approaches to Managing Atherosclerotic Risk.","Giglio RV","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22094633","33924893","PMC8125277",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009471","Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.","Eftekhari S","2020","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2020.173102","32283060",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009472","Editorial on \"GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated lip(a) levels: A multicenter retrospective study\" IJCJOURNAL-D-26-01993R1.","Jones GB","2026","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2026.134632","42331181",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; editorial"],["R0009473","Increased priority for regimens involving incretin-based and insulin therapy.","Rodbard HW","2013","The Journal of family practice","narrative_review","article",null,"24340348",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009474","Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review.","Popovic DS","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-021-01170-3","34699021","PMC8546380",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009475","Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos.","Yeung AWK","2025","JMIR infodemiology","other","article","10.2196/59767","40198905","PMC12015341",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009476","Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus.","Knudsen LB","2016","Journal of diabetes investigation","preclinical","article","10.1111/jdi.12463","27186357","PMC4854506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009477","In Vitro Evaluation of GLP-1R-Associated Activity of a Sustainable Standardized Phospholipid-Formulated Bergamot Extract.","Khan A","2026","Biomedicines","preclinical","article","10.3390/biomedicines14051111","42193436","PMC13204717",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009478","Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","Pulipati VP","2020","European journal of preventive cardiology","systematic_review","article","10.1177/2047487320903638","32089007",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0009479","HIV and obesity: updates in management strategies.","Parra-Rodriguez L","2023","Current opinion in HIV and AIDS","narrative_review","article","10.1097/coh.0000000000000781","36644952",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009480","Clinical Use of IDegLira: Initiation to Titration After Basal Insulin.","Warren M","2020","Clinical diabetes : a publication of the American Diabetes Association","nonrandomized_study","article","10.2337/cd19-0015","31975753","PMC6969665",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009481","Pediatric Obesity: Diagnostic and Therapeutic Approaches in the Context of International Guidelines With a Focus on Polish Practice.","Łuczak PM","2026","Cureus","narrative_review","article","10.7759/cureus.101545","41694933","PMC12906244",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009482","From Glycemic Response to Clinical Trajectories: Extending Phenotyping in GLP-1RA-SGLT2 Inhibitor Combination Therapy.","Corrao S","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","commentary","article","10.1016/j.eprac.2026.08.022","42697487",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009483","Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review.","Mima A","2023","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2023.115032","37331253",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0009484","The Role of GLP-1 Analogues in the Treatment of Obesity-Related Asthma Phenotype.","Radzik-Zając J","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13112610","41301704","PMC12650403",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009485","The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson's disease with diabetes co-morbidity.","Zhang X","2025","Frontiers in neuroscience","preclinical","article","10.3389/fnins.2025.1596506","40606832","PMC12213772",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009486","Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis.","Mima A","2023","Metabolism open","systematic_review","article","10.1016/j.metop.2023.100236","36923991","PMC10009293",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0009487","The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?","Papachristou S","2021","Diabetes/metabolism research and reviews","other","article","10.1002/dmrr.3503","34626443",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009488","Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate.","Kim DH","2026","Pharmaceutics","preclinical","article","10.3390/pharmaceutics18060680","42357295","PMC13306039",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009489","GLP-1 receptor agonists: The good, the bad, and the ugly-A comprehensive guide for NPs.",null,"2026","The Nurse practitioner","other","article","10.1097/01.npr.0000000000000439","42021008",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009490","Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma.","Lawrence ECN","2023","Frontiers in cellular neuroscience","preclinical","article","10.3389/fncel.2023.1156829","37362000","PMC10288152",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009491","When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered?","David J","2019","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2019.107473","31668591",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0009492","Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity.","Taylor B","2025","Cureus","case_report","article","10.7759/cureus.96564","41393655","PMC12697224",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009493","Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.","Yang D","2025","Cardiovascular research","preclinical","article","10.1093/cvr/cvaf033","40036855",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009494","Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog.","Guo W","2023","Molecular metabolism","randomized_trial","article","10.1016/j.molmet.2023.101762","37364710","PMC10339203","ClinicalTrials.gov:NCT04389775","S002332","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; research-article; article"],["R0009495","Exogenous succinate impacts mouse brown adipose tissue mitochondrial proteome and potentiates body mass reduction induced by liraglutide.","Gaspar RS","2023","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00231.2022","36724126",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009496","Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.","Lingvay I","2023","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-023-01797-5","36964557","PMC10039543",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009497","Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis.","Pinto LC","2019","Scientific reports","systematic_review","article","10.1038/s41598-019-38956-2","30787365","PMC6382780",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; research-article; review"],["R0009498","GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN.","Gorelik Y","2025","Journal of Crohn's & colitis","nonrandomized_study","article","10.1093/ecco-jcc/jjae160","39441993",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0009499","Metabolic Heterogeneity of Obesity and Outcome-Specific Effects of GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome.","Fauchier L","2026","JACC. Advances","commentary","article","10.1016/j.jacadv.2026.102808","42134059","PMC13196401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0009500","Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.","Iizuka K","2021","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14537","34472693","PMC9293167",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0009501","The Potential for Delay in Coordinated Care of Complex Patients Receiving Mohs Micrographic Surgery Due to GLP-1 Receptor Agonists.","Lin RJ","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","other","article","10.1097/dss.0000000000005149","42210889",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009502","Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.","Alissou M","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70141","41068996","PMC12673431",null,"S002747","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0009503","Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.","Li L","2025","Clinical nuclear medicine","other","article","10.1097/rlu.0000000000005533","39499011",null,"ClinicalTrials.gov:NCT05034783","S000547","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comparative Study; article"],["R0009504","The Effect of GLP-1 Receptor Agonists on Epilepsy: No Appetite for Seizures.","Karakis I","2026","Epilepsy currents","nonrandomized_study","article","10.1177/15357597261440716","41988100","PMC13076450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article-commentary; article"],["R0009505","Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.","Harris KB","2016","Pharmacotherapy","nonrandomized_study","article","10.1002/phar.1804","27485823",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0009506","Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis.","Bak M","2024","Acta psychiatrica Scandinavica","systematic_review","article","10.1111/acps.13734","39048532",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Review; review"],["R0009507","How Should Thyroid Nodules and Risk of Thyroid Cancer Be Managed in Patients on GLP-1 Receptor Agonists?","Anderson C","2026","The Laryngoscope","other","article","10.1002/lary.70604","42097991",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009508","Deep learning-enhanced 3D imaging unveils semaglutide impact on cardiac fibrosis.","Barrado-Ballestero S","2026","British journal of pharmacology","preclinical","article","10.1111/bph.70217","41121520",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint; article"],["R0009509","GLP-1 receptor agonists in multiple sclerosis: Weight loss without disease modification - Are we measuring the right outcomes?","Sajjad M","2026","Multiple sclerosis and related disorders","commentary","article","10.1016/j.msard.2026.107257","42166855",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009510","The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.","Banerjee Y","2021","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2021.1970744","34424130","PMC8425441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0009511","Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.","Barbery CE","2021","American heart journal","commentary","article","10.1016/j.ahj.2021.03.013","33905751",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0009512","Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.","Desai RJ","2022","American heart journal","nonrandomized_study","article","10.1016/j.ahj.2022.09.008","36150454",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0009513","Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats.","Fang J","2023","Brain research bulletin","preclinical","article","10.1016/j.brainresbull.2022.11.012","36410565",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009514","Dulaglutide: A Review in Type 2 Diabetes.","Scott LJ","2020","Drugs","nonrandomized_study","article","10.1007/s40265-020-01260-9","32002850",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; Review; other; article"],["R0009515","Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy.","Silveira SQ","2023","Journal of clinical anesthesia","nonrandomized_study","article","10.1016/j.jclinane.2023.111091","36870274",null,null,"S002295; S002429; S002680","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009516","Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review.","Berlie H","2012","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s27528","22826635","PMC3402010",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review-article; review"],["R0009517","Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.","McKee A","2020","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaa037","32342023","PMC7182131",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0009518","Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs.","Colston KJ","2025","Nature communications","other","article","10.1038/s41467-025-64891-0","41152279","PMC12568990",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009519","Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.","Rodriguez N","2025","Pharmacological reviews","randomized_trial","article","10.1016/j.pharmr.2025.100058","40554267",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0009520","Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.","Home PD","2021","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14518","34402153","PMC9290816",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; research-article; review"],["R0009521","Mechanisms of interaction between type 2 diabetes and psychological disorders and therapeutic interventions: a narrative review.","Sui H","2026","Frontiers in medicine","narrative_review","article","10.3389/fmed.2026.1777797","42136854","PMC13168012",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0009522","Analysis of patient-specific factors contributing to effectiveness of glucagon-like peptide-1 receptor agonists.","Mazzei KA","2020","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2020.06.023","32778515","PMC8358935",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009523","Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes After Efsubaglutide Alfa Treatment.","Sun R","2026","Advances in therapy","randomized_trial","article","10.1007/s12325-025-03467-2","41498879",null,"ClinicalTrials.gov:NCT06605287","S001773","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0009524","Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy.","Madej J","2026","ACG case reports journal","case_report","article","10.14309/crj.0000000000002032","41767340","PMC12947982",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009525","Preoperative fasting and GLP-1 receptor agonists: gastric retention without increased aspiration risk.","Di Vezza F","2026","Brazilian journal of anesthesiology (Elsevier)","commentary","article","10.1016/j.bjane.2026.844763","42070630","PMC13254858",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0009526","GLP-1 receptor agonists and their implications for female reproductive health.","Eagles E","2026","Case reports in women's health","commentary","article","10.1016/j.crwh.2026.e00812","42282144","PMC13250481",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009527","Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.","Zhu Y","2021","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2021.769069","34956080","PMC8696030","PROSPERO:CRD42021265806",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; review"],["R0009528","Mono-PEGylates of exenatide in branched and dimeric structures can improve in vivo stability and hypoglycemic bioactivity.","Thi Nguyen NT","2019","Journal of biotechnology","preclinical","article","10.1016/j.jbiotec.2019.09.016","31580912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009529","Comment on: The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.","Hsu AY","2025","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2025.05.053","40545015",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0009530","Geographic variation in eligibility and uptake of GLP-1 receptor agonists for obesity in US adults.","Jian X","2026","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2026.101653","42403442","PMC13329512",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0009531","7215 Skeletal Muscle Mass Loss with Use of Dual GLP-1 GIP Receptor Agonist Tirzepitide",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454108",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0009532","Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice.","Newsome PN","2026","Journal of internal medicine","narrative_review","article","10.1111/joim.70143","42671251","PMC13569230",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009533","A Clinical Overview of Once-weekly Glucagon-like Peptide-1 Receptor Agonists.","Unger J","2018","The Journal of family practice","other","article",null,"29912994",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009534","Correction to \"Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes\".",null,"2026","Pharmacoepidemiology and drug safety","notice","article","10.1002/pds.70333","41566767",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0009535","A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.","Pandey A","2025","Naunyn-Schmiedeberg's archives of pharmacology","narrative_review","article","10.1007/s00210-025-03918-1","40014122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0009536","Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.","Elganyny MKE","2026","La Clinica terapeutica","systematic_review","article","10.7417/ct.2026.2083","42340790",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0009537","Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats.","Tonon CR","2026","Antioxidants (Basel, Switzerland)","preclinical","article","10.3390/antiox15050538","42193161","PMC13203684",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009538","Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus.","Ida S","2021","Current diabetes reviews","systematic_review","article","10.2174/1573399816666200705210006","32628589",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0009539","Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.","Dhindsa DS","2019","Current cardiology reports","narrative_review","article","10.1007/s11886-019-1197-6","31352613",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009540","Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.","Ishii H","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00985-w","33460016","PMC7846658","ClinicalTrials.gov:NCT03015220","S000234","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; article"],["R0009541","Correct Diabetes Diagnosis and Treatment Allows Sailor to Remain on Active Duty.","Frazier AR","2020","Military medicine","case_report","article","10.1093/milmed/usaa012","32373933",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009542","Balancing Act: Exploring the Gut Microbiota-Brown Adipose Tissue Axis in PCOS Pathogenesis and Therapeutic Frontiers.","Li Y","2024","Frontiers in bioscience (Landmark edition)","narrative_review","article","10.31083/j.fbl2906208","38940030",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009543","SGLT2 Inhibitors versus GLP-1 Receptor Agonists in Type 2 Diabetes, The Kidney Conundrum.","Shah J","2026","Clinical journal of the American Society of Nephrology : CJASN","commentary","article","10.2215/cjn.0000001068","42054103","PMC13493008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0009544","Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.","Baron HL","2017","The Journal of family practice","case_report","article",null,"28991933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009545","GLP-1 and Parkinson's Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy.","Mezabrovschi R","2026","Cells","narrative_review","article","10.3390/cells15090804","42121905","PMC13163113",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009546","Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.","Bonaventura A","2019","Journal of internal medicine","nonrandomized_study","article","10.1111/joim.12890","30888088",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0009547","Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial.","Zhang Y","2023","Nutrients","randomized_trial","article","10.3390/nu15030556","36771262","PMC9920202",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0009548","MSDC-0602K, A Novel Insulin-Sensitizer Improves Insulinemia and Fatty Liver Disease Alone and in Addition to Liraglutide in Mice","Kamm DR","2020","bioRxiv","preclinical","preprint","10.1101/2020.12.10.420190",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009549","Efficacy and safety of Efsubaglutide Alfa in \"overrun\" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.","Jia W","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70112","40977363",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Multicenter Study; article"],["R0009550","Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network pharmacology.","Deng G","2023","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2023.1125753","36865917","PMC9971732",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009551","Response to the Letter to the Editor on \"Perioperative GLP-1 Receptor Agonist Use is Associated with Reduced Revisions and Complications Following ACDF: A Propensity-Matched Analysis\".","Kim MT","2026","Global spine journal","nonrandomized_study","article","10.1177/21925682261431792","41786648","PMC12965887",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; letter"],["R0009552","7358 Profile of Circulating miRNAs Associated with Body Weight Reduction in Type 2 Diabetes Patients Treated with GLP-1 Receptor Agonist Dulaglutide: Secondary Analysis of AWARD-7 Trial",null,"2024","Journal of the Endocrine Society","other_trial","article",null,null,"PMC11453755",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0009553","Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.","Wharton S","2023","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2302392","37351564",null,"ClinicalTrials.gov:NCT05051579","S000353; S002337","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; article"],["R0009554","Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.","Liaw J","2022","Diabetes care","nonrandomized_study","article","10.2337/dc22-0224","35984049","PMC12081776",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009555","Oxidative stress as a culprit in diabetic kidney disease.","Su S","2023","Life sciences","narrative_review","article","10.1016/j.lfs.2023.121661","37028547",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009556","Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA.","De Giorgi R","2026","BMJ mental health","randomized_trial","article","10.1136/bmjment-2026-302828","42624612","PMC13504872",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0009557","Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.","Gómez-Huelgas R","2022","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2021.11.008","34799233",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009558","Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.","Saeed ZI","2025","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-025-01369-w","41410846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0009559","Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes.","Marasinghe DH","2022","Canadian journal of diabetes","other","article","10.1016/j.jcjd.2022.02.002","35739042",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0009560","Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services.","Dao K","2024","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2023-083550","38663923","PMC11043712",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0009561","[Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].","Paquot N","2021","Revue medicale de Liege","other_trial","article",null,"34881835",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","5","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0009562","Evaluating the effectiveness and underlying mechanisms of incretin-based treatments for hypothalamic obesity: A narrative review.","Chartoumpekis DV","2024","Obesity pillars","narrative_review","article","10.1016/j.obpill.2024.100104","38463533","PMC10924130",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0009563","Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury.","Goto H","2011","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2010.12.131","21215253",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009564","Response to the Letter to the Editor for \"Association of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study\".","Chang Y","2026","Global spine journal","nonrandomized_study","article","10.1177/21925682261442934","41937279","PMC13053384",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; letter"],["R0009565","Cardioprotective Effects of Pioglitazone in Type 2 Diabetes.","Tripathy D","2021","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds20-0078","34511850","PMC8387608",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009566","Glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists in dermatology: only one piece of the puzzle.","Patel NP","2026","Clinical and experimental dermatology","other","article","10.1093/ced/llag091","41703789",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009567","Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS.","Reiser E","2022","Journal of clinical medicine","randomized_trial","article","10.3390/jcm12010067","36614868","PMC9820988",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0009568","Exendin-4 stimulates autophagy in pancreatic β-cells via the RAPGEF/EPAC-Ca2+-PPP3/calcineurin-TFEB axis.","Zummo FP","2022","Autophagy","preclinical","article","10.1080/15548627.2021.1956123","34338148","PMC9037459",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009569","Counseling patients through an obesity diagnosis: a brief primer for healthcare providers.","Heeren FAN","2026","International journal of obesity (2005)","narrative_review","article","10.1038/s41366-026-02020-7","41654634",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009570","Preferences of Individuals With Obesity for Online Medical Consultation in Different Demand Scenarios: Discrete Choice Experiments.","Hu Y","2024","Journal of medical Internet research","other","article","10.2196/53140","39602197","PMC11635326",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009571","Nonmechanical Small Bowel Obstruction in a Patient on Zepbound Without a Surgical History: A Case Report.","Lorenz N","2025","Cureus","case_report","article","10.7759/cureus.90657","40978855","PMC12449828",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009572","Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.","Gómez-Huelgas R","2015","International journal of clinical pharmacology and therapeutics","narrative_review","article","10.5414/cp202052","25066229",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0009573","The Anti-Inflammatory Effects of Glucagon-Like Peptide Receptor Agonist Lixisenatide on the Retinal Nuclear and Nerve Fiber Layers in an Animal Model of Early Type 2 Diabetes.","Chung YW","2020","The American journal of pathology","preclinical","article","10.1016/j.ajpath.2020.01.011","32354571",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009574","Trends in Glucagon-Like Peptide-1 Agonist Use and BMI Among Obese Adults With Type 2 Diabetes: Analysis of the 2010-2015 National Ambulatory Medical Care Survey (NAMCS), Adjusted for Cardiovascular Comorbidity.","Eneh V","2025","Cureus","nonrandomized_study","article","10.7759/cureus.90054","40951131","PMC12432795",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009575","Prevention of Diabetes Macrovascular Complications and Heart Failure.","Sattar N","2021","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2021.05.004","34399954",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0009576","Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.","Lyu B","2023","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-022-07726-8","35831767","PMC9849518",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0009577","The impacts of new antidiabetic drugs on the risk of ischemic and hemorrhagic strokes: a comprehensive review and meta-analysis of clinical trials.","Azhari HF","2024","Frontiers in stroke","systematic_review","article","10.3389/fstro.2024.1363954","41542235","PMC12802736","PROSPERO:CRD42017067889",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0009578","Glucagon-like peptide-1 Agonists and Common Hand Procedures: Perioperative and Postoperative Risks and Complications.","Amen TB","2025","The Journal of hand surgery","nonrandomized_study","article","10.1016/j.jhsa.2025.08.004","41055617",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009579","The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.","Li Y","2024","European journal of clinical investigation","systematic_review","article","10.1111/eci.14125","37950521",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0009580","Reply to Comment on the Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy.","Abbass NJ","2025","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2025.06.025","40545011",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0009581","Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI).","Sprung VS","2020","BMJ open","protocol","article","10.1136/bmjopen-2020-038856","32699168","PMC7380950","ISRCTN:ISRCTN16250774; EudraCT:2014-000988-41",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009582","Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.","Barenbaum SR","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70179","41902614",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0009583","GLP-1 receptor agonist-associated eosinophilic duodenitis presenting as a bowel obstruction : a case report and literature review.","Davidts S","2026","Acta gastro-enterologica Belgica","case_report","article","10.51821/89.1.14613","41745643",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009584","GLP-1 receptor agonists and functional gastrointestinal obstruction: mechanistic rationale, emerging evidence, and clinical implications.","Riaz L","2026","Annals of medicine and surgery (2012)","randomized_trial","article","10.1097/ms9.0000000000005086","42254260","PMC13236236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0009585","Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes.","Yaribeygi H","2020","Life sciences","narrative_review","article","10.1016/j.lfs.2019.117152","31837333",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009586","The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.","Min T","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00981-0","33325008","PMC7843845",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; other; article"],["R0009587","Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.","van Ruiten CC","2022","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2022.863592","35600575","PMC9114766",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0009588","Short-term outcomes of switching from GLP-1 receptor agonists to tirzepatide in type 2 diabetes: A retrospective, observational study in clinical practice.","Matsushiro M","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16237","39895173",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0009589","Semaglutide treatment of hypothalamic obesity - a real-life data study.","Svendstrup M","2024","Pituitary","other","article","10.1007/s11102-024-01429-5","39120810","PMC11513754",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0009590","Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports.","Alorfi NM","2026","Medicine","nonrandomized_study","article","10.1097/md.0000000000048811","42152320","PMC13183005",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009591","Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?","Jiang Y","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16106","39592891",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009592","Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression.","Hariyanto TI","2021","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2021.109031","34461139","PMC8397482",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0009593","6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor.","Aspnes GE","2023","Bioorganic & medicinal chemistry letters","other","article","10.1016/j.bmcl.2023.129454","37591316",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0009594","Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.","Hanefeld M","2017","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1080/17425255.2017.1251579","27776453",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009595","Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials.","Chen JY","2025","American journal of kidney diseases : the official journal of the National Kidney Foundation","systematic_review","article","10.1053/j.ajkd.2024.11.013","39863261",null,"PROSPERO:CRD42023449059",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0009596","Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital.","Jha AK","2026","The Journal of the Association of Physicians of India","nonrandomized_study","article","10.59556/japi.74.1508","42543936",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0009597","The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4.","Lin MH","2023","International immunopharmacology","preclinical","article","10.1016/j.intimp.2022.109653","36587502",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009598","Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.","Vijiaratnam N","2025","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(24)02808-3","39919773",null,"ClinicalTrials.gov:NCT04232969; EudraCT:2018-003028-35","S001156","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, N.I.H., Intramural; article"],["R0009599","Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study.","Peng XV","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00905-y","32902774","PMC7547934",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0009600","In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.","Alhalabi H","2026","Journal of pharmaceutical and biomedical analysis","preclinical","article","10.1016/j.jpba.2026.117418","41702251",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009601","Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs.","Bornebusch AB","2019","eNeuro","preclinical","article","10.1523/eneuro.0443-18.2019","31058214","PMC6498420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0009602","Potential Role of Hypothalamic and Plasma Ghrelin in the Feeding Behavior of Obese Type 2 Diabetic Rats with Intraventricular Glucagon-Like Peptide-1 Receptor Agonist Intervention.","Lu K","2021","Obesity facts","preclinical","article","10.1159/000509956","33341811","PMC7983563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009603","Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.","Yandrapalli S","2020","Cardiology in review","randomized_trial","article","10.1097/crd.0000000000000311","32271194",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0009604","Incretins and the cardiovascular system: bridging digestion with metabolism.","Avogaro A","2025","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(25)00166-4","40639391",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009605","Incretin therapy and obesity: current and future pharmacologic possibilities.","Moss E","2026","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2025-0151","41499766",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009606","Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.","Zhou Y","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s348025","35046686","PMC8763271",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009607","Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation.","Huang YN","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70786","42010367","PMC13243989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009608","Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG?","Chen M","2026","Cardiovascular drugs and therapy","commentary","article","10.1007/s10557-026-07832-3","41801639",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009609","Accidental overdoses and adverse effects from compounded GLP-1 agonists.","O'hara J","2026","Nursing","other","article","10.1097/nsg.0000000000000471","42765760",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009610","Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.","Dai Y","2020","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2020.622589","33664710","PMC7924308",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; review"],["R0009611","Simplification of complex insulin therapy: a story of dogma and therapeutic resignation.","Giugliano D","2021","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2021.108958","34280468",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0009612","Type 2 Diabetes in Pregnancy: Management and Novel Therapies.","Wilkie G","2026","Clinical obstetrics and gynecology","narrative_review","article","10.1097/grf.0000000000001008","41879623",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009613","Author response to OSIN-D-26-00705 Comment on: The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study.","Kvist AV","2026","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","nonrandomized_study","article","10.1007/s00198-026-08071-w","42201385",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Letter"],["R0009614","In the Emerging Era of GLP-1 Receptor Agonists There Is an Unrecognized Need to Change the Formulation of Oral Urologic Agents for Erectile Dysfunction, Benign Prostatic Hyperplasia, and Overactive Bladder.","Ramaswamy A","2026","The Journal of urology","commentary","article","10.1097/ju.0000000000005120","42190231",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0009615","Characterizing Disparities in GLP-1 Receptor Agonist Use Among US Adults With and Without Diabetes.","Castrillon J","2026","Journal of general internal medicine","commentary","article","10.1007/s11606-026-10506-3","42098577","PMC13631183",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009616","The novel antidiabetic medications on diabetic retinopathy: relevant molecular mechanisms, advancing diagnostic innovations, and therapeutic implications.","Wen S","2025","Frontiers in medicine","narrative_review","article","10.3389/fmed.2025.1670643","41608415","PMC12835220",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009617","Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis.","Marzano F","2026","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-026-03215-y","42186086","PMC13479731",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0009618","Intranasal Absorption Enhancement of Antidiabetic Therapeuticals by the Functional Peptide Segment of Latroeggtoxin-VI.","Sun M","2025","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.5c00293","40515721",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009619","The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs -- Therapeutic potential exploration in lung injury","Pang J","2021","Authorea Preprints","other","preprint","10.22541/au.163913208.81687299/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009620","[Peptide hormone analogue-based pharmacotherapy for obesity is effective : What is the evidence on hard end points and the long-term course?].","Hussain M","2026","Chirurgie (Heidelberg, Germany)","other_trial","article","10.1007/s00104-025-02402-z","41191087","PMC12804224",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","English Abstract; Journal Article; Review; review-article; article"],["R0009621","Glucagon-like peptide-1 receptor PET/CT with 68Ga-exendin-4 for localizing insulinoma: a real-world, single-center study.","Zhang H","2025","European journal of nuclear medicine and molecular imaging","nonrandomized_study","article","10.1007/s00259-025-07298-9","40310561",null,"ClinicalTrials.gov:NCT02560376","S001232","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009622","Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan.","Shao SC","2022","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2022.101318","35017100",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Multicenter Study"],["R0009623","Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.","Chou OHI","2024","Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","nonrandomized_study","article","10.1007/s10120-024-01512-7","38856768","PMC11335951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0009624","Trends in Metabolic and Bariatric Surgery Use During the GLP-1 Receptor Agonist Era.","Rohde SC","2026","JAMA surgery","other","article","10.1001/jamasurg.2026.0049","41779405","PMC12961594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009625","Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure.","Talha KM","2022","Methodist DeBakey cardiovascular journal","randomized_trial","article","10.14797/mdcvj.1155","36561085","PMC9733124",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0009626","GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.","Gilbert MP","2020","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2020.00178","32308645","PMC7145895",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009627","Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.","Price H","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13182","29205856","PMC5873250",null,"S000056","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0009628","Exendin-4 Inhibits Matrix Metalloproteinase-9 Activation and Reduces Infarct Growth After Focal Cerebral Ischemia in Hyperglycemic Mice.","Kuroki T","2016","Stroke","preclinical","article","10.1161/strokeaha.116.012934","26979865",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009629","Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea.","Preshy A","2026","Chronic diseases and translational medicine","other_trial","article","10.1002/cdt3.70040","42254821","PMC13238883",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0009630","Dominant PDX1 deficiency causes highly penetrant diabetes at different ages, associated with obesity and exocrine pancreatic deficiency: Lessons for precision medicine.","Kouidrat Y","2024","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2023.101507","38141807",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0009631","GLP-1 receptor agonists, psychiatric training, and metabo-psychiatric practice.","Gorman BL","2026","Psychiatry research","commentary","article","10.1016/j.psychres.2026.117153","41950541",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009632","The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice.","Thomsen M","2017","Pharmacology, biochemistry, and behavior","preclinical","article","10.1016/j.pbb.2017.07.014","28778739",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009633","Recent advances in incretin-based therapies.","Russell-Jones D","2012","Clinical endocrinology","narrative_review","article","10.1111/j.1365-2265.2012.04483.x","22804841",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0009634","Glucagon-like peptide-1 receptor agonist reduces di(2-ethylhexyl) phthalate-induced atherosclerotic processes in vascular smooth muscle cells.","Kim JH","2020","Physiological research","preclinical","article","10.33549/physiolres.934480","33129247","PMC8549877",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009635","Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.","De Ciuceis C","2018","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","other","article","10.1007/s40292-018-0279-7","30203268",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0009636","Idiopathic Intracranial Hypertension After Abrupt Cessation of Medication: A Case Report of Abrupt Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Cessation and Review of the Literature.","Heckel B","2024","Current pain and headache reports","case_report","article","10.1007/s11916-024-01215-9","38573570","PMC11156736",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; Review; article"],["R0009637","GLP-1R agonists for the treatment of obesity: a patent review (2015-present).","Liu C","2020","Expert opinion on therapeutic patents","other_trial","article","10.1080/13543776.2020.1811851","32799587",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0009638","GLP-1 receptor signaling restores aquaporin 4 subcellular polarization in reactive astrocytes and promotes amyloid β clearance in a mouse model of Alzheimer's disease.","Sasaki K","2024","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2024.151016","39577079",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009639","Beyond glycemia: Comparing tirzepatide to GLP-1 analogues.","Andraos J","2023","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-023-09825-1","37526853","PMC10697893",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Review; review-article; article"],["R0009640","Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","de Boer IH","2022","Diabetes care","narrative_review","article","10.2337/dci22-0027","36189689","PMC9870667",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Consensus Statement; review-article; article; other"],["R0009641","Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT/mTOR inhibition.","Lin J","2026","Journal of orthopaedic translation","preclinical","article","10.1016/j.jot.2026.101166","42381999","PMC13316188",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009642","Type 2 Diabetes Mellitus and Asthma: Pathomechanisms of Their Association and Clinical Implications.","Uppal P","2023","Cureus","narrative_review","article","10.7759/cureus.36047","37056543","PMC10089620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009643","Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications.","Bajaj HS","2018","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000000562","30142096",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009644","Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats.","Reddiar SB","2024","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2024.114339","38789061",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009645","Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.","Rosenstock J","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2505669","40544435",null,"ClinicalTrials.gov:NCT05971940","S001950","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; article"],["R0009646","Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.","Shukla AP","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70215","41187971","PMC12673425",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0009647","Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis.","Benn M","2021","Diabetologia","systematic_review","article","10.1007/s00125-021-05436-0","33765180",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't"],["R0009648","Too good to be true: Are GLP-1 receptor agonists the new metformin?","Kowall B","2024","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2024.108851","39236411",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009649","Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers.","Vetrano E","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18111703","41304947","PMC12655567",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009650","Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes.","Chen WH","2024","PloS one","nonrandomized_study","article","10.1371/journal.pone.0297208","38285682","PMC10824445",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0009651","Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia.","Franch-Nadal J","2019","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm8091389","31491916","PMC6780172",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009652","Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.","Guo L","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00133-6","42575111",null,"ClinicalTrials.gov:NCT06041217","S001641","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0009653","GLP-1 Receptor Agonist Weight Loss Therapy and Arthroplasty: Are Women at Greater Risk for Complications?","Browne VG","2026","The Journal of arthroplasty","commentary","article","10.1016/j.arth.2026.03.063","41967884",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0009654","The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents.","Vallöf D","2016","Addiction biology","preclinical","article","10.1111/adb.12295","26303264","PMC5049632",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009655","Semaglutide (Wegovy): Therapeutic area: Weight management: Reimbursement Review",null,"2025","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"41474860",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0009656","Neuroprotective Effects of Semaglutide in Cyclophosphamide-Induced Neuropathy: Restoring SIRT1/AMPK, PI3K/AKT/mTOR, and Antioxidant Pathways.","Elbadawy HM","2026","Journal of molecular neuroscience : MN","preclinical","article","10.1007/s12031-026-02521-0","42043683",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009657","Rhabdomyolysis Associated with the Use of Tirzepatide.","Sonavane K","2025","European journal of case reports in internal medicine","other","article","10.12890/2025_005392","40352714","PMC12061213",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009658","Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.","Pandey RK","2025","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70134","41296780","PMC12653021",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0009659","The comparative efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists on metabolic benefits in T2DM patients: a systematic review and network meta-analysis.","Tong J","2026","European journal of medical research","systematic_review","article","10.1186/s40001-026-03986-w","41620788","PMC12952054","PROSPERO:CRD42021247584",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0009660","Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review.","Babazadeh D","2025","Advances in nutrition (Bethesda, Md.)","randomized_trial","article","10.1016/j.advnut.2025.100491","40812508","PMC12592236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Scoping Review; review-article; article"],["R0009661","[GLP-1 agonists : cardio-renal benefit in type 2 diabetic patient].","Levy J","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.920.47290","40443144",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0009662","A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal.","Khalil HA","2026","BMC chemistry","preclinical","article","10.1186/s13065-025-01716-7","41588418","PMC12918740",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0009663","Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms.","Yaribeygi H","2021","Oxidative medicine and cellular longevity","narrative_review","article","10.1155/2021/9959320","34007411","PMC8099522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009664","Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond.","Muzurović E","2026","Metabolism: clinical and experimental","nonrandomized_study","article","10.1016/j.metabol.2026.156494","41564595",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0009665","Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis.","Ding C","2022","Acta diabetologica","systematic_review","article","10.1007/s00592-021-01830-7","34988690",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0009666","Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.","Rosenstock J","2023","JAMA","randomized_trial","article","10.1001/jama.2023.20294","37786396","PMC10548360","ClinicalTrials.gov:NCT04537923","S000108","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0009667","Reprogramming of GLP-1 Response at Prediabetes for the Prevention of Type 2 Diabetes: The Role of Albumin and GLP-1 Receptor Agonists","Ahmed A","2023","Qeios","other","preprint","10.32388/911ok2",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009668","In-silico and in-vitro hybrid approach to identify glucagon-like peptide-1 receptor agonists from anti-diabetic natural products.","Chatterjee D","2023","Natural product research","nonrandomized_study","article","10.1080/14786419.2022.2106567","35924731",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0009669","Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes.","Decker SRR","2026","Diabetes care","other","article","10.2337/dc25-1619","41348220",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009670","Effects of glucagon-like peptide-1 agonist therapy on vertebral bone mineral density as measured by CT-based Hounsfield units.","Martini ML","2025","Journal of neurosurgery. Spine","nonrandomized_study","article","10.3171/2025.7.spine25791","41270274",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009671","Parkinson's disease and diabetes mellitus: common mechanisms and treatment repurposing.","Labandeira CM","2022","Neural regeneration research","narrative_review","article","10.4103/1673-5374.332122","35017411","PMC8820685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009672","Semaglutide: a promising new glucagon-like peptide-1 receptor agonist.","Scheen AJ","2017","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(17)30012-8","28110912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0009673","Beyond Volume: Tissue-Level Considerations on Combined Filler Regimens for GLP-1 RA-Associated Facial Changes.","Ou Q","2026","Aesthetic surgery journal","other","article","10.1093/asj/sjag176","42771336",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009674","Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.","Mishriky BM","2021","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2020.05.002","32439471",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0009675","Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R.","Li Z","2020","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2020.110523","32702632",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009676","ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide.","Bossi AC","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00929-4","32974879","PMC7547933",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0009677","Extending the Reach of GLP-1 Receptor Agonists for Cardiovascular Risk Reduction.","Lincoff AM","2026","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2026.02.5106","41879585",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0009678","Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement.","Xie D","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.61200","39982723","PMC11846009",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009679","Targeting epicardial adipose tissue: A potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus.","Shi YJ","2023","World journal of diabetes","randomized_trial","article","10.4239/wjd.v14.i6.724","37383601","PMC10294070",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0009680","Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.","Hussein H","2019","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.13898","30653708",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0009681","GLP-1 receptor agonists and atrial fibrillation: Chronotropy, atrial substrate, and cardiometabolic mechanisms.","Karakasis P","2026","Metabolism: clinical and experimental","commentary","article","10.1016/j.metabol.2026.156605","41942045",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009682","Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study.","Herrera HO","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.02.042","41707704",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0009683","Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation.","Martinez-Corral I","2026","British journal of pharmacology","narrative_review","article","10.1111/bph.70636","42592781",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009684","Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.","Kosiborod MN","2023","JACC. Heart failure","protocol","article","10.1016/j.jchf.2023.05.010","37294245",null,"ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; article"],["R0009685","Assessing the Compliance of Physicians With the American Diabetes Association (ADA) Guidelines in Prescribing Cardioprotective Antihyperglycemic Agents to Diabetic Patients at a University Hospital in Jeddah, Saudi Arabia.","Sheikh AM","2023","Cureus","nonrandomized_study","article","10.7759/cureus.44133","37753033","PMC10518268",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009686","Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development.","Ahrén B","2019","Journal of diabetes investigation","narrative_review","article","10.1111/jdi.12911","30099845","PMC6400152",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009687","Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.","Lugner M","2021","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-021-01258-x","33752680","PMC7983265",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0009688","New Glucose-Lowering Agents for Diabetic Kidney Disease.","de Vos LC","2018","Advances in chronic kidney disease","narrative_review","article","10.1053/j.ackd.2018.01.002","29580579",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009689","Targeting obesity for therapeutic intervention in heart failure patients.","Sato R","2024","Expert review of cardiovascular therapy","other_trial","article","10.1080/14779072.2024.2363395","38864827",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0009690","The GLP-1 Analog Liraglutide Reduces Fever Through Sex-Dependent Neuroinflammatory Modulation.","de Sousa GLS","2025","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph18111738","41304982","PMC12655475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0009691","Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review.","Pasquariello T","2026","Nephron","nonrandomized_study","article","10.1159/nef/adtag006","42743093",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Case Reports; Journal Article; article"],["R0009692","Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists.","Umapathysivam MM","2023","medRxiv : the preprint server for health sciences","preclinical","article","10.1101/2023.04.07.23288197","37090505","PMC10120798",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0009693","Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer's Disease.","Crook H","2024","Journal of Alzheimer's disease : JAD","narrative_review","article","10.3233/jad-240730","39422964",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article; book-chapter"],["R0009694","Present and future directions in diabetic kidney disease.","Limonte CP","2022","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2022.108357","36403478","PMC9764992",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0009695","Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence.","Arévalo-Lorido JC","2018","High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension","nonrandomized_study","article","10.1007/s40292-018-0280-1","30251110",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009696","Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.","McGuire DK","2023","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.15058","36945734",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; article"],["R0009697","Correction: Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.","Alwafi H","2026","Frontiers in medicine","notice","article","10.3389/fmed.2026.1778742","41728591","PMC12917757",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0009698","A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.","Zoungas S","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00032-x","42114520",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0009699","Relationship Between Frailty and Diabetic Pharmacologic Therapy in Older Adults with Type 2 Diabetes: A Cross-Sectional Study.","Nishimura A","2024","Drugs & aging","nonrandomized_study","article","10.1007/s40266-024-01119-8","38795310","PMC11193829",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009700","Author response to OSIN-D-26-00775 Letter to the Editor regarding \"The association between GLP-1 receptor agonists and fractures: a nationwide Danish nested case-control study\".","Kvist AV","2026","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","nonrandomized_study","article","10.1007/s00198-026-08069-4","42201383",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Letter"],["R0009701","Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.","Pineda-Wieselberg RJ","2026","Nutrients","nonrandomized_study","article","10.3390/nu18091419","42124020","PMC13165399",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; Preprint; article; preprint"],["R0009702","Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.","Nair R","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01320-1","36131064","PMC9663782",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009703","[Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day].","Sklyanik IA","2021","Terapevticheskii arkhiv","randomized_trial","article","10.26442/00403660.2021.10.201070","36286822",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","English Abstract; Journal Article; article"],["R0009704","Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.","Marsico F","2020","European heart journal","systematic_review","article","10.1093/eurheartj/ehaa082","32077924",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; review"],["R0009705","GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy.","Choi T","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2026.9917","42060307","PMC13133691",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009706","Liraglutide Modulates Zinc Release and Improves Mitochondrial Function in Insulin-Resistant Senescent Cardiomyocytes.","Hosseinpourshirazi F","2026","Cardiovascular toxicology","other","article","10.1007/s12012-026-10095-x","41604031","PMC12852161",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; book-chapter"],["R0009707","Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.","Krüger N","2025","JAMA","nonrandomized_study","article","10.1001/jama.2025.14092","40886075","PMC12400167","ClinicalTrials.gov:NCT06914102; ClinicalTrials.gov:NCT06914154; ClinicalTrials.gov:NCT06914141","S000120; S000347; S000960; S001115","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; research-article; article"],["R0009708","Precision Medicine in Overlap Syndrome (COPD-Obstructive Sleep Apnea): From Phenotypes and Endotypes to Treatable Traits.","Afloarei CA","2026","Advances in respiratory medicine","randomized_trial","article","10.3390/arm94050063","42776697","PMC13600113",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0009709","CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy.","Russo GT","2022","Nutrition, metabolism, and cardiovascular diseases : NMCD","other","article","10.1016/j.numecd.2022.01.026","35260306",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009710","Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options.","Rizvi AA","2021","Biomedicines","other","article","10.3390/biomedicines9111579","34829807","PMC8615620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0009711","Diet context gates AgRP neuron involvement in Semaglutide-induced weight loss","d’Ávila M","2025","bioRxiv","preclinical","preprint","10.1101/2025.07.13.664597",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009712","Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model.","Kristensen JB","2026","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00011.2026","41973550",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009713","Comparisons of clinical outcomes between newly diagnosed early- and late-onset T2DM: a real-world study from the Shanghai Hospital Link Database.","Tao X","2024","Endocrine connections","nonrandomized_study","article","10.1530/ec-23-0474","38078943","PMC10831584",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009714","Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study.","Akuta N","2022","Hepatology communications","nonrandomized_study","article","10.1002/hep4.2005","35581956","PMC9426401",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009715","Cardiometabolic risk factors efficacy of semaglutide in the STEP program.","Amaro A","2022","Postgraduate medicine","other_trial","article","10.1080/00325481.2022.2147325","36691308",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial, Phase III; Journal Article; article"],["R0009716","Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders.","Talebloo J","2026","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2026.2713043","42618986",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0009717","Concerns with the statistical analysis in \"Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study\".","Mokalla TR","2026","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-026-02136-w","42420605","PMC13461341",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Comment; article"],["R0009718","GLP-1-mediated delay in gastric emptying and impact on levodopa absorption in Parkinson's disease: Clinical implications.","Savica R","2026","Parkinsonism & related disorders","narrative_review","article","10.1016/j.parkreldis.2026.108951","42641565",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009719","Losing Weight and Gaining Wrinkles: The Impact of Weight Loss Drugs on Facial Aesthetics.","Barişkan S","2026","The Journal of craniofacial surgery","other","article","10.1097/scs.0000000000012582","41842736",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009720","HbA1c kinetics as a prognostic marker of ophthalmic risk in GLP-1 receptor agonist therapy.","Margoni A","2026","Metabolism open","narrative_review","article","10.1016/j.metop.2026.100468","42064181","PMC13125155",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009721","Letter to the Editor: Special Vision Considerations for GLP-1 Receptor Agonists Use Among Military Aircrew Members.","Tsui JC","2026","Military medicine","commentary","article","10.1093/milmed/usag140","41984632",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; letter"],["R0009722","Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation.","Tanaka Y","2026","Frontiers in endocrinology","case_report","article","10.3389/fendo.2026.1868458","42422421","PMC13341865",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009723","Engineering Supramolecular Nanofiber Depots from a Glucagon-Like Peptide-1 Therapeutic.","Chen W","2024","ACS nano","preclinical","article","10.1021/acsnano.4c10248","39471057",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009724","Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review.","Miao L","2022","Clinical and molecular hepatology","randomized_trial","article","10.3350/cmh.2022.0015","35286799","PMC9597221",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0009725","Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.","Bethel MA","2018","The lancet. Diabetes & endocrinology","systematic_review","article","10.1016/s2213-8587(17)30412-6","29221659",null,null,"S000691","pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0009726","Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes.","Limonte CP","2022","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2022.108204","35537891",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; article"],["R0009727","Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial.","Wilmot EG","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00076-8","42035781",null,"ClinicalTrials.gov:NCT05944432",null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Equivalence Trial; Research Support, Non-U.S. Gov't; article"],["R0009728","Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.","Regmi A","2024","Cell metabolism","preclinical","article","10.1016/j.cmet.2024.05.010","38878772",null,null,"S001989","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0009729","Repurposing Anti‐diabetic GLP‐1 Receptor Agonists for the Treatment of Alzheimer's Disease","Mohammed A","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","other","article","10.1002/alz70855_101740","41456599","PMC12744920",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0009730","Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.","van der Aart-van der Beek AB","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14175","32803900","PMC7756541",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0009731","Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.","Wang K","2019","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2019.08.003","31514971",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009732","Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy.","Shubrook JH","2018","The Journal of family practice","other","article",null,"30137054",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009733","Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.","Del Prato S","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14020","32128957","PMC7383886","ClinicalTrials.gov:NCT02081118","S000719","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0009734","The glucagon-like peptide-1 receptor agonist Exendin-4, ameliorates contrast-induced nephropathy through suppression of oxidative stress, vascular dysfunction and apoptosis independent of glycaemia.","Hussien NI","2018","Clinical and experimental pharmacology & physiology","preclinical","article","10.1111/1440-1681.12944","29637584",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009735","Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'.","Wang CY","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70618","41749445",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0009736","Pharmacometabolomic Modulation of Biomarkers and Analytical Challenges in GLP-1 Receptor Agonist Therapy.","Khokhar M","2026","Indian journal of clinical biochemistry : IJCB","commentary","article","10.1007/s12291-026-01417-5","42205223","PMC13201775",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009737","Coronary Artery Calcium Scoring Improves Allocation of the GLP-1 Receptor Agonist Semaglutide.","Kloner RA","2025","JACC. Cardiovascular imaging","commentary","article","10.1016/j.jcmg.2024.10.007","39797880",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009738","Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.","Inoue H","2019","British journal of clinical pharmacology","systematic_review","article","10.1111/bcp.13807","30394576","PMC6339993",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; article"],["R0009739","Simultaneous bilateral NAION following initiation of high-dose semaglutide: a case report.","Asensio-Sánchez VM","2026","Archivos de la Sociedad Espanola de Oftalmologia","case_report","article","10.1016/j.oftale.2026.502490","41796736",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009740","P-227. Impact Of GLP-1 Receptor Agonists on Body Weight in Persons with HIV Compared to Persons Without HIV",null,"2026","Open forum infectious diseases","other","article",null,null,"PMC12792257",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0009741","Targeting PFKFB3 Metabolic Gatekeeping of β-Cell Dysfunctional States Enables Durable Glucose Tolerance in Type 2 Diabetes.","Raval K","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.09.20.752954","42818175","PMC13622115",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0009742","GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity.","Falk S","2023","Cell reports","preclinical","article","10.1016/j.celrep.2023.112466","37148870",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009743","GLP-1 receptor agonist fails to halt Alzheimer's disease.","O'Leary K","2026","Nature medicine","commentary","article","10.1038/d41591-026-00018-2","41917443",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0009744","GLP-1 Receptor Agonists and Acne: Evidence and Inference.","Rocha M","2026","International journal of dermatology","commentary","article","10.1111/ijd.70368","41795125",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009745","Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment.","Lohia S","2023","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms241713540","37686344","PMC10488289",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009746","Exendin-4 protects the hearts of rats from ischaemia/reperfusion injury by boosting antioxidant levels and inhibition of JNK/p66 Shc/NADPH axis.","Eid RA","2020","Clinical and experimental pharmacology & physiology","preclinical","article","10.1111/1440-1681.13299","32149419",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009747","Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.","Tran S","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13137","29364587",null,"PROSPERO:CRD42017057115",null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0009748","Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.","Raccah D","2017","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2017.1268598","27924636",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009749","Letter regarding \"GLP-1 receptor agonists reduce risk of major adverse limb events\".","Ji X","2026","Journal of vascular surgery","commentary","article","10.1016/j.jvs.2025.10.093","41881616",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0009750","Review of Article: Yahyavi et al. Benefits of glucagon-like peptide (GLP)-1 receptor agonists on 5-year risk of major amputation, all-cause mortality, myocardial infarction, and ischemic stroke in patients with chronic limb-threatening ischemia. Vasc Med. 2026;31(1):719-727.","Whipple MO","2026","Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing","narrative_review","article","10.1016/j.jvn.2026.07.003","42637488",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009751","[In obese, non-diabetic adults, tirzepatide results in greater weight loss than semaglutide.].","Serafini A","2025","Recenti progressi in medicina","other","article","10.1701/4588.45983","41176671",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009752","Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform: reply.","Eshak N","2026","Rheumatology (Oxford, England)","nonrandomized_study","article","10.1093/rheumatology/keag255","42143728",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; Comment; letter"],["R0009753","Cardioprotective diabetes drugs: what cardiologists need to know.","Brown JM","2019","Cardiovascular endocrinology & metabolism","narrative_review","article","10.1097/xce.0000000000000181","31942550","PMC6946151",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009754","Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin.","Chan JCN","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15700","38992869",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0009755","Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.","Jensterle M","2025","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgaf278","40341357",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0009756","Global uptake of GLP-1 receptor agonists in obese, non-diabetic patients with cardiovascular disease.","Chi KY","2026","European heart journal. Quality of care & clinical outcomes","other","article","10.1093/ehjqcco/qcaf104","40892440","PMC12766428",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009757","Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery.","Kweon S","2023","Biomaterials research","preclinical","article","10.1186/s40824-023-00421-7","37660070","PMC10474648",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0009758","Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.","Fu EL","2023","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000000000000115","36827225","PMC10278835",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0009759","GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study.","Salmanoglu M","2026","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina62010143","41597428","PMC12843924",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0009760","A sensitive method for the quantitation of the peptide-based glucagon-like peptide-1 receptor agonist liraglutide in plasma using microfluidics chromatography tandem MS.","King-Ahmad AJ","2018","Bioanalysis","other","article","10.4155/bio-2017-0239","29516741",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Validation Study; article"],["R0009761","Insulin Autoimmune Syndrome: Imaging Findings and Uptake Pattern With 68 Ga-Exendin-4 and 68 Ga-DOTATATE PET-CT.","Barapatre R","2026","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000005916","40258371",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0009762","Exenatide: pharmacokinetics, clinical use, and future directions.","Knop FK","2017","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2017.1282463","28085521",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0009763","Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patients","Lohia S","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.05.03.23289439",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0009764","Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient.","Wells DA","2026","Hospital pharmacy","case_report","article","10.1177/00185787261426980","41756106","PMC12932128",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009765","[Basal insulin glargine-lixisenatide fixed ratio combination (Suliqua®)].","Scheen AJ","2019","Revue medicale de Liege","other","article",null,"30793566",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009766","The residual cardiorenal risk in type 2 diabetes.","Giugliano D","2021","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-021-01229-2","33546683","PMC7866734",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; editorial; article"],["R0009767","Ophthalmic safety considerations when initiating GLP-1 receptor agonists in patients with diabetic retinopathy.","Joshi D","2026","The American journal of medicine","commentary","article","10.1016/j.amjmed.2025.11.001","41856732",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0009768","Management of NAFLD in primary care settings.","Wong VWS","2022","Liver international : official journal of the International Association for the Study of the Liver","narrative_review","article","10.1111/liv.15404","35986897",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009769","Corrigendum to \"Real-World Impact of GLP-1 Receptor Agonists on Health-Related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)\" [Clin Ther. 2026;48:291-293].","Seijas-Amigo J","2026","Clinical therapeutics","notice","article","10.1016/j.clinthera.2026.04.015","42177143",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0009770","Editorial: Global Obesity Rates Continue to Rise with Challenges for New Drug Treatments Including GLP-1 Receptor Agonists.","Parums DV","2025","Medical science monitor : international medical journal of experimental and clinical research","nonrandomized_study","article","10.12659/msm.950816","40746073","PMC12323555",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; editorial"],["R0009771","A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.","Chetty AK","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2023.12.010","38122931",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0009772","Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.","Jermendy G","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0483-4","30120754","PMC6167279",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; other; article"],["R0009773","Integrating a genotype-based follow-up algorithm in clinical surveillance to mitigate the risk of pancreatitis in patients treated with GLP-1R agonists.","Margoni A","2025","Pharmacological research","commentary","article","10.1016/j.phrs.2025.108060","41360350",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0009774","Publisher Correction: Microneedle patches deliver targeted GLP-1RAs-loaded nanoparticles for the treatment of rheumatoid arthritis.","Zhang H","2026","Journal of nanobiotechnology","notice","article","10.1186/s12951-026-04454-7","42185921","PMC13200345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0009775","An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.","Novodvorský P","2022","Expert opinion on drug safety","randomized_trial","article","10.1080/14740338.2021.1978974","34641742",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0009776","[Onset of type 1 diabetes after treatment with online-prescribed semaglutide].","Hasse L","2026","Ugeskrift for laeger","case_report","article","10.61409/v06250507","41738100",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; English Abstract; article"],["R0009777","Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.","Singh AK","2020","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2020.04.051","32470852",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0009778","Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial.","Shuai Y","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14198","32965075",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009779","Liraglutide Mortality Effect on Atrial Fibrillation Patients","Haloot J","2021","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.163858750.00925195/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0009780","Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?","Le Roux C","2024","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2024.2311731","38299476",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Review; Journal Article; article"],["R0009781","GLP-1RA Use and the Risk of Heart Failure in Patients With Diabetes: Association or Causation?","Inoue K","2026","Circulation","randomized_trial","article","10.1161/circulationaha.126.078150","41973838","PMC13134813",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; research-article; editorial"],["R0009782","Beyond GLP-1 Agonists: An Adaptive Ketogenic-Mediterranean Protocol to Counter Metabolic Adaptation in Obesity Management.","García-Gorrita C","2025","Nutrients","protocol","article","10.3390/nu17162699","40871728","PMC12389659",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0009783","Re-evaluating GLP-1 receptor agonist-associated changes in copeptin.","Jiang C","2026","European journal of endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag065","41986882",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; Comment; article"],["R0009784","Journal club: GLP-1 receptor agonists in idiopathic intracranial hypertension.","Cleaver J","2026","Practical neurology","other","article","10.1136/pn-2025-005071","41825874",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009785","Diagnosis 101: diabetic kidney disease.","Lerma EV","2022","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfac163","36158143","PMC9494539",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; article"],["R0009786","Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists.","Giorgino F","2016","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.2775","26787264","PMC5071744",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0009787","Evaluating the bioequivalence and safety of liraglutide injection versus Victoza® in healthy Chinese subjects: a randomized, open, two-cycle, self-crossover phase I clinical trial.","Liu C","2023","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2023.1326865","38186650","PMC10766854",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0009788","Weight changes following antidiabetic mediation use: Real-world evidence from health system data.","Lyu B","2022","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.600","36238229","PMC9535667",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009789","Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials","Njei B","2024","Authorea Preprints","systematic_review","preprint","10.22541/au.171585503.34303032/v1",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","3","FALSE","Preprint; preprint"],["R0009790","Most Favored Nation Pricing and Affordability of GLP-1RAs for Obesity Treatment in Medicare.","Kim DD","2026","JAMA network open","other","article","10.1001/jamanetworkopen.2026.13098","42138925","PMC13179543",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009791","Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management.","Hoffman K","2026","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2026.09.045","42759720",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0009792","Microbial expression of Exendin-4 analog and its efficacy in mice model.","Kodaganti BP","2017","Biologicals : journal of the International Association of Biological Standardization","preclinical","article","10.1016/j.biologicals.2017.05.002","28554726",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009793","GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity.","Cooper ME","2025","The Journal of clinical investigation","narrative_review","article","10.1172/jci194749","41178712","PMC12578383",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0009794","Peritoneal Incretin Deficiency and Tirzepatide as a Multi-Axis Adjuvant Hypothesis in Treatment-Refractory Endometriosis: A Mechanistic Framework Linking Metabolism, Immunity, Fibrosis, and Nociception.","Jacobsen L","2026","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms27135678","42449952","PMC13362427",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; other; article"],["R0009795","Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA.","Shin H","2021","Diabetes care","nonrandomized_study","article","10.2337/dc20-2926","34385345","PMC8385465",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article; other"],["R0009796","Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.","Aroda VR","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14453","34060209","PMC8453868",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0009797","Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.","Lucey M","2021","Molecular pharmacology","preclinical","article","10.1124/molpharm.121.000270","34315812","PMC8626645",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009798","Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.","Raya PM","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13660","30740861","PMC6594226",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009799","Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland.","Vaden A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70920","42264960","PMC13449066",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009800","Incretin-Based Therapies in Women With Obesity-Related HFpEF: Time to STEP Into a Paradigm of Integrated Care.","Ostrominski JW","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.06.006","38917937",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009801","Effect of anti-hyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells.","Kapadia P","2021","European journal of pharmacology","other","article","10.1016/j.ejphar.2021.174249","34116042",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0009802","Sarcopenia in the era of GLP-1 receptor agonists: Implications for the internist.","Shaooli RC","2026","The American journal of medicine","commentary","article","10.1016/j.amjmed.2026.02.034","41794205",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009803","RYGB induces vagal sensory neuropathy characterized by altered Glp1r expression and enhanced exendin-4 responsiveness in male mice.","Merchant W","2026","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00452.2025","41385561","PMC12797217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009804","Semaglutide Alleviates Ovary Inflammation via the AMPK/SIRT1/NF‑κB Signaling Pathway in Polycystic Ovary Syndrome Mice.","Liu M","2024","Drug design, development and therapy","preclinical","article","10.2147/dddt.s484531","39247793","PMC11380913",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009805","A case series of incidents reported to webAIRS relating to glucagon-like peptide 1 agonist use.","Lam CY","2025","Anaesthesia and intensive care","case_report","article","10.1177/0310057x241311597","40145463",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009806","Production of active Exendin-4 in Nicotiana benthamiana and its application in treatment of type-2 diabetics.","Akter S","2022","Frontiers in plant science","preclinical","article","10.3389/fpls.2022.1062658","36618620","PMC9812950",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009807","[Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease].","Pintos C","2023","Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)","nonrandomized_study","article","10.31053/1853.0605.v80.n4.42272","38150199","PMC10851389",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","English Abstract; Journal Article; research-article; article"],["R0009808","Effects of GLP1-RAs and SGLT2i on liver steatosis and fibrosis in MASLD with type 2 diabetes.","Mega A","2026","Minerva medica","other","article","10.23736/s0026-4806.26.09922-2","42507338",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009809","Glucagon-Like Peptide-1 Agonist Effects on Weight Loss and Heart Failure Hemodynamics.","Alvarado A","2026","JACC. Case reports","other_trial","article","10.1016/j.jaccas.2026.110528","42788915",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Case Reports; Journal Article; article"],["R0009810","Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study.","McKenzie AL","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01547-0","38421559","PMC10951146",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009811","Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists.","Labandeira CM","2021","Frontiers in neuroendocrinology","narrative_review","article","10.1016/j.yfrne.2021.100914","33845041",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009812","Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.","Yang W","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15414","38172083",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0009813","Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission.","Figueredo Y","2023","Cureus","case_report","article","10.7759/cureus.34331","36865977","PMC9972903",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009814","GLP-1 receptor agonists and clinical outcomes in patients with type 2 diabetes undergoing transcatheter aortic valve implantation.","Pham HN","2026","European heart journal. Quality of care & clinical outcomes","nonrandomized_study","article","10.1093/ehjqcco/qcaf135","41206745",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0009815","Transitioning to non-insulin therapy in a patient receiving high dose insulin.","Mishriky BM","2020","Journal of the American Association of Nurse Practitioners","case_report","article","10.1097/jxx.0000000000000403","32282568",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009816","Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.","Athyros VG","2016","Current vascular pharmacology","other_trial","article","10.2174/1570161114666160909161537","27633290",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; editorial"],["R0009817","The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice.","Cai J","2024","Protein expression and purification","preclinical","article","10.1016/j.pep.2023.106373","37730142",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009818","[Features of the course of COVID-19 in patients with type 2 diabetes mellitus].","Karaseva EA","2023","Terapevticheskii arkhiv","nonrandomized_study","article","10.26442/00403660.2023.11.202478","38158945",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","English Abstract; Journal Article; article"],["R0009819","GLP-1 receptor agonists are associated with reduced nicotine dependence in hidradenitis suppurativa: A TriNetX new-user, active-comparator study.","Golbasi NC","2026","JAAD international","other","article","10.1016/j.jdin.2026.04.006","42179894","PMC13196019",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0009820","Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis.","Barer Y","2026","Parkinsonism & related disorders","systematic_review","article","10.1016/j.parkreldis.2025.108171","41468681",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0009821","Recurrent bilateral brachial plexus neuritis following rapid semaglutide-induced weight loss: a case report.","Lesinszki LS","2026","BMC neurology","case_report","article","10.1186/s12883-026-04664-4","41588354","PMC12918017",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0009822","Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.","Banerjee M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70187","41063381",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0009823","Antagonizing GIPR adds fire to the GLP-1R flame.","Novikoff A","2024","Trends in endocrinology and metabolism: TEM","other_trial","article","10.1016/j.tem.2024.04.016","38763780",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0009824","First oral GLP-1 receptor agonist approved for weight loss.","Aschenbrenner DS","2026","The American journal of nursing","other","article","10.1097/ajn.0000000000000276b","41881936",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009825","Management of type 2 diabetes in chronic kidney disease.","Triozzi JL","2021","BMJ open diabetes research & care","other","article","10.1136/bmjdrc-2021-002300","34312158","PMC8314731",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0009826","Letter: From Safety to Precision-Optimising the Use of GLP-1 Receptor Agonists in Gastroenterology.","St-Pierre J","2026","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.70538","41856913",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0009827","GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.","Rodbard HW","2019","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other_trial","article","10.4158/ep-2018-0444","30865526",null,null,"S000329; S000372; S000878; S001219; S001872; S001876","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0009828","Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism.","Joly A","2025","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaf158","41163813","PMC12559790",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0009829","Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist.","Banning F","2017","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/dme.13527","29044799",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009830","Meta-analysis of the association between new hypoglycemic agents and digestive diseases.","Wang YW","2022","Medicine","systematic_review","article","10.1097/md.0000000000030072","36042668","PMC9410596",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0009831","GLP-1 receptor agonist use for obesity in service personnel.","Jecks N","2026","BMJ military health","commentary","article","10.1136/military-2025-003159","41072951",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0009832","Obesity-Related Glomerulopathy: Clinical Management.","Herman-Edelstein M","2021","Seminars in nephrology","narrative_review","article","10.1016/j.semnephrol.2021.06.007","34715965",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009833","Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation.","Yan C","2023","Journal of molecular cell biology","preclinical","article","10.1093/jmcb/mjad014","36866528","PMC10478625",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009834","Liraglutide-mediated protection against ethanol-induced gastric ulcer in male and female rats: enhancement of mucosal defense, anti-inflammatory and antioxidant mechanism.","Doğan A","2026","The Journal of pharmacy and pharmacology","randomized_trial","article","10.1093/jpp/rgag065","42341220",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0009835","The journey to understanding incretin systems: Theory, practice and more theory.","Yabe D","2019","Journal of diabetes investigation","other","article","10.1111/jdi.13123","31361402","PMC6717807",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009836","Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.","Sun F","2015","Diabetes technology & therapeutics","systematic_review","article","10.1089/dia.2014.0188","25375397","PMC4290796",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; research-article; review"],["R0009837","Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.","Lavernia F","2020","Postgraduate medicine","randomized_trial","article","10.1080/00325481.2020.1798638","32815436",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; Video-Audio Media; article"],["R0009838","The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study.","Koska J","2021","Diabetes care","randomized_trial","article","10.2337/dc20-2014","33495294","PMC8247511","ClinicalTrials.gov:NCT02162550","S000600","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Pragmatic Clinical Trial; research-article; article; other"],["R0009839","Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","Luo L","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70986","42310900","PMC13448963",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Network Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0009840","GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension.","Sterling JK","2020","Cell reports","preclinical","article","10.1016/j.celrep.2020.108271","33147455","PMC7660987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0009841","Effect of GLP-1RA on mortality and cardiovascular risk in adults with psoriasis and type 2 diabetes.","Lin C","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","commentary","article","10.1111/jdv.70454","41964316","PMC13505685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0009842","An Exhaustive Exploration of the Semaglutide-GLP-1R Sequence Space towards the Design of Semaglutide Analogues with Elevated Binding Affinity to GLP-1R","Li W","2024","Preprints.org","other","preprint","10.20944/preprints202405.0258.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009843","Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study.","Wang J","2019","British journal of clinical pharmacology","other_trial","article","10.1111/bcp.14091","31396983","PMC6955414","ClinicalTrials.gov:NCT02467790","S001838","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009844","Use of dipeptidyl peptidase-4 inhibitors and risk of splanchnic vein thrombosis: A Danish nationwide new-user active comparator cohort study.","Pottegård A","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14253","33184953",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0009845","Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.","Vedtofte L","2017","Expert opinion on drug safety","other_trial","article","10.1080/14740338.2017.1288715","28150516",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0009846","A review on cardiovascular effects of newer hypoglycaemic medications.","Cutshall BT","2017","Annals of medicine","narrative_review","article","10.1080/07853890.2017.1335428","28540743",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009847","GLP-1 agonists for people living with HIV and obesity, is there a potential?","Zino L","2023","HIV medicine","other","article","10.1111/hiv.13521","37340561",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009848","JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk.","Wyne KL","2022","Journal of clinical lipidology","randomized_trial","article","10.1016/j.jacl.2022.03.007","35430025",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0009849","Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.","Dhir G","2018","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","narrative_review","article","10.1136/jim-2017-000554","28918389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009850","Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.","Kostadinova KA","2026","Chemistry (Weinheim an der Bergstrasse, Germany)","other","article","10.1002/chem.71280","42315994","PMC13628533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009851","Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis.","Ness A","2025","Helicobacter","nonrandomized_study","article","10.1111/hel.70014","39902748","PMC11792433",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009852","Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.","Hageen AW","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70313","42706739","PMC13550879",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Comparative Study; Review; review-article; article"],["R0009853","[A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide].","Troshina EA","2025","Problemy endokrinologii","other","article","10.14341/probl13677","41640144","PMC12954439",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; research-article; article"],["R0009854","Exploring the Protective Effects of Traditional Antidiabetic Medications and Novel Antihyperglycemic Agents in Diabetic Rodent Models.","Tartau CG","2025","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph18050670","40430489","PMC12114790",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009855","Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.","Levi O","2026","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","randomized_trial","article","10.1093/europace/euag091","42015513","PMC13191121",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Comparative Study; research-article; article"],["R0009856","Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.","Sabouret P","2023","Minerva cardiology and angiology","systematic_review","article","10.23736/s2724-5683.22.05900-2","35195376",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Systematic Review; Network Meta-Analysis; article"],["R0009857","Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions.","Tommerdahl KL","2023","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2023.2203319","37071054","PMC10198950",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; research-article; article"],["R0009858","Letter: From Safety to Precision-Optimising the Use of GLP-1 Receptor Agonists in Gastroenterology: Authors' Reply.","Pomenti S","2026","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.70547","41874346",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0009859","CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.","Schnell O","2025","Cardiovascular diabetology","other_trial","article","10.1186/s12933-025-02700-0","40316962","PMC12048985",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; letter; article"],["R0009860","Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions.","Georgiou A","2026","Communications medicine","other","article","10.1038/s43856-026-01471-3","41760788","PMC13066627",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009861","Effect of Semaglutide Combined With Conventional Insulin Therapy on Blood Glucose Control and Renal Function in Elderly Patients With Type 2 Diabetes.","Ye L","2026","International journal of endocrinology","randomized_trial","article","10.1155/ije/1543983","42087924","PMC13136936",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0009862","The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review.","Kaye AD","2024","Cureus","narrative_review","article","10.7759/cureus.67232","39301360","PMC11410460",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0009863","Calculating cost per event avoided using a composite number needed to treat.","Toliver J","2026","Journal of medical economics","other","article","10.1080/13696998.2026.2615606","41562647",null,"ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT01394952","S000147; S000716","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0009864","Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients with Type 2 Diabetes Mellitus: A Retrospective Review.","Kim HS","2021","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2020.0180","33535737","PMC8640157",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009865","Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).","Wilson L","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70436","41491349","PMC12890754",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0009866","A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?","Maitra NS","2022","Current cardiology reports","narrative_review","article","10.1007/s11886-022-01694-5","35352278",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0009867","Oral GLP-1 receptor agonists: competition for efficacy and tolerability.","Nauck MA","2026","Lancet (London, England)","other","article","10.1016/s0140-6736(26)00360-0","41765027",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009868","Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss.","Thorsø Larsen A","2023","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2023.175837","37329973",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009869","Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.","Buckley ST","2018","Science translational medicine","other","article","10.1126/scitranslmed.aar7047","30429357",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009870","Inappropriate use of GLP-1-based antiobesity medications: beyond appropriate drug use toward appropriate weight reduction.","Ogawa W","2026","Diabetology international","commentary","article","10.1007/s13340-026-00926-1","42656873","PMC13507000",null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0009871","High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.","Fried L","2023","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","nonrandomized_study","article","10.1093/ndt/gfac140","35389468","PMC9976755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009872","Methodological Concerns Regarding BMI Imbalance and Competing Risks in a Head-to-Head Comparison of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Incident Dementia.","Jean SS","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70784","41983525",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009873","RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control.","Ullah H","2026","Endocrine connections","notice","article","10.1530/ec-25-0723","41532579","PMC13159619",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retraction Notice; Retracted Publication; Retraction of Publication; retraction; article"],["R0009874","Attitudes towards injectable GLP-1 drugs for obesity treatment: a qualitative interview study with healthcare professionals","Capaian RC","2025","PsyArXiv","other","preprint","10.31234/osf.io/k2njg_v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009875","GLP-1 receptor agonists and male sexual health: Translating cardiometabolic benefits into erectile outcomes.","Noakes J","2026","International journal of impotence research","narrative_review","article","10.1038/s41443-026-01254-3","41840125",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009876","2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes.","Chiang CE","2021","JACC. Asia","randomized_trial","article","10.1016/j.jacasi.2021.08.003","36338159","PMC9627904",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0009877","Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins.","Ríos JL","2019","Planta medica","narrative_review","article","10.1055/a-0897-7492","31064029",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009878","Comment on \"Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study\" and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid.","Schwager Z","2019","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2019.01.086","30738123",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Letter; Comment; article"],["R0009879","Semaglutide and tirzepatide: Oral cavity effects of weight-loss therapies.","Bernardo ME","2026","EXCLI journal","commentary","article","10.17179/excli2025-9065","41768861","PMC12946442",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article; letter"],["R0009880","The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease.","Vachliotis ID","2023","Current obesity reports","narrative_review","article","10.1007/s13679-023-00519-y","37407724","PMC10482776",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009881","Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia","Uhrenholt N","2022","European psychiatry : the journal of the Association of European Psychiatrists","randomized_trial","article","10.1192/j.eurpsy.2022.2064",null,"PMC9567870",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0009882","Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures.","Pugliese NR","2025","Cardiovascular diabetology","other_trial","article","10.1186/s12933-025-02778-6","40405237","PMC12096527",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0009883","Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential.","Al-Noshokaty TM","2025","Toxicology reports","narrative_review","article","10.1016/j.toxrep.2025.101895","39911322","PMC11795145",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009884","Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.","Østergaard L","2016","Expert review of clinical pharmacology","other_trial","article","10.1586/17512433.2016.1121808","26573176",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0009885","The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.","Lyu X","2021","International journal of endocrinology","systematic_review","article","10.1155/2021/6616693","33679973","PMC7910049","PROSPERO:CRD42020173199",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0009886","GLP-1 Receptor Agonists: A Paradigm Shift in Cardiovascular Prevention Beyond Diabetes.","Almohammadi AA","2026","International journal of preventive medicine","nonrandomized_study","article","10.4103/ijpvm.ijpvm_388_25","42441124","PMC13336522",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0009887","Training for prevention: exercise prescription as an Olympic discipline in the era of GLP-1 receptor agonists.","Mapelli M","2026","European journal of internal medicine","commentary","article","10.1016/j.ejim.2026.106823","41813478",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009888","GLP-1 Agonists' Effect on Infection and Union after Tibiotalar Fusion, Subtalar Fusion, Triple Arthrodesis.","Levidy MF","2025","Foot & ankle international","nonrandomized_study","article","10.1177/10711007251328370","40162958","PMC12145462",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009889","Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency.","Alavi SE","2019","Molecular pharmaceutics","narrative_review","article","10.1021/acs.molpharmaceut.9b00308","31050435",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0009890","GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease.","Kalinderi K","2024","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms25073812","38612620","PMC11011817",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0009891","Association Between Semaglutide or Tirzepatide Therapy and Residual Gastric Content: A Potential Danger During Upper Endoscopy.","Wen J","2025","Cureus","nonrandomized_study","article","10.7759/cureus.96771","41393547","PMC12701735",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009892","GLP-1 receptor agonists in cardiovascular disease: a guide for cardiologists.","Ayton SL","2026","The British journal of cardiology","other","article","10.5837/bjc.2026.038","42719822","PMC13557138",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009893","A Matched Pairs Analysis of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.","Lam T","2026","American journal of clinical dermatology","commentary","article","10.1007/s40257-026-01014-5","41739351",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009894","RF04 | PSUN295 Evolution of Monomeric Multi-Agonists of GLP-1 and NPY Receptors",null,"2022","Journal of the Endocrine Society","preclinical","article",null,null,"PMC9625289",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0009895","The Effect of Exenatide on Platelets Ratio Index and Fibrosis-4 Index in Obese Patients With Diabetes Mellitus.","Sezer GE","2025","International journal of endocrinology","nonrandomized_study","article","10.1155/ije/6332117","40330499","PMC12052462",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0009896","Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.","Falster MO","2026","British journal of clinical pharmacology","other","article","10.1002/bcp.70715","42515931",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009897","Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system.","Rosselot C","2024","Science translational medicine","preclinical","article","10.1126/scitranslmed.adg3456","38985854","PMC12051162",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0009898","Assessing the Geriatric Risk: Excessive Weight Loss and Risk of Falls With GLP-1 Receptor Agonists.","Ahmed SU","2026","Journal of the American Medical Directors Association","commentary","article","10.1016/j.jamda.2026.106159","41796610",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009899","PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice.","Holt MK","2020","Molecular metabolism","preclinical","article","10.1016/j.molmet.2020.101024","32446875","PMC7317700",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009900","Case Report: A case of occult insulinoma localized by [18F] FB (ePEG12)12-exendin-4 positron emission tomography with negative findings of selective arterial calcium stimulation test.","Sakaki K","2025","Frontiers in endocrinology","case_report","article","10.3389/fendo.2025.1556813","40405975","PMC12095015",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0009901","Hearing protection and damage mitigation in Chinchillas exposed to repeated low-intensity blasts.","Jiang S","2023","Hearing research","preclinical","article","10.1016/j.heares.2023.108703","36680874",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, U.S. Gov't, Non-P.H.S."],["R0009902","Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes.","Kim C","2026","Nature communications","nonrandomized_study","article","10.1038/s41467-026-71307-0","41935054","PMC13396638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0009903","Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches.","Boer GA","2020","Biology","narrative_review","article","10.3390/biology9120473","33339298","PMC7766765",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0009904","The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.","Liebisch-Rey H","2023","F1000Research","nonrandomized_study","article","10.12688/f1000research.128441.2","38125558","PMC10730985",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; research-article; article"],["R0009905","The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Mahar MU","2024","Journal of obesity & metabolic syndrome","systematic_review","article","10.7570/jomes24008","39681390","PMC11704219",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0009906","Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage.","Niazi SK","2026","Frontiers in drug delivery","narrative_review","article","10.3389/fddev.2026.1776167","41939723","PMC13047097",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009907","Response to Comment on Hong et al. Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes Care 2025;48:1728-1736.","Hong AT","2026","Diabetes care","nonrandomized_study","article","10.2337/dci26-0037","42160602",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0009908","Patients after acute myocardial infarction: potential of semaglutide in prognosis for reducing events and mortality.","Velasco Á","2026","Revista clinica espanola","nonrandomized_study","article","10.1016/j.rceng.2026.502455","41520703",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Case Reports; article"],["R0009909","Response to letter to the editor: \"re-evaluating GLP-1 receptor agonist-associated changes in copeptin\".","Leibnitz S","2026","European journal of endocrinology","commentary","article","10.1093/ejendo/lvag066","41986886",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; letter"],["R0009910","Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.","Ferdinand KC","2014","Hypertension (Dallas, Tex. : 1979)","randomized_trial","article","10.1161/hypertensionaha.114.03062","24980665",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009911","Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis.","Ghosal S","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-022-01359-0","36566447","PMC9943809",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0009912","Therapies based on GLP-1 receptor agonists: significance, challenges, and opportunities.","Jackson-Morris A","2026","The Lancet. Global health","other","article","10.1016/s2214-109x(26)00009-4","41763239",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009913","Reply to: \"Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid\".","Varpuluoma O","2019","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2019.02.005","30738121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; letter"],["R0009914","Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.","Valentine V","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-017-0287-y","28721686","PMC5544623",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0009915","Combination of SGLT2 Inhibitors and GLP-1 Receptor Agonists in PTDM Treatment in Kidney Transplant Recipients: Synergistic Effect With Added Value in Terms of Nephroprotection.","Juric I","2024","Transplantation proceedings","other","article","10.1016/j.transproceed.2024.02.026","39069457",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009916","Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.","Tannu M","2024","Circulation","randomized_trial","article","10.1161/circulationaha.124.068962","38934111",null,"ClinicalTrials.gov:NCT03936660","S002431","pubmed; europepmc; openalex","FALSE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0009917","Patterns of Medication Use and Prescription Fills for Cardioprotective Anti-Hyperglycemic Agents in the United States","Nargesi AA","2022","medRxiv","nonrandomized_study","preprint","10.1101/2022.01.31.22270187",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0009918","Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.","Tanaka A","2018","Cardiovascular diabetology","commentary","article","10.1186/s12933-018-0731-y","29895290","PMC5996475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0009919","Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus.","Kurinami N","2025","Endocrinology and metabolism (Seoul, Korea)","nonrandomized_study","article","10.3803/enm.2025.2420","41088952","PMC12765867",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009920","Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology.","Hong T","2021","Diabetes/metabolism research and reviews","other","article","10.1002/dmrr.3416","33120435",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Consensus Statement; article"],["R0009921","The glucagon-like peptide-1 receptor agonist liraglutide improves hypoxia-induced pulmonary hypertension in mice partly via normalization of reduced ET(B) receptor expression.","Honda J","2018","Physiological research","preclinical","article","10.33549/physiolres.933822","29947538",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0009922","A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota.","Zhao L","2018","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2018.00233","29867765","PMC5966539",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009923","Efficacy of Polyethylene Glycol Loxenatide in Combination with Basal Insulin in Patients with Type 2 Diabetes Mellitus: A Retrospective Real-World Study.","Liu X","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01737-4","40214898","PMC12317928","ChiCTR:ChiCTR2400086699",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009924","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference.","Gupta K","2024","Current atherosclerosis reports","randomized_trial","article","10.1007/s11883-024-01218-2","38829515",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0009925","Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report.","Denny O","2024","Journal of pharmacy practice","case_report","article","10.1177/08971900241256775","38794807",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0009926","Addition of low-dose liraglutide to insulin therapy is useful for glycaemic control during the peri-operative period: effect of glucagon-like peptide-1 receptor agonist therapy on glycaemic control in patients undergoing cardiac surgery (GLOLIA study).","Makino H","2019","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/dme.14084","31335979",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0009927","Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment.","Pelle MC","2021","Life (Basel, Switzerland)","other_trial","article","10.3390/life12010029","35054422","PMC8779403",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0009928","Implementation or Intrinsic Efficacy? Interpreting Real-World Comparisons of GLP-1 Receptor Agonists.","Cheng R","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70174","41792037",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0009929","Effects of Semaglutide on Dumping Syndrome and Reactive Hypoglycemia After Bariatric Surgery: A Systematic Review and Meta-Analysis.","Eisa N","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70161","42140745",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0009930","Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates.","Abdelmannan D","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2023.111045","38070546",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0009931","Endocrine regulation of cardiac fibrosis: implications for HFpEF.","Chaturvedi R","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1911465","42602176","PMC13473827",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009932","Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review.","Branyiczky MK","2026","International journal of dermatology","systematic_review","article","10.1111/ijd.70133","41174840","PMC13067326",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; brief-report; review"],["R0009933","Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.","Herfarth H","2024","The American journal of gastroenterology","randomized_trial","article","10.14309/ajg.0000000000002801","38668926","PMC11365596",null,"S001081; S001709","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0009934","Evaluation of social media videos on weight-loss surgery and GLP-1 agonists: a content quality and reliability analysis.","Lee S","2025","Surgical endoscopy","other","article","10.1007/s00464-025-11938-4","40634725","PMC12408733",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009935","The Efficacy of Glucagon-like Peptide-1 Based Therapies in Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis.","Christophides T","2026","Journal of clinical medicine","systematic_review","article","10.3390/jcm15124450","42355618","PMC13301924","PROSPERO:CRD42024606997",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0009936","The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer.","Stein MS","2024","Endocrine oncology (Bristol, England)","preclinical","article","10.1530/eo-23-0015","38313829","PMC10831528",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009937","Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis.","Zufry H","2026","Obesity research & clinical practice","systematic_review","article","10.1016/j.orcp.2026.02.002","41723034",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Comparative Study; review"],["R0009938","Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.","Johnston SS","2014","Advances in therapy","nonrandomized_study","article","10.1007/s12325-014-0166-0","25408484",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009939","Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease.","Chan JCH","2022","Current cardiology reviews","narrative_review","article","10.2174/1573403x18666220511114443","35546744","PMC9893147",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009940","Clinical application of cluster analysis in patients with newly diagnosed type 2 diabetes.","Wang Y","2025","Hormones (Athens, Greece)","other","article","10.1007/s42000-024-00593-4","39230795",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0009941","443. Do people living with HIV lose weight on GLP-1 agonist therapy?",null,"2022","Open forum infectious diseases","nonrandomized_study","article",null,null,"PMC9752354",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0009942","Clarifying Divergent Mortality and MACE Findings With GLP-1 RA-SGLT2i Combination Therapy.","Zhang Z","2026","Journal of gastroenterology and hepatology","commentary","article","10.1111/jgh.70662","42587268",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009943","Associations between Eating Behaviours and Psychological Characteristics with Body Mass Index Change and Appetite-Related Changes during Incretin-Based Therapy.","Kapan A","2026","Obesity facts","other","article","10.1159/000550051","41379758","PMC12846313",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009944","Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.","Arnold SV","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15032","36843558",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009945","BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.","AlTaweel M","2026","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2026.2692167","42381378",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0009946","Glucagon like Peptide-1 (GLP‑1) receptor agonists: There is no such thing as a free lunch.","Hendrickse PW","2026","The American journal of medicine","commentary","article","10.1016/j.amjmed.2026.02.026","41785948",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009947","Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.","Nassar M","2023","Journal of diabetes","systematic_review","article","10.1111/1753-0407.13359","36690377","PMC9934962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0009948","Continuation of GLP-1 Receptor Agonists During Post-Acute Skilled Nursing Facility Stays and 30-Day Outcomes",null,"2025","Innovation in aging","other","article",null,null,"PMC12762668",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0009949","Cardiovascular Disease Prevention: Pharmacologic Prevention.","Reamy BV","2022","FP essentials","other","article",null,"36069719",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009950","Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial.","Nelson AJ","2025","American journal of preventive cardiology","other_trial","article","10.1016/j.ajpc.2025.101058","40809819","PMC12345323",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0009951","Effect of Glucagon-Like Peptide-1 Deprescription Following Nutrition Therapy via Telemedicine on Glycemia and Body Weight among People with Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study","McKenzie AL","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.06.18.23291518",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0009952","γδ T-cell interferon-γ production reflects metabolic improvement during SGLT2 inhibitor-based therapy in type 2 diabetes.","Troskot Cuculić M","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1922668","42798540","PMC13612360",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009953","Editorial: Two for the Price of One-GLP-1 Receptor Agonists Could Be More Effective Than MAUD in Patients With AUD and Metabolic Dysfunction.","Fozouni L","2026","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/apt.70655","41933385",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Editorial; editorial"],["R0009954","Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study.","Al Refaie A","2025","Endocrine","nonrandomized_study","article","10.1007/s12020-024-04085-8","39521749",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Preprint; preprint; article"],["R0009955","The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.","Thomas MC","2017","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(17)30069-1","28431667",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0009956","Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic.","Kvapil M","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-017-0323-y","29063511","PMC5688988",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009957","FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity.","Do D","2026","JACC. Advances","other","article","10.1016/j.jacadv.2025.102575","41576595","PMC12860981",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0009958","Comment on: Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform.","Wang J","2026","Rheumatology (Oxford, England)","nonrandomized_study","article","10.1093/rheumatology/keag151","41923358",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; Comment; letter"],["R0009959","GLP-1 receptor agonists in rheumatic disease.","The Lancet Rheumatology","2026","The Lancet. Rheumatology","commentary","article","10.1016/s2665-9913(26)00011-1","41605556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0009960","Ozempic, Semaglutide Injection Misuse Reported Among a Nationally Representative Sample in the United States","Ware OD","2025","medRxiv","other","preprint","10.64898/2025.12.25.25343021",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009961","Addressing Tamoxifen-Associated Weight Gain: Lifestyle and Pharmacotherapy Options.","Fore-Williams L","2026","Journal of the advanced practitioner in oncology","narrative_review","article","10.6004/jadpro.2026.17.3.3","42170166","PMC13188626",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0009962","Pharmacological Treatment of Obesity in Older Adults.","Žižka O","2024","Drugs & aging","narrative_review","article","10.1007/s40266-024-01150-9","39514148","PMC11554829",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; research-article; article"],["R0009963","Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice.","Desjardins EM","2023","Cell reports. Medicine","preclinical","article","10.1016/j.xcrm.2023.101193","37729871","PMC10518624",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0009964","Once-Weekly Semaglutide in Adolescents with Obesity.","Weghuber D","2022","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2208601","36322838","PMC9997064","ClinicalTrials.gov:NCT04102189","S001529; S001945","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0009965","Correction: Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.","Lingvay I","2025","Diabetologia","notice","article","10.1007/s00125-025-06435-1","40323333","PMC12176977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0009966","Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer.","Zhu C","2024","Frontiers in pharmacology","other","article","10.3389/fphar.2024.1387243","39104385","PMC11298396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009967","HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression.","Bethel MA","2021","Diabetes care","systematic_review","article","10.2337/dc20-1815","33444163","PMC7783944",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review-article; other; review"],["R0009968","The heart rate paradox and inferential limits of the GLP-1 receptor agonist-atrial fibrillation association.","Zhan X","2026","Metabolism: clinical and experimental","commentary","article","10.1016/j.metabol.2026.156598","41895462",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0009969","The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy.","Hornick MA","2026","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-026-02120-4","42225949",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0009970","Obesity and Metabolic Syndrome: Current Insights and Future Directions.","Zarkasi Z","2025","British journal of hospital medicine (London, England : 2005)","narrative_review","article","10.12968/hmed.2025.0127","40994370",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0009971","Therapeutic role of GLP-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis.","Gadelmawla AF","2026","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","systematic_review","article","10.1007/s10072-026-08843-6","41772331",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0009972","Endoplasmic reticulum stress: A common pharmacologic target of cardioprotective drugs.","Mooradian AD","2022","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2022.175221","35998751",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009973","In Vitro Characterization of Agonist and Antagonist Peptide Binding Interaction Kinetics to GLP-1R in HEK293T Cells Using Surface Plasmon Resonance Microscopy.","A Thirumurthy M","2026","ACS medicinal chemistry letters","preclinical","article","10.1021/acsmedchemlett.6c00091","42157826","PMC13181479",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009974","Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.","Douros A","2018","Diabetes care","nonrandomized_study","article","10.2337/dc17-2280","30150234",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0009975","Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: A prospective cohort.","Graybill S","2021","Andrology","nonrandomized_study","article","10.1111/andr.12966","33400403",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0009976","Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial","Fox C","2021","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC8089220",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0009977","Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.","Yang CT","2020","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-020-01053-0","32534570","PMC7293792",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; Preprint; other; preprint; article"],["R0009978","A multi-organ atlas of microcirculatory signatures for systemic profiling of diabetic and therapeutic states.","Li Y","2026","Scientific data","preclinical","article","10.1038/s41597-026-07430-w","42120879","PMC13427728",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Dataset; data-paper"],["R0009979","Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis.","Masson W","2021","European journal of preventive cardiology","systematic_review","article","10.1093/eurjpc/zwaa074","33606884",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0009980","GLP-1 receptor agonism reduces PTSD-like anxiety and alters amygdala-hippocampal activity patterns in a Chemogenetic mouse model.","Akillioglu K","2026","Progress in neuro-psychopharmacology & biological psychiatry","preclinical","article","10.1016/j.pnpbp.2026.111804","42342196",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009981","AMD Risk in Users of GLP-1RAs and Other Weight-Loss Drugs.","Mihalache A","2026","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2026.0007","41784989",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009982","Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.","Kondo N","2021","Annals of nuclear medicine","preclinical","article","10.1007/s12149-020-01540-0","33067731",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009983","Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.","Hidayat K","2019","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","systematic_review","article","10.1007/s00198-019-04968-x","31134305",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0009984","GLP-1 Receptor Agonist Exposure During Pregnancy: A Systematic Review and Meta-Analysis of Adverse Pregnancy Outcomes.","Kodali LSM","2026","JACC. Advances","systematic_review","article","10.1016/j.jacadv.2026.102649","41925658","PMC13309306",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; article"],["R0009985","Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.","Neves JS","2026","Diabetologia","randomized_trial","article","10.1007/s00125-025-06637-7","41419618",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; article"],["R0009986","Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.","Hong EG","2024","Advances in therapy","nonrandomized_study","article","10.1007/s12325-024-02830-z","38512540","PMC11052798",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0009987","Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia.","Gelhorn HL","2020","Patient preference and adherence","other","article","10.2147/ppa.s265126","33204074","PMC7667182",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0009988","Adoption of new medicines in primary care: A comparison between the uptake of new oral anticoagulants and diabetes medicines.","Dankers M","2024","British journal of clinical pharmacology","nonrandomized_study","article","10.1111/bcp.15959","37945350",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0009989","Generation of High-Affinity Anti-GIPR Antagonist Antibodies with Sustained and Non-rebound Weight Loss in DIO Mice by AlfaBodY","Long Y","2026","bioRxiv","preclinical","preprint","10.64898/2026.04.21.719783",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0009990","Response to comment on \"Exploratory real-world experience with GLP-1 receptor agonists vs. metformin in youth with new-onset type 2 diabetes: a single-center retrospective study\".","Zeier T","2026","Journal of pediatric endocrinology & metabolism : JPEM","nonrandomized_study","article","10.1515/jpem-2026-0184","42035284",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0009991","Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis.","Armentaro G","2026","Internal and emergency medicine","narrative_review","article","10.1007/s11739-026-04438-3","42313337",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0009992","The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials.","Weisnagel SJ","2018","Annals of translational medicine","commentary","article","10.21037/atm.2018.03.29","29951516","PMC5994526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0009993","Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.","Yun JS","2021","Metabolism: clinical and experimental","nonrandomized_study","article","10.1016/j.metabol.2021.154838","34333002",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0009994","Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.","Omura T","2026","Cureus","nonrandomized_study","article","10.7759/cureus.113681","42535213","PMC13423406",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0009995","Exendin-4 promotes ischemia-reperfusion flap survival by upregulating Gpx4 to inhibit ferroptosis.","Yu W","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.177029","39366501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0009996","Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.","Wang F","2022","Clinical drug investigation","systematic_review","article","10.1007/s40261-021-01110-w","34894326",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0009997","The Liver Left Behind: GLP-1 Receptor Agonists and the Prospect of Metabolic Adjuvant Therapy After HCC Resection.","Lonardo A","2026","Metabolites","commentary","article","10.3390/metabo16070499","42506450","PMC13413997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0009998","Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient.","Kotsis V","2020","Journal of hypertension","nonrandomized_study","article","10.1097/hjh.0000000000002279","31764586",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Consensus Statement; article"],["R0009999","Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.","van Schaik J","2020","Obesity facts","nonrandomized_study","article","10.1159/000509302","32781455","PMC7590745",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010000","Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.","Bielka W","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22147605","34299225","PMC8306903",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010001","Dulaglutide for the treatment of type 2 diabetes.","Scheen AJ","2017","Expert opinion on biological therapy","other_trial","article","10.1080/14712598.2017.1296131","28274140",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0010002","Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.","Zimmerman RS","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12969","28407414",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010003","Once-weekly glucagon-like peptide 1 receptor agonists.","Kalra S","2015","JPMA. The Journal of the Pakistan Medical Association","narrative_review","article",null,"26160096",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010004","Cardiovascular Safety and Superiority of Anti-Obesity Medications.","Alobaida M","2021","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s311359","34285527","PMC8286099",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010005","Gut delivery of pentameric GLP-1 using genetically engineered  <i>Bacillus subtilis<\/i>","Ye N","2025","bioRxiv","preclinical","preprint","10.1101/2025.10.07.680898",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010006","Liraglutide and empagliflozin alleviate diabetic cardiomyopathy by reducing oxidative stress and inflammation.","Uçar-Ekin C","2025","Gaceta medica de Mexico","preclinical","article","10.24875/gmm.25000112","41061250",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010007","Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.","Nreu B","2020","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2020.108087","32084455",null,null,"S000313","pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis"],["R0010008","Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.","Terauchi Y","2019","Journal of diabetes investigation","other_trial","article","10.1111/jdi.13066","31033218","PMC6825952",null,"S002566","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; research-article; article"],["R0010009","Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.","Coskun T","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00092-0","40609566",null,"ClinicalTrials.gov:NCT04867785","S000489","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; article"],["R0010010","Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy.","Kim Y","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.880164","35784534","PMC9248324",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010011","Euglycemic Ketoacidosis From Semaglutide in a Patient Without Diabetes.","Sood N","2024","JCEM case reports","case_report","article","10.1210/jcemcr/luae156","39221223","PMC11362620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010012","Incretin-based therapy and pancreatic beta cells.","Chon S","2014","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2014.05.003","25443548",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010013","A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.","Evans M","2013","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-012-0015-6","23225378","PMC3687099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010014","Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review.","Woo YS","2020","International journal of molecular sciences","narrative_review","article","10.3390/ijms21186969","32971941","PMC7554794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010015","The 2026 American College of Cardiology Expert Consensus Decision Pathway for Heart Failure with Preserved Ejection Fraction: Implications for Cardiothoracic and Vascular Anesthesia.","Ripoll JG","2026","Journal of cardiothoracic and vascular anesthesia","narrative_review","article","10.1053/j.jvca.2026.08.160","42760239",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010016","GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.","Liu J","2018","Peptides","other_trial","article","10.1016/j.peptides.2018.07.001","30003931",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0010017","GLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities.","Kim C","2026","JAMA pediatrics","other","article","10.1001/jamapediatrics.2025.5708","41557442","PMC12820773",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010018","Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop",null,"2025","National Academies Press (US), Washington (DC)","narrative_review","article",null,"40029954",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0010019","The Enterolimbic Axis: Gut-Brain Affective Circuits at the Crossroad of Metabolism, Emotion, and Behavior.","Gasbarrini A","2026","The American journal of gastroenterology","narrative_review","article","10.14309/ajg.0000000000003907","41504341",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010020","Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.","Ambika Gopalakrishnan U","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71069","42403263","PMC13449013","CTRI:CTRI/2025/04/085487",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Equivalence Trial; Multicenter Study; research-article; article"],["R0010021","Long-Term Retrospective Evaluation of Radiochemical Yield Reproducibility of ⁶⁸Ga-Radiopharmaceuticals Using an SiO₂-Based ⁶⁸Ge/⁶⁸Ga Generator.","Nanabala R","2026","Nuclear medicine and molecular imaging","nonrandomized_study","article","10.1007/s13139-026-01018-3","42824596","PMC13627561",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0010022","Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption.","Kårhus ML","2021","BMJ open","protocol","article","10.1136/bmjopen-2020-044711","33558360","PMC7871677","EudraCT:2018-003575-34",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0010023","Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis.","Tang T","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13131","29053203",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010024","Metabolic medicines and addiction: what GLP-1 receptor agonists might add to substance use care.","Qeadan F","2026","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.s325","41781016",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010025","Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis.","Chang W","2019","Molecular immunology","other","article","10.1016/j.molimm.2019.09.021","31630078",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010026","Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.","Wang W","2024","Alzheimer's & dementia : the journal of the Alzheimer's Association","nonrandomized_study","article","10.1002/alz.14313","39445596","PMC11667504",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0010027","Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.","Browne SK","2025","JHEP reports : innovation in hepatology","randomized_trial","article","10.1016/j.jhepr.2025.101483","41113119","PMC12529369","ClinicalTrials.gov:NCT05292911","S000420","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0010028","The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study.","Li B","2020","BMC pharmacology & toxicology","nonrandomized_study","article","10.1186/s40360-020-00422-5","32539783","PMC7296654","ClinicalTrials.gov:NCT04303819","S000555","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010029","Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China.","Han G","2022","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2022.1011624","36467033","PMC9716023",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010030","Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents.","Geisler CE","2023","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14843","36054312","PMC10362946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010031","Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.","Yamada T","2020","Current medical research and opinion","other","article","10.1080/03007995.2019.1706043","31855074",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0010032","The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk.","Valdecantos MP","2024","Nature communications","other","article","10.1038/s41467-024-54080-w","39609390","PMC11605122",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010033","Effects of Tirzepatide on Body Composition, Metabolic Parameters, and Sleep Outcomes: A Real-World One-Year Prospective Study.","Adamidis N","2026","Cureus","randomized_trial","article","10.7759/cureus.107081","42147626","PMC13178192",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010034","Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.","Fink-Jensen A","2025","Psychopharmacology","randomized_trial","article","10.1007/s00213-024-06637-2","38884652","PMC11742737",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010035","Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS.","Vafeidou K","2026","Expert review of endocrinology & metabolism","commentary","article","10.1080/17446651.2026.2634086","41742335",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0010036","Non-thyroidal Illness Syndrome as an Adaptive Longevity Program: Reframing Low T3 in Acute and Chronic Disease.","Mazza AD","2026","Cureus","narrative_review","article","10.7759/cureus.110397","42416936","PMC13340417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010037","Pilot study rectifies real-world study design to support regulatory decision making","Major-Pedersen A","2022","Authorea Preprints","protocol","preprint","10.22541/au.166999205.50183341/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0010038","Interaction Between Metabolic Diseases, GLP-1 Receptor Agonists, and Helicobacter pylori Infection: An Updated Evidence Summary.","Lee JY","2026","The Korean journal of helicobacter and upper gastrointestinal research","commentary","article","10.7704/kjhugr.2025.0088","41846439","PMC12997068",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0010039","The role of vasopressin deficiency in the fluid intake suppression hyper-responsivity to central glucagon-like peptide-1 in the Brattleboro rat.","David SA","2025","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2025.114958","40409558","PMC12161460",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0010040","AMD Risk in Users of GLP-1RAs and Other Weight-Loss Drugs-Reply.","Ahuja AS","2026","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2026.0010","41784983",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010041","Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity.","Ferrulli A","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70105","41451880",null,"ClinicalTrials.gov:NCT03009695",null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Clinical Trial; Journal Article; article"],["R0010042","Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart-liver metabolic axis perspective.","Wu X","2026","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2026.1863710","42292836","PMC13253480",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010043","Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.","Kapan A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70599","41733056","PMC13071259",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010044","Advancing Diabetes Management and Glycemic Control While Exploring CagriSema's Impact on Obesity Management.","Hadid S","2025","Cardiology in review","other","article","10.1097/crd.0000000000000940","40327810",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010045","Design of biomimetic chylomicrons based on 1,3-diolein grafted hyaluronic acid to drive biomacromolecules across the intestinal mucosal barrier.","Cui S","2026","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.114504","41352647",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0010046","Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.","Moreno-Pérez Ó","2026","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-026-03156-6","41913157","PMC13126886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Pragmatic Clinical Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010047","Obesity medication lorcaserin requires brainstem GLP-1 neurons to reduce food intake in mice","Wagner S","2022","bioRxiv","preclinical","preprint","10.1101/2022.05.06.490598",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010048","Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.","Newman TV","2021","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2021.27.4.435","33769857","PMC10391293",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0010049","A single centre retrospective study of the long‑term weight and pregnancy-related outcomes in women of reproductive age before and after liraglutide exposure.","Chukir T","2026","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-026-02111-5","42174221","PMC13649548",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010050","Computational phenotyping of effort-based decision-making in type-2 diabetes on and off semaglutide.","Mehrhof SZ","2026","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","other","article","10.1038/s41386-026-02433-y","42086986","PMC13597482",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010051","Intermittent Use of a Short-Course Glucagon-like Peptide-1 Receptor Agonist Therapy Limits Adverse Cardiac Remodeling via Parkin-dependent Mitochondrial Turnover.","Germano JF","2020","Scientific reports","preclinical","article","10.1038/s41598-020-64924-2","32427925","PMC7237417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0010052","Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.","Funch D","2021","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s305496","34140791","PMC8203194",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010053","When drugs meet disease: disentangling diabetes, obesity, and periconceptional GLP-1 receptor agonist safety.","Zhu Y","2026","Human reproduction open","nonrandomized_study","article","10.1093/hropen/hoag016","41852578","PMC12995392",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article-commentary; article"],["R0010054","Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations.","Tran HD","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2026.102321","41570980","PMC12925471",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010055","Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy.","Fath AR","2025","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2025.133082","39983877",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010056","Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline.","Pratley RE","2022","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2021-002207","35042751","PMC8768911","ClinicalTrials.gov:NCT02075281","S000743","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010057","Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?","Packer M","2018","Journal of cardiac failure","narrative_review","article","10.1016/j.cardfail.2017.12.007","29305970",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010058","Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials.","Sridhar VS","2022","Transplantation","narrative_review","article","10.1097/tp.0000000000003919","34381005",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010059","Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.","Nicze M","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25158202","39125772","PMC11311839",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010060","Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease.","Deng Y","2022","Journal of clinical & translational endocrinology","nonrandomized_study","article","10.1016/j.jcte.2022.100309","36620756","PMC9816064",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010061","Semaglutide: a new drug for the treatment of obesity.","Lexchin J","2023","Drug and therapeutics bulletin","randomized_trial","article","10.1136/dtb.2023.000007","37879878",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0010062","Glucagon-like peptide 1 analogues in patients with inflammatory bowel disease with metabolic disorders: More than weight loss?","Birda CL","2026","Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","commentary","article","10.1007/s12664-025-01854-9","40788346",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010063","Gastrointestinal safety across the albiglutide development programme.","Leiter LA","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12679","27097971",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010064","Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) - a systematic review and meta-analysis.","Alwafi H","2025","Frontiers in medicine","systematic_review","article","10.3389/fmed.2025.1639704","41488069","PMC12756447","PROSPERO:CRD420251007882",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0010065","Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.","Tinsley IC","2021","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.1c00185","33677970","PMC8279408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0010066","Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.","Berra CC","2020","Pharmacological research","nonrandomized_study","article","10.1016/j.phrs.2020.104996","32574827",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0010067","Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial.","Sharma PK","2026","Metabolism open","randomized_trial","article","10.1016/j.metop.2026.100460","41953358","PMC13054606","CTRI:CTRI/2025/03/082620",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010068","GLP-1 Receptor Agonists in Overweight and Obese Patients With Hidradenitis Suppurativa.","Encarnacion IN","2026","Journal of drugs in dermatology : JDD","other","article","10.36849/jdd.9586","41642138",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010069","In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.","Agarwal A","2025","Annals of internal medicine","commentary","article","10.7326/annals-25-03745-jc","41052437",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0010070","Robustness of Multiple Imputation Methods for Missing Risk Factor Data from Electronic Medical Records for Observational Studies.","Paul SK","2022","Journal of healthcare informatics research","nonrandomized_study","article","10.1007/s41666-022-00119-w","36744084","PMC9892403",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; research-article"],["R0010071","Tirzepatide (Zepbound) for obstructive sleep apnea.",null,"2025","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2025.1722c","39946698",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010072","Abstract 447: GLP‐1 Receptor Agonists and Idiopathic Intracranial Hypertension: A Propensity Score‐Matched Study","Sioutas G","2025","Stroke (Hoboken, N.J.)","nonrandomized_study","article","10.1161/svi270000_447",null,"PMC12850408",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0010073","Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress.","Liu DX","2022","Parkinson's disease","preclinical","article","10.1155/2022/6813017","35873704","PMC9300292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010074","Circulating Apelin-13, β-catenin and bone mineral density in postmenopausal women.","Yao Q","2026","Endocrine connections","other","article","10.1530/ec-25-0886","42447047","PMC13545753",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010075","Diabetes medications and risk of HCC.","Plaz Torres MC","2022","Hepatology (Baltimore, Md.)","narrative_review","article","10.1002/hep.32439","35239194","PMC9790535",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0010076","Effects of Glucagon-Like Peptide-1 Receptor Agonists on Hypothalamic-Pituitary-Adrenal Axis in Healthy Volunteers.","Winzeler B","2019","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2018-01420","30272170",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010077","Additional benefits of combining GLP-1 receptor agonist use with lifestyle modification.","Del Prato S","2026","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(26)00006-9","41763235",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010078","Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real-World Evidence Study.","Blanco CA","2023","The Permanente journal","nonrandomized_study","article","10.7812/tpp/22.137","36913542","PMC10013722",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Multicenter Study; Journal Article; research-article; article"],["R0010079","The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.","Bain SC","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-014-0073-z","25027491","PMC4269639",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; article"],["R0010080","Letter to the Editor Regarding \"The Effect of GLP-1 Receptor Agonists on Reoperation Following Anterior Cervical Discectomy and Fusion\".","Wang J","2026","World neurosurgery","commentary","article","10.1016/j.wneu.2026.124894","41771377",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0010081","Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin.","Parikh M","2026","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgag033","41604435","PMC13271809",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0010082","Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release.","Ko JW","2020","Annals of dermatology","case_report","article","10.5021/ad.2020.32.3.230","33911742","PMC7992610",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010083","Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.","Nauck MA","2017","Circulation","other_trial","article","10.1161/circulationaha.117.028136","28847797",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0010084","Circulating alarin concentrations are high in patients with type 2 diabetes and increased by glucagon-like peptide-1 receptor agonist treatment: An Consort-compliant study.","Hu W","2019","Medicine","other_trial","article","10.1097/md.0000000000016428","31305464","PMC6641675","ChiCTR:ChiCTR-OCS-13003185",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0010085","The impact of nutrition, exercise, and pharmacotherapy on menstrual health in adolescents with overweight and obesity.","Wu J","2026","Nutrition (Burbank, Los Angeles County, Calif.)","narrative_review","article","10.1016/j.nut.2025.113021","41386097",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010086","The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.","Liao C","2023","PloS one","systematic_review","article","10.1371/journal.pone.0289616","37616255","PMC10449217",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0010087","GLP-1 receptor agonists for obesity: eligibility across 99 countries.","Yoo SGK","2026","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(25)00356-0","41519598","PMC12923076",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; research-article; article"],["R0010088","Emerging role of incretin-based therapy as first-line antihypertensives in obesity.","Rahimi K","2024","Heart (British Cardiac Society)","commentary","article","10.1136/heartjnl-2024-324842","39153844",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0010089","Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients.","Wei R","2023","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-023-01141-7","37598203","PMC10439551",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010090","Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.","Lee S","2017","Annals of pediatric endocrinology & metabolism","narrative_review","article","10.6065/apem.2017.22.1.15","28443255","PMC5401818",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010091","Association of tirzepatide and the risk of suicide in a real-world cohort.","Yu WS","2025","Frontiers in psychiatry","nonrandomized_study","article","10.3389/fpsyt.2025.1626103","41334076","PMC12667738",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010092","A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function.","Yaribeygi H","2020","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/1871530319666191014110414","31612835",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010093","Acylation of the incretin peptide exendin-4 directly impacts GLP-1 receptor signalling and trafficking","Lucey M","2021","bioRxiv","preclinical","preprint","10.1101/2021.04.01.438030",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010094","A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.","Schneider EL","2020","Domestic animal endocrinology","preclinical","article","10.1016/j.domaniend.2019.07.001","31479925",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010095","Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population.","Liu H","2022","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13716","34797962","PMC9017614",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; brief-report; article"],["R0010096","Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.","Shi Q","2024","Lancet (London, England)","systematic_review","article","10.1016/s0140-6736(24)00351-9","38582569",null,"PROSPERO:CRD42021245678",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis"],["R0010097","Impact of Incretin-Based Therapies on Adipokines and Adiponectin.","Yaribeygi H","2021","Journal of diabetes research","narrative_review","article","10.1155/2021/3331865","34660808","PMC8516550",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010098","SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight.","Kennis VCW","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70722","41969210","PMC13146202",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010099","Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.","Umpierrez GE","2013","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep12292.ra","23512382",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010100","The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.","Radkhah H","2025","Eating and weight disorders : EWD","systematic_review","article","10.1007/s40519-025-01720-9","39891848","PMC11787217",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0010101","Lixisenatide: A New Option for Managing Type 2 Diabetes.","Newsome JS","2017","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","other","article","10.1177/8755122517711958","34860974","PMC5998422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010102","Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.","Vashisht R","2023","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2023.36613","37782497","PMC10546239",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0010103","Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.","Gasoyan H","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70660","41816857","PMC13146129",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010104","Combination GLP-1 RA Plus SGLT2i Therapy in MASLD and Type 2 Diabetes: Methodological Considerations for the Three Pairwise Target Trial Emulations.","Zubairi R","2026","Journal of gastroenterology and hepatology","nonrandomized_study","article","10.1111/jgh.70703","42638155",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0010105","Role of glucagon-like peptide 1 receptor agonists in management of obesity.","Isaacs D","2016","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.2146/ajhp150990","27521241",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010106","Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.","Altabas V","2025","Journal of personalized medicine","systematic_review","article","10.3390/jpm15110539","41295241","PMC12653122",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0010107","Battle of GLP-1 delivery technologies.","Yu M","2018","Advanced drug delivery reviews","narrative_review","article","10.1016/j.addr.2018.07.009","30009885","PMC6843995",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article"],["R0010108","Convergent Metabolic Pathways in MASH Therapeutics: An AMPK-Centric Analysis.","Choi S","2026","Journal of cellular and molecular medicine","narrative_review","article","10.1111/jcmm.71023","41545323","PMC12811076",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010109","Trends in the Use of Medications for Secondary Ischemic Stroke Prevention in Denmark, 2005-2021.","Skajaa N","2024","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000209309","38648572","PMC11226314",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010110","Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats.","Herman RJ","2023","Psychopharmacology","preclinical","article","10.1007/s00213-023-06376-w","37129617","PMC11088902",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010111","Re: GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations.","Karim A","2026","Journal of gastroenterology and hepatology","nonrandomized_study","article","10.1111/jgh.70681","42610485",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0010112","Identification of semaglutide use through detection of U6 and U7 metabolites in human urine.","Timms M","2026","Analytical and bioanalytical chemistry","other","article","10.1007/s00216-025-06263-7","41364333",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010113","Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial.","Mamas MA","2025","European heart journal open","randomized_trial","article","10.1093/ehjopen/oeaf117","40980721","PMC12448458","ClinicalTrials.gov:NCT05822830","S000093","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0010114","Letter to Editor in Response to \"GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations\".","Shaikh MA","2026","Journal of gastroenterology and hepatology","nonrandomized_study","article","10.1111/jgh.70699","42643117",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0010115","Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide.","Sherwin M","2023","Canadian journal of anaesthesia = Journal canadien d'anesthesie","nonrandomized_study","article","10.1007/s12630-023-02549-5","37466909",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Journal Article; article"],["R0010116","Switching from insulin to dulaglutide therapy in patients with type 2 diabetes: A real-world data study.","Lee J","2021","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.3466","33957706",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010117","RETRACTED: Chung et al. Long-Lasting Exendin-4-Loaded PLGA Nanoparticles Ameliorate Cerebral Ischemia/Reperfusion Damage in Diabetic Rats. J. Pers. Med. 2022, 12, 390.","Chung CH","2024","Journal of personalized medicine","notice","article","10.3390/jpm15010011","39852232","PMC11766983",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; retraction"],["R0010118","A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.","Owens DR","2017","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12998","28474401","PMC5697665",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0010119","Network and Pairwise Meta-Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus.","Ye X","2026","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.70202","42455922","PMC13372237",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review-article; article"],["R0010120","Body Weight Considerations in the Management of Type 2 Diabetes.","Apovian CM","2019","Advances in therapy","narrative_review","article","10.1007/s12325-018-0824-8","30465123","PMC6318231",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0010121","Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials.","Qiu M","2022","European journal of preventive cardiology","systematic_review","article","10.1093/eurjpc/zwab221","34939100",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0010122","MON-646 Novel Use of GLP-1 Receptor Agonist Therapy in MODY-1 (HNF4A Mutation)","Broome D","2020","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaa046.397",null,"PMC7209230",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0010123","Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes.","Lee MMY","2021","Diabetes care","systematic_review","article","10.2337/dc20-3007","33707305",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; other; article"],["R0010124","Efficacy and acceptability of liraglutide for obesity in people with HIV: results of an open-label clinical trial in South Africa.","Behuhuma N","2026","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","other_trial","article","10.1093/cid/ciag337","42203210","PMC13249519",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; article"],["R0010125","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.","Wroge J","2016","The Annals of pharmacotherapy","narrative_review","article","10.1177/1060028016663218","27531946",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010126","Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.","Westerink J","2022","Diabetes care","nonrandomized_study","article","10.2337/dc21-1138","35263432","PMC9174968",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article; other"],["R0010127","What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus.","Chan WB","2017","Journal of diabetes","narrative_review","article","10.1111/1753-0407.12515","27976513",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010128","Impact of GLP-1 Receptor Agonist Discontinuation on Liver-Related Parameters: A Systematic Review and Meta-Analysis.","Souza M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70642","41804222",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0010129","Inotropic effects of retatrutide in isolated human atrial preparations.","Neumann J","2026","Naunyn-Schmiedeberg's archives of pharmacology","other","article","10.1007/s00210-025-04421-3","40613938","PMC12894140",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010130","Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review.","Pantea I","2026","Journal of diabetes research","randomized_trial","article","10.1155/jdr/1853763","41964153","PMC13068985",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0010131","The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.","Hoffmann K","2026","Expert opinion on drug safety","systematic_review","article","10.1080/14740338.2025.2586703","41200927",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; Systematic Review; article; review"],["R0010132","Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders.","Qiao Y","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s559587","41710720","PMC12912186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010133","Obesity, inflammation, and systemic autoimmune diseases: are GLP-1RAs the missing link?","Yıldız Ç","2026","Clinical rheumatology","commentary","article","10.1007/s10067-026-08051-9","41854991",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010134","Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities.","McCoy RG","2021","Diabetes care","nonrandomized_study","article","10.2337/dc20-2977","34348996","PMC8929191",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0010135","Key takeaways from the updated multidisciplinary European MASLD guidelines.","Horn P","2025","eGastroenterology","narrative_review","article","10.1136/egastro-2025-100196","40510733","PMC12161374",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010136","ABSTRACT NUMBER: ESOC2026A262 STROKE RISK WITH SGLT2I, GLP-1RA, AND DPP-4I IN TYPE 2 DIABETES: REAL-WORLD LONGITUDINAL ESTIMATES IN THE CONTEXT OF TRIAL AND OBSERVATIONAL EVIDENCE",null,"2026","European stroke journal","nonrandomized_study","article",null,null,"PMC13146521",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0010137","The Impact of GLP-1 Receptor Agonists on Surgical Outcomes in Achilles Tendon Repair",null,"2025","Foot & ankle orthopaedics","other","article",null,null,"PMC12745587",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0010138","Corrigendum to \"Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study\" [Endocrine Practice 30 (2024) 424-430].","Lin YH","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","notice","article","10.1016/j.eprac.2025.01.006","39945693",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0010139","Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression.","Wagner S","2023","Molecular metabolism","other","article","10.1016/j.molmet.2022.101665","36592795","PMC9841057",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0010140","Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.","Sattar N","2026","European journal of preventive cardiology","randomized_trial","article","10.1093/eurjpc/zwag408","42572119",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0010141","Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice.","Wunderlich M","2024","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.101992","39019114","PMC11338133",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010142","Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.","Chan ZH","2026","Cardiology in review","systematic_review","article","10.1097/crd.0000000000001209","41711462",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0010143","Use of insulin pumps and closed-loop systems among people living with diabetes: A narrative review of clinical and cost-effectiveness to enable access to technology and meet the needs of payers.","Jendle J","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15087","37046364",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0010144","The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.","Retnakaran R","2022","Nature communications","randomized_trial","article","10.1038/s41467-022-33867-9","36244997","PMC9573864",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010145","Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.","Hiramatsu T","2020","Diabetes & vascular disease research","other","article","10.1177/1479164120971220","33371732","PMC7919219",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010146","Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events.","Meiring S","2022","Cardiovascular diabetology","other_trial","article","10.1186/s12933-022-01628-z","36138441","PMC9503196",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0010147","Enteroendocrine cell regulation of the gut-brain axis.","Barton JR","2023","Frontiers in neuroscience","other_trial","article","10.3389/fnins.2023.1272955","38027512","PMC10662325",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0010148","Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.","van Ruiten CC","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14732","35491524","PMC9546212",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010149","Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life.","Longato E","2020","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2020-001451","32591373","PMC7319723","ClinicalTrials.gov:NCT04184947","S000433","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0010150","Cardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks.","Wong ND","2022","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2022-0065","35772176",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010151","The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.","Meade LT","2019","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/1060028019857557","31215219",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010152","Effects of insulin and the glucagon-like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice.","Liljedahl L","2017","Physiological reports","preclinical","article","10.14814/phy2.13187","28330952","PMC5371560",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010153","Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.","Wish JB","2022","Mayo Clinic proceedings. Innovations, quality & outcomes","narrative_review","article","10.1016/j.mayocpiqo.2022.09.002","36277502","PMC9578990",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010154","Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.","Marso SP","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0370-z","29397532","PMC6104267",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0010155","Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.","Ruan Z","2023","Expert review of clinical pharmacology","systematic_review","article","10.1080/17512433.2023.2174099","36706368",null,"PROSPERO:CRD42022306164",null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Systematic Review; Journal Article; review"],["R0010156","Role of the GAPDH-mediated glycolysis-senescence axis in osteoarthritis chondrocytes and its modulation by semaglutide.","Liu D","2026","Joint bone spine","preclinical","article","10.1016/j.jbspin.2026.106072","42107588",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010157","Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease.","Wang N","2024","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox13040455","38671903","PMC11047699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010158","GLP-1RAs and cardiovascular risk in HS: concerns about follow-up time and effect estimates.","Jastrząb B","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","commentary","article","10.1111/jdv.70227","41340594","PMC13425694",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0010159","Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.","Lu N","2015","PloS one","preclinical","article","10.1371/journal.pone.0132744","26177280","PMC4503456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010160","Tolerance Does Not Develop Toward Liraglutide's Glucose-Lowering Effect.","Sedman T","2017","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2017-00199","28379427",null,"ClinicalTrials.gov:NCT02089256; EudraCT:2014-000238-43","S000403","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0010161","Weight gain, adipose tissue remodeling and cardiometabolic disease in people with HIV.","Gorwood J","2026","Current opinion in HIV and AIDS","narrative_review","article","10.1097/coh.0000000000001069","42817202",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010162","Prehospital exenatide in hyperglycemic stroke-A randomized trial.","Larsson M","2019","Acta neurologica Scandinavica","randomized_trial","article","10.1111/ane.13166","31518433",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0010163","Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.","Andreadis P","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13361","29756388",null,null,"S000393","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0010164","12506 Vagal Glp-1 Receptors Are Essential In The Efficacy Of Orally Administered Exendin-4",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453795",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0010165","Hepatic function of glucagon-like peptide-1 and its based diabetes drugs.","Feng JN","2024","Medical review (2021)","narrative_review","article","10.1515/mr-2024-0018","39135602","PMC11317081",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0010166","β-Cell Mass in Individuals With and Without Postbariatric Hypoglycemia After Roux-en-Y Gastric Bypass.","Tokgöz S","2025","Diabetes","other","article","10.2337/db25-0572","41066755","PMC12645168",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010167","A metabolic balance of GLP-1 and NMDA receptors in the brain.","Yue JTY","2024","Cell","other","article","10.1016/j.cell.2024.06.031","39059361",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010168","Efficacy of a Digital Educational Intervention for Patients With Type 2 Diabetes Mellitus: Multicenter, Randomized, Prospective, 6-Month Follow-Up Study.","Caballero Mateos I","2025","Journal of medical Internet research","randomized_trial","article","10.2196/60758","40209213","PMC12022518","ClinicalTrials.gov:NCT06850129","S002487","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0010169","Genetically Proxied GIP-GIPR Pathway Perturbation and Fracture Risk.","Cheng W","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.71378","42811415",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010170","GLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases.","Chi KY","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2026.1311","41811319","PMC12980253",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010171","Efficacy of Semaglutide and Other GLP-1 Agonists in Patients with Heart Failure With Preserved Ejection Fraction and Obesity: A Systemic Review and Meta-Analysis.","Beshr MS","2025","Cardiology in review","systematic_review","article","10.1097/crd.0000000000000915","40243299",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0010172","The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control.","Gautier T","2021","Journal of diabetes science and technology","randomized_trial","article","10.1177/1932296819891170","31810389","PMC8256059",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0010173","Considerations for evaluating the impact of GLP-1 receptor agonist use on inpatient outcomes.","Schwartz JL","2026","Journal of hospital medicine","commentary","article","10.1002/jhm.70275","41674484",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0010174","The Effects of the New Therapeutic Treatments for Diabetes Mellitus on the Male Reproductive Axis.","Pelusi C","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.821113","35518937","PMC9065269",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010175","Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment.","Li C","2021","International journal of nanomedicine","narrative_review","article","10.2147/ijn.s283416","33628020","PMC7898203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010176","Semaglutide in the Real World: Attitudes of the Population.","Rušić D","2025","Pharmacy (Basel, Switzerland)","nonrandomized_study","article","10.3390/pharmacy13050128","40981248","PMC12452689",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010177","Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth.","Wang L","2025","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/clinem/dgaf053","39908200","PMC12448615",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010178","68 Ga-NODAGA-EXENDIN-4 PET/CT in the Detection or the Exclusion of Occult Sporadic Insulinomas.","Aveline C","2025","Clinical nuclear medicine","other_trial","article","10.1097/rlu.0000000000005946","41223138","PMC12617306",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0010179","Letter to the Editor on \"GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes\".","Pes I","2026","Acta diabetologica","commentary","article","10.1007/s00592-026-02674-9","41706184",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0010180","Coprescribing GLP-1 Receptor Agonists and Lifestyle.","Rockwell MS","2026","JAMA internal medicine","other","article","10.1001/jamainternmed.2025.6248","41324944",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010181","When lactate speaks: Rewiring astrocyte-neuron metabolism in Alzheimer's disease.","Furtado J","2026","Cell metabolism","commentary","article","10.1016/j.cmet.2026.05.007","42551412",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0010182","Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.","Busch RS","2017","Postgraduate medicine","other_trial","article","10.1080/00325481.2017.1342509","28657399",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0010183","Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.","Zhao X","2019","BMC endocrine disorders","systematic_review","article","10.1186/s12902-018-0332-5","30616638","PMC6323665",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0010184","Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.","Bellido V","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)01861-1","42810372",null,"ClinicalTrials.gov:NCT05929079","S001886","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; article"],["R0010185","Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control.","Jalleh RJ","2022","Diabetologia","narrative_review","article","10.1007/s00125-022-05796-1","36194250","PMC9630190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0010186","Cost-Effectiveness of Glucose-Lowering Therapies as Add-on to Standard Care for People With Type 2 Diabetes in Malaysia.","Sim R","2023","Value in health regional issues","nonrandomized_study","article","10.1016/j.vhri.2023.05.006","37419012",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article"],["R0010187","GLP-1 Receptor Agonists for Obesity in Adolescents.","Schoenherr DT","2026","American family physician","other","article",null,"41544290",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010188","Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS.","Akimoto H","2020","American journal of Alzheimer's disease and other dementias","nonrandomized_study","article","10.1177/1533317519899546","32162525","PMC11005324",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0010189","Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.","Dong Y","2017","Clinics and research in hepatology and gastroenterology","systematic_review","article","10.1016/j.clinre.2016.11.009","28065744",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0010190","Erratum: Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages. Clinical Diabetes 2023;41:467-473.","Whitley HP","2024","Clinical diabetes : a publication of the American Diabetes Association","notice","article","10.2337/cd24-er04","39429459","PMC11486853",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0010191","Glucagon modulates proliferation and differentiation of human adipose precursors.","Cantini G","2019","Journal of molecular endocrinology","preclinical","article","10.1530/jme-19-0095","31525727",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010192","Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.","Gabery S","2025","Life sciences","nonrandomized_study","article","10.1016/j.lfs.2025.123845","40628316",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0010193","Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.","Tibaldi JM","2014","Advances in therapy","narrative_review","article","10.1007/s12325-014-0100-5","24535623","PMC3961600",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0010194","Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes.","Kizilkaya HS","2024","Nature metabolism","preclinical","article","10.1038/s42255-024-01061-4","38871982","PMC11272584",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010195","Glucagon-like peptide-1 analogues reduce alcohol intake.","O'Farrell M","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16152","39748222","PMC11802387",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0010196","Title: Gene expression, neuroinflammation, and neural plasticity in type 2 diabetes: Translational insights from exercise and cognitive modulation.","Diniz CG","2026","Neuroscience and biobehavioral reviews","randomized_trial","article","10.1016/j.neubiorev.2026.106922","42648513",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0010197","Impact of cardiometabolic and renal phenotypes on the prevalence of type 2 diabetes in the geriatric population of Añisok, Equatorial Guinea: a prospective cohort study (2024-2025)","Abogo MNA","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9496968/v1",null,null,null,null,"europepmc","FALSE","free_to_read","4",null,"Preprint"],["R0010198","Semaglutide is effective in type 2 diabetes and obesity with schizophrenia.","Noda K","2022","Diabetology international","case_report","article","10.1007/s13340-022-00590-1","36117924","PMC9477985",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010199","Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.","Hellenkamp K","2025","Med (New York, N.Y.)","other","article","10.1016/j.medj.2024.12.004","39954669",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010200","Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists.","Scheen AJ","2015","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(15)00256-9","26276241",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0010201","Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.","Abrahami D","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15196","37395339","PMC10527897",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0010202","Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations.","Theofilis P","2022","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v28.i39.5691","36338895","PMC9627426",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010203","Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022.","Hahr AJ","2022","American journal of kidney diseases : the official journal of the National Kidney Foundation","narrative_review","article","10.1053/j.ajkd.2021.05.023","34600745",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010204","Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.","Patel H","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-019-00709-9","31605302","PMC6848683",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; other; article"],["R0010205","Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events.","Chen D","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1785129","41948731","PMC13050862",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010206","Turning obesity into an iatrogenic disease?","Quilliot D","2026","Clinical nutrition ESPEN","commentary","article","10.1016/j.clnesp.2026.103332","42134647",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010207","Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer's disease, vascular dementia, and other dementia types among patients with type 2 diabetes.","Sun M","2025","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2025.101623","39952607",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comparative Study; article"],["R0010208","Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.","Singh AK","2020","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2020.02.012","32142999",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0010209","Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient.","Singhal R","2025","Cureus","case_report","article","10.7759/cureus.91679","41054677","PMC12497442",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010210","Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.","Doumas M","2018","Current pharmaceutical design","narrative_review","article","10.2174/1381612824666180604113653","29865997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010211","Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?","Pugliese G","2023","Journal of endocrinological investigation","randomized_trial","article","10.1007/s40618-023-02084-6","37093453","PMC10372121",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0010212","A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.","Posada MM","2025","CPT: pharmacometrics & systems pharmacology","other","article","10.1002/psp4.70101","40842022","PMC12706417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010213","SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity","Ishøy P","2017","Schizophrenia bulletin","randomized_trial","article","10.1093/schbul/sbx024.017",null,"PMC5476046","ClinicalTrials.gov:NCT01794429","S002041","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; conference-abstract"],["R0010214","Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.","Bae JH","2020","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2019.0018","31701698","PMC7188972",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010215","Recent advances in new-onset diabetes mellitus after kidney transplantation.","Montada-Atin T","2021","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v12.i5.541","33995843","PMC8107982",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0010216","Reply to Letter to the Editor About the Article \"GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations\".","Alkuwaiti MA","2026","Journal of gastroenterology and hepatology","nonrandomized_study","article","10.1111/jgh.70698","42638184",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0010217","Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial.","Hulst AH","2020","Journal of clinical medicine","randomized_trial","article","10.3390/jcm9030673","32131527","PMC7141279",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010218","Hypothalamic regulation of obesity: Revealing the therapeutic potential of a novel anti-obesity peptide.","Choo YN","2025","Vascular pharmacology","narrative_review","article","10.1016/j.vph.2025.107553","41093047",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010219","Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention.","Fang QH","2019","Hepatology research : the official journal of the Japan Society of Hepatology","preclinical","article","10.1111/hepr.13330","30861258",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010220","GLP-1 Receptor Agonist Medications: Interactions With Addiction Neurocircuitry.","Volkow ND","2026","Biological psychiatry","other","article","10.1016/j.biopsych.2026.01.011","41616957",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010221","Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.","Mensberg P","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12797","27717126","PMC5298031",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010222","Charge-based supramolecular peptide nanocomplexes for oral delivery via transporter-driven endocytosis.","Park SH","2026","Biomaterials","other","article","10.1016/j.biomaterials.2025.123903","41411844",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010223","Is addiction the next frontier for GLP-1 receptor agonists?","Healey N","2026","Nature medicine","commentary","article","10.1038/d41591-025-00069-x","41361575",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0010224","Diabetes and Stroke: What Are the Connections?","Mosenzon O","2023","Journal of stroke","randomized_trial","article","10.5853/jos.2022.02306","36592968","PMC9911852",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0010225","Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease.","Oikonomou E","2023","Current pharmaceutical design","narrative_review","article","10.2174/1381612829666230703161058","37403390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0010226","GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review.","Furió-Novejarque C","2025","Journal of diabetes science and technology","nonrandomized_study","article","10.1177/19322968241285925","39411979","PMC11571630",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; meeting-report; review"],["R0010227","Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.","Elfers CT","2024","Clinical nutrition (Edinburgh, Scotland)","preclinical","article","10.1016/j.clnu.2024.05.035","38861891","PMC12285839",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article"],["R0010228","Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.","Wang W","2024","Annals of internal medicine","nonrandomized_study","article","10.7326/m23-2718","39074369","PMC12721465",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0010229","A two-tier protection strategy for oral delivery of GLP-1 peptides: lipid-based formulation combined with enteric capsules.","Dumont C","2026","Frontiers in drug delivery","preclinical","article","10.3389/fddev.2026.1770094","42256195","PMC13236653",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010230","Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?","Ahmad E","2020","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph13120427","33261058","PMC7761522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010231","Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities.","Kanwal A","2022","Biomedicines","narrative_review","article","10.3390/biomedicines10020331","35203540","PMC8869656",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010232","Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study.","Vidal SI","2026","JAAD international","nonrandomized_study","article","10.1016/j.jdin.2026.01.014","41858311","PMC12997224",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0010233","Coprescribing GLP-1 Receptor Agonists and Lifestyle-Reply.","Mehrtash F","2026","JAMA internal medicine","other","article","10.1001/jamainternmed.2025.6251","41324971",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010234","Toward Precision Secondary Prevention After Myocardial Infarction and Stroke With GLP-1 Receptor Agonists.","Ahmadizar F","2026","European journal of preventive cardiology","randomized_trial","article","10.1093/eurjpc/zwag068","41605254",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Editorial; Comment; article; editorial"],["R0010235","Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.","Ciudin A","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16508","40537987","PMC12326929",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0010236","Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).","Desouza C","2020","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2020-001830","33376084","PMC7778743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0010237","Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.","Natale P","2025","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd015849.pub2","39963952","PMC11834151","ClinicalTrials.gov:NCT03496298; ClinicalTrials.gov:NCT01621178; ClinicalTrials.gov:NCT02963766; ClinicalTrials.gov:NCT01761318; ClinicalTrials.gov:NCT02660047; ClinicalTrials.gov:NCT01336023; ClinicalTrials.gov:NCT01392573; ClinicalTrials.gov:NCT01676116; ClinicalTrials.gov:NCT01618162; ClinicalTrials.gov:NCT01952145; ClinicalTrials.gov:NCT01147250; ClinicalTrials.gov:NCT01144338; ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT01798706; ClinicalTrials.gov:NCT01794143; ClinicalTrials.gov:NCT02465515; ClinicalTrials.gov:NCT01394341; ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01098539; ClinicalTrials.gov:NCT02730377; ClinicalTrials.gov:NCT01620489; ClinicalTrials.gov:NCT00097500; ClinicalTrials.gov:NCT01847313; ClinicalTrials.gov:NCT03550378; ClinicalTrials.gov:NCT02827708; ClinicalTrials.gov:NCT02692716; ClinicalTrials.gov:NCT01394952; ClinicalTrials.gov:NCT04515849; ClinicalTrials.gov:NCT04061200; ClinicalTrials.gov:NCT03914326; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT03136484; ClinicalTrials.gov:NCT03824002; ClinicalTrials.gov:NCT02545738; ClinicalTrials.gov:NCT02690883; ClinicalTrials.gov:NCT00712673; ClinicalTrials.gov:NCT00763451; ClinicalTrials.gov:NCT00707031; ClinicalTrials.gov:NCT05536804; ClinicalTrials.gov:NCT06182891; ClinicalTrials.gov:NCT06555146; ClinicalTrials.gov:NCT04865770","S000142; S000147; S000164; S000200; S000237; S000344; S000395; S000508; S000557; S000566; S000604; S000688; S000755; S000873; S000904; S000905; S000938; S000953; S001020; S001074; S001234; S001276; S001328; S001381; S001417; S001439; S001496; S001504; S001563; S001654; S001818; S001847; S001902; S001933; S001991; S002025; S002039; S002088; S002179; S002188; S002227; S002285","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; article"],["R0010238","Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes.","Bahtiyar G","2018","Current diabetes reports","narrative_review","article","10.1007/s11892-018-1043-z","30171481",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010239","Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus.","Vikulova OK","2018","Terapevticheskii arkhiv","other","article","10.26442/terarkh201890659-64","30701906",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010240","Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.","Badve SV","2025","The lancet. Diabetes & endocrinology","systematic_review","article","10.1016/s2213-8587(24)00271-7","39608381",null,"ClinicalTrials.gov:NCT03574597; PROSPERO:CRD42024528864","S000716","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0010241","Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes.","Matthews JE","2016","Postgraduate medicine","other_trial","article","10.1080/00325481.2016.1174565","27043162",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0010242","The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.","Fisman EZ","2021","Cardiovascular diabetology","commentary","article","10.1186/s12933-021-01412-5","34819089","PMC8613929",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0010243","Association of COVID-19 outcomes with diabetes in the Veneto region (north-east italy): Epidemiological insights for the endemic phase?","Piarulli F","2023","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2023.06.016","37543520","PMC10290544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010244","Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity.","Levine J","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.11.13.25340005","41292626","PMC12642718",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0010245","Comparative Outcomes of GLP-1 Receptor Agonists vs Bariatric Surgery in Patients Undergoing Atrial Fibrillation Ablation.","Patel H","2026","JACC. Clinical electrophysiology","other","article","10.1016/j.jacep.2025.12.035","41649433",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010246","Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.","Zhu D","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other_trial","article","10.1093/ndt/gfae210","39907541","PMC11852343",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0010247","Use of GLP1RAs and occurrence of respiratory disorders: A meta-analysis of large randomized trials of GLP1RAs.","Wei JP","2021","The clinical respiratory journal","systematic_review","article","10.1111/crj.13372","33825329",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0010248","Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spot.","Mullard A","2025","Nature reviews. Drug discovery","commentary","article","10.1038/d41573-025-00183-y","41199002",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0010249","[Not Available].","Leiter LA","2017","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","other_trial","article","10.1055/s-0043-103969","28724168",null,null,"S000235","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0010250","Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.","Boye KS","2019","Drugs in R&D","other","article","10.1007/s40268-019-0273-0","31115873","PMC6544605",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010251","Cardiovascular and kidney benefits of GLP-1 receptor agonists across large randomized placebo-controlled trials.","Yoshiji S","2025","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.70166","41047752","PMC12679168",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article-commentary; article"],["R0010252","Emerging uses of glucagon-like peptide 1 (GLP-1) receptor agonists following ileal resection: literature review and case examples.","Conley TE","2023","Frontline gastroenterology","narrative_review","article","10.1136/flgastro-2023-102402","37854779","PMC10579548",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010253","Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.","Divino V","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-014-0087-6","25366334","PMC4269654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010254","FDG PET/CT Images Demonstrating Subclinical Pancreatitis in a Patient on a GLP-1 Receptor Agonist.","Lenkov R","2025","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000005856","40103000",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0010255","The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats.","Aranäs C","2024","Acta neuropsychiatrica","preclinical","article","10.1017/neu.2024.58","39639536","PMC13130276",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010256","The efficacyand safety of once weekly injectable semaglutide (Ozempic) among patients with Type 2 diabete sintertiary care hospital: A Retrospective Study.","Jabeen M","2026","JPMA. The Journal of the Pakistan Medical Association","nonrandomized_study","article","10.47391/jpma.23206","42261018",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0010257","Abstract 446: Impact of GLP‐1 Receptor Agonists After Mild Stroke in Obese Patients: A Multicenter Propensity Score‐Matched Analysis","Sioutas G","2025","Stroke (Hoboken, N.J.)","nonrandomized_study","article","10.1161/svi270000_446",null,"PMC12849848",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0010258","GLP-1 Receptor Agonist and SGLT2 Inhibitor Use and Transcatheter Aortic Valve Replacement Outcomes: A Critique and Partial Re-Analysis.","Wang J","2026","The American journal of cardiology","commentary","article","10.1016/j.amjcard.2026.03.014","41806961",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010259","Rethinking the Heuristic Approach to Perioperative GLP-1 Receptor Agonist Management in Neurosurgical Patients.","Thakkar K","2026","Journal of neurosurgical anesthesiology","other","article","10.1097/ana.0000000000001098","41664962",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010260","GLP-1 receptor agonists after ACS in diabetes: credible plaque signals, but comparators, confounding, and access will decide impact.","Vijayasimha M","2026","Acta diabetologica","commentary","article","10.1007/s00592-026-02649-w","41665655",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010261","A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.","Vekic J","2022","Metabolites","narrative_review","article","10.3390/metabo12020108","35208183","PMC8879153",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010262","Gastrinoma demonstrating intense uptake on 68Ga-exendin-4 PET/CT.","Zhang H","2025","European journal of nuclear medicine and molecular imaging","other","article","10.1007/s00259-025-07263-6","40198357",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010263","A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.","Zhang Y","2021","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2021.108599","33965397","PMC8217212",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0010264","Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens.","Aranäs C","2025","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","preclinical","article","10.1016/j.euroneuro.2025.07.001","40644799",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010265","Liraglutide modulates olfactory ensheathing cell migration with activation of ERK and alteration of the extracellular matrix.","Tseng YT","2021","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2021.111819","34126351",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010266","Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.","Jamal A","2026","Acta diabetologica","systematic_review","article","10.1007/s00592-025-02635-8","41498807",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0010267","The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.","Ueda P","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14598","34738703",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010268","Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review.","Caliezi A","2026","Journal of clinical medicine","systematic_review","article","10.3390/jcm15082909","42074711","PMC13116881",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review; article"],["R0010269","Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials","Mahmood A","2026","F1000Res","systematic_review","preprint","10.12688/f1000research.186694.1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; review"],["R0010270","From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management?","Koufakis T","2026","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2025.102589","41371122",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010271","Implementation of Cardiometabolic Centers and Training Programs.","Taha MB","2022","Current diabetes reports","narrative_review","article","10.1007/s11892-022-01459-y","35316465",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010272","The GLP-1 agonist, exendin-4, stimulates LH secretion in female sheep.","Simpson EM","2023","The Journal of endocrinology","preclinical","article","10.1530/joe-23-0105","37466202","PMC10448581",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010273","Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study.","Minakata Y","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70550","41674229","PMC13071243",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0010274","Pharmacological management of type 2 diabetes mellitus in children and adolescents: A systematic review and network meta-analysis.","Gagnon CA","2025","World journal of diabetes","systematic_review","article","10.4239/wjd.v16.i7.106890","40697609","PMC12278083","PROSPERO:CRD42022382165",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0010275","Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.","Pasternak B","2024","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2023-078225","38683947","PMC11004669",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010276","Glycemic control, weight-loss effects, and safety of cotadutide in individuals with type 2 diabetes: A systematic review and meta-analysis.","Kamrul-Hasan ABM","2025","World journal of diabetes","systematic_review","article","10.4239/wjd.v16.i12.112830","41480597","PMC12754120","PROSPERO:CRD42024511703",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0010277","Exendin-4 Reduces Senescence of Inflammation-Induced Periodontal Ligament Stem Cells Through SIRT1/Notch1 Signaling.","Xu Y","2025","Stem cells international","other","article","10.1155/sci/7639451","41333237","PMC12668836",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010278","Use of High-Potency GLP-1 Receptor Agonists With OpenAPS Automated Insulin Dosing Algorithm Eliminates Need for Meal Announcements to Achieve Glycemic Goals.","Akcan T","2026","Diabetes care","randomized_trial","article","10.2337/dc25-2569","41511751","PMC12998392",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0010279","Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.","Gao L","2026","JAMA","randomized_trial","article","10.1001/jama.2026.8142","42251595","PMC13244275","ClinicalTrials.gov:NCT06164873","S000397","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; article"],["R0010280","Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.","Kobayashi K","2023","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/14791641231222837","38096503","PMC10725108",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; other; article"],["R0010281","Incretins and microRNAs: Interactions and physiological relevance.","Radbakhsh S","2020","Pharmacological research","narrative_review","article","10.1016/j.phrs.2020.104662","31982487",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010282","Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.","Frias JP","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13979","31984598","PMC7318331",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010283","SOUL searching in GLP-1 therapy: Oral semaglutide confirms cardioprotection in type 2 diabetes.","Schwarz CR","2025","Med (New York, N.Y.)","other_trial","article","10.1016/j.medj.2025.100774","40782670",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010284","OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.","Melander SA","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2023.176215","38056618",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010285","Integrating GLP-1 receptor agonists with anti-amyloid immunotherapy for Alzheimer's disease: a phased clinical roadmap.","Huang J","2025","Life medicine","commentary","article","10.1093/lifemedi/lnaf036","41425897","PMC12715310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","News; article"],["R0010286","A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.","Selvarajah V","2024","Kidney international","randomized_trial","article","10.1016/j.kint.2024.08.023","39218393",null,null,"S001902","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0010287","A one-dimensional semaglutide-GLP-1R-based mini static GIBAC","Li W","2024","Preprints.org","other","preprint","10.20944/preprints202406.0953.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010288","Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020-Nationwide Data from a Register-Based Analysis.","Jermendy G","2022","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina58101382","36295543","PMC9612371",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010289","Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management.","Hiramoto B","2024","The American journal of gastroenterology","systematic_review","article","10.14309/ajg.0000000000002820","38634551","PMC11150091",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, N.I.H., Extramural; research-article; review"],["R0010290","Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.","Singhal M","2019","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2019-000704","31798890","PMC6861096",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010291","At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.","Ruder K","2024","JAMA","other","article","10.1001/jama.2023.23141","38055301",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010292","Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis.","Wu Y","2024","American journal of translational research","systematic_review","article","10.62347/mcee4840","39678621","PMC11645625",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0010293","Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.","Shaman AM","2022","Circulation","randomized_trial","article","10.1161/circulationaha.121.055459","34903039","PMC8860212",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010294","Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis.","Borner T","2020","Cell reports","other","article","10.1016/j.celrep.2020.107768","32553160","PMC7376604",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0010295","Glucagon-like peptide-1 receptor agonist exendin-4 protects against interleukin-1β-mediated inhibition of glucose-stimulated insulin secretion by mouse insulinoma β cells.","Niu B","2017","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2017.4803","28947919","PMC5609319",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010296","Obesity, Low-Grade Chronic Inflammation, and Clinical Outcomes in Spondyloarthritis: A Translational Synthesis.","Belančić A","2026","Metabolites","randomized_trial","article","10.3390/metabo16050347","42188056","PMC13208230",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0010297","Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations.","Tiwari A","2026","Xenobiotica; the fate of foreign compounds in biological systems","other","article","10.1080/00498254.2026.2683901","42233942",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010298","Comparing Telepharmacy to Conventional Pharmacy Care: An Economic Evaluation.","Tam S","2026","Journal of pharmacy practice","other","article","10.1177/08971900261427109","41685675",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0010299","Efficacy and Safety of Mazdutide in Adults with Obesity or Overweight, With or Without Diabetes: A Bayesian Network Meta-Analysis","Tuersun A","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-9477385/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0010300","Epicardial adipose tissue in contemporary cardiology.","Iacobellis G","2022","Nature reviews. Cardiology","narrative_review","article","10.1038/s41569-022-00679-9","35296869","PMC8926097",null,"S000637; S002234","pubmed; europepmc","TRUE","open_europepmc","5",null,"Journal Article; Review; review-article"],["R0010301","Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.","Lamprea-Montealegre JA","2022","JAMA","other","article","10.1001/jama.2022.13885","36066519","PMC9449794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0010302","Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis.","Jensen JK","2022","Atherosclerosis","randomized_trial","article","10.1016/j.atherosclerosis.2022.03.032","35400496","PMC9241989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010303","Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity.","Abegaz TM","2026","JACC. Heart failure","other_trial","article","10.1016/j.jchf.2026.103060","42012431",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0010304","An Update on GLP-1 Receptor Agonists.","Bloomgarden Z","2025","Journal of diabetes","commentary","article","10.1111/1753-0407.70147","40842408","PMC12371248",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010305","From diabetes to donor lungs: the emerging role of GLP-1R agonists targeting lung transplant injury.","Khalid M","2025","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000003776","41181468","PMC12578013",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0010306","Top 20 Research Studies of 2023 for Primary Care Physicians.","Grad R","2024","American family physician","randomized_trial","article",null,"39028784",null,null,null,"pubmed; europepmc","FALSE","no_doi","2",null,"Journal Article; Review"],["R0010307","[New developments in endocrinology/diabetology].","Blüher M","2026","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-026-02154-w","42455323",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0010308","Glucagon-Like Peptide-1 Receptor Agonist Treatment for Pediatric Obesity.","Kelly AS","2016","Endocrine development","narrative_review","article","10.1159/000439323","26683061",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; book-chapter"],["R0010309","[Successful treatment of KCNJ11 neonatal diabetes without insulin].","Gade-Rasmussen B","2018","Ugeskrift for laeger","case_report","article",null,"30417822",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0010310","Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.","Brønden A","2017","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-016-0499-8","28050889",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0010311","Comments on \"Abdominoplasty Outcomes After GLP-1 Agonist-Induced Versus Postbariatric Massive Weight Loss: A Retrospective Comparative Case Series\".","D'Anna G","2026","Plastic and reconstructive surgery","nonrandomized_study","article","10.1097/prs.0000000000013427","42695811",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010312","Medication-Induced Gastroparesis: A Case Report.","Kalas MA","2021","Journal of investigative medicine high impact case reports","case_report","article","10.1177/23247096211051919","34663102","PMC8529310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010313","Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease.","Katsiki N","2021","Current pharmaceutical design","narrative_review","article","10.2174/1381612827666210104124320","33397230",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010314","Novel use of GLP-1 receptor agonist therapy for pediatric idiopathic intracranial hypertension: a case report.","Benabdelhak A","2026","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","case_report","article","10.1016/j.jcjo.2026.01.013","41620204",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0010315","Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.","Johansen NJ","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14078","32543021",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0010316","Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury.","Hirata Y","2013","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2012.11.057","23220706",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010317","Association between PNPLA3 rs738409 variant and 5-year estimated glomerular filtration rate decline in post-menopausal women with type 2 diabetes: A panel-data analysis.","Mantovani A","2023","Nutrition, metabolism, and cardiovascular diseases : NMCD","other","article","10.1016/j.numecd.2023.03.004","37208069",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0010318","The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.","Chen Y","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.895458","35692410","PMC9186017","PROSPERO:CRD42021288200",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; article"],["R0010319","Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.","Sun F","2015","Journal of diabetes research","systematic_review","article","10.1155/2015/157201","25688373","PMC4320855",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; research-article; review"],["R0010320","Glucose-Lowering Medications and Cardiovascular Outcomes.","Shanmugasundaram M","2021","Current cardiology reports","narrative_review","article","10.1007/s11886-021-01452-z","33655453",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010321","Emerging glucose-lowering therapies: a guide for cardiologists.","Gulsin GS","2020","Heart (British Cardiac Society)","narrative_review","article","10.1136/heartjnl-2019-315758","31551292",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010322","Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.","Unni S","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13107","28862808",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010323","Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus.","Alkabbani W","2022","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.14858","35460294","PMC9546240",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0010324","Letter to the Editor Regarding \"GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations\".","Zafar K","2026","Journal of gastroenterology and hepatology","nonrandomized_study","article","10.1111/jgh.70658","42563486",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; letter"],["R0010325","Diabetes: Pharmacotherapy for Type 2 Diabetes.","St Onge E","2021","FP essentials","other","article",null,"33970588",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010326","FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists.","van Beurden W","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2025.108978","39999536",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0010327","Erratum.",null,"2026","Obesity facts","notice","article","10.1159/000552927","42334973","PMC13290248",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0010328","Aortic stenosis: a review on acquired pathogenesis and ominous combination with diabetes mellitus.","Wal P","2023","The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology","narrative_review","article","10.1186/s43044-023-00345-6","37027109","PMC10082141",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010329","Glucagon-like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-like Behaviors in Diabetic Mice.","Yang F","2022","Nutrients","preclinical","article","10.3390/nu15010038","36615696","PMC9824834",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010330","Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.","Trujillo JM","2017","Pharmacotherapy","systematic_review","article","10.1002/phar.1962","28556176",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0010331","Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.","Long W","2026","Pakistan journal of pharmaceutical sciences","randomized_trial","article","10.36721/pjps.2026.39.7.204.1","42170981",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; article"],["R0010332","Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.","Masson W","2026","Reviews in endocrine & metabolic disorders","systematic_review","article","10.1007/s11154-025-09991-4","41032183",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0010333","Semaglutide for the Treatment of Type 2 Diabetes Mellitus.","Miles KE","2018","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","other_trial","article","10.1177/8755122518790925","34861016","PMC6231279",null,"S000298","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0010334","Stroke and Diabetes in Adults","Chen C","2023","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)","randomized_trial","article",null,"41370623",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0010335","Effects of Incretin-based Therapy on High-sensitivity C-reactive Protein in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Wu Y","2020","Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion","systematic_review","article","10.24875/ric.20000308","33861731",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; review"],["R0010336","Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.","Arslanian SA","2022","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2204601","35658022",null,"ClinicalTrials.gov:NCT02963766","S000604","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0010337","Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.","Goldenberg RM","2018","Current medical research and opinion","narrative_review","article","10.1080/03007995.2017.1372118","28836861",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010338","Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.","Gasoyan H","2025","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70058","41039650","PMC12636059",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010339","Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis.","Wang Y","2021","Journal of psychopharmacology (Oxford, England)","systematic_review","article","10.1177/02698811211035391","34311625",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Comparative Study; Journal Article; Systematic Review; Network Meta-Analysis; other; review"],["R0010340","Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach.","Kim BK","2026","The Kaohsiung journal of medical sciences","narrative_review","article","10.1002/kjm2.70227","42028921","PMC13399682",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010341","Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany.","Qiao Q","2016","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s99732","27418849","PMC4934555",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010342","Worsening Diabetic Retinopathy With GLP-1 Receptor Agonists in Kidney Transplant Recipients: An Emerging Signal Requiring Ophthalmologic Vigilance.","Hara S","2026","Clinical transplantation","commentary","article","10.1111/ctr.70486","41700969",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010343","Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).","Ordóñez-Vázquez AL","2022","Medical science monitor : international medical journal of experimental and clinical research","commentary","article","10.12659/msm.938365","36093924","PMC9479660",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0010344","Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview.","Davies C","2025","Nursing standard (Royal College of Nursing (Great Britain) : 1987)","narrative_review","article","10.7748/ns.2025.e12464","40383978",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010345","Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift.","Maranta F","2021","International journal of cardiology","other","article","10.1016/j.ijcard.2021.05.050","34058289",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010346","Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes.","Schwartz SS","2015","Postgraduate medicine","narrative_review","article","10.1080/00325481.2015.996504","25547241",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010347","Improved Glycaemic Control with IDegLira in Chinese Adults with Type 2 Diabetes in Real-World Settings: A Retrospective, Database Cohort Study.","Wang S","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-026-01852-w","41848819","PMC13103104",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010348","Achieving Diabetes Remission: Current Guidelines and Emerging Pharmacotherapies in India.","Arpan","2025","The Journal of the Association of Physicians of India","systematic_review","article","10.59556/japi.73.1184","41100333",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0010349","Methodological concerns regarding \"Alopecia after GLP-1 agonist therapy: A TriNetX database active comparator retrospective cohort study\".","Jean SS","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.06.154","42641691",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0010350","Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes.","Zhang Y","2021","Drug design, development and therapy","other","article","10.2147/dddt.s312347","34285470","PMC8285923",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010351","GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.","Trujillo JM","2014","Pharmacotherapy","nonrandomized_study","article","10.1002/phar.1507","25382096",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0010352","Antigen-specific immunotherapy combined with a regenerative drug in the treatment of experimental type 1 diabetes.","Villalba A","2020","Scientific reports","preclinical","article","10.1038/s41598-020-76041-1","33144616","PMC7609712",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010353","Childhood Obesity, Medications, and Surgeries.","Raghav S","2026","Cardiology in review","other","article","10.1097/crd.0000000000001230","41986930",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010354","Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide.","Eggert S","2018","Expert opinion on pharmacotherapy","systematic_review","article","10.1080/14656566.2018.1444882","29471700",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; Comment; article"],["R0010355","GLP-1 receptor agonist safety in a perioperative setting: more questions than answers.","Aquilina G","2026","Expert review of clinical pharmacology","commentary","article","10.1080/17512433.2026.2621247","41566715",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0010356","Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.","Al-Ozairi E","2023","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23677","36811241",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010357","Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats.","Jensen MN","2025","Fluids and barriers of the CNS","preclinical","article","10.1186/s12987-025-00652-x","40275284","PMC12020230",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010358","Clinical efficacy of tirzepatide for weight regain and suboptimal glycemic control following laparoscopic sleeve gastrectomy: a case series of three patients with obesity-associated type 2 diabetes.","Fujishiro M","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1895420","42666183","PMC13521790",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Case Reports; research-article; article"],["R0010359","Refining free fatty acid receptor agonism for metabolic control: Pharmacological and functional features of novel dual GPR40/GPR120 ligands.","Brunetti K","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2026.119735","42413138",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010360","Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.","Amini A","2025","Acta ophthalmologica","nonrandomized_study","article","10.1111/aos.17473","40055951","PMC12340176",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0010361","Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.","Fu L","2026","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2026.156594","41850421",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0010362","Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice.","Hu W","2025","International immunopharmacology","preclinical","article","10.1016/j.intimp.2024.113937","39752752",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010363","Semaglutide effects on energy balance are mediated by Adcyap1+ neurons in the dorsal vagal complex.","Teixidor-Deulofeu J","2025","Cell metabolism","preclinical","article","10.1016/j.cmet.2025.04.018","40409256",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010364","Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes.","Wang YC","2023","iScience","preclinical","article","10.1016/j.isci.2023.107680","37680468","PMC10481356",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010365","Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties.","Nielsen JC","2024","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.4c00417","38977267","PMC11284799",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010366","GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.","Tsapas A","2021","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2021.108921","34144086",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0010367","12461 The Impact Of Switching From A Glp-1 Analog To Tirzepatide On Blood Glucose Levels, Body Weight, And Liver Function In Patients With Type 2 Diabetes",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453393",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0010368","Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.","Wilding JP","2016","Diabetes care","narrative_review","article","10.2337/dcs15-3005","27440828",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010369","Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice.","Artigas CF","2015","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2015.1052740","26077113",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Review; editorial"],["R0010370","SGLT2i and GLP-1RA Use in the USA.","Steiger K","2026","Journal of general internal medicine","commentary","article","10.1007/s11606-026-10456-w","42014641","PMC13305227",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0010371","Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure.","Lopez PD","2022","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2022.07.012","35963825",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010372","Polycystic Ovary Syndrome: A Contemporary Clinical Approach.","Bjekić-Macut J","2021","Current pharmaceutical design","narrative_review","article","10.2174/1381612827666210119104721","33463457",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010373","Targeting the incretin system in obesity and type 2 diabetes mellitus.","Ansari S","2024","Nature reviews. Endocrinology","narrative_review","article","10.1038/s41574-024-00979-9","38632474",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010374","Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.","Handelsman Y","2019","Advances in therapy","narrative_review","article","10.1007/s12325-019-01126-x","31646466","PMC6860469",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; other; article"],["R0010375","Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study.","Lengsfeld S","2023","Trials","protocol","article","10.1186/s13063-023-07164-9","37081574","PMC10120253","ClinicalTrials.gov:NCT03204396","S000115","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; other; article"],["R0010376","Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.","Chu L","2021","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2021.07.015","34426012",null,"ClinicalTrials.gov:NCT04445181","S002610; S002662","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0010377","OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9624686",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0010378","Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis.","Dong R","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s557994","41926503","PMC12790963",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010379","Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice.","Iwasaki S","2017","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.117.242651","28698254",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010380","Distilling the evidence for GLP-1 receptor agonists in alcohol use disorder.","Bernstein EY","2025","Addiction science & clinical practice","commentary","article","10.1186/s13722-025-00638-y","41437082","PMC12729087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010381","Activation of glucagon-like peptide-1 receptors and skilled reach foraging.","Vestlund J","2021","Addiction biology","preclinical","article","10.1111/adb.12953","32770792","PMC8244104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010382","Oral Delivery of Liraglutide Formulated with PLGA for Sustained Obesity Management.","Chen N","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27073300","41977481","PMC13072843",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010383","Polyethylene Glycol Loxenatide (PEX-168) Reduces Body Weight and Blood Glucose in Simple Obese Mice.","Wu Y","2021","International journal of endocrinology","preclinical","article","10.1155/2021/9951463","34721575","PMC8550851",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010384","GLP-1 Receptor Agonists in Pediatric Obesity Care: Promise, Pitfalls, and Practical Realities.","Alcocer Alkureishi L","2026","Pediatric annals","commentary","article","10.3928/19382359-20251125-01","41480871",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010385","The expanding role of the microbiome in GLP-1 pharmacology.","Massey WJ","2026","Cell host & microbe","commentary","article","10.1016/j.chom.2026.05.006","42269588",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0010386","Comment On: Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists; An Examination of the FAERS Database.","Sánchez VMA","2026","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2026.01.042","41672365",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0010387","Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.","St-Pierre J","2024","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-024-08720-2","39516435",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Preprint; preprint; article"],["R0010388","Transformer-based models for ADR detection: cross-drug validation and benchmarking against large language models.","Kim M","2025","Therapeutic advances in drug safety","nonrandomized_study","article","10.1177/20420986251405082","41426306","PMC12715130",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010389","Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection.","Sridhar VS","2020","Jornal brasileiro de nefrologia","narrative_review","article","10.1590/2175-8239-jbn-2020-0100","32926067","PMC7860654",null,"S002662","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0010390","GLP-1 receptor agonists and reduced dementia risk: Real-world evidence stacks up.","Lam YW","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70451","41507114",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0010391","Escalate or Switch? Treating the Post-Titration GLP-1 Non-Responder: A Target Trial Emulation With Dose-Equivalence Reclassification","Erly B","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.07.14.26357491",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0010392","Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN).","Guo L","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","protocol","article","10.1007/s13300-022-01268-2","35583797","PMC9174375",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0010393","Epicardial adipose tissue in obesity-related cardiac dysfunction.","Ayton SL","2022","Heart (British Cardiac Society)","narrative_review","article","10.1136/heartjnl-2020-318242","33985985",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010394","Response to concerns with the statistical analysis in \"Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study\".","Naude J","2026","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-026-02135-x","42509259",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0010395","Improving the Quality of Two Lives by Treating Obesity.","Nagy N","2025","Reports (MDPI)","case_report","article","10.3390/reports8020085","40710876","PMC12196773",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010396","Beyond Weight Loss: A Geriatric Perspective on GLP-1 RAs in Older Adults With Obesity.","Mendes-Piteira S","2026","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.70233","42242897",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010397","A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.","Abreu M","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13794","31144435",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Pragmatic Clinical Trial; article"],["R0010398","Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy.","Bal HS","2026","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2026.101451","41767450","PMC12946939",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0010399","Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.","Hsia SH","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00160-9","42628555",null,"ClinicalTrials.gov:NCT06124807","S001915","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0010400","Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.","Visaria J","2021","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2021.03.003","33785221",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010401","Semaglutide targets the Isg15-FUNDC1 axis: suppressing IFN-β overactivation and attenuating blood-brain barrier injury in diabetic intracerebral hemorrhage.","Wang Y","2026","Journal of neuroinflammation","preclinical","article","10.1186/s12974-026-03877-1","42186030","PMC13386872",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010402","Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis.","Kahl S","2022","Seminars in liver disease","other","article","10.1055/s-0041-1732354","34289506",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010403","Gut Hormones and Inflammatory Bowel Disease.","Weng J","2025","Biomolecules","narrative_review","article","10.3390/biom15071013","40723884","PMC12292665",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0010404","Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain.","Hsu CC","2022","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph15070904","35890201","PMC9320491",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010405","Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.","Alkabbani W","2022","Canadian journal of diabetes","nonrandomized_study","article","10.1016/j.jcjd.2021.12.005","35513988",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0010406","Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.","Mensah MO","2024","The New England journal of medicine","commentary","article","10.1056/nejmc2407932","39167820",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0010407","RWC Update: GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Concern or Coincidence?; The Glowport; Retinocytoma.","Sharma A","2026","Ophthalmic surgery, lasers & imaging retina","other","article","10.3928/23258160-20260114-01","41666351",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010408","Beyond Blood Sugar: Investigating the Cardiovascular Effects of Antidiabetic Drugs.","Ahmad BA","2023","Cureus","narrative_review","article","10.7759/cureus.46373","37920618","PMC10618835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010409","Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?","Sharma A","2021","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000000892","34173772",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010410","Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel.","Consoli A","2020","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14102","32476244",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; Consensus Statement; article"],["R0010411","Reply to Comment on: \"Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS Database\".","Murray M","2026","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2026.02.004","41679369",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0010412","Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice.","Shahabian L","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27125311","42353032","PMC13300714",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010413","Management of Type 2 Diabetes in Frail Older Adults.","Bahat G","2023","Drugs & aging","other","article","10.1007/s40266-023-01049-x","37434085",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010414","Females are protected from semaglutide-induced muscle loss in ob/ob mice.","Rout S","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.03.03.709376","41867824","PMC13001401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0010415","Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol.","Hussein H","2018","BMJ open","systematic_review","article","10.1136/bmjopen-2018-023206","30413509","PMC6231581","PROSPERO:CRD42018091306",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; protocol; review"],["R0010416","Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide - a review.","Lu M","2026","International journal of retina and vitreous","narrative_review","article","10.1186/s40942-026-00811-8","41851808","PMC13113116",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0010417","Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States : A Population-Based Cohort Study.","Ostrominski JW","2025","Annals of internal medicine","nonrandomized_study","article","10.7326/annals-24-02870","40228298","PMC12718076",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0010418","Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants.","Vera Ponce VJ","2026","Obesity pillars","other","article","10.1016/j.obpill.2026.100308","42565180","PMC13446298",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010419","What have we learnt from \"real world\" data, observational studies and meta-analyses.","Chatterjee S","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13178","29364585",null,null,"S002638","pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010420","CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.","Schnell O","2026","Cardiovascular diabetology","other_trial","article","10.1186/s12933-026-03140-0","42092956","PMC13147710",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Conference Proceedings; letter; article"],["R0010421","New Evidence in Heart Failure: 2026 Update.","Liguori V","2026","ESC heart failure","other","article","10.1093/eschf/xvag216","42679357",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010422","Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers.","Kim C","2025","JAMA oncology","nonrandomized_study","article","10.1001/jamaoncol.2025.4560","41196576","PMC12593664",null,"S002468","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0010423","Obesity and Weight Loss Strategies for Patients With Heart Failure.","Vest AR","2024","JACC. Heart failure","narrative_review","article","10.1016/j.jchf.2024.06.006","39093256",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0010424","The pharmacological management of metabolic syndrome.","Rask Larsen J","2018","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2018.1429910","29345505",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010425","Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities.","Prikhodko VA","2026","Biomedicines","nonrandomized_study","article","10.3390/biomedicines14040909","42072449","PMC13113231",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0010426","Emerging Role of Taste Receptors, Entero-Endocrine Cells in Type 2 Diabetes and Metabolic Disorders.","Su Khin KL","2026","Nutrients","narrative_review","article","10.3390/nu18050759","41829929","PMC12986535",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010427","Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis.","Wood DT","2023","Clinical rheumatology","other","article","10.1007/s10067-023-06647-z","37264145",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010428","Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.","Gu S","2026","Drug, healthcare and patient safety","nonrandomized_study","article","10.2147/dhps.s556918","41531800","PMC12989282",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010429","Exendin-4 alleviates Aβ1-40-induced apoptosis and calcium dysregulation in RPE cells through the CHP1/NHE1 complex.","Shu Q","2026","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2026.117789","41679663",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010430","Evaluating the Role of GLP-1 Receptor Agonists in Modifying Risks of Visual and CSF Complications in Idiopathic Intracranial Hypertension.","Nayak A","2026","International forum of allergy & rhinology","other","article","10.1002/alr.70095","41532705",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010431","Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure.","Joubert M","2017","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(17)30071-x","28431670",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010432","Suicide risk and depressive symptoms in obese patients treated with GLP-1 receptor agonists","Del Valle Martín M","2025","European psychiatry : the journal of the Association of European Psychiatrists","other","article",null,null,"PMC12447346",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0010433","GLP-1 and Its Role in Glycogen Production: A Narrative Review.","Lotosky J","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13071610","40722684","PMC12292085",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0010434","The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy.","Kuo CY","2025","Cellular and molecular life sciences : CMLS","preclinical","article","10.1007/s00018-024-05558-9","39779525","PMC11711727",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010435","Response to \"Beyond Weight Loss: A Geriatric Perspective on GLP-1 RAs in Older Adults With Obesity\".","Rego de Figueiredo I","2026","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.70232","42242706",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010436","\"Why you should (not) use semaglutide?\": A critical discourse analysis on health professionals' videos of semaglutide for weight loss on Douyin.","Huang X","2025","Social science & medicine (1982)","other","article","10.1016/j.socscimed.2025.118339","40582256",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010437","Liraglutide reduces the apoptosis of feeding and appetite-suppressing neurons in the hypothalamus of obese rats association with the PI3K/AKT/Foxo1 pathway.","Yang W","2026","Experimental brain research","preclinical","article","10.1007/s00221-026-07274-1","41865318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010438","Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes","Feingold KR","2000","MDText.com, Inc., South Dartmouth (MA)","narrative_review","article",null,"25905364",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0010439","Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study.","Yoshiji S","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01231-1","35285007","PMC8991285",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010440","Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study.","López-Cano C","2022","Scientific reports","randomized_trial","article","10.1038/s41598-022-07250-z","35217772","PMC8881618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010441","Astrocyte polarization in glaucoma: a new opportunity.","Liu YX","2022","Neural regeneration research","narrative_review","article","10.4103/1673-5374.339470","35662185","PMC9165360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010442","Increasing Postpartum Use of GLP-1 Receptor Agonists.","Bliddal M","2025","JAMA","other","article","10.1001/jama.2025.20947","41284290","PMC12645395",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010443","The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients.","Mazin I","2022","Journal of clinical medicine","narrative_review","article","10.3390/jcm11071904","35407513","PMC9000034",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010444","Association of semaglutide with retained gastric contents on endoscopy: Retrospective analysis.","Gu GH","2025","Endoscopy international open","nonrandomized_study","article","10.1055/a-2550-1468","40230563","PMC11996017",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010445","Cardiovascular benefits of liraglutide in patients with type 2 diabetes: an in-depth exploration.","Alluri AA","2025","Minerva cardiology and angiology","nonrandomized_study","article","10.23736/s2724-5683.25.06846-2","40923921",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010446","Efficacy of Weight-Lowering Agents on Fat Distribution: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","Qiao X","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70100","41554634","PMC13243349",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; review-article; review"],["R0010447","One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.","Holt J","2026","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.70043","40998556","PMC12724041","ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32","S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; brief-report; article"],["R0010448","Interaction of Semaglutide and Ziprasidone in a Patient With Schizophrenia: A Case Report.","Hejdak D","2024","Cureus","case_report","article","10.7759/cureus.59319","38817502","PMC11137324",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010449","The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.","Newman JD","2018","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2018.07.071","30286929","PMC6178226",null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article"],["R0010450","A systematic review and meta-analysis comparing the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 agonists in type 2 diabetes.","Khan LA","2025","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-025-01741-2","41084518","PMC12515190",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review"],["R0010451","Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases.","Al-Shamasi AA","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms222312677","34884494","PMC8657861",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010452","Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence.","Spreckley M","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","randomized_trial","article","10.1111/obr.70079","41500509","PMC13136787",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Scoping Review; review-article; article"],["R0010453","Type 2 Diabetes Mellitus: GLP1 Receptor Agonists and SGLT2 Inhibitors in Patients Referred to Ambulatory Consultant Cardiology Clinics.","Antonelli D","2023","The Israel Medical Association journal : IMAJ","other","article",null,"36841985",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010454","Cardiometabolic Profiles and Treatment Trajectories of GLP-1 Receptor Agonist Users With Obstructive Sleep Apnea: Real-World Evidence From a Large Private Healthcare Cohort in Poland.","Nowak K","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70644","41804236",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Letter; article"],["R0010455","Development and validation of stability-indicating assay method and identification of force degradation products of glucagon-like peptide-1 synthetic analog Exenatide using liquid chromatography coupled with Orbitrap mass spectrometer.","Badgujar D","2024","European journal of mass spectrometry (Chichester, England)","other","article","10.1177/14690667241262935","39056322",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Validation Study; article"],["R0010456","Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: \"INSIST\" study.","Mohammedi K","2024","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-024-02257-4","38812009","PMC11137927",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0010457","Myeloid cells in retinal and brain degeneration.","Guo M","2022","The FEBS journal","preclinical","article","10.1111/febs.16177","34478598","PMC8891394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0010458","Tolerability and safety of concomitant GLP-1 receptor agonist and biologic therapy: A retrospective chart review.","Khang J","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.01.016","41571150",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010459","GLP-1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?","Zgardau A","2026","The Laryngoscope","other","article","10.1002/lary.70022","40772609","PMC13158822",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0010460","Impact of the COVID-19 pandemic on the glycemic control in people with diabetes mellitus: A retrospective cohort study.","Ohkuma K","2023","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14021","37118898","PMC10360387",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010461","The association between weight loss medications and cardiovascular complications.","Baser O","2024","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24037","38706431",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0010462","Obesity and chronic kidney disease: A current review.","Nawaz S","2023","Obesity science & practice","narrative_review","article","10.1002/osp4.629","37034567","PMC10073820",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010463","Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus.","Sharma PK","2026","Metabolism open","randomized_trial","article","10.1016/j.metop.2026.100476","42253408","PMC13235369","CTRI:CTRI/2025/03/082615",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010464","Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.","Nee R","2023","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","narrative_review","article","10.1093/ndt/gfac283","36264305","PMC9976771",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; review-article; article"],["R0010465","Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series.","Lajthia E","2019","Pharmacy practice","nonrandomized_study","article","10.18549/pharmpract.2019.4.1588","31897252","PMC6935552",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010466","Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study.","Brown RE","2019","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2019.107820","31446111",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010467","Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study.","Wu JY","2025","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2025.112279","40412626",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0010468","The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.","Morton JI","2021","Diabetologia","nonrandomized_study","article","10.1007/s00125-020-05304-3","33078206",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0010469","Sex and Cardiovascular Outcomes with CKD.","Shah S","2026","Clinical journal of the American Society of Nephrology : CJASN","other","article","10.2215/cjn.0000001167","42536413",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010470","Chemoenzymatic Synthesis of Rhamnolipid-Modified Exendin-4: A Dual Approach for Long-Acting Glycemic Control through Endogenous Antibody Recruitment and Albumin Interaction.","Dai S","2025","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.5c02146","41163197",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010471","Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity.","Jeromson S","2025","The Journal of physiology","preclinical","article","10.1113/jp289449","40982727",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010472","An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.","Madsbad S","2011","Diabetes, obesity & metabolism","other_trial","article","10.1111/j.1463-1326.2011.01357.x","21208359",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010473","Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study.","Bołdys A","2025","International journal of molecular sciences","other","article","10.3390/ijms26125883","40565353","PMC12192618",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010474","Combined use of GABA and sitagliptin promotes human β-cell proliferation and reduces apoptosis.","Liu W","2021","The Journal of endocrinology","preclinical","article","10.1530/joe-20-0315","33258801",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010475","[Type 2 diabetes treatment and cardiovascular risk: what can we learn from trials?].","Consoli A","2016","Giornale italiano di cardiologia (2006)","other","article","10.1714/2616.26912","28151518",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010476","Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.","Otto T","2019","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2018.1538011","30328731",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010477","The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease.","Andreasen CR","2023","Diabetologia","narrative_review","article","10.1007/s00125-023-05966-9","37498367",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010478","Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.","van Ruiten CC","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14410","33908691","PMC8360098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0010479","Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.","Fiorucci S","2025","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2025.2546812","40782123",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0010480","A Short-Term Cost-Effectiveness Analysis of Tirzepatide Versus Semaglutide for the Treatment of Obesity in Greece.","Papantoniou P","2025","Healthcare (Basel, Switzerland)","other","article","10.3390/healthcare13162011","40868627","PMC12385529",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010481","GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.","Preston W","2023","The New England journal of medicine","nonrandomized_study","article","10.1056/nejmc2311840","38091541",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0010482","Patient-Level Multidimensional Response Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study.","Bujdei-Tebeică I","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15145671","42513584","PMC13413080",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010483","Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis.","Kamrul-Hasan ABM","2025","World journal of diabetes","systematic_review","article","10.4239/wjd.v16.i5.103244","40487607","PMC12142189",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0010484","GLP-1 receptor agonists for Parkinson's disease: An updated meta-analysis.","Albuquerque MB","2025","Parkinsonism & related disorders","systematic_review","article","10.1016/j.parkreldis.2024.107220","39642803",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0010485","Income disparities and accessibility to Semaglutide: implications for diabetes management and policy reform.","Vaidya V","2026","International journal for quality in health care : journal of the International Society for Quality in Health Care","other","article","10.1093/intqhc/mzaf131","41437637",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010486","A comprehensive study on the identification and characterization of major degradation products of synthetic liraglutide using liquid chromatography-high resolution mass spectrometry.","Badgujar D","2025","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.3652","39162000",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010487","Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital.","Shannon K","2025","Journal of pharmacy practice","case_report","article","10.1177/08971900241294122","39438027",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0010488","A Pharmacological Dose of Liraglutide Improves Mitochondrial Performance in Mouse Leydig Cells.","Oliveira-Lopes B","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms26188903","41009468","PMC12469514",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010489","Metabolic miracle or misguided shift? Tirzepatide in the era of obstructive sleep apnea (OSA).","Chandani DK","2025","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000004135","41377342","PMC12688795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010490","The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study.","Wu T","2022","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2022.02.008","35300912",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0010491","Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.","Mody R","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13603","30520248","PMC6590811",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0010492","Shrinking appetites: Will GLP-1 adoption in high-income countries accelerate Big Food's push into low- and middle-income countries?","Even B","2026","Globalization and health","other","article","10.1186/s12992-026-01217-9","42210374","PMC13430823",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0010493","SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12544991",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0010494","Are GLP-1 receptor agonists associated with reduced atrial fibrillation risk? Analyzing data duplication and uncertainty.","Barbosa LM","2026","Metabolism: clinical and experimental","commentary","article","10.1016/j.metabol.2025.156490","41478556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010495","Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6.","Strain WD","2022","Stroke","randomized_trial","article","10.1161/strokeaha.121.037775","35582947","PMC9389936","ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010496","Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol.","Duncan J","2026","Obesity pillars","protocol","article","10.1016/j.obpill.2025.100236","41438798","PMC12719667",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0010497","Tirzepatide vs. Semaglutide for Obesity Treatment.","Muskiet MHA","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2510962","41124642",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0010498","GLP-1 Receptor Agonists and Transjugular Intrahepatic Portosystemic Shunt: A Word of Caution.","Strohbehn I","2026","Journal of vascular and interventional radiology : JVIR","commentary","article","10.1016/j.jvir.2025.107961","41397556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010499","Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.","Maagensen H","2021","Psychiatry research","randomized_trial","article","10.1016/j.psychres.2020.113670","33373806",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0010500","Phasic dopamine responses to a food-predictive cue are suppressed by the glucagon-like peptide-1 receptor agonist Exendin-4.","Konanur VR","2020","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2019.112771","31821815","PMC8112128",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0010501","Circulating levels of PYY are increased in individuals with bile acid diarrhoea.","Lange AH","2026","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgag295","42496159",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0010502","Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial.","Kårhus ML","2022","The lancet. Gastroenterology & hepatology","randomized_trial","article","10.1016/s2468-1253(22)00198-4","35868334",null,"EudraCT:2018-003575-34","S001709","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; article"],["R0010503","Liraglutide ameliorates diabetic-induced testicular dysfunction in male rats: role of GLP-1/Kiss1/GnRH and TGF-β/Smad signaling pathways.","Fathy MA","2023","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2023.1224985","37497106","PMC10367011",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010504","Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.","Gabe MBN","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15951","39279639",null,"ClinicalTrials.gov:NCT05804162","S002210","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0010505","[Mechanism of action of glucagon-like peptide-1 receptor agonist in promoting the apoptosis of hepatic stellate cells based on the extracellular signal-regulated kinase signaling pathway].","Wu LK","2017","Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","other","article","10.3760/cma.j.issn.1007-3418.2017.09.012","29108195","PMC12677293",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010506","Advances in oral peptide therapeutics.","Drucker DJ","2020","Nature reviews. Drug discovery","narrative_review","article","10.1038/s41573-019-0053-0","31848464",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0010507","The cardiovascular safety of GLP-1 receptor agonists: From glucose control to cardiometabolic protection.","Ghaffari S","2025","Journal of cardiovascular and thoracic research","commentary","article","10.34172/jcvtr.025.33793","41836208","PMC12980093",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0010508","Reconsidering Semaglutide Use for Chronic Obesity in Patients of Asian Descent: A Critical Review.","Lu J","2024","Cureus","narrative_review","article","10.7759/cureus.73111","39650923","PMC11622169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010509","Prevalence, Glycemic Efficacy, and Safety of Four Non-Insulin Antidiabetic Drug Combinations in Patients with Type 2 Diabetes.","Papaetis GS","2026","Endocrine, metabolic & immune disorders drug targets","randomized_trial","article","10.2174/0118715303402479251129144029","41582388",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0010510","Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view.","Scheen AJ","2020","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2019.05.005","31108136",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010511","Repurposing Antidiabetic Drugs for Cardiovascular Disease.","Schubert M","2020","Frontiers in physiology","narrative_review","article","10.3389/fphys.2020.568632","33041865","PMC7522553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010512","The transformative role of GLP-1 receptor agonists in obesity and chronic disease: clinical insights from a dialogue with artificial intelligence.","Gandhi R","2026","Journal of basic and clinical physiology and pharmacology","commentary","article","10.1515/jbcpp-2025-0209","41494191",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010513","Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review.","Honka H","2021","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2021.02.057","33888253","PMC8091273",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review; abstract"],["R0010514","[Which injectable therapy after failure of oral antidiabetic agents in type 2 diabetes ?].","Scheen AJ","2020","Revue medicale de Liege","other","article",null,"31920046",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010515","Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study.","Polonsky W","2021","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds20-0025","34149258","PMC8178715",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010516","GLP-1 receptor agonist exenatide uncouples food intake from hedonic and anticipatory regulation in non-human primates: insights from an operant meal schedule paradigm.","Knakker B","2024","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/s41386-024-01981-5","39232188","PMC11631970",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; preprint; article"],["R0010517","From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity.","Kistkins S","2024","Endocrine connections","narrative_review","article","10.1530/ec-23-0529","38579770","PMC11046332",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010518","Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.","Tong L","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13156","29119712","PMC5887884",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0010519","Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.","Ripa RS","2021","Circulation. Cardiovascular imaging","randomized_trial","article","10.1161/circimaging.120.012174","34187185","PMC8300846","ClinicalTrials.gov:NCT03449654","S001895","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010520","Managing obesity-related male infertility: insights from weight loss intervention.","Pereira TA","2025","Human reproduction (Oxford, England)","narrative_review","article","10.1093/humrep/deaf180","41024420",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010521","Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.","Reifsnider OS","2022","Diabetes, obesity & metabolism","other","article","10.1111/dom.14625","34910356","PMC9305296",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010522","GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.","Davies ML","2016","Pharmacotherapy","randomized_trial","article","10.1002/phar.1792","27340935",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0010523","Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin.","Poloju A","2023","AACE clinical case reports","case_report","article","10.1016/j.aace.2023.04.005","37520757","PMC10382614",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010524","Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.","Schernthaner G","2020","Cardiovascular diabetology","commentary","article","10.1186/s12933-020-01154-w","33097060","PMC7585305",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0010525","Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey.","Gibble TH","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100288","42436850","PMC13355407",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010526","Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study.","Chauhan A","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01419-z","37289358","PMC10299979",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010527","GLP-1 receptor agonist use in patients with psoriasis or hidradenitis suppurativa.","Granovsky R","2026","JAAD international","other","article","10.1016/j.jdin.2025.12.008","41630868","PMC12861177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0010528","Sleeve Gastrectomy Versus Semaglutide for Weight Loss in a Severely Obese Minority Cohort: A Propensity-Matched Study.","Masrur MA","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-07712-z","39875789",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0010529","Pharmacological Management of Diabetic Nephropathy.","Papademetriou V","2020","Current vascular pharmacology","narrative_review","article","10.2174/1570161117666190405164749","30961500",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010530","Skeletal effects and signalling mechanisms of glucagon-like peptide-1 receptor agonists in bone","Pereira M","2017","Royal Veterinary College (University of London)","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0010531","GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials.","Jia X","2018","Cardiovascular drugs and therapy","systematic_review","article","10.1007/s10557-018-6773-2","29445896",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0010532","Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes.","Setji T","2013","Expert review of endocrinology & metabolism","other_trial","article","10.1586/eem.13.2","30780810",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0010533","A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes.","Yanai H","2022","Cardiology research","nonrandomized_study","article","10.14740/cr1441","36405226","PMC9635779",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010534","Disconnect between signalling potency and  <i>in vivo<\/i>  efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists","Lucey M","2019","bioRxiv","preclinical","preprint","10.1101/855874",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010535","Weighty matters: Ozempic, autonomy and the ethics of health reform.","Räsänen J","2026","Journal of medical ethics","other","article","10.1136/jme-2025-111117","40921625",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010536","A New Drug for Obesity: Tirzepatide.","Sidhu JK","2025","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/0118715303319530240703111013","38994609",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010537","Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.","Navaneethan SD","2023","Annals of internal medicine","other","article","10.7326/m22-2904","36623286",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0010538","The First Successful Desensitization Protocol in Exenatide Allergy: A Case Report","Yeğit OO","2022","Research Square","protocol","preprint","10.21203/rs.3.rs-2059070/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0010539","GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes.","Monney M","2023","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2023.101470","37657738",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010540","Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment - A qualitative study.","Trocchio LL","2026","Obesity pillars","other","article","10.1016/j.obpill.2025.100237","41399811","PMC12702257",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010541","The Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.","St Onge E","2017","Journal of translational internal medicine","other","article","10.1515/jtim-2017-0015","28721339","PMC5506406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010542","Effects of Digitization of Self-Monitoring of Blood Glucose Records Using a Mobile App and the Cloud System on Outpatient Management of Diabetes: Single-Armed Prospective Study.","Handa T","2024","JMIR diabetes","nonrandomized_study","article","10.2196/48019","38241065","PMC10837757","jRCT:jRCTs042190057",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010543","AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models.","Saigal A","2026","Nature communications","preclinical","article","10.1038/s41467-026-73370-z","42486853","PMC13392390",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010544","Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.","Jastreboff AM","2026","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2604169","42814954",null,"ClinicalTrials.gov:NCT05929066","S001035","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0010545","Redox Homeostasis in Metabolic Syndrome and Type II Diabetes: Role of Skeletal Muscle and Impact of Gold-Standard Treatments.","Wilkinson MS","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms262110370","41226411","PMC12610530",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010546","Pharmacologic options for the treatment of overweight and obesity.","Hurtado Andrade MD","2025","Menopause (New York, N.Y.)","narrative_review","article","10.1097/gme.0000000000002573","40554633",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010547","Obesity and multiple myeloma: Emerging mechanisms and perspectives.","Tentolouris A","2023","Seminars in cancer biology","narrative_review","article","10.1016/j.semcancer.2023.04.003","37030643",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010548","Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial.","Jørgensen PG","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12900","28188972",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0010549","Theoretical Mechanisms of GLP-1 Receptor Agonist-Induced Depression in Obesity Treatment","Stewart A","2025","European psychiatry : the journal of the Association of European Psychiatrists","other","article","10.1192/j.eurpsy.2025.411",null,"PMC12437141",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0010550","Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).","Brown RE","2020","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14117","32538541","PMC7689820",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0010551","[Semaglutide in Chronic Kidney Disease: Great Enthusiasm. But How Does It Work?].","Iorio F","2024","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","narrative_review","article","10.69097/41-03-2024-04","38943325",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0010552","Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes.","Avramidis I","2020","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd19-0090","32699473","PMC7364453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010553","Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?","Seidu S","2021","Primary care diabetes","narrative_review","article","10.1016/j.pcd.2020.07.011","32826189",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010554","Exendin-4 Improves Cognitive Function of Diabetic Mice via Increasing Brain Insulin Synthesis.","Peng X","2021","Current Alzheimer research","preclinical","article","10.2174/1567205018666210929150004","34587885",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010555","Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.","Mathieu C","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00096-8","40482671",null,"ClinicalTrials.gov:NCT05352815","S000458","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0010556","Impact of surfactants on the stability of therapeutic peptides under interfacial stress.","Hamada N","2026","Journal of pharmaceutical sciences","other","article","10.1016/j.xphs.2026.104493","42679928",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010557","Decoding neural signals to build metabolic therapies.","Pers TH","2026","Cell metabolism","other","article","10.1016/j.cmet.2026.06.010","42551408",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010558","Insulin and Incretin Receptor Agonists Reciprocally Alter Their Blood-Brain Barrier Permeabilities.","Fry A","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27104611","42196588","PMC13207238",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010559","Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.","Mabilleau G","2018","The Journal of endocrinology","narrative_review","article","10.1530/joe-17-0278","28855317",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010560","Next-Generation GLP-1 Agonist Bioassays: Integrating Precision with Biological Relevance.","Graf C","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27188068","42794498","PMC13607436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010561","Synthesis and in vitro biological evaluation of new pyrimidines as glucagon-like peptide-1 receptor agonists.","AlNeyadi SS","2017","Bioorganic & medicinal chemistry letters","preclinical","article","10.1016/j.bmcl.2017.09.032","28988756",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010562","GLP-1 RA Therapy After Bariatric Surgery: Phenotype, Strategy and Success.","Sun M","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70897","42219268",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010563","Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.","Van Laren J","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70579","41713959",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0010564","Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.","Jendle J","2016","Diabetes/metabolism research and reviews","other_trial","article","10.1002/dmrr.2810","27102969",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0010565","Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials","Qin J","2020","Research Square","systematic_review","preprint","10.21203/rs.2.16671/v3",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0010566","Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature.","Zhang Y","2025","Open medicine (Warsaw, Poland)","case_report","article","10.1515/med-2025-1184","40292250","PMC12032985",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010567","7529 A Silent Menace Of Mounjaro: Acute Renal Failure Associated With Tirzepatide",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454838",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0010568","Chemical chaperone-conjugated exendin-4 as a cytoprotective agent for pancreatic β-cells.","Son S","2018","The international journal of biochemistry & cell biology","preclinical","article","10.1016/j.biocel.2018.09.018","30273669",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010569","Novel glucose-lowering drugs for non-alcoholic fatty liver disease.","Fu ZD","2021","World journal of diabetes","randomized_trial","article","10.4239/wjd.v12.i1.84","33520110","PMC7807257",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010570","Microneedle-Assisted Delivery of Biologics: From Large Molecules to Cancer Vaccines.","Younas S","2026","AAPS PharmSciTech","narrative_review","article","10.1208/s12249-026-03387-6","41876813",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010571","Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.","Cahn A","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14179","32844557",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010572","SIRT1/HSF1/HSP pathway is essential for exenatide-alleviated, lipid-induced hepatic endoplasmic reticulum stress.","Zheng X","2017","Hepatology (Baltimore, Md.)","preclinical","article","10.1002/hep.29238","28439947",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010573","Brainstem GLP-1 neurons modulate physiological satiation and drive sustained weight loss in obese mice.","Jiang W","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2026.102347","41786245","PMC13015735",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010574","Glucagon-like peptide-1 receptor agonists and risk of breast cancer.","Bolen SD","2016","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.i5519","27797789",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0010575","Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?","Lafferty RA","2024","The Journal of endocrinology","preclinical","article","10.1530/joe-23-0339","38861364","PMC11301427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010576","Social Perceptions of Weight Loss With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Black and White Women With Obesity.","Post SM","2026","Stigma and health","randomized_trial","article","10.1037/sah0000689","42181798","PMC13196875",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010577","Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?","Goncalves E","2017","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.12897","28176440",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Letter; article"],["R0010578","Approach to the Patient With Nonalcoholic Fatty Liver Disease.","Belfort-DeAguiar R","2023","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgac624","36305273",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010579","Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.","Robinson S","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00839-5","32524494","PMC7324465",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; other; article"],["R0010580","Renoprotective effects of tubular glucagon receptor activation mediated by V-ATPase.","Qu H","2026","Science advances","preclinical","article","10.1126/sciadv.aeg2534","42555719","PMC13440415",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010582","Prevention of macrovascular complications in patients with type 2 diabetes mellitus: Review of cardiovascular safety and efficacy of newer diabetes medications.","Kant R","2019","World journal of diabetes","narrative_review","article","10.4239/wjd.v10.i6.324","31231455","PMC6571484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010583","Of Fasts and Feasts: Catholic Ethics and the Right Use of GLP-1 Agonists for Weight Loss.","Starr AYA","2026","The Linacre quarterly","other","article","10.1177/00243639261450700","42182885","PMC13190365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010584","Azoramide, a novel regulator, favors adipogenesis against osteogenesis through inhibiting the GLP-1 receptor-PKA-β-catenin pathway.","Yan Z","2025","Human cell","preclinical","article","10.1007/s13577-025-01192-0","40108027","PMC11923014",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010585","iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.","Guo X","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15074","36999231",null,"ClinicalTrials.gov:NCT03798054; ClinicalTrials.gov:NCT03798080","S000170; S002110","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010586","Oral Glucagon-Like Peptide 1 Analog as an Adjuvant Therapy in Generalized Lipodystrophy.","Lebenthal Y","2025","Diabetes care","commentary","article","10.2337/dc25-0272","40105772","PMC12034891",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0010587","Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system.","Baalmann A","2026","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2026.32.6.660","42166306","PMC13193313",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0010588","Bidirectional relationship between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus.","Mantovani A","2026","EXCLI journal","narrative_review","article","10.17179/excli2026-9462","42376436","PMC13312791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010589","Tirzepatide mitigates thoracic aortic aneurysm and dissection by alleviating the loss of the contractile phenotype in vascular smooth muscle cells and reducing vascular inflammation.","Tan L","2026","Vascular pharmacology","preclinical","article","10.1016/j.vph.2026.107581","41610999",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010590","Toxicity of Semaglutide upon sub chronic administration in Rabbits.","Vishwanath C","2026","Toxicological research","other","article","10.1007/s43188-025-00308-w","41503438","PMC12770063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010591","Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis.","Alshahawey M","2024","European review for medical and pharmacological sciences","other","article","10.26355/eurrev_202405_36181","38766793",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0010592","Readability and understandability of online patient education on semaglutide.","Wilson AQ","2026","Health informatics journal","other","article","10.1177/14604582261428308","41877445",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010593","Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).","Nomoto H","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","protocol","article","10.1007/s13300-020-00986-9","33491111","PMC7947125","jRCT:jRCT1011200008; UMIN:UMIN000042369",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0010594","Remission of type 2 diabetes: always more questions, but enough answers for action.","Rothberg A","2024","Diabetologia","narrative_review","article","10.1007/s00125-023-06069-1","38189935","PMC10904507",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010595","The \"Early Treatment\" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique.","Russo G","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-021-01045-7","33768493","PMC8099991",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010596","[Side effects and pharmacovigilance of GLP1 agonists].","Maria Tablado MA","2026","Atencion primaria","nonrandomized_study","article","10.1016/j.aprim.2025.103411","41456483","PMC12796857",null,null,"pubmed; europepmc","TRUE","open_europepmc","4",null,"Letter"],["R0010597","Semaglutide interferes with postnatal development of juvenile mice with compromised growth","Joly A","2024","bioRxiv","preclinical","preprint","10.1101/2024.05.06.592704",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010598","Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.","Gelhorn HL","2016","Patient preference and adherence","other","article","10.2147/ppa.s109289","27524889","PMC4966566",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010599","Sémaglutide et tirzépatide : nouvel espoir dans le traitement de l’insuffisance cardiaque ?","Hibbert D","2025","Revue medicale suisse","commentary","article",null,"41262025",null,null,null,"europepmc","FALSE",null,null,null,"News"],["R0010600","Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.","Yang S","2025","PloS one","systematic_review","article","10.1371/journal.pone.0314787","40014613","PMC11867386",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0010601","Trajectory of glycated haemoglobin over time, using real-world data, in type 2 diabetes patients with obesity on a U-100 basal-bolus insulin regimen.","Chen J","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15022","36799018",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010602","Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening.","Varughese GI","2024","The journal of the Royal College of Physicians of Edinburgh","narrative_review","article","10.1177/14782715241244843","38578067",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010603","Time-Related Biases in Observational Studies of GLP-1 Agonists and Cancer Risk.","Lu F","2026","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.70202","41796058","PMC12967869",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0010604","GLP-1 receptor agonists and diabetic retinopathy: Comment on a case report.","Wang JY","2026","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2025.102999","41308788",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010605","Intense Uptake of 68 Ga-exendin-4 in a Patient With WHO Grade 3 Insulinoma and Extensive Intrahepatic Metastases.","Zhang H","2025","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000005834","40065404",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0010606","Acute pancreatitis during GLP-1 receptor agonist treatment. A case report.","Chis BA","2018","Clujul medical (1957)","case_report","article","10.15386/cjmed-804","29440961","PMC5808258",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010607","Bioactive compounds in milk/dairy foods and their value to health at key life stages: Functionality beyond nutrient supply.","Givens DI","2025","The Proceedings of the Nutrition Society","narrative_review","article","10.1017/s0029665125102024","41277238",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010608","Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.","Evans M","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01408-2","37120480","PMC10203087",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010609","New-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I, DPP4I and GLP1a: A population-based cohort study","Chou OHI","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.11.25.23298886",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0010610","In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicidal Ideation and Substance Use Disorder.","Sharafshah A","2025","Current neuropharmacology","other","article","10.2174/011570159x349579241231080602","39865816","PMC12174944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010611","Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence.","Carls GS","2017","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.116","29071110","PMC5598021",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010612","Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice.","Hammoud R","2024","JCI insight","preclinical","article","10.1172/jci.insight.174825","39723966","PMC11948578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010613","Role of sodium-glucose cotransporter-2 inhibitors in risk of chronic kidney disease among patients with type 2 diabetes mellitus.","Chen TS","2023","Journal of nephrology","nonrandomized_study","article","10.1007/s40620-022-01522-7","36534314",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010614","Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.","Park J","2023","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgad471","37561012",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0010615","Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution.","Jalleh R","2020","Nutrients","randomized_trial","article","10.3390/nu12071962","32630191","PMC7400134",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0010616","Implications of GLP-1 RA Therapy on Skeletal Health and Orthopedics: A Commentary.","Gertzulin M","2026","HSS journal : the musculoskeletal journal of Hospital for Special Surgery","commentary","article","10.1177/15563316261450988","42170589","PMC13186914",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial"],["R0010617","Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes.","Rizzo M","2017","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.12883","28098425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0010618","Perioperative Glucagon-Like Peptide-1 Agonist Use and Rates of Pseudarthrosis After Single-Level Lumbar Fusion: A Large Retrospective Cohort Study.","Agrawal V","2024","Neurosurgery","nonrandomized_study","article","10.1227/neu.0000000000003291","39589142",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0010619","Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Wang W","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-017-0282-3","28616805","PMC5544618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0010620","No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.","Ishøy PL","2017","Acta psychiatrica Scandinavica","randomized_trial","article","10.1111/acps.12711","28260235",null,"ClinicalTrials.gov:NCT01794429","S002041","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0010621","Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023.","Mahapatro A","2024","Annals of medicine and surgery (2012)","narrative_review","article","10.1097/ms9.0000000000002592","39525800","PMC11543192",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010622","Real-world evaluation of care for type 2 diabetes in Malaysia: A cross-sectional analysis of the treatment adherence to guideline evaluation in type 2 diabetes (TARGET-T2D) study.","Lim LL","2024","PloS one","nonrandomized_study","article","10.1371/journal.pone.0296298","38166049","PMC10760741",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010623","Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.","Owens DR","2013","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2013.09.004","24156868",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010624","Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome.","Chatterjee S","2016","World journal of diabetes","narrative_review","article","10.4239/wjd.v7.i18.441","27795818","PMC5065664",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; review-article; article"],["R0010625","C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice.","Tang D","2018","Journal of pharmacological sciences","preclinical","article","10.1016/j.jphs.2018.08.009","30309736",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010626","Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.","GRADE Study Research Group","2022","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2200433","36129996","PMC9829320","ClinicalTrials.gov:NCT01794143","S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0010627","Reprogramming NAD+ homeostasis and FOXO3a-Nrf2 signaling mitigates bleomycin-driven pulmonary fibrosis.","Mo'men M","2026","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2026.118045","42763059",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010628","GLP-1 RAs could reduce risk of developing colorectal cancer.","Lawrence L","2026","Cancer","commentary","article","10.1002/cncr.70367","42083470",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0010629","[GLP1 receptor agonist drug treatments and adult obesity].","Carette C","2025","Soins; la revue de reference infirmiere","other","article","10.1016/j.soin.2025.05.020","40669985",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0010630","The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.","Pan X","2020","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2020.599355","33335511","PMC7736403",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010631","The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines.","Douros JD","2024","The Journal of endocrinology","systematic_review","article","10.1530/joe-23-0226","38451873",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010632","In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary.","O'Brien C","2024","Annals of internal medicine","commentary","article","10.7326/j24-0028","38710089",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0010633","Updates from the FDA on GLP-1 agonists.","Aschenbrenner DS","2026","The American journal of nursing","other","article","10.1097/ajn.0000000000000313","42162985",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010634","Effect of lixisenatide on liquid gastric emptying in type 2 diabetes - Implications for the use of GLP-1 receptor agonists before procedures.","Kovoor JG","2024","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2024.108793","38870730",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0010635","Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.","Mari A","2025","Diabetes care","other_trial","article","10.2337/dc25-0763","40694530","PMC12368374",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; other; article"],["R0010636","Effect of Oral Semaglutide on Volumetric BMD and Bone Microarchitecture in Overweight/Obese Individuals with Type 2 Diabetes.","Das L","2025","Calcified tissue international","nonrandomized_study","article","10.1007/s00223-025-01417-2","40782266",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010637","Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study.","Sbraccia P","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14945","36514273",null,null,"S000884","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010638","Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline.","Agarwal A","2025","BMJ (Clinical research ed.)","randomized_trial","article","10.1136/bmj-2024-082071","40813129","PMC12355350",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Practice Guideline; other; article"],["R0010639","Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use.","Kalra S","2015","Indian journal of endocrinology and metabolism","randomized_trial","article","10.4103/2230-8210.149313","25729679","PMC4319257",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; editorial; article"],["R0010640","The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.","Weng W","2019","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.76","31294089","PMC6613222",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010641","Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.","Gadde KM","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12908","28205322","PMC5485171","ClinicalTrials.gov:NCT01652729","S001157","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0010642","Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.","Carretero Gómez J","2019","Canadian journal of diabetes","nonrandomized_study","article","10.1016/j.jcjd.2018.09.001","30415909",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0010643","Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications.","Abu-Alfa AK","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-022-01340-x","36517708","PMC9880119",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0010644","Reply: Time-Related Biases in Observational Studies of GLP-1 Agonists and Cancer Risk.","Cheng Z","2026","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.70203","41796059","PMC12967868",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; letter"],["R0010645","Characterization and Role of Glucagon-Like Peptide 1 Receptor in the Lacrimal Gland: Novel Insights into Diabetic Dry Eye Pathogenesis.","Sun Y","2025","The American journal of pathology","preclinical","article","10.1016/j.ajpath.2024.12.003","39725294",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010646","Type IIB PKA serves as the primary effector of Gs-coupled receptor-potentiated insulin secretion in mice by orchestrating ion channels and granule phenotype.","Liu Y","2026","Diabetologia","preclinical","article","10.1007/s00125-026-06781-8","42337176","PMC13424381",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010647","Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity.","Ma W","2025","Journal of diabetes investigation","preclinical","article","10.1111/jdi.14372","39661011","PMC11871401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010648","Comment on \"Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients\".","Liu S","2026","Cardiovascular drugs and therapy","nonrandomized_study","article","10.1007/s10557-025-07812-z","41240220",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0010649","The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease.","Du H","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.1033479","36465634","PMC9714676",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0010650","Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients.","Hopkins ND","2013","Diabetes, obesity & metabolism","other","article","10.1111/dom.12089","23451821",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Multicenter Study; article"],["R0010651","BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.","Zimmermann T","2022","Molecular metabolism","preclinical","article","10.1016/j.molmet.2022.101633","36356832","PMC9679702",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010652","The GLP-1R Agonist Exenatide Improves Sheep Sperm Motility by Regulating Cellular Metabolic Levels","Wang Z","2024","Research Square","other","preprint","10.21203/rs.3.rs-4747909/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010653","Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.","Zhao M","2020","Clinical journal of the American Society of Nephrology : CJASN","systematic_review","article","10.2215/cjn.11220720","33376101","PMC7792639",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Systematic Review; Network Meta-Analysis; research-article; review"],["R0010654","Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.","Leiter LA","2017","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2017.05.010","28587789",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0010655","Response to \"GLP-1 receptor agonists and diabetic retinopathy: Comment on a case report\".","Ko J","2026","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2025.103000","41297883",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010656","Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.","Jastreboff AM","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2504214","40549887",null,"ClinicalTrials.gov:NCT05669599","S001779","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; article"],["R0010657","Loxenatide Alleviates High Glucose-Induced Pancreatic β-Cell Senescence via Regulating the PERK/eIF2α Pathway.","Yuan J","2024","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","other","article","10.1055/a-2407-9360","39333044",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010658","Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.","Shinde S","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.71322","42750540",null,"ClinicalTrials.gov:NCT05869903","S001722","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0010659","Effect of Weight-Neutral Treatment With Semaglutide or Tirzepatide on β-Cell Identity in db/db Mice.","Deng Z","2026","Acta physiologica (Oxford, England)","preclinical","article","10.1111/apha.70141","41354136",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010660","The Colonic Mucus Layer is Thinner and is Associated with Goblet Cell Hyperplasia in the  <i>db/db<\/i>  Mouse Model of Type 2 Diabetes","Rowe MC","2026","bioRxiv","preclinical","preprint","10.64898/2026.04.02.716104",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010661","Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.","Su Y","2022","European journal of pharmacology","other_trial","article","10.1016/j.ejphar.2022.175029","35584709",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0010662","Comment on \"Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain after Bariatric Surgery\".","Sarkar R","2026","Obesity surgery","commentary","article","10.1007/s11695-025-08470-8","41454116",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010663","Nanoassembly-Mediated Exendin-4 Derivatives to Decrease Renal Retention.","Zhou Z","2024","ACS omega","other","article","10.1021/acsomega.3c04644","38708210","PMC11064033",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010664","Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment.","Aroda VR","2022","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14830","35929480","PMC9804800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010665","Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity.","Son AJ","2026","JCI insight","preclinical","article","10.1172/jci.insight.205174","41915442","PMC13232713",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; letter; article"],["R0010666","Retatrutide Treatment in Streptozotocin-Induced Diabetic Rats: Renal Inflammatory Cytokines, HIF‑1α Signalling, and Histopathological Injury Profile","Keskin U","2026","Research Square","preclinical","preprint","10.21203/rs.3.rs-10191227/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010667","SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.","Gurgle HE","2016","Vascular health and risk management","nonrandomized_study","article","10.2147/vhrm.s83088","27350752","PMC4902150",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0010668","Glucagon-like Peptide-1 Receptor Agonists Cardio-protective Effects: An Umbrella Review.","Elnour AA","2020","Current diabetes reviews","systematic_review","article","10.2174/1573399816666200522214554","32442089",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0010669","Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases.","Yang F","2022","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2022.113236","35691154",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010670","GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review.","Abubakar M","2024","Current topics in medicinal chemistry","other_trial","article","10.2174/0115680266293416240515075450","38803170",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0010671","Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment.","Beck J","2025","European journal of preventive cardiology","randomized_trial","article","10.1093/eurjpc/zwaf055","40037282",null,"ClinicalTrials.gov:NCT03204396","S000115","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; article"],["R0010672","[Glucagon-like peptide 1 agonists : the fourth pillar of nephroprotection in type 2 diabetes].","Lamine F","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.920.47251","40443145",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0010673","Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.","Rosenstock J","2021","Diabetes care","randomized_trial","article","10.2337/dc21-0393","34183429","PMC8740944",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article; other"],["R0010674","Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.","Ross SA","2013","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2013.837817","23971789",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010675","What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline.","Johansson KS","2020","Expert opinion on drug discovery","other_trial","article","10.1080/17460441.2020.1791078","32646248",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0010676","Supaglutide alleviates hepatic steatosis in monkeys with spontaneous MASH.","Wang Q","2024","Diabetology & metabolic syndrome","preclinical","article","10.1186/s13098-024-01513-7","39695722","PMC11658388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010677","Glucagon-like peptide-1 receptor agonists inhibit hepatic stellate cell activation by blocking the p38 MAPK signaling pathway.","Wu LK","2015","Genetics and molecular research : GMR","other","article","10.4238/2015.december.29.17","26782560",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010678","Use of GLP-1 Analogues in Obesity and the Risk of Non-Arteritic Ischaemic Optic Neuropathy: Let's Clarify!","Muscogiuri G","2026","Clinical obesity","commentary","article","10.1111/cob.70078","42070904",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010679","Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.",null,"2026","JAMA","other","article","10.1001/jama.2026.8427","42251596",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010680","Pharmacogenomics of Anti-Obesity Drugs: A Bioinformatics Approach","Andrade LJdO","2025","Research Square","other","preprint","10.21203/rs.3.rs-6370544/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0010681","Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis.","Barkas F","2019","European journal of neurology","systematic_review","article","10.1111/ene.13905","30629331",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0010682","Semaglutide-Induced Hepatic Injury: A Rare Case of Drug Induced Liver Injury.","Kundu R","2025","Clinical case reports","other","article","10.1002/ccr3.70783","40771557","PMC12326266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; preprint; article"],["R0010683","How Should We Approach GLP-1 Receptor Agonist Users During Endoscopy?","Ito S","2026","Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society","other","article","10.1111/den.70083","41392939",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010684","Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome.","Takemoto M","2021","Geriatrics & gerontology international","other","article","10.1111/ggi.14083","33169495",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0010685","Tirzepatide-Induced Ketoacidosis in Non-Diabetic Patients.","Iqbal PMR","2024","European journal of case reports in internal medicine","other","article","10.12890/2024_004357","38584893","PMC10997393",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010686","GLP-1 receptor agonist therapy is associated with reduced atrial fibrillation recurrence after catheter ablation: a meta-analysis.","Kilic ME","2026","Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing","systematic_review","article","10.1007/s10840-025-02233-2","41493516",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; article"],["R0010687","Cardiovascular safety trials of incretin-based drugs: What do they mean?","Yabe D","2017","Journal of diabetes investigation","other_trial","article","10.1111/jdi.12576","27612317","PMC5415478",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; article-commentary; article"],["R0010688","Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review.","Hidalgo Ramos RA","2025","Cureus","systematic_review","article","10.7759/cureus.89656","40926946","PMC12415119",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0010689","EGLP-1 lowers body weight better than exendin-4 by reducing food intake and increasing basal energy expenditure in diet-induced obese mice.","Gao H","2021","Experimental cell research","preclinical","article","10.1016/j.yexcr.2020.112454","33359447",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010690","Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.","Pinelli NR","2011","The Annals of pharmacotherapy","systematic_review","article","10.1345/aph.1q024","21730278",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review"],["R0010691","Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data.","Dziewierz A","2026","Cardiovascular drugs and therapy","commentary","article","10.1007/s10557-025-07789-9","41075125",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0010692","Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.","Lamprea-Montealegre JA","2022","Diabetes care","nonrandomized_study","article","10.2337/dc22-0614","36156061","PMC9998844",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; other; article"],["R0010693","Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?","Schröder B","2021","Liver international : official journal of the International Association for the Study of the Liver","other","article","10.1111/liv.14846","34155798",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010694","Cardiovascular benefits of GLP-1 receptor agonists in nonobese patients with HFpEF.","Haider E","2025","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000004283","41377411","PMC12689119",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0010695","Role of insulin in female reproduction.","Tebeau KS","2026","Current opinion in obstetrics & gynecology","narrative_review","article","10.1097/gco.0000000000001121","42306903",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0010696","Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes.","Li Y","2023","International journal of environmental research and public health","nonrandomized_study","article","10.3390/ijerph20054036","36901047","PMC10001625",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0010697","Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.","Cummings JL","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)00459-9","41865758",null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0010698","Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.","Davis PN","2015","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.2146/ajhp140260","26092960",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010699","Impact of virtual patient engagement on glycemic control in type 2 diabetes: a retrospective observational study from GluCare hybrid care model.","Zakaria H","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1695381","41356012","PMC12675252",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0010700","The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes.","Evans M","2023","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14917","36342041",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0010701","Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.","Rhea EM","2024","Tissue barriers","preclinical","article","10.1080/21688370.2023.2292461","38095516","PMC11583597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0010702","Differential Cardiovascular and Renal Benefits of SGLT2 Inhibitors and GLP1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus","Kim CH","2021","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-734897/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0010703","Comparative Effectiveness and Safety of Oral Versus Subcutaneous Semaglutide in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Karedath J","2025","Cureus","systematic_review","article","10.7759/cureus.82497","40385819","PMC12085783",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0010704","Effect of bariatric surgery and pharmacological treatments on cardiovascular risk factors for adults with overweight and obesity: a systematic review and network meta-analysis.","Yang Y","2026","International journal of surgery (London, England)","systematic_review","article","10.1097/js9.0000000000004566","41738616","PMC13105548",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0010705","[A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists].","Scheen A","2024","Revue medicale de Liege","narrative_review","article",null,"39262368",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0010706","Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.","Sharma A","2020","Canadian journal of diabetes","narrative_review","article","10.1016/j.jcjd.2019.09.003","31882322",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010707","Impact of AIFA Note 100 on innovative antidiabetic prescribing eligibility in two Italian local health authorities: drug utilization and patient characteristics.","Bruno GM","2026","Global & regional health technology assessment","nonrandomized_study","article","10.33393/grhta.2026.3790","42368998","PMC13308343",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010708","Response to the letter to the editor regarding \"Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management\".","Amin AM","2026","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","commentary","article","10.1016/j.pan.2025.12.011","41469267",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0010709","Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.","Blood AJ","2024","Circulation","randomized_trial","article","10.1161/circulationaha.124.069494","38583146",null,"ClinicalTrials.gov:NCT06046560","S002701","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0010710","Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study.","Sugiyama S","2025","Cureus","nonrandomized_study","article","10.7759/cureus.99998","41583249","PMC12831498",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010711","Synthetic exendin-4 disrupts responding to reward predictive incentive cues in male rats.","Wakabayashi KT","2024","Frontiers in behavioral neuroscience","preclinical","article","10.3389/fnbeh.2024.1363497","38549620","PMC10976559",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010712","Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes.","Mirabelli M","2019","International journal of environmental research and public health","nonrandomized_study","article","10.3390/ijerph17010207","31892206","PMC6981922",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010713","Pharmacogenetics of novel glucose-lowering drugs.","Rathmann W","2021","Diabetologia","narrative_review","article","10.1007/s00125-021-05402-w","33594477","PMC8099830",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0010714","Exendin-4 increases the firing activity of hippocampal CA1 neurons through TRPC4/5 channels.","Sun HZ","2024","Neuroscience research","preclinical","article","10.1016/j.neures.2023.08.001","37595875",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010715","GLP-1 Receptor Agonists for Pharmacologically Induced Weight Gain.","Zierhut M","2025","JAMA psychiatry","other","article","10.1001/jamapsychiatry.2025.2536","40991279",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010716","Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics.","Touny AA","2022","Scandinavian journal of gastroenterology","other_trial","article","10.1080/00365521.2022.2041084","35234561",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; article"],["R0010717","Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion.","Saponaro C","2026","Diabetologia","preclinical","article","10.1007/s00125-026-06779-2","42350670",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010718","Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.","Kugathasan L","2026","Kidney international reports","nonrandomized_study","article","10.1016/j.ekir.2026.106547","42205183","PMC13206652",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0010719","Efficacy and Safety of Once-Weekly IcoSema in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2025","AACE endocrinology and diabetes","systematic_review","article","10.1016/j.aed.2025.07.012","41048697","PMC12495584",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0010720","Web Exclusive. Annals On Call - Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control Is Inadequate With Dulaglutide.","Centor RM","2025","Annals of internal medicine","other","article","10.7326/annals-25-03404-oc","40759012",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010721","Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.","Monfeuga T","2024","Molecular metabolism","preclinical","article","10.1016/j.molmet.2023.101850","38065435","PMC10772820",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010722","Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome.","Doycheva I","2022","Fertility and sterility","randomized_trial","article","10.1016/j.fertnstert.2022.03.020","35512974",null,null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural"],["R0010723","A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses.","Maloney A","2019","Clinical pharmacology and therapeutics","systematic_review","article","10.1002/cpt.1307","30457671",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0010724","A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.","Webb DR","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14023","32157772",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0010725","SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes.","Liakos A","2026","Current diabetes reports","nonrandomized_study","article","10.1007/s11892-025-01616-z","41528550","PMC12799618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0010726","Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review.","Livadas S","2022","World journal of diabetes","narrative_review","article","10.4239/wjd.v13.i1.5","35070056","PMC8771268",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010727","SAT-725 Impact of Ozempic (Semaglutide) on Reducing Total Knee Replacement Procedures in Patients with Osteoarthritis",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544451",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0010728","Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.","Zhang L","2019","Journal of Parkinson's disease","other_trial","article","10.3233/jpd-181503","30741689",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010729","Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin.","Melander SA","2023","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2022.175397","36414113",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010730","No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.","Bergmann NC","2020","Diabetes care","randomized_trial","article","10.2337/dc19-0578","31949084",null,"ClinicalTrials.gov:NCT03526289","S002395","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0010731","Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy.","Dejgaard TF","2017","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.12807","27735120",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Introductory Journal Article; article"],["R0010732","Novel Antidiabetic Medications in Polycystic Ovary Syndrome.","Somagutta MR","2022","Discoveries (Craiova, Romania)","narrative_review","article","10.15190/d.2022.4","36518222","PMC9745014",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010733","Elevation of ghrelin by B-adrenergic activation is independent of glucose variations and feeding regimen in the rat.","Alvarez-Crespo M","2025","Endocrine","preclinical","article","10.1007/s12020-024-04156-w","40169505","PMC12069131",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010734","Step-by-step: GLP-1 agonist use is associated with lower risk of knee replacement.","D'Souza RS","2026","Regional anesthesia and pain medicine","nonrandomized_study","article","10.1136/rapm-2026-108024","42336491",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010735","GLP-1 receptor agonists in Parkinson's disease: an updated comprehensive systematic review with meta-analysis.","Helal MM","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-01888-1","40849485","PMC12374370",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0010736","Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation.","Rroji M","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13030728","40149704","PMC11940462",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010737","Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes.","Scott LJ","2017","Drugs","other_trial","article","10.1007/s40265-017-0783-4","28667587",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; article"],["R0010738","Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study.","Terui S","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01147-2","34533697","PMC8519979",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010739","[The role of obesity and weight reduction in obstructive sleep apnea].","Horváth G","2026","Orvosi hetilap","randomized_trial","article","10.1556/650.2026.33589","42365594",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; English Abstract; article"],["R0010740","Steatotic liver disease and cardiovascular-kidney-metabolic syndrome: A case study.","Kolodziejczyk H","2026","Nursing","case_report","article","10.1097/nsg.0000000000000389","42144672",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; Review; article"],["R0010741","[The GLP-1 analogue battle: effects of semaglutide 0,5 mg/weekly versus liraglutide 3 mg/daily on anthropometric parameters after 3 months in a real world-scenario].","Pujol Calafat A","2024","Nutricion hospitalaria","nonrandomized_study","article","10.20960/nh.05244","39512012",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; English Abstract; article"],["R0010742","Elevated endogenous glucagon-like peptide-1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Aβ pathology.","Li J","2026","General psychiatry","other","article","10.1002/gps3.70052","42677190","PMC13528448",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010743","Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.","Urva S","2021","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-021-01012-2","33778934","PMC8332596","ClinicalTrials.gov:NCT03482024","S000127","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0010744","Emerging Mechanisms Underlying Dedifferentiation and Transdifferentiation in Pancreatic B Cell","Pal D","2026","Preprints.org","other","preprint","10.20944/preprints202609.0211.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010745","Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.","Lindamood CA","2015","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2015.01.003","25659912",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0010746","Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics.","Zhai J","2020","Drug delivery","preclinical","article","10.1080/10717544.2020.1850919","33241694","PMC7875555",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010747","Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study.","van Baar ACG","2021","Gastrointestinal endoscopy","randomized_trial","article","10.1016/j.gie.2020.12.021","33359437",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial; Journal Article; article"],["R0010748","Renal Evaluation and Protection.","Amir R","2020","Clinics in geriatric medicine","narrative_review","article","10.1016/j.cger.2020.04.004","32586473",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010749","Targeting UBE2B-mediated U2AF1 degradation to alleviate endothelial dysfunction in renal ischemia-reperfusion injury: therapeutic potential of semaglutide.","Wang Q","2025","Molecular biology reports","other","article","10.1007/s11033-025-11221-8","41186784",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010750","Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity","Welling M","2021","Journal of the Endocrine Society","other","article","10.1530/endoabs.73.aep280",null,"PMC8265706",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract; article"],["R0010751","Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.","Van J","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-021-01140-9","34514554","PMC8479017",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010752","Divergent acute versus prolonged pharmacological GLP-1R responses in adult β cell-specific β-arrestin 2 knockout mice.","Bitsi S","2023","Science advances","preclinical","article","10.1126/sciadv.adf7737","37134170","PMC10156113",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010753","The impact of approved anti-obesity medications on osteoarthritis.","Baser O","2024","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2024.2391524","39129529",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0010754","GLP-1R agonists protect against Alzheimer's disease by rewiring energy regulation.","Na D","2025","Nature aging","other","article","10.1038/s43587-025-00881-7","40394226",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010755","Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.","Rangaswami J","2020","Circulation","narrative_review","article","10.1161/cir.0000000000000920","32981345",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010756","Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.","Su B","2015","Endocrine","systematic_review","article","10.1007/s12020-014-0361-4","25074632",null,null,"S001459","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; review"],["R0010757","Risk of Postoperative Aspiration Pneumonia in Patients Undergoing ACDF With Preoperative Use of GLP-1 Receptor Agonists.","Chang Y","2026","Journal of neurosurgical anesthesiology","other","article","10.1097/ana.0000000000001078","41490219",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010758","Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Heart Failure Outcomes: A Scoping Review of Contemporary Randomized Controlled Trials.","Patel J","2026","Cureus","randomized_trial","article","10.7759/cureus.112239","42569733","PMC13450878",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0010759","Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.","Gohda T","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms232213749","36430228","PMC9696577",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010760","Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.","Gu W","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70181","41084959","PMC12673463",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Comparative Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0010761","Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece.","Papantoniou P","2025","Frontiers in public health","other_trial","article","10.3389/fpubh.2025.1690211","41229480","PMC12602536",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0010762","Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity.","Nguyen T","2023","American journal of therapeutics","other","article","10.1097/mjt.0000000000001643","37449929",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010763","Non-Insulin Antidiabetic Agents and Lung Cancer Risk in Drug-Naive Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study.","Tabernacki T","2024","Cancers","nonrandomized_study","article","10.3390/cancers16132377","39001440","PMC11240387",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0010764","Exclusion of Older Adults from Obesity Treatment Pivotal Trials of GLP-1RAs and GIP/GLP-1RAs.","Chen AS","2026","Journal of general internal medicine","commentary","article","10.1007/s11606-025-09769-z","40728804","PMC12894575",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; research-article; article"],["R0010765","Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.","Regatti PR","2026","Protein science : a publication of the Protein Society","other","article","10.1002/pro.70594","42124529","PMC13168870",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010766","Cardiovascular outcomes and safety of semaglutide in non-overweight populations with type 2 diabetes: a comparison with dipeptidyl peptidase 4 inhibitors.","Kishimori T","2025","European heart journal. Quality of care & clinical outcomes","nonrandomized_study","article","10.1093/ehjqcco/qcaf065","40676725",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; article"],["R0010767","Control of human pancreatic beta cell kinome by GLP-1R biased agonism","Xiao J","2023","bioRxiv","other","preprint","10.1101/2023.02.25.530040",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010768","Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management.","Richardson B","2022","Hepatology communications","narrative_review","article","10.1002/hep4.1876","34921530","PMC9134800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010769","The rise of \"Ozempic Face\": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists.","Mansour MR","2024","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","commentary","article","10.1016/j.bjps.2024.07.051","39098289",null,null,"S002478","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; article"],["R0010770","Comparative effects of incretin-based therapy on early-onset diabetic nephropathy in rats: Role of TNF-α, TGF-β and c-caspase-3.","Habib HA","2021","Life sciences","preclinical","article","10.1016/j.lfs.2021.119624","34004254",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0010771","Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report.","Eason K","2025","Obesity pillars","case_report","article","10.1016/j.obpill.2025.100219","41211573","PMC12593633",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010772","Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.","Varshney N","2021","Therapeutic advances in drug safety","nonrandomized_study","article","10.1177/2042098621997703","33854754","PMC8010840",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010773","A Research Update on Exendin-4 as a Novel Molecule Against Parkinson's Disease.","Singh NK","2023","Current molecular medicine","preclinical","article","10.2174/1566524023666230529093314","37254536",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0010774","iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.","Goldman J","2017","The Annals of pharmacotherapy","narrative_review","article","10.1177/1060028017717281","28645216",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0010775","Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis.","Golzarand M","2025","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-025-01807-4","40382437",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0010776","Principal components analysis on genes related to inflammasome complex and microglial activation in the hypothalamus of obese mice treated with semaglutide (GLP-1 analog).","Marinho TS","2025","Brain research","preclinical","article","10.1016/j.brainres.2024.149225","39243951",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010777","Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.","Green JB","2018","American heart journal","protocol","article","10.1016/j.ahj.2018.03.030","30015066",null,"ClinicalTrials.gov:NCT02465515","S001074","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; article"],["R0010778","Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.","Marques Vidas M","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13175166","39274378","PMC11396478",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010779","Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.","Gao H","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1562815","40556828","PMC12185272",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review-article; review"],["R0010780","Real-world effects of incretin-based Obesity medications on body composition.","Bhatti R","2025","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2025.100229","41322079","PMC12662107",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010781","GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity.","Kumar V","2025","Open biology","narrative_review","article","10.1098/rsob.240303","40592472","PMC12212992",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010782","\"And just like that, quiet\": a content analysis of TikTok videos on food noise.","Hayashi D","2026","Nutrition & diabetes","other","article","10.1038/s41387-026-00423-z","42049707","PMC13265739",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010783","From glucose lowering agents to disease/diabetes modifying drugs: a \"SIMPLE\" approach for the treatment of type 2 diabetes.","Mosenzon O","2021","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-021-01281-y","33910583","PMC8082901",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010784","Poster 6: GLP-1 Receptor Agonist Use Is Not Associated With an Increased Risk of Complications After Anatomic Total Shoulder Arthroplasty",null,"2025","Orthopaedic journal of sports medicine","other","article",null,null,"PMC12475759",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0010785","Cyclic Hydroxylamines for Native Residue-Forming Peptide Ligations: Synthesis of Ubiquitin and Tirzepatide.","Han J","2025","Journal of the American Chemical Society","other","article","10.1021/jacs.5c11881","40934092","PMC12464992",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010786","Comment on \"Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes\".","Bhise MR","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70294","41243568",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0010787","Impact of Nutrient-Stimulated Hormone (NUSH) Dynamics on Body Weight","Andrade LJdO","2024","Research Square","other","preprint","10.21203/rs.3.rs-4013174/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010788","HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.","Wysham CH","2018","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep-2017-0066","29547044",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0010789","Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Cardiovascular Disease: Implications of the LEADER Study.","Swislocki AL","2016","Metabolic syndrome and related disorders","commentary","article","10.1089/met.2016.29008.swi","27552667",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Comment; editorial"],["R0010790","Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine.","Zhang MX","2021","World journal of diabetes","randomized_trial","article","10.4239/wjd.v12.i8.1141","34512883","PMC8394225",null,null,"pubmed; europepmc","TRUE","open_europepmc","2",null,"Editorial"],["R0010791","Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.","Ji Q","2017","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2017.03.013","28526416",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0010792","Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews.","Armanious AJ","2026","Journal of medical Internet research","nonrandomized_study","article","10.2196/78391","41512288","PMC12904099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010793","Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents.","Edvardsson CE","2026","EBioMedicine","preclinical","article","10.1016/j.ebiom.2026.106219","41875498","PMC13049583",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010794","Real-World Off-Label Use of Semaglutide for Weight Reduction: User Behavior, Effectiveness, and Satisfaction.","Al-Qaaneh AM","2025","Patient preference and adherence","nonrandomized_study","article","10.2147/ppa.s549716","41199795","PMC12588353",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010795","Impact of Fasting on Physical Activity Motivation and Weight Reduction in Patients Administered Glucagon-Like Peptide-1 Agonists: A Qualitative Study.","Almaqhawi A","2025","Patient preference and adherence","other","article","10.2147/ppa.s496613","39764476","PMC11700478",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010796","Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus.","Gorgojo-Martínez JJ","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14030678","39941348","PMC11818433",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010797","Comparative Effects of Tirzepatide and Semaglutide on Asthma-Related Complications: A Target Trial Emulation Using the TriNetX Networks","Chen BS","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-7126343/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0010798","Radiosynthesis and preclinical evaluation of [11C]Methyl-V-0219, a small molecule glucagon-like peptide-1 allosteric modulator for PET brain imaging.","Lechi F","2026","EJNMMI radiopharmacy and chemistry","preclinical","article","10.1186/s41181-026-00486-4","42606761","PMC13481929",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010799","An Online Prescription for Hospitalisation: Euglycaemic Ketoacidosis Caused by an Online Tirzepatide Prescription.","Sathambihai T","2025","Cureus","case_report","article","10.7759/cureus.97410","41431533","PMC12718496",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010800","GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS.","Yang Z","2022","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2022.925377","36386208","PMC9640975",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010801","Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany.","Bongaerts B","2022","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","nonrandomized_study","article","10.1055/a-1702-5151","34942670",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010802","Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea.","Bajpai J","2025","World journal of experimental medicine","nonrandomized_study","article","10.5493/wjem.v15.i4.109762","41497691","PMC12767249",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0010803","A joint industry-sponsored data monitoring committee model for observational, retrospective drug safety studies in the real-world setting.","Major-Pedersen A","2021","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.5172","33179845","PMC8247341","ClinicalTrials.gov:NCT01511393","S001174","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0010804","Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics.","De Block C","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-024-01660-0","39531161","PMC11759727","ClinicalTrials.gov:NCT03954834; ClinicalTrials.gov:NCT03987919; ClinicalTrials.gov:NCT03882970; ClinicalTrials.gov:NCT03730662; ClinicalTrials.gov:NCT04039503","S000095; S000407; S001287; S001591; S001608","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0010805","Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults.","Wang T","2018","Diabetes care","nonrandomized_study","article","10.2337/dc17-2285","30012674","PMC6105327",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0010806","Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study.","Zerovnik S","2021","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2021-051549","34518273","PMC8438902",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0010807","Tirzepatide Outperforms Dulaglutide for Type 2 Diabetes Control.","Anderer S","2025","JAMA","other","article","10.1001/jama.2025.5645","40314963",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010808","The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.","Lin DS","2021","Diabetologia","systematic_review","article","10.1007/s00125-021-05529-w","34536085",null,"PROSPERO:CRD42020206600",null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Research Support, Non-U.S. Gov't; Review; Network Meta-Analysis"],["R0010809","Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss.","Wean J","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.102074","39612941","PMC11946504",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010810","Health care resource utilization and health care costs among digital weight-loss intervention participants and nonparticipants.","Tak C","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24337","40808402","PMC12381601",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010811","Dipeptidyl-Peptidase-4 and Glucagon-like-Peptide-1, a Link in the Connection between Periodontitis and Diabetes Mellitus-What Do We Know So Far?-A Scoping Review.","Gheonea TC","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13030903","38337597","PMC10856081",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; review-article; article"],["R0010812","Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.","Budd J","2020","Current diabetes reports","narrative_review","article","10.1007/s11892-020-01349-1","33015726",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010813","Adverse cardiovascular effects and potential molecular mechanisms of DEHP and its metabolites-A review.","Wen ZJ","2022","The Science of the total environment","narrative_review","article","10.1016/j.scitotenv.2022.157443","35868369",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010814","Malnutrition is Common in Patients Utilizing Glucagon-Like Peptide-1 Agonists Prior to Total Joint Arthroplasty.","Jodoin Z","2025","Arthroplasty today","nonrandomized_study","article","10.1016/j.artd.2025.101865","41079677","PMC12512160",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010815","Even with diet and exercise, Ozempic use reduces perceived effort and praiseworthiness of resulting weight loss.","Bachmakova M","2025","Social science & medicine (1982)","other","article","10.1016/j.socscimed.2025.118657","41092747",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint; article"],["R0010816","Use of incretin-based therapy in hospitalized patients with hyperglycemia.","Umpierrez GE","2014","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep13471.ra","25100362",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; book-chapter; article"],["R0010817","Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.","Wyckoff JA","2025","European journal of endocrinology","randomized_trial","article","10.1093/ejendo/lvaf116","40652450","PMC12342393",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; research-article; article"],["R0010818","Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis.","Song Z","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18091261","41011133","PMC12473131",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010819","GLP-1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy.","Lin T","2024","Clinical and experimental pharmacology & physiology","preclinical","article","10.1111/1440-1681.70003","39477212",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010820","Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.","Urva S","2022","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-022-01140-3","35674880","PMC9287213","ClinicalTrials.gov:NCT03940742","S000610","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010821","GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.","Brunton SA","2020","Postgraduate medicine","nonrandomized_study","article","10.1080/00325481.2020.1798099","32815454",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; Video-Audio Media; article"],["R0010822","Retraction Note: Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study.","Naude J","2026","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-025-02006-x","41420079",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","TRUE","Journal Article; Retraction Notice; retraction"],["R0010823","Multi-predictor pathogenicity filtering and membrane-specific stability analysis prioritize and characterize candidate destabilizing missense variants of the GIP receptor (GIPR)","Antor SA","2026","Research Square","other","preprint","10.21203/rs.3.rs-10159812/v2",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0010824","Hyperferritinemia: Pathophysiology, Etiologies, and Diagnostic Approach.","Kim Y","2026","European journal of haematology","narrative_review","article","10.1111/ejh.70285","42559859","PMC13619345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0010825","ALOX15 Aggravates Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice with Type 2 Diabetes via Activating the PPARγ/CD36 Axis.","Yan W","2025","Antioxidants & redox signaling","preclinical","article","10.1089/ars.2024.0670","39815992",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010826","Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data.","Kugler AJ","2018","Diabetes, metabolic syndrome and obesity : targets and therapy","other_trial","article","10.2147/dmso.s134960","29780260","PMC5951211",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0010827","Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.","Lin J","2017","ClinicoEconomics and outcomes research : CEOR","nonrandomized_study","article","10.2147/ceor.s117200","28053550","PMC5192057",null,"S002638","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010828","Engineering a high-throughput clone for industrial-scale production of long-acting GLP-1 analogue with retained bio-efficacy.","J PKR","2025","Biotechnology progress","other","article","10.1002/btpr.3529","39846515",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010829","Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.","Ericsson Å","2018","PloS one","nonrandomized_study","article","10.1371/journal.pone.0191953","29408938","PMC5800677",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010830","Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure.","Packer M","2018","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.13618","29532519",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010831","Polyagonists in Type 2 Diabetes Management.","Dissanayake HA","2024","Current diabetes reports","other_trial","article","10.1007/s11892-023-01530-2","38150106",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0010832","Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use.","Cesta CE","2025","JAMA","commentary","article","10.1001/jama.2025.19841","41284284",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0010833","No causal link between the supply of GLP-1 receptor agonists and antidepressants: Real-world evidence from the Australian Pharmaceutical Benefits Scheme.","Almeida OP","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70376","41369009",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0010834","Liver Disease: Nonalcoholic Fatty Liver Disease.","Cooper J","2021","FP essentials","other","article",null,"34855339",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010835","The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.","Seufert J","2014","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12251","24373150",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010836","The Impact of Liraglutide on Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","So JE","2025","Journal of gastroenterology and hepatology","nonrandomized_study","article","10.1111/jgh.70134","41194677",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010837","Association Between GLP-1 RAs and Idiopathic Intracranial Hypertension.","Manzano-Hernández L","2026","JAMA neurology","other","article","10.1001/jamaneurol.2026.0001","41697677",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010838","GLP-1 Receptor Agonists: A New Challenge in Parkinson’s Disease Treatment","Kalinderi K","2024","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202402.1245.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0010839","Treatment of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Evidence from Randomized Controlled Trials-A Short Review.","Kitsios K","2024","Metabolic syndrome and related disorders","randomized_trial","article","10.1089/met.2024.0059","39088384",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0010840","The Effectiveness of Tirzepatide on weight loss in patients with type 2 Diabetes Mellitus","Olalere M","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.09.19.25336122",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0010841","Stroke: Long-Term Poststroke Management.","Tai WA","2022","FP essentials","other","article",null,"35006663",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010842","New antihyperglycaemic agents and cardiovascular disease: let's be optimistic.","Pafili K","2018","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000000524","29702499",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010843","The Effect of Semaglutide on Gut Microbiota in Chinese Patients with Type 2 Diabetes Poorly Controlled by Metformin.","Chen Y","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s537001","41132642","PMC12542850",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010844","Correction: Are Glucagon-Like Peptide‑1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review.","West J","2025","Neurology and therapy","notice","article","10.1007/s40120-025-00758-2","40560293","PMC12255586",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0010845","Efficacy evaluation and mechanistic investigation of transcutaneous auricular vagus nerve stimulation in enhancing the therapeutic effects of semaglutide and reducing its gastrointestinal side effects: a randomized controlled trial protocol.","Tian X","2025","Frontiers in neurology","protocol","article","10.3389/fneur.2025.1653900","41426986","PMC12716152",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; methods-article; article"],["R0010846","Jordanian Population Knowledge, Attitude and Practices on the Uses of Antidiabetics for Weight Loss Purposes: A Cross Sectional Study","Abutaima R","2023","Research Square","other","preprint","10.21203/rs.3.rs-3325697/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; article; preprint"],["R0010847","Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control.","Stenlid R","2023","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2023.1293093","38027106","PMC10646558","ClinicalTrials.gov:NCT02794402","S001285; S002621","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010848","Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective.","Capehorn M","2025","Advances in therapy","other_trial","article","10.1007/s12325-025-03288-3","40788459","PMC12474619",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Comparative Study; research-article; article"],["R0010849","Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach.","Batiha GE","2023","Inflammopharmacology","narrative_review","article","10.1007/s10787-023-01239-4","37208555","PMC10198595",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010850","Improving sensitivity and drug tolerance of assays for neutralizing anti-drug antibodies to semaglutide and native GLP-1.","Videbæk N","2025","Bioanalysis","other","article","10.1080/17576180.2025.2596576","41334584","PMC12785235",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010851","Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen.","Lin YH","2022","European journal of medical research","other","article","10.1186/s40001-022-00892-9","36463197","PMC9719195",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010852","Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial.","Coelho C","2023","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-023-01368-4","37696925","PMC10599987","EudraCT:2015-005402-11",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010853","Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.","Newsome JS","2026","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","randomized_trial","article","10.1177/87551225261466571","42483637","PMC13385150",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; article"],["R0010854","Type 2 diabetes pharmacotherapy trends in high-risk subgroups.","Bae J","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14678","35243741","PMC9314938",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0010855","Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus.","Kurozumi A","2022","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2022.109836","35314256",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010856","Early economic modelling of a new pharmacotherapeutic treatment pathway for children with monogenic obesity","Dixon P","2026","medRxiv","other","preprint","10.64898/2026.05.13.26353098",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010857","Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan.","Su YC","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14445","34047442",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0010858","Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.","Helsted MM","2026","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(26)00075-6","42173109",null,"ClinicalTrials.gov:NCT05078255","S002118","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0010859","Does Mounjaro cause hair loss?","Lang K","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-100403","42526939",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010860","Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics.","Montero N","2022","Clinical kidney journal","other","article","10.1093/ckj/sfab131","35265335","PMC8901587",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010861","GLP-1 Receptor Agonists Help Legs.","Goldenberg RM","2025","Diabetes care","commentary","article","10.2337/dci25-0070","40971644",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0010862","Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?","Simpson R","2015","Expert review of clinical pharmacology","other","article","10.1586/17512433.2015.1017562","25697410",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010863","Exploring the nephroprotective effects of combined finerenone and exenatide therapy in diabetic nephropathy.","Kocak A","2025","International immunopharmacology","preclinical","article","10.1016/j.intimp.2025.115661","41101220",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010864","FATP2 at the crossroads of fatty acid transport, lipotoxicity, and complex disease.","Black PN","2025","The Journal of clinical investigation","preclinical","article","10.1172/jci199873","41321315","PMC12646644",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article-commentary; article"],["R0010865","An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.","Evans M","2018","Journal of medical economics","other_trial","article","10.1080/13696998.2017.1409228","29164973",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial, Phase III; Journal Article; article"],["R0010866","[Cardioprotective effects of glucagon-like peptide 1 receptor agonists].","Ametov AS","2014","Kardiologiia","randomized_trial","article","10.18565/cardio.2014.7.92-96","25177820",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","English Abstract; Journal Article; Review; article"],["R0010867","Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.","Thein D","2020","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-020-01078-5","32631337","PMC7339487",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; research-article; other; article"],["R0010868","Fast-tracked innovation: orforglipron approval under the FDA's National Priority Voucher program.","Sheikh M","2026","Annals of medicine and surgery (2012)","randomized_trial","article","10.1097/ms9.0000000000005213","42433749","PMC13354403",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0010869","New Therapeutic Strategies for Type 2 Diabetes CME.","Yehya A","2018","Methodist DeBakey cardiovascular journal","narrative_review","article","10.14797/mdcj-14-4-281","30788014","PMC6369623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010870","GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach.","Wang JY","2023","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2023.1085799","36843578","PMC9945324",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0010871","Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial.","Gad AI","2024","Diseases (Basel, Switzerland)","other_trial","article","10.3390/diseases12080186","39195185","PMC11354027",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0010872","The \"Weight\" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.","Deravi M","2024","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","other_trial","article","10.1177/87551225241285326","39507873","PMC11536522",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; article-commentary; article"],["R0010873","Normalization of glucose metabolism by Exendin-4 in the chronic phase after stroke promotes functional recovery in diabetes","Augestad I","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-210113/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010874","Semaglutide once-weekly: improved efficacy with a new safety warning.","Coon SA","2018","Expert review of clinical pharmacology","randomized_trial","article","10.1080/17512433.2018.1534201","30296182",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0010875","Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.","Gu Y","2023","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2023.1102792","36992825","PMC10040540",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0010876","Association Between GLP-1 RAs and Idiopathic Intracranial Hypertension-Reply.","Sioutas GS","2026","JAMA neurology","other","article","10.1001/jamaneurol.2026.0004","41697692",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010877","Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.","Nadeau DA","2013","Postgraduate medicine","narrative_review","article","10.3810/pgm.2013.05.2666","23748512",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010878","Brainstem GLP-1 neurons modulate physiological satiation and drive sustained weight loss in obese mice","Jiang W","2025","bioRxiv","preclinical","preprint","10.64898/2025.11.29.691273",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0010879","Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.","Aronne LJ","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2416394","40353578",null,"ClinicalTrials.gov:NCT05822830","S000093","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; article"],["R0010880","Impact of Glucagon-Like Peptide-1 Analogues in the Treatment of Obstructive Sleep Apnoea: A Pro/Con Debate.","Mediano O","2025","Archivos de bronconeumologia","commentary","article","10.1016/j.arbres.2025.03.009","40187925",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0010881","Prolonged signaling of backbone-modified glucagon-like peptide-1 analogues with diverse receptor trafficking.","Cary BP","2025","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.2407574122","40168114","PMC12002026",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010882","Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain.","Zhao L","2020","Nature communications","preclinical","article","10.1038/s41467-020-18249-3","32887883","PMC7474063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010883","Tinkering with weight loss medication in clinical encounters: An ethnographic study.","Jensen SD","2025","Social science & medicine (1982)","other","article","10.1016/j.socscimed.2025.118538","40957378",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010884","Is there an association between liraglutide use and female breast cancer in a real-world setting?","Funch D","2018","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s171503","30538516","PMC6254592",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010885","Advances in the management of diabetes: therapies for type 2 diabetes.","Tsoutsouki J","2020","Postgraduate medical journal","narrative_review","article","10.1136/postgradmedj-2019-137404","32467106",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010886","The Pleiotropic Therapeutic Perspectives of GLP-1 and GIP Receptor Agonists in Spinal Cord Injury: A Narrative Review.","Zhang S","2026","Molecular neurobiology","narrative_review","article","10.1007/s12035-026-06090-6","42538520",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010887","Update on cardiovascular risk in nonalcoholic fatty liver disease.","Johnston MP","2021","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000000861","34059612",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010888","Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.","Harrison SA","2025","Journal of hepatology","randomized_trial","article","10.1016/j.jhep.2024.07.006","39002641",null,"ClinicalTrials.gov:NCT05006885","S002346","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0010889","The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome.","Punapart M","2021","Genes","preclinical","article","10.3390/genes12111717","34828323","PMC8621801",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010890","Liraglutide promotes diabetic corneal epithelial and nerve regeneration by suppressing oxidative stress via the PI3K/AKT signalling pathway.","Han W","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.178264","41109401",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010891","Causes and consequences of discontinuation of GLP1RAs or tirzepatide.","Ceriello A","2026","Nature reviews. Endocrinology","nonrandomized_study","article","10.1038/s41574-026-01258-5","42168641",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; review"],["R0010892","Quality of Diabetes Care Among Older Adults in Germany-Results of the Study on Health of Older People 2022/2023 Compared With Previous National Health Surveys.","Du Y","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.71184","42581634","PMC13646352",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0010893","Comparative Effects of GLP-1 Agonists, Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Diabetes Mellitus Outcomes.","Essop T","2024","Current diabetes reports","randomized_trial","article","10.1007/s11892-024-01554-2","39325334",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; Comparative Study; article"],["R0010894","Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes.","Tan JWC","2021","European cardiology","narrative_review","article","10.15420/ecr.2020.52","33976709","PMC8086420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010895","Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.","D'Marco L","2021","TouchREVIEWS in endocrinology","narrative_review","article","10.17925/ee.2021.17.2.84","35118452","PMC8676102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010896","GLP-1 Receptor Agonists in Orthopaedic Surgery: Implications for Perioperative Care and Outcomes: An Orthopaedic Surgeon's Perspective.","Ramanathan R","2025","The Journal of bone and joint surgery. American volume","narrative_review","article","10.2106/jbjs.24.01287","40833394","PMC12356572",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010897","Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.","Aristizábal-Colorado D","2025","Frontiers in endocrinology","notice","article","10.3389/fendo.2025.1663787","40909226","PMC12406488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0010898","Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis.","Qiu M","2021","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2020.107803","33293207",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Comparative Study; Journal Article; Network Meta-Analysis"],["R0010899","GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression.","Qiu M","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-020-00912-z","32852698","PMC7509017",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; case-report; review"],["R0010900","Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway.","Wang ZJ","2023","Neuropharmacology","other_trial","article","10.1016/j.neuropharm.2023.109716","37730113",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010901","A roadmap to achieve pharmacological precision medicine in diabetes.","Florez JC","2022","Diabetologia","other_trial","article","10.1007/s00125-022-05732-3","35748917","PMC9522818",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0010902","Liraglutide-Driven Weight Loss Modulates Placental Remodeling in Obese Pregnancies in Mice.","Rodrigo N","2025","Cells","preclinical","article","10.3390/cells14242009","41440029","PMC12731410",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010903","SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review.","Janež A","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-021-01104-z","34244976","PMC8342745",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; review"],["R0010904","Pancreatic β-cell turnover in health and disease.","Alcibahy Y","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70191","41159407",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010905","Role of Cholesterol Metabolism in the Link Between Diabetes and Alzheimer's Disease.","Sharma P","2026","CNS & neurological disorders drug targets","other","article","10.2174/0118715273444881260119053309","42316561",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010906","The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery.","Timmermans M","2022","Minerva endocrinology","randomized_trial","article","10.23736/s2724-6507.21.03296-x","33759444",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Review; Journal Article; article"],["R0010907","GLP-1 receptor agonists: cardiovascular benefit beyond weight loss.","Garagoli F","2026","Medicina","commentary","article",null,"42330406",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comment; Journal Article; letter"],["R0010908","Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review.","Alsaqaaby MS","2024","The lancet. Diabetes & endocrinology","systematic_review","article","10.1016/s2213-8587(24)00098-6","38723646",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Systematic Review; Journal Article; Research Support, Non-U.S. Gov't"],["R0010909","Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.","Barrea L","2026","EXCLI journal","nonrandomized_study","article","10.17179/excli2025-9067","41768862","PMC12946444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010910","Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.","Fu EL","2022","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2022.01.042","35074492",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Comparative Study; Journal Article; article"],["R0010911","RF32 | PSUN59 Glucagon-Like Peptide-1 Analogues: A New Way to Quit Smoking? SKIP – a Randomised Controlled Study",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9625035",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0010912","Correspondence on: \"Breast implant explantation with mastopexy in patients using GLP-1 receptor agonists: A retrospective comparative analysis\".","Tomaselli F","2026","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","nonrandomized_study","article","10.1016/j.bjps.2025.11.014","41273948",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0010913","An indirect treatment comparison of tirzepatide 10 and 15 mg versus high-dose semaglutide 7.2 mg in people with obesity and type 2 diabetes.","Goldenberg RM","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70253","41159434",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010914","SUN-694 Case Study of Nonalcoholic Steatohepatitis Reversibility in Type Two Diabetic Patient with Weight Loss Using Liraglutide","Shaghouli A","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.1801",null,"PMC7207809",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0010915","Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.","Billings LK","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00052-x","40482670",null,"ClinicalTrials.gov:NCT05013229","S001633","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Equivalence Trial; article"],["R0010916","Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm.","Miyagi M","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0486-1","30121725","PMC6167274","UMIN:UMIN000012224",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010917","Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms.","Koshibu M","2019","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00511.2018","30860874",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010918","Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.","Ambika Gopalakrishnan U","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70891","42219226","PMC13341390","CTRI:CTRI/2025/02/080592",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Equivalence Trial; research-article; article"],["R0010919","Demystifying Nutritional Consequences of Pharmacological Weight Loss and Performance Enhancement-A Critical Narrative Review.","Soni R","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00729-0","42277394",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010920","Efficacy and safety of different doses of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","Zhu J","2024","Research Square","systematic_review","preprint","10.21203/rs.3.rs-3894429/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0010921","Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.","Aroda VR","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)00802-0","42259343",null,"ClinicalTrials.gov:NCT06579105; CTIS:2024-512562-34-00","S002189","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; article"],["R0010922","Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.","Butt MI","2024","Annals of Saudi medicine","nonrandomized_study","article","10.5144/0256-4947.2024.361","39651921","PMC11627033",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0010923","Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data.","Raccah D","2013","Expert review of endocrinology & metabolism","other_trial","article","10.1586/eem.12.82","30736171",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0010924","The Evolution of Medications for Obesity Management.","Gill J","2026","JGH open : an open access journal of gastroenterology and hepatology","narrative_review","article","10.1002/jgh3.70466","42701351","PMC13545273",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010925","Pharmacological Privilege: How Glucagon-Like Peptide-1 (GLP-1) Medications are Widening Health Inequalities.","Brennan-Davies AH","2025","Cureus","commentary","article","10.7759/cureus.97124","41426804","PMC12712549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0010926","European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.","Seferović PM","2020","European journal of heart failure","other_trial","article","10.1002/ejhf.1673","31816162",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Consensus Statement; article"],["R0010927","Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.","Camilleri M","2024","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.23941","37927173","PMC10841973",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; Comment; research-article; article"],["R0010928","GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.","Xu Y","2022","Kidney international","nonrandomized_study","article","10.1016/j.kint.2021.10.033","34826514",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010929","[GLP-1 receptor agonists: it is time to assess major adverse limb events in clinical trials].","Garagoli F","2025","Archivos de cardiologia de Mexico","commentary","article","10.24875/acm.25000107","41027558","PMC13375609",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; editorial"],["R0010930","Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).","Ji L","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-026-01908-x","42599381","PMC13620080","ClinicalTrials.gov:NCT06214741","S001893","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0010931","Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice.","McMorrow HE","2025","The Journal of clinical investigation","preclinical","article","10.1172/jci186652","40857106","PMC12578400",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0010932","Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.","Miras AD","2026","Obesity science & practice","narrative_review","article","10.1002/osp4.70141","41947825","PMC13052175",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010933","LIRAGLUTIDE ALLEVIATES ACUTE LUNG INJURY AND MORTALITY IN PNEUMONIA-INDUCED SEPSIS THROUGH REGULATING SURFACTANT PROTEIN EXPRESSION AND SECRETION.","Guo J","2024","Shock (Augusta, Ga.)","preclinical","article","10.1097/shk.0000000000002285","38150354","PMC11009087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0010934","Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: A network meta-analysis.","Shi W","2021","Heart rhythm","systematic_review","article","10.1016/j.hrthm.2021.03.007","33684547",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Review; Network Meta-Analysis"],["R0010935","Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities.","Shao S","2022","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2022.108270","36002078",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0010936","Safety and tolerability of orforglipron in Japanese people with type 2 diabetes.","Nauck MA","2026","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(26)00182-8","42607699",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010937","New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease.","Diaz LA","2025","Hepatology (Baltimore, Md.)","narrative_review","article","10.1097/hep.0000000000000645","37862466",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0010938","Medicaid Expansion and Utilization of Antihyperglycemic Therapies.","Sumarsono A","2020","Diabetes care","other","article","10.2337/dc20-0735","32887711","PMC8051258",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article; other"],["R0010939","The future of new drugs for diabetes management.","Bailey CJ","2019","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2019.107785","31326453",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010940","Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study.","Kır Y","2026","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-026-03024-w","42611111",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010941","Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes.","Rocha GR","2025","World journal of diabetes","commentary","article","10.4239/wjd.v16.i2.99928","39959274","PMC11718485",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0010942","Blocking C3d+/GFAP+ A1 Astrocyte Conversion with Semaglutide Attenuates Blood-Brain Barrier Disruption in Mice after Ischemic Stroke.","Zhang Q","2022","Aging and disease","preclinical","article","10.14336/ad.2021.1029","35656116","PMC9116904",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010943","Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.","Forst T","2016","Expert opinion on pharmacotherapy","other","article","10.1080/14656566.2016.1206079","27341040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010944","Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands.","Hunt B","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-017-0266-3","28523483","PMC5544604",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010945","Impact of automatic e-consults on use of SGLT2i and GLP-1 RA in rural veterans with type 2 diabetes and chronic kidney disease.","Sarwal A","2026","Primary care diabetes","other","article","10.1016/j.pcd.2026.04.004","41963153",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010946","Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.","Jenniskens K","2026","Annals of internal medicine","systematic_review","article","10.7326/annals-24-03766","42296505",null,"PROSPERO:CRD42023491646",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Review; review"],["R0010947","Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.","Bolli GB","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12253","24373190",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010948","Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats.","Sun HX","2015","Journal of diabetes","preclinical","article","10.1111/1753-0407.12282","25753217",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0010949","SAT-626 Use of GLP-1R Agonists in Pediatric Patients with Type 1 Diabetes and Obesity: A Case Series",null,"2025","Journal of the Endocrine Society","case_report","article",null,null,"PMC12544630",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0010950","[Management of patients with type 2 diabetes at cardiovascular and renal risk : ESC versus ADA-EASD].","Scheen AJ","2020","Revue medicale suisse","other","article",null,"32852167",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010951","A renal indication for semaglutide (Ozempic).",null,"2025","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2025.1723d","40009989",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010952","Insulinoma With Ambiguous Biochemistry, Positive 68Ga-DOTA-Exendin-4 PET-CT, and Effective Endoscopic Ablation.","Loo FJJ","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luae232","39790938","PMC11711475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0010953","Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.","Sardu C","2018","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-018-0778-9","30348145","PMC6196445","ClinicalTrials.gov:NCT03282136",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0010954","Exendin-4 alleviates myocardial ischemia reperfusion injury by enhancing autophagy through promoting nuclear translocation of TFEB.","He W","2023","Experimental cell research","preclinical","article","10.1016/j.yexcr.2023.113469","36627100",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0010955","Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.","Tye SC","2022","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2022.786767","35496307","PMC9044907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0010956","Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions.","von Haehling S","2025","Journal of cachexia, sarcopenia and muscle","other_trial","article","10.1002/jcsm.70147","41362110","PMC12686571",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; meeting-report; article"],["R0010957","The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight.","Hinrichs GR","2024","American journal of physiology. Cell physiology","randomized_trial","article","10.1152/ajpcell.00476.2023","38105752","PMC11193450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0010958","Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.","Nguyen NN","2022","Metabolism: clinical and experimental","systematic_review","article","10.1016/j.metabol.2022.155196","35367460","PMC8970613",null,null,"pubmed; europepmc","TRUE","open_europepmc","3",null,"Journal Article; Meta-Analysis; Systematic Review; research-article"],["R0010959","Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.","Emanuel EJ","2024","The New England journal of medicine","other","article","10.1056/nejmp2400978","38630999",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010960","Gut Microbiota-Bile Acid Axis in Type 2 Diabetes-Associated Gallbladder Diseases: Mechanisms and Therapeutic Potential.","Zhang Q","2026","Metabolites","narrative_review","article","10.3390/metabo16030212","41893361","PMC13028018",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010961","Erratum to: Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.","Dicembrini I","2017","Acta diabetologica","notice","article","10.1007/s00592-017-1049-z","28924916",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0010962","Beyond weight loss: Disentangling the direct effects of semaglutide vs equivalent calorie restriction on reproductive systems of male and female rats.","Sotzen MR","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2026.102436","42692145","PMC13601064",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010963","Future GLP-1 receptor co-agonists and their cardiac effects.","Neumann J","2026","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-026-05908-3","42768195",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0010964","Case Report: Small Bowel Obstruction After Starting Tirzepatide (Mounjaro).","Morgenthaler L","2024","American family physician","case_report","article",null,"39700350",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010965","The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.","Chuong V","2023","JCI insight","preclinical","article","10.1172/jci.insight.170671","37192005","PMC10371247",null,"S000504","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; research-article; article"],["R0010966","Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.","Schiavon M","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14394","33822469","PMC8359969","ClinicalTrials.gov:NCT02973321","S000763","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0010967","Albiglutide: first global approval.","Poole RM","2014","Drugs","other","article","10.1007/s40265-014-0228-2","24861909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010968","From measured BMI to documented obesity in hospitalized adults: a decade-long analysis and implications for cardiometabolic care.","Avivi I","2026","International journal of obesity (2005)","other","article","10.1038/s41366-026-02201-4","42687002",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0010970","Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.","Yang Y","2026","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2026.1849647","42389271","PMC13318716",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0010971","What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes.","Ferraro RA","2019","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2019.02.050","30904510",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010972","The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells","Holmes S","2018","Lancaster University","other","article","10.17635/lancaster/thesis/478",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0010973","Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013-2019.","Wang E","2025","Diabetologia","nonrandomized_study","article","10.1007/s00125-024-06321-2","39514094","PMC11663158",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0010974","Long-acting PYY3 -36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies.","Wulff BS","2025","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.24329","40629530","PMC12304869",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0010975","Exposure-response modeling for nausea incidence for cotadutide using a Markov modeling approach.","Yu H","2024","CPT: pharmacometrics & systems pharmacology","other","article","10.1002/psp4.13194","39044369","PMC11533102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010976","The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes.","Gelhorn HL","2023","Patient preference and adherence","other_trial","article","10.2147/ppa.s401465","36987498","PMC10040168",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0010977","GLP-1 Agonists for Weight Loss: Do They Increase Complications in Non-diabetic Patients Undergoing Primary Total Hip Arthroplasty?","Verhey JT","2025","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2025.03.012","40081604",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0010978","Development and implementation of a diagnostic and therapeutic care pathway for type 2 diabetes management in the hospital setting: preliminary findings from an Italian retrospective observational study.","Conti M","2025","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-025-01745-y","41098473","PMC12518725",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0010979","GLP-1 Receptor Agonists in Patients With Diabetes and Peripheral Artery Disease: In Pursuit of Excellence.","Henkin S","2026","The American journal of cardiology","other","article","10.1016/j.amjcard.2025.10.008","41106652",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0010980","Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis.","Li X","2021","Journal of clinical medicine","narrative_review","article","10.3390/jcm10112419","34072487","PMC8199251",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0010981","Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus.","Patoulias D","2022","Endocrinology and metabolism (Seoul, Korea)","randomized_trial","article","10.3803/enm.2021.1296","35144333","PMC8901958",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0010982","Residual Gastric Content in Hospitalised GLP-1RA Users: Considerations for Interpretation.","Xia J","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70614","41733081",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0010983","Metabolic dysfunction-associated steatotic liver disease: Integrating metabolic and hepatic management into pharmacy practice.","Knorr JP","2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.1093/ajhp/zxag095","41885169",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0010984","Recent updates on GLP-1 agonists: Current advancements & challenges.","Sharma D","2018","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2018.08.088","30372907",null,null,"S002311","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0010985","Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).","Klausen MK","2025","BMJ open","protocol","article","10.1136/bmjopen-2024-086454","39779270","PMC11749217","ClinicalTrials.gov:NCT05895643","S002359","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0010986","GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia.","Masulli M","2025","Internal and emergency medicine","narrative_review","article","10.1007/s11739-025-04117-9","40975854",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0010987","Tirzepatide Once Weekly for the Treatment of Obesity.","Jastreboff AM","2022","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2206038","35658024",null,"ClinicalTrials.gov:NCT04184622","S000741; S000760; S001026; S001029; S001077; S001709; S001978; S002042; S002373; S002674","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0010988","GLP-1 receptor agonists: effects on cardiovascular risk reduction.","Lorber D","2013","Cardiovascular therapeutics","preclinical","article","10.1111/1755-5922.12000","23865382",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0010989","The neuroprotective properties of GLP‐1R agonists correlate with their ability to cross the blood‐brain barrier","Holscher C","2024","Alzheimer's & dementia : the journal of the Alzheimer's Association","other_trial","article","10.1002/alz.088069",null,"PMC11713650",null,null,"europepmc; openalex","TRUE","open_europepmc","5","FALSE","Abstract; article"],["R0010990","Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy.","Khalifa O","2022","Biomedicines","other","article","10.3390/biomedicines10102652","36289914","PMC9599706",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0010991","Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?","Rubin R","2024","JAMA","commentary","article","10.1001/jama.2024.1017","38639975",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0010992","Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.","Neff GW","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70148","41025406",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0010993","Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic review.","Bhandari P","2026","Metabolism open","systematic_review","article","10.1016/j.metop.2026.100495","42750798","PMC13578459",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0010994","SAT-662 Effects of SGLT Inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis","Lim S","2020","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC7207432",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0010995","Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.","Li C","2026","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.70054","41189318","PMC13535721",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; article"],["R0010996","Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.","Ishøy PL","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12795","27717222","PMC5299524","ClinicalTrials.gov:NCT01794429","S002041","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0010997","Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study.","Nino A","2017","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12749","28921915","PMC5934244",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0010998","Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.","Driessen JH","2015","Calcified tissue international","nonrandomized_study","article","10.1007/s00223-015-0037-y","26184119","PMC4598352",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0010999","Liraglutide induces enhanced suppression of food intake in mice lacking the growth hormone secretagogue receptor.","Cassano DA","2025","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2025.112627","40738311",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011000","Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control: Role of Proximal Tubule Na+/H+ Exchanger Isoform 3, Renal Angiotensin II, and Insulin Sensitivity.","Martins FL","2020","Hypertension (Dallas, Tex. : 1979)","preclinical","article","10.1161/hypertensionaha.120.14868","32755467",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011001","MON-591 Effect of Liraglutide Treatment on Proglucagon-Derived Peptides","Kim S","2020","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC7208465",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0011002","Turning back time: a comprehensive list of interventions that decrease next-generation epigenetic aging clocks in humans.","Johnson AA","2026","Frontiers in genetics","narrative_review","article","10.3389/fgene.2026.1836446","42294499","PMC13258529",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011003","Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.","Forbes AK","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15111","37202870",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0011004","An Integrated Interprofessional Continuing Medical Education and Quality Improvement Initiative to Address Cardiovascular and Renal Risk in Patients with Type 2 Diabetes in Community-Based Primary Care Practices.","Lazure P","2025","Journal of CME","other","article","10.1080/28338073.2025.2571295","41103746","PMC12523461",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011005","Engineered microenvironments and pancreatic islet-on-chips for screening sugar substitute and antidiabetic compounds.","Shi J","2024","Food research international (Ottawa, Ont.)","other","article","10.1016/j.foodres.2024.115084","39614569",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0011006","Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS.","Sauter M","2020","Journal of pharmaceutical analysis","other","article","10.1016/j.jpha.2020.02.008","32612869","PMC7322758",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011007","Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process.","Shaifutdinov RR","2025","Pharmaceuticals (Basel, Switzerland)","other","article","10.3390/ph18121896","41471386","PMC12736101",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011008","Real-World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study.","Arteaga-Diaz JM","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71018","42331628","PMC13449073",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0011009","Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4.","Tweedie D","2016","Alzheimer's & dementia : the journal of the Alzheimer's Association","preclinical","article","10.1016/j.jalz.2015.07.489","26327236","PMC4715981",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0011010","Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.","Page LC","2020","Current obesity reports","randomized_trial","article","10.1007/s13679-020-00409-7","33085056",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0011011","Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.","Malhotra A","2025","Sleep medicine","randomized_trial","article","10.1016/j.sleep.2025.106853","41135142","PMC12723708","ClinicalTrials.gov:NCT05412004","S000156","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0011012","Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.","Wise J","2026","BMJ (Clinical research ed.)","other_trial","article","10.1136/bmj-2026-101016","42823062",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0011013","Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial.","Nielsen CK","2026","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2026.103801","41768273","PMC12945526","ClinicalTrials.gov:NCT05788601; CTIS:2022-501649-54-00","S002006","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0011014","Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study.",null,"2025","Gastroenterology & hepatology","nonrandomized_study","article",null,"41658350","PMC12879064",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; other; article"],["R0011015","Cost-effectiveness analysis of once-daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model.","Shao H","2023","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/dme.15112","37035994",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; Equivalence Trial; article"],["R0011016","The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke.","Shan Y","2019","Journal of neuroinflammation","preclinical","article","10.1186/s12974-019-1638-6","31779652","PMC6883580",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0011017","Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?","de Heer J","2014","Expert opinion on drug safety","randomized_trial","article","10.1517/14740338.2014.955013","25270593",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0011018","The GLP-1 Receptor Agonist Revolution: Is it Time for Everyone to Get Onboard the Incretin Train?","Nicholls SJ","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2025.08.083","41224402",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0011019","The effects of glucagon-like peptide 1 receptor agonist (exenatide) on memory impairment, and anxiety- and depression-like behavior induced by REM sleep deprivation.","Turan I","2021","Brain research bulletin","preclinical","article","10.1016/j.brainresbull.2021.06.011","34146656",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011020","Drug-drug interactions with glucagon-like peptide-1 receptor agonists.","Hurren KM","2012","The Annals of pharmacotherapy","narrative_review","article","10.1345/aph.1q583","22510669",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011021","Supporting Weight Management for Kidney Transplant Candidates in People With Obesity on Haemodialysis: The First National Survey of UK Kidney Healthcare Providers.","Brown A","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70900","42219274","PMC13341359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011022","Preventive Effects of Dulaglutide on Disuse Muscle Atrophy Through Inhibition of Inflammation and Apoptosis by Induction of Hsp72 Expression.","Nguyen TTN","2020","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2020.00090","32153405","PMC7046759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011023","Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo.","Xia J","2023","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2023.106422","36906110",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011024","GLP-1 receptor agonists: an emerging tool for obesity-related cancer prevention?","Yarmolinsky J","2025","Journal of the National Cancer Institute","randomized_trial","article","10.1093/jnci/djaf212","40901707",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Comment; editorial"],["R0011025","Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.","Zheng Z","2024","Signal transduction and targeted therapy","other_trial","article","10.1038/s41392-024-01931-z","39289339","PMC11408715",null,"S002468; S002726","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0011026","Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia.","Piatkowski T","2026","Drug and alcohol review","commentary","article","10.1111/dar.70231","42559975","PMC13445994",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0011027","Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice.","Zhang Y","2016","Oncology reports","preclinical","article","10.3892/or.2015.4476","26648451",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011028","SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.","Escobar C","2021","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.14502","33368612",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0011029","GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.","Jespersen MJ","2013","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1517/17425255.2013.731394","23094590",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011030","Considering the protective effect of exendin-4 against oxidative stress in spiral ganglion neurons.","Wu H","2023","Iranian journal of basic medical sciences","preclinical","article","10.22038/ijbms.2023.69190.15076","37970444","PMC10634057",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011031","Comparative Outcomes of Tirzepatide and Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes.","Kishimori T","2026","Journal of cardiac failure","other","article","10.1016/j.cardfail.2025.07.026","40945773",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011032","Correction to: The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.","Aranishi T","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-025-01697-9","39918684","PMC11867985",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0011033","Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.","Edison P","2026","Nature medicine","randomized_trial","article","10.1038/s41591-025-04106-7","41326666","PMC12823385","ClinicalTrials.gov:NCT01843075","S000689","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; research-article; article"],["R0011034","Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.","Sun F","2015","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2014.11.008","25554560",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0011035","Induction of Caveolin-3/RyR2 By Liraglutide Ameliorates Diabetic Cardiomyopathy","Li X","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-1052211/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011036","Effect of combined GLP-1 analogue and bupropion/naltrexone on weight loss: a retrospective cohort study.","Naude J","2024","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-024-01526-2","38724682",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","TRUE","Journal Article; Retracted Publication; article"],["R0011037","Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study.","Sørum ME","2024","BMJ open","protocol","article","10.1136/bmjopen-2024-089862","39384243","PMC11474865","ClinicalTrials.gov:NCT06449625; CTIS:2022-502139-20-00","S001227","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0011038","Glucagon-like peptide-1 agonists' effects on glycemic control, weight loss, and beta cells function in type 1 diabetes.","Mirghani HO","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1758755","41890182","PMC13013066",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; systematic-review; article"],["R0011039","Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis.","de Paiva IHR","2024","Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","preclinical","article","10.1007/s11481-024-10142-w","39042202",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011040","National Institute on Drug Abuse (NIDA) clinical trials network (CTN) stimulant use disorder (StUD) task force results: 2024 update.","Kittirattanapaiboon C","2026","Journal of substance use and addiction treatment","other","article","10.1016/j.josat.2026.209994","42035883",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011041","Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence.","Arif A","2025","Cureus","systematic_review","article","10.7759/cureus.92976","41141089","PMC12547187",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0011042","A system approach to improving guideline-directed therapy for cardio-renal-metabolic conditions: The \"beyond diabetes\" initiative.","Hirsh BJ","2023","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2023.100608","37822579","PMC10562667",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011043","Non-insulin diabetes medicines: a narrative review for anaesthetists and intensivists.","Tinsley S","2025","British journal of anaesthesia","narrative_review","article","10.1016/j.bja.2025.05.050","40651878","PMC12674081",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0011044","Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.","Tack CJ","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13826","31282028","PMC6852575","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011045","Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice.","Sugawara T","2025","Scientific reports","preclinical","article","10.1038/s41598-025-24927-3","41266634","PMC12635150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0011046","Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice.","Tan AJ","2026","Journal of diabetes investigation","preclinical","article","10.1111/jdi.70363","42394413","PMC13398539",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011047","Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy.","Ninčević V","2022","Current issues in molecular biology","preclinical","article","10.3390/cimb44030072","35723295","PMC8947663",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011048","Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program.","Kim DD","2024","Health affairs scholar","other","article","10.1093/haschl/qxae055","38828004","PMC11138958",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011049","[Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)].","Scheen AJ","2018","Revue medicale de Liege","other","article",null,"30335259",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011050","Long-term functional alterations following prenatal GLP-1R activation.","Graham DL","2021","Neurotoxicology and teratology","preclinical","article","10.1016/j.ntt.2021.106984","33864929","PMC8555578",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0011051","Response to Cromer and Alkabbani regarding: \"GLP-1 agonist use increases the incidence of adhesive capsulitis and odds of requiring operative management in type 2 diabetes patients: a matched propensity score analysis\".","Bergstein VE","2026","Journal of shoulder and elbow surgery","nonrandomized_study","article","10.1016/j.jse.2026.07.003","42468772",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0011052","Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD.","Araújo de Lucena L","2026","Current diabetes reports","systematic_review","article","10.1007/s11892-026-01619-4","41806022",null,"PROSPERO:CRD420251083622",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0011053","Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction-A Specific HFpEF Phenotype.","Elsanhoury A","2021","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2021.720690","34604353","PMC8484763",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011054","A Brief Review of Incretin Mimetics Intended for the Management of Diabetes and Associated Comorbidities","Haider F","2024","Preprints.org","narrative_review","preprint","10.20944/preprints202405.1369.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011055","The impact of GLP-1 receptor agonists on clinical outcomes and healthcare utilization in hidradenitis suppurativa patients: A retrospective cohort study using TriNetX.","Fite J","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.11.017","41223997",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011056","Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.","Jensen SBK","2019","BMJ open","protocol","article","10.1136/bmjopen-2019-031431","31678947","PMC6830609","EudraCT:2015-005585-32","S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; protocol; article"],["R0011057","Trends in Pharmacological Treatment of Patients With New Onset Type 2 Diabetes: Usage Patterns in an Evolving Guideline Landscape.","Hou W","2025","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.70108","40464139","PMC12134773",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011058","Repurposing liraglutide to the management of DSS-induced colitis: a potential for promoting autophagy.","Saadoun AA","2025","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-025-04339-w","40471244","PMC12678552",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011059","Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.","Singh AK","2020","Expert review of clinical pharmacology","systematic_review","article","10.1080/17512433.2020.1736041","32129106",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review"],["R0011060","Lixisenatide",null,"2006","National Institute of Child Health and Human Development, Bethesda (MD)","narrative_review","article",null,"30000034",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0011061","FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist",null,"2023","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC10554467",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0011062","Silent reflux underlying GLP-1RA-associated chronic cough.","Zheng H","2026","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2026.101739","41679597",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011063","Reduced incretin receptor trafficking upon activation enhances glycemic control and reverses obesity in diet-induced obese mice.","Bauri R","2024","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00474.2023","38738303",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011064","GLP-1 RAs and Kidney Cancer Risk: Methodological Considerations in Active-Comparator Selection.","Lopez DS","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70700","41852253",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011065","Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.","Hankosky ER","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16401","40321113","PMC12146454",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0011066","Glucagon like peptide-1 receptor agonists may ameliorate the metabolic adverse effect associated with antiretroviral therapy.","Culha MG","2016","Medical hypotheses","other","article","10.1016/j.mehy.2016.07.016","27515222",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011067","Positioning Incretin-Based and Next-Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta-Analyses.","Monami M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71046","42387279","PMC13449067","PROSPERO:CRD420261425340",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; methods-article; review"],["R0011068","Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.","Zhang Z","2019","Diabetes care","other","article","10.2337/dc18-2584","31221697",null,"ClinicalTrials.gov:NCT02738671","S000596; S001736","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011069","Type 2 diabetes and cardiovascular prevention: the dogmas disputed.","Giugliano D","2018","Endocrine","randomized_trial","article","10.1007/s12020-017-1418-y","28895030",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0011070","Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety.","Zhu Z","2025","Science (New York, N.Y.)","preclinical","article","10.1126/science.adt0773","40146831","PMC12009138",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011071","Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise.","Hu Y","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01716-9","40106226","PMC12006588",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011072","Perioperative Considerations for Patients on GLP1 Agonists.","VanderWielen BA","2024","Advances in anesthesia","narrative_review","article","10.1016/j.aan.2024.07.002","39443044",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011073","Muscle Dysfunction and Bone Loss in a Woman With Cystic Fibrosis and Obesity Treated With Glucagon-Like Peptide 1 Agonist: A Case Report.","Kumar S","2026","Respirology case reports","case_report","article","10.1002/rcr2.70541","41821646","PMC12975330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0011074","New insights into nanomedicines for oral delivery of glucagon-like peptide-1 analogs.","Pinto SFT","2024","Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","narrative_review","article","10.1002/wnan.1952","38500351",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011075","New-onset infective endocarditis in diabetic patients receiving SGLT2I, DPP4I and GLP1a: A population-based cohort study","Chou OH","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.08.06.23293730",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0011076","Polycystic ovary syndrome: a \"risk-enhancing\" factor for cardiovascular disease.","Guan C","2022","Fertility and sterility","narrative_review","article","10.1016/j.fertnstert.2022.03.009","35512976",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0011077","Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?","Mansur RB","2018","Neuropharmacology","narrative_review","article","10.1016/j.neuropharm.2018.01.048","29481915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011078","The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients.","Kukla A","2020","Transplantation direct","nonrandomized_study","article","10.1097/txd.0000000000000971","32095510","PMC7004635",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011079","Multi-predictor pathogenicity filtering and membrane-specific stability analysis identify and characterize candidate destabilizing missense variants of the GIP receptor (GIPR)","Antor SA","2026","Research Square","other","preprint","10.21203/rs.3.rs-10159812/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0011080","The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities.","Friuli M","2026","British journal of pharmacology","narrative_review","article","10.1111/bph.70649","42674554",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Preprint; article"],["R0011081","The First Triple Agonist for Antiobesity: Retatrutide.","Tetelbaun L","2026","Cardiology in review","other_trial","article","10.1097/crd.0000000000000793","39724554",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0011082","Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.","Gasiorek A","2025","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(25)01176-6","40550229",null,"ClinicalTrials.gov:NCT05369390","S003230","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; article"],["R0011083","Implications of Cardiovascular Outcomes Trials in Type 2 Diabetes for Primary Care.","Unger J","2018","The Journal of family practice","other","article",null,"29912999",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011084","Semaglutide and Tirzepatide to Treat Obesity.","Greenway FL","2025","The New England journal of medicine","other_trial","article","10.1056/nejme2507452","40601944",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; article"],["R0011085","GERD and Its Complications Associated With GLP-1 Receptor Agonists.","Hanscom M","2026","Gastroenterology","other","article","10.1053/j.gastro.2025.09.015","40946869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011086","Exenatide and renal outcomes in patients with type 2 diabetes and diabetic kidney disease: a multi-center, randomized, parallel study","Wang X","2020","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-24153/v1",null,null,"ClinicalTrials.gov:NCT02690883","S002088","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0011087","Reply to Editorial Comment on \"Impact of GLP-1 Receptor Agonists on Male Fertility: Emerging Evidence and Future Directions\".","Kuchakulla M","2026","Urology","commentary","article","10.1016/j.urology.2025.10.027","41106521",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0011088","Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip.","Luconi M","2017","International journal of cardiology","narrative_review","article","10.1016/j.ijcard.2017.02.126","28285800",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011089","The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Obstructive Sleep Apnea and Obesity.","Ellberg CC","2025","Current pulmonology reports","narrative_review","article","10.1007/s13665-025-00384-1","40727552","PMC12289732",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011090","Liraglutide enhances myotube differentiation and muscle contractile activity upon electric pulse stimulation in mouse skeletal muscle cells.","Mukai R","2025","Bioscience, biotechnology, and biochemistry","preclinical","article","10.1093/bbb/zbaf060","40258338",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011091","Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.","Seshasai SR","2015","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12448","25656522",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; article"],["R0011092","Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.","McCoy RG","2025","Clinical diabetes : a publication of the American Diabetes Association","other_trial","article","10.2337/cd24-0007","39829688","PMC11739335",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0011093","Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.","Afshari S","2025","International journal of preventive medicine","systematic_review","article","10.4103/ijpvm.ijpvm_368_24","41098876","PMC12520633",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0011094","Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes.","Patti AM","2020","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm9040912","32225082","PMC7230245",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0011095","8699 ​​Efficacy of Glucagon-like Peptide-1 Analogs In Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC11455214",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0011096","Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.","Liu L","2025","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.70077","40214296","PMC11987204",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; letter; article"],["R0011097","Antidiabetic medications and arterial thrombotic risk reduction: a narrative review.","Santilli F","2026","Internal and emergency medicine","narrative_review","article","10.1007/s11739-026-04502-y","42667518",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0011098","Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes.","Takemoto M","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-22337-z","41184416","PMC12583695",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011099","Semaglutide and Diabetic Retinopathy Risk: Evidence from FAERS Database Analysis and Protective Effects on High Glucose-Stimulated Retinal Microvascular Endothelial Cells","Yue X","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-8660362/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0011100","Web Exclusive. Annals On Call - Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes.","Centor RM","2025","Annals of internal medicine","other","article","10.7326/annals-25-03594-oc","40825216",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011101","Effects of dulaglutide on alcohol consumption during smoking cessation.","Probst L","2023","JCI insight","randomized_trial","article","10.1172/jci.insight.170419","37991022","PMC10721313","ClinicalTrials.gov:NCT03204396","S000115","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0011102","Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network.","Hinton W","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13710","30900349","PMC6619442",null,"S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011103","Tirzepatide and Gut Microbiome: A Narrative Review of Current Evidence and Future Implications","Savithri Nandeesha S","2025","Preprints.org","narrative_review","preprint","10.20944/preprints202509.1540.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011104","A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide.","Mao CY","2026","Organic letters","other","article","10.1021/acs.orglett.6c02001","42224238",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011105","Saxagliptin for Disorders of Consciousness: AI, Retrospective Observations, and Preclinical Data","Toker D","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-4810276/v1",null,null,null,null,"europepmc","FALSE","free_to_read","4",null,"Preprint"],["R0011106","Women and Diabetes: Preventing Heart Disease in a New Era of Therapies.","Galati G","2021","European cardiology","randomized_trial","article","10.15420/ecr.2021.22","34777580","PMC8576483",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0011107","Demographic Mix of Care Homes and Personalised Use of SGLT-2 Inhibitors and GLP-1RAs in Residents with Type 2 Diabetes Mellitus.","Sinclair AJ","2026","Journal of personalized medicine","nonrandomized_study","article","10.3390/jpm16020062","41745355","PMC12941576",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0011108","Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond.","Sciacqua A","2023","Heart failure reviews","randomized_trial","article","10.1007/s10741-021-10182-x","34859336",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0011109","Need for and design of a trial to test efficacy of weight loss interventions for cancer prevention: an international consensus using expert nominal group and Delphi methods.","Harris M","2026","British journal of cancer","other_trial","article","10.1038/s41416-026-03356-7","41772274","PMC13036015",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Consensus Statement; Journal Article; review-article; article"],["R0011110","Commentary on \"Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)\".","Zhang Y","2025","Journal of diabetes investigation","commentary","article","10.1111/jdi.70143","40827446","PMC12578661",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; editorial"],["R0011111","Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study.","Formichi C","2021","International journal of molecular sciences","other","article","10.3390/ijms22179454","34502360","PMC8431190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011112","Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.","Kawai T","2020","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.2014879117","33177239","PMC7703558",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011113","Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis.","Tan Y","2025","Acta diabetologica","systematic_review","article","10.1007/s00592-025-02468-5","39985672",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0011114","SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.","Brunetti VC","2021","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.5192","33428309",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011115","Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association.","Cariou B","2015","Diabetes & metabolism","preclinical","article","10.1016/s1262-3636(16)30006-4","26774017",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0011116","Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery.","Spreckley M","2026","International journal of obesity (2005)","narrative_review","article","10.1038/s41366-025-01952-w","41241664","PMC12913018",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011117","GLP-1 in the Hypothalamic Paraventricular Nucleus Promotes Sympathetic Activation and Hypertension.","Xu XY","2024","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.2032-23.2024","38565292","PMC11112640",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011118","Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review.","Jensterle M","2022","Advances in therapy","narrative_review","article","10.1007/s12325-022-02153-x","35503498","PMC9063254",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0011119","Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?","Miñambres I","2017","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-017-0204-6","28115994","PMC5241936",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011120","Orforglipron Calcium.",null,"2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","other","article","10.1093/ajhp/zxag144","42138709",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011121","Plasma volume status in type 2 diabetes and its association with antidiabetic therapy.","Cutruzzolà A","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-03015-w","41382161","PMC12805681",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0011122","Glucose-Lowering Drugs and Fracture Risk-a Systematic Review.","Al-Mashhadi Z","2020","Current osteoporosis reports","systematic_review","article","10.1007/s11914-020-00638-8","33165875",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Research Support, N.I.H., Extramural; Systematic Review"],["R0011123","How to execute research projects in clinical practice in a large medium secure forensic psychiatric facility","Brandt-Christensn A","2022","European psychiatry : the journal of the Association of European Psychiatrists","randomized_trial","article","10.1192/j.eurpsy.2022.889",null,"PMC9563218",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0011124","Liraglutide and Dapagliflozin Synergistically Reshape Gut Microbiota and Metabolic Profiles to Ameliorate Type‑2 Diabetes in Mice.","Tan AJ","2026","ACS omega","preclinical","article","10.1021/acsomega.5c13612","42294227","PMC13261592",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011125","Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans.","Liu X","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.29842","40880091","PMC12397888",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011126","Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.","Trujillo JM","2014","The Annals of pharmacotherapy","narrative_review","article","10.1177/1060028014545807","25136065",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011127","6411 Ozempic - Oh no! Acute Renal Failure Associated with Initiation of Semaglutide",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455306",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011128","Repurposing of semaglutide by targeting SIRT1 and TGF-β/Smad signaling in hepatic fibrosis.","Hawary OA","2026","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-025-04675-x","41111129","PMC12935754",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011129","Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023).","Dai JJ","2023","World journal of gastroenterology","nonrandomized_study","article","10.3748/wjg.v29.i37.5339","37899789","PMC10600806",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0011130","Spotlight on the Mechanism of Action of Semaglutide.","Papakonstantinou I","2024","Current issues in molecular biology","preclinical","article","10.3390/cimb46120872","39728000","PMC11674233",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011131","Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.","Zhu D","2026","Diabetologia","notice","article","10.1007/s00125-026-06711-8","41854861",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0011132","Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner.","Chan JSF","2024","The Journal of endocrinology","randomized_trial","article","10.1530/joe-24-0032","38860519",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011133","Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management.","Cigrovski Berkovic M","2020","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v26.i21.2740","32550751","PMC7284186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011134","Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","Eisa N","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2026.04.014","42061648",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0011135","Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide.","Quintilhano DL","2021","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-020-02006-w","33128591",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011136","Cost-Effectiveness of Highly Effective Glucose-Lowering Agents: Do Current Practices Optimize Clinical and Economic Outcomes?","Hoog M","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-026-01846-8","41806266","PMC13103030",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011137","Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control.","Iacobellis G","2025","Nutrition, metabolism, and cardiovascular diseases : NMCD","randomized_trial","article","10.1016/j.numecd.2024.08.019","39277531",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0011138","Editorial Comment on \"Impact of GLP-1 Receptor Agonists on Male Fertility: Emerging Evidence and Future Directions\".","Helo S","2026","Urology","commentary","article","10.1016/j.urology.2025.09.046","41047084",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0011139","Tirzepatide mitigates cognitive decline in zebrafish model of type 2 diabetes mellitus induced by high-fat diet.","Misra S","2025","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-025-03827-3","39873719",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011140","Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide.","Louwagie EJ","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf028","39949871","PMC11822847",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011141","Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-β peptide-induced impairment of spatial learning and memory in rats.","Jia XT","2016","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2016.03.016","26992957",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011142","Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.","Pinto LC","2020","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgaa534","32797182",null,"PROSPERO:CRD42019132807",null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0011143","Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people.","Emmerton D","2021","Hospital practice (1995)","other","article","10.1080/21548331.2021.1905414","33729898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011144","Effects of glucagon-like peptide 1 receptor signaling in the dorsolateral septum on ethanol operant self-administration and relapse behaviors.","Xiao Y","2025","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2025.110640","40818544",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011145","Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction.","Maruhashi T","2021","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox10081306","34439553","PMC8389282",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011146","Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.","Sattar N","2026","Annals of the rheumatic diseases","randomized_trial","article","10.1016/j.ard.2025.10.009","41198460",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0011147","Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study.","Nasir AB","2026","PloS one","nonrandomized_study","article","10.1371/journal.pone.0356138","42636218","PMC13502699",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011148","Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK.","Bain SC","2019","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.14058","31254356","PMC6771802",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; Consensus Statement; review-article; article"],["R0011149","On \"The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use a network meta-analysis of 68 randomized controlled trials\" - correspondence.","Wang B","2026","International journal of surgery (London, England)","systematic_review","article","10.1097/js9.0000000000003969","41222906",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Letter; Journal Article; review"],["R0011150","Nonglycemic Outcomes of Antidiabetic Medications.","Morse C","2019","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd18-0015","31057219","PMC6468830",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011151","Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.","Wang Y","2017","Clinical drug investigation","randomized_trial","article","10.1007/s40261-017-0569-1","28932995",null,"ClinicalTrials.gov:NCT01342042","S000168","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0011152","Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity.","Mechanick JI","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","other_trial","article","10.1111/obr.13841","39295512","PMC11611443",null,"S002529","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0011153","Fracture-Centred Skeletal Reporting Profiles of Glucose-Lowering Drug Classes in FAERS and JADER: Cross-Database and Regional Reporting-Context Analyses.","Huang B","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71319","42734024",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011154","The multifaceted effects of semaglutide: exploring its broad therapeutic applications.","Alkhatib M","2025","Future science OA","narrative_review","article","10.1080/20565623.2025.2483607","40904035","PMC12413075",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011155","Evidence-based practice use of incretin-based therapy in the natural history of diabetes.","Schwartz S","2014","Postgraduate medicine","narrative_review","article","10.3810/pgm.2014.05.2757","24918793",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011156","Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach.","Strathe A","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70678","41906858","PMC13146121",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0011157","Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.","Cai X","2017","Expert opinion on pharmacotherapy","systematic_review","article","10.1080/14656566.2017.1400011","29090600",null,"PROSPERO:CRD42017053952",null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review; article"],["R0011158","Impact of weight status on risk of venous thromboembolism associated with GLP-1 receptor agonists.","Chiang CH","2025","Expert review of hematology","commentary","article","10.1080/17474086.2025.2562077","40944901",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0011159","7279 Survodutide and Semaglutide Both Induce Weight Loss but Show Different Effects on Food Preference and Dyslipidemia in the Free Choice Diet-induced Obese Hamster Model",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453350",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011160","Perioperative Practice Patterns of Anaesthesiologists Surrounding Glucagon-Like Peptide-1 (GLP-1) Agonist Medications.","Brennan M","2025","Turkish journal of anaesthesiology and reanimation","other","article","10.4274/tjar.2025.241653","40116433","PMC11931257",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011161","Exendin-4 improves long-term potentiation and neuronal dendritic growth in vivo and in vitro obesity condition.","Wang M","2021","Scientific reports","preclinical","article","10.1038/s41598-021-87809-4","33859286","PMC8050263",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011162","Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.","Handelsman Y","2020","Advances in therapy","notice","article","10.1007/s12325-019-01185-0","31873867","PMC7004417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0011163","Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.","Anderson S","2021","The Annals of pharmacotherapy","systematic_review","article","10.1177/1060028020951955","32795145",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0011164","Heart-liver co-management: epidemiology, mechanisms, and novel therapeutic approaches for metabolic dysfunction-associated steatotic liver disease and coronary artery disease.","Zhu S","2026","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2026.1843719","42577170","PMC13453754",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011165","Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.","Flint A","2021","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/apt.16608","34570916","PMC9292692","ClinicalTrials.gov:NCT03357380","S000576","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011166","Transient suppression of ovarian function Induced by Dulaglutide: a case report and review of the literature","Guo Y","2022","Research Square","case_report","preprint","10.21203/rs.3.rs-1698787/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011167","Beyond eGFR and Albuminuria: Biological Pathways and Multiomics in Cardiovascular-Kidney-Metabolic Disease.","Marshall WR","2026","Kidney international reports","narrative_review","article","10.1016/j.ekir.2026.106592","42290908","PMC13264040",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011168","Epicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective?","Iacobellis G","2025","Current cardiology reports","narrative_review","article","10.1007/s11886-025-02325-5","41307857",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011169","Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?","Gastaldelli A","2016","Journal of hepatology","commentary","article","10.1016/j.jhep.2015.11.031","26643784",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; article"],["R0011170","Exendin-4 Improves Long-Term Potentiation and Neuronal Dendritic Growth in High-Fat Diet Mice and Neurons Under Metabolic Imbalance Conditions","Song J","2020","Research Square","preclinical","preprint","10.21203/rs.3.rs-109387/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011171","Dual incretin agonist survodutide benefits in MASLD","Afzal S","2026","Authorea Preprints","other","preprint","10.22541/authorea.15005660/v1",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0011172","Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model.","Fang T","2021","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","preclinical","article","10.1055/a-1240-4936","32961563",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011173","Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β Pathways.","Wu YC","2019","International journal of molecular sciences","preclinical","article","10.3390/ijms20143435","31336911","PMC6678531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011174","Semaglutide Use Linked to Lower COVID-19 and Influenza Severity with Better Cardiovascular, Pulmonary, Renal Outcomes After Pandemic or Seasonal Infection","Matson R","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202606.0635.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0011175","Use of glucose-lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose-lowering drug groups.","Csatordai M","2019","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.14117","31456231",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011176","Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review.","El Nekidy WS","2025","Hospital pharmacy","nonrandomized_study","article","10.1177/00185787251340645","40417637","PMC12095202",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011177","Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?","Belli M","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms232314598","36498924","PMC9737325",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011178","Association Between Time in Range and HbA1c in Japanese Patients With Type 2 Diabetes Mellitus","Kurozumi A","2021","Research Square","other","preprint","10.21203/rs.3.rs-777755/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011179","Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials.","Kyriakos G","2020","Current cardiology reviews","narrative_review","article","10.2174/1573403x15666190603111056","31161994","PMC7903512",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011180","Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.","Bobu AM","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14103536","40429530","PMC12111957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011181","Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway.","Fang Y","2020","Frontiers in cell and developmental biology","preclinical","article","10.3389/fcell.2020.602574","33330497","PMC7729067",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011182","Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus.","Hu Y","2019","Chronic diseases and translational medicine","nonrandomized_study","article","10.1016/j.cdtm.2019.01.001","30993261","PMC6449766",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011183","Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.","Zhang L","2018","Neuropeptides","other_trial","article","10.1016/j.npep.2018.07.003","30017231",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0011184","Impact of Glucose-Lowering Medications on Cardiometabolic Risk in Type 2 Diabetes","Patti AM","2019","Preprints.org","nonrandomized_study","preprint","10.20944/preprints201911.0264.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0011185","Costs for commercially insured adults prescribed second-line diabetes medications.","Liss DT","2021","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2021.88601","33720672",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011186","Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.","Mimura H","2025","Journal of diabetes investigation","other_trial","article","10.1111/jdi.14395","39891527","PMC12057373",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011187","Indirect effects of glucagon-like peptide-1 receptor agonist exendin-4 on the peripheral circadian clocks in mice.","Ando H","2013","PloS one","preclinical","article","10.1371/journal.pone.0081119","24260546","PMC3829942",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011188","Innovations and Future Directions in the Management of Eustachian Tube Dysfunction.","Poe D","2026","Otolaryngologic clinics of North America","narrative_review","article","10.1016/j.otc.2026.05.005","42557207",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011189","Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice.","Hou S","2015","Journal of diabetes research","preclinical","article","10.1155/2015/817839","26351642","PMC4553314",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011190","Comparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-analysis.","Ni W","2026","Journal of clinical and translational hepatology","systematic_review","article","10.14218/jcth.2025.00596","42724131","PMC13558243",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0011191","Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS).","Zhou Y","2022","Clinical endocrinology","nonrandomized_study","article","10.1111/cen.14660","34913180",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011192","Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Gan S","2020","Diabetes care","systematic_review","article","10.2337/dc19-2419","33534728","PMC7372059",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review-article; review"],["R0011193","Mechanisms and treatment of obesity-related hypertension-Part 2: Treatments.","Parvanova A","2025","Clinical kidney journal","narrative_review","article","10.1093/ckj/sfaf035","40130230","PMC11932351",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011194","A comprehensive analysis of community pharmacists' practices, barriers, and strategies in patient education on Saxenda®: a qualitative study.","Turki AS","2026","Journal of pharmaceutical health care and sciences","other","article","10.1186/s40780-026-00575-1","42015323","PMC13097631",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0011195","Development of NAFLD-Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation.","You XY","2026","Cell proliferation","other","article","10.1111/cpr.70118","40873114","PMC13052169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011196","Plasma GDF15 levels are not modified in response to weight loss induced by liraglutide in patients with type 2 diabetes mellitus","Straat M","2023","Research Square","other","preprint","10.21203/rs.3.rs-3030074/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011197","Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.","Alkhouri N","2022","Journal of hepatology","randomized_trial","article","10.1016/j.jhep.2022.04.003","35439567",null,"ClinicalTrials.gov:NCT03987074","S000863; S001368","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011198","Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study.","Bang C","2020","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13877","31486269",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Historical Article; Journal Article; article"],["R0011199","Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use.","Tsai CJ","2022","Journal of personalized medicine","nonrandomized_study","article","10.3390/jpm12111915","36422091","PMC9698961",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011200","Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure.","Xanthopoulos A","2023","Life (Basel, Switzerland)","nonrandomized_study","article","10.3390/life13081778","37629635","PMC10455594",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011201","GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD.","Zhang Q","2025","Prostaglandins & other lipid mediators","other","article","10.1016/j.prostaglandins.2025.106987","40180281",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011202","Exendin-4 inhibits atrial arrhythmogenesis in a model of myocardial infarction-induced heart failure via the GLP-1 receptor signaling pathway.","Chen J","2020","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2020.9089","32855719","PMC7444344",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011203","Retatrutide effects on diabetic rats' cognition.","Ferreira J","2026","Lab animal","preclinical","article","10.1038/s41684-026-01778-7","42527705",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011204","Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.","Yang CY","2021","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-020-01211-4","33468131","PMC7816439",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review; research-article; other; review"],["R0011205","Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies.","Chan DC","2021","Current opinion in lipidology","narrative_review","article","10.1097/mol.0000000000000795","34636776",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011206","Feasibility of the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant Program: A Group-Based Lifestyle Intervention and GLP-1 Receptor Agonist Therapy for End-Stage Kidney Disease Candidates Ineligible Due to Obesity.","Sisson EM","2026","The science of diabetes self-management and care","other_trial","article","10.1177/26350106261483738","42800900",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0011207","Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.","Chen N","2025","Langmuir : the ACS journal of surfaces and colloids","preclinical","article","10.1021/acs.langmuir.5c00949","40347179",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011208","Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.","Iacobellis G","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvz042","32190806","PMC7069837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011209","Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.","Overgaard RV","2021","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-021-01025-x","33969456","PMC8505367","ClinicalTrials.gov:NCT01572753; ClinicalTrials.gov:NCT01619345; ClinicalTrials.gov:NCT02014259; ClinicalTrials.gov:NCT02016911; ClinicalTrials.gov:NCT02249871; ClinicalTrials.gov:NCT02172313; ClinicalTrials.gov:NCT02877355","S000195; S000456; S000471; S000848; S000870; S001380; S002292","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011210","Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.","Weiskirchen R","2025","Medical sciences (Basel, Switzerland)","nonrandomized_study","article","10.3390/medsci13040265","41283266","PMC12642005",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; Preprint; article; preprint"],["R0011211","Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.","Myat A","2015","Cardiovascular diabetology","protocol","article","10.1186/s12933-015-0193-4","25848859","PMC4358711","ClinicalTrials.gov:NCT02315001","S001491","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011212","Use of Premixed Insulin, Metformin, and a Glucagon-Like Peptide 1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes.","Ehrhardt N","2020","Diabetes spectrum : a publication of the American Diabetes Association","randomized_trial","article","10.2337/ds19-0025","32425456","PMC7228818",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0011213","Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.","Dei Cas A","2024","Journal of endocrinological investigation","randomized_trial","article","10.1007/s40618-024-02320-7","38565814","PMC11368991","ClinicalTrials.gov:NCT03881371",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011214","Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.","Savarese G","2022","Cardiovascular research","other_trial","article","10.1093/cvr/cvab271","34390570",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0011215","Peptide Mapping Using Multienzyme Digestion Strategies Integrated with LC-HRMS Workflow: A Case Study.","Maheshwari D","2026","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.70089","41699960",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011216","Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunities.","Bruemmer D","2020","Cardiovascular endocrinology & metabolism","narrative_review","article","10.1097/xce.0000000000000199","32803139","PMC7410032",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011217","Cystic fibrosis-related diabetes: The unmet need.","Pozo L","2020","World journal of diabetes","commentary","article","10.4239/wjd.v11.i6.213","32547695","PMC7284020",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0011218","Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.","Pratley RE","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13824","31264757","PMC6851541",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011219","Advantage of Semaglutide: Comprehensive Analysis of Metabolic Impact of Semaglutide-Treated and Pair-Fed Rats.","Byun S","2025","Comprehensive physiology","preclinical","article","10.1002/cph4.70083","41405347","PMC12710457",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0011220","Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism.","Killion EA","2020","Nature communications","preclinical","article","10.1038/s41467-020-18751-8","33020469","PMC7536395",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011221","Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.","Leah OM","2026","American journal of therapeutics","other_trial","article","10.1097/mjt.0000000000002156","42340212",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0011222","Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.","Kallenbach L","2018","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep-2017-0261","29975575",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study; Research Support, Non-U.S. Gov't"],["R0011223","Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.","Davidson JA","2010","Mayo Clinic proceedings","narrative_review","article","10.4065/mcp.2010.0469","21106865","PMC2996165",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Review; research-article; article"],["R0011224","Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.","Bays HE","2026","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.70106","41508550","PMC12933218","ClinicalTrials.gov:NCT06068946","S000714","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0011225","Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord.","Lee SO","2024","Cells","preclinical","article","10.3390/cells13221857","39594606","PMC11593193",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011226","GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?","Horska K","2022","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2022.06.005","35902330",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0011227","Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.","Papaetis GS","2020","Clinical drug investigation","randomized_trial","article","10.1007/s40261-020-00942-2","32583294",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0011228","From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role in Prostate Cancer.","Alhajahjeh A","2024","Cancers","narrative_review","article","10.3390/cancers16081538","38672620","PMC11048615",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011229","Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes.","Natale P","2025","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd015906.pub2","41263251","PMC12631961",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0011230","A new angle for glp-1 receptor agonist: the medical economics argument. Editorial on: Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of the once-daily glp-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ 2015: 1-13 [Epub ahead of print].","Valencia WM","2015","Journal of medical economics","commentary","article","10.3111/13696998.2015.1069297","26337323",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0011231","Type B insulin resistance with glycemic extremes: a case report and literature review.","Ngo EMT","2026","Frontiers in endocrinology","case_report","article","10.3389/fendo.2026.1852784","42255432","PMC13236523",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; Review; case-report; article"],["R0011232","Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.","Alexander L","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70164","41782434","PMC13032058",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Practice Guideline; research-article; article"],["R0011233","Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis.","Bakker W","2022","Cell reports","other","article","10.1016/j.celrep.2022.111698","36417883","PMC9715912",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0011234","A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity.","Beetz N","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15984","39373311",null,"ClinicalTrials.gov:NCT04903509","S002124","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; article"],["R0011235","Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea.","Kim KK","2019","Korean journal of family medicine","narrative_review","article","10.4082/kjfm.19.0013","30929417","PMC6444089",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0011236","[Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus].","Khamnueva LY","2023","Problemy endokrinologii","randomized_trial","article","10.14341/probl13245","37448270","PMC10204790",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","English Abstract; Journal Article; Review; research-article; article"],["R0011237","Walking Further with GLP-1RAs: Lessons from the STRIDE Trial.","Pantazopoulos D","2026","The international journal of lower extremity wounds","other_trial","article","10.1177/15347346251385584","41170686",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; article"],["R0011238","Liraglutide preserves endothelial function in ophthalmic arteries of septic mice via prevention of oxidative stress.","Böhm EW","2025","Experimental eye research","preclinical","article","10.1016/j.exer.2025.110562","40744307",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011239","Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.","Pagidipati NJ","2023","JAMA","randomized_trial","article","10.1001/jama.2023.2854","36877177","PMC9989955","ClinicalTrials.gov:NCT03936660","S002431","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0011240","Dual-phase exenatide delivery system: PLGA nanoparticles embedded in thermosensitive PLGA-PEG-PLGA hydrogel for sustained glycemic control.","Pan S","2025","Expert opinion on drug delivery","preclinical","article","10.1080/17425247.2025.2564870","40977331",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011241","Geographic Variation in Cardiovascular Disease Prevention by GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Meta-Analysis","Ilany J","2025","Research Square","systematic_review","preprint","10.21203/rs.3.rs-6863965/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0011242","Overview of Glucagon-like Peptide-1 Receptor Agonists.","Steadman L","2015","Home healthcare now","narrative_review","article","10.1097/nhh.0000000000000312","26529445",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011243","Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss.","Heald AH","2025","Advances in therapy","other","article","10.1007/s12325-025-03261-0","40536760","PMC12313766",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011244","GLP-1 RAs in dentoalveolar surgery.","Sandhu N","2026","British dental journal","commentary","article","10.1038/s41415-026-9552-7","41577761",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0011245","Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.","Kaplan LM","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04479-3","42252333","PMC13472939",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; research-article; article"],["R0011246","Network meta-analysis of glucose-lowering drug treatment regimens with the potential risk of hypoglycemia in patients with type 2 diabetes mellitus in terms of glycemic control and severe hypoglycemia.","Kodama S","2023","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","systematic_review","article","10.1177/10815589221149188","36695427",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Network Meta-Analysis; review"],["R0011247","2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea.","Kim MK","2019","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2019.0137","31441247","PMC6712226",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; Review; review-article; article"],["R0011248","GLP-1/GIP dual agonist tirzepatide alleviates mice model of Parkinson's disease by promoting mitochondrial homeostasis.","Tian R","2025","International immunopharmacology","preclinical","article","10.1016/j.intimp.2025.115443","40886502",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011249","Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.","Htoo PT","2016","European journal of clinical pharmacology","nonrandomized_study","article","10.1007/s00228-016-2068-3","27165664","PMC4945406",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011250","Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats.","Lee TS","2023","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","preclinical","article","10.1016/j.jchromb.2023.123688","36989942",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011251","Assessing student pharmacists' confidence and knowledge of basic diabetes self-management skills.","Axon DR","2022","Currents in pharmacy teaching & learning","other","article","10.1016/j.cptl.2022.07.017","36055707",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0011252","[Imeglimin: features of the mechanism of action and potential benefits].","Kuznetsov KO","2022","Problemy endokrinologii","other","article","10.14341/probl12868","35841169","PMC9762543",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011253","Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults with Overweight and Obesity in the US: A Real-World Evidence Study","Rodriguez PJ","2023","medRxiv","randomized_trial","preprint","10.1101/2023.11.21.23298775",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0011254","Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study.","Henry RR","2018","Diabetes care","randomized_trial","article","10.2337/dc17-1519","29301824",null,"ClinicalTrials.gov:NCT01785771","S001548","pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011255","Spatially diffuse cAMP signalling with oppositely biased GLP-1 receptor agonists in β-cells despite differences in receptor localisation.","Chen S","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102304","41391570","PMC12808597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011256","GLP-1 Agonists: More Answers, More Questions.",null,"2026","Anesthesia and analgesia","other","article","10.1213/ane.0000000000007994","41824957",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011257","In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide.","Lesser LI","2025","Annals of internal medicine","other","article","10.7326/annals-25-04321-jc","41183340",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0011258","Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation.","Pradeep A","2026","Transplantation proceedings","nonrandomized_study","article","10.1016/j.transproceed.2026.05.018","42259739",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; article"],["R0011259","Advances in neurological therapies: A review of clinical trials in Alzheimer's, Parkinson's, and multiple sclerosis.","de Souza PC","2026","The American journal of medicine","other_trial","article","10.1016/j.amjmed.2025.11.025","41318018",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0011260","Side effects of GLP-1 receptor agonists.","Manne-Goehler J","2025","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.r1606","40759433",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0011261","Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.","Thieu VT","2019","Patient preference and adherence","narrative_review","article","10.2147/ppa.s187907","31114170","PMC6483112",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011262","Patient experiences with liraglutide for obesity and binge eating disorder-A qualitative study.","Følling IS","2025","PloS one","other","article","10.1371/journal.pone.0335806","41171863","PMC12578197",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011263","Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial.","Anderer S","2025","JAMA","other_trial","article","10.1001/jama.2025.7798","40478570",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0011264","Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists.","Jiang N","2021","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2020.113118","33422984",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011265","Exendin-4 enhances proliferation of senescent osteoblasts through activation of the IGF-1/IGF-1R signaling pathway.","Zhang M","2019","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2019.06.112","31256933",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011266","GLP-1 receptor agonists: panacea or affirmation of societal failure?","Kallis TJ","2025","The British journal of general practice : the journal of the Royal College of General Practitioners","commentary","article","10.3399/bjgp25x741069","40147964","PMC11961190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0011267","Association of antidiabetic medications with depression risk and All-Cause mortality in type 2 Diabetes: A TriNetX-Based cohort study.","Chen IC","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112167","40204122",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0011268","The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.","Aranishi T","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01675-7","39708085","PMC11868005",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011269","Causes of sarcopenia and frailty in people taking GLP1RAs.","Langer HT","2026","Nature reviews. Endocrinology","other","article","10.1038/s41574-026-01254-9","41981276",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011270","Corrigendum to \"Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study\" [Endocrine Practice 30 (2024) 424-430].","Lin YH","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","notice","article","10.1016/j.eprac.2024.06.012","39023469",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0011271","A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models.","Ceglia M","2025","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2025.117364","40998023",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011272","Tirzepatide improves pancreatic β-cell function in mice and patients with type 2 diabetes","Li Z","2026","bioRxiv","preclinical","preprint","10.64898/2026.02.13.704343",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0011273","GLP-1R agonist NLY01 reduces retinal inflammation, astrocyte reactivity, and retinal ganglion cell death secondary to ocular hypertension","Sterling JK","2020","bioRxiv","preclinical","preprint","10.1101/2020.06.18.146720",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011274","Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients.","Nielsen GL","2026","Scandinavian journal of gastroenterology","case_report","article","10.1080/00365521.2026.2661978","42057457",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011275","Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting.","Trinh H","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16343","40116184","PMC12046463",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0011276","Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF.","Kwaah PA","2025","JACC. Advances","other","article","10.1016/j.jacadv.2025.101857","40466245","PMC12172265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0011277","The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date.","Antza C","2019","Drug design, development and therapy","randomized_trial","article","10.2147/dddt.s166765","31686781","PMC6709822",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article; review"],["R0011278","Association Between Pharmaceutical Manufacturer Payments and GLP-1RA Prescribing in the United States.","Khunte M","2026","Mayo Clinic proceedings","other","article","10.1016/j.mayocp.2025.10.021","41579137","PMC12834475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011279","Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.","Sim R","2022","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.14780","34962662",null,"PROSPERO:CRD42020168322",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0011280","Can GLP-1 receptor agonists slow the progression of Autosomal Dominant Polycystic Kidney Disease?","Ali H","2025","BMC nephrology","other_trial","article","10.1186/s12882-025-04217-w","40468228","PMC12139107",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; letter; article"],["R0011281","The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function.","Wajdlich M","2024","Scientific reports","other","article","10.1038/s41598-024-55724-z","38424466","PMC10904847",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011282","Tirzepatide (Zepbound) for the Treatment of Obesity.","Coppenrath V","2024","American family physician","other","article",null,"39172681",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011283","New horizons for idiopathic intracranial hypertension: advances and challenges.","Mollan SP","2020","British medical bulletin","other","article","10.1093/bmb/ldaa034","33200788",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011284","Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis.","Liang R","2020","Endocrine connections","preclinical","article","10.1530/ec-20-0294","33027757","PMC7583131",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011285","Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial.","van Ruiten CC","2022","Psychoneuroendocrinology","randomized_trial","article","10.1016/j.psyneuen.2022.105667","35033928",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011286","Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures.","Schwarzenbach M","2021","World journal of transplantation","narrative_review","article","10.5500/wjt.v11.i7.254","34316450","PMC8290999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011287","Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.","MacConell L","2015","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s77290","26056482","PMC4445788",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0011288","The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.","Mitchell JL","2023","Brain : a journal of neurology","randomized_trial","article","10.1093/brain/awad003","36907221","PMC10151178",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0011289","GLP-1 Receptor Agonists for Metabolic Liver Disease: Strengths and Limitations of Current Evidence.","Miao J","2025","Liver international : official journal of the International Association for the Study of the Liver","commentary","article","10.1111/liv.70301","40833206",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011290","Exendin-4 alleviates β-Amyloid peptide toxicity via DAF-16 in a Caenorhabditis elegans model of Alzheimer's disease.","Song X","2022","Frontiers in aging neuroscience","other","article","10.3389/fnagi.2022.955113","35992601","PMC9389237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011291","Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review.","Sevencan B","2025","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","nonrandomized_study","article","10.5664/jcsm.11682","40114470","PMC12320683",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Review; Research Support, Non-U.S. Gov't; review-article"],["R0011292","Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.","Punthakee Z","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15926","39239702",null,"ClinicalTrials.gov:NCT03862716","S001947","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0011293","Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.","Hepprich M","2025","European journal of endocrinology","randomized_trial","article","10.1093/ejendo/lvaf153","40747712",null,"ClinicalTrials.gov:NCT04909333","S001699","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0011294","Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study.","Braca S","2025","Headache","nonrandomized_study","article","10.1111/head.14991","40525593","PMC12638507",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011295","Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus.","Harris KB","2015","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018814558242","25678952","PMC4321868",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011296","Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.","Sai W","2017","International journal of molecular sciences","preclinical","article","10.3390/ijms18030578","28282854","PMC5372594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011297","Reducing Kidney Function Decline in Patients With CKD: Core Curriculum 2021.","Chen TK","2021","American journal of kidney diseases : the official journal of the National Kidney Foundation","case_report","article","10.1053/j.ajkd.2020.12.022","33892998","PMC8227808",null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review; research-article"],["R0011298","Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight.","Feetham CH","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102214","40681104","PMC12336652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011299","Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge.","Pasquel FJ","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14347","33591621","PMC8571803",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0011300","Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.","Ayesh H","2024","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000001756","39292847",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Letter; Meta-Analysis; review"],["R0011301","Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus.","Yandrapalli S","2017","Journal of thoracic disease","narrative_review","article","10.21037/jtd.2017.06.70","28840014","PMC5542996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011302","Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?","Lee D","2024","AIDS (London, England)","commentary","article","10.1097/qad.0000000000003816","38416553",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0011303","Comparisons of new-onset peripheral arterial disease in Type 2 diabetes mellitus patients exposed to SGLT2I, DPP4I or GLP1a: a population-based cohort study","Chou OH","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.08.21.23294389",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0011304","Synthesis and Preclinical Evaluation of Novel 68Ga-Labeled Bispecific SSTR/GLP-1R Targeting Probes for Neuroendocrine Neoplasms Imaging","Ruan C","2024","Research Square","preclinical","preprint","10.21203/rs.3.rs-4317886/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011305","Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis.","Fenta ET","2023","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-023-01202-x","38012781","PMC10683270",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0011306","Acute Kidney Injury Associated With Semaglutide.","Leehey DJ","2021","Kidney medicine","case_report","article","10.1016/j.xkme.2020.10.008","33851124","PMC8039426",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011307","ABCA1 as a Gatekeeper of Pancreatic β-Cell Cholesterol Homeostasis: Links Between Lipoprotein Stress, Lipotoxicity, and Insulin Secretion.","Fukunaga K","2026","Nutrients","preclinical","article","10.3390/nu18172879","42739051","PMC13567051",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011308","Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases.","Chamchoum E","2025","World journal of experimental medicine","narrative_review","article","10.5493/wjem.v15.i3.107020","41523775","PMC12781666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011309","Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples.","Mounsey LA","2026","JAMA cardiology","nonrandomized_study","article","10.1001/jamacardio.2025.5305","41604173","PMC12853287",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0011310","Semaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection.","Matson R","2026","Biology methods & protocols","nonrandomized_study","article","10.1093/biomethods/bpag042","42540132","PMC13425107",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011311","GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.","Mayendraraj A","2022","Peptides","narrative_review","article","10.1016/j.peptides.2022.170749","35065096",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0011312","The Effects of Glucagon-Like Peptide-1 Agonist Therapy on Risk of Infection, Fracture, and Early Revision in Primary Total Joint Arthroplasty.","Levidy MF","2025","The Journal of the American Academy of Orthopaedic Surgeons","nonrandomized_study","article","10.5435/jaaos-d-24-01284","40397943",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011313","Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.","Mishriky BM","2019","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13805","31168889",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0011314","Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.","Im GY","2026","Journal of clinical gastroenterology","nonrandomized_study","article","10.1097/mcg.0000000000002147","40549581","PMC12312645",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; article"],["R0011315","Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study.","Campforts B","2024","BMC psychiatry","randomized_trial","article","10.1186/s12888-024-06317-7","39616309","PMC11607825",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0011316","Semaglutide Alters Behaviour and Nucleus Accumbens Oscillatory Activity in Healthy Mice","Mosqueira A","2024","bioRxiv","preclinical","preprint","10.1101/2024.09.06.611514",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011317","Sex-dependent additive effects of dorzagliatin and incretin on insulin secretion in a novel mouse model of GCK-MODY.","Salazar S","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.11.09.622781","39605321","PMC11601264",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0011318","Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap.","Thakkar A","2021","European cardiology","narrative_review","article","10.15420/ecr.2021.24","34815749","PMC8591616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011319","A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease.","Ahmad T","2021","European cardiology","other_trial","article","10.15420/ecr.2020.01.r1","33897837","PMC8054345",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0011320","Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines.","Platz E","2026","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2026.01.013","41811272",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Review"],["R0011321","Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury.","Yamamoto K","2013","BioMed research international","preclinical","article","10.1155/2013/315848","23984340","PMC3747455",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011322","ENT1 inhibition enhances weight control and metabolic health in diet-induced obesity.","Chaible L","2025","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2025.118848","41371040",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011323","Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.","Wegeberg AL","2020","United European gastroenterology journal","randomized_trial","article","10.1177/2050640620925968","32390563","PMC7437086",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0011324","Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.","Gastaldelli A","2022","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(22)00070-5","35468325",null,"ClinicalTrials.gov:NCT03882970","S001591","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011325","Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy.","Valdecantos MP","2018","Scientific reports","preclinical","article","10.1038/s41598-018-33949-z","30405191","PMC6220318",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011326","Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study).","Kapoor N","2026","Cureus","randomized_trial","article","10.7759/cureus.105749","41884323","PMC13010369",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0011327","Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.","Aroda VR","2012","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2012.04.013","22608780",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0011328","Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types.","Liu L","2025","Biochemistry","narrative_review","article","10.1021/acs.biochem.4c00867","39983043",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Intramural; article"],["R0011329","Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study.","Gojani EG","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms26010421","39796271","PMC11720205",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0011330","Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.","Albèr A","2017","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12911","28211611",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0011331","Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus.","Taheri S","2019","Iranian journal of pharmaceutical research : IJPR","systematic_review","article","10.22037/ijpr.2019.14733.12619","32184883","PMC7059053",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0011332","Proposal for a Value-Based Agreement to Reimburse Anti-obesity Medicines in Traditional Medicare","Sexton Ward A","2025","medRxiv","other","preprint","10.1101/2025.07.10.25331289",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011333","Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.","Zhuo M","2021","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2021.30762","34705014","PMC8552056",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0011334","Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease.","Tuttle KR","2022","Clinical journal of the American Society of Nephrology : CJASN","other","article","10.2215/cjn.02980322","35649722","PMC9269635",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011335","Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.","Zimmermann T","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2026.102326","41638399","PMC12925197",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011336","Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases.","Raut S","2025","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox14121490","41462689","PMC12729538",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011337","Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.","Baekdal TA","2018","Journal of clinical pharmacology","other_trial","article","10.1002/jcph.1131","29693715","PMC6175428","ClinicalTrials.gov:NCT02016911","S000456","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011338","Effective and safe delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles in vitro and in vivo.","Geng S","2021","Biomaterials","preclinical","article","10.1016/j.biomaterials.2021.120763","33780737",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0011339","Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: Research Summary.",null,"2026","JAMA","other","article","10.1001/jama.2026.9759","42251766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011340","Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity.","Stumpf MAM","2023","European journal of preventive cardiology","systematic_review","article","10.1093/eurjpc/zwad280","37648659",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Review; Journal Article; article"],["R0011341","Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.","Gracen L","2023","Annals of hepatology","nonrandomized_study","article","10.1016/j.aohep.2023.101142","37468097",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0011342","GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction?: Faster Heart Rate, So Not So Fast.","Litwin SE","2025","JACC. Heart failure","commentary","article","10.1016/j.jchf.2025.102642","40972388",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0011343","Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study.","Brown A","2025","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-025-11942-8","40691334",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Comparative Study; article"],["R0011344","Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables.","Santos Cavaiola T","2019","Clinical therapeutics","other","article","10.1016/j.clinthera.2018.11.015","30655008",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011345","GLP-1RA Medications Significantly Reduce Fracture Risk in the Diabetic Foot and Ankle Patient Population",null,"2025","Foot & ankle orthopaedics","other","article",null,null,"PMC12743888",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011346","Peptide YY in Type 2 Diabetes: A Complementary Gut Hormone with Therapeutic Potential Beyond GLP-1.","Nguyen NT","2025","Nutrients","narrative_review","article","10.3390/nu17213468","41228539","PMC12609743",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011347","GLP-1RA Promotes Osteogenic Differentiation of Jaw Bone Marrow Mesenchymal Stem Cells by Modulating CREB/YAP/STAT3/BRD4-Mediated Proliferation and Stemness for Osteoporosis Treatment","Liu H","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-6073024/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0011348","Dual defense: Opportunities and challenges of GLP-1 receptor agonists in reducing dementia risk in type 2 diabetes!","Adnan S","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","commentary","article","10.1002/alz.70336","40442874","PMC12122254",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0011349","Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.","Jeljeli R","2026","International journal of environmental research and public health","other","article","10.3390/ijerph23050638","42196730","PMC13206472",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011350","Impact of renal function on antidiabetic drug selection in Japan: A real-world analysis using the J-DREAMS database.","Kubota M","2026","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70280","41755685","PMC13137285",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011351","Navigating the \"MACE\" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.","Hupfeld C","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13740","30957945",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0011352","Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double-blind, placebo-controlled trial (LIGHT 2).","Jia W","2026","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.70556","41669874",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Clinical Trial Protocol; article"],["R0011353","Lanifibranor and semaglutide demonstrate multiple metabolic benefits in free-choice diet induced obese hamster models of MASH and MetALD.","Briand F","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.177945","40653077",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011354","Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice.","Xu F","2020","International journal of obesity (2005)","preclinical","article","10.1038/s41366-019-0513-y","31911662",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011355","Clinical Manifestations of Semaglutide Overdose: A Case Study.","Branch MR","2024","Journal of psychiatric practice","case_report","article","10.1097/pra.0000000000000824","39655973",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0011356","Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis.","Huang YZ","2021","World journal of diabetes","systematic_review","article","10.4239/wjd.v12.i9.1576","34630909","PMC8472495",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0011357","Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplantation.","Sweiss H","2022","Progress in transplantation (Aliso Viejo, Calif.)","other","article","10.1177/15269248221122867","36039519",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011358","Diabetes mellitus as a risk factor for aortic stenosis: from new mechanisms to clinical implications.","Natorska J","2021","Kardiologia polska","narrative_review","article","10.33963/kp.a2021.0137","34643267",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011359","WITHDRAWN: Using genetics to aid detection of adverse drug effects: a Mendelian randomisation analysis of genetically proxied GLP-1RA in 1,020,464 participants across three population-based cohorts","Mason AC","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.05.22.26353860",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; Preprint-withdrawal; preprint"],["R0011360","The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.","Paul SK","2021","European heart journal","nonrandomized_study","article","10.1093/eurheartj/ehaa956","33289789",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011362","Laxative Properties of Microencapsulated Oleic Acid Delivered to the Distal Small Intestine in Patients with Constipation after Bariatric Surgery or Treatment with Glucagon-Like- Peptide 1 Analogues.","Al-Humadi AW","2024","Obesity surgery","randomized_trial","article","10.1007/s11695-024-07492-y","39235686","PMC11464573",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011363","The effects of antidiabetic agents on heart failure.","Wijnen M","2022","Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation","narrative_review","article","10.1007/s12471-021-01579-2","34097240","PMC8799792",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011364","GLP-1 agonists and hair loss: a call for further investigation.","Desai DD","2024","International journal of dermatology","narrative_review","article","10.1111/ijd.17246","38741261",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011365","Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.","Muta Y","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1358573","38601470","PMC11005912",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011366","Effect of the GLP-1 Receptor Agonist Exenatide on Impaired Awareness of Hypoglycemia in Type 1 Diabetes: A Randomized Controlled Trial.","van Meijel LA","2019","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2019-00087","30958544",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; article"],["R0011367","WITHDRAWN: Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.","Zhou P","2021","Life sciences","preclinical","article","10.1016/j.lfs.2021.119844","34293397",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Retracted Publication"],["R0011368","Exendin-4 protects β-cells against interleukin-1β-induced apoptosis via upregulating GMRP-1.","Xiao T","2025","American journal of translational research","preclinical","article","10.62347/kken8585","41415050","PMC12709340",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011369","GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity.","Alharbi AG","2025","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","narrative_review","article","10.1007/s44446-025-00038-y","40991062","PMC12460220",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011370","Analysis of the long-term impact of glucagon-like peptide-1 (GLP-1) receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis.","Jia IT","2025","Surgical endoscopy","systematic_review","article","10.1007/s00464-025-12086-5","41028671",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0011371","LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.","Alawadhi AA","2026","BMJ open","protocol","article","10.1136/bmjopen-2026-116911","42020128","PMC13110620","ClinicalTrials.gov:NCT06885736","S000003","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; article"],["R0011372","Incretin Mimetics and Cardiovascular Events-The Evolving Comparative Effectiveness Landscape.","O'Connor PJ","2025","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2025.37304","41082236",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0011373","Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts.","Deng F","2023","International journal of endocrinology","preclinical","article","10.1155/2023/9926462","37584041","PMC10425251",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011374","Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes.",null,"2025","Annals of internal medicine","other","article","10.7326/annals-24-00775-ps","40523285",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011375","Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report.","Morrissette K","2024","Cureus","case_report","article","10.7759/cureus.76267","39845205","PMC11753719",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011376","Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","Luo Q","2022","Frontiers in medicine","systematic_review","article","10.3389/fmed.2022.793203","35280867","PMC8914474","PROSPERO:CRD42021283129",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0011377","The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury.","Pang J","2022","Acta pharmaceutica Sinica. B","narrative_review","article","10.1016/j.apsb.2022.06.003","36386481","PMC9643154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011378","Correspondence on: Breast reduction outcomes in massive weight loss: A comparative analysis of GLP-1 receptor agonist users, post-bariatric surgery patients, and controls.","Tomaselli F","2025","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","commentary","article","10.1016/j.bjps.2025.10.033","41173767",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0011379","Medical vs. Surgical Obesity Management: A Narrative Review of Efficacy, Safety, and Long-Term Outcomes.","Akwe J","2025","Cureus","narrative_review","article","10.7759/cureus.91677","41054685","PMC12497434",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0011380","Reversable Bilateral Ischemic Optic Neuropathy Following Semaglutide Discontinuation with Crowded Optic Discs","Alsakran WA","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-7587757/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0011381","Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial.","Cao Y","2024","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2024.1387993","39099671","PMC11294108","ChiCTR:ChiCTR2300070919",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011382","Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.","Meier JJ","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13935","31793165",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011383","INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA).","Kero J","2022","Diabetic medicine : a journal of the British Diabetic Association","protocol","article","10.1111/dme.14913","35797241","PMC9540026","ClinicalTrials.gov:NCT02611232; ClinicalTrials.gov:NCT02898506; ClinicalTrials.gov:NCT02908087","S001314; S001704; S001917","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011384","Intra-articular GLP-1 analogues: A new disease-modifying strategy for osteoarthritis?","Berenbaum F","2026","Joint bone spine","commentary","article","10.1016/j.jbspin.2026.106045","41747858",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0011385","GLP-1 Receptor Agonists vs SGLT2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.","Tang H","2025","The Canadian journal of cardiology","commentary","article","10.1016/j.cjca.2025.08.359","40921381",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011386","Dissecting Hidden Liraglutide Oligomerization Pathways via Direct Mass Technology, Electron-Capture Dissociation, and Molecular Dynamics.","Kuo ST","2025","Analytical chemistry","other","article","10.1021/acs.analchem.5c01851","40521838","PMC12224166",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0011387","Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials.","Zeng BY","2026","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2026.104026","42376494","PMC13311999","PROSPERO:CRD42024626613",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0011388","Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.","Ahrén B","2017","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2017.02.017","28284167",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0011389","Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis.","Salem AM","2023","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2023.02.004","36764610",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Observational Study; Journal Article"],["R0011390","Obesity-induced alterations in the gut microbiome in female mice fed a high-fat diet are antagonized by dietary supplementation with a novel, wax ester-rich, marine oil.","Schots PC","2020","Nutrition research (New York, N.Y.)","preclinical","article","10.1016/j.nutres.2020.09.002","33049454",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011391","Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.","Noureddin M","2025","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(25)02114-2","41237796",null,"ClinicalTrials.gov:NCT05989711","S000412","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0011392","GLP-1 Analogue-Loaded Glucose-Responsive Nanoparticles as Allies of Stem Cell Therapies for the Treatment of Type I Diabetes.","Marques JM","2024","ACS pharmacology & translational science","preclinical","article","10.1021/acsptsci.4c00173","38751616","PMC11092009",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011393","Can the NHS afford Mounjaro? It spent £574m on the jab last year despite most eligible patients not getting it.","Wilkinson E","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-100104","42373101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011394","Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Zhou Q","2023","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-023-01198-4","37904255","PMC10614386",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0011395","The role of GLP-1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system.","Sebaratnam D","2025","The Medical journal of Australia","commentary","article","10.5694/mja2.70042","40879113",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011396","EXENATIDE TREATMENT REDUCES THYROID GLAND VOLUME, BUT HAS NO EFFECT ON THE SIZE OF THYROID NODULES.","Köseoğlu D","2020","Acta endocrinologica (Bucharest, Romania : 2005)","other","article","10.4183/aeb.2020.275","33363646","PMC7748234",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011397","Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine.","Peng LN","2026","Journal of the Chinese Medical Association : JCMA","randomized_trial","article","10.1097/jcma.0000000000001374","41957871","PMC13193294",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0011398","TOWARD, a metabolic health intervention, demonstrates robust 1-year weight loss and cost-savings through deprescription.","Buchanan L","2025","Frontiers in nutrition","other","article","10.3389/fnut.2025.1548609","40028226","PMC11868080",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011399","Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial.","Hansen MS","2024","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2024.102624","38737002","PMC11087719","ClinicalTrials.gov:NCT04702516","S001321","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0011400","Hierarchical network meta-analysis models for synthesis of evidence from randomised and non-randomised studies.","Hussein H","2023","BMC medical research methodology","systematic_review","article","10.1186/s12874-023-01925-5","37087450","PMC10122363",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; research-article; other; article"],["R0011401","Exploring the causal relationship between GLP-1R agonists and diseases related to the thyroid and parathyroid: a mendelian randomization study.","Li C","2025","Journal of diabetes and metabolic disorders","commentary","article","10.1007/s40200-025-01567-y","39927177","PMC11799478",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; letter; article"],["R0011402","Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes: rationale and design of the semaglutide treatment on coronary progression trial.","Hamal S","2020","Coronary artery disease","protocol","article","10.1097/mca.0000000000000830","32271261",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial Protocol; Journal Article; article"],["R0011403","Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials.","Rocha NA","2018","Kidney international supplements","narrative_review","article","10.1016/j.kisu.2017.10.004","30675434","PMC6336216",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0011404","Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.","McInnes N","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15234","37580972",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011405","Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.","Aronoff SL","2017","Postgraduate medicine","narrative_review","article","10.1080/00325481.2017.1285191","28118069",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011406","Both subcutaneous semaglutide and calorie restriction improves pancreatic cell hyperplasia and gut microbiota in high-fat diet-induced obese mice.","Luo Y","2025","Nutrition & metabolism","preclinical","article","10.1186/s12986-025-00987-0","40775354","PMC12330110",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011407","Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know.","Chan PYW","2024","JBJS reviews","randomized_trial","article","10.2106/jbjs.rvw.23.00167","38181103",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0011408","Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?","Kopp KO","2024","Ageing research reviews","narrative_review","article","10.1016/j.arr.2024.102343","38762101","PMC11378160",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural; research-article"],["R0011409","Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US.","Kim C","2025","JAMA","nonrandomized_study","article","10.1001/jama.2025.4735","40299371","PMC12042086",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011410","Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density.","Eriksson R","2018","Frontiers in psychiatry","randomized_trial","article","10.3389/fpsyt.2018.00781","30745885","PMC6360839",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0011411","Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.","Wehler E","2021","PharmacoEconomics","nonrandomized_study","article","10.1007/s40273-020-00967-7","33150566","PMC7882575",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011412","Obesity Management in Adults: A Review.","Elmaleh-Sachs A","2023","JAMA","narrative_review","article","10.1001/jama.2023.19897","38015216","PMC11325826",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Review; Journal Article; research-article; article"],["R0011413","The role of GLP-1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system.","Bolton PG","2025","The Medical journal of Australia","commentary","article","10.5694/mja2.70044","40879111",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011414","Personalized Medical Nutrition Therapy and Physical Exercise: The Future of Diabesity Care.","Verde L","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00688-6","41813871","PMC12979325",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011415","Glucagon-like peptide-1 receptor agonist administration suppresses both water and saline intake in rats.","McKay NJ","2013","Journal of neuroendocrinology","preclinical","article","10.1111/jne.12086","23957745","PMC3794436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0011416","GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives.","Nevola R","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms24021703","36675217","PMC9865319",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011417","Positive modulation of glucagon-like peptide 1 (GLP-1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes.","Khan FB","2026","British journal of pharmacology","preclinical","article","10.1111/bph.70677","42811773",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011418","GLP-1R activation restores Gas6-driven efferocytosis in senescent foamy macrophages to promote neural repair.","Xia M","2025","Redox biology","preclinical","article","10.1016/j.redox.2025.103857","40915106","PMC12446625",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011419","Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.","Yu H","2025","British journal of clinical pharmacology","randomized_trial","article","10.1002/bcp.70093","40344607",null,"ClinicalTrials.gov:NCT04515849","S001902","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; article"],["R0011420","Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.","Ferrari F","2022","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2022.108277","36064147",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0011421","Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.","Khat DZ","2018","Current diabetes reports","narrative_review","article","10.1007/s11892-018-1011-7","29886514",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011422","In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.","Lau D","2023","Annals of internal medicine","commentary","article","10.7326/j23-0077","37782925",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0011423","Evaluation of [68Ga]DO3A-VS-Cys40-Exendin-4 as a PET Probe for Imaging Human Transplanted Islets in the Liver.","Li J","2019","Scientific reports","preclinical","article","10.1038/s41598-019-42172-3","30952975","PMC6450933",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011424","Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.","Armstrong MJ","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16065","39609879","PMC11701178","ClinicalTrials.gov:NCT03357380; ClinicalTrials.gov:NCT02970942; ClinicalTrials.gov:NCT03987451","S000576; S000922; S001764","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011425","Glucagonlike Peptide-1 Receptor Agonists: The Good, the Bad, and the Ugly-Benefits for Glucose Control and Weight Loss with Side Effects of Delaying Gastric Emptying.","Parkman HP","2024","Journal of nuclear medicine technology","other","article","10.2967/jnmt.123.266800","38443105",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011426","Letter to the Editor regarding \"Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management\".","Wu J","2026","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","commentary","article","10.1016/j.pan.2025.08.019","40914663",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0011427","Dietary recommendations for pediatric and adolescent patients utilizing GLP-1 receptor agonists for weight management: A narrative review of current literature.","Kennedy C","2026","Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition","narrative_review","article","10.1002/ncp.11356","40714863",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0011428","LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.","Petrie JR","2016","Journal of hypertension","randomized_trial","article","10.1097/hjh.0000000000000890","26855018","PMC4856174","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0011429","Revisiting 'intensive' blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials.","Huang CJ","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14819","35848464",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0011430","Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023).","Gastaldi G","2023","Swiss medical weekly","nonrandomized_study","article","10.57187/smw.2023.40060","37011604",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0011431","Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112.","Sun J","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2024.116965","38925019",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011432","Drug Design of GLP-1 Receptor Agonists: Importance of In Silico Methods.","Sharma S","2021","Current pharmaceutical design","other","article","10.2174/1381612826666201118094502","33213316",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011433","Antismoking agents do not contribute synergistically to semaglutide's ability to reduce alcohol intake in rats.","Aranäs C","2023","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2023.1180512","37719854","PMC10500129",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011434","Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.","Heise T","2022","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(22)00085-7","35468322",null,"ClinicalTrials.gov:NCT03951753","S000593","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011435","GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes.","Rojano Toimil A","2021","Journal of clinical medicine","narrative_review","article","10.3390/jcm10173955","34501404","PMC8432108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011436","Retatrutide and the urinary tract infection signal: Is the answer hidden in timing?","Koufakis T","2026","European journal of internal medicine","commentary","article","10.1016/j.ejim.2026.107099","42493254",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011437","Response to: \"Correspondence on: Breast reduction outcomes in massive weight loss: A comparative analysis of GLP-1 receptor agonist users, post-bariatric surgery patients, and controls\".","Friedman O","2025","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","commentary","article","10.1016/j.bjps.2025.10.036","41173768",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011438","Compounded GLP-1 Receptor Agonists: Opportunity for Compassionate Conversation.","Chetty AK","2026","Journal of general internal medicine","commentary","article","10.1007/s11606-025-09765-3","40696223","PMC12855695",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; research-article; article"],["R0011439","Underutilization of GLP-1 receptor agonists for non-diabetic weight management by cardiologists in Poland.","Dziewierz A","2026","Kardiologia polska","other","article","10.33963/v.phj.107918","40792680",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011440","GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics.","Wright SC","2023","Nature communications","other","article","10.1038/s41467-023-41893-4","37813859","PMC10562414",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011441","Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.","Sun F","2015","Endocrine","systematic_review","article","10.1007/s12020-014-0373-0","25115635",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0011442","Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature.","Cieslik LK","2022","Internal medicine journal","nonrandomized_study","article","10.1111/imj.15137","33197121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0011443","Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m2, and chronic kidney disease - A randomised, controlled pilot study.","Al Ozairi E","2026","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2025.113066","41435968",null,"ClinicalTrials.gov:NCT05390307","S001116","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0011444","Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.","Pereira M","2015","Bone","preclinical","article","10.1016/j.bone.2015.08.006","26314515",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011445","Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.","Athauda D","2018","Neuropharmacology","other_trial","article","10.1016/j.neuropharm.2017.09.023","28927992",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0011446","Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes.","Yabe D","2014","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.2014.949672","30736202",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011447","Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.","Patorno E","2016","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12665","27003762",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011448","Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis.","Yang YT","2026","Respiratory medicine","systematic_review","article","10.1016/j.rmed.2026.108671","41616874",null,"PROSPERO:CRD420251165267",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis; Systematic Review; Comparative Study; Research Support, Non-U.S. Gov't"],["R0011449","Cellular loci for cagrilintide action identified.","Hevesi Z","2026","Nature metabolism","other","article","10.1038/s42255-026-01541-9","42260118",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011450","Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.","Davidson JA","2015","Postgraduate medicine","other_trial","article","10.1080/00325481.2015.1096743","26428031",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0011451","Daily briefing: Narcolepsy drug could kick off an Ozempic-style moment for the brain.","Graham F","2026","Nature","commentary","article","10.1038/d41586-026-02589-z","42613446",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0011452","[Adverse reactions of GLP-1 analogues when used to treat obesity in non-diabetic patients].","Barcelo Colomer ME","2026","Atencion primaria","commentary","article","10.1016/j.aprim.2026.103478","41806785","PMC12989983",null,null,"pubmed; europepmc","TRUE",null,null,null,"Letter"],["R0011453","Structure-aware fragment assignment for interpreting tandem mass spectrometry of modified and cyclic peptides.","Erckes V","2026","The Analyst","other","article","10.1039/d6an00162a","42189055",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011454","SAT-LB105 A Transcribed Ultraconserved Noncoding RNA, Uc.336-As, Promotes White to Brown Conversion in 3T3-L1 Cells","He X","2020","Journal of the Endocrine Society","other","article",null,null,"PMC7209049",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011455","Glucose-lowering treatment patterns in patients with diabetic kidney disease.","Iyer NN","2022","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2022.89152","35981131",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011456","Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice.","Chen P","2021","Journal of cardiovascular pharmacology and therapeutics","preclinical","article","10.1177/1074248420942007","32686479",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011457","Orforglipron (Foundayo) for adults with obesity.","Zhou Q","2026","Trends in pharmacological sciences","other","article","10.1016/j.tips.2026.06.007","42420063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011458","AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.","Fletcher MM","2021","The Journal of pharmacology and experimental therapeutics","other_trial","article","10.1124/jpet.121.000567","33727283",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Comparative Study; article"],["R0011459","Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide.","Le TDV","2023","eLife","preclinical","article","10.7554/elife.80944","37930356","PMC10691799",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0011460","GLP-1-Mediated Pregnancy and Neonatal Complications in Mice.","Ramamoorthy R","2025","Journal of developmental biology","preclinical","article","10.3390/jdb13030029","40843897","PMC12372104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011461","Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.","Gan L","2026","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph19030371","41901218","PMC13028924",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011462","Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes.","Goldenberg RM","2019","Canadian journal of diabetes","other_trial","article","10.1016/j.jcjd.2018.05.008","30195966",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0011463","Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.","Ma RL","2021","Chinese medical journal","randomized_trial","article","10.1097/cm9.0000000000001712","34732660","PMC8667970","ClinicalTrials.gov:NCT04029272","S000952; S001012","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011464","Bullous Pemphigoid Development in a Patient Treated with Dulaglutide: A Case Report",null,null,"Spartan medical research journal","case_report","article",null,null,"PMC13428597",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011465","Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.","Dejgaard TF","2015","BMJ open","protocol","article","10.1136/bmjopen-2015-007791","25838513","PMC4390685","ClinicalTrials.gov:NCT01612468","S000597","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; protocol; article"],["R0011466","Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.","Vijiaratnam N","2021","BMJ open","protocol","article","10.1136/bmjopen-2020-047993","34049922","PMC8166598","ClinicalTrials.gov:NCT04232969; ISRCTN:ISRCTN14552789","S001156","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0011467","Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome.","Fitchett DH","2020","CJC open","other_trial","article","10.1016/j.cjco.2020.04.002","32995726","PMC7499366",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0011468","Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes.","Hansen CS","2019","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2019.00242","31031712","PMC6473101",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0011469","Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery.","Ariaee A","2026","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2026.114711","41672308",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011470","A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.","Lynn J","2022","Journal of Alzheimer's disease : JAD","narrative_review","article","10.3233/jad-210612","34842187",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0011471","Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial.","Yan X","2024","The Lancet regional health. Western Pacific","randomized_trial","article","10.1016/j.lanwpc.2024.101101","38948164","PMC11214404","ClinicalTrials.gov:NCT04504370","S000217","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; article"],["R0011472","Exenatide inhibits necrosis by enhancing angiogenesis and ameliorating ischemia/reperfusion injury in a random skin flap rat model.","He JB","2021","International immunopharmacology","preclinical","article","10.1016/j.intimp.2020.107192","33214096",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011473","Preventing and treating kidney disease in patients with type 2 diabetes.","Delanaye P","2019","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2018.1551362","30462565",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011474","Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database.","Meyhöfer S","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14616","34882949",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0011475","Orforglipron",null,"2006","National Institute of Child Health and Human Development, Bethesda (MD)","narrative_review","article",null,"42044252",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0011476","Insights into New Therapeutic Approaches for the Treatment and Management of Polycystic Ovary Syndrome: An Updated Review.","Bashir R","2022","Current pharmaceutical design","nonrandomized_study","article","10.2174/1381612828666220518150754","35593345",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0011477","Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes.","Skolnik NS","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-021-01050-w","33914300","PMC8179861",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011478","Adjunctive diabetes therapies and cardiovascular protection in type 1 diabetes: tackling the challenging Tchaikovsky piece.","Wang WT","2026","Current opinion in endocrinology, diabetes, and obesity","other_trial","article","10.1097/med.0000000000000940","41123381",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0011479","Incretin-based therapies: focus on effects beyond glycemic control alone.","Davidson JA","2013","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-013-0040-0","24057947","PMC3889321",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0011480","Failure of GLP-1 Agonist Therapy to Improve Weight in a 3-Year-Old Patient With Tumor-Related Obesity.","Petlansky R","2025","Case reports in pediatrics","other_trial","article","10.1155/crpe/1707315","41323567","PMC12659972",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0011481","Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.","Gao Y","2020","American heart journal","other","article","10.1016/j.ahj.2020.03.017","32304879",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Multicenter Study"],["R0011482","Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.","Mather KJ","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16159","39762971",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; article"],["R0011483","Self-Reported Side Effects Among Reddit Users Taking Nonapproved Retatrutide","Sehgal NKR","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.05.28.26352819",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0011484","[GLP-1 Receptor Agonists: For Which Patients with Type-2 Diabetes?].","Mächler T","2023","Praxis","other","article","10.1024/1661-8157/a004011","37042408",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0011485","Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial.","Raaschou-Oddershede D","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.71062","42387302","PMC13448972",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011486","Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials","Abdu E","2025","medRxiv","systematic_review","preprint","10.64898/2025.12.22.25342824",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0011487","Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.","Liu C","2025","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70021","39718468","PMC11667988",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Clinical Trial; research-article; article"],["R0011488","To Assess Liraglutide's Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System.","Yin J","2021","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s331833","34744445","PMC8565899",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011489","GLP-1 Agonists, Aspiration Risk, and Anaesthetic Consent in Ireland.","Singleton B","2026","Irish medical journal","other","article",null,"41728834",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011490","How does survodutide work? Plain language review of a potential new medication for obesity and liver disease.","Almandoz JP","2026","Therapeutic advances in gastroenterology","narrative_review","article","10.1177/17562848261457269","42254697","PMC13241674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011491","Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon Papio hamadryas.","Fiorentino TV","2019","JCI insight","other","article","10.1172/jci.insight.93091","31536476","PMC6824445",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0011492","Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.","Hamamoto Y","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-025-01704-z","39951042","PMC11926299","ClinicalTrials.gov:NCT03861052","S000239","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; article"],["R0011493","Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States.","Hoog M","2022","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2022.04.005","35618571",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011494","Retatrutide: Obesity drug opens to \"compassionate use\" in US after speculation Trump took it.","Brown C","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-100530","42567543",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011495","GLP-1R Agonist Exendin-4 Protects Against Hemorrhagic Transformation Induced by rtPA After Ischemic Stroke via the Wnt/β-Catenin Signaling Pathway.","Liu C","2022","Molecular neurobiology","preclinical","article","10.1007/s12035-022-02811-9","35359227","PMC9148281",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011496","AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys.","Jensen MH","2024","Molecular metabolism","other","article","10.1016/j.molmet.2024.102006","39128651","PMC11382121",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011497","Novel Treatment Options in Patients with Maturity-Onset Diabetes of the Young.","Müssig K","2025","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","narrative_review","article","10.1055/a-2436-7723","39379059",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011498","Melatonin and Diabetic Nephropathy: From Mechanistic Pathways to Translational Opportunities in Clinical Management.","Chapani MS","2026","Current medicinal chemistry","nonrandomized_study","article","10.2174/0109298673480116260915111102","42813623",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011499","The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome.","Anala AD","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm12144575","37510690","PMC10380206",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011500","Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model.","Wang Z","2019","Transplantation","preclinical","article","10.1097/tp.0000000000002448","30211824",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011501","Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.","Jammah AA","2021","Primary care diabetes","other_trial","article","10.1016/j.pcd.2020.08.004","32839127",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0011502","The growing range of complications of diabetes mellitus.","Hamblin PS","2025","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2024.12.006","39755491",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011503","Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.","Yokote K","2026","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.70862","42219222","PMC13341362","ClinicalTrials.gov:NCT06176365","S000798","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; methods-article; article"],["R0011504","SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.","Komatsu S","2020","Endocrine journal","other","article","10.1507/endocrj.ej19-0428","31776304",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011505","Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.","Baviera M","2022","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-022-01572-y","35999556","PMC9400295",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0011506","Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus
.","Zang YN","2017","International journal of clinical pharmacology and therapeutics","other","article","10.5414/cp202973","28513427",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011507","Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Hong B","2025","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph18071058","40732345","PMC12300051","PROSPERO:CRD420251077610",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0011508","When Is Enough Precedent Enough? A Decision-Responsive Stopping Rule for Regulatory Precedent Research in Target Product Profile and Label Development","Kay S","2026","Research Square","other","preprint","10.21203/rs.3.rs-9888005/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0011509","Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes.","Luna-Marco C","2023","Redox biology","other","article","10.1016/j.redox.2023.102849","37591012","PMC10457591",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; preprint; article"],["R0011510","Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.","Vilsbøll T","2012","Diabetes, obesity & metabolism","other_trial","article","10.1111/j.1463-1326.2012.01579.x","22405268",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0011511","Immune and Vascular Function in Cardiometabolic Disorders: Interplay With Sex Differences and Impact on Incretin Therapy.","Muralikrishnan AS","2025","Acta physiologica (Oxford, England)","narrative_review","article","10.1111/apha.70091","40838278","PMC12368768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011512","Critical Insights on \"Psychosocial Outcomes and Aesthetic Expectations in Female Patients Undergoing Body Contouring After GLP-1-Induced Weight Loss: A Prospective Pilot Comparative Study with Post-Bariatric Patients\".","Irfan A","2026","Aesthetic plastic surgery","commentary","article","10.1007/s00266-026-06242-y","42675286",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0011513","Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.","Carretero Gómez J","2020","International journal of clinical practice","other","article","10.1111/ijcp.13586","32533906",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011514","Comment on \"Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study\".","Dhanya Dedeepya S","2026","Diabetes & metabolic syndrome","other_trial","article","10.1016/j.dsx.2026.103418","41967333",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; letter"],["R0011515","Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy.","Juthi SS","2026","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2026.1798309","41971071","PMC13062330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011516","Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.","Kaplan LM","2026","Nature medicine","notice","article","10.1038/s41591-026-04650-w","42642663",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0011517","Exendin-4 blockade of T1R2/T1R3 activation improves Pseudomonas aeruginosa-related pneumonia in an animal model of chemically induced diabetes.","Yu S","2024","Inflammation research : official journal of the European Histamine Research Society ... [et al.]","preclinical","article","10.1007/s00011-024-01891-8","38748233","PMC11214611",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011518","Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.","Oe Y","2022","Journal of diabetes research","nonrandomized_study","article","10.1155/2022/5603864","35097130","PMC8793345",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0011519","Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.","Noureddin M","2026","Hepatology (Baltimore, Md.)","other_trial","article","10.1097/hep.0000000000001825","42545725",null,"ClinicalTrials.gov:NCT04771273","S001877","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0011520","No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.","de la Peña A","2017","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-017-0531-7","28357715",null,"ClinicalTrials.gov:NCT01458210; ClinicalTrials.gov:NCT01436201; ClinicalTrials.gov:NCT01432938; ClinicalTrials.gov:NCT01250834","S000082; S000799; S001506; S001623; S001958","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Controlled Clinical Trial; Journal Article; Randomized Controlled Trial; article"],["R0011521","Persistently low initiation of GLP-1 receptor agonists for weight management in individuals without diabetes in Poland: a major unmet need.","Dziewierz A","2025","Archives of medical science : AMS","nonrandomized_study","article","10.5114/aoms/209719","41078940","PMC12509864",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0011522","Unlocking the potential of microfluidic assisted formulation of exenatide-loaded solid lipid nanoparticles.","Birro BA","2025","International journal of pharmaceutics","other","article","10.1016/j.ijpharm.2025.125686","40354907",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011523","An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method.","Martin AA","2016","Diabetes, metabolic syndrome and obesity : targets and therapy","other_trial","article","10.2147/dmso.s100775","27274297","PMC4876841",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0011524","Nutrient-stimulated Hormone-based Therapies: A New Frontier in the Prevention and Management of MASH-associated Hepatocellular Carcinoma.","Phillips R","2025","Journal of clinical and translational hepatology","narrative_review","article","10.14218/jcth.2025.00303","41473259","PMC12745189",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011525","Recommendations for the management of patients with type 2 diabetes at hospital discharge after an ischaemic cardiovascular event.","Renna NF","2024","Hipertension y riesgo vascular","narrative_review","article","10.1016/j.hipert.2024.07.006","39551547",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; Review; article"],["R0011526","HYPOTHYROIDISM COULD BE A POTENTIAL FACTOR TO PROLONG SUBCUTANEOUS NODULES OF EXENATIDE ONCE WEEKLY: A CASE REPORT.","Ito A","2019","AACE clinical case reports","case_report","article","10.4158/accr-2018-0418","31967033","PMC6876937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011527","Dulaglutide",null,"2006","National Institute of Child Health and Human Development, Bethesda (MD)","narrative_review","article",null,"30000038",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0011528","GLP-1 receptor agonists risk becoming another story of global health inequity-what can we learn from the response to HIV/AIDS?","Ratevosian J","2025","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.r1940","40957640",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0011529","Liraglutide attenuates clozapine-induced mitochondrial dysfunction and improves energy metabolism in the brain of rats.","He Y","2025","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2025.117091","40588078",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011530","iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan-L-CN study.","Yuan X","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15968","39360440",null,"ClinicalTrials.gov:NCT03798080","S002110","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0011531","KBN2202 Suppresses Gonadal White Adipose Tissue Expansion in Female Mice Fed a High-Fat Diet.","Kim M","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27020627","41596279","PMC12841312",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011532","Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?","Amici F","2024","Journal of basic and clinical physiology and pharmacology","preclinical","article","10.1515/jbcpp-2023-0029","38484469",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011533","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea.","Oh S","2015","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2015.39.3.177","26124987","PMC4483602",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011534","Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.","Nohara H","2020","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2020.01.081","31996306",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011535","Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.","Feier CVI","2024","International journal of molecular sciences","systematic_review","article","10.3390/ijms25084346","38673931","PMC11050669",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0011536","Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials.","Singh A","2025","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2025.103212","40086043",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Comparative Study; review"],["R0011537","KBN2202 Suppresses Adipose Tissue Expansion in a High-Fat Diet-Induced Obesity Mouse Model","Kim M","2025","Preprints.org","preclinical","preprint","10.20944/preprints202511.1806.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011538","Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care.","Dobbie LJ","2021","Journal of clinical medicine","other","article","10.3390/jcm10245755","34945051","PMC8706667",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011539","\"GLP-1 patches\": High street wellness brand slammed for its \"literally Ozempic\" ads.","Mahase E","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-100542","42580753",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011540","Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.","Pearson ER","2025","Diabetes","other","article","10.2337/db25-0276","40633089","PMC12451090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; research-article; other; article"],["R0011541","Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting.","Ghosh A","2020","Current diabetes reviews","nonrandomized_study","article","10.2174/1573399815666191104115449","31686642",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011542","Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.","Mancinetti F","2026","European geriatric medicine","nonrandomized_study","article","10.1007/s41999-025-01271-3","40624450",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011543","Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.","Wu X","2017","Experimental cell research","preclinical","article","10.1016/j.yexcr.2017.09.018","28919123",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011544","Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes.","Strollo F","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-024-01624-4","39085745","PMC11330428",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0011545","The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous?","Gallwitz B","2014","European endocrinology","commentary","article","10.17925/ee.2014.10.02.98","29872471","PMC5983089",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial; article"],["R0011546","The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice.","Alawami F","2026","Irish journal of medical science","nonrandomized_study","article","10.1007/s11845-025-04194-x","41283946",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011547","Mini-review. Vitamin D for the prevention of type 2 diabetes: Evidence and implications.","Amrein K","2026","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2026.156566","41707752",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; review"],["R0011548","Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression.","Giugliano D","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14047","32250550",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0011549","The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents.","Qasim A","2026","Frontiers in gastroenterology (Lausanne, Switzerland)","nonrandomized_study","article","10.3389/fgstr.2026.1850915","42564069","PMC13441763",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0011550","The Impact of GLP-1 Receptor Agonists on Outcomes in Nondiabetic Patients Undergoing Posterior Cervical Spine Surgery: A Retrospective Analysis.","Rivera NM","2026","Clinical spine surgery","nonrandomized_study","article","10.1097/bsd.0000000000002064","42615893",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011551","Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.","Morano S","2015","Acta diabetologica","other","article","10.1007/s00592-014-0710-z","25577244",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011552","Impact of GLP-1 receptor agonists on capsule endoscopy: Proposal for adaptation of preparation protocols.","García-Rodríguez A","2026","Gastroenterologia y hepatologia","commentary","article","10.1016/j.gastrohep.2025.502627","41213425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011553","Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.","Singh AK","2017","Expert review of clinical pharmacology","other_trial","article","10.1080/17512433.2017.1318061","28393583",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0011554","Exendin-4 promotes pancreatic β-cell proliferation via inhibiting the expression of Wnt5a.","Wu X","2017","Endocrine","preclinical","article","10.1007/s12020-016-1160-x","27826714",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011555","The GLP-1 analog exendin-4 modulates HSP72 expression and ERK1/2 activity in BTC6 mouse pancreatic cells.","Madhu D","2020","Biochimica et biophysica acta. Proteins and proteomics","preclinical","article","10.1016/j.bbapap.2020.140426","32272193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011556","A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.","Witkowski M","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-018-0428-y","29713961","PMC5984931",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0011557","Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes.","Lamos EM","2016","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1080/17425255.2016.1216974","27467569",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0011558","Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.","Enache V","2026","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina62091742","42796348","PMC13609224",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0011559","Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs.","Villarroya F","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00660-w","40892365","PMC12405374",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011560","Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis.","Sindhu U","2024","Epilepsia open","systematic_review","article","10.1002/epi4.13091","39487832","PMC11633680",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0011561","Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.","Bethel MA","2020","Circulation","randomized_trial","article","10.1161/circulationaha.119.043353","32098501",null,"ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011562","Forward for: Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.","Leikin JB","2026","Disease-a-month : DM","systematic_review","article","10.1016/j.disamonth.2026.102112","41936525",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Editorial; review"],["R0011563","ALDOB influences β-cell insulin secretion through modulating GLP-1R signaling in type 2 diabetes","Yin H","2026","Research Square","preclinical","preprint","10.21203/rs.3.rs-10616609/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0011564","Glucagon-Like Peptide-1 Receptor Agonist and Glucagon Increase Glucose-Stimulated Insulin Secretion in Beta Cells via Distinct Adenylyl Cyclases.","Lee YS","2018","International journal of medical sciences","preclinical","article","10.7150/ijms.24492","29725251","PMC5930462",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011565","Metabolic polygenic risk scores for prediction of obesity, type 2 diabetes, and related morbidities.","Kim MS","2026","Cell metabolism","other","article","10.1016/j.cmet.2026.02.009","41844147","PMC13092120",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0011566","Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: A systematic review and meta-analysis.","Sukkar GA","2026","Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","systematic_review","article","10.4103/sjg.sjg_455_25","41848415","PMC13441243",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review-article; review"],["R0011567","Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions.","De Oliveira-Gomes D","2026","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-026-01395-2","41686329",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011568","GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction.","Zhang L","2020","Chemico-biological interactions","preclinical","article","10.1016/j.cbi.2020.109252","32898504",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011569","Mapping Models of Tirzepatide Delivery for Obesity Management in Primary Care Settings","Coulman K","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.07.24.26358784",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0011570","Exploring molecular targets in diabetic kidney disease.","Maruno S","2022","Kidney research and clinical practice","other_trial","article","10.23876/j.krcp.21.251","35354246","PMC9590302",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0011571","GLP-1 receptor agonist therapy is not associated with adverse events following shoulder surgery: a systematic review and meta-analysis.","Moews LD","2026","Journal of shoulder and elbow surgery","systematic_review","article","10.1016/j.jse.2025.12.005","41619919",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0011572","Efficacy and safety of exenatide as add-on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double-blind trial.","Joubert M","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14225","33043591",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011573","GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.","Sposito AC","2018","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-018-0800-2","30545359","PMC6292070",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0011574","Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.","Lu J","2026","International journal of medical sciences","systematic_review","article","10.7150/ijms.133077","42328113","PMC13280743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0011575","Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists.","Nauck MA","2023","Lancet (London, England)","commentary","article","10.1016/s0140-6736(23)01201-1","37369233",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0011576","Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.","Hepşen S","2025","European journal of medical research","nonrandomized_study","article","10.1186/s40001-025-02836-5","41074095","PMC12512425",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0011577","Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial.","Giugliano D","2021","Diabetes care","randomized_trial","article","10.2337/dc20-2623","33883195","PMC8247516","ClinicalTrials.gov:NCT04196231","S002277","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Pragmatic Clinical Trial; research-article; other; article"],["R0011578","Differential Anti-Inflammatory Effects of Semaglutide and Tirzepatide in Experimental Diabetes Mellitus.","Dobriceanu RC","2026","Current issues in molecular biology","preclinical","article","10.3390/cimb48070675","42510916","PMC13407247",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011579","Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.","Møller M","2022","CNS spectrums","randomized_trial","article","10.1017/s1092852920002217","33308348",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0011580","Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.","Zeitler P","2024","Diabetes care","other_trial","article","10.2337/dc23-2356","38639997","PMC11116907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0011581","Retained Gastric Contents After Adequate Fasting Associated with GLP-1 Receptor Agonist Use: A Report of 3 Cases.","Kittner SL","2023","JBJS case connector","case_report","article","10.2106/jbjs.cc.23.00506","37943967",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0011582","Metformin and cardiorenal outcomes in diabetes: A reappraisal.","Petrie JR","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13984","32009286","PMC7317924",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review; review-article; article"],["R0011583","Effects of semaglutide on vessel morphology: Studies on the chicken chorioallantoic membrane.","Chen PH","2026","Microvascular research","preclinical","article","10.1016/j.mvr.2025.104880","41125168","PMC13088174",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0011584","Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.","Davidson JA","2020","Diabetic medicine : a journal of the British Diabetic Association","other_trial","article","10.1111/dme.14094","31365765","PMC7003844","ClinicalTrials.gov:NCT02058147; ClinicalTrials.gov:NCT02058160","S001199; S001409","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011585","Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.","Torres Fernandez ED","2019","Endocrinology","preclinical","article","10.1210/en.2019-00450","31593246","PMC6825516",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0011586","Response to Comment on: Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.","Pourabhari Langroudi A","2025","International journal of impotence research","nonrandomized_study","article","10.1038/s41443-025-01143-1","40775124",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011587","Ozempic and thin line between therapy and dependence.","Maheen T","2026","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.32369","42703141",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011588","Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism.","Henriksen K","2025","Diabetologia","preclinical","article","10.1007/s00125-025-06425-3","40374968","PMC12176928",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011589","Exendin-4 inhibits small intestinal glucose sensing and absorption through repression of T1R2/T1R3 sweet taste receptor signalling in streptozotocin diabetic mice.","Ercin M","2022","Translational research : the journal of laboratory and clinical medicine","preclinical","article","10.1016/j.trsl.2022.03.012","35385790",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011590","Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults.","Rooks D","2026","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgag091","41873146","PMC13466935",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011591","Metformin induces diarrhea in mice under over-eating conditions.","Chikama K","2025","Diabetology international","preclinical","article","10.1007/s13340-025-00822-0","40607156","PMC12209130",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011592","Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.","Carbone LJ","2016","Journal of gastroenterology and hepatology","systematic_review","article","10.1111/jgh.13026","26111358",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0011593","Exploration of individual beta cell function over time in vivo: effects of hyperglycemia and glucagon-like peptide-1 receptor (GLP1R) agonism.","Delgadillo-Silva LF","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.03.31.646461","40236128","PMC11996457",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0011594","Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.",null,"2023","Journal of diabetes investigation","notice","article","10.1111/jdi.14080","37767853","PMC10688101",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0011595","The impact of semaglutide on fusion rates following posterior lumbar fusion surgery in patients with type 2 diabetes.","Chang Y","2025","International journal of surgery (London, England)","nonrandomized_study","article","10.1097/js9.0000000000002492","40434727",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0011596","FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications.","Anderer S","2026","JAMA","commentary","article","10.1001/jama.2025.26370","41615669",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; Comment; article"],["R0011597","Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.","Rydén A","2017","The patient","other","article","10.1007/s40271-017-0225-0","28315192",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0011598","Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus.","Jang CW","2024","Journal of personalized medicine","nonrandomized_study","article","10.3390/jpm14030280","38541022","PMC10971117",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0011599","Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.","Hunt B","2019","Advances in therapy","other_trial","article","10.1007/s12325-019-01125-y","31650514","PMC6860465",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0011600","Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.","Azam MH","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70643","41804840",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Review; article"],["R0011601","The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials.","Maiorino MI","2019","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2019.06.009","31238059",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0011602","Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!","Ranjbar G","2019","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2019.154001","31672448",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011603","Fighting Type-2 Diabetes: Present and Future Perspectives.","Yu CG","2019","Current medicinal chemistry","narrative_review","article","10.2174/0929867324666171009115356","28990512",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011604","Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.","Mody RR","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-023-01470-w","37770706","PMC10597950",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0011605","jabbrv-ltwa-all.ldf jabbrv-ltwa-en.ldf Anti-obesity medicines: An overview of the clinical landscape","O'Connor N","2024","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.172923845.58953877/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0011606","Sodium-glucose co-transporter inhibitors: Medications that mimic fasting for cardiovascular prevention.","Giaccari A","2019","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13814","31209982",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011607","Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.","Yu M","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04651-9","42811187",null,"ClinicalTrials.gov:NCT06672172","S000213","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0011608","[Nephrology : what's new in 2025].","Nanchen G","2026","Revue medicale suisse","other","article","10.53738/revmed.2026.22.945.47996","41540866",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0011609","Differential Modulation of GLP-1R by Dietary Ginsenosides Points to a Putative Extracellular Allosteric Site.","Caspi A","2026","International journal of molecular sciences","other","article","10.3390/ijms27125630","42353344","PMC13299201",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011610","Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic (CKM) Syndrome.","Guerrero-Mauvecin J","2025","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox14060701","40563333","PMC12189499",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011611","Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner.","Li Z","2021","Communications biology","preclinical","article","10.1038/s42003-021-02208-9","34079050","PMC8172568",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011612","Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study.","Malik ME","2023","The lancet. Healthy longevity","nonrandomized_study","article","10.1016/s2666-7568(23)00164-2","37734395",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011613","Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages.","Baris E","2025","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-025-04225-5","40448826","PMC12552294",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011614","Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options.","Schmitz SH","2025","Endocrinology and metabolism clinics of North America","other_trial","article","10.1016/j.ecl.2024.09.003","39919879",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0011615","The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.","Basson M","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-017-0321-0","29134607","PMC5801216",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0011616","Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease.","Bakkar NZ","2022","Clinical science (London, England : 1979)","other","article","10.1042/cs20220404","36383188",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011617","GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway.","Wei L","2022","Journal of diabetes research","preclinical","article","10.1155/2022/1861940","36387940","PMC9649324",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011618","GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.","Divino V","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-016-0224-5","28070733","PMC5306123",null,"S002638","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011619","The Effect of Lifestyle Coaching Approach on Patient Engagement and Weight Loss in a Semaglutide-Supported Digital Obesity Program in the UK: A Comparative Retrospective Cohort Study","Talay L","2024","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202410.1674.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0011620","A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.","Dennis JM","2025","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(24)02617-5","40020703",null,"ClinicalTrials.gov:NCT00622284; ClinicalTrials.gov:NCT01167881",null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Validation Study; Research Support, Non-U.S. Gov't; article"],["R0011621","Solvent induced amyloid polymorphism and the uncovering of the elusive class 3 amyloid topology.","Dürvanger Z","2024","Communications biology","other","article","10.1038/s42003-024-06621-8","39122990","PMC11316126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011622","Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.","Wu F","2024","Canadian journal of anaesthesia = Journal canadien d'anesthesie","nonrandomized_study","article","10.1007/s12630-024-02719-z","38485835",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article"],["R0011623","CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.","Schnell O","2024","Cardiovascular diabetology","other_trial","article","10.1186/s12933-024-02180-8","38504284","PMC10953147",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0011624","GLP-1RAs increase risk for cholelithiasis and GERD but not other GI or biliary adverse events vs. placebo.","Anderson KL","2026","Annals of internal medicine","commentary","article","10.7326/annals-25-05161-jc","41490510",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0011625","Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project.","Alkas J","2023","Journal of nephrology","nonrandomized_study","article","10.1007/s40620-022-01505-8","36459371","PMC10090010",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011626","Metabolic Outcomes in Patients With Type 2 Diabetes Prescribed Incretin-Based Therapy and Referred or Not to a Weight Management Clinic: A Single-Center Retrospective Analyses.","Robinson KM","2026","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.70114","41531807","PMC12791153",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011628","What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?","Doumas M","2019","Current vascular pharmacology","narrative_review","article","10.2174/157016111705190703102816","31418344",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011629","iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.","Guja C","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15027","36810874",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011630","Refining Meta-Analyses of GLP-1RA Safety: Sparse Event Data, Confounding, and Sex Differences.","Huang J","2026","Gastroenterology","systematic_review","article","10.1053/j.gastro.2025.06.039","41422838",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; article"],["R0011631","Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection.","Andreasen CR","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14500","34519400",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0011632","A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.","Andersen A","2021","Drugs","other_trial","article","10.1007/s40265-021-01499-w","33964002","PMC8217049",null,"S000298","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0011633","Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.","Yang JY","2020","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2020.107706","32843283","PMC7657660",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0011634","Pharmacoeconomic Review Report: Lixisenatide (Adlyxine): (Sanofi-aventis Canada Inc.): Indication: As an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with metformin, a sulfonylurea (alone or with metformin), pioglitazone (alone or with metformin), a basal insulin (alone or with metformin)",null,"2017","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"30480929",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0011635","Navigating Access: The Future of Compounded GLP-1 Receptor Agonists for Weight Loss.","Dudding J","2025","Missouri medicine","commentary","article",null,"40787017","PMC12331335",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0011636","Double Diabetes: A Growing Problem Requiring Solutions.","Popovic DS","2022","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","other","article","10.1055/a-1392-0590","33636739",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011637","Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.","Chrysavgis LG","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25073832","38612640","PMC11012092",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011638","A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.","Abd El Aziz MS","2017","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12804","27717195",null,null,"S000691","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0011639","Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes.","Zhang X","2021","Cell reports","other","article","10.1016/j.celrep.2021.109374","34260945",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Preprint; preprint; article"],["R0011640","The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS.","Keerie A","2021","Scientific reports","preclinical","article","10.1038/s41598-021-96418-0","34426623","PMC8382676",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011641","Diabetes drugs in the fight against Alzheimer's disease.","Boccardi V","2019","Ageing research reviews","narrative_review","article","10.1016/j.arr.2019.100936","31330313",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011642","Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell.","Knerr L","2021","Journal of the American Chemical Society","preclinical","article","10.1021/jacs.0c12043","33626278",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011643","Efficacy of polyethylene glycol loxenatide for type 2 diabetes mellitus patients: a systematic review and meta-analysis.","Liu Y","2024","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2024.1235639","38469407","PMC10925615",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0011644","Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.","Sun F","2015","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2015.07.015","26358202",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0011645","Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study.","Wang W","2025","Journal of Alzheimer's disease : JAD","randomized_trial","article","10.1177/13872877251351329","40552638","PMC12262134",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0011646","Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.","Kanie T","2021","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd013650.pub2","34693515","PMC8812344","ClinicalTrials.gov:NCT03619213; ClinicalTrials.gov:NCT03087773; ClinicalTrials.gov:NCT03485222; ClinicalTrials.gov:NCT03057951; ClinicalTrials.gov:NCT04146155; ClinicalTrials.gov:NCT02917031; ClinicalTrials.gov:NCT02397421; ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03485092","S000716; S002174","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; systematic-review; article"],["R0011647","The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review.","Breit S","2025","Psychoneuroendocrinology","systematic_review","article","10.1016/j.psyneuen.2025.107415","40138849",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0011648","Perceived Credibility of Social Media Narratives About GLP-1 Receptor Agonists and Acceptance of Integrated Obesity Care: Implications for Nutrition and Lifestyle Support.","Żurawski T","2026","Nutrients","other","article","10.3390/nu18162718","42654298","PMC13516904",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011649","Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes.","Zhu Y","2025","PloS one","preclinical","article","10.1371/journal.pone.0326897","40608828","PMC12225814",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011650","Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle.","Dineen SL","2015","Diabetes","randomized_trial","article","10.2337/db14-1790","25845661","PMC4542436",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0011651","GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner.","Trammell TS","2021","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","preclinical","article","10.1007/s10072-020-04910-8","33222103","PMC8140064",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0011652","The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Wang J","2019","Journal of diabetes research","systematic_review","article","10.1155/2019/8083417","31772945","PMC6854923",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review-article; review"],["R0011653","Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.","Thazhath SS","2017","Diabetes & vascular disease research","randomized_trial","article","10.1177/1479164116666761","27941058",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0011654","Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.","Edwards KL","2015","Core evidence","narrative_review","article","10.2147/ce.s55944","25657615","PMC4295897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011655","An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists.","Edwards KL","2012","Diabetes technology & therapeutics","narrative_review","article","10.1089/dia.2012.0098.edw","22845681",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011656","The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis.","Gupta NA","2012","The American journal of pathology","other","article","10.1016/j.ajpath.2012.07.015","22960075","PMC5691335",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011657","Self-Emulsifying delivery systems for oral administration of exenatide: Hydrophobic ion pairs vs. Dry reverse micelles.","Schmidt MR","2025","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2025.125711","40360092",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0011658","Obesity update: cardiovascular risk and therapeutic innovations (focus on semaglutide and tirzepatide).","Di Odoardo LAF","2025","European heart journal supplements : journal of the European Society of Cardiology","other_trial","article","10.1093/eurheartjsupp/suaf032","40248309","PMC12001795",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0011659","Obesity as a Part of Polycysric Ovary Syndrome (PCOS)-A Review of Pathophysiology and Comprehensive Therapeutic Strategies.","Bila J","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14165642","40869469","PMC12386588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011660","Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.","Capel M","2020","PharmacoEconomics - open","other","article","10.1007/s41669-019-0171-y","31338828","PMC7248155",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011661","Endothelial Dysfunction in Obesity and Therapeutic Targets.","Engin A","2024","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-3-031-63657-8_17","39287863",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011662","Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data.","Aamir AB","2025","Journal of clinical medicine research","systematic_review","article","10.14740/jocmr6231","40503067","PMC12151102",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0011663","Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach.","Kalra S","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-014-0058-y","24549850","PMC4065297",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0011664","Weight Loss Medications in Youth: Decision-Making Experiences, Eating Behaviors, and Uncertainty About Endpoint.","Nehushtan H","2026","The Journal of adolescent health : official publication of the Society for Adolescent Medicine","other","article","10.1016/j.jadohealth.2026.03.017","42233931",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011665","Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.","Hannon TS","2025","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(25)01774-x","40975112",null,"ClinicalTrials.gov:NCT05260021","S000249","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0011666","Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia.","Ja'arah D","2021","Clinical medicine insights. Endocrinology and diabetes","narrative_review","article","10.1177/11795514211051697","34690504","PMC8527576",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011667","Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis.","Koehler JA","2015","Diabetes","preclinical","article","10.2337/db14-0883","25277394",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011668","Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke.","Kim S","2017","Experimental neurobiology","preclinical","article","10.5607/en.2017.26.4.227","28912645","PMC5597553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011669","Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.","Shi Q","2023","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj-2022-074068","37024129","PMC10077111","PROSPERO:CRD42022325948",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; research-article; review"],["R0011670","Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders.","Baik J","2025","Journal of bone metabolism","narrative_review","article","10.11005/jbm.25.919","41423189","PMC12719006",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0011671","Effects of GLP-1 RA Initiation in Patients With HFrEF and Implantable Cardiac Devices Divided for BMI Values.","Sardu C","2026","JACC. Heart failure","commentary","article","10.1016/j.jchf.2025.102839","41638817",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011672","Do anti-obesity medical treatments have a direct effect on adipose tissue?","Vergès B","2024","Annales d'endocrinologie","preclinical","article","10.1016/j.ando.2024.05.021","38871515",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011673","[Safety and tolerability of GLP-1 receptor agonists].","Soldevila B","2014","Medicina clinica","narrative_review","article","10.1016/s0025-7753(14)70107-1","25326842",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; English Abstract"],["R0011674","GLP-1 as a regulator of sepsis outcomes: Insights into cellular metabolism, inflammation, and therapeutic potential.","Fan W","2025","International immunopharmacology","preclinical","article","10.1016/j.intimp.2025.114390","40068523",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011675","Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms.","Yaghmayee S","2025","Neuroscience","narrative_review","article","10.1016/j.neuroscience.2025.06.009","40494410",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011676","Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis.","Wu R","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1554795","40933383","PMC12417197","PROSPERO:CRD42024618146",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0011677","GLP-1RA Reduces Supraspinatus Fatty Infiltration and Promotes Functional Recovery in a Rat Model of Rotator Cuff Repair.","Yoon JP","2025","The American journal of sports medicine","preclinical","article","10.1177/03635465251369517","40938084",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011678","Inhibition of daily torpor in mice requires calories, not just feeding: a potential role for GLP-1.","McLear GM","2026","Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology","preclinical","article","10.1007/s00360-025-01649-6","41806000",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0011679","GLP-1 and Its Analogs: Does Sex Matter?","Börchers S","2025","Endocrinology","narrative_review","article","10.1210/endocr/bqae165","39715341","PMC11733500",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011680","Summary for Patients: Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide.",null,"2025","Annals of internal medicine","other","article","10.7326/annals-24-03849-ps","40340500",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011681","Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.","Cornell S","2012","Journal of clinical pharmacy and therapeutics","systematic_review","article","10.1111/j.1365-2710.2012.01342.x","22436069",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0011682","Initiators of Semaglutide in General Practice in New South Wales, 2020-2023: A Retrospective Cohort Study.","Kuo NI","2026","Heart, lung & circulation","nonrandomized_study","article","10.1016/j.hlc.2025.09.012","41667347",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; article"],["R0011683","Cardiovascular benefits of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists: Synergistic mechanism or additive effects?","Wang Y","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133658","40706814",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011684","GLP-1 Promotes Cortical and Medullary Perfusion in the Human Kidney and Maintains Renal Oxygenation During NaCl Loading.","Haddock B","2023","Journal of the American Heart Association","randomized_trial","article","10.1161/jaha.122.027712","36734354","PMC9973647","ClinicalTrials.gov:NCT04337268",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011685","Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature.","McElroy SL","2018","Medical hypotheses","randomized_trial","article","10.1016/j.mehy.2017.12.029","29407005",null,null,"S002311","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0011686","Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients.","Saraiva JFK","2021","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-021-01417-0","34911560","PMC8675489",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; other; article"],["R0011687","SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice.","Martos-Guillami N","2024","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2024.1415879","39434906","PMC11491409",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011688","[Liraglutide alleviates lipotoxic liver cell damage and promotes autophagy to improve non-alcoholic fatty liver].","Zhang Q","2021","Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","preclinical","article","10.3760/cma.j.cn501113-20200427-00219","34107584","PMC12814099",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011689","Design of glucagon-like Peptide-1 receptor agonist for diabetes mellitus from traditional chinese medicine.","Tang HC","2014","Evidence-based complementary and alternative medicine : eCAM","nonrandomized_study","article","10.1155/2014/385120","24891870","PMC4033432",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011690","SGLT2 Inhibitor, GLP-1 Receptor Agonist, and the Risk of Atrial Fibrillation.","Liao KF","2025","American journal of therapeutics","other","article","10.1097/mjt.0000000000002003","41201361",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011691","Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar.","Wilcox T","2020","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2020.02.056","32327107","PMC7219531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0011692","Exploring Perspectives on Ozempic: A Netnographic Qualitative Evaluation of the Pro-Eating Disorder Community on X (Formerly Twitter).","Sun D","2026","The International journal of eating disorders","other","article","10.1002/eat.70190","42604953",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011693","Glucagonlike peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in ischemic strokes with diabetes 2.","Hastrup S","2024","European journal of neurology","nonrandomized_study","article","10.1111/ene.16329","38715389","PMC11235957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0011694","Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.","Liu QK","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2514331","41337722",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0011695","The Drug Update: Recent drug approvals, summer 2025 edition.","Marino AB","2025","The Nurse practitioner","other","article","10.1097/01.npr.0000000000000344","40722217",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011696","Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.","Nauck MA","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14988","36700380",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0011697","In brief: Removal of suicidality warning from GLP-1 Agonists for weight management.",null,"2026","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2026.1748e","41649364",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011698","Cost-effectiveness of diabetes treatment sequences to inform step therapy policies.","Hung A","2020","The American journal of managed care","nonrandomized_study","article","10.37765/ajmc.2020.42639","32181619",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011699","Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study.","Wai KM","2024","American journal of ophthalmology","nonrandomized_study","article","10.1016/j.ajo.2024.04.010","38636788","PMC12145121",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0011700","[GLP1-agonists and SGLT2 inhibitors in the perioperative setting].","Stobbe AY","2025","Nederlands tijdschrift voor geneeskunde","narrative_review","article",null,"40503811",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0011701","Incretins and cardiovascular disease: to the heart of type 2 diabetes?","Solini A","2023","Diabetologia","narrative_review","article","10.1007/s00125-023-05973-w","37542009","PMC10473999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011702","The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial.","Dekkers IA","2021","Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation","randomized_trial","article","10.1053/j.jrn.2020.09.006","33293204",null,"ClinicalTrials.gov:NCT01761318; ClinicalTrials.gov:NCT02660047","S000142; S000566","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011703","Comment on: Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.","Pozzi E","2025","International journal of impotence research","nonrandomized_study","article","10.1038/s41443-025-01126-2","40681805",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; letter"],["R0011704","Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide.","Masood A","2024","Frontiers in molecular biosciences","other","article","10.3389/fmolb.2024.1458675","39324112","PMC11422103",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011705","Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study.","Ching LM","2025","JAAD international","nonrandomized_study","article","10.1016/j.jdin.2025.07.003","41133117","PMC12541142",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0011706","MON-817 Association of Semaglutide and Tirzepatide Use on Bone Density and Fracture Risk in Obese Patients with and without Diabetes",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544599",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011707","Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis.","Alamoudi A","2026","Eye (London, England)","systematic_review","article","10.1038/s41433-026-04904-4","42786281",null,"PROSPERO:CRD420251077729",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Review"],["R0011708","New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?","Ryan DH","2025","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-025-09967-4","40320499","PMC12534358",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011709","\"They Call Us Cheaters\": Exploring Stigma Management Communication Strategies During GLP-1 Medication Use.","Lazenby B","2026","Health communication","other","article","10.1080/10410236.2026.2734167","42760821",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011710","Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.","Clegg LE","2019","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-019-0942-x","31640705","PMC6805385","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0011711","Managing loss of glycemic control in middle-aged patients with diabetes: the role of GLP-1 receptor agonists in combination-therapy regimens.","Repas TB","2014","The Journal of the American Osteopathic Association","narrative_review","article","10.7556/jaoa.2014.085","24769504",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011712","Overview of weight loss medicines and practical advice for patients.","Boocock RC","2026","Nursing standard (Royal College of Nursing (Great Britain) : 1987)","other","article","10.7748/ns.2026.e12753","42676263",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011713","The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs.","Rodbard HW","2018","Diabetes technology & therapeutics","other","article","10.1089/dia.2018.0103","29870275",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011714","REPLY: Effects of GLP-1 RA Initiation in Patients With HFrEF and Implantable Cardiac Devices Divided for BMI Values.","Marques P","2026","JACC. Heart failure","commentary","article","10.1016/j.jchf.2025.102837","41638814",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0011715","Retatrutide fact check: Has a man died after taking the unapproved weight loss jab?","Mahase E","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-100245","42425580",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011716","Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.","Yoon KH","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14032","32175655","PMC7383501",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011717","Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?","Ghouri N","2021","Current diabetes reviews","other_trial","article","10.2174/1573399817666201228120725","33371853",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0011718","Comment on: \"Efficacy and safety of GLP-1 receptor agonists in obstructive sleep apnea - a systematic review and meta-analysis\" by Kow et al.","Sharma A","2025","Sleep medicine","systematic_review","article","10.1016/j.sleep.2025.106708","40763546",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0011719","Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.","McGarry A","2024","The Lancet. Neurology","randomized_trial","article","10.1016/s1474-4422(23)00378-2","38101901",null,"ClinicalTrials.gov:NCT04154072","S001973","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011720","Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus.","Chatterjee R","2025","Drug delivery and translational research","narrative_review","article","10.1007/s13346-025-01965-y","40914786",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011721","Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.","D'Andrea E","2020","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-020-01133-1","32993654","PMC7525990",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Systematic Review; research-article; Preprint; other; preprint; review"],["R0011722","Oral contraception and GLP-1 agonists.","BMJ Publishing Group Ltd","2025","Drug and therapeutics bulletin","other","article","10.1136/dtb.2025.000049","41136186",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011723","Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.","Igarashi A","2021","Advances in therapy","other_trial","article","10.1007/s12325-020-01561-1","33245530","PMC7854394",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0011724","Intestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1.","Gao L","2025","Science advances","preclinical","article","10.1126/sciadv.adv3201","40446026","PMC12124353",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011725","Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.","Reitz J","2025","Molecular psychiatry","other","article","10.1038/s41380-025-03199-3","40931165","PMC12602350",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011726","Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada.","Carney G","2022","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2022-002995","36356988","PMC9660664",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011727","Basal Insulin Use With GLP-1 Receptor Agonists.","Anderson SL","2016","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/diaspect.29.3.152","27574369","PMC5001217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011728","The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment.","Louis M","2025","Cureus","narrative_review","article","10.7759/cureus.83903","40497223","PMC12151308",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011729","Development of a Follow-Up Protocol for Patients Treated with Injectable Semaglutide for Weight Loss: Design of a Research Study in Community Pharmacy.","Acuña Elvira N","2026","Farmaceuticos comunitarios","protocol","article","10.33620/fc.2173-9218.(2026).03","41540992","PMC12801701",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0011730","Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway.","Zhai Y","2025","Journal of Alzheimer's disease : JAD","preclinical","article","10.1177/13872877251329439","40151913",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011731","Is combined exercise and incretin-based therapy the way forward for weight-loss maintenance?","Abildgaard J","2023","Nature reviews. Endocrinology","commentary","article","10.1038/s41574-023-00873-w","37430036",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0011732","The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.","Davies M","2016","Clinical pharmacology : advances and applications","randomized_trial","article","10.2147/cpaa.s82008","27382338","PMC4922775",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0011733","Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition.","Agcakaya E","2023","Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","other","article","10.29271/jcpsp.2023.03.308","36945162",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011734","Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.","Zhang YJ","2014","Archives of pharmacal research","preclinical","article","10.1007/s12272-013-0253-9","24178744","PMC4016675",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011735","Comment on: Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.","Kohn TP","2025","International journal of impotence research","nonrandomized_study","article","10.1038/s41443-025-01121-7","40665040",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; letter"],["R0011736","Wegovy weight loss pill now available to UK patients-how will it affect doctors?","Iacobucci G","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-100204","42413987",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other"],["R0011737","[18F]FB(ePEG12)12-exendin-4 noninvasive imaging of insulinoma negative for insulin immunostaining on specimen from endoscopic ultrasonography-guided fine needle aspiration: a case report with review of literature.","Otani D","2024","Endocrine journal","nonrandomized_study","article","10.1507/endocrj.ej24-0187","38839345",null,"jRCT:jRCTs051200156",null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Case Reports; Review; article"],["R0011738","Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.","Elkind-Hirsch KE","2021","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgab408","34097062",null,"ClinicalTrials.gov:NCT02635386","S002140","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Equivalence Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0011739","Inhibitory effects of peripheral administration of exendin-4 on food intake are attenuated by lesions of the central nucleus of amygdala.","Qiao H","2019","Brain research bulletin","preclinical","article","10.1016/j.brainresbull.2019.03.002","30862486",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011740","Mechanistic insights into the inhibition of insulin amyloidogenesis and associated toxicity by the p.M14L variant of exenatide.","Bahrami Z","2026","The FEBS journal","other","article","10.1111/febs.70732","42782086",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011741","Comparison of SGLT-2i and GLP-1RA on cardiovascular and renal outcomes in elderly patients with T2DM: a single-center retrospective cohort study.","Qin Y","2026","International urology and nephrology","nonrandomized_study","article","10.1007/s11255-025-04748-z","40911179",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0011742","Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree.","Bjørnholm KD","2021","Endocrinology, diabetes & metabolism","preclinical","article","10.1002/edm2.234","34277961","PMC8279630",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011743","Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET.","Deden LN","2021","Brain sciences","other","article","10.3390/brainsci11121647","34942949","PMC8699257",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011744","Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study.","Chan RNC","2022","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvac138","36267596","PMC9562787",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011745","Pancreaticobiliary side effects of GLP-1 agonists: a meta-analysis of published randomized control trials and a real-world pharmacovigilance profile.","Hughes A","2026","The British journal of surgery","systematic_review","article","10.1093/bjs/znag022","41783935",null,"PROSPERO:CRD420251018806",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0011746","Prescriber Uncertainty as Opportunity to Improve Care of Type 2 Diabetes with Chronic Kidney Disease: Mixed Methods Study.","Flory JH","2023","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-022-07838-1","36316625","PMC10160326",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0011747","A scoping review on weight loss injections and eating disorders: therapeutic impact, risks of misuse, and emerging harms.","Barrett P","2026","Journal of eating disorders","nonrandomized_study","article","10.1186/s40337-026-01634-6","42324477","PMC13491749",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0011748","Patients taking GLP-1 agonists for weight-loss prior to posterior lumbar decompression and fusion have similar surgical and patient-reported outcomes.","Baidya J","2026","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","other","article","10.1007/s00586-026-09849-6","41801400",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011749","GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.","Castellana M","2019","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.3082","30270567",null,"PROSPERO:CRD42017079547",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0011750","The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as a Type of Conservative Treatment of Endometrial Cancer in Women of Reproductive Age: A Review of the Literature and a Call for Study.","Bourou MZ","2024","Cureus","narrative_review","article","10.7759/cureus.69678","39429275","PMC11489137",null,"S000735","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0011751","Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.","McKay NJ","2011","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00472.2011","21975647","PMC3233845",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0011752","An Online, Multi-institutional Debate on Diabetes Medications by Advanced Pharmacy Practice Experience Students.","Hess R","2023","American journal of pharmaceutical education","other","article","10.5688/ajpe8815","35042682","PMC10159597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0011753","Indeed, safety comes first for the use of GLP-1RAs.","Pathare ADS","2025","Acta obstetricia et gynecologica Scandinavica","commentary","article","10.1111/aogs.15090","39991992","PMC11981097",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0011754","Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.","Odawara M","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12602","26661514","PMC5064615",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011755","New Horizons in Metabolic Health: Unveiling the Future of Drug Discovery and Development.","Zhao J","2026","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/0118715303453651260321115118","42003658","PMC13598739",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; review-article; article"],["R0011756","Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff.","Liu B","2025","Scientific reports","other","article","10.1038/s41598-025-96545-y","40185826","PMC11971348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011757","Obesity and Mental Health: A Missing Piece in the Puzzle.","Fonseca NKOD","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","other","article","10.1111/obr.70205","42567717",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011758","Neovascular Age-Related Macular Degeneration and GLP-1 RAs.","Ziemssen F","2025","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2025.3711","41129165",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011759","Successful Resolution of Glucose Toxicity With the Use of Fixed-Ratio Combination Injection of Basal Insulin and Short-Acting Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist.","Miura H","2022","Cureus","case_report","article","10.7759/cureus.25889","35844351","PMC9277572",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011760","Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review.","Yammine L","2019","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2019.01.033","30735771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011761","Prescription Patterns for GLP-1 Receptor Agonists and SGLT2 Inhibitors by Physicians' Years in Practice.","Inoue K","2025","Journal of general internal medicine","commentary","article","10.1007/s11606-025-09380-2","39843667","PMC12405120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0011762","GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients.","Adeghate EA","2024","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2024.2328796","38458647",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0011763","Basal Insulin and GLP-1 Receptor Agonist Combination Therapy in Frail Older Inpatients: A Real-World Observational Study.","Niccolai F","2025","Drugs & aging","nonrandomized_study","article","10.1007/s40266-025-01241-1","40782292",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0011764","Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study.","Lavens A","2024","Diabetologia","nonrandomized_study","article","10.1007/s00125-024-06273-7","39271516","PMC11604828",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011765","Epidemiology of hypoglycaemia : trends, risk factors and outcomes","Zaccardi F","2018","University of Leicester","randomized_trial","article",null,null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Dissertation; dissertation"],["R0011766","Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.","Mari A","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12671","27059816",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011767","Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs.","Zelniker TA","2019","Cardiac failure review","other_trial","article","10.15420/cfr.2018.44.1","30847242","PMC6396066",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0011768","Characterization of Peptide-Preservative Interaction and Reversibility by NMR Spectroscopy.","Xie D","2025","Molecular pharmaceutics","other","article","10.1021/acs.molpharmaceut.5c00448","41092029",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011769","Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.","Scheen AJ","2016","Expert review of clinical pharmacology","other_trial","article","10.1586/17512433.2016.1141046","26761217",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Comparative Study; Journal Article; article"],["R0011770","Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism.","Hansford R","2025","Cell metabolism","preclinical","article","10.1016/j.cmet.2025.07.009","40812310","PMC7619446",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011771","CNS-PENETRANT NLRP3 INHIBITOR ACHIEVES DURABLE WEIGHT LOSS AND REVERSES HYPOTHALAMIC INFLAMMATION IN DIET-INDUCED OBESITY","Guo J","2025","bioRxiv","preclinical","preprint","10.1101/2025.10.06.680810",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011772","Neovascular Age-Related Macular Degeneration and GLP-1 RAs.","Feldman-Billard S","2025","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2025.3717","41129172",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011773","Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.","Al Yami MS","2018","Heart, lung & circulation","systematic_review","article","10.1016/j.hlc.2018.03.018","29887418",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0011774","Comparative effectiveness of subcutaneous GLP-1 receptor agonists versus SGLT2 inhibitors on metabolic and hepatic outcomes in T2DM with MASLD: a propensity score-matched study.","Toffoli B","2026","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-026-02976-3","42440238","PMC13627211",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0011775","Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis.","Diallo A","2022","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2022.101697","36263397","PMC9574412","PROSPERO:CRD42022347901",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0011776","Neovascular Age-Related Macular Degeneration and GLP-1 RAs.","Alkabbani W","2025","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2025.3720","41129178",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011777","Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice.","Augestad IL","2022","British journal of pharmacology","other_trial","article","10.1111/bph.15524","33973246","PMC8820185",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011778","Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists?","Kannan S","2015","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.81a.13066","25932736",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011779","The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin.","Ozatik FY","2025","Journal of molecular histology","randomized_trial","article","10.1007/s10735-025-10440-4","40341588",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0011780","Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study.","Hejjaji V","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14745","35546275",null,"ClinicalTrials.gov:NCT02322762; ClinicalTrials.gov:NCT02226822",null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; article"],["R0011781","Glp-1 receptor agonists: A boon for kidney transplant recipients?","Pullen LC","2025","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","nonrandomized_study","article","10.1016/j.ajt.2025.05.032","40447260",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0011782","Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways.","AlAsmari AF","2020","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","preclinical","article","10.1016/j.jsps.2020.03.002","32273812","PMC7132601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011783","Neovascular Age-Related Macular Degeneration and GLP-1 RAs.","Mammo DA","2025","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2025.3714","41129166",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011784","Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: A systematic review and network meta-analysis of randomized controlled trials.","Zheng H","2022","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.3515","34951928",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0011785","Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers-A Pilot Study.","Bułdak Ł","2024","Metabolites","preclinical","article","10.3390/metabo14100554","39452935","PMC11509483",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011786","Effect of GLP-1 agonist initiation on remotely monitored pulmonary arterial pressures in patients with heart failure.","Lanier A","2025","ESC heart failure","commentary","article","10.1002/ehf2.70015","41213801","PMC12719800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0011787","Arterial hypertension - Clinical trials update 2021.","Al Ghorani H","2022","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2021.09.007","34690044","PMC8444354",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review; review-article"],["R0011788","Question: Do GLP-1 and Dual GIP/GLP-1 Agonists Interact With Lithium, and What Are the Monitoring Implications?","Leung JG","2026","Journal of clinical psychopharmacology","other","article","10.1097/jcp.0000000000002138","41676881",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0011789","Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease.","Escott GM","2021","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2020.107774","33168397",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0011790","Assessing Predictive Performance of Fibrosis-4 Index in Settings With Lower Prevalence of Liver Fibrosis.","Rinella ME","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2025.12.014","41448477",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0011791","Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes.","Tran DT","2024","Diabetology & metabolic syndrome","preclinical","article","10.1186/s13098-024-01525-3","39582036","PMC11587750",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0011792","Exendin-4 Protects Human Retinal Pigment Epithelial Cells from H2O2-Induced Oxidative Damage via Activation of NRF2 Signaling.","Cui R","2020","Ophthalmic research","other","article","10.1159/000504891","31865348",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011793","Hypertension in diabetes care: emerging roles of recent hypoglycemic agents.","Tanaka A","2021","Hypertension research : official journal of the Japanese Society of Hypertension","narrative_review","article","10.1038/s41440-021-00665-7","33990790",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011794","Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes.","Greig SL","2015","Drugs","other_trial","article","10.1007/s40265-015-0448-0","26242767",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0011795","GLP-1 receptor agonists: MHRA to study possible side effects after acute pancreatitis cases.","O'Dowd A","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r1344","40578853",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0011796","GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model.","Jing F","2023","Neuroscience letters","preclinical","article","10.1016/j.neulet.2023.137397","37442520",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011797","Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.","Vijiaratnam N","2025","Annals of neurology","randomized_trial","article","10.1002/ana.70004","40727970","PMC12577669",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011798","Novel management of diabetes in kidney transplantation.","Ong SC","2021","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000000665","33186216",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; article"],["R0011799","Targeting Obesity for Heart Failure.","Morris E","2025","European cardiology","narrative_review","article","10.15420/ecr.2025.37","41523265","PMC12784267",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011800","The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime?","De Fano M","2023","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2023.110828","37481116",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011801","Liraglutide improves depressive and cognitive deficits in a high-fat diet rat model of obesity: the role of hippocampal autophagy and the PI3K/Akt/mTOR pathway.","Magdy YM","2025","Psychopharmacology","preclinical","article","10.1007/s00213-025-06834-7","40526304","PMC12675702",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011802","Advances in the treatment of type 2 diabetes: impact of dulaglutide.","Thompson AM","2016","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s75452","27217788","PMC4861603",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011803","Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.","Kumarathurai P","2017","Journal of hypertension","randomized_trial","article","10.1097/hjh.0000000000001275","28129251",null,"ClinicalTrials.gov:NCT01595789","S001197","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0011804","Molecular dynamics insights into the binding interactions of semaglutide with human serum albumin.","Liu Y","2026","Journal of biomolecular structure & dynamics","other","article","10.1080/07391102.2025.2532848","40720332",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011805","Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception.","Wespiser M","2026","Cancer treatment reviews","randomized_trial","article","10.1016/j.ctrv.2026.103200","42556070",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0011806","Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management.","Gallo G","2024","Nutrients","narrative_review","article","10.3390/nu16162781","39203917","PMC11356794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011807","Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin.","Mayyas F","2025","Life sciences","preclinical","article","10.1016/j.lfs.2025.123721","40389022",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0011808","Long-Term Effect of Semaglutide on the Glomerular Filtration Rate Slope in High-Risk Patients with Diabetic Nephropathy: Analysis in Real-World Clinical Practice.","Luna E","2025","Pharmaceutics","nonrandomized_study","article","10.3390/pharmaceutics17070943","40733151","PMC12298743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0011809","The association between GLP-1R expression and cardiovascular-kidney-metabolic-related diseases in non-diabetic and non-obese population: evidence triangulation using Mendelian randomization, observational and polygenic score association analysis.","Chen Z","2026","BMC medicine","nonrandomized_study","article","10.1186/s12916-026-04888-8","42192387","PMC13471553",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0011810","WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.","Lovshin JA","2017","Canadian journal of diabetes","other","article","10.1016/j.jcjd.2017.02.003","28392300",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011811","Ensuring safety first: GLP-1RAs in reproductive and endometrial research.","Viganò P","2025","Acta obstetricia et gynecologica Scandinavica","commentary","article","10.1111/aogs.15060","39989374","PMC11981093",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0011812","Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.","Wang XC","2014","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v20.i40.14821","25356042","PMC4209545",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011813","Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP-1 Agonists and Thyroid Cancer.","Watts E","2026","Clinical endocrinology","other","article","10.1111/cen.70084","41423434","PMC13040510",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0011814","Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists?","Doggrell SA","2015","Expert opinion on drug safety","commentary","article","10.1517/14740338.2015.1034106","25891299",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0011815","Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.","Zagaroli L","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-026-01884-2","42295651","PMC13388877",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0011816","Novel mono-lipidated dimeric glucagon-like peptide-1 receptor agonist with improved long-acting and hypoglycemic activity.","Sun L","2019","RSC advances","preclinical","article","10.1039/c9ra00833k","35520704","PMC9062351",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011817","Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.","Wang X","2020","American journal of nephrology","randomized_trial","article","10.1159/000510255","32966971","PMC7677996",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011818","Current issues in GLP-1 receptor agonist therapy for type 2 diabetes.","Bloomgarden ZT","2012","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.4158/ep12300.ra","23315305",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011819","Semaglutide: A Novel Oral Glucagon-Like Peptide Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.","Chan M","2021","Cardiology in review","other","article","10.1097/crd.0000000000000351","32897887",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011820","Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease.","Verma A","2024","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2024.176936","39182542",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011821","[Heart and diabetes : What is the importance of GLP-1 receptor agonists in cardiology?].","Moellmann J","2022","Herz","narrative_review","article","10.1007/s00059-022-05130-w","35857081",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011822","The Role of GLP-1 Agonists in Psoriatic Arthritis: Erratum.","Gilbert N","2026","American journal of therapeutics","other","article","10.1097/mjt.0000000000002083","41505168",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; erratum"],["R0011823","Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related Glomerulopathy.","He J","2017","Metabolic syndrome and related disorders","preclinical","article","10.1089/met.2017.0057","28737448","PMC5576269",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011824","GLP-1 receptor agonist therapy for relapsed diabetes following 6q24-related transient neonatal diabetes due to paternal uniparental disomy: A case report.","Giangreco F","2025","Diabetes, obesity & metabolism","case_report","article","10.1111/dom.70065","40867068",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011825","MON-716 Real-world Weight Loss Observed With Semaglutide And Tirzepatide In Patients With Overweight Or Obesity And Without Type 2 Diabetes",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12543990",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0011826","Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.","Giugliano D","2019","Endocrine","systematic_review","article","10.1007/s12020-019-01931-y","31028667",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review"],["R0011827","Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide.","Steveling EH","2014","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","case_report","article","10.1177/8755122514539462","34860904","PMC5990155",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011828","Dynamic structural analysis-based epitope prediction of Exendin-4 in aqueous solution.","He J","2023","Physical review. E","other","article","10.1103/physreve.108.024403","37723773",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011829","[Incretin-based therapy for treating patients with type 2 diabetes].","Jermendy G","2011","Orvosi hetilap","narrative_review","article","10.1556/oh.2011.29238","22071295",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011830","The \"Real-World\" Effect of Anti-hyperglycemic Drugs on the Development of Chronic Kidney Disease in a Retrospective Cohort of Patients With Incident Diabetes: A Research Letter.","Dahiya A","2025","Canadian journal of kidney health and disease","nonrandomized_study","article","10.1177/20543581251365364","40861172","PMC12374082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0011831","Neovascular Age-Related Macular Degeneration and GLP-1 RAs-Reply.","Shor R","2025","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2025.3723","41129131",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011832","Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes.","Kuo CY","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1880132","42851503","PMC13645759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011833","Therapeutic strategies for diabetic cardiomyopathy: SGLT2 inhibitors, GLP-1 receptor agonists, and beyond.","Pérez-Belmonte LM","2025","Kardiologia polska","other","article","10.33963/v.phj.106670","40485630",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011834","Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.","Hansen MSS","2018","Basic & clinical pharmacology & toxicology","preclinical","article","10.1111/bcpt.12850","28722834",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011835","Liraglutide, GLP-1 receptor agonist, for chronic weight loss.","Moore KG","2016","Expert review of endocrinology & metabolism","other","article","10.1080/17446651.2016.1220295","30058906",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011836","Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.","Mahapatra MK","2022","Pharmaceutical research","preclinical","article","10.1007/s11095-022-03302-1","35650449","PMC9159769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0011837","Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.","Ludwig L","2020","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-020-01034-3","32404155","PMC7222529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; editorial; article"],["R0011838","Person-Centered, Outcomes-Driven Treatment: A New Paradigm for Type 2 Diabetes in Primary Care","Harris SB","2020","American Diabetes Association, Arlington (VA)","narrative_review","article","10.2337/db2020-02","32667763",null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Review; article"],["R0011839","RETRACTION: Effects of GLP-1 Receptor Agonists on Cognitive Function in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials.",null,"2026","Diabetes, obesity & metabolism","notice","article","10.1111/dom.70552","41667890",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retraction Notice; retraction"],["R0011840","Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies.","Home P","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16360","40176458","PMC12046479",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; research-article; review"],["R0011841","GLP-1 Receptor Agonists and Perioperative Care: Reply.","Joshi GP","2025","Anesthesiology","other","article","10.1097/aln.0000000000005428","40358347",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011842","GLP-1 receptor agonists and addiction-related behaviours: A translational perspective.","Kulicka N","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16481","40420600",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011843","Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody.","Zhang Y","2015","Angewandte Chemie (International ed. in English)","preclinical","article","10.1002/anie.201410049","25556336",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011844","GLP-1 Receptor Agonists and Perioperative Care: Comment.","Mizubuti GB","2025","Anesthesiology","other","article","10.1097/aln.0000000000005427","40358346",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011845","Liraglutide promotes osteogenic differentiation of mesenchymal stem cells by inhibiting M1 macrophage polarization and CXCL9 release in vitro.","He Y","2025","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2024.112441","39706561",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011846","Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.","Deacon CF","2012","Diabetes, obesity & metabolism","systematic_review","article","10.1111/j.1463-1326.2012.01603.x","22471248",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0011847","What's next in psoriatic arthritis therapy? A look at the pipeline.","Soriano ER","2026","Current opinion in rheumatology","other_trial","article","10.1097/bor.0000000000001157","41841660",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0011848","The potential role of incretin therapy in the hospital setting.","Macdonald JJ","2015","Clinical diabetes and endocrinology","other","article","10.1186/s40842-015-0005-5","28702223","PMC5469200",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011849","Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line.","Wei Q","2012","Peptides","preclinical","article","10.1016/j.peptides.2012.06.018","22776329",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011850","EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.","European Association for the Study of the Liver","2024","Diabetologia","other","article","10.1007/s00125-024-06196-3","38869512","PMC11519095",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; brief-report; article"],["R0011851","AI-assisted assessment of the IFSO consensus on obesity management medications in the context of metabolic bariatric surgery.","Kermansaravi M","2025","PLOS digital health","other","article","10.1371/journal.pdig.0001132","41417777","PMC12716726",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011852","68Ga-NODAGA-Exendin-4 PET/CT Findings in a Case of Metastatic Insulinoma With Refractory Hypoglycemia Controlled by 90Y Transarterial Radioembolization.","Şahin R","2024","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000005266","38967509",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0011853","GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells.","Takahashi H","2019","Journal of atherosclerosis and thrombosis","preclinical","article","10.5551/jat.43414","29962378","PMC6365156",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011854","Effects of glucagon-like peptide-1 analogue treatment in genetic obesity: A case series.","Welling MS","2021","Clinical obesity","case_report","article","10.1111/cob.12481","34291582","PMC9286843",null,"S000945","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0011855","Hydrogen Sulfide Deficiency and Therapeutic Targeting in Cardiometabolic HFpEF: Evidence for Synergistic Benefit with GLP-1/Glucagon Agonism.","Doiron JE","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.09.16.613349","39345440","PMC11429683",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0011856","Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes.","Murphy BL","2024","Innovations in pharmacy","nonrandomized_study","article","10.24926/iip.v15i4.6432","40401295","PMC12090087",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011857","Cardiovascular safety and benefits of GLP-1 receptor agonists.","Dalsgaard NB","2017","Expert opinion on drug safety","other","article","10.1080/14740338.2017.1281246","28102093",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011858","Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.","Gao L","2023","Nature medicine","randomized_trial","article","10.1038/s41591-023-02344-1","37231074",null,"ClinicalTrials.gov:NCT04093752","S000909","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011859","Comment on \"Glycated hemoglobin and body mass index as mediators of GLP-1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes\".","Zhu X","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","commentary","article","10.1002/alz.70295","40387268","PMC12086988",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0011860","Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.","Howse PM","2016","American journal of kidney diseases : the official journal of the National Kidney Foundation","systematic_review","article","10.1053/j.ajkd.2016.06.014","27528374",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0011861","Increased energy expenditure through intermittent cold exposure does not enhance tirzepatide-induced weight loss in obese mice.","Bellucci A","2026","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00220.2026","42722006",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0011862","The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.","Ruan Z","2021","Expert review of pharmacoeconomics & outcomes research","systematic_review","article","10.1080/14737167.2021.1860022","33317348",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Comparative Study; Journal Article; Systematic Review; review"],["R0011863","Evaluating Cardio-Protective Molecules by Efficacy Based on Weight Reduction and HbA1c Targets.","Salmen T","2025","Biomedicines","nonrandomized_study","article","10.3390/biomedicines13092306","41007868","PMC12467376",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011864","Cancer risk with GLP-1RA: what can real-world data really tell us?","Jessen N","2025","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2025.101383","40704041","PMC12284705",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; discussion; article"],["R0011865","Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.","Al-Zaid B","2026","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2026.178805","41905447",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0011866","An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption.","Kyriakos G","2022","Cureus","case_report","article","10.7759/cureus.21536","35223310","PMC8864188",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011867","Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?","Binet Q","2022","Acta gastro-enterologica Belgica","systematic_review","article","10.51821/85.2.9775","35709779",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; article"],["R0011868","A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.","Chiu WY","2012","Experimental diabetes research","nonrandomized_study","article","10.1155/2012/924168","22693487","PMC3368340",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0011869","The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes.","Thomas MC","2023","Cell metabolism","narrative_review","article","10.1016/j.cmet.2023.01.004","36754019",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0011870","Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists.","Dubois-Laforgue D","2014","Diabetes research and clinical practice","case_report","article","10.1016/j.diabres.2013.11.014","24447807",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0011871","Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal.","Torre C","2020","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.14168","31692117",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011872","Cotadutide reversible self-assembly based long-acting injectable depot for sustained delivery of GLP-1 glucagon receptor agonists with controlled burst release.","Yang B","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.01.064","39875074",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011873","Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.","Ji L","2021","Diabetologia","randomized_trial","article","10.1007/s00125-021-05392-9","33687487","PMC8012337","ClinicalTrials.gov:NCT03520972","S002761","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011874","ASSESSING GEROTHERAPEUTIC POTENTIAL OF GLP-1 RECEPTOR AGONISTS",null,"2024","Innovation in aging","other","article",null,null,"PMC11689768",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011875","Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.","Davies MJ","2016","PharmacoEconomics","nonrandomized_study","article","10.1007/s40273-016-0433-9","27438706",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011876","Echoes of Dormancy: Anomic Aphasia Unveils Neurocysticercosis Reactivation in a Patient on Semaglutide.","Osorio Borjas M","2025","NeuroSci","case_report","article","10.3390/neurosci6020040","40407613","PMC12101238",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011877","GLP-1 receptor agonists in alcohol use disorder and alcohol-associated liver disease.","Singal AK","2025","The lancet. Gastroenterology & hepatology","other","article","10.1016/s2468-1253(25)00134-7","40482663",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011878","Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register.","Lim LL","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14865","36082513","PMC10087907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011879","Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis.","Calvarysky B","2026","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.70116","41392524","PMC12703130",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011880","Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.","Ayesh H","2024","Biomedicines","systematic_review","article","10.3390/biomedicines12091943","39335457","PMC11428590",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0011881","Low long-term persistence with GLP-1 receptor agonists treatment: Real-world evidence from a large Polish cohort.","Siudak Z","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16590","40620195",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Letter; article"],["R0011882","Corrigendum to: Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus: A Narrative Review.","Tiwari RK","2026","Current diabetes reviews","narrative_review","article","10.2174/157339982209260506141308","42453024",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; erratum"],["R0011883","Predicting treatment response to GLP-1 receptor agonists: still tossing the coin or doing better?","Apostolopoulou M","2025","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2025.2517802","40476563",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0011884","Confronting the Global Rise of Obesity and Cardiovascular Disease: The Role of GLP-1 RAs.","Spatz ES","2025","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2025.09.1599","41298033",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0011885","A Systems Pharmacology Model of Ageing Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health","Goryanin I","2026","medRxiv","other","preprint","10.64898/2026.04.22.26351392",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011886","[The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?].","Ritz C","2017","Revue medicale suisse","other","article",null,"28639755",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011887","Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.","Zhou Y","2020","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.3223","31642583",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Review; article"],["R0011888","[From the discovery of incretin hormones to GIP / GLP-1 / glucagon double and triple agonists].","Phan F","2024","Medecine sciences : M/S","narrative_review","article","10.1051/medsci/2024153","39656981",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Historical Article; English Abstract; article"],["R0011889","The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.","Arnott C","2021","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14386","33769679",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011890","The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.","Kuhre RE","2025","EBioMedicine","preclinical","article","10.1016/j.ebiom.2025.105862","40706446","PMC12309853",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011891","Considerations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Isotretinoin.","Zhu H","2025","Journal of drugs in dermatology : JDD","other","article",null,"40465493",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011892","Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.","Bruen R","2019","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.119.258343","31270216",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011893","Urinary incontinence in US adults aged ≥55 years with type 2 diabetes and indications for SGLT2is: NHANES 2013-2020.","Lee AK","2025","BMJ open diabetes research & care","other","article","10.1136/bmjdrc-2025-004929","40750119","PMC12314932",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011894","Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients.","Rigato M","2020","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgaa178","32271381",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0011895","Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice.","Warden BA","2021","American journal of preventive cardiology","nonrandomized_study","article","10.1016/j.ajpc.2020.100144","34327487","PMC8315383",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011896","The Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in China: Results from the Cross-Sectional CAPTURE Study.","Hong T","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-022-01243-x","35312971","PMC9076769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011897","Perioperative management of patients on GLP-1 receptor agonist treatment: Risks and recommendations.","Simón Polo E","2025","Revista espanola de anestesiologia y reanimacion","commentary","article","10.1016/j.redare.2025.501859","40553819",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011898","Cardiorenal outcomes and mortality with GLP-1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta-analysis.","Neves JS","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16603","40654219",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; review"],["R0011899","Glucagon‑like peptide‑1 analogue exendin‑4 modulates serotonin transporter expression in intestinal epithelial cells.","Cui X","2020","Molecular medicine reports","preclinical","article","10.3892/mmr.2020.10976","32319618","PMC7057813",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011900","Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge.","Dicembrini I","2019","Nutrition, metabolism, and cardiovascular diseases : NMCD","other_trial","article","10.1016/j.numecd.2018.12.009","30718142",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0011901","Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.","Miyagawa J","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12534","26179187","PMC5042083",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0011902","[Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].","Avogaro A","2016","Giornale italiano di cardiologia (2006)","other_trial","article","10.1714/2214.23894","27093207",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0011903","New Treatment Options for MASLD Patients with Type 2 Diabetes.","Mega A","2026","Life (Basel, Switzerland)","narrative_review","article","10.3390/life16020254","41752891","PMC12942142",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011904","Discontinuation of Tirzepatide and Semaglutide Prior to Gastric Sleeve Surgery: Clinical Considerations and Guidelines.","Kassir R","2025","Obesity surgery","commentary","article","10.1007/s11695-025-07833-5","40163291",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0011905","A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease.","Poupon-Bejuit L","2022","Scientific reports","other_trial","article","10.1038/s41598-022-17338-1","35970890","PMC9378686",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011906","Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials.","Orme ME","2017","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s116810","28435304","PMC5386609",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0011907","Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database.","Noguchi Y","2018","Journal of pharmaceutical health care and sciences","nonrandomized_study","article","10.1186/s40780-018-0109-z","29946474","PMC6004661",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011908","Screening of GLP-1r agonists from natural products using affinity ultrafiltration screening coupled with UPLC-ESI-Orbitrap-MS technology: a case study of Panax ginseng.","Wang HP","2025","Journal of Asian natural products research","other","article","10.1080/10286020.2024.2378821","39037429",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011909","The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China.","Wang S","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16580","40600464",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0011910","Glucagon-like peptide-1 analog, liraglutide, regulates Sertoli cell energy metabolism.","Dasso ME","2024","The Journal of endocrinology","preclinical","article","10.1530/joe-24-0274","39303739",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011911","PSUN124 Weight Loss from Combination Anti-Obesity Medications Including Glucagon-Like Peptide-1 Receptors Agonists can Approach that Achieved from Bariatric Surgery",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9624763",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011912","OR19-05 Efficacy of Tirzepatide versus Semaglutide in Achieving Therapeutic Targets in Type 2 Diabetes: a post hoc analysis of SURPASS-2 Trial",null,"2025","Journal of the Endocrine Society","other_trial","article",null,null,"PMC12545168",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0011913","[Nonalcoholic Fatty Liver Disease and Weight Loss].","Ping F","2018","Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae","narrative_review","article","10.3881/j.issn.1000-503x.10524","30404689",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011914","The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease.","Maskery M","2020","American journal of Alzheimer's disease and other dementias","preclinical","article","10.1177/1533317520953041","32959677","PMC10623903",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011915","Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases.","Lyons SA","2023","Endocrinology","narrative_review","article","10.1210/endocr/bqad153","37823483","PMC10612476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; review-article; article"],["R0011916","Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.","Kalra S","2014","JPMA. The Journal of the Pakistan Medical Association","narrative_review","article",null,"24864619",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011917","Acute GIP and GLP-1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals.","Krogh LSL","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70940","42225304","PMC13341357","ClinicalTrials.gov:NCT06895408","S002419","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011918","The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes.","McHugh KR","2018","Clinical cardiology","narrative_review","article","10.1002/clc.23054","30125365","PMC6490104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011919","Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review.","de Jong JCBC","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1880500","42528510","PMC13414124","OSF:osf.io/cnw4e",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Scoping Review; systematic-review; article"],["R0011920","High serum Fetuin-B levels are associated with the presence of metabolic syndrome in women: a case-controlled study and interventional studies","Xue S","2020","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-32699/v1",null,null,"ChiCTR:ChiCTR-OCS-13003185",null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0011921","Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020.","Ostrominski JW","2023","JAMA cardiology","nonrandomized_study","article","10.1001/jamacardio.2023.3241","37755728","PMC10535010",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011922","Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes.","Patel KV","2020","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000000762","32649348","PMC8855785",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0011923","Epicardial Adipose Tissue-A Novel Therapeutic Target in Obesity Cardiomyopathy.","Wiszniewski K","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26167963","40869284","PMC12386334",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011924","Examining Off-Label Prescribing of Ozempic for Weight-Loss","Wojtara M","2023","Qeios","other","preprint","10.32388/t6y97s",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0011925","Multiple endocrine neoplasia type 1 with concurrent Cushing's disease, prolactinoma, and multifocal pancreatic neuroendocrine tumors including insulinoma: a case report.","da Silva BT","2026","Upsala journal of medical sciences","case_report","article","10.48101/ujms.v131.14421","42729617","PMC13563435",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011926","Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics.","Cernea S","2020","Drugs","randomized_trial","article","10.1007/s40265-020-01393-x","32930957",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0011927","Psychosocial Outcomes in Telemedicine and Long-Acting Incretin-Specific Behavioral Intervention.","Heinberg LJ","2026","Obesity science & practice","other_trial","article","10.1002/osp4.70149","42256457","PMC13240154",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0011928","Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.","Pillai AA","2026","Cardiology in review","other_trial","article","10.1097/crd.0000000000001310","42108533",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0011929","Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?","van Baar MJB","2020","Current opinion in nephrology and hypertension","other_trial","article","10.1097/mnh.0000000000000559","31714285",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0011930","Tirzepatide","Farzam K","2026","StatPearls Publishing, Treasure Island (FL)","other","article",null,"36251836",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0011931","Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.","von Scholten BJ","2015","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2015.04.004","25935863",null,"ClinicalTrials.gov:NCT01499108","S001811","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011932","Corrigendum to \"GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models\" [Europ. J. Pharmacol. 928 (2022) 175107].","Zhang M","2026","European journal of pharmacology","notice","article","10.1016/j.ejphar.2026.178742","41813513",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0011933","Dose-Dependent Efficacy and Safety of Tirzepatide for Weight Loss in Non-diabetic Adults With Obesity: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Kasagga A","2025","Cureus","systematic_review","article","10.7759/cureus.85531","40630338","PMC12234836",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0011934","Sensitive RP-LC Method Enabling PTM-Specific Quality Control and MS-Compatible Characterization of Fc-Containing GLP-1 Therapeutics.","Xu J","2026","Journal of the American Society for Mass Spectrometry","other","article","10.1021/jasms.6c00052","42087717",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011935","Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).","Takahashi Y","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14998","36722623",null,null,"S002311","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011936","Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis.","Batzias K","2018","Journal of diabetes research","systematic_review","article","10.1155/2018/1232583","30622967","PMC6304901",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0011937","Clarifying the causal contrast: An empirical example applying the prevalent new user study design.","Young JC","2024","Pharmacoepidemiology and drug safety","protocol","article","10.1002/pds.5790","38575389",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0011938","Exploring the off-Label use of liraglutide in the treatment of obesity: a review","Braga CBA","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-6631957/v1",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0011939","Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial.","Ganeshalingam AA","2024","BMJ open","protocol","article","10.1136/bmjopen-2023-077173","38503415","PMC10953037","ClinicalTrials.gov:NCT05193578; EudraCT:2020-004374-22","S001361","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011940","Increased Weight Loss With the Combination of Levoketoconazole and Semaglutide in a Patient With Mild Hypercortisolism.","Kargutkar S","2025","AACE endocrinology and diabetes","case_report","article","10.1016/j.aed.2025.06.009","41048691","PMC12495587",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0011941","Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL.","Gooding KM","2024","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2024.111685","38670496",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0011942","Beyond Endoscopy: A Narrative Review of the Emerging Role of Gastroenterologists in Obesity Medicine, GLP-1 (Glucagon-Like Peptide-1) Therapy, and Metabolic Care.","Alali M","2026","Cureus","narrative_review","article","10.7759/cureus.109979","42382903","PMC13317932",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0011943","Response to \"Letter to the Editor: The effect of GLP-1RAs on mental health and psychotropics induced metabolic disorders: A systematic review\".","Breit S","2025","Psychoneuroendocrinology","systematic_review","article","10.1016/j.psyneuen.2025.107572","40803162",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0011944","The emerging role of GLP-1 receptor agonists in treating or preventing cancer.","Benjamin DJ","2024","Cancer drug resistance (Alhambra, Calif.)","randomized_trial","article","10.20517/cdr.2024.116","39931650","PMC11810457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; other; article"],["R0011945","Noninsulin medication therapy for hospitalized patients with diabetes mellitus.","Petite SE","2018","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","randomized_trial","article","10.2146/ajhp170869","30190293",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0011946","MON-690 Impact of GLP-1 Receptor Agonists on Late Complications Following Bariatric Surgery",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12543649",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011947","Wegovy weight loss pill gets UK approval.","Iacobucci G","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-059332","42285560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011948","Potential Therapeutic Role of GLP-1 Receptor Agonists in the Management of Opioid Use Disorders: A Literature Review.","Bronson S","2025","Addiction & health","narrative_review","article","10.34172/ahj.1682","41431626","PMC12718424",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011949","Affective Destabilisation Associated With Tirzepatide in a Patient With Narcissistic Personality Traits","Rangith G",null,"BJPsych open","other","article",null,null,"PMC13329475",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011950","Eradicating hyperandrogenism? Hormonal changes following Helicobacter pylori eradication in women with polycystic ovary syndrome: an observational case series.","Wutke-Ostręga J","2026","Endokrynologia Polska","nonrandomized_study","article","10.5603/ep.110428","42053337",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0011951","GLP-1 agonists: A hidden challenge for airway management.","Fernández-Vaquero MA","2026","Revista espanola de anestesiologia y reanimacion","commentary","article","10.1016/j.redare.2025.501991","41397668",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0011952","Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs.","Eissa NG","2021","International journal of pharmaceutics","narrative_review","article","10.1016/j.ijpharm.2021.120317","33540005",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0011953","Response to comment on \"Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: A systematic review and meta-analysis of randomized, placebo-controlled trials\".","Kow CS","2025","Sleep medicine","systematic_review","article","10.1016/j.sleep.2025.106709","40795454",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0011954","EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).","European Association for the Study of the Liver (EASL)","2024","Journal of hepatology","other","article","10.1016/j.jhep.2024.04.031","38851997","PMC11299976",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Practice Guideline; other; article"],["R0011955","In adults with T1D and overweight or obesity, adding GLP-1 RAs to insulin reduces weight, HbA1c levels, and insulin dose.","McDonnell DJ","2026","Annals of internal medicine","other","article","10.7326/annals-26-00583-jc","41941730",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011956","Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage.","Yaribeygi H","2019","Life sciences","narrative_review","article","10.1016/j.lfs.2019.06.013","31176776",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011957","Tirzepatide",null,"2006","National Institute of Child Health and Human Development, Bethesda (MD)","narrative_review","article",null,"35759552",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0011958","Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?","Tomlinson JW","2025","The Journal of clinical investigation","preclinical","article","10.1172/jci191822","40519161","PMC12165807",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article-commentary; article"],["R0011959","Glucagon-like peptide-1 receptor agonists and their effects on weight reduction.","Shin SJ","2012","Journal of diabetes investigation","randomized_trial","article","10.1111/j.2040-1124.2012.00241.x","24843612","PMC4015426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article-commentary; article"],["R0011960","Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.","Scheen AJ","2019","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2018.10.003","30477733",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0011961","Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function.","Morita A","2016","Endocrine","preclinical","article","10.1007/s12020-015-0733-4","26349938",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011962","Assessment of the Potential of GLP-1 Analogs in the Treatment of Addictions: A Literature Review.","Noemi Torres I","2026","Substance use & addiction journal","nonrandomized_study","article","10.1177/29767342251351111","40765170",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0011963","A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes.","Yoshida Y","2020","Current diabetes reports","systematic_review","article","10.1007/s11892-020-1292-5","32166504",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0011964","SAT-696 A Comparison of Tirzepatide vs Semaglutide for Weight Reduction over 6 Months of Treatment in Adults with Obesity in US Clinical Practice Settings",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544570",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011965","Azoramide, a novel regulator, favors adipogenesis against osteogenesis through inhibiting the GLP-1 receptor-PKA-β-catenin pathway","Yan Z","2024","Research Square","preclinical","preprint","10.21203/rs.3.rs-4866288/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0011966","Beneficial effects of empagliflozin and liraglutide on the cerebral microcirculation of diabetic rats.","d'Avila JC","2023","Microcirculation (New York, N.Y. : 1994)","preclinical","article","10.1111/micc.12825","37549191",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011967","Unilateral Graves' Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report.","Deto Y","2026","Case reports in endocrinology","case_report","article","10.1155/crie/9628050","42676928","PMC13527387",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0011968","BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.","Giugliano D","2025","Diabetologia","commentary","article","10.1007/s00125-025-06535-y","40877579",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011969","Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial.","Zhang S","2023","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2023.1171399","37214446","PMC10194654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0011970","Utility of Pharmacological Agents for Diabetes Mellitus in the Prevention of Alzheimer's Disease: Comparison of Metformin, Glucagon-Like Peptide-1 (GLP-1) Agonists, Insulin, and Sulfonylureas.","DiGiovanni A","2025","Cureus","nonrandomized_study","article","10.7759/cureus.87350","40761983","PMC12321270",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0011971","Understanding the activation mechanism of GLP-1R/GIPR by dual agonist Tirzepatide via molecular dynamics and protein-peptide binding.","Zou X","2025","International journal of biological macromolecules","other","article","10.1016/j.ijbiomac.2025.146141","40692063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011972","Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.","Lin YH","2024","PloS one","protocol","article","10.1371/journal.pone.0302155","38701096","PMC11068176","ChiCTR:ChiCTR2300070674",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011973","Interpreting GLP-1RA Cost-Effectiveness: A Call for Caution.","Xia Q","2025","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.70036","41047345",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0011974","Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes?-A Review of Intervention Studies.","Uldal S","2022","Nutrients","narrative_review","article","10.3390/nu14112299","35684097","PMC9182892",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011975","Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.","Luna-Marco C","2024","Free radical biology & medicine","narrative_review","article","10.1016/j.freeradbiomed.2024.01.015","38220031",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0011976","Design and fabrication of a mesoporous silica scaffold for oral delivery of peptides.","Mehmood Y","2025","Scientific reports","preclinical","article","10.1038/s41598-025-12728-7","40796593","PMC12343837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011977","GLP-1 Agonists Increase Risk of Surgical Site Infection and Nonunion in Patients Undergoing Operative Fixation of Ankle Fractures",null,"2025","Foot & ankle orthopaedics","other","article",null,null,"PMC12743756",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011978","Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options.","Cesaro A","2023","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2023.1187735","37576108","PMC10421666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011979","GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort study.","Chou PP","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","nonrandomized_study","article","10.1111/jdv.20874","40693677",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0011980","GLP-1 Agonist Receptor Associated Gastric Sarcina ventriculi Infection.","Mesquita P","2026","Digestive diseases and sciences","other","article","10.1007/s10620-026-09676-1","41545745",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011981","Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation.","Wang A","2019","Pharmaceutical development and technology","preclinical","article","10.1080/10837450.2019.1651857","31368418",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011982","Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.","Buse JB","2020","Diabetes care","other_trial","article","10.2337/dc19-2251","32366578","PMC7305014","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0011983","OR09-05 Perioperative Weight Loss With GLP-1 Receptor Agonists in Patients Receiving Bariatric Surgery",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545351",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0011984","Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials.","Giugliano D","2019","Journal of the American Heart Association","systematic_review","article","10.1161/jaha.119.012356","31166153","PMC6645638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review-article; review"],["R0011985","Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.","Bergman BK","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16337","40083081","PMC12046485",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0011986","Intensification patterns and the probability of HbA1c goal attainment in Type 2 diabetes mellitus: real-world evidence for the concept of 'intensification inertia'.","Pantalone KM","2020","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.13900","30653705",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0011987","\"Ozempic Face\": An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)-Our Experience.","Catalfamo L","2025","Journal of clinical medicine","other","article","10.3390/jcm14155269","40806889","PMC12346945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011988","Top 20 Research Studies of 2024 for Primary Care Physicians.","Grad R","2025","American family physician","other_trial","article",null,"40736492",null,null,null,"pubmed; europepmc","FALSE","no_doi","5",null,"Journal Article; Review"],["R0011989","Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.","Kiyosue A","2018","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12759","28984041","PMC6031500",null,"S000233","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0011990","GLP-1 receptor agonist exenatide restores atypical antipsychotic clozapine treatment-associated glucose dysregulation and damage of pancreatic islet beta cells in mice.","Hsu BR","2016","Toxicology reports","preclinical","article","10.1016/j.toxrep.2016.04.005","28959568","PMC5615926",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011991","Tirzepatide attenuates cardiac microvascular injury and ferroptosis-related lipid peroxidation in diabetic mice: endothelial responses in the context of partial PRKN silencing.","Lu G","2026","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2026.179387","42826814",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0011992","GLP-1RA in the Real World: 1-year Compliance and Outcomes of Semaglutide use in Patients With or Without Previous History of Bariatric Surgery.","Medhati P","2025","Annals of surgery","nonrandomized_study","article","10.1097/sla.0000000000006748","40334053",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0011993","BAF60a-dependent chromatin remodeling preserves β cell function and contributes to the therapeutic benefits of GLP-1R agonists.","Qiu X","2025","The Journal of clinical investigation","preclinical","article","10.1172/jci177980","41052246","PMC12646663",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0011994","GLP-1 receptor agonists and MASLD in diabetes: A promising path?","Pennisi G","2025","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2025.109041","40288935",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0011995","Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling Pathway.","Tong G","2022","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2022.901559","36034798","PMC9399678",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011996","Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.","Lei S","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.176419","38360293",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0011997","Mendelian randomization study of GLP-1R effects on ovarian cancer subtypes mediated by metabolic factors.","Liu J","2026","Communications medicine","other","article","10.1038/s43856-026-01379-y","41526703","PMC12901151",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0011998","Mechanisms underlying cognitive impairment and management strategies in type 2 diabetes.","Chen X","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1655768","41169480","PMC12568408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0011999","Letter to the Editor: \"GLP-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery: A Study Among Over 15,000 Patients\" by Wiener et al.","Dai L","2026","Spine","commentary","article","10.1097/brs.0000000000005468","40726444",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0012000","Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.","Gammoh O","2025","Molecular biology reports","narrative_review","article","10.1007/s11033-025-10641-w","40471368","PMC12141419",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012001","Functional-vs-Cognitive Decline Heterogeneity in Alzheimer’s Disease: LLM-Curation of Decades of Clinical Notes and GLP1RA Trial Design","Murugadoss K","2026","Preprints.org","other_trial","preprint","10.20944/preprints202606.0711.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","5","FALSE","Preprint; preprint"],["R0012002","Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.","Athyros VG","2020","Current vascular pharmacology","randomized_trial","article","10.2174/1570161117666190405164313","30961499",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0012003","Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists.","Kang YM","2016","Endocrinology and metabolism (Seoul, Korea)","randomized_trial","article","10.3803/enm.2016.31.2.258","27118277","PMC4923410",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012004","The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes.","Khalid SI","2025","Clinical neurology and neurosurgery","nonrandomized_study","article","10.1016/j.clineuro.2025.108952","40381509",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0012005","Effectiveness of liraglutide in the treatment of adolescent obesity.","Ruiz Pons M","2025","Anales de pediatria","nonrandomized_study","article","10.1016/j.anpede.2025.503856","40645873",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0012006","Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?","Ferrannini E","2021","Diabetes care","randomized_trial","article","10.2337/dc20-0913","33608325","PMC7896267",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; discussion; article"],["R0012007","Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice.","Sun L","2025","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2025.1562896","40552153","PMC12183439",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012008","Mazdutide Ameliorates Non-Alcoholic Fatty Liver Disease by Modulating Endoplasmic Reticulum Stress","Gan L","2026","Preprints.org","preclinical","preprint","10.20944/preprints202601.1103.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012009","Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment.","Mohan V","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-019-00733-9","31773420","PMC6965543",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012010","Behavioral Changes Following Tirzepatide Treatment in Prader–Willi Syndrome: A Case Report","Pavesic Radonja A",null,"European psychiatry : the journal of the Association of European Psychiatrists","case_report","article",null,null,"PMC13443067",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012011","Exendin-4 protects HUVECs from tunicamycin-induced apoptosis via inhibiting the IRE1a/JNK/caspase-3 pathway.","Wu L","2017","Endocrine","other","article","10.1007/s12020-016-1190-4","27915415",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012012","Ten Top Tips for the Management of GLP-1 Receptor Agonists in Adults within Primary Care.","Dobbie LJ","2025","Obesity facts","commentary","article","10.1159/000546472","40388902","PMC12194299",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; other; article"],["R0012013","Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance.","Zeigler Z","2026","Healthcare (Basel, Switzerland)","randomized_trial","article","10.3390/healthcare14152345","42588312","PMC13464992",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0012014","GLP-1 receptor agonist use during hospitalisation: Better glycaemic control compared to premixed insulin.","Jervis M","2022","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.3574","36052434",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Observational Study; Journal Article; article"],["R0012015","Unveiling the Hidden: Dissecting Liraglutide Oligomerization Dual Pathways via Direct Mass Technology, Electron-Capture Dissociation, and Molecular Dynamics.","Kuo ST","2025","bioRxiv : the preprint server for biology","other","article","10.1101/2025.02.27.640645","40093118","PMC11908122",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0012016","A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design.","Davidy T","2024","Mechanisms of ageing and development","protocol","article","10.1016/j.mad.2023.111898","38159613",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Clinical Trial Protocol; Research Support, Non-U.S. Gov't; article"],["R0012017","Elevated Circulating Fetuin-B Levels Are Associated with Insulin Resistance and Reduced by GLP-1RA in Newly Diagnosed PCOS Women.","Mokou M","2020","Mediators of inflammation","other_trial","article","10.1155/2020/2483435","33061822","PMC7545451","ChiCTR:ChiCTR-IIR-16007901",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012018","The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.","Somm E","2021","Translational research : the journal of laboratory and clinical medicine","preclinical","article","10.1016/j.trsl.2020.07.008","32711187",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012019","Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study.","Szépkúti S","2022","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-022-01139-8","36104712","PMC9476268",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0012020","[Pharmacological management of non-insulin-treated type 2 diabetes: practical implementation of HAS guidelines].","Hadjadj H","2025","La Revue du praticien","other","article",null,"41575133",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0012021","Blocking A1 astrocyte conversion with semaglutide attenuates blood-brain barrier disruption in mice after middle cerebral artery occlusion","Zhang Q","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-434590/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012022","Concerns regarding \"GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes\".","Weng CH","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70293","41236181",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012023","Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide).","Tang Y","2025","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2025.151967","40398094",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012024","The GLP-1R Agonist Exendin-4 Attenuates Hyperglycemia-Induced Chemoresistance in Human Endometrial Cancer Cells Through ROS-Mediated Mitochondrial Pathway.","Zhang Y","2021","Frontiers in oncology","other","article","10.3389/fonc.2021.793530","34988025","PMC8721044",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012025","The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery.","Wang X","2025","Clinical endocrinology","other_trial","article","10.1111/cen.15262","40432243",null,"ChiCTR:ChiCTR2400094933",null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0012026","Statement of Clarification—Reid TS: Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care. Clinical Diabetes 31:148–157, 2013. DOI: 10.2337/diaclin.31.4.148","Tim Reid","2014","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/diaclin.32.2.58",null,"PMC4485247",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","correction; Corrected and Republished Article; article"],["R0012027","Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study.","Lin TK","2022","Frontiers in cardiovascular medicine","nonrandomized_study","article","10.3389/fcvm.2022.966708","36035934","PMC9406283",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012028","Uveitis Risk and GLP-1RA Use-Signal, Confounding, or Both?","Toy BC","2025","JAMA ophthalmology","commentary","article","10.1001/jamaophthalmol.2025.2824","40875214",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0012029","Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice.","Bohne LJ","2023","JACC. Basic to translational science","preclinical","article","10.1016/j.jacbts.2023.01.005","37719430","PMC10504404",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012030","Development of Flow-NMR Spectroscopy for Real-Time Monitoring and Kinetics Studies of Biomolecules: Case Study of Liraglutide Oligomerization.","Xu X","2025","Analytical chemistry","other","article","10.1021/acs.analchem.4c06988","40230214",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012031","Observation of unique stable nano-assemblies of a lipidated glucagon-like peptide 1 analogue.","Prada Brichtova E","2025","Soft matter","other","article","10.1039/d5sm00801h","41251522",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012032","SGLT2 inhibitor, GLP-1 receptor agonist, and dementia risk.","Lai SW","2025","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2025.101663","40360024",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012033","Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.","Yoon JH","2018","Scientific reports","systematic_review","article","10.1038/s41598-018-22443-1","29511288","PMC5840350",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; research-article; article"],["R0012034","Methodological and statistical inconsistencies compromise the efficacy and safety analyses of orforglipron.","Imran R","2026","Acta diabetologica","commentary","article","10.1007/s00592-026-02696-3","41984238",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012035","Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide.","Katz BJ","2025","JAMA ophthalmology","nonrandomized_study","article","10.1001/jamaophthalmol.2024.6058","39883468","PMC11783245",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012036","Design of a Dual Agonist of Exendin-4 and FGF21 as a Potential Treatment for Type 2 Diabetes Mellitus and Obesity.","Zhang C","2023","Iranian journal of pharmaceutical research : IJPR","preclinical","article","10.5812/ijpr-131015","38116563","PMC10728834",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012037","[Novel antidiabetic drugs and cardiovascular complications].","Pareek M","2018","Ugeskrift for laeger","randomized_trial","article",null,"29429477",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Review; article"],["R0012038","Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept.","Varadhan L","2022","Clinical drug investigation","other_trial","article","10.1007/s40261-021-01105-7","35107773","PMC8809249",null,null,"pubmed; europepmc","TRUE","open_europepmc","5",null,"Journal Article; Review; review-article"],["R0012039","GLP-1 receptor agonists: a magic bullet for obesity?","The Lancet Regional Health-Western Pacific","2024","The Lancet regional health. Western Pacific","commentary","article","10.1016/j.lanwpc.2024.101233","39526176","PMC11549520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0012040","MON-037 GLP-1 Receptor Agonists in MEN1-Associated Glucagonoma: Exploring Glycemic Control and Tumor Stability",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545935",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012041","GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction: Meta-Analysis of Randomized Clinical Trials.","Neves JS","2025","JACC. Heart failure","systematic_review","article","10.1016/j.jchf.2025.03.035","40434323",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; article"],["R0012042","The Role of GLP-1 Receptor Agonists in Heart Failure: Promise and Unanswered Questions.","Farkouh ME","2025","JACC. Heart failure","commentary","article","10.1016/j.jchf.2025.02.014","40335228",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0012043","Ibero-American position statement on therapeutic recommendations for the preventive management of cardiovascular complications in latin-American patients with type 2 diabetes mellitus: consensus of the prevention council of the inter-American society of cardiology (SIAC-PREVENT).","Wyss F","2026","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-026-02157-5","41968371","PMC13214458",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012044","Current and future therapies for type 1 diabetes.","von Scholten BJ","2021","Diabetologia","narrative_review","article","10.1007/s00125-021-05398-3","33595677","PMC8012324",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012045","Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.","Blonde L","2012","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2012.01575.x","22405266",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0012046","GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?","Santulli G","2025","Future cardiology","commentary","article","10.1080/14796678.2024.2433381","39589856","PMC11812426",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0012047","Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.","Hwang JH","2025","JAMA health forum","other_trial","article","10.1001/jamahealthforum.2024.5586","40085108","PMC11909610",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012048","Modulating Matrix Metalloproteinase Activity in Obesity: Comparative Effects of Bariatric Surgery and GLP-1/GIP-Based Pharmacotherapy.","Wiśniewski K","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14217648","41227041","PMC12608666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; Preprint; preprint; article"],["R0012049","Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer's disease.","Abdulhameed N","2024","Alzheimer's research & therapy","preclinical","article","10.1186/s13195-024-01537-1","39085976","PMC11293113",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; other; article"],["R0012050","SUN-703 Post Bariatric Hypoglycemia Successfully Treated With GLP-1 Receptor Agonist",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544546",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012051","Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.","Ayesh H","2024","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000001743","38976545",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Letter; Comparative Study; review"],["R0012052","Glucagon receptor agonist aggravates a murine model of Balkan nephropathy.","Kanoo S","2026","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00160.2026","42789963",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012053","Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism.","Errafii K","2022","Biomedicines","other","article","10.3390/biomedicines10051020","35625757","PMC9138370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012054","Molecular Biomarkers and Therapeutic Approach of Patients with Diabetes and Obstructive Sleep Apnea.","Elian V","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms262010234","41155523","PMC12564514",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Preprint; review-article; preprint; article"],["R0012055","Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment.","de Boer IH","2020","Kidney international","randomized_trial","article","10.1016/j.kint.2020.06.024","32653403",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Practice Guideline; Journal Article; article"],["R0012056","Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence.","Gale SE","2018","Pharmacotherapy","narrative_review","article","10.1002/phar.2128","29800506",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012057","Changes in glomerular filtration rate in patients with body mass index ≥35 kg/m2 treated with metabolic and bariatric surgery versus GLP-1 agonist at 1-year follow-up.","Henao-Carrillo DC","2024","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.782","39130193","PMC11316517",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012058","The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.","Thazhath SS","2016","Diabetes","randomized_trial","article","10.2337/db15-0893","26470783",null,"ANZCTR:ACTRN12608000428369","S001698; S001709","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012059","Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.","Nathan BM","2016","Clinical obesity","other","article","10.1111/cob.12128","26683756","PMC4721217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0012060","Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis.","Papantoniou P","2025","PharmacoEconomics - open","randomized_trial","article","10.1007/s41669-025-00561-7","39847271","PMC12037448",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0012061","Urinary Glucose Is Mass: A Mass-Balance Critique of the Energy-Centric Explanation for Attenuated Weight Loss in Type 2 Diabetes","Manninen AH","2026","Preprints.org","other","preprint","10.20944/preprints202610.0071.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012062","Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease.","Smilowitz NR","2014","Circulation","narrative_review","article","10.1161/circulationaha.113.006985","24891623",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012063","Semaglutide vs Tirzepatide Dosages for Weight Loss.","Levy ME","2025","JAMA internal medicine","other","article","10.1001/jamainternmed.2024.5768","39585682",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012064","Nutrient-Stimulating Hormone-Based Therapies for Obesity.","Cristancho C","2025","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2024.10.006","39919868",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012065","Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.","Mansouri ES","2026","Journal of the American Heart Association","systematic_review","article","10.1161/jaha.125.044249","42714458",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0012066","Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.","Teng Y","2024","BMC endocrine disorders","systematic_review","article","10.1186/s12902-024-01805-z","39719583","PMC11668020","PROSPERO:CRD42024537006",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Comparative Study; Systematic Review; Network Meta-Analysis; review-article; article"],["R0012067","GLP-1 Receptor Agonist Outcomes, Safety, and Body Mass Index Change in a National Cohort of Patients on Dialysis.","Orandi BJ","2025","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000000750","40526425","PMC12342107",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012068","Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.","Coleman RL","2025","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-025-02866-7","40849664","PMC12374271",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0012069","Trimming the Fat: Does GLP-1 Receptor Agonist Therapy Impact Clinical and Functional Results After Tibial Plateau Fracture Fixation?","Goldstein AR","2026","The journal of knee surgery","nonrandomized_study","article","10.1055/a-2851-0573","41985491",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012070","Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.","Nelson AJ","2022","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2021.48030","35175345","PMC8855234",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0012071","Pharma-cology 101: Educating future prescribers on drug reps, dead drugs, and the hidden scripts of pharmaceutical industry relationships.","Oldani MJ","2026","Social science & medicine (1982)","other","article","10.1016/j.socscimed.2026.118952","41519058",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012072","Pharmacoeconomic Review Report: Insulin glargine + lixisenatide (Soliqua): (Sanofi-Aventis): Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) alone or in combination with metformin",null,"2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"31141327",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0012073","Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients with Semaglutide-Associated Weight Loss.","Garbaccio NC","2025","Aesthetic plastic surgery","systematic_review","article","10.1007/s00266-025-05112-3","40835770",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0012074","Comparing the performance of electrostatic repulsion-reversed phase chromatography approaches in the resolution of complex peptide mixture: Liraglutide as case study.","Manetto S","2025","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","other","article","10.1016/j.ejps.2025.107120","40339761",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0012075","The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.","Franch-Nadal J","2022","Advances in therapy","nonrandomized_study","article","10.1007/s12325-022-02156-8","35553372",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012076","GLP-1 Receptor Agonists-From Breakthroughs in Cardiometabolic Treatment to Emerging Neuroprotective Potential.","Thiara D","2025","JAMA neurology","commentary","article","10.1001/jamaneurol.2025.0237","40193095",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0012077","Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.","Kumar S","2025","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-025-09218-1","40629230",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0012078","Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment.","Panchal R","2023","Journal of managed care & specialty pharmacy","narrative_review","article","10.18553/jmcp.2023.29.2.139","36705280","PMC10387929",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; research-article; article"],["R0012079","A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.","Persson F","2021","Annals of translational medicine","other_trial","article","10.21037/atm-20-4841","33987414","PMC8106054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; review"],["R0012080","Right Ventricular Dysfunction and Exercise Impairment in Patients with Heart Failure, Insulin Resistance, and Diabetes Mellitus: Insights from the T.O.S.CA. Registry (Cardiovascular Diabetology 2022).","Triggiani D","2023","Endocrine, metabolic & immune disorders drug targets","nonrandomized_study","article","10.2174/1871530323666230227113252","36843372",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012081","SUN-343 Is GLP-1 Receptor Agonist Contraindicated In MEN2A Syndrome Despite A Prophylactic Thyroidectomy?",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12546403",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012082","Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes.","Snell-Bergeon JK","2025","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2024.0328","39745353",null,null,"S001837","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0012083","The Discovery and Development of Liraglutide and Semaglutide.","Knudsen LB","2019","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2019.00155","31031702","PMC6474072",null,"S002080","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0012084","Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.","Maiorino MI","2021","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-021-01401-8","34663316","PMC8522255",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; other; article"],["R0012085","New hypoglycaemic therapy in frail older people with diabetes mellitus-phenotypic status likely to be more important than functional status.","Abdelhafiz AH","2020","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2020.108438","32920102",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012086","Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?","Williams DM","2023","Stroke","other_trial","article","10.1161/strokeaha.122.042109","36861476",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0012087","Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.","Li Q","2026","Diabetology & metabolic syndrome","preclinical","article","10.1186/s13098-026-02116-0","41964043","PMC13214175",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012088","Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Cocaine-Mediated Behavior by Inhibiting Toll-Like Receptor 4 Signaling in Mice.","Zhu C","2021","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2021.694476","34349653","PMC8327264",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012089","Semaglutide (Wegovy): Indication: As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: Reimbursement Recommendation",null,"2025","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","other_trial","article",null,"41021710",null,null,null,"europepmc","TRUE","free_to_read","5",null,"Review"],["R0012090","Effects of GLP-1 Receptor Agonist on Glycolipid Metabolism and Micro Inflammatory Status in Patients with Abdominal Obesity and Type 2 Diabetes.","Shao W","2024","Alternative therapies in health and medicine","other","article",null,"38940809",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012091","Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective.","Haluzík M","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00777-2","32144742","PMC7136377",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0012092","[Advances in Anti-Dementia Therapies in Older Adults].","Schnieder M","2026","Deutsche medizinische Wochenschrift (1946)","nonrandomized_study","article","10.1055/a-2676-7649","42214359",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; English Abstract; article"],["R0012093","Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.","Heerspink HJL","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","protocol","article","10.1093/ndt/gfaf230","41160422","PMC13218929","ClinicalTrials.gov:NCT06383390; ClinicalTrials.gov:NCT05936151","S000696; S001365","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0012094","Evaluating the glucagon-like peptide-1 receptor in managing asthma.","Wu AY","2022","Current opinion in allergy and clinical immunology","nonrandomized_study","article","10.1097/aci.0000000000000797","34772827","PMC8842827",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review; research-article; article"],["R0012095","Metabolic rebound and weight cycling following incretin mimetic drug withdrawal: a cause for concern?","Alexander SE","2026","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000001232","42130328",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012096","Exenatide",null,"2006","National Institute of Child Health and Human Development, Bethesda (MD)","narrative_review","article",null,"30000037",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0012097","The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells.","Onuma H","2014","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2014.07.136","25109805",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012098","Prolonged signaling of backbone-modified glucagon-like peptide-1 analogues with diverse receptor trafficking","Cary BP","2024","bioRxiv","other","preprint","10.1101/2024.04.17.589632",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012099","GLP-1 Receptor Agonist Prescribing Practices in a Pediatric Weight Management Program.","Siegel R","2025","Childhood obesity (Print)","nonrandomized_study","article","10.1089/chi.2025.0004","40465478",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012100","Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?","Procacci A","2025","Obesity research & clinical practice","nonrandomized_study","article","10.1016/j.orcp.2025.03.001","40133108",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012101","Drug-induced gastric motility disorders: A disproportionality analysis from the FAERS and CVARD databases.","Qian Z","2026","PloS one","nonrandomized_study","article","10.1371/journal.pone.0351731","42284324","PMC13262828",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012102","Structural Dynamics of GLP-1 Analogues: Folding Energetics, Lipidation-Driven Assembly, and Aggregation Mechanisms.","Santoro A","2026","Molecules (Basel, Switzerland)","narrative_review","article","10.3390/molecules31152556","42588408","PMC13468180",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012103","Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice.","Zhang Y","2021","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2021.781856","34938192","PMC8685428",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012104","Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.","Giorgino F","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13844","31364266","PMC6852007",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0012105","Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.","Shomali ME","2017","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.13185","27412701","PMC5248619",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0012106","Bioengineered Nanomedicines Targeting the Intestinal Fc Receptor Achieve the Improved Glucoregulatory Effect of Semaglutide in a Type 2 Diabetic Mice Model.","Pinto S","2024","ACS nano","preclinical","article","10.1021/acsnano.4c11172","39356547",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012107","Protective effects of melatonin and glucagon-like peptide-1 receptor agonist (liraglutide) on gastric ischaemia-reperfusion injury in high-fat/sucrose-fed rats.","Mubarak HA","2018","Clinical and experimental pharmacology & physiology","preclinical","article","10.1111/1440-1681.12956","29697857",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012108","Orexin 2 receptor Crosstalk with GLP1 receptor reveals dual therapy for improvement of Sleep deprivation-induced obesity:  An Integrated Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation approach","Chhabra V","2025","Research Square","other","preprint","10.21203/rs.3.rs-8183695/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0012109","Cardioprotective effects of semaglutide on isolated human ventricular myocardium.","Krammer T","2025","European journal of heart failure","other","article","10.1002/ejhf.3644","40107718","PMC12370581",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012110","Hypertension after solid-organ transplantation: special considerations for management.","Feliberti J","2025","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000001230","40401425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012111","GLP-1 receptor agonists versus testosterone in male reproductive health: A critical perspective.","Oliveira Torres J","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16404","40259520",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012112","Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-Like Peptide-1 Conjugates.","Han J","2018","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.7b00712","29239601",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012113","Not just obesity: GLP-1 receptor agonists advance on addiction.","Sheridan C","2025","Nature biotechnology","commentary","article","10.1038/s41587-025-02644-6","40229381",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0012114","A Long Way to Find a Small Tumor: The Hunt for an Insulinoma.","Arjunan D","2024","JCEM case reports","case_report","article","10.1210/jcemcr/luae192","39465233","PMC11505447",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0012115","Peri-operative management of Ozempic and other GLP-1 agonists during cosmetic surgery: What plastic surgeons need to know.","Thomson DR","2023","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","other","article","10.1016/j.bjps.2023.10.080","39492251",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012116","Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.","Williams DM","2022","TouchREVIEWS in endocrinology","narrative_review","article","10.17925/ee.2022.18.1.43","35975210","PMC9354511","ClinicalTrials.gov:NCT01272219","S000492","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0012117","Treating latent autoimmune diabetes in adults in the era of cardiovascular outcomes trials: Old dog should learn new tricks.","Koufakis T","2021","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.14496","33306839",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0012118","Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology.","Trivedi K","2026","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2025-0163","41549356",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012119","Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.","Matthews DR","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14143","32691499","PMC7693248","ClinicalTrials.gov:NCT01032629; ClinicalTrials.gov:NCT01989754",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0012120","Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm.","Caturano A","2025","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm43143","41356318","PMC12681021",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012121","Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex-sumo wrestler.","Bade S","2024","Clinical case reports","case_report","article","10.1002/ccr3.9403","39219781","PMC11362018",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0012122","Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.","Naeem M","2024","Health science reports","commentary","article","10.1002/hsr2.1864","38323122","PMC10844714",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter; Journal Article; article"],["R0012123","[Process to insulin for type 2 diabetes mellitus therapy].","Cosmi F","2022","Giornale italiano di cardiologia (2006)","randomized_trial","article","10.1714/3715.37063","34985463",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0012124","Multidisciplinary care of pediatric obesity and its impact on sleep: a review.","Inja R","2025","Frontiers in sleep","narrative_review","article","10.3389/frsle.2025.1634185","41550266","PMC12807914",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012125","Lixisenatide - A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes.","Vidal J","2013","European endocrinology","other_trial","article","10.17925/ee.2013.09.02.76","29922357","PMC6003584",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0012126","Future perspectives of the pharmacological management of diabetic dyslipidemia.","Patti AM","2019","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2019.1567328","30644763",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012127","The Effect of GLP-1RA on the Motor Function of Patients With Parkinson Disease: A Systematic Review and Meta-Analysis.","Ristori Costa G","2025","Neurology. Clinical practice","systematic_review","article","10.1212/cpj.0000000000200548","41089206","PMC12516850",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Review; article"],["R0012128","Meal Replacement Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Severe Obesity.","Rode JB","2026","Childhood obesity (Print)","other_trial","article","10.1177/21532176261457202","42281167",null,"ClinicalTrials.gov:NCT02496611","S001050","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase II; Journal Article; article"],["R0012129","Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.","Shubrook JH","2022","Postgraduate medicine","narrative_review","article","10.1080/00325481.2021.2009726","34817311",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012130","Tradipitant: First Approval.","Lee A","2026","Drugs","other_trial","article","10.1007/s40265-026-02313-1","41945307",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0012131","Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.","Boyle JG","2018","Clinical science (London, England : 1979)","narrative_review","article","10.1042/cs20171299","30115742",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0012132","Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study.","Chen HY","2026","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.64898/2026.01.06.26343548","41542680","PMC12803377",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; Observational Study; research-article; preprint; article"],["R0012133","Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?","Morillas C","2021","International journal of environmental research and public health","other","article","10.3390/ijerph18105388","34070103","PMC8158374",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0012134","Choice of first injectable therapy in type 2 diabetes.","Kalra S","2016","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"27686319",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012135","DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.","Pei Y","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14522","34387411","PMC9291809",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012136","Insulin Dosage Adjustments After Initiation of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes.","Chen M","2022","Journal of pharmacy practice","nonrandomized_study","article","10.1177/0897190021993625","33593125",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012137","Prevalence of Pruritus in Type 2 Diabetic Patients on GLP-1 Agonist Therapy.","Chu D","2026","Journal of drugs in dermatology : JDD","other","article","10.36849/jdd.9647","41493261",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012138","Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.","Sourris KC","2024","Kidney international","preclinical","article","10.1016/j.kint.2023.09.029","38069998",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012139","Effect of Incretin-Based Weight Loss Drugs on Testosterone Concentrations in Men.","Portillo-Canales S","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.01.003","41544705",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0012140","2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide.","Wong MT","2025","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.4c02153","40044142","PMC11956005",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012141","Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis.","Wang S","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-026-01915-y","42803912",null,"ClinicalTrials.gov:NCT06351748","S000366","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0012142","Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity.","Zhang J","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26041651","40004115","PMC11855704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012143","The GLP-1 RA Era - A positive disruptor to the ecological framework of population health.","Pronk NP","2026","Current problems in cardiology","narrative_review","article","10.1016/j.cpcardiol.2025.103210","41242439",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012144","Effect of Liraglutide on Type B Insulin Resistance Syndrome and Insulin Allergy in Type 2 Diabetes: A Case Report.","Matsumoto Y","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","case_report","article","10.1007/s13300-017-0291-2","28836180","PMC5630548",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0012145","Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.","De Block C","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14831","35929488","PMC10087310",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0012146","Mesolimbic exendin-4 attenuates reward salience evoked by neuropeptide Y and ghrelin.","Brigande AM","2023","Behavioural brain research","preclinical","article","10.1016/j.bbr.2022.114249","36496077",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012147","Inhibitory effect of exendin-4 on secretory group IIA phospholipase A2.","Lee W","2015","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2015.02.165","25757907",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012148","Prevalence and Clinical Determinants of Obesity in Adults With Type 1 Diabetes Mellitus: A Single-Center Retrospective Observational Study.","Tsushima Y","2022","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2022.01.008","35091100",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study"],["R0012149","State-of-the-art Medical Therapy Versus Roux-en-Y Gastric Bypass Alone for Treatment of Early Diabetic Kidney Disease.","Friedman AN","2022","Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation","other_trial","article","10.1053/j.jrn.2022.03.003","35367357",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0012150","Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.","Xie Z","2022","Clinical epidemiology","systematic_review","article","10.2147/clep.s391819","36510488","PMC9738168",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0012151","SUN-576 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists For Alcohol Use Disorder: a Systematic Review and Meta-analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12544629",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0012152","Obesity Medication Treatment Perspectives Among People with Overweight or Obesity.","Ostrominski JW","2025","Patient preference and adherence","nonrandomized_study","article","10.2147/ppa.s555622","40969562","PMC12442898",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012153","Semaglutide vs Tirzepatide Dosages for Weight Loss-Reply.","Rodriguez PJ","2025","JAMA internal medicine","other","article","10.1001/jamainternmed.2024.5771","39585685",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012154","Beta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass.","Tokgöz S","2026","Diabetologia","other_trial","article","10.1007/s00125-025-06659-1","41555052","PMC13005773","ClinicalTrials.gov:NCT02542059",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0012155","Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis.","Rebelo TG","2025","International journal of cardiology","systematic_review","article","10.1016/j.ijcard.2025.133683","40752805",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0012156","Exendin-4 does not modify growth or apoptosis of human colon cancer cells.","Wenjing H","2017","Endocrine research","preclinical","article","10.1080/07435800.2017.1292525","28318339",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012157","GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review.","Mori Y","2020","International journal of molecular sciences","systematic_review","article","10.3390/ijms21041509","32098413","PMC7073149",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0012158","GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression","Athauda D","2024","bioRxiv","other_trial","preprint","10.1101/2024.02.28.582460",null,null,"ClinicalTrials.gov:NCT01971242","S002139","europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0012159","Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review.","Schmidt PHS","2025","Obesity research & clinical practice","systematic_review","article","10.1016/j.orcp.2025.01.009","39904668",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0012160","Pharmacotherapy for obesity management.","Noeth M","2025","South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde","other","article","10.7196/samj.2025.v115i9b.3767","41378657",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012161","Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real-world experience.","Huang CJ","2026","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.70275","41919486","PMC13257900",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012162","SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis.","Goodarzi S","2025","International ophthalmology","systematic_review","article","10.1007/s10792-025-03768-z","41042286",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Meta-Analysis"],["R0012163","Improving nutritional assessment in GLP-1RA therapy: Beyond self-reports to equitable interventions.","Aphale P","2025","Obesity pillars","commentary","article","10.1016/j.obpill.2025.100213","41103374","PMC12524169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012164","Diabetes injectable therapy: type 2 diabetes management in Danish practice.","Sterzi D","2017","Current medical research and opinion","other","article","10.1080/03007995.2017.1377165","28875722",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012165","Weight Regain During Continued Incretin Therapy Is Associated With an Inflammatory Signature at Weight Nadir and Higher Cardiovascular Event Rates","Matson R","2026","Preprints.org","other","preprint","10.20944/preprints202608.1478.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012166","Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.","Mudher Mikhael E","2016","Journal of diabetes research","narrative_review","article","10.1155/2016/6962574","27642611","PMC5013205",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0012167","A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.","Plenn E","2025","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.70085","40771966","PMC12327412",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012168","MON-826 Impact Of Demographic And Social Determinants On Access To SGLT2 Inhibitors And GLP-1 Receptor Agonists: A Systematic Review And Meta-Analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12544773",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0012169","Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI.","Kis JT","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-024-01644-0","39276292","PMC11467142",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012170","Effect of dietary reinforcement combined or not with GLP-1 receptor agonist therapy on histological outcomes in MASLD among patients with type 2 diabetes.","Guerci B","2025","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2025.101679","40543801",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012171","Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1.","Jerlhag E","2020","Brain research","nonrandomized_study","article","10.1016/j.brainres.2019.146562","31759971",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0012172","Tirzepatide gains US Food and Drug Administration approval for the management of obstructive sleep apnea: Implications for oral health care providers.","Hassan MG","2025","Journal of the American Dental Association (1939)","narrative_review","article","10.1016/j.adaj.2025.05.007","40569229",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012173","New Radiolabeled Exendin Analogues Show Reduced Renal Retention.","Joosten L","2023","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.3c00117","37265006","PMC10324399",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012174","Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.","Ji L","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71193","42755112",null,"ClinicalTrials.gov:NCT06973681","S003330","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0012175","SUN-682 Prevalence of Eating Disorders Among GLP-1 Receptor Agonist Users: A Cross-Sectional Analysis",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545209",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012176","Mitochondrial control of fuel switching via carnitine biosynthesis.","Auger C","2025","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2025.12.16.694762","41446161","PMC12724661",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0012177","Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database.","Mali G","2021","Journal of clinical pharmacy and therapeutics","nonrandomized_study","article","10.1111/jcpt.13259","32926446",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0012178","Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity.","Huang YN","2025","Communications medicine","nonrandomized_study","article","10.1038/s43856-025-01066-4","40750822","PMC12316913",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012179","Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing.","Zhang W","2025","Biosensors & bioelectronics","other","article","10.1016/j.bios.2024.116938","39566332",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; preprint; article"],["R0012180","Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.","Chawla H","2017","American journal of cardiovascular drugs : drugs, devices, and other interventions","randomized_trial","article","10.1007/s40256-017-0215-6","28197977",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0012181","GLP-1 receptor agonists and suicidality.","Ueda P","2025","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.r351","40010805",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0012182","Trends in glycaemic control and drug use in males and females with type 2 diabetes: Results of the Australian National Diabetes Audit from 2013 to 2019.","Xiang AS","2021","Diabetes, obesity & metabolism","other","article","10.1111/dom.14506","34338406",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012183","Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation.","Abou Elezz AM","2025","Inflammopharmacology","systematic_review","article","10.1007/s10787-025-01873-0","40762930","PMC12397177",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; article"],["R0012184","Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.","Nauck MA","2017","Diabetes care","other_trial","article","10.2337/dc16-0984","28283565",null,null,"S000313","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; article"],["R0012185","Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Maiorino MI","2017","Diabetes care","systematic_review","article","10.2337/dc16-1957","28325801",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0012186","Tirzepatide for overweight and obesity management.","Hamza M","2025","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2024.2436595","39632534",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0012187","The Treatment of Extreme Obesity in Adolescents and Young Adults with GLP-1 Receptor Agonists.","Brandt-Heunemann S","2025","Deutsches Arzteblatt international","commentary","article","10.3238/arztebl.m2024.0250","40579971","PMC12516206",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012188","MON-183 Effect of GLP-1 Receptor Agonists on Anthropometric, Metabolic and Fertility Parameters in Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12543721",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0012189","Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.","Avgerinos I","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13899","31637820",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0012190","Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.","Polyzos SA","2021","Alimentary pharmacology & therapeutics","narrative_review","article","10.1111/apt.16575","34416040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012191","Prevention and Management of Recurrent Weight Gain After Bariatric Surgery: Integrating Behavioural, Pharmacological and Procedural Approaches.","Tucker SL","2026","Obesity surgery","narrative_review","article","10.1007/s11695-026-08741-y","42191978",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012192","Alea Iacta Est: Casting the Die in Favor of Evidence-Based, Rational GLP-1RA Use.","Belančić A","2025","Hospital pharmacy","commentary","article","10.1177/00185787251390772","41210557","PMC12592116",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012193","Semaglutide and Other GLP-1 Agonists: A Boon for the Arthroplasty Industry?","Magruder ML","2024","The Journal of arthroplasty","commentary","article","10.1016/j.arth.2023.12.014","38182322",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0012194","Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial.","Hygum K","2020","Bone","randomized_trial","article","10.1016/j.bone.2019.115197","31870634",null,null,"S000828","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012195","Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.","Barrera-Chimal J","2020","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13969","32267077",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0012196","Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.","Lang K","2026","BMJ (Clinical research ed.)","other_trial","article","10.1136/bmj-2026-102036","42264536",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; other"],["R0012197","Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice.","Patoulias D","2020","Current vascular pharmacology","randomized_trial","article","10.2174/1570161117666190426162746","32013815",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0012198","Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.","Ma X","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70783","41994902","PMC13243956","ClinicalTrials.gov:NCT06440980","S001593","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0012199","Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy.","Kido K","2024","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2023.09.011","37797920",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; article"],["R0012200","Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society.","Napoli R","2020","Nutrition, metabolism, and cardiovascular diseases : NMCD","randomized_trial","article","10.1016/j.numecd.2020.07.012","32928628",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0012201","The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.","Tacke F","2025","Lancet (London, England)","other_trial","article","10.1016/s0140-6736(25)02304-9","41352959",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0012202","[A revolution in the management of type 2 diabetes : antidiabetic agents providing a cardiovascular and renal protection independently of glucose control !].","Scheen AJ","2020","Revue medicale de Liege","other","article",null,"32496686",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012203","Novel Therapeutic Approaches in Diabetes.","Gallwitz B","2016","Endocrine development","narrative_review","article","10.1159/000439372","26824365",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; book-chapter"],["R0012204","GLP-1 receptor agonists are associated with rare adverse effect during surgery.","Aschenbrenner DS","2025","The American journal of nursing","other","article","10.1097/01.naj.0001110536.78475.3b","40140040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012205","Immunometabolism drives metabolic and infectious disease progression through bidirectional metabolic reprogramming and epigenetic remodeling.","Tan W","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1914506","42713277","PMC13551734",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012206","Glucose-Lowering Drugs with Proven Cardiovascular Benefit Following Acute Coronary Syndrome in Patients with Type 2 Diabetes: Treatment Gaps and Outcomes.","Naoum I","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13185541","39337027","PMC11432281",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012207","Costs of Cutting Weight-An Economic Evaluation of GLP-1 Agonists vs Gastric Bypass.","Luo WY","2025","JAMA surgery","other","article","10.1001/jamasurg.2025.4385","41123898","PMC12547674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012208","The mechanism of the transient increase of blood pressure caused by GLP-1 receptor agonist liraglutide in diabetic patients with severely impaired kidney function.","Wajdlich M","2023","Research Square","other","preprint","10.21203/rs.3.rs-3124086/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012209","A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management.","García-Carro C","2021","Frontiers in medicine","narrative_review","article","10.3389/fmed.2021.655871","33928108","PMC8076523",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012210","Longitudinal association of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes.","Suzuki Y","2025","Scientific reports","other","article","10.1038/s41598-025-91101-0","40097434","PMC11914064",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012211","MicroRNA-21-5p promotes mucosal type 2 inflammation via regulating GLP1R/IL-33 signaling in chronic rhinosinusitis with nasal polyps.","Luan G","2022","The Journal of allergy and clinical immunology","preclinical","article","10.1016/j.jaci.2022.05.030","35835254",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012212","Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review.","Cooper DH","2023","Journal of psychiatric research","systematic_review","article","10.1016/j.jpsychires.2023.05.041","37331261",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Research Support, N.I.H., Extramural; review"],["R0012213","Obesity versus China: how Ozempic is complicating the world's largest weight loss campaign.","Murphy F","2026","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2026-523232","42297440",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012214","SUN-674 Metabolic Outcomes Combining Endoscopic Bariatric Procedures and GLP-1 Receptor Agonist Pharmacotherapy in Veterans with Obesity",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544080",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012215","Should metformin remain the first-line therapy for treatment of type 2 diabetes?","Baker C","2021","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018820980225","33489086","PMC7809522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012216","Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10.","Capehorn M","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00796-z","32193837","PMC7193006","ClinicalTrials.gov:NCT01930188; ClinicalTrials.gov:NCT01885208; ClinicalTrials.gov:NCT02128932; ClinicalTrials.gov:NCT03191396","S000329; S000584; S001219; S001876","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0012217","Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance and Improve Cardiovascular Outcomes in Type 2 Diabetes-A Narrative Review.","Janssen JAMJL","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27052150","41828377","PMC12984968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0012218","Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation.","Yoo J","2018","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2018.09.032","30253173",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012219","Emerging Role of Semaglutide and GLP-1 Agonist Medications in Plastic Surgery: A Note of Caution.","Borab ZM","2024","Plastic and reconstructive surgery","other","article","10.1097/prs.0000000000011418","38507525",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012220","Weight loss efficiency and safety of tirzepatide: A Systematic review.","Lin F","2023","PloS one","systematic_review","article","10.1371/journal.pone.0285197","37141329","PMC10159347",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Meta-Analysis; Journal Article; research-article; review"],["R0012221","GLP-1 Receptor Agonists for CKD: Remaining Issues or Mission Complete?","Kosjerina V","2025","American journal of kidney diseases : the official journal of the National Kidney Foundation","commentary","article","10.1053/j.ajkd.2025.03.001","40100187",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0012222","Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.","Thomas MK","2021","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgaa863","33236115","PMC7823251",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012223","Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","Hernandez AF","2018","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(18)32261-x","30291013",null,"ClinicalTrials.gov:NCT02465515","S000291; S000760; S001074; S002638","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0012224","Genetic predictors of GLP1 receptor agonist weight loss and side effects.","Su QJ","2026","Nature","other","article","10.1038/s41586-026-10330-z","41951734","PMC13190316",null,"S002095","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012225","Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPARγ-FOXA2-phosphatase signaling.","Choi W","2020","Mucosal immunology","preclinical","article","10.1038/s41385-020-0262-1","32034274","PMC7664156",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0012226","The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.","Moon HS","2011","Archives of pharmacal research","narrative_review","article","10.1007/s12272-011-0721-z","21811909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012227","Prevalence of Weight Related Comorbidities and Eligibility for Tirzepatide in an Acute Adult Psychiatric Inpatient Population Prescribed Antipsychotics in Northern Ireland","Norris E",null,"BJPsych open","other","article",null,null,"PMC13328878",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012228","SAT-065 Comparison of Long-Acting and Short-Acting GLP-1 Receptor Agonists on Copeptin in Euvolemic Participants - A Secondary Analysis of Three Prospective Trials",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545322",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012229","Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.","Hecking M","2021","Transplant international : official journal of the European Society for Organ Transplantation","nonrandomized_study","article","10.1111/tri.13783","33135259","PMC7839745",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0012230","Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study.","Abdul-Ghani M","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14153","32729222",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012231","Liraglutide use in congenital generalized lipodystrophy: glycemic and metabolic outcomes.","Araújo JS","2026","Frontiers in endocrinology","other","article","10.3389/fendo.2026.1912138","42840192","PMC13638587",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012232","Rural-Urban Disparities in the Uptake of New Diabetes Medications.","Zhu B","2025","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds23-0075","39959517","PMC11825407",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0012233","Chronic semaglutide treatment attenuates cue-induced reinstatement of cocaine-seeking and cocaine-induced stereotypy in male and female rats.","Turner CA","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.09.21.753157","42856215","PMC13648365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; preprint"],["R0012234","Point-of-Care Ultrasound Aids in the Management of Patient Taking Semaglutide Before Surgery: A Case Report.","Hodgson JA","2024","A&A practice","case_report","article","10.1213/xaa.0000000000001762","38498670",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0012235","Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use.","Seufert J","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15609","38685598",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0012236","Anti-Diabetic Medications for the Pharmacologic Management of NAFLD.","Cholankeril R","2018","Diseases (Basel, Switzerland)","narrative_review","article","10.3390/diseases6040093","30282916","PMC6313421",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012237","Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review.","Meece J","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-018-0395-3","29574634","PMC5984906",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012238","Predictive factors for HbA1c and weight loss associated with semaglutide treatment in type 2 diabetes mellitus: real-world clinical evidence.","Milushewa P","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1621892","41036135","PMC12479283",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012239","[Incretin therapies and multifactorial clinical approach to cardiometabolic patients].","Consoli A","2016","Giornale italiano di cardiologia (2006)","randomized_trial","article","10.1714/2206.23818","27030119",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","English Abstract; Journal Article; article; other"],["R0012240","Therapeutics candidates and repurposing strategies to target parkinson's disease pathology: current evidence and future directions.","Dhanush Y","2026","Metabolic brain disease","other_trial","article","10.1007/s11011-026-01961-2","42714656",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0012241","Peripheral artery disease in diabetes.","Amin S","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1811582","42087878","PMC13135919",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012242","Lixisenatide in early parkinson's disease: efficacy, safety, and future directions: a correspondence.","Irfan H","2024","Neurosurgical review","other_trial","article","10.1007/s10143-024-02475-0","38787469",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; article"],["R0012243","Recurrent Small Bowel Obstruction Following Combined Use of Clozapine and Tirzepatide: A Case Illustrating Additive Gastrointestinal Hypomotility","de Oliveira M",null,"BJPsych open","other","article",null,null,"PMC13329305",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012244","Neoadjuvant GLP-1 Receptor Agonists in Sleep Surgery.","Cheong RCT","2025","JAMA otolaryngology-- head & neck surgery","other","article","10.1001/jamaoto.2024.4593","39745728",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012245","18F-labeled PEGylated exendin-4 imaging noninvasively differentiates insulinoma from an accessory spleen: the first case report of [18F]FB(ePEG12)12-exendin-4 positron emission tomography/computed tomography for insulinoma.","Sakaki K","2023","Frontiers in endocrinology","case_report","article","10.3389/fendo.2023.1245573","37720533","PMC10501723",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Research Support, Non-U.S. Gov't; Journal Article; case-report; article"],["R0012246","GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction.","Reitz J","2026","Biological psychiatry global open science","narrative_review","article","10.1016/j.bpsgos.2026.100793","42741173","PMC13572310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012247","Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting.","Melzer-Cohen C","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-00725-9","31808132","PMC6965556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0012248","Comparing GLP-1 agonists versus other weight loss interventions on risk of atrial fibrillation recurrence after catheter ablation: a meta-analysis.","Li HY","2026","Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing","systematic_review","article","10.1007/s10840-026-02297-8","41843238","PMC13221330",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Comparative Study; Review; research-article; review"],["R0012249","Liraglutide and GLP-1(9-37) alleviated hepatic ischemia-reperfusion injury by inhibiting ferroptosis via GSK3β/Nrf2 pathway and SMAD159/Hepcidin/FTH pathway.","Lu C","2025","Redox biology","preclinical","article","10.1016/j.redox.2024.103468","39693850","PMC11719303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012250","The novel GLP-1 / GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease.","Feng P","2025","European journal of pharmacology","randomized_trial","article","10.1016/j.ejphar.2025.177972","40683437",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0012251","Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats.","Zhang Y","2020","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/s41386-019-0531-4","31581176","PMC6969180",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0012252","Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.","Sattar N","2022","Nature medicine","systematic_review","article","10.1038/s41591-022-01707-4","35210595","PMC8938269","ClinicalTrials.gov:NCT03131687; ClinicalTrials.gov:NCT03954834; ClinicalTrials.gov:NCT03987919; ClinicalTrials.gov:NCT03882970; ClinicalTrials.gov:NCT03730662; ClinicalTrials.gov:NCT04039503; ClinicalTrials.gov:NCT03861052","S000010; S000095; S000239; S000407; S001287; S001591; S001608","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0012253","Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study.","Alkabbani W","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70963","42244136",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012254","5PSQ-009 Adequacy of use and effectiveness of glp-1 receptor agonists in real clinical practice","Esteban S","2018","European Journal of Hospital Pharmacy","nonrandomized_study","article","10.1136/ejhpharm-2018-eahpconf.363",null,"PMC7535169",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","meeting-report; Meeting Report; conference-paper"],["R0012255","Helospectin from Heloderma Venom: A VIP‐Like Vasodilatory Peptide for Erectile Dysfunction and Clitoral Engorgement—A Theoretical Preclinical Proposal","Ahmed A","2025","Preprints.org","randomized_trial","preprint","10.20944/preprints202512.0658.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0012256","A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors.","Iqbal S","2026","Cureus","case_report","article","10.7759/cureus.113391","42504310","PMC13401805",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0012257","Immunometabolic integration in therapeutic strategies for managing MASLD.","González-Serrano S","2025","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1693753","41293239","PMC12640830",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0012258","[Diagnosis and treatment of maturity onset diabetes of the young type 3].","Rose K","2018","Ugeskrift for laeger","narrative_review","article",null,"29429476",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012259","Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.","Blonde L","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0429-x","29675797","PMC5984932",null,"S002638","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0012260","Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression.","Yi B","2014","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2014.1873","25187821","PMC4151638",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012261","Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists' Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells.","Reed J","2024","International journal of molecular sciences","preclinical","article","10.3390/ijms25126331","38928038","PMC11203424",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0012262","Incretin effect of glucagon-like peptide 1 receptor agonist is preserved in presence of ABCC8/SUR1 mutation in β-cell.","Bourron O","2012","Diabetes care","other_trial","article","10.2337/dc12-0535","23093687","PMC3476900",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Letter; Research Support, Non-U.S. Gov't; article"],["R0012263","Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.","Fulcher GR","2022","Advances in therapy","nonrandomized_study","article","10.1007/s12325-022-02212-3","35752730","PMC9244059","ClinicalTrials.gov:NCT04042441",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012264","Interactions between dietary intake and GLP-1 biology: implications for metabolic dysfunction and aging.","Han Y","2026","Critical reviews in food science and nutrition","narrative_review","article","10.1080/10408398.2026.2728313","42704078",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012265","Design, synthesis, and biological activity of novel oxazole-based small molecule allosteric GLP-1R agonists.","Wang R","2026","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2026.119206","42570411",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012266","Assessment of Thermal and Photolytic Stress Effects on the Stability of Primary Structure of Synthetic Liraglutide Using LC-HRMS/MS.","Badgujar D","2025","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.70050","40814845",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012267","Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms.","Goldenberg RM","2025","Current medical research and opinion","narrative_review","article","10.1080/03007995.2025.2458538","39871617",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0012268","A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies.","Ahmed IS","2026","Journal of obesity","nonrandomized_study","article","10.1155/jobe/6556057","41973072","PMC13075284",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0012269","The effects of liraglutide and metformin treatment on fracture healing in partially insulinopenic diabetic rats.","Turhan B","2025","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2025.1703958","41195211","PMC12582942",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012270","Balancing procedural safety and therapeutic continuity: GLP-1 receptor agonists and upper endoscopy.","Wei LC","2025","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.24279","40128635",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012271","Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.","Buzzi RM","2026","BMJ case reports","case_report","article","10.1136/bcr-2026-276106","42843917","PMC13646524",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0012272","Injectable Coformulations in Diabetology.","Kalra S","2015","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-015-0106-2","25801349","PMC4478180",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0012273","Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence.","Pozo L","2019","World journal of diabetes","randomized_trial","article","10.4239/wjd.v10.i5.291","31139316","PMC6522760",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012274","Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel.","Cardio-Metabolic Academy Europe East","2021","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2020.108535","33189792",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; article"],["R0012275","Exendin-4 increases absence-like seizures and anxiety-depression-like behaviors in WAG/Rij rats.","Aygun H","2021","Epilepsy & behavior : E&B","preclinical","article","10.1016/j.yebeh.2021.108246","34385055",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012276","GLP-1 Receptor Agonists and Cardiac Health: Insights from a Systematic Review.","Pedrosa MR","2025","Cardiovascular drugs and therapy","systematic_review","article","10.1007/s10557-025-07680-7","40088397",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0012277","Risk stratification tools for heart failure in the diabetes clinic.","Cannistraci R","2020","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2020.03.022","32475628",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012278","Effect of liraglutide on endoplasmic reticulum stress in the renal tissue of type 2 diabetic rats.","Zhao XY","2020","World journal of diabetes","preclinical","article","10.4239/wjd.v11.i12.611","33384768","PMC7754169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012279","Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.","Dagenais GR","2020","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-020-01179-1","33239067","PMC7690176","ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0012280","Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agents.","Murphy A","2025","Discover oncology","narrative_review","article","10.1007/s12672-025-01878-9","40024963","PMC11872791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012281","Diabetes Mellitus and Cardiovascular Disease.","Schmidt AM","2019","Arteriosclerosis, thrombosis, and vascular biology","narrative_review","article","10.1161/atvbaha.119.310961","30786741","PMC6532416",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review; research-article; article"],["R0012282","Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial.","Lingvay I","2026","Diabetes care","randomized_trial","article","10.2337/dc26-0784","42782193",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; other; article"],["R0012283","Insights into incretin-based therapies for treatment of diabetic dyslipidemia.","Stemmer K","2020","Advanced drug delivery reviews","narrative_review","article","10.1016/j.addr.2020.05.008","32485206",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review"],["R0012284","Exendin-4, a GLP-1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia-reperfusion injury.","Zhai R","2020","British journal of pharmacology","other","article","10.1111/bph.15059","32232832","PMC7348095",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012285","Novel Diabetes Drugs and the Cardiovascular Specialist.","Sattar N","2017","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2017.04.014","28545639",null,null,"S002431","pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0012286","Efficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-Analysis","Yassin MN","2025","Research Square","systematic_review","preprint","10.21203/rs.3.rs-7884657/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0012287","The prevalence and consequences of support for off-label Ozempic prescriptions.","Callaghan T","2025","Health economics, policy, and law","other","article","10.1017/s1744133124000306","39763244",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012288","Systemic evaluation of the effects of monomeric GLP-1R-based agonists on MASLD and its complications.","Cai Y","2025","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-025-01870-x","40731367","PMC12305972",null,null,"pubmed; europepmc","TRUE","open_europepmc","4",null,"Journal Article; research-article"],["R0012289","Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope?","Touzot M","2022","Clinical kidney journal","other","article","10.1093/ckj/sfac090","36003674","PMC9394711",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012290","Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity.","Lei Y","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2026.37779","42842253","PMC13647145",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012291","Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model.","McEwan P","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16141","39828939","PMC11885066",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012292","Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis.","Galaviz KI","2022","American journal of preventive medicine","systematic_review","article","10.1016/j.amepre.2021.10.020","35151523","PMC10420389",null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Research Support, N.I.H., Extramural; Systematic Review; Network Meta-Analysis; research-article"],["R0012293","OR03-1 Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program",null,"2022","Journal of the Endocrine Society","other_trial","article",null,null,"PMC9624730",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0012294","Exploring the antioxidant properties of semaglutide: A comprehensive review.","Yaribeygi H","2024","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2024.108906","39549371",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012295","Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes.","Kukova L","2024","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1080/17425255.2024.2401589","39268978",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012296","Evaluation of Consistency of Treatment Response Across Regions-the LEADER Trial in Relation to the ICH E17 Guideline.","Nielsen HK","2021","Frontiers in medicine","other_trial","article","10.3389/fmed.2021.662775","34136501","PMC8201994","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012297","MON-521 GLP-1 Receptor Agonists and Risk for Dialysis, Cardiovascular Disease and Mortality in Patients with Type 2 Diabetes Mellitus and End Stage Renal Disease",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545162",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012298","SAT-064 Copeptin Levels at Baseline and in Response to Short-Acting GLP-1 Receptor Agonists in Patients with Endogenous Hyperinsulinemic Hypoglycemia and Healthy Controls - A Secondary Analysis",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544150",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012299","Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2.","Maranta F","2021","Advances in experimental medicine and biology","other","article","10.1007/5584_2020_514","32266607",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012300","Decoding Immunometabolic Dynamics of Adipose Tissue in Obesity: Evolving Evidence and Way Forward.","Kumari K","2026","ACS pharmacology & translational science","narrative_review","article","10.1021/acsptsci.6c00071","42614861","PMC13482895",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012301","A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders.","Lee JY","2026","Science advances","other","article","10.1126/sciadv.aed3119","42627907","PMC13496183",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012302","The effect of incretin-based drugs on the riks of acute pancreatitis: a review.","Czaplicka A","2024","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-024-01430-6","38932809","PMC11196466",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0012303","Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.","Milicevic Z","2016","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12640","26847401",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012304","Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats.","Sisley S","2014","Peptides","preclinical","article","10.1016/j.peptides.2014.05.008","24879927","PMC4113007",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0012305","Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach.","Ganakumar V","2025","World journal of diabetes","commentary","article","10.4239/wjd.v16.i4.102390","40236868","PMC11947912",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0012306","Semaglutide Reduces Odorant-Driven Chemotaxis and Reproductive Output in Caenorhabditis elegans.","Kousnetzov S","2026","microPublication biology","other","article","10.17912/micropub.biology.002168","42852039","PMC13647127",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; Brief Report; article"],["R0012307","Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.","Nauck MA","2022","Cardiovascular diabetology","other_trial","article","10.1186/s12933-022-01604-7","36050763","PMC9438179",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; other; article"],["R0012308","Obesity and respiratory diseases: mechanisms, phenotypes, and clinical implications.","Soliman AR","2026","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-026-02164-6","42116176","PMC13169587",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0012309","Microbes, mood, and metabolism/obesity: Pharmacological insights into the gut-obesity-depression triad.","Yadav A","2026","Cellular and molecular life sciences : CMLS","narrative_review","article","10.1007/s00018-025-06022-y","41774188","PMC12979749",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012310","Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials.","Zhang F","2017","Scientific reports","systematic_review","article","10.1038/s41598-017-16018-9","29167470","PMC5700049",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0012311","Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.","Patel H","2026","Cureus","systematic_review","article","10.7759/cureus.111786","42534203","PMC13419888",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0012312","(Un)intended consequences of mass-prescribing GLP-1s.","Hagenaars LL","2026","Science (New York, N.Y.)","commentary","article","10.1126/science.ael8715","42691159",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0012313","Tirzepatida (Mounjaro®, Zepbound®)",null,"1994","Organization of Teratology Information Specialists (OTIS), Brentwood (TN)","narrative_review","article",null,"39631016",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0012314","Liraglutide restores impaired associative learning in individuals with obesity.","Hanssen R","2023","Nature metabolism","randomized_trial","article","10.1038/s42255-023-00859-y","37592007","PMC10447249",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012315","Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway.","Qiao H","2018","Molecular medicine reports","preclinical","article","10.3892/mmr.2018.8371","29328405","PMC5802177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retracted Publication; research-article; article"],["R0012316","Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.","Wang B","2013","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12085","23433305",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0012317","Comparative Outcomes of GLP-1 Therapy vs. Bariatric Surgery in Patients with Cirrhosis.","Aburumman R","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08823-x","42348118",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0012318","Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.","Frandsen CS","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12830","27868372",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012319","The Intertwined Epidemics of Obesity and Obstructive Sleep Apnea: A Comprehensive Analysis.","Patil S","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.70235","42779137",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012320","Target trial emulation of cardiovascular outcome trials of medications used to treat type 2 diabetes using real-world data: a systematic review of observational studies.","Wang W","2025","Journal of clinical epidemiology","systematic_review","article","10.1016/j.jclinepi.2025.111872","40550404",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0012321","Disease‑Modifying Therapies for Parkinson’s Disease: Biological Mechanisms, Pharmacological Strategies, and Clinical Pipeline","Pitton Rissardo J","2025","Preprints.org","randomized_trial","preprint","10.20944/preprints202512.2271.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0012322","Effects of glucagon-like peptide-1 receptor agonists on renal function.","Filippatos TD","2013","World journal of diabetes","narrative_review","article","10.4239/wjd.v4.i5.190","24147203","PMC3797884",null,"S002088","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0012323","Repurposing the hypoglycaemic agents for neuroinflammation, a comprehensive review.","Blossom V","2025","3 Biotech","preclinical","article","10.1007/s13205-025-04455-7","40771585","PMC12325842",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012324","Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management.","Williams S","2022","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2022.09.002","36272822",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0012325","The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.","Malkin SJP","2022","Diabetology & metabolic syndrome","other_trial","article","10.1186/s13098-022-00801-4","35164855","PMC8845275",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012326","A biomimetic multimodal nanoplatform combining neutrophil-coated two-dimensional metalloporphyrinic framework nanosheet and exendin-4 to treat obesity-related osteoporosis.","Yang Q","2025","Materials today. Bio","preclinical","article","10.1016/j.mtbio.2025.102009","40673132","PMC12264616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012327","Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats.","Liberini CG","2019","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.13591","30456866","PMC7274726",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0012328","PSUN241 A Case of Dulaglutide-Induced Acute Pancreatitis in a Diabetic Patient – A Case Report",null,"2022","Journal of the Endocrine Society","case_report","article",null,null,"PMC9627820",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012329","Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.","Aronne LJ","2026","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2026.100333","42831032","PMC13634289","ClinicalTrials.gov:NCT04184622","S001077","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0012330","Author Correction: Mapping the effectiveness and risks of GLP-1 receptor agonists.","Xie Y","2025","Nature medicine","notice","article","10.1038/s41591-025-03542-9","39891006",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0012331","GLP-1 Receptor Agonists Show Promise Beyond Diabetes and Weight Loss.","Roush K","2025","The American journal of nursing","other","article","10.1097/ajn.0000000000000074b","40269414",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012332","GLP-1 receptor agonists causing euglycemic ketoacidosis in patients without diabetes: a brief review.","Sood N","2025","International journal of obesity (2005)","narrative_review","article","10.1038/s41366-025-01749-x","40114022",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012333","Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data.","Davidson JA","2020","Clinical diabetes and endocrinology","randomized_trial","article","10.1186/s40842-019-0088-5","31956422","PMC6961286","ClinicalTrials.gov:NCT00715624; ClinicalTrials.gov:NCT00975286; ClinicalTrials.gov:NCT00866658","S000488; S000792; S002023","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0012334","Comment on: Comparison of SGLT‑2i and GLP‑1RA on cardiovascular and renal outcomes in elderly patients with T2DM: a single‑center retrospective cohort study.","Khan MAUH","2026","International urology and nephrology","nonrandomized_study","article","10.1007/s11255-025-04828-0","41065935",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; letter"],["R0012335","Semaglutide, Popularly Known as Ozempic-What the Facial Plastic Surgeon Needs to Know.","Sciscent BY","2025","Facial plastic surgery & aesthetic medicine","other","article","10.1089/fpsam.2024.0083","39056124",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012336","Exenatide administration time-dependently affects the hepatic circadian clock through glucagon-like peptide-1 receptors in the central nervous system.","Xu P","2024","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2024.116567","39369911",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012337","Proteomic Profiling of GLP-1-Mediated Cardioprotection in a Large Animal Model of Chronic Coronary Artery Disease.","Zheng C","2025","Medical research archives","nonrandomized_study","article","10.18103/mra.v13i11.7114","41717240","PMC12916146",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012338","A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.","le Roux CW","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70531","41635114","PMC12992187",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; research-article; article"],["R0012339","Comparison of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Atrial Fibrillation in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.","Kumar A","2026","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000001968","40304630",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0012340","Semaglutide and bariatric surgery induce distinct changes in the composition of mouse white adipose tissue.","Emont MP","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102126","40139440","PMC11999362",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012341","Silencing the Sirens: Weight-Loss Drugs, Food Noise, and the Ethics of Effortless Self‑Control.","Malanowski SC","2026","The Journal of medical humanities","other","article","10.1007/s10912-026-10054-1","42678482",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012342","Electroacupuncture enables semaglutide dose sparing in type 2 diabetes by boosting drug concentration and suppressing β-cell apoptosis.","Yang X","2026","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2026.1880819","42718474","PMC13553360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012343","Worldwide burden of antidiabetic drug-induced sarcopenia: An international pharmacovigilance study.","Kong J","2025","Archives of gerontology and geriatrics","nonrandomized_study","article","10.1016/j.archger.2024.105656","39447350",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0012344","Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.","Hunt B","2017","Journal of medical economics","other_trial","article","10.1080/13696998.2017.1301943","28294641",null,null,"S001328","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0012345","MON-684 Comparative Effectiveness and Safety of GLP-1 Receptor Agonist versus Traditional Anti-obesity Medications: A Real-world Evidence Study",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12544569",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0012346","Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy.","Abdelhafiz AH","2020","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2020.107639","32595017",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0012347","SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis.","He Z","2026","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2026.1882227","42851802","PMC13646529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0012348","Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies.","Koufakis T","2021","Maturitas","narrative_review","article","10.1016/j.maturitas.2020.10.005","33308617",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012349","Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.","Salameh TS","2020","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2020.114187","32755557","PMC7606641",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0012350","Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels.","Çalık Başaran N","2025","International journal of obesity (2005)","narrative_review","article","10.1038/s41366-024-01461-2","38225284","PMC11971041",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0012351","Liraglutide, a GLP-1 agonist, as a new adjunct treatment in Hailey-Hailey disease: a case report.","Barry R","2024","Clinical and experimental dermatology","case_report","article","10.1093/ced/llad429","38039150",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0012352","Semaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn?","Zhou XD","2026","eGastroenterology","other","article","10.1136/egastro-2026-100619","42825265","PMC13630009",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0012353","Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes.","Garg SK","2024","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2023.0490","38444317",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0012354","GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice.","Liu C","2024","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2024.109946","38599494",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012355","Update on antiobesity pharmacotherapy in adults: Current and emerging options.","Ziyadeh F","2026","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.93a.24112","41482465",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012356","Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.","Pratley RE","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00994-9","33660198","PMC7994454","ClinicalTrials.gov:NCT02607865; ClinicalTrials.gov:NCT02863419; ClinicalTrials.gov:NCT02827708; ClinicalTrials.gov:NCT02849080; ClinicalTrials.gov:NCT03021187","S000133; S001153; S002025; S002267; S002369","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012357","Topical Volumizing Cream Improves Facial Volume and Skin Health in Adults With Rapid Weight Loss From Pharmacologic (GLP-1/GIP Agonists), Surgical, or Behavioral Interventions.","Nguyen N","2026","Journal of cosmetic dermatology","other","article","10.1111/jocd.70681","41556403","PMC12817327",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012358","Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis.","Liu Y","2025","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2025.1529652","40183087","PMC11965666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012359","SGLT2i and GLP1RA Use in the USA.","Burmeister JR","2026","Journal of general internal medicine","commentary","article","10.1007/s11606-026-10449-9","41979727","PMC13304056",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012360","Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.","Chen C","2019","BMC cardiovascular disorders","systematic_review","article","10.1186/s12872-019-01275-5","31870322","PMC6927173",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; research-article; other; review"],["R0012361","Pancreatic δ-cells are resistant to auto- and paracrine inhibition in human type-2 diabetes","Omar-Hmeadi M","2025","bioRxiv","other","preprint","10.64898/2025.12.12.693197",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012362","Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases.","Li Y","2016","Reviews in the neurosciences","narrative_review","article","10.1515/revneuro-2016-0018","27276528",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012363","Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.","Koye DN","2020","Drugs","nonrandomized_study","article","10.1007/s40265-020-01279-y","32141024",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0012364","Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway.","Wang A","2017","PloS one","preclinical","article","10.1371/journal.pone.0169469","28122026","PMC5266308",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012365","Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","Kristensen SL","2019","The lancet. Diabetes & endocrinology","systematic_review","article","10.1016/s2213-8587(19)30249-9","31422062",null,null,"S000760; S002638; S002726","pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0012366","Heterogeneity of Multiple Pancreatic Neuroendocrine Tumors Identified by 68Ga-DOTANOC and 68Ga-Exendin-4 PET/CT in a Patient with Endogenous Hyperinsulinemic Hypoglycemia and Multiple Endocrine Neoplasia 1.","Xu J","2024","Neuroendocrinology","case_report","article","10.1159/000538285","38471465",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0012367","Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies.","Kamrul-Hasan ABM","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2025.11.010","41297885",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0012368","Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment.","Longo M","2025","Endocrine","commentary","article","10.1007/s12020-025-04243-6","40274685",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012369","Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.","Spellman CW","2012","The Journal of the American Osteopathic Association","other_trial","article",null,"22267302",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0012370","Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy.","Owens DR","2017","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12977","28432748","PMC5637910",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0012371","Discontinuation and Reinitiation of GLP-1 Receptor Agonists Among US Adults with Overweight or Obesity","Rodriguez PJ","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.07.26.24311058",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0012372","Acute hyperglycemia induces podocyte apoptosis by monocyte TNF-α release, a process attenuated by vitamin D and GLP-1 receptor agonists.","Zhang RM","2025","The Journal of steroid biochemistry and molecular biology","other","article","10.1016/j.jsbmb.2025.106676","39818342","PMC11859504",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0012373","Management of mitochondrial diabetes in the era of novel therapies.","Yeung RO","2021","Journal of diabetes and its complications","case_report","article","10.1016/j.jdiacomp.2020.107584","32331977","PMC7554068",null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Research Support, N.I.H., Intramural; Journal Article; research-article"],["R0012374","Association between body mass index reduction and epicardial adipose tissue changes across pharmacological and lifestyle interventions: a multilevel meta-regression analysis.","Mączyńska A","2026","Cardiovascular diabetology","other_trial","article","10.1186/s12933-026-03299-6","42471652",null,"PROSPERO:CRD420261367140",null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0012375","Attenuation of High Glucose-Induced Rat Cardiomyocyte Apoptosis by Exendin-4 via Intervention of HO-1/Nrf-2 and the PI3K/AKT Signaling Pathway.","Zhao SM","2017","The Chinese journal of physiology","preclinical","article","10.4077/cjp.2017.baf434","28464602",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012376","Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.","Liu S","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1513641","39968298","PMC11832366","PROSPERO:CRD42024554005",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; Systematic Review; systematic-review; review"],["R0012377","Developing a Comprehensive Approach for Managing Cardiorenal Metabolic Diseases (CRMD) in Saudi Arabia: Thinking beyond Single Disease-Literature Review and Multidisciplinary Consensus Report.","Alshaikh A","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-025-01826-4","41317223","PMC12909734",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012378","Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.","Smits MM","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12612","26640129",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012379","Assessing the antidepressant effects of GLP-1 receptor agonists using Mendelian randomization.","Guo Q","2025","Asian journal of psychiatry","commentary","article","10.1016/j.ajp.2025.104416","40088752",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012380","[Renal effects of GLP-1 agonists in type 2 diabetes].","Elbert A","2022","Medicina","narrative_review","article",null,"35904915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012381","HFpEF, Aging, Inflammaging, and the Future of Anti-Inflammatory: Therapy in Heart Failure with Preserved Ejection Fraction.","Grzeczka A","2026","Aging and disease","narrative_review","article","10.14336/ad.2026.0265","42149096",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012382","Ozempic generic approved in Canada after Novo Nordisk doesn't pay $250 government fee.","Owens B","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-597166","42156111",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012383","Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP.","Hjelmesæth J","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71323","42764399",null,"ClinicalTrials.gov:NCT05646706","S001354","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0012384","Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.","Madsbad S","2019","Expert review of cardiovascular therapy","other_trial","article","10.1080/14779072.2019.1615444","31055989",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0012385","Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine.","Valencia WM","2018","Current diabetes reports","systematic_review","article","10.1007/s11892-018-1052-y","30187176",null,null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Systematic Review"],["R0012386","New Ways to Keep Muscle as You Age: Ozempic, similar drugs and aging take off muscle. New therapies could retain it.","Youmshajekian L","2026","Scientific American","other","article","10.1038/scientificamerican062026-1ptahwhfiwlqeuvbshy2kd","42153865",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012387","Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial.","Jensen JK","2021","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2021.790405","34917038","PMC8669791",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012388","Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.","Chien CL","2020","Current medical research and opinion","randomized_trial","article","10.1080/03007995.2020.1815686","32851879",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012389","Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.","Mabilleau G","2014","Journal of diabetes","systematic_review","article","10.1111/1753-0407.12102","24164867",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0012390","Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.","Cariou B","2021","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14322","33464677","PMC8248154",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Systematic Review; review-article; article"],["R0012391","Long-Term clinical efficacy of liraglutide for type 2 diabetes: real-world evidence and outcomes from Pakistan.","Butt MD","2024","Journal of pharmaceutical policy and practice","nonrandomized_study","article","10.1080/20523211.2024.2432462","39640418","PMC11619037",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012392","Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses.","Wang L","2026","Metabolism: clinical and experimental","other","article","10.1016/j.metabol.2026.156711","42532176",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012393","Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?","Abdul-Ghani M","2017","Diabetes care","other","article","10.2337/dc16-2736","28637886","PMC5481984",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0012394","Management of type 2 diabetes in young adults aged 18-30 years: ADS/ADEA/APEG consensus statement.","Wong J","2022","The Medical journal of Australia","other","article","10.5694/mja2.51482","35430745",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Consensus Statement; article"],["R0012395","GLP-1 RAs for Idiopathic Intracranial Hypertension-Time for a Trial.","Newman NJ","2025","JAMA neurology","other_trial","article","10.1001/jamaneurol.2025.2019","40658403",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; article"],["R0012396","GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.","Zhang X","2023","Cellular and molecular biology (Noisy-le-Grand, France)","other","article","10.14715/cmb/2023.69.14.37","38279433",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012397","Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand.","Chepulis L","2025","BMC health services research","nonrandomized_study","article","10.1186/s12913-025-12601-3","40140836","PMC11938655",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012398","Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells.","He W","2016","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2016.07.032","27496641",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012399","GLP-1 receptor agonists: even for kidney transplant recipients with pre-existing diabetes?","Cortinovis M","2025","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(24)00399-1","40056924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0012400","Exploring the Therapeutic Potential of Bioactive Peptides in Modulating Tau Protein Interactions via the PI3K/Akt Pathway in Neurodegenerative Diseases.","Singh K","2026","Current molecular medicine","other","article","10.2174/0115665240423631251207115337","42634167",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012401","Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.","Jones KL","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13633","30623563",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012402","Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.","Klausen MK","2022","JCI insight","randomized_trial","article","10.1172/jci.insight.159863","36066977","PMC9675448","ClinicalTrials.gov:NCT03232112; EudraCT:2016-003343-11","S001488","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012403","Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study.","Palanca A","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2023.111071","38142748",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Comparative Study; Journal Article; article"],["R0012404","Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.","Nestor JJ","2022","Scientific reports","preclinical","article","10.1038/s41598-022-10577-2","35461369","PMC9035150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; article; preprint"],["R0012405","Effects of sodium-glucose cotransporter 2 inhibitors on body weight and metabolic parameters in obese patients with and without type 2 diabetes: a systematized narrative review.","Baletic D","2026","Current medical research and opinion","narrative_review","article","10.1080/03007995.2026.2690834","42339604",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0012406","Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.","McAdam-Marx C","2016","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2016.11.003","27889301",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Comparative Study; Journal Article; article"],["R0012407","[Conservative Therapy in CKD: New Frontiers].","Ruotolo C","2024","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","narrative_review","article","10.69097/41-06-2024-04","39931962",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0012408","The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.","Harris K","2018","The Annals of pharmacotherapy","narrative_review","article","10.1177/1060028017726348","28799414",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012409","Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.","Hanlon P","2025","JAMA","systematic_review","article","10.1001/jama.2024.27402","39899304","PMC11791772",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0012410","Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation.","Zhou Y","2015","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2015.09.179","26519882",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012411","Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches.","De Groot AS","2025","Pharmaceutical research","other","article","10.1007/s11095-025-03843-1","40126816","PMC12159091",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012412","Dulaglutide-Associated Choroidal Lymphoid Hyperplasia.","Francis JH","2026","The New England journal of medicine","commentary","article","10.1056/nejmc2600397","42127399","PMC13215208",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; research-article; article"],["R0012413","Comparative cardiovascular effects of GLP-1 agonists using real-world data.","Wallia A","2023","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.339","36825925","PMC10164426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012414","Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes.","Malik ME","2023","Clinical research in cardiology : official journal of the German Cardiac Society","other","article","10.1007/s00392-022-02016-z","35396632",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012415","Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019.","Sun JW","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14237","33118291",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012416","Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies.","Standl E","2020","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2020.108054","32035874",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Historical Article; Journal Article; Review"],["R0012417","Parabrachial Nucleus Contributions to Glucagon-Like Peptide-1 Receptor Agonist-Induced Hypophagia.","Swick JC","2015","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/npp.2015.50","25703200","PMC4839524",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0012418","Implicit Rationing of Incretin Therapy in Diabetic Kidney Disease: A Call for Deliberate Allocation.","de Silva D","2026","Cureus","randomized_trial","article","10.7759/cureus.115170","42787678","PMC13602831",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0012419","Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance.","Cacciatori V","2018","Journal of the Endocrine Society","other","article","10.1210/js.2017-00300","29379894","PMC5779107",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012420","GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials.","Smits MM","2019","Nutrition (Burbank, Los Angeles County, Calif.)","randomized_trial","article","10.1016/j.nut.2019.06.005","31415908",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Evaluation Study; Journal Article; article"],["R0012421","Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.","Nowell J","2023","Ageing research reviews","other_trial","article","10.1016/j.arr.2023.101979","37328112",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; review"],["R0012422","The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats.","Wójcicka G","2019","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2019.02.014","30768981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012423","Early Post-Renal Transplant Hyperglycemia.","Iqbal A","2022","The Journal of clinical endocrinology and metabolism","case_report","article","10.1210/clinem/dgab697","34558599","PMC8500128",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Review; case-report; article"],["R0012424","Control of human pancreatic beta cell kinome by glucagon-like peptide-1 receptor biased agonism.","Xiao J","2023","Diabetes, obesity & metabolism","other","article","10.1111/dom.15083","37039251","PMC10947446",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012425","Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization.","Ansari Lari S","2026","Cureus","nonrandomized_study","article","10.7759/cureus.112694","42602535","PMC13474186",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0012426","The South Asian Health Foundation (UK) guidelines for managing diabetes during Ramadan.","Hanif W","2020","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2020.108145","32335096",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012427","GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.","Holst JJ","2024","Nature metabolism","narrative_review","article","10.1038/s42255-024-01113-9","39160334",null,null,"S002754","pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0012428","Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion.","Ng MK","2025","The spine journal : official journal of the North American Spine Society","nonrandomized_study","article","10.1016/j.spinee.2025.03.023","40154624",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012429","Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes.","de Bhailís ÁM","2021","Therapeutic advances in endocrinology and metabolism","other_trial","article","10.1177/20420188211020664","34104399","PMC8165820",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0012430","Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry.","Essien UR","2022","Diabetes care","nonrandomized_study","article","10.2337/dc21-1178","35796766","PMC9577184",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; other; article"],["R0012431","Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?","Budd J","2020","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2020.01.007","32017891",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012432","Glucagon-like peptide-1 receptor agonists vs. insulin in inadequately controlled patients with type 2 diabetes. Is this meta-analysis miscalculated?","Liatis S","2014","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12213","24495116",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; Comment; article"],["R0012433","GLP-1R agonist medications for addiction treatment.","Volkow ND","2025","Addiction (Abingdon, England)","commentary","article","10.1111/add.16626","39049203","PMC12771407",null,"S000817","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Editorial; research-article; article"],["R0012434","GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction.","Mocciaro G","2025","BMJ nutrition, prevention & health","commentary","article","10.1136/bmjnph-2025-001206","40771503","PMC12322565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0012435","GLP1 receptor analogues and perioperative management considerations: A narrative review.","Vázquez Lima A","2026","Revista espanola de anestesiologia y reanimacion","narrative_review","article","10.1016/j.redare.2026.501985","41539425",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012436","Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity.","Quddos F","2023","Scientific reports","nonrandomized_study","article","10.1038/s41598-023-48267-2","38017205","PMC10684505",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012437","Association Between Preoperative GLP-1 Receptor Analog Use and Postoperative Complications and Mortality Following Lumbar Fusion Surgery.","Kesaria AA","2026","Global spine journal","nonrandomized_study","article","10.1177/21925682251391693","41138231","PMC12553540",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012438","Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists.","Ashruf OS","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.0802","40048168","PMC11886721",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012439","Misrepresentation of semaglutide in social media.","Propfe LE","2026","Naunyn-Schmiedeberg's archives of pharmacology","other","article","10.1007/s00210-025-04403-5","40682686","PMC12894124",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012440","Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.","Gamble JM","2016","Medicine","nonrandomized_study","article","10.1097/md.0000000000003995","27368005","PMC4937919",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0012441","Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.","Ottney A","2013","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.2146/ajhp130081","24249759",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0012442","Molecular imaging for neuroendocrine tumours.","Antwi K","2019","Swiss medical weekly","narrative_review","article","10.4414/smw.2019.20017","30852831",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012443","Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.","Zhang B","2024","Diabetes care","randomized_trial","article","10.2337/dc23-1287","37943529","PMC10733643","ClinicalTrials.gov:NCT04965506","S000140; S000578","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0012444","Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?","Luo G","2016","British journal of clinical pharmacology","nonrandomized_study","article","10.1111/bcp.12777","27099876","PMC4693579",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; book-review; article"],["R0012445","The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.","O'Keefe JH","2019","Progress in cardiovascular diseases","randomized_trial","article","10.1016/j.pcad.2019.08.001","31408637",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0012446","Pathways to Sustainable GLP-1 Receptor Agonist Off-Ramping.","Athinarayanan SJ","2025","JAMA internal medicine","other","article","10.1001/jamainternmed.2024.7675","39869343",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012447","S.E.N., SLANH, and SEEDO consensus report on obesity-related kidney disease: proposal for a new classification.","Rico-Fontalvo J","2025","Kidney international","other","article","10.1016/j.kint.2025.06.013","40617478",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Consensus Statement; Journal Article; Research Support, Non-U.S. Gov't"],["R0012448","SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?","Mone P","2024","The lancet. Healthy longevity","commentary","article","10.1016/j.lanhl.2024.08.001","39284335","PMC11472278",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; research-article; article"],["R0012449","A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.","Newsome PN","2021","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2028395","33185364",null,"ClinicalTrials.gov:NCT02970942","S000174; S000922; S001368; S002481","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012450","Safety and Efficacy of Liraglutide and Semaglutide in Kidney Transplant Recipients.","Kahwaji J","2025","Kidney360","other","article","10.34067/kid.0000000706","39847451","PMC12136651",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012451","Exploring the surge of Ozempic in Pakistan:Are we overlooking its oral health impact?","Ashraf M","2026","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.31883","42261041",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012452","The extent and predictors of off-label use of GLP-1 receptor agonists for weight loss management.","Siudak Z","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16313","40028686",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012453","Comparison of semaglutide in combined with empagliflozin versus semaglutide and empagliflozin monotherapy in non-alcoholic fatty liver disease with type 2 diabetes: study protocol for a randomised controlled clinical trial","Lin Y","2023","medRxiv","protocol","preprint","10.1101/2023.12.11.23299784",null,null,"ChiCTR:ChiCTR2300070674",null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0012454","The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD.","Schattenberg JM","2025","JHEP reports : innovation in hepatology","commentary","article","10.1016/j.jhepr.2025.101401","40524694","PMC12167468",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0012455","Comment on \"SGLT2i-GLP-1RA combination and cardiovascular outcomes in T2D with ACS\".","Koker G","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133700","40754114",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0012456","Exendin-4 differentially modulates essential functions of human dermal fibroblasts under normoglycemic and hyperglycemic conditions.","Wolak M","2021","Journal of physiology and pharmacology : an official journal of the Polish Physiological Society","other","article","10.26402/jpp.2021.3.14","34873069",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012457","Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.","Liu J","2019","EBioMedicine","other_trial","article","10.1016/j.ebiom.2019.02.037","30827929","PMC6443026",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Controlled Clinical Trial; Journal Article; research-article; article"],["R0012458","Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes.","Yen FS","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112357","40602532",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0012459","A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.","Witkowski M","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-018-0424-2","29675798","PMC5984927",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0012460","Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study.","Haluzík M","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16276","40098261","PMC11965013","EudraCT:2021-003711-25",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial, Phase IV; Multicenter Study; research-article; article"],["R0012461","Recent achievements and future directions of anti-obesity medications.","Grandl G","2024","The Lancet regional health. Europe","narrative_review","article","10.1016/j.lanepe.2024.101100","39582489","PMC11585837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012462","A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity.","Samms RJ","2025","Diabetes","narrative_review","article","10.2337/dbi24-0026","40521890","PMC12278790",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012463","ChatGPT as a Glucagon-Like Peptide-1 Agonists Information Source: Balancing Quality, Readability, and Patient Safety.","Yildizgoren MT","2026","Journal of diabetes science and technology","commentary","article","10.1177/19322968251409205","41489154","PMC12774803",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012464","Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice.","Lee J","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s231272","31920354","PMC6938178",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012465","A cost-effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada.","Gupta N","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16627","40686094","PMC12409247",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012466","Optimising lifestyle modification for people with osteoarthritis and obesity in the era of GLP-1 receptor agonists.","Shadbolt C","2025","Osteoarthritis and cartilage","commentary","article","10.1016/j.joca.2025.02.779","39988195",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0012467","Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetes.","Alatrach M","2018","Endocrinology, diabetes & metabolism","other","article","10.1002/edm2.34","30815562","PMC6354804",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012468","Dual GIPR and GLP-1R agonist tirzepatide inhibits aeroallergen-induced allergic airway inflammation in mouse model of obese asthma.","Toki S","2023","Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","preclinical","article","10.1111/cea.14252","36377605","PMC10163938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0012469","Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor.","Bu X","2026","Bioorganic & medicinal chemistry letters","preclinical","article","10.1016/j.bmcl.2026.130786","42801961",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012470","Ileum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration.","Blümlinger M","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.114164","40850442",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012471","Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.","Trevaskis JL","2017","Diabetes","preclinical","article","10.2337/db16-0916","28408435",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012472","Mounjaro: Online pharmacy is investigated after supplying fake weight loss pens.","Mahase E","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.s376","41740997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012473","Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status.","Gasoyan H","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24331","40491239","PMC12381620",null,"S001387","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012474","Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.","Al Batran R","2018","Peptides","narrative_review","article","10.1016/j.peptides.2017.12.005","29412838",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0012475","Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States.","Mody R","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01684-6","39794609","PMC11794899",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012476","Lower Risk of Postoperative Complications and Rotator Cuff Retear Associated With Semaglutide Use in Patients with Type II Diabetes Mellitus Undergoing Arthroscopic Rotator Cuff Repair.","Seddio AE","2025","Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association","nonrandomized_study","article","10.1016/j.arthro.2024.09.057","39490542",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012477","Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy.","Tschöp M","2023","Diabetologia","narrative_review","article","10.1007/s00125-023-05929-0","37209227","PMC10474213",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0012478","Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions.","Herbst R","2017","Current diabetes reports","other_trial","article","10.1007/s11892-017-0898-8","28726152",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0012479","Dulaglutide-Associated Lichen Planus Pemphigoides.","Long V","2026","The Australasian journal of dermatology","case_report","article","10.1111/ajd.70132","42083939","PMC13570475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; letter; article"],["R0012480","Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.","Dahl D","2022","JAMA","randomized_trial","article","10.1001/jama.2022.0078","35133415","PMC8826179","ClinicalTrials.gov:NCT04039503","S001608","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012481","The role of glucagon-like peptide-1 receptor agonists for the treatment of adolescent obesity.","Kelly AS","2013","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.2013.811913","30736144",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012482","6488 Factors associated with the response to SGLT2 inhibitors and GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453245",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012483","Stimulation of GLP-1 Receptor Inhibits Methylglyoxal-Induced Mitochondrial Dysfunctions in H9c2 Cardiomyoblasts: Potential Role of Epac/PI3K/Akt Pathway.","Nuamnaichati N","2020","Frontiers in pharmacology","other","article","10.3389/fphar.2020.00805","32547400","PMC7274035",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012484","Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis.","Lund LC","2021","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.5252","33881179",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012485","Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.","Jendle J","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13816","31215727","PMC6771774","ClinicalTrials.gov:NCT01930188; ClinicalTrials.gov:NCT01885208; ClinicalTrials.gov:NCT02128932; ClinicalTrials.gov:NCT02305381; ClinicalTrials.gov:NCT02648204; EudraCT:2012-004827-19; EudraCT:2012-004826-92; EudraCT:2013-004392-12; EudraCT:2013-004502-26; EudraCT:2014-005375-91","S000329; S000372; S001219; S001872; S001876","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012486","Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy.","Zaitoon H","2023","Acta diabetologica","case_report","article","10.1007/s00592-023-02109-9","37160786",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Case Reports; Journal Article; article"],["R0012487","Association Between GLP-1 Receptor Agonists and Incidence of Lung Cancer in Treatment-Naïve Type 2 Diabetes.","Song J","2025","Journal of general internal medicine","commentary","article","10.1007/s11606-024-09076-z","39365528","PMC11914447",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012488","Legal Challenges to Compounding Drugs for Weight Loss.","Combs BE","2025","International journal of pharmaceutical compounding","narrative_review","article",null,"40961473",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012489","Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats.","Celik-Tekeli M","2021","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2020.105644","33197556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012490","GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder.","Jerlhag E","2025","Endocrinology","narrative_review","article","10.1210/endocr/bqaf028","39980336","PMC11879929",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012491","Diabetic Ketoacidosis Complicating Gestational Diabetes Mellitus.","Villavicencio CA","2022","AACE clinical case reports","case_report","article","10.1016/j.aace.2022.07.002","36189139","PMC9508574",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0012492","Drug repurposing for disease-modifying effects in multiple system atrophy.","Jeong SH","2026","Translational neurodegeneration","randomized_trial","article","10.1186/s40035-026-00551-7","42010648","PMC13097543",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012493","Improved Localization of Insulinomas Using 68Ga-NODAGA-Exendin-4 PET/CT.","Boss M","2024","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","other","article","10.2967/jnumed.124.268158","39419553","PMC11619583",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0012494","A Unique Multi- and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Description and Assessment of Outcomes.","Dubrofsky L","2022","Canadian journal of kidney health and disease","nonrandomized_study","article","10.1177/20543581221081207","35251673","PMC8891862",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0012495","Tirzepatide-Based Therapy for Multidomain Metabolic Improvement in an Active Duty Service Member: A Case Report.","Kim SK","2026","Cureus","case_report","article","10.7759/cureus.114114","42703498","PMC13546570",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0012496","SELECT: a 10% reduction in body weight with GLP-1 receptor agonists improves kidney outcomes in overweight and obese patients without diabetes.","Theodorakopoulou M","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfae207","39304535",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0012497","Untangling obese asthma: Design of proof-of-concept study of semaglutide in poorly controlled asthma.","Tomasello A","2026","The journal of allergy and clinical immunology. Global","randomized_trial","article","10.1016/j.jacig.2025.100627","41567689","PMC12816845","ClinicalTrials.gov:NCT05254314","S001527","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0012498","Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.","Jacob L","2021","Diabetes, obesity & metabolism","other","article","10.1111/dom.14293","33319440",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012499","Action Mechanisms of Metformin Combined with Exenatide and Metformin Only in the Treatment of PCOS in Obese Patients.","Gan J","2023","International journal of endocrinology","other","article","10.1155/2023/4288004","38131036","PMC10735721",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012500","Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease.","Packer M","2020","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2019.09.002","31622581",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012501","Semaglutide-Associated Ischemic Colitis in a Patient Without Traditional Risk Factors: A Case Report.","Sekhon S","2025","Cureus","case_report","article","10.7759/cureus.78832","40084311","PMC11904261",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0012502","What is the evidence regarding the safety of new obesity pharmacotherapies.","Vidal J","2025","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-024-01488-5","38336863",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0012503","Endothelial Dysfunction and Platelet Hyperaggregation in Type 2 Diabetes Mellitus: The Era of Novel Anti-diabetic Agents.","Daios S","2021","Current medicinal chemistry","nonrandomized_study","article","10.2174/0929867327666201009143816","33038906",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0012504","Exploring the Impact of Semaglutide on Cognitive Function and Anxiety-Related Behaviors in a Murine Model of Alzheimer's Disease.","Boboc IKS","2024","Biomedicines","preclinical","article","10.3390/biomedicines12122689","39767596","PMC11673043",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012505","Letter to the Editor. Methodological concerns regarding a TriNetX-based analysis of GLP-1-RA use following IIH.","Huang KF","2025","Journal of neurosurgery","commentary","article","10.3171/2025.6.jns251620","41105984",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0012506","The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes.","Larsen AT","2024","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00092.2024","38864815",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012507","Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review.","Pardeshi G","2026","Clinical obesity","systematic_review","article","10.1111/cob.70042","40832978",null,"PROSPERO:CRD42024614466",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0012508","ADDITION OF DULAGLUTIDE FOR A HIGH-DOSE INSULIN REQUIRING PATIENT WITH TYPE 2 DIABETES MELLITUS: A REMARKABLE RESPONSE.","Kazim M","2019","AACE clinical case reports","case_report","article","10.4158/accr-2018-0192","31967020","PMC6873854",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0012509","Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials.","Ghosal S","2020","Current diabetes reviews","other","article","10.2174/1573399816666200206113549","32026781",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012510","Incretin based therapeutics: connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: \"Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation\" by Dai et al.","Dear AE","2013","Cardiovascular drugs and therapy","commentary","article","10.1007/s10557-013-6465-x","23722420",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0012511","A GLP-1 analog lowers ER stress and enhances protein folding to ameliorate homocysteine-induced endothelial dysfunction.","Cheng CK","2021","Acta pharmacologica Sinica","preclinical","article","10.1038/s41401-020-00589-x","33495519","PMC8463564",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012512","Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study.","Ilanga M","2023","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-023-10387-1","37700013",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012513","Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.","Handelsman Y","2019","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2018.11.009","30600136",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012514","Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes.","Philis-Tsimikas A","2024","Journal of diabetes science and technology","other_trial","article","10.1177/19322968221149041","36710452","PMC11089877","ClinicalTrials.gov:NCT01952145; ClinicalTrials.gov:NCT02501161","S001131; S001328","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Randomized Controlled Trial; Comparative Study; research-article; other; article"],["R0012515","Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types.","Alba MM","2025","Discover oncology","other","article","10.1007/s12672-025-04097-4","41331220","PMC12779865",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012516","A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes.","Alshali KZ","2016","Saudi medical journal","narrative_review","article","10.15537/smj.2016.8.15800","27464858","PMC5018698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Review; review-article; article"],["R0012517","Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.","Wang Y","2014","Journal of diabetes","case_report","article","10.1111/1753-0407.12077","23879890",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; Research Support, Non-U.S. Gov't; article"],["R0012518","Incretin-based therapies for type 2 diabetes mellitus.","Lovshin JA","2009","Nature reviews. Endocrinology","narrative_review","article","10.1038/nrendo.2009.48","19444259",null,null,"S000691","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; review"],["R0012519","Managing Adverse Effects of GLP-1 Agonists: Practical Insights From Dr. Bridget E. Shields.","Shields BE","2025","Cutis","other","article","10.12788/cutis.1286","41524642",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012520","Evaluation of Glycemic Control and Cost Savings Associated With Liraglutide Dose Reduction at a Veterans Affairs Hospital.","Imarhia FI","2020","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article","10.12788/fp.0057","33132682","PMC7592900",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012521","Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study.","Brancatisano A","2025","Obesity science & practice","other_trial","article","10.1002/osp4.70097","41234488","PMC12606011",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012522","A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.","Hauber AB","2016","Current medical research and opinion","other","article","10.1185/03007995.2015.1117433","26549576",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012523","Tirzepatide (Zepbound) for chronic weight management.",null,"2023","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2023.1692c","38133594",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012524","Body weight course in the DIAbetes and LifEstyle Cohort Twente (DIALECT-1)-A 20-year observational study.","Gant CM","2019","PloS one","nonrandomized_study","article","10.1371/journal.pone.0218400","31216324","PMC6583961",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0012525","Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis.","Berg G","2022","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2022.102562","35816950",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0012526","Risk of aspiration during general anaesthesia in patients on glucagon-like peptide-1 (GLP-1) receptor agonists: implications for patients on the kidney transplant waiting list.","Wijetunga I","2025","Clinical kidney journal","commentary","article","10.1093/ckj/sfaf110","40322681","PMC12044328",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012527","Tirzepatide among patients with psoriasis and obesity.","Nicolau J","2026","Medicina clinica","other","article","10.1016/j.medcli.2026.107618","42810204",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012528","Potential Lives Saved Through Widespread Global Availability of GLP-1 Receptor Agonists: A Modeling Study","Brook D","2024","medRxiv","other","preprint","10.1101/2024.11.11.24317112",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012529","Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression.","Hamaguchi E","2015","European review for medical and pharmacological sciences","preclinical","article",null,"25912591",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012530","The case for primary prevention of obesity in the era of GLP-1 therapies.","Holm S","2026","The Lancet regional health. Europe","narrative_review","article","10.1016/j.lanepe.2026.101679","42403918","PMC13330260",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012531","Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia.","Yanay O","2015","Journal of inflammation research","randomized_trial","article","10.2147/jir.s84993","26244029","PMC4521677",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0012532","Distinctive detection of insulinoma using [18F]FB(ePEG12)12-exendin-4 PET/CT.","Murakami T","2021","Scientific reports","preclinical","article","10.1038/s41598-021-94595-6","34294854","PMC8298522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012533","Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.","van der Aart-van der Beek AB","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14067","32329160","PMC7496075",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012534","Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential.","Alamgir M","2026","Drug design, development and therapy","other_trial","article","10.2147/dddt.s560039","41939431","PMC13050165",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0012535","Response to Cho et al's \"GLP-1 receptor agonist use is associated with increased rates of acne vulgaris diagnosis in non-diabetic obese women but not men: A retrospective cohort study\".","Thang CJ","2025","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.03.102","40451302",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0012536","Great Weight, Low Pressure-One Problem: GLP-1 Receptor Agonist-Associated Colonic Ischemia.","Ramrakhiani H","2025","Digestive diseases and sciences","other","article","10.1007/s10620-025-08984-2","40126752",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012537","Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review.","Lewandowski M","2026","Dermatology and therapy","narrative_review","article","10.1007/s13555-026-01909-5","42768237",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012538","Tirzepatide-Induced Functional Small Bowel Obstruction in a Surgically Naïve Patient: A Case Report.","Shimada T","2026","Clinical case reports","case_report","article","10.1002/ccr3.73085","42404678","PMC13328208",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0012539","Ghrelin and Orexin Interact to Increase Meal Size Through a Descending Hippocampus to Hindbrain Signaling Pathway.","Suarez AN","2020","Biological psychiatry","preclinical","article","10.1016/j.biopsych.2019.10.012","31836175","PMC7188579",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0012540","Unlocking the broad health benefits and risks of GLP-1 receptor agonist drugs.",null,"2025","Nature medicine","other","article","10.1038/s41591-024-03476-8","39849063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012541","In vitro performance of composition-equivalent PLGA microspheres encapsulating exenatide acetate by solvent evaporation.","Chandrashekar A","2023","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2023.123213","37423376",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012542","Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?","Eckel RH","2019","Clinical diabetes : a publication of the American Diabetes Association","other_trial","article","10.2337/cd19-0001","31660005","PMC6794224",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012543","Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity.","Yuan J","2024","Scientific reports","preclinical","article","10.1038/s41598-024-66998-8","39030216","PMC11271627",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012544","The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.","Brunchmann A","2019","Physiology & behavior","systematic_review","article","10.1016/j.physbeh.2019.03.029","30946836","PMC6520118",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review; research-article; review"],["R0012545","Real-world implementation of the 2020 KDIGO guidelines for diabetes management in chronic kidney disease: a single-center retrospective study.","Levin-Iaina N","2025","Frontiers in nephrology","nonrandomized_study","article","10.3389/fneph.2025.1664369","41031090","PMC12477010",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012546","Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes.","Palanca A","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01382-9","36847952","PMC10064368","ClinicalTrials.gov:NCT05535322","S002638","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012547","Definite benefits of GLP-1 receptor agonists: what is the risk of gastroparesis and lung aspiration?","Camilleri M","2025","Gut","other","article","10.1136/gutjnl-2024-333036","39153846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012548","Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.","Xiao C","2012","Arteriosclerosis, thrombosis, and vascular biology","randomized_trial","article","10.1161/atvbaha.112.246207","22492091",null,"ClinicalTrials.gov:NCT01056549","S001163","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012549","Abstract 198: Association of GLP‐1 Receptor Agonist Use with Clinical Outcomes in Diabetic Patients Hospitalized for Ischemic Stroke","Iourinets J","2024","Stroke (Hoboken, N.J.)","nonrandomized_study","article","10.1161/svin.04.suppl_1.198",null,"PMC12774021",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0012550","Liraglutide.","Drucker DJ","2010","Nature reviews. Drug discovery","other","article","10.1038/nrd3148","20357801",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012551","Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring-Driven Virtual Care Program: Prospective Study.","Majithia AR","2022","JMIR formative research","other_trial","article","10.2196/31629","35147501","PMC9019640","ClinicalTrials.gov:NCT03865381",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012552","GLP-1 Agonists and Body Contouring: Beyond Timing, Toward Tissue Quality and Total Body Strategies.","Tomaselli F","2025","Aesthetic plastic surgery","commentary","article","10.1007/s00266-025-05374-x","41145856",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012553","Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.","Li L","2016","BMC cardiovascular disorders","systematic_review","article","10.1186/s12872-016-0260-0","27169565","PMC4863354",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0012554","The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study.","Lewis JE","2025","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/14791641251322909","40080656","PMC11907515",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0012555","Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease.","Cruz AJL","2026","Cells","narrative_review","article","10.3390/cells15151377","42587786","PMC13464688",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012556","From Molecular Mechanisms to Clinical Strategies: A Comprehensive Overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).","Świerczek D","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27177825","42737722","PMC13565781",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012557","Can Semaglutide Bind Tighter to GLP-1R?","Li W","2020","Preprints.org","other","preprint","10.20944/preprints202007.0582.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012558","Therapeutic effects of exendin-4 on spinal cord injury via restoring autophagy function and decreasing necroptosis in neuron.","Gao X","2024","CNS neuroscience & therapeutics","preclinical","article","10.1111/cns.14835","39004783","PMC11246977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012559","[Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].","Scheen AJ","2014","Revue medicale suisse","other","article",null,"25272672",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0012560","DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.","Wang W","2022","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.13286","35762390","PMC9366571",null,"S000081","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0012561","GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.","Kumari P","2018","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2018.03.199","29601817",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012562","GLP-1 RAs and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Older Patients With Diabetes.","Fung KW","2025","JAMA ophthalmology","nonrandomized_study","article","10.1001/jamaophthalmol.2025.2299","40742732","PMC12314771",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012563","Association between GLP-1-based therapy and small-bowel transit time during capsule endoscopy: a prospective, multicentre, observational study.","Baker FA","2026","BMJ open gastroenterology","nonrandomized_study","article","10.1136/bmjgast-2026-002360","42457308","PMC13374423",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0012564","Wegovy: GPs to prescribe weight loss jab to prevent heart attacks and strokes.","Mahase E","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.s627","41916657",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0012565","Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.","Broglio F","2017","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12810","27762096",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0012566","Effect of Anti-Diabetic Medication Use on Sepsis Risk in Type 2 Diabetes Mellitus: A Multivariate Analysis.","Ulambayar B","2025","Geriatrics (Basel, Switzerland)","nonrandomized_study","article","10.3390/geriatrics10040108","40863575","PMC12385283",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012567","Obesity in Type 1 Diabetes: Moving Beyond the \"Lean\" Disease Paradigm to Understand Risk, Complications, and Treatment.","Tentolouris A","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00693-9","41721160","PMC12923423",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012568","Using Second-Generation Anti-Obesity Medications.","Schmitz SH","2024","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/dsi24-0002","39649687","PMC11623031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012569","Use of IDegLira to Intensify, Simplify, and Increase Appropriateness of Type 2 Diabetes Therapy: A Real-Life Experience.","Romano I","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01489-z","37883002","PMC10786810",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012570","Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial.","Hulst AH","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13927","31749275","PMC7079116",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; research-article; article"],["R0012571","Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions.","Mondoh A","2026","Obesity pillars","other","article","10.1016/j.obpill.2026.100256","41815755","PMC12972522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012572","Semaglutide Treatment Effects on Liver Fat Content in Obese Subjects with Metabolic-Associated Steatotic Liver Disease (MASLD).","Dusilová T","2024","Journal of clinical medicine","randomized_trial","article","10.3390/jcm13206100","39458050","PMC11508983",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0012573","Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease.","Inzucchi SE","2018","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2017.10.011","29407048",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012574","Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis.","Spiazzi BF","2026","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2026.113431","42442557",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0012575","Type 3c diabetes associated with chronic pancreatitis: A narrative review.","Rasheed A","2025","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","narrative_review","article","10.1016/j.pan.2025.08.005","40819996",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012576","Semaglutide, a Long-Acting GLP-1 Analogue, for the Management of Early-Onset Obesity due to MC4R Defect: A Case Report.","Gokul PR","2025","Hormone research in paediatrics","case_report","article","10.1159/000537921","38402868",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0012577","Missed Opportunities for Screening and Management of Dysglycemia among Patients Presenting with Acute Myocardial Infarction in North India: The Prospective NORIN STEMI Registry.","Ostrominski JW","2022","Global heart","nonrandomized_study","article","10.5334/gh.1140","36051328","PMC9374010",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012578","Allostatic Load in Patients with Type 2 Diabetes Treated with GLP-1 Receptor Agonists.","Yu Y","2026","Metabolic syndrome and related disorders","other","article","10.1177/15578518261431688","41830481",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012579","Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all.","Koufakis T","2020","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.12982","31449359",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0012580","Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.","Inagaki N","2022","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(22)00188-7","35914543",null,"ClinicalTrials.gov:NCT03861052","S000239","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012581","The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype.","Noguchi T","2024","Frontiers in neuroscience","preclinical","article","10.3389/fnins.2024.1342944","38426018","PMC10902060",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012582","Atherosclerotic features in patients with heart failure.","Ceasovschih A","2025","Archives of medical science : AMS","other","article","10.5114/aoms/208372","41078932","PMC12509874",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012583","[GLP-1 receptor agonists in hypertension - a new approach for difficult-to-treat blood pressure?].","van der Giet M","2025","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-025-4837-3","40180744",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012584","Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.","Holst JJ","2013","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2012.01628.x","22646532",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012585","A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.","Haddad F","2023","Life (Basel, Switzerland)","narrative_review","article","10.3390/life13041012","37109541","PMC10144237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012586","Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide.","Wang B","2025","Biomedical materials (Bristol, England)","preclinical","article","10.1088/1748-605x/adb2cf","39908666",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012587","GLP-1 Analogs Are Superior in Mediating Weight Loss But Not Glycemic Control in Diabetic Patients on Antidepressant Medications: A Retrospective Cohort Study.","Gonzalez CL","2021","The primary care companion for CNS disorders","nonrandomized_study","article","10.4088/pcc.20m02868","34507389",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012588","GLP-1 agonists: Good for what ails you?",null,"2025","The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry","other","article","10.1177/10738584251379859","40946153",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012589","GLP-1RAs in patients with psoriasis.","Paschou IA","2025","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-025-00635-5","39971882","PMC12339632",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012590","GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?","Brunton S","2014","International journal of clinical practice","narrative_review","article","10.1111/ijcp.12361","24499291","PMC4238422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Review; research-article; article"],["R0012591","Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study.","Matsushita M","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0474-5","30056503","PMC6167306",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; other; article"],["R0012592","Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis.","Kamalinia S","2020","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.100","31922027","PMC6947712",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0012593","Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies.","Witaszek T","2025","Biomedicines","randomized_trial","article","10.3390/biomedicines13102362","41153649","PMC12561117",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012594","The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test.","Isacson R","2011","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2010.10.008","20951130",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012595","Type 2-low Asthma: Epidemiology, Multiomics, and Emerging Therapies.","Mendez P","2026","Current allergy and asthma reports","narrative_review","article","10.1007/s11882-026-01294-1","42747714","PMC13582353",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012596","Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods.","Paduraru DN","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13123117","41463126","PMC12730309",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012597","Exploring Hypoglycemic Ketoacidosis in Nondiabetic Patients on Tirzepatide: Is Starvation the Culprit?","Bitar Z","2024","The American journal of case reports","case_report","article","10.12659/ajcr.946133","39686534","PMC11660008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; research-article; article"],["R0012598","Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink.","Jameson K","2016","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2015.1101372","26428701",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0012599","GLP-1 and GIP Changes after Sleeve Gastrectomy and Weight Regain in Adolescents. Do we need a Boost?","Shehata M","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-08168-x","40887512","PMC12540580",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012600","Benchmarking the medication efficiency and technological progress of diabetes drugs.","Zhang H","2024","Frontiers in public health","other","article","10.3389/fpubh.2024.1396832","39583077","PMC11582034",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012601","Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes.","Cattadori G","2019","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2019.107835","31479706",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012602","From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model.","Bosch R","2025","CPT: pharmacometrics & systems pharmacology","nonrandomized_study","article","10.1002/psp4.70074","40665896","PMC12439278","ClinicalTrials.gov:NCT03244800","S000151","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012603","The association between pre-pregnancy use of obesity medications and gestational weight gain: a retrospective cohort study","Piccinini-Vallis H","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9817569/v1",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0012604","Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report.","Khan AB","2023","Cureus","case_report","article","10.7759/cureus.38630","37284401","PMC10241188",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0012605","Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity.","Pennington B","2025","PharmacoEconomics","nonrandomized_study","article","10.1007/s40273-025-01520-0","40717166","PMC12450117",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0012606","Once-Weekly Semaglutide for Weight Management: A Clinical Review.","Fornes A","2022","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","other_trial","article","10.1177/87551225221092681","35832567","PMC9272494",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0012607","Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus.","Yaribeygi H","2021","BioMed research international","narrative_review","article","10.1155/2021/8163153","34471642","PMC8405289",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012608","Evaluation of glucagon-like peptide-1 receptor expression in nondiabetic and diabetic atherosclerotic mice using PET tracer 68Ga-NODAGA-exendin-4.","Ståhle M","2021","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00465.2020","33843281",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012609","When rapid weight loss backfires: hepatic encephalopathy from GLP-1 RA in MASH cirrhosis.","Lunardon LM","2025","Journal of gastrointestinal and liver diseases : JGLD","other","article","10.15403/jgld-6191","41004821",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012610","Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management.","Kanumilli N","2021","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2020.107813","33419634",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012611","Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.","Lorenz M","2013","Bioorganic & medicinal chemistry letters","narrative_review","article","10.1016/j.bmcl.2013.05.022","23743288",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012612","Research Progress of Diabetes-related Glaucoma: Mechanisms, Impacts and Management Strategies.","He L","2026","Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)","narrative_review","article","10.1007/s44402-026-00164-7","42642606",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012613","Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice.","Park S","2022","The Journal of biological chemistry","preclinical","article","10.1016/j.jbc.2022.102682","36356900","PMC9730228",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012614","Mounjaro: GP incentive to prescribe weight loss jabs won't tackle rollout problems, experts warn.","Mahase E","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.s370","41734965",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012615","Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists.","Mattingly TJ","2025","JAMA health forum","other","article","10.1001/jamahealthforum.2024.5015","39820386",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012616","Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.","Dejgaard TF","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13911","31696598",null,null,"S000485; S002165","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012617","Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation.","Usui R","2018","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.12858","29974670","PMC6031522",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Comment; letter"],["R0012618","Glucose lowering drug or strategy dependent impact of weight reduction on the prevention of CVD outcomes in Type 2 diabetes: a systematic review of CVOTs.","Lalić NM","2024","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2024.111816","39147102",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Systematic Review; Journal Article"],["R0012619","A new indication for semaglutide (Wegovy).",null,"2024","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2024.1701b","38691645",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012620","Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.","Davies MJ","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)00748-8","42259337",null,"ClinicalTrials.gov:NCT06579092","S003339","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; article"],["R0012621","Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.","Kawaguchi Y","2022","Advances in therapy","randomized_trial","article","10.1007/s12325-022-02138-w","35403949","PMC9122848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012622","Guideline-Directed Medical Therapies for Diabetic Kidney Disease Among Thai People With Type 2 Diabetes: A Real-World Data Based on Theptarin Diabetes Staging.","Chongvoranond P","2026","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.041.01.6239","42311550","PMC13269334",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012623","GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care.","Manne-Goehler J","2025","JAMA internal medicine","other","article","10.1001/jamainternmed.2024.3579","39401020",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012624","The Involvement of the Peptidergic Systems in Breast Cancer Development.","Sánchez ML","2025","Cancers","narrative_review","article","10.3390/cancers17223662","41301028","PMC12651768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012625","Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.","Rosenstock J","2023","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(23)01053-x","37385280",null,"ClinicalTrials.gov:NCT04867785","S000489","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012626","Introduction: Adolescent bariatric surgery in modern pediatric practice.","Tashiro J","2025","Current problems in pediatric and adolescent health care","other","article","10.1016/j.cppeds.2025.101883","41318287",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Introductory Journal Article; article"],["R0012627","Treatment of type 2 diabetes among medicare beneficiaries with and without alzheimer's disease: A retrospective cohort study.","Wang Y","2026","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-025-01838-8","41510365","PMC12775190",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0012628","Noninvasive quantitative evaluation of viable islet grafts using 111 In-exendin-4 SPECT/CT.","Botagarova A","2023","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.202201787rr","36906290","PMC11977520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012629","Clinical Insights into the Pathogenesis and Treatment Strategies of Acanthosis Nigricans: A Bibliometric Study of Current Trends and Future Directions.","Zeng J","2026","Clinical, cosmetic and investigational dermatology","other","article","10.2147/ccid.s572050","41835959","PMC12984052",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012630","Scalable and sustainable DMF-free solid-phase synthesis of liraglutideby 1-tert-butyl-3-ethylcarbodiimide-mediated couplings and catch-and-release acylation and purification strategies","Pacini L","2025","Research Square","other","preprint","10.21203/rs.3.rs-5738025/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0012631","Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.","Moonschi FH","2018","Acta diabetologica","narrative_review","article","10.1007/s00592-017-1086-7","29264724",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012632","Correction: Regimen comprising GLP‑1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre‑mixed insulin regimen.","Lin YH","2024","European journal of medical research","notice","article","10.1186/s40001-024-02149-z","39609905","PMC11603978",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0012633","Controversies on the effects of GLP-1 receptor agonist treatment on gastric emptying.","Rubio-Herrera MA","2025","Endocrinologia, diabetes y nutricion","other","article","10.1016/j.endien.2025.101538","39920030",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012634","Oxidation of methionine - is it limiting the diagnostic properties of 99mTc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist?","Janota B","2016","Nuclear medicine review. Central & Eastern Europe","preclinical","article","10.5603/nmr.2016.0021","27479787",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012635","Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66).","Yokoyama H","2022","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2021-002727","35504696","PMC9066475",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0012636","An expert narrative review on the brain-kidney axis in diabetic kidney disease: Mechanisms and therapeutic insights.","Zhang Z","2026","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2025.113055","41401898",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0012637","6567 Novel Indication of GLP-1 Receptor Agonists Beyond Weight Loss: Addressing Post-Gastric Bypass Late Dumping Syndrome",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455476",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012638","The 40% weight-reduction craze: market volatility, metabolic nuance, and the quest for sustainable health.","Han W","2026","Molecules and cells","narrative_review","article","10.1016/j.mocell.2026.100364","42070752","PMC13235340",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0012639","9232 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454755",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012640","6531 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454730",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012641","Liraglutide attenuates high glucose-induced endothelial cell senescence and dysfunction via SIRT1-mediated deacetylation of p53/p65.","Zhong W","2025","Tissue & cell","other","article","10.1016/j.tice.2025.102882","40198926",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012642","Correction to: Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.",null,"2026","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","notice","article","10.1093/europace/euag279","42837319","PMC13641080",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; Corrected and Republished Article; erratum"],["R0012643","GLP-1 receptor agonists and obesity care.","Franco JVA","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q2732","39672568",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0012644","First phase 3 trial of GLP-1 receptor agonist for neurodegeneration.","Kalia LV","2025","Lancet (London, England)","other_trial","article","10.1016/s0140-6736(25)00161-8","39919774",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; article"],["R0012645","GLP-1RA Exposure and Nonarteritic Anterior Ischemic Optic Neuropathy Prevalence by Diabetes Status.","Nagdeve P","2025","JAMA ophthalmology","nonrandomized_study","article","10.1001/jamaophthalmol.2025.2332","40705351","PMC12290904",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012646","Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.","Schmider W","2019","Current medical research and opinion","other","article","10.1080/03007995.2018.1558852","30550345",null,"ClinicalTrials.gov:NCT02058147; ClinicalTrials.gov:NCT02058160","S001199; S001409","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012647","Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.","Seino Y","2018","Journal of diabetes investigation","other_trial","article","10.1111/jdi.12694","28502112","PMC5835450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; research-article; article"],["R0012648","Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany.","Talay L","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70916","42186215","PMC13341323",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012649","Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites.","Chen N","2025","Journal of orthopaedic translation","preclinical","article","10.1016/j.jot.2025.09.002","41089557","PMC12516549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012650","Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson's Disease.","Panagaki T","2023","Journal of Parkinson's disease","other","article","10.3233/jpd-230030","37718851","PMC10657688",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012651","9189 Medullary Thyroid Cancer Due To A Novel Ret Oncogene Mutation In A Patient On Glp-1 Receptor Agonist",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454292",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012652","New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes.","Lee WY","2017","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2017.32.1.1","28181428","PMC5368107",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012653","Microglial M2 Polarization Mediated the Neuroprotective Effect of Morroniside in Transient MCAO-Induced Mice.","Liu H","2021","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2021.784329","34867417","PMC8640454",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012654","Liraglutide",null,"2006","National Institute of Child Health and Human Development, Bethesda (MD)","narrative_review","article",null,"30000036",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0012655","Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.","Kristensen KB","2021","Diabetologia","nonrandomized_study","article","10.1007/s00125-021-05424-4","33715024",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0012656","The effects of anti-obesity medications on bone metabolism: A critical appraisal.","Anastasilakis AD","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16541","40555693",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012657","Anaphylaxis to tirzepatide confirmed by positive skin prick testing.","Steele C","2026","Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology","other","article","10.1016/j.anai.2026.09.727","42735799",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012658","Commentary-Fasting Implications of GLP-1 Agonist Use in Pediatric Procedural Sedation.","Sullivan MD","2025","Anesthesia progress","commentary","article","10.2344/24-0034","41905387","PMC12169184",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0012659","Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.","Garber AJ","2011","Diabetes care","other_trial","article","10.2337/dc11-s231","21525469","PMC3632193",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0012660","Periprocedural Risks Associated With GLP-1 Receptor Agonists.","Khan R","2025","Gastroenterology","other","article","10.1053/j.gastro.2024.12.004","39701191",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012661","Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia.","Wu TH","2026","Journal of the Chinese Medical Association : JCMA","randomized_trial","article","10.1097/jcma.0000000000001394","42290292","PMC13387786","ClinicalTrials.gov:NCT01270191","S001002","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012662","Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster.","Alves PL","2017","Toxicon : official journal of the International Society on Toxinology","preclinical","article","10.1016/j.toxicon.2017.06.001","28579479",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012663","GLP-1 receptor agonists and retained gastric content: Is it much ado about nothing?","Camilleri M","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24215","39828635",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0012664","A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.","Gao X","2024","Clinical and translational science","randomized_trial","article","10.1111/cts.13775","38651744","PMC11036873","ClinicalTrials.gov:NCT05459285","S001958","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Comparative Study; research-article; article"],["R0012665","Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.","Dailey G","2019","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2018-000581","31114694","PMC6501856","ClinicalTrials.gov:NCT02058147; ClinicalTrials.gov:NCT02058160","S001199; S001409","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012666","Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.","Pereira MJ","2019","Drugs","narrative_review","article","10.1007/s40265-019-1057-0","30701480","PMC6394798",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0012667","GLP-1 receptor agonists beyond diabetes management.","eClinicalMedicine","2024","EClinicalMedicine","commentary","article","10.1016/j.eclinm.2024.103021","39764543","PMC11701480",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0012668","GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.","Marx N","2022","Circulation","narrative_review","article","10.1161/circulationaha.122.059595","36508493",null,null,"S001795","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0012669","Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart.","Lindsay RT","2023","Physiological reports","preclinical","article","10.14814/phy2.15597","36946315","PMC10031586",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012670","Using Compounded GLP-1 Receptor Agonists-Informing and Protecting Consumers.","Donohue JM","2025","JAMA health forum","other","article","10.1001/jamahealthforum.2024.5012","39820390",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012671","Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.","Rodbard HW","2018","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2018-00070","29688502","PMC5991220","ClinicalTrials.gov:NCT02305381","S001872","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; research-article; article"],["R0012672","Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy.","Zhou L","2021","JCI insight","preclinical","article","10.1172/jci.insight.93382","34673570","PMC8675187",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0012673","Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.","Sattar N","2021","The lancet. Diabetes & endocrinology","systematic_review","article","10.1016/s2213-8587(21)00203-5","34425083",null,"PROSPERO:CRD42021259711","S001260; S002481","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; review"],["R0012674","A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.","Sesti G","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13957","31903724","PMC7187233","ClinicalTrials.gov:NCT02501161","S001131","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0012675","Can the incidence of voluntarily reported side effects support the argument for a clinically relevant GLP-1RA tachyphylaxis? Comment on Br J Anaesth 2025; 134:1486-1496.","Hobai IA","2025","British journal of anaesthesia","commentary","article","10.1016/j.bja.2025.03.015","40348676","PMC12597420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012676","Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine.","Tomono T","2020","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2020.07.003","32681963",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012677","Design, evaluation, and in vitro-in vivo correlation of self-nanoemulsifying drug delivery systems to improve the oral absorption of exenatide.","Venkatasubramanian R","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.01.013","39805462",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012678","Hospitalization in adults aged 75 years and older with type 2 diabetes: the role of kidney impairment and glycemic control.","Magamba B","2026","BMC geriatrics","nonrandomized_study","article","10.1186/s12877-026-08386-7","42834370","PMC13640178",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; article"],["R0012679","Molecular Anatomy of GLP-1 Signaling in the Human Nodose Ganglion.","Sapio MR","2026","The Journal of comparative neurology","preclinical","article","10.1002/cne.70146","41814131",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0012680","The role of glucagon-like peptides in osteosarcopenia.","Tufail E","2025","The Journal of endocrinology","narrative_review","article","10.1530/joe-24-0210","39656031",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012681","Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.","Sattar N","2026","PloS one","randomized_trial","article","10.1371/journal.pone.0345032","42594122","PMC13472364",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0012682","A Retrospective Analysis of Liraglutide (GLP-1 Agonist) Use in a Chinchilla (Chinchilla lanigera) Model of Auditory Blast Injury.","Marchi D","2024","Comparative medicine","nonrandomized_study","article","10.30802/aalas-cm-23-000077","38649263","PMC11267444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; article"],["R0012683","Role of Exendin-4 Functional Imaging in Diagnosis of Insulinoma: A Systematic Review.","Sidrak MMA","2023","Life (Basel, Switzerland)","systematic_review","article","10.3390/life13040989","37109517","PMC10142629",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0012684","GLP-1 Receptor Agonists, Allostatic Load, and Reframing the Glaucoma Paradigm.","Bhartiya S","2025","Journal of current glaucoma practice","commentary","article","10.5005/jp-journals-10078-1471","40417146","PMC12096885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0012685","Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.","Davies MJ","2017","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12980","28432746","PMC5697595","ClinicalTrials.gov:NCT02058147","S001199","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Equivalence Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0012686","Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment.","Phakey S","2024","Australian journal of general practice","nonrandomized_study","article","10.31128/ajgp/04-23-6814","38316483",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0012687","Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.","Van Gaal L","2014","Journal of clinical & translational endocrinology","randomized_trial","article","10.1016/j.jcte.2014.03.001","29159080","PMC5685032",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0012688","Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.","Drake T","2024","Annals of internal medicine","systematic_review","article","10.7326/m23-1490","38639549",null,"PROSPERO:CRD42022322129",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; Network Meta-Analysis; review"],["R0012689","Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.","Lisco G","2021","Endocrine, metabolic & immune disorders drug targets","randomized_trial","article","10.2174/1871530320666200705211224","32628602",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0012690","Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations.","Sonmez A","2022","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.13266","35434900","PMC9366572",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0012691","Glucagon Receptor Signaling and Lipid Metabolism.","Galsgaard KD","2019","Frontiers in physiology","other","article","10.3389/fphys.2019.00413","31068828","PMC6491692",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012692","Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.","Mann JFE","2020","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.11881019","32132141","PMC7133133","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0012693","Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.","Gallwitz B","2011","Drugs","narrative_review","article","10.2165/11592810-000000000-00000","21902291",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012694","Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy.","Viana DPDC","2026","Maturitas","narrative_review","article","10.1016/j.maturitas.2026.109116","42721915",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012695","A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials.","Aroda VR","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13162","29364586",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0012696","Response to Thang et al's \"Response to Cho et al's 'GLP-1 receptor agonist use is associated with increased rates of acne vulgaris diagnosis in non-diabetic obese women but not men: A retrospective cohort study'\".","Cho SW","2025","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.04.085","40451305",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0012697","FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management.","Abbasi J","2023","JAMA","other","article","10.1001/jama.2023.24539","37966831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012698","Administration of the GLP-1 receptor agonist exenatide in rats improves functional recovery after spinal cord injury by reducing endoplasmic reticulum stress.","Nomura S","2023","IBRO neuroscience reports","preclinical","article","10.1016/j.ibneur.2023.09.003","37822517","PMC10562917",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012699","The Effect of Feeding Behavior on Hypothalamus in Obese Type 2 Diabetic Rats with Glucagon-like Peptide-1 Receptor Agonist Intervention.","Lu K","2018","Obesity facts","preclinical","article","10.1159/000486316","29788009","PMC6103358",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012700","Considerations on peri-operative management of GLP-1 receptor agonists.","Mizubuti GB","2025","Anaesthesia","commentary","article","10.1111/anae.16524","39689899",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012701","GLP-1 receptor agonists and the emergence of treatment-related stigma: a call for conceptual clarity.","Post SM","2026","International journal of obesity (2005)","narrative_review","article","10.1038/s41366-026-02200-5","42608457",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012702","Ghrelin system and GLP-1 as potential treatment targets for alcohol use disorder.","Jerlhag E","2024","International review of neurobiology","preclinical","article","10.1016/bs.irn.2024.07.006","39523062",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0012703","Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes.","Yamazaki S","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-022-01292-2","35793047","PMC9309109","UMIN:UMIN000034951",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0012704","Pharmacological intervention for diabetes after pregnancy prevention in women with prior gestational diabetes: A scoping review.","Pancer J","2020","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2020.107998","31911249",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Scoping Review"],["R0012705","THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10555414",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012706","Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025;48:292-300.","Huang J","2025","Diabetes care","systematic_review","article","10.2337/dc25-0267","40392995",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; letter"],["R0012707","Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.","Badjatiya A","2019","Circulation. Cardiovascular interventions","other_trial","article","10.1161/circinterventions.119.008018","31752517",null,"ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0012708","Exenatide Prevents Diet-induced Hepatocellular Injury in A CEACAM1-Dependent Mechanism.","Ghadieh HE","2017","Journal of diabetes and treatment","preclinical","article","10.29011/2574.7568.000033","29431170","PMC5806705",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012709","Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.","Xie Y","2020","Diabetes care","nonrandomized_study","article","10.2337/dc20-1890","32938746",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0012710","Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial.","Caballero-Corbalán J","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71204","42595732","PMC13646360",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0012711","Incretin-based therapies in 2021 - Current status and perspectives for the future.","Rizzo M","2021","Metabolism: clinical and experimental","commentary","article","10.1016/j.metabol.2021.154843","34333000","PMC8321622",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0012712","Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New.","Goldenberg RM","2018","Canadian journal of diabetes","case_report","article","10.1016/j.jcjd.2017.06.008","28822777",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article; Review"],["R0012713","Diabetes Care During Hajj.","Shaikh S","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-020-00944-5","33063269","PMC7561249",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012714","[How I manage a patient with type 2 diabetes not well controlled with a metformin plus gliptin combination].","Scheen AJ","2019","Revue medicale de Liege","other","article",null,"31486312",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Practice Guideline; Journal Article; other"],["R0012715","Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).","Frias JP","2024","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgae038","38252888","PMC11180500",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0012716","Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354.","Rees TA","2024","Frontiers in pharmacology","other","article","10.3389/fphar.2024.1463313","39464637","PMC11502443",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012717","Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.","Yang B","2022","Molecular metabolism","preclinical","article","10.1016/j.molmet.2022.101638","36400403","PMC9719863",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012718","Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.","Kaul S","2017","Diabetes care","randomized_trial","article","10.2337/dc17-0291","28637887",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0012719","Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.","Tang M","2025","Journal of the American Society of Nephrology : JASN","other","article","10.1681/asn.0000000620","39774583","PMC11975254",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012720","Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl syndrome mouse model.","Singh A","2025","The Journal of clinical investigation","preclinical","article","10.1172/jci184636","40233116","PMC12165790",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012721","Reduced insulin use and diabetes complications upon introduction of SGLT-2 inhibitors and GLP1-receptor agonists in low- and middle-income countries: A microsimulation.","Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)","2025","PLoS medicine","other_trial","article","10.1371/journal.pmed.1004559","40245017","PMC12005516",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012722","Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice.","Rout S","2026","Diabetes","preclinical","article","10.2337/db26-0229","42390988","PMC13493208",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article; other"],["R0012723","Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).","Mentz RJ","2017","American heart journal","randomized_trial","article","10.1016/j.ahj.2017.02.005","28454792","PMC9849915","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0012724","Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.","Karagiannis T","2024","Diabetologia","systematic_review","article","10.1007/s00125-024-06144-1","38613667","PMC11153294","PROSPERO:CRD42022382594",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review-article; review"],["R0012725","[Nephrology highlights in 2025: Diagnostic and therapeutic advances and emerging challenges].","Flahault A","2026","Nephrologie & therapeutique","other","article","10.1684/ndt.2026.157","41493087",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012726","Investigating socioeconomic disparities in prescribing new diabetes medications in individuals with type 2 diabetes and very high cardiovascular risk in the Netherlands.","Ardesch FH","2025","Primary care diabetes","other","article","10.1016/j.pcd.2024.12.011","39809690",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012727","Intranasal Exendin-4 modifies necroptosis-mediated innate immune response to combat septic encephalopathy in rats: Role of mTORC1 in immunogenic and tolerogenic cell demise.","Zaky DA","2023","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2023.176191","37967645",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012728","Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?","Deed G","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-019-0663-x","31292928","PMC6778570",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0012729","Exploratory safety investigations in normal, freely moving Göttingen Minipigs using telemetry: Pharmacological validation.","Jacobsen J","2025","Journal of pharmacological and toxicological methods","preclinical","article","10.1016/j.vascn.2025.108395","40934983",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012730","Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.","Woodward HN","2014","Patient preference and adherence","other_trial","article","10.2147/ppa.s53075","24926194","PMC4049886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article; review"],["R0012731","Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database.","Mata-Cases M","2021","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2021.02.003","33602606",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012732","The era of GLP-1 receptor agonists: costs versus benefits.","The Lancet Diabetes Endocrinology","2025","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(24)00376-0","39674182",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0012733","Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.","Khani E","2026","Journal of clinical pharmacology","systematic_review","article","10.1002/jcph.70248","42612051","PMC13485131","PROSPERO:CRD42025649542",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; Review; review"],["R0012734","Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD).","Michalak W","2025","Journal of medical economics","nonrandomized_study","article","10.1080/13696998.2025.2526282","40579810",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0012735","Tirzepatide and Glucagon-like Peptide-1/Glucose-dependent Insulinotropic Polypeptide Therapy: Quality of Life, Filipino Diet Culture, and Safe Access.","Funa AA","2026","JMA journal","commentary","article","10.31662/jmaj.2026-0320","42840407","PMC13639644",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012736","Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models.","Vercalsteren E","2026","Diabetologia","preclinical","article","10.1007/s00125-025-06567-4","41094027","PMC12686085",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012737","GLP-1 Receptor Agonists and the Risk of Thyroid Cancer.","Bezin J","2023","Diabetes care","nonrandomized_study","article","10.2337/dc22-1148","36356111",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0012738","Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.","Bandyopadhyay I","2022","Current drug targets","narrative_review","article","10.2174/1389450122666210901125420","34468297",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012739","The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration.","Cencioni C","2025","Journal of experimental & clinical cancer research : CR","preclinical","article","10.1186/s13046-024-03263-w","39828692","PMC11744909",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0012740","Responses to Editorial on Prescribing GLP-1 Agonists for Weight Loss.","Spencer J","2025","American family physician","commentary","article",null,"40961295",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0012741","Emergence of \"ozempic face\": addressing unintended consequences of rapid weight loss.","Jodat Z","2026","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000004254","41675819","PMC12889234",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012742","Impact of Semaglutide on Osteoarthritis Risk in Obese Patients: A Retrospective Cohort Study","Baser O","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3443036/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0012743","Thin Evidence, Heavy Need: The Case for GLP-1 Agonist Trials Specific to Patients With HFrEF.","Vest AR","2026","JACC. Heart failure","commentary","article","10.1016/j.jchf.2025.102715","41128714",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0012744","Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH","Perakakis N","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.642",null,"PMC8089912",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0012745","Senescent obesity signature in breast cancer: a paradigm of reverse cardio-oncology.","Carbone F","2026","European heart journal","narrative_review","article","10.1093/eurheartj/ehag144","41885139","PMC13577752",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012746","Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0·9 million adults with Diabetes in Hong Kong (2002-2019).","Yang A","2022","The Lancet regional health. Western Pacific","nonrandomized_study","article","10.1016/j.lanwpc.2022.100509","35789825","PMC9249907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012747","Exendin-4 affects calcium signalling predominantly during activation and activity of beta cell networks in acute mouse pancreas tissue slices.","Paradiž Leitgeb E","2023","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2023.1315520","38292770","PMC10826511",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012748","Semaglutide engages distinct brainstem-to-hypothalamus circuits to suppress motivated feeding and regulate ketogenesis and energy expenditure","Sköldheden SB","2026","bioRxiv","other","preprint","10.64898/2026.09.04.749561",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012749","Response to Comment on Wong et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025;48:292-300.","Wong HJ","2025","Diabetes care","systematic_review","article","10.2337/dci25-0023","40392996",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; review"],["R0012750","Is insulin the most effective injectable antihyperglycaemic therapy?","Buse JB","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12402","25323312",null,null,"S002098","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012751","Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.","Wilson JM","2026","Alzheimer's & dementia : the journal of the Alzheimer's Association","other_trial","article","10.1002/alz.71391","41988866","PMC13084528","ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0012752","Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide.","Kato K","2025","The American journal of the medical sciences","case_report","article","10.1016/j.amjms.2024.06.030","38986908",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0012753","Effects of Semaglutide on Body Weight in Clozapine-Treated Individuals with Schizophrenia and Obesity: A Randomized Controlled Trial","Siskind D",null,"European psychiatry : the journal of the Association of European Psychiatrists","randomized_trial","article",null,null,"PMC13443650",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0012754","Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists.","Kane MP","2021","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.1093/ajhp/zxaa413","33354706","PMC7970404",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0012755","The promise and hope of GLP-1 receptor agonists.","Sumithran P","2025","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(24)00315-2","39608382",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0012756","12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453490",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012757","Evaluation of cultivation performance of S. cerevisiae strains expressing GLP-1-GIP peptide precursors.","Voulgaris I","2026","Biotechnology letters","other","article","10.1007/s10529-026-03704-w","41642357",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012758","Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin.","Uchinuma H","2020","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-020-0542-5","32381085","PMC7203793",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0012759","Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward.","Toro-Tobon D","2025","Thyroid : official journal of the American Thyroid Association","commentary","article","10.1089/thy.2024.0690","39772719","PMC11958912",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0012760","Exendin-4 regulates the MAPK and WNT signaling pathways to alleviate the osteogenic inhibition of periodontal ligament stem cells in a high glucose environment.","Wang M","2023","Open medicine (Warsaw, Poland)","other","article","10.1515/med-2023-0692","37034502","PMC10080709",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012761","Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study.","Tang B","2024","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2024.102689","39429814","PMC11490655",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012762","TikTok's take on adverse effects for glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.","Wantuch GA","2025","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2025.102384","40049364",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study"],["R0012763","Impact of ethnicity and antihyperglycemic medications on dementia incidence in older adults with type 2 diabetes.","Chertok Shacham E","2026","Endocrine connections","nonrandomized_study","article","10.1530/ec-25-0593","41670429","PMC12926960",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012764","The Benefits of Exercise Training in Combination With Weight Loss Therapies.","Jiang BC","2025","Diabetes","narrative_review","article","10.2337/dbi25-0001","40627343","PMC12418233",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012765","GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks.","Ilias I","2024","Frontiers in clinical diabetes and healthcare","nonrandomized_study","article","10.3389/fcdhc.2024.1530811","39850851","PMC11754396",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; discussion; article"],["R0012766","Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?","Papaetis GS","2025","Archives of medical sciences. Atherosclerotic diseases","other","article","10.5114/amsad/202298","40620743","PMC12223985",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012767","A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications.","Jordan B","2026","Expert opinion on drug safety","other","article","10.1080/14740338.2026.2663185","42010938",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012768","Exploring omics signature in the cardiovascular response to semaglutide: Mechanistic insights and clinical implications.","Vitorino R","2025","European journal of clinical investigation","narrative_review","article","10.1111/eci.14334","39400314",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012769","Optimal Design of Drug-Drug Interaction Studies for the GLP-1 Receptor Agonist Drug Class for Weight Management: Closing a Potential Data Gap.","Weber E","2025","Journal of clinical pharmacology","other","article","10.1002/jcph.70020","40099699",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012770","Titration and discontinuation of semaglutide for weight management in commercially insured US adults.","Xu Y","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24315","40464214","PMC12213178",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012771","One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.","Svensson CK","2019","Acta psychiatrica Scandinavica","randomized_trial","article","10.1111/acps.12982","30374965",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012772","Compounding stigma: An experimental study comparing perceptions of an individual using Ozempic, bariatric surgery, or behavior modification.","Rosenthal MH","2026","Social science & medicine (1982)","randomized_trial","article","10.1016/j.socscimed.2026.119710","42612445",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0012773","Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease - from Pathophysiology to Effective Management Overview.","Prisacaru V","2026","International journal of chronic obstructive pulmonary disease","narrative_review","article","10.2147/copd.s609302","42261400","PMC13242804",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review; article"],["R0012774","Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.","Okamoto A","2021","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-021-00899-9","34900848","PMC8630305",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0012775","Weight Management in Adolescents with Polycystic Ovary Syndrome.","Moore JM","2021","Current obesity reports","narrative_review","article","10.1007/s13679-021-00437-x","34043216","PMC8898097",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0012776","Effects of a long-acting secretin peptide analog alone and in combination with a GLP-1R agonist in a diet-induced obesity mouse model.","Loeffler M","2023","Molecular metabolism","preclinical","article","10.1016/j.molmet.2023.101765","37390979","PMC10344952",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012777","Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.","Cho YM","2013","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2013.28.4.262","24396690","PMC3871042",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012778","Dumping Syndrome After Bariatric Surgery: Advanced Nutritional Perspectives and Integrated Pharmacological Management.","Cano R","2025","Nutrients","randomized_trial","article","10.3390/nu17193123","41097200","PMC12525866",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012779","Transdermal \"Natural GLP-1\" Dietary Supplements Violate Law and Place Patients at Risk.","White CM","2026","The Annals of pharmacotherapy","commentary","article","10.1177/10600280251407145","41480958",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0012780","Noninvasive evaluation of donor and native pancreases following simultaneous pancreas-kidney transplantation using positron emission tomography/computed tomography.","Murakami T","2023","Journal of diabetes investigation","other","article","10.1111/jdi.14045","37377043","PMC10512903",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0012781","Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?","Muskiet MHA","2026","Lancet (London, England)","other_trial","article","10.1016/s0140-6736(25)01776-3","41207308",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0012782","Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesity.","Brancato D","2026","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2026.109419","42805130",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0012783","Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes.","Mahase E","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p2074","37696547",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012784","Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.","Monami M","2011","Experimental diabetes research","systematic_review","article","10.1155/2011/215764","21584276","PMC3092497",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0012785","Novel treatments for Parkinson's disease.","Yin Y","2026","Chinese medical journal","randomized_trial","article","10.1097/cm9.0000000000004163","42366511",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0012786","Liraglutide Attenuates Hepatocyte Ferroptosis in an In Vitro Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.","Bai J","2026","Physiological research","preclinical","article",null,"42695487",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012787","Characteristics of pregnant women with diabetes using injectable glucose-lowering drugs in the EVOLVE study.","Mathiesen ER","2022","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians","other","article","10.1080/14767058.2021.1940132","34182866",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Multicenter Study; Journal Article; article"],["R0012788","Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.","Brock C","2019","British journal of clinical pharmacology","randomized_trial","article","10.1111/bcp.14063","31338868","PMC6848951","ClinicalTrials.gov:NCT02138045","S001560","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012789","Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.","Martin CK","2025","Nature medicine","randomized_trial","article","10.1038/s41591-025-03774-9","40555748","PMC12443625","ClinicalTrials.gov:NCT04311411","S000411","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0012790","Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.","Kumarathurai P","2017","Diabetes care","randomized_trial","article","10.2337/dc16-1580","27797930",null,"ClinicalTrials.gov:NCT01595789","S001197","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0012791","Methodological Considerations in Assessing the Association Between GLP-1 RA and Pancreatitis.","Jean SS","2025","The American journal of gastroenterology","other","article","10.14309/ajg.0000000000003623","40758134",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012792","Pharmacological interventions for the treatment of obesity in children and adolescents.","Gerardi C","2026","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd015986","42125960","PMC13169147","PROSPERO:CRD42023433123",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0012793","Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.","Janez A","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13944","31858673","PMC7079143",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0012794","Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.","Raparelli V","2020","Journal of the American Heart Association","randomized_trial","article","10.1161/jaha.119.012940","31902326","PMC6988160",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012795","Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.","Davidson JA","2016","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12653","26936426",null,null,"S001094; S002222; S002230; S002361","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; Meta-Analysis; article"],["R0012796","GLP-1 analogs and regional adiposity: A systematic review and meta-analysis.","Akoumianakis I","2023","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13574","37191219",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0012797","Effects of glucose-lowering agents on ischemic stroke.","Avgerinos K","2017","World journal of diabetes","randomized_trial","article","10.4239/wjd.v8.i6.270","28694927","PMC5483425",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012798","New therapeutic options for metabolic-associated steatotic liver disease.","Straatmijer T","2026","British journal of clinical pharmacology","narrative_review","article","10.1002/bcp.70795","42661253",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012799","Effect of sex on sodium-glucose co-transporter-2 antagonists and glucagon-like peptide-1 agonists in heart failure.","Philip MA","2024","ESC heart failure","systematic_review","article","10.1002/ehf2.14979","39041458","PMC11631328",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; research-article; article"],["R0012800","Storage and Utilization of Glycogen by Mouse Liver during Adaptation to Nutritional Changes Are GLP-1 and PASK Dependent.","Pérez-García A","2021","Nutrients","preclinical","article","10.3390/nu13082552","34444712","PMC8399311",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012801","Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale.","Winhusen TJ","2026","Contemporary clinical trials","protocol","article","10.1016/j.cct.2026.108437","42600923",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Clinical Trial Protocol; article"],["R0012802","Sex-specific metabolic responses to modulation of the glucagon-FGF21 axis in female mice","Merrild C","2025","bioRxiv","preclinical","preprint","10.1101/2025.04.09.647697",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012803","Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.","Singh AK","2022","World journal of cardiology","randomized_trial","article","10.4330/wjc.v14.i6.329","35979179","PMC9258221",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012804","The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study.","Fan Y","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16203","39840511",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; article"],["R0012805","Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety.","Mills EP","2018","Therapeutic advances in endocrinology and metabolism","randomized_trial","article","10.1177/2042018817741852","29344336","PMC5761952",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012806","Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study.","Pérez-Pevida B","2026","Clinical nutrition ESPEN","randomized_trial","article","10.1016/j.clnesp.2026.105005","42542297",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Observational Study; article"],["R0012807","Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.","Cherney DZI","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","protocol","article","10.1093/ndt/gfaf114","40608494","PMC12559791","ClinicalTrials.gov:NCT04865770","S000395","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0012808","Peer Referral Pathways and 6-Month Outcomes in a Tirzepatide-Supported Digital Weight Loss Service: Retrospective Cohort Study.","Talay L","2026","Journal of medical Internet research","nonrandomized_study","article","10.2196/105583","42804756","PMC13618988",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; letter; article"],["R0012809","Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation.","Rutledge C","2024","Cardiovascular drugs and therapy","nonrandomized_study","article","10.1007/s10557-023-07482-9","37382868","PMC10788853",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; research-article; article"],["R0012810","The role of GLP-1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system.","Kanellis C","2025","The Medical journal of Australia","randomized_trial","article","10.5694/mja2.52582","39789665",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0012811","Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages.","Whitley HP","2023","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd23-0023","37456085","PMC10338283",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012812","Can Semaglutide offer hope for patients with obesity-related heart failure?","Olatunji G","2024","Current problems in cardiology","narrative_review","article","10.1016/j.cpcardiol.2024.102697","38871039",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012813","GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats.","Oertel M","2024","Endocrine connections","randomized_trial","article","10.1530/ec-23-0398","38300808","PMC10895316",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0012814","β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy.","Seino S","2017","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12995","28880474",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012815","Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide.","Faurschou A","2014","Acta diabetologica","randomized_trial","article","10.1007/s00592-011-0359-9","22160246",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Case Reports; Journal Article; article"],["R0012816","A microencapsulation strategy for intranasal semaglutide delivery.","Baldelli A","2026","Journal of microencapsulation","other","article","10.1080/02652048.2026.2722030","42642986",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012817","Tirzepatide: Clinical review of the \"twincretin\" injectable.","Krauss Z","2023","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.1093/ajhp/zxad080","37070418",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; article"],["R0012818","Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care 2026;49:XXXX-XXXX.","Chen L","2026","Diabetes care","randomized_trial","article","10.2337/dc26-0540","42765971",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","2","FALSE","Letter; article"],["R0012819","Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk.","de Oliveira Costa J","2025","European journal of clinical pharmacology","other","article","10.1007/s00228-025-03870-2","40588647","PMC12398476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012820","Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.","Milluzzo A","2026","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-026-02189-x","42668312",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0012821","The use of GLP-1 receptor agonists in hospitalised patients: An untapped potential.","Mustafa OG","2019","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.3191","31141838","PMC6899667",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012822","Novel Trajectories Towards Possible Effects of Semaglutide for Amelioration of Reserpine-induced Fibromyalgia in Rats: Contribution of cAMP/PKA/p-CREB and M1/M2 Microglia Polarization.","Shafiek MZ","2025","Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","preclinical","article","10.1007/s11481-025-10196-4","40240584","PMC12003577",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012823","Pharmacokinetics and Food Effect of HDM1002, a Novel Oral Small-Molecule GLP-1 Receptor Agonist, in Healthy Chinese Volunteers: A Bioequivalence Study.","Huang C","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70931","42310909","PMC13448887","ChiCTR:ChiCTR2500111569",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0012824","Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.","Longato E","2021","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-021-01414-3","34774054","PMC8590792",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0012825","Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice","Liu W","2023","Research Square","preclinical","preprint","10.21203/rs.3.rs-3274996/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012826","Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.","Leuthardt AS","2023","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2023.175912","37454968",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012827","Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management","Enebo L","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.051",null,"PMC8089143",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0012828","Changes in fibroblast growth factor 21 levels associated with alcohol consumption and smoking cessation.","Sailer CO","2026","Endocrine connections","other","article","10.1530/ec-25-0713","41384608","PMC12782897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012829","Zepbound: A novel pharmacological approach to Obstructive Sleep Apnoea management.","Aamir MB","2025","JPMA. The Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.30330","41418157",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0012830","Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats.","Shi S","2022","Drug delivery","preclinical","article","10.1080/10717544.2022.2036873","35156499","PMC8856071",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012831","Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.","Bentley-Lewis R","2015","American heart journal","randomized_trial","article","10.1016/j.ahj.2015.02.002","25965710",null,"ClinicalTrials.gov:NCT01147250","S001991","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012832","Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes.","Cowart K","2021","Journal of clinical pharmacy and therapeutics","systematic_review","article","10.1111/jcpt.13270","33067896",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0012833","Novel Drugs for Diabetes Therapy.","Heise T","2022","Handbook of experimental pharmacology","narrative_review","article","10.1007/164_2021_574","35112236",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012834","Case Report: Tirzepatide improves glycemic control in Rabson-Mendenhall syndrome.","Araújo-Vilar D","2026","Frontiers in endocrinology","case_report","article","10.3389/fendo.2026.1945251","42729636","PMC13563371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0012835","Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2.","Carydias E","2022","Children (Basel, Switzerland)","systematic_review","article","10.3390/children9101572","36291508","PMC9600106",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0012836","Criteria of frail older people with type 2 diabetes who are suitable for SGLT-2 inhibitors and GLP-1RA therapy.","Abdelhafiz AH","2025","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2025.109193","41124773",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012837","Harnessing Herbal Power: A Systematic Review of Phytopharmaceuticals in Type 2 Diabetes Management.","Chattopadhyay K","2026","Journal of the American Nutrition Association","systematic_review","article","10.1080/27697061.2026.2650457","42008388",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Review; review"],["R0012838","Insights into Nutrient-stimulated Hormone Dynamics and Obesity: A Mathematical Modeling Study Using Bioinformatics Tools","Andrade LJdO","2023","Research Square","other","preprint","10.21203/rs.3.rs-3464228/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012839","Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.","Angarita GA","2021","Drug and alcohol dependence","preclinical","article","10.1016/j.drugalcdep.2021.108614","33621809","PMC8026565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0012840","Changes in diabetes prescription patterns following Affordable Care Act Medicaid expansion.","Gemelas J","2021","BMJ open diabetes research & care","other","article","10.1136/bmjdrc-2021-002135","34933870","PMC8679078",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; research-article; conference-abstract"],["R0012841","Precision nutrition testing is the future of personalized care: evidence and coverage policies for equitable access.","Horn DM","2026","Health affairs scholar","commentary","article","10.1093/haschl/qxag247","42799244","PMC13614476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0012842","Glycosylation Improves the Proteolytic Stability of Exenatide.","Chandrashekar C","2023","Bioconjugate chemistry","other","article","10.1021/acs.bioconjchem.3c00120","37192432",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012843","[Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes].","Álvarez-Guisasola F","2019","Atencion primaria","other","article","10.1016/j.aprim.2019.05.014","31320123","PMC6836897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012844","Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.","Luo J","2022","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-021-07331-1","35048301","PMC9585108",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0012845","Metabolic Syndrome: From Mechanisms to Therapeutic Interventions.","Yan M","2026","MedComm","narrative_review","article","10.1002/mco2.70934","42639235","PMC13501127",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012846","County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries.","Hanna J","2022","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2022.100370","35968531","PMC9364091",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012847","The 100 top-cited articles in diabetic kidney disease: a bibliometric analysis.","Huang Z","2021","Renal failure","other","article","10.1080/0886022x.2021.1919528","33941037","PMC8901283",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012848","In Older Adults With Type 2 Diabetes, GLP-1 Receptor Agonists Decrease Major Adverse Cardiovascular Events; SGLT-2 Inhibitors Prevent Heart Failure Hospitalizations.","Barry HC","2025","American family physician","other","article",null,"40106300",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012849","FRI067 Efficacy And Safety Of Glucagon-like Peptide 1 Analogs And Agonists (aGLP1) In Overweight/Obese Patients: A Systematic Review And An Updated Network Meta-analysis",null,"2023","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC10553987",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0012850","Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.","Mody R","2020","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2020.09.011","33256915",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0012851","The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case-control study.","Harmatz D","2022","Israel journal of health policy research","nonrandomized_study","article","10.1186/s13584-022-00513-0","35241170","PMC8896278",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012852","Exendin-4 inhibits glioma cell migration, invasion and epithelial-to-mesenchymal transition through GLP-1R/sirt3 pathway.","Nie ZJ","2018","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","other","article","10.1016/j.biopha.2018.07.092","30119208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012853","SPIRIT – Assessing clinical parameters associated with using IDegLira in patients with Type 2 Diabetes in a real-world setting in Colombia: a single arm, retrospective, chart review study","Ramírez A","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3059502/v1",null,null,"ClinicalTrials.gov:NCT05324462","S000109","europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; article; preprint"],["R0012854","Recommendations for real-world evidence of efficacy and safety of GLP-1 agonists in Prader-Willi syndrome: Report of a workshop held by the Foundation for Prader-Willi Research and International Prader Willi Syndrome Organisation.","Finer N","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70282","41243595",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012855","GLP-1 agonist Liraglutide prevents MK‑801-induced schizophrenia‑like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb/c mice.","Kutlu MD","2023","Behavioural brain research","preclinical","article","10.1016/j.bbr.2023.114386","36948022",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012856","Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis.","Poljo A","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-08136-5","40794223","PMC12457577",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012857","Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S.","Onishi Y","2015","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12275","25802728","PMC4364855",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0012858","Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study.","Wang B","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70407","41424209",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012859","Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.","Vega-Hernandez G","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-017-0250-y","28349443","PMC5446377",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012860","New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials.","Kongmalai T","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1182037","37441498","PMC10335801","PROSPERO:CRD42021259336",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Research Support, Non-U.S. Gov't; Journal Article; Network Meta-Analysis; systematic-review; review"],["R0012861","Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study.","Samson SL","2021","Pituitary","randomized_trial","article","10.1007/s11102-021-01161-4","34275099","PMC8550309","ClinicalTrials.gov:NCT02060383","S002111","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0012862","Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.","Jendle J","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12705","27279266",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012863","Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome.","Alalami H","2019","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018818805674","30800265","PMC6378434",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012864","Metabolic inflammation and cancer risk: A potential target with GLP-1 agonist or bariatric surgery?","Cheung D","2025","Cancer","nonrandomized_study","article","10.1002/cncr.70124","41091624",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0012865","Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.","Wang L","2021","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-020-01188-0","33397369","PMC7783984",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0012866","Genome-wide reversal of glial and neurovascular cell transcriptomic aging signatures by GLP-1R agonism","Li Z","2020","bioRxiv","other","preprint","10.1101/2020.12.21.423879",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012867","Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Bai L","2026","Current diabetes reviews","systematic_review","article","10.2174/0115733998359708250822102217","40947681",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0012868","8418 Association of GLP-1 Receptor Agonists and SGLT-2 Inhibitors with Major Adverse Cardiovascular Events and Serious Liver Events among Patients with Type 2 Diabetes and MASLD",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455299",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012869","Effects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy.","Tran BC","2026","Pediatric obesity","other_trial","article","10.1111/ijpo.70140","42538646","PMC13428085",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0012870","Hormonal multireceptor agonism for treatment of metabolic and non-metabolic conditions - potential value of glucagon receptor agonism","Kovacic IB","2025","Authorea Preprints","other","preprint","10.22541/au.176536999.91447281/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012871","Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.","Umpierrez G","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16075","39604042","PMC11701201",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0012872","Transcriptomic Changes Elicited by Semaglutide in Human Ventricular Tissue Support Cell Survival and Lipid Metabolism.","Underwood L","2026","Circulation. Heart failure","commentary","article","10.1161/circheartfailure.126.014421","42657478","PMC13623079",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; research-article; article"],["R0012873","Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions.","Mehta K","2021","Current protein & peptide science","other_trial","article","10.2174/1389203721999201208195901","33292149",null,null,"S000729; S000821","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0012874","Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis.","Evans M","2023","Diabetes & vascular disease research","systematic_review","article","10.1177/14791641231221740","38111352","PMC10734357","PROSPERO:CRD42022335504",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review-article; review"],["R0012875","Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study.","Ena J","2021","Revista clinica espanola","other","article","10.1016/j.rceng.2019.12.015","34752263",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012876","Reply: Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.","Woo KA","2026","Brain : a journal of neurology","other_trial","article","10.1093/brain/awag195","42217255",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; Comment; letter"],["R0012877","An analysis of national news coverage of semaglutide for weight loss.","Gionfriddo MR","2025","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2024.102297","39580054",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012878","Dulaglutide restores endothelial progenitor cell levels in diabetic mice and mitigates high glucose-induced endothelial injury through SIRT1-mediated mitochondrial fission.","Mei X","2024","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2024.150002","38697011",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012879","Heteropolymer ferritin nanocages as delivery vehicles for oral delivery of GLP-1 peptides.","Qian Y","2026","Journal of colloid and interface science","preclinical","article","10.1016/j.jcis.2025.139092","41005135",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0012880","Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.","Kaneto H","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14005","32072742",null,"ClinicalTrials.gov:NCT02752412","S000356","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0012881","Comment on: GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region.",null,"2025","Saudi medical journal","commentary","article","10.15537/smj.2025.46.20250193","40840942","PMC12376149",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; in-brief; letter"],["R0012882","Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.","Wu S","2017","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2017.07.036","28827024",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Network Meta-Analysis"],["R0012883","Comparing the risks of new-onset gastric cancer or gastric diseases in type 2 diabetes mellitus patients exposed to SGLT2I, DPP4I or GLP1A: a population-based cohort study","Chou OHI","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.07.02.23292063",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0012884","Structural basis of peptidomimetic agonism revealed by small- molecule GLP-1R agonists Boc5 and WB4-24.","Cong Z","2022","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.2200155119","35561211","PMC9171782",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; preprint; article"],["R0012885","Pharmacological Effects of EGLP-1, a Novel Analog of Glucagon-Like Peptide-1, on Carbohydrate and Lipid Metabolism.","Gao H","2018","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","preclinical","article","10.1159/000491978","30041175",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012886","Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI.","Cusi K","2026","Liver international : official journal of the International Association for the Study of the Liver","other_trial","article","10.1111/liv.70837","42576670","PMC13458421","ClinicalTrials.gov:NCT03882970","S001591","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0012887","[Extended indications for antidiabetic agents with cardio-renal protection in updated international recommendations for themanagement of at risk patients with type2 diabetes].","Scheen AJ","2020","Revue medicale de Liege","other","article",null,"32267111",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012888","Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials.","Aroda VR","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13896","31608552","PMC7065219",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012889","Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence.","Herman RJ","2024","Physiology & behavior","narrative_review","article","10.1016/j.physbeh.2024.114565","38663460","PMC11128349","ClinicalTrials.gov:NCT05610800","S001464","pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review; Research Support, N.I.H., Intramural; research-article"],["R0012890","Diabetes medications and cardiovascular disease: at long last progress.","Lupsa BC","2018","Current opinion in endocrinology, diabetes, and obesity","randomized_trial","article","10.1097/med.0000000000000400","29369916",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0012891","A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes.","Ross SA","2015","Current medical research and opinion","narrative_review","article","10.1185/03007995.2014.973939","25299351",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0012892","Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.","Mirabelli M","2021","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm10050985","33801192","PMC7957905",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012893","Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk.","Palazzi S","2025","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph18060856","40573252","PMC12195834",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012894","Supporting evidence for the association between GLP-1 agonists and NAION: Insights from a large national cohort.","Dziewierz A","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70128","40926730",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Letter; article"],["R0012895","Liraglutide Attenuates Atorvastatin-Induced Hepatotoxicity by Restoring GLP-1R Expression and Activating Nrf2 and Autophagy Pathways in Wistar Rats.","Elsiad EA","2025","Toxics","preclinical","article","10.3390/toxics13070594","40711038","PMC12299754",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012896","Evaluation of the Clinical Effectiveness and Cost-Effectiveness of Tirzepatide for Type 2 Diabetes in Canada Using Bayesian Transportability Analysis.","Metcalfe RK","2026","Value in health regional issues","other_trial","article","10.1016/j.vhri.2026.101666","42383939",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0012897","Additional Considerations Regarding GLP-1RA Use and Thyroid Cancer Risk.","Yalamanchi P","2025","JAMA otolaryngology-- head & neck surgery","other","article","10.1001/jamaoto.2025.0605","40310621",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012898","The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice.","Li PC","2016","BMC neuroscience","preclinical","article","10.1186/s12868-016-0272-9","27296974","PMC4907076",null,"S001115","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012899","Evaluation of Pre-Treatment Assessment of Semaglutide Users: Balancing the Benefits of Weight Loss vs. Potential Health Consequences.","Bin Dayel FF","2025","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare13151827","40805859","PMC12346479",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012900","Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes.","Hamersky CM","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-019-0617-3","31054132","PMC6531561",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0012901","G protein-Coupled Receptor Associated Sorting Protein GASP1 mediated trafficking of the Glucagon Like Peptide-1 Receptor contributes to the development of tolerance to incretin drugs","Gaur A","2024","bioRxiv","preclinical","preprint","10.1101/2024.08.09.607397",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012902","Incretin-based therapy of metabolic disease.","Holst JJ","2022","Danish medical journal","other","article",null,"36629298",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012903","The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity.","Lempesis IG","2022","Metabolism open","randomized_trial","article","10.1016/j.metop.2022.100220","36530219","PMC9747662",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012904","Overview of the cardiovascular benefit with diabetic agents and novel combination products for type 2 diabetes.","Morello CM","2017","The American journal of managed care","other","article",null,"28978218",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012905","Common patient concerns about the use of glucagon-like peptide-1 receptor agonists in diabetes mellitus management.","Freeman JS","2012","The Journal of the American Osteopathic Association","case_report","article",null,"22267301",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0012906","Clinical benefits of tirzepatide in patients with steatotic liver disease and cardiometabolic dysfunction.","Shiau BW","2026","Communications medicine","nonrandomized_study","article","10.1038/s43856-026-01759-4","42373761",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0012907","Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management.","Delrue C","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25179351","39273299","PMC11395482",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012908","Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial.","Nakajima A","2026","Journal of gastroenterology","randomized_trial","article","10.1007/s00535-026-02507-0","42663669",null,"ClinicalTrials.gov:NCT04822181","S000511","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0012909","A review of survodutide: a new dual acting agonist.","Yathindra MR","2026","Minerva endocrinology","narrative_review","article","10.23736/s2724-6507.26.04406-4","41855048",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012910","Additional Considerations Regarding GLP-1RA Use and Thyroid Cancer Risk.","Gamarra E","2025","JAMA otolaryngology-- head & neck surgery","other","article","10.1001/jamaoto.2025.0599","40310623",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012911","Hemoglobinopathies and diabetes mellitus: from pathophysiology to clinical practice.","Manganas K","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113581","42785638",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0012912","[Glucagon-like peptide-1 receptor agonists].","Kurose T","2012","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"22768599",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012913","WITHDRAWN: Liraglutide suppresses ferroptosis by activating NRF2 target in type 2 diabetic cardiomyopathy","chen x","2025","Research Square","preclinical","preprint","10.21203/rs.3.rs-5036735/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Preprint-withdrawal; preprint"],["R0012914","Incorporating estimands into meta-analyses of clinical trials.","Remiro-Azócar A","2026","Research synthesis methods","systematic_review","article","10.1017/rsm.2026.10107","42527984",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; article"],["R0012915","Peptide delivery in the management of diabetes: Exploring bioinspired nanoarchitectures using stimuli-responsive materials and supramolecular depots.","Abdullahi AD","2026","International journal of pharmaceutics","narrative_review","article","10.1016/j.ijpharm.2026.127169","42419654",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0012916","Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review.","De Fano M","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s466328","39072348","PMC11283249",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0012917","Effects of a glucagon-like peptide-1 analog on appetitive and consummatory behavior for rewarding and aversive gustatory stimuli in rats.","Douton JE","2021","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2020.113279","33285178","PMC7794656",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0012918","Considerations and challenges in microdosing of GLP-1-based receptor agonists.","Beck H","2026","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2026.2740393","42788826",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012919","Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.","Osumili B","2024","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2024.111717","38777128",null,"ClinicalTrials.gov:NCT03987919; ClinicalTrials.gov:NCT02648204","S000095; S000372","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Comparative Study; Randomized Controlled Trial; article"],["R0012920","Smoke or fire? Acute pancreatitis and the liraglutide trials.","Gale EA","2015","Diabetes care","nonrandomized_study","article","10.2337/dc15-0346","25998284",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0012921","Combining SGLT2is, GLP1-RAs and nsMRAs in Diabetes: A Scoping Review of Current and Future Perspectives.","Stougaard EB","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-025-01726-7","40088324","PMC12006599",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0012922","Once-weekly exenatide as a treatment for Type 2 diabetes.","Schauerhamer MB","2015","Expert review of cardiovascular therapy","other_trial","article","10.1586/14779072.2015.1038242","26000560",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0012923","Semaglutide-induced satiation, nausea, and food reward suppression are mediated by GLP-1 receptors in the area postrema","Jones LA","2026","bioRxiv","other","preprint","10.64898/2026.08.10.744052",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0012924","Management of Late Dumping Syndrome Induced Hypoglycemia With GLP-1R Agonist","Shaghouli A","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.849",null,"PMC8090020",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0012925","Gastric point-of-care ultrasound in the GLP-1 receptor agonist era: clinical impact and competency.","Kelly DN","2025","Anaesthesia","randomized_trial","article","10.1111/anae.16548","39815651",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Editorial; article"],["R0012926","Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors.","Solini A","2026","Handbook of experimental pharmacology","randomized_trial","article","10.1007/164_2026_847","42778649",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0012927","GLP-1 Therapies and Mortality Risk: Implications for Life Insurers.","Guzman GC","2026","Journal of insurance medicine (New York, N.Y.)","other","article","10.17849/insm-53-2-1-7.1","42307559",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012928","Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.","Bandara N","2016","Molecular imaging and biology","preclinical","article","10.1007/s11307-015-0861-5","25987465","PMC4877185",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0012929","Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.","Khan I","2026","Endocrine","other_trial","article","10.1007/s12020-026-04686-5","42387035",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0012930","Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits.","Sudo M","2017","Atherosclerosis","preclinical","article","10.1016/j.atherosclerosis.2017.06.920","28693828",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012931","8647 Reversal Of Left Atrial Dilation In Heart Failure With Preserved Ejection Fraction (HFpEF) Treated With A GLP-1 Receptor Agonist And A Mineralocorticoid Receptor Antagonist",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455374",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0012932","Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study.","Seijas-Amigo J","2022","Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria","randomized_trial","article",null,"36520578",null,null,"S001352","pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Multicenter Study; Journal Article; article"],["R0012933","Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.","Cena H","2020","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgaa285","32442310","PMC7457958",null,"S001012; S002080","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0012934","Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial.","Gurney R","2026","Brain : a journal of neurology","other_trial","article","10.1093/brain/awag186","42175654",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; Comment; Journal Article; article"],["R0012935","Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens.","Lodrigues AB","2026","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70253","42244165","PMC13511409",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0012936","Unveiling the Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: An Updated Narrative Review.","Rajagopal D","2024","Cureus","narrative_review","article","10.7759/cureus.65910","39219906","PMC11365716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0012937","In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists.",null,"2024","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2024.1718a","39762187",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012938","The role of GLP-1 agonists in perioperative care: a suspension dilemma.","Araújo MR","2025","Brazilian journal of anesthesiology (Elsevier)","commentary","article","10.1016/j.bjane.2025.844668","40754201","PMC12357290",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012939","Dorsolateral septum GLP-1R neurons regulate feeding via lateral hypothalamic projections.","Lu Y","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.03.26.586855","38585874","PMC10996601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; Research Support, N.I.H., Extramural; research-article; preprint; article"],["R0012940","Antinociceptive Behavior, Glutamine/Glutamate, and Neopterin in Early-Stage Streptozotocin-Induced Diabetic Neuropathy in Liraglutide-Treated Mice under a Standard or Enriched Environment.","Gateva P","2024","International journal of molecular sciences","preclinical","article","10.3390/ijms251910786","39409118","PMC11477071",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012941","Obesity pharmacotherapy: incretin action in the central nervous system.","Boer GA","2023","Trends in pharmacological sciences","narrative_review","article","10.1016/j.tips.2022.11.001","36462999",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0012942","Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.","Madsbad S","2008","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0b013e328302f414","18542012",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012943","Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.","Hölscher C","2014","Sheng li xue bao : [Acta physiologica Sinica]","preclinical","article",null,"25331995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0012944","Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.","Tan X","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-026-01919-8","42753116",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0012945","Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release.","Greenwood MP","2023","Molecular metabolism","other","article","10.1016/j.molmet.2023.101692","36773648","PMC9969259",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012946","Tirzepatide and cardiovascular outcomes.","Dani SS","2026","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj-2026-100366","42556867",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0012947","Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.","Berra C","2024","Pharmacological research","nonrandomized_study","article","10.1016/j.phrs.2024.107517","39613122",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0012948","Semaglutide reduces proteomic organ-specific biological age across randomized clinical trials","Dermit M","2026","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-11082091/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0012949","Initiating semaglutide therapy reduces tobacco cigarette smoking intensity among people with HIV.","Ruderman SA","2026","AIDS (London, England)","nonrandomized_study","article","10.1097/qad.0000000000004596","42558050",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0012950","Acute pancreatitis national audit of practice: a national prospective audit of acute pancreatitis in the era of GLP-1 agonists-the PANDORA audit protocol.","PANDORA Study Group","2025","The British journal of surgery","protocol","article","10.1093/bjs/znaf214","41074717",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0012951","Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction.","Homoródi N","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13112595","41301689","PMC12650328",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012952","Letter to the editor from Akinci and Oral: \"Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy\".","Akinci B","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag362","42770910",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0012953","Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation.","Husereau D","2026","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other_trial","article","10.1016/j.jval.2026.09.3116","42810438",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0012954","Impact of GLP-1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol-Associated Liver Disease and Type 2 Diabetes.","Rashid Z","2025","Liver international : official journal of the International Association for the Study of the Liver","nonrandomized_study","article","10.1111/liv.16132","39403816","PMC11892336",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012955","Advances in Drug Treatments for Companion Animal Obesity.","Zomer HD","2024","Biology","preclinical","article","10.3390/biology13050335","38785817","PMC11117622",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012956","Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.","Scott LJ","2014","Drugs","nonrandomized_study","article","10.1007/s40265-014-0321-6","25367717",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0012957","Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.","Chakravarty A","2018","Journal of medical economics","other","article","10.1080/13696998.2018.1434182","29376760",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012958","Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide use.","Kearney M","2026","Irish medical journal","nonrandomized_study","article",null,"42808150",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Case Reports; Journal Article; article"],["R0012959","Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies.","Khera R","2022","BMJ open","protocol","article","10.1136/bmjopen-2021-057977","35680274","PMC9185490",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0012960","New treatment modalities for obesity.","Grandone A","2018","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2018.06.007","30086873",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0012961","Additional Considerations Regarding GLP-1RA Use and Thyroid Cancer Risk-Reply.","Brito JP","2025","JAMA otolaryngology-- head & neck surgery","other","article","10.1001/jamaoto.2025.0602","40310620",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012962","Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.","Marso SP","2020","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2019.12.063","32164886",null,"ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0012963","Bronchopulmonary dysplasia induced by hyperoxia attenuated by A GLP-1 analog, Liraglutide, by regulating the ACE-2/Ang(1-7)/Mas receptor pathway.","Huang B","2026","Pediatric research","randomized_trial","article","10.1038/s41390-025-04293-6","40897883",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0012964","Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).","Yin Y","2026","Med (New York, N.Y.)","randomized_trial","article","10.1016/j.medj.2026.101183","42296968",null,"ClinicalTrials.gov:NCT05963022","S001055","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; article"],["R0012965","Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice.","de Azevedo Miranda D","2026","Oral diseases","commentary","article","10.1111/odi.70484","42695200",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0012966","Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years.","Cintra RM","2021","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgab428","34125217",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0012967","[New therapeutic developments in the treatment of type 2 diabetes mellitus].","Hintze SC","2022","Deutsche medizinische Wochenschrift (1946)","other","article","10.1055/a-1496-5414","35545072",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012968","Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation.","Wong CK","2022","Cell metabolism","other","article","10.1016/j.cmet.2022.08.003","36027914",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0012969","Evaluating the benefits of the early use of GLP-1 receptor agonists.","Zushin PH","2025","Lancet (London, England)","other","article","10.1016/s0140-6736(24)02255-4","39547251","PMC11921982",null,"S002474","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0012970","GLP-1 Receptor Agonists for the Dermatologist: Uses and Considerations.","Vidal SI","2024","Journal of drugs in dermatology : JDD","other","article",null,"39496131",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0012971","Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial.","Petković-Dabić J","2025","Biomolecules","randomized_trial","article","10.3390/biom15010046","39858442","PMC11763288",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0012972","Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study.","Zakaria H","2024","Metabolism open","nonrandomized_study","article","10.1016/j.metop.2024.100283","38699398","PMC11064605",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0012973","GLP-1 receptor agonists for the treatment of obstructive sleep apnea and obesity.","Romariz L","2025","European journal of internal medicine","commentary","article","10.1016/j.ejim.2024.10.027","39550278",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012974","Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.","Hansen KB","2021","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.14655","34291491",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0012975","Understanding Obesity as a Multisystem Disease: Advancing Research, Redefining Diagnostic Criteria, and Establishing Modern Therapeutic Approaches.","Abdallah H","2026","Nutrients","nonrandomized_study","article","10.3390/nu18142317","42514386","PMC13414990",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0012976","Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.","Ipaye T","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70090","40903861","PMC12587238",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0012977","A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes-2nd Edition (English version).","Bouchi R","2024","Diabetology international","case_report","article","10.1007/s13340-024-00723-8","39101173","PMC11291844",null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article; case-report"],["R0012978","Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.","Tesfaye H","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16303","40019137","PMC12049256",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; research-article; article"],["R0012979","Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).","Almandoz JP","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.71318","42755136",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012980","Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices: A Pilot User-Based Study.","Stauder U","2014","Journal of diabetes science and technology","randomized_trial","article","10.1177/1932296813511733","24876548","PMC4454110",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0012981","Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.","Balena R","2013","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12025","23061470","PMC3662998",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review-article; review"],["R0012982","Detection and Excretion Profiling of Semaglutide Use in Human Urine by UHPLC-HRMS for Anti-Doping Purpose.","Tian T","2026","Drug testing and analysis","nonrandomized_study","article","10.1002/dta.70160","42823892",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0012983","Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies.","Cao B","2026","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2026.1783567","42368857","PMC13294277",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0012984","GLP-1 receptor agonists and bronchial aspiration risk: what the evidence tells us.","Fuccio L","2024","The lancet. Gastroenterology & hepatology","commentary","article","10.1016/s2468-1253(24)00278-4","39520997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0012985","Can amylin-based drugs upstage GLP-1 agonists?","Harrison C","2025","Nature biotechnology","commentary","article","10.1038/s41587-025-02778-7","40764822",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0012986","Efficacy and Safety of Semaglutide in Glycemic Control and Body Weight Management Among Obese Type 2 Diabetes Patients Initiated or Switched to Semaglutide From Other GLP-1 Receptor Agonists","Okamoto A","2021","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-586388/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0012987","Efficacy and safety of tirzepatide in overweight or obese adults without diabetes: systematic review and meta-analysis of randomized controlled trials","Liu L","2024","Research Square","systematic_review","preprint","10.21203/rs.3.rs-4184273/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0012988","GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress.","Tian Y","2025","International immunopharmacology","preclinical","article","10.1016/j.intimp.2024.113877","39700965",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012989","Evaluating the impact of efpeglenatide on cardiometabolic and safety outcomes in individuals with diabetes: a systematic review and meta-analysis.","Qazi SU","2024","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-024-01409-3","38932865","PMC11196538",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0012990","GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice.","Chen Z","2024","The Journal of clinical investigation","preclinical","article","10.1172/jci178239","39225090","PMC11364389",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0012991","Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.","Fei Y","2018","International journal of cardiology","systematic_review","article","10.1016/j.ijcard.2017.12.039","29277321",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis"],["R0012992","Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes.","Ishøy PL","2013","The American journal of psychiatry","case_report","article","10.1176/appi.ajp.2013.12101344","23732970",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; Research Support, Non-U.S. Gov't; article"],["R0012993","Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.","Terauchi Y","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14139","33404200",null,"ClinicalTrials.gov:NCT02749890; ClinicalTrials.gov:NCT02752828; ClinicalTrials.gov:NCT02752412","S000356; S002018; S002305","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0012994","Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist.","Li W","2012","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","other","article","10.1159/000341454","22890152",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0012995","Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide.","Koro C","2018","Drugs - real world outcomes","other","article","10.1007/s40801-017-0128-3","29218595","PMC5825391",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012996","[Weight loss in hip and knee osteoarthritis].","Ladefoged MR","2026","Ugeskrift for laeger","narrative_review","article","10.61409/v09250729","42261598",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0012997","Registered clinical trials targeting type 2 diabetes remission with pharmacological interventions.","Shoung N","2025","Scientific reports","systematic_review","article","10.1038/s41598-025-00080-9","40419497","PMC12106727","PROSPERO:CRD42024511198",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; article"],["R0012998","Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson's Disease Mice.","Huang Y","2024","International journal of nanomedicine","preclinical","article","10.2147/ijn.s479670","39430307","PMC11490209",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0012999","Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.","Berry SA","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71080","42410316","PMC13538728",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013000","Prevention of Weight Regain After GLP1RA Cessation With Oral TIX100.","Jo S","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70633","41804207","PMC13146154",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0013001","Comprehensive Framework of Heart Failure with Preserved Ejection Fraction Management for Hospitalists: A Scoping Review.","Northway J","2026","Journal of Brown hospital medicine","narrative_review","article","10.56305/001c.163599","42405364","PMC13330571",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; book-chapter"],["R0013002","Treatment of Diabetes in Patients with Heart Failure.","Bowes CD","2018","Current cardiology reports","narrative_review","article","10.1007/s11886-018-1032-5","30151728",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013003","Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study.","Purcell AR","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71063","42387290","PMC13448848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013004","Potential Therapeutic Benefits of Glucagon-Like-Peptide-1 Agonists and Atrial Fibrillation.","Zhang H","2025","Cardiology in review","randomized_trial","article","10.1097/crd.0000000000001003","40679509",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0013005","Older Adults' Views on Insurance Coverage for Weight Management Medications.","Oshman L","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.2008","40136299","PMC11947835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0013006","Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).","Bethel MA","2019","Diabetes care","randomized_trial","article","10.2337/dc18-2028","31010875","PMC6973544","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0013007","An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking.","Merkel R","2025","Science advances","preclinical","article","10.1126/sciadv.adr5051","40009667","PMC11864183",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013008","Choline and metabolic health, a missing link in a critical chain.","Paules EM","2026","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000001252","42573983",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013009","Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients.","Tonneijck L","2018","Hypertension (Dallas, Tex. : 1979)","randomized_trial","article","10.1161/hypertensionaha.117.10740","29915021",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013010","Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution.","Du Plessis SS","2024","Frontiers in physiology","randomized_trial","article","10.3389/fphys.2024.1496416","39624455","PMC11609151",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; discussion; article"],["R0013011","Tirzepatide as a possible trigger of bullous pemphigoid: A case report.","Hernández Madrid P","2026","Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","case_report","article","10.1111/ddg.70438","42656044",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0013012","Enhancing the Therapeutic Efficacy of GLP-1 for Hyperglycemia Treatment: Overcoming Barriers of Oral Gene Therapy with Taurocholic Acid-Conjugated Protamine Sulfate and Calcium Phosphate.","Shahriar SMS","2024","ACS nanoscience Au","other","article","10.1021/acsnanoscienceau.3c00035","38912289","PMC11191724",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013013","Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner.","Buldak L","2022","Journal of applied biomedicine","preclinical","article","10.32725/jab.2022.015","36708718",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013014","Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits Aβ25-35-induced apoptosis in PC12 cells by suppressing the expression of endoplasmic reticulum stress-related proteins.","Zhang J","2015","International journal of clinical and experimental pathology","preclinical","article",null,"26722468","PMC4680413",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013015","Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.","Thomsen M","2019","Psychopharmacology","randomized_trial","article","10.1007/s00213-018-5089-z","30382353","PMC6428196",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013016","One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.","Gasoyan H","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.33326","39269703","PMC11400221",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013017","Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathway.","He Y","2026","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2026.111163","42669356",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013018","International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes.","Cengiz E","2024","Hormone research in paediatrics","other","article","10.1159/000543169","39884261",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0013019","Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.","Dahl K","2025","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(25)01185-7","40550231",null,"ClinicalTrials.gov:NCT06064006","S003223","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; article"],["R0013020","The impact of type 2 diabetes on aging: multidimensional approaches to preserve cognitive health.","Lucia S","2025","Acta diabetologica","narrative_review","article","10.1007/s00592-025-02583-3","40892247","PMC12727764",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013021","PSUN192 Therapeutic Benefit of GLP-1 Agonists in Patients with Type 1 Diabetes on Insulin Therapy: an Updated Systematic Review and Meta-analysis",null,"2022","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC9624572",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0013022","From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework.","Alhazmi AM","2026","Current problems in cardiology","systematic_review","article","10.1016/j.cpcardiol.2026.103423","42586458",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0013023","How May GIP Enhance the Therapeutic Efficacy of GLP-1?","Samms RJ","2020","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2020.02.006","32396843",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0013024","Incretin-based therapies.","Stonehouse AH","2012","Journal of diabetes","narrative_review","article","10.1111/j.1753-0407.2011.00143.x","21707956","PMC3380568",null,"S000485","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0013025","Assessing the Impact of Once-Weekly Semaglutide on Glycemic Control in Psychiatric Outpatients with Type 2 Diabetes: A 4-Year Observational Study","Argitis P",null,"European psychiatry : the journal of the Association of European Psychiatrists","other","article",null,null,"PMC13441688",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013026","Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice.","Liu W","2024","Neurochemical research","preclinical","article","10.1007/s11064-023-04093-6","38267691",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013027","Acute Duodenal Ulcer Perforation Following Tirzepatide Treatment: A Case Report.","Hayashi M","2025","Cureus","case_report","article","10.7759/cureus.80671","40236372","PMC11999657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013028","Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature.","Posso-Osorio I","2023","Clinical rheumatology","case_report","article","10.1007/s10067-023-06612-w","37199890","PMC10412476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Review; review-article; article"],["R0013029","The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.","Heerspink HJL","2025","Kidney international reports","randomized_trial","article","10.1016/j.ekir.2025.03.049","40630318","PMC12231004",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013030","Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis.","Oikonomaki D","2021","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2020.108604","33338553",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0013031","Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study","Owen EC","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.09.08.26362528",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0013032","Wegovy: FDA accuses Novo Nordisk of \"false or misleading\" ad for weight loss pill.","Dyer O","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.s304","41690782",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013033","GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.","Zhao X","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.721135","34497589","PMC8419463",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0013034","The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.","Li X","2018","Endocrine","systematic_review","article","10.1007/s12020-018-1708-z","30101378",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0013035","Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.","Fernandes A","2025","Cureus","systematic_review","article","10.7759/cureus.99805","41438726","PMC12720054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013036","Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach.","Isaacs DM","2021","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds20-0016","33627989","PMC7887531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013037","Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis: A Systematic Review.","Ahmed T","2025","Cureus","systematic_review","article","10.7759/cureus.89969","40951083","PMC12426967",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013038","Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.","Aronson R","2013","Expert review of clinical pharmacology","narrative_review","article","10.1586/17512433.2013.842465","24147558",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0013039","Prevention of cardiovascular disease in women with type 2 diabetes: the role of incretin mimetics and sodium-glucose cotransporter-2 inhibitors.","Ibrahim E","2025","American journal of physiology. Cell physiology","narrative_review","article","10.1152/ajpcell.00765.2024","39672547","PMC11901335",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0013040","Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care.","Haidar L","2026","AIDS (London, England)","other","article","10.1097/qad.0000000000004598","42558052",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013041","Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model.","Morningstar M","2023","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.23902","37840407",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013042","Web Exclusive. Annals Video Summary - Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.",null,"2025","Annals of internal medicine","other","article","10.7326/annals-24-03525-vs","39761589",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013043","Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.","Demircan F","2026","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-026-02422-8","42464179","PMC13393939",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013044","Response to \"Semaglutide in Diabetic Periodontitis-Induced Osteoblast Ferroptosis: Pharmacological and Methodological Insights\" [Response to Letter].","Zhang Z","2026","Drug design, development and therapy","commentary","article","10.2147/dddt.s642305","42633295","PMC13499568",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Letter; reply; article"],["R0013045","Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.","Pratley RE","2017","Clinical diabetes : a publication of the American Diabetes Association","nonrandomized_study","article","10.2337/cd16-0063","28761216","PMC5510927",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013046","GLP-1a: Going beyond Traditional Use.","Laurindo LF","2022","International journal of molecular sciences","systematic_review","article","10.3390/ijms23020739","35054924","PMC8775408",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0013047","Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent.","Jensen ME","2020","Neurochemistry international","preclinical","article","10.1016/j.neuint.2020.104772","32464226","PMC7452124",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0013048","Albiglutide for the treatment of type 2 diabetes.","Muscogiuri G","2014","Drugs of today (Barcelona, Spain : 1998)","narrative_review","article","10.1358/dot.2014.50.10.2214156","25374965",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013049","Favorable Appendicular Skeletal Muscle Mass Changes in Older Patients With Type 2 Diabetes Receiving GLP-1 Receptor Agonist and Basal Insulin Co-Therapy.","Osaka T","2023","Clinical medicine insights. Endocrinology and diabetes","nonrandomized_study","article","10.1177/11795514231161885","37025567","PMC10070754",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013050","Sarcopenia Is Associated With a Risk of Mortality in People With Type 2 Diabetes Mellitus.","Takahashi F","2021","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2021.783363","34858351","PMC8632440",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013051","Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.","Krämer AL","2020","Journal of veterinary internal medicine","randomized_trial","article","10.1111/jvim.15915","33001499","PMC7694851",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial, Veterinary; research-article; article"],["R0013052","Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.","Nauck MA","2018","Diabetes & vascular disease research","randomized_trial","article","10.1177/1479164118783935","29947247","PMC6130125","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; other; article"],["R0013053","Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.","Zinman B","2019","Diabetes care","randomized_trial","article","10.2337/dc19-0898","31530667","PMC7364672","ClinicalTrials.gov:NCT03021187","S002369","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0013054","Improvement of Rosacea With Tirzepatide: A Case Report.","Mirza MN","2026","Journal of drugs in dermatology : JDD","case_report","article","10.36849/jdd.10058","42555072",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013055","Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications.","Bell DSH","2019","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13652","30724013",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013056","Tirzepatide attenuates mammary tumor progression in diet-induced obese mice.","Glenny EM","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.01.20.576484","38328151","PMC10849495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0013057","Plaque-targeted, proteolysis-resistant, activatable and MRI-visible nano-GLP-1 receptor agonist targets smooth muscle cell differentiation in atherosclerosis.","Maiseyeu A","2022","Theranostics","preclinical","article","10.7150/thno.66456","35401813","PMC8965488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013058","Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK.","Trachsel B","2023","EJNMMI radiopharmacy and chemistry","preclinical","article","10.1186/s41181-023-00206-2","37665477","PMC10477158",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0013059","Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes.","Mishriky BM","2022","Primary care diabetes","other","article","10.1016/j.pcd.2022.03.012","35396200",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013060","Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.","Panchapakesan U","2013","Clinical science (London, England : 1979)","narrative_review","article","10.1042/cs20120167","22963445",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013061","Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis.","Wen B","2018","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2018.6043","29805533","PMC5958780",null,"S000828","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0013062","Medications for Obesity: A Review.","Gudzune KA","2024","JAMA","randomized_trial","article","10.1001/jama.2024.10816","39037780",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0013063","GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis.","Schneider R","2020","Obesity surgery","systematic_review","article","10.1007/s11695-020-04750-7","32500274",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0013064","GIPR:GCGR co-agonism restores normal weight in obese rodents.","Perez-Tilve D","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2026.102365","41997446","PMC13141540",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013065","Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus.","Jung CH","2020","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2020.35.2.260","32615710","PMC7386121",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0013066","8443 Incretin-Mimetic Therapy In Hypertriglyceridemia-Induced Pancreatitis - A Case Report",null,"2024","Journal of the Endocrine Society","case_report","article",null,null,"PMC11453841",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013067","Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.","Krüger N","2026","BMJ (Clinical research ed.)","randomized_trial","article","10.1136/bmj-2026-100011","42556854",null,"ClinicalTrials.gov:NCT07203677","S000794","pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Observational Study; article"],["R0013068","Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease.","Trueman C","2023","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2023.29.12.1275","38058135","PMC10776252",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013069","Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.","Ten Kulve JS","2016","Diabetes care","randomized_trial","article","10.2337/dc15-0772","26283736",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013070","Semaglutide alters gut microbiota and improves NAFLD in db/db mice.","Mao T","2024","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2024.149882","38583231",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013071","A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain - CORRIGENDUM.","Menon T","2024","CNS spectrums","notice","article","10.1017/s1092852924002402","39655439",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0013072","Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.","Goetz IA","2025","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2025.100220","41216380","PMC12596213","ClinicalTrials.gov:NCT04881760","S001653","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0013073","Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.","Smits MM","2016","British journal of clinical pharmacology","other_trial","article","10.1111/bcp.12843","26609792","PMC4799913",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013074","Microbial metabolism of mannitol as a tracer for the non-invasive measurement of oral-cecal transit","Vieira DE","2025","bioRxiv","preclinical","preprint","10.1101/2025.10.28.685202",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013075","A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland.","Barrett R","2025","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","protocol","article","10.1016/j.jval.2025.03.017","40246067",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Observational Study; article"],["R0013076","[Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].","Haluzík M","2015","Vnitrni lekarstvi","other_trial","article",null,"26375689",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; article"],["R0013077","Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.","Johnston SS","2015","Journal of medical economics","nonrandomized_study","article","10.3111/13696998.2015.1039539","25867133",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013078","The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review.","Llewellyn DC","2023","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.23600","36502288","PMC10107620","PROSPERO:CRD420212716429","S001448","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0013079","Diagnostic Modalities, Management Considerations, and Outcomes of Insulinoma: A Case Series from a Tertiary Care Centre.","Shetty AJ","2024","Indian journal of endocrinology and metabolism","case_report","article","10.4103/ijem.ijem_359_23","39086573","PMC11288522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013080","Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.","Ji L","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2411528","40421736",null,"ClinicalTrials.gov:NCT05607680","S000751","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; article"],["R0013081","Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial.","Esteghamati A","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-023-01462-w","37707701","PMC10570258","ClinicalTrials.gov:NCT03421119","S001123","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0013082","Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study.","Baechle C","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16149","39727159",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0013083","Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution.","Ueda T","2010","Bioorganic & medicinal chemistry letters","preclinical","article","10.1016/j.bmcl.2010.06.002","20576431",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013084","Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts.","Garg S","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71262","42681821","PMC13646362",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013085","Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions.","Fei S","2026","MedComm","narrative_review","article","10.1002/mco2.70895","42549109","PMC13430505",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013086","Contemporary Medical Management of Carotid Artery Stenosis.","Salameh MJ","2026","Seminars in vascular surgery","narrative_review","article","10.1053/j.semvascsurg.2026.01.001","41866673",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013087","Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?","Bowes CD","2019","Current diabetes reports","narrative_review","article","10.1007/s11892-019-1154-1","31127397",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013088","Obesity-related thyroid reflections: from weight gain to weight loss.","Croce L","2026","European thyroid journal","narrative_review","article","10.1530/etj-26-0082","42340816","PMC13386241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013089","Correction to 'Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis'.",null,"2026","Liver international : official journal of the International Association for the Study of the Liver","notice","article","10.1111/liv.70790","42446260","PMC13367184",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0013090","The \"pandemic\" increase of GLP-1 receptor agonists use and the time of discontinuation before anesthesia: Something new?","Vetrugno L","2025","Journal of clinical anesthesia","commentary","article","10.1016/j.jclinane.2024.111693","39592284",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0013091","Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.","Bradley CL","2023","The Annals of pharmacotherapy","randomized_trial","article","10.1177/10600280221134127","36367094",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0013092","Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway.","Cheng Y","2022","BMC musculoskeletal disorders","preclinical","article","10.1186/s12891-022-05396-5","35581617","PMC9112483",null,"S000828","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0013093","SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application.","Bae JH","2025","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2025.0220","40367988","PMC12086580",null,"S002726","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0013094","Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature.","Salazar CE","2024","Archives of dermatological research","narrative_review","article","10.1007/s00403-024-02969-3","38795152",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013095","Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Notoriety Bias or True Ocular Toxicity?","Jiang J","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.09.06.26362369",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0013096","Incretin physiology and pathophysiology from an Asian perspective.","Cho YM","2015","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.12305","26417406","PMC4578486",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0013097","Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.","Nunn E","2024","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.101880","38218536","PMC10832506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0013098","Treatment of 'Diabesity': Beyond Pharmacotherapy.","Singh H","2018","Current drug targets","narrative_review","article","10.2174/1389450119666180621093833","29929463",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013099","Unveiling the Interplay of Klotho Protein, Chemotherapy-Induced Klotho Protein Deficiency, and the Pivotal Role of GLP-1 Agonists like Ozempic in Cancer Survivorship Patient Survival Rate after Chemotherapy Treatment","Akl MM","2023","Qeios","other","preprint","10.32388/ephlkx",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013100","What is \"triple strength\" Wegovy, and why has the MHRA approved it?","Lang K","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.s111","41554571",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013101","The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes.","Avgerinos I","2024","Expert opinion on drug discovery","other_trial","article","10.1080/17460441.2024.2324918","38654653",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0013102","Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.","Rubino D","2021","JAMA","randomized_trial","article","10.1001/jama.2021.3224","33755728","PMC7988425","ClinicalTrials.gov:NCT03548987","S000521; S000735; S001427; S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0013103","Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.","Gæde P","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-019-0638-y","31152431","PMC6612334",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0013104","Demand Shock Exposes Surgical Training Problem: What Bariatric Volume Collapse Reveals About the Future of Minimally Invasive Surgery Fellowship Training.","Dallal RM","2026","Journal of the American College of Surgeons","other","article","10.1097/xcs.0000000000002071","42307590",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013105","Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study.","Santos-Pardo I","2021","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2021.02.011","33621623",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0013106","Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.","Zhang YS","2021","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2021.735824","34721294","PMC8553257","PROSPERO:CRD42020189464",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; systematic-review; review"],["R0013107","Multi-omics profiling implicates gut microbiota-sphingolipid interplay in the neuroprotective effects of semaglutide on diabetic cognitive impairment.","Qi L","2026","Frontiers in microbiology","preclinical","article","10.3389/fmicb.2026.1705784","41971325","PMC13061865",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013108","Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases.","Bashier A","2019","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-019-0476-0","31572499","PMC6761728",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0013109","Weight loss drug waste: what happens to the Ozempic pens?","Adey M","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r2495","41730573",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013110","166. Active GLP-1 RA Use Correlates With Lower Rates of Surgical Complications Across Diabetic BMI Cohorts: A Retrospective Analysis of 72,578 Surgical Encounters","Salingaros S","2025","Plastic and reconstructive surgery. Global open","nonrandomized_study","article","10.1097/01.gox.0001112612.59633.ce",null,"PMC12023120",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0013111","GLP-1 receptor agonism results in reduction in hepatic ethanol metabolism.","Zahrawi F","2025","npj metabolic health and disease","preclinical","article","10.1038/s44324-025-00077-y","40968135","PMC12446429",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013112","A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.","Webb N","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-018-0397-1","29574633","PMC5984907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; other; article"],["R0013113","Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta-Analysis.","Ren Q","2025","Journal of evidence-based medicine","systematic_review","article","10.1111/jebm.70021","40229658",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0013114","Malnutrition with use of GLP-1 agonists is an underestimated real world harm.","Fallows E","2025","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj.r1512","40691004",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Editorial; editorial"],["R0013115","GLP-1-RA und SGLT2-Hemmer: Alter beeinflusst ihre Wirksamkeit.","Patzer KH","2025","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-025-5119-9","40640668",null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0013116","SUN-660 Appetite Suppressing Effects of Glucoregulatory Chimeric Peptides Devoid of Nausea","Roth C","2020","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaa046.1927",null,"PMC7208290",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0013117","A novel gene therapy platform for the treatment of type 2 diabetes and obesity.","Lourie J","2025","Molecular therapy. Nucleic acids","preclinical","article","10.1016/j.omtn.2025.102739","41216426","PMC12597059",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013118","What Is the Impact of Different Glucose-lowering Agents for Atrial Fibrillation Risk: A Systematic Review and a Network Meta-analysis&nbsp;","Shi W","2020","Research Square","systematic_review","preprint","10.21203/rs.3.rs-123781/v1",null,null,"PROSPERO:CRD42020212994",null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0013119","Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).","Moreira RO","2024","Archives of endocrinology and metabolism","narrative_review","article","10.20945/2359-4292-2024-0422","39664998","PMC11634287",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Consensus Statement; research-article; article"],["R0013120","Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial.","Josey K","2026","medRxiv : the preprint server for health sciences","randomized_trial","article","10.1101/2025.05.12.25327466","40463568","PMC12132110",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Preprint; preprint; article"],["R0013121","Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights.","Manueli Laos EG","2026","Clinical obesity","nonrandomized_study","article","10.1111/cob.70084","42145153",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013122","GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice.","Quarta C","2022","Nature metabolism","preclinical","article","10.1038/s42255-022-00617-6","35995995","PMC9398908",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013123","Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi Syndrome and type 2 diabetes.","Giménez-Palop O","2024","Endocrinologia, diabetes y nutricion","narrative_review","article","10.1016/j.endien.2023.12.001","38553173",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013124","GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice.","Díaz-Trastoy O","2020","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2019.12.012","32005534",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013125","Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.","Syed YY","2015","Drugs","randomized_trial","article","10.1007/s40265-015-0420-z","26071140",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0013126","Should we still be concerned about the potential side effects of glucagon-like peptide-1 receptor agonists on thyroid C cells?","Cao Y","2015","Endocrine","preclinical","article","10.1007/s12020-014-0354-3","25033998",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013127","Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults.","Amioka M","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71162","42521631","PMC13538803",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Comparative Study; research-article; article"],["R0013128","Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups.","Ou Y","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1463657","39568578","PMC11576270",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013129","Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018.","Shao H","2021","Diabetes care","nonrandomized_study","article","10.2337/dc20-2871","33563653",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; other; article"],["R0013130","Glucagon-like Peptide-1 Receptor Activation Reduces Pulmonary Vein Arrhythmogenesis and Regulates Calcium Homeostasis.","Chan CS","2023","International journal of molecular sciences","preclinical","article","10.3390/ijms241713100","37685906","PMC10488086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013131","GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons.","Papaetis GS","2022","Advances in clinical and experimental medicine : official organ Wroclaw Medical University","narrative_review","article","10.17219/acem/151695","35951627",null,null,"S001012","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0013132","The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide.","Pinheiro MM","2024","Current medical research and opinion","case_report","article","10.1080/03007995.2024.2386047","39072425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0013133","Shifting the Scales: Tirzepatide's Breakthrough in Obesity Management.","Sallam M","2024","Cureus","commentary","article","10.7759/cureus.60545","38887332","PMC11181455",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0013134","Scalable Hypothalamic Arcuate Neuron Differentiation from Human Pluripotent Stem Cells Suitable for Modeling Metabolic and Reproductive Disorders.","Jovanovic VM","2024","bioRxiv : the preprint server for biology","other","article","10.1101/2024.06.27.601062","39005353","PMC11244856",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0013135","Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats.","Eakin K","2013","PloS one","preclinical","article","10.1371/journal.pone.0082016","24312624","PMC3847068",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0013136","Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.","Monami M","2014","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12175","23829656",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0013137","Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy.","Moellmann J","2018","Diabetes","preclinical","article","10.2337/db17-1212","30104246",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013138","Methodology of Study on GLP-1 Receptor Agonists and Hepatocellular Carcinoma Risk.","Wei JC","2025","Gastroenterology","commentary","article","10.1053/j.gastro.2024.09.037","39426485",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013139","Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.","Muskiet MH","2016","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12601","26636423",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013140","Methodological considerations in assessing GLP-1 receptor agonists and gastrointestinal cancer risk.","Hung CH","2024","Pharmacological research","commentary","article","10.1016/j.phrs.2024.107481","39476940",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013141","Economic evaluation of liraglutide versus sitagliptin in the treatment of type 2 diabetes mellitus inadequately controlled with metformin.","Yang F","2026","Frontiers in clinical diabetes and healthcare","other","article","10.3389/fcdhc.2026.1906364","42630210","PMC13493274",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013142","Comparative Hepatic Outcomes of SGLT2i or DPP4i versus GLP-1RA in CHB and T2DM Patients: Expanding the Research Horizon.","Zhu Y","2025","Liver international : official journal of the International Association for the Study of the Liver","commentary","article","10.1111/liv.70124","40323195",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013143","Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections.","Rizvi AA","2022","Expert opinion on drug safety","commentary","article","10.1080/14740338.2022.2043848","35188012",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0013144","Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.","Røder ME","2018","Therapeutic advances in chronic disease","narrative_review","article","10.1177/2040622317735283","29344329","PMC5761941",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013145","Molecular Dynamics Insights into the Binding Interactions of Semaglutide with Human Serum Albumin","Liu Y","2024","Authorea Preprints","other","preprint","10.22541/au.173514456.61074903/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013146","Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers.","Kushner P","2023","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd22-0029","37092144","PMC10115620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0013147","Success story of GLP-1 agonist (Liraglutide) treatment in someone with type 1 diabetes: a life transformed.","Heald AH","2023","Cardiovascular endocrinology & metabolism","case_report","article","10.1097/xce.0000000000000293","37779603","PMC10540910",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013148","Off-label ozempic and pancreatitis: legitimate concern or overblown fear?","Ajmal H","2025","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000003951","41180652","PMC12577794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013149","Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease.","Tignanelli CJ","2021","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2021.05.029","34326020","PMC8238640",null,null,"pubmed; europepmc","TRUE","open_europepmc","4",null,"Journal Article; Observational Study; research-article"],["R0013150","Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.","Montvida O","2019","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.13835","30306620",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013151","Glycolytic Reprogramming in Parkinson's Disease: From Bioenergetic Crosstalk to Therapeutic Modulation.","Yi Y","2026","Medicinal research reviews","narrative_review","article","10.1002/med.70103","42695230",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013152","Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.","Nelson AJ","2025","American heart journal","randomized_trial","article","10.1016/j.ahj.2024.12.006","39716628",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0013153","GLP-1 Receptor Agonists' Role in Reducing Hepatocellular Carcinoma Risk.","Liu Z","2025","Gastroenterology","commentary","article","10.1053/j.gastro.2024.09.038","39424235",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013154","Hemodynamic effect of a single dose of glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide in patients with diabetic kidney disease.","Wajdlich M","2021","Journal of physiology and pharmacology : an official journal of the Polish Physiological Society","other","article","10.26402/jpp.2021.5.10","35288477",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013155","Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis.","Dutta D","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70391","41424191",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0013156","Obesity and diabetes: the final frontier.","Rendell MS","2023","Expert review of endocrinology & metabolism","narrative_review","article","10.1080/17446651.2023.2168643","36710450",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013157","Tirzepatide for treatment of postbariatric hypoglycemia after Roux-en-Y gastric bypass: a report of 3 cases.","Milosavljevic J","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag216","42694629","PMC13539356",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013158","Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.","Aroda VR","2019","Diabetes & metabolism","other_trial","article","10.1016/j.diabet.2018.12.001","30615985",null,null,"S000329; S000372; S000878; S001219; S001872; S001876; S001933","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0013159","A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.","Jensterle M","2015","Hormones (Athens, Greece)","randomized_trial","article","10.1007/bf03401383","25885106",null,null,"S001012","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013160","The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity.","Burmeister MA","2017","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00113.2017","28811293","PMC6109646",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013161","Author reply to: Exploring the impact of short-acting GLP-1 receptor agonists on GERD risk.","Liu BD","2024","Gut","commentary","article","10.1136/gutjnl-2024-332058","38383143",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013162","Development of an 111In-Labeled Glucagon-Like Peptide-1 Receptor-Targeting Exendin-4 Derivative that Exhibits Reduced Renal Uptake.","Iikuni S","2022","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.2c00068","35138111",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013163","Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.","Liu T","2026","Journal of enzyme inhibition and medicinal chemistry","other","article","10.1080/14756366.2026.2714331","42578506","PMC13463442",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013164","Comparative efficacy and safety of non-insulin antihyperglycemic agents versus insulin in patients over 65 years with type 2 diabetes and advanced or end-stage chronic kidney disease on dialysis: a systematic review of studies published in the last 10 years.","Marroquín JJ","2026","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-026-01928-1","41822052","PMC12976236",null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Review"],["R0013165","Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.","Singhal M","2017","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2017.16334","28230449","PMC10398136",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013166","Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.","Saunders WB","2016","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s103972","27486339","PMC4956055",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013167","GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review.","Roy E","2026","Drugs in context","randomized_trial","article","10.7573/dic.2025-12-4","42306018","PMC13267946",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0013168","5PSQ-004 Adequacy and effectiveness of liraglutide in patients with type-2 diabetes mellitus","Rosa V","2018","European Journal of Hospital Pharmacy","nonrandomized_study","article","10.1136/ejhpharm-2018-eahpconf.358",null,"PMC7535523",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","meeting-report; Meeting Report; conference-paper"],["R0013169","IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.","Freemantle N","2015","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-015-0142-y","26582052","PMC4674480",null,"S000926","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0013170","Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.","Davies MJ","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13125","28950422","PMC5836948",null,"S000492; S001278; S001402; S001792; S002315","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; brief-report; article"],["R0013171","Comparing GLP-1 agonists versus other weight loss interventions on atrial fibrillation recurrence after catheter ablation: a meta-regression analysis",null,"2025","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","other","article",null,null,"PMC12099954",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013172","Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.","Bain SC","2019","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.13553","30284349","PMC6587508",null,"S001381","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; research-article; article"],["R0013173","Peptide Coated Polycaprolactone-Benzalkonium Chloride Nanocapsules for Targeted Drug Delivery to the Pancreatic β-Cell.","Collins J","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.07.15.603612","39071322","PMC11275727",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0013174","Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.","Stenlid R","2023","Annals of nutrition & metabolism","randomized_trial","article","10.1159/000534725","37883939",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013175","FRAILTY AND THE EFFECTIVENESS AND SAFETY OF NEW GLUCOSE-LOWERING DRUGS IN OLDER ADULTS WITH TYPE 2 DIABETES","Kim D","2019","Innovation in aging","nonrandomized_study","article",null,null,"PMC6841166",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0013176","Divergent acute  <i>versus<\/i>  prolonged pharmacological GLP-1R responses in adult beta cell-selective β-arrestin 2 knockout mice","Bitsi S","2022","bioRxiv","preclinical","preprint","10.1101/2022.04.21.489075",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013177","Semaglutide restores astrocyte-vascular interactions and blood-brain barrier integrity in a model of diet-induced metabolic syndrome.","Estato V","2025","Diabetology & metabolic syndrome","preclinical","article","10.1186/s13098-024-01528-0","39754250","PMC11699651",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013178","The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018.","Li P","2021","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2021.1971181","34429001",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0013179","Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations - a registry-based analysis.","Bramlage P","2021","BMC nephrology","nonrandomized_study","article","10.1186/s12882-021-02394-y","34011313","PMC8135159",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013180","Mounjaro: Experts issue warning over black market jabs, with fifth of areas still lacking NHS access.","Mahase E","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.s48","41513268",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013181","Understanding difficulties of the use of GLP-1 analogues: patient reported obstacles.","Manueli Laos EG","2026","Updates in surgery","commentary","article","10.1007/s13304-025-02290-2","40522390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013182","Neurologic Complications of Endocrine Disorders.","Mustafa R","2026","Continuum (Minneapolis, Minn.)","case_report","article","10.1212/cont.0000000000001658","41631909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Case Reports; article"],["R0013183","Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial.","Sun R","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70262","41208635",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0013184","Cardiorenal effects of therapies for type 2 diabetes and obesity.","Bailey CJ","2024","The British journal of cardiology","nonrandomized_study","article","10.5837/bjc.2024.041","41846863","PMC12991798",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013185","Medication use for the treatment of diabetes in obese individuals.","Wilding JPH","2018","Diabetologia","narrative_review","article","10.1007/s00125-017-4288-1","28501906","PMC6448959",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013186","Semaglutide Demonstrates Benefits Across Frailty Levels.","Anderer S","2026","JAMA","other","article","10.1001/jama.2026.20008","42826015",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013187","Gastrin - A Potential Predictor of Response to Incretin Therapy in Diabetes Type 2 Patients.","Bilic-Curcic I","2017","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/1871530317666171003162104","28982341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013188","Co-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era.","Qeadan F","2026","Drug and alcohol dependence reports","nonrandomized_study","article","10.1016/j.dadr.2026.100474","42750843","PMC13578398",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0013189","Sex-specific metabolic responses to glucagon receptor agonism and modulation of the FGF21-glucagon axis in female mice.","Merrild C","2026","The Journal of physiology","preclinical","article","10.1113/jp289817","41931110",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013190","Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.","Brønden A","2015","Expert opinion on drug metabolism & toxicology","other_trial","article","10.1517/17425255.2015.1068288","26166682",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013191","Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach.","Brønden A","2023","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.15157","37249579",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Review; Network Meta-Analysis; article"],["R0013192","Early Glycemic Control With iGlarLixi Versus IDegAsp in Chinese Adults With Type 2 Diabetes: A Post Hoc Analysis of the Soli-D Study.","Wu X","2025","Journal of diabetes","commentary","article","10.1111/1753-0407.70171","41292281","PMC12647919",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013193","Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.","Hougen I","2021","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2021-002352","34969692","PMC8718392",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013194","Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.","Driessen JH","2015","Calcified tissue international","nonrandomized_study","article","10.1007/s00223-015-9993-5","25894068","PMC4491344",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013195","How to treat antipsychotic-related weight gain and metabolic disturbances: Is there a role for GLP-1 receptor agonists?","Fink-Jensen A","2025","Acta psychiatrica Scandinavica","commentary","article","10.1111/acps.13769","39513427",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0013196","Letter to the Editor: Combination treatment of Sglt2i and Glp-1ra associated with improved cardiovascular outcomes in Type-2 diabetes patients with acute coronary syndrome: A propensity score-matched Cohort study.","Ramsha Azmat","2025","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2025.133660","40706810",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0013197","Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis.","Giugliano D","2019","Journal of endocrinological investigation","systematic_review","article","10.1007/s40618-019-01047-0","30955180",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0013198","EHR Data Suggest Tirzepatide Outdoes Semaglutide for Weight Loss.","Harris E","2024","JAMA","commentary","article","10.1001/jama.2024.13770","39093576",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0013199","The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","Jiao R","2023","Expert opinion on pharmacotherapy","systematic_review","article","10.1080/14656566.2023.2181693","36799287",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review; article"],["R0013200","Familial Partial Lipodystrophy (FPLD): Recent Insights.","Bagias C","2020","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s206053","32440182","PMC7224169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013201","The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration.","Hinkle JT","2019","Movement disorders : official journal of the Movement Disorder Society","preclinical","article","10.1002/mds.27718","31136698","PMC6642014",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0013202","Hyodeoxycholic acid suppresses hepatic steatosis in a PPARα-dependent manner via distinct GLP-1- and iNKT cell-mediated pathways.","Lee E","2026","Cell reports","preclinical","article","10.1016/j.celrep.2026.117822","42566309",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013203","Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.","Nauck MA","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12802","27709794",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013204","From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management.","Pani A","2020","International journal of endocrinology","narrative_review","article","10.1155/2020/6276187","32587614","PMC7298266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013205","Next Generation Weight Loss Drugs for the Prevention of Cancer?","Carbonell C","2024","Cancer control : journal of the Moffitt Cancer Center","other","article","10.1177/10732748241241158","38516742","PMC10981222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0013206","Weekly Journal Scan: SURMOUNT and MAINTAIN the summit: tirzepatide after successful bodyweight loss.","Liuzzo G","2026","European heart journal","other","article","10.1093/eurheartj/ehag621","42619286",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013207","GLP-1 RA Use and Survival Among Older Adults With Cancer and Type 2 Diabetes.","Radwan RM","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.21887","40679827","PMC12274974",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013208","Glucagon-like peptide 1 receptor agonist ameliorates the insulin resistance function of islet β cells via the activation of PDX-1/JAK signaling transduction in C57/BL6 mice with high-fat diet-induced diabetes.","Hao T","2017","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2017.2910","28290604",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013209","Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.","Eriksson O","2021","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","other","article","10.2967/jnumed.118.213306","33097629",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013210","Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.","Bhattachar SN","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70040","40832785","PMC12515780","ClinicalTrials.gov:NCT05623839","S001559","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0013211","Recommendation for Clarifying FDA Policy in Evaluating \"Sameness\" of Higher Order Structure for Generic Peptide Therapeutics.","Rogers-Crovak JA","2024","The AAPS journal","other","article","10.1208/s12248-024-00994-8","39586870",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013212","Glucagon-like Peptide-1 Therapy in Obesity-Related Heart Failure with Preserved Ejection Fraction: Mechanisms, Clinical Evidence, and Implications.","Abedi MM","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15103767","42194729","PMC13207071",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0013213","Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach.","Lund N","2026","PharmacoEconomics","nonrandomized_study","article","10.1007/s40273-026-01659-4","42722807",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013214","Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus Triggers","Georgiou A","2025","bioRxiv","other","preprint","10.1101/2025.03.14.643306",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013215","Changes in Abdominal Adiposity and Associations with Metabolic Health Markers Following Tirzepatide in Japanese Participants with Obesity Disease: Results from the SURMOUNT-J Study.","Waki H","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.1016/j.eprac.2026.09.006","42762980",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0013216","7. Impact of GLP-1 Agonist Weight Loss Drugs on Surgical Wound Complications Following Plastic Surgery Procedures","Lee C","2025","Plastic and reconstructive surgery. Global open","other","article",null,null,"PMC12076332",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013217","The G Protein-First Mechanism for Activation of the Class B Glucagon-like Peptide 1 Receptor Coupled to N-Terminal Domain-Mediated Conformational Progression.","Li B","2024","Journal of the American Chemical Society","other","article","10.1021/jacs.4c08128","39266057",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0013218","Beyond Pleasure: Unraveling the Multifaceted Role of Dopamine in Obesity and Metabolic Regulation.","Yang S","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00763-y","42776350","PMC13601120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013219","Pharmacological management of obesity in adults: a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of obesity management medications","Ciudin A","2025","Research Square","systematic_review","preprint","10.21203/rs.3.rs-6449183/v1",null,null,"PROSPERO:CRD42024625338",null,"europepmc","FALSE","open_pdf","3",null,"Preprint"],["R0013220","Morphology-driven zinc oxide biointeractive carriers with biological barrier modulating effects for pulmonary delivery of liraglutide.","Jeong JH","2026","Journal of nanobiotechnology","preclinical","article","10.1186/s12951-026-04085-y","41622258","PMC13200438",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013221","Paired editorial for \"GLP-1 receptor agonists and the risk of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy: a single-center, retrospective cohort study\".","Zevin B","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2024.12.007","39743444",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0013222","Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.","Chang LS","2019","Current diabetes reports","narrative_review","article","10.1007/s11892-019-1260-0","31802265",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013223","Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.","Azoulay L","2015","Diabetes care","nonrandomized_study","article","10.2337/dc15-0347","25998285",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0013224","Improvement of small fiber neuropathy assessed by corneal confocal microscopy following semaglutide treatment: a case report and literature review.","Anastasiou IA","2026","Hormones (Athens, Greece)","case_report","article","10.1007/s42000-026-00826-8","42726191",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013225","Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials.","Savarese G","2020","ESC heart failure","randomized_trial","article","10.1002/ehf2.12937","32909376","PMC7755024",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0013226","Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design.","Longwell CK","2021","ACS chemical biology","randomized_trial","article","10.1021/acschembio.0c00722","33307682","PMC8068314",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013227","Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test.","Seo MK","2023","Journal of affective disorders","other_trial","article","10.1016/j.jad.2022.12.089","36566932",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013228","Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.","Neumiller JJ","2017","Journal of the American Society of Nephrology : JASN","narrative_review","article","10.1681/asn.2016121372","28465376","PMC5533243",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; brief-report; article"],["R0013229","Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.","Carlsson Petri KC","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-018-0458-5","29907893","PMC6064581","ClinicalTrials.gov:NCT02054897; ClinicalTrials.gov:NCT01930188; ClinicalTrials.gov:NCT01885208; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02207374","S000329; S000878; S001498; S001876; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0013230","Increased Dipeptidyl Peptidase-4 Promotes Adipose Inflammation and Dysfunction in Mice Under Chronic Stress.","Zhang M","2025","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","randomized_trial","article","10.1096/fj.202502147r","40742315","PMC12312669",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013231","Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis.","Tian Y","2026","iScience","preclinical","article","10.1016/j.isci.2026.116347","42305583","PMC13267571",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013232","A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe.","Koomen JV","2021","Frontiers in pharmacology","other_trial","article","10.3389/fphar.2021.626766","33995023","PMC8113630",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0013233","Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study.","Heinberg LJ","2026","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.70056","41253738",null,"ClinicalTrials.gov:NCT06034457",null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0013234","Validating ChatGPT's role in systematic reviews and meta-analyses: A case study on GLP-1 receptor agonists and all-cause mortality.","Teperikidis L","2025","European journal of internal medicine","systematic_review","article","10.1016/j.ejim.2024.10.017","39613702",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0013235","Effect of tirzepatide on body weight in Czech soldiers.","Pavlik V","2026","BMJ military health","commentary","article","10.1136/military-2025-003076","40750116",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013236","Evaluating the Impact of Tirzepatide on Clinical Outcomes in Patients With Heart Failure.","Bin Abdul Malik MH","2025","Cureus","randomized_trial","article","10.7759/cureus.82118","40357081","PMC12066815",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013237","The GLP-1 agonist semaglutide ameliorates cognitive regression in P301S tauopathy mice model via autophagy/ACE2/SIRT1/FOXO1-Mediated Microglia Polarization.","Elbadawy NN","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.177305","39875022",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013238","Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction.","Khopade AJ","2026","Pharmaceutical development and technology","preclinical","article","10.1080/10837450.2026.2731988","42709517",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013239","Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.","Fei Y","2019","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-019-0916-z","31462224","PMC6714383",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; other; article"],["R0013240","Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.","Maiorino MI","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13343","29732679",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0013241","The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes.","García-Carro C","2019","Journal of clinical medicine","narrative_review","article","10.3390/jcm8060864","31212945","PMC6617211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013242","Incretins and SGLT-2i Therapy of Type 2 Diabetes - Real Life Study of Their Therapeutic and Economic Effects.","Mitkova Z","2019","Frontiers in pharmacology","other","article","10.3389/fphar.2019.00364","31040779","PMC6477021",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013243","Exploring the impact of short-acting GLP-1 receptor agonists on GERD risk.","Cheng HW","2024","Gut","commentary","article","10.1136/gutjnl-2024-331899","38365277",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013244","Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin.","Olewi NZ","2026","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-026-05346-1","42065757",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0013245","The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective.","Catakli D","2026","Basic & clinical pharmacology & toxicology","narrative_review","article","10.1111/bcpt.70294","42693696","PMC13542629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013246","In vitro cellular uptake and insulin secretion studies on INS-1E cells of exendin-4-loaded self-nanoemulsifying drug delivery systems.","Çelik Tekeli M","2024","Pharmaceutical development and technology","preclinical","article","10.1080/10837450.2024.2423823","39474799",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013247","Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis.","Rodionov RN","2021","European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery","nonrandomized_study","article","10.1016/j.ejvs.2021.09.031","34782230",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Comparative Study; Journal Article; Observational Study"],["R0013248","Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.","Laursen HVB","2021","Current drug safety","nonrandomized_study","article","10.2174/1574886315666200819114629","32814538",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013249","GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials.","Cao C","2019","Endocrine","systematic_review","article","10.1007/s12020-019-02055-z","31420784",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0013250","Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice.","Sørensen G","2016","Alcoholism, clinical and experimental research","preclinical","article","10.1111/acer.13199","27579999","PMC5048549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013251","Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.","Hallakou-Bozec S","2021","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14277","33269554","PMC8049051",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0013252","Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents.","Goldenberg RM","2011","Canadian journal of diabetes","nonrandomized_study","article","10.1016/s1499-2671(11)80008-0","24854977",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0013253","Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk.","Alonso-Troncoso I","2019","Endocrinologia, diabetes y nutricion","nonrandomized_study","article","10.1016/j.endinu.2018.09.005","30528642",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0013254","12590 Glp1 Agonists Role On Prediabetes Reversal, A Meta-analysis",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC11454423",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0013255","Evaluation of distinct and similar pathological features between diabetes and Alzheimer's disease.","Reed J","2026","EXCLI journal","narrative_review","article","10.17179/excli2026-9429","42712645","PMC13550658",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013256","The global transcriptional response of isolated human islets of langerhans to glucagon-like Peptide-1 receptor agonist liraglutide.","Zhao X","2012","ISRN endocrinology","other","article","10.5402/2012/608672","23056957","PMC3465925",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013257","Spatial-Bioenergetic-Immune Axis in Type 2 Diabetes Mellitus-Associated Sarcopenia: A Review from Pathogenesis to Targeted Reconstruction.","Wu L","2026","Journal of inflammation research","narrative_review","article","10.2147/jir.s627857","42676423","PMC13526654",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013258","Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.","Deng B","2024","Endocrine","systematic_review","article","10.1007/s12020-024-03857-6","38740695",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0013259","Anti-inflammatory benefits of semaglutide: State of the art.","Yaribeygi H","2024","Journal of clinical & translational endocrinology","narrative_review","article","10.1016/j.jcte.2024.100340","38576822","PMC10992717",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013260","Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats.","Zhou X","2015","Cardiovascular diabetology","preclinical","article","10.1186/s12933-015-0194-3","25888997","PMC4476171",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013261","Expanding lifestyle intervention beyond \"Diet and Exercise\" in the GLP-1RA era.","Hsu R","2025","International journal of obesity (2005)","commentary","article","10.1038/s41366-025-01767-9","40211058",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013262","Confluent and reticulated papillomatosis improvement with tirzepatide-associated weight loss: A case report.","Bindra H","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.07.054","42699764","PMC13544326",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013263","Do incretin-based therapies cause acute pancreatitis?","Olansky L","2010","Journal of diabetes science and technology","commentary","article","10.1177/193229681000400129","20167189","PMC2825646",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Evaluation Study; Journal Article; discussion; editorial"],["R0013264","The Emerging Role of GLP-1 Agonists in Burn Care: What Do We Know?","Manasyan A","2025","Journal of burn care & research : official publication of the American Burn Association","narrative_review","article","10.1093/jbcr/irae189","39405180",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013265","Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway.","Yu HH","2022","BioMed research international","other","article","10.1155/2022/4246086","35872844","PMC9307340",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013266","A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.","McGovern AJ","2026","PharmacoEconomics","nonrandomized_study","article","10.1007/s40273-026-01647-8","42503575",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0013267","Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study).","Bajaj HS","2017","Diabetes care","nonrandomized_study","article","10.2337/dc16-1582","27913575",null,null,"S000235","pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; article"],["R0013268","Differential impact of pre-operative tirzepatide compared to glucagon-like-peptide-1 single receptor agonists on outcomes of spinal fusion surgery in obese patients.","Sacks GI","2026","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society","nonrandomized_study","article","10.1007/s00586-026-10099-9","42315695",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013269","Core-shell hydrogel beads co-encapsulating kunitz-type trypsin inhibitor: A synergistic strategy for enhanced stability of oral active peptides.","Li W","2026","Food research international (Ottawa, Ont.)","other","article","10.1016/j.foodres.2026.120103","42637435",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0013270","Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model.","Kapur R","2026","The Journal of clinical investigation","preclinical","article","10.1172/jci202856","42334870","PMC13430024",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013271","Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer.","He L","2017","OncoTargets and therapy","other","article","10.2147/ott.s150701","29200876","PMC5703165",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013272","Semaglutide for obesity: a pill for every ill?","Puntis JW","2026","Archives of disease in childhood","commentary","article","10.1136/archdischild-2025-330170","41916684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0013273","Microdosing Tirzepatide in Multi-Dose Pens: Clinical Individualization, Safety, and Evidence Gaps.","Vidal-Ostos De Lara F","2026","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.70282","42571951",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013274","[Pharmacotherapy of obesity in Germany].","Blüher M","2025","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-025-01897-2","40278869",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0013275","Risk of New Headaches Following GLP-1RA Initiation in Older Adults with Type 2 Diabetes: A Target Trial Emulation.","Dai H","2026","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-025-09612-5","40392462","PMC13125673",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0013276","Semaglutide for Treating Paediatric Craniopharyngioma-Related Obesity: A Multicentre Case Series.","Dornberger J","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71403","42806285",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0013277","GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity-Matched Real-World Analysis.","Tentolouris A","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70841","42092242","PMC13243945",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013278","The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials.","Aldawsari M","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s387116","36890965","PMC9987242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013279","Glucagon-like peptide-1 agonists usage to widen the living donor pool for liver transplantation: A novel metabolic strategy.","Alnagar A","2026","World journal of transplantation","narrative_review","article","10.5500/wjt.v16.i2.118702","42281856","PMC13248179",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013280","Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists for Obesity Management.","Lin K","2024","JAMA network open","other","article","10.1001/jamanetworkopen.2024.41380","39453660","PMC11581531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013281","Semaglutide mechanisms of action: the missing pieces.","Verma S","2026","European heart journal","other","article","10.1093/eurheartj/ehag602","42777686",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013282","A Case of Prolonged Paralytic Ileus Following a Tirzepatide Overdose in a Patient with Bulimia Nervosa.","Asada K","2026","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.7186-26","42144326",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013283","Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.","Anholm C","2019","Atherosclerosis","randomized_trial","article","10.1016/j.atherosclerosis.2019.07.007","31326727",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013284","Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.","Bailey CJ","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13492","30091169",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0013285","Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.","Horn DB","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)00656-2","42119587",null,"ClinicalTrials.gov:NCT06047548","S001952","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0013286","Weight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weekly","Hastings J","2026","medRxiv","randomized_trial","preprint","10.64898/2026.09.15.26363172",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0013287","Perceptions of general practitioners on initiation and intensification of type 2 diabetes injectable therapies. A quantitative study in the United Kingdom.","Sterzi D","2017","Primary care diabetes","other","article","10.1016/j.pcd.2017.03.003","28395938",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013288","Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention.","McGrath K","2019","American family physician","other","article",null,"31194487",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013289","Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.","Qian D","2018","PloS one","systematic_review","article","10.1371/journal.pone.0202563","30148851","PMC6110472",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; article"],["R0013290","Accuracy of Water Intake During Simulated Administration of Oral Semaglutide.","Ketaroonrut N","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71395","42816449",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013291","Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.","Hunt B","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-016-0219-2","28058656","PMC5306118",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013292","Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus.","Pereira M","2017","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2017.00327","29209277","PMC5701968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013293","Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application.","Toliver JC","2025","Advances in therapy","nonrandomized_study","article","10.1007/s12325-025-03325-1","40768192","PMC12474656",null,"S000735","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013294","What Is the Role of Public Health in the Era of GLP-1 Receptor Agonists.","Moore JB","2024","Journal of public health management and practice : JPHMP","other","article","10.1097/phh.0000000000002064","39311884",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013295","ODP259 Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonist in T1DM Patients",null,"2022","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC9628966",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0013296","Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.","Shaddinger BC","2017","Journal of clinical pharmacology","randomized_trial","article","10.1002/jcph.940","28543352",null,"ClinicalTrials.gov:NCT02496221","S000805","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013297","Reply to the letter to the editor on the combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in T2D with ACS.","Liu T","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133362","40355049",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0013298","Beyond the antrum: troubleshooting pitfalls of gastric ultrasound.","Cheng P","2026","Regional anesthesia and pain medicine","other","article","10.1136/rapm-2025-107362","41554629",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013299","Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.","Mehta R","2020","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14128","32618405","PMC7689716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0013300","Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.","Mantovani A","2020","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2019.12.007","31923578",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Research Support, Non-U.S. Gov't; Systematic Review"],["R0013301","Second revolution in cardiovascular prevention.","Chiang CE","2020","Journal of the Chinese Medical Association : JCMA","other_trial","article","10.1097/jcma.0000000000000276","32101893","PMC13048146",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0013302","Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model.","Kim JH","2021","Endocrinology and metabolism (Seoul, Korea)","preclinical","article","10.3803/enm.2020.781","33677937","PMC7937856",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013303","A Simplified Three-Tailed N-Alkyl Phosphoramidate Lipid Platform Enables Inguinal Adipose-Accumulated mRNA Delivery for Anti-Obesity Therapy.","Ma B","2026","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.202517672","41431190","PMC12915099",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013304","Childhood Obesity and GLP-1 Receptor Agonists - A Coming of Age?","Barrett T","2025","The New England journal of medicine","commentary","article","10.1056/nejme2410560","39258849",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0013305","Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.","Gelhorn HL","2015","Patient preference and adherence","other","article","10.2147/ppa.s90842","26635470","PMC4646588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013306","The Interplay of Metabolic Dysfunction, Neuroinflammation, and Mitochondrial Dysfunction in Balance Impairment: Insights from Type 2 Diabetes Mellitus and Alzheimer's Disease.","Fakorede S","2026","Molecular neurobiology","narrative_review","article","10.1007/s12035-026-06237-5","42789205",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013307","Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function.","Park S","2006","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m508307200","16272563",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0013308","Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.","Rasmussen BS","2026","International journal of qualitative studies on health and well-being","other","article","10.1080/17482631.2026.2717809","42610532","PMC13487855",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013309","Semaglutide and Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: An Exploratory Indirect Comparison.","Mantovani A","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71110","42454420","PMC13538817",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013310","Adjuvant Pharmacotherapies to Insulin for the Treatment of Type 1 Diabetes.","Tosur M","2018","Current diabetes reports","narrative_review","article","10.1007/s11892-018-1041-1","30116997",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013311","The GLP-1 receptor agonist revolution comes to nephrology.","Thomas MC","2024","Nature reviews. Nephrology","other","article","10.1038/s41581-024-00876-4","39075285",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013312","Effects from treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective.","Reitzinger S","2025","Scientific reports","other_trial","article","10.1038/s41598-025-97472-8","40234554","PMC12000402",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0013313","GLP-1 Analogue, Exendin-4, Modulates MAPKs Activity but not the Heat Shock Response in Human HepG2 Cells.","Madhu D","2018","Proteomics. Clinical applications","preclinical","article","10.1002/prca.201600169","29105359",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013314","A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.","Winzeler B","2021","The Journal of clinical investigation","randomized_trial","article","10.1172/jci151800","34473645","PMC8516458","ClinicalTrials.gov:NCT02770885","S002343","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0013315","Incretin-based therapy for glycemic control of hospitalized patients with type 2 diabetes: a systematic review.","Gracia-Ramos AE","2022","Revista clinica espanola","systematic_review","article","10.1016/j.rceng.2021.09.003","34872879",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0013316","Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.","Mathieu C","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13313","29603872","PMC6055818",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0013317","Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™.","Gibble TH","2026","Advances in therapy","nonrandomized_study","article","10.1007/s12325-026-03580-w","41965443","PMC13222200",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013318","In Reply: GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know.","Abdulrazeq H","2024","Neurosurgery","randomized_trial","article","10.1227/neu.0000000000003206","39360844",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; letter"],["R0013319","GLP-1R Agonists in Psoriasis Patients.","McAdam RF","2024","Journal of cutaneous medicine and surgery","commentary","article","10.1177/12034754231220929","38156613",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; other; article"],["R0013320","Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.","Leon N","2017","P & T : a peer-reviewed journal for formulary management","other","article",null,"29089722","PMC5642155",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0013321","Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.","Yang W","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14722","35441412",null,"ClinicalTrials.gov:NCT03798054","S000170","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013322","Scalable route to high-purity 17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic acid, an intermediate for therapeutic peptide synthesis","Jeon JH","2025","Tetrahedron letters","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Journal Article"],["R0013323","CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?","Mora PF","2017","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other_trial","article","10.4158/ep161481.ra","27819769",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0013324","GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes.","Li P","2024","JAMA","other","article","10.1001/jama.2024.18581","39441612","PMC11500011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013325","Accidental intradermal injection of tirzepatide associated with increased adverse events.","Di Guardo A","2026","Postgraduate medical journal","other","article","10.1093/postmj/qgag104","42507846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013326","Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.","Wharton S","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70263","41216778","PMC12803687","ClinicalTrials.gov:NCT06066528","S002304","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0013327","A Practical Approach to Hypertension Management in Diabetes.","Shaikh A","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-017-0310-3","28929319","PMC5630564",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013328","Metformin in T2DM: neurocognitive mechanisms and precision pharmacotherapy.","Tang Z","2026","Reviews in the neurosciences","narrative_review","article","10.1515/revneuro-2026-0013","42068584",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013329","GLP-1 receptor agonists in lean diabetes in racial and ethnic minority groups: closing the treatment gap.","Chilunga FP","2024","Diabetologia","commentary","article","10.1007/s00125-024-06297-z","39432078",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013330","Design, synthesis, and biological evaluation of a potential long-acting glucagon-like peptide-1 (GLP-1) analog.","Zhang J","2023","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2023.117291","37098289",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013331","Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub-analysis of Hokkaido-TZP study data.","Abe T","2026","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70355","42289805","PMC13399590",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; brief-report; article"],["R0013332","Top 20 Research Studies of 2021 for Primary Care Physicians.","Ebell MH","2022","American family physician","nonrandomized_study","article",null,"35839363",null,null,null,"pubmed; europepmc","FALSE","no_doi","4",null,"Journal Article"],["R0013333","Letter: GLP-1 Receptor Agonists: Beyond Diabetes-What the Neurosurgeon Needs to Know.","Patel SA","2024","Neurosurgery","randomized_trial","article","10.1227/neu.0000000000003205","39360816",null,"ClinicalTrials.gov:NCT05347147","S001970","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Letter; article"],["R0013334","Glucagon-like peptide-1 analog liraglutide reduces fat deposition in chicken adipocytes.","Zhang J","2024","Poultry science","preclinical","article","10.1016/j.psj.2024.103766","38759567","PMC11107459",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013335","Exendin-4 gene modification and microscaffold encapsulation promote self-persistence and antidiabetic activity of MSCs.","Zhang Y","2021","Science advances","preclinical","article","10.1126/sciadv.abi4379","34215590","PMC11060038",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013336","Diabetic Retinopathy During Pregnancy: Implications of Intensive Control Prior to Pregnancy with Incretin Mimetic Therapy in Type 2 Diabetes Mellitus-Response.","Widyaputri F","2025","Clinical & experimental ophthalmology","commentary","article","10.1111/ceo.14532","40170433",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013337","Identifying and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease Among At-Risk Veterans.","Niezen S","2025","The American journal of gastroenterology","nonrandomized_study","article","10.14309/ajg.0000000000003312","39774063","PMC12230180",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013338","Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.","Jessen L","2012","Endocrinology","preclinical","article","10.1210/en.2012-1358","23033273","PMC3512077",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0013339","Beyond metabolism: sexual dysfunction and weight-loss drugs.","Fuentes-Mendoza JM","2026","Sexual medicine reviews","nonrandomized_study","article","10.1093/sxmrev/qeaf074","41427954",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0013340","Abrupt Smoking Cessation Due to Sensory Aversion Following Tirzepatide Initiation.","Ceesay OI","2026","The primary care companion for CNS disorders","other","article","10.4088/pcc.25cr04174","42530904",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013341","Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design.","Hamidi H","2024","American heart journal","protocol","article","10.1016/j.ahj.2024.08.015","39187147",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013342","Metabolic Adaptation and Weight Regain in Obesity Treatment: The Central Role of Nutrition in the Era of Bariatric Surgery and GLP-1-Based Pharmacotherapy.","Pereira LV","2026","Nutrients","narrative_review","article","10.3390/nu18111725","42280368","PMC13257815",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0013343","Targeting with toxins: an overview of venom peptides in drug delivery.","Mazurs A","2025","International journal of pharmaceutics","narrative_review","article","10.1016/j.ijpharm.2025.126193","40983118",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013344","The effect of obesity pharmacotherapy on body composition, including muscle mass.","Argyrakopoulou G","2025","International journal of obesity (2005)","narrative_review","article","10.1038/s41366-024-01533-3","38745020",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013345","Beyond insulin-like growth factor-1 (IGF-1) normalization: portal insulin and hepatic growth hormone (GH) sensitivity across metabolic disease.","van AJ","2026","Archives of endocrinology and metabolism","narrative_review","article","10.20945/2359-4292-2026-0115","42776131","PMC13599771",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0013346","Combined Treatment With Exenatide and Cyclosporine A or Parstatin 1-26 Results in Enhanced Reduction of Infarct Size in a Rabbit Model.","Alexopoulos P","2017","Journal of cardiovascular pharmacology","preclinical","article","10.1097/fjc.0000000000000492","28679129",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013347","Identification of glicentin as a low-potency glucose-dependent insulinotropic polypeptide receptor agonist.","James-Okoro PP","2026","Peptides","preclinical","article","10.1016/j.peptides.2026.171507","42425317",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013348","Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?","Giugliano D","2020","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13881","31495989",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013349","Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015.","Tandon N","2015","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.152762","25932385","PMC4366768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013350","Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP/PS1 mice.","Yang S","2024","Peptides","preclinical","article","10.1016/j.peptides.2024.171271","39002758",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013351","Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.","Ji L","2022","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2022.101691","36247927","PMC9561728","ClinicalTrials.gov:NCT04440345","S001410","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0013352","Diabetic Retinopathy During Pregnancy: Implications of Intensive Control Prior to Pregnancy With Incretin Mimetic Therapy in Type 2 Diabetes Mellitus.","Varughese MS","2025","Clinical & experimental ophthalmology","commentary","article","10.1111/ceo.14529","40135679",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013353","Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Glibenclamide in a Young Adult With KCNJ11 Permanent Neonatal Diabetes.","Crowley MT","2024","Diabetes care","commentary","article","10.2337/dc24-1163","39403023",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013354","Role of Exendin-4 in Brain Insulin Resistance, Mitochondrial Function, and Neurite Outgrowth in Neurons under Palmitic Acid-Induced Oxidative Stress.","Jo D","2021","Antioxidants (Basel, Switzerland)","preclinical","article","10.3390/antiox10010078","33435277","PMC7827489",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013355","Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments.","Iwakura K","2019","Journal of echocardiography","narrative_review","article","10.1007/s12574-019-00446-9","31617144",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013356","Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide.","Langeskov EK","2022","Pharmacology research & perspectives","other","article","10.1002/prp2.962","35799471","PMC9263537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013357","Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial.","Gullaksen S","2026","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2026.109397","42679726",null,"EudraCT:2019-000781-38",null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013358","GLP-1 receptor agonists: A new frontier in combating metabolic liver disease complications.","Fatima A","2024","Alimentary pharmacology & therapeutics","commentary","article","10.1111/apt.18244","39328070",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013359","Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.","Cersosimo E","2023","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgad438","37481263","PMC12187005",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0013360","The Multidisciplinary Approach to GLP-1 RA and SGLT2 Inhibitors in Cardiometabolic Care: A New Era for Patients with Diabetes and Heart Disease.","Lucà F","2025","Journal of clinical medicine","commentary","article","10.3390/jcm14144834","40725524","PMC12295575",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0013361","Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.","Shi Q","2022","Lancet (London, England)","systematic_review","article","10.1016/s0140-6736(21)01640-8","34895470",null,"PROSPERO:CRD42021245678",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis; Systematic Review; Retracted Publication"],["R0013362","Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.","Hedrington MS","2018","Expert opinion on biological therapy","narrative_review","article","10.1080/14712598.2018.1439014","29431519",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013363","The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.","Kelly AS","2013","JAMA pediatrics","randomized_trial","article","10.1001/jamapediatrics.2013.1045","23380890","PMC4010226","ClinicalTrials.gov:NCT01237197","S001542","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0013364","Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.","Bansal MB","2026","Hepatology (Baltimore, Md.)","other_trial","article","10.1097/hep.0000000000001608","41201884",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Practice Guideline; Review; article"],["R0013365","Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study.","Vencio S","2022","Diabetology & metabolic syndrome","other_trial","article","10.1186/s13098-021-00775-9","35012646","PMC8751351","ClinicalTrials.gov:NCT03786406; ClinicalTrials.gov:NCT03811288",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0013366","Effects of oral antidiabetic agents on the renin-angiotensin-aldosterone system.","Yang X","2025","European journal of clinical pharmacology","narrative_review","article","10.1007/s00228-025-03830-w","40167623",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013367","Transcriptomics of S3 segment in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.","Kim YC","2026","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00109.2026","42213650","PMC13339211",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0013368","A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol.","Brown E","2021","BMJ open","protocol","article","10.1136/bmjopen-2020-045663","34285005","PMC8292819","ISRCTN:ISRCTN52028580; EudraCT:2015-005242-60",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0013369","Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.","Nakatani Y","2017","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2017.05.009","28648835",null,null,"S001155; S001709; S002429","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0013370","Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension.","Buss N","2018","Journal of applied toxicology : JAT","preclinical","article","10.1002/jat.3640","29806696",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013371","Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study​.","Raj FP","2026","Cureus","nonrandomized_study","article","10.7759/cureus.114569","42741750","PMC13574109",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013372","GLP 1 receptor agonists and obesity-associated cancers: a disproportionality analysis in Vigibase®.","Montastruc JL","2024","European journal of clinical pharmacology","nonrandomized_study","article","10.1007/s00228-024-03761-y","39331139",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0013373","Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications.","Tsai YH","2025","Diabetologia","commentary","article","10.1007/s00125-024-06300-7","39476020",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013374","Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy.","Bahdi F","2025","Clinical obesity","nonrandomized_study","article","10.1111/cob.70001","39909715",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0013375","Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes-A Systematic Review.","Viggers R","2023","JBMR plus","systematic_review","article","10.1002/jbm4.10817","38025038","PMC10652182",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013376","Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.","Feher M","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-017-0241-z","28281244","PMC5380503",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013377","Semaglutide for Weight Loss in Patients with a Family History of Thyroid or Uterine Cancer: A Systemic Review","Munshi M","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.02.27.25323032",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0013378","A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","Griffith DA","2020","bioRxiv","preclinical","preprint","10.1101/2020.09.29.319483",null,null,"ClinicalTrials.gov:NCT03309241","S002228","europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0013379","Cardiovascular risk, meet the twins: Optimizing cardiometabolic care with SGLT2i and GLP-1RA combination therapy.","Karakasis P","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133272","40250766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0013380","Hormonal Contraception and Initiation of Semaglutide Therapy.","Bager MD","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2026.24382","42485041","PMC13392808",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013381","A Unified Mechanistic Framework for Metabolism-Based Therapeutics in MASH: A Comprehensive Review of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Statins","Choi K","2025","Preprints.org","narrative_review","preprint","10.20944/preprints202508.0991.v3",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013382","Metabolic reprogramming in diabetes and cancer: the role of PI3K/AKT/mTOR and beyond.","Alharthi NS","2026","American journal of cancer research","narrative_review","article","10.62347/ogyt1108","42724341","PMC13559360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013383","New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease.","Almutairi M","2022","Frontiers in physiology","narrative_review","article","10.3389/fphys.2022.904626","35832485","PMC9271769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013384","Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes.","Abdul-Ghani M","2024","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(24)00127-x","39098317",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0013385","Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trials","Dawed AY","2022","medRxiv","randomized_trial","preprint","10.1101/2022.05.27.22271124",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0013386","Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals.","LaRue S","2019","Journal of diabetes science and technology","other","article","10.1177/1932296818798376","30234374","PMC6399794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Study; research-article; article"],["R0013387","GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation.","Go EJ","2024","Experimental & molecular medicine","preclinical","article","10.1038/s12276-024-01342-8","39482537","PMC11612315",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0013388","The effects of liraglutide in mice with diet-induced obesity studied by metabolomics.","Bugáňová M","2017","The Journal of endocrinology","preclinical","article","10.1530/joe-16-0478","28138003",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013389","From abdominal adiposity to liver fibrosis: Expanding promise of semaglutide for Asian Indians.","Ghosh A","2026","Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","commentary","article","10.1007/s12664-025-01881-6","41071271",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0013390","Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.","Klein KR","2026","Diabetes care","randomized_trial","article","10.2337/dc26-0112","41893299","PMC13191398",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article; other"],["R0013391","Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency.","Caputo C","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag110","42051284","PMC13112428",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013392","Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes.","d'Aquino AI","2023","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2023.01.28.526057","36778223","PMC9915491",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0013393","Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients.","Guo C","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s472174","39224113","PMC11368103",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013394","The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.","von Scholten BJ","2022","Therapeutic advances in endocrinology and metabolism","randomized_trial","article","10.1177/20420188221112490","35874312","PMC9301118",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0013395","Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.","Carvas AO","2025","EBioMedicine","other_trial","article","10.1016/j.ebiom.2025.105836","40609154","PMC12270663",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; preprint; article"],["R0013396","Automated production of [68Ga]Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis module.","Kraihammer M","2023","Nuclear medicine and biology","other","article","10.1016/j.nucmedbio.2023.108381","37634398",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013397","A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: soli de-escalation.","Giorgino F","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112945","41092981",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0013398","A Novel, Widespread Impurity in Mass-Compounded Tirzepatide/B12 Products: Patient Safety Implications","Jordan B","2026","medRxiv","other","preprint","10.64898/2026.03.09.26347818",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013399","Non-invasive in vivo imaging of porcine islet xenografts in a preclinical model with [68Ga]Ga-exendin-4.","Lindheimer F","2023","Frontiers in nuclear medicine","preclinical","article","10.3389/fnume.2023.1157480","39355020","PMC11440980",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013400","Emerging PEGylated non-biologic drugs.","Park EJ","2019","Expert opinion on emerging drugs","narrative_review","article","10.1080/14728214.2019.1604684","30957581",null,"ClinicalTrials.gov:NCT01492101; ClinicalTrials.gov:NCT02367820; ClinicalTrials.gov:NCT00520390; ClinicalTrials.gov:NCT02119819; ClinicalTrials.gov:NCT03520972; ClinicalTrials.gov:NCT03604419; ClinicalTrials.gov:NCT00804986; ClinicalTrials.gov:NCT03672604; ClinicalTrials.gov:NCT01089517; ClinicalTrials.gov:NCT01944839; ClinicalTrials.gov:NCT01940900; ClinicalTrials.gov:NCT01940887; ClinicalTrials.gov:NCT00932100; ClinicalTrials.gov:NCT00715455; ClinicalTrials.gov:NCT01872572; ClinicalTrials.gov:NCT01848106; ClinicalTrials.gov:NCT00432770; ClinicalTrials.gov:NCT00632242; ClinicalTrials.gov:NCT00742612; ClinicalTrials.gov:NCT00507338; ClinicalTrials.gov:NCT02397954; ClinicalTrials.gov:NCT00976378; ClinicalTrials.gov:NCT01486797; ClinicalTrials.gov:NCT01521533; ClinicalTrials.gov:NCT01085292; ClinicalTrials.gov:NCT01547897; ClinicalTrials.gov:NCT01372137; ClinicalTrials.gov:NCT01691040; ClinicalTrials.gov:NCT02079896","S001550; S001846; S002761; S002771","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0013401","Glucagon-Like Peptide-1 Receptor Activation Stimulates PKA-Mediated Phosphorylation of Raptor and this Contributes to the Weight Loss Effect of Liraglutide","Le TDV","2022","bioRxiv","preclinical","preprint","10.1101/2022.04.21.489078",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013402","Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.","Alfaris N","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70991","42303274","PMC13449079",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0013403","Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and amylin in male rats.","Aranäs C","2025","British journal of pharmacology","preclinical","article","10.1111/bph.17406","39622492",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013404","Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.","Willard FS","2020","JCI insight","preclinical","article","10.1172/jci.insight.140532","32730231","PMC7526454",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0013405","IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis.","Liu Y","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1643386","40958912","PMC12434752",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Comparative Study; systematic-review; review"],["R0013406","LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.","Coskun T","2022","Cell metabolism","other_trial","article","10.1016/j.cmet.2022.07.013","35985340",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0013407","Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study.","Masuzaki H","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70850","42108080","PMC13341361","ClinicalTrials.gov:NCT04844918","S001216","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0013408","GLP1 agonists in cardio-oncology: is it time for a specific focus?","López-Fernández T","2025","European journal of preventive cardiology","commentary","article","10.1093/eurjpc/zwaf064","39921479",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; editorial"],["R0013409","Semaglutide alleviates the pancreatic β cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice.","Luo Y","2025","Life sciences","preclinical","article","10.1016/j.lfs.2024.123328","39719165",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013410","Glucagon-like peptide-1 receptor agonists for intensifying diabetes treatment.","Bush MA","2011","The Journal of family practice","other","article",null,"21912773",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013411","Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.","Rayner B","2026","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfag036","41728915","PMC13518088","ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0013412","Optimal Timing for Initiating Liraglutide 3.0 mg in Patients With Persistent Obesity Six Months After Metabolic and Bariatric Surgery.","Ouyang Y","2026","Obesity surgery","other","article","10.1007/s11695-026-08838-4","42446801",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013413","Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study","Owen EC","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.09.08.26362532",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0013414","Role of glucagon in metabolic diseases.","Kitamura T","2026","Journal of diabetes investigation","other_trial","article","10.1111/jdi.70416","42593182","PMC13471711",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0013415","Correction to: \"Atypical retrobulbar optic neuropathy after semaglutide escalation\".",null,"2026","JCEM case reports","notice","article","10.1210/jcemcr/luag179","42440707","PMC13334094",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0013416","Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?","Inzucchi SE","2026","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgag290","42478869",null,"ClinicalTrials.gov:NCT03914326","S002179","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; article"],["R0013417","GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation.","Helmstädter J","2021","Antioxidants (Basel, Switzerland)","preclinical","article","10.3390/antiox10081175","34439423","PMC8388926",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013418","Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.","Inoue M","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13757","31050109","PMC6771557",null,"S001735","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0013419","Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia.","Teramoto S","2011","Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","preclinical","article","10.1038/jcbfm.2011.51","21487412","PMC3170947",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013420","Effects of Semaglutide on Glycemic Control and Body Weight in Patients With Type 2 Diabetes: A Retrospective Cohort Study in a Primary Care Setting.","Alzahrani M","2025","Cureus","nonrandomized_study","article","10.7759/cureus.82123","40357116","PMC12068361",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013421","The \"microdosing\" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.","Trainer N","2026","Journal of the American Association of Nurse Practitioners","other","article","10.1097/jxx.0000000000001296","42201545",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013422","Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.","Viebahn GK","2025","American journal of physiology. Gastrointestinal and liver physiology","other_trial","article","10.1152/ajpgi.00164.2025","41056349","PMC12643026",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0013423","Glucose potentiates β-cell function by inducing Tph1 expression in rat islets.","Zhang Y","2017","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.201700351r","28794173",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013424","[Prescription of GLP-1 receptor agonists and iSGLT2 in geriatrics, is there a risk?].","Moro D","2024","Revue medicale suisse","other","article","10.53738/revmed.2024.20.893.1983","39478377",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0013425","Exendin-4 improves β-cell function in autophagy-deficient β-cells.","Abe H","2013","Endocrinology","preclinical","article","10.1210/en.2013-1578","24105478",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013426","A Comprehensive Review on Recent Advancements in Navigating the Complexities of Polycystic Ovarian Syndrome (PCOS).","Waqar MA","2026","Reproductive sciences (Thousand Oaks, Calif.)","narrative_review","article","10.1007/s43032-026-02087-7","41917318",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013427","Real-world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA-elderly).","Fiore V","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16174","39789997",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0013428","12621 Convergence Of Sglt2 Inhibitors And Glp1 Agonists: Unveiling The Recipe For Euglycemic Diabetic Ketoacidosis",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454998",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013429","Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance.","Abdesselam I","2015","Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance","preclinical","article","10.1186/s12968-015-0198-x","26546347","PMC4636800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0013430","Physiological monitoring of the complex multimorbid heart failure patient - diabetes and monitoring glucose control.","Seferović PM","2019","European heart journal supplements : journal of the European Society of Cardiology","other","article","10.1093/eurheartj/suz219","31908611","PMC6937507",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013431","Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.","Reusch J","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12382","25155146",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013432","Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.","Packer M","2025","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2025.03.009","40162940",null,"ClinicalTrials.gov:NCT04847557","S000047","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0013433","EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2/F3 fibrosis: An analysis of ESSENCE.","Augusto M","2026","JHEP reports : innovation in hepatology","randomized_trial","article","10.1016/j.jhepr.2026.101993","42580587","PMC13651485",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0013434","Metabolic Polygenic Risk Scores for Prediction of Obesity, Type 2 Diabetes, and Related Morbidities","Kim MS","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.11.01.24316620",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0013435","Evaluation of Patient Factors Associated With Achieving Goal Hemoglobin A1c in Collaborative Drug Therapy Management Ambulatory Care Clinics by Clinical Pharmacists: A Retrospective Chart Review.","Torkos S","2021","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","nonrandomized_study","article","10.1177/8755122520949449","34752551","PMC7809326",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013436","Once-Weekly Mazdutide in Obesity or Overweight.","Zhang Y","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2509841","40929641",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0013437","Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy.","Zhou Y","2019","Brain research","preclinical","article","10.1016/j.brainres.2018.11.007","30408479",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013438","Evidence-Based Practice in Prescribing SGLT2i and GLP-1 RA Across Ethnic and Racial Groups: a Systematic Review and Meta-analysis of Observational Studies.","Ananthesh L","2026","Journal of racial and ethnic health disparities","systematic_review","article","10.1007/s40615-025-02410-z","40259185",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0013439","Characterizing GLP-1 Receptor Agonist Use in Preadolescent and Adolescent Populations.","Miller MG","2024","JAMA network open","other","article","10.1001/jamanetworkopen.2024.39887","39412809","PMC11581558",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013440","Alzheimer's disease: Clinical trials to watch.","Sabbagh MN","2025","Med (New York, N.Y.)","narrative_review","article","10.1016/j.medj.2025.100771","40782673","PMC13290110",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural; research-article"],["R0013441","Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.","Seufert J","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16161","39757952","PMC11802399",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0013442","Short-Term HbA1c Non-Inferiority of Synthetic Semaglutide Should Not Be Conflated With Full Therapeutic Interchangeability.","Singh AK","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71097","42420782","PMC13448871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013443","Pharmacological treatment of MASH.","Stefan N","2026","Diabetologia","narrative_review","article","10.1007/s00125-026-06796-1","42467088","PMC13627253",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013444","Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study.","Morieri ML","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13840","31364233","PMC6852173","ClinicalTrials.gov:NCT03959865","S000691","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0013445","Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.","Rantanen R","2026","Journal of clinical psychopharmacology","case_report","article","10.1097/jcp.0000000000002241","42495981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013446","Public Health Responsibilities in the Era of GLP-1 Receptor Agonists.","Wang G","2024","Journal of public health management and practice : JPHMP","other","article","10.1097/phh.0000000000002039","39190662",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013447","Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Zhong Y","2026","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2026.1916932","42757217","PMC13584767","PROSPERO:CRD420261354386",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0013448","GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions.","Yu JH","2022","Kidney research and clinical practice","narrative_review","article","10.23876/j.krcp.22.001","35391537","PMC8995488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0013449","Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease.","Anholm C","2019","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-019-0438-6","31164926","PMC6543623","ClinicalTrials.gov:NCT01595789","S001197","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0013450","Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.","Overgaard RV","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70769","42023428","PMC13243942",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Comparative Study; research-article; article"],["R0013451","Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial.","Gatta-Cherifi B","2024","European journal of endocrinology","randomized_trial","article","10.1093/ejendo/lvae024","38450721",null,null,"S002338","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Multicenter Study; Journal Article; Equivalence Trial; article"],["R0013452","GLP-1 receptor agonists in heart failure.","Vaduganathan M","2024","Lancet (London, England)","commentary","article","10.1016/s0140-6736(24)01598-8","39181582",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0013453","Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.","Sawamura T","2022","Medicina (Kaunas, Lithuania)","case_report","article","10.3390/medicina58020289","35208612","PMC8876704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013454","Beyond efficacy: health inequities limiting access to semaglutide for obesity management.","Islam K","2026","Postgraduate medical journal","other","article","10.1093/postmj/qgag129","42770197",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013455","Thinner and wiser? Prospects of GLP-1 agonists in psychiatry.","Vieta E","2025","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","other","article","10.1016/j.euroneuro.2025.05.006","40409236",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013456","Sight Unseen: Glucagon-Like Peptide-1 (GLP-1) Agonism Therapy and Nonarteritic Anterior Ischemic Optic Neuropathy.","Barnett MJ","2026","Cureus","nonrandomized_study","article","10.7759/cureus.100953","41523719","PMC12781142",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013457","Comments on \"Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes\".","Wei JC","2025","Gastroenterology","commentary","article","10.1053/j.gastro.2024.09.039","39426486",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013458","Salivary Glands treated with AAV vectors encoding PYY and exendin-4 impact upon taste perception and body mass accumulation in mice","Iyer S","2022","bioRxiv","preclinical","preprint","10.1101/2022.12.06.519331",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013459","Breast reduction outcomes in massive weight loss: A comparative analysis of GLP-1 receptor agonist users, post-bariatric surgery patients, and controls.","Friedman O","2025","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","nonrandomized_study","article","10.1016/j.bjps.2025.09.023","41066871",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Comparative Study; Journal Article; Observational Study; article"],["R0013460","Symmetrical Drug-Related Intertriginous and Flexural Exanthema in Setting of GLP-1 Agonist: A Case Report.","El Jbeily R","2026","International journal of dermatology","case_report","article","10.1111/ijd.17984","40698594",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013461","Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis.","Liu L","2025","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2024.103020","39834714","PMC11743856","PROSPERO:CRD42024547905",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0013462","Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy.","Bu LL","2021","Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","preclinical","article","10.1007/s13311-021-01018-5","33723752","PMC8423983",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013463","The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.","Malkin SJP","2019","Advances in therapy","nonrandomized_study","article","10.1007/s12325-019-00965-y","31168765","PMC6822857",null,"S000372","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0013464","The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus.","De Fano M","2025","Nutrients","systematic_review","article","10.3390/nu17193038","41097116","PMC12526187",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0013465","Activation of glucagon-like peptide-1 receptor in microglia exerts protective effects against sepsis-induced encephalopathy via attenuating endoplasmic reticulum stress-associated inflammation and apoptosis in a mouse model of sepsis.","Yi H","2023","Experimental neurology","preclinical","article","10.1016/j.expneurol.2023.114348","36813224",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0013466","Semaglutide and Limb Events: Expanding the Cardiovascular Prevention Paradigm?","Canonico ME","2026","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwag494","42751734",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013467","Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.","Castaneda R","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70231","42290037","PMC13535754",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013468","Tirzepatide and Cardiometabolic Effects in Obese Non-diabetic Adults: A Systematic Review, Meta-Analysis, and Narrative Synthesis of Cardiovascular Outcomes.","Chaparala P","2026","Cureus","systematic_review","article","10.7759/cureus.109350","42326175","PMC13282936",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013469","[Role of incretins in energy metabolism and weight changes after smoking cessation].","Pánková A","2016","Casopis lekaru ceskych","narrative_review","article",null,"27256148",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013470","Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.","Reaney M","2015","Diabetes, obesity & metabolism","other","article","10.1111/dom.12527","26095190",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0013471","Obesity and the kidney: mechanistic links and therapeutic advances.","Yau K","2024","Nature reviews. Endocrinology","narrative_review","article","10.1038/s41574-024-00951-7","38351406",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural"],["R0013472","GLP-1 receptor agonists: new kids in the block of renoprotection for people with type 2 diabetes and chronic kidney disease.","Koufakis T","2024","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2024.2416584","39392012",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0013473","Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats.","Ma X","2013","Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","preclinical","article","10.1002/jbmr.1898","23427056",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013474","GLP-1 agonists on a roll: from obesity to psoriasis - an elixir to watch!","Stratakis CA","2025","Hormones (Athens, Greece)","commentary","article","10.1007/s42000-025-00697-5","40699508",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0013475","Distinct metabolomic profiles in lean and non-lean polyendocrine metabolic ovarian syndrome.","Vagios S","2026","Journal of assisted reproduction and genetics","nonrandomized_study","article","10.1007/s10815-026-04015-9","42658451",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0013476","The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.","Christensen M","2014","Expert opinion on drug discovery","narrative_review","article","10.1517/17460441.2014.942638","25119443",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013477","Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively.","Seddio AE","2025","The Journal of the American Academy of Orthopaedic Surgeons","nonrandomized_study","article","10.5435/jaaos-d-25-00439","40549942",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013478","Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).","le Roux CW","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70196","41187967","PMC12673442","ClinicalTrials.gov:NCT06066515","S000367","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0013479","Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.","Kaore S","2024","Cureus","systematic_review","article","10.7759/cureus.56939","38665722","PMC11044191",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013480","Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials.","Caruso I","2019","Trends in endocrinology and metabolism: TEM","other_trial","article","10.1016/j.tem.2019.07.004","31401015",null,null,"S000760","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; review"],["R0013481","Proglucagon signalling in the rat Dorsomedial Hypothalamus - Physiology and high-fat diet-mediated alterations.","Sanetra AM","2023","Molecular and cellular neurosciences","preclinical","article","10.1016/j.mcn.2023.103873","37295578",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013482","Anti-Hyperglycemic Medication Management in the Perioperative Setting: A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist.","Goron AR","2024","Journal of clinical medicine","narrative_review","article","10.3390/jcm13206259","39458209","PMC11509032",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013483","Efficacy and safety of European Medicines Agency (EMA)-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta-analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity.","Barazzoni R","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70204","41111360","PMC12673438","PROSPERO:CRD42024625338",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; article"],["R0013484","Signatures of proteomics and glycoproteomics revealed liraglutide ameliorates MASLD by regulating specific metabolic homeostasis in mice.","Chen Y","2025","Journal of pharmaceutical analysis","preclinical","article","10.1016/j.jpha.2025.101273","41377138","PMC12688686",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013485","Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro.","Zhou H","2015","Scientific reports","preclinical","article","10.1038/srep12898","26250571","PMC4528192",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013486","Negative effects of semaglutide on bone in obese mice.","Eisner K","2026","Cell reports. Medicine","nonrandomized_study","article","10.1016/j.xcrm.2026.102875","42314683","PMC13400159",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0013487","Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes.","Fujikawa T","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-021-01008-y","33586119","PMC7947132",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013488","Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.","Zhang Y","2026","Tissue & cell","preclinical","article","10.1016/j.tice.2026.103557","42119472",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013489","Bypassing Prescribers and Pharmacists: Online Purchasing of Semaglutide and Tirzepatide \"For Research Purposes\".","Belcourt J","2025","The Annals of pharmacotherapy","commentary","article","10.1177/10600280241277551","39285774",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0013490","Effects of GLP-1 Receptor Agonists on Heart Failure Outcomes: The FLOW of Evidence.","Kittipibul V","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.08.016","39217554",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0013491","Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Domecq JP","2019","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/jc.2019-01269","31365088",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; review"],["R0013492","The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis.","Tseng PT","2025","BMC medicine","systematic_review","article","10.1186/s12916-025-04018-w","40189519","PMC11974209","PROSPERO:CRD42021252381",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; other; article"],["R0013493","Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease.","Zhou Z","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71305","42750649",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0013494","Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration.","van Zuylen ML","2024","British journal of anaesthesia","commentary","article","10.1016/j.bja.2024.01.001","38290907",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; article"],["R0013495","Optimizing outcomes with incretin-based therapies: practical information for nurse practitioners to share with patients.","Fleury-Milfort E","2009","Journal of the American Academy of Nurse Practitioners","narrative_review","article","10.1111/j.1745-7599.2009.00454.x","19900195",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013496","Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.","Rodbard HW","2016","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12574","26343931","PMC5063148",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0013497","Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?","Chavez AM","2025","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000001130","40401903",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013498","Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components.","Liu Q","2026","Neuromolecular medicine","preclinical","article","10.1007/s12017-026-08945-6","42622904",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013499","I-M-150847, a novel GLP-1 and GIP receptor dual agonist, improves glycemic control and reduces obesity in the rodent model of type 2 diabetes and obesity","Bauri R","2021","bioRxiv","preclinical","preprint","10.1101/2021.12.05.471325",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013500","Christensenella intestinihominis MNO-863 improve obesity and related metabolic disorders via SCFAs-induced GLP-1 hormone secretion.","Kong P","2025","Frontiers in nutrition","preclinical","article","10.3389/fnut.2025.1668786","41356823","PMC12677068",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013501","GLP-1 receptor agonists in heart failure: how far to expand use?","Hage C","2024","Lancet (London, England)","commentary","article","10.1016/s0140-6736(24)01763-x","39222643",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0013502","Differential effects of the anti-obesity drug tirzepatide on adipose tissues: Brown fat as a key target.","Mestres-Arenas A","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2026.119057","41592522",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013503","Tirzepatide (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus.","Rebitch CB","2023","American family physician","other","article",null,"37440749",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013504","Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease.","Gao Y","2019","Clinical cardiology","narrative_review","article","10.1002/clc.23252","31448852","PMC6837027",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013505","iGlarLixi for type 2 diabetes: a systematic review and meta-analysis.","Liu Y","2024","Endocrine","systematic_review","article","10.1007/s12020-024-03868-3","38740694",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0013506","Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.","Pallavi K","2025","Maedica","systematic_review","article","10.26574/maedica.2025.20.4.824","41537067","PMC12767911",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013507","Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.","Jellinger PS","2011","Postgraduate medicine","nonrandomized_study","article","10.3810/pgm.2011.01.2245","21293084",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0013508","Semaglutide in Schizophrenia-A Top Clinical Trial.","Öngür D","2026","JAMA psychiatry","other_trial","article","10.1001/jamapsychiatry.2026.2043","42384388",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0013509","GLP-1 Receptor Agonists and Suicidality-Caution Is Needed.","Salvo F","2024","JAMA network open","other","article","10.1001/jamanetworkopen.2024.23335","39163050",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013510","A New Era of Disease‐Modifying Pharmacotherapy in Cardiovascular Medicine","Varrassi G","2025","Preprints.org","other","preprint","10.20944/preprints202512.0979.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013511","Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Obese Polycystic Ovary Syndrome Patients.","Su L","2025","The Tohoku journal of experimental medicine","preclinical","article","10.1620/tjem.2025.j009","39880646",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013512","Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.","Verspohl EJ","2009","Pharmacology & therapeutics","preclinical","article","10.1016/j.pharmthera.2009.06.002","19545590",null,null,"S001352","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0013513","Synergistic effect of glucagon-like peptide-1 analogue liraglutide and ZnO on the antibacterial, hemostatic, and wound healing properties of nanofibrous dressings.","Wu F","2022","Journal of bioscience and bioengineering","preclinical","article","10.1016/j.jbiosc.2022.06.004","35760699",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013514","Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.","Ojima A","2013","The American journal of pathology","preclinical","article","10.1016/j.ajpath.2012.09.016","23159951",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013515","Semaglutide in Bipolar Disorder: A Differential Finding Needs a Differential Mechanism.","Demas A","2026","Acta psychiatrica Scandinavica","commentary","article","10.1111/acps.70143","42754946",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013516","Why Do We Lose Bone During Weight Loss: Can It Be Prevented?","Shapses SA","2026","Current osteoporosis reports","randomized_trial","article","10.1007/s11914-026-00984-z","42714789","PMC13558454",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0013517","Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.","le Roux CW","2024","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(23)00356-x","38330987",null,"ClinicalTrials.gov:NCT04667377; EudraCT:2020-002479-37","S002375","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013518","Oligomerization, albumin binding and catabolism of therapeutic peptides in the subcutaneous compartment: An investigation on lipidated GLP-1 analogs.","Gallo M","2022","Journal of pharmaceutical and biomedical analysis","nonrandomized_study","article","10.1016/j.jpba.2021.114566","35042144",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013519","Corrigendum to \"Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in Indian adults with obesity: A phase III randomized non-inferiority trial\" [Metabol Open 30 (2026) 100460].","Sharma PK","2026","Metabolism open","notice","article","10.1016/j.metop.2026.100477","42327013","PMC13282489",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0013520","SUN-820 The Impact of GLP-1 Agonists on the Development of Body Dysmorphic Disorder",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544937",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013521","Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials.","Chiang CH","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70980","42297743","PMC13449091",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; article"],["R0013522","Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.","Gudbergsen H","2019","BMJ open","protocol","article","10.1136/bmjopen-2018-024065","31061017","PMC6501972","ClinicalTrials.gov:NCT02905864","S001734","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; protocol; article"],["R0013523","Euglycemic diabetic ketoacidosis following treatment with tirzepatide and SGLT-2 inhibitors: A case report and literature review.","Sawamura T","2026","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.6816-25","41850834",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013524","Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.","Wen Y","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16661","40726454","PMC12409240",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase II; Journal Article; research-article; article"],["R0013525","Is exenatide the next big thing in Parkinson's disease?","Simuni T","2014","Journal of Parkinson's disease","randomized_trial","article","10.3233/jpd-149001","24748153",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Comment; article"],["R0013526","Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study.","Mao X","2025","Journal of the National Cancer Institute","nonrandomized_study","article","10.1093/jnci/djaf163","40632592","PMC12593220",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013527","Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement.","Wu CT","2026","Gut","other","article","10.1136/gutjnl-2025-337374","41770836",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Consensus Statement; article"],["R0013528","Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies.","Kamrul-Hasan ABM","2026","Postgraduate medical journal","systematic_review","article","10.1093/postmj/qgaf238","41536268",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0013529","Retatrutide: a triple incretin receptor agonist for obesity management.","Ray A","2023","Expert opinion on investigational drugs","other","article","10.1080/13543784.2023.2276754","37902090",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013530","GLP-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: A Case Report.","Ayada G","2025","Diabetes technology & therapeutics","case_report","article","10.1089/dia.2024.0367","39360432",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013531","Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis.","Cleto AS","2025","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-024-01646-9","39396098",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0013532","Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.","Kjaergaard J","2025","Circulation. Cardiovascular interventions","randomized_trial","article","10.1161/circinterventions.124.014961","40265262",null,"ClinicalTrials.gov:NCT02673931","S001685","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0013533","The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.","de Boer SA","2016","International journal of clinical pharmacy","nonrandomized_study","article","10.1007/s11096-015-0219-8","26597956","PMC4733138",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0013534","The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies.","Rochira V","2024","Diseases (Basel, Switzerland)","systematic_review","article","10.3390/diseases12090204","39329873","PMC11431103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013535","Obesity-related glomerulopathy: How it happens and future perspectives.","Lee-Boey JS","2025","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.70042","40226862","PMC12080990",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0013536","Corrigendum: Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.","Humphrey CD","2023","Facial plastic surgery : FPS","notice","article","10.1055/s-0044-1779676","38604246",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0013537","Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis.","Bignamini AA","2021","Advances in therapy","systematic_review","article","10.1007/s12325-021-01620-1","33502688","PMC7932977",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0013538","Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014.","Christensen DH","2016","Clinical epidemiology","nonrandomized_study","article","10.2147/clep.s113211","27789974","PMC5072551",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013539","Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?","Christensen M","2010","Current diabetes reports","narrative_review","article","10.1007/s11892-010-0102-x","20425571",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013540","Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.","Bachmann KN","2020","Pharmacology research & perspectives","nonrandomized_study","article","10.1002/prp2.637","32881317","PMC7507366",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0013541","New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention.","Katsanos AH","2020","JAMA neurology","systematic_review","article","10.1001/jamaneurol.2020.2494","32716473",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0013542","The Unintended Psychosocial Consequences of GLP-1 Receptor Agonists for Children and Adolescents: A Call for More Research.","Côté M","2025","Childhood obesity (Print)","commentary","article","10.1089/chi.2024.0317","39239749",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0013543","Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity.","Takizawa H","2026","Endocrinology, diabetes & metabolism case reports","case_report","article","10.1530/edm-26-0002","41925328","PMC13052794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013544","Correction to \"Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli\".",null,"2026","Protein science : a publication of the Protein Society","notice","article","10.1002/pro.70657","42233323","PMC13239699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0013545","Exendin-4 Exacerbates Burn-Induced Mortality in Mice by Switching to Th2 Response.","Hao JW","2022","The Journal of surgical research","preclinical","article","10.1016/j.jss.2022.07.029","36030610",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013546","Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis.","Zhu K","2026","Journal of diabetes investigation","preclinical","article","10.1111/jdi.70398","42549609","PMC13435296",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013547","Clinical potential of treatment with semaglutide in type 2 diabetes patients.","Røder ME","2019","Drugs in context","other_trial","article","10.7573/dic.212585","31844422","PMC6905643",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0013548","SUN-661 Impact of GLP-1 Analogs vs. Lipid Lowering Agents on Risk for Acute Pancreatitis in Hypertriglyceridemia: A TriNetX Analysis",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545017",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013549","Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.","Dubourg J","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14613","34866306","PMC9305103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0013550","Drug discovery approaches targeting the incretin pathway.","Deng X","2020","Bioorganic chemistry","narrative_review","article","10.1016/j.bioorg.2020.103810","32325333",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0013551","Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.","Yabut JM","2023","Endocrine reviews","other","article","10.1210/endrev/bnac018","35907261",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013552","Persistent Adipose Inflammation Despite Metabolic Recovery Reveals Tissue-Specific Immunomodulation by Tirzepatide.","Seo M","2026","Endocrinology and metabolism (Seoul, Korea)","preclinical","article","10.3803/enm.2025.2766","42136381",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013553","Comment on 'Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan'.","Shahid F","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71109","42443711","PMC13448868",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0013554","Stem-Cell-Derived Islets as a Model of Human Islet Inflammation: A Comparative Analysis of Pro-inflammatory Cytokine Responses","Svane CAB","2026","bioRxiv","other","preprint","10.64898/2026.05.01.722128",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013555","The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.","Imamura S","2013","The Tohoku journal of experimental medicine","other_trial","article","10.1620/tjem.231.57","24064677",null,null,"S002088","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; article"],["R0013556","Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK.","Lee J","2015","Endocrinology and metabolism (Seoul, Korea)","preclinical","article","10.3803/enm.2015.30.2.177","26194078","PMC4508262",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013557","Rhabdomyolysis Associated With Semaglutide Therapy: A Case Report.","Billings SA","2023","Cureus","case_report","article","10.7759/cureus.50227","38192938","PMC10773591",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013558","Evaluation of Novel GLP‐1 analogue in the treatment of Alzheimer’s disease","Edison P","2024","Alzheimer's & dementia : the journal of the Alzheimer's Association","randomized_trial","article","10.1002/alz.089799",null,"PMC11713359",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0013559","Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: A retrospective real-life study in 131 patients.","Hemmer A","2019","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2018.09.007","30641721",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0013560","Bariatric Surgery as a Potential Risk Factor for Patulous Eustachian Tube: A Comprehensive Literature Review.","Almasri K","2026","Cureus","narrative_review","article","10.7759/cureus.115965","42724661","PMC13560892",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013561","Are GLP-1R agonists the long-sought-after panacea for obesity?","Dowsett GKC","2023","Trends in molecular medicine","other","article","10.1016/j.molmed.2023.06.008","37460364",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013562","Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.","Guja C","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00815-z","32306296","PMC7324446","ClinicalTrials.gov:NCT00637273; ClinicalTrials.gov:NCT00676338; ClinicalTrials.gov:NCT02229383; ClinicalTrials.gov:NCT02229396; ClinicalTrials.gov:NCT00641056; ClinicalTrials.gov:NCT01652729; ClinicalTrials.gov:NCT00935532; ClinicalTrials.gov:NCT01003184","S000402; S000632; S000703; S000791; S001157; S001355; S001768; S001966","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0013563","Cardiovascular Outcome Trials with Glucose-Lowering Drugs.","Thethi TK","2021","Current cardiology reports","narrative_review","article","10.1007/s11886-021-01505-3","34081215",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013564","68Ga-DOTA-Exendin-4 PET/CT Demonstrated a Higher Detection Efficacy for Double-Primary Insulinomas Than MRI: A Case Report.","Qiu L","2023","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000004508","36723891",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0013565","Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.","Kokkinos A","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71009","42348366","PMC13448863","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657003","S001077; S001712","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; research-article; article"],["R0013566","Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study.","Đekić D","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01407-3","37211579","PMC10241758",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013567","Incretin hormones and type 2 diabetes.","Nauck MA","2023","Diabetologia","narrative_review","article","10.1007/s00125-023-05956-x","37430117","PMC10474001",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0013568","Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol.","Hinton W","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","protocol","article","10.1007/s13300-018-0390-8","29605893","PMC5984905",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0013569","Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview.","Wieczorek-Surdacka E","2020","Folia medica Cracoviensia","narrative_review","article","10.24425/fmc.2020.136207","33821854",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013570","LINAGLIPTIN-INDUCED PANCREATITIS.","Mosquera JE","2020","AACE clinical case reports","case_report","article","10.4158/accr-2019-0307","33163625","PMC7279777",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013571","Unveiling the Therapeutic Potential of Dulaglutide in Mitigating Tacrolimus-Induced Nephrotoxicity Through Targeting the miR-22/HMGB-1/TLR4/MyD88/NF-κB Trajectory.","Abdelhady R","2025","Archiv der Pharmazie","preclinical","article","10.1002/ardp.202500023","40205909","PMC11983086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013572","Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review.","Chen Q","2025","Seminars in thrombosis and hemostasis","randomized_trial","article","10.1055/a-2546-0353","40154507","PMC12431824",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0013573","A GLP‑1 receptor agonist attenuates human islet amyloid polypeptide‑induced autophagy and apoptosis in MIN6 cells.","Chen X","2019","Molecular medicine reports","other","article","10.3892/mmr.2018.9741","30569165",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013574","Heart failure with preserved ejection fraction: updated diagnostic and therapeutic strategies. SEMI consensus document.","Fernández Rodríguez JM","2026","Revista clinica espanola","narrative_review","article","10.1016/j.rceng.2026.502471","41638556",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Consensus Statement; Journal Article; Review; article"],["R0013575","Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting.","Sanyal D","2013","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/2230-8210.119629","24251194","PMC3830340",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; other; article"],["R0013576","Inflammation-mediated facial nodules to compounded tirzepatide.","Moore LC","2026","JAAD case reports","commentary","article","10.1016/j.jdcr.2026.06.026","42598502","PMC13471048",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013577","Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells.","Krause GC","2019","EXCLI journal","other","article","10.17179/excli2019-1415","31611738","PMC6785771",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013578","Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials.","Ukkonen M","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71087","42410302","PMC13538721",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0013579","Gastrin analogue administration adds no significant glycaemic benefit to a glucagon-like peptide-1 receptor agonist acutely or after washout of both analogues.","Bokvist K","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13695","30848033",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013580","GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance.","Khound R","2017","Arteriosclerosis, thrombosis, and vascular biology","preclinical","article","10.1161/atvbaha.117.310251","29074588",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013581","Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.","Tanaka K","2015","Clinical drug investigation","randomized_trial","article","10.1007/s40261-015-0331-5","26369653",null,"UMIN:UMIN000004243",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013582","Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.","Messak M","2025","Naunyn-Schmiedeberg's archives of pharmacology","systematic_review","article","10.1007/s00210-025-03932-3","40067438","PMC12350457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review-article; review"],["R0013583","The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension: Body Weight.","Mollan SP","2021","Neurology. Clinical practice","preclinical","article","10.1212/cpj.0000000000001063","34484948","PMC8382420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013584","Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes.","Xu W","2015","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","preclinical","article","10.1097/jim.0000000000000129","25479064",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013585","[Basal insulin degludec (Tresiba®)].","Scheen AJ","2019","Revue medicale de Liege","other_trial","article",null,"30997973",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","5","FALSE","Journal Article; article"],["R0013586","Quantification of β-Cell Mass in Intramuscular Islet Grafts Using Radiolabeled Exendin-4.","Espes D","2016","Transplantation direct","preclinical","article","10.1097/txd.0000000000000598","27819034","PMC5082995",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013587","[Therapeutic options for a type 2 diabetic patient not well controlled with metformin plus basal insulin].","Scheen AJ","2017","Revue medicale suisse","other","article",null,"28837278",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013588","Psychosocial aspects and contributions of behavioural science to medication-taking for adults with type 2 diabetes.","Winkley K","2020","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.14214","31837158",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Historical Article; Journal Article; Review; article"],["R0013589","The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.","Liu M","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15724","38922731",null,"ClinicalTrials.gov:NCT05413369","S000073","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0013590","Orforglipron, quand le GLP-1 devient simple et oral.","Comte D","2025","Revue medicale suisse","commentary","article","10.53738/revmed.2025.21.942.2207","41340450",null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","News; article"],["R0013591","Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.","Peri RV","2025","Nutrition & diabetes","narrative_review","article","10.1038/s41387-025-00397-4","41276534","PMC12644520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013592","Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease.","Dalbøge LS","2022","Biomedicines","preclinical","article","10.3390/biomedicines10071661","35884965","PMC9313388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013593","Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.","Skandov MD","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71092","42420793","PMC13538733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0013594","Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.","Vishnoi S","2026","Journal of computer-aided molecular design","other","article","10.1007/s10822-026-00903-5","42530676","PMC13424190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013595","A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants.","Nielsen MS","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-024-01674-8","39708086","PMC11794934","ClinicalTrials.gov:NCT05227196","S002083","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0013596","418 Activation of the Glucagon-Like Peptide-1 Pathway in Obese Pre-Diabetic Individuals Improves Endothelial Function Independently of Weight Loss","Mashayekhi M",null,"Journal of clinical and translational science","randomized_trial","article",null,null,"PMC9209271",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0013597","Comparative Effects of Weight Loss and Incretin-Based Therapies on Vascular Endothelial Function, Fibrinolysis, and Inflammation: A Randomized, Controlled Trial","Mashayekhi M","2022","medRxiv","randomized_trial","preprint","10.1101/2022.02.23.22271434",null,null,"ClinicalTrials.gov:NCT03101930","S001436","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0013598","Association of glucagon-like peptide-1 agonist use with atopic dermatitis in obese patients: A retrospective cohort study.","Burke SM","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.09.080","41033491","PMC13527738",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013599","Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues.","Tews D","2008","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","preclinical","article","10.1055/s-2008-1042426","18348079",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013600","Diagnosis and Management of Stable Angina: A Review.","Joshi PH","2021","JAMA","randomized_trial","article","10.1001/jama.2021.1527","33944871",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0013601","Exendin-4 for Parkinson's disease.","Esparza-Salazar FJ","2021","Brain circulation","narrative_review","article","10.4103/bc.bc_21_21","34084977","PMC8057099",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013602","RETRACTED: Paladugu et al. Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. Int. J. Mol. Sci. 2021, 22, 860.","Paladugu L","2026","International journal of molecular sciences","notice","article","10.3390/ijms27157042","42561097","PMC13446551",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retraction Notice; Retraction of Publication; retraction"],["R0013603","Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.","Brunton S","2016","Clinical therapeutics","narrative_review","article","10.1016/j.clinthera.2016.01.014","26926319",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0013604","Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.","Auernhammer CJ","2026","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgaf705","41518601","PMC13183451",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013605","Linking GLP-1 activation with steroidogenesis, redox, endoplasmic reticulum stress, mitophagy, and the apoptotic regulatory network unlocks the emerging impacts of semaglutide on 5-fluorouracil-induced testicular toxicity.","Hassan NF","2025","Life sciences","preclinical","article","10.1016/j.lfs.2025.124014","41072890",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013606","A cross-regional initiative for improving type 2 diabetes mellitus care quality measurement in Spain - The Diabetes Lighthouse project.","Arzuaga A","2026","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2026.07.013","42575755",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0013607","Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.","Platz E","2026","JACC. Heart failure","other_trial","article","10.1016/j.jchf.2025.102780","41329105",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0013608","Data and Temporal Risk Concerns of Semaglutide and NAION.","Yu CH","2026","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2026.3445","42658542",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013609","Glycemic Control in the Treatment of Psoriasis.","Ip W","2017","Dermatology (Basel, Switzerland)","narrative_review","article","10.1159/000472149","28538228",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013610","Scientific report: a case of acute pancreatitis due to liraglutide.","Quesada-Vázquez N","2019","Revista espanola de enfermedades digestivas","case_report","article","10.17235/reed.2018.5912/2018","30561221",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0013611","A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.","Fraser DA","2022","Journal of hepatology","preclinical","article","10.1016/j.jhep.2021.12.004","34915054",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0013612","What the Scale Does Not Show: A Patient's Reflection on Semaglutide, Strength, and the SMART Trial.","Schumacher E","2026","Clinical journal of the American Society of Nephrology : CJASN","other_trial","article","10.2215/cjn.0000001124","42308137","PMC13379113",null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; editorial"],["R0013613","The Risk of Retinal Vascular Events in Patients Using Semaglutide: A Scoping Review.","Choujaa Goudira S","2026","Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde","randomized_trial","article","10.1159/000553235","42348481",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0013614","Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes.","Baldassarre MPA","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71371","42768825",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0013615","Exposure to GLP-1 receptor agonists in early pregnancy did not increase the risk of congenital malformations.","Kuitunen I","2024","Acta paediatrica (Oslo, Norway : 1992)","other","article","10.1111/apa.17412","39206800",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013616","Mediterranean Dietary Pattern in Type 2 Diabetes Management: Pathways and Clinical Evidence.","Majić Milotić D","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14061350","42351778","PMC13297350",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013617","Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.","Venerito V","2026","RMD open","nonrandomized_study","article","10.1136/rmdopen-2026-006830","42532547","PMC13423080",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0013618","Future directions for quality of life research with second-generation GLP-1RAs for obesity.","Hsu R","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16036","39468376",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013619","Optimizing management of glycaemia.","Chatterjee S","2016","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2016.06.002","27432074",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013620","Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.","Liakos A","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13541","30242948",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013621","GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms.","Rizzo M","2018","Biochimica et biophysica acta. Molecular basis of disease","narrative_review","article","10.1016/j.bbadis.2018.05.012","29778663",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013622","When Weight Loss Turns Dangerous: A Case Report of Tirzepatide-Induced Ketoacidosis in a Non-diabetic Woman.","Sadiq H","2026","Cureus","case_report","article","10.7759/cureus.113368","42639616","PMC13503014",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013623","The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.","Jiang P","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2024.116485","38518602",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013624","Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T.","Eleftheriadou A","2025","Diabetologia","commentary","article","10.1007/s00125-024-06314-1","39505765",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013625","Systematic AI-Driven Drug Repurposing via Clinical Trial Data Mining: A Framework and Six Cross-Therapeutic Case Studies","Gote V","2026","bioRxiv","nonrandomized_study","preprint","10.64898/2026.06.11.731629",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0013626","[Cardiovascular pharmacotherapy in the era of RNA-based precision medicine].","Derda AA","2026","Herz","narrative_review","article","10.1007/s00059-026-05375-9","41946839",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; English Abstract"],["R0013627","When dose follows response: Interpreting lower-dose semaglutide effectiveness in clinical practice.","Kılınç S","2026","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.70479","42748286",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013628","A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.","Jiang Y","2023","Clinical drug investigation","randomized_trial","article","10.1007/s40261-023-01255-w","36943659",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Evaluation Study; Journal Article; article"],["R0013629","Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity.","Akhtar A","2025","Cell reports. Medicine","other","article","10.1016/j.xcrm.2025.102021","40107240","PMC11970383",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013630","An extended release GLP-1 analogue increases α-synuclein accumulation in a mouse model of prodromal Parkinson's disease.","Bergkvist L","2021","Experimental neurology","other_trial","article","10.1016/j.expneurol.2021.113693","33727096","PMC10461454",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013631","Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.","Natale P","2024","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd015588.pub2","38770818","PMC11106805","ClinicalTrials.gov:NCT02836873; ClinicalTrials.gov:NCT01032629; ClinicalTrials.gov:NCT01989754; ClinicalTrials.gov:NCT03242018; ClinicalTrials.gov:NCT02532855; ClinicalTrials.gov:NCT02065791; ClinicalTrials.gov:NCT03036150; ClinicalTrials.gov:NCT03036124; ClinicalTrials.gov:NCT04350593; ClinicalTrials.gov:NCT01730534; ClinicalTrials.gov:NCT02547935; ClinicalTrials.gov:NCT02268214; ClinicalTrials.gov:NCT02460978; ClinicalTrials.gov:NCT02413398; ClinicalTrials.gov:NCT03594110; ClinicalTrials.gov:NCT01370005; ClinicalTrials.gov:NCT01159600; ClinicalTrials.gov:NCT01177813; ClinicalTrials.gov:NCT01131676; ClinicalTrials.gov:NCT01210001; ClinicalTrials.gov:NCT01164501; ClinicalTrials.gov:NCT03057951; ClinicalTrials.gov:NCT03057977; ClinicalTrials.gov:NCT03078101; ClinicalTrials.gov:NCT01193218; ClinicalTrials.gov:NCT01294423; ClinicalTrials.gov:NCT00663260; ClinicalTrials.gov:NCT01316094; ClinicalTrials.gov:NCT01646320; ClinicalTrials.gov:NCT01137474; ClinicalTrials.gov:NCT02682563; ClinicalTrials.gov:NCT00683878; ClinicalTrials.gov:NCT03315143; ClinicalTrials.gov:NCT03521934; ClinicalTrials.gov:NCT01381887; ClinicalTrials.gov:NCT01986881; ClinicalTrials.gov:NCT01986855; ClinicalTrials.gov:NCT03436693; ClinicalTrials.gov:NCT01195662; ClinicalTrials.gov:NCT00673231; ClinicalTrials.gov:NCT01555008; ClinicalTrials.gov:NCT00528879; ClinicalTrials.gov:NCT00855166; ClinicalTrials.gov:NCT00968812; ClinicalTrials.gov:NCT01031680; ClinicalTrials.gov:NCT00528372; ClinicalTrials.gov:NCT00688701; ClinicalTrials.gov:NCT01512849; ClinicalTrials.gov:NCT00984867; ClinicalTrials.gov:NCT01042977; ClinicalTrials.gov:NCT04243850; ClinicalTrials.gov:NCT02096705; ClinicalTrials.gov:NCT05359263; ClinicalTrials.gov:NCT04662723; ClinicalTrials.gov:NCT04061200; ClinicalTrials.gov:NCT04238702; ClinicalTrials.gov:NCT01167881","S000557; S002333","pubmed; europepmc","FALSE","open_pdf","3",null,"Systematic Review; Journal Article; Meta-Analysis; systematic-review"],["R0013632","Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.","Lu TT","2025","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-025-01719-3","39865161",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Research Support, Non-U.S. Gov't"],["R0013633","Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data.","Chin KL","2020","Drugs & aging","nonrandomized_study","article","10.1007/s40266-020-00759-w","32227290",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0013634","Exendin-4 Pretreatment Attenuates Kainic Acid-Induced Hippocampal Neuronal Death.","Ahn YJ","2021","Cells","preclinical","article","10.3390/cells10102527","34685508","PMC8534217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013635","Liraglutide pretreatment attenuates sepsis-induced acute lung injury.","Baer B","2023","American journal of physiology. Lung cellular and molecular physiology","preclinical","article","10.1152/ajplung.00041.2023","37489855","PMC10639010",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0013636","Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study.","Jagtap N","2026","Endoscopy","randomized_trial","article","10.1055/a-2891-4165","42259388",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comparative Study; article"],["R0013637","International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches.","Dellgren JL","2024","Lancet (London, England)","narrative_review","article","10.1016/s0140-6736(24)01356-4","39159651",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0013638","Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.","Wysham C","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12961","28386990","PMC5638095","ClinicalTrials.gov:NCT02058160","S001409","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0013639","The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.","Rosenstock J","2013","Diabetes care","randomized_trial","article","10.2337/dc12-0709","23139373","PMC3579343","ClinicalTrials.gov:NCT00717457","S000414","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0013640","Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.","Hansen MB","2023","Facial plastic surgery : FPS","commentary","article","10.1055/s-0044-1785450","38604245",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0013641","Determinants of good metabolic control without weight gain in type 2 diabetes management: a machine learning analysis.","Giorda CB","2020","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2020-001362","32928790","PMC7490948",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013642","Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.","Zhang F","2015","Journal of diabetes","systematic_review","article","10.1111/1753-0407.12198","25043423",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0013643","The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis.","Kushima H","2017","Cardiovascular diabetology","other_trial","article","10.1186/s12933-017-0603-x","28969637","PMC5625638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0013644","Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.","Mortada I","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.105384","42516860","PMC13404063",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013645","Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.","Osonoi T","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15296","37794628",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013646","Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes.","Mayyas F","2026","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2026.109362","42341385",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0013647","The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.","Kanoski SE","2012","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2011.12.022","22227019","PMC4183930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0013648","Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A critical appraisal.","Corrao S","2026","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.70298","41914139","PMC13238931",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0013649","Correction: Gizdović et al. Changes in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition. Cells 2026, 15, 1258.","Gizdović I","2026","Cells","notice","article","10.3390/cells15151386","42587838","PMC13464950",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0013650","Therapeutic strategies for type 2 diabetes mellitus in women after menopause.","Paschou SA","2019","Maturitas","narrative_review","article","10.1016/j.maturitas.2019.05.003","31239121",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013651","Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis.","Twigg SM","2016","Journal of diabetes","systematic_review","article","10.1111/1753-0407.12372","26729046",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; article"],["R0013652","Physiology and pathophysiology of incretins in the kidney.","von Websky K","2014","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/01.mnh.0000437542.77175.a0","24257158",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013653","Addressing the role of diabetes progression and GLP-1 analog usage in perioperative aspiration risk.","Cagatay U","2025","Journal of clinical anesthesia","commentary","article","10.1016/j.jclinane.2025.111867","40381231",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013654","Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis.","Al-Badri MR","2014","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018814543483","25152810","PMC4141528",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013655","Data and Temporal Risk Concerns of Semaglutide and NAION-Reply.","Heberer KR","2026","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2026.3442","42658546",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013656","Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.","Frías JP","2021","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2107519","34170647",null,"ClinicalTrials.gov:NCT03987919","S000095; S000760; S001115; S001795; S001837","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013657","A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.","Nauck MA","2016","Diabetes care","randomized_trial","article","10.2337/dc15-0165","26358288",null,"ClinicalTrials.gov:NCT00696657","S000135","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013658","Management of High Cardiovascular Risk in Diabetic Patients: Focus on Low Density Lipoprotein Cholesterol and Appropriate Drug Use in General Practice.","Rottura M","2021","Frontiers in cardiovascular medicine","nonrandomized_study","article","10.3389/fcvm.2021.749686","34760944","PMC8572969",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013659","Diabetes and Hypertension: Clinical Update.","Khangura D","2018","American journal of hypertension","narrative_review","article","10.1093/ajh/hpy025","29548029",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013660","Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists.","Cook TM","2025","Neuropharmacology","narrative_review","article","10.1016/j.neuropharm.2024.110269","39675463","PMC11702201",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; research-article; article"],["R0013661","Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.","Choby B","2017","FP essentials","narrative_review","article",null,"28530382",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013662","Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.","Ayyaz F","2026","Internal and emergency medicine","commentary","article","10.1007/s11739-026-04539-z","42799976",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013663","Liraglutide Inhibits the Apoptosis of MC3T3-E1 Cells Induced by Serum Deprivation through cAMP/PKA/β-Catenin and PI3K/AKT/GSK3β Signaling Pathways.","Wu X","2018","Molecules and cells","preclinical","article","10.14348/molcells.2018.2340","29463067","PMC5881097",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013664","Longitudinal Changes in Body Composition, Adaptive Thermogenesis, and Muscle Strength in Patients with Obesity Treated with Semaglutide.","Filippi-Arriaga F","2026","Obesity facts","nonrandomized_study","article","10.1159/000553510","42640861","PMC13623382",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013665","Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity.","Tseng TC","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.08.006","42580629",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013666","Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: A letter to editor.","Fatima H","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133313","40280341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013667","Neuroinflammation and Autophagy in Neurodegeneration: Cellular Mechanisms and Therapeutic Strategies.","Verma A","2026","CNS & neurological disorders drug targets","other","article","10.2174/0118715273459017260922073618","42817119",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013668","Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice.","Wang V","2024","Journal of biomedical science","preclinical","article","10.1186/s12929-024-01025-6","38627765","PMC11022395",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0013669","Replicating cardiovascular outcome trials of medications used to treat type 2 diabetes using real-world data: A systematic review of observational studies","Wang W","2024","medRxiv","systematic_review","preprint","10.1101/2024.11.28.24317099",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0013670","Short-term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice.","Feng JN","2023","Physiological reports","preclinical","article","10.14814/phy2.15620","36905134","PMC10006666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013671","Heart Disease and Diabetes","Kalyani RR","2023","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)","randomized_trial","article",null,"38117924",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0013672","Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.","Thorsteinsdottir S","2026","Pediatric obesity","nonrandomized_study","article","10.1111/ijpo.70139","42543796","PMC13430127",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013673","Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.","Rescalli MB","2026","Human psychopharmacology","nonrandomized_study","article","10.1002/hup.70066","42803597",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0013674","Diabetes drugs activate neuroprotective pathways in models of neonatal hypoxic-ischemic encephalopathy.","Poupon-Bejuit L","2024","EMBO molecular medicine","preclinical","article","10.1038/s44321-024-00079-1","38783166","PMC11178908",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013675","Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018-2024).","Würtz Yazdanfard PD","2026","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2026.101716","42205711","PMC13208826",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013676","Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses.","Buchan TA","2021","Heart (British Cardiac Society)","systematic_review","article","10.1136/heartjnl-2021-319243","33833070",null,"PROSPERO:CRD42020168351",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0013677","Proposed treatment strategy for reactive hypoglycaemia.","Younes YR","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1332702","38370356","PMC10869498",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013678","Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [68Ga]Ga-NODAGA-Exendin-4.","Tokgöz S","2023","Methods in molecular biology (Clifton, N.J.)","protocol","article","10.1007/978-1-0716-2807-2_9","36507990",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; book-chapter"],["R0013679","Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial.","Tronieri JS","2026","The American journal of clinical nutrition","randomized_trial","article","10.1016/j.ajcnut.2026.101403","42323166","PMC13494093","ClinicalTrials.gov:NCT05548647","S001294","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; research-article; article"],["R0013680","Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.","Zaccardi F","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13185","29205774",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0013681","Mounjaro: Discount deal for UK pharmacies to mitigate price hike.","Bowie K","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r1836","40882998",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013682","Papular granuloma annulare associated with tirzepatide: A case report.","Howard T","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.06.046","42499401","PMC13396619",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013683","Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group.","Diaz LA","2025","Annals of hepatology","other","article","10.1016/j.aohep.2025.101903","40089151",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Consensus Statement; Journal Article; Practice Guideline; article"],["R0013684","OR08-07 Real-World Evidence on GLP-1 Analogues: Insights into NAION Risk in Type 2 Diabetes Mellitus Patients",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12545482",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0013685","Editorial: GLP-1 receptor agonists in inflammatory bowel disease-Is it time?","Arvanitakis K","2024","Alimentary pharmacology & therapeutics","commentary","article","10.1111/apt.18152","39034605",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; editorial"],["R0013686","Comment on 'The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies'.","Bao J","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71071","42410311","PMC13448844",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013687","Wegovy Now Approved for Treatment of Severe Liver Disease.","Schneider L","2025","JAMA","other","article","10.1001/jama.2025.13358","40911321",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013688","ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9624873","ClinicalTrials.gov:NCT04440345","S001410","europepmc","TRUE","open_europepmc","1",null,"Abstract"],["R0013689","Why Did the \"Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists\" Differ From Previous Randomized Controlled Study?","Ng K","2024","The Journal of arthroplasty","randomized_trial","article","10.1016/j.arth.2024.08.035","39523049",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Letter; article"],["R0013690","Semaglutide as a potential treatment for obesity in Smith-Kingsmore syndrome (SKS) patients: A mosaic mutation case report.","Bonnet JB","2024","Obesity research & clinical practice","case_report","article","10.1016/j.orcp.2024.03.009","38582735",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0013691","The Connection Between the Appetite-Regulatory Peptides Ghrelin and GLP-1 and Alcohol Use Disorder.","Jerlhag E","2025","Advances in experimental medicine and biology","preclinical","article","10.1007/978-3-031-89525-8_8","40442388",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013692","The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice.","Egecioglu E","2013","PloS one","preclinical","article","10.1371/journal.pone.0069010","23874851","PMC3712951",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013693","Effect of Lipidation on the Structure, Oligomerization, and Aggregation of Glucagon-like Peptide 1.","Přáda Brichtová E","2025","Bioconjugate chemistry","other","article","10.1021/acs.bioconjchem.4c00484","39841169","PMC11926786",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013694","Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study.","Yang YS","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1341363","39027329","PMC11256048",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013695","Glucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization study.","Yang G","2026","Translational psychiatry","other_trial","article","10.1038/s41398-026-04244-7","42443148","PMC13642936",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0013696","GLP‑1 receptor agonist protects palmitate-induced insulin resistance in skeletal muscle cells by up-regulating sestrin2 to promote autophagy.","Tian X","2023","Scientific reports","preclinical","article","10.1038/s41598-023-36602-6","37296162","PMC10256699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013697","Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.","Di Napoli M","2026","American journal of surgery","other","article","10.1016/j.amjsurg.2026.117027","42173727",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0013698","Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.","Di Loreto C","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01218-y","35230650","PMC8886341",null,"S001761","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013699","The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review.","Krishnanda SI","2025","Journal of clinical medicine","systematic_review","article","10.3390/jcm14072239","40217690","PMC11990051",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013700","Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.","Tonneijck L","2018","Diabetes, obesity & metabolism","other","article","10.1111/dom.13223","29341461","PMC5899927",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0013701","Tirzepatide Improves Early Dumping Syndrome and Glucose Nadir in Postbariatric Hypoglycemia After Sleeve Gastrectomy.","Stortz E","2024","JCEM case reports","case_report","article","10.1210/jcemcr/luae194","39444516","PMC11497600",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013702","Obesity, fasting, and chronic migraine: Can semaglutide disrupt the vicious cycle?","Abacıoğlu HB","2026","Headache","commentary","article","10.1111/head.70209","42689439",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013703","Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons.","Gao C","2026","Nature metabolism","preclinical","article","10.1038/s42255-026-01534-8","42174184",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013704","Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys40(AhxHYNIC-[99mTc]/EDDA)NH2]-Exendin-4 over Conventional Imaging Modalities for Localization of Insulinoma.","Senica K","2020","Molecular imaging and biology","other","article","10.1007/s11307-019-01372-z","31098984",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013705","An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression.","Lingvay I","2022","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgab905","34922383","PMC9016460",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review-article; article"],["R0013706","Corrigendum to \"Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan\" [Obesity Pillars 19 (2026) 100291].","Nagayama D","2026","Obesity pillars","notice","article","10.1016/j.obpill.2026.100294","42694725","PMC13540666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0013707","Potential of insulin deprescription adding a GLP-1 receptor agonist as a therapeutic strategy to improve the metabolic profiles of patients with type 2 diabetes mellitus.","Perez de Arenaza Pozo V","2024","Endocrinologia, diabetes y nutricion","case_report","article","10.1016/j.endien.2024.11.007","39608966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0013708","Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.","Anson M","2024","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2024.102777","39246719","PMC11377141",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013709","SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?","Escobar Cervantes C","2024","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(24)00183-9","38991583",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0013710","Interconnected Mechanistic Pathways, Molecular Biomarkers, and Therapeutic Approach of Oral Cancer in Patients with Diabetes Mellitus.","Elian V","2025","Current issues in molecular biology","narrative_review","article","10.3390/cimb47110929","41296433","PMC12651534",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013711","Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes","Mirabelli M","2021","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvab048.680",null,"PMC8089678",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0013712","Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps.","Chen D","2024","FEBS open bio","preclinical","article","10.1002/2211-5463.13499","36271684","PMC11301266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013713","The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.","Eisa N","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70992","42297754","PMC13448870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review-article; review"],["R0013714","Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.","Node K","2026","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2026.2686052","42287159",null,"ClinicalTrials.gov:NCT04844918","S001216","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; article"],["R0013715","OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes","Kayed A","2021","Research Square","other","preprint","10.21203/rs.3.rs-223237/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013716","Liraglutide alleviates sepsis-induced acute lung injury by regulating pulmonary surfactant through inhibiting autophagy.","Guo J","2024","Immunopharmacology and immunotoxicology","preclinical","article","10.1080/08923973.2024.2384897","39112014",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0013717","Emerging Therapeutics in the Treatment of Substance Use Disorders: A Focus on GLP-1 Receptor Agonists, D3R Antagonists, and CRF Antagonists.","Draghmeh K","2025","Journal of integrative neuroscience","narrative_review","article","10.31083/jin26361","40302255",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013718","Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus.","Kohut T","2021","JPGN reports","case_report","article","10.1097/pg9.0000000000000141","37206449","PMC10191552",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013719","DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.","Sasset L","2026","Molecular therapy. Nucleic acids","preclinical","article","10.1016/j.omtn.2026.102946","42211692","PMC13213231",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013720","Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease.","Amamoo J","2026","Advances in therapy","nonrandomized_study","article","10.1007/s12325-026-03744-8","42776473",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0013721","Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.","Trautmann ME","2016","Clinical therapeutics","other","article","10.1016/j.clinthera.2016.03.039","27126504",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013722","Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy.","Matsuo K","2013","Internal medicine (Tokyo, Japan)","other","article","10.2169/internalmedicine.52.8622","23291680",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013723","Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.",null,"2017","The Medical letter on drugs and therapeutics","other","article",null,"28880845",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013724","Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.","Wei Y","2026","Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology","nonrandomized_study","article","10.1080/01443615.2026.2701996","42495930",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Comparative Study; article"],["R0013725","Glucagon-like peptide-1 receptor action in the vasculature.","Almutairi M","2019","Peptides","other_trial","article","10.1016/j.peptides.2018.09.002","30227157",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0013726","Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes.","Polsky S","2026","Diabetes technology & therapeutics","randomized_trial","article","10.1177/15209156261468108","42452840",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0013727","GLP-1 agonists: a new hope for patients, a new challenge for anaesthetists.","Doroba O","2025","Anaesthesiology intensive therapy","commentary","article","10.5114/ait/203167","40420610","PMC12210373",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013728","Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.","Chen JC","2026","Therapeutic advances in endocrinology and metabolism","nonrandomized_study","article","10.1177/20420188261460592","42404804","PMC13332288",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013729","Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort.","Mirani M","2018","Pharmacological research","nonrandomized_study","article","10.1016/j.phrs.2018.09.003","30213563",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0013730","Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?","Neves JS","2024","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2024.06.026","39115523",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0013731","Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment.","Cao Y","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70060","40859465","PMC12590533",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0013732","Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.","Vinciguerra F","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08754-7","42247124","PMC13323781",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0013733","Semaglutide 6-months therapy of type 2 diabetes mellitus restores adipose progenitors potential to develop metabolically active adipocytes.","Stafeev I","2024","European journal of pharmacology","other","article","10.1016/j.ejphar.2024.176476","38493915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013734","Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature.","Tibble CA","2013","Expert review of endocrinology & metabolism","narrative_review","article","10.1586/eem.13.20","30780817",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013735","Predictors of liver fibrosis progression in cohort of type 2 diabetes mellitus patients with MASLD.","Alfadda AA","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2024.108910","39675110",null,"ClinicalTrials.gov:NCT05697991",null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study; Research Support, Non-U.S. Gov't"],["R0013736","Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes.","Inzucchi SE","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.05.045","39084830",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0013737","7440 Both GLP-1RA and SGLT2i medications are associated with lower depression scores in veterans compared to metformin and insulin",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453236",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013738","Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.","Augustin R","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102205","40619099","PMC12311552",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013739","The Role of the Dietitian in Weight Management of Adults With Obesity Without Diabetes Using Glucagon Like Peptide-1 Agonist Receptors: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials.","Moetaz I","2025","Clinical obesity","systematic_review","article","10.1111/cob.70030","40530685",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0013740","NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY.","Rajagopal R","2024","Retina (Philadelphia, Pa.)","other_trial","article","10.1097/iae.0000000000004252","39151204",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0013741","Getting to the Real Skinny on GLP-1RAs and the Risk of Aspiration During Endoscopy.","Christie J","2025","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","commentary","article","10.1016/j.cgh.2024.08.035","39362616",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0013742","Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists.","Ard JD","2024","JAMA","commentary","article","10.1001/jama.2024.7062","38744427",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; article"],["R0013743","Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study.","Đogatović K","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15124672","42355840","PMC13301378",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0013744","Acute pancreatitis followed by leukocytoclastic vasculitis induced by tirzepatide: A first case report with this new medication.","Zgolli F","2026","Therapie","case_report","article","10.1016/j.therap.2026.06.003","42660749",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013745","The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.","Wu S","2018","Expert opinion on drug safety","systematic_review","article","10.1080/14740338.2018.1424826","29320889",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Comparative Study; Journal Article; Systematic Review; Network Meta-Analysis; article; review"],["R0013746","Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary.","Kolotkin RL","2026","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/20420188261437874","42110523","PMC13153531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013747","Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.","Victorino DB","2021","Pharmaceutical medicine","other","article","10.1007/s40290-020-00374-5","33409802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013748","Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.","Kaku K","2019","Drug safety","nonrandomized_study","article","10.1007/s40264-019-00857-8","31654243","PMC6834733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0013749","Effects of all-trans retinoid acid and exendin-4 on islet transplantation in NOD mice.","Juang JH","2014","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2014.05.072","25131079",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013750","Idiopathic intracranial hypertension: Evolving trends of weight management with newer incretin mimetics and options for precision medicine in obesity.","Varughese MS","2025","Eye (London, England)","commentary","article","10.1038/s41433-024-03426-1","39511446","PMC11751137",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0013751","Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin(9-39).","Collado Camps E","2023","European journal of nuclear medicine and molecular imaging","preclinical","article","10.1007/s00259-022-06041-y","36446951","PMC9931918",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0013752","Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.","Alsakran WA","2026","BMC ophthalmology","nonrandomized_study","article","10.1186/s12886-026-05122-y","42432542","PMC13644001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Case Reports; case-report; article"],["R0013753","Metabolite sensing in cardiometabolic HFpEF: mechanisms and therapeutic perspectives.","Fan Y","2026","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2026.113432","42442550",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013754","Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.","Kumarathurai P","2016","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-016-0425-2","27455835","PMC4960858","ClinicalTrials.gov:NCT01595789","S001197","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; other; article"],["R0013755","Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials.","Andonie CR","2026","Endocrinology, diabetes & metabolism","systematic_review","article","10.1002/edm2.70157","41466530","PMC12750095",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; Systematic Review; review-article; article"],["R0013756","Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.","Lee SM","2019","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2019.25.3.350","30816819","PMC10398328",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0013757","A Multimodal Framework for Organ- and Cell-Resolved Biological Aging and Longevity Intervention Discovery.","Al Dajani SA","2026","medRxiv : the preprint server for health sciences","other","article","10.64898/2026.05.08.26352759","42180333","PMC13193044",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0013758","Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.","Yu M","2017","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2017.11.001","29196084",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study"],["R0013759","Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014-2026).","Ricardo RR","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.70209","42630042",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013760","SUN-668 A Severe Case of Pica Resolved With GLP-1 Agonist Therapy",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545837",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013761","Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.","Onishi Y","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-024-01534-5","38310163","PMC10942919","ClinicalTrials.gov:NCT03861052","S000239","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0013762","Addressing Renal Sodium Avidity in Chronic Heart Failure: There Is Always More than One Way to Skin a Cat.","Montomoli M","2025","Cardiorenal medicine","narrative_review","article","10.1159/000545017","40228493",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013763","Evaluating Causality and Diagnostic Completeness in Suspected Semaglutide-Associated Venous Thromboembolism","Wajid MA","2026","Authorea Preprints","other","preprint","10.22541/authorea.15008024/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013764","Obstructive sleep apnoea and hypertension: Current understanding, diagnosis and management.","Afzal M","2026","Clinical medicine (London, England)","narrative_review","article","10.1016/j.clinme.2026.100575","41903652","PMC13126342",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013765","Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.","Zhong X","2019","Molecules (Basel, Switzerland)","preclinical","article","10.3390/molecules24040779","30795583","PMC6412877",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013766","Evaluation of the Efficacy of Semaglutide Dose Escalation in Reducing HbA1c Levels and Insulin Dose in Type 2 Diabetes Patients: Real-World Semaglutide Data from Türkiye, SEMA-TR Study.","Sumbul HE","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15114105","42278967","PMC13257441",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013767","Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment.","Sato J","2025","Scientific reports","preclinical","article","10.1038/s41598-025-90896-2","40108209","PMC11923236",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013768","Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats.","Klotsman M","2021","Frontiers in veterinary science","other","article","10.3389/fvets.2021.661546","34046446","PMC8144329",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0013769","Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes.","Neuen BL","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.07.002","39142724",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0013770","From mouth to colon: a framework for engineering food matrices to engage the satiety cascade and endogenous GLP-1 signaling.","Ratanpaul V","2026","The American journal of clinical nutrition","other","article","10.1016/j.ajcnut.2026.101535","42772453",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article; preprint"],["R0013771","Albiglutide: a unique GLP-1 receptor agonist.","Rendell MS","2016","Expert opinion on biological therapy","narrative_review","article","10.1080/14712598.2016.1240780","27677385",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013772","The Utilization of Glucagon-like Peptide 1 Agonists and Risk of Following External Eye Diseases in Type 2 Diabetes Mellitus Individuals: A Population-Based Study.","Fan YC","2023","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare11202749","37893823","PMC10606163",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013773","GLP-1 agonists may modulate treatment efficacy in central centrifugal cicatricial alopecia.","Desir N","2025","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2025.04.058","40339808",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013774","Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.","Jensterle M","2015","Endocrine research","other_trial","article","10.3109/07435800.2014.966385","25330463",null,"ClinicalTrials.gov:NCT01911468","S000679; S000723; S002311","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013775","Heart failure with a preserved ejection fraction: synergy between cardiac and extracardiac mechanisms and effects of novel therapies.","Nassiri S","2026","Heart failure reviews","narrative_review","article","10.1007/s10741-026-10671-x","42764312","PMC13590455",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013776","A81 GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN OVERWEIGHT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS",null,"2025","Journal of the Canadian Association of Gastroenterology","systematic_review","article",null,null,"PMC11807682",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0013777","A Review of the Management of Obesity in Primary Care.","Parretti HM","2026","Clinical obesity","narrative_review","article","10.1111/cob.70040","40831325","PMC12705257",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013778","Early changes in body composition with tirzepatide in adults with obesity: a real-world BIA study.","Angelopoulos N","2026","Nutrition (Burbank, Los Angeles County, Calif.)","nonrandomized_study","article","10.1016/j.nut.2026.113286","42275945",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013779","Variant screening of PYY3-36 leads to potent long-acting PYY analogs with superior Y2 receptor selectivity.","Østergaard S","2025","Science translational medicine","preclinical","article","10.1126/scitranslmed.adq6392","40138456",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013780","SUN-031 Efficacy Of The Glp-1 Agonists In The Treatment Of Idiopathic Intracranial Hypertension: A Systematic Review And Meta-analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12544221",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0013781","Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists.","Khedagi A","2023","American journal of preventive cardiology","narrative_review","article","10.1016/j.ajpc.2023.100477","36915710","PMC10006446",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013782","Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.","Husain M","2019","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1901118","31185157",null,"ClinicalTrials.gov:NCT02692716","S001381","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013783","Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.","Davies MJ","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14543","34617398","PMC9293415","ClinicalTrials.gov:NCT02058147","S001199","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0013784","The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies.","Overgaard RV","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71030","42337822","PMC13448876",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013785","Understanding Weight Regain After Tirzepatide Withdrawal.","Chuan F","2026","JAMA internal medicine","other","article","10.1001/jamainternmed.2026.1007","42043833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013786","Contractile effects of retatrutide in isolated mouse atrial preparations.","Neumann J","2025","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-025-04335-0","40464942","PMC12678479",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013787","Residual gastric content after tirzepatide discontinuation: is one week enough?","Hidiroglu EE","2026","Minerva anestesiologica","other","article","10.23736/s0375-9393.26.20145-1","42329593",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013788","Obesity: WHO calls for increased production of Ozempic and other weight loss drugs.","Taylor L","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r2540","41330627",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0013789","The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case-Control Study.","Hu Y","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0435-z","29754323","PMC5984938",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0013790","Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes.","Ma Z","2023","Journal of diabetes research","narrative_review","article","10.1155/2023/5891532","37096236","PMC10122586","ClinicalTrials.gov:NCT04166773","S000031","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0013791","Efficacy and safety of retatrutide for overweight/obesity or type 2 diabetes: a systematic review and meta-analysis","Xiao Y","2025","Research Square","systematic_review","preprint","10.21203/rs.3.rs-7103001/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0013792","MON-189 Comparative Effectiveness of GLP-1 Analogues and Metformin in Managing Polycystic Ovarian Syndrome: Insights from a Propensity-Matched Cohort Study",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12545562",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0013793","\"From evidence to practice\" - Insights from the multidisciplinary team on the optimal integration of GLP-1 receptor agonists in obesity management services.","Brown A","2024","Nutrition bulletin","commentary","article","10.1111/nbu.12700","39136338",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; article"],["R0013794","Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes.","Shloush M","2026","Archives of endocrinology and metabolism","case_report","article","10.20945/2359-4292-2026-0028","41945627","PMC13055641",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013795","GLP-1 agonists before endoscopy: separating fact from fiction.","Shah T","2026","Current opinion in gastroenterology","narrative_review","article","10.1097/mog.0000000000001195","42762178",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013796","Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity.","Xu J","2023","Peptides","preclinical","article","10.1016/j.peptides.2023.171073","37536423",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013797","Real-World Type 2 Diabetes Second-Line Treatment Allocation Among Patients.","Davidson J","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.03.26.25324631","40196266","PMC11974982",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0013798","Rebuilding After Weight Loss: A Nationwide Retrospective Cohort Study on the Outcomes of Autologous Breast Reconstruction in Post-Bariatric Patients.","Mehdizadeh M","2026","Annals of plastic surgery","nonrandomized_study","article","10.1097/sap.0000000000004698","41838092",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013799","Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity: comment.","Odic P","2026","Internal and emergency medicine","commentary","article","10.1007/s11739-026-04533-5","42762372",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013800","Preoperative management of patients receiving treatment with GLP-1 analogues: Withhold or individualize?","Crespo J","2025","Revista de gastroenterologia de Mexico (English)","commentary","article","10.1016/j.rgmxen.2024.11.007","40500599",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013801","Insulin degludec + liraglutide (Xultophy°) in type 2 diabetes.",null,"2017","Prescrire international","other","article",null,"30730669",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013802","Are glucagon-like peptide 1 analogues effective and safe in severe COVID-19 patients with type 2 diabetes?-a case report.","Chen S","2021","Annals of palliative medicine","case_report","article","10.21037/apm-20-1982","33440950",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0013803","Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats.","Heslep N","2026","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/s41386-026-02386-2","41986468","PMC13191343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0013804","Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.","Yang SH","2018","Cardiovascular diabetology","preclinical","article","10.1186/s12933-018-0689-9","29618348","PMC5885408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0013805","The administration of Exendin-4 and CCK affects food intake differentially in female and male rats tested on an alternate day fasting paradigm.","Lopez TJ","2023","Neuroscience letters","preclinical","article","10.1016/j.neulet.2023.137275","37116572","PMC12309525",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0013806","A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.","Liu L","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1397029","38910884","PMC11190169",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013807","SAT-405 TSH testing patterns for patients with type 2 diabetes and hypothyroidism after GLP-1 RA initiation in a target trial setting",null,"2025","Journal of the Endocrine Society","other_trial","article",null,null,"PMC12543656",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0013808","Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.","Zaazouee MS","2022","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2022.102511","35623229",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0013809","Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.","Sørensen KK","2026","Clinical trials (London, England)","randomized_trial","article","10.1177/17407745261449668","42227113",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0013810","Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting.","Al Ozairi E","2026","BMJ open","protocol","article","10.1136/bmjopen-2026-117431","42097660","PMC13157797","ClinicalTrials.gov:NCT07096908","S001787","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0013811","[New s in nephroprotection].","Sens F","2025","La Revue du praticien","narrative_review","article",null,"40546164",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0013812","Preoperative GLP-1 Receptor Agonists and Risk of Postoperative Respiratory Complications.","Milder DA","2024","JAMA","commentary","article","10.1001/jama.2024.10029","38819986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0013813","Preoperative GLP-1 Receptor Agonists and Risk of Postoperative Respiratory Complications.","Hobai IA","2024","JAMA","commentary","article","10.1001/jama.2024.10026","38819980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0013814","Inter-regulation of gastric emptying and incretin hormone secretion: implications for postprandial glycemic control.","Wu T","2016","Biomarkers in medicine","other","article","10.2217/bmm-2016-0164","27734721",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013815","GLP-1 receptor agonists: A revolution in the treatment of Parkinson's disease?","Javed D","2024","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","commentary","article","10.1016/j.euroneuro.2024.06.003","38909543",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013816","Popularity of Surgical and Pharmacological Obesity Treatment Methods Searched by Google Users: the Retrospective Analysis of Google Trends Statistics in 2004-2022.","Kamiński M","2024","Obesity surgery","nonrandomized_study","article","10.1007/s11695-023-06971-y","38103152","PMC10899289",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013817","Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes?","Singh AK","2021","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2020.108536","33181201",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0013818","Immunometabolic regulation of macrophage function in cardio-hepatic-renal comorbidities: Mechanisms and therapeutic opportunities.","Bai X","2026","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2026.112918","42759644",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0013819","Correction: Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.","Afentou N","2026","Obesity surgery","notice","article","10.1007/s11695-026-08885-x","42579270","PMC13562131",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0013820","Metabolic reprogramming in chronic kidney disease-cardiovascular disease comorbidity: from molecular mechanisms to therapeutic strategies.","Chai XJ","2026","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2026.1801502","42494528","PMC13392259",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0013821","Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro.","Dalvi PS","2012","Endocrinology","preclinical","article","10.1210/en.2011-1795","22334721",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013822","Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.","Rosenior-Patten O","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71067","42560020","PMC13538779",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013823","Metabolic reprogramming in diabetic panvascular disease: Molecular mechanism and therapeutic strategies.","Bai Y","2026","iScience","other_trial","article","10.1016/j.isci.2026.117578","42823960","PMC13626920",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0013824","Discontinuation of Semaglutide Therapy for Obesity Management.","Mailhac A","2026","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2026.31371","42664011","PMC13525464",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013825","Preoperative GLP-1 Receptor Agonists and Risk of Postoperative Respiratory Complications.","Levi M","2024","JAMA","commentary","article","10.1001/jama.2024.10023","38819978",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0013826","SAT-550 A Hidden Culprit: Insulinoma Masquerading as GLP-1 Agonist-Induced Hypoglycemia",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544850",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013827","Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.","Wang S","2025","Journal of medicinal chemistry","other","article","10.1021/acs.jmedchem.5c02032","40958513",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013828","Treatment of obesity with liraglutide in bipolar disorder: a case report.","Cipolla S","2026","Frontiers in psychiatry","case_report","article","10.3389/fpsyt.2026.1855446","42597211","PMC13467832",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013829","Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications.","Mohan V","2026","Cureus","commentary","article","10.7759/cureus.114959","42769283","PMC13591026",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0013830","Emerging Strategies for Cardio-Renal Protection Beyond RAAS Blockade: Emphasis on Non-diabetic CKD and Resistant Hypertension.","Alrashidi FS","2026","Saudi medical journal","other_trial","article","10.15537/1658-3175.8819","42445746","PMC13360674",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0013831","Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study.","Hepprich M","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01016-y","33615400","PMC7947039",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013832","The safety of albiglutide for the treatment of type 2 diabetes.","Rendell MS","2017","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2017.1351538","28678550",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013833","Disproportionality Analysis of Tirzepatide-Associated Ketoacidosis.","Frey C","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.05.036","42248357",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0013834","Contemporary management of advanced chronic kidney disease: An evidence-based review.","Baker LW","2026","European journal of internal medicine","nonrandomized_study","article","10.1016/j.ejim.2025.106557","41130867","PMC12560998",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Review; research-article"],["R0013835","Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.","Jin M","2024","Brain and behavior","preclinical","article","10.1002/brb3.3448","38444330","PMC10915471",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013836","Semaglutide in Adolescents Living With Obesity: A Real-World Data Study Exploring Predictors of Treatment Response.","Cimador V","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70926","42236275","PMC13341411",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0013837","Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach.","Sievenpiper JL","2026","Obesity pillars","narrative_review","article","10.1016/j.obpill.2025.100228","41502845","PMC12768930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013838","The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.","Sahraoui A","2015","PloS one","preclinical","article","10.1371/journal.pone.0121204","25793295","PMC4368803",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013839","GLP-1 and amylin receptor multiagonism with amycretin for obesity management.","Khoo B","2025","Lancet (London, England)","other","article","10.1016/s0140-6736(25)01250-4","40550232",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013840","Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury.","Liu C","2019","Frontiers in pharmacology","other","article","10.3389/fphar.2019.00789","31396081","PMC6664686",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013841","Rapid progression of amyotrophic lateral sclerosis after initiation of GLP-1 agonist: a case report.","Stolwyk K","2025","Amyotrophic lateral sclerosis & frontotemporal degeneration","case_report","article","10.1080/21678421.2024.2446847","39772789","PMC12005962",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013842","Improvement of Refractory Restless Legs Syndrome in a Parkinson's Disease Patient After Semaglutide Treatment: A Novel Clinical Observation.","Pecoraro PM","2026","Journal of movement disorders","commentary","article","10.14802/jmd.26097","42276762","PMC13461288",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0013843","Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.","Tonneijck L","2016","Diabetologia","randomized_trial","article","10.1007/s00125-016-3938-z","27038451","PMC4901099","ClinicalTrials.gov:NCT01744236","S002312","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0013844","Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease.","Tuttle KR","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13986","32009296","PMC7317405",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0013845","SUN-480 GLP-1 Agonist Therapy Managing the Effects of Excess Glucocorticoid Production",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545672",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013846","Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.","McCormack PL","2014","Drugs","narrative_review","article","10.1007/s40265-013-0172-6","24435322",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013847","Gastric content and aspiration risk after semaglutide cessation.","Chang Y","2026","Anaesthesia","commentary","article","10.1111/anae.70319","42608018",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013848","Insufficient exclusion of infectious and biofilm-related complications in reported tirzepatide-associated filler nodules.","Pitak-Arnnop P","2026","JAAD case reports","commentary","article","10.1016/j.jdcr.2026.06.027","42598504","PMC13471218",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013849","Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity.","Tayyaba","2023","JPMA. The Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.7685","37218275",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0013850","Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β-Cell Regeneration, Immune Modulation, and Exosome-Mediated Glucose Homeostasis.","Yang J","2026","Stem cells international","narrative_review","article","10.1155/sci/2759804","42292743","PMC13263637",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013851","Effect of preoperative liraglutide 3.0 mg on incidence of intraoperative adhesions in laparoscopic sleeve gastrectomy.","Martines G","2024","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-024-11231-w","39347961","PMC11614929",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013852","SUN-666 Sex-based Differences In Body Composition Changes Among Adolescents With Obesity Under Glp-1 Analogue Therapy",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544784",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013853","Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway.","Khalifa O","2022","Scientific reports","preclinical","article","10.1038/s41598-022-06143-5","35140289","PMC8828858",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013854","Wegovy approved for MASH.",null,"2025","Nature biotechnology","commentary","article","10.1038/s41587-025-02828-0","40954266",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0013855","Hyperglycemia induces NF-κB activation and MCP-1 expression via downregulating GLP-1R expression in rat mesangial cells: inhibition by metformin.","Kang Z","2019","Cell biology international","preclinical","article","10.1002/cbin.11184","31136032",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013856","Digestive Hormones and Their Impact on Bariatric and Pharmacologic Weight-Loss Therapies.","Amoyel M","2026","Endocrine reviews","other","article","10.1210/endrev/bnag032","42584007",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013857","Effectiveness of Adjuvant Semaglutide Following Bariatric Metabolic Surgery.","Ferguson J","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-07703-0","39982604","PMC11906545",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013858","Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.","Faurschou A","2015","Journal of the European Academy of Dermatology and Venereology : JEADV","randomized_trial","article","10.1111/jdv.12629","25139195",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013859","Synthetic Versus Reference Semaglutide for Weight Management: Reporting Gaps and Clinical Claims.","Singh AK","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71283","42638223",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013860","Preoperative GLP-1 Receptor Agonists and Risk of Postoperative Respiratory Complications-Reply.","Dixit AA","2024","JAMA","commentary","article","10.1001/jama.2024.10032","38819982",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0013861","GLP-1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions.","Bartkoski M","2025","Clinical and translational science","other","article","10.1111/cts.70262","40434284","PMC12117883",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; other; article"],["R0013862","Targeted Regulation of Pancreatic Islet Function by Natural Products Against Type 2 Diabetes Mellitus: Advances and Prospects.","Qiao G","2026","Biomolecules","narrative_review","article","10.3390/biom16091338","42793170","PMC13604893",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013863","Comparative safety and efficacy analysis of GLP-1 receptor agonists and SGLT-2 inhibitors among frail individuals with type 2 diabetes in the era of continuous population ageing.","Karakasis P","2025","European journal of internal medicine","commentary","article","10.1016/j.ejim.2024.09.020","39362805",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013864","Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.","Dawed AY","2023","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(22)00340-0","36528349",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013865","Tirzepatide improves angiogenesis after diabetic hindlimb ischemia through Akt/eNOS and ERK1/2 pathways.","Li J","2026","Peptides","preclinical","article","10.1016/j.peptides.2026.171489","42002077",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013866","Yonder: Wishbones, gifts from patients, and Christmas Ozempic advertising.","Burrell A","2025","The British journal of general practice : the journal of the Royal College of General Practitioners","other","article","10.3399/bjgp25x743781","41309317","PMC12770850",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013867","Evaluation of gastric content in fasting patient during semaglutide use: an observational study.","Queiroz VNF","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2024.08.039","39343660",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0013868","Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19.","Wander PL","2021","Diabetes care","other","article","10.2337/dc21-1351","34615690","PMC8669528",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0013869","Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells.","Ren L","2026","Circulation","commentary","article","10.1161/circulationaha.125.076669","42330097","PMC13288756",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; research-article; article"],["R0013870","Diabetes Mellitus and Atrial Fibrillation: Mechanistic Insights and Therapeutic Impacts of Glucose-Lowering Drugs.","Grigore M","2025","Life (Basel, Switzerland)","narrative_review","article","10.3390/life16010016","41598171","PMC12842679",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013871","Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease.","Cummings JL","2026","Neurodegenerative disease management","other_trial","article","10.1080/17582024.2026.2666332","42159155","PMC13390525",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; other; article"],["R0013872","Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.","Lund A","2014","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2014.03.005","24694879",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0013873","Off-label and investigational drugs in the treatment of gambling disorder: a critical review.","Bissig L","2026","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2026.1806954","42147309","PMC13176223",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0013874","Gastric content and aspiration risk after semaglutide cessation: a reply.","Vlaeminck N","2026","Anaesthesia","nonrandomized_study","article","10.1111/anae.70328","42601802",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0013875","Management of Cirrhosis in Diabetes: A Pragmatic Approach to the Patient.","Kumar A","2026","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgag321","42576448",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013876","From awareness to action: evolving endocrinologist practices in obesity treatment in Italy.","Chianelli M","2025","Frontiers in endocrinology","other","article","10.3389/fendo.2025.1705670","41244051","PMC12615178",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013877","GLP-1 RAs and Nonarteritic Anterior Ischemic Optic Neuropathy-Making Sense of the Data.","Etminan M","2025","JAMA ophthalmology","commentary","article","10.1001/jamaophthalmol.2024.6181","39883452",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0013878","<p class=\"MDPI13authornames\">Improving Erectile Function and Quality of Life in Hypogonadal Euglycemic and Diabetic Men with Refractory Erectile Dysfunction","Mendias CL","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202605.1580.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0013879","Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.","Cheng W","2025","Frontiers in endocrinology","case_report","article","10.3389/fendo.2025.1654506","41030857","PMC12477040",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013880","Liraglutide and Liver Injury: Rare Case Report with Literature Review.","Salehi AM","2024","Endocrine, metabolic & immune disorders drug targets","case_report","article","10.2174/0118715303180615231011053011","37885115",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Case Reports; Journal Article; article"],["R0013881","User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.","Shaefer CF","2015","Postgraduate medicine","narrative_review","article","10.1080/00325481.2015.1090295","26371721",null,null,"S000665; S001427","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0013882","Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort study","Levy ME","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.10.31.24316494",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0013883","Exploring the Therapeutic Potential of GLP-1 Agonists in Hidradenitis Suppurativa.","Parvathaneni A","2025","Journal of drugs in dermatology : JDD","other","article",null,"40196946",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013884","SUN-688 Unexpected Consequences: Guillain-Barre Syndrome Following GLP-1 Agonist Therapy",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545049",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013885","Impact of Semaglutide on Hippocampal Injury in a Streptozotocin-Induced Model of Alzheimer's Disease.","Stavrovskaya AV","2026","Biomedicines","preclinical","article","10.3390/biomedicines14061257","42351685","PMC13297022",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013886","Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan.","Hussain A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71043","42365987","PMC13448986","ANZCTR:ACTRN12625000610437",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0013887","A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress Pyroptosis.","Duan B","2026","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.202602960r","42762056",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013888","Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.","Garcia de Lucas MD","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.995646","36187123","PMC9523693",null,"S001761","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0013889","Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.","Godfrey H","2025","Journal of the European Academy of Dermatology and Venereology : JEADV","nonrandomized_study","article","10.1111/jdv.20197","38925559",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0013890","Characterizing the role of extracellular domain in GLP-1R biased agonism.","Xie L","2025","The international journal of biochemistry & cell biology","other","article","10.1016/j.biocel.2025.106867","40998235",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013891","Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses.","Kanu C","2026","Sleep","randomized_trial","article","10.1093/sleep/zsag184","42412744",null,"ClinicalTrials.gov:NCT05412004","S000156","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0013892","Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.","Komatsu M","2021","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13525","33595901","PMC8409843",null,"S001965; S002038","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0013893","Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study.","Persson F","2018","Endocrinology, diabetes & metabolism","other","article","10.1002/edm2.36","30815564","PMC6354817",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013894","Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.","Ryan DH","2023","Cardiovascular endocrinology & metabolism","other","article","10.1097/xce.0000000000000279","36777095","PMC9911203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0013895","Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis.","Balata M","2026","Clinical research in cardiology : official journal of the German Cardiac Society","nonrandomized_study","article","10.1007/s00392-025-02694-5","40493069",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013896","Regulation of fatty acid oxidation by liraglutide via SIRT1 in hepatocytes: A mechanistic study","Shen B","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9999800/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0013897","GLP-1 Receptor Signaling Differentially Modifies the Outcomes of Sterile vs Viral Pulmonary Inflammation in Male Mice.","Sato T","2020","Endocrinology","preclinical","article","10.1210/endocr/bqaa201","33125041","PMC7678414",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013898","The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R)-induced deregulation of endothelial tube formation.","Xiao M","2020","RSC advances","preclinical","article","10.1039/c9ra09959j","35498599","PMC9050383",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013899","Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial.","Lappin JM","2026","Schizophrenia research","other_trial","article","10.1016/j.schres.2026.06.021","42372344",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013900","GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD.","Jiang H","2024","Current pharmaceutical design","narrative_review","article","10.2174/0113816128283153231226103218","38532322",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0013901","SAT-621 Real World Utilization of GLP-1 Agonists in Adolescents and Young Adults With Type 1 Diabetes (T1D) and Obesity",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12544651",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0013902","Anti-CGRP monoclonal antibodies counteract establishment of food aversive memories and chemotherapy-induced anorexia and weight loss.","Pistolesi A","2025","Pharmacological research","preclinical","article","10.1016/j.phrs.2025.107818","40490094",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013903","Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using 111In-exendin-4 SPECT/CT imaging and the perspective of mitochondrial involvements.","Fauzi M","2022","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2022.1010825","36246910","PMC9559817",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013904","Comment on Klein et al. Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.","Tang B","2026","Diabetes care","commentary","article","10.2337/dc26-1219","42623535","PMC13493325",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013905","Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.","Peng TR","2026","British journal of clinical pharmacology","systematic_review","article","10.1002/bcp.70629","42273973","PMC13420891","PROSPERO:CRD420261288562",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; article"],["R0013906","Maintaining weight loss with tirzepatide . . . and other research.","Nolan T","2026","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.s964","42208988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0013907","Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations.","Elena C","2018","Current pharmaceutical biotechnology","nonrandomized_study","article","10.2174/1389201020666190102145305","30605054",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0013908","Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis.","Provenzani A","2026","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2026.1735987","41908834","PMC13021596","PROSPERO:CRD420251154851",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0013909","Development and validation of a sensitive HPLC-MS/MS method for the analysis of semaglutide in human plasma.","Tudan C","2026","Bioanalysis","other","article","10.1080/17576180.2026.2712160","42544568","PMC13540083",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Validation Study; research-article; article"],["R0013910","Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway.","Yang S","2020","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00195.2019","32985256",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013911","Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.","Jamal M","2024","Obesity surgery","nonrandomized_study","article","10.1007/s11695-024-07137-0","38430320",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013912","Targeting the gastrointestinal tract to treat type 2 diabetes.","Bauer PV","2016","The Journal of endocrinology","narrative_review","article","10.1530/joe-16-0056","27496374",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0013913","Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.","Clift AK","2026","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvag177","42634795","PMC13500189",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013914","Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.","Ninčević V","2019","International journal of molecular sciences","narrative_review","article","10.3390/ijms20235831","31757028","PMC6928920",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013915","Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update.","Kumar A","2024","Current diabetes reviews","narrative_review","article","10.2174/0115733998261903230921102620","37888820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013916","Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.","Montvida O","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12790","27629433",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; article"],["R0013917","Insights Into the Protective Role of GLP-1RAs in the Treatment of Type 2 Diabetes Mellitus: Implications for Hepatocellular Carcinoma and Hepatic Dysfunction.","Wang Z","2025","Gastroenterology","commentary","article","10.1053/j.gastro.2024.09.036","39426488",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013918","Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease.","Raschi E","2018","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2018.1531126","30299993",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0013919","Effects of Semaglutide on Cardiometabolic Risk in People with Obesity, With and Without Type 2 Diabetes: A Retrospective Observational Study.","Deaconu L","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15124421","42355589","PMC13301239",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013920","Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson's disease: a systematic review and meta-analysis.","Nogueira LOS","2025","Arquivos de neuro-psiquiatria","systematic_review","article","10.1055/s-0045-1806824","40288416","PMC12034413",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0013921","Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.","Afentou N","2026","Obesity surgery","other","article","10.1007/s11695-026-08854-4","42484827","PMC13562181",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0013922","Oral semaglutide for obesity: clarifying comparative evidence and real-world applicability.","Zou Y","2026","Postgraduate medicine","nonrandomized_study","article","10.1080/00325481.2026.2721720","42622205",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0013923","On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT.","Kaul S","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.03.085","42233554",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013924","SAT-812 Can Sglt-2 And Glp-1 Ra Combination Therapy Facilitate Insulin Discontinuation In Patients With Long-standing Uncontrolled Type 2 Diabetes?",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545167",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0013925","Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.","Home P","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14148","32700442",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0013926","Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db mice.","O'Harte FPM","2020","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2019.110695","31904406",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0013927","Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis.","Kapodistria K","2018","Journal of cellular and molecular medicine","preclinical","article","10.1111/jcmm.13259","29524296","PMC5980190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013928","Glucagon-like peptide-1 analogues: An overview.","Gupta V","2013","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.111625","23869296","PMC3712370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0013929","Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.","Yang Q","2024","BMC pharmacology & toxicology","nonrandomized_study","article","10.1186/s40360-024-00789-9","39267168","PMC11391863",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013930","Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular-Kidney-Metabolic Disease","Kim B","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202609.0768.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0013931","Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.","Ishii H","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-023-01485-3","37843771","PMC10597937","ClinicalTrials.gov:NCT03861052","S000239","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; article"],["R0013932","A Comprehensive Analysis of Diabetic Complications and Advances in Management Strategies.","Iwasaki H","2025","Journal of atherosclerosis and thrombosis","narrative_review","article","10.5551/jat.65551","39805627","PMC12055507",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013933","Quality of Life in Japanese People with Type 2 Diabetes Switching from Multiple Daily Insulin Injections to Once-Daily iGlarLixi: SIMPLIFY Japan.","Ishii H","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01645-z","39347902","PMC11466927","jRCT:jRCT1041210151",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013934","Exendin-4 Preserves Blood-Brain Barrier Integrity via Glucagon-Like Peptide 1 Receptor/Activated Protein Kinase-Dependent Nuclear Factor-Kappa B/Matrix Metalloproteinase-9 Inhibition After Subarachnoid Hemorrhage in Rat.","Xie Z","2021","Frontiers in molecular neuroscience","preclinical","article","10.3389/fnmol.2021.750726","35002615","PMC8733623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013935","Enhanced bone regeneration via endochondral ossification using Exendin-4-modified mesenchymal stem cells.","He Z","2024","Bioactive materials","preclinical","article","10.1016/j.bioactmat.2023.12.007","38186959","PMC10770633",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013936","Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.","Zaheer H","2024","Diabetes research and clinical practice","commentary","article","10.1016/j.diabres.2024.111759","38925293",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comparative Study; article"],["R0013937","A novel Dual GLP-1/CCK Receptor Agonist Improves Cognitive Performance and Synaptogenesis in the 5 × FAD Alzheimer Mouse Model.","Ma H","2025","Molecular neurobiology","preclinical","article","10.1007/s12035-025-05037-7","40338455",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0013938","Development of Cagrilintide, a Long-Acting Amylin Analogue.","Kruse T","2021","Journal of medicinal chemistry","nonrandomized_study","article","10.1021/acs.jmedchem.1c00565","34288673",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013939","The Glucagonocentric Basis of Diabetic Cardiomyopathy: Pancreas-Heart Crosstalk Linking α-Cell Dysregulation to Cardiac Metabolic Stress and Fibrosis.","Ganamurali N","2026","Comprehensive physiology","narrative_review","article","10.1002/cph4.70145","41947455",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013940","Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus.","Nisal K","2012","BMC medicine","narrative_review","article","10.1186/1741-7015-10-152","23198896","PMC3599222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Review; review-article; article"],["R0013941","Case Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin.","Lunati ME","2026","Frontiers in endocrinology","case_report","article","10.3389/fendo.2026.1833794","42453509","PMC13364524",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0013942","Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study.","Bailey TS","2021","Diabetes spectrum : a publication of the American Diabetes Association","randomized_trial","article","10.2337/ds20-0079","34866875","PMC8603128",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013943","Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.","Vilsbøll T","2012","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj.d7771","22236411","PMC3256253",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0013944","Update on GLP-1 agonist drugs for weight loss and diabetes.","Aschenbrenner DS","2025","The American journal of nursing","other","article","10.1097/ajn.0000000000000067a","40269423",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0013945","Long-term effects of weight-reducing drugs in people with hypertension.","Spary-Kainz U","2026","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd007654.pub6","42318855","PMC13281032",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; article"],["R0013946","Effect of glucagon-like peptide-1 analogue liraglutide on primary cultures of rat hepatocytes isolated from lean and steatotic livers.","Fontana J","2019","General physiology and biophysics","preclinical","article","10.4149/gpb_2019016","31241045",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013947","Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation.","Eun Y","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000218174","42308439","PMC13278381",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013948"," Advancing Diabetes Management: A Study of BIOS Health and Continuous Glucose Monitoring for Diabetes Remission","Shaikh A","2023","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-3671659/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0013949","Semaglutide treatment fails but might prevent Alzheimer's disease.","Koychev I","2026","Lancet (London, England)","commentary","article","10.1016/s0140-6736(26)01647-8","42594906",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0013950","Novel GLP-1 receptor agonists for diabetes.","Garber AJ","2012","Expert opinion on investigational drugs","narrative_review","article","10.1517/13543784.2012.638282","22111970",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0013951","Application of the Chelator-Based Clickable Radiotheranostic Platform to Moderate-Molecular-Weight Ligands.","Nakashima K","2022","ACS medicinal chemistry letters","preclinical","article","10.1021/acsmedchemlett.2c00320","36262405","PMC9575180",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; rapid-communication; article"],["R0013952","Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.","Gross B","2013","Journal of pharmacy practice","narrative_review","article","10.1177/0897190012465985","23204146",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0013953","Treatment with liraglutide or naltrexone-bupropion in patients with genetic obesity: a real-world study.","Welling MS","2024","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2024.102709","39050109","PMC11268126",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013954","Comparative effects of central and peripheral PDE10A inhibition on weight gain following semaglutide cessation in diet-induced obese mice","Grey J","2026","bioRxiv","preclinical","preprint","10.64898/2026.09.07.749896",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0013955","Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.","Xiao YJ","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70105","40922121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0013956","Obesity Medicine Intervention at an Academic Medical Center in a Resource-Limited Population Shows Promise.","Grew EC","2024","Journal of health care for the poor and underserved","nonrandomized_study","article","10.1353/hpu.2024.a919807","38661859",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013957","Fatty Kidney Disease: From Renal Lipid Dysregulation to Fibrosis.","Onodera T","2026","Biology","narrative_review","article","10.3390/biology15131021","42450569","PMC13359859",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013958","Wegovy (semaglutide): a new weight loss drug for chronic weight management.","Singh G","2022","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","nonrandomized_study","article","10.1136/jim-2021-001952","34706925","PMC8717485",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0013959","The Novel Chimeric Multi-Agonist Peptide (GEP44) Reduces Energy Intake and Body Weight in Male and Female Diet-Induced Obese Mice in a Glucagon-Like Peptide-1 Receptor-Dependent Manner.","Blevins JE","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.05.17.594690","38826286","PMC11142068",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; research-article; preprint; article"],["R0013960","\"I Believe in Santa Claus\" and Ozempic: A Foucauldian Discourse Analysis of Holiday Health Advertising.","Joy P","2026","Qualitative health research","other","article","10.1177/10497323251350876","40536021","PMC13538904",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013961","GLP-1 receptor agonists and bariatric surgery: complement, not competition: An integrated framework for contemporary obesity management: a narrative review.","Chumakova-Orin M","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","randomized_trial","article","10.1016/j.soard.2026.07.021","42823265",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0013962","Future glucose-lowering drugs for type 2 diabetes.","Bailey CJ","2016","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(15)00462-3","26809680",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0013963","The benefits of GLP1 receptors in cardiovascular diseases.","Ferhatbegović L","2023","Frontiers in clinical diabetes and healthcare","narrative_review","article","10.3389/fcdhc.2023.1293926","38143794","PMC10739421",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013964","Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes.","Fetzner J","2025","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgae817","39998927",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0013965","Analyses of Off-Target Effects on Cardiac and Skeletal Muscles by Berberine, a Drug Used to Treat Cancers and Induce Weight Loss.","Wang J","2025","Cytoskeleton (Hoboken, N.J.)","other","article","10.1002/cm.21950","39526308","PMC12065930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013966","Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study","Vencio S","2021","Research Square","other_trial","preprint","10.21203/rs.3.rs-768461/v1",null,null,"ClinicalTrials.gov:NCT03786406; ClinicalTrials.gov:NCT03811288",null,"europepmc","FALSE","open_pdf","5",null,"Preprint"],["R0013967","Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.","Tonneijck L","2019","American journal of physiology. Renal physiology","randomized_trial","article","10.1152/ajprenal.00432.2018","30353743",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0013968","Peripheral nerve complications from medications utilised for weight loss: a systematic review.","O'Gorman C","2026","Journal of neurology","systematic_review","article","10.1007/s00415-026-14048-w","42547656","PMC13433482",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0013969","Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G.","De Fano M","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71002","42304199","PMC13448885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013970","Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study.","Mao D","2021","EBioMedicine","nonrandomized_study","article","10.1016/j.ebiom.2021.103242","33684886","PMC7938253",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013971","Weight Loss in Veterans with Schizophrenia and Multimorbidity Prescribed Semaglutide: Results From a National Retrospective Cohort Study.","Browne J","2026","Schizophrenia bulletin","nonrandomized_study","article","10.1093/schbul/sbaf143","40819269","PMC13007793",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013972","Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitochondrial respiration.","Jansen KM","2023","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2023.1098391","37033212","PMC10076843",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013973","Response to Comment on Klein et al. Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.","Menacher A","2026","Diabetes care","commentary","article","10.2337/dci26-0087","42623532","PMC13493327",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013974","The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study.","Jamal MH","2026","Saudi medical journal","nonrandomized_study","article","10.15537/1658-3175.8778","42239562","PMC13227433",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0013975","The Role of Antidiabetic Drugs in Bone Health: Assessing the Risk of Osteoporosis Subtypes and Fractures Using Mendelian Randomization.","Deng G","2025","Orthopedic research and reviews","nonrandomized_study","article","10.2147/orr.s508278","40206636","PMC11980942",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0013976","Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.","Giblin K","2026","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.70209","41090431","PMC12673447",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; methods-article; article"],["R0013977","Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.","Dutta D","2025","Indian journal of endocrinology and metabolism","systematic_review","article","10.4103/ijem.ijem_366_24","40688625","PMC12274044",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0013978","Exendin-4 inhibits endothelial protein C receptor shedding in vitro and in vivo.","Ku SK","2014","Pharmacological research","preclinical","article","10.1016/j.phrs.2014.04.005","24769195",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0013979","The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies.","Patil M","2026","Bioscience reports","narrative_review","article","10.1042/bsr20250114","42307179","PMC13376848",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013980","Schrödinger’s mouse: human observation erases a drug-induced behavioral phenotype","Krausz TA","2026","bioRxiv","nonrandomized_study","preprint","10.64898/2026.09.25.754328",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","4","FALSE","Preprint; preprint"],["R0013981","Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.","Liu FP","2015","Journal of diabetes","systematic_review","article","10.1111/1753-0407.12200","25047138",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0013982","Preoperative continuation of GLP-1 receptor agonists. Response to Br J Anaesth 2024; 133: 437-8.","van Zuylen ML","2024","British journal of anaesthesia","commentary","article","10.1016/j.bja.2024.06.026","39030130",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0013983","Obesity and the Genome: Emerging Insights from Studies in 2024 and 2025.","Yoo LG","2025","Genes","narrative_review","article","10.3390/genes16091015","41009961","PMC12469687",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013984","Animal studies on the modulation of differential efficacy of polyethylene glycol loxenatide by intestinal flora.","Wenjiao D","2025","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2025.1508473","40612440","PMC12221906",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0013985","The comparison of three different molecular imaging methods in localization and grading of insulinoma.","Chang L","2023","Frontiers in endocrinology","other","article","10.3389/fendo.2023.1163176","37455905","PMC10348808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0013986","Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model.","Zhang LY","2021","Neural regeneration research","other_trial","article","10.4103/1673-5374.303045","33433498","PMC8323666",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0013987","Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.","Misra S","2025","Journal of basic and clinical physiology and pharmacology","systematic_review","article","10.1515/jbcpp-2025-0113","40728138",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0013988","Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen.","Seufert J","2019","BMJ open diabetes research & care","systematic_review","article","10.1136/bmjdrc-2019-000679","31641521","PMC6777409",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review-article; review"],["R0013989","CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.","Mosenzon O","2021","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-021-01344-0","34315481","PMC8317423","ClinicalTrials.gov:NCT03786406; ClinicalTrials.gov:NCT03811288",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0013990","The Cardio-Renal-Hepatic Axis in MASLD. Role of BDNF, NGF, and Metabolic Cross-Talk.","Taylor LC","2026","Current hypertension reports","narrative_review","article","10.1007/s11906-026-01388-1","42693357","PMC13541824",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0013991","Emulating real-world GLP-1 efficacy in type 2 diabetes through causal learning and virtual patients.","MacLellan CR","2025","PLOS digital health","randomized_trial","article","10.1371/journal.pdig.0000927","40690490","PMC12279107",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0013992","Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.","Yuan Z","2020","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2020.1761312","32338068",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0013993","Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.","Sato T","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70710","42516042",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0013994","Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia.","Chou WL","2021","Pharmacological research","narrative_review","article","10.1016/j.phrs.2021.105693","34048925",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013995","Tirzepatide: A turning point in obesity related heart failure with preserved ejection fraction?","Goraya R","2026","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.32630","42363364",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0013996","Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes.","Le Pen C","2021","Annales d'endocrinologie","nonrandomized_study","article","10.1016/j.ando.2020.12.009","33417963",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Comparative Study; Journal Article; article"],["R0013997","Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks.","Heerspink HJL","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70622","41796090","PMC13071235",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0013998","Stimulus-Secretion Coupling in Beta-Cells: From Basic to Bedside.","Islam MS","2020","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-3-030-12457-1_37","31646540",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0013999","Polyethylene Glycol Loxenatide Injection (GLP-1) Protects Vascular Endothelial Cell Function in Middle-Aged and Elderly Patients With Type 2 Diabetes by Regulating Gut Microbiota.","Chen F","2022","Frontiers in molecular biosciences","other","article","10.3389/fmolb.2022.879294","35782875","PMC9240776",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014000","Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.","Kiyosue A","2026","Advances in therapy","other_trial","article","10.1007/s12325-026-03660-x","42334799","PMC13499850",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014001","Mounjaro: Less than half of England has NHS access to jab months after roll-out, distressing patients and GPs.","Mahase E","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r1855","40908029",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014002","Erratum.",null,"2025","Obesity facts","notice","article","10.1159/000547937","40961007","PMC12503749",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0014003","Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.","Stanley C","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04416-4","42174253","PMC13375533","ClinicalTrials.gov:NCT05073835","S000434","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0014004","Effect of Efpeglenatide on Heart Failure Outcomes: A Participant-Level Exploratory Analysis of the Randomized AMPLITUDE-O Trial.","Branch KRH","2025","Diabetes care","randomized_trial","article","10.2337/dc24-2629","40489260",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Letter; article"],["R0014005","Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.","De Luca M","2026","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.70083","41539943","PMC12850565","PROSPERO:CRD42024623707",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; review-article; article"],["R0014006","Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.","Zhou Q","2025","Annual review of pharmacology and toxicology","narrative_review","article","10.1146/annurev-pharmtox-061324-011832","39259982",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0014007","A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial.","Ölmestig J","2022","Frontiers in aging neuroscience","randomized_trial","article","10.3389/fnagi.2022.899389","36636739","PMC9831269","ClinicalTrials.gov:NCT02838589","S000341","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0014008","Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.","Kodera R","2011","Diabetologia","preclinical","article","10.1007/s00125-010-2028-x","21253697",null,null,"S001234","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014009","Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.","Adinolfi LE","2026","Expert review of endocrinology & metabolism","other_trial","article","10.1080/17446651.2026.2714267","42552573",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0014010","The AMPK/NRF2/FOXO Axis in CKD-Molecular and Clinical Perspectives.","Lučić I","2026","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox15040409","42072052","PMC13113364",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014011","The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations.","Liabeuf S","2025","Clinical kidney journal","other","article","10.1093/ckj/sfae380","39906070","PMC11788569",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014012","Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.","Hernández C","2016","Diabetes","preclinical","article","10.2337/db15-0443","26384381",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014013","Pityriasis Lichenoides et Varioliformis Acuta Associated With Tirzepatide: A First Report.","Deniz MS","2026","Journal of diabetes","commentary","article","10.1111/1753-0407.70233","42307617","PMC13274550",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014014","Strengthening Reproducibility and Interpretability in FAERS Analysis through Drug Standardization, Event Harmonization, and Exposure Normalization","Ma L","2026","Authorea Preprints","nonrandomized_study","preprint","10.22541/authorea.15009958/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0014015","Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.","Peters AE","2025","Scientific reports","randomized_trial","article","10.1038/s41598-025-14414-0","40825966","PMC12361379",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0014016","Early Generic Semaglutide in Canada-Implications for US Patients and Policy.","Tu SS","2026","JAMA internal medicine","other","article","10.1001/jamainternmed.2026.2209","42258199",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014017","Comment on: risk factors associated with prediabetes-to-diabetes conversion in a majority-minority county: a real-world analysis.","Gull U","2026","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-026-02056-6","42656620","PMC13507009",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Letter"],["R0014018","Weight effects of antidiabetic agents.","Higbea AM","2017","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2017.1395694","30063431",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014019","Serendipitous Discovery and Characterization of Two Different Pathologies on 68 Ga-DOTATATE and 68 Ga-Exendin PET/CT in a Patient With Hyperinsulinemic Hypoglycemia Leading to Diagnosis of MEN-1.","Barapatre R","2025","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000005840","40096661",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0014020","Digital Engagement Phenotypes and 6-Month Weight Loss in a Tirzepatide-Supported Digital Weight-Loss Program: A Retrospective Cohort Study.","Talay L","2026","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina62091647","42796254","PMC13609581",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014021","NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics.","Kounatidis D","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12040826","38672181","PMC11048710",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014022","Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.","Shin JI","2019","Current diabetes reports","randomized_trial","article","10.1007/s11892-019-1171-0","31286271",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0014023","Compare the Decrease in Visceral Adipose Tissue in People with Obesity and Prediabetes vs Obesity and Type 2 Diabetes Treated with Liraglutide","Hernández-Flandes R","2025","Preprints.org","randomized_trial","preprint","10.20944/preprints202503.0855.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint; article"],["R0014024","Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study.","White GE","2023","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23622","36621904","PMC9877131",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014025","Linking Metabolic Syndrome to Neurodegeneration Mechanisms and Potential Treatments.","Džidić-Krivić A","2025","Molecular neurobiology","narrative_review","article","10.1007/s12035-025-04947-w","40272771",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014026","Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.","Jensen SBK","2024","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2024.102475","38544798","PMC10965408","ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32","S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0014027","Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice.","Su H","2008","PloS one","preclinical","article","10.1371/journal.pone.0002892","18682834","PMC2483413",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014028","Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity.","Chhabra KR","2026","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70209","42089543",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0014029","Glucagon-Like Peptide-1 Inhibits the Progression of Abdominal Aortic Aneurysm in Mice: The Earlier, the Better.","Zhao X","2024","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-023-07456-x","37145254",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0014030","Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss.","Murugadoss K","2026","NPJ cardiovascular health","nonrandomized_study","article","10.1038/s44325-026-00146-1","42432224","PMC13365446",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0014031","Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD.","Lünswilken P","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag350","42657770",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0014032","Glucagon-like peptide-1 receptor differentially controls mossy cell activity across the dentate gyrus longitudinal axis.","Steiner A","2022","Hippocampus","preclinical","article","10.1002/hipo.23469","36063105","PMC9675713",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; Preprint; preprint; article"],["R0014033","No Difference in Short-term Surgical Outcomes From Semaglutide Treatment for Type 2 Diabetes Mellitus After Cervical Decompression and Fusion: A Propensity Score-matched Analysis.","Tao X","2025","Spine","nonrandomized_study","article","10.1097/brs.0000000000005099","39034750",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014034","Semaglutide-associated NAION: a proposed 'two-hit' model involving buried optic disc drusen and sustained hypohydration.","Zhao G","2026","The British journal of ophthalmology","other","article","10.1136/bjo-2026-329598","42547311",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014035","Bariatric metabolic surgery is associated with a lower risk for heart failure versus GLP-1RAs.",null,"2024","Nature medicine","other","article","10.1038/s41591-024-03120-5","39009781",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014036","First Approval of Semaglutide for MASH in India: A Paradigm Shift in MASLD Management?","Ezhilarasan D","2026","Drug discovery today","other","article","10.1016/j.drudis.2026.104762","42575231",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014037","Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study.","Rivera Gutierrez RJ","2026","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvag210","42812847","PMC13621189",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014038","[Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].","Spasov AA","2015","Biomeditsinskaia khimiia","narrative_review","article","10.18097/pbmc20156104488","26350740",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Review; article"],["R0014039","The role of hormonal and nutritional biomarkers in predicting immune checkpoint inhibitor efficacy: current limitations and future prospects.","Yuan R","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1857147","42661660","PMC13518150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; brief-report; article"],["R0014040","Hypoglycemic medicines in the treatment of Alzheimer's disease: Pathophysiological links between AD and glucose metabolism.","Wang Y","2023","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2023.1138499","36909158","PMC9995522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014041","Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trials.","Figard C","2025","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2025.103529","41140453","PMC12547021","PROSPERO:CRD42023420729; OSF:osf.io/2jvsx",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0014042","Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.","Hanefeld M","2017","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12986","28449324","PMC5655920",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0014043","GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.","Motso A","2025","Cell","randomized_trial","article","10.1016/j.cell.2025.05.042","40555230",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0014044","Epidemiology of hypoglycaemic episodes leading to hospitalisations in Denmark in 1998-2018.","Jensen MH","2021","Diabetologia","nonrandomized_study","article","10.1007/s00125-021-05507-2","34245315",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article"],["R0014045","Exendin-4 alleviates hepatic steatosis by lowering FABP1 and raising FOXA1 expression via the Wnt/-catenin signaling pathway","Khalifa O","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-898584/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014046","Characterization of Interchanging Incretin Analogs in Clinical Practice: A Descriptive Report.","Hvisdas CM","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2024.09.117","39414234",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0014047","Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association.","Ko SH","2017","The Korean journal of internal medicine","systematic_review","article","10.3904/kjim.2017.298","29056038","PMC5668403",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Practice Guideline; Systematic Review; Review; review-article; article"],["R0014048","Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.","Giorda CB","2015","Endocrine","systematic_review","article","10.1007/s12020-014-0386-8","25146552",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0014049","Editorial: Beyond Clinical Trials-Real-World Data Suggest Usefulness of GLP-1 RAs in MASLD Treatment.","Candels LS","2025","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/apt.70010","40019269",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Editorial; editorial"],["R0014050","6680 GLP-1 Agonists in Type 1 Diabetes - Indications and Use",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455259",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014051","Semaglutide for Weight Loss: Was It Worth the Weight?","Novograd J","2022","Cardiology in review","other","article","10.1097/crd.0000000000000430","36201244",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014052","Response to Crespo et al., regarding 'Preoperative management of patients receiving treatment with GLP-1 analogues: Withhold or individualize?'.","Velarde-Ruiz Velasco JA","2025","Revista de gastroenterologia de Mexico (English)","commentary","article","10.1016/j.rgmxen.2024.12.004","40500598",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014053","1982. GLP-1 Receptor Agonists Promote Weight Loss Among People with HIV",null,"2023","Open forum infectious diseases","other","article",null,null,"PMC10679091",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014054","Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion.","Zhao M","2024","Reproductive biology and endocrinology : RB&E","other_trial","article","10.1186/s12958-024-01269-9","39107809","PMC11302332",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014055","GLP-1 receptor agonist tachyphylaxis and perioperative recommendations.","Wu F","2024","British journal of anaesthesia","commentary","article","10.1016/j.bja.2024.04.049","38834487",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0014056","Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.","Cuthbertson DJ","2012","PloS one","other","article","10.1371/journal.pone.0050117","23236362","PMC3516516",null,"S000885","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014057","Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort.","Ma J","2026","AIDS (London, England)","nonrandomized_study","article","10.1097/qad.0000000000004544","42138385","PMC13220901",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014058","Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.","Haluzík M","2014","Drug safety","other","article","10.1007/s40264-014-0238-8","25391858",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014059","A Subphenotype of Obesity With Reduced Enteroendocrine Glucagon-Like Peptide 1 Synthesis and Enhanced Tirzepatide Response.","Ticho AL","2026","Gastroenterology","nonrandomized_study","article","10.1053/j.gastro.2026.05.019","42250890","PMC13325417",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014060","Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.","van Raalte DH","2011","Diabetes care","randomized_trial","article","10.2337/dc10-1677","21216851","PMC3024359","ClinicalTrials.gov:NCT00744224","S000569","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014061","Two-timepoint assays of neural responses increase the sensitivity and specificity of single-cell whole-brain activity screens","Ramirez A","2025","bioRxiv","preclinical","preprint","10.1101/2025.03.07.641687",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0014062","Cardiovascular outcome trials of glucose-lowering medications: an update.","Home P","2019","Diabetologia","narrative_review","article","10.1007/s00125-018-4801-1","30607467",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014063","Lixisenatide: a review of its use in patients with type 2 diabetes mellitus.","Scott LJ","2013","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","other_trial","article","10.1007/s40259-013-0057-y","23918699",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0014064","The effects of Beinaglutide on obesity and related factors: a systematic review and meta-analysis of randomized controlled trials.","Poshtdar S","2025","Expert review of endocrinology & metabolism","systematic_review","article","10.1080/17446651.2025.2491404","40214160",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0014065","Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic β-cell destruction induced by encephalomyocarditis virus.","Sano H","2011","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2010.12.020","21144822",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014066","LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.","Coskun T","2018","Molecular metabolism","randomized_trial","article","10.1016/j.molmet.2018.09.009","30473097","PMC6308032","ClinicalTrials.gov:NCT02759107","S000482; S000760; S000942","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014067","Semaglutide/Acarbose combination protects against diabetic nephropathy in rats; a novel insight into modulation of Nrf-2/HO-1& TGF-β/Smad pathways.","Elborei MA","2026","International immunopharmacology","preclinical","article","10.1016/j.intimp.2026.117277","42580144",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014068","Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.","Mortada I","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.03.020","41862113",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014069","Signaling Mechanism for Modulation by GLP-1 and Exendin-4 of GABA Receptors on Rat Retinal Ganglion Cells.","Zhang T","2022","Neuroscience bulletin","preclinical","article","10.1007/s12264-022-00826-9","35278196","PMC9206055",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014070","Lixisenatide for the treatment of type 2 diabetes.","Petersen AB","2013","Drugs of today (Barcelona, Spain : 1998)","narrative_review","article","10.1358/dot.2013.49.9.2020940","24086950",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0014071","Glucagon in glucose homeostasis and metabolic disease: from physiology to therapeutics.","Amin A","2025","Journal of basic and clinical physiology and pharmacology","narrative_review","article","10.1515/jbcpp-2025-0005","40314189",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014072","New Fuels for a Failing Engine: The Impact of Novel Heart Failure Drugs on Functional Capacity.","Baracchini N","2025","Reviews in cardiovascular medicine","randomized_trial","article","10.31083/rcm41919","41089789","PMC12516751",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0014073","Beneficial Influence of Exendin-4 on Specific Organs and Mechanisms Favourable for the Elderly with Concomitant Obstructive Lung Diseases.","Figat M","2022","Brain sciences","narrative_review","article","10.3390/brainsci12081090","36009152","PMC9405576",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014074","Modifying the aggregation state may improve the activity of Ozempic","Bolaño Alvarez A","2024","bioRxiv","other","preprint","10.1101/2024.11.19.624403",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014075","Out-of-Pocket Costs and Adherence to Semaglutide for Obesity Among Commercially Insured Adults.","Shin E","2026","JAMA health forum","nonrandomized_study","article","10.1001/jamahealthforum.2026.3113","42663997","PMC13525458",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014076","5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.","Niu S","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15332","37867175","PMC11115367",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0014077","Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus.","Yoon KH","2017","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2017.41.1.69","28029018","PMC5328698",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014078","Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.","Stottlemyer BA","2023","Therapeutic advances in drug safety","nonrandomized_study","article","10.1177/20420986231181334","37332887","PMC10272667",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0014079","Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss.","Bozadjieva-Kramer N","2026","Diabetes","preclinical","article","10.2337/db25-0466","41920187","PMC13191413",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0014080","Insulin secretion induced by glucose-dependent insulinotropic polypeptide requires phosphatidylinositol 3-kinase γ in rodent and human β-cells.","Kolic J","2014","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m114.577510","25288806","PMC4231687",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014081","Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk.","Diab H","2024","Nutrients","other","article","10.3390/nu16172886","39275201","PMC11397063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014082","A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.","Nassif ME","2019","The American journal of cardiology","randomized_trial","article","10.1016/j.amjcard.2019.10.025","31741435",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0014083","Glucagon-like peptide-1 analogues exenatide and liraglutide exert inhibitory effect on the early phase of liver regeneration after partial hepatectomy in rats.","Fontana J","2017","Physiological research","preclinical","article","10.33549/physiolres.933464","28730824",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014084","Suitable Use of Injectable Agents to Overcome Hypoglycemia Risk, Barriers, and Clinical Inertia in Community-Dwelling Older Adults with Type 2 Diabetes Mellitus.","Valencia WM","2019","Drugs & aging","narrative_review","article","10.1007/s40266-019-00706-4","31565780","PMC7481154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014085","Mechanisms of Hypertension in Women: Interactions Between Vascular Ageing, Metabolic Dysfunction, and Hormonal Regulation.","Hooshmandi S","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14081667","42652050","PMC13509265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014086","Incretin-based therapy for diabetic ulcers: from bench to bedside.","Ku HC","2018","Expert opinion on investigational drugs","narrative_review","article","10.1080/13543784.2018.1548607","30449201",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014087","Efficacy and Safety of Glucagon Like Peptide-1 Receptor Agonism Based Therapies in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis.","Dutta D","2025","Indian journal of endocrinology and metabolism","systematic_review","article","10.4103/ijem.ijem_365_24","40181850","PMC11964357",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0014088","Current state of medical rehabilitation for adult short bowel syndrome patients with intestinal failure.","Jeppesen PB","2026","Current opinion in organ transplantation","narrative_review","article","10.1097/mot.0000000000001296","42299728",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014089","Treatment Outcomes and Tolerability Following Initiation of GLP-1 Receptor Agonists Among Type 2 Diabetes Patients in Primary Care Practices in Germany.","Qiao Q","2017","Journal of diabetes science and technology","nonrandomized_study","article","10.1177/1932296816661349","27470665","PMC5478013",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014090","Structural determinants of beta-cell failure in type 2 diabetes: a multimodality imaging study.","Yamazaki H","2026","Metabolism: clinical and experimental","nonrandomized_study","article","10.1016/j.metabol.2026.156631","42134453",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014091","Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.","McCormick N","2024","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2024-080035","39477370","PMC11524131",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0014092","Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.","Rubino DM","2026","Contemporary clinical trials communications","other_trial","article","10.1016/j.conctc.2026.101611","41704810","PMC12907877",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014093","Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection.","Shin MH","2026","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph19050791","42198465","PMC13210338",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014094","Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.","Montvida O","2018","Diabetes care","nonrandomized_study","article","10.2337/dc17-1414","29109299",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014095","Weight loss drugs: What do we know about the effects of Ozempic on children?","Lang K","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r2387","41253427",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014096","Exploring the GLP-1-GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography.","Manell E","2021","BMJ open diabetes research & care","preclinical","article","10.1136/bmjdrc-2020-002083","33903116","PMC8076945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014097","Adverse events associated with tirzepatide: a focus on subgroup-specific differences.","Yu Z","2026","BMC pharmacology & toxicology","nonrandomized_study","article","10.1186/s40360-026-01105-3","41742317","PMC13041219",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0014098","Anorexigenic and anti-inflammatory signaling pathways of semaglutide via the microbiota-gut--brain axis in obese mice.","da Silva RS","2025","Inflammopharmacology","preclinical","article","10.1007/s10787-024-01603-y","39586940",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014099","Comment on \"effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study\".","Siddiraju S","2026","Clinical nutrition ESPEN","commentary","article","10.1016/j.clnesp.2026.105077","42674357",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0014100","Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?","Wild D","2021","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","narrative_review","article","10.2967/jnumed.120.246009","34230073",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0014101","6486 Gastroparesis Exacerbation by a GLP-1 Agonist",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453597",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014102","Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.","Zisman A","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0507-0","30218434","PMC6167304","ClinicalTrials.gov:NCT02058160","S001409","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; other; article"],["R0014103","Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use.","Peng DS","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.06.006","42541308","PMC13427499",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014104","Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model.","Sun X","2025","bioRxiv : the preprint server for biology","other_trial","article","10.64898/2025.12.18.695152","41509321","PMC12776102",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Preprint; preprint"],["R0014105","Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation.","Fauchier L","2026","Diabetes research and clinical practice","commentary","article","10.1016/j.diabres.2026.113331","42155604",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014106","Effect of semaglutide on left ventricular mass in patients with type 2 diabetes: A cardiac CT substudy of the STOP trial.","Mora R","2026","Journal of cardiovascular computed tomography","other_trial","article","10.1016/j.jcct.2026.08.010","42665510",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; article"],["R0014107","Pharmacological Management of Diabetes Mellitus: A Century of Expert Opinions in Cecil Textbook of Medicine.","Manu P","2021","American journal of therapeutics","preclinical","article","10.1097/mjt.0000000000001401","34228650",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014108","A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.","Yuan Z","2017","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2017.06.029","28666800",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014109","[Towards evidence-based medicine: large-scale intervention trials with glucagon-like peptide-1 receptor agonists].","Consoli A","2012","Giornale italiano di cardiologia (2006)","randomized_trial","article","10.1714/1203.13333","23258125",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0014110","Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone.","Trujillo JM","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13444","29923298","PMC6221077","ClinicalTrials.gov:NCT02058160; ClinicalTrials.gov:NCT02058147","S001199; S001409","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; brief-report; article"],["R0014111","Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?","Van Gaal LF","2008","European journal of endocrinology","narrative_review","article","10.1530/eje-07-0804","18322302",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014112","A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice.","Davies I","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70300","41287212","PMC12803606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0014113","Tirzepatide-Associated Lithium Toxicity Necessitating Hemodialysis in Previously Stable Bipolar I Disorder.","Patarroyo-Rodriguez L","2026","Journal of clinical psychopharmacology","other","article","10.1097/jcp.0000000000002207","42227267",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014114","Editorial: Beyond Clinical Trials-Real-World Data Suggest Usefulness of GLP-1 RAs in MASLD Treatment. Authors' Reply.","Kuo CC","2025","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.70063","40019295",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Editorial; editorial"],["R0014115","Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury.","Ismaeil A","2022","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph15060720","35745639","PMC9228343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014116","Targeting GLP-1 Signaling Ameliorates Cystogenesis in a Zebrafish Model of Nephronophthisis.","Eckert P","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms26157366","40806500","PMC12347336",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014117","Pharmacologic Management of Obesity in Neuro-Oncology: A Case Report.","Lardieri A","2025","Case reports in oncology","case_report","article","10.1159/000543178","39980512","PMC11785398",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014118","Non-type 1 and non-type 2 diabetes in a young man due to novel mutation in HNF1A.","Liu YC","2025","BMJ case reports","case_report","article","10.1136/bcr-2025-265503","41397788","PMC12718537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0014119","Weight loss with GLP-1 analogues in preparation for transplantation.","O'Callaghan M","2024","BMJ case reports","case_report","article","10.1136/bcr-2023-256099","38594196","PMC11015230",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014120","Inhibition of notch signalling and mesangial expansion by combined glucagon like peptide-1 agonist and crocin therapy in animal model of diabetic nephropathy.","Amin SN","2023","Archives of physiology and biochemistry","preclinical","article","10.1080/13813455.2020.1846203","33280420",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014121","Patients' Experiences of Obstructive Sleep Apnea and Tirzepatide Treatment: An Exit Interview Study.","Shinde S","2026","The patient","other_trial","article","10.1007/s40271-026-00808-3","41793578","PMC13287229","ClinicalTrials.gov:NCT05412004","S000156","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014122","Emerging Perspectives in the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Narrative Review.","Djeagou A","2025","Cureus","narrative_review","article","10.7759/cureus.95288","41287682","PMC12640531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0014123","Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells.","Carraro-Lacroix LR","2009","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00082.2009","19776173",null,null,"S000128; S002726","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014124","Concerns regarding the inclusion of a preprint in a meta-analysis on GLP-1 agonists in Parkinson's Disease.","Aubignat M","2025","Parkinsonism & related disorders","systematic_review","article","10.1016/j.parkreldis.2025.107798","40122718",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; article"],["R0014125","Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.","Rathmann W","2016","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12673","27062643",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014126","12442 Effectiveness Of An Electronic Decision Support Algorithm To Optimize Recommendation Of SGLT2i And GLP-1RA In Patients With Type 2 Diabetes Upon Discharge From Internal Medicine Wards",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455207",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014127","Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.","Arslanian S","2026","Diabetes care","randomized_trial","article","10.2337/dc25-0824","41296499","PMC13191423","ClinicalTrials.gov:NCT04102189","S001529","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; research-article; article; other"],["R0014128","Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.","Zhang L","2024","Journal of clinical pharmacology","systematic_review","article","10.1002/jcph.2483","38874130",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; article"],["R0014129","Off-label semaglutide: A call for monitoring protocols in non-obese populations.","Rehman M","2026","JPMA. The Journal of the Pakistan Medical Association","nonrandomized_study","article","10.47391/jpma.33096","42703150",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0014130","Potential implications of long-acting GLP-1 receptor agonists for critically ill.","Wang L","2024","Critical care (London, England)","commentary","article","10.1186/s13054-024-04945-9","38741192","PMC11091986",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014131","Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface.","Raubenheimer JE","2024","BMC global and public health","nonrandomized_study","article","10.1186/s44263-024-00095-w","39681910","PMC11622965",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014132","Multivalent γ-PGA-Exendin-4 Conjugates to Target Pancreatic β-Cells.","Rossi L","2022","Chembiochem : a European journal of chemical biology","other","article","10.1002/cbic.202200196","35762648","PMC9542156",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014133","Exendin-4 enhances osteogenic differentiation of adipose tissue mesenchymal stem cells through the receptor activator of nuclear factor-kappa B and osteoprotegerin signaling pathway.","Habib SA","2022","Journal of cellular biochemistry","preclinical","article","10.1002/jcb.30236","35338509",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014134","Beyond Weight Loss: Evaluating Cardiovascular Advantages of GLP-1 Receptor Agonists.","Vezza T","2024","American journal of cardiovascular drugs : drugs, devices, and other interventions","commentary","article","10.1007/s40256-024-00650-8","38748390",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0014135","Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations.","Jones KL","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13956","31903712",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0014136","The Use of GLP-1 Agonists in the Management of Cutaneous Disease.","Lal K","2024","The Journal of clinical and aesthetic dermatology","narrative_review","article",null,"39263264","PMC11386968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014137","Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway.","Song S","2022","CNS neuroscience & therapeutics","preclinical","article","10.1111/cns.13791","34985189","PMC8841291",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014138","GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response.","Zhao Q","2019","Artificial cells, nanomedicine, and biotechnology","other","article","10.1080/21691401.2019.1620248","31174433",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Retracted Publication; article"],["R0014139","Initiating a glucagon-like peptide-1 receptor agonist in the management of type 2 diabetes mellitus.","Gavin JR","2012","The Journal of the American Osteopathic Association","narrative_review","article",null,"22267299",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014140","The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.","Ravindhran B","2026","European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery","other_trial","article","10.1016/j.ejvs.2026.07.037","42462869",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; article"],["R0014141","Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.","Home PD","2017","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2017.06.013","28683300",null,"ClinicalTrials.gov:NCT00849056; ClinicalTrials.gov:NCT00849017; ClinicalTrials.gov:NCT00838903; ClinicalTrials.gov:NCT00838916; ClinicalTrials.gov:NCT00839527","S000029; S000099; S000852; S001136; S001892","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0014142","The diabetes cardiovascular outcomes trials and racial and ethnic minority enrollment: impact, barriers, and potential solutions.","Sinclair MR","2024","Frontiers in public health","nonrandomized_study","article","10.3389/fpubh.2024.1412874","39525461","PMC11545964",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0014143","Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study).","Kapoor N","2026","Cardiovascular diabetology. Endocrinology reports","randomized_trial","article","10.1186/s40842-026-00290-8","42026662","PMC13107781",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0014144","Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.","Haluzík M","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-023-01375-8","36787044","PMC10064361",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014145","Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1.","Sattar N","2026","Journal of endocrinological investigation","randomized_trial","article","10.1007/s40618-026-02883-7","42082865","PMC13219146",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; brief-report; article"],["R0014146","Cardiovascular outcomes with GLP-1 RAs in patients with type 2 diabetes mellitus and atrial fibrillation.","Vignarajah A","2025","Heart rhythm","other","article","10.1016/j.hrthm.2025.01.023","39864477",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014147","Mounjaro: UK price set to rise by up to 170% after Trump complaint-will patients have to pay?","Bowie K","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r1776","40835380",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0014148","Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.","Telci Caklili O","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s392684","37337548","PMC10277000",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article; review"],["R0014149","Intestinal fructose metabolism drives unsaturated fat absorption and synergizes with GLP-1 receptor agonism to promote weight loss.","Echeverría CE","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.06.03.729910","42327235","PMC13278148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0014150","Individual paraventricular hypothalamic GLP-1R neurons track ingestion across energy states.","Savani RH","2025","iScience","other","article","10.1016/j.isci.2025.114070","41403831","PMC12704261",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014151","SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.","Rutter MK","2026","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.70247","42297568",null,"ClinicalTrials.gov:NCT07247084","S001985","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; article"],["R0014152","Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).","Maegawa H","2021","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.13352","32643314","PMC7926254",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014153","Advances in the treatment of pediatric hidradenitis suppurativa: emerging therapies and future directions.","Chajecki A","2026","Current opinion in pediatrics","narrative_review","article","10.1097/mop.0000000000001590","42290223",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014154","Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus.","Bretón-Romero R","2018","Journal of the American Heart Association","other","article","10.1161/jaha.118.009379","30371206","PMC6222937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014155","From the Discovery of GLP-1 to Today's Diabetes/Obesity Therapy and Beyond.","Holst JJ","2026","Biological psychiatry","narrative_review","article","10.1016/j.biopsych.2026.04.010","42035861",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0014156","Narrative Review \"Dual Frontiers in Neurodegeneration: Pharmacological Synergies and Divergences in Parkinson's Disease and Type 2 Diabetes Mellitus\".","Sharallah OA","2026","Cellular and molecular neurobiology","narrative_review","article","10.1007/s10571-026-01702-0","41931123","PMC13172232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0014157","Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks.","Lupianez-Merly C","2024","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/apt.17856","38169126",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0014158","Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.","Kawaguchi T","2014","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2014.1826","24993337",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014159","Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study.","Engström A","2023","Diabetes care","nonrandomized_study","article","10.2337/dc22-0714","36508322",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014160","Adoption and Prescribing Practices of Sodium-Glucose Transport Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Agonists in Cardiology: A Cross-Sectional Study in Saudi Arabia.","Jamsheer F","2025","Cureus","other_trial","article","10.7759/cureus.80610","40230756","PMC11994844",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014161","Semaglutide ameliorated autism-like behaviors and DNA repair efficiency in male BTBR mice by recovering DNA repair gene expression.","Hussein MH","2024","Progress in neuro-psychopharmacology & biological psychiatry","preclinical","article","10.1016/j.pnpbp.2024.111091","39032854",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014162","GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.","Samms RJ","2021","The Journal of clinical investigation","preclinical","article","10.1172/jci146353","34003802","PMC8203452",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014163","Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study.","Bellido D","2018","Current therapeutic research, clinical and experimental","nonrandomized_study","article","10.1016/j.curtheres.2018.09.001","30455779","PMC6218842",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014164","SAT-534 Trulicity Troubles: When Diabetes Medications Go Kidney-ward",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12543944",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014165","Achieving Good Metabolic Control Without Weight Gain with the Systematic Use of GLP-1-RAs and SGLT-2 Inhibitors in Type 2 Diabetes: A Machine-learning Projection Using Data from Clinical Practice.","Giorda CB","2023","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2023.06.006","37451913",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0014166","Current and emerging pharmacotherapies for obesity in Australia.","Hocking S","2017","Obesity research & clinical practice","other_trial","article","10.1016/j.orcp.2017.07.002","28818558",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0014167","Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.","Farngren J","2016","Diabetes care","randomized_trial","article","10.2337/dc15-1274","26537183",null,"ClinicalTrials.gov:NCT02020629","S000820","pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0014168","Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics.","Asaad GF","2025","Naunyn-Schmiedeberg's archives of pharmacology","narrative_review","article","10.1007/s00210-024-03532-7","39453501","PMC11919990",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014169","Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi).","González-Gálvez G","2020","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2019.05.020","32561160",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0014170","The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.","Drucker DJ","2006","Lancet (London, England)","narrative_review","article","10.1016/s0140-6736(06)69705-5","17098089",null,null,"S001260; S001544; S002653","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014171","Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.","Freeman J","2015","The Journal of family practice","narrative_review","article",null,"26845016",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014172","Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway.","Zhan JK","2014","Cardiovascular diabetology","other","article","10.1186/s12933-014-0153-4","25407893","PMC4241215",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014173","Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.","Angelopoulos N","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70810","42037110",null,"ANZCTR:ACTRN12625000071426",null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0014174","Diabetes and vascular disease: New therapeutic avenues.","Del Prato S","2024","Vascular pharmacology","commentary","article","10.1016/j.vph.2023.107247","38036017",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0014175","Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","Luan S","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.1047883","36387915","PMC9650490",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; Journal Article; systematic-review; review"],["R0014176","Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.","Ahrén B","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-016-0179-6","27319011","PMC5014785","ClinicalTrials.gov:NCT00712673; ClinicalTrials.gov:NCT00713830","S000491; S002188","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; article"],["R0014177","Structural Assumptions in Semaglutide Cost-Effectiveness.","Zavaleta-Monestel E","2026","JAMA cardiology","other","article","10.1001/jamacardio.2026.1360","42160088",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014178","[Optimizing basal insulin therapy in type 2 diabetes].","Scheen AJ","2017","Revue medicale de Liege","other","article",null,"28387494",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014179","Incretin therapy for diabetes mellitus type 2.","Holst JJ","2020","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000516","31815785",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014180","Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration-A Danish Cohort Study.","Ladebo L","2024","Diabetes care","nonrandomized_study","article","10.2337/dc24-1082","39106205",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; other; article"],["R0014181","Addressing Confounders in GLP-1RA Effects on ALD Outcomes.","Hsu CK","2025","Liver international : official journal of the International Association for the Study of the Liver","commentary","article","10.1111/liv.16151","39530491",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014182","GLP-1 Agonists in Patients With Hidradenitis Suppurativa: A Case Series.","Rames MM","2025","Journal of cutaneous medicine and surgery","case_report","article","10.1177/12034754251320045","39966104",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014183","Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time-in-ranges in Chinese adults with Type 2 diabetes: A post hoc analysis of the Soli-D study.","Liu J","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16646","40709642","PMC12409237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014184","Analysis of the effects of incretin-based peptides on human neuroblastoma SH-SY5Y cells","Sharma MK","2013","Ulster University","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0014185","Opportunities of Antidiabetic Drugs in Cardiovascular Medicine: A Meta-Analysis and Perspectives for Trial Design.","Yan C","2020","Hypertension (Dallas, Tex. : 1979)","systematic_review","article","10.1161/hypertensionaha.120.14791","32639887",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0014186","Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis.","Sun F","2012","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2012.09.004","23020934",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; Network Meta-Analysis; article"],["R0014187","Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.","Mohamed ZI","2026","Endocrinology, diabetes & metabolism","randomized_trial","article","10.1002/edm2.70298","42533465","PMC13425598",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0014188","\"Emerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions\".","Moka MK","2025","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-024-02363-5","39254745",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0014189","Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.","Seino Y","2016","Journal of diabetes investigation","narrative_review","article","10.1111/jdi.12490","27186364","PMC4854513",null,"S000298","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0014190","A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder.","Allison KC","2023","Obesity science & practice","randomized_trial","article","10.1002/osp4.619","37034559","PMC10073825",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014191","Liraglutide protects against diastolic dysfunction and improves ventricular protein translation","Rutledge C","2022","bioRxiv","nonrandomized_study","preprint","10.1101/2022.08.23.504997",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0014192","Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE -/- mice.","Zhang K","2024","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2024.116170","38548245",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014193","Pharmacosimilars In Obesity Medicine: Informed Choice, Appropriate Choice.","Kalra S","2025","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.25-61","40851146",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014194","A Retrospective Study Evaluating the Efficacy and Safety of Oral Semaglutide Compared to Injectables in Controlling Diabetes and Weight Reduction","Ullah Z","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202604.0987.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0014195","Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.","Carls GS","2017","Diabetes care","randomized_trial","article","10.2337/dc16-2725","28801475",null,null,"S002638","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0014196","[Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].","Scheen A","2024","Revue medicale de Liege","narrative_review","article",null,"39697128",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0014197","A Conserved Hydrophobic Moiety and Helix-Helix Interactions Drive the Self-Assembly of the Incretin Analog Exendin-4.","Wolff M","2021","Biomolecules","other","article","10.3390/biom11091305","34572518","PMC8472270",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014198","The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action.","Alexiadou K","2024","Trends in cardiovascular medicine","narrative_review","article","10.1016/j.tcm.2024.03.003","38555029",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014199","Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.","Volčanšek Š","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-025-01733-8","40332747","PMC12085449",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014200","The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia.","Chen F","2016","Journal of neuroinflammation","preclinical","article","10.1186/s12974-016-0661-0","27566245","PMC5002167",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0014201","Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas.","Jansen TJP","2024","EJNMMI research","other_trial","article","10.1186/s13550-024-01159-6","39405026","PMC11480297","ClinicalTrials.gov:NCT03889496; ClinicalTrials.gov:NCT04733508","S001298; S002176","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014202","Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. Comment on Br J Anaesth 2024; 132: 644-8.","Potnuru PP","2024","British journal of anaesthesia","commentary","article","10.1016/j.bja.2024.05.043","39060159",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0014203","Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R.","Zhang H","2021","Brain research bulletin","preclinical","article","10.1016/j.brainresbull.2020.11.008","33197537",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014204","Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.","Mannucci E","2017","Advances in therapy","systematic_review","article","10.1007/s12325-016-0432-4","27844335","PMC5216099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0014205","LiCl-driven direct synthesis of mono-protected esters from long-chain dicarboxylic fatty acids.","Kuang Y","2025","RSC advances","other","article","10.1039/d5ra04970a","41064142","PMC12502634",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014206","Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.","Wysham CH","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13056","28685973","PMC5724491","ClinicalTrials.gov:NCT01652716","S001982","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; research-article; article"],["R0014207","Reply: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?","Cheung KS","2025","Hepatology (Baltimore, Md.)","randomized_trial","article","10.1097/hep.0000000000001034","39047080",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; letter"],["R0014208","Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.","Kanu C","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16662","40735804","PMC12409224",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0014209","Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial.","Colhoun HM","2026","European heart journal","other_trial","article","10.1093/eurheartj/ehag524","42777687",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0014210","Semaglutide Modulates Visceral Adipose Tissue Lipid Metabolism in Type 2 Diabetic Mice: A Lipidomics Study.","Chen X","2026","Frontiers in bioscience (Landmark edition)","preclinical","article","10.31083/fbl49873","42411489",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014211","In adults with early uncontrolled T2D, tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y.","Davidson MB","2026","Annals of internal medicine","other","article","10.7326/annals-26-03022-jc","42673598",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014212","Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation.","Garczorz W","2018","Cardiovascular therapeutics","other","article","10.1111/1755-5922.12317","29283509",null,null,"S000371","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0014213","Semaglutide Exposure and Risk of Oral Mucositis, Systemic Complications, and Mortality After Hematopoietic Stem-Cell Transplantation: A Propensity-Matched Found Data Analysis","Ahmed Z","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202610.0332.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0014214","The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist.","Cho YK","2023","Journal of lipid and atherosclerosis","other_trial","article","10.12997/jla.2023.12.3.213","37800107","PMC10548186",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0014215","Metabolic imbalance and brain tumors: The interlinking metabolic pathways and therapeutic actions of antidiabetic drugs.","Kim YK","2025","Pharmacological research","narrative_review","article","10.1016/j.phrs.2025.107719","40174814",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014216","Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.","Yabe D","2011","Clinical medicine insights. Endocrinology and diabetes","other_trial","article","10.4137/cmed.s5976","22879794","PMC3411533",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0014217","Erratum: What Is the Current State of Evidence Regarding Any Mood-Improving Properties of GLP-1 Receptor Agonists, and Are Psychiatrists Prescribing Them?",null,"2024","Journal of clinical psychopharmacology","notice","article","10.1097/jcp.0000000000001897","38935570",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0014218","Incretin-based therapies.","Neumiller JJ","2015","The Medical clinics of North America","narrative_review","article","10.1016/j.mcna.2014.08.013","25456646",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014219","Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.","Liu WJ","2011","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2011.01272.x","21323903","PMC3221096",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014220","Dulaglutide Improves Gliosis and Suppresses Apoptosis/Autophagy Through the PI3K/Akt/mTOR Signaling Pathway in Vascular Dementia Rats.","Guan T","2023","Neurochemical research","preclinical","article","10.1007/s11064-022-03853-0","36571662",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014221","Clinical Impact of Semaglutide in Patients with Heart Failure and Preserved Ejection Fraction.","Hida Y","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15124831","42355999","PMC13301344",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014222","Liraglutide for weight management: a critical review of the evidence.","Mehta A","2017","Obesity science & practice","randomized_trial","article","10.1002/osp4.84","28392927","PMC5358074",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014223","SUN-653 Impact of GLP-1 Agonist on Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-Analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12545291",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0014224","Delays in access to generic semaglutide point to key missing pieces in Canada's drug approval system.","Eisenkraft Klein D","2026","Health policy (Amsterdam, Netherlands)","other","article","10.1016/j.healthpol.2026.105779","42815318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014225","Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.","Ohki T","2016","Clinical drug investigation","nonrandomized_study","article","10.1007/s40261-016-0383-1","26914659",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014226","The tip of the iceberg: Will GLP-1 receptor agonists unintentionally contribute to titanic cardiovascular events in certain individuals?","Arena R","2024","Current problems in cardiology","narrative_review","article","10.1016/j.cpcardiol.2024.102676","38795802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014227","Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.","Feng P","2018","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2018.02.012","29462693",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014228","Weight loss drugs: Doctor who prescribed Ozempic to her partner is suspended.","Dyer C","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r2175","41101982",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014229","Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.","Chen YH","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13340","29708650","PMC6099453",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014230","Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery.","Wilmington R","2024","Obesity surgery","nonrandomized_study","article","10.1007/s11695-023-06895-7","38012508","PMC10781788",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0014231","Liraglutide ameliorates oxidized LDL-induced endothelial dysfunction by GLP-1R-dependent downregulation of LOX-1-mediated oxidative stress and inflammation.","Ying W","2023","Redox report : communications in free radical research","preclinical","article","10.1080/13510002.2023.2218684","37278349","PMC10249460",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014232","Therapeutic Benefit or Ocular Risk? Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: Retraction.","Batool S","2026","Retina (Philadelphia, Pa.)","other","article","10.1097/iae.0000000000004884","42468029",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Retraction Notice; article"],["R0014233","Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced.","Zhou R","2020","Metabolic syndrome and related disorders","nonrandomized_study","article","10.1089/met.2019.0122","32580677",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0014234","In adults with overweight or obesity and without diabetes, GLP-1 RAs increase weight loss vs. placebo.","Lau D","2025","Annals of internal medicine","commentary","article","10.7326/annals-25-01325-jc","40324188",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0014235","Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison.","le Roux CW","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15148","37344384",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014237","Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.","Lebwohl M","2026","JAMA dermatology","randomized_trial","article","10.1001/jamadermatol.2026.1753","42139049","PMC13179568","ClinicalTrials.gov:NCT06588283","S000032","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0014238","Curbing the appetites and restoring the capacity for satisfaction: The impact of GLP-1 agonists on the reward circuitry.","Krupa AJ","2025","Neuroscience applied","other","article","10.1016/j.nsa.2025.105512","40654594","PMC12244148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0014239","The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies.","Jerlhag E","2023","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2023.1063033","37063267","PMC10097922",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014240","Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.","Chadwick J","2025","Journal of clinical pharmacology","other_trial","article","10.1002/jcph.70077","40619592","PMC12555109",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014241","Letter: Non-Invasive Tests After Semaglutide in MASH as Disease-Activity Readouts Rather Than Response Biomarkers. Authors' Reply.","Nitze LM","2026","Alimentary pharmacology & therapeutics","commentary","article","10.1111/apt.70897","42608958",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0014242","Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.","Varpuluoma O","2018","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2018.05.030","29803903",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0014243","Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.","Li CL","2015","Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban","preclinical","article","10.1007/s11596-015-1433-2","26072069",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014244","[68 Ga]Ga-DOTATATE PET/CT versus [68 Ga]Ga-Exendin-4 PET/CT in the evaluation of metastatic insulinoma.","Guo W","2023","European journal of nuclear medicine and molecular imaging","other","article","10.1007/s00259-023-06182-8","36872390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014245","A bifunctional anti-PCSK9 scFv/Exendin-4 fusion protein exhibits enhanced lipid-lowering effects via targeting multiple signaling pathways in HFD-fed mice.","Xu M","2023","International journal of biological macromolecules","preclinical","article","10.1016/j.ijbiomac.2023.127003","37739280",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014246","The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects.","Jensen TL","2024","Patient preference and adherence","other_trial","article","10.2147/ppa.s419304","38352159","PMC10861994",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0014247","Sex Differences in Obesity and Its Treatment.","Ghanta A","2025","Current psychiatry reports","narrative_review","article","10.1007/s11920-025-01601-z","40100584",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014248","Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.","Stolar MW","2013","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s48837","24285927","PMC3840776",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014249","Key advances in secondary prevention after coronary artery bypass grafting.","Elsherbini A","2026","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000001333","42592902",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014250","From MRI to Ozempic: breakthroughs that show why fundamental research must be protected.",null,"2025","Nature","commentary","article","10.1038/d41586-025-03470-1","41162725",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","News; editorial"],["R0014251","Diabetes and the liver.","Dadey E","2026","Clinical medicine (London, England)","narrative_review","article","10.1016/j.clinme.2025.100528","41205653","PMC12757520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014252","Liraglutide for treating type 1 diabetes.","Dejgaard TF","2016","Expert opinion on biological therapy","randomized_trial","article","10.1517/14712598.2016.1160050","26926662",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Journal Article; Review; other; article"],["R0014253","Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6.","Bajaj HS","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-026-01859-3","41961454","PMC13156352","ClinicalTrials.gov:NCT04039503; ClinicalTrials.gov:NCT04537923","S000108; S001608","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; article"],["R0014254","Preliminary Review Finds No Link Between GLP-1 Receptor Agonists and Suicidality.","Aschenbrenner DS","2024","The American journal of nursing","narrative_review","article","10.1097/01.naj.0001016352.54091.a1","38661695",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014255","Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide.","Rzepiński Ł","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms262412028","41465455","PMC12733150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014256","Metabolic Crosstalk in Diabetic Kidney Disease: Synergistic Effects of Glucotoxicity and Lipotoxicity.","Cao J","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s580866","41907101","PMC13023403",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014257","PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease.","Monroe RE","2026","European heart journal. Cardiovascular pharmacotherapy","other_trial","article","10.1093/ehjcvp/pvag055","42647148",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0014258","Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.","Salmen T","2024","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph17101322","39458963","PMC11510241","PROSPERO:CRD42024507397",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0014259","Structural Assumptions in Semaglutide Cost-Effectiveness-Reply.","Hennessy S","2026","JAMA cardiology","other","article","10.1001/jamacardio.2026.0710","42160096",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014260","Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial Infarction by Activating β-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting β-Catenin.","Eid RA","2021","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-020-07006-9","32474680",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014261","A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist.","Komala MG","2022","Clinical diabetes : a publication of the American Diabetes Association","case_report","article","10.2337/cd21-0142","36385974","PMC9606557",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014262","Leptin Reduction as a Required Component for Weight Loss.","Zhao S","2024","Diabetes","preclinical","article","10.2337/db23-0571","37935033","PMC10796304",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article; other"],["R0014263","Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists.","Saraiva FK","2014","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-014-0142-7","25338737","PMC4216654",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0014264","Obesity in children and adolescents.","Berman C","2026","Journal of clinical lipidology","narrative_review","article","10.1016/j.jacl.2025.07.004","41708218",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014265","Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis.","Schlesinger S","2023","Diabetologia","systematic_review","article","10.1007/s00125-023-05928-1","37204441","PMC10198038","PROSPERO:CRD42020193692",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; research-article; review"],["R0014266","Monogenic obesity due to MC4R deficiency: lessons from a multigenerational case.","Giannopoulou EZ","2026","Molecular and cellular pediatrics","other","article","10.1186/s40348-025-00214-z","41489710","PMC12770134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014267","GLP-1-Based Therapies in Pain Medicine: A Narrative Review and Expert Opinion on Obesity-Related Low Back and Knee Pain.","Hasoon J","2026","Current pain and headache reports","narrative_review","article","10.1007/s11916-026-01546-9","42572056",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0014268","A Systemic Review of Pharmacological Management of Pediatric Obesity.","Gupta S","2025","Journal of pharmacy & bioallied sciences","randomized_trial","article","10.4103/jpbs.jpbs_661_24","40511007","PMC12156768",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0014269","Correction: Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weigh Gain After Primary Bariatric Surgery?","Rivero-Moreno Y","2026","Obesity surgery","notice","article","10.1007/s11695-026-08887-9","42560442",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0014270","GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice.","Sridhar A","2023","Peptides","preclinical","article","10.1016/j.peptides.2023.171093","37660881",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014271","Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid.","Tang C","2020","RSC advances","preclinical","article","10.1039/d0ra01002b","35496622","PMC9050719",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014272","Contemporary Management of Acute Coronary Syndromes in the Cardiac Intensive Care Unit: From Rapid Diagnosis to Early Secondary Prevention.","Giamundo DM","2026","Journal of cardiovascular development and disease","narrative_review","article","10.3390/jcdd13080393","42645864","PMC13513317",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014273","The impact of current and novel anti-diabetic therapies on cardiovascular risk.","Ussher JR","2012","Future cardiology","narrative_review","article","10.2217/fca.12.68","23176691",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014274","Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.","Wang J","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16585","40600452",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; article"],["R0014275","GLP-1 agonists: 82 deaths linked to adverse reactions, UK data show.","Iacobucci G","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r390","40000110",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0014276","Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios.","Kamada Y","2026","Journal of health economics and outcomes research","nonrandomized_study","article","10.36469/001c.162614","42394652","PMC13327695",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014277","GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice.","Laker RC","2025","Nature communications","preclinical","article","10.1038/s41467-025-59773-4","40399267","PMC12095689",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014278","Targeting Cellulite as a Metabolic-Dermal Interface: Effects of Tirzepatide and a Multi-Pathway Topical Therapy (G21) in a 12-Month Observational Study.","Adamidis N","2026","Cureus","nonrandomized_study","article","10.7759/cureus.107073","42147579","PMC13176885",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014279","Adverse Effects Associated With Newer Diabetes Therapies.","Akiyode OF","2017","Journal of pharmacy practice","narrative_review","article","10.1177/0897190015594732","26169212",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014280","Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.","Rudinsky AJ","2015","Domestic animal endocrinology","preclinical","article","10.1016/j.domaniend.2014.12.003","25594949",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014281","The Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Regulates Sirtuin-1-Mediated Neutrophil Extracellular Traps to Improve Diabetes-Induced Bone Metabolism Imbalance.","Zhong S","2024","Iranian journal of pharmaceutical research : IJPR","preclinical","article","10.5812/ijpr-148139","40066121","PMC11892751",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014282","Albiglutide for the management of type 2 diabetes.","Rendell MS","2018","Expert review of endocrinology & metabolism","narrative_review","article","10.1080/17446651.2018.1419061","30063441",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014283","Molecular mechanisms of blood-brain barrier dysfunction caused by obesity: pathophysiological understandings and treatment targets.","Pillai RK","2026","Metabolic brain disease","narrative_review","article","10.1007/s11011-026-01986-7","42730797",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014284","Can semaglutide influence tumor biomarkers? Insight from a clinical case.","Schianchi A","2026","Journal of food and drug analysis","case_report","article","10.38212/2224-6614.3594","42485519","PMC13391009",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014285","LBSUN319 Characteristics And Treatment Patterns Of Hispanic/latino Patients Initiating First Injectable Glp-1ra Or Basal Insulin",null,"2022","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC9629366",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0014286","Reply - Letter to the editor: Comment on \"effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study.","Bolek T","2026","Clinical nutrition ESPEN","commentary","article","10.1016/j.clnesp.2026.105080","42674355",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0014287","Letter to the Editor: Aspirin and GLP-1RAs-The missing confounders of empagliflozin for MASLD without diabetes mellitus?","Hu Y","2025","Hepatology (Baltimore, Md.)","commentary","article","10.1097/hep.0000000000001033","39042838",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0014288","State of the Science on Ultra-processed Foods and the Ultra-processed Food Addiction Construct.","LaFata EM","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00758-9","42726423",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014289","New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs.","Gilor C","2016","Journal of feline medicine and surgery","preclinical","article","10.1177/1098612x16660441","27562982","PMC11148896",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014290","Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores.","Suissa S","2017","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.4107","27610604",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Comparative Study; Journal Article; article"],["R0014291","Response to Wang and Winterstein: Robustness of GIP/GLP-1 RA findings in substance use disorders.","Qeadan F","2025","Addiction (Abingdon, England)","commentary","article","10.1111/add.70011","39895465",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014292","Investigational drugs for alcohol use disorders: a review of preclinical data.","Ch'Ng SS","2018","Expert opinion on investigational drugs","narrative_review","article","10.1080/13543784.2018.1472763","29723484",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014293","Semaglutide improves markers of cardiovascular risk in people with HIV.","Lake JE","2026","AIDS (London, England)","other_trial","article","10.1097/qad.0000000000004538","42084141","PMC13573316",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial, Phase II; research-article; article"],["R0014294","Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004-2014.","Maltese G","2024","Diabetes care","commentary","article","10.2337/dc23-2420","38527117","PMC10973905",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0014295","The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies.","Pietroluongo E","2025","Clinical lung cancer","case_report","article","10.1016/j.cllc.2025.03.002","40157899",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0014296","Factors Associated With Semaglutide Initiation Among Adults With Obesity.","Podolsky MI","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.55222","39836425","PMC11751746",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0014297","Obesity in the United States: A public health perspective.","Myerson M","2026","Journal of clinical lipidology","narrative_review","article","10.1016/j.jacl.2025.05.013","41708213",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014298","Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.","Mandour MO","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag126","41866320","PMC13466956",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0014299","Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response.","Mian MHS","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-026-01888-y","42295649","PMC13457989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014300","The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.","Lane W","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12286","24589127",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0014301","Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series.","Ishii S","2019","Journal of clinical medicine research","case_report","article","10.14740/jocmr3647","30834046","PMC6396779",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014302","GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA.","Hernandez NS","2021","Molecular psychiatry","preclinical","article","10.1038/s41380-020-00957-3","33257815","PMC8164646",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0014303","Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.","Evers A","2018","Journal of medicinal chemistry","other","article","10.1021/acs.jmedchem.8b00292","29879354",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014304","The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents.","Di Lullo L","2017","Diabetes & metabolic syndrome","narrative_review","article","10.1016/j.dsx.2017.03.005","28292575",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014305","Delayed Gastric Emptying Under Treatment with GLP-1 Agonists.","Rau M","2025","Deutsches Arzteblatt international","case_report","article","10.3238/arztebl.m2024.0233","40189476","PMC12434718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; letter; article"],["R0014306","Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons - Implications for energy balance and glucose control.","He Z","2019","Molecular metabolism","preclinical","article","10.1016/j.molmet.2019.07.008","31446151","PMC6822260",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014307","Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map.","Zhu J","2020","The lancet. Diabetes & endocrinology","systematic_review","article","10.1016/s2213-8587(19)30422-x","32006518",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0014308","Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?","Paneni F","2021","European heart journal","randomized_trial","article","10.1093/eurheartj/ehab636","34724707",null,"ClinicalTrials.gov:NCT04255433","S002212","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Comment; article"],["R0014309","Rational design of α-helix-stabilized exendin-4 analogues.","Rovó P","2014","Biochemistry","nonrandomized_study","article","10.1021/bi500033c","24828921",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014310","Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study.","Di Loreto C","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01564-z","38605275","PMC11096145",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014311","HMB and Liraglutide Confer Complementary Protection Against Lipotoxic and Atrophic Alterations in High-Glucose Plus Free Fatty Acid-Treated C2C12 Myotubes.","Chen LY","2026","Nutrients","preclinical","article","10.3390/nu18121865","42356253","PMC13304607",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014312","Geographical variation in the use of glucose-lowering drugs in type-2 diabetes in Denmark: A nationwide drug utilization study.","Rasmussen L","2026","British journal of clinical pharmacology","nonrandomized_study","article","10.1002/bcp.70343","41297971",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Preprint; preprint; article"],["R0014313","Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies.","Tang M","2026","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2026.1829315","42325618","PMC13275242","PROSPERO:CRD420261292638",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; systematic-review; article"],["R0014314","Your Weight and Your Wallet: Comparing Out-of-Pocket Costs of Bariatric Surgery and GLP1 Agonists.","Brown A","2024","Annals of surgery","other","article","10.1097/sla.0000000000006583","39502036",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014315","GLP-1 peptide analogs for targeting pancreatic beta cells.","Alavi SE","2021","Drug discovery today","narrative_review","article","10.1016/j.drudis.2021.03.032","33839290",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014316","Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations.","Mohapatra D","2026","Indian pediatrics","commentary","article","10.1007/s13312-026-00408-2","42474946",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014317","A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.","Perry RA","2021","Bioscience reports","preclinical","article","10.1042/bsr20211275","34370015","PMC8390788",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014318","Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care.","Patoulias D","2024","Pragmatic and observational research","nonrandomized_study","article","10.2147/por.s471476","39130529","PMC11316468",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0014319","Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis.","Tian S","2023","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.3673","37302139",null,"PROSPERO:CRD42022347280",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; review"],["R0014320","Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes.","Gluud LL","2014","BMJ open","systematic_review","article","10.1136/bmjopen-2014-005325","25526792","PMC4275683","PROSPERO:CRD42013005779",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0014321","Efficacy of IAPP suppression in mouse and human islets by GLP-1 analogue conjugated antisense oligonucleotide.","Gurlo T","2023","Frontiers in molecular biosciences","preclinical","article","10.3389/fmolb.2023.1096286","36814640","PMC9939749",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014322","Anti-diabetic drugs and weight loss in patients with type 2 diabetes.","Lazzaroni E","2021","Pharmacological research","systematic_review","article","10.1016/j.phrs.2021.105782","34302978",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Systematic Review"],["R0014323","Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.","Philis-Tsimikas A","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13666","30761720","PMC6593861",null,"S001236","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014324","Epicardial fat: a new cardiovascular therapeutic target.","Iacobellis G","2016","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2016.01.004","26848943",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014325","An updated review on cancer risk associated with incretin mimetics and enhancers.","Tseng CH","2015","Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews","preclinical","article","10.1080/10590501.2015.1003496","25803196",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014326","An overview of recent developments in clinical trials of anti-diabetic drugs.","Madhuri Y","2025","Panminerva medica","other_trial","article","10.23736/s0031-0808.25.05314-5","40457780",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0014327","GLP1 Receptor Agonists Reduce Fluid Intake in Primary Polydipsia","Winzeler B","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.1052",null,"PMC8090681",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0014328","[GLP-1 receptor agonists for the treatment of patients with heart failure? : STEP-HFpEF and STEP-HFpEF DM].","Schröder SC","2024","Innere Medizin (Heidelberg, Germany)","other","article","10.1007/s00108-024-01763-7","39196356",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014329","Interpreting Lean Mass Changes During Tirzepatide-Induced Weight Loss: Beyond Quantitative Metrics.","Uyanık T","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70874","42115704",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014330","Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.","Giugliano D","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13629","30609236",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0014331","EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.","Davidson JA","2016","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep161337.or","27540883",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0014332","Shedding light on weight loss: A narrative review of medications for treating obesity.","Darapaneni H","2024","Romanian journal of internal medicine = Revue roumaine de medecine interne","narrative_review","article","10.2478/rjim-2023-0023","37752761",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0014333","Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.","Cirincione B","2017","The AAPS journal","nonrandomized_study","article","10.1208/s12248-016-9975-1","27896683",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0014334","Morphology-driven zinc oxide biointeractive carriers with biological barrier modulating effects for pulmonary delivery of liraglutide","Jeong J","2025","Research Square","preclinical","preprint","10.21203/rs.3.rs-7849390/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014335","PSUN326 An Interim Analysis of Healthcare Professionals’ Gaps in Incretin Knowledge Before and After Education",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9627475",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014336","Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.","Shestakova MV","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.909874","36017317","PMC9396282",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0014337","Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel.","Kalra S","2020","Indian heart journal","narrative_review","article","10.1016/j.ihj.2020.01.001","32423565","PMC7231843",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014338","Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.","Meneghini L","2020","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.14178","31705547","PMC7003817","ClinicalTrials.gov:NCT01952145; ClinicalTrials.gov:NCT02420262","S001328; S001760","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014339","Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications.","Moss L","2025","Current obesity reports","narrative_review","article","10.1007/s13679-024-00598-5","39753939",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014340","The Immunometabolic Bridge: Targeting Metainflammation to Prevent the Transition from Obesity to Cardiovascular Disease.","Wu M","2026","Journal of inflammation research","other","article","10.2147/jir.s612935","42572701","PMC13453367",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0014341","The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health.","Hanna A","2015","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.2015.972370","30289042",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014342","Semaglutide in Diabetic Periodontitis-Induced Osteoblast Ferroptosis: Pharmacological and Methodological Insights [Letter].","Dong Y","2026","Drug design, development and therapy","commentary","article","10.2147/dddt.s637327","42453931","PMC13367464",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014343","Genetic architecture of obesity and advances in precision pharmacotherapy: a comprehensive review.","Kavaja F","2026","Acta biochimica Polonica","narrative_review","article","10.3389/abp.2026.15484","42022796","PMC13096749",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014344","Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.","Schmidt PHS","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70529","41705736",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0014345","Doubly robust estimation of the weighted average treatment effect for a target population.","Tao Y","2019","Statistics in medicine","nonrandomized_study","article","10.1002/sim.7980","30302780",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014346","Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders.","Olukorode JO","2024","Cureus","narrative_review","article","10.7759/cureus.72080","39574978","PMC11579408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014347","Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy.","Kapitza C","2015","Journal of clinical pharmacology","randomized_trial","article","10.1002/jcph.549","25998481",null,null,"S001276; S001703","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0014348","Clinical Potential of GIP in Type 2 Diabetes and Obesity.","Nauck M","2026","Diabetes care","narrative_review","article","10.2337/dci25-0141","41973737","PMC13385947",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0014349","Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series.","Drayne R","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","case_report","article","10.1111/jdv.70614","42466886",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014350","Metabolic dysregulation and antibody-mediated rejection after kidney transplantation: interacting mechanisms and emerging clinical strategies.","Yang Q","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1826005","42253967","PMC13233235",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014351","Secondary alopecia due to semaglutide.","Obando Pacheco J","2026","Medicina clinica","commentary","article","10.1016/j.medcli.2026.107507","42364353",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0014352","Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance.","Zinzi A","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1805842","42137313","PMC13168152",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014353","Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.","Sood A","2024","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2024.2310070","38265050",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014354","Challenges in the management of idiopathic intracranial hypertension.","Belanger K","2026","Journal of neurointerventional surgery","narrative_review","article","10.1136/jnis-2025-024599","41558864",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014355","Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.","Irfan H","2024","Current problems in cardiology","randomized_trial","article","10.1016/j.cpcardiol.2023.102060","37640171",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0014356","Nmnat2 deficiency in the arcuate nucleus or paraventricular nucleus induces Sarm1-independent neuron loss and liraglutide-reversible obesity.","Yu H","2025","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.202402546r","39964232",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014357","Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss.","Gross K","2024","Frontiers in endocrinology","other","article","10.3389/fendo.2024.1449653","39109078","PMC11300307",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0014358","Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.","Evers A","2017","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.7b00174","28448133",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014359","Interactions between nutrition, GLP-1 secretion, and composition of the gut microbiome.","Kouraki A","2026","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000001235","42165244",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014360","Incretin-based therapies: where will we be 50 years from now?","Meier JJ","2015","Diabetologia","other","article","10.1007/s00125-015-3608-6","25994073",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014361","Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.","Smits MM","2015","BMJ open","randomized_trial","article","10.1136/bmjopen-2015-009579","26586327","PMC4654309","ClinicalTrials.gov:NCT01744236","S002312","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; protocol; article"],["R0014362","Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.","Akturk HK","2026","Diabetes technology & therapeutics","randomized_trial","article","10.1177/15209156251398060","41804540",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0014363","Tirzepatide and Metformin Effects on Hunger and BMI in an Adolescent with Hyperphagia and Severe Obesity due to MC4R Deficiency: A Case Report.","van der Walle EEPL","2026","Obesity facts","nonrandomized_study","article","10.1159/000551729","41926561","PMC13268650",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0014364","Liraglutide intervention improves high-glucose-induced reactive gliosis of Müller cells and ECM dysregulation.","Shan Y","2023","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2023.112013","37442365",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014365","FRI064 The Role Of GLP-1 Receptor Agonists In The Treatment Of Pituitary And Hypothalamic Tumor Induced Obesity",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10555945",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014366","Effects of exenatide on coronary stent's endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study.","Santos-Pardo I","2023","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-023-02071-4","38066597","PMC10709975","ClinicalTrials.gov:NCT02621489","S001903","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0014367","Fighting Diabetes Mellitus: Pharmacological and Non-pharmacological Approaches.","Wang X","2020","Current pharmaceutical design","narrative_review","article","10.2174/1381612826666200728144200","32723251",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014368","Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases.","Giri S","2025","Neuropeptides","narrative_review","article","10.1016/j.npep.2025.102563","41004910",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014369","Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.","Ishigaki Y","2026","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.70131","41612966","PMC12933229","ClinicalTrials.gov:NCT04184622","S001077","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; research-article; article"],["R0014370","SAT-669 Impact of GLP-1 agonist in patients with heart failure and dyslipidemia affected by Metabolic Dysfunction-Associated Steatotic Liver Disease: A prospective case control study",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12545387",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0014371","Glycemic, renal, and graft outcomes with dulaglutide versus multiple daily insulin therapy after kidney transplantation in type 2 diabetes.","Kim MJ","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112978","41175980",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014372","GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.","Kaneko S","2018","European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes","randomized_trial","article","10.1159/000494768","30537714",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0014373","P-069 SEVERE DIARRHEA FOLLOWING TIRZEPATIDE THERAPY IN A WOMAN WITH CELIAC DISEASE",null,"2026","JCEM case reports","other","article",null,null,"PMC12796667",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014374","Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.","Chuan F","2026","The New England journal of medicine","commentary","article","10.1056/nejmc2600572","41985142",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0014375","Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study.","Seminara G","2026","Minerva endocrinology","other","article","10.23736/s2724-6507.26.04541-0","41801155",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014376","Correction to: \"Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures\".",null,"2026","JCEM case reports","notice","article","10.1210/jcemcr/luaf331","41613300","PMC12851106",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0014377","Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models.","Demkes EJ","2021","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2021.702326","34381364","PMC8352472",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014378","GLP-1 Analog Alleviated Cognitive Dysfunction in Aged Rats Anaesthetized with Sevoflurane.","Zhang Q","2022","BioMed research international","preclinical","article","10.1155/2022/9339824","35615010","PMC9126689",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retracted Publication; research-article; article"],["R0014379","Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.","Hodge RJ","2016","PloS one","randomized_trial","article","10.1371/journal.pone.0153151","27093610","PMC4836696","ClinicalTrials.gov:NCT01725126","S001223","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0014380","LBSUN213 An Investigation Into The Effects Of Dapagliflozin On Ketogenesis In Type 1 Diabetes",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9625043",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0014381","Latest advances and controversies of exercise therapy in the management of type 2 diabetes.","Hao J","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1822069","41993978","PMC13079025",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0014382","Delivery Device Patents on GLP-1 Receptor Agonists.","Alhiary R","2024","JAMA","other","article","10.1001/jama.2024.0919","38315473","PMC10845039",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0014383","Effect of the Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists on Autonomic Function in Subjects With Diabetes: a Systematic Review and Meta-analysis.","Greco C","2021","Research Square","systematic_review","preprint","10.21203/rs.3.rs-244365/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0014384","Glucagon and heart in type 2 diabetes: new perspectives.","Ceriello A","2016","Cardiovascular diabetology","other_trial","article","10.1186/s12933-016-0440-3","27568179","PMC5002329",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0014385","Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats.","Yang Y","2018","Molecular medicine reports","preclinical","article","10.3892/mmr.2018.9180","29916537",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014386","GLP-1 at the Metabolic-Cognitive Interface: Reward, Affect, and Memory.","Gao SX","2026","Comprehensive physiology","narrative_review","article","10.1002/cph4.70129","41876956","PMC13013742",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014387","GLP-1 and Its Derived Peptides Mediate Pain Relief Through Direct TRPV1 Inhibition Without Affecting Thermoregulation.","Park CK","2024","Research square","preclinical","article","10.21203/rs.3.rs-4233732/v1","38798444","PMC11118710",null,null,"pubmed; europepmc","FALSE",null,null,null,"Preprint; Journal Article"],["R0014388","Managing the new wave of weight loss medication in general practice: A qualitative study.","Andreassen P","2024","Clinical obesity","other","article","10.1111/cob.12666","38660941",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014389","Glycemic control and the incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.","Lin C","2020","Endocrine","systematic_review","article","10.1007/s12020-020-02376-4","32533507",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't"],["R0014390","Semaglutide Inhibits Neuronal Apoptosis and Improves Cognitive Function in Mice after Traumatic Brain Injury, Mainly via the Caspase-Dependent Pathway.","Chen X","2026","Neurocritical care","other_trial","article","10.1007/s12028-025-02446-3","41644924",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0014391","[Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].","Camafort-Babkowski M","2013","Medicina clinica","narrative_review","article","10.1016/j.medcli.2012.11.016","23332622",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0014392","GLP-1 Receptor Agonists and Gastrointestinal Adverse Events.","Suissa K","2024","JAMA","commentary","article","10.1001/jama.2024.0046","38470390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Research Support, U.S. Gov't, P.H.S.; Letter; Comment; article"],["R0014393","Met@MPDA rejuvenates BMSC energy metabolism to promote bone regeneration in semaglutide-treated obese periodontitis.","Jiang T","2026","Materials today. Bio","preclinical","article","10.1016/j.mtbio.2026.103231","42182879","PMC13197780",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014394","Effect of GLP-1 Receptor Agonists on Renal Functions and Diabetic Nephropathy in Type 2 Diabetes Mellitus (T2DM) Patients: A Systematic Review and Meta-Analysis.","Mohamed AJ","2024","Cureus","systematic_review","article","10.7759/cureus.71739","39553106","PMC11568967",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0014395","GLP-1 receptor agonist ameliorates experimental lung fibrosis.","Fandiño J","2020","Scientific reports","preclinical","article","10.1038/s41598-020-74912-1","33093510","PMC7581713",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014396","Neuroprotective Role of GLP-1 Analog for Retinal Ganglion Cells via PINK1/Parkin-Mediated Mitophagy in Diabetic Retinopathy.","Zhou HR","2020","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2020.589114","33679385","PMC7928389",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014397","Complete Skin Remission of Lichen Planus With Tirzepatide.","Bhullar H","2026","The Australasian journal of dermatology","case_report","article","10.1111/ajd.70125","41979937",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0014398","Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications.","Dixit AA","2024","JAMA","nonrandomized_study","article","10.1001/jama.2024.5003","38648036","PMC11036309",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0014399","Effects of weight loss from oral semaglutide administration on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a retrospective analysis using propensity score matching.","Aoyama K","2024","Diabetology international","nonrandomized_study","article","10.1007/s13340-024-00744-3","39469553","PMC11512971",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014400","Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5).","Ahmadi SS","2019","Obesity science & practice","randomized_trial","article","10.1002/osp4.324","31019730","PMC6469338",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014401","Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.","Mapelli C","2009","Journal of medicinal chemistry","preclinical","article","10.1021/jm900752a","19702274",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014402","Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.","Yang Z","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70966","42236268","PMC13341338","ChiCTR:ChiCTR2400090908",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0014403","Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review.","Parab P","2023","Cureus","systematic_review","article","10.7759/cureus.45487","37859909","PMC10584355",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0014404","The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model.","Pantalone KM","2020","Diabetes care","nonrandomized_study","article","10.2337/dc19-0968","32527797","PMC7372043",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; other; article"],["R0014405","Comment on \"Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes\".","Huang X","2026","Medicina clinica","nonrandomized_study","article","10.1016/j.medcli.2026.107573","42520650",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0014406","Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX).","Siskind D","2020","Journal of psychiatric research","randomized_trial","article","10.1016/j.jpsychires.2020.02.015","32087425",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0014407","Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. A systematic review and network meta-analysis.","Goetz-Kundera Z","2025","Comprehensive psychiatry","systematic_review","article","10.1016/j.comppsych.2025.152632","40934730",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; review"],["R0014408","Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.","Wenjing H","2020","The Prostate","preclinical","article","10.1002/pros.23951","31967357",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014409","GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction.","Goldney J","2024","Nature reviews. Gastroenterology & hepatology","other","article","10.1038/s41575-024-00977-2","39242961",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014410","Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults.","Hennessy S","2026","JAMA cardiology","nonrandomized_study","article","10.1001/jamacardio.2025.5243","41637062","PMC12874069",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0014411","Retrospective Case-Control Study of Pre-Diagnosis Observational and Prescription Data in Parkinson’s Disease","Doherty P","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.08.11.25333439",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0014412","Capitalizing on the GLP-1 RA revolution for behavioral health through digital companions.","Naegele C","2025","Digital health","commentary","article","10.1177/20552076251406308","41376848","PMC12686351",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0014413","Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling.","Andrés-Rozas M","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","other","article","10.1016/j.biopha.2026.119711","42392029",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014414","The Impact of GLP-1 Agonist Therapy in Tibiotalar and Subtalar Fusion: A Propensity-Matched Analysis",null,"2024","Foot & ankle orthopaedics","nonrandomized_study","article",null,null,"PMC11686775",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0014415","Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.","Bonadonna RC","2017","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.2897","28303626","PMC5600123",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0014416","GLP-1R Agonist Liraglutide Attenuates Inflammatory Reaction and Neuronal Apoptosis and Reduces Early Brain Injury After Subarachnoid Hemorrhage in Rats.","Tu XK","2021","Inflammation","preclinical","article","10.1007/s10753-020-01344-4","32951103",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014417","Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.","Macut D","2018","Current pharmaceutical design","narrative_review","article","10.2174/1381612825666190117100751","30652641",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014418","Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass.","Castelletto V","2026","Biomacromolecules","other","article","10.1021/acs.biomac.5c02669","41917693","PMC13080979",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014419","Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis.","Zhong X","2015","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2015.05.048","26233934",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Research Support, Non-U.S. Gov't; Review; Network Meta-Analysis"],["R0014420","Craniopharyngioma - What's next.","Müller HL","2025","Pituitary","commentary","article","10.1007/s11102-025-01602-4","41205018",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0014421","Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.","Sacre JW","2020","Diabetes care","systematic_review","article","10.2337/dc20-0654","32958618",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0014422","Anti-obesity drugs: comprehensive review and emerging therapies.","Marne P","2026","Endocrine","narrative_review","article","10.1007/s12020-025-04528-w","41627597",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014423","IDegLira Improves Metabolic Control in Patients with Type 2 Diabetes Previously Treated with Premix Insulin.","Bostandzic AD","2022","Medical archives (Sarajevo, Bosnia and Herzegovina)","other","article","10.5455/medarh.2022.76.96-100","35774039","PMC9233474",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014424","Sexual Dysfunction in Diabetes","Hariharan L","2000","MDText.com, Inc., South Dartmouth (MA)","narrative_review","article",null,"25905326",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0014425","Observational studies on the association of outpatient antidiabetic medication use and COVID-19 outcomes: are the findings more relevant to diabetes management than to COVID-19 pathology? A mini-review.","Dimnjaković J","2026","Frontiers in clinical diabetes and healthcare","randomized_trial","article","10.3389/fcdhc.2026.1760695","42058503","PMC13121069",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0014426","FDA Accepts Application for Oral Version of Wegovy.","Anderer S","2025","JAMA","other","article","10.1001/jama.2025.7761","40445594",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014427","Liraglutide regulates the viability of pancreatic α-cells and pancreatic β-cells through cAMP-PKA signal pathway.","Xu X","2018","Life sciences","preclinical","article","10.1016/j.lfs.2017.12.012","29225111",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014428","Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.","Briones M","2006","Expert opinion on pharmacotherapy","preclinical","article","10.1517/14656566.7.8.1055","16722815",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014429","Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio.","Ziebarth J","2026","International journal of biological macromolecules","preclinical","article","10.1016/j.ijbiomac.2026.153507","42442575",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014430","Updates on Anti-Obesity Medications in Children and Adolescents.","Salama M","2025","Children (Basel, Switzerland)","narrative_review","article","10.3390/children12101390","41153573","PMC12564601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014431","Antidiabetic activity of mefloquine via GLP-1 receptor modulation against STZ-NA-induced diabetes in albino wistar rats.","Yadav RK","2018","3 Biotech","preclinical","article","10.1007/s13205-018-1250-y","29744272","PMC5935600",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0014432","Bridging the gap in early cardio-renal risk prevention in type 2 diabetes: evidence, guidelines, and real-world insights from the PRECARE NO LiMITS initiative.","Bucciarelli L","2026","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-026-02798-y","42814157",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0014433","Efficacy of Semaglutide in Reactive Hypoglycemia Related to Dumping Syndrome after Bariatric Surgery.","Fiore A","2024","Endocrine, metabolic & immune disorders drug targets","other","article","10.2174/0118715303318399240715065513","39041260",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014434","Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes.","Kemmotsu R","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag054","41971636","PMC13069485",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014435","Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.","Yabe D","2016","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2016.05.018","27267268",null,"ClinicalTrials.gov:NCT00712673; ClinicalTrials.gov:NCT00713830","S000491; S002188","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0014436","Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors.","Scheen AJ","2022","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2022.101405","36334794",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0014437","Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy.","Alanazi AS","2026","Frontiers in psychiatry","nonrandomized_study","article","10.3389/fpsyt.2026.1893173","42569002","PMC13448544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0014438","Severe Dumping and Persistent Obesity in a Post-Roux-en-Y Gastric Bypass Patient With a Non-discernible Gastric Pouch and Symptomatic Improvement on Tirzepatide: A Case Report.","Frank AL","2026","Cureus","case_report","article","10.7759/cureus.113316","42634712","PMC13500055",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014439","SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study.","Al-Mashhadi ZK","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.861422","36060970","PMC9437938",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014440","Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells.","Fang Z","2020","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms21218404","33182425","PMC7664906",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014441","Weighed Down by Paperwork: Identifying Barriers to Metabolic and Bariatric Surgery Evaluation in the United States.","Barber R","2026","Obesity surgery","other","article","10.1007/s11695-026-08888-8","42667566","PMC13645983",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014442","Marked improvement in severe hidradenitis suppurativa following tirzepatide therapy: a case report.","Alqefari GB","2026","International journal of women's dermatology","nonrandomized_study","article","10.1097/jw9.0000000000000257","42369846","PMC13308910",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014443","SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes.","Davila E","2024","Academic emergency medicine : official journal of the Society for Academic Emergency Medicine","narrative_review","article","10.1111/acem.14895","38494877",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014444","Effects of exendin-4 on colonic motility in rats and its underlying mechanism.","Yan L","2019","Neurogastroenterology and motility","preclinical","article","10.1111/nmo.13482","30303298",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014445","New Indication for Weight Loss Drug Semaglutide.","Aschenbrenner DS","2023","The American journal of nursing","other","article","10.1097/01.naj.0000938724.36679.23","37233137",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014446","Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD.","Villaseñor-Tapia EC","2026","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics18050584","42198278","PMC13210413",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014447","FRI657 Case Series On GLP-1 Receptor Agonist Related Acute Pancreatitis",null,"2023","Journal of the Endocrine Society","case_report","article",null,null,"PMC10554251",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014448","GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes.","Do D","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.13172","38787563","PMC11127113",null,"S002591","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014449","GLP-1 Receptor Agonists and Gastrointestinal Adverse Events-Reply.","Rezaeianzadeh R","2024","JAMA","commentary","article","10.1001/jama.2024.0049","38470387",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0014450","Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study.","Ena J","2020","Revista clinica espanola","other","article","10.1016/j.rce.2019.12.009","32279949",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014451","GIPR signaling modulates PYY-induced hypophagia and malaise in rodents.","Borner T","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2026.102334","41679433","PMC13080594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014452","Refining metabolic-response signals after liraglutide therapy in type 1 diabetes.","Zheng J","2026","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.70417","42400252",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014453","Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review.","Ntentakis DP","2024","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","systematic_review","article","10.1007/s00417-023-06236-5","37728754",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Review"],["R0014454","GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome.","Seppa K","2019","Scientific reports","preclinical","article","10.1038/s41598-019-52295-2","31673100","PMC6823542",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014455","On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice.","Rosol TJ","2013","Toxicologic pathology","preclinical","article","10.1177/0192623312472402","23471186",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014456","Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1β/CXCR7-AMPK/p38-MAPK/IL-6 axis.","Yang Y","2020","Acta diabetologica","preclinical","article","10.1007/s00592-020-01551-3","32556532",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014457","Exenatide enhances INS-1 rat pancreatic β‑cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein.","Quan H","2014","Molecular medicine reports","preclinical","article","10.3892/mmr.2014.2538","25190495",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014458","Correction to \"Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3\".",null,"2026","Diabetes, obesity & metabolism","notice","article","10.1111/dom.70591","41713957","PMC13652206",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0014459","Chronic Kidney Disease, Nutrition, and the Brain: How to Maintain Brain Health Through Nutrition in Chronic Kidney Disease.","Levassort H","2026","Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation","narrative_review","article","10.1053/j.jrn.2026.01.005","41644021",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014460","Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study).","C A","2026","Metabolism open","randomized_trial","article","10.1016/j.metop.2026.100489","42598626","PMC13472031","CTRI:CTRI/2025/06/089290",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014461","Tirzepatide-induced body composition changes: Implications from the SURPASS-3 MRI substudy.","Yen IW","2026","Journal of diabetes investigation","commentary","article","10.1111/jdi.70232","41482821","PMC12950923",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0014462","Exendin-4 partly ameliorates - hyperglycemia-mediated tissue damage in lungs of streptozotocin-induced diabetic mice.","Oztay F","2018","Peptides","preclinical","article","10.1016/j.peptides.2017.12.007","29225158",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014463","Effect of ketogenic diet plus dulaglutide on glucose and lipid metabolism in diabetes mellitus.","Gao R","2025","Pakistan journal of pharmaceutical sciences","randomized_trial","article","10.36721/pjps.2025.38.6.reg.13419.1","41241797",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0014464","Liraglutide ameliorates diabetic lung injury and muscle damage via modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways.","Mohammed MA","2026","Molecular biology reports","preclinical","article","10.1007/s11033-026-11978-6","42189284",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014465","Tirzepatide Heralds the Hope of Chronic Disease Eradication.","Tchang BG","2026","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgaf444","40754464",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0014466","Identifying high-risk combinations of metformin during COVID-19.","Dimnjaković J","2026","PloS one","nonrandomized_study","article","10.1371/journal.pone.0343979","41779712","PMC12959685",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014467","High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination.","Chua MWJ","2021","Clinics and practice","case_report","article","10.3390/clinpract12010001","35076486","PMC8788265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014468","Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options.","Raccah D","2017","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2016.11.007","28169086",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0014469","Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.","Bihan H","2016","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2016.08.011","27622682",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0014470","Hypothalamic anorexigenic signaling pathways (leptin, amylin, and proopiomelanocortin) are semaglutide (GLP-1 analog) targets in obesity control in mice.","Martins FF","2023","Life sciences","preclinical","article","10.1016/j.lfs.2022.121268","36493878",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014471","The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.","Billings LK","2021","Journal of diabetes science and technology","randomized_trial","article","10.1177/1932296820906888","32107930","PMC8120051","ClinicalTrials.gov:NCT02420262","S001760","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0014472","Update Psychopharmacotherapy.","Laux G","2017","Medizinische Monatsschrift fur Pharmazeuten","narrative_review","article",null,"29952523",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014473","Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists.","Yang Y","2025","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2025.118215","40311601","PMC13532390",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014474","New Advances in Cardiovascular Drugs: In Memory of Professor Akira Endo","Bharaj IS","2025","Preprints.org","other","preprint","10.20944/preprints202507.0009.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014475","Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment.","Lok KH","2022","Pharmacological research","preclinical","article","10.1016/j.phrs.2022.106237","35487405","PMC7614293",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't; research-article"],["R0014476","[Gastrointestinal metabolic surgery improves salt-sensitive hypertension via GLP-1-mediated inhibition of the RAS/NHE3 axis].","Tong D","2026","Zhonghua xin xue guan bing za zhi","preclinical","article","10.3760/cma.j.cn112148-20260310-00156","42595520",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0014477","Advances in proteomics research related to semaglutide: evidence from humans and animals.","Jia Q","2026","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-026-02989-y","42489869",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0014478","The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.","Larsen AT","2021","BMC endocrine disorders","preclinical","article","10.1186/s12902-020-00678-2","33413317","PMC7791885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; other; preprint; article"],["R0014479","A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes.","Fralick M","2021","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.237","34277962","PMC8279599",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014480","Case study on adverse reactions of dulaglutide: literature review.","Zhou Y","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1736083","41693775","PMC12901407",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; data-paper; article"],["R0014481","Methylation status of vault RNA 2-1 promoter is a predictor of glycemic response to glucagon-like peptide-1 analog therapy in type 2 diabetes mellitus.","Lin CH","2021","BMJ open diabetes research & care","other","article","10.1136/bmjdrc-2020-001416","33674278","PMC7938984",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014482","In-silico study of the interactions between acylated glucagon like-peptide-1 analogues and the native receptor.","Frimann TM","2023","Journal of biomolecular structure & dynamics","other","article","10.1080/07391102.2022.2078409","35612899",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014483","Size-exclusion LC-UV/HRMS based method for the analysis of aggregates in synthetic GLP-1 analog liraglutide and evaluation of excipient impact on aggregation.","Badgujar D","2024","Biomedical chromatography : BMC","other","article","10.1002/bmc.5983","39113387",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014484","Insights from changes in NDEV biomarkers of metabolism: effects of PPARγ and GLP1 receptor agonists on brain metabolism.","Evers A","2026","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/clinem/dgag176","41992726","PMC13577777",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0014485","Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents.","van den Brink W","2017","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2017.02.010","28213092",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014486","Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes.","Stupalkowska W","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70757","41969188","PMC13243962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0014487","GLP-1 Receptor Agonists, the Holy Grail Preventing Atrial Fibrillation in Patients With T2D?","Stoll L","2023","JACC. Basic to translational science","commentary","article","10.1016/j.jacbts.2023.03.022","37719426","PMC10504427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0014488","Comparative thromboembolic risk and polypharmacy-related drug-drug interaction signals among antidiabetic medications: a large-scale FAERS pharmacovigilance study.","Bafail D","2026","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2026.1826021","42292795","PMC13253616",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014489","Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [68Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method.","Migliari S","2022","Molecules (Basel, Switzerland)","other","article","10.3390/molecules27020543","35056858","PMC8778103",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Validation Study; research-article; article"],["R0014490","Anti-Obesity Drugs: The Rising Significance of GLP-1Agonist, Tirzepatide.","Agrawal PK","2026","Journal of mid-life health","commentary","article","10.4103/jmh.jmh_259_25","42583331","PMC13460700",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0014491","Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.","Mulvagh SL","2026","JAMA cardiology","randomized_trial","article","10.1001/jamacardio.2026.0245","41879791","PMC13019341","ClinicalTrials.gov:NCT03914326","S002179","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0014492","Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study.","Petroni ML","2019","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.82","31592154","PMC6775466",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014493","Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?","Grøndahl MF","2017","Current diabetes reports","narrative_review","article","10.1007/s11892-017-0967-z","29080075",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014494","Semaglutide Attenuates Anxious And Depressive-Like Behaviors and Reverses The Cognitive Impairment in a Type 2 Diabetes Mellitus Via The Microbiota-Gut-Brain Axis","de Paiva IHR","2023","Research Square","preclinical","preprint","10.21203/rs.3.rs-3249869/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014495","Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.","Horn DB","2026","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2025.6112","41284285","PMC12645400","ClinicalTrials.gov:NCT04660643","S000242","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014496","A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.","Scott DA","2013","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12007","22958381",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; article"],["R0014497","Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide.","Schmickl CN","2026","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","notice","article","10.1007/s44470-026-00074-y","42151574","PMC13184012",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0014498","GLP-1 agonists may raise risk of pulmonary aspiration during surgery, MHRA warns.","Mahase E","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r205","39884703",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014499","Structure-Activity Relationships and Pharmacokinetics of 111In-Labeled Glucagon-like Peptide-1 Receptor-Targeting Exendin-4 Derivatives Conjugated with Albumin Binder Moieties.","Iikuni S","2022","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.2c00201","35757958",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014500","Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.","Snaith JR","2026","Diabetes care","randomized_trial","article","10.2337/dc25-2379","41264593","PMC12719702",null,"S001048","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; other; article"],["R0014501","Semaglutide 2.4 mg Cardiometabolic Long-Term Effects in Patients With Obesity or Overweight in a Real-World Setting: A Retrospective Cohort Study in the United States (SMILE).","Ruseva A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70746","42046181","PMC13243985",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014502","Saxagliptin Combined with Liraglutide vs. Saxagliptin Alone on Microinflammation and Adipokines in Obese T2DM Patients with Poor Metformin Response.","Zhang L","2026","Journal of visualized experiments : JoVE","nonrandomized_study","article","10.3791/70462","42507607",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Video-Audio Media; Research Support, Non-U.S. Gov't; article"],["R0014503","Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?","Gentile S","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-016-0187-6","27456528","PMC5014793",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014504","[Metabolic adverse drug reactions related to psychotropic drugs].","Gahr M","2025","Fortschritte der Neurologie-Psychiatrie","narrative_review","article","10.1055/a-2405-5087","39313203",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; English Abstract"],["R0014505","Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.","Nordanstig J","2026","European heart journal","randomized_trial","article","10.1093/eurheartj/ehag129","41780559","PMC13318418","ClinicalTrials.gov:NCT04560998","S001363","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; brief-report; article"],["R0014506","Perivascular adipokine signaling in abdominal aortic aneurysm: cardiometabolic drivers of vascular remodeling and translational opportunities.","Zhang X","2026","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-026-03254-5","42288888","PMC13491601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0014507","Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.","Seino Y","2018","Journal of diabetes investigation","other_trial","article","10.1111/jdi.12646","28195447","PMC5754539",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; research-article; article"],["R0014508","New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.","Stratina E","2024","Diagnostics (Basel, Switzerland)","nonrandomized_study","article","10.3390/diagnostics14141475","39061612","PMC11275343",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014509","Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.","Tang W","2016","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.2713","26381272",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0014510","Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.","Arakawa M","2010","Diabetes","preclinical","article","10.2337/db09-1694","20068138","PMC2844811",null,"S000371; S002653","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014511","Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.","Chen SC","2026","American journal of therapeutics","nonrandomized_study","article","10.1097/mjt.0000000000002132","41992281","PMC13549456",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0014512","Dulaglutide Effect on Proteins Associated With CKD Progression.","McFarlin BE","2026","Kidney international reports","other_trial","article","10.1016/j.ekir.2026.103789","41732754","PMC12925400",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014513","Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis.","Yeong T","2022","ESC heart failure","systematic_review","article","10.1002/ehf2.13822","35092176","PMC8934935",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; article"],["R0014514","Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients.","Morieri ML","2020","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgaa204","32301492",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0014515","Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.","Kumar A","2014","Expert opinion on biological therapy","nonrandomized_study","article","10.1517/14712598.2014.904851","24702171",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0014516","GLP-1 Receptor Activation Abrogates β-Cell Dysfunction by PKA Cα-Mediated Degradation of Thioredoxin Interacting Protein.","He S","2019","Frontiers in pharmacology","other","article","10.3389/fphar.2019.01230","31708773","PMC6824261",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014517","GLP-1 receptor agonists in clinical practice.","Pérez A","2024","Medicina clinica","commentary","article","10.1016/j.medcli.2024.02.018","38688736",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; article"],["R0014518","Computational modelling of dynamic cAMP responses to GPCR agonists for exploration of GLP-1R ligand effects in pancreatic β-cells and neurons.","Bridge L","2024","Cellular signalling","other","article","10.1016/j.cellsig.2024.111153","38556030",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014519","Investigation of Thyroid Disorders in Women with Diabetes in the United Arab Emirates: A Retrospective Cross-Sectional Study.","Mussa BM","2025","Women's health reports (New Rochelle, N.Y.)","nonrandomized_study","article","10.1089/whr.2024.0136","40130034","PMC11931100",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014520","Investigating the collective advantages of sodium-glucose cotransporter-2 inhibitors and GLP-1 analogs in addressing metabolic health issues linked to obese type 2 diabetes mellitus and related comorbidities.","Al-Rashid S","2025","Indian journal of pharmacology","commentary","article","10.4103/ijp.ijp_559_24","40509766","PMC12236412",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0014521","Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis.","Marzioni M","2009","Gut","preclinical","article","10.1136/gut.2008.150870","18829977","PMC2695839",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0014522","Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice.","Martins FF","2022","Cell biochemistry and function","preclinical","article","10.1002/cbf.3751","36169111",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014523","Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes.","Nagae K","2018","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2018.10.013","30367901",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014524","Tolerance develops toward GLP-1 receptor agonists' glucose-lowering effect in mice.","Sedman T","2020","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2020.173443","32750365",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014525","Diagnosis and management of diastolic dysfunction in arterial hypertension.","Blanch P","2025","Hipertension y riesgo vascular","narrative_review","article","10.1016/j.hipert.2025.06.002","40713386",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014526","The role of GLP-1/GIP receptor agonists in Alzheimer's disease.","Yu CJ","2020","Advances in clinical and experimental medicine : official organ Wroclaw Medical University","preclinical","article","10.17219/acem/121007","32614526",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014527","Perioperative and anaesthetic considerations in rural patients on GLP-1 receptor agonists: An update.","Chan LKM","2024","The Australian journal of rural health","commentary","article","10.1111/ajr.13096","38421903",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014528","Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records.","Powell WJB","2026","Clinical obesity","nonrandomized_study","article","10.1111/cob.70076","41830068",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; Comparative Study; article"],["R0014529","Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program.","Morillas C","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-019-0671-x","31359366","PMC6778580",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014530","A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design.","Davidy T","2023","Mechanisms of ageing and development","protocol","article","10.1016/j.mad.2023.111825","37245533","PMC12120971",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Retracted Publication; Clinical Trial Protocol; research-article; article"],["R0014531","Tirzepatide and Cardioprotection in Type 2 Diabetes: Insights From SURPASS-CVOT.","Cosentino N","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70766","41983524",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014532","Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts.","Durak A","2023","Journal of physiology and biochemistry","preclinical","article","10.1007/s13105-022-00939-9","36515811",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014533","Mitochondrial dynamics and metabolic regulation in cellular inflammation: From mechanisms to precision therapeutics.","Park WH","2026","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2026.109086","42463065",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014534","Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant.","Yap MKK","2019","Basic & clinical pharmacology & toxicology","narrative_review","article","10.1111/bcpt.13169","30417596",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014535","Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.","Rubino DM","2022","JAMA","randomized_trial","article","10.1001/jama.2021.23619","35015037","PMC8753508","ClinicalTrials.gov:NCT04074161","S001331; S001600; S001692","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0014536","Editorial commentary: Understanding the cardiovascular benefits of glucagon-like peptide-1 (GLP-1) receptor agonists.","Raven LM","2024","Trends in cardiovascular medicine","commentary","article","10.1016/j.tcm.2024.03.007","38552887",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0014537","Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in Obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF)","Win KZ","2023","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-2520819/v1",null,null,"ClinicalTrials.gov:NCT05221229","S001800","europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0014538","A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.","Henry RR","2013","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2013.03.011","23578605",null,"ClinicalTrials.gov:NCT01798264","S000736","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0014539","Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.","Ganeshalingam AA","2026","Diabetes care","randomized_trial","article","10.2337/dc25-2041","41778920","PMC13094869",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0014540","Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.","Yuan X","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14803","35762489","PMC9795930","ClinicalTrials.gov:NCT03798080","S002110","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; research-article; article"],["R0014541","P086 An unusual case of declining mobility following initiation of tirzepatide therapy",null,"2025","Rheumatology advances in practice","other","article",null,null,"PMC12585188",null,null,"europepmc","FALSE",null,null,null,"Abstract"],["R0014542","Survodutide: a novel peptide for treatment of obesity and metabolic diseases.","Vinton TY","2025","Proceedings (Baylor University. Medical Center)","commentary","article","10.1080/08998280.2025.2498840","40557206","PMC12184103",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; editorial"],["R0014543","Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus.","Grannes H","2024","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-024-02237-8","38685051","PMC11059692",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comparative Study; research-article; other; article"],["R0014544","Liraglutide alleviated alpha-pyrrolidinovalerophenone (α-PVP) induced cognitive deficits in rats by modifying brain mitochondrial impairment.","Noruzi M","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.176776","38936451",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014545","Beyond weight: a stigma-free, integrated approach to obesity in patients affected by cancer.","Watanabe M","2026","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-026-10074-1","42611363",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014546","Diabetic Status, Advanced Age, and Hispanic Ethnicity Predict Poorer Weight Loss in Patients With Obesity Receiving Semaglutide.","Cornet NC","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2026.05.029","42248359",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014547","Anti-obesity medication use sparks effort-based sanctions and social penalties.","Tissot TT","2026","Scientific reports","other","article","10.1038/s41598-026-42166-y","42014743","PMC13100314",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014548","The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes.","Hædersdal S","2018","Mayo Clinic proceedings","narrative_review","article","10.1016/j.mayocp.2017.12.003","29307553",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014549","SnapShot: Brain-targeting anti-obesity medications.","Petersen J","2025","Cell metabolism","other","article","10.1016/j.cmet.2025.02.006","40043693",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014550","Beyond glycaemic control: reduced pneumonia and sepsis risk with GLP-1 RAs and SGLT2 inhibitors in patients with type 2 diabetes.","Rezaeianzadeh R","2024","Thorax","commentary","article","10.1136/thorax-2024-222540","39645258",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0014551","Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?","Leehey DJ","2020","Kidney360","randomized_trial","article","10.34067/kid.0001252019","35372914","PMC8809273",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0014552","Preoperative GLP-1 agonist use is not associated with perioperative aspiration or pneumonia: an observational study using US national data.","Poeran J","2025","British journal of anaesthesia","commentary","article","10.1016/j.bja.2025.01.038","40089398",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014553","GLP-1 RAs in the heart failure field: Kill many birds with one stone.","Christina A","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2024.132739","39557088",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014554","Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons.","Adams JM","2018","Diabetes","preclinical","article","10.2337/db17-1385","29776968","PMC6054439",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014555","Improved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: a promising new addition to preoperative optimization.","Seddio AE","2025","JSES international","nonrandomized_study","article","10.1016/j.jseint.2024.10.006","40486798","PMC12144951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014556","Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.","Qin W","2024","Endocrine","systematic_review","article","10.1007/s12020-024-03896-z","38850440","PMC11445313",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0014557","Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.","Kramer CM","2025","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2024.11.001","39566869",null,"ClinicalTrials.gov:NCT04847557","S000047; S001989","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0014558","Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.","Bonora BM","2024","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-024-02309-2","38369592","PMC11142994",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0014559","Effect of Glucagon-like Peptide-1 Receptor Agonism on Aortic Valve Stenosis Risk: A Mendelian Randomization Analysis.","Karakasis P","2024","Journal of clinical medicine","other","article","10.3390/jcm13216411","39518550","PMC11546526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014560","Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.","Grunberger G","2013","Journal of diabetes","narrative_review","article","10.1111/1753-0407.12046","23489968",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014561","Liraglutide attenuates aluminum chloride-induced Alzheimer's disease in rats by modulating the oxLDL/LPA/LPAR1 pathway.","Abo El-Magd NF","2026","Communications biology","preclinical","article","10.1038/s42003-026-09531-z","41673096","PMC12914051",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014562","[Exendin-4 promotes autophagy to relieve lipid deposition in a NAFLD cell model by activating AKT/mTOR signaling pathway].","Lin C","2021","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article","10.12122/j.issn.1673-4254.2021.07.16","34308859","PMC8329682",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014563","Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors.","Singh AK","2022","World journal of diabetes","commentary","article","10.4239/wjd.v13.i6.466","35800411","PMC9210541",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; letter"],["R0014564","Paradigm shift in obesity treatment: an extensive review of current pipeline agents.","Çetin E","2025","Turkish journal of medical sciences","other_trial","article","10.55730/1300-0144.5938","40104296","PMC11913498",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0014565","Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.","Pratley RE","2018","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(18)30024-x","29397376",null,"ClinicalTrials.gov:NCT02648204","S000372; S000485; S001352; S001739","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; article"],["R0014566","GLP-1 Agonists May Reduce Risk of Alcohol Use Disorder Hospitalizations.","Anderer S","2025","JAMA","nonrandomized_study","article","10.1001/jama.2024.25503","39705025",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014567","Does X mark the spot? A case series of discrepant preoperative insulinoma localization.","Goh S","2025","Endocrinology, diabetes & metabolism case reports","case_report","article","10.1530/edm-25-0041","40980831","PMC12455282",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0014568","Letter: Non-Invasive Tests After Semaglutide in MASH as Disease-Activity Readouts Rather Than Response Biomarkers.","Mao G","2026","Alimentary pharmacology & therapeutics","commentary","article","10.1111/apt.70837","42402644",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014569","GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1.","Xu F","2016","Diabetologia","preclinical","article","10.1007/s00125-016-3896-5","26924394",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014570","Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V.","Ferrannini G","2020","Diabetes care","nonrandomized_study","article","10.2337/dc19-2165","32079627",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0014571","Weight Drop-Foot Drop: A Case Series of Peroneal Nerve Palsy from Leg Crossing after Tirzepatide-Mediated Weight Loss.","Tanyous AI","2026","Case reports in neurology","case_report","article","10.1159/000552890","42524366","PMC13412237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014572","Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.","Kopp KO","2022","Pharmacological research","narrative_review","article","10.1016/j.phrs.2022.106550","36372278","PMC9712272",null,"S001115","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, N.I.H., Intramural; research-article; article"],["R0014573","GLP-1 receptor agonists for hidradenitis suppurativa: Navigating benefits, risks, and ethical considerations.","Gu Y","2024","International journal of dermatology","commentary","article","10.1111/ijd.17108","38415751",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014574","Molecular Mechanisms and Antidiabetic Effects of Mango (Mangifera indica) Leaf Extract as a GLP-1 Analogue in Type 2 Diabetic Rats.","Jariyapongskul A","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms262412149","41465578","PMC12734274",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014575","Incretin Signaling Neighborhoods and Adverse Drug Reactions.","Wright SC","2026","Annual review of pharmacology and toxicology","narrative_review","article","10.1146/annurev-pharmtox-062124-015046","40929510",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0014576","Evaluating Semaglutide's Protection in H/R - Injured AC16 Cardiomyocytes: Oxidative Stress, Inflammation, Apoptosis, and Autophagy Insights.","Li L","2026","International journal of general medicine","other","article","10.2147/ijgm.s564902","41737537","PMC12927803",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014577","Cardiorenometabolic medicine as a new subspecialty in the light of novel pharmaceuticals with dual or triple benefits.","Medenica S","2026","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2026.2648248","41860010",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014578","Incretin hormones, obesity and gut microbiota.","Angelini G","2024","Peptides","narrative_review","article","10.1016/j.peptides.2024.171216","38636809",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014579","Type 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies.","Corrao S","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-025-01761-4","40512404","PMC12317941",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0014580","Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes?","Murphy KG","2007","Proceedings of the National Academy of Sciences of the United States of America","commentary","article","10.1073/pnas.0610679104","17213306","PMC1783373",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Journal Article; article-commentary; article"],["R0014581","Surgical Implications of GLP-1 Agonists for Weight Loss: Are These Patients Suitable for Elective Surgery?","Oleru OO","2024","Plastic and reconstructive surgery","other","article","10.1097/prs.0000000000011313","38262614","PMC11263498",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0014582","Pharmacotherapy of Weight-loss and Obesity with a Focus on GLP 1-Receptor Agonists.","Myerson M","2024","Journal of clinical pharmacology","narrative_review","article","10.1002/jcph.2487","38924121",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0014583","Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.","Higashijima Y","2015","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00590.2014","25656369",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014584","Predicting Weight Outcomes From Obesity Medications in a Paediatric Population.","Mottalib MM","2026","Pediatric obesity","nonrandomized_study","article","10.1111/ijpo.70089","41679912","PMC13450681",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014585","Oral self-nanoemulsifying formulation of GLP-1 agonist peptide exendin-4: development, characterization and permeability assesment on Caco-2 cell monolayer.","Tekeli MC","2021","Amino acids","preclinical","article","10.1007/s00726-020-02926-0","33398527",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014586","Hyperpolarized 13C and 31P MRS detects differences in cardiac energetics, metabolism, and function in obesity, and responses following treatment.","Lewis AJM","2024","NMR in biomedicine","preclinical","article","10.1002/nbm.5206","38994722","PMC11571269",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014587","Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus.","Brice R","2015","Drugs in context","nonrandomized_study","article","10.7573/dic.212269","25657811","PMC4316811",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014588","A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.","Strathe A","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15211","37424165",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014589","GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?","Scheen AJ","2013","Annales d'endocrinologie","narrative_review","article","10.1016/j.ando.2012.06.002","23570814",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014590","Systematic review and synthesis without meta-analysis (SWiM) reveals lack of clinical studies and weak preclinical evidence for interaction between glucose regulating drugs and environmental contaminant exposure.","Bennett KA","2026","Biochemical pharmacology","systematic_review","article","10.1016/j.bcp.2025.117575","41330518",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0014591","Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study.","Matsunuma S","2026","International journal of clinical pharmacology and therapeutics","nonrandomized_study","article","10.5414/cp204899","41582648",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0014592","Question: What Is the Current State of Evidence Regarding Any Mood-Improving Properties of GLP-1 Receptor Agonists, and Are Psychiatrists Prescribing Them?","McElroy SL","2024","Journal of clinical psychopharmacology","commentary","article","10.1097/jcp.0000000000001867","38639431",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0014593","Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.","Khanna A","2026","Indian journal of pharmacology","other_trial","article","10.4103/ijp.ijp_686_25","42060800","PMC13258287",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0014594","Systematic review of incretin therapy during peri-operative and intensive care.","Hulst AH","2018","Critical care (London, England)","systematic_review","article","10.1186/s13054-018-2197-4","30428906","PMC6236901","PROSPERO:CRD42017071926",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; other; review"],["R0014595","SUN-682 Type Two Diabetes Patient in Remission After Twelve Years of Diagnosis","Shaghouli A","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.782",null,"PMC7208939",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0014596","Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.","Zeng Q","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1214334","37908750","PMC10613702","PROSPERO:CRD42023412400",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; Journal Article; systematic-review; review"],["R0014597","The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.","Wheeler DC","2020","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfaa234","32862232","PMC7538235","ClinicalTrials.gov:NCT03036150",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014598","Response to: Impact of GLP-1RA on Adverse Liver Outcomes Among Patients With Alcohol-Associated Liver Disease and Type 2 Diabetes.","Rashid Z","2025","Liver international : official journal of the International Association for the Study of the Liver","commentary","article","10.1111/liv.16161","39530487",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014599","[Modern treatment of type 2 diabetes: 3 medications and 3 targets].","Wiesli P","2026","Praxis","narrative_review","article","10.23785/praxis.2026.02.004","41784517",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0014600","Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy.","Naseralallah L","2023","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2023.2181074","36820516",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Review; Journal Article; article; other"],["R0014601","GLP-1 analogs and childhood obesity.","O'Leary K","2024","Nature medicine","commentary","article","10.1038/d41591-024-00071-9","39349680",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0014602","Antidiabetic Effect of Abextide, a Long-Acting Exendin-4 Analogue in Cynomolgus Monkeys.","Niu G","2019","Advanced healthcare materials","preclinical","article","10.1002/adhm.201800686","30300471",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; article"],["R0014603","Real-World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study.","Tran TH","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71355","42736030",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0014604","Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study.","Jin CL","2026","BMC cardiovascular disorders","nonrandomized_study","article","10.1186/s12872-026-05958-8","42210124","PMC13418757",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0014605","Atherosclerotic Cardiovascular Disease in CKD: Contemporary Insights into Pathogenesis, Diagnosis, and Management.","Correa S","2026","Clinical journal of the American Society of Nephrology : CJASN","other","article","10.2215/cjn.0000001199","42735033",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014606","Tirzepatide and Autonomic Dysfunction: Insights From Postural Orthostatic Tachycardia Syndrome.","Zhan ZQ","2025","JACC. Case reports","commentary","article","10.1016/j.jaccas.2025.106326","41945548","PMC12802868",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014607","The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East.","Albukhari AF","2026","Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit","commentary","article","10.26719/2026.32.6.394","42487380",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014608","Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice.","Zhang H","2022","Biotechnology letters","preclinical","article","10.1007/s10529-022-03288-1","36006576",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014609","The other side of the incretin story: GIPR signaling in energy homeostasis.","Nakandakari SCBR","2025","Cell metabolism","narrative_review","article","10.1016/j.cmet.2024.12.003","39778517",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014610","Role of Liraglutide Use in Patients With Heart Failure.","Allam S","2023","Cureus","narrative_review","article","10.7759/cureus.50065","38186489","PMC10769535",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014611","SGK2 Promotes NEDD4L-Mediated ACSL4 Ubiquitination to Inhibit Ferroptosis and Alleviate Diabetic Kidney Disease.","Zhang F","2026","Antioxidants & redox signaling","preclinical","article","10.1177/15230864261487908","42730475",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014612","Assessment of basal insulin adherence using 2 methodologies among Texas Medicaid enrollees with type 2 diabetes.","Zhang H","2020","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2020.26.11.1434","33119450","PMC10390939",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; research-article; article"],["R0014613","Semaglutide ameliorates coronary microembolization-induced injury by suppressing apoptosis and inflammation via the HMGB1/RAGE/NF-κB p65 pathway.","Yang HF","2026","Journal of geriatric cardiology : JGC","preclinical","article","10.26599/1671-5411.2026.02.001","41835369","PMC12983068",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014614","Clarifying methodological approaches in the assessment of GLP-1 RAs and gastrointestinal cancer risk.","Figlioli G","2024","Pharmacological research","commentary","article","10.1016/j.phrs.2024.107482","39490913",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014615","Facial nodules following filler injections after initiating compounded tirzepatide use.","Luke M","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.03.042","42088720","PMC13137039",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014616","Tirzepatide during Ramadan in people with obesity without diabetes: A critical knowledge gap.","Monjur MR","2026","British journal of clinical pharmacology","commentary","article","10.1002/bcp.70545","41902340",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014617","How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access.","Levi J","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70241","42437874","PMC13422654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0014618","Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open-Label Pilot Study.","Hvistendahl M","2018","JPEN. Journal of parenteral and enteral nutrition","randomized_trial","article","10.1177/0148607116672265","27875281",null,"EudraCT:2013-005499-16","S001698; S001709","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0014619","Assessment of Carbon Emission Impact of Semaglutide in Patients With Type 2 Diabetes in the United Kingdom Using an Innovative Modeling Approach.","Lund N","2026","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2026.03.2249","42061677",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014620","Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic.","Williams DM","2018","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2018.06.029","30006093",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Multicenter Study; article"],["R0014621","Drugs for Treating Obesity.","Ryan DH","2022","Handbook of experimental pharmacology","other_trial","article","10.1007/164_2021_560","34783910",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article"],["R0014622","A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026.","Abbasi J","2026","JAMA","other","article","10.1001/jama.2026.7591","42313535",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014623","Sustained Glycaemic Control and Preserved Beta-Cell Function in Newly Diagnosed Type 1 Diabetes Treated With Semaglutide.","Carollo M","2026","Diabetes/metabolism research and reviews","commentary","article","10.1002/dmrr.70191","42272327",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014624","2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes : Statement of endorsement by the NVVC.","Martens FMAC","2025","Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation","narrative_review","article","10.1007/s12471-025-01967-y","40634662","PMC12274173",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014625","Acute Deep Vein Thrombosis in the Setting of Tirzepatide Use: A Case Highlighting Emerging Concerns.","Sonavane K","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf248","41179274","PMC12574538",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014626","Functional maturation and longitudinal imaging of intraportal neonatal porcine islet grafts in genetically diabetic pigs.","Pilz J","2024","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","preclinical","article","10.1016/j.ajt.2024.02.026","38432328",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014627","The Cautious Promise of GLP-1 Receptor Agonists.","Dauterive RS","2024","Ochsner journal","other","article","10.31486/toj.24.5045","39280876","PMC11398621",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014628","From prescription to trend: the misuse of Ozempic in the age of social media.","Muhammad HE","2025","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000003801","41181496","PMC12577951",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014629","Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.","Patel V","2013","Journal of diabetes","preclinical","article","10.1111/j.1753-0407.2012.00227.x","22830490",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014630","Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.","Reitzel SB","2023","Current medical research and opinion","other_trial","article","10.1080/03007995.2023.2231275","37415503",null,"ClinicalTrials.gov:NCT03987919","S000095","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0014631","A systematic review of semaglutide-associated kidney injury case reports.","Xiu X","2026","Frontiers in medicine","systematic_review","article","10.3389/fmed.2026.1793349","42305970","PMC13265316",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0014632","Amplifying the antidiabetic actions of glucagon-like peptide-1: Potential benefits of new adjunct therapies.","Tanday N","2021","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.14699","34562330",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014633","Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.","Han J","2018","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2018.07.072","30096651",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014634","Adipose-Joint Crosstalk in Obesity-Induced Osteoarthritis: Mechanisms, Biomarkers, and Translational Therapeutic Opportunities.","Hang W","2026","Current rheumatology reports","narrative_review","article","10.1007/s11926-026-01229-9","42570127","PMC13452861",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014635","A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance.","Ludwig MQ","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.01.13.632726","39868309","PMC11760743",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0014636","Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE - primary prevention study.","Smolderen KG","2026","American journal of preventive cardiology","nonrandomized_study","article","10.1016/j.ajpc.2026.101521","42291047","PMC13261233",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014637","Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.","Deacon CF","2007","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2007.00765.x","17877544",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014638","EX4 stabilizes and activates Nrf2 via PKCδ, contributing to the prevention of oxidative stress-induced pancreatic beta cell damage.","Kim MH","2017","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2016.12.005","27939242",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014639","Long-Lasting Exendin-4-Coated Gold Nanoparticles: Synthesis and In Vivo Evaluation of Hypoglycemic Activity.","Amatya R","2024","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph17111475","39598387","PMC11597054",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014640","Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016.","Zhao JZ","2021","Kidney medicine","nonrandomized_study","article","10.1016/j.xkme.2020.09.016","33851113","PMC8039422",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014641","Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials.","Geiser JS","2016","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-015-0338-3","26507721",null,null,"S001958","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; article"],["R0014642","Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.","Yokote K","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70315","41290555","PMC12803658","ClinicalTrials.gov:NCT04844918","S001216","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0014643","Stem Cell Origin of Cancer: Biological Principles and Clinical Strategies for Chemoprevention and Maintenance Therapy in Cancer Care.","Medik Y","2025","Cancers","other","article","10.3390/cancers17162621","40867250","PMC12385061",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0014644","[Current State of Pharmacotherapy in Obesity].","Kim WJ","2024","The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi","narrative_review","article","10.4166/kjg.2024.016","38522852","PMC12285376",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Review; review-article; article"],["R0014645","Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway.","Albokhadaim I","2026","Toxicology research","preclinical","article","10.1093/toxres/tfag010","41756101","PMC12934394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014646","SAT-635 Results of a Preclinical Pilot Study Evaluating 24-Hour Subcutaneous Infusion of the GLP-1 Analogue Liraglutide Delivered via the H-Patch Wearable Device","Barnes J","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.1739",null,"PMC7208354",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0014647","Testicular cytoprotective effect of glucagon like peptide-1 in diabetic rats involves inhibition of apoptosis, endoplasmic reticulum stress and activation of autophagy.","Abdel-Hakeem EA","2023","General physiology and biophysics","preclinical","article","10.4149/gpb_2022064","36896943",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014648","Heart failure with preserved ejection fraction beyond the heart: exploring the heart-liver-pancreas axis.","Tun HN","2026","ESC heart failure","narrative_review","article","10.1093/eschf/xvag040","41711215","PMC13108270",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014649","Interaction of serotonin/GLP-1 circuitry in a dual preclinical model for psychiatric disorders and metabolic dysfunction.","Kolling LJ","2024","Psychiatry research","preclinical","article","10.1016/j.psychres.2024.115951","38735240","PMC11267813",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article"],["R0014650","A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors.","Merkel R","2021","Neuroscience and biobehavioral reviews","preclinical","article","10.1016/j.neubiorev.2021.10.026","34715149","PMC8642311",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review; research-article; article"],["R0014651","Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.","Tuttle KR","2017","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12816","27766728","PMC5347883",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Journal Article; brief-report; article"],["R0014652","Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide.","Schmickl CN","2026","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","other","article","10.1007/s44470-025-00024-0","41731227","PMC12994968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014653","Symmetrical drug-related intertriginous and flexural exanthema associated with tirzepatide.","Goodman W","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.03.033","42064416","PMC13127263",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014654","Neuroprotective Mechanisms of Glucagon-like Peptide-1-based Therapies in Ischaemic Stroke: A Systematic Review based on Pre-Clinical Studies.","Marlet IR","2018","Basic & clinical pharmacology & toxicology","systematic_review","article","10.1111/bcpt.12974","29411931",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0014655","The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson's disease: A systematic review and meta-analysis.","Dahiya S","2022","Clinical parkinsonism & related disorders","systematic_review","article","10.1016/j.prdoa.2022.100133","35128376","PMC8804263",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0014656","Comment on Sattar et al. Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2. Diabetes Care 2025;48:e136-e137.","Corrao S","2026","Diabetes care","commentary","article","10.2337/dc25-2212","42160590",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014657","Correction: Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis.","Provenzani A","2026","Frontiers in pharmacology","notice","article","10.3389/fphar.2026.1834664","42137317","PMC13168872",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0014658","Glucagon like peptide-1 receptor agonists and di-peptidyl peptidase inhibitors... A new class of drugs for the treatment of diabetes.","Khan MO","2009","JPMA. The Journal of the Pakistan Medical Association","commentary","article",null,"19813696",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0014659","Impact of renal lipid droplet dynamics on tubular health.","Heneberg P","2026","Journal of lipid research","preclinical","article","10.1016/j.jlr.2026.101101","42705609",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014660","The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice.","Sørensen G","2015","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2015.06.013","26072178","PMC4668599",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014661","O-18 SUCCESSFUL ANTIHYPERGLYCEMIC AND WEIGHT LOSS EFFECTS OF TIRZEPATIDE IN A WOMAN WITH OBESITY AND GENETICALLY CONFIRMED TBC1D4 MUTATION",null,"2026","JCEM case reports","other","article",null,null,"PMC12796688",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0014662","Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico.","Rosas-Guzman J","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16357","40183194","PMC12046447",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0014663","Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide.","Pinto S","2024","Journal of controlled release : official journal of the Controlled Release Society","other","article","10.1016/j.jconrel.2024.01.015","38215986",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014664","Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration Timing on Blood Sugar Profiles.","Gautier T","2022","Journal of diabetes science and technology","other_trial","article","10.1177/19322968211015671","34013770","PMC8847729",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0014665","Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis.","Karakus KE","2026","Diabetes care","randomized_trial","article","10.2337/dc25-2249","41429002","PMC13094866",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0014666","Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.","The Editors Of The Lancet","2026","Lancet (London, England)","notice","article","10.1016/s0140-6736(26)01241-9","42330995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Expression of Concern; article"],["R0014667","Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective.","Gómez Lumbreras A","2023","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2023.03.012","37088648",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0014668","To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications.","Peary A","2026","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-026-01426-y","42183911","PMC13201336",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014669","In brief: Semaglutide (Wegovy) for weight loss in children.",null,"2023","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2023.1670d","36757837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014670","FRAP analysis of peptide diffusion in extracellular matrix mimetic hydrogels as an in vitro model for subcutaneous injection.","Parlow J","2024","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2024.124628","39179009",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014671","Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB.","Velmurugan K","2012","Endocrinology","preclinical","article","10.1210/en.2011-1895","22253425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014672","Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.","Nanna MG","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70686","41889157","PMC13146205",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014673","Er-Chen Decoction ameliorates metabolic dysfunction-associated steatotic liver disease via gut microbiota-barrier axis-driven hepatic metabolic reprogramming.","Yang K","2026","Frontiers in microbiology","preclinical","article","10.3389/fmicb.2026.1768664","41918527","PMC13033753",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014674","Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.","Heintjes EM","2017","Clinical therapeutics","other","article","10.1016/j.clinthera.2017.09.016","29108837",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Multicenter Study"],["R0014675","[Not Available].","Rogal K","2024","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-024-4310-8","39322888",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0014676","Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.","Johansen NJ","2018","BMJ open","protocol","article","10.1136/bmjopen-2018-021861","29950475","PMC6042609","ClinicalTrials.gov:NCT03017352","S000283","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; protocol; article"],["R0014677","Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.","Heise T","2023","Diabetes care","randomized_trial","article","10.2337/dc22-1710","36857477","PMC10154650","ClinicalTrials.gov:NCT03951753","S000593","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014678","An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking.","Merkel R","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.06.20.599574","38979354","PMC11230186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0014679","Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan.","Yabe D","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01531-8","38363541","PMC10942962","UMIN:UMIN000044126",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014680","Le tirzépatide pour la perte pondérale.","Cheung KA","2025","Canadian family physician Medecin de famille canadien","other","article","10.46747/cfp.711112e278","41285617","PMC12668422",null,null,"europepmc","FALSE",null,null,null,"other; Journal Article"],["R0014681","The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.","Shaefer CF","2016","Postgraduate medicine","narrative_review","article","10.1080/00325481.2016.1103640","26548422",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014682","[New drug therapy approaches in the management of hidradenitis suppurativa].","Pinter A","2026","Dermatologie (Heidelberg, Germany)","narrative_review","article","10.1007/s00105-026-05734-x","42384054",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0014683","Real-world use of oral semaglutide in adults with type 2 diabetes.","Roslind K","2026","Danish medical journal","nonrandomized_study","article","10.61409/a06250520","42592768",null,"ClinicalTrials.gov:NCT04537637","S000069","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; article"],["R0014684","GORD and GLP-1 receptor agonists: an emerging concern for gastroenterologists.","Massey BT","2024","Gut","commentary","article","10.1136/gutjnl-2023-331027","37918890",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0014685","From Glucose to Neuroprotection: Exploring Antidiabetic Medications as a Novel Approach to Alzheimer's Disease Treatment.","Pandiyan CK","2024","Cureus","narrative_review","article","10.7759/cureus.70710","39493064","PMC11530258",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014686","Quality and Reliability of Semaglutide-Related Short Videos on TikTok and Bilibili.","Zeng J","2026","American journal of health promotion : AJHP","other","article","10.1177/08901171261447644","42077173",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014687","Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.","Fisher M","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12380","25155010",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0014688","The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment.","Cariou B","2022","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14651","35014161",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014689","Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study.","Simões de Carvalho F","2023","Cureus","other","article","10.7759/cureus.33509","36628395","PMC9826698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014690","Tirzepatide modulates gut microbiota homeostasis to protect against diabetic kidney disease.","Ma J","2025","Frontiers in molecular biosciences","randomized_trial","article","10.3389/fmolb.2025.1715024","41458627","PMC12740902",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014691","Semaglutide (Wegovy) for the Treatment of Obesity.","Bald E","2023","American family physician","other","article",null,"36689981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014692","Severe diabetic ketoacidosis associated with insulin dose reduction after tirzepatide initiation.","Aung ET","2026","BMJ case reports","case_report","article","10.1136/bcr-2025-270158","41802735",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0014693","A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico.","González-Gálvez G","2026","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70219","41986942","PMC13083220","ClinicalTrials.gov:NCT04601753","S001039","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0014694","Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study.","Williams DM","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01015-z","33565043","PMC7872110",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014695","Sustained exenatide delivery via intracapsular microspheres for improved survival and function of microencapsulated porcine islets.","Lew B","2018","Drug delivery and translational research","preclinical","article","10.1007/s13346-018-0484-x","29372538",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014696","Antidiabetic Drugs Consumption in France Over a Decade: An Observational Study.","David B","2025","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2025.02.005","40087082",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0014697","Non-insulin treatments for Type 1 diabetes: critical appraisal of the available evidence and insight into future directions.","Wright LA","2019","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.13941","30801765",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014698","Unimolecular GLP-1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta-Cell Survival and Glycaemic Regulation.","Sridhar A","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70647","41834752","PMC13146130",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014699","Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis.","Azuri J","2023","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.23752","37203328",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0014700","Acute changes in systemic glycaemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis","Bakker W","2020","bioRxiv","other","preprint","10.1101/2020.07.11.198341",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014701","Use of Obesity Medications in the Era of GLP-1 Agonists: An Expert Panel Discussion.","Ard J","2024","The Permanente journal","other","article","10.7812/tpp/24.176","39654407","PMC11648321",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014702","Metabolic Dysfunction and Metabolic Management in Episodic Migraine.","Denney DE","2026","Current pain and headache reports","nonrandomized_study","article","10.1007/s11916-026-01500-9","42068433","PMC13135573",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0014703","[Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].","Mannucci E","2011","Giornale italiano di cardiologia (2006)","other_trial","article","10.1714/985.10683","22158420",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0014704","Electronic word-of-mouth and off-label use of Ozempic and other GLP-1 medications.","Ugwu H","2026","Journal of health psychology","other","article","10.1177/13591053251409613","41604144",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014705","Safety and Efficacy of GLP-1 Agonists in a Cohort of Patients with Fontan Circulation.","Freddo AM","2025","Pediatric cardiology","nonrandomized_study","article","10.1007/s00246-024-03700-9","39531075","PMC12496293",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; article"],["R0014706","Exendin-4-enriched exosomes from hUCMSCs alleviate diabetic nephropathy via gut microbiota and immune modulation.","Wang L","2024","Frontiers in microbiology","preclinical","article","10.3389/fmicb.2024.1399632","39282564","PMC11392743",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014707","Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity.","Waldrop SW","2024","Nature medicine","other","article","10.1038/s41591-023-02669-x","38172631","PMC10921848",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014708","Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity.","Gaffey RH","2024","Expert opinion on investigational drugs","narrative_review","article","10.1080/13543784.2024.2377319","38984950",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014709","Hepatoprotective Effects of Quercetin-Chitosan Nanoparticles on Nonalcoholic Fatty Liver Disease: In Vivo Study.","Babaalizadeh B","2026","Food science & nutrition","preclinical","article","10.1002/fsn3.71617","41971603","PMC13062281",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014710","Adjunctive therapy for glucose control in patients with type 1 diabetes.","Harris K","2018","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s141700","29731652","PMC5927142",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014711","Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study.","Issachar A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70763","41969200","PMC13243961",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014712","Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.","Michałowska J","2021","Nutrients","narrative_review","article","10.3390/nu13020351","33503878","PMC7910956",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014713","Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.","Yang S","2022","PloS one","systematic_review","article","10.1371/journal.pone.0267025","35421174","PMC9009659","PROSPERO:CRD42020208090",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; review"],["R0014714","Early onset stage III diabetic nephropathy in a child with Prader-Willi syndrome treated with dulaglutide: a case report.","He Y","2024","Translational pediatrics","nonrandomized_study","article","10.21037/tp-23-518","38840685","PMC11148744",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0014715","The impact of preadmission/prediagnosis use of GLP-1 receptor agonists on COVID-19 mortality in patients with diabetes: A systematic review and meta-analysis.","Kow CS","2023","Health science reports","systematic_review","article","10.1002/hsr2.1549","37720167","PMC10500111",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; letter; article; review"],["R0014716","Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.","Hölscher C","2022","British journal of pharmacology","narrative_review","article","10.1111/bph.15508","33900631","PMC8820183",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014717","Low Preoperative Free Triiodothyronine, Particularly in Females, Is Associated With Reduced Weight Loss and Diabetes Remission After Bariatric Surgery in Euthyroid Adults.","Li S","2026","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.70228","42733963","PMC13572958",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014718","Quality Plus Quantity: Evaluation of a Virtual GLP-1 Programme With Physical Activity Support to Promote Healthy Body Composition Change During GLP-1 Weight Loss.","Stanton LA","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.71152","42680164",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0014719","Administration of Exendin-4 but not CCK alters lick responses and trial initiation to sucrose and intralipid during brief-access tests.","Treesukosol Y","2022","Chemical senses","other_trial","article","10.1093/chemse/bjac004","35427413","PMC9012268",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0014720","Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.","Jouihan H","2017","Molecular metabolism","preclinical","article","10.1016/j.molmet.2017.09.001","29107284","PMC5681275",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014721","Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial.","Lengsfeld S","2023","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2023.101865","36874396","PMC9981899","ClinicalTrials.gov:NCT03204396","S000115","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0014722","Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.","Ghosal S","2018","Clinical diabetes and endocrinology","nonrandomized_study","article","10.1186/s40842-018-0061-8","29760945","PMC5941332",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014723","Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes.","Lyu J","2020","Molecular metabolism","preclinical","article","10.1016/j.molmet.2019.12.015","32180556","PMC6997505",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014724","Advances in Diabetes Pharmacotherapy: An Update for the Emergency Provider.","Mazer-Amirshahi M","2018","The Journal of emergency medicine","narrative_review","article","10.1016/j.jemermed.2017.08.024","28987311",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014725","Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.","Yang W","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13072","28742225","PMC5813270","ClinicalTrials.gov:NCT01632163","S001963","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014726","Strengths and limitations of HFpEF probability scores in the era of precision medicine.","Wilk M","2026","Frontiers in medicine","narrative_review","article","10.3389/fmed.2026.1799451","42023091","PMC13095507",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014727","GLP-1 agonists and risk of suicidal thoughts and behaviours: Confound by indication once again? A narrative review.","Strumila R","2024","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","narrative_review","article","10.1016/j.euroneuro.2024.07.001","39068741",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0014728","Spinal cord-wide structural disruption in type 2 diabetes rescued by exenatide \"a glucagon-like peptide-1 analogue\" via down-regulating inflammatory, oxidative stress and apoptotic signaling pathways.","Mandour DA","2022","Journal of chemical neuroanatomy","preclinical","article","10.1016/j.jchemneu.2022.102079","35143896",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014729","Tirzepatide attenuates atherosclerosis through weight loss-independent anti-inflammatory mechanisms","Chen S","2026","bioRxiv","preclinical","preprint","10.64898/2026.06.22.733886",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014730","The local GLP-1 system in the olfactory bulb is required for odor-evoked cephalic phase of insulin release in mice.","Montaner M","2023","Molecular metabolism","preclinical","article","10.1016/j.molmet.2023.101738","37182561","PMC10212752",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0014731","Exendin-4 in combination with adipose-derived stem cells promotes angiogenesis and improves diabetic wound healing.","Seo E","2017","Journal of translational medicine","preclinical","article","10.1186/s12967-017-1145-4","28202074","PMC5311833",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014732","GLP-1-Induced Weight Loss and the Face: Anatomical Mechanisms and Rationale for Collagen-Stimulating and Volumizing Aesthetic Treatments.","Frank K","2026","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","narrative_review","article","10.1097/dss.0000000000005180","42210888",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014733","Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist.","Cases A","2023","Nefrologia","narrative_review","article","10.1016/j.nefroe.2023.09.003","37813741",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014734","Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease.","Nowell J","2023","Molecular psychiatry","other_trial","article","10.1038/s41380-022-01792-4","36258018","PMC9812772",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0014735","Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.","Alhiary R","2023","JAMA","nonrandomized_study","article","10.1001/jama.2023.13872","37505513","PMC11457043",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014736","Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.","Seino Y","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13082","28786547","PMC5813234","ClinicalTrials.gov:NCT02254291","S002082","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014737","Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity.","Alzahrani AM","2025","Integrated pharmacy research & practice","narrative_review","article","10.2147/iprp.s503501","40225951","PMC11987703",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014738","Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.","Tonon CR","2024","International journal of molecular sciences","preclinical","article","10.3390/ijms25115833","38892020","PMC11172760",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014739","Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.","Mazidi M","2017","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2016.05.022","28479155",null,"PROSPERO:CRD42016036868",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0014740","Semaglutide in Non-diabetic Obese East Asian Patients with Acute Coronary Syndrome: A Multicenter Retrospective Study","Jin C","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9161583/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0014741","Tolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real-world Experience From a Single-center Study.","Hussain SM","2026","Transplantation","nonrandomized_study","article","10.1097/tp.0000000000005711","41952049",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014742","Government subsidies for GLP-1 agonists in mental health patients with metabolic syndrome: A call for quality-of-life improvement and cost reduction.","Akosile W","2025","Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists","commentary","article","10.1177/10398562251313696","39801485","PMC12138133",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014743","Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.","Velusamy B","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.03.015","42011394","PMC13091949",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014744","Metabolic syndrome after liver transplantation: A silent threat to long-term success.","Chan SY","2025","World journal of gastrointestinal pharmacology and therapeutics","narrative_review","article","10.4292/wjgpt.v16.i4.111073","41378074","PMC12686996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014745","Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.","Bruhn D","2016","Journal of medical economics","other_trial","article","10.3111/13696998.2016.1154567","26882484",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0014746","Recent advances in the treatment of patients with obesity and chronic kidney disease.","Abdul Wahab R","2023","Annals of medicine","randomized_trial","article","10.1080/07853890.2023.2203517","37086110","PMC10124979",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0014747","Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes.","Beck RW","2024","Clinical diabetes : a publication of the American Diabetes Association","commentary","article","10.2337/cd23-0107","39429449","PMC11486843",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0014748","Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study.","Shah J","2026","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2026.01.013","41577258",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0014749","Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.","McNeill AM","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-019-0566-x","30689140","PMC6437246",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0014750","Abdominoplasty","Dawson-Amoah K","2026","StatPearls Publishing, Treasure Island (FL)","other","article",null,"28613712",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0014751","Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.","Fadini GP","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13280","29516612","PMC6175069",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; brief-report; article"],["R0014752","The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation.","Park YJ","2013","Diabetologia","other","article","10.1007/s00125-012-2802-z","23262664",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014753","The estrogenic reduction in water intake stimulated by dehydration involves estrogen receptor alpha and a potential role for GLP-1.","Howell JA","2024","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2024.114484","38331374","PMC10896180",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Intramural; research-article"],["R0014754","Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.","Gerstein HC","2021","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2108269","34215025",null,"ClinicalTrials.gov:NCT03496298","S000755","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0014755","Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.","Bjerre Knudsen L","2010","Endocrinology","other_trial","article","10.1210/en.2009-1272","20203154",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial; Journal Article; article"],["R0014756","Tirzepatide a major breakthrough in treatment of obstructive sleep apnoea.","Ahmad A","2026","JPMA. The Journal of the Pakistan Medical Association","other_trial","article","10.47391/jpma.31027","42017745",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0014757","First Large Study of GLP-1 Receptor Agonists During Pregnancy.","Harris E","2024","JAMA","other","article","10.1001/jama.2023.26112","38170560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014758","Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.","Van Sloten T","2026","Endocrine connections","nonrandomized_study","article","10.1530/ec-25-0903","41800807","PMC13034523",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014759","[Tirzepatide in real-world clinical practice: changes in body composition and muscle function in patients with obesity].","Blanco Anesto J","2026","Nutricion hospitalaria","nonrandomized_study","article","10.20960/nh.06592","42037504",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","English Abstract; Journal Article; article"],["R0014760","Emerging perspectives on once-weekly insulins in type 1 and type 2 diabetes: a mini-review.","Denimal D","2025","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2025.1656884","40937414","PMC12420296",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; discussion; review"],["R0014761","Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs.","Kim SY","2026","Korean journal of radiology","other_trial","article","10.3348/kjr.2025.0937","41494676","PMC12780372",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0014762","Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.","Li Z","2024","Hepatology (Baltimore, Md.)","nonrandomized_study","article","10.1097/hep.0000000000000812","38441957",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; letter"],["R0014763","Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.","Guja C","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13266","29473704","PMC6032936","ClinicalTrials.gov:NCT02229383","S000703","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014764","Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy.","Kjeldsen SAS","2023","iScience","randomized_trial","article","10.1016/j.isci.2023.108190","37953952","PMC10638073",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014765","Impact of glucagon-like peptide receptor agonists on endoscopy and its preoperative management: Guidelines, challenges, and future directions.","Singh S","2024","World journal of gastrointestinal endoscopy","commentary","article","10.4253/wjge.v16.i6.292","38946857","PMC11212520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0014766","Semaglutide Induces Changes in Gastric Electrical Activity in Patients With Overweight and Obesity: A Pilot Study.","Abraham R","2026","Journal of neurogastroenterology and motility","other","article","10.5056/jnm25156","41952406","PMC13076063",null,"S000517","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014767","Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm.","van Bruggen FH","2026","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2026.100327","42733607","PMC13571586",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; discussion; article"],["R0014768","Microvascular dysfunction and neurovascular signalling impairment in diabetic silent myocardial ischemia.","Rajasekaran HK","2026","Microvascular research","narrative_review","article","10.1016/j.mvr.2026.104983","42324025",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014769","Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease.","Ougaard ME","2020","Nephron","preclinical","article","10.1159/000509418","32877912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014770","Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin.","Johnson EL","2018","Postgraduate medicine","narrative_review","article","10.1080/00325481.2018.1452515","29569978",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0014771","Treating patients with type 2 diabetes: what is after lifestyle management and metformin? A focus on the glucagon-like peptide-1 receptor agonists.",null,"2009","The Journal of family practice","other","article",null,"19774730",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Introductory Journal Article; other"],["R0014772","Hindbrain octadecaneuropeptide gliotransmission as a therapeutic target for energy balance control without nausea or emesis.","Geisler CE","2025","Science translational medicine","preclinical","article","10.1126/scitranslmed.adu6764","40700519","PMC12980401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0014773","Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.","Pop-Busui R","2026","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2025.7774","41627802","PMC12865694","ClinicalTrials.gov:NCT03914326","S002179","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; research-article; article"],["R0014774","[Pharmacological treatment of obstructive sleep apnea syndrome].","Tardov MV","2026","Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","randomized_trial","article","10.17116/jnevro202612605248","42268272",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; English Abstract; article"],["R0014775","Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion.","Du X","2014","Molecular biology reports","preclinical","article","10.1007/s11033-014-3252-0","24549718",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014776","Combined Semaglutide and Exercise Ameliorate HFpEF-Associated MASH: Multi-Omics Insights","Liu G","2026","Research Square","preclinical","preprint","10.21203/rs.3.rs-9722472/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014777","Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.","Tsutsumi Y","2015","PloS one","preclinical","article","10.1371/journal.pone.0139709","26439622","PMC4595004",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014778","Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.","Bilato C","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","other_trial","article","10.1016/j.numecd.2026.104872","42469146",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0014779","Olanzapine and peripheral metabolic dysregulation: organ-resolved mechanisms, risk, and MASLD-aligned care pathways.","Weng S","2025","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2025.1729264","42007333","PMC13082975",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014780","Obesity medications and acquired hypothalamic obesity in adults: A two-case experience.","Lang H","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100246","41624164","PMC12857365",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0014781","Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.","Goldberg A","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13704","38355887",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0014782","Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.","Winiarska A","2021","International journal of molecular sciences","preclinical","article","10.3390/ijms221910822","34639160","PMC8509708",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014783","NSAID-Induced Enteropathy Affects Regulation of Hepatic Glucose Production by Decreasing GLP-1 Secretion.","Herz H","2021","Nutrients","preclinical","article","10.3390/nu14010120","35010994","PMC8746549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014784","[Promising molecules for treatment of hyperglycemia in patients with type 2 diabetes].","Kvapil M","2016","Vnitrni lekarstvi","narrative_review","article",null,"27921428",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014785","Effects of concomitant combination of SGLT-2 inhibitor and GLP-1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series.","Kuhadiya ND","2021","Clinical case reports","case_report","article","10.1002/ccr3.4022","33936685","PMC8077383",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014786","Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?","Smits MM","2023","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.3699","37485788",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0014787","Dulaglutide as a Bridging Therapy Before Insulin for Diabetes Following Pancreatectomy on Congenital Hyperinsulinism.","Motegi S","2026","JCEM case reports","other_trial","article","10.1210/jcemcr/luaf281","41347115","PMC12673381",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0014788","Health Center Visits by Adults With Type 2 Diabetes: United States, 2024.","Santo L","2026","NCHS data brief","other","article","10.15620/cdc/252468","42727233","PMC13573276",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Book; report"],["R0014789","Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes.","Omori Y","2026","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70240","41555812","PMC12950920",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; Observational Study; research-article; article"],["R0014790","Effects of Hypoglycemic Agents on Pulmonary Diseases: A Comprehensive Narrative Review.","Yang Y","2025","Journal of inflammation research","narrative_review","article","10.2147/jir.s556790","41497535","PMC12765701",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0014791","Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving in-situ stability.","Tian H","2024","Expert opinion on drug delivery","preclinical","article","10.1080/17425247.2024.2305110","38224039",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014792","The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liraglutide, a glucagon-like peptide 1 receptor agonist, in mice.","Nonogaki K","2011","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2011.06.175","21756875",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014793","Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.","Egger A","2016","Current osteoporosis reports","narrative_review","article","10.1007/s11914-016-0337-9","27709509",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014794","Tirzepatide.","Brož J","2026","Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti","narrative_review","article","10.36290/csf.2026.020","42334912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014795","Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.","Nicholls SJ","2024","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-024-02147-9","38341541","PMC10859014",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0014796","[The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes].","Shimoda K","2018","Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","case_report","article","10.1248/yakushi.18-00060","30270278",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014797","Liraglutide prevents β-cell apoptosis via inactivation of NOX2 and its related signaling pathway.","Ding M","2019","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2018.12.013","30772113",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014798","Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.","Scheen AJ","2015","Clinical pharmacokinetics","narrative_review","article","10.1007/s40262-014-0198-2","25331711",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014799","Incretin-mimetic therapies and pancreatic disease: a review of observational data.","Suarez EA","2014","Current medical research and opinion","randomized_trial","article","10.1185/03007995.2014.960515","25180611",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0014800","Assessing the therapeutic potential of Tirzepatide in modulating inflammatory responses and mitigating acute pancreatitis.","Alawaji R","2025","Animal models and experimental medicine","preclinical","article","10.1002/ame2.70083","41116319","PMC12660503",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014801","Pharmacomicrobiomics in metabolic syndrome and type 2 diabetes: the microbiome-drug-host triad.","Strilić D","2026","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2026.1831882","42707375","PMC13547828",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014802","Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.","Ji L","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14232","33074557","PMC7839591",null,"S001311","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014803","Immunometabolism Reframes Alzheimer's Disease: From Systemic Dysmetabolism to Glial Rewiring.","Bach DH","2026","Cellular and molecular neurobiology","narrative_review","article","10.1007/s10571-026-01691-0","41688855","PMC12957698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014804","Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.","Yu H","2026","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.70267","42644866","PMC13511386",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; Review; review"],["R0014805","The role of incretin-based therapies in prediabetes: a review.","Ahmadieh H","2014","Primary care diabetes","narrative_review","article","10.1016/j.pcd.2014.02.005","24666932",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014806","Real world tirzepatide treatment for fatty liver disease.","Maung ST","2026","Hepatology international","nonrandomized_study","article","10.1007/s12072-026-11065-9","41776028",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Editorial; article"],["R0014807","SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis.","Xu F","2014","Diabetes","preclinical","article","10.2337/db14-0263","24947350",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014808","Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.","Sherry NA","2007","Endocrinology","preclinical","article","10.1210/en.2007-0358","17673522",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0014809","Beyond inflammation: metabolic implications of biological and TsDMARD therapies in dermatologic and rheumatologic diseases.","Corrao S","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1668159","41766878","PMC12935618",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014810","Impact of gastric emptying and small intestinal carbohydrate absorption on glycemia in health and diabetes: therapeutic implications.","Jalleh RJ","2026","Physiological reviews","narrative_review","article","10.1152/physrev.00009.2025","42113557",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0014811","SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.","Zou H","2017","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-017-0547-1","28511711","PMC5434580",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014812","Practical applications of therapy with a glucagon-like peptide-1 receptor agonist.","Shomali ME","2009","The Journal of family practice","narrative_review","article",null,"19744424",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014813","Crossing the line: BMI category changes with tirzepatide.","Kelsey MD","2026","American journal of preventive cardiology","commentary","article","10.1016/j.ajpc.2026.101490","42006419","PMC13084107",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0014814","Current status of anti-obesity medications and performance, an EHR based survey","Ruan X","2024","medRxiv","randomized_trial","preprint","10.1101/2024.12.02.24318314",null,null,null,null,"europepmc","FALSE","open_pdf","2",null,"Preprint"],["R0014815","The use of incretins and fractures - a meta-analysis on population-based real life data.","Driessen JH","2017","British journal of clinical pharmacology","systematic_review","article","10.1111/bcp.13167","27780288","PMC5346876",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0014816","Erratum. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen Diabetes Care 2025;48:1607-1611.","Eldor R","2026","Diabetes care","notice","article","10.2337/dc26-er02a","41337783","PMC12824793",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0014817","Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.","Alsuhibani AA","2025","Frontiers in medicine","nonrandomized_study","article","10.3389/fmed.2025.1537181","40740949","PMC12307327",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014818","Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice.","Tweedie D","2013","Experimental neurology","preclinical","article","10.1016/j.expneurol.2012.10.001","23059457","PMC3534795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014819","Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis.","Ghadieh HE","2018","Hepatology communications","preclinical","article","10.1002/hep4.1117","29404511","PMC5776867",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014820","Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD.","Koh G","2024","Diabetes & metabolism journal","commentary","article","10.4093/dmj.2024.0096","38556703","PMC10995481",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0014821","Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF.","Driggin E","2024","Journal of cardiac failure","other","article","10.1016/j.cardfail.2024.01.005","38301742","PMC12217443",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014822","Comment on Shah and Ayala. Interpreting Stage-Dependent Changes in Semaglutide Response: From Patterns to Mechanisms.","Ragozzino G","2026","Diabetes","commentary","article","10.2337/db26-0171","42160524","PMC13191377",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014823","Add on Exenatide Treatment is Beneficial in Poorly Controlled Obese Type 2 Diabetics under Intensive Insulin Regimens.","Sönmez A","2017","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","randomized_trial","article","10.1055/s-0042-120708","28201828",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0014824","Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.","Gaggini M","2025","Cells","narrative_review","article","10.3390/cells14050387","40072115","PMC11898734",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014825","Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.","van Genugten RE","2009","Diabetes research and clinical practice","other","article","10.1016/s0168-8227(09)70006-3","20115929",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014826","Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.",null,"2026","The New England journal of medicine","notice","article","10.1056/nejmx250014","41880634",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; article"],["R0014827","Improvement of Compulsive Shopping on Tirzepatide: A Case Report.","Guerdjikova AI","2026","Journal of clinical psychopharmacology","case_report","article","10.1097/jcp.0000000000002135","41632102",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014828","GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?","Kumar S","2024","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2024.100682","38840935","PMC11152602",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0014829","A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.","Frias JP","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-018-0547-5","30539523","PMC6349286",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; other; article"],["R0014830","Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.","Krishnan K","2024","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2023.111034","38061446",null,"CTRI:CTRI/2022/02/040261",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0014831","The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study.","Paul SK","2015","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-015-0178-3","25616979","PMC4314769",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0014832","GLP-1 Agonists and Blood Pressure: A Review of the Evidence.","Goud A","2016","Current hypertension reports","preclinical","article","10.1007/s11906-015-0621-6","26803771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014833","Systemic Interactions in HFpEF: A Multiorgan Perspective on Pathways and Therapeutic Targets.","Cui X","2025","Journal of cardiovascular translational research","narrative_review","article","10.1007/s12265-025-10699-8","40982203",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0014834","Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide.","Basalay MV","2019","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-019-06915-8","31721014","PMC6994526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0014835","Semaglutide: Real World Results, Realistic Recommendations.","Kalra S","2026","JPMA. The Journal of the Pakistan Medical Association","nonrandomized_study","article","10.47391/jpma.26-42","42261005",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Editorial; article"],["R0014836","What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue.","Klair N","2023","Cureus","other_trial","article","10.7759/cureus.46197","37905277","PMC10613430",null,"S002418","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0014837","Why Do Patients with Type 2 Diabetes Lose Less Weight on GLP-1s? A Mathematical Modeling Analysis","Hall KD","2026","bioRxiv","other","preprint","10.64898/2026.09.08.750112",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014838","Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review.","Ahmed A","2024","Journal of clinical & translational endocrinology","narrative_review","article","10.1016/j.jcte.2024.100375","39764279","PMC11702000",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014839","Efficacy and Safety of Semaglutide for Managing Antipsychotic-associated Weight Gain: A Systematic Review and Meta-analysis.","Jena S","2026","Indian journal of endocrinology and metabolism","systematic_review","article","10.4103/ijem.ijem_1037_25","42238556","PMC13229256",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0014840","Advances in Endocrine Tumor PET Imaging Targeting CXCR4 and GLP-1.","Mena E","2025","Seminars in nuclear medicine","narrative_review","article","10.1053/j.semnuclmed.2025.05.001","40447542","PMC12313406",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0014841","Update on the impact of lipid and glucose control on diabetic wound healing.","Sun R","2025","Metabolism open","narrative_review","article","10.1016/j.metop.2025.100408","41321406","PMC12657400",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014842","[Phentermine-topiramate and GLP-1 receptor agonists are the most effective medications for facilitating weight loss in adults who are overweight or obese.].","Kurotschka PK","2024","Recenti progressi in medicina","other","article","10.1701/4334.43181","39269354",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014843","Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.","Enebo LB","2021","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(21)00845-x","33894838",null,"ClinicalTrials.gov:NCT03600480","S001618","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0014844","Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis.","Fan SM","2020","Medicine","systematic_review","article","10.1097/md.0000000000020695","32629641","PMC7337581",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review-article; article"],["R0014845","A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment.","Tobaiqy M","2024","Pharmacological reports : PR","randomized_trial","article","10.1007/s43440-024-00629-x","39093550",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0014846","Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia.","Mondragon A","2014","PloS one","preclinical","article","10.1371/journal.pone.0104873","25119717","PMC4132080",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014847","No benefit of additional treatment with exenatide in patients with an acute myocardial infarction.","Roos ST","2016","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2016.06.283","27394978",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0014848","Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.","Iwasaki Y","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.113072","41448390",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0014849","Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials.","Almandoz JP","2026","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2026.100248","41640675","PMC12865613","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657003; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT04660643","S000242; S001077; S001712; S002157","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; brief-report; article"],["R0014850","Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia.","Dayel FFB","2026","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare14070845","41975849","PMC13073150",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014851","Connectivity maps for biosimilar drug discovery in venoms: the case of Gila monster venom and the anti-diabetes drug Byetta®.","Aramadhaka LR","2013","Toxicon : official journal of the International Society on Toxinology","nonrandomized_study","article","10.1016/j.toxicon.2013.03.018","23602926",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014852","Molecular engineering of designer diabetes therapeutics.","DeWolf EL","2026","Journal of controlled release : official journal of the Controlled Release Society","narrative_review","article","10.1016/j.jconrel.2026.114705","41662883",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0014853","Phase I results for AMG 133.","Greenhill C","2024","Nature reviews. Endocrinology","other_trial","article","10.1038/s41574-024-00967-z","38388678",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0014854","The potential protective effect of liraglutide on valproic acid induced liver injury in rats: Targeting HMGB1/RAGE axis and RIPK3/MLKL mediated necroptosis.","Atef MM","2023","Cell biochemistry and function","preclinical","article","10.1002/cbf.3855","37771193",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014855","Single-cell insights into maladaptive endothelial plasticity and therapeutic targets in diabetic vascular complications.","Alnuaimi NS","2026","Cardiovascular diabetology","preclinical","article","10.1186/s12933-026-03187-z","42092877","PMC13317339",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0014856","Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.","Li Y","2015","Journal of neurochemistry","preclinical","article","10.1111/jnc.13169","25982185","PMC4644713",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014857","Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.","Kaku K","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13856","31407845","PMC6899795","ClinicalTrials.gov:NCT02607306","S001965","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014858","[GLP-1 and GIP receptor agonists: emerging therapies for obesity].","Chartoumpekis D","2023","Revue medicale suisse","other","article","10.53738/revmed.2023.19.819.555","36950785",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0014859","Forword for efficacy and safety of tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.","Leikin JB","2026","Disease-a-month : DM","systematic_review","article","10.1016/j.disamonth.2026.102098","41862385",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Editorial; article"],["R0014860","Systemic effects of type 2 diabetes therapies: an integrated perspective on the cardio-renal- cerebral-metabolic axis.","Zhu L","2026","Frontiers in medicine","narrative_review","article","10.3389/fmed.2026.1746457","41952890","PMC13055241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014861","Pharmacological treatment of obesity in adults in Norway 2004-2022.","Ruiz PL","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15515","38419410",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0014862","[Newer anti - diabetic therapies and chronic kidney disease].","Di Lullo L","2017","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","narrative_review","article",null,"28177092",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014863","Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.","Zaccardi F","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70770","41994903","PMC13243996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0014864","Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.","Yang Q","2024","PeerJ","preclinical","article","10.7717/peerj.17055","38500527","PMC10946396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014865","Correction: Weight loss efficiency and safety of tirzepatide: A Systematic review.","Lin F","2026","PloS one","notice","article","10.1371/journal.pone.0346588","41926378","PMC13046150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0014866","Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.","Roell W","2026","Molecular metabolism","randomized_trial","article","10.1016/j.molmet.2025.102298","41391569","PMC12808604","ClinicalTrials.gov:NCT04586907",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; research-article; article"],["R0014867","ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations.","Godzo H","2026","Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy","other","article","10.1016/j.saa.2026.128280","42330703",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014868","Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway.","Welling MS","2025","Endocrine reviews","narrative_review","article","10.1210/endrev/bnaf004","39929239","PMC12063102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014869","GLP1R haplotypes are associated with insulin secretion and sensitivity in children and adolescents with obesity.","Zusi C","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag283","42464735",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0014870","Lixisenatide requires a functional gut-vagus nerve-brain axis to trigger insulin secretion in controls and type 2 diabetic mice.","Charpentier J","2018","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00348.2017","30070580",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014871","Comparative impact of different weight loss strategies on obstructive sleep apnea: an integrated review of surgical, pharmacological, and lifestyle interventions.","Song GQ","2025","Frontiers in neurology","narrative_review","article","10.3389/fneur.2025.1719923","41473219","PMC12745281",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014872","Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.","Kanoski SE","2011","Endocrinology","preclinical","article","10.1210/en.2011-0174","21693680","PMC3138234",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0014873","SGLT-2 Inhibitors, GLP-1 Agonists Provide Greater Benefit for Patients With Type 2 Diabetes.","Shaughnessy AF","2024","American family physician","other","article",null,"39700374",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014874","Delayed administration of the GLP-1 receptor agonist liraglutide improves metabolic and functional recovery after cerebral ischemia in rats.","Dong W","2017","Neuroscience letters","preclinical","article","10.1016/j.neulet.2017.01.045","28122257",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014875","Response to Comment on Shah and Ayala. Interpreting Stage-Dependent Changes in Semaglutide Response: From Patterns to Mechanisms.","Shah H","2026","Diabetes","commentary","article","10.2337/dbi26-0013","42160528",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014876","Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.","Liu Q","2026","Diabetes care","other_trial","article","10.2337/dc25-2808","41771053","PMC13191384",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; letter"],["R0014877","Understanding insurance coverage policies for incretin mimetics for weight management.","Griauzde DH","2025","The American journal of managed care","other","article","10.37765/ajmc.2025.89685","40705731","PMC12710463",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0014878","Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.","Roan JN","2017","The Journal of surgical research","preclinical","article","10.1016/j.jss.2016.09.024","27993221",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014879","Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis.","Amini-Salehi E","2025","Annals of medicine and surgery (2012)","narrative_review","article","10.1097/ms9.0000000000003089","40212217","PMC11981388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014880","Nanoparticles as potential drug delivery systems for anti-diabetic peptide therapeutics","Craythorne NL","2014","Ulster University","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0014881","Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial.","Lin P","2024","Frontiers in pharmacology","other_trial","article","10.3389/fphar.2024.1433587","39239660","PMC11375898",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014882","Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.","Gallwitz B","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13086","28817231","PMC6084353",null,"S000291","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014883","Pharmacological Support for the Treatment of Obesity-Present and Future.","Kosmalski M","2023","Healthcare (Basel, Switzerland)","narrative_review","article","10.3390/healthcare11030433","36767008","PMC9914730",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014884","[Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].","Zheng YC","2015","Yao xue xue bao = Acta pharmaceutica Sinica","preclinical","article",null,"27169293",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014885","IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.","Ji L","2021","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2021.101088","34430840","PMC8374649","ClinicalTrials.gov:NCT04440345","S001410","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0014886","Effects of Oral Semaglutide on Renal Function in Diabetic Kidney Disease: A Short-term Clinical Study.","Mima A","2024","In vivo (Athens, Greece)","nonrandomized_study","article","10.21873/invivo.13440","38148042","PMC10756470",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014887","When type 1 diabetes isn't the answer: A case series of siblings with misdiagnosed diabetes mellitus later confirmed as maturity-onset diabetes of the young.","Alfares KA","2026","Journal of family medicine and primary care","case_report","article","10.4103/jfmpc.jfmpc_1747_25","42023347","PMC13098871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0014888","Tirzepatide and the NHS: are we creating a two-tier obesity treatment system?","Dobbie LJ","2025","The British journal of general practice : the journal of the Royal College of General Practitioners","other_trial","article","10.3399/bjgp.2025.0610","41167963","PMC12745640",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Editorial; article"],["R0014889","[Dyspeptic syndrome associated with antidiabetic therapy].","Smahelová A","2011","Vnitrni lekarstvi","narrative_review","article",null,"21612066",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014890","Integrative Insights Into Mitochondrial Dysfunction and Organelle Crosstalk in Diabetic Kidney Disease.","Cao W","2026","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","narrative_review","article","10.1096/fj.202504735r","41863504",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014891","Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.","Chen WJY","2017","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-017-0549-z","28526033","PMC5438489","ClinicalTrials.gov:NCT00766857","S001750","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0014892","Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog.","Moore MC","2013","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00354.2013","24148347","PMC3882379",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0014893","Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment.","Liu Y","2016","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.5b00625","26641886","PMC5219937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014894","Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury.","Bader M","2019","Frontiers in cell and developmental biology","preclinical","article","10.3389/fcell.2019.00356","31998717","PMC6965031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014895","Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats.","Aranäs C","2023","EBioMedicine","preclinical","article","10.1016/j.ebiom.2023.104642","37295046","PMC10363436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014896","Quantifying antihypertensive effects of GLP-1 agonists.","Cohen JB","2024","European heart journal","randomized_trial","article","10.1093/eurheartj/ehae520","39217501",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Editorial; Comment; article"],["R0014897","Exendin-4 promotes proliferation of adipose-derived stem cells through PI3K/Akt-Wnt signaling pathways.","Ye X","2018","Neuroscience letters","preclinical","article","10.1016/j.neulet.2018.06.028","29920298",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014898","Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.","Hunter K","2012","BMC neuroscience","preclinical","article","10.1186/1471-2202-13-33","22443187","PMC3352246",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014899","Semaglutide-induced lean mass loss: clinical concern or physiological adaptation.","Qaseem M","2026","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000005145","42254092","PMC13236199",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0014900","Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea.","Ziemke F","2025","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2025.100178","40487675","PMC12137197",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014901","Association between tirzepatide use and risk of mortality, hospitalization, and suicidal behavior in patients with schizophrenia spectrum disorders: A one-year retrospective cohort study of 3618 patients.","Liu TH","2026","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","nonrandomized_study","article","10.1016/j.euroneuro.2025.11.016","41389474",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014902","Reappraisal of Goal-Directed Medical Therapy in Diabetic Kidney Disease: Beyond the Quadruple Therapy Paradigm.","Mathew GG","2026","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","narrative_review","article","10.69097/43-02-2026-03","42143746",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014903","Development of the European Association for the Study of Obesity (EASO) Grade-Based Framework on the Pharmacological Treatment of Obesity: Design and Methodological Aspects.","McGowan B","2026","Obesity facts","randomized_trial","article","10.1159/000546855","40743997","PMC12503508",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0014904","Overweight and obesity induce Toll-like receptor 2-induced Type I IFN signaling.","Elkins M","2026","npj metabolic health and disease","preclinical","article","10.1038/s44324-026-00125-1","42547779","PMC13434816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014905","Challenging the Consensus Statement: Is It Time to Recognise Pharmacological Remission of Type 2 Diabetes?","Bianchi C","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70674","41852334",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Consensus Statement; Review; article"],["R0014906","GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy.","Lafferty RA","2023","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2023.2192865","36927378",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Review; Journal Article; article"],["R0014907","GLP-1 Receptor Agonists in Weight Loss and Bariatric Surgery: Balancing Efficacy and Gastrointestinal Adverse Events.","Au K","2024","Obesity surgery","commentary","article","10.1007/s11695-024-07061-3","38198099",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0014908","Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial.","Lüthi H","2024","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2024.102429","38371479","PMC10873660","ClinicalTrials.gov:NCT03204396","S000115","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0014909","Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates.","Rangraze IR","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-026-01868-2","42029986","PMC13253930",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0014910","Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study.","Ueda P","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","nonrandomized_study","article","10.1016/j.cgh.2023.08.034","37716613",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0014911","Pharmaceutical Approval Update.","Choy M","2017","P & T : a peer-reviewed journal for formulary management","other","article",null,"28250698","PMC5312631",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; other"],["R0014912","Semaglutide (Wegovy): CADTH Reimbursement Review: Therapeutic area: Weight management",null,"2022","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"38507535",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0014913","Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.","Rossing P","2026","Diabetes care","other_trial","article","10.2337/dc26-0466","42160608","PMC13191419",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0014914","More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.","Frias J","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13368","29785837","PMC6099242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0014915","Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review.","Aladel A","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s417374","37915772","PMC10617533","PROSPERO:CRD42022313002",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0014916","Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies.","Fotheringham P","2026","Drugs","narrative_review","article","10.1007/s40265-025-02279-6","41619150","PMC12963221",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014917","Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.","Wharton S","2021","International journal of obesity (2005)","other_trial","article","10.1038/s41366-021-00831-4","34083744","PMC8310797",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014918","Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.","Qaseem A","2024","Annals of internal medicine","other","article","10.7326/m23-2788","38639546","PMC11614146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; research-article; article"],["R0014919","Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis.","Guo W","2018","Chinese medical journal","systematic_review","article","10.4103/0366-6999.235107","29941715","PMC6032690",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0014920","Tirzepatide (Mounjaro) for type 2 diabetes.",null,"2022","The Medical letter on drugs and therapeutics","other","article",null,"35802842",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014921","Dual GIP/GLP-1 Receptor Co-Agonism Reprograms White Adipose Tissue Toward a Thermogenic Phenotype: Mechanistic Insights and Implications for Obesity Pharmacotherapy","Andrade LJdO","2026","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-9783878/v1",null,null,null,null,"europepmc","FALSE","open_pdf","4",null,"Preprint"],["R0014922","Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.","Franklin ZJ","2022","Biochimie","preclinical","article","10.1016/j.biochi.2022.04.005","35439540",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014923","Residual cardiovascular risk beyond LDL-cholesterol control: what remains unaddressed?","Taha M","2026","American journal of cardiovascular disease","other_trial","article","10.62347/crjo2924","42787573","PMC13601777",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; article"],["R0014924","Zebrafish as a translational model for peptide-mediated synaptic dysfunction related to obesity.","Rodrigues AC","2026","Frontiers in synaptic neuroscience","preclinical","article","10.3389/fnsyn.2026.1845252","42639131","PMC13500655",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014925","Reassessment of antibody-based detection of the murine T cell GLP-1 receptor.","Wong CK","2025","Cell metabolism","preclinical","article","10.1016/j.cmet.2025.06.012","40902582",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014926","Bone health in adults with obesity before and after interventions to promote weight loss.","Paccou J","2024","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(24)00163-3","39053479",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0014927","Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond.","Murakami T","2021","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2021.714348","34248856","PMC8270651",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0014928","Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.","Usui R","2018","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.12773","29106046","PMC6031501",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0014929","Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation.","Dai Y","2013","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-013-6463-z","23657563",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0014930","Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C10) and salcaprozate sodium (SNAC).","Twarog C","2022","International journal of pharmaceutics","other","article","10.1016/j.ijpharm.2022.122131","36028084",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014931","Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.","Meyhöfer SM","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04281-1","41928037","PMC13190271","ClinicalTrials.gov:NCT03574597","S000716; S001989","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0014932","Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: A focused time-to-event meta-analysis.","Abomohsen M","2026","Heart rhythm","systematic_review","article","10.1016/j.hrthm.2026.05.048","42217600",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0014933","In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA1c vs. placebo at 40 wk.","Shahid M","2025","Annals of internal medicine","commentary","article","10.7326/annals-25-03825-jc","41052453",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; editorial"],["R0014934","Rebalancing the Gut: Glucagon-Like Peptide-1 Agonists as a Strategy for Obesity and Metabolic Health.","Singh K","2024","Cureus","narrative_review","article","10.7759/cureus.64738","39156410","PMC11329331",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014935","GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity.","Wang L","2024","JAMA oncology","nonrandomized_study","article","10.1001/jamaoncol.2023.5573","38060218","PMC10704339",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0014936","Does GLP-1 receptor agonist liraglutide alter food-related sensory pleasure in patients with obesity? A randomized controlled trial","Coppin G","2022","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-1722974/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0014937","Access Barriers and Variable Response to Semaglutide in Severe Adolescent Obesity: A Case Series.","Nguyen AT","2026","Case reports in pediatrics","randomized_trial","article","10.1155/crpe/5562574","42369344","PMC13304229",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; case-study; article"],["R0014938","Beyond the known: prospective research directions for the gut-brain axis in obesity and type 1 diabetes mellitus.","Yang D","2026","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-025-02038-3","42050719","PMC13122937",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0014939","In alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk.","Rose M","2026","Annals of internal medicine","other","article","10.7326/annals-26-02636-jc","42546302",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014940","Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease.","Luong TV","2025","World journal of cardiology","narrative_review","article","10.4330/wjc.v17.i7.107751","40741021","PMC12304865",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014941","GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling.","Wang Y","2018","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2017.11.048","29223528",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014942","When New Therapies Meet Old Challenges: Tirzepatide-Warfarin Interaction in A Mechanical Mitral Valve Patient.","Natale R","2025","European journal of case reports in internal medicine","other","article","10.12890/2025_005823","41064709","PMC12503860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014943","Clinical Outcomes Associated with the Use of a Family-Based Digital Support Program in Patients with Pharmacologic Treatment for Obesity.","de Arriba Muñoz A","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15010222","41517470","PMC12786419",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014944","In brief: GI effects of GLP-1 receptor agonists.",null,"2023","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2023.1690e","37983121",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014945","Gestational diabetes: from pathogenesis to therapeutic intervention.","Zhang X","2026","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-026-02156-6","42035121","PMC13261929",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014946","Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.","Wang S","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-026-01848-6","41848818","PMC13103031","ClinicalTrials.gov:NCT06351748","S000366","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014947","Exendin-4 modifies adipogenesis of human adipose-derived stromal cells isolated from omentum through multiple mechanisms.","He X","2018","International journal of obesity (2005)","preclinical","article","10.1038/s41366-018-0024-2","29515208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014948","Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: \"The Earlier, the Better\" in Therapy with Incretin-Based Medicine.","Kaneto H","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22157917","34360682","PMC8348147",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014949","Molecular, genetic, and pharmacological advances in type 2 diabetes (2015-2025).","Romero R","2026","Biomolecular concepts","narrative_review","article","10.1515/bmc-2025-0059","42406681",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014950","Spatiotemporal Correlation Spectroscopy Reveals a Protective Effect of Peptide-Based GLP-1 Receptor Agonism against Lipotoxicity on Insulin Granule Dynamics in Primary Human β-Cells.","Ferri G","2021","Pharmaceutics","other","article","10.3390/pharmaceutics13091403","34575477","PMC8464798",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014951","Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.","Nicholls SJ","2026","JAMA cardiology","randomized_trial","article","10.1001/jamacardio.2025.4824","41433034","PMC12728728","ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0014952","Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetic Nephropathy: A Review of Clinical Effectiveness","Banerjee S","2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"31725208",null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Review; review"],["R0014953","Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction.","Kamei N","2018","Scientific reports","preclinical","article","10.1038/s41598-018-36210-9","30518944","PMC6281676",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014954","Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.","Brockmeyer M","2024","Journal of nephrology","systematic_review","article","10.1007/s40620-023-01858-8","38236473","PMC11043149",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0014955","Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System.","Thaibah HA","2025","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph18020214","40006028","PMC11858861",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014956","Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.","Monami M","2009","European journal of endocrinology","systematic_review","article","10.1530/eje-09-0101","19318378",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; review"],["R0014957","Molecular and cellular mechanisms of muscle-adipose tissue crosstalk driving sarcopenic obesity: an integrative review of human, animal, and in vitro models.","Seliem MA","2026","Nutrition & metabolism","preclinical","article","10.1186/s12986-026-01123-2","42129838","PMC13169740",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014958","Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity.","Gao W","2023","Nature metabolism","other","article","10.1038/s42255-023-00889-6","37709961","PMC11610247",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0014959","Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro.","Takaku S","2021","International journal of molecular sciences","preclinical","article","10.3390/ijms22062971","33804063","PMC7999558",null,"S000729; S000821","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0014960","The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder.","Chaves Filho AJM","2020","Progress in neuro-psychopharmacology & biological psychiatry","preclinical","article","10.1016/j.pnpbp.2020.109872","31954756",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014961","Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials.","Jiang G","2025","Aging clinical and experimental research","systematic_review","article","10.1007/s40520-025-03017-4","40325308","PMC12053337",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Comparative Study; Systematic Review; Network Meta-Analysis; research-article; review"],["R0014962","Weight loss associated with semaglutide use is linked to improved reproductive measures in polyendocrine metabolic ovarian syndrome: a proof-of-concept analysis.","Cree MG","2026","Fertility and sterility","other","article","10.1016/j.fertnstert.2026.06.002","42252045",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014963","Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).","Pozzilli P","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12937","28294499",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0014964","Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome.","Śledziona J","2026","Nutrients","nonrandomized_study","article","10.3390/nu18081275","42075085","PMC13118979",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0014965","Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment.","Zoccali C","2026","European heart journal","narrative_review","article","10.1093/eurheartj/ehag220","41914187",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0014966","Epidemiological Studies on Type 2 Diabetes Using the German Disease Analyser Database: A Narrative Review.","Kostev K","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71089","42410298","PMC13538734",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0014967","Targeting Vascular Calcification: Novel Insights into Molecular Pathways and Clinical Interventions.","Chen J","2026","Cardiovascular drugs and therapy","narrative_review","article","10.1007/s10557-025-07831-w","41569401",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0014968","Glucagon and glucagon-like peptide-1 dual agonist therapy: A possible future towards fatty kidney disease.","Kanbay M","2025","European journal of clinical investigation","narrative_review","article","10.1111/eci.14330","39400355",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0014969","Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.","Holman RR","2016","American heart journal","protocol","article","10.1016/j.ahj.2015.12.009","26995376",null,"ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial, Phase III; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Pragmatic Clinical Trial; article"],["R0014970","Analog of prolactin-releasing peptide reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.","Feetham CH","2026","Cell metabolism","preclinical","article","10.1016/j.cmet.2025.10.021","41330374",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0014971","Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.","Hirshberg B","2015","Current diabetes reports","other_trial","article","10.1007/s11892-015-0663-9","26370698",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0014972","The role of bone in energy metabolism: A focus on osteocalcin.","Smith C","2024","Bone","preclinical","article","10.1016/j.bone.2024.117238","39153587",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0014973","Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.","Tewari J","2025","Expert review of clinical pharmacology","systematic_review","article","10.1080/17512433.2025.2450254","39817343",null,"PROSPERO:CRD42024566153",null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0014974","Liraglutide Lowers Endothelial Vascular Cell Adhesion Molecule-1 in Murine Atherosclerosis Independent of Glucose Levels.","Punjabi M","2023","JACC. Basic to translational science","preclinical","article","10.1016/j.jacbts.2022.08.002","36908664","PMC9998474",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014975","Managing type 2 diabetes in the primary care setting: beyond glucocentricity.","Kuritzky L","2010","The American journal of the medical sciences","narrative_review","article","10.1097/maj.0b013e3181d64344","20571352",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0014976","Topography of the GLP-1/GLP-1 receptor system in the spinal cord of male mice.","Ruska Y","2024","Scientific reports","preclinical","article","10.1038/s41598-024-65442-1","38909126","PMC11193760",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014977","Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway.","Huetson P","2015","Journal of medical economics","other","article","10.3111/13696998.2015.1038271","25853868",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0014978","Acute tubular injury following a single dose of tirzepatide in a patient with diabetic kidney disease: a cautionary case.","Sathiavageesan S","2026","Postgraduate medical journal","other","article","10.1093/postmj/qgaf153","40966606",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014979","The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.","Malkin SJP","2021","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2021.108759","33744377",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0014980","Liraglutide directly protects cardiomyocytes against reperfusion injury possibly via modulation of intracellular calcium homeostasis.","Hu SY","2017","Journal of geriatric cardiology : JGC","preclinical","article","10.11909/j.issn.1671-5411.2017.01.008","28270843","PMC5329734",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0014981","GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.","Sun R","2024","American journal of hematology","commentary","article","10.1002/ajh.27348","38655752","PMC12556597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; research-article; article"],["R0014982","Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.","Guarnotta V","2021","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2021.07.015","34518091",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0014983","Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus.","Unger J","2010","Mayo Clinic proceedings","narrative_review","article","10.4065/mcp.2010.0470","21106866","PMC2996167",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0014984","Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.","Diz-Chaves Y","2022","International journal of molecular sciences","preclinical","article","10.3390/ijms23179583","36076972","PMC9455625",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0014985","Acute GLP-1 infusion in male adults lowers circulating angiotensin II without changing angiotensinogen, ACE, ACE2, or angiotensin-(1-7) concentrations.","Asmar A","2026","Physiological reports","randomized_trial","article","10.14814/phy2.70940","42249648","PMC13241703",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0014986","Endoluminal device induces insulin sensitivity and greater weight control than semaglutide in pigs.","Russo S","2026","Gut","other","article","10.1136/gutjnl-2025-337077","42120185",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0014987","Analysis of the neuroprotective effect of GLP-1 receptor agonist peptide on cerebral ischemia-reperfusion injury by Quantitative Proteomics Mass Spectrometry.","Li Y","2021","Brain and behavior","preclinical","article","10.1002/brb3.2190","34018701","PMC8213929",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0014988","Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations.","Meier JJ","2021","Frontiers in endocrinology","commentary","article","10.3389/fendo.2021.760153","34630338","PMC8496444",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Introductory Journal Article; Research Support, Non-U.S. Gov't; editorial"],["R0014989","Early protein restriction increases intra-islet GLP-1 production and pancreatic β-cell proliferation mediated by the β-catenin pathway.","da Rosa-Santos CA","2020","European journal of nutrition","preclinical","article","10.1007/s00394-020-02192-6","32076803",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0014990","Glucagon‐like peptide‐1 analogues for overweight or obese adults","Madrid E","2022","The Cochrane database of systematic reviews","narrative_review","article","10.1002/14651858.cd015092",null,"PMC9454257",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","systematic-review; Review; article"],["R0014991","Comparison of medication adherence and persistence in type 2 diabetes: A systematic review and meta-analysis.","McGovern A","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13160","29135080",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0014992","Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis.","Kim JS","2024","Diabetes & metabolism journal","systematic_review","article","10.4093/dmj.2022.0421","38273787","PMC10995485",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0014993","LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.","Urva S","2022","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(22)02033-5","36354040",null,"ClinicalTrials.gov:NCT04143802","S001665","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase I; Journal Article; article"],["R0014994","IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience.","Di Loreto C","2020","European review for medical and pharmacological sciences","nonrandomized_study","article","10.26355/eurrev_202010_23425","33155225",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0014995","GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.","Leggio L","2023","Nature medicine","other","article","10.1038/s41591-023-02634-8","38001271","PMC12320759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural; research-article; article"],["R0014996","Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions.","Anderer S","2026","JAMA","commentary","article","10.1001/jama.2026.2123","42030062",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0014997","Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity.","Wu JY","2026","Annals of the American Thoracic Society","nonrandomized_study","article","10.1093/annalsats/aaoaf070","41915556",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0014998","Profiling human hypothalamic neurons reveals a candidate combination drug therapy for weight loss","Chen HC","2023","bioRxiv","preclinical","preprint","10.1101/2023.07.18.549357",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0014999","Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.","Villela R","2022","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","commentary","article","10.1136/jim-2021-002227","34949728",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0015000","Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.","Terauchi Y","2014","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej14-0147","25029955",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0015001","Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.","Sinha R","2023","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes22067","36750526","PMC10088547",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015002","Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH).","Wood E","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70314","41365848",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0015003","Navigating the Evolving Roles of GLP-1 Agonists Safely and Effectively.","Ockerman KM","2024","Aesthetic surgery journal","nonrandomized_study","article","10.1093/asj/sjae166","39041863",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Editorial; article"],["R0015004","Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey.","Gibble TH","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100298","42518363","PMC13382417",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015005","Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats.","Ziebarth J","2024","Pharmaceutics","preclinical","article","10.3390/pharmaceutics16050634","38794296","PMC11125159",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015006","Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes.","Pablo Frias J","2019","Current medical research and opinion","randomized_trial","article","10.1080/03007995.2018.1541316","30360647",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015007","PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.","Chen Y","2020","Endocrine","preclinical","article","10.1007/s12020-020-02470-7","32862405",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015008","Glucagon-like peptide-1 receptor PET/CT in patients with and without post gastric bypass hypoglycemia – a prospective, matched case-control study","Hepprich M","2022","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-1561857/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0015009","Lux is not just lux: Method for determining the photostability of drug products.","Tawfieq M","2026","Journal of pharmaceutical sciences","other","article","10.1016/j.xphs.2026.104259","41876085",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015010","Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics.","Li F","2026","BMJ open gastroenterology","narrative_review","article","10.1136/bmjgast-2026-002343","42392673","PMC13331188",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015011","Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.","Gibble TH","2025","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.70011","40903801","PMC12559773","ClinicalTrials.gov:NCT04660643","S000242","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0015012","The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.","Maida A","2008","Endocrinology","preclinical","article","10.1210/en.2008-0336","18669601",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015013","Tirzepatide reduces intracellular lipid content by promoting the browning of white fat via the cAMP signaling pathway.","Sun Y","2026","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2026.178523","41506434",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015014","Latent Autoimmune Diabetes in Adults: Current Status and New Horizons.","Pozzilli P","2018","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2018.33.2.147","29947172","PMC6021307",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015015","Semaglutide and health risk: Development and validation of a LC-HRMS method for testing semaglutide in whole blood and application to real cases.","Arbouche N","2024","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","other","article","10.1016/j.jchromb.2024.124187","38880054",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015016","Weight-Reduction and Safety Profile of Once-Weekly Non-Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real-World Retrospective Study.","Hasan MR","2026","Health science reports","nonrandomized_study","article","10.1002/hsr2.71745","41523850","PMC12783696",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015017","Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes.","Candido R","2023","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm12186052","37762991","PMC10532177",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015018","Pre-Clinical Evaluation of a Modified Cyclodextrin-Based Nanoparticle for Intestinal Delivery of Liraglutide.","Presas E","2021","Journal of pharmaceutical sciences","preclinical","article","10.1016/j.xphs.2020.10.058","33152374",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015019","[Results of the LEADER study: current evidence and perspectives in research].","Mannucci E","2016","Giornale italiano di cardiologia (2006)","other_trial","article","10.1714/2616.26913","28151519",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0015020","Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study.","Tankova T","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-019-00748-2","31898083","PMC6995808",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015021","GLP-1 receptor agonists: European drug regulator asks makers for evidence of self-harm.","Cohen D","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p2906","38084503",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015022","Feasibility of a Scale-down Production of [68Ga]Ga-NODAGA-Exendin-4 in a Hospital Based Radiopharmacy.","Migliari S","2022","Current radiopharmaceuticals","other","article","10.2174/1874471014666210309151930","33687908",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015023","Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.","Shao H","2022","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2022.108132","35101326",null,"ClinicalTrials.gov:NCT02058147; ClinicalTrials.gov:NCT00069784","S001199","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015024","Structural determinants of dual incretin receptor agonism by tirzepatide.","Sun B","2022","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.2116506119","35333651","PMC9060465",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015025","Case Report: Rhabdomyolysis following initiation of tirzepatide.","Bodanowitz JM","2025","Frontiers in pharmacology","case_report","article","10.3389/fphar.2025.1660785","40910008","PMC12405190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015026","Increasing Direct-to-Consumer Use of Semax and Selank Peptides Decoded from LLM-Curated Clinical Notes and Physician Adjudication","Marwaha A","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202609.2396.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0015027","The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.","Erlandson KM","2026","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","other","article","10.1093/cid/ciaf652","41299212","PMC13017447","ClinicalTrials.gov:NCT04216589","S001796","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0015028","Association of novel antihyperglycaemic drugs versus metformin with COPD exacerbations.","Kimura Y","2025","ERJ open research","nonrandomized_study","article","10.1183/23120541.00757-2024","40432813","PMC12107380",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015029","Backbone N-Methylation Improves PPCA-Binding of a Stylissatin A Analogue via Conformational Modulation.","Luthfiana D","2026","Chemistry, an Asian journal","other","article","10.1002/asia.70906","42502249","PMC13401725",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015030","Efficacy of the glucagon-like peptide-1 agonist Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomized double-blind clinical trial","Kjaergaard J","2024","medRxiv","randomized_trial","preprint","10.1101/2024.10.15.24315567",null,null,"EudraCT:2015-003050-41",null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0015031","Exendin-4 inhibits structural remodeling and improves Ca2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway.","Chen J","2017","Peptides","preclinical","article","10.1016/j.peptides.2017.02.008","28242257",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015032","Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial.","Jensterle M","2021","Trials","protocol","article","10.1186/s13063-021-05442-y","34281590","PMC8287101","ClinicalTrials.gov:NCT04263415","S000894","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; other; article"],["R0015033","A comprehensive review of GLP-1 and aerobic training in cardiovascular disease management.","Kordi N","2025","Clinical hemorheology and microcirculation","narrative_review","article","10.1177/13860291251414840","41960862",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015034","Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making.","Scholz GH","2014","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018814556099","25419451","PMC4236299",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015035","Establishing best practices for obesity and metabolic syndrome in liver transplantation: Insights from a modified Delphi-based controversies conference.","Davis JPE","2026","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","other","article","10.1016/j.ajt.2025.10.008","41135885",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015036","Efficacy and safety of iGlarLixi versus insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.","Li J","2025","Endocrine","systematic_review","article","10.1007/s12020-025-04207-w","40011373",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Comparative Study; review"],["R0015037","SEMAGLUTIDE: Weight loss, glycaemic control and safety profile in obese patients with and without type-II diabetes-An experience from Karachi, Pakistan.","Memon MY","2024","Journal of family medicine and primary care","nonrandomized_study","article","10.4103/jfmpc.jfmpc_159_24","39629429","PMC11610810",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015038","Hyperkaliémie chez les diabétiques : quel effet attendu des iSGLT2, GLP-1-RA et inhibiteurs iDPP-4 ?","Chheang C","2024","Revue medicale suisse","commentary","article","10.53738/revmed.2024.20.895.2147","39544068",null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","News; article"],["R0015039","External Validation of an Automated Segmentation Tool for Abdominal Fat Tissue using DIXON MRI: Data from the CutDM trial","Linden FH","2025","medRxiv","other_trial","preprint","10.1101/2025.05.14.25327583",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0015040","Reduced GLP-1R availability in the caudate nucleus with Alzheimer's disease.","Barrett E","2024","Frontiers in aging neuroscience","nonrandomized_study","article","10.3389/fnagi.2024.1350239","38915346","PMC11194438",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0015041","Liraglutide Ameliorates Injury-Related Vascular Repair by Activating Autophagy Through Modulation of the PI3K-mTOR Signaling Pathway.","Zhang Z","2026","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.202501740rr","41486848","PMC12766259",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015042","Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.","Cusi K","2018","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.13697","29869810",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015043","Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats.","Chen YC","2017","PloS one","preclinical","article","10.1371/journal.pone.0187434","29095895","PMC5667749",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015044","Regulation of microRNA-375 by cAMP in pancreatic β-cells.","Keller DM","2012","Molecular endocrinology (Baltimore, Md.)","preclinical","article","10.1210/me.2011-1205","22539037","PMC3355542",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0015045","Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study.","Ashraf AR","2024","Journal of medical Internet research","other","article","10.2196/65440","39509151","PMC11582493",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015046","Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom.","Brod M","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-019-0636-0","31127490","PMC6612333",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015047","Glucagon-like peptide-1 receptors in the gustatory cortex influence food intake","Dossat AM","2022","bioRxiv","preclinical","preprint","10.1101/2022.08.26.505475",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015048","Obesity, Nutrition and the Multiple Sclerosis Risk in Adolescents.","Giovengo M","2026","Brain sciences","narrative_review","article","10.3390/brainsci16030283","41892626","PMC13025375",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015049","Alpha-to-beta cell crosstalk: Adaptive mechanisms shaping islet function.","Tröster P","2026","Advances in biological regulation","preclinical","article","10.1016/j.jbior.2025.101121","41067947",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0015050","Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution.","Zhang N","2026","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.6c00466","42125916",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015051","Obesity management in the setting of endometrial cancer and hyperplasia: A narrative review.","Moshayedi N","2025","Gynecologic oncology reports","narrative_review","article","10.1016/j.gore.2025.101929","40917133","PMC12408227",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0015052","Psoriasis flare following tirzepatide initiation in a patient with plaque psoriasis in remission: A case report.","Neptune Rosa JM","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.02.006","42005509","PMC13089024",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015053","Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study.","Ritzel R","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01798-5","41269514","PMC12847599",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015054","GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.","Tentolouris A","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71045","42380553","PMC13538808",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015055","Addendum 2: Forum for Injection Technique, India","Kalra S","2014","Indian Journal of Endocrinology and Metabolism","narrative_review","article","10.4103/2230-8210.141344",null,"PMC4192984",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","review-article; Review; Journal Article; article"],["R0015056","Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression.","Cai Y","2012","Molecular biology reports","preclinical","article","10.1007/s11033-012-1961-9","23053967",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015057","Comprehensive Review of Sepsis-Related Skeletal Muscle Atrophy: Mechanisms, Diagnosis and Therapeutic Strategies.","Wu Q","2025","Journal of inflammation research","narrative_review","article","10.2147/jir.s554850","41458356","PMC12741264",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015058","Differential Effects of Prostaglandin E  <sub>2<\/sub>  Production and Signaling through the Prostaglandin EP3 Receptor on Human Beta-cell Compensation","Truchan NA","2019","bioRxiv","preclinical","preprint","10.1101/670000",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015059","Weight loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk.","Karam L","2025","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.24341","40537906",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015060","Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.","Mader JK","2016","Clinical pharmacokinetics","randomized_trial","article","10.1007/s40262-016-0413-4","27282158","PMC5069309","ClinicalTrials.gov:NCT01536665","S002381","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0015061","Cardiovascular Implications of Diabetes Mellitus: A Systematic Literature Review.","Gupta PK","2026","Cureus","randomized_trial","article","10.7759/cureus.109607","42359232","PMC13292806",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0015062","Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes.","Sato G","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-026-01864-6","41949717","PMC13156336","UMIN:UMIN000059813",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015063","Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).","Yabe D","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14882","36184780","PMC10092154",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015064","Microencapsulated Oleic Acid for Laxative Effect in Post-Bariatric Surgery and GLP-1 Analogue Patients.","Li L","2024","Obesity surgery","commentary","article","10.1007/s11695-024-07549-y","39425862",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015065","Semaglutide restores metabolic and structural homeostasis along the gut-heart-metabolic axis in a cafeteria diet-induced obesity model.","Doganay S","2026","Scientific reports","preclinical","article","10.1038/s41598-026-41954-w","41872245","PMC13168637",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015066","Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?","Nauck MA","2013","Diabetologia","other","article","10.1007/s00125-013-2953-6","23748861",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015067","Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.","Xie Y","2023","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(23)00171-7","37499675",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; article"],["R0015068","Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.","Yu H","2025","European journal of nuclear medicine and molecular imaging","nonrandomized_study","article","10.1007/s00259-025-07288-x","40259061",null,"ClinicalTrials.gov:NCT06690957; ClinicalTrials.gov:NCT06725693","S001660","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Observational Study; article"],["R0015069","A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.","Tashiro Y","2014","Peptides","preclinical","article","10.1016/j.peptides.2013.12.015","24418070",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015070","Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity",null,"2026","National Institute for Health and Care Excellence (NICE), London","narrative_review","article",null,"42384840",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0015071","Bariatric surgery - time to replace with GLP-1?","Webb DL","2017","Scandinavian journal of gastroenterology","narrative_review","article","10.1080/00365521.2017.1293154","28276830",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015072","Tirzepatide and Kidney Protection in Obesity: Unanswered Questions.","Zhu Z","2025","Journal of the American Society of Nephrology : JASN","other_trial","article","10.1681/asn.0000000837","40960876","PMC12677810",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; letter; article"],["R0015073","Semaglutide in metabolic dysfunction-associated alcohol-related liver disease: a potential dual-target therapy for metabolic dysfunction and alcohol use.","Nery F","2026","European journal of gastroenterology & hepatology","other","article","10.1097/meg.0000000000003185","42214023",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015074","Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real-World Evidence From the REALISED Study.","Wannachalee T","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70701","41877352","PMC13146152",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0015075","Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.","Baggio LL","2021","Molecular metabolism","narrative_review","article","10.1016/j.molmet.2020.101090","32987188","PMC8085566",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0015076","Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies.","Williams DM","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-020-00917-8","32880877","PMC7471542",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0015077","An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program.","Frías JP","2023","Expert review of endocrinology & metabolism","other_trial","article","10.1080/17446651.2023.2184796","36908082",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0015078","[Semaglutide is safe and effective for prediabetes and obesity in patients with schizofrenia.].","Serafini A","2026","Recenti progressi in medicina","other","article","10.1701/4649.46626","41716099",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015079","Noninvasive Evaluation of GIP Effects on β-Cell Mass Under High-Fat Diet.","Kiyobayashi S","2022","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2022.921125","35909510","PMC9326491",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015080","Tirzepatide reverses hypothalamic inflammation, cellular stress, and neuropeptide imbalance in metabolic-menopausal dysfunction.","Marinho TS","2026","Brain research","preclinical","article","10.1016/j.brainres.2025.150113","41407242",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015081","Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH.","Hupa-Breier KL","2021","Biomedicines","preclinical","article","10.3390/biomedicines9040353","33808404","PMC8066839",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015082","PSUN276 GLP1RAs use for treating NALFD in a multidisciplinary clinic in low socioeconomic community",null,"2022","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC9627257",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0015083","Liraglutide ameliorates delirium-like behaviors of aged mice undergoing cardiac surgery by mitigating microglia activation via promoting mitophagy.","Jia M","2024","Psychopharmacology","preclinical","article","10.1007/s00213-023-06492-7","37968531","PMC10927895",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015084","Managing bile acid diarrhea: aspects of contention.","Walters JRF","2024","Expert review of gastroenterology & hepatology","narrative_review","article","10.1080/17474124.2024.2402353","39264409",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015085","Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.","Kim SH","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14242","33140542","PMC7856054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0015086","Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting.","Canivell S","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13663","30756446",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015087","Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study.","Falkentoft AC","2022","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2022.100308","35146474","PMC8802041",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015088","Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause.","Nicolau J","2025","Metabolic syndrome and related disorders","other","article","10.1089/met.2024.0124","39761057",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015089","Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.","Farmer RE","2021","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2020.12.015","33581878",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0015090","Emerging technologies for early risk stratification and precision management of diabetic kidney disease: a multimodal framework integrating digital phenotypes and clinical biomarkers.","Meng L","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1728293","41585789","PMC12827177",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0015091","Response to \"Weight-loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk\".","Kushner RF","2025","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.24345","40545770",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015092","Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways.","Nagayama K","2015","PloS one","preclinical","article","10.1371/journal.pone.0137960","26379274","PMC4574935",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015093","Circulating GDF15 and HbA1c Response to Add-On Exenatide Therapy in Type 2 Diabetes: A Post Hoc Analysis from a Multicenter Trial.","Wu Q","2026","Biomedicines","other_trial","article","10.3390/biomedicines14030572","41898219","PMC13024465",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0015094","Type 2 Diabetes Mellitus: Outpatient Insulin Management.","Howard-Thompson A","2018","American family physician","other","article",null,"29365240",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015095","Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment.","Kozlitina J","2026","Hepatology (Baltimore, Md.)","other","article","10.1097/hep.0000000000001758","41962050",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015096","Liraglutide: A New Option for the Treatment of Obesity.","Nuffer WA","2015","Pharmacotherapy","nonrandomized_study","article","10.1002/phar.1639","26497479",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0015097","Exendin-4 Promotes Survival of Mouse Pancreatic β-Cell Line in Lipotoxic Conditions, through the Extracellular Signal-Related Kinase 1/2 Pathway.","Gu J","2016","Journal of diabetes research","preclinical","article","10.1155/2016/5294025","27656657","PMC5021481",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015098","Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.","Xu S","2022","Bioengineered","preclinical","article","10.1080/21655979.2021.1995993","34696658","PMC8974032",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015099","Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway.","Qi R","2024","Reproductive biology and endocrinology : RB&E","preclinical","article","10.1186/s12958-024-01202-0","38509558","PMC10953080",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015100","Exendin-4 promotes the vascular smooth muscle cell re-differentiation through AMPK/SIRT1/FOXO3a signaling pathways.","Liu Z","2018","Atherosclerosis","preclinical","article","10.1016/j.atherosclerosis.2018.07.016","30036742",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015101","Injections vs. Scalpels: Where Do Surgery and GLP-1's Align in Modern Obesity treatment?","Lindquist M","2025","Missouri medicine","narrative_review","article",null,"40787019","PMC12331298",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0015102","The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.","Viljoen A","2023","The European journal of health economics : HEPAC : health economics in prevention and care","nonrandomized_study","article","10.1007/s10198-022-01514-1","36114904","PMC10290607",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015103","Early hypocortisolism with persistent remission following osilodrostat in a patient with long-standing Cushing disease.","Sasson L","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag033","41858510","PMC12996763",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015104","Obesity-driven low-grade chronic inflammation as a mechanistic bridge to chronic pain: from adipose tissue remodeling to central sensitization.","Ma YX","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1889437","42597587","PMC13469887",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015105","Is Maternal Diabetes Mellitus Type 2 a Protective Factor for Atopic Dermatitis in Children? A Nationwide Retrospective Cohort Study.","Weissmann S","2026","Dermatitis : contact, atopic, occupational, drug","nonrandomized_study","article","10.1177/17103568261454831","42249778",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015106","Emerging GLP-1 receptor agonists.","Lund A","2011","Expert opinion on emerging drugs","narrative_review","article","10.1517/14728214.2011.616493","21905764",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015107","First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.","Rendell M","2015","Drugs of today (Barcelona, Spain : 1998)","narrative_review","article","10.1358/dot.2015.51.3.2294596","25876562",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015108","A deep learning-based system for automatic detection of emesis with high accuracy in Suncus murinus.","Lu Z","2025","Communications biology","preclinical","article","10.1038/s42003-025-07479-0","39930110","PMC11811283",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015109","GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway.","Wu L","2022","Biochimica et biophysica acta. Molecular cell research","preclinical","article","10.1016/j.bbamcr.2022.119300","35636559",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015110","Remission of erythromelalgia after semaglutide initiation: A case report.","Laugsand SS","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.03.061","42088719","PMC13137036",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015111","Prescribing GLP-1 Agonists for Weight Loss: Wrestling With Our Philosophical Angst.","Rao M","2024","American family physician","commentary","article",null,"39418563",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0015112","Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology.","Xie H","2026","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2025.2469273","40049721",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0015113","The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF.","Komić L","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27020612","41596265","PMC12841457",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015114","Subtype-Specific Causal Effects of Antidiabetic Drug Targets on Ovarian Cancer: Mendelian Randomization and Colocalization Evidence.","Tang E","2026","International journal of women's health","nonrandomized_study","article","10.2147/ijwh.s578124","41835849","PMC12988754",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015115","Glucagon orchestrates stress-induced hyperglycaemia.","Harp JB","2016","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12668","27027662","PMC5084782",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015116","Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort.","Liu S","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71004","42297751","PMC13449065",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0015117","Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.","Ahrén B","2014","World journal of diabetes","narrative_review","article","10.4239/wjd.v5.i1.40","24567800","PMC3932426",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015118","Correction: Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study.","Hirotsu T","2026","Frontiers in clinical diabetes and healthcare","notice","article","10.3389/fcdhc.2026.1914250","42518971","PMC13383096",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0015119","Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake.","Klemets A","2026","Scientific reports","other","article","10.1038/s41598-026-36318-3","41580554","PMC12902008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015120","68Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism.","Boss M","2022","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","other","article","10.2967/jnumed.121.262327","34215672","PMC8805776",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015121","Converging neurotrophic-immune signaling in autism spectrum disorder: integrative roles of klotho, GDNF/GFRA-1, IGF-1 and GLP-1 pathways.","Verma J","2026","Metabolic brain disease","narrative_review","article","10.1007/s11011-026-01866-0","42154377",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015122","Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism.","Chen X","2026","Frontiers in clinical diabetes and healthcare","other","article","10.3389/fcdhc.2026.1815726","42232304","PMC13222939",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015123","Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets.","Sloop KW","2010","Diabetes","preclinical","article","10.2337/db10-0689","20823098","PMC2992771",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015124","Bone: incretin hormones perceiver or receiver?","Dicembrini I","2012","Experimental diabetes research","preclinical","article","10.1155/2012/519784","22761607","PMC3385656",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0015125","Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.","Guo L","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00248-7","41167231",null,"ClinicalTrials.gov:NCT05691712","S000043","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0015126","The promoting roles of GLP1R and GIPR in stemness maintenance and multiple lineage-specific differentiation of PDLSCs.","Shen Y","2026","Cellular & molecular biology letters","preclinical","article","10.1186/s11658-026-00867-2","41673566","PMC12903609",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015127","ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.","Zheng Z","2026","Molecular metabolism","randomized_trial","article","10.1016/j.molmet.2026.102340","41833222","PMC12990342","ClinicalTrials.gov:NCT05121441",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0015128","Glucagon-like Peptide-1 Acts as Signaling Mediator to Modulate Human Sperm Performance via Targeting Akt, JNK and IRS-1 Cell Signaling Cascades: Novel Insights into Sperm Physiopathology.","Castiglione R","2023","Journal of clinical medicine","other","article","10.3390/jcm12113844","37298039","PMC10254041",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015129","Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.","Iglesias P","2015","Obesity surgery","other_trial","article","10.1007/s11695-014-1563-9","25589020",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0015130","Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y2 receptor tri-agonist for obesity and type 2 diabetes.","Liu X","2025","International journal of biological macromolecules","preclinical","article","10.1016/j.ijbiomac.2025.147553","40935040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015131","Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date.","Pearson S","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s229802","31819577","PMC6897065",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015132","FDA Approves Higher-Dose Injectable Semaglutide.","Anderer S","2026","JAMA","other","article","10.1001/jama.2026.1030","41931277",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015133","[Liraglutide improves cardiac structure and function in mice with advanced diabetic nephropathy and massive proteinuria].","Yan Y","2026","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article","10.12122/j.issn.1673-4254.2026.05.12","42198969","PMC13213353",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; research-article; other"],["R0015134","Epicardial Fat Paradox and Differential Effects of GLP-1 Receptor Agonists Across Heart Failure Phenotypes.","Banerjee M","2023","Circulation. Heart failure","commentary","article","10.1161/circheartfailure.123.010966","38010208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0015135","Developing a novel exenatide-based incretin mimic (αB-Ex): Expression, purification and structural-functional characterization.","Ghanbarnezhad MM","2022","Biochimica et biophysica acta. General subjects","preclinical","article","10.1016/j.bbagen.2022.130150","35417766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015136","Future directions for peptide therapeutics development.","Kaspar AA","2013","Drug discovery today","narrative_review","article","10.1016/j.drudis.2013.05.011","23726889",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0015137","Is there a place for incretin therapies in obesity and prediabetes?","Holst JJ","2013","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2013.01.004","23415157",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015138","The Effect of Liraglutide on the Hypolipidemic, Anti-Inflammatory, and Antioxidant Properties of Atorvastatin Mediated via the Nrf2/HO-1 Signaling Pathway: In Vivo and In Silico Validation.","Kamar SA","2026","Pharmaceutics","preclinical","article","10.3390/pharmaceutics18040490","42076140","PMC13118698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015139","Male Obesity and Cardiometabolic Risk: Inflammatory Mechanisms and Clinical Implications.","Medeiros RO","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14071414","42511889","PMC13403745",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015140","Exendin-4 promotes bone formation in diabetic states via HDAC1-Wnt/β-catenin axis.","Deng Y","2021","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2021.01.039","33516884",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015141","Spint1 disruption in mouse pancreas leads to glucose intolerance and impaired insulin production involving HEPSIN/MAFA.","Lin HH","2024","Nature communications","preclinical","article","10.1038/s41467-024-54927-2","39627229","PMC11615295",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015142","How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access Ahead of Patent Expiry","Levi J","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.03.04.26347508",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0015143","Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.","Hu S","2022","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2022.831364","35250578","PMC8894868",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015144","Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes.","Sennik D","2012","Expert review of endocrinology & metabolism","other","article","10.1586/eem.11.79","30736106",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015145","Mitochondrial Dysfunction in Type 2 Diabetes and Metabolic Syndrome: Mechanisms, Biomarkers, and Emerging Therapies.","Alghzawi HM","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s627029","42807121","PMC13616595",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015146","Thermosensitive hydrogels for sustained semaglutide release: overcoming weight loss plateau in diet-induced obese rats.","Wang J","2026","Pharmaceutical development and technology","preclinical","article","10.1080/10837450.2026.2703559","42454991",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015147","Delayed Administration of the Glucagon-Like Peptide 1 Analog Liraglutide Promoting Angiogenesis after Focal Cerebral Ischemia in Mice.","Chen Y","2018","Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","preclinical","article","10.1016/j.jstrokecerebrovasdis.2017.12.015","29395648",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015148","Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations.","Fouad Y","2026","Expert review of endocrinology & metabolism","narrative_review","article","10.1080/17446651.2026.2698115","42397248",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015149","Enhanced lymphatic transportation of SLN by mimicking oligopeptide transportation route.","Jia F","2025","Asian journal of pharmaceutical sciences","preclinical","article","10.1016/j.ajps.2025.101019","40503058","PMC12152548",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015150","Exploring Liraglutide's mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway.","Chen Q","2025","Scientific reports","preclinical","article","10.1038/s41598-025-85658-z","39799153","PMC11724886",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015151","Advances and challenges of targeting epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT).","Liu D","2025","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-025-02763-z","40760703","PMC12323123",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015152","The Effect of Liraglutide on Lung Cancer and Its Potential Protective Effect on High Glucose-Induced Lung Senescence and Oxidative Damage.","Pu Z","2023","Frontiers in bioscience (Landmark edition)","preclinical","article","10.31083/j.fbl2810259","37919054",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015153","Correction: Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway.","Wu A","2026","Scientific reports","notice","article","10.1038/s41598-026-57581-4","42286095","PMC13263326",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0015154","Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects.","Zhang Q","2023","Expert opinion on biological therapy","randomized_trial","article","10.1080/14712598.2023.2189009","36880118",null,"ChiCTR:ChiCTR2200066519",null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0015155","Diet-induced obesity impairs refeeding responses and downregulates lateral septal GLP-1R in male rats: an effect reversed by weight-loss treatment.","Covarrubias MJ","2026","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2026.1801283","42137341","PMC13167487",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015156","The Impact of Novel Medications for Obesity on Weight Stigma and Societal Attitudes: A Narrative Review.","Heitmann BL","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00611-5","39907856","PMC11799028",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0015157","Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence.","Murvelashvili N","2023","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23736","36998152","PMC12398307",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015158","Medication-Stratified Analysis of LDL-C Equation Miscalibration in Diabetes: Evidence from the All of Us Research Program and a Medication-Agnostic Machine-Learning Correction.","Doku R","2025","medRxiv : the preprint server for health sciences","other","article","10.1101/2025.10.23.25338682","41282653","PMC12633579",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0015159","Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.","Nakashima R","2014","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2014.05.014","24858371",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015160","SELFormer-guided discovery of xanthohumol and cirsilineol as multi-target natural therapeutics for type 2 diabetes: computational prediction and experimental validation.","Zhou J","2026","Food & function","preclinical","article","10.1039/d5fo03765d","41923660",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015161","Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.","Jin P","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70849","42219225","PMC13341324",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; research-article; article"],["R0015162","Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.","Fadini GP","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13508","30136354","PMC6585815",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0015163","The Metabolic Heart: Reframing Heart Failure With Preserved Ejection Fraction as a Systemic Cardio-Metabolic Syndrome.","Baidya D","2026","Cureus","randomized_trial","article","10.7759/cureus.100590","41635389","PMC12862494",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015164","Chronic Kidney Disease Stage G4 in a Diabetic Patient Improved by Multi-Disciplinary Treatments Based Upon Literature Search for Therapeutic Evidence.","Yanai H","2022","Cardiology research","other_trial","article","10.14740/cr1424","36405227","PMC9635773",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0015165","Regional and national trends in prescription of guideline directed cardio-kidney protective medications in people with type 2 diabetes and cardio-kidney disease.","Agarwal S","2026","Primary care diabetes","other","article","10.1016/j.pcd.2026.07.015","42552183",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015166","GLP-1 and diabetic nephropathy share key molecular targets.","Melo W","2026","Canadian journal of physiology and pharmacology","other","article","10.1139/cjpp-2025-0146","41593860",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015167","[Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].","Scheen AJ","2019","Revue medicale de Liege","other_trial","article",null,"31486321",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; article"],["R0015168","Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.","Chen H","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-016-0198-3","27655330","PMC5118236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0015169","[Pharmacological treatments for obesity : what does the future hold?].","Correia JC","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.910.542","40111297",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0015170","Glucagon-Like Peptide-1 Receptors in the Gustatory Cortex Influence Food Intake.","Dossat AM","2023","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.1668-22.2023","37127362","PMC10254994",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0015171","The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice.","Burmeister MA","2017","Diabetes","preclinical","article","10.2337/db16-1102","27908915","PMC5248999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015172","Metabolic and Bariatric Surgery as a Therapeutic Option for MASLD: Outcome, Mechanism, and Long-Term Implications.","Tuffs C","2026","Zeitschrift fur Gastroenterologie","narrative_review","article","10.1055/a-2927-4771","42777698",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015173","GLP-1 Agonists for Obesity.","Kurian M","2024","JAMA","commentary","article","10.1001/jama.2024.12071","39083283",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0015174","Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial.","Mangalesh S","2026","Lancet (London, England)","other_trial","article","10.1016/s0140-6736(26)00255-2","42035776",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; article"],["R0015175","How to fight obesity with antidiabetic drugs: targeting gut or kidney?","Baretić M","2015","Minerva endocrinologica","narrative_review","article",null,"25366984",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015176","Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis.","Momeni P","2026","Online journal of public health informatics","nonrandomized_study","article","10.2196/80660","41734897","PMC12976598",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article; preprint"],["R0015177","Interventions for High Body Mass Index in Children and Adolescents: An Evidence Update for the U.S. Preventive Services Task Force","O’Connor E","2024","Agency for Healthcare Research and Quality (US), Rockville (MD)","randomized_trial","article",null,"38913817",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0015178","Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats.","Hernandez NS","2018","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/s41386-018-0010-3","29497166","PMC6098066",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015179","GLP-1 Agonists for Obesity.","Moran AJ","2024","JAMA","commentary","article","10.1001/jama.2024.12074","39083284",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0015180","GLP-1 Agonists for Obesity.","Langland JT","2024","JAMA","commentary","article","10.1001/jama.2024.12065","39083266",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0015181","GLP-1 Agonists for Obesity.","Dellgren J","2024","JAMA","commentary","article","10.1001/jama.2024.12068","39083262",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0015182","Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.","Verge D","2010","Current diabetes reviews","narrative_review","article","10.2174/157339910791658853","20380625",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Evaluation Study; Journal Article; Review; article"],["R0015183","Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial.","Tondt J","2026","Lancet (London, England)","other_trial","article","10.1016/s0140-6736(26)00256-4","42035775",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; article"],["R0015184","Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story.","Inceu AI","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms24043385","36834796","PMC9965280",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015185","Slimming the risks: GLP-1 receptor agonist therapy may reduce in-hospital complications and hospital readmissions rates for hip fractures compared to obese patients not on these medications.","Goldstein AR","2025","European journal of orthopaedic surgery & traumatology : orthopedie traumatologie","nonrandomized_study","article","10.1007/s00590-025-04477-0","40892123",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015186","Hypoglycaemia in Older Adults with Diabetes: Pathophysiology, Prevention, and Personalized Care in an Aging Population.","Boccardi V","2025","Drugs & aging","narrative_review","article","10.1007/s40266-025-01236-y","40928600",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015187","Synergistic role of exercise and liraglutide in modulating GLP-1R binding and metabolic outcomes: a combined computational and experimental study.","Razmi S","2026","3 Biotech","preclinical","article","10.1007/s13205-025-04692-w","41710474","PMC12909655",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015188","Obesity treatment as a bridge to solid organ transplantation: A comparison of bariatric surgery to medical therapy.","Roddy KL","2025","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2025.100199","40918087","PMC12408390",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0015189","Geroprotective Effects of Drugs Modulating Metabolic Pathways: Perspectives of Pharmacology in Anti-Aging Therapy.","Grycan M","2026","International journal of molecular sciences","randomized_trial","article","10.3390/ijms27177521","42737424","PMC13565775",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015190","Comparative effectiveness of long-term anti-obesity medications in routine clinical practice: a retrospective cohort study using real-world data.","Kim CG","2025","Translational and clinical pharmacology","nonrandomized_study","article","10.12793/tcp.2025.33.e20","41551732","PMC12806651",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015191","Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.","Tuttle KR","2026","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2026.02.5125","42233552",null,"ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0015192","Increasing β-cell mass requires additional stimulation for adaptation to secretory demand.","Mondal P","2015","Molecular endocrinology (Baltimore, Md.)","preclinical","article","10.1210/me.2014-1265","25387052","PMC4280528",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0015193","Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.","Heise T","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70863","42229460","PMC13341334",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0015194","Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus.","Petersen AB","2013","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s45379","23825925","PMC3698027",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0015195","An Exceedingly Rare Case of Liraglutide-Induced Liver Injury.","Parvataneni S","2021","Case reports in gastrointestinal medicine","case_report","article","10.1155/2021/6306149","34471551","PMC8405313",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015196","An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors.","Kılıçkap M","2021","Anatolian journal of cardiology","narrative_review","article","10.14744/anatoljcardiol.2020.06630","33583813","PMC8114646",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015197","Incretin-based therapies, glucometabolic health and endovascular inflammation.","Rizzo M","2014","Current pharmaceutical design","preclinical","article","10.2174/1381612819666131206102255","24320037",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015198","Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.","Wang Y","2011","Diabetes, obesity & metabolism","systematic_review","article","10.1111/j.1463-1326.2011.01436.x","21651690",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; article"],["R0015199","Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.","Rodbard HW","2017","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/dme.13256","27589252","PMC5811787",null,"S000164","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0015200","In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs.","Tanner M","2021","Annals of internal medicine","randomized_trial","article","10.7326/acpj202106150-067","34058114",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0015201","The role of endoscopic therapies for patients with metabolic dysfunction-associated steatotic liver disease (MASLD).","Llach J","2026","Expert review of gastroenterology & hepatology","randomized_trial","article","10.1080/17474124.2026.2632873","41688294",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0015202","P017 Association Between Tirzepatide and Fatigue and Functioning Based on Baseline Characterization: SURMOUNT-OSA Trials",null,"2025","Sleep advances : a journal of the Sleep Research Society","other","article",null,null,"PMC12492188",null,null,"europepmc","FALSE",null,null,null,"Abstract"],["R0015203","The lack of efficacy of tirzepatide in mitigating cisplatin-induced neurotoxicity and cognitive impairment in rats.","Almutairi HM","2026","Frontiers in toxicology","preclinical","article","10.3389/ftox.2026.1752511","41625437","PMC12855076",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015204","Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.","Azuri J","2023","Diabetes, obesity & metabolism","other","article","10.1111/dom.14940","36507900",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015205","Is Bariatric Surgery at Risk Due to Semaglutide?","Tian J","2025","Journal of metabolic and bariatric surgery","nonrandomized_study","article","10.17476/jmbs.2025.14.3.202","41568129","PMC12817805",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015206","Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.","Chang G","2022","The Journal of dermatological treatment","systematic_review","article","10.1080/09546634.2021.1882658","33934692",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0015207","Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.","Giorda CB","2014","Endocrine","systematic_review","article","10.1007/s12020-014-0179-0","24510630",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0015208","GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity.","Kato ET","2023","European heart journal. Cardiovascular pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvad072","37777847",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0015209","The Molecular Exposome of Visible Age Reversal: From Organ-Skin Axes to Regenerative Aesthetics.","Yamada H","2026","Molecules (Basel, Switzerland)","narrative_review","article","10.3390/molecules31071147","41976189","PMC13074460",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015210","Cross-sectional analysis of the reliability and engagement metrics of YouTube videos on semaglutide for weight loss.","Güler Sönmez T","2026","Medicine","other","article","10.1097/md.0000000000049173","42260873","PMC13246070",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015211","The emerging role of glucagon-like peptide 1 in binge eating.","Balantekin KN","2024","The Journal of endocrinology","narrative_review","article","10.1530/joe-23-0405","38642585","PMC11156433",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; research-article; article"],["R0015212","Should GLP-1 agonists be considered an alternative or adjunct to pediatric metabolic and bariatric surgery? more questions than answers.","Michalsky MP","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","other","article","10.1016/j.soard.2024.10.018","39580334",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015213","Efficacy and safety of once-weekly insulins in type 2 diabetes: A systematic review and meta-analysis.","Bourron O","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70497","41574970","PMC13071184",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review-article; review"],["R0015214","GI adverse effects associated with GLP-1 agonists for weight loss.","BMJ Publishing Group Ltd","2024","Drug and therapeutics bulletin","other","article","10.1136/dtb.2024.000047","39038930",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015215","AI-Based Screening for At-Risk MASLD and Advanced Fibrosis in the US Population: A Cost-Effectiveness Analysis.","Njei B","2026","Digestive diseases and sciences","other","article","10.1007/s10620-026-09811-y","41806252",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015216","Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK.","Roborel de Climens A","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-020-00843-9","32533547","PMC7376801",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0015217","The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions.","Camilleri M","2024","Neurogastroenterology and motility","narrative_review","article","10.1111/nmo.14660","37638839",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015218","Obesity, diabetes, and inflammation: Pathophysiology and clinical implications.","Donath MY","2025","Immunity","narrative_review","article","10.1016/j.immuni.2025.09.011","41045922",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015219","350 Effects of GLP-1 Agonist on Pediatric Populations in a Real-World Setting","Barajas G",null,"Journal of clinical and translational science","nonrandomized_study","article",null,null,"PMC11035192",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0015220","Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements.","Dusetzina SB","2026","JAMA","other","article","10.1001/jama.2026.2615","41926100","PMC13047485",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015221","Response to letter to the editor-Hypersensitivity to liraglutide: A case report.","Marino-Fernández AG","2025","Asia Pacific allergy","case_report","article","10.5415/apallergy.0000000000000224","41341677","PMC12672168",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0015222","No evidence that tirzepatide can worsen diabetic retinopathy. Reply to Fadini GP [letter]. Reassessing retinopathy risk with tirzepatide therapy. Reply to Zhang N, Wang W, Wan G [letter].","Buckley AJ","2025","Diabetologia","commentary","article","10.1007/s00125-025-06562-9","41051410",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015223","Research progress of diabetic osteoporosis: a comprehensive review.","Ma X","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1595228","40964165","PMC12436113",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015224","Obesity and gastrointestinal cancer: A converging epidemic with surgical consequence.","Gosavi R","2025","European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology","randomized_trial","article","10.1016/j.ejso.2025.110358","40818296",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0015225","GLP-1 Agonists for Obesity-Reply.","Mozaffarian D","2024","JAMA","commentary","article","10.1001/jama.2024.12077","39083314",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment; article"],["R0015226","Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.","Johansen NJ","2020","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(20)30030-9","32135138",null,"ClinicalTrials.gov:NCT03017352","S000283; S000485","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0015227","Re: Liu et al.: Rate and risk of nonarteritic anterior ischemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis (Ophthalmology. 2026;133;589-598).","Nordvall LM","2026","Ophthalmology","systematic_review","article","10.1016/j.ophtha.2026.05.017","42283648",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; Comment; letter"],["R0015228","Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.","Rossing P","2025","Diabetes care","randomized_trial","article","10.2337/dc25-0472","40730031","PMC12583412",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0015229","Synthesis and evaluation of zirconium-89 labelled and long-lived GLP-1 receptor agonists for PET imaging.","Jacobsen CB","2020","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2019.11.006","32000047",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015230","Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.","Grossman SS","2014","Advances in therapy","nonrandomized_study","article","10.1007/s12325-014-0101-4","24535624","PMC3961598",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0015231","β-cell 14-3-3-ζ and sex are key regulators of α-cell form and function.","Shishani R","2026","Endocrinology","preclinical","article","10.1210/endocr/bqag098","42644279","PMC13621187",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015232","Pharmacological progress in obesity: tirzepatide's rising advantage over semaglutide.","Khan S","2026","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000004507","41497097","PMC12768109",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0015233","Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.","Tan X","2026","Advances in therapy","nonrandomized_study","article","10.1007/s12325-026-03610-7","42060161","PMC13290940",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0015234","Semaglutide for the treatment of overweight and obesity: A review.","Bergmann NC","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14863","36254579","PMC10092086",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0015235","Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.","le Roux CW","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16167","39821928","PMC11885088","ClinicalTrials.gov:NCT04667377","S002375","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; research-article; article"],["R0015236","Metabolic complications and their mechanisms in patients with craniopharyngioma.","Erfurth EM","2025","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2025.101999","40274451",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0015237","Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost-effectiveness modelling study.","Ponnana SR","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70515","41622983","PMC12992155",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015238","RFX6 maturity-onset diabetes of the young: clinical considerations and novel use of tirzepatide.","Gopalakrishnan PP","2026","Endocrinology, diabetes & metabolism case reports","case_report","article","10.1530/edm-25-0142","41636221","PMC12850626",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015239","Reduction of hippocampal IL-6 levels in LPS-injected rats following acute exendin-4 treatment.","Géa LP","2020","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-020-01867-5","32363414",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015240","Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus.","Rella S","2023","Therapeutic advances in endocrinology and metabolism","protocol","article","10.1177/20420188231207348","37916028","PMC10617296","ClinicalTrials.gov:NCT04979130","S000512","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0015241","Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study.","Nicolau J","2024","Journal of addictive diseases","nonrandomized_study","article","10.1080/10550887.2024.2315365","38369467",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0015242","Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice.","Vestlund J","2022","Translational psychiatry","nonrandomized_study","article","10.1038/s41398-022-02209-0","36229445","PMC9561171",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015243","Combined Treatment of Type 2 Diabetes and Hypothyroidism: Impact of Oral Semaglutide and Levothyroxine on Cardiometabolic and Thyroid Parameters: A 6-Month Comparative Study.","Tilici DM","2026","Epidemiologia (Basel, Switzerland)","other","article","10.3390/epidemiologia7020041","41873990","PMC13010780",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015244","Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials.","Müller-Wieland D","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70752","41969169","PMC13243933",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0015245","Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets.","Piccirillo F","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms241210164","37373310","PMC10299555",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015246","Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.","Zhou G","2026","Medicine","nonrandomized_study","article","10.1097/md.0000000000048123","41894290","PMC13034935",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0015247","SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.","Brown E","2021","Lancet (London, England)","narrative_review","article","10.1016/s0140-6736(21)00536-5","34216571",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0015248","How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?","Gou Y","2023","The Journal of clinical investigation","commentary","article","10.1172/jci174597","37781919","PMC10541183",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; editorial; article"],["R0015249","Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.","Gomez-Peralta F","2019","Drug design, development and therapy","randomized_trial","article","10.2147/dddt.s165372","30863012","PMC6388990",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015250","Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient.","Dolan RD","2020","ACG case reports journal","case_report","article","10.14309/crj.0000000000000380","32607380","PMC7289281",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015251","The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes.","Ali ES","2016","Biochimica et biophysica acta","preclinical","article","10.1016/j.bbamcr.2016.05.006","27178543",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015252","Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs.","Asano D","2023","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics16010047","38258058","PMC10820198",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015253","A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.","Jin CH","2009","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2008.09.091","18977255",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015254","Sex specific responses to oral vs. subcutaneous semaglutide in type 2 diabetes mellitus: A 12-month real-world study.","Piccione A","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2025.104462","41475990",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0015255","[Any expectations from the more powerful dulaglutide?].","Škrha J","2022","Vnitrni lekarstvi","other","article","10.36290/vnl.2022.023","36208927",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015256","Semaglutide for Alzheimer's disease after evoke and evoke.","Schneider LS","2026","Lancet (London, England)","other","article","10.1016/s0140-6736(26)00514-3","41865757",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015257","Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.",null,"2018","The Medical letter on drugs and therapeutics","other","article",null,"29364197",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015258","When Sex Shapes Diabetes Care: Evidence from the AMD Annals Registry.","Da Porto A","2026","Journal of women's health (2002)","nonrandomized_study","article","10.1177/15409996261479909","42596603",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015259","Albiglutide: a review of its use in patients with type 2 diabetes mellitus.","Blair HA","2015","Drugs","narrative_review","article","10.1007/s40265-015-0370-5","25777969",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015260","Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery.","Muñoz MPS","2024","Updates in surgery","other","article","10.1007/s13304-024-01828-0","38573447",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015261","Foods as Modulators of GLP-1 Secretion.","Tkaczenko H","2026","Nutrients","narrative_review","article","10.3390/nu18182995","42796978","PMC13610508",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015262","Evaluating the antidepressant effects of tirzepatide on unpredictable chronic mild stress-induced depression in Swiss Albino mice.","Maradia J","2026","Tzu chi medical journal","preclinical","article","10.4103/tcmj.tcmj-d-25-00078","42131414","PMC13167083",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015263","GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential.","Ma X","2021","International journal of biological sciences","narrative_review","article","10.7150/ijbs.59965","34131405","PMC8193264",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0015264","Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.","Lee BW","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70111","40954943","PMC12587258",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; research-article; article"],["R0015265","The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials.","Liu L","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-02064-1","41390457","PMC12781576","PROSPERO:CRD420251054743",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0015266","Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.","Heymsfield SB","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04204-0","41772149","PMC13004672","ClinicalTrials.gov:NCT05616013","S000715","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0015267","Real-life effects of adding weekly subcutaneous semaglutide to insulin for the treatment of type 2 diabetes mellitus.","Ares-Blanco J","2022","Revista clinica espanola","nonrandomized_study","article","10.1016/j.rceng.2022.06.001","35817680",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015268","GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models.","Borner T","2021","Diabetes","preclinical","article","10.2337/db21-0459","34380697","PMC8564411",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0015269","Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.","Igoillo-Esteve M","2020","JCI insight","other_trial","article","10.1172/jci.insight.134221","31877117","PMC7098728",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0015270","Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.","Kishimori T","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70433","41492180",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0015271","[Nutritional management of type 2 diabetes with GLP-1 and GLP-1/GIP agonists].","Pabion C","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.920.47028","40443143",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0015272","Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction.","Kahles F","2020","European heart journal","nonrandomized_study","article","10.1093/eurheartj/ehz728","31620788",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015273","Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial.","Kugathasan L","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70525","41623193","PMC12992154",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0015274","Personalized medicine in diabetes: the role of 'omics' and biomarkers.","Pearson ER","2016","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.13075","26802434","PMC4879510",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0015275","Effectiveness of Liraglutide in Patients With Obesity Who Are Early Non-Responders to Lifestyle Intervention: A Real-World Study.","Gilardini L","2026","Journal of obesity","nonrandomized_study","article","10.1155/jobe/1224246","42658045","PMC13520785",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0015276","Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.","Marathe CS","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-022-01258-4","35460043","PMC9174387","ClinicalTrials.gov:NCT02308254","S000473","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; article"],["R0015277","Oral semaglutide for the treatment of type 2 diabetes.","Hedrington MS","2019","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2018.1552258","30499733",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015278","Lipotoxicity: A New Perspective in Type 2 Diabetes Mellitus.","Chen B","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s511436","40297768","PMC12036605",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015279","Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.","Guan H","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70047","40926359","PMC12515763","ClinicalTrials.gov:NCT03730662","S001287","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0015280","Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance.","Dandona P","2017","Diabetes technology & therapeutics","narrative_review","article","10.1089/dia.2016.0372","28771387","PMC5647495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0015281","Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF) protocol.","Win KZ","2024","Pilot and feasibility studies","protocol","article","10.1186/s40814-024-01454-y","38383462","PMC10880291","ClinicalTrials.gov:NCT05221229","S001800","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0015282","Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J-mono post hoc analysis.","Yoneda M","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70225","41144905","PMC12673444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0015283","Metabolic Remodeling and Mitochondrial Stress in Atrial Fibrillation: Mechanisms and Translational Targets.","Grigoriou K","2025","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm44688","41524040","PMC12781006",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015284","Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study.","Cowart K","2022","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14579","34676657",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0015285","Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?","Burgmaier M","2013","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/j.1464-5491.2012.03746.x","22804451",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0015286","Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.","Thompson PL","2017","Clinical therapeutics","narrative_review","article","10.1016/j.clinthera.2016.10.008","27863704",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015287","Clinical implications of the interaction between metabolic risk factors, coronary artery disease and atrial fibrillation.","Voorhout LJ","2026","Future cardiology","narrative_review","article","10.1080/14796678.2025.2603066","41389033","PMC12773616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015288","Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes.","Ang KH","2017","Expert opinion on drug delivery","narrative_review","article","10.1080/17425247.2017.1360862","28774208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015289","Semaglutide, weight loss, and cardiovascular outcomes in the SELECT trial - Authors' reply.","Deanfield J","2026","Lancet (London, England)","other_trial","article","10.1016/s0140-6736(26)00706-3","42035774",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; letter"],["R0015290","Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).","Wharton S","2025","Obesity (Silver Spring, Md.)","protocol","article","10.1002/oby.24184","39495965","PMC11664303","ClinicalTrials.gov:NCT06066515; ClinicalTrials.gov:NCT06066528","S000367; S002304","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; article"],["R0015291","Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns","Venkatakrishnan A","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.04.14.26350891",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; article; preprint"],["R0015292","Emergent role of Ozempic in treating women with PCOS related fertility issues.","Naveed F","2025","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.21283","40500853",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015293","OP21 Long-Term Cost-Effectiveness Of IDegLira Versus Basal-Bolus Insulin Therapy In Patients With Type 2 Diabetes In Chinese Setting",null,"2025","International journal of technology assessment in health care","other","article",null,null,"PMC11719241",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0015294","Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.","Rosenstock J","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15339","37935463",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0015295","A Daunting and Challenging Task to Prove the Effectiveness of Reducing Acute Exacerbation in COPD Patients with Type 2 Diabetes by GLP-1 Receptor Agonists.","Li Q","2023","American journal of respiratory and critical care medicine","commentary","article","10.1164/rccm.202309-1671le","37855726","PMC10765392",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0015296","Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist.","Smith LL","2016","P & T : a peer-reviewed journal for formulary management","other","article",null,"27313432","PMC4894510",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0015297","GLP1 agonists and risk of major adverse liver outcomes.","Ray K","2024","Nature reviews. Gastroenterology & hepatology","other","article","10.1038/s41575-024-00911-6","38355757",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015298","Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.","Zhang W","2025","Current gastroenterology reports","randomized_trial","article","10.1007/s11894-025-01026-x","41258558",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0015299","Chronic incretin-based therapy in cystic fibrosis-related diabetes: A tale of 3 patients treated with sitagliptin for over 5 years.","Olatunbosun ST","2021","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","case_report","article","10.1016/j.jcf.2021.02.005","33674210",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0015300","The mechanistic role of tirzepatide in atherosclerosis: A review.","Al-Kuraishy HM","2025","International journal of biological macromolecules","narrative_review","article","10.1016/j.ijbiomac.2025.147734","40972917",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015301","Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.","Koska J","2015","Diabetes","other","article","10.2337/db14-0976","25720388","PMC4477348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0015302","Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.","Hunt B","2019","BMJ open diabetes research & care","other","article","10.1136/bmjdrc-2019-000705","31641522","PMC6777406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015303","Awareness and perceptions of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: The SPARK-CVD China survey.","Liu X","2026","Atherosclerosis plus","nonrandomized_study","article","10.1016/j.athplu.2026.100570","42376232","PMC13311795",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015304","Alternate-day fat diet and exenatide modulate the brain leptin JAK2/STAT3/SOCS3 pathway in a fat diet-induced obesity and insulin resistance mouse model.","Tawfik MK","2023","Archives of medical science : AMS","preclinical","article","10.5114/aoms/158534","37732053","PMC10507768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015305","Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance.","Reiner DJ","2016","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.3579-15.2016","27013681","PMC4804010",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0015306","C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.","Ohbatake A","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-019-0586-6","30788807","PMC6437227",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015307","Triple therapy in type 2 diabetes; a systematic review and network meta-analysis.","Downes MJ","2015","PeerJ","systematic_review","article","10.7717/peerj.1461","26664803","PMC4675096",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0015308","Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial).","Raskin P","2010","Expert opinion on pharmacotherapy","other_trial","article","10.1517/14656566.2010.497142","20536293",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Comment; Journal Article; article"],["R0015309","Exenatide Is Neuroprotective in a New Rabbit Model of Hypoxia-Ischemia.","Rocha-Ferreira E","2025","Cells","nonrandomized_study","article","10.3390/cells14211715","41227362","PMC12609083",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015310","Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.","Packer M","2019","Journal of cardiac failure","randomized_trial","article","10.1016/j.cardfail.2019.09.002","31541742",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Comparative Study; Journal Article; Review"],["R0015311","Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study.","Candido R","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01328-7","36376644","PMC9663199",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015312","The unified cardiometabolic disease continuum: mechanistic stages of a single pathophysiological process.","Quirino-Vela LM","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1897556","42494872","PMC13391316",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015313","Effect of glucose-lowering therapies on heart failure.","Nassif M","2018","Nature reviews. Cardiology","randomized_trial","article","10.1038/nrcardio.2017.211","29368701",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0015314","Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform.","Hernandez I","2024","Journal of general internal medicine","commentary","article","10.1007/s11606-023-08416-9","37715099","PMC10853087",null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0015315","Dulaglutide plus dapaglifozin use until the second trimester of pregnancy in a woman with type 2 diabetes.","Burlina S","2026","Acta diabetologica","other","article","10.1007/s00592-025-02601-4","41231281",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015316","Exendin-4, a glucagon-like peptide receptor agonist, facilitates osteoblast differentiation via connexin43.","Chen JH","2021","Endocrine","other","article","10.1007/s12020-021-02664-7","33641073",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015317","Correction: Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.","Wang W","2026","Molecular neurobiology","notice","article","10.1007/s12035-026-05872-2","41996021",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0015318","Impact of Insulin Degludec/Liraglutide Fixed Combination on the Gut Microbiomes of Elderly Patients With Type 2 Diabetes: Results From A Subanalysis of A Small Non-Randomised Single Arm Study.","Rizza S","2023","Aging and disease","randomized_trial","article","10.14336/ad.2023.0118","37008061","PMC10017153",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0015319","The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review.","Shen MR","2024","Journal of addiction medicine","narrative_review","article","10.1097/adm.0000000000001347","39092831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Scoping Review; article"],["R0015320","Diabetic encephalopathy: metabolic reprogramming as a potential driver of accelerated brain aging and cognitive decline.","Huai JX","2025","Frontiers in cell and developmental biology","narrative_review","article","10.3389/fcell.2025.1701406","41332987","PMC12665671",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015321","Liraglutide promotes the angiogenic ability of human umbilical vein endothelial cells through the JAK2/STAT3 signaling pathway.","Di Y","2020","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2020.01.004","31948746",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015322","Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction.","Li Y","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70594","41749403","PMC13071215",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015323","The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice.","Yun C","2024","Nature metabolism","preclinical","article","10.1038/s42255-024-01041-8","38769396",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015324","Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.","Lu YT","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70452","41508932",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review"],["R0015325","A comprehensive impact of GLP1Ras on CKM syndrome.","Horiuchi Y","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133012","39870116",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015326","Striatal signaling tracks naturalistic short-term fluctuations in hunger-satiety.","Mourra D","2025","bioRxiv : the preprint server for biology","other","article","10.1101/2025.04.29.651295","40655018","PMC12247698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0015327","Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial.","Eckard AR","2024","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(24)00150-5","38964353","PMC11417641","ClinicalTrials.gov:NCT04019197","S001425","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Research Support, N.I.H., Extramural; research-article; article"],["R0015328","GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.","Smits MM","2015","Arteriosclerosis, thrombosis, and vascular biology","preclinical","article","10.1161/atvbaha.115.305447","25908765",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015329","A new form of diabetes caused by INS mutations defined by zygosity, stem cell and population data.","Tong Y","2026","EMBO molecular medicine","nonrandomized_study","article","10.1038/s44321-025-00362-9","41484206","PMC12905373",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015330","Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.","Dziewierz A","2026","JACC. Heart failure","commentary","article","10.1016/j.jchf.2026.102949","41951288",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0015331","Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.","Scheen AJ","2018","Circulation research","other_trial","article","10.1161/circresaha.117.311588","29748368","PMC5959222",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0015332","Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review.","De R","2023","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2023.2254698","37653675",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; review"],["R0015333","Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.","Hansen KB","2009","International journal of clinical practice","narrative_review","article","10.1111/j.1742-1241.2009.02086.x","19624785",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015334","The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus.","Bolli GB","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70751","42046184","PMC13243952",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015335","Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.","Hankosky ER","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70143","41017451","PMC12587230",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0015336","Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.","Gu Y","2023","Expert review of gastroenterology & hepatology","systematic_review","article","10.1080/17474124.2023.2172397","36689199",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Comparative Study; Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0015337","iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes.","Hinnen D","2018","Diabetes spectrum : a publication of the American Diabetes Association","other_trial","article","10.2337/ds17-0014","29773934","PMC5951239",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0015338","FRI652 Type 2 Diabetes Management: More GLP1 Agonists And Less Metformin?",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10555779",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0015339","Exendin-4 - A potential therapeutic for type 2 diabetes-linked cervical cancer?","Mishra N","2021","EBioMedicine","commentary","article","10.1016/j.ebiom.2021.103273","33714887","PMC7966980",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; discussion; article"],["R0015340","Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program",null,"2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article",null,null,"PMC9067785",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0015341","Anti-inflammatory properties of antidiabetic drugs: A \"promised land\" in the COVID-19 era?","Katsiki N","2020","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2020.107723","32900588","PMC7448766",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Review; review-article"],["R0015342","Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers.","Yang Y","2014","Endocrinology","preclinical","article","10.1210/en.2014-1052","24949661","PMC4138563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0015343","Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics.","Bendicho-Lavilla C","2022","Acta pharmaceutica Sinica. B","narrative_review","article","10.1016/j.apsb.2021.08.003","35256935","PMC8897023",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015344","Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease.","Wang V","2021","ACS pharmacology & translational science","preclinical","article","10.1021/acsptsci.1c00013","33860208","PMC8033754",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015345","Prevalence of Incretin-Mimetic and Sodium-Glucose-Transporter-2-Inhibitor Therapy in German Hospitalized Type-2 Diabetics Following Myocardial Revascularization: An Observational Study.","Pliquett RU","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00956-1","33196958","PMC7843777",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0015346","What impact could tirzepatide have on major cardiovascular complications in patients with obstructive sleep apnea?","Kumar AJ","2025","Expert review of cardiovascular therapy","commentary","article","10.1080/14779072.2025.2561067","40946170","PMC12720394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; research-article; article; editorial"],["R0015347","Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.","Davies MJ","2011","Diabetes, obesity & metabolism","other_trial","article","10.1111/j.1463-1326.2010.01330.x","21205109",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0015348","Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability.","Fadini GP","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70840","42108418","PMC13243947",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015349","GLP-1 agonist use increases the incidence of adhesive capsulitis and odds of requiring operative management in type 2 diabetes patients: a matched propensity score analysis.","Bergstein VE","2025","Journal of shoulder and elbow surgery","nonrandomized_study","article","10.1016/j.jse.2024.11.041","39855332",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015350","A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes.","Karagiannis T","2024","Diabetes care","systematic_review","article","10.2337/dc23-0925","38241493",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Review; Research Support, Non-U.S. Gov't; other; article"],["R0015351","Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265.","Li S","2026","Diabetes care","randomized_trial","article","10.2337/dc26-0265","42160606",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0015352","Necrotizing Pancreatitis Secondary to Dulaglutide Use","Bhat S","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.800",null,"PMC8089879",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0015353","Pre-operative concerns and post-operative satisfaction: comparing attitudes toward bariatric surgery and medication intervention for weight loss on Reddit.","Del Carmen GA","2026","Surgical endoscopy","other","article","10.1007/s00464-026-13149-x","42477216",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comparative Study"],["R0015354","Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.","Madsbad S","2009","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2009.03.008","19748064",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015355","Patient honesty about NPO status in the era of GLP-1 agonists and liberal ERAS protocols: A randomized response technique study.","Pham LN","2024","Journal of clinical anesthesia","randomized_trial","article","10.1016/j.jclinane.2024.111650","39388831",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0015356","The current landscape for diabetes treatment: Preventing diabetes-associated CV risk.","Dardano A","2024","Atherosclerosis","narrative_review","article","10.1016/j.atherosclerosis.2024.117560","38688748",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0015357","Study on chitosan/carrageenan core-shell nanoparticles for oral co-administration of insulin/exenatide enhance insulin secretion in type 2 diabetes.","Nguyen TV","2026","International journal of biological macromolecules","preclinical","article","10.1016/j.ijbiomac.2026.151537","41865922",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015358","Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus.","Torimoto K","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-019-0596-4","30875066","PMC6531533","UMIN:UMIN000015699",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; other; article"],["R0015359","Semaglutide for Aboriginal and Torres Strait Islander cardiovascular care: equity, cost and real-world hurdles.","Sami MM","2026","Internal medicine journal","nonrandomized_study","article","10.1111/imj.70387","41943227",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0015360","Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.","Sugimoto DH","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13438","29923361",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015361","Two for the price of one: GLP-1 analogues, a new approach in treating severe COPD patients with diabetes.","Beech A","2025","ERJ open research","commentary","article","10.1183/23120541.01133-2024","40230433","PMC11995275",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0015362","Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes.","Isaacs D","2019","The Annals of pharmacotherapy","narrative_review","article","10.1177/1060028018816728","30499305",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0015363","Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.","Abdelwahed OM","2018","Brain research bulletin","preclinical","article","10.1016/j.brainresbull.2018.02.002","29421245",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015364","Metabonomic analysis of the therapeutic effect of exendin-4 for the treatment of tBHP-induced injury in mouse glomerulus mesangial cells.","Wang L","2018","Free radical research","preclinical","article","10.1080/10715762.2018.1449948","29526117",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015365","Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.","Vilsbøll T","2019","Diabetes, obesity & metabolism","other","article","10.1111/dom.13675","30785655","PMC6593827",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0015366","A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist.","Schneider EL","2017","ACS chemical biology","preclinical","article","10.1021/acschembio.7b00218","28605180",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0015367","Fluoride-induced gut dysbiosis in metabolic disorders: Mechanisms and public health implications.","Meenakshi S","2026","Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)","narrative_review","article","10.1016/j.jtemb.2025.127806","41389504",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015368","Sustained-Release Intra-Articular Drug Delivery: PLGA Systems in Clinical Context and Evolving Strategies.","Lee JW","2025","Pharmaceutics","nonrandomized_study","article","10.3390/pharmaceutics17101350","41155985","PMC12566636",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0015369","Tirzepatide Combined With Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnoea Syndrome With Comorbid Obesity: Effects on Weight, Daytime Sleepiness, and Cognitive Performance.","Fernandes M","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70604","41757398",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0015370","Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.","Rigato M","2014","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s37644","24672252","PMC3964023",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015371","Pathophysiology and pharmacotherapy of cardiovascular complications in metabolic syndrome.","Dhalla NS","2026","Journal of molecular and cellular cardiology","narrative_review","article","10.1016/j.yjmcc.2026.04.007","42034309",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015372","From Product to Patient: An Integrated Product Profile for Access, Adoption, and Health Impact","Mathur A","2026","Research Square","other_trial","preprint","10.21203/rs.3.rs-11103078/v1",null,null,null,null,"europepmc","FALSE","open_pdf","5",null,"Preprint"],["R0015373","Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.","Kaya E","2024","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2024.2441865","39663847",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0015374","The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review.","Asiabar AS","2024","European journal of clinical pharmacology","systematic_review","article","10.1007/s00228-024-03755-w","39254692",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0015375","Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).","Ajmera V","2026","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/apt.70516","41527269",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0015376","Exendin-4 as a Versatile Therapeutic Agent for the Amelioration of Diabetic Changes.","Rajabi H","2022","Advanced pharmaceutical bulletin","narrative_review","article","10.34172/apb.2022.025","35620334","PMC9106955",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015377","The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.","Drummond R","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13375","29797389","PMC6175071",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015378","Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.","He YM","2025","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.70097","41100405",null,"PROSPERO:CRD42024620051",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0015379","Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.","Grossman S","2009","Pharmacotherapy","narrative_review","article","10.1592/phco.29.pt2.25s","19947814",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015380","GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats.","Fortin SM","2020","Science translational medicine","preclinical","article","10.1126/scitranslmed.aay8071","32132220","PMC7211411",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0015381","National trends in prescription drug expenditures and projections for 2026.","Tichy EM","2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxag115","42059345",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015382","Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.","Ramos M","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00883-1","32700188","PMC7434815",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0015383","The Gut-Immune Axis in Treated HIV Infection: From Mucosal Damage to Chronic Inflammation and Therapeutic Opportunities-A Clinician-Oriented Narrative Review.","Nitsotolis TN","2026","Microorganisms","other_trial","article","10.3390/microorganisms14061229","42354854","PMC13303623",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review"],["R0015384","Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.","Pfeffer MA","2015","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1509225","26630143",null,"ClinicalTrials.gov:NCT01147250","S001991","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0015385","[Semaglutide and Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review].","Masson W","2026","Acta gastroenterologica Latinoamericana","systematic_review","article","10.52787/agl.v56i1.591","42569707","PMC13450854",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","English Abstract; Journal Article; research-article; article"],["R0015386","A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.","Emoto M","2015","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej15-0401","26477324",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0015387","Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265.","Mann JFE","2026","Diabetes care","randomized_trial","article","10.2337/dci26-0039","42160596",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0015388","Structural pharmacology and mechanisms of GLP-1R signaling.","Zhou Q","2025","Trends in pharmacological sciences","narrative_review","article","10.1016/j.tips.2025.03.003","40221226",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0015389","The renoprotective effect of once-weekly GLP-1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67).","Tsuchida KI","2022","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.13877","35735780","PMC9623516",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015390","Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal.","Silva Miguel L","2024","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-024-01338-4","38689367","PMC11059577",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0015391","Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.","Yang DY","2019","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-019-0853-x","30961600","PMC6454617","PROSPERO:CRD42016042063",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review-article; review"],["R0015392","Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.","Pandey A","2026","JACC. Heart failure","commentary","article","10.1016/j.jchf.2026.102951","41951287",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0015393","Next Chapter for Weight Control - Small-Molecule GLP-1 Receptor Agonists?","Abel ED","2023","The New England journal of medicine","commentary","article","10.1056/nejme2307285","37672699",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0015395","The evolving role of GLP-1 agonists in ischemic stroke prevention in diabetic patients.","Shankar A","2024","Cardiovascular endocrinology & metabolism","randomized_trial","article","10.1097/xce.0000000000000308","39148946","PMC11326472",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015396","Long-lasting Glucagon-like Peptide 1 Analogue Exendin-4 Ameliorates the Secretory and Synthetic Function of Islets Isolated From Severely Scalded Rats.","Zhao D","2018","Journal of burn care & research : official publication of the American Burn Association","preclinical","article","10.1093/jbcr/irx014","29579298",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015397","Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis.","Soliman A","2026","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-026-01880-0","41883513","PMC13009421","PROSPERO:CRD42025633998",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review"],["R0015398","Association of One-Leg Standing Time with Discontinuation of Injectable Medications During Hospitalization Among Patients with Type 2 Diabetes.","Sugimoto K","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-020-00814-0","32274679","PMC7192981",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0015399","Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice.","Chen X","2022","Drug design, development and therapy","preclinical","article","10.2147/dddt.s383537","36388084","PMC9656502",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015400","The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States.","Durden E","2019","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2019.18429","30896359","PMC10397904",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015401","[Psychotropic drug-induced obesity in older adults: complications, preventive and therapeutic interventions].","Nadubinszky G","2026","Orvosi hetilap","narrative_review","article","10.1556/650.2026.33499","41838052",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0015402","Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial.","Tuttle KR","2026","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.0000000974","41706532","PMC13143484","ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0015403","Resistant Hypertension: Integration of Novel Agents and Interventional Approaches in Clinical Practice.","Arriola-Montenegro J","2026","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm45429","41659095","PMC12873673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015404","Efficacy and safety of exenatide once weekly: an overview of the DURATION trials.","De Block CE","2012","Expert review of endocrinology & metabolism","other","article","10.1586/eem.12.51","30754123",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015405","Reduction in TNF alpha and oxidative stress by liraglutide: Impact on ketamine-induced cognitive dysfunction and hyperlocomotion in rats.","Sedky AA","2021","Life sciences","preclinical","article","10.1016/j.lfs.2021.119523","33891942",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015406","Oxidative stress and inflammation in COVID-19: potential application OF GLP-1 receptor agonists.","Abudalo RA","2023","European review for medical and pharmacological sciences","narrative_review","article","10.26355/eurrev_202307_33007","37458671",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; review"],["R0015407","68Ga-NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.","Banerjee I","2022","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","commentary","article","10.2967/jnumed.121.262984","35232880",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0015408","Correction: Discontinuation of oral semaglutide due to adverse effects: a database study on Japanese individuals with type 2 diabetes.","Ishiguro M","2026","Diabetology international","notice","article","10.1007/s13340-026-00893-7","42181140","PMC13190982",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0015409","Reply: 68Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.","Prasad V","2022","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","commentary","article","10.2967/jnumed.121.263167","35232881",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; letter"],["R0015410","Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.","Abdrabou Abouelmagd A","2025","Proceedings (Baylor University. Medical Center)","systematic_review","article","10.1080/08998280.2025.2456441","40291085","PMC12026077",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0015411","Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.","Maselli DB","2021","Advances in experimental medicine and biology","narrative_review","article","10.1007/5584_2020_496","32077010",null,null,"S002429","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0015412","Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial.","Hramiak I","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14787","35670659","PMC9546064","ClinicalTrials.gov:NCT03767543","S001367","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; research-article; article"],["R0015413","Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet.","Yoon JH","2026","Pharmaceutics","preclinical","article","10.3390/pharmaceutics18040440","42076092","PMC13118580",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015414","Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.","Seggelke SA","2017","Current diabetes reports","randomized_trial","article","10.1007/s11892-017-0884-1","28699089",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0015415","Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.","Li XN","2017","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","preclinical","article","10.1055/s-0042-112368","28008585",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015416","Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.","Davies M","2012","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2012.01595.x","22420869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0015417","Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.","Becker RH","2015","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.2647","25773712","PMC4744661",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0015418","Exploring the pathophysiological links between obesity, diabetes, and myocardial dysfunction: an in-depth narrative review.","Naderian R","2025","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-025-01802-6","41358324","PMC12678695",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015419","Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis.","Abuali A","2025","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","systematic_review","article","10.1055/a-2737-6110","41187775",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0015420","Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes.","Pappa E","2022","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2022.108286","36115184",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015421","Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective.","Zeng X","2025","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2025.1574385","40492139","PMC12146339",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015422","Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages.","Guo C","2016","Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","preclinical","article","10.1590/1414-431x20165826","27878229","PMC5188858",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015423","Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.","Dardano A","2022","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2022.847778","35295985","PMC8918572",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Case Reports; Journal Article; case-report; article"],["R0015424","Independent effects of 15 commonly prescribed drugs on all-cause mortality among US elderly patients with type 2 diabetes mellitus.","Baik SH","2020","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2019-000940","32341050","PMC7202731",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Intramural; research-article; article"],["R0015425","Mechanisms and Current Therapeutic Targets of Podocyte Damage in Diabetic Kidney Disease.","Erdem BK","2026","Current diabetes reviews","randomized_trial","article","10.2174/0115733998492007260723100211","42613708",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0015426","Hormonal Modulation in Chronic Coronary Syndrome: From Neurohormonal Activation to Endocrine Targets.","Brie AD","2026","Biomedicines","randomized_trial","article","10.3390/biomedicines14091954","42792696","PMC13604452",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015427","Cardiovascular effects of GLP-1 receptor agonism.","Winquist RJ","2022","Advances in pharmacology (San Diego, Calif.)","systematic_review","article","10.1016/bs.apha.2022.02.005","35659373",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; book-chapter"],["R0015428","Insulinoma: Metastatic Recurrence 38 Years Following Initial Diagnosis in Pregnancy.","Preston CA","2024","JCEM case reports","case_report","article","10.1210/jcemcr/luad168","38196815","PMC10773549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015429","MASH and the race for liver antifibrotics.","Wills Q","2025","Frontiers in gastroenterology (Lausanne, Switzerland)","other","article","10.3389/fgstr.2025.1704078","41822287","PMC12952438",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0015430","Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.","Nicolucci A","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13830","31297947","PMC6852520","ClinicalTrials.gov:NCT02322762; ClinicalTrials.gov:NCT02226822",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0015431","In-vitro metabolite identification for MEDI7219, an oral GLP-1 analog, using LC-MS/MS with CID and EAD approaches.","Liu K","2025","Bioanalysis","preclinical","article","10.1080/17576180.2025.2535954","40827388","PMC12369624",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015432","Local administration of high-dose diabetes medicine exendin-4 inhibits orthodontic tooth movement in mice.","Shen WR","2021","The Angle orthodontist","preclinical","article","10.2319/021320-103.1","33289799","PMC8032283",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015433","Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.","Ituarte BE","2024","Journal of drugs in dermatology : JDD","commentary","article",null,"39231072",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0015434","Innovative Therapeutic Approaches Targeting Obesity: Can Flavonoids Improve the Efficacy of Anti-Obesogenic Drugs?","Scarpa ES","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms262010142","41155431","PMC12562994",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015435","Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.","Pieber TR","2025","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2025.1627947","40964167","PMC12436105","ClinicalTrials.gov:NCT04050553","S000183","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; research-article; article"],["R0015436","[Incretin-based treatment of diabetes and cardiovascular complications].","Haluzík M","2020","Vnitrni lekarstvi","other","article","10.36290/vnl.2020.012","32942880",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015437","Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide.","Banji D","2025","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","nonrandomized_study","article","10.1007/s44446-025-00050-2","41405657","PMC12712260",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0015438","Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.","Chen S","2018","Scientific reports","preclinical","article","10.1038/s41598-018-28449-z","30013201","PMC6048117",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0015439","Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV.","Hahn AW","2025","Diabetes care","nonrandomized_study","article","10.2337/dc25-0236","40971637","PMC12451842",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015440","Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review.","Sofogianni A","2020","Advances in therapy","randomized_trial","article","10.1007/s12325-020-01478-9","32886267",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; review"],["R0015441","Heart failure with preserved ejection fraction, from pathophysiology to technology tools aim improve patients' management.","Pozzi A","2025","Heart failure reviews","narrative_review","article","10.1007/s10741-025-10585-0","41320694",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015442","Single-dose pharmacokinetics of sublingual semaglutide in rats.","Liu Y","2026","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","randomized_trial","article","10.1016/j.ejps.2025.107406","41386332",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0015443","The Diabetes-Viral Respiratory Syndemic: Pathophysiological Insights and Precision Management: A Scoping Review.","Mihai AM","2026","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina62040770","42075641","PMC13117808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Scoping Review; review-article; article"],["R0015444","Role of Liraglutide in Weight Management and Reproductive Health in Women with Obesity and PMOS- A Critical Review of the Evidence","Shetty S","2026","F1000Res","nonrandomized_study","preprint","10.12688/f1000research.167998.3",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; article"],["R0015445","Genetic Variants and Therapeutic Approaches in Maturity-Onset Diabetes of the Young: A Retrospective Analysis","Deng L","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.05.20.24307619",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0015446","Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.","Lingvay I","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13043","28643425","PMC5763397","ClinicalTrials.gov:NCT01952145","S001328","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0015447","Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.","Garber AJ","2010","The American journal of managed care","narrative_review","article",null,"20809667",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0015448","Putting More Weight on Obesity Trials in Heart Failure.","Harrington J","2024","Current heart failure reports","narrative_review","article","10.1007/s11897-024-00655-z","38619690",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015449","Species-specific actions of incretin: from the evolutionary perspective.","Kawasaki Y","2010","Japanese clinical medicine","other","article","10.4137/jcm.s5915","23946675","PMC3738467",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0015450","Euthyroid Sick Syndrome Precipitated By Rapid Weight Loss Following Semaglutide Initiation: A Case Report.","Elmezayen ZW","2026","Clinical medicine insights. Endocrinology and diabetes","case_report","article","10.1177/11795514261443862","42052217","PMC13111885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015451","Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.","Frandsen CS","2016","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(16)00039-5","26969516",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015452","Emerging risk of non-arteritic anterior ischemic optic neuropathy (NAION) with semaglutide: a safety alert for clinicians.","Safi MQ","2026","Annals of medicine and surgery (2012)","nonrandomized_study","article","10.1097/ms9.0000000000004914","42078635","PMC13132267",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0015453","Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System.","Ji XJ","2019","Mediators of inflammation","preclinical","article","10.1155/2019/2750528","30800001","PMC6360064",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015454","Data-Driven Multidimensional Clinical Phenotypes and Longitudinal Changes in Type 2 Diabetes Mellitus: A Retrospective Cohort Study.","Igna AD","2026","Biomedicines","nonrandomized_study","article","10.3390/biomedicines14091903","42792646","PMC13604856",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015455","Consumption of carotenoid-rich Momordica cochinchinensis (Gac) aril improves glycemic control in type 2 diabetic mice partially through taste receptor type 1 mediated glucagon-like peptide 1 secretion.","Hsieh YY","2024","Food & function","preclinical","article","10.1039/d4fo04316b","39535879",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015456","Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis.","Tabák ÁG","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-00735-7","31848983","PMC6965545","ClinicalTrials.gov:NCT02058160; ClinicalTrials.gov:NCT01768559","S001409; S001630","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0015457","Behavioral medicine in the GLP-1 era.","Tomiyama AJ","2025","Annals of behavioral medicine : a publication of the Society of Behavioral Medicine","commentary","article","10.1093/abm/kaae069","39657161","PMC11783292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article-commentary; article"],["R0015458","Benign small bowel pneumatosis intestinalis: report of a rare adverse effect of tirzepatide.","Newcomer K","2025","Trauma surgery & acute care open","case_report","article","10.1136/tsaco-2025-001858","41458895","PMC12742133",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015459","Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.","Cheng H","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70153","41736232",null,"ChiCTR:ChiCTR1900022948",null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Observational Study; article"],["R0015460","Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.","Richards J","2023","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2023.100080","37990682","PMC10661993",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0015461","Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER.","Arnold SV","2022","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-022-01026-2","35473607","PMC9040320",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0015462","Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide.","Fortin SM","2020","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2020.112870","32179053","PMC7227776",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0015463","Retrospective Study of Real-World Treatment Patterns of Subcutaneous Semaglutide Use Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in the United States.","Kim Y","2025","ClinicoEconomics and outcomes research : CEOR","nonrandomized_study","article","10.2147/ceor.s546841","41147033","PMC12554272",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015464","Comment on 'Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach'.","Kumar K V V","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70761","41979001",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015465","Tirzepatide affects NAc activity and food preoccupation.","Welberg L","2025","Nature neuroscience","other","article","10.1038/s41593-025-02180-1","41339983",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015466","Systematic review of cost-effectiveness analyses of weight loss interventions for knee osteoarthritis.","Gao Y","2026","BMJ open","systematic_review","article","10.1136/bmjopen-2026-117500","42772870","PMC13599885",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; review"],["R0015467","Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson's disease.","Sun S","2026","Neural regeneration research","preclinical","article","10.4103/nrr.nrr-d-24-00941","40145958","PMC13452710",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015468","Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.","Vanlaer Y","2026","BMJ open","protocol","article","10.1136/bmjopen-2026-118191","42493207","PMC13404484","ClinicalTrials.gov:NCT05569772; CTIS:2022-502082-22-00","S001290","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0015469","EBM BLS: Tirzepatide Leads to Resolution of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Without Worsening of Fibrosis.","Campbell LA","2026","Journal of general internal medicine","commentary","article","10.1007/s11606-025-10123-6","41540304","PMC13083707",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0015470","People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.","Li X","2026","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.70067","41187013","PMC12724063","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT04660643","S000242; S001077; S002157","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0015471","Diabetes and Glucose Management in People on Hemodialysis.","Agarwal S","2025","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/dsi24-0015","39959530","PMC11825408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015472","ROCK signaling at the crossroads of redox stress, mitochondrial dynamics, and metabolic disease.","Nagai Y","2026","Redox biology","narrative_review","article","10.1016/j.redox.2026.104109","41791289","PMC12972520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0015473","Semaglutide improves contractile function in human atrial myocardium of patients with heart failure and preserved ejection fraction.","Hegner P","2026","Cardiovascular research","other","article","10.1093/cvr/cvag039","41632787","PMC13123652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015474","Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.","Scheen AJ","2014","Clinical pharmacokinetics","narrative_review","article","10.1007/s40262-014-0157-y","25091053",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015475","Current concepts and challenges in pediatric diastolic dysfunction and heart failure with preserved ejection fraction.","Losordo LD","2026","Pediatric research","narrative_review","article","10.1038/s41390-026-05038-9","42162279","PMC13329742",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0015476","GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.","Derosa G","2012","Current clinical pharmacology","narrative_review","article","10.2174/157488412800958686","22432846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015477","Recent advances in non-alcoholic steatohepatitis-associated hepatocellular carcinoma: immune cells, metabolic dysregulation, and therapeutic strategies.","Liu L","2025","Frontiers in oncology","narrative_review","article","10.3389/fonc.2025.1744299","41647835","PMC12867836",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015478","Multispecialty Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: Optimizing Cardiometabolic Risk","Hoseini S","2025","Preprints.org","other","preprint","10.20944/preprints202511.2318.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015479","DUTCH weight control in atrial fibrillation study (DUTCH-WAIST) : Design and rationale of a randomised controlled trial.","Voorhout L","2026","Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation","protocol","article","10.1007/s12471-026-02074-2","42734721","PMC13615193",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0015480","Correction: Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weight Gain After Primary Bariatric Surgery?","Rivero-Moreno Y","2026","Obesity surgery","notice","article","10.1007/s11695-026-08675-5","41979776",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0015481","Quantifying Medicare prescription payment plan benefits under Medicare Part D.","Zhang YW","2026","Journal of the American Pharmacists Association : JAPhA","other","article","10.1016/j.japh.2026.103540","42829039",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015482","Semaglutide as a potential tool in pre-lung transplant weight loss optimization.","Ali R","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag040","41928866","PMC13043148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015483","A pH-Triggered Self-Unpacking Capsule Containing Zwitterionic Hydrogel-Coated MOF Nanoparticles for Efficient Oral Exendin-4 Delivery.","Zhou Y","2021","Advanced materials (Deerfield Beach, Fla.)","preclinical","article","10.1002/adma.202102044","34216408",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015484","GHSR-1 agonist sensitizes rat colonic intrinsic and extrinsic neurons to exendin-4: A role in the manifestation of postprandial gastrointestinal symptoms in irritable bowel syndrome?","Buckley MM","2019","Neurogastroenterology and motility","preclinical","article","10.1111/nmo.13684","31311066",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015485","Beyond BMI: Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine.","Tanasescu MD","2025","Diagnostics (Basel, Switzerland)","narrative_review","article","10.3390/diagnostics15233025","41374408","PMC12691488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015486","A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.","Galindo RJ","2023","Diabetes care","randomized_trial","article","10.2337/dc22-2426","37459574","PMC10465828",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; brief-report; article; other"],["R0015487","Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial.","Hany M","2024","International journal of surgery (London, England)","randomized_trial","article","10.1097/js9.0000000000000990","38100630","PMC10942244",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0015488","Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.","Rampersaud N","2012","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2012.02100.x","22774922","PMC3514760",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; research-article; article"],["R0015489","Causal Inference in Non-Allergic Asthma Associated with Obesity: Application of the Bradford Hill Viewpoints to a Complex Epidemiological Association","Martínez JJL","2026","Preprints.org","randomized_trial","preprint","10.20944/preprints202606.0451.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0015490","Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents.","Yang Q","2022","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2022.114214","35231829",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015491","Pharmacological Treatment for Gestational Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of 71 Randomised Controlled Trial.","Liu X","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70823","42082193",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; review"],["R0015492","Weight-centric treatment of type 2 diabetes mellitus.","Ghusn W","2022","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2022.100045","37990663","PMC10662009",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0015493","Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials.","Zhang S","2026","European journal of pharmacology","systematic_review","article","10.1016/j.ejphar.2026.178587","41580006",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0015494","Real-World Kidney and Glycaemic Outcomes Following Semaglutide Initiation in Adults with Type 2 Diabetes and Mild Chronic Kidney Disease.","Rabbani SA","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15145577","42513491","PMC13412203",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015495","Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial.","Giorgino F","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13857","31423722","PMC6899526",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0015496","Can obesity pharmacotherapy modify osteoarthritis? Interpreting pain relief, weight-loss quality, and structural outcomes.","Rombach J","2026","Osteoarthritis and cartilage","randomized_trial","article","10.1016/j.joca.2026.09.007","42767324",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0015497","Chronic kidney disease in the primary care setting: A narrative review.","Safdar F","2025","Journal of general and family medicine","narrative_review","article","10.1002/jgf2.70054","40904443","PMC12404170",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0015498","An Incidental Finding of a Glucagon-Like Peptide 1 (GLP-1)-Induced Acute Kidney Injury: A Case Report.","Aleman Espino A","2023","Cureus","case_report","article","10.7759/cureus.45261","37720126","PMC10503877",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015499","All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study.","Toulis KA","2017","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2017.02.003","28325589",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015500","Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT-MAINTAIN.","Horn DB","2025","Obesity (Silver Spring, Md.)","protocol","article","10.1002/oby.70014","40916045","PMC12477106","ClinicalTrials.gov:NCT06047548","S001952","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0015501","GLP-1 Is Not Enough: Can Glucagon Fill the Energy Expenditure Gap?","Beji S","2026","Neuroendocrinology","narrative_review","article","10.1159/000550812","41678436",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015502","Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising candidates.","More PS","2026","Ageing research reviews","narrative_review","article","10.1016/j.arr.2026.103113","41956136",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015503","Exendin-4 and Liraglutide Attenuate Glucose Toxicity-Induced Cardiac Injury through mTOR/ULK1-Dependent Autophagy.","Yu W","2018","Oxidative medicine and cellular longevity","preclinical","article","10.1155/2018/5396806","29849901","PMC5932983",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015504","Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.","Drygalski K","2025","Polish archives of internal medicine","systematic_review","article","10.20452/pamw.17141","41117588",null,"PROSPERO:CRD420251017953",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0015505","Injecting New Ideas Into Managing Type 2 Diabetes: Evolving Roles of GLP-1 Receptor Agonists.","Anderson JE","2025","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2019.02.001","30776319",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015506","Centrally administered GLP-1 analogue improves intestinal barrier function through the brain orexin and the vagal pathway in rats.","Funayama T","2023","Brain research","preclinical","article","10.1016/j.brainres.2023.148371","37076092",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015507","SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.","Bel Lassen P","2026","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.70697","41884974","PMC13146160",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Observational Study; methods-article; article"],["R0015508","Exendin-4 may improve type 2 diabetes by modulating the epigenetic modifications of pancreatic histone H3 in STZ-induced diabetic C57BL/6 J mice.","Tu P","2022","Journal of physiology and biochemistry","preclinical","article","10.1007/s13105-021-00835-8","34410626",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015509","Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer's disease.","An J","2019","Behavioural brain research","preclinical","article","10.1016/j.bbr.2019.111932","31082410",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015510","Exendin-4 inhibits high glucose-induced oxidative stress in retinal pigment epithelial cells by modulating the expression and activation of p66Shc.","Al Sabaani N","2021","Cutaneous and ocular toxicology","preclinical","article","10.1080/15569527.2020.1844727","34275397",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015511","Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.","Talay L","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70462","41532325","PMC12992185",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0015512","Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.","Han J","2018","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.8b00336","29799205",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015513","Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.","Nicolau J","2026","Medicina clinica","nonrandomized_study","article","10.1016/j.medcli.2026.107364","41722140",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0015514","Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.","Clements J","2015","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.2015.1098532","30289034",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015515","Heart Failure With Preserved Ejection Fraction and Chronic Kidney Disease: From Pathophysiology to Treatment.","Grilo RM","2026","The American journal of cardiology","narrative_review","article","10.1016/j.amjcard.2025.10.013","41135791",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015516","Pathomechanisms, genetic insights, and therapeutics in diabetes-associated dementia.","Meher R","2025","The Journal of endocrinology","narrative_review","article","10.1530/joe-25-0016","41196686",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015517","Managing weight and glycaemic targets in people with type 2 diabetes-How far have we come?","Blüher M","2022","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.330","35298097","PMC9094453",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0015518","Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy.","Shi S","2023","Endocrine connections","preclinical","article","10.1530/ec-23-0284","37522848","PMC10503227",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015519","First Experience With Semaglutide for the Treatment of Obesity in Nondiabetic Patient With Progressive Dysfunction of Renal Graft.","Miertová Z","2026","American journal of therapeutics","other","article","10.1097/mjt.0000000000002097","41839779",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015520","Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.","Rubio-Herrera MA","2023","Biomedicines","other","article","10.3390/biomedicines11102785","37893158","PMC10604375",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015521","Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges.","Brandfon S","2023","Cureus","narrative_review","article","10.7759/cureus.46623","37937009","PMC10626572",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015522","The Role of Bariatric Surgery in Kidney Disease: Evidence, Controversies, and Future Needs.","Calderon Martinez E","2026","Obesity surgery","randomized_trial","article","10.1007/s11695-026-08901-0","42627475",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0015523","Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.","Almby KE","2019","European journal of endocrinology","randomized_trial","article","10.1530/eje-19-0171","31176298",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0015524","Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension.","Helmstädter J","2020","Arteriosclerosis, thrombosis, and vascular biology","preclinical","article","10.1161/atv.0000615456.97862.30","31747801","PMC6946108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015525","Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran.","Ekhlasi M","2022","Value in health regional issues","other","article","10.1016/j.vhri.2022.07.005","36087364",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015526","Diabetes Mellitus and Osteoporosis After Organ Transplantation: Frequency, Clinical Features, and Treatment.","Sarabhai T","2026","Deutsches Arzteblatt international","randomized_trial","article","10.3238/arztebl.m2026.0019","41711448","PMC13291625",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015527","The Effect of Frailty on Body Composition and Its Impact on the Use of SGLT-2 Inhibitors and GLP-1RA in Older Persons with Diabetes.","Sinclair A","2025","Metabolites","narrative_review","article","10.3390/metabo15060381","40559405","PMC12194996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015528","Tirzepatide as adjunct to insulin for the treatment of type 1 diabetes.","Patoulias D","2026","European journal of internal medicine","commentary","article","10.1016/j.ejim.2025.106624","41339161",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015529","Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.","Anastasiou IΑ","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00623-1","40210807","PMC11985575",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015530","Increased myocardial vulnerability to ischemia-reperfusion injury in the presence of left ventricular hypertrophy.","Mølgaard S","2016","Journal of hypertension","preclinical","article","10.1097/hjh.0000000000000826","26820478",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015531","Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.","Matza LS","2021","Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation","other","article","10.1007/s11136-021-02808-2","33886044","PMC8233232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015532","Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.","DeFronzo RA","2017","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12982","28432726","PMC5643008",null,"S002481","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0015533","Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents With Variants in Monogenic Obesity-Related Genes.","Salama M","2026","Pediatric obesity","nonrandomized_study","article","10.1111/ijpo.70091","41667135",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015534","Lifetime cost-effectiveness of semaglutide for secondary prevention in atherosclerotic cardiovascular disease: A select-based simulation study.","Ponnana SR","2026","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2026.101543","42395069","PMC13325729",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0015535","Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.","Cerchi E","2025","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-025-01920-4","41015578",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0015536","Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study.","Nikolic D","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01217-z","35167051","PMC8853434","ClinicalTrials.gov:NCT01715428","S001748","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015537","Quality of care for migrant populations with type 2 diabetes mellitus in Italy: a retrospective analysis of data from the the Italian AMD (Associations of Medical Diabetologists) annals initiative.","Occhipinti M","2026","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-026-02675-8","42340410","PMC13534151",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015538","The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2.","Yue W","2019","IUBMB life","other","article","10.1002/iub.2046","30969479",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015539","Comment on Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Study.","Lum F","2024","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2024.08.037","39245132",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0015540","Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.","Wan H","2024","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-024-01501-x","39508238","PMC11542446",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0015541","Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.","Svanström H","2019","The lancet. Diabetes & endocrinology","nonrandomized_study","article","10.1016/s2213-8587(18)30320-6","30527909",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015542","Central mechanisms underlying the synergistic anorectic effect of CCK and GLP-1 combination therapy","Roth EM","2019","University of Cambridge","preclinical","article","10.17863/cam.43501",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0015543","Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.","Arora P","2026","Expert review of pharmacoeconomics & outcomes research","nonrandomized_study","article","10.1080/14737167.2025.2610206","41524543",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0015544","Combination of Intranasal insulin and oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk","Shamrok H","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","randomized_trial","article","10.1002/alz70860_102127","41434629","PMC12726504",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0015545","Pipeline treatments on psoriatic disease.","Ribeiro AL","2025","Best practice & research. Clinical rheumatology","randomized_trial","article","10.1016/j.berh.2025.102090","40987667",null,null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Review"],["R0015546","Combined Probe Strategy to Increase the Enzymatic Digestion Rate and Accelerate the Renal Radioactivity Clearance of Peptide Radiotracers.","Zhang M","2022","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.2c00051","35357154",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015547","Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no.","Madsbad S","2012","European journal of internal medicine","commentary","article","10.1016/j.ejim.2011.11.003","22284242",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0015548","Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.","Rosenstock J","2016","Diabetes care","randomized_trial","article","10.2337/dc16-0014","27222510",null,"ClinicalTrials.gov:NCT01768559","S001630","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0015549","Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.","Wong M","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70137","41732031","PMC13250739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015550","Direct medical costs for patients with type 2 diabetes in 16 tertiary hospitals in urban China: A multicenter prospective cohort study.","Li X","2019","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.12905","30079578","PMC6400170",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0015551","The neuroprotective promise of semaglutide for Alzheimer's disease.","Hamdar H","2025","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000003952","41377300","PMC12689029",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0015552","Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.","Alsararatee HH","2025","BMJ case reports","case_report","article","10.1136/bcr-2025-266561","40669882",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0015553","FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10554689",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0015554","Novel Plasma Proteomics and Phosphoproteomics Platform Captures Pleiotropic Cardiometabolic Spectrum Effects of Semaglutide in Patients with T2D and Atherosclerosis: A Companion Diagnostic Pilot Study from the STOP (Semaglutide Treatment On coronary atherosclerosis Progression) Randomized Trial","Manousopoulou A","2026","bioRxiv","randomized_trial","preprint","10.64898/2026.02.16.706239",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0015555","Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF.","Capone F","2024","Current opinion in cardiology","other_trial","article","10.1097/hco.0000000000001117","38294187",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015556","Semaglutide and weight loss in obese patients with and without type 2 diabetes.","Gupta H","2026","Journal of family medicine and primary care","nonrandomized_study","article","10.4103/jfmpc.jfmpc_1769_24","42257166","PMC13241141",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0015557","Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.","Li A","2023","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2023.110605","36871874",null,null,"S000766","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0015558","Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.","Zhao HJ","2020","Journal of molecular endocrinology","preclinical","article","10.1530/jme-19-0186","31855560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015559","Gastrointestinal Incretins-Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease-State of the Art.","Jonik S","2022","Biology","narrative_review","article","10.3390/biology11020288","35205155","PMC8869592",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015560","Endoscopic and Open Carpal Tunnel Release in Patients With Type II Diabetes Mellitus: Influence of Preoperative Semaglutide Use on Postoperative Outcomes.","Seddio AE","2025","The Journal of hand surgery","nonrandomized_study","article","10.1016/j.jhsa.2025.09.003","41105066",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015561","Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management.","Paschou SA","2017","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/jc.2017-00042","28938433",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0015562","Cost-Effectiveness of Access to Obesity Care and Treatments for Adolescents.","Doan TT","2026","Childhood obesity (Print)","nonrandomized_study","article","10.1177/21532176261454487","42233337",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015563","Prescribing patterns before the initiation of novel antidiabetic medicines in public, occupational, and private healthcare: a register study reflecting the guidelines of care in type 2 diabetes.","Rättö H","2024","BMC health services research","other","article","10.1186/s12913-024-12010-y","39639300","PMC11619279",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0015564","Looking beyond fat in obesity: the frequently overlooked importance of muscle mass.","Hegazi R","2025","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-025-09986-1","40676357","PMC12534304",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Introductory Journal Article; review-article; article"],["R0015565","COVID-19 in Diabetic Patients: Mechanisms, Risks, and Therapeutic Considerations.","Hamdy R","2026","Reviews in medical virology","narrative_review","article","10.1002/rmv.70085","41346074",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015566","Liraglutide exerts protective effects on MASLD independently of lipophagy, and the combination with kombucha presents no additional advantage","de Almeida JS","2025","bioRxiv","preclinical","preprint","10.1101/2025.10.24.684466",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015567","Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats.","Katsurada K","2019","Scientific reports","preclinical","article","10.1038/s41598-019-49364-x","31537818","PMC6753091",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015568","Pharmacological interactions between asthma and T2DM therapies: clinical and metabolic implications.","Matera MG","2026","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1080/17425255.2026.2632668","41685674",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015569","[Modern strategies for the treatment of childhood obesity].","Okorokov PL","2022","Problemy endokrinologii","narrative_review","article","10.14341/probl13208","36689718","PMC9939972",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; English Abstract; Journal Article; research-article; article"],["R0015570","Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.","Norwood P","2017","Diabetes, obesity & metabolism","other","article","10.1111/dom.12972","28417535","PMC5655847",null,"S001276; S001328","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015571","Two Cases of Diabetes Remission through Temporary Tirzepatide Treatment.","Sawamura T","2026","Internal medicine (Tokyo, Japan)","nonrandomized_study","article","10.2169/internalmedicine.5779-25","40803851","PMC13019020",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Case Reports; case-report; article"],["R0015572","Efficacy of Subcutaneous Semaglutide Dose Escalation in Reducing Insulin in Patients With Type 2 Diabetes.","Halver A","2025","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article","10.12788/fp.0642","42666995","PMC13524180",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015573","The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.","Spezani R","2022","Life sciences","narrative_review","article","10.1016/j.lfs.2021.120188","34861287",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015574","Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.","Rosenstock J","2018","Diabetes care","randomized_trial","article","10.2337/dc17-1306","29242349",null,"ClinicalTrials.gov:NCT01455857","S002013","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0015575","Niacin exacerbates β cell lipotoxicity in diet-induced obesity mice through upregulation of GPR109A and PPARγ2: Inhibition by incretin drugs.","Zhang X","2022","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2022.1057905","36568082","PMC9768175",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015576","Weight gain after Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: is there a role for GLP-1 agonists?","Del Prete E","2025","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","commentary","article","10.1007/s10072-024-07720-4","39126445",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015577","Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.","le Roux CW","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16052","39582349","PMC11701180",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0015578","Tirzepatide for weight loss.","Cheung KA","2025","Canadian family physician Medecin de famille canadien","other","article","10.46747/cfp.711112729","41285630","PMC12668397",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0015579","Recommendations for the evaluation and treatment of patients with diabetes and albuminuria. Role of non-steroidal mineralocorticoid antagonism.","Payán López J","2025","Nefrologia","narrative_review","article","10.1016/j.nefroe.2025.501359","41219079",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015580","The transition from preclinical to clinical obesity: the importance of a borderline stage.","Maldonado-Arvizu JE","2026","Clinical science (London, England : 1979)","narrative_review","article","10.1042/cs20256728","41496660","PMC12870741",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015581","[Does liraglutide have a place in psychiatry ?].","Frantz J","2022","Revue medicale suisse","other","article","10.53738/revmed.2022.18.774.522","35343120",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015582","Thyroid Dysfunction Following Tirzepatide Use in a Post-thyroidectomy Patient on Stable Levothyroxine Therapy: A Case Study.","Adams EW","2026","Cureus","case_report","article","10.7759/cureus.106680","42109981","PMC13155940",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015583","GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia.","Medak KD","2020","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00309.2020","33017220",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; dissertation; article"],["R0015584","An Update on the Treatment of Arterial Stiffness.","Ramirez AJ","2026","Current hypertension reviews","narrative_review","article","10.2174/0115734021400629251107114355","41239924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015585","Semaglutide utilization associated with reduced 90-day postoperative complications following single-level posterior lumbar fusion for patients with type II diabetes.","Seddio AE","2025","The spine journal : official journal of the North American Spine Society","nonrandomized_study","article","10.1016/j.spinee.2024.10.011","39491749",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015586","Tirzepatide and the prevention of heart failure in obesity: a multi-center cohort study using the TriNetX database.","Wu JY","2026","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf663","41123417",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0015587","A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents.","Mietlicki-Baase EG","2018","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.13222","29327400","PMC5899935",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0015588","Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.","Rosenstock J","2019","JAMA","randomized_trial","article","10.1001/jama.2019.2942","30903796","PMC6484814","ClinicalTrials.gov:NCT02607865","S002267","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0015589","Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.","Watada H","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13859","31423685","PMC6900157",null,"S002038","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0015590","A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet.","de Ceglia M","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms26062420","40141063","PMC11942104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015591","Impaired Ca2+ signaling due to hepatic steatosis mediates hepatic insulin resistance in Alström syndrome mice that is reversed by GLP-1 analog treatment.","Ali ES","2021","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00020.2021","34106786",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015592","Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial.","Buse JB","2025","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2025-005161","41093600","PMC12530410","ClinicalTrials.gov:NCT03596450","S000545","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Pragmatic Clinical Trial; Comparative Study; Multicenter Study; research-article; article"],["R0015593","Alzheimer's Disease as Type 3 Diabetes: The Impact of Insulin Resistance and the Therapeutic Potential of Semaglutide in Cognitive Decline","Verma I","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","other_trial","article","10.1002/alz70855_103762","41439359","PMC12728472",null,null,"europepmc; openalex","TRUE","open_europepmc","5","FALSE","Abstract; article"],["R0015594","Exendin-4 disrupts responding to reward predictive incentive cues in rats","Wakabayashi KT","2018","bioRxiv","preclinical","preprint","10.1101/315705",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015595","Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation.","Chen C","2017","Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","preclinical","article","10.1186/s40199-017-0186-9","28870261","PMC5583966",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015596","Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.","Gangopadhyay KK","2017","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/ijem.ijem_512_16","28459036","PMC5367241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015597","Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment.","Yokota K","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag107","42158165","PMC13180639",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015598","Liraglutide improves cognitive function by reducing amyloid-beta peptide accumulation and inhibiting inflammation in 5×FAD mice","Qi L","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-845788/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015599","Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.","DeRemer CE","2021","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2021.107972","34247911",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0015600","Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?","Doggrell SA","2018","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2018.1519547","30234389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015601","Recognizing overweight and obesity as chronic diseases and acknowledging root causes.","Falahee BE","2025","Med (New York, N.Y.)","narrative_review","article","10.1016/j.medj.2025.100782","40738102",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015602","Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.","Mezquita-Raya P","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-017-0239-6","28224463","PMC5380501","ClinicalTrials.gov:NCT01973231","S001337","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015603","Dipeptidyl peptidase-4 inhibitor linagliptin improves fibrosis, apoptosis, and cardiac function in a large animal model of chronic myocardial ischemia.","Harris DD","2025","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1016/j.jpet.2024.100532","40023609","PMC13095462",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0015604","Glucagon‐like peptide 1 (GLP‐1) receptor agonists for people with chronic kidney disease and diabetes","Natale P","2023","The Cochrane database of systematic reviews","narrative_review","article","10.1002/14651858.cd015849",null,"PMC10108660",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","systematic-review; Review; article"],["R0015605","Efficacy of a glucagon-like peptide-1 agonist and restrictive versus liberal oxygen supply in patients undergoing coronary artery bypass grafting or aortic valve replacement: study protocol for a 2-by-2 factorial designed, randomised clinical trial.","Wiberg S","2021","BMJ open","protocol","article","10.1136/bmjopen-2021-052340","34740932","PMC8573662","ClinicalTrials.gov:NCT02673931","S001685","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0015606","Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials.","Bo Y","2025","BMC women's health","systematic_review","article","10.1186/s12905-025-03594-6","39955537","PMC11829492",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review-article; review"],["R0015607","Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?","Labuzek K","2013","European journal of internal medicine","nonrandomized_study","article","10.1016/j.ejim.2013.01.009","23375875",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0015608","Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist.","Connolly BM","2012","Molecular imaging and biology","preclinical","article","10.1007/s11307-011-0481-7","21394533",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015609","[Weight Recurrence After Bariatric Surgery: Definitions, Diagnosis, and Management Strategies. Part 2].","Díaz R","2026","Revista medica de Chile","narrative_review","article","10.4067/s0034-98872026000400564","42441680",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0015610","Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.","Shigeoka T","2020","Journal of diabetes investigation","preclinical","article","10.1111/jdi.13247","32146725","PMC7477521",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015611","Effects of obesity treatments on bone mineral density, bone turnover and fracture risk in adults with overweight or obesity.","Harper C","2016","Hormone molecular biology and clinical investigation","narrative_review","article","10.1515/hmbci-2016-0025","27665425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015612","Dietary and pharmacological energy restriction and exercise for healthspan extension.","Cagigas ML","2025","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2025.04.001","40318928",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015613","Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials.","Cai Z","2025","The journal of prevention of Alzheimer's disease","systematic_review","article","10.1016/j.tjpad.2025.100111","40023730","PMC12183985",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; research-article; review"],["R0015614","Six-month effects of liraglutide and dapagliflozin on lipid profile, cardiovascular risk, and NT-proBNP levels in patients with metabolic dysfunction-associated steatotic liver disease.","Cherniavskyi V","2026","Wiadomosci lekarskie (Warsaw, Poland : 1960)","randomized_trial","article","10.36740/wlek/216930","42139606",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0015615","Beyond Lipids and Platelets: A Review of Anti-Inflammatory Strategies in Secondary Prevention of Acute Coronary Syndromes.","Pathangey G","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14227910","41302946","PMC12653462",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015616","Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss: A Systematic Review and Meta-Analysis.","Liu Z","2026","Ophthalmology","systematic_review","article","10.1016/j.ophtha.2025.12.022","41475544",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; article"],["R0015617","Reply to Comment On: Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study.","Wai KM","2024","American journal of ophthalmology","commentary","article","10.1016/j.ajo.2024.08.036","39241978","PMC13384241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article-commentary; letter"],["R0015618","Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.","Pizzimenti V","2016","Journal of clinical pharmacy and therapeutics","nonrandomized_study","article","10.1111/jcpt.12373","26936090",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0015619","Protein restriction in CKD: an outdated strategy in the modern era.","Bawazir A","2025","Jornal brasileiro de nefrologia","narrative_review","article","10.1590/2175-8239-jbn-2024-po03en","39933007","PMC11813190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; editorial; article"],["R0015620","The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data.","Anagnostis P","2018","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-018-0017-5","29858866",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015621","Splenectomy prevents brain orexin, ghrelin, or oxytocin but not GLP-1-induced improvement of intestinal barrier function in rats.","Funayama T","2025","Neurogastroenterology and motility","preclinical","article","10.1111/nmo.14949","39450642",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015622","Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical Trials in Nephrology.","Berube AJ","2026","Kidney international reports","nonrandomized_study","article","10.1016/j.ekir.2026.106350","41858318","PMC12997310",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0015623","Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine.","Buchanan AM","2026","ACS chemical neuroscience","preclinical","article","10.1021/acschemneuro.5c00954","42219687","PMC13281379",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015624","A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.","Prasad-Reddy L","2015","Drugs in context","narrative_review","article","10.7573/dic.212283","26213556","PMC4509428",null,"S002223","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0015625","Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.","Pandey A","2025","JACC. Heart failure","randomized_trial","article","10.1016/j.jchf.2025.102610","40956259",null,"ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; article"],["R0015626","Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity?","Gisondi P","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","commentary","article","10.1111/jdv.70208","41239939",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015627","Clinical efficacy of liraglutide combined with pioglitazone in obese polycystic ovary syndrome and its effects on the serum chemerin/visfatin ratio.","Zhang J","2026","American journal of translational research","nonrandomized_study","article","10.62347/wndz4386","42491030","PMC13376015",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015628","Significant improvement of postural orthostatic tachycardia syndrome (POTS) with semaglutide: a case report.","Blitshteyn S","2026","Clinical autonomic research : official journal of the Clinical Autonomic Research Society","case_report","article","10.1007/s10286-026-01197-1","41739421",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015629","Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients.","Teti C","2020","Journal of endocrinological investigation","commentary","article","10.1007/s40618-019-01106-6","31473983",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0015630","Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.","Fadini GP","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70151","40990044","PMC12587239",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Comparative Study; research-article; article"],["R0015631","Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss.","Han SH","2024","Aesthetic surgery journal","other","article","10.1093/asj/sjad364","38085071",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015632","A quinoxaline-based compound ameliorates bone loss in ovariectomized mice.","Zhou Y","2021","Experimental biology and medicine (Maywood, N.J.)","preclinical","article","10.1177/15353702211032133","34308655","PMC8649934",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015633","The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists.","Fang Z","2020","ACS pharmacology & translational science","other","article","10.1021/acsptsci.0c00022","32296773","PMC7155199",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015634","India: Doctors report surge in use of off label GLP-1 agonists among rich.","Lal N","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1605","39029939",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; other"],["R0015635","Post-semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system.","Wang N","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70571","41705640",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0015636","Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.","Patel H","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15333","37853960",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015637","6926 Subgroup Analysis by Gender and Body Mass Index (BMI) in People Living With Overweight/Obesity in the Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, Phase II Trial",null,"2024","Journal of the Endocrine Society","other_trial","article",null,null,"PMC11453361",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0015638","Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.","Sumida Y","2017","Hepatology research : the official journal of the Japan Society of Hepatology","narrative_review","article","10.1111/hepr.12856","28019064",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015639","Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives.","Drygalski K","2025","International journal of molecular sciences","randomized_trial","article","10.3390/ijms26136518","40650294","PMC12249978",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015640","GLP-1R as a potential link between diabetes and Alzheimer's disease.","Li S","2025","Frontiers in aging neuroscience","narrative_review","article","10.3389/fnagi.2025.1601602","40778306","PMC12328308",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015641","MON-681 Dulaglutide Commonly Known as Trulicity; An Anti-Diabetic Medication Causing Small Bowel Obstruction","Gandhi A","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.609",null,"PMC7209367",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0015642","The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.","Zhou M","2017","Oncogene","preclinical","article","10.1038/onc.2017.38","28319060",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015643","Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.","Yu M","2016","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2015.11.017","26706658",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0015644","Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro.","Al-Dwairi A","2018","Journal of inflammation research","preclinical","article","10.2147/jir.s152835","29593427","PMC5865574",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015645","The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases.","Li M","2024","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","narrative_review","article","10.1055/a-2266-1503","38471571",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015646","Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.","Singh AK","2014","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.141319","25364668","PMC4192978",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015647","[Effect of semaglutide on serum metabolomics in obese patients with type 2 diabetes mellitus complicated with metabolic-associated fatty liver disease].","Niu S","2025","Zhonghua nei ke za zhi","randomized_trial","article","10.3760/cma.j.cn112138-20250424-00235","41338557",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","English Abstract; Journal Article; other"],["R0015648","The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity.","Coveleskie K","2017","Obesity science & practice","other","article","10.1002/osp4.124","29259802","PMC5729499",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015649","Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.","Granhall C","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-021-01106-x","34319564","PMC8384972","ClinicalTrials.gov:NCT02911870",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; case-report; article"],["R0015650","Discovery and Preclinical Evaluation of TPM003: A Novel GLP-1/GIP/Glucagon Triple Hormone Receptor Agonist with Robust Efficacy in Obesity and NASH.","Zheng N","2026","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.5c03845","41640214",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015651","Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study.","Wu JY","2025","Hepatology international","nonrandomized_study","article","10.1007/s12072-025-10857-9","40668509",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Multicenter Study; article"],["R0015652","Do People Reduce Attempts At Lifestyle Change After Initiating Weight Loss Medication? A Review Of Trial Evidence","Macfarlane M","2024","medRxiv","other_trial","preprint","10.1101/2024.01.12.24301166",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0015653","The 'astounding' rise of semaglutide - and what's next for weight-loss drugs.","Nogrady B","2026","Nature","commentary","article","10.1038/d41586-026-00228-1","41680520",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0015654","Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease.","Cavender MA","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2025.12.071","42552888",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015655","Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics.","Anagnostopoulou L","2026","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.70167","41954023","PMC13063214",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015656","Investigating GLP-1 Injections: Potential Mitochondrial Dysfunction in Non-Diabetic Patients Presenting with Migraines and Hypoglycemia: A Case Report.","Jamail J","2024","Integrative medicine (Encinitas, Calif.)","case_report","article",null,"39830428","PMC11737221",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015657","What Is Food Noise? A Conceptual Model of Food Cue Reactivity.","Hayashi D","2023","Nutrients","narrative_review","article","10.3390/nu15224809","38004203","PMC10674813",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015658","Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.","Eisa N","2026","AACE endocrinology and diabetes","systematic_review","article","10.1016/j.aed.2026.01.001","41938304","PMC13043474",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0015659","Tirzepatide increased force of contraction in the isolated human atrium.","Neumann J","2025","Naunyn-Schmiedeberg's archives of pharmacology","other","article","10.1007/s00210-025-04214-8","40299022","PMC12511147",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015660","The Therapeutic Target of SGLT2 Inhibitors and GLP-1 Agonists Is Superoxide Induced Diuretic Resistance","Kaesemeyer MD W","2024","Preprints.org","other","preprint","10.20944/preprints202409.1354.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015661","Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells.","Kosowska A","2017","Endocrine connections","other","article","10.1530/ec-17-0294","29042458","PMC5682419",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015662","Insulin Degludec / Liraglutide (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V",null,"2015","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany","narrative_review","article",null,"29144650",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0015663","Long-term administration of liraglutide for weight management in pediatric patients under 18 years: evidence from 7 randomized controlled trials.","Dong J","2026","Pediatric research","systematic_review","article","10.1038/s41390-025-04537-5","41184626",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Review; article"],["R0015664","Enhanced FGF21 Delivery via Neutrophil-Membrane-Coated Nanoparticles Improves Therapeutic Efficacy for Myocardial Ischemia-Reperfusion Injury.","Rao Z","2025","Nanomaterials (Basel, Switzerland)","preclinical","article","10.3390/nano15050346","40072149","PMC11901824",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015665","Prospecting the use of tirzepatide in combating obesity in Pakistan.","Talha M","2025","JPMA. The Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.30598","41418149",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0015666","GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis.","Chadda KR","2021","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13177","33354917",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0015667","Incretin Mimetics as Potential Therapeutics for Concussion and Traumatic Brain Injury: A Narrative Review.","Sipos S","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms27010045","41515925","PMC12786247",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0015668","[Diabetes mellitus and road traffic-A position paper of the Austrian Diabetes Association (Update 2026)].","Abrahamian H","2026","Wiener klinische Wochenschrift","other","article","10.1007/s00508-025-02655-y","42162484","PMC13190499",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Consensus Statement; English Abstract; research-article; article"],["R0015669","[Smoking and nicotine use, heated tobacco products, psychological and socioeconomic aspects of dependence, alcohol, infections, vaccination and diabetes mellitus (Update 2026)].","Brath H","2026","Wiener klinische Wochenschrift","narrative_review","article","10.1007/s00508-025-02680-x","42162466","PMC13190427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; research-article; article"],["R0015670","Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease- A Growing Threat Beyond the Liver.","Zahid MD","2025","Current atherosclerosis reports","nonrandomized_study","article","10.1007/s11883-025-01353-4","41165963",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0015671","Correction to \"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight\".",null,"2025","Diabetes, obesity & metabolism","notice","article","10.1111/dom.70050","40832789","PMC12710557",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0015672","Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond.","Olanrewaju OA","2023","Cureus","narrative_review","article","10.7759/cureus.51151","38283440","PMC10811430",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0015673","Liraglutide treatment reverses unconventional cellular defects in induced pluripotent stem cell-derived β cells harboring a partially functional WFS1 variant","Torchio S","2024","bioRxiv","preclinical","preprint","10.1101/2024.08.06.606801",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0015674","Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs.","Raičević BB","2025","Pharmacology research & perspectives","nonrandomized_study","article","10.1002/prp2.70080","39995024","PMC11850437",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015675","Pharmacological therapy selection of type 2 diabetes based on the SWARA and modified MULTIMOORA methods under a fuzzy environment.","Eghbali-Zarch M","2018","Artificial intelligence in medicine","other","article","10.1016/j.artmed.2018.03.003","29606521",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015676","Advances in Diagnosis and Management of Diabetes in Children and Adults with Focus on Drugs, Insulin, and Dietary Interventions","Shukla S","2026","Preprints.org","other","preprint","10.20944/preprints202602.0253.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015677","Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome.","Freitas FPC","2023","Scientific reports","randomized_trial","article","10.1038/s41598-023-40366-4","37567946","PMC10421848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0015678","Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.","Swedberg JE","2016","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m116.724542","27226591","PMC4957059",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015679","Causal Inference in Non-Allergic Asthma Associated with Obesity: Application of the Bradford Hill Viewpoints to a Complex Epidemiological Association.","Leija-Martinez JJ","2026","Epidemiologia (Basel, Switzerland)","randomized_trial","article","10.3390/epidemiologia7040107","42644891","PMC13512083",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015680","Seeing Beyond GLP-1: A Systems View of Sustainable Obesity Care.","Mui Y","2026","Journal of human nutrition and dietetics : the official journal of the British Dietetic Association","narrative_review","article","10.1111/jhn.70300","42359780","PMC13306915",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0015681","Aldolase-regulated G3BP1/2+ condensates control insulin mRNA storage in beta cells.","Quezada E","2025","The EMBO journal","preclinical","article","10.1038/s44318-025-00448-7","40355555","PMC12216156",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015682","Cardiovascular efficacy of tirzepatide: what real-world evidence promises.","Nasoufidou A","2025","Expert review of cardiovascular therapy","nonrandomized_study","article","10.1080/14779072.2025.2587294","41199614",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Editorial; editorial"],["R0015683","Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD.","Shi Y","2026","Hepatology international","commentary","article","10.1007/s12072-025-10962-9","41258966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0015684","Benchmarking size-exclusion chromatography columns for the analysis of therapeutic peptides and model oligonucleotides.","Buff M","2026","Journal of chromatography. A","other","article","10.1016/j.chroma.2026.466909","41894894",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015685","GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.","Porcellati F","2015","Diabetes & metabolism","other","article","10.1016/s1262-3636(16)30004-0","26774015",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015686","New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy.","Victor S","2022","European journal of pediatrics","randomized_trial","article","10.1007/s00431-021-04320-8","34820702","PMC8897336",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015687","Managing metabolic risks in coronary artery disease: A scoping review of recent clinical and therapeutic evidence.","Gudla SS","2026","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-026-01916-5","41867418","PMC13003029",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015688","Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.","Jastreboff AM","2023","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2301972","37366315",null,"ClinicalTrials.gov:NCT04881760","S001653; S002674","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; article"],["R0015689","PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.","Nakamura T","2014","Laboratory investigation; a journal of technical methods and pathology","preclinical","article","10.1038/labinvest.2013.133","24217090","PMC3879597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0015690","GLP-1 Receptor Agonists for Weight Loss in People without Type 2 Diabetes: What is the Current Evidence?","Gluud LL","2023","The American journal of clinical nutrition","commentary","article","10.1016/j.ajcnut.2023.07.007","37661102",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0015691","The influence of peptide context on signalling and trafficking of glucagon-like peptide-1 receptor biased agonists","Fang Z","2020","bioRxiv","other","preprint","10.1101/2020.02.24.961524",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015692","Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH.","Carvalho T","2023","Nature medicine","commentary","article","10.1038/d41591-023-00055-1","37340082",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; other"],["R0015693","Cost-Effectiveness Analysis of Pharmacological Treatment With Insulin and Insulin Analogs for Type 1 and Type 2 Diabetes Mellitus in Colombia.","Ramirez LEO","2025","Value in health regional issues","nonrandomized_study","article","10.1016/j.vhri.2024.101073","39919670",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0015694","Role of Sodium-Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review.","Kamrul-Hasan A","2025","TouchREVIEWS in endocrinology","systematic_review","article","10.17925/ee.2025.21.1.2","40485656","PMC12140633",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0015695","Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease.","Wolfe MM","2025","Endocrine reviews","narrative_review","article","10.1210/endrev/bnaf006","39951489","PMC12259236",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015696","Discovery of novel glucagon-like peptide 1/cholecystokinin 1 receptor dual agonists.","Chenxu Z","2024","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2024.106818","38801960",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015697","Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.","Lütkemeyer C","2024","Archives of endocrinology and metabolism","systematic_review","article","10.20945/2359-4292-2023-0469","39420937","PMC11460968",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review-article; review"],["R0015698","A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects.","Zhou R","2022","Clinical and translational science","randomized_trial","article","10.1111/cts.13374","35871497","PMC9579399","ClinicalTrials.gov:NCT05294536","S001458","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015699","Intracellular Pharmacokinetics of Antidiabetic Drugs: A Focused Narrative Review of Subcellular Distribution (2015-2025).","Bafail DA","2026","Diseases (Basel, Switzerland)","narrative_review","article","10.3390/diseases14020062","41745100","PMC12939389",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0015700","The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.","Frias JP","2017","Cell metabolism","randomized_trial","article","10.1016/j.cmet.2017.07.011","28768173",null,null,"S001868","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0015701","Adipose-androgen crosstalk in polycystic ovary syndrome: mechanisms and therapeutic implications.","Ni M","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1731179","41476920","PMC12747969",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015702","Spontaneous Pneumomediastinum Associated with Semaglutide Therapy: A Case Report.","Diebold J","2026","Case reports in gastroenterology","case_report","article","10.1159/000551669","42291462","PMC13263006",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015703","Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.","Mann JFE","2018","Circulation","randomized_trial","article","10.1161/circulationaha.118.036418","30566006","PMC6296845","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0015704","Role of endogenous GLP-1 on arterial stiffness and renal haemodynamics following bariatric surgery.","Moriconi D","2024","European journal of clinical investigation","other","article","10.1111/eci.14256","38774979",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015705","Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.","Glotfelty EJ","2020","Expert opinion on investigational drugs","randomized_trial","article","10.1080/13543784.2020.1764534","32412796","PMC10477949",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0015706","Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.","Gao L","2022","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","other","article","10.1055/a-1608-0345","34856624","PMC9286864",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015707","Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption.","Shams N","2026","Biomaterials advances","preclinical","article","10.1016/j.bioadv.2026.214714","41604908",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015708","Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.","Home PD","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12414","25406730",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0015709","Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.","Permana H","2022","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2022.102640","36274410",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0015710","GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis.","Malhotra K","2020","Journal of neurology","systematic_review","article","10.1007/s00415-020-09813-4","32246253",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0015711","Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes.","Kanai R","2024","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2023.100098","38230266","PMC10789635",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015712","Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome.","Toots M","2018","Scientific reports","preclinical","article","10.1038/s41598-018-28314-z","29976929","PMC6033861",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015713","Radioguided Surgery in Insulinoma Using 68Ga Labeled Exendin-4: a Case Report.","Das SS","2021","Nuclear medicine and molecular imaging","case_report","article","10.1007/s13139-021-00698-3","34721718","PMC8517054",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015714","New weight loss pill outperforms oral semaglutide for diabetes patients, study reports.","Wise J","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj.s399","41760125",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015715","Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages.","Bułdak Ł","2015","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-015-1124-3","25980358","PMC4537507",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015716","Advancing the Science of Weight Loss and Cancer Risk: A Framework for Future Investigation","Osterman TJ","2026","Preprints.org","other","preprint","10.20944/preprints202601.2362.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015717","Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.","Frías JP","2020","Expert review of endocrinology & metabolism","other_trial","article","10.1080/17446651.2020.1830759","33030356",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0015718","HISTORI Experience – a qualitative study of HISTORI patients´ experiences with Semaglutide and placebo","Rasmussen B","2025","European psychiatry : the journal of the Association of European Psychiatrists","randomized_trial","article","10.1192/j.eurpsy.2025.2252",null,"PMC12420439",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0015719","The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability.","Girges C","2021","Drugs & aging","other_trial","article","10.1007/s40266-021-00853-7","33738783",null,null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0015720","Potential Role of GLP-1 Based Therapeutics in Coronary Artery Disease.","Xiong Q","2023","Frontiers in bioscience (Landmark edition)","narrative_review","article","10.31083/j.fbl2811315","38062835",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0015721","Kynurenic acid mediates epicardial fat-induced lymphatic metabolic dysfunction in atrial fibrillation.","Takahashi M","2026","Nature communications","preclinical","article","10.1038/s41467-026-72974-9","42156758","PMC13381822",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015722","The role of gut microbiota in Tirzepatide-mediated alleviation of high-fat diet-induced obesity.","Wang R","2025","European journal of pharmacology","randomized_trial","article","10.1016/j.ejphar.2025.177827","40516844",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0015723","Semaglutide for metabolic dysfunction-associated steatohepatitis (MASH): Estimating eligibility from the 2021-2023 National Health and Nutrition Examination Survey (NHANES).","Hughes JW","2025","Hepatology communications","nonrandomized_study","article","10.1097/hc9.0000000000000860","41325108","PMC12668583",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; letter; article"],["R0015724","Balancing the scales: the interplay of diet, exercise, GLP-1 receptor agonists, and obesity in shaping male reproductive health.","Ammar OF","2023","Human reproduction (Oxford, England)","other","article","10.1093/humrep/dead126","37344147",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015725","Efficacy of Semaglutide as Adjuvant Treatment for Sleeve Gastrectomy: A Proof-of-Concept Study in Mice.","Frey S","2025","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.70003","40898674",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0015726","The Use of Complementary and Alternative Treatments in Adolescent Obesity: A Narrative Review.","Shrestha M","2025","International journal of environmental research and public health","narrative_review","article","10.3390/ijerph22020281","40003506","PMC11855505",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0015727","Primary Cilia as Integrative Hubs of Metabolic Signaling in Type 2 Diabetes: Inter-Organ Evidence From Central, Peripheral, and Pancreatic Islet Tissues.","Liang M","2026","Journal of cellular physiology","narrative_review","article","10.1002/jcp.70208","42436646","PMC13356578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0015728","Adiponectin Signaling Dysfunction and Pro-inflammation in Perivascular Adipose Tissue in Non-obstructive Ischemic Heart Disease: A Narrative Literature Review of New Endocrine-Metabolic Therapeutic Targets.","Cisneros Clavijo PE","2026","Cureus","randomized_trial","article","10.7759/cureus.111759","42534143","PMC13419870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015729","Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study.","Barakat KE","2025","Obesity surgery","randomized_trial","article","10.1007/s11695-025-08368-5","41212463","PMC12722407",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; research-article; article"],["R0015730","Gestational Weight Gain and Pregnancy Outcomes After Semaglutide Exposure.","Yu Y","2026","Obstetrics and gynecology","nonrandomized_study","article","10.1097/aog.0000000000006325","42208070",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015731","Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.","Šantić R","2026","Metabolites","narrative_review","article","10.3390/metabo16060364","42346344","PMC13303403",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015732","Mice Deficient in Proglucagon-Derived Peptides Exhibit Glucose Intolerance on a High-Fat Diet but Are Resistant to Obesity.","Takagi Y","2015","PloS one","preclinical","article","10.1371/journal.pone.0138322","26378455","PMC4574859",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015733","Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.","Hartman ML","2020","Diabetes care","other_trial","article","10.2337/dc19-1892","32291277","PMC7245348","ClinicalTrials.gov:NCT03131687","S000010","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0015734","Endogenous Incretin Insufficiency in Obesity: Etiological Defect or Metabolic Maladaptation?","Andrade LJdO","2026","Research Square","other","preprint","10.21203/rs.3.rs-9453154/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0015735","Euglycemic Diabetic Keto Acidosis in a Type 1 Diabetic Patient After Glucose Like Peptide-1 Administration: A Case Presentation.","Widhalm C","2023","Journal of investigative medicine high impact case reports","case_report","article","10.1177/23247096231206333","37843126","PMC10580709",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015736","Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease.","Patel P","2025","Journal of clinical medicine","other_trial","article","10.3390/jcm14176060","40943823","PMC12428801",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0015737","Real-World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE-RWD).","Moreno-Pérez O","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71160","42533276","PMC13538796",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0015738","Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model.","Suzuki K","2019","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2018.12.028","30572033","PMC6369909",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0015739","Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.","Werner U","2014","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2013.06.003","23992745",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0015740","Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.","Pandey A","2025","European journal of heart failure","randomized_trial","article","10.1002/ejhf.70049","41290376","PMC12765414",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; brief-report; article"],["R0015741","Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin.","Santeusanio AD","2018","Diabetes spectrum : a publication of the American Diabetes Association","nonrandomized_study","article","10.2337/ds17-0068","30140142","PMC6092894",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015742","Protective effect of Dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-β/PI3K/NF-κB signaling pathway.","Mahdy RNE","2025","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-024-03631-5","39579211","PMC11985593",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015743","Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.","Sharma DC","2017","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/ijem.ijem_442_16","28670548","PMC5477452",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015744","Developing 68Ga-Labeled Exendin(9-39) Derivatives for PET Imaging of Insulinomas.","Li T","2025","Bioconjugate chemistry","other","article","10.1021/acs.bioconjchem.5c00513","41204628",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015745","Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure.","Vignarajah A","2026","JACC. Clinical electrophysiology","other","article","10.1016/j.jacep.2025.09.038","41231182",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015746","Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India.","Singh AK","2022","Diabetes & metabolic syndrome","randomized_trial","article","10.1016/j.dsx.2022.102436","35245858",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0015747","Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis.","Shah R","2021","Clinical endocrinology","systematic_review","article","10.1111/cen.14406","33386617",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0015748","Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide.","Mortada I","2026","Therapeutic advances in cardiovascular disease","nonrandomized_study","article","10.1177/17539447261478928","42605954","PMC13482057",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0015749","Targeted Optical Imaging of the Glucagonlike Peptide 1 Receptor Using Exendin-4-IRDye 800CW.","Boss M","2020","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.119.234542","31924726","PMC7383075",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015750","Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass.","Iepsen EW","2020","Journal of bone and mineral metabolism","preclinical","article","10.1007/s00774-019-01034-8","31471646",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015751","Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.","Watada H","2020","Diabetes care","randomized_trial","article","10.2337/dc19-2452","32295808","PMC7245357","ClinicalTrials.gov:NCT02749890","S002018","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0015752","Integrated Management Strategies for Hypertension and Diabetes in Cardiovascular Disease Prevention: A Systematic Review.","Sen N","2026","Cureus","systematic_review","article","10.7759/cureus.111603","42516458","PMC13403756",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0015753","Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM.","Boggild MK","2021","Annals of internal medicine","randomized_trial","article","10.7326/acpj202109210-106","34487441",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0015754","Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review.","Hidalgo Ramos RA","2025","Cureus","systematic_review","article","10.7759/cureus.89020","40895971","PMC12394919",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0015755","The GLP-1 Receptor Agonist Exendin-4 and Diazepam Differentially Regulate GABAA Receptor-Mediated Tonic Currents in Rat Hippocampal CA3 Pyramidal Neurons.","Korol SV","2015","PloS one","preclinical","article","10.1371/journal.pone.0124765","25927918","PMC4415774",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015756","SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.","van Baar MJB","2018","Diabetes care","narrative_review","article","10.2337/dc18-0588","30030256",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015757","What to Know About the New Semaglutide Pill for Obesity.","Schweitzer K","2026","JAMA","other","article","10.1001/jama.2026.0035","41543841",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015758","Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.","Sheffield M","2026","Canadian journal of kidney health and disease","other","article","10.1177/20543581261476643","42602345","PMC13473795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015759","Unimolecular GLP-1/APJ receptor co-agonism improves metabolism and dyslipidaemia as well as normalising hepatic triglyceride and aminotransferase elevation in high-fat-fed mice.","Sridhar A","2026","Diabetologia","preclinical","article","10.1007/s00125-026-06863-7","42758304",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015760","Coverage is the Key to Realizing the Promise of Semaglutide.","Gasoyan H","2026","Journal of general internal medicine","commentary","article","10.1007/s11606-026-10195-y","41559293","PMC13125465",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0015761","Thinner is better: Intentional weight loss and cardiovascular risk.","Abraham J","2024","Med (New York, N.Y.)","other_trial","article","10.1016/j.medj.2024.01.016","38614070",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article"],["R0015762","Tirzepatide Induces Ferroptosis in Glioblastoma Cell Lines via the SOX2/SLC7A11 Axis: A Potential Therapeutic Strategy for Glioma Treatment.","Wang J","2025","Journal of biochemical and molecular toxicology","other","article","10.1002/jbt.70392","40678831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015763","Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors.","Falsetti L","2026","European journal of clinical pharmacology","randomized_trial","article","10.1007/s00228-026-04023-9","41811498","PMC12979277",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015764","SAT675 GLP-1RA Therapy And Intussusception: A Case Report Of Bowel Telescoping In Anobese Patient After Successful Weight Loss On Therapy",null,"2023","Journal of the Endocrine Society","case_report","article",null,null,"PMC10554870",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0015765","Management of Type 2 Diabetes Mellitus in Native Americans and Alaska Natives: A Systematic Review.","Norris Q","2025","Journal of racial and ethnic health disparities","systematic_review","article","10.1007/s40615-025-02668-3","40971128",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Review"],["R0015766","GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment.","Mahase E","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1645","39043396",null,null,"S000067","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","News; article"],["R0015767","Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review.","Bauersachs J","2025","ESC heart failure","narrative_review","article","10.1002/ehf2.15345","40533425","PMC12450771",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015768","Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.","Huang YS","2026","Obesity surgery","randomized_trial","article","10.1007/s11695-026-08748-5","42174244",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Controlled Clinical Trial; article"],["R0015769","Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study.","Baekdal TA","2021","Clinical pharmacology in drug development","randomized_trial","article","10.1002/cpdd.938","33750044","PMC8251533",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0015770","The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.","Ojo O","2016","International journal of environmental research and public health","systematic_review","article","10.3390/ijerph13100941","27669277","PMC5086680",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0015771","Factors associated with treatment satisfaction in patients with type 2 diabetes mellitus using oral glucose-lowering agents: a cross-sectional study in urban districts in Japan.","Hayashi I","2018","Endocrine journal","other","article","10.1507/endocrj.ej18-0182","30033945",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015772","Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.","Rosenstock J","2009","Diabetes care","randomized_trial","article","10.2337/dc09-0366","19592625","PMC2752910","ClinicalTrials.gov:NCT00518115","S000060","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0015773","[Diabetology : what's new in 2024].","Gariani K","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.900-1.26","39812281",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0015774","Glucagon-Like Peptide 1 Protects Pancreatic β-Cells From Death by Increasing Autophagic Flux and Restoring Lysosomal Function.","Zummo FP","2017","Diabetes","other","article","10.2337/db16-1009","28232493",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015775","Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.","Firkins SA","2024","Obesity surgery","nonrandomized_study","article","10.1007/s11695-024-07181-w","38512645",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0015776","Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression.","Hu G","2013","Cardiology journal","preclinical","article","10.5603/cj.2013.0159","24338536",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015777","Exendin-4 Induces Bone Marrow Stromal Cells Migration Through Bone Marrow-Derived Macrophages Polarization via PKA-STAT3 Signaling Pathway.","Wang N","2017","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","randomized_trial","article","10.1159/000485776","29216639",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0015778","Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action.","Schernthaner-Reiter MH","2016","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.2016.1151783","30058933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015779","Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs.","Galatou E","2022","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox11061060","35739957","PMC9220192",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015780","Glucose-Responsive Nanochaperones Mediate Exendin-4 Delivery for Enhancing Therapeutic Effects.","Zhang Y","2022","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.2c13291","36153949",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015781","Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea.","Lu Z","2017","Neuropeptides","preclinical","article","10.1016/j.npep.2017.04.006","28456436",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015782","Hydrophobic Tag-Assisted Liquid-Phase Synthesis of Tirzepatide.","Pang ZJ","2025","Organic letters","other","article","10.1021/acs.orglett.5c03314","40928256",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015783","Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.","Mann JFE","2026","Diabetes care","randomized_trial","article","10.2337/dc25-1080","41380027","PMC12824789","ClinicalTrials.gov:NCT03914326","S002179","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0015784","Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes.","Alnima T","2026","Lancet (London, England)","commentary","article","10.1016/s0140-6736(25)01632-0","41654369",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015785","Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction.","McLean BA","2022","Molecular metabolism","preclinical","article","10.1016/j.molmet.2022.101641","36396031","PMC9706177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015786","Research Design Concerns in a TriNetX Study of Tirzepatide and Heart Failure Prevention in Obese Patients.","Tsai KW","2025","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf721","41225710",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015787","Engineered probiotic restores GLP-1 signaling to ameliorate fiber-deficiency exacerbated colitis.","Brockmann L","2025","Science advances","preclinical","article","10.1126/sciadv.adx6869","41202140","PMC12594200",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0015788","The Duodenum-Centered Neurohormonal Hypothesis of Type 2 Diabetes: A Mechanistic Review and Therapeutic Perspective.","Kapralou AN","2025","Current issues in molecular biology","narrative_review","article","10.3390/cimb47080657","40864811","PMC12384155",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015789","Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery.","Venne JL","2026","Angewandte Chemie (International ed. in English)","other","article","10.1002/anie.9595531","42283322","PMC13480816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015790","Sheep placental extract ameliorates polycystic ovary syndrome in rats by regulating ERβ-mediated Treg cells via the TGF-β1/Smad3 signaling pathway.","Zhang C","2026","Frontiers in immunology","preclinical","article","10.3389/fimmu.2026.1777841","42051511","PMC13110950",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015791","Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies.","Speeckaert R","2026","Journal of clinical medicine","narrative_review","article","10.3390/jcm15030921","41682601","PMC12898249",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015792","Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats.","Darsalia V","2012","Clinical science (London, England : 1979)","preclinical","article","10.1042/cs20110374","22150224","PMC3268352",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015793","Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective.","Ala M","2023","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.13563","36951144",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015794","Impact of Liraglutide on Insulin Clearance in Patients with Type 2 Diabetes Mellitus: Evidence from a Randomized Controlled Trial.","Boelling M","2026","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2025.1081","41813267","PMC12996959",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0015795","Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics.","AlTaib HN","2026","PloS one","nonrandomized_study","article","10.1371/journal.pone.0342153","41628129","PMC12863516",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015796","Pericoronary adipose tissue: potential for pathological diagnosis and therapeutic applications.","Hara T","2025","Cardiovascular intervention and therapeutics","narrative_review","article","10.1007/s12928-025-01126-5","40185991",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015797","Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy.","Malik IO","2022","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.23521","35872608","PMC9420816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015798","GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor.","Fusco J","2017","Scientific reports","preclinical","article","10.1038/s41598-017-09898-4","28831150","PMC5567347",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015799","A peripherally restricted cannabinoid-1 receptor inverse agonist promotes insulin secretion and protects from cytokine toxicity in human pancreatic islets.","Ghosh A","2023","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2023.175589","36773683",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015800","Liraglutide reduces oxidative stress and improves energy metabolism in methylglyoxal-induced SH-SY5Y cells.","Qi L","2022","Neurotoxicology","other","article","10.1016/j.neuro.2022.08.007","35985417",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015801","3, 2, 1! From GLP-2 to GLP-1 analog over a 10-year journey.","Tapia-Sanchiz MS","2026","Endocrinologia, diabetes y nutricion","case_report","article","10.1016/j.endien.2025.501662","41309330",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0015802","Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation.","Bækdal TA","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-021-01078-y","34080123","PMC8266944","ClinicalTrials.gov:NCT02172313; ClinicalTrials.gov:NCT01572753","S000848; S002292","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0015803","Hypoglycemic agents and potential anti-inflammatory activity.","Kothari V","2016","Journal of inflammation research","narrative_review","article","10.2147/jir.s86917","27114714","PMC4833364",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015804","Incretin-based therapy for the treatment of bone fragility in diabetes mellitus.","Mabilleau G","2018","Peptides","narrative_review","article","10.1016/j.peptides.2017.12.008","29412811",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0015805","Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.","Fadini GP","2020","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-019-01445-z","31673896",null,null,"S002638","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0015806","68Ga-Exendin-4 PET/CT Differentiates Insulinoma From Accessory Spleen in a Patient Presenting Indeterminate MRI and 68Ga-DOTATATE PET/CT Findings.","Pang Y","2022","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000003895","34507334",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0015807","Emerging therapeutic options in the management of diabetes: recent trends, challenges and future directions.","Ansari MA","2023","International journal of obesity (2005)","narrative_review","article","10.1038/s41366-023-01369-3","37696926",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015808","Renal AA amyloidosis associated with severe obesity: improvement in kidney function and proteinuria following semaglutide-associated weight loss.","Atay I","2026","Journal of nephrology","other","article","10.1093/joneph/aajag252","42791222",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015809","Aging and metabolism in HFpEF: Pathophysiology and therapeutic implications.","Ye M","2026","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2025.156460","41352525",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0015810","Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring.","Li Y","2026","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2026.109089","42492739",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015811","Liraglutide for Alzheimer's disease . . . and other research.","Nolan T","2026","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.r2633","41506720",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0015812","Exploring the cardiopulmonary effects of tirzepatide in atrial fibrillation and comorbid chronic obstructive pulmonary disease.","Tan MC","2026","The American journal of medicine","nonrandomized_study","article","10.1016/j.amjmed.2025.09.018","40998187",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015813","Evolving kidney disease phenotypes in type 2 diabetes: declining albuminuria and increasing isolated low eGFR.","De Cosmo SA","2026","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfag069","42017029","PMC13092974",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015814","Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling.","Lee J","2020","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2020.07.136","32800550",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015815","Rhabdomyolysis triggered by initiation of tirzepatide.","Fushimi Y","2025","Diabetology international","case_report","article","10.1007/s13340-025-00825-x","40607146","PMC12209126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015816","Tirzepatide",null,"2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"35780672",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0015817","Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.","McGowan BM","2024","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(24)00182-7","39089293",null,"ClinicalTrials.gov:NCT05040971","S000832","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0015818","Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.","Vadher K","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14775","35589616","PMC9546430",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015819","Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.","Bonora BM","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.108686","33548335",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; article"],["R0015820","Persistent organic pollutant concentrations in human pancreas and peripancreatic adipose tissues correlate with markers of beta cell dysfunction","Hoyeck MP","2025","medRxiv","other","preprint","10.1101/2025.04.26.25326263",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015821","Body Composition Changes with Semaglutide: A Systematic Review and Meta-Analysis","Giorelli G","2025","medRxiv","systematic_review","preprint","10.1101/2025.09.29.25336760",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0015822","Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.","Wahba AS","2025","Behavioural pharmacology","preclinical","article","10.1097/fbp.0000000000000835","40536052",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015823","Ameliorative effect of GLP1 agonist on vascular calcification in normoglycemic aged rat aorta via miR34a/SIRT6/NRF2/HO-1 signalling pathway.","Abdelfattah AM","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.177741","40383222",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015824","Long-Acting and Stapled GLP-1R/GIPR/GCGR Triple Agonist for the Treatment of Obesity and Atherosclerosis.","Zhou Y","2025","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.5c01399","40707865",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015825","Targeting PGC-1α by miRNA-374 Simultaneously Improve β-Cell Dysfunction and Suppress Hepatic Glucose Overproduction.","Kim JW","2026","Diabetes & metabolism journal","preclinical","article","10.4093/dmj.2025.0287","41183804","PMC13175703",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015826","Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment.","Rafiullah M","2023","Current issues in molecular biology","other","article","10.3390/cimb45020092","36826037","PMC9956006",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015827","Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis.","Kong W","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70301","41321175",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0015828","GLP-1 AGONISTS: EFFECT IN MANAGEMENT OF DIABETES AND WEIGHT LOSS IN OLDER ADULTS WITH OVERWEIGHT AND OBESITY",null,"2023","Innovation in aging","other","article",null,null,"PMC10736693",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0015829","Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy.","Longo M","2019","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2019.00045","30833929","PMC6387929",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015830","Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.","Fisher M","2015","The lancet. Diabetes & endocrinology","systematic_review","article","10.1016/s2213-8587(15)00233-8","26276240",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article; review"],["R0015831","Pathogenesis of diabetic cardiomyopathy and emerging therapeutic strategies: a network-based perspective.","Ren H","2026","Frontiers in clinical diabetes and healthcare","randomized_trial","article","10.3389/fcdhc.2026.1823872","42232301","PMC13223134",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0015832","Online CME Successful at Improving Awareness, Understanding, and Clinical Use of T2D Treatments","Larkin A","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.965",null,"PMC8089712",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0015833","The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study.","De Fano M","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112119","40174863",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0015834","Liraglutide prevents lupus-associated diffuse alveolar hemorrhage via inhibiting lymphocyte infiltration and promoting macrophage M2 polarization.","Jiang L","2026","Journal of translational autoimmunity","randomized_trial","article","10.1016/j.jtauto.2026.100349","41626528","PMC12857370",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0015835","Resolution of severe lumbar spinal epidural lipomatosis following tirzepatide-induced weight loss: illustrative case.","Tazhibi M","2026","Journal of neurosurgery. Case lessons","other","article","10.3171/case25886","41587457","PMC12839452",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0015836","Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.","Pratley R","2019","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(19)31271-1","31186120",null,"ClinicalTrials.gov:NCT02863419; EudraCT:2015-005210-30","S000133","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0015837","Reassessing retinopathy risk with tirzepatide therapy.","Zhang N","2025","Diabetologia","commentary","article","10.1007/s00125-025-06566-5","41051411",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015838","Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes.","Kim K","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13694","30848039","PMC6618330",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0015839","Weight management medications for chronic use in 37 veterans affairs medical centers-A medication use evaluation.","Walczuk S","2024","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.70002","39219745","PMC11362804",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015840","Liraglutide-Induced Pancreatitis: A Case Report and Literature Review.","Javed H","2023","Cureus","case_report","article","10.7759/cureus.38263","37252522","PMC10225244",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015841","A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.","Freeman JS","2010","Mayo Clinic proceedings","narrative_review","article","10.4065/mcp.2010.0467","21106868","PMC2996163",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0015842","Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).","Rodbard HW","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71132","42504064","PMC13538791",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0015843","Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia.","Machado-Duque ME","2025","Drugs - real world outcomes","nonrandomized_study","article","10.1007/s40801-025-00518-6","41042496","PMC12635016",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015844","Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.","Borlaug BA","2025","JACC. Heart failure","randomized_trial","article","10.1016/j.jchf.2025.102660","41045908","PMC12688318","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0015845","Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis.","Yang CC","2025","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2025.5592","40709382","PMC12306598",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015846","The Neuroprotective Potentials of Dual GIP/GLP1-RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review.","Hawas Y","2026","Brain and behavior","nonrandomized_study","article","10.1002/brb3.71702","42608956","PMC13482023",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; review-article; article"],["R0015847","Exendin-4 attenuates inflammation-mediated endothelial cell apoptosis in varicose veins through inhibiting the MAPK-JNK signaling pathway.","Hu C","2020","Journal of receptor and signal transduction research","other","article","10.1080/10799893.2020.1756326","32338116",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015848","Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).","Giorgino F","2015","Diabetes care","randomized_trial","article","10.2337/dc14-1625","26089386",null,"ClinicalTrials.gov:NCT01075282","S000993; S001130","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0015849","Gut hormone co-agonists for the treatment of obesity: from bench to bedside.","Nogueiras R","2023","Nature metabolism","narrative_review","article","10.1038/s42255-023-00812-z","37308724",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015850","Gut Microbiota and Metabolic Health: From Dysbiosis to Therapeutics.","Sasidharan Pillai S","2026","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-026-01851-x","41762381","PMC13103032",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015851","ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine.","Russo S","2025","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70167","41025205","PMC12587247",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015852","Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study.","Almutair A","2024","Frontiers in endocrinology","case_report","article","10.3389/fendo.2024.1294264","38524636","PMC10957750",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0015853","Liraglutide Mitigates Renal Injury in Diabetic Kidney Disease by Suppressing Podocyte Cholesterol Accumulation Through mTOR/VMP1-Regulated Autophagy.","Zou Q","2025","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.202502041rrr","41246995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015854","Comment on: GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.","Mao T","2024","Clinical research in cardiology : official journal of the German Cardiac Society","systematic_review","article","10.1007/s00392-024-02474-7","38916609",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0015855","EBM BLS: Tirzepatide Remains Effective for Obesity Treatment and Diabetes Prevention at 3 Years of Follow-up.","Cunningham JM","2026","Journal of general internal medicine","other","article","10.1007/s11606-025-09988-4","41269512","PMC12960876",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015856","FRI639 Effect Of Early Initiation Of GLP-1 RAs On Weight Reduction Among People With Type 2 Diabetes",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10555450",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0015857","[Recommendations for the treatment of type 2 diabetes].","Laraki I","2025","Revue medicale de Liege","other","article",null,"40518899",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Guideline; Journal Article; other"],["R0015858","\"Heart\" Outcome in Organ Transplant Recipients With Diabetes: Is GLP-1-RA the Leader of the Pack?","Lim WH","2024","Transplantation","randomized_trial","article","10.1097/tp.0000000000005045","38644532",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Comment; article"],["R0015859","The effect of glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide receptor agonists on neurogenesis, differentiation, and plasticity (Neuro-GDP): potential mechanistically informed therapeutics in the treatment and prevention of mental disorders.","McIntyre RS","2025","CNS spectrums","narrative_review","article","10.1017/s1092852925000124","39964126","PMC13064783",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0015860","Obstructive Sleep Apnea and Type 2 Diabetes: An Update.","Gentile S","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14155574","40807193","PMC12347911",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015861","Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials.","Ayesh H","2024","Biomedicines","systematic_review","article","10.3390/biomedicines12102328","39457640","PMC11505228",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0015862","Drug-drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure?","Poloni A","2025","The Journal of antimicrobial chemotherapy","other","article","10.1093/jac/dkaf245","40674289",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015863","Semaglutide for Alcohol Use Disorder.","Modesto-Lowe V","2026","The primary care companion for CNS disorders","other","article","10.4088/pcc.25lr04040","41499192",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015864","Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.","Takayanagi R","2018","Biological & pharmaceutical bulletin","other","article","10.1248/bpb.b17-00237","29386477",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0015865","Strengthening muscle for healthy ageing: innovative treatments for sarcopenia.","Ancel S","2026","Nature reviews. Drug discovery","narrative_review","article","10.1038/s41573-026-01514-3","42706321",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015866","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.","Abdul Jabbar AB","2026","Current atherosclerosis reports","other_trial","article","10.1007/s11883-026-01424-0","42142201",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0015867","Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction-associated steatohepatitis?","Polyzos SA","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70507","41556066",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015868","Adipocyte-Derived CTRP3 Exhibits Anti-Inflammatory Effects via LAMP1-STAT3 Axis in Psoriasis.","Xue K","2022","The Journal of investigative dermatology","preclinical","article","10.1016/j.jid.2021.09.027","34687744",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0015869","Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.","Pantalone KM","2018","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-018-0699-7","29636104","PMC5892008",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015870","Exenatide once weekly: opportunities in the primary care setting.","Davidson JA","2013","Postgraduate medicine","narrative_review","article","10.3810/pgm.2013.05.2662","23748508",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015871","Egg Microneedle for Transdermal Delivery of Active Liraglutide.","You J","2023","Advanced healthcare materials","preclinical","article","10.1002/adhm.202202473","36617627",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015872","Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit.","Tempia Valenta S","2023","Eating and weight disorders : EWD","nonrandomized_study","article","10.1007/s40519-023-01625-5","38015342","PMC10684642",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015873","Hyperglycemia and systemic inflammation differentially shape immune dysregulation, tissue destruction, and microbiota in experimental periodontitis and peri-implantitis in diabetic mice.","Memida T","2026","Frontiers in immunology","preclinical","article","10.3389/fimmu.2026.1847456","42421935","PMC13341294",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015874","Finerenone in diabetic kidney disease: a new frontier for slowing disease progression.","Alhomoud IS","2025","Frontiers in medicine","narrative_review","article","10.3389/fmed.2025.1580645","40529138","PMC12171220",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015875","Incretins and Lipid Metabolism.","Tsimihodimos V","2018","Current medicinal chemistry","narrative_review","article","10.2174/0929867324666170414164244","28413961",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015876","Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.","Liu W","2015","Neuroscience","other_trial","article","10.1016/j.neuroscience.2015.06.054","26141845",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015877","Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide.","Schmickl CN","2025","medRxiv : the preprint server for health sciences","other","article","10.1101/2025.10.02.25337176","41256163","PMC12622115",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0015878","Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).","Smolderen KG","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70080","40926360","PMC12515752","ClinicalTrials.gov:NCT06874751","S000739","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0015879","Emulating the LEADER trial in China: a regulatory science case study on non-interventional research.","Zhao J","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1777954","41907546","PMC13017370",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0015880","Implications of GLP-1 agonist use on airway management.","Mizubuti GB","2024","The American journal of emergency medicine","commentary","article","10.1016/j.ajem.2024.05.018","38821845",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0015881","Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.","Raccah D","2014","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.2548","24687427",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0015882","The effects of a GLP-1 analog liraglutide on reward value and the learned inhibition of appetitive behavior in male and female rats.","Jones S","2019","International journal of obesity (2005)","preclinical","article","10.1038/s41366-018-0240-9","30367111","PMC6486456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0015883","RETRACTED: Long-Lasting Exendin-4-Loaded PLGA Nanoparticles Ameliorate Cerebral Ischemia/Reperfusion Damage in Diabetic Rats.","Chung CH","2022","Journal of personalized medicine","preclinical","article","10.3390/jpm12030390","35330390","PMC8951777",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retracted Publication; research-article; article"],["R0015884","No evidence that tirzepatide can worsen diabetic retinopathy.","Fadini GP","2025","Diabetologia","commentary","article","10.1007/s00125-025-06564-7","41051409",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015885","Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes - Authors' reply.","Bonaca MP","2026","Lancet (London, England)","commentary","article","10.1016/s0140-6736(25)02640-6","41654370",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0015886","Reply to \"Comment on: GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis\".","Villaschi A","2024","Clinical research in cardiology : official journal of the German Cardiac Society","systematic_review","article","10.1007/s00392-024-02475-6","38916608",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; letter"],["R0015887","Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.","Standl E","2016","Circulation research","nonrandomized_study","article","10.1161/circresaha.116.306924","27230644",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0015888","Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.","Castellana M","2019","Scientific reports","systematic_review","article","10.1038/s41598-019-55524-w","31852920","PMC6920368",null,"S002481","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0015889","Inflammation: The Mother of All Diseases Meets the Mother of All Therapies.","Chatanaka MK","2025","EJIFCC","narrative_review","article",null,"41098220","PMC12519629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015890","White analytical insight for sensitive fluorescent determination of semaglutide and tirzepatide in pharmaceuticals and biological matrices.","Mansour NM","2024","Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy","other","article","10.1016/j.saa.2024.124159","38508074",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015891","Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials.","Patoulias DI","2021","World journal of cardiology","systematic_review","article","10.4330/wjc.v13.i10.585","34754403","PMC8554356",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0015892","The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.","Wu S","2014","Journal of clinical pharmacy and therapeutics","randomized_trial","article","10.1111/jcpt.12102","24127768",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0015893","Efficacy of anti-obesity medication (AOM) and endoscopic gastric remodeling (EGR): Analysis of combination therapy with optimal timing and agents.","Jirapinyo P","2024","Endoscopy international open","nonrandomized_study","article","10.1055/a-2463-9784","39691741","PMC11651918",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015894","Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review.","Konings LAM","2025","European journal of clinical investigation","systematic_review","article","10.1111/eci.70003","39937036","PMC11891831",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0015895","Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials.","Ko D","2026","Cell reports. Medicine","systematic_review","article","10.1016/j.xcrm.2026.102614","41850241","PMC13006432","PROSPERO:CRD420251086132",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0015896","Effect of Exenatide on Nonalcoholic Steatohepatitis and Inflammation-Related Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease.","Menekşe B","2023","Metabolic syndrome and related disorders","nonrandomized_study","article","10.1089/met.2022.0088","36944132",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0015897","A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.","Sanyal AJ","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2401755","38847460",null,"ClinicalTrials.gov:NCT04771273; EudraCT:2020-002723-11","S001877","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; article"],["R0015898","Next-Generation Nerve-Sparing Techniques in Robotic Radical Prostatectomy: A Contemporary Review.","Piyevsky B","2025","Current urology reports","narrative_review","article","10.1007/s11934-025-01292-2","41026298",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015899","Targeting metabolic syndrome with ALIAmides: A novel multi-mechanistic approach.","Palenca I","2025","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2025.118611","41043198",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015900","Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions.","Astrup A","2024","European journal of clinical nutrition","narrative_review","article","10.1038/s41430-024-01460-6","38890501","PMC11230893",null,"S002624","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0015901","An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke.","Zhang H","2016","PloS one","preclinical","article","10.1371/journal.pone.0148827","26863436","PMC4749391",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015902","Exendin-4 Promotes Schwann Cell Proliferation and Migration via Activating the Jak-STAT Pathway after Peripheral Nerve Injury.","Pan B","2020","Neuroscience","preclinical","article","10.1016/j.neuroscience.2020.04.017","32334071",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015903","Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis.","Tong K","2023","Medicine","systematic_review","article","10.1097/md.0000000000035488","37904345","PMC10615484",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; research-article; review"],["R0015904","Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide.","Albarmawi H","2025","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2025.2596430","41363882",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0015905","Neutrophil Extracellular Traps in Diabetic Kidney Disease: Mechanisms of Pathogenesis and Emerging Therapeutic Strategies.","Wang B","2026","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s583077","41756312","PMC12935511",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015906","GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms.","Gómez-Peralta F","2023","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2023.108553","37385011",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0015907","Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management.","Zhang J","2025","Endocrinology","narrative_review","article","10.1210/endocr/bqaf130","40817831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015908","Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.","Dutta D","2025","Medicine","systematic_review","article","10.1097/md.0000000000046446","41398803","PMC12708229",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0015909","In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin.","Egan AM","2024","Annals of internal medicine","commentary","article","10.7326/j24-0015","38560907",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0015910","Tirzepatide for weight reduction in people without diabetes.",null,"2025","Drug and therapeutics bulletin","other","article","10.1136/dtb.2025.000018","40461177",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015911","Re \"Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA\" - Perspective on potential weight-independent effects.","Van Bruggen FH","2026","Sleep medicine","commentary","article","10.1016/j.sleep.2025.108650","41260002",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0015912","Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications.","Packer M","2018","European journal of heart failure","narrative_review","article","10.1002/ejhf.1183","29566300",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015913","Response of Gambling Disorder to Semaglutide.","Grant JE","2026","Journal of clinical psychopharmacology","other","article","10.1097/jcp.0000000000002117","41410610",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015914","Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.","Mu Y","2024","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(23)00388-1","38330988",null,"ClinicalTrials.gov:NCT04251156","S001288","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0015915","AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication.","Hashash JG","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2023.11.002","37944573",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Practice Guideline; Journal Article; article"],["R0015916","Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses.","Stefanovski D","2022","BMC veterinary research","randomized_trial","article","10.1186/s12917-022-03394-2","35906619","PMC9336084",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial, Veterinary; research-article; article"],["R0015917","Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.","Abdel Razek NS","2025","Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)","preclinical","article","10.1016/j.jtemb.2025.127755","40972223",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015918","The weight-loss drugs being tested in 2025: will they beat Ozempic?","Guglielmi G","2025","Nature","commentary","article","10.1038/d41586-025-00376-w","39915597",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; other"],["R0015919","Can weight loss drugs like Ozempic treat obesity in children?","Lang K","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.q2656","39848663",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015920","Incretin-based therapies in type 2 diabetes: a review of clinical results.","Bosi E","2008","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2008.10.003","19022515",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0015921","Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke.","Nizari S","2021","Basic research in cardiology","preclinical","article","10.1007/s00395-021-00873-9","33942194","PMC8093159",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015922","Patient education and monitoring recommendations for the use of glucagon-like peptide-1 receptor agonists.","Haines ST","2009","The Journal of family practice","case_report","article",null,"19744425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0015923","The obesity and lipid paradoxes in chronic kidney disease: mechanisms, interventions, and future directions.","Takahashi R","2026","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000001131","41263048",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015924","Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects.","van Hout M","2023","Clinical pharmacokinetics","randomized_trial","article","10.1007/s40262-023-01223-9","36932262","PMC10023024","ClinicalTrials.gov:NCT04513704","S001070","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015925","Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs.","Carmina E","2023","Journal of clinical medicine","other","article","10.3390/jcm12185921","37762862","PMC10531549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015926","Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease.","Domingues I","2023","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2023.03.012","36907563","PMC7614370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015927","Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.","DeSouza C","2020","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgz072","31769496",null,"ClinicalTrials.gov:NCT02054897; ClinicalTrials.gov:NCT01930188; ClinicalTrials.gov:NCT01885208; ClinicalTrials.gov:NCT02128932; ClinicalTrials.gov:NCT02305381; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02648204","S000329; S000372; S000878; S001219; S001872; S001876; S001933","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0015928","Obesity and Hypertension: Etiology and the Effects of Diet, Bariatric Surgery, and Antiobesity Drugs.","Elattar S","2025","Cardiology in review","other","article","10.1097/crd.0000000000000937","40265912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015929","7792 Efficacy of Retatrutide for Weight Reduction and Its Cardiometabolic Effects Among Adults: A Systematic Review and Meta-Analysis",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC11453264",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0015930","On target? Cardiovascular risk factor patterns in type 1 and type 2 diabetes: real-world attainment of cardiovascular risk factor targets and medication prescriptions.","Lit VF","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113440","42448043",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0015931","Exendin-4 Ameliorates Cardiac Remodeling in Experimentally Induced Myocardial Infarction in Rats by Inhibiting PARP1/NF-κB Axis in A SIRT1-Dependent Mechanism.","Eid RA","2020","Cardiovascular toxicology","preclinical","article","10.1007/s12012-020-09567-5","32193876",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015932","Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.","Kim JC","2022","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph15121585","36559036","PMC9781085",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015933","Beyond Traditional Risk Factors: Integrating Epicardial Adipose Tissue into the Comorbidity Landscape of HFpEF.","Mihăilă MD","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14176139","40943899","PMC12429259",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015934","GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy.","Shiraki A","2019","Cardiovascular diabetology","preclinical","article","10.1186/s12933-019-0966-2","31779634","PMC6881987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015935","Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats.","Shekunova EV","2020","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2019.172835","31794708",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015936","The glucagon-like peptide-1 analog exendin-4 antagonizes the effect of acyl ghrelin on the respiratory exchange ratio.","Abtahi S","2016","Neuroreport","preclinical","article","10.1097/wnr.0000000000000650","27454242",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015937","β-catenin mediates the effect of GLP-1 receptor agonist on ameliorating hepatic steatosis induced by high fructose diet.","Gao Z","2020","European journal of histochemistry : EJH","preclinical","article","10.4081/ejh.2020.3160","32930541","PMC7507137",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015938","The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome.","Wójcicka G","2023","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2023.115637","37290595",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015939","Genetic variation in targets of antihyperglycemic drugs and inflammatory bowel disease' risk: A mendelian randomization study.","Zhao J","2025","Diabetes & metabolic syndrome","other","article","10.1016/j.dsx.2025.103204","40023995",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0015940","Mitochondrial Dysfunction at the Intersection of CKM Syndrome: Molecular Mechanisms and Path-to-Target Therapies.","Kuo YJ","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27094120","42123698","PMC13163551",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015941","Exendin-4 Protects Against Myocardial Ischemia-Reperfusion Injury by Upregulation of SIRT1 and SIRT3 and Activation of AMPK.","Eid RA","2021","Journal of cardiovascular translational research","preclinical","article","10.1007/s12265-020-09984-5","32239434",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015942","The expanding incretin universe: from basic biology to clinical translation.","Drucker DJ","2023","Diabetologia","narrative_review","article","10.1007/s00125-023-05906-7","36976349",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0015943","Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice.","Longato E","2020","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-020-01049-w","32522260","PMC7288543",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0015944","Heart failure with preserved ejection fraction therapeutics: in search of the pillars.","Rafei AE","2025","Heart failure reviews","narrative_review","article","10.1007/s10741-025-10524-z","40399553",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0015945","Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.","Cai HY","2018","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2017.11.114","29175324",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015946","Impact of tirzepatide treatment on participant-reported food craving and food preference: Secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction.","Kennedy SF","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70063","40874370","PMC12515769",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0015947","[Arthritis secondary to tirzepatide. Case report].","Martín Correa E","2025","Atencion primaria","case_report","article","10.1016/j.aprim.2025.103313","40513494","PMC12205528",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0015948","Can Diabetes Drugs like Ozempic Tackle the Mental Health Crisis?","Hlavinka E","2024","ACS central science","commentary","article","10.1021/acscentsci.4c01250","39220694","PMC11363322",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","News; other"],["R0015949","Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease.","Pechenov S","2021","Scientific reports","other","article","10.1038/s41598-021-01750-0","34795324","PMC8602401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015950","GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades.","Watanabe H","2025","Virchows Archiv : an international journal of pathology","other","article","10.1007/s00428-025-04098-2","40281248","PMC12213902",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015951","Neuropsychiatric side effects of semaglutide in patients with dementia.","Jamshed N","2025","BMJ case reports","case_report","article","10.1136/bcr-2024-262743","40759509",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0015952","Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.","Yamada Y","2020","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(20)30075-9","32333875",null,"ClinicalTrials.gov:NCT03018028","S001943","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0015953","Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats.","Kwon DY","2009","Journal of pharmacological sciences","preclinical","article","10.1254/jphs.09178fp","20019445",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0015954","Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats.","Long XF","2025","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2025.1599879","41384017","PMC12689399",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0015955","Comments on \"GLP-1 agonists: A review for emergency clinicians\".","Mattingly TJ","2024","The American journal of emergency medicine","narrative_review","article","10.1016/j.ajem.2024.03.034","38582620",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0015956","Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.","Yang SI","2026","Nature communications","randomized_trial","article","10.1038/s41467-026-71080-0","41876542","PMC13187202","ClinicalTrials.gov:NCT06309667",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0015957","Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).","Matza LS","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13902","31646727","PMC7064885",null,"S001552","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0015958","Is There a Natural, Non-addictive, and Non-anti-reward, Safe, Gene-based Solution to Treat Reward Deficiency Syndrome? KB220 Variants vs GLP-1 Analogs.","Modestino EJ","2024","Journal of addiction psychiatry","other","article",null,"39618491","PMC11606528",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015959","Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist.","Pan CQ","2006","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m600127200","16505481",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015960","Real -world experience with anti-obesity medications treatment in children and adolescents with overweight and obesity in Israel.","Shalitin S","2025","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-025-01801-w","40374727","PMC12283415",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0015961","Effect of liraglutide on subclinical atherosclerosis and cardiometabolic risk factors in adults with type 1 diabetes: A prospective pilot study.","Sánchez-García D","2026","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.70222","41693130",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0015962","Comparison of Fracture Risk Following Semaglutide Treatment vs Sleeve Gastrectomy.","Noreña JA","2025","AACE endocrinology and diabetes","nonrandomized_study","article","10.1016/j.aed.2025.10.001","41467149","PMC12744784",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0015963","Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines.","Kaul S","2025","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2025.06.036","40835369",null,null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0015964","Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.","McCrimmon RJ","2021","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.14354","33606908",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; article"],["R0015965","Diabetes Optimization in Total Joint Arthroplasty: Perioperative Markers, Pharmacologic Strategies, and Wound Care Best Practices.","Khan U","2026","Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews","nonrandomized_study","article","10.5435/jaaosglobal-d-25-00214","41697874","PMC12908745",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0015966","Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.","Angelopoulos N","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2025.109181","41075711",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0015967","High-Density Lipoprotein Dysfunction and Atherosclerotic Cardiovascular Disease: From Quantity to Quality.","Arun AJ","2025","Cardiology in review","other","article","10.1097/crd.0000000000001126","41233948",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015968","Potential therapeutic strategies for MASH: from preclinical to clinical development.","Xie Z","2024","Life metabolism","narrative_review","article","10.1093/lifemeta/loae029","39872142","PMC11749562",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015969","Pharmacological strategies for preventing post-stroke seizures and epilepsy.","Kawamura Y","2025","Frontiers in neurology","narrative_review","article","10.3389/fneur.2025.1709077","41586111","PMC12823330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015970","Optical Control of Insulin Secretion Using an Incretin Switch.","Broichhagen J","2015","Angewandte Chemie (International ed. in English)","preclinical","article","10.1002/anie.201506384","26585495","PMC4736448",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0015971","Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications.","Młynarska E","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26031094","39940862","PMC11817707",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015972","Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).","Yu Pan C","2014","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.2541","24639432",null,"ClinicalTrials.gov:NCT01169779","S001185","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0015973","GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder.","Panfili E","2023","Frontiers in clinical diabetes and healthcare","preclinical","article","10.3389/fcdhc.2023.1171091","37333802","PMC10275359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0015974","Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.","Mocarski M","2018","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2017.17218","29406841","PMC10397965",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0015975","On-demand peptide therapeutics for multi-year space exploration: analysis of clinical and operational relevance and recombinant production feasibility.","Donovan JJ","2026","NPJ microgravity","nonrandomized_study","article","10.1038/s41526-026-00630-z","42420311",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Preprint; article"],["R0015976","Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret.","Lu Z","2014","Journal of translational medicine","preclinical","article","10.1186/s12967-014-0327-6","25491123","PMC4272567",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015977","Ketone therapy prevents semaglutide-induced loss of cardiac mass.","Schmidt MA","2026","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwaf605","41026893","PMC12771339",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0015978","The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England.","Ramos M","2025","Journal of medical economics","other_trial","article","10.1080/13696998.2025.2575692","41090945",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0015979","Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice.","Niu S","2025","World journal of hepatology","preclinical","article","10.4254/wjh.v17.i10.110402","41179732","PMC12576712",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015980","Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.","Deanfield J","2024","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(24)01498-3","39181597",null,"ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; article"],["R0015981","Methodological considerations in tirzepatide-bariatric surgery comparative study.","Chin SY","2025","Diabetes research and clinical practice","commentary","article","10.1016/j.diabres.2025.112928","41057114",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0015982","Advancing heart failure management: a comprehensive review of current and emerging therapies for heart failure with preserved ejection failure.","Agrawal SP","2025","Minerva medica","narrative_review","article","10.23736/s0026-4806.25.09656-9","40146048",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0015983","Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.","Balfour PC","2014","Current hypertension reports","narrative_review","article","10.1007/s11906-014-0455-7","24908134","PMC4573590",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article"],["R0015984","Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors and Pancreatic Islet Cell Protection by Salmon-Derived Bioactive Peptides.","Currie C","2024","Marine drugs","preclinical","article","10.3390/md22110490","39590770","PMC11595994",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0015985","In response: Considerations regarding compounding pharmacies and GLP-1 agonists.","Long B","2024","The American journal of emergency medicine","commentary","article","10.1016/j.ajem.2024.03.037","38600000",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0015986","Semaglutide Use With Automated Insulin Delivery in Adults With Type 1 Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Randomized Controlled Trial.","Pasqua MR","2026","Canadian journal of diabetes","randomized_trial","article","10.1016/j.jcjd.2025.10.175","41175929",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0015987","Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis.","Mimura H","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-025-01775-y","40711720","PMC12399453","ClinicalTrials.gov:NCT03861052; ClinicalTrials.gov:NCT03861039","S000239; S001385","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0015988","Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis.","Galindo RJ","2026","Journal of the Endocrine Society","other","article","10.1210/jendso/bvag190","42656588","PMC13507312",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0015989","Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.","Olivieri AV","2024","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-024-01467-w","38291203","PMC11058048",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015990","Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway.","Zhao YY","2022","Biochemistry and cell biology = Biochimie et biologie cellulaire","narrative_review","article","10.1139/bcb-2021-0365","34658256",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0015991","Exploring the Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Genitourinary Toxicities in Prostate Cancer Patients Undergoing Radiation Therapy: A Case Study and Discussion.","Andrianu K","2024","Practical radiation oncology","case_report","article","10.1016/j.prro.2024.04.006","38752974",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Case Reports"],["R0015992","Hepatic GCGR is required for the superior weight loss effects of a structurally related analogue of the dual GCGR/GLP1R agonist survodutide","Long F","2024","bioRxiv","other","preprint","10.1101/2024.09.09.611134",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0015993","Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.","Davies MJ","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13791","31124299","PMC6772132","ClinicalTrials.gov:NCT02058147","S001199","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0015994","Reduction of Neuroinflammation as a Common Mechanism of Action of Anorexigenic and Orexigenic Peptide Analogues in the Triple Transgenic Mouse Model of Alzheimer´s Disease.","Mengr A","2025","Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","preclinical","article","10.1007/s11481-025-10174-w","39932627","PMC11813825",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015995","Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.","Yamauchi T","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16500","40490415","PMC12232350",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0015996","Exendin-4 enhances the migration of adipose-derived stem cells to neonatal rat ventricular cardiomyocyte-derived conditioned medium via the phosphoinositide 3-kinase/Akt-stromal cell-derived factor-1α/CXC chemokine receptor 4 pathway.","Zhou H","2015","Molecular medicine reports","preclinical","article","10.3892/mmr.2015.3243","25625935","PMC4394957",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0015997","In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes.",null,"2022","The Medical letter on drugs and therapeutics","other","article",null,"35536124",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015998","The effects of Exendin-4 on bone marrow-derived mesenchymal cells.","Luciani P","2018","Endocrine","preclinical","article","10.1007/s12020-017-1430-2","29094257",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0015999","National Cancer Institute-Supported Obesity and Cancer Research, 2015-2022.","Dwyer LA","2026","JAMA network open","other","article","10.1001/jamanetworkopen.2026.28773","42584888",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0016000","Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial.","Buse JB","2023","BMJ open diabetes research & care","protocol","article","10.1136/bmjdrc-2022-003206","37137527","PMC10163526","ClinicalTrials.gov:NCT03596450","S000545","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016001","Liraglutide Overdose-Induced Acute Pancreatitis.","AlSaadoun AR","2022","Cureus","case_report","article","10.7759/cureus.21616","35228970","PMC8874232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016002","Targeted Ileal Bile Acid Transporter Inhibition as Rescue Therapy for Tirzepatide-Induced Severe Constipation: A Case Report.","Choudhuri B","2026","Case reports in gastroenterology","case_report","article","10.1159/000552414","42421979","PMC13345612",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016003","Pattern of semaglutide prescription in a real-world Canadian patient cohort.","Farahvash A","2025","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2025.06.006","40562647",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0016004","Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial.","Helsted MM","2023","BMJ open","protocol","article","10.1136/bmjopen-2022-065736","36849212","PMC9972408","ClinicalTrials.gov:NCT05078255; EudraCT:2020-004774-22","S002118","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016005","Weight loss, wakefulness, and what's missing: addressing comorbid insomnia and sleep apnea in the era of tirzepatide.","Meira E Cruz M","2025","Sleep","other","article","10.1093/sleep/zsaf188","40637266",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016006","Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.","Lau DC","2015","Canadian journal of diabetes","narrative_review","article","10.1016/j.jcjd.2015.10.001","26654857",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016007","Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.","Golubic R","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15579","38562018",null,"ClinicalTrials.gov:NCT03596177","S002062","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; article"],["R0016008","Development and characterization of exendin-4 loaded self-nanoemulsifying system and in vitro evaluation on Caco-2 cell line.","Aktas Y","2020","Journal of microencapsulation","preclinical","article","10.1080/02652048.2019.1692945","31714163",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016009","The Effect of Frailty on Body Composition and Its Impact on the Use of SGLT-2 Inhibitors and GLP-1RA in Older People with Diabetes","Sinclair A","2025","Preprints.org","other","preprint","10.20944/preprints202505.0453.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016010","The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.","Baggio LL","2017","Molecular metabolism","preclinical","article","10.1016/j.molmet.2017.08.010","29107282","PMC5681270",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016011","Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice.","Dahir NS","2024","The Journal of clinical investigation","preclinical","article","10.1172/jci178250","39007271","PMC11245150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0016012","Shared Metabolic-Proteinopathy Axis in Alzheimer's Disease and Parkinson's Disease: Evidence for a Convergent but Not Identical Disease Spectrum.","Yao SY","2026","Aging medicine (Milton (N.S.W))","narrative_review","article","10.1002/agm2.70099","42688951","PMC13535938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016013","Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment.","Dai S","2020","Carbohydrate polymers","preclinical","article","10.1016/j.carbpol.2020.116864","32933691",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016014","Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys.","Cui Q","2021","The Journal of endocrinology","preclinical","article","10.1530/joe-20-0255","33258802",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016015","Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.","Wharton S","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2500969","40934115",null,"ClinicalTrials.gov:NCT05564117","S000786","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0016016","GLP-1R in diabetes mellitus: from basic discovery to therapeutics development.","Li S","2025","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2025.1610512","40520185","PMC12162565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016017","Generic Liraglutide - Overlooked but Not Forgotten.","Gondi S","2026","The New England journal of medicine","other","article","10.1056/nejmp2515668","41370797",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016018","Cardiovascular actions of incretin-based therapies.","Ussher JR","2014","Circulation research","narrative_review","article","10.1161/circresaha.114.301958","24855202",null,null,"S002372","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0016019","Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.","Sarti S","2025","Cancers","randomized_trial","article","10.3390/cancers17223597","41300964","PMC12651551",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0016020","Effects of Tirzepatide on Low-Density Lipoprotein Cholesterol Levels in Adults: A Systematic Review.","Hong I","2025","Cureus","systematic_review","article","10.7759/cureus.88390","40842811","PMC12365184",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0016021","The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01.","Lv M","2021","Brain and behavior","other_trial","article","10.1002/brb3.2231","34125470","PMC8413783",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016022","The impact of exenatide (a GLP-1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions.","Bułdak Ł","2019","Experimental and therapeutic medicine","other","article","10.3892/etm.2019.7245","30906473","PMC6425227",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016023","Dulaglutide Ameliorates Intrauterine Adhesion by Suppressing Inflammation and Epithelial-Mesenchymal Transition via Inhibiting the TGF-β/Smad2 Signaling Pathway.","Wang Y","2023","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph16070964","37513876","PMC10384231",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016024","Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.","Yang C","2015","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s87253","26316789","PMC4548726",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016025","Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms.","Akyay OZ","2022","Nigerian journal of clinical practice","randomized_trial","article","10.4103/njcp.njcp_1640_21","35859471",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0016026","Fatal, Fulminant, Necrotizing Pancreatitis Associated With Recent Tirzepatide Initiation.","Grennan K","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf087","40270999","PMC12015157",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016027","iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.","Skolnik N","2017","Current medical research and opinion","other_trial","article","10.1080/03007995.2017.1359518","28741967",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0016028","Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial.","Gerstein HC","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15957","39284790",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; article"],["R0016029","Current evidence on immune-driven depression.","Wessa C","2026","Current opinion in psychiatry","other_trial","article","10.1097/yco.0000000000001047","41217347","PMC12672047",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0016030","Neuroprotective effects of GLP-1 class drugs in Parkinson's disease.","Lv D","2024","Frontiers in neurology","narrative_review","article","10.3389/fneur.2024.1462240","39719978","PMC11667896",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016031","The therapeutic potential of GLP-1 receptor biased agonism.","Jones B","2022","British journal of pharmacology","preclinical","article","10.1111/bph.15497","33880754","PMC8820210",null,"S001387","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0016032","Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.","Galindo RJ","2026","JAMA network open","systematic_review","article","10.1001/jamanetworkopen.2026.3274","41885866","PMC13022736","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT04660643","S000242; S001077; S002157","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0016033","The Insulin–Cortisol–Vitamin C Axis: A Missing Regulatory Framework in Metabolic and Hormonal Homeostasis A Narrative Review","Cheng RZ","2026","Preprints.org","narrative_review","preprint","10.20944/preprints202512.0217.v3",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0016034","Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.","Pampanelli S","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70538","41725422","PMC13071210",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016035","Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients.","Vahora I","2024","Cureus","nonrandomized_study","article","10.7759/cureus.65050","39165448","PMC11335185",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0016036","Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.","Savvidou S","2026","Metabolic syndrome and related disorders","nonrandomized_study","article","10.1177/15578518251409025","41944572",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0016037","Reno-protective effects of GLP-1 receptor agonist and anti-platelets in experimentally induced diabetic kidney disease in male albino rats.","El Amin Ali AM","2022","Iranian journal of basic medical sciences","preclinical","article","10.22038/ijbms.2022.65061.14494","36544522","PMC9742563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016038","A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).","Dungan KM","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12634","26799540","PMC5067625",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016039","Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.","Chai S","2019","BMJ open diabetes research & care","systematic_review","article","10.1136/bmjdrc-2019-000728","31641525","PMC6777405",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; research-article; review"],["R0016040","Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.","Pasqualotto E","2024","Metabolism open","systematic_review","article","10.1016/j.metop.2024.100321","39318607","PMC11420505",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0016041","Single-Center Experience of Using Liraglutide in Adolescents With Obesity +/- Type 2 Diabetes.","Dauleh H","2024","Cureus","nonrandomized_study","article","10.7759/cureus.58720","38779269","PMC11110091",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016042","From bench to bedside: adipose tissue fibrosis in obesity, anti-diabetic therapies, and bariatric surgery.","Seo M","2026","The Korean journal of internal medicine","narrative_review","article","10.3904/kjim.2025.363","41430209","PMC12999253",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016043","Coronary inflammation: Identification, clinical impact and possible therapeutical solutions.","Prati F","2026","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2026.134229","41662913",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0016044","Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.","Rosenstock J","2021","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(21)01324-6","34186022",null,"ClinicalTrials.gov:NCT03954834","S000407","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0016045","Cardiometabolic effects of GLP-1 analogs in obese and overweight patients with preexisting cardiovascular disease: A systematic review and meta analysis of randomized controlled trials.","Natali LD","2025","Heart & lung : the journal of critical care","systematic_review","article","10.1016/j.hrtlng.2025.07.009","40682989",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0016046","Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness.","Anderson SL","2016","Therapeutic advances in chronic disease","nonrandomized_study","article","10.1177/2040622315609312","26770666","PMC4707429",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0016047","Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.","Al-Horani RA","2023","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/1871530322666221004151212","36200219","PMC10473544",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; research-article; article"],["R0016048","The Preparation and Physicochemical Characterization of a Triple Synergistic Nanoplatform Designed for Targeted Subcutaneous Delivery of Sitagliptin with Potential for β-Cell Preservation.","Alsmadi MM","2026","AAPS PharmSciTech","preclinical","article","10.1208/s12249-026-03489-1","42393437",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016049","Structural analysis of the dual agonism at GLP-1R and GCGR.","Li Y","2023","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.2303696120","37549266","PMC10438375",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016050","GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis.","Rezaei S","2021","Canadian journal of gastroenterology & hepatology","systematic_review","article","10.1155/2021/8936865","34805029","PMC8604595",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0016051","Engagement Phenotypes in a Real-World Tirzepatide-Based Dig-Ital Weight-Loss Program: Unsupervised Clustering of Self-Tracking, Human Coaching, and AI Conversational Support","Talay L","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202606.2106.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0016052","Weight Loss Pharmacotherapy: Current and Future Therapies.","Jordan G","2024","Gastrointestinal endoscopy clinics of North America","narrative_review","article","10.1016/j.giec.2024.06.006","39277293","PMC11407733",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0016053","Tirzepatide attenuates dopamine reward signaling and suppresses alcohol drinking and relapse-like behaviors in rodents","Edvardsson CE","2025","bioRxiv","preclinical","preprint","10.1101/2025.08.26.672374",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016054","Exendin-4 Prevents Memory Loss and Neuronal Death in Rats with Sporadic Alzheimer-Like Disease.","Zago AM","2024","Molecular neurobiology","preclinical","article","10.1007/s12035-023-03698-w","37919602",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016055","Molecular Mechanisms of Liraglutide Aggregation Induced by Dual Air-Water and Silicone-Oil-Water Interfacial Stress.","Hamada N","2026","Molecular pharmaceutics","other","article","10.1021/acs.molpharmaceut.5c01837","41572471",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016056","Successful Glycemic Control Decreases the Elevated Serum FGF21 Level without Affecting Normal Serum GDF15 Levels in a Patient with Mitochondrial Diabetes.","Murakami T","2016","The Tohoku journal of experimental medicine","case_report","article","10.1620/tjem.239.89","27212224",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0016057","Effects of first-line antidiabetic drugs on the improvement of arterial stiffness: A Bayesian network meta-analysis.","Wang J","2023","Journal of diabetes","systematic_review","article","10.1111/1753-0407.13405","37165762","PMC10415870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; research-article; article"],["R0016058","Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities.","Manavi MA","2022","Neuropeptides","narrative_review","article","10.1016/j.npep.2022.102250","35561568",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016059","Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues.","Battini V","2024","Journal of neurology","nonrandomized_study","article","10.1007/s00415-024-12300-9","38517522","PMC11136777",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0016060","Epicardial adipose tissue as a metabolically active visceral fat depot: an emerging target in cardiovascular disease.","Rojas-Bergés I","2026","Frontiers in cardiovascular medicine","randomized_trial","article","10.3389/fcvm.2026.1824863","42581975","PMC13457019",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0016061","Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism.","Zheng S","2023","Applied biochemistry and biotechnology","other","article","10.1007/s12010-023-04505-x","37140780",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016062","Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats.","Habib HA","2021","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2020.173721","33159934",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016063","Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss.","Weber M","2023","British journal of anaesthesia","commentary","article","10.1016/j.bja.2023.05.005","37302962",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016064","The management of hypothalamic obesity in craniopharyngioma.","Dimitri P","2025","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2025.102018","40514321",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016065","The Clock is Still Ticking: Tirzepatide and the Myth of Halting the Natural History of Type 2 Diabetes.","Fadini GP","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","commentary","article","10.1007/s13300-025-01759-y","40526203","PMC12317936",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0016066","Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM.","Tian J","2025","Hormones (Athens, Greece)","randomized_trial","article","10.1007/s42000-025-00649-z","40214965",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; article"],["R0016067","Association of Novel Antihyperglycemic Drugs Versus Metformin With a Decrease in Asthma Exacerbations.","Kimura Y","2024","The journal of allergy and clinical immunology. In practice","nonrandomized_study","article","10.1016/j.jaip.2024.05.002","38734374",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0016068","Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study.","Chen K","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15360","37945546",null,"ChiCTR:ChiCTR1900023428",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; article"],["R0016069","[New pharmacological treatment methods of type 2 diabetes].","Madsbad S","2012","Ugeskrift for laeger","other","article",null,"22971293",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016070","12322 Unraveling The Complexity Of Stiff-Person Syndrome: A Case Of Ozempic-Induced Gastric Paralysis In A Patient With Comorbid Type 2 Diabetes Mellitus",null,"2024","Journal of the Endocrine Society","case_report","article",null,null,"PMC11454535",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0016071","PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease.","Yu SJ","2020","Frontiers in neuroscience","preclinical","article","10.3389/fnins.2020.00785","32848559","PMC7431885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016072","Oxidative Stress in Peripheral Diabetic Neuropathy: Key Mechanisms and Therapeutic Targets","El-Masri T","2025","Authorea Preprints","other","preprint","10.22541/au.176199324.45430645/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016073","Incretin response in Asian type 2 diabetes: Are Indians different?","Singh AK","2015","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.146861","25593823","PMC4287776",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016074","Crosstalk Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Atrial Fibrillation: Shared Mechanism, Diagnostic Integration, and Management Implications.","Morawska A","2025","Life (Basel, Switzerland)","nonrandomized_study","article","10.3390/life15111713","41302136","PMC12653846",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0016075","Ozempic babies: are weight loss drugs leading to unintended pregnancies?","Nadarajah S","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.q2440","39880463",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016076","Discovery of a long-acting glucagon-like peptide-1 analog with enhanced aggregation propensity.","Takeuchi M","2018","Peptides","nonrandomized_study","article","10.1016/j.peptides.2018.01.014","29391187",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016077","Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis.","Viana DPDC","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms262110741","41226777","PMC12608556",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0016078","Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.","Viljoen A","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13564","30362224","PMC6587509",null,"S000372","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016079","Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model.","Bosch R","2024","British journal of pharmacology","other_trial","article","10.1111/bph.16336","38403793",null,"ClinicalTrials.gov:NCT02548585","S000451","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Randomized Controlled Trial; Clinical Trial, Phase II; article"],["R0016080","Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.","Ruan Z","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01301-4","35934763","PMC9500126",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016081","Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.","Zhang Z","2023","Frontiers in endocrinology","notice","article","10.3389/fendo.2023.1270115","37900146","PMC10600365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0016082","Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.","Simó R","2015","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-015-0279-z","26338040","PMC4558893","ClinicalTrials.gov:NCT00359762","S001097","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016083","Effects of Glucose-Lowering Medications on Intrapancreatic Fat Deposition: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Agon HC","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70087","41622606",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0016084","Development of a long-acting unbiased GIP receptor agonist for studies of GIP's role in bone metabolism.","Tordrup EK","2025","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2025.116893","40132763",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0016085","The GLP1R Agonist Semaglutide Inhibits Reactive Astrocytes and Enhances the Efficacy of Neural Stem Cell Transplantation Therapy in Parkinson's Disease Mice.","Song D","2025","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.202417664","40874950","PMC12631936",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016086","Mitochondrial-Endothelial Crosstalk in Cardiometabolic Disease: Mechanisms and Translational Opportunities in the Multi-omics Era.","Liu D","2026","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm47549","42238644","PMC13227359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016087","Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes.","Ito D","2015","Journal of clinical medicine research","other","article","10.14740/jocmr2237w","26251684","PMC4522987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016088","Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.","Tian Q","2025","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2025.1593134","40747302","PMC12310450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; systematic-review; review"],["R0016089","Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.","Monami M","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70617","41804193","PMC13071265",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Network Meta-Analysis; Journal Article; research-article; review"],["R0016090","Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered Questions.","Heerspink HJL","2025","Journal of the American Society of Nephrology : JASN","nonrandomized_study","article","10.1681/asn.0000000838","40960873","PMC12677812",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; letter"],["R0016091","GLP-1 Receptor Signaling Has Different Effects on the Perikarya and Axons of the Hypophysiotropic Thyrotropin-Releasing Hormone Synthesizing Neurons in Male Mice.","Ruska Y","2024","Thyroid : official journal of the American Thyroid Association","preclinical","article","10.1089/thy.2023.0284","38062754",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016092","Female Underweight/Undernutrition Syndrome (FUS): An Emerging Health Concept in Premenopausal Women - Secondary Publication (English Translation of the Japanese Statement).","Tamura Y","2026","The journal of obstetrics and gynaecology research","narrative_review","article","10.1111/jog.70201","41721462","PMC12923648",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0016093","Pharmacological Treatment for Adamantinomatous Craniopharyngioma.","Zhao C","2025","Current oncology reports","narrative_review","article","10.1007/s11912-025-01731-w","41400734",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016094","The effect of beinaglutide on visceral fat and body weight in obese type 2 diabetic patients.","Wang GY","2026","Archives of medical science : AMS","other","article","10.5114/aoms.2020.98168","42305292","PMC13266512",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016095","Predicting Sustained Benefit From Tirzepatide in SURPASS-4: Who Benefits and Why?","Varadinova M","2025","Diabetes","commentary","article","10.2337/dbi25-0033","40971612",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0016096","A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity.","Coppin G","2023","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-023-01370-w","37626125","PMC10663148",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016097","A potentially serious adverse effect of GLP-1 receptor agonists.","Lu J","2023","Acta pharmaceutica Sinica. B","commentary","article","10.1016/j.apsb.2023.02.020","37250165","PMC10213739",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0016098","Brain insulin resistance: role in neurodegenerative disease and potential for targeting.","Hölscher C","2020","Expert opinion on investigational drugs","narrative_review","article","10.1080/13543784.2020.1738383","32175781",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0016099","Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines.","Liang D","2026","British journal of clinical pharmacology","narrative_review","article","10.1002/bcp.70733","42550082",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016100","O-GlcNAcylation of myocyte-specific enhancer factor 2D negatively regulates insulin secretion from pancreatic β-cells.","Yoshida M","2022","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2022.03.036","35316768",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0016101","[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?].","Lanthier L","2023","La Revue de medecine interne","commentary","article","10.1016/j.revmed.2022.11.005","36443201",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016102","Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.","Matza LS","2018","Patient preference and adherence","other","article","10.2147/ppa.s159620","29922043","PMC5995299",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016103","Effects of liraglutide on the testis of rats with experimental diabetes and ischemia-reperfusion injury.","Hazir S","2025","Biotechnic & histochemistry : official publication of the Biological Stain Commission","preclinical","article","10.1080/10520295.2025.2537045","40757489",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016104","Effect of Semaglutide on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study.","Guo J","2025","Circulation. Arrhythmia and electrophysiology","other","article","10.1161/circep.125.014069","41064855",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016105","GLP-1-based therapies for diabetes, obesity and beyond.","Drucker DJ","2025","Nature reviews. Drug discovery","narrative_review","article","10.1038/s41573-025-01183-8","40281304",null,null,"S002468; S002726","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; review"],["R0016106","Cyclic AMP-dependent activation of ERK via GLP-1 receptor signalling requires the neuroendocrine cell-specific guanine nucleotide exchanger NCS-RapGEF2.","Xu W","2021","Journal of neuroendocrinology","preclinical","article","10.1111/jne.12974","33960038","PMC8571116",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016107","A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.","Ji L","2023","Nature communications","randomized_trial","article","10.1038/s41467-023-44067-4","38092790","PMC10719339","ClinicalTrials.gov:NCT04904913","S000578; S001183","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; research-article; article"],["R0016108","Treatment of Pediatric Type 2 Diabetes.","Smith JD","2016","The Annals of pharmacotherapy","randomized_trial","article","10.1177/1060028016655179","27307414",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0016109","Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?","Masarone D","2024","Journal of clinical medicine","other_trial","article","10.3390/jcm13226867","39598011","PMC11594938",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; other; article"],["R0016110","Future potential therapeutics to treat MASH.","Mahajan S","2025","Drug discovery today","narrative_review","article","10.1016/j.drudis.2025.104451","40803572",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016111","Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population-based cohort study.","Her QL","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70002","40760781","PMC12758837",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016112","GLP-1 Agonists for Obesity-A New Recipe for Success?","Mozaffarian D","2024","JAMA","other","article","10.1001/jama.2024.2252","38421659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0016113","Brain Site-Specific Inhibitory Effects of the GLP-1 Analogue Exendin-4 on Alcohol Intake and Operant Responding for Palatable Food.","Colvin KJ","2020","International journal of molecular sciences","preclinical","article","10.3390/ijms21249710","33352692","PMC7766977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016114","Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.","Boye KS","2019","Journal of medical economics","other","article","10.1080/13696998.2019.1609482","31010349",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016115","Central and peripheral GLP-1 systems independently and additively suppress eating","Brierley DI","2020","bioRxiv","preclinical","preprint","10.1101/2020.08.03.234427",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016116","Long-Term Efficacy of Bariatric Surgery Compared to Modern Medical Therapy in Type 2 Diabetes and Obesity: A Systematic Review.","Afzal A","2025","Cureus","systematic_review","article","10.7759/cureus.89409","40918897","PMC12412261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0016117","Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists.","Gimeno-Orna JA","2016","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","nonrandomized_study","article","10.1016/j.endonu.2015.11.009","26830854",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016118","Special Considerations in the Treatment of Idiopathic Intracranial Hypertension.","Friedman DI","2024","Current neurology and neuroscience reports","other_trial","article","10.1007/s11910-024-01398-z","39656331",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0016119","Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.","Kirk RK","2017","Diabetes, obesity & metabolism","other","article","10.1111/dom.12879","28094469",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016120","Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide.","Ishihara Y","2022","Cureus","case_report","article","10.7759/cureus.26916","35983392","PMC9376210",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016121","Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.","Wang JY","2025","Clinical obesity","systematic_review","article","10.1111/cob.70036","40685889",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0016122","Dynamic Regulation of Macrophage Polarization in Acute Myocardial Infarction and Its Therapeutic Potential.","Xu A","2025","Journal of inflammation research","narrative_review","article","10.2147/jir.s543139","41416126","PMC12711377",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016123","Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study.","Darpo B","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-014-0055-1","24510375","PMC4065291",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0016124","Effects of Contemporary Therapies on Cardiovascular and Renal Outcomes in Diabetic Kidney Disease: A Systematic Review of Randomized Controlled Trials (RCTs).","Bachar Al Sumodi W","2025","Cureus","systematic_review","article","10.7759/cureus.95400","41293379","PMC12643440",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0016125","Liraglutide (Saxenda): CADTH Reimbursement Review: Therapeutic area: Chronic weight management in adults",null,"2021","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"37616430",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0016126","Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway.","Wei H","2019","Journal of diabetes research","preclinical","article","10.1155/2019/8905917","31886288","PMC6925927",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016127","Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.","Gomes DS","2026","Pulmonology","nonrandomized_study","article","10.1080/25310429.2026.2640663","41804593",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Scoping Review; article"],["R0016128","Oral Semaglutide in Adults with Overweight or Obesity.","Kermansaravi M","2025","The New England journal of medicine","nonrandomized_study","article","10.1056/nejmc2515109","41370811",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0016129","Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.","Levi J","2023","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23725","36815242",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0016130","Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide","Ghosh A","2021","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvab048.955",null,"PMC8089580",null,null,"europepmc; openalex","TRUE","open_europepmc","5","FALSE","Abstract; conference-abstract"],["R0016131","A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide.","Huang M","2025","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1608657","40667509","PMC12259682",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016132","Divergent effects of exendin-4 and interleukin-6 on rat colonic secretory and contractile activity are associated with changes in regional vagal afferent signaling.","O'Brien R","2021","Neurogastroenterology and motility","preclinical","article","10.1111/nmo.14160","33945195",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016133","Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease.","Yao Y","2025","European journal of medical research","systematic_review","article","10.1186/s40001-025-03241-8","41188987","PMC12584374",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0016134","Semaglutide drives weight loss through cAMP-dependent mechanisms in GLP1R-expressing hindbrain neurons","Gao C","2025","bioRxiv","other","preprint","10.1101/2025.08.12.668772",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0016135","Synthesis and evaluation of 18F-PTTCO-Cys40-Exendin-4 for PET imaging of ectopic insulinomas in rodents.","Li J","2020","Bioorganic chemistry","preclinical","article","10.1016/j.bioorg.2020.103718","32171991",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016136","Sustained Weight Loss With Combined LEAP2 and Semaglutide Treatment in Mice.","Holm SK","2025","Diabetes","preclinical","article","10.2337/db24-1056","40590720","PMC12585159",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0016137","Real-world effectiveness, safety, and quality of life of biosynthetic semaglutide in Pakistani adults with type 2 diabetes mellitus: a study protocol.","Daoud Butt M","2026","Journal of pharmaceutical policy and practice","protocol","article","10.1080/20523211.2026.2631932","41783580","PMC12954801","ANZCTR:ACTRN12625000610437",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; other; article"],["R0016138","Therapeutic efficacy of synthetic analogues of gut hormones in a mouse model of Alzheimer's disease.","Denver P","2026","Neuroscience","preclinical","article","10.1016/j.neuroscience.2026.01.038","41616952",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016139","NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?","Lafferty RA","2024","Peptides","narrative_review","article","10.1016/j.peptides.2024.171256","38825012",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0016140","First-Line Therapy: Semaglutide Rise.","Ahmed M","2025","Diabetes care","commentary","article","10.2337/dc25-1032","41264827",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016141","[Cardiology. Coronary and structural interventional cardiology].","Barrier A","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.900-1.13","39812278",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0016142","Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.","Aung MM","2019","Diabetologia","randomized_trial","article","10.1007/s00125-019-4918-x","31203378","PMC6677680","ClinicalTrials.gov:NCT01677104","S001948","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016143","The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment.","Gunturu S","2024","Indian journal of psychological medicine","commentary","article","10.1177/02537176241246744","38699771","PMC11062310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0016144","Exendin-4 Reduces Ventricular Arrhythmia Activity and Calcium Sparks-Mediated Sarcoplasmic Reticulum Ca Leak in Rats with Heart Failure.","Chen J","2020","International heart journal","preclinical","article","10.1536/ihj.19-327","31956148",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016145","Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).","Riddle MC","2013","Diabetes care","randomized_trial","article","10.2337/dc12-2454","23628617","PMC3747925","ClinicalTrials.gov:NCT00975286","S000792; S002023","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016146","Multimodal imaging reveals distinct cardiac benefits of dulaglutide versus dapagliflozin in a mouse model of glucotoxic cardiomyopathy.","Joubert M","2025","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70012","40772552",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016147","Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD): a growing health concern in the age of childhood obesity.","Venu S","2026","BMJ paediatrics open","narrative_review","article","10.1136/bmjpo-2025-003846","42161382","PMC13202044",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016148","Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.","Hamilton A","2011","Journal of neuroscience research","preclinical","article","10.1002/jnr.22565","21312223",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016149","Baseline characteristics of patients with type 1 and type 2 diabetes in the Asahi Diabetes Complications Study (Asahi Study): a clinic-based prospective observational study.","Yoshida Y","2026","Diabetology international","nonrandomized_study","article","10.1007/s13340-026-00881-x","41815886","PMC12972451",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0016150","Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs.","Staby A","2020","Pharmaceutical research","other","article","10.1007/s11095-020-02817-9","32514880",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016151","[Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].","Nauck M","2017","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-017-9803-2","28643293",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016152","Correction: Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial.","Ghosh S","2025","Cardiovascular diabetology. Endocrinology reports","notice","article","10.1186/s40842-025-00233-9","41013740","PMC12362860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0016153","Moving beyond the scale: musculoskeletal risks, evidence gaps and emerging combination strategies to optimize the quality of weight loss pharmacotherapy in older adults.","Reid KF","2025","Frontiers in aging","other","article","10.3389/fragi.2025.1640030","41209422","PMC12592101",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0016154","Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.","Caussy C","2025","Diabetes care","randomized_trial","article","10.2337/dc25-1306","41066427","PMC12635880","ClinicalTrials.gov:NCT04166773","S000031","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; other; article"],["R0016155","Improvement in Walking Distance With Semaglutide in Smokers With Peripheral Artery Disease: STRIDE Trial Subgroup Analysis.","Sourij H","2026","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2025.10.080","41532935",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0016156","New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review.","Jalil JE","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25084407","38673991","PMC11049921",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016157","Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice.","Karasawa T","2025","Cell metabolism","preclinical","article","10.1016/j.cmet.2025.07.004","40769122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016158","Recurrent Weight Gain after Weight Loss Induced by Lifestyle Intervention, Metabolic and Bariatric Surgery, or Semaglutide in Adults with Obesity: A Systematic Review of Randomized Controlled Trials.","Chen H","2026","Obesity surgery","systematic_review","article","10.1007/s11695-025-08415-1","41483046",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Review; review"],["R0016159","Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.","Araki E","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12540","26179754","PMC5042081",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016160","Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.","Bain SC","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-00736-6","31833042","PMC6965564",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0016161","Immunological alterations with GLP-1 agonists in people living with HIV.","Noe S","2024","HIV medicine","commentary","article","10.1111/hiv.13631","38433467",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0016162","Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.","Wang Y","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.818537","35370959","PMC8969579",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; systematic-review; article"],["R0016163","Dulaglutide: first global approval.","Sanford M","2014","Drugs","narrative_review","article","10.1007/s40265-014-0320-7","25367716",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016164","Response by Zile et al to Letter Regarding Article, \"Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity\".","Zile MR","2025","Circulation","commentary","article","10.1161/circulationaha.125.075872","41212937",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016165","Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.","Roeb E","2022","Visceral medicine","other_trial","article","10.1159/000519611","35614896","PMC9082206",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; review"],["R0016166","Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities.","Zhou XD","2026","Gut","narrative_review","article","10.1136/gutjnl-2025-337431","41475978",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0016167","Association of oral semaglutide with cardiovascular outcomes in a real-world primary prevention population.","Cowart K","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70412","41457323",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0016168","Are GLP-1 agonists the answer to our obesity epidemic?","Dapre E","2023","The British journal of general practice : the journal of the Royal College of General Practitioners","other","article","10.3399/bjgp23x734589","37500468","PMC10405951",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0016169","A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals.","Trevaskis JL","2025","Nature metabolism","other","article","10.1038/s42255-025-01383-x","40999040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016170","Peptide-Based Therapeutics for Alzheimer's Disease: Medicinal Chemistry, AI-Guided Computational Design, and Blood-Brain Barrier Delivery.","Al Khzem AH","2026","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s597087","42007396","PMC13089476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article; review"],["R0016171","Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide.","Hartman ML","2025","JHEP reports : innovation in hepatology","randomized_trial","article","10.1016/j.jhepr.2025.101472","40689147","PMC12276444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0016172","Liraglutide Attenuates Multiorgan Oxidative, Astroglial, and Mitochondrial Stress Responses in Thioacetamide-Induced Hepatic Encephalopathy.","Bilgin Y","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27177538","42737442","PMC13566862",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016173","Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.","Rayner CK","2020","Diabetes care","randomized_trial","article","10.2337/dc20-0190","32471908",null,"ANZCTR:ACTRN12616001059459",null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; other; article"],["R0016174","A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults.","Patino LR","2025","Journal of affective disorders","randomized_trial","article","10.1016/j.jad.2025.04.046","40203970",null,"ClinicalTrials.gov:NCT00845507","S001173","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0016175","Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.","Chuang LH","2016","Journal of medical economics","other","article","10.1080/13696998.2016.1203329","27310712",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0016176","SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes.","Jeon JH","2024","Diabetes & metabolism journal","commentary","article","10.4093/dmj.2024.0079","38556704","PMC10995490",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0016177","Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post-hoc analysis from a double-blinded randomized controlled trial.","Pasqua MR","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70185","41063383","PMC12673461",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0016178","The role of mast cells in cellular modifications evoked by Exendin-4 in treated wounds: a preclinical study.","Paroli G","2022","Journal of wound care","preclinical","article","10.12968/jowc.2022.31.8.701","36001707",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016179","A real-world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672).","Stryker MD","2018","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.4","30815541","PMC6360919","ClinicalTrials.gov:NCT02895672","S000410","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016180","Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.","Fulcher G","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12589","26450639",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016181","Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.","Hanefeld M","2014","Advances in therapy","systematic_review","article","10.1007/s12325-014-0146-4","25143188",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0016182","Tirzepatide drives weight loss in people with obesity due to MC4R deficiency.",null,"2025","Nature medicine","other","article","10.1038/s41591-025-03915-0","40913173",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016183","Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction.","Zhou D","2024","Chinese medical journal","other_trial","article","10.1097/cm9.0000000000003355","39470028","PMC11611247",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016184","Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus.","Yue D","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1684395","41255528","PMC12620217",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016185","Mechanistic insights into psoriasis and type 2 diabetes mellitus comorbidity - Implications for treatment: A review.","Ouyang L","2026","Biomolecules & biomedicine","narrative_review","article","10.17305/bb.2026.13484","41564383","PMC13021029",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016186","Improved glucose tolerance with DPPIV inhibition requires β-cell SENP1 amplification of glucose-stimulated insulin secretion.","Ferdaoussi M","2020","Physiological reports","preclinical","article","10.14814/phy2.14420","32339440","PMC7185381",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016187","Letter by Zhao et al Regarding Article, \"Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity\".","Zhao N","2025","Circulation","commentary","article","10.1161/circulationaha.125.074627","41212939",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016188","Regulated and adaptive in vivo insulin secretion from islets only containing β-cells.","Perez-Frances M","2024","Nature metabolism","preclinical","article","10.1038/s42255-024-01114-8","39169271","PMC11422169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016189","The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.","Salheen SM","2015","Pharmacological research","preclinical","article","10.1016/j.phrs.2015.02.003","25697548",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016190","Post-sleeve gastrectomy weight loss: Role of botulinum toxin and semaglutide injections.","Li Z","2026","Endoscopy international open","other","article","10.1055/a-2793-9945","41777326","PMC12951029",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016191","Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process.","Fu Z","2020","Frontiers in physiology","preclinical","article","10.3389/fphys.2020.00555","32547420","PMC7274078",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016192","Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.","Zhao L","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16439","40329666",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0016193","Continuous Glucose Monitoring Metrics Using FreeStyle Libre3 in Patients with Type 2 Diabetes and Gastroparesis: A Pilot Prospective Investigator-Initiated Study.","Garg S","2026","Diabetes technology & therapeutics","other","article","10.1177/15209156251408393","41804538",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016194","A red light-controlled probiotic bio-system for in-situ gut-brain axis regulation.","Zhang X","2023","Biomaterials","preclinical","article","10.1016/j.biomaterials.2023.122005","36701997",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0016195","The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill.","Deane AM","2010","Critical care (London, England)","commentary","article","10.1186/cc9281","20979668","PMC3219279",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Journal Article; research-article; article"],["R0016196","Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.","Ferdinand KC","2016","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-016-0355-z","26912057","PMC4765050",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0016197","Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.","Ryan DH","2020","American heart journal","protocol","article","10.1016/j.ahj.2020.07.008","32916609",null,null,"S000716","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial Protocol; Journal Article; article"],["R0016198","Decoding the impact of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist on cardiometabolic health: inflammatory mediators at the focus.","Cheng F","2025","Diabetology & metabolic syndrome","other","article","10.1186/s13098-025-01744-2","40426228","PMC12117674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016199","Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.","Gibble TH","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16463","40365662","PMC12232368",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0016200","Long-Tail Pharmacovigilance: The Semaglutide–NAION Case and a Pilot Benchmark for Language Models","Xiong J","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202610.0511.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0016201","A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.","Guldhammer A","2026","Scandinavian journal of primary health care","other","article","10.1080/02813432.2026.2636584","41838446","PMC12997375",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016202","Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.","Smits MM","2017","European journal of endocrinology","randomized_trial","article","10.1530/eje-16-0507","27777261",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0016203","Differences in National Diabetes Treatment Patterns and Trends between Older and Younger Adults.","Pilla SJ","2019","Journal of the American Geriatrics Society","other","article","10.1111/jgs.15790","30703251","PMC6488408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; research-article; article"],["R0016204","Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial.","Han CY","2023","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2023.1267503","38125788","PMC10731293","ChiCTR:ChiCTR2200061003",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016205","Semaglutide-associated hyposalivation: A report of case series.","Mawardi HH","2023","Medicine","case_report","article","10.1097/md.0000000000036730","38206684","PMC10754586",null,"S001428","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0016206","How Continuous Glucose Monitoring Reports Inform Clinical Decision-Making for Older Adults With Type 2 Diabetes: Mapping Clinical Workflow to Situation Awareness.","Savoy A","2026","Journal of diabetes science and technology","other","article","10.1177/19322968261449829","42137973","PMC13179298",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016207","Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.","Wang H","2019","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2019.01.001","30711143",null,"PROSPERO:CRD42018089761",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis"],["R0016208","Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.","Knerr PJ","2022","Molecular metabolism","preclinical","article","10.1016/j.molmet.2022.101533","35809773","PMC9305623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016209","Liraglutide 3.0 mg and Mental Health: Can Psychiatric Symptoms Predict Adherence to Therapy? Insights from a clinical audit","Tempia Valenta S","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-2402581/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0016210","Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.","Muskiet MHA","2018","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(18)30268-7","30292589",null,"ClinicalTrials.gov:NCT01147250","S001991","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016211","Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.","Mañas-Martinez AB","2023","Diabetes care","commentary","article","10.2337/dc23-0076","37185691",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0016212","Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study.","Wu JY","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112294","40456414",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Comparative Study; article"],["R0016213","THU334 Trends In GLP-1 Agonist Utilization In Diabetics With And Without Vascular Disease",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10553762",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0016214","Improvement of cognitive function, glucose and lipid homeostasis and serum osteocalcin levels by liraglutide in diabetic rats.","Sedky AA","2021","Fundamental & clinical pharmacology","preclinical","article","10.1111/fcp.12664","33683755",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016215","Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.","Frias JP","2018","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(18)32260-8","30293770",null,"ClinicalTrials.gov:NCT03131687","S000010; S000760","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0016216","Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.","Pratley RE","2018","Journal of diabetes science and technology","randomized_trial","article","10.1177/1932296818776993","29893144","PMC6232729",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0016217","Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.","Malhotra A","2026","Nature medicine","randomized_trial","article","10.1038/s41591-025-04071-1","41540105","PMC12920140","ClinicalTrials.gov:NCT05412004","S000156","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; research-article; article"],["R0016218","Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J).","Eguchi Y","2015","Hepatology research : the official journal of the Japan Society of Hepatology","other","article","10.1111/hepr.12351","24796231",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016219","Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways.","Al-Mahdawi MA","2026","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2026.1842207","42534639","PMC13421410",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016220","Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope?","Caruso P","2023","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.3627","36812501",null,"ClinicalTrials.gov:NCT04560998; ClinicalTrials.gov:NCT04146155; ClinicalTrials.gov:NCT04881110","S000264; S001363; S002174","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0016221","Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial.","Katrevula A","2026","Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","randomized_trial","article","10.1007/s12664-025-01856-7","41066034",null,"ClinicalTrials.gov:NCT05442450","S000017","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; article"],["R0016222","Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation.","Fang S","2020","Journal of diabetes research","randomized_trial","article","10.1155/2020/9084567","32090125","PMC7023845",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0016223","N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.","Zhao LH","2026","Cell reports","preclinical","article","10.1016/j.celrep.2026.117718","42467532",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016224","Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.","Endo M","2023","Diabetes care","commentary","article","10.2337/dc22-2454","37185687",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0016225","Pharmacomicrobiomics: Exploring the role of gut microbiota in type 2 diabetes and antidiabetic drug mechanisms.","Wen D","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2025.104379","41152039",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016226","Targeting Superoxide to Prevent Diuretic Resistance and Reduce Heart Failure Mortality.","Kaesemeyer W","2025","Cardiology in review","other","article","10.1097/crd.0000000000000969","40576354",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016227","Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.","Arora P","2025","Expert review of pharmacoeconomics & outcomes research","nonrandomized_study","article","10.1080/14737167.2025.2570688","41059919",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comparative Study; article"],["R0016228","Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.","Smits MM","2023","Diabetes care","commentary","article","10.2337/dc23-0134","37185688",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0016229","GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.","Iepsen EW","2015","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2015-1176","26043228",null,"ClinicalTrials.gov:NCT02094183","S000828","pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016230","The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.","Vinué Á","2017","Diabetologia","preclinical","article","10.1007/s00125-017-4330-3","28608285",null,null,"S000443","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016231","Integrating physical healthcare into psychiatry for severe mental illness: A narrative review and position statement from the ECNP PAN-Health group.","Nielsen RE","2026","Neuroscience applied","narrative_review","article","10.1016/j.nsa.2026.106993","41852684","PMC12992995",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0016232","Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.","Goldenberg RM","2023","Diabetes care","commentary","article","10.2337/dc22-2300","37185678",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0016233","Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials.","Zhuang XD","2018","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-018-0722-z","29871636","PMC5989345","PROSPERO:CRD42016042063",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; Network Meta-Analysis; review-article; review"],["R0016234","Facilitators and barriers to SGLT2i and GLP1a prescribing in Northern Ontario: a qualitative interview study","Olar P","2025","medRxiv","other","preprint","10.1101/2025.10.27.25338651",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016235","The Effect of Body Mass Index on the Efficacy of Semaglutide Use at the Time of Total Knee Arthroplasty.","Xu JJ","2026","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2025.09.056","41072554",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016236","Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.","Zhuo M","2022","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2022.35995","36219443","PMC9554705",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0016237","Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.","Lingvay I","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00225-6","40961953",null,"ClinicalTrials.gov:NCT05649137","S001158","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0016238","Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study.","Zhao L","2025","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.24306","40437798",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0016239","Evaluation of the Short-Term Effect of Tirzepatide on Liver Fibrosis Biomarkers Stratified by the Fibrosis-3 Index (FIB-3) in Patients With Type 2 Diabetes Mellitus.","Yamamori D","2025","Cureus","other","article","10.7759/cureus.97279","41431568","PMC12718664",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016240","Cardioprotective effect of diabetic medication on cancer patients undergoing proven cardiotoxic chemotherapy: a systematic review and meta-analysis.","El-Helbawy A","2026","Cardio-oncology (London, England)","systematic_review","article","10.1186/s40959-025-00424-4","41540487","PMC12853835",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review; other"],["R0016241","Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities.","Wu X","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14010213","41595747","PMC12839070",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016242","Exenatide extended-release: a review of its use in type 2 diabetes mellitus.","Scott LJ","2012","Drugs","narrative_review","article","10.2165/11209750-000000000-00000","22867046",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016243","The Key Role of Liraglutide in Preventing Autophagy of Vascular Smooth Muscle Cells in High Glucose Conditions.","Shi L","2024","Balkan medical journal","preclinical","article","10.4274/balkanmedj.galenos.2023.2023-8-44","37953594","PMC10767783",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016244","Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS Database.","Ritsinger V","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70899","42304551","PMC13448875",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016245","Mechanism-guided pharmacotherapy for cardiometabolic multimorbidity: from pathophysiology to phenotype-prioritized treatment.","Dong H","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1724965","41404511","PMC12702714",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016246","Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β.","Zhou M","2019","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2019.01.103","30773255",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016247","The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest.","Wiberg S","2018","Critical care medicine","randomized_trial","article","10.1097/ccm.0000000000002814","29189347",null,"ClinicalTrials.gov:NCT02442791","S001005","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016248","Surgical and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Class I Obese Patients: a Short-Term Outcome.","Bhandari M","2017","Obesity surgery","other_trial","article","10.1007/s11695-017-2770-y","28601988",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Clinical Trial; Journal Article"],["R0016249","Liraglutide: from clinical trials to clinical practice.","Gough SC","2012","Diabetes, obesity & metabolism","other_trial","article","10.1111/j.1463-1326.2012.01576.x","22405267",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0016250","EBM BLS: Tirzepatide Helps Obese Patients Lose Weight.","Ortega H","2025","Journal of general internal medicine","other","article","10.1007/s11606-025-09815-w","40900412","PMC12686265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0016251","Liraglutide as a novel therapeutic for overweight in canines: A clinical study.","Dik B","2025","Veterinary journal (London, England : 1997)","other_trial","article","10.1016/j.tvjl.2025.106376","40436366",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0016252","Glucagon-like peptide-1 stimulates acute secretion of pro-atrial natriuretic peptide from the isolated, perfused pig lung exposed to warm ischemia.","Balk-Møller E","2022","Frontiers in transplantation","preclinical","article","10.3389/frtra.2022.1082634","38994393","PMC11235333",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016253","A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.","Tham LS","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14582","34697882","PMC9298861",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016254","Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF).","Michalak W","2025","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2025.07.018","40813184",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0016255","What effect does semaglutide have on those living with obesity?","Jordan V","2025","Journal of primary health care","other","article","10.1071/hc25208","41346202",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016256","Effects of Hypolipidemic Drugs on Psoriasis.","Matwiejuk M","2023","Metabolites","nonrandomized_study","article","10.3390/metabo13040493","37110152","PMC10142060",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0016257","Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1.","Wang X","2015","International journal of endocrinology","narrative_review","article","10.1155/2015/651757","26366173","PMC4558455",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0016258","Incretin-Related Pathology and Serum Exosome Detection in Experimental Alcohol-Related Brain Damage.","de la Monte SM","2025","Biomolecules","preclinical","article","10.3390/biom15121670","41463326","PMC12731142",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0016259","Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.","Cusi K","2019","Hepatology (Baltimore, Md.)","randomized_trial","article","10.1002/hep.30670","31006135",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Editorial; Comment; article"],["R0016260","Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.","Voronova V","2018","Diabetes, obesity & metabolism","other","article","10.1111/dom.13326","29663628",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016261","Response to Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384-390.","Bezin J","2023","Diabetes care","commentary","article","10.2337/dci23-0016","37185689",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0016262","GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy.","Złotek M","2023","Biomedicines","narrative_review","article","10.3390/biomedicines11113035","38002034","PMC10669527",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016263","Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.","Ard J","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16554","40677091","PMC12326891","ClinicalTrials.gov:NCT04184622","S001077","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0016264","Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects?","Gorard L","2026","Current opinion in gastroenterology","nonrandomized_study","article","10.1097/mog.0000000000001169","41866997",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0016265","Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.","Kanu C","2025","Sleep medicine","randomized_trial","article","10.1016/j.sleep.2025.106719","40774158","PMC12720398","ClinicalTrials.gov:NCT05412004","S000156","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0016266","Epicardial Fat and Heart Failure in Type 2 Diabetes: Metabolism, Imaging and Novel Biomarkers-A Translational Perspective.","Gil-Millan P","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14238413","41375727","PMC12693676",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016267","Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.","Kendall DM","2009","The American journal of medicine","other_trial","article","10.1016/j.amjmed.2009.03.015","19464427",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0016268","In vitro comparison of various antioxidants and flavonoids from Rooibos as beta cell protectants against lipotoxicity and oxidative stress-induced cell death.","Moens C","2022","PloS one","preclinical","article","10.1371/journal.pone.0268551","35580081","PMC9113568",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016269","The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis.","Zhang J","2021","Nagoya journal of medical science","case_report","article","10.18999/nagjms.83.2.343","34239182","PMC8236694",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016270","Age-Related Usage of GLP-1 Agonists in Obese Patients With Heart Failure and Preserved Ejection Fraction.","Achanta A","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.01.033","38569765",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016271","Effect of semaglutide add-on therapy for people living with type 1 diabetes and excess weight.","Minsky NC","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70389","41417475",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0016272","Disruption of the microenvironmental ecosystem in subchondral bone marrow lesions: Roles in osteoarthritis pathophysiology, pain and progression.","Mobasheri A","2026","Osteoarthritis imaging","other","article","10.1016/j.ostima.2025.100374","42238192","PMC13228727",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016273","Should Prediabetes be Treated Pharmacologically?","Davidson MB","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-023-01449-7","37490238","PMC10499716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0016274","GLP-1 analogue therapy for obesity in people from Asia.","Khoo B","2024","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(24)00031-7","38330985",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0016275","Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2.","Sattar N","2025","Diabetes care","commentary","article","10.2337/dc25-1442","40838997","PMC12583394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016276","Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors.","Kurukulasuriya LR","2010","Cardiovascular diabetology","narrative_review","article","10.1186/1475-2840-9-45","20804556","PMC2940872",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016277","Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.","Beti C","2019","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","nonrandomized_study","article","10.1055/a-0818-6374","30690693",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0016278","Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling.","Gao Y","2025","Drug metabolism and disposition: the biological fate of chemicals","other","article","10.1016/j.dmd.2025.100199","41352168",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016279","Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes.","Gutgesell RM","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-024-01566-x","38573467","PMC11043266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016280","High glucose promotes atherosclerosis by regulating miRNA let7d-5p level.","Wang H","2024","Journal of diabetes investigation","preclinical","article","10.1111/jdi.14180","38483136","PMC11143425",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016281","Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.","Schlögl H","2013","Diabetes care","randomized_trial","article","10.2337/dc12-1925","23462665","PMC3687323",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016282","Clinical Review Report: Insulin glargine and lixisenatide injection (Soliqua): (Sanofi-Aventis): Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) alone or in combination with metformin",null,"2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"31145567",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0016283","Semaglutide and survival in lean type 2 diabetes: emerging enigma.","Pacheco AP","2025","European heart journal. Quality of care & clinical outcomes","commentary","article","10.1093/ehjqcco/qcaf116","40991735",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0016284","[Specific Fasting Requirements for Special Patient Groups].","Beck C","2025","Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS","other","article","10.1055/a-2505-3616","41290011",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0016285","Immunopathogenic mechanisms and immunoregulatory therapies in MASLD.","He Y","2025","Cellular & molecular immunology","narrative_review","article","10.1038/s41423-025-01307-5","40494889","PMC12480724",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0016286","Metabolic Parkinson's disease.","Invernizzi F","2025","Frontiers in aging neuroscience","narrative_review","article","10.3389/fnagi.2025.1665957","41143244","PMC12549673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016287","Embedding MASLD Risk Stratification in Primary Care: Results from a Community Health Center Pilot","Wexler R","2026","Research Square","other","preprint","10.21203/rs.3.rs-9408563/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0016288","Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients.","Lin YH","2023","Scientific reports","nonrandomized_study","article","10.1038/s41598-023-49870-z","38110464","PMC10728170",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016289","Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis.","Kovalic AJ","2018","Hepatology international","narrative_review","article","10.1007/s12072-018-9854-1","29600430",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016290","Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.","Fala L","2015","American health & drug benefits","other","article",null,"26629277","PMC4665069",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; research-article; article"],["R0016291","Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study.","Rozani V","2024","Parkinsonism & related disorders","nonrandomized_study","article","10.1016/j.parkreldis.2024.107132","39260107",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0016292","Effects of liraglutide on depressive behavior and cognitive function in the probe trial of Morris water maze test","Jon D","2025","European psychiatry : the journal of the Association of European Psychiatrists","other_trial","article",null,null,"PMC12420177",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0016293","Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus.","Song J","2022","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2022.949990","36051387","PMC9424689","ChiCTR:ChiCTR-CCC13003536",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016294","THU122 Effects Of A GLP-1 Agonist On Consumption Of Alcohol In Patients Treated For Smoking Cessation",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10553923",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0016295","Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.","Chepurny OG","2019","The Journal of biological chemistry","other","article","10.1074/jbc.ra118.005682","30622136","PMC6416420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0016296","Independent Risk Factors for Sacral Fracture After Lumbosacral Fusion in Adults: A Cox Proportional Hazards Retrospective Analysis.","Baumann AN","2026","Clinical spine surgery","nonrandomized_study","article","10.1097/bsd.0000000000001999","41538249",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016297","Landscape of diabetic kidney disease drug clinical trials in China (2013-2023): global implications for innovation and policy.","Yang Y","2026","Renal failure","other_trial","article","10.1080/0886022x.2026.2629639","41724716","PMC12927394",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0016298","Liraglutide Treatment May Affect Renin and Aldosterone Release.","Sedman T","2017","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","other_trial","article","10.1055/s-0042-109065","27300475",null,"ClinicalTrials.gov:NCT02089256","S000403","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0016299","Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.","Buse JB","2013","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(12)61267-7","23141817",null,"ClinicalTrials.gov:NCT01029886","S000352; S000506","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016300","Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.","Pratley RE","2014","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(13)70214-6","24703047",null,"ClinicalTrials.gov:NCT01128894","S001824","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016301","Not Just Skin Deep: A Hidden Complication of Tirzepatide Therapy.","Phelan LN","2025","Obesity surgery","commentary","article","10.1007/s11695-025-08214-8","40906268",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0016302","Cardiovascular protective properties of incretin-based therapies in type 2 diabetes.","Simsek S","2012","Current opinion in lipidology","narrative_review","article","10.1097/mol.0b013e3283590b8f","23160401",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016303","Liraglutide attenuates post-cardiac arrest brain injury by inhibiting autophagy and ferroptosis","Xing C","2023","Research Square","preclinical","preprint","10.21203/rs.3.rs-2858822/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016304","Identifying carcinogenic hazards among pharmaceutical agents: An update from the IARC Monographs programme.","Pasqual E","2026","Cancer epidemiology","narrative_review","article","10.1016/j.canep.2026.103165","42447522",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016305","Nanofiber matrix formulations for the delivery of Exendin-4 for tendon regeneration: In vitro and in vivo assessment.","Abdulmalik S","2023","Bioactive materials","preclinical","article","10.1016/j.bioactmat.2023.01.013","36733930","PMC9876843",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016306","Metabolic disease drug discovery- \"hitting the target\" is easier said than done.","Moller DE","2012","Cell metabolism","other","article","10.1016/j.cmet.2011.10.012","22225873",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0016307","Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications.","Lewis KH","2026","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70208","42120922",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0016308","Cardiorenal disease management in type 2 diabetes: An expert consensus.","Mohan V","2022","Diabetes & metabolic syndrome","narrative_review","article","10.1016/j.dsx.2022.102661","36375366",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Consensus Statement"],["R0016309","Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management.","Dutta N","2025","Cureus","nonrandomized_study","article","10.7759/cureus.94070","41209894","PMC12592220",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016310","Differential Protective Actions of Dulaglutide and Dexamethasone in Methotrexate Induced Pulmonary Fibrosis: Relationship with AMPK and Beclin-1 Levels.","Maher OW","2026","Biomedicines","preclinical","article","10.3390/biomedicines14081714","42652097","PMC13509837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016311","Up-regulation of GLP-1R improved the dysfunction of late EPCs under hyperglycemia by regulating SIRT1 expression.","Tu Q","2021","Molecular and cellular endocrinology","other","article","10.1016/j.mce.2021.111455","34509564",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016312","The neurobiology of overeating.","Stuber GD","2025","Neuron","narrative_review","article","10.1016/j.neuron.2025.03.010","40185087",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0016313","Correction to: \"GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns\".",null,"2023","The Journal of clinical endocrinology and metabolism","notice","article","10.1210/clinem/dgad022","36656760",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0016314","Postconditioning with curaglutide, a novel GLP-1 analog, protects against heart ischemia-reperfusion injury in an isolated rat heart.","Salling HK","2012","Regulatory peptides","preclinical","article","10.1016/j.regpep.2012.06.007","22749991",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016315","Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew).","Chan SW","2013","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2013.01.013","23357334",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016316","Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.","Horowitz M","2013","Advances in therapy","other_trial","article","10.1007/s12325-013-0009-4","23423907",null,null,"S000473","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0016317","Can tirzepatide transform HFpEF management in Pakistan? A call for action.","Soomro AM","2025","JPMA. The Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.30399","41378422",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0016318","Cognition and Long COVID: a Review.","van der Feltz-Cornelis CM","2026","Current neurology and neuroscience reports","narrative_review","article","10.1007/s11910-026-01485-3","41824149",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016319","Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity.","Hoog MM","2025","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.24310","40512029","PMC12210105",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0016320","Integrative gene-metabolite network analysis of GLP-1 receptor agonists and related incretin pathways in cardiometabolic health.","Wicik Z","2025","NPJ systems biology and applications","other","article","10.1038/s41540-025-00619-6","41274923","PMC12738799",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016321","Semaglutide and Musculoskeletal Health: A Mendelian Randomization Study Based on GLP-1 Receptor Expression.","Li D","2026","Endocrine, metabolic & immune disorders drug targets","randomized_trial","article","10.2174/0118715303422692260617052555","42405390",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0016322","Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14.","Zeng Z","2016","PloS one","other","article","10.1371/journal.pone.0165130","27764251","PMC5072737",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016323","Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice.","Cardoso LEM","2023","Life sciences","preclinical","article","10.1016/j.lfs.2023.121502","36796719",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016324","Polycystic ovarian syndrome and long-term risk of acute myocardial infarction and ischaemic stroke.","Havers-Borgersen E","2026","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf351","40882992",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0016325","New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs.","Gether IM","2019","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2018-01008","30137354",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0016326","GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.","O'Connor-Semmes RL","2014","Clinical pharmacology and therapeutics","randomized_trial","article","10.1038/clpt.2014.187","25238251",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016327","[Oral intake of 25 mg semaglutide in adults with overweight or obesity].","Finze A","2026","Chirurgie (Heidelberg, Germany)","other","article","10.1007/s00104-026-02452-x","41575550",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016328","Tirzepatide associated autoimmune encephalitis: A case report.","Abdi A","2025","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2025.102474","40609684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0016329","Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus.","Okada J","2019","Journal of health, population, and nutrition","commentary","article","10.1186/s41043-019-0197-x","31727181","PMC6854662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Letter; article"],["R0016330","The Unmet Medical Needs of Current Injectable Antidiabetic Therapies in China: Patient and Health Care Professional Perspectives.","Chen T","2020","Clinical therapeutics","other","article","10.1016/j.clinthera.2020.06.006","32782136",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0016331","Quieting \"Food Noise\": How GLP-1s and Mindfulness Rewire the Default Mode Network (DMN) and Reward Circuits.","Cook G","2026","Cureus","narrative_review","article","10.7759/cureus.100818","41502834","PMC12770913",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016332","Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation.","Dunn W","2026","Med (New York, N.Y.)","other_trial","article","10.1016/j.medj.2026.101172","42285042",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0016333","Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.","Sanada J","2021","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2021.714447","34484124","PMC8415741",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0016334","Transforming a protease inhibitor into a peptide Guardian: BBI-armed hydrogel beads for Oral delivery of active peptides.","Xu Q","2026","Food research international (Ottawa, Ont.)","preclinical","article","10.1016/j.foodres.2026.119229","42116484",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016335","Uncertainties around incretin-based therapies: A literature review.","Al Tulaihi B","2017","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","randomized_trial","article","10.1016/j.jsps.2015.06.009","28223856","PMC5310157",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0016336","Molecular mechanisms underlying obesity-induced memory dysfunction: a comprehensive narrative review.","Golkar A","2026","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2025.115119","41043536",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016337","Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.","Seino Y","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12276","24524806","PMC4312941",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016338","The semaglutide paradox in non-overweight diabetes: a benefit without explanation.","Shamsulddin AB","2025","European heart journal. Quality of care & clinical outcomes","commentary","article","10.1093/ehjqcco/qcaf082","40796132",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0016339","Dual Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Thyroid Dysfunction Following Tirzepatide Use.","Humaida S","2025","Cureus","case_report","article","10.7759/cureus.85123","40458348","PMC12127604",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016340","Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.","Vergès B","2011","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2011.07.001","21871831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016341","Cardiovascular outcomes with tirzepatide in heart failure with preserved ejection fraction associated with obesity.","Fauchier L","2025","European journal of heart failure","other","article","10.1002/ejhf.70012","40880118",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016342","Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders.","Fiorucci S","2025","Pharmaceuticals (Basel, Switzerland)","other_trial","article","10.3390/ph18091424","41011291","PMC12472620",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016343","[Update on cardiovascular prevention 2025].","Wienbergen H","2025","Herz","narrative_review","article","10.1007/s00059-025-05305-1","40153005",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; English Abstract"],["R0016344","Management of Blood Glucose with Noninsulin Therapies in Type 2 Diabetes.","George CM","2015","American family physician","randomized_trial","article",null,"26132124",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; article"],["R0016345","Application of mechanochemistry to green, scalable, and continuous manufacturing of pharmaceutically relevant peptides by twin-screw extrusion.","Daurio D","2025","Journal of pharmaceutical sciences","other","article","10.1016/j.xphs.2025.103941","40782893",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016346","Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.","Henry R","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13133","29053202",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016347","The power of three: Retatrutide's role in modern obesity and diabetes therapy.","Abdul-Rahman T","2024","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2024.177095","39515565",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016348","Liraglutide ameliorates diabetes-associated cognitive dysfunction via rescuing autophagic flux.","Zhang M","2021","Journal of pharmacological sciences","preclinical","article","10.1016/j.jphs.2021.07.004","34507632",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016349","Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy.","Cesta CE","2024","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2023.6663","38079178","PMC10714281",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0016350","Real-world experience of semaglutide 2.4 mg in the US: a retrospective analysis of profiles, satisfaction, and treatment patterns in people with obesity and overweight.","Zhang Y","2026","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2026.2689307","42312439",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0016351","Cognitive Dysfunction and Dementia in Type 2 Diabetes Mellitus: Insights into Mechanisms, Models, and Therapeutics.","Zeng J","2025","ACS pharmacology & translational science","narrative_review","article","10.1021/acsptsci.5c00086","40810170","PMC12340629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016352","The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.","Gotfredsen CF","2014","Diabetes","other","article","10.2337/db13-1087","24608440",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0016353","Semaglutide Reverses Ectopic Lipid Accumulation, Impaired Myocardial Perfusion Reserve, and Diastolic Dysfunction in a Mouse Model of Cardiometabolic Heart Disease.","Skacel TP","2026","JACC. Basic to translational science","preclinical","article","10.1016/j.jacbts.2026.101554","42090755","PMC13158358",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016354","The causal relationship between anti-diabetic drugs and gastrointestinal disorders: a drug-targeted mendelian randomization study.","Ju M","2024","Diabetology & metabolic syndrome","other","article","10.1186/s13098-024-01359-z","38918852","PMC11201305",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0016355","Investigation of the Transport Pathways Associated with Enhanced Brain Delivery of Peptide Drugs by Intranasal Coadministration with Penetratin.","Kamei N","2021","Pharmaceutics","other","article","10.3390/pharmaceutics13111745","34834159","PMC8618983",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016356","GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis.","Yang Z","2026","Stem cell reports","preclinical","article","10.1016/j.stemcr.2026.103008","42425087","PMC13476890",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016357","Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.","Hu S","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15645","38738340",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0016358","Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice.","Viby NE","2013","Endocrinology","preclinical","article","10.1210/en.2013-1666","24092637",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016359","Quality and reliability of semaglutide content on different Chinese short video platforms: a study focusing on side effects.","Song J","2026","Frontiers in public health","nonrandomized_study","article","10.3389/fpubh.2026.1750738","41815966","PMC12971943",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016360","Liraglutide for the treatment of type 2 diabetes: a clinical update.","Peters KR","2013","American journal of therapeutics","narrative_review","article","10.1097/mjt.0b013e3182204c16","21734532",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0016361","Author Reply to The semaglutide paradox in non-overweight diabetes: a benefit without explanation.","Kishimori T","2025","European heart journal. Quality of care & clinical outcomes","other","article","10.1093/ehjqcco/qcaf090","40826494",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016362","Exendin-4-based imaging in endogenous hyperinsulinemic hypoglycaemia cohort: A tertiary Endocrine centre experience.","Garg R","2020","Clinical endocrinology","nonrandomized_study","article","10.1111/cen.14299","32716527",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016363","Commentary on \"Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study\".","Zhao Y","2026","Hepatology international","nonrandomized_study","article","10.1007/s12072-025-10958-5","41222619",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; editorial"],["R0016364","The NUTRI-OBEDIGITHUM Pathway: Integrating Personalized Exchange-Based Nutrition into Digitally Enabled Obesity Care and a Retrospective Real-World Cohort Analysis.","Vázquez C","2026","Nutrients","nonrandomized_study","article","10.3390/nu18182985","42796969","PMC13609962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0016365","Exenatide extended-release; clinical trials, patient preference, and economic considerations.","Doggrell SA","2013","Patient preference and adherence","other_trial","article","10.2147/ppa.s30627","23341736","PMC3546804",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0016366","'Ozempic, you're able': a festive parody song from the Nature Podcast.","Baker N","2024","Nature","commentary","article","10.1038/d41586-024-04239-8","39719479",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0016367","Maternal GLP-1 receptor activation inhibits fetal growth.","Qiao L","2024","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00361.2023","38197791","PMC11193516",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016368","Dulaglutide: A Review in Type 2 Diabetes.","Burness CB","2015","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","randomized_trial","article","10.1007/s40259-015-0143-4","26423061",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0016369","Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome.","Fransson L","2014","Diabetology & metabolic syndrome","preclinical","article","10.1186/1758-5996-6-3","24423471","PMC3905931",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016370","Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice.","Zhang F","2021","iScience","preclinical","article","10.1016/j.isci.2021.103382","34841227","PMC8605346",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article; preprint"],["R0016371","Effect of semaglutide on mortality and cardiovascular events in patients at high cardiovascular risk: an updated systematic review and meta-analysis.","Spagnolo M","2026","European journal of preventive cardiology","systematic_review","article","10.1093/eurjpc/zwaf358","40567168",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; review"],["R0016372","Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes.","Su Y","2023","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2023.1054946","36755915","PMC9899911","ChiCTR:ChiCTR1900026514",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016373","Insulin resistance and exendin-4 treatment for multiple system atrophy.","Bassil F","2017","Brain : a journal of neurology","other_trial","article","10.1093/brain/awx044","28334990","PMC6248513",null,"S000204","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0016374","Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.","Nahra R","2021","Diabetes care","randomized_trial","article","10.2337/dc20-2151","34016612","PMC8247525","ClinicalTrials.gov:NCT03235050","S000257","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016375","Effects of once-weekly semaglutide in obese/overweight patients: A systematic review and meta-analysis","Wang M","2022","Research Square","systematic_review","preprint","10.21203/rs.3.rs-2346356/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0016376","2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology.","Kittleson MM","2025","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2025.05.008","40512113",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Practice Guideline"],["R0016377","Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months.","Garg SK","2025","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2024.0481","40098470",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0016378","Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-Induced Obesity.","Liu J","2023","Diabetes","preclinical","article","10.2337/db22-0745","37074396","PMC10281235",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; other; article"],["R0016379","Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.","Ferrannini E","2015","European heart journal","narrative_review","article","10.1093/eurheartj/ehv239","26063450",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0016380","Exendin-4(Lys27 PAL)/gastrin/xenin-8-Gln: A novel acylated GLP-1/gastrin/xenin hybrid peptide that improves metabolic status in obese-diabetic (ob/ob) mice.","Hasib A","2019","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.3106","30499633",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016381","New perspectives on semaglutide in cardiovascular disease.","Seferović PM","2025","Lancet (London, England)","other","article","10.1016/s0140-6736(25)01734-9","41206157",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016382","Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects.","Sørensen MS","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16222","39905646","PMC11885084",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016383","GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns.","Dimitriadis GD","2023","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgac704","36507904",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0016384","Cardiovascular Effects of Incretin-Based Therapies.","White WB","2016","Annual review of medicine","other_trial","article","10.1146/annurev-med-050214-013431","26768240",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; review"],["R0016385","Appendicitis After Initiation of Tirzepatide.","Chan G","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","case_report","article","10.2147/dmso.s496739","39906694","PMC11791653",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016386","Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations.","Moradi A","2026","Aesthetic surgery journal. Open forum","other","article","10.1093/asjof/ojag011","41768029","PMC12937588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016387","Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction-associated steatotic liver disease treated with semaglutide: A case series.","Schenker R","2026","JPGN reports","nonrandomized_study","article","10.1002/jpr3.70131","42110146","PMC13150997",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0016388","Liraglutide in type 2 diabetes mellitus.","Baruah MP","2012","Journal of the Indian Medical Association","narrative_review","article",null,"23360033",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016389","Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia.","Peterson G","2011","Hospital practice (1995)","narrative_review","article","10.3810/hp.2011.10.927","22056828",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0016390","Design Differences and Usability Risks in GLP-1 Pen Injectors: A Comparative Study of a Generic and Reference Device.","Brunet-Manquat L","2026","PDA journal of pharmaceutical science and technology","nonrandomized_study","article","10.5731/pdajpst.2025-000043.1","41698692",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0016391","Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.","Li WX","2010","Current therapeutic research, clinical and experimental","systematic_review","article","10.1016/j.curtheres.2010.08.003","24688145","PMC3969618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0016392","GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.","Beiroa D","2014","Diabetes","preclinical","article","10.2337/db14-0302","24917578",null,null,"S002367","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016393","The Effectiveness of Semaglutide on a Composite Endpoint of Glycemic Control and Weight Reduction and Its Effect on Lipid Profile Among Obese Type 2 Diabetes Patients.","Alarfaj SJ","2025","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina61081393","40870438","PMC12387961",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016394","Ion-exchange chromatography for impurity profiling of therapeutic peptides.","Goyon A","2026","Journal of chromatography. A","other","article","10.1016/j.chroma.2026.467292","42531818",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016395","New forms of insulin and insulin therapies for the treatment of type 2 diabetes.","Cahn A","2015","The lancet. Diabetes & endocrinology","nonrandomized_study","article","10.1016/s2213-8587(15)00097-2","26051044",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0016396","Add-on therapies to metformin for type 2 diabetes.","Shomali M","2011","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2011.542150","21142694",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0016397","Cardiovascular Outcomes in Low-Risk Non-Diabetic Patients Treated with Semaglutide","Komatsoulis G","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.05.20.25327768",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0016398","Tirzepatide protects the heart from doxorubicin-induced cardiotoxicity by modulating endoplasmic reticulum (ER) stress and HMGCoA reductase 1 expression.","Glembotski CC","2025","Cardiovascular research","commentary","article","10.1093/cvr/cvaf163","41077767","PMC12551385",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; editorial"],["R0016399","Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.","Natividade GR","2025","JAMA ophthalmology","systematic_review","article","10.1001/jamaophthalmol.2025.2489","40810985","PMC12355393",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; article"],["R0016400","Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.","Mustafa S","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16558","40555685","PMC12326907",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016401","Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH.","Nitze LM","2026","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/apt.70376","40985232","PMC12807327","ClinicalTrials.gov:NCT02970942","S000922","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; research-article; article"],["R0016402","Exploring the Need for Sustained GLP-1 Agonist Therapy: a Perspective on Weight Regain After Bariatric Surgery.","Chang PC","2024","Obesity surgery","commentary","article","10.1007/s11695-024-07229-x","38619774",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0016403","Semaglutide-associated Twiddler syndrome.","Seiler T","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luag103","42100587","PMC13148150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016404","Synergistic effects of Akebia saponin D and Semaglutide on diabetic nephropathy and osteoporosis via the Klotho‑p53 signaling axis.","Zhang Q","2026","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2025.5696","41268608","PMC12651106",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016405","SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.","Bao Y","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16107","39639835",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0016406","Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.","Stoian AP","2020","Journal of cardiovascular pharmacology and therapeutics","narrative_review","article","10.1177/1074248420937868","32618198",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0016407","Time-restricted eating promotes sustained fat loss in Drosophila.","Gatto JA","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.08.05.742897","42845407","PMC13640577",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0016408","Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.","Pieber TR","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12473","25855340",null,"ClinicalTrials.gov:NCT01536665","S002381","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016409","Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.","Drab SR","2010","Pharmacotherapy","randomized_trial","article","10.1592/phco.30.6.609","20500049",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0016410","Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice.","Khin PP","2021","Aging","preclinical","article","10.18632/aging.203546","34537761","PMC8507261",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016411","Proglucagon-derived peptides: human physiology and therapeutic potential.","Gasbjerg LS","2026","Physiological reviews","narrative_review","article","10.1152/physrev.00057.2024","40720286",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0016412","Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide.","Savvidou S","2016","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2015.12.003","26803355",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0016413","Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.","Verma S","2022","Diabetes, obesity & metabolism","other","article","10.1111/dom.14700","35332654","PMC9325529","ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446","S001496; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016414","Clinical trends in Catalonia's Primary Care Setting (2018-2023) in Elderly (≥75 years) and Frail Adults with Type 2 Diabetes.","Ramon-Granés M","2026","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2026.03.010","41916804",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0016415","Efficacy of glucocorticoid modulator PT150 as a weight loss strategy","Glass V","2026","bioRxiv","preclinical","preprint","10.64898/2026.04.06.712688",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016416","Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist.","Lear S","2020","Molecules (Basel, Switzerland)","preclinical","article","10.3390/molecules25112508","32481528","PMC7321126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016417","Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.","Shao H","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-022-01300-5","35930188","PMC9399315",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0016418","Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease.","Muzurović E","2026","Current pharmaceutical design","narrative_review","article","10.2174/0113816128378484250619080753","40641020",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016419","Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.","Petta S","2025","Liver international : official journal of the International Association for the Study of the Liver","other_trial","article","10.1111/liv.70407","41144918","PMC12558666",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0016420","Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.","Calsolaro V","2015","CNS drugs","narrative_review","article","10.1007/s40263-015-0301-8","26666230",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016421","Generation of Potent and Stable GLP-1 Analogues Via \"Serine Ligation\".","Levine PM","2022","ACS chemical biology","other","article","10.1021/acschembio.2c00075","35319882","PMC9173702",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0016422","Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or Obesity.","Færch K","2026","Advances in therapy","randomized_trial","article","10.1007/s12325-026-03507-5","41718940","PMC13065523",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0016423","GLP-1 Receptor Agonists and Kidney Protection.","Greco EV","2019","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina55060233","31159279","PMC6630923",null,"S000485","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Review; review-article; article"],["R0016424","Glycaemic and Cardiometabolic Effects of Oral Semaglutide in Patients Aged ≥65 Years with Type 2 Diabetes","Labate AM","2026","Preprints.org","other","preprint","10.20944/preprints202601.0470.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint; article"],["R0016425","Practical Considerations for the Use of Semaglutide in MASH.","Odenwald MA","2026","The American journal of gastroenterology","other","article","10.14309/ajg.0000000000003816","41128632",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016426","Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.","Varanasi A","2012","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep11169.or","21856595",null,null,"S000404","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016427","Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review.","Deng Y","2022","Therapeutic advances in chronic disease","systematic_review","article","10.1177/20406223221108064","35813188","PMC9260566",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; other; review"],["R0016428","Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.","Igarashi A","2020","Advances in therapy","other_trial","article","10.1007/s12325-020-01476-x","32870471",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0016429","Liraglutide-induced acute kidney injury.","Kaakeh Y","2012","Pharmacotherapy","case_report","article","10.1002/phar.1014","22392833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0016430","Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature.","Zhang X","2021","Medicine","case_report","article","10.1097/md.0000000000025076","33787590","PMC8021326",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Review; case-report; article"],["R0016431","Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.","Knapen LM","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12833","27883260",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0016432","GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.","Panjwani N","2013","Endocrinology","preclinical","article","10.1210/en.2012-1937","23183176",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016433","Semaglutide exerts neuroprotective effects by blocking the interleukin-17/NOD-like receptor family pyrin domain containing 3-mediated neuroinflammation pathway after traumatic brain injury.","Zhang B","2026","Neural regeneration research","preclinical","article","10.4103/nrr.nrr-d-25-00990","41622481","PMC13557656",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016434","Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective.","Dharmalingam M","2014","Therapeutic advances in endocrinology and metabolism","nonrandomized_study","article","10.1177/2042018814552657","25489471","PMC4257981",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0016435","Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.","Knop FK","2023","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(23)01185-6","37385278",null,"ClinicalTrials.gov:NCT05035095","S001472","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; article"],["R0016436","Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials.","Neves JS","2023","Journal of cardiac failure","systematic_review","article","10.1016/j.cardfail.2023.03.017","37028749",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0016437","Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.","Hansen HH","2016","PloS one","preclinical","article","10.1371/journal.pone.0158205","27421117","PMC4946784",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016438","Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide.","Hegedűs ZI","2025","Cardiovascular diabetology","other_trial","article","10.1186/s12933-025-02806-5","40517248","PMC12166642",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0016439","Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes.","LaRue S","2015","Journal of diabetes science and technology","other","article","10.1177/1932296815576186","25759181","PMC4525643",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016440","Tirzepatide-Induced Liver Injury: A Rare Medication Side Effect.","Phox M","2025","ACG case reports journal","case_report","article","10.14309/crj.0000000000001661","40212859","PMC11984778",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016441","Why are we still in need for novel anti-obesity medications?","Novikoff A","2024","The Lancet regional health. Europe","narrative_review","article","10.1016/j.lanepe.2024.101098","39726721","PMC11670685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016442","Associations Between Self-Stigma and Health Promotion Behaviors in Overweight/Obese Patients With Type 2 Diabetes: A Cross-Sectional Study.","Niu S","2025","Journal of diabetes research","other","article","10.1155/jdr/9142949","40458291","PMC12129618",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016443","GLP-1 Agonists in Type 1 Diabetes Mellitus.","Janzen KM","2016","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/1060028016651279","27252246",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0016444","Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.","Fournier M","2014","German medical science : GMS e-journal","randomized_trial","article","10.3205/000199","25332702","PMC4202665",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0016445","Dulaglutide ameliorates chronic stress-induced cognitive impairment via regulating gut microbiota and serum metabolites in mice","Zhang S","2024","Research Square","preclinical","preprint","10.21203/rs.3.rs-5279490/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016446","Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.","Gourgari E","2025","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.24348","40717199","PMC12381612","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT04660643","S000242; S001077; S002157","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0016447","Epac2-dependent mobilization of intracellular Ca²+ by glucagon-like peptide-1 receptor agonist exendin-4 is disrupted in β-cells of phospholipase C-ε knockout mice.","Dzhura I","2010","The Journal of physiology","preclinical","article","10.1113/jphysiol.2010.198424","21041529","PMC3036185",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0016448","Two new doses of dulaglutide (Trulicity) for diabetes.",null,"2020","The Medical letter on drugs and therapeutics","other","article",null,"33429412",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016449","Clinical Review Report: Insulin degludec and liraglutide injection (Xultophy): (Novo Nordisk Canada Inc.): Indication: An adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 U daily) or liraglutide (less than or equal to 1.8 mg daily) do not provide adequate glycemic control",null,"2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"32182001",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0016450","Long-Lasting Exendin-4-Loaded PLGA Nanoparticles Ameliorate Cerebral Ischemia/Reperfusion Evoked Brain Injury and Voiding Dysfunction in Diabetic Rats","Chung C","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-929309/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016451","Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic.","Seier S","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70096","40903862","PMC12587240","OSF:osf.io/86kmc",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; preprint; article"],["R0016452","Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats.","Hernandez NS","2019","Addiction biology","preclinical","article","10.1111/adb.12583","29226617","PMC5995617",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0016453","Body Composition Remodelling During GLP-1-Based Therapy: A Systematic Review and Meta-Analysis Using a Hierarchical Physiological Framework.","Lopes Menezes ML","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71220","42608323","PMC13646380","PROSPERO:CRD420261411693",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; review-article; Review; review"],["R0016454","Idiopathic intracranial hypertension: expanding our understanding.","Markey K","2023","Current opinion in neurology","randomized_trial","article","10.1097/wco.0000000000001209","37865852",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Review; Journal Article; article"],["R0016455","Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.","Østoft SH","2015","Danish medical journal","randomized_trial","article",null,"26324089",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0016456","Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity.","Huang C","2022","ACS medicinal chemistry letters","preclinical","article","10.1021/acsmedchemlett.2c00218","35978702","PMC9377023",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; rapid-communication; article"],["R0016457","Newer Vistas in Glucagon-Like Peptide-1 Analog Therapy - Marvels of Peptide Engineering.","Jacob JJ","2021","Indian journal of endocrinology and metabolism","commentary","article","10.4103/2230-8210.337826","35355912","PMC8959194",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0016458","Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.","Ren Q","2025","Drug design, development and therapy","nonrandomized_study","article","10.2147/dddt.s531778","40631351","PMC12235021",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016459","PIONEER REAL Saudi Arabia: A multicentre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia.","ElBadawi H","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70317","41309294","PMC12803558",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0016460","[Exendin-4 protected murine MIN6 pancreatic beta-cells from oxidative stress-induced apoptosis via down-regulation of NF-kappaB-iNOS-NO pathway].","Liu LB","2008","Yao xue xue bao = Acta pharmaceutica Sinica","preclinical","article",null,"18819471",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016461","Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis.","Yu H","2024","Clinical pharmacokinetics","other","article","10.1007/s40262-023-01337-0","38236561",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016462","Tirzepatide, Mortality, Cardiovascular, and Renal Outcomes in Sleep Apnea: Evidence From Real World Data.","Mazzotti DR","2025","Chest","nonrandomized_study","article","10.1016/j.chest.2025.05.019","40935542",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0016463","Treating Prediabetes With Tirzepatide Helps Obese Patients Lose Weight and Decreases Likelihood of Type 2 Diabetes.","Ebell MH","2025","American family physician","other","article",null,"40961318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016464","Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes.","He L","2013","Journal of diabetes investigation","other","article","10.1111/jdi.12063","24843684","PMC4020234",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016465","Clinical Effectiveness of Semaglutide for Weight Loss in a Veterans Affairs' Anti-Obesity Pharmacotherapy Clinic.","McGinnis T","2026","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-025-09943-3","41233692","PMC13125407",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0016466","Out-of-Pocket Costs among Commercially Insured Individuals with type 2 Diabetes and Obesity: Comparison between Ozempic and Sleeve Gastrectomy.","Edwards MA","2024","Annals of surgery","nonrandomized_study","article","10.1097/sla.0000000000006353","38775477",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016467","Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?","Sohani ZN","2016","Diabetes research and clinical practice","commentary","article","10.1016/j.diabres.2016.04.031","27329019",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016468","Dopamine signalling in pancreatic islet cells and role in adaptations to metabolic stress.","Sridhar A","2024","The Journal of pharmacy and pharmacology","preclinical","article","10.1093/jpp/rgae049","38652540",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016469","Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor.","Rode AKO","2022","Cells","other","article","10.3390/cells11162587","36010663","PMC9406769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016470","Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient.","Costanzo G","2021","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-21-0007","34463640","PMC8428016",null,"S000918","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0016471","The promise of tirzepatide: A narrative review of metabolic benefits.","Sokary S","2025","Primary care diabetes","randomized_trial","article","10.1016/j.pcd.2025.03.008","40221292",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0016472","Preventing obesity-related cancer with the revolution in obesity management: the challenges of undertaking a clinical trial and potential solutions.","Harris M","2026","British journal of cancer","other_trial","article","10.1038/s41416-026-03355-8","41735582","PMC13133257",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016473","Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus.","Diz-Chaves Y","2022","Vitamins and hormones","other","article","10.1016/bs.vh.2021.12.005","35180937",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; book-chapter"],["R0016474","206. EFFECTS OF SEMAGLUTIDE ON BODY WEIGHT IN CLOZAPINE-TREATED INDIVIDUALS WITH SCHIZOPHRENIA AND OBESITY: A RANDOMIZED CONTROLLED TRIAL",null,"2025","The international journal of neuropsychopharmacology","randomized_trial","article",null,null,"PMC12359386",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0016475","Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery.","Hall KD","2024","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.24027","38644683","PMC11132924",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0016476","Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial.","Wiberg S","2016","Circulation","randomized_trial","article","10.1161/circulationaha.116.024088","27838646",null,"ClinicalTrials.gov:NCT02442791","S001005","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0016477","Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss.","Richards JR","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","other","article","10.1111/obr.13709","38320760","PMC11144546",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0016478","A Convergent Hybrid Gram-Scale Synthesis of Tirzepatide: Tangential Flow Filtration Assisted Native Chemical Ligation-Desulfurization Approach.","Jalan A","2026","Angewandte Chemie (International ed. in English)","other","article","10.1002/anie.202520060","41437654",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016479","Is insulin the preferred treatment for HbA1c >9%?","Bloomgarden Z","2017","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.12575","28589542",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0016480","The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial.","Foghsgaard S","2013","BMJ open","protocol","article","10.1136/bmjopen-2013-003834","24176797","PMC3816238","ClinicalTrials.gov:NCT01795248; EudraCT:2012-001371-37","S001419","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; protocol; article"],["R0016481","Pharmacological management of major complications following left ventricular assist device implantation in type 2 diabetes mellitus.","Zhang YL","2025","World journal of diabetes","narrative_review","article","10.4239/wjd.v16.i11.113005","41278442","PMC12635750",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016482","Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.","Sattar N","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00027-0","40318682",null,"ClinicalTrials.gov:NCT03882970","S001591","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0016483","Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.","Niswender K","2013","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2012.01673.x","22862847",null,null,"S001094; S001502; S001584; S002098; S002222; S002230; S002361","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016484","Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.","Hayes MR","2011","Obesity (Silver Spring, Md.)","preclinical","article","10.1038/oby.2011.50","21415845",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0016485","Effect of Once Weekly Semaglutide in Patients with Type 2 Diabetes in National Guard Primary Health Care, Jeddah, Saudi Arabia: a retrospective cohort study.","Alzahrani MA","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3298884/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0016486","Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients.","Buitinga M","2019","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","other","article","10.2967/jnumed.118.219980","30504139",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016487","Effects of Exendin-4 on human adipose tissue inflammation and ECM remodelling.","Pastel E","2016","Nutrition & diabetes","other","article","10.1038/nutd.2016.44","27941938","PMC5223133",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016488","Predicting the response to GLP-1 receptor agonists: an unexpected role for β-arrestin-1.","Sladek R","2023","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(22)00357-6","36528348",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0016489","Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.","Wharton S","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00226-8","40961952",null,"ClinicalTrials.gov:NCT05646706","S001354","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, N.I.H., Extramural; article"],["R0016490","Retatrutide.","Ramsbacher N","2024","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd24-0062","39429457","PMC11486854",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016491","Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study.","Xu Y","2019","PloS one","nonrandomized_study","article","10.1371/journal.pone.0211820","30759121","PMC6373953",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016492","Cardioprotective Mechanisms of Exenatide in Isoprenaline-induced Myocardial Infarction: Novel Effects on Myocardial α-Estrogen Receptor Expression and IGF-1/IGF-2 System.","Darwesh AM","2018","Journal of cardiovascular pharmacology","preclinical","article","10.1097/fjc.0000000000000557","29256971",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016493","Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions.","Kamrul-Hasan ABM","2026","Endocrinology, diabetes & metabolism","narrative_review","article","10.1002/edm2.70307","42581493","PMC13462310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016494","Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis.","Nguefang GL","2026","Orphanet journal of rare diseases","nonrandomized_study","article","10.1186/s13023-026-04322-5","41904481","PMC13047803",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0016495","Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial.","Herman R","2025","Trials","protocol","article","10.1186/s13063-025-09045-9","40847412","PMC12374325","ClinicalTrials.gov:NCT06893211","S001922","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0016496","Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity.","Han J","2018","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2018.07.032","30031858",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016497","Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue.","Samms RJ","2022","Molecular metabolism","preclinical","article","10.1016/j.molmet.2022.101550","35921984","PMC9396640",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016498","Letter by Zhao Regarding Article, \"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial\".","Zhao YT","2026","Circulation","randomized_trial","article","10.1161/circulationaha.125.076451","41525434",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0016499","Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies.","Grigoriou K","2025","Current issues in molecular biology","narrative_review","article","10.3390/cimb47070559","40729028","PMC12293880",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016500","Novel Insights into the Causal Relationship between Antidiabetic Drugs and Adverse Perinatal Outcomes: A Mendelian Randomization Study.","Su C","2025","Diabetes & metabolism journal","other","article","10.4093/dmj.2024.0521","40452211","PMC12620689",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016501","Impact of real-time glucose monitoring using FreeStyle Libre 3 on glycaemia in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial protocol.","Wilmot EG","2025","BMJ open","protocol","article","10.1136/bmjopen-2024-090154","40233956","PMC12182046","ClinicalTrials.gov:NCT05944432",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0016502","Immuno-inflammatory-metabolic interactions in cardiovascular diseases: a review from basic mechanisms to clinical translation.","Zhu X","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1818835","42064066","PMC13124526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016503","IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study.","Malighetti ME","2025","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-024-02361-7","39235480","PMC11872972",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0016504","Influence of pH, Buffering Capacity, Ionic Strength, Bile Salts, and Model Drugs on Micellization Behaviour of Salcaprozate Sodium in Physiological Range pH Buffers.","Akbar S","2026","AAPS PharmSciTech","other","article","10.1208/s12249-026-03424-4","42010013",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016505","Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.","Christensen M","2009","IDrugs : the investigational drugs journal","other_trial","article",null,"19629885",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0016506","Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD.","Seghieri M","2018","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2018.00649","30459715","PMC6232120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016507","Tirzepatide and Hydrochlorothiazide Coadministration in CKD: A Real-World Signal for Hypercalcemia Risk.","Malapati SN","2025","American journal of therapeutics","nonrandomized_study","article","10.1097/mjt.0000000000002041","40748859",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016508","Cardioprotective effects of a 'twincretin' drug tirzepatide in heart failure following myocardial infarction.","Shang R","2025","Cardiovascular research","other_trial","article","10.1093/cvr/cvaf006","39902650","PMC12038244","ClinicalTrials.gov:NCT04255433; ClinicalTrials.gov:NCT05556512","S001921; S002212","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Editorial; Comment; editorial"],["R0016509","GLP-1R/NPY2R regulate gene expression, ovarian and adrenal morphology in HFD mice.","Khan D","2025","The Journal of endocrinology","preclinical","article","10.1530/joe-24-0189","39692365","PMC11798413",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016510","GLP-1 programs the neurovascular landscape.","Chen B","2024","Cell metabolism","narrative_review","article","10.1016/j.cmet.2024.09.003","39357509",null,null,"S002468","pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0016511","Semaglutide-associated psychiatric disorders: A case report and literature review.","Escolà-Rodríguez A","2025","Endocrinologia, diabetes y nutricion","case_report","article","10.1016/j.endien.2025.501613","41173570",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0016512","Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and Japan.","Inoue K","2025","JAMA cardiology","nonrandomized_study","article","10.1001/jamacardio.2025.3109","40991302","PMC12461593",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016513","Pancreatic islet remodeling in cotadutide-treated obese mice.","Spezani R","2023","Life sciences","preclinical","article","10.1016/j.lfs.2023.121858","37315839",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016514","The impact of morbid obesity and metabolic syndrome in elective spine surgery outcomes: A systematic review.","Ferraz VR","2026","North American Spine Society journal","systematic_review","article","10.1016/j.xnsj.2026.100912","42569195","PMC13449414",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0016515","Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.","Kjærgaard K","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71099","42443134","PMC13538804",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016516","Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta-Analysis.","Shi S","2025","Journal of diabetes","systematic_review","article","10.1111/1753-0407.70044","39789833","PMC11717902",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; article"],["R0016517","Opportunities and challenges of incretins-based hypoglycemic agents treating of T2DM from the insight of physiological disposition","Xie Y","2024","Authorea Preprints","other","preprint","10.22541/au.170670903.33408087/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016518","PERSPECTIVE: Beyond the GH-IGF-1 axis: a network perspective integrating clinical observations and mechanistic insights.","Yoshimichi G","2026","Endocrine connections","narrative_review","article","10.1530/ec-26-0317","42319153","PMC13386144",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0016519","Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes.","Kawaguchi Y","2022","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13677","34551215","PMC8902399",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0016520","Lower Risk of Death and Cardiovascular Events in Unselected Type 2 Diabetes Patients Initiated on GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Two Large Italian Cohorts","Baviera M","2020","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-89359/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0016521","In-Home Management of Diabetes and Obesity.","Kowalski S","2024","Home healthcare now","other","article","10.1097/nhh.0000000000001223","38190158",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016522","A Case of an Invisible Pancreatic Neuroendocrine Tumor Decoded by Endoscopic Ultrasound.","Joseph J","2026","Cureus","case_report","article","10.7759/cureus.109296","42326176","PMC13281997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016523","Cerebrovascular Complications of Diabetes: Alpha Glucosidase Inhibitor as Potential Therapy.","Patel SS","2016","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","narrative_review","article","10.1055/s-0035-1565181","26575305",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016524","Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care.","Kattinakere Sreedhara S","2025","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2025-005180","41161770","PMC12574359","ClinicalTrials.gov:NCT05577728","S002308","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Clinical Trial, Phase IV; Comparative Study; research-article; article"],["R0016525","Effect of Liraglutide on Intermittent Hypoxia-Induced Metabolic Dysfunction: From Bench to Bedside.","O'Donnell C","2026","Journal of sleep research","randomized_trial","article","10.1111/jsr.70152","40718907","PMC13003280","ClinicalTrials.gov:NCT04186494","S001827","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016526","Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies.","Williams DM","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-020-00976-x","33417153","PMC7846638",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0016527","Hypertension Associated with the Risk of Extrahepatic Cancers in the Metabolic Dysfunction-associated Steatotic Liver Disease Population: A Multicenter Cross-sectional Study in China.","Zhao X","2026","Journal of clinical and translational hepatology","nonrandomized_study","article","10.14218/jcth.2025.00423","41970195","PMC13063123",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016528","Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review.","Panico C","2023","Cardiovascular diabetology","preclinical","article","10.1186/s12933-023-01855-y","37391739","PMC10314539",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0016529","Puerarin ameliorates hyperglycemia in HFD diabetic mice by promoting β-cell neogenesis via GLP-1R signaling activation.","Wang C","2020","Phytomedicine : international journal of phytotherapy and phytopharmacology","preclinical","article","10.1016/j.phymed.2020.153222","32361558",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016530","Effect of Semaglutide versus placebo on prediabetes, psychotic symptoms, and quality of life (HISTORI): A randomized clinical trial among patients with schizophrenia","Uhrenholt N","2025","European psychiatry : the journal of the Association of European Psychiatrists","randomized_trial","article","10.1192/j.eurpsy.2025.2278",null,"PMC12420184",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0016531","Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats.","Swarbrick MM","2023","Endocrinology, diabetes & metabolism","preclinical","article","10.1002/edm2.392","36480511","PMC9836246",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0016532","Patient With Tirzepatide-treated Type 2 Diabetes With Difficult Visualization During Esophagogastroduodenoscopy.","Dobashi H","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf044","40123805","PMC11925847",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016533","The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials.","Vancampfort D","2019","World psychiatry : official journal of the World Psychiatric Association (WPA)","systematic_review","article","10.1002/wps.20614","30600626","PMC6313230",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; brief-report; article"],["R0016534","The cardiovascular safety of incretin-based therapies: a review of the evidence.","Petrie JR","2013","Cardiovascular diabetology","randomized_trial","article","10.1186/1475-2840-12-130","24011363","PMC3847044",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0016535","GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?","Papaetis GS","2023","Archives of medical sciences. Atherosclerotic diseases","other","article","10.5114/amsad/161170","37153372","PMC10161791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016536","Cardiac energy metabolism in diabetes: emerging therapeutic targets and clinical implications.","Panwar A","2025","American journal of physiology. Heart and circulatory physiology","narrative_review","article","10.1152/ajpheart.00615.2024","40192025",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0016537","Anti-obesity Pharmacotherapy for Transplant Recipients.","Haugen CE","2026","Current atherosclerosis reports","randomized_trial","article","10.1007/s11883-026-01388-1","41575672",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0016538","Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.","Lawitz EJ","2024","Journal of hepatology","randomized_trial","article","10.1016/j.jhep.2024.06.003","38857788",null,"ClinicalTrials.gov:NCT05296733","S000203","pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Clinical Trial, Phase I; Multicenter Study; article"],["R0016539","Understanding the Benefit of Combining GLP-1 Agonists With Exercise: Time Will Tell.","Malin SK","2024","The Journal of clinical endocrinology and metabolism","commentary","article","10.1210/clinem/dgad426","37493062","PMC10795893",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, N.I.H., Extramural; Comment; article-commentary; article"],["R0016540","Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKCε/ERK1/2 pathway.","Zhu Q","2023","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2023.01.049","36706596",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016541","Glucagon-like peptide-1 receptor promotes osteoblast differentiation of dental pulp stem cells and bone formation in a zebrafish scale regeneration model.","Zhai S","2023","Peptides","preclinical","article","10.1016/j.peptides.2023.170974","36775021",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0016542","Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.","Smits MM","2021","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2021.101223","33429063",null,"ClinicalTrials.gov:NCT01744236","S002312","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0016543","Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis.","Zhang X","2018","BMC pharmacology & toxicology","systematic_review","article","10.1186/s40360-018-0246-x","30223891","PMC6142638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0016544","Response to comments on tirzepatide versus bariatric metabolic surgery in adults with obstructive sleep apnea and obesity.","Wu JY","2025","Diabetes research and clinical practice","commentary","article","10.1016/j.diabres.2025.112459","40914231",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016545","Sintilimab-related fulminant autoimmune diabetes mellitus manifesting as diabetic ketoacidosis and rare insulin resistance: A case report and literature review.","Zhang J","2026","Endocrine journal","case_report","article","10.1507/endocrj.ej25-0295","41083372","PMC12819062",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; Review; case-report; article"],["R0016546","Semaglutide (Wegovy) for weight loss.",null,"2021","The Medical letter on drugs and therapeutics","narrative_review","article",null,"34543259",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016547","GLP-1 and exendin-4 transiently enhance GABAA receptor-mediated synaptic and tonic currents in rat hippocampal CA3 pyramidal neurons.","Korol SV","2015","Diabetes","preclinical","article","10.2337/db14-0668","25114295",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016548","Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.","Guzauskas GF","2021","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2021.27.4.455","33769850","PMC10390985",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016549","Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment.","Li X","2015","Clinical interventions in aging","narrative_review","article","10.2147/cia.s74042","25792818","PMC4360697",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016550","[Pathophysiological background for incretin therapy: is it capable of more than we think?].","Haluzík M","2011","Vnitrni lekarstvi","narrative_review","article",null,"22165692",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0016551","A review of immunometabolic crosstalk in PCOS-related pregnancy loss: mechanisms and emerging therapeutic strategies.","Zhang F","2025","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","narrative_review","article","10.1080/09513590.2025.2600160","41384809",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0016552","Lysosome-Associated Membrane Protein 3 Induces Lysosome-Dependent Cell Death by Impairing Autophagic Caspase 8 Degradation in the Salivary Glands of Individuals With Sjögren's Disease.","Nakamura H","2023","Arthritis & rheumatology (Hoboken, N.J.)","preclinical","article","10.1002/art.42540","37096570","PMC11132095",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0016553","Changes in eating behavior and diet-related quality of life in individuals treated with tirzepatide for type 2 diabetes.","Toga-Sato S","2025","Diabetology international","other","article","10.1007/s13340-025-00829-7","41111575","PMC12532984",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016554","Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM).","Heller SR","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13051","28671753","PMC5724506","ClinicalTrials.gov:NCT02072096","S000999","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016555","Exendin-4 Induces Cytotoxic Autophagy in Two Ovarian Cancer Cell Lines through Inhibition of Mtorc1 Mediated by Activation of AMPK and Suppression of Akt.","Badi RM","2020","Folia biologica","preclinical","article","10.14712/fb2020066050186","34087975",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016556","Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.","Fahrbach JL","2016","International journal of clinical practice","systematic_review","article","10.1111/ijcp.12775","26916354",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; article"],["R0016557","Immune-metabolic interactions shape the fibrotic landscape of diabetic kidney disease: emerging mechanisms and therapeutic prospects.","Gao Y","2025","Frontiers in physiology","narrative_review","article","10.3389/fphys.2025.1736472","41648789","PMC12867825",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016558","Metabolic Cardiovascular Renal Disease (Met-CVRD): A New Nomenclature.","Pozzilli P","2025","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.70083","40888594","PMC12400897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article-commentary; article"],["R0016559","Tirzepatide differentially affects body weight in mice and humans.","Novikoff A","2025","Nature reviews. Endocrinology","preclinical","article","10.1038/s41574-025-01139-3","40490496",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016560","Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.","Bergenstal RM","2026","Diabetes care","randomized_trial","article","10.2337/dc25-3055","41925680","PMC13186179",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; research-article; other; article"],["R0016561","The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.","Egecioglu E","2013","PloS one","preclinical","article","10.1371/journal.pone.0077284","24204788","PMC3799694",null,"S002326","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016562","Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution.","Souza M","2026","Alimentary pharmacology & therapeutics","systematic_review","article","10.1111/apt.70565","41645601",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; Comparative Study; Review; article"],["R0016563","Preoperative Glucagon-like Peptide-1 Therapy in Bariatric Surgery Patients With Morbid Obesity (PreMO): Rationale and Study Design for a Randomized Controlled Trial.","Jain V","2026","The Journal of surgical research","protocol","article","10.1016/j.jss.2026.01.004","41643256","PMC13159554","ClinicalTrials.gov:NCT06721507","S000196","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0016564","Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?","Górriz JL","2015","Journal of clinical medicine","narrative_review","article","10.3390/jcm4101866","26512703","PMC4626660",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016565","Overcoming barriers to adherence through innovative injectable medications: A systematic review of therapeutic options for cardiovascular disease, reported adherence, and perspectives on their use.","Bajorek B","2026","British journal of clinical pharmacology","systematic_review","article","10.1002/bcp.70286","41126794",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0016566","Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).","Kuchay MS","2020","Diabetologia","randomized_trial","article","10.1007/s00125-020-05265-7","32865597",null,"ClinicalTrials.gov:NCT03590626","S000993","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016567","Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes.","Denimal D","2023","Cardiovascular diabetology","other_trial","article","10.1186/s12933-023-01845-0","37143040","PMC10158384","ClinicalTrials.gov:NCT02721888","S000705","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0016568","Erratum. Liraglutide Treatment Reverses Unconventional Cellular Defects in Induced Pluripotent Stem Cell-Derived β-Cells Harboring a Partially Functional WFS1 Variant. Diabetes 2025;74:1273-1288.","Torchio S","2025","Diabetes","notice","article","10.2337/db25-er10a","40763279","PMC12451072",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0016569","Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.","Granhall C","2019","Clinical pharmacokinetics","randomized_trial","article","10.1007/s40262-018-0728-4","30565096",null,"ClinicalTrials.gov:NCT01037582; ClinicalTrials.gov:NCT01686945","S000224; S002113","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016570","Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes.","Lisco G","2023","Biomedicines","narrative_review","article","10.3390/biomedicines11112993","38001993","PMC10669051",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016571","Prevalence and risk factors of atherosclerotic cardiovascular disease in Egyptians with type 2 diabetes: findings from the PACT-MEA study and call for action.","Assaad-Khalil SH","2025","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2024-092861","40754331","PMC12320059","ClinicalTrials.gov:NCT05317845",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0016572","[GLP-1 agonists reduce the risk of major cardiovascular events in older patients with type 2 diabetes, and SGLT2 inhibitors prevent hospitalizations for acute heart failure.].","Forte V","2024","Recenti progressi in medicina","other","article","10.1701/4392.43920","39688044",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016573","Correction to: Use of IDegLira to Intensify, Simplify, and Increase Appropriateness of Type 2 Diabetes Therapy: A Real-Life Experience.","Romano I","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-024-01576-9","38634974","PMC11096284",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0016574","Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss.","Udawatta M","2025","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","nonrandomized_study","article","10.1007/s10072-024-07701-7","39030327",null,null,"S002208","pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Preprint; article; preprint"],["R0016575","Synergistic cardioprotection by liraglutide and deferoxamine against doxorubicin-induced cardiotoxicity via modulation of ACSL-4/Nrf-2/GPX-4 signaling.","Monir N","2026","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-026-05646-6","42470452",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016576","Mechanisms of Obesity-Related Kidney Disease: From Adipose Depot Biology to the Chymase-Aldosterone and Ghrelin-Leptin Axes.","Hsu HC","2026","Biomolecules","narrative_review","article","10.3390/biom16081155","42650821","PMC13510496",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016577","Exendin-4 protects Aβ(1-42) oligomer-induced PC12 cell apoptosis.","Qiu C","2016","American journal of translational research","other","article",null,"27648144","PMC5009406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016578","Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro-con debate.","Patel SR","2026","European respiratory review : an official journal of the European Respiratory Society","narrative_review","article","10.1183/16000617.0255-2025","42128481","PMC13169064",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0016579","Semaglutide in Peripheral Artery Disease: A Step Toward Sex-Specific Care.","Salah HM","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2025.09.322","41224404",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0016580","Imaging of the Glucose-Dependent Insulinotropic Polypeptide Receptor Using a Novel Radiolabeled Peptide Rationally Designed Based on Endogenous GIP and Synthetic Exendin-4 Sequences.","Velikyan I","2022","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph16010061","36678558","PMC9864903",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016581","Abnormal response to the anorexic effect of GHS-R inhibitors and exenatide in male Snord116 deletion mouse model for Prader-Willi syndrome.","Lin D","2014","Endocrinology","preclinical","article","10.1210/en.2013-2083","24735326",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016582","Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.","Galindo RJ","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16620","40707399","PMC12409245",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016583","Diabetes mellitus-driven pulmonary injury: multidimensional mechanisms linking metabolic dysregulation to gut-lung axis and promising therapies.","Sun J","2025","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2025.1689522","41208872","PMC12588953",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016584","Journal of Diabetes: Ushering in Volume 10.","Bloomgarden Z","2018","Journal of diabetes","other_trial","article","10.1111/1753-0407.12609","28940787",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; article"],["R0016585","Liraglutide attenuates doxorubicin-induced cardiomyocyte ferroptosis via DHHC7-mediated STAT3 palmitoylation.","Gao G","2025","Life sciences","preclinical","article","10.1016/j.lfs.2025.123912","40819789",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016586","Disparities in diabetes treatment and monitoring for people with and without mental disorders: a systematic review and meta-analysis.","Wagner E","2026","The lancet. Psychiatry","systematic_review","article","10.1016/s2215-0366(25)00332-3","41506273",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0016587","The Impact of a Metformin Recall on Patient Hemoglobin A1c Levels at a VA Network.","Greck BD","2024","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article","10.12788/fp.0523","39839575","PMC11745362",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016588","PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.","Sun Z","2015","Theranostics","preclinical","article","10.7150/thno.10226","25553112","PMC4279188",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0016589","Weight-Dependent and -Independent Effects of Semaglutide in Participants With MASH: Secondary Analysis of the Phase 3 ESSENCE Trial.",null,"2025","Gastroenterology & hepatology","other_trial","article",null,"41660648","PMC12879062",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; other; article"],["R0016590","Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide.","Ge Y","2021","Pharmaceutics","other","article","10.3390/pharmaceutics13060816","34070856","PMC8226777",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016591","Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetes.","Agrawal R","2014","Biochimica et biophysica acta","preclinical","article","10.1016/j.bbadis.2014.05.007","24840661","PMC4372388",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0016592","Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study.","Lin YM","2025","Nature communications","randomized_trial","article","10.1038/s41467-025-59616-2","40368924","PMC12078458",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0016593","Emerging Trends in Endoscopic Bariatric Therapies: Personalization Through Genomics and Synergistic Pharmacotherapy.","Ghusn W","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14134681","40649055","PMC12250154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016594","Obesity-linked genes may promote prostate cancer among Asian and Hispanic immigrants to North America.","Mercola D","2026","Frontiers in public health","narrative_review","article","10.3389/fpubh.2026.1742476","41737617","PMC12926505",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016595","Semaglutide and colorectal tumors: methodological pitfalls and translational gaps - Letter to the Editor.","Sun M","2026","International journal of surgery (London, England)","commentary","article","10.1097/js9.0000000000003790","41202322",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0016596","Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons.","Anand U","2018","PloS one","preclinical","article","10.1371/journal.pone.0198024","29813107","PMC5973579",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016597","Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.","Gu YM","2026","Acta pharmacologica Sinica","other","article","10.1038/s41401-025-01635-2","40847076","PMC12764919",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016598","Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy.","Miao Y","2026","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v17.i2.112867","41696107","PMC12897521",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016599","Semaglutide After Catheter Ablation: A New Chapter in Atrial Fibrillation Care?","Middeldorp ME","2025","Circulation. Arrhythmia and electrophysiology","commentary","article","10.1161/circep.125.014508","41159264",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; editorial"],["R0016600","Comparative effectiveness of Chinese herbal medicine versus liraglutide for weight loss in adults with obesity: A 12-month real-world target trial emulation study.","Liao YN","2026","Integrative medicine research","nonrandomized_study","article","10.1016/j.imr.2026.101291","42500463","PMC13398280",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016601","Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.","Lambadiari V","2018","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-017-0646-z","29310645","PMC5759220","ClinicalTrials.gov:NCT03010683","S000291; S000389; S002327","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0016602","Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.","Lim S","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(25)00164-0","40825340",null,"ClinicalTrials.gov:NCT04998136","S002150","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0016603","Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol.","Purcell AR","2025","BMJ open","protocol","article","10.1136/bmjopen-2024-093775","40962353","PMC12443176","ClinicalTrials.gov:NCT06180616","S000623","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0016604","Combining Abdominal Hernia Repair With Abdominoplasty-Is it Safe?","Alaniz L","2026","Aesthetic surgery journal. Open forum","nonrandomized_study","article","10.1093/asjof/ojag069","42232107","PMC13225315",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016605","Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier.","Tiwari A","2025","Biomedicines","nonrandomized_study","article","10.3390/biomedicines13092079","41007643","PMC12467964",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0016606","Progression to type 2 diabetes among post-myocardial infarction patients with overweight or obesity: a real-world cohort study.","Tonnesen PT","2026","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-026-03085-4","41580697","PMC12911086",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0016607","Partial blockade of Kv2.1 channel potentiates GLP-1's insulinotropic effects in islets and reduces its dose required for improving glucose tolerance in type 2 diabetic male mice.","Sukma Rita R","2015","Endocrinology","preclinical","article","10.1210/en.2014-1728","25337656",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016608","The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.","Barnett AH","2012","Diabetes, obesity & metabolism","other_trial","article","10.1111/j.1463-1326.2011.01523.x","22051096","PMC3488291",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0016609","The prostaglandin E2 EP3 receptor has disparate effects on islet insulin secretion and content in β-cells in a high-fat diet-induced mouse model of obesity.","Neuman JC","2024","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00061.2023","38477664","PMC11376488",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0016610","Daphnetin modulates GLP-1R to alleviate cognitive dysfunction in diabetes: implications for inflammation and oxidative stress.","Liang F","2024","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2024.1438926","39257395","PMC11384579",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016611","Incretin-based therapies: mimetics versus protease inhibitors.","Brubaker PL","2007","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2007.06.005","17629492",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review"],["R0016612","Mental Health Effects of Tirzepatide: A Report of 2 Patients.","Mudd MK","2025","The primary care companion for CNS disorders","other","article","10.4088/pcc.25cr03931","40650872",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016613","Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats.","Baylan U","2022","European journal of clinical investigation","preclinical","article","10.1111/eci.13807","35488737","PMC9539594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016614","Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.","Edvardsson CE","2026","EBioMedicine","preclinical","article","10.1016/j.ebiom.2025.106119","41506148","PMC12808897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016615","Structural factors and their influence on the use of novel antidiabetic agents: Making the case for increased awareness and access to clinical pharmacy services.","Kweyete OMT","2025","Journal of the American College of Clinical Pharmacy : JACCP","other","article","10.1002/jac5.2050","40051646","PMC11880900",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016616","Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists.","Novikoff A","2021","Molecular metabolism","other","article","10.1016/j.molmet.2021.101181","33556643","PMC7921015",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016617","GLP 1 receptor agonists, glycemic variability, oxidative stress and acute coronary syndrome.","Del Olmo García MI","2020","Medical hypotheses","other","article","10.1016/j.mehy.2019.109504","31794876",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016618","Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.","Tekin Uzman D","2026","Hepatology research : the official journal of the Japan Society of Hepatology","commentary","article","10.1111/hepr.70039","40931935",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016619","Incretin pharmacology: a review of the incretin effect and current incretin-based therapies.","Neumiller JJ","2012","Cardiovascular & hematological agents in medicinal chemistry","narrative_review","article","10.2174/187152512803530379","22827291",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0016620","OGT Ameliorates Diabetes-Associated Cognitive Decline via Modulation of DRP1 Function and Mitochondrial Homeostasis.","Li T","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70758","41979043",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016621","Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro.","Vaittinen M","2023","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2023.110635","36958431",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016622","Effects of Incretin-Based Therapies on Neuro-Cardiovascular Dynamic Changes Induced by High Fat Diet in Rats.","Marques-Neto SR","2016","PloS one","preclinical","article","10.1371/journal.pone.0148402","26828649","PMC4735118",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016623","Meta-analysis on GLP-1 mediated modulation of autophagy in islet β-cells: Prospectus for improved wound healing in type 2 diabetes.","Xia W","2024","International wound journal","systematic_review","article","10.1111/iwj.14841","38512120","PMC10956537",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","TRUE","Meta-Analysis; Journal Article; Review; Retracted Publication; review-article; article"],["R0016624","Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4.","Lietzau G","2016","Oncotarget","preclinical","article","10.18632/oncotarget.6823","26744321","PMC4868727",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016625","Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years.","Sabbagh M","2025","Alzheimer's & dementia (New York, N. Y.)","other","article","10.1002/trc2.70076","40337158","PMC12056300",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016626","GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.","Gallwitz B","2011","Handbook of experimental pharmacology","narrative_review","article","10.1007/978-3-642-17214-4_3","21484567",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; book-chapter"],["R0016627","Integrating the management of ultra-processed food addiction into type 2 diabetes care: a clinical response to De Silva et al, (2025) and practical recommendations for practitioners.","Bennett E","2025","Frontiers in psychiatry","randomized_trial","article","10.3389/fpsyt.2025.1653982","41625619","PMC12852319",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0016628","Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies.","Chong K","2024","The Kaohsiung journal of medical sciences","narrative_review","article","10.1002/kjm2.12800","38183334","PMC11895656",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016629","Exendin-4 antagonizes Aβ1-42-induced attenuation of spatial learning and memory ability.","Wang X","2016","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2016.3742","27882091","PMC5103720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016630","Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.","Lorenz M","2013","Regulatory peptides","randomized_trial","article","10.1016/j.regpep.2013.04.001","23665027",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016631","Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes: A systematic review and meta-analysis.","Liang T","2022","Frontiers in nutrition","systematic_review","article","10.3389/fnut.2022.825897","35923194","PMC9339904",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0016632","Medication Use and Self-Care Practices in Persons With Diabetes","Hirsch IB","2023","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)","nonrandomized_study","article",null,"39298640",null,null,null,"europepmc","TRUE","free_to_read","4",null,"Review"],["R0016633","Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study.","Rodríguez-Miguel A","2024","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph17101299","39458940","PMC11510410",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016634","Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.","Hu W","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.927859","35898463","PMC9309474","PROSPERO:CRD42021289121",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; Journal Article; systematic-review; review"],["R0016635","Incretin drugs as modulators of atherosclerosis.","Gallego-Colon E","2018","Atherosclerosis","narrative_review","article","10.1016/j.atherosclerosis.2018.09.011","30248550",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016636","Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet.","Touceda V","2024","Current research in pharmacology and drug discovery","preclinical","article","10.1016/j.crphar.2024.100185","38846009","PMC11153889",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016637","Pioneering pharmacometrics practice in Korea: an eight-year retrospective analysis of 192 projects from the first dedicated service organization (2016-2024).","Lee SJ","2026","Translational and clinical pharmacology","nonrandomized_study","article","10.12793/tcp.2026.34.e4","41969997","PMC13062166",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0016638","Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.","Xu CL","2025","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2025.1622526","40607222","PMC12213378","ClinicalTrials.gov:NCT05990374","S002108","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0016639","Future directions in obesity pharmacotherapy.","Finer N","2021","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2021.04.024","34024701",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016640","Tirzepatide: First Approval.","Syed YY","2022","Drugs","other_trial","article","10.1007/s40265-022-01746-8","35830001",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0016641","Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway.","Wu L","2018","Aging cell","preclinical","article","10.1111/acel.12763","29659121","PMC6052396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016642","Health Benefits In 2025: Family Premiums Rise 6 Percent, Large Employers Increase Coverage Of GLP-1s For Weight Loss.","Claxton G","2025","Health affairs (Project Hope)","other","article","10.1377/hlthaff.2025.01106","41122830",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016643","Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies.","Alkhouri N","2026","Alimentary pharmacology & therapeutics","other_trial","article","10.1111/apt.70639","41941221",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0016644","Semaglutide",null,"2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"31643889",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0016645","Application of Obtainable Biological Agent Characteristics in Efficacy Stratification of Oral Anti-Obesity Drugs","Wang Y","2026","Preprints.org","other","preprint","10.20944/preprints202603.1639.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint; conference-paper"],["R0016646","Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).","Bala C","2022","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2022-060852","35623748","PMC9150149",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016647","Genetic Evidence for GLP-1 and GIP Receptors as Targets for Treatment and Prevention of MASLD/MASH.","Yan R","2025","Liver international : official journal of the International Association for the Study of the Liver","other","article","10.1111/liv.16150","39487684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016648","Recent advances and ongoing challenges in diabetes prevention and control in China.","Geng T","2026","Innovation (Cambridge (Mass.))","narrative_review","article","10.1016/j.xinn.2025.101083","41737324","PMC12925905",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016649","Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi-institutional propensity score-matched study.","Wu JY","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16353","40109063",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Comparative Study; article"],["R0016650","From steatosis to cirrhosis: the role of obesity in the progression of liver disease.","Nowak K","2025","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-025-01754-x","41104308","PMC12521716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016651","GLP-1 receptor agonism in Alzheimer's disease after EVOKE: From single hypothesis to stratified program.","Pereira Da Silva AM","2026","Journal of Alzheimer's disease : JAD","other_trial","article","10.1177/13872877261485580","42720565",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; editorial"],["R0016652","Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).","Nauck M","2014","Diabetes care","randomized_trial","article","10.2337/dc13-2761","24742660","PMC4113177",null,"S000291; S000993","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0016653","Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.","Yang W","2018","Journal of diabetes investigation","systematic_review","article","10.1111/jdi.12764","29047219","PMC6031492",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0016654","Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","Eisa N","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2025.11.018","41419187",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Review; review"],["R0016655","A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease.","Alshehri GH","2025","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2025.177979","40706971",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0016656","Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.","Cincotta AH","2022","International journal of molecular sciences","other","article","10.3390/ijms23168851","36012132","PMC9407769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016657","The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes.","Zomer E","2025","European heart journal. Quality of care & clinical outcomes","other_trial","article","10.1093/ehjqcco/qcae063","39096165",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0016658","Response to the letter to the editor entitled \"Semaglutide and kidney function: direct kidney protection or an artifact?\".","Perkovic V","2025","Kidney international","commentary","article","10.1016/j.kint.2025.07.008","41110891",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0016659","Recent Advances in Individualized Clinical Strategies for Polycystic Ovary Syndrome: Evidence From Clinical Trials and Emerging Pharmacotherapies.","Moka MK","2025","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2024.11.015","39709252",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0016660","Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.","Hunt B","2017","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2017.05.354","28625506",null,"ClinicalTrials.gov:NCT01973231","S001337","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0016661","Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.","Malmenäs M","2013","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2013.03.021","23642290",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016662","Correction: Al-Zamel, N., et al. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor. Int. J. Mol. Sci. 2019, 20, 3532.","Al-Zamel N","2020","International journal of molecular sciences","notice","article","10.3390/ijms21093357","32397501","PMC7246989",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0016663","EBM BLS: Semaglutide Reduces Kidney Disease Progression in Patients with Type 2 Diabetes and Chronic Kidney Disease.","Alemu LS","2026","Journal of general internal medicine","other","article","10.1007/s11606-025-09906-8","41251961","PMC12960894",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0016664","Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020.","Johansson KS","2023","The lancet. Healthy longevity","nonrandomized_study","article","10.1016/s2666-7568(23)00210-6","38042161",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0016665","Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.","Sikirica MV","2017","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s141235","29033597","PMC5630073",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016666","Deciphering Mental Illness: Neurons vs. Neuroglia.","Khan A","2026","Journal of clinical psychopharmacology","narrative_review","article","10.1097/jcp.0000000000002216","42306816","PMC13506203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article-commentary; article"],["R0016667","A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.","Genovese S","2017","Advances in therapy","randomized_trial","article","10.1007/s12325-017-0499-6","28674957","PMC5565650",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0016668","GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.","Zhang ZQ","2020","Peptides","preclinical","article","10.1016/j.peptides.2019.170184","31705913",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016669","Reliability of bioimpedance in the assessment of visceral fat in patients with obesity and metablic syndrome treated with liraglutide for 6 months","RODRIGUES C","2023","Research Square","other","preprint","10.21203/rs.3.rs-2781457/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016670","Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.","Jia S","2021","Acta diabetologica","systematic_review","article","10.1007/s00592-020-01542-4","32514989",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0016671","Combined metformin and exenatide versus only metformin treatments in polycystic ovary syndrome with abdominal obesity and network pharmacology of gene expression: evidence from a randomized clinical trial.","Xuesong D","2025","Therapeutic advances in endocrinology and metabolism","randomized_trial","article","10.1177/20420188251355411","40843067","PMC12365428","ClinicalTrials.gov:NCT04029272","S000952","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0016672","Development and Value of a Centralized Text Message-based Tracking and Support Program for the PRECIDENTD Study.","Nelson LA","2026","Medical care","other","article","10.1097/mlr.0000000000002246","41504753","PMC12783332",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016673","Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.","Keller J","2012","Regulatory peptides","randomized_trial","article","10.1016/j.regpep.2012.08.005","22960288",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016674","New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.","Liu Y","2022","Frontiers of medicine","narrative_review","article","10.1007/s11684-021-0873-2","35226299","PMC8883012",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016675","Comment on \"Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis\".","Zhang C","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70366","41365837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016676","Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner.","Wei R","2016","American journal of physiology. Endocrinology and metabolism","other_trial","article","10.1152/ajpendo.00400.2015","27072494",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; article"],["R0016677","A novel GCGR/GLP-1R dual-agonist TB001 ameliorates kidney fibrosis via inhibiting PERK-mediated endoplasmic reticulum stress pathway.","Lai W","2025","Frontiers in immunology","preclinical","article","10.3389/fimmu.2025.1665860","41280890","PMC12636095",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016678","Therapy for obesity based on gastrointestinal hormones.","Bagger JI","2011","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2011.8.339","22262071","PMC3280668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016679","Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure.","Liu L","2014","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m114.601864","25157099","PMC4207999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0016680","Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics.","Liang J","2025","Lipids in health and disease","preclinical","article","10.1186/s12944-024-02416-2","39794823","PMC11720920",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016681","Association of GLP-1 inhibitors with cardiovascular outcomes in patients undergoing coronary artery bypass surgery.","Hasan I","2026","The Journal of thoracic and cardiovascular surgery","nonrandomized_study","article","10.1016/j.jtcvs.2026.02.005","41713699",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0016682","Adding Semaglutide to SGLT2 Inhibitors Reduces Liver Enzymes in Patients with Type 2 Diabetes Complicated by Metabolic Dysfunction Associated Steatotic Liver Disease: A Retrospective Observational Study.","Sato K","2026","Internal medicine (Tokyo, Japan)","randomized_trial","article","10.2169/internalmedicine.6239-25","41062312","PMC13265098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; research-article; article"],["R0016683","Postprandial Hypotension-Methods for the Evaluation and Management.","Ishikawa J","2026","Geriatrics & gerontology international","narrative_review","article","10.1111/ggi.70456","41918339","PMC13040132",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016684","Post-transplant diabetes mellitus after kidney transplantation: pathogenesis, risk factors, and management strategies.","Long J","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1829579","42130741","PMC13167200",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016685","The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS.","Wang J","2025","Cardiorenal medicine","nonrandomized_study","article","10.1159/000546238","40349689",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016686","Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data.","Chudleigh RA","2020","Diabetes, metabolic syndrome and obesity : targets and therapy","other_trial","article","10.2147/dmso.s193693","32110076","PMC7035886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016687","Post-transcriptional regulation of insulin mRNA storage by G3BP1/2  <sup>+<\/sup>  condensates in beta cells","Quezada E","2024","bioRxiv","preclinical","preprint","10.1101/2024.05.25.595863",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016688","Incretin based therapy in the management of steroid induced diabetes mellitus.","El Ghandour S","2014","Current diabetes reviews","narrative_review","article","10.2174/1573399810666141015102900","25316147",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016689","High-Dose Semaglutide: Balancing Marginal Glycemic Benefits With Tolerability Trade-Offs.","Zhu J","2025","Diabetes care","commentary","article","10.2337/dc25-1048","41115224",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016690","Effectiveness and predictors of weight reduction with low-dose tirzepatide in Japanese patients with type 2 diabetes: A pilot retrospective cohort study.","Kanazawa K","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70062","40874299",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0016691","Obesity-Mediated Inflammation and Its Influence on Inflammatory Bowel Disease: Pathophysiology, Clinical Impact, and Therapeutic Implications.","Casas-Deza D","2025","Biomolecules","randomized_trial","article","10.3390/biom15081185","40867629","PMC12384180",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0016692","[The SOUL trial: a new era for oral semaglutide in reducing cardiovascular risk in high-risk patients with diabetes].","Patti G","2025","Giornale italiano di cardiologia (2006)","other_trial","article","10.1714/4531.45328","40718965",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0016693","The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers.","Shrestha N","2018","Nanoscale","preclinical","article","10.1039/c7nr07736j","29235598",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016694","Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management.","Singh A","2025","Cureus","narrative_review","article","10.7759/cureus.94134","41209959","PMC12594268",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016695","A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond.","Han S","2024","Electrolyte & blood pressure : E & BP","narrative_review","article","10.5049/ebp.2024.22.2.21","39780853","PMC11704317",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016696","Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action.","Meece JD","2014","The Diabetes educator","other_trial","article","10.1177/0145721714527802","24841710",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0016697","Recurrent weight gain after sleeve gastrectomy: conversion to Roux-en-Y gastric bypass versus novel GLP-1 s.","Wasden K","2025","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-025-11910-2","40603615",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Comparative Study"],["R0016698","Long-term preservation of kidney function with SGLT-2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease.","Fadini GP","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16569","40600449","PMC12326893",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0016699","Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.","Shi A","2021","Advances in therapy","randomized_trial","article","10.1007/s12325-020-01548-y","33159658","PMC7854449","ClinicalTrials.gov:NCT03288740","S000680","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0016700","Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics.","Garzon-Escamilla N","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14020316","41751214","PMC12937842",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016701","Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review.","Teshome G","2020","Hepatic medicine : evidence and research","systematic_review","article","10.2147/hmer.s265631","33061687","PMC7522518","PROSPERO:CRD42018087262",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0016702","A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.","Montanya E","2012","Expert opinion on pharmacotherapy","other_trial","article","10.1517/14656566.2012.692777","22725703",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0016703","GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment.","Krass M","2015","Acta neuropsychiatrica","preclinical","article","10.1017/neu.2014.36","25469828",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016704","Treatment-refractory Addictions: Clinical Characterization and an Operational Model for Integrated Management.","Torales J","2026","Current drug research reviews","nonrandomized_study","article","10.2174/0125899775434631260211074804","41941316",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016706","Navigating uncharted waters: long-term implications of GLP-1 agonist use.","Sher T","2024","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","commentary","article","10.1016/j.soard.2024.01.005","38368200",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016707","Glucagon-like peptide-1 treatment reduces the risk of diabetes-type 2 related amputations: A cohort study in Denmark.","Schäfer Z","2023","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2023.110799","37391034",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0016708","Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.","Tobin GS","2012","International journal of clinical practice","randomized_trial","article","10.1111/ijcp.12032","23061886","PMC3549476",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0016709","Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.","Newsome P","2019","Alimentary pharmacology & therapeutics","other_trial","article","10.1111/apt.15316","31246368","PMC6617813",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016710","Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth.","Cornelius P","2026","Frontiers in oncology","preclinical","article","10.3389/fonc.2026.1751681","41789003","PMC12958372",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016711","Assessing Clinical Inertia on Implementing Clinical Guideline Recommendations in Patients with Type 2 Diabetes: A Clinician Survey Study.","Stephenson JJ","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s573007","41907102","PMC13025705",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016712","Management of type 2 diabetes in the new era.","Liakos A","2023","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-023-00488-w","37700155","PMC10651701",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016713","A case of euglycaemic diabetic ketoacidosis in a T2DM patient using Tirzepatide.","Chaudhury N","2025","Postgraduate medical journal","case_report","article","10.1093/postmj/qgaf079","40408634",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016714","GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality.","Anderberg RH","2016","Psychoneuroendocrinology","preclinical","article","10.1016/j.psyneuen.2015.11.021","26724568",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016715","Associations of body mass index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study (a NorthStar substudy).","Malmborg M","2026","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-03062-3","41606731","PMC12922329",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0016716","GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.","Meier JJ","2012","Nature reviews. Endocrinology","narrative_review","article","10.1038/nrendo.2012.140","22945360",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0016717","Semaglutide beyond weight loss: Mechanistic insights and functional paradoxes from the SEMALEAN study.","Samajdar SS","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70242","41145354",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016718","Wegovy: GP pilot scheme could be scrapped after failing to launch.","Mahase E","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1715","39095069",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016719","Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.","Verma S","2025","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2025.08.046","40892617",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0016720","Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.","Larsen JR","2017","JAMA psychiatry","randomized_trial","article","10.1001/jamapsychiatry.2017.1220","28601891","PMC5710254","ClinicalTrials.gov:NCT01845259","S001109","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0016721","Semaglutide can only be responsible for exercise intolerance and muscle wasting after all other causes have been carefully excluded.","Finsterer J","2026","Korean journal of family medicine","commentary","article","10.4082/kjfm.25.0296","41326954","PMC12835673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016722","Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?","Strain WD","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-016-0165-z","27010644","PMC4900975",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016723","Long-Term Assessment of Weight Loss Medications in a Veteran Population.","Rodriguez AD","2024","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article","10.12788/fp.0490","39411075","PMC11473024",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016724","Customizable Click Biochemistry Strategy for the Design and Preparation of Glucagon-like Peptide-1 Conjugates and Coagonists.","Zheng Y","2024","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.4c00169","38700695",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016725","Beyond glycemic control: cardiovascular effects of incretin-based therapies.","Angeli FS","2014","Frontiers of hormone research","narrative_review","article","10.1159/000360598","24943305",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; book-chapter"],["R0016726","Low dose oral semaglutide for obesity . . . and other research.","Nolan T","2025","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.r2050","41067754",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0016727","Comparison of A1c Reduction, Weight Loss, and Changes in Insulin Requirements With Addition of GLP-1 Agonists vs SGLT-2 Inhibitors in Patients Using Multiple Daily Insulin Injections.","Wehrman G","2024","Journal of pharmacy practice","nonrandomized_study","article","10.1177/08971900221134174","36227709",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016728","The Amount of Residual Incretin Regulates the Pancreatic β-cell Function and Glucose Homeostasis.","Kondo T","2021","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.6026-20","33952814","PMC8170253",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016729","Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare.","Dayer VW","2025","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","nonrandomized_study","article","10.1016/j.jval.2025.07.007","40701338",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0016730","Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service.","Johnson H","2026","Journal of medical Internet research","nonrandomized_study","article","10.2196/83718","41538282","PMC12856402",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016731","Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.","He M","2010","PloS one","preclinical","article","10.1371/journal.pone.0014205","21151924","PMC2997064",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016732","Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.","Kadowaki T","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(24)00377-2","40031941",null,"ClinicalTrials.gov:NCT04844918","S001216","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0016733","Letter to Editor on \"As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes\".","Vaishya R","2026","The Journal of arthroplasty","commentary","article","10.1016/j.arth.2025.09.031","41371803",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016734","Control of water intake by a pathway from the nucleus of the solitary tract to the paraventricular hypothalamic nucleus.","Volcko KL","2022","Appetite","other","article","10.1016/j.appet.2022.105943","35131386","PMC9903207",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0016735","Is semaglutide cost-effective at closing the gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity without type 2 diabetes?","Hargovan S","2025","Internal medicine journal","nonrandomized_study","article","10.1111/imj.70160","40693572","PMC12515466",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016736","The effect of exenatide (GLP-1a) and sitagliptin (DPP-4i) on paraoxonase 1 (PON1) activity and expression in normal and fructose-fed rats.","Wójcicka G","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2025.178197","41043573",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016737","SAT-527 Addition of Dulaglutide to Immunosuppressive Therapy Markedly Reduces Insulin Requirements in a Patient with Insulin Antibody-Mediated Resistance",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12543664",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0016738","Effect of Long-term Incretin-Based Therapies on Ischemic Heart Diseases in Patients with Type 2 Diabetes Mellitus: A Network Meta-analysis.","Chou CY","2017","Scientific reports","systematic_review","article","10.1038/s41598-017-16101-1","29150631","PMC5694013",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; article"],["R0016739","GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes.","Tourtourikov I","2026","Pharmacogenetics and genomics","nonrandomized_study","article","10.1097/fpc.0000000000000577","40996853",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016740","Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark.","Hasselbalch RB","2025","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2025.101398","41624087","PMC12859550",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016741","Increased risk of telogen effluvium with tirzepatide compared to other weight loss medications: A retrospective cohort TriNetX database study.","Neubauer Z","2025","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.08.033","40848975",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016742","Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells.","Lu K","2015","Molecular medicine reports","preclinical","article","10.3892/mmr.2015.3682","25936390",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016743","Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2024.12.005","39672540",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Comparative Study; review"],["R0016744","Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus.","Wang RF","2018","Epilepsy research","preclinical","article","10.1016/j.eplepsyres.2018.03.009","29549796",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016745","Activation of Nrf2 contributes to the protective effect of Exendin-4 against angiotensin II-induced vascular smooth muscle cell senescence.","Zhou T","2016","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00093.2016","27488664",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016746","Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.","Maselli D","2022","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23481","35894080","PMC9335902","ClinicalTrials.gov:NCT02647944","S001045","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0016747","Semaglutide and improved spinal fusion outcomes: a correspondence.","Qi Y","2026","International journal of surgery (London, England)","commentary","article","10.1097/js9.0000000000003490","40990673","PMC12825835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; research-article; Journal Article; article"],["R0016748","Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System.","Chiou HC","2019","International journal of molecular sciences","preclinical","article","10.3390/ijms20071584","30934882","PMC6479396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016749","Comparative Efficacy of Endoscopic Sleeve Gastroplasty (Esg) Versus Liraglutide in Weight Loss and Remission Of Obesity-Related Comorbidities: Twelve Months Follow-Up Results.","Nigro S","2025","Obesity surgery","randomized_trial","article","10.1007/s11695-025-08155-2","40779281",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; article"],["R0016750","Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis.","Shankar SS","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","randomized_trial","article","10.1016/j.cgh.2024.04.017","38729399",null,"ClinicalTrials.gov:NCT04019561","S002293","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016751","In Reply \"As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes\".","Seddio AE","2026","The Journal of arthroplasty","commentary","article","10.1016/j.arth.2025.09.029","41371804",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0016752","Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study.","Bolek T","2026","Clinical nutrition ESPEN","other","article","10.1016/j.clnesp.2025.102885","41421448",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016753","Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa.","Henry T","2023","International journal of dermatology","other","article","10.1111/ijd.16892","37897079",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016754","Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites.","Li C","2018","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2018.01.029","29355505",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016755","Adipokine dysregulation and oxidative stress in type 2 diabetes: Implications for neurodegeneration and neuroprotective eff ects of antidiabetic therapies.","Kashmoola IO","2026","Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology","randomized_trial","article",null,"42389857",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Review; article"],["R0016756","Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).","Femminella GD","2020","Trials","notice","article","10.1186/s13063-020-04608-4","32684162","PMC7370449",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0016757","GLP‑1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NF‑κB signaling pathways in streptozotocin‑induced diabetic rats.","Ma J","2018","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2018.3509","29484377",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016758","Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Randomized Clinical Trial.","Brown WA","2025","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2025.39848","41160027","PMC12573037","ANZCTR:ACTRN12617001613392",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016759","Insulin resistance in cancer risk and prognosis.","Jacobo-Tovar E","2025","Seminars in cancer biology","narrative_review","article","10.1016/j.semcancer.2025.06.006","40517920",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016760","Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes.","Nagahisa T","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-019-00680-5","31440988","PMC6778572",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0016761","An overview of new GLP-1 receptor agonists for type 2 diabetes.","Tomlinson B","2016","Expert opinion on investigational drugs","other_trial","article","10.1517/13543784.2016.1123249","26587691",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0016762","The role of GLP-1 receptor agonists in managing type 2 diabetes.",null,"2022","Cleveland Clinic journal of medicine","notice","article",null,"36192028",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Published Erratum"],["R0016763","Managing diabetes in patients with diabetes of long duration.","Triplitt CL","2012","The Diabetes educator","case_report","article","10.1177/0145721712449390","22661393",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0016764","Tirzepatide for Obesity Treatment and Diabetes Prevention.","Birkenfeld AL","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2504728","40561543",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0016765","Short-Term Weight Loss Outcomes of 1.0 mg Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy.","He M","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70006","40964805",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016766","GLP-1 receptor agonists for Parkinson's disease.","Mulvaney CA","2020","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd012990.pub2","32700772","PMC7390475",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; article"],["R0016767","Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.","Khunti K","2016","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12626","26743666","PMC5067688",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016768","Clinical Profile and Prognosis of Patients With Acute Decompensated Heart Failure Who Met the Obesity-Related Eligibility for Subcutaneous Semaglutide　- Findings From the CURE-HF Registry.","Nishikawa K","2025","Circulation reports","nonrandomized_study","article","10.1253/circrep.cr-25-0041","40497126","PMC12149744",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016769","A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model.","Zheng S","2023","Clinical and translational science","preclinical","article","10.1111/cts.13543","37154518","PMC10432867",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016770","Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.","Shenoy A","2026","Gut and liver","other_trial","article","10.5009/gnl260175","42670691","PMC13575885",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016771","From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome.","Lo Re C","2026","Pediatric nephrology (Berlin, Germany)","other_trial","article","10.1007/s00467-025-07046-z","41243004","PMC12852298",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016772","Dual-Target Insight into Drug Discovery from Natural Products as Modulators of GLP-1 and the TXNIP-Thioredoxin Antioxidant System in Metabolic Syndrome.","Agu PC","2025","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox14111364","41300521","PMC12649192",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016773","Diagnostic Challenges in Difficult-to-Localize Insulinomas: A Case Report and Review of Literature.","Grubor NM","2024","Diagnostics (Basel, Switzerland)","case_report","article","10.3390/diagnostics14151600","39125476","PMC11311322",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016774","A Bivalent Protease-Activated Receptor-Derived Peptide Mimics Neuronal Anti-Apoptotic Activity of Activated Protein C.","Sagare A","2025","Bioengineering (Basel, Switzerland)","preclinical","article","10.3390/bioengineering12090899","41007144","PMC12467444",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016775","How would the use of Semaglutide impact the Chilean population? An estimated analysis following the SELECT trial approach.","Petermann-Rocha F","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70260","41177925",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; article"],["R0016776","Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.","Zhou J","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16621","40704485","PMC12409197","ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0016777","Managing metabolic syndrome in bipolar disorder: multidisciplinary monitoring and treatment strategies.","Correia JC","2026","Frontiers in psychiatry","narrative_review","article","10.3389/fpsyt.2026.1699908","42100768","PMC13144086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016778","Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.","Johansen P","2019","Advances in therapy","notice","article","10.1007/s12325-019-00945-2","30980280","PMC6824373",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0016779","Obesity-Related Glomerulosclerosis-How Adiposity Damages the Kidneys.","Zbrzeźniak-Suszczewicz J","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26136247","40650024","PMC12249739",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016780","Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.","MacIsaac RJ","2025","Future cardiology","other_trial","article","10.1080/14796678.2025.2511412","40458885","PMC12258229",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016781","Obstructive sleep apnea and the gut microbiota - mechanisms and opportunities.","Alcock J","2025","Current opinion in pulmonary medicine","narrative_review","article","10.1097/mcp.0000000000001211","40916965",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0016782","Glucagon-like peptide-1 receptor activation maintains extracellular matrix integrity by inhibiting the activity of mitogen-activated protein kinases and activator protein-1.","Peng Y","2021","Free radical biology & medicine","other","article","10.1016/j.freeradbiomed.2021.10.034","34737144",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016783","A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.","Saghazadeh A","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70108","41766347","PMC13131993",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; review-article; review"],["R0016784","Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.","Tzefos M","2012","The Annals of pharmacotherapy","randomized_trial","article","10.1345/aph.1q379","22232377",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0016785","Current diabetes therapy and use of diabetes technology in people living with cystic fibrosis-related diabetes (CFRD): Insights from the DPV network.","Hörtenhuber T","2026","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","nonrandomized_study","article","10.1016/j.jcf.2026.07.002","42498598",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0016786","Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study.","Terauchi Y","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-0604-8","30912033","PMC6531579","ClinicalTrials.gov:NCT02589626","S002442","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0016787","Pregnancy outcomes following first trimester exposure to semaglutide.","Morton A","2026","Obstetric medicine","nonrandomized_study","article","10.1177/1753495x251346330","40487375","PMC12141256",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016788","Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.","Diamant M","2014","Diabetes care","randomized_trial","article","10.2337/dc14-0876","25011946",null,"ClinicalTrials.gov:NCT00960661","S000235; S000236; S000393; S000609","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0016789","Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist.","Pontes-da-Silva RM","2022","International journal of obesity (2005)","preclinical","article","10.1038/s41366-021-00955-7","34465857",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016790","What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?","Pack A","2025","Sleep","other_trial","article","10.1093/sleep/zsaf045","40184186","PMC13142739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0016791","Semaglutide-Induced Lupus Erythematosus With Multiorgan Involvement.","Castellanos V","2024","Cureus","case_report","article","10.7759/cureus.55324","38559525","PMC10981839",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016792","Efficacy of pharmacological and nutritional interventions for glucose dysfunction in schizophrenia-A systematic review and network meta-analysis.","Liu CI","2026","Journal of psychopharmacology (Oxford, England)","systematic_review","article","10.1177/02698811261443680","42104950",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0016793","Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.","Butler J","2024","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(24)00469-0","38599221","PMC11317105","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0016794","Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.","Niu X","2020","RSC advances","preclinical","article","10.1039/d0ra00104j","35495226","PMC9049141",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016795","Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism.","Guo Y","2026","Scientific reports","other","article","10.1038/s41598-026-50299-3","42336886","PMC13574780",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016796","Modulation of circulating extracellular vesicles by antihyperglycemic therapies: A pilot randomized controlled trial.","Baldassarre MPA","2026","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2026.109273","41621217",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016797","'This Is My Decision': A Qualitative Study of Individuals' Perspectives on Use of Semaglutide for Weight Loss.","Graabæk T","2025","Basic & clinical pharmacology & toxicology","other","article","10.1111/bcpt.70069","40521912","PMC12168653",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016798","Non-positive Airway Pressure Therapies for Obstructive Sleep Apnoea and Central Sleep Apnoea.","Mora J","2026","Cardiac failure review","narrative_review","article","10.15420/cfr.2025.24","42775131","PMC13595264",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016799","Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus.","Ke Z","2025","Microbiology spectrum","preclinical","article","10.1128/spectrum.02828-24","40530879","PMC12323307",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016800","Activation of GLP-1 receptors enhances the osteogenic differentiation process of STRO-1-positive BMSCs.","Zhou W","2025","Molecular biology reports","preclinical","article","10.1007/s11033-025-10648-3","40478323","PMC12143992",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016801","Impacts of tirzepatide on older patients with diminished β-cell function and dementia.","Sawamura T","2025","Geriatrics & gerontology international","commentary","article","10.1111/ggi.70018","40001315","PMC11973003",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016802","Effects of oral semaglutide on kidney outcomes in people with type 2 diabetes: a nationwide, multicentre, retrospective, observational study (Renal_ENDO2S-RWD substudy).","Moreno-Pérez O","2025","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfaf227","40800212","PMC12343100",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016803","GLP-1 agonist shortage will last until end of 2024, government warns.","Mahase E","2024","BMJ (Clinical research ed.)","other","article","10.1136/bmj.q28","38182266",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016804","Response to the letter titled \"Targeting dementia prevention with semaglutide: the case for APOE4 homozygotes\".","Xu R","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","commentary","article","10.1002/alz.70423","40572020","PMC12202463",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016805","Restoring Satiety After GLP-1/GIP Pharmacotherapy: Metabolic Stability, Diet Quality, and the Gut Microbiota.","Lasik L","2026","International journal of molecular sciences","other_trial","article","10.3390/ijms27114658","42278190","PMC13257195",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016806","Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?","Meral R","2025","Diabetes care","nonrandomized_study","article","10.2337/dc24-2408","40063619","PMC12034899",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article; other"],["R0016807","Safety and Effectiveness of Tirzepatide in Solid-Organ Transplant Recipients.","Sweiss H","2025","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds24-0071","40823610","PMC12357208",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016808","Glucagon-like peptide-1 inhibits the progression of abdominal aortic aneurysm in mice:The earlier the better","Zhao X","2023","Research Square","preclinical","preprint","10.21203/rs.3.rs-2502990/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016809","Exendin-4 analogs in insulinoma theranostics.","Jansen TJP","2019","Journal of labelled compounds & radiopharmaceuticals","narrative_review","article","10.1002/jlcr.3750","31070270","PMC6771680",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0016810","Periodontal disease and endocrine imbalance: a molecular pathways perspective.","Martínez-García M","2026","Frontiers in dental medicine","narrative_review","article","10.3389/fdmed.2026.1886028","42539866","PMC13424463",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016811","GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale.","Rosenkilde MM","2025","Diabetes","other_trial","article","10.2337/dbi24-0027","40521869","PMC12278783",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016812","A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities.","He M","2012","Acta pharmacologica Sinica","narrative_review","article","10.1038/aps.2011.169","22301855","PMC4010345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0016813","Cagrilintide plus semaglutide for obesity management.","Becerril S","2021","Lancet (London, England)","commentary","article","10.1016/s0140-6736(21)00944-2","33894837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0016814","Implications of incretin-based therapies on cardiovascular disease.","Rotz ME","2015","International journal of clinical practice","randomized_trial","article","10.1111/ijcp.12572","25363540",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0016815","Bone Marrow-Derived Mesenchymal Stem Cells and Pioglitazone or Exendin-4 Synergistically Improve Insulin Resistance via Multiple Modulatory Mechanisms in High-Fat Diet/Streptozotocin-Induced Diabetes in Rats.","Mesbah Mohamed M","2023","Reports of biochemistry & molecular biology","preclinical","article","10.52547/rbmb.12.1.42","37724145","PMC10505456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016816","Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.","Blonde L","2015","Cardiovascular diabetology","other","article","10.1186/s12933-014-0171-2","25645567","PMC4324846",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016817","Add-on value of tirzepatide versus semaglutide.","Scheen AJ","2022","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(22)00116-4","35468323",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0016818","Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model.","Hur J","2021","Pulmonary pharmacology & therapeutics","preclinical","article","10.1016/j.pupt.2021.102003","33588055",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016819","Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.","Gough SC","2014","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(14)70174-3","25190523",null,"ClinicalTrials.gov:NCT01336023","S001276","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0016820","Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi-centric observational study.","Bilic-Curcic I","2022","European review for medical and pharmacological sciences","nonrandomized_study","article","10.26355/eurrev_202204_28608","35503623",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0016821","Cardiovascular Effectiveness and Safety of Antidiabetic Drugs in Patients with Type 2 Diabetes and Peripheral Artery Disease: Systematic Review.","Cimellaro A","2024","Medicina (Kaunas, Lithuania)","systematic_review","article","10.3390/medicina60091542","39336583","PMC11434261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0016822","Redemptive narratives of remission: agency, free will and type 2 diabetes in the era of Ozempic.","Murphy KF","2026","Medical humanities","other","article","10.1136/medhum-2026-014041","42373312",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016823","Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice.","Zhang WY","2019","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2019.04.160","31047638",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016824","Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience.","Foltynie T","2020","Progress in brain research","randomized_trial","article","10.1016/bs.pbr.2019.10.008","32247373",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0016825","Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).","Berra CC","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.1099451","36743930","PMC9889982",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016826","Semaglutide in HFpEF and Obesity: Targeting Both for Functional Gains.","Carbone S","2025","JACC. Heart failure","commentary","article","10.1016/j.jchf.2025.102665","40992091",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0016827","A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.","Coulter-Parkhill A","2023","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2023.115544","37044298",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016828","Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKD.","Karalliedde J","2025","Kidney international reports","other","article","10.1016/j.ekir.2025.07.028","41141497","PMC12545811",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0016829","Bibliometric analysis of global research trends on the relationship between alzheimer's disease and type 2 diabetes mellitus.","da Silva AMP","2026","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-025-01812-4","41451400","PMC12728145",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0016830","Comparison of MAESTRO-NASH and ESSENCE: Effects of Resmetirom and Semaglutide Relative to Placebo on Primary and Secondary Liver Biopsy Endpoints Using Aligned Endpoints and Statistical Methods.",null,"2025","Gastroenterology & hepatology","other","article",null,"41660652","PMC12879040",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other; article"],["R0016831","Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.","Hunter Gibble T","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16330","40084533","PMC12046461",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016832","Synthesis and pharmaceutical characterization of site specific mycophenolic acid-modified Xenopus glucagon-like peptide-1 analogs.","Han J","2018","MedChemComm","preclinical","article","10.1039/c7md00471k","30108901","PMC6072475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016833","Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.","Kaneko S","2022","TouchREVIEWS in endocrinology","other_trial","article","10.17925/ee.2022.18.1.10","35949358","PMC9354517","ClinicalTrials.gov:NCT04255433","S001795; S002212","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016834","Clinical Outcomes After Hospitalization for Acute Coronary Syndrome in Patients Treated with Semaglutide Versus Bariatric Surgery: A Retrospective Multicenter Analysis.","Ascandar N","2025","HCA healthcare journal of medicine","nonrandomized_study","article","10.36518/2689-0216.1960","40642578","PMC12240409",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016835","A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer.","Jaiswal P","2021","Current cancer drug targets","narrative_review","article","10.2174/1568009621666210901101851","34468298",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0016836","The Impact of GLP-1 RAs and DPP-4is on Hospitalisation and Mortality in the COVID-19 Era: A Two-Year Observational Study.","Greco S","2023","Biomedicines","nonrandomized_study","article","10.3390/biomedicines11082292","37626788","PMC10452157",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016837","[SURMOUNT-OSA study : tirzepatide improves obstructive sleep apnoea in patients with obesity].","Scheen A","2025","Revue medicale de Liege","other","article",null,"40243250",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0016838","Obesity as a Multifactorial Chronic Disease: Molecular Mechanisms, Systemic Impact, and Emerging Digital Interventions.","Młynarska E","2025","Current issues in molecular biology","narrative_review","article","10.3390/cimb47100787","41150735","PMC12564886",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016839","Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System.","Daniele G","2015","Diabetes","randomized_trial","article","10.2337/db14-1718","26116695","PMC6908417","ClinicalTrials.gov:NCT01588418","S001239","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016840","Rewriting the will: Autonomy and pharmacological desire modification in semaglutide use.","Frant J","2026","Journal of medical ethics","other","article","10.1136/jme-2025-111137","41033788",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016841","GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.","Han Y","2019","Reproductive biomedicine online","systematic_review","article","10.1016/j.rbmo.2019.04.017","31229399",null,null,"S001012; S002080","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review"],["R0016842","Automated Insulin Delivery for Patients with Type 2 Diabetes: A Narrative Review.","Kitsios K","2026","Current diabetes reviews","randomized_trial","article","10.2174/0115733998418695251203105337","41788003",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; review"],["R0016843","Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial.","Ghosh S","2025","Cardiovascular diabetology. Endocrinology reports","other_trial","article","10.1186/s40842-025-00219-7","41013709","PMC11964147",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0016844","From Endoscopic Inspection to Gene-Expression: A Thorough Assessment of the Duodenal Mucosa After Resurfacing-A Prospective Study.","Meiring S","2025","Digestive diseases and sciences","other","article","10.1007/s10620-024-08710-4","39779586","PMC11920325",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016845","Multi-ancestry Transcriptome-Wide Association Study (TWAS)-Informed Prioritization of Antipsychotic Metabolic Risk: Evaluation of GLP1R as a Shared Mechanistic Link.","Cheung N","2026","Cureus","nonrandomized_study","article","10.7759/cureus.112759","42465707","PMC13373678",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016846","Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.","Deanfield J","2025","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(25)01375-3","41138739",null,"ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0016847","The need to address the risk of osteosarcopenia induced by tirzepatide therapy.","De Mattia G","2025","Clinical and experimental rheumatology","commentary","article","10.55563/clinexprheumatol/el8zor","40556629",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016848","Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India.","Dutta A","2024","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/ijem.ijem_266_24","39881769","PMC11774408",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016849","Semaglutide in the treatment of a patient with type 2 diabetes mellitus, psoriasis, and metabolic dysfunction-associated steatotic liver disease: a case report.","Lin B","2025","Frontiers in medicine","case_report","article","10.3389/fmed.2025.1684204","41020234","PMC12463625",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016850","Metabolic Syndrome and Periodontitis-From Shared Mechanisms to Interdisciplinary Care: A Narrative Review of Clinical Evidence.","Gherbon AM","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15145510","42513424","PMC13412585",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0016851","GLP-1 mimetics and cognition.","Yaribeygi H","2021","Life sciences","narrative_review","article","10.1016/j.lfs.2020.118645","33121988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016852","Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.","Li W","2024","Cell discovery","other_trial","article","10.1038/s41421-024-00700-0","39019866","PMC11255275",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0016853","Cotadutide (GLP-1/Glucagon dual receptor agonist) modulates hypothalamic orexigenic and anorexigenic neuropeptides in obese mice.","Spezani R","2024","Peptides","preclinical","article","10.1016/j.peptides.2023.171138","38147963",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016854","Inhibiting or antagonizing glucagon: making progress in diabetes care.","Lefèbvre PJ","2015","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12480","25924114",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016855","Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales.","Dahlén AD","2021","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2021.807548","35126141","PMC8807560",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016856","Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes.","Fala L","2015","American health & drug benefits","other","article",null,"26629278","PMC4665063",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; research-article; article"],["R0016857","Dulaglutide Alleviates Alzheimer's Disease by Regulating Microglial Polarization and Neurogenic Activity.","Wang Y","2025","Combinatorial chemistry & high throughput screening","preclinical","article","10.2174/1386207325666220726163514","35894460",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016858","Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes in spite of new drugs: analysis based on health insurance data from Germany.","Müller N","2017","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.13397","28586530",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016859","Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease.","Kishimori T","2025","Open heart","nonrandomized_study","article","10.1136/openhrt-2025-003382","40628673","PMC12243591",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0016860","From weight loss to muscle loss: rhabdomyolysis linked to semaglutide.","Jadvani R","2025","Clinical kidney journal","case_report","article","10.1093/ckj/sfaf356","41383908","PMC12690205",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016861","Euglycemic Ketoacidosis in a Non-diabetic Patient After Tirzepatide Use: A Cautionary Tale.","Singh R","2025","Cureus","case_report","article","10.7759/cureus.83187","40443633","PMC12121683",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016862","Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials.","Mansour MEM","2026","Journal of psychopharmacology (Oxford, England)","systematic_review","article","10.1177/02698811251399544","41439550",null,"PROSPERO:CRD42024599597",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; review"],["R0016863","An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice.","Lu W","2020","British journal of pharmacology","preclinical","article","10.1111/bph.15069","32293707","PMC7348098",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016864","Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.","Cui X","2025","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.202407494","39868848","PMC11923992",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016865","The impact of semaglutide on peri-operative cardiovascular outcomes in diabetes.","Castrillon F","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70145","40988574",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0016866","Treating the obese diabetic.","Kenkre J","2013","Expert review of clinical pharmacology","narrative_review","article","10.1586/ecp.13.5","23473594",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016867","Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.","Ruseva A","2025","Advances in therapy","nonrandomized_study","article","10.1007/s12325-025-03320-6","40768189","PMC12474578",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Comparative Study; research-article; article"],["R0016868","Semaglutide versus caloric restriction-induced weight loss: insights into effects on skeletal muscle mass and function.","Shah H","2025","The Journal of physiology","other","article","10.1113/jp290060","41137723",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016869","Atrial Fibrillation Risk Management and Emerging Therapies.","Vaughan M","2026","Journal of clinical medicine","randomized_trial","article","10.3390/jcm15124612","42355780","PMC13301562",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; Preprint; preprint; article"],["R0016870","Exendin-4 exhibits a tumour suppressor effect in SKOVR-3 and OVACR-3 ovarian cancer cells lines by the activation of SIRT1 and inhibition of NF-κB.","Khaleel EF","2020","Clinical and experimental pharmacology & physiology","other","article","10.1111/1440-1681.13288","32072679",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016871","A role for vagal activity in preventing the suppression of glucagon secretion by GLP-1 during hypoglycemia.","Lobato CB","2026","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00236.2025","41973537",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016872","Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.","Shomali M","2014","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/diaclin.32.1.32","26246677","PMC4521427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016873","Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.","Arai T","2025","Hepatology research : the official journal of the Japan Society of Hepatology","other_trial","article","10.1111/hepr.14241","40616360",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0016874","A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.","Johansen P","2019","Advances in therapy","other","article","10.1007/s12325-019-00915-8","30875029","PMC6824375",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0016875","Life-Threatening Ventricular Fibrillation Linked to High-Dose Tirzepatide-Induced Gastrointestinal Side Effects.","Kammaripalle TKC","2025","Cureus","case_report","article","10.7759/cureus.85366","40621252","PMC12227335",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0016876","Exenatide modulates metalloproteinase expression in human cardiac smooth muscle cells via the inhibition of Akt signaling pathway.","Gallego-Colon E","2018","Pharmacological reports : PR","other","article","10.1016/j.pharep.2017.10.003","29414148",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016877","Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.","Wang F","2025","European journal of medical research","systematic_review","article","10.1186/s40001-025-02801-2","40696486","PMC12281775",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Review; review-article; review"],["R0016878","Tirzepatide in Obesity-Related Heart Failure With Preserved EF: Weight Loss and Structural Adaptations.","Fauchier L","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2025.03.549","40562517",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0016879","Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin.","Shibuki K","2022","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2022.102474","35378386",null,"PROSPERO:CRD42021178888",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0016880","Correlates of second-line type 2 diabetes medication selection in the USA.","Ackermann RT","2017","BMJ open diabetes research & care","other","article","10.1136/bmjdrc-2017-000421","29225892","PMC5706487",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016881","The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population.","Petrakis V","2026","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","nonrandomized_study","article","10.1055/a-2737-6227","41187787",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0016882","Very low-calorie ketogenic diet and liraglutide as a synergistic strategy for the treatment of obesity: A short-term, non-randomised, observational, real-world clinical evaluation.","Camajani E","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16658","40734597","PMC12409220",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0016883","The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.","Ng NBH","2022","Clinical endocrinology","systematic_review","article","10.1111/cen.14583","34448208",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0016884","Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.","Holscher C","2010","Recent patents on CNS drug discovery","preclinical","article","10.2174/157488910791213130","20337586",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016885","Incretin drugs effect on epigenetic machinery: New potential therapeutic implications in preventing vascular diabetic complications.","Scisciola L","2020","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","other","article","10.1096/fj.202000860rr","33090591",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016886","Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres.","Li T","2021","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2020.10.008","33122118",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016887","GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice.","Itoh A","2017","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2017.05.013","28684145",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016888","Monitoring β-Cell Survival After Intrahepatic Islet Transplantation Using Dynamic Exendin PET Imaging: A Proof-of-Concept Study in Individuals With Type 1 Diabetes.","Jansen TJP","2023","Diabetes","other","article","10.2337/db22-0884","37068261",null,"ClinicalTrials.gov:NCT03785236","S003392","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016889","Weight response to GLP-1 receptor agonists: Why women do it better?","Jensterle M","2022","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2022.108310","36150366",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016890","Prevalence and Incidence of Medication-Treated Diabetes and Pattern of Glucose-Lowering Treatment During the COVID-19 Pandemic: Real-World Data from the Electronic Greek Prescription Database.","Siafarikas C","2024","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","nonrandomized_study","article","10.1055/a-2307-4631","38626912",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016891","Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.","Heerspink HJL","2025","Journal of the American Society of Nephrology : JASN","randomized_trial","article","10.1681/asn.0000000764","40512543","PMC12591676","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657003; ClinicalTrials.gov:NCT05536804","S000200; S001077; S001712","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0016892","Therapeutic Benefit or Ocular Risk? Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy [RETRACTED].","Suhayya Batool","2025","Retina (Philadelphia, Pa.)","other","article","10.1097/iae.0000000000004709","41144820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"TRUE","Journal Article; Retracted Publication; article"],["R0016893","Preliminary evaluation of 18F‑AlF‑NOTA‑MAL‑Cys40‑Exendin‑4 in rodent heart after myocardial ischemia and reperfusion.","Pan X","2019","Molecular medicine reports","preclinical","article","10.3892/mmr.2019.10432","31257516","PMC6691274",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016894","The discovery of peptides used for the treatment of diabetes/obesity: A personal journey.","Marks V","2023","Peptides","commentary","article","10.1016/j.peptides.2023.171115","37924847",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0016895","Structure-Property-Performance Engineering of Hydrogel Depots for Long-Acting Peptide Delivery.","Dong C","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.05.17.725768","42239112","PMC13228347",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0016896","A Cross-Sectional Analysis of Plastic Surgery With GLP-1-Related Content on TikTok.","Gupta R","2026","Aesthetic surgery journal. Open forum","other","article","10.1093/asjof/ojag094","42518992","PMC13384429",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016897","Dulaglutide mitigates high dietary fructose-induced renal fibrosis in rats through suppressing epithelial-mesenchymal transition mediated by GSK-3β/TGF-β1/Smad3 signaling pathways.","Mohamad HE","2022","Life sciences","preclinical","article","10.1016/j.lfs.2022.120999","36182846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"TRUE","Journal Article; Retracted Publication; article"],["R0016898","Incretin-based therapies in prediabetes: Current evidence and future perspectives.","Papaetis GS","2014","World journal of diabetes","narrative_review","article","10.4239/wjd.v5.i6.817","25512784","PMC4265868",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016899","Fatty Pancreas: Its Potential as a Risk Factor for Pancreatic Cancer and Clinical Implications.","Otsuka N","2025","Cancers","narrative_review","article","10.3390/cancers17111765","40507246","PMC12153785",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016900","Daily Briefing: Drugs like Ozempic seem to help everything from Alzheimer's to infertility. But how?","Graham F","2024","Nature","commentary","article","10.1038/d41586-024-03166-y","39327515",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0016901","SUN-444 Hydrocortisone Absorption While on Tirzepatide",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545464",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0016902","Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.","Jamialahamdi T","2025","Obesity surgery","systematic_review","article","10.1007/s11695-025-07848-y","40418526",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0016903","Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.","Tchang BG","2025","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.24254","40074721","PMC12015656",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0016904","SAT680 Mounjaro: A Side Effect",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10553921",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0016905","SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?","Patoulias D","2022","Journal of clinical and translational hepatology","other","article","10.14218/jcth.2022.00278","36062276","PMC9396330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0016906","Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.","Ji L","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70031","40843773","PMC12515755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0016907","GLP1 receptor agonism alters growth and therapeutic response in prostate cancer.","Bera S","2025","Endocrine-related cancer","other","article","10.1530/erc-25-0185","41257454","PMC12713343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016908","Letter to the editor: Semaglutide-associated recurrent distal intestinal obstruction in cystic fibrosis.","Kamoua R","2026","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","commentary","article","10.1016/j.jcf.2025.09.007","41027812",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0016909","PSUN113 Evaluating The Efficacy Of Anti-Obesity Medications In a Multidisciplinary Weight Management Clinic At a VA Medical Center",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9627143",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0016910","GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight.","Monti G","2022","Cells","preclinical","article","10.3390/cells11132023","35805109","PMC9265397",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0016911","Dual behavior of histidine during sensitized photo-oxidation of model compounds and proteins.","Frąckowiak KJ","2024","Free radical biology & medicine","other","article","10.1016/j.freeradbiomed.2024.08.040","39241987",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0016912","Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.","Glaesner W","2010","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.1080","20503261",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016913","Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study.","Zhao Y","2024","Progress in neuro-psychopharmacology & biological psychiatry","nonrandomized_study","article","10.1016/j.pnpbp.2024.111128","39181309",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0016914","The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.","Sillassen CDB","2025","BMC medicine","systematic_review","article","10.1186/s12916-025-04486-0","41286875","PMC12642075","PROSPERO:CRD42024499511",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0016915","Proinflammatory switch from Gαs to Gαi signaling by Glucagon-like peptide-1 receptor in murine splenic monocyte following burn injury.","Zhang QH","2018","Inflammation research : official journal of the European Histamine Research Society ... [et al.]","preclinical","article","10.1007/s00011-017-1104-9","29022064",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016916","Five years liraglutide treatment improves glucose tolerance in women with previous gestational diabetes mellitus-Results from a randomised controlled trial.","Andersen ES","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70286","41208570",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0016917","Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.","Palermo A","2015","Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","narrative_review","article","10.1007/s00198-015-3123-0","25910746",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016918","MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)","Samson S","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-mon-lb079",null,"PMC6550842","ClinicalTrials.gov:NCT02060383","S002111","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; article"],["R0016919","Comment on Komé et al. One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.","Tejera-Pérez C","2025","Diabetes care","commentary","article","10.2337/dc25-0566","40540673","PMC12178608",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0016920","[Oral semaglutide: why we can no longer do without it?].","Temporelli PL","2025","Giornale italiano di cardiologia (2006)","other","article","10.1714/4488.44883","40292501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016921","The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?","Jung HN","2022","Journal of obesity & metabolic syndrome","randomized_trial","article","10.7570/jomes22012","35314521","PMC8987449",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0016922","Diabetic ketoacidosis in a patient with type I diabetes treated with tirzepatide.","Roche E","2025","Acta diabetologica","other","article","10.1007/s00592-025-02535-x","40471291",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016923","Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents.","Vallöf D","2019","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2019.02.020","30772374",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016924","Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.","Eng C","2014","Lancet (London, England)","systematic_review","article","10.1016/s0140-6736(14)61335-0","25220191",null,null,"S000485","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0016925","Retracted: GLP-1 Analog Alleviated Cognitive Dysfunction in Aged Rats Anaesthetized with Sevoflurane.","International BR","2023","BioMed research international","notice","article","10.1155/2023/9862825","38188842","PMC10769629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; article"],["R0016926","Medical Management of Coronary Artery Disease: An Update.","Hullon D","2025","The International journal of angiology : official publication of the International College of Angiology, Inc","randomized_trial","article","10.1055/a-2645-8838","41210669","PMC12591713",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0016927","Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?","Seetharaman R","2024","Journal of basic and clinical physiology and pharmacology","commentary","article","10.1515/jbcpp-2023-0234","38048046",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0016928","Weekly Journal Scan: long-term effects of tirzepatide for diabetes prevention in persons with obesity and prediabetes.","Pedicino D","2025","European heart journal","other_trial","article","10.1093/eurheartj/ehaf236","40249363",null,"ClinicalTrials.gov:NCT05822830; ClinicalTrials.gov:NCT05556512","S000093; S001921","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0016929","Preparation and Therapeutic Evaluation of Engineered Semaglutide and Statin-Lipid Conjugate-Based Nanoparticle.","Lee KJ","2025","Pharmaceutics","other","article","10.3390/pharmaceutics17040480","40284475","PMC12030043",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016930","Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonizts.","Zhou F","2022","Peptides","preclinical","article","10.1016/j.peptides.2022.170811","35594964",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0016931","New drugs approved by European medicines agency during 2024.","Hu R","2025","European journal of medicinal chemistry","narrative_review","article","10.1016/j.ejmech.2025.117761","40409054",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016932","Parkinson's Disease and glucose dysregulation: shared pathophysiological mechanisms and clinical implications.","Chmiela T","2025","Neurologia i neurochirurgia polska","narrative_review","article","10.5603/pjnns.104405","40387205",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016933","Effects of liraglutide on β-cell-specific glucokinase-deficient neonatal mice.","Shirakawa J","2012","Endocrinology","preclinical","article","10.1210/en.2012-1165","22569791",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016934","Semaglutide in overweight non-diabetic peritoneal dialysis patients: a real-world single-center experience.","Paribello G","2025","Journal of nephrology","nonrandomized_study","article","10.1007/s40620-025-02453-9","41060612",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0016935","Nephroprotective effects of GLP-1 receptor agonists: where do we stand?","Mosterd CM","2020","Journal of nephrology","other_trial","article","10.1007/s40620-020-00738-9","32356231","PMC7560915",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0016936","High glucose impairs cognitive function through inducing mitochondrial calcium overload in Treg cells.","Hui Y","2024","iScience","other","article","10.1016/j.isci.2023.108689","38226157","PMC10788441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016937","Interventions for Weight Management in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.","O'Connor EA","2024","JAMA","systematic_review","article","10.1001/jama.2024.6739","38888913",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Research Support, U.S. Gov't, P.H.S.; article"],["R0016938","The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus.","Algarni AA","2024","Journal of family medicine and primary care","nonrandomized_study","article","10.4103/jfmpc.jfmpc_1031_23","38605766","PMC11006082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016939","Semaglutide in non-diabetic patients with Fabry disease.","Riccio E","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other","article","10.1093/ndt/gfaf088","40338621",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016940","Metabolic Inflammation as a Common Thread in Cardio-Endocrine Diseases: Toward a Unified Therapeutic Framework.","Patil N","2026","Cureus","narrative_review","article","10.7759/cureus.102160","41732594","PMC12925614",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016941","Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system.","Psota M","2017","ClinicoEconomics and outcomes research : CEOR","other","article","10.2147/ceor.s143127","29276398","PMC5731336",null,"S001328","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0016942","Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies.","Marso SP","2011","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/1479164111408937","21653676",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016943","Insights into the central pathways involved in the emetic and behavioural responses to exendin-4 in the ferret.","Lu Z","2017","Autonomic neuroscience : basic & clinical","preclinical","article","10.1016/j.autneu.2016.09.003","27692857",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016944","Tirzepatide for Obstructive Sleep Apnea: A Novel Therapeutic Promise and the Perioperative Considerations.","Kukanti C","2025","Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India","randomized_trial","article","10.1007/s12070-025-05485-6","40420878","PMC12103393",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0016945","Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.","Shu X","2019","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2019.04.018","31015047",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016946","Reply: Tirzepatide in Obesity-Related Heart Failure With Preserved EF: Weight Loss and Structural Adaptations.","Kramer CM","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2025.04.034","40562518",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0016947","Incretin-based therapies in type 2 diabetes mellitus.","Chia CW","2008","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2007-2109","18628530","PMC2579648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Evaluation Study; Journal Article; Research Support, N.I.H., Intramural; Review; review-article; article"],["R0016948","Semaglutide Aggregates into Oligomeric Micelles and Short Fibrils in Aqueous Solution.","Hamley IW","2025","Biomacromolecules","other","article","10.1021/acs.biomac.5c00342","40355389","PMC12152837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016949","Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification.","Xu L","2026","Molecular biomedicine","preclinical","article","10.1186/s43556-026-00488-3","42410087","PMC13338083",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016950","Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.","Del Prato S","2024","Cardiovascular diabetology","other_trial","article","10.1186/s12933-024-02432-7","39342203","PMC11439209",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0016951","Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs.","Malbert CH","2020","BMJ open diabetes research & care","preclinical","article","10.1136/bmjdrc-2020-001540","33132211","PMC7607594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016952","The Role of Glucagon-like Peptide 1 Receptor Modulators for the Management of Dumping Syndrome in Patients Who have Undergone Metabolic and Bariatric Surgery: a Scoping Review.","Rogers-Seeley M","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08587-4","41854998","PMC13222205",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; research-article; article"],["R0016953","Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months).","Ruseva A","2025","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2025.2591464","41351543",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0016954","Evexomostat (SDX-7320), a Methionine Aminopeptidase Type 2 (METAP2) Inhibitor, Stimulates Weight Loss and Inhibits Obesity-Accelerated Tumor Growth","Cornelius P","2026","bioRxiv","preclinical","preprint","10.64898/2026.01.28.702362",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0016955","Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.","Hansen HH","2016","Brain research","preclinical","article","10.1016/j.brainres.2016.05.038","27233809",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016956","Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials.","Yamada Y","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14571","34622548","PMC9299616",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; brief-report; article"],["R0016957","RAASi, MRA and FGF-23 in CKD progression: the usual suspects?","Cianciolo G","2026","Minerva urology and nephrology","narrative_review","article","10.23736/s2724-6051.25.06082-3","40910758",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0016958","Resilience Selection: A Grave Potential Bias in Clinical Trials","Watve M","2025","Preprints.org","randomized_trial","preprint","10.20944/preprints202501.2344.v1",null,null,null,null,"europepmc","FALSE","open_pdf","2",null,"Preprint"],["R0016959","Beyond the Scale: Changes in Pain, Physical Function (WOMAC), and Low-Grade Inflammation Following Semaglutide Treatment in Patients with Knee Osteoarthritis-Results from a Six-Month Real-World Cohort.","Conforti A","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15155876","42589980","PMC13466628",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016960","Weight loss drugs: Semaglutide boosts heart health regardless of how much weight patients lose, study suggests.","Wise J","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r2238","41130633",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016961","GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R.","Yusta B","2015","Diabetes","preclinical","article","10.2337/db14-1577","25735732",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016962","Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial.","Hunter Gibble T","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-025-01723-w","40120035","PMC12006608","ClinicalTrials.gov:NCT04657003","S001712","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0016963","Weekly Journal Scan: semaglutide in patients with peripheral artery disease and diabetes-a real STRIDE in their management?","Vergallo R","2025","European heart journal","randomized_trial","article","10.1093/eurheartj/ehaf535","40910353",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0016964","A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy.","George RE","2014","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","narrative_review","article","10.1016/j.jsps.2013.05.005","25473328","PMC4246366",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016965","The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial.","Tommerdahl KL","2022","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.00020122","35396319","PMC9269664","ClinicalTrials.gov:NCT04865770; ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT04889157; ClinicalTrials.gov:NCT05048719","S000395; S000605; S000953; S002265","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0016966","Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.","Bhatnagar P","2025","Nature medicine","other_trial","article","10.1038/s41591-025-03913-2","40858971","PMC12532586",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0016967","Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study.","Evans M","2025","Advances in therapy","randomized_trial","article","10.1007/s12325-025-03194-8","40251452","PMC12085389",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0016968","Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study.","Li X","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70132","40954925","PMC12587237",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; research-article; article"],["R0016969","Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis.","Dutta D","2021","Indian journal of endocrinology and metabolism","systematic_review","article","10.4103/ijem.ijem_423_21","35355921","PMC8959203",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; other; article"],["R0016970","Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real-world evidence.","Weinreich AA","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70208","41098062",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0016971","Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta (1-42)-induced cognitive deficit rats.","Garabadu D","2019","Neurochemistry international","preclinical","article","10.1016/j.neuint.2019.04.006","31004737",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016972","Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs.","Haque TS","2010","Peptides","preclinical","article","10.1016/j.peptides.2010.01.008","20138099",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016973","Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake.","Cawthon CR","2023","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvad074","37388574","PMC10306276",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016974","Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys.","Vahle JL","2015","Endocrinology","preclinical","article","10.1210/en.2014-1717","25860028",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016975","Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues.","Bech EM","2017","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.7b00787","28771355",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0016976","Knowledge and Attitude of the General Population in Saudi Arabia Toward Weight Management Medications (WMMs): A Cross-Sectional Study.","Algarni MA","2023","Cureus","other","article","10.7759/cureus.42875","37664345","PMC10474326",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016977","GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.","Zhang M","2022","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2022.175107","35718129",null,null,"S000981","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0016978","Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives.","Liu Y","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1687601","41427055","PMC12714653",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016979","Apolipoprotein B in the Risk Assessment, Diagnosis, and Treatment of Cardiometabolic Diseases.","Patel S","2025","Cardiology and cardiovascular medicine","other","article","10.26502/fccm.92920466","41346943","PMC12674602",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0016980","Comparison of Type 2 Diabetes Mellitus Management by an Ambulatory Care Pharmacist vs Usual Care in a Medically Underserved Population.","Chow A","2026","Journal of pharmacy practice","nonrandomized_study","article","10.1177/08971900261450730","42117347",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0016981","Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.","Li Y","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","systematic_review","article","10.1007/s40256-025-00738-9","40493329",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0016982","Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study.","Irace C","2020","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/1479164119883540","31726866","PMC7510381",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0016983","Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians' Perspective in a Real-World Setting, Insight from a Web Survey.","Imai K","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0476-3","30058059","PMC6167295",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0016984","99mTc-Hydrazinonicotinamide-aminohexanoic acid-Lys40-exendin-4","Leung K","2004","National Center for Biotechnology Information (US), Bethesda (MD)","narrative_review","article",null,"22553894",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0016985","The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies.","Tonin G","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.13978","40650397","PMC12620113",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0016986","Lactobacillus reuteri JCM 1112 ameliorates chronic acrylamide-induced glucose metabolism disorder via the bile acid-TGR5-GLP-1 axis and modulates intestinal oxidative stress in mice.","Yue Z","2024","Food & function","preclinical","article","10.1039/d4fo01061b","38804210",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0016987","The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study.","Bechlioulis A","2023","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2023.108436","36842186",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0016988","Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.","Jojima T","2017","Atherosclerosis","preclinical","article","10.1016/j.atherosclerosis.2017.04.001","28445811",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0016989","A Perfect MASH Comparing Resmetirom and GLP-1 Agonists for Metabolic-Associated Steatohepatitis: What Does the Current Evidence Suggest?","Lin J","2025","Journal of clinical gastroenterology","narrative_review","article","10.1097/mcg.0000000000002234","40758726",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0016990","From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies.","Modica R","2026","Endocrine","randomized_trial","article","10.1007/s12020-026-04644-1","42081011","PMC13139237",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0016991","Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.","Alnaimi SJ","2026","Clinical obesity","systematic_review","article","10.1111/cob.70092","42307450","PMC13274556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0016992","A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.","Chigutsa E","2025","Clinical pharmacology and therapeutics","other_trial","article","10.1002/cpt.3750","40556483","PMC12641085",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0016993","Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.","Sanyal AJ","2024","Nature medicine","randomized_trial","article","10.1038/s41591-024-03018-2","38858523","PMC11271400","ClinicalTrials.gov:NCT04881760","S001653","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; research-article; article"],["R0016994","Liraglutide modulates GABAergic signaling in rat hippocampal CA3 pyramidal neurons predominantly by presynaptic mechanism.","Babateen O","2017","BMC pharmacology & toxicology","preclinical","article","10.1186/s40360-017-0191-0","29246184","PMC5732397",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0016995","The revolution of the anti-diabetic drugs in cardiology.","Verdecchia P","2020","European heart journal supplements : journal of the European Society of Cardiology","other_trial","article","10.1093/eurheartj/suaa084","32523463","PMC7270967",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0016996","Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.","Pasqua MR","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70213","41144928","PMC12673448",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0016997","Is there a role for the incretin system in blood pressure regulation?","Rao A","2014","Current hypertension reports","narrative_review","article","10.1007/s11906-013-0417-5","24470204",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0016998","Achieving BMI <25 kg/m2 was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on tirzepatide or placebo: a post hoc analysis of SURMOUNT-1, -3, and -CN.","Guo L","2026","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2025.103722","41536939","PMC12796590","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT05024032","S001077; S001086; S002157","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0016999","Smoldering inflammation: The silent flame driving heart failure.","Wilk MM","2025","Dental and medical problems","narrative_review","article","10.17219/dmp/210102","41186161",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017000","Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.","Guerdjikova AI","2025","International journal of psychiatry in clinical practice","randomized_trial","article","10.1080/13651501.2025.2549307","40849800",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0017001","The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials.","Austregésilo de Athayde De Hollanda Morais B","2024","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2024.108834","39178623",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0017002","Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.","Zelniker TA","2019","Circulation","systematic_review","article","10.1161/circulationaha.118.038868","30786725",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0017003","Liraglutide as add-on therapy to insulin in type 2 diabetes mellitus: a retrospective, observational study from a daily clinical practice setting in Switzerland.","Lipowsky C","2015","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-014-0093-8","25576400","PMC4374072",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017004","GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK.","Yang J","2019","Experimental and molecular pathology","other","article","10.1016/j.yexmp.2019.01.014","30776356",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017005","Differentiation of the mesenchymal stem cells to pancreatic β-like cells in alginate/trimethyl chitosan/alginate microcapsules.","Hosseini SR","2022","Progress in biomaterials","other","article","10.1007/s40204-022-00194-7","35802251","PMC9374854",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0017006","Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice.","Yin QH","2016","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m116.730564","27784780","PMC5159509",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017007","Correction: Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.","Tian Q","2025","Frontiers in endocrinology","notice","article","10.3389/fendo.2025.1683829","40927296","PMC12415865",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0017008","Clinical approaches to preserve beta-cell function in diabetes.","Wajchenberg BL","2010","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-90-481-3271-3_23","20217513",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017009","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.","Tzotzas T","2017","Current vascular pharmacology","narrative_review","article","10.2174/1570161114666161221115324","28003008",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017010","How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?","Tibaldi J","2020","Clinical diabetes : a publication of the American Diabetes Association","nonrandomized_study","article","10.2337/cd20-0014","33132503","PMC7566936",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017011","Corrigendum to 'FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide' [Journal of Molecular and Cellular Cardiology volume 210 (2026) 12-27].","Sánchez-López D","2026","Journal of molecular and cellular cardiology","notice","article","10.1016/j.yjmcc.2025.11.015","41338057",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0017012","Evidence for Glucagon Secretion and Function Within the Human Gut.","Sun EW","2021","Endocrinology","preclinical","article","10.1210/endocr/bqab022","33534908",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017013","Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.","Koh B","2026","Hepatology (Baltimore, Md.)","systematic_review","article","10.1097/hep.0000000000001028","39028914","PMC11913421",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Comparative Study; Network Meta-Analysis; research-article; review"],["R0017014","Real-World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study.","Tchang B","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70120","41367196",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017015","Effect of liraglutide treatment on mitigation of hearing damage induced by multiday repeated high-intensity blasts.","Jiang S","2025","The Journal of the Acoustical Society of America","preclinical","article","10.1121/10.0039047","40853101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017016","Comment on Wang et al. Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. Diabetes Care 2018;41:1998-2009.","Feldman-Billard S","2019","Diabetes care","nonrandomized_study","article","10.2337/dc18-1825","30811336",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Letter; Comment; letter"],["R0017017","Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on food and drug administration adverse event report system database.","Zhang L","2022","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2022.977582","36467046","PMC9716078",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017018","SAT-685 Low-dose Tirzepatide For The Treatment Of Patient With Lipedema: A Case Report",null,"2025","Journal of the Endocrine Society","case_report","article",null,null,"PMC12545275",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017019","MON-720 Beyond Age: Sex as the Key Weight Loss Predictor with Tirzepatide",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545098",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017020","[Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)].","Scheen AJ","2014","Revue medicale de Liege","other","article",null,"24923102",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0017021","Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.","Thomsen RW","2021","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.120.019356","34032121","PMC8483550",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0017022","Exendin-4 regulates redox homeostasis in rats fed with high-fat diet.","Niu S","2015","Acta biochimica et biophysica Sinica","preclinical","article","10.1093/abbs/gmv027","25910576",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017023","GLP-1 agonists linked to adverse gastrointestinal events in weight loss patients.","Mahase E","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p2330","37813459",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0017024","Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan.","Fang C","2025","Current opinion in nephrology and hypertension","other_trial","article","10.1097/mnh.0000000000001101","40726372","PMC12313211",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0017025","Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.","Verma S","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13698","30851070","PMC6619033","ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446","S001496; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0017026","Letter to the Editor: Oral Semaglutide did not Significantly Improve Volumetric BMD in Overweight/Obese Type 2 Diabetes.","Daly RM","2025","Calcified tissue international","commentary","article","10.1007/s00223-025-01437-y","41062906",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0017027","Strategies for improving research on semaglutide in cocaine use disorder.","Shen MY","2025","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","commentary","article","10.1016/j.euroneuro.2025.08.450","40865350",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017028","Preoperative semaglutide before sleeve gastrectomy compared to surgery alone is associated with greater short-term weight loss and dyslipidemia remission: a prospective nonrandomized controlled trial.","Liu D","2026","International journal of surgery (London, England)","other_trial","article","10.1097/js9.0000000000004001","41247825",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0017029","Pharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials.","Luu S","2025","Sleep medicine reviews","randomized_trial","article","10.1016/j.smrv.2025.102169","40974973",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0017030","Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.","Karakasis P","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15410","38116693",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Meta-Analysis; Journal Article; review"],["R0017031","[Diagnosis and treatment of heart failure with preserved ejection fraction].","Soltani S","2025","Herz","other","article","10.1007/s00059-025-05327-9","40853593",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0017032","The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers.","Bouhajib M","2025","Journal of basic and clinical physiology and pharmacology","other","article","10.1515/jbcpp-2025-0026","40425315",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; Randomized Controlled Trial; article"],["R0017033","Preoperative Use of Liraglutide in Weight Loss Surgery: Limitations and Future Research.","Wang A","2025","Obesity surgery","commentary","article","10.1007/s11695-025-08257-x","40936053",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0017034","Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies.","Adil M","2017","Pharmacological reports : PR","narrative_review","article","10.1016/j.pharep.2017.05.008","29132091",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017035","Management of obesity.","Cross L","2025","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.1093/ajhp/zxae273","39325384",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017036","Cardiovascular outcome with SGLT2i and GLP1RA.","Lim S","2024","European journal of internal medicine","commentary","article","10.1016/j.ejim.2024.05.030","38849275",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0017037","Semaglutide and the Eyes-A Literature Glut, but Little Clarity.","Li T","2025","JAMA ophthalmology","commentary","article","10.1001/jamaophthalmol.2025.2493","40810949",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0017038","Semaglutide (Ozempic) for weight loss.",null,"2021","The Medical letter on drugs and therapeutics","other","article",null,"33830968",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017039","Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Shi FH","2018","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2018.00576","29915538","PMC5994433",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; systematic-review; review"],["R0017040","Semaglutide targets MASH molecular pathways beyond weight loss.","Michel M","2025","Nature medicine","other","article","10.1038/s41591-025-03927-w","40890553",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017041","Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023.","Adekunle OA","2026","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70151","41741949","PMC13032055",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017042","Pathophysiology of vascular ageing and the effect of novel cardio-renal protective medications in preventing progression of chronic kidney disease in people living with diabetes.","Fountoulakis N","2025","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.15464","39497615","PMC11733662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017043","Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.","Loomba R","2023","The lancet. Gastroenterology & hepatology","randomized_trial","article","10.1016/s2468-1253(23)00068-7","36934740","PMC10792518","ClinicalTrials.gov:NCT03987451","S001764","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0017044","Distinct and complementary metabolic effects of GLP-1 and glucagon receptor agonism in diet-induced obese mice.","Winther-Sørensen M","2026","Peptides","preclinical","article","10.1016/j.peptides.2025.171462","41429191",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017045","Physiology of the Weight Loss Plateau after Calorie Restriction, GLP-1 Receptor Agonism, and Bariatric Surgery.","Hall KD","2023","bioRxiv : the preprint server for biology","other","article","10.1101/2023.11.05.565699","38076965","PMC10705578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0017046","Investigational glucagon-like peptide-1 agonists for the treatment of obesity.","Tomlinson B","2016","Expert opinion on investigational drugs","narrative_review","article","10.1080/13543784.2016.1221925","27563838",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017047","New directions in childhood obesity treatment - A path forward or wishful thinking?","Reilly JL","2025","Journal of clinical lipidology","narrative_review","article","10.1016/j.jacl.2025.05.010","40975571",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017048","Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice.","Zhu R","2023","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2023.1095432","37025414","PMC10070826",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017049","SAT-520 Tirzepatide-associated Interstitial Kidney Injury: A Case Report",null,"2025","Journal of the Endocrine Society","case_report","article",null,null,"PMC12545737",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017050","Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.","Hunt B","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12890","28124820",null,"ClinicalTrials.gov:NCT01973231","S001337","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017051","Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.","Pop-Busui R","2025","Diabetes care","randomized_trial","article","10.2337/dc25-1087","40986645","PMC12583396",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article; other"],["R0017052","Understanding MASLD - from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist.","Ratti C","2025","Atherosclerosis","narrative_review","article","10.1016/j.atherosclerosis.2025.120495","40876178",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017053","Association of Semaglutide and NAION Reviewed.","Lum F","2025","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2025.1829","40569602",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017054","Understanding semaglutide action in the brain.","Crunkhorn S","2025","Nature reviews. Drug discovery","commentary","article","10.1038/d41573-025-00112-z","40555764",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0017055","Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD).","Reis-Barbosa PH","2024","Fundamental & clinical pharmacology","preclinical","article","10.1111/fcp.13024","38923017",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0017056","Liraglutide as a treatment option for weight regain after laparoscopic sleeve gastrectomy in patients with obesity and higher anaesthesiologist risk.","Martines G","2025","Frontiers in surgery","nonrandomized_study","article","10.3389/fsurg.2025.1624455","41079295","PMC12510984",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017057","The association between depressive symptom severity and metabolic disturbances in major depressive and bipolar disorders: A systematic review and meta-analysis.","Wong S","2026","Journal of affective disorders","systematic_review","article","10.1016/j.jad.2025.120783","41318004",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0017058","Insulin degludec + liraglutide: a complementary combination.","Stinkens K","2016","Expert opinion on biological therapy","other_trial","article","10.1080/14712598.2016.1217328","27484310",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0017059","Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition.","Streckel E","2015","Journal of translational medicine","preclinical","article","10.1186/s12967-015-0431-2","25890210","PMC4362632",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017060","GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection.","Aroda VR","2023","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2023.06.005","37532423",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0017061","Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.","Lee CH","2018","Molecular neurobiology","preclinical","article","10.1007/s12035-017-0550-2","28456941",null,null,"S000443","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article"],["R0017062","Semaglutide-Associated Hepatic Cytolysis.","Viard D","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2025.07.029","40749812",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017063","Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.","Popoviciu MS","2023","International journal of molecular sciences","randomized_trial","article","10.3390/ijms241310449","37445623","PMC10341852",null,"S001434","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0017064","Oral Semaglutide and Cardiovascular Outcomes.","Dos Santos MCF","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2508958","40802952",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0017065","Incretin-based approaches for type 2 diabetes therapy: effects on circulating cytokines and adipocyte's secretome.","Agareva M","2025","BMC endocrine disorders","other","article","10.1186/s12902-025-01999-w","40676576","PMC12269230",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017066","Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.","Tuttolomondo A","2021","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-020-01183-5","33397395","PMC7784355",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0017067","Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.","Idorn T","2013","BMJ open","protocol","article","10.1136/bmjopen-2013-002764","23624993","PMC3641449","ClinicalTrials.gov:NCT01394341","S002227","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; protocol; article"],["R0017068","Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.","Rasouli N","2025","Diabetes care","randomized_trial","article","10.2337/dc25-1082","40543068","PMC12368379","ClinicalTrials.gov:NCT04560998","S001363","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; research-article; other; article"],["R0017069","Semaglutide 7·2 mg: another step towards tackling diseases mediated by obesity.","Sattar N","2025","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(25)00262-1","40961951",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017070","Semaglutide attenuates lipotoxicity-induced cardiac injury by inhibiting Slc27a2 expression.","Pan X","2025","Chemico-biological interactions","preclinical","article","10.1016/j.cbi.2025.111583","40456371",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017071","Personalised Approach to the Management of Older People with Type 2 Diabetes Mellitus-A Comprehensive Narrative Review.","Sinclair A","2026","Journal of personalized medicine","narrative_review","article","10.3390/jpm16040213","42042580","PMC13117061",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0017072","IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.","Miller E","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13851","31385425","PMC6899651",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0017073","Successful Treatment of Hypothalamic Obesity with Tirzepatide.","Brijmohan S","2025","AACE endocrinology and diabetes","case_report","article","10.1016/j.aed.2025.03.004","40677794","PMC12268545",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017074","Noninvasive Evaluation of GPR119 Agonist Effects on β-Cell Mass in Diabetic Male Mice Using 111In-Exendin-4 SPECT/CT.","Murakami T","2019","Endocrinology","preclinical","article","10.1210/en.2019-00556","31613319",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"TRUE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017075","Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database.","Weng W","2017","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2016-000382","28761654","PMC5530246",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017076","18F-Tetrazine-trans-cyclooctene-Cys40-exendin-4","Leung K","2004","National Center for Biotechnology Information (US), Bethesda (MD)","preclinical","article",null,"23638493",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0017077","Retraction Notice: \"Jinshui He, Xu Zhang, Chaowei Lian, Jinzhi Wu, Yanling Fang, Xiaoling Ye. Exendin-4 prevented pancreatic beta cells from apoptosis in (Type I) diabetic mouse via keap1-Nrf2 signaling\".",null,"2020","Experimental biology and medicine (Maywood, N.J.)","notice","article","10.1177/1535370220952051","32787685","PMC7802386",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; retraction"],["R0017078","Modulation of GLP-1 signalling as an innovative strategy counteracting the onset of heart failure: Potential for natural compound supplementation.","Gliozzi M","2025","Pharmacological research","narrative_review","article","10.1016/j.phrs.2025.107744","40268125",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017079","FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.","Bacha F","2019","The Lancet. Child & adolescent health","other","article","10.1016/s2352-4642(19)30236-6","31345736",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017080","Exposure to High-Dose Liraglutide in a Pregnant Woman With Obesity.","Abushanab D","2025","O&G open","case_report","article","10.1097/og9.0000000000000077","41000293","PMC12456597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017081","Association of Semaglutide and NAION Reviewed.","Klonoff DC","2025","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2025.1823","40569601",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017082","Trends and projections of the global burden of T2DM-associated CKD related to high BMI: A global burden of disease study 2021.","Zhang J","2025","PloS one","nonrandomized_study","article","10.1371/journal.pone.0333672","41071800","PMC12513629",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017083","Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.","Lin Y","2024","Medicine","systematic_review","article","10.1097/md.0000000000038018","38758855","PMC11098233",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; article"],["R0017084","Glucagon-like peptide-1 receptor controls exocytosis in chromaffin cells by increasing full-fusion events.","González-Santana A","2021","Cell reports","preclinical","article","10.1016/j.celrep.2021.109609","34433018",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017085","Pre-pregnancy treatment of semaglutide improves high-fat-diet-induced placental and fetal hypothalamic alterations in a sex-specific manner in rats†.","Wang J","2025","Biology of reproduction","preclinical","article","10.1093/biolre/ioaf178","40794822",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017086","Growing evidence for semaglutide efficacy in Asian adults with obesity.","Sumithran P","2025","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(25)00201-3","40825341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017087","Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking.","Fremaux J","2019","Chemical science","other","article","10.1039/c9sc02079a","32015811","PMC6977461",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017088","Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment.","Kruger DF","2015","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s71923","25653546","PMC4303400",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017089","Chronic semaglutide treatment reveals stage-dependent changes to feeding behavior and metabolic adaptations in male mice.","Shah H","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.07.24.666640","40766625","PMC12324234",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0017090","A hybrid construct of decellularized matrix and fibrin for differentiating adipose stem cells into insulin-producing cells, an optimized in vitro assessment.","Bozorgi A","2024","Cell biochemistry and function","preclinical","article","10.1002/cbf.4038","38736214",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017091","The pancreatic β-cell incretin response is modulated by mitochondrial transaminase GPT2.","Sen S","2025","Research square","preclinical","article","10.21203/rs.3.rs-6950998/v1","40630539","PMC12236903",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Preprint"],["R0017092","dulaglutide (Trulicity°) weekly in type 2 diabetes: Cardiovascular reactions should be better documented.",null,"2016","Prescrire international","other","article",null,"30645827",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017093","How do drugs such as Ozempic work for weight loss . . . and everything else?","Guenot M","2024","BMJ (Clinical research ed.)","other","article","10.1136/bmj.q1767","39159969",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017094","Association of Semaglutide and NAION Reviewed-Reply.","Cai CX","2025","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2025.1826","40569577",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017095","Finerenone is associated with pronounced uric acid reduction in hyperuricemic diabetic kidney disease: a real-world analysis.","Lin Y","2026","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1782658","41847129","PMC12989612",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017096","Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of GLP-1 receptor in type 1 diabetic rat hearts.","Artinian SB","2011","Experimental diabetes research","preclinical","article","10.1155/2011/489708","21747829","PMC3124137",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017097","SUN-344 Much Ado About Nothing: Tirzepatide and Medullary Thyroid Cancer Debunked",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544941",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017098","Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting.","Thewjitcharoen Y","2023","Journal of the ASEAN Federation of Endocrine Societies","randomized_trial","article","10.15605/jafes.038.01.11","37252413","PMC10213164",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017099","ODP181 Diabetes Mellitus and Advanced Liver Fibrosis – is Cirrhosis Reversible and Who Should We Screen?",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9628255",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017100","Semaglutide: Double-edged Sword with Risks and Benefits.","Pillarisetti L","2025","Archives of internal medicine research","other","article","10.26502/aimr.0189","39902055","PMC11790292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017101","Frailty and Semaglutide in Obesity-Related HFpEF: Another STEP in the Right Direction.","Butt JH","2025","JACC. Heart failure","commentary","article","10.1016/j.jchf.2025.102643","40884983",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0017102","Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.","Wretlind A","2022","Frontiers in clinical diabetes and healthcare","randomized_trial","article","10.3389/fcdhc.2022.856485","36992761","PMC10012104","ClinicalTrials.gov:NCT03449654","S001895","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; brief-report; article"],["R0017103","Efficacy of Antiobesity Medications in Patients With Celiac Disease on a Gluten-free Diet: A Retrospective Matched Cohort Study.","Anazco D","2024","Journal of clinical gastroenterology","nonrandomized_study","article","10.1097/mcg.0000000000001931","37983763","PMC10972774",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0017104","Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.","Puglisi S","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.738848","34745006","PMC8567993",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0017105","Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report.","Zhang L","2022","World journal of clinical cases","case_report","article","10.12998/wjcc.v10.i21.7495","36158023","PMC9353915",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017106","[In patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced liver fibrosis, does semaglutide (2.4mg subcutaneously every week) improve liver histology compared to placebo, and is it safe?].","Mutchmore A","2025","La Revue de medecine interne","commentary","article","10.1016/j.revmed.2025.08.009","40957814",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0017107","Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT.","Michalski K","2020","Clinical nuclear medicine","nonrandomized_study","article","10.1097/rlu.0000000000003093","32453080",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017108","p38α MAPK Regulation of Energy Metabolism in Skeletal Muscle Offers a Therapeutic Path for Type 2 Diabetes.","Bengal E","2025","Cells","narrative_review","article","10.3390/cells14161277","40862756","PMC12384146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017109","Common peroneal neuropathy following significant weight loss induced by tirzepatide therapy.","Wentling J","2025","PM & R : the journal of injury, function, and rehabilitation","commentary","article","10.1002/pmrj.13409","40391981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0017110","Oral semaglutide and cardiovascular outcomes: The overlooked variables.","Singh J","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133764","40789549",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0017111","[What is established in the medical treatment of heart failure?].","Soltani S","2025","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-025-01998-y","41060409",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0017112","Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.","Gorgojo-Martínez JJ","2017","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2016.11.007","28077257",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0017113","Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease.","Checa-Ros A","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15103641","42194603","PMC13207412","ClinicalTrials.gov:NCT07309094","S000128","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0017114","Enzymatic synthesis and functional characterization of site-specific S/O-linked N-glycopeptides: Elucidating the impact of glycosidic linkage patterns on bioactivity.","Zhai X","2025","Carbohydrate polymers","other","article","10.1016/j.carbpol.2025.123871","40733803",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0017115","Weight management during pregnancy, what is new?","Dib S","2025","Current opinion in clinical nutrition and metabolic care","other_trial","article","10.1097/mco.0000000000001127","40294128",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0017116","Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease.","Song J","2025","PloS one","nonrandomized_study","article","10.1371/journal.pone.0329965","40824899","PMC12360558",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017117","A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.","Yabe D","2025","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70099","40711887","PMC12489328",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0017118","Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.","Ayoub M","2026","Alimentary pharmacology & therapeutics","other_trial","article","10.1111/apt.70921","42608656","PMC13651924",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0017119","R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25.","Arora P","2026","Journal of comparative effectiveness research","nonrandomized_study","article","10.57264/cer-2026-0073","41987656","PMC13248995",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; editorial; article"],["R0017120","Cardiovascular benefits of Tirzepatide: A breakthrough in cardio-metabolic care.","Majid M","2025","JPMA. The Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.22967","40500849",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0017121","Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial.","Hauge C","2021","Expert opinion on drug metabolism & toxicology","other_trial","article","10.1080/17425255.2021.1955856","34289755",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Controlled Clinical Trial; Journal Article; article"],["R0017122","111In-Diethylenetriaminepentaacetic acid-aminohexanoic acid-Lys40-exendin-4","Leung K","2004","National Center for Biotechnology Information (US), Bethesda (MD)","narrative_review","article",null,"20641774",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0017123","MON-637 A Case of Euglycemic Ketoacidosis Following Treatment With an SGLT2 Inhibitor and Tirzepatide",null,"2025","Journal of the Endocrine Society","case_report","article",null,null,"PMC12543655",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017124","The differential antiemetic properties of GLP-1 receptor antagonist, exendin (9-39) in Suncus murinus (house musk shrew).","Chan SW","2014","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2014.03.016","24726308",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017125","The role of GLP-1 receptor agonists in managing type 2 diabetes.","Nachawi N","2022","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.89a.21110","35914933",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017126","Obesity therapeutics: The end of the beginning.","Gribble FM","2021","Cell metabolism","randomized_trial","article","10.1016/j.cmet.2021.03.012","33826913",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Comment"],["R0017127","Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.","Luo S","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2509454","40834308",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0017128","Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1).","Ang R","2018","Circulation. Arrhythmia and electrophysiology","preclinical","article","10.1161/circep.118.006740","30354404","PMC6553567",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017129","Does Ozempic boost fertility? What the science says.","Dohrn G","2024","Nature","commentary","article","10.1038/d41586-024-02045-w","38918627",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; other"],["R0017130","Does tirzepatide treatment improve skeletal muscle composition?","Stefan N","2025","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(25)00054-3","40318684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0017131","Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Kommu S","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13961","40510020","PMC12531717",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, N.I.H., Extramural; review-article; review"],["R0017132","Exenatide for once-weekly administration.",null,"2012","Drug and therapeutics bulletin","other","article","10.1136/dtb.2012.06.0115","22789767",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0017133","SAT-570 Should Severe Hypertriglyceridemia Also Be Considered as a Contraindication for Use of Glucagon like Peptide 1 (GLP-1) Agonists?","Guzman A","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.242",null,"PMC7209679",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0017134","Analysis of the Mechanism of PGLP-1 Inhibiting Gluconeogenesis Based on Whole Transcriptome Sequencing.","Gao H","2025","Current pharmaceutical biotechnology","preclinical","article","10.2174/0113892010382822250516034835","40390217",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017135","Daily briefing: Cheaper versions of drugs like Wegovy are on their way.","Graham F","2024","Nature","commentary","article","10.1038/d41586-024-02077-2","38907054",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0017136","Decoding polycystic ovary syndrome: an integrated review of epidemiology, molecular mechanisms, animal models, and the expanding therapeutic landscape.","Sharata EE","2026","Naunyn-Schmiedeberg's archives of pharmacology","narrative_review","article","10.1007/s00210-026-05559-4","42307637",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017137","Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics.","Varghese JS","2025","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-025-01885-4","40817129","PMC12634428",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017138","Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.","Semenya AM","2020","American family physician","other","article",null,"33179892",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017139","Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.","Look M","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16275","39996356","PMC11965027",null,"S002042; S002095","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0017140","Unraveling the multifactorial pathophysiology of polycystic ovary syndrome: exploring lifestyle, prenatal influences, neuroendocrine dysfunction, and post-translational modifications.","Senthilkumar H","2025","Molecular biology reports","narrative_review","article","10.1007/s11033-025-11081-2","41045390",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017141","GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy.","Sharma S","2011","PloS one","preclinical","article","10.1371/journal.pone.0025269","21957486","PMC3177901",null,"S000885","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0017142","Glucagon-Like Peptide-1 Analog Liraglutide Attenuates Pressure-Overload Induced Cardiac Hypertrophy and Apoptosis through Activating ATP Sensitive Potassium Channels.","Bai XJ","2021","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-020-07088-5","33057968",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017143","Pancreatic Exocrine Insufficiency After Metabolic and Bariatric Surgery.","Bathobakae L","2026","Digestive diseases and sciences","narrative_review","article","10.1007/s10620-025-09325-z","40839328",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017144","Real-World Persistence and Characteristics of Type 2 Diabetes Patients Prescribed Semaglutide in Scotland.","Dickie DA","2025","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.70102","40400146","PMC12095173",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0017145","La normativité du poids à l’œuvre : Sémaglutide et obésité","Lexchin J","2025","Canadian family physician Medecin de famille canadien","commentary","article",null,null,"PMC11998703",null,null,"europepmc","FALSE",null,null,null,"Comment; discussion"],["R0017146","Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations.","Frederiksen TM","2015","Biophysical journal","other","article","10.1016/j.bpj.2015.07.051","26340816","PMC4576320",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017147","The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.","Talbot K","2014","Alzheimer's & dementia : the journal of the Alzheimer's Association","narrative_review","article","10.1016/j.jalz.2013.12.007","24529520","PMC4018451",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0017148","Semaglutide and the retina: Weighing evidence against concern.","Muzurović E","2025","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2025.109148","40769838",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0017149","Development of novel radioiodinated exendin-4 derivatives targeting GLP-1 receptor for detection of β-cell mass.","Ogawa Y","2021","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2021.116496","34808404",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017150","Therapeutic Misconceptions and Weight Outcomes With Semaglutide.","Shaikh AK","2025","Clinical diabetes : a publication of the American Diabetes Association","commentary","article","10.2337/cd25-0052","41140721","PMC12547069",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0017151","Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.","Zhang M","2019","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.9b00280","31181890",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; article"],["R0017152","Diabetes mellitus and kidney disease in the elderly.","Iglesias P","2014","Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia","narrative_review","article","10.3265/nefrologia.pre2014.feb.12319","24798557",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017153","Semaglutide in Adults with Type 1 Diabetes and Obesity.","Shah VN","2025","NEJM evidence","randomized_trial","article","10.1056/evidoa2500173","40550013",null,"ClinicalTrials.gov:NCT05537233","S002321","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0017154","The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management.","Moncho F","2025","Clinical kidney journal","narrative_review","article","10.1093/ckj/sfaf260","40927376","PMC12415520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017155","Liraglutide attenuates intestinal ischemia/reperfusion injury via NF-κB and PI3K/Akt pathways in mice.","Zou Z","2022","Life sciences","preclinical","article","10.1016/j.lfs.2022.121045","36206837",null,null,"S001698","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0017156","Compare SGLT2I versus non-SGLT2I users in type-2 diabetic mellitus patients on GLP-1 receptor agonist: A population-based and machine learning causal inference analysis","Luo Z","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.11.06.23298185",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0017157","Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.","Yamada S","2021","Clinical and experimental nephrology","randomized_trial","article","10.1007/s10157-020-02007-2","33409761",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0017158","[Multimodal obesity therapy-preconditioning neoadjuvant strategies prior to bariatric surgery].","Seidemann L","2026","Chirurgie (Heidelberg, Germany)","narrative_review","article","10.1007/s00104-025-02388-8","41105218",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0017159","Psychosocial Outcomes and Aesthetic Expectations in Female Patients Undergoing Body Contouring After GLP-1-Induced Weight Loss: A Prospective Pilot Comparative Study with Post-Bariatric Patients.","Ponzo M","2026","Aesthetic plastic surgery","nonrandomized_study","article","10.1007/s00266-026-06002-y","42310082",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Comparative Study"],["R0017160","Optic disc edema during semaglutide therapy: case report and literature review.","Yang T","2025","American journal of ophthalmology case reports","randomized_trial","article","10.1016/j.ajoc.2025.102476","41311659","PMC12648079",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Case Reports; Journal Article; case-report; article"],["R0017161","Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.","Ozturk ZA","2014","World journal of hepatology","narrative_review","article","10.4254/wjh.v6.i4.199","24799988","PMC4009475",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017162","Exenatide ameliorates hydrogen peroxide-induced pancreatic β-cell apoptosis through regulation of METTL3-mediated m6A methylation.","Zhou S","2022","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2022.174960","35436474",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017163","Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue.","Sanz Segura P","2022","Gastroenterologia y hepatologia","case_report","article","10.1016/j.gastrohep.2020.11.021","33545249",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0017164","Semaglutide ameliorates aortic endothelial cell dysfunction in sarcopenia through the SIRT1/cGAS-STING signaling axis.","Liu Y","2026","Free radical biology & medicine","preclinical","article","10.1016/j.freeradbiomed.2026.04.011","41951015",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017165","Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.","von Scholten BJ","2015","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/dme.12594","25251901",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017166","Tirzepatide for Heart Failure and Obesity.","Wagner J","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2502743","40267436",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0017167","The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats.","Bernosky-Smith KA","2016","Pharmacology, biochemistry, and behavior","preclinical","article","10.1016/j.pbb.2015.12.007","26701752","PMC5467700",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0017168","The multifaceted regulation of white adipose tissue browning and their therapeutic potential.","Satheesan A","2025","Journal of physiology and biochemistry","narrative_review","article","10.1007/s13105-025-01117-3","40785003",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017169","Anti-diabetic Biologicals: Exploring the Role of Different Analytical Techniques.","Yaseen Z","2026","Critical reviews in analytical chemistry","narrative_review","article","10.1080/10408347.2025.2472793","40088445",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017170","Liraglutide in combination with zoledronic acid and calcium carbonate and vitamin D3 for diabetic osteoporosis: efficacy and glycometabolism impact.","Wu Z","2026","American journal of translational research","other","article","10.62347/kqui1289","42769574","PMC13590999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017171","[Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].","Scheen AJ","2016","Revue medicale de Liege","other_trial","article",null,"27311248",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","5","FALSE","Comparative Study; English Abstract; Journal Article; article"],["R0017172","Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.","Rubino DM","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16176","39789843","PMC11885085",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; research-article; article"],["R0017173","Exploration of structure-activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis.","Haque TS","2010","Peptides","preclinical","article","10.1016/j.peptides.2010.04.013","20420872",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017174","Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.","Lv R","2023","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2023.1125693","36860374","PMC9968798",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0017175","Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.","Nanna MG","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16370","40183412","PMC12046440",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017176","Osteogenic effects of metformin and exenatide on bone regeneration in non-diabetic rats: A Micro-CT and histological study.","Ozturk H","2025","Journal of oral and maxillofacial pathology : JOMFP","preclinical","article","10.4103/jomfp.jomfp_4_25","41069630","PMC12507372",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017177","Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study","Nyland JE","2020","SSRN","randomized_trial","preprint","10.2139/ssrn.3725612",null,null,null,null,"europepmc","FALSE","free_to_read","2",null,"Preprint"],["R0017178","Erratum: Influence of GLP-1 receptor agonist on insulin dosage and blood glucose control of patients with type 2 diabetes mellitus.","Shen Y","2022","American journal of translational research","notice","article",null,"35559423","PMC9091095",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0017179","Exendin-4 regulates endoplasmic reticulum stress to protect endothelial progenitor cells from high-glucose damage.","Yang Y","2020","Molecular and cellular probes","preclinical","article","10.1016/j.mcp.2020.101527","31996309",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017180","Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography.","Li J","2026","Hepatology communications","other","article","10.1097/hc9.0000000000001024","42579768","PMC13466114",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; research-article; article"],["R0017181","Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor.","Kedees MH","2013","Peptides","preclinical","article","10.1016/j.peptides.2013.07.022","23927844",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017182","Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.","Malkin SJP","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0542-x","30535837","PMC6349296",null,"S000329","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0017183","An overview of the pharmacokinetics, efficacy and safety of liraglutide.","Bode B","2012","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2011.12.015","22245694",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0017184","EndoCompass project: research roadmap for diabetes, obesity, and metabolism.","Mathieu C","2025","European journal of endocrinology","nonrandomized_study","article","10.1093/ejendo/lvaf065","41104472","PMC12698134",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0017185","Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitor as an Add-on Drug to GLP-1 Receptor Agonists for Glycemic Control of a Patient with Prader-Willi Syndrome: A Case Report.","Horikawa Y","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","case_report","article","10.1007/s13300-018-0369-5","29335890","PMC5801255",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; other; article"],["R0017186","Plasma proteomics reveals an improved cardio-metabolic profile in patients with type 2 diabetes post-liraglutide treatment.","Ekhzaimy AA","2022","Diabetes & vascular disease research","other","article","10.1177/14791641221094322","35616478","PMC9152203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0017187","GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.","Mundil D","2012","Diabetes & vascular disease research","narrative_review","article","10.1177/1479164112441526","22496442",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0017188","Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: A randomized trial.","Tuttolomondo A","2020","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-51124/v2",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0017189","Exenatide improves random-pattern skin flap survival via TFE3 mediated autophagy augment.","Li J","2021","Journal of cellular physiology","preclinical","article","10.1002/jcp.30102","33044023",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017190","Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?","Graham GV","2020","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.14171","33462968",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0017191","MASH and liver fibrosis: Clinical trials to watch.","Zhang X","2026","Med (New York, N.Y.)","other_trial","article","10.1016/j.medj.2026.101069","41966712",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0017192","Efficacy of GLP-1 Agonist Therapy in Autosomal Dominant WFS1-Related Disorder: A Case Report.","Scully KJ","2020","Hormone research in paediatrics","case_report","article","10.1159/000510852","33075784",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0017193","Correction: Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.","Ni XY","2025","Acta pharmacologica Sinica","notice","article","10.1038/s41401-025-01559-x","40263569","PMC12373789",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0017194","Future Medications for Obesity and Clinical Implications.","Garvey WT","2024","Diabetes spectrum : a publication of the American Diabetes Association","other_trial","article","10.2337/dsi24-0004","39649698","PMC11623045",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0017195","Proteomic signatures reflect effects of semaglutide treatment for MASH.","Schattenberg JM","2025","JHEP reports : innovation in hepatology","randomized_trial","article","10.1016/j.jhepr.2025.101521","40980163","PMC12447996","ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT02970942","S000144; S000922; S001740","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0017196","Incretin manipulation in diabetes management.","Pappachan JM","2015","World journal of diabetes","commentary","article","10.4239/wjd.v6.i6.774","26131320","PMC4478574",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0017197","Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.","Snitker S","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14349","33591618","PMC8251561",null,"S000979","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0017198","Management of Hypoglycemia Using Continuous Glucose Monitoring During Tirzepatide Initiation or Uptitration When Used in Addition to Other Glucose-Lowering Agents.","Mews K","2025","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds24-0074","41257224","PMC12620735",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; research-article; article"],["R0017199","A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists.","Poonawalla IB","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.108800","33845052",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0017200","Reply: The Impact of Semaglutide on Cardiac Mass and Function Requires Further Investigation.","Abuetabh Y","2025","JACC. Basic to translational science","commentary","article","10.1016/j.jacbts.2025.02.026","40306861","PMC12134558",null,null,"pubmed; europepmc","TRUE",null,null,null,"Letter"],["R0017201","OR09-06 Tirzepatide as a Promising Treatment for Metabolic Hypogonadism in Obese Men: Effects on Metabolic and Hormonal Parameters",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545151",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017202","Efficacy of semaglutide in reducing atrial fibrillation recurrence post-catheter ablation: propensity score-matched analysis",null,"2025","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","nonrandomized_study","article",null,null,"PMC12100199",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0017203","Human Plasma Proteomics Links Modifiable Lifestyle Exposome to Disease Risk.","Isaac S","2025","medRxiv : the preprint server for health sciences","other","article","10.1101/2025.05.07.25327178","40385387","PMC12083611",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0017204","Tirzepatide: a novel therapeutic approach for Alzheimer's disease.","Alshehri GH","2025","Metabolic brain disease","narrative_review","article","10.1007/s11011-025-01649-z","40498212","PMC12159100",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017205","Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.","Zhang X","2016","Journal of hypertension","systematic_review","article","10.1097/hjh.0000000000000782","26682782",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0017206","Correction: Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.","Petralli G","2025","Acta diabetologica","notice","article","10.1007/s00592-025-02482-7","40105914",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0017207","[Emerging disease-modifying therapies for Parkinson's disease].","Mahul-Mellier AL","2025","Revue medicale suisse","narrative_review","article","10.53738/revmed.2025.21.915.47096","40275845",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0017208","Exploring the Molecular Mechanisms of Tirzepatide in Alleviating Metabolic Dysfunction- Associated Fatty Liver in Mice through Integration of Metabolomics, Lipidomics, and Proteomics","Liang J","2024","Research Square","preclinical","preprint","10.21203/rs.3.rs-5274949/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017209","Weight for rhythm: is the evidence for atrial fibrillation risk with semaglutide still premature?: reply.","Cesaro A","2025","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwaf465","40855814",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017210","Glucagon-Like Peptide 1 Increases β-Cell Regeneration by Promoting α- to β-Cell Transdifferentiation.","Lee YS","2018","Diabetes","preclinical","article","10.2337/db18-0155","30257975",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017211","Metabolic-Associated Fatty Liver Disease and Diabetes: A Double Whammy.","Kapoor N","2023","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2023.02.006","37495338",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017212","Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.","Wang T","2016","Diabetes/metabolism research and reviews","systematic_review","article","10.1002/dmrr.2804","27037787",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; review; article"],["R0017213","Injection technique practices in a population of Canadians with diabetes: results from a recent patient/diabetes educator survey.","Berard L","2015","Canadian journal of diabetes","other","article","10.1016/j.jcjd.2014.10.003","25623619",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017214","Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.","Salehi P","2017","Pediatric obesity","randomized_trial","article","10.1111/ijpo.12131","27071367","PMC5288290",null,"S001478","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0017215","The effects of liraglutide on expressions of insulin secretion and beta cell survive associated GPCR genes in pancreatic beta cells.","Türkol M","2025","Turkish journal of medical sciences","preclinical","article","10.55730/1300-0144.5997","40342327","PMC12058015",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017216","A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.","Jalewa J","2017","Neuropharmacology","other_trial","article","10.1016/j.neuropharm.2017.02.013","28223210",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0017217","[Suboptimal treatment success after metabolic bariatric surgery-Additive pharmacotherapy or surgical conversion?].","Lauerer J","2026","Chirurgie (Heidelberg, Germany)","narrative_review","article","10.1007/s00104-025-02384-y","40958007",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0017218","68Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-aminohexanoic acid-Lys40-exendin-4","Leung K","2004","National Center for Biotechnology Information (US), Bethesda (MD)","narrative_review","article",null,"22553890",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0017219","The GLP-1 analog liraglutide attenuates acute liver injury in mice.","Milani L","2019","Annals of hepatology","preclinical","article","10.1016/j.aohep.2019.04.011","31151874",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017220","[Current and future medical treatments for metabolic dysfunction-associated steatohepatitis].","Anty R","2026","La Revue du praticien","narrative_review","article",null,"42083849",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0017221","Inhibition of the melanocortin-3 receptor (MC3R) causes generalized sensitization to anorectic agents.","Dahir NS","2023","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2023.12.05.570114","38106197","PMC10723368",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0017222","Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.","Kanda R","2018","BMC cancer","other","article","10.1186/s12885-018-4570-8","29907137","PMC6003019",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0017223","A Rare Case of Tirzepatide-Induced Hepatotoxicity.","Sohal A","2024","ACG case reports journal","case_report","article","10.14309/crj.0000000000001484","39372916","PMC11452087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017224","Peripheral targets in obesity treatment: a comprehensive update.","Chatzigeorgiou A","2014","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.12163","24612276",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017225","U.S. Emergency Department Visits Attributed by Clinicians to Semaglutide Adverse Events, 2022-2023.","Lovegrove MC","2025","Annals of internal medicine","other","article","10.7326/annals-24-03258","40194288","PMC13245651",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017226","Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.","Pugliese N","2025","United European gastroenterology journal","nonrandomized_study","article","10.1002/ueg2.70055","40468530","PMC12463688",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0017227","Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.","Li Y","2019","Scientific reports","preclinical","article","10.1038/s41598-019-53356-2","31748513","PMC6868133",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017228","Semaglutide: FDA approves weight loss jab to treat severe liver disease.","Bowie K","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r1788","40841128",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017229","Glucagon-Like Peptide-1 (GLP-1) Agonists may Warrant Revival of Preemptive Pharmacologic Prokinesis Preoperatively till Bring Your Own Ultrasonographic Stethoscope (BYoUS) Policy Becomes the Norm.","Gupta D","2024","Annals of cardiac anaesthesia","commentary","article","10.4103/aca.aca_137_23","38722134","PMC10876147",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017230","Cotadutide improves brown adipose tissue thermogenesis in obese mice.","Spezani R","2023","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2023.115852","37832793",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017231","Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment.","King A","2005","Diabetologia","preclinical","article","10.1007/s00125-005-1922-0","16132945",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0017232","Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.","Buse JB","2011","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2010-2822","21450987",null,"ClinicalTrials.gov:NCT00294723; ClinicalTrials.gov:NCT00331851; ClinicalTrials.gov:NCT00333151; ClinicalTrials.gov:NCT00395746; ClinicalTrials.gov:NCT00518882; ClinicalTrials.gov:NCT00614120","S000862; S001094; S001502; S001581; S001584; S002098; S002222; S002230","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017233","Letter: Tirzepatide in Type 1 Diabetic Obese Patient Using Hybrid Closed-Loop.","Baretić M","2025","Diabetes technology & therapeutics","commentary","article","10.1089/dia.2025.0245","40607933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0017234","Liraglutide protects against lethal renal ischemia-reperfusion injury by inhibiting high-mobility group box 1 nuclear-cytoplasmic translocation and release.","Li Y","2021","Pharmacological research","preclinical","article","10.1016/j.phrs.2021.105867","34481074",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017235","Semaglutide and MASH resolution: A pooled analysis of recent trials.","Abouelmagd AA","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16651","40726455",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0017236","The glucose tolerance test in mice: Sex, drugs and protocol.","Kennard MR","2022","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.14811","35815375","PMC9795999",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017237","The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome.","Liu S","2020","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2020.00136","32184723","PMC7059191",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017238","Clinical and Cross-Domain Validation of an LLM-Guided, Literature-Based Gene Prioritization Framework","Khan T","2026","bioRxiv","nonrandomized_study","preprint","10.64898/2026.01.22.701191",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0017239","Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE).","Amamoo J","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01721-y","40146378","PMC12006634",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017240","IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.","Fadini GP","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15486","38327240",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017241","MON-325 Tirzepatide Improves Metabolic Dysfunction in High-Fat Diet-Fed Brca1+/- Mice",null,"2025","Journal of the Endocrine Society","preclinical","article",null,null,"PMC12544066",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017242","From Liver to Kidney: The Overlooked Burden of Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease.","Bogdan RG","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14072486","40217935","PMC11989420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017243","Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.","Gerich J","2013","International journal of general medicine","narrative_review","article","10.2147/ijgm.s51665","24403842","PMC3884108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017244","Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.","Hasib A","2019","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2019.172733","31614140",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017245","An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners.","Kesavadev J","2025","Advances in therapy","narrative_review","article","10.1007/s12325-025-03250-3","40481909","PMC12313841",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017246","Individual Variability in the Cardiometabolic Response to Tirzepatide: Moving Beyond the Average.","Khan SU","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2025.04.004","40368576",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0017247","Weekly Journal Scan: The ESSENCE of metabolic risk: targeting metabolic dysfunction-associated steatohepatitis with semaglutide.","Liuzzo G","2025","European heart journal","randomized_trial","article","10.1093/eurheartj/ehaf420","40679608",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0017248","Brain Insulin Signaling Pathway Regulation of Hippocampal Neuroplasticity in Neurocognitive Disorders: Mechanisms and Therapeutic Implications.","He Y","2025","Journal of integrative neuroscience","narrative_review","article","10.31083/jin39446","40919624",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017249","Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients.","Chou CA","2020","Journal of diabetes investigation","other","article","10.1111/jdi.13314","32506681","PMC7610111",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017250","Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study.","Ohara M","2025","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-025-01691-y","40229852","PMC11998411","jRCT:jRCT1031210620",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017251","Acute Coronary Syndromes: State-of-the-Art Diagnosis, Management, and Secondary Prevention.","Yuan X","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15010016","41517261","PMC12787086",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0017252","Change in irritable bowel syndrome symptom severity among members of a multi-omic digital food-as-medicine program: a retrospective single-arm cohort study with estimates corrected for regression to the mean","Pedroso I","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.10.01.26364558",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0017253","A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass.","Lahooti A","2025","Obesity surgery","randomized_trial","article","10.1007/s11695-025-07671-5","39885064",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0017254","Fabrication and Preclinical Evaluation of Hyaluronic Acid/Aminoclay Nanocomposite Microneedles for Noninvasive Delivery of Semaglutide in Anti-Obesity Therapy.","Woo CR","2025","International journal of nanomedicine","preclinical","article","10.2147/ijn.s544952","41030572","PMC12478211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017255","GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.","Esposito K","2011","Current medical research and opinion","systematic_review","article","10.1185/03007995.2011.590127","21663496",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0017256","The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy.","Funderburg NT","2025","Open forum infectious diseases","randomized_trial","article","10.1093/ofid/ofaf152","40160348","PMC11950536","ClinicalTrials.gov:NCT04019197","S001425","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0017257","WHO Warns of Counterfeit Ozempic in the Global Supply Chain-Here's What to Know.","Ruder K","2024","JAMA","commentary","article","10.1001/jama.2024.13507","39028647",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; Research Support, Non-U.S. Gov't; article"],["R0017258","Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.","Karakasis P","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26052196","40076813","PMC11900163",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017259","Geriatric Pharmacotherapy Case Series: Medications for Diabetes-A Focus on Secondary Stroke Prevention.","Warren S","2024","The Senior care pharmacist","case_report","article","10.4140/tcp.n.2024.350","39358879",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; Review; article"],["R0017260","Diabetes: Doctors are told not to start new patients on GLP-1 agonists because of shortages.","Iacobucci G","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p2019","37657814",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017261","The cardiovascular effects of GLP-1 receptor agonists.","Okerson T","2012","Cardiovascular therapeutics","other_trial","article","10.1111/j.1755-5922.2010.00256.x","21167014","PMC3488299",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0017262","Gut hormones and appetite regulation.","Hong SH","2024","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000859","38511400",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0017263","Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study.","Bjornstad P","2024","Diabetes care","randomized_trial","article","10.2337/dc24-0322","38954432",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; other; article"],["R0017264","Periodontal Inflammatory Burden and Multi-Organ Microvascular Impairment in Type 2 Diabetes: A Cross-Sectional Observational Study.","Martu MA","2026","Current issues in molecular biology","other","article","10.3390/cimb48060601","42353605","PMC13297860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017265","Liraglutide targets the gut microbiota and the intestinal immune system to regulate insulin secretion.","Charpentier J","2021","Acta diabetologica","preclinical","article","10.1007/s00592-020-01657-8","33723651",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017266","Real-World Analysis of Semaglutide and Naltrexone for Alcohol Reduction, Anxiety Relief, and Side Effects Using Self-Reported Data from Reddit","Kumar S","2025","PsyArXiv","nonrandomized_study","preprint","10.31234/osf.io/r2fnz_v2",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0017267","Exendin-4 enhances expression of Neurod1 and Glut2 in insulin-producing cells derived from mouse embryonic stem cells.","Zhao Q","2016","Archives of medical science : AMS","preclinical","article","10.5114/aoms.2016.57596","26925137","PMC4754381",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017268","Risk of Hair Loss with Semaglutide for Weight Loss","Sodhi M","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.02.23.25322568",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0017269","Transcriptomics and proteomics characterizing the antioxidant mechanisms of semaglutide in diabetic mice with cognitive impairment.","Yang Y","2025","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2025.5497","39886945","PMC11819768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017270","[GLP-1 receptor agonists in the treatment of diabetes mellitus type 2: cardioprotection, and more!].","Granata A","2021","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","narrative_review","article",null,"34919794",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017271","Weight Loss Medications for Adult Patients With Obesity and Binge Eating-A Systematic Review and Meta-analysis.","Violante-Cumpa JR","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2025.11.002","41513086",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Meta-Analysis; Review"],["R0017272","Can Carica papaya Serve as an Adjunct to Semaglutide in Mitigating Diabetes-Induced Testicular Injury Through Modulation of Oxidative Stress, Inflammation, Apoptosis, and the miR-34c/miR-155-SIRT1/FOXO1 Axis? An Experimental and Chem-Bio-Informatics Study.","Zeweil MM","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27156956","42589610","PMC13467597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017273","[Diagnostic and therapeutic management of MASLD].","Horn P","2025","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-025-01896-3","40418344",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; English Abstract"],["R0017274","Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.","Dungan KM","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-023-01413-5","37256503","PMC10299987",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; case-report; article"],["R0017275","Use of exenatide and liraglutide in Denmark: a drug utilization study.","Pottegård A","2014","European journal of clinical pharmacology","nonrandomized_study","article","10.1007/s00228-013-1595-4","24145815",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017276","KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know.","Awdishu L","2025","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.1093/ajhp/zxaf044","40197825","PMC12158546",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; brief-report; article"],["R0017277","Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.","Sauer N","2015","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","other","article","10.1055/s-0034-1387793","25230325",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017278","Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study.","Östlund Papadogeorgos N","2021","Microcirculation (New York, N.Y. : 1994)","randomized_trial","article","10.1111/micc.12670","33151597",null,"EudraCT:2008-008367-95",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0017279","Exploring the Effects of Tirzepatide on Obstructive Sleep Apnea: A Literature Review.","Wen J","2025","Cureus","narrative_review","article","10.7759/cureus.80164","40190919","PMC11972082",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017280","Brain Neuromodulation via Endoscopic Gastric Implant Improves Glycemic Control in Insulin-Dependent Type-2 Diabetes: First-in-Human Feasibility and Autonomic Response Study.","Cigaina V","2026","Journal of laparoendoscopic & advanced surgical techniques. Part A","case_report","article","10.1177/10926429261468981","42414233",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0017281","Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.","Patoulias D","2022","The New England journal of medicine","commentary","article","10.1056/nejmc2114590","35172065","PMC8941980",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article-commentary; article"],["R0017282","Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect.","Nikolic D","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00962-3","33210276","PMC7843804","ClinicalTrials.gov:NCT01715428","S001748","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0017283","Semaglutide: a gendered phenomenon-women's increased vulnerability to adverse drug reactions in the global weight loss trend.","Castellana E","2025","Therapeutic advances in drug safety","commentary","article","10.1177/20420986251332737","40290513","PMC12033487",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017284","Effect of proton pump inhibitors on glycemic control in patients with diabetes.","Takebayashi K","2015","World journal of diabetes","randomized_trial","article","10.4239/wjd.v6.i10.1122","26322158","PMC4549663",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; editorial; article"],["R0017285","Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study.","Abdul-Ghani M","2025","BMJ open diabetes research & care","other_trial","article","10.1136/bmjdrc-2025-004981","40288809","PMC12035423","ClinicalTrials.gov:NCT01107717","S000437","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase IV; Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0017286","Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators.","Decara J","2016","BioFactors (Oxford, England)","preclinical","article","10.1002/biof.1295","27213962",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017287","Translational research on cognitive impairment in chronic kidney disease.","Wagner CA","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","narrative_review","article","10.1093/ndt/gfae229","39400744",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017288","Factors Associated With New-Onset Atrial Fibrillation in Thai Adults with Hypertension.","Limpijankit V","2025","American journal of hypertension","nonrandomized_study","article","10.1093/ajh/hpaf149","40796195",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017289","MON-829 Sex-Specific Cardiometabolic Benefits of Tirzepatide: A Real-World Study on ASCVD Risk Mitigation",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12543685",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0017290","Bridging the gap to arthroplasty: genicular artery embolization and semaglutide in a patient with severe obesity and refractory knee osteoarthritis.","Ciaffi J","2025","Scandinavian journal of rheumatology","other","article","10.1080/03009742.2025.2547454","40879538",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017291","Ozempic and dental therapy.","Kosinski TF","2024","General dentistry","commentary","article",null,"38639998",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0017292","Liraglutide Regulates Mitochondrial Quality Control System Through PGC-1α in a Mouse Model of Parkinson's Disease.","Wu P","2022","Neurotoxicity research","preclinical","article","10.1007/s12640-021-00460-9","35043376",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017293","Sustained release of exendin-4 from tannic acid/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes.","He Z","2019","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2019.03.014","30894322",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017294","New drugs for weight loss: Why change in body composition matters and why nutrition and exercise remain paramount.","Bosomworth NJ","2025","Canadian family physician Medecin de famille canadien","narrative_review","article","10.46747/cfp.711112705","41285626","PMC12668427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017295","Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss","Richards J","2023","PsyArXiv","other","preprint","10.31234/osf.io/uxa78",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017296","Effect of Semaglutide on Epicardial Adipogenesis and hiPSC-Atrial Cardiomyocytes New Hope in Targeting Epicardial Adipose Tissue.","Gaborit B","2025","JACC. Basic to translational science","commentary","article","10.1016/j.jacbts.2025.101349","40992826","PMC12539453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0017297","[From evidence-based to precision medicine: advancing a new paradigm for the diagnosis and treatment of obstructive sleep apnea].","Xiao Y","2026","Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","other","article","10.3760/cma.j.cn112147-20251114-00711","41820033",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0017298","Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.","Gong J","2025","Journal of diabetes investigation","systematic_review","article","10.1111/jdi.14340","39569606","PMC11693576",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0017299","Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.","Vanderheiden A","2016","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2016.1540","27273731",null,"ClinicalTrials.gov:NCT01505673","S001129","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0017300","MON-734 TIrzepatide Reverses Insulin Resistance Independent of Weight Loss in Individuals Without Diabetes",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12543602",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017301","Beyond Hunger: Structure, Signaling and Systemic Roles of Ghrelin","Polishchuk H","2025","Preprints.org","other","preprint","10.20944/preprints202510.0358.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017302","Design, synthesis, and in-vitro evaluation of 2-(heteroarylthio)acetamido-1H-benzo[d]imidazole derivatives as PTP1B inhibitors for the treatment of type 2 diabetes.","Kumar P","2026","3 Biotech","preclinical","article","10.1007/s13205-026-04824-w","42179932","PMC13190879",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017303","Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis.","Hassanein M","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-024-01642-2","39249672","PMC11467161",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017304","Risk of pancreatitis in patients treated with incretin-based therapies.","Meier JJ","2014","Diabetologia","nonrandomized_study","article","10.1007/s00125-014-3231-y","24723174",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017305","Hot weight loss drugs tested against addiction.","Leslie M","2023","Science (New York, N.Y.)","commentary","article","10.1126/science.adk5720","37651529",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0017306","Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease.","Patel V","2018","Canadian journal of physiology and pharmacology","preclinical","article","10.1139/cjpp-2017-0683","29406832",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017307","85. Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients With Semaglutide-Associated Weight Loss","Garbaccio N","2025","Plastic and reconstructive surgery. Global open","other_trial","article","10.1097/01.gox.0001112292.24666.f4",null,"PMC12023156",null,null,"europepmc; openalex","TRUE","open_europepmc","5","FALSE","Abstract; article"],["R0017308","Semaglutide in MASH: A Promising Step Forward With Room for Improvement.","Lens S","2026","Gastroenterology","other","article","10.1053/j.gastro.2025.07.023","40712938",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017309","Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.","Prattichizzo F","2021","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2021.154799","34029597",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0017310","Switching from Multiple Insulin Injections to a Fixed Combination of Degludec and Liraglutide in Patients with Type 2 Diabetes Mellitus: Results from the Simplify Study After 6 Months.","Martinka E","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-023-01435-z","37402960","PMC10363096",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017311","Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway.","Sun Y","2020","International journal of endocrinology","other","article","10.1155/2020/8821077","33488706","PMC7780226",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017312","Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes.","Xie C","2026","Diabetes","randomized_trial","article","10.2337/db25-0980","41591292",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; other; article"],["R0017313","Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study.","Heersche N","2025","Cancer communications (London, England)","commentary","article","10.1002/cac2.70030","40308149","PMC12365537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0017314","A real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database.","Li J","2025","Endocrine journal","nonrandomized_study","article","10.1507/endocrj.ej24-0286","39603650","PMC11913559",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017315","Recent advances in the pharmacotherapeutic management of diabetic kidney disease.","Block TJ","2022","Expert opinion on pharmacotherapy","other","article","10.1080/14656566.2022.2054699","35522659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017316","Semaglutide use before single-level lumbar fusion associated with fewer readmissions and 90-day costs.","Ng MK","2025","Journal of craniovertebral junction & spine","nonrandomized_study","article","10.4103/jcvjs.jcvjs_156_25","41377827","PMC12688301",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017317","In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.","Kauffman RP","2022","Annals of internal medicine","randomized_trial","article","10.7326/j22-0023","35500264",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0017318","T44. 12-MONTH FOLLOW UP OF METABOLIC MEASURES FOLLOWING A RANDOMISED CONTROLLED TRIAL OF TREATMENT OF CLOZAPINE ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX)","Siskind D","2020","Schizophrenia bulletin","randomized_trial","article","10.1093/schbul/sbaa029.604",null,"PMC7233862",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; conference-abstract"],["R0017319","In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide.","Gandhi GY","2021","Annals of internal medicine","commentary","article","10.7326/acpj202111160-127","34724396",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0017320","OR22-05 Weight Loss and Change in Body Composition in a DIO Mouse Model by the Combined AMPK and Mitochondrial Activator, ATX-304, Alone, in Combination With Semaglutide, and After Semaglutide Withdrawal",null,"2025","Journal of the Endocrine Society","preclinical","article",null,null,"PMC12545902",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017321","[Evaluation of the electronic consultation tool between primary care pharmacists and general practitioner for resolving potentially inappropriate prescriptions and drug-related problems].","Pía-Morandeira A","2026","Semergen","other","article","10.1016/j.semerg.2025.102679","41558138",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0017322","Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite.","McMorrow HE","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.03.18.585583","38562891","PMC10983981",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0017323","Does evidence matter? Comparative effectiveness research and prescribing of Type 2 diabetes mellitus drugs.","Arora P","2019","Journal of comparative effectiveness research","nonrandomized_study","article","10.2217/cer-2019-0127","31789054",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017324","Awareness Of Use Of GLP-1 Agonists In The Treatment Of Diabetes Mellitus In Pakistan.","Baig MU","2023","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.8210","37697792",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017325","Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery.","Yang PY","2016","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.1601653113","27035989","PMC4839405",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017326","Synthesis and in vivo behaviour of an exendin-4-based MRI probe capable of β-cell-dependent contrast enhancement in the pancreas.","Clough TJ","2020","Dalton transactions (Cambridge, England : 2003)","preclinical","article","10.1039/d0dt00332h","32207493","PMC7116436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017327","Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer.","Iuliano S","2026","Current opinion in oncology","randomized_trial","article","10.1097/cco.0000000000001202","41222548",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0017328","Pharmacological management of testosterone deficiency in men current advances and future directions.","Corona G","2024","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2024.2366505","38853775",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017329","Mitigation of Hearing Damage After Repeated Blast Exposures in Animal Model of Chinchilla.","Jiang S","2022","Journal of the Association for Research in Otolaryngology : JARO","preclinical","article","10.1007/s10162-022-00862-2","35906449","PMC9613841",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0017330","Enhanced Stability and Transdermal Delivery of Semaglutide Using an L-Arginine Based Dissolving Microneedle System.","Panchal P","2026","AAPS PharmSciTech","preclinical","article","10.1208/s12249-026-03455-x","42393458",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017331","Mode of administration of dulaglutide: implications for treatment adherence.","Amblee A","2016","Patient preference and adherence","other_trial","article","10.2147/ppa.s82866","27330280","PMC4898439",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0017332","Self-Assembly of a Therapeutic Peptide Surfactant: A Small-Angle X-ray Scattering Study.","Brunzell E","2026","Langmuir : the ACS journal of surfaces and colloids","other","article","10.1021/acs.langmuir.5c06529","41716033","PMC12961922",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017333","Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Wang T","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-024-01689-1","39797937","PMC11868037",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0017334","Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.","Mok J","2023","JAMA surgery","randomized_trial","article","10.1001/jamasurg.2023.2930","37494014","PMC10372755","ClinicalTrials.gov:NCT03341429","S000466","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017335","The Effect of SGLT-2 inhibitors and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis","Jogimahanti A","2022","Research Square","systematic_review","preprint","10.21203/rs.3.rs-1930982/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0017336","GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis.","Wang C","2018","PloS one","preclinical","article","10.1371/journal.pone.0193473","29590132","PMC5873987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017337","Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines.","Alqatari SG","2025","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina61071292","40731921","PMC12299311",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017338","Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.","Bækdal TA","2019","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-019-00756-2","30945118","PMC6719321",null,"S000675; S001510","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017339","Tirzepatide Affect Sexual Function in Women: Case Report.","Mohammed GF","2025","Clinical medicine insights. Case reports","case_report","article","10.1177/11795476251347753","40487373","PMC12144364",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017340","[Tirzepatide for heart failure with preserved ejection fraction (HFpEF) and obesity-the cardiometabolic turnaround?].","Störk S","2025","Innere Medizin (Heidelberg, Germany)","other","article","10.1007/s00108-025-01932-2","40640401",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017341","Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium.","Wallner M","2015","Journal of molecular and cellular cardiology","other","article","10.1016/j.yjmcc.2015.09.018","26432951",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017342","SAT-629 Treatment of Prediabetes and Obesity with Tirzepatide in a Patient with History of Type 1 Diabetes with Pancreas and Kidney Transplant",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545414",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017343","β-Cell Knockout of SENP1 Reduces Responses to Incretins and Worsens Oral Glucose Tolerance in High-Fat Diet-Fed Mice.","Lin H","2021","Diabetes","preclinical","article","10.2337/db20-1235","34462260","PMC8564408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0017344","New developments in incretin-based therapies: the current state of the field.","Robertson C","2009","Journal of the American Academy of Nurse Practitioners","narrative_review","article","10.1111/j.1745-7599.2009.00453.x","19900194",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0017345","DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular Disease.","Sonoda K","2022","American family physician","commentary","article",null,"35839371",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0017346","Burden of obesity in patients undergoing dialysis, and hopes associated with semaglutide treatment for transplant listing: An interview study.","Vanek L","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.70011","40855623","PMC12515747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017347","Rare coding mutations in the glucagon-like peptide-2 pathway are associated with increased risk of binge eating disorders.","Lutter M","2026","Behavioural brain research","nonrandomized_study","article","10.1016/j.bbr.2025.115940","41248737",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0017348","7625 Functional and structural neuronal changes of dulaglutide compared to placebo during smoking cessation - a randomized placebo-controlled trial",null,"2024","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC11454102",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0017349","Tirzepatide therapy counters inflammatory and apoptotic responses induced by high-fat diet in rat liver.","Alathary A","2025","Wiadomosci lekarskie (Warsaw, Poland : 1960)","preclinical","article","10.36740/wlek/202970","40367464",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017350","Incretin-based therapies: can we achieve glycemic control and cardioprotection?","Angeli FS","2014","The Journal of endocrinology","narrative_review","article","10.1530/joe-13-0195","23926280",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017351","ERRATUM FOR \"WITHDRAWN AS DUPLICATE: Noninvasive Evaluation of GPR119 Agonist Effects on β-Cell Mass in Diabetic Male Mice Using 111In-Exendin-4 SPECT/CT\".",null,"2020","Endocrinology","notice","article","10.1210/endocr/bqaa073","32386294",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0017352","Weight normativity in action: Semaglutide and obesity.","Lexchin JR","2025","Canadian family physician Medecin de famille canadien","other","article","10.46747/cfp.710285","39965963","PMC11998722",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0017353","The Limitations and Risks Associated With Semaglutide Treatment.","Rahman V","2025","JAMA cardiology","other","article","10.1001/jamacardio.2025.1095","40366642",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017354","Tirzepatide-induced lichen planus pigmentosus.","Fisher CM","2025","JAAD case reports","case_report","article","10.1016/j.jdcr.2025.02.018","41394532","PMC12696406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017355","Semaglutide for clozapine-treated patients with schizophrenia.","Agarwal SM","2025","The lancet. Psychiatry","other","article","10.1016/s2215-0366(25)00166-x","40506202",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017356","Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression.","Wai KM","2023","Ophthalmic surgery, lasers & imaging retina","nonrandomized_study","article","10.3928/23258160-20230217-02","36944068",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017357","Tirzepatide in the NHS: The known unknowns of treating obesity at a national scale.","Clift AK","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16375","40197843",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017358","Cotadutide effect in liver and adipose tissue in obese mice.","Marcondes-de-Castro IA","2023","Journal of molecular endocrinology","other_trial","article","10.1530/jme-22-0168","36753306",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017359","Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists?","Okiro JO","2017","BMJ case reports","case_report","article","10.1136/bcr-2017-220437","28710307","PMC5534999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017360","From Risk Assessment to Management: Cardiovascular Complications in Pre- and Post-Kidney Transplant Recipients: A Narrative Review.","Beaudrey T","2025","Diagnostics (Basel, Switzerland)","narrative_review","article","10.3390/diagnostics15070802","40218153","PMC11988545",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0017361","The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.","Juel CTB","2020","Diabetologia","randomized_trial","article","10.1007/s00125-020-05158-9","32394228",null,"ClinicalTrials.gov:NCT02640118","S001535","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0017362","In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.","Friedman JH","2024","Annals of internal medicine","other_trial","article","10.7326/annals-24-01662-jc","39222514",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; article"],["R0017363","Tirzepatide-Associated Colonic Ischemia.","Bayless D","2024","ACG case reports journal","case_report","article","10.14309/crj.0000000000001551","39507503","PMC11540430",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017364","Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin.","Polishchuk H","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms262210996","41303478","PMC12651995",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017365","Oral semaglutide in HFpEF: Real-world evidence and causal considerations.","Catalán V","2025","European journal of internal medicine","nonrandomized_study","article","10.1016/j.ejim.2025.07.024","40716975",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017366","Neuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway.","Li H","2015","International journal of clinical and experimental pathology","preclinical","article",null,"26191175","PMC4503047",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017367","Optimizing nutrition, diet, and lifestyle communication in GLP-1 medication therapy for weight management: A qualitative research study with registered dietitians.","Despain D","2024","Obesity pillars","other","article","10.1016/j.obpill.2024.100143","39498283","PMC11533596",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0017368","The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.","de Wit HM","2016","British journal of clinical pharmacology","systematic_review","article","10.1111/bcp.12925","26935973","PMC4917794",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0017369","Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.).","Moyad MA","2023","Current urology reports","narrative_review","article","10.1007/s11934-023-01180-7","37659049",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017370","Impact of Endoscopic Bariatric and Metabolic Therapies on Chronic Kidney Disease in Patients with Impaired Glycemic Control.","Pasam RT","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08583-8","41832390",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study"],["R0017371","Endoscopic sleeve gastroplasty (ESG) ‒ A semi-systematic review of current evidence, metabolic impact, special populations, and comparative strategies.","Espinet-Coll E","2025","Revista espanola de enfermedades digestivas","systematic_review","article","10.17235/reed.2025.11719/2025","41410254",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0017372","Beyond the BMI Paradox: Unraveling the Cellular and Molecular Determinants of Metabolic Health in Obesity.","Tsuchiya K","2025","Biomolecules","narrative_review","article","10.3390/biom15091278","41008585","PMC12467578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017373","Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome.","Ammar RA","2022","Inflammopharmacology","preclinical","article","10.1007/s10787-022-00956-6","35364735","PMC9135867",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017374","Kaempferol‑copper complex alleviates oxidative stress and inflammatory response in acute alcoholic liver injury by inhibiting the TLR4/MAPK/NF-κB signaling pathway.","Gong S","2026","International immunopharmacology","other","article","10.1016/j.intimp.2026.116192","41544531",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017375","Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts.","Du J","2016","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00194.2015","26739490","PMC4864970",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0017376","A case report of semaglutide induced sarcopenia: causes of fatigue in older adults.","Mohamad AA","2025","Korean journal of family medicine","case_report","article","10.4082/kjfm.25.0008","40223309","PMC12301675",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017377","Steatotic liver disease and liver transplantation: Candidate selection and post-transplant management.","Colmenero J","2026","JHEP reports : innovation in hepatology","narrative_review","article","10.1016/j.jhepr.2025.101704","41631128","PMC12861030",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017378","Role of liraglutide in Alzheimer's disease pathology.","Vargas-Soria M","2021","Alzheimer's research & therapy","other_trial","article","10.1186/s13195-021-00853-0","34118986","PMC8199799","ClinicalTrials.gov:NCT01843075","S000689","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0017379","Erratum to \"2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults\" [Can J Cardiol (2022):1153-1167].",null,"2022","The Canadian journal of cardiology","notice","article","10.1016/j.cjca.2022.10.008","36333251",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0017380","Once-Weekly Exenatide in Youth With Type 2 Diabetes.","Tamborlane WV","2022","Diabetes care","randomized_trial","article","10.2337/dc21-2275","35679098","PMC9346995","ClinicalTrials.gov:NCT01554618","S000457","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article; other"],["R0017381","The potential impact of GLP-1 agonists on obstructive sleep apnoea.","Hamilton GS","2023","Respirology (Carlton, Vic.)","randomized_trial","article","10.1111/resp.14545","37419864",null,"ClinicalTrials.gov:NCT05412004","S000156","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0017382","Cycling alpha cells in regenerative drug-treated human pancreatic islets may serve as key beta cell progenitors.","Karakose E","2024","Cell reports. Medicine","other","article","10.1016/j.xcrm.2024.101832","39626675","PMC11722108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0017383","GLP-1 Use, Downstream Medical Spending, and Acute-Care Burden Among Adults with BMI-Defined Obesity: An Overlap-Weighted MEPS Analysis.","Çelebi O","2026","Healthcare (Basel, Switzerland)","other","article","10.3390/healthcare14152362","42588330","PMC13465546",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017384","Aspiration risk with glucagon-like peptide 1 (GLP-1) agonists.","Marroquin-Harris M","2023","Anaesthesia","commentary","article","10.1111/anae.16099","37443429",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017385","The Plateau as Physical Necessity: Why the Weight-Loss Trajectory Under Long-Term GLP-1 Receptor Agonism Does Not Require an Energy-Gap Explanation","Manninen AH","2026","Preprints.org","other","preprint","10.20944/preprints202609.2173.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017386","7098 Paradoxical Worsening of Dyslipidemia with Tirzepatide",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453247",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017387","Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.","Tuttle KR","2018","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(18)30104-9","29910024",null,"ClinicalTrials.gov:NCT01621178","S000237","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0017388","[Tirzepatide reduces body weight and improves symptoms in patients with obstructive sleep apnea syndrom.].","Forte V","2025","Recenti progressi in medicina","other","article","10.1701/4416.44118","39840872",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017389","Can epicardial fat glucagon-like peptide-1 receptor open up to the cardiovascular benefits of glucagon-like peptide-1 analogues?","Iacobellis G","2021","Polish archives of internal medicine","commentary","article","10.20452/pamw.15904","33783174",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0017390","Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials.","Beccuti G","2024","Current obesity reports","other_trial","article","10.1007/s13679-024-00592-x","39378016","PMC11522180",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0017391","Magnetic Resonance Imaging of Transplanted Porcine Neonatal Pancreatic Cell Clusters Labeled with Exendin-4-Conjugated Manganese Magnetism-Engineered Iron Oxide Nanoparticles.","Juang JH","2022","Nanomaterials (Basel, Switzerland)","preclinical","article","10.3390/nano12071222","35407339","PMC9000895",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017392","Racial and Ethnic Disparities and Facility-Level Variation in GLP-1 RA Prescription among US Veterans with CKD.","Gregg LP","2023","Clinical journal of the American Society of Nephrology : CJASN","commentary","article","10.2215/cjn.0000000000000266","37490295","PMC10637447",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; research-article; article"],["R0017393","Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes.","Hribal ML","2010","Expert review of endocrinology & metabolism","other","article","10.1586/eem.10.20","30780808",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017394","Chronic low-grade inflammation drives skeletal aging and neurocognitive decline: inflammaging as a central hub coupling bone-brain aging.","Yu M","2026","Frontiers in immunology","randomized_trial","article","10.3389/fimmu.2026.1874465","42761784","PMC13587232",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0017395","Clinical Profile and Management of Patients with Newly Diagnosed Type 2 Diabetes Mellitus in Hospital Setting.","Muñoz Moreno D","2025","Clinical medicine insights. Endocrinology and diabetes","nonrandomized_study","article","10.1177/11795514251323831","40078450","PMC11898092",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017396","Effectiveness of an academic detailing service to support appropriate prescribing and care in patients with type 2 diabetes.","Chu C","2025","Family practice","nonrandomized_study","article","10.1093/fampra/cmaf101","41510816",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017397","9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model.","Li Y","2026","European radiology experimental","preclinical","article","10.1186/s41747-026-00719-w","42090063","PMC13149678",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0017398","A patient-centered approach to managing patients with type 2 diabetes.","Pratley RE","2014","The American journal of medicine","other","article","10.1016/j.amjmed.2014.10.007","25447628",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Interactive Tutorial; Research Support, Non-U.S. Gov't; Journal Article"],["R0017399","Liraglutide Treatment Restores Cardiac Function After Isoprenaline-Induced Myocardial Injury and Prevents Heart Failure in Rats.","Bajic Z","2025","Life (Basel, Switzerland)","preclinical","article","10.3390/life15030443","40141787","PMC11943469",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017400","Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications.","Sukhram SD","2026","Pharmaceutics","randomized_trial","article","10.3390/pharmaceutics18010081","41599188","PMC12845205",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0017401","Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial.","Scholte M","2011","Trials","protocol","article","10.1186/1745-6215-12-240","22067476","PMC3235971","ClinicalTrials.gov:NCT01254123","S001622","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0017402","Mollugin activates GLP-1R to improve cognitive dysfunction in type 2 diabetic mice.","Wang Z","2023","Life sciences","preclinical","article","10.1016/j.lfs.2023.122026","37607641",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017403","GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study.","Loizidis G","2026","Clinical rheumatology","nonrandomized_study","article","10.1007/s10067-026-08212-w","42274932",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017404","Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice.","Zhang A","2025","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.16294","40000395",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017405","Effect of Semaglutide Versus Placebo on Heart Failure With Preserved Ejection Fraction in Obese Patients: A Systematic Review.","Umaña Mejia CA","2025","Cureus","systematic_review","article","10.7759/cureus.85250","40605908","PMC12221394",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0017406","Physicians' real-world experience with IDegLira: results of a European survey.","Drummond R","2018","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2018-000531","29942526","PMC6014227",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017407","The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus-A pilot study.","Melis P","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16368","40116342","PMC12046454",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017408","Comparison of glucose control by added liraglutide to only insulin infusion in diabetic patient undergoing cardiac surgery: A preliminary randomized-controlled trial.","Sindhvananda W","2023","Annals of cardiac anaesthesia","randomized_trial","article","10.4103/aca.aca_214_20","36722590","PMC9997471",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0017409","Public Policies in Historical Context and the Association Between Education and US Older Adults' Health.","Hayward MD","2026","The Milbank quarterly","other","article","10.1111/1468-0009.70115","42591010","PMC13559944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0017410","Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes.","Duncan J","2025","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2025.100188","40687923","PMC12272120",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0017411","Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.","Ponzani P","2012","Minerva endocrinologica","other","article",null,"22382611",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017412","Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.","Mezquita Raya P","2013","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-013-0044-9","24132613","PMC3889333","ClinicalTrials.gov:NCT00700817","S002361","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0017413","Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.","Kalavalapalli S","2019","The Journal of endocrinology","preclinical","article","10.1530/joe-19-0007","31082799",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017414","Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.","King J","2019","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2019.25.6.646","31134855","PMC10397906",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017415","Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.","Wysham CH","2018","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2018.1454417","29557199",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017416","Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia.","Sebastião I","2014","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2014.00110","25071725","PMC4086025",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017417","Enhancing future liver remnant hypertrophy: innovative preoperative strategies and emerging technologies.","Ren Y","2026","Translational gastroenterology and hepatology","randomized_trial","article","10.21037/tgh-2025-151","42291162","PMC13263980",null,null,"pubmed; europepmc","TRUE","open_europepmc","2",null,"Journal Article; Review; review-article"],["R0017418","Adding liraglutide to diet and exercise to maintain weight loss - is it worth it?","Doggrell SA","2022","Expert opinion on pharmacotherapy","other","article","10.1080/14656566.2021.2019707","34913784",null,"ClinicalTrials.gov:NCT04122716","S000371","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0017419","Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).","Femminella GD","2019","Trials","protocol","article","10.1186/s13063-019-3259-x","30944040","PMC6448216","ClinicalTrials.gov:NCT01843075","S000689; S000766","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; other; article"],["R0017420","Adult-onset nesidioblastosis: a challenging diagnosis revealed by glucagon-like-peptide-1 receptor imaging.","Demartin S","2022","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-22-0325","36448840","PMC9716366",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017421","Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy.","Hou G","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1602594","40698245","PMC12279506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017422","Protein Kinases in Obesity, and the Kinase-Targeted Therapy.","Engin A","2024","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-3-031-63657-8_7","39287853",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017423","Liraglutide inhibits the proliferation of rat hepatic stellate cells under high glucose conditions by suppressing the ERK signaling pathway.","Fan B","2025","Scientific reports","randomized_trial","article","10.1038/s41598-025-97872-w","40246983","PMC12006524",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017424","Prevalence of Overweight and Obesity Among Patients Admitted With Acute Coronary Syndromes: Implications for Semaglutide Eligibility to Further Reduce Residual Risk.","Lim MY","2025","Heart, lung & circulation","other","article","10.1016/j.hlc.2025.07.008","40897571",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017425","Dry eye disease in patients with type II diabetes mellitus: A retrospective, population-based cohort study in Taiwan.","Pan LY","2022","Frontiers in medicine","randomized_trial","article","10.3389/fmed.2022.980714","36082275","PMC9445241",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017426","Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China.","Hu S","2021","Frontiers in pharmacology","other","article","10.3389/fphar.2021.701446","34177604","PMC8220214",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017427","The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.","Reis-Barbosa PH","2022","Clinics and research in hepatology and gastroenterology","preclinical","article","10.1016/j.clinre.2022.101922","35427802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017428","Cardiovascular-kidney-metabolic syndrome and treatment advances: a narrative review.","Pena C","2025","Minerva medica","randomized_trial","article","10.23736/s0026-4806.25.09607-7","40146047",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; review"],["R0017429","Immunomodulation in post-transplant diabetes mellitus: Challenges and management.","Maoz H","2025","Transplant immunology","narrative_review","article","10.1016/j.trim.2025.102304","41083056",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017430","Mechanobiology of the diabetic cardiomyocyte: insulin signaling, titin elasticity, and multiscale mechanical dysfunction.","Kaçmaz M","2026","Biophysical reviews","narrative_review","article","10.1007/s12551-026-01444-9","42621150","PMC13486435",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017431","Novel potential pharmacological approaches in treating eating disorders comorbid with substance use disorders.","Xi ZX","2025","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2025.118327","40616879","PMC12276861",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0017432","Pharmacoeconomic Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adults patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment)",null,"2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"31305974",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0017433","The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION).",null,"2025","Saudi medical journal","commentary","article","10.15537/1658-3175.8655","40840943","PMC12376166",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; news; article"],["R0017434","Varying Hypopnea Definitions and Treatment Eligibility in Obstructive Sleep Apnea.","Oo HH","2026","Sleep & breathing = Schlaf & Atmung","nonrandomized_study","article","10.1007/s11325-026-03667-2","41925927",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0017435","Treatment of obesity in spinal cord injury with tirzepatide: a case report.","Juszczak M","2025","Spinal cord series and cases","case_report","article","10.1038/s41394-025-00699-w","40025019","PMC11873185",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0017436","Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial.","Xu Z","2023","Expert review of clinical pharmacology","randomized_trial","article","10.1080/17512433.2023.2188192","36883362",null,"ClinicalTrials.gov:NCT05029076","S001520","pubmed; europepmc; openalex","TRUE","paywalled","1","FALSE","Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0017437","Alterations in one-carbon metabolism in metabolic dysfunction associated steatotic liver disease may be modified by semaglutide.","Werge MP","2025","Annals of hepatology","preclinical","article","10.1016/j.aohep.2025.102107","40889707",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017438","OCT1 Variants Are Associated with Metformin Clearance and Gluconeogenesis: Mechanistic Insights for Youth-Onset Type 2 Diabetes in the MIGHTY Study.","Cantor SL","2026","medRxiv : the preprint server for health sciences","randomized_trial","article","10.64898/2026.05.27.26354152","42245022","PMC13232362",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Preprint; preprint"],["R0017439","Tirzepatide Causes Weight Loss and Improves Sleep Apnea Symptoms.","Ebell MH","2025","American family physician","other","article",null,"40238986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017440","Reno-Protective Effect of GLP-1 Receptor Agonists in Type1 Diabetes: Dual Action on TRPC6 and NADPH Oxidases.","Youssef N","2021","Biomedicines","preclinical","article","10.3390/biomedicines9101360","34680477","PMC8533165",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017441","Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.","Saulsberry WJ","2015","International journal of clinical practice","systematic_review","article","10.1111/ijcp.12698","26215321",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Review; Network Meta-Analysis; article"],["R0017442","GPs can prescribe tirzepatide to priority patient groups from June.","Wise J","2025","BMJ (Clinical research ed.)","other","article","10.1136/bmj.r665","40174951",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017443","Heterogeneous associations of antidiabetic medications with cancer prognosis: Evidence from 61 studies with over 1.1 million patients.","Luo P","2026","Pharmacological research","systematic_review","article","10.1016/j.phrs.2026.108420","42668074",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0017444","[New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus].","Gorgojo-Martínez JJ","2019","Hipertension y riesgo vascular","other","article","10.1016/j.hipert.2019.03.005","31079957",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017445","Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study.","Mata-Cases M","2016","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2016-012463","27707830","PMC5073475",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017446","Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.","Shi X","2024","BMJ case reports","case_report","article","10.1136/bcr-2023-257657","38719260","PMC11085790",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017447","The Future of Diabetes Therapies: New Insulins and Insulin Delivery Systems, Glucagon-Like Peptide 1 Analogs, Sodium-Glucose Cotransporter Type 2 Inhibitors, and Beta Cell Replacement Therapy.","Reinhart JM","2023","The Veterinary clinics of North America. Small animal practice","narrative_review","article","10.1016/j.cvsm.2023.01.003","36854632",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017448","Impact of a clinical pharmacist on provider prescribing patterns in a primary care clinic.","Wei ET","2022","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2021.10.007","34756524",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0017449","Liraglutide prevents high glucose induced HUVECs dysfunction via inhibition of PINK1/Parkin-dependent mitophagy.","Zhang Y","2022","Molecular and cellular endocrinology","other","article","10.1016/j.mce.2022.111560","35032624",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017450","DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus.","Shao Y","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s457830","38601038","PMC11005929",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017451","A crosstalk between E2F1 and GLP-1 signaling pathways modulates insulin secretion","Bourouh C","2021","bioRxiv","preclinical","preprint","10.1101/2021.04.16.440172",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017452","Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.","Kadowaki T","2025","Obesity research & clinical practice","randomized_trial","article","10.1016/j.orcp.2025.03.003","40189961",null,"ClinicalTrials.gov:NCT03811574","S002102","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0017453","Incidental detection of multiple endocrine neoplasia and medullary thyroid carcinoma before starting GLP-1 agonist: A case report.","Glasgow K","2024","Heliyon","case_report","article","10.1016/j.heliyon.2024.e33420","39015810","PMC11250875",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017454","Semaglutide (Wegovy): CADTH Reimbursement Recommendation: Indication: As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea",null,"2022","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"38620354",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0017455","Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.","Wu R","2025","European journal of medical research","systematic_review","article","10.1186/s40001-025-03124-y","40890879","PMC12403603",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; other; review"],["R0017456","SAT-688 One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women with and without Hormone Therapy",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12544038",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0017457","SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation.","Arnold MJ","2022","American family physician","other","article",null,"35704807",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017458","Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.","Horn DB","2025","Clinical obesity","randomized_trial","article","10.1111/cob.12734","39800653","PMC12096058","ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04660643","S000242; S001077","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0017459","The ketogenic diet is not for everyone: contraindications, side effects, and drug interactions.","Dyńka D","2026","Annals of medicine","narrative_review","article","10.1080/07853890.2025.2603016","41486865","PMC12777878",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0017460","Weight for Rhythm: Is the Evidence for AF Risk with Semaglutide Still Premature?","Shahmohamadi E","2025","European journal of preventive cardiology","commentary","article","10.1093/eurjpc/zwaf415","40638784",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0017461","Systematic Review and Meta-Analysis of Liraglutide Treatment in Children Who Are Overweight or Obese: A Therapeutic Paradigm Shift?","Muñoz Rossi FA","2025","Cureus","systematic_review","article","10.7759/cureus.83738","40486450","PMC12145503",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0017462","Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.","McClean PL","2014","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2014.07.015","25107586",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017463","Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists.","Zhang X","2020","Molecular cell","other","article","10.1016/j.molcel.2020.09.020","33027691",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Preprint; preprint"],["R0017464","Correction to: Liraglutide enhances myotube differentiation and muscle contractile activity upon electric pulse stimulation in mouse skeletal muscle cells.",null,"2025","Bioscience, biotechnology, and biochemistry","notice","article","10.1093/bbb/zbaf116","40823871",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0017465","The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy.","Sportiello L","2016","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2015.10.002","26461922",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0017466","Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial Cardiomyocytes.","Basdas R","2025","JACC. Basic to translational science","other","article","10.1016/j.jacbts.2025.03.009","40471762","PMC12539479",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017467","Semaglutide: First Global Approval.","Dhillon S","2018","Drugs","narrative_review","article","10.1007/s40265-018-0871-0","29363040",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0017468","The Limitations and Risks Associated With Semaglutide Treatment-Reply.","Shi I","2025","JAMA cardiology","other","article","10.1001/jamacardio.2025.1098","40366706",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017469","Wegovy: FDA approves weight loss drug to cut cardiovascular risk.","Tanne JH","2024","BMJ (Clinical research ed.)","other","article","10.1136/bmj.q642","38479760",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017470","Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.","Gu W","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16253","40069849","PMC11964988","ClinicalTrials.gov:NCT04251156","S001288","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0017471","GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.","Smits MM","2016","Arteriosclerosis, thrombosis, and vascular biology","randomized_trial","article","10.1161/atvbaha.116.307930","27562916",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0017472","Ozempic keeps wowing: trial data show benefits for kidney disease.","Fairbank R","2024","Nature","other_trial","article","10.1038/d41586-024-01564-w","38789608",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","News; other"],["R0017473","Updates on cardiovascular outcome trials in diabetes.","Schnell O","2017","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-017-0610-y","29020969","PMC5637292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017474","Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan.","Murakami T","2022","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.13730","34863032","PMC8902377",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article-commentary; article"],["R0017475","Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report.","Candler T","2020","Journal of pediatric endocrinology & metabolism : JPEM","case_report","article","10.1515/jpem-2019-0389","32447330",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0017476","Medication De-escalation in Type 2 Diabetes: A Review of Evidence-Based Strategies for Combination Therapy Reduction.","Oraibi O","2026","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/0118715303468215260624091738","42439333",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017477","Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.","Cobble M","2012","Diabetology & metabolic syndrome","narrative_review","article","10.1186/1758-5996-4-8","22390369","PMC3310739",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0017478","Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats.","Song X","2021","Stem cells and development","randomized_trial","article","10.1089/scd.2020.0137","33677993",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017479","Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease in Patients with Diabetes","Feingold KR","2000","MDText.com, Inc., South Dartmouth (MA)","randomized_trial","article",null,"25905182",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0017480","iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.","Niemoeller E","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-017-0336-6","29143919","PMC5801222","ClinicalTrials.gov:NCT02058160","S001409","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; other; article"],["R0017481","Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus.","Sethi B","2025","Cureus","narrative_review","article","10.7759/cureus.87002","40741551","PMC12307720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017482","Exendin-4 promotes actin cytoskeleton rearrangement and protects cells from Nogo-A-Δ20 mediated spreading inhibition and growth cone collapse by down-regulating RhoA expression and activation via the PI3K pathway.","Zhao F","2019","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","other","article","10.1016/j.biopha.2018.10.008","30396070",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017483","Impact of Antidepressants on Weight Gain: Underlying Mechanisms and Mitigation Strategies.","Mouawad M","2025","Archives of clinical and biomedical research","other","article","10.26502/acbr.50170450","40444017","PMC12121960",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017484","Genetic Variation in Targets of Antidiabetic Drugs and Amyotrophic Lateral Sclerosis Risk.","Wan M","2024","Biomedicines","other","article","10.3390/biomedicines12122733","39767639","PMC11726913",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017485","Anti-inflammatory and pro-healing impacts of exendin-4 treatment in Zucker diabetic rats: Effects on skin wound fibroblasts.","Wolak M","2019","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2018.10.053","30391742",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017486","Diabetes mellitus in SHORT syndrome managed with multi-agent oral therapies: a case report and literature review.","Yang Y","2025","Therapeutic advances in endocrinology and metabolism","case_report","article","10.1177/20420188251405363","41459015","PMC12739102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017487","The Cost-effectiveness of Subcutaneous Semaglutide 2.4 mg Injection for Chronic Weight Management in Canada: A Societal Perspective","Olivieri A","2022","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-2135939/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0017488","New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals.","Wysham CH","2010","Postgraduate medicine","other","article","10.3810/pgm.2010.05.2142","20463414",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017489","The Impact of Different Antidiabetic Drugs on Fracture Risk in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials With a Focus on SGLT2 Inhibitors.","Admani B","2025","American journal of medicine open","systematic_review","article","10.1016/j.ajmo.2025.100115","41473904","PMC12745141",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0017490","New-generation antidiabetic medications and dementia risk in older adults with type 2 diabetes: A retrospective cohort study.","Cohen A","2025","The journal of prevention of Alzheimer's disease","nonrandomized_study","article","10.1016/j.tjpad.2025.100199","40345929","PMC12413712",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017491","Semaglutide ameliorates metabolic disorders in offspring via regulation of oocyte ROS of pre-pregnancy obesity mice.","Zhang JK","2025","Acta pharmacologica Sinica","preclinical","article","10.1038/s41401-025-01501-1","39984623","PMC12098875",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017492","Semaglutide promotes angiogenesis and blood-brain barrier repair after traumatic brain injury via PDGF-BB/PDGFRβ/Ang1/Tie2/VEGF signaling pathway.","Shi Y","2026","Scientific reports","preclinical","article","10.1038/s41598-026-62312-w","42471364",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017493","Correction: Chavda et al. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules 2022, 27, 4315.","Chavda VP","2025","Molecules (Basel, Switzerland)","notice","article","10.3390/molecules30061190","40142172","PMC11944464",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0017494","Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.","Nomoto H","2025","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgae213","38695547",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0017495","Effect of miR-19b on the protective effect of Exendin-4 on islet cells in non-obese diabetic mice.","He J","2019","Experimental and therapeutic medicine","randomized_trial","article","10.3892/etm.2019.7598","31258687","PMC6566081",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017496","Safety and Efficacy of Tirzepatide in Solid-Organ Transplant Recipients: Experience of a Quaternary Care Center in the Middle East.","El Khatib O","2025","Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","nonrandomized_study","article","10.6002/ect.2024.0284","39918190",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0017497","External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes.","Baser O","2025","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2025.2518329","40489337",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017498","Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity.","Zhang Z","2021","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2021.154728","33581130",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017499","Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.","Antwi K","2019","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000002522","30889001",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0017500","Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.","Rodriquez de Fonseca F","2000","Metabolism: clinical and experimental","preclinical","article","10.1053/meta.2000.6251","10877194",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017501","The Role of Pericardial Fat in Cardiometabolic Disease: Emerging Evidence and Therapeutic Potential.","Shahrori Z","2025","Current cardiology reports","narrative_review","article","10.1007/s11886-025-02305-9","41071445","PMC13589704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017502","Relapse in Anorexia Nervosa Associated With Tirzepatide: A Case Report.","Guerdjikova AI","2025","Journal of clinical psychopharmacology","case_report","article","10.1097/jcp.0000000000001975","40132115",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017503","Extra-pancreatic effects of incretin-based therapies.","Gallwitz B","2014","Endocrine","narrative_review","article","10.1007/s12020-014-0223-0","24604239",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017504","Potential Drug Interaction Between Liraglutide and Clonazepam: A Case Report.","Kheradmand A","2025","Case reports in psychiatry","case_report","article","10.1155/crps/9100558","39974287","PMC11835470",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017505","Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.","Wu S","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.897776","36034458","PMC9402979","PROSPERO:CRD42021284897",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Research Support, Non-U.S. Gov't; Journal Article; Network Meta-Analysis; systematic-review; review"],["R0017506","Early induction of insulin sensitisation treated by tirzepatide: a prospective, single-arm, open-label study in Japanese individuals with obesity and type 2 diabetes.","Yamaguchi Y","2025","Diabetologia","other_trial","article","10.1007/s00125-025-06493-5","40694059",null,"UMIN:UMIN000056862",null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Clinical Trial; article"],["R0017507","Tirzepatide, HFpEF, and the Kidney: A Triangular Relationship Requiring Measurement of GFR, Not Guesses.","Ter Maaten JM","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2025.03.508","40183720",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0017508","Daily briefing: How obesity drugs like Ozempic create a full feeling.","Graham F","2024","Nature","commentary","article","10.1038/d41586-024-02152-8","38956240",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0017509","Algorithm-Based Common Microcirculatory Framework for Monitoring and Visualizing the Integrated Pancreatic Microcirculation in Type 2 Diabetes Mellitus Mice.","Li Y","2026","Journal of diabetes","preclinical","article","10.1111/1753-0407.70188","41635279","PMC12869126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0017510","Modified translationally controlled tumor protein-derived protein transduction domain enhances nasal delivery of exendin-4 as shown with insulin.","Bae HD","2018","Drug delivery","preclinical","article","10.1080/10717544.2018.1491653","30044154","PMC6096457",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017511","Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status.","Du L","2022","Frontiers in cardiovascular medicine","other","article","10.3389/fcvm.2022.1011535","36148068","PMC9485680",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0017512","Dulaglutide rescues the elevated testicular dysfunction in a mouse model of high-fat diet-induced obesity.","Attia SM","2024","Mutation research. Genetic toxicology and environmental mutagenesis","randomized_trial","article","10.1016/j.mrgentox.2024.503805","39147447",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0017513","Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial.","Antonsen KK","2018","BMJ open","protocol","article","10.1136/bmjopen-2017-019562","30012779","PMC6082448",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; protocol; article"],["R0017514","Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice.","Wang ZJ","2024","Neuroscience","preclinical","article","10.1016/j.neuroscience.2024.11.022","39547338",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017515","Oral Janus nanomotor covalent conjugation rapeseed protein-derived DPP-IV inhibitory peptide and liraglutide: A self-propelled targeted delivery system for promoting insulin secretion and glucose-lowering.","Dong H","2026","Food research international (Ottawa, Ont.)","preclinical","article","10.1016/j.foodres.2026.120182","42692655",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017516","Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.","Dai C","2022","Medicine","randomized_trial","article","10.1097/md.0000000000031334","36316938","PMC9622638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Observational Study; Journal Article; research-article; article"],["R0017517","A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis.","Salmen T","2023","International journal of molecular sciences","systematic_review","article","10.3390/ijms24119760","37298707","PMC10253587","PROSPERO:CRD42022330442",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review-article; review"],["R0017518","Shaping the UK's long term relationship with tirzepatide.","Robertson P","2025","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.r394","40021222",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0017519","Advancements and challenges in the management of obesity using pharmacotherapy (Review).","Alotaibi SS","2025","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2025.12912","40630229","PMC12235241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017520","A85 PATTERN OF SEMAGLUTIDE PRESCRIPTION IN A REAL-WORLD PATIENT COHORT",null,"2025","Journal of the Canadian Association of Gastroenterology","nonrandomized_study","article",null,null,"PMC11807619",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0017521","The Bidirectional Relationship Between Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.","Williams DM","2024","Cureus","nonrandomized_study","article","10.7759/cureus.75993","39835079","PMC11743228",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017522","Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial.","Gullaksen S","2025","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2025.109039","40239470",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0017523","12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data.","Cominato L","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1663499","41048426","PMC12491053",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017524","Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling: Making the Case for a Functionally Gs Protein-Selective GPCR.","Lymperopoulos A","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26157239","40806371","PMC12347461",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0017525","Obesity Management for the Treatment of Type 2 Diabetes","Rothberg AE","2023","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)","narrative_review","article",null,"38696642",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0017526","A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes.","Schmidt LJ","2014","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12269","24476092",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0017527","Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.","Liu Z","2025","Diabetes care","systematic_review","article","10.2337/dc24-2241","40392993","PMC12094200",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0017528","Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.","Patel T","2023","Annals of medicine","systematic_review","article","10.1080/07853890.2023.2239830","37498865","PMC10375936",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0017529","Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery.","Lewis JE","2025","Aesthetic surgery journal","nonrandomized_study","article","10.1093/asj/sjae241","39665435","PMC11913076",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017530","Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies.","Goto H","2025","Journal of obesity & metabolic syndrome","randomized_trial","article","10.7570/jomes25017","40537153","PMC12318698",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0017531","Erectile dysfunction, type 2 diabetes, and cardiovascular disease: a narrative review and insights from a global real-world cohort analysis.","Martínez Mores S","2026","Frontiers in clinical diabetes and healthcare","randomized_trial","article","10.3389/fcdhc.2026.1781581","41867241","PMC13003461",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0017532","Tirzepatide-Induced Weight Loss and Normalization of Glycemia With Nerve Regeneration in Type 2 Diabetes: A Case Report.","Gad HY","2025","Clinical diabetes : a publication of the American Diabetes Association","case_report","article","10.2337/cd25-0066","41438327","PMC12719335",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017533","Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature.","Dumbrill JL","2018","Primary care diabetes","systematic_review","article","10.1016/j.pcd.2017.06.009","28732654",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0017534","The Insulin–Cortisol–Vitamin C Axis: A Missing Regulatory Framework in Metabolic and Hormonal Homeostasis A Narrative Review","Cheng R","2025","Preprints.org","narrative_review","preprint","10.20944/preprints202512.0217.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017535","The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.","Yang J","2017","PloS one","systematic_review","article","10.1371/journal.pone.0187537","29206832","PMC5716604",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; review"],["R0017536","Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.","Ridge T","2012","Diabetes, obesity & metabolism","systematic_review","article","10.1111/j.1463-1326.2012.01639.x","22734440","PMC3533770",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0017537","Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.","Blaslov K","2014","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v20.i23.7356","24966606","PMC4064081",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017538","Atypical Presentation of a Preexisting Pancreatic Pseudocyst with Glucagon-Like Peptide-1 Agonist as a Possible Trigger for Exacerbation: A Case Report.","Raza MM","2023","Cureus","nonrandomized_study","article","10.7759/cureus.47559","38022107","PMC10665757",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0017539","A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).","Morioka T","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15644","38715179",null,"ClinicalTrials.gov:NCT04809220","S001400","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Equivalence Trial; Research Support, Non-U.S. Gov't; article"],["R0017540","Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity.","Nolen-Doerr E","2019","Current obesity reports","narrative_review","article","10.1007/s13679-019-00350-4","31124035",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017541","Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy.","Rocha-Ferreira E","2018","Brain : a journal of neurology","preclinical","article","10.1093/brain/awy220","30165597","PMC6158761",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017542","Mitigating muscle loss during weight loss: can nutritional ketosis make a difference? A call for more research.","Athinarayanan SJ","2025","Obesity (Silver Spring, Md.)","narrative_review","article","10.1002/oby.24235","39948767","PMC11897860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0017543","Semaglutide-Mediated Lithium Toxicity.","Onggo S","2025","Journal of clinical psychopharmacology","other","article","10.1097/jcp.0000000000002017","40440507",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017544","The effect of obesity interventions on male fertility: a systematic review and meta-analysis.","Peel A","2026","Human reproduction update","systematic_review","article","10.1093/humupd/dmaf025","41065428","PMC13016750","PROSPERO:CRD42022349665",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0017545","Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.","Jones AG","2016","Diabetes care","other","article","10.2337/dc15-0258","26242184","PMC4894547","ClinicalTrials.gov:NCT01503112","S002449","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017546","Combination of Insulin with a GLP1 Agonist Is Associated with Better Memory and Normal Expression of Insulin Receptor Pathway Genes in a Mouse Model of Alzheimer's Disease.","Robinson A","2019","Journal of molecular neuroscience : MN","preclinical","article","10.1007/s12031-019-1257-9","30635783","PMC6549496",null,"S000766","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0017547","Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.","Dushay J","2012","Diabetes care","randomized_trial","article","10.2337/dc11-0931","22040840","PMC3241299",null,"S002248","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0017548","Diabetes Mellitus and Cardiovascular Disease: An Evidence-Based Review of Provincial Formulary Coverage.","Riar SS","2018","The Canadian journal of cardiology","narrative_review","article","10.1016/j.cjca.2018.07.011","30269833",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017549","Semaglutide for Type I Diabetes - A New Twist on an Old Story.","Rosen CJ","2025","NEJM evidence","commentary","article","10.1056/evide2500178","40550008",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0017550","Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study.","Kondo Y","2024","Diabetology international","randomized_trial","article","10.1007/s13340-024-00717-6","39101164","PMC11291836",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017551","An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon-like peptide-1 and glucagon receptor in healthy subjects.","Goodman J","2026","British journal of clinical pharmacology","protocol","article","10.1002/bcp.70282","41025322","PMC12850551",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0017552","Diabetic gastroparesis: clinical features, diagnosis and management.","Ahmed MSO","2023","Irish journal of medical science","narrative_review","article","10.1007/s11845-022-03191-8","36266392",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017553","Protective Effect of Semaglutide on Obesity-Induced Renal Disease and Obesity-Induced Kidney Renal Clear Cell Carcinoma.","Wang S","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s498447","40124099","PMC11930019",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017554","Physical activity promotes gut adaptation, responses to nutrients, and sensitivity to gut peptides","Bæch-Laursen C","2025","bioRxiv","preclinical","preprint","10.1101/2025.05.12.653520",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017555","Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.","Yuliantie E","2020","Biochemical pharmacology","other","article","10.1016/j.bcp.2020.114001","32360365",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0017556","Glucagon-Like Peptide-1 Receptor Signaling in the Lateral Dorsal Tegmental Nucleus Regulates Energy Balance.","Reiner DJ","2018","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/npp.2017.225","28920591","PMC5770766",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0017557","Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.","Le TA","2012","Journal of clinical and experimental hepatology","other","article","10.1016/s0973-6883(12)60104-2","25755424","PMC3940181",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0017558","Regulation of glucose homeostasis by GLP-1.","Nadkarni P","2014","Progress in molecular biology and translational science","narrative_review","article","10.1016/b978-0-12-800101-1.00002-8","24373234","PMC4159612",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review; research-article"],["R0017559","Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review.","Skrobucha A","2024","Frontiers in cardiovascular medicine","randomized_trial","article","10.3389/fcvm.2024.1446468","39741663","PMC11685754",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0017560","Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab.","Tada H","2026","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.6198-25","40866272","PMC13106759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0017561","Oral semaglutide for the treatment of obesity: a retrospective real-world study.","Krajnc M","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1593334","40510489","PMC12158668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017562","Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.","Tzefos M","2010","The Annals of pharmacotherapy","nonrandomized_study","article","10.1345/aph.1p047","20530705",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0017563","Metabolic and nutritional stress-associated dilated cardiomyopathy in the setting of semaglutide use and long-term nicotine replacement therapy: a case report and literature review.","Sriram S","2026","Therapeutic advances in drug safety","case_report","article","10.1177/20420986261448034","42152984","PMC13180106",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017564","Binding Kinetics, Bias, Receptor Internalization and Effects on Insulin Secretion in vitro and in vivo of a Novel GLP-1R/GIPR Dual Agonist, HISHS-2001.","Manchanda Y","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.01.13.632834","39868265","PMC11760779",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; article; preprint"],["R0017565","Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.","Linetzky B","2025","Annals of internal medicine","randomized_trial","article","10.7326/annals-24-02623","40550133",null,"ClinicalTrials.gov:NCT04184622","S001077","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; article"],["R0017566","Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?","Bakbak E","2021","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-021-09669-7","34228302",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0017567","Granuloma annulare after starting semaglutide.","Jones T","2025","JAAD case reports","case_report","article","10.1016/j.jdcr.2025.05.005","40642503","PMC12240130",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017568","Revealing Anisotropic Growth of Liraglutide Oligomers by Native Ion Mobility Mass Spectrometry and Molecular Dynamics Simulation.","Xi Z","2025","ACS central science","other","article","10.1021/acscentsci.5c00431","40726781","PMC12291117",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article; preprint"],["R0017569","Metformin and beyond: glucose-lowering therapy as a potential modulator of abdominal aortic aneurysm growth and stability- systematic review with narrative synthesis.","Dimova MP","2026","Cardiovascular diabetology. Endocrinology reports","systematic_review","article","10.1186/s40842-026-00275-7","41764584","PMC12950239",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0017570","Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD.","Østergaard JA","2022","Kidney international reports","commentary","article","10.1016/j.ekir.2022.09.001","36531885","PMC9751839",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0017571","Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity.","Rivera Gutierrez R","2025","Mayo Clinic proceedings","nonrandomized_study","article","10.1016/j.mayocp.2024.07.006","39601745",null,null,"S001837","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017572","[Nephrology : what's new in 2024 (II)].","De Seigneux S","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.902.136","39846098",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0017573","Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.","Caruso P","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16419","40276845","PMC12146450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0017574","Comment on \"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US\".","Salehi-Abargouei A","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","nonrandomized_study","article","10.1002/alz.70035","40356047","PMC12069008",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; letter; article"],["R0017575","Semaglutide for Metabolic Dysfunction-Associated Steatohepatitis.","Simon TG","2025","The New England journal of medicine","commentary","article","10.1056/nejme2504717","40466070",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0017576","Immune Dysregulation in Obesity.","Jiang Z","2025","Annual review of pathology","narrative_review","article","10.1146/annurev-pathmechdis-051222-015350","39854190",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review"],["R0017577","Efficacy and safety of liraglutide plus acarbose in obese patients with type 2 diabetes mellitus: A meta-analysis","Wang Y","2025","Authorea Preprints","systematic_review","preprint","10.22541/au.174625036.66012183/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0017578","Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.","Scheen AJ","2014","Expert opinion on drug metabolism & toxicology","narrative_review","article","10.1517/17425255.2014.902444","24669954",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017579","Promising treatment options with tirzepatide for Japanese individuals with obesity disease.","Nauck MA","2025","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(25)00024-5","40031942",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0017580","The limitation of lipidation: Conversion of semaglutide from once-weekly to once-monthly dosing.","Schneider EL","2024","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.2415815121","39531496","PMC11588095",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; Preprint; preprint; article"],["R0017581","The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel.","Reiner J","2022","Annals of the New York Academy of Sciences","preclinical","article","10.1111/nyas.14791","35580981",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017582","Glucagon-like Peptide-1 Agonist Liraglutide Induces Temporary Impairment to Gastric Electrical Activity in Healthy Volunteers.","Coutinho S","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2025.07.027","40744348",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017583","MiR-7, miR-9 and miR-375 contribute to effect of Exendin-4 on pancreatic β-cells in high-fat-diet-fed mice.","Guo C","2018","Clinical and investigative medicine. Medecine clinique et experimentale","preclinical","article","10.25011/cim.v41i1.29459","29603687",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017584","Hypertension in chronic kidney disease and future heart failure.","Burnier M","2025","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000001206","39998630",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017585","Preventing CXCL12 elevation helps to reduce acute exacerbation of COPD in individuals co-existing type-2 diabetes: A bioinformatics and clinical pharmacology study.","Xue H","2024","International immunopharmacology","nonrandomized_study","article","10.1016/j.intimp.2024.111894","38569426",null,"ChiCTR:ChiCTR2200055611",null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0017586","Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients with Type 2 Diabetes.","Pinto M","2025","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","nonrandomized_study","article","10.1177/87551225241289959","39545243","PMC11559783",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017587","Glucagon-like peptide-1 receptor expression after myocardial infarction: Imaging study using 68Ga-NODAGA-exendin-4 positron emission tomography.","Ståhle M","2020","Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology","preclinical","article","10.1007/s12350-018-01547-1","30547299","PMC7749060",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017588","Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues.","Cary BP","2019","Chembiochem : a European journal of chemical biology","nonrandomized_study","article","10.1002/cbic.201900300","31172641","PMC6861653",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0017589","Effect of exenatide on peripheral nerve excitability in type 2 diabetes.","Issar T","2021","Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology","nonrandomized_study","article","10.1016/j.clinph.2021.05.033","34455311",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017590","Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism.","Järvinen A","2019","Frontiers in psychiatry","case_report","article","10.3389/fpsyt.2019.00097","30881319","PMC6405420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017591","Silk fibroin hollow microneedle system for sustained transdermal administration of liraglutide: development and characterization.","Jia T","2025","International journal of biological macromolecules","preclinical","article","10.1016/j.ijbiomac.2025.146884","40816406",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017592","Semaglutide treats MASH liver disease.","O'Leary K","2025","Nature medicine","commentary","article","10.1038/d41591-025-00034-8","40442483",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0017593","Defining and achieving treatment success in patients with type 2 diabetes mellitus.","Stolar MW","2010","Mayo Clinic proceedings","narrative_review","article","10.4065/mcp.2010.0471","21106864","PMC2996162",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0017594","Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials.","Tchang BG","2025","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.24202","39756397","PMC11774009",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0017595","Comparing Efficacy of Chiglitazar, Pioglitazone, and Semaglutide in Type 2 Diabetes: A Retrospective Study.","Li W","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01724-9","40126828","PMC12006573",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017596","Liraglutide Inhibits Autophagy to Ameliorate Post-Cardiac Arrest Brain Injury and Ferroptosis in Rats.","Xing C","2025","Neurochemical research","preclinical","article","10.1007/s11064-025-04412-z","40349290",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017597","Comparative effectiveness of tirzepatide versus thiazolidinedione in adults with MASLD: a propensity score-matched cohort study.","Wu JY","2026","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2026.1769425","42222172","PMC13219383",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017598","Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.","Mody R","2018","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2017.1421146","29271258",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017599","The glucagon like peptide 1 analogue, exendin-4, attenuates oxidative stress-induced retinal cell death in early diabetic rats through promoting Sirt1 and Sirt3 expression.","Zeng Y","2016","Experimental eye research","preclinical","article","10.1016/j.exer.2016.05.002","27212443",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017600","Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole‑kindled mice.","Wang L","2021","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2021.5052","34676876","PMC8547541",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017601","Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis.","Zhang X","2022","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2021.12.007","34922031",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Review; Network Meta-Analysis"],["R0017602","Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids.","Fiorenza M","2024","Cell reports. Medicine","other","article","10.1016/j.xcrm.2024.101629","38959886","PMC11293340",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017603","Plant Polyphenols and Exendin-4 Prevent Hyperactivity and TNF-α Release in LPS-Treated In vitro Neuron/Astrocyte/Microglial Networks.","Gullo F","2017","Frontiers in neuroscience","preclinical","article","10.3389/fnins.2017.00500","28932183","PMC5592223",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017604","Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication.","Saengboonmee C","2021","Canadian journal of diabetes","other_trial","article","10.1016/j.jcjd.2020.09.008","33218924",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0017605","Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.","Jendle J","2012","Expert opinion on investigational drugs","randomized_trial","article","10.1517/13543784.2012.707190","22799463",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0017606","Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).","Zinman B","2009","Diabetes care","randomized_trial","article","10.2337/dc08-2124","19289857","PMC2699702","ClinicalTrials.gov:NCT00333151","S000767; S001123; S002222","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0017607","Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050.","Tonneijck L","2019","Diabetes care","notice","article","10.2337/dc19-er03","30674545","PMC6385692",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0017608","A new trivalent recombinant protein for type 2 diabetes mellitus with oral delivery potential: design, expression, and experimental validation.","Ehsasatvatan M","2025","Journal of biomolecular structure & dynamics","preclinical","article","10.1080/07391102.2024.2329290","38468545",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017609","Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.","Kushner RF","2025","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.24222","39948761","PMC11897845",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0017610","Incretin therapy and its effect on body weight in patients with diabetes.","Lind M","2012","Primary care diabetes","narrative_review","article","10.1016/j.pcd.2012.04.006","22613745",null,null,"S002357","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0017611","Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model.","Abdulreda MH","2016","Cell metabolism","preclinical","article","10.1016/j.cmet.2016.01.009","26876561","PMC4785083",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0017612","[Prescribing semaglutide for overweight: is it allowed?].","Rijk PC","2024","Nederlands tijdschrift voor geneeskunde","other","article",null,"39606869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0017613","Effect of exendin (exenatide)--GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model.","Bulchandani D","2012","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2012.07.024","22819704",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017614","Management of type 2 diabetes mellitus in self-motivated patients: optimized diet, exercise, and medication for weight loss and cardiometabolic fitness.","Nadeau DA","2014","The Physician and sportsmedicine","case_report","article","10.3810/psm.2014.11.2091","25419888",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017615","SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.",null,"2022","BMJ (Clinical research ed.)","notice","article","10.1136/bmj.o1080","35483730",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Published Erratum; article"],["R0017616","Prescriptions for Obesity Medications Among Adolescents Aged 12-17 Years with Obesity - United States, 2018-2023.","Kompaniyets L","2025","MMWR. Morbidity and mortality weekly report","other","article","10.15585/mmwr.mm7420a1","40471858","PMC12140182",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017617","Expression Profile of the GLP-1 Receptor in the Gastrointestinal Tract and Pancreas in Adult Female Mice.","Grunddal KV","2022","Endocrinology","preclinical","article","10.1210/endocr/bqab216","34662392",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017618","Use of semaglutide in a 54-year-old patient with cocaine abuse and weight loss: a case report.","Romeo VM","2025","Journal of medical case reports","case_report","article","10.1186/s13256-025-05049-w","39962582","PMC11834608",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017619","Exendin-4 antagonizes the metabolic action of acylated ghrelinergic signaling in the hypothalamic paraventricular nucleus.","Abtahi S","2019","General and comparative endocrinology","preclinical","article","10.1016/j.ygcen.2018.10.008","30336120","PMC6886705",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0017620","Effect of tirzepatide on weight and metabolism in a multiethnic cohort with and without diabetes.","El Ghandour S","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16287","40033710","PMC11965022",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0017621","Comment on Yang et al. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease. Diabetes Care 2022;45:1184-1192.","Hung CH","2022","Diabetes care","commentary","article","10.2337/dc22-0701","36455119",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0017622","Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?","Sullivan SD","2011","Current diabetes reports","other","article","10.1007/s11892-010-0170-y","21207204",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017623","Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes.","Son JW","2021","Endocrinology and metabolism (Seoul, Korea)","commentary","article","10.3803/enm.2021.109","33677927","PMC7937850",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0017624","Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients.","Brindisi MC","2019","Diabetes & metabolic syndrome","other_trial","article","10.1016/j.dsx.2019.06.021","31405666",null,"ClinicalTrials.gov:NCT02674893","S001317","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0017625","Incretin-Based Therapies: Revisiting Their Mode of Action.","Layden BT","2017","Endocrinology","preclinical","article","10.1210/en.2017-00252","28575434","PMC5460946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Comment; article-commentary; article"],["R0017626","The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.","Tandon S","2021","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14221","33026152",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0017627","GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.","Madsen LW","2012","Endocrinology","preclinical","article","10.1210/en.2011-1864","22234463","PMC3281535",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0017628","Association of pancreatitis with glucagon-like peptide-1 agonist use.","Anderson SL","2010","The Annals of pharmacotherapy","other_trial","article","10.1345/aph.1m676","20371755",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0017629","Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.","Yamamoto T","2016","World journal of gastroenterology","preclinical","article","10.3748/wjg.v22.i8.2512","26937139","PMC4768197",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017630","Tirzepatide-Related Acute Liver Injury.","Abdullah I","2024","European journal of case reports in internal medicine","other","article","10.12890/2024_004813","39247248","PMC11379107",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017631","Liraglutide Inhibits Osteoclastogenesis and Improves Bone Loss by Downregulating Trem2 in Female Type 1 Diabetic Mice: Findings From Transcriptomics.","Yu J","2021","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2021.763646","34975749","PMC8715718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017632","Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats.","Bin Dayel AF","2024","The Journal of pharmacy and pharmacology","preclinical","article","10.1093/jpp/rgae127","39403839",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017633","Emerging links between type 2 diabetes and Alzheimer's disease.","Sridhar GR","2015","World journal of diabetes","narrative_review","article","10.4239/wjd.v6.i5.744","26069723","PMC4458503",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017634","Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.","Nanna MG","2023","JAMA cardiology","nonrandomized_study","article","10.1001/jamacardio.2022.3839","36322056","PMC9631221",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0017635","Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.","Pradhan R","2022","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2022-071380","36318979","PMC9623550",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017636","Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes.","Daly T","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","randomized_trial","article","10.1002/alz.70422","40572012","PMC12202457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0017637","Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk.","Goncalves E","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-018-0420-6","29623594","PMC5984923",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; other; article"],["R0017638","Insight in the safety profile of antidiabetic agents glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors in daily practice from the patient perspective.","van Gorp AM","2020","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.5077","32854158",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017639","METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE.","Dezan MGF","2025","Arquivos de gastroenterologia","nonrandomized_study","article","10.1590/s0004-2803.24612025-117","40929458","PMC12435743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0017640","Tirzepatide for Congenital Generalized Lipodystrophy.","Ten S","2025","The New England journal of medicine","commentary","article","10.1056/nejmc2413871","39886995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0017641","Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program.","Khunti K","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-017-0252-9","28332144","PMC5446379","ClinicalTrials.gov:NCT01336023; ClinicalTrials.gov:NCT01392573; ClinicalTrials.gov:NCT01618162","S000164; S001276; S002285","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; article"],["R0017642","Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.","Karkare S","2019","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2019.18321","30730232","PMC10397686",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017643","A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.","Al-Zamel N","2019","International journal of molecular sciences","other","article","10.3390/ijms20143532","31330984","PMC6678630",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017644","GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time.","Caruso I","2022","Diabetes care","commentary","article","10.2337/dc21-1839","35020816","PMC8914435",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017645","Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies.","Wei L","2025","Kidney diseases (Basel, Switzerland)","randomized_trial","article","10.1159/000548367","41321783","PMC12659455",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0017646","Alopecia areata following semaglutide treatment for weight loss: A case report.","Alzahrani WS","2025","JAAD case reports","case_report","article","10.1016/j.jdcr.2025.06.012","40787040","PMC12329471",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017647","Engineered probiotics Clostridium butyricum-pMTL007-GLP-1 improves blood pressure via producing GLP-1 and modulating gut microbiota in spontaneous hypertension rat models.","Wang XL","2023","Microbial biotechnology","preclinical","article","10.1111/1751-7915.14196","36528874","PMC10034621",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017648","Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes.","Lu S","2022","Epidemiology (Cambridge, Mass.)","nonrandomized_study","article","10.1097/ede.0000000000001486","35394977",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017649","Semaglultide targets Spp1+ microglia/macrophage to attenuate neuroinflammation following perioperative stroke.","Li Y","2025","Journal of neuroinflammation","preclinical","article","10.1186/s12974-025-03465-9","40426210","PMC12117698",null,"S000497","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Preprint; research-article; article"],["R0017650","Effect of metformin dose reduction versus continuation at imeglimin initiation on glycemic control in type 2 diabetes: a retrospective real-world analysis.","Fushimi Y","2026","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-026-02662-z","41661272",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0017651","Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.","Wysham C","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2403953","39254740",null,"ClinicalTrials.gov:NCT05362058","S002606","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; article"],["R0017652","MON-639 A Case of Acute Pancreatitis Induced by Semaglutide",null,"2025","Journal of the Endocrine Society","case_report","article",null,null,"PMC12543584",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017653","A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice.","Hornigold DC","2018","Appetite","preclinical","article","10.1016/j.appet.2018.05.131","29782892","PMC6026274",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017654","Effect of tirzepatide on OSA-related cardiometabolic risk measures in SURMOUNT-OSA","Bednarik J","2025","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-6313346/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0017655","A Validated, Stability-Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance.","Zhang L","2025","Biomedical chromatography : BMC","other","article","10.1002/bmc.70118","40442972",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017656","Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?","Peterson G","2012","Annals of medicine","narrative_review","article","10.3109/07853890.2011.653392","22530845",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0017657","Pharmaceutical Analysis of Protein-Peptide Coformulations and the Influence of Polysorbates.","Whiteley J","2025","Molecular pharmaceutics","other","article","10.1021/acs.molpharmaceut.5c00119","40304029","PMC12135063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017658","Serum GDF3 is Associated with Visceral Obesity, Insulin Resistance, and Inflammation in Non-Diabetic Adults: A Cross-Sectional Study with an Interventional Component.","Li Z","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s609998","42610056","PMC13480179",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017659","Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?","Lah S","2025","Internal medicine journal","narrative_review","article","10.1111/imj.16625","39981788",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017660","Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective case-series study.","Buysschaert M","2014","The British journal of dermatology","other","article","10.1111/bjd.12886","24506139",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017661","Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis.","Ma J","2025","Endocrine","preclinical","article","10.1007/s12020-024-04013-w","39222203",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017662","Weekly Journal Scan: Effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes and high risk profile.","Gallo G","2025","European heart journal","other_trial","article","10.1093/eurheartj/ehaf299","40296649",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0017663","An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective.","Saisho Y","2020","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2020.1776262","32521177",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017664","Response to Comment on Yang et al. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease. Diabetes Care 2022;45:1184-1192.","Yang YS","2022","Diabetes care","commentary","article","10.2337/dci22-0021","36455127",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0017665","Tirzepatide for Obesity Treatment and Diabetes Prevention.","Jastreboff AM","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2410819","39536238",null,"ClinicalTrials.gov:NCT04184622","S001077; S001115; S001709; S001978","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; article"],["R0017666","[Focus on obesity drug treatments].","Favre L","2024","Revue medicale suisse","narrative_review","article","10.53738/revmed.2024.20.866.570","38506456",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; English Abstract; Journal Article; article"],["R0017667","Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.","Iepsen EW","2014","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2014.965678","25260877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017668","Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.","Liu D","2021","Hepatology (Baltimore, Md.)","preclinical","article","10.1002/hep.31856","33851458",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017669","Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.","Simonsen E","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16316","40098249","PMC12046482",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017670","Activation of glucagon-like peptide-1 receptor in microglia attenuates neuroinflammation-induced glial scarring via rescuing Arf and Rho GAP adapter protein 3 expressions after nerve injury.","Qian Z","2022","International journal of biological sciences","preclinical","article","10.7150/ijbs.68974","35280691","PMC8898359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017671","Proteomic changes upon treatment with semaglutide in individuals with obesity.","Maretty L","2025","Nature medicine","randomized_trial","article","10.1038/s41591-024-03355-2","39753963","PMC11750704",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0017672","PI3K/AKT/GSK3β regulatory axis in bone mesenchymal stem cells initiates diabetic myocardial infarction via miR-142-3p.","Gao N","2025","World journal of experimental medicine","preclinical","article","10.5493/wjem.v15.i3.103948","41523760","PMC12781669",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017673","Carnitine Deficiency Caused by Salcaprozic Acid Sodium Contained in Oral Semaglutide in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency.","Mikami-Saito Y","2025","International journal of molecular sciences","case_report","article","10.3390/ijms26072962","40243535","PMC11989126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017674","Rare variants of the glucagon-like peptide-1 receptor (GLP1R) gene are overrepresented in a severe obesity cohort and associated with type 2 diabetes in the UK Biobank","Handley D","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.05.22.23290347",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0017675","Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss.","Kumar N","2022","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgac276","35536590",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017676","[Semaglutide in the treatment of metabolic dysfunction-associated steatohepatitis (MASH)-a turning point?].","Demir M","2025","Innere Medizin (Heidelberg, Germany)","other","article","10.1007/s00108-025-01971-9","40877405",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017677","The \"Burden\" of Childhood Obesity on Bone Health: A Look at Prevention and Treatment.","Farella I","2025","Nutrients","preclinical","article","10.3390/nu17030491","39940349","PMC11821239",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017678","Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%).","Virani S","2025","The Canadian journal of cardiology","nonrandomized_study","article","10.1016/j.cjca.2025.07.027","41110921",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Practice Guideline; Retracted Publication"],["R0017679","New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions.","Chatzianagnostou K","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25116218","38892417","PMC11173177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017680","DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.","Okabe K","2020","Hypertension (Dallas, Tex. : 1979)","preclinical","article","10.1161/hypertensionaha.119.14400","32160098",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017681","Pancreatic Gα  <sub>s<\/sub>  ablation disrupts tissue architecture and YAP signaling and unveils a compensatory regenerative response","Rossotti M","2026","bioRxiv","preclinical","preprint","10.64898/2026.04.20.718494",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017682","Medication Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Gonzalez JS","2026","Diabetes care","randomized_trial","article","10.2337/dc25-2008","41557987","PMC12824802",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0017683","An intervention study of the general practice management of older adults with cardiovascular metabolic comorbidities.","Li Y","2026","PloS one","randomized_trial","article","10.1371/journal.pone.0350895","42340964","PMC13293440","ChiCTR:ChiCTR2500112212",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0017684","Spinal microglial β-endorphin signaling mediates IL-10 and exenatide-induced inhibition of synaptic plasticity in neuropathic pain.","Ma L","2021","CNS neuroscience & therapeutics","preclinical","article","10.1111/cns.13694","34111331","PMC8446220",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017685","Secretome-based screening of fusion partners and their application in recombinant protein secretion in Saccharomyces cerevisiae.","Bae JH","2022","Applied microbiology and biotechnology","preclinical","article","10.1007/s00253-021-11750-9","34971409",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017686","Liraglutide: effects beyond glycaemic control in diabetes treatment.","McGill JB","2010","International journal of clinical practice. Supplement","narrative_review","article","10.1111/j.1742-1241.2010.02495.x","20887302",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0017687","Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.","Chiquette E","2012","Vascular health and risk management","other_trial","article","10.2147/vhrm.s37969","23166441","PMC3500143","ClinicalTrials.gov:NCT00308139","S002279","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0017688","[Cardiovascular Effects of Antidiabetic Therapies].","Laubner K","2017","Deutsche medizinische Wochenschrift (1946)","other","article","10.1055/s-0043-100564","28514822",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017689","EFFECTS OF LIRAGLUTIDE ON BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.","Wang Y","2025","Acta endocrinologica (Bucharest, Romania : 2005)","randomized_trial","article","10.4183/aeb.2025.207","42569730","PMC13450665",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017690","PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.","Speliotes EK","2025","Liver international : official journal of the International Association for the Study of the Liver","narrative_review","article","10.1111/liv.16106","39559944","PMC11815600",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; review-article; article"],["R0017691","Tirzepatide-Induced Gastrointestinal disturbances leading to cardiac arrythmias: A Case Report","Gul M","2025","Authorea Preprints","case_report","preprint","10.22541/au.174106084.42888816/v1",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0017692","Multi-pathway-driven hepatic protection: Semaglutide combined with HIIT counteracts diabetic liver injury in db/db mice.","Yu W","2025","Journal of diabetes investigation","preclinical","article","10.1111/jdi.70174","41065060","PMC12679177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017693","Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.","Simeone P","2022","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-022-01469-w","35277168","PMC8917620","EudraCT:2013-001356-36",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0017694","Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.","Neumiller JJ","2009","The Annals of pharmacotherapy","other_trial","article","10.1345/aph.1m134","19638470",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0017695","Impact on Knowledge, Competence, and Performance of a Faculty-Led Web-Based Educational Activity for Type 2 Diabetes and Obesity: Questionnaire Study Among Health Care Professionals and Analysis of Anonymized Patient Records.","Okemah J","2023","JMIR formative research","other","article","10.2196/49115","37703084","PMC10534284",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017696","Assessing Cardiovascular Target Attainment in Type 2 Diabetes Mellitus Patients in Tertiary Diabetes Center in Romania.","Salmen T","2024","Pharmaceuticals (Basel, Switzerland)","other","article","10.3390/ph17091249","39338411","PMC11434711",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017697","GLP1R boosts survival, migration and invasion of endometrial cancer cells and protects against ferroptotic cell death.","Li W","2024","Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology","other","article","10.1080/01443615.2023.2301324","38269495",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017698","A case of once-weekly basal insulin therapy for a dementia patient with Type 2 Diabetes mellitus and living alone.","Yoshino H","2026","Journal of family medicine and primary care","case_report","article","10.4103/jfmpc.jfmpc_1936_25","42023334","PMC13098815",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017699","Effects of newly introduced antidiabetic drugs on autophagy.","Ashrafizadeh M","2019","Diabetes & metabolic syndrome","narrative_review","article","10.1016/j.dsx.2019.06.028","31405658",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017700","Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry.","García-Vega D","2024","The American journal of medicine","randomized_trial","article","10.1016/j.amjmed.2024.04.032","38729592",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0017701","GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.","Muskiet MHA","2017","Nature reviews. Nephrology","randomized_trial","article","10.1038/nrneph.2017.123","28869249",null,null,"S000930","pubmed; europepmc","FALSE","free_to_read","1",null,"Journal Article; Review"],["R0017702","Artificial intelligence and natural language processing of patient narratives to evaluate semaglutide for weight loss.","Bhagavathula AS","2025","Annals of epidemiology","nonrandomized_study","article","10.1016/j.annepidem.2025.09.003","40957545",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017703","Chronic social defeat stress induces a hypoglycemic shift and depression-related behaviors, both prevented by antidiabetic drugs.","Qiu W","2026","The international journal of neuropsychopharmacology","preclinical","article","10.1093/ijnp/pyag046","42633587","PMC13557117",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017704","Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys.","Liao Y","2022","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2022.106218","35618199",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017705","Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease.","Caramori ML","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70640","41816887","PMC13071197",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017706","The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis.","Huang R","2025","BMC women's health","systematic_review","article","10.1186/s12905-025-03787-z","40481408","PMC12143058",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0017707","Liraglutide, a glucagon-like peptide-1 analog, inhibits high glucose-induced oxidative stress and apoptosis in neonatal rat cardiomyocytes.","Zhang L","2019","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2019.7388","30988759","PMC6447768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017708","Semaglutide Improves Severe Liver Disease in Phase 3 Trial.","Anderer S","2025","JAMA","other_trial","article","10.1001/jama.2025.6462","40408124",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0017709","[In patients with type 2 diabetes at high risk of cardiovascular events, does oral semaglutide decrease the risk of major adverse cardiovascular events compared to placebo, and is it safe?].","Mutchmore A","2025","La Revue de medecine interne","commentary","article","10.1016/j.revmed.2025.05.010","40399176",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0017710","Circulating and hepatic levels of growth differentiation factor 15 in patients with metabolic dysfunction-associated steatotic liver disease.","Werge MP","2025","Hepatology research : the official journal of the Japan Society of Hepatology","nonrandomized_study","article","10.1111/hepr.14148","40317579",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017711","Preparation of [177Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies.","Guleria M","2019","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2019.11.003","31731177",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017712","Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes: Findings from PIONEER REAL India.","Sanyal D","2025","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/ijem.ijem_179_25","41229720","PMC12604836","ClinicalTrials.gov:NCT05502562","S001000","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017713","Efficacy of Semaglutide in Modulating Cardiac Remodeling in Mice: A Review of Mechanisms and Outcomes.","Fairy R","2025","Research in heart yield and translational medicine","nonrandomized_study","article","10.18502/jthc.v20i3.20114","42787320","PMC13601643",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0017714","Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.","Jensen SBK","2022","Nature communications","randomized_trial","article","10.1038/s41467-022-32307-y","35970829","PMC9378667","ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32","S000371; S001692","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0017715","A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.","Evans LM","2021","Endocrinology, diabetes & metabolism","randomized_trial","article","10.1002/edm2.259","34277983","PMC8279621",null,"S001381","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017716","Integrative proteogenomic analyses implicate KLK13 as a glycaemia-linked circulating protein in diabetic kidney disease.","Liu D","2026","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2026.113329","42155607",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017717","Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.","Garber AJ","2011","The Journal of the American Osteopathic Association","narrative_review","article",null,"21813733",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017718","Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles.","Soudry-Kochavi L","2018","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2018.10.013","30342089",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017719","Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review.","Singh AK","2016","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.172278","26904466","PMC4743381",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017720","Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.","Granhall C","2018","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-018-0649-2","29623579","PMC6267549","ClinicalTrials.gov:NCT02014259","S000870","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0017721","Semaglutide enhances PINK1/Parkin‑dependent mitophagy in hypoxia/reoxygenation‑induced cardiomyocyte injury.","Li L","2025","Molecular medicine reports","preclinical","article","10.3892/mmr.2025.13476","40017118","PMC11884227",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017722","Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.","Kong W","2024","Gynecologic oncology","randomized_trial","article","10.1016/j.ygyno.2024.10.004","39388742","PMC12419173",null,"S002362","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0017723","Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).","Aristizabal-Colorado D","2025","Cureus","nonrandomized_study","article","10.7759/cureus.83416","40462821","PMC12131103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017724","Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.","Zhang Q","2010","Advances in therapy","nonrandomized_study","article","10.1007/s12325-010-0024-7","20464538",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017725","Expanding cardiovascular indications for semaglutide: results from the SOUL and STRIDE trials.","Huynh K","2025","Nature reviews. Cardiology","other","article","10.1038/s41569-025-01158-7","40229511",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017726","GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein.","Hoffman S","2022","Molecular metabolism","preclinical","article","10.1016/j.molmet.2022.101590","36067913","PMC9486018",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017727","Metabolically healthy obesity: Misleading phrase or healthy phenotype?","Tanriover C","2023","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2023.02.025","36890010",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017728","Control of liver glucokinase activity: A potential new target for incretin hormones?","Francini F","2015","Peptides","preclinical","article","10.1016/j.peptides.2015.10.006","26524624",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0017729","Exendin-4 reduces food intake via the PI3K/AKT signaling pathway in the hypothalamus.","Yang Y","2017","Scientific reports","preclinical","article","10.1038/s41598-017-06951-0","28761132","PMC5537284",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0017730","PGLP-1, a novel long-acting dual-function GLP-1 analog, ameliorates streptozotocin-induced hyperglycemia and inhibits body weight loss.","Gao H","2017","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.201700002r","28461341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017731","7255 Tirzepatide Helps Achieve Glycemic Control and Lower Triglycerides in Seven Patients with Lipodystrophy",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453939",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017732","Syringaldehyde Alleviates Cardiac Hypertrophy Induced by Hyperglycemia in H9c2 Cells Through GLP-1 Receptor Signals.","Li Y","2025","Pharmaceuticals (Basel, Switzerland)","other","article","10.3390/ph18010110","39861172","PMC11768131",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017733","Effect of Tirzepatide in an Adolescent With Early-Onset Obesity, Hyperphagia, and Type 2 Diabetes.","Khurshid BN","2025","Cureus","case_report","article","10.7759/cureus.94770","41113899","PMC12531706",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017734","What a Modern Physician Should Know About microRNAs in the Diagnosis and Treatment of Diabetic Kidney Disease.","Rodzoń-Norwicz M","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26146662","40724919","PMC12294747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017735","Response to the letter titled \"Comment on associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US\".","Xu R","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","randomized_trial","article","10.1002/alz.14581","40356039","PMC12069016",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0017736","Semaglutide administration protects cardiomyocytes in db/db mice via energetic improvement and mitochondrial quality control.","Tian MY","2025","Acta pharmacologica Sinica","preclinical","article","10.1038/s41401-024-01448-9","39856432","PMC12032422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017737","Liraglutide suppresses proliferation and induces adipogenic differentiation of 3T3-L1 cells via the Hippo-YAP signaling pathway.","Li Y","2018","Molecular medicine reports","preclinical","article","10.3892/mmr.2018.8438","29344656","PMC5802226",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017738","GLP-1 modulates the supramammillary nucleus-lateral hypothalamic neurocircuit to control ingestive and motivated behavior in a sex divergent manner.","López-Ferreras L","2019","Molecular metabolism","preclinical","article","10.1016/j.molmet.2018.11.005","30528281","PMC6358540",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0017739","Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus.","Groeneveld ON","2016","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12420","26816596","PMC4718099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0017740","Mental Health Factors in Semaglutide Discontinuation.","Endo M","2025","JAMA internal medicine","other","article","10.1001/jamainternmed.2024.8390","40094686",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017741","Prevalence of Incretin-mimetic and Sodium-Glucose-Transporter-2-Inhibitor Therapy in Hospitalized Type-2-Diabetics following Myocardial Revascularization: an Observational Study","Pliquett RU","2020","Research Square","other","preprint","10.21203/rs.3.rs-52203/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017742","Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.","Packer M","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2410027","39555826",null,"ClinicalTrials.gov:NCT04847557","S000047; S000913","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0017743","Combination therapy when metformin is not an option for type 2 diabetes.","Goldman-Levine JD","2015","The Annals of pharmacotherapy","randomized_trial","article","10.1177/1060028015572653","25770115",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0017744","From liver to hormones: The endocrine consequences of cirrhosis.","Quiroz-Aldave JE","2024","World journal of gastroenterology","nonrandomized_study","article","10.3748/wjg.v30.i9.1073","38577191","PMC10989500",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0017745","Kidney Transplant: More than Immunological Problems.","Gelpi R","2025","Journal of clinical medicine","narrative_review","article","10.3390/jcm14062101","40142909","PMC11942657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017746","Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide.","Fonseca VA","2019","The Journal of clinical endocrinology and metabolism","other","article","10.1210/jc.2018-02685","30938762",null,null,"S000329; S000878; S001876","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0017747","Non-invasive tests for fibrotic MASH: Decision aids in MASH therapeutics and predictors of liver-related events.","Theocharidou E","2026","Med (New York, N.Y.)","commentary","article","10.1016/j.medj.2025.100965","41690295",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0017748","Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway.","Li Y","2025","Life sciences","preclinical","article","10.1016/j.lfs.2024.123267","39608448",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017749","Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies.","Aboukaoud M","2025","The Annals of pharmacotherapy","systematic_review","article","10.1177/10600280241312432","39885375","PMC12357981",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Review; review-article; review"],["R0017750","Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study.","Xu X","2019","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2019.03.002","30844468",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017751","Renin-angiotensin-aldosterone system variations in type 2 diabetes mellitus patients with different complications and treatments: Implications for glucose metabolism.","Wang N","2025","PloS one","other","article","10.1371/journal.pone.0316049","40106408","PMC11922211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017752","Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility.","Lee JG","2018","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2018.03.004","29522713",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017753","Novel Insights into Diabetic Kidney Disease.","Młynarska E","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms251810222","39337706","PMC11432709",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017754","Cardiometabolic Therapies Shape Non-Coding RNA Landscapes in Cardiovascular Fibrosis.","Floris E","2025","Metabolites","preclinical","article","10.3390/metabo15100664","41149642","PMC12565879",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017755","Recombinant Lactococcus lactis expressing bioactive exendin-4 to promote insulin secretion and beta-cell proliferation in vitro.","Zeng Z","2017","Applied microbiology and biotechnology","preclinical","article","10.1007/s00253-017-8410-6","28828521",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017756","Endocrine and metabolic consequences of childhood-onset craniopharyngioma during the transition age: A literature review by the TALENT study group.","De Alcubierre D","2025","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-025-09972-7","40622633","PMC12602652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017757","The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction.","Diz-Chaves Y","2018","Journal of neuroinflammation","randomized_trial","article","10.1186/s12974-018-1370-7","30518432","PMC6282252",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017758","Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation.","Davies I","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102094","39788289","PMC11786100",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0017759","Construction and Evaluation of Liraglutide Delivery System based on Milk Exosomes: A New Idea for Oral Peptide Delivery.","Shi Y","2022","Current pharmaceutical biotechnology","preclinical","article","10.2174/1389201022666210820114236","34414872",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017760","Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.","Rennert-May E","2025","The Canadian journal of cardiology","randomized_trial","article","10.1016/j.cjca.2024.09.025","39772331",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0017761","The supramammillary nucleus controls anxiety-like behavior; key role of GLP-1R.","López-Ferreras L","2020","Psychoneuroendocrinology","preclinical","article","10.1016/j.psyneuen.2020.104720","32563174",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0017762","Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m2 or higher: A phase I, randomized, double-blind, placebo-controlled study.","Asano M","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15107","37337366",null,"ClinicalTrials.gov:NCT04208620","S000682","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0017763","Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial.","Gill R","2026","American journal of preventive cardiology","randomized_trial","article","10.1016/j.ajpc.2026.101426","42291060","PMC13261207",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017764","Targeting Altered Mitochondrial Biogenesis in the Brain of Diabetic Rats: Potential Effect of Pioglitazone and Exendin-4.","Mostafa Tork O","2019","Reports of biochemistry & molecular biology","preclinical","article","10.5281/zenodo.7954713","32274400","PMC7103073",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017765","Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model.","Luciani P","2010","Cellular and molecular life sciences : CMLS","other","article","10.1007/s00018-010-0398-3","20496097","PMC11115565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017766","Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial.","Fan Y","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15359","37975640",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Letter; article"],["R0017767","Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review.","Chavda VP","2022","Molecules (Basel, Switzerland)","narrative_review","article","10.3390/molecules27134315","35807558","PMC9268041",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0017768","Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.","Unger J","2011","The Journal of the American Osteopathic Association","other","article",null,"21389296",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017769","Reporting on the real-world safety and effectiveness of oral semaglutide in improving glycemic control and reducing cardiovascular risk: a letter to the editor.","Labate AM","2026","Minerva endocrinology","nonrandomized_study","article","10.23736/s2724-6507.25.04395-7","40599046",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0017770","A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?","Vincent RK","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14196","32945071",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0017771","Current trends in insulin therapy.","Štechová K","2025","Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti","narrative_review","article","10.36290/csf.2025.011","41412766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017772","Review on cardioprotective strategies in the setting of chemotherapy-induced cardiotoxicity.","Dao V","2026","Cardio-oncology (London, England)","randomized_trial","article","10.1186/s40959-026-00480-4","41975552","PMC13195918",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0017773","Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs.","Rydén A","2016","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2016.04.002","27179248",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017774","Semaglutide-A ray of hope for CKD in diabetic patients.","Khan U","2025","JPMA. The Journal of the Pakistan Medical Association","other_trial","article","10.47391/jpma.21163","40500852",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0017775","Mental Health Factors in Semaglutide Discontinuation-Reply.","Wadden TA","2025","JAMA internal medicine","other","article","10.1001/jamainternmed.2024.8393","40094647",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017776","GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery.","Shankar A","2025","Cardiovascular endocrinology & metabolism","narrative_review","article","10.1097/xce.0000000000000321","39649679","PMC11620716",null,"S001187","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0017777","Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery.","Bao X","2023","Journal of nanobiotechnology","preclinical","article","10.1186/s12951-022-01743-9","36647125","PMC9843898",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017778","Proteomic signatures of pediatric cardiovascular and cardiometabolic traits demonstrate long-term modifiable drivers of adult disease.","Landman JM","2025","medRxiv : the preprint server for health sciences","other","article","10.1101/2025.10.27.25338754","41282792","PMC12636639",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0017779","The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial.","Golub IS","2025","Nutrition, metabolism, and cardiovascular diseases : NMCD","randomized_trial","article","10.1016/j.numecd.2025.104036","40287313",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0017780","MON-636 Growth of Pancreatic Heterotopic Tissue: A Rare Adverse Effect of Semaglutide",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12543514",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017781","Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.","Lim F","2023","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2023.29178","37651143","PMC10472196",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0017782","Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review.","Cehic MG","2018","Journal of transplantation","narrative_review","article","10.1155/2018/1025893","29623219","PMC5829348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017783","Correction: Efficacy of Liraglutide for Weight Loss in Overweight and Obese Non-diabetic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Quinapanta Castro NI","2025","Cureus","notice","article","10.7759/cureus.c277","40895700","PMC12391847",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; review"],["R0017784","Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.","Caruso P","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16594","40620210",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Comparative Study; article"],["R0017785","GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation.","Carlessi R","2017","Scientific reports","preclinical","article","10.1038/s41598-017-02838-2","28572610","PMC5454020",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017786","Dulaglutide reduces oxidative DNA damage and hypermethylation in the somatic cells of mice fed a high-energy diet by restoring redox balance, inflammatory responses, and DNA repair gene expressions.","Attia SM","2024","Journal of biochemical and molecular toxicology","preclinical","article","10.1002/jbt.23764","38963172",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017787","PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes.","Manti R","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-025-01719-6","40128506","PMC12006614","ClinicalTrials.gov:NCT05230615","S000278","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017788","Cardiovascular Outcomes of New Medications for Type 2 Diabetes.","Trujillo JM","2016","Diabetes technology & therapeutics","other_trial","article","10.1089/dia.2016.0295","27835045",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0017789","Real-world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre-diabetes.","Coon SA","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16349","40104893",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0017790","Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports.","Oliveira J","2017","Journal of medical case reports","case_report","article","10.1186/s13256-016-1175-1","28086952","PMC5237351",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017791","Exercise and weight loss with a left ventricular assist device: A case report and review of the literature.","Guerrero EL","2024","Current problems in cardiology","case_report","article","10.1016/j.cpcardiol.2024.102753","39079618",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Case Reports; Review"],["R0017792","Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts.","Thompson CA","2023","Diabetes care","commentary","article","10.2337/dci22-0052","36525594","PMC9887624",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; Comment; article-commentary; article"],["R0017793","Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE.","Liang B","2020","Cardiovascular diabetology","commentary","article","10.1186/s12933-020-01088-3","32631360","PMC7339504",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0017794","Achieving Over 30% Body Weight Loss With Semaglutide in a Patient: A Case Report.","Danish S","2025","Cureus","case_report","article","10.7759/cureus.79254","40125230","PMC11925721",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017795","Letter: Amiodarone-Induced Thyrotoxicosis Following Semaglutide-Associated Weight Loss.","Giordani I","2025","Thyroid : official journal of the American Thyroid Association","commentary","article","10.1089/thy.2025.0145","40470537",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0017796","Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.","Frechtel G","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15125","37253689",null,"EudraCT:2017-003370-13",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017797","Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.","Hölscher C","2018","Neuropharmacology","narrative_review","article","10.1016/j.neuropharm.2018.01.040","29402504",null,null,"S001115","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0017798","Exendin-4 decreases ghrelin levels through mTOR signaling.","Hong X","2016","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2016.08.039","27569528",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017799","Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","Cardoso P","2023","medRxiv","other","preprint","10.1101/2023.08.04.23293636",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017800","Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease.","Severini G","2025","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1664988","41394161","PMC12698426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017801","Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.","Ludvik B","2021","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(21)01443-4","34370970",null,"ClinicalTrials.gov:NCT03882970","S001591","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0017802","Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK.","Hall GC","2013","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.12137","23330649","PMC3698690",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017803","Small peptide-based GLP-1R ligands: an approach to reduce the kidney uptake of radiolabeled GLP-1R-targeting agents?","Felber VB","2021","EJNMMI radiopharmacy and chemistry","preclinical","article","10.1186/s41181-021-00136-x","34432147","PMC8387526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0017804","A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes.","Cornell SA","2013","Journal of clinical pharmacy and therapeutics","other","article","10.1111/jcpt.12040","23442106",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017805","[Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors].","Scheen AJ","2015","Revue medicale de Liege","randomized_trial","article",null,"26054173",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","2","FALSE","English Abstract; Journal Article; Review; article; other"],["R0017806","Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits.","Yip JMX","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26010364","39796218","PMC11719901",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017807","Innovative strategies and nanocarrier approaches for enhancing the oral bioavailability of macromolecular therapeutics.","Manjunath PG","2025","Iranian journal of basic medical sciences","narrative_review","article","10.22038/ijbms.2025.87167.18839","41586190","PMC12829707",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017808","Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation.","Kodama G","2025","Scientific reports","preclinical","article","10.1038/s41598-025-95673-9","40181096","PMC11968945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017809","Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes.","Ghafoury R","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-025-01743-6","40343683","PMC12182550",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0017810","Targeting microglial GLP1R in epilepsy: A novel approach to modulate neuroinflammation and neuronal apoptosis.","Zhang K","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.176903","39154823",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017811","Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes.","Wang Y","2026","The Journal of nutritional biochemistry","preclinical","article","10.1016/j.jnutbio.2025.110206","41314560","PMC12765557",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017812","GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment.","Gan Y","2015","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","randomized_trial","article","10.1055/s-0035-1548797","25962403",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017813","Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?","Barth SD","2023","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","nonrandomized_study","article","10.1055/a-1927-4454","35981560",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017814","Exendin-4-Conjugated Manganese Magnetism-Engineered Iron Oxide Nanoparticles as a Potential Magnetic Resonance Imaging Contrast Agent for Tracking Transplanted β-Cells.","Juang JH","2021","Nanomaterials (Basel, Switzerland)","preclinical","article","10.3390/nano11113145","34835906","PMC8625548",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017815","Practical implementation of automated insulin delivery systems in 2025: A French position statement update.","Bismuth E","2025","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2025.101637","40073966",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Consensus Statement"],["R0017816","Endometrial Transcriptome Changes following Short-Term Liraglutide Treatment in Infertile Women with Polycystic Ovarian Syndrome and Obesity.","Salamun V","2026","Gynecologic and obstetric investigation","preclinical","article","10.1159/000547513","40695252",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017817","Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.","Shyangdan DS","2010","BMC endocrine disorders","systematic_review","article","10.1186/1472-6823-10-20","21143938","PMC3017518",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0017818","Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity.","Du M","2024","Diabetology & metabolic syndrome","other","article","10.1186/s13098-024-01540-4","39707524","PMC11660634",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017819","The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis.","Lautenbach A","2022","Obesity surgery","randomized_trial","article","10.1007/s11695-022-06211-9","35879524","PMC9532334",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017820","Comparative Effects of Liraglutide-R-Alpha Lipoic Acid Combination and Donepezil on Diazepam-Induced Amnesia in Rats.","Kumar S","2025","Cureus","randomized_trial","article","10.7759/cureus.87148","40755635","PMC12315603",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017821","SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus","khazaali A","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.860",null,"PMC7208632",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0017822","MON-702 Semaglutide as a Potential Tool in Pre-Lung Transplant Weight Loss Optimization",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12545344",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017823","Incretins in the Therapy of Diabetic Kidney Disease.","Przezak A","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms222212312","34830194","PMC8617946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017824","Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials.","Barbarawi M","2018","Journal of community hospital internal medicine perspectives","systematic_review","article","10.1080/20009666.2018.1542919","30559943","PMC6292369",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0017825","Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta-analysis.","Ling J","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.70028","40855964","PMC12515772",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0017826","Evaluating the managed care implications of longer-acting basal insulin analog therapies.","Logan T","2018","The American journal of managed care","nonrandomized_study","article",null,"29620817",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; Review; article"],["R0017827","Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat.","Bao W","2013","Cardiovascular diabetology","preclinical","article","10.1186/1475-2840-12-148","24125539","PMC3852957",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0017828","MON-705 Initiation of Semaglutide: Understanding National Prescription Behaviors in Real-World Practice",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12544765",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0017829","Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.","Hasib A","2018","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2018.07.027","30025814",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017830","Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets.","Karakasis P","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms26010209","39796066","PMC11720255",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017831","Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.","Flory JH","2016","Current atherosclerosis reports","randomized_trial","article","10.1007/s11883-016-0633-y","27817160","PMC5509052",null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Review; research-article"],["R0017832","The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4.","Sattar N","2025","Circulation","commentary","article","10.1161/circulationaha.124.072889","40354448",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017833","Brunner's Gland Hyperplasia in a Patient after Roux-Y Gastric Bypass: An Important Pitfall in GLP-1 Receptor Imaging.","Hepprich M","2020","Case reports in endocrinology","case_report","article","10.1155/2020/4510910","32313706","PMC7160728",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017834","Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect.","Giglio RV","2020","Metabolites","other","article","10.3390/metabo10100391","33008044","PMC7599907",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017835","Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.","Pasqua MR","2025","Nature medicine","randomized_trial","article","10.1038/s41591-024-03463-z","39794615","PMC12003151","ClinicalTrials.gov:NCT05205928","S000181; S001837","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0017836","Tirzepatide for managing overweight and obesity",null,"2024","National Institute for Health and Care Excellence (NICE), London","narrative_review","article",null,"39883820",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0017837","Lipid level stabilization following combination therapy with IdaGlar and Semaglutide in type 2 diabetes: a retrospective study.","Li F","2025","American journal of translational research","nonrandomized_study","article","10.62347/tzry3855","41552324","PMC12808060",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017838","The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.","Fu BY","2022","European journal of gastroenterology & hepatology","other","article","10.1097/meg.0000000000002150","33852508",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017839","Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status","Kutz A","2021","Innovation in aging","nonrandomized_study","article","10.1093/geroni/igab046.803",null,"PMC8682322",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0017840","Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes.","Tokarek J","2023","Biomedicines","narrative_review","article","10.3390/biomedicines11102611","37892985","PMC10604380",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017841","The future of PCOS management: Disease modification through regenerative, metabolic, and digital therapeutics.","Arisha R","2026","Pathology, research and practice","randomized_trial","article","10.1016/j.prp.2026.156397","41666555",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0017842","Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker-256 tumour-bearing rats.","Quintilhano DL","2021","Cell biochemistry and function","preclinical","article","10.1002/cbf.3588","32911572",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017843","Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.","Nicholas SB","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15194","37395334",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; article"],["R0017844","SAT-693 The Wealth of Nations and the Weight Loss Revolution: Demographics and Economic Influences of Semaglutide",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544972",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017845","Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.","Chakhtoura M","2023","EClinicalMedicine","narrative_review","article","10.1016/j.eclinm.2023.101882","36992862","PMC10041469",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017846","FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea.","Anderer S","2025","JAMA","other","article","10.1001/jama.2024.28055","39853991",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017847","8447 A Short-Term Tirzepatide Treatment Improves Insulin Sensitivity and Reduces Leptin-Ghrelin Ratio in Diet-Induced Obese Mice",null,"2024","Journal of the Endocrine Society","preclinical","article",null,null,"PMC11453762",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017848","Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.","Kadowaki T","2024","Obesity research & clinical practice","randomized_trial","article","10.1016/j.orcp.2025.01.002","39824696",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0017849","Lifetime Risk from Obesity, and benefits of anti-obesity pharmacotherapy and global impact: A Multinational pooled analysis and modelling Study","Li C","2025","Research Square","other","preprint","10.21203/rs.3.rs-7603884/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0017850","Letter to \"Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: Insights from an EXSCEL post-hoc analysis\".","Wang M","2025","Diabetes research and clinical practice","commentary","article","10.1016/j.diabres.2025.112199","40268140",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0017851","[In patients with obesity and moderate to severe obstructive sleep apnea, is tirzepatide effective in reducing the apnea-hypopnea index compared to placebo, and is it safe?].","Mutchmore A","2025","La Revue de medecine interne","commentary","article","10.1016/j.revmed.2024.12.002","39694725",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0017852","Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.","Abdel-Latif RG","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.118592","33065146",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0017853","Target Trial of Glucagon-Like Peptide-1 Agonists versus Dipeptidyl Peptidase-4 Inhibitors and Mortality in Hemodialysis.","Le D","2026","Kidney international reports","nonrandomized_study","article","10.1016/j.ekir.2026.106618","42381765","PMC13315691",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017854","Semaglutide and the Retina.","Bloomgarden ZT","2025","Journal of diabetes","commentary","article","10.1111/1753-0407.70085","40229996","PMC11997011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0017855","Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity","John L","2021","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvab048.108",null,"PMC8089144",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0017856","Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?","Cheng JWM","2019","The Annals of pharmacotherapy","randomized_trial","article","10.1177/1060028018816466","30516068",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0017857","[68Ga]Ga-NOTA-MAL-Cys39-exendin-4, a potential GLP-1R targeted PET tracer for the detection of insulinoma.","Zhang P","2019","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2019.08.002","31450071",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017858","Comprehensive treatment of diabetic endothelial dysfunction based on pathophysiological mechanism.","Liu Z","2025","Frontiers in medicine","randomized_trial","article","10.3389/fmed.2025.1509884","40093018","PMC11906411",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0017859","Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.","Nalisa DL","2024","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2024.1309118","38440786","PMC10911117","PROSPERO:CRD42023403859",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; review"],["R0017860","Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.","Patel KN","2014","Canadian journal of physiology and pharmacology","preclinical","article","10.1139/cjpp-2014-0310","25361428",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017861","Recent Developments in the Drug Treatment of Parkinson's Disease.","Leiter S","2026","Drugs","other_trial","article","10.1007/s40265-026-02327-9","42162439","PMC13375751",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0017862","Anti-obesity compounds, Semaglutide and LiPR, and PrRP do not change the proportion of human and mouse POMC+ neurons.","Jörgensen SKM","2025","PloS one","preclinical","article","10.1371/journal.pone.0329268","40802598","PMC12349008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017863","[Effect of exendin-4 on lipid deposition in skeletal muscle of diet-induced obese mice and its underlying mechanism].","Cao HY","2017","Zhonghua yi xue za zhi","preclinical","article","10.3760/cma.j.issn.0376-2491.2017.02.011","28088959",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017864","Adverse effects with tirzepatide: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.","Sillassen CDB","2025","BMJ open","systematic_review","article","10.1136/bmjopen-2024-094947","40233950","PMC12001356","PROSPERO:CRD42024599035",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0017865","Targeting macrophages GLP-1 receptor pathways as emerging therapies to ameliorate cardiac remodelling associated with diabetes","Abudalo R","2020","Queen's University Belfast","preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0017866","NAION risk with semaglutide: what we know so far.","Hsu AY","2025","Eye (London, England)","commentary","article","10.1038/s41433-025-03833-y","40335680","PMC12130526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0017867","Management of acute kidney disease in type 2 diabetes: the potential role of GLP-1 RAs and SGLT2-Is.","Giugliano D","2024","Journal of nephrology","narrative_review","article","10.1007/s40620-024-02107-2","39356417",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017868","α/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo.","Shi Y","2023","Acta pharmaceutica Sinica. B","other","article","10.1016/j.apsb.2022.10.014","37139407","PMC10149899",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017869","Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy.","Malerbi FK","2025","International journal of retina and vitreous","commentary","article","10.1186/s40942-024-00622-9","39844307","PMC11752717",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0017870","The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.","Zarowitz BJ","2009","Pharmacotherapy","narrative_review","article","10.1592/phco.29.pt2.55s","19947817",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0017871","Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.","Lau DCW","2021","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(21)01751-7","34798060",null,"ClinicalTrials.gov:NCT03856047","S001532","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0017872","Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.","Chang KC","2020","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-020-01148-8","33036617","PMC7547475",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; Preprint; other; preprint; article"],["R0017873","Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide.","Abeer MM","2019","Pharmaceutics","other","article","10.3390/pharmaceutics11080418","31430872","PMC6723263",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017874","Cardiomodulatory Effects of Cardiometabolic and Antihyperglycemic Medications: The Roles of Oxidative and Endoplasmic Reticulum Stress.","Mooradian AD","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","narrative_review","article","10.1007/s40256-024-00685-x","39392561",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017875","Metabolic State Determines Central and Peripheral Mechanisms of Liraglutide-Enhanced Insulin Secretion","Bonner C","2024","Research Square","preclinical","preprint","10.21203/rs.3.rs-5544620/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017876","Disparities in liver-related care among transgender adults with steatotic liver disease: a retrospective cohort study.","Ortega Abad M","2026","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvag129","42306227","PMC13268767",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017877","Efficacy and tolerance of liraglutide for weight loss in obese, type 2 diabetes and haemodialysis patients.","Touzot M","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16484","40432380",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0017878","U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial.","Yan H","2025","JACC. Advances","other_trial","article","10.1016/j.jacadv.2025.101773","40402121","PMC12277595",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0017879","Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue.","Oliveira FCB","2021","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2021.803363","35069450","PMC8771968",null,"S002367","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0017880","Orthostatic hypotension after kidney transplantation in a patient with diabetic kidney disease: an underrecognized and therapeutic challenge.","Sakai M","2025","CEN case reports","case_report","article","10.1007/s13730-025-01030-0","40892118","PMC12605729",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Case Reports; case-report"],["R0017881","Glucagon like Peptide-1 and atherosclerosis.","Mita T","2012","Cardiovascular & hematological agents in medicinal chemistry","narrative_review","article","10.2174/187152512803530388","22827292",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0017882","Use of Semaglutide for Successful Weight Loss and Maintenance in a Non-Obese Population: An Observational, Retrospective Chart Review","Giese S","2025","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202506.1737.v2",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0017883","Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors.","Bostrom JA","2021","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-021-00961-0","34351556","PMC9953388",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0017884","GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal lipid and energy metabolism homeostasis: revealed by metabolomics","Wang C","2017","bioRxiv","preclinical","preprint","10.1101/194654",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017885","What should I consider when prescribing semaglutide for children living with obesity?","Van Boxel E","2025","Archives of disease in childhood. Education and practice edition","other","article","10.1136/archdischild-2024-327412","39242181",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017886","Achieving glycemic control in patients with type 2 diabetes and renal impairment.","Avogaro A","2013","Acta diabetologica","narrative_review","article","10.1007/s00592-012-0442-x","23212669",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0017887","Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!","Schwartz S","2013","Diabetes care","other","article","10.2337/dc12-2060","23801800","PMC3687277",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0017888","[Exendin-4 alleviates oxidative stress and liver fibrosis by activating Nrf2/HO-1 in streptozotocin-induced diabetic mice].","Fang S","2019","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","randomized_trial","article","10.12122/j.issn.1673-4254.2019.04.13","31068291","PMC6743994",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017889","Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells.","Jia Y","2018","Experimental & molecular medicine","other","article","10.1038/s12276-018-0084-3","29717107","PMC5938044",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017890","Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice.","Liu D","2022","Canadian journal of diabetes","preclinical","article","10.1016/j.jcjd.2021.08.012","35568421",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017891","Validation of a Questionnaire for Assessing the Emotional Impact of Treatment for Type 2 Diabetes.","Matza LS","2025","Patient related outcome measures","randomized_trial","article","10.2147/prom.s536043","41393977","PMC12700010",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017892","Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.","Mavrych V","2026","Frontiers in aging","nonrandomized_study","article","10.3389/fragi.2026.1790247","42021992","PMC13095733",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0017893","Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes.","Mathur V","2025","JAMA surgery","nonrandomized_study","article","10.1001/jamasurg.2025.0001","40042864","PMC11883598",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017894","The novel GLP-1/GIP dual receptor agonist DA3-CH is neuroprotective in the pilocarpine-induced epileptogenesis rat model.","Tian MJ","2019","Epilepsy research","preclinical","article","10.1016/j.eplepsyres.2019.05.008","31121474",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017895","Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.","Matza LS","2022","The patient","other_trial","article","10.1007/s40271-022-00578-8","35513765","PMC9095514",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017896","Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.","Jinnouchi H","2015","Journal of diabetes research","other_trial","article","10.1155/2015/706416","25922845","PMC4398938","UMIN:UMIN000015201",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0017897","The potential antidepressant effect of antidiabetic agents: New insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase.","Battini V","2023","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2023.1128387","36873988","PMC9981969",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017898","Liraglutide for Children 6 to <12 Years of Age with Obesity.","Malozowski S","2025","The New England journal of medicine","other_trial","article","10.1056/nejmc2503084","40334165",null,"ClinicalTrials.gov:NCT04605861; ClinicalTrials.gov:NCT04074161","S000615; S001600","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0017899","Dipeptidyl peptidase-4 disturbs adipocyte differentiation via the negative regulation of the glucagon-like peptide-1/adiponectin-cathepsin K axis in mice under chronic stress conditions.","Zhang M","2024","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.202400158r","38795334",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017900","Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia.","Koot R","2017","European journal of case reports in internal medicine","other","article","10.12890/2017_000712","30755910","PMC6346799",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017901","Tirzepatide improves cardiorenal health in obese individuals with HFpEF.","Tavosanis A","2025","Nature cardiovascular research","other","article","10.1038/s44161-024-00601-1","39753978",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017902","Neuropsychiatric Effects of Tirzepatide: A Systematic Review and Meta-Analysis.","Kamrul-Hasan ABM","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2024.12.017","39733942",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0017903","Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.","Zhao T","2025","BMC ophthalmology","nonrandomized_study","article","10.1186/s12886-025-04096-7","40289093","PMC12036213",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0017904","Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.","Østoft SH","2014","Diabetes care","randomized_trial","article","10.2337/dc13-3007","24929431",null,"ClinicalTrials.gov:NCT01610934; EudraCT:2012-000592-17","S001935","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0017905","Liraglutide Attenuates Restenosis After Vascular Injury in Rabbits With Diabetes Via the TGF-β/Smad3 Signaling Pathway.","Ding HX","2022","Alternative therapies in health and medicine","preclinical","article",null,"35751893",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017906","Exendin-4 promotes the osteogenic differentiation of osteoblasts via the Hedgehog/Gli1 signaling pathway.","Gao L","2018","American journal of translational research","preclinical","article",null,"29423016","PMC5801369",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017907","Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population-based studies.","Khanmohammadi S","2024","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.15437","39340770",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0017908","Glucagon-Like Peptide-1 Receptor Activation Does not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury.","Eriksson L","2015","Journal of vascular research","preclinical","article","10.1159/000381097","25966620",null,null,"S001903","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017909","Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats.","Fujita S","2015","PloS one","preclinical","article","10.1371/journal.pone.0141921","26536615","PMC4633148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017910","Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices.","Pinho AR","2019","Journal of pharmaceutical analysis","narrative_review","article","10.1016/j.jpha.2019.02.001","31297291","PMC6598173",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017911","Dapagliflozin, Liraglutide, and Their Combination Attenuate Diabetes Mellitus-Associated Hepato-Renal Injury-Insight into Oxidative Injury/Inflammation/Apoptosis Modulation.","El-Sherbiny M","2022","Life (Basel, Switzerland)","other","article","10.3390/life12050764","35629430","PMC9144980",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017912","VivoTag-S 750-(S)-2-amino-4-pentynoic acid12-exendin-4","Leung K","2004","National Center for Biotechnology Information (US), Bethesda (MD)","preclinical","article",null,"22238793",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0017913","Falsification periods seen with an immediate reduction in Alzheimer's disease with semaglutide.","Widera E","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","commentary","article","10.1002/alz.70150","40364443","PMC12075090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0017914","[Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.","Vilarrasa E","2024","Actas dermo-sifiliograficas","nonrandomized_study","article","10.1016/j.ad.2023.10.019","37918631",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0017915","Effectiveness of Sodium-Glucose Transporter 2 Inhibitors and Semaglutide on Body Composition in Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Real-World Cohort Study with Bioelectrical Impedance Analysis.","Yang Q","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s531413","40837607","PMC12363543",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017916","Quality of information and social norms in Spanish-speaking TikTok videos as levers of commercial practices: The case of semaglutide.","Campos-Rivera PA","2025","Social science & medicine (1982)","other","article","10.1016/j.socscimed.2024.117646","39827687",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017917","Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation.","John S","2025","Bioelectronic medicine","narrative_review","article","10.1186/s42234-025-00172-x","40301996","PMC12042417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017918","Synthetic protease-activated class B GPCRs.","Willard FS","2020","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2020.07.021","32828294",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017919","Idiosyncratic acute liver failure induced by Tirzepatide.","Terrington I","2024","Journal of gastrointestinal and liver diseases : JGLD","commentary","article","10.15403/jgld-5967","39733320",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0017920","The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice.","Monmirel-Fauconnier M","2025","Cardiovascular diabetology","preclinical","article","10.1186/s12933-025-02935-x","41286930","PMC12645716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017921","A study to evaluate the impact of PB-119 injection (a pegylated exenatide formulation) on the pharmacokinetic profiles of Digoxin and Warfarin sodium in healthy subjects.","Yu Y","2026","SAGE open medicine","randomized_trial","article","10.1177/20503121261424728","41732153","PMC12925031",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0017922","Pancreatic islet cells disarray, apoptosis, and proliferation in obese mice. The role of Semaglutide treatment.","Marinho TS","2022","Biochimie","preclinical","article","10.1016/j.biochi.2021.10.017","34742857",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017923","Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations.","Moka MK","2025","Current research in translational medicine","narrative_review","article","10.1016/j.retram.2025.103496","39847829",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017924","In MASH with moderate or advanced liver fibrosis, weekly semaglutide improved histologic steatohepatitis and fibrosis at 72 wk.","Imperiale TF","2025","Annals of internal medicine","other","article","10.7326/annals-25-03308-jc","40889372",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017925","Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD","Sano M","2024","Alzheimer's & dementia : the journal of the Alzheimer's Association","randomized_trial","article","10.1002/alz.088735",null,"PMC11713595","ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; article"],["R0017926","Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.","Kaeppeli SAM","2019","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.9b00271","31393738",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017927","Short-Term Effects of Tirzepatide in Obese Adults: A Real-World Prospective Study.","Adamidis N","2025","Cureus","nonrandomized_study","article","10.7759/cureus.85970","40662047","PMC12256807",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017928","Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway.","Wang S","2025","Diabetology & metabolic syndrome","preclinical","article","10.1186/s13098-025-01736-2","40410781","PMC12102821",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017929","Glucagon-Like Peptide-1 Agonists and General Anesthesia: Perioperative Considerations and the Utility of Gastric Ultrasound.","Willson CM","2024","Cureus","narrative_review","article","10.7759/cureus.58042","38738030","PMC11088359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017930","HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study.","Gil-Millan P","2025","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-025-02995-z","41185008","PMC12581349",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Comparative Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; Preprint; article"],["R0017931","5183 Tirzepatide Improved Health-Related Quality of Life in People with Obesity or Overweight: Results from SURMOUNT-4 Phase 3 Trial",null,"2024","Journal of the Endocrine Society","other_trial","article",null,null,"PMC11454066",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0017932","Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication).","/","2025","Australian prescriber","narrative_review","article","10.18773/austprescr.2025.024","40568689","PMC12187477",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017933","Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.","Refardt J","2021","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-020-09552-x","32495250",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017934","Untargeted metabolomics reveals the impact of Liraglutide treatment on metabolome profiling and metabolic pathways in type-2 diabetes mellitus.","Benabdelkamel H","2024","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","other","article","10.1016/j.jsps.2024.102172","39381269","PMC11458941",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017935","Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.","Nozue T","2016","Heart and vessels","nonrandomized_study","article","10.1007/s00380-015-0734-5","26293570",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017936","[Renal replacement therapy in Germany: An overview with a clinical focus].","Günther M","2025","Deutsche medizinische Wochenschrift (1946)","randomized_trial","article","10.1055/a-2261-3753","39809432",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; English Abstract; article"],["R0017937","WITHDRAWN AS DUPLICATE: Noninvasive Evaluation of GPR119 Agonist Effects on β-Cell Mass in Diabetic Male Mice Using 111In-Exendin-4 SPECT/CT.","Takaaki Murakami","2020","Endocrinology","notice","article","10.1210/endocr/bqz003","32639011",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; article"],["R0017938","Characteristics and food consumption for current, previous, and potential consumers of GLP-1 s","Dilley A","2025","Food Quality and Preference.","other","article","10.1016/j.foodqual.2025.105507",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017939","Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.","Tsapas A","2021","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14451","34047443",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0017940","Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.","Huang L","2026","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2026.103112","41962807",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0017941","Complexity of metabolic dysfunction-associated steatotic liver disease: State of the art review.","Yeh HY","2025","Journal of the Chinese Medical Association : JCMA","narrative_review","article","10.1097/jcma.0000000000001254","40506815","PMC12637118",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017942","Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration.","Zhang J","2024","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2024.1471615","39502525","PMC11534668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017943","Preserved Ejection, Lost Rhythm: A Narrative Review of the Pathophysiology and Management of Heart Failure with Preserved Ejection Fraction and Concomitant Atrial Fibrillation.","Ballatore A","2026","Journal of clinical medicine","narrative_review","article","10.3390/jcm15030969","41682651","PMC12897707",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0017944","Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges.","Tran J","2024","Life sciences","narrative_review","article","10.1016/j.lfs.2024.123001","39173996",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017945","GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation.","Movahednasab M","2025","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-025-01623-w","39962520","PMC11834518",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017946","Intestinal interleukin-22 enhances GLP-1 production via the STAT3 pathway to improve glucose homeostasis during high-fat diet induced obesity in a study with male mice.","Kim CW","2026","Nature communications","preclinical","article","10.1038/s41467-026-69734-0","41723134","PMC13035814",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017947","Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series.","Rojas Ortiz V","2021","Cureus","case_report","article","10.7759/cureus.14082","33903842","PMC8063915",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0017948","MON-704 Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents with Variants in Monogenic Obesity-related Genes",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544039",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017949","Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.","Hamayal M","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","systematic_review","article","10.1007/s40256-025-00727-y","40106161",null,"PROSPERO:CRD42024580784",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0017950","Exendin-4 and eldecalcitol synergistically promote osteogenic differentiation of bone marrow mesenchymal stem cells through M2 macrophages polarization via PI3K/AKT pathway.","Lu Y","2022","Stem cell research & therapy","preclinical","article","10.1186/s13287-022-02800-8","35313964","PMC8935829",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0017951","PYY3-36 infused systemically or directly into the VTA attenuates fentanyl seeking in male rats.","Caffrey A","2023","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2023.109686","37572954","PMC10528880",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0017952","MON-241 Efficacy and Safety of Liraglutide in Managing Obesity in Children and Adolescents: A Systematic Review and Meta-Analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12545259",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0017953","Imaging of Insulinoma by Targeting Glucagonlike Peptide-1 Receptor.","Luo Y","2021","PET clinics","narrative_review","article","10.1016/j.cpet.2020.12.008","33589387",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017954","Economic value and clinical association of a supervised lifestyle-improving program for MASLD.","Polignano M","2025","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1708451","41625336","PMC12856267","ClinicalTrials.gov:NCT06026293",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0017955","The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders.","Calkin CV","2013","Annals of medicine","narrative_review","article","10.3109/07853890.2012.687835","22621171",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017956","The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes.","Meyer J","2023","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/10600280221107381","35778801",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; other; article"],["R0017957","The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.","Van Wagner LB","2011","Therapeutic advances in gastroenterology","narrative_review","article","10.1177/1756283x11403809","21765869","PMC3131169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0017958","Effects of Incretin Pathway Elements on Bone Properties.","Abdi AM","2023","Cureus","preclinical","article","10.7759/cureus.33656","36643078","PMC9833274",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017959","Structural and Functional Diversity among Agonist-Bound States of the GLP-1 Receptor","Cary BP","2021","bioRxiv","nonrandomized_study","preprint","10.1101/2021.02.24.432589",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0017960","Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions.","Saisho Y","2018","Annals of translational medicine","commentary","article","10.21037/atm.2018.02.24","29955591","PMC6015951",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0017961","Engineering a protease-based and site-specific PEGylation-based strategy for the controlled release of exenatide.","Zhang A","2020","RSC advances","preclinical","article","10.1039/d0ra01010c","35517470","PMC9055162",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017962","Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews.","Hu X","2025","Endocrine","systematic_review","article","10.1007/s12020-025-04179-x","39955702",null,"PROSPERO:CRD42023493235",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0017963","EFFECT OF SEMAGLUTIDE ON PHYSICAL FUNCTION, BODY COMPOSITION, AND BIOMARKERS OF AGING IN OLDER ADULTS",null,"2024","Innovation in aging","other","article",null,null,"PMC11690356",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017964","Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.","Rosenstock J","2016","Diabetes care","randomized_trial","article","10.2337/dc16-0917","27527848",null,"ClinicalTrials.gov:NCT02058147","S001199","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0017965","Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.","Ishihara H","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-018-0455-8","29926400","PMC6064587","ClinicalTrials.gov:NCT02291874","S002618","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0017966","Bioprospection of rattlesnake venom peptide fractions with anti-adipose and anti-insulin resistance activity in vitro.","Meléndez-Martínez D","2024","Toxicon: X","preclinical","article","10.1016/j.toxcx.2024.100209","39398348","PMC11471244",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0017967","Semaglutide Inducing Resolution of Proliferative Diabetic Retinopathy: A Case Report.","Cool D","2024","Case reports in ophthalmological medicine","case_report","article","10.1155/crop/5834769","39691771","PMC11651726",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; Preprint; preprint; article"],["R0017968","Advances in Type 1 Diabetes Mellitus Management in Children.","Bahal M","2024","Cureus","narrative_review","article","10.7759/cureus.67377","39310514","PMC11416143",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017969","Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide.","Vaghasiya JD","2010","Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","preclinical","article","10.4103/1319-3767.65187","20616412","PMC3003206",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017970","Pregnancy Outcomes After Semaglutide Exposure.","Kolding L","2025","Basic & clinical pharmacology & toxicology","other","article","10.1111/bcpt.70021","40083043","PMC11906903",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0017971","Correspondence: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study.","Hsu CY","2025","Pharmacological research","nonrandomized_study","article","10.1016/j.phrs.2025.107639","39900209",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Letter; letter"],["R0017972","Advancing Medicinal Chemistry Through FMO: Sygnature's Platform.","Heifetz A","2026","Methods in molecular biology (Clifton, N.J.)","other","article","10.1007/978-1-0716-5420-0_4","42604897",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0017973","[Diagnosis and treatment of bile acid diarrhea].","Hansson M","2025","Lakartidningen","narrative_review","article",null,"40272084",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0017974","[Cardiovascular Effects of Incretin-Based Therapies and Their Therapeutic Potential].","Tyurenkov IN","2017","Vestnik Rossiiskoi akademii meditsinskikh nauk","narrative_review","article","10.15690/vramn732","29308856",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0017975","A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese non-human primate model","Zheng S","2022","bioRxiv","other","preprint","10.1101/2022.12.05.519153",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0017976","Therapeutic Potential of Sotagliflozin in Animal Models of Non-alcoholic Fatty Liver Disease with and without Diabetes.","Deshmukh NJ","2025","Drug research","preclinical","article","10.1055/a-2557-8927","40228542",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017977","Three years of liraglutide treatment offers continuously optimal glycemic control in a pediatric patient with maturity-onset diabetes of the young type 3.","Urakami T","2015","Journal of pediatric endocrinology & metabolism : JPEM","case_report","article","10.1515/jpem-2014-0211","25332292",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0017978","Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs.","Talbot K","2014","Neurodegenerative disease management","narrative_review","article","10.2217/nmt.13.73","24640977","PMC4465775",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0017979","O064 Tirzepatide reduced sleep apnea severity in adults with obstructive sleep apnea and obesity: results from the SURMOUNT-OSA trial",null,"2024","Sleep advances : a journal of the Sleep Research Society","other_trial","article",null,null,"PMC11645917",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0017980","Oxidative Stress as a Pathophysiological Core of Obesity: Preclinical Evidence for Antioxidant-Based Therapy Strategies.","Pereira MM","2026","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph19091414","42797459","PMC13610611",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017981","[Diabetology: what's new in 2023].","Gariani K","2024","Revue medicale suisse","other","article","10.53738/revmed.2024.20.856-7.32","38231096",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0017982","Tirzepatide's innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health.","Yang J","2024","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2024.1453825","39263564","PMC11387164",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017983","Semaglutide and Risk of NAION-Additional Insights.","Rizzo JF","2025","JAMA ophthalmology","commentary","article","10.1001/jamaophthalmol.2025.0005","39976950",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0017984","Liraglutide improves cognition function in streptozotocin-induced diabetic rats by downregulating β-secretase and γ-secretase and alleviating oxidative stress in HT-22 cells.","Ma LY","2025","Endocrine journal","preclinical","article","10.1507/endocrj.ej23-0723","39647916","PMC11913553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017985","How 'miracle' weight-loss semaglutide promises to change medicine but can we afford the expense?","Weiskirchen R","2025","British journal of pharmacology","narrative_review","article","10.1111/bph.70003","39947645",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0017986","Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice.","Kim S","2014","The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology","preclinical","article","10.4196/kjpp.2014.18.4.333","25177166","PMC4146636",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017987","GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?","Simó R","2017","Diabetes","other_trial","article","10.2337/db16-1364","28533296",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0017988","Application of the OBIMAP (One-Bead Interchain Multipeptide Assembly Platform) to Long Peptide Synthesis: Liraglutide as a Case Study.","AlShaer D","2026","ACS omega","other","article","10.1021/acsomega.6c00648","41970854","PMC13063175",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0017989","Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study.","Nyland JE","2021","Diabetes","randomized_trial","article","10.2337/db21-0385","34580086","PMC8660979",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; research-article; other; article"],["R0017990","GLP-1: A Prospective Guardian for Comprehensive Myocardial Perfusion.","Li Z","2024","Diabetes/metabolism research and reviews","other_trial","article","10.1002/dmrr.70004","39520208",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0017991","Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.","Apperloo EM","2025","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other_trial","article","10.1093/ndt/gfae150","38955363","PMC11792646",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0017992","Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue.","Xian Y","2019","The Journal of endocrinology","preclinical","article","10.1530/joe-18-0639","31137012",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0017993","Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry.","Arnold SV","2023","American heart journal","nonrandomized_study","article","10.1016/j.ahj.2023.05.002","37164146",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0017994","SAT-701 Rising Above the Rest: Worldwide Trends in Public Interest for Semaglutide Among Weight Loss Alternatives",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544516",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0017995","Semaglutide and nonarteritic anterior ischaemic optic neuropathy.","BMJ Publishing Group Ltd","2025","Drug and therapeutics bulletin","other","article","10.1136/dtb.2025.000002","39870391",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0017996","Lipid metabolism in MASLD and MASH: From mechanism to the clinic.","Carli F","2024","JHEP reports : innovation in hepatology","narrative_review","article","10.1016/j.jhepr.2024.101185","39583092","PMC11582433",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0017997","Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.","van Bloemendaal L","2014","The Journal of endocrinology","narrative_review","article","10.1530/joe-13-0414","24323912",null,null,"S000665; S000930; S001538","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0017998","Semaglutide Shows Promise in Reducing Alcohol Cravings.","Anderer S","2025","JAMA","other","article","10.1001/jama.2025.1354","40085100",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0017999","Risque de neuropathie optique ischémique chez les utilisateurs de sémaglutide.","Grandmaison G","2025","Revue medicale suisse","commentary","article",null,"40336239",null,null,null,"europepmc","FALSE",null,null,null,"News"],["R0018000","Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease.","Balk-Møller E","2020","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvz034","32010874","PMC6984785",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018001","Sublingual Delivery of Human GLP-1 Loaded Nanoliposomal Hydrogel for Treatment of Type 2 Diabetes Mellitus.","Khopade S","2025","AAPS PharmSciTech","preclinical","article","10.1208/s12249-025-03152-1","40461722",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0018002","Beyond the Liver: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Associated 35% Higher Risk of Clinically Diagnosed Heart Failure With Preserved Ejection Fraction (HFpEF).","Hegazy MA","2026","Current cardiology reports","systematic_review","article","10.1007/s11886-026-02408-x","42714692",null,"PROSPERO:CRD42025644064",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0018003","The role of the beta cell in type 2 diabetes: new findings from the last 5 years.","Yau B","2025","Diabetologia","narrative_review","article","10.1007/s00125-025-06499-z","40768044","PMC12423227",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018004","Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice.","Sancar-Bas S","2015","Growth factors (Chur, Switzerland)","preclinical","article","10.3109/08977194.2015.1125349","26728502",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018005","Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin.","Nambu T","2013","Journal of diabetes investigation","other","article","10.1111/j.2040-1124.2012.00242.x","24843633","PMC4019290",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018006","An investigation into the mechanisms of action of incretin-based anti-diabetic therapies in the human vasculature","Freeman LAR","2021","University of Exeter","other","article",null,null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Dissertation; dissertation"],["R0018007","What Week 8 Knows: Forecasting Six-Month GLP-1 Outcomes","Erly B","2026","medRxiv","nonrandomized_study","preprint","10.64898/2026.07.14.26357506",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0018008","Time for testing incretin therapies in early type 1 diabetes?","Bosi E","2010","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2009-2741","20525907",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018009","Real-world efficacy of tirzepatide in patients with heart failure without diabetes.","Augusto SN","2025","Current problems in cardiology","nonrandomized_study","article","10.1016/j.cpcardiol.2025.102998","39890046","PMC12090002",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0018010","Is liraglutide safe and effective in the elderly obese patients?: A single center experience.","Oral A","2025","Medicine","nonrandomized_study","article","10.1097/md.0000000000042155","40258760","PMC12014040",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0018011","New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.","George C","2018","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2018.05.043","29969616",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018012","MON-242 Effects of Liraglutide on Body Composition Distribution in Adolescents with Refractory Obesity Post-Vertical Sleeve Gastrectomy",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12543852",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018013","The Anti-Seizure Effect of Liraglutide on Ptz-Induced Convulsions Through its Anti-Oxidant and Anti-Inflammatory Properties.","Erdogan MA","2023","Neurochemical research","randomized_trial","article","10.1007/s11064-022-03736-4","36040609",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0018014","5184 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-4 phase 3 Trial",null,"2024","Journal of the Endocrine Society","other_trial","article",null,null,"PMC11453938",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0018015","Recurrent Weight Gain after Metabolic Bariatric Surgery (MBS): Emerging Insights on Kidney Function.","Fazeli SA","2026","Obesity surgery","narrative_review","article","10.1007/s11695-025-08406-2","41340012",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0018016","EADSG Guidelines: Insulin Therapy in Diabetes.","Silver B","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-018-0384-6","29508275","PMC6104264",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018017","Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes.","Al-Najim W","2025","Nutrients","other_trial","article","10.3390/nu17111934","40507203","PMC12157928",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0018018","Acquired Brain Injury-Induced Hyperphagia and Obesity, Successfully Treated With a GLP-1 Agonist","Ngu M","2021","Journal of the Endocrine Society","other","article",null,null,"PMC8265742",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018019","Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome.","Song J","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1449558","39429734","PMC11486649",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018020","Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.","Blonde L","2015","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(15)60936-9","26009229",null,"ClinicalTrials.gov:NCT01191268","S001198","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018021","Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.","Pratley RE","2020","BMJ open","other_trial","article","10.1136/bmjopen-2020-037883","33199417","PMC7670946","ClinicalTrials.gov:NCT02648204","S000372","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018022","Finerenone and semaglutide: Role in heart failure with reduced ejection fraction.","Gulzar MAR","2025","World journal of cardiology","commentary","article","10.4330/wjc.v17.i5.105822","40496391","PMC12146962",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018023","Increased Risk of Cancer-An Integral Component of the Cardio-Renal-Metabolic Disease Cluster and Its Management.","Standl E","2025","Cells","narrative_review","article","10.3390/cells14080564","40277890","PMC12025391",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0018024","Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species.","Jensen L","2017","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2017.03.020","28323117",null,null,"S000504; S000602","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0018025","Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells.","Fidan-Yaylalı G","2016","Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","other","article","10.1007/s13277-015-4104-9","26399993",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018026","Molecular Design of Unimolecular Tetra-Receptor Agonists.","Dinsmore TC","2025","Journal of the American Chemical Society","other","article","10.1021/jacs.5c04095","40461942","PMC12560177",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0018027","Effect of Semaglutide on C-peptide levels in patients with type 2 diabetes.","Fan P","2025","Pakistan journal of pharmaceutical sciences","other","article","10.36721/pjps.2025.38.2.reg.13485.1","40501244",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018028","Exendin-4 antagonizes Aβ1-42-induced suppression of long-term potentiation by regulating intracellular calcium homeostasis in rat hippocampal neurons.","Wang X","2015","Brain research","preclinical","article","10.1016/j.brainres.2015.09.015","26390937",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018029","Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.","Eldor R","2025","Diabetes care","randomized_trial","article","10.2337/dc25-0690","40673973",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0018030","Exendin-4 impairs the autophagic flux to induce apoptosis in pancreatic acinar AR42J cells by down-regulating LAMP-2.","Li Z","2018","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2018.01.037","29317206",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018031","Improved ovarian adiponectin system expression in polycystic ovary syndrome treated with exenatide.","Vatankhah A","2025","Clinical and experimental reproductive medicine","preclinical","article","10.5653/cerm.2024.06912","39084682","PMC11900662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0018032","Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.","Bajaj HS","2022","Canadian journal of diabetes","randomized_trial","article","10.1016/j.jcjd.2022.02.003","35752566",null,"ClinicalTrials.gov:NCT03819790","S000235","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0018033","Real-world impact on monthly glucose-lowering medication cost, HbA1c, weight, and polytherapy after initiating a GLP-1 receptor agonist.","Rose TN","2020","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2019.09.001","31611005",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018034","Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.","Brom M","2012","Contrast media & molecular imaging","preclinical","article","10.1002/cmmi.475","22434628","PMC4246000",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0018035","Impact of Short-Term Liraglutide Therapy on Non-Invasive Markers of Liver Fibrosis in Patients with MASLD.","Bołdys A","2025","Metabolites","other_trial","article","10.3390/metabo15080510","40863129","PMC12388381",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018036","The effects of DPP4 inhibitors, SGLT2 inhibitors and GLP1-RA on the AGE/RAGE pathway: implications for diabetes and its complications.","Abolfazli S","2025","Glycoconjugate journal","narrative_review","article","10.1007/s10719-025-10197-8","41085793",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018037","Blood pH Analysis in Combination with Molecular Medical Tools in Relation to COVID-19 Symptoms.","Siebert HC","2023","Biomedicines","preclinical","article","10.3390/biomedicines11051421","37239092","PMC10216059",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018038","Visceral Obesity and Metabolic Dysfunction in IgA Nephropathy: Nutritional and Metabolic Perspectives on Disease Progression.","Skibicka A","2025","Nutrients","systematic_review","article","10.3390/nu17203307","41156559","PMC12567062",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0018039","Efficacy of switching from dipeptidyl peptidase-4 inhibitors to dulaglutide in patients with type 2 diabetes","Chiba K","2019","Research Square","nonrandomized_study","preprint","10.21203/rs.2.12557/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0018040","The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.","Secrest MH","2017","Trends in cardiovascular medicine","randomized_trial","article","10.1016/j.tcm.2017.01.009","28291655",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0018041","Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.","Billings LK","2018","Diabetes care","randomized_trial","article","10.2337/dc17-1114","29483185",null,"ClinicalTrials.gov:NCT02420262","S001760","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018042","Beta cell specific probing with fluorescent exendin-4 is progressively reduced in type 2 diabetic mouse models.","Lehtonen J","2015","Islets","preclinical","article","10.1080/19382014.2015.1137415","26963143","PMC4878261",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018043","Racial and ethnic differences in prescribing antihyperglycemic medications to persons with type 2 diabetes: An all of us cohort study.","Brady VJ","2025","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2025.05.011","40461295",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Comparative Study; Research Support, N.I.H., Extramural"],["R0018044","Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance.","Hardonova M","2023","International journal of molecular sciences","other","article","10.3390/ijms241311162","37446338","PMC10342844",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018045","Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity.","Kim W","2021","Alimentary pharmacology & therapeutics","commentary","article","10.1111/apt.16641","34741326",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; editorial"],["R0018046","Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database.","Chen H","2025","Expert opinion on drug safety","nonrandomized_study","article","10.1080/14740338.2025.2468860","40037695",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018047","Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model.","Chen BD","2013","International journal of molecular sciences","preclinical","article","10.3390/ijms141224293","24351817","PMC3876111",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018048","First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [18F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas.","Fujimoto H","2021","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2021.717101","34489868","PMC8417326",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018049","An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.","Painter NA","2013","Journal of the American Board of Family Medicine : JABFM","other","article","10.3122/jabfm.2013.02.120174","23471935",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018050","Efficacy of Liraglutide for Weight Loss in Overweight and Obese Non-diabetic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Quinapanta Castro NI","2025","Cureus","systematic_review","article","10.7759/cureus.82479","40385831","PMC12085759","PROSPERO:CRD42025637238",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0018051","Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.","Wolff G","2023","ESC heart failure","systematic_review","article","10.1002/ehf2.14213","36337026","PMC9871670",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; research-article; article"],["R0018052","Exploring Conformational Transitions in Biased and Balanced Ligand Binding of GLP-1R.","Xu M","2025","Molecules (Basel, Switzerland)","other","article","10.3390/molecules30153216","40807391","PMC12348053",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0018053","Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats.","Padrutt I","2015","Research in veterinary science","preclinical","article","10.1016/j.rvsc.2014.12.001","25648286",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018054","The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials.","Younes AM","2021","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2021.108878","34058302",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018055","Cardio-Reno-Microvascular Phenotypes and Multifactorial Cardiometabolic Target Achievement in Type 2 Diabetes.","Luca SA","2026","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm15041674","41753361","PMC12941537",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018056","Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.","Kannan S","2016","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.12301","25929426",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0018057","Erratum to \"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial\" Am J Clin Nutr. 2021: 113: 314-323.","Gudbergsen H","2025","The American journal of clinical nutrition","notice","article","10.1016/j.ajcnut.2025.07.013","40701184",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0018058","Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved.","Trenson L","2022","Obesity facts","nonrandomized_study","article","10.1159/000520217","34808630","PMC8820228",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018059","Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.","Li C","2019","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2019.115070","31471103",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018060","Olfactory dysfunction in type II diabetes: Therapeutic options and lessons learned from other etiologies - A scoping review.","Sivakumar R","2022","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2022.05.003","35659730","PMC10184301",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Scoping Review; research-article"],["R0018061","Incretin-based therapies: review of current clinical trial data.","Peters A","2010","The American journal of medicine","other_trial","article","10.1016/j.amjmed.2009.12.007","20206729",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0018062","Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes.","Ehsasatvatan M","2023","Scientific reports","other","article","10.1038/s41598-023-45185-1","37853095","PMC10584922",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018063","In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y.","Ades M","2025","Annals of internal medicine","commentary","article","10.7326/annals-25-03196-jc","40889359",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0018064","SUN-579 Patient with No Prior History of Diabetes Mellitus Develops Acute Pancreatitis and Diabetic Ketoacidosis on Compounded Semaglutide",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12546512",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018065","9229 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-4 phase 3 Trial",null,"2024","Journal of the Endocrine Society","other_trial","article",null,null,"PMC11453977",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0018066","[Current status and influencing factors for physicians in different departments prescribing novel hypoglycemic agent with cardiovascular benefits].","Zhou LQ","2023","Zhonghua yi xue za zhi","other","article","10.3760/cma.j.cn112137-20220615-01319","36822869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0018067","Comparative Efficacy, Safety, and Cost-Utility of DPP-4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real-World Clinical and Economic Outcomes.","Jimoh AO","2026","Journal of diabetes research","systematic_review","article","10.1155/jdr/8464330","41925338","PMC13045289",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Comparative Study; review-article; review"],["R0018068","Disulfide-Directed Multicyclic Peptides with N-Terminally Extendable α-Helices for Recognition and Activation of G Protein-Coupled Receptors.","Fan S","2025","Journal of the American Chemical Society","other","article","10.1021/jacs.4c12808","39688263",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018069","Current perspectives in obesity management: unraveling the impact of different therapy approach in real life obesity care.","Khorrami Chokami K","2024","Journal of translational medicine","nonrandomized_study","article","10.1186/s12967-024-05322-4","38844956","PMC11155047",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0018070","Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network.","Sheth S","2025","Journal of psoriasis and psoriatic arthritis","other","article","10.1177/24755303251337020","40454109","PMC12119537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018071","Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study.","Azzam AY","2025","Annals of clinical and translational neurology","nonrandomized_study","article","10.1002/acn3.52300","39949066","PMC12040499",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018072","Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.","Thomsen RW","2015","Diabetes care","nonrandomized_study","article","10.2337/dc13-2983","25633664",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018073","Clinical Outcomes and Complications of Basal, Bolus, and Combination Insulin Regimens in Type 2 Diabetes Mellitus: Evidence from Published Case Reports.","Natsir RM","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","case_report","article","10.2147/dmso.s545571","40927666","PMC12415096",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018074","Kidney Disease and Diabetes","Pavkov ME","2023","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)","narrative_review","article",null,"39571058",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0018075","Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents.","Gnudi L","2016","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfv093","25858586","PMC4917060",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; article"],["R0018076","A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder.","Celik M","2024","Brain sciences","narrative_review","article","10.3390/brainsci14030294","38539681","PMC10969323",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0018077","The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study.","Pignatelli P","2022","Antioxidants (Basel, Switzerland)","other_trial","article","10.3390/antiox11101878","36290601","PMC9598474",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018078","Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3.","Tsutsumi YM","2014","Cardiovascular diabetology","preclinical","article","10.1186/s12933-014-0132-9","25194961","PMC4172825",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018079","Are GLP-1 receptor agonists useful against traumatic brain injury?","Combs CK","2015","Journal of neurochemistry","preclinical","article","10.1111/jnc.13224","26234912",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0018080","Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.","Campbell RK","2010","The Journal of family practice","case_report","article",null,"20824236",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0018081","Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K/Akt signaling.","Chen L","2024","Peptides","preclinical","article","10.1016/j.peptides.2024.171245","38801993",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018082","Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.","Krumholz HM","2024","Heart (British Cardiac Society)","randomized_trial","article","10.1136/heartjnl-2024-324170","39084707","PMC11420724","ClinicalTrials.gov:NCT04184622","S001077; S001084","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0018083","Assessing the Impact of the Inflation Reduction Act on Medicare Prescription Drug Coverage","Zhang YW","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.07.24.25332155",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0018084","Tirzepatide: a dual-action solution for obstructive sleep apnea and obesity.","Afridi Z","2025","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000002975","40110282","PMC11918728",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0018085","Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects.","Lymperopoulos A","2024","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics16060693","38931817","PMC11206770",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018086","7947 Semaglutide Induced Pancreatitis: A Case Report",null,"2024","Journal of the Endocrine Society","case_report","article",null,null,"PMC11453221",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018087","[The highlights of nephrology in 2024].","Cohen C","2025","Nephrologie & therapeutique","narrative_review","article","10.1684/ndt.2025.110","40208671",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018088","Biomarkers associated with glycaemic control, comorbidity and response to GLP-1 analogue therapy","English A","2018","Ulster University","other","article",null,null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0018089","Remission of Sequestrant-refractory Bile Acid Diarrhea in Patients on Liraglutide With Pragmatic Dose Escalation: A Case Series.","Borup C","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","case_report","article","10.1016/j.cgh.2025.03.016","40368130",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018090","Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models.","Zhang Y","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2024.117540","39405916",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018091","Treatment and practical considerations of diabetic kidney disease.","Bilen Y","2023","Frontiers in medicine","narrative_review","article","10.3389/fmed.2023.1264497","38105902","PMC10722293",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018092","The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review.","Li X","2022","Journal of pediatric endocrinology & metabolism : JPEM","systematic_review","article","10.1515/jpem-2021-0533","36315979",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; review"],["R0018093","Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland.","Gorry C","2024","Applied health economics and health policy","other","article","10.1007/s40258-024-00904-1","39133443","PMC11470914",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018094","Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence.","Shetty S","2025","F1000Research","nonrandomized_study","article","10.12688/f1000research.167998.2","42723672","PMC13555055",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Preprint; review-article; article"],["R0018095","[Corrigendum] Protective effects of exendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells.","Lu K","2020","Molecular medicine reports","notice","article","10.3892/mmr.2020.11159","32468031",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0018096","An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass.","Chon S","2016","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2016.40.2.99","27126881","PMC4853229",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018097","Weight and body composition outcomes with liraglutide in individuals with well-treated hypothyroidism: A retrospective case-control study.","Chukir T","2025","PloS one","nonrandomized_study","article","10.1371/journal.pone.0332091","40934243","PMC12425291",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018098","Management of hyperglycaemia in people with obesity.","Mourougavelou V","2023","Clinical medicine (London, England)","other","article","10.7861/clinmed.2023-0135","37524409","PMC10541039",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018099","Exendin-4 improves thermogenic capacity by regulating fat metabolism on brown adipose tissue in mice with diet-induced obesity.","Wei Q","2015","Annals of clinical and laboratory science","preclinical","article",null,"25887869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018100","Kidney transplantation in adult candidates with obesity: Guidelines by the Association Française d'Urologie and Société Francophone de Transplantation.","Timsit MO","2026","The French journal of urology","systematic_review","article","10.1016/j.fjurol.2026.103100","41912112",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Practice Guideline; Systematic Review"],["R0018101","Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA.","Tsukamoto M","2015","Histochemistry and cell biology","preclinical","article","10.1007/s00418-015-1333-3","26026990",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018102","The Impact of Semaglutide on Cardiac Mass and Function Requires Further Investigation.","Xu Q","2025","JACC. Basic to translational science","commentary","article","10.1016/j.jacbts.2025.02.027","40306860","PMC12134537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018103","Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.","Jensterle Sever M","2014","European journal of endocrinology","randomized_trial","article","10.1530/eje-13-0797","24362411","PMC3922503",null,"S000679; S001012; S001072; S001423; S002080","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018104","International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece.","Bolli GB","2011","Diabetes technology & therapeutics","other","article","10.1089/dia.2011.0179","21864094","PMC3160268",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Conference Proceedings; meeting-report; article"],["R0018105","Impact of Visceral and Hepatic Fat on Cardiometabolic Health.","Khawaja T","2024","Current cardiology reports","narrative_review","article","10.1007/s11886-024-02127-1","39235730","PMC11538208",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018106","SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.","Sarafidis P","2019","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","randomized_trial","article","10.1093/ndt/gfy407","30753708",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Consensus Statement; article"],["R0018107","Unveiling the potential therapeutic role of nifuroxazide and liraglutide combination in mitigating LPS-induced acute lung injury through modulation of AT1R/JAK-2/STAT-3 by ACE2/ Ang1-7/MasR signaling in male albino rats: in vivo and in silico study.","Khalifa AK","2025","International immunopharmacology","randomized_trial","article","10.1016/j.intimp.2025.115261","40706208",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0018108","Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.","Stefanakis K","2023","Diabetes, obesity & metabolism","other","article","10.1111/dom.15141","37246799","PMC10524619",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0018109","Automatic Processing of Gastrointestinal Endoscopy Referrals and Patient Communication Using Large Language Models","Gorelik Y","2025","Research Square","other","preprint","10.21203/rs.3.rs-7860274/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0018110","Patient-Centered Outcomes in Heart Failure Pharmacotherapy: A Meta-Analysis of Randomized Controlled Trials.","Kido K","2025","JACC. Advances","systematic_review","article","10.1016/j.jacadv.2025.102356","41447282","PMC12834078",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0018111","Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.","Vázquez LA","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-024-01587-6","38722495","PMC11211290",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0018112","Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management.","Lian K","2024","Life sciences","narrative_review","article","10.1016/j.lfs.2024.122801","38862060",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018113","Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center.","Muschler K","2025","Clinical toxicology (Philadelphia, Pa.)","nonrandomized_study","article","10.1080/15563650.2024.2444642","39803696",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018114","Semaglutide for the treatment of post transplantation diabetes mellitus in patients following liver transplantation is safe and effective.","Bot D","2025","Annals of hepatology","commentary","article","10.1016/j.aohep.2025.101920","40311873",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018115","Liraglutide increases islet Ca2+ oscillation frequency and insulin secretion by activating hyperpolarization-activated cyclic nucleotide-gated channels.","Zaborska KE","2022","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14747","35546791","PMC9843726",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0018116","Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.","Luo J","2022","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2022.109855","35346753","PMC10767977",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018117","Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor-Positive Lesions.","Boss M","2020","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.119.238998","32385165","PMC8679620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018118","Investigating the effects of semaglutide in early Alzheimer’s disease using single‐cell transcriptomics and proteomics – rationale and design","Johannsen P","2024","Alzheimer's & dementia : the journal of the Alzheimer's Association","protocol","article","10.1002/alz.090259",null,"PMC11712370","ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409; ClinicalTrials.gov:NCT05891496","S000624; S001717; S002335","europepmc; openalex","TRUE","open_europepmc","5","FALSE","Abstract; article"],["R0018119","Oral semaglutide (Rybelsus) for type 2 diabetes.",null,"2019","The Medical letter on drugs and therapeutics","narrative_review","article",null,"31770356",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018120","Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program.","Mayer CS","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15911","39248157","PMC11462475",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0018121","▾ Liraglutide for weight management.",null,"2017","Drug and therapeutics bulletin","narrative_review","article","10.1136/dtb.2017.7.0502","28701318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018122","Differential effects of liraglutide naltrexone/bupropion, and caloric restriction on metabolic parameters and beta-cell regeneration in type 2 diabetic rat model: role of beta arrestin 1.","Merzeban DH","2024","Journal of molecular histology","randomized_trial","article","10.1007/s10735-024-10326-x","39704859",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0018123","Correction to: A Cost‑effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.","Jiang Y","2023","Clinical drug investigation","notice","article","10.1007/s40261-023-01269-4","37115344",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0018124","Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4.","Lee SJ","2016","Molecular metabolism","preclinical","article","10.1016/j.molmet.2016.04.008","27408779","PMC4921942",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018125","The potential for renoprotection with incretin-based drugs.","Tanaka T","2014","Kidney international","narrative_review","article","10.1038/ki.2014.236","25007170",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0018126","Beneficial metabolic effects of dietary epigallocatechin gallate alone and in combination with exendin-4 in high fat diabetic mice.","Pathak NM","2018","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2017.07.024","28754350",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018127","Use of Semaglutide for Successful Weight Loss and Maintenance in a Non-Obese Population: An Observational Study","Giese S","2025","Preprints.org","randomized_trial","preprint","10.20944/preprints202506.1737.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0018128","PET evaluation of light-induced modulation of microglial activation and GLP-1R expression in depressive rats.","Liu Y","2021","Translational psychiatry","preclinical","article","10.1038/s41398-020-01155-z","33414373","PMC7791059",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018129","Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity - authors' reply.","Flint A","2021","Alimentary pharmacology & therapeutics","commentary","article","10.1111/apt.16669","34741327",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; editorial"],["R0018130","GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: United States, 2024.","Vahratian A","2025","NCHS data brief","other","article","10.15620/cdc/174616","41022371","PMC12498180",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Book; report"],["R0018131","GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7.","Koehler JA","2015","Cell metabolism","preclinical","article","10.1016/j.cmet.2015.02.005","25738454",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018132","Optoacoustic Imaging of Glucagon-like Peptide-1 Receptor with a Near-Infrared Exendin-4 Analog.","Roberts S","2021","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.120.252262","33097631","PMC8729860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0018133","Exendin-4 enhances radiation response of prostate cancer.","He W","2018","The Prostate","preclinical","article","10.1002/pros.23687","30009503",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018134","Bioactive Phytoconstituents Targeting Energy Expenditure and Appetite to Combat Obesity: A Comprehensive Review.","Thapa G","2026","Current nutrition reports","narrative_review","article","10.1007/s13668-025-00718-0","41484835",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018135","Effects of antidiabetic drugs on bone metabolism.","Padilla Apuntate N","2024","Advances in laboratory medicine","nonrandomized_study","article","10.1515/almed-2024-0038","38634079","PMC11019883",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018136","GLP-1 promotes osteogenic differentiation of human ADSCs via the Wnt/GSK-3β/β-catenin pathway.","Li Y","2020","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2020.110921","32615283",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0018137","Tirzepatide for Weight Reduction in Chinese Adults With Obesity-Reply.","Zhao L","2024","JAMA","other","article","10.1001/jama.2024.21783","39602185",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018138","The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice.","Bai Y","2021","Microbial pathogenesis","preclinical","article","10.1016/j.micpath.2020.104645","33285220",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018139","[Glycemia reduction in type 2 diabetes patients with low cardiovascular risk].","Serné EH","2023","Nederlands tijdschrift voor geneeskunde","other_trial","article",null,"37930171",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","English Abstract; Journal Article; other"],["R0018140","Glucagon-like peptide-1 analog improves neuronal and behavioral impairment and promotes neuroprotection in a rat model of aluminum-induced dementia.","Abd El-Rady NM","2021","Physiological reports","preclinical","article","10.14814/phy2.14651","33355990","PMC7757676",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018141","Letter by Ma et al Regarding Article, \"Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial\".","Ma LL","2017","Circulation","randomized_trial","article","10.1161/circulationaha.116.027072","28507254",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0018142","Changes in Serum Testosterone After Sublingual Enclomiphene Citrate Combined With a Mineral Oxide Delivery System: A Retrospective Case Series of 15 Men.","Warren S","2026","Cureus","nonrandomized_study","article","10.7759/cureus.109299","42170362","PMC13189365",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018143","Short-Term Protocols to Obtain Insulin-Producing Cells from Rat Adipose Tissue: Signaling Pathways and In Vivo Effect.","Wartchow KM","2019","International journal of molecular sciences","preclinical","article","10.3390/ijms20102458","31109026","PMC6566438",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018144","Differential effects of intra-VTA ghrelin and glucagon-like peptide-1 on the stimulatory action of amphetamine and cocaine-induced alcohol intake","Colvin K","2021","Authorea Preprints","preclinical","preprint","10.22541/au.161726288.88720936/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018145","Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.","Yabe D","2022","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13764","35112504","PMC9153832",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0018146","Therapy in the early stage: incretins.","Cernea S","2011","Diabetes care","narrative_review","article","10.2337/dc11-s223","21525466","PMC3632190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0018147","Molecular Imaging to the Surgeons Rescue: Gallium-68 DOTA-Exendin-4 Positron Emission Tomography-Computed Tomography in Pre-operative Localization of Insulinomas.","Pallavi UN","2019","Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India","randomized_trial","article","10.4103/ijnm.ijnm_119_18","30713372","PMC6352648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018148","What Is Aging, and How Can We Defeat It?","Kovalev MA","2025","Preprints.org","other","preprint","10.20944/preprints202511.1362.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018149","Insight into the etiology of Alzheimer's disease from GLP-1R knockout mice: Commentary on \"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes\".","Thompson GJ","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","preclinical","article","10.1002/alz.70033","39989452","PMC11848582",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018150","A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza®) in Healthy Male Subjects.","Mai G","2020","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2020.610880","33584289","PMC7878668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018151","Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.","Martin B","2009","Diabetes","preclinical","article","10.2337/db08-0799","18984744","PMC2628604",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; article"],["R0018152","Reply to \"Eligibility for and practical implications of semaglutide in overweight and obese patients with acute coronary syndrome, a letter to editor\".","Gragnano F","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133336","40311697",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0018153","Tirzepatide for Weight Reduction in Chinese Adults With Obesity.","Chen Z","2024","JAMA","other","article","10.1001/jama.2024.21780","39602179",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018154","Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.","van Genugten RE","2013","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12050","23216746",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0018155","Injectable Schiff base-engineered hydrogel for spatiotemporal liraglutide delivery orchestrates diabetic periodontitis regression via multimodal microenvironment reprogramming.","Li J","2026","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2026.114688","41651380",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018156","Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation.","Akbar S","2026","Pharmaceutical research","other","article","10.1007/s11095-026-04094-4","42086873",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018157","Eligibility for Semaglutide 2.4 mg in Patients With Acute Myocardial Infarction and Overweight or Obesity Without Diabetes: A Real-World Analysis.","Ajmera R","2025","Heart, lung & circulation","nonrandomized_study","article","10.1016/j.hlc.2025.01.011","40374414",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0018158","Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives.","Jensterle M","2022","Biomedicines","randomized_trial","article","10.3390/biomedicines10081989","36009535","PMC9405922",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0018159","Potential side effects to GLP-1 agonists: understanding their safety and tolerability.","Consoli A","2015","Expert opinion on drug safety","nonrandomized_study","article","10.1517/14740338.2015.987122","25496749",null,null,"S000204","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0018160","The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions.","Miao X","2018","Peptides","preclinical","article","10.1016/j.peptides.2017.07.006","28712893",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018161","Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis.","Bernhard J","2025","Current cardiology reports","randomized_trial","article","10.1007/s11886-024-02185-5","39826021","PMC11742736",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0018162","Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.","Al Hayek AA","2022","Advances in therapy","nonrandomized_study","article","10.1007/s12325-022-02053-0","35119622",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018163","Response by Wiberg et al to Letter Regarding Article, \"Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial\".","Wiberg S","2017","Circulation","randomized_trial","article","10.1161/circulationaha.117.027774","28507255",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Letter; Comment; article"],["R0018164","National trends in prescription drug expenditures and projections for 2025.","Tichy EM","2025","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxaf092","40263109",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018165","Study Finds Modest Link Between Semaglutide and a Type of Vision Impairment.","Anderer S","2025","JAMA","other","article","10.1001/jama.2025.1351","40053340",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018166","GLP-1-based medications: Mechanisms involved in obesity treatment.","Salvador J","2025","Medicina clinica","narrative_review","article","10.1016/j.medcli.2025.107035","40466247",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0018167","Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.","Ayesh H","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15725","38923379",null,"OSF:osf.io/gd67x",null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Comparative Study; Systematic Review; Network Meta-Analysis; review; article"],["R0018168","Reducing or Discontinuing Insulin or Sulfonylurea When Initiating a Glucagon-like Peptide-1 Agonist.","Herron E","2024","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article","10.12788/fp.0452","38835925","PMC11147431",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018169","Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.","Bonaca MP","2025","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(25)00509-4","40169145",null,"ClinicalTrials.gov:NCT04560998","S001363","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0018170","[GLP-1 analogues in 2019 : for whom and how ?].","Gariani K","2019","Revue medicale suisse","narrative_review","article",null,"31148423",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018171","Open-Source Generative AI Enables De Novo Design of an Orally Bioavailable Triple GLP-1/GIP/Glucagon Receptor Agonist for Type 2 Diabetes","Andrade LJdO","2025","Research Square","other","preprint","10.21203/rs.3.rs-8214757/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0018172","Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation.","Sun Z","2024","International immunopharmacology","preclinical","article","10.1016/j.intimp.2024.113258","39340991",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018173","Generalized Edema Caused by Albiglutide: A Case Report.","Aziz K","2018","Cureus","case_report","article","10.7759/cureus.2801","30116680","PMC6089702",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018174","Reply to \"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US\".","Rydberg MG","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","nonrandomized_study","article","10.1002/alz.14620","39950434","PMC11826322",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; letter"],["R0018175","Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study.","Giaccari A","2026","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2026.113244","41951127",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0018176","Daily briefing: Drugs such as Ozempic could help with Alzheimer's and Parkinson's.","Graham F","2024","Nature","commentary","article","10.1038/d41586-024-00272-9","38291330",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0018177","Triple-Hormone-Receptor Agonist Retatrutide for Obesity.","Bisson A","2023","The New England journal of medicine","commentary","article","10.1056/nejmc2310645","37888925",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0018178","Impact of degradation in subcutaneous tissue and lymphatic fluid on absorption of Fc-fusion proteins following subcutaneous administration.","Yokoyama M","2025","Drug metabolism and pharmacokinetics","preclinical","article","10.1016/j.dmpk.2025.101500","40912139",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0018179","The role of glucagon-like peptide-1 (GLP-1) in fluid and food intakes in vasopressin-deficient Brattleboro rats.","Brakey DJ","2023","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2023.114093","36706972","PMC9974868",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0018180","Radiolabeled glucagon-like peptide-1 analogues: a new pancreatic β-cell imaging agent.","Zhang Y","2012","Nuclear medicine communications","narrative_review","article","10.1097/mnm.0b013e32834e7f47","22262216",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0018181","[Drug therapy of type-2-diabetes-is metformin dispensable now?].","Gallwitz B","2024","Innere Medizin (Heidelberg, Germany)","nonrandomized_study","article","10.1007/s00108-024-01755-7","39167190",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"English Abstract; Journal Article"],["R0018182","The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials.","Sheng L","2024","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2024.111617","38490492",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0018183","Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?","Miras AD","2014","International journal of obesity (2005)","narrative_review","article","10.1038/ijo.2013.205","24213310","PMC3950585",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0018184","Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.","Rydén AK","2017","Journal of autoimmunity","preclinical","article","10.1016/j.jaut.2017.07.006","28711285",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018185","Case Report: long-term misdiagnosis and follow-up of a patient with HNF4A-MODY carrying a new de novo mutation.","Luo J","2025","Frontiers in endocrinology","case_report","article","10.3389/fendo.2025.1509135","40589512","PMC12207682",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018187","A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.","Lofton HF","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","randomized_trial","article","10.1016/j.soard.2024.08.037","39401933",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0018188","The NAVETA obesity consensus tool: a multidimensional framework for clinical and patient-reported outcome assessment.","Mercadal-Orfila G","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1731194","41585787","PMC12823478",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Practice Guideline; research-article; article"],["R0018189","[Synergistic effects of GABA and hypoglycemic drugs].","Tyurenkov IN","2023","Problemy endokrinologii","nonrandomized_study","article","10.14341/probl13257","37694868","PMC10520901",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","English Abstract; Journal Article; research-article; article"],["R0018190","Neuroinflammatory Biomarkers in Alzheimer's Disease: From Pathophysiology to Clinical Implications.","Roveta F","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms252211941","39596011","PMC11593837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018191","Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.","Hemmingsen B","2017","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd012204.pub2","28489279","PMC6481586",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0018192","Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells.","Kim MJ","2015","Islets","preclinical","article","10.1080/19382014.2015.1129096","26744903","PMC4878271",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018193","Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity.","Knudsen LB","2019","ACS pharmacology & translational science","commentary","article","10.1021/acsptsci.9b00048","32259078","PMC7088919",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0018194","Review of Article: Wu JY, Tu WL, Yu T, Liao KM, Lin YM. Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients. Diabetes Res Clin Pract. 2025;222:112,083.","Whipple MO","2025","Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing","nonrandomized_study","article","10.1016/j.jvn.2025.04.001","40484580",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018195","Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide.","Huang R","2025","Chinese medical journal","randomized_trial","article","10.1097/cm9.0000000000003417","39654450","PMC11745866","ClinicalTrials.gov:NCT04822181; ClinicalTrials.gov:NCT06318169; ClinicalTrials.gov:NCT05500222; ClinicalTrials.gov:NCT06419374","S000511","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; editorial; article"],["R0018196","Double Diabetes: A Converging Metabolic and Autoimmune Disorder Redefining the Classification and Management of Diabetes.","Chaudhary RK","2025","Cureus","narrative_review","article","10.7759/cureus.80495","40225541","PMC11992394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018197","Regulation of GLP-1R signalling by endocytic membrane trafficking and its significance for pancreatic β-cell insulin secretion","Buenaventura T","2019","Imperial College London","other","article","10.25560/70966",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; article"],["R0018198","Alopecia and Semaglutide: Connecting the Dots for Patient Safety.","Haykal D","2025","Journal of cosmetic dermatology","randomized_trial","article","10.1111/jocd.70125","40087997","PMC11909624",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0018199","12338 Risk Of Retinopathy In Patients With Type 2 Diabetes On Semaglutide",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454334",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018200","6468 Once-Weekly Semaglutide and Taste Perception in Women with Obesity",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453302",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018201","Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report.","Funamizu N","2025","Medicine","nonrandomized_study","article","10.1097/md.0000000000045445","41137356","PMC12558295",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Case Reports; research-article; article"],["R0018202","Effect of Exenatide Use on Cognitive and Affective Functioning in Obese Patients With Type 2 Diabetes Mellitus: Exenatide Use Mediates Depressive Scores Through Increased Perceived Stress Levels.","Eren-Yazicioglu CY","2021","Journal of clinical psychopharmacology","other","article","10.1097/jcp.0000000000001409","34016830",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018203","SUN-675 Very Low Energy Ketogenic Therapy In Combination With Liraglutide As A Synergic Strategy For The Treatment Of Obesity: A Real-world Clinical Evaluation",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12546109",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0018204","Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)",null,"2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article",null,null,"PMC9067867","ClinicalTrials.gov:NCT03548935","S000144","europepmc","TRUE","open_europepmc","1",null,"Abstract"],["R0018205","Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study.","Wu JY","2026","Hepatology international","nonrandomized_study","article","10.1007/s12072-025-11021-z","41535629",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Comparative Study; article"],["R0018206","Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.","Fitchett DH","2017","European journal of heart failure","narrative_review","article","10.1002/ejhf.633","27653447",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0018207","GLP-1 analogue liraglutide as adjunct treatment in diabetes type 2 after failed bariatric/metabolic surgery.","Hellström PM","2019","Annals of translational medicine","commentary","article","10.21037/atm.2019.08.94","31656819","PMC6789358",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0018208","A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity.","Phan A","2025","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.24300","40384505",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018209","GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3β pathway.","Çiçekli MN","2022","Journal of receptor and signal transduction research","preclinical","article","10.1080/10799893.2022.2032747","35133924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018210","[Innovations in the treatment of type 2 diabetes mellitus: use of incretins].","Dedov II","2010","Terapevticheskii arkhiv","commentary","article",null,"21341455",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; English Abstract; editorial"],["R0018211","Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease","van der Flier W","2024","Alzheimer's & dementia : the journal of the Alzheimer's Association","other","article",null,null,"PMC11713752",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018212","Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes.","Samajdar SS","2024","Pain management","other","article","10.1080/17581869.2024.2402214","39301951","PMC11485723",null,"S000353","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018213","Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?","Popovic DS","2024","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2024.108800","38889536",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018214","Advances in the treatment of functional male hypogonadism.","Corona G","2024","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2023.2296022","38117229",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0018215","The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study.","Thong KY","2014","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.12367","24246138",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0018216","Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation.","Li Y","2024","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-024-02445-2","39342279","PMC11439223",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0018217","Effect of Oral Semaglutide Versus Comparators on Multiple Cardiometabolic Risk Factor Control in Adults With Type 2 Diabetes.","Aroda VR","2025","Diabetes care","commentary","article","10.2337/dc24-2373","40063715","PMC12034892",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018218","Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes.","Shao H","2022","Diabetes care","commentary","article","10.2337/dc21-1800","35020817",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0018219","Exendin-4 protects mice from D-galactose-induced hepatic and pancreatic dysfunction.","Ahangarpour A","2018","Pathobiology of aging & age related diseases","preclinical","article","10.1080/20010001.2017.1418593","29321828","PMC5757233",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018220","Glucagon-Like Peptide Analogs Are Superior for Diabetes and Weight Control in Patients on Antipsychotic Medications: A Retrospective Cohort Study.","Perlis LT","2020","The primary care companion for CNS disorders","nonrandomized_study","article","10.4088/pcc.19m02504","32027785",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; article"],["R0018221","New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.","Barrea L","2020","Minerva endocrinologica","narrative_review","article","10.23736/s0391-1977.20.03179-x","32643356",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018222","Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies.","Ban K","2009","Journal of the American Society of Hypertension : JASH","preclinical","article","10.1016/j.jash.2009.04.001","20409967",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018223","[LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY].","Scheen AJ","2016","Revue medicale de Liege","narrative_review","article",null,"27337846",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Review; article; other"],["R0018224","A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats.","Peters CT","2001","The Journal of nutrition","preclinical","article","10.1093/jn/131.8.2164","11481412",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018225","Effectiveness of Semaglutide in Overweight or Obese Patients With IgA Nephropathy Without Diabetes.","Si FL","2025","Nephrology (Carlton, Vic.)","commentary","article","10.1111/nep.70023","40159445",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0018226","Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.","Santos LB","2024","Journal of clinical anesthesia","nonrandomized_study","article","10.1016/j.jclinane.2024.111668","39476514",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0018227","Tirzepatide: Obesity injection will get phased rollout to avoid overwhelming GPs.","Wise J","2024","BMJ (Clinical research ed.)","other","article","10.1136/bmj.q2744","39638348",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0018228","Reducing Cardiac Steatosis: Interventions to Improve Diastolic Function: A Narrative Review.","Heshmat-Ghahdarijani K","2023","Current problems in cardiology","narrative_review","article","10.1016/j.cpcardiol.2023.101739","37040852",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018229","GLP-1RAs for the treatment of obesity in women after menopause.","Paschou SA","2022","Maturitas","commentary","article","10.1016/j.maturitas.2021.12.003","34922787",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0018230","Development of the Weight and Emotions Scale (WES).","Kanu C","2026","Obesity science & practice","other_trial","article","10.1002/osp4.70119","41589220","PMC12832084","ClinicalTrials.gov:NCT04881760","S001653","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018231","De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).","Rodriguez P","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16057","39532398","PMC11701190",null,"S000460","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0018232","Glucagon-like peptide-1 receptors and sexual behaviors in male mice.","Vestlund J","2020","Psychoneuroendocrinology","preclinical","article","10.1016/j.psyneuen.2020.104687","32388229",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018233","A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides.","Esposito S","2018","Journal of pharmaceutical and biomedical analysis","preclinical","article","10.1016/j.jpba.2018.07.009","30041153",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Validation Study"],["R0018234","Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist.","Yuan Y","2023","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2022.115036","36571995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018235","Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.","O'Neil PM","2018","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(18)31773-2","30122305",null,"ClinicalTrials.gov:NCT02453711; ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT03611582; ClinicalTrials.gov:NCT03548987","S000144; S000521; S000988; S001740; S002036; S002317; S002445","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018236","Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials.","Giorgino F","2025","Diabetes care","other_trial","article","10.2337/dc24-2790","40100982","PMC12034897",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; research-article; article; other"],["R0018237","SAT-573 Should We Be Keeping a Closer Eye? A Case of Non-arteritic Anterior Ischemic Optic Neuropathy (Naion) After Semaglutide Initiation",null,"2025","Journal of the Endocrine Society","case_report","article",null,null,"PMC12544656",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018238","Effects of Exenatide on Blood Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes","Zhang Y","2021","Research Square","other","preprint","10.21203/rs.3.rs-292137/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018239","Liraglutide Attenuates Hepatic Ischemia-Reperfusion Injury by Modulating Macrophage Polarization.","Li SL","2022","Frontiers in immunology","preclinical","article","10.3389/fimmu.2022.869050","35450076","PMC9016191",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018240","A Review of the Renoprotective Effects of Novel Antidiabetic Agents.","Leite KM","2021","Journal of pharmacy practice","narrative_review","article","10.1177/0897190020902344","32067559",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018241","8088 Connecting the Dots: Semaglutide, Constipation, and Diverticulitis - A case report",null,"2024","Journal of the Endocrine Society","case_report","article",null,null,"PMC11454901",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018242","A New Protractor Potentiates Glucagon-Like Peptide 1 with Slow-Release Depot and Long-Term Action.","Jing W","2025","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.4c02970","40118774",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018243","Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.","Wang T","2014","PloS one","systematic_review","article","10.1371/journal.pone.0103798","25089625","PMC4121242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0018244","Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.","DeNicola M","2014","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00109.2014","25117407","PMC4200306",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0018245","Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study.","Goderis G","2022","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","other","article","10.1055/a-1508-3912","34154020",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018246","CagriSema and the link between obesity and type 2 diabetes.","Apovian CM","2023","Lancet (London, England)","commentary","article","10.1016/s0140-6736(23)01291-6","37364591",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0018247","Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.","McEwan P","2025","Journal of medical economics","nonrandomized_study","article","10.1080/13696998.2025.2459529","39882599",null,"ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; article"],["R0018248","Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.","Kubota-Okamoto S","2026","Journal of diabetes investigation","preclinical","article","10.1111/jdi.70252","41631452","PMC13042871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018249","Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity.","Lear S","2020","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.0c00740","32844654",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018250","Effects of Exendin-4 on pancreatic islets function in treating hyperglycemia post severe scald injury in rats.","Li D","2018","The journal of trauma and acute care surgery","randomized_trial","article","10.1097/ta.0000000000002066","30211851",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018251","Exendin-4 protects hypoxic islets from oxidative stress and improves islet transplantation outcome.","Padmasekar M","2013","Endocrinology","preclinical","article","10.1210/en.2012-1983","23471218",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018252","Long-Acting, Longer-Acting, and Ultralong-Acting Antiobesity Peptides.","Schneider EL","2025","Journal of medicinal chemistry","narrative_review","article","10.1021/acs.jmedchem.4c02647","39895561",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018253","Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis.","Shi FH","2018","Medicine","systematic_review","article","10.1097/md.0000000000010420","29668601","PMC5916683",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review-article; article"],["R0018254","Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance.","Apostolopoulou M","2025","Endocrine reviews","narrative_review","article","10.1210/endrev/bnae032","39998445","PMC12063105",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018255","Exendin-4 Plays a Protective Role in a Rat Model of Spinal Cord Injury Through SERCA2.","Sun Z","2018","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","preclinical","article","10.1159/000490017","29794460",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018256","Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.","Rodbard HW","2019","Diabetes care","randomized_trial","article","10.2337/dc19-0883","31530666",null,"ClinicalTrials.gov:NCT02863328","S000251","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018257","[Glucagon-like peptide-1 analogues: effects on body weight and glycemia].","Ruffo M","2010","Giornale italiano di cardiologia (2006)","narrative_review","article",null,"21361051",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018258","Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.","Iepsen EW","2015","International journal of obesity (2005)","randomized_trial","article","10.1038/ijo.2014.177","25287751","PMC4424381",null,"S000371; S001692","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018259","Déjà vu! A Case of Recurrent Metabolic Dysfunction-Associated Steatohepatitis 70 Days After Liver Transplantation.","Still M","2026","ACG case reports journal","case_report","article","10.14309/crj.0000000000002232","42433972","PMC13354390",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018260","Correction to: Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.",null,"2023","Circulation","notice","article","10.1161/cir.0000000000001157","37276255",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0018261","GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies.","Scheen AJ","2025","Diabetes & metabolism","preclinical","article","10.1016/j.diabet.2025.101681","40571191",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0018262","IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.","Holst JJ","2015","Journal of diabetes science and technology","randomized_trial","article","10.1177/1932296815610124","26443290","PMC4773967","ClinicalTrials.gov:NCT01336023","S001276","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018263","The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study.","Tan Y","2025","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2025.101680","40545031",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0018264","Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with 111In-labeled exendin-4.","Hamamatsu K","2019","Scientific reports","preclinical","article","10.1038/s41598-019-54722-w","31797889","PMC6893013",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018265","The locus coeruleus contributes to the anorectic, nausea, and autonomic physiological effects of glucagon-like peptide-1.","Fortin SM","2023","Science advances","preclinical","article","10.1126/sciadv.adh0980","37729419","PMC10511187",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018266","Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice.","Bomba M","2018","Neurobiology of aging","preclinical","article","10.1016/j.neurobiolaging.2017.12.009","29331730",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018267","Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials.","Liu L","2024","International journal of clinical pharmacy","systematic_review","article","10.1007/s11096-024-01779-x","39037553","PMC11576767",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0018268","The Etiology of Reduced Muscle Mass with Surgical and Pharmacological Weight Loss and the Identification of Potential Countermeasures.","Faria I","2024","Nutrients","narrative_review","article","10.3390/nu17010132","39796566","PMC11723338",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018269","Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.","Helmstädter J","2022","British journal of pharmacology","narrative_review","article","10.1111/bph.15462","33764504","PMC8820186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0018270","Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study.","Kuo CC","2025","Hepatology international","nonrandomized_study","article","10.1007/s12072-024-10752-9","39602049",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0018271","Tirzepatide reduces diet-induced senescence and NETosis-mediated liver fibrosis in mice","Chen F","2025","bioRxiv","preclinical","preprint","10.1101/2025.05.27.656284",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0018272","Analysis of the Efficacy of Polyenyl Phosphatidylcholine in Combination with Liraglutide in Nonalcoholic Fatty Liver Disease and the Effect of Omentin-1 and Vaspin Expression.","Jin Y","2025","Alternative therapies in health and medicine","randomized_trial","article",null,"38814610",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0018273","Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS.","Peters AL","2025","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/clinem/dgae372","38824910","PMC11913103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; research-article; other; article"],["R0018274","Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6.","Bain SC","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-024-01659-7","39520501","PMC11759736","ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018275","Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","Sobral MVS","2025","American journal of cardiovascular drugs : drugs, devices, and other interventions","systematic_review","article","10.1007/s40256-025-00721-4","39907981",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0018276","MON-641 Effectiveness Of Semaglutide On Renal Outcomes In Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12544276",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0018277","Mo1622: EFFICACY OF GLP-1 ANALOGS AND AGONISTS ON PROPORTION OF WEIGHT LOSS IN OVERWEIGHT OR OBESE DIABETICS AND NONDIABETICS: A SYSTEMATIC REVIEW AND META-ANALYSIS",null,"2022","Gastroenterology","systematic_review","article",null,null,"PMC9212452",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0018278","Examining the Use of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.","Lichtenstein GR","2025","Gastroenterology & hepatology","other","article",null,"40115606","PMC11920026",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0018279","Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.","Zhao L","2024","JAMA","randomized_trial","article","10.1001/jama.2024.9217","38819983","PMC11337071","ClinicalTrials.gov:NCT05024032","S001086","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018280","NEJM at AHA - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.","Rubin EJ","2025","The New England journal of medicine","commentary","article","10.1056/nejme2414470","39555797",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0018281","Research advances in the diagnosis and treatment of MASLD/MASH.","Wang D","2025","Annals of medicine","narrative_review","article","10.1080/07853890.2024.2445780","41421798","PMC11703476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018282","Cardiovascular-Endocrine-Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic.","Theodorakis N","2025","Biomolecules","narrative_review","article","10.3390/biom15030373","40149908","PMC11940337",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018283","Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.","Heckmann ND","2024","Arthroplasty today","other","article","10.1016/j.artd.2024.101327","39071832","PMC11282421",null,"S002680","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018284","MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice.","Li S","2026","Current hypertension reports","narrative_review","article","10.1007/s11906-026-01380-9","42541628","PMC13428797",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018285","SUN-676 Impact Of Once-weekly Semaglutide On Heart Failure Hospitalizations And Weight Loss In Obese Patients With Preserved Ejection Fraction (Hfpef): A Meta-analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12546518",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0018286","MON-516 Effectiveness of Semaglutide on Cardiovascular Outcomes in Chronic Kidney Disease (CKD) Patients with Type 2 Diabetes Mellitus: A Systemic Review and Meta-analysis",null,"2025","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC12545257",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0018287","First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers.","Pu J","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16610","40662378",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; article"],["R0018288","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference.","Abdul Jabbar AB","2025","Current atherosclerosis reports","other_trial","article","10.1007/s11883-025-01355-2","41145911",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0018289","Eligibility for and practical implications of semaglutide in overweight and obese patients with acute coronary syndrome, A letter to editor.","Malik AP","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133237","40194565",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0018290","A Clinical Review of the Connections Between Diabetes Mellitus, Periodontal Disease, and Cardiovascular Pathologies.","Țica O","2025","Biomedicines","nonrandomized_study","article","10.3390/biomedicines13092309","41007869","PMC12467886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0018291","Exendin-4 prevented pancreatic beta cells from apoptosis in (Type I) diabetic mouse via keap1-Nrf2 signaling.","He J","2019","Experimental biology and medicine (Maywood, N.J.)","preclinical","article","10.1177/1535370218823549","30638057","PMC6362529",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; research-article; article"],["R0018292","Levels of DEFA1, Progranulin, and NRG4 in Patients with Autonomic Neuropathy: Potential Biomarkers for Diagnosis and Prognosis.","Nikolova D","2025","Metabolites","other","article","10.3390/metabo15030169","40137134","PMC11944139",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018293","Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian randomization study","Yang G","2025","medRxiv","other_trial","preprint","10.1101/2025.02.12.25322150",null,null,null,null,"europepmc","TRUE","open_pdf","5",null,"Preprint"],["R0018294","Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation.","Li AQ","2015","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00249.2014","25377089",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018295","Central and peripheral GLP-1 systems independently suppress eating.","Brierley DI","2021","Nature metabolism","preclinical","article","10.1038/s42255-021-00344-4","33589843","PMC7116821",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0018296","Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE- 2 study.","Berra C","2025","Pharmacological research","nonrandomized_study","article","10.1016/j.phrs.2025.107640","39900210",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Letter; letter"],["R0018297","Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study.","Han J","2024","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2023.0030","38310883","PMC11140407",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0018298","[Exendin-4 alleviates diabetic cardiomyopathy in mice by regulating Sirt1/PGC1α].","Cai YY","2018","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article","10.3969/j.issn.1673-4254.2018.05.03","29891446","PMC6743905",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018299","Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis.","Chen B","2025","Clinical nutrition ESPEN","systematic_review","article","10.1016/j.clnesp.2025.01.056","39892787",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0018300","Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4.","Kaeppeli SAM","2019","EJNMMI radiopharmacy and chemistry","preclinical","article","10.1186/s41181-019-0060-9","31659487","PMC6522624",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0018301","Oral semaglutide and reduction in major adverse cardiovascular events.","Barton Duell P","2025","Journal of clinical lipidology","commentary","article","10.1016/j.jacl.2025.04.001","40250965",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0018302","Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight.","Jelsing J","2012","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2012.01557.x","22226053",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018303","Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice.","Ren L","2019","Frontiers in physiology","preclinical","article","10.3389/fphys.2019.00930","31404283","PMC6670290",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018304","Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome.","De Sio V","2025","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2025.133028","39890028",null,"ClinicalTrials.gov:NCT02219984",null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0018305","Efficacy and Safety of Pharmacologic Therapies in HFpEF: A Systematic Review and Network Meta-Analysis","Armani MN","2025","medRxiv","systematic_review","preprint","10.1101/2025.09.17.25335973",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0018306","Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.","Rizzo M","2016","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-016-0480-8","27912784","PMC5135832","ClinicalTrials.gov:NCT01715428","S001748","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0018307","Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.","Thomson SC","2018","Current diabetes reports","other_trial","article","10.1007/s11892-018-0991-7","29654381","PMC6426321",null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review; research-article"],["R0018308","Efficacy and safety benefits of HR17031, a fixed-ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open-label, randomised, parallel three-arm, treat-to-target trial.","Ji L","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70036","40859882",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Clinical Trial, Phase II; Randomized Controlled Trial; article"],["R0018309","Therapeutic potential of targeting ceramide for early cardiometabolic lipotoxicity in vivo study.","Shalaby YM","2025","Scientific reports","preclinical","article","10.1038/s41598-025-31001-5","41392183","PMC12800147",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018310","Exenatide reduces atrial fibrillation susceptibility by inhibiting hKv1.5 and hNav1.5 channels.","Zhou Q","2024","The Journal of biological chemistry","preclinical","article","10.1016/j.jbc.2024.107294","38636665","PMC11109313",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018311","The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.","Lübker C","2025","Advances in therapy","randomized_trial","article","10.1007/s12325-025-03176-w","40156748","PMC12006245","ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; article"],["R0018312","The Real-World Use of Semaglutide to Promote Weight Loss in Obese Adults With Hemodialysis: A Multicenter Cross-Sectional Descriptive Study.","Couture J","2025","Canadian journal of kidney health and disease","randomized_trial","article","10.1177/20543581251324588","40104387","PMC11915253",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018313","Incretin hormones and the satiation signal.","Holst JJ","2013","International journal of obesity (2005)","other_trial","article","10.1038/ijo.2012.208","23295502","PMC3768099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0018314","Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study.","Barnard-Kelly K","2022","BMC psychiatry","randomized_trial","article","10.1186/s12888-021-03666-5","34996406","PMC8740474",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018315","Systemic Inflammatory Response Syndrome Following High-Dose Intravenous Glutathione-Containing Revitalising Solution in a Patient on Tirzepatide: A Case Report.","Sharma D","2025","Cureus","case_report","article","10.7759/cureus.84736","40556995","PMC12185258",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018316","8348 A Rare Case Of Liraglutide-Associated Angioedema Requiring Emergent Intubation",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454003",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018317","Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.","Mital S","2023","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2023.36400","37824146","PMC10570871",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018318","Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study.","Zamora MG","2024","Pharmacological research","nonrandomized_study","article","10.1016/j.phrs.2024.107295","38971270",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018319","GLP-1 Receptor Agonist Exenatide Attenuates the Detrimental Effects of Obesity on Inflammatory Profile in Testis and Sperm Quality in Mice.","Zhang E","2015","American journal of reproductive immunology (New York, N.Y. : 1989)","preclinical","article","10.1111/aji.12420","26287267",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018320","Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.","Hammoud R","2023","Nature reviews. Endocrinology","narrative_review","article","10.1038/s41574-022-00783-3","36509857",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0018321","Preliminary evaluation of GLP-1R PET in the diagnosis and risk stratification of pheochromocytomas.","Li M","2020","Neoplasma","preclinical","article","10.4149/neo_2019_190227n163","31686522",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018322","Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report.","Brand K","2025","BMC nephrology","case_report","article","10.1186/s12882-025-04068-5","40197299","PMC11977914",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0018323","Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.","Rogliani P","2019","Respiratory medicine","nonrandomized_study","article","10.1016/j.rmed.2019.06.015","31228775",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0018324","A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice.","Craig SL","2020","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2019.113723","31756326",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018325","Outcomes of Semaglutide Use in Achieving Target Body Mass Index Before Renal Transplant in Five End-Stage Renal Disease Patients: A Case Series.","Al-Saad N","2024","Cureus","case_report","article","10.7759/cureus.71511","39553100","PMC11563773",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018326","Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA.","Razavi AC","2025","JACC. Cardiovascular imaging","other_trial","article","10.1016/j.jcmg.2024.10.004","39797878","PMC12273534",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0018327","Liraglutide and Colesevelam Change Serum and Fecal Bile Acid Levels in a Randomized Trial With Patients With Bile Acid Diarrhea.","Ellegaard AM","2024","Clinical and translational gastroenterology","randomized_trial","article","10.14309/ctg.0000000000000772","39602188","PMC11596762","EudraCT:2018-003575-34",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018328","Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.","Packer M","2018","European journal of heart failure","narrative_review","article","10.1002/ejhf.1185","29603541",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0018329","GLP-1RA promotes brown adipogenesis of C3H10T1/2 mesenchymal stem cells via the PI3K-AKT-mTOR signaling pathway.","Wang X","2018","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2018.10.197","30404729",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018330","Correction: Semaglutide restores astrocyte-vascular interactions and blood-brain barrier integrity in a model of diet-induced metabolic syndrome.","Estato V","2025","Diabetology & metabolic syndrome","notice","article","10.1186/s13098-025-01703-x","40269900","PMC12016140",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0018331","Incretin-based therapy for type 2 diabetes mellitus: pancreatic and extrapancreatic effects.","Hartman I","2013","American journal of therapeutics","other","article","10.1097/mjt.0b013e318235f27d","23459193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018332","Determinants of VO2peak responsiveness to aerobic exercise training in adults with Type 2 diabetes: the PROTECTION study.","Michielsen M","2026","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwag150","41906954",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018333","A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects.","Linnebjerg H","2011","International journal of clinical pharmacology and therapeutics","randomized_trial","article","10.5414/cp201462","21961484",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018334","Cardiovascular outcomes of glucose lowering therapy in chronic kidney disease patients: a systematic review with meta-analysis.","Kamdar A","2021","Reviews in cardiovascular medicine","systematic_review","article","10.31083/j.rcm2204152","34957787",null,"PROSPERO:CRD42021268563",null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0018335","Pharmacist-initiated interventions using RxChange message communication with prescribers for electronic prescriptions: A retrospective descriptive study.","Gong J","2024","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2024.102188","39029625",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0018336","Trends and patterns in antidiabetic medication prescriptions: Insights from Greece's electronic prescription database.","Karakolias S","2025","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2025.08.004","40803974",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0018337","18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.","Wu H","2013","Nuclear medicine communications","preclinical","article","10.1097/mnm.0b013e3283614187","23652208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018338","Systemic and brain delivery of antidiabetic peptides through nasal administration using cell-penetrating peptides.","Maeng J","2022","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2022.1068495","36452220","PMC9703138",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018339","Response to the letter titled reply to \"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US\".","Xu R","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","randomized_trial","article","10.1002/alz.14611","39950490","PMC11826321",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0018340","FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression.","Anderer S","2025","JAMA","other","article","10.1001/jama.2025.0548","40019747",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018341","Critically appraised paper: Once-weekly semaglutide in people with obesity and knee osteoarthritis [commentary].","Adie S","2025","Journal of physiotherapy","other","article","10.1016/j.jphys.2025.02.008","40122756",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018342","Patient experiences with group consultations when treated with semaglutide for obesity: a qualitative case study in a Danish general practice.","Dahl-Larsen R","2025","BMJ open","other","article","10.1136/bmjopen-2024-093357","40713055","PMC12306293",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018343","Comparative analysis of bias and quality in YouTube videos on bariatric surgery and weight-loss medications.","Botvinov J","2026","Surgical endoscopy","other","article","10.1007/s00464-026-12795-5","42377523","PMC13160955",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0018344","Health disparities in diabetes treatment: The challenge of G6PD deficiency.","Israel A","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111965","39710070",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0018345","The role of incretins and incretin-based drugs in autoimmune diseases.","Radbakhsh S","2021","International immunopharmacology","narrative_review","article","10.1016/j.intimp.2021.107845","34126341",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018346","Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment.","Trapp S","2022","British journal of pharmacology","narrative_review","article","10.1111/bph.15638","34323288","PMC8820179",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0018347","Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels.","Xie S","2025","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","nonrandomized_study","article","10.1055/a-2618-7509","40473254",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018348","Incretin-mediated control of cardiac energy metabolism.","Chan JSF","2024","The Journal of endocrinology","narrative_review","article","10.1530/joe-24-0011","39013412",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018349","Has the \"obesity paradox\" been resolved by semaglutide trials?","Jiesisibieke ZL","2025","European journal of epidemiology","commentary","article","10.1007/s10654-025-01211-2","40184017",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0018350","Liraglutide-Conjugated Poly(methyl vinyl ether-alt-maleic acid)-Coated Core-Shell Upconversion Nanoparticles for Theranostics of Diabetes.","Shapoval O","2025","ACS applied materials & interfaces","other","article","10.1021/acsami.5c11275","40665745","PMC12314866",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018351","Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes.","Gutierrez AD","2022","Cell reports. Medicine","preclinical","article","10.1016/j.xcrm.2022.100813","36384099","PMC9729831",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; brief-report; article"],["R0018352","Weight-loss drug lowers cardiovascular disease risk in new trial of Novo Nordisk's Wegovy.","Johnson B","2023","Nature medicine","other_trial","article","10.1038/d41591-023-00075-x","37620618",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","News; other"],["R0018353","8002 A Dose Beyond Limits: Semaglutide and Insulin Overdose - A Novel Approach to Management",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453850",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018354","Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside.","Chung S","2021","Life (Basel, Switzerland)","narrative_review","article","10.3390/life11050389","33923115","PMC8146249",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018355","An Uncommon Cause of Recurrent Presyncope, Dizziness, and Tachycardia: A Case Report of Diffuse, Adult-Onset Nesidioblastosis/Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS).","Dieterle MP","2023","Biomedicines","case_report","article","10.3390/biomedicines11061741","37371836","PMC10296627",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018356","Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages: evidence for M1/M2 homeostasis restoration.","Kang M","2026","Archives of pharmacal research","preclinical","article","10.1007/s12272-026-01610-3","41904760",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018357","Longstanding insulin dependent diabetics may not require insulin after the introduction of GLP-1 analogues.","Raja UY","2015","JRSM cardiovascular disease","case_report","article","10.1177/2048004015576008","26668738","PMC4359167",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018358","Modern-Day Management of the Dysglycemic Continuum: An Expert Viewpoint from the Arabian Gulf.","Alessa T","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s491591","39712240","PMC11662629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018359","Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6/STAT3 signaling in hepatocellular carcinoma.","Lu X","2021","Translational oncology","other","article","10.1016/j.tranon.2020.100872","32979685","PMC7516274",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018360","Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.","Ovalle F","2011","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2011.04.006","21635987",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0018361","Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.","Marx N","2021","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(20)30343-0","33159841","PMC12140926","ClinicalTrials.gov:NCT04007926",null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article"],["R0018362","Critically appraised paper: Once-weekly semaglutide in people with obesity and knee osteoarthritis [synopsis].","Moseng T","2025","Journal of physiotherapy","other","article","10.1016/j.jphys.2025.02.011","40122757",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018363","Role of LRP5/6/GSK-3β/β-catenin in the differences in exenatide- and insulin-promoted T2D osteogenesis and osteomodulation.","Chen Z","2024","British journal of pharmacology","preclinical","article","10.1111/bph.16421","38804080",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018364","US Population Eligibility and Estimated Impact of Tirzepatide Treatment on Obesity Prevalence and Cardiovascular Disease Events.","Wong ND","2025","Cardiovascular drugs and therapy","other_trial","article","10.1007/s10557-024-07583-z","38850368","PMC12296773",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018365","Obesity in women's life: role of GLP-1 agonists.","Palacios S","2022","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","commentary","article","10.1080/09513590.2022.2163235","36599366",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; editorial"],["R0018366","Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.","Jensterle M","2021","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2021.108935","34217774",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0018367","In adults with moderate-to-severe OSA and obesity, tirzepatide reduced apnea-hypopnea events vs. placebo.","Cheskin LJ","2024","Annals of internal medicine","other","article","10.7326/annals-24-02174-jc","39348697",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018368","Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.","Parkes DG","2013","Expert opinion on drug discovery","narrative_review","article","10.1517/17460441.2013.741580","23231438",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018369","Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.","Solomon SD","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.08.021","39217567",null,"ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0018370","The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus.","Gavriilidis S","2025","Endocrine","nonrandomized_study","article","10.1007/s12020-024-04007-8","39179734",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018371","Effect of High‑Fat-Diet and Semaglutide on Bladder Cancer in Mice","Liu Y","2024","Research Square","preclinical","preprint","10.21203/rs.3.rs-4899171/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018372","Exendin-4 overcomes cytokine-induced decreases in gap junction coupling via protein kinase A and Epac2 in mouse and human islets.","Farnsworth NL","2019","The Journal of physiology","preclinical","article","10.1113/jp276106","30412665","PMC6332825",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0018373","PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.","Aroda VR","2019","Diabetes care","randomized_trial","article","10.2337/dc19-0749","31186300",null,"ClinicalTrials.gov:NCT02906930","S001741; S001914","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018374","Weekly Journal Scan: tirzepatide SURMOUNTs obesity-related obstructive sleep apnoea.","Liuzzo G","2024","European heart journal","randomized_trial","article","10.1093/eurheartj/ehae568","39302811",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0018375","Biomimetic Hematoma Enables Healing in Complex Periprosthetic Fracture Nonunion with Multiple Comorbidities: A Case Report.","Maestas A","2026","JBJS case connector","case_report","article","10.2106/jbjs.cc.26.00065","42247569",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0018376","Role of Metabolic Abnormalities During the Progression of Chronic Kidney Disease and Preventive Strategies.","Zha D","2025","International journal of medical sciences","narrative_review","article","10.7150/ijms.114382","40959557","PMC12434826",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018377","Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats.","Colvin KJ","2022","Behavioural brain research","preclinical","article","10.1016/j.bbr.2021.113726","34954300",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0018378","Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability.","Ismail R","2019","Pharmaceutics","preclinical","article","10.3390/pharmaceutics11110599","31726699","PMC6920980",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018379","The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.","Scirica BM","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.08.007","39217559",null,"ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0018380","Correction: Preparation and characterization of BSA‑loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis.","He M","2024","Journal of nanobiotechnology","notice","article","10.1186/s12951-024-02947-x","39523311","PMC11552298",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0018381","Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.","Loomba R","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2401943","38856224",null,"ClinicalTrials.gov:NCT04166773","S000031; S001705; S002481","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; article"],["R0018382","Effects of semaglutide on heart failure outcomes.","Han J","2025","Lancet (London, England)","commentary","article","10.1016/s0140-6736(24)02861-7","39955113",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0018383","Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging.","Antwi K","2020","Clinical nuclear medicine","randomized_trial","article","10.1097/rlu.0000000000003124","32558709",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0018384","Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).","Al-Ozairi E","2024","Trials","protocol","article","10.1186/s13063-024-07930-3","38365744","PMC10874012","ClinicalTrials.gov:NCT05390307","S001116","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; other; article"],["R0018385","Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates.","Zhang Y","2023","Cell metabolism","preclinical","article","10.1016/j.cmet.2023.01.001","36706758",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018386","An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits.","Xia X","2024","iScience","other","article","10.1016/j.isci.2024.109377","38510128","PMC10951637",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018387","Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide.","Taktaz F","2024","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-024-02319-7","38987789","PMC11238498",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0018388","Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome.","Górecka W","2025","Pharmaceutics","nonrandomized_study","article","10.3390/pharmaceutics17060768","40574081","PMC12196407",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0018389","Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide.","Verma S","2025","European heart journal","other","article","10.1093/eurheartj/ehae744","39673759",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018390","Perceptions of injectable therapies with cardiovascular benefit: an ACNAP survey of healthcare professionals to explore facilitators and barriers.","Khatib R","2022","European journal of cardiovascular nursing","other","article","10.1093/eurjcn/zvab106","34849708",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018391","A Case of Semaglutide-Induced Euphoria in a Patient With Bipolar Disorder.","Greenberg NR","2025","The Journal of clinical psychiatry","case_report","article","10.4088/jcp.25cr15778","39999771",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018392","Inhibition of the MAP3 kinase Tpl2 protects rodent and human β-cells from apoptosis and dysfunction induced by cytokines and enhances anti-inflammatory actions of exendin-4.","Varin EM","2016","Cell death & disease","preclinical","article","10.1038/cddis.2015.399","26794660","PMC4816180",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018393","An integrated cell and medium engineering approach for production of a nanobody fusion in Saccharomyces cerevisiae.","Niemelä LRK","2026","Applied microbiology and biotechnology","other","article","10.1007/s00253-025-13700-1","41611879","PMC12858493",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018394","Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.","Wang Y","2024","Drugs","systematic_review","article","10.1007/s40265-024-02015-6","38478331",null,"PROSPERO:CRD42023404309",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Comparative Study; Journal Article; Systematic Review; Network Meta-Analysis"],["R0018395","FDA Approves Generic Liraglutide to Address GLP-1 Drug Shortage.","Anderer S","2025","JAMA","other","article","10.1001/jama.2024.28813","39888628",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018396","FRI075 Single Center Retrospective Matched Cohort Study Of glp1ra-induced Weight Loss In Patients With Post-bariatric Weight Regain Vs Non-surgical Controls",null,"2023","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC10555869",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0018397","Effects of semaglutide on heart failure outcomes.","Neves JS","2025","Lancet (London, England)","commentary","article","10.1016/s0140-6736(24)02860-5","39955112",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018398","Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.","Lau J","2015","Journal of medicinal chemistry","other_trial","article","10.1021/acs.jmedchem.5b00726","26308095",null,null,"S000504","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0018399","Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats.","Wu LM","2021","Peptides","preclinical","article","10.1016/j.peptides.2021.170624","34375684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018400","Effect of liraglutide on proliferation and differentiation of human adipose stem cells.","Cantini G","2015","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2014.12.021","25575456",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018401","Type 2 Diabetes in a 4-Year-Old With Obesity: Considerations for Use of Semaglutide and Bariatric Surgery in Children.","Connard J","2025","JCEM case reports","case_report","article","10.1210/jcemcr/luaf142","40689302","PMC12269755",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018402","Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.","Cessario J","2021","Pharmacological reports : PR","preclinical","article","10.1007/s43440-021-00224-4","33555600",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018403","Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).","Buse JB","2014","Diabetes care","randomized_trial","article","10.2337/dc14-0785","25114296",null,null,"S002285","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018404","Youth-Onset Type 2 Diabetes Before and After COVID-19 Pandemic-Related Public Health Restrictions: Trends in Incidence, Severity, and Remission.","Grundman JB","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14227995","41303028","PMC12653032",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018405","Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease.","Lamos EM","2021","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2021.1917374","33882758",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018406","Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment.","Wang L","2016","Scientific reports","preclinical","article","10.1038/srep33251","27633081","PMC5025740",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018407","Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.","Sridharan K","2025","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-025-01988-y","41126373","PMC12542482",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0018408","Correction to \"Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus\".",null,"2025","Diabetes, obesity & metabolism","notice","article","10.1111/dom.16083","39552537",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0018409","Design of Electrostatic Nanocomplex of Semaglutide with Protamine and Zinc for Subcutaneous Prolonged Delivery.","Yang IG","2025","Nanomaterials (Basel, Switzerland)","preclinical","article","10.3390/nano15181399","41003035","PMC12472674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018410","Risk Factors for Hypoglycemia in Type 2 Diabetes Mellitus Patients Using Once-Weekly Semaglutide: A Matched Case-Control Study.","Amirthalingam P","2026","Therapeutics and clinical risk management","nonrandomized_study","article","10.2147/tcrm.s610579","42266882","PMC13245618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018411","Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.","Cotter G","2021","American heart journal","systematic_review","article","10.1016/j.ahj.2021.06.001","34107289",null,null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Meta-Analysis"],["R0018412","Baicalein: A potential GLP-1R agonist improves cognitive disorder of diabetes through mitophagy enhancement.","Liu N","2024","Journal of pharmaceutical analysis","preclinical","article","10.1016/j.jpha.2024.100968","39258173","PMC11386286",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018413","Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial.","Apperloo EM","2025","Diabetes care","randomized_trial","article","10.2337/dc24-2244","39792380",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Letter; article"],["R0018414","Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.","Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)","2021","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(21)00240-0","34656210",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018415","Retraction notice to \"Dulaglutide mitigates high dietary fructose-induced renal fibrosis in rats through suppressing epithelial-mesenchymal transition mediated by GSK-3β/TGF-β1/Smad3 signaling pathways\" [Life Sci. 309 (2022) 120999].","Mohamad HE","2025","Life sciences","notice","article","10.1016/j.lfs.2025.123372","39799041",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"TRUE","Journal Article; Retraction Notice; retraction"],["R0018416","Effects of diabetes drugs on the skeleton.","Meier C","2016","Bone","narrative_review","article","10.1016/j.bone.2015.04.026","25913633",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018417","The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression.","Ala M","2025","Journal of endocrinological investigation","systematic_review","article","10.1007/s40618-024-02459-3","39347905",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0018418","Long-term quality of life and hypothalamic dysfunction after craniopharyngioma.","Müller HL","2025","Journal of neuro-oncology","nonrandomized_study","article","10.1007/s11060-025-04987-1","40097882",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0018419","Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.","Glotfelty EJ","2019","ACS pharmacology & translational science","narrative_review","article","10.1021/acsptsci.9b00003","31396586","PMC6687335",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0018420","Incretin mimetics restore the ER-mitochondrial axis and switch neuronal fate towards survival.","Panagaki T","2021","Authorea Preprints","preclinical","preprint","10.22541/au.161012556.64083407/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018421","Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.","Yabe D","2020","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(20)30074-7","32333876",null,"ClinicalTrials.gov:NCT03015220","S000234","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018422","Obesity-related hypertension: Implications for advanced nursing practice.","Benenson I","2023","The Nurse practitioner","other","article","10.1097/01.npr.0000000000000055","37227309",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018423","Milk-derived exosomes as a promising vehicle for oral delivery of hydrophilic biomacromolecule drugs.","Li Y","2023","Asian journal of pharmaceutical sciences","other","article","10.1016/j.ajps.2023.100797","37035132","PMC10073618",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018424","[Effect of semaglutide treatment on the body weight and the glucose, insulin and thyroid hormone levels in aging rats with diet-induced obesity.].","Derkach KV","2025","Advances in gerontology = Uspekhi gerontologii","preclinical","article",null,"41477783",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0018425","Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.","Fox CK","2025","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2407379","39258838",null,"ClinicalTrials.gov:NCT04775082","S000318","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; article"],["R0018426","[A novel cell model targeted on GLP-1 receptor for application to anti-diabetic candidates screening].","Huan Y","2009","Yao xue xue bao = Acta pharmaceutica Sinica","preclinical","article",null,"19449529",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018427","Glycemic levels and cardiovascular events in type 2 diabetes: A cohort study of drugs with different hypoglycemic potentials.","Lin YC","2025","Scientific reports","nonrandomized_study","article","10.1038/s41598-025-10215-7","40753098","PMC12318049",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0018428","Infected necrotizing pancreatitis: clinical features, microbial patterns, and outcomes in a Saudi tertiary center.","Abulfaraj M","2025","Frontiers in cellular and infection microbiology","nonrandomized_study","article","10.3389/fcimb.2025.1689728","41170292","PMC12568644",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018429","Money being paid for prescribing Wegovy in pilot studies is \"over the top,\" say critics.","Cohen D","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p2918","38081654",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018430","An overview of the once-weekly GLP-1 receptor agonists from the pharmacist's perspective.","Patel D","2020","Journal of clinical pharmacy and therapeutics","randomized_trial","article","10.1111/jcpt.13227","32910491","PMC7540275",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; Research Support, Non-U.S. Gov't; article"],["R0018431","A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks.","Nauck MA","2013","Diabetes care","commentary","article","10.2337/dc12-2504","23645884","PMC3687264",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; discussion; article"],["R0018432","Impact of Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Therapy and Nutrition Counseling on Body Composition.","Hoffman K","2026","The Journal of nutrition","nonrandomized_study","article","10.1016/j.tjnut.2026.101618","42214684","PMC13494190",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0018433","Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase.","Yu C","2025","BMJ open","protocol","article","10.1136/bmjopen-2024-095382","40840993","PMC12374654","ClinicalTrials.gov:NCT05313529","S000596","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Clinical Trial Protocol; research-article; article"],["R0018434","Competing Cultural Discourses of GLP-1 Agonists: An Application of Relational Dialectics Theory.","Unruh MA","2026","Qualitative health research","other","article","10.1177/10497323251326041","40294302",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018435","Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.","Bonora BM","2019","Acta diabetologica","systematic_review","article","10.1007/s00592-019-01347-0","30993527",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0018436","Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis.","Dixit TS","2013","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2013.03.008","23523479",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018437","Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.","Cusi K","2016","Diabetologia","other_trial","article","10.1007/s00125-016-3952-1","27101131","PMC4861748",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0018438","PEX-168 improves insulin resistance, inflammatory response and adipokines in simple obese mice: a mechanistic exploration.","Guo Z","2021","BMC endocrine disorders","other_trial","article","10.1186/s12902-021-00908-1","34923973","PMC8686575",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018439","GLP-1 receptor agonists: which added value when increasing the dose?","Scheen AJ","2021","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(21)00205-9","34293305",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0018440","An shRNA screen in primary human beta cells identifies the serotonin 1F receptor as a negative regulator of survival during transplant.","Lee RA","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.05.01.591950","38746433","PMC11092577",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0018441","Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice.","Yang T","2020","Food & function","preclinical","article","10.1039/d0fo01954b","33216087",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018442","Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.","Scheen AJ","2014","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(14)70004-x","24731666",null,null,"S000235","pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0018443","Cutting-edge biotherapeutics and advanced delivery strategies for the treatment of metabolic dysfunction-associated steatotic liver disease spectrum.","Hong J","2025","Journal of controlled release : official journal of the Controlled Release Society","narrative_review","article","10.1016/j.jconrel.2025.02.008","39923856",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0018444","Trends in Presentation and Management of Endogenous Hyperinsulinaemic Hypoglycaemia Over the Last Three Decades at a Tertiary Care Centre (1992-2022).","Gupta S","2024","Indian journal of endocrinology and metabolism","other","article","10.4103/ijem.ijem_87_24","39371650","PMC11451956",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018445","Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction: The Underlying Role of Visceral Adiposity.","Packer M","2025","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2025.08.086","41091083","PMC12758563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0018446","Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation.","Luo X","2019","Archives of biochemistry and biophysics","other","article","10.1016/j.abb.2019.07.008","31302140",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018447","12602 The Effect of Three-Month Semaglutide Treatment on Serum TSH and Thyroid Hormones in Individuals with Obesity",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455135",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018448","Bezlotoxumab.","Baker DE","2017","Hospital pharmacy","other_trial","article","10.1310/hpj5203-229","28439138","PMC5396991",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018449","Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.","Kang ZF","2013","Diabetologia","preclinical","article","10.1007/s00125-012-2776-x","23188390","PMC3536946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018450","Tirzepatide alleviates non-alcoholic fatty liver disease by regulating lipid metabolism through activation of the AMPK/NF-κB signaling pathway.","Wu P","2025","American journal of translational research","preclinical","article","10.62347/snzk2023","41552345","PMC12808014",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018451","Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.","Mahaffey KW","2025","European heart journal","randomized_trial","article","10.1093/eurheartj/ehae613","39211948","PMC11931213",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0018452","Dulaglutide as a demethylating agent to improve the outcome of breast cancer.","Tatsch JM","2023","Epigenomics","other","article","10.2217/epi-2023-0332","38174426",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018453","Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.","Elvert R","2018","Endocrinology","preclinical","article","10.1210/en.2018-00399","29992313",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018454","RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9624574",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0018455","Patient preferences for newer oral therapies in type 2 diabetes.","Savarese G","2023","International journal of cardiology","other_trial","article","10.1016/j.ijcard.2022.09.009","36096275",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0018456","Polypharmacy in older patients with diabetes mellitus: a population based-study of northern Italy.","Succurro E","2025","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-025-02523-1","40471298","PMC12640330",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018457","Efficacy and Safety of Adding Empagliflozin to Liraglutide on Renal Function in Patients with Advanced-Stage Type 2 Diabetic Kidney Disease: A Randomized Controlled Trial.","Sunagawa K","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s471535","39430135","PMC11488354",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018458","Centrally Acting Agents for Obesity: Past, Present, and Future.","Coulter AA","2018","Drugs","other_trial","article","10.1007/s40265-018-0946-y","30014268","PMC6095132",null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review; research-article"],["R0018459","Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 Inhibitors and GLP-1 Analogs?","Gill GS","2022","Current problems in cardiology","nonrandomized_study","article","10.1016/j.cpcardiol.2021.100878","34078543",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0018460","Identification of reversible and druggable pathways to improve beta-cell function and survival in Type 2 diabetes.","Sithara S","2023","Islets","other","article","10.1080/19382014.2023.2165368","36709757","PMC9888462",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018461","Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.",null,"2024","The New England journal of medicine","notice","article","10.1056/nejmx240005","39413392",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; article"],["R0018462","Combination of obesity and high-fat feeding diminishes sensitivity to GLP-1R agonist exendin-4.","Duca FA","2013","Diabetes","preclinical","article","10.2337/db12-1204","23423571","PMC3712059",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0018463","Beyond metformin: initiating combination therapy in patients with type 2 diabetes mellitus.","Goldman-Levine JD","2011","Pharmacotherapy","narrative_review","article","10.1592/phco.31.12.44s","22122222",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018464","Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.","Pozzilli P","2020","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgaa149","32219329",null,"ClinicalTrials.gov:NCT02284009","S001460","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018465","Effects of semaglutide on heart failure outcomes - Author's reply.","Deanfield J","2025","Lancet (London, England)","commentary","article","10.1016/s0140-6736(24)02862-9","39955114",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0018466","Adipokines at the Metabolic-Brain Interface: Therapeutic Modulation by Antidiabetic Agents and Natural Compounds in Alzheimer's Disease.","Ormazabal P","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18101527","41155642","PMC12566813",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018467","Use of dulaglutide in a pregnant woman with type 2 diabetes until third trimester of pregnancy.","Molteni M","2024","Acta diabetologica","other","article","10.1007/s00592-024-02331-z","39126516","PMC11531414",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0018468","A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?","Butler PC","2013","Diabetes care","other","article","10.2337/dc12-2713","23645885","PMC3687282",null,"S001544","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; discussion; article"],["R0018469","Liraglutide Treatment Improves Glycaemic Dysregulation, Body Composition, Cardiometabolic Variables and Uncontrolled Eating Behaviour in Adolescents with Severe Obesity.","Apperley L","2025","Journal of clinical research in pediatric endocrinology","nonrandomized_study","article","10.4274/jcrpe.galenos.2024.2023-10-10","39311553","PMC11923471",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018470","Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort.","Hironaka J","2025","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/14791641251318309","39878627","PMC11780656",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; brief-report; article"],["R0018471","Combined effect of SDF-1 peptide and angiogenic cues in co-axial PLGA/gelatin fibers for cutaneous wound healing in diabetic rats.","Shafiq M","2023","Colloids and surfaces. B, Biointerfaces","preclinical","article","10.1016/j.colsurfb.2023.113140","36669437",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0018472","Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.","Aroda VR","2016","Diabetes care","randomized_trial","article","10.2337/dc16-1495","27650977",null,"ClinicalTrials.gov:NCT02058160","S001409","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0018473","Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions.","Hafez A","2026","Current cardiology reports","narrative_review","article","10.1007/s11886-026-02426-9","42827168",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018474","A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?","Øhrstrøm CC","2019","European journal of endocrinology","other","article","10.1530/eje-19-0473","31370002",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018475","Inter-organ communication shapes human metabolic tissue states and resolves anti-diabetic drug response modes in a six-tissue microphysiological system.","McGilvrey M","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.05.22.726943","42244566","PMC13232138",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0018476","CB1 and GLP-1 Receptors Cross Talk Provides New Therapies for Obesity.","Zizzari P","2021","Diabetes","preclinical","article","10.2337/db20-0162","33144338",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018477","Incretin-based therapies and cardiovascular risk.","Mannucci E","2012","Current medical research and opinion","narrative_review","article","10.1185/03007995.2012.678940","22439700",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018478","Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.","Valenzuela-Vallejo L","2022","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2022.155237","35700837","PMC11426964",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0018479","Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.","Macconell L","2013","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s35801","23358123","PMC3555554","ClinicalTrials.gov:NCT00308139","S002279","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0018480","OR09-07 Dynamic Proteomic Profiling in a 5-week Crossover Trial of Liraglutide in Obesity Reveals Weight-Dependent Myostatin Downregulation and Multi-Pathway Effects Beyond Weight Reduction",null,"2025","Journal of the Endocrine Society","other_trial","article",null,null,"PMC12544363",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0018481","Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.","Marzook A","2021","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2021.114656","34129856","PMC8346945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; preprint; article"],["R0018482","Exendin-4 improves ER stress-induced lipid accumulation and regulates lipin-1 signaling in HepG2 cells.","Lee J","2018","Cell stress & chaperones","other","article","10.1007/s12192-017-0872-z","29934713","PMC6045528",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018483","Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes.","Melzer Cohen C","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112086","40058653",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0018484","Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting.","Conti M","2025","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-024-02424-9","39680131",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Comparative Study; article"],["R0018485","Treatment of chronic kidney disease in older populations.","Kishi S","2024","Nature reviews. Nephrology","narrative_review","article","10.1038/s41581-024-00854-w","38977884",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018486","8752 The Ethical Concerns Of Improper Semaglutide Administration After Acquisition From A Compounded Pharmacy",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11453547",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018487","GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome.","Danielpur L","2016","The Journal of clinical endocrinology and metabolism","case_report","article","10.1210/jc.2016-2240","27459537",null,"ClinicalTrials.gov:NCT01302327","S001027","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Case Reports; Journal Article; article"],["R0018488","Examining the Effects of High Blood Sugar Levels and Non-Insulin Diabetes Medicines on Risk of Hospitalization for COVID-19 among Patients with Diabetes","Flory J","2023","Patient-Centered Outcomes Research Institute (PCORI), Washington (DC)","nonrandomized_study","article",null,"40763222",null,null,null,"europepmc","TRUE","free_to_read","4",null,"Review"],["R0018489","Impact of Ambulatory Care Pharmacist-Led Management on Hemoglobin A1c Values among Patients with Uncontrolled Diabetes in a Primary Care Clinic vs Usual Care over Two Years.","Mohammad I","2023","Innovations in pharmacy","nonrandomized_study","article","10.24926/iip.v14i1.5444","38035312","PMC10686668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018490","Proarrhythmic Lipid Inflammatory Mediators: Mechanisms in Obesity Arrhythmias.","Bahrami P","2025","Journal of cellular physiology","narrative_review","article","10.1002/jcp.70012","39943721","PMC11822244",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; review-article; article"],["R0018491","Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.","Hsia DS","2025","Diabetes care","randomized_trial","article","10.2337/dc24-2839","40424051","PMC12178615",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; research-article; article"],["R0018492","Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.","Lingvay I","2020","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgaa577","32827435","PMC7549924","ClinicalTrials.gov:NCT01930188; ClinicalTrials.gov:NCT01885208; ClinicalTrials.gov:NCT03136484; ClinicalTrials.gov:NCT02863328","S000251; S000329; S001847; S001876","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0018493","“Weight loss, Semaglutide and Manic Episode”: A case report","Romay Gonzalez J","2024","European psychiatry : the journal of the Association of European Psychiatrists","case_report","article",null,null,"PMC11862632",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018494","Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor.","Khalil A","2024","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2024.108876","38241936",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018495","Hepatocyte nuclear factor 1 in renal lipid metabolism: molecular mechanisms and therapeutic potentials.","Zhu W","2025","Cell biology and toxicology","narrative_review","article","10.1007/s10565-025-10097-5","41291157","PMC12647356",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0018496","Dual agonism at the GLP-1 and glucagon receptor -- haemodynamic effects in healthy male volunteers","Goodman J","2025","Authorea Preprints","randomized_trial","preprint","10.22541/au.174134885.55958956/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0018497","GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats.","van der Velden WJC","2021","ACS pharmacology & translational science","preclinical","article","10.1021/acsptsci.0c00193","33615180","PMC7887852",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018498","Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know.","Forsmark CE","2016","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","narrative_review","article","10.1016/j.pan.2015.11.009","26795258",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018499","The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery.","Shen Y","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01643-1","39443333","PMC11561203",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018500","The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma.","Cui QN","2022","British journal of pharmacology","narrative_review","article","10.1111/bph.15683","34519040","PMC8820182",null,"S000497","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; review-article; article"],["R0018501","GLP-1 receptor signaling increases PCSK1 and β cell features in human α cells.","Saikia M","2021","JCI insight","preclinical","article","10.1172/jci.insight.141851","33554958","PMC7934853",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0018502","One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens.","Komé AM","2025","Diabetes care","commentary","article","10.2337/dc24-2575","39808463","PMC12964163",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018503","Expression of Concern: Paladugu et al. Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. Int. J. Mol. Sci. 2021, 22, 860.","Internation Journal Of Molecular Sciences Editorial Office","2025","International journal of molecular sciences","notice","article","10.3390/ijms26104467","40429612","PMC12111656",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Expression of Concern; expression-of-concern; article"],["R0018504","Anatomical and Functional Characterization of Central Amygdala Glucagon-Like Peptide 1 Receptor Expressing Neurons.","Zeng N","2021","Frontiers in behavioral neuroscience","preclinical","article","10.3389/fnbeh.2021.724030","35002645","PMC8739476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018505","MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women.","Milani I","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13040855","40299427","PMC12024897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018506","Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.","Ueda P","2021","Diabetologia","nonrandomized_study","article","10.1007/s00125-021-05508-1","34254177","PMC8423638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0018507","Two-pronged approach: Therapeutic effect of biological scaffold combined with immune intervention and β-cell replacement on type 1 diabetic mice.","Dai L","2025","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.16373","40150917",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018508","Age- and sex- differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data","Hanlon P","2024","medRxiv","systematic_review","preprint","10.1101/2024.06.23.24309242",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0018509","Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity.","Weina H","2018","Brain research","preclinical","article","10.1016/j.brainres.2018.04.031","29705602",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018510","Tirzepatide-Induced Rapid Weight Loss-Related Thyrotoxicosis.","Karakus KE","2024","JAMA internal medicine","case_report","article","10.1001/jamainternmed.2024.2919","39102259",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018511","Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.","Muhammed A","2024","Expert opinion on drug safety","systematic_review","article","10.1080/14740338.2023.2284992","37986140",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0018512","Clinical use of pasireotide for Cushing's disease in adults.","Ceccato F","2015","Therapeutics and clinical risk management","narrative_review","article","10.2147/tcrm.s37314","25834454","PMC4370333",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article; review"],["R0018513","Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes.","Hindsø M","2021","European journal of case reports in internal medicine","other","article","10.12890/2021_002352","33869096","PMC8046272",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018514","Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.","Iványi T","2012","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2012.04.022","22608106",null,"ClinicalTrials.gov:NCT00044668","S000713","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018515","Recent Data From the ESSENCE Trial on Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.","Alkhouri N","2025","Gastroenterology & hepatology","other_trial","article",null,"40115605","PMC11920021",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; discussion; article"],["R0018516","Semaglutide Awareness in Maxillofacial Surgery.","Grillo R","2025","World journal of plastic surgery","commentary","article","10.61882/wjps.14.3.108","41607581","PMC12842943",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018517","A comment on: \"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide\".","Hasanzad M","2024","Journal of diabetes and metabolic disorders","commentary","article","10.1007/s40200-024-01493-5","39610506","PMC11599685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0018518","Semaglutide as an Adjunctive Therapy to Standard Management for Idiopathic Intracranial Hypertension: A Real-World Data-Based Retrospective Analysis.","Azzam AY","2024","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2024.11.12.24317197","39677446","PMC11643286",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0018519","Cognitive dysfunction in diabetes - the 'forgotten' diabetes complication: a narrative review.","Sjöholm Å","2025","Scandinavian journal of primary health care","narrative_review","article","10.1080/02813432.2025.2455136","39876043","PMC12090258",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; review"],["R0018520","Evaluating the safety profile of semaglutide: an updated meta-analysis.","Rivera FB","2024","Current medical research and opinion","systematic_review","article","10.1080/03007995.2024.2383731","39046272",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0018521","Protective Effects of Lixisenatide against Lipopolysaccharide-Induced Inflammation Response in MAC-T Bovine Mammary Epithelial Cells: A Therapeutic Implication in Mastitis.","Li P","2020","Chemical research in toxicology","preclinical","article","10.1021/acs.chemrestox.9b00524","32191445",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018522","Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?","Sourris KC","2016","Current drug targets","preclinical","article","10.2174/1389450116666150722141418","26201485",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0018523","Food noise: definition, measurement, and future research directions.","Dhurandhar EJ","2025","Nutrition & diabetes","narrative_review","article","10.1038/s41387-025-00382-x","40628707","PMC12238327",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018524","Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management.","Mittal R","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26052320","40076938","PMC11900321",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018525","Non-glycemic effects of pioglitazone and incretin-based therapies.","Rizzo M","2013","Expert opinion on therapeutic targets","commentary","article","10.1517/14728222.2013.804067","23691979",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0018526","Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes.","Guan Y","2022","Clinical pharmacokinetics","other","article","10.1007/s40262-021-01094-y","35235191",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018527","Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner.","Bułdak Ł","2016","Pharmacological reports : PR","other","article","10.1016/j.pharep.2015.10.008","26922535",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018528","LncRNA-Malat1 is Involved in Lipotoxicity-Induced ß-cell Dysfunction and the Therapeutic Effect of Exendin-4 via Ptbp1.","Xiong L","2020","Endocrinology","preclinical","article","10.1210/endocr/bqaa065","32324218",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018529","Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.","Husain M","2020","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-020-01106-4","32998732","PMC7526237","ClinicalTrials.gov:NCT02054897; ClinicalTrials.gov:NCT01930188; ClinicalTrials.gov:NCT01885208; ClinicalTrials.gov:NCT02128932; ClinicalTrials.gov:NCT02305381; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02207374; ClinicalTrials.gov:NCT02254291; ClinicalTrials.gov:NCT02906930; ClinicalTrials.gov:NCT02863328; ClinicalTrials.gov:NCT02607865; ClinicalTrials.gov:NCT02863419; ClinicalTrials.gov:NCT02827708; ClinicalTrials.gov:NCT02692716; ClinicalTrials.gov:NCT02849080; ClinicalTrials.gov:NCT03021187; ClinicalTrials.gov:NCT03018028; ClinicalTrials.gov:NCT03015220","S000133; S000234; S000251; S000329; S000878; S001153; S001219; S001381; S001498; S001741; S001872; S001876; S001933; S001943; S002025; S002082; S002267; S002369","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0018530","Optoacoustic imaging of GLP-1 Receptor with a near-infrared exendin-4 analog","Roberts S","2020","bioRxiv","other","preprint","10.1101/2020.04.29.068619",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018531","Food-drug interactions of novel drugs used in cardiologic and diabetic patients - a PRISMA scoping review.","Pawłowska I","2026","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2026.1786007","42124949","PMC13158454",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0018532","Estimating treatment effects in clinical studies of Alzheimer's disease: What are estimands and why do we need them?","Hendrix S","2026","Alzheimer's & dementia : the journal of the Alzheimer's Association","narrative_review","article","10.1002/alz.71676","42644414","PMC13508584",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018533","Investigating difficult to detect pancreatic lesions: Characterization of benign pancreatic islet cell tumors using multiparametric pancreatic 3-T MRI.","Antwi K","2021","PloS one","other","article","10.1371/journal.pone.0253078","34115803","PMC8195423",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018534","Assessment of pancreatic β-cell function: review of methods and clinical applications.","Cersosimo E","2014","Current diabetes reviews","narrative_review","article","10.2174/1573399810666140214093600","24524730","PMC3982570",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0018535","UK regulator warns public after seizing hundreds of fake Ozempic pens.","Mahase E","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p2506","37890883",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018536","Management of diabetes across the course of disease: minimizing obesity-associated complications.","Apovian CM","2011","Diabetes, metabolic syndrome and obesity : targets and therapy","other_trial","article","10.2147/dmso.s24022","22135499","PMC3224657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0018537","Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","Gerstein HC","2019","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(19)31149-3","31189511",null,"ClinicalTrials.gov:NCT01394952","S000147; S000291; S000485; S000760; S000766; S001352; S001837; S002571","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0018538","Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 2016;39:2026-2035.","Rosenstock J","2017","Diabetes care","notice","article","10.2337/dc17-er06c","28420696","PMC5439410",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0018539","Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes.","Wewer Albrechtsen NJ","2016","Cell reports","preclinical","article","10.1016/j.celrep.2016.11.051","27974199",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018540","The pathogenesis of metabolic dysfunction-associated steatotic liver disease and nucleoside reverse transcriptase inhibitors (NRTIs) -based HIV-antiretroviral regimens: A comprehensive narrative review.","Horn M","2025","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2025.118633","41061582",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0018541","Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic β-cell bioenergetic parameters and metabolism in BRIN-BD11 cells.","Rowlands J","2018","Peptides","other","article","10.1016/j.peptides.2017.11.015","29412813",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018542","ODP255 Woman With Maturity-Onset Diabetes of the Young Type 2 (MODY2) Mistakenly Diagnosed and Treated as Type 2 Diabetes Mellitus",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9629328",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018543","Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.","Martín V","2020","Advances in therapy","nonrandomized_study","article","10.1007/s12325-020-01464-1","32862365",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0018544","Retraction Note: Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis.","Alafifi SA","2025","Naunyn-Schmiedeberg's archives of pharmacology","notice","article","10.1007/s00210-025-04046-6","40105924","PMC11978673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retraction Notice; Retraction of Publication; retraction"],["R0018545","Cardiovascular-kidney-metabolic syndrome: prevalence, risks, disease trajectories, and early-stage management.","Gunnarsson S","2026","American journal of physiology. Cell physiology","nonrandomized_study","article","10.1152/ajpcell.00499.2025","41269265",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0018546","LBODP002 Phase II Open-label Pilot Trial Of Liraglutide In Adolescents With Obesity After Vertical Sleeve Gastrectomy: Interim Results From 8-weeks Of Treatment",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9625068","ClinicalTrials.gov:NCT04883346","S000388","europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0018547","Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.","Roed SN","2014","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2013.11.010","24275181",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018548","Differentiation of canine adipose mesenchymal stem cells into insulin-producing cells: comparison of different culture medium compositions.","Camara BOS","2021","Domestic animal endocrinology","preclinical","article","10.1016/j.domaniend.2020.106572","33039930",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0018549","Glucagon-like peptide-1 receptors modulate the binge-like feeding induced by µ-opioid receptor stimulation of the nucleus accumbens in the rat.","Pierce-Messick Z","2020","Neuroreport","preclinical","article","10.1097/wnr.0000000000001545","33165198",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018550","Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.","Hölscher C","2012","CNS drugs","preclinical","article","10.2165/11635890-000000000-00000","22938097",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0018551","Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.","Korakas E","2024","Journal of clinical medicine","randomized_trial","article","10.3390/jcm13247497","39768420","PMC11678541","ClinicalTrials.gov:NCT06611904","S002327","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0018552","SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.","Shaughnessy AF","2021","American family physician","other","article",null,"34383432",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018553","Decoding the Significance of Alpha Cell Function in the Pathophysiology of Type 1 Diabetes.","Carroll J","2024","Cells","narrative_review","article","10.3390/cells13221914","39594662","PMC11593172",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018554","The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus.","Baruah MP","2012","Recent patents on endocrine, metabolic & immune drug discovery","narrative_review","article","10.2174/187221412800604563","22435393",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018555","Treatment of type 2 diabetes: challenges, hopes, and anticipated successes.","Nauck MA","2021","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(21)00113-3","34181914",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018556","Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.","Shah SJ","2024","European heart journal","randomized_trial","article","10.1093/eurheartj/ehae322","38739118","PMC11400859","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0018557","Long-term efficacy of daily oral semaglutide as add-on or switch therapy in adults with type 2 diabetes: a 12-month real-world retrospective study.","Sansone D","2025","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-025-02475-6","40014091",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018558","Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.","Wright FL","2014","Psychopharmacology","preclinical","article","10.1007/s00213-014-3507-4","24682505",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018559","SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.","Li S","2021","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj.n1091","33975892",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Consensus Statement; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; article"],["R0018560","7501 The Effect Of Liraglutide On Postprandial Hypoglycemia In Non-Bariatric Surgery Patients; A Case Series And Review Of Literature",null,"2024","Journal of the Endocrine Society","case_report","article",null,null,"PMC11453647",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018561","Managing Aesthetic Needs in Prescription Medication-Driven Rapid Weight Loss Patients: Results of an International Consensus. The Clinician Perspective.","Nikolis A","2026","Journal of cosmetic dermatology","other","article","10.1111/jocd.70644","41560373","PMC12820441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Consensus Statement; research-article; article"],["R0018562","Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats.","Akalestou E","2016","Pancreas","preclinical","article","10.1097/mpa.0000000000000585","26731187","PMC4820085",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018563","Essential Role Of High Glucose-Induced Overexpression Of PKCβ And PKCδ In GLP-1 Resistance In Rodent Cardiomyocytes.","Pan X","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s215789","31807042","PMC6839579",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018564","Making semaglutide accessible in Pakistan: A crucial step for heart failure treatment.","Sattar S","2025","JPMA. The Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.21483","39948813",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0018565","Prevalence of painful and painless diabetic peripheral neuropathy in the Northern Danish Region: A population-based study.","Røikjer J","2024","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2024.08.006","39217071",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018566","Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?","Moreno-Fernandez J","2020","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2019.05.006","31171461",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Observational Study; article"],["R0018567","Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients.","Gracia-Ramos AE","2022","Current medical research and opinion","narrative_review","article","10.1080/03007995.2021.1997288","34694181",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018568","Eating disorder psychopathology relates to weight loss medication and supplement use 6 months later in women.","Rosenbaum DL","2026","Eating and weight disorders : EWD","other","article","10.1007/s40519-026-01833-9","41790422","PMC13079474",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018569","Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide.","Park JK","2024","Biomacromolecules","preclinical","article","10.1021/acs.biomac.4c00376","38949062",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018570","Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?","Ryan DH","2021","Journal of obesity & metabolic syndrome","other_trial","article","10.7570/jomes21033","34518444","PMC8526285",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0018571","SAT-680 Reduction of liver steatosis following semaglutide treatment, bariatric surgery, and conservative multimodal therapy in patients with obesity: real-world evidence from a german university obesity center",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12545418",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0018572","DNA-mediated UCP1 overexpression in adipose tissue: A promising anti-obesity gene therapy.","Zhao ZW","2025","Clinical and translational medicine","preclinical","article","10.1002/ctm2.70491","41039748","PMC12491148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018573","Effects of liraglutide among patients with psoriatic arthritis and obesity.","Nicolau J","2025","Reumatologia clinica","commentary","article","10.1016/j.reumae.2025.501809","39855978",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018574","Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.","Zhang J","2020","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-020-01014-7","32334592","PMC7183674","ChiCTR:ChiCTR-1800015658",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0018575","Population health management of diabetic kidney disease in Los Angeles county municipal health system.","Kalantar-Zadeh K","2026","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000001139","41263046",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018576","Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.","Azoulay L","2016","BMJ (Clinical research ed.)","randomized_trial","article","10.1136/bmj.i581","26888382","PMC4772785","ClinicalTrials.gov:NCT02475499","S001777","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0018577","An open-label 16-week study of liraglutide in adolescents with obesity post-sleeve gastrectomy.","Zenno A","2024","Pediatric obesity","other_trial","article","10.1111/ijpo.13154","39103247","PMC11486571",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018578","The future of incretin-based therapy: novel avenues--novel targets.","Ahrén B","2011","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2011.01457.x","21824270",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0018579","Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection.","Shabto JM","2025","JAMA neurology","other","article","10.1001/jamaneurol.2024.5149","39928352",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018580","Reevaluating Semaglutide in Postbariatric Contouring Surgery: The Role of Undermined Immune Response and Nutritional Deficiency in Wound Complications.","Zhang L","2025","Aesthetic surgery journal","nonrandomized_study","article","10.1093/asj/sjaf008","39815693",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018581","Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.","Zhang Q","2024","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.202405987","39159301","PMC11497045",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018582","Clinical Pharmacokinetics of Semaglutide: A Systematic Review.","Yang XD","2024","Drug design, development and therapy","systematic_review","article","10.2147/dddt.s470826","38952487","PMC11215664",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0018583","Protective effects of liraglutide on hypercholesterolemia-associated atherosclerosis involve attenuation of endothelial-monocyte adhesion through down-regulating the LOX-1/NF-κB signaling pathway.","Wu A","2025","Scientific reports","preclinical","article","10.1038/s41598-025-13014-2","40721629","PMC12304136",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018584","Examination of a Viral Infection Mimetic Model in Human iPS Cell-Derived Insulin-Producing Cells and the Anti-Apoptotic Effect of GLP-1 Analogue.","Baden MY","2015","PloS one","other","article","10.1371/journal.pone.0144606","26659307","PMC4676675",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018585","The metabolic syndrome influences the response to incretin-based therapies.","Fadini GP","2011","Acta diabetologica","randomized_trial","article","10.1007/s00592-011-0296-7","21574000",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial; Journal Article; article"],["R0018586","Semaglutide seems to be more effective the other GLP-1Ras.","Holst JJ","2017","Annals of translational medicine","commentary","article","10.21037/atm.2017.11.10","29299466","PMC5750268",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0018587","Potential risk of non-arteritic anterior ischaemic optic neuropathy in semaglutide users: pharmacovigilance insights.","Castellana E","2025","European journal of hospital pharmacy : science and practice","nonrandomized_study","article","10.1136/ejhpharm-2024-004333","39242186",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0018588","Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study).","Hong S","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70258","41190361","PMC12803648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0018589","GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss?","Mantovani A","2021","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","commentary","article","10.1016/j.dld.2021.07.013","34366254",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0018590","Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.","Johansen P","2019","PharmacoEconomics - open","nonrandomized_study","article","10.1007/s41669-019-0131-6","30927241","PMC6861407",null,"S000372","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018591","Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.","Young MA","2014","Postgraduate medicine","other_trial","article","10.3810/pgm.2014.11.2836","25387217",null,"ClinicalTrials.gov:NCT00938158; ClinicalTrials.gov:NCT01406262; ClinicalTrials.gov:NCT00537719; ClinicalTrials.gov:NCT01077505; ClinicalTrials.gov:NCT01147731; ClinicalTrials.gov:NCT01147718; ClinicalTrials.gov:NCT01147692; ClinicalTrials.gov:NCT00354536; ClinicalTrials.gov:NCT00394030; ClinicalTrials.gov:NCT00530309; ClinicalTrials.gov:NCT01357889; ClinicalTrials.gov:NCT00518115; ClinicalTrials.gov:NCT01098461; ClinicalTrials.gov:NCT01475734; ClinicalTrials.gov:NCT00849017; ClinicalTrials.gov:NCT00838916; ClinicalTrials.gov:NCT00839527; ClinicalTrials.gov:NCT01098539","S000029; S000060; S000097; S000099; S000494; S000852; S000938; S001169; S001266; S001453; S001509; S001658; S001774; S001911; S002100; S002216; S002552; S003206","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0018592","Pituitary Adenlylate Cyclase Activating Peptide Protects Adult Neural Stem Cells from a Hypoglycaemic milieu.","Mansouri S","2016","PloS one","preclinical","article","10.1371/journal.pone.0156867","27305000","PMC4909203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018593","Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies.","Li X","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1722245","41488145","PMC12757217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018594","Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain.","Kim H","2025","Archives of pharmacal research","preclinical","article","10.1007/s12272-025-01575-9","41199017","PMC12680861",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0018595","Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.","Andersen E","2022","Human reproduction (Oxford, England)","randomized_trial","article","10.1093/humrep/deac096","35580859","PMC9247415","ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32","S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018596","Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert Panel.","Candido R","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-024-01625-3","39039353","PMC11330423",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0018597","Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide.","Minze MG","2016","Therapeutics and clinical risk management","narrative_review","article","10.2147/tcrm.s73579","27099505","PMC4820208",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018598","5185 A Meta-Analysis Evaluating the Efficacy of Liraglutide in Reducing Cardiovascular Complications Among Patients With Type 2 Diabetes",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC11453669",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0018599","Once-Weekly Semaglutide Improves Body Composition in Spanish Obese Adults with Type 2 Diabetes: A 48-Week Prospective Real-Life Study.","Caballero-Mateos I","2025","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm14155434","40807054","PMC12346962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018600","Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.","Hicks BM","2016","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj.i5340","27797785",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0018601","Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin.","Meng J","2016","Stem cell reports","preclinical","article","10.1016/j.stemcr.2016.02.002","26947974","PMC4834036",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018602","Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.",null,"2022","BMJ (Clinical research ed.)","notice","article","10.1136/bmj.o109","35044930","PMC8764512",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; review"],["R0018603","Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity.","Yang Y","2014","Journal of physiology and pharmacology : an official journal of the Polish Physiological Society","preclinical","article",null,"24930506",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018604","Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice.","Avogaro A","2016","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-016-0431-4","27514514","PMC4982334",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0018605","PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction.","Guo J","2026","Nature communications","preclinical","article","10.1038/s41467-026-72148-7","42399637","PMC13332248",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018606","Overview of diabetes agents in cardiovascular disease: it takes an orchestra to play Tchaikovsky in symphony.","Loh WJ","2025","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000892","39692101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018607","Exendin-4 improves resistance to Listeria monocytogenes infection in diabetic db/db mice.","Liu HY","2012","Journal of veterinary science","preclinical","article","10.4142/jvs.2012.13.3.245","23000581","PMC3467399",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018608","GLP-1 Receptor Agonists in Diabetic Kidney Disease.","Michos ED","2021","Clinical journal of the American Society of Nephrology : CJASN","case_report","article","10.2215/cjn.18771220","33849933","PMC8499005",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Clinical Conference; Journal Article; research-article; article"],["R0018609","7347 The Efficacy And Safety Of Oral Semaglutide In Asian Patients With Type 2 Diabetes:A Systematic Review And Meta-Analysis",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC11453676",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0018610","Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging.","Ortiz GU","2024","Ageing research reviews","narrative_review","article","10.1016/j.arr.2024.102582","39547367",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0018611","Therapeutic effect of liraglutide on expression of CTGF and BMP-7 in induced diabetic nephropathy.","Ramzy MM","2019","Journal of cellular biochemistry","preclinical","article","10.1002/jcb.29015","31127659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018612","Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel.","Reiner J","2022","JPEN. Journal of parenteral and enteral nutrition","preclinical","article","10.1002/jpen.2286","34705281",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018613","Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.","Ferrannini G","2021","European heart journal","randomized_trial","article","10.1093/eurheartj/ehaa777","33197271",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018614","[(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].","Luo YP","2018","Zhonghua wai ke za zhi [Chinese journal of surgery]","nonrandomized_study","article","10.3760/cma.j.issn.0529-5815.2018.11.009","30392304",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018615","The use of tirzepatide to successfully treat persistent genital arousal disorder/genitopelvic dysesthesia: a case report.","Burr E","2025","Sexual medicine","case_report","article","10.1093/sexmed/qfaf073","41001580","PMC12459093",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018616","Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.","Bajaj HS","2021","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(21)00115-7","34153269",null,"ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0018617","Association between longitudinal weight change and clinical outcome in individuals with MASLD.","Shi Y","2026","Hepatology (Baltimore, Md.)","other","article","10.1097/hep.0000000000001557","41061041",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Multicenter Study; article"],["R0018618","Recurrent Idiopathic Intracranial Hypertension-Related Papilledema After Abrupt Discontinuation of Semaglutide.","Phillips MJ","2025","Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society","other","article","10.1097/wno.0000000000002293","39905586",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018619","Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity.","Marrano N","2021","Biomolecules","narrative_review","article","10.3390/biom11020286","33671882","PMC7918991",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0018620","Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states.","Farr S","2012","Current opinion in lipidology","narrative_review","article","10.1097/mol.0b013e32834d68f0","22123671",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0018621","The \"entanglement\" between bullous pemphigoid and diabetes mellitus: a comprehensive review and expert recommendations.","Li JH","2025","Expert review of clinical immunology","narrative_review","article","10.1080/1744666x.2024.2428621","39521622",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0018622","The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism.","Andreozzi F","2016","Journal of translational medicine","preclinical","article","10.1186/s12967-016-0985-7","27473212","PMC4967343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0018623","Use of liraglutide after bariatric surgery: a 36-month follow-up in a real-world setting in Chile.","Farías MM","2024","Archives of endocrinology and metabolism","nonrandomized_study","article","10.20945/2359-4292-2023-0234","39420938","PMC11460972",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0018624","Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.","Whyte MB","2019","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2018-01176","30215735","PMC6300412","ClinicalTrials.gov:NCT02049034","S002130","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018625","Nutritional Considerations During Major Weight Loss Therapy: Focus on Optimal Protein and a Low-Carbohydrate Dietary Pattern.","Volek JS","2024","Current nutrition reports","narrative_review","article","10.1007/s13668-024-00548-6","38814519","PMC11327213",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018626","GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications.","Moore PW","2023","Advances in therapy","narrative_review","article","10.1007/s12325-022-02394-w","36566341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018627","Update on Pediatric Anti-obesity Medications-Current Landscape and Approach to Prescribing.","Ahn YJ","2024","Current obesity reports","narrative_review","article","10.1007/s13679-024-00566-z","38689134",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018628","Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention.","Laeeq T","2024","Cancers","narrative_review","article","10.3390/cancers16071325","38611003","PMC11011099",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018629","Unlocking the Potential of Type 2 Diabetes Mellitus Remission.","Sharma P","2023","Cureus","narrative_review","article","10.7759/cureus.48704","38094528","PMC10716578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018630","ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?","Monda VM","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-020-00898-8","32749644","PMC7400747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; other; article"],["R0018631","The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats.","Albanna AA","2025","Journal of experimental pharmacology","randomized_trial","article","10.2147/jep.s522053","40655462","PMC12248737",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018632","Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6).","Boye KS","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-024-01620-8","39008236","PMC11330430","ClinicalTrials.gov:NCT04537923","S000108","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0018633","Harnessing hibernation: Unlocking nature's secrets for advances in healthy aging, critical care, and space exploration.","Drew KL","2025","Annals of the New York Academy of Sciences","narrative_review","article","10.1111/nyas.70013","40760795","PMC12327768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0018634","Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide.","Gajahi Soudahome A","2018","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m117.815274","29414771","PMC5880132",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018635","Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial.","Yin TT","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0412-6","29744819","PMC5984915",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018636","From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD.","Chrysavgis L","2026","International journal of molecular sciences","randomized_trial","article","10.3390/ijms27188368","42794795","PMC13607588",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; other; article"],["R0018637","Liraglutide preconditioning attenuates myocardial ischemia/ reperfusion injury via homer1 activation.","Cui X","2021","Aging","preclinical","article","10.18632/aging.202429","33535171","PMC7993747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018638","Semaglutide vs Revisional Bariatric Surgery: What Is the Best Option for Suboptimal Clinical Response or Recurrent Weight Gain After MBS? ","Rivero-Moreno Y","2025","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-6033446/v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0018639","Ginsenosides Rb1 and Rg1 suppress triglyceride accumulation in 3T3-L1 adipocytes and enhance beta-cell insulin secretion and viability in Min6 cells via PKA-dependent pathways.","Park S","2008","Bioscience, biotechnology, and biochemistry","preclinical","article","10.1271/bbb.80205","18997435",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018640","8132 Prolonged Refractory Hypoglycemia For Seven Days After Discontinuation Of Neutral Protamine Hagedorn (NPH) Insulin And Injectable Semaglutide",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454716",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018641","An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics.","Geiger MJ","2012","Journal of diabetes science and technology","randomized_trial","article","10.1177/193229681200600610","23294776","PMC3570871",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018642","Impaired central sensitivity to thyroid hormone is associated with decreased glycemic variability in patients with type 2 diabetes.","Li Y","2026","Nutrition, metabolism, and cardiovascular diseases : NMCD","other","article","10.1016/j.numecd.2025.104418","41620300",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0018643","Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension.","Banks TE","2022","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2022.175048","35644422",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0018644","GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk.","Liuzzo G","2021","European heart journal","commentary","article","10.1093/eurheartj/ehab175","33822032",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0018645","Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.","Grieco M","2019","Frontiers in neuroscience","narrative_review","article","10.3389/fnins.2019.01112","31680842","PMC6813233",null,"S001263","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0018646","Lixisenatide as add-on therapy to basal insulin.","Brown DX","2013","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s45108","24363554","PMC3865973",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0018647","When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.","Cohen O","2016","Diabetes care","other_trial","article","10.2337/dcs15-3029","27440831",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0018648","Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.","Chedid V","2018","Neurogastroenterology and motility","other","article","10.1111/nmo.13313","29488276","PMC6003833",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0018649","Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis.","Cameron-Vendrig A","2016","Diabetes","preclinical","article","10.2337/db15-1141","26936963",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018650","The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent.","Furman BL","2012","Toxicon : official journal of the International Society on Toxinology","preclinical","article","10.1016/j.toxicon.2010.12.016","21194543",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018651","In adults with HF with preserved ejection fraction and obesity, tirzepatide reduced a composite of CV death or worsening HF at 2 y.","Ynalvez LA","2025","Annals of internal medicine","other","article","10.7326/annals-25-00468-jc","40163881",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018652","Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models.","Ruiz-Gonzalez CE","2026","Nature communications","preclinical","article","10.1038/s41467-026-75202-6","42481504","PMC13389251",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0018653","Investigations of Enteric-Coated Tablet Propyl Gallate-Induced Nephrotoxicity in Beagles as well as Human and Dog Renal Proximal Tubule Epithelial Cells.","Mou S","2025","ACS pharmacology & translational science","other","article","10.1021/acsptsci.4c00563","40370985","PMC12070228","ClinicalTrials.gov:NCT03362593",null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018654","Molecular and clinical roles of incretin-based drugs in patients with heart failure.","Orabi B","2018","Heart failure reviews","other_trial","article","10.1007/s10741-018-9702-3","29682682",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0018655","A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.","Abdalla MA","2020","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018820938305","32670541","PMC7338645",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018656","Re: Chou et al.: Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study (Ophthalmology. 2025;132:381-388).","Lum F","2025","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2025.03.011","40214636",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; letter"],["R0018657","Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment.","Umpierrez GE","2013","Diabetes care","commentary","article","10.2337/dc12-2233","23801801","PMC3687276",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment; discussion; article"],["R0018658","[Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].","Jahn E","2009","Medizinische Monatsschrift fur Pharmazeuten","narrative_review","article",null,"19947303",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0018659","Liraglutide in oral antidiabetic drug combination therapy.","Garber AJ","2012","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2012.01574.x","22405265",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0018660","Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.","Chen H","2025","Reproductive biology and endocrinology : RB&E","randomized_trial","article","10.1186/s12958-025-01447-3","40713699","PMC12297736","ChiCTR:ChiCTR2400090908",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0018661","Liraglutide Improves Endothelial Function via the mTOR Signaling Pathway.","Wu H","2021","Journal of diabetes research","other","article","10.1155/2021/2936667","34447854","PMC8384515",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018662","MAFLD/MASLD: Past, Present, and Future.","Wong VW","2026","Journal of gastroenterology and hepatology","narrative_review","article","10.1111/jgh.70619","42578314","PMC13534336",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0018663","Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.","Nakata H","2012","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.51.7876","23124148",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0018664","Liraglutide-Induced Hepatotoxicity.","Maor Y","2021","Biomedicines","nonrandomized_study","article","10.3390/biomedicines9020106","33498980","PMC7911918",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018665","Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.","Faber R","2015","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-015-0206-3","25896352","PMC4407869","ClinicalTrials.gov:NCT01931982","S002107; S002372","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018666","Tirzepatide for Lipodystrophy.","Meral R","2024","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2024.09.25.24313345","39802778","PMC11722473",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0018667","Facial Remodeling Addressing Fat Loss and Skin Sagging With Poly- l -Lactic Acid SCA and Hyaluronic Acid Filler After Semaglutide-Associated Prescriptive Weight Loss.","Sarlos P","2025","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","other","article","10.1097/dss.0000000000004659","40277199",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018668","Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline.","Yi B","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.176905","39154828",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018669","Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.","Boland ML","2020","Nature metabolism","preclinical","article","10.1038/s42255-020-0209-6","32478287","PMC7258337",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0018670","Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures.","Wikarek A","2024","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina60030393","38541119","PMC10972440",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; Preprint; article; preprint"],["R0018671","Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression.","Yan M","2024","Endocrine","preclinical","article","10.1007/s12020-024-03823-2","38647981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018672","Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.","Popovic DS","2024","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2024.111758","38925294",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0018673","Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.","Duah J","2025","Reproductive biology and endocrinology : RB&E","narrative_review","article","10.1186/s12958-024-01339-y","39762910","PMC11702155",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0018674","Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.","Hoog M","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01542-5","38427164","PMC10951167",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018675","How to apply artificial intelligence (AI) to facilitate and enhance MASH trials.","Lim DYZ","2026","Hepatology international","narrative_review","article","10.1007/s12072-026-11150-z","42749968",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018676","Comparing incretin-based therapies. Evaluating GLP-1 agonists and DPP-4 inhibitors for type 2 diabetes mellitus.","Urquhart BS","2010","Advance for NPs & PAs","narrative_review","article",null,"21299149",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0018677","Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats.","Romaní-Pérez M","2013","Endocrinology","preclinical","article","10.1210/en.2012-1786","23354098",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018678","Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.","Muscogiuri G","2017","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2016.10.001","27871675",null,"ClinicalTrials.gov:NCT01255163; ClinicalTrials.gov:NCT01469351; ClinicalTrials.gov:NCT01843075","S000009; S000689; S001707","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0018679","Trends in type 2 diabetes medication use and guideline adherence in Belgian primary care (2019-2023).","Raat W","2025","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2024.10.007","39487060",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018680","A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.","Kim DS","2017","Cell transplantation","other_trial","article","10.1177/0963689717721234","29113464","PMC5680957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0018681","[Lixisenatide (Lyxumia), a new agonist of glucagon-like peptide-1 receptors with a predominant postprandial action].","Scheen AJ","2014","Revue medicale de Liege","other","article",null,"24683832",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018682","Exendin-4 improves cardiovascular function and survival in flow-induced pulmonary hypertension.","Roan JN","2018","The Journal of thoracic and cardiovascular surgery","preclinical","article","10.1016/j.jtcvs.2017.10.085","29249493",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Video-Audio Media; article"],["R0018683","Gut-brain axis : central impact of gut peptides and metabolic drug on monoamine neurotransmission","Omoloye A","2019","De Montfort University","preclinical","article",null,null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0018684","NHS England consults on rolling out obesity injection tirzepatide to meet demand.","Limb M","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q2180","39366704",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0018685","Semaglutide Eases Knee Osteoarthritis Pain in People With Obesity.","Anderer S","2025","JAMA","other_trial","article","10.1001/jama.2024.24260","39641950",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0018686","New antidiabetic therapy and HFpEF: light at the end of tunnel?","Tadic M","2022","Heart failure reviews","narrative_review","article","10.1007/s10741-021-10106-9","33843015","PMC9197886",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0018687","Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.","Son S","2009","Journal of medicinal chemistry","preclinical","article","10.1021/jm901153x","19827752",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018688","Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.","Del Olmo-García MI","2020","The Journal of international medical research","randomized_trial","article","10.1177/0300060520926063","32567433","PMC7309403",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0018689","Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.","Robinson LE","2013","BMJ open","systematic_review","article","10.1136/bmjopen-2012-001986","23355666","PMC3563145",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0018690","PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice.","Kjaergaard M","2019","Neuropeptides","preclinical","article","10.1016/j.npep.2018.11.004","30471778",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018691","Facial oedema and necrotic ulcers: a cutaneous reaction to liraglutide.","Santana-Gutiérrez A","2025","Clinical and experimental dermatology","other","article","10.1093/ced/llae398","39412255",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018692","Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects.","Zhang H","2015","Nature communications","preclinical","article","10.1038/ncomms9918","26621478","PMC4686834",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018693","Design of self-emulsifying oral delivery systems for semaglutide: reverse micelles versus hydrophobic ion pairs.","Sandmeier M","2025","Drug delivery and translational research","other","article","10.1007/s13346-024-01729-0","39427069","PMC12037675",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018694","Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.","Gerstein HC","2019","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(19)31150-x","31189509",null,"ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0018695","liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.",null,"2016","Prescrire international","randomized_trial","article",null,"26942248",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; article"],["R0018696","Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection.","Ussher JR","2014","Molecular metabolism","preclinical","article","10.1016/j.molmet.2014.04.009","25061556","PMC4099509",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018697","Analysis of clinical studies on clozapine from 2012-2022.","Freibüchler A","2024","Naunyn-Schmiedeberg's archives of pharmacology","nonrandomized_study","article","10.1007/s00210-024-03209-1","38918233","PMC11582105",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; research-article; article"],["R0018698","Progress towards a personalized management of antidiabetic medications in the elderly with type 2 diabetes.","Scheen AJ","2025","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2025.2527092","40586635",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018699","Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.","Heerspink HJL","2022","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(22)00243-1","36152639",null,"ClinicalTrials.gov:NCT03730662","S001287","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018700","Liraglutide and the Management of Overweight and Obesity in People with Severe Mental Illness: Qualitative Sub-Study","Barnard-Kelly K","2021","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-763259/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0018701","Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.","Ala M","2024","International journal of obesity (2005)","systematic_review","article","10.1038/s41366-024-01621-4","39210008",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0018702","Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.","Annemans L","2026","Journal of medical economics","nonrandomized_study","article","10.1080/13696998.2026.2646079","42021523",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0018703","Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.","Schou M","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.04.038","38913004",null,"ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0018704","Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.","Forst T","2013","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2013.838559","24087882",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0018705","Micellar Nanomedicine of Novel Fatty Acid Modified Xenopus Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes.","Han J","2017","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.7b00632","28945431",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018706","Cardiovascular effects of antidiabetic drugs.","Sørensen AM","2018","Drugs of today (Barcelona, Spain : 1998)","narrative_review","article","10.1358/dot.2018.54.9.2872500","30303495",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018707","Irisin and liraglutide combination therapy mitigates myocardial reperfusion injury in obese rats: Role of endoplasmic reticulum stress and apoptosis.","Ma T","2025","Archives of biochemistry and biophysics","preclinical","article","10.1016/j.abb.2025.110370","40049268",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018708","Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data.","Kuss O","2022","Acta diabetologica","systematic_review","article","10.1007/s00592-022-01917-9","35879478","PMC9402762",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0018709","The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy.","He Y","2020","Annals of hepatology","preclinical","article","10.1016/j.aohep.2019.06.023","31787541",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018710","Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats.","Wang N","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.176793","38960061",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018711","Commentary on \"Facial Remodeling Addressing Fat Loss and Skin Sagging With Poly- l -Lactic Acid SCA and Hyaluronic Acid Filler After Semaglutide-Associated Prescriptive Weight Loss\".","Miot HA","2025","Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]","commentary","article","10.1097/dss.0000000000004660","40277248",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0018712","Hepatobiliary effects and safety of tirzepatide: A systematic review and meta-analysis.","Kamrul-Hasan ABM","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15948","39268951",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; review"],["R0018713","Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.","Ryan DH","2024","Nature medicine","other_trial","article","10.1038/s41591-024-02996-7","38740993","PMC11271387","ClinicalTrials.gov:NCT03574597","S000716; S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0018714","Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice.","Feng J","2024","PeerJ","randomized_trial","article","10.7717/peerj.17891","39148685","PMC11326427",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018715","Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog.","Meece J","2009","Pharmacotherapy","narrative_review","article","10.1592/phco.29.pt2.33s","19947815",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018716","Assessment of Serum Glucagon-Like Peptide-1 and Dipeptidyl Peptidase-4 Levels in Patients with Migraine","Gultekin M","2025","Research Square","other","preprint","10.21203/rs.3.rs-7178212/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0018717","Molecular Insight into Obesity-Associated Nephropathy: Clinical Implications and Possible Strategies for its Management.","Gupta H","2025","Current drug targets","narrative_review","article","10.2174/0113894501314788241008115712","39411934",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018718","Coronary Artery Disease Risk Assessment by Coronary Artery Calcium Scoring in Asymptomatic Thai People with Diabetes Mellitus.","Thewjitcharoen Y","2026","Vascular health and risk management","other","article","10.2147/vhrm.s582744","41710087","PMC12912155",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018719","Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.","Apperloo EM","2025","Nature medicine","randomized_trial","article","10.1038/s41591-024-03327-6","39455729",null,"ClinicalTrials.gov:NCT04889183","S002054","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018720","[Incretin-based therapies and cardiovascular outcome: analyses, pooled analyses and meta-analyses].","Mannucci E","2012","Giornale italiano di cardiologia (2006)","systematic_review","article","10.1714/1203.13331","23258123",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","English Abstract; Journal Article; other"],["R0018721","Unravelling Shared Pathways Linking Metabolic Syndrome, Mild Cognitive Impairment, Dementia, and Sarcopenia.","Ceccarelli Ceccarelli D","2025","Metabolites","nonrandomized_study","article","10.3390/metabo15030159","40137124","PMC11943464",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0018722","Synthesis and biological evaluation of an 111In-labeled exendin-4 derivative as a single-photon emission computed tomography probe for imaging pancreatic β-cells.","Kimura H","2017","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2017.09.005","28927802",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018723","Humanization of N-glycan-dependent protein quality control system in  <i>Kluyveromyces marxianus<\/i>  promotes glycoprotein secretion","Ai Y","2026","bioRxiv","other","preprint","10.64898/2026.05.08.723133",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0018724","Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition.","Xie Y","2023","Acta pharmaceutica Sinica. B","narrative_review","article","10.1016/j.apsb.2022.11.008","37425060","PMC10326166",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018725","Liraglutide Ameliorates Lipotoxicity-Induced Oxidative Stress by Activating the NRF2 Pathway in HepG2 Cells.","Zhu CG","2020","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","other","article","10.1055/a-1157-0166","32375182",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018726","The Up-to-date Treatment for Diabetes and Prevention of its Complications.","Nishida Y","2024","Juntendo Iji zasshi = Juntendo medical journal","other","article","10.14789/ejmj.jmj24-0030-r","39840001","PMC11745827",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0018727","GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting.","Naveed M","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.16405","40259493",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018728","Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.","Norwood P","2012","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2012.09.007","23031623",null,"ClinicalTrials.gov:NCT00753896","S000518","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018729","Deficiency of proton-sensing ovarian cancer G protein-coupled receptor 1 attenuates glucose-stimulated insulin secretion.","Nakakura T","2012","Endocrinology","preclinical","article","10.1210/en.2012-1164","22733973",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018730","Tirzepatide's role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance.","Xia Y","2024","International immunopharmacology","preclinical","article","10.1016/j.intimp.2024.113499","39471690",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018731","Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.","Manubolu VS","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.05.065","39168573",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Letter; Randomized Controlled Trial; article"],["R0018732","Predicting heart failure in asymptomatic diabetes: derivation and internal validation of a clinical prediction model for early detection of diabetic cardiomyopathy.","Cao Y","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1882872","42440594","PMC13333415",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Validation Study; research-article; article"],["R0018733","The risk of common hypoglycemic and antihypertensive medications and COVID-19: A 2-sample Mendelian randomization study.","Wang Y","2024","Medicine","other","article","10.1097/md.0000000000036423","38335406","PMC10860956",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018734","Potential cardiovascular effects of incretin-based therapies.","Deacon CF","2012","Expert review of cardiovascular therapy","preclinical","article","10.1586/erc.12.5","22390806",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018735","Simultaneous analysis of antihyperglycemic small molecule drugs and peptide drugs by means of dual liquid chromatography high-resolution mass spectrometry.","Vollmer AC","2023","Clinical chemistry and laboratory medicine","other","article","10.1515/cclm-2022-1316","37011023",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018736","Corrigendum to Mann JFE, Muskiet MHA. Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. Kidney Int. 2021;99:314-318.",null,"2021","Kidney international","notice","article","10.1016/j.kint.2021.10.005","34802566",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0018737","This octopus-inspired patch could deliver drugs like Ozempic through your cheek.","Naddaf M","2023","Nature","commentary","article","10.1038/d41586-023-03050-1","37759126",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; other"],["R0018738","New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.","Namba M","2013","Clinical and experimental nephrology","narrative_review","article","10.1007/s10157-012-0709-0","23135865",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018739","Prevention of cardiorenal complications in people with type 2 diabetes and obesity.","Drucker DJ","2024","Cell metabolism","narrative_review","article","10.1016/j.cmet.2023.12.018","38198966",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018740","Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes.","Søndergaard CS","2023","Current oncology reports","nonrandomized_study","article","10.1007/s11912-022-01344-7","36445570",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0018741","Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes.","Grauslund J","2024","International journal of retina and vitreous","nonrandomized_study","article","10.1186/s40942-024-00620-x","39696569","PMC11657653",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0018742","Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.","McDonell AL","2015","ClinicoEconomics and outcomes research : CEOR","nonrandomized_study","article","10.2147/ceor.s69981","25674008","PMC4321412",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018743","Liraglutide treatment in children with obesity.","Kotsiliti E","2024","Nature reviews. Gastroenterology & hepatology","other","article","10.1038/s41575-024-01010-2","39406986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018744","Evaluating risks and benefits of Newer Diabetes medications when Used in Routine care (ENDURe)","Colacci M","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.02.20.25322631",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0018745","Is cardioprotection with GLP-1 receptor agonists a class effect?","Rydén L","2021","European journal of preventive cardiology","randomized_trial","article","10.1093/eurjpc/zwaa103","33623981",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Editorial; Comment; editorial"],["R0018746","Weight loss and body composition after compounded semaglutide treatment in a real world setting.","Chun E","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16162","39776038",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018747","The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.","Mu Y","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15857","39157869",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0018748","Exendin-4 stimulates islet cell replication via the IGF1 receptor activation of mTORC1/S6K1.","Xie J","2014","Journal of molecular endocrinology","preclinical","article","10.1530/jme-13-0200","24994913",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018749","Semaglutide and blood pressure: an individual patient data meta-analysis.","Kennedy C","2024","European heart journal","systematic_review","article","10.1093/eurheartj/ehae564","39217502","PMC11458150",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article; review"],["R0018750","Retraction notice to \"A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design\" [Mech. Ageing Dev. 213 (2023) 111825].","Davidy T","2024","Mechanisms of ageing and development","notice","article","10.1016/j.mad.2024.111937","38702256","PMC12124240",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Retraction Notice; Retraction of Publication; retraction"],["R0018751","Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.","Harris E","2023","JAMA","other","article","10.1001/jama.2023.12055","37405802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018752","Enteric neurons modulate colorectal cancer cell cycle through a PCSK1 - Methionine-Enkephalin Axis.","Seika P","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.05.03.722515","42146522","PMC13174311",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0018753","[Management of hyperglycaemia of type 2 diabetes. Paradigm change according to the ADA-EASD consensus report 2018].","Scheen AJ","2018","Revue medicale de Liege","other","article",null,"30570234",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018754","Letter to Editor From Ishaq MU et al: \"Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease\".","Ishaq MU","2024","Journal of the Endocrine Society","commentary","article","10.1210/jendso/bvae217","39697666","PMC11653077",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article-commentary; article"],["R0018755","Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation.","Iwaya C","2017","Endocrinology","preclinical","article","10.1210/en.2017-00461","29045658",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018756","Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study","Ohara M","2024","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-4850653/v1",null,null,"jRCT:jRCT1031210620",null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0018757","Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus.","Vilsbøll T","2008","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","narrative_review","article","10.2165/00063030-200822040-00004","18611067",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018758","A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.","Hasib A","2018","Peptides","preclinical","article","10.1016/j.peptides.2017.10.015","29412820",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0018759","[Underuse of SGLT2 inhibitors in clinical practice].","Scheen AJ","2024","Revue medicale suisse","randomized_trial","article","10.53738/revmed.2024.20.884.1498","39219393",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","English Abstract; Journal Article; article"],["R0018760","Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide.","Avignon A","2025","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.24262","40177856","PMC12015648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018761","Analysis of Prediabetes in Veterans: Assessing Diagnosis and Population Characteristics Across a Region of Veterans Affairs Health Care Systems.","Greck BD","2025","Healthcare (Basel, Switzerland)","other","article","10.3390/healthcare13233061","41373277","PMC12692100",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018762","Erratum. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care 2021;44:1433-1442.","Nahra R","2022","Diabetes care","notice","article","10.2337/dc22-er12","36228195","PMC9763024",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0018763","Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.","Battelino T","2022","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(22)00077-8","35468321",null,"ClinicalTrials.gov:NCT03882970","S001591","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018764","Semaglutide alleviates knee osteoarthritis pain in persons with obesity.","Aman Y","2025","Nature aging","other","article","10.1038/s43587-025-00809-1","39810052",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018765","The Tirzepatide Drop: Beware of Slimmer's Paralysis.","Tucker JM","2024","Journal of investigative medicine high impact case reports","case_report","article","10.1177/23247096241264635","39051436","PMC11273815",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0018766","Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats.","Babic I","2021","Journal of psychopharmacology (Oxford, England)","preclinical","article","10.1177/0269881120981377","33570012",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018767","Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements.","Metzner V","2022","Journal of clinical medicine","randomized_trial","article","10.3390/jcm11030753","35160204","PMC8836549",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018768","Forecasting cardiovascular risk reduction with semaglutide in overweight and obese with heart disease: a nationwide cohort study.","Lassen MCH","2025","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwae224","39021164",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018769","Semaglutide Eligibility Across All Current Indications for US Adults.","Shi I","2025","JAMA cardiology","other","article","10.1001/jamacardio.2024.4657","39556764","PMC11574724",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018770","Proinflammatory cytokine-induced alpha-cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism","Henriksen K","2024","bioRxiv","preclinical","preprint","10.1101/2024.06.26.600877",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018771","Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.","Wang Y","2014","British journal of pharmacology","preclinical","article","10.1111/bph.12490","24490861","PMC3969084",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018772","For Patients with Type 2 Diabetes Mellitus Who Are Taking a GLP-1 Receptor Agonist, an SGLT2 Inhibitor May Be Preferred to a Sulfonylurea as Add-on Therapy.","Ebell MH","2021","American family physician","nonrandomized_study","article",null,"34652104",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; article"],["R0018773","Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.","Campbell RK","2010","The Journal of family practice","randomized_trial","article",null,"20824235",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Case Reports; Journal Article; article"],["R0018774","LiverPRO Reduces False Positives and Screening Costs Compared With Fibrosis-4 Index in Steatotic Liver Disease.","Thorhauge K","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2026.01.024","41633461",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0018775","Effect of tirzepatide on leptin and adiponectin levels.","Simental-Mendía LE","2024","European journal of internal medicine","commentary","article","10.1016/j.ejim.2024.07.037","39089971",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0018776","Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.","Wang H","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13177","29193572",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0018777","Bariatric surgery and semaglutide in a youth with juvenile Huntington disease and severe obesity: a case report.","Vidmar AP","2025","Journal of medical case reports","case_report","article","10.1186/s13256-025-05615-2","41121434","PMC12538795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0018778","The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.","Hansen HH","2016","Brain research","preclinical","article","10.1016/j.brainres.2015.12.052","26746341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018779","The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis.","Li YK","2018","Pharmacological research","preclinical","article","10.1016/j.phrs.2018.03.004","29530599",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018780","Noninvasive longitudinal quantification of β-cell mass with [111In]-labeled exendin-4.","Fujita N","2019","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.201900555rr","31370679","PMC6902711",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018781","Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.","Fujihara K","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15887","39192522",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018782","Lifestyle Interventions in a Patient Identified as Super-Super Obese With a Body Mass Index of 90.5.","Al Ghareeb G","2024","Journal of medical cases","case_report","article","10.14740/jmc4194","38646420","PMC11027765",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018783","Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities.","Dyndał K","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26178755","40943672","PMC12429090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018784","Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure.","Xie J","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00722-7","42249250",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018785","An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.","Ma T","2022","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2021.174635","34800466",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018786","Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials.","Giorgino F","2024","Diabetes care","other_trial","article","10.2337/dc23-2366","38530948","PMC11116914",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; other; article"],["R0018787","How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart.","Iacobellis G","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.08.088","39779063",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018788","Long-Acting, Longer-Acting and Ultralong-Acting Peptides","Schneider E","2024","Preprints.org","other","preprint","10.20944/preprints202410.0475.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018789","Liraglutide ameliorates TAC-induced cardiac hypertrophy and heart failure by upregulating expression level of ANP expression.","Li R","2024","Heliyon","other","article","10.1016/j.heliyon.2024.e32229","38868006","PMC11168427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018790","Stromal cell-derived factor-1/Exendin-4 cotherapy facilitates the proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells in vitro and promotes periodontal bone regeneration in vivo.","Liang Q","2021","Cell proliferation","preclinical","article","10.1111/cpr.12997","33511708","PMC7941242",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018791","Exploring the role of two polypeptide nanofiber gels derived from RADA16-I self-assembly in accelerating burn wound healing.","Song C","2025","Scientific reports","preclinical","article","10.1038/s41598-025-08666-z","40628849","PMC12238610",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018792","Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.","Larsen AT","2022","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2022.113842","36242844",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0018793","Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia.","Park JS","2021","Medicine","nonrandomized_study","article","10.1097/md.0000000000023780","33466127","PMC7808520",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0018794","Directed evolution of conformation-specific antibodies for sensitive detection of polypeptide aggregates in therapeutic drug formulations.","Lou W","2021","Biotechnology and bioengineering","nonrandomized_study","article","10.1002/bit.27610","33095442",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018795","[GLP-1 analogues in treatment of type 1 diabetes mellitus].","Tölle S","2014","Deutsche medizinische Wochenschrift (1946)","systematic_review","article","10.1055/s-0034-1387304","25289919",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","English Abstract; Journal Article; Systematic Review; article"],["R0018796","Albiglutide (Tanzeum) for Diabetes Mellitus.","Trietley G","2017","American family physician","narrative_review","article",null,"28409609",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018797","Response to \"Letter to Editor From Ishaq MU et al: 'Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease'\".","Korakas E","2024","Journal of the Endocrine Society","commentary","article","10.1210/jendso/bvae218","39711847","PMC11663492",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Letter; reply; article"],["R0018798","Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides.","Aziz A","2005","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00850.2004","15879053",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018799","Semaglutide and GLP-1 analogues as weight-loss agents.","Kluger AY","2018","Lancet (London, England)","commentary","article","10.1016/s0140-6736(18)31826-9","30122306",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0018800","Harnessing the Reactivity of Sulfinate Salts With Cystine: An Umpolung Approach to Residue-Specific Peptide Modification.","Hammond JM","2026","Angewandte Chemie (International ed. in English)","other","article","10.1002/anie.5484068","42412011","PMC13549023",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article; preprint"],["R0018801","Physician perceptions of GLP-1 receptor agonists in the UK.","Matza LS","2016","Current medical research and opinion","other","article","10.1185/03007995.2016.1147025","26807507",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018802","Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake","Klemets A","2024","Research Square","other","preprint","10.21203/rs.3.rs-4823981/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; other; preprint"],["R0018803","Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.","Zile MR","2025","Circulation","randomized_trial","article","10.1161/circulationaha.124.072679","39556714","PMC11893002","ClinicalTrials.gov:NCT04847557","S000047; S000913","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0018804","ACUTE PANCREATITIS AND TYPE 2 DIABETES MELLITUS: GLP-1 RECEPTOR AGONIST OR IDIOPATHIC, A DIAGNOSTIC DILEMMA, A CASE REPORT WITH LITERATURE REVIEW.","Cheng C","2021","Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates","case_report","article","10.1097/sga.0000000000000602","34269709",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0018805","Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity.","Sardar MB","2024","Current problems in cardiology","other_trial","article","10.1016/j.cpcardiol.2024.102489","38417475",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0018806","Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.","Carris NW","2014","Drugs","randomized_trial","article","10.1007/s40265-014-0325-2","25414121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0018807","Re: Chou et al.: Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study (Ophthalmology. 2025:132:381-388).","Zhu H","2025","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2025.02.024","40186600",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; letter"],["R0018808","Proinflammatory Stress Activates Neutral Sphingomyelinase 2-Based Generation of a Ceramide-Enriched β-Cell EV Subpopulation.","Xu J","2025","Diabetes","other","article","10.2337/db24-0341","40896819","PMC12585158",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0018809","A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine.","Xia J","2020","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2020.00372","32273846","PMC7113385",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018810","Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study.","Pantalone KM","2023","Diabetes spectrum : a publication of the American Diabetes Association","nonrandomized_study","article","10.2337/ds22-0064","37583559","PMC10425231",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article; other"],["R0018811","Gut Microbiota-Derived Metabolites Orchestrate Metabolic Reprogramming in Diabetic Cardiomyopathy: Mechanisms and Therapeutic Frontiers.","Jin JY","2025","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","nonrandomized_study","article","10.1096/fj.202501579rr","40899744","PMC12406765",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0018812","Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.","Wang J","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15860","39188242",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018813","Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level.","Yang Y","2016","Molecular and cellular neurosciences","preclinical","article","10.1016/j.mcn.2015.10.005","26640240",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018814","Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.","Borlaug BA","2026","JACC. Heart failure","other","article","10.1016/j.jchf.2025.102712","41099689","PMC12614479","ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT03914326","S000716; S000953; S002179","pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0018815","Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice.","Bensignor MO","2024","Current opinion in pediatrics","randomized_trial","article","10.1097/mop.0000000000001365","38774967","PMC11222026",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0018816","The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.","Mancini MC","2017","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-017-0242-0","28580018","PMC5452636",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018817","Reply: How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart.","Lakshmanan S","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.10.116","39779064",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0018818","Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: A UK multisite 12-month prospective observational study.","Dunkley AJ","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13690","30843327",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0018819","Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.","Gabe MBN","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15802","39082206",null,null,"S002178; S002621","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018820","Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study.","Klein G","2023","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-023-01239-1","37140727","PMC10256642","ClinicalTrials.gov:NCT03235375","S000042","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018821","Incretin mimetics as emerging treatments for type 2 diabetes.","Joy SV","2005","The Annals of pharmacotherapy","other_trial","article","10.1345/aph.1e245","15562141",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0018822","Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.","Palmer SC","2021","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj.m4573","33441402","PMC7804890","PROSPERO:CRD42019153180",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; review"],["R0018823","STARTing a new path in cardiovascular prevention: Lessons from SELECT and real-world evidence on Semaglutide in obesity-driven risk.","Andò G","2025","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2025.133058","39954788",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0018824","Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.","Wang W","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15263","37732487",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018825","Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.","Ahrén B","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13353","29766634","PMC6099440",null,"S000329; S000878; S001219; S001872; S001876","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018826","Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH).","Liu H","2026","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s543657","42719321","PMC13557022",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018827","Correction: Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.","Kim JY","2018","PloS one","notice","article","10.1371/journal.pone.0191744","29352297","PMC5774838",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0018828","Incretin-based therapies for obesity treatment.","de Mello AH","2015","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2015.05.012","26072135",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018829","Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.","Khoo J","2009","Therapeutics and clinical risk management","narrative_review","article","10.2147/tcrm.s4975","19707284","PMC2731024",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0018830","Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation.","Gao H","2021","Scientific reports","preclinical","article","10.1038/s41598-021-83201-4","33574570","PMC7878925",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018831","Experience with dulaglutide in a diabetic and obese patient on incremental peritoneal dialysis.","González Sanchidrián S","2024","Nefrologia","commentary","article","10.1016/j.nefroe.2023.10.009","38871561",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0018832","Radiosynthesis and evaluation of an 18F-labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma.","Dialer LO","2018","EJNMMI radiopharmacy and chemistry","preclinical","article","10.1186/s41181-017-0036-6","29503858","PMC5824708",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018833","Baseline Pancreatic Beta Cell Imaging After Pancreatic Transplantation Using Whole-Body 68Ga-DOTA-Exendin-4 PET/CT: A Spectrum of 2 Cases of Diabetes Mellitus.","Gambhir A","2019","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000002461","30688734",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0018834","High rate of complications in a real-world cohort of youth with T2D: a multicenter analysis.","Patel D","2025","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2025.109091","40570536","PMC12272727",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; research-article"],["R0018835","Liraglutide in the management of obesity: real world data (Portugal).","Tavares Bello C","2025","Minerva endocrinology","randomized_trial","article","10.23736/s2724-6507.24.04161-7","39012306",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Observational Study; article"],["R0018836","Liraglutide Effect on Ventricular Transient Outward K +  Channel and Connexin-43 Protein Expression.","Ramadan NM","2021","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","randomized_trial","article","10.1055/a-1162-8196","32559789",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0018837","68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.","Antwi K","2019","The Journal of clinical endocrinology and metabolism","other","article","10.1210/jc.2018-02754","31298706",null,"ClinicalTrials.gov:NCT02127541","S000994","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018838","68Ga-labeled exendin-4 to image cardiac repair after myocardial infarction: From lizard venom to laboratory and beyond.","Wardak M","2020","Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology","commentary","article","10.1007/s12350-019-01641-y","30805772",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment; article"],["R0018839","Instrumental Variable Methods to Target Hypothetical Estimands With Longitudinal Repeated Measures Data: Application to the STEP 1 Trial.","Bowden J","2025","Statistics in medicine","randomized_trial","article","10.1002/sim.70076","40214049","PMC11987489",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018840","The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy.","Gopal K","2020","Frontiers in physiology","narrative_review","article","10.3389/fphys.2020.603247","33364978","PMC7750477",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018841","Evaluation of A Novel GLP-1R Ligand for PET Imaging of Prostate Cancer.","Yue Y","2019","Anti-cancer agents in medicinal chemistry","preclinical","article","10.2174/1871520618666180801101730","30068284",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018842","Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.","Polyzos SA","2022","Current obesity reports","narrative_review","article","10.1007/s13679-022-00474-0","35501557",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018843","Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories.","Chen S","2024","Medicine","nonrandomized_study","article","10.1097/md.0000000000040438","39809212","PMC11596640",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0018844","Using a Reporter Mouse to Map Known and Novel Sites of GLP-1 Receptor Expression in Peripheral Tissues of Male Mice.","Andersen DB","2021","Endocrinology","preclinical","article","10.1210/endocr/bqaa246","33508122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018845","Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.","Chen S","2018","Scientific reports","notice","article","10.1038/s41598-018-31455-w","30209317","PMC6135809",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0018846","[Risk Factor Management for Polyvascular Atherosclerosis].","Reuser A","2025","Deutsche medizinische Wochenschrift (1946)","narrative_review","article","10.1055/a-2362-4893","40436382",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; Research Support, Non-U.S. Gov't; article"],["R0018847","The Regulation Role of the Gut-Islets Axis in Diabetes.","Yang S","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s455026","38533266","PMC10964787",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018848","The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents.","Egecioglu E","2013","Psychoneuroendocrinology","preclinical","article","10.1016/j.psyneuen.2012.11.009","23219472",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018849","Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction.","Turnock LA","2025","The International journal on drug policy","other","article","10.1016/j.drugpo.2025.104854","40418873",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018850","Increased cholesterol interactions in the active conformational state of the glucagon-like peptide-1 receptor.","Naglekar A","2026","Biophysical journal","other","article","10.1016/j.bpj.2025.09.003","40913315","PMC12968845",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0018851","Daily briefing: Blockbuster anti-obesity drug Wegovy slashes heart-attack risk.","Krämer K","2023","Nature","commentary","article","10.1038/d41586-023-02579-5","37582939",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0018852","Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.","Scheen AJ","2012","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2011.10.007","22284241",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0018853","No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects.","Demmel V","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0442-0","29799100","PMC6064589","ClinicalTrials.gov:NCT02064348","S001221","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0018854","Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.","Ji L","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15888","39279647",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0018855","Semaglutide Ameliorates Hepatocyte Steatosis in a Cell Co-Culture System by Downregulating the IRE1α-XBP1-C/EBPα Signaling Pathway in Macrophages.","Hu Q","2025","Pharmacology","preclinical","article","10.1159/000540654","39089233",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018856","Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction.","Yan H","2024","Drug design, development and therapy","preclinical","article","10.2147/dddt.s491970","39640291","PMC11618856",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018857","Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.","Husain M","2020","Diabetes, obesity & metabolism","other","article","10.1111/dom.13955","31903692","PMC7064975","ClinicalTrials.gov:NCT02054897; ClinicalTrials.gov:NCT01930188; ClinicalTrials.gov:NCT01885208; ClinicalTrials.gov:NCT02128932; ClinicalTrials.gov:NCT02305381; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02906930; ClinicalTrials.gov:NCT02863328; ClinicalTrials.gov:NCT02607865; ClinicalTrials.gov:NCT02863419; ClinicalTrials.gov:NCT02827708; ClinicalTrials.gov:NCT02692716; ClinicalTrials.gov:NCT02849080; ClinicalTrials.gov:NCT03021187; ClinicalTrials.gov:NCT03018028; ClinicalTrials.gov:NCT03015220","S000133; S000234; S000251; S000329; S000878; S001153; S001219; S001381; S001741; S001872; S001876; S001933; S001943; S002025; S002267; S002369","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018858","Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.","Kahn SE","2024","Diabetes care","randomized_trial","article","10.2337/dc24-0491","38907683","PMC11282386",null,"S000578","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0018859","GLP-1R signaling does not modify the severity of experimental graft versus host disease.","Yusta B","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102235","40846075","PMC12414834",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0018860","A Bibliometric Analysis of Research Hotspots and Frontiers in Diabetes and Cardiovascular Disease Comorbidity from 2005 to 2024","Wang J","2024","medRxiv","other","preprint","10.1101/2024.09.29.24314577",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018861","Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.","Jackson SH","2010","P & T : a peer-reviewed journal for formulary management","other_trial","article",null,"20975808","PMC2957743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0018862","Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis.","Maddaloni E","2025","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2025.112125","40154887",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0018863","Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis.","Wilke T","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00903-0","32876862","PMC7509007",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0018864","Opaganib Promotes Weight Loss and Suppresses High-Fat Diet-Induced Obesity and Glucose Intolerance.","Maines LW","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s514548","40191829","PMC11971975",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018865","In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo.","Bandi SSS","2025","Annals of internal medicine","other","article","10.7326/annals-25-02173-jc","40587855",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018866","Top studies of 2023 relevant to primary care: From the PEER team.","Thomas BS","2024","Canadian family physician Medecin de famille canadien","narrative_review","article","10.46747/cfp.7004245","38626998","PMC11280662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018867","Semaglutide for the management of diabesity: The real-world experience.","Alkhalifah M","2024","World journal of methodology","randomized_trial","article","10.5662/wjm.v14.i3.91832","39310241","PMC11230069",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018868","Very-low-calorie-diet, tirzepatide, and bariatric surgery: a multidisciplinary success in super-super obesity.","Daou C","2025","Journal of surgical case reports","case_report","article","10.1093/jscr/rjae816","40161879","PMC11954371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018869","General practitioner and nurse experiences of type 2 diabetes management and prescribing in primary care: a qualitative review following the introduction of funded SGLT2i/GLP1RA medications in Aotearoa New Zealand.","Norman K","2024","Primary health care research & development","narrative_review","article","10.1017/s1463423624000264","39282819","PMC11464800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018870","Practice Patterns in Body Mass Index Optimization Among US Arthroplasty Surgeons: Results of a National American Association of Hip and Knee Surgeons Survey.","Seckin T","2026","Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews","other","article","10.5435/jaaosglobal-d-25-00187","41706617","PMC12915733",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018871","Maladaptive Eating Behaviours, Generalised Anxiety Disorder and Depression Severity: A Comparative Study between Adult Women with Overweight, Obesity, and Normal Body Mass Index Range.","Witaszek T","2023","Nutrients","other","article","10.3390/nu16010080","38201910","PMC10780963",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018872","Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.","Cefalu WT","2014","Diabetes care","other","article","10.2337/dc14-1395","25147257","PMC5169170",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; meeting-report; article"],["R0018873","Correction to: Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Cui Y","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-024-01632-4","39283412","PMC11467149",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0018874","Cardiometabolic Effects of a New Class of Antidiabetic Agents.","Desouza CV","2015","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2015.02.016","25754876",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0018875","Controlling Obesity and Metabolic Diseases by Hydrodynamic Delivery of a Fusion Gene of Exendin-4 and α1 Antitrypsin.","Gao M","2019","Scientific reports","preclinical","article","10.1038/s41598-019-49757-y","31530849","PMC6748963",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018876","Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.","Lingvay I","2024","Diabetes care","randomized_trial","article","10.2337/dc24-0764","38907684","PMC11282385",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018877","Good clinical practice recommendations for the management of gastroesophageal reflux disease. A Latin American expert review.","Valdovinos-Díaz MA","2025","Revista de gastroenterologia de Mexico (English)","narrative_review","article","10.1016/j.rgmxen.2025.02.001","40500596",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Practice Guideline; article"],["R0018878","Semaglutide May Ameliorate Fibrosis and Inhibit Epithelial-Mesenchymal Transition in Intrauterine Adhesion Models.","Wu L","2024","International journal of molecular sciences","preclinical","article","10.3390/ijms25116196","38892384","PMC11172622",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018879","An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides.","Tian R","2019","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.9b00258","31082207",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; article"],["R0018880","New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.","Campbell RK","2009","The Diabetes educator","narrative_review","article","10.1177/0145721709342900","19783765",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0018881","Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks.","Kadowaki T","2011","Journal of diabetes investigation","randomized_trial","article","10.1111/j.2040-1124.2010.00084.x","24843486","PMC4014921","ClinicalTrials.gov:NCT00577824","S000752","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0018882","ReverseScreen.ai: Pharmacophore-Guided Reverse Screening Across the Growing Co-Complex Proteome","Muskal SM","2026","bioRxiv","other","preprint","10.64898/2026.09.09.750461",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018883","Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.","Kim JY","2016","PloS one","systematic_review","article","10.1371/journal.pone.0153502","27078018","PMC4831684",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; research-article; review"],["R0018884","Utility of 68 Ga-DOTA-Exendin-4 positron emission tomography-computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia.","Kalff V","2021","Internal medicine journal","nonrandomized_study","article","10.1111/imj.15141","33314504",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Case Reports; Journal Article; article"],["R0018885","The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study.","Jensterle M","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1366940","38665260","PMC11043580",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0018886","Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.","Cannon AJ","2020","Journal of managed care & specialty pharmacy","randomized_trial","article","10.18553/jmcp.2019.19035","31856636","PMC10391176","ClinicalTrials.gov:NCT01952145; ClinicalTrials.gov:NCT02420262","S001328; S001760","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0018887","Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes.","Mertens J","2026","Diabetes technology & therapeutics","nonrandomized_study","article","10.1177/15209156251362497","40712645",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0018888","[Semaglutide for heart failure with preserved ejection fraction].","Dürschmied D","2025","Innere Medizin (Heidelberg, Germany)","other","article","10.1007/s00108-024-01844-7","39820736",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0018889","Circulating Dopamine Is Regulated by Dietary Glucose and Controls Glucagon-like 1 Peptide Action in White Adipose Tissue.","Tavares G","2023","International journal of molecular sciences","preclinical","article","10.3390/ijms24032464","36768789","PMC9916853",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018890","Perspectives in GLP-1 Research: New Targets, New Receptors.","Cantini G","2016","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2016.03.017","27091492",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0018891","Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single-Centre Retrospective Study.","Mima A","2024","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.489","38718272","PMC11078529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018892","Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.","Ditzenberger GL","2025","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","other_trial","article","10.1093/cid/ciae384","39046173","PMC11848261","ClinicalTrials.gov:NCT04216589","S001796","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0018893","Erratum to: Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria.","DellaValle B","2016","Malaria journal","notice","article","10.1186/s12936-016-1544-7","31265540","PMC5039887",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0018894","Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ.","Karakus KE","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-024-01592-9","38743306","PMC11211304",null,"S001837","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; article"],["R0018895","Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study.","Tofé S","2019","Endocrinology, diabetes & metabolism","randomized_trial","article","10.1002/edm2.51","30815578","PMC6354754",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0018896","The Modified Exenatide Microspheres: PLGA-PEG-PLGA Gel and Zinc-Exenatide Complex Synergistically Reduce Burst Release and Shorten Platform Stage.","Jiang W","2023","AAPS PharmSciTech","preclinical","article","10.1208/s12249-023-02705-6","38036924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018897","Glucagon-like peptide analogues for type 2 diabetes mellitus.","Shyangdan DS","2011","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd006423.pub2","21975753","PMC6486297",null,"S001234","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; systematic-review; article"],["R0018898","Real-world experience of adjunct weekly semaglutide in Type 1 diabetes. Is it worth it?","Cohen N","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111979","39732202",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0018899","Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies.","Jain P","2025","Clinics and research in hepatology and gastroenterology","narrative_review","article","10.1016/j.clinre.2025.102584","40157567",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018900","Corrigendum to \"Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in A protein kinase A and B/Akt manner'' [Pharmacol. Rep. 68 (2016) 329-337].","Bułdak Ł","2019","Pharmacological reports : PR","notice","article","10.1016/j.pharep.2019.05.019","31257077",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0018901","Letter to the Editor in response to the article \"Semaglutide and post kidney transplantation in patients with diabetes\".","Hussein M","2024","Journal of clinical & translational endocrinology","commentary","article","10.1016/j.jcte.2024.100358","39099756","PMC11296003",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0018902","Tirzepatide-Induced Biphasic Anaphylactic Reaction: A Case Report.","He Z","2023","Cureus","case_report","article","10.7759/cureus.50112","38186543","PMC10771104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018903","Production of Fc-fused receptor agonists for glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) in the milk of transgenic mice.","Rao Y","2025","Transgenic research","preclinical","article","10.1007/s11248-025-00458-5","40753531",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0018904","Gut hormone analogues and skeletal health in diabetes and obesity: Evidence from preclinical models.","Mabilleau G","2024","Peptides","narrative_review","article","10.1016/j.peptides.2024.171228","38657908",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0018905","Liraglutide preserves intracellular calcium handling in isolated murine myocytes exposed to oxidative stress.","Palee S","2017","Physiological research","preclinical","article","10.33549/physiolres.933558","28730832",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018906","The glucose tolerance test in mice: sex, drugs and protocol.","Kennard M","2021","Authorea Preprints","protocol","preprint","10.22541/au.162515866.61067774/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0018907","The effect of exercise in NAFLD and a GLP-1 receptor agonist in type 2 diabetes on lipid metabolism","Sharaf SE","2016","University of Surrey","randomized_trial","article",null,null,null,null,null,"europepmc; openalex","FALSE","free_to_read","2","FALSE","Dissertation; dissertation"],["R0018908","The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.","Athauda D","2016","Drug discovery today","other_trial","article","10.1016/j.drudis.2016.01.013","26851597",null,null,"S000204","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0018909","OAF Blocks SIAH1-Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD.","Li Z","2026","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.77451","42666127","PMC13525414",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018910","The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis.","Que Q","2019","Journal of inflammation (London, England)","preclinical","article","10.1186/s12950-019-0218-y","31182934","PMC6554939",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018911","Effects of Semaglutide on CKD in Patients With Type 2 Diabetes.","Kotwal SS","2025","Kidney international reports","commentary","article","10.1016/j.ekir.2024.11.1365","39990872","PMC11843104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0018912","Achievement of guideline targets among people with type 2 diabetes with eASCVD and high risk of ASCVD in the UAE: Results of the PACT-MEA-UAE cohort.","Bashier A","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112030","39909317",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0018913","Tirzepatide-New Evidence for the Treatment of Obesity From China.","Jia W","2024","JAMA","commentary","article","10.1001/jama.2024.9104","38819984",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; article"],["R0018914","Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.","Chewcharat A","2020","International urology and nephrology","systematic_review","article","10.1007/s11255-020-02520-z","32524495",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis"],["R0018915","First Report of Tirzepatide Hepatotoxicity with Jaundice.","Fontana RJ","2024","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2024.06.025","38964597",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018916","New developments in diabetes management: medications of the 21st century.","Fonseca VA","2014","Clinical therapeutics","narrative_review","article","10.1016/j.clinthera.2014.01.018","24594068",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0018917","The effect and mechanism of liraglutide on the biological functions of BMSCs in diabetic patients.","Wang Y","2024","Oral diseases","preclinical","article","10.1111/odi.14931","38501359",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018918","Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study.","Kato S","2025","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2025.112913","40983113",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0018919","Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.","Pencek R","2012","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2012.07.2567","22913891",null,"ClinicalTrials.gov:NCT00039026; ClinicalTrials.gov:NCT00039013; ClinicalTrials.gov:NCT00082381; ClinicalTrials.gov:NCT00035984; ClinicalTrials.gov:NCT00082407; ClinicalTrials.gov:NCT00381342; ClinicalTrials.gov:NCT00360334; ClinicalTrials.gov:NCT00375492; ClinicalTrials.gov:NCT00603239; ClinicalTrials.gov:NCT00765817; ClinicalTrials.gov:NCT00577824; ClinicalTrials.gov:NCT00434954","S000320; S000345; S000441; S000706; S000752; S000790; S000898; S000965; S001222; S001323; S001737; S002301","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018920","Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus.","Duong A","2024","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/10600280231199852","37743669",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; Observational Study; other; article"],["R0018921","Abnormal Lipid Signaling Characterizes Diastolic Dysfunction in Pediatric Cardiomyopathy.","Turinsky AL","2026","JACC. Basic to translational science","other","article","10.1016/j.jacbts.2026.101491","41707622","PMC12926570",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018922","Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.","Kissow H","2012","Regulatory peptides","preclinical","article","10.1016/j.regpep.2012.08.016","22989472",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018923","GLP1R Single-Nucleotide Polymorphisms rs3765467 and rs10305492 Affect β Cell Insulin Secretory Capacity and Apoptosis Through GLP-1.","Li W","2020","DNA and cell biology","other","article","10.1089/dna.2020.5424","32721233",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018924","Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells.","Chen-Liaw AY","2017","In vitro cellular & developmental biology. Animal","other","article","10.1007/s11626-017-0181-y","28707223",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; book-chapter"],["R0018925","FRI646 Dulaglutide-induced Acute Liver Injury - A Case Report",null,"2023","Journal of the Endocrine Society","case_report","article",null,null,"PMC10554152",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0018926","Second-year results from CINEMA: A novel, patient-centered, team-based intervention for patients with Type 2 diabetes or prediabetes at high cardiovascular risk.","Neeland IJ","2024","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2023.100630","38223296","PMC10787236",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018927","Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI).","García Del Blanco B","2021","Basic research in cardiology","randomized_trial","article","10.1007/s00395-021-00842-2","33495853",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0018928","Host-Derived BiP Overexpression Prolongs Productive Secretion and Enhances GLP-1–Fc Titer in CHO Cells","Shaifutdinov RR","2026","Preprints.org","other","preprint","10.20944/preprints202607.1628.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018929","Erratum to semaglutide seems to be more effective the other GLP-1Ras.","Holst JJ","2018","Annals of translational medicine","notice","article","10.21037/atm.2018.01.20","29611550","PMC5879530",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0018930","Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex.","Ohtake N","2014","Regulatory peptides","preclinical","article","10.1016/j.regpep.2014.04.003","24769307",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018931","The safety of incretin-based therapies--review of the scientific evidence.","Drucker DJ","2011","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/jc.2011-0599","21734003",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0018932","Correction to: Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.","Zisman A","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-018-0544-8","30515716","PMC6349285",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0018933","Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats.","Nozu T","2018","Journal of gastroenterology and hepatology","preclinical","article","10.1111/jgh.13808","28440889",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0018934","Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.","Campbell RK","2010","The Journal of family practice","case_report","article",null,"20824239",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0018935","Pharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus.","Blahova J","2021","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph14080806","34451903","PMC8398612",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018936","Liraglutide Protects Nucleus Pulposus Cells Against High-Glucose Induced Apoptosis by Activating PI3K/Akt/ mTOR/Caspase-3 and PI3K/Akt/GSK3β/Caspase-3 Signaling Pathways.","Yao M","2021","Frontiers in medicine","other","article","10.3389/fmed.2021.630962","33681258","PMC7933515",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018937","Collecting Real-World Patient Reported Outcome Through Community Pharmacies A Pilot Exploratory Study Applied on the Effects of Introducing the Fixed Dose Combination Xultophy in the Management of Type 2 Diabetes Mellitus","Alkis NB","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3201858/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0018938","Molecular Docking Analysis of Selected Phytochemicals Targeting GLP-1R, GIPR, and DPP4","Frincu RM","2025","Preprints.org","other","preprint","10.20944/preprints202511.1303.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018939","Liraglutide for the Treatment of Severe Hypoglycemia Following Total Pancreatectomy and Islet Autotransplantation.","Chan C","2024","JCEM case reports","case_report","article","10.1210/jcemcr/luae178","39450137","PMC11500716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018940","Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).","Hashim MMA","2025","Cureus","nonrandomized_study","article","10.7759/cureus.86963","40734888","PMC12306519",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0018941","Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.","Aronne LJ","2024","JAMA","randomized_trial","article","10.1001/jama.2023.24945","38078870","PMC10714284","ClinicalTrials.gov:NCT04660643","S000242","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0018942","Incretin impact on gastric function in obesity: physiology, and pharmacological, surgical and endoscopic treatments.","Camilleri M","2025","The Journal of physiology","narrative_review","article","10.1113/jp287535","39580615",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0018943","Insulin Degludec / Liraglutide: Benefit Assessment According to §35a Social Code Book V",null,"2015","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany","narrative_review","article",null,"29144653",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0018944","Glucagon-Like Peptide-1 Regulates the Proopiomelanocortin Neurons of the Arcuate Nucleus both Directly and Indirectly via Presynaptic Action.","Péterfi Z","2021","Neuroendocrinology","preclinical","article","10.1159/000512806","33152734",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018945","Second-line agents for glycemic control for type 2 diabetes: are newer agents better?","Zhang Y","2014","Diabetes care","nonrandomized_study","article","10.2337/dc13-1901","24574345",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Validation Study; article"],["R0018946","Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?","Nauck M","2009","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2009.03.002","19748068",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0018947","Exenatide for obesity in children and adolescents: Systematic review and meta-analysis.","Chen B","2024","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2024.1290184","38633611","PMC11022205",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0018948","Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.","Verma S","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.08.023","39217565","PMC11486552","ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0018949","Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.","Xing C","2020","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgaa337","32490533","PMC7365687",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; research-article; article"],["R0018950","Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.","Ericsson Å","2017","Applied health economics and health policy","nonrandomized_study","article","10.1007/s40258-016-0301-y","28063135","PMC5343072",null,"S002285","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018951","Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.","Merola JF","2026","Arthritis & rheumatology (Hoboken, N.J.)","randomized_trial","article","10.1002/art.70134","41903163","PMC13619038","ClinicalTrials.gov:NCT06588296","S001889; S001989","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0018952","Sodium glycocholate liposome encapsulated semaglutide increases oral bioavailability by promoting intestinal absorption.","Li Y","2024","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2024.124669","39244070",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018953","Comment on generalizability of GLP-1 RA CVOTs in US T2D population.","Lage MJ","2019","The American journal of managed care","other_trial","article",null,"30986012",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Letter; Comment; letter"],["R0018954","Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.","Garg SK","2024","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2024.0050","38512447",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0018955","Bariatric surgery and tirzepatide-Friends, not foes!","Nagendra L","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15778","38978177",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0018956","Semaglutide cuts kidney risk in obesity.","Giugliano D","2025","Journal of endocrinological investigation","other","article","10.1007/s40618-024-02494-0","39495477",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018957","Books: Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs : The rise of semaglutide",null,"2024","The British journal of general practice : the journal of the Royal College of General Practitioners","narrative_review","article",null,null,"PMC11299680",null,null,"europepmc","FALSE",null,null,null,"book-review; Book Review"],["R0018958","The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.","Hansen HH","2015","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-143090","25869785","PMC4878312",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018959","Cardiovascular effects of the incretin-based therapy: the good, the bad, or the ugly?","Cho YM","2015","Journal of diabetes investigation","commentary","article","10.1111/jdi.12386","26543530","PMC4627533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0018960","Incretin-based therapy for type 2 diabetes: What have we learned from the meta-analyses?","Barakat AF","2017","International journal of cardiology","systematic_review","article","10.1016/j.ijcard.2017.01.144","28560966",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Comment; article"],["R0018961","Neoglycolipids for Prolonging the Effects of Peptides: Self-Assembling Glucagon-like Peptide 1 Analogues with Albumin Binding Properties and Potent in Vivo Efficacy.","van Witteloostuijn SB","2017","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.6b00787","28005376",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018962","A Review Article: The Relationship Between Obesity and Colorectal Cancer.","Nguyen L","2024","Current diabetes reports","narrative_review","article","10.1007/s11892-024-01556-0","39621160","PMC11611961",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018963","Liraglutide Effect on Weight and A1C in Patients with Type 2 Diabetes Mellitus: Real-World Data from a Single Tertiary Care Center in Saudi Arabia.","AlRashidi A","2024","Journal of pharmacy & bioallied sciences","nonrandomized_study","article","10.4103/jpbs.jpbs_473_24","39926854","PMC11805097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018964","[Changes in weight, body composition, metabolic parameters and vitamin D in subjects with grade 3 and 4 obesity treated with liraglutide 3 mg].","Blanco Anesto J","2024","Nutricion hospitalaria","other","article","10.20960/nh.05267","39037190",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0018965","Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.","Clemmensen C","2015","EMBO molecular medicine","preclinical","article","10.15252/emmm.201404508","25652173","PMC4364946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0018966","Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients.","Zameer R","2020","Cureus","nonrandomized_study","article","10.7759/cureus.9937","32864274","PMC7449611",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018967","The safety of semaglutide in patients with depression and obesity.","Yang Z","2024","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.24142","39497569",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0018968","Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines.","Ventorp F","2017","Journal of Parkinson's disease","preclinical","article","10.3233/jpd-171068","28387682","PMC5438473",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018969","Semaglutide-induced fixed drug eruption.","Talasila S","2025","JAAD case reports","case_report","article","10.1016/j.jdcr.2024.10.012","39845462","PMC11750519",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018970","A case report of postoperative poor drainage of perianal abscess in an obese diabetic patient treated with comprehensive therapy.","Li F","2026","Journal of surgical case reports","case_report","article","10.1093/jscr/rjag349","42100606","PMC13147442",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0018971","Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed mice.","Mohan S","2021","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14462","34105240",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018972","Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.","Davies MJ","2025","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(24)00304-8","39848268",null,"ClinicalTrials.gov:NCT04916470","S000161","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0018973","Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Etminan M","2024","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2024.4530","39480440",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018974","111In-Diethylenetriaminepentaacetic acid-Lys40-exendin-3","Leung K","2004","National Center for Biotechnology Information (US), Bethesda (MD)","narrative_review","article",null,"21061499",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0018975","[Diabetes Mellitus Type 2: Recent Publications and New Drugs].","Elbelt U","2018","Deutsche medizinische Wochenschrift (1946)","randomized_trial","article","10.1055/s-0043-117490","29807374",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0018976","Fragment-Guided New Therapeutic Molecule Discovery and Mapping of Clinically Relevant Interactomes.","Kanapeckaitė A","2026","Journal of chemical information and modeling","other_trial","article","10.1021/acs.jcim.5c02503","41601187",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","5","FALSE","Journal Article; article"],["R0018977","Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.","Malhotra A","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2404881","38912654","PMC11598664","ClinicalTrials.gov:NCT05412004","S000156","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0018978","Semaglutide and kidney function: direct kidney protection or an artifact?","Ayoub I","2025","Kidney international","commentary","article","10.1016/j.kint.2024.11.003","39566843",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0018979","Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?","Formichi C","2024","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-024-02369-4","38683498","PMC11473455",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Comparative Study; research-article; article"],["R0018980","Self-Assembly of Exendin-4-Derived Dual Peptide Agonists is Mediated by Acylation and Correlated to the Length of Conjugated Fatty Acyl Chains.","Wolff M","2020","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.9b01195","31968941",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018981","Type 2 diabetic disease and current drug treatments: clinical and governance aspects.","Ferrara F","2025","Endocrine","other","article","10.1007/s12020-025-04263-2","40346323",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0018982","Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function.","De Barra C","2023","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23772","37157931",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0018983","Effect of type 2 diabetes medications on fracture risk.","Guja C","2019","Annals of translational medicine","narrative_review","article","10.21037/atm.2019.09.51","31807561","PMC6861738",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0018984","Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports.","Censani M","2015","Journal of obesity and weight-loss medication","case_report","article","10.23937/2572-4010.1510004","27182560","PMC4864000",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0018985","Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study.","Williams DM","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01590-x","38722497","PMC11211302",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; article"],["R0018986","Homodimerized GLP-1R agonists produce better efficacy in hypoglycemic effect or/and pancreatic protection in T2D models","Zhang X","2020","Research Square","other","preprint","10.21203/rs.3.rs-30052/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0018987","Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany.","Qiao Q","2016","PloS one","nonrandomized_study","article","10.1371/journal.pone.0152281","27019360","PMC4809528",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0018988","Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.","Cheng JWM","2017","Current medical research and opinion","randomized_trial","article","10.1080/03007995.2017.1284052","28097882",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0018989","Disparities in Antidiabetic Medication Discontinuation Between Non-Hispanic White and Black Beneficiaries in Medicare Across Diabetes Belt and Surrounding Area.","Zhang P","2026","Journal of racial and ethnic health disparities","nonrandomized_study","article","10.1007/s40615-025-02388-8","40088385",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, N.I.H., Extramural"],["R0018990","Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial.","Myat A","2021","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-021-00635-6","33579317","PMC7881597","ClinicalTrials.gov:NCT02315001","S001491","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0018991","Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches.","Szolomajer J","2022","RSC advances","other","article","10.1039/d2ra02784d","36128537","PMC9412715",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0018992","Response to \"The safety of semaglutide in patients with depression and obesity\".","Kushner RF","2024","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.24144","39497516",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Letter; article"],["R0018993","Rare Presentation of Heterozygous PCSK1 Deficiency in an Adolescent Male.","Metzger T","2026","Case reports in pediatrics","other","article","10.1155/crpe/3460735","41768936","PMC12947662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-study; article"],["R0018994","Testosterone and the prevention of type 2 diabetes mellitus: therapeutic implications from recent trials.","Wittert G","2024","Current opinion in endocrinology, diabetes, and obesity","randomized_trial","article","10.1097/med.0000000000000884","39285839",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0018995","Safety and effectiveness of iGlarLixi in adults with type 2 diabetes mellitus from Gulf countries during Ramadan holy month: A subgroup analysis of the SoliRam observational study.","Hassanein M","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111567","38341039",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Journal Article; article"],["R0018996","Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.","Patel V","2013","Pharmacological reports : PR","preclinical","article","10.1016/s1734-1140(13)71074-0","24145087",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018997","Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.",null,"2024","Gastroenterology & hepatology","other_trial","article",null,"39896971","PMC11784563",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; other; article"],["R0018998","Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Maro JC","2024","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2024.4527","39480446",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0018999","Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Cui QN","2024","JAMA ophthalmology","commentary","article","10.1001/jamaophthalmol.2024.4533","39480409","PMC11960834",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0019000","Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Kim DW","2024","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2024.4524","39480405",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019001","Long-Acting Release Formulation of Exendin-4 Based on Biomimetic Mineralization for Type 2 Diabetes Therapy.","Chen W","2017","ACS nano","preclinical","article","10.1021/acsnano.7b01809","28437610",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; article"],["R0019002","Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Xie JS","2024","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2024.4518","39480447",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019003","Clinical Impact of Liraglutide as a Treatment of Obesity.","Alruwaili H","2021","Clinical pharmacology : advances and applications","narrative_review","article","10.2147/cpaa.s276085","33732030","PMC7958997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019004","New avenues for the pharmacological management of type 2 diabetes: an update.","Cuny T","2012","Annales d'endocrinologie","narrative_review","article","10.1016/j.ando.2012.09.002","23078974",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019005","Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis.","Zhao S","2024","Diabetes & metabolic syndrome","randomized_trial","article","10.1016/j.dsx.2023.102921","38128261",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0019006","SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy.","Jensterle M","2022","Acta diabetologica","other","article","10.1007/s00592-022-01908-w","35662365","PMC9165537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0019007","Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.","Aston-Mourney K","2011","Diabetologia","preclinical","article","10.1007/s00125-011-2143-3","21484213","PMC3220951",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0019008","Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study).","Caballero Mateos I","2024","Nutrients","randomized_trial","article","10.3390/nu16152545","39125424","PMC11314012",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0019009","Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists.","Laux G","2016","BMC family practice","other","article","10.1186/s12875-016-0543-7","27760528","PMC5070366",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019010","Liraglutide for psychiatric disorders: clinical evidence and challenges.","Camkurt MA","2018","Hormone molecular biology and clinical investigation","narrative_review","article","10.1515/hmbci-2018-0031","30020885",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019011","Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.","Younossi ZM","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2026.03.030","41950980",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Consensus Statement"],["R0019012","Retrospective Study on the Efficacy and Safety of Dulaglutide in Patients with Diabetes and Moderate-Advanced Chronic Kidney Disease.","Kosaraju S","2024","International journal of nephrology and renovascular disease","nonrandomized_study","article","10.2147/ijnrd.s450772","38827627","PMC11143983",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; letter; article"],["R0019013","Super response to liraglutide in people with obesity: A case report and literature review.","Gutiérrez Medina S","2024","Endocrinologia, diabetes y nutricion","case_report","article","10.1016/j.endien.2024.11.012","39617632",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0019014","Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes.","Garg V","2019","Progress in cardiovascular diseases","narrative_review","article","10.1016/j.pcad.2019.07.005","31381891",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019015","Adiposuppression: Silencing the Tyrant Organ with Dual/Triple Incretin Agonists","Cervoni E","2025","Authorea Preprints","other","preprint","10.22541/au.176341008.88126711/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0019016","Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.","Aso Y","2021","International journal of clinical practice","randomized_trial","article","10.1111/ijcp.13734","33099848",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0019017","Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis.","Karrar HR","2023","Cureus","systematic_review","article","10.7759/cureus.46091","37908927","PMC10614464",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0019018","Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Feldman-Billard S","2024","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2024.4521","39480455",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019019","Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Lusk JB","2024","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2024.4515","39480407",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019020","Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus.","Niedermier V","2017","American family physician","other","article",null,"28925668",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019021","Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)","Mosenzon O","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.013",null,"PMC8265765","ClinicalTrials.gov:NCT03548987","S000521","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; conference-abstract"],["R0019022","Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials.","Kommu S","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13792","38923272",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; Research Support, N.I.H., Extramural; review"],["R0019023","Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.","Chae SY","2010","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2009.10.025","19900495",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019024","Characteristics of WBN/Kob diabetic fatty rats supplemented with a fructose-rich diet as a metabolic syndrome model: response to a GLP-1 receptor agonist.","Namekawa J","2018","The Journal of veterinary medical science","preclinical","article","10.1292/jvms.18-0306","30175725","PMC6207516",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019025","EASO Position Statement: Women with Obesity across the Reproductive Life - Fertility, Preconception, Pregnancy, Postpartum, and Breastfeeding.","Filippi-Arriaga F","2025","Obesity facts","narrative_review","article","10.1159/000546449","40544836","PMC12306975",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Consensus Statement; other; article"],["R0019026","Hormones and diet, but not body weight, control hypothalamic microglial activity.","Gao Y","2014","Glia","preclinical","article","10.1002/glia.22580","24166765","PMC4213950",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019027","CADTH Canadian Drug Expert Committee Recommendation: Insulin Degludec and Liraglutide (Xultophy — Novo Nordisk Canada Inc.): Indication: Adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily), do not provide adequate glycemic control",null,"2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"32134607",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0019028","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.","Boye KS","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00908-9","32880876","PMC7509014",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0019029","Extrapancreatic insulinoma.","Garg R","2020","World journal of nuclear medicine","case_report","article","10.4103/wjnm.wjnm_41_19","32939209","PMC7478312",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019030","A Narrative Review of the Interplay Between Carbohydrate Intake and Diabetes Medications: Unexplored Connections and Clinical Implications.","Mphasha MH","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26020624","39859337","PMC11765648",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0019031","Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.","Lim SM","2015","Journal of pharmaceutical sciences","preclinical","article","10.1002/jps.24238","25407390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019032","Hypoglycemic Events in Diabetic Patients under Non-insulin Regimens During Ramadan: A Frequentist Network Meta-Analysis","Kacimi SEO","2022","medRxiv","systematic_review","preprint","10.1101/2022.05.28.22275730",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; preprint"],["R0019033","Ten Year Follow-Up After Explantation of the Duodenal-jejunal Bypass Liner.","Beeren FMM","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-08291-9","40999299","PMC12594694",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019034","Quadruple Non-Insulin Therapy for Advanced Type 2 Diabetes Mellitus With Cognitive Impairment: A Case Report.","Skudar S","2026","Cureus","case_report","article","10.7759/cureus.108113","42226859","PMC13222685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019035","Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)","Wilding J","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.018",null,"PMC8089593","ClinicalTrials.gov:NCT03548935","S000144","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; conference-abstract"],["R0019036","Correction to: Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.","Thomsen M","2020","Psychopharmacology","notice","article","10.1007/s00213-019-05374-1","31768561",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0019037","Glucagon-like peptide-1 control of GnRH secretion in female sheep.","Arbabi L","2021","The Journal of endocrinology","preclinical","article","10.1530/joe-20-0335","33446613",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019038","PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.","Delgado Álvarez E","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16523","40555703","PMC12326947","ClinicalTrials.gov:NCT05443334","S001844","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0019039","The vascular complications of diabetes: a review of their management, pathogenesis, and prevention.","Meir J","2024","Expert review of endocrinology & metabolism","systematic_review","article","10.1080/17446651.2023.2279533","37947481",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Review; article"],["R0019040","Obesity and GLP-1 RAs.","Bright T","2022","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","commentary","article","10.1136/jim-2021-002268","34949727",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0019041","Residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound.","Hulst AH","2025","Anaesthesia","commentary","article","10.1111/anae.16504","39635940",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019042","Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases.","Zeng J","2025","Journal of nanobiotechnology","narrative_review","article","10.1186/s12951-025-03677-4","41088364","PMC12522959",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019043","Response to \"Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis\". Response to related letter.","De La Flor JC","2024","Nefrologia","commentary","article","10.1016/j.nefroe.2023.10.010","38862303",null,"ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Letter; Comment; article"],["R0019044","Identification of transcriptional targets during pancreatic growth after partial pancreatectomy and exendin-4 treatment.","De León DD","2006","Physiological genomics","preclinical","article","10.1152/physiolgenomics.00156.2005","16410542",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0019045","The Impact of Differentiation on Cytotoxicity and Insulin Sensitivity in Streptozotocin Treated SH-SY5Y Cells.","Bagaméry F","2021","Neurochemical research","other","article","10.1007/s11064-021-03269-2","33616807","PMC8084777",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019046","The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model.","Røge RM","2015","CPT: pharmacometrics & systems pharmacology","other","article","10.1002/psp4.11","26225223","PMC4369758",null,"S000333; S001702","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0019047","SAT672 Dulaglutide Might Reduce Visceral Fat In Patients With Metabolic Syndrome",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10553872",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019048","Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.","Stenberg E","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15952","39295084",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0019049","Liraglutide: a review of the first once-daily GLP-1 receptor agonist.","Bode B","2011","The American journal of managed care","randomized_trial","article",null,"21517658",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019050","Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core.","Fortin SM","2017","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2017.03.019","28315693","PMC5763906",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0019051","A review of the evidence on cardiovascular outcomes from obesity treatment.","Abdul Wahab R","2023","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2023.100071","37990679","PMC10661857",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0019052","Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy-Reply.","Rizzo JF","2024","JAMA ophthalmology","other","article","10.1001/jamaophthalmol.2024.4536","39480403",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019053","Risk Factor Control in a Portuguese Vascular Risk Clinic: A 16-Month Retrospective Cohort Study.","Gante C","2026","Cureus","nonrandomized_study","article","10.7759/cureus.102735","41777939","PMC12952857",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019054","DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.","Buse JB","2010","Diabetes care","randomized_trial","article","10.2337/dc09-1914","20215461","PMC2875434","ClinicalTrials.gov:NCT00308139","S002279","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0019055","Intensive management of obesity in people with severe chronic kidney disease: A review.","Song R","2021","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14409","33904629",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019056","Hydrogel microcapsules containing engineered bacteria for sustained production and release of protein drugs.","Han C","2022","Biomaterials","preclinical","article","10.1016/j.biomaterials.2022.121619","35700622",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0019057","Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.","Sidik S","2023","Nature","commentary","article","10.1038/d41586-023-02092-9","37369789",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; other"],["R0019058","Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.","Hansen KB","2010","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s7004","21437085","PMC3047973",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0019059","GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.","Liu CM","2025","Nature metabolism","preclinical","article","10.1038/s42255-025-01295-w","40301582","PMC12198008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019060","Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.","Masson W","2024","Frontiers in cardiovascular medicine","systematic_review","article","10.3389/fcvm.2024.1379189","39055657","PMC11270812","PROSPERO:CRD42024500551",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; review"],["R0019061","Increased Expression of GLP-1R in Proliferating Islets of Men1 Mice is Detectable by [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 /PET.","Monazzam A","2018","Scientific reports","preclinical","article","10.1038/s41598-017-18855-0","29335487","PMC5768696",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019062","Development of 1 Month Sustained-Release Microspheres Containing Liraglutide for Type 2 Diabetes Treatment.","Gao Z","2024","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.4c04010","38728411",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019063","Inflammation and incretins.","Hatwal A","2012","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.104049","23565388","PMC3603036",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0019064","Generation of novel long-acting GLP-1R agonists using DARPins as a scaffold.","Tan H","2021","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2021.121043","34450223",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019065","Late Facial Edema After Lip Filling With Hyaluronic Acid: Possible Association With the Use of Ozempic.","de Oliveira Ciaramicolo N","2024","The Journal of craniofacial surgery","case_report","article","10.1097/scs.0000000000010588","39190785",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019066","Semaglutide (Ozempic) for Type 2 Diabetes Mellitus.","Chamberlin S","2019","American family physician","other","article",null,"31305048",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019067","Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies.","Binu AJ","2024","Heart international","commentary","article","10.17925/hi.2024.18.1.1","39006466","PMC11239134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0019068","Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production.","Sélley E","2014","Cardiovascular diabetology","preclinical","article","10.1186/1475-2840-13-69","24693878","PMC3976540",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019069","Re: Sperm Count is Increased by Diet-induced Weight Loss and Maintained by Exercise or GLP-1 Analogue Treatment: A Randomized Controlled Trial.","Lokeshwar SD","2022","European urology","randomized_trial","article","10.1016/j.eururo.2022.08.016","36058803",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Journal Article; letter"],["R0019070","Several birds with one stone; GLP-1 agonists for the glucose control, weight reduction, and prevention of cardiac and renal outcomes.","Sonmez A","2022","International journal of cardiology","commentary","article","10.1016/j.ijcard.2022.08.041","36028093",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0019071","Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants​.","Wang ZY","2026","Journal of visualized experiments : JoVE","preclinical","article","10.3791/73743","42775729",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Video-Audio Media; Review; article"],["R0019072","Combination of exendin-4 and DPP-4 silencing promoted angiogenesis of human coronary artery endothelial cells via activation of PI3K/Akt pathway.","Qi X","2017","Pakistan journal of pharmaceutical sciences","preclinical","article",null,"28650320",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019073","The influence of donor body mass index on human pancreatic islet function, structure and islet transplant outcome","Walker JN","2011","University of Oxford","preclinical","article","10.5287/ora-noq5jbga7",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0019074","Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study.","Moulton CD","2016","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2015.06.003","26137918",null,null,"S000532","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0019075","Time-Efficacy Relationship of Semaglutide in the Treatment of Type 2 Diabetes Mellitus: A Model-Based Meta-Analysis.","Zhang K","2024","Clinical pharmacokinetics","systematic_review","article","10.1007/s40262-024-01449-1","39549228",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0019076","[Protective effect of glucagon-like peptide-1 analogue on cardiomyocytes injury induced by hypoxia/reoxygenation].","Liu MM","2016","Zhonghua nei ke za zhi","other","article","10.3760/cma.j.issn.0578-1426.2016.04.013","27030622",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019077","Wegovy: Weight loss drug to be available from GPs in pilot scheme.","Iacobucci G","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p1308","37290805",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019078","Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice.","Zhang N","2021","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2021.02.065","33640604",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019079","Developing a novel algorithm to identify incident and prevalent dementia in Medicare claims-the ARIC Study.","Wang T","2025","American journal of epidemiology","nonrandomized_study","article","10.1093/aje/kwaf166","40754790","PMC12459984",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0019080","Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.","Buckley A","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15680","38783825",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0019081","Efficacy of Tirzepatide for Weight Loss in China: Implications for the Global Obesity Epidemic.","Qian F","2024","JAMA","commentary","article","10.1001/jama.2024.7928","38819975",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0019082","Unraveling the safety and efficacy of semaglutide for people living with HIV and metabolic co-morbidities.","Patoulias D","2025","Expert opinion on drug safety","commentary","article","10.1080/14740338.2024.2435426","39610149",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0019083","Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Letter].","Panjaitan NSD","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","commentary","article","10.2147/dmso.s471933","38645654","PMC11027923",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019084","[Estimation of body fat in a diabetic population from a health area using the Clínica Universitaria de Navarra-Body Adiposity Estimator formula [CUN-BAE]].","Iturralde-Iriso JM","2025","Semergen","nonrandomized_study","article","10.1016/j.semerg.2025.102548","40700844",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study; English Abstract"],["R0019085","Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications.","Fralick M","2020","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","nonrandomized_study","article","10.1016/j.jval.2019.11.004","32327160",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0019086","Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications.","Tudurachi BS","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12061314","38927520","PMC11201699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019087","The adolescent with obesity: what perspectives for treatment?","Nicolucci A","2022","Italian journal of pediatrics","randomized_trial","article","10.1186/s13052-022-01205-w","35033162","PMC8761267",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0019088","Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.","Zhao F","2022","Nature communications","other","article","10.1038/s41467-022-28683-0","35217653","PMC8881610",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019089","Allele frequencies and genotype distribution of three metformin transporter polymorphisms in Mexican population and their application in pharmacogenomics of type 2 diabetes.","Chávez-Arreola OI","2024","Frontiers in pharmacology","other","article","10.3389/fphar.2024.1466394","39555090","PMC11565514",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019090","Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Cui Y","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-024-01540-7","38402331","PMC10951192","PROSPERO:CRD42023489588",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0019091","Liraglutide prevents cellular senescence in human retinal endothelial cells (HRECs) mediated by SIRT1: an implication in diabetes retinopathy.","Hou L","2024","Human cell","other","article","10.1007/s13577-024-01038-1","38438663","PMC11016519",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019092","GLP-1 preserves β cell function via improvement on islet insulin signaling in high fat diet feeding mice.","Yang H","2021","Neuropeptides","preclinical","article","10.1016/j.npep.2020.102110","33307381",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019093","[What can you do to … not be influenced?].","Dankers M","2023","Nederlands tijdschrift voor geneeskunde","nonrandomized_study","article",null,"38175558",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Observational Study; English Abstract; Journal Article; article"],["R0019094","Trimeric PEG-Conjugated Exendin-4 for the Treatment of Sepsis.","Lee W","2016","Biomacromolecules","other","article","10.1021/acs.biomac.5b01756","26905040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019095","Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways.","Doğan GO","2024","Cirugia y cirujanos","preclinical","article","10.24875/ciru.23000304","39383838",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019096","The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice.","Mansur SA","2019","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2019.00051","30809192","PMC6380209",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019097","PM426. Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment","Babic I","2016","The international journal of neuropsychopharmacology","other_trial","article","10.1093/ijnp/pyw041.426",null,"PMC5616361",null,null,"europepmc; openalex","TRUE","open_europepmc","5","FALSE","Abstract; conference-abstract"],["R0019098","Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut.","Morrow NM","2024","Peptides","narrative_review","article","10.1016/j.peptides.2024.171200","38555054",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0019099","Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update.","Koniari I","2022","Journal of clinical medicine","narrative_review","article","10.3390/jcm11164660","36012897","PMC9409680",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019100","Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment.","Chianelli M","2024","Journal of endocrinological investigation","other","article","10.1007/s40618-024-02361-y","38630213",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0019101","Liraglutide improves antioxidant defense in hearts of spontaneously hypertensive female rats independently of changes in blood pressure in a pre-clinical model of menopause.","Santos WCD","2025","Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","preclinical","article","10.1590/1414-431x2025e14209","40243818","PMC11996164",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019102","Semaglutide for Chronic Kidney Disease in Type 2 Diabetes.","da Hora Passos R","2024","The New England journal of medicine","nonrandomized_study","article","10.1056/nejmc2410532","39504528",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0019103","Semaglutide for Weight Reduction in Type 1 Diabetes: Promising Results With Uncertain Glycemic Impact.","Orrange S","2025","Journal of diabetes science and technology","commentary","article","10.1177/19322968241304779","39655368","PMC11629341",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019104","Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction.","Li X","2024","Redox biology","preclinical","article","10.1016/j.redox.2024.103129","38574433","PMC11000183",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019105","Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.","Buysman EK","2015","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-015-0064-8","26527413","PMC4630836",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019106","Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients.","Chen X","2017","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.12397","26989888",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0019107","Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment [Response to Letter].","Chen S","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","commentary","article","10.2147/dmso.s473832","38660463","PMC11042472",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Letter; reply; article"],["R0019108","Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence.","Singh AK","2024","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2024.103024","38718449",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0019109","The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats.","Korkmaz Y","2024","Fundamental & clinical pharmacology","preclinical","article","10.1111/fcp.12975","38149676",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comparative Study; article"],["R0019110","Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study.","Park J","2025","Annals of nutrition & metabolism","nonrandomized_study","article","10.1159/000547347","40675139",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0019111","Effectiveness of a Psychiatrist-Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study.","Stogios N","2026","Acta psychiatrica Scandinavica","nonrandomized_study","article","10.1111/acps.70093","41902362","PMC13242973",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019112","The acute anorexic effect of liraglutide, a GLP-1 receptor agonist, does not require functional leptin receptor, serotonin, and hypothalamic POMC and CART activities in mice.","Nonogaki K","2016","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2016.08.009","27585115",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019113","Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes.","Li X","2019","Artificial cells, nanomedicine, and biotechnology","other","article","10.1080/21691401.2019.1593996","30942623",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019114","Fatty Liver Disease in the Diabetic Population: A Cross-Sectional Study From Pakistan.","Liaquat Memon H","2025","Cureus","other","article","10.7759/cureus.85510","40630376","PMC12234818",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019115","Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy.","Kan M","2012","Journal of neuropathology and experimental neurology","preclinical","article","10.1097/nen.0b013e3182580673","22588388",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019116","Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis.","Li J","2023","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2022.108362","36462459",null,"PROSPERO:CRD42022326382",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't"],["R0019117","Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial.","Baur F","2023","BMJ nutrition, prevention & health","randomized_trial","article","10.1136/bmjnph-2023-000781","38264360","PMC10800263","ClinicalTrials.gov:NCT03204396","S000115","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0019118","Liraglutide Attenuates Aβ42 Generation in APPswe/SH-SY5Y Cells Through the Regulation of Autophagy.","Kong J","2020","Neuropsychiatric disease and treatment","other","article","10.2147/ndt.s260160","32801716","PMC7394597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019119","L-Carnitine and extendin-4 improve outcomes following moderate brain contusion injury.","Chen H","2018","Scientific reports","preclinical","article","10.1038/s41598-018-29430-6","30046063","PMC6060156",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019120","Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.","Ma J","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00955-2","33161492","PMC7843818","ClinicalTrials.gov:NCT01648582","S001404","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0019121","A gut-liver lipid flux checkpoint mediates FAHFA protection from MASLD.","Xie H","2026","Pharmacological research","other","article","10.1016/j.phrs.2025.108085","41485679",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019122","Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.","Kaku K","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-014-0086-7","25341477","PMC4269643",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0019123","Letter to the Editor Regarding: Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment.","Iwahori T","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","commentary","article","10.1007/s13300-020-00899-7","32767277","PMC7509023",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0019124","Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition.","Pamfil C","2026","International journal of molecular sciences","case_report","article","10.3390/ijms27062898","41898754","PMC13026503",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019125","Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study.","Costa S","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16314","40045764",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0019126","The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH.","Foglia B","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27188213","42794644","PMC13607418",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019127","Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.","Mosenzon O","2022","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-022-01585-7","36056351","PMC9440529","ClinicalTrials.gov:NCT01885208; ClinicalTrials.gov:NCT02906930; ClinicalTrials.gov:NCT02863328; ClinicalTrials.gov:NCT02827708","S000251; S000329; S001741; S002025","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0019128","Could setmelanotide be the game-changer for acquired hypothalamic obesity?","van Santen HM","2023","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2023.1307889","38239988","PMC10794340",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; brief-report; article"],["R0019129","Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.","Ma J","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15446","38302718",null,"ClinicalTrials.gov:NCT04093752","S000909","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0019130","Efficacy and safety of finerenone in obesity-related glomerulopathy.","Qiu DD","2025","Clinical kidney journal","nonrandomized_study","article","10.1093/ckj/sfaf157","40510688","PMC12160826",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019131","Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis.","Masson W","2024","Endocrinologia, diabetes y nutricion","systematic_review","article","10.1016/j.endien.2024.03.012","38555109",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; Review; article"],["R0019132","Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta-analysis of randomized controlled trials.","Wang H","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13727","38509775",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; article"],["R0019133","The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors.","Mietlicki-Baase EG","2013","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00413.2013","24105414","PMC3882373",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019134","Effects of glucagon-like peptide 1 analogue on the early phase of revascularization of transplanted pancreatic islets in a subcutaneous site.","Nishimura R","2013","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2013.01.047","23769065",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019135","GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.","Kadouh H","2020","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgz140","31665455","PMC7105351","ClinicalTrials.gov:NCT02647944","S001045; S002684","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0019136","Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress.","Yang G","2017","Atherosclerosis","preclinical","article","10.1016/j.atherosclerosis.2017.07.014","28734203",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019137","Discovery of DDO-4279 as a PP5 degrader for the treatment of obesity.","Gu M","2026","RSC medicinal chemistry","preclinical","article","10.1039/d6md00191b","42433646","PMC13353691",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019138","Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.","Armstrong MJ","2016","Journal of hepatology","randomized_trial","article","10.1016/j.jhep.2015.08.038","26394161","PMC4713865","ClinicalTrials.gov:NCT01237119","S002015","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0019139","Exendin-4 protects murine pancreatic β-cells from free fatty acid-induced apoptosis through PI-3K signaling.","Liu L","2013","Endocrine research","preclinical","article","10.3109/07435800.2012.713423","22913774",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019140","Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.","Blakely KK","2020","Nursing for women's health","other","article","10.1016/j.nwh.2020.07.005","32890462",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019141","Incretin-based therapy for type 2 diabetes: A real class effect?","Savarese G","2017","International journal of cardiology","narrative_review","article","10.1016/j.ijcard.2016.11.018","27866064",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019142","Human GLP1R variants affecting GLP1R cell surface expression contribute to impaired glucose control and increased adiposity","gao w","2022","Research Square","other","preprint","10.21203/rs.3.rs-2114208/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0019143","Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Davies MJ","2018","Diabetologia","other","article","10.1007/s00125-018-4729-5","30288571",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Consensus Statement"],["R0019144","Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome.","He W","2024","Scientific reports","preclinical","article","10.1038/s41598-024-62465-6","38782946","PMC11116553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019145","Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents.","Gurjar AA","2020","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2019.154044","31812628",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019146","Molecular mechanisms and drug therapy of metabolism disorders in psoriasis.","Liang Y","2024","The Journal of dermatological treatment","narrative_review","article","10.1080/09546634.2024.2375580","39013549",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019147","Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)","Rubino D","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.129",null,"PMC8089318","ClinicalTrials.gov:NCT03548987","S000521","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; article"],["R0019148","Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme.","Yale JF","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15794","39118222",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019149","FRI068 Gender Differences In Smoking Cessation? Results Of A Randomized Controlled Trial Of Dulaglutide-assisted Smoking Cessation",null,"2023","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC10554125",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0019150","Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review.","De Luca C","2025","Genes","systematic_review","article","10.3390/genes16111377","41300829","PMC12652249",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0019151","PET-Based Human Dosimetry of 68Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging.","Boss M","2020","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","other","article","10.2967/jnumed.119.228627","31519801","PMC6954461",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019152","Semaglutide use for decreasing hidradenitis suppurativa resource utilization: A retrospective cohort study utilizing TriNetX.","Hill MA","2025","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2024.11.039","39615553",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0019153","Semaglutide alleviates early brain injury following subarachnoid hemorrhage by suppressing ferroptosis and neuroinflammation via SIRT1 pathway.","Chen L","2024","American journal of translational research","preclinical","article","10.62347/izgj1332","38715815","PMC11070367",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019154","Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study.","Prázný M","2022","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-022-01631-4","36209118","PMC9548172","ClinicalTrials.gov:NCT03807440",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0019155","Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.","Conget I","2016","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2015-010197","27466235","PMC4964200",null,"S002638","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0019156","The evolving place of incretin-based therapies in type 2 diabetes.","Gallwitz B","2010","Pediatric nephrology (Berlin, Germany)","narrative_review","article","10.1007/s00467-009-1435-z","20130920","PMC2874027",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Review; review-article; article"],["R0019157","The Role Of Drug Indication On Incidence Rate Heterogeneity: A Large-Scale, Systematic Evaluation Across An International Network Of Observational Databases.","Chen HY","2025","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2025.10.22.25338563","41282870","PMC12633590",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; preprint"],["R0019158","Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments.","Boye KS","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-021-01097-9","34297341","PMC8385031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019159","7808 Effect of Oral Semaglutide on Hepatic Steatosis and Fibrosis, and Bone Microarchitecture in Non-alcoholic Fatty Liver Disease Complicating Type 2 Diabetes Mellitus: A Prospective, Interventional, Open-Label, Paired Study",null,"2024","Journal of the Endocrine Society","other_trial","article",null,null,"PMC11453580",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0019160","The Effect of Lifestyle Coaching Design on Patient Engagement and Weight Loss in Non-diabetic Patients of a Semaglutide-Supported Digital Obesity Program in the UK: A Comparative Retrospective Cohort Study.","Talay LA","2024","Cureus","nonrandomized_study","article","10.7759/cureus.74321","39583610","PMC11585375",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019161","Asthma-OSA overlap syndrome: A distinct endophenotype?","Fabozzi A","2025","Respiratory medicine","narrative_review","article","10.1016/j.rmed.2025.108344","40915327",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019162","Incretin-based therapy and risk of cholangiocarcinoma: a nested case-control study in a population of subjects with type 2 diabetes.","Giorda CB","2020","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-019-01444-0","31691043",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0019163","Silica-Coated Nanoparticles with a Core of Zinc, l-Arginine, and a Peptide Designed for Oral Delivery.","Hristov D","2020","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.9b16104","31802658",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019164","Semaglutide early intervention attenuated testicular dysfunction by targeting the GLP-1-PPAR-α-Kisspeptin-Steroidogenesis signaling pathway in a testicular ischemia-reperfusion rat model.","Abdullah DM","2022","Peptides","preclinical","article","10.1016/j.peptides.2021.170711","34920048",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019165","Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats.","Knezovic A","2025","Journal of neural transmission (Vienna, Austria : 1996)","preclinical","article","10.1007/s00702-025-02979-z","40646278","PMC12568868",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019166","Calories to satiation-A new predictor of anti-obesity therapy outcome?","Edwin Thanarajah S","2025","Cell metabolism","other","article","10.1016/j.cmet.2025.07.003","40769127",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019167","Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.","Verma S","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.06.001","38913003",null,"ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0019168","Semaglutide in Psychiatry-Opportunities and Challenges.","Agarwal SM","2024","JAMA psychiatry","other_trial","article","10.1001/jamapsychiatry.2024.2412","39167395",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0019169","New therapies for obesity.","Papamargaritis D","2024","Cardiovascular research","narrative_review","article","10.1093/cvr/cvac176","36448672","PMC10874276",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; review-article; article"],["R0019170","Dramatic Changes in Thiopurine Metabolite Levels in a Patient With Inflammatory Bowel Disease Treated With Tirzepatide for Weight Loss.","Klein JA","2024","ACG case reports journal","case_report","article","10.14309/crj.0000000000001544","39507506","PMC11540429",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019171","Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats.","Xie Z","2018","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2017.09.040","28986282","PMC5714662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019172","Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.","Wen Q","2023","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2023.1156521","37347114","PMC10280986","ChiCTR:ChiCTR2000033741",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019173","Pancreatic-liver crosstalk, novel molecular mediators, and 2025 therapeutic breakthroughs.","Pan HY","2026","World journal of methodology","narrative_review","article","10.5662/wjm.v16.i3.118728","42626202","PMC13491158",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019174","Myths and Facts Regarding Low-Carbohydrate Diets.","Teicholz N","2025","Nutrients","narrative_review","article","10.3390/nu17061047","40292478","PMC11944661",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0019175","Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes.","Herzlinger S","2013","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2012.11.009","23332049",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019176","The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2.","Dilla T","2017","Journal of medical economics","other_trial","article","10.1080/13696998.2016.1275651","28008768",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0019177","Comparative Study of the Solid-Liquid Interfacial Adsorption of Proteins in Their Native and Amyloid Forms.","Ábrahám Á","2022","International journal of molecular sciences","other","article","10.3390/ijms232113219","36362007","PMC9656260",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019178","Treatment of insulin resistance with tirzepatide leading to improvement of hair loss.","Gordon ER","2024","JAAD case reports","case_report","article","10.1016/j.jdcr.2024.06.001","39135763","PMC11318540",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019179","Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer's disease.","Ikeda Y","2021","World journal of biological chemistry","narrative_review","article","10.4331/wjbc.v12.i6.104","34904048","PMC8637616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019180","The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.","Urva S","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15167","37311727",null,"ClinicalTrials.gov:NCT04143802","S001665","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0019181","Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020.","Sherrill CH","2024","The Annals of pharmacotherapy","other","article","10.1177/10600280231178886","37323006",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019182","Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980.","Aroda VR","2017","Diabetes care","notice","article","10.2337/dc17-er06d","28428368","PMC5439418",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0019183","Evaluating the accuracy of ChatGPT in delivering patient instructions for medications: an exploratory case study.","Abanmy NO","2025","Frontiers in artificial intelligence","other","article","10.3389/frai.2025.1550591","40235859","PMC11996888",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019184","Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.","Koliaki C","2011","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-011-0002-3","22127804","PMC3144767",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0019185","Obesity-Associated Osteoarthritis: Mechanical-Metabolic Pathogenesis, Obesity Memory and Dual-Target Therapy.","Wang Y","2026","Current obesity reports","narrative_review","article","10.1007/s13679-026-00761-0","42747716",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019186","Lixisenatide Reduced Damage in Hippocampus CA1 Neurons in a Rat Model of Cerebral Ischemia-Reperfusion Possibly Via the ERK/P38 Signaling Pathway.","Gad SN","2020","Journal of molecular neuroscience : MN","preclinical","article","10.1007/s12031-020-01497-9","32040827",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019187","The glucagon-like peptide-1 (GLP-1) analog exenatide ameliorates intrauterine adhesions in mice.","Ma XL","2021","Peptides","preclinical","article","10.1016/j.peptides.2020.170481","33450323",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019188","The omics revolution in obesity: from molecularsignatures to clinical solutions.","Mustafa M","2025","Molecular omics","nonrandomized_study","article","10.1039/d5mo00074b","41133487",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0019189","Triazination/IEDDA Cascade Modular Strategy Installing Pyridines/Pyrimidines onto Tyrosine Enables Peptide Screening and Optimization.","Zuo Q","2025","Journal of the American Chemical Society","other","article","10.1021/jacs.4c17615","39885681",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019190","Incretin-based therapies for type 2 diabetes mellitus: effects on insulin resistance.","Grigoropoulou P","2013","Current diabetes reviews","narrative_review","article","10.2174/15733998113099990070","23855508",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019191","A diabetic patient increased premature ventricular contractions after using liraglutide: a case report.","Huang L","2024","Frontiers in cardiovascular medicine","case_report","article","10.3389/fcvm.2024.1332754","38357515","PMC10865887",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019192","Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.","Kosiborod MN","2024","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(24)01643-x","39222642",null,"ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03819153; ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S000716; S000868; S000953; S002012","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural; article"],["R0019193","Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients.","Choi WS","2026","Therapeutic advances in psychopharmacology","nonrandomized_study","article","10.1177/20451253261419609","41727810","PMC12923937",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019194","Comparison of the Effects of Liraglutide on Islet Graft Survival Between Local and Systemic Delivery.","Lee SM","2020","Cell transplantation","preclinical","article","10.1177/0963689720971245","33172296","PMC7784585",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019195","Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.","Gill A","2010","Cardiovascular diabetology","randomized_trial","article","10.1186/1475-2840-9-6","20109208","PMC2823663","ClinicalTrials.gov:NCT00516074","S000435","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0019196","In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.","Collister D","2024","Annals of internal medicine","other_trial","article","10.7326/annals-24-01579-jc","39222509",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; article"],["R0019197","Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma.","Honors MA","2014","Hormones & cancer","preclinical","article","10.1007/s12672-013-0163-9","24101584","PMC3947106",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019198","Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system.","Ostrominski JW","2025","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.24186","39696750","PMC11774016",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0019199","Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas.","Nachnani JS","2010","Diabetologia","preclinical","article","10.1007/s00125-009-1515-4","19756486",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019200","Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.","Marbury TC","2017","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-017-0528-2","28349386","PMC5648736","ClinicalTrials.gov:NCT00833716","S000247","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0019201","GLP-1 analogue recovers impaired insulin secretion from human islets treated with palmitate via down-regulation of SOCS2.","Chowdhury AI","2017","Molecular and cellular endocrinology","other","article","10.1016/j.mce.2016.08.034","27566229",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019202","The generation and evaluation of novel gut derived peptides for the treatment of Type 2 diabetes and obesity","Perry R","2019","Ulster University","preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0019203","68Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-Lys40-exendin-3","Leung K","2004","National Center for Biotechnology Information (US), Bethesda (MD)","narrative_review","article",null,"21061498",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0019204","Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.","Lusk JB","2024","American heart journal","nonrandomized_study","article","10.1016/j.ahj.2024.05.007","39182939",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0019205","Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.","Nomiyama T","2014","Diabetes","preclinical","article","10.2337/db13-1169","24879833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019206","Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome.","Yousefi Z","2025","BMC gastroenterology","preclinical","article","10.1186/s12876-025-04545-z","41413484","PMC12831306",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0019207","Incretin-based therapy in chronic kidney disease.","Pinelli NR","2010","Advances in chronic kidney disease","narrative_review","article","10.1053/j.ackd.2010.06.003","20727514",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019208","Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis.","Farr S","2015","Arteriosclerosis, thrombosis, and vascular biology","preclinical","article","10.1161/atvbaha.114.304873","25675997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019209","iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study.","Lajara R","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14974","36633506",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019210","Multi-target PET evaluation in APP/PS1/tau mouse model of Alzheimer's disease.","Liu Y","2020","Neuroscience letters","preclinical","article","10.1016/j.neulet.2020.134938","32278026",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0019211","Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.","Małecki MT","2023","Diabetes care","other_trial","article","10.2337/dc23-1135","37824793","PMC10698219",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019212","Growth Promotion and Increased ATP-Binding Cassette Transporters Expression by Liraglutide in Triple Negative Breast Cancer Cell Line MDA-MB-231.","Shadboorestan A","2021","Drug research","preclinical","article","10.1055/a-1345-7890","33477190",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019213","Protective effect of exendin-4 treatment on erectile dysfunction induced by chronic methylglyoxal administration in rats.","Dalaklioglu S","2018","Peptides","preclinical","article","10.1016/j.peptides.2018.05.005","29792899",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019214","Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice.","Tamura K","2015","PloS one","preclinical","article","10.1371/journal.pone.0126003","25938469","PMC4418765",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019215","Exendin-4 enhances the differentiation of Wharton's jelly mesenchymal stem cells into insulin-producing cells through activation of various β-cell markers.","Kassem DH","2016","Stem cell research & therapy","other","article","10.1186/s13287-016-0374-4","27515427","PMC4981957",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0019216","Semaglutide and thyroid cancer: preclinical risk data, actual evidence and discrepancies in information provided by regulatory agencies.","Campo CBFd","2024","Authorea Preprints","nonrandomized_study","preprint","10.22541/au.173323641.19720394/v1",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","4","FALSE","Preprint; preprint"],["R0019217","Liraglutide-induced acute pancreatitis.","Jeyaraj S","2014","The Journal of the Association of Physicians of India","case_report","article",null,"25327099",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0019218","Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.","Parker VER","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14712","35403793","PMC9323481","ClinicalTrials.gov:NCT03550378","S002039","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0019219","Incretin-based therapies: facing the realities of benefits versus side effects.","Lebovitz HE","2013","Diabetes technology & therapeutics","commentary","article","10.1089/dia.2013.0274","24111860","PMC3817865",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0019220","Effects of different hypoglycaemic drugs on beta-cell function in type 2 diabetes mellitus: a systematic review and network meta-analysis.","Guo Z","2025","European journal of medical research","systematic_review","article","10.1186/s40001-025-02368-y","39985051","PMC11843998",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; review"],["R0019221","Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.","Kumarathurai P","2021","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-020-01205-2","33413428","PMC7791686","ClinicalTrials.gov:NCT01595789","S001197","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0019222","The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD.","Li C","2020","Brain and behavior","preclinical","article","10.1002/brb3.1505","31960630","PMC7066337",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019223","CCK Response Deficiency in Synphilin-1 Transgenic Mice.","Smith WW","2015","PloS one","preclinical","article","10.1371/journal.pone.0142314","26569394","PMC4646498",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0019224","Oral capsule administration of biomacromolecules that achieves bioavailability and pharmacokinetics comparable to subcutaneous injection in dogs - the BIONDD® technology.","Skak N","2026","Drug delivery and translational research","other","article","10.1007/s13346-026-02157-y","42207426",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019225","High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.","Mul JD","2013","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00588.2012","23616105","PMC3727026",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019226","Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis.","Salles GN","2018","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.8b12649","30298718",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019227","ER stress and unfolded protein response (UPR) signaling modulate GLP-1 receptor signaling in the pancreatic islets.","Gao Y","2024","Molecules and cells","preclinical","article","10.1016/j.mocell.2023.12.002","38376482","PMC10880082",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019228","GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance.","Taher J","2014","Molecular metabolism","other","article","10.1016/j.molmet.2014.09.005","25506548","PMC4264039",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019229","Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.","King NE","2022","Pulmonary circulation","narrative_review","article","10.1002/pul2.12028","35506082","PMC9052991",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019230","Exploring the impact of semaglutide on renal function.","Noor N","2025","International urology and nephrology","commentary","article","10.1007/s11255-024-04215-1","39312018",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019231","Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor's anti-inflammatory effects.","Stoicovy RA","2024","Inflammation research : official journal of the European Histamine Research Society ... [et al.]","preclinical","article","10.1007/s00011-024-01950-0","39305297",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019232","Regeneration of pancreatic islets after partial pancreatectomy in mice does not involve the reactivation of neurogenin-3.","Lee CS","2006","Diabetes","preclinical","article","10.2337/diabetes.55.02.06.db05-1300","16361411",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0019233","Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity.","Verma S","2025","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2024.11.008","39566870",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019234","Individualized treatment of diabetes mellitus in older adults.","Araki A","2024","Geriatrics & gerontology international","narrative_review","article","10.1111/ggi.14979","39375857","PMC11628902",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019235","Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.","Nylander M","2017","Reproductive biomedicine online","randomized_trial","article","10.1016/j.rbmo.2017.03.023","28479118",null,null,"S002080","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0019236","Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.","Reiss AB","2025","Biomolecules","narrative_review","article","10.3390/biom15030408","40149944","PMC11940170",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019237","Is the GLP-1 system a viable therapeutic target for weight reduction?","Tong J","2011","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-011-9170-8","21336840","PMC3145813",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0019238","Pancreatitis in incretin-based therapies.","Famularo G","2015","Clinics and research in hepatology and gastroenterology","commentary","article","10.1016/j.clinre.2014.11.007","25573492",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019239","Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells.","Kwon KC","2013","Plant biotechnology journal","preclinical","article","10.1111/pbi.12008","23078126","PMC3535676",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019240","Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease.","Ritsinger V","2024","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-024-02365-1","39113013","PMC11304712",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0019241","Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.","Srivastava G","2018","Current obesity reports","narrative_review","article","10.1007/s13679-018-0300-4","29504049",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019242","Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes.","Vora J","2013","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2012.08.002","23022130",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019243","Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies.","Rho S","2026","Drug design, development and therapy","other_trial","article","10.2147/dddt.s612176","42333387","PMC13283388",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0019244","Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk.","Peters AL","2009","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.76.s5.04","19952300",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019245","Baicalein Ameliorates Insulin Resistance of HFD/STZ Mice Through Activating PI3K/AKT Signal Pathway of Liver and Skeletal Muscle in a GLP-1R-Dependent Manner.","Liu N","2024","Antioxidants (Basel, Switzerland)","preclinical","article","10.3390/antiox13101246","39456499","PMC11505556",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019246","Exendin-4 promotes proliferation of adipose-derived stem cells through ERK and JNK signaling pathways.","Zhang Y","2016","In vitro cellular & developmental biology. Animal","preclinical","article","10.1007/s11626-016-0003-7","26932601",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019247","In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level.","Zhu D","2024","Annals of internal medicine","other_trial","article","10.7326/annals-24-02457-jc","39496170",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; editorial"],["R0019248","Severe Visceral Obesity, Fatty Liver and Diabetes after Orchiectomy for Prostate Cancer.","Kajitani N","2020","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.4653-20","32522924","PMC7578597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019249","Long-term liraglutide ameliorates nigrostriatal impairment via regulating AMPK/PGC-1a signaling in diabetic mice.","Ma D","2019","Brain research","preclinical","article","10.1016/j.brainres.2019.02.030","30826352",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019250","Efficacy and safety of semaglutide combined with metformin in treating T2DM with overweight or obesity: a systematic review and meta-analysis.","Li J","2024","American journal of translational research","systematic_review","article","10.62347/ryln5360","39262717","PMC11384358",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0019251","Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.","Mogensen UM","2014","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12314","24827939",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019252","Long-term effects of esaxerenone in patients with type 2 diabetes, diabetic kidney disease, and hypertension (JDDM77).","Uchida D","2025","Diabetology international","nonrandomized_study","article","10.1007/s13340-024-00779-6","39877444","PMC11769913",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; research-article"],["R0019253","Presentation and Management of Liraglutide-Related Pancreatitis: Systematic Review of Case Reports","Singh S","2021","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvab048.853",null,"PMC8089576",null,null,"europepmc; openalex","TRUE","open_europepmc","3","FALSE","Abstract; conference-abstract"],["R0019254","The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.","Jensterle M","2019","Human reproduction update","nonrandomized_study","article","10.1093/humupd/dmz019","31260047",null,null,"S000630","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0019255","Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the AMPK pathway.","Xu WW","2014","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","preclinical","article","10.1159/000358623","24556697",null,null,"S002088","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0019256","Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.","Guo L","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15590","38600796",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0019257","Systemic medications and their impact on age-related macular degeneration development and progression: a review of current evidence.","Yuan M","2026","Current opinion in ophthalmology","randomized_trial","article","10.1097/icu.0000000000001198","41481850",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0019258","Liraglutide Protects Cardiomyocytes against Isoprenaline-Induced Apoptosis in Experimental Takotsubo Syndrome.","Bajic Z","2024","Biomedicines","preclinical","article","10.3390/biomedicines12061207","38927414","PMC11200478",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019259","Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis.","Chang YF","2020","Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","other_trial","article","10.1016/j.jocn.2020.09.054","33222922",null,null,"S000766","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0019260","Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials.","Mahmoud AN","2017","International journal of cardiology","systematic_review","article","10.1016/j.ijcard.2016.12.113","28043676",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0019261","The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities.","Wadden TA","2023","Current obesity reports","narrative_review","article","10.1007/s13679-023-00534-z","38041774","PMC10748770",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019262","Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.","Arai T","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15898","39223865",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0019263","Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations.","Builes-Montaño C","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-023-01471-9","37736786","PMC10570232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019264","A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus.","Alhabeeb W","2024","Journal of the Saudi Heart Association","other","article","10.37616/2212-5043.1407","39822337","PMC11737320",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019265","Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study.","Able C","2025","International journal of impotence research","nonrandomized_study","article","10.1038/s41443-024-00895-6","38778151",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0019266","Racial and Ethnic Differences in Semaglutide Prescriptions for Veterans With Overweight or Obesity in the Veterans Affairs Healthcare System.","Tisdale RL","2025","Circulation. Cardiovascular quality and outcomes","commentary","article","10.1161/circoutcomes.124.011649","39524000","PMC11745747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019267","Novel strategy for oral peptide delivery in incretin-based diabetes treatment.","Xu Y","2020","Gut","preclinical","article","10.1136/gutjnl-2019-319146","31401561","PMC7229891",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019268","The effect of antidiabetic drugs on bone metabolism: a concise review.","Psachna S","2025","Endocrine","narrative_review","article","10.1007/s12020-024-04070-1","39402366",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019269","Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus.","Riederer A","2016","Journal of veterinary internal medicine","randomized_trial","article","10.1111/jvim.13817","26700409","PMC4913624",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Controlled Clinical Trial; Journal Article; research-article; article"],["R0019270","CREB-mediated generation and neuronal growth regulates the behavioral improvement of geniposide in diabetes-associated depression mouse model.","Sun B","2021","Neuroscience research","preclinical","article","10.1016/j.neures.2020.05.003","32428538",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019271","Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease.","Korakas E","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae122","38979402","PMC11228545",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019272","Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus.","Ma J","2024","Alternative therapies in health and medicine","randomized_trial","article",null,"38294744",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0019273","FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10555009",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019274","Diet-Microbiota-Host Interactions in Regulation of Cardiometabolic Homeostasis: Emerging Mechanisms and Therapeutic Potential.","Plata AA","2025","Microbiota and host","other","article","10.1530/mah-25-0008","41367820","PMC12685066",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019275","Renal tubule-specific Atgl deletion links kidney lipid metabolism to glucagon-like peptide 1 and insulin secretion independent of renal inflammation or lipotoxicity.","Fernandes MF","2024","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.101887","38280449","PMC10850971",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019276","Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa.","Posada Posada MI","2025","Journal of the European Academy of Dermatology and Venereology : JEADV","commentary","article","10.1111/jdv.20392","39425524",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019277","NICE recommendations on tirzepatide for weight loss could increase NHS access.","Wilkinson E","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1239","38839081",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0019278","Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Davies MJ","2018","Diabetes care","narrative_review","article","10.2337/dci18-0033","30291106","PMC6245208",null,"S000691","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Consensus Statement; review-article; article"],["R0019279","[Incretins: do they exert cardiovascular effects?].","Gallwitz B","2010","Herz","other","article","10.1007/s00059-010-3333-3","20467925",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0019280","Glycaemic Control in Diabetes.","Müller-Wieland D","2022","Handbook of experimental pharmacology","other","article","10.1007/164_2021_537","34467427",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; book-chapter"],["R0019281","Fully automated GMP production of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for clinical use.","Velikyan I","2017","American journal of nuclear medicine and molecular imaging","other","article",null,"28721305","PMC5511121",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019282","CADTH Canadian Drug Expert Committee Recommendation: Insulin Glargine and Lixisenatide (Soliqua — Sanofi-Aventis Canada Inc.): Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) alone or in combination with metformin",null,"2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"31120707",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0019283","Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists.","Mann JFE","2021","Kidney international","other","article","10.1016/j.kint.2020.08.036","33509353",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019284","A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.","Zhang L","2014","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2014.02.045","24565847",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019285","Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)","Kushner R","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.046",null,"PMC8089676","ClinicalTrials.gov:NCT03548935","S000144","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; conference-abstract"],["R0019286","Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.","Hu Y","2023","BMC endocrine disorders","systematic_review","article","10.1186/s12902-023-01497-x","37974132","PMC10652559",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0019287","Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.","Morino J","2019","CEN case reports","case_report","article","10.1007/s13730-019-00379-3","30663011","PMC6450986",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019288","Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery.","Ismail R","2020","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2020.04.025","32371152",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019289","Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes.","Suki M","2025","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph18071075","40732362","PMC12300756",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019290","GLP-1 and exendin-4 for imaging endocrine pancreas. A review. Labelled glucagon-like peptide-1 analogues: past, present and future.","Hubalewska-Dydejczyk A","2015","The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...","narrative_review","article",null,"25719487",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019291","Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions.","Patil R","2026","Drugs","other_trial","article","10.1007/s40265-026-02301-5","41831171",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0019292","Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, 18F-labeled [Nle14,Lys40]exendin-4 analog, shows promise for clinical imaging.","Mikkola K","2016","EJNMMI research","preclinical","article","10.1186/s13550-016-0243-2","27957723","PMC5153397",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019293","The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China.","Gu S","2024","Health economics review","randomized_trial","article","10.1186/s13561-024-00499-2","38564113","PMC10988849",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0019294","Alterations in pancreatic islet cell function in response to small bowel resection.","Courtney CM","2020","American journal of physiology. Gastrointestinal and liver physiology","nonrandomized_study","article","10.1152/ajpgi.00282.2019","32463335","PMC7468758",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; research-article"],["R0019295","The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic β cells.","Bourouh C","2022","Cell reports","other","article","10.1016/j.celrep.2022.111170","35947949",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019296","The influence of incretin mimetics on cardiovascular risk factors in diabetes.","Kinalska I","2012","ISRN endocrinology","other_trial","article","10.5402/2012/625809","22462016","PMC3302114",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0019297","Unlocking Therapeutic Synergy: Tailoring Drugs for Comorbidities such as Depression and Diabetes through Identical Molecular Targets in Different Cell Types.","Coppola T","2023","Cells","narrative_review","article","10.3390/cells12232768","38067196","PMC10706795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0019298","Liraglutide combined with HIIT preserves contractile apparatus and blunts the progression of heart failure in diabetic cardiomyopathy rats.","Cai H","2025","Scientific reports","preclinical","article","10.1038/s41598-025-85699-4","39934246","PMC11814110",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019299","Translating Subphenotypes of Newly Diagnosed Type 2 Diabetes from Cohort Studies to Electronic Health Records in the United States","Li Z","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.10.08.24315128",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0019300","[Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].","Forst T","2017","Der Internist","narrative_review","article","10.1007/s00108-017-0189-0","28120022",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019301","Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system.","Xiao C","2012","Cardiovascular & hematological agents in medicinal chemistry","narrative_review","article","10.2174/187152512803530315","22827289",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019302","Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice.","Martens MD","2024","JACC. Basic to translational science","preclinical","article","10.1016/j.jacbts.2024.07.006","39822607","PMC11733746",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0019303","Tirzepatide, a dual receptor agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, enhances β-cell survival and maintenance markers in obese diabetic ovariectomized mice.","Reis-Barbosa PH","2024","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.15937","39307961",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019304","Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre.","McCarron EP","2025","Molecular genetics and metabolism reports","nonrandomized_study","article","10.1016/j.ymgmr.2025.101229","40485669","PMC12144493",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019305","Bariatric surgery, novel glucose-lowering agents, and insulin for type 2 diabetes and obesity: Bayesian network meta-analysis of randomized controlled trials.","Wu T","2023","BJS open","systematic_review","article","10.1093/bjsopen/zrad077","37542473","PMC10404007","PROSPERO:CRD42020201507",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; review-article; review"],["R0019306","Mechanisms for anesthesia, unawareness, OIRD, sleep and memory replay: MHb→IPN→ PAG + DRN + MRN→claustrum→ cortical slow-waves.","Vadovičová K","2026","ScienceOpen Preprints","other","preprint","10.14293/pr2199.000799.v11",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0019307","A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.","van Velsen EF","2014","The Netherlands journal of medicine","other","article",null,"26219757",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019308","Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart.","Ding W","2019","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2019.00202","31024445","PMC6459897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019309","Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss.","Buller S","2024","American journal of physiology. Endocrinology and metabolism","narrative_review","article","10.1152/ajpendo.00250.2023","38381398","PMC11193531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019310","Real-World Safety and Effectiveness of iGlarLixi in People With Type 2 Diabetes who Fast During Ramadan: Results From Wave 1 of the SOLIRAM Study","Hassanein M","2021","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvab048.681",null,"PMC8090142",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0019311","Pancreatitis associated with incretin-based therapies.","Iyer SN","2013","Diabetes care","commentary","article","10.2337/dc12-1987","23520376","PMC3609483",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019312","Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice.","Kooijman S","2015","Diabetologia","preclinical","article","10.1007/s00125-015-3727-0","26254578","PMC4589565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019313","iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study.","McCrimmon RJ","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14844","36123617","PMC10087837",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019314","Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.","Arnold SV","2017","European journal of preventive cardiology","nonrandomized_study","article","10.1177/2047487317729252","28870145",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0019315","A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data.","Du Y","2024","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14229","38943656","PMC11442840",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019316","Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells.","Erdogdu Ö","2012","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2012.02.106","22390929",null,null,"S001903","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019317","Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study.","Oral A","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13206121","39458071","PMC11508960",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019318","Sweetening the deal: An infodemiological study of worldwide interest in semaglutide using Google Trends","RAUBENHEIMER JE","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-4284610/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0019319","Glucagon-like peptide-1 receptors agonists (GLP1 RA).","Kalra S","2013","JPMA. The Journal of the Pakistan Medical Association","narrative_review","article",null,"24392570",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019320","The Effect of Counterions in Hydrophobic Ion Pairs on Oral Bioavailability of Exenatide.","Phan TNQ","2020","ACS biomaterials science & engineering","preclinical","article","10.1021/acsbiomaterials.0c00637","33455296",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019321","Can tirzepatide untie the Gordian knot of eating disorders among individuals with type 2 diabetes and obesity?","Patoulias D","2024","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2024.108812","39018899",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0019322","Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity.","Xiao Y","2024","JAMA","commentary","article","10.1001/jama.2024.2600","38630501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0019323","Sex differences in GLP-1 signaling across species","Roseberry T","2025","bioRxiv","nonrandomized_study","preprint","10.1101/2025.03.17.643822",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0019324","Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.","Polonsky WH","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14822","36053820","PMC9805099","EudraCT:2017-003370-13",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019325","The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.","Vrang N","2012","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00182.2012","22589391",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019326","[Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients].","Sesti G","2012","Giornale italiano di cardiologia (2006)","nonrandomized_study","article","10.1714/1203.13332","23258124",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0019327","Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.","Bays HE","2022","Obesity pillars","other_trial","article","10.1016/j.obpill.2022.100018","37990711","PMC10662004",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; other; article"],["R0019328","Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.","Inagaki N","2012","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2012.07.007","22884767",null,"ClinicalTrials.gov:NCT00935532","S000632","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019329","How to 'drug' our way out of the obesity crisis (or not): the roll-out of semaglutide.","Khan N","2024","The British journal of general practice : the journal of the Royal College of General Practitioners","other","article","10.3399/bjgp24x737241","38664050","PMC11060807",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0019330","Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.","Montvida O","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13288","29536608",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019331","Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review.","Dumitru CN","2026","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph19081313","42653808","PMC13516377",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0019332","PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.","Kuo TT","2023","International journal of molecular sciences","preclinical","article","10.3390/ijms24054687","36902115","PMC10002999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019333","Screening GLP-1 Receptor Ligands from Natural Products in Herbs through High-Content Technique.","Qin K","2019","Combinatorial chemistry & high throughput screening","preclinical","article","10.2174/1386207322666190919143735","31538889",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019334","Semaglutide may reduce cardiovascular disease and heart failure.","Korda M","2024","Nature cardiovascular research","commentary","article","10.1038/s44161-024-00556-3","39367214",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0019335","Rare genetic forms of obesity in childhood and adolescence: A narrative review of the main treatment options with a focus on innovative pharmacological therapies.","Mainieri F","2024","European journal of pediatrics","narrative_review","article","10.1007/s00431-024-05427-4","38227053",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019336","Engineering 3'-UTR hairpin structures to modulate mRNA stability and recombinant protein production in Escherichia coli.","Khasanshina Z","2027","Protein expression and purification","other","article","10.1016/j.pep.2026.106993","42674194",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019337","Incretin accelerates platelet-derived growth factor-BB-induced osteoblast migration via protein kinase A: The upregulation of p38 MAP kinase.","Kawabata T","2020","Scientific reports","preclinical","article","10.1038/s41598-020-59392-7","32047216","PMC7012849",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019338","Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia.","Tan TM","2022","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(22)00038-9","35131036",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; article"],["R0019339","Enhanced Incretin Effects of Exendin-4 Expressing Chimeric Plasmid Based On Two-Step Transcription Amplification System with Dendritic Bioreducible Polymer for the Treatment of Type 2 Diabetes.","Kim PH","2013","Journal of gene therapy","preclinical","article","10.13188/2381-3326.1000002","24839613","PMC4020291",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019340","A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat.","Han L","2016","Neuroreport","preclinical","article","10.1097/wnr.0000000000000490","26555034",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019341","Letter to the Editor Regarding \"The Cardiovascular Conundrum: Navigating Semaglutide Shortages and Patient Well-being\".","Leslie A","2024","Heart, lung & circulation","commentary","article","10.1016/j.hlc.2024.04.311","39521577",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0019342","Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.","Irace C","2018","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-018-0695-y","29631585","PMC5891980",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; research-article; article"],["R0019343","Aliskiren, exendin-4, and insulin: their impact on endothelin receptor subtype(s) regulation/binding in type 1 diabetic rat hearts.","Al Lafi SM","2013","Canadian journal of physiology and pharmacology","preclinical","article","10.1139/cjpp-2013-0095","24144054",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019344","Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity-Reply.","Aronne LJ","2024","JAMA","commentary","article","10.1001/jama.2024.2603","38630499",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0019345","Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling Pathways.","Farkas I","2016","Frontiers in cellular neuroscience","preclinical","article","10.3389/fncel.2016.00214","27672360","PMC5018486",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019346","Effective treatment for fatty liver of liraglutide via inhibiting endoplasmic reticulum stress, oxidative stress and apoptosis pathways.","Li J","2025","Archives of medical science : AMS","nonrandomized_study","article","10.5114/aoms/186658","41078944","PMC12509818",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019347","Predictors of rapid eGFR decline in early to moderate chronic kidney disease (stages G1-G4): insights from a real-world Thai cohort incorporating KDIGO 2024 guidelines.","Anumas S","2025","Renal failure","nonrandomized_study","article","10.1080/0886022x.2025.2593732","41309361","PMC12667306",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019348","Blood pressure-lowering effects of incretin-based diabetes therapies.","Lovshin JA","2014","Canadian journal of diabetes","narrative_review","article","10.1016/j.jcjd.2014.05.001","25284699",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019349","Correlation between long-term glycemic variability and cognitive function in middle-aged and elderly patients with type 2 diabetes mellitus: a retrospective study.","Ding J","2023","PeerJ","nonrandomized_study","article","10.7717/peerj.16698","38144199","PMC10748480",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019350","Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.","Cox AR","2017","Endocrinology","nonrandomized_study","article","10.1210/en.2017-00027","28323942","PMC5460937",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019351","Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.","Chen X","2021","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.1016/j.eprac.2021.03.015","33831552",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0019352","Microporous Polymer Scaffolds for the Transplantation of Embryonic Stem Cell Derived Pancreatic Progenitors to a Clinically Translatable Site for the Treatment of Type I Diabetes.","Kasputis T","2018","ACS biomaterials science & engineering","nonrandomized_study","article","10.1021/acsbiomaterials.7b00912","30345348","PMC6191190",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019353","Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice.","Zhang H","2016","The AAPS journal","preclinical","article","10.1208/s12248-015-9854-1","26689204","PMC4779090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019354","Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review.","Goldenberg R","2014","Current medical research and opinion","systematic_review","article","10.1185/03007995.2013.852078","24106875",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0019355","Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents.","Gentilella R","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-0625-3","31055780","PMC6531505",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019356","Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high-fat diet.","Kaji N","2020","Animal models and experimental medicine","preclinical","article","10.1002/ame2.12106","32318661","PMC7167233",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019357","Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease.","Chen X","2023","Drug delivery","other","article","10.1080/10717544.2022.2160518","36576203","PMC9809356",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019358","Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic βTC-6 cells -1mTORβTC-6.","Zhou J","2015","Journal of diabetes","preclinical","article","10.1111/1753-0407.12177","24909811",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019359","Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes.","Vora J","2013","Diabetes care","nonrandomized_study","article","10.2337/dcs13-2036","23882050","PMC3920804",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0019360","Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.","Zhong X","2018","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2018.03.050","29597167",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019361","12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.","De Giorgi R","2024","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2024.102726","39764175","PMC11701436",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019362","Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.","Herold KC","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14121","32573927","PMC8009602",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019363","Outcomes of obesity medications in those with low response to a low-energy diet meal replacement programme: An observational study.","Shand J","2026","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100245","41551724","PMC12810329",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019364","Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice.","Ma DL","2015","Journal of neurochemistry","preclinical","article","10.1111/jnc.13248","26183127",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019365","Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.","Claus TH","2007","The Journal of endocrinology","preclinical","article","10.1677/joe-06-0018","17283237",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019366","Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.","Del Prato S","2021","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(21)02188-7","34672967",null,"ClinicalTrials.gov:NCT03730662","S001287","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; article"],["R0019367","Functional segregation of body-brain signals in the area postrema.","López-Cruz A","2026","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2026.06.15.732473","42453677","PMC13361401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0019368","Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors.","Uti DE","2025","International journal of nanomedicine","narrative_review","article","10.2147/ijn.s529250","40859950","PMC12377373",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Comparative Study; review-article; article"],["R0019369","Next-generation GLP-1 therapy: an introduction to liraglutide.","Repas T","2011","Postgraduate medicine","other_trial","article","10.3810/pgm.2011.09.2480","21904107",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0019370","Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.","Wadden TA","2024","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2024.4346","39226070","PMC11372653","ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT03611582; ClinicalTrials.gov:NCT03693430","S000144; S000214; S000988; S001740","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0019371","Corrigendum to \"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series\".",null,"2024","Therapeutic advances in psychopharmacology","notice","article","10.1177/20451253241258536","38808099","PMC11131394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0019372","EFFECTS OF EXENDIN-4 ON ENDOPLASMIC RETICULUM STRESS-MEDIATED INSULIN RESISTANCE IN 3T3-L1 ADIPOCYTES.","Guan B","2019","Acta endocrinologica (Bucharest, Romania : 2005)","other","article","10.4183/aeb.2019.158","31508171","PMC6711649",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019373","Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.","Fralick M","2019","Annals of internal medicine","systematic_review","article","10.7326/m18-0567","30597484","PMC6602870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0019374","Semaglutide improves metabolic dysfunction-associated steatohepatitis: A 10-year retrospective study.","Shah P","2024","JGH open : an open access journal of gastroenterology and hepatology","nonrandomized_study","article","10.1002/jgh3.13037","38389719","PMC10883239",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019375","EBM BLS: Adding tirzepatide to long-acting insulin is superior to adding mealtime insulin for type 2 diabetes mellitus.","Fuest S","2024","Journal of general internal medicine","other","article","10.1007/s11606-024-08901-9","39090425","PMC11535102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0019376","Association Between Renal Fat Fraction and Early Biomarkers of Kidney Injury in Patients with Type 2 Diabetes Mellitus.","Adnan E","2026","Journal of clinical medicine","other","article","10.3390/jcm15083025","42074825","PMC13116439",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019377","The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.","Vidal J","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-019-00751-7","31925724","PMC6995797",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0019378","Anti-Diabetic Therapies and Cancer: From Bench to Bedside.","Kounatidis D","2024","Biomolecules","nonrandomized_study","article","10.3390/biom14111479","39595655","PMC11591849",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0019379","Accidental Once-Daily Use of Dulaglutide: A Case Report.","Moore HE","2024","Clinical diabetes : a publication of the American Diabetes Association","case_report","article","10.2337/cd23-0035","39015162","PMC11247031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019380","Key role for hypothalamic interleukin-6 in food-motivated behavior and body weight regulation.","López-Ferreras L","2021","Psychoneuroendocrinology","preclinical","article","10.1016/j.psyneuen.2021.105284","34090139",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019381","Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice.","Chen SY","2024","Clinical science (London, England : 1979)","preclinical","article","10.1042/cs20231016","38315575","PMC10876416",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019382","Incretin based therapies for type 2 diabetes mellitus.","Ghosh S","2008","Journal of the Indian Medical Association","other","article",null,"18839649",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019383","Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.","Pace E","2017","American family physician","other","article",null,"29094890",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019384","Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study.","Ko HY","2025","The Lancet regional health. Western Pacific","nonrandomized_study","article","10.1016/j.lanwpc.2024.101242","40226782","PMC11992583",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019385","Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.","Rangwala HS","2024","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-024-01412-8","38932909","PMC11196572",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0019386","Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.","Brown E","2019","Obesity reviews : an official journal of the International Association for the Study of Obesity","nonrandomized_study","article","10.1111/obr.12841","30972878",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019387","Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity.","Mentias A","2024","Circulation. Heart failure","nonrandomized_study","article","10.1161/circheartfailure.122.010453","38275114",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0019388","Semaglutide attenuates Alzheimer's disease model progression by targeting microglial NLRP3 inflammasome-mediated neuroinflammation and ferroptosis.","Zheng M","2026","Experimental neurology","preclinical","article","10.1016/j.expneurol.2025.115537","41173224",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019389","Weekly Journal Scan: SELECT renoprotective effects of semaglutide in non-diabetic, obese patients with cardiovascular disease.","Vergallo R","2024","European heart journal","randomized_trial","article","10.1093/eurheartj/ehae567","39228366",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0019390","Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.","Zhao G","2022","Expert review of clinical pharmacology","systematic_review","article","10.1080/17512433.2022.2117152","36039827",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0019391","Integrating Drug Target Information in Deep Learning Models to Predict the Risk of Adverse Events in Patients with Comorbid Post-Traumatic Stress Disorder and Alcohol Use Disorder.","Miranda O","2024","Biomedicines","other","article","10.3390/biomedicines12122772","39767679","PMC11673068",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019392","Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.","Guo L","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00869-z","32621083","PMC7376772","ClinicalTrials.gov:NCT01648582; ClinicalTrials.gov:NCT01644500","S001064; S001404","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0019393","Small-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives.","Sun X","2022","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2022.112722","35202915",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019394","Multiscale modeling of the subcutaneous administration of peptides","Kuhar S","2026","bioRxiv","other","preprint","10.64898/2026.06.01.724102",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0019395","Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.","Verma S","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2024.08.028","39217564",null,"ClinicalTrials.gov:NCT04788511; ClinicalTrials.gov:NCT04916470","S000161; S002012","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0019396","Correction to \"Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials\".",null,"2025","Diabetes, obesity & metabolism","notice","article","10.1111/dom.16205","39807614",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0019397","Laser Acupuncture versus Liraglutide in Treatment of Obesity: A Multi-Institutional Retrospective Cohort Study.","Yu WL","2024","Healthcare (Basel, Switzerland)","nonrandomized_study","article","10.3390/healthcare12131279","38998814","PMC11241425",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019398","Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.","Lingvay I","2019","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(19)30311-0","31540867",null,"ClinicalTrials.gov:NCT03136484","S001847","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019399","Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery.","Lewis AL","2022","Drug delivery and translational research","other_trial","article","10.1007/s13346-021-01000-w","34024013",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0019400","Using albumin to improve the therapeutic properties of diabetes treatments.","Ahrén B","2012","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2011.01482.x","21812895",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019401","A Massive Type IV Hiatal Hernia With Gastric Volvulus and the Complicated Road to Recovery.","Barnes S","2026","Cureus","case_report","article","10.7759/cureus.108043","42220762","PMC13222075",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019402","Response to \"Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment\".","Brooks AB","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","commentary","article","10.1007/s13300-020-00900-3","32767278","PMC7509018",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0019403","Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation.","van Bloemendaal L","2015","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.21200","26331843",null,null,"S000930","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019404","The Crunchometer: A Low-Cost, Open-Source Acoustic Analysis of Feeding Microstructure.","Gil-Lievana E","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.07.25.666891","40766613","PMC12324344",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; preprint"],["R0019405","From metabolic dysregulation to neurodegenerative pathology: the role of hyperglycemia, oxidative stress, and blood-brain barrier breakdown in T2D-driven Alzheimer's disease.","Raza A","2025","Metabolic brain disease","narrative_review","article","10.1007/s11011-025-01700-z","41003796","PMC12474712",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019406","Protective effects of ACF210, a dual GLP-1/APJ receptor agonist, against cardiovascular-kidney-metabolic syndrome induced by T2D.","Wu Q","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2026.119726","42401045",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019407","Incretin - based therapy in diabetes mellitus: present scenario and expanding horizons.","Kohli SC","2016","Nepal journal of epidemiology","commentary","article","10.3126/nje.v6i2.15159","27774341","PMC5073170",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0019408","Exploring the Effect and Mechanism of Liraglutide in Treating Depression Based on Network Pharmacology and Experimental Analysis.","Sun J","2025","Journal of cellular and molecular medicine","preclinical","article","10.1111/jcmm.70630","40461955","PMC12133450",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019409","Hot Water Eliminates the Bitter Taste of Oral Semaglutide: A Report of Four Cases.","Okada S","2024","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.2608-23","38220187","PMC11414362",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019410","Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan.","Su YC","2022","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2022.32584","36136333","PMC9500553",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019411","Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.","McBrayer DN","2017","Drug development research","narrative_review","article","10.1002/ddr.21404","28786125","PMC5602594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0019412","Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism.","Hoffman S","2024","Medical review (2021)","narrative_review","article","10.1515/mr-2024-0011","39135603","PMC11317082",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0019413","The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV.","Lake JE","2024","Annals of internal medicine","other_trial","article","10.7326/m23-3354","38684100","PMC11210743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; Research Support, N.I.H., Extramural; research-article; article"],["R0019414","Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.","Li Y","2023","European journal of gastroenterology & hepatology","systematic_review","article","10.1097/meg.0000000000002471","36468565",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; review"],["R0019415","The activity of sulfono-γ-AApeptide helical foldamers that mimic GLP-1.","Sang P","2020","Science advances","other","article","10.1126/sciadv.aaz4988","32440547","PMC7228743",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0019416","Intranasal treatment of lixisenatide attenuated emotional and olfactory symptoms via CREB-mediated adult neurogenesis in mouse depression model.","Ren G","2021","Aging","preclinical","article","10.18632/aging.202358","33461175","PMC7906191",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019417","Effect of SGLT-2 inhibitors on COPD exacerbations in individuals with type 2 diabetes: A meta-analysis and Bayesian sensitivity analysis.","Shabil M","2025","Journal of diabetes investigation","systematic_review","article","10.1111/jdi.70111","40600829","PMC12400361",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; article"],["R0019418","Data-driven prioritization of high-risk individuals for weight loss interventions.","Demircan K","2026","Nature medicine","nonrandomized_study","article","10.1038/s41591-026-04353-2","42062622","PMC13279260",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019419","Influence of Buffering Capacity, pH, and Temperature on the Stability of Semaglutide: A Preformulation Study.","Malgave A","2025","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.70039","40635175",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019420","Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.","Pratley RE","2008","The review of diabetic studies : RDS","other_trial","article","10.1900/rds.2008.5.73","18795210","PMC2556445",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0019421","Gastrointestinal adverse effects of old and new antidiabetics: How do we deal with them in real life?","Barrientos-Ávalos JR","2024","Revista de gastroenterologia de Mexico (English)","narrative_review","article","10.1016/j.rgmxen.2024.10.008","39455403",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019422","Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment.","Baldassarre MPA","2024","Journal of clinical medicine","other","article","10.3390/jcm13113054","38892765","PMC11172469",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019423","Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.","Kim PH","2012","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2012.06.010","22705459","PMC3426869",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019424","GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control.","Nomiyama T","2016","Expert review of endocrinology & metabolism","other","article","10.1080/17446651.2016.1191349","30058925",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019425","Cardiovascular safety outcomes of new antidiabetic therapies.","LeBras MH","2017","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","randomized_trial","article","10.2146/ajhp160279","28483748",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0019426","GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification.","Lagou V","2023","Nature genetics","systematic_review","article","10.1038/s41588-023-01462-3","37679419","PMC10484788",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019427","IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study.","Fadini GP","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","protocol","article","10.1007/s13300-022-01287-z","35717487","PMC9309107",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0019428","Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial.","Hamidi V","2020","Metabolic syndrome and related disorders","randomized_trial","article","10.1089/met.2019.0102","32228379","PMC7262649","ClinicalTrials.gov:NCT02104739","S001060","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0019429","\"Cardiometabolic outpatient clinics: evidence from collaborative academic tertiary centers-research article\".","Korakas E","2025","Endocrine","nonrandomized_study","article","10.1007/s12020-025-04450-1","41091292",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0019430","Anti-obesity compounds, Semaglutide and LiPR, do not change the proportion of human and mouse POMC+ neurons","Jörgensen SK","2024","bioRxiv","preclinical","preprint","10.1101/2024.12.06.627140",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0019431","The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets.","Takasu M","2025","Kidney international reports","narrative_review","article","10.1016/j.ekir.2024.10.035","39990900","PMC11843125",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019432","Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.","Nagaike H","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0560-8","30612316","PMC6349295",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0019433","PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.","Yabe D","2024","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14291","39172634","PMC11527839",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0019434","Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm.","Bin Hussain AK","2019","Diabetes & metabolic syndrome","narrative_review","article","10.1016/j.dsx.2019.04.028","31235118",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019435","The Mechanism of Leptin Resistance in Obesity and Therapeutic Perspective.","Engin A","2024","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-3-031-63657-8_16","39287862",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019436","Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).","Furusawa S","2024","Endocrine journal","nonrandomized_study","article","10.1507/endocrj.ej23-0648","38658349",null,"UMIN:UMIN000050583",null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0019437","ITCA 650.","Bertsch T","2018","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd18-0039","30078949","PMC6053850",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0019438","Erratum. Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-Induced Obesity. Diabetes 2023;72:918-931.","Liu J","2024","Diabetes","notice","article","10.2337/db24-er07a","38652481","PMC11189826",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0019439","Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.","Li P","2017","Molecular medicine reports","preclinical","article","10.3892/mmr.2017.6978","28713911",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019440","Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study.","Feldt-Rasmussen U","2024","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2024.1250822","38577574","PMC10993249","ClinicalTrials.gov:NCT02060383","S002111","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; research-article; article"],["R0019441","Insulin Degludec / Liraglutide (Addendum to Commission A15-15)",null,"2015","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany","narrative_review","article",null,"29144677",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0019442","[The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].","Giglio RV","2016","Giornale italiano di cardiologia (2006)","narrative_review","article","10.1714/2214.23896","27093208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; article"],["R0019443","Unraveling the impaired incretin effect in obesity and type 2 diabetes: Key role of hyperglycemia-induced unscheduled glycolysis and glycolytic overload.","Rabbani N","2024","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2024.111905","39447679",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019444","Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?","Bellary S","2020","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(20)30301-6","32971039",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0019445","Incretin effect: GLP-1, GIP, DPP4.","Kazafeos K","2011","Diabetes research and clinical practice","narrative_review","article","10.1016/s0168-8227(11)70011-0","21864749",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019446","A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.","Kaur M","2024","European journal of clinical pharmacology","other_trial","article","10.1007/s00228-024-03646-0","38367045",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0019447","Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis.","Lv Q","2024","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2024.1403606","38883606","PMC11176463","PROSPERO:CRD42024519474",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; systematic-review; review"],["R0019448","Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity.","Wang G","2021","Archives of endocrinology and metabolism","other","article","10.20945/2359-3997000000388","34283904","PMC10522179",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019449","Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents.","Vallöf D","2019","Psychoneuroendocrinology","preclinical","article","10.1016/j.psyneuen.2019.02.006","30771711",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019450","Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts.","Hantouche CM","2010","Canadian journal of physiology and pharmacology","preclinical","article","10.1139/y09-095","20130739",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019451","Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1, and preproinsulin in the pancreas of diabetic rats.","Barakat G","2016","Journal of physiology and biochemistry","preclinical","article","10.1007/s13105-017-0565-1","28589533",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019452","Glucagon-like peptide-1, a matter of taste?","Jensterle M","2021","Reviews in endocrine & metabolic disorders","nonrandomized_study","article","10.1007/s11154-020-09609-x","33123893",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0019453","A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes.","Ampudia-Blasco FJ","2015","Diabetes technology & therapeutics","other","article","10.1089/dia.2014.0260","25347226","PMC4346378",null,"S002440","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019454","The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease.","Wu X","2023","Frontiers in physiology","narrative_review","article","10.3389/fphys.2023.1166685","37153213","PMC10160444",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019455","Factors contributing to whether or not people with obesity undergo bariatric surgery.","Choi CW","2023","Obesity research & clinical practice","other","article","10.1016/j.orcp.2023.11.003","38000977",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019456","Incretin-based therapies and pancreatitis risk: myth or reality.","Pappachan JM","2015","Endocrine","commentary","article","10.1007/s12020-014-0490-9","25433430",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0019457","Intranasal administration of Exendin-4 antagonizes Aβ31-35-induced disruption of circadian rhythm and impairment of learning and memory.","Wang X","2016","Aging clinical and experimental research","preclinical","article","10.1007/s40520-016-0548-z","26920423",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019458","Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study","Wilding J","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.030",null,"PMC8089287",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0019459","68Ga-Exendin-4 PET/CT in Evaluation of Endoscopic Ultrasound-Guided Ethanol Ablation of an Insulinoma.","Luo Y","2017","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000001563","28134698",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0019460","How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials.","Kuss O","2023","Diabetologia","randomized_trial","article","10.1007/s00125-023-05951-2","37338539","PMC10390610",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019461","Adjuvant Treatment with Empagliflozin or Semaglutide Increases Endothelial Progenitor Cells in Subjects with Well-Controlled Type 1 Diabetes Mellitus.","Preložnik Navodnik M","2025","Current issues in molecular biology","other","article","10.3390/cimb47010054","39852169","PMC11764144",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019462","Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism.","Ceccarelli E","2013","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2013.00073","23785355","PMC3684850",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0019463","US eligibility and preventable cardiovascular disease events from semaglutide in type 2 diabetes.","Karthikeyan H","2025","Diabetes & vascular disease research","other_trial","article","10.1177/14791641251376551","40908778","PMC12413520",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0019464","Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Lee H","2021","Journal of clinical medicine","systematic_review","article","10.3390/jcm10184078","34575189","PMC8470178",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0019465","Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).","Capehorn MS","2020","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2019.101117","31539622",null,null,"S000485; S000584; S001837","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019466","Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.","Kadowaki T","2021","Expert opinion on drug safety","systematic_review","article","10.1080/14740338.2021.1898585","33706621",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; article; other"],["R0019467","Ozempic face: A new challenge for facial plastic surgeons.","Tay JQ","2023","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","commentary","article","10.1016/j.bjps.2023.04.057","37126934",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019468","Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.","Chalmer T","2015","Expert opinion on drug safety","narrative_review","article","10.1517/14740338.2015.975205","25363438",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019469","GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress.","Yusta B","2006","Cell metabolism","preclinical","article","10.1016/j.cmet.2006.10.001","17084712",null,null,"S002455","pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0019470","Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.","Xu YY","2024","Endocrine journal","systematic_review","article","10.1507/endocrj.ej24-0168","38910131",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0019471","Individualizing care with injectable glucose-lowering agents.","Miller EM","2013","The Journal of family practice","other","article",null,"24340344",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019472","Eczematous liraglutide eruption managed by dupilumab: A case report.","Paganini C","2024","JAAD case reports","case_report","article","10.1016/j.jdcr.2024.08.018","39430632","PMC11488440",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019473","Glucagon-like peptide-1 analogues in nonalcoholic steatohepatitis: From bench to bedside.","Armstrong MJ","2017","Clinical liver disease","narrative_review","article","10.1002/cld.650","30992756","PMC6467104",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019474","Is semaglutide a target therapy for acquired hypothalamic obesity?","Prodam F","2024","Pituitary","commentary","article","10.1007/s11102-024-01443-7","39212830",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0019475","Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.","Swift C","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01589-4","38722496","PMC11211303",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019476","Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).","Htike ZZ","2016","Cardiovascular diabetology","protocol","article","10.1186/s12933-016-0421-6","27440110","PMC4955217","ClinicalTrials.gov:NCT02043054","S000535","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0019477","Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.","Hankosky ER","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15269","37700443",null,"ClinicalTrials.gov:NCT04184622","S001077","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019478","Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.","Watson E","2010","Journal of clinical pharmacology","other","article","10.1177/0091270009354996","20133507",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0019479","The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.","Miao XY","2013","Peptides","preclinical","article","10.1016/j.peptides.2012.10.006","23116613",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019480","THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES.","Bode BW","2016","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep15869.ra","26484403",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0019481","[Injection of submandibular gland with recombinant Exendin-4 and adeno-associated virus for the treatment of diabetic rats].","Wang J","2015","Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences","preclinical","article","10.11817/j.issn.1672-7347.2015.11.003","26643419",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019482","Liraglutide and Naringenin relieve depressive symptoms in mice by enhancing Neurogenesis and reducing inflammation.","Abdelkawy YS","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.176525","38561101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019483","Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.","Kang C","2021","Scientific reports","randomized_trial","article","10.1038/s41598-021-99527-y","34625598","PMC8501012",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Preprint; research-article; preprint; article"],["R0019484","Unremitting Nausea Due to Lurasidone After Semaglutide Initiation.","Hean AC","2024","The primary care companion for CNS disorders","case_report","article","10.4088/pcc.24cr03736","39208529",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0019485","Lixisenatide: first global approval.","Elkinson S","2013","Drugs","narrative_review","article","10.1007/s40265-013-0033-3","23558600",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019486","Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs.","Lin H","2025","Drug delivery and translational research","preclinical","article","10.1007/s13346-024-01582-1","38619705",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019487","In HFpEF, semaglutide reduced a composite of worsening HF or CV death.","Lam SHM","2025","Annals of internal medicine","commentary","article","10.7326/annals-24-03382-jc","39761583",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0019488","The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.","Ehlers LH","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-021-01040-y","33856655","PMC8099952",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0019489","Incretin-mimetics associated pancreatitis: evidence from the spontaneous adverse drug reactions reporting in Italy.","Delfino M","2014","Expert opinion on drug safety","nonrandomized_study","article","10.1517/14740338.2014.853036","24219498",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0019490","Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.","Grimm M","2013","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2013.05.2660","23748506",null,"ClinicalTrials.gov:NCT00308139; ClinicalTrials.gov:NCT00637273; ClinicalTrials.gov:NCT00641056; ClinicalTrials.gov:NCT00676338; ClinicalTrials.gov:NCT00877890; ClinicalTrials.gov:NCT01029886","S000352; S000402; S001308; S001768; S001966; S002279","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019491","Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction.","Temporelli PL","2024","European heart journal supplements : journal of the European Society of Cardiology","randomized_trial","article","10.1093/eurheartjsupp/suae011","38867875","PMC11167989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article"],["R0019492","Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial.","Malhotra A","2024","Contemporary clinical trials","protocol","article","10.1016/j.cct.2024.107516","38547961","PMC11168245","ClinicalTrials.gov:NCT05412004","S000156","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; research-article; preprint; article"],["R0019493","Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling.","Guan R","2023","Frontiers in pharmacology","other","article","10.3389/fphar.2023.1326373","38089044","PMC10714946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019494","[Cardiovascular risk reduction in the management of diabetic patients: what has changed since the '90s in the clinical approach?].","Consoli A","2014","Giornale italiano di cardiologia (2006)","other","article","10.1714/1762.19114","25623547",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0019495","Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes.","Doggrell SA","2017","Evidence-based medicine","other_trial","article","10.1136/ebmed-2016-110566","27849161",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Comment; article"],["R0019496","Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression.","Kim Chung le T","2009","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2009.10.015","19850014",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019497","A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss.","Tzoulis P","2024","Cureus","randomized_trial","article","10.7759/cureus.59558","38826889","PMC11144277",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019498","Management of obesity in an individual with ROHHAD syndrome with semaglutide 2.4 mg/week: a case report.","Bonnet JB","2025","Clinical autonomic research : official journal of the Clinical Autonomic Research Society","case_report","article","10.1007/s10286-024-01072-x","39340692",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019499","Semaglutide: An emerging treatment option for patients with obesity related HFpEF.","Khaskheli SA","2024","JPMA. The Journal of the Pakistan Medical Association","other_trial","article","10.47391/jpma.20158","39279100",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; article"],["R0019500","Duodenal-Jejunal Bypass Maintains Gut Permeability by Suppressing Gut Inflammation.","Kashihara H","2019","Obesity surgery","preclinical","article","10.1007/s11695-019-03922-4","31209833",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019501","Nonoperative Case of Acute Type A Aortic Dissection in a Young Patient.","El-Andari R","2025","JACC. Case reports","case_report","article","10.1016/j.jaccas.2025.104177","40681234","PMC12441422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019502","Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus.","Al Zweihary AM","2024","Cureus","nonrandomized_study","article","10.7759/cureus.51788","38322055","PMC10844768",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0019503","Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes.","Imai K","2014","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/1758-5996-6-110","25349635","PMC4209043",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019504","Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.","Hankosky ER","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15318","37932236",null,null,"S000913","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019505","Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.","Eriksson O","2014","The Journal of clinical endocrinology and metabolism","case_report","article","10.1210/jc.2013-3541","24512490","PMC4010711",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019506","Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.","Han J","2013","Journal of medicinal chemistry","preclinical","article","10.1021/jm4017448","24308627",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019507","A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats.","Zhang Q","2019","PeerJ","preclinical","article","10.7717/peerj.6567","30863684","PMC6408912",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019508","Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1.","Sedman T","2016","Journal of diabetes research","preclinical","article","10.1155/2016/9239530","27069934","PMC4812441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019509","Semaglutide Updates, Hypertension Triple Pills, and More-Heart Health Highlights From ESC Congress.","Abbasi J","2024","JAMA","other","article","10.1001/jama.2024.19544","39365594",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019510","[Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)].","Chinese Thoracic Society","2026","Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","other","article","10.3760/cma.j.cn112147-20251108-00694","41820035",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Practice Guideline; English Abstract"],["R0019511","In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products.","Liao S","2015","PloS one","preclinical","article","10.1371/journal.pone.0116805","25723538","PMC4344207",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019512","Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats.","DellaValle B","2016","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2016.00433","27917122","PMC5114298",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019513","Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.","Perakakis N","2021","Liver international : official journal of the International Association for the Study of the Liver","randomized_trial","article","10.1111/liv.14888","33788377",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0019514","GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials.","Costantino S","2019","Vascular pharmacology","narrative_review","article","10.1016/j.vph.2019.03.003","30926561",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019515","Corrigendum to \"Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE -/- mice\" [Biochem. Pharmacol. 223 (2024) 116170].","Zhang K","2025","Biochemical pharmacology","notice","article","10.1016/j.bcp.2024.116707","39700676",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0019516","The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp.","Wu H","2014","Journal of diabetes research","preclinical","article","10.1155/2014/524517","25580440","PMC4279913",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019517","One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes.","Taybani ZJ","2023","Endocrinology, diabetes & metabolism","other_trial","article","10.1002/edm2.390","36461758","PMC9836254",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0019518","Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity.","Ouyang Y","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1580159","40475994","PMC12137074",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019519","Treating patients with diabetes of long duration: GLP-1 receptor agonists and insulin in combination.","Moghissi ES","2014","The Journal of the American Osteopathic Association","narrative_review","article","10.7556/jaoa.2014.086","24769505",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019520","Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real-world observational study.","Zhao X","2026","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70368","42332386","PMC13399391",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0019521","A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis.","Lee K","2022","General hospital psychiatry","systematic_review","article","10.1016/j.genhosppsych.2022.07.006","35863294",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0019522","Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells.","Chang JT","2017","BMC pharmacology & toxicology","preclinical","article","10.1186/s40360-017-0172-3","29065926","PMC5655807",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019523","FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report",null,"2023","Journal of the Endocrine Society","case_report","article",null,null,"PMC10554206",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019524","Treatment of obesity with liraglutide in cardiovascular prevention: Case series by the \"ITACARE-P Light-Heart Lab\" working group.","Maranta F","2024","International journal of cardiology. Cardiovascular risk and prevention","case_report","article","10.1016/j.ijcrp.2024.200272","39118985","PMC11305995",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019525","Bariatric outcomes of high BMI patients with preoperative anti-obesity medications.","Obermark AD","2025","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-025-11851-w","40640624",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0019526","Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.","Farr OM","2016","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2016.03.009","27282865","PMC4902873",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0019527","Lightening the Load: Generative AI to Mitigate the Burden of the New Era of Obesity Medical Therapy.","Stevens ER","2024","JMIR diabetes","other","article","10.2196/58680","39622675","PMC11611792",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019528","FRI612 Tirzepatide For The Treatment Of Post-bariatric Surgery Hypoglycemia And Early Dumping Syndrome",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10555241",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019529","Tirzepatide and Glycemic Control Metrics Using Continuous Glucose Monitoring in Older Patients with Type 2 Diabetes Mellitus: An Observational Pilot Study.","Omura T","2024","Geriatrics (Basel, Switzerland)","case_report","article","10.3390/geriatrics9020027","38525744","PMC10961786",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019530","Therapy for HFpEF: A step forward brings new hope for people with obesity and diabetes.","Lim LL","2024","Med (New York, N.Y.)","other","article","10.1016/j.medj.2024.06.011","39127032",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0019531","Uncovering the role of prokineticin pathway on Epicardial Adipose Tissue (EAT) development and EAT-associated cardiomyopathy.","Vincenzi M","2025","Trends in cardiovascular medicine","narrative_review","article","10.1016/j.tcm.2025.02.006","39955015",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0019532","Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK/mTOR Signaling Pathway.","Liao Z","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s447182","38343582","PMC10854402",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019533","Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.","Fralick M","2020","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj.m2812","32843476","PMC7445737",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019534","Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies.","Bagepally BS","2020","BMJ open diabetes research & care","systematic_review","article","10.1136/bmjdrc-2019-001020","32690574","PMC7371226","PROSPERO:CRD42018105193",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; review"],["R0019535","Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.","Giugliano D","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15892","39219442",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019536","Drug-Associated Parosmia: New Perspectives from the WHO Safety Database.","Merino D","2022","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm11164641","36012880","PMC9409668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019537","The effects of liraglutide on liver enzymes and metabolic factors in patients with nonalcoholic steatohepatitis: a meta-analysis of randomized controlled trials.","Malik A","2023","Przeglad gastroenterologiczny","systematic_review","article","10.5114/pg.2022.112775","37007754","PMC10050979",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0019538","Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation.","Deganutti G","2022","Nature communications","other","article","10.1038/s41467-021-27760-0","35013280","PMC8748714",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019539","Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2.","Koullias ES","2022","Journal of clinical and translational hepatology","narrative_review","article","10.14218/jcth.2021.00564","36304499","PMC9547270",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019540","Urinary Peptidomic Profiling In Post-Acute Sequelae of SARS-CoV-2 Infection: A Case-Control Study.","Gülmez D","2026","Proteomics","nonrandomized_study","article","10.1002/pmic.70074","41273049","PMC12809007",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0019541","Approach to Obesity in the Older Population.","Buch A","2021","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgab359","34406394",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019542","Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.","Wang W","2024","Nature communications","randomized_trial","article","10.1038/s41467-024-48780-6","38806481","PMC11133479",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019543","How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion.","Volpe M","2023","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2023.03.054","37001648",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0019544","Associations between self-stigma and health promotion behaviors in overweight/obese patients with type 2 diabetes: a cross-sectional study","Niu S","2024","Research Square","other","preprint","10.21203/rs.3.rs-4549917/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0019545","Glucagon-like peptide-1, fibroblast growth factor 21, and other endocrine responses to alcohol ingestion in women before and after metabolic surgery.","Molina-Castro M","2025","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2025.1575156","40474966","PMC12137268","ClinicalTrials.gov:NCT02766322",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019546","Bridging the gaps: recent advances in diagnosis, care, and outcomes in congenital hyperinsulinism.","Rosenfeld E","2023","Current opinion in pediatrics","narrative_review","article","10.1097/mop.0000000000001243","36974442","PMC10330427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0019547","Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling.","Seo MH","2016","PloS one","preclinical","article","10.1371/journal.pone.0166913","27907035","PMC5131969",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019548","Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.","Li YM","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00799-w","32219675","PMC7192982","ClinicalTrials.gov:NCT01644500","S001064","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0019549","Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health.","Saeed D","2023","Cureus","narrative_review","article","10.7759/cureus.51362","38292979","PMC10825078",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019550","Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.","Jorsal A","2017","European journal of heart failure","randomized_trial","article","10.1002/ejhf.657","27790809",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019551","Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study.","Ishii H","2017","Diabetology & metabolic syndrome","other_trial","article","10.1186/s13098-016-0202-0","28074109","PMC5219656","UMIN:UMIN000007159",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0019552","The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity.","Khalilnezhad A","2019","The International journal of neuroscience","preclinical","article","10.1080/00207454.2018.1543671","30422728",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019553","Let's Be More Sensitive-How SGLT-2 Inhibitors and GLP-1 Receptor Agonists Affect β-Cell Function in Type 2 Diabetes.","Pratley R","2020","The Journal of clinical endocrinology and metabolism","commentary","article","10.1210/clinem/dgaa666","33074334",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0019554","The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.","Pi-Sunyer FX","2009","Postgraduate medicine","narrative_review","article","10.3810/pgm.2009.09.2056","19820278","PMC2879281",null,"S002357","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0019555","FRI483 Changes In Thyroid Function Test With Tirzepatide Use In Patients With Hypothyroidism",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10555370",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019556","Reply - \"Letter to the Editor-Very-low calorie diet and Semaglutide: Synergy and long-term impact on type 2 diabetes management\".","Anyiam O","2024","Clinical nutrition (Edinburgh, Scotland)","commentary","article","10.1016/j.clnu.2024.10.033","39515068",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0019557","The role of G protein-coupled receptor kinases in GLP-1R β-arrestin recruitment and internalisation.","McNeill SM","2024","Biochemical pharmacology","other","article","10.1016/j.bcp.2024.116119","38461904",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019558","Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial.","Pandey A","2024","Journal of cachexia, sarcopenia and muscle","randomized_trial","article","10.1002/jcsm.13445","38561962","PMC11154779",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0019559","Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism.","Lutz TA","2016","Current opinion in lipidology","narrative_review","article","10.1097/mol.0000000000000293","27031273",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019560","Human EndoC-βH1 β-cells form pseudoislets with improved glucose sensitivity and enhanced GLP-1 signaling in the presence of islet-derived endothelial cells.","Spelios MG","2018","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00272.2017","29351476",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019561","Addressing Meta-Inflammation in the Comprehensive Management of Chronic Pain.","McMasters M","2025","Cureus","narrative_review","article","10.7759/cureus.94863","41257114","PMC12621917",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019562","The metabolic effect of combined liraglutide treatment and lifestyle modification on obese adolescents in a tertiary center, Riyadh.","Babiker A","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1573109","40303643","PMC12037372",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019563","The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice.","Pacini G","2024","Peptides","preclinical","article","10.1016/j.peptides.2023.171117","37984684",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019564","Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects.","Wang Z","2018","Endocrinology, diabetes & metabolism","other","article","10.1002/edm2.9","30815546","PMC6360918",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019565","Improvement of psoriasis during exenatide treatment in a patient with diabetes.","Buysschaert M","2012","Diabetes & metabolism","case_report","article","10.1016/j.diabet.2011.11.004","22227407",null,null,"S001754","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Case Reports; Journal Article; article"],["R0019566","Comparative Efficacy and Safety of Resmetirom Versus Semaglutide in Treating MASH and MASLD: A Network Meta-Analysis.","Ayesh H","2025","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000001808","39297757",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0019567","Liraglutide: Weight loss injection is effective in children aged 6-11, study reports.","Mahase E","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1998","39260881",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0019568","Differential risk of systemic complications and mortality in HFrEF and HFpEF patients undergoing total knee arthroplasty: A nationwide propensity matched study with cox regression analysis.","Wahid M","2025","Journal of orthopaedic surgery (Hong Kong)","nonrandomized_study","article","10.1177/10225536251395952","41187943",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0019569","Physiology, Gastric Inhibitory Peptide","Patel T","2025","StatPearls Publishing, Treasure Island (FL)","preclinical","article",null,"31536259",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0019570","A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes.","Feng P","2023","Advances in therapy","randomized_trial","article","10.1007/s12325-023-02536-8","37285081","PMC10329955","ClinicalTrials.gov:NCT04235959","S000277","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019571","Prescription Fills for Semaglutide Products by Payment Method.","Scannell C","2024","JAMA health forum","other","article","10.1001/jamahealthforum.2024.2026","39093590","PMC11297375",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019572","Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.","Lim S","2023","Nutrients","randomized_trial","article","10.3390/nu15010248","36615904","PMC9824054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0019573","From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling.","Santulli G","2026","Cardiovascular diabetology. Endocrinology reports","preclinical","article","10.1186/s40842-026-00321-4","42351310","PMC13308489",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019574","Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-analysis.","de Moraes FCA","2024","Obesity surgery","systematic_review","article","10.1007/s11695-024-07384-1","38987454",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0019575","Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia.","Aguilar-Ballester M","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22020660","33440821","PMC7826980",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019576","A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.","Noyan-Ashraf MH","2013","Circulation","preclinical","article","10.1161/circulationaha.112.091215","23186644",null,null,"S000371","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019577","[Impact on weight loss and body composition of a food education intervention associated with Liraglutide treatment to address obesity].","Dearos Sanchis M","2024","Nutricion hospitalaria","randomized_trial","article","10.20960/nh.04995","38450509",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; English Abstract; article"],["R0019578","Exendin-4 protects hindlimb ischemic injury by inducing angiogenesis.","Kang HM","2015","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2015.08.080","26299927",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019579","Too much of a good thing.","Varghese D","2026","Survey of ophthalmology","case_report","article","10.1016/j.survophthal.2026.01.001","41520798",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0019580","Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease.","Katsarou A","2024","Hormones (Athens, Greece)","randomized_trial","article","10.1007/s42000-024-00588-1","39112786",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0019581","Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway.","Ao N","2020","Peptides","preclinical","article","10.1016/j.peptides.2020.170375","32771373",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019582","The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.","Gasbjerg LS","2023","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.15216","37551549",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019583","Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis.","Dar S","2022","Annals of medicine and surgery (2012)","systematic_review","article","10.1016/j.amsu.2022.103633","35637990","PMC9142616",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0019584","Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.","Mollan SP","2024","JAMA ophthalmology","commentary","article","10.1001/jamaophthalmol.2024.2514","38958953",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; article"],["R0019585","Deciphering the Effects of Semaglutide Across the Glycemic Spectrum.","Misra S","2024","Diabetes care","commentary","article","10.2337/dci24-0057","38907681",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0019586","Cav3.1 is a neuronal leucine sensor that mediates satiety and weight loss in response to dietary protein.","Tsang AH","2026","Cell metabolism","preclinical","article","10.1016/j.cmet.2026.03.017","42025169",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019587","THU255 Tirzepatide-induced Weight Loss In A Type 2 Diabetic Taking Oral Contraceptives",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10555013",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019588","[How is the management of diabetic hypertensive patients different?].","Dufey Teso A","2022","Revue medicale suisse","other","article","10.53738/revmed.2022.18.795.1710","36103122",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019589","[Gastroenterology and hepatology : what's new in 2025].","Fraga M","2026","Revue medicale suisse","narrative_review","article","10.53738/revmed.2026.22.945.48122","41540864",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0019590","Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus, With or Without Cardiovascular Disease: A Systematic Review and Meta-Analysis of 10,013 Patients.","Raja A","2025","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000001828","40338694",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0019591","Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study.","Patel S","2019","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2019-000761","31803482","PMC6887507","ClinicalTrials.gov:NCT01966978","S002252","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Pragmatic Clinical Trial; research-article; article"],["R0019592","Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges.","Riboldi I","2024","Alpha psychiatry","narrative_review","article","10.5152/alphapsychiatry.2024.241464","39148594","PMC11322710",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019593","Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.","Kanbay M","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15272","37700437",null,null,"S001084","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Journal Article; article"],["R0019594","Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.","Ramos M","2021","Cost effectiveness and resource allocation : C/E","other_trial","article","10.1186/s12962-021-00299-z","34348729","PMC8336098",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0019595","Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice.","He L","2017","Scientific reports","preclinical","article","10.1038/s41598-017-01952-5","28496193","PMC5431757",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019596","Liraglutide Attenuates Endothelial Dysfunction by Inhibiting Hyperglycemia-Induced Endothelial Cell Senescence Through the LARP7/SIRT1 Pathway.","Zhong W","2026","Archivum immunologiae et therapiae experimentalis","other","article","10.2478/aite-2026-0006","41343751",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019597","Liraglutide Attenuates Gentamicin-Induced Nephrotoxicity in Rats by Reducing Oxidative Stress","Degirmentepe RB","2024","Authorea Preprints","preclinical","preprint","10.22541/au.170667637.73384804/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; article; preprint"],["R0019598","The potential of precision diabetology for type 2 diabetes treatment-evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials.","Kuss O","2025","Acta diabetologica","systematic_review","article","10.1007/s00592-024-02425-8","39666113","PMC12283822",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; article"],["R0019599","Improvement of Transdermal Delivery of Exendin-4 Using Novel Tip-Loaded Microneedle Arrays Fabricated from Hyaluronic Acid.","Liu S","2016","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.5b00765","26649921",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019600","Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets.","Tudurí E","2016","Trends in endocrinology and metabolism: TEM","preclinical","article","10.1016/j.tem.2016.03.004","27062006",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0019601","Liraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis.","Bozadjieva-Kramer N","2024","Endocrinology","preclinical","article","10.1210/endocr/bqae090","39045670","PMC11311705",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019602","Six Substudies From the Semaglutide Trials: Identifying Mechanisms of Benefit and Whom to Treat.","Pagidipati NJ","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.08.038","39218241",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0019603","Salcaprozate Sodium as a Permeation Enhancer-Mechanism, Applications and Unresolved Questions.","Dinkov B","2026","Pharmaceutics","preclinical","article","10.3390/pharmaceutics18091171","42797346","PMC13610844",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019604","Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.","Shah VN","2025","Journal of diabetes science and technology","randomized_trial","article","10.1177/19322968241305647","39717993","PMC11669135","ClinicalTrials.gov:NCT01836523; ClinicalTrials.gov:NCT02098395","S001732; S002341","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; meeting-report; article"],["R0019605","SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes.","Gajos G","2024","Cardiology journal","commentary","article","10.5603/cj.102158","39287154","PMC11544414",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0019606","Unraveling Chronic Cardiovascular and Kidney Disorder through the Butterfly Effect.","Bedo D","2024","Diagnostics (Basel, Switzerland)","narrative_review","article","10.3390/diagnostics14050463","38472936","PMC10930393",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019607","Editorial Comment: Retrospective Opportunistic CT for Assessment of Changes in Body Composition Related to Semaglutide Therapy.","Crim J","2024","AJR. American journal of roentgenology","nonrandomized_study","article","10.2214/ajr.24.32063","39320356",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comment; Editorial; Journal Article; editorial"],["R0019608","Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S226–S232","Jiten P Vora","2013","Diabetes care","other","article","10.2337/dc13-er12b",null,"PMC3836119",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","correction; Corrected and Republished Article; article"],["R0019609","Neuroprotective Effects of Liraglutide and/or Rivastigmine Combination on the Rat Hippocampus.","Abdel-Aal RA","2025","Drug development research","preclinical","article","10.1002/ddr.70160","41000001",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019610","Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment.","Balestrieri ML","2015","Diabetes","preclinical","article","10.2337/db14-1149","25325735",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019611","Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.","Da Porto A","2020","Diabetes & metabolic syndrome","randomized_trial","article","10.1016/j.dsx.2020.03.009","32289741",null,null,"S002311","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0019612","Tirzepatide: A promising treatment for obesity?","Niedbala CG","2023","JAAPA : official journal of the American Academy of Physician Assistants","other","article","10.1097/01.jaa.0000979484.51712.33","37884034",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019613","Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages.","Tate M","2016","Basic research in cardiology","preclinical","article","10.1007/s00395-015-0518-1","26597728","PMC4656717",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019614","Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex.","Verma S","2024","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2024.08.022","39217575",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019615","Corrigendum to \"Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes\" [J. Clin. Translat. Endoc. 36C (2024) 100343].","Mohammed Mahzari M","2024","Journal of clinical & translational endocrinology","notice","article","10.1016/j.jcte.2024.100360","39764278","PMC11701984",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0019616","Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases.","Ashraf AR","2024","JAMA network open","other","article","10.1001/jamanetworkopen.2024.28280","39093567","PMC11297364",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019617","The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis.","Yan W","2019","Life sciences","preclinical","article","10.1016/j.lfs.2019.116566","31201846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019618","Pharmacological management of type 2 diabetes: the potential of incretin-based therapies.","Charbonnel B","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2010.01317.x","21199262",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019619","Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).","Nathan DM","2013","Diabetes care","protocol","article","10.2337/dc13-0356","23690531","PMC3714493",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019620","Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes.","Chaudhuri A","2011","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2011.01423.x","21569185",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019621","Albiglutide: Is a better hope against diabetes mellitus?","Sharma AK","2016","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","other_trial","article","10.1016/j.biopha.2015.12.015","26796275",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0019622","Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.","Jones RB","2014","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2014.02.004","24530555",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019623","The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy.","Almutairi M","2021","The Canadian journal of cardiology","nonrandomized_study","article","10.1016/j.cjca.2020.02.098","32640211",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019624","Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and 68Ga-DOTATATE PET/CT.","Bongetti E","2018","Clinical case reports","case_report","article","10.1002/ccr3.1448","29636947","PMC5889260",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019625","2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Buse JB","2020","Diabetologia","other","article","10.1007/s00125-019-05039-w","31853556",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Consensus Statement"],["R0019626","68Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic β-cell and insulinoma.","Li L","2021","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2021.10.001","34695640",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019627","Comment on the Meta-analysis of Liraglutide for Weight Regain: Methodological Considerations.","Conte C","2024","Obesity surgery","systematic_review","article","10.1007/s11695-024-07445-5","39126592",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Comment; review"],["R0019628","Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder.","Wang W","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.35247","39320894","PMC11425147",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; research-article; article"],["R0019629","Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.","Miller LA","2012","Journal of medical economics","nonrandomized_study","article","10.3111/13696998.2012.679756","22443463",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019630","MicroRNA-451a downregulation in liraglutide-treated individuals with diabetes: A potential cardiovascular protective mechanism.","Kongrat S","2024","Diabetes & vascular disease research","commentary","article","10.1177/14791641241278527","39325062","PMC11437537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Research Support, Non-U.S. Gov't; Journal Article; letter; article"],["R0019631","The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs.","Zhan JK","2015","International journal of cardiology","other","article","10.1016/j.ijcard.2015.04.086","25897902",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019632","Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients.","Ballav C","2020","Endocrinology, diabetes & metabolism","randomized_trial","article","10.1002/edm2.130","32704555","PMC7375047",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019633","SUN-347 Glucagon-like Peptide 1 (GLP-1) Acts Directly On Human Osteoclasts To Increase Differentiation And Bone Resorptive Activity","Hansen M","2020","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaa046.080",null,"PMC7208122",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0019634","PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice.","Catrina SB","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01614-6","39052163","PMC11330427","ClinicalTrials.gov:NCT04601753","S001039","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019635","Common food additive carrageenan inhibits proglucagon expression and GLP-1 secretion by human enteroendocrine L-cells.","Bhattacharyya S","2024","Nutrition & diabetes","preclinical","article","10.1038/s41387-024-00284-4","38755184","PMC11099076",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019636","Exendin-4 protects HUVECs from t-BHP-induced apoptosis via PI3K/Akt-Bcl-2-caspase-3 signaling.","Wang L","2016","Endocrine research","other","article","10.3109/07435800.2015.1110162","27030608",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019637","Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice.","Nonogaki K","2018","Journal of diabetes research","preclinical","article","10.1155/2018/6482958","29484303","PMC5816835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019638","Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.","Ryan GJ","2011","Journal of clinical pharmacy and therapeutics","narrative_review","article","10.1111/j.1365-2710.2010.01180.x","21545609",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019639","Prevention of Type 2 Diabetes in Adults","Ackermann RT","2023","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda (MD)","nonrandomized_study","article",null,"41284805",null,null,null,"europepmc","TRUE","free_to_read","4",null,"Review"],["R0019640","A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy.","Ampofo E","2026","Obesity science & practice","systematic_review","article","10.1002/osp4.70188","42707648","PMC13547837",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0019641","Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry.","Echouffo-Tcheugui JB","2022","The American journal of medicine","nonrandomized_study","article","10.1016/j.amjmed.2022.06.016","35872090",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0019642","Correlation of HbA1c levels with CT-based body composition biomarkers in diabetes mellitus and metabolic syndrome.","Warner JD","2024","Scientific reports","nonrandomized_study","article","10.1038/s41598-024-72702-7","39300115","PMC11413398",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; article"],["R0019643","Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial.","Yang X","2024","Heliyon","other_trial","article","10.1016/j.heliyon.2023.e23309","38169889","PMC10758788",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0019644","Author Correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.","Wadden TA","2024","Nature medicine","notice","article","10.1038/s41591-024-02883-1","38409593","PMC11186756",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0019645","The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.","Froud T","2008","Transplantation","other","article","10.1097/tp.0b013e31817c4ab3","18622276","PMC2772201",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019646","Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors: A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase®.","Gautier P","2025","Drug safety","nonrandomized_study","article","10.1007/s40264-025-01546-5","40232585","PMC12259762",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019647","Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.","Perkovic V","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2403347","38785209",null,"ClinicalTrials.gov:NCT03819153","S000018; S000128; S000953; S002468; S002481; S002726","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, N.I.H., Extramural; article"],["R0019648","Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.","Karras SN","2017","Current clinical pharmacology","nonrandomized_study","article","10.2174/1574884713666180221121512","29473524",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0019649","Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter.","Alvarez-Mon MA","2021","Journal of medical Internet research","nonrandomized_study","article","10.2196/24336","34698653","PMC8579215",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0019650","Efficacy and Safety of FGF21 Versus Semaglutide in the Management of Metabolic-Associated Steatotic Liver Disease: A Network Meta-analysis.","Ayesh H","2024","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000001814","39297747",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0019651","Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism.","Lee MY","2019","International journal of molecular sciences","preclinical","article","10.3390/ijms20184569","31540136","PMC6769880",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019652","Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.","Kramer CK","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12858","28181363",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0019653","Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet.","Duan X","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.176440","38402930",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019654","Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes.","Gazda CL","2021","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23146","33818009",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019655","The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.","Kounatidis D","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00612-4","39934485",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019656","Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.","Bao Y","2024","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.24030","38803303",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0019657","Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy.","Marchand L","2021","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.14390","32799379",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019658","Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes.","Greco D","2015","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/dme.12726","25683470",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0019659","Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial.","Wexler DJ","2025","Diabetes care","randomized_trial","article","10.2337/dc24-2825","40267365","PMC12094209",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0019660","Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes.","Sommer WH","2025","Current topics in behavioral neurosciences","nonrandomized_study","article","10.1007/7854_2025_586","40646424",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0019661","Advances in the pathophysiology, diagnosis and management of chronic diarrhoea from bile acid malabsorption: a systematic review.","Di Ciaula A","2024","European journal of internal medicine","systematic_review","article","10.1016/j.ejim.2024.07.008","39069430",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; review"],["R0019662","Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.","Hari Kumar KV","2013","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2013.01.020","23490599",null,"ClinicalTrials.gov:NCT01235819","S001475","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0019663","Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.","Wang W","2024","Diabetologia","randomized_trial","article","10.1007/s00125-024-06142-3","38985162","PMC11410837","ClinicalTrials.gov:NCT04109547","S001791","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; research-article; article"],["R0019664","Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information-Based Mapping Exercises Across the 42 Integrated Care Boards of England.","de Bray A","2026","Clinical obesity","other","article","10.1111/cob.70044","40931685","PMC12705252",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019665","Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations.","Skrivanek Z","2012","Journal of diabetes science and technology","randomized_trial","article","10.1177/193229681200600609","23294775","PMC3570870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; conference-abstract"],["R0019666","Diagnosis, treatment and prevention of type 2 diabetes mellitus in children and adolescents.","Serbis A","2021","World journal of diabetes","narrative_review","article","10.4239/wjd.v12.i4.344","33889284","PMC8040084",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Review; review-article"],["R0019667","A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.","Bækdal TA","2018","Expert opinion on drug metabolism & toxicology","randomized_trial","article","10.1080/17425255.2018.1488965","29897249",null,null,"S000195","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; other; article"],["R0019668","Neuroprotective effects of incretin mimetics upon chronic endoplasmic reticulum (ER) stress : implications for novel therapeutic pathways and opportunities in Alzheimer's disease","Panagaki T","2018","Lancaster University","other_trial","article","10.17635/lancaster/thesis/324",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","5","FALSE","Dissertation; dissertation"],["R0019669","Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months).","Ruseva A","2025","Postgraduate medicine","nonrandomized_study","article","10.1080/00325481.2025.2482274","40122077",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0019670","Exendin-4 decreases amphetamine-induced locomotor activity.","Erreger K","2012","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2012.03.014","22465309","PMC3348974",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019671","Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice.","Gumuslu E","2016","Fundamental & clinical pharmacology","preclinical","article","10.1111/fcp.12192","26935863",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019672","Glycaemic Control in Diabetes","Müller-Wieland D","2022","Springer, Cham (CH)","narrative_review","article",null,"36122114",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0019673","GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.","Jolivalt CG","2011","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2011.01431.x","21635674","PMC3177968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019674","Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.","de Lemos JA","2024","Hypertension (Dallas, Tex. : 1979)","commentary","article","10.1161/hypertensionaha.123.22022","38314555","PMC10956672","ClinicalTrials.gov:NCT04184622","S001077","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0019675","Exenatide, a GLP-1 analog, has healing effects on LPS-induced autism model: Inflammation, oxidative stress, gliosis, cerebral GABA, and serotonin interactions.","Solmaz V","2020","International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","preclinical","article","10.1002/jdn.10056","32745285",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019676","Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.","Taylor K","2011","BMC endocrine disorders","other_trial","article","10.1186/1472-6823-11-9","21529363","PMC3112417","ClinicalTrials.gov:NCT00308139","S002279","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0019677","Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study.","Chou CC","2025","Ophthalmology","nonrandomized_study","article","10.1016/j.ophtha.2024.10.030","39491755",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0019678","Accessibility of Diabetes Therapy Management for Patients with Visual Impairment.","Nguyen C","2024","Innovations in pharmacy","nonrandomized_study","article","10.24926/iip.v15i3.6233","39483511","PMC11524210",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0019679","Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.","Mosenzon O","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14126","32618386","PMC7689857",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0019680","Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells.","Krause GC","2017","European journal of pharmacology","other","article","10.1016/j.ejphar.2017.05.015","28501576",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019681","Role of intestinal glucagon-like peptide-1 in impaired counter-regulatory responses to hypoglycemia.","Dodamani MH","2024","World journal of diabetes","preclinical","article","10.4239/wjd.v15.i12.2394","39676808","PMC11580583",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0019682","Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice.","Liu Q","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.118457","32961235",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019683","Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetes.","Gong JY","2024","Internal medicine journal","case_report","article","10.1111/imj.16499","39239945",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Case Reports; article"],["R0019684","Idiopathic and Metabolic Triggers Leading to Recurrent Acute Pancreatitis in a 30-Year-Old Woman.","Ahmed F","2025","Hospital pharmacy","case_report","article","10.1177/00185787251321072","39981190","PMC11836965",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019685","Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide.","Voukali M","2014","Journal of diabetes research","randomized_trial","article","10.1155/2014/304032","25165723","PMC4137738",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0019686","Semaglutide in people with HIV-associated lipohypertrophy.","Hwang YJ","2024","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(24)00162-1","38964354",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0019687","Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class.","Bain EK","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14487","34324260",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0019688","Semaglutide, COVID-19 Mortality, and the Power of Harnessing Ongoing Clinical Trials During Unexpected Outbreaks.","Faust JS","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.08.035","39217571",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0019689","Development of a new thiol site-specific prosthetic group and its conjugation with [Cys(40)]-exendin-4 for in vivo targeting of insulinomas.","Yue X","2013","Bioconjugate chemistry","preclinical","article","10.1021/bc400084u","23750453","PMC3779517",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019690","The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors.","Dickson SL","2012","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.6326-11.2012","22492036","PMC6620919",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019691","Comment on: \"Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus\".","Raschi E","2015","Clinical pharmacokinetics","commentary","article","10.1007/s40262-015-0248-4","25721222",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; letter"],["R0019692","Current Perspectives in Pre- and Diabetic Peripheral Neuropathy Diagnosis and Management: An Expert Statement for the Gulf Region.","Beshyah SA","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-024-01658-8","39460909","PMC11561195",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019693","Combination therapy with Exendin-4 and islet transplantation as a synergistic treatment for diabetic nephropathy in rats.","Xie Z","2021","Life sciences","preclinical","article","10.1016/j.lfs.2021.119207","33571517",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019694","Tirzepatide Lowered Blood Pressure in People With Obesity.","Harris E","2024","JAMA","other","article","10.1001/jama.2024.0726","38381469",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019695","TERT/FOXO1 signaling promotes islet β-cell dysfunction in type 2 diabetes mellitus by regulating ATG9A-mediated autophagy.","Lei XT","2025","World journal of diabetes","preclinical","article","10.4239/wjd.v16.i5.102994","40487620","PMC12142190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019696","Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.","Tong L","2018","Postgraduate medicine","narrative_review","article","10.1080/00325481.2018.1457397","29667921",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019697","Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies.","Thompson SE","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13030624","40149601","PMC11940501",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019698","Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.","Bruinstroop E","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0438-9","29779196","PMC5984941",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; case-report; other; article"],["R0019699","Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.","Darbalaei S","2020","Biochemical pharmacology","other","article","10.1016/j.bcp.2020.114150","32682761",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019700","Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.","Himeno T","2011","Diabetes","preclinical","article","10.2337/db10-1462","21810596","PMC3161330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019701","Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy: A case report.","Ding B","2021","Medicine","case_report","article","10.1097/md.0000000000026086","34032745","PMC8154494",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019702","GLP-1 Limits Adipocyte Inflammation and Its Low Circulating Pre-Operative Concentrations Predict Worse Type 2 Diabetes Remission after Bariatric Surgery in Obese Patients.","Izaguirre M","2019","Journal of clinical medicine","other","article","10.3390/jcm8040479","30970605","PMC6518381",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019703","Semaglutide: UK regulator approves drug for prevention of cardiovascular events.","Iacobucci G","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1660","39053933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0019704","Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study.","Yao MY","2020","Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","randomized_trial","article","10.1590/1414-431x20198652","31859911","PMC6915907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0019705","Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.","Irwin N","2010","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2009.11.022","19917278",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019706","Emphasizing the use of semaglutide; a significant advancement in the management of chronic kidney disease in diabetic patients.","Fasieh H","2025","International urology and nephrology","commentary","article","10.1007/s11255-024-04185-4","39158628",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019707","A biodegradable suction patch for sustainable transbuccal peptide delivery.","Krupke H","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.113947","40513668",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019708","[Effects of exendin-4 on extracellular matrix metabolism in human mesangial cells cultured in high glucose].","Xiao ZZ","2016","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","other","article",null,"27063165",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019709","Semaglutide treatment for children with obesity: an observational study.","van Boxel EJ","2024","Archives of disease in childhood","nonrandomized_study","article","10.1136/archdischild-2023-326687","38471743",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0019710","Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.","Henry RR","2013","Diabetes care","randomized_trial","article","10.2337/dc12-2410","23645886","PMC3747935","ClinicalTrials.gov:NCT00943917","S001812","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0019711","Insulin deficiency, but not resistance, exaggerates cognitive deficits in transgenic mice expressing human amyloid and tau proteins. Reversal by Exendin-4 treatment.","King MR","2020","Journal of neuroscience research","preclinical","article","10.1002/jnr.24706","32737929",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0019712","Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review.","Koshatwar M","2023","Cureus","preclinical","article","10.7759/cureus.44763","37809189","PMC10556988",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019713","Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.","Dhanesha N","2013","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2013.06.015","23810686",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019714","[Diabetes and cognitive decline - An often overlooked association].","Sjöholm Å","2023","Lakartidningen","other","article",null,"37317892",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0019715","Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.","Chaitoff A","2024","Annals of internal medicine","commentary","article","10.7326/annals-24-00308","39186788",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019716","What the SELECT trial of semaglutide means for clinicians.","Sattar N","2024","Nature medicine","other_trial","article","10.1038/s41591-024-03013-7","38796654",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","News; Comment; article"],["R0019717","GLP-1R agonist therapy for diabetes: benefits and potential risks.","Samson SL","2013","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0b013e32835edb32","23403741",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; article"],["R0019718","Continuous Glucose Monitoring and the Effect of Liraglutide in Cardiac Surgery Patients: A Substudy of the Randomized Controlled GLOBE Trial.","Oosterom-Eijmael MJP","2024","Journal of cardiothoracic and vascular anesthesia","randomized_trial","article","10.1053/j.jvca.2024.06.015","38977382",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0019719","Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.","Knudsen LB","2013","Diabetes care","commentary","article","10.2337/dc13-1134","24265382","PMC3836151",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0019720","Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.","Bauman A","2015","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.115.159186","26251418",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019721","The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.","Withaar C","2021","Cardiovascular research","preclinical","article","10.1093/cvr/cvaa256","32871009","PMC8318109",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019722","Characteristics of the clinical treatment of Brazilian and French older adults with diabetes.","Bezerra CB","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.109088","34648889",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0019723","Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials.","Li H","2022","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph15080953","36015100","PMC9412496",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0019724","Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-κB pathway.","Ma GF","2014","Acta pharmacologica Sinica","preclinical","article","10.1038/aps.2013.128","24335838","PMC4651214",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019725","Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","Ali MM","2022","BMC endocrine disorders","systematic_review","article","10.1186/s12902-022-01031-5","35488292","PMC9055739","PROSPERO:CRD42021257670",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; other; review"],["R0019726","Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.","McCrimmon RJ","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-022-01267-3","35543869","PMC9174356",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019727","Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis.","Chen S","2016","Neuroscience letters","preclinical","article","10.1016/j.neulet.2015.12.007","26679229",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0019728","Real-life use of liraglutide 3 mg in obesity management: The SAX-RL study.","Goëau-Brissonnière M","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15845","39169527",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019729","Neuroprotective and glucoregulatory actions of incretin-based therapies in obesity and diabetes","Porter WD","2011","Ulster University","preclinical","article",null,null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0019730","Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.","Selvaraju RK","2014","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2014.03.017","24857864",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0019731","[Lixisenatide (Lyxumia), subcutaneous].",null,"2014","Journal de pharmacie de Belgique","other","article",null,"25055456",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019732","Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight.","Baggio LL","2014","The Journal of clinical investigation","commentary","article","10.1172/jci78371","25202976","PMC4191040",null,"S001853","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; article-commentary; article"],["R0019733","Semaglutide: FDA publishes warning amid reports of patients overdosing.","Mahase E","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1696","39079728",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0019734","PSAT043 Liraglutide Ameliorates Symptoms of Cushing Syndrome in a Pediatric Patient",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9624795",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019735","Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery.","Pechenov S","2017","Advanced drug delivery reviews","narrative_review","article","10.1016/j.addr.2017.01.006","28153578",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019736","AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.","Grunvald E","2022","Gastroenterology","other","article","10.1053/j.gastro.2022.08.045","36273831",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Practice Guideline; Journal Article"],["R0019737","Ectopic insulinoma: case report.","Sun M","2019","BMC surgery","case_report","article","10.1186/s12893-019-0661-y","31852474","PMC6921582",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019738","A two-step method preparation of semaglutide through solid-phase synthesis and inclusion body expression.","Peng D","2024","Protein expression and purification","other","article","10.1016/j.pep.2024.106477","38527576",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019739","Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL).","Kaneto H","2022","Advances in therapy","other","article","10.1007/s12325-022-02311-1","36207508","PMC9618543",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019740","Semaglutide lowers body weight in rodents via distributed neural pathways.","Gabery S","2020","JCI insight","preclinical","article","10.1172/jci.insight.133429","32213703","PMC7213778",null,"S001761","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019741","Late-stage generation of 14C/3H-radiolabeled lysine residues via hydroformylation of peptides.","Schick A","2026","Nature communications","other","article","10.1038/s41467-026-74115-8","42285941","PMC13272800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019742","Uncovering the potential molecular mechanism of liraglutide to alleviate the effects of high glucose on myoblasts based on high-throughput transcriptome sequencing technique.","Fan D","2024","BMC genomics","other","article","10.1186/s12864-024-10076-w","38331723","PMC10851481",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0019743","GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.","Fyfe MC","2008","Expert opinion on drug discovery","other","article","10.1517/17460441.3.4.403","23489096",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019744","The Diabetes-Cardiovascular Connection in Women: Understanding the Known Risks, Outcomes, and Implications for Care.","Broni EK","2022","Current diabetes reports","narrative_review","article","10.1007/s11892-021-01444-x","35157237",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review"],["R0019745","Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.","McCrimmon RJ","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14825","36054624","PMC9804337",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019746","Peptide Oligomerization Memory Effects and Their Impact on the Physical Stability of the GLP-1 Agonist Liraglutide.","Bothe JR","2019","Molecular pharmaceutics","nonrandomized_study","article","10.1021/acs.molpharmaceut.9b00106","30990695",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0019747","Adverse effects with semaglutide: a protocol for a systematic review with meta-analysis and trial sequential analysis.","Sillassen CDB","2024","BMJ open","systematic_review","article","10.1136/bmjopen-2024-084190","38908837","PMC11331358","PROSPERO:CRD42024499511",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0019748","Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.","Abd El Aziz M","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13924","31750601",null,null,"S000313","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; article"],["R0019749","Ameliorative Impact of Liraglutide on Chronic Intermittent Hypoxia-Induced Atrial Remodeling.","Wang J","2022","Journal of immunology research","preclinical","article","10.1155/2022/8181474","35465349","PMC9020937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retracted Publication; research-article; article"],["R0019750","Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives.","Varda L","2026","Kidney & blood pressure research","preclinical","article","10.1159/000550085","41632731","PMC12962719",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019751","The association between previous use of anti-obesity medication and semaglutide weight loss outcomes.","Ghusn W","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15523","38469598",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0019752","Boosting GLP-1 by Natural Products.","Yaribeygi H","2021","Advances in experimental medicine and biology","other","article","10.1007/978-3-030-73234-9_36","34981502",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019753","Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial.","Pedicino D","2024","European heart journal","randomized_trial","article","10.1093/eurheartj/ehae429","38985093",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0019754","A national audit of facilities, human and material resources for the comprehensive management of diabetes in Ghana-A 2023 update.","Yorke E","2024","PloS one","other","article","10.1371/journal.pone.0303624","38768080","PMC11104593",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019755","Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.","Herrington WG","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejme2406408","38986062",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Editorial; article"],["R0019756","Semaglutide mitigates testicular damage in diabetes by inhibiting ferroptosis.","Zhou L","2024","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2024.149996","38678781",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019757","Atypical Antipsychotics-Induced Glucose and Lipid Metabolism Disorders and Therapeutic Intervention.","Xia A","2026","Journal of applied toxicology : JAT","nonrandomized_study","article","10.1002/jat.70036","41387116",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0019758","Weekly journal scan: SURMOUNTing body weight regain with tirzepatide after successful lifestyle intervention.","Liuzzo G","2024","European heart journal","randomized_trial","article","10.1093/eurheartj/ehae076","38365916",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0019759","Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.","Matza LS","2018","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2018.1465903","29661026",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0019760","Very-low calorie diet and Semaglutide: Synergy and long-term impact on type 2 diabetes management.","Zheng Z","2024","Clinical nutrition (Edinburgh, Scotland)","commentary","article","10.1016/j.clnu.2024.09.008","39265294",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019761","The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats.","Skarbaliene J","2015","Peptides","preclinical","article","10.1016/j.peptides.2015.03.024","25849341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019762","Influence of Hydrophobic Ion Pairing on Formulation Performance of Liraglutide in PLGA Microspheres.","Vitore JG","2025","AAPS PharmSciTech","other","article","10.1208/s12249-025-03195-4","40730914",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019763","Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.","Ghusn W","2024","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-023-01456-5","38302591",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0019764","In adults with obesity and knee OA, adding weekly semaglutide to diet and activity counseling reduced weight and knee pain at 68 wk.","Bell DSH","2025","Annals of internal medicine","other","article","10.7326/annals-24-03988-jc","39899871",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019765","Ineffectiveness of tirzepatide in mitigating Doxorubicin-induced oxidative stress and cognitive deficits in a rat model.","Alolayan SA","2025","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2025.1638527","40894223","PMC12392119",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019766","Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.","Colhoun HM","2024","Nature medicine","other_trial","article","10.1038/s41591-024-03015-5","38796653","PMC11271413","ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0019767","THU296 Effect Of Tirzepatide In GADA-positive Individuals With T2D: A Post Hoc Analysis Of The SURPASS 2-5 Trials",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10555850",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019768","Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinositide 3-kinase.","MacDonald PE","2004","Endocrinology","preclinical","article","10.1210/en.2004-0028","15231713",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019769","Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.","Rizzo M","2009","Expert opinion on investigational drugs","narrative_review","article","10.1517/14728220903241633","19758106",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019770","Pancreatic safety of newer incretin-based therapies: are the \"-tides\" finally turning?","Devaraj S","2014","Diabetes","other_trial","article","10.2337/db14-0545","24962922",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Comment; article"],["R0019771","GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A.","Dai Y","2014","Journal of cardiovascular pharmacology","other","article","10.1097/fjc.0000000000000087","24705175",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0019772","Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.","Haraguchi A","2014","Minerva endocrinologica","nonrandomized_study","article",null,"25371055",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019773","Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats.","Abdel-Latif RG","2018","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-018-1497-1","29671019",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019774","Prescribing trends of glucose-lowering drugs in older adults from 2010 to 2021: A population-based study of Northern Italy.","Foresta A","2023","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2023.110742","37270072",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0019775","Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells.","Luciani P","2013","PloS one","other","article","10.1371/journal.pone.0071716","23990978","PMC3750033",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019776","Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.","Ji L","2024","Diabetologia","randomized_trial","article","10.1007/s00125-024-06133-4","38985161","PMC11410852","ClinicalTrials.gov:NCT04017832","S000522","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0019777","Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic β-Cell Regeneration In Situ in Type 1 Diabetic Mice.","Gu L","2021","Journal of diabetes research","preclinical","article","10.1155/2021/7765623","39280767","PMC11401728",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019778","Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.","Gasoyan H","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15473","38287140","PMC11001528",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019779","A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide.","Chan LJ","2024","JAAD case reports","case_report","article","10.1016/j.jdcr.2024.02.023","39319185","PMC11421363",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019780","Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus.","Alobaid SM","2024","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph17030374","38543160","PMC10975938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019781","Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.","McElroy SL","2024","Journal of clinical psychopharmacology","randomized_trial","article","10.1097/jcp.0000000000001803","38227621",null,"ClinicalTrials.gov:NCT03158805","S002262","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0019782","Megestrol acetate as an overlooked cause of hyperglycemia in end-stage renal disease: A case of polypharmacy.","Aurora J","2024","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2024.102248","39277084",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0019783","Aptamer Functionalized Liposomes Co-Loaded with Exenatide-4 and Coenzyme Q10 Ameliorate Type 2 Diabetes Mellitus by Improving Pancreatic β Cell Function.","Xiao S","2025","International journal of nanomedicine","preclinical","article","10.2147/ijn.s510240","40125440","PMC11928442",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019784","Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.","Schwartz S","2010","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmsott.s11389","21437091","PMC3047965",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0019785","The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials.","Gu J","2016","Scientific reports","systematic_review","article","10.1038/srep32714","27600499","PMC5013324",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0019786","[Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents].","Scheen AJ","2008","Revue medicale de Liege","narrative_review","article",null,"18561773",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019787","Potential New Treatments for Chronic Kidney Diseases: A Concise Review.","Al-Horani RA","2025","Current pharmaceutical design","nonrandomized_study","article","10.2174/0113816128360091250117040009","39936428","PMC12325688",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0019788","The Influence of Non-Pharmacological and Pharmacological Interventions on the Course of Autosomal Dominant Polycystic Kidney Disease.","Kędzierska-Kapuza K","2024","Nutrients","narrative_review","article","10.3390/nu16183216","39339816","PMC11434835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019789","Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects.","Tanaka M","2016","Metabolism: clinical and experimental","other","article","10.1016/j.metabol.2015.10.009","26773924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019790","Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice.","Wang X","2021","International journal of endocrinology","randomized_trial","article","10.1155/2021/6620289","33986800","PMC8093078",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019791","Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity.","Barrea L","2025","Current obesity reports","narrative_review","article","10.1007/s13679-024-00602-y","39753703",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019792","Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells.","Chen A","2018","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2018.03.142","29571736",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019793","GLP-1 rescued gestational diabetes mellitus-induced suppression of fetal thalamus development.","You L","2023","Journal of biochemical and molecular toxicology","preclinical","article","10.1002/jbt.23258","36424357",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019794","New treatments in type 2 diabetes: a focus on the incretin-based therapies.","Barnett AH","2009","Clinical endocrinology","other_trial","article","10.1111/j.1365-2265.2008.03396.x","18771570",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0019795","Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity.","Carretero Gómez J","2021","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2021.1965563","34357836",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0019796","S90. A SYSTEMATIC REVIEW AND META-ANALYSIS OF PHARMACOLOGICAL INTERVENTIONS FOR REDUCTION OF WEIGHT GAIN IN PEOPLE WITH SCHIZOPHRENIA: 2019 UPDATE","Agarwal S","2020","Schizophrenia bulletin","systematic_review","article","10.1093/schbul/sbaa031.156",null,"PMC7234538",null,null,"europepmc; openalex","TRUE","open_europepmc","3","FALSE","Abstract; review"],["R0019797","Tirzepatide inhibits tumor growth in mice with diet-induced obesity","Huang L","2023","bioRxiv","preclinical","preprint","10.1101/2023.06.22.546093",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0019798","Overcoming Challenges in the Metabolism of Peptide Therapeutics: Strategies and Case Studies for Clinical Success.","Ma B","2025","Journal of medicinal chemistry","narrative_review","article","10.1021/acs.jmedchem.5c02276","41348552",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019799","Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model.","Xia H","2025","Radiology","preclinical","article","10.1148/radiol.243780","40828048",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019800","Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease.","Connelly KA","2014","Clinical and investigative medicine. Medecine clinique et experimentale","randomized_trial","article","10.25011/cim.v37i3.21384","24895991",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019801","Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence.","Papaetis GS","2020","Current diabetes reviews","nonrandomized_study","article","10.2174/1573399816666191230113446","31886752",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0019802","The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis.","Guo M","2020","Endocrine","systematic_review","article","10.1007/s12020-019-02175-6","31900793",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0019803","Response to comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.","Gale EA","2013","Diabetes care","commentary","article","10.2337/dc13-1542","24265383","PMC3836141",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0019804","The investigation of therapeutic potential of oxytocin and liraglutide on vincristine-induced neuropathy in rats.","Erdoğan MA","2020","Journal of biochemical and molecular toxicology","preclinical","article","10.1002/jbt.22415","31682045",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019805","Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach.","Papathanasiou T","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13985","32009288","PMC7317899",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019806","Efficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People.","Song CE","2024","Endocrine, metabolic & immune disorders drug targets","other","article","10.2174/0118715303283400240521120048","38808720",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019807","GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1 Signaling Pathway.","Zhu T","2018","Mediators of inflammation","preclinical","article","10.1155/2018/3601454","29950925","PMC5987313",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019808","Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.","Dorneles G","2024","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","systematic_review","article","10.1055/a-2303-8558","38599612",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0019809","Tirzepatide and exercise training in obesity.","Bagherzadeh-Rahmani B","2024","Clinical hemorheology and microcirculation","randomized_trial","article","10.3233/ch-242134","38640145",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","TRUE","Journal Article; Randomized Controlled Trial; Retracted Publication; article"],["R0019810","Obesity medications: A narrative review of current and emerging agents.","Qi QYD","2024","Osteoarthritis and cartilage open","nonrandomized_study","article","10.1016/j.ocarto.2024.100472","38737985","PMC11088184",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; review"],["R0019811","A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease.","Salles GN","2017","Molecular neurobiology","preclinical","article","10.1007/s12035-016-0200-0","27766537",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0019812","Precision Pharmacotherapy for Obstructive Sleep Apnea: Matching Targeted Drugs to Patient Endophenotypes.","Oh J","2026","Pharmaceuticals (Basel, Switzerland)","randomized_trial","article","10.3390/ph19091361","42797407","PMC13610825",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0019813","Therapies for the treatment of type 2 diabetes mellitus based on incretin action.","Gallwitz B","2006","Minerva endocrinologica","preclinical","article",null,"16682937",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019814","CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice.","Parlevliet ET","2009","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.108.144154","18849357",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019815","Optimization of Enzymolysis Clearance Strategy To Enhance Renal Clearance of Radioligands.","Zhang M","2021","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.1c00392","34486879",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019816","Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria.","DellaValle B","2016","Malaria journal","preclinical","article","10.1186/s12936-016-1486-0","27554094","PMC4995661",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019817","Commentary on \"Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study\".","Lim HH","2023","Annals of pediatric endocrinology & metabolism","commentary","article","10.6065/apem.2322098edi010","38173379","PMC10765026",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; editorial"],["R0019818","A review regarding the article 'Semaglutide and heart failure: Updated meta-analysis'.","Yuan D","2024","Current problems in cardiology","systematic_review","article","10.1016/j.cpcardiol.2024.102736","38944224",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Review; Meta-Analysis; Letter; article"],["R0019819","Hypertension associated with the risk of extrahepatic cancers in MASLD population: a multicenter cross-sectional study in China","Zhao X","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.07.28.25332237",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0019820","Smoking and diabetes.","Rouland A","2024","Annales d'endocrinologie","narrative_review","article","10.1016/j.ando.2024.08.001","39218351",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0019821","Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients - Real World Study.","Balcázar-Valencia CM","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s443115","38616987","PMC11016261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019822","Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.","Hiramatsu T","2018","European journal of clinical investigation","randomized_trial","article","10.1111/eci.13007","30054920","PMC6175244",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; review-article; article"],["R0019823","Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases.","Sonne N","2021","Molecular metabolism","narrative_review","article","10.1016/j.molmet.2020.101109","33166741","PMC8085567",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0019824","Effects of Dulaglutide in Doxorubicin Induced Renal Toxicity in Rats.","Hama Said HJ","2025","Biologics : targets & therapy","randomized_trial","article","10.2147/btt.s523547","40630078","PMC12235444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019825","Design of experiments approach for the development of a validated method to determine the exenatide content in poly(lactide-co-glycolide) microspheres.","Sheikhi M","2023","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","other","article","10.1016/j.ejpb.2023.09.016","37783361",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article; preprint"],["R0019826","Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure.","Giorgino F","2020","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2019.154045","31821814",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019827","[News in diabetology: what's new in 2022].","Gariani K","2023","Revue medicale suisse","other","article","10.53738/revmed.2023.19.809-10.25","36660832",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0019828","Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes.","Popovic DS","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15535","38456523",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019829","Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice.","Hytting-Andreasen R","2018","PloS one","preclinical","article","10.1371/journal.pone.0198046","29864142","PMC5986149",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019830","Therapeutic and Bioactive Peptides in Musculoskeletal Medicine: A Narrative Review.","Jeyaraman M","2026","Indian journal of orthopaedics","other_trial","article","10.1007/s43465-026-01746-w","42824576","PMC13627596",null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0019831","Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes.","Hinnen D","2006","Journal of the American Board of Family Medicine : JABFM","other_trial","article","10.3122/jabfm.19.6.612","17090794",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Case Reports; Journal Article; article"],["R0019832","STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?","Ostrominski JW","2024","European heart journal","other_trial","article","10.1093/eurheartj/ehae410","39056260",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0019833","Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life.","Lyons D","2024","The British journal of dermatology","randomized_trial","article","10.1093/bjd/ljae216","38771673",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0019834","Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.","Torimoto K","2015","Cardiovascular diabetology","other_trial","article","10.1186/s12933-015-0188-1","25849903","PMC4339392","UMIN:UMIN000015699",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0019835","[Effects of Exenatide-4 on proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells].","Liang QY","2020","Shanghai kou qiang yi xue = Shanghai journal of stomatology","preclinical","article",null,"33043336",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019836","Liraglutide: an injectable option for the management of obesity.","Clements JN","2015","The Annals of pharmacotherapy","randomized_trial","article","10.1177/1060028015586806","25986009",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0019837","The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.","Pitt B","2022","Cardiovascular drugs and therapy","narrative_review","article","10.1007/s10557-021-07291-y","34750713","PMC9090862",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019838","Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb.","Gatford KL","2013","PloS one","preclinical","article","10.1371/journal.pone.0056553","23424667","PMC3570470",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019839","Obesity/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials.","Verma R","2024","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000001113","38294186",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0019840","Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is.","Du L","2022","Frontiers in cardiovascular medicine","other","article","10.3389/fcvm.2022.1034095","36330012","PMC9623002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0019841","Pharmacist-led medication therapy management improving medication adherence in a patient with type 2 diabetes: case report.","Jiang H","2026","Frontiers in medicine","case_report","article","10.3389/fmed.2026.1910565","42698756","PMC13542644",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019842","Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective.","Scholte M","2024","PharmacoEconomics","commentary","article","10.1007/s40273-024-01394-8","38717708","PMC11249712",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0019843","Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus.","Baba Y","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15823","39091271",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019844","Prevention of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide: Involvement of brain antioxidant and BDNF upregulating properties.","de Souza AG","2019","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2018.10.066","30399578",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019845","Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?","Darmon P","2015","Diabetes & metabolism","other","article","10.1016/s1262-3636(16)30005-2","26774016",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019846","Efficacy and safety of add-on treatment with finerenone in patients with diabetic kidney disease already treated with SGLT-2 inhibitors.","Antonič M","2025","Clinical nephrology","nonrandomized_study","article","10.5414/cnp104s16","41307428","PMC12912646",null,null,"pubmed; europepmc","TRUE","open_europepmc","4",null,"Journal Article; research-article"],["R0019847","Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.","Cohen C","2024","The New England journal of medicine","other_trial","article","10.1056/nejmc2406233","39047251",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0019848","Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.","Nauck M","2009","Diabetes care","randomized_trial","article","10.2337/dc08-1355","18931095","PMC2606836","ClinicalTrials.gov:NCT00318461","S000767; S001123; S001502; S002036; S002445","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0019849","68Ga-NOTA-Exendin-4 PET/CT in Localization of an Occult Insulinoma and Appearance of Coexisting Esophageal Carcinoma.","Luo Y","2016","Clinical nuclear medicine","case_report","article","10.1097/rlu.0000000000001087","26647001","PMC4779726",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; research-article; article"],["R0019850","Comparison of effectiveness between phentermine/topiramate and liraglutide in obese patients with nonalcoholic fatty liver disease","Park SJ","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-4183955/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0019851","Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials.","Marx N","2020","European heart journal","randomized_trial","article","10.1093/eurheartj/ehaa174","32227240",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; editorial"],["R0019852","SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10554080",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019853","Peripheral Artery Disease in the Legs.","McDermott MM","2026","The New England journal of medicine","narrative_review","article","10.1056/nejmcp2501200","41604641",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019854","Transcriptome analysis reveals the mechanism of stromal cell-derived factor-1 and exendin-4 synergistically promoted periodontal ligament stem cells osteogenic differentiation.","Kang W","2021","PeerJ","other","article","10.7717/peerj.12091","34532163","PMC8404574",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019855","The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus.","Akyay OZ","2023","Medicine","randomized_trial","article","10.1097/md.0000000000035394","37773814","PMC10545322",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0019856","Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats.","Al-Barazanji KA","2000","Obesity research","preclinical","article","10.1038/oby.2000.38","10933308",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019857","SAT658 Tirzepatide Reduces The Predicted Risk Of Developing Atherosclerotic Cardiovascular Disease: A Post-hoc Analysis Of The Surmount-1 Trial",null,"2023","Journal of the Endocrine Society","other_trial","article",null,null,"PMC10554341",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0019858","Impact of SGLT-2i on COPD exacerbations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.","Satapathy P","2025","Diabetes & metabolism","systematic_review","article","10.1016/j.diabet.2025.101646","40220861",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Meta-Analysis"],["R0019859","Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching.","Yuan Z","2026","PloS one","nonrandomized_study","article","10.1371/journal.pone.0341745","41628085","PMC12863472",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Comparative Study; research-article; article"],["R0019860","Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study.","Glaros SB","2025","Gut microbes","randomized_trial","article","10.1080/19490976.2025.2558071","41020378","PMC12482426","ClinicalTrials.gov:NCT02960659","S001259","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0019861","Semaglutide for weight loss: unanswered questions.","Tzoulis P","2024","Frontiers in endocrinology","other","article","10.3389/fendo.2024.1382814","38904050","PMC11188346",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0019862","Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway.","Zhou R","2020","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2020.600175","33746742","PMC7970416",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019863","The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.","Pi-Sunyer FX","2008","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2008.07.1785","18654064",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0019864","Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents.","Su J","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms241713381","37686185","PMC10487533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019865","Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.","Persano M","2021","European review for medical and pharmacological sciences","randomized_trial","article","10.26355/eurrev_202101_24661","33577047",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","2","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0019866","Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes.","Ruiz-Sánchez JG","2025","Medicina clinica","other","article","10.1016/j.medcli.2025.107179","41014747",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019867","CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis.","Khomtchouk BB","2024","Frontiers in endocrinology","other","article","10.3389/fendo.2024.1359780","38962682","PMC11219943",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019868","Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide.","Lee DSU","2023","Journal of diabetes research","nonrandomized_study","article","10.1155/2023/7917641","37305431","PMC10250096",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; article"],["R0019869","Genetic variants and characterization of MODY in a single, large pediatric referral center.","Deng L","2025","Journal of clinical & translational endocrinology","nonrandomized_study","article","10.1016/j.jcte.2025.100398","40486976","PMC12141876",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019870","Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.","Rubino D","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15620","38698650",null,"ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT03611582; ClinicalTrials.gov:NCT03548987","S000144; S000521; S000988; S001740","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019871","Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.","Harris SB","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12892","28124817","PMC5484356","ClinicalTrials.gov:NCT02298192","S001217","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0019872","Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment.","Pang J","2021","Obesity medicine","nonrandomized_study","article","10.1016/j.obmed.2020.100312","33426364","PMC7785422",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0019873","Genetically proxied antidiabetic drugs targets and stroke risk.","Zhu Y","2023","Journal of translational medicine","other","article","10.1186/s12967-023-04565-x","37777789","PMC10544120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019874","Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes.","Kuriyama T","2024","Clinical nutrition ESPEN","nonrandomized_study","article","10.1016/j.clnesp.2023.12.005","38220377",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019875","Design of Auto-Adaptive Drug Delivery System for Effective Delivery of Peptide Drugs to Overcoming Mucus and Epithelial Barriers.","Ding R","2024","The AAPS journal","other","article","10.1208/s12248-024-00971-1","39266802",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0019876","Author's reply to De Ponti et al.: \"Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus\".","Scheen AJ","2015","Clinical pharmacokinetics","commentary","article","10.1007/s40262-015-0249-3","25721223",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0019877","Age-related change of GLP-1R expression in rats can be detected by [18F]AlF-NOTA-MAL-Cys39-exendin-4.","Wang L","2018","Brain research","preclinical","article","10.1016/j.brainres.2018.08.022","30144405",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019878","Semaglutide Reverses the Chronic Myopathy of Hyperkalemic Periodic Paralysis: A Case Report","Brand K","2024","Research Square","case_report","preprint","10.21203/rs.3.rs-4908191/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0019879","Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys.","Vahle JL","2015","Toxicologic pathology","preclinical","article","10.1177/0192623315588999","26059826",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019880","The bone-preserving effects of exendin-4 in ovariectomized rats.","Sun HX","2016","Endocrine","preclinical","article","10.1007/s12020-015-0667-x","26109471",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019881","Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study.","Rasmussen L","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15876","39164856",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0019882","Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.","Pabreja K","2014","British journal of pharmacology","narrative_review","article","10.1111/bph.12313","23889512","PMC3952792",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0019883","Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.","Bayne S","2024","Advanced biology","narrative_review","article","10.1002/adbi.202300496","38065929",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0019884","Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers.","Kheira HS","2024","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2024.150337","38986220",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019885","Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial.","Lee EY","2023","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2023.110884","37595844",null,"KCT:KCT0006157",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; article"],["R0019886","A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes.","Carney EF","2024","Nature reviews. Nephrology","other_trial","article","10.1038/s41581-024-00865-7","38956439",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; article"],["R0019887","Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.","Cai X","2017","Journal of diabetes investigation","systematic_review","article","10.1111/jdi.12625","28106956","PMC5497054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; research-article; article"],["R0019888","Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats.","Guo X","2023","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2023.1146960","37701028","PMC10493299",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019889","Effect of semaglutide on major cardiovascular events.","BMJ Publishing Group Ltd","2024","Drug and therapeutics bulletin","other","article","10.1136/dtb.2024.000007","38237952",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019890","Oral GLP-1 Analogue Ameliorates Obesity-Induced Diabetes In Db/Db Mouse","Zhang H","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-812353/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0019891","Semaglutide and weight loss - A concern for diabetics and pharmaceuticals.","Admani B","2024","JPMA. The Journal of the Pakistan Medical Association","other_trial","article","10.47391/jpma.10705","38949006",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; article"],["R0019892","Lixisenatide for type 2 diabetes mellitus.","Christensen M","2011","Expert opinion on investigational drugs","narrative_review","article","10.1517/13543784.2011.562191","21391833",null,null,"S000473","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0019893","Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.","Antwi K","2015","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","randomized_trial","article","10.2967/jnumed.115.157768","25999434",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019894","CADTH Canadian Drug Expert Committee Recommendation: Semaglutide (Ozempic — Novo Nordisk Canada Inc.): Indication: Diabetes mellitus, type 2 to improve glycemic control",null,"2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"31287630",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0019895","Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.","Gilbert MP","2009","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2009.03.013","19464424",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019896","Exendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway.","Tang Z","2018","Molecular medicine reports","randomized_trial","article","10.3892/mmr.2018.9345","30085331","PMC6102738",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019897","Assessment of Second-Generation Diabetes Medication Initiation Among Medicare Enrollees From 2007 to 2015.","Gilstrap LG","2020","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2020.5411","32442290","PMC7244990",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0019898","Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition.","Stoll F","2025","Obesity research & clinical practice","nonrandomized_study","article","10.1016/j.orcp.2025.02.004","39952885",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0019899","Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.","Wilkinson L","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0402-8","29557057","PMC5984908",null,"S000372","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0019900","Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).","Jain AB","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15493","38468125",null,"ClinicalTrials.gov:NCT04559815","S001519","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019901","Expression of a glucagon-like peptide-1 analogue, as a therapeutic agent for type II diabetes, with enhanced bioactivity and increased N-terminal homogeneity in Pichia pastoris.","Qian K","2015","Biotechnology letters","other","article","10.1007/s10529-015-1900-7","26160109",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019902","Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.","Anholm C","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13761","31050161",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019903","Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.","Anderson JE","2016","Postgraduate medicine","other_trial","article","10.1080/00325481.2016.1218260","27488824",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0019904","The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society.","Wełnicki M","2022","Kardiologia polska","other","article","10.33963/kp.a2022.0282","36601885",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0019905","Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).","Wysham C","2014","Diabetes care","randomized_trial","article","10.2337/dc13-2760","24879836",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019906","Study: Semaglutide Lowered Chronic Kidney Disease-Related Risks.","Bock A","2024","JAMA","commentary","article","10.1001/jama.2024.10349","38904969",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0019907","A Novel Multiphase Modified Ketogenic Diet: An Effective and Safe Tool for Weight Loss in Chinese Obese Patients.","Wu W","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","other_trial","article","10.2147/dmso.s365192","35999869","PMC9393022",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Clinical Trial; Journal Article; case-report; article"],["R0019908","Tirzepatide and Glycemic Control Metrics Using Continuous Glucose Monitoring in Older Patients with Type 2 Diabetes Mellitus: An Observational Pilot Study","Omura T","2023","Preprints.org","other","preprint","10.20944/preprints202312.2024.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0019909","Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease.","Bernardini F","2023","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics15071858","37514043","PMC10386670",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019910","Mo-Rubbing abdominal improves metabolic homeostasis in type 2 diabetes mellitus mice via a jejunum-specific GLP1-dependent mechanism.","Zhang Z","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70563","41725452",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019911","Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice.","Tsai TH","2019","Cells","preclinical","article","10.3390/cells8060589","31207939","PMC6628350",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0019912","Comment on Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double‑Blind Single‑Centre Study.","Lovato A","2024","Obesity surgery","randomized_trial","article","10.1007/s11695-024-07463-3","39167150",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Comment; article"],["R0019913","Letter by Weir Regarding Article, \"Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity\".","Weir RAP","2024","Circulation","commentary","article","10.1161/circulationaha.123.067970","39226380",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019914","GLP1RAs vs SGLT2is were associated with lower risk of major adverse limb events and similar risks of heart failure hospitalisation and stroke?","Du L","2023","Diabetologia","commentary","article","10.1007/s00125-022-05835-x","36399206",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0019915","Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation.","Feng Y","2016","Journal of molecular endocrinology","preclinical","article","10.1530/jme-15-0264","26647389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019916","Exendin-4 promotes extracellular-superoxide dismutase expression in A549 cells through DNA demethylation.","Yasuda H","2016","Journal of clinical biochemistry and nutrition","other","article","10.3164/jcbn.15-16","26798195","PMC4706090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019917","Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway.","Liu H","2020","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s253097","32943896","PMC7478378",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019918","Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach.","Palasantzas VEJM","2026","Nutrients","systematic_review","article","10.3390/nu18030388","41683214","PMC12899271",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; article"],["R0019919","Clinical comments related to medullary thyroid cancer diagnosis and management.","Duntas LH","2013","Thyroid research","nonrandomized_study","article","10.1186/1756-6614-6-s1-s6","23514614","PMC3599727",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; review-article; article"],["R0019920","GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?","Nauck MA","2020","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(20)30043-7","32135134",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0019921","Type 2 diabetes mellitus: pathogenesis and genetic diagnosis.","Himanshu D","2020","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-020-00641-x","33520871","PMC7843813",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0019922","Heart failure in 2025: new insights, therapies, and clinical directions.","Shen Z","2026","Journal of thoracic disease","other_trial","article","10.21037/jtd-2026-1-0188","42182770","PMC13190018",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0019923","A commentary on 'Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial'.","Han T","2024","International journal of surgery (London, England)","randomized_trial","article","10.1097/js9.0000000000001094","38241302","PMC11020054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019924","Impact of Cotadutide Drug on Obese Individuals with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis","Ali MM","2022","Research Square","systematic_review","preprint","10.21203/rs.3.rs-1236048/v1",null,null,"PROSPERO:CRD42021257670",null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0019925","Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake.","Patel V","2016","Canadian journal of physiology and pharmacology","other","article","10.1139/cjpp-2014-0457","26629909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019926","Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity.","Wilkinson L","2023","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23842","37605636",null,"ClinicalTrials.gov:NCT03548987; ClinicalTrials.gov:NCT03693430","S000214; S000521","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019927","Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3.","Tong G","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15416","38185739",null,"ClinicalTrials.gov:NCT04591626","S002368","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; article"],["R0019928","Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.","Yu M","2022","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-022-00924-8","36271423","PMC9585736",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0019929","The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.","Rohani P","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1230206","37621649","PMC10446893",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0019930","Tirzepatide, a dual incretin analog, is a boon in metabolic syndrome: an editorial.","Bardhan M","2024","Annals of medicine and surgery (2012)","commentary","article","10.1097/ms9.0000000000001782","38463093","PMC10923294",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0019931","The GLP-1 analogue liraglutide protects cardiomyocytes from high glucose-induced apoptosis by activating the Epac-1/Akt pathway.","Wu XM","2014","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","preclinical","article","10.1055/s-0034-1384584","25140997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019932","Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.","Klonoff DC","2024","Journal of diabetes science and technology","nonrandomized_study","article","10.1177/19322968241268050","39080859","PMC11529103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0019933","Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis.","Yang L","2024","Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences","systematic_review","article","10.4103/jrms.jrms_693_23","39629036","PMC11613982","PROSPERO:CRD42023450979",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0019934","Morphologically 'invisible' proinsulin - secreting adenoma detected by Ga-68 Exendin-4 (GLP-1 Receptor) positron emission tomography/CT.","Werner C","2018","Journal of medical imaging and radiation oncology","case_report","article","10.1111/1754-9485.12704","29399966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0019935","Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.","Kaisho T","2017","International journal of obesity (2005)","preclinical","article","10.1038/ijo.2017.176","28757640",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019936","Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.","Liu H","2022","RSC advances","preclinical","article","10.1039/d2ra05872c","36380917","PMC9639207",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0019937","Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.","Molina Vega M","2018","Expert opinion on drug metabolism & toxicology","other_trial","article","10.1080/17425255.2018.1420160","29260924",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0019938","Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats.","Reidelberger R","2012","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00058.2012","22510712","PMC3378160",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0019939","1984. Effects of Semaglutide on Adipose Tissue in HIV-Associated Lipohypertrophy",null,"2023","Open forum infectious diseases","other","article",null,null,"PMC10678417",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019940","New Drugs for Type 2 Diabetes: Second-Line Therapy — Science Report",null,"2017","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"30325623",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0019941","[Among patients with type 2 diabetes and chronic kidney disease, does semaglutide prevent end-stage renal disease, significant loss of kidney function, or death from renal or cardiovascular causes compared to placebo, and is it safe?].","Lanthier L","2024","La Revue de medecine interne","commentary","article","10.1016/j.revmed.2024.07.011","39129120",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0019942","Semaglutide therapy and iatrogenic thyrotoxicosis.","Barnett MJL","2025","Endocrinology, diabetes & metabolism case reports","case_report","article","10.1530/edm-25-0065","40638337","PMC12260150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0019943","[Incretin-based therapy in patients with type 1 diabetes mellitus].","Miyagawa J","2011","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"21595283",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0019944","New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences.","Popović L","2025","Diagnostics (Basel, Switzerland)","narrative_review","article","10.3390/diagnostics15030284","39941214","PMC11816453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019945","Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study.","Torre E","2020","ClinicoEconomics and outcomes research : CEOR","other","article","10.2147/ceor.s240183","32308446","PMC7152542",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019946","PSUN172 Prescribing SGLT-2 Inhibitors and GLP-1 Agonists in Primary Care: Improving Rates of Guideline-Concordant Practice",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9629331",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0019947","Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves.","Mayer F","2020","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00189.2019","32421358","PMC7468754",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0019948","Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.","Gregorič N","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16042","39511836","PMC11701185","ClinicalTrials.gov:NCT06489457","S000079","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0019949","Cost-effectiveness of endoscopic treatments for obesity: a clinical evidence map and systematic review to inform a model-based cost-effectiveness analysis.","Albon E","2025","Health technology assessment (Winchester, England)","systematic_review","article","10.3310/pwkq2310","41424377","PMC12746199","PROSPERO:CRD42022302942",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0019950","Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control?","Nicolau J","2025","Medicina clinica","other","article","10.1016/j.medcli.2025.106941","40267547",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019951","Cost effectiveness analysis of six non insulin agents for type 2 diabetes in Iran using a patient level simulation with UKPDS OM2.","Darvishi A","2025","Scientific reports","other","article","10.1038/s41598-025-25456-9","41285895","PMC12644787",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019952","Evaluating the Efficacy of Sodium Glucose Cotransporter-2 Inhibitors in Management of Obstructive Sleep Apnea; a Systematic Review and Meta-Analysis.","Murtaza S","2026","Journal of sleep research","systematic_review","article","10.1111/jsr.70196","40974185",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Review; review"],["R0019953","Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).","Clemens KK","2026","BMJ open","protocol","article","10.1136/bmjopen-2026-120427","42580835","PMC13475350","ClinicalTrials.gov:NCT06396416","S000781","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; article"],["R0019954","Extracellular vesicle encapsulated mesoporous molecularly imprinted silica for peptide drug delivery.","Wang M","2025","Colloids and surfaces. B, Biointerfaces","preclinical","article","10.1016/j.colsurfb.2025.114971","40706096",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0019955","The effectiveness and safety of exenatide in the treatment of polycystic ovary syndrome: A systematic review and meta-analysis","Hu Y","2023","Research Square","systematic_review","preprint","10.21203/rs.3.rs-2737787/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0019956","Nebulized Lipid Nanoparticles Deliver mRNA to the Liver for Treatment of Metabolic Diseases.","Ren H","2025","Nano letters","preclinical","article","10.1021/acs.nanolett.5c03184","40916925",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019957","Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.","Borderie G","2021","The New England journal of medicine","commentary","article","10.1056/nejmc2115776","34818489",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0019958","Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.","Arbel R","2018","The American journal of cardiology","other_trial","article","10.1016/j.amjcard.2018.06.010","30075890",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; article"],["R0019959","Changes in Body Weight in Severely Obese Patients Treated with the Anorexiant Mazindol.","Tanaka Y","2024","Journal of clinical medicine","other","article","10.3390/jcm13071860","38610625","PMC11012520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019960","Semaglutide improves cardiovascular health independently of weight loss.","Korda M","2024","Nature cardiovascular research","commentary","article","10.1038/s44161-024-00499-9","39196231",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0019961","GLP-1 Receptor Agonist as Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia.","Redondo MJ","2020","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgaa314","32485735","PMC7316204",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Comment; discussion; article"],["R0019962","[Not Available].","Da Graça S","2024","Revue medicale suisse","commentary","article","10.53738/revmed.2024.20.882.1380","39021110",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"News"],["R0019963","Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.","Skov J","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12651","26910107",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0019964","Glycemic Control and Body Weight Reduction with Once-Weekly Semaglutide in Colombian Adults with Type 2 Diabetes: Findings from the COLIBRI Study.","Serpa-Díaz D","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01586-7","38691323","PMC11096134",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019965","GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.","Sharma AN","2015","Metabolic brain disease","preclinical","article","10.1007/s11011-014-9591-7","25023888",null,"ClinicalTrials.gov:NCT01845259","S001109","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0019966","PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan.","Suzuki R","2024","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.14219","38711208","PMC11292382",null,"S001319","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0019967","SERCA2a dysfunction in the pathophysiology of heart failure with preserved ejection fraction: a direct role is yet to be established.","Shooshtarian AK","2025","Heart failure reviews","narrative_review","article","10.1007/s10741-025-10487-1","39843817","PMC11991975",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0019968","The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes.","Ruda AI","2023","Medicine and pharmacy reports","nonrandomized_study","article","10.15386/mpr-2425","36818328","PMC9924803",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019969","Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.","Foley JE","2010","Vascular health and risk management","randomized_trial","article","10.2147/vhrm.s10952","20730070","PMC2922315",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0019970","Efficacy of oral semaglutide after switching from DPP-4 inhibitors in Japanese type 2 diabetes patients with obesity","Okamoto A","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-4009873/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0019971","Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study.","Harris ST","2021","Diabetes care","nonrandomized_study","article","10.2337/dc21-0529","34344714","PMC8929186",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0019972","Correction to Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonist.","Evers A","2017","Journal of medicinal chemistry","notice","article","10.1021/acs.jmedchem.7b00887","28677386",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0019973","The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes.","Gadsby R","2010","Primary care diabetes","other_trial","article","10.1016/j.pcd.2010.03.003","20418194",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019974","Circulating HHIP Levels in Women with Insulin Resistance and PCOS: Effects of Physical Activity, Cold Stimulation and Anti-Diabetic Drug Therapy.","Zhou X","2023","Journal of clinical medicine","other","article","10.3390/jcm12030888","36769536","PMC9918013",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019975","Tirzepatide-associated starvation ketoacidosis.","Mercer J","2023","Clinical toxicology (Philadelphia, Pa.)","commentary","article","10.1080/15563650.2023.2277337","37938168",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0019976","Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.","Verma S","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14140","32643857","PMC7689837","ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446","S001496; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; brief-report; article"],["R0019977","The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling.","Li R","2019","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2019.00537","31231210","PMC6560159",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019978","After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?","Vergès B","2017","Diabetes & metabolism","other_trial","article","10.1016/s1262-3636(17)30067-8","28431669",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0019979","Exendin-4 attenuates lipopolysaccharides induced inflammatory response but does not protects H9c2 cells from apoptosis.","Chen TH","2012","Immunopharmacology and immunotoxicology","other","article","10.3109/08923973.2011.630398","22121853",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0019980","Congenital Glucagon-like Peptide-1 Deficiency in the Pathogenesis of Protracted Diarrhea in Mitchell-Riley Syndrome.","Nóbrega S","2021","The Journal of clinical endocrinology and metabolism","case_report","article","10.1210/clinem/dgaa916","33382423",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0019981","GLP-1 receptor agonist increases the expression of CTRP3, a novel adipokine, in 3T3-L1 adipocytes through PKA signal pathway.","Li X","2015","Journal of endocrinological investigation","preclinical","article","10.1007/s40618-014-0156-8","25149084",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019982","A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life.","Lindgren J","2014","Biopolymers","preclinical","article","10.1002/bip.22474","24549714",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019983","Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality.","Du L","2022","Frontiers in cardiovascular medicine","commentary","article","10.3389/fcvm.2022.987025","35990975","PMC9386073",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article-commentary; editorial"],["R0019984","Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?","Lamont BJ","2014","The Journal of endocrinology","narrative_review","article","10.1530/joe-13-0577","24424288",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0019985","Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity.","Jantrapirom S","2020","International journal of molecular sciences","preclinical","article","10.3390/ijms21051725","32138327","PMC7084306",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019986","Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.","Tseng CM","2017","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","nonrandomized_study","article","10.1016/j.pan.2016.10.003","27743712",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0019987","Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide.","Umpierrez G","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13662","30756511",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0019988","Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy.","Bugianesi E","2024","Pragmatic and observational research","nonrandomized_study","article","10.2147/por.s472468","39403308","PMC11472768",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0019989","GLP-1-based strategies: a physiological analysis of differential mode of action.","Burcelin R","2014","Physiology (Bethesda, Md.)","narrative_review","article","10.1152/physiol.00009.2013","24583767",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0019990","Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial.","Wang XJ","2021","JGH open : an open access journal of gastroenterology and hepatology","randomized_trial","article","10.1002/jgh3.12464","33553655","PMC7857298",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0019991","Ketosis Prone Diabetes in an Obese Male Adolescent: A Case Report","Alhammad Z","2021","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvab048.795",null,"PMC8089784",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0019992","Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review.","Alfawaz S","2024","Cureus","narrative_review","article","10.7759/cureus.67080","39286709","PMC11404706",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019993","Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment.","Zisis M","2025","Biomolecules","randomized_trial","article","10.3390/biom15030324","40149860","PMC11940321",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0019994","Glucagon-like peptide-1 gene therapy.","Rowzee AM","2011","Experimental diabetes research","narrative_review","article","10.1155/2011/601047","21747830","PMC3124282",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0019995","Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.","Neumiller JJ","2011","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2011.04.024","21665041",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0019996","Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction.","Le Y","2016","Journal of the renin-angiotensin-aldosterone system : JRAAS","preclinical","article","10.1177/1470320316677918","27913661","PMC5843888",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0019997","A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report.","Wu S","2020","Frontiers in endocrinology","case_report","article","10.3389/fendo.2020.608966","33584541","PMC7876378",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Research Support, Non-U.S. Gov't; Journal Article; case-report; article"],["R0019998","Therapy of obesity in women with PCOS using GLP-1 analogues - benefits and limitations [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 - korzyści i ograniczenia].","Baranowska-Bik A","2022","Endokrynologia Polska","narrative_review","article","10.5603/ep.a2022.0047","36059178",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0019999","DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model","Sasset L","2025","bioRxiv","preclinical","preprint","10.1101/2025.05.30.656889",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0020000","Pre-Diagnosis Observational and Prescription History Associated with Alzheimer’s Disease Incidence","Williams G","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.07.17.24310553",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0020001","Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.","Tan X","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01509-y","38060149","PMC10838880",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020002","Pancreas and liver uptake of new radiolabeled incretins (GLP-1 and Exendin-4) in models of diet-induced and diet-restricted obesity.","Seo D","2017","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2017.03.002","28365524",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020003","Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer.","Wang X","2026","Nature biomedical engineering","preclinical","article","10.1038/s41551-026-01725-4","42373803",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020004","Exendin-4 improves neuron protection and functional recovery in experimental spinal cord injury in rats through regulating PCBP2 expression","Luo H","2020","bioRxiv","randomized_trial","preprint","10.1101/2020.11.09.373993",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0020005","GLP-1 receptor agonist-induced polyarthritis: a case report.","Ambrosio ML","2014","Acta diabetologica","case_report","article","10.1007/s00592-013-0525-3","24158775",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020006","A call to update anesthetic protocols: the hidden risks of semaglutide.","Santos LB","2024","Canadian journal of anaesthesia = Journal canadien d'anesthesie","commentary","article","10.1007/s12630-024-02774-6","38807009",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0020007","ODP632 Preadmission Use Of Antidiabetic Medications And Mortality Among Patients With Covid-19 Having Type 2 Diabetes: A Meta-analysis",null,"2022","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC9628116",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0020008","Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes.","Castro Conde A","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm12123925","37373620","PMC10299569",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020009","Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins.","Gumieniczek A","2023","Biomedicines","preclinical","article","10.3390/biomedicines11082127","37626624","PMC10452759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020010","Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke.","Du L","2023","The Canadian journal of cardiology","commentary","article","10.1016/j.cjca.2022.08.223","36007809",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0020011","Cell death-induced chronic inflammation as a therapeutic target for metabolic dysfunction-associated steatohepatitis.","Suganami T","2026","Pharmacology & therapeutics","preclinical","article","10.1016/j.pharmthera.2026.109123","42716188",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0020012","Protective Effect of a GLP-1 Analog on Ischemia-Reperfusion Induced Blood-Retinal Barrier Breakdown and Inflammation.","Gonçalves A","2016","Investigative ophthalmology & visual science","preclinical","article","10.1167/iovs.15-19006","27163772","PMC4868093",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020013","Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients.","Gupta N","2024","Cureus","systematic_review","article","10.7759/cureus.64668","39149678","PMC11326657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0020014","Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review.","Liarakos AL","2023","Biomedicines","narrative_review","article","10.3390/biomedicines11071875","37509514","PMC10377278",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0020015","New incretin hormonal therapies in humans relevant to diabetic cats.","Reusch CE","2013","The Veterinary clinics of North America. Small animal practice","narrative_review","article","10.1016/j.cvsm.2012.11.003","23522180",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Review"],["R0020016","Distinguishing among incretin-based therapies. Introduction.","Campbell RK","2010","The Journal of family practice","other","article",null,"20824238",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Introductory Journal Article; other"],["R0020017","Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway.","Liu Q","2023","International immunopharmacology","preclinical","article","10.1016/j.intimp.2023.110311","37196559",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020018","GLP-1 signaling-regulated SNAP25 is involved in improved insulin secretion in diabetic GK rats after Roux-en-Y gastric bypass surgery.","Kong X","2024","Molecular biology reports","preclinical","article","10.1007/s11033-023-09165-y","38227062",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020019","Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.","Wu YR","2019","Cardiovascular diabetology","preclinical","article","10.1186/s12933-019-0954-6","31706303","PMC6842145",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020020","A Revolution in Medicine and Surgery Has Begun.","Spector R","2025","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2025.02.012","39956504",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020021","Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for semaglutide.","Lan NSR","2024","Obesity research & clinical practice","nonrandomized_study","article","10.1016/j.orcp.2024.02.001","38331597",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0020022","Input Estimation for Extended-Release Formulations Exemplified with Exenatide.","Trägårdh M","2017","Frontiers in bioengineering and biotechnology","other","article","10.3389/fbioe.2017.00024","28470000","PMC5395652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020023","Novel Use of GLP-1 Receptor Agonist Therapy in HNF4A-MODY.","Broome DT","2020","Diabetes care","nonrandomized_study","article","10.2337/dc20-0012","32265191","PMC7245355",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0020024","Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.","Guo T","2023","Molecular medicine (Cambridge, Mass.)","preclinical","article","10.1186/s10020-023-00721-7","37770820","PMC10540362",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020025","PNPLA3 Risk Allele Association With ALT Response to Semaglutide Treatment.","Urias E","2024","Gastroenterology","other_trial","article","10.1053/j.gastro.2023.11.018","37972824","PMC10922261",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0020026","Effect of low dose Semaglutide in people with Type 1 Diabetes and excess weight.","Grassi BA","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111593","38403174",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0020027","SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.","Sarafidis P","2020","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","notice","article","10.1093/ndt/gfz137","31397476",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; article"],["R0020028","Corrigendum to \"Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury\" [Neurobiology of Disease Volume 124 (2019) 439-453 /YNBDI_4338].","Bader M","2024","Neurobiology of disease","notice","article","10.1016/j.nbd.2024.106563","38890024",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0020029","Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?","Basalay MV","2020","Neural regeneration research","randomized_trial","article","10.4103/1673-5374.280313","32246632","PMC7513965",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; other; article"],["R0020030","Overview of oxidative stress and inflammation in diabetes.","Weinberg Sibony R","2024","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.70014","39435991","PMC11494684",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0020031","Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.","Girges C","2026","Clinical trials (London, England)","other_trial","article","10.1177/17407745251387571","41321006","PMC12909607","ClinicalTrials.gov:NCT04232969; ClinicalTrials.gov:NCT04431713","S000204; S001156","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020032","Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity.","Tang M","2025","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.16466","40452343",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0020033","Evolution of exenatide as a diabetes therapeutic.","Bhavsar S","2013","Current diabetes reviews","other_trial","article","10.2174/1573399811309020007","23256660","PMC3664512",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0020034","Neuroprotective effect of GLP-1 receptor agonist exendin-4 in rat models of Parkinson's disease","Harkavyi A","2009","University College London (University of London)","preclinical","article",null,null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0020035","Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.","Yabe D","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12817","27800649","PMC5347937",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0020036","Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats.","Romaní-Pérez M","2015","Endocrinology","preclinical","article","10.1210/en.2014-1685","26196539",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020037","Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model.","Samson SL","2008","Molecular therapy : the journal of the American Society of Gene Therapy","preclinical","article","10.1038/mt.2008.198","18781141","PMC2582376",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020038","Effects of liraglutide on ANP secretion and cardiac dynamics.","Luo S","2023","Endocrine connections","preclinical","article","10.1530/ec-23-0176","37681442","PMC10563649",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020039","Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway.","Han X","2020","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2020.03.032","32171530",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020040","Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.","Pinkney J","2010","Therapeutics and clinical risk management","narrative_review","article","10.2147/tcrm.s7313","20856686","PMC2940748",null,"S001234","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0020041","Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells.","Zitman-Gal T","2019","Journal of diabetes","preclinical","article","10.1111/1753-0407.12891","30575282",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020042","The expanding role of incretin-based therapies: how much should we expect?","Haluzik M","2014","The Journal of endocrinology","commentary","article","10.1530/joe-14-0056","24623799",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; article"],["R0020043","Liraglutide Ameliorates Gamma Radiation-Induced Hepatic Damage in Rats: The Role of an Autophagy Flux Activation via LKB1/AMPK/mTOR Axis.","Samy EM","2026","Archives of medical research","preclinical","article","10.1016/j.arcmed.2025.103296","40913889",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020044","The treatment of diabetes mellitus of patients with chronic liver disease.","García-Compeán D","2015","Annals of hepatology","narrative_review","article","10.5604/16652681.1171746","26436350",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0020045","New Directions in Imaging Neuroendocrine Neoplasms.","Refardt J","2021","Current oncology reports","narrative_review","article","10.1007/s11912-021-01139-2","34735669","PMC8568754",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0020046","Acute generalized exanthematous pustulosis sine pustules following semaglutide injection.","Shetty NP","2024","JAAD case reports","case_report","article","10.1016/j.jdcr.2024.05.036","39345280","PMC11437238",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020047","Beyond Blood Sugar: How Left Atrium Strain Predicts Cardiac Outcomes in Type 2 Diabetes.","Benchea LC","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12081690","39200155","PMC11351471",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020048","Human Relevance of Pharmaceutical Drug-Induced Thyroid Tumors in Rats, Labeling Implications, and Carcinogenicity Study Requirements.","Hollingshead BD","2025","Journal of applied toxicology : JAT","preclinical","article","10.1002/jat.4779","40083171",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020049","Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).","Furusawa S","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15393","38073422",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Multicenter Study; Journal Article; article"],["R0020050","Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity.","Lee JY","2020","Biomaterials","preclinical","article","10.1016/j.biomaterials.2020.120250","32736262",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020051","Implementation of the IWQOL-Lite-CT in Observational Research: Comparison of Baseline Scores With a Clinical Trial Population and Psychometric Evaluation.","Smith LVH","2026","Clinical obesity","nonrandomized_study","article","10.1111/cob.70087","42235931",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Comparative Study; Observational Study; article"],["R0020052","Comment on: Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study.","Unal S","2025","International journal of impotence research","nonrandomized_study","article","10.1038/s41443-024-00960-0","39122866",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; letter"],["R0020053","Meta-analysis of randomized controlled trials for the development of the International Federation for Surgery of Obesity and Metabolic Disorders-European Chapter (IFSO-EC) guidelines on multimodal strategies for the surgical treatment of obesity.","De Luca M","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16352","40197859",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; article"],["R0020054","Weight loss associated with semaglutide treatment among people with HIV.","Haidar L","2024","AIDS (London, England)","nonrandomized_study","article","10.1097/qad.0000000000003791","37976053","PMC10922142",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; Preprint; article; preprint"],["R0020055","Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases.","Zeng Y","2024","mBio","narrative_review","article","10.1128/mbio.02032-23","38055342","PMC10790698",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0020056","Emerging Approaches for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease: The Application of Nanomedicines.","Shi T","2026","International journal of nanomedicine","narrative_review","article","10.2147/ijn.s603396","42152979","PMC13180397",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020057","GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence.","Jerlhag E","2018","Neuropharmacology","narrative_review","article","10.1016/j.neuropharm.2018.01.013","29337226",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020058","Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.","Stone CR","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.08.15.608191","39211263","PMC11361037",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; Research Support, N.I.H., Extramural; research-article; preprint; article"],["R0020059","Sustained release of GLP-1 analog from γ-PGA-PAE copolymers for management of type 2 diabetes.","Zhang L","2023","Biomaterials advances","other","article","10.1016/j.bioadv.2023.213352","36867980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020060","Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation.","Jing F","2021","The journal of headache and pain","preclinical","article","10.1186/s10194-021-01302-x","34325647","PMC8323319",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0020061","GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.","van Bloemendaal L","2014","Diabetes","randomized_trial","article","10.2337/db14-0849","25071023",null,"ClinicalTrials.gov:NCT01281228","S000930; S002156; S002326","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020062","Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.","Nauck MA","2011","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2010.11.002","21194578",null,null,"S002604","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0020063","Tirzepatide for type 2 diabetes.",null,"2023","Australian prescriber","narrative_review","article","10.18773/austprescr.2023.028","38152319","PMC10751079",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020064","Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice.","Irwin N","2009","Regulatory peptides","preclinical","article","10.1016/j.regpep.2008.11.007","19073224",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020065","Real-world safety and effectiveness of iGlarLixi in people with type 2 diabetes who fast during Ramadan: The SoliRam observational study.","Hassanein M","2023","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2023.102707","36680967",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Observational Study; Journal Article; article"],["R0020066","Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.","St Onge EL","2010","Expert opinion on biological therapy","other_trial","article","10.1517/14712598.2010.481281","20367248",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0020067","The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.","El K","2023","Nature metabolism","preclinical","article","10.1038/s42255-023-00811-0","37277609","PMC10290954",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020068","Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids.","Fuchs CD","2018","Gut","preclinical","article","10.1136/gutjnl-2017-314553","29636383","PMC6109278",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020069","A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.","Alves C","2012","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2012.09.008","23010561",null,null,"S000330; S000860; S000862; S001094; S001502; S001581; S001584; S002098; S002222; S002230; S002361","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0020070","Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.","Stein LL","2009","Advances in therapy","narrative_review","article","10.1007/s12325-009-0072-z","19921118","PMC6659744",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review; research-article"],["R0020071","Advancing precision health discovery in a genetically diverse health system.","Haas R","2026","Cell","other","article","10.1016/j.cell.2026.03.007","41903539","PMC13353064",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020072","Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6.","Shirazi R","2013","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.1306799110","24048027","PMC3791711",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020073","GLP-1 analogs containing disulfide bond exhibited prolonged half-life in vivo than GLP-1.","Li Y","2011","Peptides","preclinical","article","10.1016/j.peptides.2011.04.001","21515323",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020074","Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.","Elvert R","2018","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.13212","29938884","PMC6055720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0020075","Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat.","Yang H","2013","The Journal of surgical research","preclinical","article","10.1016/j.jss.2013.06.042","23890403",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020076","The pro-healing effect of exendin-4 on wounds produced by abrasion in normoglycemic mice.","Bacci S","2015","European journal of pharmacology","randomized_trial","article","10.1016/j.ejphar.2015.06.056","26164788",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020077","Correction to: Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK‑3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high‑fat dietstreptozocin rat model.","Moghazy HM","2024","Pflugers Archiv : European journal of physiology","notice","article","10.1007/s00424-024-02959-4","38575720","PMC11033220",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0020078","[Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].","Tamaki C","2015","Nihon yakurigaku zasshi. Folia pharmacologica Japonica","other_trial","article","10.1254/fpj.146.215","26656966",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0020079","Semaglutide in NASH-related Compensated Cirrhosis: Is There a Silver Lining?","Kumar A","2023","Journal of clinical and experimental hepatology","commentary","article","10.1016/j.jceh.2023.06.006","37975043","PMC10643501",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0020080","Plastic surgery amid a semaglutide epidemic: Direction for future studies and service implications.","Ragsdale LB","2024","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","commentary","article","10.1016/j.bjps.2024.05.045","38889587",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0020081","Enhancing GLP-1 expression via IVT mRNA and fusion protein technology for diabetes therapy.","Wu X","2025","Journal of pharmaceutical sciences","preclinical","article","10.1016/j.xphs.2025.103829","40393145",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020082","Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes.","Qiu M","2022","European journal of clinical pharmacology","systematic_review","article","10.1007/s00228-021-03261-3","34860262",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Network Meta-Analysis; article"],["R0020083","The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease.","Guo Z","2024","Pharmacological reports : PR","narrative_review","article","10.1007/s43440-024-00609-1","38890260",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020084","Multidisciplinary interventions: mapping new horizons in diabetes care.","Horton E","2008","The Diabetes educator","other","article","10.1177/0145721708321s148","18664711",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020085","Liraglutide suppresses TNF-α-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis.","Mei J","2019","American journal of translational research","other","article",null,"31497200","PMC6731440",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020086","A mouse model of weight gain after nicotine withdrawal.","Takeda K","2022","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2021.12.064","34954521",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020087","Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus.","Lim SW","2016","Scientific reports","preclinical","article","10.1038/srep29921","27436514","PMC4951772",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020088","GLP-1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of Bullous Pemphigoid.","Varpuluoma O","2021","The Journal of investigative dermatology","nonrandomized_study","article","10.1016/j.jid.2021.05.015","34116060",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0020089","Comprehensive Evaluation of a Levonorgestrel Intrauterine Device (LNG-IUD), Metformin, and Liraglutide for Fertility Preservation in Endometrial Cancer: Protocol for a Randomized Clinical Trial.","Leipold G","2024","Life (Basel, Switzerland)","protocol","article","10.3390/life14070835","39063589","PMC11278026",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0020090","Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model.","Fang X","2021","Life sciences","nonrandomized_study","article","10.1016/j.lfs.2020.118966","33482185",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0020091","Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption.","Chen C","2015","Journal of biomedical nanotechnology","preclinical","article","10.1166/jbn.2015.1971","26349398",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020092","Antihyperglycemic Drug Use in Long-Stay Nursing Home Residents with Diabetes Mellitus.","Hume AL","2022","The journal of nursing home research sciences","other","article",null,"36451895","PMC9706405",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020093","PI 3-kinase- and ERK-MAPK-dependent mechanisms underlie Glucagon-Like Peptide-1-mediated activation of Sprague Dawley colonic myenteric neurons.","O'Brien R","2019","Neurogastroenterology and motility","preclinical","article","10.1111/nmo.13631","31121089",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020094","Exendin-4 Promotes Beta Cell Proliferation via PI3k/Akt Signalling Pathway.","Wang C","2015","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","preclinical","article","10.1159/000374027","25895469",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020095","Protein transduction domain of translationally controlled tumor protein: characterization and application in drug delivery.","Maeng J","2022","Drug delivery","preclinical","article","10.1080/10717544.2022.2122636","36104954","PMC9481085",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0020096","Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes.","Huang J","2023","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2023.1130470","37255975","PMC10225703",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020097","Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.","Frias JP","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13764","31050143",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020098","Glycemic and weight control in people with type 2 diabetes: A real-world observational study in primary care.","Orozco-Beltran D","2025","Primary care diabetes","randomized_trial","article","10.1016/j.pcd.2024.12.002","39741072",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Observational Study; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0020099","Muscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase Data.","Ueta S","2026","Journal of cachexia, sarcopenia and muscle","nonrandomized_study","article","10.1002/jcsm.70251","41980862","PMC13078952",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020100","Epicardial adipose tissue and residual cardiovascular risk: a comprehensive case analysis and therapeutic insights with Liraglutide.","Cacciapuoti F","2024","Journal of cardiovascular medicine (Hagerstown, Md.)","case_report","article","10.2459/jcm.0000000000001652","38916237",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Case Reports; article"],["R0020101","Liraglutide (Victoza) for type 2 diabetes.",null,"2010","The Medical letter on drugs and therapeutics","other","article",null,"20360660",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020102","OR10-05 Improved Mental And Psychosocial Patient-Reported Outcomes Among People With Obesity Treated With Tirzepatide: Results From SURMOUNT-1 Study",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10553979",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0020103","No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery.","Welk B","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15711","38860419",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0020104","Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stresses.","Kim MK","2013","PloS one","preclinical","article","10.1371/journal.pone.0073340","24069189","PMC3777936",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020105","Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies.","Shubrook JH","2014","The Journal of the American Osteopathic Association","narrative_review","article","10.7556/jaoa.2014.088","24769506",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0020106","Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta-Analysis.","Faghfouri AH","2025","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13946","40437653",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0020107","Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis.","Heerspink HJL","2023","Diabetes care","other","article","10.2337/dc23-0261","37267479","PMC10369133",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; brief-report; article; other"],["R0020108","Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis.","Kushner RF","2024","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23946","37989717",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020109","Antidiabetic drug therapy alleviates type 1 diabetes in mice by promoting pancreatic α-cell transdifferentiation.","Sarnobat D","2020","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2020.114216","32926875","PMC7614179",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; preprint"],["R0020110","Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database.","Liu Y","2025","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1534628","39925851","PMC11802529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020111","Mortality for Any Hepatic Cause in People With Diabetes Compared to the Non-Diabetic Population. A 10-Year-Observational Study.","Giorda CB","2025","Liver international : official journal of the International Association for the Study of the Liver","nonrandomized_study","article","10.1111/liv.70075","40287817",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0020112","Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.","Wassef MAE","2018","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","preclinical","article","10.1055/s-0043-106859","28449155",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020113","Trimming down with semaglutide improves cardiac health in non-diabetic patients.","Tavosanis A","2024","Nature cardiovascular research","other","article","10.1038/s44161-024-00498-w","39196229",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020114","GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.","Kim M","2013","Nature medicine","preclinical","article","10.1038/nm.3128","23542788",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020115","Sex-divergent effects of hindbrain GLP-1-producing neuron activation in rats.","Lopez-Ferreras L","2023","Frontiers in neuroscience","preclinical","article","10.3389/fnins.2023.1265080","37942137","PMC10629595",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020116","A Shelf Stable Fmoc Hydrazine Resin for the Synthesis of Peptide Hydrazides.","Bird MJ","2022","Peptide science (Hoboken, N.J.)","other","article","10.1002/pep2.24268","36387422","PMC9662761",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article; preprint"],["R0020117","AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update.","Associazione Italiana per lo Studio del Fegato (AISF)","2026","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","other_trial","article","10.1016/j.dld.2026.02.014","41864758",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0020118","Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study.","Akturk HK","2025","Journal of diabetes science and technology","randomized_trial","article","10.1177/19322968231223991","38317405","PMC11571402",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0020119","Association of semaglutide with risk of suicidal ideation in a real-world cohort.","Wang W","2024","Nature medicine","nonrandomized_study","article","10.1038/s41591-023-02672-2","38182782","PMC11034947",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0020120","Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis.","Li Y","2012","PloS one","preclinical","article","10.1371/journal.pone.0032008","22384126","PMC3285661",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; research-article; article"],["R0020121","Glucose-Dependent Insulinotropic Polypeptide-A Postprandial Hormone with Unharnessed Metabolic Potential.","Guccio N","2022","Annual review of nutrition","narrative_review","article","10.1146/annurev-nutr-062320-113625","35609956",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0020122","Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.","Drab SR","2009","Pharmacotherapy","other_trial","article","10.1592/phco.29.pt2.43s","19947816",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0020123","Reduction of serum FABP4 level by sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus.","Furuhashi M","2015","Journal of lipid research","other","article","10.1194/jlr.m059469","26467280","PMC4655983",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Clinical Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020124","Author Correction: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.","Wang W","2024","Nature communications","notice","article","10.1038/s41467-024-49655-6","38890337","PMC11189541",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0020125","Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study.","Kick A","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01525-y","38240875","PMC10942937","ClinicalTrials.gov:NCT04537624","S000621","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020126","Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis.","Vinciguerra F","2024","Obesity surgery","systematic_review","article","10.1007/s11695-023-07053-9","38183597","PMC10811090",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020127","Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice.","Steven S","2017","British journal of pharmacology","preclinical","article","10.1111/bph.13549","27435156","PMC5446582",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020128","Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.","Bradley CL","2024","The Annals of pharmacotherapy","narrative_review","article","10.1177/10600280231224021","38247049","PMC10941707",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; reply; letter"],["R0020129","Tendency of Semaglutide to Induce Gastroparesis: A Case Report.","Chaudhry A","2024","Cureus","case_report","article","10.7759/cureus.52564","38371020","PMC10874596",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020130","The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.","Gaspari T","2013","Diabetes & vascular disease research","other_trial","article","10.1177/1479164113481817","23673376",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020131","Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update.","Prosperi D","2022","Journal of clinical medicine","narrative_review","article","10.3390/jcm11226836","36431313","PMC9694730",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020132","Using Corneal Confocal Microscopy to Identify Therapeutic Agents for Diabetic Neuropathy.","Jolivalt CG","2022","Journal of clinical medicine","preclinical","article","10.3390/jcm11092307","35566433","PMC9104226",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020133","THU280 Acute Interstitial Nephritis- A Complication Of Semaglutide Use",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10553574",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0020134","Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.","van der Aart-van der Beek AB","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15033","36843215",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0020135","Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE-/- mice.","Zhang L","2019","Annals of translational medicine","preclinical","article","10.21037/atm.2019.06.74","31555683","PMC6736830",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020136","Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model.","Moghazy HM","2024","Pflugers Archiv : European journal of physiology","preclinical","article","10.1007/s00424-024-02933-0","38536493","PMC11033245",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020137","A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.","Wilkins JJ","2014","Journal of clinical pharmacology","other_trial","article","10.1002/jcph.192","24122776",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020138","GLP-1 based therapies and disease course of inflammatory bowel disease.","Villumsen M","2021","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2021.100979","34386751","PMC8343256",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article; preprint"],["R0020139","Comparative Analysis of Pioglitazone and Tirzepatide on Body Weight, Glucose Levels, Neuroinflammation, and Oxidative Stress in Diabetic Rats.","Alhowail A","2025","Drug design, development and therapy","preclinical","article","10.2147/dddt.s525690","40771859","PMC12325112",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comparative Study; research-article; article"],["R0020140","Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.","Fadini GP","2024","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2024.100847","38328413","PMC10847023",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020141","Effect of placental restriction and neonatal exendin-4 treatment on postnatal growth, adult body composition, and in vivo glucose metabolism in the sheep.","Liu H","2015","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00487.2014","26219868","PMC4631533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020142","Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond.","Tsilingiris D","2024","Metabolism: clinical and experimental","other","article","10.1016/j.metabol.2023.155741","37995806",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020143","Semaglutide: A potential treatment of obesity in PCOD patients","Javeria f","2023","Authorea Preprints","other","preprint","10.22541/au.169502404.44735603/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020144","Cardiovascular Disease in Diabetes and Chronic Kidney Disease.","Swamy S","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm12226984","38002599","PMC10672715",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020145","Structural and functional diversity among agonist-bound states of the GLP-1 receptor.","Cary BP","2022","Nature chemical biology","nonrandomized_study","article","10.1038/s41589-021-00945-w","34937906","PMC8950777",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0020146","Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.","Nielsen LL","2004","Regulatory peptides","narrative_review","article","10.1016/j.regpep.2003.10.028","14700743",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020147","Efficacy and safety of incretin based therapies: clinical trial data.","White J","2009","Journal of the American Pharmacists Association : JAPhA","randomized_trial","article","10.1331/japha.2009.09079","19801363",null,null,"S000473","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020148","Expression of CTRP3, a novel adipokine, in rats at different pathogenic stages of type 2 diabetes mellitus and the impacts of GLP-1 receptor agonist on it.","Li X","2014","Journal of diabetes research","preclinical","article","10.1155/2014/398518","25177707","PMC4142547",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020149","Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.","Jacob S","2024","The Annals of pharmacotherapy","narrative_review","article","10.1177/10600280231224039","38247052","PMC10941706",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Letter; article"],["R0020150","2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Buse JB","2020","Diabetes care","other","article","10.2337/dci19-0066","31857443","PMC6971782",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Historical Article; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Consensus Statement; research-article; article"],["R0020151","Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis.","Wilke T","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-015-0149-4","26695499","PMC4801815",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020152","Investigation of the pancreatic safety of proglucagon-derived peptides and the development of novel anti-obesity agents","Akalestou E","2015","Imperial College London","other","article","10.25560/52648",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0020153","Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks.","German J","2025","medRxiv : the preprint server for health sciences","other","article","10.1101/2024.09.11.24313458","39314946","PMC11419199",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0020154","Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists: A meta-analysis.","Dai D","2019","Medicine","systematic_review","article","10.1097/md.0000000000017081","31490412","PMC6739021",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review-article; article"],["R0020155","Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.","Lee YS","2014","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2013.09.010","24140094",null,null,"S002543","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0020156","Effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial.","Waki K","2024","NPJ digital medicine","randomized_trial","article","10.1038/s41746-024-01114-8","38678094","PMC11055918",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020157","Glycaemic control in type 2 diabetes: targets and new therapies.","Tahrani AA","2010","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2009.11.001","19931305",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0020158","Small Bowel Obstruction Following Dislodgement of an Intragastric Balloon: A Case Report.","Brizuela L","2024","Cureus","case_report","article","10.7759/cureus.67738","39318932","PMC11421580",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020159","Exendin-4-encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes.","Fakhraei Lahiji S","2018","Scientific reports","preclinical","article","10.1038/s41598-018-19789-x","29348573","PMC5773556",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020160","Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes.","Cha AS","2021","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgaa894","33248440",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0020161","Adherence of physicians to evidence-based management guidelines for treating type 2 diabetes and atherosclerotic cardiovascular disease in Ajman, United Arab Emirates.","Alliabi FJA","2022","BMC primary care","nonrandomized_study","article","10.1186/s12875-022-01672-4","35392814","PMC8988318",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020162","Will Tirzepatide Become a Game-Changer Anti-Obesity Drug?","Kumar A","2023","Journal of clinical and experimental hepatology","commentary","article","10.1016/j.jceh.2023.01.012","37250871","PMC10213833",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0020163","[Prescribing a SGLT2 inhibitor for treating heart failure without inducing hypoglycaemia].","Scheen AJ","2022","Revue medicale de Liege","other","article",null,"36354232",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Practice Guideline; Journal Article; other"],["R0020164","Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.","Petralli G","2025","Acta diabetologica","other_trial","article","10.1007/s00592-025-02466-7","39954057",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0020165","Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.","Kanu C","2026","Advances in therapy","other_trial","article","10.1007/s12325-025-03386-2","41201783","PMC12858465","ClinicalTrials.gov:NCT04881760","S001653","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020166","Cardiovascular Protection with Anti-hyperglycemic Agents.","Deedwania P","2019","American journal of cardiovascular drugs : drugs, devices, and other interventions","other_trial","article","10.1007/s40256-019-00325-9","30767126",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0020167","Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.","Xia W","2024","Medicine","systematic_review","article","10.1097/md.0000000000037432","38489694","PMC10939689",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0020168","Preclinical Testing in Translational Animal Models of Prader-Willi Syndrome: Overview and Gap Analysis.","Carias KV","2019","Molecular therapy. Methods & clinical development","preclinical","article","10.1016/j.omtm.2019.03.001","30989085","PMC6447752",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020169","Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis.","Peverelle M","2023","World journal of gastroenterology","commentary","article","10.3748/wjg.v29.i47.6165","38186682","PMC10768411",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0020170","Pancreatic imaging using an antibody fragment targeting the zinc transporter type 8: a direct comparison with radio-iodinated Exendin-4.","Eriksson O","2018","Acta diabetologica","preclinical","article","10.1007/s00592-017-1059-x","29064047","PMC5794837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0020171","Neurobehavioral effects of liraglutide and sitagliptin in experimental models.","Kamble M","2016","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2016.02.003","26849938",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020172","Weekend therapy in diabetes.","Kalra S","2016","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"27183953",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020173","(64)Cu labeled sarcophagine exendin-4 for microPET imaging of glucagon like peptide-1 receptor expression.","Wu Z","2014","Theranostics","preclinical","article","10.7150/thno.7759","24955138","PMC4063975",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020174","Exenatide","Bridges A","2023","StatPearls Publishing, Treasure Island (FL)","other","article",null,"30085523",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0020175","Correction: Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.","Gullaksen S","2024","Diabetologia","notice","article","10.1007/s00125-024-06167-8","38739291",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0020176","Non-peptidic glucose-like peptide-1 receptor agonists: aftermath of a serendipitous discovery.","Wang MW","2010","Acta pharmacologica Sinica","commentary","article","10.1038/aps.2010.107","20676118","PMC4002298",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; editorial; article"],["R0020177","Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice.","Park KA","2020","Pharmaceutics","preclinical","article","10.3390/pharmaceutics12020159","32079069","PMC7076426",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020178","Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.","Li CX","2021","PloS one","systematic_review","article","10.1371/journal.pone.0244689","33606705","PMC7895346",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0020179","Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice.","Wan Y","2017","Frontiers in physiology","preclinical","article","10.3389/fphys.2017.00294","28555111","PMC5430033",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020180","Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?","Ferreira JP","2024","Journal of cardiac failure","other","article","10.1016/j.cardfail.2024.05.006","38838981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020181","SURMOUNTing body weight barriers in type 2 diabetes.","Novikoff A","2023","Med (New York, N.Y.)","other_trial","article","10.1016/j.medj.2023.11.007","38070476",null,null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020182","The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.","Varadhan L","2014","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2013.12.041","24456992",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020183","Society of Family Planning Committee Statement: Contraception and body weight.","Zwayne N","2025","Contraception","other","article","10.1016/j.contraception.2024.110725","39396749",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Practice Guideline"],["R0020184","Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India.","Kaur P","2014","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/2230-8210.126572","24701434","PMC3968738",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020185","Glucagon-Like Peptide-1-, but not Growth and Differentiation Factor 15-, Receptor Activation Increases the Number of Interleukin-6-Expressing Cells in the External Lateral Parabrachial Nucleus.","Anesten F","2019","Neuroendocrinology","preclinical","article","10.1159/000499693","30889580",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020186","Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.","Bailey CJ","2020","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(19)30414-0","31843565",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020187","Cerebral glucagon-like peptide-1 receptor activation alleviates traumatic brain injury by glymphatic system regulation in mice.","Lv C","2023","CNS neuroscience & therapeutics","preclinical","article","10.1111/cns.14308","37353947","PMC10651945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020188","GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.","Hegedüs L","2011","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2010-2318","21209033",null,"ClinicalTrials.gov:NCT00294723; ClinicalTrials.gov:NCT00318422; ClinicalTrials.gov:NCT00318461; ClinicalTrials.gov:NCT00333151; ClinicalTrials.gov:NCT00393718; ClinicalTrials.gov:NCT00395746","S000330; S000862; S001094; S001502; S001584; S002222","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0020189","[Incretin and incretin-based therapies].","Harada N","2010","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"20446595",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0020190","Emerging utility of once-weekly exenatide in patients with type 2 diabetes.","Goud A","2015","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s69354","26527891","PMC4621218",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020191","Wernicke Encephalopathy Associated With Semaglutide Use.","Sheth K","2024","Cureus","case_report","article","10.7759/cureus.61783","38975533","PMC11227085",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020192","Treatment patterns of antidiabetic and kidney protective therapies among patients with type 2 diabetes mellitus and chronic kidney disease in Colombia. The KDICO descriptive study.","Machado-Duque ME","2023","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-023-01126-6","37403118","PMC10318702",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0020193","Glucagon-like peptide-1 receptor biased agonism and its functional consequences in type 2 diabetes","Jones B","2017","Imperial College London","other","article","10.25560/65750",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0020194","Stable Constitutive BiP Expression Prolongs Late-Stage GLP-1-Fc Accumulation in CHO Cells.","Shaifutdinov RR","2026","Bioengineering (Basel, Switzerland)","other","article","10.3390/bioengineering13091001","42791873","PMC13603897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020195","GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.","Crisci I","2015","Acta diabetologica","other","article","10.1007/s00592-015-0800-6","26293127",null,null,"S000291","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020196","Liraglutide modulates morpho-functional and inflammatory gastrointestinal responses in rats.","Gusmão-Nascimento JW","2024","European journal of clinical investigation","preclinical","article","10.1111/eci.14112","37846206",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020197","Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives.","Ding B","2024","Acta pharmaceutica Sinica. B","narrative_review","article","10.1016/j.apsb.2024.02.019","38799624","PMC11120284",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020198","GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats.","Ku HC","2010","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-010-0559-9","20852989",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0020199","[Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].","Sugii H","2010","Nihon yakurigaku zasshi. Folia pharmacologica Japonica","other","article","10.1254/fpj.136.233","20948161",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020200","Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.","Kim YG","2014","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12293","24655583",null,null,"S000298","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0020201","Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases.","Behrooz L","2023","Current cardiology reports","narrative_review","article","10.1007/s11886-023-01961-z","37874468","PMC10682277",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0020202","Long-acting preparations of exenatide.","Cai Y","2013","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s46970","24039406","PMC3771853",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0020203","Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes.","Mahzari MM","2024","Journal of clinical & translational endocrinology","nonrandomized_study","article","10.1016/j.jcte.2024.100343","38623181","PMC11016780",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020204","Anti-Obesity Medication and Household Food Waste","Mansouri J","2024","Preprints.org","other","preprint","10.20944/preprints202408.2067.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020205","Combining SNAC and C10 in oral tablet formulations for gastric peptide delivery: A preclinical and clinical study.","Niu Z","2025","Journal of controlled release : official journal of the Controlled Release Society","other","article","10.1016/j.jconrel.2024.11.078","39645088",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020206","Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses.","Saumoy M","2023","Gut","other","article","10.1136/gutjnl-2023-330437","37524445",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020207","Pilot study to test the safety, tolerability and feasibility of dulaglutide during a low-energy diet for weight loss and improved glycaemic control.","Shand JAD","2023","BMJ nutrition, prevention & health","nonrandomized_study","article","10.1136/bmjnph-2023-000733","38264361","PMC10800248",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020208","Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.","Verma S","2021","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14360","33606902","PMC8251906","ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0020209","Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison.","Yokote K","2024","Advances in therapy","systematic_review","article","10.1007/s12325-024-02941-7","39039386","PMC11349800",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0020210","Obestatin can potentially differentiate Wharton's jelly mesenchymal stem cells into insulin-producing cells.","El-Asfar RK","2018","Cell and tissue research","preclinical","article","10.1007/s00441-017-2725-6","29159483",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020211","Novel XTENylated AWRK6 analog with hypoglycemic activity, and anti-HSV-2 potential in combination with double shRNA.","Zhang X","2021","Life sciences","preclinical","article","10.1016/j.lfs.2021.119313","33667511",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020212","Semaglutide may provide sustained weight loss for at least four years, study reports.","Mahase E","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1113","38754922",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; other"],["R0020213","Exenatide reverts the high-fat-diet-induced impairment of BDNF signaling and inflammatory response in an animal model of Alzheimer’s disease","Bomba M","2018","bioRxiv","preclinical","preprint","10.1101/487629",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020214","Efficacy of semaglutide versus liraglutide in clinical practice.","Goncalves E","2020","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2019.10.001","31606525",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0020215","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Alters Bone Marrow Exosome-Mediated miRNA Signal Pathways in Ovariectomized Rats with Type 2 Diabetes.","Li J","2017","Medical science monitor : international medical journal of experimental and clinical research","preclinical","article","10.12659/msm.906603","29133778","PMC5699170",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020216","Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures.","Guy A","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15436","38240127",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0020217","Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes.","Barnett AH","2011","Core evidence","other_trial","article","10.2147/ce.s15525","22022289","PMC3195668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0020218","In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status.","Lau D","2024","Annals of internal medicine","other_trial","article","10.7326/j24-0025","38710083",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; article"],["R0020219","FRI063 Effectiveness Of Liraglutide In Treating Obesity And Improving Hepatic Steatosis",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10553479",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0020220","Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes.","Patoulias D","2024","European journal of internal medicine","commentary","article","10.1016/j.ejim.2023.12.022","38151420",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0020221","Sex-Differences in Response to Treatment with Liraglutide 3.0 mg.","Milani I","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13123369","38929898","PMC11204191",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020222","MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues.","Ha S","2026","Science bulletin","other_trial","article","10.1016/j.scib.2026.04.048","42115049",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0020223","Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.","Kosiborod MN","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2313917","38587233",null,"ClinicalTrials.gov:NCT04916470","S000161","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0020224","Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of rapamycin pathway in a streptozotocin-induced mouse model of diabetes.","Kong FJ","2018","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2018.01.001","29305122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020225","[Incretin-based therapy in type 2 diabetes does not increase the risk of hospitalization for heart failure].","Steurer J","2016","Praxis","other","article","10.1024/1661-8157/a002393","27329712",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020226","Coronary Artery Calcium for the Allocation of GLP-1RA for Primary Prevention of Atherosclerotic Cardiovascular Disease.","Cainzos-Achirica M","2021","JACC. Cardiovascular imaging","commentary","article","10.1016/j.jcmg.2020.12.024","33582063",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0020227","Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review.","Christ E","2010","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2010.09.003","21095545",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020228","Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.","Anyanwagu U","2018","American heart journal","nonrandomized_study","article","10.1016/j.ahj.2017.10.003","29421011",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Comparative Study; Journal Article; article"],["R0020229","Generic Long-Acting Injectable Product Availability and Approval Standards.","Anim Anno K","2026","Pharmaceutical research","other","article","10.1007/s11095-026-04159-4","42675372","PMC13636437",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0020230","Dietary Calanus oil recovers metabolic flexibility and rescues postischemic cardiac function in obese female mice.","Jansen KM","2019","American journal of physiology. Heart and circulatory physiology","preclinical","article","10.1152/ajpheart.00191.2019","31125256",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020231","Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways.","Wang J","2021","Acta biochimica et biophysica Sinica","preclinical","article","10.1093/abbs/gmab099","34357376",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020232","Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.","Antwi K","2018","European journal of nuclear medicine and molecular imaging","randomized_trial","article","10.1007/s00259-018-4101-5","30054698",null,"ClinicalTrials.gov:NCT02127541","S000994","pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Clinical Trial; Comparative Study; Journal Article; article"],["R0020233","Updates of precision medicine in type 2 diabetes.","Xia M","2023","Cambridge prisms. Precision medicine","narrative_review","article","10.1017/pcm.2023.12","38550950","PMC10953763",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020234","Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes.","Lo CWH","2021","Cardiac failure review","narrative_review","article","10.15420/cfr.2020.19","33747548","PMC7970669",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020235","Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.","Kakimoto T","2013","The Journal of endocrinology","preclinical","article","10.1530/joe-12-0456","23092878",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Validation Study; article"],["R0020236","Semaglutide: A Promising Treatment for Alcohol Use Disorder","Patton C","2023","Preprints.org","other","preprint","10.20944/preprints202310.1883.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020237","Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study.","van Houtum W","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-024-01588-5","38861137","PMC11263532","ClinicalTrials.gov:NCT04601740","S001499","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020238","Response by Kosiborod et al to Letter Regarding Article, \"Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial\".","Kosiborod MN","2024","Circulation","other_trial","article","10.1161/circulationaha.124.069707","39226383",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; article"],["R0020239","Azoramide, a novel regulator, favors adipogenesis against osteogenesis through inhibiting the GLP-1 receptor-PKA-β-catenin pathway.","Ruan B","2018","Stem cell research & therapy","preclinical","article","10.1186/s13287-018-0771-y","29523188","PMC5845182",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; research-article; article"],["R0020240","Serious acute biliary reporting with glucagon-like peptide-1-based therapies versus sodium-glucose cotransporter-2 inhibitors in type 2 diabetes","Martinc B","2026","Authorea Preprints","other","preprint","10.22541/authorea.15006544/v1",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0020241","Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts.","Tian L","2011","Transplant international : official journal of the European Society for Organ Transplantation","preclinical","article","10.1111/j.1432-2277.2011.01275.x","21627696",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020242","Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness.","Rogliani P","2016","American journal of respiratory cell and molecular biology","other","article","10.1165/rcmb.2015-0311oc","27447052",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020243","Detection of impaired cognitive function in rat with hepatosteatosis model and improving effect of GLP-1 analogs (exenatide) on cognitive function in hepatosteatosis.","Erbaş O","2014","TheScientificWorldJournal","preclinical","article","10.1155/2014/946265","24741367","PMC3967460",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020244","Unraveling the impact of semaglutide in a diabetic rat model of testicular dysfunction: Insights into spermatogenesis pathways and miRNA-148a-5p.","Abdel-Wahab BA","2025","Steroids","preclinical","article","10.1016/j.steroids.2024.109537","39551458",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020245","A Specific HPLC Method to Determine Residual HEPES in [68Ga]Ga-Radiopharmaceuticals: Development and Validation.","Migliari S","2022","Molecules (Basel, Switzerland)","other","article","10.3390/molecules27144477","35889351","PMC9323806",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020246","Efficacy of Anti-Obesity Medications in Adult and Older Adult Veteran Populations.","Smit H","2025","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","other","article","10.12788/fp.0553","40529839","PMC12169629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020247","GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.","Pastel E","2017","Clinical science (London, England : 1979)","randomized_trial","article","10.1042/cs20160803","28049736",null,null,"S000371; S002196","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0020248","In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.","Koutroumpakis E","2024","Annals of internal medicine","other_trial","article","10.7326/j24-0008","38437690",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; article"],["R0020249","Tirzepatide (type 2 diabetes mellitus): Benefit assessment according to §35a SGB V, IQWiG Reports – Commission No. A23-112",null,"2024","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne (Germany)","narrative_review","article",null,"39808009",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0020250","Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.","McCoy RG","2021","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2020.35792","33523188","PMC7851726",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0020251","Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective.","Song ZH","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.900114","35707460","PMC9190279",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0020252","Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.","Jones B","2021","The Journal of biological chemistry","other","article","10.1074/jbc.ra120.016334","33268378","PMC7948418",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020253","Chronic Disease and Disability in the United States: Trends, Inequities, and Imperatives for Policy Reform.","Mokdad AH","2026","The Milbank quarterly","other","article","10.1111/1468-0009.70109","42596762","PMC13559945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0020254","Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis.","Fan R","2010","Diabetes, obesity & metabolism","other","article","10.1111/j.1463-1326.2010.01238.x","20649634",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020255","Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second-line treatment), and in combination with metformin and sulfonylurea (third-line treatment)",null,"2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"31305971",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0020256","Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis.","Suri J","2022","World journal of gastroenterology","other_trial","article","10.3748/wjg.v28.i35.5129","36188726","PMC9516677",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0020257","Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and Readmissions.","Magruder ML","2024","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2023.12.023","38122837",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0020258","Exploratory Biomarker-Defined Phenotypic Heterogeneity Beyond a Single Physiological Reserve Construct.","AlTaweel MO","2026","Journal of personalized medicine","nonrandomized_study","article","10.3390/jpm16090481","42783512","PMC13608149",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020259","Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.","Marchesini G","2019","Acta diabetologica","other","article","10.1007/s00592-018-1236-6","30306406",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020260","Albumin-based delivery systems: Recent advances, challenges, and opportunities.","Murphy G","2025","Journal of controlled release : official journal of the Controlled Release Society","narrative_review","article","10.1016/j.jconrel.2025.01.035","39842723",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0020261","Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes.","Bayram E","2020","Brain : a journal of neurology","nonrandomized_study","article","10.1093/brain/awaa287","33103730","PMC7586082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment; discussion; article"],["R0020262","Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.","Xu Q","2015","Journal of drug targeting","preclinical","article","10.3109/1061186x.2015.1020808","25758750",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020263","Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.","Pedersen SD","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15140","37246796",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020264","Approved and Commercialized Antidiabetic Medicines (Excluding Insulin) in Seven European Countries-A Cross-Sectional Comparison.","Atănăsoie AM","2024","Pharmaceuticals (Basel, Switzerland)","other","article","10.3390/ph17060793","38931460","PMC11207096",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020265","Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care.","Morieri ML","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-023-01490-6","37848758","PMC10597935",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020266","Obesity and Asthma: Implementing a Treatable Trait Care Model.","Mendes FC","2024","Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","narrative_review","article","10.1111/cea.14520","38938020",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0020267","Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors","Zhao F","2021","bioRxiv","other","preprint","10.1101/2021.07.29.454286",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020268","[Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances].","Liu Y","2017","Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","narrative_review","article","10.3760/cma.j.issn.1007-3418.2017.06.018","28763870","PMC12769154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020269","Comments to the Editor Concerning the Paper Entitled \"Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4\" Mohamed Abd Elaziz Wassef et al.","Hamza AA","2018","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","commentary","article","10.1055/s-0043-121266","29117623",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; letter"],["R0020270","Food Cravings and Obesity in Women with Polycystic Ovary Syndrome: Pathophysiological and Therapeutic Considerations.","Stefanaki K","2024","Nutrients","narrative_review","article","10.3390/nu16071049","38613082","PMC11013286",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020271","Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.","Oe Y","2023","Advances in therapy","randomized_trial","article","10.1007/s12325-022-02327-7","36306064",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Letter; letter"],["R0020272","Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.","Ohri S","2026","American family physician","narrative_review","article",null,"42301877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020273","Losing weight plus vitamin B12 following semaglutide administration? A case of false B12 deficiency","Rizos EC","2024","Research Square","case_report","preprint","10.21203/rs.3.rs-4007021/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020274","Tirzepatide for treating type 2 diabetes",null,"2023","National Institute for Health and Care Excellence (NICE), London","narrative_review","article",null,"40198027",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0020275","Do GLP-1 Receptor Agonists Care if You Have Heart Failure?","Arnott C","2019","Circulation","commentary","article","10.1161/circulationaha.119.043303","31710527",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0020276","Efficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis.","Yang XL","2017","Journal of cellular biochemistry","systematic_review","article","10.1002/jcb.26115","28471499",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; Network Meta-Analysis; article"],["R0020277","Sustained metabolic benefits of ΔTRTX-Ac1, a tarantula venom-derived peptide, when administered together with exenatide in high-fat fed mice.","Coulter-Parkhill A","2024","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.15319","37818589",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020278","Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats.","Briyal S","2012","Brain research","preclinical","article","10.1016/j.brainres.2011.10.026","22055454",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020279","Liraglutide provides neuroprotection by regulating autophagy through the AMPK-FOXO3 signaling pathway in a spinal contusion injury rat model.","Zhang D","2020","Neuroscience letters","preclinical","article","10.1016/j.neulet.2020.134747","31927057",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020280","Does liraglutide alleviate inflammation in brain-dead donors? A randomized clinical trial.","Custódio G","2024","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","randomized_trial","article","10.1097/lvt.0000000000000298","37938130",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020281","A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.","King AB","2017","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2016.0405","28282219","PMC5399738","ClinicalTrials.gov:NCT01336023; ClinicalTrials.gov:NCT01392573","S001276; S002285","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0020282","Liraglutide protects palmitate-induced INS-1 cell injury by enhancing autophagy mediated via FoxO1.","Li XD","2021","Molecular medicine reports","preclinical","article","10.3892/mmr.2020.11786","33355375","PMC7789139",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020283","Semaglutide and Patients Receiving Hemodialysis: Case Reports of Unexpected Benefits for Hyperphosphatemia and Hyperkalemia.","Dobson R","2024","The Canadian journal of hospital pharmacy","case_report","article","10.4212/cjhp.3534","38720915","PMC11060791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020284","Exenatide promotes regeneration of injured rat sciatic nerve.","Kuyucu E","2017","Neural regeneration research","preclinical","article","10.4103/1673-5374.205105","28553346","PMC5436364",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020285","Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.","Yu M","2016","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12624","26691396",null,"ClinicalTrials.gov:NCT00734474; ClinicalTrials.gov:NCT01064687; ClinicalTrials.gov:NCT01075282; ClinicalTrials.gov:NCT01126580; ClinicalTrials.gov:NCT01191268; ClinicalTrials.gov:NCT01624259","S001130; S001184; S001198; S001242; S001786; S002153","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020286","Dermatologic findings associated with semaglutide use: A scoping review.","Tran MM","2024","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2024.03.021","38554940",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; Scoping Review; article"],["R0020287","Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice.","Gezginci-Oktayoglu S","2011","Peptides","preclinical","article","10.1016/j.peptides.2010.10.025","21055431",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020288","The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type Ⅱ collagen and aggrecan in human SW1353 chondrocytes.","Li H","2020","Chemico-biological interactions","other","article","10.1016/j.cbi.2020.108968","32004530",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020289","Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats.","Kloock S","2024","Nutrients","randomized_trial","article","10.3390/nu16060904","38542814","PMC10974407",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020290","GLP-1R knockdown abrogates the protective effects of liraglutide on ischaemic stroke via inhibition of M2 polarisation and activation of NLRP3 inflammasome by reducing Nrf2 activation.","Tu XK","2023","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2023.109603","37236529",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020291","Semaglutide in Heart Failure With Preserved Ejection Fraction: Benefits Above and Beyond Weight Loss.","Kobak KA","2023","JACC. Basic to translational science","commentary","article","10.1016/j.jacbts.2023.07.016","38094694","PMC10714162",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0020292","[Exendin-4 promotes paracrine action of adipose-derived stem cells through PI3K/Akt signaling pathways].","Zhou H","2014","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article",null,"25345931",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020293","Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications.","Unger JR","2011","Diabetes therapy : research, treatment and education of diabetes and related disorders","preclinical","article","10.1007/s13300-010-0013-5","22127767","PMC3124643",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0020294","Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon-a Case-Matched Study.","Badurdeen D","2021","Obesity surgery","randomized_trial","article","10.1007/s11695-020-05117-8","33211267",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0020295","Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943.","Regmi A","2023","STAR protocols","other","article","10.1016/j.xpro.2023.102304","37178114","PMC10200971",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020296","Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use.","Hurtado MD","2024","Menopause (New York, N.Y.)","nonrandomized_study","article","10.1097/gme.0000000000002310","38446869","PMC11209769",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020297","Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials.","Araki E","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14536","34472698","PMC9293331",null,"S000133; S001741; S002267","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0020298","Advances in the clinical measurement of glucagon: from diagnosis to therapy.","Kitamura T","2024","Diabetology international","narrative_review","article","10.1007/s13340-024-00704-x","39101188","PMC11291789",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0020299","An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.","Okere AN","2018","Current diabetes reviews","systematic_review","article","10.2174/1573399813666170724113240","28738763",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0020300","Anti-Obesity Medication Use in Children and Adolescents with Prader-Willi Syndrome: Case Review and Literature Search.","Goldman VE","2021","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm10194540","34640558","PMC8509766",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020301","Glycemia shifts pancreatic islet rhythmicity by influencing interactions between δ cells and α cells.","Deng Y","2026","Cell systems","preclinical","article","10.1016/j.cels.2026.101568","41916313",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020302","An update on exenatide, a novel therapeutic option for patients with type 2 diabetes.","Crasto W","2011","Drugs of today (Barcelona, Spain : 1998)","other_trial","article","10.1358/dot.2011.47.11.1688575","22146227",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020303","Revealing the tissue-level complexity of endogenous glucagon-like peptide-1 receptor expression and signaling.","Ast J","2023","Nature communications","preclinical","article","10.1038/s41467-022-35716-1","36653347","PMC9849236",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020304","Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA/ROCK Pathway and Autophagy in Diabetes Mellitus.","Yuan P","2020","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2020.01257","32903510","PMC7435068",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020305","Effects of exendin-4 on male reproductive parameters of d-galactose induced aging mouse model.","Ahangarpour A","2014","The world journal of men's health","preclinical","article","10.5534/wjmh.2014.32.3.176","25606567","PMC4298821",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020306","Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.","Gejl M","2017","Scientific reports","randomized_trial","article","10.1038/s41598-017-17718-y","29235507","PMC5727512",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0020307","Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System.","Yang M","2020","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2020.00432","32322207","PMC7156971",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020308","Semaglutide Pretreatment Induces Cardiac Autophagy to Reduce Myocardial Injury in Septic Mice.","Zhang W","2023","Discovery medicine","preclinical","article","10.24976/discov.med.202335178.80","37811623",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020309","Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.","Cukierman-Yaffe T","2020","The Lancet. Neurology","randomized_trial","article","10.1016/s1474-4422(20)30173-3","32562683",null,"ClinicalTrials.gov:NCT01394952","S000147; S000766","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020310","Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study.","Seo JY","2023","Annals of pediatric endocrinology & metabolism","nonrandomized_study","article","10.6065/apem.2244196.098","36758973","PMC10765027",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020311","Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa.","Nicolau J","2024","Medicina clinica","other","article","10.1016/j.medcli.2023.11.007","38044187",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020312","The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide.","Shapira-Furman T","2024","Molecules (Basel, Switzerland)","preclinical","article","10.3390/molecules29163909","39202988","PMC11356839",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020313","The Novel Tetra-Specific Drug C-192, Conjugated Using UniStac, Alleviates Non-Alcoholic Steatohepatitis in an MCD Diet-Induced Mouse Model.","Kim J","2023","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph16111601","38004466","PMC10674394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020314","Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice.","Rachmany L","2013","Age (Dordrecht, Netherlands)","preclinical","article","10.1007/s11357-012-9464-0","22892942","PMC3776106",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020315","Therapeutic targets of antidiabetic drugs and kidney stones: A druggable mendelian randomization study and experimental study in rats.","Wu M","2025","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.177197","39662658",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020316","The Potential Weight Loss Benefits Of Tirzepatide: A Double-Edged Sword?","Nasim MT","2023","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.9519","38013572",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020317","Reply to Du et al.-Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke.","Ali MU","2023","The Canadian journal of cardiology","commentary","article","10.1016/j.cjca.2022.09.017","36152771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; letter"],["R0020318","Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist.","Bossart M","2022","Cell metabolism","preclinical","article","10.1016/j.cmet.2021.12.005","34932984",null,"ClinicalTrials.gov:NCT04521738","S003242","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020319","Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation.","Moschovaki Filippidou F","2020","The American journal of pathology","randomized_trial","article","10.1016/j.ajpath.2019.10.008","31759969",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020320","Towards Sustainable Synthesis of Peptide Therapeutics via Tag-Assisted Peptide Synthesis and Aryl Selenoester Aminolysis Ligation.","Egelund PHG","2026","Journal of the American Chemical Society","other","article","10.1021/jacs.6c05882","42275598",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020321","SUN-165 The Largest Single-Center Experience of GLP-1 Receptor Agonists as a Safe and Effective Agent for the Management of Diabetes in Solid Organ Transplant (SOT) Recipients","Singh P","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-sun-165",null,"PMC6553350",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0020322","Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.","Vergès B","2021","Diabetes care","preclinical","article","10.2337/dc20-1843","33531418",null,"ClinicalTrials.gov:NCT02721888","S000705","pubmed; europepmc; openalex","TRUE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0020323","Glucose metabolism impairment in Parkinson's disease.","Dai C","2023","Brain research bulletin","narrative_review","article","10.1016/j.brainresbull.2023.110672","37210012",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0020324","Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.","Shamardl HAMA","2023","Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","preclinical","article","10.1007/s40199-023-00458-y","36991247","PMC10238348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020325","The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications.","Drucker DJ","2018","Diabetes","narrative_review","article","10.2337/dbi18-0008","30135132",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020326","Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.","Gastaldelli A","2013","Metabolism: clinical and experimental","other_trial","article","10.1016/j.metabol.2013.05.001","23831441",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020327","Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis.","Hu S","2023","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-023-01195-7","37891683","PMC10612199",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; other; review"],["R0020328","A comprehensive assessment of the association between common drugs and psychiatric disorders using Mendelian randomization and real-world pharmacovigilance database.","Chen Z","2024","EBioMedicine","nonrandomized_study","article","10.1016/j.ebiom.2024.105314","39191171","PMC11400609",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020329","Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.","Liu L","2023","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","randomized_trial","article","10.1055/a-2145-1004","37524110","PMC10645484","ClinicalTrials.gov:NCT02303730","S000885","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Multicenter Study; Journal Article; research-article; article"],["R0020330","Response by Lam and Gerstein to Letter Regarding Article, \"Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial\".","Lam CSP","2022","Circulation","other_trial","article","10.1161/circulationaha.122.060526","35858159",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Letter; Comment; article"],["R0020331","Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.","McClean PL","2010","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2009.12.023","20035739",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020332","Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice.","Yang Y","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s456336","38496002","PMC10942255",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020333","Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.","Liu C","2021","Bioorganic chemistry","preclinical","article","10.1016/j.bioorg.2020.104492","33268008",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020334","Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?","Hamasaki H","2018","World journal of diabetes","commentary","article","10.4239/wjd.v9.i8.138","30147850","PMC6107470",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0020335","Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model.","Navabi R","2021","Life sciences","randomized_trial","article","10.1016/j.lfs.2021.119374","33745896",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0020336","Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders.","Mansur RB","2017","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","other_trial","article","10.1016/j.euroneuro.2017.08.433","28867303",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0020337","Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.","Zhu T","2015","International journal of molecular sciences","preclinical","article","10.3390/ijms160920195","26343632","PMC4613197",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020338","A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.","Gaspari T","2011","Diabetes & vascular disease research","preclinical","article","10.1177/1479164111404257","21562063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020339","The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.","Secher A","2014","The Journal of clinical investigation","preclinical","article","10.1172/jci75276","25202980","PMC4215190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020340","Is It Time for a New Algorithm for the Pharmacotherapy of Steroid-Induced Diabetes?","Ostrowska-Czyżewska A","2024","Journal of clinical medicine","narrative_review","article","10.3390/jcm13195801","39407860","PMC11605232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020341","Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review.","Epelde F","2024","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina60121986","39768866","PMC11727843",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020342","Discovery of a potential positive allosteric modulator of glucagon-like peptide 1 receptor through virtual screening and experimental study.","Redij T","2019","Journal of computer-aided molecular design","preclinical","article","10.1007/s10822-019-00254-4","31758355",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0020343","Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 Inhibitor Use and Recent Sleeve Gastrectomy.","Smith A","2021","Cureus","case_report","article","10.7759/cureus.14297","33968511","PMC8097746",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020344","Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.","Kawaguchi Y","2023","Advances in therapy","randomized_trial","article","10.1007/s12325-022-02328-6","36261771",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Letter; letter"],["R0020345","Depot-specific differences and heterogeneity of adipose-derived stem cells in diet-induced obesity.","Guo H","2024","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.24149","39496515",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020346","The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study.","Stougaard EB","2025","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.16606","40726451",null,null,"S002443","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Clinical Trial Protocol; article"],["R0020347","Semaglutide and Cardiovascular Outcomes.","Taqueti VR","2024","The New England journal of medicine","other_trial","article","10.1056/nejmc2400414","38381682",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0020348","Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.","Ludvik B","2018","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(18)30023-8","29483060",null,"ClinicalTrials.gov:NCT02597049","S000305","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; article"],["R0020349","Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging Therapies","Beiriger J","2023","Preprints.org","narrative_review","preprint","10.20944/preprints202308.1134.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; article; preprint"],["R0020350","Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss.","Avraham SA","2024","Anaesthesia reports","case_report","article","10.1002/anr3.12278","38225986","PMC10788311",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020351","Oral proniosomal amitriptyline and liraglutide for management of diabetic neuropathy: Exceptional control over hyperglycemia and neuropathic pain.","Eissa RG","2023","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2023.123549","37890645",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020352","Management of Type 2 Diabetes Mellitus in the Very Elderly: One Practice's Experience.","Grajower MM","2023","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.1016/j.eprac.2023.03.271","36965656",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0020353","Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond.","Dutta P","2023","Cureus","other_trial","article","10.7759/cureus.38379","37265914","PMC10231274",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0020354","Correction: Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.","Chepurny OG","2019","The Journal of biological chemistry","notice","article","10.1074/jbc.aac119.009193","31152095","PMC6552436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0020355","Potential cardiorenal benefits of efpeglenatide in diabetes.","Ma J","2021","Nature reviews. Nephrology","other","article","10.1038/s41581-021-00475-7","34385677",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020356","The impact of glucagon and exenatide on oxidative stress levels and antioxidative enzyme expression in in vitro induced steatosis in HepG2 cell culture.","Bołdys A","2024","Endokrynologia Polska","preclinical","article","10.5603/ep.99891","39279311",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020357","Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear.","Sarpatwari A","2021","Health affairs (Project Hope)","other","article","10.1377/hlthaff.2020.01436","33939506",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020358","The crucial relationship between miRNA-27 and CSE/H2S, and the mechanism of action of GLP-1 in myocardial hypertrophy.","Gao S","2024","International journal of medical sciences","preclinical","article","10.7150/ijms.93720","38616996","PMC11008482",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020359","Research digest: pioneering an oral GLP-1 receptor agonist.","Atkinson MA","2019","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(19)30360-2","31748168",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020360","When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning.","Emanuele E","2026","Fundamental & clinical pharmacology","narrative_review","article","10.1111/fcp.70109","42485552","PMC13391034",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020361","Role of Lrp5/6-activated Wnt signaling in the promotion of implant osseointegration and regulation of osteogenic &amp; lipogenic induction via exenatide in T2DM rats","Liu X","2023","Research Square","preclinical","preprint","10.21203/rs.3.rs-2781618/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020362","New labdane diterpenoids from Alpinia galanga: A new type of GLP-1 secretagogues targeting the PKA-CREB and PI3K-Akt signaling axes.","Liu P","2024","Archiv der Pharmazie","other","article","10.1002/ardp.202400383","39031533",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020363","Case report: Tirzepatide for mitochondrial diabetes mellitus with a mutation at position 3271 and transient GAD antibody positivity.","Suzuki Y","2024","Diabetes research and clinical practice","case_report","article","10.1016/j.diabres.2023.111035","38061447",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0020364","Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice.","Simonds SE","2019","Diabetes","preclinical","article","10.2337/db18-1149","30674622",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020365","Alleviation of hyperglycemia induced vascular endothelial injury by exenatide might be related to the reduction of nitrooxidative stress.","Zhao Q","2013","BioMed research international","preclinical","article","10.1155/2013/843657","24371833","PMC3858999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020366","Vagal mediation of GLP-1's effects on food intake and glycemia.","Krieger JP","2015","Physiology & behavior","narrative_review","article","10.1016/j.physbeh.2015.06.001","26048300",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0020367","Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.","Giorgino F","2011","Journal of endocrinological investigation","narrative_review","article","10.1007/bf03346698","21233599",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020368","Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice.","Zhou Y","2023","Journal of cardiovascular development and disease","randomized_trial","article","10.3390/jcdd10090386","37754815","PMC10531705",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020369","Direct suppression of human islet dedifferentiation, progenitor genes, but not epithelial to mesenchymal transition by liraglutide.","Rattanaamnuaychai P","2020","Heliyon","other","article","10.1016/j.heliyon.2020.e04951","32995630","PMC7501427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020370","Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice.","Egede LE","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00850-w","32506223","PMC7324461",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0020371","Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.","Zeng Q","2024","Frontiers in endocrinology","notice","article","10.3389/fendo.2024.1342543","38549766","PMC10976973",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0020372","Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.","Wang M","2013","International journal of nanomedicine","preclinical","article","10.2147/ijn.s41457","23658482","PMC3607418",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020373","FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade.","Idrees Z","2022","Cureus","nonrandomized_study","article","10.7759/cureus.29262","36277516","PMC9579826",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0020374","A microporous liraglutide-releasing silk fibroin scaffold improves islet transplantation outcomes through anti-inflammatory effect.","Zhan Y","2025","Cell transplantation","preclinical","article","10.1177/09636897251374147","40956865","PMC12441293",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020375","Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease.","Li S","2018","Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","preclinical","article","10.1590/1414-431x20187299","29924135","PMC6010322",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020376","Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis.","Yu B","2022","Scientific reports","systematic_review","article","10.1038/s41598-022-22263-4","36316432","PMC9622886",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; research-article; review"],["R0020377","Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY.","Doggrell SA","2015","Expert review of endocrinology & metabolism","randomized_trial","article","10.1586/17446651.2015.995629","30298769",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0020378","Correction: In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products.","PLOS ONE Staff","2015","PloS one","notice","article","10.1371/journal.pone.0125296","25881191","PMC4399979",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0020379","Mechanisms and therapeutic insights into MASH-associated fibrosis.","Zhu Y","2026","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2025.09.004","41015698","PMC12958455",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0020380","Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB.","Cunha DA","2009","Diabetes","preclinical","article","10.2337/db09-0685","19720788","PMC2780890",null,"S002455","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020381","Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats.","Abtahi S","2018","Neuroreport","preclinical","article","10.1097/wnr.0000000000001071","29927808",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020382","Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).","Buse JB","2009","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(09)60659-0","19515413",null,"ClinicalTrials.gov:NCT00518882","S001123; S002230","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020383","Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.","Ali DA","2025","Journal of biochemical and molecular toxicology","preclinical","article","10.1002/jbt.70606","41268769",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020384","Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.","Frazer M","2023","Advances in therapy","nonrandomized_study","article","10.1007/s12325-023-02677-w","37740832","PMC10567941",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020385","Novel Monoclonal Antibody Is an Allosteric Insulin Receptor Antagonist That Induces Insulin Resistance.","Cieniewicz AM","2017","Diabetes","preclinical","article","10.2337/db16-0633","27797911",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020386","Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.","Butler J","2023","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2023.09.811","37993201","PMC11185158","ClinicalTrials.gov:NCT04788511","S002012","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0020387","Liraglutide for type 2 diabetes mellitus.","Kela R","2011","Expert opinion on biological therapy","other_trial","article","10.1517/14712598.2011.583641","21563859",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020388","No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.","Duvillard L","2024","Diabetes & metabolism","other","article","10.1016/j.diabet.2024.101535","38653365",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020389","Letter by Groothof et al Regarding Article, \"Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial\".","Groothof D","2022","Circulation","other_trial","article","10.1161/circulationaha.122.060263","35858158",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; Comment; article"],["R0020390","Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.","Gou H","2023","European journal of pediatrics","systematic_review","article","10.1007/s00431-023-05186-8","37672063",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0020391","Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.","Hakariya H","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15638","38747140",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0020392","Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.","Pieber TR","2019","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(19)30194-9","31189520",null,"ClinicalTrials.gov:NCT02849080; EudraCT:2015-005593-38","S001153","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020393","Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis.","Mahmood T","2026","Journal of diabetes and metabolic disorders","systematic_review","article","10.1007/s40200-026-02089-x","42802751","PMC13615951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0020394","Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?","Donal E","2024","Lancet (London, England)","commentary","article","10.1016/s0140-6736(24)00653-6","38599218",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; article"],["R0020395","A Hidden Tumor: Unraveling a Gastrointestinal Stromal Tumor in a 44-Year-Old Male Patient With Epigastric Pain.","Harutyunyan N","2025","Cureus","case_report","article","10.7759/cureus.78953","40091963","PMC11910190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020396","Insulin and Exendin-4 Reduced Mutated Huntingtin Accumulation in Neuronal Cells.","Rea S","2020","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2020.00779","32547392","PMC7270204",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020397","Semaglutide",null,"1994","Organization of Teratology Information Specialists (OTIS), Brentwood (TN)","narrative_review","article",null,"38349989",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0020398","Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures.","Gupta G","2017","EXCLI journal","commentary","article","10.17179/excli2017-283","28827991","PMC5547386",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0020399","Effects of liraglutide on hemodynamic parameters in patients with heart failure.","Zhang JY","2017","Oncotarget","randomized_trial","article","10.18632/oncotarget.18570","28977981","PMC5617541",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020400","Glucocorticoids Inhibit Basal and Hormone-Induced Serotonin Synthesis in Pancreatic Beta Cells.","Hasni Ebou M","2016","PloS one","preclinical","article","10.1371/journal.pone.0149343","26901633","PMC4763453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020401","Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.","Vemulapalli HS","2023","Cureus","systematic_review","article","10.7759/cureus.45421","37854744","PMC10581595",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0020402","Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL - 2024.","Pinsky LL","2025","Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego","narrative_review","article","10.36740/merkur202501117","40063921",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0020403","Weight Gain on Lorlatinib Is Associated With Accumulation of Visceral Adipose Tissue.","Mantz L","2026","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","nonrandomized_study","article","10.1016/j.jtho.2026.104078","42419484",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0020404","Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.","Yoneda C","2024","Diabetology international","nonrandomized_study","article","10.1007/s13340-024-00734-5","39101186","PMC11291808",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020405","Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.","Radziszewska E","2013","Medical science monitor basic research","preclinical","article","10.12659/msmbr.883726","23291632","PMC3638658",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020406","Exendin-4 regulates Wnt and NF-κB signaling in lipopolysaccharide-induced human periodontal ligament stem cells to promote osteogenic differentiation.","Liu H","2019","International immunopharmacology","other","article","10.1016/j.intimp.2019.105801","31401384",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020407","Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.","Campbell RK","2011","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2011.04.015","21665040",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0020408","GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis.","Standl E","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(19)30267-0","31422061",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0020409","Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.","Kosiborod MN","2024","Circulation","randomized_trial","article","10.1161/circulationaha.123.067505","37952180","PMC10782938","ClinicalTrials.gov:NCT04788511","S000913; S002012","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020410","GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling.","Chang CC","2018","International journal of molecular sciences","preclinical","article","10.3390/ijms19092505","30149534","PMC6164932",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0020411","Dose-dependent erythema nodosum after initiation of semaglutide.","Sobieraj J","2024","JAAD case reports","case_report","article","10.1016/j.jdcr.2024.02.014","38689866","PMC11058707",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020412","Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.","Mather KJ","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15365","37989596",null,"ClinicalTrials.gov:NCT05556512; ClinicalTrials.gov:NCT04255433","S001921; S002212","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Letter; article"],["R0020413","Response to semaglutide of non-drinker subjects with type 2 diabetes.","Petralli G","2024","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-024-01344-6","38760852","PMC11100230",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0020414","Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs.","Ekström K","2017","Scandinavian cardiovascular journal : SCJ","randomized_trial","article","10.1080/14017431.2016.1197417","27309633",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; article"],["R0020415","Liraglutide ameliorates hepatic steatosis via retinoic acid receptor-related orphan receptor α-mediated autophagy pathway.","Yu X","2023","IUBMB life","preclinical","article","10.1002/iub.2760","37310057",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020416","Tirzepatide Therapy in a Patient with Type 2 Diabetes Mellitus, Chylomicronemia, and Heterozygosity for Lipoprotein Lipase Deficiency.","Babirak SP","2023","AACE clinical case reports","case_report","article","10.1016/j.aace.2023.05.005","37520761","PMC10382611",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020417","Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.","Bergenstal RM","2010","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(10)60590-9","20580422",null,"ClinicalTrials.gov:NCT00637273","S000204; S000402; S000506","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020418","Investigational insulin secretagogues for type 2 diabetes.","Scheen AJ","2016","Expert opinion on investigational drugs","narrative_review","article","10.1517/13543784.2016.1152260","26881467",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020419","Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.","Lotfy M","2011","The open medicinal chemistry journal","other","article","10.2174/1874104501105010082","21966329","PMC3174521",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020420","Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.","Pantanetti P","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1394506","39015186","PMC11250060",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0020421","Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.","Asano M","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14412","33908687",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020422","64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats.","Mikkola K","2014","Molecular imaging and biology","preclinical","article","10.1007/s11307-013-0691-2","24101374",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020423","Chronic Kidney Disease and Obesity.","Hojs R","2023","Nephron","narrative_review","article","10.1159/000531379","37271131",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020424","Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers.","Gupta P","2024","Current drug research reviews","nonrandomized_study","article","10.2174/0125899775243787231103075804","37966282",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0020425","The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.","Wang B","2015","PloS one","randomized_trial","article","10.1371/journal.pone.0121915","25849542","PMC4388383",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020426","Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.","Smits MM","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12748","27451030","PMC5129471","ClinicalTrials.gov:NCT01744236","S002312","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0020427","Redefining peptide therapeutics with semaglutide.","Kruse T","2024","Nature chemistry","other","article","10.1038/s41557-023-01434-4","38321235",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020428","Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes.","Lerman JB","2022","Scientific reports","randomized_trial","article","10.1038/s41598-022-12973-0","35654972","PMC9163122","ClinicalTrials.gov:NCT01800968","S002350","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0020429","Prevention and Reversal of Diabetes by All-Trans Retinoid Acid and Exendin-4 in NOD Mice.","Juang JH","2014","International journal of endocrinology","preclinical","article","10.1155/2014/435481","24995016","PMC4065745",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020430","Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.","Sun F","2012","Experimental diabetes research","systematic_review","article","10.1155/2012/230624","23365557","PMC3540917",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0020431","Addition of very low calorie diet (VLCD) during initiation of semaglutide in individuals with type 2 diabetes – interim results","Anyiam O","2023","Clinical medicine (London, England)","randomized_trial","article","10.7861/clinmed.23-6-s71","38182193","PMC11046661",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","research-article; Journal Article; article"],["R0020432","Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery.","Bonnet JB","2024","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23922","37927153",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0020433","Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.","Chen SY","2024","Biochimica et biophysica acta. Molecular basis of disease","preclinical","article","10.1016/j.bbadis.2023.166908","37793464","PMC10908303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020434","Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats.","Krieger JP","2018","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00068.2018","29847161","PMC6230883",null,"S002367","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020435","The incretin/glucagon system as a target for pharmacotherapy of obesity.","Del Prato S","2022","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.13372","34713962","PMC9286339",null,"S001387","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0020436","68 Ga-DOTATATE PET/CT imaging in endogenous hyperinsulinemic hypoglycemia: A tertiary endocrine centre experience.","Shah R","2022","Clinical endocrinology","nonrandomized_study","article","10.1111/cen.14586","34498757",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0020437","Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment.","Chodorge M","2018","Scientific reports","preclinical","article","10.1038/s41598-018-35869-4","30510163","PMC6277417",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020438","A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model.","Liu Y","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2026.119717","42372355",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020439","THU283 Oral Semaglutide, Effectiveness, Safety And Tolerability In Real Life: A Short-term Retrospective Observational Study",null,"2023","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC10553466",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0020440","Precision treatment of beta-cell monogenic diabetes: a systematic review.","Naylor RN","2024","Communications medicine","systematic_review","article","10.1038/s43856-024-00556-1","39025920","PMC11258280",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0020441","The chronic administration of two novel long-acting Xenopus glucagon-like peptide-1 analogs xGLP159 and xGLP296 potently improved systemic metabolism and glycemic control in rodent models.","Han J","2019","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.201801479r","30860869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020442","Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist.","Li Y","2017","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.201601339r","28270518","PMC5434659",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020443","Novel Therapeutics for Type 2 Diabetes Mellitus-A Look at the Past Decade and a Glimpse into the Future.","Chee YJ","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12071386","39061960","PMC11274090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020444","Fatty liver-induced changes in stereotypic behavior in rats and effects of glucagon-like peptide-1 analog on stereotypy.","Erbaş O","2014","The Kaohsiung journal of medical sciences","preclinical","article","10.1016/j.kjms.2014.05.007","25224767","PMC11915970",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020445","Linoleic acid co-administration promotes oral delivery of exenatide-loaded butyrate-decorated nanocapsules.","Yuan H","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.113744","40246242",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020446","Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.","Gan S","2020","Diabetes care","systematic_review","article","10.2337/dci20-0049","33218985","PMC7770275",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; Comment; review"],["R0020447","Mitochondrial heteroplasmy-phenotype correlation and response to glucose lowering therapy in subjects with m.3243A>G mutations.","Ng N","2025","Diabetes & metabolism","other","article","10.1016/j.diabet.2025.101678","40541739",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020448","Successful outcome of assisted reproductive technology in women with polycystic ovary syndrome combined with empty follicle syndrome: A case report.","Guo D","2025","Medicine","other_trial","article","10.1097/md.0000000000043001","40587668","PMC12212853",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Case Reports; research-article; article"],["R0020449","Advent of tirzepatide: boon for diabetic and obese?","Bhusal A","2023","Annals of medicine and surgery (2012)","randomized_trial","article","10.1097/ms9.0000000000000173","36845823","PMC9949822",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020450","A Novel Microfluidic Strategy for the Fabrication of α-Lactalbumin Nanomicelles Paves a New Path for Antiobesity Technology.","Bao C","2026","Advanced healthcare materials","preclinical","article","10.1002/adhm.71486","42516046","PMC13507571",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020451","Proteomic Profiling of Early-Stage Heart Failure Identifies Candidate Biomarkers and Molecular Pathways of Cardiac Inflammation in the Project Baseline Health Study","Kottilil K","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.12.20.24319438",null,null,"ClinicalTrials.gov:NCT03154346",null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0020452","Tirzepatide and prevention of chronic kidney disease.","Bosch C","2023","Clinical kidney journal","randomized_trial","article","10.1093/ckj/sfac274","37151412","PMC10157759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0020453","Proteomic analysis of INS-1 rat insulinoma cells: ER stress effects and the protective role of exenatide, a GLP-1 receptor agonist.","Kim MK","2015","PloS one","preclinical","article","10.1371/journal.pone.0120536","25793496","PMC4368701",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020454","Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials.","Mellbin LG","2024","European heart journal","nonrandomized_study","article","10.1093/eurheartj/ehae028","38416593","PMC11015952","ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0020455","Insights from a double-blind, randomized, direct-to-participant intervention trial for Long COVID","Vogel JM","2026","medRxiv","randomized_trial","preprint","10.64898/2026.08.19.26360832",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0020456","Pre-immunization of diet-induced obese male mice with inactivated pathogens increases power in a liraglutide intervention study.","Falkenberg C","2025","Laboratory animals","preclinical","article","10.1177/00236772241279058","39696895",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020457","Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.","Zinman B","2019","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(19)30066-x","30833170",null,"ClinicalTrials.gov:NCT03086330","S000483; S000485","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020458","Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study.","Stier C","2022","Clinical nutrition ESPEN","nonrandomized_study","article","10.1016/j.clnesp.2022.05.009","35871930",null,"ClinicalTrials.gov:NCT02616003","S001853","pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Clinical Trial, Phase IV"],["R0020459","Dumping syndrome: Update on pathophysiology, diagnosis, and management.","Tack J","2025","Neurogastroenterology and motility","narrative_review","article","10.1111/nmo.14962","39529492",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020460","In adults with BMI ≥27 kg/m2 and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.","Davidson MB","2023","Annals of internal medicine","randomized_trial","article","10.7326/j23-0089","37931265",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0020461","Exendin‑4 inhibits lipotoxicity‑induced oxidative stress in β‑cells by inhibiting the activation of TLR4/NF‑κB signaling pathway.","Shen X","2020","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2020.4490","32124969",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020462","Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.","Luo Y","2016","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","nonrandomized_study","article","10.2967/jnumed.115.167445","26795291","PMC5227553",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0020463","Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis.","Neyer M","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16084","39604296",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0020464","Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.","Borlaug BA","2023","Nature medicine","other_trial","article","10.1038/s41591-023-02526-x","37635157","PMC10504076","ClinicalTrials.gov:NCT04788511","S002012","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020465","GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer's disease by regulating mitochondrial dysfunction via the cAMP/PKA pathway.","Xie Y","2021","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2021.114578","33895160",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020466","THU285 Predictive Factors Of Response To Liraglutide In Long-standing Type 2 Diabetes: A Real-life Study",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10553569",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0020467","A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.","Liu H","2009","The Journal of endocrinology","preclinical","article","10.1677/joe-08-0468","19136619",null,null,"S000838","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020468","Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Patients with Polycystic Ovary Syndrome and Obesity.","Zhao H","2025","Gynecologic and obstetric investigation","nonrandomized_study","article","10.1159/000539039","38768579",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0020469","GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials.","Hamedi Z","2021","Diabetes/metabolism research and reviews","other","article","10.1002/dmrr.3436","33440044",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020470","Potentiation of endothelium-dependent vasorelaxation of mesenteric arteries from spontaneously hypertensive rats by gemigliptin, a dipeptidyl peptidase-4 inhibitor class of anti-diabetic drug.","Kim HJ","2018","The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology","preclinical","article","10.4196/kjpp.2018.22.6.713","30402032","PMC6205934",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0020471","A Pilot Study of Exenatide Actions in Alzheimer's Disease.","Mullins RJ","2019","Current Alzheimer research","randomized_trial","article","10.2174/1567205016666190913155950","31518224","PMC7476877","ClinicalTrials.gov:NCT01255163","S000009","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020472","Safety and adverse effects associated with GLP-1 analogues.","Stephens JW","2007","Expert opinion on drug safety","other_trial","article","10.1517/14740338.6.4.417","17688385",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0020473","Liraglutide protects cardiac function in diabetic rats through the PPARα pathway.","Zhang Q","2018","Bioscience reports","preclinical","article","10.1042/bsr20180059","29440457","PMC5857913",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020474","Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.","Ratziu V","2024","Hepatology (Baltimore, Md.)","randomized_trial","article","10.1097/hep.0000000000000723","38112484","PMC11185915","ClinicalTrials.gov:NCT02970942","S000922","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0020475","Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.","Rossing P","2023","Cardiovascular diabetology","other_trial","article","10.1186/s12933-023-01949-7","37620807","PMC10463803","ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020476","GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.","Ciardullo S","2024","Acta diabetologica","narrative_review","article","10.1007/s00592-024-02300-6","38831203","PMC11329401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020477","Pancreatic insulin and exocrine secretion are under the modulatory control of distinct subpopulations of vagal motoneurones in the rat.","Babic T","2012","The Journal of physiology","preclinical","article","10.1113/jphysiol.2012.234955","22711959","PMC3547274",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0020478","Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model.","Zhang Y","2015","Behavioural brain research","other_trial","article","10.1016/j.bbr.2015.07.021","26187689",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020479","Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.","Patorno E","2018","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj.k119","29437648","PMC5799855",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020480","Liraglutide treatment effects on rat ovarian and uterine tissues.","Saber SM","2019","Reproductive biology","preclinical","article","10.1016/j.repbio.2019.07.003","31350200",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020481","Crowdsourcing-Based Knowledge Graph Construction for Drug Side Effects Using Large Language Models with an Application on Semaglutide.","Duan Z","2024","AMIA ... Annual Symposium proceedings. AMIA Symposium","nonrandomized_study","article",null,"41726410","PMC12919570",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; research-article; conference-paper"],["R0020482","Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway.","Yusta B","2017","Molecular metabolism","preclinical","article","10.1016/j.molmet.2017.03.006","28580281","PMC5444019",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020483","Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development.","Sills ES","2025","Reproductive biology and endocrinology : RB&E","narrative_review","article","10.1186/s12958-025-01435-7","40781307","PMC12333279",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0020484","Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes.","Nadeau DA","2010","Postgraduate medicine","other","article","10.3810/pgm.2010.05.2137","20463409",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020485","Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery.","Modi R","2018","Obesity surgery","case_report","article","10.1007/s11695-018-3249-1","29667023",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0020486","Pharmaceutical Approval Update.","Choy M","2016","P & T : a peer-reviewed journal for formulary management","other","article",null,"27904299","PMC5083074",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; other"],["R0020487","Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis.","Nielsen MH","2025","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00110.2024","39404770",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020488","Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.","Ipsen DH","2018","Basic & clinical pharmacology & toxicology","randomized_trial","article","10.1111/bcpt.13082","29953740",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0020489","Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways.","Wang D","2025","Molecular medicine (Cambridge, Mass.)","preclinical","article","10.1186/s10020-025-01312-4","40702450","PMC12285096",null,"S001115","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0020490","Biomarker-Defined Phenotyping Reveals Patient Heterogeneity Not Captured by a Single Physiological Reserve Score","AlTaweel M","2026","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202608.1744.v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0020491","A microfluidic in vitro method predicting the fate of peptide drugs after subcutaneous administration.","Wanselius M","2024","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2024.124849","39454976",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020492","Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?","Patoulias D","2023","Future cardiology","narrative_review","article","10.2217/fca-2022-0112","37552101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020493","Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology.","Crespo J","2026","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph19081145","42653643","PMC13516156",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020494","One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.","Sato R","2024","Med (New York, N.Y.)","other","article","10.1016/j.medj.2023.12.012","38460497",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020495","In-vivo half-life and hypoglycemic bioactivity of a fusion protein of exenatide and elastin-based polypeptide from recombinant Saccharomyces cerevisiae.","Jung SJ","2019","Journal of biotechnology","preclinical","article","10.1016/j.jbiotec.2019.06.304","31278957",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020496","VMP1-related autophagy induced by a fructose-rich diet in β-cells: its prevention by incretins.","Maiztegui B","2017","Clinical science (London, England : 1979)","preclinical","article","10.1042/cs20170010","28188238",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020497","Letter to the Editor: Can semaglutide result in a tangible cardiovascular benefit in recipients of liver transplants?","Sensi B","2024","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","nonrandomized_study","article","10.1097/lvt.0000000000000364","38497771",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Letter; Comment; letter"],["R0020498","Emodin, a rising star in the treatment of glycolipid metabolism disorders: a preclinical systematic review and meta-analysis.","Xiao Y","2025","PeerJ","systematic_review","article","10.7717/peerj.19221","40386230","PMC12085882",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; research-article; review"],["R0020499","The importance of estradiol for body weight regulation in women.","Vigil P","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.951186","36419765","PMC9677105",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020500","Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment.","Salinas CBG","2018","Scientific reports","preclinical","article","10.1038/s41598-018-28496-6","29985439","PMC6037685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020501","Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry.","Bhatt AS","2024","Journal of cardiac failure","nonrandomized_study","article","10.1016/j.cardfail.2023.09.005","37757995",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0020502","Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.","Avogaro A","2014","Current diabetes reports","narrative_review","article","10.1007/s11892-014-0483-3","24676508",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020503","Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR.","Arshad A","2021","Kidney international reports","systematic_review","article","10.1016/j.ekir.2021.06.029","34514202","PMC8418973",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0020504","Selective N-Terminal Modification of Peptides and Proteins Using Fatty Acyl Phosphates.","Pérez LR","2026","Angewandte Chemie (International ed. in English)","other","article","10.1002/anie.202513289","41510599",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020505","Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway.","Feng Y","2020","Stem cell research & therapy","preclinical","article","10.1186/s13287-019-1492-6","31900217","PMC6942368",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; research-article; other; article"],["R0020506","Concurrent pharmacological modification of cannabinoid-1 and glucagon-like peptide-1 receptor activity affects feeding behavior and body weight in rats fed a free-choice, high-carbohydrate diet.","Radziszewska E","2014","Behavioural pharmacology","preclinical","article","10.1097/fbp.0000000000000018","24370558",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020507","Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk.","Marx N","2020","European heart journal","randomized_trial","article","10.1093/eurheartj/ehz853","31800036",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0020508","Dual-sensitive gelatin-coated chitosan microparticles for targeted semaglutide pulmonary delivery: a novel approach to enhancing anti-inflammatory and anti-fibrotic effects.","Hamad RS","2025","International immunopharmacology","other","article","10.1016/j.intimp.2025.115480","40915185",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020509","Liraglutide Suppresses Myocardial Fibrosis Progression by Inhibiting the Smad Signaling Pathway.","Sun W","2023","Current medical science","randomized_trial","article","10.1007/s11596-023-2776-8","37594676",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0020510","BrazIliaN Type 1 & 2 DiabetEs Disease Registry (BINDER): longitudinal, real-world study of diabetes mellitus control in Brazil.","de Almeida-Pititto B","2022","Frontiers in clinical diabetes and healthcare","nonrandomized_study","article","10.3389/fcdhc.2022.934629","36992732","PMC10012111",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020511","New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets.","Wojtasińska A","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms242316735","38069058","PMC10706703",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020512","Preventing Oxidative Stress in the Liver: An Opportunity for GLP-1 and/or PASK.","Hurtado-Carneiro V","2021","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox10122028","34943132","PMC8698360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020513","Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice.","van der Aart-van der Beek AB","2020","Nature reviews. Nephrology","nonrandomized_study","article","10.1038/s41581-020-0312-7","32541904",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Comment; article"],["R0020514","Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease.","Frąk W","2024","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox13060687","38929126","PMC11200916",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0020515","Balancing oral sequential absorption barriers of semaglutide-loaded nanoparticles by optimization of surface glycocholic acid density.","Zeng H","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.114316","41083011",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020516","Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Cherrington AL","2024","Diabetes care","randomized_trial","article","10.2337/dc23-1648","38190625","PMC10973906",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0020517","Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.","Hansen MK","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2023.12.029","38418010",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0020518","[Medication or lifestyle for obesity? New medication is a wake-up call for the general practitioner].","Assendelft WJJ","2022","Nederlands tijdschrift voor geneeskunde","other","article",null,"35899752",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020519","Semaglutide and beyond: a turning point in obesity pharmacotherapy.","The Lancet Regional Health-Europe","2024","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2024.100860","38362559","PMC10866919",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; Comment; article"],["R0020520","Once-weekly GLP-1R agonists: moving the goal posts.","Tahrani AA","2018","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(18)30049-4","29397375",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0020521","Crystallographic and physicochemical characterization of salcaprozoic acid: a structural basis for SNAC-enabled drug delivery systems.","Roy P","2025","Acta crystallographica. Section C, Structural chemistry","other","article","10.1107/s2053229625008691","41051497","PMC12587319",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020522","Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix.","Robinson E","2015","Basic research in cardiology","preclinical","article","10.1007/s00395-015-0476-7","25725809","PMC4344953",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020523","Correction to: Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.",null,"2021","Circulation","notice","article","10.1161/cir.0000000000000964","33617317",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0020524","In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.","Lipscombe LL","2019","Annals of internal medicine","randomized_trial","article","10.7326/acpj201909170-029","31525763",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0020525","Sex-Specific Effect of High-Fat Diet on Glycerol Metabolism in Murine Adipose Tissue and Liver.","Iena FM","2020","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2020.577650","33193093","PMC7609944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020526","Liraglutide promotes autophagy by regulating the AMPK/mTOR pathway in a rat remnant kidney model of chronic renal failure.","Xue L","2019","International urology and nephrology","preclinical","article","10.1007/s11255-019-02274-3","31531806",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020527","Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.","Chen B","2019","Oncology letters","other","article","10.3892/ol.2019.10497","31423269","PMC6607039",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020528","Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.","Swift C","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15516","38418411",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020529","Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review.","Germino FW","2011","Clinical therapeutics","narrative_review","article","10.1016/j.clinthera.2011.10.020","22136979",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020530","Effect of Liraglutide combined with Jinlida granules on glycolipid metabolism and islet function of type 2 diabetes mellitus.","Wang X","2024","Cellular and molecular biology (Noisy-le-Grand, France)","other","article","10.14715/cmb/2024.70.2.22","38430027",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020531","Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.","Marcum ZA","2015","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/1060028014563951","25515869","PMC4876962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0020532","Fragment-Guided New Therapeutic Molecule Discovery and Mapping of Clinically Relevant Interactomes","Kanapeckaitė A","2025","bioRxiv","other_trial","preprint","10.1101/2025.07.09.663848",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0020533","Tirzepatide and potential use for metabolically healthy obesity.","Copur S","2023","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2023.05.012","37183081",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020534","Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease.","Kim S","2022","PloS one","nonrandomized_study","article","10.1371/journal.pone.0273004","35960776","PMC9374206",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020535","Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.","Lüdemann J","2015","Therapeutic advances in endocrinology and metabolism","randomized_trial","article","10.1177/2042018815595584","26301063","PMC4525127",null,"S001021","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0020536","Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.","Hausner H","2017","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-017-0532-6","28349387","PMC5648738",null,"S000595; S000726","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0020537","Metagenomics study on taxonomic and functional change of gut microbiota in patients with obesity with PCOS treated with exenatide combination with metformin or metformin alone.","Gan J","2023","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","other","article","10.1080/09513590.2023.2219342","37290480",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020538","Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.","Briere DA","2025","Molecular metabolism","randomized_trial","article","10.1016/j.molmet.2025.102271","41109426","PMC12640043","ClinicalTrials.gov:NCT05295940",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; research-article; article"],["R0020539","Effect of Semaglutide on High-Fat-Diet-Induced Liver Cancer in Obese Mice.","Liu Y","2024","Journal of proteome research","preclinical","article","10.1021/acs.jproteome.3c00498","38227547","PMC10846501",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020540","Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.","Gier B","2012","Diabetes","preclinical","article","10.2337/db11-1109","22266668","PMC3331736",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020541","Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.","Wick A","2009","Journal of the American Academy of Nurse Practitioners","nonrandomized_study","article","10.1111/j.1745-7599.2009.00455.x","19900193",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0020542","A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.","van Eyk HJ","2019","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-019-0890-5","31288820","PMC6615254","ClinicalTrials.gov:NCT02660047","S000142","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0020543","The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.","Smolen HJ","2014","Journal of managed care & specialty pharmacy","randomized_trial","article","10.18553/jmcp.2014.20.9.968","25166296","PMC10438249",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020544","Turning fat into muscle: can this be an alternative to anti-obesity drugs such as semaglutide?","Wackerhage H","2024","The Journal of physiology","other","article","10.1113/jp286430","38426245",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020545","Gender-Difference in Response to Treatment with Liraglutide 3.0 mg","Milani I","2024","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202405.0568.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0020546","Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.","Buysman EK","2018","Journal of comparative effectiveness research","nonrandomized_study","article","10.2217/cer-2017-0032","28814107",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0020547","SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?","Scheen AJ","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(19)30310-9","31540866",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0020548","The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.","Ligumsky H","2012","Breast cancer research and treatment","preclinical","article","10.1007/s10549-011-1585-0","21638053",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020549","GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?","Du L","2022","International journal of cardiology","commentary","article","10.1016/j.ijcard.2022.07.015","35839931",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0020550","Differential mobility spectrometry tandem mass spectrometry with multiple ion monitoring for the bioanalysis of liraglutide.","Meng X","2017","Analytical and bioanalytical chemistry","preclinical","article","10.1007/s00216-017-0431-6","28660337",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Validation Study; article"],["R0020551","LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet.","Hao T","2019","Molecular medicine reports","preclinical","article","10.3892/mmr.2019.10304","31180545",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020552","Semaglutide Misuse in Atypical Anorexia Nervosa-A Case Report.","Guerdjikova AI","2024","Journal of clinical psychopharmacology","case_report","article","10.1097/jcp.0000000000001820","38329147",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0020553","Structural Modeling and in Silico Screening of Potential Small-Molecule Allosteric Agonists of a Glucagon-like Peptide 1 Receptor.","Redij T","2019","ACS omega","preclinical","article","10.1021/acsomega.8b03052","31459371","PMC6648429",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020554","The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.","Gao H","2015","Biological & pharmaceutical bulletin","preclinical","article","10.1248/bpb.b14-00505","25947915",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020555","Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity.","Lee SJ","2018","Molecular metabolism","preclinical","article","10.1016/j.molmet.2018.03.008","29650350","PMC6001878",null,"S002367","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020556","Exendin-4 shows no effects on the prostatic index in high-fat-diet-fed rat with benign prostatic hyperplasia by improving insulin resistance.","Zheng JX","2015","Andrologia","preclinical","article","10.1111/and.12252","24605934",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020557","Neuer GLP1-Agonist hilft beim Abnehmen : Medikamentöse Adipositastherapie.","Facharztmagazine R","2020","MMW Fortschritte der Medizin","other","article","10.1007/s15006-020-4438-0","33020889",null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020558","Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.","Rosenstock J","2014","Diabetes care","randomized_trial","article","10.2337/dc14-0001","24898300",null,"ClinicalTrials.gov:NCT00976391","S000235; S001145","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020559","Obesity in Adolescents: A Review.","Kelly AS","2024","JAMA","narrative_review","article","10.1001/jama.2024.11809","39102244",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0020560","Current and future state of pharmacological management of pediatric obesity.","Fox CK","2025","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-024-01465-y","38321079",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0020561","Circulating microRNA-375 as biomarker of pancreatic beta cell death and protection of beta cell mass by cytoprotective compounds.","Song I","2017","PloS one","preclinical","article","10.1371/journal.pone.0186480","29040320","PMC5645134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020562","The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke.","Yang X","2019","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2019.107748","31465784",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020563","[Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review].","Golovina EL","2023","Terapevticheskii arkhiv","nonrandomized_study","article","10.26442/00403660.2023.03.202150","37167150",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Review; English Abstract; Journal Article; article"],["R0020564","The stem cell adjuvant with Exendin-4 repairs the heart after myocardial infarction via STAT3 activation.","Liu J","2014","Journal of cellular and molecular medicine","preclinical","article","10.1111/jcmm.12272","24779911","PMC4124022",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020565","GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions.","Li H","2021","Frontiers in cell and developmental biology","preclinical","article","10.3389/fcell.2021.777026","34869379","PMC8636013",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020566","No More Needles: Oral Semaglutide for Weight Loss.","Arvanitakis M","2024","Gastroenterology","other","article","10.1053/j.gastro.2024.01.021","38253185",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020567","Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.","Dempsey M","2018","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other_trial","article","10.4158/ep-2018-0134","30308134",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020568","Blurring Fact and Fiction: A Complex Case of Recurrent Emergency Presentations, Polypharmacy, and Psychiatric Conflict.","Reyad B","2025","Cureus","case_report","article","10.7759/cureus.98979","41523523","PMC12790413",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020569","A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.","Gurung T","2015","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s34418","26316788","PMC4541559",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0020570","Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes.","Mather KJ","2018","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2018-00712","30020461","PMC6126889","ClinicalTrials.gov:NCT01232946","S001148","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020571","Evaluation of The Relationships of Liraglutite, Red Yeast Rice And Atorvastatin With Metabolic Parameters In Rats Feed With A High-Fat Diet","SEDEFOĞLU G","2024","Research Square","preclinical","preprint","10.21203/rs.3.rs-4708073/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0020572","Exenatide modulates visual cortex responses.","Binda P","2019","Diabetes/metabolism research and reviews","other","article","10.1002/dmrr.3167","30974038","PMC6718343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020573","The design of the liraglutide clinical trial programme.","Nauck MA","2012","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2012.01573.x","22405264",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0020574","Liraglutide for Type 2 diabetes and obesity: a 2015 update.","Iepsen EW","2015","Expert review of cardiovascular therapy","narrative_review","article","10.1586/14779072.2015.1054810","26106933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020575","Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4.","Mi B","2016","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2016.01.184","26850848",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020576","Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.","Gerstein HC","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15417","38116691",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0020577","Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.","Ahrén B","2014","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12290","24641271",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0020578","Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.","Vilsbøll T","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13172","29178519","PMC5888154",null,"S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0020579","R-spondin-1 is a novel beta-cell growth factor and insulin secretagogue.","Wong VS","2010","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m110.129874","20442404","PMC2898385",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020580","Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis.","Chiu HY","2023","In vivo (Athens, Greece)","preclinical","article","10.21873/invivo.13178","37103096","PMC10188031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020581","Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.","Knudsen JS","2020","PloS one","nonrandomized_study","article","10.1371/journal.pone.0229621","32130249","PMC7055862",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020582","Dichrostachys glomerata and Cissus quadrangularis Extracts Enhance GLP-1 Secretion and Inhibit DPP-4 Activity in Overweight and Obese Individuals: A Randomized Controlled Trial","Youovop J","2025","Authorea Preprints","randomized_trial","preprint","10.22541/au.175664716.64802840/v1",null,null,"ClinicalTrials.gov:NCT06827002","S001538","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0020583","JNK3 is required for the cytoprotective effect of exendin 4.","Ezanno H","2014","Journal of diabetes research","other","article","10.1155/2014/814854","25025079","PMC4083605",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020584","Semaglutide Linked With Lower Risk of Suicidal Thoughts.","Harris E","2024","JAMA","other","article","10.1001/jama.2023.27968","38265825",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020585","GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells.","Shilleh AH","2024","Peptides","other","article","10.1016/j.peptides.2024.171179","38360354","PMC7618508",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020586","PEGylated prodrugs of antidiabetic peptides amylin and GLP-1.","Böttger R","2018","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2018.05.001","29729352",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020587","Exogenous supplement of glucagon like peptide-1 protects the heart against aortic banding induced myocardial fibrosis and dysfunction through inhibiting mTOR/p70S6K signaling and promoting autophagy.","Zheng RH","2020","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2020.173318","32621911",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020588","Selecting among ADA/EASD tier 1 and tier 2 treatment options.","McGill JB","2009","The Journal of family practice","narrative_review","article",null,"19744422",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020589","The Future of the GLP-1 Receptor Agonists.","Hirsch IB","2019","JAMA","commentary","article","10.1001/jama.2019.2941","30903797",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0020590","Assessing Consistency in a Network Meta-Analysis to Compare Once Weekly Dulaglutide Versus Other Glp-1 Receptor Agonists in Patients with Type 2 Diabetes.","Hawkins N","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","systematic_review","article","10.1016/j.jval.2014.08.641","27200592",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; article"],["R0020591","Could semaglutide be related to increasing the risk of developing a disordered eating?","Oskinis S","2024","L'Encephale","commentary","article","10.1016/j.encep.2023.11.022","38311483",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0020592","A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.","Weghuber D","2020","Pediatric obesity","randomized_trial","article","10.1111/ijpo.12624","32062862",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020593","Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.","Hansen HH","2023","Scientific reports","other_trial","article","10.1038/s41598-023-50328-5","38155202","PMC10754821",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0020594","Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis.","Fan Y","2014","Molecular vision","randomized_trial","article",null,"25489228","PMC4225140",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020595","Altered Mental Status Due to Amantadine Withdrawal: A Case Report.","Asal NJ","2026","Reports (MDPI)","case_report","article","10.3390/reports9010085","41893446","PMC13030137",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020596","Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.","Rico-Fontalvo J","2024","Jornal brasileiro de nefrologia","randomized_trial","article","10.1590/2175-8239-jbn-2024-0101en","39514688","PMC11548866",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0020597","Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.","Alabduljabbar K","2024","Endocrine","randomized_trial","article","10.1007/s12020-023-03534-0","37735340",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Observational Study; Journal Article; article"],["R0020598","Effect of New Antidiabetics on Steatosis in Nerve Tissues and Nerve Conduction Velocity: Possible Role of Nerve Growth Factor (NGF)/Synaptophysin and Nrf2/HO-1 Pathways.","Abdel-Halim NHM","2024","Cureus","preclinical","article","10.7759/cureus.65726","39211670","PMC11358857",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020599","Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction.","Maki KC","2023","Expert review of endocrinology & metabolism","narrative_review","article","10.1080/17446651.2023.2209176","37199542",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020600","Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.","Joffe D","2010","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","other_trial","article","10.2146/ajhp090230","20689121",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020601","Long-Term Exposure of Pancreatic β-Cells to Palmitate Results in SREBP-1C-Dependent Decreases in GLP-1 Receptor Signaling via CREB and AKT and Insulin Secretory Response.","Natalicchio A","2016","Endocrinology","preclinical","article","10.1210/en.2015-2003","27035653",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020602","The Novel Tetra-specific Drug C-192, Conjugated Using UniStac, Alleviates Non-alcoholic Steatosis Hepatitis in MCD Diet-induced Mouse Model","Kim J","2023","Preprints.org","preclinical","preprint","10.20944/preprints202309.0859.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020603","Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation","Deganutti G","2021","bioRxiv","other","preprint","10.1101/2021.03.10.434902",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020604","Estimation of Interventional Effects in Clinical Trials With a Repeatedly Measured Mediator.","Skov Breum M","2025","Statistics in medicine","randomized_trial","article","10.1002/sim.70305","41201167",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0020605","New horizon of the combined BCG vaccine with probiotic and liraglutide in augmenting beta cell survival via suppression of TXNIP/NLRP3 pyroptosis signaling in Streptozocin-Induced diabetes mellitestype-1 in rats.","Khalifa AK","2024","Heliyon","randomized_trial","article","10.1016/j.heliyon.2024.e38932","39640632","PMC11620097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020606","Microglial Activation of GLP-1R Signaling in Neuropathic Pain Promotes Gene Expression Adaption Involved in Inflammatory Responses.","Ma L","2021","Neural plasticity","preclinical","article","10.1155/2021/9923537","34512747","PMC8426070",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020607","Management of Diabetes and Hyperglycemia in Hospitalized Patients","Dhatariya K","2000","MDText.com, Inc., South Dartmouth (MA)","narrative_review","article",null,"25905318",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0020608","The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.","Nauck MA","2016","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(15)00482-9","26876794",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020609","Current and future treatment strategies for type 2 diabetes: the beta-cell as a therapeutic target.","Tyrberg B","2001","Current opinion in investigational drugs (London, England : 2000)","narrative_review","article",null,"11763159",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020610","GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial.","Wiberg S","2016","Trials","protocol","article","10.1186/s13063-016-1421-2","27363489","PMC4929765","ClinicalTrials.gov:NCT02442791; EudraCT:2013-004311-45","S001005","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; other; article"],["R0020611","Post hoc analysis of the Exenatide-PD trial-Factors that predict response.","Athauda D","2019","The European journal of neuroscience","randomized_trial","article","10.1111/ejn.14096","30070753",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020612","Effects of Pegylated Glucagon-Like Peptide-1 Analogue in C57Bl/6 Mice under Optimal Conditions and During Streptozotocin-Induced Diabetes.","Skurikhin EG","2017","Bulletin of experimental biology and medicine","preclinical","article","10.1007/s10517-017-3867-y","28948559",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020613","Deducing Insulin-Producing Cells from Goat Adipose Tissue-Derived Mesenchymal Stem Cells.","Dubey A","2022","Cellular reprogramming","preclinical","article","10.1089/cell.2022.0029","35787695",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020614","Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.","Park CW","2007","Journal of the American Society of Nephrology : JASN","preclinical","article","10.1681/asn.2006070778","17360951",null,null,"S002088","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0020615","Sustained Release of Exendin 4 Using Injectable and Ionic-Nano-Complex Forming Polymer Hydrogel System for Long-Term Treatment of Type 2 Diabetes Mellitus.","Seo BB","2019","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.8b19669","30945843",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020616","Bioenergetic dysfunction in the pathogenesis of intervertebral disc degeneration.","Song C","2024","Pharmacological research","narrative_review","article","10.1016/j.phrs.2024.107119","38417775",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0020617","Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study.","Wang L","2013","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2012-002348","23633415","PMC3641450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020618","Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.","Qin W","2024","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15386","38016699",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0020619","Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.","Aini K","2019","International heart journal","preclinical","article","10.1536/ihj.19-117","31735774",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020620","Which incretin-based therapy for type 2 diabetes?","Scheen AJ","2014","Lancet (London, England)","commentary","article","10.1016/s0140-6736(14)61097-7","25018117",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0020621","Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats.","Zhang Q","2018","Experimental biology and medicine (Maywood, N.J.)","preclinical","article","10.1177/1535370217743765","29171288","PMC5788162",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020622","Physiologically based pharmacokinetic modelling of semaglutide in children and adolescents with healthy and obese body weights.","Machado TR","2023","British journal of clinical pharmacology","other","article","10.1111/bcp.15816","37293836",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020623","Biological activity of AC3174, a peptide analog of exendin-4.","Hargrove DM","2007","Regulatory peptides","preclinical","article","10.1016/j.regpep.2006.12.021","17292977",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Evaluation Study; Journal Article; article"],["R0020624","Liraglutide and obesity: a review of the data so far.","Ladenheim EE","2015","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s58459","25848222","PMC4386791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020625","[Novel indications for GLP-1-analogues and SGLT-2-inhibitors: when should a general practitioner prescribe these agents?].","Gallwitz B","2021","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-021-0085-3","34370254",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020626","Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.","Smits MM","2015","Diabetes care","nonrandomized_study","article","10.2337/dc15-0367","26106231",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; Comment; article"],["R0020627","A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.","Lingvay I","2018","Diabetes care","randomized_trial","article","10.2337/dc17-2381","30026333",null,"ClinicalTrials.gov:NCT02461589","S000827","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020628","Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.","Gullaksen S","2023","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2023.108472","37062189",null,"EudraCT:2019-000781-38",null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020629","CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects.","Zheng Y","2024","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","other","article","10.1002/advs.202400819","38837628","PMC11304330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020630","Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization.","Darsalia V","2014","PloS one","preclinical","article","10.1371/journal.pone.0103114","25101679","PMC4125154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020631","SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion.","Rajan S","2012","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00486.2011","22234371","PMC3311292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020632","Impact of post-RYGB gastrogastric fistula repair on metabolic and reflux outcomes.","Martin TJ","2025","Surgical endoscopy","other","article","10.1007/s00464-025-11954-4","40634724",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020633","Semaglutide and risk of suicidal ideations.",null,"2024","Nature medicine","other","article","10.1038/s41591-023-02691-z","38182786",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020634","Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.","Tan X","2017","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2017.1360274","28741970",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0020635","Liver Organoids: From Disease Modelling to Regenerative Medicine.","Wang T","2026","Cell proliferation","narrative_review","article","10.1111/cpr.70268","42599088","PMC13475025",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020636","Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.","Przezak A","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms23126500","35742943","PMC9224227",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020637","Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.","Hu S","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14881","36193880",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020638","[Update: new forms of therapy for type-2-diabetes].","Fischli S","2020","Therapeutische Umschau. Revue therapeutique","narrative_review","article","10.1024/0040-5930/a001198","32996424",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020639","Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons.","Kawatani M","2018","Peptides","preclinical","article","10.1016/j.peptides.2018.07.010","30081042",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020640","The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney disease.","Christensen JC","2025","Contemporary clinical trials","protocol","article","10.1016/j.cct.2024.107766","39608749","PMC11875690",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0020641","Effect of hydroxyethyl starch on drug stability and release of semaglutide in PLGA microspheres.","Zeng H","2024","International journal of pharmaceutics","other","article","10.1016/j.ijpharm.2024.123991","38471578",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020642","Recycling reaction and separation for FACylation of loxenatide by trade-off between miscibility and immiscibility of reactants and product in methanol solution.","Wang SC","2022","Journal of chromatography. A","other","article","10.1016/j.chroma.2022.463239","35709607",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020643","Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies.","Fadini GP","2019","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13623","30578607","PMC6590315",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Multicenter Study; Research Support, Non-U.S. Gov't; brief-report; article"],["R0020644","Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats.","Luo X","2013","Journal of diabetes","preclinical","article","10.1111/1753-0407.12061","23590680",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020645","Non-invasive quantification of stem cell-derived islet graft size and composition.","Lithovius V","2024","Diabetologia","nonrandomized_study","article","10.1007/s00125-024-06194-5","38871836","PMC11410899",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020646","Effects of multicomponent exercise on frailty in older adults with type 2 diabetes: Differential responses by metabolic frailty phenotype.","Zha X","2026","JAR life","randomized_trial","article","10.1016/j.jarlif.2026.100069","42004413","PMC13091225","ChiCTR:ChiCTR2400090109",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020647","[Glycemia normalization in patients with obesity and type 2 diabetes mellitus: bariatric surgery vs pharmacological therapy].","Sklyanik IA","2019","Terapevticheskii arkhiv","other","article","10.26442/00403660.2019.10.000375","32598629",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020648","New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.","Frias PF","2017","Current diabetes reports","narrative_review","article","10.1007/s11892-017-0926-8","28822051",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020649","Tetrazine-TCO Ligation: A Potential Simple Approach to Improve Tumor Uptake through Enhanced Blood Circulation.","Wang M","2020","Bioconjugate chemistry","other","article","10.1021/acs.bioconjchem.0c00264","32491846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0020650","GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation.","Liu C","2024","Journal of translational medicine","preclinical","article","10.1186/s12967-024-05753-z","39434134","PMC11492558",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020651","Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","Davies M","2021","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(21)00213-0","33667417",null,"ClinicalTrials.gov:NCT03552757","S000735; S001740; S002102","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; article"],["R0020652","Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real-world UK data: A clinical evaluation of a multi-ethnic population.","Dobbie LJ","2024","Clinical obesity","nonrandomized_study","article","10.1111/cob.12649","38438339",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0020653","Uncovering drug-associated risk signals for neovascular age-related macular degeneration: an integrative pharmacovigilance and proteogenomic study.","Sun H","2026","Eye (London, England)","nonrandomized_study","article","10.1038/s41433-026-04524-y","42225822","PMC13416144",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0020654","Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study.","Elkind-Hirsch KE","2022","Fertility and sterility","randomized_trial","article","10.1016/j.fertnstert.2022.04.027","35710599",null,"ClinicalTrials.gov:NCT03480022","S000534","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020655","Prevalence, impact and management of hypertension-mediated organ damage in type 2 diabetes patients.","Romero-Secin AA","2024","Semergen","nonrandomized_study","article","10.1016/j.semerg.2024.102220","38554607",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Multicenter Study; Observational Study"],["R0020656","Urinary Frequency and Polydipsia Mimicking Diabetes Mellitus: Obesity-Related Secondary Focal Segmental Glomerulosclerosis with Concurrent Overactive Bladder — A Case Report","Arain MSBA","2026","Research Square","case_report","preprint","10.21203/rs.3.rs-10244737/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0020657","Microvascular Dysfunction in Obesity-Hypertension.","Do T","2023","Current hypertension reports","narrative_review","article","10.1007/s11906-023-01272-2","37837517",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020658","De-escalating treatment indications for patients who achieve metabolic goals.","Cristina García-Ulloa A","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111096","38244782",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Review; Journal Article; article"],["R0020659","Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.","Knop FK","2008","IDrugs : the investigational drugs journal","narrative_review","article",null,"18600596",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020660","Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL/6 mice: Implications on GLP-1R and cAMP/PKA signaling pathway in the hippocampus.","Darwish AB","2023","Life sciences","preclinical","article","10.1016/j.lfs.2023.121546","36878280",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; preprint; article"],["R0020661","Glucagon-Like Peptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT2c) Receptor Agonists in the Ventral Tegmental Area (VTA) Inhibit Ghrelin-Stimulated Appetitive Reward.","Howell E","2019","International journal of molecular sciences","preclinical","article","10.3390/ijms20040889","30791361","PMC6412472",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020662","The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.","Smits MM","2017","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2016.12.011","28086201",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0020663","Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like-Peptide-1 Use Following 10-Session Cognitive-Behavioural Therapy for Binge-Eating Disorder: A Single-Case Experimental Design.","Dunford A","2026","European eating disorders review : the journal of the Eating Disorders Association","case_report","article","10.1002/erv.70135","42250261",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0020664","More on Semaglutide in Early Type 1 Diabetes.","DeVries JH","2024","The New England journal of medicine","randomized_trial","article","10.1056/nejmc2311608","38231640",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Letter; Comment; article"],["R0020665","Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.","Tonneijck L","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12985","28449402",null,"ClinicalTrials.gov:NCT02276196","S000423","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase IV; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020666","The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?","Muskiet MH","2014","Nature reviews. Nephrology","preclinical","article","10.1038/nrneph.2013.272","24375052",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020667","Effect of Liraglutide on Cardiac Function in Individuals With Type 2 Diabetes: A Meta-Analysis.","Haroon H","2023","Cureus","systematic_review","article","10.7759/cureus.42651","37644927","PMC10461595",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0020668","Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few.","Liuzzo G","2024","European heart journal","randomized_trial","article","10.1093/eurheartj/ehad823","38103177",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0020669","Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial.","Rosenstock J","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15325","37880822",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0020670","Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas.","Gezginci-Oktayoglu S","2009","Biochemistry and cell biology = Biochimie et biologie cellulaire","preclinical","article","10.1139/o09-046","19767827",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020671","FLIM-based pH measurements reveal incretin-induced rejuvenation of aged insulin secretory granules","Neukam M","2017","bioRxiv","other","preprint","10.1101/174391",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020672","Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report.","Nguyen JT","2024","Obesity facts","case_report","article","10.1159/000540241","39250902","PMC11661835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020673","Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence.","Corrao S","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1402583","38978621","PMC11228148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020674","Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway.","Fan SH","2020","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2020.111005","32877753",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020675","MON-605 Serum CD163, but Not Gal-3, Predicts Response to Liraglutide Therapy in Obese Patients","Mat A","2020","Journal of the Endocrine Society","other","article",null,null,"PMC7209270",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0020676","GLP-1 receptor agonist as a modulator of innate immunity.","Chen J","2022","Frontiers in immunology","preclinical","article","10.3389/fimmu.2022.997578","36569936","PMC9772276",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0020677","Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.","O'Harte FP","2016","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12713","27357054",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020678","Clinical Trial Highlights - GLP-1 agonists.","McFarthing K","2020","Journal of Parkinson's disease","other_trial","article","10.3233/jpd-200002","32250322","PMC7242848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; other; article"],["R0020679","First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level.","Shahbazi M","2023","Cureus","case_report","article","10.7759/cureus.40576","37465801","PMC10351928",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020680","Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.","Ahmann AJ","2018","Diabetes care","randomized_trial","article","10.2337/dc17-0417","29246950",null,"ClinicalTrials.gov:NCT01885208","S000329; S000372; S000485; S001837","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020681","Effects of Dichrostachys glomerata and Cissus quadrangularis Extracts on GLP-1 Secretion and DPP-4 Activity in Overweight and Obese Individuals: A Randomized Controlled Trial.","Youovop J","2025","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina62010041","41597327","PMC12842617",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Preprint; research-article; article; preprint"],["R0020682","Differentiating incretin-based therapies for population-based health care.","Calabrese D","2011","The American journal of managed care","nonrandomized_study","article",null,"21517657",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020683","Enzymatic Stability and Comparative Effects of Kisspeptin-14, Kisspeptin-13 and Kisspeptin-10 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation.","Spratt JA","2026","Metabolites","preclinical","article","10.3390/metabo16090686","42783811","PMC13609550",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020684","Pediatric Obesity: Complications and Current Day Management.","Vajravelu ME","2023","Life (Basel, Switzerland)","narrative_review","article","10.3390/life13071591","37511966","PMC10381624",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020685","The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes.","Thong KY","2015","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2015.04.009","25937541",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0020686","SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10557020",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0020687","GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea.","O'Donnell C","2024","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.24126","39169732",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0020688","Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review.","Niechciał E","2024","Nutrients","narrative_review","article","10.3390/nu16234084","39683477","PMC11644648",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020689","T160. TREATMENT OF CLOZAPINE-ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX) IN ADULTS WITH SCHIZOPHRENIA: A RANDOMISED CONTROLLED TRIAL","Siskind D","2018","Schizophrenia bulletin","randomized_trial","article","10.1093/schbul/sby016.436",null,"PMC5888874",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; conference-abstract"],["R0020690","Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study.","Acosta A","2015","Physiological reports","randomized_trial","article","10.14814/phy2.12610","26542264","PMC4632965",null,"S000865","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0020691","The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus.","Nguyen T","2020","Journal of diabetes research","narrative_review","article","10.1155/2020/4727390","32656265","PMC7320283",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020692","Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.","Alfayez OM","2019","Primary care diabetes","systematic_review","article","10.1016/j.pcd.2019.01.003","30713085",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Network Meta-Analysis"],["R0020693","Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.","Thomsen RW","2015","Diabetes care","nonrandomized_study","article","10.2337/dc15-0675","26106232",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0020694","Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report.","Pach D","2013","International journal of endocrinology","other","article","10.1155/2013/384508","23606839","PMC3626320",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020695","Semaglutide: A New Medical Swiss Army Knife?","Marijic J","2024","Journal of cardiothoracic and vascular anesthesia","commentary","article","10.1053/j.jvca.2023.12.032","38246820",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0020696","Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States.","Hunt B","2017","Journal of medical economics","other_trial","article","10.1080/13696998.2017.1347793","28651479",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0020697","[Anti-diabetic therapy and cardiovascular risk: the opportunity of incretin-based therapies. Introduction].","Mannucci E","2013","Giornale italiano di cardiologia (2006)","other","article","10.1714/1375.15274","24362780",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020698","Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.","Ahern T","2013","Journal of the European Academy of Dermatology and Venereology : JEADV","nonrandomized_study","article","10.1111/j.1468-3083.2012.04609.x","22691169",null,null,"S001234","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020699","Reply to \"GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?\".","Hwang IC","2022","International journal of cardiology","commentary","article","10.1016/j.ijcard.2022.08.047","36028096",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0020700","Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.","Jaiswal M","2015","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2015.07.013","26264399","PMC4656068","ClinicalTrials.gov:NCT00855439","S001884","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020701","Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist.","Baraboi ED","2010","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00326.2009","20106992",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020702","Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.","Yao J","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-023-01369-6","36809495","PMC10064411","ClinicalTrials.gov:NCT00975286; ClinicalTrials.gov:NCT00715624; ClinicalTrials.gov:NCT01632163","S000792; S001963; S002023","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0020703","Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.","Basolo A","2024","Journal of endocrinological investigation","commentary","article","10.1007/s40618-023-02290-2","38157134",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0020704","A systematic review of the value of clinical decision support systems in the prescription of antidiabetic drugs.","Tlili NE","2024","International journal of medical informatics","systematic_review","article","10.1016/j.ijmedinf.2024.105581","39106772",null,null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Systematic Review; Research Support, Non-U.S. Gov't"],["R0020705","Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.","Niswender K","2010","Diabetes, obesity & metabolism","other_trial","article","10.1111/j.1463-1326.2009.01175.x","20380648",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020706","Marketing of medicines in primary care: An analysis of direct marketing mailings and advertisements.","Dankers M","2023","PloS one","other","article","10.1371/journal.pone.0290603","37639431","PMC10461816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020707","Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes.","van Eyk HJ","2020","Nutrition, metabolism, and cardiovascular diseases : NMCD","randomized_trial","article","10.1016/j.numecd.2019.12.005","32127340",null,"ClinicalTrials.gov:NCT01761318","S000566; S002367","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020708","Exenatide protects against hypoxia/reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells.","Chang G","2014","Experimental biology and medicine (Maywood, N.J.)","preclinical","article","10.1177/1535370214522177","24586099",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020709","Identification of novel positive allosteric modulators of GLP1R that stimulate its interaction with ligands and Gα subunits.","Kang S","2021","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2021.10.071","34739856",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020710","The potential of incretin-based therapies in type 1 diabetes.","Suen CS","2012","Drug discovery today","preclinical","article","10.1016/j.drudis.2011.08.017","21920456",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020711","Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.","Salim HM","2017","Vascular pharmacology","preclinical","article","10.1016/j.vph.2017.03.003","28347868",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020712","RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis.","Jamaluddin A","2023","Journal of molecular endocrinology","narrative_review","article","10.1530/jme-23-0014","36943057","PMC10160555",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; review-article; article"],["R0020713","Microfluidic-based systems for the management of diabetes.","Zhang S","2024","Drug delivery and translational research","narrative_review","article","10.1007/s13346-024-01569-y","38509342","PMC11445324",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0020714","Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.","Ji L","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15309","37822270",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020715","Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?","Murphy CF","2018","Annals of translational medicine","randomized_trial","article","10.21037/atm.2018.03.06","29951508","PMC5994527",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; Comment; article"],["R0020716","Liraglutide ameliorates high glucose-induced vascular endothelial injury through TRIB3/NF-κB signaling pathway.","Shi L","2024","In vitro cellular & developmental biology. Animal","other","article","10.1007/s11626-024-00947-7","39039329",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020717","[Non-Alcoholic Fatty Liver Disease and Diabetes: the bad marriage].","Nascè A","2023","Revue medicale suisse","other","article","10.53738/revmed.2023.19.829.1090","37260205",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0020718","Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.","Leventhal-Perek S","2023","Family practice","randomized_trial","article","10.1093/fampra/cmac141","36477550",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020719","Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.","Bomba M","2013","Cell death & disease","preclinical","article","10.1038/cddis.2013.139","23640454","PMC3674348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020720","[New oral antidiabetic drugs].","Müller-Wieland D","2020","Herz","other","article","10.1007/s00059-020-04946-8","32601754",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020721","Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.","Chen WR","2015","American heart journal","randomized_trial","article","10.1016/j.ahj.2015.07.014","26542491",null,null,"S000767; S001769","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0020722","Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.","Fineman M","2011","Clinical pharmacokinetics","nonrandomized_study","article","10.2165/11585880-000000000-00000","21142268",null,"ClinicalTrials.gov:NCT00103935","S002251","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020723","Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options.","Artasensi A","2023","Molecules (Basel, Switzerland)","narrative_review","article","10.3390/molecules28073094","37049856","PMC10095867",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020724","[News in diabetology 2021].","Gariani K","2022","Revue medicale suisse","other","article","10.53738/revmed.2022.18.764-65.21","35048574",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020725","Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.","Grabner M","2013","Postgraduate medicine","nonrandomized_study","article","10.3810/pgm.2013.05.2656","23748521",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020726","Functional Performance of Silk Nanoparticles for Oral Drug Delivery.","Jacobus C","2026","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.6c06529","42198918",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020727","Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.","Petri KCC","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13358","29748996","PMC6099226",null,"S000329; S000878; S001498; S001876","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020728","Semi-microbiological synthesis of an active lysinoalanine-bridged analog of glucagon-like-peptide-1.","Kuipers A","2017","Peptides","other","article","10.1016/j.peptides.2017.03.004","28300673",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020729","Exendin-4 protects rat islets against loss of viability and function induced by brain death.","Carlessi R","2015","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2015.05.009","25976662",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020730","Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study.","Gastaldelli A","2016","Hepatology (Baltimore, Md.)","other","article","10.1002/hep.28827","27639082",null,"ClinicalTrials.gov:NCT01588418","S001239","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0020731","An Insight into the Pathogenesis of Diabetic Cardiomyopathy Along with the Novel Potential Therapeutic Approaches.","Vig H","2024","Current diabetes reviews","narrative_review","article","10.2174/1573399819666230502110511","37138437",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0020732","Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?","Packer M","2018","European journal of heart failure","randomized_trial","article","10.1002/ejhf.1047","29082598",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Editorial; article"],["R0020733","The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?","Stafeev I","2021","Current molecular medicine","narrative_review","article","10.2174/1566524020666201201095029","33261539",null,null,"S002367","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020734","The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics.","Chae SY","2010","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2010.01.024","20093159",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020735","Corrigendum to \"Liraglutide inhibited AGEs induced coronary smooth muscle cell phenotypic transition through inhibiting the NF-κB signal pathway\" [Peptides 112 (2019) 125-132].","Di B","2024","Peptides","notice","article","10.1016/j.peptides.2024.171241","38763035",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0020736","Sulphonylurea efficacy and end-organ outcomes in the management of HNF4A-MODY.","Crowley MT","2025","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.70139","40954556","PMC12628745",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020737","The efficacy of liraglutide combined with intragastric balloon on weight loss.","Yilmaz A","2023","Revista da Associacao Medica Brasileira (1992)","other","article","10.1590/1806-9282.20230571","37971120","PMC10645169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020738","Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis.","Morsali M","2023","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2023.06.003","37400324",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Review; Research Support, Non-U.S. Gov't; Network Meta-Analysis"],["R0020739","Rb and p107 are required for alpha cell survival, beta cell cycle control and glucagon-like peptide-1 action.","Cai EP","2014","Diabetologia","preclinical","article","10.1007/s00125-014-3381-y","25249236",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020740","Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.","Kim N","2022","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2022.28.7.740","35737858","PMC10372962",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020741","Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.","Hölscher C","2014","The Journal of endocrinology","narrative_review","article","10.1530/joe-13-0221","23999914",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020742","Test of a biobehavioral model linking weight suppression to binge-eating severity via leptin and glucagon-like peptide 1 in bulimia nervosa and related syndromes in women.","Keel PK","2025","Psychological medicine","other","article","10.1017/s0033291725100871","40576074","PMC12234017",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0020743","Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.","Roshanov PS","2015","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2015.10.014","26643128",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0020744","Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.","Parthsarathy V","2018","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.13068","28730728",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020745","Correction to: Liraglutide ameliorates delirium-like behaviors of aged mice undergoing cardiac surgery by mitigating microglia activation via promoting mitophagy.","Jia M","2024","Psychopharmacology","notice","article","10.1007/s00213-024-06538-4","38265494","PMC10927767",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0020746","Evolutionary perspectives on substance and behavioural addictions: Distinct and shared pathways to understanding, prediction and prevention.","Hunt A","2024","Neuroscience and biobehavioral reviews","narrative_review","article","10.1016/j.neubiorev.2024.105603","38402919",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0020747","The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice.","Li C","2017","BMC pharmacology & toxicology","preclinical","article","10.1186/s40360-017-0143-8","28629388","PMC5477380",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0020748","[Glucagon-like peptide-1 analogues and cardiovascular risk factors: evidence from clinical trials].","Mannucci E","2010","Giornale italiano di cardiologia (2006)","randomized_trial","article",null,"21361053",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","English Abstract; Journal Article; other"],["R0020749","Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?","Berkovic MC","2020","World journal of diabetes","randomized_trial","article","10.4239/wjd.v11.i11.540","33269065","PMC7672794",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020750","Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real-world study.","Wu Y","2025","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70023","40087914","PMC12131924","ChiCTR:ChiCTR2400087169",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020751","Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database.","Rathmann W","2022","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-022-01943-7","35933524","PMC9519725",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020752","An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review.","Alsayed Hasan M","2023","Obesity surgery","randomized_trial","article","10.1007/s11695-023-06758-1","37530920",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0020753","Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.","Wang T","2015","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12386","25200423",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0020754","Effects of Aerobic Training and Semaglutide Treatment on Pancreatic β-Cell Secretory Function in Patients With Type 2 Diabetes.","Ingersen A","2023","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgad326","37265222",null,"ClinicalTrials.gov:NCT04383197","S002112","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020755","Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.","Ishøy PL","2014","BMJ open","protocol","article","10.1136/bmjopen-2013-004158","24401727","PMC3902332","ClinicalTrials.gov:NCT01794429; EudraCT:2012-005404-17","S002041","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; protocol; article"],["R0020756","Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.","Phizackerley D","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q53","38224977",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0020757","Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.","Yu X","2019","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2019.172715","31593687",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020758","A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.","Niafar M","2016","Archives of gynecology and obstetrics","systematic_review","article","10.1007/s00404-015-3976-7","26660657",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0020759","Glucose enhances rat islet function via stimulating CART expression.","Xu W","2016","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2016.11.012","27823935",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020760","The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review.","Guerrero-Hreins E","2021","Progress in neuro-psychopharmacology & biological psychiatry","preclinical","article","10.1016/j.pnpbp.2021.110303","33741445",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020761","Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR).","Colin IM","2016","Physiological reports","preclinical","article","10.14814/phy2.12886","27511983","PMC4985551",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020762","Liraglutide inhibits the apoptosis of human nucleus pulposus cells induced by high glucose through PI3K/Akt/caspase-3 signaling pathway.","Ming-Yan Y","2019","Bioscience reports","other","article","10.1042/bsr20190109","31383790","PMC6702359",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020763","Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes.","Coulter-Parkhill A","2021","Clinical medicine insights. Endocrinology and diabetes","narrative_review","article","10.1177/11795514211006071","34621137","PMC8491154",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020764","Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.","Lee KH","2017","International journal of cardiology","preclinical","article","10.1016/j.ijcard.2017.01.123","28159361",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020765","[Effect and mechanism of liraglutide on the apoptosis of human hepatocellular carcinoma HepG2 cells induced with palmitic acid].","Ao N","2019","Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","other","article","10.3760/cma.j.issn.1007-3418.2019.06.011","31357761","PMC12769844",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020766","Successful medical management of insulinoma with diazoxide for 27 years.","Warren AM","2020","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-20-0132","33434168","PMC7576657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020767","Emerging Anesthesia Risks with Semaglutide.","Fezza R","2023","Plastic and reconstructive surgery. Global open","other","article","10.1097/gox.0000000000005427","38025626","PMC10662908",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020768","The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.","Kobayashi K","2021","Journal of diabetes research","nonrandomized_study","article","10.1155/2021/6573369","35028319","PMC8749372",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020769","Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor.","Zhang Z","2024","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.4c01177","39140772",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020770","Efficient synthesis of Aib8 -Arg34 -GLP-1 (7-37) by liquid-phase fragment condensation.","Zhang J","2022","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.3407","35064598",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020771","Isolation of Positive Modulator of Glucagon-like Peptide-1 Signaling from Trigonella foenum-graecum (Fenugreek) Seed.","King K","2015","The Journal of biological chemistry","other","article","10.1074/jbc.m115.672097","26336108","PMC4646272",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020772","Protein-Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection.","Petsas E","2025","Molecules (Basel, Switzerland)","narrative_review","article","10.3390/molecules30214240","41226200","PMC12609854",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020773","Semaglutide in the spotlight: weighing benefits against rising concerns.","Ashinze P","2024","Therapeutic advances in endocrinology and metabolism","commentary","article","10.1177/20420188231222394","38188532","PMC10768618",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0020774","Liraglutide Ameliorates β-Amyloid Deposits and Secondary Damage in the Ipsilateral Thalamus and Sensory Deficits After Focal Cerebral Infarction in Rats.","Zhu HL","2018","Frontiers in neuroscience","preclinical","article","10.3389/fnins.2018.00962","30618584","PMC6304750",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020775","SA47. RCT of Exenatide for Clozapine-Associated Obesity","Siskind D","2017","Schizophrenia bulletin","randomized_trial","article","10.1093/schbul/sbx023.046",null,"PMC5475939",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; conference-abstract"],["R0020776","Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: A systematic review and meta-analysis of randomized controlled trials.","Abdelhaleem IA","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14602","34766431",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Meta-Analysis; Systematic Review; review"],["R0020777","Effectiveness and tolerability of liraglutide for the management of weight regain following sleeve gastrectomy.","Jamal M","2024","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.706","38259354","PMC10801437",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020778","Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow.","Jensen EP","2015","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00527.2014","25656368",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020779","Modulation of mRNA Expression of Biomarkers in the UPR-PERK Pathway by Ellagic Acid in Metabolic Dysfunction-Associated Fatty Liver Disease.","Pastrana-Cruz S","2026","International journal of molecular sciences","preclinical","article","10.3390/ijms27104491","42196469","PMC13206915",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020780","Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice.","Koshal P","2016","Molecular and cellular biochemistry","preclinical","article","10.1007/s11010-016-2678-1","26965494",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020781","Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis","Li C","2020","Research Square","systematic_review","preprint","10.21203/rs.3.rs-16511/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0020782","Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-α stimulated human retinal pigment epithelial cells.","Garczorz W","2019","Pharmacological reports : PR","other","article","10.1016/j.pharep.2018.10.003","30554037",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020783","Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!","Nauck MA","2014","Journal of diabetes science and technology","other","article","10.1177/1932296814532874","24876434","PMC4764228",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020784","Corrigendum to \"Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner\" [Pharmacological Reports 68 (2016) 329-337].","Bułdak Ł","2017","Pharmacological reports : PR","notice","article","10.1016/j.pharep.2016.12.009","28179083",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0020785","Bile acid treatment and FXR agonism lower postprandial lipemia in mice.","Farr S","2020","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00386.2018","32003602",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020786","A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β-Cells.","Buenaventura T","2018","Diabetes","preclinical","article","10.2337/db17-0639","29284659",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020787","In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.","Ali HJ","2023","Annals of internal medicine","other_trial","article","10.7326/j23-0101","38048584",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; article"],["R0020788","[Summary of the 2023 European Society of Cardiology clinical guidelines on the management of cardiovascular disease in patients with diabetes mellitus].","Erlikh AD","2024","Problemy endokrinologii","other","article","10.14341/probl13414","39302869","PMC11551801",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; research-article; article"],["R0020789","Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models.","Renner S","2016","The Journal of pathology","preclinical","article","10.1002/path.4655","26455904",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020790","The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.","Gullaksen S","2024","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2023.108673","38219335",null,"EudraCT:2019-000781-38",null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020791","Delayed-Onset Amiodarone Induced Thyrotoxicosis After Glucagon-Like Peptide-1 Agonist-Related Weight Loss.","Black ML","2026","JCEM case reports","case_report","article","10.1210/jcemcr/luaf313","41531741","PMC12794021",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020792","Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history.","Avogaro A","2022","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(22)00247-9","36182702",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020793","OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10554582",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0020794","Cystic fibrosis related diabetes--a new perspective on the optimal management of postprandial glycemia.","Perano S","2014","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2014.06.012","25060530",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020795","Exendin-4 attenuates endoplasmic reticulum stress through a SIRT1-dependent mechanism.","Lee J","2014","Cell stress & chaperones","other","article","10.1007/s12192-013-0490-3","24446069","PMC4147070",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020796","Adolescent bariatric surgery-a survey of referring practitioners.","Cromwell P","2024","Irish journal of medical science","other","article","10.1007/s11845-024-03624-6","38459246","PMC11294410",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020797","Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting.","Ramírez-Rincón A","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.828607","35573995","PMC9097264",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0020798","Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study.","Farrell AM","2026","JHEP reports : innovation in hepatology","randomized_trial","article","10.1016/j.jhepr.2026.101787","41831607","PMC13058968","ANZCTR:ACTRN12623000756628",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0020799","[Among adults with cardiovascular disease and BMI≥27kg/m2 but no diabetes, does semaglutide lower risk of cardiovascular mortality, myocardial infarction, or stroke when compared with placebo, and is it safe?].","Lanthier L","2024","La Revue de medecine interne","commentary","article","10.1016/j.revmed.2024.01.006","38228454",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0020800","Incretins: their physiology and application in the treatment of diabetes mellitus.","Tasyurek HM","2014","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.2501","24989141",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0020801","Insulin Degludec/Liraglutide.","Baker DE","2017","Hospital pharmacy","other_trial","article","10.1177/0018578717715383","28804155","PMC5551637",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0020802","Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.",null,"2019","The Medical letter on drugs and therapeutics","other","article","10.1001/jama.2019.2702","30845101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Corrected and Republished Article; article"],["R0020803","Enhanced protection against renal ischemia-reperfusion injury with combined melatonin and exendin-4 in a rodent model.","Chang YC","2016","Experimental biology and medicine (Maywood, N.J.)","preclinical","article","10.1177/1535370216642528","27037275","PMC4994899",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020804","[Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].","Verburg AFE","2019","Nederlands tijdschrift voor geneeskunde","other_trial","article",null,"30676706",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0020805","Cerebral Glucose Metabolism following TBI: Changes in Plasma Glucose, Glucose Transport and Alternative Pathways of Glycolysis-A Translational Narrative Review.","Gribnau A","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25052513","38473761","PMC10931358",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0020806","Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.","Forst T","2012","Experimental diabetes research","narrative_review","article","10.1155/2012/635472","22577369","PMC3345223",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0020807","Characterizing the D-Amino Acid Position in Peptide Epimers by Using Higher-Energy Collisional Dissociation Tandem Mass Spectrometry: A Case Study of Liraglutide.","Chen YC","2024","International journal of molecular sciences","other","article","10.3390/ijms25031379","38338662","PMC10855602",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020808","Injectable non-immunogenic PEG-like conjugate that forms a subcutaneous depot and enables sustained delivery of a peptide drug","Ozer I","2021","Research Square","other","preprint","10.21203/rs.3.rs-737658/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0020809","Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.","Zhang L","2016","Scientific reports","systematic_review","article","10.1038/srep18904","26742577","PMC4705511",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0020810","The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.","Bell DSH","2024","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15559","38516874",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020811","Lean Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): Pathophysiology, Diagnostic Challenges, Clinical Outcomes, and Management.","Albusta N","2026","Diseases (Basel, Switzerland)","nonrandomized_study","article","10.3390/diseases14050173","42187885","PMC13205529",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0020812","Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis.","Lee J","2014","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2014.04.011","24933399",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020813","Semaglutide in Patients Undergoing Anesthesia for Otolaryngologic Procedures.","Casazza JA","2024","The Laryngoscope","nonrandomized_study","article","10.1002/lary.31214","38038217",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0020814","Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.","Tan Q","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.838410","35299971","PMC8921987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0020815","Acquisition of absorption-enhancing abilities of cationic oligopeptides with short chain arginine residues through conjugation to hyaluronic acid.","Tomono T","2022","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2022.121519","35093459",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020816","Progress in anti-ageing drug research for age-related diseases: A review.","Zhou ZY","2026","Ageing research reviews","narrative_review","article","10.1016/j.arr.2025.102982","41344575",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0020817","Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.","Li D","2024","Clinical pharmacology and therapeutics","nonrandomized_study","article","10.1002/cpt.3139","38069538",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020818","Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome, Implicating the Role of the AKT/GSK3β/NF-κB/NLRP3 Pathway.","Hegab II","2024","International journal of molecular sciences","preclinical","article","10.3390/ijms26010001","39795860","PMC11720588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020819","An oral hypoglycemic agent for T2DM with the function of alleviating multi-complications","Zhang S","2024","Research Square","other","preprint","10.21203/rs.3.rs-4577178/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0020820","Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.","Aroda VR","2019","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(19)30184-6","31189519",null,"ClinicalTrials.gov:NCT02501161","S001131","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0020821","Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.","Xu Y","2014","Journal of cancer research and clinical oncology","preclinical","article","10.1007/s00432-014-1701-8","24838847","PMC11824134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020822","Synthesis and preclinical characterization of [64Cu]NODAGA-MAL-exendin-4 with a Nε-maleoyl-L-lysyl-glycine linkage.","Yim CB","2013","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2013.06.012","23932646",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020823","[SEMERGEN position paper on chronic kidney disease].","Pérez-León N","2026","Semergen","other","article","10.1016/j.semerg.2026.102690","41722153",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Consensus Statement; English Abstract; Practice Guideline"],["R0020824","The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.","Nyborg NC","2012","Diabetes","preclinical","article","10.2337/db11-0936","22338093","PMC3331765",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020825","Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide.","Tuttle KR","2023","American journal of nephrology","other","article","10.1159/000529374","36754023",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; article"],["R0020826","Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.","Gao Y","2023","The New England journal of medicine","commentary","article","10.1056/nejmc2312296","38118034",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0020827","Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes.","Lin CH","2015","Scientific reports","randomized_trial","article","10.1038/srep16968","26607841","PMC4660278",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0020828","Isolation of Rat Adipose Tissue Mesenchymal Stem Cells for Differentiation into Insulin-producing Cells.","Kassem DH","2022","Journal of visualized experiments : JoVE","preclinical","article","10.3791/63348","36094253",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Video-Audio Media; Research Support, Non-U.S. Gov't; article"],["R0020829","A single-center study on the biochemical effect and clinical effectiveness of liraglutide in Turkish patients.","Cetiner S","2023","European review for medical and pharmacological sciences","nonrandomized_study","article","10.26355/eurrev_202309_33796","37782186",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0020830","Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight.","Anderberg RH","2017","Diabetes","preclinical","article","10.2337/db16-0755","28057699","PMC6237271",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020831","Exendin-4 pretreated adipose derived stem cells are resistant to oxidative stress and improve cardiac performance via enhanced adhesion in the infarcted heart.","Liu J","2014","PloS one","preclinical","article","10.1371/journal.pone.0099756","24915574","PMC4051823",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020832","Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.","Cariou B","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15566","38528819",null,"ClinicalTrials.gov:NCT03882970","S001591","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020833","Gastrointestinal Disorders in Diabetes","Marathe CS","2000","MDText.com, Inc., South Dartmouth (MA)","narrative_review","article",null,"31986000",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0020834","Insulin resistance and Alzheimer's disease: Exploring research hotspots and frontiers from a bibliometric and visual analysis (2005-2024).","Zhang Y","2025","Journal of Alzheimer's disease reports","narrative_review","article","10.1177/25424823251361056","40687177","PMC12276435",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020835","Both classic Gs-cAMP/PKA/CREB and alternative Gs-cAMP/PKA/p38β/CREB signal pathways mediate exenatide-stimulated expression of M2 microglial markers.","Wu HY","2018","Journal of neuroimmunology","preclinical","article","10.1016/j.jneuroim.2017.12.005","29249556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020836","The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.","Terauchi Y","2022","Advances in therapy","nonrandomized_study","article","10.1007/s12325-022-02121-5","35449321","PMC9122860",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0020837","Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.","Kosiborod MN","2023","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2306963","37622681",null,"ClinicalTrials.gov:NCT04788511","S000913; S002012","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020838","NFκB mediates the anti-inflammatory actions of liraglutide and sitagliptin in experimentally model of colitis in mice","Azmy O","2024","Authorea Preprints","preclinical","preprint","10.22541/au.170667172.24354635/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020839","Efficacy and Tolerability of Semaglutide in Patients With Type-2 Diabetes Mellitus: Experience of a Tertiary Care Hospital, Pakistan.","Wajid M","2023","Clinical medicine insights. Endocrinology and diabetes","nonrandomized_study","article","10.1177/11795514231213568","38023735","PMC10676067",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0020840","N-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-4-[18F]-fluorobenzamide ([18F]FBEM) conjugated to EM3106B, an analog of glucagon-like peptide-1","Chopra A","2004","National Center for Biotechnology Information (US), Bethesda (MD)","preclinical","article",null,"22457885",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0020841","Liraglutide in Combination with Insulin Has a Superior Therapeutic Effect to Either Alone on Fracture Healing in Diabetic Rats.","Liu H","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s404392","37151908","PMC10155808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020842","The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells.","Zheng C","2019","Chemico-biological interactions","other","article","10.1016/j.cbi.2019.06.001","31173752",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020843","A Visual Diagnosis: Lipodystrophy.","Bhat SZ","2023","JCEM case reports","case_report","article","10.1210/jcemcr/luad066","37313426","PMC10259177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020844","Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.","Avgerinos I","2021","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14291","33300282",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0020845","SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes.","Fernández-Ruiz I","2024","Nature reviews. Cardiology","commentary","article","10.1038/s41569-023-00970-3","38036669",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0020846","Semaglutide Improved Cardiovascular Health in People Without Diabetes.","Harris E","2023","JAMA","other","article","10.1001/jama.2023.23508","38019508",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020847","Predicting responsiveness to GLP-1 pathway drugs using real-world data.","Zhu X","2024","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-024-01798-9","39695549","PMC11654408",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0020848","\"What would be left of me?\" Patient perspectives on the risks of obesity treatment: An innovative health initiative stratification of obesity phenotypes to optimise future obesity therapy (IMI2 SOPHIA) qualitative study.","Farrell E","2024","Obesity pillars","other","article","10.1016/j.obpill.2024.100129","39268014","PMC11389537",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0020849","Second- and Third-Line Pharmacotherapy for Type 2 Diabetes — Update of CADTH 2010 Reviews — Project Protocol",null,"2012","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","protocol","article",null,"27195345",null,null,null,"europepmc","TRUE","free_to_read","5",null,"Review"],["R0020850","Exendin-4 Reversed the PC12 Cell Damage Induced by circRNA CDR1as/miR-671/GSK3β Signaling Pathway.","Quan H","2021","Journal of molecular neuroscience : MN","preclinical","article","10.1007/s12031-020-01698-2","32889692",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020851","Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis.","Duan CM","2019","Medicine","systematic_review","article","10.1097/md.0000000000017860","31725627","PMC6867782",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; article"],["R0020852","Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease.","Bomba M","2019","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-190237","31256135",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020853","FLOW trial stopped early due to evidence of renal protection with semaglutide.","Gragnano F","2024","European heart journal. Cardiovascular pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvad080","37934595",null,"ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0020854","Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.","Elkind-Hirsch KE","2020","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2020.107548","32046931",null,"ClinicalTrials.gov:NCT01234649","S000625","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020855","Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial.","Papamargaritis D","2024","The Lancet regional health. Europe","randomized_trial","article","10.1016/j.lanepe.2024.100853","38803628","PMC11129336","ClinicalTrials.gov:NCT03036800","S001687","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0020856","Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.","Eržen S","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25031517","38338796","PMC10855385",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020857","Glucose-Lowering Therapy in Patients With Postpancreatitis Diabetes Mellitus: A Nationwide Population-Based Cohort Study.","Viggers R","2021","Diabetes care","nonrandomized_study","article","10.2337/dc21-0333","34362812",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0020858","Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.","Heerspink HJL","2023","Diabetes care","nonrandomized_study","article","10.2337/dc22-1889","36801984","PMC10090901","ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT03611582","S000144; S000988; S001740","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0020859","Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy).","Reyes-Garcia R","2025","Nutrients","nonrandomized_study","article","10.3390/nu17142349","40732973","PMC12300082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; research-article; article"],["R0020860","[SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].","Scheen AJ","2018","Revue medicale de Liege","other","article",null,"29388411",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020861","Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment.","Rudzki G","2024","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph17080987","39204092","PMC11357592",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020862","Action of GLP-1 (7-36) amide and exendin-4 on Suncus murinus (house musk shrew) isolated ileum.","Chan SW","2007","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2007.03.050","17475239",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020863","Semaglutide offers new route to cardiovascular risk reduction.","O'Leary K","2023","Nature medicine","commentary","article","10.1038/d41591-023-00099-3","38036698",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0020864","[New oral antidiabetic drugs].","Féry F","2014","Revue medicale de Bruxelles","other","article",null,"25675642",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020865","Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty.","Svane MS","2022","Neurogastroenterology and motility","preclinical","article","10.1111/nmo.14210","34378827",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020866","Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.","Nauck M","2016","Diabetes care","randomized_trial","article","10.2337/dc15-2479","27311491",null,"ClinicalTrials.gov:NCT01973231","S001337","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0020867","Liraglutide alleviates myocardial ischemia‒reperfusion injury in diabetic mice.","Fang B","2023","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2023.111954","37172886",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020868","Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.","Yammine L","2018","Medicine","protocol","article","10.1097/md.0000000000009567","29480848","PMC5943874",null,"S000617","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0020869","Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial.","Gerstein HC","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14954","36546588",null,"ClinicalTrials.gov:NCT01147250","S001991","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020870","Patient Adherence to a Real-World Digital, Asynchronous Weight Loss Program in Australia That Combines Behavioural and GLP-1 RA Therapy: A Mixed Methods Study.","Talay L","2024","Behavioral sciences (Basel, Switzerland)","nonrandomized_study","article","10.3390/bs14060480","38920813","PMC11200677",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; research-article; article; preprint"],["R0020871","Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients.","Xiong W","2024","American journal of translational research","nonrandomized_study","article","10.62347/vysw5854","39114730","PMC11301491",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020872","Optical tools for visualizing and controlling human GLP-1 receptor activation with high spatiotemporal resolution.","Duffet L","2023","eLife","other","article","10.7554/elife.86628","37265064","PMC10262203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; article; preprint"],["R0020873","Treatment with glucagon-like Peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor.","Simmons JH","2012","Hormone research in paediatrics","case_report","article","10.1159/000339469","22831918",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0020874","Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide.","Lampropoulou E","2016","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2015.09.011","26683792",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020875","US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events.","Wong ND","2025","Cardiovascular drugs and therapy","other_trial","article","10.1007/s10557-023-07488-3","37578663","PMC11802588",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020876","Structure-based insight into development of selective and non-selective amylin and calcitonin receptor agonists","Cao J","2022","Research Square","other","preprint","10.21203/rs.3.rs-2268316/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0020877","Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.","BouSaba J","2023","Pharmacogenomics","systematic_review","article","10.2217/pgs-2022-0192","36999540","PMC10152409",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review-article; review"],["R0020878","Semaglutide is beneficial in patients with HFpEF and obesity.","Fernández-Ruiz I","2023","Nature reviews. Cardiology","other","article","10.1038/s41569-023-00935-6","37709935",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020879","Piperazine-Functionalized Nanoparticles Enable Oral Insulin Delivery in Obese Mice.","Cao Y","2026","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.202520918","41793198","PMC13170209",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020880","Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.","Bader M","2019","Neurobiology of disease","preclinical","article","10.1016/j.nbd.2018.11.023","30471415","PMC6710831",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020881","Effects of iron overload and exenatide on erythrocyte deformability in a rat model.","Kuskonmaz SM","2015","Bratislavske lekarske listy","preclinical","article","10.4149/bll_2015_147","26924147",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020882","Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway.","Zhao L","2014","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00151.2014","25298426",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020883","Intelligent Escape System for the Oral Delivery of Liraglutide: A Perfect Match for Gastrointestinal Barriers.","Yin M","2020","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.9b01307","32267705",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020884","Liraglutide Exerts Potential Anti-inflammatory Effect in Type 1 Diabetes by Inhibiting IFN-γ Production via Suppressing JAK-STAT Pathway.","Zhao Y","2019","Endocrine, metabolic & immune disorders drug targets","preclinical","article","10.2174/1871530319666190301115654","30827273",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020885","Emerging role of GLP-1 receptor agonists in the treatment of obesity.","Neff LM","2010","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmsott.s6816","21437094","PMC3047971",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0020886","The influence of exendin-4 intervention on -obese diabetic mouse blood and the pancreatic tissue immune microenvironment.","He J","2016","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2016.3694","27882092","PMC5103724",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020887","Adherence to ADA Clinical Guidelines in Type 2 Diabetes Management in Public Health Clinics in Palestine.","Abukhalil AD","2024","Patient preference and adherence","nonrandomized_study","article","10.2147/ppa.s494951","39734752","PMC11682676",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020888","Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.","Chudleigh RA","2017","Expert opinion on drug safety","other_trial","article","10.1080/14740338.2017.1313225","28387138",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0020889","Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.","Takahara M","2024","Internal medicine (Tokyo, Japan)","nonrandomized_study","article","10.2169/internalmedicine.1441-22","37225492","PMC10824647",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; article"],["R0020890","Lax oversight of semaglutide advertising could harm patients, warn critics.","Boytchev H","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p2919","38164641",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020891","Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.","Unger J","2019","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.13682","30828917","PMC6617804",null,"S000508","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; research-article; article"],["R0020892","Therapies for neonatal encephalopathy: Targeting the latent, secondary and tertiary phases of evolving brain injury.","Chakkarapani AA","2021","Seminars in fetal & neonatal medicine","narrative_review","article","10.1016/j.siny.2021.101256","34154945",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020893","Commentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection.","Caruso I","2020","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2020.154272","32470349",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; editorial"],["R0020894","Application of Ga(68) -DOTA-exendin-4 PET/CT to localize an occult insulinoma.","Cuthbertson DJ","2016","Clinical endocrinology","case_report","article","10.1111/cen.12973","26562613",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0020895","Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.","Seaquist ER","2024","PloS one","randomized_trial","article","10.1371/journal.pone.0309907","39546502","PMC11567630","ClinicalTrials.gov:NCT01794143","S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0020896","Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.","Gopalasingam N","2024","Circulation","randomized_trial","article","10.1161/circulationaha.124.069732","39162035",null,"ClinicalTrials.gov:NCT05236335",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0020897","The effect of liraglutide on microvascular complications and cardiovascular risk in patients with type 2 diabetes","Sivaraman SC","2014","University of Warwick","nonrandomized_study","article",null,null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Dissertation; dissertation"],["R0020898","Glycogen synthesis kinase-3β involves in the analgesic effect of liraglutide on diabetic neuropathic pain.","Zhang Y","2023","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2023.108416","36773433",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020900","Liraglutide (Saxenda) for weight loss.","Whitten JS","2015","The Medical letter on drugs and therapeutics","narrative_review","article","10.1001/jama.2016.2083","26079762",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020901","Liraglutide promotes angiogenesis in adipose tissue via suppression of adipocyte-derived IL-6.","Zhang R","2023","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2023.02.007","36774663",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020902","Peptide hormones and bile acids shaping immune tolerance of the liver: implications and applications.","van Niekerk G","2026","Protein & cell","narrative_review","article","10.1093/procel/pwaf096","41208029","PMC13161479",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020903","Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review.","Jurca CM","2023","Genes","case_report","article","10.3390/genes14020433","36833359","PMC9957184",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Case Reports; Journal Article; case-report; article"],["R0020904","HNF1B-MODY (MODY-5): a rare form of diabetes with multisystemic features-two case reports.","Carvalho T","2026","Frontiers in endocrinology","case_report","article","10.3389/fendo.2026.1841040","42369057","PMC13293842",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0020905","Liraglutide and learning.","Wiseman S","2023","Nature neuroscience","other","article","10.1038/s41593-023-01466-6","37789197",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020906","Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects.","Palleria C","2017","Behavioural brain research","preclinical","article","10.1016/j.bbr.2017.01.004","28062257",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020907","Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level.","Alarcon C","2006","Diabetologia","preclinical","article","10.1007/s00125-006-0433-y","17053883",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0020908","Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.","Tang B","2022","Neurology","other_trial","article","10.1212/wnl.0000000000200771","35654594","PMC9484609",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0020909","Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.","Maddaloni E","2025","Diabetes care","randomized_trial","article","10.2337/dc24-1455","39576722",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; other; article"],["R0020910","Preptin analogues: chemical synthesis, secondary structure and biological studies.","Buchanan CM","2013","Chemical biology & drug design","preclinical","article","10.1111/cbdd.12168","23745966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020911","A case report of severe adverse reaction of exenatide: Anaphylactic shock.","Liu X","2022","Medicine","case_report","article","10.1097/md.0000000000030805","36181058","PMC9524889",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; research-article; article"],["R0020912","Increased Risk of Hypoglycemia Following Roux-en-Y Gastric Bypass Surgery in Patients Without Diabetes: a Propensity Score-Matched Analysis.","Toraih EA","2024","Obesity surgery","nonrandomized_study","article","10.1007/s11695-024-07565-y","39532813","PMC11671553",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020913","Feeding and GLP-1 receptor activation stabilize β-catenin in specific hypothalamic nuclei in male rats.","McEwen HJL","2018","Journal of neuroendocrinology","preclinical","article","10.1111/jne.12607","29752762",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020914","The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery.","Colbourne JRM","2023","Langenbeck's archives of surgery","nonrandomized_study","article","10.1007/s00423-023-02805-8","36867261","PMC9984502",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020915","Corrigendum to \"Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs\" [Nucl Med Biol 43 (2016) 397-402].","Rydén A","2016","Nuclear medicine and biology","notice","article","10.1016/j.nucmedbio.2016.08.013","27614382",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0020916","Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score.","Ghusn W","2024","EClinicalMedicine","nonrandomized_study","article","10.1016/j.eclinm.2024.102625","38756106","PMC11096862",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020917","Comparative analysis of serious adverse effects of antidiabetic drugs and complications associated with type II diabetes mellitus.","Barakat HE","2026","BMC pharmacology & toxicology","nonrandomized_study","article","10.1186/s40360-026-01211-2","42786528","PMC13602756",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Multicenter Study; Comparative Study; article"],["R0020918","Anti-thrombotic and glucose lowering therapy in diabetic patients with coronary artery disease undergoing PCI with stent implantation: A prospective multicenter observational study on prescription patterns and clinical outcomes. Baseline inclusion data of the ARTHEMIS registry.","Bravo Baptista S","2025","Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology","nonrandomized_study","article","10.1016/j.repc.2025.03.006","40738464",null,"ClinicalTrials.gov:NCT04481997",null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Multicenter Study; Clinical Trial; article"],["R0020919","Chitosan: A promising therapeutic agent and effective drug delivery system in managing diabetes mellitus.","Sarkar S","2020","Carbohydrate polymers","narrative_review","article","10.1016/j.carbpol.2020.116594","32829787",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020920","Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).","Park EJ","2016","Expert opinion on therapeutic patents","narrative_review","article","10.1080/13543776.2016.1192130","27196800",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020921","Exploring the DPP IV inhibitory potential: molecular docking and dynamic simulations of pyridine-3-carboxylic acid and pyrrolidine-2-carboxylic acid analogs.","Puranik HH","2025","Journal of biomolecular structure & dynamics","other","article","10.1080/07391102.2024.2439579","39671243",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020922","Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons.","Koufakis T","2023","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2023.2237414","37450311",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0020923","The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease.","Lincoff AM","2024","European heart journal. Cardiovascular pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvad097","38066700",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0020924","Incretin based therapies: do they hold their promise?","Holst JJ","2012","Journal of diabetes","nonrandomized_study","article","10.1111/j.1753-0407.2012.00186.x","22248344",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; Comment; article"],["R0020925","Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells.","Pugazhenthi S","2015","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2015.02.024","25720341",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020926","The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.","Cobbold JF","2026","The lancet. Gastroenterology & hepatology","nonrandomized_study","article","10.1016/s2468-1253(26)00077-4","42070581",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Consensus Statement; Review"],["R0020927","Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity.","Dhore-Patil A","2021","Frontiers in physiology","narrative_review","article","10.3389/fphys.2021.785879","35242044","PMC8886215",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020928","Cardiovascular Safety of Antihyperglycemic Agents: \"Do Good or Do No Harm\".","Manolis AA","2018","Drugs","narrative_review","article","10.1007/s40265-018-0985-4","30251174",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020929","Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.","Goodman J","2025","Scientific reports","randomized_trial","article","10.1038/s41598-025-04559-3","40593987","PMC12217732",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0020930","PANoptosis in Alzheimer's disease: The expanding landscape of programmed cell death mechanisms and therapeutic interventions.","Paidlewar M","2026","Free radical biology & medicine","narrative_review","article","10.1016/j.freeradbiomed.2026.03.053","41864364",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0020931","Metformin and incretin-based therapies up-regulate central and peripheral Adenosine monophosphate-activated protein affecting appetite and metabolism.","Nakano M","2012","Indian journal of endocrinology and metabolism","commentary","article","10.4103/2230-8210.105567","23565485","PMC3602979",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0020932","Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.","Wong E","2023","American journal of therapeutics","other_trial","article","10.1097/mjt.0000000000001588","36516422",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0020933","Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.","Mann KV","2014","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s35331","25018644","PMC4075952",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0020934","Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.","Dungan KM","2014","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(14)60976-4","25018121",null,"ClinicalTrials.gov:NCT01624259","S000993; S001184","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020935","GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.","Ryan D","2015","Obesity (Silver Spring, Md.)","narrative_review","article","10.1002/oby.21107","25959380","PMC4692091",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0020936","Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake.","Singh I","2022","Cell & bioscience","preclinical","article","10.1186/s13578-022-00914-3","36309763","PMC9618215",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; other; preprint; article"],["R0020937","Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model.","Qi L","2016","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2016.04.052","27131827",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020938","Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?","Elder MJ","2023","Journal of pharmacy practice","narrative_review","article","10.1177/08971900211049032","34620002",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0020939","Liraglutide modulates adhesion molecules and enhances cell properties in three-dimensional cultures of olfactory ensheathing cells.","Tseng YT","2023","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","other","article","10.1016/j.biopha.2023.115084","37399717",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020940","Liraglutide Attenuates Myocardial Ischemia/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R/PI3K/Akt Pathway.","Zhou G","2023","Cardiovascular toxicology","preclinical","article","10.1007/s12012-023-09789-3","36934206",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020941","Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes.","Del Prete M","2025","Eating and weight disorders : EWD","nonrandomized_study","article","10.1007/s40519-024-01711-2","39786599","PMC11717789",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020942","The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model.","Panagaki T","2018","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-180584","30282365",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020943","GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?","Zweck E","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(18)30351-6","30683221",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0020944","Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.","Thong KY","2012","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/j.1464-5491.2011.03475.x","21988449",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0020945","The use of an automatic remote weight management system to track treatment response, identified drugs supply shortage and its consequences: A pilot study.","Roth I","2025","Digital health","other","article","10.1177/20552076251314090","39866891","PMC11758857",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020946","Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.","Mroz PA","2019","Molecular metabolism","preclinical","article","10.1016/j.molmet.2018.12.001","30578168","PMC6358549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020947","SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide.","Frandsen CS","2023","Lancet (London, England)","commentary","article","10.1016/s0140-6736(23)01292-8","37385274",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0020948","Treatment strategy for children and adolescents with type 2 diabetes-based on ISPAD Clinical Practice Consensus Guidelines 2022.","Urakami T","2023","Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology","narrative_review","article","10.1297/cpe.2023-0007","37362170","PMC10288292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020949","Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.","Chen H","2016","Theranostics","preclinical","article","10.7150/thno.14322","26877782","PMC4729772",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0020950","Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future.","Mallik R","2022","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/20420188221081601","35281302","PMC8905210",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020951","Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).","Siskind DJ","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13167","29194917",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020952","Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.","Pulleyblank R","2023","PharmacoEconomics - open","nonrandomized_study","article","10.1007/s41669-023-00416-z","37178435","PMC10333151","ClinicalTrials.gov:NCT02863328; ClinicalTrials.gov:NCT02607865; ClinicalTrials.gov:NCT01930188; ClinicalTrials.gov:NCT03136484","S000251; S001847; S001876; S002267","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020953","Regulation of nanoparticle exocytosis direction via receptors transfer: A novel strategy to enhance therapeutic efficacy of semaglutide.","Wang Y","2025","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2025.125439","40064382",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020954","Glucagon-Like Peptide 1 Receptor (Glp1r) Deficiency Does Not Appreciably Alter Airway Inflammation or Gut-Lung Microbiome Axis in a Mouse Model of Obese Allergic Airways Disease and Bariatric Surgery.","Kim YJ","2025","Journal of asthma and allergy","preclinical","article","10.2147/jaa.s478329","40046174","PMC11880686",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020955","Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.","Velikyan I","2015","American journal of nuclear medicine and molecular imaging","preclinical","article",null,"25973333","PMC4396004",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020956","Correction to: The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.",null,"2024","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","notice","article","10.1093/ndt/gfad252","38033315","PMC10966322",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0020957","Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression.","Zhao W","2018","Molecular medicine reports","other","article","10.3892/mmr.2018.8475","29393459","PMC5865986",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020958","Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.","Tao Y","2019","IUBMB life","other","article","10.1002/iub.2031","30897288",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020959","Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss.","Simeone P","2018","Nutrients","randomized_trial","article","10.3390/nu10121872","30513818","PMC6315606",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0020960","Tirzepatide: A Systematic Update.","Forzano I","2022","International journal of molecular sciences","systematic_review","article","10.3390/ijms232314631","36498958","PMC9741068",null,"S001026","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; Review; article"],["R0020961","Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity.","Yazıcı D","2023","Obesity facts","narrative_review","article","10.1159/000526808","36349778","PMC10028372",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020962","South Asian consensus guideline: Use of GLP-1 receptor agonists during Ramadan: Update 2016 Revised Guidelines on the use of GLP-1A in Ramadan.","Pathan F","2016","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"27339589",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020963","Revisiting macrophage metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: mechanisms, regulation, and therapeutic breakthroughs.","Zhu L","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1899587","42676633","PMC13527444",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020964","Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)","Siskind D","2023","BJPsych open","protocol","article","10.1192/bjo.2023.532",null,"PMC10375878","ANZCTR:ACTRN12621001539820",null,"europepmc; openalex","TRUE","open_europepmc","5","FALSE","research-article; Journal Article; article"],["R0020965","Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.","Henry RR","2014","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2013.12.009","24631129",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020966","Potential roles for eNOS and NrF₂ /HO-1 signaling in the ameliorative effect of lixisenatide on diabetes-induced kidney injury in rats and its amplification by ticagrelor co-administration.","Sleem M","2024","Die Pharmazie","preclinical","article","10.1691/ph.2024.4566","39407425",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020967","Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study.","Alsheikh A","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-023-01516-z","38110660","PMC10838866",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0020968","The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice.","Fosgerau K","2013","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2012.01676.x","22862961",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020969","Folic acid-modified reverse micelle-lipid nanocapsules overcome intestinal barriers and improve the oral delivery of peptides.","He J","2023","Drug delivery","preclinical","article","10.1080/10717544.2023.2181744","36855953","PMC9980025",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020970","SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review.","El Mouhayyar C","2020","International journal of endocrinology","preclinical","article","10.1155/2020/1762164","32190049","PMC7066394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020971","New Insights into the Use of Liraglutide-Impact on Cardiovascular Risk and Microvascular Outcomes.","Wronka M","2023","Biomedicines","narrative_review","article","10.3390/biomedicines11041159","37189777","PMC10136170",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0020972","Lipid-lowering and hepatoprotective effects of Ocimum sanctum L. (Thai holy basil) flower against MASLD and liver inflammation in rats.","Inchai J","2026","Food research international (Ottawa, Ont.)","preclinical","article","10.1016/j.foodres.2026.119968","42680287",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020973","Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity.","Valladales-Restrepo LF","2023","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2023.2178900","36755412",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0020974","An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks.","Usborne A","2015","Toxicologic pathology","randomized_trial","article","10.1177/0192623315596857","26269615",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0020975","Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies.","Yuan YC","2024","Signal transduction and targeted therapy","preclinical","article","10.1038/s41392-024-01923-z","39128897","PMC11317495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020976","Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?","Deane AM","2014","Diabetes care","commentary","article","10.2337/dc13-1616","24459168",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0020977","Two drugs converged in a pancreatic β cell.","Scavuzzo MA","2020","Science translational medicine","commentary","article","10.1126/scitranslmed.aba7359","32051228",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0020978","Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years.","Block TJ","2023","Presse medicale (Paris, France : 1983)","other_trial","article","10.1016/j.lpm.2023.104178","37783423",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; article"],["R0020979","Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.","Mora P","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)01248-1","42532080",null,"ClinicalTrials.gov:NCT06542874","S003224","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; article"],["R0020980","Type 2 Diabetes Management in Aotearoa New Zealand: A Comparison of Urban and Rural Primary Care Clinics.","Mustafa S","2025","The Australian journal of rural health","nonrandomized_study","article","10.1111/ajr.70098","41024742","PMC12481175",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Comparative Study; research-article; article"],["R0020981","Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.","Shi C","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15552","38497231",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; Observational Study; Research Support, Non-U.S. Gov't; Comparative Study; article"],["R0020982","A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.","Jun LS","2014","PloS one","preclinical","article","10.1371/journal.pone.0093746","24695667","PMC3973576",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020983","Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.","Wang W","2017","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2017.05.007","28552612",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0020984","GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells.","da Silva Lima N","2024","Cellular and molecular life sciences : CMLS","other","article","10.1007/s00018-024-05507-6","39607493","PMC11604888",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020985","Fabrication and Evaluation of a pH-Responsive Nanocomposite-Based Colonic Delivery System for Improving the Oral Efficacy of Liraglutide.","Song JG","2023","International journal of nanomedicine","preclinical","article","10.2147/ijn.s413515","37489139","PMC10363350",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020986","A genetic screen identifies Crat as a regulator of pancreatic beta-cell insulin secretion.","Berdous D","2020","Molecular metabolism","preclinical","article","10.1016/j.molmet.2020.100993","32298772","PMC7225740",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0020987","Cardiovascular biology of the incretin system.","Ussher JR","2012","Endocrine reviews","narrative_review","article","10.1210/er.2011-1052","22323472","PMC3528785",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0020988","In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes.","Skarbaliene J","2017","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2017.09.026","28928089",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0020989","Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.","Weghuber D","2023","Journal of comparative effectiveness research","other_trial","article","10.2217/cer-2022-0187","36534451","PMC10288970","ClinicalTrials.gov:NCT04102189","S001529","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Patient Education Handout; other; article"],["R0020990","Semaglutide and pregnancy.","Skov K","2023","International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics","other","article","10.1002/ijgo.15092","37688299",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020991","Peptides originally derived from Chilobrachys jingzhao tarantula venom possess beneficial effects on pancreatic beta cell health and function.","Coulter-Parkhill A","2023","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2023.175855","37391009",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0020992","A Scalable Application of Artificial Intelligence-Driven Insulin Titration Program to Transform Type 2 Diabetes Management.","Warren M","2024","Diabetes technology & therapeutics","other","article","10.1089/dia.2024.0041","38452101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0020993","A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects.","Ikushima I","2018","Advances in therapy","randomized_trial","article","10.1007/s12325-018-0677-1","29536338","PMC5910468","ClinicalTrials.gov:NCT02146079; JapicCTI:JAPICCTI-142550","S001888","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0020994","The role of exendin-4-conjugated superparamagnetic iron oxide nanoparticles in beta-cell-targeted MRI.","Zhang B","2013","Biomaterials","preclinical","article","10.1016/j.biomaterials.2013.04.021","23642536",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020995","Experiences and Translatability of In Vitro and In Vivo Models to Evaluate Caprate as a Permeation Enhancer.","Emeh P","2024","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.3c00872","38054599",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0020996","Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.","Ahn S","2013","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2013.05.031","23747732",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0020997","Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson's Disease Using In Vitro Models.","Shtilbans A","2025","Antioxidants (Basel, Switzerland)","preclinical","article","10.3390/antiox14040396","40298667","PMC12024093",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020998","AWRK6, a Novel GLP-1 Receptor Agonist, Attenuates Diabetes by Stimulating Insulin Secretion.","Wang Q","2018","International journal of molecular sciences","preclinical","article","10.3390/ijms19103053","30301245","PMC6213269",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0020999","Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism.","Yan X","2022","Cells","preclinical","article","10.3390/cells11233821","36497087","PMC9736458",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021000","The Cardiovascular Biology of Glucagon-like Peptide-1.","Drucker DJ","2016","Cell metabolism","narrative_review","article","10.1016/j.cmet.2016.06.009","27345422",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0021001","[Does a higher dose of oral semaglutide treatment make sense?].","Martin S","2024","Innere Medizin (Heidelberg, Germany)","other","article","10.1007/s00108-023-01639-2","38214721",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021002","GLP-1R activation alleviated sepsis-induced cardiac dysfunction by modulating macrophage polarization via the STING/ P65 pathway.","Zhang Y","2026","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2026.118131","42242503",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021003","A Role for GLP-1 in Treating Hyperphagia and Obesity.","Grill HJ","2020","Endocrinology","narrative_review","article","10.1210/endocr/bqaa093","32516384","PMC7899438",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0021004","Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.","Dave CV","2021","Circulation","randomized_trial","article","10.1161/circulationaha.120.047965","33302723","PMC7902404",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021005","GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation.","Biagioli M","2022","Cells","preclinical","article","10.3390/cells11071187","35406751","PMC8998127",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021006","Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.","Kesavadev J","2015","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2014.04.034","25605673",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0021007","Incretins and their role in the management of diabetes.","Frias JP","2007","Current opinion in endocrinology, diabetes, and obesity","other_trial","article","10.1097/med.0b013e32825ea2ba","17940451",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0021008","Short-term monotherapy with Liraglutide for weight management: A case study.","Almarshad F","2019","Journal of family medicine and primary care","case_report","article","10.4103/jfmpc.jfmpc_213_19","31198765","PMC6559087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021009","Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.","Suzuki S","2017","Health and quality of life outcomes","randomized_trial","article","10.1186/s12955-017-0696-7","28606095","PMC5468988","ClinicalTrials.gov:NCT01558271; ClinicalTrials.gov:NCT01584232","S000246; S000837","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; other; article"],["R0021010","Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.","Tella SH","2015","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018815580257","26137215","PMC4480552",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021011","Incretin-based therapies: viewpoints on the way to consensus.","Nauck MA","2009","Diabetes care","narrative_review","article","10.2337/dc09-s315","19875556","PMC2811437",null,"S001945","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0021012","Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway.","Chang G","2018","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2017.3318","29286061",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021013","Review of the therapeutic uses of liraglutide.","Ryan GJ","2011","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2011.06.004","21741090",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0021014","Evaluation of the in vitro and in vivo angiogenic effects of exendin-4.","Kang HM","2013","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2013.03.053","23541581",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021015","Correction to \"Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial\".",null,"2023","Obesity (Silver Spring, Md.)","notice","article","10.1002/oby.23843","37559487",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0021016","Optimized Methods for the Production and Bioconjugation of Site-Specific, Alkyne-Modified Glucagon-like Peptide-1 (GLP-1) Analogs to Azide-Modified Delivery Platforms Using Copper-Catalyzed Alkyne-Azide Cycloaddition.","Alavi SE","2020","Bioconjugate chemistry","other","article","10.1021/acs.bioconjchem.0c00291","32543833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021017","The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus.","Brice KR","2011","Clinical medicine insights. Endocrinology and diabetes","randomized_trial","article","10.4137/cmed.s4086","22879790","PMC3411513",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; article"],["R0021018","Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats.","Sharma AN","2015","Metabolic brain disease","preclinical","article","10.1007/s11011-014-9627-z","25380665",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021019","Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.","Umpierrez GE","2018","Journal of diabetes","narrative_review","article","10.1111/1753-0407.12576","28581207",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021020","Incretin-based therapies and a potential drug interaction.","Gabb GM","2011","Internal medicine journal","commentary","article","10.1111/j.1445-5994.2011.02609.x","22737698",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0021021","Supramolecular prodrug of SN38 based on endogenous albumin and SN38 prodrug modified with semaglutide side chain to improve the tumor distribution.","Wei Q","2024","Bioorganic & medicinal chemistry","other","article","10.1016/j.bmc.2024.117754","38728869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021022","Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study.","Mathur W","2024","Obesity surgery","randomized_trial","article","10.1007/s11695-023-06975-8","38091192",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0021023","Liraglutide Accelerates Ischemia-Induced Angiogenesis in a Murine Diabetic Model.","Zhu YX","2023","Journal of the American Heart Association","preclinical","article","10.1161/jaha.122.026586","36789853","PMC10111486",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021024","[New concepts in the treatment of type 2 diabetes].","Meier JJ","2007","Der Internist","narrative_review","article","10.1007/s00108-007-1876-z","17541529",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Review"],["R0021025","Once weekly semaglutide and cardiovascular outcomes in patients with type 2 diabetes and heart failure with reduced left ventricular ejection fraction.","Pérez-Velasco MA","2024","Revista espanola de cardiologia (English ed.)","case_report","article","10.1016/j.rec.2023.12.008","38237661",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Case Reports; article"],["R0021026","High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery.","Vinciguerra F","2023","Frontiers in nutrition","other","article","10.3389/fnut.2023.1183899","37771756","PMC10524598",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021027","Semaglutide reduces risk of major cardiovascular events by 20%, finds study.","Wise J","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p2668","37957004",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021028","RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus.","O'Brien JT","2022","Alzheimer's research & therapy","other_trial","article","10.1186/s13195-022-01103-7","36369100","PMC9650797",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Consensus Statement; review-article; article"],["R0021029","The impact of bariatric and metabolic surgery on cancer development.","Lunger F","2022","Frontiers in surgery","narrative_review","article","10.3389/fsurg.2022.918272","35910464","PMC9334768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021030","GLP-1 receptor agonists and cardiovascular risk in routine clinical practice.","Schernthaner G","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(18)30340-1","30527908",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021031","A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes - 2nd edition (English version).","Bouchi R","2024","Journal of diabetes investigation","other","article","10.1111/jdi.14202","38988282","PMC11363114",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Consensus Statement; research-article; article"],["R0021032","Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More.","Abbasi J","2023","JAMA","other","article","10.1001/jama.2023.22707","37991804",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021033","Risk of pulmonary aspiration during semaglutide use and anesthesia in a fasting patient: a case report with tomographic evidence.","Queiroz VNF","2023","Einstein (Sao Paulo, Brazil)","case_report","article","10.31744/einstein_journal/2023rc0628","38126547",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021034","A wearable osmotic microneedle patch provides high-capacity sustained drug delivery in animal models.","Zhao S","2024","Science translational medicine","preclinical","article","10.1126/scitranslmed.adp3611","39602507",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021035","Influence and significance of intervening diabetes microRNA expression profile of NOD mice with exendin-4.","He JS","2016","European review for medical and pharmacological sciences","preclinical","article",null,"27831640",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021036","Lixisenatide ameliorates cerebral ischemia-reperfusion injury via GLP-1 receptor dependent/independent pathways.","Abdel-Latif RG","2018","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2018.05.045","29864411",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021037","Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.","Garg A","2018","Current drug safety","systematic_review","article","10.2174/1574886313666180601082412","29852875",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0021038","GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.","Noyan-Ashraf MH","2009","Diabetes","preclinical","article","10.2337/db08-1193","19151200","PMC2661586",null,"S000424; S000767; S000838; S002372","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021039","Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis.","Abdul-Ghani MA","2013","Journal of endocrinological investigation","systematic_review","article","10.3275/8367","22522662",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; review"],["R0021040","A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.","Montanya E","2009","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2009.11.034","20109994",null,null,"S000404","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0021041","What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives.","Alfieri CM","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25147728","39062970","PMC11276657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021042","Related expressional change of HIF-1α to the neuroprotective activity of exendin-4 in transient global ischemia.","Jin J","2014","Neuroreport","preclinical","article","10.1097/wnr.0000000000000046","24201448",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021043","Semaglutide Plus Metformin Versus Metformin Alone For Antipsychotic-Induced Weight Gain In Patients With Type 2 Diabetes Mellitus.","Vu C","2025","The Psychiatric quarterly","nonrandomized_study","article","10.1007/s11126-025-10137-7","40227520",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0021044","Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?","Magruder ML","2023","The Journal of arthroplasty","nonrandomized_study","article","10.1016/j.arth.2023.05.071","37279843",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0021045","Liraglutide alleviates cardiac fibrosis through inhibiting P4hα-1 expression in STZ-induced diabetic cardiomyopathy.","Zhao T","2019","Acta biochimica et biophysica Sinica","randomized_trial","article","10.1093/abbs/gmy177","30883649",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0021046","Paraventricular Thalamic Control of Food Intake and Reward: Role of Glucagon-Like Peptide-1 Receptor Signaling.","Ong ZY","2017","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/npp.2017.150","28811669","PMC5645740",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0021047","A polyphenol-metal nanoparticle platform for tunable release of liraglutide to improve blood glycemic control and reduce cardiovascular complications in a mouse model of type II diabetes.","He Z","2020","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2019.12.014","31838207",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021048","The prospective record-breaking obesity drug tirzepatide raises concerns about affordability.","Seetharaman R","2023","Journal of basic and clinical physiology and pharmacology","commentary","article","10.1515/jbcpp-2023-0129","37326670",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0021049","Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.","Miras AD","2019","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(19)30157-3","31174993",null,"ISRCTN:ISRCTN13643081; EudraCT:2014-003923-23",null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021050","Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.","McReelis KD","2017","Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","commentary","article","10.1016/j.jcjo.2017.07.028","29074013",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0021051","Potential of incretin-based therapies for non-alcoholic fatty liver disease.","Samson SL","2013","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2012.12.005","23352496",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; article"],["R0021052","Beyond glycemic control: treating the entire type 2 diabetes disorder.","Brunton S","2009","Postgraduate medicine","narrative_review","article","10.3810/pgm.2009.09.2054","19820276",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021053","The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.","Hsieh J","2010","Diabetologia","preclinical","article","10.1007/s00125-009-1611-5","19957161",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021054","Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study.","Kim HS","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.1032793","36387922","PMC9659594",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021055","Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.","Harrison LB","2013","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","nonrandomized_study","article","10.2310/jim.0b013e318279b7d6","23222002",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0021056","Response to comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?","Schwartz S","2014","Diabetes care","commentary","article","10.2337/dc13-1783","24459169",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0021057","Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.","Katout M","2014","American journal of hypertension","systematic_review","article","10.1093/ajh/hpt196","24263424",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0021058","Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea.","Jiang W","2023","Sleep & breathing = Schlaf & Atmung","randomized_trial","article","10.1007/s11325-022-02768-y","36542275","PMC10539428",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0021059","Renal effects of exendin-4 in an animal model of brain death.","Lemos NE","2019","Molecular biology reports","randomized_trial","article","10.1007/s11033-019-04674-1","30759298",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0021060","Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis.","Saadi MSS","2024","International journal of molecular sciences","systematic_review","article","10.3390/ijms25147988","39063229","PMC11277066",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review-article; review"],["R0021061","[Smeglutide inhibits high glucose-induced proliferation of myocardial fibroblasts by downregulating TGFβ/Smad3 signaling].","Li J","2023","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article","10.12122/j.issn.1673-4254.2023.11.14","38081612","PMC10713456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; research-article; other"],["R0021062","Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.","Zhan K","2023","The Annals of pharmacotherapy","systematic_review","article","10.1177/10600280221133577","36314281","PMC9618918",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; other; review"],["R0021063","Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia.","Lasalvia P","2017","Value in health regional issues","nonrandomized_study","article","10.1016/j.vhri.2016.10.006","29254540",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0021064","Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.","Duarte AI","2013","Biochimica et biophysica acta","narrative_review","article","10.1016/j.bbadis.2013.01.008","23314196",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0021065","Effects of Replacing a Central Glycine Residue in GLP-1 on Receptor Affinity and Signaling Profile.","Brown KA","2023","Chembiochem : a European journal of chemical biology","nonrandomized_study","article","10.1002/cbic.202300504","37624685","PMC10666649",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021066","Effects of liraglutide on astrocyte polarization and neuroinflammation in db/db mice: focus on iron overload and oxidative stress.","An JR","2023","Frontiers in cellular neuroscience","preclinical","article","10.3389/fncel.2023.1136070","37323581","PMC10267480",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021067","The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report.","Hirai H","2016","Journal of medical case reports","case_report","article","10.1186/s13256-016-0994-4","27456688","PMC4960667",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021068","GLP-1 receptor agonists, CKD, and eGFR trajectory.","van Baar MJB","2018","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(18)30241-9","30266180",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0021069","Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.","Neumiller JJ","2009","Journal of the American Pharmacists Association : JAPhA","narrative_review","article","10.1331/japha.2009.09078","19801361",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0021070","Treating obesity in type 1 diabetes mellitus - review of efficacy and safety.","Freeby M","2024","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000841","37820077",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021071","The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.","Gerstein HC","2020","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(19)30423-1","31924562",null,"ClinicalTrials.gov:NCT01394952","S000147; S000766","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0021072","Favorable Effect on Blood Volume Control in Hemodialysis Patients with Type 2 Diabetes after Switching from Insulin Therapy to Liraglutide, a Human Glucagon-like Peptide-1 Analog--Results from a Pilot Study in Japan-.","Kondo M","2017","The Tokai journal of experimental and clinical medicine","nonrandomized_study","article",null,"28413872",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; article"],["R0021073","Web Exclusive. Annals On Call - The Good, the Bad, and the Ugly-the Sequel: GLP1 Agonists.","Centor RM","2020","Annals of internal medicine","other","article","10.7326/a19-0023","32016338",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021074","Retrospective cohort study of the predictors of weight loss after 3 months of treatment with Liraglutide for patients with obesity/overweight at the “Centre d’Obésité et de Contrôle du Poids” (COCP)","Moujaes G","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3345740/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0021075","Liraglutide via Activation of AMP-Activated Protein Kinase-Hypoxia Inducible Factor-1α-Heme Oxygenase-1 Signaling Promotes Wound Healing by Preventing Endothelial Dysfunction in Diabetic Mice.","Huang H","2021","Frontiers in physiology","preclinical","article","10.3389/fphys.2021.660263","34483951","PMC8415222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021076","Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis.","Alsanea S","2024","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.1016/j.eprac.2024.05.009","38782201",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Meta-Analysis; review"],["R0021077","[Recent advance in treatment of diabetes mellitus, impact of incretin-based therapy].","Maegawa H","2013","Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology","narrative_review","article",null,"24189820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021078","Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.","Wharton S","2023","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23673","36655300",null,null,"S000214; S001761","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021079","Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates.","Zhang J","2021","Bioorganic & medicinal chemistry","other","article","10.1016/j.bmc.2021.116291","34216986",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021080","Glycemic Control in Hospitalized Stroke Patients: A Review.","Patel VN","2021","Current diabetes reports","other_trial","article","10.1007/s11892-021-01416-1","34851461",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0021081","Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control.","El Meouchy P","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms232012305","36293177","PMC9604511",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021082","Prophylactic effects of the glucagon-like Peptide-1 analog liraglutide on hyperglycemia in a rat model of type 2 diabetes mellitus associated with chronic pancreatitis and obesity.","Nagakubo D","2014","Comparative medicine","preclinical","article",null,"24674587","PMC3997290",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021083","Author Correction: Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice.","Shi Y","2023","Scientific reports","notice","article","10.1038/s41598-023-39548-x","37532725","PMC10397290",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0021084","Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.","Vilsbøll T","2016","Clinical drug investigation","other","article","10.1007/s40261-016-0376-0","26894800","PMC4801992",null,"S001276; S002285","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021085","Insulin-sensitizing agents for infertility treatment in woman with polycystic ovary syndrome: a narrative review of current clinical practice.","Sparić R","2024","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-023-00494-y","37792213",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021086","Defining the Intravital Renal Disposition of Fluorescence-Quenched Exenatide.","Bryniarski MA","2023","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.2c00671","36626167","PMC9907348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021087","Liraglutide Activates mTORC1 Signaling and AMPA Receptors in Rat Hippocampal Neurons Under Toxic Conditions.","Park SW","2018","Frontiers in neuroscience","preclinical","article","10.3389/fnins.2018.00756","30405339","PMC6205986",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021088","Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.","Tanabe A","2016","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2016.04.005","27220544",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021089","Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.","Anandhakrishnan A","2016","World journal of diabetes","narrative_review","article","10.4239/wjd.v7.i20.572","28031776","PMC5155232",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; review-article; article"],["R0021090","Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity.","Rodrigo N","2024","Scientific reports","preclinical","article","10.1038/s41598-024-68234-9","39075112","PMC11286933",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021091","The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects.","Liu Y","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16285","40028667",null,null,"S000981","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Multicenter Study; article"],["R0021092","Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.","Fiorentino TV","2016","Endocrine","narrative_review","article","10.1007/s12020-015-0811-7","26611248",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021093","Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life.","Rizza S","2021","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","nonrandomized_study","article","10.1016/j.biopha.2021.112341","34678725",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0021094","Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.","Milliken BT","2021","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.0c01783","33449689","PMC7956155",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0021095","Utilization and impact of SLGT2 inhibitors among diabetes patients in a nationally representative survey: Findings from NHANES 2013-2020.","Shen TH","2023","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2023.108625","37804691",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021096","Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.","Lingvay I","2016","JAMA","randomized_trial","article","10.1001/jama.2016.1252","26934259",null,"ClinicalTrials.gov:NCT01952145","S001328","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021097","Fabrication of liraglutide-encapsulated triple layer hyaluronic acid microneedles (TLMs) for the treatment of obesity.","Juhng S","2023","Lab on a chip","preclinical","article","10.1039/d2lc01084d","36919574",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021098","Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms.","Kanoski SE","2015","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12423","25475828","PMC4320650",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021099","Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial.","Geyer MC","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13544","30259623",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021100","Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.","Su N","2016","International journal of cardiology","systematic_review","article","10.1016/j.ijcard.2016.06.028","27343423",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0021101","Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.","Drucker DJ","2010","Diabetes care","narrative_review","article","10.2337/dc09-1499","20103558","PMC2809297",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; review-article; article"],["R0021102","Glucagon-like peptide 1 (GLP-1) analogues and weight loss.",null,"2020","Archives of disease in childhood","other","article","10.1136/archdischild-2020-319809","32561667",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021103","Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.","Pozzilli P","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13237","29377522",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021104","Liraglutide treatment is associated with progression of coronary artery fibrous plaque: a prospective 1-year follow-up study in asymptomatic patients with type 2 diabetes.","Heinsen LJ","2023","BMC cardiovascular disorders","other","article","10.1186/s12872-023-03228-5","37118678","PMC10148401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021105","A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.","Nørregaard PK","2018","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.13034","28598027",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0021107","Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study).","Oe Y","2024","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-024-01658-6","39049060","PMC11267784",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; Preprint; other; preprint; article"],["R0021108","Improvement of liraglutide release from PLGA microspheres by a porous microsphere-gel composite system.","Liu L","2024","Pharmaceutical development and technology","preclinical","article","10.1080/10837450.2024.2329763","38466377",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021109","Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use.","Davis H","2021","Family practice","nonrandomized_study","article","10.1093/fampra/cmab021","33755123",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021110","Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial.","Kolotkin RL","2023","Clinical obesity","randomized_trial","article","10.1111/cob.12589","36905345",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Randomized Controlled Trial; Journal Article; article"],["R0021111","Sixty seconds on . . . the cost of semaglutide.","Kmietowicz Z","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p2009","37652469",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0021112","Semaglutide Treatment in Adult-Onset Autoimmune Diabetes: A Case Study With Long-Term Follow-Up and Periodic Evaluation of Beta-Cell Function.","Da Porto A","2024","Cureus","case_report","article","10.7759/cureus.55771","38586652","PMC10999013",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021113","Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study.","Martínez-Montoro JI","2024","Journal of internal medicine","nonrandomized_study","article","10.1111/joim.13737","37902577",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0021114","Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.","Bonadonna RC","2016","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2016.05.007","27373139",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0021115","Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.","Parker VER","2020","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgz047","31608926",null,"ClinicalTrials.gov:NCT03244800","S000151","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021116","Protection of exenatide for retinal ganglion cells with different glucose concentrations.","Fu Z","2012","Peptides","preclinical","article","10.1016/j.peptides.2012.06.006","22727809",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021117","FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial.","Wai-Sun Wong V","2023","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2023.102310","38058795","PMC10696384","ClinicalTrials.gov:NCT02970942","S000922","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0021118","Exenatide reduces oxidative stress and cell death in testis in iron overload rat model.","Yesil S","2018","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2018.6795","30546390","PMC6256837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021119","Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.","Duez H","2009","Endocrinology","preclinical","article","10.1210/en.2008-1137","18801896",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021120","The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs.","Østergaard S","2021","Scientific reports","other","article","10.1038/s41598-021-00654-3","34707178","PMC8551270",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021121","Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis.","Li YC","2021","Communications biology","nonrandomized_study","article","10.1038/s42003-021-01652-x","33514826","PMC7846859",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0021122","Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.","Song JE","2024","Drug design, development and therapy","nonrandomized_study","article","10.2147/dddt.s445415","38524878","PMC10959752",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021123","Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions.","Tsend-Ayush E","2016","Scientific reports","preclinical","article","10.1038/srep37744","27898108","PMC5127184",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021124","Pharmacological management of type 2 diabetes: what's new in 2017?","Scheen AJ","2017","Expert review of clinical pharmacology","randomized_trial","article","10.1080/17512433.2017.1376652","28879786",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0021125","Liraglutide and Robust A1C Reductions Among People With Type 2 Diabetes Requiring Appetite Control: A Review of Two Cases.","Pitts MA","2024","Diabetes spectrum : a publication of the American Diabetes Association","narrative_review","article","10.2337/ds23-0052","38756434","PMC11093766",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021126","Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.","Abrahami D","2018","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj.k4880","30518618","PMC6278586",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021127","Interpretable Two-Stage Machine Learning for Early and Full Drug Release Prediction in PLGA Microspheres.","Song Y","2026","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph19050767","42198441","PMC13209779",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021128","In support of an early polypharmacy approach to the treatment of type 2 diabetes.","Wright EE","2010","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2010.01255.x","20880339",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0021129","Incretin-based Therapies for Type 2 Diabetes.","McIntosh CH","2008","Canadian journal of diabetes","other","article","10.1016/s1499-2671(08)22010-1","27056542",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021130","Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin.","Bolli GB","2020","Diabetes care","other_trial","article","10.2337/dci20-0038","32958617",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; article"],["R0021131","Enhanced Gut-to-Liver Oral Drug Delivery via Ligand-Modified Nanoparticles by Attenuating Protein Corona Adsorption.","Wang J","2024","ACS nano","nonrandomized_study","article","10.1021/acsnano.4c11453","39681528",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021132","Treatment Preferences for Novel Type 2 Diabetes Oral Medications: Insights from the Asian Diabetes Patient Preference Study.","Tiwaskar M","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-025-01770-3","40690109","PMC12399455",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021133","Potential contributors to variation in weight-loss response to liraglutide.","Webster CM","2023","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.13568","37069131",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021134","Exenatide and Sitagliptin Decrease Interleukin 1β, Matrix Metalloproteinase 9, and Nitric Oxide Synthase 2 Gene Expression But Does Not Reduce Alveolar Bone Loss in Rats With Periodontitis.","Moraes RM","2015","Journal of periodontology","preclinical","article","10.1902/jop.2015.150278","26205746",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021135","Current Perspectives on Management of Type 2 Diabetes in Youth.","Singhal S","2021","Children (Basel, Switzerland)","narrative_review","article","10.3390/children8010037","33435250","PMC7826614",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021136","Semaglutide in Early Type 1 Diabetes.","Dandona P","2023","The New England journal of medicine","commentary","article","10.1056/nejmc2302677","37672701",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0021137","Administration errors of compounded semaglutide reported to a poison control center-Case series.","Lambson JE","2023","Journal of the American Pharmacists Association : JAPhA","case_report","article","10.1016/j.japh.2023.06.017","37392810",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021138","Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity.","Ando T","2014","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.53.1646","25130112",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021139","Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet.","Zhu W","2018","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2018.09.134","30269815",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021140","HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?","Mafham M","2018","Lancet (London, England)","commentary","article","10.1016/s0140-6736(18)32348-1","30291014",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; article"],["R0021141","Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.","Hong D","2019","PharmacoEconomics","notice","article","10.1007/s40273-019-00833-1","31485924",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0021142","Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine.","Medak KD","2024","iScience","other","article","10.1016/j.isci.2023.108628","38188526","PMC10767228",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021143","Obesity and anesthesia.","Arora L","2024","Current opinion in anaesthesiology","narrative_review","article","10.1097/aco.0000000000001377","38573180",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021144","Augmented nephroprotective effect of liraglutide and rabeprazole via inhibition of OCT2 transporter in cisplatin-induced nephrotoxicity in rats.","Sharaf G","2023","Life sciences","preclinical","article","10.1016/j.lfs.2023.121609","36958435",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021145","Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.","Vedtofte L","2015","Expert review of clinical pharmacology","narrative_review","article","10.1586/17512433.2015.1029455","25816888",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0021146","DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism.","Furukawa N","2021","Heart and vessels","preclinical","article","10.1007/s00380-020-01711-z","33073318","PMC7788045",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021147","Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial.","Bensignor MO","2023","Pediatric obesity","randomized_trial","article","10.1111/ijpo.13061","37264767","PMC10926323","ClinicalTrials.gov:NCT02918279","S000599","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021148","Exenatide and weight loss.","Bradley DP","2010","Nutrition (Burbank, Los Angeles County, Calif.)","narrative_review","article","10.1016/j.nut.2009.07.008","20152707",null,null,"S002047; S002753","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0021149","GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' reply.","Tuttle KR","2018","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(18)30239-0","30266182",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0021150","Protein kinase Cβ mediates downregulated expression of glucagon-like peptide-1 receptor in hypertensive rat renal arteries.","Liu L","2015","Journal of hypertension","preclinical","article","10.1097/hjh.0000000000000480","25915883",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021151","Potentials of Natural Antioxidants in Reducing Inflammation and Oxidative Stress in Chronic Kidney Disease.","Lee OYA","2024","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox13060751","38929190","PMC11201162",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021152","Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.","An FM","2015","Neuroscience","preclinical","article","10.1016/j.neuroscience.2015.05.023","25987199",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021153","Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia.","Adiels M","2019","Diabetes, obesity & metabolism","other","article","10.1111/dom.13744","30972934",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021154","Telehealth Intervention to Improve Uptake of Evidence-Based Medications among Patients with Type 2 Diabetes and Heart Failure or Cardiovascular Disease.","Silva-Almodóvar A","2023","International journal of environmental research and public health","nonrandomized_study","article","10.3390/ijerph20043613","36834307","PMC9964915",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0021155","Elevated Glucagon-like Peptide-1 Receptor Level in the Paraventricular Hypothalamic Nucleus of Type 2 Diabetes Mellitus Patients.","Renner É","2022","International journal of molecular sciences","other","article","10.3390/ijms232415945","36555587","PMC9781792",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021156","Semaglutide, suicidal ideation and behaviour: A resting state functional magnetic resonance imaging perspective.","Verovnik B","2024","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15363","37945545",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0021157","Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome.","Kondo M","2018","Diabetologia","nonrandomized_study","article","10.1007/s00125-018-4679-y","30054673",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021158","Pharmacotherapy before and after bariatric surgery.","Alabduljabbar K","2023","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2023.155692","37730085",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0021159","Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward.","Shirazi RH","2013","PloS one","preclinical","article","10.1371/journal.pone.0061965","23613987","PMC3628574",null,"S002326","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021160","Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data.","Aubourg T","2026","BMJ neurology open","other_trial","article","10.1136/bmjno-2026-001740","42404082","PMC13331057",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021161","The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.","Morales J","2011","Postgraduate medicine","other","article","10.3810/pgm.2011.11.2508","22104467",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021162","The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes.","Wronka M","2022","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms232415743","36555387","PMC9778895",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0021163","Nephrology: What You May Have Missed in 2024.","Alfadhel A","2025","Annals of internal medicine","other_trial","article","10.7326/annals-25-00796","40163875",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0021164","SAT-LB013 The Effect of Select GLP1 Agonists and SGLT2 Inhibitors on the Unfolded Protein Response in Primary Human Coronary Artery Endothelial Cells","Kalidas P","2019","Journal of the Endocrine Society","other","article","10.1210/js.2019-sat-lb013",null,"PMC6552160",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0021165","Cardiovascular safety of therapies for type 2 diabetes.","Gupta P","2017","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2017.1239707","27652617","PMC5523835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0021166","Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).","Vettor R","2026","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-026-10027-8","42090077","PMC13167878",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021167","Safety of incretin-based therapies for type 2 diabetes.","Davis TM","2011","The Medical journal of Australia","nonrandomized_study","article","10.5694/mja11.10648","21929482",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Editorial; Research Support, Non-U.S. Gov't; article"],["R0021168","Exenatide enhanced the antitumor efficacy on PD-1 blockade by the attenuation of neutrophil extracellular traps.","Chen D","2022","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2022.06.052","35751916",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021169","The Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume.","Sencar ME","2019","European thyroid journal","other","article","10.1159/000501895","31934556","PMC6944867",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0021170","Pulse Oximetry Desaturation in the Postoperative Recovery Room in Patients with Obesity and Diabetes Using GLP-1 Agonists: A Retrospective Observational Study.","Skidmore KL","2025","Cureus","nonrandomized_study","article","10.7759/cureus.87774","40792324","PMC12338001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021171","Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.","Branch KRH","2022","European journal of heart failure","randomized_trial","article","10.1002/ejhf.2670","36073143",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021172","Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis.","Kobo O","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15396","38082468",null,"ClinicalTrials.gov:NCT01720446","S001933","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Letter; article"],["R0021173","Semaglutide Improves Heart Failure and Cardiovascular Disease.","Harris E","2023","JAMA","other","article","10.1001/jama.2023.16674","37672290",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021174","Synthesis and biological evaluation of glucagon-like peptide-1 analogs with the C-terminal helix 3 of albumin-binding domain 3.","Zhang J","2022","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2022.116725","35358863",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021175","Subcutaneous Semaglutide Use for Weight Management: Practice and Attitudes of Physicians in Israel.","Dicker D","2023","The Israel Medical Association journal : IMAJ","other","article",null,"37846993",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021176","Type 2 Diabetes in Youth.","Rao G","2020","Global pediatric health","narrative_review","article","10.1177/2333794x20981343","34036121","PMC8126957",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021177","[Nephrology: what's new in 2024 (I)].","Nanchen G","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.900-1.56","39812288",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0021178","Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.","Lapolla A","2018","Advances in therapy","randomized_trial","article","10.1007/s12325-017-0652-2","29270781","PMC5818560","ClinicalTrials.gov:NCT02255266","S001611","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0021179","Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats.","Zheng RH","2019","Drug design, development and therapy","preclinical","article","10.2147/dddt.s213910","31496651","PMC6690048",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021180","The Reasons for Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects – a Family Doctor Perspective: Does Limited Applicability of Clinical Guidelines in Real-Life Practice Matter? A Narrative Review","Kurevija T","2024","Preprints.org","narrative_review","preprint","10.20944/preprints202402.1593.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021181","Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?","Kubota S","2021","The Journal of clinical endocrinology and metabolism","commentary","article","10.1210/clinem/dgab301","33950185","PMC8372656",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; discussion; article"],["R0021182","Tirzepatide decreases systolic and diastolic blood pressure.","Copur S","2023","European journal of internal medicine","commentary","article","10.1016/j.ejim.2023.04.005","37045710",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0021183","Efficacy of Intragastric Balloon versus Liraglutide as Bridge to Surgery in Super-Obese Patients.","Martines G","2023","Obesity facts","nonrandomized_study","article","10.1159/000531459","37579738","PMC10601677",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021184","Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.","Mullins GR","2024","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/clinem/dgad532","37700637","PMC10795913",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021185","Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.","Arakawa M","2009","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2009.10.054","19836346",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021186","Semaglutide Associated With Less Insulin Need in Early Type 1 Diabetes.","Harris E","2023","JAMA","other","article","10.1001/jama.2023.17818","37728959",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021187","Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.","Holst JJ","2012","Clinical drug investigation","preclinical","article","10.2165/11595370-000000000-00000","21958333",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0021188","Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort.","van Eyk HJ","2019","Scientific reports","randomized_trial","article","10.1038/s41598-019-45593-2","31292457","PMC6620358","ClinicalTrials.gov:NCT01761318","S000566","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021189","The effectiveness and sustainability of health outcomes from a holistic digital weight-loss service with concomitant initiation of tirzepatide: A pragmatic randomized controlled trial in the UK.","Talay L","2024","Diabetes, obesity & metabolism","protocol","article","10.1111/dom.15903","39223862",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021190","Intragastric injection botulinum toxin A for obesity management with or without liraglutide.","Altunal Ç","2023","European review for medical and pharmacological sciences","nonrandomized_study","article","10.26355/eurrev_202304_32128","37140305",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0021191","Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.","Lepore JJ","2016","JACC. Heart failure","randomized_trial","article","10.1016/j.jchf.2016.01.008","27039125",null,"ClinicalTrials.gov:NCT01357850","S000291; S003208","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021192","Critical evaluation of real-world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation.","Tonegawa-Kuji R","2026","Alzheimer's & dementia (New York, N. Y.)","nonrandomized_study","article","10.1002/trc2.70193","41473419","PMC12746425",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021193","Effects of liraglutide among patients living with psoriasis and obesity.","Nicolau J","2023","Medicina clinica","other","article","10.1016/j.medcli.2023.05.021","37474395",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021194","GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes.","Gault VA","2018","Peptides","narrative_review","article","10.1016/j.peptides.2017.11.017","29412810",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0021195","Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.","Ding Y","2024","Pharmacological research","systematic_review","article","10.1016/j.phrs.2023.107031","38061595",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; article; report"],["R0021196","Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats.","Simonsen L","2009","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2009.01066.x","19508463",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021197","Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.","Lee YM","2022","Cardiology journal","systematic_review","article","10.5603/cj.a2020.0140","33140391","PMC9170323",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0021198","Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India.","Wasir JS","2018","Indian journal of endocrinology and metabolism","randomized_trial","article","10.4103/ijem.ijem_424_18","30766809","PMC6330857",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021199","Semaglutide for Type 2 Diabetes (2 mg): CADTH Health Technology Review",null,"2023","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"38096343",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0021200","Incretin-based therapy and the quest for sustained improvements in β-cell health.","Drucker DJ","2011","Diabetes care","preclinical","article","10.2337/dc11-0986","21868783","PMC3161285",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0021201","Outcomes of concomitant antiobesity medication use with endoscopic sleeve gastroplasty in clinical US settings.","Gala K","2024","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2024.100112","38831924","PMC11145356",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021202","Status of diabetes mellitus in different regions of KSA and update on its management.","Al-Rasheedi M","2024","Frontiers in clinical diabetes and healthcare","nonrandomized_study","article","10.3389/fcdhc.2024.1482090","39759947","PMC11695327",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021203","Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats.","Salem EA","2025","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-025-03920-7","40088335","PMC12449337",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021204","Semaglutide in renal ischemia-reperfusion injury in mice.","Tiba AT","2023","Journal of medicine and life","preclinical","article","10.25122/jml-2022-0291","36937464","PMC10015556",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021205","Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.","Zhang R","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1132004","37455913","PMC10338217","PROSPERO:CRD42022337099",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Research Support, Non-U.S. Gov't; Journal Article; review"],["R0021206","Type 2 diabetes mellitus and cognitive function: understanding the connections.","Dao L","2023","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000783","36385094",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0021207","Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction.","Yagi K","2021","Journal of diabetes research","other_trial","article","10.1155/2021/8838026","33855087","PMC8019623","UMIN:UMIN000005565",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021208","Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients.","Pugazhenthi U","2010","Diabetologia","preclinical","article","10.1007/s00125-010-1849-y","20635178",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021209","Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats.","Takeda K","2021","BMJ open diabetes research & care","preclinical","article","10.1136/bmjdrc-2020-002104","33879516","PMC8061802",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021210","The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs.","Ferrari F","2020","Pharmacological research","narrative_review","article","10.1016/j.phrs.2020.105018","32574826",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0021211","Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948-1957.","Singh AK","2020","Diabetes care","systematic_review","article","10.2337/dc20-1950","33218984",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; review"],["R0021212","Ferroptosis Targeting Offers a Therapeutic Strategy for Subarachnoid Hemorrhage.","Cen L","2025","CNS & neurological disorders drug targets","other","article","10.2174/0118715273401523251110063217","41327623",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021213","Integrating incretin-based therapy into type 2 diabetes management.","Brunton SA","2013","The Journal of family practice","other","article",null,"23828807",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0021214","The Necessity of POMC and MC3R Analysis in the First-Level Diagnosis of Monogenic Obesity: The Experience of Two Italian Centers.","Miedviedieva K","2026","Genes","nonrandomized_study","article","10.3390/genes17040405","42074523","PMC13116659",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0021215","Effects of Treatment with Liraglutide Early after Surgical Intervention on Clinical Outcomes in Patients with Short Bowel Syndrome: A Pilot Observational \"Real-Life\" Study.","Merlo FD","2023","Nutrients","nonrandomized_study","article","10.3390/nu15122740","37375644","PMC10305110",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; article"],["R0021216","A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.","Irwin N","2015","Diabetes","preclinical","article","10.2337/db15-0220","25883113",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021217","Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data.","Powell W","2023","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23859","37593896","PMC10702395",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021218","Detecting heart stress using NT-proBNP in patients with type 2 diabetes mellitus and hypertension or high-normal blood pressure: a cross-sectional multicentric study.","Landolfo M","2024","Cardiovascular diabetology","other","article","10.1186/s12933-024-02391-z","39135091","PMC11321074",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0021219","Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.","Levin PA","2014","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2014.20.5.501","24761822","PMC10438237",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021220","Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.","Yanai H","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms241813942","37762244","PMC10530470",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021221","Dosimetry of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human - repeated scanning in human is possible.","Selvaraju RK","2015","American journal of nuclear medicine and molecular imaging","preclinical","article",null,"26069859","PMC4446394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021222","Evolving cryo-EM structural approaches for GPCR drug discovery.","Zhang X","2021","Structure (London, England : 1993)","other","article","10.1016/j.str.2021.04.008","33957078",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Preprint; preprint"],["R0021223","Oral semaglutide: an OASIS from injectables.","Manjoo P","2023","Lancet (London, England)","commentary","article","10.1016/s0140-6736(23)01479-4","37633662",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021224","Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.","Muskiet MHA","2019","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2019.05.001","31078666",null,"ClinicalTrials.gov:NCT00097500","S001020","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0021225","Systemic Co-Administration of Low-Dose Oxytocin and Glucagon-Like Peptide 1 Additively Decreases Food Intake and Body Weight.","Maejima Y","2024","Neuroendocrinology","preclinical","article","10.1159/000538792","38599201",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021226","Fenugreek Compound (N55) Lowers Plasma Glucose through the Enhancement of Response of Physiological Glucagon-like peptide-1.","Chou IW","2017","Scientific reports","preclinical","article","10.1038/s41598-017-12290-x","28947828","PMC5613011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021227","New Drug Capsule: Tirzepatide.","Beninger P","2023","Clinical therapeutics","commentary","article","10.1016/j.clinthera.2023.02.004","36870873",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0021228","Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial.","Armstrong MJ","2013","BMJ open","protocol","article","10.1136/bmjopen-2013-003995","24189085","PMC3822302","ClinicalTrials.gov:NCT01237119","S002015","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; protocol; article"],["R0021229","Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD).","Selim DH","2025","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-025-03789-6","39820544","PMC12263778",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021230","Paracrine relationship between incretin hormones and endogenous 5-hydroxytryptamine in the small and large intestine.","Tough IR","2023","Neurogastroenterology and motility","preclinical","article","10.1111/nmo.14589","37010838","PMC10909488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021231","The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond.","Mudaliar S","2023","Journal of the Indian Institute of Science","narrative_review","article","10.1007/s41745-023-00357-w","36845885","PMC9942084",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021232","A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control","Mochel J","2023","Authorea Preprints","randomized_trial","preprint","10.22541/au.170022092.29999283/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0021233","Assessment of Glucose Lowering Medications' Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes.","Sciannameo V","2022","International journal of environmental research and public health","randomized_trial","article","10.3390/ijerph192214825","36429543","PMC9690556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Multicenter Study; Journal Article; research-article; article"],["R0021234","Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide.","Schneider EL","2016","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.5b00690","26930186",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021235","The protective roles of liraglutide on Kawasaki disease via AMPK/mTOR/NF-κB pathway.","Ding Y","2023","International immunopharmacology","preclinical","article","10.1016/j.intimp.2023.110028","36934674",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021236","Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.","Rosenstock J","2016","Diabetes care","randomized_trial","article","10.2337/dc16-0046","27284114","PMC5001145","ClinicalTrials.gov:NCT01476475","S000191","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0021237","Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning.","Basalay MV","2016","Cardiovascular research","preclinical","article","10.1093/cvr/cvw216","27702763","PMC5157137",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021238","α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4.","Oddo A","2018","Biochemistry","preclinical","article","10.1021/acs.biochem.8b00105","29877701",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021239","Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme).","Kiyosue A","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14952","36545807",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021240","Evidence for paracrine/autocrine regulation of GLP-1-producing cells.","Kappe C","2013","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00227.2013","23986202",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021241","Case report: Nerve fiber regeneration in children with melanocortin 4 receptor gene mutation related obesity treated with semaglutide.","Gad H","2024","Frontiers in endocrinology","case_report","article","10.3389/fendo.2024.1385463","38974580","PMC11227249",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021242","Adverse Effects of GLP-1 Receptor Agonists.","Filippatos TD","2014","The review of diabetic studies : RDS","nonrandomized_study","article","10.1900/rds.2014.11.202","26177483","PMC5397288",null,"S001187; S001538","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0021243","Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.","McGowan BM","2023","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23732","36876594",null,"ClinicalTrials.gov:NCT03548935","S000144","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021244","One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.","Gough SC","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12498","25980900","PMC4744775",null,"S001276","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021245","Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist.","Katsurada K","2016","Journal of diabetes investigation","narrative_review","article","10.1111/jdi.12464","27186358","PMC4854507",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021246","Repurposing drugs for the treatment of osteoarthritis.","Kuswanto W","2024","Osteoarthritis and cartilage","randomized_trial","article","10.1016/j.joca.2024.05.008","38821468",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Review"],["R0021247","The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.","Carbone S","2019","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-019-0869-2","31138195","PMC6540565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021248","Effect of Liraglutide in Different Abdominal Fat Layers Measured by Ultrasound: The Importance of Perirenal Fat Reduction.","Cuatrecasas G","2024","Obesity facts","other","article","10.1159/000538996","38643760","PMC11299965",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021249","Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial.","Thivolet C","2023","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2023.101433","36781064",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Letter; article"],["R0021250","Engineering an enhanced thrombin-based GLP-1 analog with long-lasting glucose-lowering and efficient weight reduction.","Pan H","2019","RSC advances","preclinical","article","10.1039/c9ra06771j","35529389","PMC9072222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021251","Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study.","McGrath RT","2016","BMJ open","protocol","article","10.1136/bmjopen-2015-008203","26911582","PMC4769437","ANZCTR:ACTRN12614001189617",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; protocol; article"],["R0021252","Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.","Klein SR","2023","Canadian journal of anaesthesia = Journal canadien d'anesthesie","case_report","article","10.1007/s12630-023-02440-3","36977934",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021253","Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management.","Pati S","2023","Cancers","narrative_review","article","10.3390/cancers15020485","36672434","PMC9857053",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021254","Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes.","Torre E","2018","ClinicoEconomics and outcomes research : CEOR","other_trial","article","10.2147/ceor.s169045","30100746","PMC6067612",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021255","Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), positively impacts the altered microbiota of obese, diabetic, ovariectomized mice.","Silva-Veiga FM","2025","Life sciences","preclinical","article","10.1016/j.lfs.2024.123310","39675551",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021256","Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.","Zhu K","2023","World journal of gastroenterology","systematic_review","article","10.3748/wjg.v29.i37.5327","37899788","PMC10600803",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; research-article; article"],["R0021257","Liraglutide Attenuates Hepatic Oxidative Stress, Inflammation, and Apoptosis in Streptozotocin-Induced Diabetic Mice by Modulating the Wnt/β-Catenin Signaling Pathway.","Yu J","2023","Mediators of inflammation","preclinical","article","10.1155/2023/8974960","36756089","PMC9899592",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021258","Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.","Ratner R","2010","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2010.02990.x","20536952","PMC2948428","ClinicalTrials.gov:NCT00460941","S001597","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021259","The role of glucagon on type 2 diabetes at a glance.","Godoy-Matos AF","2014","Diabetology & metabolic syndrome","narrative_review","article","10.1186/1758-5996-6-91","25177371","PMC4148933",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021260","Semaglutide is effective in achieving weight loss in liver transplant recipients.","Chow KW","2024","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","other","article","10.1097/lvt.0000000000000247","37639288",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021261","[Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].","Fiorentino TV","2013","Giornale italiano di cardiologia (2006)","other","article","10.1714/1375.15277","24362783",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021262","Letter to the Editor regarding \"Semaglutide and cancer: A systematic review and meta-analysis\" by Nagendra L et al.","Xiao Y","2023","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2023.102895","39491072",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; letter"],["R0021263","The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.","Heald AH","2018","International journal of clinical practice","other","article","10.1111/ijcp.13080","29537664",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021264","Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson's disease when considering the coexisting effects of diabetes mellitus.","Chen HC","2022","PloS one","nonrandomized_study","article","10.1371/journal.pone.0269006","35951654","PMC9371359",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021265","A practical evidence-based approach to management of type 2 diabetes in children and young people (CYP): UK consensus.","White B","2024","BMC medicine","other","article","10.1186/s12916-024-03349-4","38561783","PMC10986054",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Consensus Statement; research-article; article"],["R0021266","Cardiovascular Effects of Liraglutide.","Mikhail N","2019","Current hypertension reviews","randomized_trial","article","10.2174/1573402114666180507152620","29737256",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0021267","GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.","Liskiewicz D","2026","Nature","other_trial","article","10.1038/s41586-026-10427-5","42056522","PMC13190304",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021268","The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.","Ishii H","2018","Journal of medical economics","other_trial","article","10.1080/13696998.2018.1431918","29357718",null,"ClinicalTrials.gov:NCT01584232","S000246","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0021269","Dulaglutide for the treatment of type 2 diabetes.","Amblee A","2014","Drugs of today (Barcelona, Spain : 1998)","narrative_review","article","10.1358/dot.2014.50.4.2132740","24918645",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021270","The role of incretins in cardiovascular control.","Mafong DD","2009","Current hypertension reports","other","article","10.1007/s11906-009-0005-x","19146796",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S."],["R0021271","Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.","Boccara F","2017","Advances in therapy","narrative_review","article","10.1007/s12325-017-0586-8","28717862","PMC5565663",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021272","Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis.","Tang Y","2022","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2022.1016639","36569320","PMC9774036","PROSPERO:CRD42022319442",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0021273","Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand.","Deerochanawong C","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-023-01371-y","36719606","PMC9981833",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021274","Upregulation of the PI3K/AKT and Nrf2 Pathways by the DPP-4 Inhibitor Sitagliptin Renders Neuroprotection in Chemically Induced Parkinson's Disease Mouse Models.","Soni R","2025","ACS chemical neuroscience","preclinical","article","10.1021/acschemneuro.5c00112","40127285",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021275","Herpes Zoster Occurring After Injection of Botulinum Toxin and Hyaluronic Acid.","Liang Y","2025","The Journal of craniofacial surgery","case_report","article","10.1097/scs.0000000000011239","40172956",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; Research Support, Non-U.S. Gov't; article"],["R0021276","Body weight reduction by semaglutide administration has beneficial effect in obesity phenotype HFpEF.","Martini E","2023","Nature cardiovascular research","commentary","article","10.1038/s44161-023-00353-4","39196255",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021277","Modulation of Autophagy as a Therapeutic Target in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver disease: Evidence from Pharmacological, Nutritional, and Bioactive Compound Interventions","Almeida JSd","2025","Preprints.org","other","preprint","10.20944/preprints202512.1486.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021278","Exendin-4 modulates diabetes onset in nonobese diabetic mice.","Hadjiyanni I","2008","Endocrinology","preclinical","article","10.1210/en.2007-1137","18063685","PMC2275367",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021279","Insulin-resistance as a modifiable pathway to cognitive dysfunction in schizophrenia: A systematic review.","Salvi V","2024","Schizophrenia research","systematic_review","article","10.1016/j.schres.2024.09.008","39265262",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Systematic Review; Journal Article"],["R0021280","Addressing the obesity challenge in plastic surgery - the role of liraglutide.","Staněk K","2023","Acta chirurgiae plasticae","commentary","article","10.48095/ccachp202386","37722909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0021281","Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model.","Hirata K","2009","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2009.01.003","19150338",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021282","Design, synthesis, and structure-activity relationship study of novel GLP-1/GIP/GCG triple receptor agonists.","Zhang J","2025","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2025.118024","40749257",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021283","Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.","Babic I","2018","Journal of psychopharmacology (Oxford, England)","preclinical","article","10.1177/0269881118756061","29493378",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021284","Incretin therapy--present and future.","Garber AJ","2011","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2011.8.307","22262069","PMC3280666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0021285","High price and demand for semaglutide means lack of access for US patients.","Brown C","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p1863","37648269",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021286","Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.","Jódar E","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14615","34866291","PMC9300025",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021287","Exendin-4 therapy still offered an additional benefit on reducing transverse aortic constriction-induced cardiac hypertrophy-caused myocardial damage in DPP-4 deficient rats.","Lu HI","2016","American journal of translational research","randomized_trial","article",null,"27158369","PMC4846926",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021288","Correction to: Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand.","Deerochanawong C","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-023-01392-7","37000391","PMC10126194",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0021289","Liraglutide ameliorates palmitate-induced oxidative injury in islet microvascular endothelial cells through GLP-1 receptor/PKA and GTPCH1/eNOS signaling pathways.","Le Y","2020","Peptides","preclinical","article","10.1016/j.peptides.2019.170212","31770577",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021290","Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease.","Ying X","2023","Frontiers in microbiology","other","article","10.3389/fmicb.2023.1088187","36778868","PMC9909237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021291","[A case of an elderly diabetic patient with dementia effectively treated with weekly exenatide].","Maruyama S","2014","Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics","case_report","article","10.3143/geriatrics.51.375","25327373",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021292","Pharmacotherapy for obesity: moving towards efficacy improvement.","Coutinho W","2024","Diabetology & metabolic syndrome","other_trial","article","10.1186/s13098-023-01233-4","38172940","PMC10763391",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021293","Glucagon-like peptide-1 stimulates type 3 iodothyronine deiodinase expression in a mouse insulinoma cell line.","Akiyama S","2014","Life sciences","preclinical","article","10.1016/j.lfs.2014.09.004","25241124",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021294","Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.","Jiao R","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16012","39431379",null,null,"S001387","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0021295","Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT.","Christ E","2015","Endocrine","case_report","article","10.1007/s12020-015-0633-7","26001537",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021296","Achieving glycemic goals with addition of incretin-based therapies to insulin in patients with type 2 diabetes mellitus.","Tibaldi J","2014","The American journal of the medical sciences","other_trial","article","10.1097/maj.0000000000000202","24469234",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0021297","Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor.","Mattar P","2023","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2023.1164047","37293487","PMC10244886",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021298","Treatment of an Adolescent Female With Nonalcoholic Steatohepatitis-Related Cirrhosis With Liraglutide.","Yuen C","2023","JPGN reports","case_report","article","10.1097/pg9.0000000000000303","37200728","PMC10187831",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021299","Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus.","Tseng CH","2020","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2020.541090","33193076","PMC7642096",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021300","Protective Effects of ACF210, a Dual GLP-1/APJ Receptor Agonist, against Cardiovascular-Kidney-Metabolic Syndrome Induced by T2D","Zhao Q","2025","Research Square","preclinical","preprint","10.21203/rs.3.rs-7782667/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0021301","The effect of human serum albumin glycation on the binding of antidiabetic agent-exenatide; the multispectroscopic studies. Part II.","Śliwińska-Hill U","2023","Biophysical chemistry","other","article","10.1016/j.bpc.2022.106948","36621076",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021302","Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.","Chiu N","2022","Journal of the American Heart Association","other_trial","article","10.1161/jaha.122.026297","35929468","PMC9496310",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0021303","Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study).","Al-Najim W","2025","Metabolites","randomized_trial","article","10.3390/metabo15060398","40559422","PMC12194874",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021304","Exenatide: AC 2993, AC002993, AC2993A, exendin 4, LY2148568.","&NA;","2004","Drugs in R&D","randomized_trial","article","10.2165/00126839-200405010-00007","14725490",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0021305","Chitosan based surface modulation of core-shell nanoparticles for oral delivery of exenatide via balancing mucus penetration and cellular uptake.","Li Y","2025","International journal of pharmaceutics","other","article","10.1016/j.ijpharm.2025.125319","39921014",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021306","[Retracted] Liraglutide protects renal mesangial cells against hyperglycemia‑mediated mitochondrial apoptosis by activating the ERK‑Yap signaling pathway and upregulating Sirt3 expression.","Li J","2024","Molecular medicine reports","notice","article","10.3892/mmr.2024.13310","39219287","PMC11350627",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; article"],["R0021307","Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies.","Boniol M","2018","Diabetes care","nonrandomized_study","article","10.2337/dc17-0280","29146599",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021308","[The Preliminary Investigation of GLP-1 Receptor Agonist on Liver Steatosis in Obese Mice].","Wang X","2017","Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","preclinical","article",null,"28612554",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021309","Fluorescent exendin-4 derivatives for pancreatic β-cell analysis.","Clardy SM","2014","Bioconjugate chemistry","other","article","10.1021/bc4005014","24328216","PMC4016126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021310","Weight change and cardiovascular disease incidence in breast cancer survivors: a nationwide cohort study.","Jung W","2025","Breast cancer research and treatment","nonrandomized_study","article","10.1007/s10549-024-07594-2","39762706",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0021311","Sex differences of visceral fat with cardiac structure and function in type 2 diabetes: A cross-sectional study.","Rui-Hua C","2024","Journal of diabetes","other","article","10.1111/1753-0407.70023","39511977","PMC11544034",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021312","Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway.","Natalicchio A","2013","Diabetologia","preclinical","article","10.1007/s00125-013-3028-4","23995397",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021313","Clinical insights into management options for recurrent type 2 diabetes and cardiovascular risk after metabolic-bariatric surgery.","Lupoli R","2022","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2022.02.019","35365370",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021314","Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.","Xie D","2022","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-022-01634-1","36199064","PMC9533545",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021315","Salcaprozate-based ionic liquids for GLP-1 gastric delivery: A mechanistic understanding of in vivo performance.","Rebollo R","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2024.11.036","39566853",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021316","hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair.","Wang W","2022","Molecular medicine (Cambridge, Mass.)","preclinical","article","10.1186/s10020-022-00526-0","36514009","PMC9746121",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021317","Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.","Calabrò D","2020","Diagnostics (Basel, Switzerland)","narrative_review","article","10.3390/diagnostics10121059","33297381","PMC7762240",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021318","Tirzepatide - A major breakthrough in the fight against obesity.","Habiba U","2023","JPMA. The Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.7552","36932808",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0021319","Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.","Okuda I","2017","Current medical research and opinion","randomized_trial","article","10.1080/03007995.2016.1261817","27852119",null,"ClinicalTrials.gov:NCT01777282","S001557","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; article"],["R0021320","Peptide-based GIP receptor inhibition exhibits modest metabolic changes in mice when administered either alone or combined with GLP-1 agonism","West JA","2019","bioRxiv","preclinical","preprint","10.1101/822122",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021321","Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.","Dietsche KB","2024","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgad669","37967247","PMC11031226",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Intramural; research-article; article"],["R0021322","GLP-1 and exendin-4: not simply two of a kind.","Nguyen TD","2015","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00525.2014","25593282",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0021323","Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure.","Lautenbach A","2023","Clinical obesity","nonrandomized_study","article","10.1111/cob.12593","37364260",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0021324","Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives.","Deng W","2015","Therapeutics and clinical risk management","narrative_review","article","10.2147/tcrm.s81088","26309403","PMC4539087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021325","Exendin-4-loaded PLGA microspheres relieve cerebral ischemia/reperfusion injury and neurologic deficits through long-lasting bioactivity-mediated phosphorylated Akt/eNOS signaling in rats.","Chien CT","2015","Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","preclinical","article","10.1038/jcbfm.2015.126","26058696","PMC4635234",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021326","Long-term treatment with EXf, a peptide analog of Exendin-4, improves β-cell function and survival in diabetic KKAy mice.","Hou GJ","2013","Peptides","preclinical","article","10.1016/j.peptides.2013.01.010","23353893",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021327","Association learning is impaired in insulin resistance and restored by liraglutide.",null,"2023","Nature metabolism","other","article","10.1038/s42255-023-00870-3","37596351",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021328","Cardiovascular outcome trials of glucose-lowering therapies.","Khunti K","2020","Expert review of pharmacoeconomics & outcomes research","other_trial","article","10.1080/14737167.2020.1763796","32403956",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0021329","Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: A target to modulate cardiovascular risk?","Dozio E","2019","International journal of cardiology","other","article","10.1016/j.ijcard.2019.04.039","31023563",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021330","Engineered choline-Salcaprozate ionic liquids for enhanced non-invasive delivery of macromolecular antidiabetics.","Huang R","2026","Journal of colloid and interface science","preclinical","article","10.1016/j.jcis.2025.139463","41240566",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021331","Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2 S-RWD).","Moreno-Pérez O","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15431","38151966",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Multicenter Study; Letter; article"],["R0021332","A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes.","Zhao S","2022","British journal of pharmacology","preclinical","article","10.1111/bph.15860","35484823",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021333","Conservation of glucagon like peptide-1 level with liraglutide and linagilptin protects the kidney against angiotensin II-induced tissue fibrosis in rats.","Bai F","2020","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2019.172844","31811859",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021334","Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial.","Ebdrup BH","2018","Diabetes, obesity & metabolism","notice","article","10.1111/dom.13204","29316175","PMC6885958",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Published Erratum; correction; erratum"],["R0021335","Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.","Mosenzon O","2019","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(19)30192-5","31189517",null,"ClinicalTrials.gov:NCT02827708; EudraCT:2015-005326-19","S002025","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021336","Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.","Verma S","2018","Circulation","randomized_trial","article","10.1161/circulationaha.118.034516","30566004",null,"ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021337","The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome.","Senda M","2012","Endocrine journal","case_report","article","10.1507/endocrj.ej12-0074","22785236",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021338","Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides.","Amatya R","2020","Toxins","narrative_review","article","10.3390/toxins12050313","32397648","PMC7290885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0021339","Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.","He F","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14908","36314246",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0021340","Comparing Real-World Effectiveness of Dulaglutide and Insulin as the First Injectable for Patients with Type 2 Diabetes: An Australian Single-Site Retrospective Chart Review.","Houssarini JA","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-021-01184-x","34850355","PMC8776933",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021341","Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome.","Wauters L","2018","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2018.09.005","30273889",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0021342","Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats.","Cai HY","2017","Behavioural brain research","preclinical","article","10.1016/j.bbr.2016.10.033","27776993",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021343","The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients.","Biesenbach IIA","2023","Cardiovascular therapeutics","other","article","10.1155/2023/5126825","36714196","PMC9867582",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021344","Low Levels of Adropin Predict Adverse Clinical Outcomes in Outpatients with Newly Diagnosed Prediabetes after Acute Myocardial Infarction.","Berezina TA","2024","Biomedicines","nonrandomized_study","article","10.3390/biomedicines12081857","39200321","PMC11351681",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021345","Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.","Ueberberg S","2016","Diabetes, obesity & metabolism","other","article","10.1111/dom.12766","27545110",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021346","Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.","Stonehouse A","2011","Diabetes technology & therapeutics","narrative_review","article","10.1089/dia.2011.0076","21732798","PMC3303092",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0021347","Comparative Study of the Effect of Liraglutide and Donepezil on Learning and Memory in Diazepam-Induced Amnesic Albino Rats.","Kumari K","2023","Cureus","preclinical","article","10.7759/cureus.41495","37551235","PMC10404348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021348","Correction: Neonatal Exendin-4 Reduces Growth, Fat Deposition and Glucose Tolerance during Treatment in the Intrauterine Growth-Restricted Lamb",null,"2014","PloS one","notice","article",null,null,"PMC4000190",null,null,"europepmc","TRUE",null,null,null,"correction; Corrected and Republished Article"],["R0021349","Injection site reaction induced by liraglutide use in a female patient with obesity",null,"2023","JCEM case reports","other","article",null,null,"PMC10653154",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0021350","Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice.","Mulvihill EE","2016","Diabetes","preclinical","article","10.2337/db15-1224","26672095",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021351","Incretins and Their Endocrine and Metabolic Functions.","Seufert J","2017","Endocrine development","other","article","10.1159/000475730","28873383",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; book-chapter"],["R0021352","Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism.","Sassoon DJ","2016","Basic research in cardiology","preclinical","article","10.1007/s00395-016-0563-4","27234258","PMC5135091",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; book-chapter; article"],["R0021353","Racial/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study.","Elhussein A","2022","Lancet regional health. Americas","other_trial","article","10.1016/j.lana.2021.100111","35291207","PMC8920048",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021354","Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions.","Savage MJ","2025","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2025.0561","40935650","PMC12436035",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0021355","Combination Therapy: A New Tool for the Management of Obesity.","Prabhakar PK","2024","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/1871530323666230825140808","37641995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021356","The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.","Bjorner JB","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15090","37055712",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021357","Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline.","Bowler M","2014","A & A case reports","other","article","10.1097/acc.0b013e3182a526fa","25611153",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021358","Exenatide once weekly: clinical outcomes and patient satisfaction.","Jose B","2010","Patient preference and adherence","other_trial","article","10.2147/ppa.s7494","20859458","PMC2943223",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; review; article"],["R0021359","Clinical effectiveness of Liraglutide 3.0 mg and impact of weight loss in improving obesity-related comorbid conditions in King Fahad Medical City, Kingdom of Saudi Arabia: A real-world experience.","Alshehri A","2023","Clinical obesity","nonrandomized_study","article","10.1111/cob.12594","37194338",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0021360","Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.","Majzoub AM","2021","Alimentary pharmacology & therapeutics","systematic_review","article","10.1111/apt.16583","34435378","PMC8711247",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Systematic Review; Network Meta-Analysis; research-article; review"],["R0021361","Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones.","Cice G","2025","European heart journal supplements : journal of the European Society of Cardiology","randomized_trial","article","10.1093/eurheartjsupp/suaf019","40248297","PMC12001798",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021362","How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators.","Sabouret P","2022","Panminerva medica","narrative_review","article","10.23736/s0031-0808.21.04284-1","34060278",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021363","Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia - A Narrative Review.","Witham MD","2023","Drugs & aging","narrative_review","article","10.1007/s40266-023-01042-4","37486575","PMC10371965",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0021364","From seven combination hypotheses to one testable interaction: a gated agentic AI–QSP workflow applied to healthy-ageing interventions","Goryanin I","2026","bioRxiv","other_trial","preprint","10.64898/2026.09.29.755460",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0021365","Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.","Jimenez-Solem E","2010","Current opinion in molecular therapeutics","other_trial","article",null,"21154170",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; article"],["R0021366","Liraglutide suppresses atrial electrophysiological changes.","Nakamura H","2019","Heart and vessels","preclinical","article","10.1007/s00380-018-01327-4","30762094",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021367","Physiologically-based pharmacokinetics modelling of Semaglutide in children and adolescents with healthy and obese body weights","Machado T","2022","Authorea Preprints","other_trial","preprint","10.22541/au.167110384.41057914/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0021368","Unlocking longevity with GLP-1: A key to turn back the clock?","Chavda VP","2024","Maturitas","narrative_review","article","10.1016/j.maturitas.2024.108028","38815535",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021369","Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.","Mora P","2026","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(26)01247-x","42532079",null,"ClinicalTrials.gov:NCT06542874","S003224","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; article"],["R0021370","HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.","Kwan AYM","2022","Diabetes care","other_trial","article","10.2337/dc21-1160","35043140","PMC8918189","ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0021371","Basal Insulin/GLP-1 RA Fixed-Ratio Combinations as an Option for Advancement of Basal Insulin Therapy in Older Adults With Type 2 Diabetes.","Corriere M","2023","The Journal of family practice","other","article","10.12788/jfp.0515","36749959",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021372","[Effect of exendin-4 on monocyte chemoattractant protein-1 expression in cultured rat glomerular mesangial cells induced by tumor necrosis factor-α in vitro].","Jiang Y","2013","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article",null,"23803215",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021373","Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.","Ding X","2006","Hepatology (Baltimore, Md.)","preclinical","article","10.1002/hep.21006","16374859","PMC2925424",null,"S000566","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021374","Evidence-Based Cardiovascular Risk Management in Diabetes.","Mooradian AD","2019","American journal of cardiovascular drugs : drugs, devices, and other interventions","narrative_review","article","10.1007/s40256-019-00336-6","30793262",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021375","Semaglutide in NASH-related cirrhosis: still a long way to go?","Bhateja A","2023","The lancet. Gastroenterology & hepatology","commentary","article","10.1016/s2468-1253(23)00109-7","37453428",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0021376","Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication.","Gu G","2013","The Journal of comparative neurology","preclinical","article","10.1002/cne.23282","23238833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021377","Fathoming the Role of Semaglutide in Obesity Therapeutics.","George M","2023","Clinical therapeutics","commentary","article","10.1016/j.clinthera.2023.06.021","37442659",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0021378","Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes.","Senoo Y","2022","The New England journal of medicine","commentary","article","10.1056/nejmc2211623","36260804",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0021379","Double layer spherical nanoparticles with hyaluronic acid coating to enhance oral delivery of exenatide in T2DM rats.","Lu Y","2023","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2023.09.003","37683898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021380","UTILIZATION TRENDS OF GLUCOSE-LOWERING DRUGS FOR TYPE 2 DIABETES IN OLDER ADULTS WITH AND WITHOUT DEMENTIA",null,"2022","Innovation in aging","nonrandomized_study","article",null,null,"PMC9765796",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0021381","Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.","Dhanesha N","2012","Pharmacological reports : PR","preclinical","article","10.1016/s1734-1140(12)70740-5","22580530",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021382","Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.","Dhanesha N","2012","Journal of diabetes","preclinical","article","10.1111/j.1753-0407.2012.00193.x","22356440",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021383","Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.","Bandyopadhyay S","2023","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2023.102849","37717295",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0021384","Biological activity of EXf, a peptide analogue of exendin-4.","Song GM","2010","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2009.11.021","19919832",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021385","Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a.","Younce CW","2013","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00248.2012","23302777",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021386","A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.","Gastaldelli A","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12192","23911196",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021387","Mechanisms of action of metformin with special reference to cardiovascular protection.","Zilov AV","2019","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.3173","31021474","PMC6851752",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0021388","The Antidiabetic Drug Liraglutide Minimizes the Non-Cholinergic Neurotoxicity of the Pesticide Mipafox in SH-SY5Y Cells.","Fernandes LS","2019","Neurotoxicity research","preclinical","article","10.1007/s12640-018-9941-z","30088187",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021389","Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.","Yang J","2020","Acta diabetologica","randomized_trial","article","10.1007/s00592-020-01510-y","32206903",null,"ChiCTR:ChiCTR-IPR-15006558",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0021390","Retraction Note: Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway.","Feng Y","2023","Stem cell research & therapy","notice","article","10.1186/s13287-023-03474-6","37775785","PMC10542684",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; retraction"],["R0021391","Glutamatergic Alterations in STZ-Induced Diabetic Rats Are Reversed by Exendin-4.","Zanotto C","2019","Molecular neurobiology","preclinical","article","10.1007/s12035-018-1320-5","30145785",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021392","Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.","Du X","2018","Journal of diabetes research","other_trial","article","10.1155/2018/4019248","29541641","PMC5818885","ChiCTR:ChiCTR-OOC-17013679",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0021393","Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan.","Chang HY","2021","Scientific reports","nonrandomized_study","article","10.1038/s41598-021-86516-4","33772082","PMC7997872",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021394","Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial.","Carlson AL","2024","Journal of diabetes science and technology","other_trial","article","10.1177/19322968241234072","38439656","PMC11535359",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Clinical Trial; Research Support, Non-U.S. Gov't; meeting-report; other; article"],["R0021395","Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care.","Morieri ML","2021","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-021-01501-y","33432553",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0021396","Therapy of Type 2 diabetes: more gliflozines and less metformin?","Verdecchia P","2023","European heart journal supplements : journal of the European Society of Cardiology","other","article","10.1093/eurheartjsupp/suad098","37091638","PMC10120941",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021397","Improving Adherence to Weight-Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support.","Li A","2020","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.22930","32902905","PMC7589266",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021398","Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide.","Dăniluc L","2025","Medicina (Kaunas, Lithuania)","nonrandomized_study","article","10.3390/medicina61040567","40282858","PMC12028782",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0021399","Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform.","Kovesdy CP","2025","Nephron","nonrandomized_study","article","10.1159/000543923","40015260","PMC12215156",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021400","Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice.","Madsen MSA","2019","Scientific reports","preclinical","article","10.1038/s41598-019-52103-x","31666597","PMC6821799",null,"S001448","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021401","Rare malignant insulinoma with multiple liver metastases derived from ectopic pancreas: 3-year follow-up and literature review.","Liu Q","2018","OncoTargets and therapy","case_report","article","10.2147/ott.s154991","29662318","PMC5892612",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021402","Neuroprotective Effects of Anti-diabetic Drugs in the Treatment of Patients with Diabetes and Glaucoma or at High Risk for Glaucoma.","Weisser B","2024","Klinische Monatsblatter fur Augenheilkunde","randomized_trial","article","10.1055/a-2066-3389","37336238",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Review; Journal Article; article"],["R0021403","Gegen Qinlian decoction ameliorates insulin resistance in type 2 diabetes: A systematic review and meta-analysis of RCTs with mechanistic insights into SIRT1/AMPK pathway activation.","Liao Y","2026","Journal of ethnopharmacology","systematic_review","article","10.1016/j.jep.2025.120960","41297722",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Meta-Analysis"],["R0021404","RGB Trichromatic Whiteness Assessment of Bio Analytical Chromatographic Tool Using Fluorescence for Quantitation of Semaglutide: Application to Pharmaceutical Preparations and Spiked Plasma.","Moneim MMA","2025","Journal of fluorescence","other","article","10.1007/s10895-024-03954-9","39466481","PMC12476385",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021405","Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation.","Mitchell PD","2017","Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","other","article","10.1111/cea.12860","27928844",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021406","Treatment effect of semaglutide 2.4 mg on health-related quality of life from STEP 1 SF-6D derived from SF-36 with Australian weights.","Kral P","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15426","38195847",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0021407","Central GLP-1 receptors: Novel molecular targets for cocaine use disorder.","Hernandez NS","2019","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2019.03.026","30930091","PMC6520198",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article"],["R0021408","A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent.","Li X","2015","International journal of clinical and experimental medicine","preclinical","article",null,"26064256","PMC4443090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021409","Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases.","Huang W","2022","International journal of molecular sciences","other_trial","article","10.3390/ijms231810882","36142794","PMC9506036",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0021410","Incretins and the intensivist: what are they and what does an intensivist need to know about them?","Plummer MP","2014","Critical care (London, England)","narrative_review","article","10.1186/cc13737","24602388","PMC4015118",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0021411","Real-world evidence on the association of novel antidiabetic medication use with cancer risk and protective effects: a systematic review and network meta-analysis.","Kenawy AS","2025","Therapeutic advances in drug safety","systematic_review","article","10.1177/20420986251335214","40290515","PMC12033536","PROSPERO:CRD42023469941",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0021412","Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure.","Kimura T","2018","Diabetes & metabolism","preclinical","article","10.1016/j.diabet.2017.10.007","29525225",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021413","Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment.","Pellegrini V","2024","Cells","narrative_review","article","10.3390/cells13191662","39404426","PMC11476093",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0021414","Liraglutide and its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events.","Wiciński M","2019","International journal of molecular sciences","narrative_review","article","10.3390/ijms20051050","30823403","PMC6429395",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021415","Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-α-mediated NF-κB and MAPK pathway.","Ye Y","2019","Obesity research & clinical practice","preclinical","article","10.1016/j.orcp.2019.03.003","30952571",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021416","Therapeutic potential of multifunctional myricetin for treatment of type 2 diabetes mellitus.","Niisato N","2023","Frontiers in nutrition","narrative_review","article","10.3389/fnut.2023.1175660","37305094","PMC10251146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021417","Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility.","Nerild HH","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15017","36781820",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021418","Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes.","Zhou F","2023","Therapeutic advances in chronic disease","other_trial","article","10.1177/20406223231161516","36950020","PMC10026133",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021419","Mechanisms and therapeutic strategies of ferroptosis in Diabetic-Associated Cognitive Dysfunction: focus on the crosstalk with apoptosis, autophagy, and pyroptosis.","Zhou J","2026","Molecular biology reports","narrative_review","article","10.1007/s11033-026-11446-1","41528419",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021420","Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand.","Deerochanawong C","2019","ClinicoEconomics and outcomes research : CEOR","randomized_trial","article","10.2147/ceor.s201951","31372015","PMC6635895",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021421","GLP-1 Weight Loss Protocol: An Evidence-Based Translation Project.","Allred M","2025","Journal of doctoral nursing practice","protocol","article","10.1891/jdnp-2024-0021","40425307",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article"],["R0021422","Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.","Li Q","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-021-01182-z","34870792","PMC8776932",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021423","Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice.","Crutchlow MF","2008","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2008.03.161","18589167","PMC2517214",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021424","Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients.","Kheirandish M","2017","Current drug metabolism","narrative_review","article","10.2174/1389200218666170116105023","28093996",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021425","Human embryonic stem cell differentiation into insulin secreting β-cells for diabetes.","Bose B","2012","Cell biology international","preclinical","article","10.1042/cbi20120210","22897387",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021426","Efficacy of metformin combined with liraglutide on the glucose and lipid metabolism, vascular endothelial function, and oxidative stress of patients with T2DM and metabolic syndrome.","Liu Z","2024","Pakistan journal of medical sciences","nonrandomized_study","article","10.12669/pjms.40.1.7936","38196473","PMC10772425",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021427","Liraglutide and denatonium benzoate attenuate T2DM-induced metabolic, neurological, and testicular changes in rats: Targeting oxidative stress, inflammation, and BCRP transporter.","Harby SA","2025","Journal of molecular histology","randomized_trial","article","10.1007/s10735-025-10355-0","39881033",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0021428","Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis.","Ferrannini G","2022","Diabetes care","other_trial","article","10.2337/dc22-0903","36040063",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Research Support, Non-U.S. Gov't; Letter; article"],["R0021429","Conquering Insulin Network Dysfunctions in Alzheimer's Disease: Where Are We Today?","de la Monte SM","2024","Journal of Alzheimer's disease : JAD","narrative_review","article","10.3233/jad-240069","39422949","PMC11807374",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; book-chapter; article"],["R0021430","Dumping Syndrome in Children: A Narrative Review.","Al-Jafari M","2023","Cureus","narrative_review","article","10.7759/cureus.41407","37546099","PMC10402847",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0021431","Role of Brown Adipose Tissue in Metabolic Health and Efficacy of Drug Treatment for Obesity.","Markina NO","2024","Journal of clinical medicine","other","article","10.3390/jcm13144151","39064191","PMC11277946",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021432","[Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].","Beck-Nielsen H","2012","Ugeskrift for laeger","other","article",null,"22673382",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021433","Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based study.","Thomsen RW","2017","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.13168","27279380",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021434","Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.","Robert SA","2015","Obesity research & clinical practice","randomized_trial","article","10.1016/j.orcp.2015.03.005","25870084",null,"ClinicalTrials.gov:NCT01739049","S000368; S002311","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021435","\"Digital Clinicians\" Performing Obesity Medication Self-Injection Education: Feasibility Randomized Controlled Trial.","Coleman S","2025","JMIR diabetes","randomized_trial","article","10.2196/63503","40737494","PMC12309861",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021436","Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.","Renukuntla VS","2014","Journal of diabetes science and technology","randomized_trial","article","10.1177/1932296814542153","25030181","PMC4455387",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0021437","Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?","Grunstein RR","2023","Sleep","randomized_trial","article","10.1093/sleep/zsad224","37668448","PMC11009690",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; article-commentary; article"],["R0021438","Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo.","Qiu Y","2016","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2016.03.017","26988600",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021439","Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis.","Shu H","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-016-0207-6","27796905","PMC5118245",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0021440","Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development.","Ghose S","2024","American journal of physiology. Endocrinology and metabolism","narrative_review","article","10.1152/ajpendo.00026.2024","38630049",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021441","Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.","Frøssing S","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13053","28681988",null,"ClinicalTrials.gov:NCT02073929","S000948; S002080","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021442","[Can drug therapy for obstructive sleep apnea be expected after all?].","Fietze I","2025","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-025-01902-8","40355634",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0021443","Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.","Nielsen R","2019","Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology","randomized_trial","article","10.1007/s12350-017-1000-2","28770459",null,"ClinicalTrials.gov:NCT01472640","S001211","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0021444","Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies?","Friuli M","2024","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2024.1407336","38895630","PMC11184060",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021445","Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids.","Nguyen TD","2013","International journal of cardiology","preclinical","article","10.1016/j.ijcard.2013.07.018","23890859",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021446","Semaglutide in NASH-related cirrhosis: still a long way to go? - Authors' reply.","Loomba R","2023","The lancet. Gastroenterology & hepatology","commentary","article","10.1016/s2468-1253(23)00160-7","37453429",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; letter"],["R0021447","Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets.","Wu Z","2013","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.112.109694","23297075",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021448","Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.","Gerstein HC","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13028","28573765",null,"ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021449","A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.","Chen D","2007","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.0610173104","17213311","PMC1764862",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021450","Immunometabolic crossroads: infections as bidirectional modulators in diabetes and metabolic syndromes.","Islam MS","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1710157","41404505","PMC12702741",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021451","[Semaglutide - effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP].","Shabutdinova OR","2023","Problemy endokrinologii","randomized_trial","article","10.14341/probl13197","37448249","PMC10350618",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","English Abstract; Journal Article; Review; research-article; article"],["R0021452","A Pilot Study Showing Acute Inhibitory Effect of GLP-1 on the Bone Resorption Marker CTX in Humans.","Nissen A","2019","JBMR plus","randomized_trial","article","10.1002/jbm4.10209","31687645","PMC6820456",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021453","Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.","Candeias EM","2015","World journal of diabetes","narrative_review","article","10.4239/wjd.v6.i6.807","26131323","PMC4478577",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021454","Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System.","Wang T","2019","Diabetes care","nonrandomized_study","article","10.2337/dc18-1893","30530488","PMC6341287",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0021455","Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs.","Nalin L","2014","European journal of nuclear medicine and molecular imaging","preclinical","article","10.1007/s00259-014-2745-3","24643781",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0021456","An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug.","Ozer I","2023","Biomaterials","other","article","10.1016/j.biomaterials.2022.121985","36630826","PMC10918641",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0021457","The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.","Baptista A","2017","The European journal of health economics : HEPAC : health economics in prevention and care","systematic_review","article","10.1007/s10198-016-0837-7","27752788",null,null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Systematic Review"],["R0021458","Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections.","Sofizadeh S","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-00692-1","31564026","PMC6848584","EudraCT:2012-001941-42","S002357","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0021459","Cardiovascular effects of incretins in diabetes.","Advani A","2013","Canadian journal of diabetes","narrative_review","article","10.1016/j.jcjd.2013.06.010","24500557",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0021460","Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis.","Smith I","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s392952","36569429","PMC9769143",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0021461","Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors.","Wicki A","2014","EJNMMI research","preclinical","article","10.1186/2191-219x-4-9","24528513","PMC3937006",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021462","Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.","Elbassuoni EA","2019","Neurochemistry international","preclinical","article","10.1016/j.neuint.2019.104583","31654678",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021463","Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care.","Nyeland ME","2015","International journal of clinical practice","nonrandomized_study","article","10.1111/ijcp.12575","25302822",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0021464","Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.","Menzen M","2023","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","nonrandomized_study","article","10.1055/a-2007-2061","36599459","PMC10101737",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; article"],["R0021465","Role of lateral septum glucagon-like peptide 1 receptors in food intake.","Terrill SJ","2016","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00460.2015","27194565","PMC4967229",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021466","Effect of GLP-1 Receptor Activation on Offspring Kidney Health in a Rat Model of Maternal Obesity.","Glastras SJ","2016","Scientific reports","randomized_trial","article","10.1038/srep23525","27004609","PMC4804207",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021467","GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.","Frikke-Schmidt H","2019","Molecular metabolism","nonrandomized_study","article","10.1016/j.molmet.2019.01.003","30685336","PMC6407365",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021468","The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs.","Simonsen L","2013","Regulatory peptides","preclinical","article","10.1016/j.regpep.2012.12.012","23318502",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021469","Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE).","Ruseva A","2024","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.737","38332756","PMC10851954",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021470","Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis.","Liao XX","2022","Journal of clinical pharmacy and therapeutics","systematic_review","article","10.1111/jcpt.13588","34939679",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; article"],["R0021471","Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance.","Muskiet MHA","2019","Microcirculation (New York, N.Y. : 1994)","randomized_trial","article","10.1111/micc.12580","31313410",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021472","[Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].","Jermendy G","2016","Orvosi hetilap","randomized_trial","article","10.1556/650.2016.30409","27017851",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","English Abstract; Journal Article; Review; article"],["R0021473","What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.","Athauda D","2018","Journal of Parkinson's disease","randomized_trial","article","10.3233/jpd-181329","29843254",null,null,"S000204","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0021474","Tirzepatide: A Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus: Erratum.",null,"2023","American journal of therapeutics","notice","article","10.1097/mjt.0000000000001634","37126800",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0021475","Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.","Gorgojo-Martínez JJ","2020","Journal of medical economics","systematic_review","article","10.1080/13696998.2019.1681436","31613199",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0021476","Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices.","Zhou AY","2018","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds17-0048","30510393","PMC6243215",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021477","Differentiation of Microencapsulated Neonatal Porcine Pancreatic Cell Clusters in Vitro Improves Transplant Efficacy in Type 1 Diabetes Mellitus Mice.","Cheon GJ","2022","Diabetes & metabolism journal","preclinical","article","10.4093/dmj.2021.0202","35124687","PMC9532182",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021478","A bibliometric analysis of systematic reviews and meta-analyses on diabetes mellitus: global research trends from scopus database (1988-2024).","Dalvand A","2026","Cardiovascular diabetology. Endocrinology reports","systematic_review","article","10.1186/s40842-026-00272-w","41787495","PMC12964769",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0021479","Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor signaling reduces appetitive and motivational aspects of feeding.","Alhadeff AL","2014","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00179.2014","24944243","PMC4137150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021480","Long-term weight outcomes in patients treated with liraglutide 3.0 mg in real-world clinical practice.","Grannell A","2024","Clinical obesity","randomized_trial","article","10.1111/cob.12622","37615384",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Observational Study; Journal Article; article"],["R0021481","Semaglutide and the future of obesity care in the UK.","Fallows E","2023","Lancet (London, England)","other","article","10.1016/s0140-6736(23)01083-8","37290459",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021482","Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.","Moffett RC","2015","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.2608","25256010",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021483","Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes.","Neumiller JJ","2010","Diabetes, metabolic syndrome and obesity : targets and therapy","other_trial","article","10.2147/dmso.s7314","21437090","PMC3047975",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0021484","Gold nanoparticles as an efficient drug delivery system for GLP-1 peptides.","Pérez-Ortiz M","2017","Colloids and surfaces. B, Biointerfaces","preclinical","article","10.1016/j.colsurfb.2017.06.015","28662391",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021485","The first case of psoriatic skin lesions exacerbation after liraglutide.","Nowowiejska J","2023","Polish archives of internal medicine","case_report","article","10.20452/pamw.16527","37415553",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021486","Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.","West JA","2021","PloS one","preclinical","article","10.1371/journal.pone.0249239","33788878","PMC8011784",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021487","Introduction: Evaluating the role of incretin-based therapies in the management of type 2 diabetes.",null,"2011","The American journal of managed care","other","article",null,"21528614",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Introductory Journal Article; other"],["R0021488","Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes.","Taybani Z","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-019-0673-8","31347100","PMC6778557","ClinicalTrials.gov:NCT04020445","S000636","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021489","Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes.","Tonoike M","2019","Endocrinology, diabetes & metabolism","other","article","10.1002/edm2.43","30815572","PMC6354751",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021490","Brain GLP-1 and insulin sensitivity.","Sandoval D","2015","Molecular and cellular endocrinology","narrative_review","article","10.1016/j.mce.2015.02.017","25724479","PMC4547906",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0021491","Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells.","Kang MY","2015","Endocrinology and metabolism (Seoul, Korea)","preclinical","article","10.3803/enm.2015.30.2.216","26194081","PMC4508267",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0021492","Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.","Farr OM","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13827","31282006","PMC6800581",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021493","Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model.","Niu S","2022","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2022.1046130","36568109","PMC9780435",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021494","Renal Perfusion, Oxygenation and Metabolism: The Role of Imaging.","Päivärinta J","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm12155141","37568543","PMC10420088",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021495","Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes.","Di Pasquale G","2012","PloS one","preclinical","article","10.1371/journal.pone.0040074","22808093","PMC3396615",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021496","Effects of novel peptide therapeutics and epigallocatechin on diabetes and cognitive dysfunction","Pathak NM","2016","Ulster University","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0021497","Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine.","Wang M","2014","Biological & pharmaceutical bulletin","preclinical","article","10.1248/bpb.b13-00591","24789997",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021498","Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal.","Acuna-Goycolea C","2004","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.1607-04.2004","15371515","PMC6729787",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0021499","GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice.","Kawamori D","2017","Diabetologia","preclinical","article","10.1007/s00125-017-4303-6","28526921","PMC5508991",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0021500","Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.","Cimmaruta D","2016","Expert opinion on drug safety","systematic_review","article","10.1080/14740338.2016.1221402","27875915",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Systematic Review; review"],["R0021501","An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal-Bolus Insulin in Type 2 Diabetes.","Lingvay I","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-022-01344-7","36434159","PMC9880115",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021502","Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control.","Youssef ME","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms24076039","37047011","PMC10094124",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021503","Reactivity of N terminal histidine of peptides towards excipients/impurity of excipients: A case study of liraglutide excipient compatibility study.","Sheikh AR","2024","Journal of pharmaceutical sciences","other","article","10.1016/j.xphs.2024.08.007","39179028",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021504","Glucagon‐like peptide (GLP)‐1 analogues for normoglycaemic, overweight or obese adults","Mazzucca A","2019","The Cochrane database of systematic reviews","narrative_review","article","10.1002/14651858.cd012793.pub2",null,"PMC6398806",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","systematic-review; Review; article"],["R0021505","[GLP-1 Analogs: Recommendations for Clinical Practice].","Ritzel R","2020","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-020-0390-2","32291661",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021506","HelixDiff, a Score-Based Diffusion Model for Generating All-Atom α-Helical Structures.","Xie X","2024","ACS central science","other","article","10.1021/acscentsci.3c01488","38799672","PMC11117309",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021507","Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month post-marketing observational study.","Chin R","2023","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.13932","36367417","PMC9889676",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; article"],["R0021508","Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.","Cox DA","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14762","35546790","PMC9543252","ClinicalTrials.gov:NCT03495102","S000046","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Randomized Controlled Trial; Clinical Trial, Phase III; research-article; article"],["R0021509","MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting","Wallia A","2019","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/js.2019-mon-lb028",null,"PMC6551055",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0021510","[Recurrent hypoglycemia due to an occult insulinoma].","Breuer TG","2016","Der Internist","case_report","article","10.1007/s00108-016-0020-3","26873007",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0021511","Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.","Vyas AK","2011","PloS one","preclinical","article","10.1371/journal.pone.0017178","21359201","PMC3040766",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021512","Liraglutide and Renal Outcomes in Type 2 Diabetes.","Mann JFE","2017","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1616011","28854085",null,"ClinicalTrials.gov:NCT01179048","S000485; S001496; S002036","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Letter; Comment; article"],["R0021513","In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.","Bekiari E","2018","Annals of internal medicine","randomized_trial","article","10.7326/acpjc-2018-168-8-046","29677253",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; editorial"],["R0021514","Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.","Jiang X","2024","JPMA. The Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.8295","38219182",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0021515","Pancreatic Islet Blood Flow Dynamics in Primates.","Diez JA","2017","Cell reports","preclinical","article","10.1016/j.celrep.2017.07.039","28793270","PMC5575201",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021516","Adolescents with Type 2 Diabetes: Overcoming Barriers to Effective Weight Management.","Salama M","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s365829","36923685","PMC10010139",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021517","Utilizing type 2 diabetes medications outside glycemic parameters - where are we headed?","Malkani NP","2023","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000787","36541080","PMC9870453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021518","Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis.","Shah FA","2019","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/jc.2019-00296","31216011","PMC6763279","ClinicalTrials.gov:NCT03454087",null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; review-article; article"],["R0021519","Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function.","Marathe CS","2011","Experimental diabetes research","narrative_review","article","10.1155/2011/279530","21747825","PMC3124003",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Evaluation Study; Journal Article; Review; review-article; article"],["R0021520","Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells.","Li Z","2013","PloS one","preclinical","article","10.1371/journal.pone.0076172","24204601","PMC3811987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021521","CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.","Schnell O","2023","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-023-01788-6","36927451","PMC10019427",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0021522","Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males.","Janssen LGM","2020","Metabolism: clinical and experimental","nonrandomized_study","article","10.1016/j.metabol.2020.154167","31982480",null,"ClinicalTrials.gov:NCT03002675","S002069; S002367","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021523","Changes in insulin utilization in China from 2020 to 2022.","Chen C","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15936","39313920",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021524","The pursuit of optimal semaglutide dosing in type 2 diabetes continues.","Sherrill CH","2023","Lancet (London, England)","commentary","article","10.1016/s0140-6736(23)01233-3","37385277",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021525","In adults with obesity without diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.","Davidson MB","2022","Annals of internal medicine","commentary","article","10.7326/j22-0072","36191308",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021526","Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.","Hogan AE","2014","Diabetologia","preclinical","article","10.1007/s00125-013-3145-0","24362727",null,null,"S000371; S000641","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021527","Type 2 diabetes: an expanded view of pathophysiology and therapy.","Unger J","2010","Postgraduate medicine","narrative_review","article","10.3810/pgm.2010.05.2152","20463424",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021528","On indirect negative inotropic effects of muscarine in the isolated human atrium.","Neumann J","2026","Naunyn-Schmiedeberg's archives of pharmacology","other","article","10.1007/s00210-026-05666-2","42443635",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021529","Unique Presentation of the Follicular Occlusion Tetrad: A Case Report and Review of the Literature.","Adler R","2025","Cureus","case_report","article","10.7759/cureus.90254","40969999","PMC12443365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021530","Bariatric Surgery Complications","Burjonrappa S","2025","StatPearls Publishing, Treasure Island (FL)","other","article",null,"40465810",null,null,null,"europepmc","TRUE",null,null,null,"Study Guide"],["R0021531","Anti-Obesity Medications and the Risk of Obesity-Related Cancers in Older Women: A Propensity Score Matching Analysis of 2007-2015 SEER-Medicare Data.","Abdelgadir O","2025","Cancers","nonrandomized_study","article","10.3390/cancers17101624","40427123","PMC12109998",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021532","Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.","Schnell O","2022","Cardiovascular diabetology","other_trial","article","10.1186/s12933-022-01481-0","35395808","PMC8990484",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Conference Proceedings; Letter; article"],["R0021533","Exendin-4 protects bone marrow-derived mesenchymal stem cells against oxygen/glucose and serum deprivation-induced apoptosis through the activation of the cAMP/PKA signaling pathway and the attenuation of ER stress.","He J","2016","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2016.2509","26935620","PMC4790651",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021534","Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt.","Rupprecht LE","2013","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00367.2013","23900416","PMC3761195",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021535","SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination.","De Block C","2018","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(18)30031-7","29483059",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021536","Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.","Disse E","2025","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2025.101625","39971183",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0021537","Elderly rats fed with a high-fat high-sucrose diet developed sex-dependent metabolic syndrome regardless of long-term metformin and liraglutide treatment.","Ivić V","2023","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2023.1181064","37929025","PMC10623428",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021538","Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats.","Xu J","2018","BioMed research international","preclinical","article","10.1155/2018/1864107","29607314","PMC5828432",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021539","Potential Therapeutic Targets for the Management of Diabetes Mellitus Type 2.","Prabhakar PK","2024","Current medicinal chemistry","narrative_review","article","10.2174/0929867330666230501172557","37125833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021540","[GLP-1 agonists: an overview].","Hinneburg I","2013","Medizinische Monatsschrift fur Pharmazeuten","narrative_review","article",null,"23898602",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021541","Liraglutide Counteracts Endoplasmic Reticulum Stress in Palmitate-Treated Hypothalamic Neurons without Restoring Mitochondrial Homeostasis.","Griffin H","2022","International journal of molecular sciences","preclinical","article","10.3390/ijms24010629","36614074","PMC9820707",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021542","Semaglutide for Treating Obesity Induced by Craniopharyngioma Resection: A Successful Case Study.","Sciacovelli C","2023","JCEM case reports","case_report","article","10.1210/jcemcr/luad074","37908981","PMC10580492",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021543","Automated versus manual prior authorization for diabetes mellitus drugs: A retrospective study from Israel.","Moshel S","2023","Digital health","nonrandomized_study","article","10.1177/20552076231203889","37780061","PMC10540583",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0021544","Association of inflammation with glycemic control, insulin sensitivity, and beta-cell function in diabetic cats.","Thalmeier S","2026","Journal of veterinary internal medicine","nonrandomized_study","article","10.1093/jvimsj/aalag039","41854429","PMC13001023",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021545","Liraglutide: the therapeutic promise from animal models.","Knudsen LB","2010","International journal of clinical practice. Supplement","narrative_review","article","10.1111/j.1742-1241.2010.02499.x","20887299",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0021546","Weight Loss of Semaglutide Treatment for Patients With Overweight or Obesity: A Retrospective Observational Study in China","Zhang X","2023","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-3256039/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0021547","How does glucagon-like peptide 1 stimulate human β-cell proliferation? A lesson from islet graft experiments.","Fujitani Y","2018","Journal of diabetes investigation","preclinical","article","10.1111/jdi.12861","29770600","PMC6215945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0021548","Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.","Chuang EY","2013","Biomaterials","preclinical","article","10.1016/j.biomaterials.2013.07.021","23891516",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021549","Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection.","Huang HJ","2012","PloS one","preclinical","article","10.1371/journal.pone.0039656","22844396","PMC3402484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021550","Effect of tirzepatide on prediabetics and blood pressure with implications for future research.","Seetharaman R","2023","Journal of basic and clinical physiology and pharmacology","commentary","article","10.1515/jbcpp-2022-0305","36607902",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0021551","Pancreatic Cancer and Diabetes Mellitus.","Sharma A","2018","Current treatment options in gastroenterology","narrative_review","article","10.1007/s11938-018-0197-8","30215162","PMC6436833",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0021552","PAS kinase is a nutrient and energy sensor in hypothalamic areas required for the normal function of AMPK and mTOR/S6K1.","Hurtado-Carneiro V","2014","Molecular neurobiology","preclinical","article","10.1007/s12035-013-8630-4","24445950",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021553","Corticotropin-releasing hormone and the sympathoadrenal system are major mediators in the effects of peripherally administered exendin-4 on the hypothalamic-pituitary-adrenal axis of male rats.","Gil-Lozano M","2014","Endocrinology","preclinical","article","10.1210/en.2013-1718","24731096",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021554","Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice.","Lee J","2012","PloS one","preclinical","article","10.1371/journal.pone.0031394","22363635","PMC3281956",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021555","Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.","Cummings BP","2010","Diabetes","preclinical","article","10.2337/db09-1564","20622169","PMC3279561",null,"S001234","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021556","Estimated Costs of Production Compared with National Prices, for Drugs to Treat Clinical Obesity","Levi J","2022","SSRN","nonrandomized_study","preprint","10.2139/ssrn.4068270",null,null,null,null,"europepmc","FALSE","free_to_read","4",null,"Preprint"],["R0021557","Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.","Wang L","2022","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s358989","35651477","PMC9149770",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021558","Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.","Pelletier EM","2012","Journal of medical economics","nonrandomized_study","article","10.3111/13696998.2012.688903","22533526",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021559","Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis.","Noureddin M","2026","JHEP reports : innovation in hepatology","nonrandomized_study","article","10.1016/j.jhepr.2026.102018","42705608",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0021560","beta-cell failure in diabetes and preservation by clinical treatment.","Wajchenberg BL","2007","Endocrine reviews","preclinical","article","10.1210/10.1210/er.2006-0038","17353295",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021561","[Research in evaluation and intervention of cardiovascular complications of patients with type 1 diabetes on demand].","Kong W","2022","Zhonghua yi xue za zhi","other","article","10.3760/cma.j.cn/112137-20211009-02230","35462499",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021562","Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.","Napoli R","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15020","36789682",null,null,"S002347","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021563","Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery.","Malgave A","2025","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","protocol","article","10.1016/j.ejpb.2025.114780","40490042",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0021564","Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia/reperfusion through modulating macrophages polarization.","Zhao J","2024","Cardiovascular diabetology","preclinical","article","10.1186/s12933-024-02342-8","38970123","PMC11227217",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0021565","Willingness to Pay (WTP) for Newer Treatment Options for Diabetes: A Study Among Patients at a Tertiary Care Centre.","Vaidya S","2024","Cureus","other","article","10.7759/cureus.56103","38618372","PMC11009894",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021566","The Gut-Bone Axis in Diabetes.","Maagensen H","2023","Current osteoporosis reports","narrative_review","article","10.1007/s11914-022-00767-2","36441432",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021567","Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.","Grunberger G","2012","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2012.03745.x","22804250",null,null,"S000376","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021568","Current and future impact of clinical gastrointestinal research on patient care in diabetes mellitus.","Koch TR","2018","World journal of diabetes","commentary","article","10.4239/wjd.v9.i11.180","30479683","PMC6242723",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0021569","Common genetic variants near SLC2A2 and glycemic response to glimepiride in the GRADE comparative effectiveness clinical trial.","Li JH","2025","medRxiv : the preprint server for health sciences","other_trial","article","10.1101/2025.10.07.25336827","41282760","PMC12632647","ClinicalTrials.gov:NCT01794143","S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Preprint; preprint"],["R0021570","Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75 years.","Baronti W","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111928","39536977",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; article"],["R0021571","Sleep and circadian effects on the incretin system.","Yuan RK","2025","Current sleep medicine reports","other","article","10.1007/s40675-025-00337-9","40933800","PMC12419499",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0021572","Genetically Encoded Cholesterol-Modified Polypeptides.","Mozhdehi D","2019","Journal of the American Chemical Society","other","article","10.1021/jacs.8b10687","30608674","PMC6693588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0021573","Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.","Gejl M","2012","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2011-3456","22544917",null,"ClinicalTrials.gov:NCT00747968","S000767; S002209","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021574","Xenotransplantation of exendin-4 gene transduced pancreatic islets using multi-component (alginate, poly-L-lysine, and polyethylene glycol) microcapsules for the treatment of type 1 diabetes mellitus.","Park JB","2013","Journal of biomaterials science. Polymer edition","preclinical","article","10.1080/09205063.2013.823071","23905775",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021575","Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli.","Yin X","2005","Protein expression and purification","preclinical","article","10.1016/j.pep.2004.10.014","15866711",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021576","The Coadministration of Levosimendan and Exenatide Offers a Significant Cardioprotective Effect to Isolated Rat Hearts against Ischemia/Reperfusion Injury.","Leivaditis V","2022","Journal of cardiovascular development and disease","preclinical","article","10.3390/jcdd9080263","36005427","PMC9409795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021577","Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota.","Ni Y","2022","Acta biochimica et biophysica Sinica","narrative_review","article","10.3724/abbs.2022140","36239349","PMC9827797",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; research-article; article"],["R0021578","Exendin 4: AC 2993, AC 2993 LAR.","&NA;","2002","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","other","article","10.2165/00063030-200216030-00008","12102651",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021579","Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature.","Alayed KM","2023","Journal of obesity","narrative_review","article","10.1155/2023/8626081","38169925","PMC10761230",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0021580","Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease.","Akawi N","2021","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2021.03.314","34016263","PMC8141611","ClinicalTrials.gov:NCT02094183",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021581","Astrocyte Activation is A Potential Mechanism Underlying Depressed Mood and Apathy in People with HIV.","Ellis RJ","2022","Journal of neurology and psychology","other","article","10.13188/2332-3469.1000048","37205974","PMC10194432",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021582","Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.","Tan HC","2022","Journal of the ASEAN Federation of Endocrine Societies","systematic_review","article","10.15605/jafes.037.02.14","36578889","PMC9758543",null,"S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review-article; review"],["R0021583","Enhanced protection of Ins-1 beta cells from apoptosis under hypoxia by delivery of DNA encoding secretion signal peptide-linked exendin-4.","Ah Kim H","2009","Journal of drug targeting","other","article","10.1080/10611860902718664","19558363",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021584","Efficacy of atomoxetine and oxybutynin in the treatment of pediatric obstructive sleep apnea, a three case report.","Larramona Carrera H","2025","Frontiers in sleep","other_trial","article","10.3389/frsle.2025.1682625","41425178","PMC12713933",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0021585","Use of Insulin in the Inpatient Setting: Need for Continued Use.","Kumar S","2019","Current diabetes reports","narrative_review","article","10.1007/s11892-019-1183-9","31346798",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021586","Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results.","La Vignera S","2023","Journal of clinical medicine","other","article","10.3390/jcm12020672","36675601","PMC9860933",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021587","The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.","Hölscher C","2014","Alzheimer's & dementia : the journal of the Alzheimer's Association","other_trial","article","10.1016/j.jalz.2013.12.009","24529525",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0021588","Discovery of the GI Effects of GLP-1: An Historical Perspective.","Holst JJ","2022","Digestive diseases and sciences","narrative_review","article","10.1007/s10620-022-07519-3","35635627",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0021589","4-hydroxyisoleucine mediated IGF-1/GLP-1 signalling activation prevents propionic acid-induced autism-like behavioural phenotypes and neurochemical defects in experimental rats.","Bhalla S","2022","Neuropeptides","preclinical","article","10.1016/j.npep.2022.102296","36307249",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021590","Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States.","Lu Y","2022","Journal of the American Heart Association","other","article","10.1161/jaha.121.025545","36172953","PMC9673703",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0021591","GLP-1 as a target for therapeutic intervention.","Rajeev SP","2016","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2016.08.005","27591964",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021592","Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.","Li Y","2018","Medical science monitor : international medical journal of experimental and clinical research","preclinical","article","10.12659/msm.907227","29777582","PMC5987616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0021593","SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease.","Tuttle KR","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(19)30116-0","30992196",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021594","Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.","Thorkildsen C","2003","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.103.051987","12975499",null,null,"S002753","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0021595","Liraglutide for Pediatric Patients With Type 2 Diabetes: CADTH Health Technology Review",null,"2023","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"37782715",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0021596","Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.","Sharma MK","2014","Journal of neurochemistry","preclinical","article","10.1111/jnc.12469","24112036",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021597","Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome.","Livadas S","2020","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-19-0150","32554829","PMC7354729",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021598","68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake.","Luo Y","2015","European journal of nuclear medicine and molecular imaging","case_report","article","10.1007/s00259-014-2946-9","25398421","PMC5223098",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021599","Combination therapy with clinically approved PPARα/δ/γ subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model.","Honda A","2026","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2026.119432","42048716",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021600","Examination of quality of life in patients using exenatide with different dimensions.","Ersoy S","2022","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.0395","35713037",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021601","[Efficacy and safety of IdegLira for the intensification of type 2 diabetes treatment].","Costa Gil JE","2018","Medicina","narrative_review","article",null,"30125249",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021602","Strong Association Between Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors.","Yanagawa T","2018","Journal of clinical medicine research","commentary","article","10.14740/jocmr3587w","30214654","PMC6135005",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0021603","Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.","Margulies KB","2016","JAMA","randomized_trial","article","10.1001/jama.2016.10260","27483064","PMC5021525","ClinicalTrials.gov:NCT01800968","S002350","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0021604","Successful use of liraglutide in a female patient with type 1 Gaucher disease, type 2 diabetes mellitus and obesity",null,"2023","JCEM case reports","other","article",null,null,"PMC10653160",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0021605","Microglial activation and hypothalamic structural plasticity in HFD obesity: insights from semaglutide and minocycline.","Rong X","2025","Journal of lipid research","preclinical","article","10.1016/j.jlr.2024.100736","39724960","PMC11788729",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021606","Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.","Raubenheimer PJ","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14634","34984808",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021607","Tirzepatide alleviates oxidative stress and inflammation in diabetic nephropathy via IL-17 signaling pathway.","Yang Y","2025","Molecular and cellular biochemistry","preclinical","article","10.1007/s11010-024-05066-1","38965127",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021608","The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.","Crane J","2016","Therapeutic advances in chronic disease","other_trial","article","10.1177/2040622315620180","26977279","PMC4772342",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0021609","Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity.","Jensterle M","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14944","36511825",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021610","Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus.","Pilszyk A","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms231710101","36077491","PMC9456218",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021611","Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration.","Rachmany L","2017","Scientific reports","preclinical","article","10.1038/s41598-017-03792-9","28623327","PMC5473835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0021612","Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.","Deol H","2017","Endocrine","nonrandomized_study","article","10.1007/s12020-016-1125-0","27696231",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0021613","Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.","Ratner RE","2010","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2010.03020.x","20722676","PMC3068287",null,"S001455","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021614","Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension.","Barillas-Lara MI","2023","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000001069","37522803",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0021615","Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type-2 diabetes and chronic kidney disease: DPV registry study.","Vijayan A","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16245","39972199","PMC11965019",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021616","Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease.","Zhang L","2023","Acta diabetologica","other","article","10.1007/s00592-023-02082-3","37079136","PMC10198855",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021617","Sustained Delivery of Liraglutide Using Multivesicular Liposome Based on Mixed Phospholipids.","Zhang R","2025","Pharmaceutics","preclinical","article","10.3390/pharmaceutics17020203","40006570","PMC11859442",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021618","Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.","Jacobsen LV","2016","Clinical pharmacokinetics","narrative_review","article","10.1007/s40262-015-0343-6","26597252","PMC4875959",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0021619","Is exenatide a useful addition to diabetes therapy?","Mikhail NE","2006","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.4158/ep.12.3.307","16772206",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021620","Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.","Aroda VR","2023","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(23)01127-3","37385279",null,"ClinicalTrials.gov:NCT04707469; EudraCT:2020-000299-39","S001571","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; article"],["R0021621","Pharmaceutical approval update.","Goldenberg MM","2014","P & T : a peer-reviewed journal for formulary management","other","article",null,"25083125","PMC4103573",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; other"],["R0021622","Exendin-4 increases the expression of hypoxia-inducible factor-1α in rat islets and preserves the endocrine cell volume of both free and macroencapsulated islet grafts.","Jia X","2012","Cell transplantation","preclinical","article","10.3727/096368911x627408","22405036",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021623","Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial.","Nauck M","2013","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/dme.12003","22937895",null,"ClinicalTrials.gov:NCT00755287","S000280","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021624","Intestinal lipid absorption and transport in type 2 diabetes.","Vergès B","2022","Diabetologia","narrative_review","article","10.1007/s00125-022-05765-8","35908083",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021625","Exenatide. Amylin/Eli Lilly.","Giannoukakis N","2003","Current opinion in investigational drugs (London, England : 2000)","other_trial","article",null,"12808888",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0021626","Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.","Polyzos SA","2023","Current medicinal chemistry","commentary","article","10.2174/0929867330666230106103202","36617715",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0021627","[DIABETES AND RAMADAN FASTING - UPDATE 2019].","Zaina A","2019","Harefuah","narrative_review","article",null,"31104384",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021628","DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.","Birnbaum Y","2019","Basic research in cardiology","preclinical","article","10.1007/s00395-019-0743-0","31388770",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021629","Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)",null,"2023","National Institute for Health and Care Excellence (NICE), London","narrative_review","article",null,"40163606",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0021630","891. Minimum Manufacturing Costs and National Prices for Weight Loss Treatments, as Potential Mitigation for Anti-Retroviral Related Weight Gain in HIV","Levi J","2021","Open forum infectious diseases","nonrandomized_study","article","10.1093/ofid/ofab466.1086",null,"PMC8644642",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0021631","Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.","Iwamoto N","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-017-0346-4","29264713","PMC5801232","ClinicalTrials.gov:NCT01558271","S000837","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; other; article"],["R0021632","[Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].","Zhou B","2023","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","nonrandomized_study","article","10.12122/j.issn.1673-4254.2023.03.14","37087589","PMC10122729",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","English Abstract; Journal Article; research-article; other"],["R0021633","A systematic review of the economic value proposition for commercially available nonsurgical weight-loss interventions.","Finkelstein EA","2023","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.23760","37231621",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Journal Article; review"],["R0021634","Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.","Diene G","2022","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgac549","36181471","PMC9759167",null,"S000405","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021635","Universal peptide synthesis via solid-phase methods fused with chemputation.","Zero J","2025","Nature communications","other","article","10.1038/s41467-025-62344-2","40781087","PMC12334676",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021636","Microdroplet Mass Spectrometry Enables Rapid and Sensitive Measurement of Glucose Homeostasis for Elucidating Mechanism of Drug Action.","Yao H","2025","Analytical chemistry","preclinical","article","10.1021/acs.analchem.5c01759","40887750","PMC13245664",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021637","Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?","Munir KM","2018","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2018.1475559","29788782",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0021638","Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides.","Vrang N","2010","Progress in neurobiology","narrative_review","article","10.1016/j.pneurobio.2010.07.003","20638440",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021639","Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue.","Bai C","2022","Frontiers in endocrinology","other","article","10.3389/fendo.2022.1012904","36246878","PMC9558273",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021640","Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD).","Geary A","2026","JAAPA : official journal of the American Academy of Physician Assistants","narrative_review","article","10.1097/01.jaa.0000000000000296","41369205",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021641","Semaglutide Once Weekly Helps Adolescents Lose Weight, but 4% Developed Acute Cholelithiasis.","Ebell MH","2023","American family physician","other","article",null,"37440751",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021642","GLP-1 receptor agonists and cardiovascular protection: A class effect or not?","Scheen AJ","2018","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2017.12.009","29551531",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0021643","Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.","Kapitza C","2015","Journal of clinical pharmacology","other","article","10.1002/jcph.443","25475122","PMC4418331",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021644","Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities.","Li J","2022","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics14071445","35890340","PMC9320151",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021645","Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.","Sanghvi MM","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.05.022","42383941",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021646","Retraction Note: Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways.","Guo NF","2023","European review for medical and pharmacological sciences","other","article","10.26355/eurrev_202307_33113","37522656",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Retraction Notice; retraction"],["R0021647","Incretin-based therapy and type 2 diabetes.","Hare KJ","2010","Vitamins and hormones","narrative_review","article","10.1016/b978-0-12-381517-0.00015-1","21094909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; book-chapter"],["R0021648","Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery.","Miyata K","2018","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.8b00185","29648441",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021649","Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.","Santilli F","2017","Diabetes care","randomized_trial","article","10.2337/dc17-0589","28912305",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0021650","Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.","Bergmann NC","2019","Diabetologia","randomized_trial","article","10.1007/s00125-018-4810-0","30683945",null,"ClinicalTrials.gov:NCT02598791",null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0021651","(EX-4)2-Fc, an effective long-acting GLP-1 receptor agonist, reduces obesity-related inflammation by inhibiting leptin expression.","Zhou B","2020","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2020.06.054","32736674",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021652","Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes.","Wei J","2023","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2023.30885","37624597","PMC10457713",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021653","Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.","Han J","2020","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2020.112389","32388115",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021654","The effectiveness and value of tirzepatide for type 2 diabetes mellitus.","Nikitin D","2022","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2022.28.6.680","35621725","PMC10373002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0021655","[Cloning, expressing of exendin-4 analogue and bioactivity analysis in vivo].","Li T","2012","Sheng wu gong cheng xue bao = Chinese journal of biotechnology","preclinical","article",null,"23167199",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021656","Exendin-4 inhibits glucolipotoxic ER stress in pancreatic β cells via regulation of SREBP1c and C/EBPβ transcription factors.","Oh YS","2013","The Journal of endocrinology","preclinical","article","10.1530/joe-12-0311","23257266",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021657","Liraglutide in Prader Willi-Syndrome: The Importance of Placebo-Controlled Studies.","Aguilar Salinas CA","2023","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgad017","36638011",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Editorial; Comment; article"],["R0021658","Psychological and behavioral effects of GLP-1 and GIP agonists in weight loss: a comprehensive review.","Ameer F","2025","Journal of diabetes and metabolic disorders","narrative_review","article","10.1007/s40200-025-01770-x","41169340","PMC12569305",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021659","GLP-1 receptor agonists: differentiation within the class.","Taylor SI","2018","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(17)30413-8","29221658","PMC5988583",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment; article-commentary; article"],["R0021660","Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats.","Barakat GM","2012","Biochemical genetics","preclinical","article","10.1007/s10528-012-9532-2","22983684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021661","Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes.","Choxi R","2020","Expert review of cardiovascular therapy","narrative_review","article","10.1080/14779072.2020.1756778","32306789",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021662","Updates in Bariatric Surgery.","Hsu JL","2024","The American surgeon","narrative_review","article","10.1177/00031348231220576","38060198",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021663","GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated β-cell damage in Akita mice.","Yamane S","2011","Journal of diabetes investigation","preclinical","article","10.1111/j.2040-1124.2010.00075.x","24843469","PMC4015545",null,"S002455","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021664","GLP-1 receptor agonist on cardiovascular complications of diabetes mellitus.","Liu F","2020","Experimental and therapeutic medicine","other","article","10.3892/etm.2020.8439","32104292","PMC7027309",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021665","Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies.","Addison D","2011","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-010-0153-0","21170611","PMC3063860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0021666","Targeting mTOR with vistusertib attenuates metabolic steatohepatitis and prevents HCC development.","Sharma N","2026","Inflammation research : official journal of the European Histamine Research Society ... [et al.]","preclinical","article","10.1007/s00011-026-02265-y","42189199",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021667","Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.","Chai W","2016","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00205.2016","27436611","PMC5142002",null,"S000291","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021668","Retracted: Ameliorative Impact of Liraglutide on Chronic Intermittent Hypoxia-Induced Atrial Remodeling.","Immunology Research JO","2023","Journal of immunology research","notice","article","10.1155/2023/9821965","37621923","PMC10447045",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; article"],["R0021669","Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study.","Zhang YL","2019","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.342","31452921","PMC6700512",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021670","Exendin-4 protected against critical limb ischemia in obese mice.","Sheu JJ","2015","American journal of translational research","preclinical","article",null,"26045886","PMC4448186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021671","Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom.","Sandhu H","2023","Advances in therapy","nonrandomized_study","article","10.1007/s12325-022-02423-8","36630047","PMC9988790",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; case-report; article"],["R0021672","Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.","Lando HM","2012","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","preclinical","article","10.4158/ep11290.or","22440997",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0021673","RETRACTED: Molecular targeting of FATP4 transporter for oral delivery of therapeutic peptide.","Hu Z","2020","Science advances","preclinical","article","10.1126/sciadv.aba0145","32270048","PMC7112756",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Retracted Publication; research-article; article"],["R0021674","Correction to: Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects.","van Hout M","2023","Clinical pharmacokinetics","notice","article","10.1007/s40262-023-01276-w","37378793","PMC10338591",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0021675","The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells.","Marzook A","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.678055","34040588","PMC8143046",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0021676","Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care.","Jacob S","2021","Drugs","nonrandomized_study","article","10.1007/s40265-021-01554-6","34302636",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0021677","Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.","Younossi ZM","2026","Liver international : official journal of the International Association for the Study of the Liver","narrative_review","article","10.1111/liv.70806","42613687","PMC13486623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021678","Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial.","Deng Y","2023","BMJ medicine","randomized_trial","article","10.1136/bmjmed-2022-000419","37577025","PMC10414064",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021679","Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Cornejo-Estrada A","2023","Children (Basel, Switzerland)","systematic_review","article","10.3390/children10020208","36832337","PMC10010327","PROSPERO:CRD42022347472",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0021680","Maternal Weight Intervention in the Perinatal Period Improves Liver Health in the Offspring of Mothers with Obesity.","Purcell AR","2023","Nutrients","preclinical","article","10.3390/nu16010109","38201940","PMC10780988",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021681","The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus-ENDIS Study.","Navodnik MP","2023","Pharmaceutics","randomized_trial","article","10.3390/pharmaceutics15071945","37514131","PMC10385568",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021682","[Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report].","Cadena-Obando DA","2018","Nutricion hospitalaria","case_report","article","10.20960/nh.1525","29974787",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021683","Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.","Gallwitz B","2006","International journal of clinical practice","narrative_review","article","10.1111/j.1742-1241.2006.01196.x","17109672",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0021684","Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.","Jacobsen LV","2011","Journal of clinical pharmacology","other","article","10.1177/0091270010389471","21228406",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021685","Oral Semaglutide Led to Similar Weight Loss as Injection, Company Says.","Harris E","2023","JAMA","other","article","10.1001/jama.2023.9601","37256645",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021686","Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism.","Lee YC","2023","British journal of clinical pharmacology","other_trial","article","10.1111/bcp.15630","36575627",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; article"],["R0021687","Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic β-cells via protein kinase A.","Rajan S","2015","Molecular metabolism","preclinical","article","10.1016/j.molmet.2015.01.010","25830090","PMC4354925",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021688","[Evolution of the non-insulin therapeutic strategy in type 2 diabetes].","Vatier C","2023","La Revue de medecine interne","narrative_review","article","10.1016/j.revmed.2023.03.010","37059602",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0021689","Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.","Ortiz-Flores AE","2018","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2018.1528231","30289728",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021690","KCNQ1 variant rs163184 is a potential biomarker of glycemic response to exenatide.","Geng Z","2022","Pharmacogenomics","other","article","10.2217/pgs-2021-0154","35311356",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021691","Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.","Lipš M","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13029","28581209",null,"ClinicalTrials.gov:NCT01373216","S001322","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0021692","Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells.","Leech CA","2011","Progress in biophysics and molecular biology","narrative_review","article","10.1016/j.pbiomolbio.2011.07.005","21782840","PMC3200499",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article"],["R0021693","Long-term studies of treatments for type 2 diabetes.","Caballero AE","2017","Postgraduate medicine","randomized_trial","article","10.1080/00325481.2017.1265417","27882816",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0021694","Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study).","Schultes B","2024","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.15403","38092710",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0021695","Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.","Kajiwara M","2017","Journal of cardiology","randomized_trial","article","10.1016/j.jjcc.2016.10.009","27894787",null,"UMIN:UMIN000006817",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0021696","A National Audit of Facilities, Human and Material Resources for the Comprehensive Management of Diabetes Mellitus in Ghana-A 2023 Update","Yorke E","2023","Research Square","other","preprint","10.21203/rs.3.rs-3157326/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021697","Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double-Blind, Randomized, Placebo-Controlled Trial.","Paiman EHM","2020","Journal of magnetic resonance imaging : JMRI","randomized_trial","article","10.1002/jmri.27009","31799782","PMC7318583",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021698","99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma.","Sowa-Staszczak A","2016","PloS one","other","article","10.1371/journal.pone.0160714","27526057","PMC4985165",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021699","Sphingosine kinase 1-interacting protein is a novel regulator of glucose-stimulated insulin secretion.","Wang Y","2017","Scientific reports","preclinical","article","10.1038/s41598-017-00900-7","28396589","PMC5429731",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021700","Chemoselective sulfonyl fluoride exchange (SuFEx)-induced macrocyclization of tyrosine-containing peptides in aqueous media.","Seyrani H","2025","Chemical science","other","article","10.1039/d5sc06993a","41158548","PMC12557407",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; preprint; article"],["R0021701","Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.","Kaur P","2016","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/2230-8210.183825","27730066","PMC5040036",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021702","Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).","Lee DY","2023","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2023.0328","38043783","PMC10695716",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; Comment; article"],["R0021703","Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors.","Neumiller JJ","2022","TouchREVIEWS in endocrinology","narrative_review","article","10.17925/ee.2022.18.2.106","36694888","PMC9835817",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021704","Chronic kidney disease prevalence and outcomes in patients with type 2 diabetes or prediabetes at high cardiovascular risk: results from the CINEMA program.","Datla S","2025","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2025.101004","40469223","PMC12133703",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021705","Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia.","Zenz S","2022","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgac369","35833597",null,"ClinicalTrials.gov:NCT02408705","S000847","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021707","The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials.","Jobanputra R","2023","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13553","36721366",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; review"],["R0021708","Intestinal glucagon-like peptide-1: A new player associated with impaired counterregulatory responses to hypoglycaemia in type 1 diabetic mice.","Jin FX","2024","World journal of diabetes","preclinical","article","10.4239/wjd.v15.i8.1764","39192849","PMC11346100",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021709","A Study on Weight Loss Cause as per the Side Effect of Liraglutide.","Yu J","2022","Cardiovascular therapeutics","randomized_trial","article","10.1155/2022/5201684","36540096","PMC9733986",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; research-article; article"],["R0021710","Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis.","Araki E","2022","Journal of diabetes investigation","other_trial","article","10.1111/jdi.13905","36222597","PMC9720207",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0021711","Liraglutide mitigates TNF-α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women.","Di Tomo P","2017","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.2925","28753251",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021712","Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo.","Zheng X","2011","Peptides","preclinical","article","10.1016/j.peptides.2011.02.009","21334413",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021713","Delayed type hypersensitivity injection site reaction and tolerance induction to liraglutide for the treatment of obesity.","Yaneva M","2023","JAAD case reports","case_report","article","10.1016/j.jdcr.2023.06.010","37600731","PMC10433277",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021714","Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).","Scherbak NN","2023","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2023.0355","38043784","PMC10695721",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; Comment; reply; article"],["R0021715","From lead to market: chemical approaches to transform peptides into therapeutics.","Gare CL","2025","Trends in biochemical sciences","narrative_review","article","10.1016/j.tibs.2025.01.009","40011178",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0021716","Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.","Lee WC","2010","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2010.08.010","21194600",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0021717","Tirzepatide Once Weekly for the Treatment of Obesity.","Dekker TJA","2022","The New England journal of medicine","commentary","article","10.1056/nejmc2211120","36239652",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0021718","Lycopene Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease via PINK1/Parkin-Mediated Mitophagy Activation and Apoptosis Attenuation.","Xu Z","2026","Antioxidants (Basel, Switzerland)","preclinical","article","10.3390/antiox15050648","42193269","PMC13203502",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021719","The Food Environment, Preference, and Experience Modulate the Effects of Exendin-4 on Food Intake and Reward.","Mella R","2017","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.21939","29086500",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021720","Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis.","Romero-Gómez M","2026","Gastroenterologia y hepatologia","notice","article","10.1016/j.gastrohep.2025.502639","41571546",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0021721","Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways.","Lee MY","2016","Scientific reports","preclinical","article","10.1038/srep31788","27581840","PMC5007506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021722","Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.","Evans M","2023","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14892","36251282","PMC10092031",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021723","Effects of liraglutide on extraglycemic inflammatory markers and renal hemodynamic parameters in diabetic kidney disease (DKD).","Song W","2023","Medicine","other","article","10.1097/md.0000000000035046","37682154","PMC10489186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021724","Is time ready for combination therapy at diagnosis of type 2 diabetes?","Prattichizzo F","2021","Diabetes/metabolism research and reviews","other_trial","article","10.1002/dmrr.3460","34240524",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Editorial; Research Support, Non-U.S. Gov't; article"],["R0021725","Tirzepatide: A New Anti-Obesity Medication.","Ghoneim S","2023","Gastroenterology","commentary","article","10.1053/j.gastro.2022.09.013","36155186",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0021726","Characterization of low-level D-amino acid isomeric impurities of Semaglutide using liquid chromatography-high resolution tandem mass spectrometry.","Zhang B","2023","Journal of pharmaceutical and biomedical analysis","other","article","10.1016/j.jpba.2022.115164","36462248",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021727","Long-Term Liraglutide Administration Induces Pancreas Neogenesis in Adult T2DM Mice.","Deng H","2020","Cell transplantation","preclinical","article","10.1177/0963689720927392","32584149","PMC7563804",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0021728","Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.","Scherbak NN","2023","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2022.0342","37349083","PMC10555542","ClinicalTrials.gov:NCT01425580","S002231","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021729","Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials.","Chalmoukou K","2022","European journal of internal medicine","systematic_review","article","10.1016/j.ejim.2021.12.018","34953655",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0021730","Evaluating Weight Loss With Semaglutide in Elderly Patients With Type II Diabetes.","Huynh G","2023","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","nonrandomized_study","article","10.1177/87551225221137493","36755752","PMC9899961",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021731","Weekly Exenatide Therapy: A Real-World Comparison of Incretin Therapies.","Micale SJ","2014","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","nonrandomized_study","article","10.1177/8755122513518189","34860898","PMC5990137",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021732","Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models.","Lee J","2024","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph17040538","38675498","PMC11054907",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021733","Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial.","Fox CK","2022","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23395","35403350","PMC9050846","ClinicalTrials.gov:NCT02496611","S001050","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0021734","A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus.","Burlina S","2023","Acta diabetologica","case_report","article","10.1007/s00592-022-01954-4","36136154",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021735","Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure.","Takahashi A","2015","International heart journal","preclinical","article","10.1536/ihj.15-028","26104180",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0021736","Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes.","Sunnarborg K","2022","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.5448","35505634","PMC9542001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021737","Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.","Rieg T","2012","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00259.2012","22832924","PMC3469689",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021738","Activation of GLP-1R ameliorates microglial pyroptosis after spinal cord injury by restoring FANCC expression.","Li G","2026","Brain, behavior, and immunity","preclinical","article","10.1016/j.bbi.2026.106295","41580096",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021739","Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.","Liberini CG","2019","Scientific reports","preclinical","article","10.1038/s41598-019-44591-8","31186439","PMC6560126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021740","Knowledge and prescribing behaviour of Flemish general practitioners regarding novel glucose-lowering medications: Online cross-sectional survey.","Lecomte J","2024","Primary care diabetes","other","article","10.1016/j.pcd.2024.06.002","38862313",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021741","Self-Assembled Oligopeptoplex-Loaded Dissolving Microneedles for Adipocyte-Targeted Anti-Obesity Gene Therapy.","Choi H","2024","Advanced materials (Deerfield Beach, Fla.)","preclinical","article","10.1002/adma.202309920","38213134",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021742","Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway.","Sadek MA","2023","International immunopharmacology","preclinical","article","10.1016/j.intimp.2022.109647","36584570",null,null,"S002208","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0021743","Liraglutide-related cholelithiasis.","Korkmaz H","2015","Aging clinical and experimental research","case_report","article","10.1007/s40520-015-0335-2","25725635",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021744","Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.","Xu J","2022","Advances in therapy","randomized_trial","article","10.1007/s12325-021-01921-5","34787823",null,"ClinicalTrials.gov:NCT01667900","S001693","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021745","The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.","Kayed A","2023","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.122.001440","36418115",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021746","Deducing insulin producing cells in goat adipose tissue derived mesenchymal stem cells","Dubey A","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-243143/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0021747","Clinical implications of cardiovascular outcome trials in type 2 diabetes.","Mellbin LG","2019","Herz","other","article","10.1007/s00059-019-4789-4","30805659","PMC6507479",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021748","Association of metabolic syndrome and chronic kidney disease.","Scurt FG","2024","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.13649","37783465",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0021749","Comparative efficacy of SGLT2 Inhibitors and Obeticholic Acid in MAFLD and Fibrosis: A Systematic Review","Ganesh T","2026","Research Square","systematic_review","preprint","10.21203/rs.3.rs-8607418/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; article"],["R0021750","Hormone treatments in congestive heart failure.","Lei L","2018","The Journal of international medical research","narrative_review","article","10.1177/0300060518761262","29468912","PMC6023073",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0021751","Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.","La Vignera S","2025","Reproductive biology and endocrinology : RB&E","other","article","10.1186/s12958-025-01425-9","40604795","PMC12220628",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021752","Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia.","Lee CH","2011","Journal of neuroscience research","preclinical","article","10.1002/jnr.22596","21472764",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021753","Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.","Nicolucci A","2008","Acta bio-medica : Atenei Parmensis","narrative_review","article",null,"19260377",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0021754","Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).","Green JB","2024","Circulation","randomized_trial","article","10.1161/circulationaha.123.066604","38344820","PMC10978227","ClinicalTrials.gov:NCT01794143","S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021755","The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.","'t Hart LM","2013","Diabetes","other_trial","article","10.2337/db13-0227","23674605","PMC3749354",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021756","Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways.","Han L","2012","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2012.04.001","22560150",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021757","Parkinson's Disease and Diabetes Mellitus: Synergistic Effects on Pathophysiology and GI Motility.","Yan Y","2023","Current gastroenterology reports","narrative_review","article","10.1007/s11894-023-00868-7","37067721",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021758","Dietary resistant starch ameliorating lipopolysaccharide-induced inflammation in meat ducks associated with the alteration in gut microbiome and glucagon-like peptide 1 signaling.","Qin S","2022","Journal of animal science and biotechnology","other","article","10.1186/s40104-022-00735-x","35836245","PMC9284752",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0021759","[Victoza changes diabetes and lives of patients 5 years already].","Jiráčková J","2016","Vnitrni lekarstvi","other","article",null,"27180668",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021760","Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat.","Sebokova E","2010","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2010.01207.x","20590744",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021761","[News in Diabetology 2020].","Gariani K","2021","Revue medicale suisse","other","article",null,"33507658",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021762","Incretin-based therapy of type 2 diabetes mellitus.","Knop FK","2009","Current protein & peptide science","narrative_review","article","10.2174/138920309787315158","19275672",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021763","Reply to the letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial'.","Branch KRH","2022","European journal of heart failure","randomized_trial","article","10.1002/ejhf.2719","36224326",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Comment; letter"],["R0021764","Feasibility of once weekly exenatide-LAR and enhanced diabetes care in Indigenous Australians with type 2 diabetes (Long-acting-Once-Weekly-Exenatide laR-SUGAR, 'Lower SUGAR' study).","Ekinci EI","2021","Internal medicine journal","other_trial","article","10.1111/imj.15428","34142743",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Clinical Trial; Journal Article; article"],["R0021765","Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis.","Alafifi SA","2023","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-023-02504-7","37162541","PMC10567954",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; research-article; article"],["R0021766","Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.","Emoto M","2017","Endocrine journal","other_trial","article","10.1507/endocrj.ej16-0365","27853058",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0021767","Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.","Pratley RE","2008","Medscape journal of medicine","narrative_review","article",null,"18769687","PMC2525460",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0021768","The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss.","Bell DS","2014","The American journal of case reports","randomized_trial","article","10.12659/ajcr.890626","24753783","PMC3992216",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021769","DPP-4 Inhibitors and GLP-1 Receptor Agonists for Prevention or Delay of Type 2 Diabetes Mellitus and Associated Complications.","Smith DK","2018","American family physician","other","article",null,"29671556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021770","Targeting immunometabolic pathways for combination therapy in Alzheimer's disease.","Erichsen J","2023","Alzheimer's & dementia (New York, N. Y.)","other","article","10.1002/trc2.12423","37786483","PMC10541802",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021771","Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?","Packer M","2018","The American journal of medicine","commentary","article","10.1016/j.amjmed.2017.11.052","29309741",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0021772","Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study.","Funck KL","2022","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-022-01713-3","36496402","PMC9737743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021773","Liraglutide in type 2 diabetes: from pharmacological development to clinical practice.","Rossi MC","2009","Acta bio-medica : Atenei Parmensis","randomized_trial","article",null,"19848045",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Review; article"],["R0021774","Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.","Sakai T","2014","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00272.2014","25159327",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021775","Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Utzschneider KM","2025","Diabetes care","randomized_trial","article","10.2337/dc24-2419","39998948","PMC11932811",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0021776","Rodent models of diabetic kidney disease: human translatability and preclinical validity.","Sembach FE","2021","Drug discovery today","preclinical","article","10.1016/j.drudis.2020.05.004","32413492",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0021777","Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.","Christ E","2013","The lancet. Diabetes & endocrinology","other_trial","article","10.1016/s2213-8587(13)70049-4","24622317",null,null,"S000994","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0021778","Exenatide promotes cardiac lncRNAs HOX transcript antisense RNA (HOTAIR) in Wistar rats with liver cirrhosis; a novel role of GLP-1 receptor agonists in cirrhotic cardiomyopathy.","El-Kharashi OA","2019","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2019.05.024","31100415",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021779","Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats.","Cai H","2022","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2022.09.018","36116373",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021780","The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.","Asleh R","2018","Heart failure reviews","narrative_review","article","10.1007/s10741-017-9666-8","29270818",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021781","Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus.","Brunetti L","2008","Peptides","preclinical","article","10.1016/j.peptides.2008.04.007","18502539",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021782","[Postoperative dumping-syndrome with relevant impairment of glucose homeostasis - relief by continuous glucose monitoring and individual therapy with GLP-1 receptor agonists].","Leuz J","2021","Zeitschrift fur Gastroenterologie","other","article","10.1055/a-1324-4136","34130331",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021783","A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management.","Oshman L","2026","Obesity pillars","other","article","10.1016/j.obpill.2026.100304","42494804","PMC13393754",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021784","Exendin-4 protects INS-1 cells against palmitate-induced apoptosis through the IRE1α-Xbp1 signaling pathway.","Jiang D","2018","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2018.6240","30112049","PMC6090425",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021785","[Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].","Ohsugi M","2011","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"21595278",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0021786","Diabetes in People with HIV.","Sarkar S","2021","Current diabetes reports","narrative_review","article","10.1007/s11892-021-01382-8","33730223","PMC8208107",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review; research-article"],["R0021787","Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway.","Yu P","2019","International journal of endocrinology","preclinical","article","10.1155/2019/1567095","31236111","PMC6545813",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021788","Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease.","Yildirim Simsir I","2018","Diabetes & metabolic syndrome","narrative_review","article","10.1016/j.dsx.2018.03.002","29598932",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021789","Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Billion To $6.1 Billion.","Ippolito B","2024","Health affairs (Project Hope)","nonrandomized_study","article","10.1377/hlthaff.2024.00356","39146500",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021790","Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process.","Aviv V","2009","The Journal of biological chemistry","other","article","10.1074/jbc.m109.017608","19755420","PMC2785195",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021791","Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.","Kosiborod MN","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14890","36200477","PMC10092593","ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03548987","S000144; S000521; S001761","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021792","Glucagon-like peptide 1 and the cardiovascular system.","Fava S","2014","Current diabetes reviews","narrative_review","article","10.2174/1573399810666141030125830","25360712",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021793","Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.","Frías JP","2016","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(16)30267-4","27651331",null,"ClinicalTrials.gov:NCT02229396; ClinicalTrials.gov:NCT02597049","S000305; S000665; S000791; S000930; S002223","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0021794","Efficacy and safety of semaglutide in a diabetic and obese patient on incremental hemodialysis. Does it also contribute to preserving residual renal function?","de la Flor JC","2023","Nefrologia","commentary","article","10.1016/j.nefroe.2023.08.005","37658008",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0021795","Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.","Aroda VR","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14710","35373893","PMC9321749",null,"S000133; S000251; S001153; S001381; S001741; S002267","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021796","Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.","Kolterman OG","2003","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2002-021545","12843147",null,null,"S002115","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021797","An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.","Tacke F","2023","Journal of hepatology","narrative_review","article","10.1016/j.jhep.2023.03.038","37061196","PMC12164378",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article"],["R0021798","Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.","Perreault L","2022","Diabetes care","randomized_trial","article","10.2337/dc21-1785","35724304","PMC9862484","ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03611582; ClinicalTrials.gov:NCT03548987","S000144; S000521; S000988","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0021799","Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults.","Xiang J","2023","European review for medical and pharmacological sciences","nonrandomized_study","article","10.26355/eurrev_202310_34169","37916360",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021800","The liver-gut-brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives.","Ren Y","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1911290","42662708","PMC13520350",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0021801","Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions.","Imbernon M","2022","Cell metabolism","preclinical","article","10.1016/j.cmet.2022.06.002","35716660","PMC7613793",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021802","Response to \"Effects of Semaglutide on Cardiovascular Risk Factors and Eating Behaviors in Type 2 Diabetes\".","Venjhraj F","2023","Current problems in cardiology","commentary","article","10.1016/j.cpcardiol.2023.101802","37209797",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0021803","Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.","Jensterle M","2015","European journal of clinical pharmacology","other_trial","article","10.1007/s00228-015-1868-1","25991051",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021804","Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome.","Hoang V","2015","PloS one","preclinical","article","10.1371/journal.pone.0126119","26010091","PMC4444207",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021805","Improved human islet preparations using glucocorticoid and exendin-4.","Miki A","2014","Pancreas","other","article","10.1097/mpa.0000000000000184","25036907","PMC4206594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021806","Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists.","Fletcher MM","2018","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2018.09.003","30195733",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021807","Prognostic impact of metformin in patients with type 2 diabetes mellitus and acute heart failure: Combined analysis of the EAHFE and RICA registries.","Povar-Echeverría M","2023","Revista clinica espanola","randomized_trial","article","10.1016/j.rceng.2023.09.007","37717921",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0021808","Dysregulation of Lipid Droplet Protein Expression in Adipose Tissues and Association with Metabolic Risk Factors in Adult Females with Obesity and Type 2 Diabetes.","Park CY","2023","The Journal of nutrition","nonrandomized_study","article","10.1016/j.tjnut.2023.01.018","36931749",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021809","Inflammation-Induced Adverse Pregnancy and Neonatal Outcomes Can Be Improved by the Immunomodulatory Peptide Exendin-4.","Garcia-Flores V","2018","Frontiers in immunology","preclinical","article","10.3389/fimmu.2018.01291","29967606","PMC6015905",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021810","Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4.","Labouesse MA","2012","Journal of neuroendocrinology","preclinical","article","10.1111/j.1365-2826.2012.02364.x","22827554",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021811","Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms.","Ye J","2022","International journal of clinical practice","other","article","10.1155/2022/1786559","36311486","PMC9584744",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021812","Fractures in women with type 2 diabetes are associated with marked deficits in cortical parameters and trabecular plates.","Agarwal S","2024","Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","nonrandomized_study","article","10.1093/jbmr/zjae091","38861455","PMC11337576",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021813","Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway.","Chang SY","2013","Journal of cellular biochemistry","preclinical","article","10.1002/jcb.24425","23097217",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021814","FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients.","Dogan ADA","2024","BMC research notes","other_trial","article","10.1186/s13104-024-06820-w","38902794","PMC11188287","ClinicalTrials.gov:NCT03466021","S002322","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0021815","Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.","Bruen R","2017","Cardiovascular diabetology","preclinical","article","10.1186/s12933-017-0626-3","29110715","PMC5674826",null,"S000443","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0021816","A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.","Fakhoury WK","2010","Pharmacology","systematic_review","article","10.1159/000314690","20616619",null,null,"S000485","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review"],["R0021817","Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients.","Lawrence L","2018","Current cardiology reports","narrative_review","article","10.1007/s11886-018-1005-8","29926285",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021818","Factors Correlated to the Renoprotective Effect of Sitagliptin in Patients with Type 2 Diabetes Mellitus: Retrospective Observational Study.","Khunkit P","2024","Advances in pharmacological and pharmaceutical sciences","nonrandomized_study","article","10.1155/2024/7181515","39246417","PMC11379513",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021819","Exacerbation of atrial fibrillation related to dulaglutide use.","Lee J","2021","Clinical case reports","case_report","article","10.1002/ccr3.4223","34026191","PMC8123549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021820","MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.","Ambery PD","2018","British journal of clinical pharmacology","randomized_trial","article","10.1111/bcp.13688","29926478","PMC6138475",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021821","Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.","Iltz JL","2006","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2006.05.006","16861088",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0021822","Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy.","Butler J","2021","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","case_report","article","10.1093/ajhp/zxab045","33594405","PMC7929465",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0021823","No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.","Tatarkiewicz K","2013","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12040","23163898","PMC3654567",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021824","Semaglutide for managing overweight and obesity",null,"2023","National Institute for Health and Care Excellence (NICE), London","narrative_review","article",null,"40080622",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0021825","Exenatide substantially improves proinsulin conversion and cell survival that augment Ins2+/Akita beta cell function.","Tang W","2017","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2016.09.015","27658750",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021826","As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss.","Suran M","2023","JAMA","other","article","10.1001/jama.2023.2438","37099334",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021827","Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments.","Le GH","2025","CNS spectrums","narrative_review","article","10.1017/s109285292510045x","40790531","PMC13064781",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021828","Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes.","Dalle S","2013","Cellular signalling","narrative_review","article","10.1016/j.cellsig.2012.11.009","23159576",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021829","GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats.","Wu L","2012","Clinical science (London, England : 1979)","preclinical","article","10.1042/cs20090464","22054347",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021830","A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model.","Shi L","2017","Behavioural brain research","preclinical","article","10.1016/j.bbr.2017.03.032","28342971",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021831","GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys.","Lu SC","2021","Cell reports. Medicine","preclinical","article","10.1016/j.xcrm.2021.100263","34095876","PMC8149376",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021832","Do not forget diet and exercise during Ramadan.","Ilias I","2023","World journal of clinical cases","commentary","article","10.12998/wjcc.v11.i31.7738","38078134","PMC10698447",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0021833","Effects of Semaglutide on Cardiac Protein Expression and Cardiac Function of Obese Mice.","Pan X","2022","Journal of inflammation research","preclinical","article","10.2147/jir.s391859","36452054","PMC9704011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021834","Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome.","Alexiadou K","2020","Current diabetes reports","narrative_review","article","10.1007/s11892-020-01309-9","32436022","PMC7239829",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0021835","Effect of Liraglutide on endoplasmic reticulum stress in diabetes.","Zhao L","2013","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2013.10.026","24129189",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021836","Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: A single centre experience.","Santhakumar A","2024","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","nonrandomized_study","article","10.1016/j.jcf.2024.06.007","38997826",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0021837","Investigation of transport mechanism of exendin-4 across Madin Darby canine kidney cell monolayers.","Wang M","2012","Biological & pharmaceutical bulletin","preclinical","article","10.1248/bpb.35.745","22687411",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021838","Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.","Rotondo A","2013","International journal of obesity (2005)","other","article","10.1038/ijo.2012.101","22846777",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0021839","Once-Weekly Semaglutide in Adolescents with Obesity.","Snaith JR","2023","The New England journal of medicine","randomized_trial","article","10.1056/nejmc2300510","36947474",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Comment; article"],["R0021840","Duodenal-jejunal bypass changes the composition of the gut microbiota.","Kashihara H","2017","Surgery today","preclinical","article","10.1007/s00595-016-1373-x","27412617",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0021841","Body Weight Gain and Hyperphagia After Administration of SGLT-2 Inhibitor: A Case Report.","Hamamoto H","2015","The American journal of case reports","case_report","article","10.12659/ajcr.896233","26638727","PMC4675553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; research-article; article"],["R0021842","The inhibitory effects of Dulaglutide on cellular senescence against high glucose in human retinal endothelial cells.","Nian S","2022","Human cell","other","article","10.1007/s13577-022-00703-7","35583801",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021843","Intestinal TGR5-targeted carrier-drug conjugate improves glycemic control in mice and pigs.","Zhang Y","2025","Science translational medicine","preclinical","article","10.1126/scitranslmed.ado5177","41259536",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021844","Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.","Lind M","2012","Primary care diabetes","other","article","10.1016/j.pcd.2011.09.002","22015237",null,null,"S000766; S002357","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Multicenter Study; article"],["R0021845","Cardiometabolic drugs and kidney function – a drug target Mendelian randomisation study","Andries A","2025","medRxiv","other","preprint","10.1101/2025.06.16.25329403",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021846","Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.","Gupta NA","2014","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00210.2014","25258410","PMC4254956",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021847","Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency.","Bao W","2011","PloS one","preclinical","article","10.1371/journal.pone.0023570","21887274","PMC3162574",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021848","RF07 | PSUN366 An Uncommon Path Leading to Diagnosis of Multiple Endocrine Neoplasia 2A",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9629216",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0021849","Glucagon-like peptide-1 regulation of carbohydrate intake is differentially affected by obesogenic diets.","Pritchett CE","2012","Obesity (Silver Spring, Md.)","preclinical","article","10.1038/oby.2011.342","22134200","PMC3603269",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021850","Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice.","Sha S","2019","Endocrine","preclinical","article","10.1007/s12020-019-02081-x","31542859",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021851","Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.","Chen WR","2016","Circulation. Cardiovascular imaging","randomized_trial","article","10.1161/circimaging.116.005146","27940956",null,"ClinicalTrials.gov:NCT02001363","S000838","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0021852","Semaglutide: should the media slim down its enthusiasm?","McCartney M","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p624","36931642",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021853","Tirzepatide and kidney function: an intriguing and promising observation.","Solini A","2022","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(22)00258-3","36152638",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021854","Semaglutide: new dawn for diabetics.","Memon A","2023","JPMA. The Journal of the Pakistan Medical Association","commentary","article","10.47391/jpma.7558","36932797",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0021855","Impact of the 2021 European Society for Cardiology prevention guideline's stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease.","Holtrop J","2024","European journal of preventive cardiology","nonrandomized_study","article","10.1093/eurjpc/zwae038","38324720",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0021856","Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes.","Adinolfi LE","2026","Journal of clinical and experimental hepatology","narrative_review","article","10.1016/j.jceh.2025.103411","41480331","PMC12753517",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021857","Activity of brain stem glucagon neurons are modulated by energy state and encode sex and frequency-dependent negative valence and anxiety","Lopez C","2023","bioRxiv","preclinical","preprint","10.1101/2023.05.11.540425",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021858","Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.","Konig M","2021","Cardiovascular diabetology","other_trial","article","10.1186/s12933-021-01386-4","34563178","PMC8466679","ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021859","The effect of liraglutide on endothelial function in patients with type 2 diabetes.","Nandy D","2014","Diabetes & vascular disease research","randomized_trial","article","10.1177/1479164114547358","25212693",null,"ClinicalTrials.gov:NCT00620282","S000860","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021860","An update on diagnosis and therapeutics for type-2 diabetes mellitus.","Shyamaladevi B","2023","Bioinformation","other","article","10.6026/97320630019295","37808382","PMC10557433",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021861","[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].","Scheen AJ","2010","Revue medicale de Liege","other","article",null,"20857706",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0021862","In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4.","Selvaraju RK","2013","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.112.114066","23761918",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021863","GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side.","Dieter BP","2018","American journal of physiology. Renal physiology","narrative_review","article","10.1152/ajprenal.00211.2018","30110568","PMC6337002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0021864","Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass.","Fenske WK","2012","International journal of obesity (2005)","preclinical","article","10.1038/ijo.2011.126","21694700",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021865","Exendin-4 Protects MIN6 Cells from t-BHP-Induced Apoptosis via IRE1-JNK-Caspase-3 Signaling.","Chen WJ","2012","International journal of endocrinology","preclinical","article","10.1155/2012/549081","22518128","PMC3317221",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021866","Bidirectional effects of estradiol on the control of water intake in female rats.","Santollo J","2021","Hormones and behavior","preclinical","article","10.1016/j.yhbeh.2021.104996","34020111","PMC8277715",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0021867","Investigation of the effects of the glucagon-like peptide-1 mimetic exendin-4 on cardiac remodelling in diabetes","Tate M","2015","Queen's University Belfast","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0021868","Elucidating the Degradation Pathways of Human Insulin in the Solid State.","Fagan A","2024","Journal of analysis and testing","other","article","10.1007/s41664-024-00302-5","39184306","PMC11338979",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021869","Therapeutic utility of xenin based hybrid peptides for the treatment of obesity-diabetes","Hasib A","2017","Ulster University","preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0021870","Design, synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents.","Han J","2017","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2017.03.032","28342399",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021871","Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.","Fineman MS","2003","Diabetes care","randomized_trial","article","10.2337/diacare.26.8.2370","12882864",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021872","Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes.","Lee WC","2014","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12285","24581276",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021873","Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database.","Du P","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70790","42010884",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0021874","Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.","Henderson SJ","2016","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12735","27377054","PMC5129521",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021875","Correction: Yang et al. Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats. Polymers 2022, 14, 2181.","Yang JM","2023","Polymers","notice","article","10.3390/polym15132852","37447622","PMC10327623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0021876","[Retracted] Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway.","Qiao H","2024","Molecular medicine reports","notice","article","10.3892/mmr.2024.13192","38456535","PMC10955508",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; article"],["R0021877","Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks.","Ebell MH","2023","American family physician","other","article",null,"36689986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021878","Lipotoxicity impairs incretin signalling.","Poitout V","2013","Diabetologia","preclinical","article","10.1007/s00125-012-2788-6","23188391","PMC3537857",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment; research-article"],["R0021879","Liraglutide: can it make a difference in the treatment of type 2 diabetes?","Unger J","2010","International journal of clinical practice. Supplement","other","article","10.1111/j.1742-1241.2010.02497.x","20949698",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Introductory Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021880","Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics.","El Eid L","2022","Pharmacological research","narrative_review","article","10.1016/j.phrs.2022.106411","36007775",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0021881","Semaglutide in NASH-related cirrhosis: too late to the party?","Bril F","2023","The lancet. Gastroenterology & hepatology","commentary","article","10.1016/s2468-1253(23)00069-9","36934739",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021882","Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors.","Park BG","2022","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14546","34491605",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021883","Molecular mechanisms of β-cell dysfunction and death in monogenic forms of diabetes.","Sanchez Caballero L","2021","International review of cell and molecular biology","narrative_review","article","10.1016/bs.ircmb.2021.02.005","33832649",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0021884","Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression.","Shao Y","2015","Drug design, development and therapy","preclinical","article","10.2147/dddt.s79175","25733821","PMC4342181",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021885","Rybelsus® — erstes verfügbares orales GLP-1-Analogon : Typ-2-Diabetes.","Wedekind S","2020","MMW Fortschritte der Medizin","other","article","10.1007/s15006-020-0757-4","32780369",null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021886","Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells.","Al-Sabah S","2014","European journal of pharmacology","other","article","10.1016/j.ejphar.2014.08.019","25179575",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021887","Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications.","Körner M","2012","Frontiers in endocrinology","other","article","10.3389/fendo.2012.00158","23230431","PMC3515855",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021888","Cardioprotective potential of sulfated glycosaminoglycan from Amphioctopus marginatus against cardiotoxin-induced toxicity in human iPSC-derived cardiomyocytes.","Paulose SK","2026","International journal of biological macromolecules","other","article","10.1016/j.ijbiomac.2025.149049","41242449",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021889","Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.","Ebdrup BH","2012","BMC medicine","other","article","10.1186/1741-7015-10-92","22891821","PMC3573939",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; discussion; article"],["R0021890","Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.","Gallwitz B","2010","Drug safety","narrative_review","article","10.2165/11319130-000000000-00000","20082536",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021891","Semaglutide and laparoscopic sleeve gastrectomy in an adolescent with congenital adrenal hyperplasia due to 21-hydroxylase: a case report.","Vidmar AP","2025","Journal of medical case reports","case_report","article","10.1186/s13256-025-05047-y","39863876","PMC11765928",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0021892","Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.","Kapitza C","2017","Diabetologia","randomized_trial","article","10.1007/s00125-017-4289-0","28526920","PMC5491562","ClinicalTrials.gov:NCT02212067","S001219; S001486","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021893","Suppression of ROS Production by Exendin-4 in PSC Attenuates the High Glucose-Induced Islet Fibrosis.","Kim JW","2016","PloS one","preclinical","article","10.1371/journal.pone.0163187","27977690","PMC5157943",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021894","BIN1 deficiency leads to DNA damage and neuronal insulin resistance through ATM dysregulation","Jin Y","2025","bioRxiv","preclinical","preprint","10.1101/2025.08.20.671271",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021895","Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models.","Eldor R","2010","Journal of diabetes science and technology","preclinical","article","10.1177/193229681000400629","21129350","PMC3005065",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021896","Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.","Garvey WT","2022","Nature medicine","randomized_trial","article","10.1038/s41591-022-02026-4","36216945","PMC9556320","ClinicalTrials.gov:NCT03693430","S000214; S000735; S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021897","Correction to: Response to \"Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes\".","Cheema MRS","2023","Acta diabetologica","notice","article","10.1007/s00592-023-02078-z","36951996",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0021898","Phosphorylated proteomics-based analysis of the effects of semaglutide on hippocampi of high-fat diet-induced-obese mice.","Chen X","2023","Diabetology & metabolic syndrome","preclinical","article","10.1186/s13098-023-01023-y","36998046","PMC10064769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021899","Repeated Withdrawal of a GLPR Agonist Induces Hyperleptinemia and Deteriorates Metabolic Health in Obese Aging UM-HET3 Mice.","Jiang N","2025","Aging cell","preclinical","article","10.1111/acel.70210","40960340","PMC12507396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021900","Effects of exendin-4 on islets from type 2 diabetes patients.","Lupi R","2008","Diabetes, obesity & metabolism","commentary","article","10.1111/j.1463-1326.2007.00838.x","18201204",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0021901","The combination of insulin and GLP-1 analogues in the treatment of type 2 diabetes.","van der Klauw MM","2012","The Netherlands journal of medicine","randomized_trial","article",null,"23230012",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Review; article"],["R0021902","Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis.","Hogan AE","2011","Diabetologia","preclinical","article","10.1007/s00125-011-2232-3","21744074","PMC3188710",null,"S001234; S001754","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021903","Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin.","Thomson SC","2017","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00258.2017","28724607","PMC5668591",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021904","Liraglutide protects β-cell function by reversing histone modification of Pdx-1 proximal promoter in catch-up growth male rats.","Gao M","2018","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2018.08.002","30177467",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021905","[From GLP1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism.].","Winkler G","2023","Orvosi hetilap","narrative_review","article","10.1556/650.2023.32894","37865924",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; English Abstract; Journal Article; article"],["R0021906","Identification and functional assessment of GPCRs across human adipogenesis","Wu J","2026","bioRxiv","other","preprint","10.64898/2026.07.22.739785",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021907","Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.","Ahrén B","2017","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(17)30092-x","28385659",null,"ClinicalTrials.gov:NCT01930188","S001876","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0021908","Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).","Bifari F","2018","Pharmacological research","systematic_review","article","10.1016/j.phrs.2018.09.025","30359962",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0021909","Case report of an angiosarcoma of the abdominal wall during liraglutide injections: A coincidence?","Bergeron E","2022","International journal of surgery case reports","case_report","article","10.1016/j.ijscr.2022.107444","35878547","PMC9403282",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0021910","Anti-diabetic actions of esculentin-2CHa(1-30) and its stable analogues in a diet-induced model of obesity-diabetes.","Vasu S","2017","Amino acids","preclinical","article","10.1007/s00726-017-2469-3","28836148",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021911","Unexplained reciprocal regulation of diabetes and lipoproteins.","Higuchi S","2018","Current opinion in lipidology","narrative_review","article","10.1097/mol.0000000000000521","29708925","PMC6150711",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0021912","NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors.","Khanmohammadi S","2023","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2023.102788","37302383",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0021913","Tirzepatide highly effective for weight loss.","Tysoe O","2022","Nature reviews. Endocrinology","commentary","article","10.1038/s41574-022-00715-1","35760842",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0021914","Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.","Sun B","2020","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2020.592439","33584268","PMC7878391",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021915","Efficacy and Cardiovascular Safety of Antidiabetic Medications.","Pappachan JM","2021","Current drug safety","commentary","article","10.2174/1574886316666210112153429","33438554","PMC8080058",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0021916","Pharmacological antagonism of the incretin system protects against diet-induced obesity.","Svendsen B","2020","Molecular metabolism","preclinical","article","10.1016/j.molmet.2019.11.018","32029229","PMC6939028",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021917","A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.","Furihata K","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14572","34647404","PMC9299227",null,"S001115","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021918","Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes.","Farngren J","2019","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2019.06.016","31279738",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0021919","Letter regarding the article 'Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.","Ferreira JP","2022","European journal of heart failure","randomized_trial","article","10.1002/ejhf.2694","36114733",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Letter; Comment; article"],["R0021920","Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study.","Boye K","2021","Diabetes, obesity & metabolism","other","article","10.1111/dom.14244","33140575","PMC7839441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021921","Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.","Berry S","2023","Journal of medical economics","other_trial","article","10.1080/13696998.2023.2240957","37525970",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0021922","Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6.","Li R","2022","Drug design, development and therapy","preclinical","article","10.2147/dddt.s384884","36238196","PMC9553160",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021923","Diverse Genomes, Shared Health: Insights from a Health System Biobank.","Haas R","2025","medRxiv : the preprint server for health sciences","other","article","10.1101/2025.06.11.25329386","40585105","PMC12204455",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0021924","Liraglutide protects against glucolipotoxicity-induced RIN-m5F β-cell apoptosis through restoration of PDX1 expression.","Kornelius E","2019","Journal of cellular and molecular medicine","preclinical","article","10.1111/jcmm.13967","30353648","PMC6307795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021925","Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials.","Lin Q","2022","Expert review of clinical pharmacology","systematic_review","article","10.1080/17512433.2022.2130760","36180402",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0021926","Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases?","Sloop KW","2018","ACS pharmacology & translational science","narrative_review","article","10.1021/acsptsci.8b00009","32219200","PMC7088942",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021927","Separation of mono- and di-PEGylate of exenatide and resolution of positional isomers of mono-PEGylates by preparative ion exchange chromatography.","Nguyen NT","2016","Journal of chromatography. A","other","article","10.1016/j.chroma.2016.06.035","27363735",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021928","Dietary resistant starch ameliorating lipopolysaccharide-induced inflammation associated with alteration in gut microbiome and glucagon-like peptide 1 signaling","Qin S","2022","Research Square","other","preprint","10.21203/rs.3.rs-1285239/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021929","A genetic map of the mouse dorsal vagal complex and its role in obesity.","Ludwig MQ","2021","Nature metabolism","preclinical","article","10.1038/s42255-021-00363-1","33767443","PMC12009600",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0021930","Translating Basic Science to Clinical Applications: A Narrative Review of Repurposed Pharmacological Agents in Preclinical Models of Diabetic Neuropathy.","Andrei C","2025","Biomedicines","preclinical","article","10.3390/biomedicines13071709","40722780","PMC12292473",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0021931","Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.","Anagnostis P","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2010.01345.x","21205117",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0021932","Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial.","Besch G","2018","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-018-0784-y","30384842","PMC6211400","ClinicalTrials.gov:NCT01969149; EudraCT:2009-009254-25","S002033","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0021933","Appetite suppressant semaglutide is to be made available to treat obesity in England.","Iacobucci G","2023","BMJ (Clinical research ed.)","other","article","10.1136/bmj.p556","36889753",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021934","LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.","Barrington P","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2011.01365.x","21251179",null,null,"S001958","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; article"],["R0021935","[109th Scientific Meeting of the Japanese Society of Internal Medicine: educational lecture: 9. Incretin-based therapy for type 2 diabetes mellitus].","Inagaki N","2012","Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine","other","article","10.2169/naika.101.2698","23205457",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Lecture; article; conference-abstract"],["R0021936","Inflammatory mechanisms of pancreatic β-cell dysfunction and therapeutic strategies in type 2 diabetes mellitus: a narrative review.","Li T","2026","Journal of diabetes and metabolic disorders","randomized_trial","article","10.1007/s40200-026-02084-2","42787324","PMC13601428",null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Review"],["R0021937","Addressing the Continuum of Dysglycaemia and Vascular Complications in Prediabetes and Type 2 Diabetes: Need for Early and Intensive Treatment.","Ghannam N","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s396621","36760588","PMC9844108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021938","Exenatide exerts a neuroprotective effect against diabetic cognitive impairment in rats by inhibiting apoptosis: Role of the JNK/c‑JUN signaling pathway.","Wang G","2022","Molecular medicine reports","preclinical","article","10.3892/mmr.2022.12627","35119079","PMC8845025",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021939","The role of partial area under the curve and maximum concentrations in assessing the bioequivalence of long-acting injectable formulation of exenatide_A sensitivity analysis.","Wang HJ","2024","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","other","article","10.1016/j.ejps.2024.106718","38316168",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021940","Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat.","Bojanowska E","2011","Journal of physiology and pharmacology : an official journal of the Polish Physiological Society","preclinical","article",null,"22100840",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021941","Utilisation of compounds from venoms in drug discovery.","Trim CM","2021","Progress in medicinal chemistry","narrative_review","article","10.1016/bs.pmch.2021.01.001","34147202",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021942","Inhibition of Tumor Lipogenesis and Growth by Peptide-Based Targeting of SREBP Activation.","Luo S","2025","Advanced science (Weinheim, Baden-Wurttemberg, Germany)","preclinical","article","10.1002/advs.202508111","40959854","PMC12677653",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021943","Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs.","Huang X","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s411400","37366486","PMC10290856",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021944","Weight beneficial treatments for type 2 diabetes.","Meneghini LF","2011","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/jc.2011-1074","21900381",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021945","Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder.","Patel RN","2023","Kidney medicine","narrative_review","article","10.1016/j.xkme.2023.100705","38046909","PMC10692714",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0021946","Diabetes, Lipids, and CV Risk.","Škrha J","2021","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-021-00905-8","33464402",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0021947","Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity.","Nicolau J","2022","Physiology & behavior","other","article","10.1016/j.physbeh.2022.113967","36162525",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021948","Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways.","Erdogdu O","2013","Journal of molecular endocrinology","other","article","10.1530/jme-12-0166","23343509",null,null,"S001903","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021949","Extending the reach of Exendin-4: new pathways in the control of body weight and glucose homeostasis.","Good DJ","2012","Endocrinology","preclinical","article","10.1210/en.2012-1149","22523329","PMC3339655",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Comment; news; article"],["R0021950","Purification of family B G protein-coupled receptors using nanodiscs: Application to human glucagon-like peptide-1 receptor.","Cai Y","2017","PloS one","other","article","10.1371/journal.pone.0179568","28609478","PMC5469476",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021951","Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress.","Liu L","2014","Antioxidants & redox signaling","preclinical","article","10.1089/ars.2013.5519","24328731","PMC4174421",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021952","Role of Sodium-Glucose Co-Transporter 2 Inhibitors in Chronic Kidney Disease, Congestive Heart Failure and Stroke-A Review and Clinical Guide for Healthcare Professionals.","Singh P","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm12196202","37834846","PMC10574010",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021953","Cardiology: What You May Have Missed in 2024.","Khattak S","2025","Annals of internal medicine","narrative_review","article","10.7326/annals-25-00991","40163883",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0021954","Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials.","Verma S","2023","EClinicalMedicine","randomized_trial","article","10.1016/j.eclinm.2022.101737","36467859","PMC9713290",null,"S002726","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0021955","Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.","Franek E","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14760","35546279","PMC9543284","ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021956","GLP-1 receptor agonists, carotid atherosclerosis and retinopathy.","Rizzo M","2017","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2017.1342810","28612625",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial"],["R0021957","GLP-1 in patients with myocardial infarction complicated by cardiogenic shock-an IABP-SHOCK II-substudy.","Lehrke M","2024","Clinical research in cardiology : official journal of the German Cardiac Society","other_trial","article","10.1007/s00392-023-02366-2","38170249",null,"ClinicalTrials.gov:NCT00491036",null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Randomized Controlled Trial; Multicenter Study"],["R0021958","Exenatide: NMR/CD evaluation of the medium dependence of conformation and aggregation state.","Hudson FM","2004","Biopolymers","nonrandomized_study","article","10.1002/bip.20126","15386269",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021959","Human Beta Cell Mass Expansion In Vivo With A Harmine and Exendin-4 Combination: Quantification and Visualization By iDISCO+ 3D Imaging","Rosselot C","2020","bioRxiv","preclinical","preprint","10.1101/2020.07.24.220244",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0021960","Glycaemic management in diabetes: old and new approaches.","Ceriello A","2022","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(21)00245-x","34793722",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0021961","Liraglutide: a once-daily human glucagon-like peptide-1 analogue.","Aimaretti G","2009","Journal of endocrinological investigation","other","article","10.1007/bf03345744","19942822",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021962","[Perspectives in the management of childhood obesity].","Dubern B","2023","La Revue du praticien","other","article",null,"36820454",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0021963","Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice.","Winzell MS","2008","Journal of molecular endocrinology","preclinical","article","10.1677/jme-07-0121","18234911",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021964","Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.","Zhang X","2016","PloS one","nonrandomized_study","article","10.1371/journal.pone.0156393","27304904","PMC4909290",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0021965","Analysis of the interferences in quantitation of a site-specifically PEGylated exendin-4 analog by the Bradford method.","Qian X","2014","Analytical biochemistry","other","article","10.1016/j.ab.2014.06.009","24953009",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021966","Clinical impact of oral antidiabetic medications in heart failure patients.","Palazzuoli A","2018","Heart failure reviews","narrative_review","article","10.1007/s10741-018-9669-0","29359260",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0021967","GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK/NF-κB pathway in neuropathic pain mice.","Zhang LQ","2021","Neurobiology of learning and memory","preclinical","article","10.1016/j.nlm.2021.107463","34015440",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0021968","Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.","Frias JP","2021","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14469","34159708","PMC8518960",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021969","Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide.","Patoulias D","2022","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2022.07.003","35977865",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Meta-Analysis; article"],["R0021970","Tirzepatide to treat obesity: phase III results.","Hindson J","2022","Nature reviews. Gastroenterology & hepatology","other_trial","article","10.1038/s41575-022-00657-z","35773392",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; article"],["R0021971","Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner.","Zhao S","2012","International journal of obesity (2005)","preclinical","article","10.1038/ijo.2011.265","22249232","PMC3335926",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0021972","The possible synergistic action of sex hormones and glucagon-like peptide-1 (GLP-1) agonists on body mass decline in patients with type 2 diabetes mellitus.","Režić T","2019","Medical hypotheses","other","article","10.1016/j.mehy.2019.109308","31443779",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021973","Identification of key candidate genes and pathways revealing the protective effect of liraglutide on diabetic cardiac muscle by integrated bioinformatics analysis.","Dong Y","2020","Annals of translational medicine","nonrandomized_study","article","10.21037/atm.2020.01.94","32309328","PMC7154457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0021974","Preliminary Evidence Suggests That a 12-Week Treatment with Tirzepatide Plus Low-Energy Ketogenic Therapy Is More Effective than Its Combination with a Low-Calorie Diet in Preserving Fat-Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients with Obesity.","Schiavo L","2025","Nutrients","other","article","10.3390/nu17071216","40218974","PMC11990520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021975","Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.","Rampersaud N","2012","Neuropeptides","preclinical","article","10.1016/j.npep.2012.07.004","22921965",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"TRUE","Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; editorial"],["R0021976","Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial.","Kolkailah AA","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14941","36514266","PMC9991975",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021977","Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo.","Toki S","2018","The Journal of allergy and clinical immunology","preclinical","article","10.1016/j.jaci.2017.11.043","29331643","PMC9639650",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0021978","FAM3D: A gut secreted protein and its potential in the regulation of glucose metabolism.","Moser C","2023","Peptides","preclinical","article","10.1016/j.peptides.2023.171047","37328068",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021979","GLP-1 playing the role of a gut regulatory compound.","Hellström PM","2011","Acta physiologica (Oxford, England)","randomized_trial","article","10.1111/j.1748-1716.2010.02150.x","20518750",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0021980","Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.","Jacobsen LV","2009","British journal of clinical pharmacology","nonrandomized_study","article","10.1111/j.1365-2125.2009.03536.x","20002084","PMC2810801",null,"S000631; S001234","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0021981","Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.","Killion EA","2018","Science translational medicine","preclinical","article","10.1126/scitranslmed.aat3392","30567927",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0021982","Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.","Mali N","2022","BMC endocrine disorders","systematic_review","article","10.1186/s12902-022-01006-6","35392872","PMC8991462",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; research-article; review"],["R0021983","Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats.","Primeaux SD","2010","International journal of obesity (2005)","preclinical","article","10.1038/ijo.2010.78","20404826","PMC2910155",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0021984","An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.","Baggio LL","2008","Gastroenterology","preclinical","article","10.1053/j.gastro.2008.01.017","18313669",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0021985","Application of the integrated data platform combined with dietary management for adults with diabetes: A prospective randomized controlled trial.","Liu X","2024","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.14296","39171608","PMC11527811",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0021986","Analysis of Patient Education Guides Generated by ChatGPT and Gemini on Common Anti-diabetic Drugs: A Cross-Sectional Study.","Saji JG","2025","Cureus","other","article","10.7759/cureus.81156","40276455","PMC12020652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0021987","A novel anti-obesity mechanism for liraglutide by improving adipose tissue leptin resistance in high-fat diet-fed obese mice.","Lyu X","2022","Endocrine journal","preclinical","article","10.1507/endocrj.ej21-0802","35705299",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021988","Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects.","Pan H","2020","Artificial cells, nanomedicine, and biotechnology","preclinical","article","10.1080/21691401.2020.1770268","32468873",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0021989","Effect of Obesity Pharmacotherapy on anthropometrics, metabolic parameters and blood pressure in patients with obesity or overweight: An umbrella review of systematic reviews and meta-analyses of randomized clinical trials","Abedi-yekta A","2024","Research Square","systematic_review","preprint","10.21203/rs.3.rs-5522253/v1",null,null,null,null,"europepmc","FALSE","free_to_read","3",null,"Preprint"],["R0021990","Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor.","Yamaguchi S","2015","Diabetes research and clinical practice","case_report","article","10.1016/j.diabres.2015.05.008","26025695",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0021991","Exploring the relationship between problematic eating behaviors and bipolar disorder: A study on candidates for bariatric surgery.","Carmassi C","2025","Journal of affective disorders","other","article","10.1016/j.jad.2024.09.094","39293606",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0021992","Crosstalk of kidney and brain in diabetes-related cognitive impairment and therapeutic strategies.","Xu C","2025","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2025.1562518","40979705","PMC12443575",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0021993","Attempted suicide with liraglutide overdose did not induce hypoglycemia.","Nakanishi R","2013","Diabetes research and clinical practice","case_report","article","10.1016/j.diabres.2012.10.017","23149376",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0021994","A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes.","de Wit HM","2017","The Netherlands journal of medicine","other_trial","article",null,"28956786",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0021995","Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010.","Werner U","2008","Annales d'endocrinologie","other","article","10.1016/j.ando.2008.02.022","18417092",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0021996","Tetrazoles and Related Heterocycles as Promising Synthetic Antidiabetic Agents.","Trifonov RE","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms242417190","38139019","PMC10742751",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0021997","A high-fat diet catalyzes progression to hyperglycemia in mice with selective impairment of insulin action in Glut4-expressing tissues.","Reilly AM","2022","The Journal of biological chemistry","preclinical","article","10.1016/j.jbc.2021.101431","34801552","PMC8689209",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0021998","[Treatment strategies in diabetic nephropathy - Update 2022].","Schork A","2022","Deutsche medizinische Wochenschrift (1946)","other","article","10.1055/a-1911-0201","36318911",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0021999","Risk factors and drug discovery for cognitive impairment in type 2 diabetes mellitus using artificial intelligence interpretation and graph neural networks.","Zhang X","2023","Frontiers in endocrinology","other","article","10.3389/fendo.2023.1213711","37693358","PMC10485700",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; methods-article; article"],["R0022000","PLGA/HA sustained-release system loaded with liraglutide for the treatment of diabetic periodontitis through inhibition of necroptosis.","Pang Y","2025","Materials today. Bio","preclinical","article","10.1016/j.mtbio.2025.101582","40051526","PMC11883396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022001","Diabetes and Pancreas: Why So Difficult? Potential Mechanisms of Elevated Serum Pancreatic Enzymes.","Matteucci E","2016","Current medicinal chemistry","narrative_review","article","10.2174/0929867323666151207111201","26639098",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022002","Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes.","Liu J","2016","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2016.07.020","27503404",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022003","Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability.","Lally J","2018","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2018.1445968","29480037",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022004","Loureirin B activates GLP-1R and promotes insulin secretion in Ins-1 cells.","Ding Y","2021","Journal of cellular and molecular medicine","preclinical","article","10.1111/jcmm.16138","33300675","PMC7812269",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022005","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.","Gao W","2012","Drug metabolism and disposition: the biological fate of chemicals","preclinical","article","10.1124/dmd.111.042291","22338110","PMC3336795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0022006","Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.","Zinman B","2012","Diabetes, obesity & metabolism","systematic_review","article","10.1111/j.1463-1326.2011.01493.x","21883806",null,null,"S001094; S001502; S001584; S002098; S002222; S002230; S002361","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0022007","Novel role for the incretins in blood pressure regulation.","Yerram P","2012","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0b013e328356bccd","22871675",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022008","SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists.","Davidson MB","2019","Annals of internal medicine","nonrandomized_study","article","10.7326/acpj201912170-070","31842228",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comment; article"],["R0022009","Polymer-based delivery of glucagon-like Peptide-1 for the treatment of diabetes.","Kim PH","2012","ISRN endocrinology","narrative_review","article","10.5402/2012/340632","22701182","PMC3369441",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0022010","The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.","Batista AF","2018","The Journal of pathology","preclinical","article","10.1002/path.5056","29435980","PMC5947670",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022011","Incretin-based therapies for type 2 diabetes mellitus: New therapeutic mechanisms.","Kennedy L","2009","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.76.s5.01","19952299",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022012","Importance of beta cell mass for glycaemic control in people with type 1 diabetes.","Jansen TJP","2023","Diabetologia","other","article","10.1007/s00125-022-05830-2","36394644","PMC9669532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022013","Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis.","Ribeiro JC","2022","Biomedicines","preclinical","article","10.3390/biomedicines10051115","35625851","PMC9139030",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022014","Liraglutide attenuates hepatic iron levels and ferroptosis in db/db mice.","Song JX","2022","Bioengineered","preclinical","article","10.1080/21655979.2022.2051858","35311455","PMC9161873",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022015","A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?--Moving toward personalized management of type 2 diabetes mellitus.","Hirsch IB","2014","Postgraduate medicine","narrative_review","article","10.3810/pgm.2014.05.2763","24918799",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022016","GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation.","Bang-Berthelsen CH","2016","Inflammatory bowel diseases","preclinical","article","10.1097/mib.0000000000000847","27542128",null,null,"S001698","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022017","Semaglutide in Obesity: Unmet Needs in Men.","Jensterle M","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-022-01360-7","36609945","PMC9981825",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0022018","Incretins: Beyond type 2 diabetes.","Dandona P","2018","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13153","29364583",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022019","Correction to Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes.","Wang R","2022","ACS omega","notice","article","10.1021/acsomega.2c02325","35694462","PMC9178757",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0022020","Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.","Cai HY","2014","Neuroscience","preclinical","article","10.1016/j.neuroscience.2014.02.022","24583037",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022021","Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension.","Wang J","2019","Journal of biomedical science","preclinical","article","10.1186/s12929-019-0496-y","30634956","PMC6330403",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022022","Liraglutide inhibits AngII-induced cardiac fibroblast proliferation and ECM deposition through regulating miR-21/PTEN/PI3K pathway.","Wang J","2023","Cell and tissue banking","preclinical","article","10.1007/s10561-022-10021-9","35792987",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022023","A randomized, double-blind, placebo-controlled study of liraglutide 3 mg [LIRA 3mg] on weight, body composition, hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome (PCOS)","Elkind-Hirsch K","2021","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-799341/v1",null,null,"ClinicalTrials.gov:NCT03480022","S000534","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0022024","The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.","Shiraki A","2012","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2011.12.039","22284365",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022025","Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.","Larsen JR","2014","BMJ open","randomized_trial","article","10.1136/bmjopen-2013-004227","24667381","PMC3975765","ClinicalTrials.gov:NCT01845259; EudraCT:2013-000121-31","S001109","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; protocol; article"],["R0022026","In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor.","Wu Z","2011","Bioconjugate chemistry","preclinical","article","10.1021/bc200132t","21692471",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022027","Liraglutide: clinical pharmacology and considerations for therapy.","Sisson EM","2011","Pharmacotherapy","narrative_review","article","10.1592/phco.31.9.896","21923591",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022028","Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.","Tran H","2024","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2023.123680","38070657",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022029","Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.","Sicras-Mainar A","2016","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","nonrandomized_study","article","10.1016/j.endonu.2016.07.001","27744013",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Multicenter Study; Observational Study"],["R0022030","Innovative imaging of insulinoma: the end of sampling? A review.","Christ E","2020","Endocrine-related cancer","narrative_review","article","10.1530/erc-19-0476","31951592","PMC7040495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0022031","The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.","Aroda VR","2011","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.1202","21484979",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022032","Corrigendum to \"Exenatide ameliorates hydrogen peroxide-induced pancreatic β-cell apoptosis through regulation of METTL3-mediated m6A methylation\" [Eur. J. Pharmacol. 924 (2022) 174960].","Zhou S","2023","European journal of pharmacology","notice","article","10.1016/j.ejphar.2023.175652","36924576",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0022033","Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.","Li R","2022","Archives of gynecology and obstetrics","randomized_trial","article","10.1007/s00404-022-06700-3","35829765",null,"ChiCTR:ChiCTR-IIR-16008084","S001012","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022034","The Thyroid Pathologist Meets Therapeutic Pharmacology.","Sande CM","2023","Endocrine pathology","preclinical","article","10.1007/s12022-023-09749-1","36723855","PMC9890439",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Review; review-article"],["R0022035","Molecular Afterglow of Lophine-Based Luminophore and Its Imaging Applications.","Yang J","2025","Angewandte Chemie (International ed. in English)","preclinical","article","10.1002/anie.202507174","40852797","PMC12924693",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0022036","Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes.","Siasos G","2020","Current pharmaceutical design","randomized_trial","article","10.2174/1381612826666201109110107","33167826",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0022037","Semaglutide and social media: implications for young women with polycystic ovarian syndrome.","Keating SK","2023","The Lancet. Child & adolescent health","other","article","10.1016/s2352-4642(23)00033-0","36803633",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022038","Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.","West GM","2014","PloS one","other","article","10.1371/journal.pone.0105683","25180755","PMC4152014",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022039","Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.","Khunti K","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14400","33852202",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0022040","Metabolic syndrome in children.","Tagi VM","2020","Minerva pediatrica","narrative_review","article","10.23736/s0026-4946.20.05834-x","32274915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022041","New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury.","Chin KY","2017","Current drug targets","narrative_review","article","10.2174/1389450116666151001112020","26424394",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022042","Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.","Winther JB","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15693","38853300",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0022043","Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach.","Singh AK","2014","Indian journal of endocrinology and metabolism","randomized_trial","article","10.4103/2230-8210.139214","25285276","PMC4171882",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0022044","Incretin-based therapy and pancreatitis-what is the risk?","Sternthal E","2011","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","commentary","article","10.4158/ep11126.ed","21700560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0022045","Emerging treatment options for type 2 diabetes.","Piya MK","2010","British journal of clinical pharmacology","preclinical","article","10.1111/j.1365-2125.2010.03711.x","20831513","PMC2997303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0022046","Liraglutide attenuates the migration of retinal pericytes induced by advanced glycation end products.","Lin WJ","2018","Peptides","other","article","10.1016/j.peptides.2018.05.003","29746877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022047","The effect of liraglutide on renal function in type 2 diabetes: a meta-analysis of randomized controlled studies.","Luo C","2022","African health sciences","systematic_review","article","10.4314/ahs.v22i3.28","36910413","PMC9993257",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Meta-Analysis; Journal Article; research-article; review"],["R0022048","[Exendin-4 ameliorates high glucose- and TNF-α-induced vascular endothelial cell damage by inhibiting p38 MAPK and NF-κB p65 translocation].","Ke S","2012","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","other","article",null,"22931618",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0022049","Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects.","Sturm-Pellanda C","2015","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2015.08.022","26412802",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022050","The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study.","Rasmussen CB","2014","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2014.00140","25221543","PMC4145240",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0022051","Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.","Harreiter J","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-017-0249-4","28357772","PMC5446376","ClinicalTrials.gov:NCT02168491; EudraCT:2013-005334-37","S000598","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; article"],["R0022052","Association Between Serum Uric Acid to Creatinine Ratio and Time in Range in Patients With Type 2 Diabetes.","Gong Y","2025","Clinical endocrinology","other","article","10.1111/cen.70036","40947563",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022053","Structural basis for the identification of short novel peptides as potential GLP1R agonists using in silico approaches","Ghosh k","2022","Research Square","other_trial","preprint","10.21203/rs.3.rs-1721735/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0022054","A brush-polymer conjugate of exendin-4 reduces blood glucose for up to five days and eliminates poly(ethylene glycol) antigenicity.","Qi Y","2016","Nature biomedical engineering","preclinical","article","10.1038/s41551-016-0002","28989813","PMC5627778",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022055","Actions of novel hybrid peptides on hyperglycaemia and immunomodulation in experimental diabetes","Ofosu W","2020","University of East London","preclinical","article","10.15123/uel.8887z",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0022056","HOMA-S is associated with greater HbA1c reduction with a GLP-1 analogue in patients with type 2 diabetes.","Heald AH","2012","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","other","article","10.1055/s-0032-1309046","22639398",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022057","Chronic Liver Disease in the Older Patient-Evaluation and Management.","DiLeo DA","2023","Current gastroenterology reports","narrative_review","article","10.1007/s11894-023-00908-2","37991713",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022058","[Endocrine disease: progress in diagnosis and treatment. Topics: III. Recent topics; 1. Incretin-based therapy: present and future].","Yamada Y","2012","Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine","other","article","10.2169/naika.101.1021","22730731",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022059","Liraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue.","Gu J","2022","Journal of molecular endocrinology","preclinical","article","10.1530/jme-22-0026","35552259",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022060","Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.","Marso SP","2016","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1603827","27295427","PMC4985288","ClinicalTrials.gov:NCT01179048","S000138; S000291; S000371; S000393; S000485; S000665; S000760; S000767; S001352; S001496; S001837; S001945; S002431; S002481; S002571; S002726","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022061","Protective effect of Liraglutide on diabetic retinal neurodegeneration via inhibiting oxidative stress and endoplasmic reticulum stress.","Liu J","2020","Neurochemistry international","preclinical","article","10.1016/j.neuint.2019.104624","31794832",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022062","Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4.","Chen S","2012","Age (Dordrecht, Netherlands)","preclinical","article","10.1007/s11357-011-9303-8","21901364","PMC3448986",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022063","NUTRITIONAL INSULIN OR GLP-1 RECEPTOR AGONIST: CROSSROADS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS.","Garg R","2017","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","commentary","article","10.4158/ep-2017-0135","29190136",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0022064","Effect of Intestinal Flora on Hyperuricemia-Induced Chronic Kidney Injury in Type 2 Diabetic Patients and the Therapeutic Mechanism of New Anti-Diabetic Prescription Medications.","Yan W","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s429068","37794899","PMC10547008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022065","Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021.","Malik ME","2023","The Lancet regional health. Europe","nonrandomized_study","article","10.1016/j.lanepe.2023.100617","37265783","PMC10230617",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022066","Effects of GW002, a novel recombinant human glucagon-like peptide-1 (GLP-1) analog fusion protein, on CHO recombinant cells and BKS-db mice.","Ji WW","2017","Acta diabetologica","preclinical","article","10.1007/s00592-017-0992-z","28424924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022067","GLP-1 Increases Preovulatory LH Source and the Number of Mature Follicles, As Well As Synchronizing the Onset of Puberty in Female Rats.","Outeiriño-Iglesias V","2015","Endocrinology","preclinical","article","10.1210/en.2014-1978","26252058",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022068","Development of glucagon-like Peptide-1 lysosomal targeting chimeras for degradation of extracellular and membrane proteins.","Zhu L","2026","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2025.118473","41401593",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022069","Evaluation of ¹¹¹in-labelled exendin-4 derivatives containing different meprin β-specific cleavable linkers.","Jodal A","2015","PloS one","preclinical","article","10.1371/journal.pone.0123443","25855967","PMC4391719",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022070","Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria.","Haluzík M","2013","International journal of endocrinology","narrative_review","article","10.1155/2013/895102","24089613","PMC3780627",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0022071","New technologies and therapies in the management of diabetes.","Triplitt CL","2007","The American journal of managed care","narrative_review","article",null,"17417933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022072","A Spectroscopic and Molecular Dynamics Study on the Aggregation Properties of a Lipopeptide Analogue of Liraglutide, a Therapeutic Peptide against Diabetes Type 2.","Giannetti M","2023","Molecules (Basel, Switzerland)","other","article","10.3390/molecules28227536","38005270","PMC10674484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022073","Diabetic Ketoacidosis in a Patient With Type I Diabetes Treated With a Closed-Loop Sensor-Augmented Insulin Infusion System.","Sharma PP","2023","AACE clinical case reports","case_report","article","10.1016/j.aace.2023.04.010","37520760","PMC10382613",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022074","Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP/PKA/RhoA/ROCK2 signaling.","Fan S","2020","Acta biochimica et biophysica Sinica","preclinical","article","10.1093/abbs/gmaa038","32386193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022075","A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.","Seino Y","2022","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13789","35285173","PMC9340870","ClinicalTrials.gov:NCT02505334","S002164","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0022076","Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.","Valentine WJ","2011","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2011.09.022","22018679",null,"ClinicalTrials.gov:NCT00518882","S002230","pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Validation Study; article"],["R0022077","Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes.","Ferreira MC","2019","Diabetology & metabolic syndrome","other","article","10.1186/s13098-019-0401-6","30700996","PMC6347826",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022078","LBSUN306 Effects Of Glp-1 Receptor Agonism, Dpp4 Inhibition, And Hypocaloric Diet On Metabolic Parameters In Obese Pre-diabetic Individuals: A Randomized-controlled Trial",null,"2022","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC9629387",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0022079","Semaglutide exposures reported to the NSW Poisons Information Centre: effects of social media marketing and supply chain disruptions.","Cairns R","2023","Internal medicine journal","commentary","article","10.1111/imj.16059","37186363",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0022080","Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.","Bennett WL","2011","Annals of internal medicine","narrative_review","article","10.7326/0003-4819-154-9-201105030-00336","21403054","PMC3733115",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0022081","Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss.","Christoffersen BØ","2022","Obesity (Silver Spring, Md.)","narrative_review","article","10.1002/oby.23374","35333444","PMC9310705",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0022082","Liraglutide: a review of its use in the management of type 2 diabetes mellitus.","Perry CM","2011","Drugs","randomized_trial","article","10.2165/11208110-000000000-00000","22085389",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0022083","Response to \"Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes\".","Cheema MRS","2023","Acta diabetologica","commentary","article","10.1007/s00592-023-02061-8","36899150",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0022084","American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 1.","Croasdell G","2010","IDrugs : the investigational drugs journal","other","article",null,"20799136",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022085","Insulin Resistance is Associated with Clinical Manifestations of Diabetic Kidney Disease (Glomerular Hyperfiltration, Albuminuria, and Kidney Function Decline).","Adeva-Andany MM","2022","Current diabetes reviews","other","article","10.2174/1573399818666211117122604","34789129",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022086","Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.","Bonora E","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14465","34189841","PMC8518850",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022087","Spatially resolved multiomics of human cardiac niches.","Kanemaru K","2023","Nature","other","article","10.1038/s41586-023-06311-1","37438528","PMC10371870",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; article; preprint"],["R0022088","MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 Diabetes.","Lin L","2024","Journal of magnetic resonance imaging : JMRI","nonrandomized_study","article","10.1002/jmri.29174","38085104",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022089","Liraglutide therapy in an adolescent with Prader‑Willi syndrome and concomitant diabetes mellitus.","Li M","2023","Endokrynologia Polska","other","article","10.5603/ep.a2023.0011","36916545",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022090","HOXD9/APOC1 axis promotes macrophage M1 polarization to exacerbate diabetic kidney disease progression through activating NF-κB signaling pathway.","Feng Y","2024","Hereditas","nonrandomized_study","article","10.1186/s41065-024-00345-9","39511608","PMC11542400",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0022091","Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.","Frias JP","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14533","34463420","PMC9292947",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0022092","Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.","Meier JJ","2015","Diabetes care","randomized_trial","article","10.2337/dc14-1984","25887358",null,"ClinicalTrials.gov:NCT01596504","S001083","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022093","Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.","Aroda VR","2011","Postgraduate medicine","nonrandomized_study","article","10.3810/pgm.2011.09.2479","21904106",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0022094","PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses.","Treglia G","2021","Cancers","systematic_review","article","10.3390/cancers13205172","34680321","PMC8533943",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article"],["R0022095","Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019.","Heyward J","2021","Diabetes, obesity & metabolism","other","article","10.1111/dom.14408","33881795",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022096","GLP-1 agonist treatment: implications for diabetic retinopathy screening.","Varadhan L","2011","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2011.08.017","21906831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022097","Progressive Cholestasis and Biliary Cirrhosis After Initiating Oral Semaglutide: Report From the Drug-Induced Liver Injury Network.","Ma J","2022","ACG case reports journal","case_report","article","10.14309/crj.0000000000000922","36600793","PMC9794239",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0022098","Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells.","Chehade JM","2013","Metabolism: clinical and experimental","other","article","10.1016/j.metabol.2012.07.005","22901716",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022099","GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications.","Campbell JE","2023","Cell metabolism","narrative_review","article","10.1016/j.cmet.2023.07.010","37591245","PMC10528201",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0022100","Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes.","Younce CW","2014","Journal of molecular and cellular cardiology","preclinical","article","10.1016/j.yjmcc.2014.08.022","25200599","PMC4250388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022101","Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.","Vallon V","2014","Experimental physiology","narrative_review","article","10.1113/expphysiol.2014.078766","25085841","PMC4162767",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0022102","Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women.","Rodgers M","2021","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2021.742873","34867786","PMC8635796","ClinicalTrials.gov:NCT01590433","S000955","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022103","Endogenous incretin levels and risk of first incident cancer: a prospective cohort study.","Jujić A","2023","Scientific reports","nonrandomized_study","article","10.1038/s41598-023-27509-3","36611045","PMC9825393",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022104","[Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].","Consoli A","2011","Giornale italiano di cardiologia (2006)","preclinical","article","10.1714/985.10684","22158421",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022105","Albumin binding Nanofitins, a new scaffold to extend half-life of biologics - a case study with exenatide peptide.","Michot N","2022","Peptides","preclinical","article","10.1016/j.peptides.2022.170760","35150805",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022106","Glucagon-like peptide-1 and vitamin D: anti-inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells.","Einbinder Y","2016","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.2801","26991522",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022107","Letter to Editor. Re \"de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer,\" Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors?","Lee ATM","2023","Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","commentary","article","10.1016/j.jtho.2023.04.014","37599056",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0022108","Electrocardiographic, hemodynamic, and biochemical evidence on the protective effects of exenatide against phosphine-induced cardiotoxicity in rat model.","Bameri B","2021","Human & experimental toxicology","preclinical","article","10.1177/09603271211040819","34569344",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022109","The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide.","Lv J","2014","PloS one","preclinical","article","10.1371/journal.pone.0096833","24805918","PMC4013070",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022110","A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action.","Kim I","2011","Regulatory peptides","preclinical","article","10.1016/j.regpep.2011.02.008","21329731",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022111","Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.","Matikainen N","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13487","30073766","PMC6585708",null,"S000370","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022112","Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.","Schernthaner G","2022","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2022.155160","35143848",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022113","Discovery of a carboxyl fullerene derivative as a new lipid droplet regulator inhibiting MASLD.","Zou T","2026","Gut","preclinical","article","10.1136/gutjnl-2025-336268","41309225",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022114","GLP-1 receptor agonists: An example of the challenge for animal models to predict plaque instability/rupture and cardiovascular outcomes.","Ying YL","2017","Atherosclerosis","preclinical","article","10.1016/j.atherosclerosis.2017.08.006","28870630",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0022115","Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes.","Swift C","2025","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2024.12.014","39827023",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0022116","Novel Insights in the Physiopathology and Management of Obesity-Related Kidney Disease.","Sandino J","2022","Nutrients","narrative_review","article","10.3390/nu14193937","36235590","PMC9572176",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022117","Effects of Pharmacotherapy for the Treatment of Obesity in an Urban, Safety-Net Population.","Kim EK","2023","Cureus","nonrandomized_study","article","10.7759/cureus.47922","38034269","PMC10682737",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022118","Comparison of biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users: a cross-sectional study from Anuradhapura, Sri Lanka.","Rathish D","2019","Journal of health, population, and nutrition","other","article","10.1186/s41043-019-0160-x","30674350","PMC6343272",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0022119","Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.","Simeone PG","2025","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-025-02706-8","40514652","PMC12164075",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022120","Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide","A Astrup","2012","International journal of obesity (2005)","other","article","10.1038/ijo.2011.203",null,"PMC3461573",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","correction; Corrected and Republished Article; erratum"],["R0022121","SAT-584 Uc.336-As Inhibits White Adipocyte Differentiation and Promotes White to Brown Conversion","Li Y","2020","Journal of the Endocrine Society","other","article",null,null,"PMC7207302",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0022122","Liver histone H3 methylation and acetylation may associate with type 2 diabetes development.","Tu P","2015","Journal of physiology and biochemistry","preclinical","article","10.1007/s13105-015-0385-0","25666660",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0022123","Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector.","Snitker S","2022","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.14718","35434913","PMC9545130","ClinicalTrials.gov:NCT04007107; ClinicalTrials.gov:NCT04143945; EudraCT:2019-002284-10; EudraCT:2019-003654-83","S000528; S001051","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Research Support, Non-U.S. Gov't; Journal Article; letter; article"],["R0022124","[Cardiovascular benefits and underlying mechanisms of GLP-1 receptor agonists in patients with type 2 diabetes].","Ke J","2017","Zhonghua yi xue za zhi","other","article","10.3760/cma.j.issn.0376-2491.2017.28.002","28763894",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022125","In silico designing of putative peptides for targeting pathological protein Htt in Huntington's disease.","Kohli H","2021","Heliyon","narrative_review","article","10.1016/j.heliyon.2021.e06088","33659724","PMC7890153",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022126","Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.","Zhang DP","2020","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-020-0987-x","31969144","PMC6977298",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; other; review"],["R0022127","Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide.","Babajide O","2022","Cureus","case_report","article","10.7759/cureus.20938","35154922","PMC8815725",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0022128","[The value of incretin based therapies].","Gallwitz B","2009","Deutsche medizinische Wochenschrift (1946)","narrative_review","article","10.1055/s-0029-1222570","19421931",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022129","Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS.","Frøssing S","2018","Endocrine connections","randomized_trial","article","10.1530/ec-17-0327","29295870","PMC5754509",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0022130","Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?","Holst JJ","2022","Journal of internal medicine","narrative_review","article","10.1111/joim.13433","34982496",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022131","Combined effects of voluntary running and liraglutide on glucose homeostasis, fatty acid composition of brown adipose tissue phospholipids, and white adipose tissue browning in db/db mice.","Yin R","2022","The Chinese journal of physiology","preclinical","article","10.4103/cjp.cjp_87_21","35775530",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022132","Liraglutide ameliorates palmitate-induced insulin resistance through inhibiting the IRS-1 serine phosphorylation in mouse skeletal muscle cells.","Li Z","2018","Journal of endocrinological investigation","preclinical","article","10.1007/s40618-018-0836-x","29374854",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022133","Combination of metformin with liraglutide in treating HAIR-AN syndrome in children: A case report and literature review.","Li R","2023","Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences","case_report","article","10.11817/j.issn.1672-7347.2023.230100","38044655","PMC10929875",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Case Reports; Journal Article; research-article; review"],["R0022134","Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy.","Graham GV","2018","Peptides","preclinical","article","10.1016/j.peptides.2018.10.013","30391422",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022135","Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study.","Inaishi J","2022","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-022-00932-9","35016646","PMC8751111","jRCT:jRCTs031180320; UMIN:UMIN000016390",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; research-article; other; article"],["R0022136","The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.","Russell-Jones D","2010","International journal of clinical practice","narrative_review","article","10.1111/j.1742-1241.2010.02465.x","20716148",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022137","Exendin-4 relieves the inhibitory effects of high glucose on the proliferation and osteoblastic differentiation of periodontal ligament stem cells.","Guo Z","2018","Archives of oral biology","other","article","10.1016/j.archoralbio.2018.03.014","29621668",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022138","Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?","Lodato M","2023","Cells","preclinical","article","10.3390/cells12060940","36980281","PMC10047094",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022139","Tirzepatide Trial Demonstrates Substantial Weight Loss.","Slomski A","2022","JAMA","other_trial","article","10.1001/jama.2022.11895","35881126",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0022140","Tapping incretin-based therapy for type 2 diabetes.","Appel SJ","2011","Nursing","other","article","10.1097/01.nurse.0000394397.55390.75","21326056",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022141","Vildagliptin-induced acute pancreatitis.","Girgis CM","2011","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","case_report","article","10.4158/ep10383.cr","21324812",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0022142","Is Exenatide a Treatment for Parkinson's Disease?","Athauda D","2017","Journal of Parkinson's disease","randomized_trial","article","10.3233/jpd-171192","28777758",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0022143","Diabetic nephropathy: new approaches for improving glycemic control and reducing risk.","Schernthaner G","2013","Journal of nephrology","narrative_review","article","10.5301/jn.5000281","23807645",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022144","The Effects of Exercise Combined with Pharmacotherapy on Body Composition and Metabolic Parameters in Overweight/Obese Adults: A Meta-Analysis and Network Pharmacology Study.","Peng T","2026","Diabetes, metabolic syndrome and obesity : targets and therapy","systematic_review","article","10.2147/dmso.s590529","42094035","PMC13142718",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; article; review"],["R0022145","Use of Liraglutide for obesity in HIV. A case report","Singh S","2023","Research Square","case_report","preprint","10.21203/rs.3.rs-2776744/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0022146","Prevalence of Sarcopenia in Insulin Treated Older Adults with Type 2 Diabetes","Leite SAO","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-3216192/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0022147","D1 and D2 neurons in the nucleus accumbens enable positive and negative control over sugar intake in mice.","Sandoval-Rodríguez R","2023","Cell reports","preclinical","article","10.1016/j.celrep.2023.112190","36857179","PMC10154129",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022148","Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.","Daniels SJ","2019","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2018.12.130","30841472",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022149","The effects of glucagon-like peptide-1 on the beta cell.","Vilsbøll T","2009","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2009.01073.x","19878257",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022150","Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.","Bogman K","2019","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-019-00757-1","30968335",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022151","Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.","Hyde KM","2017","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2017.03.045","28366815","PMC5545097",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022152","Vesiculopustular dermatosis: an uncommon side-effect of liraglutide?","Besemer F","2012","Journal of diabetes and its complications","case_report","article","10.1016/j.jdiacomp.2012.05.018","22727533",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022153","The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo.","Nguyen HN","2011","Biomaterials","preclinical","article","10.1016/j.biomaterials.2010.12.044","21256586",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022154","GLP 1 Regulated Intestinal Cell's Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes.","Srivastava S","2019","Advanced pharmaceutical bulletin","preclinical","article","10.15171/apb.2019.039","31380261","PMC6664108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022155","Correction to: Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States.",null,"2023","Journal of the American Heart Association","notice","article","10.1161/jaha.121.027630","36892066","PMC10111536",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0022156","Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Kirkman MS","2024","Diabetes care","randomized_trial","article","10.2337/dc23-1332","38194519","PMC10973908",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0022157","Genetic and physiological insights into satiation variability predict responses to obesity treatment.","Cifuentes L","2025","Cell metabolism","randomized_trial","article","10.1016/j.cmet.2025.05.008","40482646","PMC12236147",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0022158","Gut-to-brain regulation of  <i>Drosophila<\/i>  aging through neuropeptide F, insulin and juvenile hormone","Chen J","2024","bioRxiv","other","article","10.1101/2024.06.26.600832","38979180",null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0022159","Downregulation of miR-139-5p contributes to the antiapoptotic effect of liraglutide on the diabetic rat pancreas and INS-1 cells by targeting IRS1.","Li J","2017","PloS one","preclinical","article","10.1371/journal.pone.0173576","28346520","PMC5367678",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022160","Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.","Rasouli N","2024","Diabetes care","randomized_trial","article","10.2337/dc23-1070","38211595","PMC10973918",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; other; article"],["R0022161","Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide.","Le Y","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-022-01310-3","35963931","PMC9500125","ChiCTR:ChiCTR-IPR-15006558",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022162","Controversies in nomenclature: From nonalcoholic steatohepatitis to the full spectrum of hepatic steatosis.","Romero-Gómez M","2025","Medicina clinica","narrative_review","article","10.1016/j.medcli.2025.107044","40513177",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0022163","Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy.","Hakim M","2022","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-022-09294-8","35488131",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Observational Study; Journal Article; article"],["R0022164","Effects of incretin-based therapy in patients with heart failure and myocardial infarction.","Mikhail N","2014","Endocrine","randomized_trial","article","10.1007/s12020-014-0175-4","24493030",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0022165","A second case of liraglutide-type localised amyloidosis.","Muhammad S","2023","Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis","other","article","10.1080/13506129.2022.2151889","36476295",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022166","Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.","Gao W","2011","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.110.175752","21156817","PMC3061535",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0022167","In vitro expansion of pancreatic islet clusters facilitated by hormones and chemicals.","Lin JY","2020","Cell discovery","preclinical","article","10.1038/s41421-020-0159-x","32284878","PMC7136205",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022168","Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.","Santini S","2023","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23596","36478514","PMC10107497",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; article"],["R0022169","Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase.","Malm-Erjefält M","2010","Drug metabolism and disposition: the biological fate of chemicals","other_trial","article","10.1124/dmd.110.034066","20709939",null,null,"S000967","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022170","Proinflammatory stress activates neutral sphingomyelinase 2 based generation of a ceramide-enriched β cell EV subpopulation.","Xu J","2024","bioRxiv : the preprint server for biology","other","article","10.1101/2024.04.17.589943","38659945","PMC11042299",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0022171","Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress.","Diz-Chaves Y","2020","Nutrients","narrative_review","article","10.3390/nu12113304","33126672","PMC7692797",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022172","The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials.","Alabduljabbar K","2022","Nutrients","narrative_review","article","10.3390/nu14112217","35684020","PMC9182751",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022173","Diet Composition and Host Genetics Interact to Modulate Gut Microbiota and Predisposition to Metabolic Syndrome in Spontaneously Hypertensive Stroke-Prone Rats (P08-023-19)","Singh A","2019","Current developments in nutrition","randomized_trial","article","10.1093/cdn/nzz044.p08-023-19",null,"PMC6818903",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0022174","Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.","Hao Q","2021","Annals of internal medicine","nonrandomized_study","article","10.7326/acpj202101190-011","33395335",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comment; editorial"],["R0022175","Semaglutide for Weight Loss: Was It Worth the Weight?: Erratum.",null,"2023","Cardiology in review","other","article","10.1097/crd.0000000000000504","36469361",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; erratum"],["R0022176","Presence of Mood and/or Anxiety Disorders Does Not Affect Success of Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease.","Bollinger B","2025","Digestive diseases and sciences","nonrandomized_study","article","10.1007/s10620-024-08724-y","39604664",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0022177","Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.","Aroda VR","2017","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(17)30085-2","28344112",null,"ClinicalTrials.gov:NCT02128932","S001219","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022178","Knowledge, Attitudes and Practices on the Use of Antidiabetic Medications for Weight Loss: A Cross-Sectional Study in the Lebanese Population.","Masri R","2026","Endocrinology, diabetes & metabolism","other","article","10.1002/edm2.70286","42447181","PMC13367752",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022179","New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024.","Tamargo J","2025","European heart journal. Cardiovascular pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvaf012","40058879","PMC12046579",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0022180","Liraglutide combined with metformin treatment for obese people with type 2 diabetes mellitus: a systematic review and meta-analysis.","Long Y","2023","Irish journal of medical science","systematic_review","article","10.1007/s11845-023-03337-2","37036569",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; review"],["R0022181","Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?","Kalogirou M","2018","World journal of hepatology","commentary","article","10.4254/wjh.v10.i11.790","30533179","PMC6280165",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0022182","Maternal-to-Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines.","Richardson K","2026","Clinical pharmacology and therapeutics","systematic_review","article","10.1002/cpt.70211","41670332","PMC13083373",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0022183","The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.","Mathiesen DS","2019","International journal of molecular sciences","other_trial","article","10.3390/ijms20174092","31443356","PMC6747202",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0022184","Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.","Marzullo P","2022","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-022-01799-2","35429298","PMC9270295",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022185","Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients With Type 2 Diabetes Mellitus Who Take Metformin.","Ebell MH","2023","American family physician","other","article",null,"37054429",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022186","Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature.","Singh AK","2021","Diabetes & metabolic syndrome","randomized_trial","article","10.1016/j.dsx.2020.12.026","33352455","PMC7832723",null,null,"pubmed; europepmc","TRUE","open_europepmc","2",null,"Journal Article; Review; review-article"],["R0022187","HIPPOCAMPAL GANGLIOSIDE COMPOSITION IS ALTERED BY METFORMIN AND LIRAGLUTIDE TREATMENT IN A HIGH-FAT HIGH-SUGAR DIET RAT MODEL.","Kuharić M","2023","Acta clinica Croatica","preclinical","article","10.20471/acc.2023.62.01.21","38304364","PMC10829952",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022188","Academic Detailing Compared with Group Meetings to Change Drug Prescribing for Type 2 Diabetes-A Randomized Controlled Trial.","Langaas HC","2024","Journal of general internal medicine","randomized_trial","article","10.1007/s11606-024-09014-z","39231850","PMC11618564",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; research-article; article"],["R0022189","The role of incretin-based therapies in the management of type 2 diabetes.","Bandyopadhyay P","2009","Drug news & perspectives","other","article","10.1358/dnp.2009.22.9.1434633","20072733",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Conference Proceedings; article"],["R0022190","Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.","Horton ES","2010","Diabetes care","nonrandomized_study","article","10.2337/dc09-2062","20460445","PMC2909058",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022191","Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2).","Wägner AM","2019","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2018.08.010","30223083",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0022192","Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.","Ban K","2010","Endocrinology","preclinical","article","10.1210/en.2009-1197","20172966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022193","Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.","Kadowaki T","2022","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(22)00008-0","35131037",null,"ClinicalTrials.gov:NCT03811574","S002102","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; article"],["R0022194","Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?","Killion EA","2020","Endocrine reviews","preclinical","article","10.1210/endrev/bnz002","31511854",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022195","A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study).","Jorsal A","2014","BMJ open","protocol","article","10.1136/bmjopen-2014-004885","24844271","PMC4039804","ClinicalTrials.gov:NCT01472640","S001211","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; protocol; article"],["R0022196","A novel GLP-1 analog, a dimer of GLP-1 via covalent linkage by a lysine, prolongs the action of GLP-1 in the treatment of type 2 diabetes.","Pan Y","2017","Peptides","preclinical","article","10.1016/j.peptides.2016.11.009","27965024",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022197","Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects.","Wu Q","2021","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2021.174203","34048741",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022198","Zwitterionic Polymer Conjugated Glucagon-like Peptide-1 for Prolonged Glycemic Control.","Tsao C","2020","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.0c00286","32510929",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0022199","Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease.","Unsal İO","2022","Scientific reports","other","article","10.1038/s41598-021-04361-x","34997159","PMC8741957",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022200","Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.","Armstrong MJ","2016","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(15)00803-x","26608256",null,"ClinicalTrials.gov:NCT01237119","S002015","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022201","Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus.","Li H","2010","Neuroscience letters","preclinical","article","10.1016/j.neulet.2010.09.040","20854877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022202","Alpha cells transdifferentiation in the pathophysiology and potential treatment of diabetes","Sarnobat DS","2020","Ulster University","preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0022203","Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)",null,"2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article",null,null,"PMC9067799","ClinicalTrials.gov:NCT03552757","S001740","europepmc","TRUE","open_europepmc","1",null,"Abstract"],["R0022204","Clinical Practice Guideline: Shared Decision Making, Diagnostic Evaluation, and Pharmacotherapy in Type 2 Diabetes.","Brockamp C","2023","Deutsches Arzteblatt international","other","article","10.3238/arztebl.m2023.0219","37874122","PMC10777312",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Practice Guideline; Journal Article; research-article; article"],["R0022205","A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo.","Gao M","2012","The Journal of pharmacy and pharmacology","preclinical","article","10.1111/j.2042-7158.2012.01545.x","23058052",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022206","Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.","Anholm C","2014","BMJ open","protocol","article","10.1136/bmjopen-2014-005942","25031198","PMC4401817","ClinicalTrials.gov:NCT01595789; EudraCT:2011-005405-78","S001197","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; protocol; article"],["R0022207","Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials.","Gao X","2022","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2022.935823","36188627","PMC9515581",null,"S002418","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0022208","GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?","Lovshin J","2015","Diabetes","commentary","article","10.2337/db15-0366","26106189",null,null,"S002726","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; article"],["R0022209","Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.","Thomson SC","2013","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00064.2012","23019232","PMC3543628",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0022210","Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.","O'Neil PM","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12963","28386912","PMC5655710",null,"S000492; S000532; S001278; S001402; S001792; S002315","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022211","Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.","Läppchen T","2017","PloS one","preclinical","article","10.1371/journal.pone.0170435","28103285","PMC5245897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022212","The metabolic effects and therapeutic utility of novel GLP-1/Glucagon receptor co-agonists in type 2 diabetes","Farooq G","2019","Imperial College London","other","article","10.25560/85332",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; article"],["R0022213","The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective.","Charokopou M","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.689","27200638",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022214","Current Practices and Challenges in Pediatric Obesity Management (POM): A Nationwide Survey of Physicians in Korea.","Lee Y","2026","Journal of Korean medical science","nonrandomized_study","article","10.3346/jkms.2026.41.e61","41664575","PMC12890466",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022215","Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.","Stonehouse A","2008","Current diabetes reviews","narrative_review","article","10.2174/157339908784220705","18473757",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022216","The Related Metabolic Diseases and Treatments of Obesity.","Yang M","2022","Healthcare (Basel, Switzerland)","narrative_review","article","10.3390/healthcare10091616","36141228","PMC9498506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022217","Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF₂ /HO-1 signaling.","Sleem M","2024","Die Pharmazie","preclinical","article","10.1691/ph.2024.4509","38877681",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022218","Liraglutide versus colesevelam for treating bile acid diarrhoea.","Zhang F","2022","The lancet. Gastroenterology & hepatology","commentary","article","10.1016/s2468-1253(22)00304-1","36370737",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0022219","Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors.","Heald AH","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-022-01259-3","35416588","PMC9006208",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022220","Glucagon-like peptide-1 agonist exendin-4 leads to reduction of weight and caloric intake in a rat model of hypothalamic obesity.","Elfers CT","2012","Hormone research in paediatrics","preclinical","article","10.1159/000338464","22831885",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022221","Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms.","Ghidewon M","2022","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14663","35129264","PMC9796095",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022222","Updates on New Therapies for Patients with CKD.","Tarun T","2024","Kidney international reports","narrative_review","article","10.1016/j.ekir.2023.10.006","38312786","PMC10831355",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022223","[GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients].","Marques AR","2015","Revue medicale suisse","narrative_review","article",null,"26211282",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0022224","Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway.","Liu Y","2021","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2021.663039","33953700","PMC8092357",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022225","[Effect of Liraglutide on platelet distribution width and carotid intima-media thickness in type 2 diabetic mellitus patients with obesity].","Meng XM","2023","Zhonghua yi xue za zhi","randomized_trial","article","10.3760/cma.j.cn112137-20220924-02018","37150681",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","English Abstract; Journal Article; Randomized Controlled Trial; other"],["R0022226","Autocrine Interleukin-10 Mediates Glucagon-Like Peptide-1 Receptor-Induced Spinal Microglial β-Endorphin Expression.","Wu HY","2017","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.1799-17.2017","29084866","PMC6705741",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022227","Tirzepatide adds hepatoprotection to its armoury.","Targher G","2022","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(22)00074-2","35468320",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0022228","Functionalized lipid nanoparticles modulate the blood-brain barrier and eliminate α-synuclein to repair dopamine neurons.","Wu X","2024","Asian journal of pharmaceutical sciences","preclinical","article","10.1016/j.ajps.2024.100904","38601010","PMC11004078",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022229","A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study).","Loganathan J","2022","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2022.108188","35382966",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022230","Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations.","Chao AM","2022","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s365416","36601368","PMC9807016",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022231","Liraglutide Nano-Preparation on Perioperative Neurocognitive Dysfunction in Aged Mice.","Zhang J","2022","Cellular and molecular biology (Noisy-le-Grand, France)","preclinical","article","10.14715/cmb/2022.68.3.39","35988182",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022232","Double-strand adeno-associated virus-mediated exendin-4 expression in salivary glands is efficient in a diabetic rat model.","Wang J","2014","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2013.12.006","24438876",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022233","Canagliflozin as a replacement therapy for patients with type 2 diabetes not responding to GLP-1 receptor agonists.","Garcia de Lucas MD","2017","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2017.03.007","28476578",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Observational Study; article"],["R0022234","Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids.","Kashihara H","2015","Journal of gastroenterology and hepatology","preclinical","article","10.1111/jgh.12690","25088988",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022235","LY6D promotes hepatic steatosis via the GRB2-AMPK-SREBP1 signaling axis.","Zhao Q","2026","International journal of obesity (2005)","preclinical","article","10.1038/s41366-026-02126-y","42332016",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022236","Zonation-dependent single-endothelial cell transcriptomic changes in the aged brain","Zhao L","2019","bioRxiv","preclinical","preprint","10.1101/800318",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0022237","Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin.","Tufvesson-Alm M","2022","Frontiers in psychiatry","preclinical","article","10.3389/fpsyt.2022.1092828","36699502","PMC9868418",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022238","Effectiveness and safety of insulin glargine Gla-300 in insulin-naïve type 2 diabetes subjects in a real-life setting-the GOAL_RO trial.","Stegaru D","2021","Annals of translational medicine","nonrandomized_study","article","10.21037/atm-20-4533","33569407","PMC7867914",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022239","Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies.","Ghosh N","2023","Biomedicines","narrative_review","article","10.3390/biomedicines11041126","37189744","PMC10135805",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022240","[Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].","Jódar E","2014","Medicina clinica","narrative_review","article","10.1016/s0025-7753(14)70103-4","25326838",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; English Abstract"],["R0022241","Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control.","Craig SL","2021","Biochimica et biophysica acta. General subjects","preclinical","article","10.1016/j.bbagen.2021.129917","33964357",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022242","Bariatric Surgery in Adolescents with Obesity: Long-Term Perspectives and Potential Alternatives.","Halloun R","2022","Hormone research in paediatrics","narrative_review","article","10.1159/000520810","34758466",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022243","Liraglutide blocks the proliferation, migration and phenotypic switching of Homocysteine (Hcy)-induced vascular smooth muscle cells (VSMCs) by suppressing proprotein convertase subtilisin kexin9 (PCSK9)/ low-density lipoprotein receptor (LDLR).","Ji J","2021","Bioengineered","preclinical","article","10.1080/21655979.2021.1982304","34666623","PMC8806487",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022244","Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.","Overgaard RV","2016","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-016-0410-7","27193270","PMC5069304",null,"S000492; S001792","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022245","Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.","Charbonnel B","2014","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2014.07.007","25130920",null,"ClinicalTrials.gov:NCT00715624; ClinicalTrials.gov:NCT00899958; ClinicalTrials.gov:NCT00975286","S000792; S002023","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0022246","Hyperglycemia-induced GLP-1R downregulation causes RPE cell apoptosis.","Kim DI","2015","The international journal of biochemistry & cell biology","preclinical","article","10.1016/j.biocel.2014.11.018","25483438",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0022247","Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.","Kim JY","2013","Life sciences","preclinical","article","10.1016/j.lfs.2013.01.001","23357248",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022248","Semaglutide alleviates inflammation-Induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes.","Pan X","2023","International immunopharmacology","preclinical","article","10.1016/j.intimp.2023.110196","37075674",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022249","Dual agonism at the glucagon and GLP-1 receptor -- haemodynamic effects in healthy male volunteers","Goodman J","2024","Authorea Preprints","randomized_trial","preprint","10.22541/au.171861520.06708642/v1",null,null,null,null,"europepmc; openalex","FALSE","free_to_read","2","FALSE","Preprint; preprint"],["R0022250","Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study.","Ito K","2023","Diabetology international","nonrandomized_study","article","10.1007/s13340-022-00592-z","36636162","PMC9829941",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022251","Second-line pharmacotherapy intensification after metformin monotherapy in type 2 diabetes: a nationwide register study from Finland during 2011-2022.","Rättö H","2024","BMC health services research","nonrandomized_study","article","10.1186/s12913-024-11325-0","39160557","PMC11331595",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0022252","Efficacy and safety of once-weekly dulaglutide in adult Chinese patients with type 2 diabetes and lower baseline body mass index.","Shi Y","2021","Journal of diabetes","commentary","article","10.1111/1753-0407.13147","33325105",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0022253","Early resuscitation with exendin-4 alleviates acute lung injury after hemorrhagic shock in rats.","Song X","2017","The Journal of surgical research","preclinical","article","10.1016/j.jss.2017.04.004","28807216",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022254","Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies.","McGill JB","2009","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2009.05.1998","19491536",null,null,"S001094; S001502; S001584; S002098; S002222; S002230","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Review; article"],["R0022255","Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists.","Girdhar K","2019","Journal of biomolecular structure & dynamics","other","article","10.1080/07391102.2018.1532818","30296922",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022256","Serum Fetuin-B Levels Are Elevated in Women with Metabolic Syndrome and Associated with Increased Oxidative Stress.","Xue S","2021","Oxidative medicine and cellular longevity","other_trial","article","10.1155/2021/6657658","34646426","PMC8505080","ChiCTR:ChiCTR-OCC-11001422",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022257","Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.","Cohen S","2022","Current diabetes reports","randomized_trial","article","10.1007/s11892-022-01461-4","35441935",null,"ClinicalTrials.gov:NCT03819153","S000953","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; article"],["R0022258","Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4.","Baraboi ED","2011","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00424.2010","21775649",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022259","Long-Term Mortality and SGLT2 Inhibitors in Type 2 Diabetes with and without Renal Impairment: An Observational Cohort Study.","Al-Muhaiteeb A","2024","Medical principles and practice : international journal of the Kuwait University, Health Science Centre","randomized_trial","article","10.1159/000537850","38359814","PMC11175602",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; article"],["R0022260","Diverse Obesity Trajectories in a Family Including Identical Twins with a Pathogenic <italic>MC4R<\/italic> Variant.","Lim JJX","2025","Obesity facts","case_report","article","10.1159/000546795","40562024","PMC12270488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0022261","Smart ultra-long-lasting sequentially triggerable and artfully implantable nozzle system for on-demand drug delivery for chronotherapy.","Zeng Q","2025","Science advances","other","article","10.1126/sciadv.adv8734","40561013","PMC12189948",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022262","Diagnostic Dilemmas and Current Treatment Approaches in Latent Onset Autoimmune Diabetes in Adults: A Concise Review.","Chandran L","2023","Current diabetes reviews","randomized_trial","article","10.2174/1573399818666220324095918","35331118",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0022263","Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes.","Bunck MC","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2010.01355.x","21205127",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0022264","The pattern of antidiabetic drugs and glycaemic control among type 2 diabetes patients in an Endocrinology Clinic in Lagos, Nigeria","Azeez TA","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.06.25.23291774",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0022265","Single-cell transcriptome reveals effects of semaglutide on non-cardiomyocytes of obese mice.","Pan X","2022","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2022.07.034","35843090",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022266","Glutamine up-regulates pancreatic sodium-dependent neutral aminoacid transporter-2 and mitigates islets apoptosis in diabetic rats.","Medras ZJH","2018","Pharmacological reports : PR","preclinical","article","10.1016/j.pharep.2017.10.009","29475006",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022267","Severe obesity in a specialist type 2 diabetes outpatient clinic: an Australian retrospective cohort study.","Thakur A","2021","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-021-00722-9","33757476","PMC7988916",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022268","[Role of exendin-4 in cardiovascular diseases].","Wang RJ","2012","Sheng li ke xue jin zhan [Progress in physiology]","narrative_review","article",null,"23520765",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022269","Synthesis and bioactivity evaluation of dipeptidyl peptidase IV resistant glucagon-like peptide-1 analogues.","Zhou J","2010","Protein and peptide letters","preclinical","article","10.2174/092986610792231546","20594158",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022270","Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.","Petit JM","2017","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2016-2775","27732328",null,null,"S000993","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; article"],["R0022271","Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.","Brown DX","2012","Journal of nutrition and metabolism","other","article","10.1155/2012/381713","23125920","PMC3483791",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022272","Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective.","Charokopou M","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.696","27200644",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022273","Treatment of type 2 diabetes with incretin-based therapies.","Madsbad S","2009","Lancet (London, England)","commentary","article","10.1016/s0140-6736(08)61247-7","18819704",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0022274","Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.","Trevaskis JL","2015","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12390","25204356",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0022275","Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis.","Zhong P","2022","Endocrine","systematic_review","article","10.1007/s12020-021-02945-1","34981419",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0022276","Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.","Lin D","2024","BMC medicine","randomized_trial","article","10.1186/s12916-024-03394-z","38807146","PMC11134614","ClinicalTrials.gov:NCT04855292","S003063","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Multicenter Study; research-article; other; article"],["R0022277","Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.","Yabe D","2022","Journal of diabetes investigation","other_trial","article","10.1111/jdi.13773","35174649","PMC9248424",null,"S000298","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0022278","Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.","Marso SP","2016","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1607141","27633186",null,"ClinicalTrials.gov:NCT01720446","S000291; S000371; S000485; S000497; S000760; S000868; S001260; S001263; S001467; S001837; S001933; S002234; S002481; S002534; S002571","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0022279","Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).","Rosenstock J","2013","Diabetes care","randomized_trial","article","10.2337/dc12-2709","23698396","PMC3781502","ClinicalTrials.gov:NCT00707031","S001439","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022280","Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes.","Malavazos AE","2023","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-23-0017","37551923","PMC10448542",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022281","Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.","Dungan KM","2016","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12575","26362460","PMC5061097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0022282","Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.","Kadowaki T","2022","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(22)00187-5","35914542",null,"ClinicalTrials.gov:NCT03861039","S001385","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022283","Lilly's tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics.","Mullard A","2022","Nature reviews. Drug discovery","commentary","article","10.1038/d41573-022-00094-2","35596075",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0022284","Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes.","Kong JH","2010","Biomaterials","preclinical","article","10.1016/j.biomaterials.2010.01.091","20149450",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022285","Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.","Vuppalanchi R","2024","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/apt.18042","38768298",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0022286","Lipidized PrRP Analog Exhibits Strong Anti-Obesity and Antidiabetic Properties in Old WKY Rats with Obesity and Glucose Intolerance.","Mráziková L","2023","Nutrients","preclinical","article","10.3390/nu15020280","36678151","PMC9864151",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022287","Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson's Disease.","Sancandi M","2018","Frontiers in cellular neuroscience","preclinical","article","10.3389/fncel.2018.00479","30618629","PMC6296349",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022288","The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.","Klausen MK","2022","British journal of pharmacology","preclinical","article","10.1111/bph.15677","34532853","PMC8820218",null,"S000504","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0022289","Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.","Wharton S","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14551","34514682","PMC9293236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0022290","Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France.","Detournay B","2021","PharmacoEconomics - open","nonrandomized_study","article","10.1007/s41669-020-00237-4","33215332","PMC8160062",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022291","p38β Mitogen-Activated Protein Kinase Signaling Mediates Exenatide-Stimulated Microglial β-Endorphin Expression.","Wu HY","2017","Molecular pharmacology","preclinical","article","10.1124/mol.116.107102","28202578",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022292","Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.","Shu Y","2022","Frontiers in public health","nonrandomized_study","article","10.3389/fpubh.2022.996179","36339230","PMC9631444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022293","Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.","Kaineder K","2017","International journal of obesity (2005)","preclinical","article","10.1038/ijo.2017.98","28507313","PMC5550563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022294","Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.","Malm-Erjefält M","2015","Molecular pharmaceutics","other","article","10.1021/acs.molpharmaceut.5b00278","26426736",null,null,"S000045","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022295","Sleeve gastrectomy decreased hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.","Zeng R","2023","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2023.02.071","36868075",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022296","Liraglutide versus colesevelam for treating bile acid diarrhoea - Authors' reply.","Kårhus ML","2022","The lancet. Gastroenterology & hepatology","commentary","article","10.1016/s2468-1253(22)00344-2","36370738",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0022297","One-pot two-step radiosynthesis of a new (18)F-labeled thiol reactive prosthetic group and its conjugate for insulinoma imaging.","Yue X","2014","Molecular pharmaceutics","preclinical","article","10.1021/mp5001857","24798315","PMC4224565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; research-article; article"],["R0022298","Corrigendum: Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: a real-world comparative cohort study.","Liao YN","2023","Frontiers in pharmacology","notice","article","10.3389/fphar.2023.1222106","37288108","PMC10243495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0022299","Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology.","Drucker DJ","2011","Diabetologia","commentary","article","10.1007/s00125-011-2297-z","21892687",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0022300","Hot Topics in Primary Care: Titratable Fixed-Ratio Combinations in Type 2 Diabetes Mellitus: Focus on GLP-1R Agonists Combined With Basal Insulin.","LaSalle J","2017","The Journal of family practice","case_report","article",null,"28375405",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0022301","Exendin-4 increases oxygen consumption and thermogenic gene expression in muscle cells.","Choung JS","2017","Journal of molecular endocrinology","preclinical","article","10.1530/jme-16-0078","27872157",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022302","State-dependent central synaptic regulation by GLP-1 is essential for energy homeostasis.","Wang L","2024","Research square","preclinical","article","10.21203/rs.3.rs-3929981/v1","38559032","PMC10980146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; article"],["R0022303","Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity","Rodrigo N","2023","Research Square","preclinical","preprint","10.21203/rs.3.rs-3734094/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0022304","Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.","Davidson JA","2017","Postgraduate medicine","other_trial","article","10.1080/00325481.2017.1387473","29083275",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0022305","Lowering blood glucose during hip surgery does not influence coagulation activation.","Sechterberger MK","2015","BBA clinical","randomized_trial","article","10.1016/j.bbacli.2015.03.001","26675337","PMC4661563",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0022306","The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes.","Seino Y","2012","Journal of diabetes investigation","randomized_trial","article","10.1111/j.2040-1124.2012.00193.x","24843595","PMC4019260","ClinicalTrials.gov:NCT00393718; ClinicalTrials.gov:NCT00395746; JapicCTI:JAPICCTI-060328; JapicCTI:JAPICCTI-060324","S000330; S000862","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0022307","A Long-Acting PYY3-36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates.","Rangwala SM","2019","Cell metabolism","other","article","10.1016/j.cmet.2019.01.017","30773465","PMC6701930",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0022308","Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.","Bizino MB","2020","Diabetologia","randomized_trial","article","10.1007/s00125-019-05021-6","31690988","PMC6890592","ClinicalTrials.gov:NCT01761318","S000566","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022309","Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.","Utzschneider KM","2024","Diabetes care","randomized_trial","article","10.2337/dc23-1059","38190619","PMC10973903",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0022310","Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.","McGlone ER","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2024.116888","38861859",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022311","Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats.","Gardiner SM","2006","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.105.093104","16221740",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022312","Therapeutic Advances in Diabetic Nephropathy.","Sawaf H","2022","Journal of clinical medicine","narrative_review","article","10.3390/jcm11020378","35054076","PMC8781778",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022313","Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.","Snitker S","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14809","35791625","PMC9805145","ClinicalTrials.gov:NCT04074161","S001600","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; Journal Article; letter; article"],["R0022314","Diets and drugs for weight loss and health in obesity - An update.","Aaseth J","2021","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2021.111789","34082399",null,null,"S002621","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0022315","Value of 68Ga-DOTATOC and Carbidopa-Assisted 18F-DOPA PET/CT for Insulinoma Localization.","Imperiale A","2022","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","nonrandomized_study","article","10.2967/jnumed.121.262401","34272321","PMC8978186",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022316","Comparison of the Tissue Distribution of a Long-Circulating Glucagon-like Peptide-1 Agonist Determined by Positron Emission Tomography and Quantitative Whole-Body Autoradiography.","Fernandes EFA","2022","ACS pharmacology & translational science","other","article","10.1021/acsptsci.2c00075","35990007","PMC9380726",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022317","Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats.","Jin L","2014","PloS one","preclinical","article","10.1371/journal.pone.0100798","24959755","PMC4069160",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022318","Factors associated with successful weight loss after liraglutide treatment for obesity.","Sannaa W","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14880","36193713","PMC9812862",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0022319","Insulinoma-Accurate Preoperative Localization Is the Key to Management: An Initial Experience.","Sharma A","2022","Indian journal of surgical oncology","nonrandomized_study","article","10.1007/s13193-022-01534-6","35782810","PMC9240150",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; research-article"],["R0022320","Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects.","Fan R","2011","PloS one","preclinical","article","10.1371/journal.pone.0020443","21655268","PMC3105063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022321","Incretin mimetics as a novel therapeutic option for hepatic steatosis.","Tushuizen ME","2006","Liver international : official journal of the International Association for the Study of the Liver","case_report","article","10.1111/j.1478-3231.2006.01315.x","16953843",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022322","Hierarchical Reaction Logic Enables Computational Design of Complex Peptide Syntheses.","Molga K","2025","Journal of the American Chemical Society","other","article","10.1021/jacs.4c17057","39977835",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022323","Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.","Neves JS","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14862","36082522","PMC9742170",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0022324","Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center.","Yoon JH","2021","Chonnam medical journal","nonrandomized_study","article","10.4068/cmj.2021.57.3.211","34621642","PMC8485082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022325","After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?","Doggrell SA","2015","Reviews on recent clinical trials","other_trial","article","10.2174/1574887110666150417164603","25881636",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0022326","Gila Monster Lizard & Incretin-mimetics.","Dhungat JP","2017","The Journal of the Association of Physicians of India","other","article",null,"28527176",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Historical Article; Journal Article; other"],["R0022327","Exendin-4 inhibits high-altitude cerebral edema by protecting against neurobiological dysfunction.","Sun ZL","2018","Neural regeneration research","preclinical","article","10.4103/1673-5374.230291","29722317","PMC5950675",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022328","Evolving Role for Pharmacotherapy in NAFLD/NASH.","Attia SL","2021","Clinical and translational science","other_trial","article","10.1111/cts.12839","32583961","PMC7877845",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0022329","Correction: Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study.","Yamada H","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-022-01365-2","36627460","PMC9981821",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0022330","Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials.","Verma S","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15081","37016488",null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0022331","18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.","Kiesewetter DO","2012","European journal of nuclear medicine and molecular imaging","preclinical","article","10.1007/s00259-011-1980-0","22170321","PMC3617488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; research-article; article"],["R0022332","Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.","Elian V","2024","International journal of molecular sciences","randomized_trial","article","10.3390/ijms25041972","38396657","PMC10888162",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0022333","[Incretin mimetic drugs: therapeutic positioning].","López Simarro F","2014","Semergen","other","article","10.1016/s1138-3593(14)74387-4","25311717",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0022334","The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size.","Scott KA","2007","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00323.2007","17581835",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0022335","Pancreatic alpha cells and glucagon secretion: Novel functions and targets in glucose homeostasis.","Wendt A","2022","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2022.102199","35245797",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review"],["R0022336","Anything New in the Treatment of Obesity in Obese Patients with CKD?","Sandino J","2022","Nephron","narrative_review","article","10.1159/000524201","35447624",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0022337","Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.","Nauck MA","2009","Diabetes care","randomized_trial","article","10.2337/dc08-1961","19366970","PMC2699710","ClinicalTrials.gov:NCT00423501","S002003","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022338","Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice.","Yue L","2022","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2022.995007","36419767","PMC9676360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022339","A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma.","Jeong BK","2024","Nature communications","preclinical","article","10.1038/s41467-024-50660-y","39090079","PMC11294468",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022340","Glucagon‐like peptide (GLP)‐1 analogues as an add‐on to insulin for adults with type 1 diabetes mellitus","Yamada T","2018","The Cochrane database of systematic reviews","narrative_review","article","10.1002/14651858.cd013164",null,"PMC6517174",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","systematic-review; Review; article"],["R0022341","Diagnosis and management of hyperglycaemia in patients treated with antipsychotic drugs.","Kosmalski M","2022","Endokrynologia Polska","other","article","10.5603/ep.a2022.0071","35971924",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022342","The gastrin-releasing peptide analog bombesin preserves exocrine and endocrine pancreas morphology and function during parenteral nutrition.","Pierre JF","2015","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00072.2015","26185331","PMC4572409",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0022343","[Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes].","Penninga E","2011","Ugeskrift for laeger","narrative_review","article",null,"21712007",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0022344","Evaluation of an [(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in Insulinoma.","Kiesewetter DO","2012","Theranostics","preclinical","article","10.7150/thno.5276","23139727","PMC3493201",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022345","IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.","Watada H","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-00730-y","31760599","PMC6965526","ClinicalTrials.gov:NCT02911948","S002038","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; other; article"],["R0022346","Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.","Kellerer M","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14765","35546450","PMC9545869","ClinicalTrials.gov:NCT03689374","S000363","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022347","EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS.","Carlson AL","2019","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep-2018-0177","30995433",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0022348","Liraglutide Improves Renal Endothelial Function in Obese Zucker Rats on a High-Salt Diet.","Sukumaran V","2019","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.118.254821","30910920",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022349","Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model.","Li T","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.117824","32445758",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022350","Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.","Liu L","2012","Hypertension (Dallas, Tex. : 1979)","preclinical","article","10.1161/hypertensionaha.112.195115","22868389",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022351","Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control.","Scheen AJ","2015","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2015.02.003","25794703",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022352","The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.","Blonde L","2009","Diabetes, obesity & metabolism","other_trial","article","10.1111/j.1463-1326.2009.01075.x","19878259",null,null,"S001094; S001502; S001584; S002098; S002222","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0022353","Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time-to-Event Outcomes Under ICH E9 (R1).","Deng Y","2025","Statistics in medicine","randomized_trial","article","10.1002/sim.70091","40386918",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0022354","Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats.","Prá M","2016","Biochemistry and cell biology = Biochimie et biologie cellulaire","preclinical","article","10.1139/bcb-2016-0016","27563837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022355","Insulin and liraglutide attenuate brain pathology in diabetic mice by enhancing the Wnt/β-catenin signaling pathway.","Zhao Y","2022","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2022.11366","35720633","PMC9185805",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022356","Glucagon-like peptide 1 receptor-mediated stimulation of a GABAergic projection from the bed nucleus of the stria terminalis to the hypothalamic paraventricular nucleus.","Povysheva N","2021","Neurobiology of stress","preclinical","article","10.1016/j.ynstr.2021.100363","34277897","PMC8271176",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0022357","[A 45-fold liraglutide overdose did not cause hypoglycaemia].","Madsen LR","2015","Ugeskrift for laeger","case_report","article",null,"25650514",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022358","Effect of liraglutide combined with metformin or acarbose on glucose control in type 2 diabetes mellitus and risk factors of gastrointestinal adverse reactions.","Ren G","2022","American journal of translational research","nonrandomized_study","article",null,"35702127","PMC9185051",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022359","Alogliptin for the treatment of Type 2 diabetes.","Seino Y","2014","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.2014.968553","30736193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022360","Effectiveness and Safety of Liraglutide in Managing Inadequate Weight Loss and Weight Regain after Primary and Revisional Bariatric Surgery: Anthropometric and Cardiometabolic Outcomes.","Elhag W","2022","Obesity surgery","nonrandomized_study","article","10.1007/s11695-021-05884-y","35060021",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0022361","Role of amylin in feeding and satiation.","Lutz TA","2025","Neuropharmacology","narrative_review","article","10.1016/j.neuropharm.2025.110587","40639451",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022362","Glucagon-Like peptide-1: A new therapeutic target to treat abdominal aortic aneurysm?","Raffort J","2018","Biochimie","systematic_review","article","10.1016/j.biochi.2018.06.026","30103898",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0022363","Euglycemic Diabetic Ketoacidosis Triggered by Sepsis in a Patient on Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor Therapy: A Case of Diagnostic and Therapeutic Challenges.","Ramalingam A","2025","Cureus","case_report","article","10.7759/cureus.87029","40741547","PMC12309426",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0022364","GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.","Grenet G","2019","PloS one","systematic_review","article","10.1371/journal.pone.0217701","31237921","PMC6592598","PROSPERO:CRD42016043823",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; research-article; review"],["R0022365","Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.","Gallwitz B","2005","Treatments in endocrinology","preclinical","article","10.2165/00024677-200504060-00005","16318402",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022366","Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice.","Chen X","2023","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2023.975830","37007007","PMC10063902",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022367","Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.","Fleischmann H","2017","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2016.12.014","27986406",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0022368","Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.","Stafford S","2022","Applied health economics and health policy","notice","article","10.1007/s40258-022-00734-z","35441978","PMC9206918",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0022369","GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes.","Love KM","2020","Journal of diabetes","narrative_review","article","10.1111/1753-0407.13045","32274893","PMC8393916",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0022370","Cardiorenal Disease and Heart Failure with Preserved Ejection Fraction: Two Sides of the Same Coin.","Núñez-Marín G","2025","Cardiorenal medicine","narrative_review","article","10.1159/000543390","39778558","PMC11844673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022371","Exendin-4 and exercise improve hepatic glucose homeostasis by promoting insulin signaling in diabetic rats.","Park S","2010","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2009.06.026","19766272",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022372","Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.","Olaywi M","2013","Hepatobiliary & pancreatic diseases international : HBPD INT","nonrandomized_study","article","10.1016/s1499-3872(13)60092-2","24322742",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0022373","Exendin-4 regulates GLUT2 expression via the CaMKK/CaMKIV pathway in a pancreatic β-cell line.","Chen K","2011","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2010.06.002","20598720",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022374","Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes.","Korytkowski MT","2015","Journal of diabetes science and technology","other","article","10.1177/1932296814564183","25526759","PMC4604553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022375","An Unusual Case of an Acute Episode of Restless Leg Syndrome Following Oral Metoclopramide Therapy.","Aljunaid MA","2024","Cureus","case_report","article","10.7759/cureus.53754","38327722","PMC10848601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0022376","Adaptive beta-cell proliferation is severely restricted with advanced age.","Rankin MM","2009","Diabetes","preclinical","article","10.2337/db08-1198","19265026","PMC2682671",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022377","Exendin-4 protects murine MIN6 pancreatic β-cells from interleukin-1β-induced apoptosis via the NF-κB pathway.","Liu XH","2013","Journal of endocrinological investigation","preclinical","article","10.3275/8938","23609920",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022378","The effects of GLP-1 analogues on pre-diabetes of the children.","Zhou QX","2017","Experimental and therapeutic medicine","randomized_trial","article","10.3892/etm.2017.4129","28413488","PMC5377282",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0022379","Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics.","Kabahizi A","2022","British journal of pharmacology","narrative_review","article","10.1111/bph.15682","34519026","PMC8820188",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; review-article; article"],["R0022380","Tirzepatide as an Insulin Sensitizer.","Ferrannini E","2022","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/clinem/dgab803","34788445",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Editorial; Comment; article"],["R0022381","Enhanced Peptide Stability Against Protease Digestion Induced by Intrinsic Factor Binding of a Vitamin B12 Conjugate of Exendin-4.","Bonaccorso RL","2015","Molecular pharmaceutics","other","article","10.1021/acs.molpharmaceut.5b00390","26260673","PMC4660977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022382","Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.","Ghazi T","2014","Diabetes care","other_trial","article","10.2337/dc13-1169","23939544","PMC3968447",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022383","CXCR4 positive cell-derived Pdx1-high/Shh-low cells originated from embryonic stem cells improve the repair of pancreatic injury in mice.","Yu T","2015","Cell biology international","preclinical","article","10.1002/cbin.10470","25820869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"TRUE","Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; article"],["R0022384","The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes.","Zhang L","2022","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2022.677202","35432194","PMC9009038","ClinicalTrials.gov:NCT03297879","S001093","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022385","Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.","Greig NH","2014","Alzheimer's & dementia : the journal of the Alzheimer's Association","other","article","10.1016/j.jalz.2013.12.011","24529527","PMC4201593",null,"S000204","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022386","Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.","Nauck MA","2016","Diabetologia","randomized_trial","article","10.1007/s00125-015-3795-1","26577795","PMC4705137","ClinicalTrials.gov:NCT00849017","S000852","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022387","Enzymatic absorption promoters for non-invasive peptide delivery.","Steiger MB","2025","Journal of controlled release : official journal of the Controlled Release Society","other","article","10.1016/j.jconrel.2025.113675","40164434",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022388","GLP-1 receptor agonist confer target organ protection in type 2 diabetes.","Bonnet F","2017","Diabetes & metabolism","commentary","article","10.1016/s1262-3636(17)30066-6","28431665",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0022389","Exendin-4 protects murine pancreatic β-cells from dexamethasone-induced apoptosis through PKA and PI-3K signaling.","Wang LX","2010","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2010.09.004","20889222",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022390","Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.","Diamant M","2014","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(14)70029-4","24731672",null,"ClinicalTrials.gov:NCT00641056","S001768","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022391","Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice.","Sasaki S","2015","Diabetologia","preclinical","article","10.1007/s00125-015-3728-z","26290048",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0022392","Random glucose GWAS in 493,036 individuals provides insights into diabetes pathophysiology, complications and treatment stratification","Lagou V","2021","medRxiv","other","preprint","10.1101/2021.04.17.21255471",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0022393","Pathological Glucose Levels Enhance Entry Factor Expression and Hepatic SARS-CoV-2 Infection.","Rao G","2025","Journal of cellular and molecular medicine","other","article","10.1111/jcmm.70581","40442985","PMC12122388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022394","Pharmaceutical approval update.","Gohil K","2014","P & T : a peer-reviewed journal for formulary management","other","article",null,"25516691","PMC4264668",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; other"],["R0022395","LBODP038 Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9624823",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0022396","A Novel Long-Acting Glucagon-Like Peptide-1 Agonist with Improved Efficacy in Insulin Secretion and β-Cell Growth.","Kim HY","2014","Endocrinology and metabolism (Seoul, Korea)","other","article","10.3803/enm.2014.29.3.320","25309791","PMC4192806",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022397","Preparation of Nanocomposite Peptide and Its Inhibitory Effect on Myocardial Injury in Type-II Diabetic Rats.","Zhang Y","2021","Journal of nanoscience and nanotechnology","preclinical","article","10.1166/jnn.2021.18652","33183487",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022398","Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.","Han C","2021","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.0c00995","34240881",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022399","Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables.","Ji LN","2013","BMC public health","other","article","10.1186/1471-2458-13-602","23800082","PMC3729491",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0022400","Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals.","Wang Y","2022","Bioengineered","preclinical","article","10.1080/21655979.2022.2051859","35383532","PMC9161981",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022401","Obesity and pancreatitis.","Khatua B","2017","Current opinion in gastroenterology","narrative_review","article","10.1097/mog.0000000000000386","28719397","PMC6640854",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0022402","Current Drug Targets in Obesity Pharmacotherapy - A Review.","Bhat SP","2017","Current drug targets","narrative_review","article","10.2174/1389450118666170227153940","28245771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022403","Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.","Cheng H","2022","Diabetes care","randomized_trial","article","10.2337/dc21-2064","35263425",null,"ClinicalTrials.gov:NCT03961659","S000596; S001736","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; other; article"],["R0022404","Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.","Eom YS","2016","PloS one","preclinical","article","10.1371/journal.pone.0168569","27997588","PMC5172620",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022405","Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells.","Jalewa J","2016","Journal of neurochemistry","other","article","10.1111/jnc.13736","27412483",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022406","Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.","Tonneijck L","2016","Diabetes care","randomized_trial","article","10.2337/dc16-1371","27585605",null,"ClinicalTrials.gov:NCT01744236","S002312","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; article"],["R0022407","The changing landscape of type 2 diabetes: the role of incretin-based therapies in managed care outcomes.","Triplitt C","2007","Journal of managed care pharmacy : JMCP","narrative_review","article","10.18553/jmcp.2007.13.9-c.1","18062735","PMC10438357",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0022408","Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients.","Correale M","2023","Heart failure reviews","narrative_review","article","10.1007/s10741-021-10157-y","34379224",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022409","GLP-1 Receptor Activation Inhibits Palmitate-Induced Apoptosis via Ceramide in Human Cardiac Progenitor Cells.","Leonardini A","2017","The Journal of clinical endocrinology and metabolism","other","article","10.1210/jc.2017-00970","28938428",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022410","Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study.","Long X","2023","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","randomized_trial","article","10.1080/09513590.2023.2223648","37406658",null,"ChiCTR:ChiCTR1900024384",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0022411","Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.","Sposito AC","2019","Cardiovascular diabetology","notice","article","10.1186/s12933-019-0825-1","30823882","PMC6396451",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0022412","Stressing diabetes? The hidden links between insulinotropic peptides and the HPA axis.","Diz-Chaves Y","2016","The Journal of endocrinology","preclinical","article","10.1530/joe-16-0118","27325244",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0022413","An update on gut microbiota: Its interaction with nutrients and metabolic syndrome","Haq Iu","2025","Nutrition clinique et métabolisme","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Journal Article"],["R0022414","Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials.","Jakhar DK","2023","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2023.122585","36621703",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022415","Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series.","Cariou B","2015","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2014.10.004","25457472",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0022416","Systematic Review of Therapeutic Strategies for Reducing Parkinson's Disease Symptoms and Progression.","Tumu S","2025","Cureus","systematic_review","article","10.7759/cureus.99206","41536408","PMC12799224",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0022417","Exendin-4 dose-dependently stimulates somatostatin and insulin secretion in perfused rat pancreas.","Egido EM","2004","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","preclinical","article","10.1055/s-2004-825921","15486809",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022418","Treating prediabetes: why and how should we do it?","Braga T","2019","Minerva medica","randomized_trial","article","10.23736/s0026-4806.18.05897-4","30371047",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0022419","Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials.","Iannone A","2023","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.15138","37254688",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; review"],["R0022420","Complexation of exenatide and cyclodextrin: An approach for the stabilization and sustained release of exenatide in PLGA microsphere.","Park H","2021","Carbohydrate polymers","preclinical","article","10.1016/j.carbpol.2021.118169","34044960",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022421","Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.","Freeman JS","2009","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.76.s5.03","19952298",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022422","Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.","Fralick M","2020","Annals of internal medicine","nonrandomized_study","article","10.7326/m19-2610","31931526","PMC7217750",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022423","Modified case-crossover estimators were unbiased in the presence of temporal trends in the exposure of interest: a simulation study.","Egsgaard S","2026","Journal of clinical epidemiology","nonrandomized_study","article","10.1016/j.jclinepi.2026.112291","42066966",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0022424","Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study.","Nagao M","2023","Scientific reports","randomized_trial","article","10.1038/s41598-022-27301-9","36599895","PMC9813363","UMIN:UMIN000010376",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022425","Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.","Han J","2014","British journal of pharmacology","preclinical","article","10.1111/bph.12843","25039358","PMC4294038",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022426","[Efficacy and safety of Cytoflavin in the treatment of diabetic polyneuropathy: results of a multicenter, double-blind, placebo-controlled, randomized CYLINDER study].","Strokov IA","2023","Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","randomized_trial","article","10.17116/jnevro2023123051100","37315248",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Multicenter Study; English Abstract; Journal Article; article"],["R0022427","Hypoglycemic drug liraglutide alleviates low muscle mass by inhibiting the expression of MuRF1 and MAFbx in diabetic muscle atrophy.","Fan D","2023","Journal of the Chinese Medical Association : JCMA","preclinical","article","10.1097/jcma.0000000000000807","36279106","PMC12755461",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022428","The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.","Mann RJ","2010","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2010.00834.x","20649595","PMC2958643",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022429","Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety.","Garcia DE Lucas MD","2025","Minerva endocrinology","nonrandomized_study","article","10.23736/s2724-6507.23.03985-4","37337740",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Multicenter Study; article"],["R0022430","Glucagon-like peptide-1 receptor expression in the human eye.","Hebsgaard JB","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13339","29707863","PMC6099507",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0022431","Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes.","Lin CH","2015","Journal of diabetes research","other","article","10.1155/2015/176949","25785276","PMC4345081",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022432","An Introduction to Tirzepatide.","Bertsch T","2022","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd22-0038","35983423","PMC9331617",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022433","Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: Secondary analyses of a randomised controlled trial.","Bartholdy C","2022","Osteoarthritis and cartilage open","randomized_trial","article","10.1016/j.ocarto.2022.100255","36475294","PMC9718081",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0022434","Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).","Janić M","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","protocol","article","10.1007/s13300-022-01226-y","35258841","PMC8989913","ClinicalTrials.gov:NCT05147896","S001858","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022435","Glucagon‐like peptide (GLP)‐1 analogues for normoglycaemic, overweight or obese adults","Mazzucca A","2017","The Cochrane database of systematic reviews","narrative_review","article","10.1002/14651858.cd012793",null,"PMC6483777",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","systematic-review; Review; article"],["R0022436","The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.","Ehlers LH","2022","Journal of comparative effectiveness research","other","article","10.2217/cer-2021-0169","34841893",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022437","DPP-IV inhibitory potential of naringin: an in silico, in vitro and in vivo study.","Parmar HS","2012","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2012.02.011","22410395",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022438","Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies.","Fonseca VA","2010","The American journal of medicine","other","article","10.1016/j.amjmed.2010.04.002","20609666",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Interactive Tutorial; Research Support, Non-U.S. Gov't; Journal Article; article"],["R0022439","Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.","Kumar J","2021","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","systematic_review","article","10.1016/j.dld.2020.08.021","32912770",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0022440","Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.","Sorli C","2017","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(17)30013-x","28110911",null,"ClinicalTrials.gov:NCT02054897","S000878; S001260","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022441","[Development of disease-modifying drugs for Parkinson's disease. Is it a tough road?].","Nagai M","2023","Nihon yakurigaku zasshi. Folia pharmacologica Japonica","other_trial","article","10.1254/fpj.22129","36990797",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","English Abstract; Journal Article; article"],["R0022442","Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine.","Schmidt HD","2016","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/npp.2015.362","26675243","PMC4869061",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0022443","Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Barboza JJ","2022","Journal of clinical medicine","systematic_review","article","10.3390/jcm11112998","35683387","PMC9181568",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0022444","Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway.","Liu J","2013","Journal of diabetes research","preclinical","article","10.1155/2013/630537","23671882","PMC3647568",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022445","GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?","Nauck MA","2016","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(16)30263-7","27651332",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0022446","Exenatide as a novel treatment for Parkinson's Disease","Aviles-Olmos I","2013","University College London (University of London)","other","article",null,null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Dissertation; dissertation"],["R0022447","Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.","Kalra S","2020","Postgraduate medicine","commentary","article","10.1080/00325481.2020.1809906","32781867",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0022448","Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.","Cariou B","2012","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2012.04.003","22672960",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022449","Exenatide (exendin-4)-induced pancreatitis: a case report.","Denker PS","2006","Diabetes care","case_report","article","10.2337/diacare.29.02.06.dc05-2043","16443920",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; Comment; article"],["R0022450","Preparation and characterization of BSA-loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis.","He M","2024","Journal of nanobiotechnology","preclinical","article","10.1186/s12951-024-02775-z","39180102","PMC11342552",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0022451","Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.","Goto M","2018","Journal of diabetes investigation","preclinical","article","10.1111/jdi.12860","29754453","PMC6215941",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022452","[Therapy of type 2 diabetes - Recommendations of the European Association for the Study of Diabetes (EASD)].","Müller-Wieland D","2020","Deutsche medizinische Wochenschrift (1946)","other","article","10.1055/a-0983-0379","32349146",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022453","Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial.","Mayfield K","2015","BJPsych open","protocol","article","10.1192/bjpo.bp.115.001073","27703725","PMC4998934",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022454","Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.","Guthrie R","2018","Postgraduate medicine","randomized_trial","article","10.1080/00325481.2018.1430446","29350569",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0022455","Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes.","Mosikian AA","2022","Future science OA","other","article","10.2144/fsoa-2021-0070","35251693","PMC8890266",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022456","Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.","Di Folco U","2022","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-022-01936-6","35842847","PMC9288662",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0022457","Shanzhiside methylester, the principle effective iridoid glycoside from the analgesic herb Lamiophlomis rotata, reduces neuropathic pain by stimulating spinal microglial β-endorphin expression.","Fan H","2016","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2015.09.010","26363192",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0022458","Is treatment with liraglutide efficient?","Mezquita Raya P","2014","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","narrative_review","article","10.1016/j.endonu.2013.09.001","24071060",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022459","Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo.","Chequin A","2021","Chemico-biological interactions","preclinical","article","10.1016/j.cbi.2021.109641","34534549",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022460","Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.","Onishi Y","2017","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej16-0552","28367916",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0022461","Efficient 18F-Labeling of Synthetic Exendin-4 Analogues for Imaging Beta Cells.","Keliher EJ","2012","ChemistryOpen","preclinical","article","10.1002/open.201200014","23997998","PMC3758109",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022462","Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective.","Pandey S","2023","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph16060836","37375783","PMC10304636",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022463","Targeting Ferroptosis: New Insights and Therapeutic Advances in MAFLD Complicating T2DM.","Yao F","2025","Frontiers in bioscience (Landmark edition)","narrative_review","article","10.31083/fbl39735","41198539",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022464","Exendin-4 protects against sulfonylurea-induced β-cell apoptosis.","Kim JY","2012","Journal of pharmacological sciences","preclinical","article","10.1254/jphs.11072fp","22186619",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022465","The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.","Bregenholt S","2005","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2005.03.013","15796922",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022466","On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide.","Bai J","2022","Journal of controlled release : official journal of the Controlled Release Society","other","article","10.1016/j.jconrel.2022.10.039","36374646",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022467","Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.","Son S","2015","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2015.08.084","26325318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022468","BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.","Giugliano D","2024","Endocrine","randomized_trial","article","10.1007/s12020-023-03547-9","37787888","PMC10850008","ClinicalTrials.gov:NCT04196231","S002277","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0022469","Toxicology profile of a novel GLP-1 receptor biased agonist-SAL0112 in nonhuman primates.","Sun J","2024","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2024.117125","39395609",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0022470","Liraglutide Enhances the Efficacy of Human Mesenchymal Stem Cells in Preserving Islet β-cell Function in Severe Non-obese Diabetic Mice.","Li LR","2016","Molecular medicine (Cambridge, Mass.)","preclinical","article","10.2119/molmed.2016.00168","27878211","PMC5193422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022471","Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro.","Ji J","2022","Bioengineered","preclinical","article","10.1080/21655979.2022.2036902","35164657","PMC8974036",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022472","A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model.","Su Y","2021","Drug research","other","article","10.1055/a-1266-3263","33022720",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022473","In vitro proliferation of adult human beta-cells.","Rutti S","2012","PloS one","preclinical","article","10.1371/journal.pone.0035801","22563404","PMC3338526",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022474","Risk stratification of patients with diabetes and the role of sodium glucose co-transporter inhibitors 2 during Ramadan fasting.","Adnan Z","2017","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2017.07.021","28778048",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022475","Gut as an emerging organ for the treatment of diabetes: focus on mechanism of action of bariatric and endoscopic interventions.","Haluzík M","2018","The Journal of endocrinology","narrative_review","article","10.1530/joe-17-0438","29378901",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022476","Providing holistic care for patients with metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions.","Chen L","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70545","41668679","PMC13094696",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0022477","[Liraglutide in the treatment of obesity : a multidisciplinary approach].","Nest S","2022","Revue medicale suisse","other","article","10.53738/revmed.2022.18.774.516","35343119",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022478","Effects of glucose-lowering agents on cardiorespiratory fitness.","Hamasaki H","2018","World journal of diabetes","narrative_review","article","10.4239/wjd.v9.i12.230","30588285","PMC6304298",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022479","Retraction. Exendin-4 reverses biochemical and behavioural deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions.",null,"2013","Neuropeptides","preclinical","article",null,"23866374",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Retraction Notice; retraction"],["R0022480","Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years.","Baccetti F","2024","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2024.111781","39002933",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0022481","A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).","Nomoto H","2015","PloS one","randomized_trial","article","10.1371/journal.pone.0135854","26284918","PMC4540491","UMIN:UMIN000005331",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022482","Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME).","Unger J","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14566","34622567","PMC9298244","ClinicalTrials.gov:NCT02730377","S000508","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022483","GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats.","Inoue T","2015","Atherosclerosis","preclinical","article","10.1016/j.atherosclerosis.2015.03.026","25818251",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022484","Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents.","Byrd RA","2015","Endocrinology","preclinical","article","10.1210/en.2014-1722","25860029",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022485","HNF4α is a novel regulator of intestinal glucose-dependent insulinotropic polypeptide.","Girard R","2019","Scientific reports","preclinical","article","10.1038/s41598-019-41061-z","30862908","PMC6414548",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022486","Effect of Weight Loss Interventions on the Symptomatic Burden and Biomarkers of Polycystic Ovary Syndrome : A Systematic Review of Randomized Controlled Trials.","Scragg J","2024","Annals of internal medicine","systematic_review","article","10.7326/m23-3179","39496172",null,"PROSPERO:CRD42022367488",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Meta-Analysis"],["R0022487","GLP-1R Activation Ameliorate Novel-object Recognition Function via Hippocampal AMPK/NF-κB Signaling Pathway in Neuropathic Pain Mice","Zhang L","2020","Research Square","preclinical","preprint","10.21203/rs.3.rs-96271/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0022488","Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.","Wang SL","2017","Oncotarget","randomized_trial","article","10.18632/oncotarget.20282","29069819","PMC5641162",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0022489","Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?","Pratley RE","2016","Diabetes technology & therapeutics","commentary","article","10.1089/dia.2016.0339","27860501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0022490","The cardioprotective effect of melatonin and exendin-4 treatment in a rat model of cardiorenal syndrome.","Chua S","2016","Journal of pineal research","preclinical","article","10.1111/jpi.12357","27465663",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022491","Retraction. Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.",null,"2013","British journal of pharmacology","notice","article","10.1111/bph.12241","23821776","PMC3682717",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; retraction"],["R0022492","Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation.","Kawasaki Y","2010","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","preclinical","article","10.1055/s-0030-1249035","20213584",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022493","Mechanism of Obesity-Related Lipotoxicity and Clinical Perspective.","Engin AB","2024","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-3-031-63657-8_5","39287851",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022494","Development of Type 1 Diabetes may occur through a Type 2 Diabetes mechanism.","Josefsen K","2022","Frontiers in endocrinology","other","article","10.3389/fendo.2022.1032822","36589856","PMC9794996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022495","Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.","Meier JJ","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14632","34957654",null,"ClinicalTrials.gov:NCT02877355","S001380","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022496","Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.","Batista AF","2019","CNS drugs","narrative_review","article","10.1007/s40263-018-0593-6","30511349",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022497","Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.","Oulhaj A","2024","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.15817","39086032",null,"ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022498","Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation.","Hu Q","2023","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2023.114252","36641921",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022499","Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets.","Higuera-de la Tijera F","2015","World journal of hepatology","commentary","article","10.4254/wjh.v7.i10.1297","26052375","PMC4450193",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial; article"],["R0022500","Liraglutide ameliorates palmitate-induced endothelial dysfunction through activating AMPK and reversing leptin resistance.","Li N","2016","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2016.07.095","27457805",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022501","Tirzepatide for Type 2 Diabetes Mellitus: CADTH Horizon Scan",null,"2022","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"38232220",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0022502","Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4.","Ranta F","2006","Diabetes","preclinical","article","10.2337/db05-1220","16644695",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022503","Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.","Liou JH","2018","Transplantation proceedings","nonrandomized_study","article","10.1016/j.transproceed.2018.03.087","30316386",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0022504","Tirzepatide for Patients With Type 2 Diabetes.","Chipkin SR","2022","JAMA","nonrandomized_study","article","10.1001/jama.2021.25016","35133426",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Editorial; Comment; article"],["R0022505","Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.","Standl E","2017","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(17)30033-5","28131656",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022506","Effect of Exenatide Therapy on Platelet Function in Type 2 Diabetes Mellitus.","Çalapkulu M","2021","Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","nonrandomized_study","article","10.29271/jcpsp.2021.09.1035","34500517",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0022507","Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes.","Saisho Y","2018","International journal of environmental research and public health","narrative_review","article","10.3390/ijerph15050947","29747423","PMC5981986",null,"S001837","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0022508","Efficacy of Liraglutide in Patients With Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials","Mali N","2021","Research Square","systematic_review","preprint","10.21203/rs.3.rs-929327/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0022509","Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart.","Brown SB","2010","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-010-6242-z","20582459","PMC4492538",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0022510","Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice.","Ji W","2014","International journal of endocrinology","preclinical","article","10.1155/2014/312452","25183970","PMC4144308",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022511","Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.","Warren M","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13331","29687620","PMC6099273",null,"S000329; S000766; S000878; S001219; S001872","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0022512","Metformin is associated with a lower risk of non-Hodgkin lymphoma in patients with type 2 diabetes.","Tseng CH","2019","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2019.05.002","31129317",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0022513","Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation.","Liu Z","2008","The Journal of biological chemistry","other","article","10.1074/jbc.m706105200","18216022","PMC2417166",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0022514","Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.","Eliasson B","2022","PharmacoEconomics - open","nonrandomized_study","article","10.1007/s41669-021-00317-z","35064550","PMC9043066","ClinicalTrials.gov:NCT02863328; ClinicalTrials.gov:NCT02607865","S000251; S002267","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022515","Tirzepatide for diabetes: on track to SURPASS current therapy.","Moura FA","2022","Nature medicine","commentary","article","10.1038/s41591-022-01733-2","35260841",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0022516","Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.","Suissa S","2018","Diabetes care","other_trial","article","10.2337/dc17-1059","29358464",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; article"],["R0022517","Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.","Blase E","2005","Journal of clinical pharmacology","randomized_trial","article","10.1177/0091270004274432","15831781",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; article"],["R0022518","The Effect and Mechanism of Duodenal-Jejunal Bypass to Treat Type 2 Diabetes Mellitus in a Rat Model.","Chen X","2022","Obesity facts","preclinical","article","10.1159/000519417","35299171","PMC9209996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022519","Successful Pregnancy after Improving Insulin Resistance with the Glucagon-Like Peptide-1 Analogue in a Woman with Polycystic Ovary Syndrome: A Case Report and Review of the Literature.","Yang Q","2016","Gynecologic and obstetric investigation","case_report","article","10.1159/000446951","27300746",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0022520","A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease.","Liu C","2022","Frontiers in physiology","preclinical","article","10.3389/fphys.2022.909569","35874522","PMC9298824",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022521","Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).","Bergenstal RM","2012","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-012-0013-8","23138449","PMC3508113",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0022522","Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice.","Tschen SI","2009","Diabetes","preclinical","article","10.2337/db08-1651","19228811","PMC2682690",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022523","Safety and Efficacy of Inpatient Diabetes Management with Non-insulin Agents: an Overview of International Practices.","Galindo RJ","2022","Current diabetes reports","randomized_trial","article","10.1007/s11892-022-01464-1","35507117","PMC9065239",null,null,"pubmed; europepmc","TRUE","open_europepmc","2",null,"Journal Article; Review; Research Support, N.I.H., Extramural; review-article"],["R0022524","Alogliptin + metformin combination for the treatment of type 2 diabetes mellitus.","Neumiller JJ","2016","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.2016.1110484","30063448",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022525","Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center.","Sofra D","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-017-0234-y","28220460","PMC5380496",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022526","The new place of enterohormones in intestinal failure.","Daoud DC","2020","Current opinion in clinical nutrition and metabolic care","other_trial","article","10.1097/mco.0000000000000672","32618723",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0022527","Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes.","Salvatore T","2022","Biomolecules","narrative_review","article","10.3390/biom12020176","35204677","PMC8961672",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022528","Can a monthly exenatide extended release regimen provide a therapeutic and cost benefit?","Elkeeb R","2021","Biopharmaceutics & drug disposition","preclinical","article","10.1002/bdd.2279","33876430",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022529","Liraglutide Improves Cognitive and Neuronal Function in 3-NP Rat Model of Huntington's Disease.","Shawki SM","2021","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2021.731483","35002691","PMC8727874",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022530","Preconception weight loss improves fertility and maternal outcomes in obese mice.","Rodrigo N","2022","The Journal of endocrinology","preclinical","article","10.1530/joe-21-0399","35080198",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022531","Liraglutide restores angiogenesis in palmitate-impaired human endothelial cells through PI3K/Akt-Foxo1-GTPCH1 pathway.","Ke J","2016","Peptides","other","article","10.1016/j.peptides.2016.10.009","27777063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022532","Drug repurposing for osteoarthritis disease modification in the early 21st century.","van Galen I","2025","Connective tissue research","other_trial","article","10.1080/03008207.2025.2538562","40751563",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0022533","Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.","Nagakura J","2016","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej15-0500","26743240",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0022535","Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model.","Parthsarathy V","2013","PloS one","preclinical","article","10.1371/journal.pone.0058784","23536825","PMC3594148",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022536","Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.","Scalzo RL","2017","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2016.10.003","27884660","PMC5787373",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0022538","GLP-1 agonists for metabolic disorders in schizophrenia.","Kouidrat Y","2019","Schizophrenia research","commentary","article","10.1016/j.schres.2018.09.019","30243855",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0022539","G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?","Patil M","2024","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2024.116245","38340396",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022540","Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity.","Gong N","2014","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.4703-13.2014","24719110","PMC6608999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022541","Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.","Berkovic MC","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-017-0324-x","29076038","PMC5688989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022542","Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells.","Dorecka M","2013","Pharmacological reports : PR","other","article","10.1016/s1734-1140(13)71069-7","24145082",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022543","Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway.","Ke J","2017","Scientific reports","randomized_trial","article","10.1038/srep41085","28145471","PMC5286534",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022544","A multidisciplinary, shared care clinic using personalized medicine and coordinated care in patients with concomitant type 2 diabetes and cardiovascular disease. Protocol and baseline characteristics.","Pontoppidan JRN","2024","Preventive medicine reports","protocol","article","10.1016/j.pmedr.2024.102594","38283962","PMC10821603",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022545","Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.","Alsafwani DM","2022","Cureus","nonrandomized_study","article","10.7759/cureus.23554","35371841","PMC8958214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","TRUE","Journal Article; Retracted Publication; research-article; article"],["R0022546","Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.","Li J","2017","Frontiers in physiology","narrative_review","article","10.3389/fphys.2017.00015","28194113","PMC5276855",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022547","Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes.","Song SO","2014","Journal of diabetes investigation","other_trial","article","10.1111/jdi.12184","25411624","PMC4188114",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022548","Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.","Wild D","2010","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.110.074914","20595511",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022549","Can GLP-1 preparations be used in children and adolescents with diabetes mellitus?","Shehadeh N","2014","Pediatric endocrinology reviews : PER","narrative_review","article",null,"24716398",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022550","Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats.","Yang JM","2022","Polymers","preclinical","article","10.3390/polym14112181","35683851","PMC9183037",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022551","Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes.","Alduraibi RK","2023","Medicine","case_report","article","10.1097/md.0000000000034027","37335652","PMC10256347",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; research-article; article"],["R0022552","Exenatide-induced granulomatous panniculitis associated with poly(d,l-lactide-co-glycolide).","Zhu CS","2022","Journal of cutaneous pathology","case_report","article","10.1111/cup.14193","34954842",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022553","Integrating advances in insulin into clinical practice: Advances In insulin formulations.","King A","2013","The Journal of family practice","narrative_review","article",null,"24080573",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022554","Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA/kainate signaling.","Mietlicki-Baase EG","2014","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.0115-14.2014","24828651","PMC4019807",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0022555","Type 2 Diabetes Mellitus Diagnosed at the Age of Eight Years: A Case Report.","Hasan MR","2025","Cureus","case_report","article","10.7759/cureus.85065","40585621","PMC12206279",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0022556","[Treatment of type 2 diabetes mellitus with GLP-1 agonists].","Haluzík M","2011","Vnitrni lekarstvi","narrative_review","article",null,"21612070",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022557","[The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].","Yan L","2015","Zhonghua nei ke za zhi","randomized_trial","article",null,"26268058",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0022558","Prolonged activity of exenatide: Detailed comparison of Site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates.","Tully M","2021","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2021.04.019","33957224",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022559","Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Kahn SE","2026","Diabetes care","randomized_trial","article","10.2337/dc25-2186","41432725","PMC12824799",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; research-article; article"],["R0022560","Optimizing outcomes for GLP-1 agonists.","Freeman JS","2011","The Journal of the American Osteopathic Association","case_report","article",null,"21389295",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0022561","Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.","Athauda D","2017","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(17)31585-4","28781108","PMC5831666","ClinicalTrials.gov:NCT01971242","S000204; S002139","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0022562","Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.","Nance KD","2017","Journal of medicinal chemistry","other","article","10.1021/acs.jmedchem.6b01706","28103022",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0022563","Effect of nano extracts of olea europaea leaves, ficus carica and liraglutide in lipidemic liver of type 2 diabetic rat model.","Alalwani AD","2022","Saudi journal of biological sciences","preclinical","article","10.1016/j.sjbs.2022.103333","35721230","PMC9198465",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022564","A big STEP for treatment of heart failure with preserved ejection fraction.","Verma S","2023","Cell metabolism","other_trial","article","10.1016/j.cmet.2023.08.003","37643614",null,null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article"],["R0022565","The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA1c(v)-Lowering Medications : Editorial to: \"GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials\" by Jia X, Alam M, Ye Y et al.","Stryker MD","2018","Cardiovascular drugs and therapy","systematic_review","article","10.1007/s10557-018-6777-y","29455345",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Editorial; Comment"],["R0022566","The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","Luo Y","2018","Clinical drug investigation","systematic_review","article","10.1007/s40261-018-0707-4","30255388",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0022567","Clinical and economic implications of incretin-based therapies.","Briggs GC","2007","Endocrinology and metabolism clinics of North America","narrative_review","article",null,"18405145",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022568","Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.","Meier JJ","2023","Diabetes, obesity & metabolism","other","article","10.1111/dom.14957","36562481",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022569","Protective roles of liraglutide against brain injury of streptozotocin induced diabetic rats.","Jia Y","2021","Pakistan journal of pharmaceutical sciences","preclinical","article",null,"35034872",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022570","New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy.","Saw M","2019","Eye (London, England)","narrative_review","article","10.1038/s41433-019-0494-z","31227789","PMC7002655",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0022571","Status and future directions of clinical trials in Parkinson's disease.","Söderbom G","2020","International review of neurobiology","other_trial","article","10.1016/bs.irn.2020.02.009","32739003",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0022572","[Effects of Exendin-4 on the differentiation of neural stem cells from subventricular zone of adult mice in vitro].","Zhao F","2019","Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","preclinical","article","10.12047/j.cjap.5848.2019.055","31257810",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022573","Gastrointestinal adverse events of semaglutide in patients with overweight or obesity.","Tariq MA","2022","European journal of internal medicine","commentary","article","10.1016/j.ejim.2022.08.015","35985949",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0022574","Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies.","Feng W","2021","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2021-002290","34452904","PMC8404431",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022575","Pax6 haploinsufficiency causes abnormal metabolic homeostasis by down-regulating glucagon-like peptide 1 in mice.","Ding J","2009","Endocrinology","preclinical","article","10.1210/en.2008-1006","19116343",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022576","The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways.","Zhu H","2016","Scientific reports","preclinical","article","10.1038/srep26859","27240461","PMC4886514",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022577","Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis.","Fralick M","2020","Journal of diabetes and its complications","systematic_review","article","10.1016/j.jdiacomp.2020.107704","32888788",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis"],["R0022578","Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.","O'Neil PM","2022","Postgraduate medicine","other_trial","article","10.1080/00325481.2022.2150006","36691307",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0022579","Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3β activity.","Kim JY","2010","Journal of Korean medical science","other","article","10.3346/jkms.2010.25.11.1626","21060752","PMC2967000",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022580","Treating bile acid diarrhoea with liraglutide.","Walters JRF","2022","The lancet. Gastroenterology & hepatology","commentary","article","10.1016/s2468-1253(22)00213-8","35868333",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0022581","Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.","Anholm C","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12891","28124822",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022582","Is exenatide advancing the treatment of type 2 diabetes?","Doggrell SA","2006","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.7.1.109","16370928",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022583","A comparison of three (67/68)Ga-labelled exendin-4 derivatives for β-cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelator.","Jodal A","2014","EJNMMI research","preclinical","article","10.1186/s13550-014-0031-9","25006548","PMC4078388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022584","A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide.","Fujishiro M","2016","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/dme.12998","26485621",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022585","GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion.","Yang Y","2013","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","preclinical","article","10.1016/j.pan.2013.07.281","24075514",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022586","Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway.","Liu ZZ","2022","Life sciences","preclinical","article","10.1016/j.lfs.2022.120370","35124000",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022587","cAMP-independent effects of GLP-1 on β cells.","Kolic J","2015","The Journal of clinical investigation","commentary","article","10.1172/jci85004","26571393","PMC4665801",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; article-commentary; article"],["R0022588","Systematic Review of Treatment of Beta-Cell Monogenic Diabetes.","Naylor RN","2023","medRxiv : the preprint server for health sciences","systematic_review","article","10.1101/2023.05.12.23289807","37214872","PMC10197799",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Preprint; Journal Article; preprint"],["R0022589","[Effects of exendin-4 on methylglyoxal-induced oxidative stress in PC12 cells].","Zhou Q","2016","Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","preclinical","article","10.13459/j.cnki.cjap.2016.05.011","29931846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022590","Le sémaglutide pour la perte pondérale.","Ojeniran M","2021","Canadian family physician Medecin de famille canadien","other","article","10.46747/cfp.6711e296","34772722","PMC8589133",null,null,"europepmc","FALSE",null,null,null,"research-article; Journal Article"],["R0022591","Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.","Liu J","2017","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj.j2499","28596247","PMC5463186",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0022592","Distinguishing among incretin-based therapies. Patient education and self-management.","Campbell RK","2010","The Journal of family practice","case_report","article",null,"20824237",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022593","Protective effect of liraglutide against ER stress in the liver of high-fat diet-induced insulin-resistant rats.","Yang J","2015","Endocrine","preclinical","article","10.1007/s12020-014-0480-y","25471281",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022594","GLP-1R polymorphism (rs1042044) and expression are associated with the risk of papillary thyroid cancer among the Egyptian population.","Abdul-Maksoud RS","2022","Gene","other","article","10.1016/j.gene.2022.146597","35598685",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022595","The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.","Long-Smith CM","2013","Neuromolecular medicine","preclinical","article","10.1007/s12017-012-8199-5","23011726",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022596","Preparation, Drug Distribution, and In Vivo Evaluation of the Safety of Protein Corona Liposomes for Liraglutide Delivery.","Ding R","2023","Nanomaterials (Basel, Switzerland)","other","article","10.3390/nano13030540","36770503","PMC9920406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022597","Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders.","Rayner CK","2017","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.12822","27862814",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0022598","Injectable sustained-release poly(lactic-co-glycolic acid) (PLGA) microspheres of exenatide prepared by supercritical fluid extraction of emulsion process based on a design of experiment approach.","Park H","2023","Bioengineering & translational medicine","preclinical","article","10.1002/btm2.10485","37206215","PMC10189459",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022599","Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.","Patoulias D","2022","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2022.03.042","35459459",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Meta-Analysis; article"],["R0022600","Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo.","Uhles S","2011","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2010.01352.x","21205124",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022601","Exenatide induced acute kidney injury.","Aijazi I","2014","Journal of Ayub Medical College, Abbottabad : JAMC","case_report","article",null,"25672206",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022602","Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R).","Koole C","2017","The Journal of biological chemistry","other","article","10.1074/jbc.m117.779496","28283573","PMC5409479",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022603","Sex-specific effects of metformin and liraglutide on renal pathology and expression of connexin 45 and pannexin 1 following long-term high-fat high-sugar diet.","Luetić M","2021","Acta histochemica","preclinical","article","10.1016/j.acthis.2021.151817","34808525",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022604","Decline in use of high-risk agents for tight glucose control among older adults with diabetes in New York City: 2017-2022.","Zhang J","2024","Journal of the American Geriatrics Society","nonrandomized_study","article","10.1111/jgs.19060","38980267","PMC11368607",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0022605","Systematic review of influence of ethnicity on efficacy and safety of pharmacotherapy for childhood and adolescent obesity.","Gupta S","2026","Clinical and experimental pediatrics","systematic_review","article","10.3345/cep.2025.02838","41582666","PMC12877414","PROSPERO:CRD42025117631",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review-article; review"],["R0022606","Application of Af4-Multidetection to Liraglutide in Its Formulation: Preserving and Representing Native Aggregation.","Marassi V","2022","Molecules (Basel, Switzerland)","other","article","10.3390/molecules27175485","36080254","PMC9457993",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022607","Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.","O'Harte FP","2016","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2016.05.012","27179756",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022608","In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk.","Singh M","2022","Annals of internal medicine","randomized_trial","article","10.7326/j22-0009","35226523",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0022609","Efficacy and Safety of Dulaglutide in Type 2 Diabetes Patients in Endocrinology Clinics of Islamabad, Pakistan.","Kamin M","2021","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/ijem.ijem_402_21","35300442","PMC8923314",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022610","Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues.","López de Maturana R","2004","Protein and peptide letters","other","article","10.2174/0929866043478491","14965274",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022611","Facilitated structure verification of the biopharmaceutical peptide exenatide by 2D heteronuclear NMR maps.","Mishra SH","2021","Journal of pharmaceutical and biomedical analysis","other","article","10.1016/j.jpba.2021.114136","34087552",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022612","In Vitro and In Vivo Investigation of the Angiogenic Effects of Liraglutide during Islet Transplantation.","Langlois A","2016","PloS one","preclinical","article","10.1371/journal.pone.0147068","26974949","PMC4790919",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022613","The incretin hormone glucagon-like peptide 1 increases mitral cell excitability by decreasing conductance of a voltage-dependent potassium channel.","Thiebaud N","2016","The Journal of physiology","preclinical","article","10.1113/jp272322","26931093","PMC4865572",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022614","Repurposing GLP1 agonists for neurodegenerative diseases.","Markaki I","2020","International review of neurobiology","narrative_review","article","10.1016/bs.irn.2020.02.007","32854860",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; book-chapter"],["R0022615","Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.","Lingvay I","2023","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.23621","36502289","PMC10107832",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022616","Near-infrared fluorescent probe for imaging of pancreatic beta cells.","Reiner T","2010","Bioconjugate chemistry","preclinical","article","10.1021/bc100184w","20583828","PMC2912453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022617","Metformin use is associated with a lower risk of uterine leiomyoma in female type 2 diabetes patients.","Tseng CH","2019","Therapeutic advances in endocrinology and metabolism","nonrandomized_study","article","10.1177/2042018819895159","31897287","PMC6920594",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0022618","Effects of Pluronic F127-PEG multi-gel-core on the release profile and pharmacodynamics of Exenatide loaded in PLGA microspheres.","Wang P","2016","Colloids and surfaces. B, Biointerfaces","preclinical","article","10.1016/j.colsurfb.2016.08.032","27559996",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022619","Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes.","Simó R","2021","Biomedicines","other_trial","article","10.3390/biomedicines9080926","34440130","PMC8392846",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022620","The Definition and Prevalence of Obesity and Metabolic Syndrome: Correlative Clinical Evaluation Based on Phenotypes.","Engin A","2024","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-3-031-63657-8_1","39287847",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022621","A 25-year-old woman with type 2 diabetes and liver disease.","Junker AE","2014","Case reports in gastroenterology","case_report","article","10.1159/000369968","25606030","PMC4296242",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0022622","[Modulation of the incretin effect in the treatment of diabetes].","Vidal J","2014","Medicina clinica","narrative_review","article","10.1016/s0025-7753(14)70102-2","25326837",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; English Abstract"],["R0022623","Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice.","Bisgaard LS","2016","PloS one","preclinical","article","10.1371/journal.pone.0168396","27992511","PMC5161477",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022624","The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).","Hsia DS","2024","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2024.108692","38354481","PMC10923170","ClinicalTrials.gov:NCT01794143","S000873","pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0022625","Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.","Bush M","2012","Postgraduate medicine","other_trial","article","10.3810/pgm.2012.11.2613","23322139",null,null,"S001169; S001509; S002216","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022626","Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).","Seino Y","2012","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2012.01618.x","22564709","PMC3466411",null,"S000488","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022627","Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.","Lingvay I","2018","Circulation","other","article","10.1161/circulationaha.117.032759","29784677",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022628","Exendin-4 regulates pancreatic ABCA1 transcription via CaMKK/CaMKIV pathway.","Li J","2010","Journal of cellular and molecular medicine","preclinical","article","10.1111/j.1582-4934.2009.00955.x","19874424","PMC3822745",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022629","Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus.","Hammerman A","2022","The American journal of cardiology","randomized_trial","article","10.1016/j.amjcard.2022.01.027","35197207",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0022630","Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.","Schmidt S","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14567","34595827",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022631","Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.","Takahashi H","2022","Hepatology communications","randomized_trial","article","10.1002/hep4.1696","34558835","PMC8710792","UMIN:UMIN000015727",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022632","Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.","Wysham CH","2020","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2019-000773","33037036","PMC7549491","ClinicalTrials.gov:NCT01652716","S001982","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022633","Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet.","Gault VA","2010","International journal of obesity (2005)","preclinical","article","10.1038/ijo.2010.59","20351729",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022634","The Mechanism and Treatment of Cognitive Dysfunction in Diabetes: A Review.","Hou Y","2025","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","narrative_review","article","10.1055/a-2480-7826","39572247",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022635","GIPR expression is induced by thiazolidinediones in a PPARγ-independent manner and repressed by obesogenic stimuli.","Cataldi S","2023","European journal of cell biology","preclinical","article","10.1016/j.ejcb.2023.151320","37130450",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022636","Glucagon-like peptide-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy in podocytes.","Guo H","2018","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00302.2017","29070572",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022637","Establishment of a method for in-vivo SPECT/CT imaging analysis of 111In-labeled exendin-4 pancreatic uptake in mice without the need for nephrectomy or a secondary probe.","Hamamatsu K","2018","Nuclear medicine and biology","preclinical","article","10.1016/j.nucmedbio.2018.06.002","30015092",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022638","DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.","Kumar K","2021","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.0c02050","33682417",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; article"],["R0022639","Diabetes Management and Cardiovascular Risk: Are SGLT-2 Inhibitors the Safest?","Swislocki AL","2016","Metabolic syndrome and related disorders","narrative_review","article","10.1089/met.2015.29003.swi","26677930",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022640","Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.","Hompesch M","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12398","25263215",null,"ClinicalTrials.gov:NCT01475734","S000097","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022641","Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.","Riddle MC","2021","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgab065","33537745","PMC8063250","ClinicalTrials.gov:NCT01394952","S000147","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022642","Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells.","Koehler JA","2006","Diabetes","preclinical","article","10.2337/db05-1145","16644694",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022643","Role of glucagon-like peptide-1 agonist in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting: A meta-analysis.","Ogbu IR","2021","American heart journal plus : cardiology research and practice","systematic_review","article","10.1016/j.ahjo.2021.100063","38549742","PMC10978116",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0022644","Application of Fabric Phase Sorptive Extraction as a Green Method for the Analysis of 10 Anti-Diabetic Drugs in Environmental Water Samples.","Misolas A","2024","Molecules (Basel, Switzerland)","other","article","10.3390/molecules29204834","39459205","PMC11509965",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022645","iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy.","Lynch L","2016","Cell metabolism","preclinical","article","10.1016/j.cmet.2016.08.003","27593966","PMC5061124",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article"],["R0022646","Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture.","Toso C","2010","Transplant international : official journal of the European Society for Organ Transplantation","preclinical","article","10.1111/j.1432-2277.2009.00984.x","19821955",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022647","Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.","Li Y","2010","Journal of neurochemistry","other","article","10.1111/j.1471-4159.2010.06731.x","20374430","PMC2912144",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022648","Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.","Zhaohu H","2022","Journal of diabetes research","randomized_trial","article","10.1155/2022/4126995","35990242","PMC9381852",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0022649","Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.","Wohlfart P","2013","Journal of translational medicine","randomized_trial","article","10.1186/1479-5876-11-84","23537041","PMC3637243","ClinicalTrials.gov:NCT01147250","S001991","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0022650","[Important alteration of the Dutch treatment algorithm in patients with type 2 diabetes mellitus].","Serné EH","2021","Nederlands tijdschrift voor geneeskunde","other","article",null,"35138747",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022651","Semaglutide Initiation in a Type 2 Diabetes Mellitus, Post-Liver Transplant Patient.","Newell BJ","2022","The Senior care pharmacist","case_report","article","10.4140/tcp.n.2022.221","35610766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022652","GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans.","Hanssen R","2021","Molecular metabolism","randomized_trial","article","10.1016/j.molmet.2021.101163","33453418","PMC7859312",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0022653","Retracted: Liraglutide Is Protective against Brain Injury in Mice with Febrile Seizures by Inhibiting Inflammatory Factors.","Methods In Medicine CAM","2022","Computational and mathematical methods in medicine","notice","article","10.1155/2022/9804321","36506596","PMC9731748",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; article"],["R0022654","Dulaglutide for erectile dysfunction in type 2 diabetes.","Madsbad S","2021","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(21)00142-x","34153270",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0022655","Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.","Westman K","2022","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2021.108110","35101325",null,"EudraCT:2012-001941-42","S002357","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022656","Surface Adsorption-Mediated Ultrahigh Efficient Peptide Encapsulation with a Precise Ratiometric Control for Type 1 and 2 Diabetic Therapy.","Zhang P","2022","Small (Weinheim an der Bergstrasse, Germany)","preclinical","article","10.1002/smll.202200449","35229498",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022657","The Effects of Mutual Interaction of Orexin-A and Glucagon-Like Peptide-1 on Reflex Swallowing Induced by SLN Afferents in Rats.","Kobashi M","2020","International journal of molecular sciences","preclinical","article","10.3390/ijms21124422","32580304","PMC7352520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022658","Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis.","Mangia A","2025","Liver international : official journal of the International Association for the Study of the Liver","narrative_review","article","10.1111/liv.70271","40815181",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0022659","New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice.","Yang PY","2020","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.0c00093","32243137",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022660","A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.","Cusi K","2020","Liver international : official journal of the International Association for the Study of the Liver","randomized_trial","article","10.1111/liv.14350","32077613",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0022661","Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors.","Kim KS","2015","Evidence-based complementary and alternative medicine : eCAM","narrative_review","article","10.1155/2015/171742","26788106","PMC4693015",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0022662","[Dulaglutide and liraglutide compared].","Bruhn C","2015","Medizinische Monatsschrift fur Pharmazeuten","other","article",null,"26364414",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0022663","Diabetes: Incretin mimetics and insulin - closing the gap to normoglycaemia.","Nauck MA","2016","Nature reviews. Endocrinology","commentary","article","10.1038/nrendo.2016.180","27831571",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0022664","Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.","DeFronzo RA","2005","Diabetes care","randomized_trial","article","10.2337/diacare.28.5.1092","15855572",null,null,"S000180; S002301","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022665","Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.","Courrèges JP","2008","Diabetic medicine : a journal of the British Diabetic Association","commentary","article","10.1111/j.1464-5491.2008.02484.x","19183322","PMC2592347",null,"S001065","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; Randomized Controlled Trial; article"],["R0022666","Liraglutide suppresses obesity and promotes browning of white fat via miR-27b in vivo and in vitro.","Wang X","2021","The Journal of international medical research","preclinical","article","10.1177/03000605211055059","34772311","PMC8593297",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022667","Amygdalin alleviates MAFLD via inhibiting cytoplasmic calcium ion overload-induced liver sinusoidal endothelial cell defenestration.","Wang J","2026","Phytomedicine : international journal of phytotherapy and phytopharmacology","preclinical","article","10.1016/j.phymed.2026.158135","41962269",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022668","Our biology working against us in obesity: A narrative review on implications for management of osteoarthritis.","Cicuttini FM","2023","Osteoarthritis and cartilage open","narrative_review","article","10.1016/j.ocarto.2023.100407","37744021","PMC10514453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0022669","Terahertz Spectroscopy: An Investigation of the Structural Dynamics of Freeze-Dried Poly Lactic-co-glycolic Acid Microspheres.","Shmool TA","2019","Pharmaceutics","other","article","10.3390/pharmaceutics11060291","31226751","PMC6631728",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022670","Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin.","Barale C","2019","Thrombosis research","other","article","10.1016/j.thromres.2019.06.010","31229924",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022671","Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.","Reidelberger RD","2011","Obesity (Silver Spring, Md.)","preclinical","article","10.1038/oby.2010.136","20559304",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0022672","Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.","Kahal H","2014","Clinical endocrinology","nonrandomized_study","article","10.1111/cen.12369","24256515",null,null,"S000679","pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0022673","Comparison of drug efficacy in two animal models of type 2 diabetes: A systematic review and meta-analysis.","Ferreira GS","2020","European journal of pharmacology","systematic_review","article","10.1016/j.ejphar.2020.173153","32360835",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review"],["R0022674","Oral GLP-1 Analog for Type 2 Diabetes on the Horizon.","Abbasi J","2018","JAMA","commentary","article","10.1001/jama.2018.11254","30120456",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0022675","A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.","Brady EM","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12249","24373063",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022676","Secreted MUP1 that reduced under ER stress attenuates ER stress induced insulin resistance through suppressing protein synthesis in hepatocytes.","Gao R","2023","Pharmacological research","preclinical","article","10.1016/j.phrs.2022.106585","36455814",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022677","Exenatide regulates inflammation and the production of reactive oxygen species via inhibition of S1PR2 synthesis.","Yang Y","2021","Advances in clinical and experimental medicine : official organ Wroclaw Medical University","other","article","10.17219/acem/133483","33984196",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022678","Enhanced macromolecule bioavailability in rats and pigs using an in situ forming synthetic epithelial lining.","Kanelli M","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.114338","41109558","PMC13078412",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022679","Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials.","Wang Q","2018","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2018.06.009","29935211",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0022680","Anti-obesity medications in the management of heart failure with preserved ejection fraction: available evidence and next STEPS.","Harrington J","2024","Heart failure reviews","narrative_review","article","10.1007/s10741-024-10410-0","38965119",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022681","A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in Egypt.","Elsisi GH","2022","Cost effectiveness and resource allocation : C/E","other","article","10.1186/s12962-021-00335-y","35033094","PMC8760653",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022682","Mucosal glucagon-like peptide 1 (GLP-1) responses are mediated by calcitonin gene-related peptide (CGRP) in the mouse colon and both peptide responses are area-specific.","Tough IR","2018","Neurogastroenterology and motility","preclinical","article","10.1111/nmo.13149","28695626",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022683","Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?","van Raalte DH","2011","Diabetes research and clinical practice","narrative_review","article","10.1016/s0168-8227(11)70012-2","21864750",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0022684","Role of ERp46 in β-cell lipoapoptosis through endoplasmic reticulum stress pathway as well as the protective effect of exendin-4.","Chen DL","2012","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2012.08.072","22935416",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022685","Examining Weight Suppression, Leptin Levels, Glucagon-Like Peptide 1 Response, and Reward-Related Constructs in Severity and Maintenance of Bulimic Syndromes: Protocol and Sample Characteristics for a Cross-Sectional and Longitudinal Study.","Keel PK","2025","JMIR research protocols","protocol","article","10.2196/66554","40198107","PMC12015349",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022686","Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?","Mosli MM","2017","Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","nonrandomized_study","article","10.4103/1319-3767.203362","28361843","PMC5385714",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022687","Awareness of Urinary Stone Risk Factors Among the Adult Population of Jazan, Saudi Arabia: A Cross-Sectional Study.","Adawi E","2023","Cureus","other","article","10.7759/cureus.49115","38125231","PMC10732336",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022688","Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris.","Zhou J","2009","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2009.02.001","19462477",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022689","Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study.","Arai T","2022","JGH open : an open access journal of gastroenterology and hepatology","other_trial","article","10.1002/jgh3.12780","35822119","PMC9260206",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022690","Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.","Werner U","2010","Regulatory peptides","other_trial","article","10.1016/j.regpep.2010.05.008","20570597",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0022691","Attenuated Postprandial GLP-1 Response in Parkinson's Disease.","Manfready RA","2021","Frontiers in neuroscience","other","article","10.3389/fnins.2021.660942","34276285","PMC8283566",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0022692","The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model.","El Medany AMH","2022","Fundamental & clinical pharmacology","preclinical","article","10.1111/fcp.12765","35106814",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022693","Liraglutide pharmacokinetics and exposure-response in adolescents with obesity.","Carlsson Petri KC","2021","Pediatric obesity","systematic_review","article","10.1111/ijpo.12799","33963681","PMC8519033",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0022694","Pharmacologic stimulation of central GLP-1 receptors has opposite effects on the alterations of plasma FGF21 levels induced by feeding and fasting.","Nonogaki K","2016","Neuroscience letters","preclinical","article","10.1016/j.neulet.2015.12.011","26683903",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0022695","Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.","Li X","2015","Drug delivery","preclinical","article","10.3109/10717544.2013.871760","24467493",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022696","Intensification of medical management in type 2 diabetes: A real-world look at primary care practice.","Zekarias K","2020","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2019.107477","31711841","PMC6920559",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0022697","Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes.","Wang R","2021","ACS omega","preclinical","article","10.1021/acsomega.0c06326","33817486","PMC8015136",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022698","[Obesity and type 2 diabetes (Update 2023)].","Clodi M","2023","Wiener klinische Wochenschrift","other","article","10.1007/s00508-023-02184-6","37101029","PMC10133053",null,null,"pubmed; europepmc","TRUE",null,null,null,"English Abstract; Journal Article; research-article"],["R0022699","Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.","Graaf Cd","2016","Pharmacological reviews","narrative_review","article","10.1124/pr.115.011395","27630114","PMC5050443",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0022700","Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration.","Mehan S","2022","Degenerative neurological and neuromuscular disease","narrative_review","article","10.2147/dnnd.s247153","35300067","PMC8921673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022701","Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease.","Park JS","2021","Acta neuropathologica communications","preclinical","article","10.1186/s40478-021-01180-z","33902708","PMC8074239",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0022702","Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis.","Bulchandani DG","2010","European journal of gastroenterology & hepatology","preclinical","article","10.1097/meg.0b013e32833b257a","20651599",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; book-chapter; article"],["R0022703","Anagliptin, a dipeptidyl peptidase-4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation.","Hotta Y","2020","Neurourology and urodynamics","randomized_trial","article","10.1002/nau.24449","32725853",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022704","Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment.","Lunati ME","2016","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2015.09.010","26683791",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022705","Optimizing expression, purification, structural and functional assessments of a novel dimeric incretin (GLP-1cpGLP-1).","Albaghlany RM","2024","Biochimie","preclinical","article","10.1016/j.biochi.2023.10.020","37931794",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022706","Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia.","Secnik J","2022","Journal of Alzheimer's disease : JAD","nonrandomized_study","article","10.3233/jad-215337","35034902","PMC9028644",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022707","The role of incretin therapy at different stages of diabetes.","Cernea S","2011","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2011.8.323","22262070","PMC3280667",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022708","Molecular imaging in the investigation of hypoglycaemic syndromes and their management.","Pattison DA","2017","Endocrine-related cancer","narrative_review","article","10.1530/erc-17-0005","28400403",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0022709","Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.","Lian J","2021","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2021.649018","33841337","PMC8024567","PROSPERO:CRD42020212025",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Research Support, Non-U.S. Gov't; Systematic Review; Journal Article; Network Meta-Analysis; systematic-review; article"],["R0022710","Weight Loss Outcomes in a Veterans Affairs Pharmacotherapy-based Weight Management Clinic.","Ni K","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae042","38515583","PMC10957131",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022711","In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.","Gejl M","2016","Frontiers in aging neuroscience","randomized_trial","article","10.3389/fnagi.2016.00108","27252647","PMC4877513","ClinicalTrials.gov:NCT01469351","S001707","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0022712","Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats.","Hall MJ","2015","Domestic animal endocrinology","preclinical","article","10.1016/j.domaniend.2014.12.001","25625650",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022713","Effect of Peptide Drug Liraglutide Nano-Formulation Combined with Sodium-Glucose Cotransporter-2 Inhibitor on Blood Lipids in Patients with Type 2 Diabetes.","She Y","2022","Cellular and molecular biology (Noisy-le-Grand, France)","other","article","10.14715/cmb/2022.68.3.25","35988179",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022714","Systematic Review of Left Ventricular Remodeling in Response to Hypoglycemic Medications: Assessing Changes in End-Systolic and End-Diastolic Diameters.","Buz BF","2024","Biomedicines","systematic_review","article","10.3390/biomedicines12081791","39200254","PMC11351395",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0022715","Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice.","Millar P","2017","The Journal of endocrinology","preclinical","article","10.1530/joe-17-0263","28611211",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022716","Scoping Review-Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions.","Habte-Asres HH","2025","Journal of diabetes science and technology","narrative_review","article","10.1177/19322968251353811","40891490","PMC12405195",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022717","An intrinsic agonist mechanism for activation of glucagon-like peptide-1 receptor by its extracellular domain.","Yin Y","2016","Cell discovery","other","article","10.1038/celldisc.2016.42","27917297","PMC5118412",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022718","Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats.","Ando H","2017","Scientific reports","preclinical","article","10.1038/s41598-017-05371-4","28717164","PMC5514038",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022719","[Unintentional weight loss in chronic kidney disease].","Radermacher J","2023","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-023-01527-9","37221379",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0022720","Semaglutide for nonalcoholic steatohepatitis: closer to a solution?","Liava C","2021","Hepatobiliary surgery and nutrition","commentary","article","10.21037/hbsn-21-231","34430539","PMC8351017",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0022721","Male-specific consequences of obesity - functional hypogonadism and fertility disorders.","Rabijewski M","2023","Endokrynologia Polska","other","article","10.5603/ep.95626","37779374",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022722","Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.","Kim S","2009","The Journal of endocrinology","preclinical","article","10.1677/joe-09-0132","19570816",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022723","Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.","Kapitza C","2013","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12076","23368510","PMC3752965","ClinicalTrials.gov:NCT01175473","S000587","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022724","Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications.","Jensterle M","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22020902","33477478","PMC7830704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022725","Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.","Manigault KR","2016","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","narrative_review","article","10.4140/tcp.n.2016.685","28074747",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022726","Monogenic Obesity; Using Drugs to Bypass the Problem.","Coll AP","2018","Cell metabolism","commentary","article","10.1016/j.cmet.2018.06.015","29972795",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comment; Journal Article"],["R0022727","Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation.","McLean BA","2021","Endocrine reviews","narrative_review","article","10.1210/endrev/bnaa032","33320179","PMC7958144",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0022728","Semaglutide and the risk of diabetic retinopathy-current perspective.","Sharma A","2022","Eye (London, England)","other","article","10.1038/s41433-021-01741-5","34373613","PMC8727607",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0022729","The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.","Rolin B","2002","American journal of physiology. Endocrinology and metabolism","other_trial","article","10.1152/ajpendo.00030.2002","12217892",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; article"],["R0022730","South Asian Consensus Guideline: Use of GLP-1 analogue therapy in diabetes during Ramadan.","Pathan MF","2012","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/2230-8210.98003","22837910","PMC3401750",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; other; article"],["R0022731","Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.","Davies M","2017","JAMA","randomized_trial","article","10.1001/jama.2017.14752","29049653","PMC5817971","ClinicalTrials.gov:NCT01923181","S001046","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0022732","A peripheral lipid sensor GPR120 remotely contributes to suppression of PGD2-microglia-provoked neuroinflammation and neurodegeneration in the mouse hippocampus.","Iwasa K","2021","Journal of neuroinflammation","preclinical","article","10.1186/s12974-021-02361-2","34961526","PMC8711188",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0022733","Gliptins, exenatide, liraglutide: \"intestinal obstruction\".",null,"2016","Prescrire international","other","article",null,"26942257",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022734","Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.","Meece J","2007","Current medical research and opinion","narrative_review","article","10.1185/030079906x167336","17407650",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022735","Incretin based therapies: bone protective effects.","Chakhtoura M","2013","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/18715303113136660046","24138054",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022736","Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner.","Mukai E","2011","Diabetes","preclinical","article","10.2337/db10-0021","20978090","PMC3012174",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022737","Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.","Rasmussen IKB","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14516","34387408",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022738","Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.","Frías JP","2021","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(21)00174-1","34293304",null,"ClinicalTrials.gov:NCT03989232; EudraCT:2018-004529-96","S001353","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022739","Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?","Amouyal C","2016","Journal of diabetes research","narrative_review","article","10.1155/2016/5908656","27382574","PMC4921140",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Review; research-article; article"],["R0022740","Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors.","Engeli S","2014","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/01.mnh.0000449846.91046.ac","24914567",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022741","Controlled release of biologics for the treatment of type 2 diabetes.","Gilroy CA","2016","Journal of controlled release : official journal of the Controlled Release Society","narrative_review","article","10.1016/j.jconrel.2015.12.002","26655062","PMC4889564",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0022742","Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis.","Bhushan S","2025","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2025.2478917","40100944",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0022743","Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats.","Gad ES","2016","Canadian journal of physiology and pharmacology","preclinical","article","10.1139/cjpp-2015-0242","27389824",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022744","In Vivo Mechanism of Action of Sodium Caprate for Improving the Intestinal Absorption of a GLP1/GIP Coagonist Peptide.","Tran H","2023","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.2c00443","36592951",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022745","Neuroprotective actions of glucagon-like peptide-1 in differentiated human neuroprogenitor cells.","Velmurugan K","2012","Journal of neurochemistry","other","article","10.1111/jnc.12036","23020846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0022746","Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.","Simonsen L","2006","Diabetologia","preclinical","article","10.1007/s00125-005-0128-9","16447056",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022747","Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic beta-cell line.","Murao K","2009","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2009.01067.x","19486109",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022748","Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery.","Muratori F","2022","Eating and weight disorders : EWD","nonrandomized_study","article","10.1007/s40519-022-01403-9","35763245","PMC9556416",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022749","Mesoporous Silica Nanoparticle as a Potential Nanocarrier to Improve the Effectiveness of Antiobesity Drugs.","Aulifa DL","2025","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s538644","41070258","PMC12506778",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0022750","[Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].","Atonal-Flores B","2023","Revista medica del Instituto Mexicano del Seguro Social","nonrandomized_study","article","10.5281/zenodo.8200442","37540652","PMC10484544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","English Abstract; Journal Article; Observational Study; research-article; article; other"],["R0022751","A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).","Calara F","2005","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2005.02.008","15811484",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022752","Peptibodies: Bridging the gap between peptides and antibodies.","Khezri H","2024","International journal of biological macromolecules","narrative_review","article","10.1016/j.ijbiomac.2024.134718","39142490",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022753","Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice.","Baggio LL","2006","Diabetes","preclinical","article","10.2337/db05-1502","16731818",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022754","Glycemia Shift Pancreatic Islets Rhythmicity via δ-α Cell in vivo, Impairment in Diabetes","Deng Y","2025","bioRxiv","preclinical","preprint","10.1101/2025.08.09.669458",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0022755","Extended-release exenatide (Bydureon) for type 2 diabetes.",null,"2012","The Medical letter on drugs and therapeutics","other","article",null,"22421818",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022756","[Starting insulin or not? And if so, which basal insulin?].","Tack CJ","2020","Nederlands tijdschrift voor geneeskunde","case_report","article",null,"33201616",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022757","Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.","Wilding JPH","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14725","35441470","PMC9542252","ClinicalTrials.gov:NCT03548935","S000144; S001434; S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022758","Glucagon-Like Peptide-1 Receptor Signaling in the Ventral Tegmental Area Reduces Alcohol Self-Administration in Male Rats.","Dixon TN","2020","Alcoholism, clinical and experimental research","preclinical","article","10.1111/acer.14437","33043520",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022759","Tirzepatide Tested for Type 2 Diabetes With High Cardiovascular Risk.","Slomski A","2021","JAMA","other","article","10.1001/jama.2021.22775","34962528",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022760","MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.","Ambery P","2018","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(18)30726-8","29945727",null,"ClinicalTrials.gov:NCT02548585","S000451","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022761","Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.","Faillie JL","2014","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-013-0544-0","24352344",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0022762","Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.","Zhou JB","2020","Metabolism: clinical and experimental","systematic_review","article","10.1016/j.metabol.2020.154265","32446679",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; article"],["R0022763","Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.","Taylor K","2005","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","other","article","10.1055/s-2005-870529","16278786",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0022764","Cardioprotective effects of incretin during ischaemia-reperfusion.","Chinda K","2012","Diabetes & vascular disease research","narrative_review","article","10.1177/1479164112440816","22496404",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022765","Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis.","Citraro R","2019","Brain research bulletin","preclinical","article","10.1016/j.brainresbull.2019.08.001","31470253",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022766","Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes.","Kaku K","2011","Journal of diabetes investigation","randomized_trial","article","10.1111/j.2040-1124.2011.00128.x","24843528","PMC4014903","ClinicalTrials.gov:NCT00393718","S000330","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0022767","Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus.","Zykov VA","2018","World journal of diabetes","randomized_trial","article","10.4239/wjd.v9.i9.149","30254724","PMC6153122",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0022768","[New and old glucose lowering drugs; a state-of-the-art review].","IJzerman RG","2020","Nederlands tijdschrift voor geneeskunde","narrative_review","article",null,"33201636",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022769","Efficacy and safety of dapagliflozin and liraglutide in patients with type 2 diabetes mellitus and newly diagnosed as overweight/obese.","Liang YL","2023","Asian journal of surgery","commentary","article","10.1016/j.asjsur.2022.07.115","35963674",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0022770","Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease.","Georgianos PI","2022","Journal of personalized medicine","randomized_trial","article","10.3390/jpm12020223","35207711","PMC8874759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0022771","Assessment of Exenatide loaded Biotinylated Trimethylated Chitosan/HP- 55 Nanoparticles.","Guo H","2022","Current drug delivery","preclinical","article","10.2174/1567201818666210614100603","34126896",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022772","Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes.","Brill AL","2016","Molecular endocrinology (Baltimore, Md.)","preclinical","article","10.1210/me.2015-1164","27049466","PMC4853566",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022773","Cardiovascular effects of glucagonlike peptide-1 agonists.","Davidson MH","2011","The American journal of cardiology","narrative_review","article","10.1016/j.amjcard.2011.03.046","21802579",null,null,"S000937","pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0022774","Psychological and quality of life changes in patients using GLP-1 analogues.","Grant P","2011","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2011.03.002","21601480",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Controlled Clinical Trial; Journal Article; article"],["R0022775","Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect.","Nodari S","2023","Heart failure reviews","narrative_review","article","10.1007/s10741-021-10203-9","35133551","PMC8821791",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Review; review-article"],["R0022776","Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent.","Colosimo S","2023","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2022.12.010","36710114","PMC11876092",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022777","Characteristics of Children, Youth, and Young Adults With Diabetes: A Cross-Sectional Study in New Zealand Aotearoa.","Mustafa S","2024","Journal of diabetes research","other","article","10.1155/jdr/9968545","39691822","PMC11651759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022778","Liraglutide ameliorates myocardial damage in experimental diabetic rats by inhibiting pyroptosis via Sirt1/AMPK signaling.","Zhang Z","2021","Iranian journal of basic medical sciences","preclinical","article","10.22038/ijbms.2021.56771.12677","35096293","PMC8769506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022779","Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes.","Frazer M","2024","Journal of diabetes and metabolic disorders","nonrandomized_study","article","10.1007/s40200-023-01341-y","38932879","PMC11196477",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022780","Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.","Carretero-Gómez J","2023","Revista clinica espanola","nonrandomized_study","article","10.1016/j.rceng.2022.12.001","36549643",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Multicenter Study; Journal Article; article"],["R0022781","[Effects of exendin-4 on rat cardiomyocyte apoptosis early after severe scald injury].","Chen YH","2011","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article",null,"21690080",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022782","Effect of liraglutide on microcirculation in rat model with absolute insulin deficiency.","Ivanov AN","2021","Microvascular research","preclinical","article","10.1016/j.mvr.2021.104206","34119534",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022783","Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).","Frias JP","2021","Diabetes care","randomized_trial","article","10.2337/dc20-1473","33397768","PMC7896253","ClinicalTrials.gov:NCT03495102","S000046","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial; research-article; other; article"],["R0022784","Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.","Dave CV","2019","Annals of internal medicine","nonrandomized_study","article","10.7326/m18-3136","31357213","PMC6989379",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022785","Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA.","Billings LK","2019","ClinicoEconomics and outcomes research : CEOR","other","article","10.2147/ceor.s194719","30962697","PMC6432901","ClinicalTrials.gov:NCT02420262","S001760","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0022786","Albiglutide",null,"2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"31643385",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0022787","New strategies to improve clinical outcomes for diabetic kidney disease.","Forst T","2022","BMC medicine","narrative_review","article","10.1186/s12916-022-02539-2","36210442","PMC9548386",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0022788","Weight Management Therapies in Metabolic Dysfunction-Associated Steatotic Liver Disease are not affected by Comorbid Psychiatric Disease","Bollinger B","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-4391484/v1",null,null,null,null,"europepmc","FALSE","free_to_read","4",null,"Preprint"],["R0022789","The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.","Ge JJ","2022","Journal of endocrinological investigation","systematic_review","article","10.1007/s40618-021-01666-6","34455568",null,null,"S001012","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0022790","NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice.","Bultinck J","2026","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102282","41242536","PMC12682222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022791","Treatment of short bowel syndrome: Breaking the therapeutic ceiling?","Wauters L","2023","Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition","randomized_trial","article","10.1002/ncp.10974","37115030",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0022792","Trends in the Degree of Control and Treatment of Cardiovascular Risk Factors in People With Type 2 Diabetes in a Primary Care Setting in Catalonia During 2007-2018.","Mata-Cases M","2021","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2021.810757","35082758","PMC8784522",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022793","Dietary salt promotes cognition impairment through GLP-1R/mTOR/p70S6K signaling pathway.","Yang X","2024","Scientific reports","preclinical","article","10.1038/s41598-024-57998-9","38575652","PMC10995169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022794","Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study.","Park T","2021","Exploratory research in clinical and social pharmacy","nonrandomized_study","article","10.1016/j.rcsop.2021.100022","35481118","PMC9031759",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0022795","Cardiovascular effects of incretin-based therapies.","Lehrke M","2011","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2011.8.382","22262075","PMC3280672",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022796","Liraglutide improves sevoflurane-induced postoperative cognitive dysfunction via activating autophagy and inhibiting apoptosis.","Hu Y","2024","Aging","preclinical","article","10.18632/aging.205558","38364258","PMC10929805",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022797","Current and new pharmacotherapy options for non-alcoholic steatohepatitis.","Sumida Y","2020","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2020.1744564","32237916",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0022798","Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.","Salim HM","2016","Vascular pharmacology","preclinical","article","10.1016/j.vph.2015.08.011","26277250",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0022799","Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time.","Jalal Eldin AW","2019","Clinical diabetes and endocrinology","case_report","article","10.1186/s40842-019-0082-y","31333877","PMC6617654",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; other; article"],["R0022800","Endothelial Shear-Stress-Responsive Gene Adenylate Cyclase 4 Suppresses Atherosclerosis by Inhibiting cAMP/PKA-NF-κB Mediated Vascular Inflammation.","Bao W","2026","Arteriosclerosis, thrombosis, and vascular biology","preclinical","article","10.1161/atvbaha.126.324797","42558048",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022801","Oral Delivery of Pentameric Glucagon-Like Peptide-1 by Recombinant Lactobacillus in Diabetic Rats.","Lin Y","2016","PloS one","preclinical","article","10.1371/journal.pone.0162733","27610615","PMC5017604",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022802","Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial.","Seino Y","2011","Journal of diabetes investigation","randomized_trial","article","10.1111/j.2040-1124.2011.00103.x","24843499","PMC4014968","ClinicalTrials.gov:NCT00395746","S000862","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0022803","[The role of obesity in the development and progression of osteoarthritis: the influence of medical and surgical therapies for obesity on the course of inflammatory arthritis: A review].","Troshina EA","2025","Terapevticheskii arkhiv","narrative_review","article","10.26442/00403660.2025.05.203230","40561489",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0022804","Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.","Hu Y","2016","Diabetes & metabolism","other","article","10.1016/j.diabet.2016.04.005","27178737",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022805","Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.","Ghusn W","2022","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2022.31982","36121652","PMC9486455",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0022806","[Evidence-based reduction of cardiovascular risk in patients with diabetes].","Schütt KA","2020","Herz","nonrandomized_study","article","10.1007/s00059-019-04876-0","31820029",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0022807","Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges.","Kuchay MS","2021","Biomedicines","narrative_review","article","10.3390/biomedicines9101346","34680463","PMC8533092",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022808","Effective oral delivery of Exenatide-Zn2+ complex through distal ileum-targeted double layers nanocarriers modified with deoxycholic acid and glycocholic acid in diabetes therapy.","Han Y","2021","Biomaterials","preclinical","article","10.1016/j.biomaterials.2021.120944","34153783",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022809","Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes.","Zupa MF","2021","Journal of comparative effectiveness research","other","article","10.2217/cer-2021-0016","34490786","PMC8656343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0022810","Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.","Shah D","2018","ClinicoEconomics and outcomes research : CEOR","nonrandomized_study","article","10.2147/ceor.s180067","30532570","PMC6241540",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022811","Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.","Usui R","2015","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2015.07.020","26279320",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022812","Exendin-4 inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis.","Lee W","2014","Inflammation","preclinical","article","10.1007/s10753-014-9919-9","24826914",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022813","Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes.","Wu H","2023","Frontiers in endocrinology","other","article","10.3389/fendo.2023.1098032","36793278","PMC9922750",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022814","Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms.","Bajaj HS","2018","Physiology (Bethesda, Md.)","narrative_review","article","10.1152/physiol.00004.2018","29638185",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022815","Reprogramming Mouse Cells With a Pancreatic Duct Phenotype to Insulin-Producing β-Like Cells.","Yamada T","2015","Endocrinology","preclinical","article","10.1210/en.2014-1987","25836667","PMC4430605",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022816","Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: A prospective randomized controlled study.","Yu D","2022","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2022.951570","36093105","PMC9458907",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022817","Pneumoperitoneum by subcutaneous injections of GLP-1 analogues. A case report.","Miras I","2018","Endocrinologia, diabetes y nutricion","case_report","article","10.1016/j.endinu.2018.06.002","30077633",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022818","Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients.","Huang J","2018","International journal of chronic obstructive pulmonary disease","other","article","10.2147/copd.s175145","30349227","PMC6186765",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022819","PET of glucagonlike peptide receptor upregulation after myocardial ischemia or reperfusion injury.","Gao H","2012","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.112.109413","23139087",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; article"],["R0022820","Complementing insulin therapy to achieve glycemic control.","Barnett AH","2013","Advances in therapy","nonrandomized_study","article","10.1007/s12325-013-0039-y","23797471",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0022821","Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus.","Bond A","2006","Proceedings (Baylor University. Medical Center)","randomized_trial","article","10.1080/08998280.2006.11928181","17252050","PMC1484540",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0022822","Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution.","Oldham S","2019","Journal of visualized experiments : JoVE","other_trial","article","10.3791/59130","31058888",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Video-Audio Media; article"],["R0022823","Intranasal Human Recombinant Modified Glucagon-Like Peptide-1: High Antihyperglycemic Activity and Duration of Action in Mice.","Rykalina NV","2020","Bulletin of experimental biology and medicine","preclinical","article","10.1007/s10517-020-04822-9","32495167",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022824","The future of insulin therapy for patients with type 2 diabetes mellitus.","Tibaldi JM","2013","The Journal of the American Osteopathic Association","narrative_review","article",null,"23545888",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022825","Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus.","Khan M","2015","Journal of diabetes research","nonrandomized_study","article","10.1155/2015/162718","25688374","PMC4320857",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0022826","Enhancing bile tolerance of Lactobacilli is involved in the hypolipidemic effects of liraglutide.","Wang C","2021","Bioscience, biotechnology, and biochemistry","preclinical","article","10.1093/bbb/zbab053","33784390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022827","Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.","Buse JB","2004","Diabetes care","randomized_trial","article","10.2337/diacare.27.11.2628","15504997",null,null,"S000180; S000477; S000898","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022828","Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.","Yu M","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00804-2","32277401","PMC7192976","ClinicalTrials.gov:NCT01644500; ClinicalTrials.gov:NCT01648582","S001064; S001404","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0022829","The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus.","Hsu WC","2022","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm11092653","35566779","PMC9101888",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022830","Liraglutide promotes UCP1 expression and lipolysis of adipocytes by promoting the secretion of irisin from skeletal muscle cells.","Zhang N","2024","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2024.112225","38570133",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022831","Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).","Green JB","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14993","36700460",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022832","Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma.","Sowa-Staszczak A","2013","European journal of nuclear medicine and molecular imaging","other","article","10.1007/s00259-012-2299-1","23224740","PMC3590421",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022833","Central GLP-1 contributes to improved cognitive function and brain glucose uptake after duodenum-jejunum bypass on obese and diabetic rats.","Ruze R","2021","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00126.2021","34370593",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0022834","Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.","Samson SL","2011","Diabetologia","randomized_trial","article","10.1007/s00125-011-2317-z","21956711","PMC3658171","ClinicalTrials.gov:NCT01432405","S002364","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022835","New therapeutic options: management strategies to optimize glycemic control.","Freeman JS","2010","The Journal of the American Osteopathic Association","case_report","article",null,"20382837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022836","Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.","Tzanetakos C","2014","BMC health services research","other_trial","article","10.1186/1472-6963-14-419","25245666","PMC4179852",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022837","Subcutaneous catabolism of peptide therapeutics: bioanalytical approaches and ADME considerations.","Esposito S","2022","Xenobiotica; the fate of foreign compounds in biological systems","narrative_review","article","10.1080/00498254.2022.2119180","36039395",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0022838","Mouse insulin cells expressing an inducible RIPCre transgene are functionally impaired.","Teitelman G","2015","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m114.615484","25533471","PMC4319030",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022839","Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review.","Rizos EC","2013","Current vascular pharmacology","systematic_review","article","10.2174/15701611113119990103","22724475",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0022840","Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.","Konstantinidou SK","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15642","38757729",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Clinical Trial; article"],["R0022841","Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study.","Sharma M","2016","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2015-010210","26769791","PMC4735176",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022842","Incretin hormones: Their role in health and disease.","Nauck MA","2018","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13129","29364588",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022843","Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).","Fonseca VA","2012","Diabetes care","randomized_trial","article","10.2337/dc11-1935","22432104","PMC3357248","ClinicalTrials.gov:NCT00688701","S000473; S002333","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022844","ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients.","Buysschaert M","2015","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2015.05.001","26004030",null,null,"S000307","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0022845","Discovery of Non-Peptide GLP-1 Positive Allosteric Modulators from Natural Products: Virtual Screening, Molecular Dynamics, ADMET Profiling, Repurposing, and Chemical Scaffolds Identification.","Gomaa MS","2024","Pharmaceutics","nonrandomized_study","article","10.3390/pharmaceutics16121607","39771585","PMC11679513",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Preprint; research-article; preprint; article"],["R0022846","A novel protective modality against rotenone-induced Parkinson's disease: A pre-clinical study with dulaglutide.","Khalaf MM","2023","International immunopharmacology","randomized_trial","article","10.1016/j.intimp.2023.110170","37075673",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0022847","Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism.","Krasner NM","2014","PloS one","other","article","10.1371/journal.pone.0097554","24835252","PMC4023984",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0022848","Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.","Mack CM","2006","International journal of obesity (2005)","preclinical","article","10.1038/sj.ijo.0803284","16534527",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022849","Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes.","Martins EB","2020","Revista da Associacao Medica Brasileira (1992)","narrative_review","article","10.1590/1806-9282.66.9.1283","33027459",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0022850","[Cushing syndrome because of herbal supplement].","Krul-Poel YHM","2024","Nederlands tijdschrift voor geneeskunde","case_report","article",null,"38989679",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022851","Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics.","Sørensen MH","2020","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-020-01135-z","32998751","PMC7528463","ClinicalTrials.gov:NCT02684331",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0022852","Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.","Takahashi M","2020","PloS one","systematic_review","article","10.1371/journal.pone.0236603","32706828","PMC7380634",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; research-article; review"],["R0022853","A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents.","Gotthardt M","2006","Regulatory peptides","preclinical","article","10.1016/j.regpep.2006.07.005","16930741",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022854","Lack of effect of prolonged treatment with liraglutide on cardiac remodeling in rats after acute myocardial infarction.","Kyhl K","2017","Peptides","randomized_trial","article","10.1016/j.peptides.2017.04.009","28460895",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0022855","Roux-en-Y Gastric Bypass and Caloric Restriction but Not Gut Hormone-Based Treatments Profoundly Impact the Hypothalamic Transcriptome in Obese Rats.","Dischinger U","2021","Nutrients","randomized_trial","article","10.3390/nu14010116","35010991","PMC8746874",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0022856","GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.","Farr OM","2016","Diabetologia","randomized_trial","article","10.1007/s00125-016-3874-y","26831302","PMC4826792","ClinicalTrials.gov:NCT01562678","S001397","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022857","Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction.","Chen YT","2013","Journal of translational medicine","preclinical","article","10.1186/1479-5876-11-270","24161164","PMC4231365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022858","Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.","Shaddinger BC","2019","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2019.04.018","31004676",null,null,"S000748","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0022859","Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons.","Eikelboom R","2021","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000000889","34138766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022860","Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor.","Bird GH","2020","ACS chemical biology","other","article","10.1021/acschembio.0c00308","32348108","PMC7366314",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022861","Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.","Bode B","2009","Hospital practice (1995)","narrative_review","article","10.3810/hp.2009.12.249","20720383",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022862","Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.","Kelly AS","2012","Cardiovascular diabetology","randomized_trial","article","10.1186/1475-2840-11-64","22681705","PMC3434036","ClinicalTrials.gov:NCT00546728","S002163","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0022863","The potential role of Tirzepatide as adjuvant therapy in countering colistin-induced nephro and neurotoxicity in rats via modulation of PI3K/p-Akt/GSK3-β/NF-kB p65 hub, shielding against oxidative and endoplasmic reticulum stress, and activation of p-CREB/BDNF/TrkB cascade.","Hassan NF","2024","International immunopharmacology","preclinical","article","10.1016/j.intimp.2024.112308","38788447",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022864","Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.","Leiter LA","2014","Diabetes care","randomized_trial","article","10.2337/dc13-2855","25048383",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022865","Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).","Umpierrez G","2014","Diabetes care","randomized_trial","article","10.2337/dc13-2759","24842985",null,"ClinicalTrials.gov:NCT01126580","S000993; S001786","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022866","Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives.","Kounatidis D","2022","Current nutrition reports","other_trial","article","10.1007/s13668-022-00433-0","35933503",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0022867","High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management.","Bradley CL","2022","The Annals of pharmacotherapy","randomized_trial","article","10.1177/10600280211053867","34706581",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0022868","Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.","Regan JA","2023","JCI insight","systematic_review","article","10.1172/jci.insight.168563","37552540","PMC10544215",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0022869","The Impact of Various Methods of Obesity Treatment on the Quality of Life and Mental Health-A Narrative Review.","Hachuła M","2023","International journal of environmental research and public health","narrative_review","article","10.3390/ijerph20032122","36767489","PMC9915720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0022870","The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.","Gallwitz B","2006","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2006.3.208","17487346","PMC1828283",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0022871","Protective effect of liraglutide on the myocardium of type 2 diabetic rats by inhibiting polyadenosine diphosphate-ribose polymerase-1.","Xue DD","2023","World journal of diabetes","preclinical","article","10.4239/wjd.v14.i2.110","36926657","PMC10011895",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022872","The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity.","Lee M","2020","Obesity science & practice","other","article","10.1002/osp4.390","32313674","PMC7156872",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022873","Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.","Trevaskis JL","2012","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00476.2011","22268099",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022874","Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies.","Longo M","2020","Cardiovascular diabetology","commentary","article","10.1186/s12933-020-01090-9","32698837","PMC7375203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0022875","Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.","Di Loreto C","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-022-01263-7","35461397","PMC9174395",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0022876","Surpassing insulin glargine in type 2 diabetes with tirzepatide.","Khoo B","2021","Lancet (London, England)","other","article","10.1016/s0140-6736(21)02279-0","34672968",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022877","Acute necrotizing pancreatitis associated with vildagliptin.","Kunjathaya P","2013","JOP : Journal of the pancreas","case_report","article","10.6092/1590-8577/1203","23306341",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0022878","EXtENDINg beta cell survival by UPRegulating ATF4 translation.","Wek RC","2006","Cell metabolism","preclinical","article","10.1016/j.cmet.2006.10.006","17084705",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Comment"],["R0022879","GLP-1 analog liraglutide enhances proinsulin processing in pancreatic β-cells via a PKA-dependent pathway.","Wang L","2014","Endocrinology","preclinical","article","10.1210/en.2014-1218","25051441",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022880","Quality of care and prescription patterns among patients with diabetic kidney disease-a large-scale cohort study from Taiwanese clinics.","Tsai KY","2022","PeerJ","nonrandomized_study","article","10.7717/peerj.13636","35915752","PMC9338750",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022881","Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies.","Brown NJ","2012","Journal of the American Society of Hypertension : JASH","narrative_review","article","10.1016/j.jash.2012.02.003","22433315","PMC3422131",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0022882","Oral Administration of Sitagliptin Activates CREB and Is Neuroprotective in Murine Model of Brain Trauma.","DellaValle B","2016","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2016.00450","27990119","PMC5130988",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022883","Neurological manifestations in m.3243A>G-related disease triggered by metformin.","Tong HF","2022","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2021.108111","35123869",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022884","Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review.","Ahmed NR","2022","Cureus","systematic_review","article","10.7759/cureus.24829","35693370","PMC9173657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0022885","Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report","Jonas D","2011","Oregon Health & Science University, Portland (OR)","other_trial","article",null,"21595121",null,null,null,"europepmc; openalex","FALSE","free_to_read","5","FALSE","Review; article"],["R0022886","Optimization of Protein Folding for Improved Secretion of Human Serum Albumin Fusion Proteins in Saccharomyces cerevisiae.","Li Y","2023","Journal of agricultural and food chemistry","other","article","10.1021/acs.jafc.3c05330","37966975",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022887","Glycemic variability and all-cause mortality in a large prospective southern European cohort of patients with differences in glycemic status.","Salinero-Fort MA","2022","PloS one","nonrandomized_study","article","10.1371/journal.pone.0271632","35877766","PMC9312379",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; article; preprint"],["R0022888","Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159-2167.","Wysham C","2015","Diabetes care","notice","article","10.2337/dc15-er07b","26106226",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0022889","Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.","Mares AC","2022","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000000955","35175229",null,"ClinicalTrials.gov:NCT03574597","S000716","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0022890","A Systematic Review of Treatment Approaches for Individuals With Coexisting Diabetes and Substance Use Disorder.","Husain B","2025","Cureus","systematic_review","article","10.7759/cureus.95352","41287656","PMC12640742",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0022891","Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes.","Shao S","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.731974","34690930","PMC8527093",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0022892","Shift of Glucose Peak Time During Oral Glucose Tolerance Test is Associated with Changes in Insulin Secretion and Insulin Sensitivity After Therapy with Antidiabetic Drugs in Patients with Type 2 Diabetes.","Jiang Y","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-021-01107-w","34342864","PMC8385093",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022893","Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells.","Buenaventura T","2019","PLoS biology","other","article","10.1371/journal.pbio.3000097","31430273","PMC6716783",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022894","Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes.","Rizzo M","2022","Expert review of clinical pharmacology","commentary","article","10.1080/17512433.2022.2108400","35924858",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; editorial"],["R0022895","Stroke in the patient with diabetes (Part 2) - Prevention and the effects of glucose lowering therapies.","Bell DSH","2020","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2020.108199","32413380",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022896","Off-label use of liraglutide in the management of a pediatric patient with type 2 diabetes mellitus.","Micale SJ","2013","Case reports in pediatrics","other","article","10.1155/2013/703925","24222881","PMC3814067",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022897","Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4.","Larsson M","2016","Bioscience reports","preclinical","article","10.1042/bsr20160437","27780892","PMC5137538",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022898","Glucagon-like peptide 1 based therapy for type 2 diabetes.","Yu BS","2008","World journal of pediatrics : WJP","nonrandomized_study","article","10.1007/s12519-008-0002-1","18402245",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0022899","Literature Commentary.",null,"2024","Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society","nonrandomized_study","article","10.1097/wno.0000000000002285","40418702",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comment; article"],["R0022900","Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus-Clinical Practice Position Statement of the Polish Society of Nephrology.","Adamczak M","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms252312941","39684653","PMC11641270",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; Review; review-article; article"],["R0022901","Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension.","Liu L","2015","Journal of cardiovascular pharmacology","narrative_review","article","10.1097/fjc.0000000000000176","25384196",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022902","Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity.","Patoulias D","2022","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2022.04.030","35599190",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Meta-Analysis; article"],["R0022903","Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy.","Arendt Nielsen T","2022","Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","randomized_trial","article","10.1089/jop.2021.0055","34918951",null,"ClinicalTrials.gov:NCT02138045","S001560","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022904","Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).","Skrivanek Z","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12305","24762094",null,"ClinicalTrials.gov:NCT00734474","S001242","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022905","Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.","Westfall E","2020","American family physician","other","article",null,"33179890",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022906","The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.","Lane W","2011","Diabetes technology & therapeutics","other","article","10.1089/dia.2010.0221","21406014",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022907","Non-alcoholic Fatty Liver Disease in Pregnancy: Clinical Implications, Adverse Outcomes, and Therapeutic Considerations.","Wyszynski DF","2026","Journal of clinical and experimental hepatology","narrative_review","article","10.1016/j.jceh.2025.103431","41542026","PMC12800500",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0022908","The Current Role of Liraglutide in the Pharmacotherapy of Obesity.","Christou GA","2016","Current vascular pharmacology","nonrandomized_study","article","10.2174/1570161113666150615111951","26074046",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0022909","How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease.","Ismaiel A","2023","American journal of therapeutics","other","article","10.1097/mjt.0000000000001174","32467498",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022910","Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.","Lovshin JA","2015","Diabetes care","randomized_trial","article","10.2337/dc14-1958","25414155",null,"ClinicalTrials.gov:NCT01755572","S001627","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022911","Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.","O'Brien MJ","2018","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2018.6125","30646315","PMC6324353",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022912","Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy.","Dutta D","2017","Journal of postgraduate medicine","narrative_review","article","10.4103/0022-3859.191007","27652986","PMC5414421",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022913","Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis.","Men P","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-020-00857-3","32562244","PMC7376816",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; other; article"],["R0022914","The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.","Shimoda M","2011","Diabetologia","preclinical","article","10.1007/s00125-011-2069-9","21340625","PMC3071950",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022915","Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).","Do A","2025","Nature reviews. Drug discovery","other_trial","article","10.1038/s41573-024-01084-2","39609545",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0022916","The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes.","Zhao N","2021","Journal of diabetes research","other","article","10.1155/2021/5578216","34825006","PMC8610652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022917","Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.","Tanaka K","2015","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej14-0602","25739726",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022918","Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.","Inoue K","2014","Diabetology & metabolic syndrome","other","article","10.1186/1758-5996-6-95","25237400","PMC4167135",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022919","Incretin-based therapies for type 2 diabetes: clinical utility.","Ratner R","2006","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/s0889-8529(07)70005-1","17424675",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022920","Drug updates and approvals: 2015 in review.","Klibanov OM","2015","The Nurse practitioner","narrative_review","article","10.1097/01.npr.0000473071.26873.3c","26545091",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022921","Highly glycosylated CD147 promotes hemorrhagic transformation after rt-PA treatment in diabetes: a novel therapeutic target?","Xie Y","2019","Journal of neuroinflammation","preclinical","article","10.1186/s12974-019-1460-1","30953513","PMC6449915",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0022922","Expression of GLP-1 receptors in insulin-containing interneurons of rat cerebral cortex.","Csajbók ÉA","2019","Diabetologia","preclinical","article","10.1007/s00125-018-4803-z","30637442",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0022923","A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure.","Munaf M","2012","International journal of peptides","systematic_review","article","10.1155/2012/249827","22811735","PMC3395195",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review-article; review"],["R0022924","Should GLP-1 receptor agonists be used with caution in high risk population for colorectal cancer?","Sun Y","2014","Medical hypotheses","other","article","10.1016/j.mehy.2013.11.034","24424394",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022925","Determinants in Tailoring Antidiabetic Therapies: A Personalized Approach.","Rizvi AA","2022","Global medical genetics","narrative_review","article","10.1055/s-0041-1741109","35707783","PMC9192178",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022926","Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.","Smits MM","2017","Diabetes care","randomized_trial","article","10.2337/dc16-0836","27998910",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0022927","A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.","Pi-Sunyer X","2015","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1411892","26132939",null,"ClinicalTrials.gov:NCT01272219","S000313; S000371; S000388; S000492; S000578; S001853","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022928","Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.","Singh S","2014","Current diabetes reports","other_trial","article","10.1007/s11892-014-0563-4","25363547",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0022929","Terahertz Spectroscopy: An investigation of the Structural Dynamics of Freeze-Dried PLGA Microspheres","Shmool T","2019","ChemRxiv","other","preprint","10.26434/chemrxiv.7547222.v2",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0022930","Incretins: a new treatment option for type 2 diabetes?","Geelhoed-Duijvestijn PH","2007","The Netherlands journal of medicine","narrative_review","article",null,"17379930",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022931","Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state.","Arnés L","2009","Regulatory peptides","preclinical","article","10.1016/j.regpep.2008.08.005","18804493",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022932","Liraglutide Promotes Cortical Neurite Outgrowth via the MEK-ERK Pathway.","Li M","2015","Cellular and molecular neurobiology","preclinical","article","10.1007/s10571-015-0193-7","25862329","PMC11488052",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022933","Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.","Lee J","2012","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2011.12.050","22226877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022934","Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes.","Charlton A","2020","Biology","narrative_review","article","10.3390/biology10010018","33396868","PMC7830433",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022935","Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.","Jensterle M","2017","BMC endocrine disorders","randomized_trial","article","10.1186/s12902-017-0155-9","28143456","PMC5286837","ClinicalTrials.gov:NCT02909933","S000499; S000679","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0022936","Noninvasive Monitoring of Glycemia-Induced Regulation of GLP-1R Expression in Murine and Human Islets of Langerhans.","Buitinga M","2020","Diabetes","preclinical","article","10.2337/db20-0616","32843570",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022937","Semaglutide in routine clinical practice: interesting news from real-world evidence.","Formoso G","2022","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-022-01810-w","35524036",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0022938","LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells.","Dai Y","2013","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2013.06.035","23806684",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022939","Comment on Abd El Aziz et al., A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.","Home P","2017","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12842","27935230",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Letter; Comment; article"],["R0022940","Effect of PANDER in βTC6-cell lipoapoptosis and the protective role of exendin-4.","Xiang JN","2012","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2012.04.065","22542939",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022941","Tirzepatide: a new low for bodyweight and blood glucose.","Bailey CJ","2021","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(21)00217-5","34419226",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022942","Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: A single-center study.","Srinivasan D","2022","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2022.100016","37990710","PMC10661916",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0022943","Liraglutide alleviates H2O2-induced retinal ganglion cells injury by inhibiting autophagy through mitochondrial pathways.","Ma X","2017","Peptides","other","article","10.1016/j.peptides.2017.04.008","28450048",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022944","Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists.","Darbalaei S","2023","Acta pharmacologica Sinica","other","article","10.1038/s41401-022-00962-y","35953646","PMC9889767",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022945","Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial.","Sahay R","2020","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2020.108148","32302665",null,"ClinicalTrials.gov:NCT02941367","S000646","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0022946","Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.","Tatarkiewicz K","2014","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00495.2013","24477544",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022947","Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.","Hong D","2019","PharmacoEconomics","systematic_review","article","10.1007/s40273-019-00774-9","30854589",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0022948","What to do about borderline hyperglycemia?",null,"1994","Therapeutics Initiative, Vancouver (BC)","narrative_review","article",null,"38620436",null,null,null,"europepmc","TRUE",null,null,null,"Book; Review"],["R0022949","Combination Therapies for Obesity.","Camilleri M","2018","Metabolic syndrome and related disorders","other_trial","article","10.1089/met.2018.0075","29993319","PMC6167613",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; review-article; article"],["R0022950","Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.","Lim S","2018","Atherosclerosis","narrative_review","article","10.1016/j.atherosclerosis.2018.03.013","29547706",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0022951","[Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].","Diamant M","2004","Nederlands tijdschrift voor geneeskunde","narrative_review","article",null,"15495988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0022952","Effects of antidiabetics and exercise therapy on suppressors of cytokine signaling-1, suppressors of cytokine signaling-3, and insulin receptor substrate-1 molecules in diabetes and obesity.","Akarsu E","2023","Revista da Associacao Medica Brasileira (1992)","preclinical","article","10.1590/1806-9282.20220856","36629649","PMC9937604",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022953","Efficacy of tirzepatide for weight loss and it's comparative effectiveness to weight loss surgery in inflammatory bowel disease.","Desai A","2026","Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology","nonrandomized_study","article","10.1007/s12664-025-01835-y","40682732",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0022954","Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.","Polyzos SA","2022","Hormones (Athens, Greece)","other","article","10.1007/s42000-022-00379-6","35668318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022955","Mechanism of GLP-1 Receptor Agonists-Mediated Attenuation of Palmitic Acid-Induced Lipotoxicity in L6 Myoblasts.","Kong MW","2022","BioMed research international","narrative_review","article","10.1155/2022/6237405","36619308","PMC9812596",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022956","Epac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytes.","Mangmool S","2015","Molecular endocrinology (Baltimore, Md.)","preclinical","article","10.1210/me.2014-1346","25719403","PMC5414745",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022957","Glucolipotoxicity and GLP-1 secretion.","Hong JH","2021","BMJ open diabetes research & care","preclinical","article","10.1136/bmjdrc-2020-001905","33627316","PMC7908300",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022958","Effects of sodium-glucose cotransporter inhibitors on cardiorenal and metabolic systems: Latest perspectives from the outcome trials.","Lim S","2019","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13696","31081588",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0022959","Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.","Boland CL","2013","The Annals of pharmacotherapy","randomized_trial","article","10.1345/aph.1r444","23548652",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0022960","Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.","Mansur RB","2017","Journal of affective disorders","other_trial","article","10.1016/j.jad.2016.09.056","27721184",null,null,"S000532","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0022961","Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor.","Erdogdu O","2010","Molecular and cellular endocrinology","other","article","10.1016/j.mce.2010.04.022","20452396",null,null,"S001903","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022962","Case Series of Nizon-Isidor Syndrome by Heterozygous Variants in MED12L With Further Evidence of Mitotic Instability in One Case With Diploid-Triploid Mosaicism.","Stewart R","2026","American journal of medical genetics. Part A","case_report","article","10.1002/ajmg.a.64233","40838347","PMC13282996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; research-article; article"],["R0022963","Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.","Taskinen MR","2021","Diabetes, obesity & metabolism","other","article","10.1111/dom.14328","33502078",null,null,"S000370","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022964","Cyclic AMP-mediated pleiotropic effects of glucagon-like peptide-1 receptor activation. Focus on \"Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a\".","Ye Y","2013","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00419.2012","23364263",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; article"],["R0022965","Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.","Vilsbøll T","2008","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2007.02333.x","18201212",null,null,"S001065","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0022966","Combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation.","Tamaki M","2010","Journal of diabetes investigation","preclinical","article","10.1111/j.2040-1124.2010.00044.x","24843429","PMC4020718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022967","Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice.","Chen LN","2013","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2013.1453","23877319",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022968","IDegLira: combining efficacy, durability, and convenience?","Bellary S","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(19)30198-6","31189518",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0022969","Attenuation of diabetic kidney injury in DPP4-deficient rats; role of GLP-1 on the suppression of AGE formation by inducing glyoxalase 1.","Sarker MK","2020","Aging","preclinical","article","10.18632/aging.102643","31905169","PMC6977656",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022970","A Liraglutide Injection Superimposing a Starvation Acidosis: a Case Report.","Alghamdi M","2022","Medical archives (Sarajevo, Bosnia and Herzegovina)","case_report","article","10.5455/medarh.2022.76.221-223","36200109","PMC9478808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0022971","Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus.","Shang J","2021","PeerJ","other","article","10.7717/peerj.11128","33850659","PMC8019531",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022972","Identification of a prolonged action molecular GLP-1R agonist for the treatment of femoral defects.","Wang N","2020","Biomaterials science","preclinical","article","10.1039/c9bm01426h","31967113",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0022973","Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting.","Ko HJ","2022","Journal of obesity & metabolic syndrome","nonrandomized_study","article","10.7570/jomes22029","36050277","PMC9579476",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022974","A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew).","Chan SW","2011","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2011.06.036","21756894",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0022975","Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.","Charbonnel PB","2015","Diabetes & metabolism","commentary","article","10.1016/s1262-3636(16)30001-5","26774014",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0022976","The Essential Role of Pancreatic α-Cells in Maternal Metabolic Adaptation to Pregnancy.","Qiao L","2022","Diabetes","preclinical","article","10.2337/db21-0923","35147704","PMC9044124",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; other; article"],["R0022977","Exenatide Reduces Tumor Necrosis Factor-α-induced Apoptosis in Cardiomyocytes by Alleviating Mitochondrial Dysfunction.","Cao YY","2015","Chinese medical journal","preclinical","article","10.4103/0366-6999.170259","26612298","PMC4794880",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0022978","Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 for bridging of hyperglycaemia during cardiac surgery.","Hulst AH","2018","BMJ open","protocol","article","10.1136/bmjopen-2018-022189","29866735","PMC5988155","NTR:NTR6323",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; protocol; article"],["R0022979","A RESPONSE TO: \"COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES\".","Kohli-Lynch CN","2021","Journal of managed care & specialty pharmacy","commentary","article","10.18553/jmcp.2021.27.8.1140","34337999","PMC10394429",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0022980","The physiologic role of incretin hormones: clinical applications.","Cefalu WT","2010","The Journal of the American Osteopathic Association","narrative_review","article",null,"20382839",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0022981","Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip.","Nakova VV","2023","Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)","nonrandomized_study","article","10.2478/prilozi-2023-0008","36987757",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0022982","Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins.","Vergès B","2022","Diabetes & metabolism","preclinical","article","10.1016/j.diabet.2021.101284","34551355",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022983","Relationship between glucagon-like peptide-1 receptor gene polymorphism and bone mineral density in postmenopausal women in Shanghai.","Zhang L","2020","Annals of palliative medicine","other","article","10.21037/apm-19-396","32527131",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0022984","Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)","Davies M","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.019",null,"PMC8089158","ClinicalTrials.gov:NCT03552757","S001740","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; article"],["R0022985","Current research on the regulation of glycolipid metabolism by plant-derived active polysaccharides","Xu J","2025","Trends in Food Science & Technology.","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Journal Article"],["R0022986","GLP-1 based therapeutics: simultaneously combating T2DM and obesity.","Heppner KM","2015","Frontiers in neuroscience","narrative_review","article","10.3389/fnins.2015.00092","25852463","PMC4367528",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0022987","Impact of Pharmacists in Therapeutic Optimization Relative to the 2020 American Diabetes Association Standards of Medical Care in Diabetes Guidelines in Patients with Clinical Atherosclerotic Cardiovascular Disease.","Waddell D","2022","Hawai'i journal of health & social welfare","other","article",null,"35028590","PMC8742303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0022988","Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.","Mari A","2007","Diabetes care","randomized_trial","article","10.2337/dc07-0310","17468345",null,null,"S001041","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0022989","Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study.","Santucci C","2018","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2018.10.006","30332619",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0022990","Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials.","Yin DG","2021","Endocrine journal","systematic_review","article","10.1507/endocrj.ej21-0129","34024887",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; review"],["R0022991","Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting.","Kesavadev J","2012","International journal of general medicine","nonrandomized_study","article","10.2147/ijgm.s27886","22536087","PMC3333831",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022992","Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.","Halawi H","2017","The lancet. Gastroenterology & hepatology","randomized_trial","article","10.1016/s2468-1253(17)30285-6","28958851",null,"ClinicalTrials.gov:NCT02647944","S000944; S001045","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; article"],["R0022993","Mapping in vivo microclimate pH distribution in exenatide-encapsulated PLGA microspheres.","Hong JKY","2022","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2022.08.043","36030989",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0022994","Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.","Irwin N","2013","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12079","23388064",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0022995","Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma.","Lopez C","2023","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms24065153","36982228","PMC10049717",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0022996","Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus.","Dharmalingam M","2011","Indian journal of endocrinology and metabolism","other_trial","article","10.4103/2230-8210.77571","21584160","PMC3079863",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0022997","Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.","Kim K","2019","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2019.25.3.314","30816811","PMC10397830",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0022998","Glucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons.","Iwasaki Y","2017","Neuropeptides","preclinical","article","10.1016/j.npep.2017.05.003","28624122",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0022999","Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs.","Zhao Y","2023","Medicine","systematic_review","article","10.1097/md.0000000000032892","36820578","PMC9907937",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0023000","Erratum to GLP-1 receptor agonists: a review of head-to-head clinical studies.",null,"2015","Therapeutic advances in endocrinology and metabolism","notice","article","10.1177/2042018815588879","26134499","PMC4480554",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0023001","Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.","Gong Q","2015","International journal of cardiology","narrative_review","article","10.1016/j.ijcard.2015.06.076","26142202","PMC7114201",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review; research-article"],["R0023002","[Effects of glucagon-like peptides on gallbladder motility].","Gether IM","2018","Ugeskrift for laeger","other","article",null,"30547877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023003","Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention.","Hornby C","2018","Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society","narrative_review","article","10.1097/wno.0000000000000684","29985799","PMC6215484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0023004","Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?","Maiza JC","2016","Minerva endocrinologica","commentary","article",null,"26878563",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0023005","Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis.","Zhong P","2021","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2021.695182","34690750","PMC8526557",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; other; review"],["R0023006","A fusion protein derived from plants holds promising potential as a new oral therapy for type 2 diabetes.","Choi J","2014","Plant biotechnology journal","preclinical","article","10.1111/pbi.12149","24373324",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023007","Liraglutide and DPP-4 inhibitors - side effects comparative clinical study.","Timofte L","2013","Clujul medical (1957)","other","article",null,"26527929","PMC4462430",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023008","Gender differences in adverse event reports associated with antidiabetic drugs.","Joung KI","2020","Scientific reports","nonrandomized_study","article","10.1038/s41598-020-74000-4","33067519","PMC7567832",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023009","Liraglutide in the treatment of obesity.","Ng SY","2014","Expert opinion on biological therapy","narrative_review","article","10.1517/14712598.2014.925870","24905058",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023010","Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication.","Müller N","2020","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.14294","32145093",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023011","Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.","Ding WX","2020","European review for medical and pharmacological sciences","preclinical","article","10.26355/eurrev_202012_24038","33336763",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023012","Evaluation of the Effectiveness of Liraglutide on Metabolic Parameters in the Treatment of Obesity.","Akkurt Kocaeli A","2023","Cureus","nonrandomized_study","article","10.7759/cureus.50544","38222220","PMC10787771",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023013","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference.","Junaid V","2025","Current atherosclerosis reports","nonrandomized_study","article","10.1007/s11883-025-01313-y","40542886",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0023014","Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.","McCarthy M","2015","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.h6702","26656272",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; Comment; article"],["R0023015","Liraglutide-induced effects on energy intake and glycemic profile are independent of total and intact GDF-15 levels in subjects with obesity and diabetes.","Valenzuela-Vallejo L","2022","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2022.101369","35777691",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0023016","Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.","Garvey WT","2024","Diabetes care","randomized_trial","article","10.2337/dc23-1782","38285957","PMC10973909",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0023017","Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential.","Darsalia V","2018","Neuropharmacology","narrative_review","article","10.1016/j.neuropharm.2017.08.022","28823610",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0023018","Diabetes pharmacotherapy and effects on the musculoskeletal system.","Kalaitzoglou E","2019","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.3100","30467957","PMC6358500",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0023019","A case of monogenic diabetes mellitus caused by a novel heterozygous RFX6 nonsense mutation in a 14-year-old girl.","Kim GL","2021","Journal of pediatric endocrinology & metabolism : JPEM","case_report","article","10.1515/jpem-2021-0275","34416793",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0023020","What has changed in the management of chronic ischaemic heart disease? The new European Society of Cardiology Guidelines 2024.","Galante D","2025","European heart journal supplements : journal of the European Society of Cardiology","other","article","10.1093/eurheartjsupp/suaf021","40248288","PMC12001768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023021","Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.","Ishii H","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-00726-8","31758520","PMC6965529","ClinicalTrials.gov:NCT02750410","S001247","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0023022","Chronic high fat diet impairs glucagon like peptide-1 sensitivity in vagal afferents.","Al Helaili A","2020","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2020.08.045","32943186",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023023","Intentional weight loss in overweight and obese patients with heart failure: A systematic review.","Peck KH","2024","European journal of heart failure","systematic_review","article","10.1002/ejhf.3270","38752254",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Journal Article; review"],["R0023024","Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway.","Liu XY","2016","Neurological research","preclinical","article","10.1080/01616412.2016.1145914","27108910",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023025","The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Hollander PA","2024","Diabetes care","randomized_trial","article","10.2337/dc23-0516","37756542","PMC10973913",null,"S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; research-article; article"],["R0023026","Glucose-stimulated insulin secretion depends on FFA1 and Gq in neonatal mouse islets.","Lorza-Gil E","2023","Diabetologia","preclinical","article","10.1007/s00125-023-05932-5","37217659","PMC10317898",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023027","[The incretin effect and type 2 diabetes].","Quintanilla-García C","2010","Revista medica del Instituto Mexicano del Seguro Social","narrative_review","article",null,"21205499",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0023028","Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study.","Germain N","2018","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2017.12.006","29253625",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0023029","Liposome-encapsulated clodronate specifically depletes spinal microglia and reduces initial neuropathic pain.","Wang YR","2018","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2018.03.177","29596830",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023030","Early- and later-stage persistence with antiobesity medications: A retrospective cohort study.","Gasoyan H","2024","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23952","38053443",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0023031","Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development.","Pallagi E","2018","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","other","article","10.1016/j.ejps.2018.07.003","30008428",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023032","The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients.","Albaker W","2021","International journal of general medicine","nonrandomized_study","article","10.2147/ijgm.s336904","34849008","PMC8627262",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023033","Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.","Egan AM","2018","Annals of internal medicine","narrative_review","article","10.7326/acpjc-2018-169-2-002","30014091",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; editorial"],["R0023034","Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.","Seewoodhary J","2010","Diabetes, metabolic syndrome and obesity : targets and therapy","other_trial","article","10.2147/dmsott.s7493","21437086","PMC3047969",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0023035","Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21.","Müller TD","2012","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.2408","22565812",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023036","Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.","Smits MM","2016","Diabetologia","randomized_trial","article","10.1007/s00125-016-4100-7","27627981","PMC6518065","ClinicalTrials.gov:NCT01744236","S002312","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0023037","Purification and bioactivity of exendin-4, a peptide analogue of GLP-1, expressed in Pichia pastoris.","Zhou J","2008","Biotechnology letters","preclinical","article","10.1007/s10529-007-9610-4","18060365","PMC2248218",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023038","Tirzepatide and the new era of twincretins for diabetes.","Tan TM","2021","Lancet (London, England)","commentary","article","10.1016/s0140-6736(21)01390-8","34186023",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0023039","Effects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption.","Kitaura H","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22126578","34205264","PMC8234693",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023040","Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight.","Gedulin BR","2005","Endocrinology","preclinical","article","10.1210/en.2004-1349","15618356",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023041","Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.","Htoo PT","2022","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2022.37606","36264574","PMC9585433",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0023042","Sitagliptin: A Review in Type 2 Diabetes.","Scott LJ","2017","Drugs","other_trial","article","10.1007/s40265-016-0686-9","28078647",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0023043","Incretin hormone mimetics and analogues in diabetes therapeutics.","Green BD","2007","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2007.09.003","18054732",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023044","Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.","Cao B","2022","Metabolic brain disease","preclinical","article","10.1007/s11011-021-00879-1","34817756",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023045","Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use.","Ampudia-Blasco FJ","2010","Expert review of endocrinology & metabolism","other","article","10.1586/eem.10.59","30780828",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023046","Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury.","Marzioni M","2014","Hepatology (Baltimore, Md.)","preclinical","article","10.1002/hep.27262","24925797",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023047","Type 2 diabetes mellitus - conventional therapies and future perspectives in innovative treatment.","Gieroba B","2025","Biochemistry and biophysics reports","narrative_review","article","10.1016/j.bbrep.2025.102037","40395625","PMC12090304",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023048","Understanding GLP-1 analogs and enhancing patients success.","Kruger DF","2010","The Diabetes educator","other","article","10.1177/0145721710374370","20736387",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023049","Cost-effectiveness analysis of surgical and non-surgical weight loss interventions in end-stage knee osteoarthritis and obesity: a Markov State model.","Panunzi S","2025","BMC public health","other","article","10.1186/s12889-025-25427-9","41413518","PMC12829240",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023050","Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats.","Cheng KC","2020","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph13110407","33233692","PMC7699724",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023051","Down-regulation of zinc transporter 8 in the pancreas of db/db mice is rescued by Exendin-4 administration.","Liu BY","2011","Molecular medicine reports","preclinical","article","10.3892/mmr.2010.392","21461562",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023052","Paradoxical new-onset psoriasiform dermatitis associated with exenatide administration.","Bostan E","2022","International journal of dermatology","commentary","article","10.1111/ijd.15863","34403495",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0023053","Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Role of Injectable Medications in Type 2 Diabetes Treatment.","Miller EM","2017","The Journal of family practice","other","article",null,"28991930",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023054","[Effects of GLP-1 receptor agonists on carbohydrate metabolism control].","Fernández-García JC","2014","Medicina clinica","narrative_review","article","10.1016/s0025-7753(14)70104-6","25326839",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023055","The promising significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy.","Li Q","2022","American journal of translational research","nonrandomized_study","article",null,"36105007","PMC9452308",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023056","Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.","Eleftheriadou I","2018","Current medicinal chemistry","randomized_trial","article","10.2174/0929867324666170530075533","28554326",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0023057","Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival.","Nakashima K","2012","Molecular and cellular endocrinology","other","article","10.1016/j.mce.2011.11.008","22108438",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023058","Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement)","Waugh N","2009","National Institute for Health and Clinical Excellence (UK), London","narrative_review","article",null,"22220324",null,null,null,"europepmc","FALSE",null,null,null,"Practice Guideline; Review"],["R0023059","Treatment evaluation of liraglutide in type 2 diabetes.","Kela R","2012","Expert opinion on biological therapy","randomized_trial","article","10.1517/14712598.2012.716823","22897447",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023060","Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.","Durden E","2016","Journal of medical economics","nonrandomized_study","article","10.3111/13696998.2015.1131703","26653068",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023061","Early (5-Day) Onset of Diabetes Mellitus Causes Degeneration of Photoreceptor Cells, Overexpression of Incretins, and Increased Cellular Bioenergetics in Rat Retina.","Adeghate JO","2021","Cells","preclinical","article","10.3390/cells10081981","34440748","PMC8394146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023062","Characterization of a site-specific PEGylated analog of exendin-4 and determination of the PEGylation site.","Qian X","2013","International journal of pharmaceutics","other","article","10.1016/j.ijpharm.2013.06.059","23827193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023063","Liraglutide, a TFEB-Mediated Autophagy Agonist, Promotes the Viability of Random-Pattern Skin Flaps.","Zhu X","2021","Oxidative medicine and cellular longevity","other","article","10.1155/2021/6610603","33868571","PMC8032515",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023064","Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide.","Long J","2022","European journal of clinical pharmacology","other","article","10.1007/s00228-021-03225-7","35034150",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023065","Antidiabetic therapy in post kidney transplantation diabetes mellitus.","Werzowa J","2015","Transplantation reviews (Orlando, Fla.)","narrative_review","article","10.1016/j.trre.2015.01.001","25641399",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0023066","Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.","Yuan GH","2012","Chinese medical journal","randomized_trial","article",null,"22931974",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023067","Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.","Coleman RL","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70280","41221791","PMC12803570",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Validation Study; research-article; article"],["R0023068","Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor.","Nadeau DA","2010","Postgraduate medicine","narrative_review","article","10.3810/pgm.2010.09.2215","20861602",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comment; Journal Article; article"],["R0023069","Treatment options for managing atherogenic dyslipidemia and fatty liver disease.","Rizzo M","2014","Expert opinion on pharmacotherapy","commentary","article","10.1517/14656566.2014.902051","24673432",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0023070","Optimized LC-MS/MS method for quantifying insulin degludec and liraglutide in rat plasma and Tissues: Application in pharmacokinetics and biodistribution.","Ziebarth J","2024","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","preclinical","article","10.1016/j.jchromb.2024.124015","38266609",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023071","GLP-1, a powerful physiological incretin: an update.","Malik J","2018","Journal of biological regulators and homeostatic agents","systematic_review","article",null,"30334409",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","3","FALSE","Letter; Systematic Review; letter"],["R0023072","Colonic Delivery of Nutrients for Sustained and Prolonged Release of Gut Peptides: A Novel Strategy for Appetite Management.","Kamakura R","2022","Molecular nutrition & food research","narrative_review","article","10.1002/mnfr.202200192","35938221","PMC9787473",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0023073","Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-alpha (TNFalpha) and inhibits TNFalpha-induced apoptosis in insulin-secreting cells.","Natalicchio A","2010","Endocrinology","other","article","10.1210/en.2009-1166","20219981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023074","New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.","Gallwitz B","2005","The review of diabetic studies : RDS","preclinical","article","10.1900/rds.2005.2.61","17491680","PMC1783553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0023075","Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.","Kaneko M","2019","Clinical drug investigation","randomized_trial","article","10.1007/s40261-019-00770-z","30887418",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0023076","Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?","Doggrell SA","2021","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2021.1904892","33764251",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; article"],["R0023077","Growth differentiation factor 15 as a potential therapeutic for treating obesity.","Hale C","2021","Molecular metabolism","narrative_review","article","10.1016/j.molmet.2020.101117","33220493","PMC8085570",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0023078","Explore the Effect and Target of Liraglutide on Islet Function in Type 2 Diabetic Rats by miRNA Omics Technology.","Guo Q","2021","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s325030","34511953","PMC8425186",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0023079","National Trends in Diabetes Medication Use in the United States: 2008 to 2015.","Raval AD","2020","Journal of pharmacy practice","nonrandomized_study","article","10.1177/0897190018815048","30572757",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0023080","The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.","Filipovic B","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms222413219","34948020","PMC8704688",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023081","Exenatide prevents high-glucose-induced damage of retinal ganglion cells through a mitochondrial mechanism.","Hao M","2012","Neurochemistry international","other","article","10.1016/j.neuint.2012.04.009","22542771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023082","The prevalence of cardiovascular diseases, chronic kidney disease, and obesity in patients with type 2 diabetes mellitus and the description of concurrent treatments: A two-center retrospective cross-sectional study in Saudi Arabia.","Alshaya OA","2024","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","nonrandomized_study","article","10.1016/j.jsps.2024.102054","38590611","PMC10999870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023083","High dosage of Exendin-4 increased early insulin secretion in differentiated beta cells from mouse embryonic stem cells.","Li H","2010","Acta pharmacologica Sinica","preclinical","article","10.1038/aps.2010.38","20418895","PMC4002753",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023084","The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.","Nauck MA","2021","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14496","34310013",null,null,"S001387","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0023085","Disorder of Glucose Metabolism and Therapy: Implications on the Natural History of Advanced Chronic Liver Disease.","Garcês Soares S","2025","GE Portuguese journal of gastroenterology","nonrandomized_study","article","10.1159/000541211","40726561","PMC12296221",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023086","The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists.","van Baar MJB","2019","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018819865398","31384419","PMC6657126",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023087","NICE recommends weight loss drug semaglutide for obese adults.","Mahase E","2022","BMJ (Clinical research ed.)","other","article","10.1136/bmj.o340","35135753",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023088","Incretin physiology and its role in type 2 diabetes mellitus.","Svec F","2010","The Journal of the American Osteopathic Association","narrative_review","article",null,"20644202",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023089","Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction in islets of diabetic rats.","Park S","2008","Life sciences","preclinical","article","10.1016/j.lfs.2007.12.018","18237751",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023090","Tirzepatide Safely Reduces Blood Glucose, Weight in Type 2 Diabetes.","Slomski A","2021","JAMA","other","article","10.1001/jama.2021.13715","34427602",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023091","Exendin-4 increases histone acetylase activity and reverses epigenetic modifications that silence Pdx1 in the intrauterine growth retarded rat.","Pinney SE","2011","Diabetologia","preclinical","article","10.1007/s00125-011-2250-1","21779870","PMC4461231",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023092","Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes.","Unger J","2013","Current diabetes reports","narrative_review","article","10.1007/s11892-013-0404-x","23955813",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023093","Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.","Flatt PR","2009","Current drug metabolism","narrative_review","article","10.2174/138920009787522124","19275548",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023094","Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.","Pratley RE","2008","Journal of the American Academy of Nurse Practitioners","case_report","article",null,"19402254",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0023095","Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways.","MacDonald PE","2003","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m307612200","14565957",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023096","Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus.","Kim SW","2010","Korean diabetes journal","narrative_review","article","10.4093/kdj.2010.34.6.331","21246005","PMC3021108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0023097","Protective effect of liraglutide on experimental testicular ischaemia reperfusion in rats.","Degirmentepe RB","2021","Andrologia","preclinical","article","10.1111/and.14000","33550644",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023098","[GLP-1 receptor agonists: current state].","Larger É","2015","La Revue du praticien","other","article",null,"26749700",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023099","Can exenatide flatten the post-prandial glucose curve in type 1 diabetes?","Boughton CK","2020","Annals of translational medicine","commentary","article","10.21037/atm-20-3654","33313280","PMC7729374",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0023100","Gut peptides and type 2 diabetes mellitus treatment.","Ahrén B","2003","Current diabetes reports","narrative_review","article","10.1007/s11892-003-0079-9","12975025",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023101","Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss.","Chang RS","2022","Journal of general internal medicine","other","article","10.1007/s11606-021-07215-4","35230621","PMC9130404",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0023102","Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020.","Marx N","2021","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2021.108870","34044026",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023103","Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ).","Boye KS","2020","Journal of patient-reported outcomes","randomized_trial","article","10.1186/s41687-020-00266-x","33296064","PMC7726085",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0023104","Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.","Ou T","2022","Alternative therapies in health and medicine","randomized_trial","article",null,"35751892",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023105","Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus.","Wang T","2020","Journal of clinical pharmacy and therapeutics","nonrandomized_study","article","10.1111/jcpt.13134","32176827",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; article"],["R0023106","Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis.","Zhao Q","2024","Acta pharmaceutica Sinica. B","preclinical","article","10.1016/j.apsb.2023.11.020","38486997","PMC10935026",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023107","New and old agents in the management of diabetic nephropathy.","Lytvyn Y","2016","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000000214","26890303","PMC5841607",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0023108","An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.","Wang S","2024","Journal for immunotherapy of cancer","preclinical","article","10.1136/jitc-2023-008431","38458640","PMC10921532",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023109","Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.","Rudofsky G","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.108931","34217773",null,"ClinicalTrials.gov:NCT03631186","S000917","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0023110","Sex and estrogens alter the action of glucagon-like peptide-1 on reward.","Richard JE","2016","Biology of sex differences","preclinical","article","10.1186/s13293-016-0059-9","26779332","PMC4715328",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023111","Antidiabetic effects of quercetin and liraglutide combination through modulation of TXNIP/IRS-1/PI3K pathway.","Eraky SM","2022","Cell biochemistry and function","preclinical","article","10.1002/cbf.3678","34855213",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023112","Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.","Gray LJ","2015","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12462","25777247",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0023113","Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature.","Xue Y","2023","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2023.1254398","38027186","PMC10658190","PROSPERO:CRD42022302648",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Research Support, Non-U.S. Gov't; systematic-review; review"],["R0023114","FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.","Samms RJ","2022","American journal of physiology. Endocrinology and metabolism","randomized_trial","article","10.1152/ajpendo.00050.2022","35723225","PMC9291413",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0023115","Exendin-4 Reverses Biochemical and Functional Alterations in the Blood-Brain and Blood-CSF Barriers in Diabetic Rats.","Zanotto C","2017","Molecular neurobiology","preclinical","article","10.1007/s12035-016-9798-1","26927659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023116","Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: Preparation and in vivo evaluation.","Wu J","2016","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2016.06.018","27343696",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023117","Effects of liraglutide on sperm characteristics and fertilization potential following experimentally induced diabetes in mice.","Pourheydar M","2021","Veterinary research forum : an international quarterly journal","preclinical","article","10.30466/vrf.2019.96822.2315","33953881","PMC8094147",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023118","Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats.","Model JFA","2021","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2021.111158","33444670",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023119","Exendin-4, a GLP-1 receptor agonist, modulates the effect of macronutrients on food intake by rats.","Aziz A","2002","The Journal of nutrition","preclinical","article","10.1093/jn/132.5.990","11983826",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023120","Liraglutide Regulates the Kidney and Liver in Diabetic Nephropathy Rats through the miR-34a/SIRT1 Pathway.","Xiao S","2021","Journal of diabetes research","preclinical","article","10.1155/2021/8873956","33880382","PMC8046563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023121","Cardio-renal-metabolic disease in primary care setting.","Ibrahim M","2024","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.3755","38115715","PMC11320716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; research-article; article"],["R0023122","Real-world Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center","Yoon JH","2020","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-59508/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0023123","Exendin-4-assisted adipose derived mesenchymal stem cell therapy protects renal function against co-existing acute kidney ischemia-reperfusion injury and severe sepsis syndrome in rat.","Sung PH","2017","American journal of translational research","preclinical","article",null,"28804538","PMC5553870",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023124","Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?","Davies MJ","2020","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2020.154242","32315698",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023125","A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?","Rossello X","2017","International journal of cardiology","commentary","article","10.1016/j.ijcard.2016.11.246","27865185",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial"],["R0023126","Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists.","Gallwitz B","2009","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2009.6.247","20043037","PMC2836196",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0023127","Insulin in Amyotrophic Lateral Sclerosis: Impairment, Tests and Treatment","Rappoport A","2023","Preprints.org","nonrandomized_study","preprint","10.20944/preprints202212.0297.v3",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0023128","Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.","Chitnis AS","2014","Advances in therapy","nonrandomized_study","article","10.1007/s12325-014-0153-5","25245811","PMC4176953",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023129","Insulin resistance and insulin sensitizing agents.","Mastrototaro L","2021","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2021.154892","34563556",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023130","Exendin-4 stimulation of cyclin A2 in beta-cell proliferation.","Song WJ","2008","Diabetes","preclinical","article","10.2337/db07-1541","18544709","PMC2518488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023131","A Budget Impact Analysis of Substituting Sitagliptin with Liraglutide in Type 2 Diabetes from A Private Health Insurance Perspective in Egypt","El-sisi GH","2021","Research Square","other","preprint","10.21203/rs.3.rs-772763/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023132","Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice.","Novelli M","2014","European journal of pharmacology","randomized_trial","article","10.1016/j.ejphar.2014.01.071","24530416",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; article"],["R0023133","Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.","Foltynie T","2014","Alzheimer's & dementia : the journal of the Alzheimer's Association","randomized_trial","article","10.1016/j.jalz.2013.12.005","24529524",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023134","Elucidation of The Effects and Underlying Mechanism of Aerobic Interval Training Combined With Liraglutide On Diabetic Cardiomyopathy","Cai H","2022","Research Square","preclinical","preprint","10.21203/rs.3.rs-1150327/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023135","Integrating micro-needle jet injection and sustained GLP-1 therapy with structured feeding: a comprehensive strategy for obesity management.","Zhang C","2025","Drug delivery","other","article","10.1080/10717544.2025.2557938","40926521","PMC12424150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023136","\"The Dynamic Duo\": The New Management of Drug Treatment for Heart Failure with Mildly Reduced or Preserved Ejection Fraction.","Wolf PJW","2025","Arquivos brasileiros de cardiologia","narrative_review","article","10.36660/abc.20240676","40435008","PMC12129481",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023137","Tirzepatide-Friend or Foe in Diabetic Cancer Patients?","Samuel SM","2022","Biomolecules","other_trial","article","10.3390/biom12111580","36358930","PMC9687454","ClinicalTrials.gov:NCT03954834; ClinicalTrials.gov:NCT03987919; ClinicalTrials.gov:NCT03882970; ClinicalTrials.gov:NCT03730662; ClinicalTrials.gov:NCT04039503; ClinicalTrials.gov:NCT04184622","S000095; S000407; S001077; S001287; S001591; S001608","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0023138","Report from the 5th cardiovascular outcome trial (CVOT) summit.","Schnell O","2020","Cardiovascular diabetology","other_trial","article","10.1186/s12933-020-01022-7","32303223","PMC7165375",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Conference Proceedings; Editorial; article"],["R0023139","Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats.","Decara J","2018","Acta physiologica (Oxford, England)","preclinical","article","10.1111/apha.13008","29193738",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023140","Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.","Zhou Y","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-021-01139-2","34453682","PMC8479006","ClinicalTrials.gov:NCT01648582","S001404","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0023141","How do these 3 diabetes agents compare in reducing mortality?","Martini J","2019","The Journal of family practice","commentary","article",null,"30870538","PMC6484967",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Comment; other; article"],["R0023142","Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.","Bizino MB","2021","Acta diabetologica","randomized_trial","article","10.1007/s00592-020-01635-0","33399989",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0023143","Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study.","Jaimes Campos MA","2023","Pharmaceuticals (Basel, Switzerland)","nonrandomized_study","article","10.3390/ph16091298","37765106","PMC10537115",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; Preprint; article; preprint"],["R0023144","ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.","Morey-Vargas OL","2014","Annals of internal medicine","randomized_trial","article","10.7326/0003-4819-161-10-201411180-02009","25402542",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; editorial"],["R0023145","Glucagon-like peptide 1 in health and disease.","Andersen A","2018","Nature reviews. Endocrinology","narrative_review","article","10.1038/s41574-018-0016-2","29728598",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Review"],["R0023146","Achieving antihyperglycemic treatment goals with incretin-related therapies.","Blonde L","2012","The American journal of managed care","other_trial","article",null,"23327432",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; article"],["R0023147","Correction: Physicians' real-world experience with IDegLira: results of a European survey.",null,"2018","BMJ open diabetes research & care","notice","article","10.1136/bmjdrc-2018-000531corr1","30002859","PMC6038837",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0023148","The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain.","Parthsarathy V","2013","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2012.12.012","23276669",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023149","Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting.","Mittag-Roussou V","2020","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.131","32704556","PMC7375113",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023150","Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.","Vanderheiden A","2016","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2015-3906","26909799",null,"ClinicalTrials.gov:NCT01505673","S001129","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023151","Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.","Mansur SA","2015","Journal of cellular physiology","preclinical","article","10.1002/jcp.25033","26016732",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023152","Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.","Dempsey M","2018","Journal of medical economics","other_trial","article","10.1080/13696998.2018.1513406","30114954",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; article"],["R0023153","Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.","Onishi Y","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00765-6","31994009","PMC7048887","ClinicalTrials.gov:NCT02750410","S001247","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; other; article"],["R0023154","Role of endogenous ROS production in impaired metabolism-secretion coupling of diabetic pancreatic β cells.","Fujimoto S","2011","Progress in biophysics and molecular biology","preclinical","article","10.1016/j.pbiomolbio.2011.07.013","21839765",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0023155","Incretin-based therapies: a clinical need filled by unique metabolic effects.","Drucker DJ","2006","The Diabetes educator","other","article","10.1177/0145721706287651","16554430",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023156","Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.","Stranges P","2012","Therapeutic advances in drug safety","randomized_trial","article","10.1177/2042098612454290","25083236","PMC4110849",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0023157","[Effect of byetta on renal osmoregulatory function in patients with diabetes mellitus].","Shakhmatova EI","2014","Eksperimental'naia i klinicheskaia farmakologiia","other","article",null,"24800522",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023158","Semaglutide for weight loss.","Ojeniran M","2021","Canadian family physician Medecin de famille canadien","other","article","10.46747/cfp.6711842","34772713","PMC8589135",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023159","New hypoglycemic agents and the kidney: what do the major trials tell us?","Smyth B","2018","F1000Research","narrative_review","article","10.12688/f1000research.16135.1","30542615","PMC6259591",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Preprint; review-article; article"],["R0023160","Corrigendum to \"Gene Therapy for Diabetes: Metabolic Effects of Helper-dependent Adenoviral Exendin 4 Expression in a Diet-induced Obesity Mouse Model\".",null,"2009","Molecular therapy : the journal of the American Society of Gene Therapy","notice","article","10.1038/mt.2009.137","28160915","PMC2835016",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0023161","A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects.","Zhao SJ","2017","International journal of nanomedicine","preclinical","article","10.2147/ijn.s130566","28356733","PMC5367579",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023162","Retraction note: 'A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells'.","Yoshiyuki Hattori","2012","Diabetologia","other","article","10.1007/s00125-011-2394-z","22170464",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; retraction"],["R0023163","The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways.","Favaro E","2012","Diabetologia","other","article","10.1007/s00125-011-2423-y","22231124","PMC3296004",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023164","Involvement of a serotonin/GLP-1 circuit in adolescent isolation-induced diabetes.","Kolling LJ","2023","bioRxiv : the preprint server for biology","nonrandomized_study","article","10.1101/2023.06.12.544498","37398179","PMC10312607",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Preprint; Journal Article; preprint"],["R0023165","[The pharmacological treatment of obesity: past, present and future].","Simonyi G","2012","Orvosi hetilap","narrative_review","article","10.1556/oh.2012.29317","22370224",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023166","Liraglutide monotherapy and add on therapy on obese women with polycystic ovarian syndromes: a systematic review and meta-analysis.","Tian D","2022","Minerva medica","systematic_review","article","10.23736/s0026-4806.21.07085-3","33555153",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0023167","Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects.","Araujo F","2014","Current pharmaceutical biotechnology","narrative_review","article","10.2174/1389201015666140915150312","25219868",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023168","How Glucagon-Like Peptide-1 Medications Are Depicted in Instagram Posts Regarding Women's Health, Nontraditional Access, and Barriers to Access: Content Analysis.","Bloom BE","2025","Journal of medical Internet research","other","article","10.2196/66400","40905615","PMC12447010",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023169","Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.","Wang X","2016","Clinical science (London, England : 1979)","preclinical","article","10.1042/cs20160061","27129181",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; article"],["R0023170","Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.","Klonoff DC","2021","Diabetes, obesity & metabolism","other","article","10.1111/dom.14509","34338402","PMC9292194",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0023171","Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.","Takada S","2016","Cardiovascular research","preclinical","article","10.1093/cvr/cvw182","27450980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023172","Genotype-Phenotype Discrepancies in Family Members With a Novel Glucokinase Mutation: Insights Into GCK-MODY and Its Interplay With Insulin Resistance.","Ji S","2025","Diabetes","preclinical","article","10.2337/db24-1036","40997347",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0023173","Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.","Zobel EH","2017","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2016.09.016","27769801",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023174","Modulation of Glucagon-like Peptide-1 (GLP-1) Potency by Endocannabinoid-like Lipids Represents a Novel Mode of Regulating GLP-1 Receptor Signaling.","Cheng YH","2015","The Journal of biological chemistry","other","article","10.1074/jbc.m115.655662","25903129","PMC4505500",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023175","Hidradenitis suppurativa patient requiring cardiac procedure with inguinal access: Case management with ertapenem.","Mainville L","2024","SAGE open medical case reports","case_report","article","10.1177/2050313x241274819","39165305","PMC11334149",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023176","[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].","Kleefstra N","2010","Nederlands tijdschrift voor geneeskunde","systematic_review","article",null,"20298625",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","3","FALSE","Journal Article; Systematic Review; article"],["R0023177","Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide.","Liu Y","2021","Clinics and research in hepatology and gastroenterology","other","article","10.1016/j.clinre.2019.07.013","33592427",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023178","Pharmacotherapeutic options for prediabetes.","Rendell M","2021","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2020.1817381","32892663",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023179","Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study.","Khera R","2024","medRxiv : the preprint server for health sciences","nonrandomized_study","article","10.1101/2024.02.05.24302354","38370787","PMC10871374",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Preprint; Journal Article; preprint"],["R0023180","Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation.","Heller C","2011","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00144.2011","21771967",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023181","Combination therapy of exendin-4 and allogenic adipose-derived mesenchymal stem cell preserved renal function in a chronic kidney disease and sepsis syndrome setting in rats.","Chen CH","2017","Oncotarget","preclinical","article","10.18632/oncotarget.21727","29245956","PMC5724998",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023182","GLP-1R Signaling Directly Activates Arcuate Nucleus Kisspeptin Action in Brain Slices but Does not Rescue Luteinizing Hormone Inhibition in Ovariectomized Mice During Negative Energy Balance.","Heppner KM","2017","eNeuro","preclinical","article","10.1523/eneuro.0198-16.2016","28144621","PMC5247618",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023183","Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats.","Xing C","2021","The Journal of steroid biochemistry and molecular biology","preclinical","article","10.1016/j.jsbmb.2021.105992","34478829",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023184","Current treatment of non-alcoholic fatty liver disease.","Paternostro R","2022","Journal of internal medicine","randomized_trial","article","10.1111/joim.13531","35796150","PMC9546342",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0023185","Novel targets for potential therapeutic use in Diabetes mellitus.","Dhankhar S","2023","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-023-00983-5","36782201","PMC9926720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023186","Combined therapy with melatonin and exendin-4 effectively attenuated the deterioration of renal function in rat cardiorenal syndrome.","Chen KH","2017","American journal of translational research","preclinical","article",null,"28337255","PMC5340662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023187","Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study.","Köseoğlu D","2021","Turkish journal of medical sciences","other","article","10.3906/sag-2004-154","32892547","PMC7991851",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023188","Hes3 is expressed in the adult pancreatic islet and regulates gene expression, cell growth, and insulin release.","Masjkur J","2014","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m114.590687","25371201","PMC4271235",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023189","Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study.","Chittepu VCSR","2019","Pharmaceutics","preclinical","article","10.3390/pharmaceutics11050238","31108878","PMC6572294",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023190","A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis.","Jin L","2021","Peptides","preclinical","article","10.1016/j.peptides.2021.170597","34118361",null,"ClinicalTrials.gov:NCT02316717",null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023191","EndoC-βH5 cells are storable and ready-to-use human pancreatic beta cells with physiological insulin secretion.","Blanchi B","2023","Molecular metabolism","other","article","10.1016/j.molmet.2023.101772","37442376","PMC10407753",null,"S001309","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023192","Total Synthesis of Semaglutide Based on a Soluble Hydrophobic-Support-Assisted Liquid-Phase Synthetic Method.","Liu X","2020","ACS combinatorial science","other","article","10.1021/acscombsci.0c00134","33058727",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023193","Medical Weight Management Considerations in Plastic Surgery.","Paranzino AB","2025","Plastic and reconstructive surgery","narrative_review","article","10.1097/prs.0000000000011445","38563562",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023194","Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: Systematic review, network meta-analysis and cost-effectiveness analysis.","Men P","2020","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13871","31469217",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0023195","Evaluation of leptin treatment on maintenance of body weight loss in diet-induced obese mice.","Breen DM","2026","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.70207","41104579","PMC12673436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023196","Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk.","Hart HE","2023","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2023.02.001","36775727",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Observational Study; Journal Article; article"],["R0023197","Exendin-4 Enhances Motor Function Recovery via Promotion of Autophagy and Inhibition of Neuronal Apoptosis After Spinal Cord Injury in Rats.","Li HT","2016","Molecular neurobiology","randomized_trial","article","10.1007/s12035-015-9327-7","26198566",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0023198","Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy.","Kim I","2010","Bioconjugate chemistry","preclinical","article","10.1021/bc100143c","20715855",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023199","Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden.","Kiadaliri AA","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-014-0080-0","25213800","PMC4269657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023200","Adjunctive therapies in type 1 diabetes mellitus.","Lane K","2021","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000602","33332928",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; article"],["R0023201","Clinical features and therapeutic perspectives on hypertension in diabetics.","Katayama S","2018","Hypertension research : official journal of the Japanese Society of Hypertension","narrative_review","article","10.1038/s41440-017-0001-5","29402981","PMC8075885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023202","Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.","Lamont BJ","2012","The Journal of clinical investigation","preclinical","article","10.1172/jci42497","22182839","PMC3248276",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023203","Optimizing weight control in diabetes: antidiabetic drug selection.","Kalra S","2010","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmsott.s11941","21437098","PMC3047980",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023204","Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells.","McKimpson WM","2024","The Journal of cell biology","preclinical","article","10.1083/jcb.202305093","38958606","PMC11222742",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023205","Qualitative and Quantitative Evaluation of an Innovative Primary and Secondary Diabetes Clinic in Western Sydney.","Ravi S","2024","International journal of integrated care","case_report","article","10.5334/ijic.7548","38406628","PMC10885848",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023206","Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes.","Monji A","2013","American journal of physiology. Heart and circulatory physiology","preclinical","article","10.1152/ajpheart.00990.2012","23709595",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023207","Editorial commentary: Weight loss for cardiovascular disease prevention - is semaglutide the answer?","Lavie CJ","2023","Trends in cardiovascular medicine","commentary","article","10.1016/j.tcm.2021.12.018","34999021",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; editorial"],["R0023208","Unlocking the miRNA-34a-5p/TGF-β and HMGB1/PI3K/Akt/mTOR crosstalk participate in the enhanced cardiac protection of liraglutide against isoproterenol-induced acute myocardial injury rat model.","Abdel-Reheim MA","2024","International immunopharmacology","preclinical","article","10.1016/j.intimp.2023.111369","38101219",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023209","Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability.","Nakatani Y","2016","Diabetes care","randomized_trial","article","10.2337/dc15-1437","26681718",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; article"],["R0023210","Type 2 diabetes mellitus treatment patterns in U.S. nursing home residents.","Zarowitz B","2015","Postgraduate medicine","nonrandomized_study","article","10.1080/00325481.2015.1035621","25850712",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023211","Is liraglutide the solution for weight loss in women with polycystic ovarian syndrome?","Shaikh TG","2022","JPMA. The Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.11-4370","35099475",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0023212","Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.","Stafford S","2022","Applied health economics and health policy","randomized_trial","article","10.1007/s40258-022-00726-z","35344191","PMC9206917","ClinicalTrials.gov:NCT03136484","S001847","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0023213","Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.","Dutour A","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12680","27106272",null,null,"S001366","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023214","A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.","Pereira MJ","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0449-6","29949016","PMC6064580",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0023215","Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials.","Moon S","2021","Endocrinology and metabolism (Seoul, Korea)","systematic_review","article","10.3803/enm.2020.934","34139800","PMC8258332",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0023216","Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.","Gargiulo P","2017","Nutrition, metabolism, and cardiovascular diseases : NMCD","systematic_review","article","10.1016/j.numecd.2017.09.006","29113708",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; review"],["R0023217","Lixisenatide enhances mitochondrial biogenesis and function through regulating the CREB/PGC-1α pathway.","Zhao Z","2019","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2018.11.135","30553453",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023218","Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat.","Bojanowska E","2007","Journal of physiology and pharmacology : an official journal of the Polish Physiological Society","preclinical","article",null,"17622702",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023219","Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.","Rizzo M","2015","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2014-2291","25393640","PMC4318909","ClinicalTrials.gov:NCT01715428","S001748","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023220","An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side.","Shevchouk OT","2021","Frontiers in neuroscience","systematic_review","article","10.3389/fnins.2021.774050","34955726","PMC8695496",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; article"],["R0023221","Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07.","Han J","2014","Chinese journal of natural medicines","preclinical","article","10.1016/s1875-5364(14)60093-5","25156287",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023222","Therapeutic effect of liraglutide on type 2 diabetic patients with nonalcoholic fatty liver disease.","Xu L","2023","Minerva surgery","other","article","10.23736/s2724-5691.21.09335-7","35088989",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023223","Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).","Davis TME","2022","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-022-01555-z","35761271","PMC9238154","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0023224","Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial.","Wang L","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-020-00904-z","32856226","PMC7509011","ClinicalTrials.gov:NCT02449603","S001146","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0023225","Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.","Arastu N","2022","International journal of clinical pharmacy","systematic_review","article","10.1007/s11096-022-01428-1","35715543",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0023226","Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.","Deng Y","2022","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj-2022-070717","36191949","PMC9527635",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0023227","Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.","Skow MA","2016","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12685","27160961",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023228","Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.","Tanday N","2021","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2021.674704","34054734","PMC8160446",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023229","Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity.","Liang Y","2016","Nutrition & diabetes","preclinical","article","10.1038/nutd.2015.37","26807509","PMC4742720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023230","Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.","Dahl K","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14373","33710717","PMC8251575",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023231","Decanoic acid-modified glycol chitosan hydrogels containing tightly adsorbed palmityl-acylated exendin-4 as a long-acting sustained-release anti-diabetic system.","Lee C","2014","Acta biomaterialia","preclinical","article","10.1016/j.actbio.2013.10.009","24140611",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023232","Comprehensive bioinformatics analysis of malignant transformation and potential therapeutic possibility of lung adenocarcinoma after lipopolysaccharide induction.","Xu W","2025","Frontiers in genetics","nonrandomized_study","article","10.3389/fgene.2025.1556366","40697537","PMC12279497",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023233","The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.","Sivalingam S","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14717","35415938",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Journal Article; article"],["R0023234","The effect of liraglutide on renal function: A randomized clinical trial.","von Scholten BJ","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12808","27753201",null,"ClinicalTrials.gov:NCT02545738","S001417","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023235","Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes.","Yang J","2021","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2020.107797","33293208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023236","The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis.","Wang H","2021","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2021.111778","34062416",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023237","Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.","Martin CL","2008","The Diabetes educator","other_trial","article","10.1177/0145721708319238","18525067",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0023238","Improvement of Glycogenic Hepatopathy With Minimal Corresponding Improvement of Glycemic Control in a Person With Type 1 Diabetes: Case Report and Literature Review.","Tessa Tonleu J","2025","AACE clinical case reports","case_report","article","10.1016/j.aace.2024.12.004","40201471","PMC11973649",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023239","Incretin-responsive human pancreatic adipose tissue organoids: A functional model for fatty pancreas research.","Lorza-Gil E","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.102067","39549913","PMC11625218",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0023240","Exposure-response analyses of liraglutide 3.0 mg for weight management.","Wilding JP","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12639","26833744","PMC5069568",null,"S000492; S001792","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023241","Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.","Nauck MA","2005","Regulatory peptides","preclinical","article","10.1016/j.regpep.2004.07.014","15780433",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023242","Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes.","Spain CV","2016","Clinical therapeutics","other","article","10.1016/j.clinthera.2016.05.009","27364806",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023243","Glucagon-like peptide-1 receptor imaging for localization of insulinomas.","Christ E","2009","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2009-1082","19820010",null,null,"S000314; S000994","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023244","Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets.","Juang JH","2008","Cell transplantation","preclinical","article","10.3727/096368908786092766","18819252",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023245","Liraglutide reduces coronary endothelial cells no-reflow damage through activating MAPK/ERK signaling pathway.","Chen Y","2021","Journal of receptor and signal transduction research","other","article","10.1080/10799893.2020.1833921","33045879",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023246","Mechanism of the beneficial and protective effects of exenatide in diabetic rats.","Lotfy M","2014","The Journal of endocrinology","preclinical","article","10.1530/joe-13-0426","24353307",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023247","Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.","Jabbour SA","2020","Diabetes care","randomized_trial","article","10.2337/dc19-1350","32816874","PMC7510043","ClinicalTrials.gov:NCT02229396","S000791","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0023248","Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.","Neeland IJ","2021","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(21)00179-0","34358471",null,"ClinicalTrials.gov:NCT03038620","S000866","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Pragmatic Clinical Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0023249","Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis.","Meguro S","2014","International journal of endocrinology","other","article","10.1155/2014/927317","24738001","PMC3967600",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023250","Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide.","Doggrell SA","2007","Reviews on recent clinical trials","other","article","10.2174/157488707779318053","18473991",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023251","Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.","Kapitza C","2009","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2009.02854.x","19929995",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023252","The emerging possibility of the use of geniposide in the treatment of cerebral diseases: a review.","Zhang W","2021","Chinese medicine","narrative_review","article","10.1186/s13020-021-00486-3","34454545","PMC8400848",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023253","Effect of Liraglutide on Corneal Kindling Epilepsy Induced Depression and Cognitive Impairment in Mice.","Koshal P","2016","Neurochemical research","preclinical","article","10.1007/s11064-016-1890-4","27017512",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023254","The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue.","Raz I","2011","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2011.8.288","22262067","PMC3280664",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023255","Once-weekly  semaglutide  for obesity  or overweight: A systematic review and meta-analysis.","He K","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14612","34866313",null,"PROSPERO:CRD42021259374",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Letter; Meta-Analysis; Systematic Review; review"],["R0023256","Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy.","Chen W","2017","Nature communications","other","article","10.1038/s41467-017-01764-1","29176623","PMC5701150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Evaluation Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023257","Incretins in obesity and diabetes.","Chia CW","2020","Annals of the New York Academy of Sciences","randomized_trial","article","10.1111/nyas.14211","31392745","PMC10131087",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Intramural; Review; research-article; article"],["R0023258","GLP-1 and Intestinal Diseases.","Hunt JE","2021","Biomedicines","narrative_review","article","10.3390/biomedicines9040383","33916501","PMC8067135",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023259","Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.","Shi LX","2020","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13075","31102326","PMC6944837","ClinicalTrials.gov:NCT01644500","S001064","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Equivalence Trial; research-article; article"],["R0023260","In persons with obesity, exercise plus liraglutide improved weight-loss maintenance vs. exercise or placebo.","Sarma S","2021","Annals of internal medicine","commentary","article","10.7326/acpj202109210-102","34487446",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023261","Evaluation of Alternative Treatment Strategies for Bile Acid Malabsorption in Inflammatory Bowel Disease Patients: A Network Meta-Analysis.","Merza N","2024","Journal of clinical medicine research","systematic_review","article","10.14740/jocmr5007","38550552","PMC10970039",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0023262","Formation of cyclic structure at amino-terminus of glucagon-like peptide-1 exhibited a prolonged half-life in vivo.","Cao Z","2012","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2012.01.010","22284602",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023263","Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.","Bertilsson G","2008","Journal of neuroscience research","preclinical","article","10.1002/jnr.21483","17803225",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023264","Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.","Mann JFE","2020","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(20)30313-2","32971040",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023265","Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.","Maida A","2009","Gastroenterology","preclinical","article","10.1053/j.gastro.2009.09.004","19766644",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0023266","An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.","Bomfim TR","2012","The Journal of clinical investigation","preclinical","article","10.1172/jci57256","22476196","PMC3314445",null,"S000009","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Video-Audio Media; research-article; article"],["R0023267","Exendin-4, a GLP-1 receptor agonist, interacts with proteins and their products of digestion to suppress food intake in rats.","Aziz A","2003","The Journal of nutrition","preclinical","article","10.1093/jn/133.7.2326","12840201",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023268","Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats.","Raab EL","2009","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00519.2009","19846744","PMC2803622",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0023269","Acute effects of glucagon-like peptide-1, GLP-19-36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers.","Bremholm L","2017","Physiological reports","randomized_trial","article","10.14814/phy2.13102","28235974","PMC5328764",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0023270","Exenatide versus glibenclamide in patients with diabetes.","Derosa G","2010","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2009.0141","20151774",null,null,"S002653","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0023271","Lixisenatide",null,"2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"31643608",null,null,null,"europepmc","TRUE",null,null,null,"Book; Review"],["R0023272","Stability of synthetic exendin-4 in human plasma in vitro.","Chen J","2007","Protein and peptide letters","preclinical","article","10.2174/092986607779117272","17266646",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023273","Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.","Irace C","2013","Diabetes & vascular disease research","other_trial","article","10.1177/1479164112449562","22732108",null,null,"S000291","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Comparative Study; Journal Article; article"],["R0023274","Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.","Rizzo M","2015","Expert opinion on pharmacotherapy","commentary","article","10.1517/14656566.2015.981528","25516459",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; editorial"],["R0023275","Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.","Di Dalmazi G","2020","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2020.07.002","32753164",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0023276","Liraglutide as First-Line Therapy for Type 2 Diabetics With Post-COVID-19 Fatigue Syndrome and Executive Function Deficits.","Manu P","2022","American journal of therapeutics","other","article","10.1097/mjt.0000000000001475","36074988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023277","SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.","Singh AK","2017","Expert review of clinical pharmacology","other_trial","article","10.1080/17512433.2017.1287562","28121469",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0023278","Exendin-4 attenuates brain death-induced liver damage in the rat.","Carlessi R","2015","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","randomized_trial","article","10.1002/lt.24317","26334443",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023279","Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.","Kaku K","2010","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2009.01194.x","20380655",null,null,"S000862","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023280","High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes.","Yang K","2021","Acta diabetologica","other_trial","article","10.1007/s00592-020-01660-z","33452595",null,"ChiCTR:ChiCTR-IPR-15006558",null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0023281","Oleanolic acid enhances insulin secretion in pancreatic beta-cells.","Teodoro T","2008","FEBS letters","preclinical","article","10.1016/j.febslet.2008.03.026","18364241",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023282","Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study.","Bennett D","2016","Diabetology international","nonrandomized_study","article","10.1007/s13340-016-0261-3","30603289","PMC6224969",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; research-article"],["R0023283","GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo.","Arcones AC","2021","BMC biology","preclinical","article","10.1186/s12915-021-00966-w","33658023","PMC7931601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0023284","Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency.","Xue S","2008","Annals of the New York Academy of Sciences","preclinical","article","10.1196/annals.1447.049","19120286",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023285","SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.","Abdelgadir E","2018","Journal of clinical medicine research","other_trial","article","10.14740/jocmr3467w","29977418","PMC6031247",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0023286","Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.","Møllerhøj MB","2022","Clinical and translational science","other_trial","article","10.1111/cts.13235","35143711","PMC9099137",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023287","Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions.","Bhalla S","2022","Neuroscience and biobehavioral reviews","narrative_review","article","10.1016/j.neubiorev.2022.104896","36191807",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023288","Neurological outcomes of antidiabetic therapy: What the neurologist should know.","Eberhardt O","2017","Clinical neurology and neurosurgery","randomized_trial","article","10.1016/j.clineuro.2017.04.014","28477558",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0023289","Edible Marine Red Alga Gracilaria coronopifolia as a Potential Functional Ingredient: Chemical Profiling and Metabolic Effects in Diet-Induced Obese Rats.","Bahtiar A","2026","Foods (Basel, Switzerland)","preclinical","article","10.3390/foods15071167","41976461","PMC13073850",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023290","The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors.","Darsalia V","2018","Cardiovascular diabetology","commentary","article","10.1186/s12933-018-0674-3","29466979","PMC5822625",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; editorial; article"],["R0023291","GLP-1 agonist associated acute kidney injury: A case report and review.","Sharma T","2019","Diabetes & metabolism","case_report","article","10.1016/j.diabet.2017.12.002","29275947",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0023292","Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan.","Patti AM","2015","Angiology","narrative_review","article","10.1177/0003319714542999","25037700",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023293","Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?","Balasubramanian P","2022","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgac154","35290464","PMC9202688",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023294","Treatments for NAFLD: State of Art.","Mantovani A","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22052350","33652942","PMC7956331",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023295","Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development.","Bose M","2022","Cells","narrative_review","article","10.3390/cells11223629","36429060","PMC9688574",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; review-article; article"],["R0023296","Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease.","Jeznach-Steinhagen A","2019","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina55050166","31137547","PMC6571590",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023297","The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.","Friedrichsen M","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14280","33269530","PMC7898914",null,"S001032; S002529","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023298","Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study.","Holmes P","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-021-01141-8","34562237","PMC8475854","ClinicalTrials.gov:NCT03876015","S000303","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0023299","Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus.","Owji AA","2002","Brain research","preclinical","article","10.1016/s0006-8993(01)03379-0","11852032",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023300","Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.","Kyrillos JV","2022","Postgraduate medicine","commentary","article","10.1080/00325481.2022.2149005","36691310",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0023301","Integrating Price Benchmarks and Comparative Clinical Effectiveness to Predict Initial Price Offers for Medicare Drug Price Negotiation (Initial Price Applicability Year 2027).","Li KH","2026","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2025.09.3054","41043560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023302","Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.","Brauer R","2020","Brain : a journal of neurology","nonrandomized_study","article","10.1093/brain/awaa262","33011770","PMC7794498",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023303","Efficacy of exenatide, ozone, and methyl prednisolone for the recovery of infraorbital nerve paresthesia after injury in rats.","Abrishami M","2021","Dental research journal","preclinical","article","10.4103/1735-3327.316652","34322211","PMC8314971",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023304","Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.","van Bloemendaal L","2015","Diabetes, obesity & metabolism","other","article","10.1111/dom.12506","26094857",null,null,"S000930","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023305","Two new GLP-1 receptor agonists for diabetes.",null,"2014","The Medical letter on drugs and therapeutics","other","article",null,"25372847",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023306","Efficacy of Liraglutide 3.0 Mg Treatment on Weight-Loss in Patients with Weight Regain After Bariatric Surgery","Muratori F","2021","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-1175016/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0023307","Update on diagnosis, pathophysiology, and management of diabetic kidney disease.","Sugahara M","2021","Nephrology (Carlton, Vic.)","narrative_review","article","10.1111/nep.13860","33550672",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0023308","Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.","Abdul-Ghani M","2017","Diabetes care","other","article","10.2337/dc16-2368","28733377","PMC5521981",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0023309","Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.","Vilsbøll T","2007","Diabetes care","randomized_trial","article","10.2337/dc06-2593","17372153",null,"ClinicalTrials.gov:NCT00154401","S001065","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023310","The Use of Liraglutide in Obese Patients With COVID-19: A Case Report","Hanada T","2021","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvab048.075",null,"PMC8090259",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0023311","Is cleaved glucagon-like peptide 1 really inactive? Effects of GLP-1(9-36) on human adipose stem cells.","Cantini G","2017","Molecular and cellular endocrinology","other","article","10.1016/j.mce.2016.10.013","27746194",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023312","Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.","Dutta D","2022","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2022.102539","35709586",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0023313","Therapeutic Effects and Mechanism of Liraglutide in Rats with Type 2 Diabetes and Metabolic-associated Fatty Liver Disease.","Zhao X","2022","Endocrine, metabolic & immune disorders drug targets","preclinical","article","10.2174/1871530322666220126151141","35081898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023314","The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer's diseases.","Alrouji M","2023","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-023-01082-1","37173803","PMC10182652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023315","The incretin hormones: from scientific discovery to practical therapeutics.","Mudaliar S","2012","Diabetologia","commentary","article","10.1007/s00125-012-2561-x","22555471",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Comment"],["R0023316","Liraglutide Activates AMPK Signaling and Partially Restores Normal Circadian Rhythm and Insulin Secretion in Pancreatic Islets in Diabetic Mice.","Wang K","2015","Biological & pharmaceutical bulletin","preclinical","article","10.1248/bpb.b15-00024","26040899",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023317","Does teneligliptin reverse the non-glycemic effects among the non-diabetic obesity subjects?","Pelluri R","2022","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-1698323/v1",null,null,"CTRI:CTRI/2020/02/023329",null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0023318","Liraglutide treatment counteracts alterations in adipose tissue metabolism induced by orchiectomy in rats.","Model JFA","2021","Life sciences","preclinical","article","10.1016/j.lfs.2021.119586","33957171",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023319","Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.","Gorgojo-Martínez JJ","2018","International journal of clinical practice","nonrandomized_study","article","10.1111/ijcp.13055","29341370",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0023320","Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.","González C","2006","Expert opinion on investigational drugs","narrative_review","article","10.1517/13543784.15.8.887","16859392",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023321","GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence.","Meloni AR","2013","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2012.01663.x","22776039","PMC3556522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023322","In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders.","Rajagopal S","2021","Annals of internal medicine","commentary","article","10.7326/acpj202107200-080","34224258",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023323","[Exenatide promotes cholesterol efflux in pancreatic tissue of obese diabetic rats].","Zhao L","2021","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article","10.12122/j.issn.1673-4254.2021.03.08","33849827","PMC8075781",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023324","Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.","Dailey GE","2019","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.12952","31094074","PMC6899823",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0023325","SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain.","Rolek B","2023","Journal of cardiovascular development and disease","randomized_trial","article","10.3390/jcdd10080322","37623335","PMC10455499",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0023326","Optimized suction patch design for enhanced transbuccal macromolecular drug delivery.","Klein Cerrejon D","2025","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2025.02.014","39938719",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023327","Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.","Zheng SL","2018","JAMA","systematic_review","article","10.1001/jama.2018.3024","29677303","PMC5933330",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; research-article; article"],["R0023328","Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.","Bøg M","2026","PharmacoEconomics","randomized_trial","article","10.1007/s40273-025-01580-2","41553702","PMC12916528",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0023329","Erratum. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2020;43:1813-1821.","Rayner CK","2021","Diabetes care","notice","article","10.2337/dc21-er01","33168655",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0023330","Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control.","Ahrén B","2015","Diabetes & metabolism","other","article","10.1016/s1262-3636(16)30002-7","26774018",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023331","[Incretin enhancer: sitagliptin].","Kondo M","2011","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"21595272",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0023332","Corrigendum: Safety of Semaglutide.","Smits MM","2021","Frontiers in endocrinology","notice","article","10.3389/fendo.2021.786732","34858353","PMC8631750",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0023333","Redefining Obstructive Sleep Apnea: Treatment in the Modern Era.","Redondo J","2026","Pathophysiology : the official journal of the International Society for Pathophysiology","randomized_trial","article","10.3390/pathophysiology33010020","41893371","PMC13029657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0023334","Place in therapy for liraglutide and saxagliptin for type 2 diabetes.","McFarland MS","2011","Southern medical journal","other_trial","article","10.1097/smj.0b013e318215fc7a","21886033",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0023335","Treating diabetes mellitus in Prader-Willi syndrome with Exenatide.","Seetho IW","2011","Diabetes research and clinical practice","case_report","article","10.1016/j.diabres.2010.12.009","21227526",null,null,"S001478","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Case Reports; Journal Article; article"],["R0023336","Carbol fuchsin stain enhances detection of poly-(d, l-lactide-co-glycolide) microspheres in exenatide extended-release cutaneous injection-site foreign body reaction.","Flugrad R","2021","Journal of cutaneous pathology","case_report","article","10.1111/cup.14110","34312889",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0023337","Obesity, metabolic and bariatric surgery, and cancer prevention: what do we need to learn and how do we get there?","Sauter ER","2023","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","narrative_review","article","10.1016/j.soard.2023.01.029","36918327","PMC10293064",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0023338","Treating prediabetes in the obese: are GLP-1 analogues the answer?","Farr OM","2017","Lancet (London, England)","commentary","article","10.1016/s0140-6736(17)30315-x","28237265",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023339","Inadequate management of cardiovascular risk factors prior to admission for an acute coronary event.","Siafarikas C","2022","Journal of preventive medicine and hygiene","other","article","10.15167/2421-4248/jpmh2022.63.4.2684","36891008","PMC9986978",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0023340","GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products.","Guglielmi V","2017","Eating and weight disorders : EWD","preclinical","article","10.1007/s40519-016-0352-y","28040864",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023341","Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats.","Williams KE","2016","Appetite","preclinical","article","10.1016/j.appet.2015.09.030","26431682","PMC4993531",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0023342","Long-Acting Release Microspheres Containing Novel GLP-1 Analog as an Antidiabetic System.","Ruan S","2018","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.8b00344","29763559",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023343","Synergistic endocrine induction by GLP-1 and TGF-beta in the developing pancreas.","Tei E","2005","Pancreas","preclinical","article","10.1097/01.mpa.0000172566.70619.58","16025000",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0023344","Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke.","Ahn CH","2019","Journal of stroke","narrative_review","article","10.5853/jos.2019.00038","31161759","PMC6549069",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023345","Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.","DeVries JH","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13396","29862621","PMC6175309",null,"S000329; S000878; S001219; S001872; S001876","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023346","Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).","Li Y","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-0646-y","31228090","PMC6612357","ClinicalTrials.gov:NCT01648582","S001404","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0023347","Gastrointestinal hormones and regulation of gastric emptying.","Camilleri M","2019","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000448","30418188","PMC6615897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0023348","Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity.","Hira T","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22126623","34205659","PMC8235588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023349","Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)",null,"2021","National Institute for Health and Care Excellence (NICE), London","narrative_review","article",null,"40811593",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0023350","A unified Bayesian framework for bias adjustment in multiple comparisons from clinical trials.","Du Y","2024","Statistics in medicine","randomized_trial","article","10.1002/sim.10064","38742595",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0023351","Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes.","El Bekay R","2016","British journal of pharmacology","preclinical","article","10.1111/bph.13481","26993859","PMC4867741",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023352","Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres.","Liu B","2010","Chemical & pharmaceutical bulletin","preclinical","article","10.1248/cpb.58.1474","21048339",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023353","Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity.","Wang X","2020","Journal of diabetes research","randomized_trial","article","10.1155/2020/9783859","32566685","PMC7273456",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0023354","The Design of a GLP-1/PYY Dual Acting Agonist.","Østergaard S","2021","Angewandte Chemie (International ed. in English)","other","article","10.1002/anie.202016464","33448563",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023355","A novel antihypertensive effect of exenatide, a GLP-1 agonist.","Dandona P","2010","American journal of hypertension","nonrandomized_study","article","10.1038/ajh.2009.271","20154655",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comment; article"],["R0023356","Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers.","Cui H","2020","European journal of drug metabolism and pharmacokinetics","randomized_trial","article","10.1007/s13318-020-00605-9","32006325",null,"ClinicalTrials.gov:NCT02084251","S000698","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0023357","Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model.","Seppa K","2021","Scientific reports","preclinical","article","10.1038/s41598-021-81768-6","33500541","PMC7838169",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023358","Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly.","Le Guiniec M","2024","European journal of clinical nutrition","case_report","article","10.1038/s41430-024-01450-8","38802605",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0023359","Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation.","Zhang H","2020","Aging","preclinical","article","10.18632/aging.202162","33298623","PMC7835012",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023360","Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.","Kothari S","2019","Journal of clinical and experimental hepatology","narrative_review","article","10.1016/j.jceh.2019.06.003","31889754","PMC6926203",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0023361","Absence of exendin-4 effects on postprandial glucose and lipids in the Gila monster, Heloderma suspectum.","Christel CM","2007","Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology","preclinical","article","10.1007/s00360-006-0115-6","16972064",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023362","Liraglutide treatment improves endothelial function in the Ldlr-/- mouse model of atherosclerosis and affects genes involved in vascular remodelling and inflammation.","Bjørnholm KD","2021","Basic & clinical pharmacology & toxicology","preclinical","article","10.1111/bcpt.13486","32896073",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023363","Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?","Kawata T","2014","Journal of clinical medicine research","other","article","10.14740/jocmr1719w","24578756","PMC3935523",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023364","Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.","Kendall DM","2006","Diabetes technology & therapeutics","narrative_review","article","10.1089/dia.2006.8.385","16800760",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023365","Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.","Abrahami D","2018","Epidemiology (Cambridge, Mass.)","nonrandomized_study","article","10.1097/ede.0000000000000793","29283894",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023366","Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity.","Hope DCD","2021","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2021.735019","34566894","PMC8457634",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0023367","Exendin-4 effects on islet volume and number in the mouse pancreas.","Khorsandi L","2014","Bratislavske lekarske listy","preclinical","article","10.4149/bll_2014_098","25246288",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023368","Slimming cardiac adipose tissue with liraglutide: pericardial is not epicardial fat (the LIRAFLAME substudy).","Gaborit B","2022","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.14595","34738693",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0023369","Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.","Buse JB","2020","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2020-001649","33318068","PMC7737050","ClinicalTrials.gov:NCT02849080","S001153","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023370","Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy.","Wiley KC","2015","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/diaspect.28.2.121","25987811","PMC4433075",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023371","Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.","Lebovitz HE","2012","Diabetes technology & therapeutics","preclinical","article","10.1089/dia.2012.0022","22650224",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023372","[Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic -  BIBYII study (observations lasting 24 months)].","Perušičová J","2013","Vnitrni lekarstvi","other","article",null,"23711049",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023373","Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.","Botros FT","2023","Diabetes care","other_trial","article","10.2337/dc23-0231","37343574",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","5","FALSE","Journal Article; other; article"],["R0023374","[Heart failure with preserved ejection fraction as a model disease for the cardio-pulmonary-renal syndrome : Importance of visceral fat expansion as central pathomechanism].","Tschöpe C","2021","Der Internist","narrative_review","article","10.1007/s00108-021-01182-y","34613426",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023375","Evaluating The Long-Term Cost-Effectiveness Of Liraglutide 1.2 Mg And Exenatide In Patients With Type 2 Diabetes Mellitus.","Shi LW","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.161","27202684",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023376","Liraglutide pharmacokinetics and exposure-response in pediatric patients with type 2 diabetes.","Petri KCC","2020","Journal of pediatric endocrinology & metabolism : JPEM","other_trial","article","10.1515/jpem-2020-0053","32817582",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0023377","Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19.","Alshanwani A","2022","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/1871530321666210809153558","34370655",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023378","Role of glucagon-like peptide- 1 in vascular endothelial dysfunction.","Goyal S","2010","Indian journal of experimental biology","preclinical","article",null,"20358868",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023379","Therapeutic efficacy of 4-hydroxyisoleucine in experimental rat model of demyelination: Neuroprotection through IGF-1 and GLP-1 level restoration.","Khan Z","2025","Phytomedicine : international journal of phytotherapy and phytopharmacology","preclinical","article","10.1016/j.phymed.2025.157448","41187648",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023380","Management of Diabetes in Patients Undergoing Bariatric Surgery.","Mulla CM","2019","Current diabetes reports","narrative_review","article","10.1007/s11892-019-1242-2","31686263",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023381","Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting.","Digenio A","2014","Postgraduate medicine","nonrandomized_study","article","10.3810/pgm.2014.10.2820","25414934",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023382","Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases.","Hölscher C","2020","International review of neurobiology","narrative_review","article","10.1016/bs.irn.2020.01.007","32854859",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023383","Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team.","Champion M","2024","Journal of primary care & community health","nonrandomized_study","article","10.1177/21501319241231398","38353180","PMC10868501",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023384","Illustrative case and discussion: a 58-year-old man with diabetes.","Freeman JS","2010","The Journal of the American Osteopathic Association","case_report","article",null,"20644203",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023385","Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.","Jendle J","2009","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2009.01158.x","19930006",null,null,"S000566; S001094; S001502","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023386","Transformation of oligomers of lipidated peptide induced by change in pH.","Wang Y","2015","Molecular pharmaceutics","other","article","10.1021/mp500519s","25569709",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023387","Controlling the Uncontrolled Variation in the Diet Induced Obese Mouse by Microbiomic Characterization","Bondarenko V","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-1061617/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023388","Modulating the elasticity of milk exosome-based hybrid vesicles to optimize transepithelial transport and enhance oral peptide delivery.","Xiao P","2025","Journal of controlled release : official journal of the Controlled Release Society","other","article","10.1016/j.jconrel.2025.01.090","39892650",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023389","Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk.","Huang WC","2021","Scientific reports","nonrandomized_study","article","10.1038/s41598-020-80753-9","33446845","PMC7809152",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0023390","Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.","Rajamand Ekberg N","2021","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2021.06.008","34183269",null,"ClinicalTrials.gov:NCT03648281","S000510; S001761","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0023391","[GLP-1 agonist supports weight loss].","Weiß M","2016","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-016-7765-4","26961053",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","News; article"],["R0023392","Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models.","Fu Z","2020","Aging","preclinical","article","10.18632/aging.103181","32392536","PMC7244034",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023393","Small-molecule GLP-1 secretagogs: challenges and recent advances.","He J","2020","Drug discovery today","narrative_review","article","10.1016/j.drudis.2020.08.003","32835725",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023394","Retraction: Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.","Alsafwani DM","2022","Cureus","notice","article","10.7759/cureus.r57","35402110","PMC8983800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Retraction Notice; Retraction of Publication; article"],["R0023395","Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population.","Wallia A","2021","Mayo Clinic proceedings. Innovations, quality & outcomes","nonrandomized_study","article","10.1016/j.mayocpiqo.2021.02.008","34195559","PMC8240148",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0023396","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions.","Hermel M","2025","Current atherosclerosis reports","other_trial","article","10.1007/s11883-025-01276-0","39913067",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0023397","Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland.","Haase CL","2021","Obesity facts","randomized_trial","article","10.1159/000518325","34515194","PMC8546436",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0023398","Squalene-PEG-Exendin as High-Affinity Constructs for Pancreatic Beta-Cells.","Babič A","2018","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.8b00186","29869878",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023399","Once-Weekly Semaglutide in Adults with Overweight or Obesity.","Wilding JPH","2021","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2032183","33567185",null,"ClinicalTrials.gov:NCT03548935","S000144; S000171; S000298; S000313; S000578; S000630; S000716; S000741; S001331; S001352; S001427; S001565; S001761; S002208; S002234; S002362; S002389; S002674","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023400","Elevated circulating GPHB5 levels in women with insulin resistance and polycystic ovary syndrome: A cross-sectional study and multiple intervention studies.","Wang Y","2022","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2022.1010714","36568071","PMC9772026",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023401","Liraglutide attenuates obese-associated breast cancer cell proliferation via inhibiting PI3K/Akt/mTOR signaling pathway.","Alanteet A","2024","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","other","article","10.1016/j.jsps.2023.101923","38223522","PMC10784703",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023402","Expression of NUCB2/nesfatin-1 in the taste buds of rats.","Cao X","2016","Endocrine journal","preclinical","article","10.1507/endocrj.ej15-0489","26522144",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023403","Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.","Schnabel CA","2006","Vascular health and risk management","narrative_review","article","10.2147/vhrm.2006.2.1.69","17319471","PMC1993968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023404","Exploring the impact of pharmacogenetics on personalized medicine: A systematic review.","Amaro-Álvarez L","2024","Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria","systematic_review","article","10.1016/j.farma.2023.12.004","38341366",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Systematic Review; Journal Article; review"],["R0023405","Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.","García Díaz E","2016","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","nonrandomized_study","article","10.1016/j.endonu.2016.01.006","26976710",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Comparative Study; Journal Article; Observational Study"],["R0023406","Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.","Kalogirou MS","2021","Clinics and research in hepatology and gastroenterology","systematic_review","article","10.1016/j.clinre.2020.10.012","33309563",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0023407","Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control.","Rhinehart AS","2015","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/diaclin.33.2.73","25897187","PMC4398015",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023408","Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics.","Osaka H","2024","PCN reports : psychiatry and clinical neurosciences","other_trial","article","10.1002/pcn5.185","38868475","PMC11114408",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0023409","Incretins and amylin in pediatric diabetes: new tools for management of diabetes in youth.","Wood JR","2013","Current opinion in pediatrics","narrative_review","article","10.1097/mop.0b013e328362fdfb","23782574",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023410","Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.","Wong MC","2014","PloS one","systematic_review","article","10.1371/journal.pone.0090963","24614606","PMC3948731",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0023411","In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.","Brown K","2023","Annals of internal medicine","commentary","article","10.7326/j22-0105","36592466",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023412","N-2-(4-[18F]-Fluorobenzamido)ethylmaleimide coupled to cysteine-tagged on the C- or N-terminal of exendin-4","Chopra A","2004","National Center for Biotechnology Information (US), Bethesda (MD)","preclinical","article",null,"22457886",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0023413","Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study","Storm CS","2020","medRxiv","other_trial","preprint","10.1101/2020.10.20.20215855",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0023414","Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model.","Park HJ","2019","Scientific reports","preclinical","article","10.1038/s41598-019-51648-1","31666643","PMC6821734",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023415","Rheumatology: What You May Have Missed in 2024.","Blau BJ","2025","Annals of internal medicine","other_trial","article","10.7326/annals-25-00927","40163867",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0023416","Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers.","Katsiki N","2021","International journal of clinical practice","randomized_trial","article","10.1111/ijcp.14833","34510676","PMC8646329",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0023417","Cardiovascular and hemodynamic effects of glucagon-like peptide-1.","Goodwill AG","2014","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-014-9290-z","24881624","PMC4119853",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article"],["R0023418","Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria.","Tews D","2009","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","preclinical","article","10.1055/s-0028-1105911","19085810",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023419","Pharmacology, physiology, and mechanisms of incretin hormone action.","Campbell JE","2013","Cell metabolism","narrative_review","article","10.1016/j.cmet.2013.04.008","23684623",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0023420","MondoA Is an Essential Glucose-Responsive Transcription Factor in Human Pancreatic β-Cells.","Richards P","2018","Diabetes","other","article","10.2337/db17-0595","29282201",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023421","Osteoarthritis year in review 2025: Epidemiology and therapy.","Dell'Isola A","2025","Osteoarthritis and cartilage","randomized_trial","article","10.1016/j.joca.2025.08.015","40914550",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0023422","Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review.","Salem V","2022","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13448","35338558","PMC9287009",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0023423","In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.","Brown K","2023","Annals of internal medicine","commentary","article","10.7326/j22-0104","36592465",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023424","High-level expression of fusion protein containing 10 tandem repeated GLP-1 analogs in yeast Pichia pastoris and its biological activity in a diabetic rat model.","Hou J","2007","Bioscience, biotechnology, and biochemistry","preclinical","article","10.1271/bbb.60694","17587676",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023425","C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis.","Rahman K","2016","Laboratory investigation; a journal of technical methods and pathology","preclinical","article","10.1038/labinvest.2016.61","27239734","PMC4965279",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023426","Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis.","Romero-Gómez M","2025","Gastroenterologia y hepatologia","other","article","10.1016/j.gastrohep.2025.502442","40221023",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Practice Guideline"],["R0023427","Association between exenatide use and incidence of Alzheimer's disease.","Zhou B","2021","Alzheimer's & dementia (New York, N. Y.)","nonrandomized_study","article","10.1002/trc2.12139","33614900","PMC7882542",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023428","Extrapancreatic actions of incretin-based therapies on bone in diabetes mellitus","Mansur SA","2015","Ulster University","other","article",null,null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0023429","Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1.","Zietek T","2016","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2016.00154","27148273","PMC4840214",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023430","Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program.","Xie F","2026","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","nonrandomized_study","article","10.1016/j.jval.2025.08.019","40939703",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023431","Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.","Mikhail N","2008","Expert opinion on investigational drugs","other_trial","article","10.1517/13543784.17.6.845","18491986",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0023432","Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice.","Heppner KM","2015","Diabetologia","preclinical","article","10.1007/s00125-015-3651-3","26049402","PMC4529364",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0023433","Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes.","Cheang JY","2018","ChemMedChem","narrative_review","article","10.1002/cmdc.201700781","29430842",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023434","Exenatide challenge in oral glucose tolerance test is insufficient for predictions of glucose metabolism and insulin secretion after sleeve gastrectomy (SG) in obese patients with type 2 diabetes: a pilot study to establish a preoperative model to estimate β-cell function following augmented glucagon-like peptide-1 secretion after SG.","Nakamura Y","2022","Endocrine journal","other","article","10.1507/endocrj.ej22-0224","35896344",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023435","[Diabetology as an interdisciplinary challenge].","Müller-Wieland D","2017","Der Internist","narrative_review","article","10.1007/s00108-017-0204-5","28233014",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023436","Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways.","Guo NF","2019","European review for medical and pharmacological sciences","randomized_trial","article","10.26355/eurrev_201905_17832","31115031",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","TRUE","Journal Article; Retracted Publication; article"],["R0023437","Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.","Dejgaard TF","2016","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(15)00436-2","26656289",null,"ClinicalTrials.gov:NCT01612468","S000597","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023438","Liraglutide regulates proliferation, differentiation, and apoptosis of preosteoblasts through a signaling network of Notch/Wnt/Hedgehog signaling pathways.","Hou HW","2020","European review for medical and pharmacological sciences","preclinical","article","10.26355/eurrev_202012_24037","33336762",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023439","Intranasal pramlintide matches intraperitoneal effects on food intake and gastric emptying in mice.","Almeida MS","2025","Endocrine","preclinical","article","10.1007/s12020-025-04220-z","40169506",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023440","Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.","Svegliati-Baroni G","2011","Liver international : official journal of the International Association for the Study of the Liver","preclinical","article","10.1111/j.1478-3231.2011.02462.x","21745271",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023441","Correction of over-dosed insulin in a type-2- diabetic led to a better control of glycemia and arterial hypertension: a case report","Abobarin-Adeagbo A","2021","Research Square","case_report","preprint","10.21203/rs.3.rs-192245/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023442","[Treatment of type 2 diabetes: Exenatide or liraglutide? - Exenatide and liraglutide in head-to-head comparison approximately coequal].","Schatz H","2013","Deutsche medizinische Wochenschrift (1946)","commentary","article","10.1055/s-0032-1329038","23404321",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comment; Journal Article"],["R0023443","Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.","Arnés L","2008","International journal of molecular medicine","preclinical","article","10.3892/ijmm.22.1.127","18575785",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023444","Retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines.","Li J","2019","Electronic journal of biotechnology : EJB","other","article","10.1016/j.ejbt.2019.07.002","32288149","PMC7125944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023445","Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.","Kramer CK","2018","JACC. Heart failure","systematic_review","article","10.1016/j.jchf.2018.05.021","30196071",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis"],["R0023446","Patterns and Predictors of Weight Loss with Exenatide Treatment in Overweight and Obese Women","Dushay J","2020","medRxiv","other","preprint","10.1101/2020.06.11.20128645",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023447","Semaglutide-associated bullous pemphigoid.","Burruss CP","2021","JAAD case reports","case_report","article","10.1016/j.jdcr.2021.07.027","34466645","PMC8385392",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023448","Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes.","Zheng W","2019","International immunopharmacology","other","article","10.1016/j.intimp.2019.05.034","31185450",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023449","Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.","Bonora E","2007","International journal of clinical practice. Supplement","narrative_review","article","10.1111/j.1742-1241.2007.01441.x","17593274",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023450","[Influences of exendin-4 on the secretion function of islet beta cells from rats in the early stage of severe scald].","Zhao DX","2016","Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns","preclinical","article","10.3760/cma.j.issn.1009-2587.2016.12.011","28043300",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023451","NESIDIOBLASTOSIS IN AN ADULT WITH SHORT GUT SYNDROME AND TYPE 2 DIABETES.","Wong M","2019","AACE clinical case reports","case_report","article","10.4158/accr-2019-0243","31967075","PMC6873840",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023452","Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1.","Xie P","2022","Carbohydrate polymers","preclinical","article","10.1016/j.carbpol.2022.119388","35450649",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023453","Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats.","Gardiner SM","2008","British journal of pharmacology","preclinical","article","10.1038/bjp.2008.75","18311183","PMC2438985",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0023454","A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice.","Mulligan CM","2013","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-013-0025-z","23715814","PMC3687089",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023455","Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.","Gallwitz B","2005","Diabetes technology & therapeutics","preclinical","article","10.1089/dia.2005.7.651","16120042",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023456","[Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus].","Toyonaga T","2011","Nihon rinsho. Japanese journal of clinical medicine","other_trial","article",null,"21595277",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0023457","AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review.","Arab JP","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","narrative_review","article","10.1016/j.cgh.2026.07.027","42776095",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Practice Guideline"],["R0023458","Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity.","Caputo M","2021","Frontiers in endocrinology","case_report","article","10.3389/fendo.2021.687918","34239499","PMC8258411",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023459","GLP-1 receptor agonists and basal insulin in type 2 diabetes.","Young LA","2014","Lancet (London, England)","commentary","article","10.1016/s0140-6736(14)61409-4","25220193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023460","Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide.","Giraudon M","2017","Diabetes, obesity & metabolism","other","article","10.1111/dom.12850","27981717",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023461","A critical review of natural products driven correction of bile acid dysregulation: a therapeutic strategy for nonalcoholic fatty liver disease.","Peng Q","2025","Frontiers in pharmacology","randomized_trial","article","10.3389/fphar.2025.1640873","41357887","PMC12678328",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0023462","Thermal stability of exenatide encapsulated in stratified dissolving microneedles during storage.","Liu H","2023","International journal of pharmaceutics","other","article","10.1016/j.ijpharm.2023.122863","36934885",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023463","Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.","Kapitza C","2011","Journal of clinical pharmacology","other","article","10.1177/0091270010374474","20671294",null,null,"S000903","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023464","Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats.","Dischinger U","2020","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2020.598843","33551994","PMC7862770",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023465","Liraglutide improves obesity-induced renal injury by alleviating uncoupling of the glomerular VEGF-NO axis in obese mice.","Li K","2020","Clinical and experimental pharmacology & physiology","preclinical","article","10.1111/1440-1681.13391","32757282",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023466","In adults with overweight or obesity, continued weekly semaglutide after a 20-wk run-in improved weight loss.","Lau D","2021","Annals of internal medicine","randomized_trial","article","10.7326/acpj202108170-088","34339232",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0023467","A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy.","Orme M","2014","Diabetology & metabolic syndrome","systematic_review","article","10.1186/1758-5996-6-73","25006351","PMC4085736",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0023468","Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes.","Dong JZ","2011","Diabetes, obesity & metabolism","other","article","10.1111/j.1463-1326.2010.01313.x","21114599",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023469","GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK.","Zhang L","2013","Liver international : official journal of the International Association for the Study of the Liver","preclinical","article","10.1111/liv.12120","23432843",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023470","Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study.","Takeshita Y","2015","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12269","25802727","PMC4364854",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0023471","Amino acids are sensitive glucagon receptor-specific biomarkers for glucagon-like peptide-1 receptor/glucagon receptor dual agonists.","Li W","2020","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14173","33463043",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023472","SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.","Mirarchi L","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms23073668","35409028","PMC8998221",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023473","Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.","Gupta NA","2010","Hepatology (Baltimore, Md.)","preclinical","article","10.1002/hep.23569","20225248","PMC2862093",null,"S000885","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023474","Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss.","Badurdeen D","2021","Gastrointestinal endoscopy","nonrandomized_study","article","10.1016/j.gie.2020.10.016","33075366",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0023475","What next when metformin isn't enough for type 2 diabetes?","Hawes EM","2016","The Journal of family practice","narrative_review","article",null,"26977458",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023476","Impact of Anti-obesity Medication Initiation and Duration on Weight Loss.","Bailony MR","2025","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.70069","40124956","PMC11928677",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023477","Thyroid safety in patients treated with liraglutide.","Gallo M","2013","Journal of endocrinological investigation","preclinical","article","10.1007/bf03346749","23481614",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023478","Gastric emptying and glycaemia in health and diabetes mellitus.","Phillips LK","2015","Nature reviews. Endocrinology","narrative_review","article","10.1038/nrendo.2014.202","25421372",null,null,"S002713","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0023479","Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice.","Bao X","2020","Journal of nanobiotechnology","preclinical","article","10.1186/s12951-020-00619-0","32345323","PMC7189518",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0023480","Effects of SGLT-2 inhibitors on clinical and biological hyperandrogenism and menstruation irregularities in patients with polycystic ovary syndrome: A systematic review of randomized trials.","Mrabet HE","2024","SAGE open medicine","systematic_review","article","10.1177/20503121241308997","39713268","PMC11660270",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0023481","[Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].","Christensen M","2012","Ugeskrift for laeger","commentary","article",null,"23077741",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0023482","Semaglutide for Weight Loss.","Carris NW","2022","The Annals of pharmacotherapy","commentary","article","10.1177/10600280211027204","34157885",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0023483","Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.","Jensen TM","2015","Diabetes care","systematic_review","article","10.2337/dc13-1210","25504028",null,null,"S000398; S000463; S000860; S000862; S001065; S001094; S001393; S001487; S001502; S001581; S001584; S001826; S002057; S002098; S002222; S002230; S002361","pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; article"],["R0023484","Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.","Feinglos MN","2005","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2005.01567.x","16026367",null,null,"S001487","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023485","Loureirin B promotes insulin secretion through GLP-1R and AKT/PDX1 pathways.","Fang H","2022","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2022.175377","36347320",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023486","The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.","Du X","2019","International immunopharmacology","other","article","10.1016/j.intimp.2019.105732","31336333",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023487","Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.","Takashima S","2016","Kidney international","preclinical","article","10.1016/j.kint.2016.06.012","27475229",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023488","Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction.","Hamad F","2021","Current diabetes reviews","systematic_review","article","10.2174/1573399816999200821164129","32867644",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0023489","Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease: Liraglutide and Diabetic Kidney Disease.","Cherney DZ","2020","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.01260120","32149722","PMC7133122","ClinicalTrials.gov:NCT00696657","S000135","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Editorial; Comment; article"],["R0023490","New insight on the role of liraglutide in alleviating dexamethasone-induced pancreatic cytotoxicity via improving redox status, autophagy flux, and PI3K/Akt/Nrf2 signaling.","Elseady WS","2021","Canadian journal of physiology and pharmacology","preclinical","article","10.1139/cjpp-2021-0183","34197718",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023491","Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.","Pols TW","2010","Gastroenterologie clinique et biologique","narrative_review","article","10.1016/j.gcb.2010.03.009","20444564",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0023492","Letter to the Editor: \"GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women\" by Iepsen E.W., et al.","Conte C","2015","The Journal of clinical endocrinology and metabolism","commentary","article","10.1210/jc.2015-2970","26439158",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0023493","Liraglutide protects pancreatic β-cells against free fatty acids in vitro and affects glucolipid metabolism in apolipoprotein E-/- mice by activating autophagy.","Wang J","2015","Molecular medicine reports","preclinical","article","10.3892/mmr.2015.3944","26080706","PMC4526029",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023494","Proper Management of People with Obesity during the COVID-19 Pandemic.","Lim S","2020","Journal of obesity & metabolic syndrome","other","article","10.7570/jomes20056","32544885","PMC7338495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0023495","[Exenatide (Byetta)].","Duh D","2008","Journal de pharmacie de Belgique","other","article",null,"18479081",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023496","Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery.","Kokkorakis M","2023","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2023.155689","37689110",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0023497","Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.","Jensterle M","2015","Journal of ovarian research","randomized_trial","article","10.1186/s13048-015-0161-3","26032655","PMC4506413","ClinicalTrials.gov:NCT02187250","S001782","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0023498","Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.","Lundgren JR","2021","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2028198","33951361",null,"ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32","S000003; S000371; S001692; S002373","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023499","Direct Effect of the Synthetic Analogue of Glucagon-Like Peptide Type 1, Liraglutide, on Mature Adipocytes Is Realized through Adenylate-Cyclase-Dependent Enhancing of Insulin Sensitivity.","Mamontova ED","2021","Biochemistry. Biokhimiia","preclinical","article","10.1134/s000629792103010x","33838634",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023500","The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.","Lin C","2020","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2020.541699","33424764","PMC7793753",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; review"],["R0023501","Clinical pathways in the management of the obese: Pre- and postoperative aspects.","Guillerme S","2023","Journal of visceral surgery","narrative_review","article","10.1016/j.jviscsurg.2022.12.009","36725452",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023502","Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.","Lønborg J","2012","European heart journal","randomized_trial","article","10.1093/eurheartj/ehr309","21920963",null,"ClinicalTrials.gov:NCT00835848","S000424; S000767; S000838; S000986; S001524; S002195","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023503","Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications.","Okubo H","2018","International journal of molecular sciences","narrative_review","article","10.3390/ijms19103064","30297626","PMC6213237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023504","Cardiovascular benefit of albiglutide.","Lim GB","2018","Nature reviews. Cardiology","other","article","10.1038/s41569-018-0113-x","30310151",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023505","Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities.","Musso G","2016","Diabetes care","narrative_review","article","10.2337/dc15-1182","27660122",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0023506","Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.","Wadden TA","2021","JAMA","randomized_trial","article","10.1001/jama.2021.1831","33625476","PMC7905697","ClinicalTrials.gov:NCT03611582","S000988; S001187; S001331; S001427; S002092","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0023507","Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor.","Underwood CR","2010","The Journal of biological chemistry","other","article","10.1074/jbc.m109.033829","19861722","PMC2804221",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023508","GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH.","Li QX","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.721198","34552561","PMC8450670",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0023509","Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease-Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors.","Lin KJ","2021","Antioxidants (Basel, Switzerland)","narrative_review","article","10.3390/antiox10121935","34943038","PMC8750793",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023510","[Study of the effect of liraglutide on the correlation between NLRP3 inflammasome and non-alcoholic fatty liver disease].","Ma ZZ","2022","Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","preclinical","article","10.3760/cma.j.cn501113-20200326-00142","36038324","PMC12770168",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023511","Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates.","Bello NT","2010","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00275.2010","20554932","PMC2944427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0023512","Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States.","Aggarwal R","2021","Progress in cardiovascular diseases","commentary","article","10.1016/j.pcad.2021.09.007","34560122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0023513","[Obesity treatment with semaglutide].","Blüher M","2021","Der Internist","other","article","10.1007/s00108-021-01119-5","34402956",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023514","Exploring Cardio-Metabolic Effects of Liraglutide in Patients With Type 2 Diabetes Through a Proteomic Approach","Ekhzaimy A","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.582",null,"PMC8265938",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0023515","Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.","Conlon JM","2022","Peptides","preclinical","article","10.1016/j.peptides.2021.170706","34861327",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0023516","A 24-week, prospective, randomized, open-label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance to assess the addition of exenatide on the efficacy of u-500 regular insulin plus metformin.","Distiller LA","2014","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep14067.or","24936555",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0023517","Semaglutide or Placebo for Nonalcoholic Steatohepatitis.","Da BL","2021","The New England journal of medicine","commentary","article","10.1056/nejmc2106921","34233104",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0023518","Dulaglutide",null,"2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"31643312",null,null,null,"europepmc","TRUE",null,null,null,"Book; Review"],["R0023519","Imeglimin Improved Plasma Glucose Levels in Patients With Latent Autoimmune Diabetes of Adults: Report of 2 Cases.","Okada S","2024","JCEM case reports","case_report","article","10.1210/jcemcr/luad161","38116160","PMC10729848",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023520","Cardiovascular outcomes and safety with antidiabetic drugs.","Aldossari KK","2018","International journal of health sciences","nonrandomized_study","article",null,"30202411","PMC6124835",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0023521","Vagal Nerve Stimulation for Glycemic Control in a Rodent Model of Type 2 Diabetes.","Yin J","2019","Obesity surgery","preclinical","article","10.1007/s11695-019-03901-9","31222497","PMC10461220",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0023522","Energy intake as a short-term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial.","Saxena AR","2021","Obesity science & practice","randomized_trial","article","10.1002/osp4.486","34123395","PMC8170575",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0023523","Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.","Lee J","2012","Regulatory peptides","preclinical","article","10.1016/j.regpep.2012.04.010","22561689",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023524","GLP-1 ANALOGUES FOR THE TREATMENT OF TYPE 2 DIABETES IN LATINOS/HISPANICS.","Caballero AE","2016","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","commentary","article","10.4158/ep161593.co","27929679",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023525","Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?","Kumbhar PS","2025","Naunyn-Schmiedeberg's archives of pharmacology","narrative_review","article","10.1007/s00210-024-03578-7","39520555",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023526","Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin.","Yang X","2020","Stem cell research & therapy","other","article","10.1186/s13287-020-01689-5","32429994","PMC7238586",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0023527","Polycystic ovarian syndrome-current pharmacotherapy and clinical implications.","Rashid R","2022","Taiwanese journal of obstetrics & gynecology","narrative_review","article","10.1016/j.tjog.2021.11.009","35181044",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0023528","Non-alcoholic fatty liver disease in 2015.","Ahmed M","2015","World journal of hepatology","narrative_review","article","10.4254/wjh.v7.i11.1450","26085906","PMC4462685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023529","GLP-1R agonists are not a quick fix for weight loss.","Iverson KA","2012","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.e1455","22374905",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0023530","Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.","Kovalic AJ","2023","European journal of gastroenterology & hepatology","systematic_review","article","10.1097/meg.0000000000002463","36468574",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; review"],["R0023531","Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.","King AB","2013","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.4158/ep12232.or","23186975",null,null,"S001094; S001502; S001584; S002098; S002222; S002230; S002361","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023532","Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action.","Varin EM","2019","Cell reports","preclinical","article","10.1016/j.celrep.2019.05.055","31189118",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023533","MON-457 Reactive Thyroid C-Cell Hyperplasia or Medullary Thyroid Cancer in a Patient with Nodular Thyroidopathy. May the Calcitonin Measurement in Fine-Needle Aspirate Washout Fluid of the Healthy Lobe Help to Define These Conditions?","Chevais A","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.222",null,"PMC7208639",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0023534","Dipeptidyl peptidase IV inhibitor improves the salivary gland histology of spontaneously diabetic mice.","da Silva Faria AL","2013","Archives of oral biology","preclinical","article","10.1016/j.archoralbio.2012.09.015","23107049",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023535","Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.","Zhao H","2014","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12291","24641303",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023536","A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction.","Patterson JT","2013","Molecular metabolism","other","article","10.1016/j.molmet.2013.01.003","24199154","PMC3817388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023537","Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies.","Lebovitz HE","2006","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.4158/ep.12.s1.142","16627399",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023538","CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's Disease.","Wang Y","2025","Research square","nonrandomized_study","article","10.21203/rs.3.rs-8206648/v1","41510304","PMC12776463",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Preprint"],["R0023539","Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.","García-Compeán D","2016","Digestive diseases and sciences","narrative_review","article","10.1007/s10620-015-3907-2","26462490",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0023540","Hydrophobic Amino Acid Tryptophan Shows Promise as a Potential Absorption Enhancer for Oral Delivery of Biopharmaceuticals.","Kamei N","2018","Pharmaceutics","preclinical","article","10.3390/pharmaceutics10040182","30308982","PMC6321321",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023541","A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center.","De la Rosa A","2022","Obesity pillars","nonrandomized_study","article","10.1016/j.obpill.2022.100046","37990666","PMC9714128",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023542","Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.","Bensignor MO","2021","Pediatric obesity","randomized_trial","article","10.1111/ijpo.12778","33634589","PMC8277686","ClinicalTrials.gov:NCT01541215","S000357","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023543","Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study.","Al-Rubeaan K","2023","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2022.2144052","36342972",null,"ClinicalTrials.gov:NCT02322762",null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article; other"],["R0023544","Comparative adherence to diabetes drugs: An analysis of electronic health records and claims data.","Flory J","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12931","28266807",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0023545","Subcutaneous adipose tissue composition and function are unaffected by liraglutide-induced weight loss in adults with type 1 diabetes.","Wegeberg AM","2021","Basic & clinical pharmacology & toxicology","randomized_trial","article","10.1111/bcpt.13575","33624417","PMC8251841",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0023546","Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists.","Swedberg JE","2015","European journal of medicinal chemistry","other","article","10.1016/j.ejmech.2015.08.046","26352676",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023547","Once-Weekly Semaglutide in Adults with Overweight or Obesity.","Javor E","2021","The New England journal of medicine","commentary","article","10.1056/nejmc2106918","34192446",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0023548","Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?","Meurot C","2022","Journal of orthopaedic translation","narrative_review","article","10.1016/j.jot.2022.02.001","35280931","PMC8888891",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023549","Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury.","Hakon J","2015","PloS one","preclinical","article","10.1371/journal.pone.0120074","25822252","PMC4379006",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023550","Encyclopaedic Review of Glipizide Pre-clinical and Clinical Status.","Mohammed S","2024","Drug research","preclinical","article","10.1055/a-2237-8566","38408478",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023551","Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.","Triplitt C","2006","Pharmacotherapy","narrative_review","article","10.1592/phco.26.3.360","16503716",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023552","A CASE OF MORBILLIFORM DRUG ERUPTION TO DULAGLUTIDE.","Rzepka PV","2020","The Journal of clinical and aesthetic dermatology","case_report","article",null,"33144906","PMC7605389",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0023553","Gastroparesis With the Initiation of Liraglutide: A Case Report.","Almustanyir S","2020","Cureus","case_report","article","10.7759/cureus.11735","33403167","PMC7773310",null,"S000944","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Case Reports; Journal Article; case-report; article"],["R0023554","The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular.","Deng J","2022","Frontiers in cell and developmental biology","narrative_review","article","10.3389/fcell.2022.844028","35252207","PMC8891560",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023555","Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic.","Kim JW","2010","BMB reports","preclinical","article","10.5483/bmbrep.2010.43.2.146","20193135",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023556","Assessment of Cardiovascular Risk Categories and Achievement of Therapeutic Targets in European Patients with Type 2 Diabetes.","Reurean-Pintilei D","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13082196","38673469","PMC11051102",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023557","Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide.","Matić A","2021","Croatian medical journal","preclinical","article","10.3325/cmj.2021.62.215","34212558","PMC8275945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023558","Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.","de Souto Barreto P","2021","The New England journal of medicine","commentary","article","10.1056/nejmc2109509","34347962",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0023559","B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells.","Hwang SL","2013","Experimental & molecular medicine","other","article","10.1038/emm.2013.47","23703573","PMC3674408",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023560","GLP-1 receptor agonists and the risk of colorectal cancer.","Kakkar AK","2014","Medical hypotheses","commentary","article","10.1016/j.mehy.2014.03.028","24746383",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0023561","Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology.","Lin K","2022","Computational intelligence and neuroscience","randomized_trial","article","10.1155/2022/8149515","35785080","PMC9242767",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0023562","Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.","Kuang J","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00910-1","32857293","PMC7509013","ClinicalTrials.gov:NCT01644500; ClinicalTrials.gov:NCT01648582","S001064; S001404","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0023563","Liraglutide restores late cardioprotective effects of remote preconditioning in diabetic rats via activation of hydrogen sulfide and nuclear factor erythroid 2-related factor 2 signaling pathway.","Wang L","2021","Acta cirurgica brasileira","preclinical","article","10.1590/acb360207","33656046","PMC7909944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023564","GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress.","Jiang Y","2018","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2018.01168","30459598","PMC6232689",null,"S001582","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0023565","Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats.","Husnik R","2020","Journal of veterinary internal medicine","randomized_trial","article","10.1111/jvim.15787","32515089","PMC7379023",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Veterinary; Journal Article; research-article; article"],["R0023566","Neuroprotective effects of liraglutide for stroke model of rats.","Sato K","2013","International journal of molecular sciences","preclinical","article","10.3390/ijms141121513","24177570","PMC3856019",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023567","Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies.","Maestri M","2023","Frontiers in nutrition","narrative_review","article","10.3389/fnut.2023.1110536","36875849","PMC9978194",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023568","The rationale for combining GLP-1 receptor agonists with basal insulin.","Cohen ND","2013","The Medical journal of Australia","narrative_review","article","10.5694/mja12.11856","23984780",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023569","Glucagon-like peptide-1 analogues for type 2 diabetes.","Wilding JP","2011","BMJ (Clinical research ed.)","randomized_trial","article","10.1136/bmj.d410","21325387",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0023570","[Anti-diabetes agents and hypoglycemia].","Consoli A","2013","Giornale italiano di cardiologia (2006)","other","article","10.1714/1375.15276","24362782",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023571","FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.","McGuire DK","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13645","30690856",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023572","Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.","Chang HY","2018","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2018.3034","30105373","PMC6142968",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0023573","Exenatide pretreatment improved graft function in nonhuman primate islet recipients compared to treatment after transplant only.","Buss JL","2012","Journal of transplantation","other","article","10.1155/2012/382518","23056916","PMC3465909",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023574","Release of exendin-4 is controlled by mechanical action in Gila monsters, Heloderma suspectum.","Christel CM","2006","Comparative biochemistry and physiology. Part A, Molecular & integrative physiology","preclinical","article","10.1016/j.cbpa.2005.10.029","16321550",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0023575","Liraglutide improves pancreatic islet β cell apoptosis in rats with type 2 diabetes mellitus by inhibiting the IKKε/NF-κB pathway.","Liu YT","2021","European review for medical and pharmacological sciences","preclinical","article","10.26355/eurrev_202107_26395","34337733",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023576","Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy.","Arakawa M","2013","Diabetes & metabolic syndrome","other","article","10.1016/j.dsx.2013.10.002","24290089",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023577","Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats.","Artunc-Ulkumen B","2015","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","preclinical","article","10.3109/09513590.2014.975686","25366063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023578","Impact of Albumin-to-Creatinine Ratio Point-of-Care Testing on the Diagnosis and Management of Diabetic Kidney Disease.","Schultes B","2023","Journal of diabetes science and technology","nonrandomized_study","article","10.1177/19322968211054520","34709065","PMC10012378",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023579","Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice.","Merani S","2008","Endocrinology","preclinical","article","10.1210/en.2008-0501","18511515",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023580","Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review.","Pan CS","2020","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2020.00070","32153507","PMC7046622",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, N.I.H., Extramural; Systematic Review; systematic-review; review"],["R0023581","Transient beneficial effects of exendin-4 treatment on the function of microencapsulated mouse pancreatic islets.","Bohman S","2007","Cell transplantation","preclinical","article","10.3727/000000007783464452","17436851",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023582","Multi-Faceted Influence of Obesity on Type 1 Diabetes in Children - From Disease Pathogenesis to Complications.","Ciężki S","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.890833","35784568","PMC9243381",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023583","Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.","Jiang J","2021","Endocrine, metabolic & immune disorders drug targets","other_trial","article","10.2174/1871530320999200831165116","32875989",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0023584","Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.","Burmeister MA","2013","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00446.2012","23341495",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023585","Pancreatic stellate cells can form new beta-like cells.","Docherty K","2009","The Biochemical journal","preclinical","article","10.1042/bj20090779","19552623",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comment; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023586","Increasing beta cell mass to treat diabetes mellitus.","Sabir S","2018","Advances in clinical and experimental medicine : official organ Wroclaw Medical University","preclinical","article","10.17219/acem/74452","29912482",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0023587","Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors.","Chepurny OG","2018","Scientific reports","other","article","10.1038/s41598-018-22106-1","29491394","PMC5830615",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023588","Semaglutide ameliorates lipopolysaccharide-induced acute lung injury through inhibiting HDAC5-mediated activation of NF-κB signaling pathway.","Jiang Z","2022","Human & experimental toxicology","preclinical","article","10.1177/09603271221125931","36075570",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023589","Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes.","Bray GA","2021","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14200","32969147",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023590","[Diabetes mellitus and road traffic-a position paper of the Austrian Diabetes Association (update 2023)].","Abrahamian H","2023","Wiener klinische Wochenschrift","other","article","10.1007/s00508-023-02193-5","37101052","PMC10133049",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Consensus Statement; research-article; article"],["R0023591","Testing a new platform to screen disease-modifying therapy in type 1 diabetes.","Lord SM","2023","PloS one","randomized_trial","article","10.1371/journal.pone.0293268","38096190","PMC10721089","ClinicalTrials.gov:NCT03632759; ClinicalTrials.gov:NCT05847413","S002242","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023592","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers.","Cui H","2021","European journal of drug metabolism and pharmacokinetics","other_trial","article","10.1007/s13318-020-00665-x","33576936",null,"ClinicalTrials.gov:NCT03062774","S002806","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Controlled Clinical Trial; Journal Article; article"],["R0023593","Understanding the complex function of gut microbiota: its impact on the pathogenesis of obesity and beyond: a comprehensive review.","Yarahmadi A","2024","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-024-01561-z","39710683","PMC11664868",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023594","Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1.","Liu Y","2011","Obesity surgery","preclinical","article","10.1007/s11695-011-0388-z","21479766",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023595","Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5'-monophosphate (AMP)-activated protein kinase signaling pathway.","Zhu XX","2021","Chinese medical journal","preclinical","article","10.1097/cm9.0000000000001363","33470656","PMC7929608",null,"S002362","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0023596","Antidepressant activity of anti-hyperglycemic agents in experimental models: A review.","Essmat N","2020","Diabetes & metabolic syndrome","preclinical","article","10.1016/j.dsx.2020.06.021","32673838",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023597","Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity.","Rayner CK","2021","JAMA","commentary","article","10.1001/jama.2021.13021","34581745",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0023598","Intestinal NAPE-PLD contributes to short-term regulation of food intake via gut-to-brain axis.","Rastelli M","2020","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00146.2020","32776827",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023599","Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment.","Scott D","2013","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s51795","24124385","PMC3795009",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article-commentary; article"],["R0023600","Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes.","Watanabe Y","2020","Journal of diabetes investigation","other_trial","article","10.1111/jdi.13146","31518492","PMC7078076",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; research-article; article"],["R0023601","Pharmacotherapy: GLP-1R agonists--the new weapon against obesity?","Koch L","2012","Nature reviews. Endocrinology","commentary","article","10.1038/nrendo.2012.13","22290361",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comment; Journal Article; article"],["R0023602","Utility of GLP-1R agonists in diabetes requires long term study.","de Oliveira JM","2012","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.e1451","22374904",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0023603","Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.","Patterson S","2015","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12483","25929155",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023604","A Remotely Delivered, Semaglutide-Supported Specialist Weight Management Program: Preliminary Findings From a Retrospective Service Evaluation.","Richards R","2023","JMIR formative research","nonrandomized_study","article","10.2196/53619","38153780","PMC10784980",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023605","An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.","Damholt B","2006","Journal of clinical pharmacology","other_trial","article","10.1177/0091270006288215","16707410",null,null,"S002045","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0023606","PRISMA-efficacy and safety of lixisenatide for type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.","Wei ZG","2018","Medicine","systematic_review","article","10.1097/md.0000000000013710","30572502","PMC6320179",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; review-article; article"],["R0023607","Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Penny Wise and Pound Foolish?","Grajower MM","2015","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","commentary","article","10.4158/ep14393.co","25628120",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023608","Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.","Polyzos SA","2019","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2018.11.014","30502373",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023609","\"Mild dysglycemia\" in type 2 diabetes: to be neglected or not?","Monnier L","2015","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2014.12.004","25572605",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023610","Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.","Moulton CD","2018","Psychoneuroendocrinology","systematic_review","article","10.1016/j.psyneuen.2018.05.010","29775878",null,null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review"],["R0023611","Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.","Savchenko LG","2019","Romanian journal of internal medicine = Revue roumaine de medecine interne","other","article","10.2478/rjim-2019-0003","30901315",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023612","Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.","Keskin L","2022","European review for medical and pharmacological sciences","other","article","10.26355/eurrev_202209_29783","36196729",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023613","Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract.","Kweon S","2024","International journal of nanomedicine","preclinical","article","10.2147/ijn.s442617","38544951","PMC10968941",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023614","Glucagon-like peptide-1 (GLP-1) improved diabetic lung fibrosis via AMPK and microRNA-27a (miR-27a).","Liu J","2021","Annals of translational medicine","other","article","10.21037/atm-21-869","33850889","PMC8039657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023615","Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial.","Inoue M","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-0605-7","30949907","PMC6531535","ClinicalTrials.gov:NCT03315780","S001614","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; other; article"],["R0023616","β cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control.","Gleizes C","2016","Journal of cellular and molecular medicine","preclinical","article","10.1111/jcmm.12683","26607759","PMC4727568",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023617","Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.","Li X","2021","Journal of diabetes research","other","article","10.1155/2021/3715026","34660809","PMC8519721",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023618","The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.","Lule KO","2022","Inflammopharmacology","preclinical","article","10.1007/s10787-021-00916-6","35072848",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023619","Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes.","Cheng H","2020","American journal of physiology. Endocrinology and metabolism","narrative_review","article","10.1152/ajpendo.00179.2019","31714795",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023620","Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss.","Ghanim H","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14090","32424935",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023621","GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.","He Q","2016","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2016.05.086","27208776",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023622","Shared and unique chromatin accessibility and 3D functional interactions of substance use disorder loci implicate cell types beyond the brain","Trang KB","2024","medRxiv","nonrandomized_study","article","10.1101/2024.07.18.24310649","39072016",null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0023623","[Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas].","Mukai E","2011","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"21595280",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0023624","Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli.","Züger D","2013","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2013.02.006","23438370",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023625","Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.","Minze MG","2013","Pharmacotherapy","narrative_review","article","10.1002/phar.1240","23553357",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0023626","Efficacy and safety of dulaglutide in patients with absolute insulin deficiency.","Kutoh E","2019","Endocrine regulations","other_trial","article","10.2478/enr-2019-0019","31517629",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; article"],["R0023627","Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?","Doggrell SA","2020","Expert opinion on biological therapy","randomized_trial","article","10.1080/14712598.2020.1724952","32005073",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Equivalence Trial; article"],["R0023628","Exenatide Use in the Management of Type 2 Diabetes Mellitus.","Kyriacou A","2010","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph3082554","27713366","PMC4033938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; review-article; article"],["R0023629","A Randomized, Double-Blind, Single-Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants.","Shaddinger BC","2019","Clinical pharmacology in drug development","randomized_trial","article","10.1002/cpdd.606","30063297",null,"ClinicalTrials.gov:NCT02660736","S000822","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023630","Acne Keloidalis Nuchae in a Caucasian Non-Hispanic Woman With Metabolic Syndrome and Autoimmune Thyroiditis: A Case Report.","Anatolieva B","2024","Cureus","case_report","article","10.7759/cureus.59119","38803744","PMC11128944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023631","Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.","Gibbons C","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14255","33184979","PMC7839771","ClinicalTrials.gov:NCT02773381","S001292","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023632","Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.","Bistola V","2018","Heart failure reviews","narrative_review","article","10.1007/s10741-018-9674-3","29383638",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023633","NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products.","Wang D","2021","Molecules (Basel, Switzerland)","other","article","10.3390/molecules26144251","34299526","PMC8307401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023634","Bullous Pemphigoid Triggered by Liraglutide.","Collins MK","2021","Cutis","commentary","article","10.12788/cutis.0262","34288861",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0023635","Liraglutide treatment and acylcarnitine profiles in Egyptian obese insulin-resistant females.","Hussein NA","2021","European journal of pharmacology","other","article","10.1016/j.ejphar.2020.173668","33098833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023636","Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors.","Abramson A","2022","Nature biotechnology","preclinical","article","10.1038/s41587-021-01024-0","34462588","PMC8766875",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0023637","[Cardiovascular effects of incretin-based therapies].","Lehrke M","2012","Herz","other","article","10.1007/s00059-012-3599-8","22430284",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0023638","Integrating semaglutide into obesity management - a primary care perspective.","Kyrillos JV","2022","Postgraduate medicine","narrative_review","article","10.1080/00325481.2022.2149964","36691306",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0023639","Composite endpoints in trials of type-2 diabetes.","Einarson TR","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12226","24148209",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023640","Human Sperm Express the Receptor for Glucagon-like Peptide-1 (GLP-1), Which Affects Sperm Function and Metabolism.","Rago V","2020","Endocrinology","preclinical","article","10.1210/endocr/bqaa031","32157297",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023641","Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.","Ji L","2021","Diabetologia","notice","article","10.1007/s00125-021-05460-0","34037812","PMC8496613",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0023642","The GLP-1 receptor herbal agonist morroniside attenuates neuropathic pain via spinal microglial expression of IL-10 and β-endorphin.","Tang X","2020","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2020.05.080","32595037",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023643","Cardiovascular biology of the GIP receptor.","Greenwell AA","2020","Peptides","narrative_review","article","10.1016/j.peptides.2019.170228","31812593",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0023644","Hedgehog interacting protein as a circulating biomarker in women with obesity: a cross-sectional study and intervention studies.","Wang H","2023","Annals of medicine","nonrandomized_study","article","10.1080/07853890.2023.2206162","37166403","PMC10309011","ChiCTR:ChiCTR2000032878; ChiCTR:ChiCTR1800019776",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023645","Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.","Mody R","2019","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2019-000884","31875137","PMC6904197",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0023646","Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index.","Gentilella R","2019","Diabetes, obesity & metabolism","other","article","10.1111/dom.13853","31392822",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023647","Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.","Romera I","2020","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2020.107575","32220551",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023648","Intensifying insulin therapy: what options are available to patients with type 2 diabetes?","Meneghini LF","2013","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2013.06.011","23953077",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0023649","Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.","Lee WC","2011","Current medical research and opinion","randomized_trial","article","10.1185/03007995.2011.559444","21348806",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023650","Liraglutide: a review of its use in the management of obesity.","Scott LJ","2015","Drugs","nonrandomized_study","article","10.1007/s40265-015-0408-8","25985864",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0023651","Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.","Ratner R","2011","Cardiovascular diabetology","systematic_review","article","10.1186/1475-2840-10-22","21410975","PMC3070629",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0023652","Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply.","Lingvay I","2021","JAMA","commentary","article","10.1001/jama.2021.13024","34581743",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0023653","Basal insulin or longacting GLP-1 receptor agonists-making the right choice.","Bloomgarden ZT","2014","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(14)70036-1","24731676",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023654","Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.","Nakouti T","2015","Current vascular pharmacology","nonrandomized_study","article","10.2174/1570161112666141121112612","25412688",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0023655","Death and dysfunction of transplanted β-cells: lessons learned from type 2 diabetes?","Potter KJ","2014","Diabetes","preclinical","article","10.2337/db12-0364","24357689",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023656","Clinical characteristics and healthcare utilisation associated with undiagnosed cognitive impairment in elderly patients with diabetes in a primary care setting: a population-based cohort study.","Merzon E","2024","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2023-078996","38272546","PMC10824016",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023657","Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.","Ingwersen SH","2015","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2015.01.001","25684604",null,null,"S001581","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023658","Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database.","Wu SN","2025","European journal of pharmacology","nonrandomized_study","article","10.1016/j.ejphar.2025.177820","40490170",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0023659","Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study.","Yoo JH","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-019-0658-7","31240562","PMC6612352",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0023660","Identification of the dipeptidyl aminopeptidase responsible for N-terminal clipping of recombinant Exendin-4 precursor expressed in Pichia pastoris.","Prabha L","2009","Protein expression and purification","other","article","10.1016/j.pep.2008.10.021","19028585",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023661","Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia.","Meek TH","2015","Diabetes","preclinical","article","10.2337/db14-1562","25633417","PMC4477352",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0023662","Understanding the cardiovascular risk with non-insulin antidiabetic drugs.","Athyros VG","2019","Expert opinion on drug safety","randomized_trial","article","10.1080/14740338.2019.1586881","30810055",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0023663","Liraglutide Does Not Adversely Impact Fat-Free Mass Loss.","Grannell A","2021","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.23098","33528919",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023664","Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.","Wajcberg E","2009","Expert opinion on pharmacotherapy","other_trial","article","10.1517/14656560802611832","19236187",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0023665","Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.","Best JH","2011","Diabetes care","nonrandomized_study","article","10.2337/dc10-1393","20929995","PMC3005487",null,"S000937","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023666","Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects.","Bagger JI","2021","Diabetes","randomized_trial","article","10.2337/db20-0998","33722838",null,"ClinicalTrials.gov:NCT01507597",null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023667","Effects of exenatide therapy on insulin resistance in the skeletal muscles of high-fat diet and low-dose streptozotocin-induced diabetic rats.","Wu H","2016","Endocrine research","preclinical","article","10.3109/07435800.2015.1015726","26361069",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023668","Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis.","Omanovic Kolaric T","2022","Current issues in molecular biology","other","article","10.3390/cimb44080239","36005135","PMC9406665",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023669","Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.","Guo W","2020","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2020.108487","33035599",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023670","Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.","Shi L","2017","Obesity research & clinical practice","randomized_trial","article","10.1016/j.orcp.2017.01.003","28161303",null,"ChiCTR:ChiCTR-OPC-16008152",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0023671","Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.","Faillie JL","2016","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2016.1531","27478902",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Comparative Study; Journal Article; article"],["R0023672","Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones.","Liu Y","2016","ACS chemical biology","preclinical","article","10.1021/acschembio.6b00630","27704775","PMC5148668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023673","Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS.","Smirnov VV","2023","Reproductive sciences (Thousand Oaks, Calif.)","narrative_review","article","10.1007/s43032-022-01013-x","35764857",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0023674","Lipotoxicity: The missing link between diabetes and periodontitis?","Sun Y","2024","Journal of periodontal research","narrative_review","article","10.1111/jre.13242","38419425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023675","Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis.","Petri KC","2015","Clinical pharmacokinetics","other_trial","article","10.1007/s40262-014-0229-z","25603819","PMC4449373","ClinicalTrials.gov:NCT00943501; ClinicalTrials.gov:NCT00993304","S001356; S001702","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023676","Presynaptic GLP-1 receptors enhance the depolarization-evoked release of glutamate and GABA in the mouse cortex and hippocampus.","Rebosio C","2018","BioFactors (Oxford, England)","preclinical","article","10.1002/biof.1406","29265673",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023677","A cognitive signature of metabolic health in effort-based decision-making","Mehrhof SZ","2024","PsyArXiv","other","preprint","10.31234/osf.io/4bkm9",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023678","Circadian Rhythm-Aligned Time-Restricted Feeding Prevents Ovariectomy-Induced Fat Gain, Insulin Resistance, and Osteosarcopenia in Rats.","Kulkarni C","2026","The Journal of nutrition","preclinical","article","10.1016/j.tjnut.2026.101509","41916467",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023679","Erratum to ‘Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making’",null,"2015","Therapeutic advances in endocrinology and metabolism","notice","article",null,null,"PMC4321871",null,null,"europepmc","FALSE",null,null,null,"correction; Corrected and Republished Article"],["R0023680","The evolving world of GLP-1 agonist therapies for type 2 diabetes.","Baynes KC","2010","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018810375414","23148151","PMC3475287",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0023681","Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk.","Piening A","2024","Nature communications","preclinical","article","10.1038/s41467-024-47359-5","38565540","PMC10987624",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023682","Effects of GLP-1 and GIP on Islet Function in Glucose-Intolerant, Pancreatic-Insufficient Cystic Fibrosis.","Nyirjesy SC","2022","Diabetes","randomized_trial","article","10.2337/db22-0399","35796669","PMC9501647","ClinicalTrials.gov:NCT01851694",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; other; article"],["R0023683","Incretin-related drugs and cardiovascular events: A comparison of GLP-1 analogue and DPP-4 inhibitor.","Higashi Y","2017","Journal of cardiology","commentary","article","10.1016/j.jjcc.2016.11.008","27986341",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0023684","Use of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six cases.","Fintini D","2014","Diabetes care","case_report","article","10.2337/dc13-2575","24652737",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0023685","Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.","Katagiri D","2013","Journal of the American Society of Nephrology : JASN","preclinical","article","10.1681/asn.2013020134","24092928","PMC3839550",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023686","Anti-obesity drugs: a review about their effects and their safety.","Derosa G","2012","Expert opinion on drug safety","other_trial","article","10.1517/14740338.2012.675326","22439841",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0023687","Methods to enhance delivery of prandial insulin and basal-prandial insulin.","Garber AJ","2013","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12067","23448198",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023688","Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis.","Hegazi OE","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s448476","38327733","PMC10847589",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0023689","Initial Experience with Alternate-Day Liraglutide for Weight Regain Following Bariatric Surgery.","Rubio MA","2021","Obesity surgery","other","article","10.1007/s11695-021-05535-2","34212346",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023690","Dipeptidyl peptidase-4 inhibitors and aerobic exercise synergistically protect against liver injury in ovariectomized rats.","Younan N","2019","Physiological reports","preclinical","article","10.14814/phy2.14191","31496048","PMC6732505",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023691","Newer Insulin Preparations and Insulin Analogs.","Tiwari DD","2024","Cureus","narrative_review","article","10.7759/cureus.74593","39734941","PMC11676328",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023692","Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one?","Del Prato S","2014","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(14)70185-8","25190524",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023693","Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients.","Lee SE","2021","Psychiatry research","randomized_trial","article","10.1016/j.psychres.2021.113830","33677189",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0023694","The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease.","Gouni-Berthold I","2014","Current pharmaceutical design","narrative_review","article","10.2174/13816128113196660676","24040873",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023695","Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro.","Wang XW","2016","Acta pharmacologica Sinica","preclinical","article","10.1038/aps.2016.72","27498780","PMC5057239",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023696","Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33).","Yokoyama H","2014","Japanese clinical medicine","randomized_trial","article","10.4137/jcm.s16585","25288908","PMC4179438",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0023697","Oral delivery of liraglutide-loaded Poly-N-(2-hydroxypropyl) methacrylamide/chitosan nanoparticles: Preparation, characterization, and pharmacokinetics.","Shi Y","2021","Journal of biomaterials applications","preclinical","article","10.1177/0885328220947889","32842851",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023698","Correction. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.","Larsen JR","2015","BMJ open","notice","article","10.1136/bmjopen-2013-004227corr1","25948402","PMC4431127",null,null,"pubmed; europepmc","TRUE",null,null,null,"Published Erratum; correction"],["R0023699","Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease.","Triggle CR","2020","Canadian journal of physiology and pharmacology","narrative_review","article","10.1139/cjpp-2019-0677","32150686",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Historical Article; Journal Article; Review; article"],["R0023700","Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.","Li YR","2018","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-017-0655-y","29301579","PMC5753457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0023701","Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes.","Villasenor A","2010","Disease models & mechanisms","preclinical","article","10.1242/dmm.003210","20616094","PMC2931535",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023702","Emulating the GRADE Trial Using Real-World Data","Deng Y","2022","medRxiv","randomized_trial","preprint","10.1101/2022.05.23.22275392",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0023703","Virtual Pharmacy: An Integrated Collaborative Redesign Targeting Medication-Related Problems in Patients with Chronic Kidney Disease.","Ong SW","2024","American journal of nephrology","other","article","10.1159/000535094","37939689",null,null,"S002662","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Research Support, Non-U.S. Gov't; Journal Article; article"],["R0023704","Anti-Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps.","Torbahn G","2025","Clinical endocrinology","narrative_review","article","10.1111/cen.15133","39257303","PMC11612549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023705","Rapid, high efficiency isolation of pancreatic ß-cells.","Clardy SM","2015","Scientific reports","preclinical","article","10.1038/srep13681","26330153","PMC4557033",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023706","Potent and Protease Resistant Azapeptide Agonists of the GLP-1 and GIP Receptors.","Dinsmore TC","2024","Angewandte Chemie (International ed. in English)","other","article","10.1002/anie.202410237","39151024","PMC13242721",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0023707","GLP-1 receptor agonists: why is once weekly inferior to once daily?","Garber AJ","2014","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(14)70014-2","24703036",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023708","Importance of glucose and its metabolism in neurodegenerative disorder, as well as the combination of multiple therapeutic strategies targeting α-synuclein and neuroprotection in the treatment of Parkinson's disease.","Siddique AHH","2024","Revue neurologique","narrative_review","article","10.1016/j.neurol.2023.08.011","38040547",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023709","Glucagon-like peptide 1 (GLP-1) can reverse AMP-activated protein kinase (AMPK) and S6 kinase (P70S6K) activities induced by fluctuations in glucose levels in hypothalamic areas involved in feeding behaviour.","Hurtado-Carneiro V","2012","Molecular neurobiology","preclinical","article","10.1007/s12035-012-8239-z","22311299",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023710","GLP-1R activation for the treatment of stroke: updating and future perspectives.","Darsalia V","2014","Reviews in endocrine & metabolic disorders","other","article","10.1007/s11154-014-9285-9","24777909",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023711","Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment.","Ingwersen SH","2012","Journal of clinical pharmacology","other","article","10.1177/0091270011430504","22174428",null,null,"S001094","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023712","[Not Available].","Bernard S","2021","Revue medicale suisse","commentary","article",null,"34133098",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"News"],["R0023713","Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.","Madsbad S","2004","Diabetes care","randomized_trial","article","10.2337/diacare.27.6.1335","15161785",null,null,"S001826","pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023714","Dulaglutide slows kidney disease in type 2 diabetes.","Oliva-Damaso N","2020","Lancet (London, England)","commentary","article","10.1016/s0140-6736(19)32550-4","32087784",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0023715","Semaglutide for obesity: four STEPs forward, but more to come.","Ryan DH","2021","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(21)00081-4","33864806",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023716","Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.","Russell-Jones D","2009","Molecular and cellular endocrinology","narrative_review","article","10.1016/j.mce.2008.11.018","19041364",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023717","Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.","Suzuki D","2013","Internal medicine (Tokyo, Japan)","other_trial","article","10.2169/internalmedicine.52.8961","23676586",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; article"],["R0023718","The kidney and cardiovascular outcome trials.","Bloomgarden Z","2018","Journal of diabetes","other_trial","article","10.1111/1753-0407.12616","29031006",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Editorial"],["R0023719","Dual factor delivery of CXCL12 and Exendin-4 for improved survival and function of encapsulated beta cells under hypoxic conditions.","Duncanson S","2013","Biotechnology and bioengineering","preclinical","article","10.1002/bit.24872","23436382",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0023720","Incretin hormones and beta-cell mass expansion: what we know and what is missing?","Tortosa F","2013","Archives of physiology and biochemistry","narrative_review","article","10.3109/13813455.2013.795175","23697580",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023721","Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial.","Becker F","2022","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2021.109152","34813910","PMC8844554","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0023722","Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.","Wang W","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13506","30129089","PMC6585712",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023723","Xenopus GLP-1-inspired discovery of novel GLP-1 receptor agonists as long-acting hypoglycemic and insulinotropic agents with significant therapeutic potential.","Han J","2017","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2017.06.132","28668697",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023724","Effect of Hypoglycemic Drugs on Patients with Heart Failure with or without T2DM: A Bayesian Network Meta-analysis.","Zhang Z","2025","Reviews in cardiovascular medicine","systematic_review","article","10.31083/rcm26154","40160590","PMC11951290",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; systematic-review; article"],["R0023725","Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance.","Gil-Lozano M","2013","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00529.2012","23531615",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023726","In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis.","Plum A","2013","Journal of pharmaceutical sciences","preclinical","article","10.1002/jps.23648","23853127","PMC3838623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023727","Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies.","Zhang CH","2020","Pharmacological research","narrative_review","article","10.1016/j.phrs.2020.104984","32502637",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0023728","Pharmacotherapy of obesity - state of the art.","Matyjaszek-Matuszek B","2018","Endokrynologia Polska","narrative_review","article","10.5603/ep.2018.0048","30209803",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0023729","[Glucagon like peptide-1 and the cardiovascular system: pathophysiological mechanisms].","Avogaro A","2010","Giornale italiano di cardiologia (2006)","other","article",null,"21361052",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0023730","NFκB mediates the anti-inflammatory actions of liraglutide and sitagliptin in experimentally model of colitis in mice","Nabeh OA","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-734267/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023731","The Novel Hepatokine Ectodysplasin A Is Increased in Obesity and Reduced after Liraglutide Management","Cai Z","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-508975/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023732","Interventions for people with type 2 diabetes mellitus fasting during Ramadan.","Lee SWH","2023","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd013178.pub2","37435938","PMC10355254","ClinicalTrials.gov:NCT01131182; ClinicalTrials.gov:NCT01340768; ClinicalTrials.gov:NCT01917656; ClinicalTrials.gov:NCT01758380; ClinicalTrials.gov:NCT02648217; ClinicalTrials.gov:NCT02941367; ClinicalTrials.gov:NCT02189135; ClinicalTrials.gov:NCT03314246; ClinicalTrials.gov:NCT02694263","S000646; S000963","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; article"],["R0023733","Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes.","Liu L","2020","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.3292","31955491",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023734","Distribution-based sub-population selection (DSPS): A method for in-silico reproduction of clinical trials outcomes.","Ganji M","2025","Computers in biology and medicine","nonrandomized_study","article","10.1016/j.compbiomed.2025.109714","39837001",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023735","Geographical variation in anti-diabetic prescribing in Ireland in 2013 and 2014: a cross-sectional analysis.","Murphy ME","2017","Family practice","nonrandomized_study","article","10.1093/fampra/cmx036","28472488",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023736","Upregulation of rat Ccnd1 gene by exendin-4 in pancreatic beta cell line INS-1: interaction of early growth response-1 with cis-regulatory element.","Kang JH","2006","Diabetologia","preclinical","article","10.1007/s00125-006-0179-6","16547599",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023737","Use of PASEF for Accelerated Protein Sequence Confirmation and De Novo Sequencing with High Data Quality.","Suckau D","2022","Methods in molecular biology (Clifton, N.J.)","other","article","10.1007/978-1-0716-1450-1_12","34478140",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023738","Use of obesity medications in a young pediatric patient with optic nerve hypoplasia and severe early-onset obesity: A case report.","Simonian A","2025","Obesity pillars","case_report","article","10.1016/j.obpill.2025.100192","40698016","PMC12282260",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023739","The current schemes of insulin therapy: Pro and contra.","Riddle MC","2021","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2021.108817","33865916",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023740","GLP-1 receptor agonist effects on normal and neoplastic pancreata.","Goggins M","2012","Diabetes","nonrandomized_study","article","10.2337/db12-0233","22517654","PMC3331774",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; Research Support, N.I.H., Extramural; Comment; article-commentary; article"],["R0023741","Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts.","Barakat GM","2011","General physiology and biophysics","preclinical","article","10.4149/gpb_2011_01_34","21460410",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023742","Semaglutide and effective weight control.","Latini R","2021","Lancet (London, England)","commentary","article","10.1016/s0140-6736(21)00377-9","33667415",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023743","Type 2 Diabetes Medication and Cardiovascular Benefits.","Shrestha A","2021","South Dakota medicine : the journal of the South Dakota State Medical Association","other","article",null,"34232594",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023744","Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).","Lind M","2015","Primary care diabetes","randomized_trial","article","10.1016/j.pcd.2014.07.010","25175385",null,"ClinicalTrials.gov:NCT02113332","S002357","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023745","[Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].","Reuter H","2007","Deutsche medizinische Wochenschrift (1946)","narrative_review","article","10.1055/s-2007-970380","17342635",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023746","Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure.","Nauck MA","2010","Journal of diabetes investigation","narrative_review","article","10.1111/j.2040-1124.2010.00004.x","24843405","PMC4020674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023747","Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography-tandem mass spectrometry method and its application.","Zhai J","2020","Biomedical chromatography : BMC","preclinical","article","10.1002/bmc.4921","32537846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023748","Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes.","Lazarus JV","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.42750","41196592","PMC12593099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023749","Liver paraoxonase 3 expression and the effect of liraglutide treatment in a rat model of diabetes.","Liu Y","2021","Advances in clinical and experimental medicine : official organ Wroclaw Medical University","preclinical","article","10.17219/acem/130605","33650330",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023750","Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial.","Gudbergsen H","2021","The American journal of clinical nutrition","randomized_trial","article","10.1093/ajcn/nqaa328","33471039",null,"ClinicalTrials.gov:NCT02905864","S001734","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023751","When oral agents fail: optimizing insulin therapy in the older adult.","Meece J","2009","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","narrative_review","article",null,"19555131",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023752","SGLT2 inhibition, incretin mimetics and novel approaches for diabetes-obesity therapy","Millar PJB","2017","Ulster University","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0023753","Dimerization/oligomerization of the extracellular domain of the GLP-1 receptor and the negative cooperativity in its ligand binding revealed by the improved NanoBiT.","Song X","2020","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","other","article","10.1096/fj.201902007r","31970836",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023754","GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis.","Toyoda K","2008","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2008.01.046","18211828",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023755","Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.","Runge S","2008","The Journal of biological chemistry","other","article","10.1074/jbc.m708740200","18287102",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023756","Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.","Konwar M","2022","International journal of clinical practice","systematic_review","article","10.1155/2022/1201977","35936066","PMC9325632",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0023757","Signal bias at glucagon family receptors: rationale and downstream impacts","Jones B","2020","bioRxiv","other","preprint","10.1101/2020.04.26.062372",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023758","Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.","Slawson DC","2021","American family physician","other","article",null,"34264618",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023759","The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway.","Li L","2017","CNS drugs","other","article","10.1007/s40263-017-0431-2","28540646",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023760","Effects of incretin agonists on endothelial nitric oxide synthase expression and nitric oxide synthesis in human coronary artery endothelial cells exposed to TNFα and glycated albumin.","Garczorz W","2015","Pharmacological reports : PR","other","article","10.1016/j.pharep.2014.08.007","25560578",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023761","The pivotal relation between glucagon-like peptides, NFκB and inflammatory bowel disease.","Azmy Nabeh O","2020","Clinical and experimental pharmacology & physiology","narrative_review","article","10.1111/1440-1681.13361","32511781",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023762","Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.","Wadden TA","2013","International journal of obesity (2005)","randomized_trial","article","10.1038/ijo.2013.120","23812094",null,"ClinicalTrials.gov:NCT00781937","S000371; S000866; S001278","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023763","Utilization and cost of drugs for diabetes and its comorbidities and complications in Kuwait.","Alowayesh MS","2022","PloS one","other","article","10.1371/journal.pone.0268495","35653361","PMC9162372",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023764","[Exenatide stimulated solute-free water excretion by human kidney].","Shakhmatova EI","2012","Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova","other_trial","article",null,"23155627",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023765","Effects of Exercise, Metformin, Pioglitazone and Exenatide Treatment on Inflammation Induced Insulin Resistance and Ubiquitin Proteasome System in Diabetes and Obesity","Akarsu E","2021","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvab048.893",null,"PMC8266031",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0023766","Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.","Heald AH","2018","Diabetes, obesity & metabolism","other","article","10.1111/dom.13281","29516618",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023767","Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).","Armato JP","2018","The lancet. Diabetes & endocrinology","nonrandomized_study","article","10.1016/s2213-8587(18)30234-1","30224284",null,"ClinicalTrials.gov:NCT03308773",null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study"],["R0023768","Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis.","Su K","2020","Pharmacological research","preclinical","article","10.1016/j.phrs.2020.104778","32247822",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023769","Future therapies for obesity.","Melson E","2023","Clinical medicine (London, England)","narrative_review","article","10.7861/clinmed.2023-0144","37524416","PMC10541050",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; research-article; article"],["R0023770","Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats.","Li Q","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.117531","32151691",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023771","Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.","Rizzo M","2014","Cardiovascular diabetology","other_trial","article","10.1186/1475-2840-13-49","24559258","PMC3948058","ClinicalTrials.gov:NCT01715428","S001748","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0023772","Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides.","Kořínková L","2020","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2020.597583","33324348","PMC7726422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0023773","[Exenatid and its position as antidiabetic drug in the treatment of type 2 diabetes mellitus].","Perusicová J","2008","Vnitrni lekarstvi","narrative_review","article",null,"18630617",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023774","HSP90-Mediates Liraglutide Preconditioning-Induced Cardioprotection by Inhibiting C5a and NF-κB.","He ST","2022","Journal of investigative surgery : the official journal of the Academy of Surgical Research","randomized_trial","article","10.1080/08941939.2021.1989729","34670452",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0023775","Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.","Gudin B","2020","Therapie","nonrandomized_study","article","10.1016/j.therap.2020.02.024","32418731",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0023776","Incretin-based therapies for type 2 diabetes: a nurse's perspective.","Hodgkiss J","2010","British journal of nursing (Mark Allen Publishing)","other","article","10.12968/bjon.2010.19.21.79997","21355358",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023777","Alpk1 Sensitizes Pancreatic Beta Cells to Cytokine-Induced Apoptosis via Upregulating TNF-α Signaling Pathway.","Ding F","2021","Frontiers in immunology","preclinical","article","10.3389/fimmu.2021.705751","34621265","PMC8490819",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023778","Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting.","Capehorn M","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00989-6","33423240","PMC7846640",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023779","Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD).","Zarghamravanbakhsh P","2021","Metabolism open","other","article","10.1016/j.metop.2021.100149","34870138","PMC8626571",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023780","Pharmacological Signatures of the Exenatide Nanoparticles Against Hepatic Ischemia/Reperfusion-induced Pancreatic Injury.","Ma Z","2019","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2019.01.031","30979489",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023781","Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.","Mannucci E","2008","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2008.08.002","18849155",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023782","Selection and dosing of medications for management of diabetes in patients with advanced kidney disease.","Reilly JB","2010","Seminars in dialysis","narrative_review","article","10.1111/j.1525-139x.2010.00703.x","20210915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023783","Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.",null,"2010","Prescrire international","randomized_trial","article",null,"20738033",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Review; article"],["R0023784","Metabolomics and molecular docking-directed anti-obesity study of the ethanol extract from Gynostemma pentaphyllum (Thunb.) Makino.","Xu S","2024","Journal of ethnopharmacology","preclinical","article","10.1016/j.jep.2024.118577","39019414",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023785","Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Nowrouzi-Sohrabi P","2021","Frontiers in pharmacology","systematic_review","article","10.3389/fphar.2021.618208","33854433","PMC8039463",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0023786","[Effects of liraglutide combined with vitamin D on non-alcoholic fatty liver induced by high fat in mice and its mechanism].","Wang F","2020","Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","preclinical","article","10.12047/j.cjap.5911.2020.057","32981283",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023787","Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.","Jiang P","2023","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.15235","37580307",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023788","Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case study.","Riz M","2014","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00603.2013","24425760",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Evaluation Study; Journal Article; article"],["R0023789","Dulaglutide slows kidney disease in type 2 diabetes - Author's reply.","Gerstein HC","2020","Lancet (London, England)","commentary","article","10.1016/s0140-6736(19)32541-3","32087783",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0023790","The putative binding site and SAR rationalization of small molecules against glucagon-like peptide-1 receptor using homology model and crystal structures: a comparative study.","Thamaraiselvan V","2022","Journal of biomolecular structure & dynamics","other","article","10.1080/07391102.2020.1835720","33118484",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0023791","Compound dietary fiber and high-grade protein diet improves glycemic control and ameliorates diabetes and its comorbidities through remodeling the gut microbiota in mice.","Ni Y","2022","Frontiers in nutrition","preclinical","article","10.3389/fnut.2022.959703","35958251","PMC9363113",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023792","Profound weight loss induces reactive astrogliosis in the arcuate nucleus of obese mice.","Harrison L","2019","Molecular metabolism","preclinical","article","10.1016/j.molmet.2019.03.009","30979678","PMC6977167",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0023793","Combined melatonin and exendin-4 therapy preserves renal ultrastructural integrity after ischemia-reperfusion injury in the male rat.","Yip HK","2015","Journal of pineal research","preclinical","article","10.1111/jpi.12273","26309060",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023794","A Hypercaloric Diet Induces Early Podocyte Damage in Aged, Non-Diabetic Rats.","Seikrit C","2021","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","preclinical","article","10.33594/000000476","34936286",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023795","Hypocalcemia secondary to hypomagnesemia in a patient on liraglutide.","Habnouny JEL","2020","Annals of medicine and surgery (2012)","case_report","article","10.1016/j.amsu.2020.10.052","33224484","PMC7662844",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023796","Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis.","Mirghani H","2023","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-023-01001-4","36829204","PMC9951503",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0023797","Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.","Williams DM","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-019-00747-3","31863343","PMC6995804",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0023798","Exploring the pharmacotherapeutic options for treating type 2 diabetes.","Kruger DF","2008","The Diabetes educator","other","article","10.1177/0145721708319234","18525066",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023799","Liraglutide ameliorates renal injury in streptozotocin‑induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor‑κB pathway.","Zhou SJ","2014","Molecular medicine reports","preclinical","article","10.3892/mmr.2014.2555","25215431",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023800","Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation.","Sullivan SD","2025","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2025.25199","40938639","PMC12467749",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023801","Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.","Montilla S","2014","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2014.07.014","25300980",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023802","Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet.","Zhang N","2020","BioMed research international","preclinical","article","10.1155/2020/2947549","32149099","PMC7049398",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023803","Impact of liraglutide on microcirculation in experimental diabetic cardiomyopathy.","Abdelrazik Soliman NG","2020","Acta histochemica","preclinical","article","10.1016/j.acthis.2020.151533","32197755",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023804","GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.","Hendarto H","2012","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2012.03.002","22554832",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023805","Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists.","Graham GV","2019","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2018.10.011","30312651",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023806","Identification of small-molecule inducers of pancreatic beta-cell expansion.","Wang W","2009","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.0811848106","19164755","PMC2635822",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023807","A long-acting, dual-agonist analogue of lamprey GLP-1 shows potent insulinotropic, β-cell protective, and anorexic activities and improves glucose homeostasis in high fat-fed mice.","Graham GV","2020","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2019.110584","31539596",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023808","GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress.","Schisano B","2012","Regulatory peptides","other","article","10.1016/j.regpep.2011.11.008","22120833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023809","Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation.","Barale C","2017","Thrombosis and haemostasis","other","article","10.1160/th16-07-0586","28405672","PMC6291961",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023810","Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).","Cvetković RS","2007","Drugs","randomized_trial","article","10.2165/00003495-200767060-00008","17428109",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Review; article"],["R0023811","The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study.","Gamble JM","2018","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2017.12.008","29258886",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0023812","[The role of GLP-1 receptor agonists and their fixed combination with insulin in the treatment of type 2 diabetes mellitus].","Schroner Z","2019","Vnitrni lekarstvi","other","article","10.36290/vnl.2019.049","31091948",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023813","Host genetics and diet composition interact to modulate gut microbiota and predisposition to metabolic syndrome in spontaneously hypertensive stroke-prone rats.","Singh A","2019","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.201801627rrr","30821497",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023814","Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein.","Gao F","2021","Annals of translational medicine","preclinical","article","10.21037/atm-21-3094","34430598","PMC8350642",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023815","The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.","Reich N","2022","Frontiers in neuroscience","other_trial","article","10.3389/fnins.2022.970925","36117625","PMC9475012",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0023816","Micronutrient Deficiency and Wernicke's Encephalopathy in the Setting of Over the Counter Transcutaneous Multivitamin Patch Use Following Bariatric Surgery.","Babu HM","2025","AACE clinical case reports","case_report","article","10.1016/j.aace.2024.10.001","39896946","PMC11784606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023817","Brain-derived uroguanylin as a regulator of postprandial brown adipose tissue activation: a potential therapeutic approach for metabolic disorders.","Habek N","2025","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2025.1569163","40351439","PMC12062040",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023818","Realisation of Remission of Diabetes Using Pharmacotherapy (DiaRem-1).","Sudhayakumar A","2025","Indian journal of endocrinology and metabolism","randomized_trial","article","10.4103/ijem.ijem_356_24","40416453","PMC12101762",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0023819","[Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].","Wang XH","2015","Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","randomized_trial","article",null,"26480664",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023820","Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment.","Marfella R","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13122","28950045",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023821","Agonist binding affinity determines palmitoylation of the glucagon-like peptide-1 receptor and its functional interaction with plasma membrane nanodomains in pancreatic beta cells","Buenaventura T","2018","bioRxiv","other","preprint","10.1101/492496",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023822","Dysfunction of a Peripheral Lipid Sensor Gpr120 Causes Pgd2-microglia-provoked Neuroinflammation","Iwasa K","2020","Research Square","preclinical","preprint","10.21203/rs.3.rs-114598/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023823","Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences.","DI Giuseppe G","2021","Minerva endocrinology","nonrandomized_study","article","10.23736/s2724-6507.21.03405-9","34218657",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0023824","Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.","Amori RE","2007","JAMA","systematic_review","article","10.1001/jama.298.2.194","17622601",null,null,"S000477; S001544","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0023825","Efficacy and Cardiovascular Safety of Sulfonylureas.","Fernandez CJ","2021","Current drug safety","narrative_review","article","10.2174/1574886315999201125211433","33243129",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023826","Early onset of acute pancreatitis in a patient on low-dose liraglutide.","Chua MWJ","2021","Diabetes & metabolic syndrome","case_report","article","10.1016/j.dsx.2021.03.010","33823330",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0023827","Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.","Armstrong MJ","2013","Alimentary pharmacology & therapeutics","systematic_review","article","10.1111/apt.12149","23163663",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0023828","Proximal cyclic AMP response element is essential for exendin-4 induction of rat EGR-1 gene.","Kang JH","2007","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00181.2006","16926376",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023829","Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.","Tzanetakos C","2018","Clinical drug investigation","other_trial","article","10.1007/s40261-017-0586-0","29080210",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0023830","Efficacy of antiobesity medications for weight reduction in older adults: a systematic review.","Chen AS","2025","Obesity (Silver Spring, Md.)","systematic_review","article","10.1002/oby.24160","39725567","PMC12198421",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; research-article; review"],["R0023831","Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms.","Krieger JP","2020","Peptides","narrative_review","article","10.1016/j.peptides.2020.170342","32522585",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023832","Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.","von Herrath M","2021","The lancet. Diabetes & endocrinology","randomized_trial","article","10.1016/s2213-8587(21)00019-x","33662334",null,"ClinicalTrials.gov:NCT02443155","S001320; S001615","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023833","Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.","Volke V","2022","BMC endocrine disorders","systematic_review","article","10.1186/s12902-022-01158-5","36261824","PMC9580135","PROSPERO:CRD42016038780",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Meta-Analysis; Systematic Review; Journal Article; research-article; review"],["R0023834","Knowledge and Perception of Anti-obesity Medications Among Primary Healthcare Center Visitors in Jeddah, Saudi Arabia in 2024: An Analytical Cross-Sectional Study.","Khalaf RM","2024","Cureus","other","article","10.7759/cureus.68240","39347191","PMC11439459",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023835","Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.","Middleton TL","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14621","34882926",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023836","Identification of Potential Therapeutic Targets and Pathways of Liraglutide Against Type 2 Diabetes Mellitus (T2DM) Based on Long Non-Coding RNA (lncRNA) Sequencing.","Huang Y","2020","Medical science monitor : international medical journal of experimental and clinical research","preclinical","article","10.12659/msm.922210","32238798","PMC7152739",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023837","Do interactions between protein and phospholipids influence the release behavior from lipid-based exenatide depot systems?","Breitsamer M","2019","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2019.06.007","31195130",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023838","Alteration of sweet taste in high-fat diet induced obese rats after 4 weeks treatment with exenatide.","Zhang XJ","2013","Peptides","preclinical","article","10.1016/j.peptides.2013.07.015","23891652",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023839","Liraglutide Use in A Real-World Setting: Patient Characteristics at Antidiabetic Treatment Initiation Modulate Cardiovascular Safety Outcomes","Gallagher A","2020","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-66177/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0023840","Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events.","Tougaard RS","2020","Scandinavian cardiovascular journal : SCJ","randomized_trial","article","10.1080/14017431.2020.1751873","32292074",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0023841","Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.","Warren AM","2019","Expert opinion on therapeutic targets","narrative_review","article","10.1080/14728222.2019.1624721","31154867",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023842","Energy loss via urine and faeces--a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight.","Elvert R","2013","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12030","23121319",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023843","Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.","Schmidt WE","2011","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2011.03276.x","21388442","PMC3123703","ClinicalTrials.gov:NCT00518882","S002230","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023844","[Benefits of telematic monitoring for weight loss in overweight and obese patients in times of confinement].","Higuera Pulgar I","2022","Nutricion hospitalaria","other","article","10.20960/nh.03910","35815766",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023845","The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A \"Me Too\" or \"the Special One\" Antidiabetic Class?","Godinho R","2015","Journal of diabetes research","narrative_review","article","10.1155/2015/806979","26075286","PMC4449938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0023846","High-Fat Diet Accelerates Pathological Progression and Intestinal Inflammation in a Type 2 Diabetes Rodent Model","Reilly A","2021","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvab048.911",null,"PMC8089488",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0023847","Hormonal Treatments in Hidradenitis Suppurativa: A Systematic Review.","Masson R","2023","Journal of drugs in dermatology : JDD","systematic_review","article","10.36849/jdd.7325","37556513",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Systematic Review; Journal Article; article"],["R0023848","The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.","Wang J","2019","BioMed research international","randomized_trial","article","10.1155/2019/2682657","31950036","PMC6943972","ClinicalTrials.gov:NCT01648582","S001404","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; research-article; article"],["R0023849","Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ.","Cabou C","2011","Diabetes","preclinical","article","10.2337/db11-0464","21810595","PMC3161335",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023850","Uptake of new antidiabetic medicines in 11 European countries.","Mardetko N","2021","BMC endocrine disorders","other","article","10.1186/s12902-021-00798-3","34172020","PMC8235847",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0023851","Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China.","Men P","2020","Current medical research and opinion","other_trial","article","10.1080/03007995.2019.1662676","31469303",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023852","Liraglutide vs. Lifestyle Intervention in Obesity Treatment: Pros and Cons","Mckenzie S","2021","ScienceOpen Preprints","other","preprint","10.14293/s2199-1006.1.sor-.ppqfkqq.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023853","A β-peptide agonist of the GLP-1 receptor, a class B GPCR.","Denton EV","2013","Organic letters","preclinical","article","10.1021/ol402568j","24087900","PMC4006878",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023854","Cost-Utility Analysis of Metabolic Bariatric Surgery for Individuals with Obesity in Saudi Arabia.","Nagi MA","2025","ClinicoEconomics and outcomes research : CEOR","other","article","10.2147/ceor.s527169","40726991","PMC12301112",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023855","Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients.","Tang L","2019","Clinical endocrinology","other","article","10.1111/cen.14056","31271659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023856","Liraglutide suppresses the plasma levels of active and des-acyl ghrelin independently of active glucagon-like Peptide-1 levels in mice.","Nonogaki K","2013","ISRN endocrinology","preclinical","article","10.1155/2013/184753","23997963","PMC3755422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023857","Chronic Kidney Disease Study in Diabetic Patients: Insights From Primary Care Units in Northern Portugal.","Afonso RJ","2024","Cureus","other","article","10.7759/cureus.61417","38947587","PMC11214725",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023858","Emotional eating in patients attending a specialist obesity treatment service.","Wong L","2020","Appetite","other","article","10.1016/j.appet.2020.104708","32283188",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023859","GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet.","Clemmensen C","2014","Diabetes","randomized_trial","article","10.2337/db13-1609","24379349",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023860","Metformin: still the sweet spot for CV protection in diabetes?","Rena G","2020","Current opinion in pharmacology","randomized_trial","article","10.1016/j.coph.2020.10.018","33271428",null,null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Review"],["R0023861","Exenatide. From the Gila monster to you. Exenatide is the first of a new class of drugs known as \"incretin mimetics\" that can enhance your blood glucose control.","Clark WL","2006","Diabetes self-management","other","article",null,"16453919",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023862","[Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].","Salvador J","2014","Medicina clinica","narrative_review","article","10.1016/s0025-7753(14)70106-x","25326841",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; English Abstract"],["R0023863","Exendin-4 induction of Egr-1 expression in INS-1 beta-cells: interaction of SRF, not YY1, with SRE site of rat Egr-1 promoter.","Kim MJ","2008","Journal of cellular biochemistry","preclinical","article","10.1002/jcb.21783","18446785",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023864","Targeting GLP-1 receptor trafficking to improve agonist efficacy.","Jones B","2018","Nature communications","preclinical","article","10.1038/s41467-018-03941-2","29686402","PMC5913239",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023865","Diabetes: Concerns about long-term use of GLP-1 analogues.","Holmes D","2016","Nature reviews. Endocrinology","commentary","article","10.1038/nrendo.2016.33","26939977",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023866","Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B.","Li L","2005","Diabetologia","preclinical","article","10.1007/s00125-005-1787-2","15902400",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023867","Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial.","Ando Y","2021","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13533","33650779","PMC8504902",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0023868","Safety and effectiveness of newer antidiabetic medications during Ramadan fasting and safety of Ramadan fasting after bariatric surgery.","Ahmed M","2022","Journal of diabetes and metabolic disorders","randomized_trial","article","10.1007/s40200-022-01145-6","36404821","PMC9672258",null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Review; review-article"],["R0023869","Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.","Ramos M","2020","Journal of comparative effectiveness research","other_trial","article","10.2217/cer-2020-0071","32573253",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023870","Liraglutide ameliorates COCl2-induced oxidative stress and apoptosis in H9C2 cells via regulating cell autophagy.","Pang Z","2020","Experimental and therapeutic medicine","other","article","10.3892/etm.2020.8630","32346436","PMC7185156",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023871","Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes.","Nielsen LL","2003","Current opinion in investigational drugs (London, England : 2000)","other","article",null,"12808878",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023872","Combination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals.","Yang X","2021","Life sciences","preclinical","article","10.1016/j.lfs.2020.119013","33417950",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023873","Pancreatic alpha cells in diabetic rats express active GLP-1 receptor: Endosomal co-localization of GLP-1/GLP-1R complex functioning through intra-islet paracrine mechanism.","Nakashima K","2018","Scientific reports","preclinical","article","10.1038/s41598-018-21751-w","29487355","PMC5829082",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023874","The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.","McClean PL","2011","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.0529-11.2011","21525299","PMC6622662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023875","The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.","Flint A","2013","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12108","23551925",null,null,"S000333","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023876","Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats.","Fan Y","2014","Experimental eye research","preclinical","article","10.1016/j.exer.2014.05.004","24910901",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023877","Semaglutide is safe and efficacious for NASH resolution.","Dickson I","2021","Nature reviews. Gastroenterology & hepatology","commentary","article","10.1038/s41575-020-00396-z","33257834",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0023878","The Intersection of Diabetes and Cardiovascular Disease-A Focus on New Therapies.","Dhindsa DS","2018","Frontiers in cardiovascular medicine","narrative_review","article","10.3389/fcvm.2018.00160","30555833","PMC6282028",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023879","[Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].","Lecube A","2014","Medicina clinica","narrative_review","article","10.1016/s0025-7753(14)70105-8","25326840",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023880","Prescription Drugs in Pregnancy and Congenital Malformations: A Population-Based Safety Screening Study.","Broe A","2025","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.70211","40859711","PMC12381547",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0023881","Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D3 Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra.","Harkavyi A","2013","Journal of neurodegenerative diseases","preclinical","article","10.1155/2013/407152","26316987","PMC4437329",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023882","Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus.","Gökçay Canpolat A","2021","Advances in experimental medicine and biology","narrative_review","article","10.1007/5584_2020_516","32200500",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0023883","[For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?].","Lanthier L","2021","La Revue de medecine interne","commentary","article","10.1016/j.revmed.2021.03.334","33838950",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0023884","DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.","Scheen AJ","2012","Diabetes & metabolism","other_trial","article","10.1016/j.diabet.2011.11.001","22197148",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0023885","Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.","Shankar SS","2018","Diabetes","randomized_trial","article","10.2337/db17-1331","29545266",null,"ClinicalTrials.gov:NCT01055340; ClinicalTrials.gov:NCT01373450","S002296","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023886","Utilization of antiobesity medications within the Military Health System.","Neuman T","2024","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.24097","39089987",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023887","Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A 7-Year Retrospective Analysis.","Osonoi T","2020","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2020.0070","32348695",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0023888","Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials.","Pradhan R","2021","Clinical pharmacology and therapeutics","nonrandomized_study","article","10.1002/cpt.2213","33615445",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023889","Exenatide ER-induced eosinophilia.","Eid TJ","2020","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","randomized_trial","article","10.1093/ajhp/zxaa105","32470112",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Case Reports; Letter; article"],["R0023890","Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies.","Tsunekawa S","2007","The Journal of endocrinology","preclinical","article","10.1677/joe-06-0148","17400804",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023891","Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension.","Mitchell JL","2019","Current opinion in neurology","narrative_review","article","10.1097/wco.0000000000000690","30865008","PMC6522204",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0023892","GLP-1 receptor agonists today.","Marre M","2011","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2011.01.004","21767888",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023893","Incretin-Based Therapy for Prevention of Diabetic Vascular Complications.","Mima A","2016","Journal of diabetes research","narrative_review","article","10.1155/2016/1379274","26881236","PMC4735992",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0023894","Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation.","Hviid AVR","2020","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00280.2019","31841385",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023895","Liraglutide overdose: A case report and an updated review.","Nafisah SB","2020","Turkish journal of emergency medicine","case_report","article","10.4103/2452-2473.276386","32355902","PMC7189825",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023896","Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats.","Xu X","2020","Tissue & cell","preclinical","article","10.1016/j.tice.2020.101382","32933722",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023897","Short term exendin-4 treatment reduces markers of metabolic disorders in female offspring of obese rat dams.","Chan YL","2015","International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","preclinical","article","10.1016/j.ijdevneu.2015.05.009","26287659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023898","Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells.","Kim HS","2013","The Journal of endocrinology","preclinical","article","10.1530/joe-12-0474","23503774",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023899","Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses.","Bi Y","2012","Journal of diabetes investigation","systematic_review","article","10.1111/j.2040-1124.2011.00187.x","24843578","PMC4014951",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0023900","Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.","Salles GN","2020","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2019.107813","31628935",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023901","Liraglutide Improves the Survival of INS-1 Cells by Promoting Macroautophagy.","Jing Yin J","2013","International journal of endocrinology and metabolism","other","article","10.5812/ijem.8088","24348591","PMC3860108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023902","A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.","Fayfman M","2019","Diabetes care","randomized_trial","article","10.2337/dc18-1760","30679302","PMC6905476","ClinicalTrials.gov:NCT02455076","S000455","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0023903","Liraglutide Lowers Body Weight Set Point in DIO Rats and its Relationship with Hypothalamic Microglia Activation.","Liao T","2020","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.22666","31773909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023904","Vascular correlates in a mouse model of Alzheimer’s disease","Kelly P","2016","Ulster University","preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0023905","Prevention and intervention against obesity and overweight in the military: a systematic review.","Scheit L","2025","Journal of occupational medicine and toxicology (London, England)","systematic_review","article","10.1186/s12995-025-00480-7","41057950","PMC12502539",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; other; review"],["R0023906","Adapting the Glaser Reaction for Bioconjugation: Robust Access to Structurally Simple, Rigid Linkers.","Silvestri AP","2017","Angewandte Chemie (International ed. in English)","other","article","10.1002/anie.201705065","28685936","PMC5708120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0023907","Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain","Hodson D","2024","Research Square","preclinical","preprint","10.21203/rs.3.rs-4835197/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0023908","Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.","Vella A","2002","Diabetologia","other","article","10.1007/s00125-002-0924-4","12378382",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0023909","[High dosage GLP-1 analogs are now available].","Pampel SL","2016","MMW Fortschritte der Medizin","other","article","10.1007/s15006-016-8074-7","27071596",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023910","Effects of GLP-1 analogue, liraglutide on inflammation, stem cell proliferation, differentiation and cognition in mouse brain","Parthsarathy V","2013","Ulster University","preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0023911","Exendin-4 protects adipose-derived mesenchymal stem cells from apoptosis induced by hydrogen peroxide through the PI3K/Akt-Sfrp2 pathways.","Zhou H","2014","Free radical biology & medicine","preclinical","article","10.1016/j.freeradbiomed.2014.09.033","25452142",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023913","Relationship of vascular complications and exenatide therapy failure in type 2 diabetic patients.","Blaslov K","2013","Acta clinica Croatica","other","article",null,"24558765",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0023914","The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis.","Bomholt T","2021","Nephron","nonrandomized_study","article","10.1159/000510613","33105146",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0023915","Acetyl-CoA Carboxylase Inhibitors for Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","Hasanatuludhhiyah N","2025","Pharmaceuticals (Basel, Switzerland)","systematic_review","article","10.3390/ph18091276","41011147","PMC12472739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0023916","Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.","Pratley RE","2012","Diabetes care","randomized_trial","article","10.2337/dc11-2113","22851600","PMC3447855",null,"S002361","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0023917","[Effect of adipose-derived mesenchymal stem cells and liraglutide on acute lung injury].","Feng Y","2020","Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","preclinical","article","10.3760/cma.j.cn112147-20200621-00733","32894910",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023918","Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.","Kielgast U","2009","Current diabetes reviews","preclinical","article","10.2174/157339909789804413","19925391",null,null,"S000485","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0023919","[Update on Diabetic Nephropathy 2018].","Böger CA","2018","Deutsche medizinische Wochenschrift (1946)","other","article","10.1055/a-0587-5363","30286495",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023920","SAT-LB103 Glucose-Dependent Insulinotropic Polypeptide Promotes Proliferation, Inhibits Apoptosis and Modifies Adipogenesis in Human Omental Adipose-Derived Stem Cells","Chen X","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.1992",null,"PMC7207670",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0023921","Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study.","Nakaguchi H","2020","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13270","32279451","PMC7610130",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0023922","A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.","Kelly AS","2020","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1916038","32233338",null,"ClinicalTrials.gov:NCT02918279","S000388; S000599; S001945","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023923","Case report of a female western Indian vegetarian with obesity.","Niranjan V","2024","Obesity pillars","case_report","article","10.1016/j.obpill.2024.100137","39469669","PMC11513479",null,null,"pubmed; europepmc","TRUE",null,null,null,"Case Reports; Journal Article; case-report"],["R0023924","Exenatide improves glucocorticoid-induced glucose intolerance in mice.","Zhao R","2011","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s15510","21448323","PMC3064408",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0023925","Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.","Schnell O","2020","Endocrinology, diabetes & metabolism","narrative_review","article","10.1002/edm2.129","32704554","PMC7375088",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023926","Hormonal Dysregulation in Major Depressive Disorder: A Systematic Review","Zehtabian K","2025","PsyArXiv","systematic_review","preprint","10.31234/osf.io/y897m_v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","3","FALSE","Preprint; review; preprint"],["R0023927","Characterisation and pharmacological regulation of GLP-1-mediated glucose homeostasis","Yeung HY","2020","University of Cambridge","other","article","10.17863/cam.63107",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0023928","Drug-induced diabetes type 2: In silico study involving class B GPCRs.","Latek D","2019","PloS one","other","article","10.1371/journal.pone.0208892","30650080","PMC6334951",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023929","Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4.","Gardiner SM","2006","British journal of pharmacology","preclinical","article","10.1038/sj.bjp.0706931","17016494","PMC2014661",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0023930","Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance.","Yang M","2012","PloS one","preclinical","article","10.1371/journal.pone.0048392","23152772","PMC3495944",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023931","Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials.","Wang L","2021","Pharmacological research","systematic_review","article","10.1016/j.phrs.2021.105765","34252552",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0023932","Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder?","Fink-Jensen A","2016","Nordic journal of psychiatry","preclinical","article","10.1080/08039488.2016.1176252","27151395",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023933","Ketoacidosis in type 2 diabetes--is it type 1 and 1/2 diabetes?","Gooderick D","2011","BMJ case reports","case_report","article","10.1136/bcr.07.2011.4460","22688490","PMC3158345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0023934","[Recommendations of the main clinical practice guidelines].","Miravet I Jiménez S","2018","Semergen","other","article","10.1016/s1138-3593(18)30369-1","30322471",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023935","Proteasome dysfunction mediates high glucose-induced apoptosis in rodent beta cells and human islets.","Broca C","2014","PloS one","preclinical","article","10.1371/journal.pone.0092066","24642635","PMC3958412",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023936","Liraglutide for managing overweight and obesity",null,"2020","National Institute for Health and Care Excellence (NICE), London","narrative_review","article",null,"40889332",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0023937","Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis.","Patikorn C","2021","Annals of hepatology","randomized_trial","article","10.1016/j.aohep.2021.100315","33515800",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0023938","Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.","Maiztegui B","2011","Clinical science (London, England : 1979)","preclinical","article","10.1042/cs20100372","20795946",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023939","Pancreatic Polypeptide Cell Proliferation in the Pancreas and Duodenum Coexisting in a Patient With Pancreatic Adenocarcinoma Treated With a GLP-1 Analog.","Talmon GA","2017","Pancreas","case_report","article","10.1097/mpa.0000000000000844","28609372",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0023940","Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.","Horowitz M","2021","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.14473","34169640",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0023941","Use of non-insulin antidiabetic drugs in children and young adults - A Scandinavian drug utilization study from 2010-2019.","Jensen HK","2021","British journal of clinical pharmacology","nonrandomized_study","article","10.1111/bcp.14867","33871080",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0023942","Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.","Cong Z","2021","Nature communications","other","article","10.1038/s41467-021-24058-z","34145245","PMC8213797",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; preprint; article"],["R0023943","Screening of a phage display library of exendin-4 mutants with the extracellular domain of rat GLP-1 receptor.","Yin X","2007","Protein and peptide letters","preclinical","article","10.2174/092986607781483679","17979825",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023944","High BMI z-Scores from Different Growth References Are Not Comparable: An Example from a Weight Management Trial with an Anti-Obesity Medication in Pubertal Adolescents with Obesity.","Hales CM","2025","Childhood obesity (Print)","other_trial","article","10.1089/chi.2024.0248","38995874","PMC12422332",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Journal Article; research-article; article"],["R0023945","[Liraglutide].","Takahashi T","2011","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"21595276",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0023946","The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.","Umpierrez GE","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2011.01366.x","21251180",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0023947","Withdrawal: \"Efficacy and safety of liraglutide 3.0 mg in obese diabetic and non-diabetic patients-A systematic review and meta-analysis of randomised controlled trials\" Mahanjit Konwar, Renju Ravi, Miteshkumar Maurya, Debdipta Bose, Sanjeet kumar Jaiswal.",null,"2021","International journal of clinical practice","systematic_review","article","10.1111/ijcp.14367","33998106",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","TRUE","Journal Article; Retracted Publication; article"],["R0023948","The intricate relationship between circadian rhythms and gastrointestinal peptides in obesity.","Ribeiro FM","2025","Peptides","narrative_review","article","10.1016/j.peptides.2025.171356","39929256",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0023949","Correction to: Reversal of Long-Term Weight Regain After Roux-en-Y Gastric Bypass Using Liraglutide or Surgical Revision. A Prospective Study.","Horber FF","2021","Obesity surgery","notice","article","10.1007/s11695-021-05426-6","33876345","PMC8329823",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0023950","Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment.","Dennis JM","2020","Diabetes","other_trial","article","10.2337/dbi20-0002","32843566","PMC7506836",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; discussion; article"],["R0023951","Depot-specific UCP1 expression in human white adipose tissue and its association with obesity-related markers.","Lim J","2020","International journal of obesity (2005)","preclinical","article","10.1038/s41366-020-0528-4","31965068",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023952","Liraglutide limits the immunogenic cell death-mediated ROS propagation and PI3K/AKT inactivation after doxorubicin-induced gonadotoxicity in rats: Involvement of the canonical Hedgehog trajectory.","Zaky DA","2023","International immunopharmacology","preclinical","article","10.1016/j.intimp.2023.110212","37094542",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023953","Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.","Hinnen D","2015","The Diabetes educator","narrative_review","article","10.1177/0145721715609420","26453595",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0023954","Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.","van Raalte DH","2016","European journal of endocrinology","randomized_trial","article","10.1530/eje-16-0286","27466218",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023955","Characterization of on-target adverse events caused by TRK inhibitor therapy.","Liu D","2020","Annals of oncology : official journal of the European Society for Medical Oncology","nonrandomized_study","article","10.1016/j.annonc.2020.05.006","32422171","PMC8341080",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0023956","Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.","Gu N","2014","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2013.12.002","24373998",null,"ClinicalTrials.gov:NCT00964262","S001619","pubmed; europepmc","FALSE","open_pdf","1",null,"Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0023957","The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis--what happens next? A personal viewpoint.","Ryder RE","2013","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.12336","24117729",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0023958","Disruption of CR6-interacting factor-1 (CRIF1) in mouse islet beta cells leads to mitochondrial diabetes with progressive beta cell failure.","Kim YK","2015","Diabetologia","preclinical","article","10.1007/s00125-015-3506-y","25660120",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023959","The Link between NAFLD and Metabolic Syndrome.","Radu F","2023","Diagnostics (Basel, Switzerland)","narrative_review","article","10.3390/diagnostics13040614","36832102","PMC9955701",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023960","Exenatide",null,"2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"31643976",null,null,null,"europepmc","TRUE",null,null,null,"Book; Review"],["R0023961","Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.","Redouane B","2020","Circulation. Heart failure","randomized_trial","article","10.1161/circheartfailure.119.006758","32362166","PMC7906045","ClinicalTrials.gov:NCT01800968","S002350","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0023962","Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.","Raun K","2007","Diabetes","randomized_trial","article","10.2337/db06-0565","17192459",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; article"],["R0023963","Liraglutide prevents high glucose level induced insulinoma cells apoptosis by targeting autophagy.","Chen ZF","2013","Chinese medical journal","preclinical","article","10.3760/cma.j.issn.0366-6999.20122331","23489805",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023964","Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.","Song T","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-021-01072-4","34002333","PMC8179869",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0023965","Liraglutide reduces hyperglycemia-induced cardiomyocyte death through activating glucagon-like peptide 1 receptor and targeting AMPK pathway.","Ma G","2020","Journal of receptor and signal transduction research","other","article","10.1080/10799893.2020.1719517","32013667",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023966","Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.","Thrasher J","2017","The American journal of medicine","other_trial","article","10.1016/j.amjmed.2017.04.004","28526182",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0023967","Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.","Fadini GP","2013","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-013-0489-3","23754673",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Clinical Trial; Journal Article; article"],["R0023968","[Therapy with incretin mimetic exenatide. Soon HbA1c value and weight decrease permanently].",null,"2006","MMW Fortschritte der Medizin","commentary","article",null,"17036908",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; News; article"],["R0023969","The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis.","Yajima T","2018","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2018.05.018","29937137",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023970","Exenatide once weekly for the treatment of type 2 diabetes.","Malone J","2009","Expert opinion on investigational drugs","other_trial","article","10.1517/13543780902766802","19243286",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0023971","Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.","Cummings J","2022","The European journal of neuroscience","preclinical","article","10.1111/ejn.15619","35128745","PMC9393901",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023972","Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.","Gudipaty L","2014","Diabetes care","randomized_trial","article","10.2337/dc14-0398","24969577","PMC4140159",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0023973","What are incretins, and how will they influence the management of type 2 diabetes?","Blonde L","2006","Journal of managed care pharmacy : JMCP","other","article","10.18553/jmcp.2006.12.s7-a.1","16981805","PMC10438057",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023974","Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report.","Fukuda G","2019","Geriatrics & gerontology international","case_report","article","10.1111/ggi.13799","31823494",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0023975","Efficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta-Analysis.","Benedictus B","2025","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2024.12.013","39843265",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Systematic Review; Journal Article; Network Meta-Analysis"],["R0023976","Exenatide alleviates adriamycin-induced heart dysfunction in mice: Modulation of oxidative stress, apoptosis and inflammation.","Fang J","2019","Chemico-biological interactions","preclinical","article","10.1016/j.cbi.2019.03.012","30885636",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0023977","Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations.","Zhang S","2021","Frontiers in chemistry","other","article","10.3389/fchem.2021.711242","34527658","PMC8435576",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023978","A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes.","Htike ZZ","2012","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-012-0003-x","22422427","PMC3508112",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; article"],["R0023979","GLP-1 based therapies: differential effects on fasting and postprandial glucose.","Fineman MS","2012","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2012.01560.x","22233527",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023980","Exenatide and acute pancreatitis.","Tripathy NR","2008","The Journal of the Association of Physicians of India","case_report","article",null,"19322980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0023981","Cardioprotective effects of exenatide against oxidative stress-induced injury.","Chang G","2013","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2013.1475","23982489",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023982","Healthcare utilization associated with obesity management in Ontario, Canada.","Wharton S","2025","Clinical obesity","nonrandomized_study","article","10.1111/cob.12720","39582393",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0023983","Redox-active injectable gel using polyion complex to achieve sustained release of exenatide and enhance therapeutic efficacy for the treatment of type 2 diabetes.","Ishii S","2019","Journal of biomedical materials research. Part A","preclinical","article","10.1002/jbm.a.36647","30720240",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023984","Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1.","Murage EN","2008","Bioorganic & medicinal chemistry","nonrandomized_study","article","10.1016/j.bmc.2008.10.006","18952440",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023985","Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons.","Belsham DD","2009","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.09-133454","19703933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0023986","Metabolic diseases drug discovery world summit. July 28-29, 2003, San Diego, CA, USA.","Sarabu R","2003","Expert opinion on investigational drugs","preclinical","article","10.1517/13543784.12.10.1721","14519091",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Conference Proceedings; article; conference-abstract"],["R0023987","Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries.","Boland BB","2022","Molecular metabolism","preclinical","article","10.1016/j.molmet.2021.101392","34781035","PMC8717237",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0023988","Hypothalamic insulin and glucagon-like peptide-1 levels in an animal model of depression and their effect on corticotropin-releasing hormone promoter gene activity in a hypothalamic cell line.","Detka J","2019","Pharmacological reports : PR","preclinical","article","10.1016/j.pharep.2018.11.001","30831439",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0023989","Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets.","Huang C","2015","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2015.2207","25976560","PMC4494597",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0023990","Weight Loss Induces Changes in Vitamin D Status in Women With Obesity But Not in Men: A Randomized Clinical Trial.","Holt R","2025","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgae775","39530599","PMC12261087","ClinicalTrials.gov:NCT04122716","S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0023991","Obesity and Post-Transplant Diabetes Mellitus in Kidney Transplantation.","Martin-Moreno PL","2021","Journal of clinical medicine","narrative_review","article","10.3390/jcm10112497","34198724","PMC8201168",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0023992","Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins.","Khafagy el-S","2009","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2009.07.022","19646515",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023993","Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide.","Wang J","2022","ACS omega","other","article","10.1021/acsomega.2c05915","36570276","PMC9773959",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0023994","Novel biological therapies for the treatment of diabetic foot ulcers.","Adeghate J","2017","Expert opinion on biological therapy","narrative_review","article","10.1080/14712598.2017.1333596","28532226",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0023995","Drug-Induced Liver Injury Due to Dulaglutide Use.","Patel AV","2019","American journal of therapeutics","case_report","article","10.1097/mjt.0000000000000826","30870146",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0023996","[The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus].","Yu DN","2021","Zhonghua nei ke za zhi","randomized_trial","article","10.3760/cma.j.cn112138-20210205-00105","34689519",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0023997","Long-term feeding on powdered food causes hyperglycemia and signs of systemic illness in mice.","Tsuchiya M","2014","Life sciences","preclinical","article","10.1016/j.lfs.2014.03.022","24690390",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0023998","Palatable food avoidance and acceptance learning with different stressors in female rats.","Liang NC","2013","Neuroscience","preclinical","article","10.1016/j.neuroscience.2012.12.068","23380501","PMC3677210",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0023999","Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.","Talsania T","2005","Endocrinology","preclinical","article","10.1210/en.2005-0473","15932924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024000","Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus.","Padda J","2021","Cureus","narrative_review","article","10.7759/cureus.17321","34557367","PMC8449987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024001","Origin and therapy for hypertriglyceridaemia in type 2 diabetes.","Pang J","2014","World journal of diabetes","narrative_review","article","10.4239/wjd.v5.i2.165","24748930","PMC3990315",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024002","Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.","Pușcașu C","2024","Life (Basel, Switzerland)","narrative_review","article","10.3390/life14111500","39598298","PMC11595627",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024003","New oral antidiabetic agents.","Cavallo Perin P","2011","Internal and emergency medicine","other","article","10.1007/s11739-011-0677-5","22009626",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024004","A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease.","Tokita J","2024","Journal of primary care & community health","nonrandomized_study","article","10.1177/21501319231223437","38185870","PMC10773280","ClinicalTrials.gov:NCT04802395","S002741","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0024005","Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes.","Kim H","2011","Biomaterials","preclinical","article","10.1016/j.biomaterials.2010.10.045","21126761",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024006","Role of Tyrosine Isomers in Acute and Chronic Diseases Leading to Oxidative Stress - A Review.","Molnár GA","2016","Current medicinal chemistry","preclinical","article","10.2174/0929867323666160119094516","26785996","PMC4997921",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0024007","Liraglutide-Loaded Milk Exosomes Lower Blood Glucose When Given by Sublingual Route.","Xu M","2022","ChemMedChem","preclinical","article","10.1002/cmdc.202100758","35199481",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024008","Two-Layer Sustained-Release Microneedles Encapsulating Exenatide for Type 2 Diabetes Treatment.","Liu H","2022","Pharmaceutics","preclinical","article","10.3390/pharmaceutics14061255","35745827","PMC9230706",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024009","Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.","Lo C","2018","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd011798.pub2","30246878","PMC6513625",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; systematic-review; article"],["R0024010","Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats.","Candeias E","2018","Molecular neurobiology","preclinical","article","10.1007/s12035-017-0622-3","28573460",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024011","Exendin-4 attenuates ischemia-induced ventricular arrhythmias in rats.","Kai Z","2013","Cardiology journal","preclinical","article","10.5603/cj.2013.0006","23558808",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024012","Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.","Wadden TA","2020","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.22726","32090517","PMC7065111",null,"S000712","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024013","Metabolic outcome analysis of patients with and without diabetes mellitus undergoing cardiac rehabilitation for ischaemic heart disease","Mannion J","2021","European Heart Journal. Acute Cardiovascular Care","other","article","10.1093/ehjacc/zuab020.221",null,"PMC8264027",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0024014","Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels.","Li L","2008","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2007.00832.x","18093209",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0024015","Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.","Tronieri JS","2019","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2019.03.005","30902750","PMC6571049","ClinicalTrials.gov:NCT02911818","S000426","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024016","GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons.","Griffioen KJ","2011","Cardiovascular research","preclinical","article","10.1093/cvr/cvq271","20736238","PMC3002870",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; research-article; article"],["R0024017","An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal.","Enright C","2023","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvac195","36686585","PMC9847544",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0024018","Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.","Manandhar B","2015","Journal of medicinal chemistry","narrative_review","article","10.1021/jm500810s","25349901","PMC4329993",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0024019","Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.","Kendall DM","2005","Diabetes care","randomized_trial","article","10.2337/diacare.28.5.1083","15855571",null,null,"S000706","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024020","Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide.","Hearn EB","2021","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/ds20-0033","33627997","PMC7887535",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024021","Prediction of subcutaneous drug absorption - Development of novel simulated interstitial fluid media for predictive subcutaneous in vitro assays.","Torres-Terán I","2024","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2024.124227","38750979",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024022","Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?","Athyros VG","2016","Current vascular pharmacology","commentary","article","10.2174/1570161114666160909161811","27633289",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0024023","Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.","Tronieri JS","2020","Obesity facts","randomized_trial","article","10.1159/000511130","33197917","PMC7802504",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024024","Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.","Holz GG","2003","Current medicinal chemistry","narrative_review","article","10.2174/0929867033456648","14529486","PMC2911578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review; research-article; article"],["R0024025","The dual GLP-1 and GIP receptor agonist tirzapetide provides an unintended interaction with the β-adrenoceptors and plays a role in glucose metabolism in hyperglycemic or senescent cardiac cells.","Aydos D","2025","Cardiovascular diabetology","preclinical","article","10.1186/s12933-025-02828-z","40826463","PMC12362930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024026","Cardiovascular effects of anti-diabetes drugs.","Younk LM","2016","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2016.1195368","27268470","PMC5036275",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0024027","Chronic GLP1 therapy reduces postprandial IL6 in obese humans with prediabetes.","Hamidi V","2024","Cardiovascular endocrinology & metabolism","other","article","10.1097/xce.0000000000000298","38187405","PMC10769508",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024028","A synthetic glucagon-like peptide-1 analog with improved plasma stability.","Ritzel U","1998","The Journal of endocrinology","preclinical","article","10.1677/joe.0.1590093","9795346",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024029","Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.","Blonde L","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14464","34132018","PMC8518913","ClinicalTrials.gov:NCT02964247","S000022","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0024030","Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density.","Chen K","2021","Journal of musculoskeletal & neuronal interactions","preclinical","article",null,"33657765","PMC8020012",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0024031","The Impact of COVID-19 Lockdown on Patients with Type 2 Diabetes Mellitus: A Brief Report.","Vozza A","2023","Endocrine, metabolic & immune disorders drug targets","nonrandomized_study","article","10.2174/1871530323666230112165948","36644863",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0024032","Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting.","Dalal MR","2015","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep14290.or","25148821",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024033","Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese Participants.","Younis IR","2024","Journal of clinical pharmacology","other_trial","article","10.1002/jcph.6114","39213138",null,"ClinicalTrials.gov:NCT04971785","S000339","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024034","Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes.","Bailey CJ","2024","Peptides","other","article","10.1016/j.peptides.2024.171168","38320643",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024035","Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes.","Dubé MC","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14050","32250534",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024036","Bariatric and endo-bariatric interventions for diabetes: What is the current evidence?","Mondal S","2024","World journal of diabetes","commentary","article","10.4239/wjd.v15.i11.2255","39582566","PMC11580570",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0024037","Exenatide Improves Endometrial Glands in PCOS Rats through AMPKα-SIRT1","He J","2020","Research Square","preclinical","preprint","10.21203/rs.3.rs-28388/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0024038","The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.","Kaya-Dagistanli F","2013","Acta histochemica","preclinical","article","10.1016/j.acthis.2012.12.007","23351716",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024039","OR33-01 Liraglutide for Weight Management in Pubertal Adolescents with Obesity: A Randomized Controlled Trial","Kelly A","2020","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaa046.413",null,"PMC7208432","ClinicalTrials.gov:NCT02918279","S000599","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; article"],["R0024040","Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice.","Han F","2019","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2019.109537","31605951",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024041","Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.","Tatarkiewicz K","2010","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00479.2010","20923958","PMC3006257",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024042","Mody-3: novel HNF1A mutation and the utility of glucagon-like peptide (GLP)-1 receptor agonist therapy.","Docena MK","2014","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.4158/ep13254.or","24014008",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024043","Separation by hydrophobic interaction chromatography and structural determination by mass spectrometry of mannosylated glycoforms of a recombinant transferrin-exendin-4 fusion protein from yeast.","Zolodz MD","2010","Journal of chromatography. A","other","article","10.1016/j.chroma.2009.10.057","19896672",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024044","Neuropathy of diabetes following initiation of a low-carbohydrate diet: Case report.","Sahyouni MJ","2024","Obesity pillars","case_report","article","10.1016/j.obpill.2024.100115","38983905","PMC11231748",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0024045","Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™.","Kelly P","2015","Microcirculation (New York, N.Y. : 1994)","preclinical","article","10.1111/micc.12186","25556713",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024046","Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.","Dupre J","2005","Regulatory peptides","narrative_review","article","10.1016/j.regpep.2004.06.003","15780434",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024047","The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial.","Whicher CA","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14334","33528914",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024048","[Conserved W52 led to reduced binding of glucogan-like peptide 1 receptor].","Gao W","2013","Sheng wu gong cheng xue bao = Chinese journal of biotechnology","preclinical","article",null,"23631121",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024049","Activation of pCREB/Nrf-2 signaling mediates re-positioning of liraglutide as hepato-protective for methotrexate -induced liver injury (MILI).","Abdelaziz AI","2019","Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","preclinical","article","10.1016/j.fct.2019.110719","31362085",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024050","The right place for Sulphonylureas today.","Webb DR","2019","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2019.107836","31479704",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0024051","Chemogenetic inhibition of the lateral hypothalamus effectively reduces food intake in rats in a translational proof-of-concept study.","Kovács P","2024","Scientific reports","preclinical","article","10.1038/s41598-024-62014-1","38762561","PMC11102470",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024052","[Benefits and risks of current pharmacotherapy in the treatment of type 2 diabetes].","Schindler C","2012","Der Internist","other","article","10.1007/s00108-012-3014-9","22388922",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0024053","Compound 19e, a Novel Glucokinase Activator, Protects against Cytokine-Induced Beta-Cell Apoptosis in INS-1 Cells.","Oh YS","2017","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2017.00169","28405188","PMC5370240",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024054","Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4).","Hiles RA","2003","Human & experimental toxicology","other","article","10.1191/0960327103ht402oa","14992323",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024055","Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.","Jendle J","2012","Journal of medical economics","randomized_trial","article","10.3111/13696998.2012.703633","22853443",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024056","Expression of human globular adiponectin-glucagon-like peptide-1 analog fusion protein and its assay of glucose-lowering effect in vivo.","Zhao T","2011","International journal of medical sciences","preclinical","article","10.7150/ijms.8.203","21448306","PMC3053492",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024057","A software interface for in silico testing of type 2 diabetes treatments.","Visentin R","2022","Computer methods and programs in biomedicine","randomized_trial","article","10.1016/j.cmpb.2022.106973","35792365",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0024058","Cardiac Wolframinopathies: A Case Report of Myocarditis and a Literature Review of Cardiac Involvement in Wolfram Syndrome 1.","Villatore A","2024","Journal of clinical medicine","case_report","article","10.3390/jcm13061803","38542026","PMC10971342",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024059","SUMO1 enhances cAMP-dependent exocytosis and glucagon secretion from pancreatic α-cells.","Dai XQ","2014","The Journal of physiology","preclinical","article","10.1113/jphysiol.2014.274084","24907310","PMC4192699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024060","IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.","Hunt B","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-017-0251-x","28349444","PMC5446378",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0024061","Pharmacotherapy for chronic obesity management: a look into the future.","Abdel-Malek M","2023","Internal and emergency medicine","narrative_review","article","10.1007/s11739-023-03237-4","37249754","PMC10326094",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024062","Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway.","Li Z","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s216455","31564937","PMC6732560",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024063","Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.","Garvey WT","2020","Diabetes care","randomized_trial","article","10.2337/dc19-1745","32139381","PMC7171937","ClinicalTrials.gov:NCT02963922","S000159","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024064","Ultrasound-targeted semaglutide-loaded PEG-nanoliposomes microbubble destruction protects diabetic cardiomyopathy by activating PI3K/Akt/Nrf2 signaling pathway.","Zhu J","2023","Heliyon","preclinical","article","10.1016/j.heliyon.2023.e19873","37809373","PMC10559235",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024065","Review of current and emerging therapies in type 2 diabetes mellitus.","Mazzola N","2012","The American journal of managed care","narrative_review","article",null,"22559854",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024066","Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes.","Sharma A","2006","Diabetologia","preclinical","article","10.1007/s00125-006-0251-2","16609877",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024067","Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.","Waser B","2011","Neuroendocrinology","preclinical","article","10.1159/000330447","21893952",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024068","Tacrolimus- and sirolimus-induced human β cell dysfunction is reversible and preventable.","Dai C","2020","JCI insight","preclinical","article","10.1172/jci.insight.130770","31941840","PMC7030815",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0024069","Optimization of Medication Regimens in Patients with Type 2 Diabetes and Clinical Atherosclerotic Cardiovascular Disease.","Prudencio J","2021","Pharmacy (Basel, Switzerland)","other","article","10.3390/pharmacy9040186","34842818","PMC8628975",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024070","Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.","Cahn A","2016","Reviews in endocrine & metabolic disorders","other_trial","article","10.1007/s11154-016-9351-6","27106831",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0024071","Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials.","Zhong Z","2021","International journal of endocrinology","systematic_review","article","10.1155/2021/9993229","34221010","PMC8219465",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0024072","Diabetic medications in pregnancy.","Young J","2009","Current diabetes reviews","narrative_review","article","10.2174/157339909789804350","19925389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024073","Semaglutide, a newly available glucagon-like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes.","Saito S","2022","Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","case_report","article","10.1111/1744-9987.13651","33830659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0024074","Liraglutide for Adolescents with Obesity.","Anker MS","2020","The New England journal of medicine","commentary","article","10.1056/nejmc2023284","32937055",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0024075","Liraglutide Protects Against Brain Amyloid-β1-42 Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation.","Duarte AI","2020","International journal of molecular sciences","preclinical","article","10.3390/ijms21051746","32143329","PMC7084254",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024076","An analogue of the Prolactin Releasing Peptide reduces obesity and promotes adult neurogenesis.","Jörgensen SK","2024","EMBO reports","preclinical","article","10.1038/s44319-023-00016-2","38177913","PMC10897398",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024077","Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.","Drucker DJ","2018","Cell metabolism","narrative_review","article","10.1016/j.cmet.2018.03.001","29617641",null,null,"S001263; S002311","pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0024078","Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration.","George J","2022","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxac046","35136945",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0024079","Review of Pharmacokinetic Data of Different Drug Classes in Goto-Kakizaki Rats, a Non-obese Model for Type 2 Diabetes Mellitus: Case Studies and Perspectives.","Patel H","2017","European journal of drug metabolism and pharmacokinetics","preclinical","article","10.1007/s13318-016-0373-y","27623996",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024080","Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease.","Sangwung P","2024","American journal of physiology. Endocrinology and metabolism","narrative_review","article","10.1152/ajpendo.00371.2023","38984948","PMC11559640",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024081","Non-alcoholic fatty liver disease in 2016.","Townsend SA","2016","British medical bulletin","other_trial","article","10.1093/bmb/ldw031","27543499","PMC5862239",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0024082","An experimental study of exenatide effects on renal injury in diabetic rats1.","Wang X","2019","Acta cirurgica brasileira","preclinical","article","10.1590/s0102-865020190010000001","30785502","PMC6585921",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024083","Mechanistic insights into the effects of quercetin and/or GLP-1 analogue liraglutide on high-fat diet/streptozotocin-induced type 2 diabetes in rats.","Gaballah HH","2017","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2017.05.086","28554128",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024084","Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes.","Cheng Q","2008","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.108.142703","18787107",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024085","Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.","Buse JB","2010","Diabetes care","randomized_trial","article","10.2337/dc09-2260","20332351","PMC2875443","ClinicalTrials.gov:NCT00518882","S002230","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024086","Age-dependent human β cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling.","Dai C","2017","The Journal of clinical investigation","other","article","10.1172/jci91761","28920919","PMC5617654",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024087","Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson's Disease Patients.","Ciocca M","2024","CNS & neurological disorders drug targets","randomized_trial","article","10.2174/1871527322666230330122444","37005519","PMC11071650",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0024088","Bornyl Derivatives of p-(Benzyloxy)Phenylpropionic Acid: In Vivo Evaluation of Antidiabetic Activity.","Kuranov S","2020","Pharmaceuticals (Basel, Switzerland)","preclinical","article","10.3390/ph13110404","33228030","PMC7699345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024089","Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system.","Richard JE","2015","PloS one","preclinical","article","10.1371/journal.pone.0119034","25793511","PMC4368564",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024090","Efficacy & safety of sodium-glucose cotransporter-2 inhibitors in polycystic ovary syndrome: A meta-analysis with trial sequential analysis.","Ahsan M","2025","The Indian journal of medical research","systematic_review","article","10.25259/ijmr_497_2025","41296583","PMC12744563","PROSPERO:CRD42024608736",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0024091","Dulaglutide efficacy.","Sandrini A","2019","Australian prescriber","commentary","article","10.18773/austprescr.2019.015","31048937","PMC6478955",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; letter"],["R0024092","Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents.","Apperley LJ","2021","Journal of pediatric endocrinology & metabolism : JPEM","other","article","10.1515/jpem-2020-0714","33823101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024093","Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes.","DeFronzo RA","2019","Diabetes & vascular disease research","randomized_trial","article","10.1177/1479164118825376","30706731",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0024094","Role of moesin in the effect of glucagon-like peptide-1 on advanced glycation end products-induced endothelial barrier dysfunction.","Liu Y","2022","Cellular signalling","other","article","10.1016/j.cellsig.2021.110193","34785348",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024095","Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors.","Wang YZ","2022","Acta pharmacologica Sinica","other","article","10.1038/s41401-021-00758-6","34446852","PMC9159978",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0024096","Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo.","Nathanson D","2009","Regulatory peptides","preclinical","article","10.1016/j.regpep.2009.07.003","19595708",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024097","Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations.","Hashimoto Takigami N","2021","Breast cancer research and treatment","other","article","10.1007/s10549-021-06288-3","34213657",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024098","[Liraglutide: new results in the treatment of type 2 diabetes mellitus].","Mateos JL","2012","Drugs of today (Barcelona, Spain : 1998)","narrative_review","article","10.1358/dot.2012.48(suppl.b).1876681","23082308",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; conference-abstract"],["R0024099","Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019.","Funck KL","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14245","33140907","PMC7839758",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024100","A New 2-Step Acceleration Protocol Using a Histone Deacetylase Inhibitor to Generate Insulin-Producing Cells From Adipose-Derived Mesenchymal Stem Cells.","Ikemoto T","2018","Pancreas","protocol","article","10.1097/mpa.0000000000001017","29517636","PMC5865483",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0024101","Liraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways.","Yang L","2022","Neurochemical research","preclinical","article","10.1007/s11064-022-03574-4","35352213",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024102","Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog.","Reiner T","2011","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.1109859108","21768367","PMC3150928",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024103","Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.","Fu H","2014","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2014.0039","25068375",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024104","Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats.","Lin FY","2021","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-020-07013-w","32623597",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024105","Regulation of brain insulin mRNA by glucose and glucagon-like peptide 1.","Madadi G","2008","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2008.09.054","18809381",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024106","Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways.","Zhou JY","2019","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2019.172594","31412267",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024107","Antihyperglycaemic therapies and cancer risk.","Lutz SZ","2014","Diabetes & vascular disease research","randomized_trial","article","10.1177/1479164114549553","25231191",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0024108","Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies?","McCormick LM","2012","Cardiovascular & hematological agents in medicinal chemistry","narrative_review","article","10.2174/187152512803530360","22827290",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024109","Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).","Jódar E","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14039","32227613","PMC7383680","ClinicalTrials.gov:NCT01720446","S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024110","Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT 2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart.","Zhang LH","2015","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-015-6592-7","25994830",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024111","Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.","Zhao D","2020","Clinical and experimental hypertension (New York, N.Y. : 1993)","systematic_review","article","10.1080/10641963.2019.1676771","31610701",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0024112","Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients with Diabetes Hospitalized With COVID-19.","Milosavljevic J","2022","Journal of community hospital internal medicine perspectives","nonrandomized_study","article","10.55729/2000-9666.1127","36845575","PMC9949726",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024113","An overview of insulin therapy for the non-specialist.","Home PD","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16280","40035222","PMC12169081",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; research-article; article"],["R0024114","Conditioning techniques and ischemic reperfusion injury in relation to on-pump cardiac surgery.","Holmberg FE","2014","Scandinavian cardiovascular journal : SCJ","randomized_trial","article","10.3109/14017431.2014.923930","24852515",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024115","The evidence for oral semaglutide in type 2 diabetes from a managed care perspective.","Heile M","2020","The American journal of managed care","other","article","10.37765/ajmc.2020.88553","33439580",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024116","Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells.","Li Z","2014","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2014.05.008","24972503",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024117","The novel GLP-1/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury.","Bai B","2021","Nutrition, metabolism, and cardiovascular diseases : NMCD","preclinical","article","10.1016/j.numecd.2020.09.002","33500109",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024118","Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients.","Russo GT","2015","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-014-0163-9","25173876",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0024119","Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology.","Chao AM","2019","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.22653","31746553","PMC6873814",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024120","PSUN134 Loss of Glp-1r Signaling in the β-Cell Impairs Adaptive Proliferation and Insulin Secretion",null,"2022","Journal of the Endocrine Society","preclinical","article",null,null,"PMC9624804",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0024121","Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al.","Dahl K","2021","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.14485","34212484",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; letter"],["R0024122","GPHB5 Is a Biomarker in Women With Metabolic Syndrome: Results From Cross-Sectional and Intervention Studies.","Xiang T","2022","Frontiers in endocrinology","other","article","10.3389/fendo.2022.893142","35757403","PMC9218212",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024123","Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice.","Nonogaki K","2014","BioMed research international","preclinical","article","10.1155/2014/751930","24804243","PMC3997887",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024124","Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.","Oda H","2013","Research in veterinary science","other_trial","article","10.1016/j.rvsc.2013.04.003","23632200",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0024125","Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.","Bode BW","2011","The American journal of geriatric pharmacotherapy","randomized_trial","article","10.1016/j.amjopharm.2011.09.007","22055210",null,null,"S001094; S001502; S001584; S002098; S002222; S002230","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024126","Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus.","Abbas G","2020","Current pharmaceutical design","narrative_review","article","10.2174/1381612826666200131143231","32003684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024127","Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.","Ali AM","2020","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgaa494","32745202",null,"ClinicalTrials.gov:NCT02324842","S000911; S001422","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024128","Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.","Steven S","2015","Basic research in cardiology","preclinical","article","10.1007/s00395-015-0465-x","25600227",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024129","Therapeutic approaches to preserve islet mass in type 2 diabetes.","Baggio LL","2006","Annual review of medicine","preclinical","article","10.1146/annurev.med.57.110104.115624","16409149",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0024130","The gastrointestinal tract in hunger and satiety signalling.","Tack J","2021","United European gastroenterology journal","other_trial","article","10.1002/ueg2.12097","34153172","PMC8280794",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0024131","Type 2 Diabetes Prescribing Habits amongst Providers to an Underserved Population.","King CA","2019","Innovations in pharmacy","other","article","10.24926/iip.v10i4.2151","34007585","PMC8051893",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024132","Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques.","Faurschou A","2013","Experimental dermatology","commentary","article","10.1111/exd.12081","23362875",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0024133","Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide long-acting release.","Takenaka K","2019","Clinical case reports","case_report","article","10.1002/ccr3.2139","31110729","PMC6509896",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0024134","Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study.","Brath H","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0558-2","30656523","PMC6437236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0024135","Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.","Guja C","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-020-00842-w","33011938","PMC7644701",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0024136","GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?","Popovic DS","2015","Current pharmaceutical design","randomized_trial","article","10.2174/0929867322666151006142224","26438316",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0024137","Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).","Tuttle KR","2019","Diabetes, obesity & metabolism","other","article","10.1111/dom.13668","30762290",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024138","In vitro cell cultures of Brunner's glands from male mouse to study GLP-1 receptor function.","Voetmann LM","2022","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00345.2021","35442827",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024139","Glucagon-like peptide 1 (GLP-1).","Müller TD","2019","Molecular metabolism","preclinical","article","10.1016/j.molmet.2019.09.010","31767182","PMC6812410",null,"S000485; S002621; S002726","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0024140","[New drugs in type 2 diabetes mellitus therapy].","Kvapil M","2013","Vnitrni lekarstvi","narrative_review","article",null,"24007229",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024141","Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.","Kaneko S","2017","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej17-0189","28904247",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0024142","Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.","Mathieu C","2007","International journal of clinical practice. Supplement","narrative_review","article","10.1111/j.1742-1241.2007.01437.x","17593275",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024143","Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity.","Kozawa J","2012","Journal of diabetes investigation","other","article","10.1111/j.2040-1124.2011.00168.x","24843579","PMC4014952",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024144","[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.","Wicki A","2007","Clinical cancer research : an official journal of the American Association for Cancer Research","preclinical","article","10.1158/1078-0432.ccr-06-2965","17575235",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024145","Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists.","Lin F","2009","Journal of molecular modeling","other","article","10.1007/s00894-008-0372-2","18941807",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024146","64Cu-Labeled 1,4,7-tris(acetic acid)-10-vinylsulfone-1,4,7,10-tetraazacyclododecane conjugated to Cys40-Exendin-4","Chopra A","2004","National Center for Biotechnology Information (US), Bethesda (MD)","preclinical","article",null,"22439162",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0024147","GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients.","Yu M","2019","Pharmacogenomics","other","article","10.2217/pgs-2018-0159","30883264",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024148","Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic beta-cells.","Shao W","2010","Cellular signalling","preclinical","article","10.1016/j.cellsig.2010.04.001","20385228",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024149","Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.","Fineman MS","2004","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.499","15343588",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024150","2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes.","Bertoluci MC","2023","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-023-01121-x","37468901","PMC10354939",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024151","Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats.","Rodriguez R","2018","Hypertension research : official journal of the Japanese Society of Hypertension","preclinical","article","10.1038/s41440-018-0070-0","29985448",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024152","Approach to Patients with Obesity and Other Cardiovascular Risk Factors in Primary Care Using the Delphi Methodology.","Morillas Blasco P","2022","Journal of clinical medicine","other","article","10.3390/jcm11144130","35887894","PMC9324671",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024153","Incretin-based therapy compared with non-insulin alternatives in elderly patients with type 2 diabetes.","Zhao Q","2013","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","nonrandomized_study","article","10.4140/tcp.n.2013.515","23906896",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; article"],["R0024154","An acidic pH and activation of phosphoinositide 3-kinase stimulate differentiation of pancreatic progenitors into insulin-producing cells.","Koblas T","2010","Transplantation proceedings","other","article","10.1016/j.transproceed.2010.05.087","20692412",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024155","Case Report: Clinical pharmacist prescriber in depression treatment in primary care settings: clinical case focused on prescribing practice.","Stuhec M","2025","Frontiers in psychiatry","case_report","article","10.3389/fpsyt.2025.1677152","40950770","PMC12423072",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0024156","A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes.","Liang Y","2021","Medicine","protocol","article","10.1097/md.0000000000023948","33545972","PMC7837848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; article"],["R0024157","Treatment With Liraglutide Exerts Neuroprotection After Hypoxic-Ischemic Brain Injury in Neonatal Rats via the PI3K/AKT/GSK3β Pathway.","Zeng SS","2019","Frontiers in cellular neuroscience","preclinical","article","10.3389/fncel.2019.00585","32082121","PMC7003644",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024158","Fluorescein-Trp25-exendin-4, a biologically active fluorescent probe for the human GLP-1 receptor.","Chicchi GG","1997","Peptides","other","article","10.1016/s0196-9781(96)00320-8","9149306",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024159","Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.","Zhang LY","2020","Clinics and research in hepatology and gastroenterology","randomized_trial","article","10.1016/j.clinre.2020.01.007","32113823",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0024160","Calcium/calmodulin-dependent serine protein kinase is involved in exendin-4-induced insulin secretion in INS-1 cells.","Zhu ZQ","2014","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2013.09.009","24140090",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024161","Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.","Malendowicz LK","2003","International journal of molecular medicine","preclinical","article","10.3892/ijmm.11.6.763","12736719",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024162","Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study.","Thakur U","2021","Obesity surgery","randomized_trial","article","10.1007/s11695-020-04850-4","32656729",null,null,"S001245; S001448","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024163","Diabetic cardiomyopathy and diastolic heart failure -- difficulties with relaxation.","Teupe C","2012","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2012.03.008","22502812",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024164","Liraglutide promotes apoptosis of HepG2 cells by activating JNK signaling pathway.","Li Q","2019","European review for medical and pharmacological sciences","other","article","10.26355/eurrev_201904_17719","31081108",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024165","Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies.","Son JW","2015","Diabetes & metabolism journal","other_trial","article","10.4093/dmj.2015.39.5.373","26566494","PMC4641966",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0024166","The physiology of incretin hormones and the basis for DPP-4 inhibitors.","McKennon SA","2007","The Diabetes educator","other","article","10.1177/0145721706297451","17272793",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024167","Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.","Perry T","2005","Current Alzheimer research","preclinical","article","10.2174/1567205054367892","15974903",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024168","64Cu-Labeled Lys40(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)NH2–conjugated exendin-4","Chopra A","2004","National Center for Biotechnology Information (US), Bethesda (MD)","nonrandomized_study","article",null,"22379636",null,null,null,"europepmc","TRUE","free_to_read","4",null,"Review"],["R0024169","Tirzepatide.","Baker DE","2023","Hospital pharmacy","other_trial","article","10.1177/00185787221125724","37216078","PMC10192986",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0024170","An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs.","Sauter M","2019","Bioanalysis","preclinical","article","10.4155/bio-2018-0322","31094209",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024171","Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.","Grabarczyk TR","2020","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/1060028020915791","32274930",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0024172","Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry.","Geier A","2023","Zeitschrift fur Gastroenterologie","nonrandomized_study","article","10.1055/a-1986-7676","36623544",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0024173","Insulin contributes to fine-tuning of the pancreatic beta-cell response to glucagon-like peptide-1.","Moon MJ","2011","Molecules and cells","preclinical","article","10.1007/s10059-011-0157-9","21904878","PMC3887647",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024174","Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas.","Silvestre RA","2003","European journal of pharmacology","preclinical","article","10.1016/s0014-2999(03)01692-3","12782202",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024175","Efficacy of Liraglutide in clinical practice: Single centre experience.","Rashid MO","2020","Pakistan journal of medical sciences","nonrandomized_study","article","10.12669/pjms.36.3.358","32292448","PMC7150369",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024176","Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study.","Torre C","2019","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2018.11.009","30573348",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Observational Study; Research Support, Non-U.S. Gov't"],["R0024177","GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.","Li Y","2009","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.0806720106","19164583","PMC2633544",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; research-article; article"],["R0024178","Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.","Becker RH","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12278","24521245","PMC4237545",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024179","Hippocampal GLP-1 receptors influence food intake, meal size, and effort-based responding for food through volume transmission.","Hsu TM","2015","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/npp.2014.175","25035078","PMC4443945",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0024180","Exenatide Reduces Graft Injury in a Rat Transplantation Model Using Kidneys Donated after Cardiac Death.","Hua Yang","2019","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2019.04.034","31303407",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024181","Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.","Lee YS","2012","Diabetologia","preclinical","article","10.1007/s00125-012-2592-3","22722451",null,null,"S000371","pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024182","The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity.","Doyle ME","2003","Regulatory peptides","preclinical","article","10.1016/s0167-0115(03)00120-4","12832104","PMC10031803",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0024183","The Capacity to Secrete Insulin Is Dose-Dependent to Extremely High Glucose Concentrations: A Key Role for Adenylyl Cyclase.","Gerber KM","2021","Metabolites","preclinical","article","10.3390/metabo11060401","34205432","PMC8235240",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024184","Advances in pharmacologic therapies for type 2 diabetes.","Morsink LM","2013","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-012-0302-8","23299642",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024185","The protective effects of exenatide against AGEs-induced articular matrix degradation in human primary chondrocytes.","Tong C","2019","American journal of translational research","other","article",null,"31105819","PMC6511778",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024186","Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.","Bonnet F","2017","Diabetes & metabolism","other_trial","article","10.1016/j.diabet.2017.04.004","28522196",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0024187","Novel double-layered PLGA microparticles-dissolving microneedle (MPs-DMN) system for peptide drugs sustained release by transdermal delivery.","Xu B","2025","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2024.125128","39722375",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024188","Liraglutide abrogates nephrotoxic effects of chemotherapies.","Xu C","2023","Pharmacological research","preclinical","article","10.1016/j.phrs.2023.106680","36746359",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024189","Banxia Xiexin Decoction Alleviated Cerebral Glucose Metabolism Disorder by Regulating Intestinal Microbiota in APP/PS1 Mice.","Gao CY","2024","Chinese journal of integrative medicine","preclinical","article","10.1007/s11655-023-3606-3","37987962",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024190","Population-Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study.","Desai RJ","2025","Clinical pharmacology and therapeutics","nonrandomized_study","article","10.1002/cpt.3583","39935003","PMC13127832",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Validation Study; Research Support, N.I.H., Extramural; research-article; article"],["R0024191","[DPP-4 inhibitors and GLP-1 receptor agonists].","Ogura M","2012","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"23156509",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024192","Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus.","Gouni-Berthold I","2017","Current pharmaceutical design","narrative_review","article","10.2174/1381612823666170609084436","28911306",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024193","Severe, prolonged thrombocytopenia in a patient sensitive to exenatide.","Vallatharasu Y","2019","American journal of hematology","commentary","article","10.1002/ajh.25381","30575104","PMC7942234",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; research-article; article"],["R0024194","Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial.","Cohen RV","2021","Diabetes care","randomized_trial","article","10.2337/dc21-1192","34362818","PMC8740946",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0024195","Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?","Aeng E","2016","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","other_trial","article",null,"30855776",null,null,null,"europepmc; openalex","TRUE","free_to_read","5","FALSE","Review; article"],["R0024196","Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis.","Dimitrios P","2020","Current diabetes reviews","systematic_review","article","10.2174/1573399815666190614141918","31203802",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article; review"],["R0024197","Liraglutide for management of adolescent obesity.","Kelishadi R","2020","Nature reviews. Endocrinology","commentary","article","10.1038/s41574-020-0371-7","32514092",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0024198","β-Glucan-based superabsorbent hydrogel ameliorates obesity-associated metabolic disorders via delaying gastric emptying, improving intestinal barrier function, and modulating gut microbiota.","Jiang Y","2025","International journal of biological macromolecules","other","article","10.1016/j.ijbiomac.2025.140846","39933677",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024199","One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.","Pratley R","2011","International journal of clinical practice","randomized_trial","article","10.1111/j.1742-1241.2011.02656.x","21355967","PMC3085127","ClinicalTrials.gov:NCT00700817","S002361","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024200","Treatment with valproate downregulates the  <i>Agtr2<\/i>  mRNA in rat lungs","Seppa K","2020","bioRxiv","preclinical","preprint","10.1101/2020.05.21.108399",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0024201","Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months.","Moreno Obregón F","2019","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2019.107916","31682882",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; article"],["R0024202","[Glucagon-like peptide-1 analogues in type 2 diabetes: beyond glycemic control].","Gensini GF","2010","Giornale italiano di cardiologia (2006)","other","article",null,"21361049",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Introductory Journal Article; other"],["R0024203","The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen.","Kapitza C","2011","Advances in therapy","randomized_trial","article","10.1007/s12325-011-0044-y","21792552",null,null,"S000333","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024204","Screening, Diagnosis, and Treatment of Cardiometabolic Risk in Persons With Spinal Cord Injury/Disease: A Scoping Review.","Nageswaran L","2025","Archives of rehabilitation research and clinical translation","nonrandomized_study","article","10.1016/j.arrct.2025.100543","41477070","PMC12750439",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0024205","The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice.","Xiong H","2013","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-130584","24008687",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0024206","Semaglutide for type 2 diabetes.",null,"2020","Australian prescriber","narrative_review","article","10.18773/austprescr.2020.046","32921892","PMC7450779",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024207","Controlling the uncontrolled variation in the diet induced obese mouse by microbiomic characterization.","Bondarenko V","2022","Scientific reports","preclinical","article","10.1038/s41598-022-17242-8","35962158","PMC9374709",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024208","Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention.","Park JH","2021","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-021-00739-z","33473176",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0024209","Mesoporous Silica Nanoparticles: Drug Delivery Vehicles for Antidiabetic Molecules.","Sarkar S","2023","Chembiochem : a European journal of chemical biology","narrative_review","article","10.1002/cbic.202200672","36719179",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024210","Dapagliflozin and Liraglutide Therapies Rapidly Enhanced Bone Material Properties and Matrix Biomechanics at Bone Formation Site in a Type 2 Diabetic Mouse Model.","Mieczkowska A","2020","Calcified tissue international","preclinical","article","10.1007/s00223-020-00720-4","32642787",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024211","Development of a Patient-Reported Outcome (PRO) Measure to Assess Emotional Impact of Treatment for Type 2 Diabetes.","Boye KS","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-023-01426-0","37351820","PMC10363102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024212","US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity.","Gomez G","2018","International journal of obesity (2005)","other","article","10.1038/ijo.2017.287","29151591","PMC6082126",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0024213","Decrease in {beta}-cell proliferation precedes apoptosis during diabetes development in bio-breeding/worcester rat: beneficial role of Exendin-4.","Pérez-Arana G","2010","Endocrinology","preclinical","article","10.1210/en.2009-1113","20410202",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024214","[Body weight and bone/calcium metabolism. The effect of incretin hormones on bone and calcium metabolism.].","Kinoshita Y","2018","Clinical calcium","preclinical","article",null,"29950546",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024215","The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome.","Drucker DJ","2019","ACS pharmacology & translational science","preclinical","article","10.1021/acsptsci.9b00016","32219218","PMC7088900",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0024216","Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.","Barrera JG","2009","Diabetes","preclinical","article","10.2337/db09-0281","19741167","PMC2780868",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024217","The efficacy of placebo-adjusted taspoglutide on body weight reduction in clinical trials.","Li HQ","2015","Die Pharmazie","systematic_review","article","10.31083/ph.2015.4716","25997251",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0024218","Effect of Stabilizers on Encapsulation Efficiency and Release Behavior of Exenatide-Loaded PLGA Microsphere Prepared by the W/O/W Solvent Evaporation Method.","Park H","2019","Pharmaceutics","other","article","10.3390/pharmaceutics11120627","31771254","PMC6955873",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024219","The Influence of Anti-Diabetic Drugs on Prostate Cancer.","Knura M","2021","Cancers","narrative_review","article","10.3390/cancers13081827","33921222","PMC8068793",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024220","[Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes].","Scheen AJ","2013","Revue medicale de Liege","other","article",null,"24396969",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0024221","[Effects of exenatide lar in type 2 diabetes mellitus and obesity].","Sierra Poyatos R","2014","Nutricion hospitalaria","nonrandomized_study","article","10.3305/nh.2015.31.1.8283","25561121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0024222","Fusion pore regulation by cAMP/Epac2 controls cargo release during insulin exocytosis.","Guček A","2019","eLife","preclinical","article","10.7554/elife.41711","31099751","PMC6557626",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024223","Monotherapy with liraglutide - Points to be focussed.","Thangaraju P","2019","Journal of family medicine and primary care","nonrandomized_study","article","10.4103/jfmpc.jfmpc_435_19","31463296","PMC6691422",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; letter; article"],["R0024224","Modifiable statin characteristics associated with potential statin-related prescribing cascades.","Wang GH","2023","Pharmacotherapy","nonrandomized_study","article","10.1002/phar.2883","37771303",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024225","Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.","Gordon M","2021","Canadian journal of diabetes","preclinical","article","10.1016/j.jcjd.2020.11.003","33388277",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024226","Isoprenoid Derivatives of Lysophosphatidylcholines Enhance Insulin and GLP-1 Secretion through Lipid-Binding GPCRs.","Drzazga A","2021","International journal of molecular sciences","preclinical","article","10.3390/ijms22115748","34072220","PMC8197866",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024227","Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes.","Tanday N","2020","The Journal of endocrinology","preclinical","article","10.1530/joe-19-0451","31977315",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024228","Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review.","Yousef CC","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.108871","34052248",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; review"],["R0024229","GLP-1 receptors are involved in the GLP-1 (7-36) amide-induced modulation of glucose homoeostasis, emesis and feeding in Suncus murinus (house musk shrew).","Lu Z","2020","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2020.173528","32871177",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024230","Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.","Leung M","2016","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/1479164116629352","26993495",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0024231","Investigation of the haemodynamic effects of exenatide in healthy male subjects.","Mendis B","2012","British journal of clinical pharmacology","randomized_trial","article","10.1111/j.1365-2125.2012.04214.x","22320349","PMC3477345",null,"S000231","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024232","Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis.","Marzioni M","2007","Gastroenterology","preclinical","article","10.1053/j.gastro.2007.04.007","17631146",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0024233","Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.","Cheong YH","2012","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2011.12.004","22177947",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0024234","[Incretins as new therapeutic targets of type 2 diabetes].","Puig-Domingo M","2007","Revista clinica espanola","narrative_review","article","10.1157/13107949","17662202",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024235","Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice.","Tentolouris A","2020","Current medicinal chemistry","other","article","10.2174/0929867326666190119154152","30663560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024236","Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.","Athauda D","2019","JAMA neurology","randomized_trial","article","10.1001/jamaneurol.2018.4304","30640362","PMC6459135",null,"S000204","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024237","Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.","Kushner RF","2020","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.22794","32441473","PMC7318657","ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT03611582; ClinicalTrials.gov:NCT03548987; ClinicalTrials.gov:NCT03693430","S000144; S000214; S000521; S000988; S001740","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024238","Liraglutide does not provide sustainable results for weight improvement in adolescents with obesity.","Brady C","2022","Archives of disease in childhood. Education and practice edition","randomized_trial","article","10.1136/archdischild-2020-319807","32988963",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Comment; article"],["R0024239","Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics.","Sun C","2013","Journal of medicinal chemistry","preclinical","article","10.1021/jm401418s","24144329",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024240","Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.","Meloni AR","2013","Cardiovascular diabetology","randomized_trial","article","10.1186/1475-2840-12-48","23522121","PMC3622579","ClinicalTrials.gov:NCT00637273; ClinicalTrials.gov:NCT00641056; ClinicalTrials.gov:NCT00676338","S000402; S001768; S001966","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; research-article; article"],["R0024241","Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada.","Skovgaard R","2015","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2015.05.496","26186809",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024242","Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications.","Byrne CD","2022","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14484","34324263",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024243","Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice.","Varin EM","2020","JCI insight","preclinical","article","10.1172/jci.insight.140418","32663193","PMC7455127",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024244","Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.","Hunt B","2017","Advances in therapy","other_trial","article","10.1007/s12325-017-0502-2","28281218","PMC5435780",null,"S001328","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0024245","Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis.","Ben-Shlomo S","2013","Digestive diseases and sciences","preclinical","article","10.1007/s10620-012-2353-7","22918684",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024246","Treatment of Diabetes Mellitus in Children and Adolescents","Yau M","2000","MDText.com, Inc., South Dartmouth (MA)","narrative_review","article",null,"25905313",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0024247","Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice.","Krass M","2012","Acta neuropsychiatrica","preclinical","article","10.1111/j.1601-5215.2012.00648.x","25286994",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024248","Acupuncture and moxibustion as effective treatments for simple obesity in children: a meta-analysis.","Cui F","2025","American journal of translational research","systematic_review","article","10.62347/gwmp1676","40225998","PMC11982837",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0024249","Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.","Chae YN","2015","PloS one","preclinical","article","10.1371/journal.pone.0144064","26633898","PMC4669177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024250","Pharmacology of Berberine and its Metabolites, is it the natures Ozempic or Imatinib?","Singh NK","2023","bioRxiv","other","preprint","10.1101/2023.08.05.552100",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; article; preprint"],["R0024251","Type II diabetes mellitus: a review on recent drug based therapeutics.","Padhi S","2020","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2020.110708","32927252",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024252","Management of type 2 diabetes in patients with heart failure.","Aguilar D","2008","Current treatment options in cardiovascular medicine","randomized_trial","article","10.1007/s11936-008-0039-4","19026177",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0024253","GLP-1 and weight loss: unraveling the diverse neural circuitry.","Kanoski SE","2016","American journal of physiology. Regulatory, integrative and comparative physiology","narrative_review","article","10.1152/ajpregu.00520.2015","27030669","PMC4888559",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0024254","Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.","Toth PP","2011","Postgraduate medicine","other_trial","article","10.3810/pgm.2011.07.2303","21680988",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024255","Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).","Méndez M","2020","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.9b01071","31596080",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024256","Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein.","Zhou W","2020","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00292.2020","32723174","PMC7839242",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024257","Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.","Garber A","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2010.01356.x","21205128","PMC3084519",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0024258","The Role of Glucagon-Like Peptide 1 Receptor PET/CT With Ga-68-NODAGA-exendin in Localising an Insulinoma: Lessons From a Clinical Case","Grigoriadou V","2021","Journal of the Endocrine Society","other","article",null,null,"PMC8265906",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0024259","Cardiology: What You May Have Missed in 2023.","Alfraih A","2024","Annals of internal medicine","other_trial","article","10.7326/m24-0581","38621242",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0024260","[Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].","Goodall G","2011","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","randomized_trial","article","10.1016/j.endonu.2011.04.005","21719364",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024261","Managing insulin resistance: role of liraglutide.","Kalra S","2010","Clinical pharmacology : advances and applications","other","article","10.2147/cpaa.s10496","22291496","PMC3262368",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024262","ACTUALITIES IN ENDOCRINE PHARMACOLOGY: ADVANCES IN THE DEVELOPMENT OF ORAL FORMULATIONS FOR CALCITONIN AND SEMAGLUTIDE.","Hamza A","2020","Acta endocrinologica (Bucharest, Romania : 2005)","other_trial","article","10.4183/aeb.2020.383","33363667","PMC7748241",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0024263","In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.","Lipscombe LL","2019","Annals of internal medicine","randomized_trial","article","10.7326/acpj201909170-027","31525761",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; editorial"],["R0024264","The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis.","Zhang P","2019","African health sciences","systematic_review","article","10.4314/ahs.v19i3.35","32127832","PMC7040262",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0024265","DA-JC1 improves learning and memory by antagonizing Aβ31-35-induced circadian rhythm disorder.","Wang L","2019","Molecular brain","preclinical","article","10.1186/s13041-019-0432-9","30744651","PMC6371467",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0024266","Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.","Penfornis A","2008","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(08)73399-8","18640590",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024267","Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.","Blonde L","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13978","31984646","PMC7317838",null,"S000022","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024268","The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF).","Metsärinne K","2022","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2021.12.012","34972659",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024269","Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors.","Gong N","2014","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2014.04.007","24747181",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024270","Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.","Kodera R","2014","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2013.12.049","24342619",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024271","Systemic delivery of proteins using novel peptides via the sublingual route.","Wu J","2024","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2024.02.042","38423473",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024272","Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.","Li Y","2003","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m209423200","12409292",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024273","Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats.","Malendowicz LK","2003","International journal of molecular medicine","other_trial","article","10.3892/ijmm.12.4.593","12964040",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; article"],["R0024274","Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness.","Ahuja V","2016","Current diabetes reports","narrative_review","article","10.1007/s11892-016-0744-4","27076180",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024275","Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes.","Meiring S","2022","American journal of physiology. Endocrinology and metabolism","nonrandomized_study","article","10.1152/ajpendo.00337.2021","34957857","PMC8858668",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0024276","Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada.","Wharton S","2020","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.420","32874678","PMC7448201",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0024277","Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.","Sumida Y","2020","International journal of molecular sciences","other_trial","article","10.3390/ijms21061907","32168769","PMC7139365",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0024278","Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis.","Yang L","2021","Mediators of inflammation","other","article","10.1155/2021/5568159","33854404","PMC8019627",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024279","Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys.","Ai G","2008","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2007.11.016","18180118",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024280","GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells.","Ogata M","2014","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2014.03.143","24709081",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024281","Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.","Wu Y","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.118025","32598933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024282","Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.","Matza LS","2017","BMC health services research","other","article","10.1186/s12913-017-2648-7","29178918","PMC5702146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024283","ADROPIN - POTENTIAL LINK IN CARDIOVASCULAR PROTECTION FOR OBESE MALE TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH LIRAGLUTIDE.","Tičinović Kurir T","2020","Acta clinica Croatica","other","article","10.20471/acc.2020.59.02.19","33456123","PMC7808222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024284","The association between liver function tests abnormalities and type 2 diabetes mellitus patients in Saudi Arabia: a cross-sectional study.","Mehyar N","2025","Frontiers in clinical diabetes and healthcare","nonrandomized_study","article","10.3389/fcdhc.2025.1617641","40799261","PMC12339336",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024285","Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.","Wharton S","2020","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.419","32874673","PMC7448157",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024286","Pre-Conception Weight Loss Improves Reproductive, Metabolic and Kidney Health in Obese Mice and Their Offspring","Rodrigo N","2021","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvab048.658",null,"PMC8089919",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0024287","Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.","Ahmed HM","2018","European heart journal","randomized_trial","article","10.1093/eurheartj/ehx668","29236983",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0024288","Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia.","Briyal S","2014","Neuroscience","preclinical","article","10.1016/j.neuroscience.2014.09.064","25301749",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024289","Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches.","Kakde SP","2024","Cureus","narrative_review","article","10.7759/cureus.69129","39398771","PMC11467241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024290","Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials.","Li HQ","2015","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","systematic_review","article","10.1016/j.jsps.2014.11.008","26106272","PMC4475818",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0024291","Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility.","Hellström PM","2010","Vitamins and hormones","other_trial","article","10.1016/b978-0-12-381517-0.00012-6","21094906",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0024292","Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day.","Chao AM","2019","Clinical obesity","randomized_trial","article","10.1111/cob.12340","31691531",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024293","Optimizing diabetes treatment in the presence of obesity.","Esquivel MA","2017","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.84.s1.04","28708480",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024294","Fluorescent blood-brain barrier tracing shows intact leptin transport in obese mice.","Harrison L","2019","International journal of obesity (2005)","preclinical","article","10.1038/s41366-018-0221-z","30283080","PMC6760579",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024295","The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials.","Zobel EH","2022","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14578","34676658","PMC9297860",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024296","Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic.","Haluzík M","2018","Vnitrni lekarstvi","nonrandomized_study","article","10.36290/vnl.2018.053","29791170",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Observational Study; article"],["R0024297","Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance.","Pujadas G","2016","Endocrine reviews","narrative_review","article","10.1210/er.2016-1078","27732058",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024298","Drugs for Diabetes: It's No Longer Just About Controlling Blood Sugar.","Reinke T","2017","Managed care (Langhorne, Pa.)","other_trial","article",null,"28661833",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; article"],["R0024299","Repairing effects of liraglutide on spinal cord injury in rats via PI3K/AKT/ENOS signaling pathway.","Qi TM","2020","Journal of biological regulators and homeostatic agents","preclinical","article","10.23812/20-263-l","33198445",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0024300","Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.","Mayfield K","2016","Journal of psychopharmacology (Oxford, England)","narrative_review","article","10.1177/0269881115625496","26801056",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024301","Preclinical update on regulation of intracranial pressure in relation to idiopathic intracranial hypertension.","Eftekhari S","2019","Fluids and barriers of the CNS","preclinical","article","10.1186/s12987-019-0155-4","31767019","PMC6878629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024302","The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity.","Gilijamse PW","2021","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","other","article","10.1016/j.soard.2021.04.022","34083134",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024303","Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.","Horowitz M","2012","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2012.02.016","22446097",null,null,"S001327; S002367","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024304","Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.","Kim TH","2012","Bioconjugate chemistry","preclinical","article","10.1021/bc300265n","23116483",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024305","Insufficient sleep predicts poor weight loss maintenance after 1 year.","Bogh AF","2023","Sleep","randomized_trial","article","10.1093/sleep/zsac295","36472579","PMC10171640","ClinicalTrials.gov:NCT04122716; EudraCT:2015-005585-32","S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024306","Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.","Horowitz M","2008","Diabetes, obesity & metabolism","commentary","article","10.1111/j.1463-1326.2008.00861.x","18435773",null,null,"S001065","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024307","Addressing Drug Shortages at Mediclinic Parkview Hospital: A ‎Five-Year Study of ‎Challenges, Impact, and Strategies.","Sallam M","2024","Cureus","nonrandomized_study","article","10.7759/cureus.76377","39867009","PMC11760331",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024308","Amylin as a Future Obesity Treatment.","Dehestani B","2021","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes21071","34929674","PMC8735818",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024309","Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.","Abuirmeileh A","2012","The Journal of pharmacy and pharmacology","preclinical","article","10.1111/j.2042-7158.2011.01394.x","22471359",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024310","Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors.","Vesa CM","2020","Diagnostics (Basel, Switzerland)","narrative_review","article","10.3390/diagnostics10050314","32429441","PMC7277953",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024311","Ultrarapid-Acting Microneedles for Immediate Delivery of Biotherapeutics.","You J","2023","Advanced materials (Deerfield Beach, Fla.)","preclinical","article","10.1002/adma.202304582","37547966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024312","Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.","Boye KS","2018","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2018.07.002","30093131",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Comparative Study; Journal Article; article"],["R0024313","Performance of the ChatGPT large language model for decision support in community pharmacy.","Shin E","2024","British journal of clinical pharmacology","nonrandomized_study","article","10.1111/bcp.16215","39191671",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Preprint; article; preprint"],["R0024314","Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?","Sumida Y","2020","International journal of molecular sciences","narrative_review","article","10.3390/ijms21144939","32668632","PMC7404115",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024315","Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study.","Dang-Tan T","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-019-00739-3","31820328","PMC6965544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0024316","Insulin and the polycystic ovary syndrome.","Macut D","2017","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2017.06.011","28646699",null,null,"S001582","pubmed; europepmc","FALSE","paywalled","1",null,"Journal Article; Review"],["R0024317","Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial.","Vellanki P","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13587","30456796","PMC7231260",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024318","Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin.","Saad ZA","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.117725","32348835",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0024319","[Not Available].","Salvador J","2014","Medicina clinica","commentary","article","10.1016/s0025-7753(14)70100-9","25326835",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Editorial; Introductory Journal Article"],["R0024320","Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.","Patel MB","2012","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","case_report","article","10.2146/ajhp110567","22644981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0024321","FGF21 as a therapeutic reagent.","Zhao Y","2012","Advances in experimental medicine and biology","preclinical","article","10.1007/978-1-4614-0887-1_14","22396172",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024322","GLP-1: physiological effects and potential therapeutic applications.","Aaboe K","2008","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2008.00853.x","18435775",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024323","Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.","Baker DJ","2014","British journal of pharmacology","preclinical","article","10.1111/bph.12498","24772483","PMC3966744",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024324","Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus.","Yan P","2011","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2011.02.030","21458097",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024325","Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.","Chan DC","2013","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-013-0309-9","23345190",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0024326","Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats.","Han WN","2013","Neurobiology of aging","preclinical","article","10.1016/j.neurobiolaging.2012.04.009","22592020",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024327","Role and development of GLP-1 receptor agonists in the management of diabetes.","Chia CW","2009","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article",null,"20148188","PMC2818016",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0024328","A spectroscopic and molecular dynamics study on the aggregation process of a long-acting lipidated therapeutic peptide: the case of semaglutide.","Venanzi M","2020","Soft matter","other","article","10.1039/d0sm01011a","32780784",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024329","A Multidisciplinary Approach for Improving Quality of Life and Self-Management in Diabetic Kidney Disease: A Crossover Study.","Helou N","2020","Journal of clinical medicine","randomized_trial","article","10.3390/jcm9072160","32650548","PMC7408890",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0024330","Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists.","Hoang HN","2015","Journal of medicinal chemistry","other","article","10.1021/acs.jmedchem.5b00166","25839426",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024331","Glucagon and glucagon-like peptide receptors as drug targets.","Estall JL","2006","Current pharmaceutical design","preclinical","article","10.2174/138161206776873671","16712485",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024332","Dulaglutide-induced cerebral venous thrombosis in a patient with type 2 diabetes mellitus.","Rajput R","2018","BMJ case reports","case_report","article","10.1136/bcr-2018-226346","30413453","PMC6229099",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0024333","Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study.","Knudsen JS","2019","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.12919","30893522",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0024334","Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.","Sangle GV","2012","Endocrinology","preclinical","article","10.1210/en.2011-1732","22186413",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024335","Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study.","Gudmundsdottir V","2018","PloS one","nonrandomized_study","article","10.1371/journal.pone.0189886","29293525","PMC5749727",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024336","Once weekly exenatide: efficacy, tolerability and place in therapy.","Wysham C","2013","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12084","23425609",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024337","Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.","Luo Y","2019","Drug design, development and therapy","preclinical","article","10.2147/dddt.s224688","31819375","PMC6896910",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024338","Peptide binding at the GLP-1 receptor.","Mann R","2007","Biochemical Society transactions","narrative_review","article","10.1042/bst0350713","17635131",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024339","Parkinson's disease in women: Mechanisms underlying sex differences.","Vaidya B","2021","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2021.173862","33450279",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024340","Diabetes Drug AIDS Weight Reduction in Adults.","Rosenberg K","2021","The American journal of nursing","other","article","10.1097/01.naj.0000751148.10877.e4","33872273",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024341","Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.","Ogawa N","2004","Diabetes","preclinical","article","10.2337/diabetes.53.7.1700","15220193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0024342","Pharmacotherapy for gestational diabetes.","Patti AM","2018","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2018.1509955","30136869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024343","Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study.","Temelkova N","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-0603-9","30919317","PMC6531544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0024344","Selective Colocalization of GHSR and GLP-1R in a Subset of Hypothalamic Neurons and Their Functional Interaction.","Aguggia J","2024","Endocrinology","preclinical","article","10.1210/endocr/bqae160","39737802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024345","Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus-a choice determined by metabolic phenotype.","Sinclair AJ","2022","Aging clinical and experimental research","narrative_review","article","10.1007/s40520-022-02142-8","35723859","PMC9208348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024346","Exendin-4, a GLP-1 receptor agonist, stimulates pituitary-adrenocortical axis in the rat: Investigations into the mechanism(s) underlying Ex4 effect.","Malendowicz LK","2003","International journal of molecular medicine","preclinical","article","10.3892/ijmm.12.2.237","12851724",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024347","Gastrointestinal peptides and nonalcoholic fatty liver disease.","Tarantino G","2020","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000514","31815784",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024348","Expression and purification of exendin-4 dimer in Escherichia coli and its interaction with GLP-1 receptor in vitro.","Yi L","2006","Protein and peptide letters","preclinical","article","10.2174/092986606777841226","17073729",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024349","Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function.","Koole C","2012","The Journal of biological chemistry","other","article","10.1074/jbc.m111.309369","22147709","PMC3281730",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024350","The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice.","Ørgaard A","2017","Diabetologia","preclinical","article","10.1007/s00125-017-4315-2","28551699","PMC5552842",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024351","Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.","Wang Q","2002","Diabetologia","preclinical","article","10.1007/s00125-002-0828-3","12242459",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0024352","Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).","Brown-Frandsen K","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13677","30793465","PMC6504564",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024353","The interaction between human serum albumin and antidiabetic agent - exenatide: determination of the mechanism binding and effect on the protein conformation by fluorescence and circular dichroism techniques - Part I.","Śliwińska-Hill U","2020","Journal of biomolecular structure & dynamics","other","article","10.1080/07391102.2019.1630007","31232198",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024354","The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials.","Nikfar S","2012","Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques","systematic_review","article","10.18433/j3g883","22365085",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; review"],["R0024355","GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose.","Iwasaki Y","2018","Nature communications","preclinical","article","10.1038/s41467-017-02488-y","29317623","PMC5760716",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024356","Saxagliptin plus metformin combination therapy.","Scheen AJ","2012","Expert review of endocrinology & metabolism","other","article","10.1586/eem.11.98","30764006",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024357","Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes.","Odegard PS","2009","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmsott.s4444","21437127","PMC3048016",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0024358","[Diabetic Kidney Disease - How to Protect the Kidney?].","Brenner S","2019","Deutsche medizinische Wochenschrift (1946)","other","article","10.1055/a-0662-1919","31163466",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024359","Reversal of Long-Term Weight Regain After Roux-en-Y Gastric Bypass Using Liraglutide or Surgical Revision. A Prospective Study.","Horber FF","2021","Obesity surgery","other","article","10.1007/s11695-020-04856-y","32691401","PMC7808975",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024360","Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia.","Cohen V","2008","Clinical toxicology (Philadelphia, Pa.)","case_report","article","10.1080/15563650701517707","17852164",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0024361","The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release.","Saponaro C","2019","Cell reports","preclinical","article","10.1016/j.celrep.2019.07.009","31390560",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024362","Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?","Patoulias DI","2019","Przeglad gastroenterologiczny","commentary","article","10.5114/pg.2019.88172","31649796","PMC6807668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0024363","Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials.","Raccah D","2014","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2013.10.003","24246441",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024364","Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass.","Abegg K","2013","Physiology & behavior","randomized_trial","article","10.1016/j.physbeh.2013.03.027","23562866","PMC3745783",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; Randomized Controlled Trial; article"],["R0024365","GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function.","Zaïmia N","2023","Cell reports","preclinical","article","10.1016/j.celrep.2023.113326","37897727",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024366","Protease-resistant glucagon like peptide-1 analogs with long-term anti-diabetes type 2 activity.","Li H","2009","Advances in experimental medicine and biology","other","article","10.1007/978-0-387-73657-0_204","19400271",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; book-chapter"],["R0024367","The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats.","Murthy SN","2010","Diabetes & vascular disease research","preclinical","article","10.1177/1479164109360269","20382777",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0024368","Liraglutide is an effective drug for the treatment of obesity also in real life.","Piantanida E","2020","Journal of endocrinological investigation","commentary","article","10.1007/s40618-020-01348-9","32613571",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0024369","Metformin alleviates glucolipotoxicity-induced pancreatic β cell ferroptosis through regulation of the GPX4/ACSL4 axis.","Sun Y","2023","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2023.175967","37549729",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024370","[Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2].","Musch A","2006","Medizinische Monatsschrift fur Pharmazeuten","narrative_review","article",null,"16550880",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024371","DPP-4 inhibitors in clinical practice.","Palalau AI","2009","Postgraduate medicine","narrative_review","article","10.3810/pgm.2009.11.2079","19940419",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024372","Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.","Busch RS","2017","International journal of clinical practice","randomized_trial","article","10.1111/ijcp.13029","29044860",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0024373","Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.","Peradze N","2019","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-019-0945-7","31672146","PMC6823961","ClinicalTrials.gov:NCT02944500","S001466","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0024374","Antidiabetic Therapy in the Treatment of NASH","Sumida Y","2020","Preprints.org","other_trial","preprint","10.20944/preprints202001.0171.v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0024375","Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.","Larsen PJ","2008","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2008.00865.x","18333889",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0024376","Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.","Otowa-Suematsu N","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0505-2","30206903","PMC6167300",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0024377","The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.","Eckerle Mize DL","2013","Current diabetes reports","narrative_review","article","10.1007/s11892-013-0377-9","23479200",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; article"],["R0024378","Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.","Lee C","2013","International journal of nanomedicine","preclinical","article","10.2147/ijn.s48197","23976850","PMC3746731",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024379","Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch® among self-injection-naïve patients with type 2 diabetes mellitus in Japan.","Asakura T","2018","Current medical research and opinion","randomized_trial","article","10.1080/03007995.2018.1448260","29504812",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024380","The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror.","Martínez MS","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22179504","34502413","PMC8431704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024381","Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection.","Andari E","2020","Current diabetes reviews","narrative_review","article","10.2174/1573399816666200120122929","31987023",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024382","Liraglutide attenuates palmitate-induced apoptosis via PKA/β-catenin/Bcl-2/Bax pathway in MC3T3-E1 cells.","Cheng L","2024","Naunyn-Schmiedeberg's archives of pharmacology","other","article","10.1007/s00210-023-02572-9","37439807",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Preprint; article; preprint"],["R0024383","The Health System in Costa Rica: Focus on the Management of Diabetes Mellitus.","Chen Ku CH","2023","Cureus","commentary","article","10.7759/cureus.40084","37425606","PMC10327611",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0024384","[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.","Wild D","2006","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article",null,"17138746",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024385","Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.","Payk SL","2015","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2015.04.011","26024569",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0024386","Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.","Maruthur NM","2016","Annals of internal medicine","systematic_review","article","10.7326/m15-2650","27088241",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0024387","Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg.","Tronieri JS","2020","Behaviour research and therapy","randomized_trial","article","10.1016/j.brat.2020.103639","32450367","PMC7336389",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024388","Tf ligand-receptor-mediated exenatide-Zn2+ complex oral-delivery system for penetration enhancement of exenatide.","Zhang L","2018","Journal of drug targeting","preclinical","article","10.1080/1061186x.2018.1455839","29619854",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024389","Functional enhancement of beta cells in transplanted pancreatic islets by secretion signal peptide-linked exendin-4 gene transduction.","Jeong JH","2012","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2012.01.029","22306337",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024390","The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study.","Farokhnia M","2022","Addiction biology","randomized_trial","article","10.1111/adb.13211","36001436","PMC12258501",null,"S000504","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; research-article; article"],["R0024391","Development of novel ligands for peptide GPCRs.","Moran BM","2016","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2016.08.009","27607913",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0024392","A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.","Barrington P","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2011.01364.x","21251178",null,null,"S001958","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024393","Correction to: Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers.","Cui H","2020","European journal of drug metabolism and pharmacokinetics","notice","article","10.1007/s13318-020-00611-x","32253720",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0024394","GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.","Liu J","2015","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.2580","25066109",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024395","Clinical use of GLP-1 agonists and DPP4 inhibitors.","Tuch BE","2016","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","narrative_review","article","10.1016/j.pan.2015.05.465","26138513",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024396","Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.","Tian B","2009","Transplantation","preclinical","article","10.1097/tp.0b013e3181933261","19155973",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024397","Prescribing costs of hypoglycaemic agents and associations with metabolic control in Wales; a national analysis of primary care data.","Taylor PN","2022","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.14908","35766972","PMC9545615",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024398","Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery.","Wharton S","2019","Clinical obesity","other","article","10.1111/cob.12323","31183988","PMC6771702",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024399","Metformin exerts synergistic anti-proliferative effects with liraglutide in human umbilical vein endothelial cells (HUVECs).","Shadboorestan A","2022","Iranian journal of basic medical sciences","other","article","10.22038/ijbms.2022.64117.14117","35656067","PMC9150808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024400","Advances in the treatment of type 2 diabetes mellitus.","Israili ZH","2011","American journal of therapeutics","narrative_review","article","10.1097/mjt.0b013e3181afbf51","19834322",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024401","Update on: effects of anti-diabetic drugs on bone metabolism.","Mabilleau G","2020","Expert review of endocrinology & metabolism","randomized_trial","article","10.1080/17446651.2020.1831911","33059497",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0024402","Compared to commercially insured patients, Medicare advantage patients adopt newer diabetes drugs more slowly and adhere to them less.","Flory JH","2021","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.245","34277970","PMC8279610",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0024403","Repression of sterol regulatory element-binding protein 1-c is involved in the protective effects of exendin-4 in pancreatic β-cell line.","Hong SW","2012","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2012.07.004","22820130",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024404","Albumin-binding domain extends half-life of glucagon-like peptide-1.","Tan H","2021","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2020.173650","33049303",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024405","INTERACTIONS OF METFORMIN AND OTHER MEDICATIONS IN REDUCING THE ODDS OF AGE-RELATED MACULAR DEGENERATION IN A COHORT OF PATIENTS WITH DIABETES.","Shaw L","2024","Retina (Philadelphia, Pa.)","nonrandomized_study","article","10.1097/iae.0000000000003949","37782954",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0024406","Detailed protocol for evaluation of dynamic perifusion of human islets to assess β-cell function.","Bentsi-Barnes K","2011","Islets","protocol","article","10.4161/isl.3.5.15938","21811103","PMC3219161",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024407","Evaluating the usability and safety of the semaglutide single-dose pen-injectors through summative (human factors) usability testing.","Klonoff DC","2021","Journal of diabetes investigation","other","article","10.1111/jdi.13429","33034163","PMC8169358",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Evaluation Study; Journal Article; research-article; article"],["R0024408","Pharmacologic treatment options for type 1 diabetes: what's new?","Nally LM","2019","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2019.1597705","30892094","PMC6488361",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0024409","GLP-1R, a novel receptor in platelets, and the use of liraglutide in the treatment of obesity in women with PCOS","Kahal H","2013","University of Hull","other","article",null,null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0024410","Sitagliptin: a review.","Subbarayan S","2011","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2011.580738","21651449",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024411","Exenatide: a novel approach for treatment of type 2 diabetes.","Mikhail N","2006","Southern medical journal","narrative_review","article","10.1097/01.smj.0000240730.86237.b6","17195423",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024412","Newly designed modifier prolongs the action of short-lived peptides and proteins by allowing their binding to serum albumin.","Shechter Y","2012","Bioconjugate chemistry","preclinical","article","10.1021/bc3000854","22759320",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024413","Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion.","Takahashi H","2015","Diabetes","preclinical","article","10.2337/db14-0576","25315008",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024414","Milk Exosome-Liposome Hybrid Vesicles with Self-Adapting Surface Properties Overcome the Sequential Absorption Barriers for Oral Delivery of Peptides.","Xiao P","2024","ACS nano","other","article","10.1021/acsnano.4c02560","39099105",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024415","Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming.","Villalba A","2020","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2020.00258","32477262","PMC7237704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024416","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions.","Hermel M","2024","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-024-01193-8","38441801",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0024417","Liraglutide in clinical practice: dosing, safety and efficacy.","Peterson GE","2010","International journal of clinical practice. Supplement","narrative_review","article","10.1111/j.1742-1241.2010.02498.x","20949699",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024418","Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart.","Sonne DP","2008","Regulatory peptides","preclinical","article","10.1016/j.regpep.2007.10.001","17976835",null,null,"S000566","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024419","Effects of obesity induced by high-calorie diet and its treatment with exenatide on muscarinic acetylcholine receptors in rat hippocampus.","Silva MFP","2019","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2019.113630","31491414",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024420","Entry of exendin-4 into brain is rapid but may be limited at high doses.","Kastin AJ","2003","International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity","preclinical","article","10.1038/sj.ijo.0802206","12629557",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; article"],["R0024421","Liraglutide",null,"2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"31643791",null,null,null,"europepmc","TRUE",null,null,null,"Book; Review"],["R0024422","[IDegLira receives extended approval].","Red","2015","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-015-3487-2","26349737",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0024424","In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatide.","Menzel C","2018","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2018.03.018","29574041",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024425","Non-alcoholic fatty liver diseases: current challenges and future directions.","Roeb E","2021","Annals of translational medicine","narrative_review","article","10.21037/atm-20-3760","33987424","PMC8106107",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024426","From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.","Dicembrini I","2011","Experimental diabetes research","preclinical","article","10.1155/2011/898913","21747834","PMC3124298",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Evaluation Study; Journal Article; Review; review-article; article"],["R0024427","GLP-1 analogue CJC-1131 prevents amyloid β protein-induced impirments of spatial memory and synaptic plasticity in rats.","Zhang SX","2017","Behavioural brain research","preclinical","article","10.1016/j.bbr.2017.03.018","28315374",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024428","Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.","Meneilly GS","2017","Diabetes care","randomized_trial","article","10.2337/dc16-2143","28188240",null,"ClinicalTrials.gov:NCT01798706","S000904","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0024429","Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.","Dupré J","2004","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2003-032001","15240633",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024430","Effectiveness of exendin-4 on blood glucose level of Streptozotocin-induced diabetic mice ","Zhu Min","2004","Shanghai Medical Journal","preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Research article"],["R0024431","Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique.","Mager DE","2004","The Journal of pharmacology and experimental therapeutics","other","article","10.1124/jpet.104.069765","15199095","PMC9973385",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0024432","Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.","Chang HY","2015","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.3770","25851403",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0024433","Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?","Snaith JR","2020","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2019.11.007","31822381",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0024434","A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.","Al-Sabah S","2003","British journal of pharmacology","other","article","10.1038/sj.bjp.0705453","12970080","PMC1574045",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024435","Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.","Meier JJ","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12968","28407415",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0024436","Liraglutide Treatment Ameliorates Neurotoxicity Induced by Stable Silencing of Pin1.","Bianchi M","2019","International journal of molecular sciences","other","article","10.3390/ijms20205064","31614723","PMC6829573",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024437","Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients.","Singh P","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13619","30565376",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0024438","Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial.","Yin TT","2018","Nutrition & metabolism","randomized_trial","article","10.1186/s12986-018-0295-6","30302121","PMC6167818","ClinicalTrials.gov:NCT02325960","S000058","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0024439","Therapeutic Potential of Liraglutide for Diabetes-Periodontitis Comorbidity: Killing Two Birds with One Stone.","Yang M","2022","Journal of diabetes research","preclinical","article","10.1155/2022/8260111","35845316","PMC9279102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024440","Liraglutide chronic treatment prevents development of tolerance to antiseizure effects of diazepam in genetically epilepsy prone rats.","De Sarro C","2022","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2022.175098","35700834",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024441","Type 2 diabetes medication and HbA1c levels in North Karelia Finland, 2013-2019.","Wikström K","2022","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.14866","35506179","PMC9543455",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024442","Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model.","Narushima D","2016","PeerJ","nonrandomized_study","article","10.7717/peerj.1753","26989609","PMC4793323",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024443","Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents.","Chen H","2014","Diabetologia","preclinical","article","10.1007/s00125-013-3132-5","24337156",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024444","Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway.","Yang P","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s206867","31308717","PMC6614831",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024445","Delayed Hypersensitivity Reaction to Liraglutide: A Case Report.","Carvallo A","2020","Journal of investigational allergology & clinical immunology","case_report","article","10.18176/jiaci.0521","32301438",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0024446","A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.","Pollock RF","2019","Journal of comparative effectiveness research","nonrandomized_study","article","10.2217/cer-2018-0073","30644328",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024447","Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.","Batchuluun B","2014","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2013.10.025","24401231",null,null,"S000291","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024448","SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?","Bloomgarden ZT","2015","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","commentary","article","10.4158/ep151013.co","26484408",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0024449","Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study.","Gorgojo-Martínez JJ","2019","International journal of clinical practice","nonrandomized_study","article","10.1111/ijcp.13399","31397946",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0024450","Association between Symptoms of Depression and Generalised Anxiety Disorder Evaluated through PHQ-9 and GAD-7 and Anti-Obesity Treatment in Polish Adult Women.","Witaszek T","2024","Nutrients","other","article","10.3390/nu16152438","39125320","PMC11314622",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; preprint; article"],["R0024451","Effects of Metformin on Renal Function, Cardiac Function, and Inflammatory Response in Diabetic Nephropathy and Its Protective Mechanism.","Zhang Z","2022","Disease markers","other","article","10.1155/2022/8326767","35692885","PMC9187446",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024452","Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization.","Jensen CB","2018","Endocrinology","preclinical","article","10.1210/en.2017-00812","29095968",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Evaluation Study; Journal Article; article"],["R0024453","Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.","Thomsen RW","2015","Diabetologia","randomized_trial","article","10.1007/s00125-015-3698-1","26277380",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024454","From Disease and Patient Heterogeneity to Precision Medicine in Type 1 Diabetes.","den Hollander NHM","2022","Frontiers in medicine","narrative_review","article","10.3389/fmed.2022.932086","35903316","PMC9314738",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024455","Combination therapy of GLP-1 analogues and insulin: do the benefits outweigh the costs?","Versmissen J","2014","The Netherlands journal of medicine","commentary","article",null,"26219754",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; editorial"],["R0024456","Liraglutide alleviates vascular injury in diabetic rabbits with lower limb vascular stenosis through regulation of RCAN1.","Ding HX","2022","European review for medical and pharmacological sciences","preclinical","article","10.26355/eurrev_202206_28968","35731069",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024457","Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.","Xiao X","2020","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13187","31758850","PMC7232276","ClinicalTrials.gov:NCT01644500; ClinicalTrials.gov:NCT01648582","S001064; S001404","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; research-article; article"],["R0024458","Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage.","Hou J","2012","Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","preclinical","article","10.1038/jcbfm.2012.133","22968320","PMC3519414",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0024459","Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.","Vijiaratnam N","2024","Movement disorders clinical practice","nonrandomized_study","article","10.1002/mdc3.14191","39169806","PMC11542297",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024460","The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review.","Frezza EE","2007","Digestive diseases and sciences","narrative_review","article","10.1007/s10620-006-9096-2","17268838",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024461","Colonic Delivery of α-Linolenic Acid by an Advanced Nutrient Delivery System Prolongs Glucagon-Like Peptide-1 Secretion and Inhibits Food Intake in Mice.","Kamakura R","2022","Molecular nutrition & food research","preclinical","article","10.1002/mnfr.202100978","34882959","PMC9285029",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024462","Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.","Hirano T","2016","Journal of diabetes investigation","preclinical","article","10.1111/jdi.12446","27186361","PMC4854510",null,"S000443","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0024463","More Unnecessary Imaginary Worlds - Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes.","Langley PC","2020","Innovations in pharmacy","other","article","10.24926/iip.v11i1.2420","34017637","PMC8132533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024464","Available Treatments and Adjunctive Therapies for Polycystic Ovarian Syndrome (PCOS) Patients of Reproductive Age: A Scoping Review.","Cochran L","2024","Cureus","nonrandomized_study","article","10.7759/cureus.70501","39479136","PMC11524647",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Scoping Review; review-article; article"],["R0024465","PET/MRI enables simultaneous in vivo quantification of β-cell mass and function.","Michelotti FC","2020","Theranostics","preclinical","article","10.7150/thno.33410","31903128","PMC6929626",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024466","Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.","Sharma A","2021","ESC heart failure","randomized_trial","article","10.1002/ehf2.13348","34061470","PMC8318489",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; brief-report; article"],["R0024467","Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor α Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease.","Shamim D","2017","Journal of central nervous system disease","preclinical","article","10.1177/1179573517722512","28811745","PMC5536370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024468","Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?","Majumdar SK","2013","Endocrine","narrative_review","article","10.1007/s12020-013-9884-3","23354728",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024469","[Pharmacological treatment of NASH].","Serfaty L","2019","Presse medicale (Paris, France : 1983)","other_trial","article","10.1016/j.lpm.2019.09.015","31757735",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0024470","Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.","McClean PL","2014","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2013.08.005","23973293",null,null,"S000116","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024471","Diabetes update: new drugs to manage type 2 diabetes.","Erlich DR","2013","FP essentials","narrative_review","article",null,"23690375",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024472","Breast Cancer, Diabetes Mellitus And Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations","Takigami NH","2021","Research Square","other","preprint","10.21203/rs.3.rs-370359/v1",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0024473","[Safety and tolerability of oral hypoglycemic therapies in type 2 diabetes mellitus patients at high cardiovascular risk].","Ambrosio G","2017","Giornale italiano di cardiologia (2006)","narrative_review","article","10.1714/2700.27609","28631762",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024474","Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1.","Zhao T","2019","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","other","article","10.1016/j.biopha.2019.109224","31349139",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024475","Impact of Glp-1RA on Heart Rate, Blood Pressure and Hypertension Among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.","Sun F","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","systematic_review","article","10.1016/j.jval.2014.08.010","27202544",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; article"],["R0024476","Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide.","Abramson A","2019","Journal of pharmaceutical sciences","other_trial","article","10.1016/j.xphs.2019.04.022","31034907","PMC6708477",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0024477","Renoprotective effects of dulaglutide in patients with T2DM and CKD.","Sorensen CM","2018","Nature reviews. Nephrology","commentary","article","10.1038/s41581-018-0055-x","30171207",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0024478","Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.","Jabbour SA","2018","Diabetes care","randomized_trial","article","10.2337/dc18-0680","30082326","PMC6150435","ClinicalTrials.gov:NCT02229396","S000791","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024479","Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system.","Lee J","2012","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2012.05.029","22634071",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024480","Inducing human parthenogenetic embryonic stem cells into islet‑like clusters.","Li J","2014","Molecular medicine reports","preclinical","article","10.3892/mmr.2014.2588","25241773","PMC4227434",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024481","Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents.","Pitocco D","2008","Journal of endocrinological investigation","narrative_review","article","10.1007/bf03346373","18475058",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024482","Liraglutide Alleviates Cognitive Deficit in db/db Mice: Involvement in Oxidative Stress, Iron Overload, and Ferroptosis.","An JR","2022","Neurochemical research","preclinical","article","10.1007/s11064-021-03442-7","34480710",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024483","Analysis of the effect of liraglutide on glycemic variability in patients with type 2 diabetes.","Xing Y","2020","Endocrine journal","systematic_review","article","10.1507/endocrj.ej19-0530","31996492",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; article"],["R0024484","Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?","Tacelli M","2018","Pharmaceuticals (Basel, Switzerland)","randomized_trial","article","10.3390/ph11040121","30413050","PMC6316860",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0024485","Clinical Use of DPP-4 Inhibitors.","Gallwitz B","2019","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2019.00389","31275246","PMC6593043",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024486","A Novel Interacting Protein SERP1 Regulates the N-Linked Glycosylation and Function of GLP-1 Receptor in the Liver.","Xiao Y","2017","Journal of cellular biochemistry","other","article","10.1002/jcb.26207","28597972",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024487","Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States.","Cai J","2016","Journal of medical economics","nonrandomized_study","article","10.1080/13696998.2016.1208208","27356271",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0024488","Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties.","Cai X","2020","Bioorganic chemistry","preclinical","article","10.1016/j.bioorg.2019.103538","31901754",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024489","Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.","Koehler JA","2009","Diabetes","preclinical","article","10.2337/db09-0626","19509017","PMC2731518",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024490","Exenatide reduces cardiomyocyte apoptosis by stimulating adiponectin secretion and activating APPL1-AMPK-PPARα axis.","Lei X","2019","Annals of translational medicine","preclinical","article","10.21037/atm.2019.06.17","31475196","PMC6694259",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024491","The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series.","Vukotic R","2020","Annals of internal medicine","randomized_trial","article","10.7326/l20-0041","32449885",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Case Reports; Letter; article"],["R0024492","Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update.","Hanefeld M","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-020-00855-5","32564335","PMC7376805",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024493","Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.","Guerci B","2019","Diabetes, obesity & metabolism","other","article","10.1111/dom.13606","30520252",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024494","Pyoderma gangrenosum associated with dulaglutide therapy.","Hamann CR","2019","International journal of dermatology","case_report","article","10.1111/ijd.14272","30345551",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0024495","Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway.","Zhou J","2019","Endocrine","preclinical","article","10.1007/s12020-018-1826-7","30535743",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024496","DPP-4 inhibitors: pharmacological differences and their clinical implications.","Ceriello A","2014","Expert opinion on drug safety","narrative_review","article","10.1517/14740338.2014.944862","25171159",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024497","Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease.","Sanchez RA","2015","World journal of diabetes","narrative_review","article","10.4239/wjd.v6.i11.1186","26380062","PMC4564814",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024498","Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.","Lozano-Ortega G","2016","Current medical research and opinion","systematic_review","article","10.1185/03007995.2015.1135110","26700585",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0024499","Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.","Tronieri JS","2020","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-019-0348-6","30926955","PMC6766432","ClinicalTrials.gov:NCT02911818","S000426","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024500","Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir.","Pedersen KM","2022","Translational research : the journal of laboratory and clinical medicine","other","article","10.1016/j.trsl.2021.08.005","34428585",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024501","Venoms classification and therapeutic uses: a narrative review.","Morsy MA","2023","European review for medical and pharmacological sciences","narrative_review","article","10.26355/eurrev_202302_31408","36876699",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; review"],["R0024502","A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory.","Bonora E","2020","Nutrition, metabolism, and cardiovascular diseases : NMCD","nonrandomized_study","article","10.1016/j.numecd.2020.08.018","32998821",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024503","PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.","Field BC","2010","Diabetes","randomized_trial","article","10.2337/db09-1859","20357366","PMC2889762",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024504","Oral Semaglutide.","Hughes S","2020","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd19-0079","31975761","PMC6969659",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024505","[2-Sulfo-9-fluorenylmethoxycarbonyl]3-exendin-4-a long-acting glucose-lowering prodrug.","Shechter Y","2003","Biochemical and biophysical research communications","preclinical","article","10.1016/s0006-291x(03)00715-0","12745087",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024506","Monitoring Utilization Trends of Glucose-Lowering Drugs for Type 2 Diabetes in Older Adults by Frailty Status","Gopalakrishnan C","2021","Innovation in aging","nonrandomized_study","article","10.1093/geroni/igab046.804",null,"PMC8682216",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0024507","Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity.","Cuomo A","2018","Frontiers in psychiatry","other","article","10.3389/fpsyt.2018.00784","30728788","PMC6351474",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0024508","LUXendins reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics","Ast J","2019","bioRxiv","other","preprint","10.1101/557132",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0024509","Advancements in pharmacotherapy options for treating diabetes ‎in children and adolescents.","Daniali M","2024","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2023.2290491","38078451",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0024510","Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry.","Zhang JF","2013","Journal of pharmaceutical analysis","other","article","10.1016/j.jpha.2012.12.007","29403823","PMC5760979",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024511","[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].","Jermendy G","2011","Orvosi hetilap","narrative_review","article","10.1556/oh.2011.29207","21893477",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024512","Discovering the most impactful treatments for aluminum phosphide cardiotoxicity gleaned from systematic review of animal studies.","Aghebat-Bekheir S","2024","Human & experimental toxicology","systematic_review","article","10.1177/09603271241290922","39378909",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0024513","New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering?","Jayawardene D","2014","Heart, lung & circulation","randomized_trial","article","10.1016/j.hlc.2014.05.007","24996388",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0024514","Hyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it?","Barbetti F","2016","Clinical diabetes and endocrinology","preclinical","article","10.1186/s40842-016-0029-5","28702245","PMC5471666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024515","Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.","Funch D","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13739","30945402","PMC6772183",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024516","EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.","Schernthaner G","2016","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2016.04.037","27210264",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article"],["R0024517","Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention.","Cheng F","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s229838","31849507","PMC6911808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024518","LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: the National Health and Nutrition Examination Surveys 2007-2016.","Fan W","2020","Cardiovascular drugs and therapy","other_trial","article","10.1007/s10557-020-07032-7","32621045",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article"],["R0024519","Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.","Martin JH","2011","Internal medicine journal","narrative_review","article","10.1111/j.1445-5994.2011.02439.x","21299778",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024520","The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.","von Scholten BJ","2015","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2015.08.007","26345339",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Comparative Study; Journal Article"],["R0024521","A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells.","Hattori Y","2010","Diabetologia","other","article","10.1007/s00125-010-1831-8","20593161",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; article"],["R0024522","Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling.","Kalra S","2012","North American journal of medical sciences","nonrandomized_study","article","10.4103/1947-2714.104315","23272306","PMC3530320",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; letter; article"],["R0024523","Enhanced oral and pulmonary delivery of biomacromolecules via amplified transporter targeting.","Xiao X","2024","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2024.04.026","38641020",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024524","Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes.","Ali AM","2020","Diabetes care","randomized_trial","article","10.2337/dc18-2460","32220916","PMC7411279","ClinicalTrials.gov:NCT02324842","S001422","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024525","Calcineurin signaling regulates human islet {beta}-cell survival.","Soleimanpour SA","2010","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m110.154955","20943662","PMC3000987",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024526","Associations of Adipokine Levels with Levels of Remnant Cholesterol: the Multi-Ethnic Study of Atherosclerosis (MESA).","Quispe R","2023","medRxiv : the preprint server for health sciences","other","article","10.1101/2023.04.24.23289072","37162928","PMC10168480",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint; article"],["R0024527","Comparative effects of lifestyle modification, metformin and exenatide/glargine combination therapy on daily glycaemic fluctuation in the setting of near-normoglycaemia.","Retnakaran R","2020","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.13943","31858681",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0024528","Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives.","Yanase T","2017","Reproductive medicine and biology","narrative_review","article","10.1002/rmb2.12039","29259475","PMC5715889",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024529","[Treatment strategy for elderly diabetic patient with insulin or GLP-1 receptor agonist].","Ando Y","2013","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"24397172",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0024530","Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.","Shaw JE","2017","Diabetes, obesity & metabolism","other","article","10.1111/dom.13022","28573708","PMC5697639",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; brief-report; article"],["R0024531","Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better.","Sanada J","2021","Scientific reports","preclinical","article","10.1038/s41598-020-80894-x","33446799","PMC7809053",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024532","Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study.","Liao YN","2022","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2022.978814","36160410","PMC9500198",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024533","Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.","Fuechtenbusch M","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13658","30737891",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024534","Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study.","Iwasaki T","2018","Diabetology international","nonrandomized_study","article","10.1007/s13340-018-0348-0","30603366","PMC6224913","UMIN:UMIN000023245",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024535","Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes.","Bergenstal RM","2022","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2021.108106","35131155",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0024536","Control of beta cell function and proliferation in mice stimulated by small-molecule glucokinase activator under various conditions.","Nakamura A","2012","Diabetologia","preclinical","article","10.1007/s00125-012-2521-5","22456697",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024537","Liraglutide protects renal mesangial cells against hyperglycemia‑mediated mitochondrial apoptosis by activating the ERK‑Yap signaling pathway and upregulating Sirt3 expression.","Li J","2019","Molecular medicine reports","other","article","10.3892/mmr.2019.9946","30816450",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retracted Publication; article"],["R0024538","Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging.","Femminella GD","2014","Alzheimer's & dementia : the journal of the Alzheimer's Association","preclinical","article","10.1016/j.jalz.2013.12.012","24529526",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024539","Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice.","Singh A","2019","Endocrine","preclinical","article","10.1007/s12020-019-01891-3","30904998",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024540","Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus.","Scuderi MA","2018","Domestic animal endocrinology","other_trial","article","10.1016/j.domaniend.2018.04.003","30015124",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Veterinary; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024541","Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress.","Lei Y","2017","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2017.05.062","28549747",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0024542","A novel strategy for production of liraglutide precursor peptide and development of a new long-acting incretin mimic.","Ahmadi S","2022","PloS one","preclinical","article","10.1371/journal.pone.0266833","35500009","PMC9060347",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024543","Potential therapeutic applications of multifunctional host-defense peptides from frog skin as anti-cancer, anti-viral, immunomodulatory, and anti-diabetic agents.","Conlon JM","2014","Peptides","preclinical","article","10.1016/j.peptides.2014.04.019","24793775",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0024544","Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.","Scheen AJ","2020","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(20)30079-6","32333865",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0024545","Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS).","Li Y","2019","Life sciences","narrative_review","article","10.1016/j.lfs.2019.04.046","31029778",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024546","The changing therapeutic armamentarium for patients with type 1 diabetes.","Comee M","2016","Current opinion in endocrinology, diabetes, and obesity","other_trial","article","10.1097/med.0000000000000239","26835799",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0024547","Chemogenetic inhibition of the lateral hypothalamus in rats: A simple but robust tool with high translational relevance to facilitate the development of central nervous system-targeted gene therapies","Kovács P","2023","Research Square","preclinical","preprint","10.21203/rs.3.rs-3620463/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0024548","GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes.","Gao H","2007","Endocrine","preclinical","article","10.1007/s12020-007-9011-4","17992607",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024549","Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.","McCrimmon RJ","2020","Diabetologia","randomized_trial","article","10.1007/s00125-019-05065-8","31897524","PMC6997246","ClinicalTrials.gov:NCT03136484","S001847; S002095","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024550","Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.","Yajima T","2018","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2017.12.005","29366733",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024551","Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.","Ponirakis G","2020","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2020-001420","32576561","PMC7312325",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024552","A model of controlled acute hyperglycemia in rats: Effects of insulin and glucagon-like peptide-1 analog.","Saha JK","2006","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.105.093534","16280413",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024553","A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus.","Thondam SK","2012","Clinical endocrinology","case_report","article","10.1111/j.1365-2265.2012.04368.x","22356092",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; Research Support, Non-U.S. Gov't; article"],["R0024554","Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution.","Al-Musawe L","2021","European journal of clinical pharmacology","nonrandomized_study","article","10.1007/s00228-021-03107-y","33743016",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0024555","Incretin-related drug therapy in heart failure.","Vest AR","2015","Current heart failure reports","other_trial","article","10.1007/s11897-014-0232-6","25323108",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0024556","Efficacy and Cardiovascular Safety of DPP-4 Inhibitors.","Subrahmanyan NA","2021","Current drug safety","systematic_review","article","10.2174/1574886315999200819150544","32819262",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0024557","Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.","Hansotia T","2007","The Journal of clinical investigation","preclinical","article","10.1172/jci25483","17187081","PMC1705821",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024558","[Combined treatment of insulin and GLP-1 analogs: what do we expect?].","de Kalbermatten B","2014","Revue medicale suisse","narrative_review","article",null,"25004768",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0024559","Design of Potent and Proteolytically Stable Oxyntomodulin Analogs.","Muppidi A","2016","ACS chemical biology","preclinical","article","10.1021/acschembio.5b00787","26727558","PMC4861236",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024560","Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.","GRADE Study Research Group","2022","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa2200436","36129997","PMC9832916","ClinicalTrials.gov:NCT01794143","S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0024561","Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions.","Holmes GM","2009","The Journal of physiology","preclinical","article","10.1113/jphysiol.2009.175067","19675064","PMC2768027",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0024562","Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man.","Boess F","2013","Journal of molecular endocrinology","preclinical","article","10.1530/jme-12-0186","23463748",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024563","Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.","Gallwitz B","2012","Clinical medicine insights. Endocrinology and diabetes","narrative_review","article","10.4137/cmed.s7274","22879795","PMC3411498",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0024564","Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation.","Williams DL","2006","Diabetes","preclinical","article","10.2337/db06-0558","17130484",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0024565","Dulaglutide for type 2 diabetes.",null,"2018","Australian prescriber","narrative_review","article","10.18773/austprescr.2018.052","30410215","PMC6202295",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024566","Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.","Fontés G","2010","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2009.12.020","20092903","PMC2834862",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024567","Development and validation of a rapid high-performance liquid chromatography method for the quantification of exenatide.","Bachhav YG","2011","Biomedical chromatography : BMC","preclinical","article","10.1002/bmc.1526","20878660",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024568","Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.","Li Y","2022","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2022.1003263","36353233","PMC9637657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; systematic-review; review"],["R0024569","Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.","Scheen AJ","2014","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(14)72689-8","25554070",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024570","The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.","Yamada C","2008","Endocrinology","preclinical","article","10.1210/en.2007-1292","18039776",null,null,"S001459","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024571","Liraglutide protects from renal damage via Akt-mTOR pathway in rats with diabetic kidney disease.","Liao TT","2019","European review for medical and pharmacological sciences","preclinical","article","10.26355/eurrev_201908_18638","31389583",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024572","GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.","Margulies KB","2014","Circulation. Heart failure","protocol","article","10.1161/circheartfailure.114.000346","25028349","PMC4102890",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0024573","Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.","Pantalone KM","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13252","29430801","PMC5969314","ClinicalTrials.gov:NCT01191268; ClinicalTrials.gov:NCT02152371","S000446; S001198","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024574","Complement 1q-like-3 protein inhibits insulin secretion from pancreatic β-cells via the cell adhesion G protein-coupled receptor BAI3.","Gupta R","2018","The Journal of biological chemistry","preclinical","article","10.1074/jbc.ra118.005403","30228187","PMC6254345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024575","In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice.","Suen PM","2006","The international journal of biochemistry & cell biology","preclinical","article","10.1016/j.biocel.2005.08.005","16172015",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024576","Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.","Köhne S","2024","Expert opinion on emerging drugs","nonrandomized_study","article","10.1080/14728214.2024.2342951","38606899",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0024577","Analysis of the protective mechanism of liraglutide on retinopathy based on diabetic mouse model.","Wu L","2019","Saudi journal of biological sciences","preclinical","article","10.1016/j.sjbs.2019.09.032","31889801","PMC6923456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024578","Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973-981.","Monnier L","2016","Diabetes care","randomized_trial","article","10.2337/dc16-1133","27660130",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Letter; Comment; article"],["R0024579","Incretin hormones and insulin sensitivity.","Hansen PA","2005","Trends in endocrinology and metabolism: TEM","other","article","10.1016/j.tem.2005.03.002","15860408",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024580","Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study.","Patti AM","2019","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2019.02.006","30759365",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0024581","A cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release in mouse pancreatic beta cells.","Kang G","2005","The Journal of physiology","preclinical","article","10.1113/jphysiol.2005.087510","15860526","PMC3583090",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0024582","Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.","Hunt B","2017","Advances in therapy","notice","article","10.1007/s12325-017-0543-6","28523624","PMC5487865",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0024583","Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.","Nauck MA","2019","Diabetes care","randomized_trial","article","10.2337/dc19-0415","31399438","PMC7364668","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0024584","Noninsulin pharmacological management of type 1 diabetes mellitus.","Garg V","2011","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.83053","21847455","PMC3152180",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0024585","Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.","Paul S","2012","Diabetes, obesity & metabolism","other","article","10.1111/j.1463-1326.2012.01609.x","22510305",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024586","Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers.","Gunning K","2020","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2020.26.9.1077","32857647","PMC10391108",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0024587","Are proton pump inhibitors a new antidiabetic drug? A cross sectional study.","Boj-Carceller D","2011","World journal of diabetes","other","article","10.4239/wjd.v2.i12.217","22174957","PMC3238490",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024588","Simultaneous quantification of intracellular and secreted active and inactive glucagon-like peptide-1 from cultured cells.","Amao M","2015","Analytical biochemistry","other","article","10.1016/j.ab.2014.11.009","25461479",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024589","Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).","Yamada Y","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12945","28345162","PMC5573929","ClinicalTrials.gov:NCT02200991","S001003","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024590","Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973-981.","O'Brien KD","2016","Diabetes care","randomized_trial","article","10.2337/dci16-0021","27660131",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Letter; Comment; article"],["R0024591","Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy.","Liu W","2019","Experimental and therapeutic medicine","systematic_review","article","10.3892/etm.2019.7577","31258671","PMC6566113",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0024592","Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.","van Can J","2014","International journal of obesity (2005)","randomized_trial","article","10.1038/ijo.2013.162","23999198","PMC4052428","ClinicalTrials.gov:NCT00978393","S001351; S001387","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024593","Liraglutide: a new treatment for type 2 diabetes.","Vilsboll T","2009","Drugs of today (Barcelona, Spain : 1998)","narrative_review","article","10.1358/dot.2009.45.2.1336104","19343230",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024594","Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.","Martin B","2012","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m112.387316","22822065","PMC3442511",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; research-article; article"],["R0024595","Metabolic and digestive response to food ingestion in a binge-feeding lizard, the Gila monster (Heloderma suspectum).","Christel CM","2007","The Journal of experimental biology","preclinical","article","10.1242/jeb.004820","17872997",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0024596","The Influence of Liraglutide for Heart Failure: A Meta-Analysis of Randomized Controlled Trials.","Zhang Y","2019","The heart surgery forum","systematic_review","article","10.1532/hsf.2513","31895026",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0024597","BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.","Giannoukakis N","2007","Current opinion in investigational drugs (London, England : 2000)","other_trial","article",null,"17907061",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0024598","GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.","Ahrén B","2004","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","narrative_review","article","10.1055/s-2004-826178","15655721",null,null,"S001538","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0024599","Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.","Drucker DJ","2013","Diabetes","preclinical","article","10.2337/db13-0822","23818527","PMC3781450",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; discussion; article"],["R0024600","Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes.","Tseng CH","2016","European journal of clinical investigation","nonrandomized_study","article","10.1111/eci.12570","26584246",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024601","Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1.","Deshmukh NJ","2024","Clinical and experimental pharmacology & physiology","preclinical","article","10.1111/1440-1681.13854","38527859",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024602","The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes.","Inagaki N","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12758","27488246","PMC5129571",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; brief-report; article"],["R0024603","Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.","Harrison SA","2020","Contemporary clinical trials","protocol","article","10.1016/j.cct.2020.106174","33039693",null,"ClinicalTrials.gov:NCT02970942","S000922","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; article"],["R0024604","Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway.","Ratner C","2019","Diabetes","preclinical","article","10.2337/db18-1009","30936142","PMC6610020",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024605","GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration.","Ackeifi C","2020","Science translational medicine","preclinical","article","10.1126/scitranslmed.aaw9996","32051230","PMC9945936",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024606","The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management.","Sabouret P","2020","European heart journal. Cardiovascular pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvaa051","32402065",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024607","Sodium-glucose Co-transporter 2 Inhibitors for the Treatment of Type 2 Diabetes: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines","Amanda S","2019","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"31433607",null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Review; review"],["R0024608","Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin.","Chen P","2021","The Journal of dermatological treatment","preclinical","article","10.1080/09546634.2019.1708853","31868553",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024609","Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD.","Heldens A","2025","JHEP reports : innovation in hepatology","preclinical","article","10.1016/j.jhepr.2025.101404","40496439","PMC12151218",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024610","Liraglutide - Indian Experience.","Anirban M","2018","Indian journal of endocrinology and metabolism","randomized_trial","article","10.4103/ijem.ijem_187_18","30766825","PMC6330852",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0024611","SAT-140 A Drug-Drug Interaction Trial of Oral Semaglutide with Levothyroxine and Multiple Coadministered Tablets","Hauge C","2019","Journal of the Endocrine Society","other_trial","article","10.1210/js.2019-sat-140",null,"PMC6552044",null,null,"europepmc; openalex","TRUE","open_europepmc","5","FALSE","Abstract; article"],["R0024612","Macrovascular Complications in Patients with Diabetes and Prediabetes.","Huang D","2017","BioMed research international","narrative_review","article","10.1155/2017/7839101","29238721","PMC5697393",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024613","Sitagliptin Ameliorates Creb5/lncRNA ENSMUST00000213271-Mediated Vascular Endothelial Dysfunction in Obese Mice.","Zong Y","2024","Cardiovascular drugs and therapy","preclinical","article","10.1007/s10557-023-07436-1","36738369",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024614","Liraglutide for the treatment of type 2 diabetes.","Shyangdan D","2011","Health technology assessment (Winchester, England)","narrative_review","article","10.3310/hta15suppl1/09","21609656",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024615","Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients.","Deng H","2019","Journal of diabetes","other","article","10.1111/1753-0407.12883","30520243","PMC6850147",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0024616","Sustained release and pharmacologic evaluation of human glucagon-like peptide-1 and liraglutide from polymeric microparticles.","Icart LP","2019","Journal of microencapsulation","preclinical","article","10.1080/02652048.2019.1677795","31594428",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024617","Cardiovascular Outcomes with Sodium-glucose Co-transporter 2 Inhibitors: A Review of the Clinical Evidence",null,"2015","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"26677500",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0024618","Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism.","Li L","2011","Molecular medicine (Cambridge, Mass.)","preclinical","article","10.2119/molmed.2011.00051","21785811","PMC3321815",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024619","Kinetic control of Phytic acid/Lixisenatide/Fe (III) ternary nanoparticles assembly process for sustained peptide release.","Wang Y","2022","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2021.121317","34838624",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024620","The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study.","Hage C","2014","Diabetes & vascular disease research","randomized_trial","article","10.1177/1479164114533355","24845072",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0024621","ODP240 Routine Glucose-lowering Therapies and Risk of Adverse Outcomes in COVID-19 Patients with Diabetes: a Network Meta-analysis",null,"2022","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC9624984",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0024622","Synthesis and evaluation of optical and PET GLP-1 peptide analogues for GLP-1R imaging.","Behnam Azad B","2015","Molecular imaging","preclinical","article","10.2310/7290.2014.00057","25762192",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024623","Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4.","Thum A","2002","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","preclinical","article","10.1055/s-2002-29087","12012270",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024624","Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats.","Brand CL","2009","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2009.01049.x","19519868",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024625","Novel pharmaceutical treatments for minimal traumatic brain injury and evaluation of animal models and methodologies supporting their development.","Deselms H","2016","Journal of neuroscience methods","preclinical","article","10.1016/j.jneumeth.2016.02.002","26868733","PMC5878044",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article"],["R0024626","Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.","Wexler DJ","2023","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2023.1487","37213109","PMC10203973","ClinicalTrials.gov:NCT01794143","S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Randomized Controlled Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024627","Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.","Sarraju A","2016","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-016-0558-5","26782825",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024628","Synthesis of CSK-DEX-PLGA Nanoparticles for the Oral Delivery of Exenatide to Improve Its Mucus Penetration and Intestinal Absorption.","Song Y","2019","Molecular pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.8b00809","30601014",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024629","Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway.","Li Z","2019","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2018.12.149","30683312",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024630","Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study.","Liang C","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13597","30474347",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0024631","Clinical and psychological characteristics of liraglutide treatment among patients with type 2 diabetes.","Al Hayek AA","2020","Journal of family medicine and primary care","other","article","10.4103/jfmpc.jfmpc_901_19","32318468","PMC7113983",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024632","Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence.","Caturano A","2021","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2021.108959","34280467",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024633","Obesity-Related Genes Expression in Testes and Sperm Parameters Respond to GLP-1 and Caloric Restriction.","Correia AS","2022","Biomedicines","preclinical","article","10.3390/biomedicines10102609","36289871","PMC9599882",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024634","Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel-group study.","Nyström T","2019","Endocrinology, diabetes & metabolism","randomized_trial","article","10.1002/edm2.58","31008366","PMC6458482",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0024635","A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.","Li H","2019","Journal of diabetes research","randomized_trial","article","10.1155/2019/6423987","31183384","PMC6515022","ClinicalTrials.gov:NCT01644500","S001064","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0024636","Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.","Baggio LL","2004","Diabetes","preclinical","article","10.2337/diabetes.53.suppl_3.s205","15561912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024637","Liraglutide Promotes the Osteogenic Differentiation in MC3T3-E1 Cells via Regulating the Expression of Smad2/3 Through PI3K/Akt and Wnt/β-Catenin Pathways.","Gao L","2018","DNA and cell biology","preclinical","article","10.1089/dna.2018.4397","30403540",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024638","Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.","Crowley MJ","2020","Diabetes care","other_trial","article","10.2337/dc20-0437","32647053","PMC7440910","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0024639","Glucagon-Like Peptide 1 Protects against Hyperglycemic-Induced Endothelial-to-Mesenchymal Transition and Improves Myocardial Dysfunction by Suppressing Poly(ADP-Ribose) Polymerase 1 Activity.","Yan F","2015","Molecular medicine (Cambridge, Mass.)","preclinical","article","10.2119/molmed.2014.00259","25715248","PMC4461581",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024640","Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia.","Albarkah YA","2019","Journal of family medicine and primary care","nonrandomized_study","article","10.4103/jfmpc.jfmpc_372_19","31334156","PMC6618200",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024641","DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.","Wysham C","2011","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2011.03301.x","21434995","PMC3123706","ClinicalTrials.gov:NCT00637273","S000402","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024642","Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.","Philis-Tsimikas A","2019","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2018.11.012","30600137",null,"ClinicalTrials.gov:NCT00308139","S002279","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024643","Effect of New Anti-Diabetic Medications in Combination with Metformin Compared to Sulfonylurea in Combination with Metformin in Patients with Type 2 Diabetes","Desser A","2014","Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH), Oslo, Norway","narrative_review","article",null,"29320023",null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Review; report"],["R0024644","Brain-Defective Insulin Signaling Is Associated to Late Cognitive Impairment in Post-Septic Mice.","Neves FS","2018","Molecular neurobiology","preclinical","article","10.1007/s12035-016-0307-3","27966074",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024645","Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date.","Howell R","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s174568","31118715","PMC6475096",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024646","Metabolic Disorder Therapeutics and their Effects on Memory.","Aggarwal P","2024","CNS & neurological disorders drug targets","narrative_review","article","10.2174/0118715273269329231013074613","37921148",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024647","Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes.","Barnard K","2010","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmsott.s10195","21437106","PMC3047989",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0024648","Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.","Seino Y","2010","Current medical research and opinion","randomized_trial","article","10.1185/03007991003672551","20199137",null,"ClinicalTrials.gov:NCT00393718","S000330","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024649","Acute pancreatitis associated with liraglutide.","Lee PH","2011","The Annals of pharmacotherapy","case_report","article","10.1345/aph.1p714","21487080",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0024650","Albiglutide for the treatment of type 2 diabetes mellitus.","McCarty DJ","2017","The Nurse practitioner","other","article","10.1097/01.npr.0000488718.72389.5c","28085780",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024651","Synaptotagmin-7 phosphorylation mediates GLP-1-dependent potentiation of insulin secretion from β-cells.","Wu B","2015","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.1513004112","26216970","PMC4538675",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024652","Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.","Smits MM","2016","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12593","26500045",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024653","New insights into the pharmacological treatment of pediatric patients with type 2 diabetes.","Urakami T","2018","Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology","other","article","10.1297/cpe.27.1","29403151","PMC5792816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024654","Novel therapeutic agents for the treatment of diabetic kidney disease.","Hartman RE","2020","Expert opinion on investigational drugs","narrative_review","article","10.1080/13543784.2020.1811231","32799584",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024655","Application of DBS for quantitative assessment of the peptide Exendin-4; comparison of plasma and DBS method by UHPLC-MS/MS.","Kehler JR","2010","Bioanalysis","preclinical","article","10.4155/bio.10.108","21083346",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024656","Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer's Disease and Type 2 Diabetes.","Carranza-Naval MJ","2021","Frontiers in aging neuroscience","other_trial","article","10.3389/fnagi.2021.741923","34975451","PMC8716860",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0024657","Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects.","Pang J","2012","Current opinion in lipidology","narrative_review","article","10.1097/mol.0b013e328354c790","22595742",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024658","Incretin mimetics: promising new therapeutic options in the treatment of type 2 diabetes.","Gleeson JM","2005","Journal of managed care pharmacy : JMCP","narrative_review","article","10.18553/jmcp.2005.11.s7.1","16137221","PMC10437539",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0024659","The use of low molecular weight protamine to enhance oral absorption of exenatide.","Zhang L","2018","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2018.05.055","29800739",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0024660","A cross-sectional study of the correlation between diabetic therapy and serum zinc concentrations.","Sakurai M","2022","Diabetology international","other","article","10.1007/s13340-021-00521-6","35059254","PMC8733126",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0024661","Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.","Frías JP","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13296","29573139","PMC5969323",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0024662","Pharmacological Signatures of the Exenatide Nanoparticles Complex Against Myocardial Ischemia Reperfusion Injury.","Zhang Y","2018","Kidney & blood pressure research","preclinical","article","10.1159/000492409","30078011",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024663","Liraglutide prevents diabetes progression in prediabetic OLETF rats.","Guo N","2013","Endocrine journal","preclinical","article","10.1507/endocrj.ej12-0094","22986487",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024664","GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice.","Parlevliet ET","2012","PloS one","preclinical","article","10.1371/journal.pone.0049152","23133675","PMC3487842",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024665","SUN-178 A Not So \"Sweet\" DKA: A Case of Euglycemic Diabetic Ketoacidosis Caused by Dapagliflozin/Liraglutide Combination","Sideri Gugger A","2019","Journal of the Endocrine Society","case_report","article",null,null,"PMC6553086",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0024666","Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.","Mastrandrea LD","2019","Pediatric obesity","randomized_trial","article","10.1111/ijpo.12495","30653847","PMC6590663",null,"S000858","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024667","All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine.","Wittbrodt E","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13145","29083520",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0024668","Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.","Scheen A","2013","Expert opinion on drug safety","randomized_trial","article","10.1517/14740338.2013.793671","23621381",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0024669","Oral delivery system for low molecular weight protamine-dextran-poly(lactic-co-glycolic acid) carrying exenatide to overcome the mucus barrier and improve intestinal targeting efficiency.","Song Y","2019","Nanomedicine (London, England)","preclinical","article","10.2217/nnm-2018-0322","31088322",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024670","SAT-139 Clinical Impact of Oral Semaglutide Compared with Sitagliptin in T2D on Metformin ± Sulfonylurea: The Pioneer 3 Trial","Rosenstock J","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-sat-139",null,"PMC6552181",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0024671","PPARα and PPARβ/δ are negatively correlated with proinflammatory markers in leukocytes of an obese pediatric population.","Vargas-Sánchez K","2020","Journal of inflammation (London, England)","other","article","10.1186/s12950-020-00264-2","33292260","PMC7602348",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; Preprint; article; other"],["R0024672","Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.","Bizino MB","2019","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-019-0857-6","31039778","PMC6492440","ClinicalTrials.gov:NCT01761318","S000566","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024673","Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.","Siddiqui NI","2009","Mymensingh medical journal : MMJ","narrative_review","article",null,"19182763",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024674","[Type 2 diabetes mellitus and obesity: should we treat the obesity or the diabetes?].","García SD","2013","Medicina clinica","narrative_review","article","10.1016/s0025-7753(13)70058-7","24444519",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024675","Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12).","Li J","2022","Frontiers in endocrinology","other","article","10.3389/fendo.2022.858096","35992135","PMC9381955",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024676","Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).","Reed SD","2020","Diabetes care","randomized_trial","article","10.2337/dc19-0950","31806653","PMC7210004","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024677","[The renal protective effect and mechanism of liraglutide in diabetic mice induced by high-fat diet].","Fu C","2019","Zhonghua yi xue za zhi","preclinical","article","10.3760/cma.j.issn.0376-2491.2019.20.012","31154726",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024678","Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.","Li LQ","2019","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej19-0016","31243192",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024679","Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.","Mells JE","2012","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00274.2011","22038829","PMC3341115",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0024680","Dissolving microneedle-assisted long-acting Liraglutide delivery to control type 2 diabetes and obesity.","Rabiei M","2021","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","other","article","10.1016/j.ejps.2021.106040","34655736",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024681","Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.","Wang B","2024","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2024.150170","38797152",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024682","Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1.","Idris I","2002","Biochemical pharmacology","preclinical","article","10.1016/s0006-2952(01)00924-8","11911852",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024683","Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11","Frias J","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.678",null,"PMC8090394",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0024684","Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.","Azim S","2014","Current cardiology reports","narrative_review","article","10.1007/s11886-014-0541-0","25303895",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024685","Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure.","Maringwa J","2021","Clinical pharmacology and therapeutics","systematic_review","article","10.1002/cpt.2130","33280092",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0024686","The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects.","Jiang J","2011","Journal of clinical pharmacology","randomized_trial","article","10.1177/0091270010389468","21273395",null,null,"S000432","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024687","Semaglutide in weight management.","Xiao Y","2019","Lancet (London, England)","commentary","article","10.1016/s0140-6736(18)33195-7","31591979",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0024688","Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.","Verma S","2019","JAMA cardiology","randomized_trial","article","10.1001/jamacardio.2019.3080","31721979","PMC6865601","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024689","In-vitro Metabolite Identification for MEDI7219, an Oral GLP-1 Peptide, using LC-MS/MS with CID and EAD Fragmentation","Liu K","2024","bioRxiv","preclinical","preprint","10.1101/2024.07.26.605352",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0024690","GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts.","Xu G","2006","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2005.11.007","16406191",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, N.I.H., Extramural; article"],["R0024691","The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany.","Bramlage P","2020","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2020-001486","32719080","PMC7388887",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024692","Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.","Li L","2014","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj.g2366","24736555","PMC3987051",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0024693","Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus.","Vergès B","2018","Arteriosclerosis, thrombosis, and vascular biology","other_trial","article","10.1161/atvbaha.118.310990","30026275",null,"ClinicalTrials.gov:NCT02721888","S000705","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024694","Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.","Liu J","2017","International journal of endocrinology","other_trial","article","10.1155/2017/9401606","29358950","PMC5735665","ClinicalTrials.gov:NCT03297879","S001093","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0024695","Review: in type 2 diabetes, GLP-1 agonists plus basal insulin reduce HbA1c without increasing hypoglycemia.","Ospina NS","2015","Annals of internal medicine","narrative_review","article","10.7326/acpjc-2015-162-2-006","25599366",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0024696","The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathy-A Review.","Matuszewski W","2021","Journal of clinical medicine","narrative_review","article","10.3390/jcm10040705","33670143","PMC7916896",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024697","Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.","Fujishima Y","2012","Cardiovascular diabetology","other","article","10.1186/1475-2840-11-107","22973968","PMC3459720",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024698","Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.","Imprialos KP","2018","Cardiovascular & hematological disorders drug targets","narrative_review","article","10.2174/1871529x18666180206144342","29412121",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024699","Renin-Angiotensin System in Liver Metabolism: Gender Differences and Role of Incretins.","Mastoor Z","2022","Metabolites","narrative_review","article","10.3390/metabo12050411","35629915","PMC9143858",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024700","What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?","Kuhre RE","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.694284","34168620","PMC8218725",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0024701","Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study.","Yang G","2020","International journal of clinical pharmacology and therapeutics","randomized_trial","article","10.5414/cp203730","32729820",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024702","Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes.","McGill JB","2009","Postgraduate medicine","other","article","10.3810/pgm.2009.01.1954","19179813",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024703","Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies.","Bell DSH","2019","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13512","30144274",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024704","Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells.","Movassat J","2002","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2002-020137","12364473",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024705","SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions.","Gharaibeh NE","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s212715","31308716","PMC6613609",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024706","The Regulation of Peripheral Metabolism by Gut-Derived Hormones.","Sun EWL","2018","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2018.00754","30662430","PMC6328484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024707","Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.","Wang L","2011","Peptides","preclinical","article","10.1016/j.peptides.2011.03.018","21453734",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024708","Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study.","Gerstein HC","2022","Diabetes care","other_trial","article","10.2337/dc22-0453","35817031",null,"ClinicalTrials.gov:NCT01147250","S001991","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; other; article"],["R0024709","[New oral hypoglycemic drugs in diabetic kidney disease].","Dylewska M","2017","Wiadomosci lekarskie (Warsaw, Poland : 1960)","narrative_review","article",null,"29533912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024710","Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).","Yu M","2017","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2017.10.002","29110972",null,"ClinicalTrials.gov:NCT02152371","S000446","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024711","Dulaglutide and renal protection in type 2 diabetes.","Cherney DZI","2018","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(18)30125-6","29910025",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; article"],["R0024712","Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.","Inoue K","2011","Cardiovascular diabetology","other","article","10.1186/1475-2840-10-109","22132774","PMC3260096",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024713","AWARE. A web application to rapidly assess cardiovascular risk in Type 2 Diabetes Mellitus.","Berra CC","2022","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-2134695/v2",null,null,null,null,"europepmc","FALSE","free_to_read","4",null,"Preprint"],["R0024714","Phosphorylation Sites of the Gastric Inhibitory Polypeptide Receptor (GIPR) Revealed by Trapped-Ion-Mobility Spectrometry Coupled to Time-of-Flight Mass Spectrometry (TIMS-TOF MS).","Brown KA","2023","Journal of the American Chemical Society","other","article","10.1021/jacs.3c09078","38091482","PMC10842860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0024715","OR14-2 Liraglutide Treatment in Overweight and Obese Patients with Type 1 Diabetes: A 26 weeks Randomized Controlled Trial","Dandona P","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-or14-2",null,"PMC6555035",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0024716","SUN-221 Effects of Liraglutide on Obesity-Associated Functional Hypogonadism in Men: A Randomized, Testosterone Replacement Treatment-Controlled Study","Jensterle Sever M","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-sun-221",null,"PMC6553253",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; conference-abstract"],["R0024717","An unusual case of a generalised cutaneous drug reaction to liraglutide.","Bovijn L","2019","European journal of dermatology : EJD","case_report","article","10.1684/ejd.2019.3691","31903972",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0024718","Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.","Lam S","2006","Cardiology in review","randomized_trial","article","10.1097/01.crd.0000223655.16253.e4","16788334",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0024719","GLP-1 improves neuropathology after murine cold lesion brain trauma.","DellaValle B","2014","Annals of clinical and translational neurology","preclinical","article","10.1002/acn3.99","25493285","PMC4241798",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024720","The Effects of a Weight-Loss Herbal Formula RCM-107 and Its Eight Individual Ingredients on Glucagon-Like Peptide-1 Secretion-An In Vitro and In Silico Study.","Luo S","2020","International journal of molecular sciences","preclinical","article","10.3390/ijms21082854","32325890","PMC7215673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024721","Liraglutide Is Protective against Brain Injury in Mice with Febrile Seizures by Inhibiting Inflammatory Factors.","Wang X","2022","Computational and mathematical methods in medicine","preclinical","article","10.1155/2022/7563281","35529274","PMC9076292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retracted Publication; research-article; article"],["R0024722","[DPP-4 inhibitors, GLP-1 receptor agonists].","Hamasaki A","2011","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"21766677",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024723","Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction.","Mafong DD","2008","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-008-0009-z","18366986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review; article"],["R0024724","Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.","Edwards CM","2001","American journal of physiology. Endocrinology and metabolism","other","article","10.1152/ajpendo.2001.281.1.e155","11404233",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024725","Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial",null,"2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article",null,null,"PMC9067834","ClinicalTrials.gov:NCT02863328","S000251","europepmc","TRUE","open_europepmc","1",null,"Abstract"],["R0024726","The effectiveness of lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with different insulin regimes: a multi-center observational study.","Božek T","2018","Diabetology & metabolic syndrome","other","article","10.1186/s13098-018-0321-x","29563974","PMC5850977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024727","Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.","Suhrs HE","2019","International journal of cardiology","other_trial","article","10.1016/j.ijcard.2018.12.005","30773266",null,"ClinicalTrials.gov:NCT02602600","S002372","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024728","Acute Kidney Injury Occurring in a Patient Initiated on Dulaglutide.","Taylor SR","2018","The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","commentary","article","10.1177/8755122518782155","34861012","PMC6109865",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0024729","Antihyperglycemic Medications and Cardiovascular Risk Reduction.","Anderson SL","2017","European endocrinology","narrative_review","article","10.17925/ee.2017.13.02.86","29632614","PMC5813471",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024730","Utilising the therapeutic potential of xenin and related molecules for diabetes and obesity","Craig S","2020","Ulster University","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0024731","Inheritance of Mildly Activating ABCC8 Mutation From a Mother With MODY Causes Permanent Neonatal Diabetes Mellitus (NDM) in Two Siblings Who Also Carry a Second Inactivating Mutation: Genetic Testing Allows for Improved Treatment With Sulfonylureas (SU)","Salguero Bermonth M","2021","Journal of the Endocrine Society","other","article",null,null,"PMC8089813",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0024732","GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.","Lin J","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12533","26179090",null,"ClinicalTrials.gov:NCT01545570",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024733","A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.","Funch D","2014","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12230","24199745","PMC4237552",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024734","Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.","Nauck MA","2020","Diabetes care","randomized_trial","article","10.2337/dci19-0067","31959650","PMC7411284","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment; article"],["R0024735","Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin.","Hinnen DA","2015","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/diaclin.33.4.175","26487791","PMC4608276",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024736","GIP analogues and the treatment of obesity-diabetes.","Bailey CJ","2020","Peptides","preclinical","article","10.1016/j.peptides.2019.170202","31756366",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024737","Liraglutide in Children and Adolescents with Type 2 Diabetes.","Tamborlane WV","2019","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1903822","31034184",null,"ClinicalTrials.gov:NCT01541215","S000357","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024738","Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.","Jabbour SA","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13206","29316164","PMC5969082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0024739","Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats.","Simonsen L","2007","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00453.2006","17431213",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024740","Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.","Sathyanarayana P","2011","Obesity (Silver Spring, Md.)","other","article","10.1038/oby.2011.152","21660077",null,null,"S000885","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024741","Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.","Seino Y","2009","Current medical research and opinion","randomized_trial","article","10.1185/03007990903372999","19863477",null,"ClinicalTrials.gov:NCT00530309","S002552","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024742","Assisted living: improving glucose control for the functionally independent patient with diabetes.","Zettervall DK","2010","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","case_report","article",null,"20726380",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024743","Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes.","Zweck E","2019","The New England journal of medicine","commentary","article","10.1056/nejmc1913157","31747739",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0024744","Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors.","Giandalia A","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22115808","34071671","PMC8198374",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024745","Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses.","Possidente C","2023","Neuroscience and biobehavioral reviews","narrative_review","article","10.1016/j.neubiorev.2023.105298","37391112",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024746","'A Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Service'.","Perera P","2022","Clinical Medicine Insights. Cardiology","nonrandomized_study","article","10.1177/11795468221133607","36329805","PMC9623351",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024747","Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery.","Zhang C","2020","International journal of pharmaceutics","narrative_review","article","10.1016/j.ijpharm.2020.119441","32442645",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024748","Exenatide improves hypertension in a rat model of the metabolic syndrome.","Laugero KD","2009","Metabolic syndrome and related disorders","preclinical","article","10.1089/met.2008.0095","19320558",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024749","Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc.","Yang Y","2016","PloS one","preclinical","article","10.1371/journal.pone.0156449","27232339","PMC4883776",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024750","Pharmacologic management of weight regain following bariatric surgery.","Lucas E","2022","Frontiers in endocrinology","other","article","10.3389/fendo.2022.1043595","36699042","PMC9868802",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0024751","Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice.","Shi Y","2018","Scientific reports","preclinical","article","10.1038/s41598-018-19170-y","29335533","PMC5768888",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024752","Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.","Tang H","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13232","29369494",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","3","FALSE","Comparative Study; Journal Article; Network Meta-Analysis; article"],["R0024753","New therapeutic options for the management of diabetes.","Sicat BL","2007","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","randomized_trial","article","10.4140/tcp.n.2007.45","17367252",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0024754","Liraglutide protects against diabetes mellitus complicated with focal cerebral ischemic injury by activating mitochondrial ATP-sensitive potassium channels.","Shi N","2019","Neuroreport","preclinical","article","10.1097/wnr.0000000000001225","30889046",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024755","Cost-Effectiveness of Saxagliptin Compared To Glp-1 Analogues As An Add-On To Insulin in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.","Charokopou M","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.711","27200661",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024756","cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells.","Kang G","2001","The Journal of physiology","preclinical","article","10.1111/j.1469-7793.2001.0375c.xd","11600673","PMC2278885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0024757","[Research progresses on interventions of obesity in children and adolescents].","Wan NJ","2023","Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]","other","article","10.3760/cma.j.cn112150-20220608-00592","37165824",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0024758","Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.","Graham GV","2018","Peptides","preclinical","article","10.1016/j.peptides.2017.11.007","29157578",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024759","2018 European Association for the Study of Diabetes.","Alexander W","2018","P & T : a peer-reviewed journal for formulary management","other","article","10.1057/978-1-349-95943-3_346","30410285","PMC6205117",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; meeting-report; article; book-chapter"],["R0024760","Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review.","Camargo Maluf F","2019","Parkinson's disease","systematic_review","article","10.1155/2019/4951379","31871617","PMC6906831",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0024761","Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.","Gydesen S","2017","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00419.2016","28292761",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024762","Emerging and future therapies for nonalcoholic steatohepatitis in adults.","Mintziori G","2016","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2016.1225727","27564402",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024763","Targeting β Cells with Cathelicidin Nanomedicines Improves Insulin Function and Pancreas Regeneration in Type 1 Diabetic Rats.","Cristelo C","2023","ACS pharmacology & translational science","preclinical","article","10.1021/acsptsci.3c00218","37854630","PMC10580391",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024764","DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.","Zhong J","2015","Circulation research","narrative_review","article","10.1161/circresaha.116.305665","25858071","PMC4394189",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0024765","Non-insulin pharmacological therapies for treating type 1 diabetes.","Frandsen CS","2018","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2018.1483339","29991320",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024766","Liraglutide reduces hepatic glucolipotoxicity‑induced liver cell apoptosis through NRF2 signaling in Zucker diabetic fatty rats.","Guo J","2018","Molecular medicine reports","preclinical","article","10.3892/mmr.2018.8919","29693190","PMC5984007",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024767","Linagliptin: from bench to bedside.","Doupis J","2014","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s59523","24851042","PMC4018312",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024768","Non-functional alpha-cell hyperplasia with glucagon-producing NET: a case report.","Cidade-Rodrigues C","2024","Frontiers in endocrinology","case_report","article","10.3389/fendo.2024.1405835","39309109","PMC11412808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0024769","Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?","Dardano A","2020","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2020.108112","32198123",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024770","Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.","Trautmann ME","2017","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2017.06.004","28669463",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0024771","Semaglutide in weight management - Author's reply.","Wilding JPH","2019","Lancet (London, England)","commentary","article","10.1016/s0140-6736(19)31904-x","31591978",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0024772","Exenatide preserves trabecular bone microarchitecture in experimental ovariectomized rat model.","Eminov E","2018","Archives of gynecology and obstetrics","preclinical","article","10.1007/s00404-018-4776-7","29696350",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024773","Using RWE research to extend clinical trials in diabetes: An example with implications for the future.","Seeger JD","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14021","32250529","PMC7216829",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0024774","Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance.","Jung MJ","2014","Endocrinology and metabolism (Seoul, Korea)","nonrandomized_study","article","10.3803/enm.2014.29.4.536","25559577","PMC4285044",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024775","DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.","Wang W","2020","Journal of endocrinological investigation","preclinical","article","10.1007/s40618-019-01153-z","31786794",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024776","Maintenance on a high-fat diet impairs the anorexic response to glucagon-like-peptide-1 receptor activation.","Williams DL","2011","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2011.04.005","21515295","PMC3666166",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0024777","The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome.","Dawson AJ","2019","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2019.00189","31001199","PMC6454834","ISRCTN:ISRCTN81902209",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0024778","Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.","DeKoven M","2014","Advances in therapy","nonrandomized_study","article","10.1007/s12325-014-0098-8","24477354","PMC3930836",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024779","Reducing HbA1c in Type 2 Diabetes Using Digital Twin Technology-Enabled Precision Nutrition: A Retrospective Analysis.","Shamanna P","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-020-00931-w","32975712","PMC7547935",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024780","Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.","Sharma A","2018","ESC heart failure","randomized_trial","article","10.1002/ehf2.12334","30120812","PMC6300815","ClinicalTrials.gov:NCT01800968","S002350","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0024781","Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.","Gomez-Peralta F","2018","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.13769","29943854",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0024782","Mono-ADP-ribosyltransferase as a potential pharmacological drug target in the GLP-1 based therapy of obesity and diabetes mellitus type 2.","Bavec A","2013","Acta chimica Slovenica","narrative_review","article",null,"23878926",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024783","Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.","Suissa K","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14367","33651454",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0024784","Liraglutide in Children and Teens with Type 2 Diabetes.","Javor E","2019","The New England journal of medicine","commentary","article","10.1056/nejmc1912498","31665591",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0024785","Kisspeptin-13 inhibits insulin secretion without affecting glucagon or somatostatin release: study in the perfused rat pancreas.","Silvestre RA","2008","The Journal of endocrinology","preclinical","article","10.1677/joe-07-0454","18252951",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024786","Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.","von Websky K","2013","Vascular health and risk management","narrative_review","article","10.2147/vhrm.s40035","24204157","PMC3818026",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024787","Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.","Zheng S","2019","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej18-0153","30918134",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024788","GPCRs and Insulin Receptor Signaling in Conversation: Novel Avenues for Drug Discovery.","Gupta MK","2019","Current topics in medicinal chemistry","narrative_review","article","10.2174/1568026619666190712211642","31512997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024789","Real World Use of Antidiabetic Drugs in the Years 2011-2017: A Population-Based Study from Southern Italy.","Ingrasciotta Y","2020","International journal of environmental research and public health","nonrandomized_study","article","10.3390/ijerph17249514","33353081","PMC7765957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024790","Liraglutide Effectiveness: Is There a Real-Word Clinical Benefit?","Souza CM","2019","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.22631","31545004",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0024791","Primary and Secondary Binding of Exenatide to Liposomes.","Stulz A","2020","Biophysical journal","other","article","10.1016/j.bpj.2019.12.028","31972156","PMC7002983",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024792","Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: Alternative approaches for treatment of Type 2 diabetes.","Malik F","2022","British journal of pharmacology","narrative_review","article","10.1111/bph.15446","33724441","PMC8820177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; review-article; article"],["R0024793","Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey.","Nouraei H","2021","Canadian journal of diabetes","other","article","10.1016/j.jcjd.2021.02.003","33839025",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024794","Neonatal GLP1R activation limits adult adiposity by durably altering hypothalamic architecture.","Rozo AV","2017","Molecular metabolism","preclinical","article","10.1016/j.molmet.2017.05.006","28702330","PMC5485307",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024795","Albiglutide-induced pancreatitis.","Jain N","2016","Therapeutic advances in drug safety","other_trial","article","10.1177/2042098616667352","27904741","PMC5117154",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Editorial; editorial"],["R0024796","Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.","Jan Maurik van den Heuvel","2020","BMJ open diabetes research & care","notice","article","10.1136/bmjdrc-2019-000705corr1","31958297","PMC6954806",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0024797","Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?","Khoury J","2018","Endocrine regulations","case_report","article","10.2478/enr-2018-0020","31517602",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0024798","Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.","El-Shafey M","2022","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2022.862394","35370937","PMC8972060",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024799","Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.","Egefjord L","2012","Danish medical journal","protocol","article",null,"23158895",null,"ClinicalTrials.gov:NCT01469351","S001707","pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024800","Liraglutide for type 2 diabetes?",null,"2010","Drug and therapeutics bulletin","narrative_review","article","10.1136/dtb.2010.01.0006","20447980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024801","Hypothalamic GABAergic Neurons Expressing Cellular Retinoic Acid Binding Protein 1 (CRABP1) Are Sensitive to Metabolic Status and Liraglutide in Male Mice.","Lavoie O","2024","Neuroendocrinology","preclinical","article","10.1159/000538716","38631315","PMC11232952",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024802","Downregulation of EGF receptor signaling in pancreatic islets causes diabetes due to impaired postnatal beta-cell growth.","Miettinen PJ","2006","Diabetes","preclinical","article","10.2337/db06-0413","17130473",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024803","Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.","Okerson T","2010","American journal of hypertension","randomized_trial","article","10.1038/ajh.2009.245","20019672",null,null,"S000404; S000885","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024804","The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders.","Mansur RB","2019","European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","other","article","10.1016/j.euroneuro.2018.10.007","30409537","PMC6368894","ClinicalTrials.gov:NCT00001260",null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Intramural; research-article"],["R0024805","Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.","Zobel EH","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13638","30663196","PMC6593738",null,"S001504","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0024806","Non-insulin treatments for diabetes.","Angueira E","2013","American journal of therapeutics","narrative_review","article","10.1097/mjt.0b013e318235f2cb","23838634",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024807","Acute Photodistributed Exanthematous Pustulosis Associated With Liraglutide Treatment.","Cogen AL","2019","JAMA dermatology","other","article","10.1001/jamadermatol.2019.1893","31389984",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024808","Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.","Tkáč I","2016","Pharmacogenomics","narrative_review","article","10.2217/pgs-2016-0011","27166975",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024809","Clinical Review Report: Lixisenatide (Adlyxine): (Sanofi-aventis Canada Inc.): Indication: As an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with metformin, a sulfonylurea (alone or with metformin), pioglitazone (alone or with metformin), a basal insulin (alone or with metformin), when the therapy listed above does not provide adequate glycemic control",null,"2017","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"30543384",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0024810","Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells.","Schlatter P","2007","Regulatory peptides","preclinical","article","10.1016/j.regpep.2006.12.016","17276524",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024811","Impact of albumin on drug delivery--new applications on the horizon.","Elsadek B","2012","Journal of controlled release : official journal of the Controlled Release Society","other_trial","article","10.1016/j.jconrel.2011.09.069","21959118",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0024812","Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment.","Marquard J","2015","Nature medicine","other_trial","article","10.1038/nm.3822","25774850",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0024813","A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.","Cao L","2016","Neuroreport","other_trial","article","10.1097/wnr.0000000000000548","26918675",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024814","Liraglutide Enhances Autophagy and Promotes Pancreatic β Cell Proliferation to Ameliorate Type 2 Diabetes in High-Fat-Fed and Streptozotocin-Treated Mice.","Fan M","2018","Medical science monitor : international medical journal of experimental and clinical research","preclinical","article","10.12659/msm.906286","29664069","PMC5917824",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024815","Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine.","Klemettilä JP","2021","Psychiatry research","other","article","10.1016/j.psychres.2021.114227","34610543",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024816","Induction of pancreatic phenotypes in central nervous system derived pluripotential progenitor cells.","Saljooque F","2011","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","preclinical","article","10.1055/s-0030-1255105","20827659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0024817","THE EFFECT OF EXENATIDE THERAPY IN PREVIOUSLY INSULIN-TREATED TYPE 2 DIABETIC PATIENTS.","Yaşar HY","2017","Acta endocrinologica (Bucharest, Romania : 2005)","randomized_trial","article","10.4183/aeb.2017.447","31149215","PMC6516540",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0024818","DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?","Halimi S","2008","Diabetes & metabolism","other_trial","article","10.1016/s1262-3636(08)73400-1","18640591",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0024819","Response to \"Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?\".","Wharton S","2019","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.22630","31545003",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0024820","Byetta (exenatide): what's your gut feeling?","Hutton SF","2006","South Dakota medicine : the journal of the South Dakota State Medical Association","other","article",null,"16610466",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024821","Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.","Brown SA","2021","Hepatology (Baltimore, Md.)","narrative_review","article","10.1002/hep.31595","33047343",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024822","Is liraglutide or exenatide better in type 2 diabetes?","Doggrell SA","2009","Expert opinion on pharmacotherapy","other_trial","article","10.1517/14656560903264051","19743940",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Comment; Journal Article; article"],["R0024823","Interleukin-6 in the central amygdala is bioactive and co-localised with glucagon-like peptide-1 receptor.","Anesten F","2019","Journal of neuroendocrinology","preclinical","article","10.1111/jne.12722","31033078","PMC6618171",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024824","[A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018)].","Martinka E","2018","Vnitrni lekarstvi","other","article","10.36290/vnl.2018.059","29791176",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0024825","Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of non-alcoholic steatohepatitis","Duparc T","2019","bioRxiv","preclinical","preprint","10.1101/640854",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0024826","Liraglutide-induced Acute Gastroparesis.","Rai P","2018","Cureus","case_report","article","10.7759/cureus.3791","30868005","PMC6402745",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0024827","Treatment with exenatide in acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycemia.","Muller C","2018","International journal of stroke : official journal of the International Stroke Society","protocol","article","10.1177/1747493018784436","30019627",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024828","Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication.","Dibonaventura MD","2010","Patient preference and adherence","other","article","10.2147/ppa.s14477","21206515","PMC3003606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024829","Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.","Wijkman MO","2019","Journal of clinical hypertension (Greenwich, Conn.)","randomized_trial","article","10.1111/jch.13447","30515978","PMC8030426",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0024830","Parameters influencing renal response to SGLT2 inhibitors and GLP1 receptor agonists in type 2 diabetes patients with preserved renal function: a comparative, prospective study.","Biancalana E","2023","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-022-01969-2","36469293",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0024831","Managed care considerations of weight management interventions for obesity.","Amaro A","2022","The American journal of managed care","other","article","10.37765/ajmc.2022.89294","36525678",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024832","Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.","Jin L","2016","Translational research : the journal of laboratory and clinical medicine","preclinical","article","10.1016/j.trsl.2016.03.012","27059001",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024833","Prevalence of normal coronary arteries by coronary computed tomography angiography (CCTA) in patients with type 2 diabetes mellitus from Semaglutide Treatment on Coronary Plaque Progression (STOP) trial.","Birudaraju D","2021","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2020.107840","33419635",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024834","Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus.","Triplitt C","2006","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.1.3.329","30764072",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024835","Risk of Hypoglycemia After Concomitant Use of Antidiabetic, Antihypertensive, and Antihyperlipidemic Medications: A Database Study.","Gosho M","2018","Journal of clinical pharmacology","nonrandomized_study","article","10.1002/jcph.1147","29762878",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024836","Impact of preoperative and postoperative anti-obesity medications on early postoperative body mass index reduction after sleeve gastrectomy in pediatrics.","Vidmar AP","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2025.10.019","41381272","PMC13491681",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0024837","The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.","Gallagher EJ","2014","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.2466","24023014","PMC5496098",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024838","Exenatide Increases IL-1RA Concentration and Induces Nrf-2‒Keap-1‒Regulated Antioxidant Enzymes: Relevance to β-Cell Function.","Dandona P","2018","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2017-02343","29346597",null,"ClinicalTrials.gov:NCT01154933","S000201","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024839","CORRIGENDUM FOR \"Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide\".",null,"2020","The Journal of clinical endocrinology and metabolism","notice","article","10.1210/clinem/dgz157","31832679",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0024840","Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice.","Dekeryte R","2019","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2019.05.020","31103416",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024841","SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT","Shaw Tronieri J","2019","Journal of the Endocrine Society","other_trial","article",null,null,"PMC6552310",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0024842","[Glucagon-like peptide 1 (GLP-1)].","Parhofer KG","2007","MMW Fortschritte der Medizin","other","article","10.1007/bf03365101","17713050",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024843","Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.","Huang L","2021","International journal of medical sciences","nonrandomized_study","article","10.7150/ijms.55421","33850463","PMC8040401",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024844","Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial.","Shi X","2017","Scientific reports","randomized_trial","article","10.1038/s41598-017-02631-1","28539618","PMC5443840",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024845","Advantages and Limitations of the Body Mass Index (BMI) to Assess Adult Obesity.","Wu Y","2024","International journal of environmental research and public health","narrative_review","article","10.3390/ijerph21060757","38929003","PMC11204233",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024846","The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge.","López de Maturana R","2002","FEBS letters","other","article","10.1016/s0014-5793(02)03492-0","12387900",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024847","Evaluation of the INS-1 832/13 cell line as a beta-cell based screening system to assess pollutant effects on beta-cell function.","Hectors TL","2013","PloS one","preclinical","article","10.1371/journal.pone.0060030","23555872","PMC3605429",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024848","Alert-LDL-2: adherence to guidelines and goals attainment in the treatment of diabetic patients with dyslipidemia.","DE Luca M","2023","Minerva cardiology and angiology","other","article","10.23736/s2724-5683.22.06189-0","36637434",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024849","GLP1 and cancer: friend or foe?","Vangoitsenhoven R","2012","Endocrine-related cancer","nonrandomized_study","article","10.1530/erc-12-0111","22691625",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0024850","Incretin therapies: effects beyond glycemic control.","Mudaliar S","2009","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2009.03.014","19464425",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review"],["R0024851","[The trend of new drug development for the treatment of diabetes mellitus].","Kaku K","2015","Nihon rinsho. Japanese journal of clinical medicine","other_trial","article",null,"26666161",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","English Abstract; Journal Article; other"],["R0024852","[Incretin-related medicine (GLP-1 receptor agonists, DPP-IV inhibitors)].","Morii T","2010","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"21661154",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024853","Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.","Karagiannis T","2012","BMJ (Clinical research ed.)","systematic_review","article","10.1136/bmj.e1369","22411919",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0024854","In vivo biological activity of exendin (1-30).","Doyle ME","2005","Endocrine","preclinical","article","10.1385/endo:27:1:001","16077164",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S."],["R0024855","The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice.","Chung HS","2011","Regulatory peptides","preclinical","article","10.1016/j.regpep.2011.05.002","21621561",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024856","Role of blood-brain barrier dysfunction in the development of poststroke epilepsy.","Meijer WC","2024","Epilepsia","narrative_review","article","10.1111/epi.18072","39101543",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024857","Metformin monotherapy for adults with type 2 diabetes mellitus.","Gnesin F","2020","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd012906.pub2","32501595","PMC7386876","ClinicalTrials.gov:NCT00679939; ClinicalTrials.gov:NCT00279045; ClinicalTrials.gov:NCT00327015; ClinicalTrials.gov:NCT00099866; ClinicalTrials.gov:NCT00138567; ClinicalTrials.gov:NCT01126580; ClinicalTrials.gov:NCT00103857; ClinicalTrials.gov:NCT00035568; ClinicalTrials.gov:NCT03010683; ClinicalTrials.gov:NCT00373178; ClinicalTrials.gov:NCT00396851; ClinicalTrials.gov:NCT01001962; ClinicalTrials.gov:NCT01779362; ClinicalTrials.gov:NCT02853630; ClinicalTrials.gov:NCT03982381","S000389; S001786; S002086","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; systematic-review; article"],["R0024858","Liraglutide improves hepatic insulin resistance via the canonical Wnt signaling pathway.","Qin Y","2018","Molecular medicine reports","preclinical","article","10.3892/mmr.2018.8737","29568881",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024859","Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome.","Kunkel D","2011","Neurogastroenterology and motility","other","article","10.1111/j.1365-2982.2011.01723.x","21557790",null,null,"S001709","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024860","Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.","Yan J","2019","Hepatology (Baltimore, Md.)","randomized_trial","article","10.1002/hep.30320","30341767","PMC6594101",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024861","Novel incretin based therapies for type 2 diabetes and obesity","Kerr B","2011","Ulster University","preclinical","article",null,null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Dissertation; dissertation"],["R0024862","Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain.","Afonso M","2017","Journal of medical economics","other_trial","article","10.1080/13696998.2017.1304395","28271733",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0024863","Diabesity: therapeutic options.","Colagiuri S","2010","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2009.01182.x","20518802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024864","Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial.","Wadden TA","2019","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.22359","30421856","PMC6800068","ClinicalTrials.gov:NCT02911818","S000426","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024865","Interplay of glucagon-like peptide-1 and transforming growth factor-beta signaling in insulin-positive differentiation of AR42J cells.","Yew KH","2004","Diabetes","preclinical","article","10.2337/diabetes.53.11.2824","15504962",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024866","Anti-diabetic therapies on dental implant success in diabetes mellitus: a comprehensive review.","Ghorbani H","2024","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2024.1506437","39723258","PMC11668599",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024867","Equine glucagon-like peptide-1 receptor physiology.","Kheder MH","2018","PeerJ","preclinical","article","10.7717/peerj.4316","29404215","PMC5793710",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024868","The Hypoglycemic and Hypocholesterolemic Activity of Dioscorea deltoidea, Tribulus terrestris and Panax japonicus Cell Culture Biomass in Rats with High-Fat Diet-Induced Obesity.","Povydysh MN","2023","Nutrients","preclinical","article","10.3390/nu15030656","36771371","PMC9918901",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024869","The Effectiveness of Adding Pharmacotherapy to Dietary Counseling for Veterans in a Veterans Health Administration Move! Weight Management Program","Alvarez D","2021","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvab048.074",null,"PMC8089938",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0024870","Major contributions of comparative endocrinology to the development and exploitation of the incretin concept.","Conlon JM","2006","Journal of experimental zoology. Part A, Comparative experimental biology","narrative_review","article","10.1002/jez.a.312","16902971",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024871","Atorvastatin reduces alloxan-induced impairment of aversive stimulus memory in mice.","Kukula O","2022","Asian biomedicine : research, reviews and news","other_trial","article","10.2478/abm-2022-0009","37551286","PMC10321169",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0024872","A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.","Polster M","2010","Journal of medical economics","other","article","10.3111/13696998.2010.529377","21034377",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024873","Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function.","Mudaliar S","2010","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2009.12.006","20206728",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review"],["R0024874","Liraglutide for the Treatment of Obesity: Analyzing Published Reviews.","Pastor R","2019","Current pharmaceutical design","systematic_review","article","10.2174/1381612825666190701155737","31267857",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0024875","Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy.","Peters AE","2023","medRxiv : the preprint server for health sciences","randomized_trial","article","10.1101/2023.05.16.23288273","37293003","PMC10246051",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Preprint; Journal Article; preprint"],["R0024876","Chronic kidney disease as a cardiovascular risk factor.","Carmena R","2020","Journal of hypertension","narrative_review","article","10.1097/hjh.0000000000002506","32649622",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0024877","Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats.","Hansen G","2012","Acta pharmacologica Sinica","preclinical","article","10.1038/aps.2011.168","22301859","PMC4010326",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024878","FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs.","Kim KH","2015","The Journal of endocrinology","narrative_review","article","10.1530/joe-15-0160","26116622",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0024879","Retrospective Analysis of Liraglutide as Add-On Therapy in Type 2 Diabetes Mellitus: Quantifying the Changes in Insulin Requirements.","Czarnowski K","2019","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article",null,"30867628","PMC6411360",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024880","An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.","Kim D","2017","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2017.04.036","28457895",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024881","Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.","Kanters S","2019","BMJ open","systematic_review","article","10.1136/bmjopen-2018-023458","31340953","PMC6661926",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; systematic-review; review"],["R0024882","Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries.","Bangshaab M","2019","British journal of pharmacology","preclinical","article","10.1111/bph.14534","30403290","PMC6329621",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024883","Liraglutide: a review of its use in type 2 diabetes mellitus.","Croom KF","2009","Drugs","other_trial","article","10.2165/11201060-000000000-00000","19747013",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0024884","β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues.","Hager MV","2016","Journal of the American Chemical Society","other","article","10.1021/jacs.6b08323","27813409","PMC5207657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024885","Major adverse cardiovascular events' reduction and their association with glucose-lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records.","Hsu H","2024","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.13604","39431844","PMC11492400",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024886","Oral administration of a fusion protein containing eight GLP-1 analogues produced in Escherichia coli BL21(DE3) in streptozotocin-induced diabetic rats.","Hou J","2007","Biotechnology letters","preclinical","article","10.1007/s10529-007-9427-1","17581704",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024887","Suppression of food intake by Glp1r/Lepr-coexpressing neurons prevents obesity in mouse models.","Rupp AC","2023","The Journal of clinical investigation","preclinical","article","10.1172/jci157515","37581939","PMC10541203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024888","A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents.","Dalbøge LS","2015","PloS one","preclinical","article","10.1371/journal.pone.0135634","26266945","PMC4534139",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024889","Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease.","Zhang Z","2018","Medical science monitor : international medical journal of experimental and clinical research","other","article","10.12659/msm.911062","30325900","PMC6199821",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024890","Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function.","Renner S","2010","Diabetes","preclinical","article","10.2337/db09-0519","20185813","PMC2857903",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024891","Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice.","Shao Y","2014","Peptides","preclinical","article","10.1016/j.peptides.2013.11.011","24406898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024892","Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.","Duarte AI","2018","Scientific reports","preclinical","article","10.1038/s41598-018-27121-w","29895889","PMC5997749",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024893","The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.","Egan JM","2002","The Journal of clinical endocrinology and metabolism","other","article","10.1210/jcem.87.3.8337","11889200",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0024894","Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.","Flint A","2010","British journal of clinical pharmacology","other_trial","article","10.1111/j.1365-2125.2010.03762.x","21175436","PMC2997321",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024895","Liraglutide Enhances the Activity of the ACE-2/Ang(1-7)/Mas Receptor Pathway in Lungs of Male Pups from Food-Restricted Mothers and Prevents the Reduction of SP-A.","Fandiño J","2018","International journal of endocrinology","randomized_trial","article","10.1155/2018/6920620","30627159","PMC6304858",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0024896","SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial","Wadden T","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-sat-099",null,"PMC6552061","ClinicalTrials.gov:NCT02963935","S000712","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; article"],["R0024897","The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.","Fujita H","2014","Kidney international","preclinical","article","10.1038/ki.2013.427","24152968",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024898","Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.","Ceriello A","2020","Diabetes care","other","article","10.2337/dc20-0941","32409501",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024899","Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states.","Neidigh JW","2001","Biochemistry","other","article","10.1021/bi010902s","11683627",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0024900","Anaphylaxis to Long-Acting Release Exenatide.","Ornelas C","2018","Journal of investigational allergology & clinical immunology","case_report","article","10.18176/jiaci.0274","30350785",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0024901","Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.","Chae SY","2008","Bioconjugate chemistry","preclinical","article","10.1021/bc700292v","18078308",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024902","Combination use of liraglutide and insulin to Japanese patients with multiple insulin injection: efficacy and cost.","Houda SM","2020","Diabetology international","other","article","10.1007/s13340-019-00404-x","31950004","PMC6942082",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024903","PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogue.","Gao H","2011","Molecular pharmaceutics","preclinical","article","10.1021/mp200141x","21800885","PMC3185201",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024904","Growth restriction and exendin 4 promote endocrine expression in cultured islet cells derived from patients with persistent hyperinsulinemic hypoglycemia of infancy (PHHI).","Webb M","2005","Endocrine research","preclinical","article","10.1080/07435800500229235","16353670",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024905","Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.","Zhao L","2019","Organic & biomolecular chemistry","preclinical","article","10.1039/c9ob01132c","31389463",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024906","A study to assess the unmet medical needs associated with the use of basal insulin in patients with type 2 diabetes.","Frechtel G","2021","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.164","33532606","PMC7831225",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024907","Exenatide: its position in the treatment of type 2 diabetes.","Guerci B","2008","Annales d'endocrinologie","narrative_review","article","10.1016/j.ando.2008.03.004","18533126",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024908","Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis.","Yang L","2019","Journal of endocrinological investigation","preclinical","article","10.1007/s40618-019-01034-5","30955181",null,null,"S000828","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0024909","A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.","Li C","2010","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2010.08.103","20804731",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024910","SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial","Shaw Tronieri J","2019","Journal of the Endocrine Society","other_trial","article",null,null,"PMC6552209",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0024911","Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide.","Emamaullee JA","2009","Endocrinology","preclinical","article","10.1210/en.2008-1116","19131571",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024912","[Cardiovascular outcome clinical trials in type 2 diabetes mellitus: what are the epidemiological and methodological evidence and the first evaluations to date?].","Fiorentino TV","2016","Giornale italiano di cardiologia (2006)","other_trial","article","10.1714/2206.23822","27030121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","English Abstract; Journal Article; article; other"],["R0024913","Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.","Alba M","2021","Clinical obesity","randomized_trial","article","10.1111/cob.12432","33475255",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0024914","Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study.","Lundershausen R","2020","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","nonrandomized_study","article","10.1055/a-0636-3961","30157532",null,null,"S000075","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; article"],["R0024915","Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes.","Sharma MD","2010","Therapeutics and clinical risk management","randomized_trial","article","10.2147/tcrm.s7679","20526441","PMC2878957",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; article"],["R0024916","Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.","Duparc T","2019","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00139.2019","31460789",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024917","The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211.","Bock T","2003","APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","preclinical","article","10.1111/j.1600-0463.2003.apm1111207.x","14678021",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024918","Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy.","Tong F","2017","International journal of nanomedicine","preclinical","article","10.2147/ijn.s136646","28721043","PMC5500490",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024919","Top studies of 2022 relevant to primary care: From the PEER team.","Perry D","2023","Canadian family physician Medecin de famille canadien","narrative_review","article","10.46747/cfp.6905325","37172982","PMC10177638",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024920","Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease.","Zheng M","2021","3 Biotech","narrative_review","article","10.1007/s13205-021-02738-3","33927970","PMC7981362",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0024921","Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide.","Uhl P","2020","Nanomedicine : nanotechnology, biology, and medicine","preclinical","article","10.1016/j.nano.2019.102132","31783138",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024922","Diet strategies for maintaining substantial therapeutic weight loss: 78-week mixed methods randomised trial.","Brosnahan N","2025","Clinical nutrition (Edinburgh, Scotland)","randomized_trial","article","10.1016/j.clnu.2025.08.009","40934815",null,"ClinicalTrials.gov:NCT02683798",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024923","Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.","Moreno P","2012","Journal of molecular endocrinology","nonrandomized_study","article","10.1530/jme-11-0127","22065862",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024924","What's New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).","Kosmalski M","2023","Journal of clinical medicine","randomized_trial","article","10.3390/jcm12051852","36902639","PMC10003344",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0024925","Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study.","Davies MJ","2009","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2009.01154.x","19930005","PMC2810445",null,"S001323","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0024926","Huanglian-Renshen-Decoction Maintains Islet β-Cell Identity in T2DM Mice through Regulating GLP-1 and GLP-1R in Both Islet and Intestine.","Wu WB","2025","Chinese journal of integrative medicine","preclinical","article","10.1007/s11655-024-3915-1","39551849",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024927","Effects of anti-somatostatin agents on glucose metabolism.","Vergès B","2017","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2017.05.003","28579289",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024928","OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial","Blonde L","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-or22-1",null,"PMC6554790","ClinicalTrials.gov:NCT02964247","S000022","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; article"],["R0024929","Understanding the cardiovascular effects of incretin.","Yoon JS","2011","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2011.35.5.437","22111033","PMC3221017",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; article"],["R0024930","Long-term effectiveness and safety of liraglutide in clinical practice.","Ponzani P","2013","Minerva endocrinologica","other","article",null,"23435446",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0024931","Current treatment landscape for obesity in Singapore.","Lee PC","2023","Singapore medical journal","narrative_review","article","10.4103/singaporemedj.smj-2022-216","36876623","PMC10071854",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024932","Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity.","Nexøe-Larsen CC","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13420","29892986","PMC6220792",null,"S000103","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0024933","Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.","Paneni F","2017","The American journal of medicine","other_trial","article","10.1016/j.amjmed.2017.04.008","28526186",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0024934","Can obesity exacerbate hyperinsulinaemia in the presence of the mutation of an insulin receptor gene?","Calcaterra V","2023","Clinical obesity","case_report","article","10.1111/cob.12619","37717597",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0024935","Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.","Tokushige K","2021","Hepatology research : the official journal of the Japan Society of Hepatology","narrative_review","article","10.1111/hepr.13688","34533266","PMC8531062",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024936","Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis.","Lautsch D","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-020-00975-y","33313996","PMC7843850",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0024937","Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.","Dennis JM","2018","Diabetes care","other","article","10.2337/dc17-1827","29386249","PMC6591121","ClinicalTrials.gov:NCT01503112","S002449","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0024938","Assessment of pyloric sphincter distensibility and pressure in patients with diabetic gastroparesis.","Desprez C","2021","Neurogastroenterology and motility","other","article","10.1111/nmo.14064","33314491",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024939","Impact of an integrated diabetes service involving specialist outreach and primary health care on risk factors for micro- and macrovascular diabetes complications in remote Indigenous communities in Australia.","Hotu C","2018","The Australian journal of rural health","nonrandomized_study","article","10.1111/ajr.12426","29864201",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0024940","Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.","Basolo A","2018","Metabolism: clinical and experimental","randomized_trial","article","10.1016/j.metabol.2018.03.017","29596853","PMC6062468","ClinicalTrials.gov:NCT00856609","S000477","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural; research-article; article"],["R0024941","Population Pharmacokinetics of Semaglutide for Type 2 Diabetes.","Overgaard RV","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-019-0581-y","30788808","PMC6437231",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0024942","Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.","Li Q","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0432-2","29744818","PMC5984935",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024943","A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss.","Chichura KS","2023","Scientific reports","preclinical","article","10.1038/s41598-023-36178-1","37308546","PMC10261008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; research-article; article"],["R0024944","Mechanisms of action of glucagon-like peptide 1 in the pancreas.","Doyle ME","2007","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2006.11.007","17306374","PMC1934514",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Intramural; Review; research-article"],["R0024945","HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.","Ahrén B","2014","Diabetes care","randomized_trial","article","10.2337/dc14-0024","24898304",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024946","Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.","Schweizer A","2013","Vascular health and risk management","narrative_review","article","10.2147/vhrm.s40972","23431062","PMC3575159",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article; review"],["R0024947","Utilising a milk-based meal replacement programme in a bariatric patient with poorly controlled type 2 diabetes mellitus.","Maher M","2019","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-19-0008","30959473","PMC6454224",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024948","Pharmacological management of appetite expression in obesity.","Halford JC","2010","Nature reviews. Endocrinology","narrative_review","article","10.1038/nrendo.2010.19","20234354",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024949","[Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control].","Roca-Rodríguez MM","2017","Atencion primaria","other","article","10.1016/j.aprim.2016.06.009","27667144","PMC6875984",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0024950","Type 2 diabetes mellitus--current therapies and the emergence of surgical options.","Lebovitz HE","2011","Nature reviews. Endocrinology","narrative_review","article","10.1038/nrendo.2011.10","21301486",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024951","CVOTs: What did the endocrinologist learn?","Valensi P","2020","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2019.107947","31778747",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024952","Are gastrointestinal symptoms related to diabetes mellitus and glycemic control?","Koch CA","2008","European journal of gastroenterology & hepatology","narrative_review","article","10.1097/meg.0b013e3282f5f75e","18794593",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comment; Journal Article; Review; article"],["R0024953","The impact of obesity and weight loss treatment on metabolic parameters, cardiovascular autonomic and sensory nerve function and in vitro fertilization outcomes in infertile women: a pilot study.","Vágvölgyi A","2025","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1548587","40463745","PMC12129780",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0024954","Exenatide therapy in insulin-treated type 2 diabetes and obesity.","Nayak UA","2010","QJM : monthly journal of the Association of Physicians","other","article","10.1093/qjmed/hcq112","20624837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024955","Vascular remodelling in a mouse model of heart failure with preserved ejection fraction.","Sanhueza-Olivares F","2026","The Journal of physiology","preclinical","article","10.1113/jp287094","39930974",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024956","A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.","Li C","2017","Biological & pharmaceutical bulletin","preclinical","article","10.1248/bpb.b17-00169","28626167",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024957","Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation.","Shiraishi D","2012","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2012.07.086","22842565",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0024958","L-arginine as a potential GLP-1-mediated immunomodulator of Th17-related cytokines in people with obesity and asthma.","Liao SY","2021","Obesity science & practice","randomized_trial","article","10.1002/osp4.500","34123401","PMC8170586",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; brief-report; article"],["R0024959","[Basal insulin and GLP-1 agonist potentiate each other (interview by Dr. med Dirk Einecke)].","Einecke D","2012","MMW Fortschritte der Medizin","other","article","10.1007/s15006-012-0840-6","22880293",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Interview; article"],["R0024960","Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.","Ozyazgan S","2005","Pharmacology","preclinical","article","10.1159/000084277","15746570",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024961","OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind","Konig M","2020","Journal of the Endocrine Society","randomized_trial","article",null,null,"PMC7207332",null,null,"europepmc","TRUE","open_europepmc","2",null,"Abstract"],["R0024962","Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.","Hwang YC","2017","BMC endocrine disorders","randomized_trial","article","10.1186/s12902-017-0220-4","29065865","PMC5655957","ClinicalTrials.gov:NCT02090673","S001551","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; other; article"],["R0024963","Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.","Kerr BD","2010","Biochemical pharmacology","other","article","10.1016/j.bcp.2010.04.021","20417187",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0024964","Saxagliptin in type 2 diabetes.","Billiones R","2010","Drugs of today (Barcelona, Spain : 1998)","other_trial","article","10.1358/dot.2010.46.2.1464700","20393638",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0024965","Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2.","Mulvihill EE","2018","Current opinion in lipidology","narrative_review","article","10.1097/mol.0000000000000495","29432213","PMC5882252",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0024966","Injectable hydrogel for sustained protein release by salt-induced association of hyaluronic acid nanogel.","Nakai T","2012","Macromolecular bioscience","preclinical","article","10.1002/mabi.201100352","22606703",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024967","Individual, healthcare professional and system-level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and meta-ethnography.","Byrne J","2022","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.14678","34432914",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0024968","Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia.","Bandsma RH","2010","Atherosclerosis","commentary","article","10.1016/j.atherosclerosis.2010.06.033","20638063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0024969","Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.","Irie S","2008","International journal of clinical pharmacology and therapeutics","randomized_trial","article","10.5414/cpp46273","18541123",null,null,"S000476","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024970","[Management of type 2 diabetes: new or previous agents, how to choose?].","Halimi S","2013","Presse medicale (Paris, France : 1983)","narrative_review","article","10.1016/j.lpm.2013.04.002","23643613",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0024971","Liraglutide inhibited AGEs induced coronary smooth muscle cell phenotypic transition through inhibiting the NF-κB signal pathway.","Di B","2019","Peptides","preclinical","article","10.1016/j.peptides.2018.11.008","30513352",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024972","Bioanalytical strategies for developing highly sensitive liquid chromatography/tandem mass spectrometry based methods for the peptide GLP-1 agonists in support of discovery PK/PD studies.","Zhang H","2011","Rapid communications in mass spectrometry : RCM","preclinical","article","10.1002/rcm.5241","22002697",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024973","Assessment of the cardioprotective effect of liraglutide on methotrexate induced cardiac dysfunction through suppression of inflammation and enhancement of angiogenesis in rats.","Mahmoud RH","2021","European review for medical and pharmacological sciences","preclinical","article","10.26355/eurrev_202110_26879","34661261",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0024974","MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg","Rubino D","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-mon-120",null,"PMC6550741","ClinicalTrials.gov:NCT02963935","S000712","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; article"],["R0024975","Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs.","Sjöholm Å","2010","Pharmaceuticals (Basel, Switzerland)","other_trial","article","10.3390/ph3030764","27713278","PMC4033979",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Review; Journal Article; review-article; article"],["R0024976","New Developments in Bile Acid Diarrhea.","Camilleri M","2023","Gastroenterology & hepatology","randomized_trial","article",null,"37771793","PMC10524409",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; discussion; article"],["R0024977","Exendin-4 regulates the expression of the ATP-binding cassette transporter A1 via transcriptional factor PREB in the pancreatic β cell line.","Miyai Y","2011","Journal of endocrinological investigation","preclinical","article","10.3275/7683","21521937",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024978","Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.","Zhou D","2018","Experimental & molecular medicine","preclinical","article","10.1038/s12276-018-0183-1","30510243","PMC6277380",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0024979","Exendin-4 normalizes islet vascularity in intrauterine growth restricted rats: potential role of VEGF.","Ham JN","2009","Pediatric research","preclinical","article","10.1203/pdr.0b013e3181a282a5","19287346","PMC2735861",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0024980","Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.","Chatterjee DJ","2009","Journal of clinical pharmacology","randomized_trial","article","10.1177/0091270009339189","19737980",null,null,"S000707","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0024981","Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling.","Oh YS","2017","International journal of molecular sciences","narrative_review","article","10.3390/ijms19010026","29271910","PMC5795977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0024982","Newer perspective on the coupling between glucose-mediated signaling and β-cell functionality.","Shirakawa J","2020","Endocrine journal","preclinical","article","10.1507/endocrj.ej19-0335","31694991",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0024983","Liraglutide Protects Neurite Outgrowth of Cortical Neurons Under Oxidative Stress though Activating the Wnt Pathway.","He W","2018","Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","preclinical","article","10.1016/j.jstrokecerebrovasdis.2018.05.039","30042033",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024984","Liraglutide ameliorates gentamicin-induced acute kidney injury in rats via PGC-1α- mediated mitochondrial biogenesis: Involvement of PKA/CREB and Notch/Hes-1 signaling pathways.","Elkhoely A","2023","International immunopharmacology","preclinical","article","10.1016/j.intimp.2022.109578","36525794",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024985","Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?","Lemon LS","2022","Gynecologic oncology","nonrandomized_study","article","10.1016/j.ygyno.2022.01.022","35140015",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0024986","Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.","Seino Y","2018","Journal of diabetes investigation","other_trial","article","10.1111/jdi.12686","28429860","PMC5754542","ClinicalTrials.gov:NCT01940965","S001225","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; research-article; article"],["R0024987","Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with Polycystic ovary syndrome: a retrospective study","Chen C","2020","Research Square","randomized_trial","preprint","10.21203/rs.3.rs-22460/v1",null,null,"ChiCTR:ChiCTR1900024384",null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0024988","Potential differentiation of islet-like cells from pregnant cow-derived placental stem cells.","Peng SY","2017","Taiwanese journal of obstetrics & gynecology","other_trial","article","10.1016/j.tjog.2017.04.007","28600038",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0024989","[Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].","Reboldi G","2009","Giornale italiano di cardiologia (2006)","other_trial","article",null,"19761101",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","English Abstract; Journal Article; Review; other"],["R0024990","Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success.","Aguilar RB","2011","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2011.04.008","21635988",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0024991","Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).","Marso SP","2018","The American journal of cardiology","other_trial","article","10.1016/j.amjcard.2018.02.030","29627109",null,"ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024992","Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators.","Chaudhuri A","2017","Diabetes, obesity & metabolism","other","article","10.1111/dom.12835","27891769",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0024993","Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.","Parkes DG","2001","Metabolism: clinical and experimental","preclinical","article","10.1053/meta.2001.22519","11319721",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024994","Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.","Kim H","2011","Pharmaceutical research","preclinical","article","10.1007/s11095-011-0427-4","21472489",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0024995","The binding and activation of the glucagon-like peptide-1 receptor by exendin-4","Nasr EMN","2010","University of Leeds","preclinical","article",null,null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0024996","Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes.","Nurunnabi M","2017","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2017.08.035","28860072",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0024997","Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics.","Kim TH","2011","Bioconjugate chemistry","preclinical","article","10.1021/bc100404x","21401109",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0024998","Liraglutide toxicity presenting to the emergency department: A case report and literature review.","Rotella JA","2019","Emergency medicine Australasia : EMA","case_report","article","10.1111/1742-6723.13343","31304652",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; Review; article"],["R0024999","Impact of GLP-1 analogue on oxidative damage and hepatic regeneration in experimental 70% hepatectomy model.","Battal M","2015","Hepato-gastroenterology","preclinical","article",null,"25916043",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025000","Implantable device actuated by manual button clicks for noninvasive self-drug administration.","Kim CR","2023","Bioengineering & translational medicine","other","article","10.1002/btm2.10320","36684080","PMC9842066",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025001","Regulator of G protein signaling 2 is a key regulator of pancreatic β-cell mass and function.","Dong H","2017","Cell death & disease","preclinical","article","10.1038/cddis.2016.216","28542139","PMC5520679",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025002","Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.","Su K","2018","American journal of therapeutics","randomized_trial","article","10.1097/mjt.0000000000000431","26844723",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0025003","Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.","Ekström N","2016","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12704","27282621",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0025004","No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.","Hegedüs L","2018","Diabetes care","randomized_trial","article","10.2337/dc17-1956","29279300",null,"ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025005","Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada.","Wharton S","2019","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.22462","31062937","PMC6593982",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025006","Al(18) F labeling of peptides and proteins.","Laverman P","2014","Journal of labelled compounds & radiopharmaceuticals","preclinical","article","10.1002/jlcr.3161","24408125",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; article"],["R0025007","Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis.","Han T","2022","Archives of medical research","systematic_review","article","10.1016/j.arcmed.2021.08.002","34412904","PMC8349690","PROSPERO:CRD42020221951",null,"pubmed; europepmc","TRUE","open_europepmc","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; research-article"],["R0025008","Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.","Nauck MA","2006","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","randomized_trial","article","10.1055/s-2006-924230","17039422",null,null,"S002057","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025009","CADTH Canadian Drug Expert Committee Recommendation: Lixisenatide (Adlyxine — Sanofi-aventis Canada Inc.): Indication: Diabetes mellitus, type 2",null,"2017","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"30475557",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0025010","An update on therapies for the treatment of diabetes-induced osteoporosis.","Mohsin S","2019","Expert opinion on biological therapy","narrative_review","article","10.1080/14712598.2019.1618266","31079501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025011","New Zealand may finally get funded access to diabetes drugs which reduce cardiovascular events and progression of kidney disease: an audit of proposed PHARMAC criteria compared with international guidelines.","Vitz M","2020","The New Zealand medical journal","nonrandomized_study","article",null,"33032305",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025012","26RFa, a novel orexigenic neuropeptide, inhibits insulin secretion in the rat pancreas.","Egido EM","2007","Peptides","preclinical","article","10.1016/j.peptides.2006.04.004","16777265",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025013","[The protection of islet β-cells in db/db mice by combination pioglitazone and glucagon like peptide-1 treatment].","Song LL","2011","Zhonghua nei ke za zhi","preclinical","article",null,"22176969",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025014","Incretins as a novel therapeutic strategy in patients with diabetes and heart failure.","Khan MA","2013","Heart failure reviews","randomized_trial","article","10.1007/s10741-012-9318-y","22570104",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0025015","GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases.","Zoicas F","2013","European journal of endocrinology","case_report","article","10.1530/eje-12-0997","23392214",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025016","An Abbreviated Protocol for In Vitro Generation of Functional Human Embryonic Stem Cell-Derived Beta-Like Cells.","Massumi M","2016","PloS one","protocol","article","10.1371/journal.pone.0164457","27755557","PMC5068782",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0025017","Time to modification of antidiabetic therapy in patients over the age of 65 years with newly diagnosed diabetes mellitus.","Machado-Alba JE","2020","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2020.108090","32088311",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0025018","A Non-Structural Protein of Severe Acute Respiratory Syndrome Coronavirus 2 with a Potential Ability to Reduce Blood Glucose for Use in Controlling Type 2 Diabetes Mellitus.","Danaeifar M","2022","Archives of Razi Institute","other","article","10.22092/ari.2022.358070.2145","37274904","PMC10237550",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025019","Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.","Umpierrez GE","2016","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12660","26969812","PMC4934019",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025020","Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes.","Nielsen LL","2008","Journal of diabetes science and technology","narrative_review","article","10.1177/193229680800200214","19885351","PMC2771486",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0025021","Obesity medications: what does the future look like?","Butsch WS","2015","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000192","26313898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025022","The Use of Omnipod® 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes With Suboptimal Glycemic Management: From Injections to Closed-Loop Therapy","Bode B","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.980",null,"PMC8090121",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0025023","Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.","Mentz RJ","2018","Circulation","randomized_trial","article","10.1161/circulationaha.118.036811","30571356",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0025024","Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.","Kaku K","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13218","29322610","PMC5969242","ClinicalTrials.gov:NCT02207374","S001498","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025025","[Advances in gastroenterology and hepatology 2021].","Bastid C","2022","Revue medicale suisse","other","article","10.53738/revmed.2022.18.764-65.31","35048576",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025026","Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.","Doliba NM","2012","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00218.2011","21952036","PMC3328091",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025027","Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas.","Roberto G","2019","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-019-0334-y","30732592","PMC6367760",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0025028","Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.","Vadini F","2020","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-020-0535-5","31965072",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025029","Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes.","Yang GR","2015","Journal of clinical pharmacology","randomized_trial","article","10.1002/jcph.386","25167840",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025030","Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease.","Liu W","2015","European journal of pharmacology","other_trial","article","10.1016/j.ejphar.2015.08.038","26302060",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025031","Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.","Korsatko S","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13422","29893488","PMC6221089",null,"S002097","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025032","Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?","Otto-Buczkowska E","2018","International journal of endocrinology and metabolism","randomized_trial","article","10.5812/ijem.13008","29696037","PMC5903388",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0025033","Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.","Darsalia V","2014","Regulatory peptides","preclinical","article","10.1016/j.regpep.2014.05.001","24821550",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025034","Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology.","Fuentes B","2021","Neurologia","randomized_trial","article","10.1016/j.nrl.2020.04.030","32981775",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0025035","Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy.","Vyas AK","2012","Cardiovascular endocrinology","preclinical","article","10.1097/xce.0b013e32835bfb24","23795310","PMC3686315",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025036","Cancer and cardiovascular disease: can understanding the mechanisms of cardiovascular injury guide us to optimise care in cancer survivors?","Truong LL","2022","Ecancermedicalscience","other_trial","article","10.3332/ecancer.2022.1430","36158986","PMC9458273",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0025037","Morroniside, a secoiridoid glycoside from Cornus officinalis, attenuates neuropathic pain by activation of spinal glucagon-like peptide-1 receptors.","Xu M","2017","British journal of pharmacology","preclinical","article","10.1111/bph.13720","28098360","PMC5345663",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025038","Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations.","Liang NC","2013","International journal of obesity (2005)","preclinical","article","10.1038/ijo.2012.16","22310470","PMC3383881",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025039","Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK.","Lautsch D","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-019-00698-9","31583647","PMC6848348",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025040","Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.","Raun K","2007","Obesity (Silver Spring, Md.)","preclinical","article","10.1038/oby.2007.204","17636089",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025041","Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice.","Hansen HH","2021","Scientific reports","preclinical","article","10.1038/s41598-021-87539-7","33850212","PMC8044192",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025042","[Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention].","Avogaro A","2016","Giornale italiano di cardiologia (2006)","other","article","10.1714/2616.26910","28151516",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025043","Lixisenatide for type 2 diabetes.",null,"2017","The Medical letter on drugs and therapeutics","narrative_review","article",null,"28118649",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025044","Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites.","Göke R","1995","The European journal of neuroscience","preclinical","article","10.1111/j.1460-9568.1995.tb00650.x","8563978",null,null,"S000766","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0025045","RETRACTED: Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease.","Paladugu L","2021","International journal of molecular sciences","preclinical","article","10.3390/ijms22020860","33467075","PMC7829894",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retracted Publication; research-article; article"],["R0025046","Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.","Henry RR","2012","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2011-3253","22539590",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025047","Microvascular and macrovascular effects of liraglutide.","Cianflone D","2019","International journal of cardiology","commentary","article","10.1016/j.ijcard.2019.02.041","30878237",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0025048","[Primary prevention of coronary heart disease : Evidence-based drug treatment].","Mühleck F","2020","Herz","other","article","10.1007/s00059-019-04873-3","31822926",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025049","Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.","Seko Y","2017","Hepatology research : the official journal of the Japan Society of Hepatology","randomized_trial","article","10.1111/hepr.12837","27917557",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0025050","Is \"Leptin Resistance\" Another Key Resistance to Manage Type 2 Diabetes?","Salazar J","2020","Current diabetes reviews","other","article","10.2174/1573399816666191230111838","31886750",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025051","Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.","Feng WH","2019","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12888","29957886","PMC6400178",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0025052","Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).","Pratley RE","2013","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12009","22958426",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025053","Evidence-based recommendations for insulin intensification strategies after basal insulin in type 2 diabetes.","Ghosh S","2017","Diabetes & metabolic syndrome","narrative_review","article","10.1016/j.dsx.2017.03.045","28433618",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025054","Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats.","Gedulin BR","2005","Diabetologia","preclinical","article","10.1007/s00125-005-1795-2","15915337",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025055","Liraglutide ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling.","Moustafa PE","2018","Journal of neurochemistry","preclinical","article","10.1111/jnc.14336","29572844",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025056","In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.","Lipscombe LL","2019","Annals of internal medicine","randomized_trial","article","10.7326/acpj201908200-016","31426059",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0025057","Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome.","Saad MA","2021","Life sciences","preclinical","article","10.1016/j.lfs.2020.118731","33160995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025058","Exenatide-Induced Panniculitis: Utility of the Acid-Fast Stain to Identify Injected Microspheres.","Vidal CI","2018","The American Journal of dermatopathology","case_report","article","10.1097/dad.0000000000000952","28700374",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0025059","SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.","Sajja AP","2019","Journal of cardiovascular pharmacology and therapeutics","narrative_review","article","10.1177/1074248419838511","31064213",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025060","Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.","Fishman MN","2011","Clinical cancer research : an official journal of the American Association for Cancer Research","nonrandomized_study","article","10.1158/1078-0432.ccr-11-1817","21994418","PMC3972922","ClinicalTrials.gov:NCT00496860","S001092","pubmed; europepmc","FALSE","open_pdf","4",null,"Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0025061","PDX-1 expression is associated with islet proliferation in vitro and in vivo.","Feanny MA","2008","The Journal of surgical research","preclinical","article","10.1016/j.jss.2007.04.018","17583748",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S."],["R0025062","Longstanding Phenytoin Use as a Cause of Progressive Dyspnea.","Walker A","2022","Chest","case_report","article","10.1016/j.chest.2021.08.079","35131079",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0025063","Self-assembling glucagon-like peptide 1-mimetic peptide amphiphiles for enhanced activity and proliferation of insulin-secreting cells.","Khan S","2012","Acta biomaterialia","preclinical","article","10.1016/j.actbio.2012.01.036","22342354","PMC3314122",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0025064","Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-β oligomer-treated hippocampal neurons.","Takach O","2015","Neurobiology of aging","preclinical","article","10.1016/j.neurobiolaging.2014.11.018","25543463",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025065","Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone.","Riswold K","2018","JAAD case reports","case_report","article","10.1016/j.jdcr.2018.06.009","30238049","PMC6143713",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0025066","Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.","Abdalla MA","2022","Clinical endocrinology","systematic_review","article","10.1111/cen.14623","34713480",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0025067","Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial.","Kaneko S","2018","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12793","29277968","PMC6031509",null,"S000361","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0025068","The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes.","Chilton RJ","2018","Current diabetes reports","other_trial","article","10.1007/s11892-018-1114-1","30406850",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0025069","Helping patients make sense of the risks of taking GLP-1 agonists.","Montori VM","2013","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.f3692","23751906",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0025070","Bringing liraglutide to market: a CER case study.","Oderda G","2012","Journal of managed care pharmacy : JMCP","nonrandomized_study","article","10.18553/jmcp.2012.18.s5-a.s12","22663295","PMC10437801",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025071","Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users.","Jensen MH","2020","Diabetes care","nonrandomized_study","article","10.2337/dc19-2535","32238426",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025072","Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.","Watson KT","2019","Behavioural brain research","randomized_trial","article","10.1016/j.bbr.2018.08.006","30099030",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025073","Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes.","Zhang WQ","2018","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-018-0392-8","30564288","PMC6296090","ChiCTR:chiCTR1800018008",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0025074","Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review.","Muñoz-Jiménez M","2020","Dementia and geriatric cognitive disorders","systematic_review","article","10.1159/000510677","33080602",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Systematic Review; Journal Article; review"],["R0025075","Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.","Nauck MA","2018","Diabetes care","randomized_trial","article","10.2337/dc17-1825","29898902","PMC6463597","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025076","Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.","Lu R","2018","PloS one","preclinical","article","10.1371/journal.pone.0198938","29897998","PMC5999272",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025077","Clinical Effectiveness of Intravenous Exenatide Infusion in Perioperative Glycemic Control after Coronary Artery Bypass Graft Surgery: A Phase II/III Randomized Trial.","Besch G","2017","Anesthesiology","randomized_trial","article","10.1097/aln.0000000000001838","28820780",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; article"],["R0025078","Pharmacist Intervention Lowers HgbA1c in Diabetic Patients Regardless of HIV Status.","Nelson NE","2021","Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia","nonrandomized_study","article","10.1002/jppr.1722","34539238","PMC8447228",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025079","Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.","Wismann P","2018","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2018.03.004","29540315",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025080","Glycaemic control with liraglutide: the phase 3 trial programme.","Raskin P","2010","International journal of clinical practice. Supplement","other_trial","article","10.1111/j.1742-1241.2010.02496.x","20887301",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025081","Preoperative use of incretins is associated with increased diabetes remission after RYGB surgery among patients taking insulin: a retrospective cohort analysis.","Wood GC","2015","Annals of surgery","nonrandomized_study","article","10.1097/sla.0000000000000588","24646545","PMC4896739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025082","Liraglutide modulates gut microbiota and reduces NAFLD in obese mice.","Moreira GV","2018","The Journal of nutritional biochemistry","preclinical","article","10.1016/j.jnutbio.2018.07.009","30292107",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025083","Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids.","Wootten D","2011","The Journal of pharmacology and experimental therapeutics","other","article","10.1124/jpet.110.176362","21075839",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025084","Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction.","Qi Q","2017","International journal of nanomedicine","preclinical","article","10.2147/ijn.s132064","28744119","PMC5511023",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025085","Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.","Holst JJ","2006","Diabetologia","narrative_review","article","10.1007/s00125-005-0107-1","16416146",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025086","A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's Perspective.","Nuijten M","2021","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s284855","34267531","PMC8275158",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025087","Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis.","le Roux C","2017","Obesity facts","randomized_trial","article","10.1159/000478099","29145215","PMC5836203",null,"S000492; S001792","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025088","Therapeutics in pediatric diabetes: insulin and non-insulin approaches. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.","Kim J","2012","Pharmacological research","narrative_review","article","10.1016/j.phrs.2011.08.011","21930210",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025089","Liraglutide combined with human umbilical cord mesenchymal stem cell transplantation inhibits beta-cell apoptosis via mediating the ASK1/JNK/BAX pathway in rats with type 2 diabetes.","Wang W","2020","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.3212","31411368",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025090","Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.","Boustani MA","2016","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12687","27161178","PMC5089646","ClinicalTrials.gov:NCT01064687; ClinicalTrials.gov:NCT01075282; ClinicalTrials.gov:NCT01126580; ClinicalTrials.gov:NCT01191268; ClinicalTrials.gov:NCT00734474; ClinicalTrials.gov:NCT01624259","S001130; S001184; S001198; S001242; S001786; S002153","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025091","Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial.","Whicher CA","2019","Trials","protocol","article","10.1186/s13063-019-3689-5","31747930","PMC6868690","EudraCT:2017-004064-35",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; other; article"],["R0025092","Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis.","Mearns ES","2015","PloS one","systematic_review","article","10.1371/journal.pone.0125879","25919293","PMC4412636",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; research-article; article"],["R0025093","Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.","Wysham CH","2016","Diabetes care","randomized_trial","article","10.2337/dc16-0238","27436275",null,"ClinicalTrials.gov:NCT01104701","S001944","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; article"],["R0025094","Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus.","Wilbrink FJ","2018","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.12857","29974671","PMC6031510",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; Comment; article"],["R0025095","Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes.","Heo CU","2019","Journal of clinical medicine","narrative_review","article","10.3390/jcm8030393","30901912","PMC6463061",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025096","Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.","GBD 2023 Disease and Injury and Risk Factor Collaborators","2025","Lancet (London, England)","other","article","10.1016/s0140-6736(25)01637-x","41092926","PMC12535840",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025097","Metformin-associated lactic acidosis precipitated by liraglutide use: adverse effects of aggressive antihyperglycaemic therapy.","Hooda A","2019","Drug and therapeutics bulletin","other","article","10.1136/dtb.2019.227102rep","31253605",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025098","Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications.","Bassi N","2018","Current cardiology reports","randomized_trial","article","10.1007/s11886-018-1050-3","30259198",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0025099","A novel approach to patients with schizophrenia and type 2 diabetes showing low treatment compliance","Argitis P","2022","European psychiatry : the journal of the Association of European Psychiatrists","other","article","10.1192/j.eurpsy.2022.1983",null,"PMC9568080",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0025100","GLP-1 Receptor Expression Within the Human Heart.","Baggio LL","2018","Endocrinology","other","article","10.1210/en.2018-00004","29444223","PMC5939638",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025101","Diabetes Therapies for Dementia.","Moran C","2019","Current neurology and neuroscience reports","narrative_review","article","10.1007/s11910-019-0973-4","31300920",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025102","Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.","Xing C","2022","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2022.945609","36060969","PMC9428699",null,"S001012","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025103","Liraglutide improves myocardial fibrosis after myocardial infarction through inhibition of CTGF by activating cAMP in mice.","Huang DD","2018","European review for medical and pharmacological sciences","preclinical","article","10.26355/eurrev_201807_15524","30058704",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025104","SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.","Saroka RM","2015","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep15877.or","26307900",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0025105","Bidirectional Relationship between Gastric Emptying and Plasma Glucose Control in Normoglycemic Individuals and Diabetic Patients.","Mihai BM","2018","Journal of diabetes research","narrative_review","article","10.1155/2018/1736959","30402500","PMC6192082",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025106","Weight loss is still an essential intervention in obesity and its complications: a review.","Xiao J","2012","Journal of obesity","narrative_review","article","10.1155/2012/369097","22811888","PMC3395150",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0025107","Construction of functional pancreatic artificial islet tissue composed of fibroblast-modified polylactic- co-glycolic acid membrane and pancreatic stem cells.","Liu L","2017","Journal of biomaterials applications","preclinical","article","10.1177/0885328217722041","28747082",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025108","Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.","Freeman JS","2012","The Journal of the American Osteopathic Association","narrative_review","article",null,"22267300",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025109","Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.","Hjerpsted JB","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13120","28941314","PMC5836914",null,"S000313; S001635","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025110","Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry.","Ritsinger V","2020","Diabetes & vascular disease research","nonrandomized_study","article","10.1177/1479164120973676","33231125","PMC7919225",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0025111","National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015.","Kitten AK","2019","PloS one","other","article","10.1371/journal.pone.0221174","31412090","PMC6693747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025112","Response to the comment on: \"Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials\".","Leslie RD","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13366","29781106",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0025113","Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.","Baumann T","2016","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2016.01.003","26971843",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025114","New therapeutic approaches in type 2 diabetes.","Scheen AJ","2008","Acta clinica Belgica","narrative_review","article","10.1179/acb.2008.083","19170358",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; conference-abstract"],["R0025115","An overview of current therapy options of non-alcoholic fatty liver disease.","Dvořák K","2022","Casopis lekaru ceskych","other","article",null,"35728962",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025116","Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3).","Dahlqvist S","2018","BMJ open diabetes research & care","randomized_trial","article","10.1136/bmjdrc-2017-000464","29527308","PMC5841497","EudraCT:2012-001941-42","S002357","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0025117","Enhanced expression of PDX-1 and Ngn3 by exendin-4 during beta cell regeneration in STZ-treated mice.","Kodama S","2005","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2004.12.120","15652518",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025118","Incretins: what is known, new and controversial in 2013?","Burcelin R","2013","Diabetes & metabolism","other","article","10.1016/j.diabet.2013.02.005","23523140",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025119","Attitudes and knowledge about weight management among primary care physicians in Israel: a cross-sectional study.","Or Unger Freinkel K","2024","BMC primary care","other","article","10.1186/s12875-024-02324-5","38504167","PMC10949690",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0025120","A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes.","Melzer-Cohen C","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-019-0583-9","30815829","PMC6437242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; other; article"],["R0025121","Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).","Hollander P","2013","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.20042","23404788",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0025122","Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.","Tuttle KR","2021","Kidney360","randomized_trial","article","10.34067/kid.0005852020","35373017","PMC8740994",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025123","Generation of insulin-producing β-like cells from human iPS cells in a defined and completely xeno-free culture system.","Shahjalal HM","2014","Journal of molecular cell biology","preclinical","article","10.1093/jmcb/mju029","24970864",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025124","Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.","Mol PGM","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13453","30294953","PMC6220800",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0025125","Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.","Aoyama M","2016","Circulation. Heart failure","preclinical","article","10.1161/circheartfailure.115.002081","26721911",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025126","Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets.","Kwon G","2004","Diabetes","preclinical","article","10.2337/diabetes.53.suppl_3.s225","15561916",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review; article"],["R0025127","Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma.","Bretault M","2020","Diabetes & metabolism","case_report","article","10.1016/j.diabet.2019.07.004","31362076",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0025128","Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.","Capozzi ME","2018","Endocrine reviews","narrative_review","article","10.1210/er.2018-00117","29905825","PMC7263842",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0025129","Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder.","Carpentieri GB","2023","Archives of endocrinology and metabolism","narrative_review","article","10.20945/2359-3997000000598","36748934","PMC10247255",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025130","In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.","Lipscombe LL","2019","Annals of internal medicine","commentary","article","10.7326/acpj201909170-028","31525762",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; editorial"],["R0025131","[The \"other\" incretin - the therapeutic rediscovery of the glucose-dependent insulinotropic polypeptide].","Winkler G","2023","Orvosi hetilap","narrative_review","article","10.1556/650.2023.32710","36774634",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; English Abstract; Journal Article; article"],["R0025132","HYPOGLYCEMIA IN THE ELDERLY WITH DIABETES: A GROWING PROBLEM WITH EMERGING SOLUTIONS.","Grajower MM","2018","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.4158/ep-2017-0182","29547043",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025133","Inhibitory effects of glucagon-like peptide-1 receptor on epilepsy.","Wen Y","2019","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2019.02.028","30770099",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025134","Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.","Øhrstrøm CC","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13796","31144430",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025135","Systemic benefits of Gc inhibition to preserve insulin sensitivity","Kuo T","2020","bioRxiv","preclinical","preprint","10.1101/2020.10.06.328963",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0025136","Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.","Fudim M","2019","Circulation","randomized_trial","article","10.1161/circulationaha.119.041659","31542942","PMC6924268","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025137","Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes.","Stanton AM","2021","Current diabetes reports","narrative_review","article","10.1007/s11892-021-01407-2","34580767",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025138","Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.","Seino Y","2015","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","other","article","10.1055/s-0035-1549875","26039935",null,"ClinicalTrials.gov:NCT00866658","S000488","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025139","Type 2 diabetes mellitus management in patients with chronic kidney disease: an update.","Kleinaki Z","2020","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-020-00212-y","32500461",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025140","Cross-talk between bone morphogenetic protein and transforming growth factor-beta signaling is essential for exendin-4-induced insulin-positive differentiation of AR42J cells.","Yew KH","2005","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m505465200","16020542",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0025141","Diabetes and cardiovascular disease: from new mechanisms to new therapies.","Gajos G","2018","Polish archives of internal medicine","randomized_trial","article","10.20452/pamw.4227","29579035",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025142","T cells in obesity-associated inflammation: The devil is in the details.","Valentine Y","2024","Immunological reviews","preclinical","article","10.1111/imr.13354","38767210","PMC11694249",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; review"],["R0025143","Exenatide (Byetta) for type 2 diabetes.",null,"2005","The Medical letter on drugs and therapeutics","other","article",null,"15933616",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025144","Liraglutide: another reason to target prediabetes?","Murphy CF","2017","Oncotarget","commentary","article","10.18632/oncotarget.22256","29245886","PMC5725077",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0025145","Sustained expression of GLP-1 receptor differentially modulates β-cell functions in diabetic and nondiabetic mice.","Kubo F","2016","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2016.01.177","26854076","PMC5403141",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0025146","Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion.","Morse BL","2019","CPT: pharmacometrics & systems pharmacology","preclinical","article","10.1002/psp4.12447","31250974","PMC6765700",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025147","Raw Material Specification, Exenatide, 250 μg/mL.","NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee","2017","CellR4-- repair, replacement, regeneration, & reprogramming","other","article",null,"30613750","PMC6319640",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025148","Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion.","Cirincione B","2017","Journal of clinical pharmacology","other_trial","article","10.1002/jcph.882","28543393","PMC5518197",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase I; Journal Article; research-article; article"],["R0025149","Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.","Camilleri M","2012","American journal of physiology. Gastrointestinal and liver physiology","randomized_trial","article","10.1152/ajpgi.00076.2012","22517769",null,null,"S002676","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025150","2024 update in heart failure.","Beghini A","2025","ESC heart failure","other_trial","article","10.1002/ehf2.14857","38806171","PMC11769673",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0025151","Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.","Vilsbøll T","2007","Expert opinion on investigational drugs","other_trial","article","10.1517/13543784.16.2.231","17243943",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0025152","Mechanism of and strategy to mitigate liraglutide-mediated positive chronotropy.","Jøns C","2021","Life sciences","preclinical","article","10.1016/j.lfs.2021.119815","34256040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025153","Glucose-Lowering Drugs and Outcomes in COVID-19 Patients with Diabetes","Zhu Z","2022","SSRN","other","preprint","10.2139/ssrn.4103144",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0025154","Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.","Egan JM","2003","American journal of physiology. Endocrinology and metabolism","other_trial","article","10.1152/ajpendo.00315.2002","12475750",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0025155","Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.","Kumar A","2012","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.2350","23280862",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0025156","The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms.","Zhao C","2017","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2017.00098","28515711","PMC5413504",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025157","Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials.","Ismail-Beigi F","2017","Journal of general internal medicine","randomized_trial","article","10.1007/s11606-017-4061-7","28550608","PMC5570736",null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Review; research-article"],["R0025158","BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.","Ding L","2017","Pharmacological research","preclinical","article","10.1016/j.phrs.2017.05.007","28619366",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025159","GLP-1 receptor agonists for type 2 diabetes.","De Block CE","2009","Lancet (London, England)","commentary","article","10.1016/s0140-6736(09)60942-9","19515414",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0025160","The risk of cardiovascular complications with current obesity drugs.","Chao AM","2020","Expert opinion on drug safety","randomized_trial","article","10.1080/14740338.2020.1806234","32750250","PMC7554173",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0025161","Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients.","Suliman M","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13672","30768836",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0025162","Antidiabetic Agents for Treatment of Parkinson's Disease: A Meta-Analysis.","Wang SY","2020","International journal of environmental research and public health","systematic_review","article","10.3390/ijerph17134805","32635358","PMC7369739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Review; review-article; review"],["R0025163","Comment on: \"Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials\".","Jones AG","2018","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.13290","29536610",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0025164","Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin's metabolic action in the presence of insulin resistance.","Chai W","2014","Diabetes","preclinical","article","10.2337/db13-1597","24658303","PMC4113068",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025165","Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.","Peng Y","2019","Journal of cellular physiology","systematic_review","article","10.1002/jcp.27097","30145806",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; article"],["R0025166","Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.","Bak AM","2011","Expert opinion on therapeutic targets","narrative_review","article","10.1517/14728222.2011.600691","21749267",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025167","Association of vitamin B12 deficiency with metformin use in patients with type 2 diabetes treated in the largest tertiary care hospital in Qatar.","Yousef Khan F","2021","Qatar medical journal","other","article","10.5339/qmj.2021.39","34540601","PMC8428509",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0025168","Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.","Idzerda NMA","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13958","31912603","PMC7187441",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025169","Development of a normothermic extracorporeal liver perfusion system toward improving viability and function of human extended criteria donor livers.","Banan B","2016","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","other","article","10.1002/lt.24451","27027254",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025170","Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats.","Li J","2017","Diabetology & metabolic syndrome","preclinical","article","10.1186/s13098-017-0289-y","29213335","PMC5710066",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025171","Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.","Seino H","2016","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-016-0151-7","27252787","PMC4888474","ClinicalTrials.gov:NCT01169779; ClinicalTrials.gov:NCT00713830","S000491; S001185","pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0025172","Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function.","Xu J","2019","Laboratory investigation; a journal of technical methods and pathology","preclinical","article","10.1038/s41374-018-0170-0","30659271",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025173","Liraglutide activates autophagy via GLP-1R to improve functional recovery after spinal cord injury.","Chen J","2017","Oncotarget","preclinical","article","10.18632/oncotarget.20791","29156769","PMC5689659",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025174","Boosting systemic absorption of peptides with a bioinspired buccal-stretching patch.","Luo Z","2023","Science translational medicine","other","article","10.1126/scitranslmed.abq1887","37756378",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025175","Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).","de Wit HM","2014","Diabetologia","randomized_trial","article","10.1007/s00125-014-3302-0","24947583",null,"ClinicalTrials.gov:NCT01392898","S000485; S001780","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025176","Mechanism of liraglutide-mediated attenuation of palmitic acid-induced lipotoxicity in L6 myoblasts","KONG M","2022","Research Square","other","preprint","10.21203/rs.3.rs-1835443/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0025177","Adult Murine Pancreatic Progenitors Require Epidermal Growth Factor and Nicotinamide for Self-Renewal and Differentiation in a Serum- and Conditioned Medium-Free Culture.","Wedeken L","2017","Stem cells and development","preclinical","article","10.1089/scd.2016.0328","28095743","PMC5393420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025178","Trends in the incidence of use of noninsulin glucose-lowering drugs between 2006 and 2013 in France.","Arnaud M","2017","Fundamental & clinical pharmacology","nonrandomized_study","article","10.1111/fcp.12298","28575541",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0025179","beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.","Li Y","2005","Diabetes","preclinical","article","10.2337/diabetes.54.2.482","15677506",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025180","Sustained usage of an app-based clinical-decision making aid for the management of atherosclerotic cardiovascular disease",null,"2022","European heart journal. Digital health","nonrandomized_study","article",null,null,"PMC9779884",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0025181","Insulin degludec, Lixisenatide, and Patiromer sorbitex calcium.","Hussar DA","2016","Journal of the American Pharmacists Association : JAPhA","other","article","10.1016/j.japh.2016.10.002","27836130",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025182","Determination of liraglutide in rat plasma by a selective liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetics study.","Dong S","2018","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","preclinical","article","10.1016/j.jchromb.2018.05.020","29803687",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025183","Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease.","Alvares D","2019","Biochimica et biophysica acta. Molecular and cell biology of lipids","narrative_review","article","10.1016/j.bbalip.2018.12.010","30578967",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025184","Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.","Ghatak SB","2011","Current diabetes reviews","other_trial","article","10.2174/157339911797415648","21916836",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0025185","A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus.","Laursen HVB","2023","PharmacoEconomics","systematic_review","article","10.1007/s40273-023-01268-5","37410277","PMC10570198",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; review-article; review"],["R0025186","Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.","Jensen L","2018","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13186","29205786","PMC5873441","ClinicalTrials.gov:NCT02210871","S000932","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0025187","The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.","de Lapertosa SB","2016","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2016.10.001","27776251",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0025188","Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus.","Ghatak SB","2010","Current diabetes reviews","other_trial","article","10.2174/157339910793499119","20879969",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0025189","Liraglutide and systolic blood pressure.","Dandona P","2019","Journal of clinical hypertension (Greenwich, Conn.)","nonrandomized_study","article","10.1111/jch.13443","30515941","PMC8030325",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article-commentary; article"],["R0025190","Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway.","Ao N","2016","Hepatology research : the official journal of the Japan Society of Hepatology","preclinical","article","10.1111/hepr.12551","26147696",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025191","Glycemic Variability: Risk Factors, Assessment, and Control.","Kovatchev B","2019","Journal of diabetes science and technology","narrative_review","article","10.1177/1932296819826111","30694076","PMC6610616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0025192","The therapeutic role of incretin mimetics and DPP-4 inhibitors.","Funnell MM","2009","The Diabetes educator","other","article","10.1177/0145721709331521","19218562",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0025193","GLP-1 analog attenuates cocaine reward.","Graham DL","2013","Molecular psychiatry","preclinical","article","10.1038/mp.2012.141","23089631","PMC3700649",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; research-article; article"],["R0025194","Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway.","Wang MD","2012","Neuroscience","preclinical","article","10.1016/j.neuroscience.2012.09.025","23000625",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025195","Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.","de Mesquita FC","2017","Scientific reports","preclinical","article","10.1038/s41598-017-02866-y","28607430","PMC5468330",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025196","Endogenous GLP-1 acts on paraventricular nucleus to suppress feeding: projection from nucleus tractus solitarius and activation of corticotropin-releasing hormone, nesfatin-1 and oxytocin neurons.","Katsurada K","2014","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2014.07.116","25089000",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025197","Intensive management of obesity in people with Prader-Willi syndrome.","Nolan BJ","2022","Endocrine","nonrandomized_study","article","10.1007/s12020-022-03064-1","35524875","PMC9242929",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025198","Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.","Ponirakis G","2021","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13582","34002953","PMC8565403",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0025199","Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.","Tahrani AA","2016","Nature reviews. Endocrinology","narrative_review","article","10.1038/nrendo.2016.86","27339889",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025200","Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trials.","Yang X","2020","Herz","systematic_review","article","10.1007/s00059-018-4748-5","30467578",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0025201","Metabolic Disorders and Cancer: Hepatocyte Store-Operated Ca2+ Channels in Nonalcoholic Fatty Liver Disease.","Ali ES","2017","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-3-319-57732-6_30","28900935",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025202","Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1.","Andersen NH","2002","Bioorganic & medicinal chemistry","other","article","10.1016/s0968-0896(01)00263-2","11738609",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025203","Mineralocorticoid Antagonism and Diabetic Kidney Disease.","Lytvyn Y","2019","Current diabetes reports","narrative_review","article","10.1007/s11892-019-1123-8","30673886",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025204","Fracture risk associated with common medications used in treating type 2 diabetes mellitus.","Wolverton D","2017","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","randomized_trial","article","10.2146/ajhp160319","28743778",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0025205","Comparison of the results of sleeve gastrectomy, gastric pilication and liragulitide in obese rats.","Bilge H","2023","Polish journal of veterinary sciences","preclinical","article","10.24425/pjvs.2023.145059","38088297",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025206","Effects of liraglutide on obesity-associated functional hypogonadism in men.","Jensterle M","2019","Endocrine connections","randomized_trial","article","10.1530/ec-18-0514","30707677","PMC6391904",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025207","[Exendin-4 improves impaired endothelial dependent vasodilation in obese rat].","Han LN","2013","Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","preclinical","article",null,"23600208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025208","Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis.","Marfella R","2018","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-017-0304-3","29308090","PMC5751832","ClinicalTrials.gov:NCT03312179",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025209","Glucose-responsive hydrogel enhances the preventive effect of insulin and liraglutide on diabetic nephropathy of rats.","Tong MQ","2021","Acta biomaterialia","preclinical","article","10.1016/j.actbio.2021.01.007","33444802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025210","Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?","Bosi E","2009","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2008.01031.x","19385978",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025211","The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.","Lykkegaard K","2008","Schizophrenia research","preclinical","article","10.1016/j.schres.2008.05.011","18579346",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025212","Cost effectiveness of liraglutide in type II diabetes: a systematic review.","Zueger PM","2014","PharmacoEconomics","systematic_review","article","10.1007/s40273-014-0192-4","25052903",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0025213","Extendin-4 protects kidney from acute ischemia-reperfusion injury through upregulation of NRF2 signaling.","Zhen YY","2017","American journal of translational research","preclinical","article",null,"29218078","PMC5714764",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025214","Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.","Oeseburg H","2010","Arteriosclerosis, thrombosis, and vascular biology","preclinical","article","10.1161/atvbaha.110.206425","20448207",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025215","Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes.","Overbeek JA","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13335","29726082","PMC6099315",null,"S002036","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025216","Oral Semaglutide.","Bui V","2018","Clinical diabetes : a publication of the American Diabetes Association","other","article","10.2337/cd18-0034","30364001","PMC6187952",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025217","Pharmaco-endoscopic therapy for weight regain post-gastric bypass: a case report.","Jarrah M","2023","Journal of surgical case reports","case_report","article","10.1093/jscr/rjad075","37069846","PMC9972808",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0025218","Tandem mass tag-based proteomic profiling revealed potential therapeutic targets and mechanisms of liraglutide for the treatment of impaired glucose tolerance.","Guo Q","2022","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2022.1031019","36452319","PMC9701722",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025219","Combination Use of Insulin and Incretins in Type 2 Diabetes",null,"2013","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"27195358",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0025220","Medial hypothalamic MC3R signalling regulates energy rheostasis in adult mice.","Possa-Paranhos IC","2025","The Journal of physiology","preclinical","article","10.1113/jp286699","39718394","PMC11737543",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0025221","Molecular Pharmacology of the Incretin Receptors.","Al-Sabah S","2016","Medical principles and practice : international journal of the Kuwait University, Health Science Centre","preclinical","article","10.1159/000433437","26111634","PMC5588519",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025222","Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.","Lundkvist P","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12954","28345814","PMC5575470",null,"S000930","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0025223","Protection of exendin-4 analogue in early experimental diabetic retinopathy.","Zhang Y","2009","Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","preclinical","article","10.1007/s00417-008-1004-3","19084986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025224","Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.","Kim TH","2012","Biological & pharmaceutical bulletin","preclinical","article","10.1248/bpb.b12-00029","22791155",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025225","The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists.","Al-Sabah S","2004","Protein and peptide letters","other","article","10.2174/0929866043478365","14965273",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025226","Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.","Horie I","2018","Diabetes research and clinical practice","other_trial","article","10.1016/j.diabres.2018.08.015","30194951",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial; Journal Article; article"],["R0025227","The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.","Dhatariya K","2018","Diabetes care","randomized_trial","article","10.2337/dc18-1094","30072400","PMC6150424","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025228","Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.","Khavinson V","2022","Cells","narrative_review","article","10.3390/cells12010106","36611900","PMC9818427",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025229","Agreement of an AI tool for joint space width measurement in radiographic knee osteoarthritis: data from the LOSEIT trial","Mayar S","2026","medRxiv","randomized_trial","preprint","10.64898/2026.06.11.26355242",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Preprint; preprint"],["R0025230","In vitro and in vivo evaluation of the effect of nano-sized collagen molecules and nicotinamide on mesenchymal stem cell differentiation.","Ma CT","2016","Journal of materials chemistry. B","preclinical","article","10.1039/c6tb00731g","32263088",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025231","How much will Incretin Mimetics contribute to hyperglycaemia management?","Reckless JP","2010","International journal of clinical practice","commentary","article","10.1111/j.1742-1241.2010.02339.x","20456185",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0025232","Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.","Gumuslu E","2018","Fundamental & clinical pharmacology","preclinical","article","10.1111/fcp.12329","29091313",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025233","Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.","Skelin M","2020","Diabetes care","randomized_trial","article","10.2337/dc19-2039","31959649",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Letter; Comment; article"],["R0025234","Regulatory Effect of Liraglutide on Endoplasmic Reticulum Stress in Non-alcoholic Fatty Pancreas Disease","Chen Y","2020","Research Square","preclinical","preprint","10.21203/rs.2.24045/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0025235","MiR-375, a microRNA related to diabetes.","Li X","2014","Gene","narrative_review","article","10.1016/j.gene.2013.09.105","24120394",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025236","Roux-en-Y gastric bypass in rats increases sucrose taste-related motivated behavior independent of pharmacological GLP-1-receptor modulation.","Mathes CM","2012","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00214.2011","22170618","PMC3774488",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0025237","Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.","Pathak NM","2018","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2018.07.021","30028989",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025238","A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.","Baggio LL","2004","Diabetes","preclinical","article","10.2337/diabetes.53.9.2492","15331566",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025239","Efficacy and tolerability of exenatide twice daily and exenatide once weekly in Asian versus White patients with type 2 diabetes mellitus: A pooled analysis.","Sheu WH","2016","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2015.12.004","26827116",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025240","Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.","Sasson K","2010","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2009.10.028","19883707",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025241","Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.","Shi L","2015","Cardiovascular diabetology","preclinical","article","10.1186/s12933-015-0177-4","25855361","PMC4327797",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025242","Projected impact of anti-obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity.","Vajravelu ME","2024","Pediatric obesity","other_trial","article","10.1111/ijpo.13103","38318987","PMC12980788",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025243","Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects.",null,"2015","Prescrire international","narrative_review","article",null,"26034806",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025244","Diabetes among Muslims during Ramadan: A narrative review.","Ochani RK","2023","World journal of clinical cases","narrative_review","article","10.12998/wjcc.v11.i26.6031","37731557","PMC10507567",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0025245","Advancing Pharmacotherapy Development from Preclinical Animal Studies.","Egli M","2018","Handbook of experimental pharmacology","other","article","10.1007/164_2017_85","29374834",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025246","Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.","Zettl H","2010","ChemMedChem","narrative_review","article","10.1002/cmdc.200900448","20029928",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025247","Cross-relationship between COVID-19 infection and anti-obesity products efficacy and incidence of side effects: A cross-sectional study.","El-Mezayen NS","2024","PloS one","other","article","10.1371/journal.pone.0309323","39173063","PMC11341056",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025248","Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment.","Blevins T","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-016-0172-0","27146799","PMC4900982","ClinicalTrials.gov:NCT00877890","S001308","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; case-report; article"],["R0025249","Glucagon-like peptide-1 is specifically involved in sweet taste transmission.","Takai S","2015","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","preclinical","article","10.1096/fj.14-265355","25678625","PMC4763871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025250","National trends in prescription drug expenditures and projections for 2024.","Tichy EM","2024","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxae105","38656319",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0025251","Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.","Badawi GA","2019","Neurotoxicity research","preclinical","article","10.1007/s12640-019-9998-3","30673988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0025252","Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study.","Jendle J","2018","Journal of the American Society of Hypertension : JASH","randomized_trial","article","10.1016/j.jash.2018.02.003","29548934",null,"ClinicalTrials.gov:NCT01425580","S002231","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025253","Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia.","Solverson KJ","2018","CJEM","case_report","article","10.1017/cem.2017.439","29397808",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0025254","Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity.","Welling MS","2023","iScience","other","article","10.1016/j.isci.2023.106199","36876127","PMC9982263",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025255","Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling.","Bułdak Ł","2016","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-016-1277-8","27424158",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0025256","Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.","Lesven S","2010","Annales d'endocrinologie","other_trial","article","10.1016/j.ando.2010.09.001","21030006",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0025257","Corrigendum to \"Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway\" [Biochem. Biophys. Res. Commun. 510 (2019) 20-26].","Li Z","2020","Biochemical and biophysical research communications","notice","article","10.1016/j.bbrc.2020.01.049","31982138",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0025258","A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo.","Kitani K","2007","The journal of physiological sciences : JPS","preclinical","article","10.2170/physiolsci.rp006607","17854513",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025259","Diabetes Medications for Adults With Type 2 Diabetes: An Update","Bolen S","2016","Agency for Healthcare Research and Quality (US), Rockville (MD)","randomized_trial","article",null,"27227214",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0025260","Preproglucagon neurons in the hindbrain have IL-6 receptor-α and show Ca2+ influx in response to IL-6.","Anesten F","2016","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00383.2015","27097661","PMC4967238",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025261","Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus.","Ohyagi Y","2019","Advances in experimental medicine and biology","preclinical","article","10.1007/978-981-13-3540-2_11","31062332",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025262","Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.","Kwon KC","2013","Advanced drug delivery reviews","narrative_review","article","10.1016/j.addr.2012.10.005","23099275","PMC3582797",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0025263","Applying the Social-Ecological Approach to Evaluate Diabetes Medication Management in Older People.","Poon IO","2021","The Senior care pharmacist","other","article","10.4140/tcp.n.2021.548","34717786","PMC8663919",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025264","Species differences in pancreatic binding of DO3A-VS-Cys40-Exendin4.","Eriksson O","2017","Acta diabetologica","preclinical","article","10.1007/s00592-017-1046-2","28891030","PMC5643362",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025265","Use of Real-World Data to Emulate a Clinical Trial and Support Regulatory Decision Making: Assessing the Impact of Temporality, Comparator Choice, and Method of Adjustment.","Abrahami D","2021","Clinical pharmacology and therapeutics","nonrandomized_study","article","10.1002/cpt.2012","32767673",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025266","Exenatide: a review from pharmacology to clinical practice.","Gentilella R","2009","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2008.01018.x","19383034",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025267","Incretin-based medications for type 2 diabetes: an overview of reviews.","Gamble JM","2015","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12465","25772666",null,"PROSPERO:CRD42013005149",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0025268","Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.","ThanThan S","2017","Domestic animal endocrinology","preclinical","article","10.1016/j.domaniend.2016.10.005","27888738",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025269","[The effect of antidiabetic treatment on the bone of patients with type 2 diabetes].","Karásek D","2016","Vnitrni lekarstvi","narrative_review","article",null,"27627081",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025270","Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat.","Zhang Y","2017","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2017.03.029","28363742",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025271","Small molecule drug discovery at the glucagon-like peptide-1 receptor.","Willard FS","2012","Experimental diabetes research","narrative_review","article","10.1155/2012/709893","22611375","PMC3352573",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025272","[Successful treatment with liraglutide in type 1 diabetes and MODY].","Deiss D","2011","Deutsche medizinische Wochenschrift (1946)","case_report","article","10.1055/s-0031-1280520","21590630",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0025273","Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.","Davies M","2011","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2010.03074.x","21309842",null,null,"S002361","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025274","Obestatin promotes proliferation and survival of adult hippocampal progenitors and reduces amyloid-β-induced toxicity.","Gargantini E","2016","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2015.11.008","26586206",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025275","Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations.","Wootten D","2013","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.1221585110","23479653","PMC3612682",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025276","The reversal of hyperglycaemia in diabetic mice using PLGA scaffolds seeded with islet-like cells derived from human embryonic stem cells.","Mao GH","2009","Biomaterials","preclinical","article","10.1016/j.biomaterials.2008.12.030","19135250",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025277","External Validation of the BRAVO Diabetes Model Using the EXSCEL Clinical Trial Data.","Shao Y","2023","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-023-01441-1","37432547","PMC10363088",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; case-report; article"],["R0025278","Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.","Liu Y","2017","Lipids in health and disease","nonrandomized_study","article","10.1186/s12944-017-0609-0","29197387","PMC5712174","ChiCTR:ChiCTR-IPR-16008578",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0025279","GLP-1 receptor regulates cell growth through regulating IDE expression level in Aβ1-42-treated PC12 cells.","Li H","2018","Bioscience reports","preclinical","article","10.1042/bsr20171284","29263141","PMC6043719",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025280","Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.","Gedulin BR","2008","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2008.01.015","18291606",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025281","Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.","de la Peña A","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12847","27976833",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025282","A year in type 2 diabetes mellitus: 2018 review based on the Endorama lecture.","Paschou SA","2019","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-019-00139-z","31630372",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025283","Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis.","Hegde NC","2024","General hospital psychiatry","systematic_review","article","10.1016/j.genhosppsych.2024.06.003","38878592",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis"],["R0025284","Controlling Pharmaceutical Costs in a Student-Run Free Clinic in a Resource-Limited Patient Setting.","He C","2023","Journal of community health","other","article","10.1007/s10900-023-01232-6","37405614",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025285","Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).","Lavynenko O","2022","Diabetes, obesity & metabolism","other","article","10.1111/dom.14650","35014145",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0025286","Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes.","Wolffenbuttel BH","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12669","27027802","PMC5111732",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025287","Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.","Holubová M","2019","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2018.11.002","30428311",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025288","Molecular mechanisms redirecting the GLP-1 receptor signalling profile in pancreatic β-cells during type 2 diabetes.","Roussel M","2016","Hormone molecular biology and clinical investigation","narrative_review","article","10.1515/hmbci-2015-0071","26953712",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025289","Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.","Barnett AH","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13318","29652101",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025290","Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis.","Gad H","2021","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2020.108562","33271228",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0025291","Targeting postprandial glycaemia in children with diabetes: Opportunities and challenges.","Geyer MC","2018","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13141","29072820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025292","Exenatide Regulates Substrate Preferences Through the p38γ MAPK Pathway After Ischaemia/Reperfusion Injury in a Rat Heart.","Zheng A","2017","Heart, lung & circulation","preclinical","article","10.1016/j.hlc.2016.07.006","27574735",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025293","Cardiovascular outcome trials of the newer anti-diabetic medications.","Acharya T","2019","Progress in cardiovascular diseases","narrative_review","article","10.1016/j.pcad.2019.08.003","31442511",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025294","Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.","Tian F","2018","Bioscience reports","randomized_trial","article","10.1042/bsr20181304","30473540","PMC6435530",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025295","An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.","Irons BK","2012","Current diabetes reviews","narrative_review","article","10.2174/157339912800564007","22429011",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025296","Author Correction: Assessment of the cardioprotective effect of liraglutide on methotrexate induced cardiac dysfunction through suppression of inflammation and enhancement of angiogenesis in rats.","Mahmoud RH","2022","European review for medical and pharmacological sciences","notice","article","10.26355/eurrev_202201_27853","35113407",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0025297","Suspension Culture Alters Insulin Secretion in Induced Human Umbilical Cord Matrix-Derived Mesenchymal Cells.","Seyedi F","2016","Cell journal","other","article","10.22074/cellj.2016.3987","27054119","PMC4819386",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025298","The effects of glucose-lowering therapies on diabetic kidney disease.","Agrawal V","2015","Current diabetes reviews","narrative_review","article","10.2174/1573399811666150331160534","25824237","PMC5398087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0025299","A Ganoderma lucidum polysaccharide F31 alleviates hyperglycemia through kidney protection and adipocyte apoptosis.","Jiao J","2023","International journal of biological macromolecules","preclinical","article","10.1016/j.ijbiomac.2022.11.231","36442553",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025300","Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study.","Fadini GP","2020","Journal of endocrinological investigation","systematic_review","article","10.1007/s40618-019-01110-w","31515744",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Meta-Analysis"],["R0025301","Cellular specificity of proexendin-4 processing in mammalian cells in vitro and in vivo.","Adatia FA","2002","Endocrinology","preclinical","article","10.1210/en.2002-220251","12193559",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025302","[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].","Winkler G","2007","Orvosi hetilap","narrative_review","article","10.1556/oh.2007.28093","17383951",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025303","Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist.","Wang Q","2010","PloS one","preclinical","article","10.1371/journal.pone.0012734","20856794","PMC2939854",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025304","Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome.","Kim YM","2020","Annals of pediatric endocrinology & metabolism","case_report","article","10.6065/apem.2020.25.1.52","32252218","PMC7136503",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0025305","Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.","Hansotia T","2004","Diabetes","preclinical","article","10.2337/diabetes.53.5.1326","15111503",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025306","Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium.","Guttuso T","2019","Journal of the neurological sciences","narrative_review","article","10.1016/j.jns.2019.05.016","31129265",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025307","The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration.","Li Y","2021","Journal of neurochemistry","preclinical","article","10.1111/jnc.15521","34569615","PMC8627453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025308","Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis.","Wang FF","2018","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.12720","30066361",null,"PROSPERO:CRD42017076625",null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0025309","GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.","Holst JJ","2009","Diabetes research and clinical practice","commentary","article","10.1016/j.diabres.2009.02.017","19299027",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0025310","Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.","ThanThan S","2013","Domestic animal endocrinology","other_trial","article","10.1016/j.domaniend.2012.09.003","23122871",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025311","Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.","Holman RR","2017","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1612917","28910237","PMC9792409","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial; research-article; article"],["R0025312","A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.","Perry T","2002","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.300.3.958","11861804",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S."],["R0025313","Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.","Drucker DJ","2008","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(08)61206-4","18782641",null,"ClinicalTrials.gov:NCT00308139","S000204; S000506; S002279","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025314","The Route from the Folded to the Amyloid State: Exploring the Potential Energy Surface of a Drug-Like Miniprotein.","Taricska N","2020","Chemistry (Weinheim an der Bergstrasse, Germany)","other","article","10.1002/chem.201903826","31647140","PMC7028080",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025315","Time-series analysis of recent antihyperglycemic medication prescribing trends for a diverse sample of Medicare enrollees with type 2 diabetes mellitus in an integrated health system.","Miller MJ","2022","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","other","article","10.1093/ajhp/zxac056","35176753",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025316","Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.","Mentz RJ","2018","Journal of the American Heart Association","other_trial","article","10.1161/jaha.118.009304","30371301","PMC6404902","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0025317","Effects of glucagon-like peptide-1 in diabetic rat small resistance arteries.","Bayram Z","2014","Journal of cardiovascular pharmacology","preclinical","article","10.1097/fjc.0000000000000120","24887687",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025318","Insulin Can Delay Neutrophil Extracellular Trap Formation In Vitro-Implication for Diabetic Wound Care?","Linnemann C","2023","Biology","preclinical","article","10.3390/biology12081082","37626968","PMC10452400",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025319","Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice.","Baggio L","2000","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m005119200","10952981",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025320","Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects.","Eldor R","2016","Diabetes care","other","article","10.2337/dc15-2706","27489336","PMC5864097",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025321","A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.","Tillner J","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13494","30091218",null,"ClinicalTrials.gov:NCT02411825","S003303","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025322","[Efficacy of GLP-1-analogs in type 2 diabetes mellitus].","Schütt M","2013","Deutsche medizinische Wochenschrift (1946)","commentary","article","10.1055/s-0032-1329135","23250688",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comment; Letter"],["R0025323","Childhood and Adolescent Obesity: A Review.","Kansra AR","2020","Frontiers in pediatrics","narrative_review","article","10.3389/fped.2020.581461","33511092","PMC7835259",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025324","Can therapies that target the incretin system improve our ability to treat type 2 diabetes?","Bell TJ","2010","Journal of the National Medical Association","narrative_review","article","10.1016/s0027-9684(15)30560-5","20575217",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025325","Improvement of islet graft function using liraglutide is correlated with its anti-inflammatory properties.","Langlois A","2016","British journal of pharmacology","preclinical","article","10.1111/bph.13575","27515367","PMC5120160",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025326","The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.","Chatzis P","2018","Folia medica","narrative_review","article","10.2478/folmed-2018-0036","31188761",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0025327","Direct actions of GLP-1 analogues on AMP-activated protein kinase activity are distinct from cyclic AMP accumulation.","Samson SL","2013","Journal of hepatology","preclinical","article","10.1016/j.jhep.2012.10.032","23159768",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0025328","[Diabetes and thyroid disorders].","Reismann P","2011","Orvosi hetilap","narrative_review","article","10.1556/oh.2011.29056","21398213",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Review; article"],["R0025329","MON-695 Multiple Recurrent Lipomatoses with Thiazolidinedione Therapy in Familial Partial Lipodystrophy, Dunnigan Variety (FPLD2)","Patni N","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.1287",null,"PMC7208106",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0025330","Evaluation of Strategies for Decreasing Blood Glucose Using Albuminbinding Domain.","Fan L","2020","Current pharmaceutical biotechnology","preclinical","article","10.2174/1389201021666200101105018","31893990",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025331","Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system.","Pérez-Tilve D","2010","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00464.2009","20197503","PMC2867369",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025332","Exenatide Induces Impairment of Autophagy Flux to Damage Rat Pancreas.","Li Z","2017","Pancreas","preclinical","article","10.1097/mpa.0000000000000692","27518464",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025333","The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.","López de Maturana R","2003","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m212147200","12524435",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025334","Biosynthetic Human Insulin and Insulin Analogs.","Rodbard HW","2020","American journal of therapeutics","narrative_review","article","10.1097/mjt.0000000000001089","31876563",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025335","Don't Play with Your Nodule: Case Report of Tachycardia and Other Adverse Reactions from Manipulation of an Exenatide Injection Site Nodule.","Sandman C","2018","The Journal of emergency medicine","case_report","article","10.1016/j.jemermed.2018.01.022","29551427",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0025336","Recombinant expression, in vitro refolding, and biophysical characterization of the human glucagon-like peptide-1 receptor.","Schröder-Tittmann K","2010","Biochemistry","preclinical","article","10.1021/bi101159s","20690636",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025337","Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson's Disease.","Aksoy D","2017","The American journal of the medical sciences","preclinical","article","10.1016/j.amjms.2017.05.002","28918840",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025338","The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.","Flint A","2011","Advances in therapy","randomized_trial","article","10.1007/s12325-010-0110-x","21340616",null,null,"S000333","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025339","[Type 2 Diabetes and Vascular Endothelial Dysfunction].","Torimoto K","2018","Journal of UOEH","narrative_review","article","10.7888/juoeh.40.65","29553076",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0025340","Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs.","Maranta F","2018","International journal of cardiology. Heart & vasculature","narrative_review","article","10.1016/j.ijcha.2018.10.001","30402533","PMC6205052",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025341","A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction.","Kyhl K","2016","EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology","randomized_trial","article","10.4244/eijv12i4a78","27436599",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0025342","Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction.","Faradji RN","2009","Cell transplantation","randomized_trial","article","10.3727/096368909x474456","20003758",null,"ClinicalTrials.gov:NCT00306098; ClinicalTrials.gov:NCT00315588","S003387","pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0025343","Exenatide Prevents Morphological and Structural Changes of Mitochondria Following Ischaemia-Reperfusion Injury.","Lee KH","2017","Heart, lung & circulation","preclinical","article","10.1016/j.hlc.2016.08.007","27743854",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025344","[The role of postprandial hyperglycemia in the development of cardiovascular diseases in type 2 diabetes mellitus].","Shvarts V","2009","Klinicheskaia meditsina","narrative_review","article",null,"20143560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0025345","Therapeutic efficacy of differentiated versus undifferentiated mesenchymal stem cells in experimental type I diabetes in rat.","Wassef MA","2016","Biochemistry and biophysics reports","preclinical","article","10.1016/j.bbrep.2016.02.001","28955854","PMC5600460",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025346","Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).","Raz I","2012","Diabetes care","randomized_trial","article","10.2337/dc11-1942","22301126","PMC3322710",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0025347","Glucagon-like peptide-1 modulates synaptic transmission to identified pancreas-projecting vagal motoneurons.","Wan S","2007","Peptides","preclinical","article","10.1016/j.peptides.2007.08.016","17889966",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, Non-P.H.S."],["R0025348","GLP-1 Receptor Mediated Targeting of a Fluorescent Zn(2+) Sensor to Beta Cell Surface for Imaging Insulin/Zn(2+) Release.","Li D","2015","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.5b00332","26121325",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0025349","Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide.","Schwartz S","2008","Current medical research and opinion","randomized_trial","article","10.1185/03007990802390795","18828960",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025350","Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients.","Fushimi N","2020","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13093","31168938","PMC6944833",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0025351","Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice.","Lennox R","2014","Peptides","preclinical","article","10.1016/j.peptides.2014.08.014","25195184",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025352","Combination of DPP-4 inhibitor and PPARγ agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression.","Hirukawa H","2015","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2015.06.010","26116826",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025353","The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus.","Fazioli KT","2020","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2020.26.9.1072","32857658","PMC10391231",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0025354","Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.","Chen XM","2018","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-018-0701-4","29636047","PMC5891985",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0025355","Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review.","Mosińska P","2016","Expert opinion on investigational drugs","nonrandomized_study","article","10.1517/13543784.2016.1142532","26765585",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025356","Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.","Blundell J","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12932","28266779","PMC5573908",null,"S000439; S001448; S001635; S002234","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025357","The PI3K/Akt1-FoxO1 Translocation Pathway Mediates EXf Effects on NIT-1 Cell Survival.","Hou GJ","2017","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","other","article","10.1055/s-0043-117048","28895639",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025358","Variables associated with insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.","Westman K","2021","Primary care diabetes","other","article","10.1016/j.pcd.2020.11.005","33303380",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025359","Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary.","Göke R","1995","Neuroendocrinology","preclinical","article","10.1159/000126997","8584112",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025360","Effects of GLP-1 analog on cellular immune function of diabetes memtus rats","Zhao Haijun",null,null,"preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Research article"],["R0025361","Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects.","Sancho V","2006","International journal of molecular medicine","other","article","10.3892/ijmm.17.6.1133","16685426",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025362","Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?","Kuhn A","2017","Current cardiology reports","other_trial","article","10.1007/s11886-017-0832-3","28251513",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0025363","Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.","Mathieu C","2016","Diabetes care","randomized_trial","article","10.2337/dc16-0691","27506222",null,"ClinicalTrials.gov:NCT01836523","S000291; S000485; S002341","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0025364","Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).","Young AA","1999","Diabetes","preclinical","article","10.2337/diabetes.48.5.1026","10331407",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025365","Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program.","Steinberg WM","2017","Diabetes care","randomized_trial","article","10.2337/dc16-2684","28473337",null,null,"S000313; S001278; S001402; S001792; S002315","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; article"],["R0025366","Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.","Gu S","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12991","28452095",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0025367","[Association between SORCS1 rs1416406 and therapeutic effect of exenatide].","Zhou LM","2017","Zhonghua yi xue za zhi","other","article","10.3760/cma.j.issn.0376-2491.2017.18.013","28535629",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025368","Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.","Abdul-Ghani M","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13189","29227578",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025369","The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.","Jiang LL","2018","Journal of endocrinological investigation","randomized_trial","article","10.1007/s40618-017-0765-0","29032494",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025370","Reply to: \"Direct actions of GLP-1 analogues on AMP-activated protein kinase activity are distinct from cyclic AMP accumulation\".","Fishman S","2013","Journal of hepatology","preclinical","article","10.1016/j.jhep.2012.11.006","23159767",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0025371","Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus.","Guclu M","2018","Endocrine connections","other","article","10.1530/ec-17-0242","29217653","PMC5776666",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; conference-abstract; article"],["R0025372","New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1).","Yu Z","2010","Cellular signalling","narrative_review","article","10.1016/j.cellsig.2009.09.032","19772917",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025373","New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.","Inzucchi SE","2008","Circulation","narrative_review","article","10.1161/circulationaha.107.735795","18227398",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025374","HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.","Weissman PN","2014","Diabetologia","randomized_trial","article","10.1007/s00125-014-3360-3","25208756",null,"ClinicalTrials.gov:NCT00838916","S000099","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025375","In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes.","Soltani N","2007","Gene therapy","preclinical","article","10.1038/sj.gt.3302944","17410180",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025376","[Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].","Lüdemann J","2011","MMW Fortschritte der Medizin","narrative_review","article",null,"23964469",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0025377","Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.","Nauck MA","2019","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13547","30260088","PMC6587748",null,"S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0025378","Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.","Tahrani AA","2009","Advances in therapy","other_trial","article","10.1007/s12325-009-0014-9","19330494",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review"],["R0025379","Insulin-Producing Cells Differentiated from Human Bone Marrow Mesenchymal Stem Cells In Vitro Ameliorate Streptozotocin-Induced Diabetic Hyperglycemia.","Xin Y","2016","PloS one","preclinical","article","10.1371/journal.pone.0145838","26756576","PMC4710504",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025380","Choosing injectable therapy: The metabolic fulcrum.","Kalra S","2016","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"27427149",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025381","Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.","Garry EM","2019","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2019.25.12.1442","31778623","PMC10398080",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025382","Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men.","Izzi-Engbeaya C","2020","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgaa072","32052032","PMC7082082",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025383","Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.","Gault VA","2011","Clinical science (London, England : 1979)","preclinical","article","10.1042/cs20110006","21332446",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025384","Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons.","Ma X","2007","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.1025-07.2007","17611265","PMC3868967",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication; brief-report; article"],["R0025385","Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.","Feng W","2017","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.12555","28332301",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025386","Novel adjunctive treatments of myocardial infarction.","Schmidt MR","2014","World journal of cardiology","narrative_review","article","10.4330/wjc.v6.i6.434","24976915","PMC4072833",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025387","Gut hormone polyagonists for the treatment of type 2 diabetes.","Brandt SJ","2018","Peptides","narrative_review","article","10.1016/j.peptides.2017.12.021","29412819","PMC5805859",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0025388","Patients and healthcare professionals views on injectables for cardiovascular disease",null,"2022","European heart journal","other","article",null,null,"PMC9619637",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0025389","A strategy for fusion expression and preparation of functional glucagon-like peptide-1 (GLP-1) analogue by introducing an enterokinase cleavage site.","Liu Y","2014","Biotechnology letters","preclinical","article","10.1007/s10529-014-1526-1","24737080",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025390","[Atherosclerosis prevention: new therapeutic strategies on the horizon].","Di Fusco SA","2021","Giornale italiano di cardiologia (2006)","narrative_review","article","10.1714/3689.36751","34709232",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025391","Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.","Weinstock RS","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12479","25912221","PMC5008205","ClinicalTrials.gov:NCT00734474","S001242","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025392","Forum for injection techniques, India: the first Indian recommendations for best practice in insulin injection technique.","Kalra S","2012","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.102929","23226630","PMC3510955",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0025393","Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.","Runge S","2007","Biochemistry","other","article","10.1021/bi062309m","17444618",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025394","Liraglutide exhibits anti-inflammatory activity through the activation of the PKA/CREB pathway.","Wang L","2019","Journal of inflammation (London, England)","preclinical","article","10.1186/s12950-019-0225-z","31632200","PMC6787966",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0025395","Obesity: Current and potential pharmacotherapeutics and targets.","Narayanaswami V","2017","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2016.10.015","27773782","PMC5274590",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0025396","Outcome of revisional bariatric surgery for insufficient weight loss after laparoscopic Roux-en-Y gastric bypass: an observational study.","Linke K","2020","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2020.04.009","32451228",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study"],["R0025397","Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.","Frías JP","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12763","27527911","PMC6168745",null,"S002311","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0025398","Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.","Li M","2017","Medicine","systematic_review","article","10.1097/md.0000000000008161","28953663","PMC5626306",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; article"],["R0025399","A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus.","Quan H","2017","Experimental and therapeutic medicine","randomized_trial","article","10.3892/etm.2017.4863","28912879","PMC5585756",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025400","PSAT002 Unilateral Adrenalectomy as a Treatment Option in Patient with Cyclical Cushing's Syndrome",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9629235",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0025401","[Contribution of metabolic sensors on feeding behaviour and the control of body weight].","Blázquez Fernández E","2012","Anales de la Real Academia Nacional de Medicina","other","article",null,"24298863",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Lecture; other"],["R0025402","Chronic Stress Alters Hippocampal Renin-Angiotensin-Aldosterone System Component Expression in an Aged Rat Model of Wolfram Syndrome.","Punapart M","2023","Genes","preclinical","article","10.3390/genes14040827","37107585","PMC10137641",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025403","Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.","Yang Z","2006","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2006.03.177","16643856",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0025404","Management of Diabetes Mellitus in Normal Renal Function, Renal Dysfunction and Renal Transplant Recipients, Focusing on Glucagon-Like Peptide-1 Agonist: A Review Based upon Current Evidence.","Tsai SF","2019","International journal of molecular sciences","narrative_review","article","10.3390/ijms20133152","31261624","PMC6651241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025405","Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study.","Capristo E","2018","Diabetes & metabolism","randomized_trial","article","10.1016/j.diabet.2017.12.007","29398254",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Controlled Clinical Trial; Journal Article; article"],["R0025406","Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.","Garg M","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12944","28304146",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0025407","Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications.","McGinty G","2024","World journal of gastroenterology","commentary","article","10.3748/wjg.v30.i27.3264","39086753","PMC11287414",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0025408","Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.","Zinman B","2018","Diabetes care","randomized_trial","article","10.2337/dc17-2677","29903847",null,"ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025409","Two novel solvent system compositions for protected synthetic peptide purification by centrifugal partition chromatography.","Amarouche N","2014","Journal of chromatography. A","other","article","10.1016/j.chroma.2014.02.052","24630060",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025410","An update on potential pharmacotherapies for cognitive impairment in bipolar disorder.","Johnson DE","2023","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2023.2194488","36946229",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0025411","Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices.","Williamson C","2014","Postgraduate medicine","other","article","10.3810/pgm.2014.05.2764","24918800",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025412","Chronic Liraglutide Administration Fails to Suppress Postprandial Glucagon Levels in Type 1 Diabetic Islet Allograft Recipients With Graft Dysfunction.","Vendrame F","2018","Transplantation","nonrandomized_study","article","10.1097/tp.0000000000001964","28957843","PMC5741482",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025413","GLP-1R-targeting magnetic nanoparticles for pancreatic islet imaging.","Wang P","2014","Diabetes","preclinical","article","10.2337/db13-1543","24458362","PMC4178324",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0025414","The impact of extended release exenatide as adjuvant therapy on hemoglobin A1C, weight, and total daily dose of insulin in patients with type 2 diabetes mellitus using U-500 insulin.","Farwig PA","2017","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2017.09.008","28951338",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0025415","Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.","Gilbert MP","2019","Annals of internal medicine","randomized_trial","article","10.7326/m18-1569","30508430",null,null,"S001496","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025416","Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial.","El-Nayir M","2024","Trials","randomized_trial","article","10.1186/s13063-024-08393-2","39175005","PMC11340079",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; other; article"],["R0025417","Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance.","Simanenkova A","2021","Scientific reports","preclinical","article","10.1038/s41598-021-86132-2","33758265","PMC7987997",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025418","Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.","Ali S","2019","Current atherosclerosis reports","other_trial","article","10.1007/s11883-019-0794-6","31230129",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0025419","Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects.","Kamarudin MNA","2019","Journal of experimental & clinical cancer research : CR","narrative_review","article","10.1186/s13046-019-1495-2","31831021","PMC6909457",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025420","Feline comorbidities: Pathophysiology and management of the obese diabetic cat.","Clark M","2021","Journal of feline medicine and surgery","randomized_trial","article","10.1177/1098612x211021540","34167340","PMC10812123",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; article"],["R0025421","Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.","Blazina I","2019","Systematic reviews","systematic_review","article","10.1186/s13643-019-1200-8","31783920","PMC6884753",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; research-article; other; review"],["R0025422","Treatment with specific soluble factors promotes the functional maturation of transcription factor-mediated, pancreatic transdifferentiated cells.","Motoyama H","2018","PloS one","preclinical","article","10.1371/journal.pone.0197175","29768476","PMC5955553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025423","[Glucose-lowering therapy in patients with cardiac comorbidities].","Meier JJ","2015","Deutsche medizinische Wochenschrift (1946)","narrative_review","article","10.1055/s-0041-101365","25924044",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0025424","[Exenatide promotes chemotactic migration of adipose-derived stem cells through SDF-1/CXCR-4/Rho GTPase pathway].","Ma Q","2016","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article",null,"27578569",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025425","Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.","Zhu E","2016","Oncotarget","preclinical","article","10.18632/oncotarget.13189","27835589","PMC5348377",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025426","Liraglutide reduces body weight by upregulation of adenylate cyclase 3.","Li Z","2017","Nutrition & diabetes","preclinical","article","10.1038/nutd.2017.17","28481334","PMC5518799",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025427","New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.","von Lewinski D","2017","BioMed research international","other_trial","article","10.1155/2017/1253425","28894748","PMC5574229",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0025428","New drugs for type 2 diabetes mellitus: what is their place in therapy?","Krentz AJ","2008","Drugs","narrative_review","article","10.2165/00003495-200868150-00005","18840004",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025429","Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study.","Frison V","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0503-4","30238228","PMC6250628",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025430","Genetically Engineered Escherichia coli Nissle 1917 Secreting GLP-1 Analog Exhibits Potential Antiobesity Effect in High-Fat Diet-Induced Obesity Mice.","Ma J","2020","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.22700","31970910",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025431","Liraglutide causes large and rapid epicardial fat reduction.","Iacobellis G","2017","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.21718","28124506",null,"ClinicalTrials.gov:NCT02014740","S000259","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025432","Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.","Holman RR","2017","The New England journal of medicine","commentary","article","10.1056/nejmc1714163","29262286",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0025433","Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials.","Mannucci E","2021","Nutrition, metabolism, and cardiovascular diseases : NMCD","systematic_review","article","10.1016/j.numecd.2020.12.030","33618919",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Network Meta-Analysis"],["R0025434","Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.","Steinberg WM","2017","Diabetes care","randomized_trial","article","10.2337/dc16-2747","28476871",null,"ClinicalTrials.gov:NCT01179048","S000313; S001496","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025435","Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis.","Kong QX","2021","Endokrynologia Polska","systematic_review","article","10.5603/ep.a2021.0031","34010433",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; article"],["R0025436","A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting.","Rashid F","2019","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2019.02.005","31336501",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0025437","Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.","Meier JJ","2003","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","narrative_review","article","10.2165/00063030-200317020-00002","12641488",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025438","Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease.","Xiao Y","2022","Metabolic syndrome and related disorders","randomized_trial","article","10.1089/met.2022.0014","35925752",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025439","Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.","Astrup A","2012","International journal of obesity (2005)","randomized_trial","article","10.1038/ijo.2011.158","21844879","PMC3374073","ClinicalTrials.gov:NCT00480909","S000866; S001402; S001419; S001448","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0025440","Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus.","Ruige JB","2008","Acta clinica Belgica","narrative_review","article","10.1179/acb.2008.63.2.004","18575047",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025441","Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism.","Wang D","2013","Diabetes","preclinical","article","10.2337/db12-1025","23364453","PMC3636622",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025442","The role of incretin on diabetes mellitus.","Sanusi H","2009","Acta medica Indonesiana","preclinical","article",null,"20737753",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025443","Gut hormones, adipokines, and pro- and anti-inflammatory cytokines/markers in loss of control eating: A scoping review.","Yu Y","2021","Appetite","nonrandomized_study","article","10.1016/j.appet.2021.105442","34111480","PMC10683926",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Scoping Review; research-article"],["R0025444","An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.","Viereck C","2011","Contemporary clinical trials","randomized_trial","article","10.1016/j.cct.2011.01.009","21266202",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0025445","Semaglutide, Ertugliflozin, and Deflazacort.","Hussar DA","2018","Journal of the American Pharmacists Association : JAPhA","other","article","10.1016/j.japh.2018.04.005","29739505",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025446","Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy.","Mattson MP","2014","Journal of Parkinson's disease","other_trial","article","10.3233/jpd-130335","24473219",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, N.I.H., Intramural; Review; article"],["R0025447","Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.","Smith GC","2009","Schizophrenia research","preclinical","article","10.1016/j.schres.2009.07.011","19679451",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025448","1,4-Benzenedimethanethiol (1,4-BDMT) as a scavenger for greener peptide resin cleavages.","Pawlas J","2019","RSC advances","other","article","10.1039/c9ra08553j","35540669","PMC9075962",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0025449","Rational design of peptidomimetics for class B GPCRs: potent non-peptide GLP-1 receptor agonists.","Ahn JM","2009","Advances in experimental medicine and biology","other","article","10.1007/978-0-387-73657-0_55","19400122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; book-chapter"],["R0025450","Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.","Paisley AN","2009","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/j.1464-5491.2009.02789.x","19719716",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0025451","Drug Therapy in Obesity: A Review of Current and Emerging Treatments.","Williams DM","2020","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-020-00816-y","32297119","PMC7261312",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0025452","Glucagon-like peptide 1 (GLP-1)-based therapy upregulates LXR-ABCA1/ABCG1 cascade in adipocytes.","Mostafa AM","2015","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2015.11.054","26603933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025453","Pancreatic beta cells in very old mice retain capacity for compensatory proliferation.","Stolovich-Rain M","2012","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m112.350736","22740691","PMC3431647",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025454","Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study.","Morgan CL","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-017-0359-z","29318537","PMC5801245",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0025455","Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors.","Davidson JA","2009","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.76.s5.05","19952301",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0025456","Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice.","Chen S","2017","Neurochemical research","preclinical","article","10.1007/s11064-017-2250-8","28382596",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025457","Direct quantification of intact FIM in monkey plasma using a selective chromatography-tandem mass spectrometry method: Application in a pharmacokinetic study.","Dong S","2020","Biomedical chromatography : BMC","preclinical","article","10.1002/bmc.4729","31656040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025458","Neuroanatomical dissection of the MC3R circuitry regulating energy rheostasis.","Possa-Paranhos IC","2024","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2024.04.22.590573","38712101","PMC11071362",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0025459","Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.","Wysham C","2016","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12702","27265893",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025460","Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.","Timmers L","2009","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2008.10.033","19195607",null,null,"S000424; S000566; S000767; S001688; S001769; S002201","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025461","[Cardiovascular effects of liraglutide therapy in patients with type 2 diabetes : Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)].","Meier JJ","2017","Der Internist","commentary","article","10.1007/s00108-017-0193-4","28138762",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0025462","Diabetes: safety and efficacy of albiglutide-results from two trials.","Derosa G","2014","Nature reviews. Endocrinology","commentary","article","10.1038/nrendo.2014.126","25069463",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0025463","The evolution and future of diabetic kidney disease research: a bibliometric analysis.","Wei Y","2021","BMC nephrology","other","article","10.1186/s12882-021-02369-z","33926393","PMC8084262",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0025464","The pathogenesis, complications and therapeutic strategy for hepatitis C virus-associated insulin resistance in the era of anti-viral treatment.","Kawaguchi T","2010","Reviews on recent clinical trials","narrative_review","article","10.2174/157488710792007257","20482494",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025465","The anorexic effect of Ex4/Fc through GLP-1 receptor activation in high-fat diet fed mice.","Liu R","2014","Acta biochimica et biophysica Sinica","preclinical","article","10.1093/abbs/gmu044","24951724",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025466","Development and Internal Validation of A Prediction Tool To Assist Clinicians Selecting Second-Line Therapy Following Metformin Monotherapy For Type 2 Diabetes.","El Sanadi CE","2021","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.1016/j.eprac.2020.10.015","33685669",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025467","Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris.","Huang YS","2008","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.942","17994612",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025468","Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.","FLAT-SUGAR Trial Investigators","2015","Diabetes care","randomized_trial","article","10.2337/dc14-2689","26068865",null,"ClinicalTrials.gov:NCT01524705","S000559","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025469","[Significance of the regulation of hyperglucagonemia in type 2 diabetes mellitus].","Miuchi M","2015","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"26666142",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025470","Preservation of β-cell function: the key to diabetes prevention.","DeFronzo RA","2011","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2011-0246","21697254",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025471","Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin-4 injected animals.","Malendowicz LK","2002","International journal of molecular medicine","preclinical","article","10.3892/ijmm.10.3.327","12165809",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0025472","Update in cardiology: vascular risk and cardiac rehabilitation.","Galve E","2015","Revista espanola de cardiologia (English ed.)","narrative_review","article","10.1016/j.rec.2014.10.005","25583549",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025473","Imaging β-Cell Function Using a Zinc-Responsive MRI Contrast Agent May Identify First Responder Islets.","Thapa B","2021","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2021.809867","35173681","PMC8842654",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025474","Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.","Bode BW","2010","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2010.01196.x","20590735","PMC2901519",null,"S001094","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025475","Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial.","Polderman JAW","2018","Anaesthesia","randomized_trial","article","10.1111/anae.14180","29230803",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025476","Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.","Khunti K","2021","The lancet. Diabetes & endocrinology","nonrandomized_study","article","10.1016/s2213-8587(21)00050-4","33798464","PMC8009618",null,null,"pubmed; europepmc","TRUE","open_europepmc","4",null,"Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article"],["R0025477","Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.","Weber EJ","2024","Clinical pharmacology in drug development","nonrandomized_study","article","10.1002/cpdd.1384","38346861",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; article"],["R0025478","Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials.","Monami M","2021","Nutrition, metabolism, and cardiovascular diseases : NMCD","systematic_review","article","10.1016/j.numecd.2020.11.031","33549430",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0025479","Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.","Rylova SN","2016","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.115.168948","27127218",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025480","Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.","Saab C","2015","Vascular health and risk management","nonrandomized_study","article","10.2147/vhrm.s73703","25750538","PMC4348128",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0025481","Legume-Derived Bioactive Peptides in Type 2 Diabetes: Opportunities and Challenges.","Hu K","2023","Nutrients","narrative_review","article","10.3390/nu15051096","36904097","PMC10005352",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025482","Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.","Degn KB","2004","Diabetes","randomized_trial","article","10.2337/diabetes.53.9.2397","15331551",null,null,"S000235","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025483","A Peptide Triple Agonist of GLP-1, Neuropeptide Y1, and Neuropeptide Y2 Receptors Promotes Glycemic Control and Weight Loss","Chichura KS","2022","bioRxiv","preclinical","preprint","10.1101/2022.11.07.515458",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0025484","Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.","Pfeffer MA","2016","The New England journal of medicine","commentary","article","10.1056/nejmc1600140","26981945",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0025485","The efficacy and safety of liraglutide.","Jeong KH","2011","International journal of clinical pharmacy","nonrandomized_study","article","10.1007/s11096-011-9552-8","21952951",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025486","In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent.","Brand C","2014","Bioconjugate chemistry","other","article","10.1021/bc500178d","24856928","PMC4215873",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025487","Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.","van Genugten RE","2014","European journal of endocrinology","randomized_trial","article","10.1530/eje-13-0610","24297090",null,"ClinicalTrials.gov:NCT00721552",null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025488","Effects of Exenatide on Metabolic Changes, Sexual Hormones, Inflammatory Cytokines, Adipokines, and Weight Change in a DHEA-Treated Rat Model.","Sun L","2016","Reproductive sciences (Thousand Oaks, Calif.)","preclinical","article","10.1177/1933719116635278","26917422",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025489","Activin, BMP and FGF pathways cooperate to promote endoderm and pancreatic lineage cell differentiation from human embryonic stem cells.","Xu X","2011","Mechanisms of development","preclinical","article","10.1016/j.mod.2011.08.001","21855631","PMC3225072",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, American Recovery and Reinvestment Act; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0025490","Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy.","Ren T","2021","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2021.120583","33839225",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025491","Letter by Xie et al Regarding Article, \"Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial\".","Xie J","2019","Circulation","other_trial","article","10.1161/circulationaha.118.039071","31136224",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0025492","The effect of glucagon-like peptide 1 on cardiovascular risk.","Sivertsen J","2012","Nature reviews. Cardiology","narrative_review","article","10.1038/nrcardio.2011.211","22290234",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025493","Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.","Lipscombe LL","2017","Annals of internal medicine","randomized_trial","article","10.7326/acpjc-2017-167-12-067","29255857",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Comment; editorial"],["R0025494","Exenatide improves liver mitochondrial dysfunction and insulin resistance by reducing oxidative stress in high fat diet-induced obese mice.","Wang Z","2017","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2017.03.010","28274877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025495","Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis.","Martins CO","2018","Haematologica","case_report","article","10.3324/haematol.2018.203000","30262557","PMC6269298",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0025496","[Cost-utility study of the combination of metformin with the different glucose-lowering medication classes in adults 80 aged and older].","Colombat S","2020","Therapie","narrative_review","article","10.1016/j.therap.2019.09.002","31607509",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025497","Liraglutide Activates the Nrf2/HO-1 Antioxidant Pathway and Protects Brain Nerve Cells against Cerebral Ischemia in Diabetic Rats.","Deng C","2018","Computational intelligence and neuroscience","preclinical","article","10.1155/2018/3094504","29623090","PMC5829331",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025498","Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?","Jankovic J","2017","Nature reviews. Neurology","other","article","10.1038/nrneurol.2017.140","28960185",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025499","Metformin, sitagliptin, and liraglutide modulate serum retinol-binding protein-4 level and adipocytokine production in type 2 diabetes mellitus rat model.","Abbas NAT","2018","Canadian journal of physiology and pharmacology","preclinical","article","10.1139/cjpp-2017-0650","30075088",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025500","Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats.","Szayna M","2000","Endocrinology","preclinical","article","10.1210/endo.141.6.7490","10830274",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025501","Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes.","Tran S","2018","American journal of physiology. Endocrinology and metabolism","randomized_trial","article","10.1152/ajpendo.00374.2017","29183873",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025502","From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy.","Holst JJ","2019","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2019.00260","31080438","PMC6497767",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025503","Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom.","Woehl A","2008","Cardiovascular diabetology","randomized_trial","article","10.1186/1475-2840-7-24","18694484","PMC2546382",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025504","In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.","Zhang Y","2016","Drug development and industrial pharmacy","preclinical","article","10.3109/03639045.2015.1107090","26558908",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025505","Investigation of exenatide elimination and its in vivo and in vitro degradation.","Copley K","2006","Current drug metabolism","preclinical","article","10.2174/138920006776873490","16724926",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025506","Adapting the GLP-1-signaling system to the treatment of type 2 diabetes.","Salvatore T","2007","Current diabetes reviews","narrative_review","article","10.2174/157339907779802076","18220652",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Evaluation Study; Journal Article; Review; article"],["R0025507","Postprandial Hyperlipidemia and Remnant Lipoproteins.","Masuda D","2017","Journal of atherosclerosis and thrombosis","narrative_review","article","10.5551/jat.rv16003","27829582","PMC5305681",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025508","Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.","Tao X","2019","Journal of ovarian research","preclinical","article","10.1186/s13048-019-0555-8","31526389","PMC6745801",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025509","Vascular endothelial PDPK1 plays a pivotal role in the maintenance of pancreatic beta cell mass and function in adult male mice.","Obata A","2019","Diabetologia","preclinical","article","10.1007/s00125-019-4878-1","31055616","PMC6560212",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025510","Exenatide Inhibits the KCa3.1 Channels of Aortic Vascular Smooth Muscle in Diabetic Rats.","Dong P","2017","Acta Cardiologica Sinica","preclinical","article","10.6515/acs20170612b","29167619","PMC5694930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025511","[Diabetes mellitus and pancreatic cancer - cause or result?].","Smahelová A","2014","Vnitrni lekarstvi","other","article",null,"25294771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0025512","Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model.","Chen P","2018","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2017.09.006","29355652",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025513","The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.","Pokala N","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12939","28608447",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025514","Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds.","Hlavaty KA","2014","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","preclinical","article","10.1111/ajt.12742","24909237","PMC4232190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0025515","Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice.","Lamont BJ","2008","Diabetes","preclinical","article","10.2337/db07-1202","17928394",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025516","[New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease].","Ahrén B","2005","Lakartidningen","narrative_review","article",null,"15786905",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025517","Continuous positive airway pressure but not Liraglutide-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: Data from a randomized proof-of-concept study","O’Donnell C","2023","medRxiv","randomized_trial","preprint","10.1101/2023.05.23.23290424",null,null,"ClinicalTrials.gov:NCT04186494","S001827","europepmc; openalex","TRUE","open_pdf","1","FALSE","Preprint; preprint"],["R0025518","Incretin-Based Drugs",null,"2012","National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","narrative_review","article",null,"31643415",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0025519","Optimized Stepwise Synthesis of the API Liraglutide Using BAL Resin and Pseudoprolines.","Carbajo D","2019","ACS omega","other","article","10.1021/acsomega.9b00974","31459957","PMC6648002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025520","How to implement incretin therapy.","Cobble ME","2008","The Journal of family practice","narrative_review","article",null,"18786341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025521","Response by Mann et al to Letter Regarding Article, \"Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial\".","Mann JFE","2019","Circulation","other_trial","article","10.1161/circulationaha.119.040419","31136226",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; Comment; article"],["R0025522","Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study.","Hiramatsu T","2017","Drug research","other","article","10.1055/s-0043-110603","28738426",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025523","Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.","Azoulay L","2016","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2016.1522","27479930",null,null,"S001028","pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Multicenter Study; article"],["R0025524","An overview of incretin clinical trials.","Garber AJ","2008","The Journal of family practice","narrative_review","article",null,"18786339",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025525","All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis.","Rados DV","2021","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2021.108688","33549676",null,"PROSPERO:CRD42018087336",null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0025526","Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells.","Shi LL","2022","Disease markers","preclinical","article","10.1155/2022/5013622","35510038","PMC9061067",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025527","Obesity prevalence and variability in management practices for patients with symptomatic peripheral artery disease.","Scierka LE","2023","Obesity research & clinical practice","nonrandomized_study","article","10.1016/j.orcp.2023.05.002","37225553",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0025528","Overexpression of GLP-1 receptors suppresses proliferation and cytokine release by airway smooth muscle cells of patients with chronic obstructive pulmonary disease via activation of ABCA1.","Sun YH","2017","Molecular medicine reports","other","article","10.3892/mmr.2017.6618","28560433",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025529","Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice.","Zhou F","2016","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2016.10.016","27756605",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025530","Discovery of Novel PTP1B Inhibitors with Once-Weekly Therapeutic Potential for Type 2 Diabetes: Design, Synthesis, and In Vitro and In Vivo Investigations of BimBH3 Peptide Analogues.","Zhang C","2023","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.2c02003","36749220",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025531","Identification of therapeutic effect of glucagon-like peptide 1 in the treatment of STZ-induced diabetes mellitus in rats by restoring the balance of intestinal flora.","Yuan X","2018","Journal of cellular biochemistry","preclinical","article","10.1002/jcb.27343","30129059",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025532","Function and expression of sulfonylurea, adrenergic, and glucagon-like peptide 1 receptors in isolated porcine islets.","Kelly AC","2014","Xenotransplantation","preclinical","article","10.1111/xen.12101","24801676","PMC4306563",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025533","Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.","Knauf C","2005","The Journal of clinical investigation","preclinical","article","10.1172/jci25764","16322793","PMC1297248",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025534","Insulin Therapy in Type 2 Diabetes.","Aschner P","2020","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000001088","31567175",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0025535","Aptamer-modified M cell targeting liposomes for oral delivery of macromolecules.","He Y","2023","Colloids and surfaces. B, Biointerfaces","other","article","10.1016/j.colsurfb.2022.113109","36599185",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025536","Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.","Dubé MC","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13063","28722271",null,"ClinicalTrials.gov:NCT01787916","S001318","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025537","Apremilast, albiglutide, and empagliflozin.","Hussar DA","2014","Journal of the American Pharmacists Association : JAPhA","other","article","10.1331/japha.2014.14533","25216888",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025538","Parkinson's Disease, Diabetes and Cognitive Impairment.","Ashraghi MR","2016","Recent patents on endocrine, metabolic & immune drug discovery","nonrandomized_study","article","10.2174/1872214810999160628105549","27396477",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0025539","Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.","Kolotkin RL","2018","Clinical obesity","other_trial","article","10.1111/cob.12226","29045079","PMC5813214",null,"S000492","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0025540","The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating β-endorphin release from spinal microglia.","Fan H","2015","British journal of pharmacology","preclinical","article","10.1111/bph.12895","25176008","PMC4280968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025541","HbA1c-Triggered Endocrinology Electronic Consultation for Type 2 Diabetes Management.","Oseran AS","2022","Journal of general internal medicine","randomized_trial","article","10.1007/s11606-021-07157-x","34608564","PMC8971272","ClinicalTrials.gov:NCT03542084",null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article"],["R0025542","Peptide Self-Assembled Nanostructures: From Models to Therapeutic Peptides.","Gatto E","2022","Nanomaterials (Basel, Switzerland)","narrative_review","article","10.3390/nano12030466","35159810","PMC8838750",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025543","Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity.","Cabou C","2008","Diabetes","preclinical","article","10.2337/db08-0121","18633100","PMC2551665",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025544","Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects.","Tiessen RG","2008","International journal of clinical pharmacology and therapeutics","other","article","10.5414/cpp46443","18793574",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025545","Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring.","Bergenstal RM","2017","Diabetes/metabolism research and reviews","other_trial","article","10.1002/dmrr.2879","28032465",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025546","Use of pharmacotherapy to improve weight loss in early non-responders to behavioral treatment","Tronieri J","2024","Research Square","randomized_trial","preprint","10.21203/rs.3.pex-2526/v1",null,null,null,null,"europepmc","FALSE","open_pdf","2",null,"Preprint"],["R0025547","Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel.","Asadollahi N","2024","EXCLI journal","preclinical","article","10.17179/excli2023-6878","38741724","PMC11089098",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0025548","Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy - A Retrospective Observational Study.","Buchholz C","2019","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","nonrandomized_study","article","10.1055/a-0972-9700","31412375",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study"],["R0025549","GLP-1-Induced AMPK Activation Inhibits PARP-1 and Promotes LXR-Mediated ABCA1 Expression to Protect Pancreatic β-Cells Against Cholesterol-Induced Toxicity Through Cholesterol Efflux.","Li R","2021","Frontiers in cell and developmental biology","preclinical","article","10.3389/fcell.2021.646113","34307343","PMC8292745",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025550","Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes.","Zheng X","2011","Diabetes research and clinical practice","preclinical","article","10.1016/j.diabres.2011.05.021","21641071",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025551","Biologic actions and therapeutic potential of the proglucagon-derived peptides.","Drucker DJ","2005","Nature clinical practice. Endocrinology & metabolism","other_trial","article","10.1038/ncpendmet0017","16929363",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025552","Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.","Irwin N","2015","ChemMedChem","preclinical","article","10.1002/cmdc.201500140","26059252",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025553","Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells.","Panagaki T","2017","Scientific reports","other_trial","article","10.1038/s41598-017-16488-x","29170452","PMC5700973",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025554","Diabetes and Its Complications: Therapies Available, Anticipated and Aspired.","Grover A","2021","Current diabetes reviews","other","article","10.2174/1573399816666201103144231","33143627",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025555","Epac2-dependent rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1.","Leech CA","2010","Vitamins and hormones","preclinical","article","10.1016/b978-0-12-381517-0.00010-2","21094904","PMC3009389",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review; research-article"],["R0025556","Treatment of diabetes with glucagon-like peptide-1 gene therapy.","Riedel MJ","2010","Expert opinion on biological therapy","narrative_review","article","10.1517/14712598.2010.532786","21029027",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025557","The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.","Meneghini LF","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13673","30768845","PMC6593824",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0025558","GLP-1 based therapies: clinical implications for gastroenterologists.","Smits MM","2016","Gut","narrative_review","article","10.1136/gutjnl-2015-310572","26786687",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025559","Meeting the Body Mass Index Requirement for Gender-affirming Surgery Using Antiobesity Medication.","Taormina JM","2023","JCEM case reports","case_report","article","10.1210/jcemcr/luad067","37388627","PMC10301860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0025560","Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.","Topyildiz F","2016","Journal of diabetes research","other_trial","article","10.1155/2016/1309502","26998491","PMC4779845",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0025561","SIRT1 as a Therapeutic Target in Diabetic Complications.","Strycharz J","2018","Current medicinal chemistry","narrative_review","article","10.2174/0929867324666171107103114","29110598",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025562","Clinical experience with liraglutide.","Bain SC","2010","International journal of clinical practice. Supplement","narrative_review","article","10.1111/j.1742-1241.2010.02494.x","20887303",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025563","Liraglutide and Glycaemic Outcomes in the LEADER Trial.","Zinman B","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-018-0524-z","30392095","PMC6250637","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0025564","Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.","Chen S","2014","Neuroscience","preclinical","article","10.1016/j.neuroscience.2013.10.038","24183963",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025565","New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022.","Tamargo J","2023","European heart journal. Cardiovascular pharmacotherapy","narrative_review","article","10.1093/ehjcvp/pvad034","37169875","PMC10236523",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0025566","Accuracy of dosage volume for halfway doses in the Victoza Pen.","King AB","2011","Journal of diabetes science and technology","commentary","article","10.1177/193229681100500643","22226289","PMC3262738",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0025567","An analysis of dosage volume for halfway doses in the Victoza Pen.","Kroon L","2011","Journal of diabetes science and technology","other_trial","article","10.1177/193229681100500644","22226290","PMC3262739",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; Comment; article"],["R0025568","ODP002 ASSOCIATION BETWEEN OBESITY AND DIABETES POTENTIATES RENAL FUNCTION IMPAIRMENT IN BARIATRIC PATIENTS",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9625562",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0025569","Incretin hormone secretion over the day.","Ahrén B","2010","Vitamins and hormones","narrative_review","article","10.1016/b978-0-12-381517-0.00007-2","21094901",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025570","Characterisation of L-cell secretory mechanisms and colonic enteroendocrine cell subpopulations","Billing L","2019","University of Cambridge","preclinical","article","10.17863/cam.37850",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0025571","Diabetes: Lixisenatide does not increase rates of CVD events.","Huynh K","2016","Nature reviews. Cardiology","commentary","article","10.1038/nrcardio.2015.199","26701217",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0025572","Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: The Contribution of Glucagon-like Peptide-1.","Moroi M","2015","Journal of cardiovascular pharmacology","preclinical","article","10.1097/fjc.0000000000000258","25853991",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025573","Oral delivery of therapeutic protein/peptide for diabetes--future perspectives.","Rekha MR","2013","International journal of pharmaceutics","narrative_review","article","10.1016/j.ijpharm.2012.03.056","22503954",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025574","Expression of pancreatic endocrine markers by mesenchymal stem cells from human adipose tissue.","Silva AC","2012","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2012.07.036","23026628",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025575","A retrospective, single-center cohort study on complications after dental extractions in patients taking biologic agents.","Davila A","2022","Journal of the American Dental Association (1939)","nonrandomized_study","article","10.1016/j.adaj.2022.07.009","36115715",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0025576","The role of the preproglucagon neurons in cardiovascular control, energy homeostasis and glucose homeostasis","Cook DR","2019","University College London (University of London)","other","article",null,null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Dissertation; dissertation"],["R0025577","Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control.","Lang Lehrskov L","2018","Cell metabolism","other","article","10.1016/j.cmet.2018.04.008","29731416",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Randomized Controlled Trial"],["R0025578","Effect of liraglutide on dietary lipid-induced insulin resistance in humans.","Koska J","2018","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13037","28605158",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; article"],["R0025579","A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.","Hoelmkjaer KM","2016","PloS one","randomized_trial","article","10.1371/journal.pone.0154727","27136422","PMC4852899",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025580","Pharmacological therapies with cardiovascular and other benefits in people with type 2 diabetes: Type 2 diabetes: Evidence review B",null,"2022","National Institute for Health and Care Excellence (NICE), London","other_trial","article",null,"35575679",null,null,null,"europepmc","FALSE","free_to_read","5",null,"Review"],["R0025581","Abdominal aortic aneurysm: a review on the role of oral antidiabetic drugs.","Ribeiro-Silva M","2020","International angiology : a journal of the International Union of Angiology","nonrandomized_study","article","10.23736/s0392-9590.20.04362-x","32286765",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0025582","Fusion pore regulation by Epac2/cAMP controls cargo release during insulin exocytosis","Gucek A","2018","bioRxiv","preclinical","preprint","10.1101/403253",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0025583","RFamide peptides 43RFa and 26RFa both promote survival of pancreatic β-cells and human pancreatic islets but exert opposite effects on insulin secretion.","Granata R","2014","Diabetes","other","article","10.2337/db13-1522","24622796",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025584","A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis.","Pan Q","2021","EBioMedicine","preclinical","article","10.1016/j.ebiom.2020.103202","33421947","PMC7806870",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025585","Molecularly engineered islet cell clusters for diabetes mellitus treatment.","Yook S","2012","Cell transplantation","preclinical","article","10.3727/096368912x640628","22613624",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025586","Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells.","Ding L","2012","Acta pharmacologica Sinica","other","article","10.1038/aps.2011.149","22120969","PMC4010269",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0025587","Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.","Milano W","2020","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/1871530320666200515112853","32410565",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0025588","Efficacy and safety of liraglutide in Indian adolescents with obesity.","Kochar IS","2019","Obesity science & practice","other","article","10.1002/osp4.328","31275599","PMC6587397",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025589","Corrigendum to \"Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study\" [Diabetes Metab. 44 (2018) 235-242].","Capristo E","2020","Diabetes & metabolism","notice","article","10.1016/j.diabet.2019.02.004","30857948",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0025590","Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.","Li CJ","2014","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/1758-5996-6-69","24917890","PMC4050987",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025591","A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice.","Hao L","2024","The journal of prevention of Alzheimer's disease","preclinical","article","10.14283/jpad.2024.6","38374745",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025592","Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.","Clegg LE","2021","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.14313","33394543",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025593","The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review.","Johns JR","2024","The British journal of dermatology","systematic_review","article","10.1093/bjd/ljae228","38819233",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Systematic Review; Journal Article; review"],["R0025594","Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.","Harreiter J","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14319","33464703","PMC8247845",null,"S000796","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025595","Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1.","Clardy-James S","2013","ChemMedChem","other","article","10.1002/cmdc.201200461","23203941","PMC3771382",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025596","Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.","Kalra S","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-016-0197-4","27613064","PMC5118235",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; editorial; article"],["R0025597","Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus.","Akhlaghi F","2017","Clinical pharmacokinetics","narrative_review","article","10.1007/s40262-016-0472-6","27832452","PMC5425330",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural; research-article"],["R0025598","Erratum to: Efficacy of liraglutide intervention in myocardial infarction : A meta-analysis of randomized controlled trials.","Yang X","2020","Herz","notice","article","10.1007/s00059-019-4784-9","30694371",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; erratum"],["R0025599","Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.","RISE Consortium","2019","Diabetes care","randomized_trial","article","10.2337/dc19-0556","31178434","PMC6702605","ClinicalTrials.gov:NCT01779362","S002086","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0025600","The effects of TNF-α on GLP-1-stimulated plasma glucose kinetics.","Lehrskov-Schmidt L","2015","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2014-4244","25675385",null,"ClinicalTrials.gov:NCT01347801",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025601","Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure.","Nathanson D","2016","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-015-0116-2","26759609","PMC4709886","ISRCTN:ISRCTN47533126",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025602","A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures.","Wootten D","2016","Molecular pharmacology","other","article","10.1124/mol.115.101246","26700562","PMC4767408",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0025603","Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.","Bouchi R","2017","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej16-0449","27916783",null,null,"S000993","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025604","Liraglutide Up-regulation Thioredoxin Attenuated Müller Cells Apoptosis in High Glucose by Regulating Oxidative Stress and Endoplasmic Reticulum Stress.","Ren X","2020","Current eye research","preclinical","article","10.1080/02713683.2020.1737137","32180468",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025605","Erratum. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes Care 2017;40:839-848.","Steinberg WM","2018","Diabetes care","notice","article","10.2337/dc18-er07","29802143","PMC6014533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0025606","Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.","Sheffield CA","2007","Pharmacotherapy","case_report","article","10.1592/phco.27.10.1449","17896900",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0025607","The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.","Garg SK","2010","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2009.0127","20082581",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025608","Coumaglutide, a novel long-acting GLP-1 analog, inhibits β-cell apoptosis in vitro and invokes sustained glycemic control in vivo.","Sun L","2015","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2015.10.028","26481165",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025609","The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide.","Jennings L","2017","The British journal of dermatology","case_report","article","10.1111/bjd.15233","27943236",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0025610","Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice.","Lee IS","2016","Obesity research & clinical practice","preclinical","article","10.1016/j.orcp.2015.07.011","26314504",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025611","Gateways to clinical trials.","Tomillero A","2010","Methods and findings in experimental and clinical pharmacology","other","article",null,"20383346",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0025612","Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.","Ostawal A","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-016-0180-0","27350545","PMC5014786",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0025613","A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity.","Lomenick JP","2016","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.21493","27133664","PMC4882247","ClinicalTrials.gov:NCT01484873","S000315","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0025614","Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.","Ahrén B","2016","Diabetes care","randomized_trial","article","10.2337/dc16-0690","27493132",null,"ClinicalTrials.gov:NCT02098395","S000291; S000485; S001732","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0025615","An Investigation into the Gastrointestinal Stability of Exenatide in the Presence of Pure Enzymes, Everted Intestinal Rings and Intestinal Homogenates.","Sun Y","2016","Biological & pharmaceutical bulletin","preclinical","article","10.1248/bpb.b15-00442","26725426",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025616","The best drug supplement for obesity treatment: a systematic review and network meta-analysis.","Salari N","2021","Diabetology & metabolic syndrome","systematic_review","article","10.1186/s13098-021-00733-5","34663429","PMC8522222",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","TRUE","Journal Article; Retracted Publication; research-article; article; review"],["R0025617","Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.","Sharma R","2018","Current medical research and opinion","systematic_review","article","10.1080/03007995.2018.1476332","29764222",null,null,"S000372; S001876","pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0025618","Obesity Pharmacotherapy is Effective in the Veterans Affairs Patient Population: A Local and Virtual Cohort Study.","Pendse J","2021","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.23075","33491308","PMC8112812",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025619","Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-331.","Abdul-Ghani M","2017","Diabetes care","notice","article","10.2337/dc17-er08d","28615237","PMC5521968",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0025620","Comparative Evaluation of Metformin and Liraglutide Cardioprotective Effect in Rats With Impaired Glucose Tolerance","Simanenkova A","2020","Research Square","preclinical","preprint","10.21203/rs.3.rs-123780/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0025621","Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study.","Darpo B","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-014-0074-y","25034668","PMC4269647",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0025622","Notification of removal of Therapeutic Advances in Endocrinology and Metabolism article",null,"2014","Therapeutic advances in endocrinology and metabolism","other","article","10.1177/2042018814547198",null,"PMC4257979",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","correction; Corrected and Republished Article; article"],["R0025623","The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes.","Gordon J","2016","Journal of medical economics","other_trial","article","10.1080/13696998.2016.1208207","27356188",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0025624","[SGLT2 inhibitors: A new era for our patients].","Halimi JM","2021","Nephrologie & therapeutique","randomized_trial","article","10.1016/j.nephro.2020.12.006","33773943",null,null,null,"pubmed; europepmc; openalex","FALSE","open_pdf","2","FALSE","Journal Article; article"],["R0025625","Liraglutide attenuates the osteoblastic differentiation of MC3T3‑E1 cells by modulating AMPK/mTOR signaling.","Hu XK","2016","Molecular medicine reports","preclinical","article","10.3892/mmr.2016.5729","27600753","PMC5042760",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025626","Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.","Harkavyi A","2008","Journal of neuroinflammation","preclinical","article","10.1186/1742-2094-5-19","18492290","PMC2426681",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025627","Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.","Lundkvist P","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12779","27550386","PMC5215525",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; research-article; article"],["R0025628","The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes.","Jimeno C","2018","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.033.02.02","33442116","PMC7784181",null,"S000824","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025629","Development of composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles for sustained drug release.","Dong N","2020","Asian journal of pharmaceutical sciences","preclinical","article","10.1016/j.ajps.2019.01.002","32636952","PMC7327764",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025630","Mechanisms underlying the prokinetic effects of endogenous glucagon-like peptide-1 in the rat proximal colon.","Nakamori H","2021","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00175.2021","34643099",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025631","Corrigendum to 'Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway' [Biochem. Biophys. Res. Commun. 510(2019):20-26.].","Li Z","2019","Biochemical and biophysical research communications","notice","article","10.1016/j.bbrc.2019.05.095","31160090",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0025632","Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.","Seino Y","2008","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2008.03.018","18495285",null,null,"S000463","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025633","Erratum to: Abstracts of the 53rd Annual Meeting of the EASD, Lisbon 2017. Abstract 788: 'Pharmacokinetics and tolerability of oral semaglutide in subjects with renal impairment'.","Anderson TW","2017","Diabetologia","notice","article","10.1007/s00125-017-4413-1","28835978","PMC7608380",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0025634","Downregulation of the GLP-1/CREB/adiponectin pathway is partially responsible for diabetes-induced dysregulated vascular tone and VSMC dysfunction.","Xiong X","2020","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","other","article","10.1016/j.biopha.2020.110218","32559849",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025635","Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide.","Young MA","2014","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2014.05.2754","24918790",null,"ClinicalTrials.gov:NCT00938158; ClinicalTrials.gov:NCT00849017; ClinicalTrials.gov:NCT00838916; ClinicalTrials.gov:NCT00839527","S000029; S000099; S000852; S001658","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial; Journal Article; article"],["R0025636","Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.","Lee YS","2016","Mediators of inflammation","preclinical","article","10.1155/2016/3094642","27110066","PMC4823510",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0025637","LBMON139 A Case of Adipsic Diabetes Insipidus In Patient With Third Ventricular Tumor And Right Frontal Craniotomy.",null,"2022","Journal of the Endocrine Society","case_report","article",null,null,"PMC9627003",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0025638","Transcriptomics of SGLT2-positive early proximal tubule segments in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.","Kim YC","2025","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00231.2024","39589189","PMC11918450",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0025639","Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion.","Kramer CK","2017","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2017-00928","28472325",null,"ClinicalTrials.gov:NCT01270789","S001528","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0025640","Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.","Seferović PM","2018","European journal of heart failure","narrative_review","article","10.1002/ejhf.1170","29520964",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Consensus Statement; article"],["R0025641","[Effect of liraglutide on glucagon secretion in obese type 2 diabetic patients].","Sun XF","2019","Zhonghua nei ke za zhi","other","article","10.3760/cma.j.issn.0578-1426.2019.01.006","30605948",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Multicenter Study; article"],["R0025642","Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.","DeFronzo RA","2008","Current medical research and opinion","randomized_trial","article","10.1185/03007990802418851","18786299",null,"ClinicalTrials.gov:NCT00477581","S002370","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025643","Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.","Upala S","2019","Hepatology (Baltimore, Md.)","randomized_trial","article","10.1002/hep.30551","30734333",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Comment; article"],["R0025644","New targets to treat obesity and the metabolic syndrome.","Martin KA","2015","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2015.03.093","26001373","PMC4573317",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review; research-article"],["R0025645","Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).","Rosenstock J","2014","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2014.01.012","24650952",null,"ClinicalTrials.gov:NCT00713830","S000491","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025646","Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr. Vivian A. Fonseca.","Fonseca VA","2011","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2010.11.005","21194580",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025647","Chronic Suppression of Glucagon-Like Peptide-1 Receptor (GLP1R) mRNA Translation in the Rat Bed Nucleus of the Stria Terminalis Reduces Anxiety-Like Behavior and Stress-Induced Hypophagia, But Prolongs Stress-Induced Elevation of Plasma Corticosterone.","Zheng H","2019","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.2180-18.2019","30683681","PMC6445994",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025648","Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease.","Khoo J","2019","Liver international : official journal of the International Association for the Study of the Liver","randomized_trial","article","10.1111/liv.14065","30721572",null,"ClinicalTrials.gov:NCT02654665","S001936","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025649","Managing diabetic kidney disease.","Zac-Varghese S","2018","British medical bulletin","narrative_review","article","10.1093/bmb/ldx047","29216336",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025650","Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation.","Hayes MR","2008","Endocrinology","preclinical","article","10.1210/en.2007-1743","18420740","PMC2488211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025651","Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management.","Karavanaki K","2022","Endocrine","narrative_review","article","10.1007/s12020-022-03172-y","36029440",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025652","Dietary plant flavonoids in prevention of obesity and diabetes.","Dinda B","2020","Advances in protein chemistry and structural biology","narrative_review","article","10.1016/bs.apcsb.2019.08.006","32085882",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025653","Buccal delivery of small molecules and biologics: of mucoadhesive polymers, films, and nanoparticles.","Morales JO","2017","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2017.07.011","28800417",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025654","Erratum: Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?",null,"2017","Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association","notice","article","10.4103/1319-3767.207738","28611347","PMC5470383",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0025655","Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia.","Giblett JP","2016","JACC. Basic to translational science","nonrandomized_study","article","10.1016/j.jacbts.2016.03.011","30167515","PMC6113423",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0025656","Albiglutide -- Benefit Assessment According to §35a Social Code Book V",null,"2014","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany","randomized_trial","article",null,"27905781",null,null,null,"europepmc","FALSE","free_to_read","2",null,"Review"],["R0025657","Correction to: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.","Bizino MB","2019","Cardiovascular diabetology","notice","article","10.1186/s12933-019-0905-2","31399033","PMC6688215",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0025658","Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice.","Lennox R","2014","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2014.06.026","24998752",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025659","[DIFFERENCES OF EXENATIDE EFFECTS ON GLYCEMIA AND RENAL WATER AND ION EXCRETION IN FROGS AND RATS].","Kutina AV","2016","Zhurnal evoliutsionnoi biokhimii i fiziologii","preclinical","article",null,"30695500",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025660","Population pharmacokinetics of exenatide.","Cirincione B","2017","British journal of clinical pharmacology","other_trial","article","10.1111/bcp.13135","27650681","PMC5306477",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0025661","Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.","Nylander M","2017","Endocrine connections","randomized_trial","article","10.1530/ec-16-0113","28119323","PMC5424770",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025662","Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?","Nauck MA","2011","Nature reviews. Endocrinology","commentary","article","10.1038/nrendo.2011.30","21326278",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0025663","Examination of mercaptobenzyl sulfonates as catalysts for native chemical ligation: application to the assembly of a glycosylated Glucagon-Like Peptide 1 (GLP-1) analogue.","Cowper B","2015","Chemical communications (Cambridge, England)","other","article","10.1039/c4cc09502b","25605668",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025664","Glucagon-like peptide-1 drugs. Are GLP-1 analogues affordable?","Macaulay D","2011","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.d1482","21385814",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0025665","Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.","Lorenzi M","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-016-0217-4","27995594","PMC5306116",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article"],["R0025666","Liraglutide improves atherosclerosis by regulating long non-coding RNA RMRP/miR-128-1-5P/Gadd45g axis.","An JH","2020","European review for medical and pharmacological sciences","other","article","10.26355/eurrev_202003_20545","32196624",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025667","A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.","Ji C","2016","Brain research","other_trial","article","10.1016/j.brainres.2015.09.035","26453833",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025668","Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.","Verma S","2018","Circulation","randomized_trial","article","10.1161/circulationaha.118.036862","30354517",null,"ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0025669","Hypoglycaemia and its management in primary care setting.","Ibrahim M","2020","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.3332","32343474",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0025670","A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus.","Seino Y","2014","Current medical research and opinion","randomized_trial","article","10.1185/03007995.2014.896327","24552155",null,"ClinicalTrials.gov:NCT01098461","S001266","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025671","Expert consensus on the use of liraglutide in the treatment of diabetes in internal medicine.","Calvo Gómez C","2016","International journal of clinical pharmacology and therapeutics","other","article","10.5414/cp202428","27487367",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Consensus Statement; article"],["R0025672","Sixty seconds on . . . semaglutide.","Hawkes N","2017","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.j5010","29092887",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0025673","Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes.","Christensen M","2015","International journal of obesity (2005)","other","article","10.1038/ijo.2015.136","26228460",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025674","Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.","Gaebler JA","2012","Vascular health and risk management","other_trial","article","10.2147/vhrm.s28744","22566747","PMC3346268","ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025675","Determination of the Plasma Protein Binding of Liraglutide Using the EScalate* Equilibrium Shift Assay.","Ungewiss J","2019","Journal of pharmaceutical sciences","other","article","10.1016/j.xphs.2018.10.018","30342006",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025676","Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors.","Rizzo MR","2016","Journal of the American Medical Directors Association","other","article","10.1016/j.jamda.2016.04.016","27262494",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025677","Persistence of newer anti-obesity medications in a real-world setting.","Ganguly R","2018","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2018.07.017","30009937",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0025678","Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model.","Christakis I","2017","Journal of investigative surgery : the official journal of the Academy of Surgical Research","preclinical","article","10.1080/08941939.2016.1231856","27689406",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Validation Study; article"],["R0025679","Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β.","Qi L","2017","American journal of translational research","preclinical","article",null,"28337257","PMC5340664",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025680","SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide.","Shirakawa J","2018","Annals of translational medicine","commentary","article","10.21037/atm.2018.01.35","29955589","PMC6015953",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0025681","Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.","Tao T","2021","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgaa692","32995892","PMC8244122","ClinicalTrials.gov:NCT03352869","S000679","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025682","GLP-1 improves adipose tissue glyoxalase activity and capillarization improving insulin sensitivity in type 2 diabetes.","Rodrigues T","2020","Pharmacological research","nonrandomized_study","article","10.1016/j.phrs.2020.105198","32942016",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025683","Purified Human Pancreatic Islets, CIT Transplant Media with Lisofylline or Exenatide.","NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee","2017","CellR4-- repair, replacement, regeneration, & reprogramming","other","article",null,"30613756","PMC6319650",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025684","Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.","Raccah D","2015","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.2588","25115916",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025685","Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.","Tuccori M","2017","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2017.1361401","28748718",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0025686","Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues.","Pohl M","1998","The Journal of biological chemistry","preclinical","article","10.1074/jbc.273.16.9778","9545315",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025687","Cerebral cortex: a target and source of insulin?","Csajbók ÉA","2016","Diabetologia","narrative_review","article","10.1007/s00125-016-3996-2","27207082",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0025688","Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.","Camastra S","2017","Diabetes, obesity & metabolism","other","article","10.1111/dom.12836","27898183",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025689","Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.","Vaduganathan M","2020","JACC. Heart failure","nonrandomized_study","article","10.1016/j.jchf.2019.12.015","32387066",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Observational Study; Research Support, Non-U.S. Gov't"],["R0025690","The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.","Nelson P","2007","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2006.0024","17705687",null,"ClinicalTrials.gov:NCT00044694; ClinicalTrials.gov:NCT00085969; ClinicalTrials.gov:NCT00111540","S000052; S001080; S001267","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025691","Cardiovascular disease leads to a new algorithm for diabetes treatment.","Rodriguez V","2017","Journal of clinical lipidology","narrative_review","article","10.1016/j.jacl.2017.07.004","28822714",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025692","Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?","Kumar A","2017","Pharmacological reports : PR","narrative_review","article","10.1016/j.pharep.2017.04.003","28822958",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025693","Purified Human Pancreatic Islets, CIT Culture Media with Lisofylline or Exenatide.","NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee","2017","CellR4-- repair, replacement, regeneration, & reprogramming","other","article",null,"30613755","PMC6319648",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025694","[Significance of glucagon control in the diabetes treatment].","Kitamura T","2015","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"25812382",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025695","Using QALYs as an Outcome for Assessing Global Prediction Accuracy in Diabetes Simulation Models.","Dakin HA","2025","Medical decision making : an international journal of the Society for Medical Decision Making","other_trial","article","10.1177/0272989x241285866","39474832","PMC11645849",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0025696","Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme.","Montanya E","2016","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12617","26662611","PMC5067695",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; Meta-Analysis; Review; Research Support, Non-U.S. Gov't; article"],["R0025697","[Tight glycemic control in the management of diabetic patients: what has changed since the '90s in the clinical approach?].","Fiorentino TV","2014","Giornale italiano di cardiologia (2006)","other","article","10.1714/1762.19112","25623546",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0025698","Investigating the influence of XAV-939, a tankyrase inhibitor, on the density and gating of erg-mediated K+ currents in mouse MA-10 Leydig tumor cells.","Ng WM","2024","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2024.176518","38556119",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025699","[Mechanism of electroacupuncture on improving insulin resistance and intestinal mucosal barrier injury via the GLP-1R/PKA signaling pathway in type 2 diabetes mellitus rats].","Lin J","2026","Zhongguo zhen jiu = Chinese acupuncture & moxibustion","randomized_trial","article","10.13703/j.0255-2930.20250312-k0002","41741988",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","English Abstract; Journal Article; other"],["R0025700","Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China.","Cao Y","2022","Frontiers in neurology","narrative_review","article","10.3389/fneur.2022.1034243","36457865","PMC9706102",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025701","Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.","Ahrén B","2014","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2014.05.012","25012990",null,null,"S000189","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025702","Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides.","Abu-Hamdah R","2009","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/jc.2008-1296","19336511","PMC2690432",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0025703","Glucagon-like peptide-1 prevented abdominal aortic aneurysm development in rats.","Yu J","2016","Surgery today","preclinical","article","10.1007/s00595-015-1287-z","26658813",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025704","Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis by modulating mitochondrial function","Jiang X","2022","Research Square","preclinical","preprint","10.21203/rs.3.rs-1259932/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0025705","Mass spectrometry imaging of free-floating brain sections detects pathological lipid distribution in a mouse model of Alzheimer's-like pathology.","Strnad Š","2020","The Analyst","preclinical","article","10.1039/d0an00592d","32436545",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025706","Serum Quantitative Proteomic Analysis Reveals Soluble EGFR To Be a Marker of Insulin Resistance in Male Mice and Humans.","Kyohara M","2017","Endocrinology","preclinical","article","10.1210/en.2017-00339","29028997",null,"UMIN:UMIN000020474",null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025707","Exenatide suppresses 1,2-dimethylhydrazine-induced colon cancer in diabetic mice: Effect on tumor angiogenesis and cell proliferation.","Tawfik MK","2016","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","randomized_trial","article","10.1016/j.biopha.2016.05.005","27470345",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0025708","Notch signaling is involved in the antiapoptotic effects of liraglutide on rat H9c2 cardiomyocytes exposed to hypoxia followed by reoxygenation.","Wu J","2020","The Journal of international medical research","preclinical","article","10.1177/0300060520948394","32967491","PMC7521049",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025709","An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes.","Wu P","2020","Current drug targets","narrative_review","article","10.2174/1389450120666191031104653","31670620",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025710","Rapid-onset clozapine-induced hyperglycaemia: pathways of glycaemic dysregulation.","Barbosa M","2021","BMJ case reports","case_report","article","10.1136/bcr-2021-243938","34518181","PMC8438955",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0025711","Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.","Dejgaard TF","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12841","27935240",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025712","Gateways to clinical trials.","Bayés M","2002","Methods and findings in experimental and clinical pharmacology","other","article",null,"12616707",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025713","[Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis].","Kobalava ZD","2019","Kardiologiia","narrative_review","article","10.18087/cardio.2019.4.10253","31002044",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0025714","Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.","Ludwig B","2014","Vitamins and hormones","narrative_review","article","10.1016/b978-0-12-800174-5.00008-9","24559919",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review"],["R0025715","Managing chronic kidney disease in diabetes patients with the latest chemical therapies.","Hu J","2019","Expert review of clinical pharmacology","other_trial","article","10.1080/17512433.2019.1552829","30509118",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0025716","N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression.","Liu HK","2004","Cell biology international","preclinical","article","10.1016/j.cellbi.2003.10.004","14759771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025717","Pharmacotherapy of 'treatment resistant' type 2 diabetes.","Scheen AJ","2017","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2017.1297424","28276972",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025718","Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and NF-kB Levels in Type 2 Diabetes.","Liu X","2019","Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","randomized_trial","article","10.29271/jcpsp.2019.03.218","30823945",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0025719","Transient neonatal diabetes mellitus gene Zac1 impairs insulin secretion in mice through Rasgrf1.","Hoffmann A","2012","Molecular and cellular biology","preclinical","article","10.1128/mcb.06637-11","22547676","PMC3434484",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025720","Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.","Bailey TS","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12736","27381275","PMC5129465",null,"S001119","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025721","Letter to Liu et al.'s \"Efficacy of Exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome\".","Legro RS","2018","Clinical endocrinology","commentary","article","10.1111/cen.13474","28898436",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0025722","Purified Human Pancreatic Islets, CIT Transplant Wash Media with Lisofylline or Exenatide.","NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee","2017","CellR4-- repair, replacement, regeneration, & reprogramming","other","article",null,"30613754","PMC6319642",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025723","Effects of liraglutide in hypothalamic arcuate nucleus of obese mice.","Barreto-Vianna AR","2016","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.21387","26916241",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025724","Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.","Dejager S","2012","Hospital practice (1995)","narrative_review","article","10.3810/hp.2012.04.965","22615074",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025725","A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions.","Ma Y","2015","Biomaterials","preclinical","article","10.1016/j.biomaterials.2015.01.064","25771000",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025726","Recent advances in the management of type 2 diabetes mellitus: a review.","Srinivasan BT","2008","Postgraduate medical journal","narrative_review","article","10.1136/pgmj.2008.067918","19017837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025727","SUN-544 Immunologic Effects of GLP-1 Activation in Obese Adipose Tissue","Mashayekhi M","2020","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaa046.736",null,"PMC7208689",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0025728","Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.","Ciresi A","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-017-0338-4","29139081","PMC5801224",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; case-report; other; article"],["R0025729","Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom.","Kindred M","2024","Applied health economics and health policy","nonrandomized_study","article","10.1007/s40258-023-00839-z","37948035","PMC10761369",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025730","Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga.","Roca-Rodríguez Mdel M","2015","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","other_trial","article","10.1016/j.endonu.2015.07.004","26423184",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Letter; Research Support, Non-U.S. Gov't; article"],["R0025731","Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.","Perry T","2002","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.102.037481","12183643",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0025732","Weight Loss Outcomes With Telemedicine During COVID-19.","Tchang BG","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.793290","35360066","PMC8960113",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0025733","Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.","Xue S","2010","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2008.12.004","19217320",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025734","Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.","Avranas K","2018","Cardiovascular & hematological disorders drug targets","systematic_review","article","10.2174/1871529x18666180206160838","29412124",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Review; article"],["R0025735","Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.","Khan RS","2019","Hepatology (Baltimore, Md.)","narrative_review","article","10.1002/hep.30429","30556145",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025736","Albiglutide approved for type 2 diabetes.","Traynor K","2014","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","commentary","article","10.2146/news140038","24830988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0025737","Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.","von Scholten BJ","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12884","28105731",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025738","Is liraglutide a useful addition to diabetes therapy?","Mikhail NE","2010","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other_trial","article","10.4158/ep10076.ra","20439238",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0025739","Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.","Pratley RE","2010","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(10)60307-8","20417856",null,"ClinicalTrials.gov:NCT00700817","S002357; S002361","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025740","Diabetes Drug Effects on the Skeleton.","Chandran M","2017","Calcified tissue international","narrative_review","article","10.1007/s00223-016-0203-x","27815568",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025741","[Pharmacotherapy in patients with reduced kidney function].","Schumacher D","2018","Therapeutische Umschau. Revue therapeutique","narrative_review","article","10.1024/0040-5930/a001012","30880621",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025742","Rat pancreatic islet size standardization by the \"hanging drop\" technique.","Cavallari G","2007","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2007.05.016","17692680",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025743","Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.","Bethel MA","2020","Diabetes care","other_trial","article","10.2337/dc19-1065","31757838","PMC7411285",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025744","[Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].","García-Casares N","2014","Revista de neurologia","systematic_review","article","10.33588/rn.5911.2014023","25418147",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Systematic Review; article"],["R0025745","Dynamic omnidirectional adhesive microneedle system for oral macromolecular drug delivery.","Chen W","2022","Science advances","other","article","10.1126/sciadv.abk1792","34985942","PMC8730401",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025746","Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).","Aroda VR","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12661","26990378","PMC5074260","ClinicalTrials.gov:NCT01664247","S000530","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025747","Progress in pediatric obesity: new and advanced therapies.","Cuda S","2022","Current opinion in pediatrics","narrative_review","article","10.1097/mop.0000000000001150","35797460",null,"ClinicalTrials.gov:NCT04102189; ClinicalTrials.gov:NCT04963231","S001529","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0025748","Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.","Pratley RE","2007","Current medical research and opinion","narrative_review","article","10.1185/030079906x162746","17407649",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025749","Recombinant production of medium- to large-sized peptides in Escherichia coli using a cleavable self-aggregating tag.","Zhao Q","2016","Microbial cell factories","other","article","10.1186/s12934-016-0534-3","27495238","PMC4975908",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0025750","GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?","Taing MW","2014","Drug design, development and therapy","preclinical","article","10.2147/dddt.s35723","24940046","PMC4051623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article; review"],["R0025751","Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).","Pinget M","2013","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12121","23627775",null,"ClinicalTrials.gov:NCT00763815","S000473; S001204","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025752","Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.","Malloy J","2013","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2013.05.2661","23748507",null,"ClinicalTrials.gov:NCT00637273; ClinicalTrials.gov:NCT00676338","S000402; S001966","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0025753","Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.","Verma S","2018","Circulation","randomized_trial","article","10.1161/circulationaha.118.033898","29760228",null,"ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025754","Recent advances in understanding the role of glucagon-like peptide 1.","Reed J","2020","F1000Research","narrative_review","article","10.12688/f1000research.20602.1","32269764","PMC7137394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; Preprint; review-article; article"],["R0025755","Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians.","Naing S","2016","Postgraduate medicine","other_trial","article","10.1080/00325481.2016.1245093","27701934",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0025756","Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.","Azar ST","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12733","27376711","PMC5095865","ClinicalTrials.gov:NCT01917656","S000963","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025757","TREATMENT OF DIABETES MELLITUS IN A GOLDEN LION TAMARIN (LEONTOPITHECUS ROSALIA) WITH THE GLUCAGON-LIKE PEPTIDE-1 MIMETIC EXENATIDE.","Johnson JG","2016","Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians","case_report","article","10.1638/2015-0270.1","27691959",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0025758","Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.","Baandrup Kristiansen MN","2019","BMC gastroenterology","preclinical","article","10.1186/s12876-019-1149-z","31883514","PMC6935483",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025759","Glucagon-like peptide-1 drugs. Use of GLP-1 analogues needs great caution.","Yudkin JS","2011","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.d1478","21385813",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0025760","Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses.","Torbahn G","2024","Pediatric obesity","systematic_review","article","10.1111/ijpo.13113","38454737",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0025761","Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study.","Al Hayek AA","2019","Clinical medicine insights. Endocrinology and diabetes","other","article","10.1177/1179551419834935","30911225","PMC6425521",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025762","Data-driven subgroups of newly diagnosed type 2 diabetes and the relationship with cardiovascular diseases at genetic and clinical levels in Chinese adults.","Wang W","2023","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2023.102850","37683311",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0025763","Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i.","Lanzinger S","2018","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2018.10.011","30367902",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article"],["R0025764","Time to insulin in type-2 diabetes: high hurdles or Santiago way?","Rotella CM","2008","Acta diabetologica","narrative_review","article","10.1007/s00592-008-0027-x","18408882",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025765","Dulaglutide (Addendum to Commission A15-07)",null,"2015","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany","narrative_review","article",null,"29144655",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0025766","Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism.","Xiao C","2015","Diabetes","narrative_review","article","10.2337/db14-1706","26106188",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025767","Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.","Seino Y","2015","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2015.07.003","26342556",null,null,"S001224","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025768","Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues.","Dal Molin M","2016","Pancreas","other","article","10.1097/mpa.0000000000000521","26495786","PMC4783303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025769","Exenatide.","Keating GM","2005","Drugs","other_trial","article","10.2165/00003495-200565120-00008","16060703",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; article"],["R0025770","Liraglutide as an Alternative to Insulin for Glycemic Control in Intensive Care Unit: A Randomized, Open-label, Clinical Study.","Verma V","2017","Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine","randomized_trial","article","10.4103/ijccm.ijccm_105_17","28970655","PMC5613607",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025771","Treating type 2 diabetes: incretin mimetics and enhancers.","Janosz KE","2009","Therapeutic advances in cardiovascular disease","narrative_review","article","10.1177/1753944709341377","19808944",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025772","The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis.","Ghosal S","2022","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2022.109824","35271879",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Preprint; article; preprint"],["R0025773","[An orally administered glucagon-like peptide 1 (GLP1) analogue: A landmark in the treatment of type 2 diabetes].","Larger É","2021","Medecine sciences : M/S","other_trial","article","10.1051/medsci/2020261","33492219",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0025774","Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.","Fass AD","2013","Advances in therapy","other_trial","article","10.1007/s12325-013-0023-6","23605247",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0025775","GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway.","Chen X","2021","The Journal of international medical research","preclinical","article","10.1177/0300060521992981","33641439","PMC7917887",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0025776","The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).","Thondam SK","2020","Peptides","preclinical","article","10.1016/j.peptides.2019.170208","31759125",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025777","Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.","Leiter LA","2019","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-019-0871-8","31167654","PMC6551895","ClinicalTrials.gov:NCT01720446","S001933","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0025778","Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.","Ratner RE","2006","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2006.00589.x","16776749",null,null,"S002301","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025779","Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.","Barragán JM","1996","Regulatory peptides","preclinical","article","10.1016/s0167-0115(96)00113-9","8952007",null,null,"S000473","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025780","Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.","Xu G","1999","Diabetes","preclinical","article","10.2337/diabetes.48.12.2270","10580413",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0025781","3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.","le Roux CW","2017","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(17)30069-7","28237263",null,"ClinicalTrials.gov:NCT01272219","S000138; S000492","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025782","Guidelines for managing diabetes in Ramadan.","Ali S","2016","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.13080","26802436",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0025783","An Increase of Heart Rate and Electrocardiographic Changes after Subcutaneous Liraglutide.","Zhou WW","2017","Chinese medical journal","other_trial","article","10.4103/0366-6999.219142","29176154","PMC5717876",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; article"],["R0025784","Exenatide.","Bray GM","2006","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.2146/ajhp050459","16484515",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025785","Pharmacotherapy of hyperglycemia.","Kulasa KM","2009","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656560903196758","19743938",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025786","Purified Human Pancreatic Islets with Exenatide, Certificate of Analysis (Product code PHPI-E-01).","NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee","2017","CellR4-- repair, replacement, regeneration, & reprogramming","other","article",null,"30613758","PMC6319655",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025787","Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis.","Gu S","2020","BMC medicine","nonrandomized_study","article","10.1186/s12916-020-01837-x","33267884","PMC7713153",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0025788","Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells.","Bai L","2005","The Journal of endocrinology","preclinical","article","10.1677/joe.1.06078","16079260",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025789","Pneumonia induced rise in glucagon promotes endothelial damage and vascular thrombogenicity","Rad PR","2024","bioRxiv","preclinical","preprint","10.1101/2024.05.03.592488",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0025790","Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.","Ionut V","2016","PloS one","randomized_trial","article","10.1371/journal.pone.0158703","27398720","PMC4939956",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025791","A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.","Nauck MA","2007","Diabetologia","randomized_trial","article","10.1007/s00125-006-0510-2","17160407",null,null,"S000441","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0025792","Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.","Galderisi A","2018","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2017-02265","29211871","PMC6276715",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025793","Antidiabetic Drugs and the Kidney.","Tsimihodimos V","2017","Current pharmaceutical design","narrative_review","article","10.2174/1381612823666170307103222","28270062",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025794","Effects of glycaemic management on diabetic kidney disease.","MacIsaac RJ","2017","World journal of diabetes","narrative_review","article","10.4239/wjd.v8.i5.172","28572879","PMC5437616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025795","The Impact of a Clinical Pharmacist in an Interdisciplinary Weight Loss Service: A Follow-Up Study.","Francis BR","2021","Innovations in pharmacy","randomized_trial","article","10.24926/iip.v12i4.4356","36033119","PMC9401365",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025796","Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats.","Solmaz V","2015","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2015.09.024","26386291",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025797","Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.","von Scholten BJ","2017","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2017.04.003","28462892",null,"ClinicalTrials.gov:NCT01272219; ClinicalTrials.gov:NCT01272232","S000492; S001792","pubmed; europepmc","FALSE","paywalled","1",null,"Journal Article; Randomized Controlled Trial"],["R0025798","Towards a multidimensional scientific approach to improve clinical practices for infertility treatment.","Zhu YH","2018","Journal of Zhejiang University. Science. B","nonrandomized_study","article","10.1631/jzus.b1801014","30387331","PMC6238113",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Editorial; research-article; editorial"],["R0025799","Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.","Alcántara AI","1997","Archives of biochemistry and biophysics","preclinical","article","10.1006/abbi.1997.9951","9143346",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025800","Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.","Patel V","2013","Canadian journal of physiology and pharmacology","preclinical","article","10.1139/cjpp-2013-0189","24289070",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025801","Liraglutide May Reduce Diabetic Kidney Disease.","Slomski A","2017","JAMA","other_trial","article","10.1001/jama.2017.15293","29067421",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0025802","ZP2495 Protects against Myocardial Ischemia/Reperfusion Injury in Diabetic Mice through Improvement of Cardiac Metabolism and Mitochondrial Function: The Possible Involvement of AMPK-FoxO3a Signal Pathway.","Li S","2018","Oxidative medicine and cellular longevity","preclinical","article","10.1155/2018/6451902","29576852","PMC5822888",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025803","American Chemical Society-239th national meeting--Investigating new therapeutic candidates: part 2. 21-25 March 2010, San Francisco, CA, USA.","Kirkham K","2010","IDrugs : the investigational drugs journal","other","article",null,"20432181",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Conference Proceedings; article"],["R0025804","Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.","Nuche-Berenguer B","2010","Regulatory peptides","preclinical","article","10.1016/j.regpep.2009.06.010","19586609",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025805","Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain.","Deutch AY","2017","JAMA psychiatry","commentary","article","10.1001/jamapsychiatry.2017.3053","28973118",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0025806","Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery.","Rye P","2018","Obesity surgery","nonrandomized_study","article","10.1007/s11695-018-3393-7","30022424",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0025807","GLP-1 agonists: improving the future of patients with type 2 diabetes.","Shubrook JH","2011","The Journal of the American Osteopathic Association","commentary","article",null,"21409846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Introductory Journal Article; conference-abstract"],["R0025808","Exenatide Improves HDL Particle Counts and Size Distribution in Patients With Long-standing Type 1 Diabetes.","Gourgari EA","2017","Diabetes care","randomized_trial","article","10.2337/dc16-2602","28515131","PMC5481982","ClinicalTrials.gov:NCT00064714","S000229","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Letter; Research Support, N.I.H., Extramural; article"],["R0025809","Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patients.","Terauchi Y","2016","Diabetes & metabolic syndrome","systematic_review","article","10.1016/j.dsx.2015.08.008","26341928",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0025810","Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.","Arturi F","2017","Endocrine","randomized_trial","article","10.1007/s12020-016-1166-4","27830456",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0025811","Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1.","Gastaldelli A","2017","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000000384","28463898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025812","Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?","Tak YJ","2021","Current obesity reports","other_trial","article","10.1007/s13679-020-00422-w","33410104","PMC7787121",null,null,"pubmed; europepmc","TRUE","open_europepmc","5",null,"Journal Article; Review; review-article"],["R0025813","Novel antidiabetic nutrients identified by in vivo screening for gastric secretion and emptying regulation in rats.","Jordi J","2014","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00273.2014","25100072",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025814","Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study.","Martinez L","2017","Advances in therapy","nonrandomized_study","article","10.1007/s12325-017-0476-0","28138803","PMC5350193","ClinicalTrials.gov:NCT01226966","S001762","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0025815","Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.","Waser B","2011","European journal of nuclear medicine and molecular imaging","preclinical","article","10.1007/s00259-010-1701-0","21210113",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025816","Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials.","Huang M","2017","Annals of medicine","systematic_review","article","10.1080/07853890.2017.1306653","28286967",null,"ClinicalTrials.gov:NCT02001363; ClinicalTrials.gov:NCT00835848; ClinicalTrials.gov:NCT01254123; ClinicalTrials.gov:NCT01580514","S000838; S001622; S002195; S002201","pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0025817","Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation.","Barreto-Vianna ARC","2017","Metabolic brain disease","preclinical","article","10.1007/s11011-017-0059-4","28681199",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025818","Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain-Reply.","Fink-Jensen A","2017","JAMA psychiatry","commentary","article","10.1001/jamapsychiatry.2017.2702","28973062",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0025819","Consensus on Current Landscape and Treatment Trends of Obesity in India for Primary Care Physicians.","Deshpande NR","2023","The Journal of the Association of Physicians of India","other","article","10.59556/japi.71.0349","38716527",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Consensus Statement; Journal Article"],["R0025820","Evidence for glucagon-like peptide-1 receptor signaling to activate ATP-sensitive potassium channels in pancreatic beta cells.","Kwon HJ","2016","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2015.11.127","26655814",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025821","Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats.","Lim S","2017","Cardiovascular research","preclinical","article","10.1093/cvr/cvw213","27702762",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0025822","The past decade in type 2 diabetes and future challenges.","Haddad JA","2018","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-018-0080-y","30519831",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Historical Article; Journal Article; Review"],["R0025823","Development of chitosan coated calcium-alginate nanocapsules for oral delivery of liraglutide to diabetic patients.","Shamekhi F","2018","International journal of biological macromolecules","other","article","10.1016/j.ijbiomac.2018.08.078","30125628",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025824","Clinical management strategies for type 2 diabetes.","Cefalu WT","2007","JAAPA : official journal of the American Academy of Physician Assistants","other_trial","article","10.1097/01720610-200712000-00002","18217246",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0025825","Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.","Ghanaat-Pour H","2009","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.896","19065603",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025826","Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.","Danne T","2017","The Journal of pediatrics","randomized_trial","article","10.1016/j.jpeds.2016.10.076","27979579",null,"ClinicalTrials.gov:NCT01789086","S001587","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025827","Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.","Levin A","2022","Clinical therapeutics","other","article","10.1016/j.clinthera.2022.01.003","35105470",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025828","Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats.","Zhang Y","2011","Investigative ophthalmology & visual science","preclinical","article","10.1167/iovs.09-4727","20688733",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025829","Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus.","Boyle PJ","2007","The Journal of the American Osteopathic Association","narrative_review","article",null,"17724013",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025830","Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease.","Steven S","2019","Oxidative medicine and cellular longevity","narrative_review","article","10.1155/2019/7092151","31341533","PMC6612399",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025831","The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial.","Giblett JP","2019","American heart journal","randomized_trial","article","10.1016/j.ahj.2019.05.013","31277053",null,"ClinicalTrials.gov:NCT02127996",null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Randomized Controlled Trial"],["R0025832","[Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes].","Scheen AJ","2007","Revue medicale suisse","narrative_review","article",null,"17896662",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0025833","Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.","Vahl TP","2007","Endocrinology","preclinical","article","10.1210/en.2006-0153","17584962",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0025834","Mucus- and pH-mediated controlled release of core-shell chitosan nanoparticles in the gastrointestinal tract for diabetes treatment.","Shi Y","2023","Journal of drug targeting","preclinical","article","10.1080/1061186x.2022.2104296","35861405",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025835","Clinically and pharmacologically relevant interactions of antidiabetic drugs.","May M","2016","Therapeutic advances in endocrinology and metabolism","narrative_review","article","10.1177/2042018816638050","27092232","PMC4821002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025836","Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.","Zang L","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12674","27060930","PMC5084818","ClinicalTrials.gov:NCT02008682","S000650","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; research-article; article"],["R0025837","Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.","Tølbøl KS","2018","World journal of gastroenterology","preclinical","article","10.3748/wjg.v24.i2.179","29375204","PMC5768937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0025838","Diabetes mellitus: new challenges and innovative therapies.","Sena CM","2010","The EPMA journal","narrative_review","article","10.1007/s13167-010-0010-9","23199048","PMC3405309",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0025839","Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?","Zinman B","2011","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2010.11.003","21194577",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025840","JunB protects β-cells from lipotoxicity via the XBP1-AKT pathway.","Cunha DA","2014","Cell death and differentiation","other","article","10.1038/cdd.2014.53","24786832","PMC4085537",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0025841","Maturity-onset diabetes of the young type 9 or latent autoimmune diabetes in adults: A case report and review of literature.","Zhou GH","2023","World journal of diabetes","case_report","article","10.4239/wjd.v14.i7.1137","37547587","PMC10401456",null,null,"pubmed; europepmc","TRUE",null,null,null,"Case Reports; Journal Article; case-report"],["R0025842","Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass.","Mitchell RK","2015","Human molecular genetics","preclinical","article","10.1093/hmg/ddu553","25355422","PMC4321446",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025843","[Prevention and treatment of antipsychotic induced weight gain].","Veerman SRT","2023","Tijdschrift voor psychiatrie","systematic_review","article",null,"37323046",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","3","FALSE","Systematic Review; English Abstract; Journal Article; review"],["R0025844","Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.","Ferjan S","2017","Metabolic syndrome and related disorders","randomized_trial","article","10.1089/met.2017.0095","29064743",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025845","Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes.","Onishi Y","2016","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej15-0518","26698689",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase III; Comparative Study; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025846","Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency.","Sebokova E","2010","Endocrinology","preclinical","article","10.1210/en.2009-1459","20382695",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025847","Nutrient Optimization Reduces Phosphorylation and Hydroxylation Level on an Fc-Fusion Protein in a CHO Fed-Batch Process.","Hou Y","2019","Biotechnology journal","preclinical","article","10.1002/biot.201700706","29877623",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025848","Severe Obesity in A Specialist Type 2 Diabetes Outpatient Clinic: An Australian Retrospective Cohort Study","Thakur A","2020","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-128134/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0025849","Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.","Waugh N","2010","Health technology assessment (Winchester, England)","systematic_review","article","10.3310/hta14360","20646668",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0025850","Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.","Hirsch IB","2014","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12136","23711193",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025851","Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.","Chilton R","2011","The American journal of medicine","preclinical","article","10.1016/j.amjmed.2010.11.004","21194579",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025852","Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.","Abdul-Ghani M","2017","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2016-3423","28324038",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025853","Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk.","FLAT-SUGAR Trial Investigators","2016","Diabetes care","randomized_trial","article","10.2337/dc15-2782","27208320",null,null,"S000559; S002311","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025854","Deficiency of peroxisomal NUDT7 stimulates de novo lipogenesis in hepatocytes.","Song J","2022","iScience","preclinical","article","10.1016/j.isci.2022.105135","36185359","PMC9523354",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025855","Role of phosphatidylinositol 3-kinasegamma in the beta-cell: interactions with glucagon-like peptide-1.","Li LX","2006","Endocrinology","preclinical","article","10.1210/en.2006-0155","16574789",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025856","What are the pharmacotherapy options for treating prediabetes?","Daniele G","2014","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2014.944160","25139488",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0025857","Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes.","Ma Z","2015","International journal of clinical pharmacology and therapeutics","randomized_trial","article","10.5414/cp202415","26365337",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025858","Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models.","Bhattacharjee J","2023","Hepatology communications","preclinical","article","10.1097/hc9.0000000000000323","37994050","PMC10666985",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025859","Liraglutide ameliorates cardiotoxicity induced by doxorubicin in rats through the Akt/GSK-3β signaling pathway.","Abbas NAT","2017","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-017-1414-z","28780599",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025860","Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study.","Clarke SJ","2019","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2018.11.013","30598343",null,"ClinicalTrials.gov:NCT02129179",null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Observational Study; Research Support, Non-U.S. Gov't"],["R0025861","Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.","Salamun V","2018","European journal of endocrinology","randomized_trial","article","10.1530/eje-18-0175","29703793",null,null,"S000630; S001012; S002080","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025862","Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.","Klonoff DC","2008","Current medical research and opinion","randomized_trial","article","10.1185/030079908x253870","18053320",null,null,"S000052","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025863","Tungstate stimulates insulin release and inhibits somatostatin output in the perfused rat pancreas.","Silvestre RA","2005","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2005.06.028","16126195",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0025864","Reappraisal of GIP Pharmacology for Metabolic Diseases.","Finan B","2016","Trends in molecular medicine","preclinical","article","10.1016/j.molmed.2016.03.005","27038883",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025865","[The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters].","Roubícek T","2010","Vnitrni lekarstvi","other_trial","article",null,"20184107",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Clinical Trial; Journal Article; article"],["R0025866","Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.","Henry RR","2016","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2016.0107","27525540","PMC5124747","ClinicalTrials.gov:NCT00308139","S002279","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0025867","Drug transport mechanism of oral antidiabetic nanomedicines.","Gundogdu E","2014","International journal of endocrinology and metabolism","narrative_review","article","10.5812/ijem.8984","24696697","PMC3968979",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025868","Glucagon-like peptide-1 cleavage product GLP-1 (9-36) amide enhances hippocampal long-term synaptic plasticity in correlation with suppression of Kv4.2 expression and eEF2 phosphorylation.","Day SM","2017","Hippocampus","preclinical","article","10.1002/hipo.22795","28833775","PMC5747370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025869","Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial.","Hassanein MM","2019","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2019.01.035","30772385",null,"ClinicalTrials.gov:NCT02941367","S000646","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025870","Lessons From LEADER - All-round Leadership.","Kalra S","2016","European endocrinology","randomized_trial","article","10.17925/ee.2016.12.02.76","29632591","PMC5813445",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Editorial; editorial"],["R0025871","Liraglutide in diabetes mellitus: More facts and findings.","Rahman IU","2016","Pakistan journal of pharmaceutical sciences","randomized_trial","article","10.36721/pjps/29/2/02.03.2016/3191/609-613","27087083",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0025872","Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).","Ahrén B","2013","Diabetes care","randomized_trial","article","10.2337/dc12-2006","23536584","PMC3747937","ClinicalTrials.gov:NCT00712673","S002188","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025873","Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB.","Engelbrechtsen L","2017","Obesity science & practice","randomized_trial","article","10.1002/osp4.133","29259801","PMC5729494",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025874","Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs.","Capuani B","2018","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2018.00719","30581418","PMC6293193",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025875","[Incretins in the treatment of diabetes].","Bulum T","2008","Lijecnicki vjesnik","narrative_review","article",null,"18979908",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0025876","Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.","Henry RR","2011","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.4158/ep.17.6.906","22193143",null,null,"S001094; S001502; S001584; S002098; S002222; S002230; S002361","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; review"],["R0025877","Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials.","Seufert J","2016","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12623","26679282","PMC5324626",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0025878","Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial.","Ilkowitz JT","2016","Journal of diabetes science and technology","randomized_trial","article","10.1177/1932296816647976","27184690","PMC5032955",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025879","Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.","Baggio LL","2004","Gastroenterology","preclinical","article","10.1053/j.gastro.2004.04.063","15300587",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025880","Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.","Esposito K","2012","Diabetes, obesity & metabolism","systematic_review","article","10.1111/j.1463-1326.2011.01512.x","21958121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0025881","Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.","Wang L","2019","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.4887","31456304","PMC6916409",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0025882","Dual GLP-1 and GIP receptor agonist Tirzapetide plays an off-target role in the modulation of the β-adrenoceptors and glucose metabolism in hyperglycemic or senescent cardiac cells","Aydos D","2025","bioRxiv","other","preprint","10.1101/2025.04.09.648025",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0025883","Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study.","Hellström PM","2009","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/j.1365-2036.2008.03870.x","18945254",null,null,"S003384","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025884","Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit.","Ballister B","2024","Journal of pharmacy practice","nonrandomized_study","article","10.1177/08971900221144399","36469659",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0025885","Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study.","Nyström T","2017","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2017.00325","29184539","PMC5694660",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025886","Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.","Lage MJ","2009","Advances in therapy","nonrandomized_study","article","10.1007/s12325-009-0002-0","19219409",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025887","A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion.","Shigeto M","2017","Journal of molecular medicine (Berlin, Germany)","preclinical","article","10.1007/s00109-017-1508-6","28097390",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0025888","PHPI, MPBR, Part 2B (Product Code PHPI-L-01 or PHPI-E-01, Islets with Lisofylline or Exenatide).","NIH CIT Consortium Chemistry Manufacturing Controls Monitoring Committee","2017","CellR4-- repair, replacement, regeneration, & reprogramming","other","article",null,"30613748","PMC6319632",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025889","[The protective effect of exenatide on the renal injury in diabetic rats].","Huang QZ","2017","Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","preclinical","article","10.12047/j.cjap.5466.2017.033","29931919",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025890","Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic Registry.","Vendrame F","2021","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2021.107884","33610436",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025891","Early changes in respiratory quotient and resting energy expenditure predict later weight changes in patients treated for poorly controlled type 2 diabetes.","Gonzalez C","2014","Diabetes & metabolism","other","article","10.1016/j.diabet.2014.02.001","24636224",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025892","[Obesity treatment-legal and illegal drugs and the future].","Hauner H","2021","Der Internist","narrative_review","article","10.1007/s00108-021-01159-x","34591131",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025893","Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers.","Abdelsameea AA","2017","Naunyn-Schmiedeberg's archives of pharmacology","randomized_trial","article","10.1007/s00210-016-1330-7","27986979",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0025894","Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.","Davies MJ","2015","JAMA","randomized_trial","article","10.1001/jama.2015.9676","26284720",null,"ClinicalTrials.gov:NCT01272232","S000371; S001792","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025895","Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.","Hou Y","2016","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00293.2015","26542397","PMC4698438",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025896","Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.","Kocyigit D","2017","Endocrine, metabolic & immune disorders drug targets","narrative_review","article","10.2174/1871530317666170424101846","28440199",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025897","Safety and efficacy of pharmacologic weight loss in patients with cirrhosis.","Fakhreddine AY","2021","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.469","33841885","PMC8019275",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025898","99mTc-exendin(9-39)/octreotide: biokinetics and radiation dosimetry in healthy individuals.","Ocampo-García BE","2017","Nuclear medicine communications","other","article","10.1097/mnm.0000000000000736","28953210",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025899","A New Dawn for the Treatment of Type 2 Diabetes: Integrating Incretin Mimetics Into Clinical Practice.",null,"2007","Journal of the American Academy of Nurse Practitioners","other","article","10.1111/j.1745-7599.2007.00286.x","18307618",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025900","Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest?","van Raalte DH","2017","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12935","28295962",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0025901","Novo Nordisk pays $58.7m to settle claims of mis-selling liraglutide.","Dyer O","2017","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.j4214","28887314",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0025902","Proliferation of sorted human and rat beta cells.","Parnaud G","2008","Diabetologia","preclinical","article","10.1007/s00125-007-0855-1","17994216",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025903","Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.","Grunberger G","2016","Diabetic medicine : a journal of the British Diabetic Association","other_trial","article","10.1111/dme.12833","26179454",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0025904","Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.","Raz I","2014","Diabetes care","randomized_trial","article","10.2337/dc13-2546","24914244",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025905","Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery.","Koole C","2015","The Journal of pharmacology and experimental therapeutics","other","article","10.1124/jpet.114.220913","25630467",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025906","Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.","Jia Y","2015","Pharmacological research","preclinical","article","10.1016/j.phrs.2015.10.008","26546042",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025907","Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.","Tatarkiewicz K","2014","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12237","24251534","PMC4237538",null,"S002223","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025908","Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.","Greig NH","1999","Diabetologia","preclinical","article","10.1007/s001250051111","10027577",null,null,"S002115","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0025909","The structure and function of the glucagon-like peptide-1 receptor and its ligands.","Donnelly D","2012","British journal of pharmacology","narrative_review","article","10.1111/j.1476-5381.2011.01687.x","21950636","PMC3415635",null,"S000504","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0025910","Exenatide Alters Gene Expression of Neural Cell Adhesion Molecule (NCAM), Intercellular Cell Adhesion Molecule (ICAM), and Vascular Cell Adhesion Molecule (VCAM) in the Hippocampus of Type 2 Diabetic Model Mice.","Gumuslu E","2016","Medical science monitor : international medical journal of experimental and clinical research","preclinical","article","10.12659/msm.897401","27465247","PMC4975365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025911","Semaglutide, lipid-lowering drugs, and NAFLD.","Katsiki N","2017","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(17)30109-2","28434490",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0025912","Effects of Liraglutide and Vitamin E in Fructose-Induced Metabolic Syndrome in Rats.","Geddawy A","2017","Pharmacology","preclinical","article","10.1159/000449429","27694749",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025913","Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.","de Wit HM","2016","Journal of internal medicine","randomized_trial","article","10.1111/joim.12447","26553486",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025914","Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.","Mary A","2017","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-017-0509-7","28202017","PMC5311847",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025915","GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats.","Habegger KM","2014","Diabetes","preclinical","article","10.2337/db13-0511","24186863","PMC3900539",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025916","Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions.","Chong JH","2019","Interventional cardiology (London, England)","narrative_review","article","10.15420/icr.2019.12","31178935","PMC6545978",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025917","Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.","Koehler JA","2011","Endocrinology","preclinical","article","10.1210/en.2011-1201","21771884",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025918","Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification.","Tsubery H","2004","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m405155200","15190059",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025919","Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes.","Yabe D","2012","Journal of diabetes investigation","other","article","10.1111/j.2040-1124.2011.00141.x","24843548","PMC4014935",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025920","Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.","Lind M","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-016-0173-z","27216947","PMC4900983","ClinicalTrials.gov:NCT02077946","S001832","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025921","Recombination and functional studies of a dual-action peptide for diabetes.","Zheng J","2013","Journal of drug targeting","preclinical","article","10.3109/1061186x.2012.761225","23336209",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025922","Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.","Liu SC","2012","Diabetes, obesity & metabolism","systematic_review","article","10.1111/j.1463-1326.2012.01606.x","22486990",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; Network Meta-Analysis; article"],["R0025923","Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial.","Li FF","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-016-0222-7","27995593","PMC5306121","ChiCTR:ChiCTR-PPR-15007045",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025924","Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control.","Borghetti G","2018","Frontiers in physiology","narrative_review","article","10.3389/fphys.2018.01514","30425649","PMC6218509",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025925","Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices.","Gupta V","2016","Annals of biomedical engineering","preclinical","article","10.1007/s10439-016-1558-x","26864536",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025926","MON-601 Obesity Pharmacotherapy Is Effective in the United States Veterans Affairs Patient Population: A Local and Virtual Cohort Study","Pendse J","2020","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaa046.1391",null,"PMC7208056",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0025927","Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158.","Nauck M","2015","Diabetes care","notice","article","10.2337/dc15-er03","25715416","PMC5321253",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; article"],["R0025928","Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.","Tourrel C","2001","Diabetes","preclinical","article","10.2337/diabetes.50.7.1562","11423477",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025929","[Immortalized adult rodent Schwann cells as useful tools for the study of peripheral nerve regeneration].","Sango K","2013","Rinsho shinkeigaku = Clinical neurology","preclinical","article","10.5692/clinicalneurol.53.1117","24291897",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0025930","Differentiation of human adipose-derived mesenchymal stem cell into insulin-producing cells: an in vitro study.","Moshtagh PR","2013","Journal of physiology and biochemistry","preclinical","article","10.1007/s13105-012-0228-1","23271274",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0025931","Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.","Rondinelli M","2017","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2016.11.001","27939305",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0025932","The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.","Skelin M","2018","International journal of clinical practice","systematic_review","article","10.1111/ijcp.13274","30295381",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; article"],["R0025933","Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus.","Bertuzzi F","2016","Transplantation","nonrandomized_study","article","10.1097/tp.0000000000001441","27517727",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0025934","Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.","Yu Y","2022","Frontiers in cardiovascular medicine","systematic_review","article","10.3389/fcvm.2022.990182","36119737","PMC9472131","PROSPERO:CRD42022341966",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0025935","Exendin-4 inhibits interleukin-1beta-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F beta-cells.","Kang JH","2009","The Journal of endocrinology","preclinical","article","10.1677/joe-08-0507","19398497",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025936","Pioglitazone for Type 2 Diabetes Mellitus and Pre-Diabetes: A Review of Safety","Marchand DK","2020","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"33231960",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0025937","Cell-specific resetting of mouse islet cellular clocks by glucagon, glucagon-like peptide 1 and somatostatin.","Petrenko V","2018","Acta physiologica (Oxford, England)","preclinical","article","10.1111/apha.13021","29271578",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025938","The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?","Pop LM","2017","Current diabetes reports","narrative_review","article","10.1007/s11892-017-0954-4","29063276",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0025939","Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction.","Sassoon DJ","2017","Diabetes","preclinical","article","10.2337/db16-1206","28483802","PMC5521862",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025940","Skp2 is required for incretin hormone-mediated β-cell proliferation.","Tschen SI","2011","Molecular endocrinology (Baltimore, Md.)","preclinical","article","10.1210/me.2011-1119","21980072","PMC3231831",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0025941","The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications.","Oh TJ","2019","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes.2019.28.3.158","31583380","PMC6774449",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0025942","Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?","Jones AG","2016","PloS one","nonrandomized_study","article","10.1371/journal.pone.0152428","27050911","PMC4822872",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025943","The case for combination therapy as first-line treatment for the type 2 diabetic patient.","Bell DS","2006","Treatments in endocrinology","other","article","10.2165/00024677-200605030-00001","16677055",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0025944","[Intermittent fasting : A solution for metabolic disorders?].","Collet TH","2021","Revue medicale suisse","narrative_review","article",null,"33443833",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025945","[When injectable diabetes therapy becomes necessary. Insulin or GLP-1 analogs?].","Stiefelhagen P","2011","MMW Fortschritte der Medizin","commentary","article","10.1007/bf03367596","24761480",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"News"],["R0025946","Protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase pathway in diabetes mellitus.","Wang D","2020","Journal of diabetes investigation","preclinical","article","10.1111/jdi.13098","31199578","PMC6944832",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025947","New therapies for type 2 diabetes based on glucagon-like peptide 1.","Salehi M","2006","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.73.4.382","16610399",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025948","The effects of exendine-4 on insulin producing cell differentiation from rat bone marrow-derived mesenchymal stem cells.","Nejad-Dehbashi F","2014","Cell journal","preclinical","article",null,"24567935","PMC4072085",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025949","[GLP-1-based treatment of type 2 diabetes mellitus].","Knop FK","2007","Ugeskrift for laeger","narrative_review","article",null,"17553390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025950","A case report: Liraglutide as a novel treatment option in late dumping syndrome.","Chiappetta S","2017","Medicine","case_report","article","10.1097/md.0000000000006348","28328816","PMC5371453",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0025951","Therapy: Liraglutide - preventing or postponing T2DM diagnosis?","Vilsbøll T","2017","Nature reviews. Endocrinology","commentary","article","10.1038/nrendo.2017.55","28474687",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0025952","Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.","Lipscombe LL","2017","Annals of internal medicine","randomized_trial","article","10.7326/acpjc-2017-167-12-066","29255856",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment; article"],["R0025953","The anorectic effect of GLP-1 in rats is nutrient dependent.","Sandoval D","2012","PloS one","preclinical","article","10.1371/journal.pone.0051870","23284795","PMC3524167",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0025954","Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study.","Baretić M","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-018-0517-y","30298444","PMC6250632","ClinicalTrials.gov:NCT02130778","S002503","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0025955","Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice.","Bech EM","2019","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2018.10.040","30396073",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0025956","Exendin-4 improves the oral glucose tolerance in diabetic rats: pancreas regeneration, better function of pancreatic islets, or impaired glucose uptake?","Strauss A","2008","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2008.02.004","18374122",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025957","Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.","Blonde L","2006","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2006.00602.x","16776751",null,null,"S000052; S000566","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025958","Role of Metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Orlistat based Multidrug Therapy in Glycemic Control, Weight Loss, and Euglycemia in Diabesity: A Real-World Experience.","Dutta D","2019","Indian journal of endocrinology and metabolism","nonrandomized_study","article","10.4103/ijem.ijem_185_19","31741907","PMC6844169",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0025959","Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.","Ye X","2017","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2017.01.008","28143735",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0025960","Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.","Levy OE","2014","PloS one","preclinical","article","10.1371/journal.pone.0087704","24503632","PMC3913652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025961","Le liraglutide améliore-t-il le pronostic rénal chez les diabétiques de type 2 ?","Brun C","2017","Revue medicale suisse","commentary","article","10.53738/revmed.2017.13.582.1964","29120548",null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0025962","Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.","Nielsen LL","2005","Drug discovery today","narrative_review","article","10.1016/s1359-6446(05)03460-4","15896683",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0025963","Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).","Bolli GB","2014","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/dme.12328","24117597",null,"ClinicalTrials.gov:NCT00763451","S001563","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025964","Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides.","Kim BJ","2010","The Journal of pharmacology and experimental therapeutics","other","article","10.1124/jpet.110.166470","20498254","PMC2939671",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Intramural; research-article"],["R0025965","Incretin mimetics vie for slice of type 2 diabetes market.","Shaffer C","2007","Nature biotechnology","commentary","article","10.1038/nbt0307-263","17344865",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0025966","Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.","Schernthaner G","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12471","25846577",null,"ClinicalTrials.gov:NCT00359762","S001097","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025967","Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy.","Korytkowski MT","2016","BMJ open diabetes research & care","other","article","10.1136/bmjdrc-2016-000206","27252874","PMC4885282",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0025968","A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo.","Li Y","2011","Peptides","preclinical","article","10.1016/j.peptides.2011.05.026","21664938",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025969","Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.","Spellman CW","2011","The Journal of the American Osteopathic Association","case_report","article",null,"21389294",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0025970","In vitro differentiation of human adipose tissue-derived stem cells into islet-like clusters promoted by islet neogenesis-associated protein pentadecapeptide.","Ren L","2014","Cells, tissues, organs","preclinical","article","10.1159/000362500","25471531",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025971","An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes.","Gomez-Peralta F","2015","BMC endocrine disorders","nonrandomized_study","article","10.1186/s12902-015-0074-6","26637348","PMC4669657",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0025972","A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.","Filion KB","2016","The New England journal of medicine","randomized_trial","article","10.1056/nejmoa1506115","27007958",null,"ClinicalTrials.gov:NCT02456428","S001806","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0025973","Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply.","Sorli C","2017","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(17)30110-9","28434491",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0025974","Control of insulin secretion by GLP-1.","Jones B","2018","Peptides","narrative_review","article","10.1016/j.peptides.2017.12.013","29412835",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0025975","GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease.","Lee J","2012","Diabetes & metabolism journal","preclinical","article","10.4093/dmj.2012.36.4.262","22950055","PMC3428412",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0025976","Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.","Bays H","2017","Current medical research and opinion","randomized_trial","article","10.1080/03007995.2016.1251892","27817208",null,"ClinicalTrials.gov:NCT01272219; ClinicalTrials.gov:NCT01272232; ClinicalTrials.gov:NCT01557166","S000492; S001278; S001792; S002315","pubmed; europepmc; openalex","TRUE","paywalled","1","FALSE","Journal Article; article"],["R0025977","Recent update on biological activities and pharmacological actions of liraglutide.","Tiwari J","2017","EXCLI journal","commentary","article","10.17179/excli2017-323","28827989","PMC5547392",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0025978","Lipidized Prolactin-Releasing Peptide Agonist Attenuates Hypothermia-Induced Tau Hyperphosphorylation in Neurons.","Pražienková V","2019","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-180837","30689580",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025979","Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India.","Wangnoo SK","2016","Indian journal of endocrinology and metabolism","other_trial","article","10.4103/2230-8210.189232","27867889","PMC5105570",null,"S001663","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0025980","Type 2 diabetes care: Improvement by standardization at a diabetes rehabilitation clinic. An observational report.","Haslacher H","2019","PloS one","nonrandomized_study","article","10.1371/journal.pone.0226132","31830073","PMC6907777",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0025981","Antiobesity drugs before and after bariatric surgery - how to make the best use of them.","Šrámková P","2022","Casopis lekaru ceskych","other","article",null,"36100447",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0025982","Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.","Chen WR","2016","Endocrine","randomized_trial","article","10.1007/s12020-015-0798-0","26573925",null,null,"S000767; S001769","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0025983","Metformin use in prediabetes: A review of evidence and a focus on metabolic features among peri-menopausal women.","Lim BSY","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.16442","40329646","PMC12094222",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0025984","Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.","Linnebjerg H","2006","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2006.01800.x","16492205",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025985","Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.","Poon T","2005","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2005.7.467","15929678",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0025986","Novel therapies for diabetic kidney disease.","Cherney DZI","2018","Kidney international supplements","other_trial","article","10.1016/j.kisu.2017.10.005","30675435","PMC6336219",null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review; review-article"],["R0025987","Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.","Fruci B","2013","International journal of molecular sciences","randomized_trial","article","10.3390/ijms141122933","24264040","PMC3856099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0025988","NN-2211 Novo Nordisk.","Mark M","2003","IDrugs : the investigational drugs journal","narrative_review","article",null,"12789615",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; conference-abstract"],["R0025989","Protection of pancreatic islets from oxidative cell death by a peripherally-active morphinan with increased drug safety.","Scholz O","2023","Molecular metabolism","preclinical","article","10.1016/j.molmet.2023.101775","37451343","PMC10403733",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0025990","Liraglutide effect on epicardial fat: Missing the forest for the trees.","Munoz AJ","2017","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.21844","28429872",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; Comment; article"],["R0025991","Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.","Xu S","2016","Trials","protocol","article","10.1186/s13063-016-1258-8","27009108","PMC4806460","ClinicalTrials.gov:NCT02449603","S001146","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0025992","Assessment of complex treatment influence on systemic inflammation in overweight type 2 diabetes patients.","Said OV","2018","Wiadomosci lekarskie (Warsaw, Poland : 1960)","other_trial","article",null,"30267490",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Clinical Trial; Journal Article; article"],["R0025993","[Insulin resistance and cognitive function].","Sasaoka T","2014","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"24796090",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0025994","Familial Partial Lipodystrophy: A Case Study and Review of Recent Literature","Tipu A","2021","Journal of the Endocrine Society","narrative_review","article","10.1210/jendso/bvab048.629",null,"PMC8265984",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0025995","Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide.","Eissele R","1994","Life sciences","preclinical","article","10.1016/0024-3205(94)00489-7","7913983",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025996","Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.","Engel SS","2010","International journal of clinical practice","other_trial","article","10.1111/j.1742-1241.2010.02382.x","20412332","PMC2904489",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0025997","Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.","Ferrario MG","2016","Primary care diabetes","randomized_trial","article","10.1016/j.pcd.2015.10.002","26546244",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; article"],["R0025998","Developing GLP-1 Conjugated Self-Assembling Nanofibers Using Copper-Catalyzed Alkyne-Azide Cycloaddition and Evaluation of Their Biological Activity.","Alavi SE","2021","Bioconjugate chemistry","other","article","10.1021/acs.bioconjchem.1c00091","33843208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0025999","Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway.","Tong W","2016","Hepatology research : the official journal of the Japan Society of Hepatology","preclinical","article","10.1111/hepr.12634","26666995",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026000","Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches.","Brayden DJ","2020","Advanced drug delivery reviews","other_trial","article","10.1016/j.addr.2020.05.007","32479930",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review"],["R0026001","Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures.","Lundgren JR","2019","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-019-0937-7","31586493","PMC6778378","ClinicalTrials.gov:NCT00237549",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0026002","Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.","Sullivan SD","2009","Cardiovascular diabetology","nonrandomized_study","article","10.1186/1475-2840-8-12","19245711","PMC2667489","ClinicalTrials.gov:NCT00318422; ClinicalTrials.gov:NCT00318461; ClinicalTrials.gov:NCT00294723; ClinicalTrials.gov:NCT00333151; ClinicalTrials.gov:NCT00331851; ClinicalTrials.gov:NCT00518882","S001094; S001502; S001584; S002098; S002222; S002230","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0026003","More choices than ever before: emerging therapies for type 2 diabetes.","Campbell RK","2008","The Diabetes educator","other","article","10.1177/0145721708317870","18535325",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026004","An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin.","Traina SB","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-017-0343-7","29236222","PMC5801229",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0026005","Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus.","Oh KS","2014","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","preclinical","article","10.1016/j.ejpb.2014.08.004","25152212",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026006","The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review.","Baye AM","2021","Frontiers in genetics","systematic_review","article","10.3389/fgene.2021.675053","34194474","PMC8236944",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0026007","Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults.","Tarazi MS","2021","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2021.1942841","34165376",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026008","Effects of exenatide in a morbidly obese patient with type 2 diabetes.","Kishimoto M","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-014-0050-6","24442463","PMC4065292",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0026009","Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes.","Komsuoglu Celikyurt I","2014","Medical science monitor basic research","preclinical","article","10.12659/msmbr.891168","25076419","PMC4138071",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026010","Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y2 Receptor Agonists.","Yang Q","2022","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.2c01385","36214844",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026011","Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin.","Buysman EK","2018","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.19","30815554","PMC6354816",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026012","Surrogate endpoint evaluation using data from one large global randomized controlled trial.","Geybels M","2021","BMC medical informatics and decision making","systematic_review","article","10.1186/s12911-021-01516-8","34016120","PMC8139150",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0026013","Three new drugs for type 2 diabetes.",null,"2008","Drug and therapeutics bulletin","other","article","10.1136/dtb.2008.06.0014","18603639",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026014","Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence.","Al Sifri S","2016","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-016-0168-9","27091198","PMC4900978",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0026015","Use of 125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig.","Singh G","1994","Regulatory peptides","preclinical","article","10.1016/0167-0115(94)90158-9","7800858",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; article"],["R0026016","Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue.","Retterstøl K","2009","Expert opinion on investigational drugs","other_trial","article","10.1517/13543780903164205","19678802",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0026017","Response to \"Liraglutide effect on epicardial fat: Missing the forest for the trees\".","Iacobellis G","2017","Obesity (Silver Spring, Md.)","other_trial","article","10.1002/oby.21843","28429888",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Letter; Comment; article"],["R0026018","Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.","Wysham CH","2015","Mayo Clinic proceedings","randomized_trial","article","10.1016/j.mayocp.2015.01.008","25744115",null,"ClinicalTrials.gov:NCT00308139","S002279","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026019","LBSUN151 The Impact Of The COVID-19 Pandemic On Diabetes & Weight Management",null,"2022","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC9624884",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0026020","ODP183 Diabetic Ketoacidosis Precipitated by Ketogenic Diet and SGLT-2 Inhibitor Use in an Individual with T2DM",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9628927",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0026021","Drug-induced lesions of the oesophageal mucosa.",null,"2015","Prescrire international","other","article",null,"26417631",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026022","Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus.","Quan H","2016","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2016.01.013","26873871",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026023","Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.","Li DJ","2021","Acta pharmacologica Sinica","preclinical","article","10.1038/s41401-021-00680-x","33976388","PMC8285380",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0026024","TCF7L2 promotes beta cell regeneration in human and mouse pancreas.","Shu L","2012","Diabetologia","preclinical","article","10.1007/s00125-012-2693-z","22945304",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026025","Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.","Davies MJ","2016","Diabetes care","randomized_trial","article","10.2337/dc14-2883","26681713",null,"ClinicalTrials.gov:NCT01620489","S001504","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026026","High Prevalence of Positive Genetic Obesity Variants in Postoperative Bariatric Surgery Patients with Weight Regain Presenting for Medical Obesity Intervention.","Samuels JM","2024","Obesity surgery","nonrandomized_study","article","10.1007/s11695-023-06952-1","37996769",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0026027","[Obesity - a chronic disease requiring treatment].","Meyhöfer S","2022","Deutsche medizinische Wochenschrift (1946)","other","article","10.1055/a-1657-2047","35636415",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026028","Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.","Marso SP","2017","The New England journal of medicine","nonrandomized_study","article","10.1056/nejmc1615712","28249135",null,null,"S001352","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0026029","GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.","Pyke C","2014","Endocrinology","other","article","10.1210/en.2013-1934","24467746",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026030","The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.","Dai X","2014","Current medical research and opinion","systematic_review","article","10.1185/03007995.2014.921608","24805140",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0026031","Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease.","de Lucas MDG","2017","European journal of internal medicine","nonrandomized_study","article","10.1016/j.ejim.2017.07.020","28711390",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Observational Study; article"],["R0026032","Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists.","Naylor J","2016","The Biochemical journal","preclinical","article","10.1042/bcj20160476","27422784",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026033","Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis.","Whyte MB","2019","PLoS medicine","nonrandomized_study","article","10.1371/journal.pmed.1002942","31589609","PMC6779242",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0026034","Gut hormones, incretin mimetics and gliptins: new understanding and novel therapies in type 2 diabetes.","Munro NM","2007","Primary care diabetes","other","article","10.1016/j.pcd.2007.04.003","18632028",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026035","Glucagon-like peptide-1 and islet lipolysis.","Sörhede Winzell M","2004","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","preclinical","article","10.1055/s-2004-826166","15655711",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026036","Expanding treatment options for type 2 diabetes: the old and the new.","Pratley RE","2009","The Diabetes educator","other","article","10.1177/0145721709331522","19218561",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026037","Euglycaemic Ketoacidosis Due to Extremely Low-Calorie Intake and Dehydration After Laparoscopic Sleeve Gastrectomy in a Patient with Type 2 Diabetes.","Liu Z","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","case_report","article","10.2147/dmso.s373712","35966831","PMC9365319",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0026038","Glycaemic control and weight loss with semaglutide in type 2 diabetes.","Madsbad S","2017","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(17)30094-3","28385658",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0026039","Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites.","Yamamoto H","2003","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.23-07-02939.2003","12684481","PMC6742071",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0026040","Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate.","Zhang B","2014","PloS one","preclinical","article","10.1371/journal.pone.0086064","24465870","PMC3897602",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026041","Improved diastolic function in type 2 diabetes after a six month liraglutide treatment.","Saponaro F","2016","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2016.04.046","27485853",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0026042","Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.","Göke R","1993","The Journal of biological chemistry","preclinical","article","10.1016/s0021-9258(19)36565-2","8396143",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026043","Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.","Liu Q","2010","Cardiovascular diabetology","preclinical","article","10.1186/1475-2840-9-76","21080957","PMC2996354",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026044","Sustained Release Strategy Designed for Lixisenatide Delivery to Synchronously Treat Diabetes and Associated Complications.","Zhuang Y","2019","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.9b10346","31361112",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026045","Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.","Khoo J","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13007","28503750",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026046","Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials.","Eto K","2015","Diabetology & metabolic syndrome","other_trial","article","10.1186/s13098-015-0104-6","26594250","PMC4654794",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0026047","Therapeutic potential of spinal GLP-1 receptor signaling.","Zhang D","2018","Peptides","narrative_review","article","10.1016/j.peptides.2018.01.003","29329976",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026048","Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction.","Chen WR","2016","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2015.12.009","26849684",null,null,"S000767","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026049","Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.","Guillermin AL","2012","Journal of medical economics","other_trial","article","10.3111/13696998.2012.670677","22369345",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026050","Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.","Ciresi A","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-018-0423-3","29637460","PMC5984926",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0026051","Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.","Irwin N","2009","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2009.01036.x","19515180",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026052","[COMMENTS ON FRENCH RECOMMENDATIONS ON GLYCEMIC CONTROL IN TYPE 2 DIABETES].","Hartemann A","2015","La Revue du praticien","other","article",null,"26749699",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026053","Liraglutide in heart failure: caution is needed.","Komajda M","2017","European journal of heart failure","randomized_trial","article","10.1002/ejhf.707","28052548",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Editorial; Comment; article"],["R0026054","The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides.","Khafagy el-S","2010","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2009.12.060","20060451",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0026055","[DPP-IV inhibitors and GLP-1 analogues].","Zettl H","2010","Pharmazie in unserer Zeit","narrative_review","article","10.1002/pauz.201000357","20196037",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026056","Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.","Mari A","2006","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","randomized_trial","article","10.1055/s-2006-956505","17163361",null,null,"S000911","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026057","Contribution of Intronic miR-338-3p and Its Hosting Gene AATK to Compensatory β-Cell Mass Expansion.","Jacovetti C","2015","Molecular endocrinology (Baltimore, Md.)","preclinical","article","10.1210/me.2014-1299","25751313","PMC5414744",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026058","Liraglutide for weight management: benefits and risks.","Tomlinson B","2017","Current medical research and opinion","commentary","article","10.1080/03007995.2016.1271315","27936966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0026059","Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide.","Guryanov I","2016","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.2890","27238390",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026060","The Effect of Alpha-Lipoic Acid on Diabetic Peripheral Neuropathy and the Upcoming Depressive Disorders of Type II Diabetics.","Karalis DT","2021","Cureus","other","article","10.7759/cureus.12773","33614362","PMC7888960",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026061","Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways.","Zhang Y","2016","Free radical biology & medicine","other","article","10.1016/j.freeradbiomed.2016.03.035","27038735",null,null,"S000767","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026062","[The history of incretin hormones].","Hyo T","2011","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"21595258",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Historical Article; Journal Article; other"],["R0026063","Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs.","Alburquerque-Béjar JJ","2015","Cardiovascular research","preclinical","article","10.1093/cvr/cvv171","26045476",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026064","Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.","Davidson JA","2008","Arquivos brasileiros de endocrinologia e metabologia","other_trial","article","10.1590/s0004-27302008000600016","18820816",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026065","Simultaneous Catabolite Identification and Quantitation of Large Therapeutic Protein at the Intact Level by Immunoaffinity Capture Liquid Chromatography-High-Resolution Mass Spectrometry.","Kang L","2017","Analytical chemistry","preclinical","article","10.1021/acs.analchem.7b00674","28457123",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026066","Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity.","Wang P","2017","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2017.05.069","28579543",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026067","Lixisenatide in the treatment of Type 2 diabetes.","Donsmark M","2014","Expert review of endocrinology & metabolism","other_trial","article","10.1586/17446651.2014.897604","30736157",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0026068","Weight considerations in pharmacotherapy for type 2 diabetes.","Cheng V","2011","Journal of obesity","narrative_review","article","10.1155/2011/984245","20885921","PMC2946585",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0026069","A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.","Ankarfeldt MZ","2017","Clinical epidemiology","randomized_trial","article","10.2147/clep.s121991","28176959","PMC5271378",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0026070","Managing diabetes in the middle-aged patient when loss of glycemic control occurs.","Peters A","2012","The Diabetes educator","case_report","article","10.1177/0145721712450620","22713264",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0026071","Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment.","Hamano K","2017","Endocrine journal","other_trial","article","10.1507/endocrj.ej16-0428","28302958",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0026072","Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity.","Fadini GP","2017","Nutrition, metabolism, and cardiovascular diseases : NMCD","protocol","article","10.1016/j.numecd.2017.08.001","28967594",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Multicenter Study"],["R0026073","Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).","Marre M","2009","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2009.02666.x","19317822","PMC2871176",null,"S000566; S001123; S001584","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0026074","Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.","Seino Y","2016","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12457","27182042","PMC4931207",null,"S000361","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0026075","Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway.","Shao N","2018","Gastroenterology research and practice","preclinical","article","10.1155/2018/1864307","29849583","PMC5925008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026076","GLP-1 receptor stimulation of the lateral parabrachial nucleus reduces food intake: neuroanatomical, electrophysiological, and behavioral evidence.","Richard JE","2014","Endocrinology","preclinical","article","10.1210/en.2014-1248","25116706","PMC4256827",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026077","Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy.","Chiefari E","2015","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2014.0412","25844858",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Evaluation Study; Journal Article; article"],["R0026078","GLP-1 analogues: a new therapeutic approach to prevent ductopenia in cholangiopathies?","Beuers U","2009","Gut","commentary","article","10.1136/gut.2008.165688","19520887",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0026079","What's next after metformin? focus on sulphonylurea: add-on or combination therapy.","Lim PC","2015","Pharmacy practice","nonrandomized_study","article","10.18549/pharmpract.2015.03.606","26445623","PMC4582747",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0026080","Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.","Frandsen CS","2015","Diabetes care","randomized_trial","article","10.2337/dc15-1037","26486191",null,"ClinicalTrials.gov:NCT02092896","S002116","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026081","Effect of water on exenatide acylation in poly(lactide-co-glycolide) microspheres.","Liang R","2013","International journal of pharmaceutics","other","article","10.1016/j.ijpharm.2013.07.012","23872225",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026082","Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.","Badawi GA","2017","Inflammopharmacology","preclinical","article","10.1007/s10787-017-0331-6","28258522",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026083","Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs.","Chakraborty C","2015","Current drug metabolism","narrative_review","article","10.2174/138920021610151210183821","26652255",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026084","Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.","Abdul-Ghani M","2021","Diabetes care","randomized_trial","article","10.2337/dc20-0978","33273042","PMC7818318","ClinicalTrials.gov:NCT01107717","S000437","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; other; article"],["R0026085","Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?","Paolisso G","2012","Advances in therapy","narrative_review","article","10.1007/s12325-012-0008-x","22411425",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026086","Stability of exenatide in poly(D,L-lactide-co-glycolide) solutions: a simplified investigation on the peptide degradation by the polymer.","Liang R","2013","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","other","article","10.1016/j.ejps.2013.08.014","23994054",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026087","Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits.","Madievsky R","2018","The Permanente journal","narrative_review","article","10.7812/tpp/18-034","30227909","PMC6141654",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026088","Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway.","Ferdaoussi M","2008","Diabetes","preclinical","article","10.2337/db07-1214","18252896",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026089","Pharmacological management of obesity in pediatric patients.","Boland CL","2015","The Annals of pharmacotherapy","randomized_trial","article","10.1177/1060028014557859","25366340",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0026090","Predictors of response to liraglutide in Japanese type 2 diabetes.","Toyoda M","2014","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2014.09.052","25458335",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0026091","Sustained release and pharmacologic effects of human glucagon-like peptide-1 and liraglutide from polymeric microparticles","Icart LP","2018","bioRxiv","preclinical","preprint","10.1101/262782",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0026092","Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center.","Ferrari F","2020","Journal of endocrinological investigation","randomized_trial","article","10.1007/s40618-020-01334-1","32594453",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0026093","Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39).","Fehmann HC","1994","Peptides","preclinical","article","10.1016/0196-9781(94)90204-6","7937318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026094","Lack of Benefit for Liraglutide in Heart Failure.","Carbone S","2016","JAMA","commentary","article","10.1001/jama.2016.15387","27959988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0026095","Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.","Coch RW","2016","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2016.06.004","27378397",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026096","[Incretin related drugs].","Hada Y","2010","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"20954337",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026097","Research resource: Gene profiling of G protein-coupled receptors in the arcuate nucleus of the female.","Rønnekleiv OK","2014","Molecular endocrinology (Baltimore, Md.)","preclinical","article","10.1210/me.2014-1103","24933249","PMC4116592",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0026098","Metformin-associated lactic acidosis precipitated by liraglutide use: adverse effects of aggressive antihyperglycaemic therapy.","Hooda A","2018","BMJ case reports","case_report","article","10.1136/bcr-2018-227102","30567126","PMC6303576",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0026099","Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.","Kolotkin RL","2016","Clinical obesity","randomized_trial","article","10.1111/cob.12146","27198973","PMC5084798",null,"S000492","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0026100","GLP-1 for type 2 diabetes.","Ahrén B","2011","Experimental cell research","preclinical","article","10.1016/j.yexcr.2011.01.010","21237153",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026101","Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP/PKA mediated down-regulation of MLC phosphorylation.","Tang ST","2019","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2019.108667","30852419",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026102","[Incretin hormones in the treatment of type 2 diabetes. Part II. Incretins - new possibilities for pharmacotherapy of type 2 diabetes].","Matuszek B","2008","Endokrynologia Polska","narrative_review","article",null,"18777503",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026103","An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.","Singh-Franco D","2016","SAGE open medicine","systematic_review","article","10.1177/2050312116659090","27516879","PMC4968114",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0026104","Liraglutide-loaded PLGA/gelatin electrospun nanofibrous mats promote angiogenesis to accelerate diabetic wound healing via the modulation of miR-29b-3p.","Yu M","2020","Biomaterials science","preclinical","article","10.1039/d0bm00442a","32578587",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026105","Involvement of Glucagon-Like Peptide-1 in the Regulation of Selective Excretion of Sodium or Chloride Ions by the Kidneys.","Marina AS","2017","Bulletin of experimental biology and medicine","preclinical","article","10.1007/s10517-017-3634-0","28243920",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026106","Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.","Idorn T","2016","Diabetes care","randomized_trial","article","10.2337/dc15-1025","26283739",null,"ClinicalTrials.gov:NCT01394341","S002036; S002227","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026107","Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).","Riddle MC","2013","Diabetes care","randomized_trial","article","10.2337/dc12-2462","23564915","PMC3747901","ClinicalTrials.gov:NCT00975286","S000792","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026108","Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys.","Chung S","2019","Frontiers in physiology","preclinical","article","10.3389/fphys.2019.00271","30941057","PMC6433843",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026109","Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study.","Osonoi T","2014","PloS one","nonrandomized_study","article","10.1371/journal.pone.0113468","25526642","PMC4272272","UMIN:UMIN000010159","S002036","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026110","Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes.","Blevins T","2010","Postgraduate medicine","narrative_review","article","10.3810/pgm.2010.01.2111","20107301",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026111","The Future: Experimental Therapies for Renal Disease in Diabetes.","Fouli GE","2019","Nephron","narrative_review","article","10.1159/000492825","30257247",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026112","Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.","Campbell-Scherer D","2017","Evidence-based medicine","randomized_trial","article","10.1136/ebmed-2016-110652","28270434",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Comment; article"],["R0026113","Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice.","Liang R","2014","Pharmaceutical research","preclinical","article","10.1007/s11095-014-1298-2","24549820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026114","Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.","Gautier JF","2015","Advances in therapy","randomized_trial","article","10.1007/s12325-015-0245-x","26424330","PMC4604502","ClinicalTrials.gov:NCT01226966","S001762","pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0026115","Lack of Benefit for Liraglutide in Heart Failure-Reply.","Margulies KB","2016","JAMA","commentary","article","10.1001/jama.2016.15394","27959992",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0026116","Effects of GLP-1 Receptor Activation on a Pentylenetetrazole-Kindling Rat Model.","Hussein AM","2019","Brain sciences","preclinical","article","10.3390/brainsci9050108","31091715","PMC6562858",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026117","Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine.","Siskind D","2016","The Australian and New Zealand journal of psychiatry","case_report","article","10.1177/0004867416636243","26979099",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0026118","Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.","Bi Y","2014","Acta diabetologica","randomized_trial","article","10.1007/s00592-014-0638-3","25118999",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026119","Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2.","Schepp W","1994","European journal of pharmacology","preclinical","article","10.1016/0922-4106(94)90085-x","7851494",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026120","Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.","Abdul-Ghani M","2017","Diabetes care","randomized_trial","article","10.2337/dc16-1738","28096223","PMC5864032","ClinicalTrials.gov:NCT02887625","S002035","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0026121","Protective Effects of Glucagon-Like Peptide-1 Analog on Renal Tubular Injury in Mice on High-Fat Diet.","Guo H","2017","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","preclinical","article","10.1159/000464118","28245463",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026122","New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.","Hussar DA","2015","Journal of the American Pharmacists Association : JAPhA","other","article","10.1331/japha.2015.15504","25575154",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026123","Validation studies on blood collection from the jugular vein of conscious mice.","Shirasaki Y","2012","Journal of the American Association for Laboratory Animal Science : JAALAS","preclinical","article",null,"22776193","PMC3358984",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Validation Study; research-article; article"],["R0026124","O-GlcNAc Engineering of GPCR Peptide-Agonists Improves Their Stability and in Vivo Activity.","Levine PM","2019","Journal of the American Chemical Society","other","article","10.1021/jacs.9b05365","31418572","PMC6860926",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026125","Diabetes: Cardiovascular benefits of semaglutide.","Lim GB","2016","Nature reviews. Cardiology","other","article","10.1038/nrcardio.2016.168","27708277",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026126","The evidence for achieving glycemic control with incretin mimetics.","Drucker DJ","2006","The Diabetes educator","narrative_review","article","10.1177/0145721706287652","16554431",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026127","Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.","Sarkar G","2014","Diabetes care","other","article","10.2337/dc13-1473","24194508","PMC3931382",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural; research-article; article"],["R0026128","Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.","Kim HJ","2017","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12607","27930863","PMC5497034",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article-commentary; article"],["R0026129","Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models.","Chen Y","2013","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2013.1252","23338623",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026130","Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats.","Cao X","2016","Journal of molecular endocrinology","preclinical","article","10.1530/jme-16-0001","27151572",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026131","Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists.","Yang Y","2022","ACS chemical biology","preclinical","article","10.1021/acschembio.2c00175","35417146","PMC9488713",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0026132","Exendin-4 promotes recovery of both behavioural and neurochemical deficits in a \"pre-motor\" rodent model of Parkinson's disease","Rampersaud N","2011","University College London (University of London)","preclinical","article",null,null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0026133","β-Cell-specific protein kinase A activation enhances the efficiency of glucose control by increasing acute-phase insulin secretion.","Kaihara KA","2013","Diabetes","preclinical","article","10.2337/db12-1013","23349500","PMC3636652",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026134","Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial.","Kaku K","2016","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12367","26816604","PMC4718097","ClinicalTrials.gov:NCT01512108","S000233","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026135","Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway.","Wang YG","2015","Journal of geriatric cardiology : JGC","preclinical","article","10.11909/j.issn.1671-5411.2015.04.013","26346224","PMC4554794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026136","Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.","Chen YE","1997","The Journal of biological chemistry","preclinical","article","10.1074/jbc.272.7.4108","9020121",null,null,"S002115","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026137","Case study 2: new insights: clinical pearls for using incretin mimetics in type 2 diabetes.","Peters AL","2007","The Diabetes educator","case_report","article","10.1177/0145721706298435","17272804",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0026138","Liraglutide regulates bone destruction and exhibits anti-inflammatory effects in periodontitis in vitro and in vivo.","Zhang Y","2020","Journal of dentistry","preclinical","article","10.1016/j.jdent.2020.103310","32119967",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026139","Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.","Bergenstal RM","2013","Diabetes, obesity & metabolism","other","article","10.1111/dom.12026","23078638","PMC3593159",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026140","Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.","Ebell MH","2017","American family physician","other","article",null,"28318215",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026141","Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.","Mittermayer F","2017","Current diabetes reviews","other_trial","article","10.2174/1573399812666160413115655","27071617","PMC5748875",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0026142","Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway.","Wang YG","2015","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2015.2741","26640549","PMC4665609",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026143","Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes.","Yang Y","2020","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2020.00190","32351447","PMC7174744",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0026144","Synthesis and Statistical Optimization of Poly (Lactic-Co-Glycolic Acid) Nanoparticles Encapsulating GLP1 Analog Designed for Oral Delivery.","Ismail R","2019","Pharmaceutical research","other","article","10.1007/s11095-019-2620-9","31087188","PMC6513835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026145","Cardiovascular effects of current and future anti-obesity drugs.","Comerma-Steffensen S","2014","Current vascular pharmacology","narrative_review","article","10.2174/1570161112666140423223529","24846238",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026146","[Liraglutide promotes proliferation and migration of cardiac microvascular endothelial cells through PI3K/Akt and MAPK/ERK signaling pathways].","Zhang Y","2015","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article",null,"26403728",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026147","New and novel approaches for enhancing the oral absorption and bioavailability of protein and peptides therapeutics.","Kanugo A","2020","Therapeutic delivery","other","article","10.4155/tde-2020-0068","33225869",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026148","Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.","Buse JB","2016","The New England journal of medicine","commentary","article","10.1056/nejmc1611289","27806225",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0026149","New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.","Wang X","2017","Lipids in health and disease","other_trial","article","10.1186/s12944-017-0462-1","28376799","PMC5379507","ClinicalTrials.gov:NCT02118376","S001214","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0026150","Suppression of the nuclear factor Eny2 increases insulin secretion in poorly functioning INS-1E insulinoma cells.","Dames P","2012","Experimental diabetes research","preclinical","article","10.1155/2012/460869","22649445","PMC3357931",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026151","Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets.","Johnson JD","2009","Cell transplantation","preclinical","article","10.3727/096368909x471198","19500470",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026152","Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.","Loughlin AM","2018","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13175","29193561","PMC5873410",null,"S002287","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026153","The effects of liraglutide on male fertility: a case report.","Fontoura P","2014","Reproductive biomedicine online","case_report","article","10.1016/j.rbmo.2014.07.009","25246122",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026154","Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini.","Malhotra R","1992","Regulatory peptides","preclinical","article","10.1016/0167-0115(92)90044-u","1279756",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026155","Glucagon-like peptide-1 receptor imaging probes translation of molecular biology into clinical application including insulinoma and islet cell imaging","Wild D","2011","University College London (University of London)","other","article",null,null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Dissertation; dissertation"],["R0026156","Effects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-Analysis.","Sheng Z","2019","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2019.00455","31354627","PMC6639788",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0026157","Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).","Lind M","2015","BMJ (Clinical research ed.)","randomized_trial","article","10.1136/bmj.h5364","26512041","PMC4624838","EudraCT:2012-001941-42","S002357","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026158","Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.","Zhou J","1999","Diabetes","preclinical","article","10.2337/diabetes.48.12.2358","10580424",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026159","Is Liraglutide Associated With Myocardial Protection in ST-Elevation Myocardial Infarction?","Flather M","2016","Circulation. Cardiovascular imaging","commentary","article","10.1161/circimaging.116.005684","27940958",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; editorial"],["R0026160","Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.","Hu M","2016","Pharmaceutical research","preclinical","article","10.1007/s11095-016-1873-9","26857900",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0026161","Plasma N-Acetylaspartate Is Related to Age, Obesity, and Glucose Metabolism: Effects of Antidiabetic Treatment and Bariatric Surgery.","Daniele G","2020","Frontiers in endocrinology","other","article","10.3389/fendo.2020.00216","32362872","PMC7181885",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026162","[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].","Scheen AJ","2004","Revue medicale de Liege","randomized_trial","article",null,"15346979",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","2","FALSE","Journal Article; article"],["R0026163","Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.","Chen W","2012","Protein and peptide letters","preclinical","article","10.2174/092986612799080194","21838700",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026164","A surface plasmon resonance assay for characterisation and epitope mapping of anti-GLP-1 antibodies.","Thomsen L","2018","Journal of molecular recognition : JMR","other","article","10.1002/jmr.2711","29671912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026165","[Treatment of an obese diabetic].","Svacina S","2010","Vnitrni lekarstvi","narrative_review","article",null,"21105456",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026166","Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the GIPR Region.","Bowker N","2021","Diabetes","other","article","10.2337/db21-0103","34426508","PMC8564402",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article; other"],["R0026167","Is GLP-1 a hormone: Whether and When?","D'Alessio D","2016","Journal of diabetes investigation","narrative_review","article","10.1111/jdi.12466","27186356","PMC4854505",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026168","Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism.","MacDonald PE","2002","Diabetes","preclinical","article","10.2337/diabetes.51.2007.s443","12475788",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026169","Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.","Wild D","2011","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","other_trial","article","10.2967/jnumed.110.085142","21680696",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0026170","Increase in cortisol/ACTH ratio after chronic treatment with liraglutide in patients with type 2 diabetes.","Kamei S","2017","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2017.01.008","28283288",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0026171","Racial and Ethnic Differences in Obesity Treatment in the Veterans Affairs Healthcare System","Tisdale RL","2024","medRxiv","nonrandomized_study","preprint","10.1101/2024.02.02.24302244",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0026172","Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment.","Peláez-Jaramillo MJ","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-018-0374-8","29411291","PMC6104273",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026173","The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors.","Tanaka T","2011","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0b013e328349af9d","21738030",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026174","Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia.","Buturovic BA","2014","Medical archives (Sarajevo, Bosnia and Herzegovina)","other","article","10.5455/medarh.2014.68.313-316","25568561","PMC4269541",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0026175","A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).","Mathieu C","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12262","24443830",null,null,"S001862","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0026176","Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program.","Garvey WT","2023","Population health management","nonrandomized_study","article","10.1089/pop.2022.0227","36735596",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026177","Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.","Ayers D","2017","Current medical research and opinion","systematic_review","article","10.1080/03007995.2017.1345730","28635331",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Comparative Study; Journal Article; Systematic Review; Network Meta-Analysis; review"],["R0026178","Liraglutide and cardiovascular outcomes in type 2 diabetes.","Jones B","2016","Annals of clinical biochemistry","other","article","10.1177/0004563216663075","28071177",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026179","Pharmacological Treatment for Obesity in Adults: An Umbrella Review.","Khalil H","2020","The Annals of pharmacotherapy","systematic_review","article","10.1177/1060028019898912","31958967",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Systematic Review; other; article"],["R0026180","Individualized HbA1c Goals, and Patient Awareness and Attainment of Goals in Type 2 Diabetes Mellitus: A Real-World Multinational Survey.","Lautsch D","2022","Advances in therapy","nonrandomized_study","article","10.1007/s12325-021-01985-3","34951678","PMC8706771",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026181","Diabetes is predominantly an intestinal disease.","Sanyal D","2013","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.119508","24251223","PMC3830370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026182","Secreted factors from dental pulp stem cells improve glucose intolerance in streptozotocin-induced diabetic mice by increasing pancreatic β-cell function.","Izumoto-Akita T","2015","BMJ open diabetes research & care","preclinical","article","10.1136/bmjdrc-2015-000128","26504525","PMC4611480",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026183","Drugs on the horizon for diabesity.","Bailey CJ","2005","Current diabetes reports","narrative_review","article","10.1007/s11892-005-0093-1","16188170",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026184","The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.","Liu Q","2010","Cardiovascular diabetology","preclinical","article","10.1186/1475-2840-9-32","20678234","PMC2922097",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026185","Corrigendum: Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study.","Nyström T","2018","Frontiers in endocrinology","notice","article","10.3389/fendo.2018.00050","29493662","PMC5826954",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0026186","The pathophysiologic role of incretins.","Freeman JS","2007","The Journal of the American Osteopathic Association","narrative_review","article",null,"17724014",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026187","Protective Effects of Liraglutide and Linagliptin in C. elegans as a New Model for Glucose-Induced Neurodegeneration.","Wongchai K","2016","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","preclinical","article","10.1055/s-0035-1549876","25951323",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026188","Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels.","Smits MM","2016","Diabetes care","commentary","article","10.2337/dc15-2489","26721816",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0026189","Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: a retrospective cohort study.","Kondo Y","2015","Endocrine journal","nonrandomized_study","article","10.1507/endocrj.ej15-0206","26249841",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0026190","Shielding effect of a PEG molecule of a mono-PEGylated peptide varies with PEG chain length.","Thi Nguyen NT","2018","Preparative biochemistry & biotechnology","other","article","10.1080/10826068.2018.1466157","29932808",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026191","Enterochromaffin 5-HT cells - A major target for GLP-1 and gut microbial metabolites.","Lund ML","2018","Molecular metabolism","preclinical","article","10.1016/j.molmet.2018.03.004","29576437","PMC6001397",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026192","Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation.","Hayes MR","2011","Cell metabolism","preclinical","article","10.1016/j.cmet.2011.02.001","21356521","PMC3108145",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0026193","Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass.","Portha B","2011","Experimental diabetes research","preclinical","article","10.1155/2011/376509","21716694","PMC3118608",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0026194","[Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].","Fabreegas B","2008","Soins; la revue de reference infirmiere","other","article",null,"18697336",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026195","Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting.","Zhang Y","2019","Neuroscience bulletin","preclinical","article","10.1007/s12264-018-00336-7","30632006","PMC6616622",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026196","Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2).","Weston C","2015","The Journal of biological chemistry","other","article","10.1074/jbc.m114.624601","26198634","PMC4645630",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026197","Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.","McClean PL","2015","Behavioural brain research","preclinical","article","10.1016/j.bbr.2015.07.024","26205827",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026198","Medications Available for Weight Reduction in Elective Total Joint Arthroplasty.","Amanatullah DF","2020","JBJS reviews","narrative_review","article","10.2106/jbjs.rvw.19.00123","33006462",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026199","Nanomedicine for the treatment of diabetes-associated cardiovascular diseases and fibrosis.","Luo XM","2021","Advanced drug delivery reviews","narrative_review","article","10.1016/j.addr.2021.01.004","33417981",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review"],["R0026200","The mechanism of glucagon-like peptide-1 participation in the osmotic homeostasis.","Natochin YV","2016","Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections","preclinical","article","10.1134/s0012496616040086","27595820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026201","Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.","Hiramatsu T","2015","Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","other","article","10.1111/1744-9987.12319","26556397",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026202","Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat.","Chen J","2018","Cell death & disease","preclinical","article","10.1038/s41419-017-0217-y","29434185","PMC5833344",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026203","Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.","Blackman A","2016","International journal of obesity (2005)","randomized_trial","article","10.1038/ijo.2016.52","27005405","PMC4973216","ClinicalTrials.gov:NCT01557166","S000466; S002315","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026204","Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.","Vioix H","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.717","27200667",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026205","A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.","Mima A","2022","Advances in therapy","other_trial","article","10.1007/s12325-022-02223-0","35751762",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0026206","Subcutaneous nodules secondary to exenatide once weekly: clinical and histological findings.","Donato S","2016","Acta diabetologica","commentary","article","10.1007/s00592-015-0827-8","26695174",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0026207","Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.","Blonde L","2009","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.76.s5.02","19952303",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0026208","Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet.","Rouse R","2014","PloS one","preclinical","article","10.1371/journal.pone.0109477","25291183","PMC4188617",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0026209","Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.","Fujioka K","2016","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.21629","27804269","PMC5129670","ClinicalTrials.gov:NCT01272219; ClinicalTrials.gov:NCT01272232","S000492; S001792","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0026210","Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.","Holden SE","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12916","28218819",null,null,"S002202","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Comparative Study; Journal Article; Observational Study; article"],["R0026211","Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.","Andrew CA","2019","Expert opinion on pharmacotherapy","other_trial","article","10.1080/14656566.2018.1561867","30614740",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0026212","Progress and challenges in anti-obesity pharmacotherapy.","Bessesen DH","2018","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(17)30236-x","28919062",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026213","Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes.","Bounthavong M","2014","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2014.06.002","25059703",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026214","Comparison of different protein precipitation and solid-phase extraction protocols for the study of the catabolism of peptide drugs by LC-HRMS.","Esposito S","2020","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.3272","32633064",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0026215","Cyclobutane derivatives as novel nonpeptidic small molecule agonists of glucagon-like peptide-1 receptor.","Liu Q","2012","Journal of medicinal chemistry","preclinical","article","10.1021/jm201150j","22103243",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026216","Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients.","Hong JY","2016","Endocrinology and metabolism (Seoul, Korea)","other","article","10.3803/enm.2016.31.1.80","26676329","PMC4803566",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026217","In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis.","Tanner M","2016","Annals of internal medicine","randomized_trial","article","10.7326/acpjc-2016-165-12-064","27992920",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; editorial"],["R0026218","GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats.","Lee SP","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s207596","31354323","PMC6580122",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026219","Additive Effects of Exenatide, Glucose-insulin-potassium, and Remote Ischemic Conditioning Against Reperfusion Ventricular Arrhythmias in Pigs.","Alburquerque-Béjar JJ","2016","Revista espanola de cardiologia (English ed.)","preclinical","article","10.1016/j.rec.2016.02.021","27131973",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0026220","Lixisenatide -- Benefit Assessment According to §35a Social Code Book V",null,"2013","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany","narrative_review","article",null,"27905754",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0026221","Drug updates and approvals: 2014 in review.","Sigler J","2014","The Nurse practitioner","narrative_review","article","10.1097/01.npr.0000456393.83499.90","25350291",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026222","Thioamide Substitution Selectively Modulates Proteolysis and Receptor Activity of Therapeutic Peptide Hormones.","Chen X","2017","Journal of the American Chemical Society","preclinical","article","10.1021/jacs.7b08417","29130686","PMC7744120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0026223","Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study.","Dib A","2022","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-021-01200-0","35034340","PMC8873332",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026224","Potential mechanism for osseointegration of dental implants in Zucker diabetic fatty rats.","Liu Z","2015","The British journal of oral & maxillofacial surgery","preclinical","article","10.1016/j.bjoms.2015.05.023","26093969",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026225","A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study.","Heller SR","2022","Diabetologia","randomized_trial","article","10.1007/s00125-021-05556-7","34704120","PMC8660716","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026226","Cognitive dysfunction in depression - pathophysiology and novel targets.","Carvalho AF","2014","CNS & neurological disorders drug targets","randomized_trial","article","10.2174/1871527313666141130203627","25470397",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026227","Liraglutide enhances insulin sensitivity by activating AMP-activated protein kinase in male Wistar rats.","Yamazaki S","2014","Endocrinology","preclinical","article","10.1210/en.2013-2157","24949659",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026228","Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia.","Zhang H","2015","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2015.01.010","25640912",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026229","Enhancing Stability of Exenatide-Containing Pressurized Metered-Dose Inhaler Via Reverse Microemulsion System.","Li X","2018","AAPS PharmSciTech","other","article","10.1208/s12249-018-1026-z","29948981",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026230","Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) Inhibition-Induced Relaxation in Arteries From Human Visceral Adipose Tissue.","De Stefano A","2021","Hypertension (Dallas, Tex. : 1979)","other","article","10.1161/hypertensionaha.120.16466","33356396",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026231","Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.","Anyanwagu U","2016","Heart (British Cardiac Society)","nonrandomized_study","article","10.1136/heartjnl-2015-309164","27217068",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Comparative Study; Journal Article; Observational Study; article"],["R0026232","Sitagliptin favorably modulates immune-relevant pathways in human beta cells.","Malvandi AM","2019","Pharmacological research","preclinical","article","10.1016/j.phrs.2019.104405","31442575",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026233","Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat.","Stoffers DA","2003","Diabetes","preclinical","article","10.2337/diabetes.52.3.734","12606515",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0026234","Global status of diabetes prevention and prospects for action: A consensus statement.","Ibrahim M","2018","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.3021","29757486",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; Consensus Statement; article"],["R0026235","Long-term Efficacy and Safety of Exenatide Treatment.","Chirapongsathorn S","2015","Mayo Clinic proceedings","commentary","article","10.1016/j.mayocp.2015.06.004","26355405",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0026236","Erratum. Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials. Diabetes Care 2015;38:1058-1066.","Jensen TM","2015","Diabetes care","notice","article","10.2337/dc15-er08","26207056",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; erratum"],["R0026237","Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.","Asche CV","2014","PharmacoEconomics","other_trial","article","10.1007/s40273-013-0117-7","24357160",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0026238","[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].","Scheen AJ","2007","Revue medicale de Liege","preclinical","article",null,"17566392",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026239","[Characteristics of purchases of hypoglycemic agents in pharmacy retail sector in 2016-2020 years dynamics].","Kurkin DV","2023","Problemy endokrinologii","other","article","10.14341/probl13200","37694867","PMC10520906",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; research-article; article"],["R0026240","Obesity and polycystic ovary syndrome.","Naderpoor N","2015","Minerva endocrinologica","randomized_trial","article","10.1159/000194971","25411807",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026241","Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.","Deng J","2015","Journal of medical economics","randomized_trial","article","10.3111/13696998.2015.1067622","26134916",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0026242","Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.","Du Q","2014","Advances in therapy","systematic_review","article","10.1007/s12325-014-0164-2","25388240",null,null,"S000485","pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; review"],["R0026243","EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.","O'Neil PM","2016","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep151181.or","27482610",null,null,"S000492; S001278; S001792; S002315","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026244","Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.","Pérez A","2015","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-015-0103-5","25742705","PMC4374077",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0026245","Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.","Yamamoto H","2002","The Journal of clinical investigation","preclinical","article","10.1172/jci15595","12093887","PMC151031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0026246","Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.","D'Alessio D","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12406","25359159",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026247","Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.","Ahmann A","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12539","26179619","PMC5054929",null,"S000926","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026248","Effectiveness and safety of liraglutide after three years of treatment.","Ponzani P","2016","Minerva endocrinologica","nonrandomized_study","article",null,"26878560",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; article"],["R0026249","Risk Factors, Clinical Consequences, Prevention, and Treatment of Childhood Obesity.","Shaban Mohamed MA","2022","Children (Basel, Switzerland)","narrative_review","article","10.3390/children9121975","36553418","PMC9776766",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026250","Relevance of weight in the management of patients with type 2 diabetes mellitus: towards an adipocentric approach to diabetes.","Gorgojo Martínez JJ","2016","Medicina clinica","other","article","10.1016/s0025-7753(17)30619-x","28760227",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026251","[Cardiovascular morbidity and mortality in patients with kidney disease].","Quack I","2016","Deutsche medizinische Wochenschrift (1946)","nonrandomized_study","article","10.1055/s-0042-118274","27903028",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0026252","[Gliptin and GLP-1 analogues - aspects of pharmaceutical care. The patient's responsibility].","Wörner W","2010","Pharmazie in unserer Zeit","narrative_review","article","10.1002/pauz.201000361","20196041",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026253","Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).","Arnold SV","2018","American heart journal","nonrandomized_study","article","10.1016/j.ahj.2018.05.016","30015065",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't"],["R0026254","Comparison of nephron-protective effects of enalapril and GLP analogues (exenatide) in diabetic nephropathy.","Çavusoglu T","2014","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","preclinical","article","10.1055/s-0034-1372584","24941431",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0026255","[Carbohydrate metabolism in patients with acromegaly and Itsenko-Cushing disease].","Matchekhina LV","2015","Terapevticheskii arkhiv","other","article","10.17116/terarkh2015871098-104","28635800",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0026256","Physiological and pathophysiological aspects of incretin hormones and glucagon.","Bagger JI","2017","Danish medical journal","narrative_review","article",null,"28007055",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026257","COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.","Gilbert MP","2016","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep15758.or","26574791",null,"ClinicalTrials.gov:NCT00294723","S001094","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026258","[Diagnosis and therapy of steroid-induced hyperglycemia based on literature reports].","Dąbrowski P","2016","Wiadomosci lekarskie (Warsaw, Poland : 1960)","narrative_review","article",null,"27941203",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026259","Liraglutide for patients with non-alcoholic steatohepatitis.","Gaborit B","2016","Lancet (London, England)","commentary","article","10.1016/s0140-6736(16)30734-6","27312302",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0026260","In reply--Long-term Efficacy and Safety of Exenatide Treatment.","Wysham CH","2015","Mayo Clinic proceedings","commentary","article","10.1016/j.mayocp.2015.06.005","26355404",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0026261","Empagliflozin and dulaglutide: community awareness project promotes improved access to newly funded medications for Pacific patients with type 2 diabetes.","Sundborn G","2023","The New Zealand medical journal","other_trial","article","10.26635/6965.5869","36958323",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026262","Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.","Eng J","1992","The Journal of biological chemistry","preclinical","article","10.1016/s0021-9258(18)42531-8","1313797",null,null,"S002115","pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0026263","Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes.","Mima A","2012","Diabetes","preclinical","article","10.2337/db11-1824","22826029","PMC3478518",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026264","Liraglutide for patients with non-alcoholic steatohepatitis.","Dale A","2016","Lancet (London, England)","commentary","article","10.1016/s0140-6736(16)30733-4","27312303",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0026265","Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide.","Millotti G","2014","Drug development and industrial pharmacy","preclinical","article","10.3109/03639045.2013.842578","24131355",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026266","[New and older pharmaceuticals influencing insulin secretion].","Olsovský J","2009","Vnitrni lekarstvi","other","article",null,"19449762",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026267","In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c.","Gonzales K","2016","Annals of internal medicine","randomized_trial","article","10.7326/acpjc-2016-165-8-040","27750300",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; editorial"],["R0026268","Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk.","Donato AA","2017","Annals of internal medicine","commentary","article","10.7326/acpjc-2017-166-2-008","28114464",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0026269","Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications.","Nguyen B","2017","Expert review of endocrinology & metabolism","other","article","10.1080/17446651.2017.1367285","30058889",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026270","Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis.","Cignarelli A","2013","Archives of physiology and biochemistry","narrative_review","article","10.3109/13813455.2013.796996","23724947",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026271","[Recent progress and novel perspectives on obesity pharmacotherapy].","Faria AM","2010","Arquivos brasileiros de endocrinologia e metabologia","narrative_review","article","10.1590/s0004-27302010000600003","20857056",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; Review; article"],["R0026272","Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.","Perry T","2003","Journal of neuroscience research","preclinical","article","10.1002/jnr.10611","12749025",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026273","Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.","Peskin BR","2011","Diabetes, obesity & metabolism","other_trial","article","10.1111/j.1463-1326.2011.01430.x","21624032",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0026274","Glutamine-Elicited Secretion of Glucagon-Like Peptide 1 Is Governed by an Activated Glutamate Dehydrogenase.","Andersson LE","2018","Diabetes","preclinical","article","10.2337/db16-1441","29229616",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Study; article"],["R0026275","Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations.","Elnaem MH","2020","International journal of general medicine","nonrandomized_study","article","10.2147/ijgm.s285191","33324086","PMC7733337",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0026276","The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.","Creutzfeldt W","2001","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","narrative_review","article","10.1055/s-2001-18589","11460578",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026277","Diabetes therapy: novel patents targeting the glucose-induced insulin secretion.","Polakof S","2010","Recent patents on DNA & gene sequences","narrative_review","article","10.2174/187221510790410778","20218954",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026278","Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function.","Rowlands J","2018","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2018.00672","30532733","PMC6266510",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026279","Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1.","Osto E","2015","Circulation","preclinical","article","10.1161/circulationaha.114.011791","25673670",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026280","Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.","Anabtawi A","2017","Current cardiology reports","narrative_review","article","10.1007/s11886-017-0872-8","28528456",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026281","Lixisenatide once daily significantly improves post-prandial glucose throughout the day due to diverse mechanistic effects.","Raccah D","2014","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.2014.897606","30736158",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026282","Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.","Roussel R","2016","Journal of medical economics","randomized_trial","article","10.3111/13696998.2015.1100998","26413789",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026283","[Combination of incretin-related drugs with other anti-hyperglycemic drugs].","Yamada Y","2011","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"21595279",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026284","Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.","Shao N","2014","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.2561","24823873",null,null,"S000885","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026285","[Cerebroprotective activity of metformin, gosogliptin, citicoline and a novel GPR119 agonist in cerebral ischemia under experimental diabetes mellitus].","Tyurenkov IN","2017","Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","preclinical","article","10.17116/jnevro201711712253-59","29411746",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026286","Medical Management of Diabesity: Do We Have Realistic Targets?","Pappachan JM","2017","Current diabetes reports","randomized_trial","article","10.1007/s11892-017-0828-9","28101792",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0026287","The Neuroprotective Effect of Liraglutide is Mediated by Glucagon-Like Peptide 1 Receptor-Mediated Activation of cAMP/PKA/CREB Pathway.","Bao Y","2015","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","preclinical","article","10.1159/000430199","26279440",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026288","Pancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis.","Traub S","2017","Cell reports","preclinical","article","10.1016/j.celrep.2017.03.005","28355570",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026289","Synergistic insulinotropic effects of succinic acid dimethyl ester and exendin-4 in anaesthetized rats.","Cancelas J","2001","International journal of molecular medicine","preclinical","article","10.3892/ijmm.8.3.269","11494054",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026290","[Treatment of type 2 diabetes].","Meier JJ","2016","Der Internist","narrative_review","article","10.1007/s00108-015-0002-x","26795946",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026291","Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.","Kuhadiya ND","2016","Diabetes care","randomized_trial","article","10.2337/dc15-1136","27208343","PMC5864130","ClinicalTrials.gov:NCT01722266","S000404","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; research-article; article"],["R0026292","Top studies of 2021 relevant to primary care: From the PEER team.","Moe SS","2022","Canadian family physician Medecin de famille canadien","narrative_review","article","10.46747/cfp.6805329","35552205","PMC9097735",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0026293","Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series.","Kutoh E","2011","Journal of medical case reports","case_report","article","10.1186/1752-1947-5-117","21443773","PMC3079672",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026294","National trends in prescription drug expenditures and projections for 2022.","Tichy EM","2022","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxac102","35385103","PMC9383648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026295","Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.","Charbonnel B","2013","Diabetologia","randomized_trial","article","10.1007/s00125-013-2905-1","23604551",null,"ClinicalTrials.gov:NCT01296412","S000080","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026296","Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.","Woo JS","2013","Arteriosclerosis, thrombosis, and vascular biology","randomized_trial","article","10.1161/atvbaha.113.301586","23868944",null,"ClinicalTrials.gov:NCT01580514","S002201; S002372","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026297","Protective action of liraglutide in beta cells under lipotoxic stress via PI3K/Akt/FoxO1 pathway.","Shao S","2014","Journal of cellular biochemistry","preclinical","article","10.1002/jcb.24763","24415347",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026298","Molecular and cellular mechanisms of pancreatic injury.","Thrower EC","2010","Current opinion in gastroenterology","narrative_review","article","10.1097/mog.0b013e32833d119e","20651589","PMC3023172",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review; research-article; article"],["R0026299","Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review.","Williams SM","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-019-00693-0","31552598","PMC6848658",null,"S000729; S000821","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; review"],["R0026300","Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.","Newsome PN","2016","Lancet (London, England)","commentary","article","10.1016/s0140-6736(16)30672-9","27312304",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0026301","[Not Available].","Winzeler B","2015","Therapeutische Umschau. Revue therapeutique","narrative_review","article","10.1024/0040-5930/a000658","25722307",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026302","Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes.","Zhang L","2016","Drug delivery","preclinical","article","10.1080/10717544.2016.1180723","27099000",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026303","OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)","Frias J","2020","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaa046.2057",null,"PMC7209020",null,null,"europepmc; openalex","TRUE","open_europepmc","2","FALSE","Abstract; article"],["R0026304","Mifepristone induced liver injury in a patient with Cushing syndrome: a case report and review of the literature.","Ault TA","2023","Journal of medical case reports","case_report","article","10.1186/s13256-022-03696-x","36732814","PMC9894739",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Case Reports; Journal Article; case-report; article"],["R0026305","Dapagliflozin.","Cada DJ","2014","Hospital pharmacy","other_trial","article","10.1310/hpj4907-647","25477585","PMC4252236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0026306","Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study.","Pérez-Durillo FT","2018","Molecules (Basel, Switzerland)","other","article","10.3390/molecules23071564","29958403","PMC6099802",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026307","A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?","Chikara G","2018","Indian journal of clinical biochemistry : IJCB","other_trial","article","10.1007/s12291-017-0668-z","29651202","PMC5891460",null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review; review-article"],["R0026308","Combining transoral outlet reduction with pharmacotherapy yields similar 1-year efficacy with improved safety compared with surgical revision for weight regain after Roux-en-Y gastric bypass (with videos).","Jirapinyo P","2023","Gastrointestinal endoscopy","nonrandomized_study","article","10.1016/j.gie.2023.04.2092","37150416",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0026309","Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.","Umpierrez GE","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12930","28256054",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026310","Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.","Utzschneider KM","2022","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23475","35894078","PMC10849844","ClinicalTrials.gov:NCT01779362; ClinicalTrials.gov:NCT01763346","S002086","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0026311","The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease.","Recio C","2016","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2016.00526","28111551","PMC5216031",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026312","When Inappropriate Use of Insulin is Dangerous: The Utility of C-Peptide Assay in the Era of Cardioprotective Antidiabetic Drugs.","Volpe S","2021","Diabetes, metabolic syndrome and obesity : targets and therapy","case_report","article","10.2147/dmso.s321340","34385826","PMC8352573",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0026313","Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.","Gastaldelli A","2020","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.13907","31692226","PMC7064910",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026314","Incretin combination therapy for the treatment of non-alcoholic steatohepatitis.","Kannt A","2020","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14035","32196896",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026315","Exendin-4 induction of cyclin D1 expression in INS-1 beta-cells: involvement of cAMP-responsive element.","Kim MJ","2006","The Journal of endocrinology","preclinical","article","10.1677/joe.1.06480","16522741",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026316","Exenatide: from the Gila monster to the pharmacy.","Triplitt C","2006","Journal of the American Pharmacists Association : JAPhA","narrative_review","article","10.1331/154434506775268698","16529340",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026317","Site-Specific Albumin-Selective Ligation to Human Serum Albumin under Physiological Conditions.","Yu X","2022","Bioconjugate chemistry","preclinical","article","10.1021/acs.bioconjchem.2c00361","36350013","PMC9782315",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0026318","Exenatide-Induced Eosinophil-Rich Granulomatous Panniculitis: A Novel Case Showing Injected Microspheres.","Andrés-Ramos I","2015","The American Journal of dermatopathology","commentary","article","10.1097/dad.0000000000000243","25545186",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0026319","Integrating cardioprotective glucose-lowering medications into clinical practice.","Mudaliar S","2018","Cardiovascular endocrinology & metabolism","narrative_review","article","10.1097/xce.0000000000000142","31646275","PMC6739882",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026320","Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats.","Tanaka K","2014","World journal of gastroenterology","preclinical","article","10.3748/wjg.v20.i10.2653","24627601","PMC3949274",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026321","Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes.","Inzucchi SE","2017","Diabetes care","commentary","article","10.2337/dc16-2372","28733378",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0026322","Alteration of BDNF, SPARC, FGF-21, and GDF-15 circulating levels after 1 year of anti-obesity treatments and their association with 1-year weight loss.","Chaiyasoot K","2023","Endocrine","nonrandomized_study","article","10.1007/s12020-023-03435-2","37436597","PMC10462550",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Observational Study; Journal Article; research-article; article"],["R0026323","Cardiovascular effects of incretin therapy in diabetes care.","Kim J","2014","Metabolic syndrome and related disorders","randomized_trial","article","10.1089/met.2014.0035","24842063","PMC4162447",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0026324","Actions of Helodermatidae venom peptides and mammalian glucagon-like peptides on gastric chief cells.","Rai A","1993","The American journal of physiology","preclinical","article","10.1152/ajpgi.1993.265.1.g118","8393295",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0026325","Prevalence and treatment of diabetes mellitus and hypertension among older adults with intellectual disability in comparison with the general population.","Axmon A","2017","BMC geriatrics","nonrandomized_study","article","10.1186/s12877-017-0658-2","29169334","PMC5701367",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0026326","Association between inflammatory markers and survival in comatose, resuscitated out-of-hospital cardiac arrest patients.","Toftgaard Pedersen A","2022","Scandinavian cardiovascular journal : SCJ","randomized_trial","article","10.1080/14017431.2022.2074093","35546563",null,"ClinicalTrials.gov:NCT02442791","S001005","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026327","Pseudo-Wang Handle for the Preparation of Fully Protected Peptides. Synthesis of Liraglutide by Fragment Condensation.","Carbajo D","2019","Organic letters","other","article","10.1021/acs.orglett.9b00813","30869905",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026328","Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male rats.","Martin WP","2022","Clinical science (London, England : 1979)","preclinical","article","10.1042/cs20220205","36259366","PMC7613831",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026329","Current and future pharmacological therapies for NAFLD/NASH.","Sumida Y","2018","Journal of gastroenterology","other_trial","article","10.1007/s00535-017-1415-1","29247356","PMC5847174",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0026330","Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.","Thompson J","2019","Cardiology clinics","other_trial","article","10.1016/j.ccl.2019.04.007","31279427",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0026331","Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study).","Xu W","2015","Journal of internal medicine","randomized_trial","article","10.1111/joim.12293","25039675",null,null,"S000885","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0026332","Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19.","Kartchner D","2023","Biology","preclinical","article","10.3390/biology12091269","37759668","PMC10526006",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026333","A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.","Misurski D","2009","Applied health economics and health policy","nonrandomized_study","article","10.1007/bf03256158","19905038",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026334","Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model.","Briand F","2020","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2020.173316","32621913",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026335","Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor.","Kirkpatrick A","2012","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.1218051109","23169631","PMC3523846",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026336","Liraglutide protects pancreatic β cells from endoplasmic reticulum stress by upregulating MANF to promote autophagy turnover.","Fu J","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.117648","32275937",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026337","Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus.","Tanaka S","2016","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2016.04.027","27321309",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026338","A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.","Inoue Y","2015","Journal of clinical pharmacology","randomized_trial","article","10.1002/jcph.483","25677642",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0026339","Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.","Perna S","2016","Aging clinical and experimental research","case_report","article","10.1007/s40520-015-0525-y","26749118",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026340","Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.","Jain M","2019","Diabetologia","randomized_trial","article","10.1007/s00125-018-4789-6","30593607",null,"ClinicalTrials.gov:NCT02524782",null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026341","National trends in prescription drug expenditures and projections for 2023.","Tichy EM","2023","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxad086","37094296",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0026342","GLP-1 analogs: satiety without malaise?","Tang-Christensen M","2007","American journal of physiology. Regulatory, integrative and comparative physiology","commentary","article","10.1152/ajpregu.00449.2007","17596320",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Comment; article"],["R0026343","Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell function.","Retnakaran R","2023","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15073","37380623",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026344","Identification of a plant-derived small molecule with potent anti-obesity and anti-diabetic activities in type 2 diabetic mice","Wang y","2022","Authorea Preprints","preclinical","preprint","10.22541/au.164873586.65024962/v1",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0026345","Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study.","Lønborg J","2014","Diabetes","randomized_trial","article","10.2337/db13-1849","24584550",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026346","Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.","Fehse F","2005","The Journal of clinical endocrinology and metabolism","other","article","10.1210/jc.2005-1093","16144950",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026347","Formation Mechanism, In vitro and In vivo Evaluation of Dimpled Exenatide Loaded PLGA Microparticles Prepared by Ultra-Fine Particle Processing System.","Zhu C","2019","AAPS PharmSciTech","preclinical","article","10.1208/s12249-018-1208-8","30627822",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026348","Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.",null,"2013","Prescrire international","other","article",null,"23885352",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026349","Obesity management: Attitudes and practice of Italian endocrinologists.","Chianelli M","2022","Frontiers in endocrinology","other","article","10.3389/fendo.2022.1061511","36733804","PMC9888662",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026350","Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.","Nagashima M","2011","Diabetologia","preclinical","article","10.1007/s00125-011-2241-2","21786155","PMC3168747",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026351","Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.","Maida A","2011","Diabetologia","preclinical","article","10.1007/s00125-010-1937-z","20972533",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026352","Joint longitudinal and time-to-event modelling compared with standard Cox modelling in patients with type 2 diabetes with and without established cardiovascular disease: An analysis of the EXSCEL trial.","Oulhaj A","2023","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.14975","36635232",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0026353","Nephrotoxicity in mice after repeated imaging using 111In-labeled peptides.","Melis M","2010","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.109.074310","20484435",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026354","Patient Experience With The Single-Use Pen For Injection of Once Weekly Dulaglutide in Injection-Naive Patients With Type 2 Diabetes.","Van BK","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.747","27200698",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026355","Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site.","Shan SJ","2014","The American Journal of dermatopathology","case_report","article","10.1097/dad.0000000000000036","24366197",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0026356","Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1.","Martins AD","2019","Toxicology and applied pharmacology","other","article","10.1016/j.taap.2018.10.009","30296456",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026357","Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.","Dambha-Miller H","2020","BMJ open","systematic_review","article","10.1136/bmjopen-2020-040644","32928868","PMC7490921",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; review"],["R0026358","Bone morphogenetic protein-9 maybe an important factor which improves insulin resistance in PCOS.","Yuan X","2022","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","preclinical","article","10.1080/09513590.2022.2109144","35957509",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026359","Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.","Ryan GJ","2013","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","narrative_review","article","10.2146/ajhp120168","23784159",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026360","Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists.","Fujihara K","2016","Journal of diabetes investigation","other","article","10.1111/jdi.12387","27042280","PMC4773680",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026361","In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.","Mazurek M","2016","Annals of internal medicine","other_trial","article","10.7326/acpjc-2016-165-8-038","27750298",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Comment; editorial"],["R0026362","Inventing new medicines: The FGF21 story.","Kharitonenkov A","2014","Molecular metabolism","preclinical","article","10.1016/j.molmet.2013.12.003","24749049","PMC3986619",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026363","Gateways to clinical trials.","Tomillero A","2009","Methods and findings in experimental and clinical pharmacology","other","article",null,"19455266",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0026364","Medications in type-2 diabetics and their association with liver fibrosis.","Siddiqui MT","2020","World journal of gastroenterology","nonrandomized_study","article","10.3748/wjg.v26.i23.3249","32684739","PMC7336333",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026365","Drug Prescribing: New Drugs and Drug Classes in Family Medicine.","Yuet WC","2021","FP essentials","other","article",null,"34491708",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026366","Use of antidiabetic drugs in the U.S., 2003-2012.","Hampp C","2014","Diabetes care","other","article","10.2337/dc13-2289","24623020",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026367","Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study.","O'Donnell C","2024","Annals of the American Thoracic Society","randomized_trial","article","10.1513/annalsats.202309-821oc","38096106",null,"ClinicalTrials.gov:NCT04186494","S001827","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026368","Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.","Finan B","2013","Science translational medicine","preclinical","article","10.1126/scitranslmed.3007218","24174327",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026369","Currently prescribed drugs in the UK that could up or downregulate ACE2 in COVID-19 disease: A systematic review","Dambha-Miller H","2020","medRxiv","systematic_review","preprint","10.1101/2020.05.19.20106856",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0026370","[Effects of glucagon-like peptide-1 on appetite and body weight: preclinical and clinical data].","Sesti G","2011","Giornale italiano di cardiologia (2006)","narrative_review","article","10.1714/985.10685","22158422",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026371","[How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].","Scheen AJ","2015","Revue medicale de Liege","other","article",null,"26867302",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0026372","Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.","Fan H","2013","Arquivos brasileiros de endocrinologia e metabologia","randomized_trial","article","10.1590/s0004-27302013000900005","24402015",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026373","Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit.","Abuannadi M","2013","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other_trial","article","10.4158/ep12196.or","23186969",null,null,"S001102","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026374","Exenatide-induced chronic damage of pancreatic tissue in rats.","Yu X","2012","Pancreas","preclinical","article","10.1097/mpa.0b013e31824e67a3","22836857",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026375","[The antidiabetic drug liraglutide lowers risk of cardiac death].","Overbeck P","2016","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-016-8410-y","27323977",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"News"],["R0026376","Anti-oxidant, anti-apoptotic, anti-hypoxic and anti-inflammatory conditions induced by PTY-2 against STZ-induced stress in islets","Srivastava S","2019","bioRxiv","preclinical","article","10.1101/670364","31597821",null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint; article"],["R0026377","[Role and indication of GLP-1 analogues in the treatment of type 2 diabetes].","Philippe J","2009","Revue medicale suisse","other","article",null,"19579421",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026378","The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.","Kramer CK","2015","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2015-2725","26230296",null,"ClinicalTrials.gov:NCT01270789","S001528","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026379","Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.","Luque MA","2002","The Journal of endocrinology","preclinical","article","10.1677/joe.0.1730465","12065236",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026380","Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice.","Bruin JE","2013","Diabetologia","preclinical","article","10.1007/s00125-013-2955-4","23771205",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026381","Foresee Novel Targets for Alzheimer's Disease by Investigating Repurposed Drugs.","Agarwal K","2023","CNS & neurological disorders drug targets","nonrandomized_study","article","10.2174/1871527321666220622162622","35733313",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0026382","Extrapancreatic effects of GIP and GLP-1.","Vella A","2004","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","narrative_review","article","10.1055/s-2004-82617","15655715",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026383","Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.","Vachliotis ID","2022","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14774","35589613",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026384","Exenatide Activates the APPL1-AMPK-PPARα Axis to Prevent Diabetic Cardiomyocyte Apoptosis.","XiaoTian L","2016","Journal of diabetes research","preclinical","article","10.1155/2016/4219735","26759813","PMC4677202",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026385","[Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture].","Hayakawa N","2012","Clinical calcium","preclinical","article",null,"22932293",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026386","Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors.","Tomkin GH","2014","World journal of diabetes","narrative_review","article","10.4239/wjd.v5.i5.636","25317241","PMC4138587",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026387","Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update.","Tiwari P","2015","Journal of diabetes research","narrative_review","article","10.1155/2015/340838","26273667","PMC4530263",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0026388","Response to comment on Sarkar et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670.","Sarkar G","2014","Diabetes care","other_trial","article","10.2337/dc14-1482","25249681","PMC4170128",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Letter; Comment; article"],["R0026389","Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.","Buse JB","2014","Current medical research and opinion","randomized_trial","article","10.1185/03007995.2014.896329","24621255",null,"ClinicalTrials.gov:NCT00765817","S000345","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0026390","[Pharmacotherapy for obesity].","van Rossum EFC","2021","Nederlands tijdschrift voor geneeskunde","other","article",null,"33560612",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026391","Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.","Matyjaszek-Matuszek B","2013","Endokrynologia Polska","randomized_trial","article","10.5603/ep.2013.0021","24186595",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026392","Characterization of the gila monster (Heloderma suspectum suspectum) venom proteome.","Sanggaard KW","2015","Journal of proteomics","preclinical","article","10.1016/j.jprot.2015.01.004","25603280",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026393","Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: a translational perspective for the cardiologist.","Yin M","2013","International journal of cardiology","other","article","10.1016/j.ijcard.2013.10.005","24383120",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026394","The role of incretins in glucose homeostasis and diabetes treatment.","Kim W","2008","Pharmacological reviews","narrative_review","article","10.1124/pr.108.000604","19074620","PMC2696340",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Intramural; Review; research-article"],["R0026395","Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes.","Li D","2015","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2015.05.051","26376464",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026396","Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study.","Pawaskar M","2013","BMC endocrine disorders","nonrandomized_study","article","10.1186/1472-6823-13-20","23799930","PMC3750447",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026397","Total parenteral nutrition drives glucose metabolism disorders by modulating gut microbiota and its metabolites","Sun H","2021","bioRxiv","nonrandomized_study","preprint","10.1101/2021.10.26.466009",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0026398","Liraglutide in Weight Management.","Pi-Sunyer X","2015","The New England journal of medicine","nonrandomized_study","article","10.1056/nejmc1509759","26510028",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0026399","Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes.","Tomkin GH","2009","Current opinion in molecular therapeutics","other_trial","article",null,"19806507",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0026400","[Liraglutide attenuates myocardial ischemia/reperfusion injury possibly through reducing cardiomyocytes apoptosis and oxidation in rats].","Cheng X","2015","Zhonghua xin xue guan bing za zhi","preclinical","article",null,"26269347",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026401","Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system.","Li Y","2020","World journal of diabetes","other","article","10.4239/wjd.v11.i12.654","33384771","PMC7754172",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026402","Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.","Jones SC","2015","Diabetes spectrum : a publication of the American Diabetes Association","other","article","10.2337/diaspect.28.4.283","26597395","PMC4647172",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026403","SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.","van Bommel EJM","2017","Clinical journal of the American Society of Nephrology : CJASN","other_trial","article","10.2215/cjn.06080616","28254770","PMC5383382",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0026404","Black widow spider alpha-latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones.","Holz GG","1998","Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","other","article","10.1016/s0305-0491(98)10088-3","9972293","PMC2924186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0026405","The Cascade System of Osmotic Homeostasis Regulation.","Natochin YV","2020","Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections","preclinical","article","10.1134/s0012496620010056","32342317",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026406","Autonomous isolation, long-term culture and differentiation potential of adult salivary gland-derived stem/progenitor cells.","Baek H","2014","Journal of tissue engineering and regenerative medicine","preclinical","article","10.1002/term.1572","22915381",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026407","Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats.","Vinodraj K","2015","Indian journal of pharmacology","preclinical","article","10.4103/0253-7613.153426","25878378","PMC4386127",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026408","Pharmacotherapy in type 2 diabetes: a functional schema for drug classification.","McGill JB","2012","Current diabetes reviews","narrative_review","article","10.2174/157339912800840541","22515702",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026409","Glucagon-like peptide-1 and its cardiovascular effects.","Heo KS","2012","Current atherosclerosis reports","preclinical","article","10.1007/s11883-012-0265-9","22878937",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026410","Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.","Standl E","2020","Diabetes care","other","article","10.2337/dc19-1079","31882409",null,"ClinicalTrials.gov:NCT01144338","S000905","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0026411","In vitro differentiation of human umbilical cord Wharton's jelly mesenchymal stromal cells to insulin producing clusters.","Nekoei SM","2015","World journal of clinical cases","preclinical","article","10.12998/wjcc.v3.i7.640","26244156","PMC4517339",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026412","A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.","Williams SA","2022","Science translational medicine","other","article","10.1126/scitranslmed.abj9625","35385337",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; article"],["R0026413","Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming.","Jeong SW","2020","Diabetes & metabolism journal","randomized_trial","article","10.4093/dmj.2020.0115","33115209","PMC7643594",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; review-article; article"],["R0026414","Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.","Retnakaran R","2014","Diabetes care","randomized_trial","article","10.2337/dc14-0893","25249651",null,"ClinicalTrials.gov:NCT01270789","S001528","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026415","Sitagliptin attenuates inflammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-κB pathway inhibition.","Lin CH","2016","Experimental and therapeutic medicine","other","article","10.3892/etm.2016.3255","27284355","PMC4887932",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026416","Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.","Sherr JL","2016","Diabetes care","other_trial","article","10.2337/dc16-0089","27208332","PMC4915555",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0026417","Alogliptin (Nesina) for Type 2 Diabetes Mellitus",null,"2015","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"26962596",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0026418","Fatty liver disease in diabetes mellitus.","Bhatt HB","2015","Hepatobiliary surgery and nutrition","narrative_review","article","10.3978/j.issn.2304-3881.2015.01.03","26005676","PMC4405411",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026419","Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.","Karagianni P","2013","Advances in medical sciences","other_trial","article","10.2478/v10039-012-0078-7","23640946",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Comparative Study; Journal Article; article"],["R0026420","Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.","Traina AN","2014","Canadian journal of diabetes","nonrandomized_study","article","10.1016/j.jcjd.2013.10.006","24797495",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0026421","Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients.","Ghuman NK","2015","Clinical medicine insights. Endocrinology and diabetes","nonrandomized_study","article","10.4137/cmed.s31756","26441485","PMC4578557",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026422","The role of oxidative stress in the pathogenesis of diabetic vascular complications.","Sasaki S","2012","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2012.36.4.255","22950054","PMC3428411",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0026423","Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents.","Ryan PM","2017","Scientific reports","nonrandomized_study","article","10.1038/s41598-017-14010-x","29051554","PMC5648875",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026424","Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration.","Seferovic JP","2018","Journal of diabetes research","randomized_trial","article","10.1155/2018/1631263","30648112","PMC6311850","ClinicalTrials.gov:NCT01147250","S001991","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0026425","Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.","Feng P","2015","Acta pharmacologica Sinica","other_trial","article","10.1038/aps.2014.136","25619391","PMC4326793",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0026426","Phytotherapy in diabetes: Review on potential mechanistic perspectives.","El-Abhar HS","2014","World journal of diabetes","nonrandomized_study","article","10.4239/wjd.v5.i2.176","24748931","PMC3990312",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0026427","Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.","Li H","2015","Journal of pharmacological sciences","systematic_review","article","10.1016/j.jphs.2014.12.004","25727954",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; article"],["R0026428","Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.","Tokuda M","2014","Endocrine journal","other","article","10.1507/endocrj.ej14-0009","24452017",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026429","Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ).","Matza LS","2018","Journal of patient-reported outcomes","other","article","10.1186/s41687-018-0064-3","30294714","PMC6153201",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0026430","Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus.","Onishi Y","2013","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12000","24843650","PMC4019273","ClinicalTrials.gov:NCT00917267","S001437","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0026431","Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study.","Ke W","2016","Journal of diabetes research","randomized_trial","article","10.1155/2016/6839735","26640805","PMC4657099",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0026432","Effects of GLP-1 in the kidney.","Skov J","2014","Reviews in endocrine & metabolic disorders","preclinical","article","10.1007/s11154-014-9287-7","24791975",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026433","Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection.","Harkavyi A","2010","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2009.00486.x","20128800","PMC2828015",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026434","[Type 2 diabetes. Lixisenatide - effective in combination].",null,"2013","MMW Fortschritte der Medizin","commentary","article",null,"24006601",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; News; article"],["R0026435","Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.","Anderson ZL","2014","JAAPA : official journal of the American Academy of Physician Assistants","other","article","10.1097/01.jaa.0000443811.42907.a5","24853156",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026436","Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.","Ard J","2016","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12632","26744025","PMC6084344",null,"S000492; S001792","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026437","[Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].","Gallwitz B","2010","MMW Fortschritte der Medizin","other","article","10.1007/bf03366604","20552881",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026438","Application of model-based methods to characterize exenatide-loaded double-walled microspheres: in vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation.","Li X","2012","Journal of pharmaceutical sciences","preclinical","article","10.1002/jps.23236","22753275",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026439","Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ).","Matza LS","2018","Journal of patient-reported outcomes","other","article","10.1186/s41687-018-0068-z","30294713","PMC6153258",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026440","Simultaneous angiotensin receptor blockade and glucagon-like peptide-1 receptor activation ameliorate albuminuria in obese insulin-resistant rats.","Rodriguez R","2020","Clinical and experimental pharmacology & physiology","preclinical","article","10.1111/1440-1681.13206","31675433",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026441","Drugs for type 2 diabetes: role in the regulation of bone metabolism.","Mannucci E","2015","Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases","narrative_review","article","10.11138/ccmbm/2015.12.2.130","26604937","PMC4625768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026442","Dulaglutide -- Benefit Assessment According to §35a Social Code Book V",null,"2015","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany","randomized_trial","article",null,"27905789",null,null,null,"europepmc","FALSE","free_to_read","2",null,"Review"],["R0026443","The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.","Suchankova P","2015","Translational psychiatry","nonrandomized_study","article","10.1038/tp.2015.68","26080318","PMC4490279",null,"S000504","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026444","Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.","Darpö B","2013","British journal of clinical pharmacology","randomized_trial","article","10.1111/j.1365-2125.2012.04416.x","22882281","PMC3612716",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026445","An improved LC-MS/MS method for the determination of taspoglutide in plasma and urine using orthogonal HILIC-RP column switching, ultra-performance LC separation and 'wrong-way-round' electrospray ionization.","Heinig K","2011","Biomedical chromatography : BMC","other","article","10.1002/bmc.1593","21308702",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026446","Substitution of insulin by exenatide in bad controlled type 2 diabetic patients: efficacy and predictive factors.","Barthélémy M","2015","Minerva endocrinologica","nonrandomized_study","article",null,"25003223",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0026447","Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.","Mathieu C","2013","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-013-0037-8","24018835","PMC3889314","ClinicalTrials.gov:NCT00635492","S001805","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026448","Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study.","Rigato M","2015","Journal of endocrinological investigation","randomized_trial","article","10.1007/s40618-015-0385-5","26328783",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0026449","A pooled analysis of exenatide use and risk of acute pancreatitis.","Dore DD","2013","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2013.838550","23981106",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026450","Pancreatic β-cell response to increased metabolic demand and to pharmacologic secretagogues requires EPAC2A.","Song WJ","2013","Diabetes","preclinical","article","10.2337/db12-1394","23578994","PMC3717830",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0026451","Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke.","He W","2020","Journal of cellular physiology","preclinical","article","10.1002/jcp.29204","31535381",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026452","Iixisenatide. Wait for conclusive results on complications of diabetes.",null,"2014","Prescrire international","other","article",null,"25964965",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026453","Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling.","Robinson E","2016","Cardiovascular diabetology","preclinical","article","10.1186/s12933-016-0386-5","27079193","PMC4832495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026454","Isolation and cloning of exendin precursor cDNAs from single samples of venom from the Mexican beaded lizard (Heloderma horridum) and the Gila monster (Heloderma suspectum).","Chen T","2006","Toxicon : official journal of the International Society on Toxinology","preclinical","article","10.1016/j.toxicon.2005.11.004","16386282",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026455","Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.","Ten Kulve JS","2016","The Journal of endocrinology","randomized_trial","article","10.1530/joe-15-0461","26769912",null,null,"S000930","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026456","Synchrotron radiation-based Fourier-transform infrared spectromicroscopy for characterization of the protein/peptide distribution in single microspheres.","Wang M","2015","Acta pharmaceutica Sinica. B","other","article","10.1016/j.apsb.2015.03.008","26579456","PMC4629252",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026457","[Effect of liraglutide on expression of insulin-like growth factor 2-mRNA binding protein 3 in liver in rats with non-alcoholic fatty liver disease].","Song YP","2016","Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","preclinical","article","10.3760/cma.j.issn.1007-3418.2016.08.011","27788710","PMC12770097",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026458","Protein Tyrosine Phosphatase 1B Inhibitors: A Novel Therapeutic Strategy for the Management of type 2 Diabetes Mellitus.","Prabhakar PK","2019","Current pharmaceutical design","narrative_review","article","10.2174/1381612825666190716102901","31333090",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026459","Liraglutide in clinical practice: Glycemic control, and predictors of good response.","Lecube A","2016","Medicina clinica","commentary","article","10.1016/j.medcli.2015.10.020","26723941",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0026460","The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis.","Peng G","2023","Reproductive biology and endocrinology : RB&E","systematic_review","article","10.1186/s12958-023-01075-9","36869381","PMC9983155","PROSPERO:CRD42020183541",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; Network Meta-Analysis; research-article; other; review"],["R0026461","Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.","Rondanelli M","2016","Patient preference and adherence","nonrandomized_study","article","10.2147/ppa.s97383","27069358","PMC4818054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026462","Glucagon-like peptides.","Drucker DJ","1998","Diabetes","preclinical","article","10.2337/diab.47.2.159","9519708",null,null,"S002455","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026463","Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.","Gurkan E","2014","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2014.09.046","25458329",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026464","The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes.","Gastaldelli A","2014","Clinical endocrinology","randomized_trial","article","10.1111/cen.12199","23574529",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; article"],["R0026465","The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study.","O'Brien EC","2021","Trials","other_trial","article","10.1186/s13063-021-05397-0","34281607","PMC8287813","ClinicalTrials.gov:NCT02465515","S001074","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; research-article; other; article"],["R0026466","Liraglutide improved glycaemic instability in a patient with diabetes with insulin antibodies.","Kato T","2016","BMJ case reports","case_report","article","10.1136/bcr-2016-216028","27440852","PMC4964153",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0026467","Physiological mechanisms for the increase in renal solute-free water clearance by a glucagon-like peptide-1 mimetic.","Kutina AV","2013","Clinical and experimental pharmacology & physiology","preclinical","article","10.1111/1440-1681.12119","23692186",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026468","A highly parallel method for synthesizing DNA repeats enables the discovery of 'smart' protein polymers.","Amiram M","2011","Nature materials","other","article","10.1038/nmat2942","21258353","PMC3075872",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0026469","A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors.","Morris LC","2014","Journal of biomolecular screening","other","article","10.1177/1087057114520971","24525870","PMC4306651",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026470","Use of liraglutide in type 1 diabetes: implications for management.","Simmons D","2016","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(15)00459-3","26656291",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0026471","Prader-Willi Syndrome: Possibilities of Weight Gain Prevention and Treatment.","Erhardt É","2022","Nutrients","narrative_review","article","10.3390/nu14091950","35565916","PMC9103725",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026472","Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.","Raufman JP","1992","The Journal of biological chemistry","preclinical","article","10.1016/s0021-9258(19)36628-1","1328231",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026473","Dickkopf-3 maintains the PANC-1 human pancreatic tumor cells in a dedifferentiated state.","Zenzmaier C","2012","International journal of oncology","preclinical","article","10.3892/ijo.2011.1180","21879258",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026474","Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.","Fineman MS","2012","Diabetes, obesity & metabolism","other","article","10.1111/j.1463-1326.2012.01561.x","22236356",null,"ClinicalTrials.gov:NCT00035984; ClinicalTrials.gov:NCT00039013; ClinicalTrials.gov:NCT00039026; ClinicalTrials.gov:NCT00044668; ClinicalTrials.gov:NCT00082381; ClinicalTrials.gov:NCT00082407; ClinicalTrials.gov:NCT00099320; ClinicalTrials.gov:NCT00099333; ClinicalTrials.gov:NCT00099619; ClinicalTrials.gov:NCT00111540; ClinicalTrials.gov:NCT00135330; ClinicalTrials.gov:NCT00308139; ClinicalTrials.gov:NCT00324363; ClinicalTrials.gov:NCT00381342; ClinicalTrials.gov:NCT00382239; ClinicalTrials.gov:NCT00637273; ClinicalTrials.gov:NCT00641056; ClinicalTrials.gov:NCT00877890","S000052; S000204; S000320; S000402; S000441; S000706; S000713; S000898; S000943; S000965; S001305; S001308; S001379; S001768; S001906; S002166; S002279; S002301; S002376","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026475","Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study.","Mezquita-Raya P","2015","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-015-0112-4","26055216","PMC4478178",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0026476","[Metformin role in the treatment of type 2 diabetes in 2008].","Spada A","2008","Revue medicale suisse","narrative_review","article",null,"18630062",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026477","Rapid ligations with equimolar reactants in water with the potassium acyltrifluoroborate (KAT) amide formation.","Noda H","2014","Journal of the American Chemical Society","other","article","10.1021/ja5018442","24684235",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026478","Change in insulin resistance, beta cell function, glucagon-like peptide-1 and calcitonin levels two weeks after bariatric surgery.","Sridharan K","2019","Diabetes & metabolic syndrome","other","article","10.1016/j.dsx.2019.05.002","31235148",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026479","Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.","Li Q","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-014-0084-9","25256818","PMC4269653",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026480","Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?","Katsiki N","2016","Current vascular pharmacology","commentary","article","10.2174/157016111401151126161741","26642873",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; editorial"],["R0026481","Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats.","Xuan J","2013","Peptides","preclinical","article","10.1016/j.peptides.2013.06.005","23770254",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026482","Obesity and hypertension in type 2 diabetes : exploring the central and peripheral effects of glucagon-like peptide-1R signalling","Robinson LE","2012","University of Warwick","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0026483","Liraglutide suppresses the metastasis of PANC-1 co-cultured with pancreatic stellate cells through modulating intracellular calcium content.","Zhao H","2019","Endocrine journal","other","article","10.1507/endocrj.ej19-0215","31474673",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026484","A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy.","Yamamoto T","2016","Diabetology international","other","article","10.1007/s13340-016-0269-8","30603295","PMC6224977",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026485","Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study.","Brooks-Worrell BM","2021","Frontiers in immunology","other_trial","article","10.3389/fimmu.2021.640251","33981301","PMC8108986",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0026486","One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.","Degn KB","2004","Diabetes","randomized_trial","article","10.2337/diabetes.53.5.1187","15111485",null,null,"S000059; S000235; S001041","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0026487","A case report of allergy to exenatide.","Pérez E","2014","The journal of allergy and clinical immunology. In practice","case_report","article","10.1016/j.jaip.2014.05.011","25439386",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0026488","[Protective effects of incretin on atherosclerosis].","Mita T","2011","Nihon rinsho. Japanese journal of clinical medicine","other_trial","article",null,"21595267",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","English Abstract; Journal Article; Review; other"],["R0026489","The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls.","Kahal H","2019","Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology","other","article","10.1080/09513590.2018.1505848","30599799",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026490","Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.","Buse JB","2007","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2007.01.015","17379054",null,null,"S000052; S000146; S000404; S000477","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026491","Therapeutic Effects of Liraglutide, Oxytocin and Granulocyte Colony-Stimulating Factor in Doxorubicin-Induced Cardiomyopathy Model: An Experimental Animal Study.","Taşkıran E","2019","Cardiovascular toxicology","preclinical","article","10.1007/s12012-019-09524-x","31054117",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0026492","[Degludec/liraglutide] fixed combination as a therapy alternative].","Einecke D","2016","MMW Fortschritte der Medizin","other","article","10.1007/s15006-016-7828-8","27119708",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026493","Efficacy of liraglutide in a real-life cohort.","Heymann A","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","randomized_trial","article","10.1007/s13300-014-0062-2","24664620","PMC4065284",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0026494","Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.","Ferrannini E","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13870","31469220",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026495","Regulation of intestinal chylomicron production by glucagon-like peptides.","Hsieh J","2012","Cardiovascular & hematological disorders drug targets","narrative_review","article","10.2174/1871529x11202020092","23030446",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026496","Effects of Exendine-4 on The Differentiation of Insulin Producing Cells from Rat Adipose-Derived Mesenchymal Stem Cells.","Khorsandi L","2016","Cell journal","preclinical","article","10.22074/cellj.2016.3844","26862531","PMC4746422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026497","Anorexigenic effects of GLP-1 and its analogues.","Gallwitz B","2012","Handbook of experimental pharmacology","preclinical","article","10.1007/978-3-642-24716-3_8","22249815",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026498","Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.","Pawaskar M","2014","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/1060028013520597","24497624",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0026499","Genetically modified rice seeds accumulating GLP-1 analogue stimulate insulin secretion from a mouse pancreatic beta-cell line.","Sugita K","2005","FEBS letters","preclinical","article","10.1016/j.febslet.2004.12.082","15710395",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026500","Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.","Miya A","2018","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.12654","28296201","PMC5754530",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0026501","Need for better diabetes treatment for improved renal outcome.","Rossing P","2011","Kidney international. Supplement","other_trial","article","10.1038/ki.2010.513","21358699",null,null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0026502","Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery.","Gorgojo-Martínez JJ","2016","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","nonrandomized_study","article","10.1016/j.soard.2016.02.013","27256860",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0026503","Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): A randomised, double-blind, controlled trial.","Wägner AM","2016","Contemporary clinical trials communications","randomized_trial","article","10.1016/j.conctc.2016.06.007","29736469","PMC5935879",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0026504","Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study.","Cegla J","2016","Annals of clinical biochemistry","randomized_trial","article","10.1177/0004563216648250","28071092",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0026505","Update on incretin hormones.","Phillips LK","2011","Annals of the New York Academy of Sciences","narrative_review","article","10.1111/j.1749-6632.2012.06491.x","22545749",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0026506","Adjuvant immunotherapy increases beta cell regenerative factor Reg2 in the pancreas of diabetic mice.","Huszarik K","2010","Journal of immunology (Baltimore, Md. : 1950)","preclinical","article","10.4049/jimmunol.1001596","20876350",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026507","Anti-diabetic drugs recent approaches and advancements.","Dowarah J","2020","Bioorganic & medicinal chemistry","narrative_review","article","10.1016/j.bmc.2019.115263","32008883",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0026508","Liraglutide-induced autoimmune hepatitis.","Kern E","2014","JAMA internal medicine","case_report","article","10.1001/jamainternmed.2014.674","24733687","PMC4423594",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026509","A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication.","Choi YJ","2023","Journal of global health","nonrandomized_study","article","10.7189/jogh.13.04095","37651636","PMC10471157",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026510","Treatment of type 2 diabetes in children: what are the specific considerations?","Grøndahl MFG","2021","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2021.1954160","34420454",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026511","Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease.","Kim KS","2020","Clinical and molecular hepatology","randomized_trial","article","10.3350/cmh.2020.0137","32791578","PMC7641556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0026512","Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.","Wolsk E","2022","Journal of the American Heart Association","other_trial","article","10.1161/jaha.121.021327","35383463","PMC9238457",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0026513","Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.","Romley JA","2012","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2012.0075","22845701","PMC3513976",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026514","Weight management in type 2 diabetes mellitus.","Siram AT","2010","The Mount Sinai journal of medicine, New York","narrative_review","article","10.1002/msj.20208","20960555",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026515","Byetta update: what we've learned from experience.","Cornell S","2010","Diabetes self-management","other","article",null,"20405747",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026516","Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate.","Kalra S","2018","The Journal of the Association of Physicians of India","other","article",null,"31313550",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026517","Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.","Li CJ","2014","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","randomized_trial","article","10.1055/s-0034-1374586","24838155",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026518","Patient Reported Outcomes (PROs) used in recent Phase 3 trials for Type 2 Diabetes: A review of concepts assessed by these PROs and factors to consider when choosing a PRO for future trials.","Reaney M","2016","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2016.04.009","27321317",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0026519","Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes.","Palleria C","2016","Frontiers in neuroendocrinology","narrative_review","article","10.1016/j.yfrne.2016.07.002","27521218",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026520","The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling.","Dods RL","2015","Bioscience reports","other","article","10.1042/bsr20150253","26598711","PMC4718506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026521","Benefits of weight loss of 10% or more in patients with overweight or obesity: A review.","Tahrani AA","2022","Obesity (Silver Spring, Md.)","narrative_review","article","10.1002/oby.23371","35333446",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026522","Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus.","Cui YM","2013","Journal of diabetes","other_trial","article","10.1111/1753-0407.12020","23332026",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026523","The Effectiveness of Nigella sativa and Ginger as Appetite Suppressants: An Experimental Study on Healthy Wistar Rats.","Al Asoom L","2023","Vascular health and risk management","preclinical","article","10.2147/vhrm.s396295","36647392","PMC9840438",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026524","Protocol of GLUcose COntrol Safety and Efficacy in type 2 DIabetes, a NETwork meta-analysis: GLUCOSE DINET protocol-Rational and design.","Grenet G","2017","Fundamental & clinical pharmacology","systematic_review","article","10.1111/fcp.12263","28036112",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0026525","Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway.","Ji Y","2014","Molecular medicine reports","preclinical","article","10.3892/mmr.2014.1956","24535553",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026526","Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.","Gautier JF","2005","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(07)70190-8","16142014",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026527","Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.","Ostenson CG","2013","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s41827","23667315","PMC3650573","ClinicalTrials.gov:NCT00635492","S001805","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026528","Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.","Schwasinger-Schmidt T","2013","Pharmacological research","preclinical","article","10.1016/j.phrs.2013.07.005","23891763",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026529","Blockade of central GLP-1 receptors prevents CART-induced hypophagia and brain c-Fos expression.","Aja S","2006","Peptides","preclinical","article","10.1016/j.peptides.2005.07.003","16154233",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0026530","Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: Effect of magnesium chloride.","Li Y","2018","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2018.10.071","30389472",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0026531","Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways.","Tang ST","2016","Endocrine","preclinical","article","10.1007/s12020-015-0852-y","26758998",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026532","Interspecies modeling and prediction of human exenatide pharmacokinetics.","Chen T","2013","Pharmaceutical research","preclinical","article","10.1007/s11095-012-0917-z","23229855","PMC3732180",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0026533","Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes.","Bashier AM","2014","Saudi medical journal","nonrandomized_study","article","10.15537/1658-3175.6088","25399222","PMC4362132",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026534","[Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism].","Winkler G","2013","Orvosi hetilap","narrative_review","article","10.1556/oh.2013.29553","23395788",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; article"],["R0026535","SUN-678 Telediabetes Improves A1C and Patient Satisfaction: A Pilot Study in a VA Institution","Behari G","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.1955",null,"PMC7207731",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0026536","Alteration of Circulating levels of BDNF, SPARC, FGF-21, and GDF-15 after 1 Year of Anti-Obesity Treatments and Their Association with 1-Year Weight Loss","Chaiyasoot K","2023","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-2715906/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0026537","Discovery of a novel glucagon-like peptide (GCGL) and its receptor (GCGLR) in chickens: evidence for the existence of GCGL and GCGLR genes in nonmammalian vertebrates.","Wang Y","2012","Endocrinology","preclinical","article","10.1210/en.2012-1586","23015292",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026538","MS-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice.","Bele S","2020","eLife","preclinical","article","10.7554/elife.52212","33349332","PMC7755393",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026539","Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes.","Kondo Y","2013","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.12082","24843711","PMC4020252",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026540","Obesity: Liraglutide--another weapon in the war against obesity?","Bray GA","2015","Nature reviews. Endocrinology","commentary","article","10.1038/nrendo.2015.133","26260142",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0026541","Improved Glycemic Control and Vascular Function and Reduction of Abdominal Fat Accumulation with Liraglutide in a Case of Werner Syndrome with Diabetes Mellitus.","Ide S","2016","Journal of the American Geriatrics Society","case_report","article","10.1111/jgs.13970","27000366",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; Research Support, Non-U.S. Gov't; article"],["R0026542","Characterization of human pancreatic progenitor cells.","Noguchi H","2010","Cell transplantation","preclinical","article","10.3727/096368910x509004","20587146",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026543","Cardiovascular effects of antiobesity drugs: are the new medicines all the same?","Cataldi M","2020","International journal of obesity supplements","randomized_trial","article","10.1038/s41367-020-0015-3","32714509","PMC7371629",null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Review; review-article"],["R0026544","Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells.","Wang H","2005","Diabetologia","preclinical","article","10.1007/s00125-005-1692-8","15756539",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026545","Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens.","Best JH","2012","The American journal of managed care","nonrandomized_study","article",null,"23039898",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Comparative Study; Journal Article; article"],["R0026546","Expression and purification of optimized rolGLP-1, a novel GLP-1 analog, in Escherichia coli BL21(DE3) and its good glucoregulatory effect on type 2 diabetic mice.","Ma B","2013","Current pharmaceutical biotechnology","preclinical","article","10.2174/1389201014666131226155553","24372241",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026547","Safety and tolerability of new-generation anti-obesity medications: a narrative review.","Patel DK","2018","Postgraduate medicine","narrative_review","article","10.1080/00325481.2018.1435129","29388462","PMC6261426",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; review"],["R0026548","Regional differences in type 2 diabetes treatment and outcomes in Germany-An analysis of the German DPV and DIVE registries.","Hartmann B","2018","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.3049","30051605",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026549","The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.","Roy D","2014","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12294","24666399",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026550","Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes.","Matsumoto S","2013","Journal of clinical biochemistry and nutrition","other","article","10.3164/jcbn.13-14","23874074","PMC3705157",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026551","Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants.","Soe K","2015","Evidence-based medicine","randomized_trial","article","10.1136/ebmed-2015-110273","26385492",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0026552","Elevated blood pressure, heart rate and body temperature in mice lacking the XLαs protein of the Gnas locus is due to increased sympathetic tone.","Nunn N","2013","Experimental physiology","preclinical","article","10.1113/expphysiol.2013.073064","23748904","PMC4223506",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026553","Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.","Pathak V","2015","Diabetologia","preclinical","article","10.1007/s00125-015-3653-1","26048235",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026554","Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.","Aviles-Olmos I","2014","Journal of Parkinson's disease","randomized_trial","article","10.3233/jpd-140364","24662192",null,null,"S000204","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026555","[Natriuretic effect of exenatide: high efficacy and site of action].","Kutina AV","2012","Eksperimental'naia i klinicheskaia farmakologiia","preclinical","article",null,"22550855",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026556","Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.","Okamoto A","2016","Drugs in R&D","other","article","10.1007/s40268-016-0137-9","27333994","PMC5045829",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026557","Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.","Blonde L","2017","Diabetes, obesity & metabolism","other","article","10.1111/dom.12815","27767249","PMC5299604",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026558","The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.","Davenport C","2015","European journal of endocrinology","randomized_trial","article","10.1530/eje-14-1137","26036811",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026559","Amplification of exocytosis by Ca2+-induced Ca2+ release in INS-1 pancreatic beta cells.","Kang G","2003","The Journal of physiology","preclinical","article","10.1113/jphysiol.2002.029959","12509487","PMC2342456",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0026560","Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.","Kiiskinen U","2013","ClinicoEconomics and outcomes research : CEOR","nonrandomized_study","article","10.2147/ceor.s44060","23874113","PMC3713896",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026561","Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.","Ji C","2016","Reviews in the neurosciences","narrative_review","article","10.1515/revneuro-2015-0021","26351802",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0026562","Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.","Chen T","2013","Journal of pharmaceutical sciences","preclinical","article","10.1002/jps.23682","23897494","PMC3808969",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026563","Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.","Rosenstock J","2012","Diabetes care","other","article","10.2337/dc11-1434","22432107","PMC3329851","ClinicalTrials.gov:NCT00765817","S000345","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; brief-report; article"],["R0026564","Desvenlafaxine-associated hyperglycemia: A case report and literature review.","Mekonnen AD","2020","The mental health clinician","case_report","article","10.9740/mhc.2020.05.085","32420005","PMC7213951",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0026565","Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes.","Marx N","2010","Cellular and molecular life sciences : CMLS","other","article","10.1007/s00018-010-0396-5","20495843","PMC11115661",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0026566","Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake.","Navarro M","1996","Journal of neurochemistry","preclinical","article","10.1046/j.1471-4159.1996.67051982.x","8863504",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026567","Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals.","Vickers SP","2012","Clinical laboratory","preclinical","article","10.7754/clin.lab.2011.110919","22997980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026568","Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.","Levin PA","2012","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep11097.or","21742605",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0026569","Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies.","Abdul-Ghani T","2022","Diabetes, obesity & metabolism","other","article","10.1111/dom.14767","35581905",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0026570","GLP-1 and type 2 diabetes: physiology and new clinical advances.","Combettes MM","2006","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2006.08.003","16987706",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026571","First-in-class positron emission tomography tracer for the glucagon receptor.","Velikyan I","2019","EJNMMI research","preclinical","article","10.1186/s13550-019-0482-0","30771019","PMC6377692",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0026572","Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.","Simioni N","2018","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-018-1124-0","29527621","PMC5959971",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; research-article; article"],["R0026573","Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.","Torekov SS","2011","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/j.1467-789x.2011.00860.x","21401851",null,null,"S001692","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0026574","Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.","Wenten M","2012","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/j.1464-5491.2012.03652.x","22416857","PMC3505380",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026575","Production of pancreatic beta-cells from stem cells.","Noguchi H","2010","Current diabetes reviews","preclinical","article","10.2174/157339910791162934","20380628",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026576","The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.","Madsbad S","2014","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12119","23617798",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026577","Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.","Steen Carlsson K","2014","Journal of medical economics","nonrandomized_study","article","10.3111/13696998.2014.933110","24950434",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026578","[Drug treatment of type 2 diabetes].","Tielmans A","2007","Presse medicale (Paris, France : 1983)","narrative_review","article","10.1016/j.lpm.2006.10.017","17258675",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0026579","GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats.","Habegger KM","2013","Diabetes","preclinical","article","10.2337/db13-0117","23775764","PMC3749327",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026580","Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.","Derosa G","2013","Pharmacotherapy","randomized_trial","article","10.1002/phar.1301","23744726",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026581","Exenatide alters absorption of hydrocortisone in a diabetic patient with panhypopituitarism: iatrogenic adrenal insufficiency.","Fujita Y","2013","Diabetes care","case_report","article","10.2337/dc12-1499","23264309","PMC3526216",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0026582","Chemoenzymatic Synthesis of Linear- and Head-to-Tail Cyclic Peptides Using Omniligase-1.","Schmidt M","2019","Methods in molecular biology (Clifton, N.J.)","other","article","10.1007/978-1-4939-9546-2_4","31161503",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026583","Letter to the Editor: Liraglutide-Induced Increase in Bone Formation Can Be Dependent on Osteocalcin.","Kizilgul M","2015","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2015-2563","26339737",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comment; Letter; letter"],["R0026584","Interventions in type 2 diabetes mellitus and cardiovascular mortality-An overview of clinical trials.","Burggraaf B","2017","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2017.04.017","28554780",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026585","Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes.","Ariel D","2014","Nutrition, metabolism, and cardiovascular diseases : NMCD","other","article","10.1016/j.numecd.2014.06.010","25280957",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026586","Exenatide as a novel weight loss modality in patients without diabetes.","Moreno JL","2012","The Annals of pharmacotherapy","randomized_trial","article","10.1345/aph.1r372","23191935",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0026587","What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?","Covino J","2018","JAAPA : official journal of the American Academy of Physician Assistants","other","article","10.1097/01.jaa.0000530303.23280.6c","29470367",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026588","Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor","Huang Y","2011","University of Leicester","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0026589","Title: Is bariatric surgery an option for obesity in autism spectrum disorder?: A case report","Erbasan Z","2023","European psychiatry : the journal of the Association of European Psychiatrists","case_report","article","10.1192/j.eurpsy.2023.634",null,"PMC10405684",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0026590","Alterations in energy balance following exenatide administration.","Bradley DP","2012","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme","other_trial","article","10.1139/h2012-068","22735035","PMC3623676","ClinicalTrials.gov:NCT00623545","S002047; S002367","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0026591","Incretin hormones as immunomodulators of atherosclerosis.","Alonso N","2012","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2012.00112","22973260","PMC3435665",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026592","Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.","Shao N","2018","Andrologia","nonrandomized_study","article","10.1111/and.13039","29740874",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Comparative Study; Journal Article; Multicenter Study; Observational Study; article"],["R0026593","Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.","Tao X","2015","International journal of clinical and experimental pathology","preclinical","article",null,"26339397","PMC4555725",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026594","[Type 2 diabetic patient with reduced beta-cell function. New substance class: incretin-mimetics].",null,"2005","MMW Fortschritte der Medizin","other","article",null,"16128203",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026595","The importance of beta-cell management in type 2 diabetes.","Standl E","2007","International journal of clinical practice. Supplement","narrative_review","article","10.1111/j.1742-1241.2007.01360.x","17594389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026596","Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.","Bird GH","2010","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.1002713107","20660316","PMC2922607",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026597","Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system.","Wang P","2018","Colloids and surfaces. B, Biointerfaces","preclinical","article","10.1016/j.colsurfb.2018.04.063","30015142",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026598","After EMPA-REG OUTCOME and LEADER: Already a \"New Era\" in Therapy of Type 2 Diabetes?","Schatz H","2016","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","commentary","article","10.1055/s-0042-111316","27701709",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0026599","High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.","Montrose-Rafizadeh C","1997","The Journal of biological chemistry","preclinical","article","10.1074/jbc.272.34.21201","9261127",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026600","Expressed Protein Ligation without Intein.","Qiao Y","2020","Journal of the American Chemical Society","other","article","10.1021/jacs.0c00252","32212692","PMC7249697",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Preprint; research-article; preprint; article"],["R0026601","Liraglutide protects Rin-m5f β cells by reducing procoagulant tissue factor activity and apoptosis prompted by microparticles under conditions mimicking Instant Blood-Mediated Inflammatory Reaction.","Gleizes C","2014","Transplant international : official journal of the European Society for Organ Transplantation","preclinical","article","10.1111/tri.12286","24612163",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026602","Liraglutide subcutaneous injection for weight loss: where does it fit?","Pahlajani S","2015","International journal of clinical practice","nonrandomized_study","article","10.1111/ijcp.12692","26119845",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Editorial; article"],["R0026603","[What can be expected from the GLP-1 agonists and DPP-4 inhibitors in the treatment of type 2 diabetes?].","Egli M","2007","Revue medicale suisse","narrative_review","article",null,"17639666",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026604","Third-line Drugs for Type 2 Diabetes — Project Protocol",null,"2017","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","protocol","article",null,"30234937",null,null,null,"europepmc","TRUE","free_to_read","5",null,"Review"],["R0026605","Exendin peptides.","Eng J","1992","The Mount Sinai journal of medicine, New York","preclinical","article",null,"1574068",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0026606","Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats.","Guo Z","2014","Diabetology & metabolic syndrome","preclinical","article","10.1186/1758-5996-6-29","24576329","PMC3942060",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026607","Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.","Fonseca VA","2014","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2014.01.009","24561125","PMC4231710","ClinicalTrials.gov:NCT00294723; ClinicalTrials.gov:NCT00318422; ClinicalTrials.gov:NCT00318461; ClinicalTrials.gov:NCT00331851; ClinicalTrials.gov:NCT00333151; ClinicalTrials.gov:NCT00518882","S001094; S001502; S001584; S002098; S002222; S002230","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026608","G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.","Zoso A","2016","PloS one","nonrandomized_study","article","10.1371/journal.pone.0157245","27285580","PMC4902232",null,"S002320","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0026609","Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice.","Ye X","2015","Endocrine","preclinical","article","10.1007/s12020-014-0503-8","25557015",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026610","Exenatide and the treatment of patients with Parkinson's disease.","Aviles-Olmos I","2013","The Journal of clinical investigation","randomized_trial","article","10.1172/jci68295","23728174","PMC3668846","ClinicalTrials.gov:NCT01174810","S000116; S000204; S002297","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026611","Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.","Uçkaya G","2005","The Journal of endocrinology","preclinical","article","10.1677/joe.1.05818","15749809",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026612","Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States.","Loughlin AM","2018","Diabetes spectrum : a publication of the American Diabetes Association","nonrandomized_study","article","10.2337/ds16-0081","29773932","PMC5951230",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026613","Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus.","Lu CH","2013","Journal of the Formosan Medical Association = Taiwan yi zhi","randomized_trial","article","10.1016/j.jfma.2012.02.027","23473527",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026614","Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.","Goring S","2014","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12239","24237939",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0026615","American Diabetes Association - 67th Scientific Sessions: pros and cons of GLP-1 agonists and DPP-IV inhibitors.","Toft AD","2007","IDrugs : the investigational drugs journal","other","article",null,"17786839",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Conference Proceedings; article"],["R0026616","The safety of pharmacologic treatment for pediatric obesity.","Chao AM","2018","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2018.1437143","29411652",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026617","Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges.","Murage EN","2010","Journal of medicinal chemistry","other","article","10.1021/jm100602m","20687610",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026618","Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet.","Sukumaran V","2020","Cardiovascular diabetology","preclinical","article","10.1186/s12933-020-01000-z","32093680","PMC7038553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026619","Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes.","Nagai Y","2014","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.12247","24320758",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0026620","Targeting prandial hyperglycemia: how important is it and how best to do this?","Monnier L","2008","Current diabetes reports","other","article","10.1007/s11892-008-0064-4","18778585",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026621","Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series.","Pinelli NR","2013","Diabetes care","case_report","article","10.2337/dc13-1066","24065848","PMC3781489",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0026622","Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study.","Shin J","2012","Diabetes & metabolism journal","nonrandomized_study","article","10.4093/dmj.2012.36.5.364","23130321","PMC3486983",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026623","Expression of pancreatic endocrine markers by mesenchymal stem cells from human umbilical cord vein.","Santos TM","2010","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2010.01.032","20304193",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026624","Structural study of an active analog of EX-4 in solution and micelle associated states.","Wang S","2011","Biopolymers","nonrandomized_study","article","10.1002/bip.21566","21072854",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026625","Pharmacotherapy for obesity in individuals with type 2 diabetes.","Chukir T","2018","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2018.1428558","29376439",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026626","Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus.","Singh S","2013","Current cardiology reports","narrative_review","article","10.1007/s11886-012-0327-1","23250663",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026627","Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach.","Soudry-Kochavi L","2015","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2015.09.012","26381898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026628","Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea.","Seino S","2012","Diabetologia","narrative_review","article","10.1007/s00125-012-2562-9","22555472",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0026629","Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action.","Day JW","2011","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.1317","21308878",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026630","Advances in Clinical Cardiology 2016: A Summary of the Key Clinical Trials.","Gray A","2017","Advances in therapy","narrative_review","article","10.1007/s12325-017-0560-5","28537000","PMC5504210",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026631","Safety concerns over the use of intestinal permeation enhancers: A mini-review.","McCartney F","2016","Tissue barriers","narrative_review","article","10.1080/21688370.2016.1176822","27358756","PMC4910835",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0026632","Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.","Howland RH","2015","Journal of psychosocial nursing and mental health services","narrative_review","article","10.3928/02793695-20150526-02","26091546",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026633","Analysis of 16 studies in nine rodent models does not support the hypothesis that diabetic polyuria is a main reason of urinary bladder enlargement.","Yesilyurt ZE","2022","Frontiers in physiology","preclinical","article","10.3389/fphys.2022.923555","36003651","PMC9393211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026634","Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.","Schnell O","2016","Cardiovascular diabetology","other_trial","article","10.1186/s12933-016-0357-x","26892706","PMC4758171",null,null,"pubmed; europepmc","TRUE","open_europepmc","5",null,"Conference Proceedings; brief-report"],["R0026635","Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery.","Briere DA","2018","Diabetes","preclinical","article","10.2337/db17-0607","29203510",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0026636","Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.","Carrington MJ","2014","Internal medicine journal","nonrandomized_study","article","10.1111/imj.12377","24877253",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026637","Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study.","Buysman EK","2015","Advances in therapy","nonrandomized_study","article","10.1007/s12325-015-0199-z","25832470","PMC4415988",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026638","GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice.","Tomas E","2015","Diabetes","preclinical","article","10.2337/db14-1708","25858562","PMC4477344",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0026639","Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus.","Marino AB","2014","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","other","article","10.2146/ajhp130301","24429016",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026640","Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial.","Bashier AM","2015","Journal of diabetes and metabolic disorders","other_trial","article","10.1186/s40200-015-0178-6","26064864","PMC4461924",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0026641","The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.","Li X","2015","Pharmaceutical research","preclinical","article","10.1007/s11095-014-1513-1","25270570",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026642","[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.","Leinung MC","2012","Regulatory peptides","preclinical","article","10.1016/j.regpep.2012.08.006","22960403",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026643","Managing diabetes and liver disease association.","Hamed AE","2018","Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology","narrative_review","article","10.1016/j.ajg.2018.08.003","30420265",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026644","Cost-Effectiveness of Exenatide Twice Daily (Bid) Added To Basal Insulin Compared To A Bolus Insulin Add-On In Turkey.","Malhan S","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.722","27200672",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026645","The permissive effects of glucose on receptor-operated potentiation of insulin secretion from mouse islets: a role for ERK1/2 activation and cytoskeletal remodelling.","Bowe JE","2013","Diabetologia","preclinical","article","10.1007/s00125-012-2828-2","23344729",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026646","Glucagon-Like Peptide-1 Strengthens the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells Under Basal and Hyperglycemia Conditions.","Fukuda S","2016","Journal of molecular neuroscience : MN","preclinical","article","10.1007/s12031-015-0696-1","26659380",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026647","Liraglutide improves weight loss in people who are overweight or obese, study shows.","Mayor S","2015","BMJ (Clinical research ed.)","randomized_trial","article","10.1136/bmj.h3545","26138725",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","News; Comment; article"],["R0026648","Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.","Li CJ","2014","Cardiovascular diabetology","nonrandomized_study","article","10.1186/1475-2840-13-36","24498905","PMC3923001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0026649","Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review.","Koshal P","2018","Neuropharmacology","narrative_review","article","10.1016/j.neuropharm.2017.11.015","29129776",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026650","Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats.","Feng WH","2013","Folia biologica","preclinical","article","10.14712/fb2013059060217","24485303",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026651","Effects of VIP and related peptides on airway mucus secretion from isolated rat trachea.","Wagner U","1998","Peptides","preclinical","article","10.1016/s0196-9781(97)00257-x","9493855",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026652","The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.","Harder H","2004","Diabetes care","randomized_trial","article","10.2337/diacare.27.8.1915","15277417",null,null,"S000306; S002367","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026653","Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.","Son JW","2020","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2020.0258","33389955","PMC7801751",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026654","Establishment of mouse pancreatic stem cell line.","Noguchi H","2009","Cell transplantation","preclinical","article","10.1177/096368970901805-612","19775518",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026655","Treatment persistence in the use of basal insulins in Poland and Germany
.","Rathmann W","2017","International journal of clinical pharmacology and therapeutics","nonrandomized_study","article","10.5414/cp202772","27879196",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Multicenter Study; article"],["R0026656","Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.","Polderman JA","2014","BMC anesthesiology","protocol","article","10.1186/1471-2253-14-91","25419179","PMC4240889","ClinicalTrials.gov:NCT02036372","S002378","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026657","Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.","Matfin G","2015","Journal of diabetes science and technology","other_trial","article","10.1177/1932296815583059","25901022","PMC4667342",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0026658","Birth and death of human β-cells in pancreases from cadaver donors, autopsies, surgical specimens, and islets transplanted into mice.","Caballero F","2014","Cell transplantation","preclinical","article","10.3727/096368912x659916","23321263","PMC3947859",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026659","The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts.","Pal S","2019","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2019.03.024","30885766","PMC7234838",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026660","Effects of weight stigma on BMI and inflammatory markers among people living with obesity.","Nicolau J","2023","Physiology & behavior","other","article","10.1016/j.physbeh.2023.114088","36657653",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026661","Bench to bedside in appetite research: Lost in translation?","Rodgers RJ","2017","Neuroscience and biobehavioral reviews","narrative_review","article","10.1016/j.neubiorev.2016.08.026","27570154",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026662","Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.","Odegard PS","2006","The Diabetes educator","other","article","10.1177/0145721706294003","16971704",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026663","Reply.","Weng J","2019","Hepatology (Baltimore, Md.)","other_trial","article","10.1002/hep.30553","30729549",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; letter"],["R0026664","Multilayer nanoparticles for sustained delivery of exenatide to treat type 2 diabetes mellitus.","Kim JY","2013","Biomaterials","preclinical","article","10.1016/j.biomaterials.2013.07.040","23895999",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026665","Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome.","Li ZY","2017","Clinics and research in hepatology and gastroenterology","other","article","10.1016/j.clinre.2016.12.007","28215540",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026666","Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice.","O'Harte FPM","2018","PloS one","preclinical","article","10.1371/journal.pone.0202350","30157220","PMC6114795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026667","Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.","Li XG","2012","Acta pharmacologica Sinica","preclinical","article","10.1038/aps.2012.33","22659626","PMC4011360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026668","Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.","Trevaskis JL","2013","PloS one","preclinical","article","10.1371/journal.pone.0078154","24167604","PMC3805588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026669","Determining predictors of response to exenatide in type 2 diabetes.","Anderson SL","2012","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1331/japha.2012.10217","22825226",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0026670","Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.","Thong KY","2011","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2011.05.015","21636161",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0026671","A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on \"Translational and Neuroscience Studies in Affective Disorders\". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.","Pozzi M","2019","Journal of affective disorders","systematic_review","article","10.1016/j.jad.2019.05.044","31153593",null,null,"S000532","pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review"],["R0026672","Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.","Derosa G","2012","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2012.03699.x","22540883",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0026673","Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.","Fujioka K","2015","Journal of diabetes science and technology","other_trial","article","10.1177/1932296815593295","26183599","PMC4738203",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026674","Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.","Langer J","2013","Journal of managed care pharmacy : JMCP","randomized_trial","article","10.18553/jmcp.2013.19.3.237","23537458","PMC10438006","ClinicalTrials.gov:NCT00700817","S002361","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026675","In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells.","Gao F","2008","Translational research : the journal of laboratory and clinical medicine","preclinical","article","10.1016/j.trsl.2008.03.003","18514140",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026676","Glucagon-like peptide 1 and appetite.","Dailey MJ","2013","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2012.11.008","23332584","PMC3594872",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0026677","Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.","Kim SH","2014","Diabetologia","randomized_trial","article","10.1007/s00125-013-3134-3","24326527","PMC5072364","ClinicalTrials.gov:NCT01784965","S000139","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026678","Characterization of the insulinostatic effect of urotensin II: a study in the perfused rat pancreas.","Silvestre RA","2009","Regulatory peptides","preclinical","article","10.1016/j.regpep.2008.11.008","19101596",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026679","Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients.","Palanisamy S","2018","Pharmacy (Basel, Switzerland)","systematic_review","article","10.3390/pharmacy6030057","29954090","PMC6164486",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0026680","A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.","Violante R","2012","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2012.03624.x","22375612",null,"ClinicalTrials.gov:NCT00870194","S000514","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026681","Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments.","Powell WR","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","systematic_review","article","10.1007/s13300-018-0443-z","29808360","PMC6064594",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0026682","[The effect of exenatide analogs on hydruretic function of rat kidney under water load].","Bogolepova AE","2012","Eksperimental'naia i klinicheskaia farmakologiia","preclinical","article",null,"23323326",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026683","Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies.","Finkelstein EA","2019","Clinical obesity","systematic_review","article","10.1111/cob.12294","30677252",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; article"],["R0026684","Postprandial Reactive Hypoglycemia.","Altuntaş Y","2019","Sisli Etfal Hastanesi tip bulteni","narrative_review","article","10.14744/semb.2019.59455","32377086","PMC7192270",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026685","Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.","Agersø H","2003","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","other_trial","article","10.1016/s0928-0987(03)00073-3","12791417",null,null,"S000647","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.; article"],["R0026686","Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients.","Ten Kulve JS","2016","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2015-3291","26672638",null,null,"S000930","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0026687","[Liraglutide for weight loss in overweight and obese adults].","Al-Khalil O","2015","Praxis","commentary","article","10.1024/1661-8157/a002141","26422076",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0026688","Glucagon-like peptide-1-(7-36)amide increases pulmonary surfactant secretion through a cyclic adenosine 3',5'-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes.","Benito E","1998","Endocrinology","preclinical","article","10.1210/endo.139.5.5998","9564846",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026689","Effect of exenatide on gastric emptying and graft survival in islet allograft recipients.","Peixoto EM","2011","Transplantation proceedings","other","article","10.1016/j.transproceed.2011.10.022","22099764","PMC3262406",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026690","Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.","Sarayani A","2023","Annals of internal medicine","nonrandomized_study","article","10.7326/m22-1743","36940443",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0026691","The role of beta-cell dysfunction in the cardiometabolic syndrome.","Lastra G","2006","Journal of the cardiometabolic syndrome","narrative_review","article","10.1111/j.0197-3118.2006.05458.x","17675900",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026692","Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.","Kuhadiya ND","2016","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2016-1451","27490915",null,"ClinicalTrials.gov:NCT02518945","S000160","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; article"],["R0026693","Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.","Ahmad NN","2021","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.13326","34423889","PMC9285776",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review-article; review"],["R0026694","Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances.","Gallwitz B","2016","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000217","26702848",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026695","Decreased circulating BMP-9 levels in patients with Type 2 diabetes is a signature of insulin resistance.","Luo Y","2017","Clinical science (London, England : 1979)","other_trial","article","10.1042/cs20160543","27940998",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0026696","Changes in patient characteristics, glucose lowering treatment, glycemic control and complications in type 2 diabetes in general practices (Disease Analyzer, Germany: 2008-2016).","Rathmann W","2018","Postgraduate medicine","nonrandomized_study","article","10.1080/00325481.2018.1421842","29291638",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0026697","Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson's disease.","Li L","2016","Neural regeneration research","preclinical","article","10.4103/1673-5374.177742","27073388","PMC4810999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026698","United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes.","Rendell M","2017","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s132581","28458515","PMC5402881",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026699","Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.","Rathmann W","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12894","28127851",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026700","Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.","Dave CV","2019","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.13531","30207042","PMC6329650",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026701","Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine.","Manu P","2022","American journal of therapeutics","other","article","10.1097/mjt.0000000000001524","35687055",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026702","GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice.","Décarie-Spain L","2019","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2019.03.035","30946847",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026703","Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.","Kothare PA","2012","BMC clinical pharmacology","randomized_trial","article","10.1186/1472-6904-12-8","22429273","PMC3378442","ClinicalTrials.gov:NCT00254800","S000296","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026704","[Type 2 diabetes and impaired glucose tolerance].","Furukawa N","2013","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"23631205",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026705","Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.","Lean ME","2014","International journal of obesity (2005)","randomized_trial","article","10.1038/ijo.2013.149","23942319","PMC4010971","ClinicalTrials.gov:NCT00422058","S001402","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0026706","Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.","Derosa G","2013","Canadian journal of physiology and pharmacology","randomized_trial","article","10.1139/cjpp-2012-0300","23984793",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0026707","Exenatide in acute ischemic stroke.","Daly SC","2013","International journal of stroke : official journal of the International Stroke Society","other_trial","article","10.1111/ijs.12073","24024920",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Letter; article"],["R0026708","Decreased complexity of glucose dynamics in diabetes in rhesus monkeys.","Raubertas R","2019","Scientific reports","preclinical","article","10.1038/s41598-018-36776-4","30723274","PMC6363759",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026709","Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast.","Weston C","2014","British journal of pharmacology","other","article","10.1111/bph.12716","24712679","PMC4128063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026710","[Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].","Olšovský J","2016","Vnitrni lekarstvi","other_trial","article",null,"27627086",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0026711","Pharmacological treatment of non-responders following bariatric surgery.","Vinciguerra F","2024","Minerva endocrinology","randomized_trial","article","10.23736/s2724-6507.21.03311-3","33792233",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0026712","Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.","de Luis DA","2015","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2015.02.010","25825013",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Controlled Clinical Trial; Journal Article; article"],["R0026713","Acute tubulointerstitial nephritis following treatment with exenatide.","Nandakoban H","2013","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/j.1464-5491.2012.03738.x","22762797",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026714","Controlled release of liraglutide using thermogelling polymers in treatment of diabetes.","Chen Y","2016","Scientific reports","preclinical","article","10.1038/srep31593","27531588","PMC4987673",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026715","Anti-obesity drug therapy in clinical practice: Evidence of a poor prescriptive attitude.","Squadrito F","2020","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","nonrandomized_study","article","10.1016/j.biopha.2020.110320","32502842",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; article"],["R0026716","Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson's Disease Mouse Model.","Zhang Z","2022","Frontiers in neuroscience","preclinical","article","10.3389/fnins.2022.814430","35368248","PMC8964967",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026717","GLP-1-induced AMPK activation inhibits PARP-1 and promotes LXR-mediated ABCA1 expression to protect pancreatic β-cells against cholesterol-induced toxicity through cholesterol efflux","Li R","2020","Research Square","preclinical","preprint","10.21203/rs.3.rs-15784/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0026718","Treating with liraglutide an obese patient with type 2 diabetes mellitus and hereditary hemochromatosis.","Tassone F","2015","Minerva endocrinologica","case_report","article",null,"25801016",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0026719","Exenatide and feeding: possible peripheral neuronal pathways.","Hunt JV","2012","Peptides","preclinical","article","10.1016/j.peptides.2011.12.009","22222610",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026720","[Management of type 2 diabetes mellitus in adolescents and young adults in primary care].","Miravet-Jiménez S","2020","Semergen","narrative_review","article","10.1016/j.semerg.2019.11.008","32094051",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026721","Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.","Staiger H","2015","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2015.12.363","27111121","PMC5275760",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026722","Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line.","Beak SA","1998","The Journal of clinical investigation","preclinical","article","10.1172/jci610","9502775","PMC508688",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026723","Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.","Turner LW","2014","Diabetes care","other","article","10.2337/dc13-2097","24198301","PMC4178325",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0026724","Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin.","Hirsch IB","2011","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep11014.or","21856602",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026725","Design of enzyme-responsive short-chain fatty acid-based self-assembling drug for alleviation of type 2 diabetes mellitus.","Shashni B","2021","Biomaterials","preclinical","article","10.1016/j.biomaterials.2021.120877","34062420",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026726","GLP-1 agonists in type 1 diabetes.","Pettus J","2013","Clinical immunology (Orlando, Fla.)","preclinical","article","10.1016/j.clim.2013.04.006","23643354",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026727","Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia.","Ionut V","2014","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00244.2014","25117408","PMC4200304",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0026728","Effects of Oral and Non-Insulin Injectable Antidiabetic Treatment in Hypertension: A Systematic Review.","Katsi V","2017","Current pharmaceutical design","systematic_review","article","10.2174/1381612823666170519144841","28741456",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0026729","[Basal insulin and liraglutide combined in a pen].","Rausch R","2015","Medizinische Monatsschrift fur Pharmazeuten","other","article",null,"26364391",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026730","Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.","Bush MA","2009","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2008.00992.x","19187286",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026731","Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.","Nauck M","2013","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12012","22985213",null,null,"S001502; S002604","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026732","Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.","Papamargaritis D","2020","BMJ open","protocol","article","10.1136/bmjopen-2019-034137","32060156","PMC7044994","ClinicalTrials.gov:NCT03036800; EudraCT:2017-002998-20","S001687","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't; protocol; article"],["R0026733","Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.","Sharma A","2022","Diabetes care","other_trial","article","10.2337/dc20-2806","34716214","PMC9004312","ClinicalTrials.gov:NCT00790205",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0026734","Eosinophil-rich granulomatous panniculitis caused by exenatide injection.","Boysen NC","2014","Journal of cutaneous pathology","case_report","article","10.1111/cup.12246","24224897",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0026735","Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain.","Sánchez-Covisa J","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.723","27200673",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026736","Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.","Kim SH","2013","Diabetes care","randomized_trial","article","10.2337/dc13-0354","23835684","PMC3781545","ClinicalTrials.gov:NCT01784965","S000139; S000767","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026737","The role and therapeutic potential of GLP-1 analogues as a treatment for type 2 diabetes","Lavery KS","2006","Ulster University","other","article",null,null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Dissertation; dissertation"],["R0026738","Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.","Thorens B","1993","Diabetes","preclinical","article","10.2337/diab.42.11.1678","8405712",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026739","Do incretins improve endothelial function?","Oyama J","2014","Cardiovascular diabetology","narrative_review","article","10.1186/1475-2840-13-21","24428883","PMC3898564",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026740","Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide-analog administration to intensive insulin therapy.","Ogawa S","2015","Journal of diabetes investigation","other","article","10.1111/jdi.12314","26221522","PMC4511303",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026741","Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis.","Cai X","2016","Expert opinion on pharmacotherapy","systematic_review","article","10.1080/14656566.2016.1202921","27322963",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article; review"],["R0026742","Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).","Schernthaner G","2017","Therapeutics and clinical risk management","other_trial","article","10.2147/tcrm.s144362","29276388","PMC5733371",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0026743","GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia.","Nuche-Berenguer B","2011","The Journal of endocrinology","preclinical","article","10.1530/joe-11-0015","21372151",null,null,"S001459","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026744","[Effects of incretin on cardiovascular disease and risk factors].","Kodama K","2011","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"21595268",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0026745","Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220.","Chepurny OG","2002","Endocrinology","preclinical","article","10.1210/endo.143.6.8870","12021195","PMC3500996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0026746","Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.","Matthews JE","2008","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2008-1518","18812476",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026747","Antidiabetic agents: past, present and future.","Mehanna A","2013","Future medicinal chemistry","narrative_review","article","10.4155/fmc.13.13","23495689",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Historical Article; Journal Article; Review; article"],["R0026748","Letter to the Editor: Comment on \"The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial\" by Kramer C.K., et al.","Kalra S","2015","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2015-3494","26544663",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; letter"],["R0026749","Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation.","Brayden DJ","2021","Expert opinion on drug delivery","other_trial","article","10.1080/17425247.2021.1942838","34128734",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026750","Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials.","Macconell L","2012","Diabetes, metabolic syndrome and obesity : targets and therapy","randomized_trial","article","10.2147/dmso.s28387","22375098","PMC3287409",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0026751","New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications.","Garvey WT","2022","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/clinem/dgab848","34865050","PMC8947217",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; review-article; article"],["R0026752","Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.","Berg JK","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2011.01428.x","21615670","PMC3258427",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0026753","Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study.","Rizvi AA","2015","Expert opinion on biological therapy","other_trial","article","10.1517/14712598.2015.1067299","26195184",null,"ClinicalTrials.gov:NCT01715428","S001748","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0026754","Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.","Tang A","2015","Diabetes care","randomized_trial","article","10.2337/dc14-2548","25813773",null,"ClinicalTrials.gov:NCT01399645","S002282","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026755","A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.","Nuijten M","2018","Journal of medical economics","other","article","10.1080/13696998.2018.1468334","29678127",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026756","New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease.","Musso G","2017","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","narrative_review","article","10.1016/j.cgh.2016.08.002","27521506",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026757","Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.","Khera R","2016","JAMA","systematic_review","article","10.1001/jama.2016.7602","27299618","PMC5617638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, N.I.H., Extramural; Systematic Review; Network Meta-Analysis; research-article; article"],["R0026758","Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass.","Tharakan G","2017","European journal of endocrinology","nonrandomized_study","article","10.1530/eje-17-0446","28855269","PMC5642268",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026759","The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats.","Gilor C","2011","Domestic animal endocrinology","randomized_trial","article","10.1016/j.domaniend.2011.03.001","21645806",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026760","Regression of diabetic macular edema after subcutaneous exenatide.","Sarao V","2014","Acta diabetologica","case_report","article","10.1007/s00592-013-0506-6","23925692",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0026761","Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.","Yamagishi S","2011","Current pharmaceutical design","narrative_review","article","10.2174/138161211798999456","22204436",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026762","Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.","Vlasakakis G","2015","Advances in therapy","nonrandomized_study","article","10.1007/s12325-015-0222-4","26160357",null,"ClinicalTrials.gov:NCT01857895","S000725","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026763","Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.","Murphy CE","2012","The Annals of pharmacotherapy","randomized_trial","article","10.1345/aph.1q722","22669803",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0026764","Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation.","Kesavadev J","2017","Advances in therapy","nonrandomized_study","article","10.1007/s12325-017-0576-x","28667580",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0026765","Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb.","Liang Y","2011","The journal of gene medicine","preclinical","article","10.1002/jgm.1598","21786368",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026766","Comment on Sarkar et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes care 2014;37:666-670.","Chaudhuri A","2014","Diabetes care","commentary","article","10.2337/dc14-1052","25249680",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0026767","Possible role of GLP-1 in antidepressant effects of metformin and exercise in CUMS mice.","Liu W","2019","Journal of affective disorders","preclinical","article","10.1016/j.jad.2018.12.112","30599373",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026768","18F-Labeled exendin(9-39)","Chopra A","2004","National Center for Biotechnology Information (US), Bethesda (MD)","nonrandomized_study","article",null,"22624171",null,null,null,"europepmc","TRUE","free_to_read","4",null,"Review"],["R0026769","Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.","Pawaskar M","2012","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep11367.or","22982784",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026770","Are targeted therapies for diabetic cardiomyopathy on the horizon?","Tate M","2017","Clinical science (London, England : 1979)","narrative_review","article","10.1042/cs20160491","28473471",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026771","A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus.","Bai X","2016","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2016.01.036","26895657",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026772","Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.","Rashid N","2012","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2012.02.030","22464691",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026773","The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.","Ohki T","2012","TheScientificWorldJournal","nonrandomized_study","article","10.1100/2012/496453","22927782","PMC3425807",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; research-article; article"],["R0026774","Surgical Technique for Weight Regain after Roux-en-Y Gastric Bypass: Pouch-resizing and the MiniMIZER® Gastric Ring.","Nixdorf L","2022","Surgical technology international","other","article","10.52198/22.sti.41.gs1647","36413791",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026775","Estimating Effects Of Second Line Therapy For Type 2 Diabetes Mellitus: Retrospective Cohort Study","Gottlieb A","2017","bioRxiv","nonrandomized_study","preprint","10.1101/130724",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0026776","Anti-inflammatory properties of exenatide in human pancreatic islets.","Cechin SR","2012","Cell transplantation","preclinical","article","10.3727/096368911x576027","21669040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026777","Real-world primary nonadherence to antiobesity medications.","Kan H","2023","Journal of managed care & specialty pharmacy","nonrandomized_study","article","10.18553/jmcp.2023.23083","37594848","PMC10586463",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026778","[Problems of differential diagnosis of paraneoplastic hypoglycaemia].","Mokáň M","2014","Vnitrni lekarstvi","other","article",null,"25294761",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0026779","Transition of care in a case of obesity with metabolic surgery.","Stroh C","2021","Zeitschrift fur Gastroenterologie","case_report","article","10.1055/a-1348-2378","33684957",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026780","Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes.","Li R","2015","Acta diabetologica","randomized_trial","article","10.1007/s00592-015-0792-2","26249206",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026781","Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.","DeGeeter M","2016","Journal of pharmacy practice","narrative_review","article","10.1177/0897190014549837","25312263",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026782","Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.","Pawaskar M","2012","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2012.686901","22519390",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026783","Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.","Usui R","2013","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.12111","24843713","PMC4020254",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026784","MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis","Chhabra S","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.612",null,"PMC7208556",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0026785","Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal-supported oral therapy.","Takahara M","2012","Journal of diabetes investigation","nonrandomized_study","article","10.1111/j.2040-1124.2012.00223.x","24843616","PMC4015430",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026786","Discovery of dual-action membrane-anchored modulators of incretin receptors.","Fortin JP","2011","PloS one","other","article","10.1371/journal.pone.0024693","21935440","PMC3173463",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026787","MON-632 The Effects of a High Intensity Glycemic Program on Weight and BMI","Guzman H","2020","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaa046.948",null,"PMC7209128",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0026788","A comparison of clinical pharmacist management of type 2 diabetes versus usual care in a federally qualified health center.","Fink RM","2019","Pharmacy practice","nonrandomized_study","article","10.18549/pharmpract.2019.4.1618","31897259","PMC6935544",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026789","Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.","Alatrach M","2022","Diabetes care","other","article","10.2337/dc21-1798","35235659","PMC9531536","ClinicalTrials.gov:NCT03331289","S000023","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026790","Detection of adverse drug reactions among ordinary users of liraglutide on the occasion of drug dispensing in the community pharmacy setting.","Christensen ST","2013","Journal of patient safety","randomized_trial","article","10.1097/pts.0000000000000054","24257065",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0026791","[Cardioprotective effects of glucagon-like peptide-1: preclinical and clinical data].","Avogaro A","2011","Giornale italiano di cardiologia (2006)","narrative_review","article","10.1714/985.10686","22158423",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026792","Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance.","Dore DD","2012","Therapeutic advances in drug safety","nonrandomized_study","article","10.1177/2042098612446473","25083233","PMC4110848",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026793","Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.","Hermansen K","2013","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12133","23683069",null,"ClinicalTrials.gov:NCT00993304","S001702","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0026794","Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.","Li CJ","2012","Cardiovascular diabetology","randomized_trial","article","10.1186/1475-2840-11-142","23153177","PMC3533748",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026795","Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.","Klein DJ","2014","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2013.0366","25036533","PMC4183917","ClinicalTrials.gov:NCT00943501","S001356","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026796","Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.","Lapolla A","2015","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2014.11.015","25626486",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; article"],["R0026797","Combination of ELISA and dried blood spot technique for the quantification of large molecules using exenatide as a model.","Lin YQ","2011","Journal of pharmacological and toxicological methods","other","article","10.1016/j.vascn.2011.04.004","21515389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026798","Pharmacologic interventions for type 1 and type 2 diabetes.","Fain JA","2006","The Nursing clinics of North America","narrative_review","article","10.1016/j.cnur.2006.07.006","17059976",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026799","The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation.","Kahles F","2018","Molecular metabolism","preclinical","article","10.1016/j.molmet.2018.05.014","29884547","PMC6034034",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0026800","Pancreatitis: a potential complication of liraglutide?","Franks AS","2012","The Annals of pharmacotherapy","other_trial","article","10.1345/aph.1q789","23136352",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0026801","Review article: new treatments in non-alcoholic fatty liver disease.","Townsend SA","2017","Alimentary pharmacology & therapeutics","other_trial","article","10.1111/apt.14210","28677333",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0026802","Immunosuppressive drug-induced diabetes.","Penfornis A","2006","Diabetes & metabolism","randomized_trial","article","10.1016/s1262-3636(06)72809-9","17130815",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0026803","THE RATIONALE FOR USE OF INCRETINS IN THE MANAGEMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT).","Sadhu AR","2015","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.4158/ep14569.ra","25786557",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026804","The effect of exenatide and erythromycin on postprandial symptoms and their relation to gastric functions.","Yoon SB","2012","Digestion","other","article","10.1159/000335933","22354133",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026805","Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes.","Linnebjerg H","2011","International journal of clinical pharmacology and therapeutics","randomized_trial","article","10.5414/cp201361","21255526",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026806","Approach to patients with obesity and other cardiovascular risk factors in primary care using the Delphi methodology","Morillas-Blasco P","2022","Research Square","other","preprint","10.21203/rs.3.rs-1533869/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0026807","Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss.","Barja-Fernandez S","2014","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s53129","25489237","PMC4257050",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article; review"],["R0026808","Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.","Samsky MD","2021","Atherosclerosis","other_trial","article","10.1016/j.atherosclerosis.2021.10.011","34741929","PMC8702379",null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0026809","Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.","Chou HC","2014","Drug safety","nonrandomized_study","article","10.1007/s40264-014-0171-x","24859164",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, U.S. Gov't, P.H.S."],["R0026810","Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis.","Pennisi G","2022","Nutrition, metabolism, and cardiovascular diseases : NMCD","systematic_review","article","10.1016/j.numecd.2022.07.001","35970684",null,"PROSPERO:CRD42021287205",null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Network Meta-Analysis"],["R0026811","Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients.","Blaslov K","2014","Clinics and research in hepatology and gastroenterology","commentary","article","10.1016/j.clinre.2013.10.013","24315013",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0026812","A new long-acting GLP-1 derivative 6- KTP ameliorates body weight and lipid metabolism in DIO mice","Wang P","2019","bioRxiv","preclinical","preprint","10.1101/846717",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0026813","Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer's Disease Treatment.","Poor SR","2021","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph14090890","34577590","PMC8465337",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026814","Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.","García de Lucas MD","2015","Diabetes & metabolism","case_report","article","10.1016/j.diabet.2014.10.005","25455831",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0026815","Diabetes and bone health.","Antonopoulou M","2013","Maturitas","narrative_review","article","10.1016/j.maturitas.2013.04.004","23628280",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026816","Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.","Kimura T","2015","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2014.11.018","25463759",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026817","The Cost-Effectiveness of Exenatide Bid Versus Insulin Lispro Tid As Add-On Therapy to Titrated Insulin Glargine in Patients With Type 2 Diabetes - An Analysis From The Swedish Health Care Perspective.","Gordon J","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.693","27200645",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026818","Antihyperglycemic agents and cardiovascular outcomes: recent insights.","Bajaj HS","2017","Current opinion in cardiology","other_trial","article","10.1097/hco.0000000000000435","28678048",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0026819","Obesity drugs in clinical development.","Halford JC","2006","Current opinion in investigational drugs (London, England : 2000)","other_trial","article",null,"16625817",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0026820","[Pharmacogenetics of insulin secretagogue antidiabetics].","Winkler G","2011","Orvosi hetilap","narrative_review","article","10.1556/oh.2011.29175","21959939",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0026821","Glucagon-like peptide-1 activates the adenylyl cyclase system in rockfish enterocytes and brain membranes.","Mommsen TP","1998","Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","preclinical","article","10.1016/s0305-0491(98)10110-4","9972283",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S."],["R0026822","Structural stability-chromatographic retention relationship on exenatide diastereomer separation.","Tsai CW","2012","Analytical and bioanalytical chemistry","other","article","10.1007/s00216-012-6352-5","22945556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026823","Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.","Pariente A","2017","European journal of clinical pharmacology","nonrandomized_study","article","10.1007/s00228-017-2326-z","28866826",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0026824","Formulation strategies to improve the efficacy of intestinal permeation enhancers.","Maher S","2021","Advanced drug delivery reviews","preclinical","article","10.1016/j.addr.2021.113925","34418495",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review"],["R0026825","Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.","Pawaskar M","2012","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/j.1463-1326.2012.01581.x","22321776",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026826","Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier.","Zhao D","2018","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2018.00062","29556215","PMC5845420",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026827","Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.","Williams DL","2009","Endocrinology","preclinical","article","10.1210/en.2008-1045","19074583","PMC2659282",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0026828","Incremental effect of liraglutide on traditional insulin injections in rats with type 2 diabetes mellitus by maintaining glycolipid metabolism and cardiovascular function.","Huang Q","2019","Experimental and therapeutic medicine","preclinical","article","10.3892/etm.2019.7148","30783461","PMC6364179",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026829","Role of central glucagon-like peptide-1 in stress regulation.","Ghosal S","2013","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2013.04.003","23623992","PMC3778098",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review; research-article"],["R0026830","Changes in components, glycyrrhizin and glycyrrhetinic acid, in raw Glycyrrhiza uralensis Fisch, modify insulin sensitizing and insulinotropic actions.","Ko BS","2007","Bioscience, biotechnology, and biochemistry","preclinical","article","10.1271/bbb.60533","17587675",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026831","Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis.","Picha KM","2008","Diabetes","preclinical","article","10.2337/db07-1775","18426860","PMC2453616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026832","New sources of pancreatic beta-cells.","Bonner-Weir S","2005","Nature biotechnology","preclinical","article","10.1038/nbt1115","16003374",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review"],["R0026833","Erratum to: Efficacy of Liraglutide in a Real-Life Cohort.","Heymann A","2014","Diabetes therapy : research, treatment and education of diabetes and related disorders","notice","article","10.1007/s13300-014-0069-8","24867237","PMC4065293",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; correction; erratum"],["R0026834","Managing diabetes in dialysis patients.","O'Toole SM","2012","Postgraduate medical journal","narrative_review","article","10.1136/postgradmedj-2011-130354","22282737",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026835","Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.","Defronzo RA","2013","Hospital practice (1995)","other_trial","article","10.3810/hp.2013.04.1062","23680744",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0026836","Pharmacologic treatment strategies in children with type 2 diabetes mellitus.","Urakami T","2013","Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology","other","article","10.1292/cpe.22.","23966754","PMC3748280",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026837","Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.","Thong KY","2011","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/j.1463-1326.2011.01393.x","21410858",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0026838","A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice.","Rosenberg L","2004","Annals of surgery","preclinical","article","10.1097/01.sla.0000143270.99191.10","15492571","PMC1356495",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026839","Divergent effects of various diabetes drugs on cardiovascular prognosis.","Bell DS","2013","Reviews in cardiovascular medicine","narrative_review","article","10.3909/ricm0671","24448252",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0026840","[Is there life after teduglutide?].","Martínez Martínez AL","2020","Nutricion hospitalaria","other_trial","article","10.20960/nh.03052","32406744",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Case Reports; Journal Article; article"],["R0026841","[Anti-diabetic drugs. Weight reduction as a favourable side effect].","Wirth A","2011","Der Internist","other","article","10.1007/s00108-011-2811-x","21344192",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0026842","Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.","Sridhar A","2022","PloS one","preclinical","article","10.1371/journal.pone.0274788","36137097","PMC9499270",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026843","Emergence of promising therapies in diabetes mellitus.","Akkati S","2011","Journal of clinical pharmacology","narrative_review","article","10.1177/0091270010376972","20705952",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026844","Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells.","Beak SA","1996","Endocrinology","preclinical","article","10.1210/endo.137.10.8828468","8828468",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026845","Neonatal pig liver-derived progenitors for insulin-producing cells: an in vitro study.","Racanicchi L","2007","Tissue engineering","preclinical","article","10.1089/ten.2007.0098","17916039",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026846","Prkar1a in the regulation of insulin secretion.","Hussain MA","2012","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","narrative_review","article","10.1055/s-0032-1321866","22951902","PMC4034137",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0026847","Gateways to clinical trials.","Tomillero A","2009","Methods and findings in experimental and clinical pharmacology","other","article",null,"19357798",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0026848","Do exenatide truly improve the myocardial infarction size?","Woo JS","2013","International journal of cardiology","commentary","article","10.1016/j.ijcard.2013.04.013","23628300",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0026849","Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus.","Purga SL","2017","Cardiovascular drugs and therapy","narrative_review","article","10.1007/s10557-017-6750-1","28871349",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026850","Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS.","Ghosal S","2016","Journal of diabetes research","randomized_trial","article","10.1155/2016/1643496","26649315","PMC4663001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; research-article; article"],["R0026851","C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.","Takabe M","2012","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2012.09.036","23068961",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026852","Induction of insulin-producing cells from human pancreatic progenitor cells.","Noguchi H","2010","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2010.05.097","20692413",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026853","[Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].","Zhao XY","2014","Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","preclinical","article","10.3760/cma.j.issn.1007-3418.2014.11.010","25531383",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026854","Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.","Willard FS","2012","Experimental diabetes research","narrative_review","article","10.1155/2012/470851","22666230","PMC3359799",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026855","Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines.","Packer M","2018","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-017-0648-x","29310647","PMC5759313",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026856","The role of adjunctive exenatide therapy in pediatric type 1 diabetes.","Raman VS","2010","Diabetes care","randomized_trial","article","10.2337/dc09-1959","20332358","PMC2875441","ClinicalTrials.gov:NCT00456300","S002325","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026857","Exenatide dosing in alpacas.","Cebra CK","2014","Journal of veterinary pharmacology and therapeutics","other_trial","article","10.1111/jvp.12103","24479825",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026858","The Akt/FoxO1/p27 pathway mediates the proliferative action of liraglutide in β cells.","Fang D","2012","Molecular medicine reports","preclinical","article","10.3892/mmr.2011.607","21964769",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026859","Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry.","Tschöpe D","2012","BMC endocrine disorders","nonrandomized_study","article","10.1186/1472-6823-12-23","23075070","PMC3515411",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0026860","Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.","Shan PF","2015","Diabetes care","randomized_trial","article","10.2337/dc15-0887","26294784",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Letter; Comment; article"],["R0026861","Oral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment.","Araki H","2014","Journal of diabetes investigation","other","article","10.1111/jdi.12169","25411603","PMC4210066",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026862","Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle.","ThanThan S","2012","Domestic animal endocrinology","preclinical","article","10.1016/j.domaniend.2011.11.004","22154917",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026863","Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives.","Jin T","2016","American journal of physiology. Endocrinology and metabolism","narrative_review","article","10.1152/ajpendo.00069.2016","27507553",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0026864","Incretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway.","Barbieri M","2017","Journal of diabetes and its complications","preclinical","article","10.1016/j.jdiacomp.2016.10.001","27771154",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0026865","Albumin as a drug delivery and diagnostic tool and its market approved products.","Sethi A","2013","Acta poloniae pharmaceutica","narrative_review","article",null,"23923383",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026866","Symlin & Byetta. An injectable drug Q and A.","Roberts SS","2007","Diabetes forecast","other","article",null,"17632925",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026867","Investigating the role of inflammatory biomarkers and incretins in the aetiology of type 2 diabetes and coronary heart disease using human genetics","Bowker N","2020","University of Cambridge","nonrandomized_study","article","10.17863/cam.70467",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Dissertation; dissertation"],["R0026868","Management of post-transplant diabetes.","Therasse A","2013","Current diabetes reports","narrative_review","article","10.1007/s11892-012-0346-8","23188594",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026869","Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.","Hager MV","2017","Biochemical pharmacology","other","article","10.1016/j.bcp.2017.03.018","28363772","PMC5794489",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article"],["R0026870","The Cost-Effectiveness of Canagliflozin Compared With Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sulfonylurea In France.","Troelsgaard A","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.707","27200657",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026871","GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor.","Yang H","1998","The American journal of physiology","preclinical","article","10.1152/ajpcell.1998.275.3.c675","9730951",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026872","Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations.","Varanasi A","2011","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep10199.or","20841306",null,null,"S000404","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0026873","Effects of exenatide in poorly controlled type 2 diabetes.","Kaimal N","2012","QJM : monthly journal of the Association of Physicians","nonrandomized_study","article","10.1093/qjmed/hcr180","22056400",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; article"],["R0026874","Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.","Tang A","2015","Diabetes care","randomized_trial","article","10.2337/dc15-1091","26294785",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Letter; Comment; article"],["R0026875","Glucagon-like peptide-1 protects NSC-34 motor neurons against glucosamine through Epac-mediated glucose uptake enhancement.","Lim JG","2010","Neuroscience letters","preclinical","article","10.1016/j.neulet.2010.05.017","20471453",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026876","Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes.","Inagaki N","2011","Journal of diabetes investigation","randomized_trial","article","10.1111/j.2040-1124.2011.00137.x","24843529","PMC4014904","ClinicalTrials.gov:NCT00577824","S000752","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0026877","Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes?","Desouza CV","2013","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2013.04.007","23809765",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review"],["R0026878","Exenatide exerts a potent antiinflammatory effect.","Chaudhuri A","2012","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2011-1508","22013105","PMC3251936",null,"S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026879","Fixed Drug Eruption: An Underrecognized Cutaneous Manifestation of a Drug Reaction in the Primary Care Setting.","Shaker G","2022","Cureus","case_report","article","10.7759/cureus.28299","36034061","PMC9397151",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0026880","Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice.","More VR","2017","PloS one","preclinical","article","10.1371/journal.pone.0186586","29065174","PMC5655430",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026881","[TREATMENT OF TYPE 2 DIABETES IN PATIENTS WITH HISTORY OF CARDIOVASCULAR DISEASE].","Vergès B","2015","La Revue du praticien","other_trial","article",null,"26749704",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","English Abstract; Journal Article; other"],["R0026882","Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β-cell mass expansion.","Bastien-Dionne PO","2011","Diabetes","preclinical","article","10.2337/db11-0101","22013015","PMC3219950",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026883","Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.","Ghosh-Swaby OR","2020","The lancet. Diabetes & endocrinology","systematic_review","article","10.1016/s2213-8587(20)30038-3","32333878",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review"],["R0026884","A cohort study of acute pancreatitis in relation to exenatide use.","Dore DD","2011","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/j.1463-1326.2011.01376.x","21320263",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026885","Menin determines K-RAS proliferative outputs in endocrine cells.","Chamberlain CE","2014","The Journal of clinical investigation","other","article","10.1172/jci69004","25133424","PMC4153699",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026886","Linker engineering for fusion protein construction: Improvement and characterization of a GLP-1 fusion protein.","Kong Y","2016","Enzyme and microbial technology","preclinical","article","10.1016/j.enzmictec.2015.09.001","26672455",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026887","Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.","Gallwitz B","2012","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(12)60479-6","22683137",null,"ClinicalTrials.gov:NCT00359762; EudraCT:2005-005448-21","S001097","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026888","New and emerging drug molecules against obesity.","George M","2014","Journal of cardiovascular pharmacology and therapeutics","other_trial","article","10.1177/1074248413501017","24064009",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0026889","Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.","Wu L","2012","Regulatory peptides","preclinical","article","10.1016/j.regpep.2012.05.091","22587909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026890","A Nickel(II)-Mediated Thiocarbonylation Strategy for Carbon Isotope Labeling of Aliphatic Carboxamides.","Pedersen SS","2021","Chemistry (Weinheim an der Bergstrasse, Germany)","other","article","10.1002/chem.202005261","33452676",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026891","An Optimized Mouse Brain Atlas for Automated Mapping and Quantification of Neuronal Activity Using iDISCO+ and Light Sheet Fluorescence Microscopy.","Perens J","2021","Neuroinformatics","preclinical","article","10.1007/s12021-020-09490-8","33063286","PMC8233272",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026892","An accidental liraglutide overdose: case report.","Elmehdawi RR","2014","The Libyan journal of medicine","case_report","article","10.3402/ljm.v9.23055","24461534","PMC3901387",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; editorial; article"],["R0026893","Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.","Pendergrass M","2012","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/j.1463-1326.2012.01567.x","22268550",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026894","Application of high-resolution MS for development of peptide and large-molecule drug candidates.","Kellie JF","2016","Bioanalysis","preclinical","article","10.4155/bio.15.249","26795399",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026895","Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.","Ji L","2013","Journal of diabetes investigation","randomized_trial","article","10.1111/j.2040-1124.2012.00238.x","24843631","PMC4019288","ClinicalTrials.gov:NCT00917267","S001437","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; research-article; article"],["R0026896","Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.","Zhang M","2014","Molecular & cellular proteomics : MCP","other","article","10.1074/mcp.m114.040196","25044020","PMC4223491",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026897","Editor's Choice- Pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome.","Rossello X","2019","European heart journal. Acute cardiovascular care","randomized_trial","article","10.1177/2048872619845283","31172789",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0026898","Impact Of Ethnicity On The Efficacy And Safety Outcomes Of Anti-Diabetes Drugs - Case Study Of Liraglutide In Asian And Non-Asian Populations.","Chen G","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.147","27202675",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026899","Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.","Lee WC","2012","Journal of medical economics","other_trial","article","10.3111/13696998.2012.716111","22834986",null,null,"S002361","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026900","Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.","Best JH","2011","Diabetes care","randomized_trial","article","10.2337/dc10-1119","21270189","PMC3024340",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026901","Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.","Díaz-Soto G","2014","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2014.01.019","24530118",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026902","Clozapine directly increases insulin and glucagon secretion from islets: implications for impairment of glucose tolerance.","Smith GC","2014","Schizophrenia research","preclinical","article","10.1016/j.schres.2014.05.003","24906220",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026903","Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes.","Blevins T","2010","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2010.05.2149","20463421",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; article"],["R0026904","Expression of pancreatic endocrine markers by prolactin-treated rat bone marrow mesenchymal stem cells.","González P","2010","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2010.01.031","20304194",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026905","A Disease-Modifying Approach for Advanced Hidradenitis Suppurativa (Regimen with Metformin, Liraglutide, Dapsone, and Finasteride): A Case Report.","Khandalavala BN","2017","Case reports in dermatology","case_report","article","10.1159/000473873","28868004","PMC5567008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0026906","Obesity: Pharmacotherapy.","Powell A","2020","FP essentials","other","article",null,"32383845",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026907","The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.","Schernthaner G","2014","Diabetes & vascular disease research","narrative_review","article","10.1177/1479164114542802","25116004","PMC4230539",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0026908","Simultaneous quantification of the glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) receptor agonists in rodent plasma by on-line solid phase extraction and LC-MS/MS.","Wang Y","2014","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","preclinical","article","10.1016/j.jchromb.2014.02.040","24657407",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0026909","The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.","Kahal H","2015","BMC endocrine disorders","other_trial","article","10.1186/s12902-015-0005-6","25880805","PMC4389314","ISRCTN:ISRCTN48560305","S000679","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Controlled Clinical Trial; Journal Article; research-article; article"],["R0026910","Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects.","Ellero C","2010","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/j.1464-5491.2010.03085.x","20854385","PMC3066409",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Clinical Trial, Phase I; Journal Article; research-article; article"],["R0026911","Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus.","Bawa T","2013","Indian journal of endocrinology and metabolism","other","article","10.4103/2230-8210.107804","23776858","PMC3659913",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026912","[Analogues of amylin, alpha-glucosidase inhibitors and the digestive system in homeostasis regulation].","Rybka J","2011","Vnitrni lekarstvi","narrative_review","article",null,"21612064",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0026913","Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.","Coopman K","2011","Molecular endocrinology (Baltimore, Md.)","other","article","10.1210/me.2011-1160","21868452","PMC5417182",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026914","Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.","Levin P","2012","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2012.654850","22216894",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Clinical Trial; Journal Article; article"],["R0026915","Mechanistic studies for monodisperse exenatide-loaded PLGA microspheres prepared by different methods based on SPG membrane emulsification.","Qi F","2014","Acta biomaterialia","preclinical","article","10.1016/j.actbio.2014.06.018","24952071",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026916","Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.","Sze L","2011","The Journal of clinical endocrinology and metabolism","other","article","10.1210/jc.2011-0038","21632815",null,null,"S001714","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026917","The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor.","Nishizawa M","2000","Journal of the autonomic nervous system","preclinical","article","10.1016/s0165-1838(99)00086-7","10742535",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026918","Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.","Derosa G","2011","European journal of pharmacology","randomized_trial","article","10.1016/j.ejphar.2011.05.051","21645507",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026919","The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management.","Katz P","2014","Diabetes & vascular disease research","narrative_review","article","10.1177/1479164114546854","25187508",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026920","Newly approved and promising antidiabetic agents.","Combettes M","2007","Therapie","preclinical","article","10.2515/therapie:2007054","17983555",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026921","Efficacy of a new sustained-release microsphere formulation of exenatide, DA-3091, in Zucker diabetic fatty (ZDF) rats.","Kwak HH","2010","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2010.03.006","20298778",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026922","Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.","Yang Y","2013","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-130491","23948890",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026923","Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production.","Jun LS","2015","Diabetes","preclinical","article","10.2337/db14-1052","25288673",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026924","Association between diabetes and mood disorders and the potential use of anti-hyperglycemic agents as antidepressants.","Grigolon RB","2019","Progress in neuro-psychopharmacology & biological psychiatry","narrative_review","article","10.1016/j.pnpbp.2019.109720","31352032",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026925","Treatment of obese diabetics.","Svacina S","2012","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-1-4614-5441-0_32","23393696",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026926","Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.","Zheng J","2015","Experimental biology and medicine (Maywood, N.J.)","preclinical","article","10.1177/1535370214567614","25710926","PMC4935360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026927","Acute interstitial nephritis after treatment with liraglutide.","Gariani K","2014","American journal of kidney diseases : the official journal of the National Kidney Foundation","case_report","article","10.1053/j.ajkd.2013.10.057","24315766",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0026928","Postmeal increment in intact glucagon-like peptide 1 level, but not intact glucose-dependent insulinotropic polypeptide levels, is inversely associated with metabolic syndrome in patients with type 2 diabetes.","Yoo S","2018","Endocrine research","other","article","10.1080/07435800.2017.1379023","29028177",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026929","Diabetes quiz. How much do you know about Byetta?","Flannery L","2007","Diabetes self-management","other","article",null,"17663084",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026930","Stem cells for the treatment of diabetes.","Noguchi H","2007","Endocrine journal","narrative_review","article","10.1507/endocrj.kr-86","17053295",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0026931","Cardiovascular risk assessment in patients with diabetes.","Bertoluci MC","2017","Diabetology & metabolic syndrome","narrative_review","article","10.1186/s13098-017-0225-1","28435446","PMC5397821",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0026932","Clinical trial risk in type-2 diabetes: importance of patient history.","Aiyere EO","2014","Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques","other_trial","article","10.18433/j3hg73","25224350",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0026933","Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states.","Farr S","2014","Cardiovascular & hematological disorders drug targets","narrative_review","article","10.2174/1871529x14666140505125300","24801723",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026934","The effect of liraglutide on the proliferation, migration, and osteogenic differentiation of human periodontal ligament cells.","Pang Y","2019","Journal of periodontal research","other","article","10.1111/jre.12607","30207387",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026935","Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor.","Nuche-Berenguer B","2010","Journal of cellular physiology","preclinical","article","10.1002/jcp.22243","20506394",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026936","The Cost-Effectiveness Of Canagliflozin Verse Liraglutide In Patients With Type 2 Diabetes (T2dm) Failing To Achieve Glycaemic Control On Metformin Monotherapy In Ireland.","Bacon T","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.700","27200650",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026937","Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.","Arnolds S","2015","Diabetes care","other_trial","article","10.2337/dc14-2418","25614698",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Letter; Comment; letter"],["R0026938","Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.","Doggrell SA","2011","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2011.576671","21534885",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026939","Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus.","Hillman M","2012","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","other","article","10.1016/j.jcf.2011.11.001","22138561",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0026940","A Review of Interventional Trials in Youth-Onset Type 2 Diabetes: Challenges and Opportunities.","Currie BM","2021","Diabetes therapy : research, treatment and education of diabetes and related disorders","other_trial","article","10.1007/s13300-021-01136-5","34554411","PMC8519987",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0026941","Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study.","Wadden TA","2015","International journal of obesity (2005)","notice","article","10.1038/ijo.2014.88","25311036",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0026942","[Physiological analysis of various types of osmotic diuresis].","Marina AS","2011","Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova","preclinical","article",null,"22384671",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Research Support, Non-U.S. Gov't; other"],["R0026943","Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability.","Lamson NG","2020","Nature biomedical engineering","preclinical","article","10.1038/s41551-019-0465-5","31686002","PMC7461704",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0026944","Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.","McIntosh B","2011","Open medicine : a peer-reviewed, independent, open-access journal","systematic_review","article",null,"22046219","PMC3205809",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review-article; review"],["R0026945","Potential use of exenatide for the treatment of obesity.","Folli F","2011","Expert opinion on investigational drugs","narrative_review","article","10.1517/13543784.2011.630660","22017240","PMC3495586",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0026946","Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.","Lønborg J","2012","Circulation. Cardiovascular interventions","randomized_trial","article","10.1161/circinterventions.112.968388","22496084",null,"ClinicalTrials.gov:NCT00835848","S002195; S002372","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026947","Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.","Hölscher C","2014","Biochemical Society transactions","narrative_review","article","10.1042/bst20140016","24646283",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0026948","Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.","Gawrieh S","2018","Clinics in liver disease","randomized_trial","article","10.1016/j.cld.2017.08.013","29128056",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; book-chapter"],["R0026949","SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.","Bajaj HS","2018","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2018.08.001","30149145",null,"ClinicalTrials.gov:NCT03233178","S001639","pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0026950","Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.","Kelly AS","2012","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1038/oby.2011.337","22076596","PMC3684414","ClinicalTrials.gov:NCT00886626","S001390","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0026951","Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.","Davies MJ","2012","Diabetic medicine : a journal of the British Diabetic Association","other_trial","article","10.1111/j.1464-5491.2011.03429.x","21883438","PMC3378710",null,"S001502; S002361","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Comparative Study; Journal Article; research-article; article"],["R0026952","Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.","Colao A","2014","Pituitary","narrative_review","article","10.1007/s11102-013-0483-3","23564338","PMC3942628",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0026953","Combination of nateglinide with thiazolidinediones in Type 2 diabetes.","Voulgari C","2009","Expert review of endocrinology & metabolism","other","article","10.1586/eem.09.40","30780794",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026954","One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.","Zavattaro M","2015","Endocrine","nonrandomized_study","article","10.1007/s12020-014-0519-0","25572181",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0026955","Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.","Rosenstock J","2010","Diabetes care","randomized_trial","article","10.2337/dc09-1203","20332357","PMC2875418","ClinicalTrials.gov:NCT00500370","S000663; S001478","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0026956","Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.","Shi S","2012","Arzneimittel-Forschung","randomized_trial","article","10.1055/s-0031-1295484","22344551",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026957","No clinical harm from a massive exenatide overdose: a short report.","Krishnan L","2013","Clinical toxicology (Philadelphia, Pa.)","case_report","article","10.3109/15563650.2012.752495","23228005",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0026958","Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells.","Zhao X","2015","International journal of molecular medicine","preclinical","article","10.3892/ijmm.2014.2052","25573030","PMC4314412",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026959","In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A Method Using Existing in silico Algorithm Infrastructure and a Vision for Future Enhancements.","Mattei AE","2022","Frontiers in drug discovery","preclinical","article","10.3389/fddsv.2022.952326","36945694","PMC10026553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0026960","Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome.","Siekmeier R","2015","Advances in experimental medicine and biology","narrative_review","article","10.1007/5584_2014_94","25427821",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026961","Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.","Wijkman MO","2020","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-020-01150-0","33046070","PMC7552471","ClinicalTrials.gov:NCT01147250","S001991","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; article; other"],["R0026962","Response to Nandakoban et al. Acute tubulointerstitial nephritis following treatment with exenatide.","Rees DO","2013","Diabetic medicine : a journal of the British Diabetic Association","commentary","article","10.1111/dme.12014","22998130",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0026963","Response to Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278.","Retnakaran R","2015","Diabetes care","randomized_trial","article","10.2337/dc14-2586","25614699",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Letter; Comment; article"],["R0026964","Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors.","Zhou J","2002","Journal of cellular physiology","preclinical","article","10.1002/jcp.10143","12124776",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0026965","The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.","Best JH","2012","Diabetes, obesity & metabolism","systematic_review","article","10.1111/j.1463-1326.2011.01533.x","22074017",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Systematic Review; review"],["R0026966","Non-alcoholic fatty liver disease: a diabetologist's perspective.","Pappachan JM","2014","Endocrine","narrative_review","article","10.1007/s12020-013-0087-8","24287794",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026967","APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.","van den Hoek AM","2014","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12252","24373179",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0026968","Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation.","Koole C","2011","Molecular pharmacology","other","article","10.1124/mol.111.072884","21616920","PMC3364496",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0026969","Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.","Pawaskar MD","2011","Journal of medical economics","nonrandomized_study","article","10.3111/13696998.2011.613505","21892855",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026970","A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.","Liutkus J","2010","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2010.01251.x","20977576",null,null,"S001737","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026971","Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers.","Pinelli NR","2011","Journal of clinical pharmacology","randomized_trial","article","10.1177/0091270010367653","20484613",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026972","Lixisenatide.","Baker DE","2017","Hospital pharmacy","other_trial","article","10.1310/hpj5201-65","28179743","PMC5278917",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0026973","New and emerging strategies for reducing cardiometabolic risk factors.","Rodgers PT","2006","Pharmacotherapy","narrative_review","article","10.1592/phco.26.5part2.13s","16637783",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0026974","Reply to Rees et al. Acute tubulointerstitial nephritis following treatment with exenatide.","Nandakoban H","2013","Diabetic medicine : a journal of the British Diabetic Association","commentary","article","10.1111/dme.12054","23088538",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0026975","Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin: a retrospective study using electronic medical record data.","Lang K","2018","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2018.1437027","29394878",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026976","Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes.","Irace C","2011","Diabetes technology & therapeutics","other_trial","article","10.1089/dia.2011.0096","21751893",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Comparative Study; Journal Article; article"],["R0026977","Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study.","Kosjerina V","2021","The lancet. Healthy longevity","nonrandomized_study","article","10.1016/s2666-7568(21)00170-7","36098008",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0026978","Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.","Maski K","2021","Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine","systematic_review","article","10.5664/jcsm.9326","34743790","PMC8636345",null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review; review-article"],["R0026979","Exendin-4 potently decreases ghrelin levels in fasting rats.","Pérez-Tilve D","2007","Diabetes","preclinical","article","10.2337/db05-0996","17192476",null,null,"S001478","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0026980","Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes.","Diamant M","2012","Diabetes care","case_report","article","10.2337/dc12-0021","22517942","PMC3329809",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0026981","The role of GLP-1 in neuronal activity and neurodegeneration.","Hölscher C","2010","Vitamins and hormones","preclinical","article","10.1016/b978-0-12-381517-0.00013-8","21094907",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0026982","Meal-anticipatory glucagon-like peptide-1 secretion in rats.","Vahl TP","2010","Endocrinology","preclinical","article","10.1210/en.2009-1002","19915164","PMC2817629",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0026983","ODP195 EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY IN ASSOCIATION WITH USE OF SGLT2I.",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9624840",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0026984","Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.","Detournay B","2015","Vascular health and risk management","nonrandomized_study","article","10.2147/vhrm.s84507","26229480","PMC4514348",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0026985","New therapies for diabetes.","Green DE","2007","Clinical cornerstone","narrative_review","article","10.1016/s1098-3597(09)60008-9","18357956",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0026986","Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.","Yamamoto S","2018","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2018.03.032","29588170",null,"UMIN:UMIN000028313",null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0026987","Association of serum fetuin-B with insulin resistance and pre-diabetes in young Chinese women: evidence from a cross-sectional study and effect of liraglutide.","Xia X","2021","PeerJ","other_trial","article","10.7717/peerj.11869","34484983","PMC8381879",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; research-article; article"],["R0026988","Extracts of Rehmanniae radix, Ginseng radix and Scutellariae radix improve glucose-stimulated insulin secretion and beta-cell proliferation through IRS2 induction.","Park SM","2008","Genes & nutrition","preclinical","article","10.1007/s12263-007-0065-y","18850229","PMC2478485",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0026989","[Importance of the structure of insulin preparations for clinical practice].","Svacina S","2009","Vnitrni lekarstvi","other","article",null,"19449759",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0026990","Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study.","Rafaniello C","2015","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2014.12.007","25686508",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0026991","Pharmacotherapy of obesity: Available medications and drugs under investigation.","Pilitsi E","2019","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2018.10.010","30391259",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0026992","Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety.","Nathanson D","2012","Diabetologia","randomized_trial","article","10.1007/s00125-011-2440-x","22246377",null,"ISRCTN:ISRCTN47533126","S000396","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0026993","Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.","Sisley S","2014","The Journal of clinical investigation","preclinical","article","10.1172/jci72434","24762441","PMC4038572",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0026994","Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis.","Li X","2014","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.3542","24741695",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; article"],["R0026995","Liraglutide effective in the severely insulin-resistant patient with type 2 diabetes requiring U-500 insulin: a case report.","Pantalone KM","2013","Diabetes technology & therapeutics","case_report","article","10.1089/dia.2012.0328","23379638",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0026996","Translating clinical trial data into new patterns of practice.","Peragallo-Dittko V","2009","The Diabetes educator","other_trial","article","10.1177/0145721708330154","19218563",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0026997","Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.","Gao L","2012","International journal of technology assessment in health care","nonrandomized_study","article","10.1017/s0266462312000608","23006540",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0026998","Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.","Tuttle KR","2013","American journal of kidney diseases : the official journal of the National Kidney Foundation","commentary","article","10.1053/j.ajkd.2013.03.026","23684754",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0026999","Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem.","Thiele TE","1998","Brain research","preclinical","article","10.1016/s0006-8993(98)00584-8","9729361",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S."],["R0027000","How do different GLP-1 mimetics differ in their actions?","Choukem SP","2006","Current diabetes reports","narrative_review","article","10.1007/s11892-006-0007-x","17076997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027001","LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.","Steinberg WM","2014","Pancreas","randomized_trial","article","10.1097/mpa.0000000000000229","25275271","PMC4206347","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027002","A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes.","Wang LG","2017","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","systematic_review","article","10.1016/j.biopha.2017.05.002","28586742",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis"],["R0027003","Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects.","Cefalu WT","2009","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.76.s5.06","19952302",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027004","Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.","Perry T","2007","Experimental neurology","preclinical","article","10.1016/j.expneurol.2006.09.028","17125767","PMC1850958",null,"S000116","pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Research Support, N.I.H., Intramural; research-article"],["R0027005","Controversies in the cardiovascular management of type 2 diabetes.","Opie LH","2011","Heart (British Cardiac Society)","narrative_review","article","10.1136/hrt.2010.214031","21106556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027006","Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study.","Matthaei S","2012","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-012-0006-7","22714818","PMC3508107",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027007","Functional hydrophilic polystyrene beads with uniformly size and high cross-linking degree facilitated rapid separation of exenatide.","Li Q","2016","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","other","article","10.1016/j.jchromb.2016.02.044","26970847",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027008","Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery.","Pajecki D","2013","Revista do Colegio Brasileiro de Cirurgioes","nonrandomized_study","article","10.1590/s0100-69912013000300005","23912365",null,null,"S000466","pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0027009","[Liraglutide in polycystic ovary syndrome].","Gómez-Pérez AM","2014","Medicina clinica","case_report","article","10.1016/j.medcli.2013.11.016","24456922",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Letter; Research Support, Non-U.S. Gov't"],["R0027010","Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.","Al-Jebawi AF","2010","Diabetes research and clinical practice","case_report","article","10.1016/j.diabres.2010.09.018","21030101",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027011","Incretin attenuates diabetes-induced damage in rat cardiac tissue.","AbdElmonem Elbassuoni E","2014","The journal of physiological sciences : JPS","preclinical","article","10.1007/s12576-014-0327-6","25011640","PMC10717745",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027012","DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.","Argyrakopoulou G","2009","Advances in therapy","narrative_review","article","10.1007/s12325-009-0009-6","19259628",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027013","Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus.","Kushner P","2010","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmsott.s10013","21437076","PMC3061431",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027014","Successful control of a case of severe insulin allergy with liraglutide.","Kawanami D","2013","Journal of diabetes investigation","case_report","article","10.1111/j.2040-1124.2012.00239.x","24843637","PMC4019294",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; case-report; article"],["R0027015","[Regulatory effect of liraglutide on the expression of eNOS in the corpus cavernosum of diabetic rats].","Yue L","2016","Zhonghua nan ke xue = National journal of andrology","preclinical","article",null,"27172659",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027016","Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.","Baggio LL","2002","Treatments in endocrinology","preclinical","article","10.2165/00024677-200201020-00005","15765627",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027017","Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.","Kuhadiya ND","2013","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep13065.or","23807520",null,null,"S000404","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0027018","In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide.","Hinke SA","2004","Life sciences","preclinical","article","10.1016/j.lfs.2004.03.024","15302229",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027019","Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.","Domecq JP","2015","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/jc.2014-3421","25590213","PMC5393509",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; review-article; article"],["R0027020","Place in therapy for liraglutide and saxagliptin for type 2 diabetes and FDA liraglutide warning.","McFarland MS","2011","Southern medical journal","commentary","article","10.1097/smj.0b013e318229ae12","21886074",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0027021","Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.","Elkhenini H","2014","European journal of internal medicine","commentary","article","10.1016/j.ejim.2013.12.009","24412647",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0027022","Challenges in pharmacotherapeutics education for diabetes in real-world clinical settings: views from family medicine and internal medicine residents.","Farahani P","2015","Clinical and investigative medicine. Medecine clinique et experimentale","nonrandomized_study","article","10.25011/cim.v38i3.22702","26026641",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027023","NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.","Ribel U","2002","European journal of pharmacology","preclinical","article","10.1016/s0014-2999(02)02189-1","12231394",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027024","A Comparison of New Pharmacological Agents for the Treatment of Obesity.","Nuffer W","2016","The Annals of pharmacotherapy","other_trial","article","10.1177/1060028016634351","26887340",null,null,"S001427","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0027025","Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.","Pawaskar M","2011","Journal of medical economics","nonrandomized_study","article","10.3111/13696998.2010.544797","21158486",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027026","Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic.","Acosta A","2021","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23120","33759389","PMC8168710","ClinicalTrials.gov:NCT03374956","S002046","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027027","Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease.","Patel V","2018","Cardiovascular & hematological agents in medicinal chemistry","preclinical","article","10.2174/1871525716666180118152158","29357809",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027028","Islet neogenesis-associated protein-related pentadecapeptide enhances the differentiation of islet-like clusters from human pancreatic duct cells.","Li J","2009","Peptides","preclinical","article","10.1016/j.peptides.2009.09.003","19747955",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027029","New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin.","Xiong X","2012","Islets","narrative_review","article","10.4161/isl.23345","23314611","PMC3605164",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0027030","Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT).","Kolotkin RL","2021","Clinical obesity","other","article","10.1111/cob.12477","34296522","PMC9285468","ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757","S000144; S001740","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0027031","Peptide conformational changes induced by tryptophan-phosphocholine interactions in a micelle.","Neidigh JW","2002","Biopolymers","other","article","10.1002/bip.10272","12389215",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0027032","Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines.","Dong Z","2017","Obesity reviews : an official journal of the International Association for the Study of Obesity","nonrandomized_study","article","10.1111/obr.12606","29024559",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0027033","Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.","Liu X","2017","Clinical endocrinology","randomized_trial","article","10.1111/cen.13454","28834553",null,null,"S001012","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0027034","Endocrinology update 2006.","Reddy SS","2006","Cleveland Clinic journal of medicine","other_trial","article","10.3949/ccjm.73.11.1019","17128544",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0027035","A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.","Giorda CB","2014","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12297","24702687",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0027036","Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus.","Okada K","2014","Endocrine","commentary","article","10.1007/s12020-014-0246-6","24696097","PMC4239782",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0027037","Type 1 diabetes and cardiovascular disease.","Schnell O","2013","Cardiovascular diabetology","other_trial","article","10.1186/1475-2840-12-156","24165454","PMC3816572",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0027038","Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.","Marso SP","2013","American heart journal","randomized_trial","article","10.1016/j.ahj.2013.07.012","24176437",null,null,"S001496","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027039","Long-acting GLP-1 analogue in V-shaped conformation by terminal polylysine modifications.","Yang X","2014","Molecular pharmaceutics","preclinical","article","10.1021/mp5002685","25243635",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027040","Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study.","Bernink FJ","2013","International journal of cardiology","commentary","article","10.1016/j.ijcard.2012.09.204","23084550",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027041","GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans.","Gil-Lozano M","2010","Endocrinology","other_trial","article","10.1210/en.2009-0915","20363879",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027042","Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.","Kolligs F","1995","Diabetes","preclinical","article","10.2337/diab.44.1.16","7813808",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027043","Liraglutide in combination with acitretin for severe recalcitrant psoriasis.","Reid CT","2013","The British journal of dermatology","case_report","article","10.1111/bjd.12380","23834125",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0027044","Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.","Porter WD","2013","International journal of obesity (2005)","preclinical","article","10.1038/ijo.2012.91","22665137",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027045","Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes.","Preumont V","2012","Acta clinica Belgica","nonrandomized_study","article","10.2143/acb.67.6.2062705","23340146",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0027046","Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2.","de Luis DA","2014","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","other","article","10.2310/jim.0000000000000032","24322329",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027047","Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.","Garg R","2010","Diabetes care","nonrandomized_study","article","10.2337/dc10-0482","20682680","PMC2963493",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027048","Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.","Bergenstal RM","2011","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2010.545814","21219119",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Evaluation Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0027049","Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.","Schwartz EA","2010","Atherosclerosis","randomized_trial","article","10.1016/j.atherosclerosis.2010.05.028","20557887",null,"ClinicalTrials.gov:NCT00974272","S000354","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0027050","A clinical update of using albumin as a drug vehicle - a commentary.","Kratz F","2014","Journal of controlled release : official journal of the Controlled Release Society","other_trial","article","10.1016/j.jconrel.2014.03.013","24637463",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0027051","MicroRNA-34a: the bad guy in age-related vascular diseases.","Raucci A","2021","Cellular and molecular life sciences : CMLS","narrative_review","article","10.1007/s00018-021-03979-4","34698884","PMC8629897",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027052","Transcriptional regulation of the IAPP gene in pancreatic beta-cells.","Shepherd LM","2004","Biochimica et biophysica acta","preclinical","article","10.1016/j.bbaexp.2004.09.009","15566941",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027053","White adipocyte-targeted dual gene silencing of FABP4/5 for anti-obesity, anti-inflammation and reversal of insulin resistance: Efficacy and comparison of administration routes.","Chung JY","2021","Biomaterials","preclinical","article","10.1016/j.biomaterials.2021.121209","34700224",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027054","Endocrine system on chip for a diabetes treatment model.","Nguyen DTT","2017","Biofabrication","preclinical","article","10.1088/1758-5090/aa5cc9","28222044",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0027055","Thermo-reversible injectable gel based on enzymatically-chopped low molecular weight methylcellulose for exenatide and FGF 21 delivery to treat types 1 and 2 diabetes.","Kim JK","2014","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2014.09.014","25245775",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027056","Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise.","Khoo EY","2010","Diabetologia","randomized_trial","article","10.1007/s00125-009-1579-1","19898831",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027057","Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride.","Campbell-Scherer DL","2013","Evidence-based medicine","randomized_trial","article","10.1136/eb-2013-101248","23474698",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Comment; article"],["R0027058","Emerging role of insulin with incretin therapies for management of type 2 diabetes.","Ahluwalia R","2011","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-011-0005-0","22127824","PMC3173595",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0027059","Decreased expression of the GLP-1 receptor after segmental artery injury in mice.","Bjørnholm KD","2021","The Journal of endocrinology","preclinical","article","10.1530/joe-20-0608","33449915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027060","Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat.","Hellström PM","2012","Regulatory peptides","preclinical","article","10.1016/j.regpep.2012.08.009","22960405",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027061","Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy.","Popelová A","2018","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-171041","29614684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027062","Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting.","Bergenstal RM","2011","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2011.628305","22085180",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0027063","Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials and Observational Studies.","Lee SWH","2016","Medicine","systematic_review","article","10.1097/md.0000000000002457","26765440","PMC4718266",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; review-article; article"],["R0027064","Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.","Zhang H","2012","Kidney & blood pressure research","randomized_trial","article","10.1159/000337929","22687869",null,null,"S002088","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027065","Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects.","Cersosimo E","2011","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2010-2146","21411546",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027066","Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats.","Kwak HH","2009","Pharmaceutical research","preclinical","article","10.1007/s11095-009-9966-3","19756973",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027067","Diabetes treatment in people with type 2 diabetes and schizophrenia: Retrospective primary care database analyses.","Rathmann W","2016","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2015.04.001","25937183",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0027068","Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.","Gromada J","1997","Pflugers Archiv : European journal of physiology","preclinical","article","10.1007/s004240050431","9242714",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027069","Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.","Buse JB","2011","Annals of internal medicine","randomized_trial","article","10.7326/0003-4819-154-2-201101180-00300","21138825",null,"ClinicalTrials.gov:NCT00765817","S000345","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027070","Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes.","Abdelgani S","2021","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgab403","34343296","PMC8787634",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027071","GLP-1: benefits beyond pancreas.","Muscogiuri G","2014","Journal of endocrinological investigation","narrative_review","article","10.1007/s40618-014-0137-y","25107343",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027072","Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.","Psallas M","2012","Hippokratia","narrative_review","article",null,"23935263","PMC3738409",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0027073","Incretins: the novel therapy of type 2 diabetes.","Thongtang N","2008","Journal of the Medical Association of Thailand = Chotmaihet thangphaet","other","article",null,"18697398",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027074","Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.","Plosker GL","2014","Drugs","randomized_trial","article","10.1007/s40265-013-0169-1","24407560",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0027075","Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice.","Xue B","2021","Stem cell research & therapy","preclinical","article","10.1186/s13287-021-02205-z","33588950","PMC7885588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0027076","Hypoglycaemia after gastric bypass: mechanisms and treatment.","Ritz P","2016","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12592","26508374",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027077","Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.","DeYoung MB","2011","Diabetes technology & therapeutics","narrative_review","article","10.1089/dia.2011.0050","21751887","PMC3202891",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0027078","Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.","Bunck MC","2010","Diabetes care","randomized_trial","article","10.2337/dc09-2361","20424219","PMC2909051",null,"S000371","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027079","Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels.","Ha SJ","2012","Arteriosclerosis, thrombosis, and vascular biology","randomized_trial","article","10.1161/atvbaha.110.222653","22155457",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027080","Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds.","Plock N","2017","Journal of clinical pharmacology","systematic_review","article","10.1002/jcph.781","27277818",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0027081","Effectiveness of exenatide in Asian Indians in a clinical care setting.","Sudhakaran C","2010","Diabetes technology & therapeutics","other","article","10.1089/dia.2010.0033","20615102",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0027082","Characteristics, Treatment Patterns, and Economic Outcomes of Patients Initiating Injectable Medications for Management of Type 2 Diabetes Mellitus in Japan: Results from a Retrospective Claims Database Analysis.","Suzuki S","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-018-0407-3","29663262","PMC5984911",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027083","Mechanisms of improved glucose handling after metabolic surgery: the big 6.","Paszkiewicz RL","2016","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","narrative_review","article","10.1016/j.soard.2016.03.008","27568470","PMC5003326",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0027084","Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*).","Yang W","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2010.01323.x","21114607",null,null,"S001581","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0027085","Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020.","Alsuhibani A","2022","International journal of clinical pharmacy","nonrandomized_study","article","10.1007/s11096-021-01330-2","34564826",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article"],["R0027086","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.","Malloy J","2009","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2009.04.005","19446153",null,"ClinicalTrials.gov:NCT00254254","S001345; S002220","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027087","Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.","López-Ruiz A","2010","Pharmacy world & science : PWS","case_report","article","10.1007/s11096-010-9423-8","20686848",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027088","Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats.","Gardiner SM","2010","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2010.00867.x","20718742","PMC2962819",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027089","Patient Preferences for Attributes of Health Canada Approved Weight Loss Medications Among Adults Living with Obesity in Canada: A Qualitative Study.","Donnan J","2022","Patient preference and adherence","other","article","10.2147/ppa.s350411","35411134","PMC8994660",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027090","Involvement of TGF-β and Autophagy Pathways in Pathogenesis of Diabetes: A Comprehensive Review on Biological and Pharmacological Insights.","Heydarpour F","2020","Frontiers in pharmacology","narrative_review","article","10.3389/fphar.2020.498758","33041786","PMC7522371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027091","The role of dysregulated glucagon secretion in type 2 diabetes.","D'Alessio D","2011","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2011.01449.x","21824266",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027092","Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.","Fiorentino TV","2015","The American journal of pathology","preclinical","article","10.1016/j.ajpath.2014.09.009","25447052","PMC4278248",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027093","Obesity Pharmacotherapy.","Saunders KH","2018","The Medical clinics of North America","narrative_review","article","10.1016/j.mcna.2017.08.010","29156182",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027094","Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data.","Wharton S","2021","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-020-00733-x","33462358","PMC8081661",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0027095","The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice.","Dalbøge LS","2014","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.114.215293","24902584",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027096","Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor.","Washington MC","2010","Brain research","preclinical","article","10.1016/j.brainres.2010.05.002","20452329",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0027097","Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation.","Cotugno M","2015","Acta diabetologica","randomized_trial","article","10.1007/s00592-014-0644-5","25218924",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Study; Comparative Study; Journal Article; article"],["R0027098","Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.","McCall AL","2009","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2008.0107","19459761","PMC2768873",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027099","Financial advantage or barrier when deprescribing for seniors: A 'case based' analysis.","Abu Fadaleh SM","2020","Research in social & administrative pharmacy : RSAP","other","article","10.1016/j.sapharm.2020.03.003","32249103",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027100","Exenatide-induced acute pancreatitis.","Ayoub WA","2010","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","case_report","article","10.4158/ep09104.crr","19703814",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027101","Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.","Pencek R","2012","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep11306.or","22446132",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0027102","Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects.","Montan PD","2019","Annals of translational medicine","narrative_review","article","10.21037/atm.2019.07.27","31555707","PMC6736799",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027103","Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience.","Anichini R","2013","Diabetes, metabolic syndrome and obesity : targets and therapy","nonrandomized_study","article","10.2147/dmso.s42729","23630427","PMC3626369",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027104","Beyond insulin replacement: addressing the additional needs of the diabetes patient.","Dailey G","2008","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2008.00847.x","18577160",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027105","Long term (4 years) improved insulin sensitivity following islet cell transplant in type 1 diabetes.","Rydzon B","2018","Diabetes/metabolism research and reviews","other_trial","article","10.1002/dmrr.2972","29230944","PMC5873303",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027106","Inside the pancreas: progress and challenges of human beta cell mass quantification.","Tiedge M","2014","Diabetologia","preclinical","article","10.1007/s00125-014-3206-z","24599112",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0027107","Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element.","Skoglund G","2000","Diabetes","preclinical","article","10.2337/diabetes.49.7.1156","10909973","PMC3045812",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0027108","Intestinal patch systems for oral drug delivery.","Banerjee A","2017","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2017.08.005","28850875",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027109","The Relevance of Insulin Action in the Dopaminergic System.","Fiory F","2019","Frontiers in neuroscience","narrative_review","article","10.3389/fnins.2019.00868","31474827","PMC6706784",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027110","Current medical treatment of diabetes type 2 and long term morbidity: how to balance efficacy and safety?","Carrera Boada CA","2013","Nutricion hospitalaria","other","article","10.3305/nh.2013.28.sup2.6707","23834040",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027111","Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.","Breitschaft A","2014","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2013.12.011","24461109",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0027112","Naturally-occurring TGR5 agonists modulating glucagon-like peptide-1 biosynthesis and secretion.","Jafri L","2016","Peptides","other","article","10.1016/j.peptides.2016.01.015","26820940",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027113","Targets for medical therapy in obesity.","Baretić M","2012","Digestive diseases (Basel, Switzerland)","narrative_review","article","10.1159/000336672","22722433",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027114","Gender-related issues in the pharmacology of new anti-obesity drugs.","Cataldi M","2019","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.12805","30589980",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027115","Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study.","Mori Y","2011","Diabetes technology & therapeutics","other_trial","article","10.1089/dia.2011.0137","21877924",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0027116","Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.","Iwamoto K","2009","Endocrine journal","randomized_trial","article","10.1507/endocrj.k09e-147","19706990",null,"ClinicalTrials.gov:NCT00612794","S000536","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027117","[Effect of liraglutide on interleukin-1β expression in the pancreatic islets of OLETF rats].","Guo N","2012","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","randomized_trial","article",null,"22699075",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0027118","Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.","Pickford P","2021","Molecular metabolism","preclinical","article","10.1016/j.molmet.2021.101242","33933675","PMC8163982",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; preprint; article"],["R0027119","Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs - a nested case-control study.","Gejl M","2015","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2014.11.096","25465309",null,null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027120","Pioglitazone--do we really need it to manage type 2 diabetes?","Sinha B","2013","Diabetes & metabolic syndrome","narrative_review","article","10.1016/j.dsx.2013.02.033","23517798",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027121","Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.","Abdul-Ghani MA","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12417","25425451","PMC5577982",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027122","Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea.","Idris I","2013","Journal of sleep research","randomized_trial","article","10.1111/j.1365-2869.2012.01030.x","22716195",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027123","Advances in non-dopaminergic treatments for Parkinson's disease.","Stayte S","2014","Frontiers in neuroscience","other_trial","article","10.3389/fnins.2014.00113","24904259","PMC4033125",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0027124","Care trajectories are associated with quality improvement in the treatment of patients with uncontrolled type 2 diabetes: A registry based cohort study.","Goderis G","2015","Primary care diabetes","nonrandomized_study","article","10.1016/j.pcd.2015.01.008","25709079",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027125","Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy.","Rogers B","2015","Current pharmaceutical design","narrative_review","article","10.2174/1381612821666150302120047","25732550",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027126","Preclinical and clinical studies of peptide receptor radionuclide therapy.","Pool SE","2010","Seminars in nuclear medicine","narrative_review","article","10.1053/j.semnuclmed.2009.12.001","20350630",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027127","Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia.","Gallwitz B","2011","Diabetes care","randomized_trial","article","10.2337/dc10-1900","21285388","PMC3041190","ClinicalTrials.gov:NCT00434954","S000790","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; brief-report; article"],["R0027128","Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system.","Gupta V","2013","PloS one","preclinical","article","10.1371/journal.pone.0057136","23483881","PMC3586668",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027129","Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review.","Noh RM","2011","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2011.589835","21668402",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027130","Diabetes and Ramadan: an update on use of glycemic therapies during fasting.","Ahmed MH","2011","Annals of Saudi medicine","narrative_review","article","10.4103/0256-4947.81802","21727749","PMC3156519",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027131","Biological activity of GLP-1-analogues with N-terminal modifications.","Siegel EG","1999","Regulatory peptides","preclinical","article","10.1016/s0167-0115(98)00155-4","10100921",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027132","Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.","Men P","2018","PloS one","systematic_review","article","10.1371/journal.pone.0197321","29787616","PMC5963790",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; research-article; review"],["R0027133","Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.","Wu JD","2011","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2010.0048","21284481",null,null,"S000641","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027134","Mild renal impairment and the efficacy and safety of liraglutide.","Davidson JA","2011","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","systematic_review","article","10.4158/ep10215.ra","21700561",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; article"],["R0027135","The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.","Hansen HH","2014","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.114.213454","24993361",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027136","[Exenatide--an alternative to insulin in the treatment of type 2 diabetes?].","Kjeldsen R","2008","Ugeskrift for laeger","narrative_review","article",null,"18822227",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027137","Preproglucagon neurons project widely to autonomic control areas in the mouse brain.","Llewellyn-Smith IJ","2011","Neuroscience","preclinical","article","10.1016/j.neuroscience.2011.02.023","21329743","PMC4298012",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0027138","GLP-1 and energy balance: an integrated model of short-term and long-term control.","Barrera JG","2011","Nature reviews. Endocrinology","preclinical","article","10.1038/nrendo.2011.77","21647189","PMC4231434",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0027139","Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.","Terawaki Y","2014","Cardiovascular diabetology","preclinical","article","10.1186/s12933-014-0154-3","25407968","PMC4240860",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027140","ODP596 Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9625667",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0027141","Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.","Forst T","2012","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2012.03589.x","22288732",null,"ClinicalTrials.gov:NCT01208012","S000185","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027142","Transplantation of insulin-producing clusters derived from adult bone marrow stem cells to treat diabetes in rats.","Gabr MM","2008","Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation","preclinical","article",null,"18954303",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027143","Diabetes: the latest developments in inhibitors, insulin sensitisers, new drug targets and novel approaches. October 18-19, 2004, The Hatton, London, UK.","Rondinone CM","2005","Expert opinion on therapeutic targets","other","article","10.1517/14728222.9.2.415","15934925",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Conference Proceedings; article"],["R0027144","10-fold liraglutide overdose over 7 months resulted only in minor side-effects.","Bode SF","2013","Journal of clinical pharmacology","case_report","article","10.1002/jcph.94","23733710",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0027145","Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia.","Joaqui VB","2021","Archives of endocrinology and metabolism","nonrandomized_study","article","10.20945/2359-3997000000319","33444492","PMC10528692",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027146","Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.",null,"2011","Prescrire international","other","article",null,"22066314",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027147","Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.","Ponirakis G","2021","Journal of diabetes investigation","randomized_trial","article","10.1111/jdi.13544","33714226","PMC8409832",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0027148","Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study.","Ankarfeldt MZ","2017","Clinical epidemiology","nonrandomized_study","article","10.2147/clep.s124054","28176886","PMC5261549",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027149","[Glucagon antagonists open a new way in treatment of type 2 diabetes Mellitus].","Vondra K","2016","Vnitrni lekarstvi","other_trial","article",null,"27627094",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0027150","Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.","Iyer SN","2012","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","case_report","article","10.4158/ep11264.cr","22068258",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027151","Pancreatitis during treatment with liraglutide.","Famularo G","2012","JOP : Journal of the pancreas","case_report","article","10.6092/1590-8577/1107","22964963",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0027152","[C-REACTIVE PROTEIN AS AN INDICATOR OF RISK OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ITS CORRECTION].","Stryuk RI","2016","Klinicheskaia meditsina","other","article","10.18821/0023-2149-2016094-9-683-687","30296044",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027153","CILP-2 is a novel secreted protein and associated with insulin resistance.","Wu T","2019","Journal of molecular cell biology","preclinical","article","10.1093/jmcb/mjz016","30896018","PMC6934158",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027154","Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations.","Jeha GS","2006","Pediatric diabetes","other","article","10.1111/j.1399-543x.2006.00159.x","16629719",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027155","Non-diabetic use of liraglutide.","Verma A","2012","Indian journal of endocrinology and metabolism","commentary","article","10.4103/2230-8210.100698","23087891","PMC3475931",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; article"],["R0027156","Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.","Tourrel C","2002","Diabetes","preclinical","article","10.2337/diabetes.51.5.1443","11978641",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027157","Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study.","Jensterle M","2016","Experimental and therapeutic medicine","randomized_trial","article","10.3892/etm.2016.3081","27073422","PMC4812364",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0027158","Identification of a pancreatic stellate cell population with properties of progenitor cells: new role for stellate cells in the pancreas.","Mato E","2009","The Biochemical journal","preclinical","article","10.1042/bj20081466","19379129",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027159","Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers.","Chae SY","2009","Journal of pharmaceutical sciences","preclinical","article","10.1002/jps.21532","18704955",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027160","Weight Loss Medications in the Treatment of Obesity and Hypertension.","Cohen JB","2019","Current hypertension reports","narrative_review","article","10.1007/s11906-019-0915-1","30747357","PMC6415530",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0027161","Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes.","Iwao T","2013","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2012.07.001","22863615",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0027162","Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.","Kielgast U","2011","Diabetes care","randomized_trial","article","10.2337/dc11-0096","21593296","PMC3120168","ClinicalTrials.gov:NCT00993720","S001442","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027163","PMON01 Alpelisib (PI3-K Inhibitor) Induced Severe Insulin Resistance Complicated by Diabetic Ketoacidosis (DKA) with Rapid Reversal Following Discontinuation: A Case Report",null,"2022","Journal of the Endocrine Society","case_report","article",null,null,"PMC9625240",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0027164","Efficacy and tolerability of liraglutide in combination with other antidiabetic drugs in type 2 diabetes.","Zenari L","2011","Acta bio-medica : Atenei Parmensis","other","article",null,"22783722",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027165","Site-specific fatty chain-modified exenatide analogs with balanced glucoregulatory activity and prolonged in vivo activity.","Sun L","2016","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2016.04.016","27155328",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027166","Enhancing incretin action for the treatment of type 2 diabetes.","Drucker DJ","2003","Diabetes care","narrative_review","article","10.2337/diacare.26.10.2929","14514604",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027167","Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine.","Song Y","2017","Oncology letters","preclinical","article","10.3892/ol.2017.5752","28454451","PMC5403711",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027168","Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.","Xiao Q","2001","Biochemistry","preclinical","article","10.1021/bi0014498","11258897",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027169","Analysis on difference in gastrointestinal hormone levels of patients with the history of diabetes and concurrent nephropathy and study on the role of liraglutide.","Zhang JH","2017","European review for medical and pharmacological sciences","other_trial","article",null,"28829486",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; article"],["R0027170","[Effects of liraglutide on the expression of local renin-angiotensin system, transforming growth factor-β1 and collagen type III in pulmonary tissue of diabetic rats].","Zhao W","2014","Zhonghua yi xue za zhi","preclinical","article",null,"24754994",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0027171","Amyloid formation reduces protein kinase B phosphorylation in primary islet β-cells which is improved by blocking IL-1β signaling.","Zhang Y","2018","PloS one","preclinical","article","10.1371/journal.pone.0193184","29474443","PMC5825069",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027172","Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.","Martinez R","2018","Diabetes","randomized_trial","article","10.2337/db17-1278","29602791","PMC7301339",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027173","The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.","Thayer S","2013","Advances in therapy","nonrandomized_study","article","10.1007/s12325-013-0074-8","24293131","PMC3898354",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027174","Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity.","Gong N","2011","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2011.01227.x","21244372","PMC3087140",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027175","Unmasking venom gland transcriptomes in reptile venoms.","Chen T","2002","Analytical biochemistry","preclinical","article","10.1016/s0003-2697(02)00404-9","12470674",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027176","Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes.","Koska J","2010","Diabetes care","randomized_trial","article","10.2337/dc09-1961","20200309","PMC2858168","ClinicalTrials.gov:NCT00974272","S000354","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0027177","Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome.","González-Ortiz M","2011","Metabolic syndrome and related disorders","other_trial","article","10.1089/met.2010.0025","20874425",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; article"],["R0027178","Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.","Oriot P","2011","Annales d'endocrinologie","case_report","article","10.1016/j.ando.2011.04.003","21652029",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027179","Compactness of Protein Folds Alters Disulfide-Bond Reducibility by Three Orders of Magnitude: A Comprehensive Kinetic Case Study on the Reduction of Differently Sized Tryptophan Cage Model Proteins.","Horváth D","2020","Chembiochem : a European journal of chemical biology","other","article","10.1002/cbic.201900470","31475422","PMC7079008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027180","Late and severe acute necrotizing pancreatitis in a patient with liraglutide.","Bourezane H","2012","Therapie","case_report","article","10.2515/therapie/2012076","23249582",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0027181","Effects of exenatide on plasma glucose and insulin concentrations in alpacas.","Smith CC","2009","Journal of veterinary internal medicine","randomized_trial","article","10.1111/j.1939-1676.2009.0335.x","19566854",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027182","Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.","Shyangdan D","2011","Health technology assessment (Winchester, England)","systematic_review","article","10.3310/hta15380","22059955","PMC4781160",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0027183","Switching from insulin to liraglutide improved glycemic control and the quality of life scores in a case of type 2 diabetes and active Crohn's disease.","Kuwata H","2014","Internal medicine (Tokyo, Japan)","case_report","article","10.2169/internalmedicine.53.2306","25088877",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027184","Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency.","Fojas EGF","2021","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2021.792354","35095762","PMC8793826",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027185","Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.","Fujioka K","2016","The Journal of family practice","other","article",null,"27565106",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027186","Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues.","Waser B","2014","European journal of nuclear medicine and molecular imaging","preclinical","article","10.1007/s00259-013-2684-4","24519555",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0027187","The effect of exenatide re-exposure on safety and efficacy.","Faludi P","2009","Peptides","other_trial","article","10.1016/j.peptides.2009.06.026","19576255",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0027188","Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.","Fraile JM","2021","Drug design, development and therapy","other_trial","article","10.2147/dddt.s315724","34588764","PMC8473845",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0027189","Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.","Zheng D","2009","Diabetes","preclinical","article","10.2337/db08-0875","19011168","PMC2628608",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027190","A Critical Role for β-Catenin in Modulating Levels of Insulin Secretion from β-Cells by Regulating Actin Cytoskeleton and Insulin Vesicle Localization.","Sorrenson B","2016","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m116.758516","27777306","PMC5207063",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027191","Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors.","Sirohi S","2016","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2016.04.013","27072507",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0027192","Clinical experience with exenatide in a routine secondary care diabetes clinic.","Natarajan B","2010","Primary care diabetes","other","article","10.1016/j.pcd.2009.11.001","20022310",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027193","Exenatide can reduce glucose independent of islet hormones or gastric emptying.","Ionut V","2008","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.90222.2008","18492781","PMC2519754",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027194","Liraglutide-associated acute pancreatitis.","Knezevich E","2012","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","case_report","article","10.2146/ajhp110221","22345417",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027195","Exenatide efficacy and safety: a systematic review.","Norris SL","2009","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/j.1464-5491.2009.02790.x","19719703",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; review"],["R0027196","Determination of taspoglutide in human and animal plasma using liquid chromatography-tandem mass spectrometry with orthogonal column-switching.","Heinig K","2009","Analytical chemistry","other","article","10.1021/ac900422e","19374429",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027197","Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.","Fabunmi R","2009","Current medical research and opinion","nonrandomized_study","article","10.1185/03007990802715199","19203299",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027198","Advancing pharmacotherapy for diabetic foot ulcers.","Eleftheriadou I","2019","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2019.1598378","30958725",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027199","Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.","Best JH","2009","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2009.02752.x","19573122","PMC2776933",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; research-article; article"],["R0027200","The use of exenatide in severely burned pediatric patients.","Mecott GA","2010","Critical care (London, England)","randomized_trial","article","10.1186/cc9222","20701787","PMC2945137","ClinicalTrials.gov:NCT00673309","S001345","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0027201","Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.","Morrow L","2011","Diabetes, obesity & metabolism","other","article","10.1111/j.1463-1326.2010.01322.x","21114606",null,null,"S001149","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027202","Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes.","Montrose-Rafizadeh C","1997","Journal of cellular physiology","preclinical","article","10.1002/(sici)1097-4652(199709)172:3<275::aid-jcp1>3.0.co;2-l","9284947",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0027203","Type 2 diabetes can be prevented with early pharmacological intervention.","DeFronzo RA","2011","Diabetes care","narrative_review","article","10.2337/dc11-s221","21525456","PMC3632162",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0027204","Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells.","Tornovsky-Babeay S","2014","Cell metabolism","other","article","10.1016/j.cmet.2013.11.007","24332968",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027205","Expression of CTB-10×rolGLP-1 in E. coli and its therapeutic effect on type 2 diabetes.","Tu P","2015","Current pharmaceutical biotechnology","preclinical","article","10.2174/138920101606150407114815","25860067",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027206","GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.","Li Y","2010","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-2010-1314","20308787","PMC2948479",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027207","Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues.","Itier R","2021","ESC heart failure","narrative_review","article","10.1002/ehf2.13222","33534958","PMC8006705",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027208","Exenatide enhances kaliuresis under conditions of hyperkalemia.","Marina AS","2011","Bulletin of experimental biology and medicine","preclinical","article","10.1007/s10517-011-1481-y","22808453",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027209","[News in diabetology 2016].","Jornayvaz FR","2017","Revue medicale suisse","other_trial","article",null,"28703534",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0027210","Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.","Davidson JA","2014","Postgraduate medicine","narrative_review","article","10.3810/pgm.2014.10.2819","25414933",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027211","Exenatide-associated ischemic renal failure.","Weise WJ","2009","Diabetes care","case_report","article","10.2337/dc08-1309","19171732","PMC6908415",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; other; article"],["R0027212","Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.","Ng CM","2018","British journal of clinical pharmacology","preclinical","article","10.1111/bcp.13463","29077992","PMC5809353",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027213","[Acute pancreatitis in a patient treated with liraglutide].","Artero A","2013","Medicina clinica","case_report","article","10.1016/j.medcli.2013.01.022","23507272",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Letter"],["R0027214","Incretins in the ICU: is insulin on its way out?","Kovalaske MA","2009","Critical care (London, England)","commentary","article","10.1186/cc7913","19591659","PMC2750134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; research-article; article"],["R0027215","Mobile Diabetes Intervention for Glycemic Control: Impact on Physician Prescribing.","Quinn CC","2014","Journal of diabetes science and technology","randomized_trial","article","10.1177/1932296813514503","24876589","PMC4455407",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0027216","Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science.","Singh AK","2015","Indian journal of endocrinology and metabolism","other","article","10.4103/2230-8210.146881","25593851","PMC4287769",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0027217","Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function.","Perfetti R","2000","European journal of endocrinology","preclinical","article","10.1530/eje.0.1430717","11124853",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027218","Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.","Zhang Z","2017","Cardiovascular diabetology","systematic_review","article","10.1186/s12933-017-0512-z","28249585","PMC5333444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; other; article"],["R0027219","SAT-667 Partial Beta-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes Mellitus","Quandt Z","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.1563",null,"PMC7207735",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0027220","Early clinical studies with liraglutide.","Schmidt WE","2010","International journal of clinical practice. Supplement","other_trial","article","10.1111/j.1742-1241.2010.02500.x","20887300",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027221","Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.","List JF","2004","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00007.2004","15140754",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review; article"],["R0027222","Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.","Beaudet A","2011","Journal of medical economics","randomized_trial","article","10.3111/13696998.2011.579213","21563878",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027223","Liraglutide in the management of type 2 diabetes.","Wajcberg E","2010","Drug design, development and therapy","narrative_review","article","10.2147/dddt.s10180","21116334","PMC2990388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027224","[Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)].","García-Hernández P","2010","Revista medica del Instituto Mexicano del Seguro Social","nonrandomized_study","article",null,"21205505",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; other"],["R0027225","PSUN263 Diagnosis of Latent Autoimmune Diabetes of Adulthood Unveiled After Initiation of an SGLT2 Inhibitor",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9624761",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0027226","LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.","Daniels GH","2015","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12444","25656058","PMC4405040",null,"S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027227","[Exenatide convinces in a six-month study: HbA1c sunk significantly].",null,"2009","MMW Fortschritte der Medizin","other","article",null,"19827448",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0027228","[Liraglutide reduces biomarkers and vascular risk in patients with diabetes mellitus type 2].","García de Lucas MD","2013","Revista medica de Chile","commentary","article","10.4067/s0034-98872013001200017","24728441",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0027229","[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].","Jermendy G","2016","Orvosi hetilap","randomized_trial","article","10.1556/650.2016.30416","27063427",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0027230","Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.","Elbrønd B","2002","Diabetes care","randomized_trial","article","10.2337/diacare.25.8.1398","12145241",null,null,"S000647","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial; Journal Article; Randomized Controlled Trial; article"],["R0027231","Exenatide once weekly in type 2 diabetes mellitus.","Bischoff LA","2011","Expert opinion on pharmacotherapy","other","article","10.1517/14656566.2011.573145","21548720",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027232","A quantitative assay for insulin-expressing colony-forming progenitors.","Winkler M","2011","Journal of visualized experiments : JoVE","preclinical","article","10.3791/3148","22143165","PMC3308582",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Video-Audio Media; research-article; article"],["R0027233","Glucose metabolism in critically ill patients: are incretins an important player?","Nielsen ST","2015","Journal of intensive care medicine","narrative_review","article","10.1177/0885066613503291","24065782",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027234","Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances.","Khunti K","2010","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2009.01186.x","20518803",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027235","The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).","Iogna Prat L","2018","Hormones (Athens, Greece)","narrative_review","article","10.1007/s42000-018-0021-9","29858843",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027236","Exenatide: excessive weight loss.",null,"2011","Prescrire international","other","article",null,"21462789",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027237","Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.","Brändle M","2009","International journal of clinical pharmacology and therapeutics","randomized_trial","article","10.5414/cpp47501","19640359",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027238","Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.","Youn YS","2007","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2006.09.013","17054919",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027239","Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation.","Torres G","2016","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2016.01.013","26807480","PMC4775317",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0027240","Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea.","Gao Y","2009","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2008.09.037","19019476",null,"ClinicalTrials.gov:NCT00324363","S002166","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027241","Impact of glucagon-like peptide-1 on endothelial function.","Sjöholm A","2009","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2009.01074.x","19878258",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027242","Novo Nordisk's reply to call for withdrawal of liraglutide.","Moses A","2012","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.e3706","22661724",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0027243","The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.","Agersø H","2002","Diabetologia","randomized_trial","article","10.1007/s00125-001-0719-z","11935150",null,null,"S000282","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial; Journal Article; Randomized Controlled Trial; article"],["R0027244","Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes.","Apovian CM","2010","The American journal of medicine","randomized_trial","article","10.1016/j.amjmed.2009.11.019","20399326",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027245","GLP-1: broadening the incretin concept to involve gut motility.","Hellström PM","2009","Regulatory peptides","preclinical","article","10.1016/j.regpep.2009.04.004","19362109",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027246","Management of Type 2 diabetes: the role of incretin mimetics.","Stonehouse AH","2006","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.7.15.2095","17020435",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027247","Evaluation of Pharmacologic Interventions for Weight Management in a Veteran Population.","Hood SR","2021","Federal practitioner : for the health care professionals of the VA, DoD, and PHS","nonrandomized_study","article","10.12788/fp.0117","34177231","PMC8221828",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027248","Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience.","Calderon G","2022","International journal of obesity (2005)","randomized_trial","article","10.1038/s41366-021-01019-6","34811486","PMC8881310",null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Multicenter Study; research-article"],["R0027249","Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.","Linnebjerg H","2008","Regulatory peptides","randomized_trial","article","10.1016/j.regpep.2008.07.003","18675854",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027250","Targeting the glucagon receptor family for diabetes and obesity therapy.","Cho YM","2012","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2012.05.009","22659620",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027251","Remission of insulin resistance in type 2 diabetic patients after gastric bypass surgery or exenatide therapy.","Yong W","2012","Obesity surgery","other","article","10.1007/s11695-012-0632-1","22441815",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027252","GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.","Egan JM","2003","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.357","12673779",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027253","Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.","Koole C","2010","Molecular pharmacology","preclinical","article","10.1124/mol.110.065664","20547734","PMC3202488",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0027254","Injectable and Thermosensitive Hydrogel Containing Liraglutide as a Long-Acting Antidiabetic System.","Chen Y","2016","ACS applied materials & interfaces","preclinical","article","10.1021/acsami.6b09415","27786459",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027255","Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.","Kothare PA","2008","Journal of clinical pharmacology","randomized_trial","article","10.1177/0091270008323750","19047364",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027256","Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.","Porter DW","2010","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2010.01259.x","20920042",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027257","Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time.","Gallwitz B","2010","International journal of clinical practice","randomized_trial","article","10.1111/j.1742-1241.2009.02265.x","19925617",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027258","Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","Nauck MA","2011","Diabetologia","narrative_review","article","10.1007/s00125-010-1896-4","20871975",null,null,"S002653","pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0027259","The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.","Fonseca T","2013","Journal of medical economics","other","article","10.3111/13696998.2013.803110","23659201",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027260","The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.","Tozzo E","2007","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.106.115337","17259449",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027261","Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care.","Nunes AP","2017","Diabetes therapy : research, treatment and education of diabetes and related disorders","nonrandomized_study","article","10.1007/s13300-017-0314-z","28983857","PMC5688980",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027262","[Case report: successful treatment with liraglutide in an insulin allergic patient with liver cirrhosis, hepatocellular carcinoma and poor glycemic control using high dose of insulin].","Fukushima S","2013","Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine","case_report","article","10.2169/naika.102.1455","23947212",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027263","Gut-Brain Axis and Metabolism in Polycystic Ovary Syndrome.","Saydam BO","2016","Current pharmaceutical design","narrative_review","article","10.2174/1381612822666160715143933","27426125",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027264","One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.","Bunck MC","2009","Diabetes care","randomized_trial","article","10.2337/dc08-1797","19196887","PMC2671094",null,"S001020","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027265","Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.","Willard FS","2012","Molecular pharmacology","other","article","10.1124/mol.112.080432","22930710",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027266","Exenatide: incretin therapy for patients with Type 2 diabetes mellitus.","Tahrani AA","2008","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.3.6.671","30764058",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027267","Para-Tyrosine Supplementation Improves Insulin- and Liraglutide- Induced Vasorelaxation in Cholesterol-Fed Rats.","Sélley E","2015","Protein and peptide letters","preclinical","article","10.2174/0929866522666150610093039","26202368",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027268","[Determination of serum acetaminophen based on the diazo reaction and its application in the evaluation of gastric emptying].","Li CN","2015","Yao xue xue bao = Acta pharmaceutica Sinica","preclinical","article",null,"26234136",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027269","Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?","Jax T","2009","Clinical research in cardiology : official journal of the German Cardiac Society","other","article","10.1007/s00392-008-0725-y","18853087",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027270","The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis.","Wang M","2022","Journal of thoracic disease","systematic_review","article","10.21037/jtd-22-550","35693625","PMC9186250",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; review"],["R0027271","Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.","Rother KI","2009","Diabetes care","randomized_trial","article","10.2337/dc09-0773","19808924","PMC2782986","ClinicalTrials.gov:NCT00064714","S000229; S000404","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural; research-article; article"],["R0027272","The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension.","Linnebjerg H","2009","International journal of clinical pharmacology and therapeutics","randomized_trial","article","10.5414/cpp47651","19840529",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027273","Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.","Diamant M","2010","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(10)60406-0","20609969",null,"ClinicalTrials.gov:NCT00641056","S000506; S001768; S002223","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027274","Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic beta-cell lines for use in transplantation.","Chepurny OG","2002","Cell and tissue research","preclinical","article","10.1007/s00441-001-0494-7","11845326","PMC2922114",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article"],["R0027275","[New drugs; exenatide and sitagliptin].","Diamant M","2008","Nederlands tijdschrift voor geneeskunde","commentary","article",null,"18717016",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0027276","Regulation of food intake and the development of anti-obesity drugs.","Chen Y","2016","Drug discoveries & therapeutics","narrative_review","article","10.5582/ddt.2016.01014","27063550",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027277","Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice","Xue B","2020","Research Square","preclinical","preprint","10.21203/rs.3.rs-25980/v3",null,null,null,null,"europepmc","FALSE",null,null,null,"Preprint"],["R0027278","Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.","Hupe-Sodmann K","1995","Regulatory peptides","other","article","10.1016/0167-0115(95)00063-h","8577927",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0027279","Euglycemic Diabetic Ketoacidosis Post Bariatric Surgery in Type II DM in the Setting of SGLT2-Inhibitor Use","Alfares K","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.775",null,"PMC8090053",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0027280","Managing patients with type 2 diabetes and obesity.","Wilding J","2015","The Practitioner","other","article",null,"25726618",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027281","One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.","Rosenstock J","2013","Journal of diabetes and its complications","randomized_trial","article","10.1016/j.jdiacomp.2013.04.008","23746555",null,null,"S000398","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027282","[Incretin role in osmotic homeostasis in rats].","Marina AS","2012","Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova","preclinical","article",null,"23431766",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Research Support, Non-U.S. Gov't; other"],["R0027283","Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.","Mahjoubin-Tehran M","2021","Molecular metabolism","nonrandomized_study","article","10.1016/j.molmet.2020.101049","32673798","PMC8324680",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0027284","Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.","DeVries JH","2012","Diabetes care","randomized_trial","article","10.2337/dc11-1928","22584132","PMC3379583","ClinicalTrials.gov:NCT00856986","S000398","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027285","Animal Venom Peptides as a Treasure Trove for New Therapeutics Against Neurodegenerative Disorders.","Yang X","2019","Current medicinal chemistry","narrative_review","article","10.2174/0929867325666181031122438","30378475",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027286","Comparative studies on exenatide-loaded poly (D,L-lactic-co-glycolic acid) microparticles prepared by a novel ultra-fine particle processing system and spray drying.","Zhu C","2015","Colloids and surfaces. B, Biointerfaces","preclinical","article","10.1016/j.colsurfb.2015.05.001","26037698",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027287","Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.","Connelly KA","2016","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.12258","25565455",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027288","Exenatide stimulates solute-free water clearance by the rat kidney in hyperhydration.","Marina AS","2011","Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections","preclinical","article","10.1134/s0012496611020128","21562952",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027289","Stapled and Xenopus Glucagon-Like Peptide 1 (GLP-1)-Based Dual GLP-1/Gastrin Receptor Agonists with Improved Metabolic Benefits in Rodent Models of Obesity and Diabetes.","Chen X","2020","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.0c00736","33125843",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027290","Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease.","Sandoval DA","2015","Physiological reviews","narrative_review","article","10.1152/physrev.00013.2014","25834231",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; review"],["R0027291","Past, present and future of pharmacotherapy for obesity.","Benaiges D","2017","Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis","narrative_review","article","10.1016/j.arteri.2017.06.002","28935287",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027292","Curcumin stimulates glucagon-like peptide-1 secretion in GLUTag cells via Ca2+/calmodulin-dependent kinase II activation.","Takikawa M","2013","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2013.04.092","23660191",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027293","Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.","Astrup A","2009","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(09)61375-1","19853906",null,"ClinicalTrials.gov:NCT00422058","S000866; S001402; S001419; S002036; S002445","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027294","Exenatide in type 2 diabetes.","Verzegnassi F","2010","Lancet (London, England)","commentary","article","10.1016/s0140-6736(10)61485-7","20870094",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0027295","Candidates for peptide receptor radiotherapy today and in the future.","Reubi JC","2005","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","narrative_review","article",null,"15653654",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027296","Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes.","Chokrungvaranon N","2007","Endocrine","nonrandomized_study","article","10.1007/s12020-008-9042-5","18266113",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; article"],["R0027297","A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.","Beinborn M","2005","Regulatory peptides","other","article","10.1016/j.regpep.2005.05.001","15975668",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S."],["R0027298","A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety.","Fitchett D","2017","The Canadian journal of cardiology","other","article","10.1016/j.cjca.2017.04.012","28668144",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Practice Guideline"],["R0027299","Pharmacological management of obesity in patients with type 2 diabetes.","Black RL","2016","Expert review of endocrinology & metabolism","other","article","10.1080/17446651.2016.1220300","30058912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027300","Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.","Tsioufis C","2017","Current vascular pharmacology","randomized_trial","article","10.2174/1570161114666161208150642","27928947",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0027301","The variable weight effect of exenatide treatment.","King AB","2008","Journal of diabetes science and technology","preclinical","article","10.1177/193229680800200329","19885224","PMC2769740",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0027302","Peptide dynamic fingerprints: a tool for investigating the role of conformational flexibility for GLP-1 analogs affinity.","Adenot M","2005","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.636","15641105",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027303","Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study.","Kahn SE","2021","Diabetes care","randomized_trial","article","10.2337/dc21-0461","34135015","PMC8740921","ClinicalTrials.gov:NCT01779362; ClinicalTrials.gov:NCT01779375; ClinicalTrials.gov:NCT01763346","S002086","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; other; article"],["R0027304","[Comments on current guidelines of type 2 diabetes mellitus treatment].","Martinka E","2017","Vnitrni lekarstvi","narrative_review","article","10.36290/vnl.2017.042","28379024",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027305","Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.","Holst JJ","2004","Expert opinion on emerging drugs","narrative_review","article","10.1517/eoed.9.1.155.32952","15155141",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027306","Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.","Ebinger M","2000","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.2000.279.1.e88","10893327",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027307","Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.","Weissler EH","2021","Diabetic medicine : a journal of the British Diabetic Association","other_trial","article","10.1111/dme.14552","33690915","PMC8429063",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027308","Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability.","Qi F","2013","Colloids and surfaces. B, Biointerfaces","preclinical","article","10.1016/j.colsurfb.2013.08.048","24075786",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027309","The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.","Chang AM","2003","Diabetes","randomized_trial","article","10.2337/diabetes.52.7.1786","12829647",null,null,"S000365","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; article"],["R0027310","Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.","Pageot C","2017","Drug safety","nonrandomized_study","article","10.1007/s40264-017-0561-y","28664354",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0027311","A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.","Sullivan SD","2009","Pharmacotherapy","randomized_trial","article","10.1592/phco.29.11.1280","19873688",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0027312","Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections.","Hallström S","2021","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2020.0577","33416422",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0027313","Hypothalamic AMPK and energy balance.","López M","2018","European journal of clinical investigation","narrative_review","article","10.1111/eci.12996","29999521","PMC6175178",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027314","One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.","Bunck MC","2010","Atherosclerosis","randomized_trial","article","10.1016/j.atherosclerosis.2010.04.024","20494360",null,"ClinicalTrials.gov:NCT00097500","S001020","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027315","Placental stem cell differentiation into islets of Langerhans-like glucagon-secreting cells.","Suşman S","2010","Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie","other","article",null,"21103634",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027316","Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.","Hermansen K","2010","Primary care diabetes","other","article","10.1016/j.pcd.2010.04.001","20444662",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027317","New Era: Endoscopic treatment options in obesity-a paradigm shift.","Glass J","2019","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v25.i32.4567","31528087","PMC6718037",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027318","Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis.","Mazze R","2009","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other_trial","article","10.4158/ep09046.orr","19454385",null,null,"S001251","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027319","Preserving insulin secretion in Type 2 diabetes mellitus.","Tibaldi J","2008","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.3.2.147","30764089",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027320","Exenatide: new drug. Type 2 diabetes for some overweight patients.",null,"2007","Prescrire international","randomized_trial","article",null,"18087791",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; article"],["R0027321","The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders.","McIntyre RS","2013","Behavioural brain research","narrative_review","article","10.1016/j.bbr.2012.09.021","23000536",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027322","Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines.","Baruah MP","2011","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.81935","21731863","PMC3125011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0027323","GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease.","Zheng J","2021","Molecular metabolism","preclinical","article","10.1016/j.molmet.2021.101180","33556642","PMC7905479",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0027324","Exenatide and renal failure.","Ferrer-Garcia JC","2010","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/j.1464-5491.2010.03009.x","20546299",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0027325","Diabetes management and hypoglycemia in safety sensitive jobs.","Lee SM","2011","Safety and health at work","narrative_review","article","10.5491/shaw.2011.2.1.9","22953182","PMC3431894",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0027326","Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.","Umapathysivam MM","2014","Diabetes","randomized_trial","article","10.2337/db13-0893","24089511","PMC3900552",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027327","Liraglutide Effect and Action in Diabetes (LEAD™) trial.","Madsbad S","2009","Expert review of endocrinology & metabolism","other_trial","article","10.1586/17446651.4.2.119","30780853",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0027328","Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets.","Sarkar SA","2007","Diabetologia","other","article","10.1007/s00125-007-0707-z","17593347",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0027329","Whole-brain activation signatures of weight-lowering drugs.","Hansen HH","2021","Molecular metabolism","preclinical","article","10.1016/j.molmet.2021.101171","33529728","PMC7895844",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027330","Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs.","Singh AK","2020","Expert review of clinical pharmacology","systematic_review","article","10.1080/17512433.2020.1698291","31770497",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0027331","The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis.","Terawaki Y","2013","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/1758-5996-5-10","23445717","PMC3598214",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0027332","Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.","Kenny PR","2010","The American journal of gastroenterology","case_report","article","10.1038/ajg.2010.363","21131943",null,null,"S000885; S002115","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Letter; Research Support, N.I.H., Extramural; article"],["R0027333","The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation.","Schnell O","2012","Journal of diabetes science and technology","narrative_review","article","10.1177/193229681200600323","22768899","PMC3440044",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027334","[Potential new antidiabetics for the next decade].","Svacina S","2009","Vnitrni lekarstvi","narrative_review","article",null,"19449764",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0027335","Potential of liraglutide in the treatment of patients with type 2 diabetes.","Deacon CF","2009","Vascular health and risk management","narrative_review","article","10.2147/vhrm.s4039","19436648","PMC2672437",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027336","Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.","Russell-Jones D","2009","Diabetologia","randomized_trial","article","10.1007/s00125-009-1472-y","19688338","PMC2744824","ClinicalTrials.gov:NCT00331851","S001123; S002098","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027337","Efficacy of liraglutide in a patient with type 2 diabetes and cryptogenic cirrhosis.","D'Amico E","2011","Acta bio-medica : Atenei Parmensis","case_report","article",null,"22480072",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027338","Rapid Identification and Validation of Novel Rheumatoid Arthritis Drug Treatments using an Integrative Bioinformatics Platform","Daugherty AC","2018","bioRxiv","other","preprint","10.1101/243998",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0027339","miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1.","Liu XL","2017","World journal of gastroenterology","preclinical","article","10.3748/wjg.v23.i46.8140","29290651","PMC5739921",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027340","Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.","Minshall ME","2008","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other_trial","article","10.1111/j.1524-4733.2007.00211.x","18237357",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Clinical Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027341","Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a post-hoc analysis.","Asakura T","2020","Current medical research and opinion","randomized_trial","article","10.1080/03007995.2020.1739636","32141343",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027342","A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner.","Schellenberger V","2009","Nature biotechnology","preclinical","article","10.1038/nbt.1588","19915550",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0027343","Evaluation of hypoglycemic and antioxidative effects of synthesized peptide MC62.","Yang B","2013","Chemical biology & drug design","preclinical","article","10.1111/cbdd.12137","23530748",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027344","Gateways to clinical trials.","Tomillero A","2009","Methods and findings in experimental and clinical pharmacology","other","article",null,"19798455",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0027345","Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.","Dore DD","2009","Current medical research and opinion","nonrandomized_study","article","10.1185/03007990902820519","19278373",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027346","Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.","Meng H","2008","Journal of medicinal chemistry","preclinical","article","10.1021/jm8008579","18950150","PMC2645917",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0027347","Exenatide and the treatment of Parkinson's disease","Athauda DS","2018","University College London (University of London)","other","article",null,null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Dissertation; dissertation"],["R0027348","Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy.","Kushner RF","2018","Progress in cardiovascular diseases","narrative_review","article","10.1016/j.pcad.2018.06.001","29890171",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027349","Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.","Bhushan R","2009","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2008.0090","19459763",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027350","Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.","Oh TJ","2013","Experimental & molecular medicine","preclinical","article","10.1038/emm.2013.58","23827952","PMC3731660",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027351","The biology of incretin hormones.","Drucker DJ","2006","Cell metabolism","preclinical","article","10.1016/j.cmet.2006.01.004","16517403",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027352","A model approach to biologics. Premera's method of analyzing the potential benefits of Byetta shows how third-party modeling can pinpoint which members can benefit from easier access--and how plans can determine authentic cost savings.","Carroll J","2007","Managed care (Langhorne, Pa.)","other","article",null,"17907710",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027353","Comment: acute pancreatitis associated with liraglutide.","Steinberg WM","2011","The Annals of pharmacotherapy","commentary","article","10.1345/aph.1p714a","21811002",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0027354","Current and emerging medications for overweight or obesity in people with comorbidities.","Fujioka K","2015","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12502","26040215","PMC4744746",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0027355","Peptibodies: An elegant solution for a long-standing problem.","Cavaco M","2017","Biopolymers","narrative_review","article","10.1002/bip.23095","29266205",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027356","Longacting exenatide in diabetes: DURATION-3.","Misra A","2010","Lancet (London, England)","commentary","article","10.1016/s0140-6736(10)60836-7","20609957",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0027357","Exenatide use in the management of metabolic syndrome: a retrospective database study.","Bhushan R","2008","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep.14.8.993","19095598",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027358","Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor.","Gremlich S","1995","Diabetes","preclinical","article","10.2337/diab.44.10.1202","7556958",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027359","Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis.","Mearns ES","2015","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.12837","26104021",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; article"],["R0027360","Geniposide ameliorates learning memory deficits, reduces tau phosphorylation and decreases apoptosis via GSK3β pathway in streptozotocin-induced alzheimer rat model.","Gao C","2014","Brain pathology (Zurich, Switzerland)","preclinical","article","10.1111/bpa.12116","24329968","PMC8029432",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027361","Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus.","Sheffield CA","2008","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.4158/ep.14.3.285","18463034",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027362","Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells.","Hadjiyanni I","2010","Diabetologia","preclinical","article","10.1007/s00125-009-1643-x","20225396",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027363","[Pharmacotherapy for obesity].","Bruun JM","2016","Ugeskrift for laeger","narrative_review","article",null,"27808050",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027364","Exenatide.","Barnett A","2007","Expert opinion on pharmacotherapy","other_trial","article","10.1517/14656566.8.15.2593","17931093",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0027365","Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.","Bergenstal R","2009","Current medical research and opinion","randomized_trial","article","10.1185/03007990802597951","19210140",null,"ClinicalTrials.gov:NCT00097877","S001674","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027366","Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.","Seino Y","2013","Journal of diabetes investigation","preclinical","article","10.1111/jdi.12065","24843641","PMC4019264",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027367","Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells.","Liu J","2006","International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","other","article","10.1016/j.ijdevneu.2006.08.009","17045447",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027368","Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.","Zanchi A","2012","Swiss medical weekly","narrative_review","article","10.4414/smw.2012.13629","22987488",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027369","Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting.","Buysman EK","2015","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2014.982750","25356602",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027370","Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings.","Rebello CJ","2016","Advances in therapy","narrative_review","article","10.1007/s12325-016-0414-6","27718159","PMC5083777",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027371","[Chronic Kidney Disease - Update 2018].","Ketteler M","2018","Deutsche medizinische Wochenschrift (1946)","other_trial","article","10.1055/s-0043-124831","29409087",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0027372","Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study.","Abdelgani S","2021","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14383","33852204","PMC8238899",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027373","The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.","Ryder RE","2013","Diabetic medicine : a journal of the British Diabetic Association","systematic_review","article","10.1111/dme.12301","24073725",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Review; article"],["R0027374","Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.","McIntosh B","2012","Open medicine : a peer-reviewed, independent, open-access journal","systematic_review","article",null,"23696771","PMC3659216",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; research-article; review"],["R0027375","The Trp cage motif as a scaffold for the display of a randomized peptide library on bacteriophage T7.","Herman RE","2007","The Journal of biological chemistry","randomized_trial","article","10.1074/jbc.m610722200","17264074",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0027376","Role of Vasopressin in the Regulation of Renal Sodium Excretion: Interaction with Glucagon-Like Peptide-1.","Kutina AV","2016","Journal of neuroendocrinology","preclinical","article","10.1111/jne.12367","26791475",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027377","Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.","Mittendorf T","2009","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2009.01099.x","19732121",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027378","Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.","Pinelli NR","2008","The Annals of pharmacotherapy","systematic_review","article","10.1345/aph.1l198","18957626",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; review"],["R0027379","Elevated glucagon-like peptide-1 plasma levels, as a possible adaptive response, in diabetic NOD mice.","Rydgren T","2012","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2012.06.011","22695119",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027380","Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.","Yanagimachi T","2017","Molecular metabolism","other","article","10.1016/j.molmet.2016.12.009","28180064","PMC5279935",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0027381","Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease.","Kaser S","2010","International journal of clinical practice","other_trial","article","10.1111/j.1742-1241.2009.02327.x","20584230",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0027382","[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].","Kress S","2010","Deutsche medizinische Wochenschrift (1946)","randomized_trial","article","10.1055/s-0030-1253676","20425675",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Case Reports; Journal Article; article"],["R0027383","Use of the analytic hierarchy process for medication decision-making in type 2 diabetes.","Maruthur NM","2015","PloS one","other","article","10.1371/journal.pone.0126625","26000636","PMC4441461",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0027384","A computer model simulating human glucose absorption and metabolism in health and metabolic disease states.","Naftalin RJ","2016","F1000Research","other","article","10.12688/f1000research.8299.1","27347379","PMC4909112",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; research-article; article"],["R0027385","The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics.","Kazda C","2009","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2009.01091.x","19758357",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0027386","Liraglutide therapy in Prader-Willi syndrome.","Cyganek K","2011","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/j.1464-5491.2011.03280.x","21388446",null,null,"S001714","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Case Reports; Letter; Research Support, Non-U.S. Gov't; article"],["R0027387","Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells.","Peyot ML","2009","PloS one","preclinical","article","10.1371/journal.pone.0006221","19593440","PMC2704866",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0027388","Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?",null,"2011","Annals of internal medicine","commentary","article","10.7326/0003-4819-154-2-201101180-00301","21135289",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Patient Education Handout; Journal Article; Comment; article"],["R0027389","Characterization of voltage operated R-type Ca2+ channels in modulating somatostatin receptor subtype 2- and 3-dependent inhibition of insulin secretion from INS-1 cells.","Mergler S","2008","Cellular signalling","preclinical","article","10.1016/j.cellsig.2008.08.015","18793718",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027390","Obesity: Pathophysiology and Management.","Gadde KM","2018","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2017.11.011","29301630","PMC7958889",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0027391","PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.","Youn YS","2008","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2007.00823.x","18034839",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027392","Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.","Moretto TJ","2008","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2008.08.006","18803987",null,null,"S000320","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027393","[Management of type 2 diabetes in 2010. Insulins and injectable drugs: role of the general practitioner].","Renneboog B","2010","Revue medicale de Bruxelles","other","article",null,"21089418",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0027394","Managing type 2 diabetes: balancing HbA1c and body weight.","Mavian AA","2010","Postgraduate medicine","narrative_review","article","10.3810/pgm.2010.05.2148","20463420",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027395","Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review.","Tak YJ","2021","The world journal of men's health","other_trial","article","10.5534/wjmh.200010","32202085","PMC7994651",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0027396","Exenatide pharmacokinetics in healthy Chinese subjects.","Zhao X","2008","International journal of clinical pharmacology and therapeutics","randomized_trial","article","10.5414/cpp46459","18793576",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027397","REAL WORLD SAFETY AND EFFICACY OF SGLT-2 INHIBITORS IN ELDERLY TYPE 2 DIABETIC PATIENTS","Trescoli Serrano C","2017","Innovation in aging","nonrandomized_study","article",null,null,"PMC6242237",null,null,"europepmc","FALSE","free_to_read","4",null,"Abstract"],["R0027398","Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.","Yamagishi S","2015","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-015-0176-5","25582643","PMC4298871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0027399","An enhanced participant information leaflet and multimedia intervention to improve the quality of informed consent to a randomised clinical trial enrolling people living with HIV and obesity: a protocol for a Study Within A Trial (SWAT).","O'Sullivan L","2022","Trials","protocol","article","10.1186/s13063-021-05979-y","35039057","PMC8762861","ClinicalTrials.gov:NCT04174755; EudraCT:2019-002314-39","S001849","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial Protocol; Journal Article; research-article; other; article"],["R0027400","Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.","Green BD","2003","Biological chemistry","preclinical","article","10.1515/bc.2003.171","14719796",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027401","Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohort.","Hartmann B","2015","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-015-0794-0","26239142",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't"],["R0027402","The endogenous preproglucagon system is not essential for gut growth homeostasis in mice.","Wismann P","2017","Molecular metabolism","preclinical","article","10.1016/j.molmet.2017.04.007","28702324","PMC5485241",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027403","The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.","Hansen HH","2014","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2014.08.010","25160746",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027404","Effect of antiobesity medications in patients with type 2 diabetes mellitus.","Choussein S","2009","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2008.01026.x","19236442",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027405","OR10-3 Long-term Weight Loss Maintenance with Obesity Pharmacotherapy: a 5-Year Retrospective Study",null,"2022","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC9624550",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0027406","Peptide-based probes for cancer imaging.","Reubi JC","2008","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","narrative_review","article","10.2967/jnumed.108.053041","18927341",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027407","Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).","Das AK","2019","The Journal of the Association of Physicians of India","other","article",null,"31801334",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Consensus Statement; article"],["R0027408","Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.","Larsen PJ","2005","Regulatory peptides","narrative_review","article","10.1016/j.regpep.2004.08.026","15780429",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027409","Exenatide effects on statin pharmacokinetics and lipid response.","Kothare PA","2007","International journal of clinical pharmacology and therapeutics","randomized_trial","article","10.5414/cpp45114","17323791",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027410","Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.","Paschou SA","2020","Endocrine","narrative_review","article","10.1007/s12020-019-02085-7","31538291",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027411","Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials.","Donekal S","2008","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2008.01.014","18314214",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027412","GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells.","Hu Y","2013","Molecular biology reports","other","article","10.1007/s11033-012-2290-8","23187735",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027413","Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.","Larsen PJ","2001","Diabetes","randomized_trial","article","10.2337/diabetes.50.11.2530","11679431",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027414","Liraglutide and calcitonin.","Bloomgarden Z","2010","Journal of diabetes","nonrandomized_study","article","10.1111/j.1753-0407.2010.00079.x","21140545",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0027415","[EFFECTS OF ORALLY AND PARENTERALLY ADMINISTERED ANALOGS OF PEPTIDE HORMONES ON RENAL WATER AND ION TRANSPORT].","Kutina AV","2016","Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova","preclinical","article",null,"30193436",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027416","Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.","Segal JB","2007","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2007.08.021","17919559",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Evaluation Study; Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0027417","Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?","Grieve DJ","2009","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2009.00376.x","19681866","PMC2765323",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0027418","Incretin-based drugs and the risk of congestive heart failure.","Yu OH","2015","Diabetes care","nonrandomized_study","article","10.2337/dc14-1459","25205143",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027419","Exenatide: a new promising antidiabetic agent.","Chakraborti CK","2010","Indian journal of pharmaceutical sciences","other_trial","article","10.4103/0250-474x.62228","20582183","PMC2883206",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0027420","[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].","Pujante Alarcón P","2012","Medicina clinica","other_trial","article","10.1016/j.medcli.2011.10.025","22209597",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Clinical Trial; Journal Article"],["R0027421","tGLP-1 and release of vasopressin and oxytocin from the isolated rat hypothalamo-neurohypophysial system: effects of a tGLP-1 receptor agonist and antagonist.","Bojanowska E","2001","Journal of physiology and pharmacology : an official journal of the Polish Physiological Society","preclinical","article",null,"11785773",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027422","[The incretin effect: a new therapeutic target in type 2 diabetes].","Féry F","2007","Revue medicale de Bruxelles","randomized_trial","article",null,"17958029",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","2","FALSE","Journal Article; article"],["R0027423","Liraglutide as additional treatment for type 1 diabetes.","Varanasi A","2011","European journal of endocrinology","other","article","10.1530/eje-11-0330","21646283",null,null,"S000404","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0027424","GLP-1 inhibits VEGFA-mediated signaling in isolated human endothelial cells and VEGFA-induced dilation of rat mesenteric arteries.","Egholm C","2016","American journal of physiology. Heart and circulatory physiology","preclinical","article","10.1152/ajpheart.00316.2016","27638877",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027425","Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.","Ghofaili KA","2007","Transplantation","other_trial","article","10.1097/01.tp.0000251379.46596.2d","17220786",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027426","Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes.","Brodows RG","2008","Current medical research and opinion","other_trial","article","10.1185/030079908x297268","18394265",null,"ClinicalTrials.gov:NCT00241423","S001006","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial, Phase III; Letter; Multicenter Study; Randomized Controlled Trial; article"],["R0027427","S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors.","Huang P","2021","Life sciences","preclinical","article","10.1016/j.lfs.2021.119136","33508289",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027428","Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.","Persson F","2021","Diabetes care","randomized_trial","article","10.2337/dc20-1622","33504496","PMC7985419","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article; other"],["R0027429","Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.","Arakaki RF","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12242","24298995","PMC4237556",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027430","Measurement of gastric emptying in diabetes.","Phillips LK","2014","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2014.06.005","25047170",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027431","Effect of pituitary adenylate cyclase-activating polypeptide in islet transplantation.","Sakuma Y","2009","Transplantation proceedings","preclinical","article","10.1016/j.transproceed.2008.10.064","19249552","PMC3777528",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0027432","Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.","Gallwitz B","2010","Diabetes, obesity & metabolism","commentary","article","10.1111/j.1463-1326.2010.01309.x","20977586",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0027433","Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.","Irwin N","2007","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.861","17486662",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027434","Application of comparative effectiveness research in evaluation of treatments for type 2 diabetes mellitus.","Ahmann A","2011","The American journal of managed care","other","article",null,"21517656",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027435","Treating diabetes with incretin hormones - clinical experience.","Handelsman Y","2008","Pediatric endocrinology reviews : PER","narrative_review","article",null,"18552752",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027436","Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk.","Ahmadieh H","2013","ISRN endocrinology","other","article","10.1155/2013/181240","23401790","PMC3562674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027437","Impaired MEK signaling and SERCA expression promote ER stress and apoptosis in insulin-resistant macrophages and are reversed by exenatide treatment.","Liang CP","2012","Diabetes","preclinical","article","10.2337/db11-1415","22751695","PMC3447920",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0027438","Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis.","Panunzi S","2021","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14304","33368954",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; article"],["R0027439","The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.","Tschöpe D","2013","Cardiovascular diabetology","narrative_review","article","10.1186/1475-2840-12-62","23574917","PMC3664601",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027440","Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.","Ihara M","2020","Journal of Alzheimer's disease : JAD","narrative_review","article","10.3233/jad-200049","32144994",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027441","The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients.","Sancho V","2007","International journal of molecular medicine","other","article","10.3892/ijmm.19.6.961","17487430",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027442","GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.","Körner M","2007","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.106.038679","17475961",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027443","Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.","Green BD","2005","The Journal of endocrinology","preclinical","article","10.1677/joe.1.05876","15845923",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027444","Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.","Yoshida M","2012","Diabetes research and clinical practice","case_report","article","10.1016/j.diabres.2011.12.024","22257418",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0027445","Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.","Davis SN","2007","Diabetes care","randomized_trial","article","10.2337/dc06-2532","17595353",null,"ClinicalTrials.gov:NCT00099333","S001379","pubmed; europepmc; openalex","FALSE","free_to_read","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0027446","Liraglutide reduces lipid accumulation in steatotic L‑02 cells by enhancing autophagy.","Zhou SW","2014","Molecular medicine reports","other","article","10.3892/mmr.2014.2569","25230688","PMC4214343",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027447","[The PROROK project results after 6 months of intervention (Prospective observation project focusing on the relevance of the difference between fasting blood glucose levels and postprandial blood glucose for estimation of success of type 2 diabetes therapy)].","-Žďarská DJ","2015","Vnitrni lekarstvi","nonrandomized_study","article",null,"26652965",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; Observational Study; article"],["R0027448","Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior.","Harasta AE","2015","Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","preclinical","article","10.1038/npp.2015.47","25669605","PMC4839521",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0027449","Rapidly dissolvable microneedle patches for transdermal delivery of exenatide.","Zhu Z","2014","Pharmaceutical research","preclinical","article","10.1007/s11095-014-1424-1","24867426",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027450","Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.","Kristensen J","2009","BMC cardiovascular disorders","randomized_trial","article","10.1186/1471-2261-9-31","19627582","PMC2728095",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027451","Incretins and preservation of endothelial function.","Koska J","2012","Cardiovascular & hematological agents in medicinal chemistry","preclinical","article","10.2174/187152512803530289","22827294",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027452","Mitofusins  <i>Mfn1<\/i>  and  <i>Mfn2<\/i>  are required to preserve glucose-but not incretin- stimulated beta cell connectivity and insulin secretion","Georgiadou E","2020","bioRxiv","preclinical","preprint","10.1101/2020.04.22.055384",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0027453","The role of incretin hormones and glucagon in patients with liver disease.","Junker AE","2017","Danish medical journal","narrative_review","article",null,"28552096",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027454","[Symptoms and early diagnostic possibilities of pancreatic endocrine cells hyperplasia (nesidioblastosis)].","Przybylik-Mazurek E","2012","Przeglad lekarski","other","article",null,"22764512",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0027455","Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.","Elashoff M","2011","Gastroenterology","nonrandomized_study","article","10.1053/j.gastro.2011.02.018","21334333","PMC4404515",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't; Webcast; research-article"],["R0027456","[New oral antidiabetic agents--clinical perspectives].","Fischer S","2008","Der Internist","narrative_review","article","10.1007/s00108-007-1999-2","18330534",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027457","Regulation of adipocyte formation by GLP-1/GLP-1R signaling.","Challa TD","2012","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m111.310342","22207759","PMC3307265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027458","Counterregulatory responses to postprandial hypoglycemia after Roux-en-Y gastric bypass.","Øhrstrøm CC","2021","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","other","article","10.1016/j.soard.2020.08.037","33039341",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027459","Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons.","Wan S","2007","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00562.2006","17322063",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0027460","The Effects of Exenatide Microsphere on Serum BGP and ALP Levels in ZDF Rats after Implantation.","Zhou W","2015","Clinical implant dentistry and related research","preclinical","article","10.1111/cid.12184","24299614",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027461","PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice.","Lee S","2006","Diabetologia","preclinical","article","10.1007/s00125-006-0234-3","16586064",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0027462","Diabetes and Ramadan: A concise and practical update.","Ahmed MH","2017","Journal of family medicine and primary care","narrative_review","article","10.4103/2249-4863.214964","29026740","PMC5629872",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027463","Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity.","Kalra S","2017","Indian journal of endocrinology and metabolism","other","article","10.4103/2230-8210.194341","28217527","PMC5240071",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0027464","Past, Present, and Future of Pharmacologic Therapy in Obesity.","Rodríguez JE","2016","Primary care","narrative_review","article","10.1016/j.pop.2015.08.011","26896200",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027465","Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.","Hansen J","2014","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-014-9286-8","24910203",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027466","Committing embryonic stem cells to early endocrine pancreas in vitro.","Ku HT","2004","Stem cells (Dayton, Ohio)","preclinical","article","10.1634/stemcells.2004-0027","15579640",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027467","Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example.","Aroda VR","2019","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13804","31168921","PMC6771751",null,"S001741","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0027468","Risk of de-novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications.","Kochhar GS","2020","Alimentary pharmacology & therapeutics","nonrandomized_study","article","10.1111/apt.15721","32319111",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0027469","5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1.","Altieri P","2017","British journal of pharmacology","other","article","10.1111/bph.13725","28127745","PMC5647192",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027470","Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.","Mathews SE","2018","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000432","30074500",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027471","[The importance of integrated treatment of type 2 diabetes].","Kawamori R","2010","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"20229807",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Research Support, Non-U.S. Gov't; other"],["R0027472","Drug-induced hypoglycaemia in type 2 diabetes.","Inkster B","2012","Expert opinion on drug safety","narrative_review","article","10.1517/14740338.2012.694424","22690846",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027473","The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.","Eleftheriadou I","2008","Current diabetes reviews","systematic_review","article","10.2174/157339908786241133","18991602",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; article"],["R0027474","Roux-en-Y Gastric Bypass","Mitchell BG","2024","StatPearls Publishing, Treasure Island (FL)","nonrandomized_study","article",null,"31985950",null,null,null,"europepmc","TRUE","free_to_read","4",null,"Study Guide"],["R0027475","GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.","Gault VA","2008","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2008.03.025","18466898",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027476","Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.","Vedtofte L","2010","Regulatory peptides","preclinical","article","10.1016/j.regpep.2009.12.005","20005262",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027477","Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.","Palmer SC","2016","JAMA","systematic_review","article","10.1001/jama.2016.9400","27434443",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis; article"],["R0027478","The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem.","Alvarez E","2005","Journal of neurochemistry","other","article","10.1111/j.1471-4159.2004.02914.x","15686481",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027479","Separation of exenatide analogue mono-PEGylated with 40 kDA polyethylene glycol by cation exchange chromatography.","Cai Y","2011","Journal of chromatography. A","other","article","10.1016/j.chroma.2011.07.107","21862025",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027480","Euglycaemic ketoacidosis: a potential new hazard to plastic surgery day case and inpatient procedures.","Sleiwah A","2017","BMJ case reports","case_report","article","10.1136/bcr-2017-220253","28794087","PMC5747659",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0027481","Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.","Cao B","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13373","29790638",null,"PROSPERO:CRD42018085967",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; Network Meta-Analysis; review"],["R0027482","The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.","Zinman B","2007","Annals of internal medicine","randomized_trial","article","10.7326/0003-4819-146-7-200704030-00003","17404349",null,"ClinicalTrials.gov:NCT00099320","S001305","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027483","Exenatide: pancreatitis. Gastrointestinal symptoms.",null,"2009","Prescrire international","other","article",null,"19588557",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027484","Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model.","Van Name M","2020","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2019.0448","31859529","PMC7869879",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027485","Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.","Cai J","2017","Current medical research and opinion","nonrandomized_study","article","10.1080/03007995.2017.1320277","28418262",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0027486","Evaluation of the therapeutic benefits and harms of exenatide: Executive summary of final report A05-23, Version 1.0",null,"2005","Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany","narrative_review","article",null,"24783281",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0027487","[Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study].","De Block C","2009","Revue medicale de Liege","nonrandomized_study","article",null,"19911661",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","4","FALSE","Journal Article; Multicenter Study; article"],["R0027488","Current strategies for the inhibition of hepatic glucose production in type 2 diabetes.","Edgerton DS","2009","Frontiers in bioscience (Landmark edition)","narrative_review","article","10.2741/3301","19273123",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027489","Adding exenatide to thiazolidinediones in type 2 diabetes: who will it help?",null,"2007","BMJ (Clinical research ed.)","other","article","10.1136/bmj.39176.666701.80",null,"PMC1851997",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Other; article"],["R0027490","Glucagon-like peptide-1 in nonalcoholic steatohepatitis","Armstrong MJ","2014","University of Birmingham","randomized_trial","article",null,null,null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Dissertation; dissertation"],["R0027491","[Exenatide trials for the treatment of type 2 diabetes].","Fernández Landó L","2009","Medicina","other_trial","article",null,"19770100",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; article"],["R0027492","Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.","Kim D","2007","Diabetes care","randomized_trial","article","10.2337/dc06-2375","17353504",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027493","Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury.","Yoon AH","2014","Journal of cardiovascular pharmacology and therapeutics","preclinical","article","10.1177/1074248414524482","24607763",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027494","Descriptive Analysis of Reported Adverse Events Associated with Antiobesity Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013-2020","Alsuhibani A","2021","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-628129/v1",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0027495","Exenatide: a new option for the treatment of type 2 diabetes.","Yoo BK","2006","The Annals of pharmacotherapy","randomized_trial","article","10.1345/aph.1h060","16985091",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0027496","GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects.","Sulistio M","2009","Current atherosclerosis reports","preclinical","article","10.1007/s11883-009-0015-9","19228481",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027497","Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.","Nakajima K","2012","International journal of hepatology","other","article","10.1155/2012/950693","23304532","PMC3523542",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027498","Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Quality Control.","Zeng K","2015","The AAPS journal","other","article","10.1208/s12248-015-9730-z","25716148","PMC4406950",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0027499","Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?","Bagnoli E","2019","The European journal of neuroscience","other_trial","article","10.1111/ejn.14115","30120857",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027500","Reducing renal uptake of radiolabeled peptides using albumin fragments.","Vegt E","2008","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","preclinical","article","10.2967/jnumed.108.053249","18703613",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0027501","Precision Obesity Treatments Including Pharmacogenetic and Nutrigenetic Approaches.","Solas M","2016","Trends in pharmacological sciences","narrative_review","article","10.1016/j.tips.2016.04.008","27236593",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0027502","Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis.","Ellrichmann M","2009","The American journal of gastroenterology","case_report","article","10.1038/ajg.2009.444","19956143",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0027503","Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.","Sinha A","2010","Diabetes care","other","article","10.2337/dc09-1488","20056950","PMC2845008",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0027504","Involvement of gut microbiota in association between GLP-1/GLP-1 receptor expression and gastrointestinal motility.","Yang M","2017","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00232.2016","28154011",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027505","A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39,845 patients.","Esposito K","2014","Acta diabetologica","systematic_review","article","10.1007/s00592-012-0370-9","24809070",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review"],["R0027506","Changes in prescribing patterns and clinical outcomes in elderly diabetic patients in 2000 and 2010: analysis of a large Italian population-based study.","Baviera M","2014","European journal of clinical pharmacology","nonrandomized_study","article","10.1007/s00228-014-1678-x","24820766",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0027507","Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?","Ahluwalia R","2009","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/j.1464-5491.2009.02753.x","19709161",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; Comment; article"],["R0027508","Defined Paraventricular Hypothalamic Populations Exhibit Differential Responses to Food Contingent on Caloric State.","Li C","2019","Cell metabolism","preclinical","article","10.1016/j.cmet.2018.10.016","30472090","PMC6402975",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; research-article"],["R0027509","Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.","Jackson EK","2015","Hypertension (Dallas, Tex. : 1979)","preclinical","article","10.1161/hypertensionaha.114.04631","25368027","PMC4268428",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0027510","[Diabetic ketoacidosis after switching insulin for exenatide].","Iglesias P","2011","Medicina clinica","case_report","article","10.1016/j.medcli.2009.10.026","20045132",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Letter"],["R0027511","Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes.","Yang M","2013","Diabetes care","other_trial","article","10.2337/dc12-0940","23275352","PMC3631846",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027512","Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets.","Singh V","2007","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2006-1578","17105845",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027513","Exenatide for type 2 diabetes.","Garattini S","2009","Lancet (London, England)","commentary","article","10.1016/s0140-6736(09)60034-9","19135608",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0027514","Liraglutide for the treatment of type 2 diabetes mellitus.",null,"2010","NICE","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Practice Guideline"],["R0027515","Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.","Rashid O","2016","BMJ case reports","case_report","article","10.1136/bcr-2016-215340","27177938","PMC4885363",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0027516","Can newer therapies delay the progression of type 2 diabetes mellitus?","Horton ES","2008","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.4158/ep.14.5.625","18753109",null,null,null,"europepmc","FALSE",null,null,null,"Review; Journal Article"],["R0027517","Exenatide and pancreatitis: an update.","Bain SC","2008","Expert opinion on drug safety","commentary","article","10.1517/14740330802432003","18983211",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0027518","Glucagon-like peptide-1.","Doyle ME","2001","Recent progress in hormone research","preclinical","article","10.1210/rp.56.1.377","11237222",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027519","Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent \"compound 2\" at the GLP-1 receptor.","Coopman K","2010","The Journal of pharmacology and experimental therapeutics","other","article","10.1124/jpet.110.166009","20507928","PMC2939672",null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; research-article"],["R0027520","NICE approves liraglutide for diabetic patients not achieving glucose control.","Mayor S","2010","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.c5062","20843934",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0027521","Exenatide: renal failure. Risk-benefit balance becoming uncertain.",null,"2009","Prescrire international","other","article",null,"19639682",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027522","Gut Microbiota of Obese, Type 2 Diabetic Individuals is Enriched in Faecalibacterium prausnitzii, Akkermansia muciniphila and Peptostreptococcus anaerobius after Weight Loss.","Remely M","2016","Endocrine, metabolic & immune disorders drug targets","other","article","10.2174/1871530316666160831093813","27577947",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027523","Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.","Andrews CN","2007","Neurogastroenterology and motility","randomized_trial","article","10.1111/j.1365-2982.2007.00923.x","17727392","PMC2538797",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0027524","Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis.","Zintzaras E","2014","Clinical therapeutics","systematic_review","article","10.1016/j.clinthera.2014.06.035","25109773",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis"],["R0027525","Efficacy of pharmacotherapy for OSA in adults: A systematic review and network meta-analysis.","Gaisl T","2019","Sleep medicine reviews","systematic_review","article","10.1016/j.smrv.2019.04.009","31075665",null,"PROSPERO:CRD42018086446",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Systematic Review; conference-abstract"],["R0027526","Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.","Garber A","2009","Lancet (London, England)","randomized_trial","article","10.1016/s0140-6736(08)61246-5","18819705",null,"ClinicalTrials.gov:NCT00294723","S000566; S000767; S000838; S001094; S002604","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027527","Noninvasive assessment of coronary microvascular dysfunction using SPECT myocardial perfusion imaging and myocardial perfusion entropy quantification in a rodent model of type 2 diabetes.","Carabelli A","2022","European journal of nuclear medicine and molecular imaging","preclinical","article","10.1007/s00259-021-05511-z","34417856",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027528","Gateways to clinical trials.","Tomillero A","2009","Methods and findings in experimental and clinical pharmacology","other","article",null,"20140276",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0027529","New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.","Hussar DA","2010","Journal of the American Pharmacists Association : JAPhA","other","article","10.1331/japha.2010.10520","20452924",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027530","Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.","Paul SK","2015","Journal of diabetes","other","article","10.1111/1753-0407.12208","25168883",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027531","Update on insulin therapy for type 2 diabetes.","Donner T","2012","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2011-2202","22442275","PMC3791411",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0027532","Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis.","Pingitore P","2019","International journal of molecular sciences","preclinical","article","10.3390/ijms20071629","30986904","PMC6480107",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027533","GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro.","Gallwitz B","2000","Regulatory peptides","preclinical","article","10.1016/s0167-0115(99)00095-6","10672909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027534","[Status of pharmacotherapy in current care of obese].","Sucharda P","2017","Casopis lekaru ceskych","other","article",null,"29212337",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027535","Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.","Glass LC","2008","Current medical research and opinion","randomized_trial","article","10.1185/030079908x260862","18218179",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027536","Anti-obesity drugs: past, present and future.","Rodgers RJ","2012","Disease models & mechanisms","narrative_review","article","10.1242/dmm.009621","22915024","PMC3424459",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article-commentary; article"],["R0027537","Exenatide use in islet transplantation: words of caution.","Rickels MR","2009","Transplantation","randomized_trial","article","10.1097/tp.0b013e318191eb48","19136906",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Letter; Comment; article"],["R0027538","Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.","Oster G","2016","Postgraduate medicine","randomized_trial","article","10.1080/00325481.2016.1241663","27690710",null,"ClinicalTrials.gov:NCT02451137","S002636","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Pragmatic Clinical Trial; article"],["R0027539","[Exenatide: use in humans].","Sierra-Ascencio ME","2006","Gaceta medica de Mexico","other_trial","article",null,"17201111",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; article"],["R0027540","Doxylamine succinate/pyridoxine hydrochloride.","Cada DJ","2013","Hospital pharmacy","other_trial","article","10.1310/hpj4809-762","24421551","PMC3857125",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0027541","Recent advances in pharmacotherapy for hypertriglyceridemia.","Sahebkar A","2014","Progress in lipid research","other_trial","article","10.1016/j.plipres.2014.07.002","25083925",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0027542","A new Alzheimer's disease interventive strategy: GLP-1.","Perry TA","2004","Current drug targets","preclinical","article","10.2174/1389450043345245","15270203",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027543","Gateways to clinical trials.","Tomillero A","2010","Methods and findings in experimental and clinical pharmacology","other","article","10.1358/mf.2010.32.7.1549223","21069103",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Bibliography; Journal Article; article"],["R0027544","Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.","Edavalath M","2010","Patient preference and adherence","other_trial","article","10.2147/ppa.s6358","20361006","PMC2846140",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0027545","A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.","McAdam-Marx C","2009","Diabetes, obesity & metabolism","commentary","article","10.1111/j.1463-1326.2009.01163.x","19930007",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0027546","Cardiovascular Effects of the New Weight Loss Agents.","Vorsanger MH","2016","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2016.06.007","27539178",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0027547","Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.","Banini BA","2016","Clinical medicine insights. Therapeutics","other","article","10.4137/cmt.s18885","28670148","PMC5491796",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027548","Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.","Nauck M","2009","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2009.05.1997","19491535",null,"ClinicalTrials.gov:NCT00318422; ClinicalTrials.gov:NCT00318461","S001502; S001584","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; article"],["R0027549","Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly.","Paul SK","2016","Journal of diabetes","other","article","10.1111/1753-0407.12269","25586464",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027550","Directed differentiation of rhesus monkey ES cells into pancreatic cell phenotypes.","Lester LB","2004","Reproductive biology and endocrinology : RB&E","narrative_review","article","10.1186/1477-7827-2-42","15200687","PMC449734",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review; review-article; article"],["R0027551","RF25 | PMON76 Kissing carotid arteries: An unusual cause of male hypogonadotropic hypogonadism.",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9625186",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0027552","PSUN259 A Severe Case of Fournier's Gangrene Associated With Dapagliflozin",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9625050",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0027553","Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.","Banerji MA","2014","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2014.05.2761","24918797",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027554","A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.","Fisman EZ","2009","Cardiovascular diabetology","narrative_review","article","10.1186/1475-2840-8-38","19619327","PMC2723076",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0027555","The intravenous glucose tolerance test in cannulated Wistar rats: a robust method for the in vivo assessment of glucose-stimulated insulin secretion.","Frangioudakis G","2008","Journal of pharmacological and toxicological methods","preclinical","article","10.1016/j.vascn.2007.12.002","18280184",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027556","Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts.","Axelsen LN","2012","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2011.01714.x","22014161","PMC3423242",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027557","Managing type 2 diabetes: new policy and interventions.","Gillibrand W","2009","British journal of community nursing","narrative_review","article","10.12968/bjcn.2009.14.7.43072","19597379",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027558","Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy.","De León DD","2003","Diabetes","preclinical","article","10.2337/diabetes.52.2.365","12540609",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0027559","Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.","Davis KL","2013","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2013.811403","23734906",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027560","Obesity Therapy: How and Why?","Paccosi S","2020","Current medicinal chemistry","other","article","10.2174/0929867326666190124121725","30678612",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027561","RF24 | PSUN127 Congenital Leptin Deficiency: Metabolic, Reproductive, and Psychological Impacts of Therapy",null,"2022","Journal of the Endocrine Society","other_trial","article",null,null,"PMC9626923",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0027562","Exenatide Use in Islet Transplantation - Reasons to Remain Optimistic.","Froud T","2009","Transplantation","randomized_trial","article","10.1097/tp.0b013e318191ebe9","20737025","PMC2925279",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0027563","Liraglutide for weight loss in obese people.","Thum T","2010","Lancet (London, England)","commentary","article","10.1016/s0140-6736(10)60226-7","20159285",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0027564","Liraglutide in islet transplantation: from bench to bedside.","Berney T","2010","Transplant international : official journal of the European Society for Organ Transplantation","commentary","article","10.1111/j.1432-2277.2009.01018.x","20456108",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Journal Article; article"],["R0027565","Catalase and nonalcoholic fatty liver disease.","Shin SK","2018","Pflugers Archiv : European journal of physiology","narrative_review","article","10.1007/s00424-018-2195-z","30120555",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027566","Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.","Forti A","2008","Current medical research and opinion","randomized_trial","article","10.1185/03007990802282398","18662495",null,"ClinicalTrials.gov:NCT00359879","S002204","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027567","Liraglutide for weight loss in obese people.","Hallberg P","2010","Lancet (London, England)","commentary","article","10.1016/s0140-6736(10)60225-5","20159284",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comment; Letter; article"],["R0027568","Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.","Reaney M","2013","Health and quality of life outcomes","nonrandomized_study","article","10.1186/1477-7525-11-217","24369764","PMC3900476","ClinicalTrials.gov:NCT00635492","S001805","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0027569","Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.","Son JP","2013","Die Pharmazie","preclinical","article","10.31083/ph.2013.2125","23444782",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027570","Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes.","Mudaliar S","2013","International journal of clinical practice","narrative_review","article","10.1111/ijcp.12154","23952467",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027571","Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.","Barnett AH","2007","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2007.11.006","18158075",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027572","The Coronary Circulation as a Target of Cardioprotection.","Heusch G","2016","Circulation research","narrative_review","article","10.1161/circresaha.116.308640","27174955",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0027573","Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.","Boyle LD","2013","Expert opinion on emerging drugs","narrative_review","article","10.1517/14728214.2013.831405","23968378",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027574","Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.","Yoon NM","2009","Clinical therapeutics","nonrandomized_study","article","10.1016/j.clinthera.2009.07.021","19695400",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027575","Suvorexant.","Cada DJ","2015","Hospital pharmacy","other_trial","article","10.1310/hpj5001-59","25684802","PMC4321430",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; research-article; article"],["R0027576","Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.","Pei Z","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.117651","32304764",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027577","Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.","Schwartz SL","2008","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2008.05.004","18555933",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027578","Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.","Ray JA","2007","Current medical research and opinion","randomized_trial","article","10.1185/030079907x178685","17355742",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027579","[Glucagon-like peptide-1: pleiotropic effects on the cardiovascular system].","Avogaro A","2008","Giornale italiano di cardiologia (2006)","narrative_review","article",null,"19058666",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0027580","Case Study: Weight loss in a patient with type 2 diabetes: Challenges of diabetes management.","Lotfi K","2015","Obesity (Silver Spring, Md.)","case_report","article","10.1002/oby.21095","25900868",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027581","Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus.","Gustavson SM","2011","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2011.01479.x","21812891",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027582","Alpelisib-Induced Hyperglycemia- A Small Case Series","Ekanayake P","2021","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvab048.744",null,"PMC8090169",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0027583","In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.","Yu L","2013","Journal of pharmaceutical sciences","preclinical","article","10.1002/jps.23735","24114868",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027584","GLP-1 acts on habenular avoidance circuits to control nicotine intake.","Tuesta LM","2017","Nature neuroscience","preclinical","article","10.1038/nn.4540","28368384","PMC5541856",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0027585","Exenatide once weekly in type 2 diabetes.","Scheen AJ","2008","Lancet (London, England)","commentary","article","10.1016/s0140-6736(08)61207-6","18782642",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0027586","[Liraglutide in the treatment of diabetes type 2].","Novak B","2011","Lijecnicki vjesnik","narrative_review","article",null,"22165195",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0027587","beta-cell function and anti-diabetic pharmacotherapy.","Del Prato S","2007","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.770","17883249",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027588","Missing data in clinical trials for weight management.","McEvoy BW","2016","Journal of biopharmaceutical statistics","narrative_review","article","10.1080/10543406.2015.1094814","26418188",null,null,"S000492; S001278; S001792","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0027589","Alogliptin benzoate for the treatment of type 2 diabetes.","Rendell M","2012","Expert opinion on pharmacotherapy","other_trial","article","10.1517/14656566.2012.656088","22296609",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027590","Persistent C-peptide: what does it mean?","Pietropaolo M","2013","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0b013e3283628610","23743645",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; article"],["R0027591","Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study.","Sam S","2021","Diabetes care","randomized_trial","article","10.2337/dc21-0027","34131048","PMC8740917","ClinicalTrials.gov:NCT01779362; ClinicalTrials.gov:NCT01779375","S002086","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article; other"],["R0027592","Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes.","Velez M","2015","Journal of cardiac failure","nonrandomized_study","article","10.1016/j.cardfail.2014.10.012","25451709","PMC4276467",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0027593","Gateways to clinical trials.","Tomillero A","2010","Methods and findings in experimental and clinical pharmacology","other","article","10.1358/mf.2010.32.4.1507200","20508873",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Bibliography; Journal Article; article"],["R0027594","[Clinical and economic benefits of the new antidiabetic drugs in the Czech Republic].","Doležal T","2015","Vnitrni lekarstvi","other","article",null,"26652966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027595","Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.","Khera R","2018","Gastroenterology","systematic_review","article","10.1053/j.gastro.2017.12.024","29305933","PMC5880739","PROSPERO:CRD42016039486",null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Research Support, N.I.H., Extramural; Systematic Review; Network Meta-Analysis; research-article"],["R0027596","Roles of cAMP signalling in insulin granule exocytosis.","Seino S","2009","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2009.01108.x","19817800",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027597","Effect of GLP-1 on glucose transport and its cell signalling in human myocytes.","González N","2005","Regulatory peptides","preclinical","article","10.1016/j.regpep.2004.10.002","15664668",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027598","[New therapies for diabetes: beyond injectable insulin and oral antidiabetics].","Alfonso JE","2008","Revista da Associacao Medica Brasileira (1992)","narrative_review","article","10.1590/s0104-42302008000500020","18989567",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0027599","Exenatide and rare adverse events.","Cure P","2008","The New England journal of medicine","commentary","article","10.1056/nejmc0707137","18450614",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0027600","Prediabetes: to treat or not to treat?","Moutzouri E","2011","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2011.10.007","22020287",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027601","Exenatide.","Barnett AH","2005","Drugs of today (Barcelona, Spain : 1998)","narrative_review","article","10.1358/dot.2005.41.9.893704","16341288",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027602","Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.","Brom M","2014","Diabetologia","nonrandomized_study","article","10.1007/s00125-014-3166-3","24488022",null,"ClinicalTrials.gov:NCT01825148; EudraCT:2012-000619-10","S002168","pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0027603","WEIGHT LOSS IN A YOUNG PATIENT WITH TYPE 2 DIABETES: CHALLENGES OF DIABETES MANAGEMENT USING ONLINE PROGRAM OF GOOD NUTRITION (CASE REPORT).","Krylov V","2018","Georgian medical news","case_report","article",null,"29745914",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027604","[New drugs; exenatide and sitagliptin].","van Bronswijk H","2008","Nederlands tijdschrift voor geneeskunde","narrative_review","article",null,"18512528",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027605","Recent evidence of sustained benefit with exenatide in Type 2 diabetes.","Doggrell SA","2006","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1517/14656566.7.14.2003","17020425",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0027606","Randomised controlled trial: Liraglutide for weight loss: more research is needed.","Tsai AG","2010","Evidence-based medicine","randomized_trial","article","10.1136/ebm1041","20436119",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Comment; Journal Article; article"],["R0027607","A dramatic deterioration in diabetic retinopathy with improvement in glycated haemoglobin (HbA(1c)) on exenatide treatment.","Brooks AM","2009","Diabetic medicine : a journal of the British Diabetic Association","case_report","article","10.1111/j.1464-5491.2008.02650.x","19236627",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0027608","Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?","Bassil F","2014","Progress in neurobiology","narrative_review","article","10.1016/j.pneurobio.2014.02.005","24582776",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027609","Obesity: Current Treatment and Future Horizons.","Omran Z","2017","Mini reviews in medicinal chemistry","narrative_review","article","10.2174/1389557516666160617100328","27320641",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027610","Exenatide and rare adverse events.","Ahmad SR","2008","The New England journal of medicine","commentary","article",null,"18456920",null,null,"S002088","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Letter; letter"],["R0027611","Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.","Juhl CB","2002","Diabetes","randomized_trial","article","10.2337/diabetes.51.2.424","11812750",null,null,"S002144","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027612","[Therapeutic behavior to follow in the following clinical case: treatment of type 2 diabetes].","Mateos L","2010","Revista clinica espanola","case_report","article","10.1016/j.rce.2009.04.003","20144794",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; English Abstract; Journal Article"],["R0027613","The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review.","Wharton S","2019","Journal of drug assessment","narrative_review","article","10.1080/21556660.2019.1678478","33110683","PMC7567517",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; review"],["R0027614","Protection of pancreatic beta-cells: is it feasible?","Bonora E","2008","Nutrition, metabolism, and cardiovascular diseases : NMCD","narrative_review","article","10.1016/j.numecd.2007.05.004","18096375",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027615","Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men.","Soon D","2006","Journal of clinical pharmacology","other_trial","article","10.1177/0091270006291622","16988207",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027616","Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.","Parks M","2010","The New England journal of medicine","narrative_review","article","10.1056/nejmp1001578","20164475",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0027617","Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients.","Koh A","2010","Transplantation","randomized_trial","article","10.1097/tp.0b013e3181bcdbe8","20145529",null,null,null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0027618","Characterization and isolation of promoter-defined nestin-positive cells from the human fetal pancreas.","Humphrey RK","2003","Diabetes","preclinical","article","10.2337/diabetes.52.10.2519","14514635",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0027619","Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.","Øhrstrøm CC","2020","Obesity surgery","other_trial","article","10.1007/s11695-020-04387-6","31907828",null,"ClinicalTrials.gov:NCT02527993","S000462","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027620","Exenatide: pancreatitis. Watch out for nausea and vomiting.",null,"2008","Prescrire international","other","article",null,"18630353",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027621","Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes.","Kadowaki T","2009","Endocrine journal","randomized_trial","article","10.1507/endocrj.k08e-296","19194050",null,null,"S001906","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027622","Peptide ligations accelerated by N-terminal aspartate and glutamate residues.","Thomas GL","2011","Organic letters","other","article","10.1021/ol2017356","21830797",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027623","Exenatide-induced depression in a geriatric patient.","Kohen I","2008","International journal of geriatric psychiatry","case_report","article","10.1002/gps.1937","18383195",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0027624","[Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].","Scheen AJ","2016","Revue medicale suisse","other","article",null,"28671791",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0027625","ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice.","Edmunds SJ","2019","Diabetologia","preclinical","article","10.1007/s00125-019-4877-2","31069401","PMC6560211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027626","Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169,572 per QALY and exenatide with $278,935 per QALY as second-line treatment in adult diabetics in the USA.","Davis WA","2010","Evidence-based medicine","commentary","article","10.1136/ebm1034","20436114",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comment; Journal Article; article"],["R0027627","Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity.","Preumont V","2010","Diabetes & metabolism","other","article","10.1016/j.diabet.2010.02.001","20447851",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027628","Anorexigenic lipopeptides ameliorate central insulin signaling and attenuate tau phosphorylation in hippocampi of mice with monosodium glutamate-induced obesity.","Špolcová A","2015","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-143150","25624414",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027629","Effect of renal impairment on the pharmacokinetics of exenatide.","Linnebjerg H","2007","British journal of clinical pharmacology","nonrandomized_study","article","10.1111/j.1365-2125.2007.02890.x","17425627","PMC2000650",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027630","[Therapy of obesity with liraglutide. NN8022-1807 study].","Scherbaum WA","2010","Der Internist","other","article","10.1007/s00108-010-2694-2","20628715",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0027631","Comparative studies on the influences of primary emulsion preparation on properties of uniform-sized exenatide-loaded PLGA microspheres.","Qi F","2014","Pharmaceutical research","preclinical","article","10.1007/s11095-013-1262-6","24398695",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027632","Continuous Subcutaneous Insulin Infusion Therapy Resulting in Improved Glycemic Control in Patient With Low Health Literacy","Mandal S","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.759",null,"PMC8090079",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0027633","Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.","Singh S","2013","JAMA internal medicine","nonrandomized_study","article","10.1001/jamainternmed.2013.2720","23440284",null,null,"S000313","pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0027634","Incretins: clinical physiology and bariatric surgery--correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure.","Lamounier RN","2007","Obesity surgery","commentary","article","10.1007/s11695-007-9098-y","17658012",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Conference Proceedings; Editorial"],["R0027635","GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.","Buteau J","2008","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(08)73398-6","18640589",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027636","Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.","Tan TM","2013","Diabetes","randomized_trial","article","10.2337/db12-0797","23248172","PMC3609580",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027637","Exenatide for the treatment of type 2 diabetes mellitus.","Ruddock B","2005","Issues in emerging health technologies","other","article",null,"16389694",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0027638","Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.","Bramlage P","2014","BMC cardiovascular disorders","nonrandomized_study","article","10.1186/1471-2261-14-162","25410473","PMC4247562",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0027639","Predictors of medication adherence in patients with type 2 diabetes mellitus.","Curkendall SM","2013","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2013.821056","23815104",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027640","Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.","Heine RJ","2005","Annals of internal medicine","randomized_trial","article","10.7326/0003-4819-143-8-200510180-00006","16230722",null,"ClinicalTrials.gov:NCT00082381","S000965","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027641","Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials.","Sargeant JA","2020","Diabetologia","other_trial","article","10.1007/s00125-020-05174-9","32483683","PMC7351852",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0027642","Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.","Opie LH","2014","Cardiovascular drugs and therapy","narrative_review","article","10.1007/s10557-014-6522-0","24825435",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027643","Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.","Giagulli VA","2015","Andrology","nonrandomized_study","article","10.1111/andr.12099","26447645",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0027644","Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.","Wilding JPH","2018","Clinical obesity","nonrandomized_study","article","10.1111/cob.12248","29689646","PMC6001483",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; review-article; article"],["R0027645","Systems pharmacology of adverse event mitigation by drug combinations.","Zhao S","2013","Science translational medicine","nonrandomized_study","article","10.1126/scitranslmed.3006548","24107779","PMC3963511",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027646","Preventing progression from gestational diabetes mellitus to diabetes: A thought-filled review.","Kasher-Meron M","2017","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.2909","28544499",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0027647","Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue.","Dias S","2018","International journal of endocrinology","narrative_review","article","10.1155/2018/2637418","29593789","PMC5822899",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027648","Effects of sitagliptin beyond glycemic control: focus on quality of life.","Sakamoto Y","2013","Cardiovascular diabetology","other_trial","article","10.1186/1475-2840-12-35","23432786","PMC3606450",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Multicenter Study; research-article; article"],["R0027649","DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.","Blevins T","2011","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2010-2081","21307137",null,null,"S000204; S000506; S001308; S002223","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0027650","Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.","Phung OJ","2010","JAMA","systematic_review","article","10.1001/jama.2010.405","20388897",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; article"],["R0027651","Synergistic weight loss and diabetes resolution with exenatide administration after laparoscopic gastric banding.","Rothkopf MM","2009","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","case_report","article","10.1016/j.soard.2008.09.005","18996762",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027652","Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.","Viswanathan P","2007","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep.13.5.444","17872344",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0027653","A case of type 2 diabetes mellitus with metformin-associated lactic acidosis initially presenting the appearance of a sulfonylurea-related hypoglycemic attack.","Nishihama K","2017","Acute medicine & surgery","case_report","article","10.1002/ams2.233","29123848","PMC5667282",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0027654","Review article: a comparison of glucagon-like peptides 1 and 2.","Janssen P","2013","Alimentary pharmacology & therapeutics","narrative_review","article","10.1111/apt.12092","23121085",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027655","Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine.","Jones AG","2014","PloS one","nonrandomized_study","article","10.1371/journal.pone.0111235","25340784","PMC4207765","ClinicalTrials.gov:NCT01503112","S002449","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0027656","The metabolic approach in patients with heart failure: effects on left ventricle remodeling.","Tang WH","2009","Current pharmaceutical design","narrative_review","article","10.2174/138161209787582138","19275649",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027657","Causes and cures for endoplasmic reticulum stress in lipotoxic β-cell dysfunction.","Cnop M","2010","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2010.01279.x","21029303",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027658","Exenatide may aggravate moderate diabetic renal impairment: a case report.","Johansen OE","2008","British journal of clinical pharmacology","case_report","article","10.1111/j.1365-2125.2008.03221.x","18537959","PMC2561107",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0027659","The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.","Heusch G","2017","European heart journal","narrative_review","article","10.1093/eurheartj/ehw224","27354052",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027660","Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications.","Edwards KL","2006","Pharmacy practice","other","article",null,"25214899","PMC4156845",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027661","Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.","Riddle MC","2006","Diabetes/metabolism research and reviews","randomized_trial","article","10.1002/dmrr.646","16634116",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027662","Adolescents' views and experiences of treatments for Type 2 diabetes: a qualitative study.","Turner KM","2015","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.12577","25186101",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027663","Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.","Davies M","2013","Diabetes care","randomized_trial","article","10.2337/dc12-1333","23275363","PMC3631870",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027664","Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.","Gadde KM","2017","Current diabetes reports","randomized_trial","article","10.1007/s11892-017-0859-2","28378293",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0027665","A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel.","Li K","2013","Biomaterials","preclinical","article","10.1016/j.biomaterials.2013.01.013","23352120",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027666","Banxia Xiexin Decoction Ameliorates t-BHP-Induced Apoptosis in Pancreatic Beta Cells by Activating the PI3K/AKT/FOXO1 Signaling Pathway.","Du LJ","2020","Journal of diabetes research","preclinical","article","10.1155/2020/3695689","32377518","PMC7191444",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027667","A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia.","Rinaman L","1999","The American journal of physiology","preclinical","article","10.1152/ajpregu.1999.277.5.r1537","10564228",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0027668","Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.","Brixner DI","2009","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/j.1463-1326.2009.01081.x","19930004",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0027669","Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.","Cervera A","2008","American journal of physiology. Endocrinology and metabolism","other","article","10.1152/ajpendo.00030.2008","18334612",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027670","The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low.","Benhalima K","2011","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2010.03.002","20462772",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027671","GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.","Hansotia T","2005","Regulatory peptides","preclinical","article","10.1016/j.regpep.2004.07.019","15780432",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027672","One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice.","Buysschaert M","2010","Diabetes & metabolism","nonrandomized_study","article","10.1016/j.diabet.2010.03.009","20598606",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0027673","DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes.","Deacon CF","2008","Frontiers in bioscience : a journal and virtual library","narrative_review","article","10.2741/2799","17981667",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027674","A selective comprehensive reversed-phase×reversed-phase 2D-liquid chromatography approach with multiple complementary detectors as advanced generic method for the quality control of synthetic and therapeutic peptides.","Karongo R","2020","Journal of chromatography. A","other","article","10.1016/j.chroma.2020.461430","32823119",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027675","Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.","Green BD","2006","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.105.097824","16648370",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027676","Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117.","Qian F","2009","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2008.10.020","19027057",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0027677","[Effects of glucagon-like peptide 1 and its receptor agonist - liraglutide on cardiovascular system].","Gajos G","2011","Kardiologia polska","narrative_review","article",null,"21769795",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027678","The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats.","Furrer D","2010","Veterinary journal (London, England : 1997)","other","article","10.1016/j.tvjl.2008.11.017","19128990",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027679","Facilitation of ß-cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac.","Leech CA","2010","Islets","preclinical","article","10.4161/isl.2.2.10582","20428467","PMC2860288",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027680","Alogliptin Plus Metformin (Kazano) for Type 2 Diabetes Mellitus",null,"2015","Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)","narrative_review","article",null,"26962605",null,null,null,"europepmc","TRUE",null,null,null,"Review"],["R0027681","Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey.","Le P","2020","Diabetes care","nonrandomized_study","article","10.2337/dc19-2424","32234720",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0027682","Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.","Kolterman OG","2005","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","randomized_trial","article","10.1093/ajhp/62.2.173","15700891",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027683","Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.","Hölscher C","2011","Biochemical Society transactions","preclinical","article","10.1042/bst0390891","21787319",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027684","Nuclear deformation mediates liver cell mechanosensing in cirrhosis.","Guixé-Muntet S","2020","JHEP reports : innovation in hepatology","preclinical","article","10.1016/j.jhepr.2020.100145","32939447","PMC7479345",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027685","Estradiol effects on hypothalamic AMPK and BAT thermogenesis: A gateway for obesity treatment?","López M","2017","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2017.03.014","28351720",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027686","Effect of exenatide on the steady-state pharmacokinetics of digoxin.","Kothare PA","2005","Journal of clinical pharmacology","other_trial","article","10.1177/0091270005278806","16100297",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027687","Progress in Therapies for Myocardial Ischemia Reperfusion Injury.","Chi HJ","2017","Current drug targets","narrative_review","article","10.2174/1389450117666160401120308","27033199",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027688","Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.","Abe M","2011","Current drug metabolism","narrative_review","article","10.2174/138920011794520053","21303332",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027689","N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity.","John H","2008","European journal of medical research","preclinical","article",null,"18424366",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027690","The role of gastrointestinal hormones in hepatic lipid metabolism.","Mells JE","2013","Seminars in liver disease","narrative_review","article","10.1055/s-0033-1358527","24222092","PMC3956077",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0027691","Managed care perspective on three new agents for type 2 diabetes.","VanDeKoppel S","2008","Journal of managed care pharmacy : JMCP","nonrandomized_study","article","10.18553/jmcp.2008.14.4.363","18500914","PMC10438140",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; research-article; article"],["R0027692","Radiopeptide imaging and therapy in Europe.","Ambrosini V","2011","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","other_trial","article","10.2967/jnumed.110.085753","22144555",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0027693","cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets.","Nakazaki M","2002","Diabetes","preclinical","article","10.2337/diabetes.51.12.3440","12453898",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0027694","Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity.","Saunders KH","2016","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-016-0589-y","27181165",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027695","Adding subcutaneous liraglutide to metformin reduces HbA1c more than adding oral sitagliptin in patients whose type 2 diabetes is poorly controlled with metformin alone.","Fonseca V","2010","Evidence-based medicine","randomized_trial","article","10.1136/ebm1098","20610447",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Comment; Journal Article; article"],["R0027696","Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.","Armato J","2012","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.4158/ep11194.or","22068250",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0027697","Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy.","Imprialos KP","2018","Current vascular pharmacology","randomized_trial","article","10.2174/1570161115666170609101502","28595561",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0027698","Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial.","Liang Z","2013","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2013.04.005","23706413",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Randomized Controlled Trial"],["R0027699","LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.","Masmiquel L","2016","Cardiovascular diabetology","other_trial","article","10.1186/s12933-016-0341-5","26864124","PMC4750199","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027700","Hyperglycemia potentiates the slowing of gastric emptying induced by exogenous GLP-1.","Plummer MP","2015","Diabetes care","randomized_trial","article","10.2337/dc14-3091","25784665",null,"ANZCTR:ACTRN12613001384741",null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027701","Carbohydrate restricted diet in conjunction with metformin and liraglutide is an effective treatment in patients with deteriorated type 2 diabetes mellitus: Proof-of-concept study.","Müller JE","2011","Nutrition & metabolism","other","article","10.1186/1743-7075-8-92","22196251","PMC3278381",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027702","Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms.","Hussein AM","2020","Biomedicines","preclinical","article","10.3390/biomedicines8030043","32106580","PMC7175346",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027703","CHALLENGES AND NEW DIRECTIONS IN OBESITY MANAGEMENT: LIFESTYLE MODIFICATION PROGRAMMES, PHARMACOTHERAPY AND BARIATRIC SURGERY.","El Ghoch M","2019","Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique","randomized_trial","article","10.15586/jptcp.v26i2.599","31577079",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Editorial; article"],["R0027704","Redox-mediated enrichment of self-renewing adult human pancreatic cells that possess endocrine differentiation potential.","Linning KD","2004","Pancreas","other","article","10.1097/00006676-200410000-00015","15367896",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0027705","The incretin system and its role in type 2 diabetes mellitus.","Holst JJ","2009","Molecular and cellular endocrinology","narrative_review","article","10.1016/j.mce.2008.08.012","18786605",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027706","Managing type 2 diabetes: going beyond glycemic control.","Stolar MW","2008","Journal of managed care pharmacy : JMCP","other","article","10.18553/jmcp.2008.14.s5-b.1","18597582","PMC10437768",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027707","[New approach in the therapy of type 2 diabetes mellitus. Exenatide lowers HbA1c and body weight].",null,"2005","MMW Fortschritte der Medizin","other","article",null,"16302496",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0027708","Assessment of the Price-Volume Agreement Program in South Korea.","Han E","2016","Health policy (Amsterdam, Netherlands)","nonrandomized_study","article","10.1016/j.healthpol.2016.07.017","27519975",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0027709","Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?","Athyros VG","2010","Current pharmaceutical design","narrative_review","article","10.2174/138161210794455085","21128892",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027710","Leptin, cardiovascular diseases and type 2 diabetes mellitus.","Katsiki N","2018","Acta pharmacologica Sinica","narrative_review","article","10.1038/aps.2018.40","29877321","PMC6289384",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0027711","Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.","Zhao H","2014","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00017.2014","24801389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027712","Pharmacological management of obesity.","Velazquez A","2018","Minerva endocrinologica","narrative_review","article","10.23736/s0391-1977.17.02654-2","28462579",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027713","O-0544 Exenatide once-weekly versus twice-daily: comparison of diurnal and postprandial glucose patterns using continuous glucose monitoring and ambulatory glucose profile analysis.","Mazze R","2009","Canadian journal of diabetes","other","article","10.1016/s1499-2671(09)33074-9","25998595",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; conference-abstract"],["R0027714","Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!","Rosenstock J","2007","Diabetes care","commentary","article","10.2337/dc07-1592","17965313",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0027715","[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].","Scheen AJ","2016","Revue medicale de Liege","narrative_review","article",null,"28383832",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027716","Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.","Corsino L","2009","Clinical medicine. Therapeutics","other","article","10.4137/cmt.s2109","22539875","PMC3335272",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027717","Sustained release subcutaneous delivery of BMS-686117, a GLP-1 receptor peptide agonist, via a zinc adduct.","Qian F","2009","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2009.03.007","19446758",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027718","Horizons in the Pharmacotherapy of Obesity.","Arch JR","2015","Current obesity reports","narrative_review","article","10.1007/s13679-015-0177-4","26346394",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027719","A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis.","Liu R","2010","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2010.10.131","21070745",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027720","Use of exenatide for weight loss in patients with diabetes.","Virji A","2007","American family physician","commentary","article",null,"17511061",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Letter"],["R0027721","Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.","Eshraghian A","2017","World journal of gastroenterology","other_trial","article","10.3748/wjg.v23.i42.7495","29204050","PMC5698243",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Editorial; article"],["R0027722","Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER.","Gigoux V","2013","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2013.00050","23641235","PMC3638125",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0027723","Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.","Rodbard HW","2009","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.4158/ep.15.6.540","19858063",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Consensus Statement; Journal Article"],["R0027724","The physiology of glucagon-like peptide 1.","Holst JJ","2007","Physiological reviews","narrative_review","article","10.1152/physrev.00034.2006","17928588",null,null,"S001419","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; review"],["R0027725","Overview of new antiobesity drugs.","Hainer V","2014","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2014.946904","25100293",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Review; article"],["R0027726","Summaries for patients. Exenatide therapy for type 2 diabetes.",null,"2007","Annals of internal medicine","other","article","10.7326/0003-4819-146-7-200704030-00002","17404346",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Patient Education Handout; article"],["R0027727","Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.","Heise T","2014","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.12304","24720741",null,"ClinicalTrials.gov:NCT01680328",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027728","Therapies for diabetes: pramlintide and exenatide.","Jones MC","2007","American family physician","other","article",null,"17619527",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027729","Diabetes: glycaemic control in type 2 (drug treatments).","Gorter KJ","2012","BMJ clinical evidence","systematic_review","article",null,"23862772","PMC3462437",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; article"],["R0027730","The development of beta-cell mass: recent progress and potential role of GLP-1.","Stoffers DA","2004","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","narrative_review","article","10.1055/s-2004-826168","15655713",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review; article"],["R0027731","Current pharmacotherapies for obesity: A practical perspective.","Golden A","2017","Journal of the American Association of Nurse Practitioners","narrative_review","article","10.1002/2327-6924.12519","29024552",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027732","Exenatide and pramlintide: new therapies for diabetes.","Want LL","2006","International journal of clinical practice","commentary","article","10.1111/j.1742-1241.2006.01219.x","17109659",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0027733","Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.","Shirakawa J","2011","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m110.217216","21613229","PMC3138313",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027734","EJE PRIZE 2017: Hypothalamic AMPK: a golden target against obesity?","López M","2017","European journal of endocrinology","narrative_review","article","10.1530/eje-16-0927","28232370","PMC5425938",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027735","Design, synthesis and biological evaluation of novel peptide MC62 analogues as potential antihyperglycemic agents.","Yang B","2014","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2013.11.043","24384551",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027736","Antidiabetic drugs and stroke risk. Current evidence.","Castilla-Guerra L","2018","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2017.09.019","28939005",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027737","New potential adjuncts to treatment of children with type 1 diabetes mellitus.","Raman VS","2009","Pediatric research","narrative_review","article","10.1203/pdr.0b013e3181975ee4","19092720",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0027738","Euglycemic DKA in Patients on SGLT2 Inhibitor and Potentially Ketotic State","Khalifa M","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.779",null,"PMC8089681",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0027739","Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells.","Hupe-Sodmann K","1997","Peptides","preclinical","article","10.1016/s0196-9781(97)00123-x","9213354",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027740","Management of obesity.","Bray GA","2016","Lancet (London, England)","narrative_review","article","10.1016/s0140-6736(16)00271-3","26868660",null,null,"S001427","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0027741","Contemporary management of patients with Type 2 diabetes.","McAdam-Marx C","2010","Expert review of cardiovascular therapy","randomized_trial","article","10.1586/erc.10.62","20528633",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","2","FALSE","Comment; Journal Article; article"],["R0027742","The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury.","Ye Y","2011","Basic research in cardiology","narrative_review","article","10.1007/s00395-011-0216-6","21892746",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027743","Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice.","Irwin N","2007","Experimental gerontology","preclinical","article","10.1016/j.exger.2006.10.017","17184947",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027744","Combined metformin-associated lactic acidosis and euglycemic ketoacidosis.","Schwetz V","2017","Wiener klinische Wochenschrift","case_report","article","10.1007/s00508-017-1251-6","28865058","PMC5599436",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; brief-report; article"],["R0027745","Future therapy of diabetes mellitus.","Takei I","2004","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2004.09.008","15589066",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027746","Peptide hormones regulating appetite--focus on neuroimaging studies in humans.","Schloegl H","2011","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.1154","21294236",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027747","Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.","Diamant M","2012","Diabetes care","randomized_trial","article","10.2337/dc11-1233","22357185","PMC3308312",null,"S001768","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027748","Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.","Bergeson JG","2013","Journal of managed care pharmacy : JMCP","nonrandomized_study","article","10.18553/jmcp.2013.19.5.374","23697475","PMC10437845",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027749","Gastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats.","Davis JF","2012","Biological psychiatry","preclinical","article","10.1016/j.biopsych.2012.01.035","22444202",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0027750","Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis.","Zhang XM","2018","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.3062","30112855","PMC6585807",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027751","Clinical observations of exenatide treatment.","King AB","2006","Diabetes care","nonrandomized_study","article","10.2337/dc06-0864","16873820",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0027752","Hypothalamic AMPK: a canonical regulator of whole-body energy balance.","López M","2016","Nature reviews. Endocrinology","narrative_review","article","10.1038/nrendo.2016.67","27199291",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0027753","Alpha cell function in health and disease: influence of glucagon-like peptide-1.","Dunning BE","2005","Diabetologia","preclinical","article","10.1007/s00125-005-1878-0","16132964",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027754","Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.","Siegel EG","1999","European journal of clinical investigation","preclinical","article","10.1046/j.1365-2362.1999.00440.x","10411667",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027755","Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis.","Plutzky J","2009","Canadian journal of diabetes","systematic_review","article","10.1016/s1499-2671(09)33072-5","25998594",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; article"],["R0027756","Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.","Secnik Boye K","2006","Health and quality of life outcomes","randomized_trial","article","10.1186/1477-7525-4-80","17034640","PMC1634743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027757","Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.","Ye Y","2013","American journal of physiology. Heart and circulatory physiology","preclinical","article","10.1152/ajpheart.00609.2012","23103492",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027758","Exenatide in combination therapy: small study, big market, and many unanswered questions.","Malozowski S","2007","Annals of internal medicine","randomized_trial","article","10.7326/0003-4819-146-7-200704030-00009","17404355",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Editorial; Comment; article"],["R0027759","[The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus].","Chen P","2016","Zhonghua nei ke za zhi","randomized_trial","article","10.3760/cma.j.issn.0578-1426.2016.05.004","27143183",null,"ClinicalTrials.gov:NCT01954147","S001871","pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0027760","Hypothalamic brain-derived neurotrophic factor regulates glucagon secretion mediated by pancreatic efferent nerves.","Gotoh K","2013","Journal of neuroendocrinology","preclinical","article","10.1111/jne.12003","23157205",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027761","Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.","Russell-Jones D","2012","Diabetes care","randomized_trial","article","10.2337/dc11-1107","22210563","PMC3263915","ClinicalTrials.gov:NCT00676338","S000506; S001966","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027762","Top studies relevant to primary care practice.","Perry D","2018","Canadian family physician Medecin de famille canadien","narrative_review","article",null,"29650603","PMC5897069",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027763","Pathophysiology of diabetes in elderly people.","Paolisso G","2010","Acta bio-medica : Atenei Parmensis","narrative_review","article",null,"20518191",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027764","Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice.","Wang Y","2020","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","randomized_trial","article","10.1016/j.biopha.2020.109914","32035395",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0027765","DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.","Riedel MJ","2010","Gene therapy","preclinical","article","10.1038/gt.2009.143","19865180",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027766","Fabrication of polymer microneedles using a two-photon polymerization and micromolding process.","Gittard SD","2009","Journal of diabetes science and technology","preclinical","article","10.1177/193229680900300211","20144361","PMC2771517",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0027767","Diabetes basics. Exenatide and pramlintide. New meds on the block.","Griffin S","2006","Diabetes self-management","other","article",null,"16888865",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027768","Diabetes care targets in older persons.","Abbatecola AM","2009","Diabetes research and clinical practice","other","article","10.1016/s0168-8227(09)70007-5","20115930",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027769","Meta-analysis of metabolic surgery versus medical treatment for macrovascular complications and mortality in patients with type 2 diabetes.","Billeter AT","2019","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","systematic_review","article","10.1016/j.soard.2019.04.029","31201113",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Systematic Review"],["R0027770","Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.","Bersoff-Matcha SJ","2019","Annals of internal medicine","narrative_review","article","10.7326/m19-0085","31060053",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027771","Long-term effects of weight-reducing drugs in people with hypertension.","Siebenhofer A","2016","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd007654.pub4","26934640",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0027772","Obesity, insulin resistance, and type 1 diabetes mellitus.","Polsky S","2015","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000170","26087341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027773","Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes.","Vara E","2001","American journal of respiratory and critical care medicine","other","article","10.1164/ajrccm.163.4.9912132","11282754",null,null,"S000332","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027774","Glycemic control and weight changes in patients with type 2 diabetes intensified to three insulin regimens after therapeutic failure to exenatide.","Buysschaert M","2012","Acta clinica Belgica","other","article","10.2143/acb.67.4.2062668","23019799",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0027775","The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake.","Grill HJ","2009","International journal of obesity (2005)","narrative_review","article","10.1038/ijo.2009.10","19363500",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0027776","Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.","Hvas CL","2018","World journal of gastroenterology","case_report","article","10.3748/wjg.v24.i21.2320","29881241","PMC5989246",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; Review; case-report; article"],["R0027777","Neuroprotective properties of GLP-1: theoretical and practical applications.","Holst JJ","2011","Current medical research and opinion","narrative_review","article","10.1185/03007995.2010.549466","21222567",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027778","Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions.","Hashiguchi M","2015","PloS one","other","article","10.1371/journal.pone.0144263","26641634","PMC4671724",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027779","Exenatide.","Davidson MB","2005","Nature reviews. Drug discovery","other","article","10.1038/nrd1828","16178120",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027780","Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.","Trahair LG","2015","Diabetologia","randomized_trial","article","10.1007/s00125-015-3638-0","26048234",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027781","Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin.","Näslund E","2002","Regulatory peptides","preclinical","article","10.1016/s0167-0115(02)00054-x","12047915",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027782","CCR2 knockout exacerbates cerulein-induced chronic pancreatitis with hyperglycemia via decreased GLP-1 receptor expression and insulin secretion.","Nakamura Y","2013","American journal of physiology. Gastrointestinal and liver physiology","preclinical","article","10.1152/ajpgi.00318.2012","23449669",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027783","Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.","Watkins JB","2006","Journal of managed care pharmacy : JMCP","nonrandomized_study","article","10.18553/jmcp.2006.12.9.726","17249905","PMC10437796",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027784","Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments.","Montecucco F","2016","European heart journal","narrative_review","article","10.1093/eurheartj/ehv592","26543047",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027785","Val⁸-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats.","Wang XH","2013","Journal of neuroscience research","preclinical","article","10.1002/jnr.23181","23335292",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027786","Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?","Roberts CA","2017","Acta diabetologica","narrative_review","article","10.1007/s00592-017-0994-x","28421338","PMC5504125",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0027787","Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.","Bunck MC","2011","Diabetes care","randomized_trial","article","10.2337/dc11-0291","21868779","PMC3161303","ClinicalTrials.gov:NCT00097500","S001020","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027788","Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis.","Kissow H","2013","Gut","preclinical","article","10.1136/gutjnl-2012-303280","23086829",null,null,"S001698","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0027789","Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).","Wexler DJ","2019","Diabetes care","randomized_trial","article","10.2337/dc19-0901","31391203","PMC6804613","ClinicalTrials.gov:NCT01794143","S000873","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027790","Regulation of cAMP dynamics by Ca2+ and G protein-coupled receptors in the pancreatic beta-cell: a computational approach.","Fridlyand LE","2007","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00555.2006","17928534",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; article"],["R0027791","Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus.","De León DD","2006","The international journal of biochemistry & cell biology","narrative_review","article","10.1016/j.biocel.2005.07.011","16202636",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027792","Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.","Zhang L","2016","Molecular imaging and biology","preclinical","article","10.1007/s11307-015-0880-2","26194012","PMC4933589",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0027793","Structure-function analysis of a series of glucagon-like peptide-1 analogs.","Parker JC","1998","The journal of peptide research : official journal of the American Peptide Society","other","article","10.1111/j.1399-3011.1998.tb00664.x","9894845",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027794","Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record.","Brouwer ES","2012","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.2262","22250059",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0027795","Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.","Edgerton DS","2013","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00160.2013","23673158","PMC3725568",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027796","Combining phenome-driven drug-target interaction prediction with patients' electronic health records-based clinical corroboration toward drug discovery.","Zhou M","2020","Bioinformatics (Oxford, England)","nonrandomized_study","article","10.1093/bioinformatics/btaa451","32657406","PMC7355254",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027797","Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.","Cernea S","2017","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2017.1300059","28276774",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027798","[Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease].","Gao H","2013","Nan fang yi ke da xue xue bao = Journal of Southern Medical University","preclinical","article",null,"24273273",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027799","Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial.","Pantalone KM","2021","JAMA network open","randomized_trial","article","10.1001/jamanetworkopen.2021.16595","34255049","PMC8278271","ClinicalTrials.gov:NCT03799198","S002147","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027800","Alzheimer's disease and type 2 diabetes: what is the connection?","Greene A","2015","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","other_trial","article","10.4140/tcp.n.2015.112","25695417",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0027801","Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells.","Lin CC","2009","Biomacromolecules","other","article","10.1021/bm900420f","19586041","PMC2745231",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027802","Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites.","Wang M","2020","RSC advances","preclinical","article","10.1039/c9ra10593j","35497855","PMC9049875",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"TRUE","Journal Article; Retracted Publication; research-article; article"],["R0027803","Brainstem sensing of meal-related signals in energy homeostasis.","Young AA","2012","Neuropharmacology","other","article","10.1016/j.neuropharm.2012.03.019","22491021",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027804","Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).","Morris LC","2014","Journal of medicinal chemistry","preclinical","article","10.1021/jm501375c","25423411","PMC4266362",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; rapid-communication; article"],["R0027805","Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.","DeFronzo RA","2010","Diabetes care","randomized_trial","article","10.2337/dc09-1521","20107105","PMC2858197","ClinicalTrials.gov:NCT00135330","S000943","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027806","Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris.","Gao Z","2009","Bioscience, biotechnology, and biochemistry","preclinical","article","10.1271/bbb.80742","19270384",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0027807","[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].","Halimi S","2008","La Revue de medecine interne","randomized_trial","article","10.1016/j.revmed.2008.05.011","18722695",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0027808","Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.","Pencek R","2012","International journal of clinical practice","systematic_review","article","10.1111/j.1742-1241.2012.03006.x","22925173","PMC3506736",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; article"],["R0027809","DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.","Shimizu S","2012","Journal of molecular endocrinology","preclinical","article","10.1530/jme-12-0039","22822047",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027810","Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report.","Kaneko K","2019","BMC endocrine disorders","case_report","article","10.1186/s12902-018-0326-3","30621663","PMC6325663",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0027811","Evaluating insulin secretagogues in a humanized mouse model with functional human islets.","Luo J","2013","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2012.07.010","22982177",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027812","MON-LB123 Diagnosis and Management of Euglycemic DKA in the Setting of SGLT2 Inhibitor Use and Prostate Abscess","Rameshkumar N","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.2250",null,"PMC7209590",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0027813","A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.","Gao Z","2009","Peptides","preclinical","article","10.1016/j.peptides.2009.07.020","19647775",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0027814","The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.","Stevens JE","2012","Alimentary pharmacology & therapeutics","randomized_trial","article","10.1111/j.1365-2036.2012.05198.x","22738299",null,"ClinicalTrials.gov:NCT00501657","S000473","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027815","New treatments for type 2 diabetes in the UK - an evolving landscape.","Barnett AH","2011","Primary care diabetes","narrative_review","article","10.1016/j.pcd.2010.09.001","20934929",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027816","Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data.","McAdam-Marx C","2014","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2013.12.038","24503045",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027817","Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.","Ban K","2008","Circulation","preclinical","article","10.1161/circulationaha.107.739938","18427132",null,null,"S000566; S002372","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027818","SUN-691 Type 2 Diabetes Management in the Context of Smith-Magenis Syndrome: Case Report","Mulvaney K","2020","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaa046.098",null,"PMC7208111",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0027819","Obesity-Induced Hypertension: New Insights.","Antza C","2017","Current pharmaceutical design","narrative_review","article","10.2174/1381612823666170608083343","28595525",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027820","Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.","Zarrinpar A","2012","Alimentary pharmacology & therapeutics","narrative_review","article","10.1111/apt.12084","23057494","PMC3535499",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0027821","New injection recommendations for patients with diabetes.","Frid A","2010","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(10)70002-1","20933208",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Practice Guideline; Review"],["R0027822","Structure/activity characterization of glucagon-like peptide-1.","Gallwitz B","1994","European journal of biochemistry","preclinical","article","10.1111/j.1432-1033.1994.1151b.x","7957206",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027823","Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.","Green JB","2007","Current diabetes reports","narrative_review","article","10.1007/s11892-007-0060-0","18173970",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027824","Vesicular phospholipid gels as drug delivery systems for small molecular weight drugs, peptides and proteins: State of the art review.","Breitsamer M","2019","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2018.12.030","30572079",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027825","Targeting the incretin system in type 2 diabetes mellitus.","Potenza M","2009","The Mount Sinai journal of medicine, New York","narrative_review","article","10.1002/msj.20112","19421968",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027826","Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.","Fifer S","2018","BMC health services research","nonrandomized_study","article","10.1186/s12913-018-3484-0","30165844","PMC6117901",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Randomized Controlled Trial; research-article; article"],["R0027827","New drugs: exenatide, pramlintide acetate, and micafungin sodium.","Hussar DA","2005","Journal of the American Pharmacists Association : JAPhA","other","article","10.1331/1544345054475504","16128511",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0027828","Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes?",null,"2005","Annals of internal medicine","other","article","10.7326/0003-4819-143-8-200510180-00002","16230718",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Patient Education Handout; Journal Article; article"],["R0027829","Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.","Clegg LE","2019","Diabetes care","nonrandomized_study","article","10.2337/dc18-1871","30523029",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027830","Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain.","McGovern SF","2012","Brain research","preclinical","article","10.1016/j.brainres.2012.07.029","22867941",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027831","GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis.","Chen J","2017","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","preclinical","article","10.1159/000478872","28668964",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0027832","Characterization of a low-level unknown isomeric degradation product using an integrated online-offline top-down tandem mass spectrometry platform.","Yu X","2013","Analytical chemistry","other","article","10.1021/ac401911n","24003984",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027833","Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials.","McQuillan C","2018","Advances in therapy","narrative_review","article","10.1007/s12325-018-0716-y","29949039","PMC11343822",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027834","Gateways to clinical trials.","Tomillero A","2009","Methods and findings in experimental and clinical pharmacology","other","article",null,"19907722",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0027835","Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?","Drucker DJ","2005","Nature clinical practice. Endocrinology & metabolism","other","article","10.1038/ncpendmet0026","16929370",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027836","Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.","Madsen AN","2010","The Journal of endocrinology","preclinical","article","10.1677/joe-10-0004","20508079",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0027837","A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus.","Pfützner A","2008","Clinical laboratory","narrative_review","article",null,"19216254",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027838","Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.","Waser B","2012","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2011-2454","22112810",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027839","A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.","Tatarkiewicz K","2014","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12181","23859463","PMC4237114",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027840","Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.","Bourdel-Marchasson I","2011","Hospital practice (1995)","other_trial","article","10.3810/hp.2011.02.369","21441754",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0027841","Pharmacological management of nonalcoholic fatty liver disease.","Barb D","2016","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2016.04.004","27301803",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027842","Defining the role of incretin mimetic therapy in the management of type 2 diabetes.","Unger J","2007","The Journal of family practice","case_report","article",null,"18664341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0027843","Pharmacological management of metabolic syndrome and its lipid complications.","Binesh Marvasti T","2010","Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","narrative_review","article",null,"22615610","PMC3304358",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0027844","DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion.","Ku HC","2011","Naunyn-Schmiedeberg's archives of pharmacology","preclinical","article","10.1007/s00210-011-0665-3","21748358",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027845","Effects of malvidin, cyanidin and delphinidin on human adipose mesenchymal stem cell differentiation into adipocytes, chondrocytes and osteocytes.","Saulite L","2019","Phytomedicine : international journal of phytotherapy and phytopharmacology","other","article","10.1016/j.phymed.2018.09.029","30668416",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027846","Analysis of the effects of novel long-acting GIP agonists on neurodegenerative hallmarks in a mouse model of Alzheimer's disease","Duffy A","2016","Ulster University","preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0027847","Islet transplantation for brittle type 1 diabetes: the UIC protocol.","Gangemi A","2008","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","protocol","article","10.1111/j.1600-6143.2008.02234.x","18444920",null,null,"S002073","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0027848","Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.","Drucker DJ","2001","Current pharmaceutical design","preclinical","article","10.2174/1381612013397401","11472275",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027849","Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes.","Jean M","2012","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","preclinical","article","10.1016/j.ejps.2011.10.029","22085632",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0027850","Drugs to treat obesity: do they work?","Kim S","2016","Postgraduate medical journal","narrative_review","article","10.1136/postgradmedj-2015-133388","27053517",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027851","Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.","Wang JH","2011","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.111.184788","21846840","PMC3199979",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article"],["R0027852","Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats.","Sancho V","2005","Journal of molecular endocrinology","preclinical","article","10.1677/jme.1.01747","16087719",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027853","High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine.","Larsen JR","2019","CNS spectrums","randomized_trial","article","10.1017/s1092852918001311","30596361",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0027854","MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.","Macut D","2017","European journal of endocrinology","randomized_trial","article","10.1530/eje-16-1063","28694246",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0027855","Drugs in the pipeline for the obesity market.","Klonoff DC","2008","Journal of diabetes science and technology","narrative_review","article","10.1177/193229680800200525","19885278","PMC2769782",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0027856","Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus.","Herrmann BL","2013","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","randomized_trial","article","10.1055/s-0033-1334905","23512415",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027857","Biology of incretins: GLP-1 and GIP.","Baggio LL","2007","Gastroenterology","narrative_review","article","10.1053/j.gastro.2007.03.054","17498508",null,null,"S002311","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0027858","Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update","Bennett WL","2011","Agency for Healthcare Research and Quality (US), Rockville (MD)","randomized_trial","article",null,"21735563",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0027859","The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.","Raschi E","2013","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-011-0340-7","22008948",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027860","Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era.","Dominguez-Rodriguez A","2014","World journal of cardiology","narrative_review","article","10.4330/wjc.v6.i3.100","24669291","PMC3964186",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027861","SUN-LB115 Is the Stepping-Down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-Controlled Diabetes on Advanced Insulin Therapy?","Naing S","2020","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaa046.2247",null,"PMC7209541","ClinicalTrials.gov:NCT02846233","S000236","europepmc; openalex","TRUE","open_europepmc","1","FALSE","Abstract; article"],["R0027862","Hyperglycemia-related central pontine demyelinization after a binge-eating attack in a patient with type-2 diabetes: a case report.","Pliquett RU","2018","BMC endocrine disorders","case_report","article","10.1186/s12902-018-0245-3","29530008","PMC5848589",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0027863","Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives.","Virally M","2007","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2007.07.001","17703979",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027864","PANORAMA: a European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus--study design.","Bradley C","2011","Primary care diabetes","protocol","article","10.1016/j.pcd.2011.04.004","21752743",null,"ClinicalTrials.gov:NCT00916513",null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't"],["R0027865","Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors. New hope for the treatment of type-2 diabetes.","Al-Omar MA","2005","Saudi medical journal","narrative_review","article","10.15537/1658-3175.3143","16228047",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0027866","Pharmacological and non-pharmacological strategies for obese women with subfertility.","Taghavi SA","2021","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd012650.pub2","33765343","PMC8094444",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; systematic-review; article"],["R0027867","GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.","Sturis J","2003","British journal of pharmacology","preclinical","article","10.1038/sj.bjp.0705397","12967942","PMC1573996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; research-article; article"],["R0027868","HYPERGLYCEMIA MANAGEMENT IN PATIENTS WITH POSTTRANSPLANTATION DIABETES.","Galindo RJ","2016","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","randomized_trial","article","10.4158/ep151039.ra","26720253",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0027869","Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management.","Jeon WS","2014","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2014.29.4.410","25559569","PMC4285049",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027870","Management of type 2 diabetes in the obese patient: current concerns and emerging therapies.","Krentz AJ","2008","Current medical research and opinion","narrative_review","article","10.1185/030079908x219661","18154689",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027871","Exenatide and biotin in conjunction with a protein-sparing fast for normalization of beta cell function in type 2 diabetics.","McCarty MF","2007","Medical hypotheses","other","article","10.1016/j.mehy.2005.09.059","17292559",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027872","Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research.","Castro M","2016","Current topics in medicinal chemistry","narrative_review","article","10.2174/1568026616666160415155644","27086785",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027873","Molecule of the month. Exenatide.",null,"2003","Drug news & perspectives","other","article",null,"14702143",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027874","Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10).","Twarog C","2019","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics11020078","30781867","PMC6410172",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027875","Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.","Lo C","2020","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd009966.pub3","32803882","PMC8477618","ClinicalTrials.gov:NCT03157414; ClinicalTrials.gov:NCT00980356; ClinicalTrials.gov:NCT00609986; ClinicalTrials.gov:NCT01643382; ClinicalTrials.gov:NCT00740363; ClinicalTrials.gov:NCT00598013; ClinicalTrials.gov:NCT00830297; ClinicalTrials.gov:NCT01680185; ClinicalTrials.gov:NCT01148680; ClinicalTrials.gov:NCT01346254; ClinicalTrials.gov:NCT00507494; ClinicalTrials.gov:NCT03642184",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; article"],["R0027876","Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.","Pölzl G","2017","International journal of cardiology","other_trial","article","10.1016/j.ijcard.2017.05.081","28571618",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Review; article"],["R0027877","New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.","Taylor JR","2013","Clinical therapeutics","other_trial","article","10.1016/j.clinthera.2012.12.012","23328274",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0027878","Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity.","Remely M","2014","Gene","other","article","10.1016/j.gene.2013.11.081","24325907",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027879","NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.","Caldwell S","2017","Clinical and molecular hepatology","randomized_trial","article","10.3350/cmh.2017.0103","28494529","PMC5497667",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0027880","Frailty and safety: the example of diabetes.","Abbatecola AM","2012","Drug safety","narrative_review","article","10.1007/bf03319104","23446787",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027881","Descriptions of Adverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance Database but Provide More Unexpected Reactions.","Karapetiantz P","2018","Frontiers in pharmacology","nonrandomized_study","article","10.3389/fphar.2018.00439","29765326","PMC5938397",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027882","Substitution of the cysteine 438 residue in the cytoplasmic tail of the glucagon-like peptide-1 receptor alters signal transduction activity.","Vázquez P","2005","The Journal of endocrinology","preclinical","article","10.1677/joe.1.06031","15817825",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027883","Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care.","Rungby J","2017","Cardiovascular endocrinology","nonrandomized_study","article","10.1097/xce.0000000000000135","29276653","PMC5704655",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0027884","Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production.","Sarrauste de Menthière C","2004","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2004.02.002","15183905",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027885","Treatment of obesity in 2015.","Shukla AP","2015","Journal of cardiopulmonary rehabilitation and prevention","narrative_review","article","10.1097/hcr.0000000000000112","25714749",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027886","Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.","Pencek R","2012","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2012.07.2568","22913892",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0027887","Adipose tissue, obesity and non-alcoholic fatty liver disease.","Polyzos SA","2017","Minerva endocrinologica","randomized_trial","article","10.23736/s0391-1977.16.02563-3","27711029",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0027888","Adipose Tissue-Derived Omentin-1 Function and Regulation.","Watanabe T","2017","Comprehensive physiology","narrative_review","article","10.1002/cphy.c160043","28640441",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article; other"],["R0027889","SUN-LB114 Remission of Type 2 Diabetes (DMT2) in Hypogonadal Men Under Long-Term Testosterone Therapy","Mskhalaya G","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.2238",null,"PMC7209298",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0027890","MON-703 Injection Technique over Insulin Dose - Nuances in Diabetes Therapy","Mehrotra N","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.1473",null,"PMC7209501",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0027891","GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP.","Green BD","2008","Archives of biochemistry and biophysics","preclinical","article","10.1016/j.abb.2008.08.001","18708025",null,null,"S000566","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027892","Weight loss medications in Canada - a new frontier or a repeat of past mistakes?","Wharton S","2017","Diabetes, metabolic syndrome and obesity : targets and therapy","commentary","article","10.2147/dmso.s141571","29042804","PMC5633321",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article; editorial"],["R0027893","An intestinal paracellular pathway biased toward positively-charged macromolecules.","Almansour K","2018","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2018.09.003","30194947","PMC6219475",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0027894","Small-molecule agonists for the glucagon-like peptide 1 receptor.","Knudsen LB","2007","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.0605701104","17213325","PMC1783418",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0027895","Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes.","Thuillier P","2015","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s54953","26457056","PMC4598200",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027896","Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.","Abbas T","2009","Behavioural brain research","preclinical","article","10.1016/j.bbr.2009.06.035","19573562",null,null,"S001707","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027897","Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.","Grimm M","2013","Postgraduate medicine","randomized_trial","article","10.3810/pgm.2013.09.2704","24113668",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; article"],["R0027898","Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259-267.","Home PD","2007","Diabetologia","commentary","article","10.1007/s00125-007-0653-9","17384924",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; letter"],["R0027899","Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.","Arnolds S","2010","Diabetes care","randomized_trial","article","10.2337/dc09-2191","20357372","PMC2890351","ClinicalTrials.gov:NCT00971659","S001719","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0027900","The Influence of Varying Cost Formats on Preferences.","Jiang CC","2017","Medical decision making : an international journal of the Society for Medical Decision Making","other","article","10.1177/0272989x16677031","27856826","PMC5130599",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027901","Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.","D'Alessio DA","2004","American journal of physiology. Endocrinology and metabolism","narrative_review","article","10.1152/ajpendo.00014.2004","15140755",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; Review; article"],["R0027902","Diabetes mellitus: new drugs for a new epidemic.","Nicholson G","2011","British journal of anaesthesia","narrative_review","article","10.1093/bja/aer120","21610015",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027903","Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.","Cooke CE","2010","Current medical research and opinion","nonrandomized_study","article","10.1185/03007990903421994","19921965",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027904","Using evolutionary information and ancestral sequences to understand the sequence-function relationship in GLP-1 agonists.","Skovgaard M","2006","Journal of molecular biology","preclinical","article","10.1016/j.jmb.2006.08.066","16989858",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027905","Anti-obesity drugs.","Rankin W","2015","Current opinion in lipidology","other_trial","article","10.1097/mol.0000000000000232","26382553",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0027906","Large-molecule quantification: sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF.","Morin LP","2013","Bioanalysis","other","article","10.4155/bio.13.87","23721442",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0027907","[Progress in the Management of NAFLD/NASH].","Aizawa Y","2016","Rinsho byori. The Japanese journal of clinical pathology","narrative_review","article",null,"30695468",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027908","Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.","Samyshkin Y","2012","Journal of medical economics","other_trial","article","10.3111/13696998.2012.708691","22793669",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027909","Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology.","Hampp C","2016","Drug safety","nonrandomized_study","article","10.1007/s40264-015-0382-9","26798052","PMC4752375",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; research-article"],["R0027910","LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ.","Rutten GE","2016","Diabetology & metabolic syndrome","other_trial","article","10.1186/s13098-016-0153-5","27274772","PMC4891842","ClinicalTrials.gov:NCT01179048","S001496","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0027911","Review of pharmacotherapy options for the management of obesity.","Bragg R","2016","Journal of the American Association of Nurse Practitioners","nonrandomized_study","article","10.1002/2327-6924.12279","26119641",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0027912","Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse.","Peterson RG","2017","PloS one","preclinical","article","10.1371/journal.pone.0179856","28640857","PMC5480999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027913","Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.","Faradji RN","2008","Transplantation","randomized_trial","article","10.1097/tp.0b013e31818fe448","19104401","PMC2759384",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027914","Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management.","Garber AJ","2005","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2005.00457.x","16219010",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027915","Targeting reperfusion injury in the era of primary percutaneous coronary intervention: hope or hype?","Lønborg JT","2015","Heart (British Cardiac Society)","randomized_trial","article","10.1136/heartjnl-2015-307804","26130664",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027916","Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.","Portillo-Sanchez P","2016","Clinical diabetes and endocrinology","narrative_review","article","10.1186/s40842-016-0027-7","28702244","PMC5471954",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0027917","Preserved GLP-1 effects in a diabetic patient with Cushing's disease.","Ritzel RA","2007","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","case_report","article","10.1055/s-2007-955096","17318778",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0027918","Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans.","Hu W","2013","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2012-2466","23185036",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027919","Pharmacotherapy for the management of obesity.","Patel D","2015","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2015.08.001","26342499",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027920","Safety and tolerability of medications approved for chronic weight management.","Fujioka K","2015","Obesity (Silver Spring, Md.)","narrative_review","article","10.1002/oby.21094","25900872",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027921","Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes.","Gallwitz B","2013","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-011-0319-4","21861172",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0027922","Effectiveness, tolerability and practical application of the newer generation anti-obesity medications.","MacDaniels JS","2016","Drugs in context","randomized_trial","article","10.7573/dic.212291","27114740","PMC4831638",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0027923","Glucagon-like peptide 1 (GLP-1) and metabolic diseases.","Rotella CM","2005","Journal of endocrinological investigation","narrative_review","article","10.1007/bf03347560","16277173",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027924","Gateways to clinical trials.","Bayés M","2003","Methods and findings in experimental and clinical pharmacology","other","article",null,"14671684",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0027925","Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.","Riedel MJ","2009","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.90768.2008","19190262",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027926","[Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues].","Hagenmeyer EG","2009","Deutsche medizinische Wochenschrift (1946)","other_trial","article","10.1055/s-0029-1208087","19277932",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0027927","Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.","Rotman Y","2017","Gut","narrative_review","article","10.1136/gutjnl-2016-312431","27646933",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0027928","Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.","Ben-Shlomo S","2011","Journal of hepatology","preclinical","article","10.1016/j.jhep.2010.09.032","21145820",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0027929","Update on Office-Based Strategies for the Management of Obesity.","Erlandson M","2016","American family physician","other","article",null,"27583422",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027930","Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience.","Qi M","2014","Acta diabetologica","other_trial","article","10.1007/s00592-014-0627-6","25034311","PMC4801517",null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0027931","Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.","Gu W","2011","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.111.179986","21471191",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0027932","[GLP-1 receptor activation effects the p38MAPK signal pathway in hepatic stellate cells].","Wu L","2015","Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","other","article","10.3760/cma.j.issn.1007-3418.2015.02.011","25880980","PMC12770304",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027933","AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings.","Bennett WL","2012","Journal of managed care pharmacy : JMCP","systematic_review","article","10.18553/jmcp.2012.18.s1-a.1","22313233","PMC10437459",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; research-article; article"],["R0027934","Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis.","Edholm T","2010","Neurogastroenterology and motility","randomized_trial","article","10.1111/j.1365-2982.2010.01554.x","20584260",null,null,"S003384","pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0027935","Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments.","Donnelly R","2006","British journal of clinical pharmacology","narrative_review","article","10.1111/j.1365-2125.2006.02675.x","16722832","PMC1885117",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0027936","A comparative examination of two Fmoc removal reagents for process improvement to produce peptide drugs.","Srivastava K","2009","Advances in experimental medicine and biology","other","article","10.1007/978-0-387-73657-0_257","19400324",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0027937","Microcosmic mechanism of dication for inhibiting acylation of acidic Peptide.","Qi F","2015","Pharmaceutical research","other","article","10.1007/s11095-015-1622-5","25585955",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027938","SAT-LB116 Extreme Insulin Resistance: The Diagnostic Challenges When Cost Is a Limitation","Cavalcante Parr N","2020","Journal of the Endocrine Society","other_trial","article",null,null,"PMC7207577",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0027939","Exenatide blocks JAK1-STAT1 in pancreatic beta cells.","Couto FM","2007","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2007.02.004","17570252",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0027940","Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells.","Sonoda N","2008","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.0710402105","18445652","PMC2373360",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027941","Pharmacologic management of the older patient with type 2 diabetes mellitus.","Neumiller JJ","2009","The American journal of geriatric pharmacotherapy","randomized_trial","article","10.1016/j.amjopharm.2009.12.002","20129254",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027942","Medications for weight loss.","Mordes JP","2015","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000140","25692921",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; article"],["R0027943","Prolonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide 1.","Yanay O","2010","The journal of gene medicine","preclinical","article","10.1002/jgm.1466","20527046","PMC2882674",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0027944","[Is there any relation between diabetes therapy and cancer risk?].","Svacina S","2011","Vnitrni lekarstvi","narrative_review","article",null,"21957771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027945","Signal transduction of the GLP-1-receptor cloned from a human insulinoma.","van Eyll B","1994","FEBS letters","other","article","10.1016/0014-5793(94)00553-2","7517895",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027946","Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway.","Xiao YF","2011","Cardiovascular diabetology","preclinical","article","10.1186/1475-2840-10-6","21251280","PMC3037307",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027947","Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control.","Cohen A","2007","Current medical research and opinion","other_trial","article","10.1185/030079907x182068","17407648",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027948","One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique.","Chen J","2007","Bioscience, biotechnology, and biochemistry","preclinical","article","10.1271/bbb.70190","17986790",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027949","Current Perspectives on Long-term Obesity Pharmacotherapy.","Wharton S","2016","Canadian journal of diabetes","narrative_review","article","10.1016/j.jcjd.2015.07.005","26507402",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027950","Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.","Flock G","2007","Diabetes","preclinical","article","10.2337/db07-0697","17717280",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027951","Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.","Madsen KS","2019","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd012368.pub2","30998259","PMC6472662",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; article"],["R0027952","New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists.","Greig NH","2004","Annals of the New York Academy of Sciences","narrative_review","article","10.1196/annals.1332.018","15681814",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, P.H.S.; Review; article"],["R0027953","Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States.","Brennan DC","2016","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","protocol","article","10.1111/ajt.13458","26433206",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0027954","Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms.","Raz I","2012","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.2265","22173845",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0027955","Synthesis of evidence for reimbursement decisions: a Bayesian reanalysis.","Woertman W","2014","International journal of technology assessment in health care","other","article","10.1017/s0266462314000385","25425179",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027956","[Role of insulin secretagogues in the treatment of type 2 diabetes].","Radermecker RP","2005","Revue medicale de Liege","narrative_review","article",null,"16035301",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027957","Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.","Hoogwerf BJ","2006","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.73.5.477","16708716",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027958","Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany. Results of the DiaRegis registry.","Gitt AK","2012","Herz","nonrandomized_study","article","10.1007/s00059-012-3611-3","22476616",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Controlled Clinical Trial; Journal Article"],["R0027959","Gateways to clinical trials.","Bayés M","2004","Methods and findings in experimental and clinical pharmacology","other","article",null,"15632957",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027960","Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.","Nauck MA","2004","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","preclinical","article","10.1055/s-2004-826175","15655719",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027961","Gateways to clinical trials.","Bayés M","2002","Methods and findings in experimental and clinical pharmacology","other","article",null,"12500432",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0027962","Glucagon acts through its own receptors in the presence of functional glucagon-like peptide-1 receptors on hamster insulinoma.","Marie JC","1996","Endocrinology","preclinical","article","10.1210/endo.137.10.8828464","8828464",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027963","[Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].","Matuszek B","2007","Endokrynologia Polska","narrative_review","article",null,"18205109",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0027964","Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels.","Reddy IA","2016","Translational psychiatry","preclinical","article","10.1038/tp.2016.86","27187231","PMC5070047",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0027965","A case of severe acute necrotizing pancreatitis after administration of sitagliptin.","Sue M","2013","Clinical medicine insights. Case reports","nonrandomized_study","article","10.4137/ccrep.s10856","23467428","PMC3576864",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Case Reports; Journal Article; case-report; article"],["R0027966","Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.","Rahelić D","2017","Annals of medicine","randomized_trial","article","10.1080/07853890.2016.1226514","27535028",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0027967","Acceleration of autoimmune diabetes in Rheb-congenic NOD mice with β-cell-specific mTORC1 activation.","Sasaki H","2011","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2011.04.026","21513702",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027968","WNT/beta-catenin increases the production of incretins by entero-endocrine cells.","García-Martínez JM","2009","Diabetologia","preclinical","article","10.1007/s00125-009-1429-1","19582394",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027969","Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID.","Baser O","2011","Journal of medical economics","nonrandomized_study","article","10.3111/13696998.2011.605818","21892858",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027970","New medications for treatment of obesity: metabolic and cardiovascular effects.","Pucci A","2015","The Canadian journal of cardiology","other_trial","article","10.1016/j.cjca.2014.11.010","25661549",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0027971","Increased secretion and expression of amylin in spontaneously diabetic Goto-Kakizaki rats treated with rhGLP-1 (7-36).","Weng HB","2008","Acta pharmacologica Sinica","preclinical","article","10.1111/j.1745-7254.2008.00782.x","18430365",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027972","Nutritional aspects of depression.","Lang UE","2015","Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","randomized_trial","article","10.1159/000430229","26402520",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0027973","Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.","Baron AD","2002","Current drug targets. Immune, endocrine and metabolic disorders","narrative_review","article","10.2174/1568005310202010063","12477297",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027974","(Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice.","Lennox R","2013","ChemMedChem","preclinical","article","10.1002/cmdc.201200409","23138973",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027975","12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus.","Perna S","2018","Clinical pharmacology : advances and applications","randomized_trial","article","10.2147/cpaa.s164785","30349407","PMC6186903",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0027976","Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.","Bharucha AE","2008","American journal of physiology. Regulatory, integrative and comparative physiology","randomized_trial","article","10.1152/ajpregu.00153.2008","18596108","PMC2536850",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; research-article; article"],["R0027977","Interleukin-6 CpG Methylation and Body Weight Correlate Differently in Type 2 Diabetes Patients Compared to Obese and Lean Controls.","Aumueller E","2015","Journal of nutrigenetics and nutrigenomics","other","article","10.1159/000381714","26067576",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027978","Nutritional status and behavior in subjects with type 1 diabetes, before and after islet transplantation.","Poggioli R","2008","Transplantation","other","article","10.1097/tp.0b013e3181629d7b","18347527",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0027979","Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion.","Yosida M","2014","Diabetes","preclinical","article","10.2337/db13-1868","24824430",null,null,"S000298","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027980","[The Study of the Effect and Mechanism of Glucagon Like Peptide-1 in Bleomycin-induced Pulmonary Fibrosis in Mice].","Liu M","2017","Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","preclinical","article",null,"28752966",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0027981","Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein.","Chen J","2006","Biochemical and biophysical research communications","preclinical","article","10.1016/j.bbrc.2006.06.027","16782054",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027982","An imaging target TGF-β1 for hepatocellular carcinoma in mice.","Zhang Y","2017","Hellenic journal of nuclear medicine","preclinical","article","10.1967/s002449910510","28315912",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027983","Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.","Krentz AJ","2016","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12657","26936802",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0027984","GLP-1 C-terminal structures affect its blood glucose lowering-function.","Li Y","2008","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.997","18200618",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027985","Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.","Lee KC","2009","Regulatory peptides","preclinical","article","10.1016/j.regpep.2008.09.008","18951927",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0027986","Inhibitors of dipeptidyl peptidase IV--recent advances and structural views.","Hunziker D","2005","Current topics in medicinal chemistry","narrative_review","article","10.2174/156802605775009685","16375746",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027987","The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.","Ye Y","2010","American journal of physiology. Heart and circulatory physiology","preclinical","article","10.1152/ajpheart.00867.2009","20207816",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027988","One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug.","Hughes RE","2016","Frontiers in neuroscience","nonrandomized_study","article","10.3389/fnins.2016.00177","27199640","PMC4842778",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0027989","Predictors and prognostic value of left atrial remodelling after acute myocardial infarction.","Kyhl K","2015","Open heart","randomized_trial","article","10.1136/openhrt-2014-000223","26082844","PMC4463489",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027990","How should postprandial glycemia be treated?","Charpentier G","2006","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(06)70481-5","17375403",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0027991","[Pharmacovigilance update].","Livio F","2010","Revue medicale suisse","nonrandomized_study","article",null,"20170031",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","English Abstract; Journal Article; other"],["R0027992","Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus.","Papanas N","2011","Expert opinion on pharmacotherapy","commentary","article","10.1517/14656566.2011.568477","21651446",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0027993","Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.","Doshi JA","2018","Circulation. Cardiovascular quality and outcomes","nonrandomized_study","article","10.1161/circoutcomes.117.003939","29326146",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0027994","Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients.","Rafferty J","2016","Current medicinal chemistry","narrative_review","article","10.2174/0929867323666160909155222","27633684",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0027995","Pharmacotherapy for obesity in menopausal women.","Samat A","2008","Menopause international","narrative_review","article","10.1258/mi.2008.008005","18519266",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0027996","[New antidiabetic medications: at the dawn of a revolution? New therapeutic options for type 2 diabetes are challenged for cardiovascular disease prevention].","Crenier L","2016","Revue medicale de Bruxelles","other","article",null,"28525236",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0027997","Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin.","Poudel RR","2012","Indian journal of endocrinology and metabolism","narrative_review","article","10.4103/2230-8210.94257","22701843","PMC3354922",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0027998","Development and characterisation of a novel glucagon like peptide-1 receptor antibody.","Biggs EK","2018","Diabetologia","preclinical","article","10.1007/s00125-017-4491-0","29119245","PMC5890879",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0027999","Biosimilar peptides: need for pharmacovigilance.","Joshi SR","2011","The Journal of the Association of Physicians of India","nonrandomized_study","article",null,"21818998",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; article"],["R0028000","Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final Report","Norris SL","2008","Oregon Health & Science University, Portland (OR)","narrative_review","article",null,"20496447",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0028001","Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.","Volz A","1995","FEBS letters","preclinical","article","10.1016/0014-5793(95)01006-z","7589426",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0028002","Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction.","Fujioka K","2007","JAAPA : official journal of the American Academy of Physician Assistants","narrative_review","article","10.1097/01720610-200712000-00001","18217245",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028003","No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.","Lerche S","2009","Clinical endocrinology","randomized_trial","article","10.1111/j.1365-2265.2008.03510.x","19094067",null,"ClinicalTrials.gov:NCT00285896",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0028004","Practical considerations of new drugs: new choices for old problems.","Frank T","2006","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","other","article","10.4140/tcp.n.2006.276","16669748",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028005","Efficacy of laparoscopic sleeve gastrectomy and intensive medical management in obese patients with type 2 diabetes mellitus.","Palikhe G","2014","Obesity surgery","other","article","10.1007/s11695-013-1114-9","24272885",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028006","Perilipin 5 regulates islet lipid metabolism and insulin secretion in a cAMP-dependent manner: implication of its role in the postprandial insulin secretion.","Trevino MB","2015","Diabetes","preclinical","article","10.2337/db14-0559","25392244","PMC4375085",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0028007","What are the important subsets of gastroparesis?","Camilleri M","2012","Neurogastroenterology and motility","narrative_review","article","10.1111/j.1365-2982.2012.01942.x","22626059","PMC3785986",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Review; research-article; article"],["R0028008","Therapeutic strategies based on glucagon-like peptide 1.","Deacon CF","2004","Diabetes","narrative_review","article","10.2337/diabetes.53.9.2181","15331525",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0028009","Peripheral blood monocytes can differentiate into efficient insulin-producing cells in vitro.","Kyventidis A","2015","Hippokratia","preclinical","article",null,"27688700","PMC5033146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0028010","Interconception care for women with a history of gestational diabetes for improving maternal and infant outcomes.","Tieu J","2017","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd010211.pub3","28836274","PMC6483533",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review; article"],["R0028011","IMPAN cells: a pancreatic model for differentiation into endocrine cells.","Klein T","2001","Archives of biochemistry and biophysics","preclinical","article","10.1006/abbi.2001.2579","11697865",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028012","High fat diet and GLP-1 drugs induce pancreatic injury in mice.","Rouse R","2014","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2014.01.021","24534256",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028013","Effects of glucagon and glucagon-like peptide-1 on glucocorticoid secretion of dispersed rat adrenocortical cells.","Andreis PG","1999","Life sciences","preclinical","article","10.1016/s0024-3205(99)00170-8","10374908",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028014","Pharmacotherapy for obesity: novel agents and paradigms.","Manning S","2014","Therapeutic advances in chronic disease","randomized_trial","article","10.1177/2040622314522848","24790728","PMC3992824",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0028015","The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study.","Brekke L","2017","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","nonrandomized_study","article","10.1016/j.jval.2017.05.019","29241884",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028016","Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1.","Green BD","2005","Diabetes, obesity & metabolism","preclinical","article","10.1111/j.1463-1326.2004.00430.x","16050949",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028017","Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.","Elkind-Hirsch K","2008","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2008-0115","18460557",null,"ClinicalTrials.gov:NCT00344851","S000679; S001133","pubmed; europepmc; openalex","TRUE","open_pdf","1","FALSE","Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0028018","Glucagon-like peptide-1: a basis for new approaches to the management of diabetes.","Deacon CF","1999","Drugs of today (Barcelona, Spain : 1998)","other","article","10.1358/dot.1999.35.3.533845","12973381",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028019","Pharmacological approaches to reperfusion therapy.","Morel O","2012","Cardiovascular research","other_trial","article","10.1093/cvr/cvs114","22514248",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0028020","Improved long-term health-related quality of life after islet transplantation.","Tharavanij T","2008","Transplantation","nonrandomized_study","article","10.1097/tp.0b013e31818a7f45","19005394","PMC2741424","ClinicalTrials.gov:NCT00021801; ClinicalTrials.gov:NCT00306098; ClinicalTrials.gov:NCT00315588; ClinicalTrials.gov:NCT00315614; ClinicalTrials.gov:NCT00315627","S003387","pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0028021","Reproducible production of a PEGylated dual-acting peptide for diabetes.","Tom I","2007","The AAPS journal","preclinical","article","10.1208/aapsj0902025","17907763","PMC2751412",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0028022","[Rare cause of insufficient metabolic control of diabetes mellitus - Case 10/2011].","Dudziak K","2011","Deutsche medizinische Wochenschrift (1946)","case_report","article","10.1055/s-0031-1289124","22009172",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0028023","Discovering new treatments for Alzheimer's disease by repurposing approved medications.","Appleby BS","2013","Current topics in medicinal chemistry","narrative_review","article","10.2174/15680266113136660162","24059463",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028024","Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay.","Chen J","2007","Peptides","preclinical","article","10.1016/j.peptides.2006.12.012","17267075",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028025","Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness.","Madsen K","2007","Journal of medicinal chemistry","other","article","10.1021/jm070861j","17975905",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028026","Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides.","Dillen L","2012","Bioanalysis","other","article","10.4155/bio.12.3","22409554",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0028027","Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.","Fisman EZ","2008","Advances in cardiology","narrative_review","article","10.1159/000115193","18230961",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; book-chapter"],["R0028028","Parkinson's disease, insulin resistance and novel agents of neuroprotection.","Aviles-Olmos I","2013","Brain : a journal of neurology","randomized_trial","article","10.1093/brain/aws009","22344583",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028029","[Diet and water-salt balance in rats].","Marina AS","2012","Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova","preclinical","article",null,"22645945",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0028030","Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations.","Riddle MC","2005","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2004.12.002","15752923",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0028031","Recent diabetes issues affecting the primary care clinician.","Sando KR","2011","Southern medical journal","narrative_review","article","10.1097/smj.0b013e318213e92b","21886036",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028032","Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs.","Mentlein R","2005","Expert opinion on investigational drugs","narrative_review","article","10.1517/13543784.14.1.57","15709922",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0028033","Gateways to clinical trials.","Bayés M","2003","Methods and findings in experimental and clinical pharmacology","other","article",null,"14571286",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028034","Using propensity scores subclassification to estimate effects of longitudinal treatments: an example using a new diabetes medication.","Segal JB","2007","Medical care","nonrandomized_study","article","10.1097/mlr.0b013e31804ffd6d","17909374",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, U.S. Gov't, P.H.S.; article"],["R0028035","Characterization of glucagon-like peptide-1 receptor-binding determinants.","Xiao Q","2000","Journal of molecular endocrinology","other","article","10.1677/jme.0.0250321","11116211",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028036","Real-world insulin treatment persistence among patients with type 2 diabetes.","Wei W","2014","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","nonrandomized_study","article","10.4158/ep13159.or","24013990",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028037","Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.","Irwin N","2007","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.729","17315241",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028038","Systemic toll-like receptor and interleukin-18 pathway activation in patients with acute ST elevation myocardial infarction.","van der Pouw Kraan TC","2014","Journal of molecular and cellular cardiology","other_trial","article","10.1016/j.yjmcc.2013.12.021","24389343",null,null,null,"pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article"],["R0028039","A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.","Wei W","2017","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12828","27860158","PMC5347924",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; research-article; article"],["R0028040","The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action.","Hareter A","1997","Endocrine journal","preclinical","article","10.1507/endocrj.44.701","9466326",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028041","Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.","Piccinni C","2011","Diabetes care","other","article","10.2337/dc10-2412","21515844","PMC3114317",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0028042","Myocardial reperfusion injury: looking beyond primary PCI.","Fröhlich GM","2013","European heart journal","narrative_review","article","10.1093/eurheartj/eht090","23536610",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028043","Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.","Little TJ","2006","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/jc.2005-2220","16492694",null,null,"S000473","pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028044","Hydrogel drug delivery system with predictable and tunable drug release and degradation rates.","Ashley GW","2013","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.1215498110","23345437","PMC3568318",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0028045","GLP-1: what is known, new and controversial in 2010?","Burcelin R","2010","Diabetes & metabolism","preclinical","article","10.1016/j.diabet.2010.09.002","21075654",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Conference Proceedings"],["R0028046","DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.","Dai Y","2014","Cardiovascular drugs and therapy","other","article","10.1007/s10557-014-6539-4","25022544",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S."],["R0028047","Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.","Roussel R","2015","Advances in therapy","narrative_review","article","10.1007/s12325-015-0261-x","26581749",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028048","Gateways to clinical trials.","Tomillero A","2010","Methods and findings in experimental and clinical pharmacology","other","article","10.1358/mf.2010.32.3.1492017","20448862",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Bibliography; Journal Article; article"],["R0028049","Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines.","Warrer P","2015","Journal of research in pharmacy practice","other","article","10.4103/2279-042x.155753","25984543","PMC4418138",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0028050","Long-term effects of weight-reducing drugs in people with hypertension.","Siebenhofer A","2021","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd007654.pub5","33454957","PMC8094237",null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review"],["R0028051","The incretins: a link between nutrients and well-being.","Burcelin R","2005","The British journal of nutrition","preclinical","article","10.1079/bjn20041340","15877888",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0028052","Incretins, insulin secretion and Type 2 diabetes mellitus.","Vilsbøll T","2004","Diabetologia","narrative_review","article","10.1007/s00125-004-1342-6","14968296",null,null,"S001419","pubmed; europepmc","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028053","Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.","Lavernia F","2010","Postgraduate medicine","case_report","article","10.3810/pgm.2010.05.2139","20463411",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0028054","cAMP Dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in beta-cells.","Kwon G","2004","The Journal of biological chemistry","preclinical","article","10.1074/jbc.m310330200","14688288",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0028055","Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile.","Farmer AD","2017","Diabetologia","randomized_trial","article","10.1007/s00125-016-4199-6","28105520",null,null,null,"pubmed; europepmc","FALSE","open_pdf","2",null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0028056","Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.","Doyle ME","2001","Endocrinology","preclinical","article","10.1210/endo.142.10.8410","11564711",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028057","Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats.","Abegg K","2015","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00331.2014","25540099",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028058","Site of action of a pentapeptide agonist at the glucagon-like peptide-1 receptor. Insight into a small molecule agonist-binding pocket.","Dong M","2012","Bioorganic & medicinal chemistry letters","other","article","10.1016/j.bmcl.2011.10.065","22079758","PMC3248963",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0028059","Insulin detemir: a review of its use in the management of diabetes mellitus.","Keating GM","2012","Drugs","randomized_trial","article","10.2165/11470200-000000000-00000","23110609",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0028060","Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.","Vinik A","2007","Clinical therapeutics","randomized_trial","article","10.1016/j.clinthera.2007.07.005","18036387",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0028061","Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.","Kim JG","2003","Diabetes","preclinical","article","10.2337/diabetes.52.3.751","12606517",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028062","Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.","Santi DV","2012","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.1117147109","22474378","PMC3341049",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0028063","Obesity and weight management in the elderly: a focus on men.","Han TS","2013","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2013.04.012","24054928",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0028064","[The pharmacotherapy of obesity].","Budai KA","2015","Acta pharmaceutica Hungarica","narrative_review","article",null,"26137782",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Historical Article; Journal Article; Review; other"],["R0028065","Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs.","Morgan CL","2012","Diabetes, obesity & metabolism","other","article","10.1111/j.1463-1326.2011.01552.x","22192841",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; article"],["R0028066","The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.","Feng YH","2011","Journal of cellular and molecular medicine","other","article","10.1111/j.1582-4934.2010.01083.x","20455996","PMC2930937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0028067","[The effects of compound CX09040 on the inhibition of PTP1B and protection of pancreatic β cells].","Tang RQ","2015","Yao xue xue bao = Acta pharmaceutica Sinica","preclinical","article",null,"26521437",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028068","Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line.","Zhang LW","2012","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2012.08.008","22925809",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028069","Novel pharmacologic agents for type 2 diabetes.","Uwaifo GI","2005","Endocrinology and metabolism clinics of North America","nonrandomized_study","article","10.1016/j.ecl.2004.11.006","15752927",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0028070","Clinical impact of serum proteins on drug delivery.","Kratz F","2012","Journal of controlled release : official journal of the Controlled Release Society","other_trial","article","10.1016/j.jconrel.2011.11.028","22155554",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0028071","Clinical pharmacokinetics and pharmacodynamics of vildagliptin.","He YL","2012","Clinical pharmacokinetics","narrative_review","article","10.2165/11598080-000000000-00000","22339447",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0028072","New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.","Abbatecola AM","2008","Drugs & aging","narrative_review","article","10.2165/0002512-200825110-00002","18947259",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0028073","The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.","Lam NT","2002","Minerva endocrinologica","narrative_review","article",null,"11961501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028074","Gateways to clinical trials. December 2008.","Tomillero A","2008","Methods and findings in experimental and clinical pharmacology","other","article",null,"19271026",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028075","Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights.","Mauvais-Jarvis F","2001","Diabetes & metabolism","narrative_review","article",null,"11547215",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028076","Hormone-based therapies in the regulation of fuel metabolism and body weight.","Kesty NC","2008","Expert opinion on biological therapy","narrative_review","article","10.1517/14712598.8.11.1733","18847308",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028077","Conditioning the heart to prevent myocardial reperfusion injury during PPCI.","Hausenloy DJ","2012","European heart journal. Acute cardiovascular care","other","article","10.1177/2048872612438805","24062884","PMC3760559",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0028078","Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.","Green BD","2004","Biological chemistry","preclinical","article","10.1515/bc.2004.035","15101559",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028079","Gateways to clinical trials.","Tomillero A","2009","Methods and findings in experimental and clinical pharmacology","other","article",null,"19649342",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028080","Obesity: new perspectives and pharmacotherapies.","Palamara KL","2006","Cardiology in review","narrative_review","article","10.1097/01.crd.0000233903.57946.fd","16924165",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028081","Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.","Green BD","2003","Journal of molecular endocrinology","preclinical","article","10.1677/jme.0.0310529","14664713",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028082","Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin.","Edwards KL","2008","Pharmacotherapy","narrative_review","article","10.1592/phco.28.4.506","18363534",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028083","Gateways to clinical trials.","Tomillero A","2010","Methods and findings in experimental and clinical pharmacology","other","article","10.1358/mf.2010.32.6.1538165","20852754",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Bibliography; Journal Article; article"],["R0028084","GLP-1 in NIDDM.","Holst JJ","1996","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1002/dme.1996.13.s6.156","8894501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028085","The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders.","McIntyre RS","2012","Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists","narrative_review","article","10.1177/104012371202400108","22303523",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review; article"],["R0028086","Islet cell transplantation.","Vaithilingam V","2008","Current opinion in organ transplantation","preclinical","article","10.1097/mot.0b013e328317a48b","19060555",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028087","A review of exenatide as adjunctive therapy in patients with type 2 diabetes.","Robles GI","2009","Drug design, development and therapy","randomized_trial","article","10.2147/dddt.s3321","19920937","PMC2769236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; article"],["R0028088","[D-Leu-4]-OB3, an orally bioavailable leptin-related synthetic peptide insulin sensitizer: a study comparing the efficacies of [D-Leu-4]-OB3 and metformin on energy balance and glycemic regulation in insulin-deficient male Swiss Webster mice.","Novakovic ZM","2013","Peptides","preclinical","article","10.1016/j.peptides.2013.02.023","23500518",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028089","Isolation and structure-function studies of a glucagon-like peptide 1 receptor from goldfish Carassius auratus: identification of three charged residues in extracellular domains critical for receptor function.","Yeung CM","2002","Endocrinology","preclinical","article","10.1210/en.2002-220694","12446592",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; article"],["R0028090","[New avenues for pharmacotherapy of type 2 diabetes mellitus].","Shvarts V","2008","Klinicheskaia meditsina","narrative_review","article",null,"19048830",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028091","Management of obesity in patients with type 2 diabetes mellitus.","Gagliardi L","2007","Current diabetes reviews","narrative_review","article","10.2174/157339907780598207","18220660",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Evaluation Study; Journal Article; Review; article"],["R0028092","Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes.","Schernthaner G","2010","Diabetes & metabolism","other_trial","article","10.1016/j.diabet.2010.04.004","20598608",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Multicenter Study; Randomized Controlled Trial"],["R0028093","Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes",null,"2009","National Institute for Health and Clinical Excellence (UK), London","narrative_review","article",null,"22220323",null,null,null,"europepmc","FALSE",null,null,null,"Practice Guideline; Review"],["R0028094","Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.","Nauck MA","1998","Acta diabetologica","narrative_review","article","10.1007/s005920050116","9840447",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028095","Screening for Prediabetes and Type 2 Diabetes Mellitus: An Evidence Review for the U.S. Preventive Services Task Force","Jonas DE","2021","Agency for Healthcare Research and Quality (US), Rockville (MD)","randomized_trial","article",null,"34554661",null,null,null,"europepmc; openalex","TRUE","free_to_read","2","FALSE","Review; article"],["R0028096","Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.","RISE Consortium","2014","Diabetes care","randomized_trial","article","10.2337/dc13-1879","24194506","PMC3931376","ClinicalTrials.gov:NCT01763346; ClinicalTrials.gov:NCT01779362; ClinicalTrials.gov:NCT01779375","S002086","pubmed; europepmc; openalex","TRUE","open_europepmc","1","FALSE","Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0028097","Diabetes: assessing the pipeline.","Lebovitz H","2006","Atherosclerosis. Supplements","other_trial","article","10.1016/j.atherosclerosissup.2006.01.007","16504599",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0028098","Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.","Stockl KM","2009","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.1700","19109802",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0028099","Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update)",null,"2008","Royal College of Physicians (UK), London","narrative_review","article",null,"21678628",null,null,null,"europepmc","FALSE",null,null,null,"Practice Guideline; Review"],["R0028100","Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways.","Friedrichsen BN","2006","The Journal of endocrinology","preclinical","article","10.1677/joe.1.06160","16522728",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028101","Gateways to clinical trials.","Tomillero A","2010","Methods and findings in experimental and clinical pharmacology","other","article","10.1358/mf.2010.32.9.1563109","21225019",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028102","Gateways to clinical trials.","Tomillero A","2009","Methods and findings in experimental and clinical pharmacology","other","article","10.1358/mf.2009.31.4.1373959","19557204",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Bibliography; Journal Article; article"],["R0028103","Imaging tumors with peptide-based radioligands.","Behr TM","2001","The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)","narrative_review","article",null,"11476170",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028104","Incretins and other peptides in the treatment of diabetes.","Todd JF","2007","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/j.1464-5491.2006.02071.x","17263764",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0028105","National trends in treatment of type 2 diabetes mellitus, 1994-2007.","Alexander GC","2008","Archives of internal medicine","other","article","10.1001/archinte.168.19.2088","18955637","PMC2868588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; research-article; article"],["R0028106","Primary Care Management of Abnormal Uterine Bleeding","Hartmann KE","2013","Agency for Healthcare Research and Quality (US), Rockville (MD)","randomized_trial","article",null,"23617013",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0028107","Gateways to clinical trials.","Tomillero A","2009","Methods and findings in experimental and clinical pharmacology","other","article",null,"19536362",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028108","Gateways to clinical trials.","Bayes M","2005","Methods and findings in experimental and clinical pharmacology","other","article",null,"16082427",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028109","Gateways to clinical trials.","Bayés M","2005","Methods and findings in experimental and clinical pharmacology","other","article",null,"16395422",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028110","Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties.","Wheeler MB","1995","Endocrinology","preclinical","article","10.1210/endo.136.10.7664683","7664683",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028111","Drugs on the horizon for treatment of type 2 diabetes.","Rachman J","1995","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/j.1464-5491.1995.tb00526.x","7648818",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028112","Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.","Nauck MA","1997","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","narrative_review","article","10.1055/s-0029-1211750","9285204",null,null,"S000485","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028113","Gateways to clinical trials.","Bayés M","2003","Methods and findings in experimental and clinical pharmacology","other","article",null,"14735233",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028114","Gateways to clinical trials.","Bayés M","2004","Methods and findings in experimental and clinical pharmacology","other","article",null,"15605126",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028115","Gateways to clinical trials.","Bayes M","2007","Methods and findings in experimental and clinical pharmacology","other","article",null,"17982511",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028116","Drug interventions for the treatment of obesity in children and adolescents.","Mead E","2016","The Cochrane database of systematic reviews","systematic_review","article","10.1002/14651858.cd012436","27899001","PMC6472619",null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review; systematic-review"],["R0028117","Gateways to clinical trials.","Bayes M","2006","Methods and findings in experimental and clinical pharmacology","narrative_review","article",null,"17003851",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0028118","Gateways to clinical trials.","Bayes M","2003","Methods and findings in experimental and clinical pharmacology","other","article",null,"14685303",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028119","Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force","LeBlanc EL","2018","Agency for Healthcare Research and Quality (US), Rockville (MD)","systematic_review","article",null,"30354042",null,null,null,"europepmc","TRUE","free_to_read","3",null,"Review"],["R0028120","The entero-insular axis: implications for human metabolism.","Ranganath LR","2008","Clinical chemistry and laboratory medicine","narrative_review","article","10.1515/cclm.2008.008","18020966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028121","Gateways to clinical trials.","Bayés M","2003","Methods and findings in experimental and clinical pharmacology","other","article",null,"12949633",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028122","Gateways to clinical trials.","Bayes M","2004","Methods and findings in experimental and clinical pharmacology","other","article",null,"15349141",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028123","Current and investigational antiobesity agents and obesity therapeutic treatment targets.","Bays HE","2004","Obesity research","narrative_review","article","10.1038/oby.2004.151","15340100",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028124","Gateways to clinical trials.","Bayés M","2004","Methods and findings in experimental and clinical pharmacology","other","article",null,"15071612",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028125","Gateways to clinical trials.","Bayes M","2005","Methods and findings in experimental and clinical pharmacology","other","article",null,"16179960",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028126","Gateways to clinical trials.","Bayés M","2005","Methods and findings in experimental and clinical pharmacology","other","article",null,"16082422",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Bibliography; Journal Article"],["R0028127","S 23521 decreases food intake and body weight gain in diet-induced obese rats.","Claret M","2004","Obesity research","preclinical","article","10.1038/oby.2004.199","15536223",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028128","Gut-derived incretin hormones and new therapeutic approaches.","Bloomgarden ZT","2004","Diabetes care","narrative_review","article","10.2337/diacare.27.10.2554","15451935",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Review"],["R0028129","A gut feeling.","Pronsati MP","2004","Advance for nurse practitioners","commentary","article",null,"15354498",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028130","[Effects of GLP-1(7-36)NH2 on insulin secretion and the changes of intracellular cAMP and insulin mRNA expression].","Liu SF","2004","Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","preclinical","article",null,"21192403",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028131","GLP-1: target for a new class of antidiabetic agents?","Edwards CM","2004","Journal of the Royal Society of Medicine","other","article","10.1177/014107680409700604","15173327","PMC1079489",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028132","A gut response. The next generation of type 2 drugs.","Kordella T","2004","Diabetes forecast","other","article",null,"15119299",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028133","Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.","Rachman J","2004","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/j.1466-5468.2004.1180h.x","15088933",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028134","Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration.","Ruggles JA","2004","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/s0889-8529(03)00098-7","15053905",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028135","Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry.","Wolf R","2004","Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","other","article","10.1016/j.jchromb.2003.11.044","15026002",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028136","Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).","Green BD","2004","Metabolism: clinical and experimental","other","article","10.1016/j.metabol.2003.09.015","14767880",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028137","The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists.","Al-Sabah S","2003","FEBS letters","other","article","10.1016/s0014-5793(03)01043-3","14572647",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028138","Diabetes treatments get sweet help from nature.","Habeck M","2003","Nature medicine","commentary","article","10.1038/nm1003-1228a","14520349",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028139","The glucagon-like peptides: a double-edged therapeutic sword?","Perry T","2003","Trends in pharmacological sciences","narrative_review","article","10.1016/s0165-6147(03)00160-3","12871671",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028140","Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats.","Schick RR","2003","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00479.2002","12776726",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028141","Pharmacologic treatment of type 2 diabetes.","Bloomgarden ZT","2003","Diabetes care","other","article","10.2337/diacare.26.2.526","12547894",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0028142","Lilly and Amylin to collaborate on potential breakthrough diabetes treatment.","Walczak IM","2002","Diabetes technology & therapeutics","commentary","article",null,"12458567",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028143","[Glucagon-like peptide-1 (GLP-1) receptor].","Taminato T","2002","Nihon rinsho. Japanese journal of clinical medicine","narrative_review","article",null,"12238094",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028144","Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models.","Mooney MH","2002","Biochimica et biophysica acta","preclinical","article","10.1016/s0304-4165(01)00237-9","11853960",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028145","Involvement of calmodulin in glucagon-like peptide 1(7-36) amide-induced inhibition of the ATP-sensitive K+ channel in mouse pancreatic beta-cells.","Ding WG","2001","Experimental physiology","preclinical","article","10.1113/eph8602173","11429650",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028146","Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo.","Bertin E","2001","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jcem.86.3.7330","11238513",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028147","Antagonism of central glucagon-like peptide-1 receptors enhances lipopolysaccharide-induced fever.","Rinaman L","2000","Autonomic neuroscience : basic & clinical","preclinical","article","10.1016/s1566-0702(00)00227-7","11189034",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, P.H.S."],["R0028148","Kinetic analysis of enzymatic and nonenzymatic degradation of peptides by MALDI-TOFMS.","Rosche F","2000","Methods in molecular biology (Clifton, N.J.)","narrative_review","article","10.1385/1-59259-045-4:251","10948507",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028149","Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.","Stoffers DA","2000","Diabetes","preclinical","article","10.2337/diabetes.49.5.741","10905482",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; article"],["R0028150","An osmotic stimulus-mediating glucagon-like peptide-1 (7-36 amide) (GLP-1) secretion in acarbose-induced sucrose malabsorption?","Ranganath L","2000","Nutrition (Burbank, Los Angeles County, Calif.)","commentary","article","10.1016/s0899-9007(99)00238-5","10674237",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0028151","Functional studies of a glucagon receptor isolated from frog Rana tigrina rugulosa: implications on the molecular evolution of glucagon receptors in vertebrates.","Ngan ES","1999","FEBS letters","preclinical","article","10.1016/s0014-5793(99)01112-6","10471837",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S."],["R0028152","Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats.","Iritani N","1999","The Journal of nutrition","preclinical","article","10.1093/jn/129.1.46","9915874",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028153","Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7-36)amide on vasopressin and oxytocin release.","Zueco JA","1999","Journal of neurochemistry","preclinical","article","10.1046/j.1471-4159.1999.0720010.x","9886049",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028154","Effects of various N-terminal fragments of glucagon-like peptide-1(7-36) on food intake in the neonatal chick.","Furuse M","1998","Brain research","preclinical","article","10.1016/s0006-8993(98)00798-7","9757042",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028155","Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety.","Asarian L","1998","Physiology & behavior","preclinical","article","10.1016/s0031-9384(98)00089-4","9748106",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, P.H.S."],["R0028156","Changes in the concentrations of glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide during the lactation cycle in goats.","Faulkner A","1998","The Journal of dairy research","preclinical","article","10.1017/s0022029998002957","9718496",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028157","Elevated post-prandial gastric inhibitory polypeptide concentrations in hypertriglyceridaemic subjects.","Gama R","1997","Clinical science (London, England : 1979)","other","article","10.1042/cs0930343","9404226",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028158","GLP-I(7-36) amide augments Ba2+ current through L-type Ca2+ channel of rat pancreatic beta-cell in a cAMP-dependent manner.","Suga S","1997","Diabetes","preclinical","article","10.2337/diab.46.11.1755","9356022",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028159","Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.","Larsen PJ","1997","Endocrinology","preclinical","article","10.1210/endo.138.10.5270","9322962",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028160","Methods for the investigation of neuropeptide catabolism and stability in vitro.","Mentlein R","1997","Brain research. Brain research protocols","preclinical","article","10.1016/s1385-299x(96)00035-9","9385060",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028161","The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.","Wettergren A","1997","Gut","other","article","10.1136/gut.40.5.597","9203936","PMC1027160",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028162","Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism.","Ding WG","1997","Diabetes","preclinical","article","10.2337/diab.46.5.792","9133546",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028163","Bioactive peptides from lizard venoms.","Raufman JP","1996","Regulatory peptides","narrative_review","article","10.1016/0167-0115(96)00135-8","8701022",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028164","The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.","Graziano MP","1996","Receptors & channels","other","article",null,"8723643",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028165","Plasma and intestinal concentrations of GIP and GLP-1 (7-36) amide during suckling and after weaning in pigs.","Knapper JM","1995","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","preclinical","article","10.1055/s-2007-980008","8770623",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028166","Effects of somatostatin-28 on plasma glucose-dependent insulinotropic polypeptide and serum insulin concentrations.","Faulkner A","1995","Biochemical Society transactions","preclinical","article","10.1042/bst023544s","8654729",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028167","Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum.","Dumoulin V","1995","Endocrinology","preclinical","article","10.1210/endo.136.11.7588257","7588257",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028168","Glucagon-like peptide-1 binding to rat hepatic membranes.","Villanueva-Peñacarrillo ML","1995","The Journal of endocrinology","preclinical","article","10.1677/joe.0.1460183","7561616",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028169","Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon.","Plaisancié P","1995","The Journal of endocrinology","preclinical","article","10.1677/joe.0.1450521","7636436",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028170","Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas.","Jia X","1995","Diabetes","preclinical","article","10.2337/diab.44.5.495","7729605",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028171","Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion.","Jia X","1995","The American journal of physiology","preclinical","article","10.1152/ajpendo.1995.268.4.e645","7733263",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028172","Highly increased insulin secretion in a patient with postprandial hypoglycemia: role of glucagon-like peptide-1 (7-36) amide.","Owada K","1995","Endocrine journal","case_report","article","10.1507/endocrj.42.147","7627258",null,null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article"],["R0028173","Structural characterization by affinity cross-linking of glucagon-like peptide-1(7-36)amide receptor in rat brain.","Calvo JC","1995","Journal of neurochemistry","preclinical","article","10.1046/j.1471-4159.1995.64010299.x","7798926",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028174","Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.","Egan JM","1994","Endocrinology","preclinical","article","10.1210/endo.135.5.7956929","7956929",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028175","Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding.","Schmidtler J","1994","The American journal of physiology","preclinical","article","10.1152/ajpgi.1994.267.3.g423","7943240",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028176","Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.","Wettergren A","1994","Scandinavian journal of gastroenterology","randomized_trial","article","10.3109/00365529409092462","7915853",null,null,null,"pubmed","FALSE","paywalled","2",null,"Clinical Trial; Journal Article; Randomized Controlled Trial"],["R0028177","Stimulation of rat parietal cell function by histamine and GLP-1-(7-36) amide is mediated by Gs alpha.","Schmidtler J","1994","The American journal of physiology","preclinical","article","10.1152/ajpgi.1994.266.5.g775","8203524",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028178","Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR.","Thornton K","1994","Biochemistry","other","article","10.1021/bi00178a009","8142350",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S."],["R0028179","Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells.","Gallwitz B","1993","Journal of molecular endocrinology","preclinical","article","10.1677/jme.0.0100259","8396943",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028180","Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable.","Orskov C","1993","Diabetes","other","article","10.2337/diab.42.5.658","8482423",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028181","Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas.","Göke R","1993","Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie","preclinical","article","10.1007/bf02576216","8516568",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028182","Discussing the role of glucagonlike peptide-I.","Holst JJ","1992","Diabetes care","commentary","article","10.2337/diacare.15.10.1440","1425120",null,null,null,"pubmed","FALSE",null,null,null,"Comment; Comparative Study; Letter"],["R0028183","Glucagonlike peptide-1(7-36)amide suppresses glucagon secretion and decreases cyclic AMP concentration in cultured In-R1-G9 cells.","Matsumura T","1992","Biochemical and biophysical research communications","preclinical","article","10.1016/s0006-291x(05)80836-8","1378730",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028184","Solubilization of active GLP-1 (7-36)amide receptors from RINm5F plasma membranes.","Göke R","1992","FEBS letters","preclinical","article","10.1016/0014-5793(92)80852-8","1313374",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028185","Interaction of glucagon-like peptide-1(7-36) amide and gastric inhibitory polypeptide or cholecystokinin on insulin and glucagon secretion from the isolated perfused rat pancreas.","Suzuki S","1992","Metabolism: clinical and experimental","preclinical","article","10.1016/0026-0495(92)90068-l","1556941",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028186","Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain.","Uttenthal LO","1992","Neuropeptides","preclinical","article","10.1016/0143-4179(92)90036-v","1352862",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028187","Entero-insular axis and diabetes mellitus.","Creutzfeldt W","1992","Hormone and metabolic research. Supplement series","preclinical","article",null,"1490680",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028188","The structure-function relationship of GLP-1 related peptides in the endocrine function of the canine pancreas.","Ohneda A","1991","The Tohoku journal of experimental medicine","preclinical","article","10.1620/tjem.165.209","1807008",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028189","Effects of glucagon-like peptide 1 (7-36) amide and glucagon on amylin release from perfused rat pancreas.","Inoue K","1991","Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","preclinical","article","10.1055/s-2007-1003714","1743611",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028190","GLP-1-(7-36) amide, -(1-37), and -(1-36) amide: potent cAMP-dependent stimuli of rat parietal cell function.","Schmidtler J","1991","The American journal of physiology","preclinical","article","10.1152/ajpgi.1991.260.6.g940","1711782",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028191","Carbachol priming increases glucose- and glucagon-like peptide-1 (7-36)amide-, but not arginine-induced insulin secretion from the isolated perfused rat pancreas.","Fehmann HC","1990","Zeitschrift fur Gastroenterologie","preclinical","article",null,"2238765",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028192","Glucagon-like peptide-1(7-37) does not stimulate either hepatic glycogenolysis or ketogenesis.","Murayama Y","1990","Endocrinologia japonica","preclinical","article","10.1507/endocrj1954.37.293","2171922",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028193","Effects of glucagonlike peptide I-(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures.","D'Alessio DA","1989","Diabetes","preclinical","article","10.2337/diab.38.12.1534","2573553",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S."],["R0028194","A LEAN treatment for non-alcoholic steatohepatitis.","Wong VW","2016","Lancet (London, England)","commentary","article","10.1016/s0140-6736(15)00982-4","26608257",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028195","Redistribution of Proximal and Distal Reabsorption of Water and Ions in Rat Kidney After Treatment with Glucagon-Like Peptide-1 Mimetic.","Natochin YV","2015","Bulletin of experimental biology and medicine","preclinical","article","10.1007/s10517-015-3085-4","26601838",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028196","The metabolic score: A decision making tool in diabetes care.","Kalra S","2015","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"26564303",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028197","Response to the Letter by Kalra S. et al.","Kramer CK","2015","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/jc.2015-3553","26544664",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Letter; Comment; article"],["R0028198","Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.","Cork SC","2015","Molecular metabolism","preclinical","article","10.1016/j.molmet.2015.07.008","26500843","PMC4588458",null,"S000204","pubmed","FALSE","open_pdf","5",null,"Journal Article"],["R0028199","Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.","Wang S","2015","Journal of diabetes research","narrative_review","article","10.1155/2015/962383","26421309","PMC4572424",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028200","GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway.","Ying Y","2015","Journal of molecular endocrinology","preclinical","article","10.1530/jme-15-0155","26386043","PMC4621609",null,"S000128","pubmed","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028201","Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.","ten Kulve JS","2015","Diabetologia","randomized_trial","article","10.1007/s00125-015-3754-x","26385462","PMC4630252","ClinicalTrials.gov:NCT01363609","S000930; S002016","pubmed","FALSE","open_pdf","1",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028202","Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies.","Petersen KE","2016","Current diabetes reviews","preclinical","article","10.2174/1573399812666150918150608","26381142","PMC5101636",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028203","New drugs 2015, part 3.","Hussar DA","2015","Nursing","narrative_review","article","10.1097/01.nurse.0000471408.58270.66","26352370",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028204","Number-Based Approach to Insulin Taxonomy.","Kalra S","2015","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-015-0129-8","26350081","PMC4674470",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028205","New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.","Nakane A","2015","Analytical biochemistry","other","article","10.1016/j.ab.2015.08.026","26341912",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028206","Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure.","Yang DH","2015","Acta pharmacologica Sinica","narrative_review","article","10.1038/aps.2015.78","26279155","PMC4561977",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028207","American Diabetes Association - 75th Scientific Sessions (June 5-9, 2015 - Boston, Massachusetts, USA).","Glessner M","2015","Drugs of today (Barcelona, Spain : 1998)","other","article","10.1358/dot.2015.51.6.2358760","26261852",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0028208","Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury.","Lim SW","2015","Laboratory investigation; a journal of technical methods and pathology","preclinical","article","10.1038/labinvest.2015.93","26237274",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028209","Pancreatic β-cell imaging in humans: fiction or option?","Laurent D","2016","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12544","26228188",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028210","Meeting of the minds: Send your stories.","Albaugh JF","2015","Science (New York, N.Y.)","commentary","article","10.1126/science.349.6244.148-a","26160935",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0028211","Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists.","Finan B","2015","Molecular and cellular endocrinology","narrative_review","article","10.1016/j.mce.2015.07.003","26151488",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028212","Screening of randomly mutagenized glucagon-like peptide-1 library by using an integrated yeast-mammalian assay system.","Shigemori T","2015","Journal of biotechnology","preclinical","article","10.1016/j.jbiotec.2015.06.392","26087314",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028213","New drugs 2015, part 2.","Hussar DA","2015","Nursing","other","article","10.1097/01.nurse.0000466441.89312.d0","26083291",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028214","[Optimizing treatment of type 2 diabetic patients].","Red","2015","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-015-3224-x","26049358",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028215","Glucose-lowering medicines for type 2 diabetes.","Davoren P","2015","Australian family physician","other_trial","article",null,"26042396",null,null,null,"pubmed; europepmc; openalex","TRUE","no_doi","5","FALSE","Case Reports; Journal Article; Review; article"],["R0028216","Weight management in Ramadan.","Sethi BK","2015","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"26013789",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028217","Newer antidiabetic drugs in Ramadan.","Bajaj S","2015","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"26013784",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028218","An alternative combination therapy for type 2 diabetes?","Østoft SH","2015","Lancet (London, England)","commentary","article","10.1016/s0140-6736(15)60615-8","26009215",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028219","Sitagliptin for Type 2 diabetes: a 2015 update.","Lee M","2015","Expert review of cardiovascular therapy","narrative_review","article","10.1586/14779072.2015.1046840","26000559",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028220","Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.","Gallwitz B","2015","Therapeutics and clinical risk management","narrative_review","article","10.2147/tcrm.s67076","25999728","PMC4437596",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0028221","Combined Optical Coherence and Fluorescence Microscopy to assess dynamics and specificity of pancreatic beta-cell tracers.","Berclaz C","2015","Scientific reports","preclinical","article","10.1038/srep10385","25988507","PMC4437378",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028222","Mixing Pens and the Future of Diabetes Drugs.","Ginsberg BH","2015","Journal of diabetes science and technology","commentary","article","10.1177/1932296815585873","25944896","PMC4525653",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028223","Drug used to treat diabetes may get ok for weight loss.","Reinke T","2014","Managed care (Langhorne, Pa.)","other","article",null,"25941730",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028224","[Possibilities of therapy GLP1 RA for diabetics with nephropathy].","Adamíková A","2015","Vnitrni lekarstvi","other","article",null,"25894260",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028225","2015 new drug update.","Hussar DA","2015","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","other","article","10.4140/tcp.n.2015.192","25893698",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028226","Can early use of insulin, GLP-1 halt diabetes progression?","Caffrey MK","2014","The American journal of managed care","other","article",null,"25830193",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0028227","Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases.","Gaggini M","2015","Hormone molecular biology and clinical investigation","narrative_review","article","10.1515/hmbci-2015-0006","25816312",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028228","Pharmacologic treatment of type 2 diabetes: injectable medications.","Tran L","2015","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/1060028015573010","25802244",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0028229","Translating What Works: A New Approach to Improve Diabetes Management.","Phillips LS","2015","Journal of diabetes science and technology","other","article","10.1177/1932296815576000","25759182","PMC4525659",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S."],["R0028230","Pharmacologic treatment of type 2 diabetes: oral medications.","Tran L","2015","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/1060028014558289","25667196",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0028231","Protective effect of rhGLP-1 (7-36) on brain ischemia/reperfusion damage in diabetic rats.","Zhao L","2015","Brain research","preclinical","article","10.1016/j.brainres.2015.01.014","25601009",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028232","Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.","Zhang L","2015","Bioconjugate chemistry","preclinical","article","10.1021/bc500584t","25594741","PMC4933591",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0028233","Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs.","Taguchi K","2015","The Journal of pharmacy and pharmacology","preclinical","article","10.1111/jphp.12338","25556343",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028234","Once-yearly device takes on daily and weekly diabetes drugs.","Mullard A","2014","Nature biotechnology","commentary","article","10.1038/nbt1214-1178","25489827",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028235","Drug induced acute pancreatitis: does it exist?","Tenner S","2014","World journal of gastroenterology","randomized_trial","article","10.3748/wjg.v20.i44.16529","25469020","PMC4248195",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article"],["R0028236","Patient involvement in drug licensing: a case study.","Britten N","2015","Social science & medicine (1982)","nonrandomized_study","article","10.1016/j.socscimed.2014.10.024","25454636",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028237","[The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].","Escalada FJ","2014","Medicina clinica","narrative_review","article","10.1016/s0025-7753(14)70101-0","25326836",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028238","Novo sets sights on obesity market with diabetes drug.","Sheridan C","2014","Nature biotechnology","commentary","article","10.1038/nbt1114-1071","25380424",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028239","[Long-term acting insulin analogues and the risks of hypoglycemic incidence].","Adamíková A","2014","Vnitrni lekarstvi","other","article",null,"25294753",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0028240","Evolving directions in obesity management.","Aronne LJ","2014","The Journal of family practice","narrative_review","article",null,"25198217",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028241","[New therapies for type 2 diabetes mellitus].","Puig-Domingo M","2015","Medicina clinica","narrative_review","article","10.1016/j.medcli.2014.03.018","25194974",null,null,null,"pubmed","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0028242","The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.","Al-Sabah S","2014","PloS one","other","article","10.1371/journal.pone.0106890","25191754","PMC4156404",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028243","The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.","Lotfy M","2014","Cell and tissue research","preclinical","article","10.1007/s00441-014-1959-9","25115772",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028244","Tolerability and safety of the new anti-obesity medications.","Hainer V","2014","Drug safety","narrative_review","article","10.1007/s40264-014-0206-3","25096956",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028245","GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma.","Ruby RJ","2014","Diabetes care","case_report","article","10.2337/dc14-0514","25061148",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Case Reports; Letter; article"],["R0028246","Hyperglycemia and adverse outcomes in acute coronary syndromes: is serum glucose the provocateur or innocent bystander?","Wei CH","2014","Diabetes","commentary","article","10.2337/db14-0571","24962919",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028247","[Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN].","Prieto MÁ","2014","Semergen","narrative_review","article","10.1016/j.semerg.2014.04.005","24882393",null,null,null,"pubmed","FALSE",null,null,null,"English Abstract; Journal Article; Review; Consensus Statement"],["R0028248","[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].","Ueno H","2014","Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine","narrative_review","article","10.2169/naika.103.753","24796150",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028249","Generation of high-yield insulin producing cells from human bone marrow mesenchymal stem cells.","Jafarian A","2014","Molecular biology reports","preclinical","article","10.1007/s11033-014-3349-5","24718781",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028250","Update on obesity pharmacotherapy.","Bray GA","2014","Annals of the New York Academy of Sciences","narrative_review","article","10.1111/nyas.12328","24641701",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028251","The nuclear option for insulinomas.","Grossman A","2013","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(13)70060-3","24622306",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028252","Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior.","Anderberg RH","2014","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2014.02.026","24560840",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028253","New and emerging regulators of intestinal lipoprotein secretion.","Xiao C","2014","Atherosclerosis","narrative_review","article","10.1016/j.atherosclerosis.2013.12.047","24534456",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028254","How does brain insulin resistance develop in Alzheimer's disease?","De Felice FG","2014","Alzheimer's & dementia : the journal of the Alzheimer's Association","narrative_review","article","10.1016/j.jalz.2013.12.004","24529521",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028255","Role of endogenous GLP-1 and its agonists in osteopenia and osteoporosis: but we little know until tried.","Papazafiropoulou A","2014","Current diabetes reviews","randomized_trial","article","10.2174/1573399810666140217114848","24527734",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0028256","Epidermal insulin resistance as a therapeutic target in acanthosis nigricans?","Malisiewicz B","2014","Acta dermato-venereologica","case_report","article","10.2340/00015555-1778","24514457",null,null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article"],["R0028257","Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy.","Chambers AP","2014","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00469.2013","24368666","PMC3923088",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028258","Activation of PPARβ/δ protects pancreatic β cells from palmitate-induced apoptosis by upregulating the expression of GLP-1 receptor.","Yang Y","2014","Cellular signalling","preclinical","article","10.1016/j.cellsig.2013.11.019","24269940",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028259","Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.","Torekov SS","2014","Diabetes, obesity & metabolism","other","article","10.1111/dom.12240","24251641",null,null,"S001692","pubmed","FALSE","paywalled","5",null,"Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0028260","The central GLP-1: implications for food and drug reward.","Skibicka KP","2013","Frontiers in neuroscience","narrative_review","article","10.3389/fnins.2013.00181","24133407","PMC3796262",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028261","A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity.","Bianchi E","2013","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2013.09.016","24094437",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028262","What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?","Zenari L","2013","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12143","24034516",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028263","Glucagon-like peptide-1: modulator of β-cell dysfunction and death.","Rondas D","2013","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12165","24003936",null,null,"S002247; S002320","pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028264","Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus.","Ballav C","2013","Clinical medicine insights. Endocrinology and diabetes","narrative_review","article","10.4137/cmed.s7314","24031162","PMC3767579",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028265","Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.","Bailey T","2013","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2013.06.009","23953074",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028266","An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.","Harja E","2013","Diabetes technology & therapeutics","nonrandomized_study","article","10.1089/dia.2013.0177","23927624",null,null,null,"pubmed","FALSE","paywalled","4",null,"Comparative Study; Journal Article"],["R0028267","Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.","Moses A","2013","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.f4386","23842435",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0028268","Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?","Holst JJ","2013","Diabetologia","preclinical","article","10.1007/s00125-013-2984-z","23820635",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0028269","Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.","Gallwitz B","2013","Therapeutic advances in endocrinology and metabolism","other","article","10.1177/2042018813486165","23730503","PMC3666443",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028270","A new approach to disease-modifying drug trials in Parkinson's disease.","Barker RA","2013","The Journal of clinical investigation","commentary","article","10.1172/jci69690","23728166","PMC3668828",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028271","CRTC2 is required for β-cell function and proliferation.","Eberhard CE","2013","Endocrinology","preclinical","article","10.1210/en.2012-2088","23677932",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028272","A gut-heart connection in cardiometabolic regulation.","Buglioni A","2013","Nature medicine","preclinical","article","10.1038/nm.3196","23652101","PMC4512286",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028273","Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats.","Femia AP","2013","International journal of cancer","preclinical","article","10.1002/ijc.28260","23649733",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028274","Extrinsic factors promoting in vitro differentiation of insulin-secreting cells from human adipose tissue-derived mesenchymal stem cells.","Dave SD","2013","Applied biochemistry and biotechnology","preclinical","article","10.1007/s12010-013-0250-y","23633267",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028275","The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.","Ortúzar N","2013","ChemMedChem","commentary","article","10.1002/cmdc.201300012","23529925",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0028276","Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.","Cohen D","2013","BMJ (Clinical research ed.)","preclinical","article","10.1136/bmj.f1304","23447395",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","News; article"],["R0028277","GLP-1 based agents and acute pancreatitis : drug safety falls victim to the three monkey paradigm.","Gale EA","2013","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.f1263","23447344",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028278","Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency.","Wilson-Pérez HE","2013","Diabetes","preclinical","article","10.2337/db12-1498","23434938","PMC3712071",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028279","Clinical trials for adolescent obesity: cooking up an alphabet stew of what to do.","Schwimmer JB","2013","JAMA pediatrics","commentary","article","10.1001/jamapediatrics.2013.1661","23381196",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Research Support, N.I.H., Extramural; Comment"],["R0028280","Dysglycaemia in the critically ill - significance and management.","Deane AM","2013","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.12078","23368662",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028281","Antidiabetic therapy effects on bone metabolism and fracture risk.","Montagnani A","2013","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12077","23368527",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0028282","Alzheimer's disease and diabetes: new insights and unifying therapies.","Vignini A","2013","Current diabetes reviews","preclinical","article","10.2174/1573399811309030003","23363296",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028283","Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes.","Gallwitz B","2013","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s23166","23319869","PMC3540954",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028284","Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 study.","Spencer K","2012","Journal of diabetes science and technology","other_trial","article","10.1177/193229681200600608","23294774","PMC3570869","ClinicalTrials.gov:NCT00734474","S001242","pubmed","FALSE","free_to_read","5",null,"Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0028285","Comparing diabetes drugs--helping clinical decisions?","Thethi T","2013","Lancet (London, England)","commentary","article","10.1016/s0140-6736(12)61576-1","23141811",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028286","Recent advancements in drug treatment of obesity.","Carter R","2012","Clinical medicine (London, England)","narrative_review","article","10.7861/clinmedicine.12-5-456","23101148","PMC4953770",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028287","Impact of system delay on infarct size, myocardial salvage index, and left ventricular function in patients with ST-segment elevation myocardial infarction.","Lønborg J","2012","American heart journal","other","article","10.1016/j.ahj.2012.07.021","23067912",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Randomized Controlled Trial"],["R0028288","The fetal origins of the metabolic syndrome: can we intervene?","Ma N","2012","Journal of pregnancy","narrative_review","article","10.1155/2012/482690","23029616","PMC3457612",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028289","cAMP-mediated and metabolic amplification of insulin secretion are distinct pathways sharing independence of β-cell microfilaments.","Mourad NI","2012","Endocrinology","preclinical","article","10.1210/en.2012-1450","22948217",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028290","Management of diabetes and pancreatic cancer.","Flaherty AM","2012","Oncology nursing forum","case_report","article","10.1188/12.onf.440-443","22940508",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; Review; article"],["R0028291","[Therapeutic use and adverse events of incretin-related drugs].","Ishikawa M","2012","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"22768601",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028292","Alzheimer’s disease: the new promise.","Strittmatter WJ","2012","The Journal of clinical investigation","commentary","article","10.1172/jci62745","22754953","PMC3314477",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028293","Human β-cell proliferation and intracellular signaling: driving in the dark without a road map.","Kulkarni RN","2012","Diabetes","preclinical","article","10.2337/db12-0018","22751699","PMC3425429",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028294","Hormone copycats.","Gebel E","2012","Diabetes forecast","other","article",null,"22737769",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028295","Alzheimer disease: Insulin resistance and AD--extending the translational path.","Craft S","2012","Nature reviews. Neurology","commentary","article","10.1038/nrneurol.2012.112","22710630",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028296","Immunotherapies in diabetes mellitus type 1.","Gupta S","2012","The Medical clinics of North America","narrative_review","article","10.1016/j.mcna.2012.04.008","22703858",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028297","Pleiotropic effects of incretins.","Gupta V","2012","Indian journal of endocrinology and metabolism","other","article","10.4103/2230-8210.94259","22701844","PMC3354942",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028298","Type 2 diabetes: which drug as add-on to metformin?","Madsbad S","2012","Lancet (London, England)","commentary","article","10.1016/s0140-6736(12)60769-7","22683136",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028299","Consumer group calls for antidiabetes drug to be withdrawn.","Lenzer J","2012","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.e3259","22570213",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","News; other"],["R0028300","Functional enhancement of transplanted islets by Extendin-4.","Park K","2012","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2012.04.031","22564813",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028301","Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.","Fang V","2012","CANNT journal = Journal ACITN","other","article",null,"22558681",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028302","South African Hypertension Society 2012 congress report.","Aalbers J","2012","Cardiovascular journal of Africa","commentary","article",null,"22555645",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings; News"],["R0028303","The role of combination therapy in type 2 diabetes in the post-ACCORD era.","Kuritzky L","2012","Current diabetes reports","other","article","10.1007/s11892-012-0276-5","22528598",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028304","Ramadan fasting: a study of changes in glucose profiles among patients with diabetes using continuous glucose monitoring.","Lessan N","2012","Diabetes care","commentary","article","10.2337/dc11-2037","22517945","PMC3329831",null,null,"pubmed","FALSE",null,null,null,"Letter; Research Support, Non-U.S. Gov't"],["R0028305","GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?","Gale EA","2012","Diabetes","commentary","article","10.2337/db11-1838","22517653","PMC3331738",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article-commentary; article"],["R0028306","Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion.","Won YW","2012","Journal of controlled release : official journal of the Controlled Release Society","other","article","10.1016/j.jconrel.2012.03.010","22450332","PMC3372625",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028307","Current challenges in type 2 diabetes.","Garber AJ","2012","Diabetes, obesity & metabolism","other","article","10.1111/j.1463-1326.2012.01572.x","22405263",null,null,null,"pubmed","FALSE",null,null,null,"Introductory Journal Article"],["R0028308","GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic β-cells from glucolipotoxicity.","Liu Z","2012","The Journal of endocrinology","preclinical","article","10.1530/joe-11-0328","22414687","PMC4096040",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028309","Glucagon-like peptide-1 agonists.","Padwal R","2012","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.d7282","22236410",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0028310","3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice.","Manni ME","2012","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2011.01823.x","22225569","PMC3417495",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028311","Activation of G-protein-coupled receptors and thyroid malignant tumors: the jury is still out.","Gagel RF","2011","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.4158/ep.17.6.957","22193147",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028312","[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].","Nicolau Ramis J","2012","Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion","commentary","article","10.1016/j.endonu.2011.11.002","22177885",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028313","18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster?","Boerman OC","2012","European journal of nuclear medicine and molecular imaging","commentary","article","10.1007/s00259-011-2020-9","22170323","PMC3276772",null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028314","Origin and convergent evolution of exendin genes.","Irwin DM","2012","General and comparative endocrinology","preclinical","article","10.1016/j.ygcen.2011.11.025","22137915",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028315","GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake.","Alhadeff AL","2012","Endocrinology","preclinical","article","10.1210/en.2011-1443","22128031","PMC3275387",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028316","Drug treatment of obesity.","Bray GA","2011","The Psychiatric clinics of North America","other","article","10.1016/j.psc.2011.08.013","22098810",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028317","Glucagon like-peptide 1 receptor and the liver.","Pedersen J","2011","Liver international : official journal of the International Association for the Study of the Liver","preclinical","article","10.1111/j.1478-3231.2011.02626.x","22093450",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0028318","Taking lizard saliva to heart.","Hausenloy DJ","2012","European heart journal","randomized_trial","article","10.1093/eurheartj/ehr382","21992997",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Editorial; Comment; editorial"],["R0028319","Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example.","Castillo GM","2012","Pharmaceutical research","preclinical","article","10.1007/s11095-011-0542-2","21830140","PMC3247650",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0028320","Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.","Fonseca VA","2011","The American journal of cardiology","narrative_review","article","10.1016/j.amjcard.2011.03.016","21802581",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review"],["R0028321","Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.","Yabe D","2011","Progress in biophysics and molecular biology","narrative_review","article","10.1016/j.pbiomolbio.2011.07.010","21820006",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article; Review"],["R0028322","Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins.","Ansar S","2011","Cardiovascular diabetology","narrative_review","article","10.1186/1475-2840-10-61","21736746","PMC3184260",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review; review-article; article"],["R0028323","GLP-1-based therapies: the dilemma of uncertainty.","Spranger J","2011","Gastroenterology","commentary","article","10.1053/j.gastro.2011.05.019","21723985",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0028324","Management of type 2 diabetes: new and future developments in treatment.","Tahrani AA","2011","Lancet (London, England)","narrative_review","article","10.1016/s0140-6736(11)60207-9","21705062",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028325","Functional association of the N-terminal residues with the central region in glucagon-related peptides.","Patterson JT","2011","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.1385","21661079",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028326","[Incretin analogues as a novel treatment strategy for Alzheimer's disease].","Sakurai T","2011","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"21595270",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028327","Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.","Crajoinas RO","2011","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00729.2010","21593184",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028328","Incretin effects on β-cell function, replication, and mass: the human perspective.","Garber AJ","2011","Diabetes care","other","article","10.2337/dc11-s230","21525465","PMC3632189",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028329","Journal withdraws article after complaints from drug manufacturers.","Hawkes N","2011","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.d2335","21482597",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028330","Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.","Shirakawa J","2011","Diabetes","preclinical","article","10.2337/db10-1338","21330637","PMC3064098",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028331","The transcription factor B-cell lymphoma (BCL)-6 modulates pancreatic {beta}-cell inflammatory responses.","Igoillo-Esteve M","2011","Endocrinology","preclinical","article","10.1210/en.2010-0790","21190961",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028332","Time for clinically relevant comparative effectiveness studies in type 2 diabetes.","Nathan DM","2011","Annals of internal medicine","randomized_trial","article","10.7326/0003-4819-154-2-201101180-00303","21135287",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Editorial; Comment; article"],["R0028333","The incretin system in the management of type 2 diabetes mellitus.","Stephens JW","2010","Clinical medicine (London, England)","narrative_review","article","10.7861/clinmedicine.10-5-491","21117386","PMC4952415",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0028334","[New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].",null,"2010","MMW Fortschritte der Medizin","commentary","article",null,"21049644",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; News"],["R0028335","[Glucagon-like peptide-1: a cardiological perspective].","Elvekjaer M","2010","Ugeskrift for laeger","narrative_review","article",null,"20961501",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028336","[Cardiac effects of glucagon-like peptide 1].","Holst JJ","2010","Ugeskrift for laeger","commentary","article",null,"20961500",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028337","Targeted ion parking for the quantitation of biotherapeutic proteins: concepts and preliminary data.","Campbell JL","2010","Journal of the American Society for Mass Spectrometry","other","article","10.1016/j.jasms.2010.08.015","20926309",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028338","Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action.","Lorenzati B","2010","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph3093005","27713388","PMC4034109",null,null,"pubmed","FALSE",null,null,null,"Review; Journal Article"],["R0028339","Overcoming challenges in Type 2 diabetes management to improve patient outcomes.","Brown MT","2010","Expert review of endocrinology & metabolism","other","article","10.1586/eem.10.45","30764026",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028340","Oligoarginine-linked polymers as a new class of penetration enhancers.","Sakuma S","2010","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2010.08.022","20800631",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028341","Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.","Moon MJ","2010","Molecules and cells","other","article","10.1007/s10059-010-0100-5","20799012",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028342","Combination therapies for type 1 diabetes: why not now?","von Herrath M","2010","Immunotherapy","commentary","article","10.2217/imt.10.23","20635894",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028343","Incretin agents in type 2 diabetes.","Ross SA","2010","Canadian family physician Medecin de famille canadien","nonrandomized_study","article",null,"20631270","PMC2922799",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0028344","Individualised incretin-based treatment for type 2 diabetes.","Nauck MA","2010","Lancet (London, England)","commentary","article","10.1016/s0140-6736(10)60998-1","20580425",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028345","Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples.","Murphy RE","2010","Journal of pharmaceutical and biomedical analysis","preclinical","article","10.1016/j.jpba.2010.04.028","20547023",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028346","Choosing among the incretin agents and why it matters.","Unger J","2010","The Journal of family practice","other","article",null,"20544056",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028347","[New hypoglycemic agents in type 2 diabetes].","Guerci B","2010","La Revue du praticien","other","article",null,"20465123",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028348","Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus.","Palumbo PJ","2010","Vascular health and risk management","narrative_review","article","10.2147/vhrm.s8564","20191079","PMC2828107",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028349","Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.","Brown A","2010","Postgraduate medicine","narrative_review","article","10.3810/pgm.2010.01.2110","20107300",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028350","Incretin concepts.","Bloomgarden ZT","2010","Diabetes care","other","article","10.2337/dc10-zb02","20103551","PMC2809302",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028351","[Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].","Kern W","2010","MMW Fortschritte der Medizin","narrative_review","article",null,"21595145",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028352","Therapeutic Strategies to Increase Human β-Cell Growth and Proliferation by Regulating mTOR and GSK-3/β-Catenin Pathways.","Rohatgi N","2010","The open endocrinology journal","preclinical","article","10.2174/1874216501004010040","24339841","PMC3856862",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028353","New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.","Gallwitz B","2010","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmsott.s4857","21437082","PMC3047961",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028354","Newer agents for glucose control in type 2 diabetes and implications for nurses.","Wood J","2009","Nursing times","other","article",null,"19899489",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028355","The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.","Jessen L","2009","Gastroenterology","commentary","article","10.1053/j.gastro.2009.10.013","19879210",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028356","Gastrointestinal hormones and weight management.","Bray GA","2009","Lancet (London, England)","commentary","article","10.1016/s0140-6736(09)61560-9","19853907",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028357","[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].",null,"2009","MMW Fortschritte der Medizin","other","article",null,"19827447",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028358","Adverse events in diabetes drug trial.","Pechlaner C","2009","Lancet (London, England)","other_trial","article","10.1016/s0140-6736(09)61736-0","19801086",null,null,null,"pubmed","FALSE","paywalled","5",null,"Letter; Comment"],["R0028359","Cyclin D2 protein stability is regulated in pancreatic beta-cells.","He LM","2009","Molecular endocrinology (Baltimore, Md.)","preclinical","article","10.1210/me.2009-0057","19628581","PMC2775938",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028360","Diabetes medications and body weight.","Mitri J","2009","Expert opinion on drug safety","narrative_review","article","10.1517/14740330903081725","19538102",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028361","[Incretin related agents for treatment of diabetes mellitus].","Miyagawa J","2009","Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine","narrative_review","article","10.2169/naika.98.809","19472544",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028362","Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.","Adler AI","2009","BMJ (Clinical research ed.)","randomized_trial","article","10.1136/bmj.b1668","19465464",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0028363","Diabetes treatment and measures of glycemia.","Bloomgarden ZT","2009","Diabetes care","commentary","article","10.2337/dc09-zb04","19336631","PMC6898972",null,null,"pubmed","FALSE",null,null,null,"News"],["R0028364","Update in diabetes management.","Cranwell-Bruce LA","2009","Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses","narrative_review","article",null,"19331300",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028365","Lizard spit and reperfusion injury.","Webb IG","2009","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2008.11.006","19195608",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028366","Insulin analog therapy: improving the match with physiologic insulin secretion.","Freeman JS","2009","The Journal of the American Osteopathic Association","case_report","article",null,"19193822",null,null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028367","[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].","Seissler J","2008","MMW Fortschritte der Medizin","other","article",null,"19024493",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028368","Combination pharmacotherapy with incretins: what works best and when?","Over RK","2008","Current diabetes reports","other","article","10.1007/s11892-008-0063-5","18778584",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028369","Surgery for diabetes at lower BMI: some caution.","Deitel M","2008","Obesity surgery","commentary","article","10.1007/s11695-008-9674-9","18758867",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028370","National Institute of Clinical Excellence provides an update on the clinical management of patients with type 2 diabetes.","Idris I","2008","Diabetes, obesity & metabolism","commentary","article","10.1111/j.1463-1326.2008.00929.x","18577162",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028371","Type 2 diabetes: the many facets of care.","Hall MA","2008","Home healthcare nurse","case_report","article","10.1097/01.nhh.0000324307.56212.dc","18562819",null,null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article; Review"],["R0028372","[Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].","Sjöholm A","2008","Lakartidningen","other","article",null,"18561535",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028373","[Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].","Seissler J","2008","MMW Fortschritte der Medizin","other","article",null,"18533605",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028374","PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation.","Wang ZV","2008","Diabetes","preclinical","article","10.2337/db07-1631","18469203","PMC2494693",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028375","Pharmacotherapy for obesity.","Neff LM","2007","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-007-0061-0","18377785",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028376","[Treatment with new preparations against type 2 diabetes not sufficiently documented].","Karlsson EA","2008","Lakartidningen","commentary","article",null,"18376713",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0028377","Beyond glycemic control: the role of incretin hormones.","Ridge TD","2007","Journal of the American Academy of Nurse Practitioners","narrative_review","article",null,"18341243",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028378","Clinical decisions. Management of type 2 diabetes--polling results.","Halperin F","2008","The New England journal of medicine","commentary","article","10.1056/nejmclde0801078","18272888",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028379","High yield production of recombinant native and modified peptides exemplified by ligands for G-protein coupled receptors.","Bosse-Doenecke E","2008","Protein expression and purification","other","article","10.1016/j.pep.2007.10.012","18248821",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028380","Gila monster's guide to surgery for obesity and diabetes.","Mason EE","2008","Journal of the American College of Surgeons","narrative_review","article","10.1016/j.jamcollsurg.2007.10.011","18222392",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028381","[Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].","Ahrén B","2007","Lakartidningen","other","article",null,"18214322",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028382","Drug interactions.","Scully C","2008","British dental journal","commentary","article","10.1038/bdj.2007.1196","18192977",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0028383","GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.","Ahrén B","2007","Current diabetes reports","narrative_review","article","10.1007/s11892-007-0056-9","18173966",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028384","[New data on hypoglycemia risk and beta cell function].",null,"2007","MMW Fortschritte der Medizin","other","article",null,"18078171",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028385","Pharmaco-economic issues for diabetes therapy.","Bottomley JM","2007","Best practice & research. Clinical endocrinology & metabolism","systematic_review","article","10.1016/j.beem.2007.08.002","18054741",null,null,null,"pubmed","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0028386","Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14.","Klinger S","2008","Diabetes","preclinical","article","10.2337/db07-1414","18025410",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028387","Glucagon-like peptide 1 and type 1 diabetes: NOD ready for prime time?","Hadjiyanni I","2007","Endocrinology","preclinical","article","10.1210/en.2007-1112","17940186",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't; Comment"],["R0028388","Management of comorbid diabetes and cancer.","Singer M","2007","Oncology (Williston Park, N.Y.)","other","article",null,"17844893",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028389","Using prandial insulin to achieve glycemic control in type 2 diabetes.","Dailey GE","2007","The Journal of family practice","narrative_review","article",null,"17764645",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028390","Type 2 diabetes: the end of clinical inertia.","Mirza SA","2007","Southern medical journal","commentary","article","10.1097/smj.0b013e3180f60827","17713297",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028391","Type 2 diabetes drug boom: is newer better?",null,"2007","The Johns Hopkins medical letter health after 50","other","article",null,"17712909",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028392","New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.",null,"2007","Heart advisor","other","article",null,"17695659",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028393","Treatment of type 2 diabetes mellitus and the incretin system.","Whitehill D","2007","South Dakota medicine : the journal of the South Dakota State Medical Association","other","article",null,"17694940",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028394","Diabetic gastroparesis.","Heine RJ","2007","The New England journal of medicine","commentary","article","10.1056/nejmc070752","17652660",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0028395","[New class of oral antidiabetic drugs. Effective in combination with metformin].",null,"2007","MMW Fortschritte der Medizin","commentary","article",null,"17619359",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028396","Emerging treatments for patients with type 2 diabetes.","Haines ST","2007","The Diabetes educator","other","article","10.1177/0145721707302s885","17548897",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028397","Are you up-to-date on diabetes medications?","Scemons D","2007","Nursing","narrative_review","article","10.1097/01.nurse.0000279434.45402.c9","17603373",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028398","Diabetes drug update: how 4 new options stack up.","Taylor JR","2007","The Journal of family practice","narrative_review","article",null,"17343811",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028399","Gliptins.","Mikhail N","2007","Lancet (London, England)","commentary","article","10.1016/s0140-6736(07)60136-6","17258655",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0028400","Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor.","Sowden GL","2007","American journal of physiology. Regulatory, integrative and comparative physiology","preclinical","article","10.1152/ajpregu.00405.2006","17038440",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028401","Animal, plant and microbial toxins - 15th World Congress.","Craik D","2006","IDrugs : the investigational drugs journal","other","article",null,"17016770",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028402","Gut hormones and related concepts.","Bloomgarden ZT","2006","Diabetes care","other","article","10.2337/dc06-zb10","17003315",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0028403","[Blood sugar and pounds down, hardly hypoglycemias. New generation of antidiabetics ante portas].","Einecke D","2006","MMW Fortschritte der Medizin","other","article","10.1007/bf03364711","16995353",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028404","[Improved blood sugar control plus weight loss].","Göke B","2006","MMW Fortschritte der Medizin","other","article",null,"16981389",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028405","[Therapy concept with future].",null,"2006","MMW Fortschritte der Medizin","other","article",null,"16981388",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028406","Treatment of type 2 diabetes. The addition of injection therapy.","Bell DS","2006","Postgraduate medicine","other","article","10.3810/pgm.2006.07.1659","16961048",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028407","American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA.","Jago C","2006","IDrugs : the investigational drugs journal","other","article",null,"16871459",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0028408","New diabetes drugs target gut hormones.","Kuehn BM","2006","JAMA","commentary","article","10.1001/jama.296.4.380","16868285",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings; News"],["R0028409","Challenges and strategies for moving patients to injectable medications.","Siminerio L","2006","The Diabetes educator","narrative_review","article","10.1177/0145721706287653","16554432",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028410","New drugs 06, part I.","Hussar DA","2006","Nursing","other","article","10.1097/00152193-200602000-00041","16462265",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028411","A look back at the most influential drug approvals of 2005.","Laustsen G","2006","The Nurse practitioner","other","article","10.1097/00006205-200602000-00006","16452899",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028412","Failure of transplanted bone marrow cells to adopt a pancreatic beta-cell fate.","Taneera J","2006","Diabetes","preclinical","article","10.2337/diabetes.55.02.06.db05-1212","16443759",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028413","New injectable drug approved for type 2 diabetes.",null,"2005","Mayo Clinic health letter (English ed.)","commentary","article",null,"16411282",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028414","[GLP-1 derivatives, for the prevention and treatment of type 2 diabetes mellitus].","Namba M","2005","Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology","other","article",null,"16318379",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028415","Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.","Carpenter T","2005","The New England journal of medicine","preclinical","article","10.1056/nejm200511173532017","16291992",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0028416","Biotechnology - 12th European Congress.","Neubauer P","2005","IDrugs : the investigational drugs journal","other","article",null,"16254798",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0028417","Animal models of type 2 diabetes with reduced pancreatic beta-cell mass.","Masiello P","2006","The international journal of biochemistry & cell biology","preclinical","article","10.1016/j.biocel.2005.09.007","16253543",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028418","Incretins: what does the future hold?","Edelman SV","2005","Diabetes technology & therapeutics","narrative_review","article","10.1089/dia.2005.7.809","16241889",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028419","Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.","D'Alessio DA","2005","Current diabetes reports","narrative_review","article","10.1007/s11892-005-0092-2","16188169",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0028420","Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.","Neary NM","2005","Endocrinology","preclinical","article","10.1210/en.2005-0237","16150917",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0028421","GLP-1 signalling and effects on glucose metabolism in myocytes from type 2 diabetic patients.","González N","2005","International journal of molecular medicine","other","article",null,"16142415",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028422","[Novel therapy in type 2 diabetes: to regulate glucose metabolism naturally].",null,"2005","MMW Fortschritte der Medizin","other","article",null,"16128202",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028423","First in class. Two new diabetes drugs.","Koredella T","2005","Diabetes forecast","other","article",null,"16124101",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028424","Differentiation of human liver-derived, insulin-producing cells toward the beta-cell phenotype.","Zalzman M","2005","Diabetes","preclinical","article","10.2337/diabetes.54.9.2568","16123344",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S."],["R0028425","Metabolic Diseases World Summit 2005. 29 June-1 July 2005, San Francisco, CA, USA.","James S","2005","IDrugs : the investigational drugs journal","other","article",null,"16118686",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028426","American diabetes association - 65th Scientific Sessions.","Erlich R","2005","IDrugs : the investigational drugs journal","other","article",null,"16044360",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0028427","Drugs for diabetes.","Abramowicz M","2005","Treatment guidelines from the Medical Letter","other","article",null,"16012392",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028428","[Treatment of diabetes mellitus. New developments and hopes].","Verspohl EJ","2005","Medizinische Monatsschrift fur Pharmazeuten","narrative_review","article",null,"15960421",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028429","New drug and dosage form.",null,"2005","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","other","article","10.1093/ajhp/62.11.1122a","15914871",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028430","[The role of incretins. Type 2 diabetes with new beginnings].",null,"2005","MMW Fortschritte der Medizin","other","article",null,"15803785",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028431","[Targeting--a new way to identify unknown tumor markers in blood vessels].","Wallin E","2005","Lakartidningen","narrative_review","article",null,"15786906",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028432","Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.","Lee SH","2005","Bioconjugate chemistry","preclinical","article","10.1021/bc049735+","15769092",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028433","Pharmacotherapy of obesity: An update.","Cignarella A","2021","Pharmacological research","narrative_review","article","10.1016/j.phrs.2021.105649","33962014",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0028434","[Not Available].","Holzgreve H","2021","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-021-9940-5","33961244",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028435","GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated.","Aetesam-Ur-Rahman M","2021","BMC cardiovascular disorders","other_trial","article","10.1186/s12872-021-02030-5","33932990","PMC8088691","ClinicalTrials.gov:NCT03502083",null,"pubmed","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial"],["R0028436","[Not Available].","Steurer J","2021","Praxis","other","article","10.1024/1661-8157/a003672","33906442",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028437","Professional continuous glucose monitoring and endocrinology eConsult for adults with type 2 diabetes in primary care: Results of a clinical pilot program.","Fantasia KL","2021","Journal of clinical & translational endocrinology","other","article","10.1016/j.jcte.2021.100254","33898271","PMC8054187",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028438","Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes.","Kamruzzaman M","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.661877","33897622","PMC8062751",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028439","REWIND Diabetes for Octogenarians.","Geberhiwot T","2021","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgab163","33880568","PMC8208656",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Editorial; Comment; article"],["R0028440","The STEP 1 trial for weight loss: a step change in treating obesity?","Adler AI","2021","Nature medicine","other_trial","article","10.1038/s41591-021-01319-4","33859431",null,null,null,"pubmed","FALSE","paywalled","5",null,"Journal Article; Comment"],["R0028441","Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled Type 2 diabetes on advanced insulin therapy?","Naing S","2021","Endocrinology, diabetes & metabolism","randomized_trial","article","10.1002/edm2.204","33855207","PMC8029542",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0028442","Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates.","Walther CP","2021","Journal of the American Society of Nephrology : JASN","nonrandomized_study","article","10.1681/asn.2020121724","33833077","PMC8259644",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Letter; Research Support, N.I.H., Extramural; article"],["R0028443","Voices: Insulin and beyond.","Roth J","2021","Cell metabolism","other","article","10.1016/j.cmet.2021.03.017","33826910",null,null,null,"pubmed","FALSE",null,null,null,"Historical Article; Interview"],["R0028444","Role of newer antidiabetic drugs on cardiovascular prevention and heart failure.","Rojas-Velázquez JM","2021","Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis","narrative_review","article","10.1016/j.arteri.2021.02.013","33820673",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028445","Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.","Schnell O","2021","Cardiovascular diabetology","other_trial","article","10.1186/s12933-021-01254-1","33789663","PMC8010779",null,null,"pubmed","FALSE","open_pdf","5",null,"Editorial"],["R0028446","Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.","Kalyani RR","2021","The New England journal of medicine","narrative_review","article","10.1056/nejmcp2000280","33789013",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028447","The Association Between Metformin Treatment and Outcomes in Type 2 Diabetes Mellitus Patients With Heart Failure With Preserved Ejection Fraction: A Retrospective Study.","Wang J","2021","Frontiers in cardiovascular medicine","randomized_trial","article","10.3389/fcvm.2021.648212","33778026","PMC7994337",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article"],["R0028448","Epigenetics in NAFLD/NASH: Targets and therapy.","Sodum N","2021","Pharmacological research","narrative_review","article","10.1016/j.phrs.2021.105484","33771699",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028449","Numaswitch: an efficient high-titer expression platform to produce peptides and small proteins.","Nguyen BN","2021","AMB Express","other","article","10.1186/s13568-021-01204-w","33765268","PMC7994495",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028450","New combination therapy shows promise for recent-onset type 1 diabetes mellitus.","Starling S","2021","Nature reviews. Endocrinology","commentary","article","10.1038/s41574-021-00485-2","33753918",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028451","Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor.","Willard FS","2021","Journal of medicinal chemistry","other","article","10.1021/acs.jmedchem.1c00029","33721487",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028452","Weight management strategies for patients with PCOS: current perspectives.","Ozgen Saydam B","2021","Expert review of endocrinology & metabolism","narrative_review","article","10.1080/17446651.2021.1896966","33719818",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028453","Functional GLP-1R antibodies identified from a synthetic GPCR-focused library demonstrate potent blood glucose control.","Liu Q","2021","mAbs","preclinical","article","10.1080/19420862.2021.1893425","33706686","PMC7971233",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028454","Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study.","Pintaudi B","2021","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-021-01251-4","33676499","PMC7936493",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; article"],["R0028455","Combination therapy in recent-onset type 1 diabetes.","Long SA","2021","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(21)00044-9","33662335",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028456","Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?: The Time to Act Is Now.","Cheng AYY","2021","Circulation","commentary","article","10.1161/circulationaha.120.053058","33617314",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; editorial"],["R0028457","STEP 1 for Effective Weight Control - Another First Step?","Ingelfinger JR","2021","The New England journal of medicine","commentary","article","10.1056/nejme2101705","33567184",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028458","Letter to the Editor from Watanabe et al: \"Long-term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study\".","Watanabe H","2021","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgab082","33564886",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; letter"],["R0028459","Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors.","Dąbrowski M","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22041680","33562380","PMC7915237",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028460","Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications.","Donate-Correa J","2020","Frontiers in medicine","narrative_review","article","10.3389/fmed.2020.628289","33553221","PMC7862763",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028461","Cardiovascular outcome trials in Type 2 diabetes: food for thought.","Chahade JJ","2021","Future cardiology","commentary","article","10.2217/fca-2021-0004","33543646",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Research Support, Non-U.S. Gov't"],["R0028462","Heterogeneity in renal end points of cardiovascular outcomes trials in Type 2 diabetes.","Balijepalli C","2021","Journal of comparative effectiveness research","other","article","10.2217/cer-2020-0137","33541137",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028463","Use of Weight Loss Medications in Patients after Bariatric Surgery.","Redmond IP","2021","Current obesity reports","randomized_trial","article","10.1007/s13679-021-00425-1","33492629",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0028464","PEGDA/HA mineralized hydrogel loaded with Exendin4 promotes bone regeneration in rat models with bone defects by inducing osteogenesis.","Liu W","2021","Journal of biomaterials applications","preclinical","article","10.1177/0885328220987046","33467965",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028465","Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives.","Bellis A","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22020775","33466656","PMC7828822",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028466","Pharmacological treatment of hyperglycemia in type 2 diabetes.","Taylor SI","2021","The Journal of clinical investigation","narrative_review","article","10.1172/jci142243","33463546","PMC7810496",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0028467","Glucagon-like peptide-1 receptor is expressed in human and rodent testis.","Caltabiano R","2020","Andrology","preclinical","article","10.1111/andr.12871","33460247",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028468","Rational design and evaluation of GLP-1 derivative for treating hyperglycemia combined with overexercise-induced myocardial injury.","Wang Y","2021","Life sciences","preclinical","article","10.1016/j.lfs.2021.119030","33453242",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028469","Therapy for NASH.","Stower H","2021","Nature medicine","other_trial","article","10.1038/s41591-020-01219-z","33442011",null,null,null,"pubmed","FALSE","paywalled","5",null,"Clinical Trial, Phase II; Journal Article"],["R0028470","Time to Follow the Evidence: Glycemic Control and Cardiovascular Benefits of New Diabetes Medications.","Draznin B","2021","The American journal of medicine","commentary","article","10.1016/j.amjmed.2020.12.012","33434557",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028471","New anti-diabetic agents: major advances with unanswered questions.","Sabouret P","2020","Reviews in cardiovascular medicine","commentary","article","10.31083/j.rcm.2020.04.220","33387991",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028472","Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?","Veelen A","2021","Molecular metabolism","narrative_review","article","10.1016/j.molmet.2020.101158","33387681","PMC8085543",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028473","Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation.","Hanif W","2021","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.14497","33301625",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review; Consensus Statement"],["R0028474","Obesity treatment in patients both with and without diabetes: current options and perspectives.","Haluzík M","2020","Casopis lekaru ceskych","narrative_review","article",null,"33297689",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028475","Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.","Campbell JE","2021","Molecular metabolism","narrative_review","article","10.1016/j.molmet.2020.101139","33290902","PMC8085569",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review"],["R0028476","Area Postrema Cell Types that Mediate Nausea-Associated Behaviors.","Zhang C","2021","Neuron","preclinical","article","10.1016/j.neuron.2020.11.010","33278342","PMC7864887",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028477","How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?","Sukkar L","2020","Kidney & blood pressure research","randomized_trial","article","10.1159/000511214","33271545",null,null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Review"],["R0028478","SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis.","Weinrauch LA","2021","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2020.107761","33234402",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028479","Paradigm Shifts to Improve Treatment in Youth with Type 2 Diabetes.","Dever M","2021","Journal of pediatric nursing","other","article","10.1016/j.pedn.2020.11.002","33223349",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028480","Discovery of a novel short peptide with efficacy in accelerating the healing of skin wounds.","Wang Y","2021","Pharmacological research","preclinical","article","10.1016/j.phrs.2020.105296","33220421",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028481","NAFLD and liver transplantation: Disease burden, current management and future challenges.","Burra P","2020","JHEP reports : innovation in hepatology","narrative_review","article","10.1016/j.jhepr.2020.100192","33163950","PMC7607500",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028482","New prospects for incretin-related drugs in the treatment of type 2 diabetes.","Kimura T","2021","Journal of diabetes investigation","other","article","10.1111/jdi.13460","33151639","PMC8264388",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028483","Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes.","Eriksson O","2020","Scientific reports","other_trial","article","10.1038/s41598-020-73815-5","33028880","PMC7542159",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0028484","Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.","Demine S","2020","International journal of molecular sciences","other_trial","article","10.3390/ijms21197274","33019671","PMC7582644",null,null,"pubmed","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0028485","Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated \"enemy\"?","Patoulias D","2020","Clinical and molecular hepatology","commentary","article","10.3350/cmh.2020.0264","32971587","PMC7641574",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0028486","Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.","Nasykhova YA","2020","International journal of molecular sciences","narrative_review","article","10.3390/ijms21186842","32961860","PMC7555942",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0028487","Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections.","Schlicht K","2020","International journal of obesity (2005)","nonrandomized_study","article","10.1038/s41366-020-00689-y","32958905","PMC7503441",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article"],["R0028488","Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia.","Gilroy CA","2020","Science advances","preclinical","article","10.1126/sciadv.aaz9890","32923621","PMC7449677",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0028489","Effects of antidiabetic drugs on psoriasis: A meta-analysis.","Chi CC","2021","European journal of clinical investigation","systematic_review","article","10.1111/eci.13377","32914429",null,null,null,"pubmed","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis"],["R0028490","Introducing a novel therapy for type 2 diabetes to primary care.","Brunton SA","2020","Postgraduate medicine","other","article","10.1080/00325481.2020.1798686","32897147",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028491","Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals.","Cui J","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.118339","32841660",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028492","Diabetes and dementia - the two faces of Janus.","Papazafiropoulou AK","2020","Archives of medical sciences. Atherosclerotic diseases","other","article","10.5114/amsad.2020.97433","32832719","PMC7433787",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028493","Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review.","Lisco G","2020","Endocrine","narrative_review","article","10.1007/s12020-020-02444-9","32779091","PMC7417102",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028494","2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.","Das SR","2020","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2020.05.037","32771263","PMC7545583",null,"S002752","pubmed","FALSE","free_to_read","5",null,"Journal Article; Practice Guideline; Research Support, N.I.H., Extramural; Consensus Statement"],["R0028495","Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.","Kellar D","2020","The Lancet. Neurology","narrative_review","article","10.1016/s1474-4422(20)30231-3","32730766","PMC9661919",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028496","Structural insights into the activation of GLP-1R by a small molecule agonist.","Ma H","2020","Cell research","commentary","article","10.1038/s41422-020-0384-8","32724086","PMC7784854",null,null,"pubmed","FALSE",null,null,null,"Letter; Research Support, Non-U.S. Gov't"],["R0028497","Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.","Akhtar S","2020","Journal of drug targeting","narrative_review","article","10.1080/1061186x.2020.1797754","32700580",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028498","Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.","Berra C","2020","Pharmacological research","systematic_review","article","10.1016/j.phrs.2020.105052","32650058",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0028499","Primary Care Physicians' Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey.","Shubrook JH","2020","Advances in therapy","other_trial","article","10.1007/s12325-020-01405-y","32621271","PMC7370970",null,null,"pubmed","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028500","Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.","Hydes TJ","2020","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.14356","32619031",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028501","Potential roles of Glucagon-like peptide-1 and its analogues in cognitive impairment associated with type 2 diabetes mellitus.","Yu ZW","2020","Mechanisms of ageing and development","narrative_review","article","10.1016/j.mad.2020.111294","32585235",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028502","Diabetes: From Research to Clinical Practice.","Islam MS","2021","Advances in experimental medicine and biology","other","article","10.1007/5584_2020_553","32583142",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028503","Combination therapy with SGLT2 inhibitors for diabetic kidney disease.","Cai Y","2020","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2020.110192","32559844",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028504","Dissecting the interaction between COVID-19 and diabetes mellitus.","Chee YJ","2020","Journal of diabetes investigation","narrative_review","article","10.1111/jdi.13326","32558211","PMC7323255",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028505","Reframing appetitive reinforcement learning and reward valuation as effects mediated by hippocampal-dependent behavioral inhibition.","Jones S","2020","Nutrition research (New York, N.Y.)","narrative_review","article","10.1016/j.nutres.2020.05.001","32544728","PMC7396278",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0028506","Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications.","Wysham C","2020","Postgraduate medicine","narrative_review","article","10.1080/00325481.2020.1771047","32543261",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028507","Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus.","Bertoluci MC","2020","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-020-00551-1","32489427","PMC7245758",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; article"],["R0028508","A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential.","Zhang J","2020","Life sciences","preclinical","article","10.1016/j.lfs.2020.117853","32470452",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028509","Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology.","Willard FS","2020","Advances in pharmacology (San Diego, Calif.)","preclinical","article","10.1016/bs.apha.2020.02.001","32416867",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028510","Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis.","Yokomori H","2020","BMJ open gastroenterology","other","article","10.1136/bmjgast-2019-000370","32414752","PMC7232783",null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028511","Colesevelam in the management of type 2 diabetes.","Kalra S","2020","JPMA. The Journal of the Pakistan Medical Association","narrative_review","article",null,"32400758",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028512","GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats.","Jensen EP","2020","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00579.2019","32390511",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028513","The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications.","Tsilingiris D","2020","Current obesity reports","narrative_review","article","10.1007/s13679-020-00378-x","32388792",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028514","Current Long-Term Pharmacotherapies for the Management of Obesity.","Kim BY","2020","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes20010","32378399","PMC7338489",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028515","Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.","Chang R","2020","The Journal of biological chemistry","other","article","10.1074/jbc.ra120.013793","32371397","PMC7363120",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0028516","Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.","Graham GV","2020","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2020.173101","32320703",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028517","Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry.","Hale PM","2020","Thyroid : official journal of the American Thyroid Association","nonrandomized_study","article","10.1089/thy.2019.0591","32316860","PMC7583321",null,null,"pubmed","FALSE","free_to_read","4",null,"Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028518","COVID-19 and diabetes management: What should be considered?","Ceriello A","2020","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2020.108151","32305399","PMC7162752",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028519","In Vitro Platform for Studying Human Insulin Release Dynamics of Single Pancreatic Islet Microtissues at High Resolution.","Misun PM","2020","Advanced biosystems","preclinical","article","10.1002/adbi.201900291","32293140","PMC7610574",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028520","The limits and challenges of antiobesity pharmacotherapy.","Gadde KM","2020","Expert opinion on pharmacotherapy","randomized_trial","article","10.1080/14656566.2020.1748599","32292094","PMC7523877",null,null,"pubmed","FALSE","free_to_read","2",null,"Journal Article; Review"],["R0028521","Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.","Stephens JW","2020","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13942","32267078",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028522","Management of diabetes today: An exciting confusion.","Ceriello A","2020","Diabetes research and clinical practice","commentary","article","10.1016/j.diabres.2020.108129","32224165",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028523","Obesity Treatment: A Focus on Pharmacotherapy of Weight Management.","Patel K","2020","Orthopedic nursing","other","article","10.1097/nor.0000000000000643","32218009",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028524","Cardiorenal risk reduction guidance in diabetes: can we reach consensus?","Sattar N","2020","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(20)30062-0","32171053",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028525","Which Drug Will \"Lead\" in Reducing Cardiac Events Among Heart Failure Patients With Diabetes?","Dec GW","2020","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2019.12.062","32164887",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028526","New insights into potential nutritional effects of dietary saponins in protecting against the development of obesity.","Jeepipalli SPK","2020","Food chemistry","preclinical","article","10.1016/j.foodchem.2020.126474","32151922",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028527","A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice.","Li T","2020","Neuropharmacology","preclinical","article","10.1016/j.neuropharm.2020.108042","32147454",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028528","Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?","Gelosa P","2020","Biochemical pharmacology","randomized_trial","article","10.1016/j.bcp.2020.113894","32142728",null,null,null,"pubmed","FALSE","free_to_read","2",null,"Journal Article; Review"],["R0028529","Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.","Sivitz WI","2020","Diabetes care","nonrandomized_study","article","10.2337/dc19-1769","32139384","PMC7171946","ClinicalTrials.gov:NCT01794143","S000873","pubmed","FALSE","free_to_read","4",null,"Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028530","Diagnosis and treatment of type 2 diabetes mellitus in patients with chronic kidney disease and eGFR < 60 mL/min - a position statement of the Polish Society of Nephrology Working Group on Metabolic and Endocrine Disorders in Kidney Diseases.","Stompór T","2020","Endokrynologia Polska","other","article","10.5603/ep.a2019.0064","32129464",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Practice Guideline"],["R0028531","Extrinsic compression of pancreactic duct by intragastric balloon treatment and its potential to cause acute pancreatitis: two case reports and clinical discussion.","Halpern B","2020","Obesity research & clinical practice","case_report","article","10.1016/j.orcp.2020.02.002","32127292",null,null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article; Review"],["R0028532","Therapeutic potential of blood flow mimetic compounds in preventing endothelial dysfunction and atherosclerosis.","Xu S","2020","Pharmacological research","narrative_review","article","10.1016/j.phrs.2020.104737","32126273",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028533","Which person with diabetes should receive cardioprotective glucose-lowering medicines?","Bloomgarden ZT","2020","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.13029","32119186",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Editorial; article"],["R0028534","Number Needed-to-Treat (NNT): Is it a necessary marker of therapeutic efficiency?","Monnier L","2020","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2020.01.004","32035226",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028535","REWIND to fast forward: time to revisit stroke prevention in type 2 diabetes?","Aroda V","2020","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(19)30427-9","31924564",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028536","Activation of the GLP-1 receptor by a non-peptidic agonist.","Zhao P","2020","Nature","other","article","10.1038/s41586-019-1902-z","31915381",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028537","Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.","Velikyan I","2020","Theranostics","narrative_review","article","10.7150/thno.38366","31903131","PMC6929622",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028538","Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.","Sternkopf M","2020","Arteriosclerosis, thrombosis, and vascular biology","preclinical","article","10.1161/atvbaha.119.313645","31893947",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0028539","[Contemporary state and perspectives of obesity pharmacotherapy].","Svačina Š","2020","Vnitrni lekarstvi","other","article",null,"33740846",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028540","Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology.","Wong ND","2021","Trends in cardiovascular medicine","other_trial","article","10.1016/j.tcm.2019.11.013","31882264",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0028541","New Drug for Type 2 Diabetes.","Aschenbrenner DS","2020","The American journal of nursing","other","article","10.1097/01.naj.0000652008.98414.51","31880702",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028542","Neuromodulatory effects of anti-diabetes medications: A mechanistic review.","Yaribeygi H","2020","Pharmacological research","narrative_review","article","10.1016/j.phrs.2019.104611","31863868",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028543","Update: Pediatric Diabetes.","Gujral J","2020","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.13012","31837125",null,null,null,"pubmed; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0028544","Drugs for type 2 diabetes.",null,"2019","The Medical letter on drugs and therapeutics","narrative_review","article",null,"31770362",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028545","More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.","Dankner R","2020","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.14179","31769894",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028546","The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes.","Wu L","2019","International journal of molecular sciences","narrative_review","article","10.3390/ijms20235853","31766545","PMC6928800",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028547","Anorectic state of obesity medications in the United States. Are leaner times ahead?","Li X","2020","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2019.1692815","31762335","PMC6980700",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0028548","Hypokalemia associated with mifepristone use in the treatment of Cushing's syndrome.","Sai K","2019","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-19-0064","31743097","PMC6865352",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028549","Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury.","Li Y","2020","Experimental neurology","preclinical","article","10.1016/j.expneurol.2019.113113","31730763","PMC12451672",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0028550","Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.","Slater TA","2020","European heart journal. Cardiovascular pharmacotherapy","other_trial","article","10.1093/ehjcvp/pvz058","31702003","PMC7225869",null,null,"pubmed; openalex","TRUE","open_europepmc","5","FALSE","Letter; Research Support, Non-U.S. Gov't; article"],["R0028551","Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy.","Zhang Q","2021","Current medicinal chemistry","narrative_review","article","10.2174/0929867326666191108160643","31701843",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028552","Personalized Management of Type 2 Diabetes.","Peter PR","2019","Current diabetes reports","narrative_review","article","10.1007/s11892-019-1244-0","31686226",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028553","Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence.","Chow HM","2019","Nature neuroscience","preclinical","article","10.1038/s41593-019-0505-1","31636448",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028554","The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.","Lytvyn Y","2020","Endocrine reviews","narrative_review","article","10.1210/endrev/bnz010","31633153","PMC7156849",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review"],["R0028555","Reply.","Yang D","2020","Hepatology (Baltimore, Md.)","commentary","article","10.1002/hep.30991","31613385",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0028556","Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.","Taneja V","2020","Hepatology (Baltimore, Md.)","commentary","article","10.1002/hep.30992","31610029",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0028557","Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis.","Rafey MF","2019","Endocrinology, diabetes & metabolism case reports","other","article","10.1530/edm-19-0087","31600728","PMC6765316",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028558","Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes.","Chudleigh RA","2020","Current medical research and opinion","commentary","article","10.1080/03007995.2019.1678344","31596638",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028559","Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.","Suzuki R","2020","Journal of medicinal chemistry","narrative_review","article","10.1021/acs.jmedchem.9b00835","31577440",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028560","Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients.","Lăcătușu CM","2019","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina55090592","31540142","PMC6780762",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028561","Functional beta-cells derived from umbilical cord blood mesenchymal stem cells for curing rats with streptozotocin-induced diabetes mellitus.","El-Sherbiny M","2020","Singapore medical journal","preclinical","article","10.11622/smedj.2019120","31535156","PMC7900811",null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028562","Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca2+ channel.","Huang L","2019","Experimental biology and medicine (Maywood, N.J.)","other","article","10.1177/1535370219876531","31510798","PMC6802160",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0028563","Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.","Adriaenssens AE","2019","Cell metabolism","preclinical","article","10.1016/j.cmet.2019.07.013","31447324","PMC6838660",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028564","Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?","Kokkinos A","2019","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2019.153960","31412266",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028565","Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding.","Vansteelandt S","2019","Statistics in medicine","randomized_trial","article","10.1002/sim.8336","31411779","PMC6852414",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028566","Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?","Valensi P","2019","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2019.07.007","31394190",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028567","High-throughput identification of peptide agonists against GPCRs by co-culture of mammalian reporter cells and peptide-secreting yeast cells using droplet microfluidics.","Yaginuma K","2019","Scientific reports","randomized_trial","article","10.1038/s41598-019-47388-x","31358824","PMC6662714",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028568","[Pharmacological treatment of obesity for Primary Care physicians].","Rubio Herrera MA","2019","Semergen","narrative_review","article","10.1016/j.semerg.2019.04.005","31350172",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028569","Commentary/Introduction for \"Debate on Insulin vs. Non-insulin Use in the Hospital Setting\" Articles.","Wallia A","2019","Current diabetes reports","other","article","10.1007/s11892-019-1182-x","31346782",null,null,null,"pubmed","FALSE",null,null,null,"Introductory Journal Article"],["R0028570","New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?","Pagidipati NJ","2019","The Journal of thoracic and cardiovascular surgery","narrative_review","article","10.1016/j.jtcvs.2019.03.140","31301898",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Review"],["R0028571","Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.","Fadini GP","2019","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.119.012244","31269877","PMC6662129",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028572","T2DM treatment trial results.","Greenhill C","2019","Nature reviews. Endocrinology","other_trial","article","10.1038/s41574-019-0234-2","31253858",null,null,null,"pubmed","FALSE","paywalled","5",null,"Journal Article; Comment"],["R0028573","Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities.","Petersen J","2019","Drugs","narrative_review","article","10.1007/s40265-019-01153-6","31243696",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0028574","GLP1R agonists: primary cardiovascular prevention and oral administration.","Lim GB","2019","Nature reviews. Cardiology","commentary","article","10.1038/s41569-019-0232-z","31239524",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0028575","A LEADER in the management of type 2 diabetes and cardiorenal disease.","Verma S","2020","The Journal of thoracic and cardiovascular surgery","commentary","article","10.1016/j.jtcvs.2019.03.134","31227180",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028576","Pioneering oral peptide therapy for patients with type 2 diabetes.","Nauck MA","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(19)30182-2","31189516",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028577","Is it time to REWIND the cardiorenal clock in diabetes?","Verma S","2019","Lancet (London, England)","commentary","article","10.1016/s0140-6736(19)31267-x","31189510",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028578","Secondary stroke prevention in patients with type 2 diabetes. Is time for more specific recommendations?","Castilla-Guerra L","2020","Diabetes research and clinical practice","commentary","article","10.1016/j.diabres.2019.05.038","31181237",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0028579","Treatment of persistent or recurrent type 2 diabetes after metabolic surgery.","Mingrone G","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(19)30195-0","31174992",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028580","Expanded table: some available insulins for type 2 diabetes.",null,"2019","The Medical letter on drugs and therapeutics","other","article",null,"31169807",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028581","Insulins for type 2 diabetes.",null,"2019","The Medical letter on drugs and therapeutics","other","article",null,"31169803",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028582","Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors.","Lear S","2019","Methods in enzymology","preclinical","article","10.1016/bs.mie.2019.02.008","31155052",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028583","Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!","Katsiki N","2019","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2019.04.011","31126705",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028584","Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?","Testani JM","2019","Circulation","other","article","10.1161/circulationaha.119.038854","31107618",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028585","[Type 2 diabetes: What's new? What is outdated? What stays?].","Hummel M","2019","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-019-0511-y","31079371",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028586","Insulin resistance: Impact on therapeutic developments in diabetes.","Bailey CJ","2019","Diabetes & vascular disease research","narrative_review","article","10.1177/1479164119827570","31014100",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028587","The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?","Davis TME","2019","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2019.03.005","31003926",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Observational Study; Research Support, Non-U.S. Gov't"],["R0028588","Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version.","Kolotkin RL","2019","Clinical obesity","randomized_trial","article","10.1111/cob.12310","30993900","PMC6593657","ClinicalTrials.gov:NCT02453711; ClinicalTrials.gov:NCT02906930","S001741; S002317","pubmed","FALSE","open_pdf","1",null,"Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Validation Study"],["R0028589","Prioritising injectable therapies in the management of type 2 diabetes.","Frias JP","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(19)30117-2","30981766",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028590","Smile: saluto-metabolic interventions for life enhancement.","Kalra S","2019","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"30890844",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028591","Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.","Vinagre I","2019","Endocrinologia, diabetes y nutricion","commentary","article","10.1016/j.endinu.2019.01.005","30890422",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Letter"],["R0028592","2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.","Arnett DK","2019","Circulation","narrative_review","article","10.1161/cir.0000000000000677","30879339","PMC8351755",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028593","Current treatment options for nonalcoholic fatty liver disease.","Shetty A","2019","Current opinion in gastroenterology","nonrandomized_study","article","10.1097/mog.0000000000000528","30844893",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0028594","Rational combination therapy for type 2 diabetes.","Del Prato S","2019","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(19)30069-5","30833171",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028595","Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives.","Quiñones M","2019","Expert opinion on drug discovery","randomized_trial","article","10.1080/17460441.2019.1583642","30821530",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028596","Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment.","Foltynie T","2018","Movement disorders clinical practice","randomized_trial","article","10.1002/mdc3.12611","30800701","PMC6336433","ClinicalTrials.gov:NCT02953665; ClinicalTrials.gov:NCT01843075","S000689; S001357","pubmed; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; article"],["R0028597","Beyond glycemic control: New guidance on cardio-renal protection.","Anastasilakis AD","2019","Metabolism: clinical and experimental","other","article","10.1016/j.metabol.2019.02.004","30797784",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028598","Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.","Sinha B","2019","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2019.02.014","30794833",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis"],["R0028599","Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure.","Osuna PM","2018","Methodist DeBakey cardiovascular journal","narrative_review","article","10.14797/mdcj-14-4-257","30788011","PMC6369617",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028600","New Agents for the Treatment of Type 2 Diabetes.","Libianto R","2019","Critical care clinics","narrative_review","article","10.1016/j.ccc.2018.11.007","30784612",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0028601","Publicising trial results before peer review.","Fralick M","2019","BMJ (Clinical research ed.)","other_trial","article","10.1136/bmj.l556","30755405",null,null,null,"pubmed","FALSE","paywalled","5",null,"Editorial"],["R0028602","The Role of Glucagon-Like Peptide-1 in Energy Homeostasis.","Salehi M","2019","Metabolic syndrome and related disorders","narrative_review","article","10.1089/met.2018.0088","30720393","PMC6610028",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0028603","Genome-Wide Association Studies of Impulsive Personality Traits (BIS-11 and UPPS-P) and Drug Experimentation in up to 22,861 Adult Research Participants Identify Loci in the CACNA1I and CADM2 genes.","Sanchez-Roige S","2019","The Journal of neuroscience : the official journal of the Society for Neuroscience","other","article","10.1523/jneurosci.2662-18.2019","30718321","PMC6435820",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028604","Heart failure among people with Type 2 diabetes mellitus: real-world data of 289 954 people from a diabetes database.","Stoyanova D","2020","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.13915","30701607","PMC7496405",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028605","Management of diabetes mellitus in patients undergoing liver transplantation.","Grancini V","2019","Pharmacological research","narrative_review","article","10.1016/j.phrs.2019.01.042","30690071",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028606","New approach to diabetes care: from blood glucose to cardiovascular disease.","Aguiar C","2019","Revista portuguesa de cardiologia","narrative_review","article","10.1016/j.repc.2018.03.013","30685291",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028607","[New antidiabetic drugs: current status and future prospects - a review of the literature].","Baranowska A","2018","Wiadomosci lekarskie (Warsaw, Poland : 1960)","narrative_review","article",null,"30684345",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028608","Cardiology and Therapy: A Summary of 2018 and Key Areas of Emerging Research in 2019.","Menown IBA","2019","Cardiology and therapy","other","article","10.1007/s40119-019-0125-6","30684154","PMC6525218",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028609","New Drugs 2019, part 1.","Hussar DA","2019","Nursing","commentary","article","10.1097/01.nurse.0000552697.50502.91","30676555",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028610","Neural-Derived Extracellular Vesicles in Clinical Trials: Message in a Bottle.","Dubal DB","2019","JAMA neurology","commentary","article","10.1001/jamaneurol.2018.4325","30640380",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0028611","Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity.","Usui R","2019","Journal of diabetes investigation","preclinical","article","10.1111/jdi.13005","30637966","PMC6626965",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0028612","The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes.","Dey AK","2019","Clinical cardiology","narrative_review","article","10.1002/clc.23152","30635924","PMC6414247",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0028613","A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019.","Evans M","2019","Diabetes therapy : research, treatment and education of diabetes and related disorders","commentary","article","10.1007/s13300-018-0559-1","30604092","PMC6349272",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028614","Is pharmacotherapy enough for urgent weight loss in severely obese patients?","Gargallo-Vaamonde J","2019","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2018.1559818","30576254",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028615","Evaluating the utility of human glucagon-like peptide 1 receptor gene as a novel radionuclide reporter gene: a promising molecular imaging tool.","Pan Y","2019","Applied microbiology and biotechnology","preclinical","article","10.1007/s00253-018-9562-8","30560451",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028616","Drug-induced thrombocytopenia: 2019 Update of clinical and laboratory data.","Mitta A","2019","American journal of hematology","narrative_review","article","10.1002/ajh.25379","30549322",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Review"],["R0028617","A promising outlook for diabetic kidney disease.","Cooper M","2019","Nature reviews. Nephrology","narrative_review","article","10.1038/s41581-018-0092-5","30532022",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028618","Targeting inflammation to reduce ASCVD in type 2 diabetes.","Jialal I","2019","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2018.11.001","30514609",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0028619","2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","Das SR","2018","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2018.09.020","30497881","PMC7560953",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Practice Guideline; Consensus Statement"],["R0028620","A traceless catch-and-release method for rapid peptide purification.","Reimann O","2019","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.3136","30479039",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028621","Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?","Cordiner RLM","2019","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13596","30471177",null,null,null,"pubmed","FALSE",null,null,null,"Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028622","Can 14-3-3 proteins serve as therapeutic targets for the treatment of metabolic diseases?","Diallo K","2019","Pharmacological research","narrative_review","article","10.1016/j.phrs.2018.11.021","30453034",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028623","Noninvasive in vivo Assessment of the Re-endothelialization Process Using Ultrasound Biomicroscopy in the Rat Carotid Artery Balloon Injury Model.","Röhl S","2019","Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine","preclinical","article","10.1002/jum.14858","30426541",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028624","[Diabetology: The most important innovations of the past 10 years].","Martin S","2018","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-018-1119-3","30421199",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028625","Second steps in managing type 2 diabetes.","Petersons CJ","2018","Australian prescriber","narrative_review","article","10.18773/austprescr.2018.043","30410209","PMC6202300",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028626","Insulin Secretion Depends on Intra-islet Glucagon Signaling.","Svendsen B","2018","Cell reports","preclinical","article","10.1016/j.celrep.2018.10.018","30380405",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028627","Hypoglycaemia and gastric emptying.","Marathe CS","2019","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13570","30378748",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028628","Modeling the impact of preplanned dose titration on delayed response.","Qu Y","2019","Journal of biopharmaceutical statistics","other","article","10.1080/10543406.2018.1535499","30359554",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028629","Targeted delivery of antisense oligonucleotides to pancreatic β-cells.","Ämmälä C","2018","Science advances","preclinical","article","10.1126/sciadv.aat3386","30345352","PMC6192685",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028630","Revisiting the Diabetes-Heart Failure Connection.","Wallner M","2018","Current diabetes reports","narrative_review","article","10.1007/s11892-018-1116-z","30343339","PMC6209037",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028631","Alzheimer's Disease, time to turn the tide.","Sensi SL","2018","Aging","commentary","article","10.18632/aging.101581","30317224","PMC6224239",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028632","Glucose lowering and the kidney: are all drug classes equal?","Wong MG","2018","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(18)30291-2","30292590",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028633","Novel ABCA1 peptide agonists with antidiabetic action.","Azhar S","2019","Molecular and cellular endocrinology","preclinical","article","10.1016/j.mce.2018.09.011","30290217","PMC6626528",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S."],["R0028634","Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.","Abdul-Ghani M","2019","Diabetes, obesity & metabolism","other","article","10.1111/dom.13546","30259621",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0028635","[Technological Innovations in Diabetes Therapy].","Strey C","2018","Praxis","narrative_review","article","10.1024/1661-8157/a003058","30227796",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028636","Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review.","Bain SC","2019","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13538","30226298","PMC6587545",null,"S002534","pubmed","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0028637","European Society of Cardiology 2018.","Kurian MJ","2019","Journal of diabetes","commentary","article","10.1111/1753-0407.12855","30221492",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings; News"],["R0028638","Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?","Warnes H","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-018-0496-z","30209797","PMC6167310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0028639","GSK-3 inhibition through GLP-1R allosteric activation mediates the neurogenesis promoting effect of P7C3 after cerebral ischemic/reperfusional injury in mice.","Wang YH","2018","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2018.08.023","30189238",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028640","Silibinin decreases hepatic glucose production through the activation of gut-brain-liver axis in diabetic rats.","Xu F","2018","Food & function","preclinical","article","10.1039/c8fo00565f","30178798",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028641","Antihyperglycemic medications for cardiovascular disease risk reduction.","Goldman JD","2018","The American journal of managed care","other","article",null,"30160394",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028642","Introduction.","McGill J","2018","Journal of managed care & specialty pharmacy","other","article","10.18553/jmcp.2018.24.9-a.s3","30156444","PMC10408403",null,null,"pubmed","FALSE",null,null,null,"Introductory Journal Article"],["R0028643","Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.","Shehadeh N","2018","Cardiovascular diabetology","other","article","10.1186/s12933-018-0760-6","30134893","PMC6103874",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028644","SGLT inhibitor adjunct therapy in type 1 diabetes.","McCrimmon RJ","2018","Diabetologia","randomized_trial","article","10.1007/s00125-018-4671-6","30132030","PMC6133151",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028645","Nanoparticle-Based Systems for Delivery of Protein Therapeutics to the Spinal Cord.","Infante JC","2018","Frontiers in neuroscience","other","article","10.3389/fnins.2018.00484","30072866","PMC6060369",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028646","[Treatment of non-alcoholic fatty liver disease].","Heebøll S","2018","Ugeskrift for laeger","narrative_review","article",null,"30064623",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028647","The present and future treatment of pediatric type 2 diabetes.","Van Name MA","2018","Expert review of endocrinology & metabolism","randomized_trial","article","10.1080/17446651.2018.1499467","30063424",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0028648","Regional gastrointestinal pH profile is altered in patients with type 1 diabetes and peripheral neuropathy.","Wegeberg AL","2018","Neurogastroenterology and motility","other","article","10.1111/nmo.13407","30062823",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0028649","Diabetic Gastroparesis.","Kalra S","2018","Diabetes therapy : research, treatment and education of diabetes and related disorders","commentary","article","10.1007/s13300-018-0475-4","30027528","PMC6167284",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028650","Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review.","Abdi H","2018","International journal of endocrinology and metabolism","narrative_review","article","10.5812/ijem.65600","30008760","PMC6035366",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0028651","Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.","Hurren KM","2018","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2018.1494727","29958007",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028652","[Cardiovascular effects of new non-insulinic anti-diabetes drugs].","Dieuzeide G","2018","Medicina","narrative_review","article",null,"29940545",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028653","Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes.","Akturk HK","2018","Diabetes technology & therapeutics","other","article","10.1089/dia.2018.0114","29916737",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028654","Comparison table: some FDA-approved drugs for weight management.",null,"2018","The Medical letter on drugs and therapeutics","other","article",null,"29913464",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028655","Diet, drugs, devices, and surgery for weight management.",null,"2018","The Medical letter on drugs and therapeutics","other","article",null,"29913463",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028656","SAD-A Promotes Glucose-Stimulated Insulin Secretion Through Phosphorylation and Inhibition of GDIα in Male Islet β Cells.","Nie J","2018","Endocrinology","preclinical","article","10.1210/en.2017-03243","29873699","PMC6693047",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028657","Current updates on pharmacological roles of glucagon-like peptide 1 in obesity.","Verma RK","2018","Panminerva medica","narrative_review","article","10.23736/s0031-0808.18.03479-1","29856185",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028658","Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease.","Rix I","2019","Clinical physiology and functional imaging","systematic_review","article","10.1111/cpf.12526","29808958",null,null,null,"pubmed","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0028659","Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations.","Blonde L","2018","Advances in therapy","narrative_review","article","10.1007/s12325-018-0694-0","29777519","PMC11343913",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028660","Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor.","Douros JD","2018","Diabetes","preclinical","article","10.2337/db18-0081","29759973","PMC6054432",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Validation Study"],["R0028661","The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides.","Schultz HS","2018","PloS one","other","article","10.1371/journal.pone.0197407","29758051","PMC5951580",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028662","Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism.","Lei S","2018","The Journal of biological chemistry","other","article","10.1074/jbc.ra118.003278","29717000","PMC6005446",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028663","Clinical assessment and treatment of diabetes in patients with chronic kidney disease.","Carretero Gómez J","2018","Revista clinica espanola","other","article","10.1016/j.rce.2018.03.016","29691065",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0028664","Old wines in new bottles: Repurposing opportunities for Parkinson's disease.","Kakkar AK","2018","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2018.04.023","29689247",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028665","Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology.","Bloodworth MH","2018","The Journal of allergy and clinical immunology","preclinical","article","10.1016/j.jaci.2018.01.053","29678751","PMC6078807",null,null,"pubmed","FALSE",null,null,null,"Letter; Research Support, Non-U.S. Gov't"],["R0028666","Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.","Cai X","2018","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2018.04.022","29673717",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028667","Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?","Andersen ES","2018","Diabetes, obesity & metabolism","other","article","10.1111/dom.13321","29654643",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Randomized Controlled Trial"],["R0028668","Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events.","Packer M","2018","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2018.03.006","29627373",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028669","Geniposide improves repeated restraint stress-induced depression-like behavior in mice by ameliorating neuronal apoptosis via regulating GLP-1R/AKT signaling pathway.","Zhao Y","2018","Neuroscience letters","preclinical","article","10.1016/j.neulet.2018.04.010","29626654",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028670","[Cardioprotection and diabetes mellitus - which antidiabetic agents seem to do better].","Roos M","2018","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-018-0386-3","29619689",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028671","Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.","Fenske RJ","2018","Experimental biology and medicine (Maywood, N.J.)","preclinical","article","10.1177/1535370218761662","29504478","PMC5882023",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0028672","Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex.","Liang YL","2018","Nature","other","article","10.1038/nature25773","29466332",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028673","GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction.","Nguyen TD","2018","Journal of cardiovascular translational research","preclinical","article","10.1007/s12265-018-9795-z","29464655",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028674","[Not Available].","Toft E","2018","Lakartidningen","other","article",null,"29461566",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028675","[Not Available].","Fischli S","2017","Therapeutische Umschau. Revue therapeutique","narrative_review","article","10.1024/0040-5930/a000937","29461151",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; Review; article"],["R0028676","Novel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients.","Naciu AM","2018","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2018.1441288","29460641",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028677","The impact of glucose-lowering medications on cardiovascular disease.","Avogaro A","2018","Cardiovascular endocrinology & metabolism","narrative_review","article","10.1097/xce.0000000000000139","31646273","PMC6739886",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028678","Potential roles for glucagon-like peptide-17-36 amide and cholecystokinin in anorectic response to the trichothecene mycotoxin T-2 toxin.","Wu W","2018","Ecotoxicology and environmental safety","preclinical","article","10.1016/j.ecoenv.2018.02.003","29433086",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028679","Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population.","Nadolsky KZ","2018","Military medicine","nonrandomized_study","article","10.1093/milmed/usx074","29420770",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0028680","Glucagon receptor signaling in metabolic diseases.","Wewer Albrechtsen NJ","2018","Peptides","preclinical","article","10.1016/j.peptides.2017.11.016","29412830",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028681","A mechanism for agonist activation of the glucagon-like peptide-1 (GLP-1) receptor through modelling & molecular dynamics.","Gómez Santiago C","2018","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2018.01.110","29397068",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028682","Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library.","Demartis A","2018","Scientific reports","other","article","10.1038/s41598-017-18494-5","29330364","PMC5766609",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0028683","Effects of Diabetes Medications Targeting the Incretin System on the Kidney.","MacIsaac RJ","2018","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.10380917","29321176","PMC5967437",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article"],["R0028684","Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment.","Terlizzese P","2018","Heart failure reviews","narrative_review","article","10.1007/s10741-017-9667-7","29318412",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028685","Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.","Wanner C","2018","Nature reviews. Nephrology","narrative_review","article","10.1038/nrneph.2017.182","29307892",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028686","Role of Incretin Axis in Inflammatory Bowel Disease.","Duan L","2017","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2017.01734","29270177","PMC5723660",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028687","Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.","Cefalu WT","2018","Diabetes care","other_trial","article","10.2337/dci17-0057","29263194","PMC5741160",null,"S001381","pubmed","FALSE","free_to_read","5",null,"Journal Article"],["R0028688","Initium novum?","Koomalsingh KJ","2018","The Journal of thoracic and cardiovascular surgery","commentary","article","10.1016/j.jtcvs.2017.10.088","29249500",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028689","Pharmacotherapy for obesity: What you need to know.","Bersoux S","2017","Cleveland Clinic journal of medicine","narrative_review","article","10.3949/ccjm.84a.16094","29244650",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028690","Antidiabetics: Structural Diversity of Molecules with a Common Aim.","Popovic-Djordjevic JB","2018","Current medicinal chemistry","nonrandomized_study","article","10.2174/0929867325666171205145309","29210642",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0028691","Discovery, characterization, and clinical development of the glucagon-like peptides.","Drucker DJ","2017","The Journal of clinical investigation","narrative_review","article","10.1172/jci97233","29202475","PMC5707151",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028692","Reduced psychological distress in familial chylomicronemia syndrome after patient support group intervention.","Wilson LM","2018","Journal of clinical lipidology","case_report","article","10.1016/j.jacl.2017.11.002","29195809",null,null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article"],["R0028693","Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.","Niessner A","2018","European heart journal","other","article","10.1093/eurheartj/ehx625","29126266",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Consensus Statement"],["R0028694","Can highly cited herbs in ancient Traditional Chinese medicine formulas and modern publications predict therapeutic targets for diabetes mellitus?","Wang H","2018","Journal of ethnopharmacology","preclinical","article","10.1016/j.jep.2017.10.032","29102765",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028695","miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function.","Jo S","2018","Diabetes","preclinical","article","10.2337/db17-0506","29101219","PMC5780066",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0028696","GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice.","van Witteloostuijn SB","2017","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.3048","29057588",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028697","Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.","Tai J","2018","Brain research","preclinical","article","10.1016/j.brainres.2017.10.012","29050859",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028698","New hope for devastating neurodegenerative disease.","Stayte S","2017","Brain : a journal of neurology","commentary","article","10.1093/brain/awx064","29050369","PMC5405336",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0028699","Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.","Wolsk E","2017","Circulation","randomized_trial","article","10.1161/circulationaha.117.029503","29038210",null,"ClinicalTrials.gov:NCT01147250","S001991","pubmed; openalex","TRUE","open_pdf","1","FALSE","Letter; article"],["R0028700","Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.","Campbell JM","2018","Burns : journal of the International Society for Burn Injuries","systematic_review","article","10.1016/j.burns.2017.09.013","29029859",null,null,null,"pubmed","FALSE","paywalled","3",null,"Journal Article; Systematic Review"],["R0028701","Is the Way to Someone's Heart Through Their Stomach? The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure.","Packer M","2017","Circulation. Heart failure","other","article","10.1161/circheartfailure.117.004551","29021350",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028702","Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.","Hocher B","2017","Nature reviews. Nephrology","commentary","article","10.1038/nrneph.2017.140","28989173",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0028703","Is it time to reassess the role of myocardial metabolic modulation for the treatment of heart failure?","Bois JP","2019","Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology","commentary","article","10.1007/s12350-017-1068-8","28975499",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028704","Gut satiety hormones cholecystokinin and glucagon-like Peptide-17-36 amide mediate anorexia induction by trichothecenes T-2 toxin, HT-2 toxin, diacetoxyscirpenol and neosolaniol.","Zhang J","2017","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2017.09.020","28964791",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028705","[Nephroprotection in patients with diabetes mellitus].","Fischereder M","2017","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-017-0012-9","28924706",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028706","No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study.","Kruszelnicka O","2017","International journal of medical sciences","nonrandomized_study","article","10.7150/ijms.19457","28924374","PMC5599926",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article"],["R0028707","[Not Available].","Füeßl HS","2017","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-017-0002-y","28900973",null,null,null,"pubmed","FALSE",null,null,null,"News; Comment"],["R0028708","Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.","Chamberlain JJ","2017","Annals of internal medicine","other","article","10.7326/m17-1259","28892816",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Practice Guideline"],["R0028709","New therapeutic perspectives in non-alcoholic steatohepatitis.","Ampuero J","2018","Gastroenterologia y hepatologia","narrative_review","article","10.1016/j.gastrohep.2017.07.006","28874313",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028710","Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).","Nunez DJ","2018","Diabetes, obesity & metabolism","other","article","10.1111/dom.13102","28842950",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028711","Antidiabetic Drug Alogliptin Protects the Heart Against Ischemia-reperfusion Injury Through GLP-1 Receptor-dependent and Receptor-independent Pathways Involving Nitric Oxide Production in Rabbits.","Baba S","2017","Journal of cardiovascular pharmacology","preclinical","article","10.1097/fjc.0000000000000531","28817485",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028712","Leaving the Glucocentric View: Can SGLT2 Inhibitors Halt CVD in Patients With Type 2 Diabetes?","Marx N","2017","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2017.06.037","28774376",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028713","Weight and type 2 diabetes: new recommendations.","Gómez Huelgas R","2016","Medicina clinica","other","article","10.1016/s0025-7753(17)30620-6","28760220",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028714","Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.","Yandrapalli S","2017","Postgraduate medicine","narrative_review","article","10.1080/00325481.2017.1358064","28749197",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028715","Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.","Portron A","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13025","28741871",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0028716","GLP-1/glucagon receptor co-agonism for treatment of obesity.","Sánchez-Garrido MA","2017","Diabetologia","narrative_review","article","10.1007/s00125-017-4354-8","28733905","PMC6448809",null,"S001387","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0028717","Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.","Schmitt C","2017","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13024","28730694",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0028718","Pharmacotherapy for obesity.","Lee PC","2017","Australian family physician","other","article",null,"28697290",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028719","NewDrugs 2017, part 2.","Hussar DA","2017","Nursing","narrative_review","article","10.1097/01.nurse.0000520502.21675.94","28590960",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028720","Crystal structure of the GLP-1 receptor bound to a peptide agonist.","Jazayeri A","2017","Nature","preclinical","article","10.1038/nature22800","28562585",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028721","Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.","Wolsk E","2017","Journal of the American Heart Association","other_trial","article","10.1161/jaha.116.004743","28554908","PMC5669146","ClinicalTrials.gov:NCT01147250","S001991","pubmed","FALSE","free_to_read","5",null,"Comparative Study; Journal Article; Randomized Controlled Trial"],["R0028722","Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators.","Song G","2017","Nature","other","article","10.1038/nature22378","28514449",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028723","Glucagonlike peptide 1 analogs in diabetes care.","Lindblad AJ","2017","Canadian family physician Medecin de famille canadien","other","article",null,"28500195","PMC5429054",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028724","2017 New Drug Update.","Hussar DA","2017","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","other","article","10.4140/tcp.n.2017.258","28483006",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028725","Reducing CV risk in diabetes: An ADA update.","Skolnik N","2017","The Journal of family practice","other","article",null,"28459890",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028726","Hypothalamic obesity after craniopharyngioma surgery: Treatment with a long acting glucagon like peptide 1 derivated.","Castro-Dufourny I","2017","Endocrinologia, diabetes y nutricion","case_report","article","10.1016/j.endinu.2016.10.006","28440760",null,null,null,"pubmed","FALSE",null,null,null,"Case Reports; Letter"],["R0028727","[GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease].","Jiao JJ","2017","Sheng li xue bao : [Acta physiologica Sinica]","preclinical","article",null,"28435972",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028728","Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.","Fani M","2017","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph10010030","28295000","PMC5374434",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028729","Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?","Grunberger G","2017","Current diabetes reports","randomized_trial","article","10.1007/s11892-017-0853-8","28293908",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0028730","Obesity Epidemic: Pharmaceutical Weight Loss.","Curry SA","2017","Rhode Island medical journal (2013)","other","article",null,"28246654",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028731","NEW FOR YOU! These innovative products aim to help make diabetes self-management easier.","Wynn P","2017","Diabetes self-management","other","article",null,"29757530",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028732","Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience.","Cadegiani FA","2017","BMC obesity","randomized_trial","article","10.1186/s40608-017-0147-3","28239482","PMC5320647",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article"],["R0028733","DREADDing proglucagon neurons: a fresh look at metabolic regulation by the brain.","Campbell JE","2017","The Journal of clinical investigation","preclinical","article","10.1172/jci92845","28218623","PMC5330747",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028734","Preclinical characterization of 55P0251, a novel compound that amplifies glucose-stimulated insulin secretion and counteracts hyperglycaemia in rodents.","Stadlbauer K","2017","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12914","28211608",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028735","Should family physicians prescribe medication for obesity? NO.","Shaw E","2017","Canadian family physician Medecin de famille canadien","other","article",null,"28209668","PMC5395374",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028736","Should family physicians prescribe medication for obesity? YES.","Bourns L","2017","Canadian family physician Medecin de famille canadien","other","article",null,"28209667","PMC5395373",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028737","Practical Use of Pharmacotherapy for Obesity.","Igel LI","2017","Gastroenterology","narrative_review","article","10.1053/j.gastro.2016.12.049","28192104",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028738","Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study.","Guss DA","2016","Hepatobiliary surgery and nutrition","commentary","article","10.21037/hbsn.2016.11.09","28124012","PMC5218908",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Comment; article"],["R0028739","Looking to a future of improved diabetes management: interview with Professor Steve Bain.","Bain S","2016","Future science OA","nonrandomized_study","article","10.4155/fsoa-2016-0069","28116136","PMC5242195",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article"],["R0028740","[Cardiovascular safety concerns of glucose-lowering drugs].","Scholze J","2017","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-017-9162-z","28097552",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028741","Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs.","Katsiki N","2017","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2016.12.006","28089090",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028742","Therapies in non-alcoholic steatohepatitis (NASH).","Oseini AM","2017","Liver international : official journal of the International Association for the Study of the Liver","narrative_review","article","10.1111/liv.13302","28052626","PMC5492893",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028743","[in process].","Reisdorf S","2017","Medizinische Monatsschrift fur Pharmazeuten","other","article",null,"29952534",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028744","Rate of Homologous Desensitization and Internalization of the GLP-1 Receptor.","Shaaban G","2016","Molecules (Basel, Switzerland)","other","article","10.3390/molecules22010022","28035964","PMC6155907",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028745","Diabesity management worldwide.","Rajeswaran C","2016","Future science OA","other","article","10.4155/fso.15.86","28031936","PMC5137961",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028746","[Antidiabetic Drugs and the Kidney].","Candido R","2016","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","other","article",null,"27960013",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028747","Pharmacological Interventions against Obesity: Current Status and Future Directions.","Schultes B","2016","Visceral medicine","narrative_review","article","10.1159/000450904","27921047","PMC5122991",null,null,"pubmed","FALSE",null,null,null,"Review; Journal Article"],["R0028748","Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.","Gupta A","2017","Diabetes & metabolic syndrome","narrative_review","article","10.1016/j.dsx.2016.09.003","27884496",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028749","Obesity Week 2016 Annual Meeting.","Marathe PH","2017","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.12509","27883282",null,null,null,"pubmed; openalex","TRUE","open_pdf","2","FALSE","News; article"],["R0028750","Novel GLP-1R/GIPR co-agonist \"twincretin\" is neuroprotective in cell and rodent models of mild traumatic brain injury.","Tamargo IA","2017","Experimental neurology","preclinical","article","10.1016/j.expneurol.2016.11.005","27845037","PMC5878017",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0028751","Metabolic, endocrine and appetite-related responses to acute and daily milk snack consumption in healthy, adolescent males.","Green BP","2017","Appetite","randomized_trial","article","10.1016/j.appet.2016.09.029","27686820",null,null,null,"pubmed","FALSE","free_to_read","2",null,"Comparative Study; Journal Article; Randomized Controlled Trial"],["R0028752","Effect of 24-h severe energy restriction on appetite regulation and ad libitum energy intake in lean men and women.","Clayton DJ","2016","The American journal of clinical nutrition","randomized_trial","article","10.3945/ajcn.116.136937","27806971",null,"ClinicalTrials.gov:NCT02696772",null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0028753","Diabetes medications improve cardiovascular outcomes: the paradigm shifts.","Cusi K","2016","Current opinion in lipidology","commentary","article","10.1097/mol.0000000000000361","27805974",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Research Support, Non-U.S. Gov't"],["R0028754","[Not Available].","Reisdorf S","2016","Medizinische Monatsschrift fur Pharmazeuten","other_trial","article",null,"29956530",null,null,null,"pubmed","FALSE","no_doi","5",null,"Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial"],["R0028755","New Injectable Drug for Type 2 Diabetes.","Aschenbrenner DS","2016","The American journal of nursing","other","article","10.1097/01.naj.0000505586.55332.9d","27787319",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028756","Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials.","Birnbaum Y","2017","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2016.09.007","27780670",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028757","New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.","Simó R","2016","Revista espanola de cardiologia (English ed.)","commentary","article","10.1016/j.rec.2016.07.009","27659856",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028758","Diabetes News.","Dove AE","2017","Journal of diabetes","other_trial","article","10.1111/1753-0407.12495","27763720",null,null,null,"pubmed; openalex","TRUE","open_pdf","5","FALSE","News; article"],["R0028759","Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs-A mechanistic revisit to understand their mode of action.","Gupta P","2016","Pharmacological research","narrative_review","article","10.1016/j.phrs.2016.09.029","27697646",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0028760","Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect.","Kalra S","2016","Indian journal of endocrinology and metabolism","other","article","10.4103/2230-8210.183826","27730088","PMC5040058",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028761","New fixed dose chemical combinations: the way forward for better diabetes type II management?","Abdulsalim S","2016","Expert opinion on pharmacotherapy","randomized_trial","article","10.1080/14656566.2016.1241235","27700188",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article"],["R0028762","Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report.","Bobart SA","2016","Annals of internal medicine","case_report","article","10.7326/l15-0535","27699391",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0028763","Activation of GLP-1 Receptor Enhances Neuronal Base Excision Repair via PI3K-AKT-Induced Expression of Apurinic/Apyrimidinic Endonuclease 1.","Yang JL","2016","Theranostics","preclinical","article","10.7150/thno.15993","27698937","PMC5039677",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028764","Development of a reliable automated screening system to identify small molecules and biologics that promote human β-cell regeneration.","Aamodt KI","2016","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00515.2015","27624103","PMC5130356",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028765","Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes.","Tomlinson B","2016","Expert opinion on drug metabolism & toxicology","other","article","10.1080/17425255.2016.1234608","27607315",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028766","Can we win the war on obesity with pharmacotherapy?","Gotthardt JD","2016","Expert review of clinical pharmacology","other","article","10.1080/17512433.2016.1232164","27590007",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028767","Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in Class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor.","Wootten D","2016","Biochemical pharmacology","other","article","10.1016/j.bcp.2016.08.015","27569426","PMC5063953",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028768","Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort?","Steg PG","2016","Circulation","randomized_trial","article","10.1161/circulationaha.116.021914","27550966",null,null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Review"],["R0028769","London buses: A cardiovascular outcome trial equivalent?","Grant PJ","2016","Diabetes & vascular disease research","other_trial","article","10.1177/1479164116663051","27543327",null,null,null,"pubmed","FALSE","open_pdf","5",null,"Editorial"],["R0028770","What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?","Lovre D","2016","Current diabetes reports","randomized_trial","article","10.1007/s11892-016-0788-5","27541296",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0028771","Pharmacotherapy for Obesity.","Saunders KH","2016","Endocrinology and metabolism clinics of North America","other_trial","article","10.1016/j.ecl.2016.04.005","27519128",null,null,null,"pubmed","FALSE","paywalled","5",null,"Journal Article; Review"],["R0028772","Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism.","Nielsen R","2018","Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology","other","article","10.1007/s12350-016-0622-0","27473218",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Randomized Controlled Trial"],["R0028773","American Diabetes Association - 76th Scientific Sessions (June 10-14, 2016 - New Orleans, Louisiana, USA).","Lam S","2016","Drugs of today (Barcelona, Spain : 1998)","other","article","10.1358/dot.2016.52.6.2516437","27458613",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0028774","Research digest.","Sattar N","2016","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(16)30161-9","27401823",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028775","Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?","Ingelfinger JR","2016","The New England journal of medicine","commentary","article","10.1056/nejme1607413","27331286",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028776","The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism.","Wootten D","2016","Cell","other","article","10.1016/j.cell.2016.05.023","27315480","PMC4912689",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028777","Pharmacogenetics: Genetic approach supports cardiovascular safety of GLP1R agonists.","Fernández-Ruiz I","2016","Nature reviews. Cardiology","other","article","10.1038/nrcardio.2016.100","27310434",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028778","The between-day reproducibility of fasting, satiety-related analytes, in 8 to 11year-old boys.","Allsop S","2016","Physiology & behavior","other","article","10.1016/j.physbeh.2016.06.002","27265877",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028779","Pharmacotherapy for Obesity and Changes in Eating Behavior: a Patient and Physician's Perspective.","Miguelgorry PL","2016","Advances in therapy","commentary","article","10.1007/s12325-016-0349-y","27246171","PMC4939162",null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0028780","Pharmacologic Therapy of Type 2 Diabetes.","Wright JJ","2016","The Medical clinics of North America","narrative_review","article","10.1016/j.mcna.2016.03.014","27235609",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028781","Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes.","Kovatchev B","2016","Diabetes care","other","article","10.2337/dc15-2035","27208366","PMC4806774",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028782","Unravelling the mechanisms of a protein refolding process based on the association of detergents and co-solvents.","Michaux C","2016","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.2893","27198040",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028783","Managing non-alcoholic fatty liver disease in diabetes: Challenges and opportunities.","Lee CH","2017","Journal of diabetes investigation","commentary","article","10.1111/jdi.12534","27181498","PMC5334302",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028784","Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?","Athyros VG","2016","Current vascular pharmacology","commentary","article","10.2174/1570161114999160513150605","27173023",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028785","Parabrachial CGRP Neurons Control Meal Termination.","Campos CA","2016","Cell metabolism","preclinical","article","10.1016/j.cmet.2016.04.006","27166945","PMC4867080",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028786","Treatment intensification for patients with type 2 diabetes and poor glycaemic control.","Fu AZ","2016","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.12683","27160505",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028787","Benefits and challenges of a QSP approach through case study: Evaluation of a hypothetical GLP-1/GIP dual agonist therapy.","Rieger TR","2016","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","other","article","10.1016/j.ejps.2016.05.006","27157042",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028788","Nutrient-induced glucagon like peptide-1 release is modulated by serotonin.","Ripken D","2016","The Journal of nutritional biochemistry","preclinical","article","10.1016/j.jnutbio.2016.03.006","27142747",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028789","The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.","João AL","2016","Obesity reviews : an official journal of the International Association for the Study of Obesity","narrative_review","article","10.1111/obr.12421","27125902",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028790","Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.","Kelly AS","2016","International journal of obesity (2005)","other_trial","article","10.1038/ijo.2016.69","27113643","PMC5546093",null,null,"pubmed","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0028791","Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.","Thompson A","2016","PloS one","other","article","10.1371/journal.pone.0154229","27100083","PMC4839733",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028792","PDGF Facilitates Direct Lineage Reprogramming of Hepatocytes to Functional β-Like Cells Induced by Pdx1 and Ngn3.","Chang FP","2016","Cell transplantation","preclinical","article","10.3727/096368916x691439","27076404",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028793","Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series.","Shankar SS","2016","American journal of physiology. Endocrinology and metabolism","other_trial","article","10.1152/ajpendo.00527.2015","27072496",null,"ClinicalTrials.gov:NCT00782418; ClinicalTrials.gov:NCT01055340; ClinicalTrials.gov:NCT01373450","S002029; S002296","pubmed","FALSE","paywalled","5",null,"Journal Article; Randomized Controlled Trial"],["R0028794","[Modern antihyperglycaemic agents--what is the patient benefit?].","Siegmund T","2016","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-016-8061-z","27071585",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028795","Emerging Therapies for Nonalcoholic Fatty Liver Disease.","Hameed B","2016","Clinics in liver disease","narrative_review","article","10.1016/j.cld.2015.10.015","27063275",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028796","Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.","Ganesh S","2016","Clinics in liver disease","narrative_review","article","10.1016/j.cld.2015.10.009","27063274",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028797","The liver in focus.","Roden M","2016","Diabetologia","commentary","article","10.1007/s00125-016-3911-x","27056371",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Research Support, Non-U.S. Gov't; Comment"],["R0028798","EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.","European Association for the Study of the Liver (EASL)","2016","Diabetologia","other","article","10.1007/s00125-016-3902-y","27053230",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028800","Novel Pharmacotherapy Options for NASH.","Ratziu V","2016","Digestive diseases and sciences","narrative_review","article","10.1007/s10620-016-4128-z","27003143",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028801","Glycemic control and the heart: it matters how you get there.","Bloomgarden Z","2016","Journal of diabetes","randomized_trial","article","10.1111/1753-0407.12398","26990043",null,null,null,"pubmed; openalex","TRUE","open_pdf","2","FALSE","Editorial; article"],["R0028802","Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.","Geurin MD","2016","American family physician","commentary","article",null,"26977827",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0028803","Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.","Bueno AB","2016","The Journal of biological chemistry","other","article","10.1074/jbc.m115.696039","26975372","PMC4865917",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028804","Importance and methods of searching for E-publications ahead of print in systematic reviews.","Thompson JC","2016","Evidence-based medicine","systematic_review","article","10.1136/ebmed-2015-110374","26912572",null,null,null,"pubmed","FALSE","paywalled","3",null,"Case Reports; Journal Article"],["R0028805","Newer antidiabetic drugs and calorie restriction mimicry.","Kalra S","2016","Indian journal of endocrinology and metabolism","preclinical","article","10.4103/2230-8210.172242","26904485","PMC4743377",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028806","Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin.","Willekens SM","2016","Molecular imaging and biology","preclinical","article","10.1007/s11307-016-0936-y","26886298","PMC5010585",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028807","Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor.","Darsalia V","2016","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12641","26847506",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0028808","Implications of immortal person-time when outcomes are nonfatal.","Liang C","2016","Annals of epidemiology","other","article","10.1016/j.annepidem.2015.12.004","26847051",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028809","Comparison of short-term energy intake and appetite responses to active and seated video gaming, in 8-11-year-old boys.","Allsop S","2016","The British journal of nutrition","randomized_trial","article","10.1017/s0007114515005437","26817510",null,null,null,"pubmed","FALSE","open_pdf","2",null,"Comparative Study; Journal Article; Randomized Controlled Trial"],["R0028810","A current perspective of supercharging reagents and peptide bioanalysis.","Kay RG","2016","Bioanalysis","narrative_review","article","10.4155/bio.15.247","26805961",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028811","A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.","Basile JN","2016","Hospital practice (1995)","other","article","10.1080/21548331.2016.1141656","26781810",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028812","Mildly acidic conditions eliminate deamidation artifact during proteolysis: digestion with endoprotease Glu-C at pH 4.5.","Liu S","2016","Amino acids","preclinical","article","10.1007/s00726-015-2166-z","26748652","PMC4795971",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0028813","Obesity in 2015: Advances in managing obesity.","Dixon JB","2016","Nature reviews. Endocrinology","narrative_review","article","10.1038/nrendo.2015.221","26729038",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028814","Novel insights into the effects of diabetes on gastric motility.","Marathe CS","2016","Expert review of gastroenterology & hepatology","nonrandomized_study","article","10.1586/17474124.2016.1129898","26647088",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0028815","The Triumph of Innovation and the Hard Work of Caring for Patients With Diabetes.","Montori VM","2016","Annals of internal medicine","randomized_trial","article","10.7326/m15-2610","26641027",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Editorial; Research Support, Non-U.S. Gov't; Comment; editorial"],["R0028816","The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs.","Nicze M","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25020815","38255888","PMC10815890",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028817","The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity.","Dalle Grave R","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s447582","38249154","PMC10798050",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028818","Ethnic Disparities in Lipid Metabolism and Clinical Outcomes between Dutch South Asians and Dutch White Caucasians with Type 2 Diabetes Mellitus.","Yuan L","2024","Metabolites","other","article","10.3390/metabo14010033","38248836","PMC10819672",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028819","Functional Foods may be Dysfunctional: A South Asian Perspective.","Kalra B","2024","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.24-03","38219186",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028820","International consensus on post-transplantation diabetes mellitus.","Sharif A","2024","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","other","article","10.1093/ndt/gfad258","38171510","PMC11024828",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Consensus Statement"],["R0028821","Ongoing challenges of off-label prescribing.","Day RO","2023","Australian prescriber","narrative_review","article","10.18773/austprescr.2023.022","38152320","PMC10751081",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028822","Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin.","Steward T","2024","Trends in molecular medicine","other","article","10.1016/j.molmed.2023.12.001","38123380",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028823","Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes.","Popovic DS","2024","Metabolism: clinical and experimental","commentary","article","10.1016/j.metabol.2023.155763","38122894",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028824","Expert Opinion on Addressing the Gap in Injection Technique and Needle Reuse for People with Diabetes in Indonesia.","Soewondo P","2023","Diabetes, metabolic syndrome and obesity : targets and therapy","other","article","10.2147/dmso.s433254","38111730","PMC10725793",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028825","Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.","Polyzos SA","2023","Current pharmaceutical design","commentary","article","10.2174/0113816128279822231211101522","38111116",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0028826","Pharmacologic Management of Obesity after Liver Transplantation: A Critical Review.","Zahrawi F","2023","Annals of gastroenterology and digestive disorders","narrative_review","article",null,"38098758","PMC10719957",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0028827","More questions than answers.","Thorp HH","2023","Science (New York, N.Y.)","commentary","article","10.1126/science.adn3693","38096295",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028828","Obesity meets its match.","Couzin-Frankel J","2023","Science (New York, N.Y.)","commentary","article","10.1126/science.adn4691","38096291",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028829","A new era in obesity management.","Stanford FC","2024","Nature reviews. Gastroenterology & hepatology","other","article","10.1038/s41575-023-00887-9","38092859","PMC10909397",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028830","Investigating the Glucagon-like Peptide-1 and Its Receptor in Human Brain: Distribution of Expression, Functional Implications, Age-related Changes and Species Specific Characteristics.","Gupta T","2023","Basic and clinical neuroscience","other","article","10.32598/bcn.2021.2554.2","38077175","PMC10700809",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028831","A cross-sectional study on the prevalence of cardiovascular disease in elderly patients with long-term type 2 diabetes mellitus mainly attended in private clinics in Mexico. The CAPTURE study.","Arenas-León JL","2023","Diabetology & metabolic syndrome","other","article","10.1186/s13098-023-01231-6","38062472","PMC10702002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0028832","Advances in incretin-based therapeutics for obesity.","Rosenkilde MM","2024","Nature reviews. Endocrinology","other","article","10.1038/s41574-023-00938-w","38062121",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028833","Beyond pounds: What else could be lost?","Idrees T","2023","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2023.108649","37992414","PMC11146663",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0028834","Out of stock: A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ± glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes.","Perreault L","2024","Journal of diabetes","commentary","article","10.1111/1753-0407.13505","37986549","PMC11128752",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0028835","Novel antidiabetics for the primary prevention of cardiopulmonary diseases.","Qiu M","2024","European journal of internal medicine","commentary","article","10.1016/j.ejim.2023.11.006","37980234",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0028836","As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging.","Ruder K","2023","JAMA","commentary","article","10.1001/jama.2023.16620","37966850",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","News; article"],["R0028837","Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies.","Prajapati S","2024","Current diabetes reviews","narrative_review","article","10.2174/0115733998256797231009062744","37962047",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028838","Patient Evaluation and Surgical Staging.","Capla J","2024","Clinics in plastic surgery","narrative_review","article","10.1016/j.cps.2023.07.004","37945077",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028839","Editorial: Childhood diabetes in low- and middle-income countries: progress, challenges, and actions needed, volume II.","Geffner ME","2023","Frontiers in endocrinology","commentary","article","10.3389/fendo.2023.1304716","37929029","PMC10622669",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0028840","The Effective Use of Anti-obesity Medications.","Schmitz SH","2023","Gastroenterology clinics of North America","other_trial","article","10.1016/j.gtc.2023.08.003","37919019",null,null,null,"pubmed","FALSE","paywalled","5",null,"Journal Article; Review"],["R0028841","Adipose tissue as a cause of endocrine dysfunction.","Kuryłowicz AE","2023","Endokrynologia Polska","narrative_review","article","10.5603/ep.95378","37902012",null,null,null,"pubmed","FALSE",null,null,null,"Review; Journal Article"],["R0028842","Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome.","Jagomäe T","2023","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2023.1234925","37900147","PMC10611518",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0028843","Novel pharmacological interventions for diabetic kidney disease.","Tan SK","2024","Current opinion in nephrology and hypertension","narrative_review","article","10.1097/mnh.0000000000000935","37889557",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0028844","Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?","Kloock S","2023","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2023.108549","37879540",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028845","Potentially active compounds that improve PAD through angiogenesis: A review.","Liu ZB","2023","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","narrative_review","article","10.1016/j.biopha.2023.115634","37879211",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028846","[Type-2-Diabetes: choosing antidiabetic therapy depending on comorbidities].","Gallwitz B","2023","MMW Fortschritte der Medizin","other","article","10.1007/s15006-023-2996-7","37857970",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028847","Exploring the nexus of binge eating disorder (BED), New Psychoactive Substances (NPS), and misuse of pharmaceuticals: charting a path forward.","Chiappini S","2023","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2023.2271389","37853742",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028848","Anti-obesity drugs' side effects: what we know so far.","Lenharo M","2023","Nature","commentary","article","10.1038/d41586-023-03183-3","37833484",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028849","[Not Available].","Overbeck P","2023","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-023-3053-2","37828312",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028850","Geniposide stimulates autophagy by activating the GLP-1R/AMPK/mTOR signaling in osteoarthritis chondrocytes.","Huang J","2023","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2023.115595","37769389",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028851","Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice.","Camilleri M","2024","The American journal of gastroenterology","narrative_review","article","10.14309/ajg.0000000000002519","37753925","PMC11026296",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; research-article; article"],["R0028852","A Quantitative Systems Pharmacology Model of the Incretin Hormones GIP and GLP1, Glucagon, Glucose, Insulin, and the Small Molecule DPP-4 Inhibitor, Linagliptin.","Wu N","2024","Journal of pharmaceutical sciences","other","article","10.1016/j.xphs.2023.09.006","37716531",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028853","A narrative review of approved and emerging anti-obesity medications.","Abdi Beshir S","2023","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","nonrandomized_study","article","10.1016/j.jsps.2023.101757","37712012","PMC10497995",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0028854","The 'Behavioral Balance Model': A new perspective on the aetiology and therapy of obesity.","Schultes B","2023","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15271","37694802",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0028855","Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.","Friedrichsen MH","2023","Molecular metabolism","randomized_trial","article","10.1016/j.molmet.2023.101801","37690519","PMC10568562",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Clinical Trial, Phase I; Randomized Controlled Trial; Journal Article; research-article; article"],["R0028856","Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment.","Cuttica CM","2023","Nutrients","narrative_review","article","10.3390/nu15173737","37686769","PMC10490004",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028857","Improving Outcomes of Chronic Obstructive Pulmonary Disease through the Treatment of Comorbidities: One Step Beyond.","Miravitlles M","2023","American journal of respiratory and critical care medicine","commentary","article","10.1164/rccm.202309-1546ed","37672750","PMC10867943",null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0028858","Editorial: Incretin agonists in the treatment of obesity.","Sun X","2023","Frontiers in endocrinology","commentary","article","10.3389/fendo.2023.1265826","37621651","PMC10446470",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; editorial"],["R0028859","Incretins: turning the venom into the antidote.","Krook A","2023","Diabetologia","commentary","article","10.1007/s00125-023-05987-4","37594570",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028860","Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?","Seetharaman R","2023","Journal of basic and clinical physiology and pharmacology","commentary","article","10.1515/jbcpp-2023-0172","37581246",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028861","Anti-obesity drug also protects against heart disease - what happens next?","Lenharo M","2023","Nature","commentary","article","10.1038/d41586-023-02528-2","37568000",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028862","Ethics of diabetic drugs for weight loss in hidradenitis suppurativa patients.","Katsetos M","2024","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2023.07.1028","37558092",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0028863","Turning the tide on obesity?","Bulik CM","2023","Science (New York, N.Y.)","commentary","article","10.1126/science.adj9953","37535715",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028864","Medical management of obesity.","Gupta S","2023","Clinical medicine (London, England)","other","article","10.7861/clinmed.2023-0183","37524427","PMC10541044",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028865","Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors.","Vishnoi S","2023","Journal of chemical information and modeling","other","article","10.1021/acs.jcim.3c00752","37523325","PMC10428222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0028866","Computational Design of Potent and Selective d-Peptide Agonists of the Glucagon-like Peptide-2 Receptor.","Valiente PA","2023","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.3c00464","37491005","PMC10424673",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028867","2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","Writing Committee Members","2023","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2023.04.003","37480922",null,null,null,"pubmed","FALSE","free_to_read","4",null,"Practice Guideline; Journal Article"],["R0028868","2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","Virani SS","2023","Circulation","nonrandomized_study","article","10.1161/cir.0000000000001168","37471501",null,null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Practice Guideline"],["R0028869","[Renal Damage and Obesity: a Silent Pairing].","Nazzaro P","2023","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","narrative_review","article",null,"37427903",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; Review; other"],["R0028870","Pharmacologic Treatment of Obesity in Reproductive Aged Women.","Nuako A","2023","Current obstetrics and gynecology reports","preclinical","article","10.1007/s13669-023-00350-1","37427372","PMC10328448",null,"S000630","pubmed","FALSE","open_pdf","5",null,"Journal Article"],["R0028871","Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?","Genchi VA","2023","Journal of endocrinological investigation","narrative_review","article","10.1007/s40618-023-02125-0","37378828","PMC10558388",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028872","Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions.","Chen J","2023","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-023-01875-8","37349787","PMC10288803",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0028873","Adipose Tissue Dysfunction in Polycystic Ovary Syndrome.","Bril F","2023","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgad356","37329216","PMC10735305",null,null,"pubmed","FALSE","open_pdf","3",null,"Systematic Review; Journal Article; Research Support, N.I.H., Extramural"],["R0028874","Severe, Complicated Pancreatitis With an Unclear Etiology.","Nohomovich B","2023","Cureus","case_report","article","10.7759/cureus.39011","37323321","PMC10264160",null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article"],["R0028875","[Obesity treatment: will pharmacotherapies replace metabolic surgery in the future?].","Müller TD","2023","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-023-01530-0","37286802","PMC10246874",null,null,"pubmed","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0028876","AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus.","Berra C","2023","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-023-02115-x","37270748","PMC10359387",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article"],["R0028877","Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.","Mehdi SF","2023","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2023.1148209","37266425","PMC10230051",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0028878","Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist.","Gibadullin R","2023","Journal of the American Chemical Society","nonrandomized_study","article","10.1021/jacs.3c01628","37235770","PMC10335629",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0028879","The etiopathogenesis and management of obesity: The quintessential quincunx.","Kalra S","2023","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.23-36","37218254",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028880","Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications.","Guglielmi V","2023","Current obesity reports","narrative_review","article","10.1007/s13679-023-00502-7","37209215","PMC10250472",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028881","Inclusion of drugs on the World Health Organization's Essential Medicines List: A game-changer for obesity?","Seetharaman R","2023","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15114","37166072",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0028882","Variation in responses to incretin therapy: Modifiable and non-modifiable factors.","Austin GO","2023","Frontiers in molecular biosciences","narrative_review","article","10.3389/fmolb.2023.1170181","37091864","PMC10119428",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028883","The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care.","Russo G","2023","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2023.110672","37084893",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028884","Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk.","Wilson RB","2023","International journal of molecular sciences","systematic_review","article","10.3390/ijms24076192","37047163","PMC10094585",null,null,"pubmed","FALSE","open_pdf","3",null,"Meta-Analysis; Systematic Review; Journal Article"],["R0028885","Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials.","Verma S","2023","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.15088","37046366",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Research Support, Non-U.S. Gov't"],["R0028886","A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects.","Lee MMY","2023","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.15085","37041663",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0028887","Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease.","Terpening CM","2023","The Annals of pharmacotherapy","narrative_review","article","10.1177/10600280231165774","37029538",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028888","Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.","van Eenige R","2023","Atherosclerosis","preclinical","article","10.1016/j.atherosclerosis.2023.03.016","37015151",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028889","Protecting the Brains of People With Type 2 Diabetes.","Milloh-Raz H","2023","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgad191","37009694",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Editorial; Comment; article"],["R0028890","Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.","Mahmoud F","2023","European journal of clinical investigation","systematic_review","article","10.1111/eci.13997","37002856",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Meta-Analysis; Journal Article; Review; article"],["R0028891","2022 FDA TIDES (Peptides and Oligonucleotides) Harvest.","Al Musaimi O","2023","Pharmaceuticals (Basel, Switzerland)","other","article","10.3390/ph16030336","36986436","PMC10056021",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028892","[Innovations in endocrinology and diabetology].","Dischinger U","2023","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-023-2419-9","36961710",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028893","The Fat Kidney.","Verde L","2023","Current obesity reports","narrative_review","article","10.1007/s13679-023-00500-9","36933154","PMC10250266",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028894","Type 2 Diabetes Mellitus Treatment and Beyond: A Glance in Our Armamentarium.","Iliodromitis K","2023","JACC. Basic to translational science","commentary","article","10.1016/j.jacbts.2022.10.005","36908672","PMC9998458",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028895","Cancer related safety with SGLT2-i and GLP1-RAs: Should we worry?","Gallo M","2023","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2023.110624","36906235",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028896","[Indications of antidiabetic drugs beyond glucose control].","Hartmann NK","2023","MMW Fortschritte der Medizin","other","article","10.1007/s15006-023-2343-z","36894856",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028897","Affinity selection of double-click triazole libraries for rapid discovery of allosteric modulators for GLP-1 receptor.","Xin Y","2023","Proceedings of the National Academy of Sciences of the United States of America","other","article","10.1073/pnas.2220767120","36893261","PMC10243133",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028898","Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy.","Chakhtoura M","2023","Metabolism: clinical and experimental","commentary","article","10.1016/j.metabol.2023.155531","36870600",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028899","Refractory and Resistant obesity: Dynamic Concepts, Contemporary Definitions.","Kalra S","2023","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.05-23","36842041",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028900","Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.","Malavazos AE","2023","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwad050","36799940",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028901","Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.","Manchanda Y","2023","Endocrinology","other","article","10.1210/endocr/bqad028","36774542","PMC10016038",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028902","Management of Type 2 Diabetes in Acute Coronary Syndromes: Current State and Future Perspectives.","Koufakis T","2023","Current pharmaceutical design","commentary","article","10.2174/1381612829666230210161306","36762749",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0028903","Dual gut hormone receptor agonists for diabetes and obesity.","Bass J","2023","The Journal of clinical investigation","other","article","10.1172/jci167952","36719381","PMC9888372",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028904","Glucagon in type 2 diabetes: Friend or foe?","Caruso I","2023","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.3609","36637256",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028905","Direct Assessment of Oligomerization of Chemically Modified Peptides and Proteins in Formulations using DLS and DOSY-NMR.","Wang K","2023","Pharmaceutical research","other","article","10.1007/s11095-022-03468-8","36627448",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028906","Glucagon-like peptide-1 receptor regulates receptor of advanced glycation end products in high glucose-treated rat mesangial cells.","Chang JT","2023","Journal of the Chinese Medical Association : JCMA","preclinical","article","10.1097/jcma.0000000000000844","36599141","PMC12755534",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028907","NAFLD and type 2 diabetes: A practical guide for the joint management.","Genua I","2023","Gastroenterologia y hepatologia","narrative_review","article","10.1016/j.gastrohep.2022.12.002","36584750",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028908","Disparities in adoption of new diabetic therapies with cardiovascular benefits.","Vasti EC","2023","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2022.110233","36581144","PMC10234597",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; research-article"],["R0028909","Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity.","Ge D","2023","Pulmonary therapy","narrative_review","article","10.1007/s41030-022-00211-x","36575356","PMC9931991",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028910","Correction: Zheng et al. Geniposide Ameliorated Dexamethasone-Induced Cholesterol Accumulation in Osteoblasts by Mediating the GLP-1R/ABCA1 Axis. Cells 2021, 10, 3424.","Zheng Y","2022","Cells","notice","article","10.3390/cells11233838","36497203","PMC9736885",null,null,"pubmed","FALSE",null,null,null,"Published Erratum"],["R0028911","Real-world evaluation of glucose-lowering therapies and the use of weight-adjusted variable rate intravenous insulin infusion in the management of hyperglycaemia in patients with acute coronary syndrome (REGULATE-ACS).","Liarakos AL","2023","International journal of cardiology","nonrandomized_study","article","10.1016/j.ijcard.2022.10.158","36441073",null,null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article"],["R0028912","Impact of Dysfunctional Adipose Tissue Depots on the Cardiovascular System.","D'Oria R","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms232214296","36430774","PMC9695168",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028913","Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology.","German CA","2022","American journal of preventive cardiology","narrative_review","article","10.1016/j.ajpc.2022.100432","36425534","PMC9679464",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028914","Increasing Societal Benefit From Cardiovascular Drugs.","Tonelli M","2022","Circulation","narrative_review","article","10.1161/circulationaha.122.059032","36409780",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0028915","Drug therapy and medication adherence in type 2 diabetes in a care facility: A cross sectional survey.","Eze UIH","2022","Exploratory research in clinical and social pharmacy","other","article","10.1016/j.rcsop.2022.100200","36406057","PMC9667283",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028916","Role of telemedicine during COVID-19 pandemic in type 2 diabetes outpatients: The AMD annals initiative.","Russo GT","2022","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2022.110158","36400169","PMC9663380",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0028917","Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: Review of the literature and lessons learned from adults.","Bensignor MO","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.1043650","36387846","PMC9647073",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028918","Drugs for type 2 diabetes.",null,"2022","The Medical letter on drugs and therapeutics","other","article",null,"36384763",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028919","The Anti-Inflammatory Effect of Novel Antidiabetic Agents.","Theofilis P","2022","Life (Basel, Switzerland)","narrative_review","article","10.3390/life12111829","36362984","PMC9696750",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028920","Long-term Care of the Adult Liver Transplant Recipient.","Neuberger J","2022","Journal of clinical and experimental hepatology","narrative_review","article","10.1016/j.jceh.2022.03.012","36340310","PMC9630008",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028921","Adherence to antidiabetic treatment among patients managed in primary care centres in Spain: the INTENSE study.","Vlacho B","2022","Primary care diabetes","other","article","10.1016/j.pcd.2022.10.004","36335018",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028922","[What is confirmed in the treatment of chronic kidney disease?].","Greite R","2022","Innere Medizin (Heidelberg, Germany)","narrative_review","article","10.1007/s00108-022-01422-9","36323846","PMC9684262",null,null,"pubmed","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0028923","Anti-Inflammatory Effects of GLP-1R Activation in the Retina.","Puddu A","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms232012428","36293281","PMC9604172",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028924","Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society.","Friedman AN","2022","American journal of kidney diseases : the official journal of the National Kidney Foundation","other","article","10.1053/j.ajkd.2022.06.007","36280397",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028925","Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.","Rossing P","2022","Kidney international","other","article","10.1016/j.kint.2022.06.013","36272755",null,null,null,"pubmed","FALSE",null,null,null,"Practice Guideline; Research Support, Non-U.S. Gov't; Journal Article"],["R0028926","Changes in racial and ethnic disparities in glucose-lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005-2018.","Li P","2023","Diabetes, obesity & metabolism","other","article","10.1111/dom.14894","36251173","PMC9812896",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0028927","How important it is to know the preferences of the diabetic patient.","Tamargo J","2023","International journal of cardiology","commentary","article","10.1016/j.ijcard.2022.10.017","36243180",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028928","Pharmacotherapy of type 2 diabetes: An update and future directions.","DeMarsilis A","2022","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2022.155332","36240884",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028929","Supplementary drug treatment to reduce weight in adolescents with severe obesity.","Rolin J","2022","Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke","other","article","10.4045/tidsskr.22.0540","36226431",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028930","Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention: A Randomized Clinical Trial.","Hurt RT","2022","Mayo Clinic proceedings. Innovations, quality & outcomes","randomized_trial","article","10.1016/j.mayocpiqo.2022.01.004","36160639","PMC9500518","ClinicalTrials.gov:NCT02412631",null,"pubmed","FALSE","free_to_read","2",null,"Journal Article"],["R0028931","Person-centered choice of anti-obesity pharmacotherapy.","Kalra S","2022","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.22-80","36156581",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028932","Chronic kidney disease after lung transplantation in a changing era.","Grootjans H","2022","Transplantation reviews (Orlando, Fla.)","narrative_review","article","10.1016/j.trre.2022.100727","36152358",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028933","Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists.","Jiménez-Martí E","2022","Nutrients","preclinical","article","10.3390/nu14183775","36145148","PMC9503433",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0028934","Hectogram-scale synthesis of [Aib8 , Arg34 ]-GLP-1 (7-37) by liquid-phase fragment condensation.","Zhang J","2023","Journal of peptide science : an official publication of the European Peptide Society","other","article","10.1002/psc.3452","36136053",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028935","Obesity in CKD: A Promising Path Forward.","Friedman AN","2022","Clinical journal of the American Society of Nephrology : CJASN","randomized_trial","article","10.2215/cjn.09150822","36126996","PMC9718013","ClinicalTrials.gov:NCT04626323; ClinicalTrials.gov:NCT03819153","S000953; S002714","pubmed; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; article"],["R0028936","Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: A network meta-analysis.","Tsai WH","2022","Diabetes research and clinical practice","systematic_review","article","10.1016/j.diabres.2022.110082","36122867",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Network Meta-Analysis"],["R0028937","Editorial: Pharmacology and treatment methods for NAFLD in the context of diabetes.","Abu-Farha M","2022","Frontiers in endocrinology","commentary","article","10.3389/fendo.2022.1010485","36120468","PMC9475286",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028938","Toward a new model for the management of type 2 diabetes: The mountain is there and there is no other option than to climb it.","Koufakis T","2022","Pharmacological research","commentary","article","10.1016/j.phrs.2022.106443","36096419",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0028939","Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents.","García-Compeán D","2023","Annals of hepatology","other","article","10.1016/j.aohep.2022.100751","36002119",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028940","Revisional Surgery or Pharmacotherapy for Insufficient Weight Loss and Weight Regain After Primary Bariatric Procedure: a Descriptive Study.","Dharmaratnam VM","2022","Obesity surgery","nonrandomized_study","article","10.1007/s11695-022-06191-w","35994181",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0028941","Modifying a Hydroxyl Patch in Glucagon-like Peptide 1 Produces Biased Agonists with Unique Signaling Profiles.","Wang P","2022","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.2c00653","35984914",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028942","Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion.","Holter MM","2022","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2022.934775","35957816","PMC9360487",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; review-article; article"],["R0028943","Newer Diabetes Management Options and Physical Fitness to Promote Cardiovascular Benefits.","Nylén E","2022","Reviews in cardiovascular medicine","narrative_review","article","10.31083/j.rcm2308282","39076636","PMC11266947",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0028944","The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 does not affect food intake in rats.","DiBrog AM","2022","Pharmacology, biochemistry, and behavior","preclinical","article","10.1016/j.pbb.2022.173444","35944617","PMC10577676",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0028945","Current and emerging drug treatment strategies for polycystic ovary syndrome.","Helvaci N","2023","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2022.2108702","35912829",null,null,null,"pubmed","FALSE","paywalled","4",null,"Review; Journal Article"],["R0028946","Editorial: Effects of pharmacologic therapy for diabetes mellitus on the endocrine system.","Giagulli VA","2022","Frontiers in endocrinology","commentary","article","10.3389/fendo.2022.960930","35909560","PMC9331276",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0028947","[GLP1 receptor agonists in the therapy of type 2 diabetes].","Winkler G","2022","Orvosi hetilap","narrative_review","article","10.1556/650.2022.32547","35895446",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0028948","Computational and Experimental Evaluation of the Stability of a GLP-1-like Peptide in Ethanol-Water Mixtures.","Lui LH","2022","Pharmaceutics","other","article","10.3390/pharmaceutics14071462","35890357","PMC9321252",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028949","Nonalcoholic Steatohepatitis in Children.","Xanthakos SA","2022","Clinics in liver disease","narrative_review","article","10.1016/j.cld.2022.05.001","35868684",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028950","Cardiovascular complications of diabetes.","Shah A","2022","Expert review of endocrinology & metabolism","narrative_review","article","10.1080/17446651.2022.2099838","35831991",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028951","GLP1 receptor agonist overcomes SGLT2 inhibitor-related overeating.","Blüher M","2022","Nature reviews. Endocrinology","commentary","article","10.1038/s41574-022-00722-2","35821108",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0028952","Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'.","Byrne CD","2022","Diabetic medicine : a journal of the British Diabetic Association","narrative_review","article","10.1111/dme.14912","35790023","PMC9546361",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0028953","[Not Available].","Steurer J","2022","Praxis","other","article","10.1024/1661-8157/a003839","35765794",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028954","The Role of Antihyperglycemic Drugs and Diet on Erectile Function: Results from a Perspective Study on a Population with Prediabetes and Diabetes.","Defeudis G","2022","Journal of clinical medicine","other","article","10.3390/jcm11123382","35743453","PMC9224931",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028955","Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States.","Al-Kindi SG","2022","Journal of diabetes and its complications","other","article","10.1016/j.jdiacomp.2022.108224","35667964",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028956","Comparison table: Some FDA-approved drugs for weight management.",null,"2022","The Medical letter on drugs and therapeutics","other","article",null,"35650673",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028957","Drugs and devices for weight management.",null,"2022","The Medical letter on drugs and therapeutics","other","article",null,"35650672",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028958","A Survey of Patient-Relevant Outcomes in Pediatric Craniopharyngioma: Focus on Hypothalamic Obesity.","Craven M","2022","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2022.876770","35615720","PMC9124861",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0028959","Medicines for long-term obesity management.","Proietto J","2022","Australian prescriber","narrative_review","article","10.18773/austprescr.2022.009","35592363","PMC9081949",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028960","Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis.","de Carvalho LSF","2022","Frontiers in cardiovascular medicine","systematic_review","article","10.3389/fcvm.2022.876795","35571207","PMC9098935","PROSPERO:CRD42020213127",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0028961","Roux-en-Y gastric bypass versus best medical treatment for type 2 diabetes mellitus in adults with body mass index between 27 and 32 kg/m2: A 5-year randomized controlled trial.","Cheng A","2022","Diabetes research and clinical practice","randomized_trial","article","10.1016/j.diabres.2022.109900","35513159",null,"ClinicalTrials.gov:NCT02041234","S002014","pubmed","FALSE","paywalled","1",null,"Journal Article; Randomized Controlled Trial"],["R0028962","Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation.","Naaman SC","2022","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgac241","35453151","PMC9282365",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; review-article; article"],["R0028963","Glucose-lowering drugs, cognition, and dementia: The clinical evidence.","Wu CY","2022","Neuroscience and biobehavioral reviews","narrative_review","article","10.1016/j.neubiorev.2022.104654","35398114",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural"],["R0028964","Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for \"Diabesity\".","Decara JM","2022","Journal of medicinal chemistry","preclinical","article","10.1021/acs.jmedchem.1c01842","35349261","PMC9014410",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028965","New Options (or not) for Treatment of Idiopathic Intracranial Hypertension.","Falardeau J","2022","Current neurology and neuroscience reports","narrative_review","article","10.1007/s11910-022-01188-5","35332515",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028966","Spotlight on the Human Brain: Central Actions of SGLT2 Inhibitors?","Hummel J","2022","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgac179","35323940","PMC9202687",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Editorial; Comment; article"],["R0028967","Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors.","Lau KTK","2022","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.121.023489","35322676","PMC9075422",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Observational Study; Research Support, Non-U.S. Gov't"],["R0028968","How to reset metabolic setpoint in obesity management.","Kalra S","2022","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.22-37","35320198",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028969","Prediabetes: A pragmatic triage for preventive pharmacotherapy.","Kalra S","2022","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.22-36","35320197",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0028970","2-Aminothiophene derivatives as a new class of positive allosteric modulators of glucagon-like peptide 1 receptor.","Redij T","2022","Chemical biology & drug design","preclinical","article","10.1111/cbdd.14039","35313084","PMC10278577",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0028971","Creating the amylin story.","Lutz TA","2022","Appetite","narrative_review","article","10.1016/j.appet.2022.105965","35183619",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review"],["R0028972","Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?","Vrablik M","2022","Current atherosclerosis reports","randomized_trial","article","10.1007/s11883-022-00983-2","35174437",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0028973","KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.","Mottl AK","2022","American journal of kidney diseases : the official journal of the National Kidney Foundation","other","article","10.1053/j.ajkd.2021.09.010","35144840","PMC9740752",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028974","Indirect treatment comparisons: Choosing the right tool for the job.","Pratley RE","2022","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.14664","35129275",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0028975","Classification of Non-Insulin Glucose Lowering Drugs.","Kalra S","2022","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.22-003","35099465",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028976","Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.","Zhao LM","2021","Frontiers in endocrinology","systematic_review","article","10.3389/fendo.2021.825100","35082762","PMC8785330",null,null,"pubmed","FALSE","free_to_read","3",null,"Journal Article; Comment"],["R0028977","Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.","Rajesh NA","2022","Journal of clinical and experimental hepatology","other","article","10.1016/j.jceh.2021.03.012","35068786","PMC8766544",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028978","Protective effect of glucagon-like peptide-1 mediated by ultrasound microbubbles on myocardial injury in rats with diabetic cardiomyopathy.","Liu Y","2022","Bioengineered","preclinical","article","10.1080/21655979.2021.2022270","35067162","PMC8974087",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Video-Audio Media; article"],["R0028979","Orally administered intelligent self-ablating nanoparticles: a new approach to improve drug cellular uptake and intestinal absorption.","Liang Y","2022","Drug delivery","preclinical","article","10.1080/10717544.2021.2023704","35037529","PMC8765251",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028980","Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week.","Mantovani A","2022","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2021.11.007","35027111",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review"],["R0028981","The year in cardiovascular medicine 2021: diabetes and metabolic disorders.","Cosentino F","2022","European heart journal","narrative_review","article","10.1093/eurheartj/ehab876","34974614",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028982","The Ominous Octet of Obesity: A framework for obesity pathophysiology.","Kalra S","2021","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"34974599",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028983","Semaglutide's Weight-Loss Benefits Were Sustained in a 2-Year Study.","Slomski A","2021","JAMA","other","article","10.1001/jama.2021.21717","34962530",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0028984","Editorial: Cell Biology, Physiology and Molecular Pharmacology of G Protein Coupled Receptors.","Gupta MK","2021","Frontiers in cell and developmental biology","commentary","article","10.3389/fcell.2021.815291","34957128","PMC8695997",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028985","Geniposide Ameliorated Dexamethasone-Induced Cholesterol Accumulation in Osteoblasts by Mediating the GLP-1R/ABCA1 Axis.","Zheng Y","2021","Cells","preclinical","article","10.3390/cells10123424","34943934","PMC8699812",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0028986","Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes.","Romero A","2021","Endocrinologia, diabetes y nutricion","randomized_trial","article","10.1016/j.endien.2021.11.031","34924163",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0028987","Reagents and models for detecting endogenous GLP1R and GIPR.","Ast J","2021","EBioMedicine","narrative_review","article","10.1016/j.ebiom.2021.103739","34911028","PMC8669301",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0028988","A new era in obesity treatment.","O'Leary K","2021","Nature medicine","commentary","article","10.1038/s41591-021-01610-4","34907386",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0028989","Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.","Evans M","2022","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.14603","34779107","PMC9299643",null,null,"pubmed","FALSE","free_to_read","3",null,"Journal Article; Research Support, Non-U.S. Gov't; Systematic Review"],["R0028990","Non-alcoholic fatty liver disease: A patient guideline.","Francque SM","2021","JHEP reports : innovation in hepatology","other","article","10.1016/j.jhepr.2021.100322","34693236","PMC8514420",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028991","Evolving Concepts of Type 2 Diabetes Management.","Abushamat LA","2021","The Medical clinics of North America","narrative_review","article","10.1016/j.mcna.2021.06.003","34688420","PMC13012870",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028992","Unconventional treatment options in psoriasis: A review.","Neema S","2022","Indian journal of dermatology, venereology and leprology","narrative_review","article","10.25259/ijdvl_22_2021","34623042",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028993","Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes.","Finer N","2022","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.14569","34622555",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028994","Adolescent obesity treatments: news, views, and evidence.","Cominato L","2021","Archives of endocrinology and metabolism","narrative_review","article","10.20945/2359-3997000000393","34591402","PMC10528567",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0028995","Difficult to defeat obesity: An 8D approach.","Kalra S","2021","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"34580534",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0028996","Emerging agents for the treatment and prevention of stroke: progress in clinical trials.","Safouris A","2021","Expert opinion on investigational drugs","randomized_trial","article","10.1080/13543784.2021.1985463","34555978",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0028997","Recent advances in peptide-based therapy for Type 2 diabetes and obesity.","Conlon JM","2021","Peptides","commentary","article","10.1016/j.peptides.2021.170652","34555424",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0028998","Cryo-EM structure of the dual incretin receptor agonist, peptide-19, in complex with the glucagon-like peptide-1 receptor.","Johnson RM","2021","Biochemical and biophysical research communications","other","article","10.1016/j.bbrc.2021.09.016","34547628",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0028999","Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation.","Senior PA","2021","Atherosclerosis","narrative_review","article","10.1016/j.atherosclerosis.2021.09.001","34520887",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029000","Copper, Iron, Selenium and Lipo-Glycemic Dysmetabolism in Alzheimer's Disease.","Aaseth J","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22179461","34502369","PMC8431716",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029001","A Facile Procedure for One-Pot Stable Conjugation of Two Proglucagon Cysteine-Containing Peptide Analogs.","He R","2021","Frontiers in endocrinology","other","article","10.3389/fendo.2021.693958","34484114","PMC8416343",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029002","Comment on \"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies\".","Qiu M","2021","Pharmacological research","systematic_review","article","10.1016/j.phrs.2021.105862","34481073",null,null,null,"pubmed","FALSE","paywalled","3",null,"Letter; Comment"],["R0029003","Novel approaches to pharmacological management of type 2 diabetes in Japan.","Kaneko S","2021","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2021.1974401","34461791",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029004","[Management of patient profiles with type2 diabetes mellitus in Primary Care in Spain: CONTROVERTI2 Program].","Obaya Rebollar JC","2022","Semergen","other","article","10.1016/j.semerg.2021.07.009","34452834",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029005","Assessing the role of ghrelin and the enzyme ghrelin O-acyltransferase (GOAT) system in food reward, food motivation, and binge eating behavior.","Micioni Di Bonaventura E","2021","Pharmacological research","preclinical","article","10.1016/j.phrs.2021.105847","34438062",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0029006","Estimands, Estimators, and Estimates.","Little RJ","2021","JAMA","other","article","10.1001/jama.2021.2886","34424281",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0029007","Presentations at the 81st scientific sessions of the American Diabetes Association, part 2.","Bloomgarden ZT","2021","Journal of diabetes","commentary","article","10.1111/1753-0407.13219","34396702",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0029008","Research in brief: Effective pharmacotherapy for the management of obesity.","Cacciottolo TM","2021","Clinical medicine (London, England)","other","article","10.7861/clinmed.2021-0253","34385300","PMC8439523",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029009","GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies.","Vaccari C","2021","PloS one","systematic_review","article","10.1371/journal.pone.0255726","34383800","PMC8360366","PROSPERO:CRD42020223435",null,"pubmed","FALSE","open_pdf","3",null,"Journal Article"],["R0029010","MicroRNA-214-5p aggravates sepsis-related acute kidney injury in mice.","Guo C","2022","Drug development research","preclinical","article","10.1002/ddr.21863","34370322",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029011","THE AUTHORS RESPOND.","Guzauskas GF","2021","Journal of managed care & specialty pharmacy","commentary","article","10.18553/jmcp.2021.27.8.1141","34337997","PMC10391291",null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0029012","Adjunctive Therapies to Optimize Closed-loop Glucose Control.","Srinivasan S","2021","Journal of diabetes science and technology","other","article","10.1177/19322968211032701","34315267","PMC8655279",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0029013","Association of IL-17 Inhibitor and SGLT2 Inhibitor with Candida Pyelonephritis.","Liles JE","2021","The American journal of medicine","case_report","article","10.1016/j.amjmed.2021.05.033","34270991",null,null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article"],["R0029014","[Medical therapy of obesity in France in 2021].","Bretault M","2021","La Revue de medecine interne","other","article","10.1016/j.revmed.2021.06.004","34215456",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029015","Intensive Medical Management to Prevent Large and Small Artery Atherothrombotic Stroke: Time to Expand the Horizon.","Lee M","2021","JAMA","other","article","10.1001/jama.2021.9917","34196657",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029016","Semaglutide's Success Could Usher in a \"New Dawn\" for Obesity Treatment.","Abbasi J","2021","JAMA","commentary","article","10.1001/jama.2021.10307","34160581",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","News; article"],["R0029017","Progress in Pharmacotherapy for Obesity.","Yanovski SZ","2021","JAMA","other","article","10.1001/jama.2021.9486","34160571","PMC8277731",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Intramural"],["R0029018","SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease.","Stanton RC","2021","Seminars in nephrology","narrative_review","article","10.1016/j.semnephrol.2021.03.003","34140099",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029019","Peripherally active dextromethorphan derivatives lower blood glucose levels by targeting pancreatic islets.","Scholz O","2021","Cell chemical biology","randomized_trial","article","10.1016/j.chembiol.2021.05.011","34118188",null,null,null,"pubmed","FALSE","free_to_read","2",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029020","The diabetic muscle.","Kalra S","2021","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"34091646",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029021","Targeted pH switched europium complexes monitoring receptor internalisation in living cells.","Fradgley JD","2021","Chemical communications (Cambridge, England)","other","article","10.1039/d1cc01029h","34002181",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029022","Newer drug treatments for type 2 diabetes.","Guo J","2021","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.n1171","33975861",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Introductory Journal Article"],["R0029023","Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy.","Rodriguez R","2025","Cell reports. Medicine","other","article","10.1016/j.xcrm.2025.102156","40460831","PMC12208311",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029024","A GLP-1R/Y1 receptor/Y2 receptor triple agonist decreases fentanyl-evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats.","Caffrey A","2025","British journal of pharmacology","preclinical","article","10.1111/bph.70096","40456683",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029025","Impact of weight on daily activities questionnaire in patients with overweight or obesity: Psychometric evaluation using data from the OASIS 1 trial.","von Huth Smith L","2025","Clinical obesity","other_trial","article","10.1111/cob.70015","40452267","PMC12289406","ClinicalTrials.gov:NCT05035095","S001472","pubmed","FALSE","open_pdf","5",null,"Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial"],["R0029026","Geniposide ameliorates cholesterol accumulation and promotes osteoblast differentiation by mediating the GLP-1R/AMPK/SREBP2 pathway.","Zhan W","2025","Journal of orthopaedic surgery and research","preclinical","article","10.1186/s13018-025-05945-3","40414881","PMC12105133",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029027","Type 2 diabetes specialist care in Italy in the AMD Annals initiative 2024: The path is traced.","Russo GT","2025","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2025.112273","40409725",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029028","Use and Eligibility for Glucose-Like Peptide-1 Receptor Agonist Treatment for Primary Prevention of Stroke.","Wilson LM","2025","Neurology","other","article","10.1212/wnl.0000000000213739","40408626","PMC12101899",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029029","Drugs for chronic heart failure.",null,"2025","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2025.1729a","40388632",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029030","Reply to \"Oral Formulation and SGLT2i Interaction: Key Nuances in Semaglutide's Effect on Atrial Fibrillation\".","Cesaro A","2025","European journal of preventive cardiology","commentary","article","10.1093/eurjpc/zwaf298","40386908",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; letter"],["R0029031","Botulism Type F: Foodborne or Adult Intestinal Colonization?","Pourshams I","2025","Gastro hep advances","case_report","article","10.1016/j.gastha.2025.100623","40385703","PMC12083993",null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article"],["R0029032","Animal models for development of anti-obesity drugs in the age of GLP-1 agents.","Culver A","2025","Expert opinion on drug discovery","preclinical","article","10.1080/17460441.2025.2507766","40380806",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029033","Weighing the Consequences: Can Patients with Inflammatory Bowel Disease Jump on the GLP-1 Bandwagon?","Feagins LA","2025","Digestive diseases and sciences","commentary","article","10.1007/s10620-025-09088-7","40380015",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029034","Response to the Letter to the Editor: Epicardial Adipose Tissue Modulation: A New Horizon for Sodium-glucose Cotransporter 2 Inhibitors.","Theofilis P","2025","Current vascular pharmacology","commentary","article","10.2174/0115701611401801250512101055","40370241",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029035","Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.","Wooster M","2025","Breast cancer research and treatment","nonrandomized_study","article","10.1007/s10549-025-07714-6","40360855",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0029036","Three-year outcomes of glucagon-like peptide-1 agonists in atrial fibrillation with sarcoidosis and diabetes.","Tan MC","2026","Heart rhythm","other","article","10.1016/j.hrthm.2025.04.067","40345465",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029037","The overlooked role of metabolic disorders in bipolar disorder.","Khayachi A","2025","Neuroscience and biobehavioral reviews","narrative_review","article","10.1016/j.neubiorev.2025.106203","40339674",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029038","A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion protein) in healthy Chinese participants.","Qin YF","2025","Expert opinion on investigational drugs","randomized_trial","article","10.1080/13543784.2025.2500303","40328758",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I"],["R0029039","Oral Formulation and SGLT2i Interaction: Key Nuances in Semaglutide's Effect on Atrial Fibrillation.","Shamsulddin A","2025","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwaf280","40327546",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029040","Trends in antidiabetic drug use in Portugal: 8 years real-world data from a nationwide retrospective observational study (2017-2024) (TREND-8 study).","Neves JS","2025","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.16429","40317996","PMC12146474",null,null,"pubmed","FALSE","free_to_read","4",null,"Letter"],["R0029041","Onboarding obesity management in cardiovascular care: A cardiologist's guide to latest advances.","Schiele F","2025","American journal of preventive cardiology","narrative_review","article","10.1016/j.ajpc.2025.100987","40297673","PMC12035917",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029042","Sarcopenic obesity and weight loss-induced muscle mass loss.","Caturano A","2025","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000001131","40296814","PMC12147736",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029043","Taste Plasticity in Nutrition and Health: A Scoping Review.","Sung H","2025","Nutrients","narrative_review","article","10.3390/nu17081336","40284201","PMC12030297",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Scoping Review"],["R0029044","Adolescent polycystic ovary syndrome: an endocrine-metabolic mode in response to ectopic fat.","Garcia-Beltran C","2025","Trends in molecular medicine","other","article","10.1016/j.molmed.2025.03.011","40268587",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029045","Efficacy of Simplifying Complex Insulin Regimen on Glycometabolic Parameters and Target Organ Damage in Type 2 Diabetes: A Retrospective Cohort Study.","Fejes R","2025","Journal of diabetes research","nonrandomized_study","article","10.1155/jdr/9141564","40264573","PMC12014261",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article"],["R0029046","Clarifying the interpretation of semaglutide's impact in the FLOW study.","Ingwiller M","2025","Kidney international","commentary","article","10.1016/j.kint.2025.01.028","40254368",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0029047","Tracking Pathways Linking Obesity with Heart Failure.","Manta E","2025","Nutrients","narrative_review","article","10.3390/nu17071250","40219007","PMC11990613",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029048","The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy.","Crecca E","2025","Pharmacology & therapeutics","narrative_review","article","10.1016/j.pharmthera.2025.108847","40216262",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029049","Risk of Urinary Tract Infections with Sodium-Glucose Transport Protein-2 Inhibitors in Subpopulations with Abnormal Genitourinary Pathology.","Xu J","2025","Clinical journal of the American Society of Nephrology : CJASN","nonrandomized_study","article","10.2215/cjn.0000000687","40215113","PMC12160950",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0029050","Cardiovascular disease in chronic kidney disease.","Marx-Schütt K","2025","European heart journal","narrative_review","article","10.1093/eurheartj/ehaf167","40196891","PMC12167664",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029051","Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events.","Wightman H","2025","PLoS medicine","systematic_review","article","10.1371/journal.pmed.1004553","40193407","PMC12052138",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Network Meta-Analysis; research-article; review"],["R0029052","Broadening Horizons with GLP-1 Receptor Analogues as an Adjunct to Bariatric Metabolic Surgery: Risk Awareness of a Possible Link to Non-arteritic Ischemic Optic Neuropathy.","Varughese MS","2025","Obesity surgery","other","article","10.1007/s11695-025-07831-7","40178745",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029053","First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.","Zhang H","2025","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","other_trial","article","10.1007/s40259-025-00715-3","40175670",null,"ClinicalTrials.gov:NCT05943886","S003257","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; article"],["R0029054","Impact of medical versus surgical weight loss on cardiovascular outcomes.","Ostapenko A","2025","Trends in cardiovascular medicine","narrative_review","article","10.1016/j.tcm.2025.03.004","40158762",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029055","Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease-A practical update for clinicians.","Beernink JM","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16359","40143452","PMC12400485",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029056","A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans.","Finan B","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2025.102129","40139439","PMC12051155","ClinicalTrials.gov:NCT03095807; ClinicalTrials.gov:NCT03661879","S003275; S003301","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; article"],["R0029057","New Curative Treatment Strategies and New Therapies for Type 1 Diabetes.","Shalitin S","2025","Hormone research in paediatrics","commentary","article","10.1159/000545519","40139178","PMC12060813",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029058","Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study.","Nikolis A","2025","Journal of cosmetic dermatology","other","article","10.1111/jocd.70094","40135477","PMC11938202",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Consensus Statement"],["R0029059","The Evolving Role of Weight Loss Pharmacotherapy.","Amini S","2025","Gastroenterology & hepatology","other","article",null,"40115654","PMC11920015",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029060","Continuous glucose monitoring guides glucagon-like peptide 1-based therapy use and optimization in people with type 2 diabetes.","Parsiani R","2025","Journal of family medicine and primary care","other","article","10.4103/jfmpc.jfmpc_773_24","40115561","PMC11922371",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029061","Effects of L-arginine supplementation on fat deposition and meat quality in growing lambs: Interactions with gut microbiota and metabolic signalling pathways.","Kang L","2025","Food chemistry","preclinical","article","10.1016/j.foodchem.2025.143677","40081064",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029062","Patients' experiences with GLP1-RAs - a systematic review.","Ibsen CK","2025","Scandinavian journal of primary health care","systematic_review","article","10.1080/02813432.2025.2477141","40071612","PMC12090293",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review-article; review"],["R0029063","Holistic View of Tirzepatide's Role in Obesity-Related HFpEF.","Pagidipati NJ","2025","Circulation","commentary","article","10.1161/circulationaha.125.073439","40063724",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Editorial; Comment; editorial"],["R0029064","Treatment of obesity-related HFpEF: a STEP closer to the SUMMIT.","Karakasis P","2025","Future cardiology","commentary","article","10.1080/14796678.2025.2477429","40055143","PMC11980504",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029065","Sweet Solutions: Unlocking the Diabetes-Dementia Connection for Better Outcomes.","Posan E","2025","Journal of insurance medicine (New York, N.Y.)","other","article","10.17849/insm-52-1-14-20.1","40047116",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029066","Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).","Manta A","2025","Molecular medicine reports","narrative_review","article","10.3892/mmr.2025.13479","40017113","PMC11894597",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029067","Blueberry Anthocyanin Extracts (BAEs) Protect Retinal and Retinal Pigment Epithelium Function from High-Glucose-Induced Apoptosis by Activating GLP-1R/Akt Signaling.","Li R","2025","Journal of agricultural and food chemistry","preclinical","article","10.1021/acs.jafc.4c08978","40017023",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029068","Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis.","Cazac-Panaite GD","2025","Journal of clinical medicine","other_trial","article","10.3390/jcm14041042","40004572","PMC11857078",null,null,"pubmed","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0029069","NAFLD vs MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)-Why the Need for a Change of Nomenclature?","Gastaldelli A","2025","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgaf094","39970128",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029070","Digging Deeper: How Looking Under the Surface May Help Understand the Mechanism of Duodenal Mucosal Resurfacing.","Guduguntla BA","2025","Digestive diseases and sciences","commentary","article","10.1007/s10620-025-08887-2","39966290",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029071","Systematic review of peptide nanoparticles for improved diabetes outcomes: insights and opportunities.","Dangana RS","2025","Discover nano","systematic_review","article","10.1186/s11671-025-04215-9","39961878","PMC11832960",null,null,"pubmed","FALSE","open_pdf","3",null,"Journal Article; Review"],["R0029072","Generalizability of SELECT to Cardiac Surgical Patients: Analysis of the TRICS III Randomized Trial.","Dhingra NK","2025","JACC. Advances","randomized_trial","article","10.1016/j.jacadv.2025.101597","39954345","PMC11872488",null,null,"pubmed","FALSE","free_to_read","2",null,"Journal Article"],["R0029073","The Year in Cardiology-Practice Changing Trials from European Society of Cardiology Congress 2023.","Pradhan A","2025","The International journal of angiology : official publication of the International College of Angiology, Inc","narrative_review","article","10.1055/s-0044-1788893","39944140","PMC11813610",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029074","Do weight loss interventions challenge the obesity paradox in heart failure?","Yurista SR","2025","Trends in endocrinology and metabolism: TEM","commentary","article","10.1016/j.tem.2025.01.006","39939208","PMC13401334",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029075","Glucagon-like peptide-1 agonist weight loss medications decrease sexual desire: a theoretical framework based in the serotonergic pathway.","Tveit MC","2025","The journal of sexual medicine","other","article","10.1093/jsxmed/qdae182","39924984",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029076","The Close Link Between Obesity and Cardiovascular Disease: Current Insights and Remaining Challenges.","Lee H","2025","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2024.10.005","39919874",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029077","Treatment of Type 2 Diabetes in Patients with Obesity: A Review.","Guzman H","2025","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2024.10.004","39919872",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029078","Unlocking Therapeutic Potential for Cardiac Remodeling in Obesity-Related HFpEF: Lessons From the SUMMIT CMR Substudy.","Nasir K","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.12.013","39918466",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029079","Stroke in the Patient With Type 2 Diabetes.","Jerkins TW","2025","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.1016/j.eprac.2025.01.010","39914491",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029080","Safety and Effectiveness of MiniMedTM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes.","Bhargava A","2025","Diabetes technology & therapeutics","other_trial","article","10.1089/dia.2024.0586","39912797",null,"ClinicalTrials.gov:NCT05238142",null,"pubmed","FALSE","open_pdf","5",null,"Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't"],["R0029081","Fecal Microbiota Transplantation as an Alternative Method in the Treatment of Obesity.","Hemachandra S","2025","Cureus","narrative_review","article","10.7759/cureus.76858","39901991","PMC11788455",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029082","Noninsulin Diabetes Medications in Hospitalized Children and Adolescents.","Vakharia M","2025","Critical care nursing clinics of North America","narrative_review","article","10.1016/j.cnc.2024.08.006","39890348",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029083","What Does the Rise of GLP-1 Drugs Mean for Bariatric Surgery?","Schweitzer K","2025","JAMA","other","article","10.1001/jama.2024.25968","39888611",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029084","Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance.","Tsakiridou G","2024","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics17010021","39861670","PMC11768147",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029085","An update on ocular effects of antidiabetic medications.","Sadeghi E","2025","Survey of ophthalmology","narrative_review","article","10.1016/j.survophthal.2025.01.010","39855606",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029086","Patients Are Flocking to Compounded Weight-Loss Drugs, but Are They Safe?","Ruder K","2025","JAMA","other","article","10.1001/jama.2024.27251","39854000",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029087","Glucagon-like peptides agonists promote maturation of intestinal organoids derived from neonates with necrotizing enterocolitis.","Biouss G","2025","Pediatric surgery international","other","article","10.1007/s00383-024-05957-w","39828765",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029088","Spotlight commentary: Changes in pharmacokinetics following significant weight loss.","Belančić A","2025","British journal of clinical pharmacology","other","article","10.1111/bcp.16401","39815694","PMC11862791",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029089","GLP-1 and the Neurobiology of Eating Control: Recent Advances.","Jones LA","2025","Endocrinology","nonrandomized_study","article","10.1210/endocr/bqae167","39813121","PMC11745901",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Review"],["R0029090","Response to the letter titled \"Analysis of semaglutide's effect on Alzheimer's disease risk\".","Xu R","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","randomized_trial","article","10.1002/alz.14509","39807703","PMC11848204",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0029091","Approach to Lipid Management in the Patient With Diabetes.","Kim S","2025","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgaf018","39797609",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029092","Treatment of rapid recurrence of severe steatosis with combined glucagon-like peptide-1 agonist and growth hormone therapy in a pediatric patient transplanted for metabolic dysfunction-associated steatohepatitis cirrhosis in the setting of hypopituitarism.","Saaybi SR","2025","American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","case_report","article","10.1016/j.ajt.2025.01.002","39793899",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0029093","Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management.","Nilsson MI","2024","Nutrients","randomized_trial","article","10.3390/nu16244407","39771028","PMC11677392",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Randomized Controlled Trial"],["R0029094","Pathology and Treatments of Alzheimer's Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes.","Yanai H","2024","Molecules (Basel, Switzerland)","narrative_review","article","10.3390/molecules29245936","39770025","PMC11677283",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029095","The Gut Microbiome's Influence on Incretins and Impact on Blood Glucose Control.","Dulai AS","2024","Biomedicines","nonrandomized_study","article","10.3390/biomedicines12122719","39767626","PMC11727616",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0029096","Use of Cardioprotective Adjuncts in Type 1 Diabetes.","Greenfield JR","2025","Diabetes therapy : research, treatment and education of diabetes and related disorders","other","article","10.1007/s13300-024-01687-3","39760824","PMC11794932",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029097","Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives.","Podobnik J","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.16154","39757938","PMC11802405",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029098","Hypoglycemic effect of C. butyricum-pMTL007-GLP-1 engineered probiotics on type 2 diabetes mellitus.","Zhou D","2025","Gut microbes","preclinical","article","10.1080/19490976.2024.2447814","39745177","PMC12931707",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029099","Analysis of semaglutide's effect on Alzheimer's disease risk.","Hsu CK","2025","Alzheimer's & dementia : the journal of the Alzheimer's Association","other","article","10.1002/alz.14462","39737725","PMC11851309",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029100","Pasireotide-induced hyperglycemia in Cushing's disease and Acromegaly: A clinical perspective and algorithms proposal.","Witek P","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1455465","39735646","PMC11672337",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029101","Annual Banned-Substance Review 17th Edition-Analytical Approaches in Human Sports Drug Testing 2023/2024.","Thevis M","2025","Drug testing and analysis","narrative_review","article","10.1002/dta.3835","39731401","PMC12319490",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029102","Current obesity treatment: A story about beliefs, devotion and confrontation.","Balibrea JM","2025","Cirugia espanola","other","article","10.1016/j.cireng.2024.11.012","39709125",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029103","Potential of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Heart Failure With Preserved Ejection Fraction: A Narrative Review.","Alsuwayh AF","2024","Cureus","randomized_trial","article","10.7759/cureus.73906","39697908","PMC11653976",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Review"],["R0029104","Why People Seek Obesity Care Through Digital Rather Than In-Person Services: A Quantitative Multinational Analysis of Patients From a Large Unsubsidized Digital Obesity Provider.","Talay LA","2024","Cureus","nonrandomized_study","article","10.7759/cureus.75603","39669645","PMC11637225",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article"],["R0029105","Novel antidiabetic therapies in patients with peripheral artery disease: current perspective.","Janić M","2024","Frontiers in clinical diabetes and healthcare","randomized_trial","article","10.3389/fcdhc.2024.1517265","39659952","PMC11628494","ClinicalTrials.gov:NCT04146155","S002174","pubmed; openalex","TRUE","open_europepmc","1","FALSE","Journal Article; article"],["R0029106","Commentary on Qeadan et al.: Leveraging opportunities to expand the substance use disorder treatment arsenal.","Schepis TS","2025","Addiction (Abingdon, England)","randomized_trial","article","10.1111/add.16725","39657706","PMC11707304",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; editorial"],["R0029107","Type 2 diabetes, heart failure and the treatment of their comorbidity.","Wang S","2025","Minerva medica","narrative_review","article","10.23736/s0026-4806.24.09264-4","39641257",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029108","GLP-1 enhances β-cell response to protein ingestion and bariatric surgery amplifies it.","Rayas M","2025","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.24182","39635951",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029109","Glp1r-Lepr coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1/leptin dual agonist.","Polex-Wolf J","2024","Science translational medicine","preclinical","article","10.1126/scitranslmed.adk4908","39630884","PMC12967300",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0029110","Glucagon-like peptide-1 receptor.","Krashes M","2024","Current biology : CB","other","article","10.1016/j.cub.2024.10.039","39626623",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029111","Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications.","Grosicki GJ","2024","Current developments in nutrition","narrative_review","article","10.1016/j.cdnut.2024.104486","39624804","PMC11609469",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029112","Editorial: Insights in obesity: 2023.","Nonogaki K","2024","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1489087","39605939","PMC11598331",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Editorial; editorial"],["R0029113","Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials.","Silverii GA","2025","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.16076","39563616","PMC11701179",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Letter; article"],["R0029114","A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity.","Samms RJ","2025","Annual review of physiology","narrative_review","article","10.1146/annurev-physiol-022724-105443","39546586",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0029115","Adequate sleep duration accentuates the effect of glucagon-like peptide-1 receptor variant on HbA1c: A gene-environment interaction study.","Wei J","2024","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2024.111927","39536975",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029116","A Case Report of Acute Pancreatitis in Food-Induced Anaphylaxis.","Wiese J","2024","Cureus","case_report","article","10.7759/cureus.71017","39525265","PMC11548797",null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article"],["R0029117","Discovery of the bioactive form of glucagon-like peptide-1: An attempt to correct some misconceptions.","Conlon JM","2024","Peptides","commentary","article","10.1016/j.peptides.2024.171319","39515660",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029118","Integrating the new pharmacological standard of care with traditional nutritional interventions in non-dialysis CKD.","De Nicola L","2025","Journal of nephrology","narrative_review","article","10.1007/s40620-024-02135-y","39508986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0029119","PREVENT Risk Score and Use of Cardioprotective Agents in Type 2 Diabetes: An Analysis of NHANES 2013 to 2020.","Mavromatis LA","2024","Journal of the American Heart Association","other","article","10.1161/jaha.124.037456","39494573","PMC11935714",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029120","Genetic associations of metabolic factors and therapeutic drug targets with polycystic ovary syndrome.","Zhang C","2025","Journal of advanced research","nonrandomized_study","article","10.1016/j.jare.2024.10.038","39489338","PMC12789731",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029121","Population Health Management and Guideline-Concordant Care in CKD: A Secondary Analysis of Kidney Coordinated HeAlth Management Partnership.","Weltman MR","2025","Journal of the American Society of Nephrology : JASN","randomized_trial","article","10.1681/asn.0000000544","39485493","PMC12059108","ClinicalTrials.gov:NCT03832595",null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article"],["R0029122","The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.","Stefanakis K","2024","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2024.156057","39481534",null,null,"S000828","pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0029123","Challenges in the care and treatment of patients with extreme obesity.","Stumpf MAM","2024","Archives of endocrinology and metabolism","other_trial","article","10.20945/2359-4292-2023-0335","39420906","PMC11326745",null,null,"pubmed","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0029124","Synergistic effects of peripheral GABA and GABA-transaminase inhibitory drugs on food intake control and weight loss in high-fat diet-induced obese mice.","Nagao T","2024","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2024.1487585","39415835","PMC11480068",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029125","Two Trials of Therapeutics for MASH with Liver Fibrosis.","Polyzos SA","2024","The New England journal of medicine","other_trial","article","10.1056/nejmc2411003","39413385",null,null,null,"pubmed; openalex","FALSE","paywalled","5","FALSE","Letter; Comment; article"],["R0029126","Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target.","Milani I","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms251910795","39409124","PMC11477334",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029127","Tackling Cravings in Medical Weight Management: An Update on Pathophysiology and an Integrated Approach to Treatment.","Kakoschke N","2024","Nutrients","narrative_review","article","10.3390/nu16193238","39408206","PMC11478323",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029128","JPEN Journal Club 88. Determining the hypothesis of a study.","Koretz RL","2025","JPEN. Journal of parenteral and enteral nutrition","other","article","10.1002/jpen.2696","39390199",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029129","Patients experience with preoperative use of anti-obesity medications and associations with bariatric surgery expectations.","Samuels JM","2025","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","other","article","10.1016/j.soard.2024.08.041","39389849","PMC12288039",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029130","A discrete choice experiment to understand preferences of patients with type 2 diabetes about the attributes of GLP1 receptor agonists in Spain.","San José P","2024","Current medical research and opinion","other","article","10.1080/03007995.2024.2407960","39360358",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; article"],["R0029131","IcoSema's leap forward: new data from COMBINE 3 paves the way.","Seetharaman R","2024","Journal of basic and clinical physiology and pharmacology","commentary","article","10.1515/jbcpp-2024-0157","39352773",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0029132","Evolving Approaches for Pharmacological Therapy of Obesity.","Chao AM","2025","Annual review of pharmacology and toxicology","narrative_review","article","10.1146/annurev-pharmtox-031124-101146","39348522","PMC11770897",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural"],["R0029133","Evidence of a bi-directional relationship between heart failure and diabetes: a strategy for the detection of glucose abnormalities and diabetes prevention in patients with heart failure.","Valensi P","2024","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-024-02436-3","39342254","PMC11439233",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029134","Epigenetic mechanisms in cardiovascular complications of diabetes: towards future therapies.","Damiano G","2024","Molecular medicine (Cambridge, Mass.)","narrative_review","article","10.1186/s10020-024-00939-z","39333854","PMC11428340",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029135","Can we target insulin signalling for cognition therapeutics?","Macrì S","2024","Expert opinion on therapeutic targets","commentary","article","10.1080/14728222.2024.2407821","39317178",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Research Support, Non-U.S. Gov't"],["R0029136","Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps.","LeBlanc ES","2024","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgae655","39312230",null,null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Review"],["R0029137","Chemistry Matters-From a Putative Peptide to Effective Treatments for Diabetes and Obesity: 2024 Lasker-DeBakey Clinical Medical Research Award.","Mojsov S","2024","JAMA","other","article","10.1001/jama.2024.17571","39297725",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029138","GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective.","D'Ávila M","2024","Endocrinology","narrative_review","article","10.1210/endocr/bqae128","39301751",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029139","Changes in 24-Hour Urine Chemistry in Patients with Nephrolithiasis during Weight Loss with Glucagon-Like Peptide 1-Based Therapies.","Feghali K","2024","Kidney360","nonrandomized_study","article","10.34067/kid.0000000580","39298632","PMC12282619",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0029140","Effect of surgical, medical, and behavioral weight loss on hormonal and sexual function in men: a contemporary narrative review.","Santamaria A","2024","Therapeutic advances in urology","randomized_trial","article","10.1177/17562872241279648","39285942","PMC11403669",null,null,"pubmed","FALSE","free_to_read","2",null,"Journal Article; Review"],["R0029141","Representation of women in randomized controlled trials of novel antidiabetic drugs: A cohort study.","Aharon-Hananel G","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15942","39267254",null,null,null,"pubmed","FALSE","open_pdf","2",null,"Letter"],["R0029142","Differential Efficacy of Weight Loss Interventions in Patients with Versus Without Diabetes.","Losada-Díaz F","2024","Diabetes therapy : research, treatment and education of diabetes and related disorders","narrative_review","article","10.1007/s13300-024-01646-y","39276293","PMC11467141",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029143","The fascinating story of lipid-lowering drugs, sodium-glucose co-transporter 2 inhibitors and GLP1-R agonists: new light shed on their beneficial effects.","Crea F","2024","European heart journal","randomized_trial","article","10.1093/eurheartj/ehae586","39276017",null,"PROSPERO:CRD42022353297",null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0029144","Frequently asked questions to the 2023 obesity medicine association position statement on compounded peptides: A call for action.","Bays HE","2024","Obesity pillars","other","article","10.1016/j.obpill.2024.100122","39228749","PMC11369382",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029145","GLP-1 Medication Use for Type 2 Diabetes Has Soared.","Hegland TA","2024","JAMA","commentary","article","10.1001/jama.2024.18219","39212980",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0029146","Cardiovascular disease risk in people of African ancestry with HIV in the United Kingdom.","Ko S","2024","HIV medicine","other","article","10.1111/hiv.13706","39209512","PMC11608579",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029147","Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure: a drug-target mendelian randomization and mediation analysis.","Mao T","2024","Diabetology & metabolic syndrome","other","article","10.1186/s13098-024-01448-z","39198854","PMC11360323",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029148","Semaglutide's CVD indication could cost US Medicare $145bn extra a year.","Mahase E","2024","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.q1878","39197936",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","News; other"],["R0029149","Nephrology: a flourishing field with plentiful emerging topics.","Yoo KD","2024","Frontiers in medicine","randomized_trial","article","10.3389/fmed.2024.1463540","39156691","PMC11327083",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0029150","Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis.","Fu K","2024","EBioMedicine","other","article","10.1016/j.ebiom.2024.105285","39153411","PMC11378937",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029151","Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon-like peptide-1 agonists.","Jamal N","2025","Clinical obesity","narrative_review","article","10.1111/cob.12700","39152660","PMC11706737",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029152","A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.","Rubin R","2024","JAMA","other","article","10.1001/jama.2024.13816","39150704",null,null,null,"pubmed","FALSE",null,null,null,"Interview; Research Support, Non-U.S. Gov't"],["R0029153","Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs.","Yuliantie E","2024","Biochemical pharmacology","other","article","10.1016/j.bcp.2024.116483","39147328",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029154","The Kidney in Obesity: Current Evidence, Perspectives and Controversies.","Kounatidis D","2024","Current obesity reports","narrative_review","article","10.1007/s13679-024-00583-y","39141201",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029155","From traditional to targeted: the changing trajectory of therapies in dermatomyositis.","Castillo RL","2024","Current opinion in rheumatology","narrative_review","article","10.1097/bor.0000000000001041","39137051",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029156","Molecular Basis of Cardiomyopathies in Type 2 Diabetes.","Giardinelli S","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25158280","39125850","PMC11313011",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029157","Synthesis and biological studies of 2-aminothiophene derivatives as positive allosteric modulators of glucagon-like peptide 1 receptor.","Campbell JA","2024","Bioorganic & medicinal chemistry","preclinical","article","10.1016/j.bmc.2024.117864","39116711","PMC11360446",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029158","GLP1R Agonists and Precision Medicine: In Search of Predictive Biomarkers.","Bagheri S","2025","The Journal of clinical endocrinology and metabolism","other","article","10.1210/clinem/dgae548","39109849",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029159","Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes.","Khan MS","2024","BMC nephrology","narrative_review","article","10.1186/s12882-024-03652-5","39090593","PMC11293206",null,"S000018","pubmed","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0029160","What Is the Role of Glucagon-Like Peptide 1 Signaling in the Nervous System and Its Potential Neuroprotective Effects?","Turcano P","2024","Neurology","narrative_review","article","10.1212/wnl.0000000000209781","39079072",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029161","Transforming obesity: The advancement of multi-receptor drugs.","Kusminski CM","2024","Cell","narrative_review","article","10.1016/j.cell.2024.06.003","39059360","PMC11286204",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0029162","New Data on GLP-1s, Diabetic Retinopathy, and CGMs-Highlights From the ADA's Scientific Sessions.","Abbasi J","2024","JAMA","other","article","10.1001/jama.2024.11510","39058476",null,null,null,"pubmed","FALSE",null,null,null,"Interview"],["R0029163","The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.","Hansen LS","2024","European journal of endocrinology","randomized_trial","article","10.1093/ejendo/lvae095","39049802",null,"ClinicalTrials.gov:NCT03246451",null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Randomized Controlled Trial"],["R0029164","Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis.","Kanwal F","2024","The New England journal of medicine","other_trial","article","10.1056/nejme2406487","39047246",null,null,null,"pubmed; openalex","FALSE","paywalled","5","FALSE","Editorial; article"],["R0029165","New insights into the effects of glucagon-like peptide-1 on heart rate and sinoatrial node function.","Kaur S","2024","Cardiovascular research","preclinical","article","10.1093/cvr/cvae150","39028688",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; Comment; Research Support, Non-U.S. Gov't; editorial"],["R0029166","The benefits of GLP-1 drugs beyond obesity.","Drucker DJ","2024","Science (New York, N.Y.)","other","article","10.1126/science.adn4128","39024455",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029167","Glucagon-Like Peptide Receptor Agonists Use Before Endoscopy Is Associated With Low Retained Gastric Contents: A Multicenter Cross-Sectional Analysis.","Phan J","2025","The American journal of gastroenterology","other","article","10.14309/ajg.0000000000002969","39016372",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Multicenter Study; article"],["R0029168","Management of obesity in menopause.","Palacios S","2024","Climacteric : the journal of the International Menopause Society","narrative_review","article","10.1080/13697137.2024.2374760","39016333",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029169","Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany.","Vokinger KN","2024","JAMA internal medicine","other","article","10.1001/jamainternmed.2024.2559","39008326",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029170","Obesity: Post-Pandemic Weight Management.","Swamy AM","2024","Pediatric clinics of North America","narrative_review","article","10.1016/j.pcl.2024.04.007","39003007",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029171","Dissociable hindbrain GLP1R circuits for satiety and aversion.","Huang KP","2024","Nature","preclinical","article","10.1038/s41586-024-07685-6","38987598","PMC12519567",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0029172","[Medical interventions for the therapy of obesity].","Schultes B","2024","Therapeutische Umschau. Revue therapeutique","narrative_review","article","10.23785/tu.2024.03.007","38984931",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0029173","Cardiovascular Safety of Glucagon-Like Receptor 1 Agonists in Patients With Type 2 Diabetes and Peripheral Arterial Disease: A Meta-Analysis of Randomized Controlled Trials.","Ashraf MT","2024","American journal of therapeutics","systematic_review","article","10.1097/mjt.0000000000001689","38976535",null,null,null,"pubmed","FALSE","paywalled","3",null,"Letter; Meta-Analysis"],["R0029174","Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?","Petroni ML","2024","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","nonrandomized_study","article","10.1016/j.dld.2024.04.021","38972788",null,null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Research Support, U.S. Gov't, P.H.S.; Review"],["R0029175","National and State Estimates of SELECT Trial Eligibility and Its Public Health Impact in the US.","Erhabor J","2024","JAMA network open","other_trial","article","10.1001/jamanetworkopen.2024.20105","38958980","PMC11222994",null,null,"pubmed; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029176","Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies.","Abdin A","2024","International journal of cardiology","narrative_review","article","10.1016/j.ijcard.2024.132304","38944348",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029177","Prolonged Activation of the GLP-1 Receptor via Covalent Capture.","Ünsal Ö","2024","ACS chemical biology","other","article","10.1021/acschembio.4c00039","38935975",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0029178","Gluco-regulation & type 2 diabetes: entrenched misconceptions updated to new governing principles for gold standard management.","Schwartz SS","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1394805","38933821","PMC11199379",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029179","Heart Failure With Preserved Ejection Fraction: Prioritizing Patients' Symptoms.","Cannata A","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.05.017","38913002",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029180","Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney.","Halimi JM","2024","Blood pressure","other","article","10.1080/08037051.2024.2368800","38910347",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Multicenter Study; article"],["R0029181","Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 Diabetes Classic by Thorens et al.","Thorens B","2024","Diabetes","other","article","10.2337/dbi24-0025","38900951","PMC11189827",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029182","JPEN Journal Club 85. Breaking the blind.","Koretz RL","2024","JPEN. Journal of parenteral and enteral nutrition","other","article","10.1002/jpen.2664","38895925",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029183","Glucagon-Like Peptide-1 Receptor Agonism and Suicide Risk: Evidence From Mendelian Randomization.","Zhao SS","2024","Journal of the American Heart Association","randomized_trial","article","10.1161/jaha.124.035948","38879463","PMC11255743",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0029184","New Perspectives in Management of Cardiovascular Risk Among People With Diabetes.","Gami A","2024","Journal of the American Heart Association","narrative_review","article","10.1161/jaha.123.034053","38879449","PMC11255726",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029185","Targeting Glucagon-Like Peptide 1 Signaling: A Potential Disease Modifying Therapy for Parkinson's Disease.","Kimura Y","2024","Movement disorders : official journal of the Movement Disorder Society","other","article","10.1002/mds.29884","38873954",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029186","In reply: Comment on: Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.","Wu F","2024","Canadian journal of anaesthesia = Journal canadien d'anesthesie","nonrandomized_study","article","10.1007/s12630-024-02781-7","38872003",null,null,null,"pubmed","FALSE","open_pdf","4",null,"Letter; Comment"],["R0029187","Comment on: Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.","Mizubuti GB","2024","Canadian journal of anaesthesia = Journal canadien d'anesthesie","nonrandomized_study","article","10.1007/s12630-024-02780-8","38872002",null,null,null,"pubmed","FALSE","open_pdf","4",null,"Letter; Comment"],["R0029188","Point-of-care gastric ultrasound: believing is seeing.","Sotiriou A","2024","Canadian journal of anaesthesia = Journal canadien d'anesthesie","commentary","article","10.1007/s12630-024-02778-2","38862867",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029189","Closing the policy gap in diabetes care for individuals with advanced CKD.","Habte-Asres HH","2025","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/dme.15381","38859547","PMC11733654",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0029190","How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.","Smetana GW","2024","Annals of internal medicine","other","article","10.7326/m24-0764","38857499",null,null,null,"pubmed","FALSE",null,null,null,"Clinical Conference; Journal Article"],["R0029191","Fatty liver disease: time to target CCR5?","Brata VD","2024","Expert opinion on therapeutic targets","commentary","article","10.1080/14728222.2024.2366880","38857170",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029192","Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable.","Harris E","2024","JAMA","commentary","article","10.1001/jama.2024.10333","38848082",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0029193","Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule.","Ben Nasr M","2024","Cell metabolism","preclinical","article","10.1016/j.cmet.2024.05.001","38838642",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029194","Winning researchers unlocked GLP-1 drugs for obesity.","Phelan M","2024","Science (New York, N.Y.)","commentary","article","10.1126/science.adq6452","38815041",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0029195","Dual-acting GLP-1 conjugate enhances weight loss.","Crunkhorn S","2024","Nature reviews. Drug discovery","commentary","article","10.1038/d41573-024-00089-1","38811796",null,null,null,"pubmed","FALSE",null,null,null,"News; Comment"],["R0029196","First in class, best in class or a wild card: who will dominate the anti-obesity medication market?","Collins E","2024","Journal of comparative effectiveness research","commentary","article","10.57264/cer-2024-0044","38808628","PMC11225158",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029197","[Not Available].","Wachter J","2024","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-024-4002-4","38806898",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0029198","Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF.","Fernández-Ruiz I","2024","Nature reviews. Cardiology","commentary","article","10.1038/s41569-024-01042-w","38806634",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0029199","Cellular and molecular mechanisms of antidiabetics beyond glycemic control.","Girardi ACC","2024","American journal of physiology. Cell physiology","commentary","article","10.1152/ajpcell.00289.2024","38798268",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Introductory Journal Article"],["R0029200","Newer treatments for diabetes mellitus: A caveat with rapid glycaemic improvement and caution regarding changes in retinopathy screening guidelines within the UK NHS programme.","Varadhan L","2024","The journal of the Royal College of Physicians of Edinburgh","commentary","article","10.1177/14782715241257970","38798184",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0029201","Overnutrition, Hyperinsulinemia and Ectopic Fat: It Is Time for A Paradigm Shift in the Management of Type 2 Diabetes.","Janssen JAMJL","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25105488","38791525","PMC11121669",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029202","Lipid Toxicity in the Cardiovascular-Kidney-Metabolic Syndrome (CKMS).","D'Elia JA","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12050978","38790940","PMC11118768",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029203","A Revolution in the Treatment of Obesity.","Spector R","2024","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2024.05.023","38788825",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029204","Emerging drugs for the treatment of short bowel syndrome.","Frau T","2024","Expert opinion on emerging drugs","nonrandomized_study","article","10.1080/14728214.2024.2357567","38761162",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0029205","Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency.","Puszkarska AM","2024","Nature chemistry","preclinical","article","10.1038/s41557-024-01532-x","38755312","PMC11374683",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029206","STEP-HFpEF: A Large Step for HFpEF.","van Kimmenade RRJ","2024","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2024.04.039","38750978",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Research Support, Non-U.S. Gov't"],["R0029207","GLP-1-directed NMDA receptor antagonism for obesity treatment.","Petersen J","2024","Nature","preclinical","article","10.1038/s41586-024-07419-8","38750368","PMC11136670",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0029208","Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.","Halimi JM","2024","Journal of hypertension","other","article","10.1097/hjh.0000000000003756","38747416",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029209","Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus.","Graczyk P","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25095027","38732253","PMC11084712",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029210","[Not Available].","Favre-Bulle T","2024","Revue medicale suisse","commentary","article","10.53738/revmed.2024.20.873.947","38717005",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0029211","A Review of Thyroid Cancer.","Beheshtirouy S","2024","JAMA","narrative_review","article","10.1001/jama.2024.5998","38709522",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0029212","A Review of Thyroid Cancer-Reply.","Boucai L","2024","JAMA","narrative_review","article","10.1001/jama.2024.6001","38709520",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0029213","Looking beyond glucagon-like peptide-1 agonists: could antagonists offer a potential therapy for gastroparesis?","Sher T","2024","Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract","other","article","10.1016/j.gassur.2024.04.028","38697602",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029214","[Anti-Proteinuric Effect of GLP1-RA as Add-On to SGLT2-i and ACE-i in a Diabetic Patient with IgA Nephropathy].","Malighetti ME","2024","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","case_report","article",null,"38695228",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; English Abstract; article"],["R0029215","Synthetic polypeptides using a biologic as a reference medicinal product - the European landscape of regulatory approvals.","Klein K","2024","Frontiers in medicine","nonrandomized_study","article","10.3389/fmed.2024.1335928","38681047","PMC11046703",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Review"],["R0029216","Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?","Keedy CA","2024","JAAPA : official journal of the American Academy of Physician Assistants","narrative_review","article","10.1097/01.jaa.0000000000000017","38662894",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029217","Trends and regional differences in antidiabetic medication use: a nationwide retrospective observational study.","Csatordai M","2024","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-024-01334-8","38658983","PMC11044416",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article"],["R0029218","A Comprehensive Review on GLP-1 Signaling Pathways in the Management of Diabetes Mellitus - Focus on the Potential Role of GLP-1 Receptors Agonists and Selenium among Various Organ Systems.","Barakat G","2024","Current diabetes reviews","narrative_review","article","10.2174/0115733998287178240403055901","38629376",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029219","Obesity drugs aren't always forever. What happens when you quit?","Prillaman M","2024","Nature","commentary","article","10.1038/d41586-024-01091-8","38627513",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0029220","Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry.","López-Ojeda W","2024","The Journal of neuropsychiatry and clinical neurosciences","narrative_review","article","10.1176/appi.neuropsych.20230226","38616646",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029221","Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?","McGlone ER","2024","Peptides","narrative_review","article","10.1016/j.peptides.2024.171219","38615717",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0029222","GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.","Rosenkilde MM","2024","Peptides","preclinical","article","10.1016/j.peptides.2024.171212","38608836",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029223","In silico screening of potential agonists of a glucagon-like peptide-1 receptor among female sex hormone derivatives.","Nedyalkova M","2025","Journal of biomolecular structure & dynamics","other","article","10.1080/07391102.2024.2330714","38587907",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029224","[Not Available].","Hubert M","2024","MMW Fortschritte der Medizin","other","article","10.1007/s15006-024-3825-3","38581522",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029225","[Not Available].","Schwinger RHG","2024","MMW Fortschritte der Medizin","commentary","article","10.1007/s15006-024-3771-0","38581499",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0029226","Differential effect of endogenous glucagon-like peptide-1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery.","Honka H","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15570","38558527","PMC11078606",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural"],["R0029227","Regulation of energy metabolism through central GIPR signaling.","Liskiewicz A","2024","Peptides","narrative_review","article","10.1016/j.peptides.2024.171198","38527521",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029228","Preventing maternal morbidity and mortality from preeclampsia and eclampsia particularly in low- and middle-income countries.","Ngene NC","2024","Best practice & research. Clinical obstetrics & gynaecology","narrative_review","article","10.1016/j.bpobgyn.2024.102473","38513504",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029229","Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs via GLP-1R-Dependent Glycolysis in Mice.","Zhang Y","2024","Arteriosclerosis, thrombosis, and vascular biology","preclinical","article","10.1161/atvbaha.124.320714","38511325",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029230","Analyses of potential causal contributors to increased waist/hip ratio-associated cardiometabolic disease: A combined and sex-stratified Mendelian randomization study.","Hashemy H","2024","Diabetes, obesity & metabolism","other","article","10.1111/dom.15542","38488265",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural"],["R0029231","State Coverage and Reimbursement of Antiobesity Medications in Medicaid.","Liu BY","2024","JAMA","other","article","10.1001/jama.2024.3073","38483403","PMC10941017",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029232","An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update.","Ray S","2024","Expert review of clinical pharmacology","randomized_trial","article","10.1080/17512433.2024.2330468","38471973",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0029233","Geniposide alleviates cholesterol-induced endoplasmic reticulum stress and apoptosis in osteoblasts by mediating the GLP-1R/ABCA1 pathway.","Zhong M","2024","Journal of orthopaedic surgery and research","commentary","article","10.1186/s13018-024-04665-4","38468352","PMC10926581",null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029234","Blockbuster obesity drug leads to better health in people with HIV.","Lenharo M","2024","Nature","commentary","article","10.1038/d41586-024-00691-8","38467815",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0029235","Young-Onset Type 2 Diabetes: When Gluconeogenesis Is Overfueled and Out of Control.","Alhenc-Gelas F","2024","The Journal of clinical endocrinology and metabolism","randomized_trial","article","10.1210/clinem/dgae123","38441504",null,null,null,"pubmed; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Comment; article"],["R0029236","A gluco-mindful approach to diabetic gastroparesis.","Kalra S","2024","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.24-08","38419246",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029237","Targeting autophagy to counteract neuroinflammation: A novel antidepressant strategy.","Gan H","2024","Pharmacological research","narrative_review","article","10.1016/j.phrs.2024.107112","38403256",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029238","Syndromic and Monogenic Obesity: New Opportunities Due to Genetic-Based Pharmacological Treatment.","Kalinderi K","2024","Children (Basel, Switzerland)","nonrandomized_study","article","10.3390/children11020153","38397265","PMC10886848",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Review"],["R0029239","Weight loss medication prescription prevalence in the active component, 2018-2023.","Lorei NC","2024","MSMR","nonrandomized_study","article",null,"38359359","PMC10914017",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article"],["R0029240","Continuous Glucose Monitoring and Reduced Diabetes-Related Hospitalizations in Patients with Type 2 Diabetes and CKD.","Hannah KL","2024","Kidney360","nonrandomized_study","article","10.34067/kid.0000000000000396","38356161","PMC11093542",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029241","Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.","Novikoff A","2024","Physiology (Bethesda, Md.)","narrative_review","article","10.1152/physiol.00032.2023","38353610","PMC11368522",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0029242","Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.","Ishikawa T","2024","Internal medicine (Tokyo, Japan)","other","article","10.2169/internalmedicine.3259-23","38346734","PMC11473285",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029243","A mathematical model of obesity-induced type 2 diabetes and efficacy of anti-diabetic weight reducing drug.","Siewe N","2024","Journal of theoretical biology","other","article","10.1016/j.jtbi.2024.111756","38307451",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029244","Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk.","Blood AJ","2024","Primary care diabetes","protocol","article","10.1016/j.pcd.2024.01.005","38302335",null,null,"S002701","pubmed","FALSE","open_pdf","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol"],["R0029245","How to assess kidney outcomes in obese people with substantial weight loss: the case of GLP1- and dual-receptor agonists.","Rothberg AE","2024","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","commentary","article","10.1093/ndt/gfae024","38299776","PMC11210982",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0029246","Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment.","Deng W","2024","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s421527","38288338","PMC10823413",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029247","Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction.","Washio T","2024","Clinical autonomic research : official journal of the Clinical Autonomic Research Society","commentary","article","10.1007/s10286-023-01013-0","38285071","PMC11031183",null,null,"pubmed","FALSE",null,null,null,"Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0029248","GLP-1RA based treatment in patients with a PCSK1 mutation has profound effects on body weight - two case reports.","Sørensen TP","2026","Obesity facts","case_report","article","10.1159/ofa/adzag012","42862815",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0029249","Weight Maintenance Following Discontinuation of Semaglutide in an Adolescent with Antipsychotic-Associated Weight Gain: A Case Report.","Griffing E","2026","Hormone research in paediatrics","case_report","article","10.1159/hrp/adaag040","42862792",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0029250","Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use.","Jurin I","2026","Cardiology","nonrandomized_study","article","10.1159/crd/absag023","42862749",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0029251","GLP-1 Receptor Agonists and Insulin Versus Insulin for Perioperative Glycemic Control in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Systematic Review.","Hassan D","2026","Annals of cardiac anaesthesia","systematic_review","article","10.4103/aca.aca_307_25","42862661",null,null,null,"pubmed; openalex","TRUE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0029252","Cardiorenal Protective Glucose-Lowering Treatment Patterns in Type 2 Diabetes Mellitus Based on a Real-World Study: A Clinical Phenotype Cluster Analysis.","Yang W","2026","Advances in therapy","nonrandomized_study","article","10.1007/s12325-026-03826-7","42862437",null,"ChiCTR:ChiCTR230007376",null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0029253","Rethinking Obstructive Sleep Apnea Care in Obesity: Continuous Positive Airway Pressure, Incretin-Based Therapy, or Both?","Maiolino G","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","randomized_trial","article","10.1111/obr.70238","42862012",null,null,null,"pubmed; openalex","TRUE","paywalled","2","FALSE","Journal Article; Review; article"],["R0029254","Neuroendocrine regulation of appetite and energy balance in metabolic disorders.","Khatun MM","2026","IBRO neuroscience reports","narrative_review","article","10.1016/j.ibneur.2026.09.017","42861025","PMC13653982",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029255","Glucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review.","Chang AY","2026","Annals of clinical and translational neurology","narrative_review","article","10.1002/acn3.70547","42860897","PMC13655708",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0029256","Diabetes-Associated Cognitive Impairment: Pathophysiology and Emerging Therapies.","Corbali O","2026","Annals of clinical and translational neurology","narrative_review","article","10.1002/acn3.70487","42860584","PMC13655242",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029257","The effects of improved access to diabetes medications on risk of Alzheimer's disease and related dementias.","Barthold D","2026","Alzheimer's & dementia : the journal of the Alzheimer's Association","other","article","10.1002/alz.71794","42860380","PMC13655229",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029258","Combined empagliflozin and liraglutide therapy protects against tacrolimus-induced pancreatic and renal injury associated with oxidative stress reduction.","Na DH","2026","Kidney research and clinical practice","preclinical","article","10.23876/j.krcp.26.147","42860337",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029259","The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.","Ard JD","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","other_trial","article","10.1111/obr.70228","42860310",null,null,null,"pubmed; openalex","TRUE","paywalled","5","FALSE","Journal Article; Review; review"],["R0029260","Clinical evaluation and treatment of obesity in women across selected life stages: a narrative review.","Lee Y","2026","Women's health nursing (Seoul, Korea)","narrative_review","article","10.4069/whn.2026.09.02","42860281","PMC13654666",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0029261","GLP-1-based therapies in lung diseases.","O'Callaghan M","2026","The European respiratory journal","randomized_trial","article","10.1183/13993003.00643-2026","42860278",null,null,null,"pubmed; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Review; article"],["R0029262","Endothelial Dysfunction and Metabolic Reprogramming in Cardiovascular Diseases.","Chen H","2026","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm51541","42859731","PMC13653175",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029263","Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report.","Niknam K","2026","International medical case reports journal","case_report","article","10.2147/imcrj.s650090","42859665","PMC13653545",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0029264","Surgery still leads: body contouring's last baseline before the glucagon-like peptide-1 receptor agonist era.","Abdelsalam MA","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","commentary","article","10.1016/j.soard.2026.09.009","42859061",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0029265","Ethical Considerations of Dual Financial Interests in Pharmacologic Weight Loss Therapy and Aesthetic Correction.","Shaikh UR","2026","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2026.10.015","42858911",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029266","A GLP-1/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson's disease.","Xu A","2026","Biochemical pharmacology","preclinical","article","10.1016/j.bcp.2026.118534","42858820",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029267","\"Ozempic Face\" and Facial Aging.","Fathizadeh S","2026","Clinics in dermatology","other","article","10.1016/j.clindermatol.2026.10.004","42858788",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029268","Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry.","Hansen MK","2026","JACC. Advances","nonrandomized_study","article","10.1016/j.jacadv.2026.103311","42858539",null,null,null,"pubmed; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0029269","Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome.","Henney AE","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgag423","42857939",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0029270","Tirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect.","Kassardjian A","2026","American journal of clinical pathology","case_report","article","10.1093/ajcp/aqag108","42857919",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; Case Reports; article"],["R0029271","Metabolic dysfunction-associated fatty liver disease: redefining the conceptual framework from nomenclature to emerging therapeutic paradigms.","Wang R","2026","Frontiers in endocrinology","other_trial","article","10.3389/fendo.2026.1950107","42857521","PMC13650771",null,null,"pubmed; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; article"],["R0029272","From PCOS to PMOS: reframing the clinical pathway around insulin sensitivity and weight-neutral metabolic risk.","Jiao H","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1909495","42856833","PMC13649376",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029273","Implications of Glucagon-Like Peptide-1 Signaling for Hemophilic Arthropathy, Joint Inflammation, and Cartilage Degeneration: A Narrative Review.","Valentino LA","2026","Haemophilia : the official journal of the World Federation of Hemophilia","narrative_review","article","10.1111/hae.70424","42856009",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0029274","Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review.","Inban P","2026","Disease-a-month : DM","systematic_review","article","10.1016/j.disamonth.2026.102231","42855378",null,null,null,"pubmed","FALSE","paywalled","3",null,"Journal Article"],["R0029275","Weight Management in Obesity-Associated Sleep-Disordered Breathing: Mechanisms, Clinical Management, and Emerging Therapies.","Varghese RT","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","narrative_review","article","10.1016/j.eprac.2026.09.120","42855133",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029276","Digestive lipases as therapeutic targets in obesity: From Orlistat to next-generation inhibitors.","Snini S","2026","Biochimie","narrative_review","article","10.1016/j.biochi.2026.10.012","42855032",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029277","Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study.","Dziewierz A","2026","Advances in medical sciences","nonrandomized_study","article","10.1016/j.advms.2026.10.005","42854961",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0029278","A stewardship framework for incretin-based therapies in weight management.","Pace H","2026","Journal of the American Pharmacists Association : JAPhA","nonrandomized_study","article","10.1016/j.japh.2026.103547","42854871",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0029279","Association between Socioeconomic Deprivation and Clinical Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure.","Qureshi S","2026","The American journal of cardiology","nonrandomized_study","article","10.1016/j.amjcard.2026.10.001","42854804",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Review; article"],["R0029280","Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease.","Gong C","2026","Medicine","nonrandomized_study","article","10.1097/md.0000000000051019","42854065","PMC13657616",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; article"],["R0029281","Idiopathic Intracranial Hypertension, Basic Concepts and Emerging Molecular, Genetic, and Immunological Therapies.","Rawson C","2026","European neurology","narrative_review","article","10.1159/ene/acsag015","42853712",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029282","ESC Guidelines, mechanisms of myocarditis, novel insights into treatment with mineralcorticoid receptor antagonists, cardiac glycosides, and GLP-1 receptor agonists.","Crea F","2026","European heart journal","other","article","10.1093/eurheartj/ehag792","42853674",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029283","A Microsimulation of Eligibility for Cardiorenal Combination Treatment and Potential Deaths Averted.","Nardone M","2026","Journal of the American Society of Nephrology : JASN","other","article","10.1681/asn.0000001287","42853614",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029284","Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.","Rubin R","2026","JAMA","other","article","10.1001/jama.2026.20514","42853576",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029285","Correction: Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia.","Prokopidis K","2026","Advances in therapy","notice","article","10.1007/s12325-026-03813-y","42853534",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0029286","Migraine and Obesity: From Shared Mechanisms to Therapeutic Strategies.","Waliszewska-Prosół M","2026","Neurology and therapy","narrative_review","article","10.1007/s40120-026-01050-7","42853529",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029287","Persistent Hyperinsulinemic Hypoglycemia After Insulinoma Surgery: Diagnostic Impact of GLP-1 Receptor PET/CT After Negative Conventional Imaging.","Taglia L","2026","Case reports in endocrinology","other","article","10.1155/crie/7874466","42852102","PMC13647209",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029288","The PTPN1/N2 Peptide Inhibitor Achieves Potent, Long-Acting Glycemic Control and Weight-Loss Dual Efficacy in Mice.","Shi Y","2026","ACS omega","preclinical","article","10.1021/acsomega.6c05930","42851992","PMC13647951",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029289","Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists.","Rabbani SA","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1902185","42851902","PMC13646783",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; article"],["R0029290","Gut-kidney signaling is impaired in individuals with type 2 diabetes.","Mosterd CM","2026","Clinical kidney journal","randomized_trial","article","10.1093/ckj/sfag315","42851342","PMC13645654",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article"],["R0029291","GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications.","Ueda P","2026","Journal of internal medicine","randomized_trial","article","10.1111/joim.70170","42851139",null,null,null,"pubmed; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Review; article"],["R0029292","Diabetes Medication Market: Costs and Utilization of Glucagon-Like Peptide 1 (GLP-1) Prescriptions From 2008 to 2023.","Mauricio K","2026","Journal of diabetes","commentary","article","10.1111/1753-0407.70278","42851013","PMC13650504",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029293","Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort.","Manueli Laos EG","2026","Clinical obesity","nonrandomized_study","article","10.1111/cob.70116","42850698",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Journal Article; Comparative Study; article"],["R0029294","The impact of semaglutide initiated six months after laparoscopic sleeve gastrectomy on long-term weight loss and metabolic outcomes: single-center preliminary study.","Jeske P","2026","Surgical endoscopy","nonrandomized_study","article","10.1007/s00464-026-13505-x","42850299",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0029295","GLP-1 Receptor Agonist Therapy for Glucocorticoid-Induced Dysglycaemia: A Systematic Review.","Jędrasek A","2026","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.71418","42850058",null,"PROSPERO:CRD420251183082",null,"pubmed; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0029296","β-Cell Mass and Function, Pancreatic Volume, and Fat Differences Between Short- and Long-Duration Type 1 Diabetes: A Detailed PET/CT Imaging Study.","Tokgöz S","2026","Journal of nuclear medicine : official publication, Society of Nuclear Medicine","other","article","10.2967/jnumed.126.272915","42850044",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029297","Contraceptive use and GLP-1 receptor agonists: an intersection of metabolic and reproductive health.","Yee HM","2026","American journal of obstetrics and gynecology","narrative_review","article","10.1016/j.ajog.2026.10.005","42849807",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029298","GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.","Koceva E","2026","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2026.179406","42849689",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029299","Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling.","He Y","2026","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2026.179418","42849688",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029300","Personalising maintenance after tirzepatide weight loss.","van Bruggen FH","2026","Lancet (London, England)","commentary","article","10.1016/s0140-6736(26)01433-9","42849469",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029301","Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?","Holst JJ","2026","Lancet (London, England)","other","article","10.1016/s0140-6736(26)01987-2","42849462",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029302","Long-term injectable non-insulin antidiabetic drug use and in-hospital mortality in sepsis: A nationwide analysis of the 2023 National Inpatient Sample.","Sultanov MB","2026","Journal of critical care","nonrandomized_study","article","10.1016/j.jcrc.2026.155767","42849299",null,null,null,"pubmed","FALSE","free_to_read","4",null,"Letter"],["R0029303","GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Health Care Utilization in Bipolar Disorder With Chronic Kidney Disease.","Singh B","2026","The Journal of clinical psychiatry","nonrandomized_study","article","10.4088/jcp.26m16392","42848524",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0029304","Are GLP-1 Receptor Agonists the Missing Therapy in Vascular Risk Reduction?","Abuhalimeh BJ","2026","JACC. Case reports","other","article","10.1016/j.jaccas.2026.110538","42848360",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029305","Re: Hong et al.: Ocular Outcomes with Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes (Ophthalmol Retina. 2026;10:625-632).","Guang X","2026","Ophthalmology. Retina","commentary","article","10.1016/j.oret.2026.08.021","42848353",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0029306","Exercise, Nutrition and GLP-1 Medicines to Improve Body Weight and Muscle Function in Heart Failure with Preserved Ejection Fraction.","Prokopidis K","2026","Current heart failure reports","narrative_review","article","10.1007/s11897-026-00780-x","42848257","PMC13649888",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029307","The therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation.","Wang Z","2026","Expert review of clinical immunology","narrative_review","article","10.1080/1744666x.2026.2747225","42848200",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029308","GLP-1 receptor agonists in perimenopause and early postmenopause: clinical role, cardiometabolic benefits and knowledge gaps.","Ozcivit Erkan IB","2026","Climacteric : the journal of the International Menopause Society","narrative_review","article","10.1080/13697137.2026.2735765","42847987",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029309","Ischemic colitis associated with oral semaglutide with recurrence upon rechallenge.","Aranda Rojas S","2026","Revista espanola de enfermedades digestivas","other","article","10.17235/reed.2026.12187/2026","42847871",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029310","Incretin Mimetics and Alcohol-Related Outcomes: A Structured Narrative Review.","Goodyear C","2026","Pharmacotherapy","narrative_review","article","10.1002/phar.70206","42847265",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0029311","Beyond the 4 pillars: aldosterone synthase inhibition as a fifth frontier in chronic kidney disease management.","Schlaich MP","2026","American journal of hypertension","randomized_trial","article","10.1093/ajh/hpag090","42847218",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0029312","Effects of a GLP-1 agonist and anti-diabetic therapies on pheochromocytoma/paraganglioma growth.","Wang K","2026","Endocrine-related cancer","other_trial","article","10.1530/erc-26-0283","42847129",null,"ClinicalTrials.gov:NCT03344016",null,"pubmed; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0029313","Knowledge, attitudes, information sources, and use of weight-loss injections among adults in Al-Ahsa, Saudi Arabia: a cross-sectional study.","Alshamrani S","2026","Frontiers in public health","other","article","10.3389/fpubh.2026.1918350","42846319","PMC13642581",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029314","Atypical depression: state of the art and future perspectives.","Ingrosso G","2026","Frontiers in psychiatry","narrative_review","article","10.3389/fpsyt.2026.1928447","42846200","PMC13643597",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029315","BBS10-related Bardet-Biedl syndrome with an atypical presentation of diabetes mellitus: A case report.","Zhang L","2026","Experimental and therapeutic medicine","case_report","article","10.3892/etm.2026.13305","42846192","PMC13643249",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0029316","Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.","Hollis-Hansen K","2026","Obesity science & practice","randomized_trial","article","10.1002/osp4.70194","42846130","PMC13643368",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article"],["R0029317","Beyond body mass index: A contemporary review of obesity and female infertility.","Han J","2026","Clinical and experimental reproductive medicine","narrative_review","article","10.5653/cerm.2026.010048","42844892",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029318","The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment.","Kulkarni NS","2026","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70311","42844829",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029319","Navigating Electroconvulsive Therapy in Patients on GLP-1 Receptor Agonists: Balancing Safety, Compliance, and Treatment Consistency: A Case Report.","Fitzmartin K","2026","The journal of ECT","case_report","article","10.1097/yct.0000000000001340","42844676",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029320","A Multicenter 13-Week Evaluation of the twiist Automated Insulin Delivery in Insulin-Treated Type 2 Diabetes: The twiist-T2D Pivotal Trial.","Levy CJ","2026","Diabetes care","other_trial","article","10.2337/dc26-1270","42844027",null,null,null,"pubmed; openalex","TRUE","paywalled","5","FALSE","Journal Article; other"],["R0029321","Association of GLP1-Receptor Agonist Use With Frailty and Falls in Adults With Type 2 Diabetes.","Zhang S","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71377","42844025",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0029322","The Future of Metabolic and Bariatric Surgery in the Glucagon-Like Peptide-1 Era: Has the Scalpel Become Obsolete?","Wong P","2026","Journal of obesity & metabolic syndrome","narrative_review","article","10.7570/jomes26007","42843854",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029323","More than just adipose. The impact of GLP1Ra on lean tissue.","Julien M","2026","American journal of physiology. Cell physiology","narrative_review","article","10.1152/ajpcell.90062.2026","42843636",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029324","Adverse Oral and Salivary Effects Associated With Glucagon-Like Peptide-1 Receptor Agonists: Clinical Insights.","Gilligan G","2026","Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","nonrandomized_study","article","10.1111/jop.70191","42843413",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0029325","Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study.","Sehtman-Shachar DR","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71402","42842950",null,null,null,"pubmed; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0029326","Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care.","Chu AH","2026","Current cardiology reports","systematic_review","article","10.1007/s11886-026-02431-y","42842171",null,null,null,"pubmed; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; review"],["R0029327","Novel device-based and catheter-directed therapies for heart failure with preserved ejection fraction.","Yamamoto E","2026","Cardiovascular intervention and therapeutics","other_trial","article","10.1007/s12928-026-01353-4","42842133",null,null,null,"pubmed; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Review; article"],["R0029328","GLP-1R expression and dermatological diseases: a mendelian randomization and real-world study.","Duan X","2026","Endocrine","nonrandomized_study","article","10.1007/s12020-026-04808-z","42842067",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0029329","Genetic evidence supports a cortical neuroprotective role of GLP-1 receptor activation in Alzheimer's disease: A drug-target Mendelian randomization study.","Jiang L","2026","Alzheimer's & dementia : the journal of the Alzheimer's Association","other","article","10.1002/alz.71845","42841315","PMC13643831",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029330","GLP-1 and Dual GLP-1/GIP Receptor Agonists in Lipedema: A Promising Therapeutic Option Requiring Rigorous Evaluation.","Litaiem N","2026","International journal of dermatology","commentary","article","10.1111/ijd.70720","42839854",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0029331","Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy.","Sukurica E","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.71422","42839755",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029332","Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial.","Gao L","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71354","42839752",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0029333","Rapid asymmetric cataract progression in patients following GLP-1 receptor agonist therapy: case series.","Eissa M","2026","Eye (London, England)","case_report","article","10.1038/s41433-026-04971-7","42839092",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029334","Temporal trends in GLP-1 receptor agonist and SGLT2 inhibitor dispensing during pregnancy in Manitoba, Canada, 2015-2023.","Peymani P","2026","Obesity research & clinical practice","nonrandomized_study","article","10.1016/j.orcp.2026.10.001","42838854",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0029335","Prevalence, risk factors and renoprotective treatment of chronic kidney disease among internal medicine outpatients at a Central European tertiary care centre: a cross-sectional study.","Zahradka I","2026","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2026-121190","42838586","PMC13647024","ClinicalTrials.gov:NCT07153432",null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; article"],["R0029336","Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).","Cavender MA","2026","American heart journal","randomized_trial","article","10.1016/j.ahj.2026.107626","42838477",null,"ClinicalTrials.gov:NCT05669755","S000149","pubmed; openalex","TRUE","free_to_read","1","FALSE","Journal Article; article"],["R0029337","Parabrachial CGRP neurons mediate incretin-induced aversion and anti-aversion, but not anorexia or weight loss.","Province HS","2026","Molecular metabolism","other","article","10.1016/j.molmet.2026.102453","42838450",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029338","Insights into natural dietary components as indirect modulators of glucagon-like Peptide-1 receptor signaling in weight management.","Ramasinghe C","2026","Clinical nutrition ESPEN","narrative_review","article","10.1016/j.clnesp.2026.105166","42838309",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029339","Building the Business Case for Access to Obesity Treatment.","Kozato A","2026","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70305","42838113",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029340","Why do some patients thrive on GLP-1 therapy while others do not? An ayurvedic perspective on metabolic heterogeneity.","Purighalla U","2026","Explore (New York, N.Y.)","other","article","10.1016/j.explore.2026.103540","42837836",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029341","Incretin Mimetics for Patients Living with Type 2 Diabetes in a Predominantly Hispanic/Latino Population: Analysis of Prescribing Frequency and Predictors of Use.","Villalva CR","2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxag321","42837617",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0029342","Medicaid's GLP-1 Coverage Gap: A Familiar and Correctable Policy Failure.","Ayyappan P","2026","Medical care","other","article","10.1097/mlr.0000000000002382","42837145",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029343","GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials.","Carvalhal G","2026","Sleep & breathing = Schlaf & Atmung","systematic_review","article","10.1007/s11325-026-03826-5","42837024",null,"PROSPERO:CRD42024564018",null,"pubmed; openalex","FALSE","paywalled","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review"],["R0029344","Individualized Treatment Approaches for Obstructive Sleep Apnea in Older Adults: Beyond Continuous Positive Airway Pressure.","Jaganathan N","2026","Advances in geriatric medicine and research","nonrandomized_study","article","10.20900/agmr20260020","42836238","PMC13638223",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0029345","Association Between GLP-1 RECEPTOR Agonist use and Survival in Surgically Treated Patients with Traumatic Brain Injury.","Khor WT","2026","Neurocritical care","other","article","10.1007/s12028-026-02676-z","42834320",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029346","Glucagon-like peptide-1 receptor PET/CT in gastrinomas: a case series demonstrating the precise characterization to guide surgical and medical treatment.","Xu J","2026","EJNMMI reports","case_report","article","10.1186/s41824-026-00320-9","42834300","PMC13638915",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029347","Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial.","Guo L","2026","Nature medicine","randomized_trial","article","10.1038/s41591-026-04713-y","42834229",null,"ClinicalTrials.gov:NCT06589765","S000558","pubmed; openalex","TRUE","open_pdf","1","FALSE","Journal Article; article"],["R0029348","Probing the many benefits of GLP-1 receptor agonists.","Kingwell K","2026","Nature reviews. Drug discovery","commentary","article","10.1038/d41573-026-00161-y","42834104",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","News; article"],["R0029349","Innovative holistic treatment for CKM: what lies ahead?","Balfanz P","2026","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2026.107222","42833987",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029350","Implementation of guideline-directed cardioprotective therapy in patients living with type 2 diabetes in outpatient cardiology ambulatory setting: the Italian CardioMET registry.","Gargiulo P","2026","European journal of internal medicine","nonrandomized_study","article","10.1016/j.ejim.2026.107183","42833986",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0029351","Cardiometabolic benefits after adrenalectomy for mild autonomous cortisol secretion.","Korman A","2026","Surgery","nonrandomized_study","article","10.1016/j.surg.2026.110600","42833940",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0029352","New insights into the pathogenesis of osteoporosis and the translational approach to personalized therapy.","Li B","2026","Best practice & research. Clinical rheumatology","narrative_review","article","10.1016/j.berh.2026.102208","42833929",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029353","Bidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries.","Liu C","2026","Peptides","nonrandomized_study","article","10.1016/j.peptides.2026.171524","42833423",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0029354","Biologic Injection-Related Pain in Severe Asthma, Its Impact on Treatment Aversion, and Pain-Relief Approach: A Multicenter Observational Study.","Matsumoto T","2026","The journal of allergy and clinical immunology. In practice","other","article","10.1016/j.jaip.2026.09.023","42833304",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029355","The Autophagy-Epigenome Axis in Hypothalamic Neurons: A Unified Framework for Understanding Obesity Persistence and Therapeutic Resistance.","Soliman AR","2026","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","other","article","10.1055/a-2961-3522","42833273",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029356","Annals On Call - Tirzepatide Versus Intensified Conventional Care for Poorly Controlled Type 2 Diabetes.","Centor RM","2026","Annals of internal medicine","other","article","10.7326/annals-26-03906-oc","42832795",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029357","In brief: A cardiovascular indication for tirzepatide (Mounjaro).",null,"2026","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2026.1765b","42832390",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029358","Metabolic and Bariatric Surgery and GLP-1 Receptor Agonist Use Among Adolescents.","Rode JB","2026","JAMA pediatrics","other","article","10.1001/jamapediatrics.2026.4584","42832242","PMC13639807",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029359","Practical Considerations for the Use of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity: A Clinician-Oriented Guide.","Alp GT","2026","Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","other","article","10.5543/tkda.2026.41542","42832185",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029360","Real-World Adherence Patterns and Predictors of GLP-1 Receptor Agonist Use for Obesity Management in a Medicaid Population.","Bazzazzadehgan S","2026","Advances in therapy","nonrandomized_study","article","10.1007/s12325-026-03806-x","42831955",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0029361","[Two trials, one result: oral semaglutide does not slow cognitive decline in early Alzheimer disease.].","Kurotschka PK","2026","Recenti progressi in medicina","other","article","10.1701/4781.48070","42831714",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029362","Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic program.","Patel A","2026","American journal of preventive cardiology","other","article","10.1016/j.ajpc.2026.101699","42828252","PMC13632018",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029363","Comment on \"Precision-guided heart failure interventions: The expanding role of advanced cardiac imaging and artificial intelligence\".","Selvapriya B","2026","American heart journal plus : cardiology research and practice","commentary","article","10.1016/j.ahjo.2026.100894","42827671","PMC13631525",null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029364","The Changing Landscape of Metabolic and Bariatric Surgery: Aligning Access With the Clinical Obesity Framework.","Papadia FS","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","other","article","10.1111/obr.70240","42827283",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029365","Weight Loss Measurements Under the Microscope: How Type and Baseline Definition Shape Clinical Response After Metabolic-Bariatric Surgery - A 2-Year Follow-up Analysis of 17,568 Patients.","Fink M","2026","Obesity surgery","nonrandomized_study","article","10.1007/s11695-026-08929-2","42821214",null,null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article"],["R0029366","GLP-1-based therapy and early response to advanced treatment in atopic dermatitis with obesity.","Paolino G","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","commentary","article","10.1111/jdv.70781","42813691",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029367","Bariatric Surgery, Medical Weight Loss, and the Upper Aerodigestive Tract.","Samreen S","2026","Otolaryngologic clinics of North America","narrative_review","article","10.1016/j.otc.2026.08.001","42810933",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029368","Creatine for glucagon-like peptide-1-associated muscle loss.","Ostojic SM","2026","Clinical nutrition (Edinburgh, Scotland)","randomized_trial","article","10.1016/j.clnu.2026.106805","42800365",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0029369","Intrapancreatic Fat and Risk of Pancreatic Ductal Adenocarcinoma-Pathophysiology, Clinical Implications, and Future Directions.","Meyhöfer S","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27187991","42794420","PMC13606341",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029370","Beyond Prescribing: GLP-1 Care and Obesity Prevention in Primary Care.","Jerjes W","2026","Journal of primary care & community health","randomized_trial","article","10.1177/21501319261494129","42789525",null,null,null,"pubmed; openalex","TRUE","free_to_read","2","FALSE","Journal Article; article"],["R0029371","Weight management in cardiology practice: challenges and opportunities.","Leening MJG","2026","Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation","narrative_review","article","10.1007/s12471-026-02075-1","42771123","PMC13615267",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029372","Parkinson's disease-Crucial advances and on-going challenges.","Söderbom G","2026","International review of neurobiology","nonrandomized_study","article","10.1016/bs.irn.2026.08.019","42767720",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0029373","Applicability of Non-Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study.","Pugliese N","2026","Liver international : official journal of the International Association for the Study of the Liver","nonrandomized_study","article","10.1111/liv.70882","42764643",null,null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Multicenter Study; Observational Study"],["R0029374","Plain language review: non-invasive screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) in primary care.","Kugelmas M","2026","Postgraduate medicine","narrative_review","article","10.1080/00325481.2026.2724170","42757508",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029375","The Incretin Mirage: Epigenetic Memory as a Potential Driver of Post-Treatment Weight Regain.","Kubant R","2026","Advances in nutrition (Bethesda, Md.)","other","article","10.1016/j.advnut.2026.100737","42754096",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029376","Severe Thrombocytopenia Associated With Glucagon-Like-1 Receptor Agonists (GPL-1RA): A SONAR Report.","Bennett CL","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71274","42750053",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029377","Nutrition Care and Dietetic Practice in Managing Metabolic and Endocrine Dysfunction in Polyendocrine Metabolic Ovarian Syndrome (PMOS): Implications and Opportunities in the Context of the Name Change of Polycystic Ovarian Syndrome to PMOS.","Vine D","2026","Advances in nutrition (Bethesda, Md.)","other","article","10.1016/j.advnut.2026.100734","42749129",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029378","Correction: Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction.","Ming Q","2026","Frontiers in nutrition","notice","article","10.3389/fnut.2026.1970493","42746432","PMC13576144",null,null,"pubmed","FALSE",null,null,null,"Published Erratum"],["R0029379","Association of GLP-1-based therapy with asthma-related outcomes in patients with obesity: a propensity-matched retrospective cohort study.","McCraw CD","2026","Expert review of respiratory medicine","nonrandomized_study","article","10.1080/17476348.2026.2730537","42733229",null,null,null,"pubmed; europepmc; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0029380","The GLP-1 Era: Rethinking Optimization and Risk in Spine Surgery.","Robertson FC","2026","Spine","other","article","10.1097/brs.0000000000005862","42721370",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029381","Weight Loss without Food Intake Suppression through Size-Dependent Retention of Anti-Inflammatory Nanomedicines.","Medina NG","2026","ACS nano","preclinical","article","10.1021/acsnano.6c00432","42708907",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029382","Uncovering the Metabolic Origins of Polycystic Ovary Syndrome.","Iyer PJ","2026","Cureus","narrative_review","article","10.7759/cureus.114165","42708062","PMC13549205",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029383","From explainability to clinical actionability: translating artificial intelligence models into decision support for endocrine disease management.","Wu T","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1887643","42699131","PMC13542687",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029384","Extracellular vesicles for liquid biopsy in major depressive disorder: Human evidence and clinical translation.","Jin W","2026","iScience","narrative_review","article","10.1016/j.isci.2026.117224","42699006","PMC13542510",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029385","Prediabetes: Impact on cardiovascular risk and emerging therapeutic strategies.","Biondi F","2026","Atherosclerosis","randomized_trial","article","10.1016/j.atherosclerosis.2026.121898","42696840",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0029386","Metabolic dysfunction and insulin resistance in depression: mechanisms, evidence, and therapeutic implications.","Palacek K","2026","Frontiers in psychiatry","narrative_review","article","10.3389/fpsyt.2026.1930167","42694803","PMC13539724",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029387","A causal effect of increased GLP1R expression on male-pattern hair loss is suggested by 2-sample Mendelian randomization.","Ramessur R","2026","The Journal of investigative dermatology","other","article","10.1016/j.jid.2026.07.024","42692190",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029388","Trends in GLP-1-Based Therapy Use Before and After Pregnancy.","Boghossian NS","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71301","42681852",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029389","Dietary Soybean vs. Palm Oils Differ in Effects on Liver Fat in Adults With MAFLD: A 16-Week, Double-Masked, Randomized Controlled Trial.","Belury MA","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71237","42677730","PMC13646368","ClinicalTrials.gov:NCT05199948",null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Randomized Controlled Trial; Comparative Study"],["R0029390","Single-nuclei RNA sequencing reveals obesity-associated rewiring of estrogen signaling in endometrioid adenocarcinoma.","Long JL","2026","iScience","other","article","10.1016/j.isci.2026.117226","42668615","PMC13524751",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029391","Pathogenesis and management of idiopathic intracranial hypertension: A narrative review.","Liu Y","2026","Brain circulation","narrative_review","article","10.4103/bc.bc_13_25","42666867","PMC13524410",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029392","De-Nterm-ining GLP1R signaling bias.","Broichhagen J","2026","Trends in pharmacological sciences","other","article","10.1016/j.tips.2026.08.002","42660721",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029393","Highlights from JAAD Case Reports: November 2026.","Mervak JE","2026","Journal of the American Academy of Dermatology","case_report","article","10.1016/j.jaad.2026.08.088","42660436",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029394","A Practical Perspective on Confronting the Obesity Epidemic: Public-Health Strategies.","Owczarczyk-Durma AC","2026","Nutrients","nonrandomized_study","article","10.3390/nu18162602","42654182","PMC13517068",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0029395","From Guidelines to Clinical Practice: Expert Perspectives on Long-Term Management of Obesity.","Chen H","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70263","42644855","PMC13511285",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Review"],["R0029396","Great Strides…Now It's Time to Run.","Bonaca MP","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.07.017","42644551",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029397","Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study.","Li J","2026","Cardiovascular diabetology","other","article","10.1186/s12933-026-03304-y","42642762","PMC13504813",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029398","Early combination therapy in type 2 diabetes: Rethinking initial treatment strategies.","Janez A","2026","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2026.109392","42641257",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029399","Selecting between pharmacotherapy and bariatric surgery in East Asia.","Keidai Y","2026","Journal of diabetes investigation","other","article","10.1111/jdi.70428","42635468","PMC13502144",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029400","Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond.","Almahmeed W","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","nonrandomized_study","article","10.1111/obr.70204","42634097",null,null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0029401","Native Mass Spectrometry of Soluble Proteins with Sodium Chloride Enabled by a Dendritic Detergent.","Fiorentino F","2026","ACS measurement science au","other","article","10.1021/acsmeasuresciau.6c00038","42631177","PMC13495734",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029402","Obesity and Upper Aerodigestive Dysfunction: Voice, Swallowing, Reflux, and Airway Considerations in Laryngology.","Ali S","2026","Otolaryngologic clinics of North America","narrative_review","article","10.1016/j.otc.2026.07.002","42629209",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029403","GLP-1 and GLP-1/GIP agonists in psoriasis: A real-world cohort study on healthcare resource usage.","Hill MA","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","nonrandomized_study","article","10.1111/jdv.70678","42627149",null,null,null,"pubmed","FALSE","paywalled","4",null,"Letter"],["R0029404","Glucagon-like peptide-1-based therapies and the intersection of metabolic and skin disease.","Ormaza-Vera A","2026","JAAD case reports","commentary","article","10.1016/j.jdcr.2026.07.008","42620743","PMC13486975",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029405","Weight loss for obstructive sleep apnoea: first-line therapy should not mean single-line therapy.","Yin Z","2026","European respiratory review : an official journal of the European Respiratory Society","commentary","article","10.1183/16000617.0169-2026","42613078","PMC13482737",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029406","Beyond Small Molecules: Applying Fragment Molecular Orbital Sygnature Platform (FMO-SP) to Emerging Modalities.","Heifetz A","2026","Methods in molecular biology (Clifton, N.J.)","other","article","10.1007/978-1-0716-5420-0_6","42604899",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029407","Is incretin therapy the missing link to silencing residual inflammation in biologic-treated psoriasis?","Merzel Šabović EK","2026","Expert opinion on biological therapy","commentary","article","10.1080/14712598.2026.2718852","42584107",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029408","Reframing GLP-1 Therapies as Cardiometabolic Health Drugs: Beyond the Race to Weight Loss.","Krumholz HM","2026","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2026.06.039","42583988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0029409","Pharmacologic management of metabolic and alcohol-associated liver disease.","Pagadala M","2026","Metabolism and target organ damage","other","article","10.20517/mtod.2026.29","42577825","PMC13455180",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029410","Introduction to virtual special issue on glucagon-like peptide-1 agonists and the skin.","Levin NA","2026","JAAD case reports","commentary","article","10.1016/j.jdcr.2026.07.005","42571454","PMC13452328",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; editorial"],["R0029411","Weight-loss-independent actions of GLP-1 medicines.","Gonzalez-Rellan MJ","2026","Cell metabolism","other","article","10.1016/j.cmet.2026.07.006","42551415",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029412","Mitochondrial dysfunction and lipid droplet dynamics in MASH: HSD17B13 as a therapeutic target.","Noor S","2026","Frontiers in cell and developmental biology","narrative_review","article","10.3389/fcell.2026.1912237","42559078","PMC13438457",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029413","Targeting kidney disease in type 1 diabetes: progress and promise.","Muskiet MHA","2026","Expert review of endocrinology & metabolism","other_trial","article","10.1080/17446651.2026.2714265","42557690",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0029414","Beyond weight loss: toward an immunometabolic treatment paradigm in psoriatic arthritis.","Kılıç G","2026","Rheumatology international","commentary","article","10.1007/s00296-026-06263-5","42550253",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029415","Cockcroft-Gault in Contemporary Clinical Trials: Legacy, Limitations, and a Pragmatic Path Forward.","Granata A","2026","Journal of the American Society of Nephrology : JASN","other","article","10.1681/asn.0000001233","42536434",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029416","SURPASS-CVOT and the Emerging Biology of Cardiometabolic Benefit.","Corrao S","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.71175","42530340","PMC13538732",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029417","Expectations and Experiences: What People with Type 1 Diabetes Really Want from Adjunctive Therapies.","Heverly JK","2026","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2026.04.011","42527004",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029418","Current State of Cardiorenal Disease in People with Type 1 Diabetes.","Fernandes S","2026","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2026.04.004","42526997",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029419","Challenges implementing treatment guidelines in electronic health records: the American Diabetes Association Standards of Care as a case example.","Demarie I","2026","JAMIA open","nonrandomized_study","article","10.1093/jamiaopen/ooag141","42519594","PMC13384065",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article"],["R0029420","Diagnostic Yield of Structured Cushing Syndrome Evaluation in Treatment-Resistant Non-Diabetic Obesity: A Retrospective Pilot Study.","Eisa N","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71161","42503493",null,null,null,"pubmed","FALSE","paywalled","4",null,"Letter"],["R0029421","Glucagon-Like Peptide-Based Therapy and Limb Outcomes in Patients With Peripheral Artery Disease and Diabetes: A Large-Scale Real-World Study.","Oletu H","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.105399","42502338","PMC13400109",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article"],["R0029422","The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.","Noureddin M","2026","The lancet. Gastroenterology & hepatology","randomized_trial","article","10.1016/s2468-1253(26)00130-5","42480572",null,"ClinicalTrials.gov:NCT06410924","S003320","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; article"],["R0029423","Wound healing pharmacotherapies: what can we expect for 2026?","Mueller SM","2026","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2026.2706077","42474110",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029424","Causal association between antidiabetic drug targets and risk of Bell's palsy: A 2-sample Mendelian randomization study.","Lu K","2026","Medicine","other","article","10.1097/md.0000000000049559","42470027","PMC13384540",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029425","Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - an overview of current clinical practice and future perspectives.","Milardović TM","2026","Expert review of clinical pharmacology","nonrandomized_study","article","10.1080/17512433.2026.2706660","42467408",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0029426","GLP-1-Based Therapy for Obstructive Sleep Apnoea.","Zheng Y","2026","Respirology (Carlton, Vic.)","commentary","article","10.1002/resp.70282","42458816","PMC13535727",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0029427","Characterization of Antidiabetic Medication Prescribing After Hospital Discharge in US Critically Ill Adults.","Wu TT","2026","The Annals of pharmacotherapy","nonrandomized_study","article","10.1177/10600280261455748","42438358",null,null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article"],["R0029428","American Academy of Dermatology 2026 Annual Meeting: Updates in Hidradenitis Suppurativa Medical Management.","Kherallah K","2026","Dermatology and therapy","narrative_review","article","10.1007/s13555-026-01849-0","42423909","PMC13558521",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029429","Beyond the Individual: Family-Level Impacts of Caregiver GLP-1 Use on Food Environments and Child Health Behaviors.","Granados I","2026","Childhood obesity (Print)","other","article","10.1177/21532176261467610","42421417",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029430","More Evidence, More Options, More Questions.","Heerspink HJL","2026","Journal of the American Society of Nephrology : JASN","other","article","10.1681/asn.0000001199","42418276",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029431","GLP-1 and MASH: When weight loss isn't the whole story.","Long MT","2026","Cell metabolism","other","article","10.1016/j.cmet.2026.06.005","42413474",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029432","Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.","Seijas-Amigo J","2026","European heart journal open","nonrandomized_study","article","10.1093/ehjopen/oeag101","42404143","PMC13329405",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0029433","Letter to the Editor \"Constructive Critique on CKM Implementation: Focusing on Non-Pharmacological Burden and Staging Utility\" regarding: \"Implementation Barriers to Evidence-Based Cardiovascular-Kidney-Metabolic Syndrome Management\" by Davis et al. Heart Lung Circ. 2025;34:1060-1068.","Aphale P","2026","Heart, lung & circulation","commentary","article","10.1016/j.hlc.2025.11.009","42392648",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029434","Weight loss, exercise haemodynamics, and health status with incretin therapy for heart failure with preserved ejection fraction and obesity.","Pandey A","2026","European heart journal","other","article","10.1093/eurheartj/ehag483","42366808",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029435","Molecular Basis of Synergistic Causal Effect of Dual GLP-1R and GIPR Agonists for Risk Reduction in Diabetic Retinopathy, Alzheimer Disease, and Coronary Artery Disease in Diabetic Patients.","Xu J","2026","Genes","other","article","10.3390/genes17060602","42353761","PMC13298441",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0029436","A two-timepoint framework for sensitive and specific single-cell activity screening.","Ramirez A","2026","Neuron","other","article","10.1016/j.neuron.2026.05.026","42349406","PMC13334391",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029437","What's new in heart failure? June 2026.","Markwirth P","2026","European journal of heart failure","other","article","10.1093/ejhf/xuag204","42343586",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029438","Surgery is no longer the only effective treatment for obesity: What does this mean?","Brunaud L","2026","Journal of visceral surgery","commentary","article","10.1016/j.jviscsurg.2026.06.004","42342545",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029439","The Pharmacological Window Hypothesis: How Emerging Obesity Medications May Realize Decades of Plant-Forward Dietary Recommendations.","Bergia RE","2026","Advances in nutrition (Bethesda, Md.)","narrative_review","article","10.1016/j.advnut.2026.100689","42320798","PMC13383861",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029440","Interruption of Early Cardiovascular Risk Pathways With GLP-1-Based Therapy for Obesity.","Everett BM","2026","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2026.05.011","42307498",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0029441","Hypertension at an Inflection Point: Aggressive Targets Meet Novel Mechanisms for Cardiovascular Prevention.","Agarwal R","2026","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2026.05.005","42307497",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029442","Heart Failure with Preserved Ejection Fraction as a Multisystem Syndrome: A Mechanistically Anchored Endotype Framework for Precision Therapy.","Krasińska B","2026","Journal of clinical medicine","other_trial","article","10.3390/jcm15114159","42279020","PMC13257889",null,null,"pubmed","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0029443","Letter: Beyond Feasibility-The Need for Longer Duration and Composite NIT Endpoints in Biopsy-Free MASH Trials: Authors' Reply.","Ajmera V","2026","Alimentary pharmacology & therapeutics","commentary","article","10.1111/apt.70782","42267708",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029444","Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches.","Moltrasio C","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1827227","42266681","PMC13243088",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029445","Italy passes obesity law: an opportunity to prevent cardiovascular disease across Europe.","Malavazos AE","2026","European heart journal. Quality of care & clinical outcomes","other","article","10.1093/ehjqcco/qcag094","42261109",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029446","Barofeedback.","Kalra S","2026","JPMA. The Journal of the Pakistan Medical Association","narrative_review","article","10.47391/jpma.-26-37","42261035",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029447","Effects of the glucagon-like peptide-1 and glucagon receptor dual agonists on glycemic markers: A systematic review and meta-analysis of randomized controlled trials.","Simental-Mendía LE","2026","Journal of investigative medicine : the official publication of the American Federation for Clinical Research","systematic_review","article","10.1177/10815589261460894","42257390",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Review; review"],["R0029449","Gucagon-like peptide-1 receptor agonists and pulmonary aspiration: stratify physiology, not prescriptions.","Szarpak L","2026","British journal of anaesthesia","commentary","article","10.1016/j.bja.2026.04.060","42242976",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029450","The GLP-1 Ceiling and GIP Dividend: Unraveling the Cardio-Metabolic Paradox in SURPASS-CVOT.","Sun Y","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.5136","42233555",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029451","FLOWing Toward Holistic Care: Heart-Kidney-Metabolic Health Re-Imagined.","Rangaswami J","2026","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2026.03.031","42233553",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029452","Obesity and Outcomes in Heart Failure: Revisiting the Obesity Paradox?","Ozkan B","2026","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2026.04.001","42233551",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029453","What Observational Research Contributes and What It Requires: The Devil Is in the Design.","Curtis LH","2026","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2026.03.079","42233550",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029454","Affordable GLP-1? When Digital Platforms Meet Policy Reform.","Zhan XJ","2026","Journal of medical Internet research","other","article","10.2196/102069","42224006","PMC13224918",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029455","Role of Physical Activity in Obesity Treatment and Cardiometabolic Health: A Scientific Statement From the American Heart Association.","Swift DL","2026","Circulation","narrative_review","article","10.1161/cir.0000000000001441","42220241","PMC13456082",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029456","From Induction to Maintenance? Rethinking GLP-1-Based Obesity Pharmacotherapy in the Era of Oral Agents.","Kamrul-Hasan ABM","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70922","42219272","PMC13341377",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029457","On the use of UDCA beyond cholestatic liver disease: How bile acid-driven intestinal GLP-1 signalling keeps the joints healthy.","Trampert DC","2026","Journal of hepatology","other","article","10.1016/j.jhep.2026.05.008","42209341",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029458","After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.","Zucker A","2026","Journal of medical Internet research","commentary","article","10.2196/101874","42206886","PMC13217571",null,null,"pubmed","FALSE",null,null,null,"News"],["R0029459","The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction.","Lee RSM","2026","Medicina (Kaunas, Lithuania)","narrative_review","article","10.3390/medicina62050870","42195123","PMC13208374",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029460","Retinal Outcomes in Diabetes: Antihyperglycemic Therapy, EWDR, and Perioperative Considerations.","Wang T","2026","Biomedicines","narrative_review","article","10.3390/biomedicines14050963","42193290","PMC13203953",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029461","Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type 2 Diabetes Mellitus and CKD.","Tanaka A","2026","Kidney international reports","randomized_trial","article","10.1016/j.ekir.2026.106546","42180819","PMC13195771",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article"],["R0029462","Opinion: a call for safe therapeutic and gastric interventions for adolescents and young adults with obesity and transplant-indicated leukemia.","Garcia MB","2026","Frontiers in oncology","preclinical","article","10.3389/fonc.2026.1813561","42180052","PMC13189877",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029463","Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists.","Sürmeli D","2026","Journal of medicinal chemistry","other","article","10.1021/acs.jmedchem.6c00745","42152230",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029464","Trends in Metabolic Bariatric Surgery Utilization in the Era of GLP-1s, 2022-2024.","Calzaretta RJ","2026","JAMA surgery","other","article","10.1001/jamasurg.2026.1343","42126850","PMC13173417",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029465","Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.","Renke G","2026","International journal of molecular sciences","randomized_trial","article","10.3390/ijms27093890","42123471","PMC13164565",null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Review"],["R0029466","Management of salt-sensitive hypertension in clinical settings: how should we approach it?","Todua I","2026","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2026.05.003","42103091",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029467","Harnessing PPAR pharmacology through dual incretin-directed delivery.","Petersen J","2026","Cell metabolism","commentary","article","10.1016/j.cmet.2026.04.009","42102815",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0029468","Type 2 Diabetes and the Lung - Cause and Consequence.","Foer D","2026","Current diabetes reports","randomized_trial","article","10.1007/s11892-026-01625-6","42095998",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0029469","Heart Failure in Type 1 vs. Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges.","Hussain MS","2026","Journal of diabetes research","narrative_review","article","10.1155/jdr/7460084","42076811","PMC13136521",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029470","Type 2 Diabetes and the Glucagon Renaissance: Restoring Bihormonal Equilibrium.","Arredouani A","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70826","42070791",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029471","BRASH syndrome: new mechanistic insights from contemporary cardiometabolic therapies.","Granata LG","2026","Journal of cardiovascular medicine (Hagerstown, Md.)","other","article","10.2459/jcm.0000000000001859","42065948",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029472","Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics.","Anderer S","2026","JAMA","other","article","10.1001/jama.2026.6177","42065899",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029473","Noninsulin Medications for Type 2 Diabetes.","Castro-Revoredo I","2026","The Medical clinics of North America","narrative_review","article","10.1016/j.mcna.2025.12.006","42036156",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029474","Medical Students and Clinicians' Perceptions of Social Media Direct-to-Consumer Advertising and Medication Requests.","Willis E","2026","JMIR formative research","other","article","10.2196/91024","42024852","PMC13105398",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029475","Barovariability.","Kalra S","2026","JPMA. The Journal of the Pakistan Medical Association","narrative_review","article","10.47391/jpma.26-20","42017734",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029476","Metabolic advances in 2025: from clinical breakthroughs to molecular reprogramming.","Dalamaga M","2026","Metabolism open","commentary","article","10.1016/j.metop.2026.100442","42005042","PMC13083644",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029477","Selected 2025 Highlights in Congenital Cardiac Anesthesia.","Patel M","2026","Journal of cardiothoracic and vascular anesthesia","nonrandomized_study","article","10.1053/j.jvca.2026.03.037","42002501",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029478","Cardiovascular Prevention at the Crossroads.","Farkouh ME","2026","European journal of preventive cardiology","commentary","article","10.1093/eurjpc/zwag222","41996582",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0029479","New Opportunities Beyond Intensive Insulin Therapy for Improving Vascular Health of People Living With Type 1 Diabetes.","Popovic DS","2026","Endocrinology, diabetes & metabolism","randomized_trial","article","10.1002/edm2.70226","41996281","PMC13089633",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Editorial; article"],["R0029480","The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis.","Alamgir M","2026","Hepatobiliary surgery and nutrition","commentary","article","10.21037/hbsn-2025-732","41983226","PMC13071624",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0029481","Assessment of knowledge, attitude, and practices towards the usage of antidiabetic drugs for weight loss among Lebanese population.","Kreidieh D","2026","BMC public health","other","article","10.1186/s12889-026-27162-1","41975362","PMC13195953",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029482","Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes.","Conte C","2026","Current diabetes reports","narrative_review","article","10.1007/s11892-026-01626-5","41973192",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029483","Biased agonists for the treatment of type 2 diabetes and obesity: a novel pharmacological paradigm edging closer to clinical reality?","Hashem IE","2026","Journal of drug targeting","other","article","10.1080/1061186x.2026.2656880","41964324",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029484","PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC.","Abbasi J","2026","JAMA","other","article","10.1001/jama.2026.2399","41961515",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029485","Response to Cestari et al.","Stark JE","2026","American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists","nonrandomized_study","article","10.1093/ajhp/zxag079","41955518",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Editorial; Comment; article"],["R0029486","Embracing Highly Effective Obesity Therapies to Improve Cancer Treatment and Survivorship.","Howard R","2026","JAMA oncology","other","article","10.1001/jamaoncol.2026.0260","41954902",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029487","Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives.","Lisco G","2026","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-026-10033-w","41954678","PMC13388822",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029488","Obesity and Heart Failure With Reduced Ejection Fraction: A Review.","Khan MS","2026","Journal of the American College of Cardiology","narrative_review","article","10.1016/j.jacc.2026.02.5083","41949514",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029489","Is Placebo Still Ethical in Trials of Incretin Therapies?","Neuen BL","2026","Circulation","other","article","10.1161/circulationaha.125.077277","41941546",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029490","Flip the fuel, and the heat is on! Carnitine synthesis as a physiological mediator of fuel adaptation.","Hathiramani NR","2026","Trends in endocrinology and metabolism: TEM","commentary","article","10.1016/j.tem.2026.03.007","41933958","PMC13091551",null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029491","Obesity Pharmacotherapy: An Urgent Need for Progressing Science, Access, and Equity-JACC: Advances Expert Panel.","Gouda P","2026","JACC. Advances","randomized_trial","article","10.1016/j.jacadv.2026.102713","41931082","PMC13221856",null,null,"pubmed","FALSE","free_to_read","2",null,"Journal Article; Review"],["R0029492","Reprogramming the mitochondrial-circadian energy code with incretins.","Nisoli E","2026","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2026.02.011","41925391",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029493","The pharmacological management of obesity in Prader-Willi syndrome: what does the future hold?","Grugni G","2026","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2026.2655969","41925226",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029494","Peripheral Eosinophilia in a Patient With Subacute Watery Diarrhea.","Roldan GA","2026","Gastroenterology","other","article","10.1053/j.gastro.2026.03.015","41921822",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029495","Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH).","Grocic M","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70662","41917764","PMC13094682",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029496","Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy.","Pipella J","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70711","41913320","PMC13146113",null,null,"pubmed","FALSE","free_to_read","5",null,"Journal Article; Review"],["R0029497","Fatty acid regulation of feeding in Caenorhabditis elegans reveals the potential ancestral origin of a GLP-1-like multiagonist signaling system.","Zhu F","2026","Proceedings of the National Academy of Sciences of the United States of America","preclinical","article","10.1073/pnas.2530979123","41911448","PMC13056082",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029498","Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness.","Nadkarni A","2026","Current opinion in critical care","narrative_review","article","10.1097/mcc.0000000000001376","41903227",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029499","Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.","Nicze M","2026","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms27062539","41898403","PMC13026205",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Review"],["R0029500","A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity.","Lee AH","2026","Healthcare (Basel, Switzerland)","narrative_review","article","10.3390/healthcare14060734","41897188","PMC13026324",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0029501","Obesity and Heart Failure With Preserved Ejection Fraction: A Clinical Nexus for Exercise Intolerance.","Pandit A","2026","Obesity (Silver Spring, Md.)","narrative_review","article","10.1002/oby.70162","41888476",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029502","Incretin polyagonists as an alternative to bariatric surgery to manage obesity.","Manoj RJ","2026","World journal of gastrointestinal pathophysiology","narrative_review","article","10.4291/wjgp.v17.i1.118132","41884205","PMC13010809",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029503","Clinical review: Menopause hormone therapy in weight management.","Younglove C","2026","Obesity pillars","randomized_trial","article","10.1016/j.obpill.2026.100258","41883510","PMC13010941",null,null,"pubmed","FALSE","free_to_read","2",null,"Journal Article; Review"],["R0029504","Unveiling the Activation Mechanism of Glucagon-Like Peptide-1 Receptor by an Ago-Allosteric Modulator via Molecular Dynamics Simulations.","Chen Y","2026","Journal of chemical information and modeling","other","article","10.1021/acs.jcim.6c00224","41879197",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029505","The need for clinical studies assessing whether weight loss improves functional outcome after stroke in diabetes.","Vercalsteren E","2026","BMC medicine","narrative_review","article","10.1186/s12916-026-04809-9","41877181","PMC13064103",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029506","From Glycemic Control to Weight-Centered Therapy: A Paradigm Shift in Type 2 Diabetes and Its Public Health Promise.","Sar Y","2026","International journal of public health","nonrandomized_study","article","10.3389/ijph.2026.1608891","41867351","PMC13002506",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Editorial; article"],["R0029507","Osteoarthritis and cardiometabolic diseases: shared mechanisms, modifiable risk factors, and integrated management strategies.","Chan PY","2026","Expert review of clinical pharmacology","narrative_review","article","10.1080/17512433.2026.2649611","41857742",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029508","Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies.","Alhazmi A","2026","Frontiers in endocrinology","randomized_trial","article","10.3389/fendo.2026.1788698","41852477","PMC12992036",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article"],["R0029509","GLP-1-derived therapies and risk of sarcopenia: myth or reality?","Scheen AJ","2026","Expert opinion on drug safety","narrative_review","article","10.1080/14740338.2026.2640980","41851969",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029510","Do GLP1-receptor agonists actually cause non-arteritic anterior ischemic optic neuropathy?","Finsterer J","2026","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2026.101753","41839257",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0029511","Lipedema and Dynapenia: Inflammatory Myosteatosis as a Mechanistic Link Between Tissue Expansion and Muscle Dysfunction.","Viana DPDC","2026","International journal of molecular sciences","narrative_review","article","10.3390/ijms27052319","41828544","PMC12985791",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029512","Genetic evidence for GLP1R agonists in non-ischaemic heart failure.","Le NN","2026","ESC heart failure","other_trial","article","10.1093/eschf/xvag077","41825483","PMC13043000",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; brief-report; article"],["R0029513","Management of subjects with type 2 diabetes hospitalized in internal medicine units: a cluster-randomized, multicenter study before and after an educational program.","Ceriello A","2026","Internal and emergency medicine","randomized_trial","article","10.1007/s11739-025-04238-1","41824238","PMC13144241","ClinicalTrials.gov:NCT04589533",null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Multicenter Study; Randomized Controlled Trial"],["R0029514","ARPA-H bets big to foster drugs that thwart aging.","Leslie M","2026","Science (New York, N.Y.)","commentary","article","10.1126/science.aeh1092","41818356",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0029515","Management of obesity in advanced chronic liver disease.","Caussy C","2026","JHEP reports : innovation in hepatology","narrative_review","article","10.1016/j.jhepr.2026.101749","41810426","PMC12969633",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029516","Trends and projections of overweight and obesity among midlife women in the United States, 1990-2050: A sub‑study of the Global Burden of Disease 2021.","Bhagavathula AS","2026","Women's health (London, England)","other","article","10.1177/17455057261430197","41805450","PMC12979888",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029517","Rethinking Muscle Health Assessment in GLP-1-Based Therapies for Obesity: Beyond Lean Mass.","Jensterle M","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70649","41804837",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029518","Association Between Off-Label Use of Cardio-Kidney-Metabolic Therapies and Risk of Cardiovascular Events in Type 1 Diabetes: A Real-World Evidence Study.","Pandey A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.70597","41804205",null,null,null,"pubmed","FALSE","paywalled","4",null,"Letter"],["R0029519","Sugar addiction at the crossroads of reward, metabolism, and culture.","Skryabin V","2026","Behavioural brain research","preclinical","article","10.1016/j.bbr.2026.116147","41794143",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029520","Correction.",null,"2026","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2026.1750f","41793387",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029521","Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities.","Evans PC","2026","European heart journal","other","article","10.1093/eurheartj/ehag116","41790457",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029522","Beyond superiority: preserved cardiovascular efficacy and emerging signals in SURPASS-CVOT.","Corrao S","2026","Acta diabetologica","commentary","article","10.1007/s00592-026-02673-w","41779170",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029523","The Role of Glucagon-like Peptide-1 in the Pathophysiology of Heart Failure: A Special Focus.","Rakisheva A","2026","Cardiac failure review","commentary","article","10.15420/cfr.2025.55","41768344","PMC12937072",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029524","Cardio-renal-metabolic syndrome: A concept in question, a clinical impact beyond doubt.","Koufakis T","2026","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.70282","41757422",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029525","Single vs. Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review.","Reytor-González C","2026","Nutrients","narrative_review","article","10.3390/nu18040553","41754068","PMC12943231",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Comparative Study; review-article; article"],["R0029526","Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments.","Pryke L","2026","Current HIV/AIDS reports","narrative_review","article","10.1007/s11904-026-00776-1","41733834","PMC12932276",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029527","Update in clinical science: MASLD in children and adolescents.","Lefere S","2026","Journal of hepatology","narrative_review","article","10.1016/j.jhep.2026.02.016","41730387",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029528","The Metabolic Dysfunction-Associated Steatotic Liver Disease-CKD Axis: Intersecting Pathways and Opportunities for Early Intervention.","Sriperumbuduri S","2026","Kidney international reports","narrative_review","article","10.1016/j.ekir.2025.103757","41726005","PMC12924124",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029529","Impact of GLP-1 and GLP-1/GIP agonists on healthcare resource utilization in individuals with scarring alopecias: A retrospective cohort analysis using TriNetX.","Hill MA","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.02.049","41713592",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0029530","Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance.","Schaefer LM","2026","The Psychiatric clinics of North America","narrative_review","article","10.1016/j.psc.2025.08.013","41708263",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029531","Challenges in the management of obesity.","Smith BL","2026","Journal of clinical lipidology","other_trial","article","10.1016/j.jacl.2025.09.023","41708210",null,null,null,"pubmed","FALSE","paywalled","5",null,"Journal Article; Review"],["R0029532","Pivotal Trials in Heart Failure in 2024-Putting Evidence into Clinical Practice!","Thandi P","2026","The International journal of angiology : official publication of the International College of Angiology, Inc","narrative_review","article","10.1055/a-2624-5735","41705088","PMC12909084",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029533","Association of incretin therapy with self-harm behaviors in people with psychiatric conditions: A retrospective cohort study.","Kalamaras H","2026","Journal of psychopharmacology (Oxford, England)","nonrandomized_study","article","10.1177/02698811261416077","41693095",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0029534","Revolutionising CKD care: semaglutide's kidney-protective leap in type 2 diabetes and chronic kidney disease.","Tayyaba S","2026","Annals of medicine and surgery (2012)","nonrandomized_study","article","10.1097/ms9.0000000000004675","41675811","PMC12889320",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0029535","Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders.","Solitano V","2026","Inflammatory bowel diseases","narrative_review","article","10.1093/ibd/izaf315","41665650",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029536","Targeting GLP1 receptor for reducing global cardiovascular risk.","Curcio A","2026","Journal of translational medicine","nonrandomized_study","article","10.1186/s12967-026-07736-8","41652617","PMC12977427",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0029537","National trends in resmetirom prescriptions for metabolic dysfunction-associated steatohepatitis in the USA.","Lee BP","2026","Clinical and molecular hepatology","other","article","10.3350/cmh.2025.1414","41644110","PMC13129765",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029538","Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA.","Indennidate C","2026","Current cardiology reports","narrative_review","article","10.1007/s11886-025-02340-6","41636929",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029539","Changes in Insulin Resistance with Different Weight Loss Methods in Patients with Type Two Diabetes Mellitus and Hypertension: A Comparative Clinical Trial.","Oshakbayev K","2026","Journal of clinical medicine","other_trial","article","10.3390/jcm15020546","41598484","PMC12842082",null,null,"pubmed","FALSE","open_pdf","5",null,"Journal Article"],["R0029540","Determinants of acute weight gain during regional conflict among individuals with overweight and obesity receiving targeted multidisciplinary care.","Minsky N","2026","Eating and weight disorders : EWD","nonrandomized_study","article","10.1007/s40519-026-01816-w","41593413","PMC12861986",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article"],["R0029541","Mitigating loss of lean muscle in GLP-1 and dual GLP-1/GIP agonists: Pipeline opportunities and limitations.","Hierholzer J","2026","Biochimica et biophysica acta. Molecular basis of disease","other_trial","article","10.1016/j.bbadis.2026.168172","41587701",null,null,null,"pubmed","FALSE","paywalled","5",null,"Journal Article; Review"],["R0029542","Biological therapies at 25 years: from incremental advances to revolutionary transformations.","Ciulla TA","2026","Expert opinion on biological therapy","commentary","article","10.1080/14712598.2026.2621022","41581012",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029543","Gut microbiome and obesity care: Bridging dietary, surgical, and pharmacological interventions.","Masi D","2026","Cell reports. Medicine","preclinical","article","10.1016/j.xcrm.2025.102573","41576942","PMC12923917",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029544","Evaluating Cardiovascular Disease Risk.","Richie RC","2026","Journal of insurance medicine (New York, N.Y.)","narrative_review","article","10.17849/insm-53-1-1-8.2","41558692",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029545","Glucagon-like peptide-1 medicines and cancer.","Yabut JM","2026","Nature cancer","narrative_review","article","10.1038/s43018-025-01110-1","41545715",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029546","Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism.","Jiang H","2026","Nature communications","preclinical","article","10.1038/s41467-026-68526-w","41545413","PMC12917164",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029547","Resolution of central sleep apnea following upper airway surgery: A case report.","Rasmussen NG","2026","Sleep medicine","case_report","article","10.1016/j.sleep.2026.108776","41534131",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Case Reports"],["R0029548","Healthcare Utilization Among Chronic Rhinosinusitis Patients Using Glucagon-Like Peptide-1 Agonists.","Wu SS","2026","International forum of allergy & rhinology","other","article","10.1002/alr.70097","41508918",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029549","Obesity Medications Beyond Glucose Control and Weight Reduction: Updates on the Expanding Benefits, Clinical Challenges, and Future Directions.","Ntelis S","2025","Current hypertension reports","narrative_review","article","10.1007/s11906-025-01349-0","41460420",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029550","The evolving role of metabolic and bariatric surgery in contemporary clinical practice.","Panichella G","2026","European journal of preventive cardiology","narrative_review","article","10.1093/eurjpc/zwaf787","41453132",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029551","Editorial: Non-insulin pharmacotherapies for the treatment of type 2 diabetes and obesity - old and new players.","Patoulias D","2025","Frontiers in clinical diabetes and healthcare","randomized_trial","article","10.3389/fcdhc.2025.1747914","41439012","PMC12719261",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Editorial; editorial"],["R0029552","The hypothalamus as a therapeutic target: Towards novel approaches for managing antipsychotic-induced weight gain.","Mukherjee S","2026","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-025-10009-2","41432886","PMC13246901",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029553","Diabetes and the Retina: The Role of Medical Treatment.","Bloomgarden Z","2025","Journal of diabetes","commentary","article","10.1111/1753-0407.70185","41429667","PMC12722105",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0029554","Peripheral nerve complications of weight loss associated with novel antihyperglycemic agents: a cohort study.","O'Gorman C","2025","Journal of neurology","nonrandomized_study","article","10.1007/s00415-025-13566-3","41417220",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Clinical Study; Journal Article"],["R0029555","Impact of weight-loss interventions on psoriasis severity: A systematic review and meta-analysis.","Morrow S","2026","Journal of the European Academy of Dermatology and Venereology : JEADV","systematic_review","article","10.1111/jdv.70247","41416383","PMC13206337",null,null,"pubmed","FALSE","open_pdf","3",null,"Journal Article; Systematic Review; Meta-Analysis"],["R0029556","Weight Management Through a Woman's Life Stages: A Practical Evidence-Based Guide.","Scholcoff C","2026","Journal of women's health (2002)","narrative_review","article","10.1177/15409996251405062","41391915",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029557","AI-powered literature mining reveals the therapeutic significance of GLP-1 receptor: Simulation of natural agonist candidates based on molecular dynamics.","Cakmak RK","2026","Computational biology and chemistry","other","article","10.1016/j.compbiolchem.2025.108828","41389576",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029558","Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides.","Østergaard S","2026","Expert opinion on drug discovery","narrative_review","article","10.1080/17460441.2025.2601113","41381216",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029559","Anti-adipogenic effect of cryptotanshinone in 3T3-L1 preadipocytes via binding to glucagon-like peptide 1 receptor and its signaling.","Rakib MA","2026","Phytomedicine : international journal of phytotherapy and phytopharmacology","preclinical","article","10.1016/j.phymed.2025.157666","41380415",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029560","From Phytochemistry to Metabolic Regulation: The Insulin-Promoting Effects of Loureirin B Analogous to an Agonist of GLP-1 Receptor.","Fang H","2025","International journal of molecular sciences","preclinical","article","10.3390/ijms262311548","41373699","PMC12692253",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029561","The SOUL trial: another important study for the reduction of CV risk in individuals with type 2 diabetes.","Marx N","2025","Cardiovascular research","randomized_trial","article","10.1093/cvr/cvaf216","41364656",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0029562","Using culinary medicine to improve adherence and prevent malnutrition in youth with obesity on antiobesity medications.","Weston S","2026","Journal of pediatric gastroenterology and nutrition","other","article","10.1002/jpn3.70296","41363054",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029563","Optimized MASH treatment eligibility cutoffs for MRE-measured liver stiffness and proton density fat fraction.","Owusu N","2026","Clinical and molecular hepatology","other","article","10.3350/cmh.2025.1267","41360082","PMC12835756",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029564","Pharmacological management of binge eating disorder.","Williams AM","2025","The mental health clinician","other","article","10.9740/mhc.2025.12.285","41358043","PMC12681222",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029565","Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials.","Barzgar H","2026","Clinica chimica acta; international journal of clinical chemistry","narrative_review","article","10.1016/j.cca.2025.120772","41354283",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029566","Editorial: Case reports in psychopharmacology, volume III.","Stuhec M","2025","Frontiers in psychiatry","case_report","article","10.3389/fpsyt.2025.1721565","41334075","PMC12668200",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0029567","Optimizing GLP-1 therapies for obesity and diabetes management.","Noronha JC","2025","Obesity pillars","other","article","10.1016/j.obpill.2025.100222","41322078","PMC12661421",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0029568","Understanding Impact of Anti-Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods.","McMath A","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","randomized_trial","article","10.1111/obr.70041","41287517","PMC13008602",null,null,"pubmed","FALSE","free_to_read","2",null,"Journal Article; Review; Research Support, N.I.H., Extramural"],["R0029569","Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy.","Standl E","2025","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-025-02959-3","41272705","PMC12636195",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Letter; article"],["R0029570","Noninsulin drugs for type 2 diabetes.",null,"2025","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2025.1742a","41259100",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029571","Body composition matters: Preserving muscle and function in the era of GLP-1-based weight loss therapies.","Emanuelsson EB","2025","The Journal of physiology","other","article","10.1113/jp290350","41251266",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029572","Meta-analysis of GLP1R, GIPR, ADCY3, and CREB1 expression in osteoarthritis identifies CREB1 as a potential biomarker and therapeutic target.","Alizargar J","2025","Journal of clinical orthopaedics and trauma","systematic_review","article","10.1016/j.jcot.2025.103256","41245346","PMC12617777","PROSPERO:CRD420251177348",null,"pubmed","FALSE","free_to_read","3",null,"Journal Article"],["R0029573","Glucagon-Like Peptide-1: The Role of Calcium in Gut-Glucose Axis.","Foamkom AI","2026","Advances in experimental medicine and biology","narrative_review","article","10.1007/978-3-032-04357-3_10","41219603",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029574","Non-insulin diabetes medicines: an emerging role in pain management? Comment on Br J Anaesth 2025; 135: 898-911.","Alcántara Montero A","2026","British journal of anaesthesia","commentary","article","10.1016/j.bja.2025.10.010","41198428",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029575","Fatty Liver Disease: A Prognostic Player in Acute Pancreatitis?","Souza M","2026","Digestive diseases and sciences","commentary","article","10.1007/s10620-025-09525-7","41193775",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029576","Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions.","Besci O","2025","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2025.2574318","41191736",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0029577","Spinal Cord Infarction Presenting as Cauda Equina Syndrome With Concurrent Pulmonary Embolism: A Case Report.","Rajeev A","2025","Cureus","case_report","article","10.7759/cureus.93778","41185833","PMC12579896",null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article"],["R0029578","Emerging in Diabetic Cardiomyopathy: Molecular Pathways and Targets for Therapeutic Intervention.","Trivedi MV","2025","Drug development research","narrative_review","article","10.1002/ddr.70187","41183131",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029579","Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.","Wong CK","2025","The Journal of clinical investigation","preclinical","article","10.1172/jci194751","41178710","PMC12578379",null,"S002468; S002726","pubmed","FALSE","free_to_read","5",null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029580","Chemoprevention of hepatocellular carcinoma.","Schwenk S","2025","Hepatology communications","narrative_review","article","10.1097/hc9.0000000000000836","41171441","PMC12577995",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029581","Clinical characteristics and intensification patterns in subjects with \"early\" type 2 diabetes in Italy- an analysis from the AMD annals initiative.","Russo GT","2026","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-025-02599-9","41165847","PMC13046648",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0029582","Key Articles and Guidelines in the Management of Chronic Coronary Disease.","Dixon DL","2026","Journal of pharmacy practice","narrative_review","article","10.1177/08971900251394069","41163183",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029583","The FLOW of Progress in Diabetic Kidney Disease: Semaglutide's Role in Combination Therapy.","Agarwal R","2025","Diabetes care","commentary","article","10.2337/dci25-0088","41115233",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0029584","Evaluate muscle mass when setting target body weight.","Yamazaki Y","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70218","41111346",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029585","Real-world data and its clinical relevance: Complementing randomized controlled trials.","Horiuchi Y","2026","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2025.133971","41110660",null,null,null,"pubmed","FALSE","paywalled","2",null,"Letter"],["R0029586","GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations.","Scheen AJ","2026","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2025.101708","41101588",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029587","The Optimal Health Weight and Lifestyle (OHWL) Clinic: Comprehensive, Multidisciplinary and Geriatric-Focused Care for Multimorbid Older Adults With Obesity.","Dewar S","2025","Current developments in nutrition","nonrandomized_study","article","10.1016/j.cdnut.2025.107526","41080466","PMC12512145",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article"],["R0029588","Obesity and hypertension new insights in management.","Catalfamo VJ","2026","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000001261","41076726",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029589","Post-Marketing Safety Assessment for Glucagon-Like Peptide-1 and Dual Incretin Therapies in Diabetes and Obesity.","Weng CH","2026","Journal of clinical pharmacology","nonrandomized_study","article","10.1002/jcph.70119","41074403",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0029590","A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways.","Park C","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1630199","41019323","PMC12460103",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029591","Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions.","Fitch A","2025","Obesity pillars","narrative_review","article","10.1016/j.obpill.2025.100205","41018564","PMC12475867",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0029592","GLP-1-based therapies, the stepwise trap, and missed surgical windows: A policy perspective on delayed access to bariatric surgery.","Hsu KF","2025","Diabetes, obesity & metabolism","other","article","10.1111/dom.70163","41017525",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029593","Crosstalk between alcohol use disorder and obesity: two sides of the same coin?","Leggio L","2025","Molecular psychiatry","narrative_review","article","10.1038/s41380-025-03259-8","41015576","PMC12602370",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029594","Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs.","Kaya E","2025","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2025.2566258","40992909",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029595","Ethics of Lifestyle Counsel Alone in a GLP-1 Era.","Stephenson KM","2025","JAMA pediatrics","other","article","10.1001/jamapediatrics.2025.3327","40982274",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029596","Are we giving too much weight to lean mass loss?","Bolte J","2025","Molecular metabolism","narrative_review","article","10.1016/j.molmet.2025.102253","40972944","PMC12506580",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029597","Is COMISA another opportunity for use of incretin drugs?","Pack AI","2025","Sleep","randomized_trial","article","10.1093/sleep/zsaf254","40971532",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Editorial; Comment; article"],["R0029598","Efficacy and Safety of Non-Insulin Antidiabetic Drugs in Cats: A Systematic Review.","Romero-Vélez F","2025","Animals : an open access journal from MDPI","systematic_review","article","10.3390/ani15172561","40941356","PMC12427183",null,null,"pubmed","FALSE","open_pdf","3",null,"Journal Article; Review"],["R0029599","Eucommia alleviates high fat diet-induced MASLD via the F. prausnitzii/butyrate/GPR43/GLP-1 signaling.","Wang Z","2026","Journal of ethnopharmacology","preclinical","article","10.1016/j.jep.2025.120587","40935212",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029600","Using obesity management medications within the first year after laparoscopic sleeve gastrectomy may enhance weight-loss outcomes.","Chen CY","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-08256-y","40931277",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0029601","A-MACE-Ing: A Real-World Analysis of Semaglutide's Impact on Major Adverse Cardiovascular Events (MACE) in Patients With Hidradenitis Suppurativa.","Islam RK","2026","International journal of dermatology","nonrandomized_study","article","10.1111/ijd.17910","40928108",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0029602","Dual incretin agonism and the gut microbiome: does the heart of metabolic regulation beat in the gut?","Koufakis T","2025","Expert review of clinical pharmacology","commentary","article","10.1080/17512433.2025.2559907","40923327",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029603","Potential Impact of Next-Generation Weight Loss Drugs on Cancer Incidence.","Brenner DR","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.30904","40920384","PMC12418124",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029604","Reply to \"Revisiting Tirzepatide's Body Composition Model: Underestimated Fat-Free Mass Loss and Clinical Implications\".","Chigutsa E","2025","Clinical pharmacology and therapeutics","commentary","article","10.1002/cpt.70056","40908596",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0029605","Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study.","Aggarwal R","2025","Progress in cardiovascular diseases","other","article","10.1016/j.pcad.2025.08.009","40907677",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029606","Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: A critical review of diagnostic, mechanistic, and therapeutic intersections.","Gupta V","2025","World journal of gastroenterology","narrative_review","article","10.3748/wjg.v31.i31.110481","40901693","PMC12400224",null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0029607","Revisiting Tirzepatide's Body Composition Model: Underestimated Fat-Free Mass Loss and Clinical Implications.","Chen CC","2025","Clinical pharmacology and therapeutics","commentary","article","10.1002/cpt.70058","40888696",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0029608","HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction.","Borlaug BA","2025","European heart journal","randomized_trial","article","10.1093/eurheartj/ehaf663","40886160","PMC12614996","ClinicalTrials.gov:NCT05592275",null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article"],["R0029609","Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention.","Gallo G","2025","International journal of molecular sciences","narrative_review","article","10.3390/ijms26168081","40869400","PMC12386202",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029610","Redefining Obesity: A Narrative Review of Diagnostic Evolution, Therapeutic Strategies and Psychosocial Determinants.","Przybyłowski A","2025","Healthcare (Basel, Switzerland)","narrative_review","article","10.3390/healthcare13161967","40868582","PMC12385716",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029611","Molecular Mechanisms Against Successful Weight Loss and Promising Treatment Options in Obesity.","Szekeres Z","2025","Biomedicines","nonrandomized_study","article","10.3390/biomedicines13081989","40868241","PMC12383577",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article; Review"],["R0029612","Potential missed opportunities to improve long-term liver allograft health.","Fallahzadeh MA","2026","Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","narrative_review","article","10.1097/lvt.0000000000000720","40879500",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029613","[A critical look at the benefits and risks of new drug options in obesity therapy].","Arjune S","2025","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-025-5150-x","40877684",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029614","Correction: Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.","Gammoh O","2025","Molecular biology reports","notice","article","10.1007/s11033-025-10965-7","40864334","PMC12391215",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0029615","Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study.","Cai Y","2025","European journal of pharmacology","other","article","10.1016/j.ejphar.2025.178088","40865863",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029616","Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain.","de Bray A","2025","Nature metabolism","preclinical","article","10.1038/s42255-025-01342-6","40830598","PMC12373499",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029617","Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors.","Sutcliffe C","2025","Frontiers in systems biology","other","article","10.3389/fsysb.2025.1593229","40810125","PMC12342020",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029618","Obstructive Sleep Apnoea Treatments-Where Are We Now?","Luu S","2025","Respirology (Carlton, Vic.)","other","article","10.1111/resp.70109","40808349","PMC12486363",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029619","Novel therapies - IMID Co-morbidities.","Lam TO","2025","Best practice & research. Clinical rheumatology","narrative_review","article","10.1016/j.berh.2025.102089","40803911",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029620","Targeting visceral and ectopic adiposity: Pharmacological and surgical interventions beyond global weight loss.","Guldan M","2025","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70019","40798892",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029621","Combined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.","Crutchlow M","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70014","40767101",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I"],["R0029622","Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.","Chakravarthy MV","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70006","40762050","PMC12890765",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; research-article; article"],["R0029623","From pathophysiology to novel approaches for obesity-associated hypertension.","Kanbay M","2025","Clinical kidney journal","narrative_review","article","10.1093/ckj/sfaf218","40761303","PMC12319540",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029624","Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies.","Xu Y","2026","Endocrine reviews","narrative_review","article","10.1210/endrev/bnaf027","40755395",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029625","The Peptide Paradox in Pharmacology of Obesity.","Kalra S","2025","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.25-53","40751630",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029626","Plain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease.","Abushamat LA","2025","Postgraduate medicine","other","article","10.1080/00325481.2025.2537617","40735825","PMC13063288",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029627","Comparison table: Some drugs for weight management.",null,"2025","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2025.1734b","40729438",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029628","Drugs and devices for weight management.",null,"2025","The Medical letter on drugs and therapeutics","other","article","10.58347/tml.2025.1734a","40729437",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029629","Managing Adverse Effects of Incretin-Based Medications for Obesity.","Kushner RF","2025","JAMA","other","article","10.1001/jama.2025.11153","40728833",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029630","Game changer: Navigating between challenges and hopes in geropharmacology.","Chen Q","2025","Advances in pharmacology (San Diego, Calif.)","narrative_review","article","10.1016/bs.apha.2025.02.007","40716936",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029631","Clinical perspective on non-sleepy obstructive sleep apnea; to treat or not to treat?","Luu S","2026","Expert review of respiratory medicine","randomized_trial","article","10.1080/17476348.2025.2539542","40704845",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0029632","Body Mass Index, Central Adiposity, and HFpEF: Some Answers But More Questions.","Klein KR","2025","Journal of the American College of Cardiology","commentary","article","10.1016/j.jacc.2025.05.043","40701670",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029633","Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease.","Kugathasan L","2025","Expert review of clinical immunology","narrative_review","article","10.1080/1744666x.2025.2537446","40693871",null,"ClinicalTrials.gov:NCT06217302; ClinicalTrials.gov:NCT05901831; ClinicalTrials.gov:NCT05822609","S001873","pubmed","FALSE","paywalled","5",null,"Journal Article; Review"],["R0029634","Cardiac digital twins: a tool to investigate the function and treatment of the diabetic heart.","Strocchi M","2025","Cardiovascular diabetology","randomized_trial","article","10.1186/s12933-025-02839-w","40682127","PMC12275252",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; other; article"],["R0029635","Obesity Solutions for Patients over 65 Years of Age: Surgeon Perspectives on Anti-obesity Medications and Metabolic Bariatric Surgery - International Survey Study.","Dowgiałło-Gornowicz N","2025","Obesity surgery","other","article","10.1007/s11695-025-08026-w","40676352","PMC12380857",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029636","Novel GLP-1/GIP Dual Receptor Agonist Alleviates Neonatal Hypoxic-Ischemic Encephalopathy by Inhibiting TLR2/NF-κB/NLRP3 Mediated-Neuroinflammation : The role of DA5-CH in neonatal hypoxic-ischemic encephalopathy.","Huang W","2025","Neurochemical research","preclinical","article","10.1007/s11064-025-04475-y","40673927",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029637","Association Between Androgenetic Alopecia and Glucagon-Like Peptide-1 Receptor Treatment in Type 2 Diabetes Mellitus Patients: A Retrospective Cohort Study.","Singal A","2025","International journal of dermatology","nonrandomized_study","article","10.1111/ijd.17971","40662424",null,null,null,"pubmed","FALSE","open_pdf","4",null,"Letter"],["R0029638","I Am Taking a GLP-1 Weight-Loss Medication-What Should I Know?","Mehrtash F","2025","JAMA internal medicine","other","article","10.1001/jamainternmed.2025.1133","40658429",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029639","Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity.","Gupta R","2025","JAAD international","other","article","10.1016/j.jdin.2025.05.004","40655535","PMC12246685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0029640","Prescription weight loss medication use and eating disorder psychopathology among adolescent boys and young men from Canada and the United States.","Ganson KT","2025","Eating behaviors","other","article","10.1016/j.eatbeh.2025.102013","40652813",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029641","Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal.","van Bruggen FH","2025","Frontiers in cardiovascular medicine","randomized_trial","article","10.3389/fcvm.2025.1564432","40612376","PMC12221899",null,null,"pubmed; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article"],["R0029642","Differential Selection of Obesity Treatments by Race/Ethnicity: Insights From the Veterans Affairs Healthcare System.","Tisdale RL","2025","JACC. Advances","other","article","10.1016/j.jacadv.2025.101819","40579055","PMC12277596",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029643","Endothelial Function and Matrix Metalloproteinase 9 (MMP9) in Women with Polycystic Ovary Syndrome (PCOS).","Lambadiari V","2025","International journal of molecular sciences","other","article","10.3390/ijms26125488","40564951","PMC12192708",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029644","Prescribing Antidiabetic Medications Among GPs in Croatia-A Real-Life Cross-Sectional Study.","Kurevija T","2025","Biomedicines","other","article","10.3390/biomedicines13061491","40564210","PMC12190737",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029645","Recent progress in the pharmacotherapy for obesity.","Lu J","2025","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2025.177850","40553780",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029646","Glucagon controls obesity-specific energy expenditure via persistent cAMP/PKA signaling.","Long F","2025","Journal of hepatology","preclinical","article","10.1016/j.jhep.2025.06.011","40550339",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029647","Therapeutic Targeting of the GIP Receptor-Revisiting the Controversies.","Campbell JE","2025","Diabetes","narrative_review","article","10.2337/db25-0393","40521880","PMC12278791",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029648","Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend.","Sood N","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf084","40520450","PMC12164287",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029649","Addressing obesity and subsequent cardiovascular risk in primary care: the relevance of high- and low-resource settings.","Schutte AE","2025","Cardiovascular research","nonrandomized_study","article","10.1093/cvr/cvaf094","40512090",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0029650","Endocrine Disorder: Advance in Understanding Diabetes and Obesity A Review.","Salunke DD","2025","Journal of pharmacy & bioallied sciences","narrative_review","article","10.4103/jpbs.jpbs_539_25","40511242","PMC12156703",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029651","Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study.","Yang GP","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.71327","42712041",null,"ChiCTR:ChiCTR2600116148; ChiCTR:ChiCTR2600123803",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0029652","Discovery of Biased Dual-Agonists of Glucagon-Like Peptide 1 and Glucagon Receptors through Mutation of a Conserved Aspartate.","Thompson RE","2026","ACS medicinal chemistry letters","preclinical","article","10.1021/acsmedchemlett.5c00668","42445014","PMC13358974",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029653","Correction: Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes.","de Lucena LA","2026","Current diabetes reports","notice","article","10.1007/s11892-026-01622-9","41961366",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0029654","Acute glucagon infusion induces natriuresis and diuresis through a direct tubular mechanism involving overlapping receptor pathways.","Billeschou Bomholt A","2026","American journal of physiology. Renal physiology","preclinical","article","10.1152/ajprenal.00195.2026","42568245",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029655","A unimolecular GLP-1 and FGF21 dual agonist for treatment of metabolic dysfunction-associated steatohepatitis.","Sirohi P","2026","Communications medicine","preclinical","article","10.1038/s43856-026-01712-5","42277193","PMC13612464",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029656","Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.","Oldenburg LIK","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.71096","42443140","PMC13538736","ClinicalTrials.gov:NCT06559527","S003207","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial, Phase I; Journal Article; research-article; article"],["R0029657","Glucose-dependent insulinotropic peptide and beyond: co-agonist innovations in the treatment of metabolic diseases.","Zhou C","2025","European journal of pharmacology","narrative_review","article","10.1016/j.ejphar.2025.177681","40306536",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029658","The role of GIPR in food intake control.","James-Okoro PP","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1532076","40166681","PMC11955450",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029659","Does Incretin Agonism Have Sustainable Efficacy?","Janket SJ","2024","Cells","randomized_trial","article","10.3390/cells13221842","39594592","PMC11592889",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0029660","Epicardial Adipose Tissue in Hyperglucagonemia mice: an experimental model for GLP-1 triple agonists","Iacobellis G","2026","Research Square","preclinical","preprint","10.21203/rs.3.rs-10616455/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0029661","A novel unimolecular GLP1 and amylin receptor agonist for glucose and weight control.","Chow E","2026","Lancet (London, England)","other","article","10.1016/s0140-6736(26)01487-x","42532081",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029662","Dual GLP-1/FGF21 agonism suppresses voluntary alcohol consumption, alcohol choice, and nucleus accumbens dopamine modulation","Cooley BJ","2026","bioRxiv","preclinical","preprint","10.64898/2026.04.30.721773",null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Preprint; preprint"],["R0029663","Systematic Design of PLGA Nanoparticles for Long-Acting Delivery of a Dual GLP-1/Glucagon Receptor Coagonist Peptide (SAR425899) via Phase Inversion Nanoencapsulation.","Baptista C","2026","Langmuir : the ACS journal of surfaces and colloids","other","article","10.1021/acs.langmuir.6c01535","42289975",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029664","Incretin Agonism: Sustainable Efficacy or Surreptitious Hazard?","Janket S","2024","Preprints.org","other","preprint","10.20944/preprints202410.0047.v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0029665","Terminus-specific antibody development and bioanalytical assay validation to quantify active DR10624 in pharmacokinetic studies.","Zhou Z","2026","Frontiers in pharmacology","other","article","10.3389/fphar.2026.1863402","42609242","PMC13477871",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029666","Appraising Cardiovascular Impact of Newer Incretin Agonists When Placebo Can No Longer Be the Control.","Inzucchi SE","2026","Diabetes care","commentary","article","10.2337/dci26-0047","42766767",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0029667","Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?","Kylies D","2026","Current hypertension reports","notice","article","10.1007/s11906-026-01377-4","42366305","PMC13310829",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0029668","A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide Receptors.","Jiang J","2024","Journal of clinical and translational hepatology","case_report","article","10.14218/jcth.2024.00287","39544242","PMC11557366",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0029669","Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance.","De Fano M","2024","International journal of molecular sciences","narrative_review","article","10.3390/ijms25168650","39201336","PMC11354636",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029670","Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease.","Feng P","2026","Peptides","preclinical","article","10.1016/j.peptides.2026.171485","41895375",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029671","Glucagon-Like Peptide-2 Receptor: A Master Integrator of Gut-Brain-Liver Communication in Metabolic and Cognitive Health.","Jiang Y","2026","Comprehensive physiology","narrative_review","article","10.1002/cph4.70144","41943399",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029672","A unimolecular GLP-1 and FGF21 dual agonist for treatment of metabolic dysfunction-associated steatohepatitis","Chilkoti A","2025","Research Square","preclinical","preprint","10.21203/rs.3.rs-7282812/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0029673","[Changes in obesity management: The clinician's perspective].","Montastier E","2026","Biologie aujourd'hui","nonrandomized_study","article","10.1051/jbio/2026002","42536829",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; English Abstract; article"],["R0029674","GLP-2 and GIP acutely increase superior mesenteric artery blood flow in male rats, and the effect is independent of nitric oxide and vasoactive intestinal peptide.","Galsgaard KD","2025","Physiological reports","preclinical","article","10.14814/phy2.70699","41388842","PMC12701523",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029675","GLP-1/GIP/GCG receptor triagonist (IUB447) enhances insulin secretion via GLP-1 receptor and Gαq signalling pathway in mice.","Schreier PCF","2025","Diabetologia","preclinical","article","10.1007/s00125-025-06525-0","40924112","PMC12534261",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029676","Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges.","Allard C","2024","Drugs","narrative_review","article","10.1007/s40265-023-01982-6","38127286",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029677","Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.","Folli F","2023","American journal of physiology. Endocrinology and metabolism","narrative_review","article","10.1152/ajpendo.00236.2023","37729025","PMC10874655",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0029678","Designer GLP1 poly-agonist peptides in the management of diabesity.","Statham L","2023","Expert review of endocrinology & metabolism","other","article","10.1080/17446651.2023.2204976","37089108",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029679","Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials.","Deusch K","2025","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70135","40959944","PMC12587243","ClinicalTrials.gov:NCT05713773; ClinicalTrials.gov:NCT05737927; ClinicalTrials.gov:NCT05803772",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; research-article; other; article"],["R0029680","Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases.","Chui ZSW","2026","Pharmacological reviews","narrative_review","article","10.1016/j.pharmr.2026.100150","42508098",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029681","A meta-analysis of glucagon-like peptide 1 receptor and dual agonists for the treatment of obstructive sleep apnea: end of the story or just the beginning?","Drager LF","2025","Sleep","systematic_review","article","10.1093/sleep/zsaf004","39758029",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Editorial; Comment; review"],["R0029682","Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future.","Zeng RQ","2026","Liver international : official journal of the International Association for the Study of the Liver","other_trial","article","10.1111/liv.70784","42438128","PMC13358175",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0029683","Anti-obesogenic effects of plant natural products: A focus on Korean traditional foods","Das G","2024","Trends in Food Science & Technology.","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Journal Article"],["R0029684","A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study.","Abdelmalek MF","2023","Contemporary clinical trials","protocol","article","10.1016/j.cct.2023.107176","37028504",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial Protocol; article"],["R0029685","Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism.","Bu T","2024","Diabetes & metabolism journal","narrative_review","article","10.4093/dmj.2023.0277","38650100","PMC11140404",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029686","MASLD as Complication of Diabetes.","Stefan N","2026","Diabetes","narrative_review","article","10.2337/dbi26-0001","42250281","PMC13381670",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029687","Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.","Liskiewicz A","2023","Nature metabolism","preclinical","article","10.1038/s42255-023-00931-7","37946085","PMC10730394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029688","Innovative Glucagon-based Therapies for Obesity.","Enyew Belay K","2024","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvae197","39574787","PMC11579655",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0029689","EPR26-152: GLP-1 and Dual Agonists and the Incidence of Skin Cancer: Evidence from Randomized Controlled Trials.","Chang YC","2026","Journal of the National Comprehensive Cancer Network : JNCCN","randomized_trial","article","10.6004/jnccn.2025.7464","42066808",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0029690","Dual incretin agonist for paediatric type 2 diabetes: an eagerly awaited opportunity.","Isganaitis E","2025","Lancet (London, England)","other","article","10.1016/s0140-6736(25)01908-7","40983068",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029691","Preliminary evaluation of oxyntomodulin as a biomarker for metabolic risk stratification in adults with obesity.","Zwierz M","2025","Journal of translational medicine","other","article","10.1186/s12967-025-07479-y","41408640","PMC12709701",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029692","Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes.","Palani A","2022","ACS medicinal chemistry letters","other","article","10.1021/acsmedchemlett.2c00217","35978682","PMC9377002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; rapid-communication; article"],["R0029693","[Incretin-based co- and tri-agonists : Innovative polypharmacology for the treatment of obesity and diabetes].","Harger A","2019","Der Internist","narrative_review","article","10.1007/s00108-019-0649-9","31346639",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029694","Oxyntomodulin - past, present and future.","Holst JJ","2025","Peptides","narrative_review","article","10.1016/j.peptides.2025.171393","40187415",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029695","Engineering Glucagon via Molecular and Formulation Strategies: From Natural Hormone to Effective and Stable Therapeutics.","Li X","2025","Chembiochem : a European journal of chemical biology","narrative_review","article","10.1002/cbic.202500270","40459429",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029696","Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes.","Fuselier T","2022","Cell reports. Medicine","preclinical","article","10.1016/j.xcrm.2022.100598","35492248","PMC9043999",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; brief-report; article"],["R0029697","Restructuring the Obesity Paradigm: Molecular Etiologies, Clinical Complexities, and the Future of Precision Intervention.","Latt TS","2026","Cureus","narrative_review","article","10.7759/cureus.106767","42116975","PMC13157649",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029698","Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture.","Holst JJ","2021","Diabetes","other","article","10.2337/dbi21-0026","34711671","PMC8928930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Lecture; Research Support, Non-U.S. Gov't; oration; article"],["R0029699","Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3-36 in the suppression of food, drug-seeking, and anxiogenesis.","Dumiaty Y","2024","Neuropeptides","narrative_review","article","10.1016/j.npep.2024.102427","38579490",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029700","Pharmacological therapies for type 2 diabetes: future approaches.","Bailey CJ","2026","Diabetologia","narrative_review","article","10.1007/s00125-025-06581-6","41174263","PMC12686082",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029701","Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes.","Brodosi L","2023","Expert opinion on pharmacotherapy","nonrandomized_study","article","10.1080/14656566.2023.2208746","37114459",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Review; Journal Article; article"],["R0029702","Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists.","Zhang X","2023","Peptides","preclinical","article","10.1016/j.peptides.2023.170948","36646385",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029703","The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction.","Rizvi AA","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s351982","35411165","PMC8994606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029704","Clinical relevance of dual agonist of glucagon and glucagon-like peptide-1 receptors to achieve functional restoration of first- and second-phase insulin secretion.","Kimura T","2022","Journal of diabetes investigation","commentary","article","10.1111/jdi.13831","35543083","PMC9340864",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0029705","Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study.","Xiang L","2025","Journal of hepatology","randomized_trial","article","10.1016/j.jhep.2024.12.006","39709140",null,"ClinicalTrials.gov:NCT05943886","S003257","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; article"],["R0029706","First Case Report: A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of GLP- 1 and GIP Receptors","Jiang， J","2024","Research Square","case_report","preprint","10.21203/rs.3.rs-4807780/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0029707","Multi-organ benefits of incretin agonists.","O'Leary K","2024","Nature medicine","other","article","10.1038/s41591-024-03391-y","39672907",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029708","Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice.","Sachs S","2021","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.14215","33001570",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029709","Corrigendum to \"Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity\" [Mol Metab 78 (2023) 101801].","Friedrichsen MH","2024","Molecular metabolism","notice","article","10.1016/j.molmet.2024.102023","39245214","PMC11415713",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0029710","The novel GLP-1/GIP dual agonist DA3-CH improves rat type 2 diabetes through activating AMPK/ACC signaling pathway.","Xu J","2023","Aging","preclinical","article","10.18632/aging.205118","37851373","PMC10637786",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029711","Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study.","Winther-Sørensen M","2024","Diabetologia","nonrandomized_study","article","10.1007/s00125-024-06160-1","38705923","PMC11343844",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0029712","Machine learning-guided optimization of triple agonist peptide therapeutics for metabolic disease.","Wong A","2025","Frontiers in bioinformatics","other","article","10.3389/fbinf.2025.1687617","41333850","PMC12665757",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029713","Emerging incretin hormones actions: focus on bone metabolism.","Grammatiki M","2019","Minerva endocrinologica","narrative_review","article","10.23736/s0391-1977.19.03008-6","30991794",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029714","Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.","Hope DCD","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15448","38229453",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; article"],["R0029715","Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic Liver Disease.","Huttasch M","2026","Diabetes care","other","article","10.2337/dc25-3077","41931030","PMC13191396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0029716","Determinants of plasma levels of gcg and metabolic impact of glucagon receptor signalling – a UK Biobank study","Winther-Sørensen M","2023","medRxiv","nonrandomized_study","preprint","10.1101/2023.12.12.23299852",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0029717","Controlling Gastric Delivery of a GIP/GLP1 Peptide in Monkeys by Mucoadhesive SNAC Tablets.","Tran H","2025","Pharmaceutical research","preclinical","article","10.1007/s11095-025-03881-9","40514617",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029718","Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity.","Zhihong Y","2023","Peptides","narrative_review","article","10.1016/j.peptides.2023.170955","36669563",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0029719","Pharmacokinetics and safety of HR17031, a fixed-ratio of INS068/Noiiglutide combination, in Chinese patients with hepatic impairment.","Wang D","2026","Diabetes, obesity & metabolism","other_trial","article","10.1111/dom.70450","41527187",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Clinical Trial; article"],["R0029720","Perspectives in weight control in diabetes - SGLT2 inhibitors and GLP-1-glucagon dual agonism.","Iqbal N","2023","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2023.110669","37075928",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029721","Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity.","Li Q","2022","Chinese journal of natural medicines","preclinical","article","10.1016/s1875-5364(22)60196-1","36427920",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029722","Approach to the Patient: Clinical Outcomes and Interim Strategies Following Discontinuation of Incretin Agonists.","Barenbaum SR","2026","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/clinem/dgaf641","41314250",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Case Reports; article"],["R0029723","Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?","Huttasch M","2024","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2024.155937","38782182",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0029724","GLP-1 - Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy.","Holst JJ","2022","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2022.102189","35231672",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0029725","Development of a First-in-Class Unimolecular Dual GIP/GLP-2 Analogue, GL-0001, for the Treatment of Bone Fragility.","Gobron B","2023","Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","preclinical","article","10.1002/jbmr.4792","36850034",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029726","A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome.","Kim ER","2022","Hepatology (Baltimore, Md.)","randomized_trial","article","10.1002/hep.32235","34773257",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029727","GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.","Holst JJ","2020","The Journal of clinical endocrinology and metabolism","narrative_review","article","10.1210/clinem/dgaa327","32459834","PMC7308078",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029728","OR10-03 Murine Bimagrumab Co-administration With Incretin Agonists Results In Additive Efficacy And Superior Quality Weight Loss In The Mouse Diet-induced Obesity Model",null,"2023","Journal of the Endocrine Society","preclinical","article",null,null,"PMC10555287",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0029729","Amino acids contribute to adaptive thermogenesis. New insights into the mechanisms of action of recent drugs for metabolic disorders are emerging.","Ruocco C","2023","Pharmacological research","narrative_review","article","10.1016/j.phrs.2023.106892","37619907",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0029730","Glucagon: Physiological and Pharmacological Functions and Pathophysiological Significance in Type 2 Diabetes.","Kitamura T","2024","Endocrinology and metabolism (Seoul, Korea)","narrative_review","article","10.3803/enm.2024.1911","38417825","PMC10901671",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0029731","Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells.","Liu H","2025","Acta pharmaceutica Sinica. B","preclinical","article","10.1016/j.apsb.2024.11.017","40041889","PMC11873616",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029732","Application of a mouse model humanized for cytochrome P450-mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugs.","Kapelyukh Y","2025","Drug metabolism and disposition: the biological fate of chemicals","other_trial","article","10.1016/j.dmd.2025.100153","40972496","PMC12799566",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0029733","Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.","Knerr PJ","2020","Peptides","narrative_review","article","10.1016/j.peptides.2019.170225","31786282",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029734","Dual activation of MC3R and MC4R drives weight loss and reduces food intake in male primates with obesity.","Seiler JL","2026","Nature communications","preclinical","article","10.1038/s41467-026-73372-x","42215442","PMC13221471",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029735","GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.","Chen Y","2022","Acta pharmacologica Sinica","narrative_review","article","10.1038/s41401-021-00836-9","34934197","PMC9061743",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029736","Activation of GLP-1 and Glucagon Receptors Regulates Bile Homeostasis Independent of Thyroid Hormone.","Patel VJ","2019","Current molecular pharmacology","preclinical","article","10.2174/1874467212666190212112402","30747091",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029737","Intervening Early in the Cardiovascular-Kidney-Metabolic Syndrome: Expert Recommendations from the United Arab Emirates on the Management of Prediabetes.","Abusnana S","2026","Vascular health and risk management","narrative_review","article","10.2147/vhrm.s579970","41783738","PMC12955368",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Practice Guideline; review-article; article"],["R0029738","Metabolic Memory Following Metabolic Bariatric Surgery: Mechanisms, Clinical Implications, and Strategies for Long-Term Success.","Fazeli SA","2025","Obesity surgery","narrative_review","article","10.1007/s11695-025-08417-z","41310268",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029739","Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues","Friedrichsen M","2022","medRxiv","randomized_trial","preprint","10.1101/2022.06.02.22275920",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0029740","Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls.","Simonsen L","2022","PloS one","preclinical","article","10.1371/journal.pone.0264974","35245328","PMC8896685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029741","GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders.","Samms RJ","2021","Diabetes","preclinical","article","10.2337/dbi21-0002","34176786","PMC8576420",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; discussion; article"],["R0029742","Overview of Novel Mechanisms in Obesity Pharmacotherapy and Implications for Cardiovascular Disease: A Narrative Review.","Bonafede M","2026","Current atherosclerosis reports","narrative_review","article","10.1007/s11883-026-01438-8","42360622","PMC13309487",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0029743","GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.","Gabe MBN","2022","Pharmacological research","randomized_trial","article","10.1016/j.phrs.2022.106058","34995796",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0029744","Photochemically-enabled, post-translational production of C-terminal amides.","Hymel D","2024","Nature communications","other","article","10.1038/s41467-024-51005-5","39616180","PMC11608224",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029745","Glucagon, from past to present: a century of intensive research and controversies.","Scheen AJ","2023","The lancet. Diabetes & endocrinology","narrative_review","article","10.1016/s2213-8587(22)00349-7","36566754",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029746","A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives.","Reed J","2021","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s319895","34413662","PMC8369920",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029747","Development of a first-in-class unimolecular dual GIP/GLP-2 analogue, GL-0001, for the treatment of bone fragility","Gobron B","2022","bioRxiv","preclinical","preprint","10.1101/2022.07.21.500659",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0029748","Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice.","Patel V","2020","Drug research","other_trial","article","10.1055/a-1201-2700","32645724",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0029749","Dual GIP-GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential.","Bastin M","2019","Diabetes, metabolic syndrome and obesity : targets and therapy","preclinical","article","10.2147/dmso.s191438","31686879","PMC6777434",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029750","Characterization of LY3324954 a long-acting glucagon-receptor agonist.","Roell W","2025","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.102073","39603505","PMC11696851",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029751","Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide.","Tran H","2022","Pharmaceutical research","preclinical","article","10.1007/s11095-022-03372-1","36050547",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029752","A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.","Finan B","2015","Nature medicine","preclinical","article","10.1038/nm.3761","25485909",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029753","Medical Management of Obesity: Current Trends and Future Perspectives.","Valladares AC","2025","Methodist DeBakey cardiovascular journal","narrative_review","article","10.14797/mdcvj.1503","39990761","PMC11844017",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029754","Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia.","Patel V","2018","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2017.12.068","29275178",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029755","The molecular pharmacology of glucagon agonists in diabetes and obesity.","Novikoff A","2023","Peptides","preclinical","article","10.1016/j.peptides.2023.171003","36997003","PMC10265134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0029756","Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.","Akindehin S","2024","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.101915","38492844","PMC10973979",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029757","GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism.","Peng L","2025","Frontiers in immunology","preclinical","article","10.3389/fimmu.2025.1551136","40230860","PMC11994718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029758","Paradigm Shift in the Management of Metabolic Diseases-Next-Generation Incretin Therapy.","Ahrén B","2023","Endocrinology","commentary","article","10.1210/endocr/bqad166","37951841",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; Comment; article"],["R0029759","(D-Ser2) oxyntomodulin recovers hippocampal synaptic structure and theta rhythm in Alzheimer's disease transgenic mice.","Yang GZ","2022","Neural regeneration research","preclinical","article","10.4103/1673-5374.335168","35142699","PMC8848598",null,null,"pubmed; europepmc","TRUE",null,null,null,"Journal Article; research-article"],["R0029760","GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease.","Sachs S","2023","Cardiovascular diabetology","preclinical","article","10.1186/s12933-023-01940-2","37592302","PMC10436634",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; Preprint; article; preprint"],["R0029761","Gut Peptide Agonism in the Treatment of Obesity and Diabetes.","Grandl G","2019","Comprehensive physiology","narrative_review","article","10.1002/cphy.c180044","31853954",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; other"],["R0029762","Glucagon Control on Food Intake and Energy Balance.","Al-Massadi O","2019","International journal of molecular sciences","narrative_review","article","10.3390/ijms20163905","31405212","PMC6719123",null,"S001387","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0029763","Anti-Obesity Therapy: from Rainbow Pills to Polyagonists.","Müller TD","2018","Pharmacological reviews","narrative_review","article","10.1124/pr.117.014803","30087160",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0029764","Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study.","Di Prospero NA","2021","Clinical obesity","randomized_trial","article","10.1111/cob.12433","33475251",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; article"],["R0029765","Recent advances of GIP and future horizons.","Holst JJ","2020","Peptides","narrative_review","article","10.1016/j.peptides.2019.170230","31838219",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029766","GLP-1-mediated delivery of the PPAR𝛼/𝛾 dual-agonist Tesaglitazar improves obesity and glucose metabolism in mice","Quarta C","2021","Research Square","preclinical","preprint","10.21203/rs.3.rs-1081959/v1",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0029767","Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus.","Patel VJ","2018","World journal of diabetes","preclinical","article","10.4239/wjd.v9.i6.80","29988851","PMC6033704",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029768","Cracking the combination: Gut hormones for the treatment of obesity and diabetes.","Alexiadou K","2019","Journal of neuroendocrinology","narrative_review","article","10.1111/jne.12664","30466162","PMC6563152",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0029769","Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.","Li Y","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15407","38105342",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II; Journal Article; article"],["R0029770","Therapeutic potential of coagonists of glucagon and GLP-1.","Patel VJ","2014","Cardiovascular & hematological agents in medicinal chemistry","preclinical","article","10.2174/1871525712666141019194025","25330114",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029771","Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists.","Miyata S","2021","Scientific reports","preclinical","article","10.1038/s41598-021-88493-0","33911126","PMC8080777",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029772","GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight in obese mice","Sachs S","2022","bioRxiv","preclinical","preprint","10.1101/2022.03.15.484530",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0029773","Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin.","Bower RL","2018","ACS pharmacology & translational science","other","article","10.1021/acsptsci.8b00002","32219203","PMC7088893",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029774","A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice.","Bianchini G","2021","Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","preclinical","article","10.1016/j.biopha.2021.111613","33895521",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029775","An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation.","Khajavi N","2018","Cellular signalling","preclinical","article","10.1016/j.cellsig.2018.07.006","30055232",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029776","Multifunctional Antibody Agonists Targeting Glucagon-like Peptide-1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide Receptors.","Wang Y","2016","Angewandte Chemie (International ed. in English)","preclinical","article","10.1002/anie.201606321","27595986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029777","Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans.","Sørensen KV","2021","Clinical nutrition (Edinburgh, Scotland)","nonrandomized_study","article","10.1016/j.clnu.2020.09.043","33059911",null,"ClinicalTrials.gov:NCT03062592; ClinicalTrials.gov:NCT03305367",null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0029778","New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders.","Irwin N","2015","World journal of diabetes","narrative_review","article","10.4239/wjd.v6.i15.1285","26557956","PMC4635139",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029779","In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic.","Säll C","2022","Drug metabolism and disposition: the biological fate of chemicals","other_trial","article","10.1124/dmd.122.000865","35680133",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; article"],["R0029780","Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments.","Messineo L","2024","Sleep medicine reviews","narrative_review","article","10.1016/j.smrv.2024.101996","39244884",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029781","Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.","Jall S","2017","Molecular metabolism","nonrandomized_study","article","10.1016/j.molmet.2017.02.002","28462078","PMC5404097",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; brief-report; article"],["R0029782","Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity.","Quarta C","2017","Cell metabolism","preclinical","article","10.1016/j.cmet.2017.08.023","28943448",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029783","A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease.","Li T","2018","Hippocampus","preclinical","article","10.1002/hipo.22837","29473979",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029784","A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.","Zhou J","2017","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2017.07.046","28772236",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029785","GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue.","Campbell JE","2022","Diabetes","preclinical","article","10.2337/db21-1166","35192688","PMC7612781",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0029786","Kisspeptin-52 partially rescues the activity of the hypothalamus-pituitary-gonadal axis in underweight male rats dosed with an anti-obesity compound.","Bolze F","2020","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2020.115152","32726590",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029787","Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors.","Khajavi N","2017","Endocrine development","other","article","10.1159/000475737","28873389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; book-chapter"],["R0029788","A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice.","Ma T","2020","European journal of medicinal chemistry","preclinical","article","10.1016/j.ejmech.2020.112496","32682196",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029789","The potential of glucagon-like peptide 1 to reverse high-fat, high-sugar diet-related metabolic damage.","Müller TD","2014","Expert review of endocrinology & metabolism","preclinical","article","10.1586/17446651.2014.914850","30763988",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; editorial"],["R0029790","Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.","Patel V","2017","Drug research","preclinical","article","10.1055/s-0043-118808","28898910",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029791","Scaling it down: new in vitro tools to get the balance right.","Biggs EK","2017","The Biochemical journal","preclinical","article","10.1042/bcj20160874","28008090",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0029792","DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.","Cao Y","2018","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2018.03.024","29551659",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029793","Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition.","Patel V","2018","Chemico-biological interactions","preclinical","article","10.1016/j.cbi.2018.01.004","29325849",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029794","Evaluating Drug-Drug Interaction Risk Associated with Peptide Analogs Using advanced In Vitro Systems.","Nørgaard RA","2024","Drug metabolism and disposition: the biological fate of chemicals","preclinical","article","10.1124/dmd.123.001441","38050097",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029795","Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson's Disease Mouse Model.","Zhang Z","2021","Journal of Parkinson's disease","preclinical","article","10.3233/jpd-202318","33523018",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029796","Effects of long-acting analogues of lamprey GLP-1 and paddlefish glucagon on alpha- to beta-cell transdifferentiation in an insulin-deficient transgenic mouse model.","Graham GV","2021","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.3328","33843129",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029797","A pH-Induced Switch in Human Glucagon-like Peptide-1 Aggregation Kinetics.","Zapadka KL","2016","Journal of the American Chemical Society","other","article","10.1021/jacs.6b05025","27998088",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029798","Seasonal heavy metal mobilization in a tropical artisanal mining system: a source-to-receptor assessment.","Isah A","2026","Environmental science and pollution research international","other","article","10.1007/s11356-026-38146-4","42604914",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029799","The preproglucagon derived peptides and energy homeostasis","Parker J","2013","Imperial College London","preclinical","article","10.25560/10956",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; article"],["R0029800","Unraveling oxyntomodulin, GLP1's enigmatic brother.","Pocai A","2012","The Journal of endocrinology","preclinical","article","10.1530/joe-12-0368","23019069","PMC3493657",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0029801","Identification of Crocetin as a Dual Agonist of GPR40 and GPR120 Responsible for the Antidiabetic Effect of Saffron.","Zhao X","2023","Nutrients","other","article","10.3390/nu15224774","38004168","PMC10675071",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029802","Modeling analysis of inositol 1,4,5-trisphosphate receptor-mediated Ca2+ mobilization under the control of glucagon-like peptide-1 in mouse pancreatic β-cells.","Takeda Y","2016","American journal of physiology. Cell physiology","preclinical","article","10.1152/ajpcell.00234.2015","26741144","PMC4888524",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0029803","Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis.","Song N","2022","Acta pharmaceutica Sinica. B","preclinical","article","10.1016/j.apsb.2021.12.016","35646543","PMC9136578",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029804","Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activity.","Camacho RC","2020","mAbs","preclinical","article","10.1080/19420862.2020.1794687","32744157","PMC7531507",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Video-Audio Media; report; article"],["R0029805","Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American Heart Association Scientific Sessions.","Abdul Jabbar AB","2026","Current atherosclerosis reports","other_trial","article","10.1007/s11883-025-01376-x","41493497",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0029806","A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.","Bhat VK","2013","Diabetologia","preclinical","article","10.1007/s00125-013-2892-2","23503814",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029807","Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.","Chiang JY","2017","Digestive diseases (Basel, Switzerland)","narrative_review","article","10.1159/000450981","28249273","PMC5470086",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0029808","Oxyntomodulin analogue increases energy expenditure via the glucagon receptor.","Scott R","2018","Peptides","preclinical","article","10.1016/j.peptides.2018.04.008","29680267","PMC5958244",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029809","Insulinotropic and glucose-lowering peptides from phylogenetically ancient fish with potential for therapy of type 2 diabetes","Graham G","2019","Ulster University","preclinical","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0029810","Oxyntomodulin: Actions and role in diabetes.","Holst JJ","2018","Peptides","narrative_review","article","10.1016/j.peptides.2017.09.018","29412831",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029811","Positive association of glucagon with bone turnover markers in type 2 diabetes: A cross-sectional study.","Guo H","2022","Diabetes/metabolism research and reviews","other","article","10.1002/dmrr.3550","35621313",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029812","Pharmacological evidence for the relationship between the NMDA receptor and nitric oxide pathway and the antidepressant-like effects of glucagon-like peptide-2 in the mouse forced-swim test.","Sasaki-Hamada S","2019","Behavioural brain research","preclinical","article","10.1016/j.bbr.2019.02.028","30779973",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029813","Obesity medications in development.","Rebello CJ","2020","Expert opinion on investigational drugs","other_trial","article","10.1080/13543784.2020.1705277","31847611","PMC6990416",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; research-article; article"],["R0029814","A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice.","Valdecantos MP","2017","Hepatology (Baltimore, Md.)","preclinical","article","10.1002/hep.28962","27880981",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029815","GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion.","Chepurny OG","2016","Molecular endocrinology (Baltimore, Md.)","preclinical","article","10.1210/me.2015-1306","27082897","PMC4884340",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029816","Hepatic hormone FGF21 and its analogues in clinical trials.","Shao W","2022","Chronic diseases and translational medicine","narrative_review","article","10.1016/j.cdtm.2021.08.005","35620160","PMC9126297",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029817","Are peptide conjugates the golden therapy against obesity?","Brandt SJ","2018","The Journal of endocrinology","narrative_review","article","10.1530/joe-18-0264","29848610","PMC6026923",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0029818","RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling.","Cegla J","2017","Endocrinology","other","article","10.1210/en.2016-1755","28586439","PMC5551549",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029819","A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus.","Mansur SA","2016","Bone","preclinical","article","10.1016/j.bone.2016.04.001","27062994",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029820","Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.","Sadry SA","2013","Nature reviews. Endocrinology","narrative_review","article","10.1038/nrendo.2013.47","23478327",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029821","Engineering an oxyntomodulin analogue for weight reduction","Price S","2015","Imperial College London","preclinical","article","10.25560/54898",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0029822","Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?","Conceição-Furber E","2022","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2022.868037","35547006","PMC9081793",null,"S002808","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0029823","The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.","Larsen AT","2019","The Journal of pharmacology and experimental therapeutics","preclinical","article","10.1124/jpet.119.257576","31028106",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029824","Publisher Correction: Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors.","Chepurny OG","2018","Scientific reports","notice","article","10.1038/s41598-018-24359-2","29654321","PMC5899092",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0029825","Max Bergmann award lecture:Macromolecular medicinal chemistry as applied to metabolic diseases.","DiMarchi RD","2018","Journal of peptide science : an official publication of the European Peptide Society","narrative_review","article","10.1002/psc.3056","29322647",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; article"],["R0029826","Action and therapeutic potential of oxyntomodulin.","Pocai A","2014","Molecular metabolism","narrative_review","article","10.1016/j.molmet.2013.12.001","24749050","PMC3986661",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029827","Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.","Pocai A","2009","Diabetes","preclinical","article","10.2337/db09-0278","19602537","PMC2750209",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029828","DPP-IV-resistant, long-acting oxyntomodulin derivatives.","Santoprete A","2011","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.1328","21294225",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029829","[Dual co-agonist CI-1206 antagonizes Aβ1-42-induced impairments in spatial learning and memory in mice].","Yang J","2016","Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","preclinical","article","10.13459/j.cnki.cjap.2016.06.018","29926629",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029830","Tumor necrosis factor α decreases glucagon-like peptide-2 expression by up-regulating G-protein-coupled receptor 120 in Crohn disease.","Tsukahara T","2015","The American journal of pathology","preclinical","article","10.1016/j.ajpath.2014.09.010","25447053",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029831","Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.","Day JW","2012","Biopolymers","preclinical","article","10.1002/bip.22072","23203689",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029832","Peptide lipidation stabilizes structure to enhance biological function.","Ward BP","2013","Molecular metabolism","preclinical","article","10.1016/j.molmet.2013.08.008","24327962","PMC3854995",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029833","FRET Reporter Assays for cAMP and Calcium in a 96-well Format Using Genetically Encoded Biosensors Expressed in Living Cells.","Milliken BT","2020","Bio-protocol","other","article","10.21769/bioprotoc.3641","32775537","PMC7409823",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; methods-article; article"],["R0029834","A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.","Day JW","2009","Nature chemical biology","preclinical","article","10.1038/nchembio.209","19597507",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029835","Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status.","Kumar MS","2019","Frontiers in nutrition","narrative_review","article","10.3389/fnut.2019.00011","30834248","PMC6388543",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029836","New pharmacologic agents for diabetes.","Bailey CJ","2001","Current diabetes reports","other_trial","article","10.1007/s11892-001-0023-9","12643107",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Review"],["R0029837","Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.","D'Amore C","2014","Journal of medicinal chemistry","preclinical","article","10.1021/jm401873d","24387325",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029838","Genotoxicity testing of peptides: folate deprivation as a marker of exaggerated pharmacology.","Guérard M","2014","Toxicology and applied pharmacology","preclinical","article","10.1016/j.taap.2014.06.022","24997324",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029839","Combined immunotherapy with \"anti-insulin resistance\" therapy as a novel therapeutic strategy against neurodegenerative diseases.","Takamatsu Y","2017","NPJ Parkinson's disease","other","article","10.1038/s41531-016-0001-1","28649604","PMC5445606",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029840","Fibroblast growth factor 21 mediates specific glucagon actions.","Habegger KM","2013","Diabetes","other_trial","article","10.2337/db12-1116","23305646","PMC3636653",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; research-article; article"],["R0029841","The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice.","Beaudry JL","2019","Molecular metabolism","preclinical","article","10.1016/j.molmet.2019.01.011","30772257","PMC6437632",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0029842","Broadband \"infinite-speed\" magic-angle spinning NMR spectroscopy.","Hu YY","2009","Journal of the American Chemical Society","other","article","10.1021/ja903334p","19489580",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029843","In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.","Chin NX","1986","Antimicrobial agents and chemotherapy","preclinical","article","10.1128/aac.29.4.675","3085584","PMC180465",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029844","Pharmacokinetic interactions between theophylline and other medication (Part I).","Upton RA","1991","Clinical pharmacokinetics","narrative_review","article","10.2165/00003088-199120010-00005","1674242",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029845","Characterization of the adrenal 11 beta-hydroxylase in inbred salt-sensitive and resistant rats.","Griffing GT","1991","Endocrine research","preclinical","article","10.1080/07435809109027190","1715269",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, P.H.S."],["R0029846","[In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].","Kawahara S","1991","Kekkaku : [Tuberculosis]","preclinical","article",null,"1942726",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; English Abstract; Journal Article"],["R0029847","Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.","Wolfhagen MJ","1990","Antimicrobial agents and chemotherapy","randomized_trial","article","10.1128/aac.34.3.409","2110437","PMC171606",null,null,"pubmed","FALSE","free_to_read","2",null,"Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0029848","In vitro activity of fleroxacin against aerobic gram-positive bacteria including Corynebacterium jeikeium.","Hohl P","1990","Chemotherapy","preclinical","article","10.1159/000238796","2127242",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0029849","Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.","Jones RN","1989","Antimicrobial agents and chemotherapy","other","article","10.1128/aac.33.6.944","2504106","PMC284260",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029850","In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.","Maeda H","1988","Antimicrobial agents and chemotherapy","preclinical","article","10.1128/aac.32.7.1080","2847640","PMC172348",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029851","In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.","Hirai K","1986","Antimicrobial agents and chemotherapy","preclinical","article","10.1128/aac.29.6.1059","2942103","PMC180500",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029852","In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.","Le Saux NM","1987","Antimicrobial agents and chemotherapy","preclinical","article","10.1128/aac.31.7.1153","2959199","PMC174890",null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0029853","Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys.","Kusajima H","1986","Antimicrobial agents and chemotherapy","preclinical","article","10.1128/aac.30.2.304","3094441","PMC180539",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029854","High-performance liquid chromatographic determination of 6,8-difluoro-1-(2-fluoroethyl)-1,4- dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid and its metabolites in laboratory animals.","Kusajima H","1986","Journal of chromatography","preclinical","article","10.1016/s0378-4347(00)83572-0","3095363",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029855","In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.","Fass RJ","1987","Diagnostic microbiology and infectious disease","preclinical","article","10.1016/0732-8893(87)90178-7","3107872",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0029856","In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.","Hohl P","1987","European journal of clinical microbiology","preclinical","article","10.1007/bf02013118","3117539",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029857","Fleroxacin (Ro 23-6240): activity in vitro against 355 enteropathogenic and non-fermentative gram-negative bacilli and Legionella pneumophila.","Hohl P","1987","The Journal of antimicrobial chemotherapy","preclinical","article","10.1093/jac/20.3.373","3119553",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029858","RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.","Fuchs PC","1987","Diagnostic microbiology and infectious disease","preclinical","article","10.1016/0732-8893(87)90066-6","3121241",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0029859","Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.","Weidekamm E","1987","Antimicrobial agents and chemotherapy","randomized_trial","article","10.1128/aac.31.12.1909","3125788","PMC175826",null,null,"pubmed","FALSE","free_to_read","2",null,"Clinical Trial; Journal Article; Randomized Controlled Trial"],["R0029860","Elimination of antibiotic-resistant plasmids by quinolone antibiotics.","Fu KP","1988","Chemotherapy","preclinical","article","10.1159/000238601","3141117",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029861","In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis.","Nagayama A","1988","Antimicrobial agents and chemotherapy","preclinical","article","10.1128/aac.32.11.1735","3150916","PMC175961",null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0029862","Comparative antibacterial activity of new quinolone-carboxylic acid derivatives.","Mitsuhashi S","1988","Reviews of infectious diseases","preclinical","article","10.1093/clinids/10.supplement_1.s27","3347811",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0029863","Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.","Jones RN","1995","Diagnostic microbiology and infectious disease","other","article","10.1016/0732-8893(94)00061-z","7554803",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029864","[Basic and clinical studies of fleroxacin on infectious enteritis. Research Group of AM-833 on infectious enteritis].","Sagara H","1994","Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases","other_trial","article","10.11150/kansenshogakuzasshi1970.68.1390","7829908",null,null,null,"pubmed","FALSE","open_pdf","5",null,"Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article; Multicenter Study"],["R0029865","Determination of bioaccumulation of heavy metals and selenium in tissues of brown trout Salmo trutta macrostigma (Duméril, 1858) from Munzur Stream, Tunceli, Turkey.","Can E","2012","Bulletin of environmental contamination and toxicology","preclinical","article","10.1007/s00128-012-0824-3","23001421",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029866","[Modern methods of correction of systemic inflammation and insulin resistance by patients with coronary heart disease and diabetes mellitus type 2].","Rasin MS","2014","Likars'ka sprava","narrative_review","article",null,"25286600",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029867","GLP-1 and Amylin in the Treatment of Obesity.","Jorsal T","2016","Current diabetes reports","narrative_review","article","10.1007/s11892-015-0693-3","26699764",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029868","Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.","Finan B","2016","Cell","preclinical","article","10.1016/j.cell.2016.09.014","27720451",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0029869","Dietary Glycine Is Rate-Limiting for Glutathione Synthesis and May Have Broad Potential for Health Protection.","McCarty MF","2018","Ochsner journal","narrative_review","article",null,"29559876","PMC5855430",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029870","Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years.","Rose F","2019","Expert opinion on drug discovery","narrative_review","article","10.1080/17460441.2019.1646243","31355685",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0029871","Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes.","Visentin R","2020","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.13939","31808298",null,"ClinicalTrials.gov:NCT02411825","S003303","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0029872","Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions.","Hasib A","2020","Clinical medicine insights. Endocrinology and diabetes","narrative_review","article","10.1177/1179551420905844","32110131","PMC7025423",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029873","Glucagon-based therapy: Past, present and future.","Patil M","2020","Peptides","narrative_review","article","10.1016/j.peptides.2020.170296","32147318",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029874","Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions.","English A","2019","Clinical medicine insights. Endocrinology and diabetes","narrative_review","article","10.1177/1179551419888871","32425629","PMC7216561",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029875","The Role of Incretins on Insulin Function and Glucose Homeostasis.","Holst JJ","2021","Endocrinology","narrative_review","article","10.1210/endocr/bqab065","33782700","PMC8168943",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029876","Ligand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery.","Mizera M","2021","International journal of molecular sciences","nonrandomized_study","article","10.3390/ijms22084060","33920024","PMC8071054",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0029877","NMR spectroscopy probes microstructure, dynamics and doping of metal halide perovskites.","Kubicki DJ","2021","Nature reviews. Chemistry","narrative_review","article","10.1038/s41570-021-00309-x","37118421",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029878","100 years of glucagon and 100 more.","Wewer Albrechtsen NJ","2023","Diabetologia","narrative_review","article","10.1007/s00125-023-05947-y","37367959","PMC13288116",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0029879","Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions.","Choudhuri G","2023","Cureus","other_trial","article","10.7759/cureus.42852","37664266","PMC10473263",null,null,"pubmed","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0029880","Antidiabetic Drugs in Breast Cancer Patients.","Garczorz W","2024","Cancers","narrative_review","article","10.3390/cancers16020299","38254789","PMC10813754",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0029881","How do we balance metabolic surgery and emerging incretin-based medical therapies for type 2 diabetes?","Saeed H","2025","Expert review of endocrinology & metabolism","commentary","article","10.1080/17446651.2025.2529386","40622565",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0029882","The role of the incretin GIP in inflammation.","Rossi G","2026","Journal of endocrinological investigation","narrative_review","article","10.1007/s40618-025-02719-w","41082103","PMC12924832",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029883","Phytoremediation patterns of riparian macrophytes along a spatial pollution gradient: an integrated risk-performance assessment in the Riva stream, Türkiye.","Sağlam R","2026","International journal of phytoremediation","other","article","10.1080/15226514.2026.2682405","42258769",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0029884","Obesity in CKD: The Double-Edged Sword.","Parmar MS","2026","Journal of nephrology","other","article","10.1093/joneph/aajag256","42841284",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029885","UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.","Zhou Z","2026","Cell metabolism","randomized_trial","article","10.1016/j.cmet.2026.09.021","42843337",null,"ClinicalTrials.gov:NCT07177469","S002813","pubmed; openalex","TRUE","free_to_read","1","FALSE","Journal Article; article"],["R0029886","Early Uptake of Oral Semaglutide for Obesity Treatment After Regulatory Approval.","Jelwan Y","2026","Annals of internal medicine","other","article","10.7326/annals-26-02436","42863123",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029887","Characterizing the Adverse Event Profile of Semaglutide: A Comprehensive U.S. Food and Drug Administration Adverse Event Reporting System-Based Pharmacovigilance Study.","Thawkar SA","2026","Clinical nutrition ESPEN","nonrandomized_study","article","10.1016/j.clnesp.2026.105169","42863671",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0029888","Cutaneous Effects and Aesthetic Management of Glucagon-like Peptide-1 Receptor Agonists: A Narrative Review.","Hu BD","2026","Clinics in dermatology","narrative_review","article","10.1016/j.clindermatol.2026.09.041","42863768",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; review"],["R0029889","Does Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?","He J","2026","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.71446","42864267",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029890","GLP-1 Receptor Agonists and Thromboembolic Risk in Patients With Atrial Fibrillation or Flutter and Type 2 Diabetes: A Propensity Score-Matched Cohort Study.","Lo SW","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71443","42864268",null,null,null,"pubmed; openalex","TRUE","paywalled","4","FALSE","Journal Article; article"],["R0029891","Hormonal regulation of human adipose tissue lipolysis: impact of adipose GIP system in overweight and obesity.","Brachs S","2025","European journal of endocrinology","other_trial","article","10.1093/ejendo/lvae151","39935317",null,"DRKS:DRKS00010049",null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; article"],["R0029892","Design and biological evaluation of triagonist GLP-1R/GCGR/GIPR peptides as potential therapeutic agents for diabetes and obesity.","Kalinowska I","2026","RSC medicinal chemistry","preclinical","article","10.1039/d5md01086a","41869515","PMC13001729",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029893","6494 GLP-1/GIP/Glucagon Triagonist Improves Glycemic Control via Gαq Signaling Pathway and TRPM5 Activation",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11454714",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0029894","Novel Peptides as GIPR/GLP-1R/GCGR Triagonists for Treating Type 2 Diabetes Mellitus.","Hu Q","2025","ACS medicinal chemistry letters","commentary","article","10.1021/acsmedchemlett.5c00435","40832525","PMC12358996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0029895","Improving Efficacy Without Increasing Side Effects? Exploring the Impact of a Novel GLP-1-Glucagon Dual Receptor Agonist Upon Metabolic Dysfunction-Associated Steatohepatitis.","Mullish BH","2026","Gastroenterology","other","article","10.1053/j.gastro.2026.01.016","41620034",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029896","Top-Line Phase 2 Results of DD01, a Dual GLP-1/Glucagon Agonist, Lead to Rapid Improvements in Liver and Metabolic Endpoints in Patients With MASLD/MASH.",null,"2025","Gastroenterology & hepatology","other_trial","article",null,"41660647","PMC12879041",null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Journal Article; other; article"],["R0029897","GLP-1/GIP/glucagon receptor triagonism gets its try in humans.","Finan B","2022","Cell metabolism","commentary","article","10.1016/j.cmet.2021.12.010","34986336",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Comment"],["R0029898","Stimulating intestinal GIP release reduces food intake and body weight in mice.","Lewis JE","2024","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.101945","38653401","PMC11070708",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029899","Correction: Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer's disease.","Abdulhameed N","2026","Alzheimer's research & therapy","notice","article","10.1186/s13195-026-02200-7","42827268","PMC13633632",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0029900","Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications.","Bloomgarden Z","2026","Journal of diabetes investigation","narrative_review","article","10.1111/jdi.70427","42678336","PMC13532683",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029901","Potential of a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes.","Araki E","2022","Journal of diabetes investigation","preclinical","article","10.1111/jdi.13896","36039895","PMC9720191",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0029902","Impaired Brain Incretin and Gut Hormone Expression in Human Alcohol-Related Brain Damage: Opportunities for Therapeutic Targeting.","de la Monte SM","2026","Biomolecules","other","article","10.3390/biom16010099","41594639","PMC12838672",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029903","Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy.","Sánchez-Garrido MA","2024","Nature communications","preclinical","article","10.1038/s41467-024-52898-y","39353946","PMC11445520",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0029904","β Cell Gαs signaling is critical for physiological and pharmacological enhancement of insulin secretion.","Capozzi ME","2025","The Journal of clinical investigation","preclinical","article","10.1172/jci183741","40526441","PMC12352888",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0029905","548. Glucagon-like peptide-1 agonists and their association with worsening mental illness in individuals with depression and anxiety. Results from a nationwide cohort study from Sweden",null,"2026","The international journal of neuropsychopharmacology","nonrandomized_study","article",null,null,"PMC13556605",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0029906","GLP-1 receptor agonism extends median lifespan in mice.","Kriebs A","2026","Nature aging","preclinical","article","10.1038/s43587-026-01224-w","42693292",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029907","GLP-1 receptor agonism in prostate cancer: insights and perspectives.","La Vignera S","2026","Endocrine-related cancer","other","article","10.1530/erc-26-0398","42659461",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029908","Nonarteritic Anterior Ischemic Optic Neuropathy and Glucagon-Like Peptide-1 Agonist Therapies: An Important Rare Issue, Lacking Adequate Data.","Kupersmith MJ","2026","Ophthalmology","commentary","article","10.1016/j.ophtha.2026.08.024","42758068",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0029909","Response to Jean et al, \"Alopecia after glucagon-like peptide-1 agonist therapy: A TriNetX Database active comparator retrospective cohort study\".","Lauck KC","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.08.074","42637046",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0029910","Commentary on: Genetic predictors of GLP1 receptor agonist weight loss and side effects (Nature volume 653, pages 770-775 (2026)).","Toda G","2026","Journal of diabetes investigation","commentary","article","10.1111/jdi.70436","42723561","PMC13563256",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; editorial"],["R0029911","Persistence in GLP-1-Based Therapy Among Adults with Obesity and Type 2 Diabetes: A Narrative Review of Definitions, Real-World Outcomes, and Determinants.","Wang T","2026","Current diabetes reports","nonrandomized_study","article","10.1007/s11892-026-01639-0","42603234","PMC13477449",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; review"],["R0029912","Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.","Mozaffarian D","2025","American journal of lifestyle medicine","notice","article","10.1177/15598276251344827","40452753","PMC12125019",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Published Erratum; research-article; correction; erratum; article"],["R0029913","Letter from the Editor: Glucagon-like peptide-1 agonists in dermatology.","Elston DM","2026","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2026.06.133","42398779",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0029914","All roads lead to Rome: Emergence of Mechanistic Divergence Shapes Activation of Class B1 G-Protein Coupled Receptors.","Bansal P","2026","bioRxiv : the preprint server for biology","other","article","10.64898/2026.01.05.697796","41542565","PMC12803111",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0029915","Glucagon-like peptide-1 receptor agonism in dermatology: Emerging immunologic potential for chronic inflammatory skin diseases.","Said JT","2025","Journal of the European Academy of Dermatology and Venereology : JEADV","other","article","10.1111/jdv.70097","41287446",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029916","Five-year outcomes of glucagon-like peptide-1 agonists in hypertrophic cardiomyopathy: A population-based retrospective study.","Ong TE","2026","Journal of cardiology","nonrandomized_study","article","10.1016/j.jjcc.2026.06.015","42349649",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0029917","Incretin Receptor Agonists and CPAP Use in Adults With Diabetes, Obesity, and Obstructive Sleep Apnea.","Tang H","2025","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2025.50978","41632138","PMC12723546",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0029918","Glucagon-like peptide-1 agonist use for obesity treatment in patients with left ventricular assist devices.","Edwards M","2024","JHLT open","other","article","10.1016/j.jhlto.2024.100114","40143903","PMC11935309",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; brief-report; article"],["R0029919","Safety, tolerability, pharmacodynamics, and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects.","Ding Y","2021","Expert opinion on investigational drugs","randomized_trial","article","10.1080/13543784.2021.2008906","34793265",null,"ChiCTR:ChiCTR-IPC-15007190",null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; article"],["R0029920","Glucagon-like peptide-1 agonists for treating substance use disorders: ready for clinical use?","Meulman G","2026","Internal medicine journal","commentary","article","10.1111/imj.70458","42126341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0029921","Molecular strategies for heterocyclic frameworks in antidiabetic drug discovery: a vision from 2020-2024.","Tahlan S","2026","Future medicinal chemistry","narrative_review","article","10.1080/17568919.2026.2658007","42003351","PMC13166244",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029922","The wide world of glucagon-like peptide-1 agonist therapy: The thrill of weight loss and the agony of alopecia.","Heymann WR","2026","Journal of the American Academy of Dermatology","commentary","article","10.1016/j.jaad.2026.04.1979","42069253",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0029923","Recent Advances in Diabetes Therapies in Asia.","Qian L","2026","Diabetes care","other_trial","article","10.2337/dci26-0057","42627354",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0029924","Incretin Receptor Agonists and Nonarteritic Anterior Ischemic Optic Neuropathy and Other Ocular Complications.","Ong SS","2025","JAMA network open","other","article","10.1001/jamanetworkopen.2025.26336","40788651",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029925","Gastric Emptying, Colon Filling, and Multiregional Gut Transit Delays Are Prevalent on Glucagon-Like Peptide-1 Agonists.","Rolak SC","2026","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2026.02.025","41825625",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029926","Incretin-based multi-agonist reverses obesity and diabetes.","Crunkhorn S","2026","Nature reviews. Drug discovery","commentary","article","10.1038/d41573-026-00087-5","42174311",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0029927","Erratum to: A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease.","Cai HY","2023","Journal of Alzheimer's disease : JAD","notice","article","10.3233/jad-239006","37545245",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0029928","Corrigendum to \"Glucagon-like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome\": [AACE Endocrinology and Diabetes 12 (2025) 67-70].","Auth R","2026","AACE endocrinology and diabetes","notice","article","10.1016/j.aed.2026.01.002","41938276","PMC13043468",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; Corrected and Republished Article; erratum"],["R0029929","Alopecia after glucagon-like peptide-1 agonist therapy: A TriNetX Database active comparator retrospective cohort study.","Lauck KC","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.03.015","41825835",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; article"],["R0029930","Delivery of incretin receptor agonists to the brain","Rhea E","2024","Alzheimer's & dementia : the journal of the Alzheimer's Association","preclinical","article","10.1002/alz.089829",null,"PMC11712837",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0029931","Sarcopenia considerations when prescribing glucagon-like peptide-1 agonists to older adults.","Mohamad AA","2026","Korean journal of family medicine","commentary","article","10.4082/kjfm.25.0397","41593882","PMC13033422",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029932","Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists.","Chang YC","2026","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwaf017","39878555",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029933","Genetic factors influence GLP1 receptor agonist response.","Brandt M","2026","Nature genetics","other","article","10.1038/s41588-026-02621-y","42135474",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029934","Glucagon-Like Peptide-1 Agonists Confer no Additional Benefit during Bunion Correction Procedures with Regards to Complications and Adverse Effects",null,"2025","Foot & ankle orthopaedics","other","article",null,null,"PMC12743936",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0029935","GLP-1 receptor agonism counteracts omics aging in mice.","Kriebs A","2026","Nature aging","preclinical","article","10.1038/s43587-025-01063-1","41540278",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029936","The Safety of GLP1 Receptor Agonist Usage in Mohs Micrographic Surgery Patients.","Schoenberg M","2026","Journal of drugs in dermatology : JDD","other","article","10.36849/jdd.9753","41931680",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029937","Multiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors.","Mayne KJ","2026","European journal of internal medicine","narrative_review","article","10.1016/j.ejim.2026.107193","42786044",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029938","Incretin receptor agonists rapidly and markedly attenuate multi‐cause insulin resistance in the hippocampal formation from MCI and AD dementia cases","Talbot K","2024","Alzheimer's & dementia : the journal of the Alzheimer's Association","other","article","10.1002/alz.089821",null,"PMC11713402",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0029939","Obesity-Related Functional Hypogonadism Requires Therapeutic Recalibration: Implications for GLP-1-Based Therapies.","Jensterle M","2026","Andrology","other","article","10.1111/andr.70264","42206835","PMC13432575",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0029940","Relative effects of genetically proxied glucagon-like peptide-1 receptor agonism on muscle and fat mass: A Mendelian randomization study.","Liang Y","2025","Diabetes, obesity & metabolism","commentary","article","10.1111/dom.16171","39762985",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029941","Oxidative stress, aging, metabolism, SIRT1, and the gut microbiota: the neurocardiac basis of cognitive loss.","Maiese K","2027","Medical gas research","narrative_review","article","10.4103/mgr.medgasres-d-26-00073","42545731",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029942","Glucagon-like peptide-1 agonists, weight and blood pressure change after smoking cessation.","Berlin I","2025","European journal of preventive cardiology","commentary","article","10.1093/eurjpc/zwaf180","40130541",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0029943","A minimal three-arm oral regimen for healthspan: mechanistic alignment with transcriptomic signals from a large parental-lifespan GWAS.","Cheung N","2026","Frontiers in aging","other","article","10.3389/fragi.2026.1856979","42688195","PMC13533926",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; preprint; article"],["R0029944","Care of the Patient Taking Glucagon-like Peptide-1 Agonists.","Clifford T","2025","Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses","other","article","10.1016/j.jopan.2025.05.002","40750133",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029945","GLP-1s: New daily weight loss pill Foundayo approved by UK regulator.","Wise J","2026","BMJ (Clinical research ed.)","other","article","10.1136/bmj-2026-100547","42580768",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029946","Corrigendum to \"Glucagon-like peptide-1 agonists alleviate adenine-induced nephrotoxicity in rats: interaction with the renin-angiotensin system and role of NLRP-3 inflammasome, nephrin and KIM-1\" [Biochem. Pharmacol. 242(P4) (2025) 117431].","Nematalla HA","2026","Biochemical pharmacology","notice","article","10.1016/j.bcp.2025.117552","41275668",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0029947","Evolution of myocardial steatosis in patients with type 2 diabetes treated by GLP1 receptor agonists: LICAS study","Houbachi L","2024","Research Square","nonrandomized_study","preprint","10.21203/rs.3.rs-4706592/v1",null,null,null,null,"europepmc; openalex","TRUE","free_to_read","4","FALSE","Preprint; preprint"],["R0029948","Cardiac  <i>GLP1R<\/i>  gene Expression: A Cross-Species Single-Cell Transcriptomic Analysis","Dostal C","2026","bioRxiv","preclinical","preprint","10.64898/2026.01.18.700176",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint; article"],["R0029949","Pharmacotherapy for Management of Type 2 Diabetes and CKM Syndrome: SGLT2 Inhibitors and GLP-1-Based Therapies for All vs a Risk-Based Approach?","Pandey A","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.06.012","42554383",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029950","Running out the clock: Circadian rhythm dysfunction in cognitive disease.","Maiese K","2026","International review of neurobiology","narrative_review","article","10.1016/bs.irn.2026.08.015","42767717","PMC13595999",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; research-article"],["R0029951","[Psychotropic drug-related weight gain-Are incretins/twincretins an option?].","Paulzen M","2025","Der Nervenarzt","narrative_review","article","10.1007/s00115-024-01788-1","39774952",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0029952","Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy.","Hope DCD","2023","Peptides","preclinical","article","10.1016/j.peptides.2023.170962","36736539",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Review; Journal Article; Research Support, Non-U.S. Gov't"],["R0029953","Can glucagon-like peptide 1 agonists redefine polycystic ovary syndrome weight loss management?","Mason I","2025","Fertility and sterility","commentary","article","10.1016/j.fertnstert.2025.06.018","40562296",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0029954","HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo-Controlled, Ascending-Dose Phase 1b Study.","Xu H","2026","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.70160","41803652",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; article"],["R0029955","Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care.","Mogna-Peláez P","2026","The Journal of nutrition","nonrandomized_study","article","10.1016/j.tjnut.2026.101684","42323133","PMC13494215",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0029956","An obligatory role for AgRP neurons in maintaining body temperature during time-restricted feeding.","Su C","2026","Metabolism: clinical and experimental","preclinical","article","10.1016/j.metabol.2026.156595","41850420","PMC13200282",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0029957","Balancing weight and muscle loss in GLP1 receptor agonist therapy.","Sanchis-Gomar F","2025","Nature reviews. Endocrinology","other","article","10.1038/s41574-025-01160-6","40721501",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029958","Comment on: Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study.","Weng CH","2026","Drug safety","nonrandomized_study","article","10.1007/s40264-025-01617-7","41003919",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; letter"],["R0029959","Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders.","Farrugia MA","2025","Current obesity reports","other_trial","article","10.1007/s13679-025-00646-8","40562950","PMC12198343",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0029960","The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus.","Popovic DS","2025","Nature reviews. Endocrinology","other","article","10.1038/s41574-025-01154-4","40670682",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029961","Response to Comment on Foss-Freitas et al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653-659.","Foss-Freitas MC","2025","Diabetes care","nonrandomized_study","article","10.2337/dci24-0080","39977641","PMC11870280",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Letter; article"],["R0029962","Authors' Response to Weng et al.'s Comment on \"Association of GLP1-Receptor Agonists with Risk of Hepatocellular Carcinoma: A Retrospective Cohort Study\".","Mansi IA","2026","Drug safety","nonrandomized_study","article","10.1007/s40264-025-01616-8","41003918",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0029963","A new GLP1, GIP and glucagon receptor triagonist.","Starling S","2022","Nature reviews. Endocrinology","commentary","article","10.1038/s41574-021-00631-w","34992235",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0029964","Glucagon-Like Peptide-1 Agonists in Total Hip Arthroplasty: Complications, Readmissions, and Patient-Reported Outcomes",null,"2024","Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews","narrative_review","article",null,null,"PMC11573327",null,null,"europepmc","TRUE",null,null,null,"review-article; Review; Journal Article"],["R0029965","Combined amylin analogue and GLP1 receptor agonist therapies are highly promising for weight loss.","Tysoe O","2025","Nature reviews. Endocrinology","other","article","10.1038/s41574-025-01156-2","40691511",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029966","Agitation, Alzheimer's disease, and autophagy: mechanistic insights into aging pathways, gut microbiome, and artificial intelligence.","Maiese K","2026","Frontiers in immunology","narrative_review","article","10.3389/fimmu.2026.1846280","42327728","PMC13278926",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029967","Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.","Young KG","2023","Communications medicine","systematic_review","article","10.1038/s43856-023-00359-w","37794166","PMC10551026",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; research-article; article; review"],["R0029968","SAT-661 Hepatic and Cardiovascular Outcomes of Patients with Metabolic Dysfunction-Associated Steatotic-Liver Disease and Diabetes Mellitus Type 2 Treated with Glucagon-Like Peptide 1 Agonists",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12546000",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0029969","An obligatory role for AgRP neurons in maintaining body temperature during time-restricted feeding.","Su C","2025","bioRxiv : the preprint server for biology","preclinical","article","10.64898/2025.12.16.694714","41446256","PMC12724553",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0029970","Glucagon-Like Peptide-1 Agonists and Pediatric Obesity.","Shanti Vaidya S","2025","Pediatrics in review","randomized_trial","article","10.1542/pir.2024-006455","39889784",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0029971","SAT-661 1. Hepatic and Cardiovascular Outcomes of Patients with Metabolic Dysfunction-Associated Steatotic-Liver Disease and Diabetes Mellitus Type 2 Treated with Glucagon-Like Peptide 1 Agonists",null,"2025","Journal of the Endocrine Society","other","article",null,null,"PMC12544146",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0029972","If treating obesity with GLP-1-based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials.","Tentolouris A","2026","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.70394","41486572","PMC12890730",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; article-commentary; article"],["R0029973","Letter to the editor: Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy.","Tareen MK","2025","International journal of cardiology","commentary","article","10.1016/j.ijcard.2025.133211","40164318",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0029974","Pharmacoequity and the Promise of GLP-1 Therapies in Cardiovascular Disease.","Essien UR","2026","Circulation","commentary","article","10.1161/circulationaha.126.080521","42296211",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; editorial"],["R0029975","Muscle mass loss during GLP1 receptor agonist therapy prevented with GDF8 and activin A blockade.","Tysoe O","2025","Nature reviews. Endocrinology","other","article","10.1038/s41574-025-01140-w","40467968",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029976","Building Effective Multimodal Care for Obesity and Comorbidities in the GLP-1 Therapy Era.","Celletti F","2026","JAMA","other","article","10.1001/jama.2026.16540","42821295",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029977","Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","Davies MJ","2026","Diabetes care","other","article","10.2337/dci26-0141","42825450",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article; other"],["R0029978","Identifying predictors of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 agonist use in hospital among adults with diabetes.","Pak LK","2025","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2025.109022","40246666",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0029979","Exploring the hair loss risk in glucagon-like peptide-1 agonists: Emerging concerns and clinical implications.","Buontempo MG","2025","Journal of the European Academy of Dermatology and Venereology : JEADV","other","article","10.1111/jdv.20512","39854119",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029980","Letter: GLP-1 therapy and changing levothyroxine requirements.","Zhang C","2026","Cleveland Clinic journal of medicine","commentary","article","10.3949/ccjm.93c.09003","42680532",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0029981","In Reply: GLP-1 therapy and changing levothyroxine requirements.","Sweis NWG","2026","Cleveland Clinic journal of medicine","commentary","article","10.3949/ccjm.93c.09004","42680528",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter"],["R0029982","Distinct lateral hypothalamic GABAergic ensembles encode motivational salience and value-scaled consumption.","Lee M","2026","Cell reports","other","article","10.1016/j.celrep.2026.118049","42800033",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0029983","Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists.","Reed J","2018","Cardiovascular endocrinology & metabolism","narrative_review","article","10.1097/xce.0000000000000147","31646274","PMC6739887",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0029984","Comment on Foss-Freitas et al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653-659.","Zhou Y","2025","Diabetes care","nonrandomized_study","article","10.2337/dc24-1777","39977632",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Letter; letter"],["R0029985","GLP-1 therapies: an emerging approach for alcohol reduction?","Hendershot CS","2026","Lancet (London, England)","other","article","10.1016/s0140-6736(26)00513-1","42070556",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029986","Allostatic load and pain: instability of a bio-social ecosystem.","Borsook D","2025","Pain","narrative_review","article","10.1097/j.pain.0000000000003716","41086323",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0029987","[Obesity meets Inflammatory Bowel Disease - a Double Whammy? A narrative Review].","Stein J","2026","Zeitschrift fur Gastroenterologie","narrative_review","article","10.1055/a-2778-5748","41862196",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0029988","Should the canine weight-loss drug dirlotapide be resurrected?","Krecic MR","2025","American journal of veterinary research","preclinical","article","10.2460/ajvr.25.05.0175","40882685",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029989","Response to the \"Letter to Editor: GLP-1 Therapy and Wound Healing: Interpreting Conflicting Evidence in Body Contouring Surgery\".","Menkü Özdemir FD","2026","Annals of plastic surgery","commentary","article","10.1097/sap.0000000000004867","42684911",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0029990","Parkinson's disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics.","Foroozanmehr B","2025","Brain research","narrative_review","article","10.1016/j.brainres.2025.149738","40449678",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0029991","Dementia, mood disorders, and aging: Bridging new avenues of care through shared biological pathways.","Maiese K","2026","Aging advances","other","article","10.4103/agingadv.agingadv-d-26-00011","42370305","PMC13309236",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029992","BMI trajectories and their relation to medication, comorbidities, and healthcare service use among people with type 2 diabetes mellitus.","Koivunen S","2026","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2026.113515","42632459",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0029993","WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults.","Dellepiane D","2026","JAMA","other","article","10.1001/jama.2026.0684","41885807",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029994","WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults.","Fallahzadeh MK","2026","JAMA","other","article","10.1001/jama.2026.0678","41885811",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029995","WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults.","Redmond P","2026","JAMA","other","article","10.1001/jama.2026.0681","41885806",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029996","Prehabilitation for Aesthetic Surgery: An Evidence-based Guide.","Malek AJ","2026","Plastic and reconstructive surgery. Global open","other","article","10.1097/gox.0000000000008070","42781611","PMC13600570",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0029997","WHO Guideline on GLP-1 Therapies for Treatment of Obesity in Adults-Reply.","Celletti F","2026","JAMA","other","article","10.1001/jama.2026.0687","41885820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0029998","A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease.","Cai HY","2021","Journal of Alzheimer's disease : JAD","preclinical","article","10.3233/jad-210256","34366339",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0029999","Metabolic control by liver-kidney crosstalk and glucagon in health and disease.","Vallon V","2026","Nature reviews. Nephrology","narrative_review","article","10.1038/s41581-026-01111-y","42811087",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030000","Clarifying Statistical Methods in a TriNetX Study of GLP-1 Therapy on Post-ERCP Outcomes.","Wang J","2026","Journal of clinical gastroenterology","other","article","10.1097/mcg.0000000000002425","42454708",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030001","Metabolic and Bariatric Fellowship Training in the Era of GLP-1 Therapy: Workforce Implications.","Kothari SN","2026","Journal of the American College of Surgeons","other","article","10.1097/xcs.0000000000002090","42429274",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030002","12624 The Efficacy Of Glp1 Receptor Agonists As Adjunct Therapy To Insulin In Patients With Type 1 Diabetes: A Meta-analysis",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC11453577",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0030003","Safety and Clinical Effectiveness of GLP1 Receptor Agonists in Inflammatory Bowel Disease Patients.","Sehgal P","2025","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","other","article","10.1016/j.cgh.2024.12.017","39892632",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030004","Advantages of Skeletal Muscle Preservation in Settings of Weight Loss.","Glass DJ","2026","Aging cell","narrative_review","article","10.1111/acel.70521","42095513","PMC13150834",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0030005","Detrimental effects of conflicts of interest in GLP-1 therapy guidance.","Agarwal A","2026","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj-2026-527061","42320917",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; article"],["R0030006","Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.","Young KG","2023","medRxiv : the preprint server for health sciences","systematic_review","article","10.1101/2023.04.21.23288868","37131814","PMC10153311",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Preprint; Journal Article; preprint"],["R0030007","8687 The Efficacy of GLP1 Receptor Agonists in Obese Women with PCOS in Promoting Weight Loss and Hormonal Regulation: A Systematic Review and Meta-Analysis",null,"2024","Journal of the Endocrine Society","systematic_review","article",null,null,"PMC11453567",null,null,"europepmc","TRUE","open_europepmc","3",null,"Abstract"],["R0030008","ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non-Small Cell Lung Cancer?","Park CJ","2025","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","commentary","article","10.1200/jco-24-02514","39772872",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Editorial; editorial"],["R0030009","Type 1 diabetes and cardiovascular medicine.","Jenkins AJ","2026","Cardiovascular diabetology. Endocrinology reports","other_trial","article","10.1186/s40842-026-00338-9","42764374","PMC13591722",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0030010","Corrigendum to \"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics\" [Biochem. Pharmacol. 180 (2020) 114187].","Salameh TS","2023","Biochemical pharmacology","notice","article","10.1016/j.bcp.2023.115474","36898278","PMC10108898",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0030011","Exploring Challenges With Widespread Use of GLP-1-Based Therapies for Adolescents and Young Adults.","Luo J","2025","JAMA pediatrics","other","article","10.1001/jamapediatrics.2025.2469","40758378",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030012","Postprandial Glucagon Action in the Human Brain.","Wagner R","2026","Diabetes, obesity & metabolism","other","article","10.1111/dom.70801","42017287","PMC13243955",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030013","Use of Glucagon-Like Peptide-1 Agonists and Increased Risk of Procedural Sedation and Endotracheal Intubation in the Emergency Department.","Dixon W","2024","Annals of emergency medicine","commentary","article","10.1016/j.annemergmed.2024.03.007","39032988",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0030014","Glucagon-Like Peptide-1 agonists in perioperative medicine: to suspend or not to suspend, that is the question.","Mendes FF","2024","Brazilian journal of anesthesiology (Elsevier)","commentary","article","10.1016/j.bjane.2024.844538","38944239","PMC11295559",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0030015","[Albuminuria for detection of chronic kidney disease: biomarker and therapeutic target].","Vásárhelyi B","2026","Orvosi hetilap","narrative_review","article","10.1556/650.2026.33622","42543015",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0030016","Corrigendum to \"Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society\".","Lifestyle Medicine","2026","Obesity (Silver Spring, Md.)","notice","article","10.1002/oby.70222","42026697","PMC13652196",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0030017","Pregnancy and diabetes: Emerging insights from contemporary diabetes research.","Aggarwal S","2025","World journal of experimental medicine","narrative_review","article","10.5493/wjem.v15.i4.109839","41497675","PMC12767240",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030018","Does use of glucagon-like peptide-1 agonists increase perioperative complications in patients undergoing shoulder arthroplasty?","Elsabbagh Z","2025","Journal of shoulder and elbow surgery","nonrandomized_study","article","10.1016/j.jse.2024.07.045","39322005",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0030019","Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?","Tantisattamo E","2026","Advances in kidney disease and health","other_trial","article","10.1053/j.akdh.2026.02.003","42397326","PMC13426288",null,null,"pubmed; europepmc","FALSE","free_to_read","5",null,"Journal Article; Review; research-article"],["R0030020","Mechanism and Context: Making Sense of Adverse Events With GLP-1-based Therapy.","Hagelqvist PG","2026","JCEM case reports","commentary","article","10.1210/jcemcr/luaf232","41347116","PMC12673376",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article-commentary; article"],["R0030021","Neoadjuvant GLP-1 Therapy vs Upfront Metabolic Bariatric Surgery: Right Care for the Right Patient at the Right Time.","Tavakkoli A","2026","Annals of surgery","other","article","10.1097/sla.0000000000007110","42204411",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030022","Unmasking the silent epidemic: Mortality trends in diabetic nephropathy.","Alvarez M","2025","World journal of nephrology","commentary","article","10.5527/wjn.v14.i3.108099","41024951","PMC12476721",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0030023","The Rise of Glucagon-Like Peptide 1 Agonists: Considerations for Oral and Maxillofacial Surgery.","Wang TT","2024","Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons","other","article","10.1016/j.joms.2024.04.005","38688461",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030024","The Path to Progress: Glucagon-like Peptide 1 Agonists, Individualized Care, and Overcoming Goal-Directed Medical Therapy Barriers in Diabetes and CKD.","Ambruso SL","2024","Kidney international reports","commentary","article","10.1016/j.ekir.2024.05.027","39081722","PMC11284431",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0030025","Preoperative nutritional resilience in the era of GLP-1 therapy: implications for body contouring surgery.","Tomaselli F","2026","Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery","commentary","article","10.1016/j.soard.2026.03.028","42248747",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0030026","SUN-591 GLP1-RA, SGLT2i and Risk of Advanced Fibrosis in Patients with T2D:a Target Trial Emulation",null,"2025","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC12543680",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0030027","Author Correction: GLP-1-based therapies for diabetes, obesity and beyond.","Drucker DJ","2025","Nature reviews. Drug discovery","notice","article","10.1038/s41573-025-01231-3","40437221",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; erratum"],["R0030028","SUN-580 A Phase III Small Molecule GLP1R Agonist Acts As a Pharmacological Chaperone for Misfolded GLP1R Mutants",null,"2025","Journal of the Endocrine Society","other_trial","article",null,null,"PMC12544220",null,null,"europepmc","TRUE","open_europepmc","5",null,"Abstract"],["R0030029","Corrigendum to Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society [Am J Clin Nutr 2025; 122: 344-367].","Mozaffarian D","2026","The American journal of clinical nutrition","notice","article","10.1016/j.ajcnut.2026.101303","41962912","PMC13639435",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0030030","Corrigendum to \"Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society [Obesity Pillars 15 (2025) 100181].","Mozaffarian D","2026","Obesity pillars","notice","article","10.1016/j.obpill.2026.100263","42255463","PMC13237830",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; correction; erratum"],["R0030031","Isseki nichō (one stone, two birds): a dual incretin receptor agonist for type 2 diabetes.","Jalleh RJ","2022","The lancet. Diabetes & endocrinology","commentary","article","10.1016/s2213-8587(22)00193-0","35914541",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0030032","Peptide-based multi-agonists: a new paradigm in metabolic pharmacology.","Brandt SJ","2018","Journal of internal medicine","narrative_review","article","10.1111/joim.12837","30230640",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030033","World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults.","Celletti F","2026","JAMA","other","article","10.1001/jama.2025.24288","41324410",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Practice Guideline; article"],["R0030034","GZR101, a Novel Premixed Insulin for the Treatment of Diabetes Mellitus.","Chen W","2025","Naunyn-Schmiedeberg's archives of pharmacology","other_trial","article","10.1007/s00210-025-04366-7","40531224",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030035","Opioid Use Disorder Treatment Gaps and Emerging Therapeutics to Address Them.","Banks ML","2026","CNS drugs","narrative_review","article","10.1007/s40263-026-01300-0","42154181","PMC13303678",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030036","Hepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways.","Yaribeygi H","2025","Journal of diabetes and its complications","narrative_review","article","10.1016/j.jdiacomp.2024.108928","39644538",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030037","Heart Failure With Preserved Ejection Fraction in Patients With Obesity: A Growing Cardiometabolic Concern.","Sindone AP","2025","Heart, lung & circulation","narrative_review","article","10.1016/j.hlc.2025.08.010","40945958",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030038","GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences.","Forouzanmehr B","2025","Naunyn-Schmiedeberg's archives of pharmacology","narrative_review","article","10.1007/s00210-024-03384-1","39172148",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030039","8139 Examining the Association of GLP1-RA or DPP4i with Bullous Skin Diseases in Veterans",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455123",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0030040","Xenin-Derived Peptides: Multifaceted Regulators and Therapeutic Innovations in Metabolic Diseases.","Gong B","2025","Drug design, development and therapy","preclinical","article","10.2147/dddt.s565077","41479596","PMC12755099",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030041","Obesity as an epigenetic continuum: developmental roots, adipose remodeling, and the limits of reversibility.","Ferder L","2026","Physiological genomics","preclinical","article","10.1152/physiolgenomics.00032.2026","42296006",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030042","Body Contouring in the Era of GLP-1 Therapy: Are We Ignoring Tissue Biology?","Tomaselli F","2026","Plastic surgery (Oakville, Ont.)","commentary","article","10.1177/22925503261423545","41725638","PMC12920158",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; article"],["R0030043","Registered Dietitian Nutritionists and Medical Nutrition Therapy: A Recipe for Improving Kidney Disease Care and Outcomes.","Betz M","2026","Clinical journal of the American Society of Nephrology : CJASN","other","article","10.2215/cjn.0000001190","42497013",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030044","8462 Synergistic Outcomes Of hCG And GLP1-RA Combination Therapy: Improved Body Composition And Carbohydrate Metabolism",null,"2024","Journal of the Endocrine Society","other","article",null,null,"PMC11455063",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0030045","Glucagon-like peptide 1 agonists: a ray of hope for the treatment of polycystic ovarian syndrome.","Babar A","2023","JPMA. The Journal of the Pakistan Medical Association","other","article","10.47391/jpma.9666","38083956",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030046","Response to letter to the editor by Lai-Ming Kathleen Pak et al on: Identifying predictors of SGLT2 inhibitor and GLP1R agonist use in hospital among adults with diabetes.","Colacci M","2025","Journal of diabetes and its complications","commentary","article","10.1016/j.jdiacomp.2025.109046","40280818",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0030047","P-31 GLP1 receptor agonist in end-stage kidney disease: Are they safe and effective?",null,"2024","JCEM case reports","other","article",null,null,"PMC10784959",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0030048","Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects.","Liuzzo G","2022","European heart journal","randomized_trial","article","10.1093/eurheartj/ehac384","35866301",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0030049","Preoperative Weight Loss Before Total Joint Arthroplasty Using Novel Glucagon-Like Peptide-1 Agonists.","Seward MW","2026","Arthroplasty today","other","article","10.1016/j.artd.2026.102134","42701460","PMC13545386",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030050","The knowns and unknowns of glucagon-like peptide 1 agonists and perioperative care.","McIsaac DI","2024","Canadian journal of anaesthesia = Journal canadien d'anesthesie","commentary","article","10.1007/s12630-024-02718-0","38485834",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0030051","[The first successes of the immuno-metabolic track in precision psychiatry].","Godin O","2025","Medecine sciences : M/S","narrative_review","article","10.1051/medsci/2025063","40418011",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0030052","Emerging Nondopaminergic Medications for Parkinson's Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists.","Shang P","2021","Journal of movement disorders","narrative_review","article","10.14802/jmd.21035","34399565","PMC8490190",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0030053","Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort.","Balshi A","2025","Multiple sclerosis and related disorders","nonrandomized_study","article","10.1016/j.msard.2024.106229","39693702",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0030054","Reactive angioendotheliomatosis as a side effect of long-acting injectable insulin use.","Stoll K","2025","Dermatology online journal","case_report","article","10.25251/d8bxg891","41171799",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0030055","Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances.","Zhu B","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1753393","41635536","PMC12861893",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030056","The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications.","Banks WA","2024","Cell reports. Medicine","narrative_review","article","10.1016/j.xcrm.2024.101760","39383873","PMC11604479",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0030057","Lithium as a disease-modifying therapy for Parkinson's disease: mechanisms, preclinical evidence, and clinical prospects.","Boonstra JT","2026","Clinical parkinsonism & related disorders","other_trial","article","10.1016/j.prdoa.2026.100440","42170063","PMC13187593",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Review; review-article; article"],["R0030058","Extraglycemic Effects of SGLT2i/GLP1-ra: A Topic Update.","Alam U","2024","Clinical therapeutics","commentary","article","10.1016/j.clinthera.2024.10.005","39472157",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0030059","Fish oil supplements in patients with chronic kidney disease.","Ferro CJ","2026","Clinical kidney journal","randomized_trial","article","10.1093/ckj/sfag168","42293365","PMC13261989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0030060","Prediabetes as an indication for GLP-1 therapy. Clarifying evidence thresholds and clinical guardrails.","Wang JY","2026","International journal of obesity (2005)","commentary","article","10.1038/s41366-025-01959-3","41241665",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0030061","Beneficial outcomes of glucagon like peptide-1 agonist therapy in a patient with Bardet Biedl syndrome and kidney transplant",null,"2023","JCEM case reports","other","article",null,null,"PMC10653139",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0030062","Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.","Stensen S","2022","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.14736","35491518",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Research Support, Non-U.S. Gov't; Journal Article; article"],["R0030063","Single Cell RNA-Seq Analysis of Regenerative Drug-Treated Human Pancreatic Islets Identifies A Cycling Alpha Cell Population As Key Beta Cell Progenitors","Karakose E","2023","bioRxiv","preclinical","preprint","10.1101/2023.09.07.556578",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0030064","Letters to the editor regarding the \"Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society\".","Lifestyle Medicine","2025","Obesity pillars","commentary","article","10.1016/j.obpill.2025.100210","41031288","PMC12478263",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; letter"],["R0030065","Between the Guidelines: Variability in Management of Patients With Cystic Fibrosis and Dysglycemia.","Cooper H","2026","Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","other","article","10.1016/j.eprac.2026.03.089","41905663",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030066","Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients.","Gorrai A","2025","The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation","narrative_review","article","10.1016/j.healun.2024.12.006","39701434",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030067","Expanding applications of GLP-1 therapies: a careful view.","Azzolino D","2025","International journal of obesity (2005)","other","article","10.1038/s41366-025-01788-4","40240468",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030068","The emerging role of incretins and twincretins.","Chow E","2022","Nature reviews. Endocrinology","other","article","10.1038/s41574-021-00607-w","34873288",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030069","The Transition from Stage A to Stage B of Heart Failure: Risk Factors, Promoting Factors, and Opportunities for Prevention-An Update from the Italian Society of Cardiology Working Group on Heart Failure.","Ruocco G","2026","European journal of preventive cardiology","other","article","10.1093/eurjpc/zwag484","42715030",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030070","Comment on \"Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis\".","Alosaimi DN","2025","Obesity surgery","nonrandomized_study","article","10.1007/s11695-025-08202-y","40864374",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Letter; article"],["R0030071","Emerging Multi-Target Therapies for Type 2 Diabetes: Bridging Drug Innovation and Precision Delivery.","Singhal P","2026","Current topics in medicinal chemistry","other","article","10.2174/0115680266429073251122045133","41540544",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030072","Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.","Yun SP","2018","Nature medicine","preclinical","article","10.1038/s41591-018-0051-5","29892066","PMC6039259",null,"S001846","pubmed; europepmc","TRUE","open_europepmc","5",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0030073","Buckwheat (Fagopyrum spp.): Building Healthy Diets and Resilient Agrifood Systems.","Oliveira MEAS","2026","Journal of agricultural and food chemistry","narrative_review","article","10.1021/acs.jafc.5c17847","42031664","PMC13154188",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030074","Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease.","Shneyderman M","2024","Gastroenterology & hepatology","other","article",null,"39886003","PMC11776002",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; discussion; article"],["R0030075","Letter to the Editor: Critical Appraisal of Methodological Considerations in \"Surgical Outcomes in Patients with Preoperative GLP-1 Therapy\".","Shah HM","2025","Obesity surgery","commentary","article","10.1007/s11695-025-08238-0","40921957",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; letter"],["R0030076","Association Between GLP1R Agonists and Prostate, Kidney, and Bladder Cancers.","Bukavina L","2024","European urology oncology","commentary","article","10.1016/j.euo.2024.04.006","38702255",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0030077","NMDA receptor antagonist coupled to GLP1 analogue in highly effective experimental weight loss drug.","Tysoe O","2024","Nature reviews. Endocrinology","commentary","article","10.1038/s41574-024-01007-6","38834828",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","News; article"],["R0030078","Routine care data and the benefits of GLP1 receptor agonists on slowing kidney function decline.","Xu Y","2023","Kidney international","commentary","article","10.1016/j.kint.2023.06.009","37599022",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0030079","V-ATPase and Lysosomal Energy Sensing in Periodontitis and Medicine-Related Osteonecrosis of the Jaw.","Yang X","2025","Biomolecules","narrative_review","article","10.3390/biom15070997","40723869","PMC12292623",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0030080","GLP1 receptor agonists for Wolfram syndrome?","Starling S","2023","Nature reviews. Endocrinology","commentary","article","10.1038/s41574-023-00839-y","37076572",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0030081","Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.","Chiang CH","2025","European journal of cancer (Oxford, England : 1990)","nonrandomized_study","article","10.1016/j.ejca.2024.115170","39709670",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0030082","Targeting programmed cell death pathways: emerging therapeutic strategies for diabetic kidney disease.","Wang L","2025","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2025.1513895","40568564","PMC12187695",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030083","Severe respiratory complications in late-diagnosed Prader-Willi syndrome: a case report.","Tiwari SK","2026","Journal of medical case reports","case_report","article","10.1186/s13256-026-05922-2","41918032","PMC13162404",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Case Reports; case-report; article"],["R0030084","Glp-1 Mimetics and Autophagy in Diabetic Milieu: State-of-the-Art.","Yaribeygi H","2024","Current diabetes reviews","narrative_review","article","10.2174/0115733998276570231222105959","38299271",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030085","Weight Self-Stigma and Food Noise During Post-Metabolic Bariatric Surgery Weight Stability.","Bond DS","2026","Obesity (Silver Spring, Md.)","other","article","10.1002/oby.70318","42782188","PMC13654087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030086","Exploring BMI Classification Changes and Disparities Upon Incarceration in U.S. Federal Prisons.","Velez-Valle E","2026","Journal of correctional health care : the official journal of the National Commission on Correctional Health Care","nonrandomized_study","article","10.1177/10783458261485713","42766498",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0030087","GLP-1s Versus DPP-4s and Risk of Dementia in Patients Requiring Hemodialysis: A Target Trial Emulation Study.","Le D","2026","Diabetes care","nonrandomized_study","article","10.2337/dc25-1836","41232069","PMC12719713",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0030088","Water scarcity and conservation and their role in obesity in nature and in humans.","Johnson RJ","2025","Journal of internal medicine","narrative_review","article","10.1111/joim.70003","40754858",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030089","Negative findings from trials with NLY01 or deferiprone for Parkinson's disease.","Müller T","2024","The Lancet. Neurology","commentary","article","10.1016/s1474-4422(24)00097-8","38760091",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0030090","Humans with function-disrupting variants in the myostatin gene (MSTN) have increased skeletal muscle mass and strength, and less adiposity.","Herman JL","2026","Nature communications","nonrandomized_study","article","10.1038/s41467-026-70422-2","41826329","PMC13125550",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030091","Lifestyle Medicine and GLP-1 Therapy For Obesity: Time to Get Real.","Rippe JM","2025","American journal of lifestyle medicine","commentary","article","10.1177/15598276251336677","40452756","PMC12125005",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; editorial"],["R0030092","[The health risks and treatment options for women with overweight or obesity seeking pregnancy].","Søndersted C","2025","Ugeskrift for laeger","narrative_review","article","10.61409/v03250146","40910389",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; English Abstract; article"],["R0030093","Dyslipidemia in Patients with Diabetes","Feingold KR","2000","MDText.com, Inc., South Dartmouth (MA)","randomized_trial","article",null,"26247092",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0030094","Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study.","D'Onofrio L","2021","Diabetes research and clinical practice","nonrandomized_study","article","10.1016/j.diabres.2021.108681","33516784",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0030095","Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends.","Zacharia GS","2025","World journal of gastrointestinal pharmacology and therapeutics","narrative_review","article","10.4292/wjgpt.v16.i4.110827","41378068","PMC12687003",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030096","Design, synthesis, and biological evaluation of a small molecule oral agonist of the glucagon-like-peptide-1 receptor.","Girdhar K","2022","The Journal of biological chemistry","preclinical","article","10.1016/j.jbc.2022.101889","35378127","PMC9095748",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030097","Clinical and Pharmacotherapeutic Profile of Patients with Type 2 Diabetes Mellitus Admitted to a Hospital Emergency Department.","Lopes AC","2023","Biomedicines","other","article","10.3390/biomedicines11020256","36830792","PMC9953569",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030098","THU275 Tacrolimus Levels And Kidney Function In Kidney Transplanted (KT) Patients With Diabetes On Glucagon Like-1 Receptor Agonists (GLP1-RA)",null,"2023","Journal of the Endocrine Society","other","article",null,null,"PMC10553644",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0030099","A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss.","Cal K","2025","Nature metabolism","randomized_trial","article","10.1038/s42255-025-01311-z","40527924","PMC12373507","ANZCTR:ACTRN12622001519741",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; research-article; article"],["R0030100","Multi-Target Modulation of Polyphenols in Diabetic Kidney Disease Therapeutics: A Comprehensive Review.","Efiong EE","2025","Food science & nutrition","narrative_review","article","10.1002/fsn3.70882","41019174","PMC12464446",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030101","A brain center that controls consummatory responses.","Canovas JA","2025","Cell","preclinical","article","10.1016/j.cell.2025.08.021","40934915",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030102","Genetic variation in the glucagon-like peptide-1 receptor protein encoding region is associated with higher heart rate variability, but not with neurodegeneration of the brain, retina, and peripheral nerves: The Maastricht study.","van der Heide FCT","2025","Cardiovascular diabetology","other","article","10.1186/s12933-025-02888-1","41088211","PMC12519852",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030103","Repurposing metabolic drugs as anti-inflammatory agents.","Hogan AE","2026","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2025.07.003","40813183",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0030104","Set it and forget it: Engineered cells for drug delivery.","Herzog ED","2025","Cell systems","preclinical","article","10.1016/j.cels.2025.101484","41412109",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural"],["R0030105","Cardiac rehabilitation in overweight and obese patients: Challenges, strategies, and the role of emerging anti-obesity therapies.","De Luca M","2026","Current problems in cardiology","narrative_review","article","10.1016/j.cpcardiol.2026.103328","41802482",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030106","Effects of Bariatric Surgery and Obesity Medicines on Human Eating Behavior.","Contreras Hernández F","2026","Annual review of nutrition","narrative_review","article","10.1146/annurev-nutr-070225-105258","42139151",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review"],["R0030107","Polycystic ovary syndrome: A metabolic disorder with therapeutic opportunities.","Zhang Y","2025","Cell metabolism","narrative_review","article","10.1016/j.cmet.2025.08.002","40912248",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030108","Prevalence of Therapeutic Inertia in the Management of Overweight and Obesity in Patients With a Diagnosis of Type 2 Diabetes Who Are Followed up by Primary Care Physicians.","Aschner P","2026","Obesity science & practice","nonrandomized_study","article","10.1002/osp4.70121","41783651","PMC12952996",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030109","Top studies of 2024 relevant to primary care: From the PEER team.","Moe SS","2025","Canadian family physician Medecin de famille canadien","randomized_trial","article","10.46747/cfp.7105309","40368626","PMC12087564",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0030110","Metabolic Dysfunction and Alcohol-Associated Liver Disease: A Narrative Review.","Dunn N","2025","Clinical and translational gastroenterology","narrative_review","article","10.14309/ctg.0000000000000828","39969015","PMC12101925",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0030111","Stool Osmotic Gap: An Alternative to Invasive Workup of Chronic Diarrhea Secondary to Glucagon-Like Peptide-1 Agonist Use.","Sheehan E","2022","American journal of therapeutics","commentary","article","10.1097/mjt.0000000000001298","33136575",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; article"],["R0030112","[Endocrinology : what's new in 2024].","Ameti A","2025","Revue medicale suisse","other","article","10.53738/revmed.2025.21.902.126","39846096",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; article"],["R0030113","Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis.","Tsutsumi T","2026","Med (New York, N.Y.)","systematic_review","article","10.1016/j.medj.2026.101077","41946364",null,null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Network Meta-Analysis; Systematic Review; Comparative Study"],["R0030114","Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice.","Tareq S","2025","Pharmacological research","preclinical","article","10.1016/j.phrs.2025.107900","40769385",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030115","Neuroendocrinology and the Genetics of Obesity.","Ruggiero-Ruff RE","2025","Endocrinology","narrative_review","article","10.1210/endocr/bqaf121","40690308","PMC12342173",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030116","Pentraxin-3 as a Biomarker in Diabetes Mellitus: Insights into Inflammation, Vascular Complications, and Modulation by Antidiabetic Medications.","Dobriceanu RC","2025","Biomedicines","narrative_review","article","10.3390/biomedicines13040891","40299501","PMC12024795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030117","Pharmacological approach to rapid sequence induction/intubation: a contemporary perspective.","Sorbello M","2025","Current opinion in anaesthesiology","narrative_review","article","10.1097/aco.0000000000001528","40493782",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030118","Impact of glucagon-Like peptide-1 agonists in optimizing abdominal wall Reconstruction patients.","Tran D","2024","Hernia : the journal of hernias and abdominal wall surgery","nonrandomized_study","article","10.1007/s10029-024-03214-6","39549167",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0030119","Treatment of Obesity Before, During, and After Pregnancy: Time for Obstetricians to Get Involved.","Gustafson D","2024","Obstetrical & gynecological survey","narrative_review","article","10.1097/ogx.0000000000001329","39547257",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030120","A Review of Metabolic Dysregulation in Lymphocytic Cicatricial Alopecia: Exploring the Connections and Therapeutic Implications.","Bao A","2025","The Journal of investigative dermatology","narrative_review","article","10.1016/j.jid.2025.01.036","40100177",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030121","Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or >5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study.",null,"2024","Gastroenterology & hepatology","other","article",null,"39896969","PMC11784562",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0030122","Negative findings from trials with NLY01 or deferiprone for Parkinson's disease - Author's reply.","McGarry A","2024","The Lancet. Neurology","commentary","article","10.1016/s1474-4422(24)00163-7","38760092",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Letter; Comment; article"],["R0030123","The Impact of Glucagon-Like Peptide-1 Agonists on Hip and Knee Arthroplasty and Perioperative Considerations.","Jacofsky DJ","2024","The Journal of arthroplasty","narrative_review","article","10.1016/j.arth.2023.12.002","38070716",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030124","GLP1R agonists in NAFLD: a promising therapy on the horizon.","Bany Bakar R","2023","Nature reviews. Gastroenterology & hepatology","other","article","10.1038/s41575-023-00770-7","36977795",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030125","Pharmacological interventions to manage cardiometabolic outcomes in adults with severe mental illness: umbrella review.","Carolan A","2025","The British journal of psychiatry : the journal of mental science","systematic_review","article","10.1192/bjp.2025.10476","41340371",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; article"],["R0030126","Glucagon-Like Peptide-1 Targets in the Human Nodose Ganglion.","Merchant W","2026","The Journal of comparative neurology","preclinical","article","10.1002/cne.70135","41618954","PMC12860426",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030127","Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review.","Watkins JD","2021","Advances in nutrition (Bethesda, Md.)","narrative_review","article","10.1093/advances/nmab078","34192748","PMC8634310",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; review"],["R0030128","Pharmacologic treatments for gastroparesis.","Camilleri M","2025","Pharmacological reviews","narrative_review","article","10.1016/j.pharmr.2024.100019","40148033","PMC12599987","ClinicalTrials.gov:NCT03420781; ClinicalTrials.gov:NCT03285308; ClinicalTrials.gov:NCT03426345; ClinicalTrials.gov:NCT03383146",null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; review-article"],["R0030129","Characterizing a new tool to manipulate area postrema GLP1R+ neurons across species.","Fulton S","2024","Physiology & behavior","preclinical","article","10.1016/j.physbeh.2024.114474","38272107","PMC11184917",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Intramural; research-article; article"],["R0030130","Cav3.1 is a leucine sensor in POMC neurons mediating appetite suppression and weight loss","Tsang AH","2024","bioRxiv","preclinical","preprint","10.1101/2024.09.13.612843",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0030131","GIP-GLP1 receptor agonist shows promise.","Starling S","2022","Nature reviews. Endocrinology","commentary","article","10.1038/s41574-022-00693-4","35581349",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0030132","Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.","Walker CS","2025","Nature reviews. Endocrinology","narrative_review","article","10.1038/s41574-025-01125-9","40360789",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030133","Peptides from Animal Venoms: A Promising Frontier in Diabetes Therapy via Multi-Target Mechanisms.","de Almeida JOCS","2025","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph18101438","41155553","PMC12566817",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030134","The Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Atrial Fibrillation Burden in Diabetic Patients.","Kidess GG","2025","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2025.03.002","40058622",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Meta-Analysis"],["R0030135","Effective and appropriate use of weight loss medication in pediatric obesity: a narrative review.","Chung YL","2024","Journal of Yeungnam medical science","narrative_review","article","10.12701/jyms.2024.00353","38952016","PMC11294794",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; review"],["R0030136","Elevated C-reactive protein and cardiovascular risk.","Chia JE","2025","Current opinion in cardiology","narrative_review","article","10.1097/hco.0000000000001215","40014057",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030137","Body image and interest in GLP-1 weight loss medications.","Markey CH","2025","Body image","other","article","10.1016/j.bodyim.2025.101890","40267815",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030138","Risk and Protective Factors for Ocular Surface Disease in Patients with Type 2 Diabetic Mellitus: A Retrospective Cohort Study.","Sun CC","2025","Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","randomized_trial","article","10.1089/jop.2024.0175","40485291",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0030139","Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects.","Jin J","2023","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","randomized_trial","article","10.1016/j.ejps.2023.106448","37062422",null,"ClinicalTrials.gov:NCT03990090","S003376","pubmed; europepmc; openalex","TRUE","free_to_read","1","FALSE","Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; article"],["R0030140","Bidirectional interplay of sleep apnea syndrome and cardio-vascular disorders in diabetes.","Valensi P","2025","Diabetes research and clinical practice","narrative_review","article","10.1016/j.diabres.2024.111984","39761874",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030141","Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in mice.","Lopes T","2024","Molecular metabolism","preclinical","article","10.1016/j.molmet.2024.102024","39236784","PMC11424806",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0030142","Genetic proxies of GLP1R expression in whole blood are associated with lower risk of psoriasis and psoriatic arthritis","Ramessur R","2025","medRxiv","randomized_trial","preprint","10.1101/2025.10.12.25337838",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0030143","Starting GLP-1 therapy may induce impulse control disorders.","Playford RJ","2024","QJM : monthly journal of the Association of Physicians","other","article","10.1093/qjmed/hcae095","38710499",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030144","Glutamate and obesity - what is the link?","Chaouche L","2024","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000000991","37937722",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030145","Weight gain in people with HIV in Africa and Asia: a review of causes, consequences, and management implications.","Venter WDF","2026","Current opinion in HIV and AIDS","randomized_trial","article","10.1097/coh.0000000000001074","42817201",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0030146","Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions.","Halabitska I","2024","Biomedicines","narrative_review","article","10.3390/biomedicines12081630","39200096","PMC11351146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030147","ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.","Bansal N","2026","Journal of the American Society of Nephrology : JASN","narrative_review","article","10.1681/asn.0000001231","42684397","PMC13641481",null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Practice Guideline; review-article; Review; article"],["R0030148","Do oral antidiabetic medications alter the risk of Parkinson's disease? An updated systematic review and meta-analysis.","Xie Y","2023","Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","systematic_review","article","10.1007/s10072-023-06965-9","37500992",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Meta-Analysis; Systematic Review; Journal Article"],["R0030149","Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data.","Patel N","2026","Mayo Clinic proceedings","nonrandomized_study","article","10.1016/j.mayocp.2025.01.003","41099677",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0030150","Glucagon-like peptide-1 receptor signaling deficiency exacerbates hematopoietic stem cell graft rejection in mice.","Rusznak M","2026","Journal of immunology (Baltimore, Md. : 1950)","preclinical","article","10.1093/jimmun/vkaf251","40990163","PMC12701753",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; research-article; article"],["R0030151","Intragastric Balloon as Part of a Multidisciplinary Treatment Approach to Obesity-Related Heart Failure.","Vainer D","2025","ACG case reports journal","case_report","article","10.14309/crj.0000000000001881","41199797","PMC12588693",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0030152","Glycemic control and its associated factors in hypertensive patients with type 2 diabetes.","Jarab AS","2023","European review for medical and pharmacological sciences","nonrandomized_study","article","10.26355/eurrev_202306_32816","37401314",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0030153","Decoding MODY: exploring genetic roots and clinical pathways.","Phadnis A","2025","Diabetology international","nonrandomized_study","article","10.1007/s13340-025-00809-x","40166432","PMC11954780",null,null,"pubmed; europepmc","FALSE","free_to_read","4",null,"Journal Article; Review; review-article"],["R0030154","Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.","Schousboe JT","2024","Annals of internal medicine","systematic_review","article","10.7326/m23-1492","38639547",null,"PROSPERO:CRD42022382315",null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Research Support, Non-U.S. Gov't; review"],["R0030155","Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.","Alicic RZ","2021","Nature reviews. Nephrology","other_trial","article","10.1038/s41581-020-00367-2","33219281",null,null,null,"pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review"],["R0030156","Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist.","Millán-Rodríguez C","2023","European cardiology","other","article","10.15420/ecr.2023.22","38213666","PMC10782421",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030157","The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.","Zachou M","2024","European journal of clinical pharmacology","narrative_review","article","10.1007/s00228-023-03586-1","37938366","PMC10781828",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; research-article; review"],["R0030158","Glucagon-Like Peptide 1-Based Therapies and Risk of Pancreatic Cancer in Patients With Diabetes and Obesity.","Krishnan A","2022","Pancreas","nonrandomized_study","article","10.1097/mpa.0000000000002197","37099785",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Multicenter Study; Journal Article; article"],["R0030159","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism and Exercise: An Effective Strategy to Maintain Diet-Induced Weight Loss.","Galiuto L","2021","European heart journal","randomized_trial","article","10.1093/eurheartj/ehab356","34160039",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","2","FALSE","Journal Article; Comment; article"],["R0030160","Diabetes management in people undergoing metabolic-bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group.","Stephens JW","2026","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1111/dme.70281","41840846","PMC13074134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Practice Guideline; other; article"],["R0030161","Patient Preoperative Optimization: How to Do It and How to Be Paid for the Work.","Clarke ZH","2025","The Journal of arthroplasty","narrative_review","article","10.1016/j.arth.2025.04.040","40258501",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0030162","Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression.","Tsakiridis EE","2026","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.70624","41816810","PMC13094702",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0030163","[Injection therapy of diabetes].","Lechleitner M","2023","Wiener klinische Wochenschrift","other","article","10.1007/s00508-023-02171-x","37101024","PMC10133050",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","English Abstract; Journal Article; research-article; article"],["R0030164","Unravelling the cardio-renal-metabolic-foot connection in people with diabetes-related foot ulceration: a narrative review.","Lan NSR","2024","Cardiovascular diabetology","narrative_review","article","10.1186/s12933-024-02527-1","39696281","PMC11657306",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; review"],["R0030165","GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs.","McGuire DK","2021","The lancet. Diabetes & endocrinology","other","article","10.1016/s2213-8587(21)00212-6","34425084",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030166","Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial.","Corbin KD","2023","Obesity (Silver Spring, Md.)","randomized_trial","article","10.1002/oby.23633","36695055","PMC9881753",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural; research-article; article"],["R0030167","Polyethylene and polystyrene oxidation by host and microbial oxidoreductases in Zophobas atratus.","Son JS","2026","Journal of advanced research","other","article","10.1016/j.jare.2026.05.024","42119968",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030168","A Review of Recent Pharmacological Advances in the Management of Diabetes-Associated Peripheral Neuropathy.","Syed O","2023","Pharmaceuticals (Basel, Switzerland)","narrative_review","article","10.3390/ph16060801","37375749","PMC10304825",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030169","Preventing diabetes complications.","Templer S","2024","Internal medicine journal","narrative_review","article","10.1111/imj.16455","39023283",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030170","Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes.","Weiskorn J","2025","Hormone research in paediatrics","other_trial","article","10.1159/000539120","38688258",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0030171","Management of Acquired Hypothalamic Obesity After Childhood-Onset Craniopharyngioma-A Narrative Review.","Müller HL","2025","Biomedicines","randomized_trial","article","10.3390/biomedicines13051016","40426846","PMC12109346",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; review"],["R0030172","Future Directions in Choline: From Neurodevelopment to Cardiometabolic Health.","Paules EM","2025","Nutrients","narrative_review","article","10.3390/nu17223618","41305668","PMC12655052",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; other; article"],["R0030173","Genetic analysis of the correlation between GLP1 action and metabolic liver disease: Insights from Mendelian randomization analysis.","Ma Z","2025","Journal of diabetes investigation","nonrandomized_study","article","10.1111/jdi.70087","40452205","PMC12315234",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030174","Beyond Glucose-Rethinking Prediabetes for Precision Prevention.","Wagner R","2026","Diabetes care","randomized_trial","article","10.2337/dci25-0054","40932411","PMC12824784",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; other; article"],["R0030175","Pitstop approach: diabetologist referral and quality of care in patients with type 2 diabetes - a Swiss longitudinal study.","Ebrahimi F","2025","Swiss medical weekly","nonrandomized_study","article","10.57187/s.4031","41100838",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030176","Heartfelt Breakthroughs: Elevating Quality of Life with Cutting-Edge Advances in Heart Failure Treatment.","Devadoss R","2024","Journal of cardiovascular development and disease","narrative_review","article","10.3390/jcdd11010015","38248885","PMC10816021",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030177","Analysis of the management and therapeutic performance of diabetes mellitus employing special target.","Sun HY","2023","World journal of diabetes","narrative_review","article","10.4239/wjd.v14.i12.1721","38222785","PMC10784800",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030178","The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes.","Kearney J","2023","Pharmaceutics","narrative_review","article","10.3390/pharmaceutics15051343","37242585","PMC10223945",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030179","Changes in Food Waste among a Sample of U.S. Consumers after Beginning Anti-Obesity Medication.","Mansouri J","2024","Nutrients","nonrandomized_study","article","10.3390/nu16193274","39408241","PMC11478882",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030180","Assessing Body Fat in Obesity: Clinic and Home Monitoring Using a Portable Bioelectrical Impedance Analysis Device.","Kumar A","2026","The Journal of the Association of Physicians of India","other","article","10.59556/japi.74.1545","42543947",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030181","Clinical implications of mineralocorticoid receptor overactivation.","El Mouhayyar C","2025","Clinical kidney journal","narrative_review","article","10.1093/ckj/sfae346","39781481","PMC11704795",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030182","Utilization of Cardiovascular Procedures, Consultation Services, and Cardioprotective Medications Among Type 2 Myocardial Infarction Patients.","Goel H","2025","JACC. Advances","nonrandomized_study","article","10.1016/j.jacadv.2025.101629","39983613","PMC11891680",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030183","Transient Hyperglycemia in a Patient With Type 2 Diabetes After COVID-19 Messenger RNA Vaccination: A Case Report.","Okon-Umoren A","2024","Cureus","case_report","article","10.7759/cureus.63983","39105031","PMC11299958",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0030184","Genetically proxied glucagon-like peptide-1 receptor perturbation and risk of mood disorders: a Mendelian randomization study.","Jeon Y","2025","BMC psychiatry","other_trial","article","10.1186/s12888-025-07152-0","40770700","PMC12330103",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; other; article"],["R0030185","Systematic Characterisation of GLP-1R in Human Enteric Nervous System: Implications for GLP-1 as a Key Regulator of Colonic Activity.","Dontamsetti KD","2026","Journal of neurochemistry","other","article","10.1111/jnc.70461","42138480","PMC13178211",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030186","Appetite control: hormones or diet strategies?","Freire RH","2020","Current opinion in clinical nutrition and metabolic care","narrative_review","article","10.1097/mco.0000000000000675","32618724",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030187","D-Ser2-oxyntomodulin ameliorated Aβ31-35-induced circadian rhythm disorder in mice.","Wang L","2020","CNS neuroscience & therapeutics","preclinical","article","10.1111/cns.13211","31411808","PMC7053239",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030188","Computational approaches for clinical, genomic and proteomic markers of response to glucagon-like peptide-1 therapy in type-2 diabetes mellitus: An exploratory analysis with machine learning algorithms.","Villikudathil AT","2024","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2024.103086","39067327",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0030189","SUN-236 Testosterone and Glucagon-Like Peptide-1 Agonists for Type 2 Diabetes Mellitus: A Prospective Cohort Study","Graybill S","2019","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/js.2019-sun-236",null,"PMC6553149",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; article"],["R0030190","The Human Monoacylglycerol Acyltransferase 2 Inhibitor VB-85387 Is Associated With Weight Loss in Mice With Obesity.","Corbalan JJ","2026","Obesity science & practice","preclinical","article","10.1002/osp4.70131","41969279","PMC13066718",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030191","Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes.","Sabbour H","2024","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2024.1395630","39835266","PMC11742931",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Consensus Statement; other; article"],["R0030192","Improving Downstream Process Related Manufacturability Based on Protein Engineering-A Feasibility Study.","Capito F","2024","Engineering in life sciences","other","article","10.1002/elsc.202400019","39233725","PMC11369322",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030193","Trends in anti-hyperglycaemic drug usage among Danish type 2 diabetes patients on second-line treatment and beyond: A nationwide cohort study","Laursen HVB","2025","medRxiv","nonrandomized_study","preprint","10.1101/2025.06.20.25328883",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","4","FALSE","Preprint; preprint"],["R0030194","The unexpected role of GIP in transforming obesity treatment.","Zandvakili I","2025","Trends in endocrinology and metabolism: TEM","narrative_review","article","10.1016/j.tem.2024.07.022","39198118",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030195","Global trends in clinical trials and interventions for the metabolic syndrome: A comprehensive analysis of the WHO International Clinical Trials platform.","Muvhulawa N","2024","Contemporary clinical trials communications","nonrandomized_study","article","10.1016/j.conctc.2024.101330","39070960","PMC11283015",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030196","Constructed zinc oxide/polydopamine S-scheme heterojunction via d-π electronic coupling for enhanced carbon dioxide photoreduction.","Zhu L","2026","Journal of colloid and interface science","other","article","10.1016/j.jcis.2026.139979","41616659",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030197","Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?","Marx N","2018","JACC. Basic to translational science","commentary","article","10.1016/j.jacbts.2018.11.008","30623144","PMC6314960",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0030198","The glucagon-like peptide-1 and other endocrine responses to alcohol ingestion in women with versus without metabolic surgery.","Molina-Castro M","2024","Addiction biology","randomized_trial","article","10.1111/adb.13441","39380341","PMC11461901",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0030199","Targeting Pharmacotherapies for Inflammatory and Cardiorenal Endpoints in Kidney Disease.","Huck DM","2024","Journal of cardiovascular pharmacology","narrative_review","article","10.1097/fjc.0000000000001482","37678318","PMC10912396",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0030200","Cellular mechanisms of incretin hormone secretion.","Santos-Hernández M","2024","Journal of molecular endocrinology","narrative_review","article","10.1530/jme-23-0112","38240302","PMC10959011",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, Non-U.S. Gov't; review-article; article"],["R0030201","Sex-specific metabolic and central effects of GLP-1-estradiol conjugate in middle-aged rats on a standard or western diet.","Richard JE","2025","Brain, behavior, and immunity","preclinical","article","10.1016/j.bbi.2025.106088","40854439",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint; article"],["R0030202","Preoperative medication management turnkey order set for nonemergent adult cardiac surgery.","Rea A","2024","JTCVS open","other","article","10.1016/j.xjon.2024.06.009","39780789","PMC11704528",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030203","Intestinal glucagon-like peptide-1 in hypoglycemic counterregulation for type 1 diabetes management.","Zhang KX","2024","World journal of diabetes","commentary","article","10.4239/wjd.v15.i12.2380","39676807","PMC11580587",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; letter; editorial"],["R0030204","Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials.","An J","2023","Clinical and molecular hepatology","randomized_trial","article","10.3350/cmh.2022.0437","36537018","PMC10029953",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Review; review-article; article"],["R0030205","Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy.","Williams JC","2024","Therapeutic advances in musculoskeletal disease","nonrandomized_study","article","10.1177/1759720x241271886","39161788","PMC11331474",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0030206","Bile acid diarrhea - as bad as it gets?","BouSaba J","2023","Current opinion in gastroenterology","narrative_review","article","10.1097/mog.0000000000000916","37144536","PMC10167542",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0030207","Up-Date on Diabetic Nephropathy.","Pelle MC","2022","Life (Basel, Switzerland)","narrative_review","article","10.3390/life12081202","36013381","PMC9409996",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030208","Latest advancements in the development of new therapies for type 1 diabetes.","Alzhanuly B","2024","Bratislavske lekarske listy","nonrandomized_study","article","10.4149/bll_2024_75","38989749",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","4","FALSE","Journal Article; Review; article"],["R0030209","Cephalopod-inspired jetting devices for gastrointestinal drug delivery.","Arrick G","2024","Nature","preclinical","article","10.1038/s41586-024-08202-5","39567682","PMC11634773",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030210","The connection between hypertension and diabetes and their role in heart and kidney disease development.","Hezam AAM","2024","Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences","narrative_review","article","10.4103/jrms.jrms_470_23","38855561","PMC11162087",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030211","Systems Biology and Peptide Engineering to Overcome Absorption Barriers for Oral Peptide Delivery: Dosage Form Optimization Case Study Preceding Clinical Translation.","Tyagi P","2023","Pharmaceutics","other","article","10.3390/pharmaceutics15102436","37896196","PMC10610252",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030212","C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease-Advancing toward Precision Medicine.","Amezcua-Castillo E","2023","Biomedicines","narrative_review","article","10.3390/biomedicines11092444","37760885","PMC10525787",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030213","Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.","Regmi A","2024","Cell metabolism","notice","article","10.1016/j.cmet.2024.06.012","38945123",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Published Erratum; article"],["R0030214","An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus.","Mahgoub MO","2023","International journal of molecular sciences","narrative_review","article","10.3390/ijms24119328","37298274","PMC10253663",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030215","β-cell heterogeneity and molecular plasticity in type 2 diabetes: multi-omics perspectives and the role of gut microbiota.","Ruchko E","2025","Frontiers in cell and developmental biology","narrative_review","article","10.3389/fcell.2025.1698296","41584842","PMC12823862",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","review-article; Review; Journal Article; article"],["R0030216","Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes.","Luo J","2025","The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale","preclinical","article","10.1155/cjid/6675676","39949529","PMC11824388",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030217","Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond.","Viljoen A","2023","Endocrinology and metabolism (Seoul, Korea)","other_trial","article","10.3803/enm.2022.1642","36740965","PMC10008669",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0030218","Structural basis for ligand recognition of incretin receptors.","Underwood CR","2010","Vitamins and hormones","narrative_review","article","10.1016/b978-0-12-381517-0.00009-6","21094903",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030219","Feasibility of improving manufacturability based on protein engineering","Capito F","2023","bioRxiv","other","preprint","10.1101/2023.11.23.568267",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0030220","The impact of obesity and metabolic health on male fertility: a systematic review.","Service CA","2023","Fertility and sterility","systematic_review","article","10.1016/j.fertnstert.2023.10.017","37839720",null,null,null,"pubmed; europepmc","FALSE","open_pdf","3",null,"Systematic Review; Journal Article"],["R0030221","Why are there Variations in the Responses of Glucagon-like Peptide-1 Agonists among the Type 2 Diabetic Patients?","Ajith TA","2019","Current clinical pharmacology","other","article","10.2174/157488471403191231143537","31971106",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030222","Changing the paradigm in heart failure: shifting from treatment to prevention.","Chang AJ","2025","Heart failure reviews","narrative_review","article","10.1007/s10741-024-10454-2","39441333",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030223","Serotonin receptor 4 agonism prevents high fat diet induced reduction in GLP-1 in mice.","Vanslette AM","2023","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2023.176181","37926275",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030224","Proglucagon-Derived Peptides as Therapeutics.","Lafferty RA","2021","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2021.689678","34093449","PMC8171296",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0030225","Toxicology of Medications for Diabetes Mellitus.","Baumgartner K","2021","Critical care clinics","narrative_review","article","10.1016/j.ccc.2021.03.007","34053707",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030226","Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center.","Pirchio R","2024","Journal of endocrinological investigation","nonrandomized_study","article","10.1007/s40618-023-02299-7","38532073","PMC11266387",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030227","Gastrointestinal hormones and regulation of gastric emptying.","Mori H","2022","Current opinion in endocrinology, diabetes, and obesity","narrative_review","article","10.1097/med.0000000000000707","35081068",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030228","Identification of Theaflavin-3,3'-Digallate as a Novel Zika Virus Protease Inhibitor.","Cui X","2020","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2020.514313","33192499","PMC7609463",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030229","GLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition.","Pauza AG","2022","Circulation research","preclinical","article","10.1161/circresaha.121.319874","35100822","PMC8893134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030230","Receptor Activity-Modifying Protein 3 enhances GLP-1-mediated Insulin Secretion","Pearce A","2025","bioRxiv","preclinical","article","10.1101/2025.01.24.634724","40832355",null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint; article"],["R0030231","Benefits of GLP-1 Mimetics on Epicardial Adiposity.","Yaribeygi H","2023","Current medicinal chemistry","other","article","10.2174/0929867330666230113110431","36642880","PMC10293101",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030232","Glp-1 mimetic of sitagliptin improved oxidative stress and liver function tests via suppressing NOX-4 enzyme in hepatic tissues of diabetic rats.","Hemmati MA","2025","Biochemical and biophysical research communications","randomized_trial","article","10.1016/j.bbrc.2025.151455","39923462",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0030233","A new mechanism of action of glucagon-like peptide-1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen-related cell adhesion molecule 1.","Czech TY","2018","Hepatology communications","other_trial","article","10.1002/hep4.1147","29404506","PMC5776878",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; research-article; article"],["R0030234","Brief Report: Use and Side Effects of Sodium-Glucose Transporter 2 Inhibitors Among US People With HIV With Clinical Indications.","Sise ME","2023","Journal of acquired immune deficiency syndromes (1999)","nonrandomized_study","article","10.1097/qai.0000000000003227","37229530","PMC10524386",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0030235","Diabetic vascular diseases: molecular mechanisms and therapeutic strategies.","Li Y","2023","Signal transduction and targeted therapy","narrative_review","article","10.1038/s41392-023-01400-z","37037849","PMC10086073",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0030236","New developments in the prospects for GLP-1 therapy.","Trapp S","2022","British journal of pharmacology","preclinical","article","10.1111/bph.15788","35107170","PMC8820181",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; article"],["R0030237","[Rediscovery of pioglitazone].","Pokoly B","2023","Orvosi hetilap","randomized_trial","article","10.1556/650.2023.32783","37393546",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","English Abstract; Journal Article; article"],["R0030238","RESEARCH PROTOCOL: Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus","Khera R","2021","medRxiv","protocol","preprint","10.1101/2021.09.27.21264139",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","5","FALSE","Preprint; preprint"],["R0030239","Diabetes: how to manage cardiovascular risk in secondary prevention patients.","Anderson SL","2022","Drugs in context","narrative_review","article","10.7573/dic.2021-10-1","35775074","PMC9205572",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030240","Complications and Treatment of Early-Onset Type 2 Diabetes.","Soheilipour F","2023","International journal of endocrinology and metabolism","nonrandomized_study","article","10.5812/ijem-135004","38028250","PMC10676662",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; review-article; article"],["R0030241","Association between genetically proxied PPARG activation and early onset Alzheimer's disease: A drug target Mendelian randomization study.","Zhang L","2025","Journal of Alzheimer's disease reports","other","article","10.1177/25424823251359579","40697193","PMC12280270",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030242","A novel glucagon-like peptide 1 peptide identified from Ophisaurus harti.","Zhu J","2013","Journal of peptide science : an official publication of the European Peptide Society","preclinical","article","10.1002/psc.2538","23893560",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030243","A Very Rare Case of Diabetes Mellitus Occurring in a Patient With Hyperinsulinism Hyperammonemia Syndrome.","Komal F","2023","AACE clinical case reports","case_report","article","10.1016/j.aace.2023.04.011","37520762","PMC10382607",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Case Reports; Journal Article; case-report; article"],["R0030244","Glucagon-like peptide-1 agonists for treatment of hidradenitis suppurativa.","Emtestam L","2017","The British journal of dermatology","commentary","article","10.1111/bjd.15742","28940285",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Comment; article"],["R0030245","[Treatment of GLP1 receptor agonists and body mass control].","Žák P","2015","Vnitrni lekarstvi","other","article",null,"25894261",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030246","Preliminary asthma-related outcomes following glucagon-like peptide 1 agonist therapy.","Khan F","2017","QJM : monthly journal of the Association of Physicians","randomized_trial","article","10.1093/qjmed/hcx125","28673015",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0030247","FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES","Patorno E","2019","Innovation in aging","nonrandomized_study","article","10.1093/geroni/igz038.2158",null,"PMC6841064",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0030248","Assessment and Management of Patients with Obesity and Hypertension in European Society of Hypertension Excellence Centres. A survey from the ESH Working Group on Diabetes and Metabolic Risk Factors.","Antza C","2024","Blood pressure","other","article","10.1080/08037051.2024.2317256","38407195",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030249","Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study.","Çetin D","2025","Medicina (Kaunas, Lithuania)","randomized_trial","article","10.3390/medicina61071152","40731782","PMC12299443",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Observational Study; research-article; article"],["R0030250","Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1.","Liu XY","2021","The European journal of neuroscience","narrative_review","article","10.1111/ejn.15502","34676939",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030251","Ten-year clinical characteristics of patients with early-onset type 2 diabetes: A single-center experience in China.","Yu R","2024","Journal of diabetes","nonrandomized_study","article","10.1111/1753-0407.13477","37750029","PMC10809291",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030252","MIR192 Upregulates GLP-1 Receptor and Improves Statin-Induced Impairment of Insulin Secretion.","Kuang YL","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.03.18.643960","40166140","PMC11956930",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Preprint; preprint"],["R0030253","In silico prediction of optimal multifactorial intervention in CKD","Latosinska A","2025","medRxiv","randomized_trial","preprint","10.1101/2025.02.14.25322292",null,null,null,null,"europepmc; openalex","TRUE","open_pdf","2","FALSE","Preprint; preprint"],["R0030254","Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice: The APALUSA Study.","Barrios V","2022","Journal of clinical medicine","other","article","10.3390/jcm11123554","35743622","PMC9224728",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030255","To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases.","Lee WL","2022","Journal of the Chinese Medical Association : JCMA","narrative_review","article","10.1097/jcma.0000000000000831","36279128","PMC12755334",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; Journal Article; review-article; article"],["R0030256","The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.","Sánchez-Briales P","2024","Journal of clinical medicine","nonrandomized_study","article","10.3390/jcm13051360","38592682","PMC10931679",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030257","Patient Out-of-Pocket Costs for Type 2 Diabetes Medications When Aging Into Medicare.","Barthold D","2024","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.20724","38980673","PMC11234236",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0030258","Design of Stapled Oxyntomodulin Analogs Containing Functionalized Biphenyl Cross-Linkers.","Tian Y","2019","Tetrahedron","other","article","10.1016/j.tet.2018.11.060","30581241","PMC6300064",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0030259","MON-130 Optimal Glycemic Control in a Patient with HNF1A MODY with GLP1-RA Monotherapy: Implications for Future Therapy","Fantasia K","2019","Journal of the Endocrine Society","other","article","10.1210/js.2019-mon-130",null,"PMC6551179",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0030260","Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome.","Wang D","2022","Diabetes, metabolic syndrome and obesity : targets and therapy","narrative_review","article","10.2147/dmso.s362424","35494531","PMC9048954",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030261","Tell me what you want, what you really really want: Estimands in observational pharmacoepidemiologic comparative effectiveness and safety studies.","Luijken K","2023","Pharmacoepidemiology and drug safety","randomized_trial","article","10.1002/pds.5620","36946319",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030262","Obesity-related, metabolic asthma: a new role for glucagon-like peptide 1 agonists.","Nguyen DV","2017","The Lancet. Respiratory medicine","narrative_review","article","10.1016/s2213-2600(17)30051-6","28266322","PMC8908331",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article-commentary; article"],["R0030263","Medical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease.","Kim JA","2023","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2023.06.013","37380060",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030264","Comment on 'No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia'.","Sperandeo R","2017","Acta psychiatrica Scandinavica","commentary","article","10.1111/acps.12782","28777896",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Comment; letter"],["R0030265","'No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia': authors' response.","Ebdrup BH","2017","Acta psychiatrica Scandinavica","commentary","article","10.1111/acps.12795","28846820",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Letter; Research Support, Non-U.S. Gov't; Comment; article"],["R0030266","What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease?","Escalada San Martín FJ","2020","Revista espanola de enfermedades digestivas","other","article","10.17235/reed.2020.7148/2020","32686456",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030267","Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes.","Lundholm MD","2023","Journal of diabetes and its complications","nonrandomized_study","article","10.1016/j.jdiacomp.2023.108405","36669324",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0030268","Changing Fields-Diabetes Medications Invading the Cardiovascular Space.","Breite LD","2021","Current problems in cardiology","narrative_review","article","10.1016/j.cpcardiol.2020.100736","33218786",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030269","Factors Affecting Prescribing of Type 2 Diabetes Medications in Older Adults within an Integrated Healthcare System.","Lussier ME","2024","Journal of general internal medicine","nonrandomized_study","article","10.1007/s11606-023-08435-6","37783983","PMC10853133",null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; research-article"],["R0030270","Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2).","Navas-Acien A","2024","American heart journal","randomized_trial","article","10.1016/j.ahj.2024.04.005","38621575","PMC11162898","ClinicalTrials.gov:NCT02733185",null,"pubmed; europepmc","FALSE","free_to_read","2",null,"Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article"],["R0030271","Adherent reformed islets: a long-term primary cell-based platform for exploring mouse and human islet biology","Haq N","2023","bioRxiv","preclinical","preprint","10.1101/2023.11.22.568245",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0030272","Glucose-Lowering and the Risk of Cardiovascular Events with Novel Antidiabetic Therapies: A Systematic Review and Additive-effects Network Meta-Analysis","de Carvalho LSF","2021","Research Square","systematic_review","preprint","10.21203/rs.3.rs-983766/v1",null,null,"PROSPERO:CRD42020200649",null,"europepmc; openalex","TRUE","open_pdf","3","FALSE","Preprint; preprint"],["R0030273","Temporal trends in, and associations of, early-career general practitioner prescriptions of second-line Type 2 Diabetes medications, 2010-2018.","Patsan I","2023","PloS one","other","article","10.1371/journal.pone.0280668","36662823","PMC9858089",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030274","Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.","Libianto R","2020","The Medical journal of Australia","narrative_review","article","10.5694/mja2.50472","31910303",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030275","Enteroendocrine System and Gut Barrier in Metabolic Disorders.","Osinski C","2022","International journal of molecular sciences","narrative_review","article","10.3390/ijms23073732","35409092","PMC8998765",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030276","Diabetes, antidiabetic medications and risk of depression - A population-based cohort and nested case-control study.","Wium-Andersen IK","2022","Psychoneuroendocrinology","nonrandomized_study","article","10.1016/j.psyneuen.2022.105715","35338947",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030277","One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus.","Seetharaman R","2022","British journal of clinical pharmacology","narrative_review","article","10.1111/bcp.15100","34608666",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030278","Which Patients with Obesity Are at Risk for Renal Disease?","Sandino J","2021","Nephron","narrative_review","article","10.1159/000513868","33677441",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030279","[Prevalence and drug treatment of people with type 2 diabetes mellitus and a very high risk of cardiovascular disease].","Serné EH","2023","Nederlands tijdschrift voor geneeskunde","nonrandomized_study","article",null,"37742128",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Observational Study; English Abstract; Journal Article; article"],["R0030280","Epicardial fat links obesity to cardiovascular diseases.","Iacobellis G","2023","Progress in cardiovascular diseases","narrative_review","article","10.1016/j.pcad.2023.04.006","37105279",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030281","[Glucagon-like peptide-1 (GLP1) and the gastrointestinal tract. GLP1 receptor agonists: overemphasized gastric, forgotten intestinal (\"ileal brake\") effect?].","Winkler G","2019","Orvosi hetilap","narrative_review","article","10.1556/650.2019.31615","31786941",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030282","Targeting insulin resistance with selected antidiabetic agents prevents menopausal associated central obesity, dysglycemia, and cardiometabolic risk.","Jankie S","2021","Post reproductive health","other","article","10.1177/2053369120982753","33356861",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030283","Assessing the temporal within-day glycemic variability during hospitalization in patients with type 2 diabetes patients using continuous glucose monitoring: a retrospective observational study.","Xing Y","2024","Diabetology & metabolic syndrome","nonrandomized_study","article","10.1186/s13098-024-01269-0","38429847","PMC10908144",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; other; article"],["R0030284","Clinical utility of a novel test for assessing cardiovascular disease risk in type 2 diabetes: a randomized controlled trial.","Peabody JW","2023","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-023-01122-w","37438853","PMC10339653","ClinicalTrials.gov:NCT05237271",null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0030285","Determining the role of novel metabolic pathways in driving intracranial pressure reduction after weight loss.","Alimajstorovic Z","2023","Brain communications","nonrandomized_study","article","10.1093/braincomms/fcad272","37901040","PMC10608960",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030286","Managing obesity in people with type 2 diabetes.","Grant B","2021","Clinical medicine (London, England)","other","article","10.7861/clinmed.2021-0370","35192472","PMC8313195",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0030287","[Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)].","Saely CH","2023","Wiener klinische Wochenschrift","narrative_review","article","10.1007/s00508-023-02189-1","37101036","PMC10133364",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Review; English Abstract; Journal Article; Practice Guideline; research-article; article"],["R0030288","Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors.","Matteucci E","2015","Current medicinal chemistry","narrative_review","article","10.2174/0929867322666150227153308","25723507",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030289","Effect of incretins on skeletal health.","Starup-Linde J","2023","Current opinion in endocrinology, diabetes, and obesity","nonrandomized_study","article","10.1097/med.0000000000000813","37334507",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Review; Journal Article; article"],["R0030290","(Poly)peptide-based therapy for diabetes mellitus: insulins versus incretins.","Bavec A","2014","Life sciences","narrative_review","article","10.1016/j.lfs.2013.12.210","24412390",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0030291","Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.","Chan WK","2022","Journal of gastroenterology and hepatology","narrative_review","article","10.1111/jgh.15787","35080048","PMC9303255",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Consensus Statement; review-article; article"],["R0030292","Type 2 diabetes in adults: management: Evidence reviews for SGLT-2 inhibitors and GLP-1 mimetics",null,"2018","National Institute for Health and Care Excellence (NICE), London","narrative_review","article",null,"31769943",null,null,null,"europepmc","FALSE",null,null,null,"Review"],["R0030293","Development of stable affinity-based subcutaneous peptide formulations","Egbu R","2021","University College London (University of London)","other","article",null,null,null,null,null,"europepmc; openalex","FALSE",null,null,"FALSE","Dissertation; dissertation"],["R0030294","[Post-transplantation diabetes in kidney transplant: from the diabetologist point of view].","Pauchet A","2020","Revue medicale suisse","narrative_review","article",null,"32520459",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030295","A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.","Scott RA","2016","Science translational medicine","randomized_trial","article","10.1126/scitranslmed.aad3744","27252175","PMC5219001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0030296","GLP1 analogues among patients with overweight or obesity during lockdown.","Nicolau J","2022","Medicina clinica","other","article","10.1016/j.medcli.2020.12.039","33781571",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030297","Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.","Hung AY","2020","Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","narrative_review","article","10.1007/s13311-020-00964-w","33205384","PMC7851299",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; review-article"],["R0030298","Exploring the clinical features and complications of type 1 diabetes mellitus in Saudi Arabia: A retrospective analysis.","Al Hayek AA","2025","Journal of family medicine and primary care","nonrandomized_study","article","10.4103/jfmpc.jfmpc_1758_24","40547727","PMC12178472",null,null,"pubmed; europepmc","TRUE","open_europepmc","4",null,"Journal Article; research-article"],["R0030299","Diabetic kidney disease in children and adolescents: an update.","Lopez LN","2022","Pediatric nephrology (Berlin, Germany)","narrative_review","article","10.1007/s00467-021-05347-7","34913986","PMC9489564",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0030300","An inter-organ neural circuit for appetite suppression.","Zhang T","2022","Cell","preclinical","article","10.1016/j.cell.2022.05.007","35662413","PMC9433108",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Video-Audio Media; research-article"],["R0030301","Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification.","O'Keefe EL","2021","The American journal of cardiology","systematic_review","article","10.1016/j.amjcard.2021.08.042","34583808",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Systematic Review; article"],["R0030302","Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes.","Chi C","2017","Heart, lung & circulation","narrative_review","article","10.1016/j.hlc.2017.02.030","28473214",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030303","Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.","Ueda P","2018","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj.k4365","30429124","PMC6233755",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030304","Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus.","Fauchier L","2021","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","other","article","10.1093/europace/euab184","34411235",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030305","Prescription Patterns of Novel Antihyperglycemic Medications.","Ali AS","2022","Journal of the American Board of Family Medicine : JABFM","nonrandomized_study","article","10.3122/jabfm.2022.02.210360","35379713",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Journal Article; article"],["R0030306","UTILIZATION TRENDS OF NEWLY APPROVED GLUCOSE-LOWERING DRUGS FOR TYPE 2 DIABETES","Dave C","2019","Innovation in aging","other","article","10.1093/geroni/igz038.2155",null,"PMC6841063",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; conference-abstract"],["R0030307","Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?","Klempel N","2022","Peptides","other","article","10.1016/j.peptides.2022.170877","36108978",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030308","Effect of Incorporating Zirconia Powder into a Primer on the Resin Bond Strength to Zirconia Ceramic.","Lee E","2020","Journal of nanoscience and nanotechnology","preclinical","article","10.1166/jnn.2020.17617","32331137",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030309","Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study.","Wium-Andersen IK","2019","European journal of endocrinology","nonrandomized_study","article","10.1530/eje-19-0259","31437816",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0030310","Pancreatic β-Cell Rest Replenishes Insulin Secretory Capacity and Attenuates Diabetes in an Extreme Model of Obese Type 2 Diabetes.","Boland BB","2019","Diabetes","preclinical","article","10.2337/db18-0304","30305366","PMC13059969",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030311","Generation of iPSC lines (KAUSTi011-A, KAUSTi011-B) from a Saudi patient with epileptic encephalopathy carrying homozygous mutation in the GLP1R gene.","Alowaysi M","2021","Stem cell research","other","article","10.1016/j.scr.2020.102148","33421754",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030312","Diabetes, insulin resistance, and asthma: a review of potential links.","Wu TD","2021","Current opinion in pulmonary medicine","narrative_review","article","10.1097/mcp.0000000000000738","33002990",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030313","Linking Kidney and Cardiovascular Complications in Diabetes-Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture.","Rossing P","2021","Diabetes","narrative_review","article","10.2337/dbi19-0038","33355308","PMC7881849",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Research Support, Non-U.S. Gov't; Review; Journal Article; oration; article"],["R0030314","The impact of diabetes on heart failure development: The cardio-renal-metabolic connection.","Valensi P","2021","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2021.108831","33895192",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030315","Biomonitoring potentially toxic elements in atmospheric particulate matter of greater Dhaka region using leaves of higher plants.","Jashim ZB","2024","Environmental monitoring and assessment","other","article","10.1007/s10661-024-12612-3","38656463",null,null,null,"europepmc","FALSE",null,null,null,"Journal Article"],["R0030316","Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment.","Yin R","2022","Molecules (Basel, Switzerland)","narrative_review","article","10.3390/molecules27103055","35630534","PMC9147686",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030317","Hypocretin/orexin modulates body weight and the metabolism of glucose and insulin.","Adeghate E","2020","Diabetes/metabolism research and reviews","preclinical","article","10.1002/dmrr.3229","31655012",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030318","Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease.","Patel DM","2020","International journal of molecular sciences","narrative_review","article","10.3390/ijms21062218","32210089","PMC7139394",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030319","Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.","Zanchi A","2023","Swiss medical weekly","randomized_trial","article","10.57187/smw.2023.40004","36652726",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Consensus Statement; article"],["R0030320","[Do diabetologists choose a therapy rationally? Basic results of the PROROK project (a prospective observation project to assess the relevance of the difference between fasting glycemia and postprandial glycemia to estimation of success of type 2 diabetes therapy)].","Žďarská DJ","2015","Vnitrni lekarstvi","nonrandomized_study","article",null,"25894257",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","4","FALSE","Journal Article; Observational Study; article"],["R0030321","Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review.","Boye KS","2022","Patient preference and adherence","narrative_review","article","10.2147/ppa.s328583","35023906","PMC8747793",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; review"],["R0030322","Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.","Edwards CM","2013","British journal of hospital medicine (London, England : 2005)","narrative_review","article","10.12968/hmed.2013.74.4.198","23571389",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030323","The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective.","Fatima S","2017","Clinical cardiology","narrative_review","article","10.1002/clc.22781","28841228","PMC6490350",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030324","Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development.","Zhang Q","2023","Experimental biology and medicine (Maywood, N.J.)","narrative_review","article","10.1177/15353702231214270","38058030","PMC10800121",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; review-article; article"],["R0030325","Standardization parameters and synergism of source plant materials for the antidiabetic efficacy of the Rauvolfia-Citrus tea.","Campbell-Tofte J","2024","Fitoterapia","preclinical","article","10.1016/j.fitote.2024.106004","38744382",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030326","Will Gut Microbiota Help Design the Next Generation of GLP-1-Based Therapies for Type 2 Diabetes?","Claus SP","2017","Cell metabolism","other","article","10.1016/j.cmet.2017.06.009","28683295",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030327","[Nephrological management and drug dosing in patients with rheumatic diseases and renal insufficiency].","Weiner SM","2022","Zeitschrift fur Rheumatologie","narrative_review","article","10.1007/s00393-022-01283-5","36350405",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0030328","Pharmacological and structure-activity relationship studies of oleoyl-lysophosphatidylinositol synthetic mimetics.","Paternoster S","2021","Pharmacological research","preclinical","article","10.1016/j.phrs.2021.105822","34411732",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030329","Computational Insight into Anti-Obesity Effects of Combined Some Phytobiotics to GLP1R (Glucagon-Like Peptide 1 Receptor) Protein in  <i>Anas javanica<\/i>","Damayanti C","2023","bioRxiv","other","preprint","10.1101/2023.04.26.538390",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0030330","[Challenges in managing diabetes in chronic hemodialysis].","Lamine F","2019","Revue medicale suisse","other","article",null,"31148425",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030331","A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline for the Management of Hyperglycemia in Adults Hospitalized for Noncritical Illness or Undergoing Elective Surgical Procedures.","Seisa MO","2022","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgac277","35690929","PMC9653020",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Systematic Review; review-article; review"],["R0030332","Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies.","Costes S","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22105303","34069914","PMC8157542",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030333","Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists.","Sesti G","2011","Diabetes care","other","article","10.2337/dc11-s228","21525467","PMC3632191",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030334","Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.","Quast DR","2024","Diabetes, obesity & metabolism","randomized_trial","article","10.1111/dom.15736","38951936",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","2","FALSE","Journal Article; Randomized Controlled Trial; Comparative Study; Research Support, Non-U.S. Gov't; article"],["R0030335","Anti-obesity medication prescriptions by race/ethnicity and use of an interpreter in a pediatric weight management clinic.","Bomberg EM","2022","Therapeutic advances in endocrinology and metabolism","other","article","10.1177/20420188221090009","35432917","PMC9005816",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; other; article"],["R0030336","Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.","Kanbay M","2021","Journal of nephrology","narrative_review","article","10.1007/s40620-020-00751-y","32440840",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030337","Vitamin Intake and Loss of Muscle Mass in Older People with Type 2 Diabetes: A Prospective Study of the KAMOGAWA-DM Cohort.","Takahashi F","2021","Nutrients","nonrandomized_study","article","10.3390/nu13072335","34371843","PMC8308571",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030338","Hypertension in Diabetes","Naha S","2000","MDText.com, Inc., South Dartmouth (MA)","randomized_trial","article",null,"25905256",null,null,null,"europepmc","TRUE","free_to_read","2",null,"Review"],["R0030339","Functional screening system for yeast-secreted peptides acting on G-protein coupled receptors.","Shigemori T","2015","AMB Express","other","article","10.1186/s13568-015-0113-8","25992304","PMC4427575",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030340","Cardiovascular Disease and Diabetic Kidney Disease.","Maqbool M","2018","Seminars in nephrology","narrative_review","article","10.1016/j.semnephrol.2018.02.003","29753399",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030341","Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.","Mirabelli M","2020","International journal of environmental research and public health","other","article","10.3390/ijerph17103664","32456064","PMC7277613",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030342","Combining basal insulin analogs with glucagon-like peptide-1 mimetics.","Perfetti R","2011","Diabetes technology & therapeutics","narrative_review","article","10.1089/dia.2010.0250","21711120","PMC3160265",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0030343","Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options.","Salvatore T","2022","Biomedicines","narrative_review","article","10.3390/biomedicines10092274","36140374","PMC9496134",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030344","Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.","Song X","2015","Scientific reports","systematic_review","article","10.1038/srep10202","26111974","PMC4481643",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; research-article; review"],["R0030345","The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.","Munir KM","2015","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2015.1084502","26340427",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030346","[Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (Update 2019)].","Schernthaner G","2019","Wiener klinische Wochenschrift","narrative_review","article","10.1007/s00508-019-1460-2","30980142",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030347","CETP and SGLT2 inhibitor combination therapy improves glycemic control.","Khomtchouk BB","2023","medRxiv : the preprint server for health sciences","other","article","10.1101/2023.06.13.23291357","37398493","PMC10312876",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Preprint; Journal Article; preprint"],["R0030348","Treatment of diabetes and heart failure: a paradigm shift for cardiologists?","Brochu B","2019","Current opinion in cardiology","nonrandomized_study","article","10.1097/hco.0000000000000599","30608252",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0030349","Use of glucagon-like peptide-1 agonists to improve islet graft performance.","Wang Y","2013","Current diabetes reports","preclinical","article","10.1007/s11892-013-0402-z","23925432","PMC3888204",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0030350","Hippocampal-Dependent Inhibitory Learning and Memory Processes in the Control of Eating and Drug Taking.","Clasen MM","2020","Current pharmaceutical design","other","article","10.2174/1381612826666200206091447","32026771",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; article"],["R0030351","Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice.","Venkatachalapathy P","2021","Pharmacogenomics and personalized medicine","narrative_review","article","10.2147/pgpm.s329787","34803393","PMC8598203",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030352","Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice.","Ying Z","2023","EBioMedicine","preclinical","article","10.1016/j.ebiom.2023.104684","37379656","PMC10318458",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030353","Update in therapeutic strategies for Parkinson's disease.","Kulisevsky J","2018","Current opinion in neurology","narrative_review","article","10.1097/wco.0000000000000579","29746402",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030354","GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies.","Williams JA","2016","Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]","preclinical","article","10.1016/j.pan.2015.11.008","26751948",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030355","Assessment of clinical inertia in people with diabetes within primary care.","Meredith AH","2021","Journal of evaluation in clinical practice","nonrandomized_study","article","10.1111/jep.13429","32548871",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0030356","Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients.","Zhai MZ","2022","JAMA network open","nonrandomized_study","article","10.1001/jamanetworkopen.2022.40117","36346634","PMC9644265",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030357","Crosstalk between gut microbiota and antidiabetic drug action.","Kyriachenko Y","2019","World journal of diabetes","narrative_review","article","10.4239/wjd.v10.i3.154","30891151","PMC6422856",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030358","Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018.","Engler C","2020","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2020-001279","32873600","PMC7467522",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030359","Use of GLP-1 mimetic in type 2 diabetes mellitus: is it the end of fragility fractures?","Mabilleau G","2015","Endocrine","commentary","article","10.1007/s12020-014-0461-1","25348148",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0030360","Drug repurposing in kidney disease.","Panchapakesan U","2018","Kidney international","narrative_review","article","10.1016/j.kint.2017.12.026","29628139",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030361","Combination therapy for obesity.","Wilding JP","2017","Journal of psychopharmacology (Oxford, England)","narrative_review","article","10.1177/0269881117737401","29132230",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030362","Adherence to Nice Guidance For Initiating Glp-1 Mimetics Among Patients With Type 2 Diabetes In Primary Care In England And Wales - An Evaluation Using The Clinical Practice Research Datalink (Cprd).","Jameson K","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.794","27200745",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030363","Current treatment for polycystic ovary syndrome: focus on adolescence.","Street ME","2020","Minerva pediatrica","narrative_review","article","10.23736/s0026-4946.20.05861-2","32418411",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030364","Long-Term Stability Prediction for Developability Assessment of Biopharmaceutics Using Advanced Kinetic Modeling.","Evers A","2022","Pharmaceutics","other","article","10.3390/pharmaceutics14020375","35214107","PMC8880208",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030365","Do GLP-1-based therapies increase cancer risk?","Nauck MA","2013","Diabetes care","preclinical","article","10.2337/dcs13-2004","23882053","PMC3920789",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0030366","Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans.","Halim MA","2018","The Journal of clinical endocrinology and metabolism","other_trial","article","10.1210/jc.2017-02006","29177486",null,"ClinicalTrials.gov:NCT02731664","S003384","pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030367","Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target!","Riddle MC","2017","Diabetes care","narrative_review","article","10.2337/dc16-2380","28223444",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030368","A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns.","Secrest MH","2020","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.4878","31464069",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030369","LBODP046 Reduction In \"Cardiovascular Death Or Hospitalisation For Heart Failure\" With Sglt-2is Is Dependent On Weight Reduction: A Meta-regression Analysis",null,"2022","Journal of the Endocrine Society","other","article",null,null,"PMC9624776",null,null,"europepmc","TRUE",null,null,null,"Abstract"],["R0030370","Risk factor reduction in type 2 diabetes demands a multifactorial approach.","Rydén L","2019","European journal of preventive cardiology","other_trial","article","10.1177/2047487319872015","31766912",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Journal Article; Review; article"],["R0030371","Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs.","Renner S","2018","Molecular metabolism","other_trial","article","10.1016/j.molmet.2018.06.015","30017782","PMC6157610",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; brief-report; article"],["R0030372","A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism.","Grasset E","2017","Cell metabolism","preclinical","article","10.1016/j.cmet.2017.04.013","28467926",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030373","Prediabetes.","Khetan AK","2018","The Canadian journal of cardiology","narrative_review","article","10.1016/j.cjca.2017.12.030","29731022",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030374","The 2021-2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD.","de Sá JR","2022","Diabetology & metabolic syndrome","randomized_trial","article","10.1186/s13098-022-00843-8","35690830","PMC9188192",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0030375","Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity.","Lockie SH","2013","Journal of neuroendocrinology","narrative_review","article","10.1111/jne.12039","23590331",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030376","Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.","Elharram M","2020","International journal of cardiology","randomized_trial","article","10.1016/j.ijcard.2020.03.025","32303419",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article"],["R0030377","Short energy intake is associated with muscle mass loss in older patients with type 2 diabetes: A prospective study of the KAMOGAWA-DM cohort.","Kawano R","2021","Clinical nutrition (Edinburgh, Scotland)","nonrandomized_study","article","10.1016/j.clnu.2021.02.049","33752149",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article"],["R0030378","Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis.","Qin X","2021","Frontiers in neurology","systematic_review","article","10.3389/fneur.2021.678649","34349721","PMC8326375",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Systematic Review; Journal Article; systematic-review; review"],["R0030379","Inpatient Glycemic Management in the Setting of Renal Insufficiency/Failure/Dialysis.","Iyengar R","2018","Current diabetes reports","nonrandomized_study","article","10.1007/s11892-018-1044-y","30112652",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0030380","ODP383 Clinical Presentation and Management of Diabetes Mellitus in Youth with Prader-Willi Syndrome",null,"2022","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC9625408",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0030381","GLP-1 based therapy for type 2 diabetes.","Arulmozhi DK","2006","European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","narrative_review","article","10.1016/j.ejps.2006.01.003","16488579",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030382","The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review.","Taylor OM","2020","Current therapeutic research, clinical and experimental","systematic_review","article","10.1016/j.curtheres.2020.100596","32817765","PMC7424199",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; review-article; review"],["R0030383","Gut microbiota dysbiosis of type 2 diabetic mice impairs the intestinal daily rhythms of GLP-1 sensitivity.","Grasset E","2022","Acta diabetologica","preclinical","article","10.1007/s00592-021-01790-y","34648088",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030384","L-Cell Differentiation Is Induced by Bile Acids Through GPBAR1 and Paracrine GLP-1 and Serotonin Signaling.","Lund ML","2020","Diabetes","preclinical","article","10.2337/db19-0764","32041793","PMC7224989",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030385","Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.","Liu Y","2014","World journal of gastroenterology","randomized_trial","article","10.3748/wjg.v20.i27.9090","25083081","PMC4115340",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0030386","GLP1 analogs as treatment of postprandial hypoglycemia following gastric bypass surgery: a potential new indication?","Abrahamsson N","2013","European journal of endocrinology","case_report","article","10.1530/eje-13-0504","24086087",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Case Reports; Journal Article; article"],["R0030387","Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.","Secnik J","2020","Journal of Alzheimer's disease : JAD","nonrandomized_study","article","10.3233/jad-200618","32741836","PMC7504989",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030388","Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries.","Hartmann B","2020","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-019-01409-3","31471633",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Clinical Trial; Journal Article"],["R0030389","Antidiabetic medications in patients with heart failure.","Samia El Hayek MM","2017","Minerva endocrinologica","narrative_review","article","10.23736/s0391-1977.16.02349-x","27195949",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030390","Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG.","Rydén L","2016","Clinical therapeutics","other","article","10.1016/j.clinthera.2016.03.035","27107734",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030391","Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes.","Oduori OS","2020","The Journal of clinical investigation","preclinical","article","10.1172/jci140046","33196462","PMC7685756",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Video-Audio Media; research-article; article"],["R0030392","Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?","Campbell IW","2010","International journal of clinical practice","other_trial","article","10.1111/j.1742-1241.2009.02292.x","20518953",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","5","FALSE","Comparative Study; Journal Article; Review; article"],["R0030393","Treating people with type 2 diabetes.","Hillson R","2013","British journal of hospital medicine (London, England : 2005)","other","article","10.12968/hmed.2013.74.4.186","23752097",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030394","Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study.","Hung YC","2020","Cardiovascular diabetology","nonrandomized_study","article","10.1186/s12933-020-01056-x","32563247","PMC7306145",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; research-article; Preprint; preprint; article"],["R0030395","Epidemiology of Obesity and Pharmacologic Treatment Options.","Shettar V","2017","Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition","narrative_review","article","10.1177/0884533617713189","28632997",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030396","Anti-Obesity Medication Prescriptions by Race/Ethnicity and Use of an Interpreter in a Pediatric Weight Management Clinic","Bomberg E","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.006",null,"PMC8265710",null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Abstract; article"],["R0030397","Generation and use of new tools for the characterisation of gut hormone receptors","Biggs EK","2019","University of Cambridge","other","article","10.17863/cam.37487",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Dissertation; dissertation"],["R0030398","[The Diabetic Heart and Heart Failure - Update on Mechanisms and Therapy].","Zweck E","2019","Deutsche medizinische Wochenschrift (1946)","other","article","10.1055/a-0646-7871","30703836",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030399","Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach.","Dai Y","2013","Acta diabetologica","narrative_review","article","10.1007/s00592-013-0496-4","23824323",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review"],["R0030400","CJC-1131. ConjuChem.","Giannoukakis N","2003","Current opinion in investigational drugs (London, England : 2000)","other_trial","article",null,"14649218",null,null,null,"pubmed; europepmc; openalex","FALSE","no_doi","5","FALSE","Journal Article; Review; conference-abstract"],["R0030401","XBP1 expression in pancreatic islet cells is associated with poor glycaemic control across ancestries especially in young non-obese onset diabetes","Dupuis T","2023","medRxiv","other","preprint","10.1101/2023.05.04.23289501",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0030402","Estimating the effects of second-line therapy for type 2 diabetes mellitus: retrospective cohort study.","Gottlieb A","2017","BMJ open diabetes research & care","nonrandomized_study","article","10.1136/bmjdrc-2017-000435","29299328","PMC5730938",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030403","Effect of GLP-1 based therapies on diabetic dyslipidemia.","Patel VJ","2014","Current diabetes reviews","nonrandomized_study","article","10.2174/1573399810666140707092506","24998439",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Review; article"],["R0030404","Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.","Nishimura R","2019","BMJ open","nonrandomized_study","article","10.1136/bmjopen-2018-025806","30826768","PMC6429930",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030405","Pharmacological management of type 2 diabetes mellitus: an update.","El-Kaissi S","2011","Current diabetes reviews","narrative_review","article","10.2174/157339911797579160","21846326",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030406","Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity.","Neff LM","2017","Clinical obesity","systematic_review","article","10.1111/cob.12213","28891142",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Systematic Review; Network Meta-Analysis; article"],["R0030407","Glucagon-like peptide-1: glucose homeostasis and beyond.","Cho YM","2014","Annual review of physiology","narrative_review","article","10.1146/annurev-physiol-021113-170315","24245943",null,null,"S002311","pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review"],["R0030408","Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases.","Arsenault BJ","2018","Clinical pharmacology and therapeutics","narrative_review","article","10.1002/cpt.1110","29737015",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030409","Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards.","Gupta T","2017","Journal of the Endocrine Society","narrative_review","article","10.1210/js.2016-1055","29264482","PMC5686565",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030410","Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.","He ZX","2015","Clinical and experimental pharmacology & physiology","nonrandomized_study","article","10.1111/1440-1681.12332","25360831",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030411","AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.","Long MT","2022","Gastroenterology","narrative_review","article","10.1053/j.gastro.2022.06.023","35842345","PMC9398982",null,null,"pubmed; europepmc","FALSE",null,null,null,"Practice Guideline; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Journal Article; research-article"],["R0030412","Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.","Leonard CE","2018","Pharmacoepidemiology and drug safety","nonrandomized_study","article","10.1002/pds.4337","29108130","PMC5770147",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Comparative Study; Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0030413","[Individualized diabetes therapy in older persons].","Zeyfang A","2016","Der Internist","narrative_review","article","10.1007/s00108-016-0039-5","27080251",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030414","[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].","Valerón PF","2013","Medicina clinica","narrative_review","article","10.1016/s0025-7753(13)70059-9","24444520",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030415","Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus.","Vanhove T","2017","Transplantation reviews (Orlando, Fla.)","narrative_review","article","10.1016/j.trre.2016.09.001","27665059",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030416","Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog.","Léger R","2004","Bioorganic & medicinal chemistry letters","preclinical","article","10.1016/j.bmcl.2004.06.066","15357960",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0030417","Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.","Mannino GC","2019","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.3109","30515958","PMC6590177",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0030418","Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.","Wang X","2018","Antioxidants & redox signaling","preclinical","article","10.1089/ars.2016.6953","28635324",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030419","Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.","Ding S","2016","International journal of cardiology","systematic_review","article","10.1016/j.ijcard.2016.07.199","27526367",null,null,null,"pubmed; europepmc","FALSE","paywalled","3",null,"Journal Article; Meta-Analysis; Review"],["R0030420","Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support.","Choi SE","2019","Medical decision making : an international journal of the Society for Medical Decision Making","systematic_review","article","10.1177/0272989x19829735","30767632","PMC6469997",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; other; article"],["R0030421","Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?","Gutierrez-Buey G","2017","European journal of internal medicine","nonrandomized_study","article","10.1016/j.ejim.2017.03.006","28283346",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Validation Study"],["R0030422","Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.","Santamarina M","2019","BMC cardiovascular disorders","other_trial","article","10.1186/s12872-019-1036-0","30876392","PMC6419798",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0030423","A comparison of medication adherence and persistence across drug classes in people with type 2 diabetes","Mcgovern AP","2018","University of Surrey","nonrandomized_study","article",null,null,null,null,null,"europepmc; openalex","FALSE","free_to_read","4","FALSE","Dissertation; dissertation"],["R0030424","Facile synthesis of glucagon-like peptide-1 (GLP-1) mimetics.","Han SY","2009","Advances in experimental medicine and biology","other","article","10.1007/978-0-387-73657-0_53","19400120",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; book-chapter"],["R0030425","Activation of G-protein coupled receptors targeting gastrointestinal hormone secretion in Type 2 Diabetes","Miskelly M","2018","Ulster University","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0030426","Patient Characteristics Associated With Severe Hypoglycemia in a Type 2 Diabetes Cohort in a Large, Integrated Health Care System From 2006 to 2015.","Misra-Hebert AD","2018","Diabetes care","nonrandomized_study","article","10.2337/dc17-1834","29549082",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030427","[GLP-1 mimetics in clinical studies. Treatment by activation of the GLP-1 receptor].","Ritzel RA","2010","Pharmazie in unserer Zeit","narrative_review","article","10.1002/pauz.201000359","20196040",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030428","Protection against myocardial ischemia-reperfusion injury in clinical practice.","Garcia-Dorado D","2014","Revista espanola de cardiologia (English ed.)","narrative_review","article","10.1016/j.rec.2014.01.010","24774733",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0030429","Ban-Lan-Gen Granule Alleviates Dextran Sulfate Sodium-Induced Chronic Relapsing Colitis in Mice via Regulating Gut Microbiota and Restoring Gut SCFA Derived-GLP-1 Production.","Peng J","2022","Journal of inflammation research","preclinical","article","10.2147/jir.s352863","35250294","PMC8896204",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030430","Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas.","Waser B","2015","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","preclinical","article","10.1038/modpathol.2014.113","25216224",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030431","[Type 2 diabetes mellitus: new treatments].","Ascaso JF","2014","Medicina clinica","narrative_review","article","10.1016/j.medcli.2013.05.041","23937815",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030432","The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders.","Richards P","2021","Molecular metabolism","narrative_review","article","10.1016/j.molmet.2021.101175","33548501","PMC8085592",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030433","Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.","Bain S","2017","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.12821","27862902",null,null,null,"pubmed; europepmc; openalex","TRUE","free_to_read","3","FALSE","Comparative Study; Journal Article; Meta-Analysis; Systematic Review; article"],["R0030434","GLP-2 Is Locally Produced From Human Islets and Balances Inflammation Through an Inter-Islet-Immune Cell Crosstalk.","He W","2021","Frontiers in endocrinology","other","article","10.3389/fendo.2021.697120","34290670","PMC8287580",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030435","Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives.","Michalak A","2016","Pharmacological reports : PR","narrative_review","article","10.1016/j.pharep.2016.04.016","27238750",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030436","The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?","Papademetriou M","2018","Current vascular pharmacology","narrative_review","article","10.2174/1570161115666170621081638","28676027",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030437","Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.","Lau DC","2015","Canadian journal of diabetes","nonrandomized_study","article","10.1016/j.jcjd.2015.09.090","26654858",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Review"],["R0030438","Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.","Tramutola A","2017","Expert review of neurotherapeutics","narrative_review","article","10.1080/14737175.2017.1246183","27715341",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0030439","GLP-1-based therapy for diabetes: what you do not know can hurt you.","Butler PC","2010","Diabetes care","commentary","article","10.2337/dc09-1902","20103562","PMC2809301",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Editorial; article"],["R0030440","Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus.","Halland M","2016","Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","narrative_review","article","10.1016/j.cgh.2015.11.021","26717862","PMC4912904",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural; research-article"],["R0030441","The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies.","Zinman B","2009","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/j.1463-1326.2009.01071.x","19878255",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","4","FALSE","Editorial; article"],["R0030442","What are the best options for controlling prandial glycemia?","Clement S","2009","Current diabetes reports","randomized_trial","article","10.1007/s11892-009-0056-z","19793505",null,null,null,"pubmed; europepmc","FALSE","paywalled","2",null,"Journal Article; Review"],["R0030443","G-protein coupled receptors expressed by islet cells modulate glucagon as well as insulin secretion in type 2 diabetes","Gormley NM","2016","Ulster University","other","article",null,null,null,null,null,"europepmc","FALSE",null,null,null,"Dissertation"],["R0030444","Pharmacological treatment and therapeutic perspectives of metabolic syndrome.","Lim S","2014","Reviews in endocrine & metabolic disorders","narrative_review","article","10.1007/s11154-014-9298-4","25342235",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030445","Glucagon like peptides-1 modulators as newer target for diabetes.","Vaidya HB","2008","Current drug targets","narrative_review","article","10.2174/138945008785909284","18855626",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030446","Diabetes, Incretin Therapy and Thoracic Aortic Aneurysm - What Does the Evidence Show?","Krizhanovskii C","2019","Current vascular pharmacology","narrative_review","article","10.2174/1570161116666180828155622","30156160",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030447","Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males.","Skov J","2014","Endocrine connections","randomized_trial","article","10.1530/ec-13-0087","24327600","PMC3899585",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; research-article; article"],["R0030448","Non-Adherence And Non-Persistence Related To Glp-1 Therapy In Patients With Diabetes Mellitus Type 2 (T2dm): Analysis of A Large German Claims-Based Dataset And Comparison To Oral Anti-Diabetics.","Wilke T","2014","Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","other","article","10.1016/j.jval.2014.08.778","27200728",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0030449","Targeting inflammation in diabetes: Newer therapeutic options.","Agrawal NK","2014","World journal of diabetes","narrative_review","article","10.4239/wjd.v5.i5.697","25317247","PMC4138593",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030450","Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit.","Heald AH","2018","Diabetes, obesity & metabolism","other","article","10.1111/dom.13067","28730750",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0030451","Genetically-proxied anti-diabetic drug target perturbation and risk of cancer: a Mendelian randomization analysis","Yarmolinsky J","2022","medRxiv","other","preprint","10.1101/2022.10.24.22281370",null,null,null,null,"europepmc; openalex","TRUE",null,null,"FALSE","Preprint; preprint"],["R0030452","What to add in with metformin in type 2 diabetes?","Petrie JR","2011","QJM : monthly journal of the Association of Physicians","narrative_review","article","10.1093/qjmed/hcq237","21156663",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030453","The impact of diabetes and diabetes medications on bone health.","Gilbert MP","2015","Endocrine reviews","narrative_review","article","10.1210/er.2012-1042","25738213",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030454","Direct cardiovascular effects of glucagon like peptide-1.","Sheikh A","2013","Diabetology & metabolic syndrome","narrative_review","article","10.1186/1758-5996-5-47","23988189","PMC3765965",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0030455","Targeting the intestinal L-cell for obesity and type 2 diabetes treatment.","Albrechtsen NJW","2014","Expert review of endocrinology & metabolism","other","article","10.1586/17446651.2014.862152","30743739",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030456","Cucurbitacin B Induces Hypoglycemic Effect in Diabetic Mice by Regulation of AMP-Activated Protein Kinase Alpha and Glucagon-Like Peptide-1 via Bitter Taste Receptor Signaling.","Kim KH","2018","Frontiers in pharmacology","preclinical","article","10.3389/fphar.2018.01071","30298009","PMC6161541",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030457","Evolving treatment strategies for the management of type 2 diabetes.","Cefalu WT","2012","The American journal of the medical sciences","narrative_review","article","10.1097/maj.0b013e31823ea4af","22205062",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030458","Duration of Diabetes Predicts Aortic Pulse Wave Velocity and Vascular Events in Alström Syndrome.","Paisey RB","2015","The Journal of clinical endocrinology and metabolism","nonrandomized_study","article","10.1210/jc.2015-1577","26066530","PMC4525001",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0030459","Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs.","Efendic S","2008","Acta physiologica (Oxford, England)","narrative_review","article","10.1111/j.1748-1716.2007.01789.x","18171434",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030460","RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.","Gault VA","2018","Diabetic medicine : a journal of the British Diabetic Association","preclinical","article","10.1111/dme.13522","29044772",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; Research Support, Non-U.S. Gov't; article"],["R0030461","Glucagon-Like Peptide-1 Formulation--the Present and Future Development in Diabetes Treatment.","Lee CY","2016","Basic & clinical pharmacology & toxicology","narrative_review","article","10.1111/bcpt.12524","26551045",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030462","[Diabetes and osteoporosis].","Valkusz Z","2011","Orvosi hetilap","narrative_review","article","10.1556/oh.2011.29154","21712181",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030463","Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long-term impairment of the GIP system.","Gabe MBN","2020","Basic & clinical pharmacology & toxicology","other","article","10.1111/bcpt.13289","31299132","PMC7317972",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030464","Nutrient detection by incretin hormone secreting cells.","Diakogiannaki E","2012","Physiology & behavior","narrative_review","article","10.1016/j.physbeh.2011.12.001","22182802","PMC3361765",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0030465","The Hypothalamic-Pituitary-Testicular Axis in Exceptionally Old Men","Aleksic S","2021","Journal of the Endocrine Society","nonrandomized_study","article",null,null,"PMC8090149",null,null,"europepmc","TRUE","open_europepmc","4",null,"Abstract"],["R0030466","Current therapeutic agents and anesthetic considerations for diabetes mellitus.","Kang H","2012","Korean journal of anesthesiology","narrative_review","article","10.4097/kjae.2012.63.3.195","23060974","PMC3460146",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; review-article; article"],["R0030467","Menin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB.","Muhammad AB","2017","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00241.2016","28270438","PMC5582886",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; research-article; article"],["R0030468","Feeding and bone.","Walsh JS","2010","Archives of biochemistry and biophysics","narrative_review","article","10.1016/j.abb.2010.06.020","20599659",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030469","[Towards new recommendations for the treatment of type 2 diabetes? An expert's point of view].","Halimi S","2010","La Revue du praticien","other","article",null,"20465124",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","English Abstract; Journal Article; other"],["R0030470","Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome.","O'Malley D","2019","Experimental physiology","narrative_review","article","10.1113/ep087443","30444291",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030471","Glucagon-like peptides 1 and 2 in health and disease: a review.","Marathe CS","2013","Peptides","narrative_review","article","10.1016/j.peptides.2013.01.014","23523778",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030472","Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control.","Barchetta I","2015","Acta diabetologica","nonrandomized_study","article","10.1007/s00592-015-0721-4","25716766",null,null,null,"pubmed; europepmc","FALSE","paywalled","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0030473","Abscisic Acid Stimulates Glucagon-Like Peptide-1 Secretion from L-Cells and Its Oral Administration Increases Plasma Glucagon-Like Peptide-1 Levels in Rats.","Bruzzone S","2015","PloS one","preclinical","article","10.1371/journal.pone.0140588","26488296","PMC4619318",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030474","The gut-brain axis: a major glucoregulatory player.","Burcelin R","2010","Diabetes & metabolism","narrative_review","article","10.1016/s1262-3636(10)70468-7","21211737",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030475","Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity.","Remely M","2014","Beneficial microbes","other","article","10.3920/bm2013.006","24533976",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030476","The incretin pathway as a new therapeutic target for obesity.","Barber TM","2010","Maturitas","narrative_review","article","10.1016/j.maturitas.2010.06.018","20655673",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030477","Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence.","Lopez JM","2014","Patient preference and adherence","nonrandomized_study","article","10.2147/ppa.s58813","24855344","PMC4020884",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; research-article; article"],["R0030478","Potential role of non-insulin adjunct therapy in Type 1 diabetes.","George P","2013","Diabetic medicine : a journal of the British Diabetic Association","randomized_trial","article","10.1111/j.1464-5491.2012.03744.x","22804102",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030479","Glycemic variability: should we and can we prevent it?","Monnier L","2008","Diabetes care","other","article","10.2337/dc08-s241","18227477",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030480","Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells.","Ma X","2014","Journal of diabetes","narrative_review","article","10.1111/1753-0407.12161","24725840",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030481","Basal insulin treatment in type 2 diabetes.","Hedrington MS","2011","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2011.0062","21668335","PMC4696425",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review; research-article; article"],["R0030482","Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia.","Krieger JP","2016","Diabetes","preclinical","article","10.2337/db15-0973","26470787",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030483","New antidiabetic therapies: innovative strategies for an old problem.","Lehrke M","2012","Current opinion in lipidology","narrative_review","article","10.1097/mol.0b013e328359b19f","23069986",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030484","[Anti-diabetics and chronic kidney disease].","Garofalo C","2015","Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","narrative_review","article",null,"26480253",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030485","Structural Mapping and Functional Characterization of Zebrafish Class B G-Protein Coupled Receptor (GPCR) with Dual Ligand Selectivity towards GLP-1 and Glucagon.","Oren DA","2016","PloS one","preclinical","article","10.1371/journal.pone.0167718","27930690","PMC5145181",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030486","Bariatric surgery may reduce the risk of Alzheimer's diseases through GLP-1 mediated neuroprotective effects.","Keshava HB","2017","Medical hypotheses","other","article","10.1016/j.mehy.2017.05.002","28673587",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030487","Evaluation of type 2 diabetes mellitus medication management and control in older adults.","Thompson A","2013","The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists","nonrandomized_study","article","10.4140/tcp.n.2013.296","23649678",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; article"],["R0030488","Treating type 2 diabetes: how safe are current therapeutic agents?","Philippe J","2009","International journal of clinical practice","narrative_review","article","10.1111/j.1742-1241.2008.01980.x","19196370",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0030489","The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs.","Smith EP","2014","Cell metabolism","preclinical","article","10.1016/j.cmet.2014.04.005","24836562","PMC4109713",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; research-article"],["R0030490","At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.","Gejl M","2014","Basic & clinical pharmacology & toxicology","preclinical","article","10.1111/bcpt.12240","24684709",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030491","Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus.","Kruger DF","2011","Postgraduate medicine","narrative_review","article","10.3810/pgm.2011.07.2304","21680989",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030492","SU58. Severe Mental Illness: Where to Improve Quality of Diabetes Mellitus Care","Toender A","2017","Schizophrenia bulletin","nonrandomized_study","article","10.1093/schbul/sbx024.056",null,"PMC5476089",null,null,"europepmc; openalex","TRUE","open_europepmc","4","FALSE","Abstract; conference-abstract"],["R0030493","New animal models of Alzheimer's disease that display insulin desensitization in the brain.","Gao C","2013","Reviews in the neurosciences","preclinical","article","10.1515/revneuro-2013-0034","24259244",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030494","Midrange affinity fluorescent Zn(II) sensors of the Zinpyr family: syntheses, characterization, and biological imaging applications.","Nolan EM","2006","Inorganic chemistry","other","article","10.1021/ic061137e","17112271","PMC1821072",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; research-article; article"],["R0030495","Targeting development of incretin-producing cells increases insulin secretion.","Petersen N","2015","The Journal of clinical investigation","preclinical","article","10.1172/jci75838","25500886","PMC4382243",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030496","Managing Diabetes Mellitus: A Survey of Attitudes and Practices Among Family Physicians.","Fogelman Y","2015","Journal of community health","other","article","10.1007/s10900-015-0024-2","25877332","PMC4556738",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030497","Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer.","Cases AI","2015","Oncology reports","other","article","10.3892/or.2015.4138","26238361",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030498","Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine.","Christensen LW","2015","Physiological reports","preclinical","article","10.14814/phy2.12551","26381015","PMC4600392",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030499","The effect of antidiabetic drugs on genes regulating lipid metabolism.","Tomkin GH","2009","Current opinion in lipidology","narrative_review","article","10.1097/mol.0b013e32831ac56c","19106706",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030500","[Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].","Ampudia-Blasco FJ","2010","Medicina clinica","narrative_review","article","10.1016/s0025-7753(10)70031-2","21420536",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0030501","GLP-1 therapy: beyond glucose control.","Hausenloy DJ","2008","Circulation. Heart failure","commentary","article","10.1161/circheartfailure.108.810887","19808284",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Comment; Editorial; article"],["R0030502","Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice.","Vasu S","2013","Gene therapy","preclinical","article","10.1038/gt.2013.33","23784442",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0030503","What is the best management strategy for patients with severe insulin resistance?","Semple RK","2010","Clinical endocrinology","other","article","10.1111/j.1365-2265.2010.03810.x","20455892",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030504","The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus.","Hussain S","2019","Drugs","narrative_review","article","10.1007/s40265-019-1061-4","30742277",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030505","Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.","Tate M","2015","British journal of pharmacology","narrative_review","article","10.1111/bph.12943","25231355","PMC4301685",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; review-article; article"],["R0030506","Glucagon-like peptide-1, glucose homeostasis and diabetes.","Holst JJ","2008","Trends in molecular medicine","narrative_review","article","10.1016/j.molmed.2008.01.003","18353723",null,null,"S000371","pubmed; europepmc","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0030507","Glycemic control: a combination of lifestyle management and the use of drugs.","Standl E","2013","Cardiology and therapy","randomized_trial","article","10.1007/s40119-012-0007-7","25135285","PMC4107439",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","2","FALSE","Journal Article; review-article; article"],["R0030508","[New differential therapy of type 2 diabetes].","Schütt M","2011","Der Internist","narrative_review","article","10.1007/s00108-010-2708-0","21424146",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0030509","Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia.","Herzberg-Schäfer S","2012","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2012.01648.x","22928568",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030510","The GLP-1 response to glucose does not mediate beta and alpha cell dysfunction in Hispanics with abnormal glucose metabolism.","Adams E","2018","Diabetes research and clinical practice","other","article","10.1016/j.diabres.2017.11.010","29155153","PMC5801173",null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; research-article"],["R0030511","Health care provision for people with diabetes and postgraduate training of diabetes specialists in eastern European countries.","Doničová V","2011","Journal of diabetes science and technology","narrative_review","article","10.1177/193229681100500513","22027305","PMC3208868",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; research-article; article"],["R0030512","Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity.","Motta AJ","2012","Recent patents on cardiovascular drug discovery","narrative_review","article","10.2174/157489012799362368","22280335",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review; article"],["R0030513","Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.","Sesti G","2009","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2009.01072.x","19878256",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030514","BioPartnering North America--Programs from Pharma in Europe and the Middle East.","Croydon L","2010","IDrugs : the investigational drugs journal","other","article",null,"20191431",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Conference Proceedings"],["R0030515","Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies.","Chadwick KD","2014","Diabetes","preclinical","article","10.2337/db13-1268","24222349",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030516","β-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic β INS832/13 cells.","Talbot J","2012","Molecular and cellular endocrinology","other","article","10.1016/j.mce.2012.08.010","22939843",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0030517","[Hypoglycemia and cardiac arrhythmia in patients with diabetes mellitus type 2].","Hanefeld M","2014","Herz","other","article","10.1007/s00059-014-4086-1","24671665",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"English Abstract; Journal Article"],["R0030518","Cellular glucose availability and glucagon-like peptide-1.","Park JH","2011","Progress in biophysics and molecular biology","narrative_review","article","10.1016/j.pbiomolbio.2011.08.009","21907232",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Review"],["R0030519","Diabetes mellitus: Exploring the challenges in the drug development process.","Vaz JA","2012","Perspectives in clinical research","other","article","10.4103/2229-3485.100660","23125962","PMC3487225",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; other; article"],["R0030520","Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.","Richards P","2014","Diabetes","preclinical","article","10.2337/db13-1440","24296712","PMC4092212",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030521","Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass.","Waldron-Lynch F","2008","Novartis Foundation symposium","other","article","10.1002/9780470697405.ch14","19203097",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; other"],["R0030522","Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications.","Moreira RO","2013","Diabetes/metabolism research and reviews","other","article","10.1002/dmrr.2442","23868462",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"TRUE","Journal Article; Retracted Publication; article"],["R0030523","Glucose-incretin interaction revisited.","Ishii H","2011","Endocrine journal","narrative_review","article","10.1507/endocrj.ej11-0064","21701075",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030524","Combined MSC and GLP-1 Therapy Modulates Collagen Remodeling and Apoptosis following Myocardial Infarction.","Wright EJ","2016","Stem cells international","preclinical","article","10.1155/2016/7357096","28003833","PMC5149702",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; research-article; article"],["R0030525","Glycemic variability: Clinical implications.","Satya Krishna SV","2013","Indian journal of endocrinology and metabolism","other_trial","article","10.4103/2230-8210.113751","23961476","PMC3743360",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; review-article; article"],["R0030526","Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.","Göke R","2014","Current medical research and opinion","nonrandomized_study","article","10.1185/03007995.2013.875464","24328429",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Observational Study; Research Support, Non-U.S. Gov't; article"],["R0030527","What is known, new and controversial about GLP-1? Minutes of the 1st European GLP-1 Club Meeting, Marseille, 28-29 May 2008.","Burcelin R","2008","Diabetes & metabolism","commentary","article","10.1016/j.diabet.2008.08.002","19026584",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Conference Proceedings; News; Research Support, Non-U.S. Gov't"],["R0030528","Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.","Ahrén B","2008","Expert opinion on emerging drugs","narrative_review","article","10.1517/14728210802584126","19046129",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030529","Glucagon like peptide-1 receptor expression in the human thyroid gland.","Gier B","2012","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2011-2407","22031513","PMC3412261",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030530","Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.","Gross JL","2011","Annals of internal medicine","systematic_review","article","10.7326/0003-4819-154-10-201105170-00007","21576535",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","3","FALSE","Journal Article; Network Meta-Analysis; Research Support, Non-U.S. Gov't; Review; article"],["R0030531","Relationship between metabolic syndrome and meal-induced glucagon like peptide-1 response in type 1 diabetic patients1-1.","Blaslov K","2015","Journal of diabetes","other","article","10.1111/1753-0407.12194","25042812",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Comparative Study; Journal Article; article"],["R0030532","The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.","Dunning BE","2007","Endocrine reviews","narrative_review","article","10.1210/er.2006-0026","17409288",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030533","GLP-1, the gut-brain, and brain-periphery axes.","Cabou C","2011","The review of diabetic studies : RDS","narrative_review","article","10.1900/rds.2011.8.418","22262078","PMC3280675",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Review; review-article; article"],["R0030534","Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.","Chan HM","2011","American journal of physiology. Regulatory, integrative and comparative physiology","other_trial","article","10.1152/ajpregu.00687.2010","21307364","PMC3293513",null,null,"pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0030535","Targeting postprandial hyperglycemia.","Rendell MS","2006","Metabolism: clinical and experimental","narrative_review","article","10.1016/j.metabol.2006.05.012","16919548",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0030536","The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management.","Roges OA","2005","Expert opinion on investigational drugs","randomized_trial","article","10.1517/13543784.14.6.705","16004598",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","2","FALSE","Journal Article; Review; article"],["R0030537","Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients.","Pinelli NR","2012","The Annals of pharmacotherapy","narrative_review","article","10.1345/aph.1q417","22202493",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030538","\"The metabolic syndrome... is dead\": these reports are an exaggeration.","Tenenbaum A","2011","Cardiovascular diabetology","commentary","article","10.1186/1475-2840-10-11","21269524","PMC3036609",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Editorial; Research Support, Non-U.S. Gov't; article"],["R0030539","Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.","Holst JJ","2004","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2004.08.005","15525549",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0030540","Novel anti-obesity drugs.","Proietto J","2000","Expert opinion on investigational drugs","narrative_review","article","10.1517/13543784.9.6.1317","11060745",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030541","Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function.","Barrera JG","2011","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.2212-10.2011","21389245","PMC3700400",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0030542","Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon-like peptide 1 secreting cells.","Friedlander RS","2011","British journal of pharmacology","preclinical","article","10.1111/j.1476-5381.2010.01107.x","21054345","PMC3087130",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030543","Islet cell function: alpha and beta cells--partners towards normoglycaemia.","Göke B","2008","International journal of clinical practice. Supplement","narrative_review","article","10.1111/j.1742-1241.2007.01686.x","18269435",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030544","Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.","Hermansen K","2007","Drug safety","narrative_review","article","10.2165/00002018-200730120-00005","18035865",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0030545","Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1.","de Heer J","2007","Diabetes","preclinical","article","10.2337/db06-0738","17259389",null,null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030546","Electrical activity-triggered glucagon-like peptide-1 secretion from primary murine L-cells.","Rogers GJ","2011","The Journal of physiology","preclinical","article","10.1113/jphysiol.2010.198069","21224236","PMC3060588",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; research-article; article"],["R0030547","Minireview: update on incretin biology: focus on glucagon-like peptide-1.","Brubaker PL","2010","Endocrinology","narrative_review","article","10.1210/en.2010-0115","20305008",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; Review; article"],["R0030548","Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.","Zinsmeister AR","2013","Digestive diseases and sciences","systematic_review","article","10.1007/s10620-012-2369-z","22918691","PMC3529760",null,null,"pubmed; europepmc","FALSE","free_to_read","3",null,"Journal Article; Meta-Analysis; research-article"],["R0030549","Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men.","Nathanson D","2011","Diabetic medicine : a journal of the British Diabetic Association","nonrandomized_study","article","10.1111/j.1464-5491.2010.03207.x","21309838",null,null,null,"pubmed; europepmc; openalex","FALSE","paywalled","4","FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030550","Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study.","Sathananthan A","2010","Diabetes care","other_trial","article","10.2337/dc10-0200","20805279","PMC2928367",null,"S002498","pubmed; europepmc; openalex","TRUE","open_europepmc","5","FALSE","Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0030551","Low glycemic index foods should play a role in improving overall glycemic control in type-1 and type-2 diabetic patients and, more specifically, in correcting excessive postprandial hyperglycemia.","Slama G","2006","Nestle Nutrition workshop series. Clinical & performance programme","narrative_review","article","10.1159/000094407","16820732",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; conference-paper"],["R0030552","Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice.","Burgmaier M","2013","Atherosclerosis","preclinical","article","10.1016/j.atherosclerosis.2013.08.033","24267262",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0030553","Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease.","Nathanson D","2010","Diabetologia","nonrandomized_study","article","10.1007/s00125-009-1596-0","19936703",null,null,null,"pubmed; europepmc","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0030554","A model of GLP-1 action on insulin secretion in nondiabetic subjects.","Dalla Man C","2010","American journal of physiology. Endocrinology and metabolism","other","article","10.1152/ajpendo.00705.2009","20179243","PMC2886533",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; research-article; article"],["R0030555","Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.","Geething NC","2010","PloS one","preclinical","article","10.1371/journal.pone.0010175","20418955","PMC2854692",null,null,"pubmed; europepmc; openalex","TRUE",null,null,"FALSE","Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; research-article; article"],["R0030556","A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes.","Todd JF","2003","Lancet (London, England)","case_report","article","10.1016/s0140-6736(03)12256-8","12547550",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Case Reports; Journal Article"],["R0030557","Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.","Wiedeman PE","2003","Current opinion in investigational drugs (London, England : 2000)","narrative_review","article",null,"12808880",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030558","Biophysical and pharmacological properties of glucagon-like peptide-1 in rats under isoflurane anesthesia.","Kawano T","2012","Anesthesia and analgesia","preclinical","article","10.1213/ane.0b013e318253cbf0","22504208",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030559","Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.","Basu A","2007","American journal of physiology. Endocrinology and metabolism","randomized_trial","article","10.1152/ajpendo.00373.2007","17711996",null,null,"S000138; S000291","pubmed; europepmc; openalex","FALSE","paywalled","1","FALSE","Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; article"],["R0030560","Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1.","Holst JJ","2002","Diabetes/metabolism research and reviews","narrative_review","article","10.1002/dmrr.328","12469357",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030561","Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.","Thornberry NA","2007","Current topics in medicinal chemistry","preclinical","article","10.2174/156802607780091028","17352677",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; article"],["R0030562","Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors.","Holst JJ","2003","Advances in experimental medicine and biology","narrative_review","article","10.1007/0-306-47920-6_33","12675249",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Review; book-chapter"],["R0030563","Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1.","Holst JJ","1999","Expert opinion on investigational drugs","other","article","10.1517/13543784.8.9.1409","15992158",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0030564","Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.","Quddusi S","2003","Diabetes care","other_trial","article","10.2337/diacare.26.3.791","12610039",null,null,null,"pubmed; europepmc; openalex","TRUE","open_pdf","5","FALSE","Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; article"],["R0030565","Chlamydia pneumoniae in abdominal aortic aneurysms: abundance of membrane components in the absence of heat shock protein 60 and DNA.","Meijer A","1999","Arteriosclerosis, thrombosis, and vascular biology","other","article","10.1161/01.atv.19.11.2680","10559011",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0030566","Genes for zein subunits on maize chromosome 4.","Soave C","1982","Biochemical genetics","other","article","10.1007/bf00498930","7165689",null,null,null,"pubmed; europepmc","FALSE",null,null,null,"Journal Article"],["R0030567","No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.","Vilsbøll T","2001","Diabetic medicine : a journal of the British Diabetic Association","other","article","10.1046/j.1464-5491.2001.00424.x","11251679",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030568","No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.","Knop FK","2003","Diabetes care","other_trial","article","10.2337/diacare.26.9.2581","12941722",null,null,null,"pubmed; europepmc; openalex","FALSE","free_to_read","5","FALSE","Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030569","Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.","Byrne MM","1998","Diabetes","other","article","10.2337/diab.47.8.1259","9703326",null,null,null,"pubmed; europepmc; openalex","FALSE",null,null,"FALSE","Journal Article; Research Support, Non-U.S. Gov't; article"],["R0030570","EFFECTS OF LIRAGLUTIDE ON RENAL LIPID DEPOSITION OF OBESE RATS","Jia Liu","2016","Chengde Yixueyuan xuebao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030571","Comparison of incretin-based drugs: clinical advantage of GLP-1 analogue liraglutide","Yiming Mu","2012","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2012.09.022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030572","Peptide mapping analysis of Exenatide by LC-MS spectrometry","Yi Kong","2009","Huaxi yaoxue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030573","Comparing the GLP-1 Receptor Agonists: Byetta®, Victoza® and once-weekly Bydureon™","Todd A. Tucker","2013","Pharmacy and Wellness Review","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030574","Изменения углеводного и липидного обмена у больных сахарным диабетом 2 типа при различной тактике сахароснижающей и гиполипидемической терапии","С. В. Воробьев","2012","Medical Herald of the South of Russia","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030575","Tandem Expression,Purification and Activity Analysis of Exendin-4 in E.coli","Haiqin Rong","2011","Biotechnology(Faisalabad)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030576","治疗2型糖尿病的新颖化合物胰高血糖素样肽—1衍生物：NN2211在临床上的发展","卢曦","2002","国外医学：药学分册","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030577","New Treatment for Type 2 Oiabetes: GLP-1 Analogue","Seung Joon Oh","2006","Gajeong yihag hoeji","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030578","Effects of the exenatide on the proliferation of breast cancer cell MCF-7","Shouju Wang","2012","Shiyong yixue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030579","2020 Market Analysis","Omo Ojo","2021","Diabetes Management","other","article","10.37532/1758-1907.2021.11(5).229",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030580","Cèl.lules estrellades pancreàtiques: implicació en el procés de transdiferenciació cel.lular endocrina i caracterització del seu secretoma","Maria Lucas Gil","2008","TDX (Tesis Doctorals en Xarxa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0030581","Therapy with exenatide: our experience","Ignacio Fernandez","2010","12th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030582","Protective Effects of Exenatide on H9c2 Cardiomyocytes Oxidative Injured by H_2O_2","Shu Qin","2012","Zhongguo yaofang","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030583","リラグルチドのBody Mass Index（BMI）別臨床効果に関する解析―前治療別による比較検討―","清水 弘行","2014","Therapeutic research","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0030584","Exenatide: A review of pharmacology and therapeutic uses","Vinod Mattoo","2007","Indian Journal of Endocrinology and Metabolism","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0030585","Liraglutide, a human glucagon-like peptide-1 analogue, plays a role in reducing body weight in the patients with type 2 diabetes","Dajin Zou","2011","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2011.08.025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030586","Meta-Analysis Clarifies Differing Benefits and Risks for SGLT-2 Inhibitors and GLP-1 Receptor Agonists","Bruce Soloway","2021","Journal watch","systematic_review","article","10.1056/nejm-jw.na53083",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0030587","Effects of Exendin-4 on cognitive function and Nrf2 signaling pathway in rats with traumatic brain injury","Zhang Qicai","2019","Zhonghua xingwei yixue yu naokexue zazhi","preclinical","article","10.3760/cma.j.issn.1674-6554.2019.01.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030588","Effects of exendin-4 on glucose metabolism and pdx-1 mRNA expression in OLETF rat","Min Zhu","2005","Zhonghua laonian yixue zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030589","Exendin-4对乳鼠心肌细胞缺氧/复氧损伤的抗氧化保护作用","张晨禹","2017","中国医药导报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030590","CGMにより持効型インスリン+sitagliptinとliraglutide+glimepirideを比較しえた症例","角朝信","2013","糖尿病","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030591","Biochemistry 2018: Pharmacological treatment of obesity","Matthew Warren-James","2021","Research and reviews in biosciences","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030592","FDA grants approval to Novo Nordisk chronic weight management drug","Tracey Walker","2014","Formulary ENews","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030593","Effects of administration with recombinant exendin-4 on fasting plasma FGF-21 levels in type 2 diabetes mellitus patients","Gang Yang","2011","Zhongguo laonianxue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030594","Rapid Assembly of Long-term HSA /Exendin 4 Fusion Protein via BglBrick Method","Yanchun Shao","2014","Zhongguo shengwu gongcheng zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030595","Exendin-4 Inhibits Matrix Metalloproteinase-9 Activation and Reduces Infarct Growth After Focal Cerebral Ischemia in Hyperglycemic Mice","TakumaKuroki","2016","Stroke","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030596","Dulaglutide第三相試験におけるQOL評価-プラセボ,リラグルチド,インスリングラルギンとの比較","鈴木秀一","2015","糖尿病","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030597","Efficacy of liraglutide on metabolic parameters and pregnancy in polycystic ovary syndrome patients combined with impaired glucose tolerance and obesity","Zhao-sui Huang","2015","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2015.07.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030598","Effects of Exendin-4 on Glucose and Lipid Metabolism in Diabetic Rats","Gao Chengxia","2011","Tianjin yiyao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030599","Underuse and Misuse of Newer Antidiabetic Medication with Established Positive Cardiovascular Outcome","Syed Raza","2020","Angiology Open Access","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0030600","Экономическая ценность определения гликированного гемоглобина для диагностики сахарного диабета 2 типа","Шестакова Марина Владимировна","2020","Сахарный диабет","nonrandomized_study","article","10.14341/dm12205-9440",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0030601","Obesity and nonalcoholic fatty liver disease","Shivakumar Chitturi","2014","ANU Open Research (Australian National University)","other","article","10.3978/j.issn.2224-4778.2014.07.02",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030602","Early diagnosis, incretin-based therapies and gene therapy approaches for type 2 diabetes","Rasoul Salehi Ahmad Raza Salehi Nasimeh Vat","2016","Journal of Diabetes & Metabolism","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030603","Study progression of GLP-1 analogues in type 1 diabetes and islet transplant","Xin Su","2010","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2010.07.031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030604","利拉鲁肽单药治疗长期安全有效——LEAD-3及扩展研究浅析","Qiang Li","2010","药品评价","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030605","A Clinical Analysis on Therapy of Exenatide for Type 2 Diabetic Patients","NI Wei-hu","2014","Pharmaceutical biotechnology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030606","Exendin-4对Aβ_（1-42）所致大鼠在体海马长时程增强抑制的拮抗作用及机制","江瑞瑞","2015","神经解剖学杂志","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030607","The therapy of exenatide for two cases of type 2 diabetes in children","幸司 竹本","2014","小児科臨床","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030608","Новые перспективы терапии пациентов с сахарным диабетом 2 типа","Шамхалова Минара Шамхаловна","2012","Сахарный диабет","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030609","68Ga-exendin-4 PET/CT for the localization of insulinomas","Yaping Luo","2017","Zhonghua heyixue yu fenzi yingxiang zazhi","nonrandomized_study","article","10.3760/cma.j.issn.2095-2848.2017.03.003",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0030610","Therapeutic effects of exenatide in type 2 diabetic patients","Huang Wen-lon","2011","Zhongguo tangniaobing zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030611","利拉鲁肽对糖尿病大鼠肾脏血管紧张素II 1、2型受体表达的影响","李里","2015","重庆医科大学学报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030612","Application analysis of hypoglycemic drugs in our hospital during 2008-2012","Wei Guo-yi","2013","Chinese Journal of Drug Application and Monitoring","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030613","Exendin-4 stimulates β-cell proliferation by up-regulating pdx-1 mRNA in STZ-treated mice","Shi Hong","2005","Zhonghua neifenmi daixie zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030614","Efficacy of Liraglutide in reactive hypoglycemia related to Dumping syndrome","HulyaAbbasova","2020","Immunological Disorders and Immunotherapy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030615","Long term effect of exendin-4 on body weight reduction in rats","DU Jin-zan","2006","Parenteral & Enteral Nutrition","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030616","Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain–Gut Axis","SarahFarr","2015","Arteriosclerosis Thrombosis and Vascular Biology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030617","Dulaglutideの有効性・安全性に対する患者背景の影響-日本人2型糖尿病患者における第三相試験併合解析","大西由希子","2015","糖尿病","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030618","Effects of Inflammatory and Energy Homeostasis Factors on the Expression of KISS-1 in Breast Cancer Cell-line MCF-7","Mao Jiang-fen","2014","Military Medical Journal of South China","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030619","短時間作用型GLP‐1受容体作動薬(RA)によるPrader‐Willi症候群に伴う肥満への影響","松本俊一","2016","肥満研究","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030620","Weekly Exenatide Equals Daily Glargine Insulin for Glycemic Control","Bruce Soloway","2010","Journal watch","other","article","10.1056/jw201007130000003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030621","Caso Clinico. “Togliamo le catene al frigorifero”: utilizzo di Exenatide once weekly in paziente diabetica tipo 2 con obesità viscerale di 2° grado affetta da sindrome di Down","Paolo Desenzani","2015","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030622","短腸症候群合併2型糖尿病における糖負荷試験,活性型GLP-1測定,およびLiraglutide使用の経験","鶴田信慈","2012","糖尿病","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030623","Glucose management in type 2 diabetes combined with Obstructive Sleep Apnea Syndrome","Yaojun Ni","2012","Journal of Clinical Pulmonary Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030624","Exenatide induce the impairment of autophagy flux to damage rat pancreatic tissue","Weidong Zhu","2016","Chin J Endocr Surg","preclinical","article","10.3760/cma.j.issn.1674-6090.2016.06.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030625","Exendin-4 Promotes Proliferation of Adipose-derived Stem Cells Via JNK and ERK Signaling Pathway","Zhou Ha","2014","Xiandai shengwu yixue jinzhan","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030626","インクレチンの脳保護メカニズム : 虚血性脳損傷に対するExendin-4の脳保護作用 (AYUMI インクレチンの臓器保護作用)","貴夫 卜部","2012","医学のあゆみ","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030627","Treatment of type 2 diabetes, GLP-1 Agonist and a DPP-4 Inhibitor","Adil Omar Bahathiq","2018","Journal of Proteomics & Enzymology","other","article","10.4172/2470-1289.1000135",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030628","GLP-1 Analogues and Risk for Breast Cancer","Paul S. Mueller","2016","Journal watch","randomized_trial","article","10.1056/nejm-jw.na42648",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030629","The role of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease","Lixin Guo","2014","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2014.11.017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030630","Effect of exenatide on serum insulin level and insulin resistance in obese subjects with impaired glucose regulation","Jianjia Jiang","2013","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2013.08.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030631","Clinical Trial of Liraglutide for Obesity in Adolescence","Catherine M. Gordon","2020","Journal watch","other_trial","article","10.1056/nejm-jw.na51266",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0030632","Liraglutide Improves Glycemic Control in Type 2 Diabetics Treated with Multiple Daily Insulin Injections","Paul S. Mueller","2015","Journal watch","other","article","10.1056/nejm-jw.na39504",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030633","The role of Exenatide in managing cardiovascular risks and complications in patients with type 2 diabetes","Omorogieva Ojo","2016","Journal of Diabetes & Metabolism","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0030634","Effects of Glucagon-like Peptide-1 Mimetic Peptide on Proliferation,Apoptosis and Insulin Secretion of RINm5F Cells","Wei Li","2010","Zhongguo shengwuzhipinxue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030635","Evaluation on therapeutic efficacy and safety of exenatide treatment in type 2 diabetic patients","Zhao Shi","2012","Chinese Journal of Hospital Pharmacy","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030636","The effects of exenatide on insulin sensitivity in type 2 diabetics patients","Yan Li","2013","Zhongguo jiceng yiyao","other","article","10.3760/cma.j.issn.1008-6706.2013.19.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030637","Glucagon-like peptide 1 receptor agonist treatment inhibits allergic innate immunity-induced eosinophilic and neutrophilic inflammation in a polygenic obese mouse model","Shinji Toki","2020","Japanese Society of Allergology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030638","Exenatide LAR al Fallimento della Terapia Orale: Vantaggi in Termini di Peso","Giuseppina De Felice","2016","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030639","Effects of liraglutide on the expressions of transforming growth factor-β1 and type 1 collagen in myocardial tissue of type 2 diabetic rats","Zhenhua Wu","2018","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2018.09.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030640","Efficacy and safety of exenatide on type 2 diabetes obesity patients with blood control failure","YU Qiu-rong","2013","Shiyong yaowu yu linchuang","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030641","Adverse reactions of incretin-related agents","Bo Feng","2013","Shanghai Medical & Pharmaceutical Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030642","Establishment and Evaluation of Rat Model of Type 2 Diabetes","HE Chao-qu","2015","Guocheng gongcheng xuebao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030643","GLP-1受容体アゴニスト・Exendin-4の前立腺癌細胞増殖抑制作用におけるMKP-1(MAPK phosphatase-1)の関与","川波 賢子","2018","The Japan Endocrine Society","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030644","PEGylation Strategies of Exendin-4 for Noble Anti-diabetic Therapeutics","Kang Choon Lee","2013","한국생물공학회 학술대회","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030645","Using biologics to transform the drug marketplace : pharmaceutical and chemical sectors","Stoyan Stoychev","2012","CSIR Science Scope","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030646","Short-term liraglutide therapy as compared with basal insulin therapy on restoration effect of insulin secretion in Japanese patients with type 2 diabetes","Shingo Kaneko","2012","15th International & 14th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030647","Effect of Exendin-4 on ER-related apoptosis of rat cortical neurons induced by ischemia/reperfusion injury in vitro","LI Jun-min","2010","Journal of Apoplexy and Nervous Diseases","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030648","Randomized controlled trials of liraglutide and sitagliptin in obese patients with inadequately controlled type 2 diabetes with insulin therapy","Zhiyu Zhang","2017","Central Plains Medical Journal","randomized_trial","article","10.3760/cma.j.issn.1674-4756.2017.08.010",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030649","Association of blood pressure and body weight decline during one-year treatment with the incretin analogue exenatide","Maja Baretić","2013","Diabetologia Croatica","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0030650","Synthesis and Hypoglycemic Activities of Exenatide Analogues","Xia Chunguan","2013","Chinese Journal of Pharmaceuticals","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030651","Progress in Research of Renal Effect of GLP-1 Receptor Agonists","Qi-Zhang Xiao","2014","Xiandai shengwu yixue jinzhan","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030652","The advantages of liraglutide on cardiovascular protection in T2DM","Jia Zhang","2014","Zhongguo tangniaobing zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030653","WIN 55,212-2 and exendin-4 administered together reverse food preferences in rats maintained on a free-choice, high-sugar diet","E. Bajanowska","2013","Acta Neurobiologiae Experimentalis","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030654","Liraglutide treatment promotes beta cells proliferation via regulation of microRNA expression","Binbin Liu","2015","Chin J Diabetes Mellitus","randomized_trial","article","10.3760/cma.j.issn.1674-5809.2012.06.008",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030655","Clinical Research Progress of Liraglutide in the Treatment of Type 2 Diabetes","Meilin Xu","2015","Xiandai shengwu yixue jinzhan","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030656","Exenatide versus insulin glargine in type 2 diabetes inadequately treated with metformin","P Karagianni","2012","15th International & 14th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030657","Incretinas: Un nuevo paradigma en el tratamiento de la diabetes mellitus tipo 2","Oded Stempa Blumenfeld","2009","Revista de Endocrinología y Nutrición","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030658","Poster Session：PS 0177 ; Endocrinology : Achieving Target Blood Pressure in Type 2 Diabetes Therapy Optimization","Svetlana Podzchina","2014","대한내과학회 추계학술발표논문집","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0030659","Industrial Info. GLP1受容体アゴニストExenatide(エキセナチド)の開発","丈士 今岡","2010","細胞","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030660","Effects of exenatide on dietary habits in obese type 2 diabetic patients","Jiang Tian","2017","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2017.01.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030661","DIABETES AND ITS TREATMENT BY GLUCAGON- LIKE PEPTIDE 1 ANALOGS AND DI-PEPTIDYL PEPTIDASE 4 INHIBITORS","Muhammad Owais Khan","2011","Journal of Postgraduate Medical Institute","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0030662","Could 99mTc labeled long-acting agonist of GLP-1 (Exendin-4) scintigraphy be a new tool in the diagnostics of unknown focus of insulinoma ? preliminary results","A. Hubalewska-Dydejczyk","2011","13th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030663","Pharmacology and clinical evaluation of exenatide","Shen Zi-yu","2006","Zhongguo xin yao zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030664","Usefulness of preoperativee exenatide in control of risk factors for bariatric surgery on type 2 diabetic patients with morbid obesity","Tomás Martín Hernández","2012","15th International & 14th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030665","Incretin-Based Diabetes Drugs Aren't Associated with Excess Risk for Acute Pancreatitis","Paul S. Mueller","2014","Journal watch","other","article","10.1056/nejm-jw.na34398",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030666","REVERSAL OF TYPE-1 DIABETES IN NOD MICE WITH EXENDIN-4 AND LISOFYLLINE","Jeffrey Carter","2005","Endocrine Journal","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030667","The clinical benefit of human GLP-1 analogue Liraglutide","寛 杉井","2011","細胞","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030668","Research progress on the effects of glucagon like peptide-1 in metabolic cardiovascular disease","Xi Liang","2014","Jiefangjun yixue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030669","Long-term Effect of Exendin-4 on Weight Reduction of Normal Rats","Qingchun Liu","2007","Zhonghua linchuang yingyang zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030670","激素、维生素及相关药物——Nastech公司开发Byetta鼻用剂","张森","2007","国外药讯","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030671","Pleiotropic effects of incretin-based therapies in cardioprotection","Amin Al-Awar","2019","Interventional Cardiology Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030672","Down-regulation of miR-139-5p contributes to the anti-apoptotic effect on diabetic rat islets and INS1 cells induced by Liraglutide via targeting Irs1","Haipeng Xiao Jin Li Shubin Hong Yingying Gong Lei Su","2016","Journal of Diabetes & Metabolism","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030673","The clinic observation of exenatide therapy for patients with obese T2DM","Yali Fu","2013","Zhongguo tangniaobing zazhi","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0030674","重组胰高血糖素样肽-1受体激动剂（rExendin-4）原液质量研究","丁晓丽","2015","中国新药杂志","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030675","Role of microRNA-27a in the anti-apoptotic effects of liraglutide in cardiomyocytes","Min Yao","2017","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2017.04.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030676","Advances in Insulintropic Peptides and GLP-1 Analogs","Yang Li-ping","2006","Life Science Research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030677","Exenatide once weekly nella pratica clinica. Esperienza personale","Riccardo Fornengo","2014","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030678","STUDY OF PALM OIL AND GLUTAMINE AS FUNCTIONAL FOODS ON PEPTIDE TYROSINE TYROSINE (PYY) AND GLUCAGON-LIKE PEPTIDE 1 (GLP-1) IN OBESE PATIENTS FOLLOWING UP ON THE AMBULATORY HEALTH SERVICES OF THE PUBLIC HOSPITAL","Luciana Arantes Soares","2020","Revista Rede de Cuidados em Saúde","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030679","Victoza's association with thyroid cancer emphasized in Novo Nordisk reminder","From staff reports","2011","Drug Topics E-News","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030680","제2형 당뇨병 병인: 인슐린/IGF-1 신호전달 장애","박선민","2005","식품산업과 영양 = Food industry and nutrition","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030681","Flessibilità del momento di somministrazione di lixisenatide nei pazienti con diabete mellito tipo 2: risultati dello studio MAIN MEAL","Angela Dardano","2014","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030682","Advancement in Diabetes Care Gadgets","John Luis","2020","Journal of Medical Diagnostic Methods","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030683","Effects of Exenatide on INS-1 cells and cell cycle protein in intermittent high glucose","LJ Jin","2015","Shengwu yixue gongcheng yu linchuang","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030684","Effects of exendin-4 on glycemie control and glucose tolerance in non-diabetic mice","Huang Kui-xiang","2005","Chinese Journal of New Drugs and Clinical Remedies","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030685","Exendin-4/胰高糖素样肽受体通路在心血管疾病中的作用","王若珺","2012","生理科学进展","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030686","利西拉肽（Lixisenatide，Adlyxin）","陈凯","2017","中国药物化学杂志","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030687","Exendin-4对2型糖尿病大鼠肾组织MMP-9与TIMP-1表达的影响","Wei Li","2009","第四军医大学学报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030688","11031 Liraglutide可改善β-细胞功能","李燕燕","2006","国外药讯","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030689","Exendin-4 improves fat metabolism of brown adipose tissue in high-fat diet-induced obese C57BL/ 6J mice","Qiong Wei","2015","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2015.09.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030690","Effect of exenatide on serum nesfatin-1 level and liver fat contents in obese patients with type 2 diabetes mellitus","Sun Li-ping","2013","Journal of Shandong University","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0030691","Oral co-administration of insulin and exendin-4 loaded nanoparticles to treat type 2 diabetes in a rat model","阮氏荷江","2012","清華大學化學工程學系學位論文","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030692","Progress in the investigation of GLP-1 receptor agonists and DPP-IV inhibitors","Chi Yu-shi","2008","Zhongguo yaoke daxue xuebao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030693","Short-term efficacy of incretin-related drugs among Asian patients monitored by glucose area under the curve calculated without blood sampling","Keisuke Kosugi","2018","Diabetes Management","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030694","Treatment with GLP-1RA results in reduction of MACE in type 2 diabetes patients with established CVD","Papuc Mihai Cosmin","2019","Archives of the Balkan Medical Union","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030695","Influence of liraglutide injection on plasma adiponectin levels in patients with type 2 diabetes","Lian Wang","2015","China Medical Equipment","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030696","Glucagon-like peptide 1 receptor agonists: a new approach to type 2 diabetes management","Lynn Lambert","2013","Pharmacy management","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030697","Incretin-the new therapeutic target of sepsis","Yan Chen","2020","Zhonghua neifenmi daixie zazhi","nonrandomized_study","article","10.3760/cma.j.cn311282-20190911-00373",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0030698","Effect of Exendin-4 on the glucose tolerance and serum glucose level in normal animals","Guo Qing-long","2009","Zhongguo linchuang yaolixue yu zhiliaoxue","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030699","一個不易造成低血糖且可減重的嶄新降血糖藥物－exenatide（Byetta®）","張天鈞","2010","當代醫學","other","article","10.29941/mt.201011.0011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030700","Liraglutide protects endothelial cells from oxidative damage induced by fluctuating glucose","LI Ju-fe","2014","Zhongguo tangniaobing zazhi","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0030701","Determinnation of Acetic Aicd in Exendin-4 Acetate by RP-HPLC","Yingxiang Du","2010","Pharmaceutical biotechnology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030702","Once-Weekly Exenatide vs. Sitagliptin or Pioglitazone for Type 2 Diabetes","Bruce Soloway","2010","Journal watch","other","article","10.1056/jw201008260000001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030703","Early usage of liraglutide with benefits in type 2 diabetes","Changyu Pan","2012","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2012.04.024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030704","The possible benefits from early initiation and long-term treatment of liraglutide","Tianpei Hong","2014","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2014.12.023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030705","Exenatide（Byetta®）－有助於治療遵從性的新降血糖藥","陳昭姿","2010","當代醫學","other","article","10.29941/mt.201004.0012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030706","The Research Actuality and Prospect on Exenatide,a Novel Therapy for Type 2 Diabetes","Zhi Liu","2008","Letters in Biotechnology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030707","Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice","龍仁 姫野","2011","名古屋大学 eBooks","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0030708","Liraglutide is more effective than lifestyle changes in modulating subcutaneous and visceral fat distribution, liver steatosis, insulin sensitivity and beta-cell function after comparable weight loss","Agostino Consoli","2015","Journal of Diabetes & Metabolism","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030709","한국 신약개발 특허의 질적 수준과 협력구조 진화과정 분석","엄익천","2018","한국기술혁신학회 학술대회","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030710","Effects of exenatide combined with clomifene citrate on insulin resistance and Angiotensin II/Angiotensin-(1-7) in peripheral blood in patients with polycystic ovary syndrome","Juan Wang","2017","Biomedical Research-tokyo","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030711","Restoration of β cell function and neogenesis of islets by clinical treatment","Liu Cha","2009","International Journal of Internal Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030712","The effects of liraglutide on the proliferation and differentiation of mouse pre-osteoblasts MC3T3-E1","Jun Li","2016","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2016.03.012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030713","비알코올 지방간질환의 약물치료 업데이트","김강모","2018","춘·추계 학술대회 (KASL)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030714","Focus on Saxenda® solution for injection","Lisa Schurer Lambert","2021","South African Medical Journal","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030715","The curative effect of exenatide combined pioglitazone on type 2 diabetes","Bin Zhu","2012","The Journal of Pharmaceutical Practice","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030716","Stability of Exendin-4 Structure and Preparation of Exendin-4 Microspheres","Cheng Yuanguo","2009","Zhongguo shengwuzhipinxue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030717","Exendin-4对自发性II型糖尿病KK^Ay小鼠的治疗作用","张罗红","2008","药物生物技术","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030718","Exendin-4-Tβ4融合蛋白在毕赤酵母中的表达研究","张怡","2010","西南大学学报：自然科学版","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030719","EFFECT OF EXENATIDE ANALOG ON THE INSULIN RESISTANCE IN DIABETIC MOUSE","Yang Shi-ji","2010","Xiandai yufang yixue","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030720","Tissue distribution of exendin-4 in rats","Zhi Chen","2008","Zhongguo yaolixue yu dulixue zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030721","Incretin Mimetics: Pros and Cons, and Emerging Agents in Diabetes Treatment","Jamie M. Terrell","2013","The American Journal of Managed Care","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030722","GLP-1 agonists enhance stress-induced corticosterone release","Vallo Volke","2012","15th International & 14th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030723","Современные сахароснижающие препараты, используемые в России при лечении сахарного диабета 2 типа","Сунцов Юрий Иванович","2012","Сахарный диабет","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0030724","The role of incretin in the regulation of glucose homeostasis and treatment of type 2 diabetes","Guang Ning","2010","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2010.09.032",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030725","Islet dysfunction in type 2 diabetes mellitus and incretin-based therapy","Ping Feng","2011","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2011.11.024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030726","SGLT 2 Inhibitors: A New Therapeutic Target And Its Role In Current Clinical Practice","P. V. Shiji","2015","BMH Medical Journal    -   ISSN 2348–392X","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030727","Incretin-Based Drugs Don't Confer Risk for Pancreatic Cancer","Paul S. Mueller","2016","Journal watch","other","article","10.1056/nejm-jw.na40557",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030728","Exendin-4 Improves Yield and Function of Isolated Pre- Weaned Porcine Islets","Hien Lau","2018","Journal of Endocrinology and Diabetes","preclinical","article","10.15226/2374-6890/5/5/01115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030729","A Review on Management of Blood Glucose in Type 2 Diabetes Mellitus","Chanchal Kumar","2016","International Journal of Plant Animal and Environmental Sciences","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","review"],["R0030730","Construction of human globular adiponectin-glucagons-like peptide-1 fusion protein expression vector","Gu Wei","2006","Chongqing yixue","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030731","Exenatide Injection (Byetta): Adjunctive Therapy for Glycemic Control","Danielle Ezzo","2006","American family physician","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030732","High-Dose Semaglutide for Weight Reduction in Overweight Patients with Diabetes","Allan S. Brett","2021","Journal watch","other","article","10.1056/nejm-jw.na53321",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030733","Liraglutide improves the rate of achieving composite outcome in patients with type 2 diabetes","LU Ju-min","2012","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2012.07.022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030734","Application progress of liraglutide in type 2 diabetes treatment","Ding Zhuo-lin","2014","Shiyong yaowu yu linchuang","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030735","Exenatide in the management of diabetes mellitus","ra Kanti Chakraborti","2013","Journal of Diabetes & Metabolism","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0030736","The Down-regulation Effect of Liraglutide(Lira) on the Expression of Double-stranded RNA-dependent Protein Kinase-like Endoplasmic Reticulum Kinase(PERK) in βTC3 Cells Induced by Free Fatty Acids(FFA)","Liu Tao","2012","Xiandai shengwu yixue jinzhan","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030737","Progress on antidiabetic mechanism and clinical application of exenatide","Haiqin Rong","2011","Chinese Journal of New Drugs and Clinical Remedies","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0030738","99mTc-Hydrazinonicotinamide-aminohexanoic acid-Lys40-exendin-4","Kam Leung","2012","National Center for Biotechnology Information (US) eBooks","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0030739","The combination therapy of basal insulin and lixisenatide in Asian diabetic patients","Shuting Cai","2017","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2017.09.018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030740","Eficacia y seguridad de liraglutida para manejo de sobrepeso y obesidad. Revisión sistemática y Metaanálisis en red","Ricardo Vásquez","2018","instname:Universidad del Rosario","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0030741","【専門医に求められる最新の知識：脳血管障害】 実験脳虚血モデルから学ぶこと","鐙谷武雄","2013","脳神経外科速報","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030742","Possibility of switching from liraglutide to oral hypoglycemic agents as a useful therapeutic option for obese Japanese type 2 diabetics","Masanori Iwanishi","2018","Diabetes Management","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030743","ヒトGLP‐1アナログ製剤Liraglutide(リラグルチド)開発の経緯","片山泰之","2006","Bio Clinica","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030744","Effect of GLP-1 on the expression of NADPH oxidase subunits in the kidney of type 1 diabetic rats","Jinjin Liu","2013","Jiefangjun yixue zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030745","JAMA : High-Dose Liraglutide Causes Significant Weight Loss in Overweight Persons With T2DM","Mary K. Caffrey","2015","The American Journal of Managed Care","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030746","The research progress of the clinical function of the related agents of incretin","Jun Liu","2013","Shanghai Medical & Pharmaceutical Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030747","Pancreatitis, Diabetes, and Newer Antidiabetic Drugs","Allan S. Brett","2011","Journal watch","nonrandomized_study","article","10.1056/jw201101200000008",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0030748","An overview of incretin-based therapies in the management of type 2 diabetes : original article","Larry A. Distiller","2012","South African Journal of Diabetes","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030749","Liraglutide induced tachycardia: One case report and literature review","Xuexiu Shi","2014","Zhonghua neifenmi daixie zazhi","case_report","article","10.3760/cma.j.issn.1000-6699.2014.04.017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030750","V-Go: The new frontier in management of diabetes -","Haider Ghazanfar","2016","Rawal Medical Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030751","Liraglutide alleviates arteriosclerotic lesions and inhibits receptor for advanced glycation end-product expression in diabetic ApoE-/- mice","Peicheng Li","2016","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2016.08.012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030752","Effects of Liraglutide on plasma fibroblast growth factor-21 level in patients with type 2 diabetes mellitus","Peï-Yu Wu","2011","Chin J Endocr Surg","other","article","10.3760/cma.j.issn.1674-6090.2011.01.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030753","Effect of liraglutide on glycosylated hemoglobin, β cell function and body fat in type 2 diabetic patients with low T3 syndrome","Yingli Ma","2017","Chin J Cell Stem Cell (Electronic Edition)","other","article","10.3877/cma.j.issn.2095-1221.2017.03.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030754","The potential mechanisms of GLP-1 and gastrointestinal reaction","Guang Ning","2012","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2012.11.027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030755","Efficacy and safety of exenatide on type 2 diabetic patients","Ling Li","2012","Shiyong yaowu yu linchuang","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030756","ADA: Study says non-insulin dulaglutide demonstrates effective blood glucose control in diabetes patients","Tracey Walker","2014","Formulary ENews","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030757","GST-Exendin-4在大肠杆菌中的可溶性表达和纯化","Yi Zhang","2011","生物技术通报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030758","GLP-1 Receptor Agonist in a Patient with Craniopharyngioma-Related Obesity","Maria-Christina Antoniou","2018","ESPE Abstracts","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030759","肥胖相關的??Resistin (23-42) 和Exendin-3具抗血管增生作用","蘇信芳","2003","臺北醫學大學醫學科學研究所學位論文","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030760","A comparative hepatoprotective effect of liraglutide and nano extracts of Ficus carica and Olea Europaea leaves on diabetes-induced in laboratoryanimals","Safa H. Qahl","2020","Diabetes Case Reports","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030761","治療第2型糖尿病新型口服藥－DPP-IV抑制劑","陳建良","2007","內科學誌","other","article","10.6314/jimt.2007.18(1).03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030762","Seeking for Binding Sites of the N-Terminal Fragment of Glucogan-like Peptide-1 Receptor to Exendin-4 Through Phage Display","Weifeng Gao","2009","Anhui nongye kexue","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030763","Investigational Once-Daily Incretin Mimetic Outperforms Twice-Daily Exenatide","Bruce Soloway","2009","Journal watch","other","article","10.1056/jw200907160000003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030764","Progress in pharmacological and clinical studies of liraglutide","Deliang Fu","2010","Zhongguo xin yao zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030765","GLP‐1 receptor agonistの血管リモデリングに与える影響の検討","西雄千佳","2010","日本血管生物医学会学術集会プログラム・抄録集","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030766","Liraglutide and Renal Outcomes in Patients with Longstanding Type 2 Diabetes","Allan S. Brett","2017","Journal watch","randomized_trial","article","10.1056/nejm-jw.na44837",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030767","Effects of liraglutide combined with metformin on glucose and lipid metabolism, islet beta cell function and body fat in obesity with type 2 diabetes mellitus","Xueqin Yan","2019","Chin J Cell Stem Cell (Electronic Edition)","randomized_trial","article","10.3877/cma.j.issn.2095-1221.2019.05.004",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030768","GLP-1受体激动剂及DPP-IV抑制剂的研究进展","周映红","2008","中国药科大学学报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030769","Preparation of Liraglutide","Feng Jun","2013","Chinese Journal of Pharmaceuticals","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030770","The Physiological Functions of GLP-1 and Its Analogs on Cardiovascular System","Shen Ji","2014","Strait Pharmaceutical Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030771","Progress in treatment of nonalcoholic fatty liver disease","Shi Jun-pin","2013","Linchuang gandanbing zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030772","Advances in Studies on the Effect of Incretin-Based Therapy on Cardiovascular System","YU Qia","2014","Tianjin yiyao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030773","Esperienza Clinica: passaggio da terapia insulinica a Exenatide Lar Once Weekly in diabetici obesi ad alto rischio cardiovascolare","Lorenzo Cocco","2015","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030774","Pharmacodynamics evaluation of the fusion protein GGH in mice","Zhenghong Xu","2011","Zhongguo yaolixue tongbao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030775","Higher-Dose Liraglutide Creates New Options to Fight Obesity, but Payment Remains a Challenge","Andrew H. Smith","2015","The American Journal of Managed Care","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030776","Effect of Liraglutide on Patients with Type 2 Diabetes in Real Practice: Experience from A Regional Hospital","Baomei Wang","2020","內科學誌","other","article","10.6314/jimt.202006_31(3).08",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030777","Two Sporadic Cases of Acute Pancreatitis Associated with Vildagliptin","Murat zdede","2021","JOP, journal of the pancreas","other","article","10.36648/1590-8577.22.1.31-35",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030778","Research progress on drugs with new targets in treatment of type 2 diabetes","Liu Yong-gu","2015","Xiandai yaowu yu linchuang","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0030779","Terapi Diabetes dengan GLP-1 Receptor Agonist","Pande Made S. Dharma Pathni","2018","Cermin Dunia Kedokteran","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030780","Glucagon peptide-like 1 receptor （GLP-1R） expression per se： a new insight into neurodegenerative disease？","Dong-il","2015","中国神经再生研究：英文版","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030781","Clinical Observation of Exenatide for Type 2 Diabetes","Zhao Shi","2012","Zhongguo yaofang","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030782","A study of the effect of liraglutide in the treatment of type 2 diabetes with different body mass indexes","Lin Jia","2015","Journal of Bethune Medical Science","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030783","Effects of incretin drugs on body weight","Huanhuan Zhou","2016","Int J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2016.03.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030784","Protection of exendin-4 analog on ERG and Ops in experimental diabetic rats","Yu Zhang","2008","International Journal of Ophthalmology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030785","Effects of Exenatide on the Treatment for Different Disease Courses of Type 2 Diabetes Patients","Jing Feng","2012","Zhongguo yaofang","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030786","Effect of liraglutide on glucose transporter 4 translocation of mouse skeletal muscle cells","Zhu Li","2014","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2014.08.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030787","Glucagon-like Peptide 1 and Type 2 Diabetes: Targets and New Therapies","Robab Sheikhpour","2012","Indian Journal of Science and Technology","other","article","10.17485/ijst/2012/v5i6/30482",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030788","Liraglutide Is Effective for Type 2 Diabetes","F. Bruder Stapleton","2019","Journal watch","other","article","10.1056/nejm-jw.na49040",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030789","Glucagon-like Peptide-1 Receptor Agonists","Logan Collins","2019","StatPearls","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030790","Postprandial Hypoglycaemia following bariatric surgery;a case report","Hassan Kahal","2021","Obesity Facts","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0030791","Combination therapy with metformin and the GLP-1 analogue liraglutide as a synergistic treatment for diabetic retinopathy in a type-2 diabetic rat model","Tourki A. S. Baokbah","2021","Biomedical Research-tokyo","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030792","Application of liraglutide in patients with type 2 diabetes mellitus and acute ST-segment elevation myocardial infarction after PCI","Xiaoyan Yue","2018","国际医药卫生导报","other","article","10.3760/cma.j.issn.1007-1245.2018.23.025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030793","Clinical and pharmacological aspects of the use of exenatide for the treatment of type II diabetes mellitus.","V. C. P. Fontanive","2008","Arquivos de Ciências da Saúde da UNIPAR","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030794","Changes of glucagon–like peptide–1 (GLP–1) and effects of GLP–1 analogues in the type 2 diabetic patients with obstructive sleep apnea – hypopnea syndrome","Huifeng Zhang","2015","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674–5809.2015.05.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030795","Overview and management of type 2 diabetes mellitus","Quinten Labuschagne","2017","Pharmacy management","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030796","The Therapeutic Effect of Exendin-4 on Spontaneous Non-Insulin Dependent Diabetes (NIDD) KK~(Ay) Mice","Tianhua Yan","2008","Pharmaceutical biotechnology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030797","Dulaglutide using once-2 weeks for dialysis type 2 diabetes patients in Japan","Mari Koga Ishii Masao","2019","Diabetes Management","other","article","10.37532/1758-1907.2019.9(3).80-86",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030798","A Meta-analysis on Sitagliptin and Other Antidiabetic Drugs in the Treatment of Type 2 Diabetes","Liang Jing-jin","2015","Medical Recapitulate","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","article"],["R0030799","Exenatide monodose settimanale","Silvio Settembrini","2014","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030800","Solid Phase Peptide Synthesis and Analysis for Exendin-4","Yanjie Liu","2011","Zhongguo shengwu gongcheng zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030801","Efficacy of Liraglutide in Patients with Glucocorticoid-induced Glucose Intolerance: A Case Study","Ichiro Yamauchi","2014","Tōnyōbyō/Tounyoubyou","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030802","Efficacy of Liraglutide in treating type 2 diabetes","Gangyi Yang","2010","Xinxiang yixueyuan xuebao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030803","More About Liraglutide for Weight Reduction in Patients Without Diabetes","Allan S. Brett","2021","Journal watch","other","article","10.1056/nejm-jw.na53535",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030804","Вилдаглиптин в клинической практике: анализ сравнительных исследований лекарственных средств с инкретиновой активностью","Елена Валерьевна Бирюкова","2014","Сахарный диабет","other","article","10.14341/dm6303-4321",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030805","Three Cases of Obese Elderly Type 2 Diabetes Mellitus With Successful Glycemic Control by Long-Acting Once-Weekly Formulation of Exenatide Injected by Their Caregivers","Takemasa Ando","2015","Tōnyōbyō/Tounyoubyou","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030806","Effects of Liraglutide on plasma Vaspin level in patients with type 2 diabetes mellitus","Xia Chang","2011","Zhongguo laonianxue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030807","Advances on the research of exenatide","Weiren Xu","2008","Zhongguo xin yao zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030808","Effects of exendin-4 on expression of endoplasmic reticulum stress marker C/EBP homologous protein in hepatocyte of rats with impaired glucose tolerance","Guo Qing-hu","2012","Chinese Remedies & Clinics","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0030809","Antidiabetic agents——a new approach for the treatment of Alzheimer's disease","Xiaohu Li","2014","Chinese Journal of Geriatric Care","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030810","Weight management in overweight and obese patients with type 2 diabetes mellitus : review","Sudhesh Kumar","2011","˜The œSouth African journal of diabetes & vascular disease","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030811","Effect of liraglutide on the serum inflammatory markers in impaired glucose tolerance OLETF rats","De-hong Cai","2012","Shandong yiyao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030812","Once-Weekly Exenatide for Type 2 Diabetes","Allan S. Brett","2012","Journal watch","randomized_trial","article","10.1056/jw201202160000002",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030813","Protective effects and mechanism of exenatide on H9C2 cardiomyocytes cultured with high glucose","Ruixia Yuan","2016","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2016.10.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030814","持続性エキセナチド注射剤 ビデュリオン(R) 皮下注用2 mg―日本人／アジア人第III相臨床試験のレトロスペクティブ解析：対照薬との有効性プロファイルの比較，HbA1c に影響を与える因子の検討―","小田原雅人","2015","薬理と治療","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0030815","Combination of Intragastric Balloon and Liraglutide: Short-Term Results","Anna Carolina Hoff","2021","EC Gastroenterology and Digestive System","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030816","Underuse and Misuse of Newer Antidiabetic Medications with Established Positive Cardiovascular Outcome","Syed Raza","2020","Cardiovascular Pharmacology Open Access","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030817","肠激酶消化融合蛋白Trx-Exendin-4的特性","徐良","2012","河南科学","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030818","Combining SGLT-2 Inhibitors and GLP-1–Receptor Agonists for CV Risk Reduction in Type 2 Diabetes","Harlan M. Krumholz","2021","Journal watch","other","article","10.1056/nejm-jw.na54310",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030819","Recent progress in clinical research of exenatide","Tian-hong Luo","2010","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2010.01.031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030820","Exenatide Once-weekly（Bydureon®）－可每週注射一次的第二型糖尿病用藥","陳昭姿","2013","當代醫學","other","article","10.29941/mt.201311_(481).0011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030821","The clinical observation on low-carbohydrate diet combined with liraglutide in type 2 diabetes mellitus patients with obesity","Meirong Liu","2017","国际医药卫生导报","other","article","10.3760/cma.j.issn.1007-1245.2017.14.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030822","The Various Therapeutic Approaches for the Treatment of Diabetes","Surabhi Kavya","2016","Research and reviews : journal of pharmacology and toxicological studies","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030823","Recent Development of Exendin-4 and Its Analogs","Jingjing Liu","2007","Yaoxue jinzhan","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030824","Efficacia dell’exenatide LAR in un caso di diabete mellito tipo 2 scompensato, complicato da microangiopatie, obeso, insulino-trattato","Maria Rosa Fittipaldi","2015","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030825","Treatment of Type 2 diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps?","Smriti Sharma","2020","Chemical Biology Letters","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030826","The impact of GLP-1 on bone in patients with type 2 diabetes","Yingying Ruan","2018","Int J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2018.04.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030827","[특집 : 비만ㆍ당뇨 조절과 건강기능식품] 제2형 당뇨병 병인 : 인슐린 / IGF-1 신호전달 장애","박선민","2005","식품산업과 영양","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030828","Progress of hypoglycemics","Ying Han","2000","Chinese New Drugs Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030829","Effects of liraglutide on sleep-disordered breathing and diabetic microangiopathy in patients with type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome","Kaikun Liu","2020","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2020.02.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030830","Liraglutide vs. Sitagliptin for Type 2 Diabetes: Liraglutide Wins an Early Round","Bruce Soloway","2010","Journal watch","other","article","10.1056/jw201005180000002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030831","虚血性脳損傷に対するGLP-1受容体作動薬Exendin-4の脳保護効果の検討","卜部貴夫","2011","日本神経学会学術大会プログラム・抄録集","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030832","Three cases of Type 2 diabetes treated with daily insulin injection and Liraglutide","森田 智","2016","The Japanese Society for Pediatric Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030833","Substituting exenatide for insulin may be feasible for some type 2 diabetics","Scott Baltic","2000","The American Journal of Managed Care","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030834","Research Situation of GLP-1 Receptor Agonists on the Treatment of T2DM","Zhang Hui-l","2011","National Medical Frontiers of China","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030835","A review of pharmacotherapy in type 2 diabetes mellitus and its possible cardiovascular risk","Dilli Ram Thanait","2017","Journal of Biomedical and Pharmaceutical Research","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0030836","Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)","Wafa Latif","2021","StatPearls","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030837","Mechanisms of GLP-1 receptor agonist in obesity-related glomerulopathy","Yongjian Ye","2019","Int J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2019.01.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030838","Effects of exenatide on lipid metabolism of adipose tissue in diabetic rats","Yingying Chen","2012","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2012.12.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030839","Clinical study progression on efficacy and safety of anti-obesity drugs","Yin Shi-hong","2017","Int J Endocrinol Metab","other_trial","article","10.3760/cma.j.issn.1673-4157.2017.03.006",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0030840","Research on glucagon-like peptide-1 receptor agonist on the function and differentiation of brown adipocytes in mice","Shanmei Shen","2013","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2013.10.018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030841","Effects of liraglutide on adiponectin and insulin resistance in rats with non-alcoholic fatty liver disease","Zeng Zhi-gan","2014","Zhongguo bingli shengli zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030842","Efficacy and safety of exenatide versus insulin in patients with inadequately glycemic controlled obese type 2 diabetes with oral antidiabetic agents","Jianjia Jiang","2011","Chin J Diabetes Mellitus","randomized_trial","article","10.3760/cma.j.issn.1674-5809.2011.04.008",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030843","Two Cases of Paralytic Ileus Associated with the Administration of Liraglutide","Tetsuhiro Kitamura","2012","Tōnyōbyō/Tounyoubyou","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030844","Pharmacokinetics of rE-4 (Lyophilized Recombinant Exendin-4) in healthy volunteers after multiple subcutaneous injections","Yi Fang","2012","Zhongguo linchuang yaolixue yu zhiliaoxue","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0030845","한국 신약개발의 기술적 역량 진단과 개선방안","엄익천","2019","과학기술정책","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030846","Effect of glucagon-like peptide 1 receptor agonists on the structure and function of pancreatic alpha cells in rats with impaired glucose tolerance","Guangxia Xi","2019","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2019.10.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030847","Glucagon like peptide 1 receptor agonists: therapy for diabetes management","Natalia Andrea Rojas","2018","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030848","Aggiunta in Terapia di Exenatide r.p. in un caso di diabete tipo 2 con obesità grave e in trattamento con metformina 3 g/die con scarsi risultati","P. Alfidi","2016","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030849","Anti-oxidation effects and related mechanisms of liraglutide on high glucose-induced injury of HUVECs","Weiling Ju","2020","Central Plains Medical Journal","other","article","10.3760/cma.j.issn.1674-4756.2020.02.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030850","New Drug Application for Lixisenatide Accepted; CV Results Already in Hand","Mary K. Caffrey","2015","The American Journal of Managed Care","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030851","Improvement of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes and psoriasis","Lin Lü","2018","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2018.08.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030852","광화학적으로 유발한 뇌허혈모델에서 펩타이드호르몬 Exendin-4에 의한 치아이랑의 신경세포재생","이창섭","2009","대한체질인류학회 학술대회 연제 초록","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030853","Treatment of Type 2 Diabetes with SodiumGlucose Co-Transporter 2 Inhibitors plus Glucagon-Like Peptide-1 Receptor Agonists","Nasser Mikhail","2020","Insights in Biomedicine","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0030854","Advance in clinical research of Exendin-4","Gao Yong-y","2011","Zhongguo redai yixue","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030855","Effect of Liraglutide in Patients with Type 2 Diabetes and Obesity and on Their Micro- inflammation","Xi Yu","2013","Zhongguo quanke yixue","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030856","Correlation Study of Liraglutide,a Derivative of Glucagon-like Peptide in the Treatment of NIDDM","Wenbo Qi","2010","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030857","Pancreatic and Thyroid Cancer Related to Exenatide and Liraglutide Treatment: A Post marketing Analysis of Spontaneous Cases Reported in Eudra Vigilance Database","Ghanshyam Mali","2020","Journal of Drug Delivery and Therapeutics","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0030858","Recent Advances in Drug Treatment of Type-2 Diabetes Mellitus","Zhou Chong-chu","2013","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030859","Exendin-4干预对糖尿病肾病大鼠肾脏TGF-β_1mRNA和蛋白表达的影响","孔慧平","2012","中西医结合心脑血管病杂志","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030860","Liraglutide 3.0 mg for weight loss, is it more effective in diabetic or non-diabetic patients? A systematic review and meta-analysis","Shimaa Elsayad Ahmed","2018","American Journal of Pharmacology and Pharmacotherapeutics","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0030861","The Role of cAMP/PKA Activation on Exendin-4-Induced Cyclin D1 Expression in INS-1 Cell.","Gyeong Ryul Ryu","2005","Korean Diabetes Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030862","Cardiovascular effects of metformin combined with liraglutide in diabetic patients","金海英","2014","Chin J Postgrad Med","other","article","10.3760/cma.j.issn.1673-4904.2014.10.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030863","Clinical observation of exenatide in the treatment of type 2 diabetes","Hua Si-wen","2012","Shanxi Yike Daxue xuebao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030864","Dérivés du GLP-1 et inhibiteurs de la DPP-IV : perspectives dans le traitement du diabète de type 2","Jean‐Frédéric Blickle","2006","Sang thrombose vaisseaux","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0030865","激素、维生素及相关药物/Novo Nordisk申请Iiraglutide上市","曹菊","2008","国外药讯","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030866","Early and long-term usage of liraglutide benefits the comprehensive management of type 2 diabetes","Juming Lu","2013","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2013.05.027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030867","Insulinotropic Exendin-4 Expressing Islet Transplantation for Improving Islet Donor Shortage","Jee‐Heon Jeong","2010","한국생물공학회 학술대회","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030868","Research progress in non-insulin drugs used for treating type 2 diabetes","Chang Chen","2013","Xiandai yaowu yu linchuang","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030869","Controversy on the diabetic patients with glucagon-like peptide-1 (GLP-1) inducing pancreatitis","Guo Qing-y","2010","Chinese Journal of Geriatric Care","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030870","Evaluation of in vitro differentiation of human adipose-derived stem cells into islet-like cell clusters induced by INGAP-pp protocol","Xiang Ren","2010","Journal of Jilin University","protocol","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0030871","Effects of GLP-1 on the expression of Adiponectin receptor 1 and MCP-1 in kidney of type 1 diabetic rats","DU Shi-jin","2014","Zhongguo xiandai yixue/Zhongguo xiandai yixue zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030872","Regulating β-cell,defeating diabetes——Basic and clinical study on GLP-1 and liraglutide","Yan Gao","2009","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2009.06.035",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030873","비만 치료약물의 최신지견","박혜숙","2016","한국보건기초의학회지","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030874","Progress in Research and Development of Glucagon-like Peptide 1 Analogues as New Drugs","Yang Zi-yi","2011","Zhongguo shengwuzhipinxue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030875","Glucagon-like peptide-1: a new Alzheimers disease interventive strategy","Guanhua Du","2006","Zhongguo yaolixue tongbao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030876","Efficacy, Safety and Tolerability of Liraglutide, GLP-1 Analogue, in Indian Adolescent Population with Obesity","Aashish Sethi","2018","57th Annual ESPE","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030877","Recent advances in the Management of Type 2 Diabetes Mellitus","NI Wei-hui","2010","Pharmaceutical biotechnology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030878","The Effectiveness of Exenatide in an Unusual Case of Obese Type 2 Diabetes Mellitus with Brain Hemorrhage","Xuexue Deng","2017","Emergency Medicine Investigations","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030879","Latest Progress of Drugs Used in Type-2 Diabetes Mellitus Treatment","Shen Jianmin","2011","The Chinese Journal of Modern Applied Pharmacy","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030880","Research progress of molecular imaging in monitoring islet transplantation","Jinxin Zhou","2015","Int J Radiat Med Nucl Med","other","article","10.3760/cma.j.issn.1673-4114.2015.06.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030881","Protective Effect of Exendin-4 on Interleukin-1β-induced Apoptosis in Murine Pancreatic β-cells","Libin Liu","2012","Fujian Yike Daxue xuebao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030882","艾塞那肽对非酒精性脂肪肝大鼠肝脏NF-κB、TNF-α、TGF-β1表达的影响","冯文焕","2012","中国糖尿病杂志","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030883","Promising Early Results for Liraglutide in the Treatment of NASH","Atif Zaman","2015","Journal watch","randomized_trial","article","10.1056/nejm-jw.na39715",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030884","Liraglutide: First Once-Daily Human GLP-1 Analogue","Sreejith N Kumar","2011","Kerala Medical Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030885","Effect of liraglutide and PTEN on rats pancreatic islet cell apoptosis induced by high fat diet","Ying Xing","2011","Zhongguo tangniaobing zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030886","Effects of liraglutide intervention combined with PCI therapy on ventricular remodeling and cardiac function in patients with acute myocardial infarction and type 2 diabetes mellitus","Lei Cao","2019","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2019.02.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030887","Is Exenatide Neuroprotective in Parkinson Disease","Michael S. Okun","2017","Journal watch","other","article","10.1056/nejm-jw.na44767",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030888","Liraglutide: A novel therapy for type 2 diabetes——Report of \"Diabetes Dialogue\" International Forum","Dalong Zhu","2009","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2009.01.049",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030889","The effect of exenatide therapy on blood glucose,lipid and body weight of the patients with type 2 diabetes","Ji Hu","2013","Journal of Nantong University","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030890","Role of β-cell Failure in the Pathogenesis of Type 2 Diabetes Mellitus and Therapeutic Choice","Wei Ding","2012","Pharmaceutical and Clinical Research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030891","An Insulin Resistance Case Report: Uncontrolled Hyperglycaemia in type 1 Diabetic Patient Post COVID-19 Infection","Yousef Almehrzi","2021","Journal of Diabetes & Metabolism","case_report","article","10.35248/2155-6156.21.12.889",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030892","INVOLVEMENT OF CYCLIC AMP RESPONSE ELEMENT (CRE) IN EXENDIN-4 INDUCTION OF RAT EGR-1 GENE","Kang Jung-Hoon","2006","Korean Journal of Physiology and Pharmacology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030893","Role of glucagon-like peptide-1 analogue liraglutide played in the proliferation of CD4~+ CD25~- T cells in normal people and type 1 diabetic patients in vitro","胡瑛","2013","中国医学文摘：内科学分册（英文版）","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030894","The Clinical Efficiency of Exenatide-4 Type IIDiabetes","Zhu Bao-yan","2012","Pharmaceutical biotechnology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030895","Agonis Reseptor GLP 1 untuk Terapi Diabetes Mellitus Tipe 2","Aulia Agristika","2018","Jurnal Agromedicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030896","On the cardiovascular effects of GLP-1 from recent studies","Changyu Pan","2010","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2010.05.029",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030897","Dissolving Microneedles for Pharmaceutical Drug Delivery","정형일","2018","한국피부장벽학회지","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030898","Once-Weekly Exenatide: An 84-Week Study","Allan S. Brett","2012","Journal watch","randomized_trial","article","10.1056/jw201204260000003",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030899","Advances in research on glucagon-like peptide-1 and its analogues","Zhimin Liu","2010","Pharmaceutical Care and Research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030900","Research progress on exendin-4","Rao Chun-ming","2010","Yaowu fenxi zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030901","Exenatide inhibits JAK1/STAT1 expression and B cell apoptosis in insulin resistant rat model of type 2 diabetes mellitus","Zhengkang Feng","2010","Academic Journal of Second Military Medical University","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030902","ラット唾液アミラーゼモデルを用いたGLP‐1受容体作動薬Iiraglutide及びexenatideの催吐作用検討:ヒト特異的な嘔吐を検出・評価するための実験系としての可能性","吉岡豊晃","2012","The Journal of Toxicological Sciences","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030903","The DPP-4 inhibitors - a clinical update and perspective : original article","Laura Blacking","2011","South African Journal of Diabetes","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030904","Incretin-based therapy of type 2 diabetes:Focus on studies in China or Asia","LU Ju-min","2014","Zhongguo tangniaobing zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030905","Tirzepatide, a Potential New Agent for Type 2 Diabetes","Allan S. Brett","2021","Journal watch","other","article","10.1056/nejm-jw.na53795",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030906","Migliore efficacia del trattamento con exenatide lar verso insulina basal plus in una paziente normopeso con lunga durata di diabete mellito tipo 2","Monica Modugno","2015","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030907","Клинико-экономический анализ ликсисенатида при сахарном диабете 2 типа","Колбин Алексей Сергеевич","2015","Качественная клиническая практика","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030908","Antagonism of human glucagon-like peptide-1 analog gene on streptozotocin-induced diabetic rats","MA Wei-lie","2010","Chongqing yixue","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030909","Semaglutida ▼ Ozempic® (Novo Nordisk) en diabetes mellitus tipo 2","Carlos Fernández Moriano","2019","Panorama actual del medicamento","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030910","Research progress in cardiovascular protection by novel antidiabetic drugs","Jiang Ya","2014","Zhongguo xin yao zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030911","Recent Progress of Islets Beta-cells Dysfunction in Type 2 Diabetes","Han Hai-rong","2008","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030912","A case of liraglutide in the treatment of type 2 diabetes mellitus complicated with severe pustular psoriasis","Pin Chen","2019","Chin J Diabetes Mellitus","case_report","article","10.3760/cma.j.issn.1674-5809.2019.08.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030913","Tirzepatide: Summary of the Emerging Data on theNovel GLP-1/GIP Dual Agonist","Jessica Reid","2020","EC Diabetes and Metabolic Research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030914","Progress in New Drugs for Treatment of Type 2 Diabetes Mellitus","Wan Xing-y","2014","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030915","当院の2型糖尿病患者におけるインスリンデグルデク/リラグルチド(IDegLira)の有効性および安全性の検討","遅野井健","2020","診療と新薬","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030916","The effective assessment of diabetes mellitus and nonalcoholic fatty liver disease treated by Exenatide","Tcm Hospita","2015","Chongqing yixue","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030917","The study of mechanism for exendin-4 (exenatide) improving insulin resistance","Li Ling","2008","Zhongguo tangniaobing zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030918","Effects of glucagon-like peptide-1 receptor agonists on plasma lipid metabolism of primary type 2 diabetics","Li M","2013","Zhonghua linchuang yishi zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030919","インクレチンは小腸においてApolipoprotein B48 の合成を抑制する","熊谷 文哉","2018","薬理と治療","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030920","Exenatide induces hypothermia: one case report","Hongyan Zhu","2017","Chin J Diabetes Mellitus","case_report","article","10.3760/cma.j.issn.1674-5809.2017.04.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030921","Strategic PEGylation: Half-life extension of biologic drugs","Kang Choon Lee","2016","Pharmaceutica Analytica Acta","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030922","Antidiabetic Drugs and Exenatide","LI Xin-gan","2014","Drug Evaluation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030923","Relationship between Mechanism of GLP - 1 and Syndrome of Damp - Heat of Spleen and Stomach of Diabetes","Niu Jingjin","2013","Liaoning zhongyi zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030924","Вилдаглиптин. Возможности оптимального контроля сахарного диабета 2 типа","Аметов Александр Сергеевич","2015","Сахарный диабет","other","article","10.14341/dm7599-5589",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030925","Effect and underlying mechanism of liraglutide on fibroblast growth factor-21 production in mouse islet β cells","Lina Ge","2018","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2018.02.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030926","Clinical evaluation of liraglutide","Hua Xu","2008","World Clinical Drugs","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030927","Exenatide和β细胞功能","Tao Yang","2005","Section Endocrinol Foreign Med Sci","other","article","10.3760/cma.j.issn.1003-5435.2005.01.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030928","Effect of glucagon like peptide-1 receptor agonists on the peripheral nervous system","Min Hao","2013","Zhongguo tangniaobing zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030929","Effects of liraglutide on bone metabolism and Wnt pathway in type 2 diabetic rats with osteoporosis","Xiaobin Tang","2019","Chin J Endocr Surg","preclinical","article","10.3760/cma.j.issn.1674-6090.2019.06.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030930","The protective effect of exenatide on islet INS-1 cells exposed to intermittent high glucose environment","Cai De-hon","2011","Jiefangjun yixue zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030931","Efficacy and safety of liraglutide versus sitagliptin in obese patients with inadequately controlled type 2 diabetes with insulin therapy","Lunpan Mou","2016","Chin J Diabetes Mellitus","randomized_trial","article","10.3760/cma.j.issn.1674-5809.2016.01.008",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030932","インクレチンの脳保護メカニズム―虚血性脳損傷に対するExendin－4の脳保護作用","卜部貴夫","2012","医学のあゆみ","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030933","종설 : 새로이 개발되어 사용되기 시작하는 당뇨병 관련약제","박이병","2007","The Korean Journal of Internal Medicine","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030934","Ny strategi vid typ 2-diabetes prövas i kliniska studier. Glukagonlik peptid 1 (GLP-1) påverkar sjukdomens grundorsaker","Bo Åhrén","2005","Lund University Publications (Lund University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030935","The effect of exenatide on controlling blood glucose of patients with type 2 diabetes","Qingsong Wan","2011","Zhongguo sheng-hua yaowu zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030936","胰高血糖素样肽-1类似物对高糖诱导下肾小管上皮细胞Toll样受体4、骨桥蛋白表达的影响","孔瑜","2012","中西医结合心脑血管病杂志","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030937","A systematic review of the effectiveness of Liraglutide for the treatment of type 2 diabetes","VC Echebiri","2014","International Journal of Community Research","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0030938","Peptide Mapping Analysis of Recombinant Pancreatic Glucagon-like Peptide-1 Receptor Agonist With LC-MS","Cao Wei-ron","2013","Xiandai shengwu yixue jinzhan","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030939","Using GLP-1 Agonists or SGLT-2 Inhibitors to Simplify Complex Insulin Regimens","Allan S. Brett","2021","Journal watch","other_trial","article","10.1056/nejm-jw.na53784",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0030940","Novel therapeutic agents for diabetes mellitus","Zou Da-ji","2009","Zhongguo shiyong neike zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030941","NexP TM /Exenatide Has a Significant Effect of Long Acting GLP-1 Receptor Agonist","Jeong Soo Cho","2011","한국생물공학회 학술대회","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030942","Effective Switch From Twice-Daily Pre-Mixed Insulin 50/50 to Liraglutide to Achieve a Good Glycemic Control in Type 2 Diabetes","Hidekatsu Yanai","2011","Journal of Medical Cases","other","article","10.4021//jmc.v2i2.143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030943","Effect of molecular weight of poly(Lactic-co-Glycolide) on properties of exenatide-loaded microspheres","Chen Yan","2009","China Modern Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030944","Therapeutic effects of GLP-1 analog on rats with experimental diabetes mellitus","Xie Li-bo","2007","Journal of Jilin University","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030945","Neuroprotective activities of exendin-4 toward dorsal root ganglion neurons and Schwann cells","Kazunori Sango","2020","Japanese Society of Neurology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030946","Effect of GLP-1 agonist on type 2 diabetes","Jie Chai","2011","Central Plains Medical Journal","other","article","10.3760/cma.j.issn.1674-4756.2011.04.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030947","Effects of Exendin-4 on islet β-cell function and glucose-lipid metabolism in high fat diet rats","Chen Yu","2009","Di-san junyi daxue xuebao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030948","Liraglutide prevents endothelial damage triggered by glucose oscillations","Bruno Schisano","2010","Society for Endocrinology BES 2010","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030949","Dipeptidyl Peptidase–4阻害薬からデュラグルチドへの切替え例における血糖コントロールおよび体重変動とBody Mass Index","清水弘行","2021","Therapeutic research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030950","A Case of Acute Pancreatitis Due to Liraglutide","Noé Quesada‐Vázquez","2018","JOP, journal of the pancreas","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030951","Effects of exendin-4 on GFAP and IL-1βexpression in hippocampi of aged rats","Liang Zhang","2014","Zhonghua mazuixue zazhi","preclinical","article","10.3760/cma.j.issn.0254-1416.2014.03.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030952","Are the SGLT2 inhibitor and GLP-1 RA effective in primary CVD prevention?","강은석","2020","대한당뇨병학회 학술발표논문집","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0030953","Superiority of GLP-1 and Its Analogues in Treating Type 2 Diabetes Mellitus","Hua-zhang Yang","2010","Journal of Evidence-Based Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030954","Research Progress of Human GLP-1 Analogues for Acute Coronary Syndromes","Deng Genqu","2014","Advances in Cardiovascular Diseases","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030955","A completely novel long-acting GLP-1 receptor agonist, glutazumab","Caina Li Zhufang Shen Xiaofeng Wang","2018","Journal of Diabetes & Metabolism","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030956","IGlarLixi (insulina glargine U100/lixisenatide): nuovo approccio terapeutico combinato nella gestione del diabete tipo 2","Maria Chantal Ponziani","2018","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030957","Cardiovascular safety of antidiabetic agents including GLP-1 receptor agonist reviewed systematically by Network Meta-analysis","Shi Lu-we","2012","Chinese Journal of Evidence-Based Cardiovascular Medicine","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","article"],["R0030958","Effects of human glucagon-like peptide-1 analog gene transfection on blood glucose,insulin levels and pancreatic island in diabetic rats","Zhang Zhi-zhe","2010","Jiefangjun yixue zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030959","Determination of exenatide injection by HPLC","Zhao Huai-qing","2011","Shenyang Yaoke Daxue xuebao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030960","Oral antidiabetic drugs and GLP-1 analogues","Hannele Yki‐Järvinen","2000","EBM Guidelines","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030961","Liraglutide ameliorates hepatic expression of c-Jun N-terminal protein kinase in type 2 diabetic rats with nonalcoholic fatty liver disease","Zhiping Shi","2016","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2016.09.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030962","Semaglutide for Obesity: A Randomized Trial","Allan S. Brett","2021","Journal watch","randomized_trial","article","10.1056/nejm-jw.na53218",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0030963","胰高血糖素样肽-1受体激动剂Exendin-4在大鼠缺血性室性心律失常中的作用","张凯","2014","中西医结合心脑血管病杂志","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030964","Solid phase synthesis of glucagon-like peptide-1 analogues under microwave irradiation and their hypoglycemic activities","Hai Qian","2008","Zhongguo yaoke daxue xuebao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030965","Ce poate face farmacistul pentru pacienţii săi adulţi cu tulburări de alimentaţie sau obezitate","Cristina Daniela Marineci","2019","Farmacist ro","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030966","The potential therapeutic effects of glucagon like peptide -1 receptor agonists in patients with diabetes mellitus induced erectile dysfunction","Fengjiao Dong","2017","Chin J Postgrad Med","other","article","10.3760/cma.j.jssn.1673-4904.2017.03.027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030967","Effect of GLP-1 analogue combined with metformin on blood glucose control and insulin resistance in obese patients with type 2 diabetes mellitus","Zihan Guan","2019","Chin J Endocr Surg","nonrandomized_study","article","10.3760/cma.j.issn.1674-6090.2019.02.012",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0030968","Effect of Incretin Mimetics and DPP-IV Inhibitors for the Treatment of type 2 Diabetes","DI Fu-shen","2007","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030969","【結語】EXENDIN-4は,AΒ_(31-35)によって誘発されたHT22海馬ニューロンにおけるPER1遺伝子の異常な発現を改善する。【JST・京大機械翻訳】","Zhao Xueling","2016","Shenjing Jiepouxue Zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030970","GLP-1 receptor agonist exacerbates mucus hyper secretory phenotype in βENaC-transgenic mouse with obstructive lung diseases","Hirofumi Kai","2016","Journal of Pulmonary & Respiratory Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030971","Research progress of human GLP-1 analogues for type 2 diabetes","Yongde Peng","2010","World Clinical Drugs","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0030972","激素、维生素及相关药物 07028 Liraglutide可改善2型糖尿病患者的心血管参数","罗娟","2007","国外药讯","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030973","Glucagon-like Peptide 1 and Its Derivatives in the Treatment of Diabetes—preclinical and Clinical Results","Chen Dong-shen","2011","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030974","Incrétines, incrétinomimétiques et inhibiteurs de la DPP-4 : homéostasie glucidique et diabète de type 2","Marie Virally","2008","Sang thrombose vaisseaux","other","article","10.1684/stv.2008.0329",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030975","Нефропротективный потенциал агонистов рецепторов глюкагоноподобного пептида 1","Шамхалова Минара Шамхаловна","2020","Сахарный диабет","other","article","10.14341/dm12379-9517",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030976","Дулаглутид – агонист рецепторов глюкагоноподобного пептида-1 для введения один раз в неделю в моно- и комбинированной терапии СД 2 типа: обзор программы клинических исследований AWARD","Шестакова Марина Владимировна","2017","Сахарный диабет","other","article","10.14341/dm8347-6441",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030977","Anti-type 2 diabetes and development of exenatide","Yan Qin","2013","World Clinical Drugs","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030978","Advance of glicagon like peptide-1 liraglutide","Guo Shao-lai","2012","Chinese Journal of Drug Application and Monitoring","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030979","The latest research progress of human GLP-1 analogues liraglutide","Yang Wen-ying","2010","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2010.09.033",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030980","Gallstone Disease in Patients Treated with Liraglutide","Allan S. Brett","2019","Journal watch","other_trial","article","10.1056/nejm-jw.na50110",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0030981","Liraglutide Approved Under New Name to Treat Obesity","Mary K. Caffrey","2015","The American Journal of Managed Care","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030982","Dulaglutide Prevents Some Adverse Cardiovascular Outcomes in Patients with Diabetes","Bruce Soloway","2019","Journal watch","other","article","10.1056/nejm-jw.na49337",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030983","Liraglutide may improve glycemic control in patients with type 2 diabetes","Formulary staff","2010","Formulary ENews","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030984","Effect of liraglutide combined with bone marrow mesenchymal stem cells on glucose metabolism in experimental type 1 diabetic rats by regulating gastrointestinal hormones","Pin Chen","2015","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2015.03.019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030985","The effectiveness of exenatide on obese patients with type 2 diabetes mellitus","Shen Ha","2012","Zhongguo shiyong neike zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030986","Study on Cell Model for High Throughput Screening the Agonist of Glucagon-Like Petide-1 Receptor","Aoxue Luo","2007","Acta Scientiarum Naturalium Universitatis Sunyatseni","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030987","Efficacy and safety of liraglutide on glycaemic control in patients with type 2 diabetes: a systematic review","Songtao Tang","2011","Chin J Diabetes Mellitus","systematic_review","article","10.3760/cma.j.issn.1674-5809.2011.06.003",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0030988","Efficacy and effect on β cell functions comparison between liraglutide and biphasic insulin aspart 30 in obese patients with type 2 diabetes mellitus","Yan Shua","2014","World Clinical Drugs","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030989","Research Progress on Exendin-4","WU Hai-sheng","2013","Anhui nongye kexue","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030990","Exendin-4 improves abnormal expression of the per1 gene induced by A.BETA.(31-35) via antagonizing calcium overload in HT22 cells","Xueling Zhao","2016","Shenjing Jiepouxue Zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030991","LIRAGLUTIDE MENDS COGNITIVE IMPAIRMENT IN POLYCYSTIC OVARY SYNDROME IN RATS.","Muhammed A. Saad","2020","Journal of Applied Pharmacy","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030992","Overview of incretin-based therapy in type 2 diabetes mellitus","Isil Uyanik","2016","Scripta Scientifica Pharmaceutica","other","article","10.14748/ssp.v3i0.2447",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030993","Study on the Expression of Exendin-4 and Its activity to Decrease Plasma Glucose","Xiaochun Wang","2009","Pharmaceutical biotechnology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030994","Advance in clinical studies of new antidiabetic drugs","Zhai Suo-di","2010","Zhongguo xin yao zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030995","Novo Nordisk公司的GLP-1类似物的进展","景新","2004","国外药讯","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030996","Sitagliptin-associated Acute Pancreatitis: A Case Report","Le-Yu Tsai","2011","內科學誌","case_report","article","10.6314/jimt.2011.22(4).06",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030997","Role of GLP-1 analogues in cardiovascular","Nariman Fehmi","2020","Diabetes Case Reports","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0030998","Preparation and characterization of biotinylated Exendin-4 loaded alginate nanoparticles with enhanced peroral bioavailability","박찬웅","2009","한국고분자학회 학술대회 연구논문 초록집","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0030999","Эволюция агонистов рецепторов глюкагоноподобного пептида-1 в терапии сахарного диабета 2 типа","Галстян Гагик Радикович","2017","Сахарный диабет","other","article","10.14341/dm8804-6915",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031000","Albiglutide Potentially Beneficial in Type 2 Diabetes Management","Julio Rosenstock","2010","American family physician","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031001","新的降血糖又可減重和避免低血糖副作用的第2型糖尿病治療藥物－liraglutide（Victoza®）","張天鈞","2013","當代醫學","other","article","10.29941/mt.201301_(471).0003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031002","Research Progress of the Relationship between Liraglutide and Adiponectin","Wan Jie-ju","2014","Medical Recapitulate","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031003","Projected Cost-Effectiveness of Liraglutide, a Glucagon-Like Insulin Peptide-1Analogue in Comparison to Insulin Glargine in Type 2 Diabetes Patients withSuboptimal Glycaemic Control in Malaysia","Kamaruddin Na","2016","Medical economics","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031004","A Fixed Combination of Long-Acting Insulin and GLP-1 Receptor Agonist","Allan S. Brett","2016","Journal watch","randomized_trial","article","10.1056/nejm-jw.na40646",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031005","Clinical analysis of glargine and GLP-1 analogue in the treatment of type 2 diabetes mellitus","Yongqing Niu","2017","国际医药卫生导报","other","article","10.3760/cma.j.issn.1007-1245.2017.10.036",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031006","Dulaglutide and Cognitive Impairment in Type 2 Diabetes","Jennifer Rose V. Molano","2020","Journal watch","other","article","10.1056/nejm-jw.na52123",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031007","ПРИМЕНЕНИЕ ЛИРАГЛУТИДА ПОСЛЕ ПЕРЕСАДКИ ПОЧКИ У ПАЦИЕНТА С ВИРУСНЫМ ГЕПАТИТОМ С","Накоренок Анна Анатольевна","2013","Pacific Medical Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031008","Effects of GLP-1 on the gastrointestinal system","Yiming Mu","2010","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2010.06.031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031009","Clinical Observation of Liraglutide Combined with Metformin in Treatment of Patients with Type 2 Diabetes Complicated with Coronary Heart Disease","Yin Liu","2015","Zhongguo yaofang","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031010","Glucose-Lowering Effectiveness of a GLP-1 Agonist vs. an SGLT-2 Inhibitor","Allan S. Brett","2020","Journal watch","other","article","10.1056/nejm-jw.na52772",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031011","Latest Progress in the Drug Development of Glucagon-Like Peptide 1 Analogues","Kun Huang","2010","The Chinese Journal of Modern Applied Pharmacy","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031012","Effects of glucagon-like peptide-1 receptor agonist on transforming growth factor-β1/Smad signaling pathway in myocardium of diabetic rats","Lin Zhang","2013","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2013.06.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031013","Nearly and long-term clinical effect of exenatide in obese adolescents with abnormal glucose metabolism","Huang Zhao-su","2015","The Chinese Journal of Clinical Pharmacology","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031014","Dulaglutide Is Noninferior to Liraglutide in Metformin-Treated Patients with Type 2 Diabetes","Bruce Soloway","2014","Journal watch","other","article","10.1056/nejm-jw.na35191",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031015","Effects of glucagon-like peptide-1 on the expression of nicotinamide adenine dinucleotide phosphate oxidase subunits in the heart of type 1 diabetic rats","Yuan-xian Yu","2013","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2013.11.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031016","The research of the effects of glucagon-like peptide-1 on bone metabolism and central nervous system and its mechanism","Lu Liu","2016","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2016.06.019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031017","Effects of glucagon-like peptide-1 analogue (exendin-4) on the function of β-cell and insulin resistance in OLETF diabetic rats","Zhu Min","2005","Zhongguo tangniaobing zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031018","How GLP-1 analogues differ from sulphonylureas and DPP-4 inhibitors : advertorial","Greg Hough","2010","South African Journal of Diabetes","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031019","An Exploration on the New Anti-hyperglycemic Medicine","Ren Zhong-xi","2011","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031020","Possible Ways of Pharmacological Correction of Ischemic Liver Damage","Dovgan Ap","2018","Journal of Pharmaceutical and Biomedical Sciences","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031021","Exenatide treatment improves nonalcoholic fatty liver phenotype by regulation of PPARα and ACOX1","WU Jun-z","2014","Basic & Clinical Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031022","Effect of glucagon-like peptide 1 on autophagy mediated by AMP activated protein kinase-mammalian target of rapamycin pathway in type 2 diabetic rats with Alzheimer′s disease","Yihong Zhang","2019","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2019.10.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031023","Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes","Gail Mkele","2013","Pharmacy management","other","article","10.1080/20786204.2013.10874407",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031024","68Ga—exendin-4 PET／CT显像定位诊断胰岛素瘤","罗亚平","2017","中华核医学与分子影像杂志","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031025","Utilizzo di exenatide LAR in un paziente con diabete mellito tipo 2, ipertensione e iperlipemia","Antonio Staglianò","2014","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031026","Combining Basal Insulin and GLP-1 Agonists Is Effective in Advanced Type 2 Diabetes","Bruce Soloway","2014","Journal watch","other","article","10.1056/nejm-jw.na35784",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031027","Effect of exenatide on expression of Bcl-2 and Bax in myocardial tissues of rats with diabetes mellitus","GU Wen-yua","2014","Shandong yiyao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031028","RETROSPECTIVE ANALYSIS OF EXENATIDE TWICE DAILY COMPARED TO LONG-ACTING INSULIN ANALOGS IN A VETERAN POPULATION","Mark Bounthavong","2013","The 35th Annual Meeting of the Society for Medical Decision Making","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031029","Exenatide,a novel incretin mimetic hormone for type 2 diabetes","Xiao Zhi-mei","2006","Drug Evaluation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031030","Analysis of the Binding Site of the N-Terminal Fragment of Glucogan-Like Peptide-1 Receptor to exendin-4","Yushu Ma","2008","Huadong Li-Gong Daxue xuebao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031031","특집 : 인크레틴을 이용한 새로운 당뇨병 치료제","오승준","2011","The Korean Journal of Internal Medicine","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031032","Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DlO-rats","Gitte","2012","中国药理学报：英文版","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031033","Review Article and Clinical Experiences: A NOVEL OAD WITH BROADSPEACTRUM THERAPEUTIC VALUE FOR PTS WITH T2DM The Roles of Galvus® for Pts with T2DM, MODY,TxDM, Pre-DM, and T1DM","Askandar Tjokroprawiro","2009","Folia Medica Indonesiana","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031034","GLP-1R Agonists Associated with Weight Loss in Overweight Patients","Paul S. Mueller","2012","Journal watch","other","article","10.1056/jw201202160000003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031035","長鎖ペプチドのN末端特異的標識体の合成法開発- 68 Ga-DOTA-exenatide(1-39)-NH 2 の合成- | 文献情報 | J-GLOBAL 科学技術総合リンクセンター","長谷川功紀","2010","日本薬学会年会要旨集","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031036","Pancreatic Adenocarcinoma, Multiple Insular-Ductualr Alterations and Malignant PPoma in a Patient Treated With Glp-1 Analogs","Parviz M. Pour","2017","JOP, journal of the pancreas","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031037","Low rate of intensification in type 2 diabetic patients inadequately controlled with basal insulin: the INTERDIA study","Ronan Roussel","2016","Diabetes Management","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031038","Effect of glucagon-like peptide-1 agonist on expression of glucose transporter 4 in the skeletal muscle of rats with impaired glucose tolerance","Yuanxing Yang","2013","Chin J Endocr Surg","randomized_trial","article","10.3760/cma.j.issn.1674-6090.2013.03.004",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031039","Development of an Extended-Release Exenatide Once a Week Depot Formulation","Jabar A. Faraj","2020","Systematic Reviews in Pharmacy","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031040","Taspoglutide单药治疗新诊断2型糖尿病患者24周的疗效与安全性：随机、双盲、空白对照3期临床试验（T-emerge 1）","编辑部","2013","中国糖尿病杂志","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031041","New Therapeutics for Diabetes Using Incretin Hormone","Seungjoon Oh","2011","The Korean Journal of Internal Medicine","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031042","Exenatide Weaks Tumor Angiogenesis within Endometrial Cancer Ishikawa Xenografts inNude Mice","Yu Zhang","2017","Journal of Sun Yat-sen University","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031043","Effects of liraglutide on weight reduction and metabolic parameters in obese patients with and without type 2 diabetes mellitus","E. A. García-Cantú","2014","Medicina Universitaria","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031044","Новые возможности достижения целевого гликемического контроля у пациентов с сахарным диабетом 2 типа с использованием комбинированной терапии лираглутидом и инсулином детемир: основания для альянса","Руяткина Людмила Александровна","2017","Сахарный диабет","randomized_trial","article","10.14341/dm8296-6397",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031045","Liraglutide regulates endothelial nitric oxide synthase through inhibiting phosphorylation of nuclear factor-kappa B in human umbilical vein endothelial cells","Yao Dai","2014","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2014.09.012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031046","Effects of human glucagon-like peptide-1 analog gene on metabolism conditions in diabetic rats","Zhizhen Zhang","2010","Zhongguo sheng-hua yaowu zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031047","Oral Semaglutide for Type 2 Diabetic Patients at High Cardiovascular Risk","Allan S. Brett","2019","Journal watch","randomized_trial","article","10.1056/nejm-jw.na49344",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031048","How Do Incretin-Based Therapies Fit Into the Treatment Algorithm?","Su-Ynn Chia","2011","The Singapore Family Physician","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031049","The Prospect of Islet Cell Regeneration for Diabetes Treatment","Yang Ta","2011","Medicine & Philosophy(Clinical Decision Making Forum Edition)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031050","Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry","Jin-feng","2013","药物分析学报：英文版","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031051","Effect of Exenatide on Serum Oxidative Stress and Heart Rate Viability in Diabetic Autonomic Neuropathy Patients","Lanxia Meng","2013","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031052","Incretin Mimetic Outperforms Sulfonylurea in Early Type 2 Diabetes","Bruce Soloway","2009","Journal watch","other","article","10.1056/jw200902240000001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031053","Effects of glucagon-like peptide-1 receptor agonists on apoptosis of pancreatic β cells in impaired glucose tolerance rats","Xiaoli Li","2011","Chin J Diabetes Mellitus","randomized_trial","article","10.3760/cma.j.issn.1674-5809.2011.06.009",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031054","A novel beneficial effect of liraglutide: the reduction in subclinical atherosclerosis in patients with type-2 diabetes","Michelle Rizzo","2012","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031055","A Two-step Exendin-4 PEGylation Process for the Treatment of Type-2 Diabetes","Thanh Nguyen Thi Ngoc","2013","한국생물공학회 학술대회","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031056","Incretin-based therapies","Sten Madsbad","2009","11th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031057","Efficacy and safety of liraglutide versus insulin in overweight and obese patients with type 2 diabetes mellitus","Rui Chen","2013","Chin J Diabetes Mellitus","randomized_trial","article","10.3760/cma.j.issn.1674-5809.2013.05.005",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031058","Another Study of Semaglutide for Weight Reduction","Allan S. Brett","2021","Journal watch","other","article","10.1056/nejm-jw.na53286",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031059","Liraglutide and exenatide treatment for obese type 2 diabetes:clinical analysis of 42 cases","Kun Qu","2015","Zhongguo shiyong neike zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031060","Once-Weekly GLP-1 Receptor Agonists Compared: A Network Meta-Analysis","Jamaluddin Moloo","2015","Journal watch","systematic_review","article","10.1056/nejm-jw.na39810",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0031061","An Oral Glucagon-Like Peptide-1 Agonist for Glycemic Control and Weight Loss","Bruce Soloway","2019","Journal watch","other","article","10.1056/nejm-jw.na49338",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031062","Research Advances of Peptides Counteracting Diabetes Mellitus","WU Wu-tong","2012","Pharmaceutical biotechnology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031063","Differentiation of bone marrow mesenchymal stem cells into insulin producing cells by liraglutide and effect on type 1 diabetes rats","Zhulin Shao","2014","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2014.03.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031064","Case Report : Exenatide Combined with Metformin and Glimepiride Allows Successful Weaning from Insulin in an Obese Diabetic Patient with Klinefelter Syndrome","Yoshio Nagai","2014","Journal of St Marianna University","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031065","A unique approach for oral administration of GLP-1 receptor agonist by using ionic liquids","Takaya Sunami","2021","The Pharmaceutical Society of Japan","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031066","Recent progress on exendin-4,a novel therapeutic drug for diabetes","Zhufang Shen","2008","The Chinese Journal of Clinical Pharmacology","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031067","Liraglutide Facilitates Weight Reduction in Nondiabetic Patients","Allan S. Brett","2015","Journal watch","other","article","10.1056/nejm-jw.na38304",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031068","VivoTag-S 750-(S)-2-amino-4-pentynoic acid12-exendin-4","Kam Leung","2012","National Center for Biotechnology Information (US) eBooks","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0031069","Advances in the research of the drugs targeting glucagon-like peptide-1 receptor","Zhufang Shen","2009","Zhongguo xin yao zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031070","Новые показания к терапии эксенатидом у больных сахарным диабетом 2 типа с ожирением","Викулова Ольга Константиновна","2010","Сахарный диабет","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031071","The molecular mechanism of human glucagon-like peptide-1 analog liraglutide on pancreatic beta-cell preservation in obese diabetic model db/db mice.","将司 下田","2010","Kawasaki medical journal","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031072","Exenatide, a New Drug for Type 2 Diabetes","Allan S. Brett","2005","Journal watch","other","article","10.1056/jg200506140000012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031073","The Potential Role of GLP-1 Analogues in Cardiovascular Disease Outcome","Nariman Fahmy Wagih","2021","Journal of Diabetes & Metabolism","other","article","10.35248/2155-6156.21.12.883",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031074","GLP-1 receptor agonistの血管リモデリングに与える影響の検討 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター","西雄千佳","2010","日本血管生物医学会学術集会プログラム・抄録集","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031075","Hypoglycemic effect of a new Exenatide analog in rats with type 2 diabetes mellitus","Shijie Yang","2010","Zhongguo xin yao zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031076","Effect of lansoprazole and exenatide on gastrin and oxyntomodulin in patients with type 2 diabetes","Hanbin Li","2015","Journal of Shandong University","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031077","Preparation and preliminary analysis of activity of recombinant GLP-1 analogue","Jingjing Liu","2011","Zhongguo yaoke daxue xuebao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031078","Nursing of patients with type 2 diabetes mellitus using exenatide targets site treatment","陆群","2012","˜The œJournal of practical nursing","other","article","10.3760/cma.j.issn.1672-7088.2012.25.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031079","The sympathetic nervous system mechanism of exendin-4 in respect of modulating T cell- mediated immune response to severe burns in mice","Xiaojing Ji","2017","Zhonghua jizhen yixue zazhi","preclinical","article","10.3760/cma.j.issn.1671-0282.2017.06.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031080","A clinical analysis on replacement therapy with exenatide for type 2 diabetic patients treated with insulin","Shinan Yin","2012","Shanxi Yike Daxue xuebao","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031081","Effects of Exendin-4 on Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Renal Tissue of Type 2 Diabetic Rats","Geng Yan","2010","Guide of China Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031082","Efficacy of liraglutide on obese type 2 diabetes patients with poor response to combinations with a variety of drugs","Ya Wang","2014","Hainan yixue","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031083","Инкретины сегодня: множественные эффекты и терапевтический потенциал","Цыганкова Оксана Васильевна","2019","Сахарный диабет","other","article","10.14341/dm9841-7514",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031084","Mechanism and countermeasurement of traumatic stress hyperglycemia","Xiangwen Wang","2017","Chin Arch Gen Surg(Electronic Edition)","other","article","10.3877/cma.j.issn.1674-0793.2017.05.017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031085","インスリングラルギン/リキシセナチド配合注射薬の特徴―iCGM を用いたインスリンデグルデク/リラグルチド配合注射薬との比較―","宮川高一","2021","Therapeutic research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031086","Process Characteristics of Aqueous-Phase, Two-Step PEGylation of Exenatide","Nguyen Thi Ngoc Thanh","2015","한국생물공학회 학술대회","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031087","Development of bio-similar to exendin-4, a major drug for type 2 diabetes","Sunit Maity","2015","Journal of Bioanalysis & Biomedicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031088","Preparation of exendin-4 microspheres and its release properties in vitro","Chen Li","2014","Northwest Pharmaceutical Journal","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031089","Comparison of efficacy and safety of liraglutide and glimepiride in combination with metformin in type 2 diabetes","Wenying Yang","2011","Chin J Diabetes Mellitus","randomized_trial","article","10.3760/cma.j.issn.1674-5809.2011.06.004",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031090","Effects of incretin- based therapies on diabetic nephropathy","Xi Zhang","2015","Dalian Yike Daxue xuebao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031091","The Associations Between Liraglutide and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes : A Meta-analysis","Young Ho Lee","2020","Journal of Korean Society of Health-System Pharmacists","systematic_review","article","10.32429/jkshp.2020.37.4.006",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0031092","Protective effects of glucagon-like polypeptide 1(GLP-1),GLP-1 mimetics and dipeptidyl peptidase IV on pancreatic function","Liu Cha","2008","International Journal of Internal Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031093","Efficacia e Sicurezza a Lungo Termine di Exenatide a Rilascio Prolungato in paziente affetta da diabete mellito tipo 2 e sindrome metabolica","Francesco Caraffa","2016","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031094","Determination of Exenatide in Exenatide for Injection by HPLC","Yan Chen","2009","China Modern Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031095","利拉鲁肽抑制高糖诱导大鼠肾小球系膜细胞系TNF-α和ICAM-1表达","孟凡东","2012","基础医学与临床","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031096","Diabetic Patients Fasting During Ramadan: Ten Years Overview","Adnan Zaina","2016","Diabetes Management","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031097","New diabetes drug up against leading brands","Christine Blank","2016","Formulary ENews","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031098","Effects of saxagliptin combined with liraglutide on glycolipid metabolism and insulin function in patients with abdominal obesity and type 2 diabetes mellitus","Lin Liu","2019","Central Plains Medical Journal","nonrandomized_study","article","10.3760/cma.j.issn.1674-4756.2019.09.034",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031099","Comparison of glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mettilus","Tian-hong Luo","2012","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2012.09.021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031100","The clinical application in early stage diabetes:Results of LIRA-DPP-4i research","Chen Lu-l","2011","Zhongguo tangniaobing zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031101","Current and Future Biotechnological Approaches for Diabetes Mellitus","Tanushree Chatterjee","2011","Asian Journal of Pharmacy and Technology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031102","GLP-1及其受体激动剂Exendin-4临床适应症的扩展","王晓婧","2010","生物技术通报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031103","Semaglutide Passes Cardiovascular Safety Test in Patients with Type 2 Diabetes","Harlan M. Krumholz","2016","Journal watch","other","article","10.1056/nejm-jw.na42363",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031104","Nuove frontiere terapeutiche degli agonisti recettoriali del GLP-1","Antonio Ceriello","2014","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031105","Construction of Recombinant Expression Vector and Secretion Expression of Exendin-4 in E.coli","Chengwei Li","2009","Journal of Henan Normal University","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031106","Liraglutideとの比較からみたDuodenal-Jejunal Bypassの糖尿病/NASH改善効果に関する実験的研究","柏原秀也","2013","日本消化器病学会雑誌","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031107","Neuroprotective role of（Val^8）GLP-1-Glu-PAL in an in vitro model of Parkinson＇s disease","Lin -","2016","中国神经再生研究：英文版","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031108","Short-term Treatment of Liraglutide in Patient with Prader-Willi Syndrome","Chong Kun Cheon","2019","58th Annual ESPE Meeting (ESPE 2019)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031109","Liraglutide, the first once-daily human GLP-1 receptor analogue","Sten Madsbad","2009","Avances en Diabetología","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031110","EFFECTS OF EXENATIDE ON OBESITY TYPE 2 DIABETES","Yan Wang","2013","Acta Academiae Medicinae Qingdao Universitatis","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031111","Preparation of sustained-release microspheres containing exenatide and their in vitro release","Zhong Yan-qiang","2011","Academic Journal of Second Military Medical University","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031112","Controlled release of pyrimidine compound using polymeric coated zif-8 metal-organic framework as glucagon-like peptide-1 receptor agonist carrier","Ruba Al‐Ajeil","2021","Journal of Pharmacognosy & Natural Products","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031113","Clinical efficacy of dapagliflozin combined with liraglutide in the treatment of type 2 diabetes mellitus with metabolic syndrome","Li Gao","2021","Linchuang huicui","other","article","10.3969/j.issn.1004-583x.2021.07.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031114","Subcutaneous injection of exendin-4 for weight reduction in rats","Ning Gong","2006","Medical Journal of the Chinese People's Armed Police Forces","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031115","Effects of liraglutide on proliferation and apoptosis in human umbilical cord mesenchymal stem cells","Xiangjin Xu","2017","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2017.01.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031116","增泌素(Incretin)類藥物治療第2型糖尿病之臨床實證","蕭淑華","2007","內科學誌","other","article","10.6314/jimt.2007.18(4).03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031117","Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: A pilot study","Juan Carlos Palma","2018","Journal of Clinical and Molecular Endocrinology","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031118","Incretin mimetics and drugs increasing the level of endogenous incretins in the treatment of type 2 diabetes mellitus","Anna Czech","2009","Przewodnik Lekarza/Guide for GPs","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031119","Dulaglutide as a Substitute for Long-Acting Insulin in a Basal-Bolus Regimen?","Bruce Soloway","2015","Journal watch","other","article","10.1056/nejm-jw.na38260",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031120","Liraglutide, an incretin mimetic : drug trends","Duma Khutsoane","2012","˜The œSouth African journal of diabetes & vascular disease","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031121","Clinical Use of GLP-1 and Related Preparations","Caiping Li","2010","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031122","POLYCYSTIC OVARY SYNDROME WITH METABOLIC SYNDROME","Zinnat ara nasreen Shaikh","2021","Journal of medical case reports and reviews","nonrandomized_study","article","10.15520/jmcrr.v4i06.257",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0031123","Zinc-finger BED domain-containing 3 expression in tissues of various organs in normal C57BL/6J mice and the changes in the ZBED3 expression levels affected by liraglutide in C57BL/6J mice and db/db mice","潘红霞","2014","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2014.08.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031124","Cardiovascular Outcomes with Another GLP-1 Receptor Agonist","Allan S. Brett","2021","Journal watch","other","article","10.1056/nejm-jw.na53801",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031125","GLP-1 receptor agonists in the management of Type 2 Diabetes","Lynn Lambert","2016","Pharmacy management","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031126","Effects of exenatide on autophagy and occurrence of brown adipocytes for white adipose tissue in obese rats","Bin Huang","2016","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2016.02.005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031127","Glucagon-like Peptide-1 and Gene Therapy of Diabetes Mellitus","Zhizhen Zhang","2008","Yixue fenzi shengwuxue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031128","Incretin mimetics : where will they make a difference? : achieving best practice","Adri Kok","2010","˜The œSouth African journal of diabetes & vascular disease","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031129","Effects of Once-Weekly Exenatide on Cardiovascular Outcomes","Allan S. Brett","2017","Journal watch","other","article","10.1056/nejm-jw.na45069",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031130","Effect of liraglutide on serum AGEs and inflammatory factors in IGT-OLETF rats","Li Yang","2013","Jiefangjun yixue zazhi","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031131","Insulin-related weight gain in patients with type 2 diabetes : case examples, mechanisms and an approach to management : review","David Webb","2013","˜The œSouth African journal of diabetes & vascular disease","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031132","Expression,Purification and Bioactivity of Prodrug of Recombinant Human GLPs","Xiaoxing Luo","2009","Zhōnghuá yàoxué zázhì","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031133","Liraglutide and Cardiovascular Outcomes in Patients with Long-Standing Type 2 Diabetes","Allan S. Brett","2016","Journal watch","randomized_trial","article","10.1056/nejm-jw.na41592",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031134","Glucagon-like peptide-1 receptor agonist for polycystic ovary syndrome","Xiaobo Zhang","2017","国际医药卫生导报","other","article","10.3760/cma.j.issn.1007-1245.2017.07.036",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031135","FDA approves once-weekly GLP-1 receptor agonist for type 2 diabetes","Gretchen L Schwenker","2014","Drug Topics E-News","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031136","Protective Effects on Hypoxia Reoxygenation Cardiomyocytes by GLP-1R Agonists via PI3K/AKT Signaling Pathway","Ling Xue","2020","International journal of gerontology","other","article","10.6890/ijge.202008_14(3).0004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031137","Liraglutide: reduction of weight and visceral fat may benefit the comprehensive management of type 2 diabetes","Dajin Zou","2013","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2013.07.027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031138","exendin-4 ji qi jie gou gai zao de yan jiu jin zhan","Zhang Meiyou","2010","Northwest Pharmaceutical Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031139","Victoza for weight management - implications for use in Pakistan -","Haider Ghazanfar","2016","Rawal Medical Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031140","Outcomes of Obese Patients with Type 2 Diabetes Following Treatment with Insulin Alone or in Combination with Liraglutide","Yan Niu","2014","Zhongguo quanke yixue","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031141","Exenatide LAR al posto di insulina glargine in paziente affetta da diabete mellito tipo 2, obesità, ipertensione arteriosa e dislipidemia mista","Francesco Caraffa","2015","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031142","IDegLira (insulina degludec/liraglutide): una nuova opportunità terapeutica per il paziente affetto da diabete tipo 2","Paola Ponzani","2018","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031143","Infection of adenovirus containing GLP-1R gene into mouse mesenchymal stem cells in vitro","Xiaohong Wu","2012","Acta Universitatis Medicinalis Nanjing","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031144","Progress in clinical studies of liraglutide","Yong‐Xiang Wang","2013","World Clinical Drugs","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031145","Studies on the Expression of Exendin-4-Tβ4 Fusion Protein in Pichia pastoris","Chengwei Li","2010","Journal of Southwest University","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031146","Effects of liraglutide on the cognitive function in patients with type 2 diabetes mellitus and the underlying mechanism","Meng Zhang","2014","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2014.02.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031147","Cardiovascular Outcomes with Newer Antidiabetes Drugs","Paul S. Mueller","2016","Journal watch","randomized_trial","article","10.1056/nejm-jw.na43024",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031148","Protective effect and mechanism of liraglutide on aorta endothelial cells in Zucker diabetic fatty rats","Li Cai","2017","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2017.09.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031149","GLP-1 agonists: a novel treatment for South African diabetic patients","Bernd Rosenkranz","2010","˜The œSouth African journal of diabetes & vascular disease","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031150","Relationship between weight loss and HbA1c during treatment with exenatide in diabetic type 5obese.","Martin Buysschaert","2010","Digital Access to Libraries","other","article","10.1016/s1262-3636(10)70110-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031151","药物安全性监察/FDA强调TNF-抑制剂皮肤反应","黄敏燕","2008","国外药讯","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031152","GLP-1 receptor agonists in the management of Type 2 Diabetes : review","Lynn Lambert","2016","Pharmacy management","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031153","Eexperimental study of exendin-4 for weight reduction in obese rats","Zheng Jing-che","2007","Medical Journal of the Chinese People's Armed Police Forces","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031154","Prospective of long-acting GLP-1 receptor agonists for the therapeutics","Kang Choon Lee","2016","Journal of Metabolic Syndrome","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031155","Liraglutide ameliorates steatosis of hepatocytes through adipose triglyceride lipase pathway","Kaikai Meng","2017","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2017.05.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031156","胰高血糖素样肽-1及其类似物EX-4促进大鼠骨髓间充质干细胞的增殖与成骨分化","周诗萌","2015","中国临床药理学与治疗学","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031157","GLP－1 受容体作動薬リラグルチドの臨床使用―リラグルチドのベネフィットの最大化に向けて―","浜野久美子","2011","Therapeutic research","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031158","Цукровий діабет 2-го типу і хронічна хвороба нирок: сучасні можливості цукрознижувальної терапії","О.М. Didushko","2020","Практикуючий лікар","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031159","Effect of liraglutide in long-term clinical remission after intensive therapy in newly-diagnosed type 2 diabetes mellitus","Yanjun Shen","2017","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2017.09.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031160","History and development of incretin effect: the evidence and promise of incretin-based therapies in the clinical practice","Tianpei Hong","2018","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2018.08.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031161","The effect of liraglutide on the expression of nuclear factorkappa B and monocyte chemoattractant protein-1 in human umbilical vein endothelial cells","Yan Zhang","2013","Zhongguo xiandai yixue/Zhongguo xiandai yixue zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031162","Zastosowanie leków inkretynowych w leczeniu cukrzycy typu 2 z powikłaniami sercowo-naczyniowymi","Piotr Barczyński","2013","Choroby Serca i Naczyń","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031163","日本人2 型糖尿病患者を対象としたデュラグルチドの安全性および有効性の検討―デュラグルチド0.75 mg 特定使用成績調査中間報告―","陳 里菜","2021","薬理と治療","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031164","Biodistribution, pharmacodynamics and pharmacokinetics of oral delivery of exendin-4 using pH-sensitive nanoparticles","阮胡玉","2010","清華大學化學工程學系學位論文","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031165","Inkretin-basierte Therapie: ein ergänzender Therapieansatz bei Patienten mit Typ-1-Diabetes?","Baptist Gallwitz","2015","Diabetologie und Stoffwechsel","other","article","10.15496/publikation-7147",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031166","Exenatide の薬理作用―中枢作用に関連する最近の報告―","中里 雅光","2015","薬理と治療","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031167","A STOCHASTIC MODEL BY THE BIRTH AND DEATH PROCESS OF IRREDUCIBLE STATIONARY PROBABILITIES FOR THE GLP-1.","D. SargunaSundari","2021","Journal of Cardiovascular Disease Research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031168","Liraglutide inhibits the proliferation of MCF-7 breast cancer cells in vitro","Zhao Lin-li","2014","Yixue yanjiusheng xuebao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031169","Biochemical Effects of Anti-Diabetic Therapies on Obesity and Insulin Resistance Induced by Monosodium Glutamate in Male Rats","Sherin M. Khodier","2020","Systematic Reviews in Pharmacy","preclinical","article","10.31838/srp.2020.11.33",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031170","Liraglutide, a novel GLP-1 analogue","Stan Landau","2010","South African Journal of Diabetes","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031171","Secretion of extracellular matrix were inhibited by Exendin-4 treatment through MAPK-NF-κB related inflammation in high glucose-induced glomerular mesangial cells","Xiaolu Lin","2017","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2017.03.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031172","Industrial Info. ヒトGLP-1アナログ製剤 Liraglutide(リラグルチド)開発の経緯","泰之 片山","2008","細胞","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031173","The Therapeutic Effect of the Induced Insulin Secreting Cells on Rat Diabetes","Wang Chang-jun Yuan Feng-shan","2011","Zhongguo shengwu gongcheng zazhi","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031174","Effects of liraglutide on level of serum nesfatin-1 and inflammatory factors in newly diagnosed obese patients with type 2 diabetes mellitus","Ting Zhu","2018","Int J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2018.06.002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031175","Glucagon like peptide-1 receptor agonist in the treatment of polycystic ovary syndrome","Guanhua Qiao","2017","Int J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2017.03.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031176","Glucagon-like peptide-1 protects the apoptosis of pancreatic β cells induced by endoplasmic reticulum stress","Feifei Zhang","2011","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2011.05.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031177","Anti-Diabetic Activity of Purified EW,an Exendin-4 Analogue","Lin Tang","2014","Zhongguo linchuang yixue","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031178","De la patogénesis al tratamiento de la diabetes tipo 2. El paradigma de la rata GK","Bernard Portha","2007","Anales de la Real Academia Nacional de Farmacia","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031179","Pharmaceutica 2016 Conference: Strategic PEGylation: Half-life extension of biologic drugs - Kang Choon Lee - SungKyunKwan University","Kang Choon Lee","2016","Journal of Drug Delivery and Therapeutics","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031180","Clone of Exendin-4 cDNA gene by overlap extension PCR and its sequence analysis","Feng Wang","2013","China Medical Herald","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031181","Research progress on long-acting glucagon-like peptide-1 receptor agonists","Weicheng Zhou","2010","World Clinical Drugs","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031182","The drug release kinetic and biocompatibility of biocompatible polysaccharide depot for delivery of type II diabetes drug","Hyun-Jung Yang","2008","한국당과학회 학술대회","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031183","Progress of Glucagon-like Peptide-1","Li Jin","2014","Strait Pharmaceutical Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031184","Liraglutide improves lipid metabolism in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease","Qiu Wei-zhon","2015","Acta Medicinae Sinica","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031185","新型糖尿病治疗药物-肠降血糖素类似物依克那肽（Exenatide）","阮健","2006","药品评价","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031186","胰高血糖素样肽－1类似物(JC003)对糖尿病大鼠血糖及胰岛功能的影响","于婷","2007","西安交通大学学报：医学版","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031187","Effectiveness of exendin-4 on blood glucose level of Streptozotocin-induced diabetic mice","Min Hu","2004","Shanghai yixue","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031188","Терапия, основанная на инкретинах: почечные эффекты","Корбут Антон Иванович","2016","Сахарный диабет","other","article","10.14341/dm7727-5621",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031189","Liraglutide, an Incretin Mimetic, Aids Weight Loss in Nondiabetic Patients","Bruce Soloway","2009","Journal watch","other","article","10.1056/jw200911240000005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031190","SP-Exendin-4 transduction needed for successful islet cell cluster transplantation","Simmyung Yook","2010","한국생물공학회 학술대회","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031191","GLP-1 Receptor Agonists: dalla farmacologia alla pratica clinica Report dal XXV Congresso Nazionale della Societa Italiana di Diabetologia, Bologna 29 Maggio 2014","Maria Chiara Rossi","2014","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031192","Liraglutide Might Prevent Progression to Diabetes","Bruce Soloway","2017","Journal watch","other","article","10.1056/nejm-jw.na43586",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031193","Effect of nicotinamide and Exendin-4 on transdifferentiation of rat bone marrow mesenchymal stem cells (BM-MSCs) into insulin-producing cells","Xiaodong Mao","2006","Zhongguo tangniaobing zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031194","Progression of exenatide and its analogs","Han Wei-yue","2008","International Journal of Pathology and Clinical Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031195","Administration of the glucagon-like peptide-1 receptor agonist liraglutide before ischemia or just after reperfusion protects against myocardial stunning in swine","Itsuko Shibata","2018","Japanese Society of Anesthesiologists","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031196","長鎖ペプチドのN末端特異的標識体の合成法開発- 68 Ga-DOTA-exenatide(1-39)-NH 2 の合成-","長谷川功紀","2010","日本薬学会年会要旨集","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031197","Direct Comparison of Long-Acting Exenatide vs. Liraglutide","Bruce Soloway","2012","Journal watch","other","article","10.1056/jw201211290000005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031198","Первый аналог человеческого глюкагоноподобного пептида-1: эффекты лираглутида по данным клинических исследований","Аметов Александр Сергеевич","2011","Сахарный диабет","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031199","Liraglutide and Exendin-4 postconditioning in both WKY and SHR-SP rats with left ventricular hypertrophy","Barbara Faricelli M Salomonsson A Consoli T Engstroem","2013","Journal of Clinical & Experimental Cardiology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031200","Когнитивные нарушения у больных сахарным диабетом 2 типа: распространенность, патогенетические механизмы, влияние противодиабетических препаратов","Остроумова Ольга Дмитриевна","2018","Сахарный диабет","other","article","10.14341/dm9660-7371",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031201","グルカゴン様ペプチド-1受容体作動薬exendin-4による内皮細胞への単球接着阻害およびアテローム硬化病変の改善","Masayuki Arakawa","2010","Diabetes","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031202","More About Incretin-Based Diabetes Drugs and Heart Failure","Allan S. Brett","2016","Journal watch","other","article","10.1056/nejm-jw.na40812",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031203","Effect of exendin-4 on the expression of survivin in pancreas in streptozotocin-induced diabetic mice","Hua Cheng","2009","Zhongguo yaolixue tongbao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031204","Pharmacology of oral hypoglycemic drugs","Miroslav M. Savić","2011","FarFar (University of Belgrade, Faculty of Chemistry (Belgrade, Serbia))","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031205","Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-KB pathway","Ge-fei","2014","中国药理学报：英文版","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031206","Effects of Exenatide Treatment on Remission Period of Patients with Type 2 Diabetes","Jing Feng","2012","Zhongguo yaofang","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031207","Neuer GLP-1-Agonist: Direktvergleich in Phase-III",null,"2011","Info Diabetologie","other","article","10.1007/bf03359334",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031208","Oral and Injectable (Non-Insulin) Pharmacological Agents for Type 2 Diabetes","Kenneth R. Feingold","2000",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031209","NT 2148 - Soliqua","Natjus Tjmg","2021",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031210","Taspoglutide","A. Arjona","2008","Drugs of the Future","other","article","10.1358/dof.2008.033.011.1277240",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031211","Exenatide 141758‐74‐9",null,"2012","Sax's Dangerous Properties of Industrial Materials","other","article","10.1002/0471701343.sdp37790",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0031212","An Overview of Allopathic Medicines in the Treatment of Diabetes Mellitus","Annie Annie","2019","Indo Global Journal of Pharmaceutical Sciences","other","article","10.35652/igjps.2019.92s32",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031213","Clinical Use of GLP-1 Analogue (Exenatide)in Obese Type 2 DM Taiwanese","李國陽","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031214","Study on the Treatment of Type 2 Diabetes with Dapagliflozin Combined with Liraglutide",null,"2022","Foreign Language Science and Technology Journal Database Medicine and Health","other","article","10.47939/mh.v3i2.221",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031215","Langwirksames Exenatide in Sicht",null,"2010","CME","other","article","10.1007/bf03360271",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031216","Liraglutide and linagliptin improve glycemic control but show differential anti-obesity and hypolipidemic efficacy in a novel hamster model of diet-induced obesity and hypercholesterolemia","H.B. Hansen","2012","Regulatory Peptides","other","article","10.1016/j.regpep.2012.05.039",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031217","Prédiabète: Liraglutide pour faciliter la perte de poids?","Antoine de Torrenté","2017","Forum Médical Suisse ‒ Swiss Medical Forum","other","article","10.4414/fms.2017.03010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031218","EFFECTIVENESS OF NESTING ON POSTURE AND MOTOR PERFORMANCE AMONG HIGH RISK NEWBORN.","K. Jeyabarathi","2018","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.2387741",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031219","Brain Glucagon-Like Peptide 1 Receptor Influence on Feeding Behavior","Diana L. Williams","2021",null,"preclinical","article","10.1201/9780367823269-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031220","Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs","Thomas A. Zelniker","2018",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031221","Liraglutide Fosters Weight Loss in Nondiabetics","ELIZABETH MECHCATIE","2009","Family Practice News","other","article","10.1016/s0300-7073(09)70929-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031222","Semaglutide reduces the risk of major kidney disease events in patients with type 2 diabetes","G. White","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002314",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031223","Pharmacy bodies warn that demand for weight-loss drug will outstrip supply",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.361932",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031224","Injectable liraglutide can help obese type 2 diabetics lose weight",null,"2015","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2015.20069188",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031225","REDDIE WP4 Analysis plan Germany: GLP1-RA versus DPP4 and metabolic outcomes","Lanzinger, Stefanie","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15303501",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031226","Treatment of Diabetes Mellitus in Children and Adolescents","Mabel Yau","2021",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031227","Liraglutide (Victoza) - the first once-daily human GLP-1 receptor analogue","Sten Madsbad","2009","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031228","Solid‐State Materials in Pharmaceutical Chemistry",null,"2025",null,"other","article","10.1002/9781394254484",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0031229","Taspoglutide","A. Arjona","2008","Drugs of the Future","other","article","10.1358/dof.2008.033.11.1277240",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031230","Liraglutide cost saving versus sitagliptin for T2DM",null,"2018","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-018-5058-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031231","Dulaglutide launched in the UK as once-weekly diabetes treatment",null,"2015","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2015.20067568",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031232","Avaliação do efeito do liraglutida nos tecidos muscular e adiposo e nos parâmetros bioquímicos em camundongos Swiss submetidos à dieta de cafeteria e a atividade física","Cybelle de Arruda Navarro Silva","2014",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031233","Management of Type 2 diabetes with liraglutide","Mette Bohl","2014","Diabetes Management","other","article","10.2217/dmt.13.72",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031234","Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized Trial","J.L. Leahy","2006","Yearbook of Medicine","randomized_trial","article","10.1016/s0084-3873(08)70593-5",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031235","Liraglutide has less adverse cardiovascular outcomes than placebo","Anne Mounsey","2017","Evidence-Based Practice","other","article","10.1097/01.ebp.0000541757.33330.e3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031236","Type 2 Diabetes: Causes, Symptoms, Diagnosis & Proven Management Strategies","Ben Taylor, Ben","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17061512",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031237","FDA Wants Controlled tQT Study of Long-Acting Exenatide","Emily Hayes","2010","Family Practice News","other","article","10.1016/s0300-7073(10)71211-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031238","Semaglutide in obesity-related heart failure with preserved ejection fraction","Kimberly Rowghani","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002273",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031239","Nurses education project management tools to help introduce the practice of the administration of parenteral incretin mimetics","Dihelné Tóth Anikó","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031240","GLP-1 Receptor Activation by Exenatide Induces Expansion of Pancreatic Duct Glands","Belinda Gier","2011",null,"other","article","10.1210/endo-meetings.2011.part2.p8.p1-485",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031241","Sustained Delivery of GLP-1 Receptor Agonists for The Treatment of Diabetes","Chang, Enmian","2022","Brown Digital Repository","other","article","10.26300/fw28-wz80",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031242","You make the choice, clinical decision making in diabetes: Use of GLP-1 receptor agonists in clinical practice",null,"2013","Osteopathic Family Physician","other","article","10.1016/j.osfp.2012.10.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031243","Mildly symptomatic liraglutide-induced acute pancreatitis in a patient with type 2 diabetes mellitus: a case report","Mohammed Ali Gameil","2020","Greater South Information System","case_report","article","10.60692/k8bjg-9qx84",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031244","Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis","Mohammed Ashraf Ali","2022","Greater South Information System","systematic_review","article","10.60692/jy4g6-nhn57",null,null,"PROSPERO:CRD42021257670",null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0031245","IDegLira cost effective for T2DM uncontrolled on basal insulin",null,"2017","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-017-4267-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031246","Liraglutide","Baptist Gallwitz","2008","Drugs of the Future","other","article","10.1358/dof.2008.033.01.1164951",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031247","Semaglutide for weight loss; another competitor for the “biggest loser”","Marianne Koenig","2022","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001596",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031248","Patients must be encouraged to ‘Talk Hypos’","Klaus H. Jensen","2015","Diabetes Management","other","article","10.2217/dmt.14.56",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031249","Machine learning to predict weight loss with dulaglutide in women with overweight or obesity","J. Belkhouribchia","2025","Clinical Nutrition ESPEN","other","article","10.1016/j.clnesp.2025.07.825",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031250","GLP-1s May Do More Than Just Lower Glucose","Mark L. Fuerst","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031251","Daily GLP-1 receptor agonist pill leads to ‘significant’ weight loss",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","randomized_trial","article","10.1211/pj.2025.1.374505",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031252","Amendment to development and license to sell and commercially dispose of the 'Exenatide LAR' products.","RoyaltyStat","2019","RoyaltyStat Library","other","article","10.34675/l31520",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031253","Semaglutide for weight loss in obesity","RA Middelburg","2021","Geneesmiddelenbulletin","other","article","10.35351/gebu.2021.9.17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031254","Treatment of type 2 diabetes mellitus by drugs modulating the incretin system","Zafar H. Israili","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031255","The Effects of Incretin Mimetic Exenatide and DPP-4 Inhibitor Sitagliptin in Experimental Mild Acute Pancreatitis","Felix Felix","2013","Journal of Clinical and Laboratory Investigation Updates","other","article","10.14205/2310-9556.2013.01.02.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031256","Increased risk of pancreatitis reported with use of GLP-1 drugs","From staff reports","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031257","Figure 18, Change in Body Weight over the Course of Study for the 82-week Exenatide Completer Cohort and the Intent-to-Treat Population","Patricia S Juang","2013",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031258","Komentář ke studii LEADER","Jindřich Olšovský","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031259","Stimulation of Insulin Secretion by a Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist in Rodent and Human Islets.","KW Sloop","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","preclinical","article","10.1210/endo-meetings.2010.part1.p10.p1-479",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031260","Using Bydureon",null,"2012","Clinical Diabetes","other","article","10.2337/diaclin.30.3.134",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031261","New therapies for type 2 diabetes: Glucagon-Like Peptide 1 (GLP-1) analogs and Dipeptidyl Peptidase-4 inhibitors","Concetta Irace","2007","IRIS Research product catalog (Sapienza University of Rome)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031262","AKT question relating to prescribing tirzepatide","Anish Kotecha","2025","InnovAiT Education and inspiration for general practice","other","article","10.1177/17557380251360588d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031263","Degludec liraglutide combination improves glucose control in type 2 diabetes",null,"2016","Clinical pharmacist","other","article","10.1211/cp.2016.20200838",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031264","Exenatide: a novel treatment of Type 2 diabetes","Bo Åhrén","2005","Therapy","other","article","10.1586/14750708.2.2.207",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031265","977-P: Trends in First-Line Glucose-Lowering Drug Use in Adults with Type 2 Diabetes in Light of Emerging Evidence for SGLT2i and GLP-1RA","HoJin Shin","2021","Diabetes","nonrandomized_study","article","10.2337/db21-977-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031266","Kardioprotektivni učinci antihiperglikemijskih lijekova","Ines Vinković","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031267","GLP-1RA Promotes Beige Differentiation in Adipose Tissue","臻 刘","2024","Advances in Clinical Medicine","other","article","10.12677/acm.2024.143795",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031268","Islet inflammation, a causal link between diabetes and pancreatic cancer? / GLP-1 based therapy and the exocrine pancreas, accelerated dysplasia and cancer?","Peter C. Butler","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031269","Therapeutic Targets for Diabetes Mellitus: An Update","Nivedita Tiwari","2014","Clinical Pharmacology & Biopharmaceutics","other","article","10.4172/2167-065x.1000117",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031270","FDA Approves Victoza for Pediatric Type-2 Diabetes","Drew Boxler","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031271","Insulin Discontinuation and Other Measures of GLP-1 RA Efficacy","Kenneth J. Bender","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031272","Insuline: «back to the future»","G Waeber","2008","Forum Médical Suisse ‒ Swiss Medical Forum","other","article","10.4414/fms.2008.06660",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031273","Liraglutide Beats Other Therapies for Lowering HbA1c","HEIDI SPLETE","2011","Internal Medicine News","other","article","10.1016/s1097-8690(11)70379-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031274","Analysis of the Effect of Liraglutide on Bone Metabolism in Patients with Type 2 Diabetes Mellitus",null,"2022","Foreign Language Science and Technology Journal Database Medicine and Health","other","article","10.47939/mh.v3i1.072",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031275","Exendin-4 treatment improves glucose tolerance and beta-cell function in beta-cell-specific autophagy-deficient mice","浩子 阿部","2012","Medical Entomology and Zoology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031276","Normalization of body weight and improvement of glycemic control in a patient with type 2 diabetes mellitus during therapy an agonist of glucagon-like peptide-1 dulaglutide under the control of flash monitoring: clinical case",null,"2021","FOCUS Endocrinology","other","article","10.47407/ef2021.2.4.0049",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031277","Exenatide trumps insulin glargine in cost effectiveness",null,"2009","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-200905860-00001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031278","Liraglutide in the treatment of type 2 diabetes","Roger Gadsby","2011","Nurse Prescribing","other","article","10.12968/npre.2011.9.8.408",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031279","Liraglutide LEADs the way for T2DM in China",null,"2013","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-013-0466-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031280","Σύνθεση τμημάτων του πεπτιδίου Liraglutide","Σταυρούλα Κατσαγάνη","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031281","Compounded Tirzepatide Therapy for Weight Loss: A Vegan Health Outcomes Researcher Perspective","Guth, Michael A. S.","2024",null,"other","article","10.13140/rg.2.2.36192.49921",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031282","Choosing an insulin regime: a developing country perspective","Sheetal Kalra","2014",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031283","Effect of Glucagon-Like Peptide 1 Receptor Agonists on Visceral Fat Adiposity, Appetite, and Food Preference","Yuya Fujishima","2014","Elsevier eBooks","other","article","10.1016/b978-0-12-407869-7.00015-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031284","GLP-1 receptor agonists in the treatment of Type 2 diabetes Review","Bo Åhrén","2013",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031285","Solution behaviour of Human Serum Albumin and GLP-1variants","Pernille Sønderby","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031286","Efficacy analysis of liraglutide and insulin glargin on patients with mild cognitive impairment in type 2 diabetes mellitus","Xiaoling Li","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031287","Original Investigation Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis","P M Howse","2016",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0031288","Synergistic Weight Loss Using Liraglutide Augmentation in Addition to a Zero Carbohydrate Ketogenic Feeding Tube Diet: A Case Report","Oliver R Di Pietro","2016","Advances in Obesity Weight Management & Control","case_report","article","10.15406/aowmc.2016.05.00138",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031289","Obesity, a Threat to Global Health: A Review","Chaithanya .K.J","2020",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0031290","Figure 19, Change in A1C in Exenatide Weekly versus Twice Daily During 52 Weeks of Treatment","Patricia S Juang","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031291","Incretin-based Therapies","Rajeev Chawla","2016","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12866_8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031292","Natural drug leads as novel DPP-IV inhibitors targeting the management of type 2 diabetes mellitus","Keddagoda Gamage Piyumi Wasana","2020","Journal of Complementary Medicine Research","preclinical","article","10.5455/jcmr.20190925040807",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031293","Il monitoraggio AIFA dei nuovi farmaci per il trattamento del diabete","Simona Moscatiello","2011","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031294","Anesthesiology in the News",null,"2023","ASA Monitor","other","article","10.1097/01.asm.0000995136.52758.da",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031295","Byetta Approved as First in New Class of Medications to Treat Type 2 Diabetes","DOUG BRUNK","2005","Family Practice News","other","article","10.1016/s0300-7073(05)70733-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031296","P.1.e.007 Liraglutide (a glucagon-like peptide-1 analog) activates the central anorexigenic pathway in diet-induced obese mice","André Rodrigues da Cunha Barreto Vianna","2014","European Neuropsychopharmacology","preclinical","article","10.1016/s0924-977x(14)70298-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031297","Management of Type 2 Diabetes","Rudy Bilous","2010",null,"other","article","10.1002/9781444391374.ch11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0031298","Oral Semaglutide (Rbbelsus) vs. Subcutaneous Liraglutide and Placebo in Type 2 Diabetes","Emmanuel Ayanjoke","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031299","Dulaglutide cost effective as third-line therapy in T2DM in Canada",null,"2019","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-019-5592-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031300","Exenatide: A Potential Disease-Modifying Agent in PD?","Veronica Hackethal","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031301","Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes","J.L. Leahy","2008","Yearbook of Endocrinology","other","article","10.1016/s0084-3741(08)79211-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031302","Interesting T2DM: FDA News & Diabetes Risk","Julie Bowen","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031303","GLP-1 Agonist Use: Should Pharmacological Weight Loss be used in conjunction with Bariatric Surgery? A Literature Review","Klein, Katherine","2025",null,"narrative_review","article","10.13140/rg.2.2.22019.82723",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031304","Liraglutide- How safe is it in clinical practice?","Shamima Yeasmin","2015","Endocrinology & Metabolic Syndrome","other","article","10.4172/2161-1017.c1.009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031305","Dulaglutide cost effective as add-on T2DM treatment in Italy",null,"2020","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-020-6742-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031306","FDA Okays Long-Acting Form Of Diabetes Drug Exenatide","ELIZABETH MECHCATIE","2012","Family Practice News","other","article","10.1016/s0300-7073(12)70127-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031307","68Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-aminohexanoic acid-Lys40-exendin-4","Kam Leung","2012","Europe PMC (PubMed Central)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031308","Preventing Muscle Loss During GLP-1 Receptor Agonist Therapy: The Role of Functional Mocktails and Reforming Ultra-Processed Foods","Multidisciplinary Surgical Research Annals","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16624111",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031309","Enhancing Diabetes Management The Role of Semaglutide and Multidisciplinary Care","Indunil Karunarathna","2024",null,"other","article","10.13140/rg.2.2.32175.55206",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031310","GLP-1 Agonist Pop Quiz","Payal Kohli","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031311","LIRA 365 Plus-A Real World Experience of 19 Months Use of Liraglutide in the Obese Indian Type 2 Diabetic Subjects","Soumyabrata Roy Chaudhuri","2016","Advances in Obesity Weight Management & Control","nonrandomized_study","article","10.15406/aowmc.2016.05.00136",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031312","Povezanost inkretinske terapije i nealkoholne steatoze jetre u bolesnika sa šećernom bolesti tipa 2","Anamarija Lončar","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031313","Glucagon Counter-Regulation to Hypoglycemia During Incretin-Based Therapy","Johan Farngren","2019","Lund University Publications (Lund University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0031314","News from the Society for Neuroscience Annual Meeting: Diabetes Drug Liraglutide Set for Clinical Trials of Alzheimer Disease on Promise of Animal Studies","Dan Hurley","2012","Neurology Today","other","article","10.1097/01.nt.0000410755.19813.06",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031315","Liraglutide and Insulin are Associated with a Decreased Risk of Acute Myocardial Infarction in Type 2 Diabetes Mellitus Patients","Jakob Starup‐Linde","2014","Journal of Diabetes & Metabolism","nonrandomized_study","article","10.4172/2155-6156.1000389",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0031316","Pharmacologic Therapy for Type 2 Diabetes Mellitus","Ralph A. DeFronzo","2000","Annals of Internal Medicine","randomized_trial","article","10.7326/0003-4819-133-1-200007040-00016",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031317","Industry Update: the Latest Developments in Therapeutic Delivery","Paul A. Burke","2012","Therapeutic Delivery","other_trial","article","10.4155/tde.12.91",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031318","GLP-1 agonists: counselling points",null,"2013","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2013.11127931",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031319","Liraglutide Tops Others for Lowering HbA1c","HEIDI SPLETE","2011","Clinical Endocrinology News","other","article","10.1016/s1558-0164(11)70241-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031320","Exendin-4通过激活Nrf2/HO-1通路减轻糖尿病小鼠的肝脏氧化应激及纤维化","方舒","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031321","Efficiency of exenatide in treatment of type 2 diabetes mellitus patients with inadequately controlled blood glucose in plateau area","Yongming Deng","2013","Academic Journal of Second Military Medical University","other","article","10.3724/sp.j.1008.2013.00341",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031322","First Incretin Mimetic, Byetta, Approved for Diabetes","DOUG BRUNK","2005","Internal Medicine News","other","article","10.1016/s1097-8690(05)70940-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031323","Steroid‐Induced Diabetes","David Levy","2015",null,"other","article","10.1002/9781119145332.ch29",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0031324","Liraglutide for the treatment of diabetes mellitus in Japan","Kohei Kaku","2011","Diabetes Management","other","article","10.2217/dmt.11.34",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031325","Glucose Control in Islet Transplanted Mice Using Long Acting Liraglutide Nanoparticles","Junhua Li","2019","Nanoscience and Nanotechnology Letters","preclinical","article","10.1166/nnl.2019.2893",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031326","Role of cyclic AMP signaling in the production and function of the incretin hormone glucagon-like peptide-1","Zhiwen Yu","2008","Science Foundation in China","other","article","10.1088/1005-0841/16/2/003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031327","Glucagon-like peptide-1 (GLP-1) receptor agonists",null,"2017","British Journal of Cardiology","other","article","10.5837/bjc.2017.030",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031328","Pharmacologically relevant drug interactions of Glucagon-like peptide-1 receptor agonists","Naina Mohamed Pakkir Maideen","2019","Journal of Analytical & Pharmaceutical Research","other","article","10.15406/japlr.2019.08.00311",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031329","Byetta, Elestrin","ELIZABETH MECHCATIE","2007","Family Practice News","other","article","10.1016/s0300-7073(07)70183-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031330","Liraglutide combined with vitamin E alleviates liver injury and insulin resistance in mice with nonalcoholic fatty liver disease","Ning-Xin Xuan","2018","World Chinese Journal of Digestology","preclinical","article","10.11569/wcjd.v26.i29.1688",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031331","Exenatide",null,"2017","The American Pharmacists Association eBooks","other","article","10.21019/druginformation.exenatide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031332","Anti-Fatness in the Ozempic Era: State of the Landscape and Considerations for Future Research","Flora Oswald","2025",null,"other","article","10.4324/9781003613404-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031333","An unusual presentation of type 2 diabetes mellitus","Yasmeen Hassan Al Sadek","2021",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031334","Emergence of GLP-1 Receptor Agonists as a Therapy for Diabetic Kidney Disease","Radica Z. Alicic","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031335","Новые терапевтические возможности в лечении сахарного диабета 2-го типа: добавление к лираглутид у инсулина детемир","E.Yu. Pashkova","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031336","Liraglutide",null,"2017","The American Pharmacists Association eBooks","other","article","10.21019/druginformation.liraglutide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031337","Weekly exenatide demonstrates QOL superiority in T2DM",null,"2009","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-200905890-00019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031338","Formulating Peptides for the Gut: A Case Study on Exenatide in Lipid-Based Formulations using Enteric Capsules","Jannin, Vincent","2025",null,"other","article","10.13140/rg.2.2.20733.88807",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031339","GLP-1 receptor agonists in the treatment of Type 2 diabetes","Bo Åhrén","2013","Diabetes Management","other","article","10.2217/dmt.13.41",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031340","Clinical Improvement of Weight, HbA1c and Liver Function by Rybelsus (Oral Semaglutide) In Patient with Type 2 Diabetes (T2D), Obesity and Fatty Liver","H Yamashita","2022","SunText Review of Medical & Clinical Research","other","article","10.51737/2766-4813.2022.061",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031341","FDA approves lixisenatide for type 2 diabetes","Lisa M. Holle","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031342","GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated β-cell damage in Akita mice","俊介 山根","2011","Medical Entomology and Zoology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031343","The Pharmacist’s Role in Managing Semaglutide Treatment","Indunil Karunarathna","2024",null,"other","article","10.13140/rg.2.2.23786.94403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031344","Screening of Indonesian Pythochemicals as Glucagon-Like Peptide-1 Receptor Agonist In Silico in Type-2 Diabetes Mellitus","Humamuddin","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031345","EFFICACY OF NEWER GLP-1 RECEPTOR AGONISTS ON NON-ALCOHOLIC FATTY LIVER DISEASE IN TYPE 2 DIABETES","Bilal Ahmad,Shahid Iqbal","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15385860",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031346","Liraglutide 1.8mg cost effective for T2DM",null,"2015","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-015-2070-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031347","Neuer GLP-1-Agonist in Phase 3 erfolgreich",null,"2012","Info Diabetologie","other_trial","article","10.1007/s15034-012-0313-0",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031348","Effect of Exenatide on Postprandial Hyperinsulinemic Hypoglycemia in Two Gastric-Bypass Patients.","SE Chang Figueroa","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","other","article","10.1210/endo-meetings.2010.part3.p11.p3-551",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031349","GLP-1 receptor agonists: why is once weekly inferior to once daily?","Richard E. Pratley","2014",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031350","99mTc labeled GLP-1 scintigraphy with the use of [Lys40-(Ahx-HYNIC/EDDA)NH2]-Exendin-4 in the insulinoma localization","Alicja Hubalewska–Dydejczyk","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031351","Exenatide",null,"2015","Elsevier eBooks","other","article","10.1016/b978-0-444-53717-1.00088-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031352","海外文献紹介 LEAD-2試験にみるLiraglutideの臨床効果","禄郎 伊藤","2009","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031353","Purification and Characterization of Glucagon-Like Peptide-1 and Human Serum Albumin Fusion Protein Expressed in Pichia pastoris","Jia Chen","2007",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031354","New diabetes drug set to rival Trulicity","Christine Blank","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031355","Relationship between the use of drugs and changes in body weight among patients: A systematic review and meta-analysis","Tauqeer Hussain Mallhi","2022","Greater South Information System","systematic_review","article","10.60692/rhss6-a7k83",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; review"],["R0031356","Another GLP-1 receptor agonist hits the market","Maria G. Tanzi","2016","Pharmacy Today","other","article","10.1016/j.ptdy.2016.08.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031357","Exenatide looks attractive in the UK setting",null,"2007","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-200705290-00009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031358","A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2","Z.F. Zin","2012",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","review"],["R0031359","Oxidative and ER stresses: breaking the cycle to preserve beta cells in diabetes","Martins de Oliveira","2019","Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; dissertation"],["R0031360","Study on Quantitative Assessment of Insulin Response in Impaired Glucose Regulation","G Sangavai","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031361","Liraglutide Beat Other Therapies for Lowering HbA1c Levels","HEIDI SPLETE","2011","Family Practice News","other","article","10.1016/s0300-7073(11)70409-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031362","GLP‐1受容体作動薬Exendin‐4とメトホルミンの併用は前立腺癌を抑制する","堤陽子","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031363","Liraglutide Beat Orlistat for Losing Weight","JANE SALODOF MACNEIL","2008","Family Practice News","other","article","10.1016/s0300-7073(08)71394-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031364","Current Situation and Problems for Weight Reduction Using GLP-1 Receptor Agonists",null,"2025","JOURNAL OF MEDICAL AND CLINICAL STUDIES","other","article","10.36266/jmcs/224",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031365","Schilddrüsenkarzinom als potenzielles Risiko bei der Behandlung mit GLP-1-RA?","Kristina Rogal","2024","Info Diabetologie","other","article","10.1007/s15034-024-4991-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031366","Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach (Keynote Presentation); 8th Edition of Global Conference on Pharmaceutics and Novel Drug Delivery Systems; March 13-14, 2023; Virtual Event; Organizer: Magnus Group LLC; Website: https://magnusconferences.com/pharmaceutical-sciences/ LECTURE: https://youtu.be/GoQeR6YAGJI?si=hl25V3LM_pqsk5XJ","Radenković, Miroslav","2023",null,"other","article","10.13140/rg.2.2.35689.16486",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031367","Exenatide in patients with Type 2 diabetes treated with basal insulin",null,"2011","Nurse Prescribing","other","article","10.12968/npre.2011.9.2.100a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031368","Could GLP-1 Analogs be a Gamechanger in Preventing Amputations in Patients with Peripheral Arterial Disease?","Khan, Abdul Wali","2025",null,"other","article","10.13140/rg.2.2.35347.34089",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031369","939: LIRAGLUTIDE ATTENUATES LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY IN MICE","Ying Zhang","2016","Critical Care Medicine","preclinical","article","10.1097/01.ccm.0000509615.06302.57",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031370","Semaglutide (Ozempic and Wegovy) Manufacturing - Process Modeling and Techno-Economic Assessment (TEA) using SuperPro Designer","Vassilis Parisis","2025",null,"other","article","10.13140/rg.2.2.24345.33129",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031371","Exendin-4有益於胰島細胞移植體的作用機轉與以 磁振造影影像偵測及追蹤植入之胰島細胞","郭健葒","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031372","Incretin-Based Therapies","Vageesh Ayyar","2015","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12535_15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031373","Effects of Liraglutide on Metabolic Parameters and Carotid Intima-Media Thickness in Patients with The Metabolic Syndrome: A 12-Month Prospective Pilot Study","Dragana Nikolić","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031374","THE IMPACT OF DEGRADATION INHIBITOR OF GLUCAGON LIKE POLYPEPTIDE 1 ON BODY WEIGHT AND BETA-CELL FUNCTION IN OBESE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME","Simona Ferjan","2018","Repository of the University of Ljubljana (University of Ljubljana)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0031375","Exenatide Plus Metformin Improves Metabolic, Hormonal Status in PCOS",null,"2008","Family Practice News","other","article","10.1016/s0300-7073(08)71419-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031376","EXENDIN-4がメチルグリオキサール誘導PC12細胞酸化ストレスに与える影響【JST・京大機械翻訳】","Zhou Qing","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031377","Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome","Andrej Janež","2016","Endocrinology & Metabolic Syndrome","other","article","10.4172/2161-1017.1000261",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031378","Exendin-4, a glucagon-like peptide-1 analogue, improves Listeria monocytogenes infection in diabetic db/db mice","Hsien-Yueh Liu","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031379","Incretin-based Therapies","Rajeev Chawla","2014","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12161_9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031380","Metformin Intolerance and Alternative Therapies Quiz","Veronica Hackethal","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031381","DIAGNOSIS AND TREATMENT OF PREDIABETES AS PREVENTION OF TYPE 2 DIABETES","Kodirova, Nargizakhon","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15396259",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031382","Establishing an Association Between the Increasingly Prescribed Glucagon-like Peptide-1 Receptor Agonists and Nonarteritic Anterior Ischemic Optic Neuropathy in Patients with Vascular Risk Factors (P9-11.017)","Jason Gandhi","2025","Neurology","other","article","10.1212/wnl.0000000000212569",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031383","1204-P: Antidiabetic Effects of GLP-1 Analogs Are Mediated by Il-6-Induced Adipocyte Beiging","Absalon Gutierrez","2021","Diabetes","preclinical","article","10.2337/db21-1204-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031384","Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database","Osei, Samuel Prince","2025","Open Collections","nonrandomized_study","article","10.14288/1.0447722",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0031385","CHAPTER 12. Manufacturing of Venom-Derived Therapeutic Peptides","Oleg Werbitzky","2015","RSC drug discovery/RSC drug discovery series","nonrandomized_study","article","10.1039/9781849737876-00290",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","book-chapter"],["R0031386","NT 28 - 2013 NATS VICTOZA","Núcleo de Avaliação de Tecnologias em Saúde","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031387","Initiating exenatide cost saving vs insulin in the US",null,"2012","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-201206510-00016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031388","1270-PUB: Utilization Pattern of Dulaglutide in Five European Countries","Ayad K. Ali","2021","Diabetes","other","article","10.2337/db21-1270-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031389","'Retatruide' drug trial: A paradigm shift in Type 2 Diabetes management","Zainab Abbas","2024","Greater South Information System","other_trial","article","10.60692/stgbb-wy931","38783470",null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0031390","Efficiency ot Liraglutide application in patients with CHD and DM type 2 ffi patients with comorbidity of CHD and DM 2 W","N F Tashkenbayeva","2020",null,"other","article","10.13140/rg.2.2.30321.71522",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031391","CE: New Insulin/GLP-1RA Agents: Overview for the Pharmacist","Alysa Martin","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031392","Effects of Glucose and Lipid Metabolism and Visceral Fat in Overweight and Obese Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide Combined with Dapagliflozin","云阁 杨","2024","Advances in Clinical Medicine","other","article","10.12677/acm.2024.1451679",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031393","Promjene metabolizma željeza u mozgu i jetri mužjaka Sprague Dawley štakora izloženih masnoj i slatkoj hrani","Katarina Mikulec","2018",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031394","CV Data Shows No Benefit, Risk to GLP-1 Receptor Agonist Lixisenatide","Leah Lawrence","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031395","新型降血糖藥Liraglutide的心血管安全性試驗－The LEADER Trial","蘇品碩","2019",null,"other_trial","article","10.6666/clinmed.201903_83(3).0032",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031396","Major diabetes drug cuts heart attack risk","Christine Blank","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031397","Recent Advances For Type 2 Diabetics Ozempic (Sub-cutaneously administered Drug)","Purab Sood","2021",null,"other","article","10.13140/rg.2.2.27096.01281",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031398","Exenatide Exerts a Potent Anti-Inflammatory Action","Ajay Chaudhuri","2011",null,"other","article","10.1210/endo-meetings.2011.part3.p34.p3-389",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031399","Future Antidiabetic Drugs","Emma Johns and","2022",null,"other_trial","article","10.1002/9781119785033.ch14",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0031400","Erster oraler GLP-1-Agonist in der EU zugelassen",null,"2020","Info Diabetologie","other","article","10.1007/s15034-020-2149-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031401","Quantitative evaluation of peptide analogue distribution in mouse tissue using 3D computer modelling","Casper Bo Jensen","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031402","재조합 대장균을 통한 EBPylated Exenatide 융합 단백질 발현","이재선","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031403","The Role of Glucagon-Like Peptide-1 (GLP-1) in Women with Obesity Planning Pregnancy","Yoel Toledano","2024",null,"other","article","10.1201/9781003355939-24",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031404","Reversing Autoimmunity: Can the DRI Do It?","Meet Alberto Pugliese","2007",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031405","Once-Weekly Formulation of Exenatide Being Developed","MIRIAM E. TUCKER","2006","Internal Medicine News","other","article","10.1016/s1097-8690(06)73764-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031406","Eye disorder is a ‘very rare’ side effect of weight-loss drugs, concludes EMA review",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","nonrandomized_study","article","10.1211/pj.2025.1.359994",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031407","Chapter-08 Glucagon-like Peptide-1 Analogues","Ajay Kumar","2014","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12153_8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031408","Generation of insulin-producing β-like cells from human iPS cells in a defined and completely xeno-free culture system","Hussain","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031409","Weekly Exenatide Improves Multiple CV Risks","BRUCE JANCIN","2009","Internal Medicine News","other","article","10.1016/s1097-8690(09)70100-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031410","Implantation of GLP-1 secreting cells fails to recapitulate effects of exogenous GLP-1 mimetics in mice","Srividya Vasu","2010","Regulatory Peptides","preclinical","article","10.1016/j.regpep.2010.07.075",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031411","TIRZEPATIDE QUANTIFICATION IN HUMAN PLASMA USING LC-MS AND APPLICATION IN BIOAVAILABILITY STUDY","Arjun Arumugam Olaganathan","2024","Journal of Applied Bioanalysis","other","article","10.53555/jab.v11si1.488",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031412","Glargine, Liraglutide Neck and Neck, Except on Cost","MIRIAM E. TUCKER","2012","Internal Medicine News","other","article","10.1016/s1097-8690(12)70541-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031413","Liraglutide LEADing the way in the former Eastern Bloc",null,"2010","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-201006170-00007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031414","Type 2 Diabetes Mellitus in Children and Adolescents","Kavitha Dileepan","2013","Pediatrics in Review","other_trial","article","10.1542/pir.34.12.541","24295815",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031415","GLP-1 acts at myenteric neurons to inhibit motility in humans: results of in vivo motility studies and in vitro characterization of responses to GLP-1 and ROSE-010 : GLP-1 and digestive motility","Abdul Halim","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031416","Liraglutide Curbs Glycemic Oscillations in Type 1 Diabetes","KERRI WACHTER","2011","Internal Medicine News","other","article","10.1016/s1097-8690(11)70604-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031417","FDA Approves First Oral GLP-1 Receptor Agonist for T2D","Grace Halsey","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031418","Complications of Youth-Onset Type 2 Diabetes",null,"2021","AAP Grand Rounds","randomized_trial","article","10.1542/gr.46-5-51",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031419","Wednesday 19 November: London",null,"2014","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2014.20066758",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031420","人胰高血糖素样肽-1类似物：利拉鲁肽","冯凭","2008","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031421","What are the experiences, views and perceptions of patients, carers and clinicians of glucagon-like-peptide-1 receptor agonists (GLP-1RAs)? A scoping review protocol","Isca Evidence","2024","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.12772703",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0031422","Liraglutide",null,"2018",null,"other","article","10.1891/9780826150356.0602",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031423","Non‐alcoholic liver disease (NAFLD)","FRCP Rudy Bilous","2021",null,"other","article","10.1002/9781118976074.ch24",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0031424","Typ-2-Diabetes: GLP-1-RA und Basalinsulin in einer Injektion",null,"2020","Diabetologie und Stoffwechsel","other","article","10.1055/a-1009-2624",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031425","GLP-1 Drugs May Play Modest Role in Cancer Prevention","Suzanne Rose","2025","Cancer Discovery","other","article","10.1158/2159-8290.cd-nw2025-0055",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031426","Victoza likely to make Bydureon's market entry difficult",null,"2011","PharmacoEconomics & Outcomes News","other","article","10.1007/bf03295180",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031427","Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients","Abstr Act","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031428","IDegLira − better outcomes at lower cost in T2DM",null,"2017","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-017-3842-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031429","BYETTA ® : A NEW PHARMACOLOGICAL OPTION FOR PATIENTS WITH DIABETES MELLITUS","Ira Schatten","2006",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031430","Chronic palmitate excess results in reduced exendin-4 action and signalling via CREB and Akt in pancreatic beta cells","Annalisa Natalicchio","2013","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031431","A trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function","Euctr At","2019",null,"other_trial","article","10.1002/central/cn-01870526",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031432","GLP-1 Receptor Agonists in Spine Surgery: Current Evidence and Future Directions",null,"2025","Contemporary Spine Surgery","other","article","10.1097/01.css.0001113696.02214.67",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031433","Promjene metabolizma željeza u mozgu i jetri ženki Sprague Dawley štakora izloženih masnoj i slatkoj hrani","Ljiljana Majić","2018",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031434","Study finds association between GLP-1 use and macular degeneration in diabetes",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","nonrandomized_study","article","10.1211/pj.2025.1.359651",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031435","TZD Effective Third-Line Rx after Failure of Long-term Metformin/GLP-1 RA","Leah Lawrence","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031436","Iodination of the isoquinoline moiety of T-0632 to generate photolabile analogs","Erin Yang","2016","Wellesley College Digital RepositoryWellesley (Wellesley College)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031437","A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.","井上 雄一郎","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031438","Exenatide",null,"2018",null,"other","article","10.1891/9780826150356.0387",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031439","Changing Treatment Paradigm with OW Semaglutide","Sumon Rahman Chowdhury","2021",null,"other","article","10.13140/rg.2.2.32372.68483",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031440","Liraglutide, a Once-Daily Incretin Mimetic, Lowers HbA1c Levels","JOHN R. BELL","2006","Internal Medicine News","other","article","10.1016/s1097-8690(06)73765-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031441","Type 2 Diabetes Patients Show No Increased CV Risk with Once-Weekly Exenatide","Mark L. Fuerst","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031442","VALIDATED RP - HPLC METHOD FOR THE ESTIMATION OF LIRAGLUTIDE IN TABLET DOSAGE","A. Madhavi","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031443","Exclusive patent, know-how, process and technology license and sublicense to research, develop, make, have made, use, import, export, sell, offer and sublicense formulations of the human glucagon-like peptide-1 analogue known as liraglutide, using licensor's 'DepoFoam' injectable sustained-release delivery system based on multivesicular liposomes.","RoyaltyStat","2019","RoyaltyStat Library","other","article","10.34675/l36817",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031444","Incretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes","Baptist Gallwitz","2013","Diabetes Management","other","article","10.2217/dmt.13.29",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031445","ADA: SGLT2 Inhibitors Match GLP-1 RAs for A1c Reduction, Weight Loss","Charles F. Shaefer","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031446","Euro Nephrology 2019: Antiproteinuric efficacy of cilnidipine as an add on therapy to Ramipril in patients of diabetic kidney disease- Aalia TausifHimalayan Institute of Medical Sciences","Aalia Tausif","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031447","Drugs like Wegovy can help treat fatty liver disease","Christa Lesté-Lasserre","2025","The New Scientist","other","article","10.1016/s0262-4079(25)00728-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031448","Once-weekly semaglutide good value for money in T2DM in the UK",null,"2020","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-020-6598-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031449","Effects of glucagon-like peptide-1 receptor agonists on bone blow flow and architecture in diabetic mice","Marie Pereira","2016","Bone Abstracts","preclinical","article","10.1530/boneabs.5.oc4.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031450","Clinical Study on Alfacalcidol Combined with Liraglutide in the Treatment of Diabetes and Osteoporosis",null,"2022","Foreign Language Science and Technology Journal Database Medicine and Health","other","article","10.47939/mh.v3i4(05).45",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031451","The effect of L-dopa and neuroprotective agents oncell replacement therapy for Parkinson’s disease.","Osama F. Elabi","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031452","Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea","Lawrence J. Kennedy","2006","Yearbook of Endocrinology","other","article","10.1016/s0084-3741(08)70258-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031453","Comparative Effect of Glucagon-Like Peptide-1 Receptor Agonists vs Other Antidiabetic Drugs on Dementia Risk: A Systematic Review and Meta-Analysis (P1-3.014)","Patricio Castro Suarez","2025","Neurology","systematic_review","article","10.1212/wnl.0000000000212675",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0031454","Relevance of Polypill for Primary Prevention of Cardiovascular Diseases in the 21st Century","Rajeev Gupta","2025","RUHS Journal of Health Science","randomized_trial","article","10.37821/ruhsjhs.10.2.2025.869",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0031455","Efficacy for Reduction of HbA1c and Body Weight by Oral Semaglutide (Rybelsus)","H Ogawa","2022","SunText Review of Medical & Clinical Research","other","article","10.51737/2766-4813.2022.062",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031456","Obesity - A Natural Cure- A Review","Brahmbhatt Ritav Viralbhai, Parikh Namrata","2018","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.1210045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031457","Albiglutide",null,"2017","The American Pharmacists Association eBooks","other","article","10.21019/druginformation.albiglutide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031458","Exenatide Benefits Treatment-Refractory Diabetics","MIRIAM E. TUCKER","2006","Internal Medicine News","other","article","10.1016/s1097-8690(06)73957-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031459","Once-weekly exenatide in T2DM good value for money in Greece",null,"2017","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-017-4503-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031460","Transcriptional dynamics driving differentiation programs in the murine intestine","Vemuri, Kiranmayi","2024","Rutgers University Community Repository (Rutgers University)","preclinical","article","10.7282/t3-00kj-n557",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0031461","Health-related quality of life in patients with type 2 diabetes and subclinical heart failure treated with either liraglutide or glimepiride, both in combination with metformin: a post hoc analysis","Filip Andersson","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031462","The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimer’s disease","Grazia Daniela Femminella","2014","Clinical Investigation","preclinical","article","10.4155/cli.14.12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031463","GLP-1 receptor agonism for somatoprotection in critical illness","Osaid Ather","2020",null,"other","article","10.13140/rg.2.2.29378.94400",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031464","Neurodegeneration as an early event in the pathogenesis of diabetic retinopathy: therapeutic implications /","Lidia Corraliza Márquez","2016","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; dissertation"],["R0031465","Papel de la endoglina y del sistema central GLP-1 en la homeostasis energética","Daniel Beiroa Tarrío","2015","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0031466","Exenatide Falls Short Outside Clinical Trials","SHERRY BOSCHERT","2008","Family Practice News","other","article","10.1016/s0300-7073(08)70811-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031467","Brain Insulin Resistance in Alzheimer Disease and Its Potential Treatment With a Mediterranean Diet and GLP-1 Analogues","Konrad Talbot","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031468","Review of Cardiovascular Effects of Antidiabetic Drugs and Recent Cardiovascular Outcome Trials","So Hun Kim","2016","Journal of Korean Diabetes","randomized_trial","article","10.4093/jkd.2016.17.1.1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031469","DK REDDIE WP4 Analysis plan: GLP1-RA versus DPP4 and metabolic outcomes","Sørensen, Kathrine Kold","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15062957",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031470","WEIGHT CONTROL IN TYPE 2 DIABETES PATIENTS TREATED WITH INCRETIN MIMETICS","Mihaela Simona Popoviciu","2011","European Journal of Internal Medicine","other","article","10.1016/s0953-6205(11)60313-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031471","Semaglutide (Ozempic): Miracle Weight Loss Drug or Medical Hype? Full Truth Explained by me.","Verma, Rakesh","2025",null,"other","article","10.13140/rg.2.2.23595.35365",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031472","Liraglutide costlier than insulin glargine in T2DM",null,"2013","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-013-0754-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031473","New therapies available for the treatment of type 2 diabetes","Caroline Day","2006","European Diabetes Nursing","other","article","10.1002/edn.46",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031474","Pharmacotherapies to manage diabesity: an update","Caroline Day","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031475","Effects of Exendin-4 on Endoplasmic Reticulum Stress Induced by High Glucose and JNK Signaling Pathway in INS -1 Cells","Qiang Zhang","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031476","NUOVE MODALITÀ DI SOMMINISTRAZIONE DEI GLP1-RA: DISPOSITIVI IMPIANTABILI","Francesca Guarini","2019","il Diabete","other","article","10.30682/ildia1902h",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031477","Glargine, Liraglutide Similar, Except on Cost","MIRIAM E. TUCKER","2012","Family Practice News","other","article","10.1016/s0300-7073(12)70595-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031478","INCRETIN MIMETICS: NEW AGE DRUGS FOR TYPE 2 DIABETES MELLITUS","Deepika Tikoo","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031479","Safety of GLP-1 receptor agonists (revision number 18)","The Diapedia Collective","2013","Diapedia.org eBooks","other","article","10.14496/dia.81043351111.18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031480","AN ANALYSIS OF COMBINATION THERAPY USING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND ENDOSCOPIC GASTRIC PLICATION FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE","Aunchalee Jaroenlapnopparat","2023","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2023.04.068",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031481","FDA Warns of Pancreatitis in Some Byetta Users","ROBERT FINN","2007","Clinical Endocrinology News","other","article","10.1016/s1558-0164(07)70575-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031482","From Kidneys to Cravings: Could GLP-1 Receptor Agonists Help Quench Thirst in Primary Polydipsia?","Blaise Abramovitz","2025","Kidney News","other","article","10.62716/kn.001952025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031483","Drugs for diabetes: part 9 prescribing for patients with cardiac disease","Miles Fisher","2012","British Journal of Cardiology","other_trial","article","10.5837/bjc.2012.017",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031484","Role of renin inhibitor, insulin and glucagon-like peptide-1 analogue in the regulation-affinity modulation of endothelin-1 receptor subtype[s] in type 1 diabetic rat hearts","Al Lafi","2010",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031485","[Table, VivoTag-S 750-(S)-2-amino-4-pentynoic acid12-exendin-4].","Kam Leung","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031486","Dulaglutide Therapy for Youths With Type 2 Diabetes",null,"2022","AAP Grand Rounds","other","article","10.1542/gr.48-3-29",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031487","Study Favors Once-Weekly Exenatide for Lowering HbA1c","MIRIAM E. TUCKER","2010","Internal Medicine News","other","article","10.1016/s1097-8690(10)70623-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031488","Liraglutide May Help Lower Heart Risk in Type 2 Diabetes","BRUCE JANCIN","2009","Internal Medicine News","other","article","10.1016/s1097-8690(09)70687-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031489","Dulaglutide: Third once-weekly GLP-1 agonist for type 2 diabetes","Maria G. Tanzi","2014","Pharmacy Today","other","article","10.1016/s1042-0991(15)30619-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031490","A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs","Beutel Darrow","2017","Digital Commons @ Butler University (Butler University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0031491","Drugs in Perspective: Liraglutide for the treatment of obesity","Julie A. Murphy","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031492","Cystatin-C and Fibronectin as key predictor of glomerulonephritis induced in male rats","Hayder Hussein Luaibi","2020","Research Journal of Pharmacy and Technology","preclinical","article","10.5958/0974-360x.2020.00029.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031493","THE EFFICACY AND PHARMACOLOGY OF SEMAGLUTIDE IN THE TREATMENT OF OBESITY","Machado, Carlos Eduardo","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14046003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031494","Exclusive patent, process and technology license to develop, commercialize and sublicense TG103 products containing a long-acting recombinant GLP-l Fc fusion protein compound, alone or in combination with one or more active ingredients, or fragments for diagnostics or injection, to treat type 2 diabetes mellitus and all related indications.","RoyaltyStat","2019","RoyaltyStat Library","other","article","10.34675/l37139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031495","A Markov Model-Based Cost-Effectiveness Analysis of Interventions for Non-Alcoholic Fatty Liver Disease and Steatohepatitis","Collins, Andrea","2022","Stanford Digital Repository","other","article","10.25740/nr644yx3574",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031496","Figure 10, [Pharmacologic effects of GLP-1.GLP-1 Receptor Agonists (Incretin Mimetics)].","Börk Balkan","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031497","GLP-1-receptor-agonisták a 2-es típusú diabeteskezelésében","Gábor Winkler","2019","Hypertonia és Nephrologia","other","article","10.33668/hn.23.023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031498","Effectiveness, Safety and Therapeutic Adherenceof Weekly Subcutaneous Semaglutide for WeightManagement in Real Practice: An Observational Study","Santiago Tofé","2021",null,"nonrandomized_study","article","10.32474/ado.2021.03.000161",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031499","Once-weekly semaglutide cost saving option in T2DM in Slovakia",null,"2019","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-019-6010-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031500","Remarkable Efficacy of Blood Glucose and Weight by Oral Semaglutide (Rybelsus) For Short Period","H Bando","2022","Suntext Review of Case Reports & Images","other","article","10.51737/2766-4589.2022.043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031501","Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors","Bo Åhrén","2013","European Diabetes Nursing","other","article","10.1002/edn.221",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031502","Rybelsus® (semaglutide) : the oral treatment of type 2 diabetes by a GLP-1 receptor agonist becomes reality !","Laurent Crenier","2022","Revue Medicale de Bruxelles","other","article","10.30637/2022.22-015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031503","Examination of a Viral Infection Mimetic Model in Human iPS Cell-Derived Insulin-Producing Cells and the Anti-Apoptotic Effect of GLP-1 Analogue","恵 馬殿","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031504","Crystal chemistry of higher tungsten oxides",null,"1995","Metal Powder Report","randomized_trial","article","10.1016/0026-0657(95)93258-5",null,null,"ClinicalTrials.gov:NCT01237119","S002015","openalex","FALSE","paywalled","1","FALSE","article"],["R0031505","Liraglutide Mortality Effect on Atrial Fibrillation Patients","Justin Haloot","2022","Journal of Atrial Fibrillation and Electrophysiology","other","article","10.4022/jafib.20200601",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031506","PET imaging of insulinoma using a 68Ga-labeled GLP-1 analog","Su‐Tang Lo","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031507","An Update on Comparative Effectiveness and Safety of Medications for Type 2 Diabetes","Wendy L. Bennett","2011","Annals of Internal Medicine","randomized_trial","article","10.7326/0003-4819-155-8-201110180-00021",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031508","Examination of a Viral Infection Mimetic Model in Human iPS Cell-Derived Insulin-Producing Cells and the Anti-Apoptotic Effect of GLP-1 Analogue ; ヒトiPS細胞から誘導したインスリン陽性細胞におけるウイルス感染モデルの検討およびウイルス感染状態におけるGLP-1アナログの抗アポトーシス効果について ; ヒトiPSサイボウカラユウドウシタインスリンヨウセイサイボウニオケルウイルスカンセンモデルノケントウオヨビウイルスカンセンジョウタイニオケルGLP-1アナログノコウアポトーシスコウカニツイテ","恵. 馬殿","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031509","Beyond Glycemic Control: Cardiovascular, Renal, and Hepatic Benefits of GLP-1 Receptor Agonists","Dina M. Khodeer","2024","Spectrum Science Journal","other","article","10.21608/sasj.2024.396448",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031510","Neointimal formation after vascular injury is attenuated by glucagon-like peptide-1 receptor agonist, exendin-4","広昌 後藤","2011","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031511","Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model","Springer Basel Ag","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031512","Potential Neuroprotective Effect of Semaglutide and Ipragliflozin in Mice Model of Endotoxaemia","Ashwaq Aleem Shnaien","2025",null,"preclinical","article","10.13140/rg.2.2.33081.48487",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031513","Liraglutide “good value for money” in type 2 diabetes",null,"2011","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-201106270-00015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031514","Liraglutide: A human GLP-1 analogue for the treatment of type 2 diabetes","PharmD candidate Stacie D. Sakauye","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031515","Incretin Mimetics Target Novel Pathways to Treat Type 2 Diabetes",null,"2004","Pharmaceutical & Diagnostic Innovation","other","article","10.1007/bf03262504",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031516","Xultophy cost effective for T2DM in Sweden",null,"2017","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-017-3708-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031517","More Weight Lost With Liraglutide Than Orlistat","JANE SALODOF MACNEIL","2009","Internal Medicine News","other","article","10.1016/s1097-8690(09)70017-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031518","Review Article Antidiabetic Drugs: An Overview","Prashant B Mane","2012",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031519","Efficacité de dulaglutide 1,5 mg en association à l'insuline chez des patients âgés, ayant un diabète de type 2 ancien traités par l'insuline et mal contrôlé : analyse post-hoc de AWARD-4 et -9","Kevin M. Pantalone","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031520","Exclusive patent, know-how, process and technology license to research, develop, make, have made, use, import, export, sell, offer, transfer and sublicense a therapeutic drug device combining a transdermal drug delivery system and its components, including a patch and applicator, with GLP-1 receptor agonists, which are substances other than native glucagon, that bind to the GLP-1 receptor in vitro and activate it with at least 10-fold higher potency than native glucagon.","RoyaltyStat","2019","RoyaltyStat Library","preclinical","article","10.34675/l33842",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031521","High density processing of ferrous alloys by supersolidus liquid phase sintering",null,"1995","Metal Powder Report","randomized_trial","article","10.1016/0026-0657(95)93284-4",null,null,"ClinicalTrials.gov:NCT01237119","S002015","openalex","FALSE","paywalled","1","FALSE","article"],["R0031522","The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems","Laura A. Schmidt","2025","Issues in Science and Technology","other","article","10.58875/teqc7966",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031523","Basal-Bolus療法へのDulaglutideの追加による血糖日内変動の改善とインスリン治療のStep-down促進効果","尚嗣 村上","2020","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031524","Germany ∙ The Albiglutide Controversy: A Paradigm Shift in Pricing Negotiations?","C. Stallberg","2017","European Pharmaceutical Law Review","other","article","10.21552/eplr/2017/1/8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031525","Improved β-Cell Targeting and Therapeutics Using Multivalent Glucagon-Like Peptide-1 (GLP-1) Linked to the α2AR Antagonist Yohimbine (YHB): Evaluating the Binding, Selectivity and Signaling","Kameswari Ananthakrishnan","2016","UA Campus Repository (The University of Arizona)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031526","Synthesis and Evaluation of Exenatide Mono-PEGylates with Novel Branched Configuration for A Type II Diabetes Therapy","응원티녹탄","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031527","Evidence from randomized clinical trials demonstrating improved glycemic control with GLP-1 receptor agonists when used with other agents vs other combination therapy strategies","Jeffrey S. Freeman","2013","Osteopathic Family Physician","randomized_trial","article","10.1016/j.osfp.2012.11.001",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031528","Effects of GLP-1 analog on cellular immune function of diabetes memtus rats","Haijun Zhao","2010","Europe PMC (PubMed Central)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031529","316-OR: Diabetes Care among Older Adults Enrolled in Medicare Advantage vs. Traditional Medicare Fee-for-Service Plans: The Diabetes Collaborative Registry","Utibe R. Essien","2021","Diabetes","nonrandomized_study","article","10.2337/db21-316-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031530","GLP-1 Receptor Agonists Significantly Improve Effects of Idiopathic Intracranial Hypertension","Dan Hurley","2025","Neurology Today","other","article","10.1097/01.wnt.0001169460.10968.89",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031531","GLP-1 Analogues vs. DPP-4 Inhibitors","Sakthivel Sivasubramanian","2013","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/11892_16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031532","Liraglutide: a human GLP-1 analog for Type 2 diabetes","Tina Vilsbøll","2009","Therapy","other","article","10.2217/14750708.6.2.199",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031533","GLP-1RAs Good for Diabetes, Good for the Heart","Mark L. Fuerst","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031534","The Antihypertensive Effect of the GLP-1 Mimetic Exenatide","Maja Baretić","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031535","Victoza® liraglutida - NT 50 2013","Núcleo de Avaliação de Tecnologias em Saúde","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031536","Antagonistic action of Exendin-4 on hippocampal LTP in vivo suppressed by Aβ1-42 and its possible mechanisms","徐云云","2015",null,"other","article","10.11670/1000-7547.201503015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031537","How incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes",null,"2010","The Internet Journal of Academic Physician Assistants","other","article","10.5580/172c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031538","Liraglutide 치료군에서 매주 L-Arginine 주사의 추가 치료에 대한 효능","이은섭","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031539","Activación del receptor de glp-1 en la fibrosis pulmonar experimental","Juan Fandiño","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031540","Molecular Targeting Probes -Radioactive and Nonradioactive Special MTA: Probes for Oncology Posters PET imaging of insulinoma using a 68 Ga-labeled GLP-1 analog","Su‐Tang Lo","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031541","Liraglutide beats sitaglitpin for T2DM in the USA",null,"2013","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-013-0319-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031542","Reversible Erhöhung von Lipase/Amylase unter Liraglutid",null,"2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-118229",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031543","ADA-EASD 2018 m. konsensusas: GLP-1 agonistų vieta gydant 2 tipo CD","Rūta Krikščiūnienė","2018","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031544","Exenatide May Aid Weight Loss in Nondiabetic Patients","JOYCE FRIEDEN","2009","Family Practice News","other","article","10.1016/s0300-7073(09)70673-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031545","Postavení IDegLira v doporučeném postupu ADA/EASD 2018 pro management diabetu 2. typu","Barbora Doležalová","2018","Digital library - University of Pardubice (University of Pardubice)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031546","PEGylation in Development of Exenatide Analogs for the Treatment of Type I I Diabetes","Yong‐Xiang Wang","2010","Journal of Diabetes & Metabolism","other","article","10.4172/2155-6156.1000007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031547","Injectable Biomimetic Hydrogels Providing Prolonged Delivery of GLP-1 Analogues for Enhanced Diabetes Treatment","Lu, Katie","2023","Stanford Digital Repository","preclinical","article","10.25740/pk538cj9584",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031548","Where do GLP-1 RAs Fit into the Management of Patients with Diabetes and CKD?","Katherine R. Tuttle","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031549","in Bio-Breeding/Worcester Rat: Beneficial Role of Exendin-4 Decrease in ²-Cell Proliferation Precedes Apoptosis during Diabetes Development","Gonzalo-Martín Pérez-Arana","2010",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031550","Typ-2-Diabetes: Exenatide per Fertigpen","Springer-Verlag","2015","CME","other","article","10.1007/s11298-015-1198-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031551","Once-weekly semaglutide good value for money in T2DM in the US",null,"2019","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-019-5748-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031552","Effect of Liraglutide Injection on Bone Metabolism in Overweight Male Patients with Type 2 Diabetes Mellitus",null,"2022","Foreign Language Science and Technology Journal Database Medicine and Health","other","article","10.47939/mh.v3i3(02).49",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031553","The ADA/EASD Position Statement on Management of Type 2 Diabetes: Winners and Losers","Charles F. Shaefer","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031554","690-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Data from Spain","Jersy Cárdenas‐Salas","2021","Diabetes","nonrandomized_study","article","10.2337/db21-690-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031555","Liraglutide cost effective in type 2 diabetes with CV implications",null,"2018","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-018-5478-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031556","Glucagon-like Peptide-1 Analogs for Obesity Management","Neeta Deshpande","2017","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/13026_68",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031557","Effect of Liraglutide on leptin and fat content in high fat diet induced obese mice","Sha Sha","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031558","Liraglutide-Induced Acute Pancreatitis","Raja Taunk","2012","The American Journal of Gastroenterology","other_trial","article","10.14309/00000434-201210001-00744",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031559","Liraglutide May Increase Bone Strength, Study Shows","Grace Halsey","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031560","OC.06.2 LIRAGLUTIDE TREATMENT IN OBESE DIABETIC PATIENTS MODULATES GAS PRODUCTION DURING LACTULOSE BREATH TEST: A NEW POTENTIAL TREATMENT TO MODULATE GUT MICROBIOTA","Valentina Tesori","2018","Digestive and Liver Disease","other","article","10.1016/s1590-8658(18)30298-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031561","A Diabetic Case Treated byImeglimin (Twymeeg) and semaglutide (Rybelsus)With Later Development of Arteriosclerosis",null,"2024","JOURNAL OF MEDICAL AND CLINICAL STUDIES","other","article","10.36266/jmcs/208",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031562","Liraglutida/VICTOZA® no tratamento do DM tipo 2 - NT 2202013","Núcleo de Avaliação de Tecnologias em Saúde Nats","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031563","Liraglutide add-on therapy cost effective in T2DM in Sweden",null,"2018","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-018-4730-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031564","Iconography : One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice","Martin Buysschaert","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031565","Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)","In‐Kyung Jeong","2018","Journal of Lipid and Atherosclerosis","other","article","10.12997/jla.2018.7.1.32",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031566","Glucagon-Like Peptide-l","Mane E. Doyle","2005",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031567","Tirzepatide Versus Long-Acting Insulin: A Systematic Review and Meta-Analysis",null,"2024","Egyptian Society of Diabetes and Lipidology Journal","systematic_review","article","10.21608/esdlj.2024.456243",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0031568","Clinical efficacy of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus with cardiovascular pathology and chronic kidney disease: emphasis on cardiorenoprotection","Evgeny Alexandrovich Kovalenko","2022","Медицинский вестник МВД","other","article","10.52341/20738080_2022_120_5_44",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031569","Η επίδραση της παρστατίνης 1-26 στη μυοκαρδιακή βλάβη από ισχαιμία και επαναιμάτωση : μελέτη σε πειραματικό μοντέλο κονίκλων","Παναγιώτης Αλεξόπουλος","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031570","Figure 17, A1C Reduction from Baseline over the Course of the Study for the 82-week Exenatide Completer Cohort and the Intent-to-Treat Population","Patricia S Juang","2013",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031571","84-OR: Semaglutide 2.4 mg Improves Health-Related Quality of Life in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial","Domenica Rubino","2021","Diabetes","randomized_trial","article","10.2337/db21-84-or",null,null,"ClinicalTrials.gov:NCT03552757","S001740","openalex","FALSE","paywalled","1","FALSE","article"],["R0031572","The effects of GLP-1R agonists on neurodegeneration.","D. Sizoo","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031573","Ozempic nas Redes Sociais","Ramos, Gabriela","2025","PROA-UA","other","article","10.34624/iciemc.v0i6.40231",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031574","Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes and Obesity Using GLP-1 Receptor Agonists: A Cohort Study (S14.004)","Filipi Fim Andreão","2025","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000212637",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031575","Safety Evaluation of Incretin Drugs","Cspc Zhong","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031576","Management of type 2 diabetes mellitus in the elderly population with cardiovascular diseases","Ravi Kant","2019","Clinical Trials in Degenerative Diseases","other","article","10.4103/2542-3975.274079",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031577","Simultaneous administration of insulin and GLP-1 agonists. Technologically possible?","Juliana Silva Barbosa","2017","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031578","Diabetes clinical decision-making in patients at risk: Taking patient complexity into account","Frank Lavernia","2013","Osteopathic Family Physician","other","article","10.1016/j.osfp.2012.11.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031579","Semaglutide reduces cardiovascular risk across risk subgroups",null,"2018","Clinical pharmacist","other_trial","article","10.1211/cp.2018.20205530",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031580","Glucagon - like peptide-1 receptor agonists in obesity management","Sanjay Kalra","2014","Journal of Obesity and Metabolic Research","other","article","10.4103/2347-9906.134402",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031581","Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of","Jens J U U L Holst","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031582","Therapeutic effects of glucagon like peptide (GLP)-1 receptor agonists in hidradenitis suppurativa: A retrospective study","R. Thibault","2025","Clinical Nutrition ESPEN","nonrandomized_study","article","10.1016/j.clnesp.2025.07.844",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031583","FDA Warns of Pancreatitis Risk With Byetta","ROBERT FINN","2007","Family Practice News","other","article","10.1016/s0300-7073(07)71288-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031584","Exclusive patent, know-how and process license to make, have made, use, import, offer, sell, have sold and sublicense exendins including AC2993, which is a synthetic exendin-4, and exendin agonists, GLP-1 and GLP-1 agonists relating to injectable, sustained release formulation systems, including the 'Medisorb' microsphere system, with licensor to supply products.","RoyaltyStat","2019","RoyaltyStat Library","other","article","10.34675/l31909",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031585","ラット唾液アミラーゼモデルを用いたGLP-1受容体作動薬liraglutide及び exenatideの催吐作用検討：ヒト特異的な嘔吐を検出・評価するための実験系としての可能性","吉岡 豊晃","2012","Medical Entomology and Zoology","other","article","10.14869/toxpt.39.1.0.p-251.0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031586","Incretin Therapy Side Effects Linked to Age, No Metformin Use","Leah Lawrence","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031587","Model of Diabetes Mellitus Type 2, T2DM",null,"2014","Journal of Nutrition & Food Sciences","other","article","10.4172/2155-9600.1000344",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031588","Effects of Liraglutide on Diastolic Function Parameters in Patients with Type 2 Diabetes and Coronary Heart Disease","传统 王","2023","Advances in Clinical Medicine","other","article","10.12677/acm.2023.1361253",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031589","Incretin-based therapies and their future in Type 2 diabetes mellitus","Travis E. Sonnett","2011","Therapy","other","article","10.2217/thy.11.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031590","The potential role of GLP1 analogues in cardiovascular disease.","Eltom, Mohamed Ahmed","2018",null,"other","article","10.13140/rg.2.2.13094.42562",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031591","Neuro Pharmacological Review on Obesity","V. Chitra","2020","Research Journal of Pharmacy and Technology","narrative_review","article","10.5958/0974-360x.2020.00281.4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031592","Once weekly exenatide is an alternative treatment to daily basal insulin","Michelle Stephenson","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031593","Appetite suppressant approved by NICE for patients with obesity",null,"2022","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2022.1.157436",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031594","Improved HbA1c value by combined treatment of Dulaglutide and Imeglimin for patient with type 2 diabetes mellitus (T2DM)",null,"2022","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/135",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031595","Značaj kombinirane terapije u liječenju šećerne bolesti tipa 2","Ivana Antal","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031596","¿Qué sigue en la era Ozempic?","Matías A. Loewy","2024","Knowable Magazine","other","article","10.1146/knowable-041624-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031597","Prandialer GLP-1-Agonist 1 x täglich","DE","2013","Der Hausarzt","other","article","10.1007/s15200-013-0495-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031598","The Effects of GLP-1 Receptor Agonists on Metabolic Inflammatory Markers in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Fang Zhao","2025",null,"systematic_review","article","10.37766/inplasy2025.4.0020",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","report"],["R0031599","The Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exendin-4 Upregulates cAMP Levels, Activates AMP Kinase and Inhibits In Vitro and In Vivo Growth of Breast Cancer Cells.","Tamar Rubinek","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","preclinical","article","10.1210/endo-meetings.2010.part3.p1.p3-45",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031600","Exendin-4","Brian L. Furman","2007","xPharm: The Comprehensive Pharmacology Reference","other","article","10.1016/b978-008055232-3.61732-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031601","Pancreatic Neuroendocrine Tumor Recurrence after Tirzepatide Use","N. Ba","2025","International Journal of Clinical Studies and Medical Case Reports","other","article","10.46998/ijcmcr.2025.52.001285",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031602","Insulin and GLP1 RA Combinations","Premlata Varthakavi","2015","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12535_20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031603","The glucagon-like peptide-1 agonist Liraglutide improves memory and learning in obese-diabetic mice","W.D. Porter","2010","Regulatory Peptides","preclinical","article","10.1016/j.regpep.2010.07.101",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031604","Glucagon like peptide-1: A new therapeutic target for diabetes mellitus","SK Patel","2006","Indian Journal of Pharmacology","other","article","10.4103/0253-7613.27018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031605","GLP-1 Receptor Agonists: dalla farmacologia alla pratica clinica","Maria Chiara Rossi","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031606","Progress of Chinese Medicine in the Prevention and Treatment of Functional Dyspepsia Caused by Type 2 Diabetes Mellitus with Semaglutide","莹莹 刘","2024","Traditional Chinese Medicine","other","article","10.12677/tcm.2024.134124",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031607","Effect of Liraglutide Combined with Metformin on Ovarian Function in Patients with Polycystic Ovary Syndrome",null,"2021","Foreign Language Science and Technology Journal Database Medicine and Health","other","article","10.47939/mh.v2i10.269",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031608","Four Facts to Remember Before Prescribing a GLP-1 Agonist","Payal Kohli","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031609","Exendin-4 analóg minifehérjék stabilitás és amiloid aggregáció vizsgálata","Horváth, Dániel","2021","Semmelweis University Repository (Semmelweis University)","other","article","10.14753/se.2021.2480",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0031610","Le liraglutide, premier analogue du GLP-1 en une injection par jour dans le diabète de type 2","Esther Sacoun","2010","Actualités Pharmaceutiques Hospitalières","other","article","10.1016/s1769-7344(10)70282-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031611","Novel insights into the regulation of insulin secretion by GLP-1, GIP and glucagon","Linda Ahlkvist","2015","Lund University Publications (Lund University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031612","EMA recommends approval of liraglutide as weight loss drug",null,"2015","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2015.20067700",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031613","Pharmacokinetics and efficacy of a new sustained-release microsphere formulation of exenatide","곽현희","2010","Seoul National University Open Repository (Seoul National University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031614","Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obses, Korean pateintw with type 2 diabetes","Sun Ok Song","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031615","METABOLIC EFFECTS OF EXENATIDE IN POST ISLET TRANSPLANT RECIPIENTS.","&NA;","2006","Transplantation","other","article","10.1097/00007890-200607152-00817",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031616","663-P: Achievement of Near-Normal HbA1c with Early Initiation of Oral Semaglutide: An Exploratory Subgroup Analysis of PIONEER 1","Vanita R. Aroda","2021","Diabetes","randomized_trial","article","10.2337/db21-663-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031617","ОЦЕНКА СОДЕРЖАНИЯ БЕЛКА В СЕМЕННОМ МАТЕРИАЛЕ СОМАКЛОНАЛЬНЫХ ЛИНИЙ СОИ","ФИСЕНКО П. В.","2020","CyberDOI","preclinical","article","10.24411/1999-6837-2020-13032",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031618","Liraglutide Effect on Blood Pressure, Lipids Profile, and Liver Enzymes in Arab Patients with Type 2 Diabetes Mellitus: A Prospective LIRA-BPL Study","Elamin Ibrahim Elamin Abdelgadir","2015","Journal of Diabetes & Metabolism","other","article","10.4172/2155-6156.1000591",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031619","Acute Exenatide Overdose","Christine Payen","2014","Journal of Clinical Toxicology","other","article","10.4172/2161-0495.1000214",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031620","Arzneimittel zur Gewichtsregulierung – Wegovy","Anna Büscher","2025","Kranken- und Pflegeversicherung","other","article","10.37307/j.2193-5661.2025.05.11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031621","DPP-4 inhibitors versus SGLT-2 inhibitors; cons and pro","Eleni Xourgia","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031622","Weight Loss in Primary Care Augmented by Liraglutide plus Behavior Therapy","Grace Halsey","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031623","First Oral GLP-1 Agonist Showcased while Approval Pending","Kenneth J. Bender","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031624","5-HT3 receptor-triggered serotonin release from guinea-pig isolated colonic mucosa: a role of Y1 and GLP-1 receptors","Shu‐ichi Kojima","2018","Proceedings for Annual Meeting of The Japanese Pharmacological Society","preclinical","article","10.1254/jpssuppl.wcp2018.0_po2-6-14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031625","Weekly Exenatide vs. Daily Liraglutide: Little Difference","SARA FREEMAN","2011","Internal Medicine News","other","article","10.1016/s1097-8690(11)70829-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031626","DPP-4 Inhibitors as Antidiabetic Agents","Shubhangi S. Soman","2010","Journal of Analytical & Bioanalytical Techniques","other","article","10.4172/2155-9872.1000032",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031627","Effects of incretin-based therapies on the gastrointestinal motility of an animal model of Multiple Sclerosis","Beatriz de Oliveira Martins","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031628","Vitamin D and prevention of diabetes: is lifelong endogenous vitamin D needed?","Alan J. Garber","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031629","Self emulsifying drug delivery system of exenatide via hydrophobic ion pairing / eingereicht von Gerlinde Bock","Gerlinde Bock","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031630","Dinamika Protein Hormon Glp-1 Dan Analognya (Exenatide Dan Liraglutide) Terhadap Protein Membran Glp-1r.","Alfi Afifah","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031631","Incretin-based Therapies","Ajit Kumthekar","2010","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/11384_14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031632","Improved β-cell Function and Prolonged Remission of Diabetes Type 1 by GLP-1 Agonist Treatment in Newly Diagnosed Adolescences","Spyridon Zarogiannis","2019",null,"other","article","10.47690/gdoaj.2019.1104",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031633","Liraglutide reduces risk of cardiovascular death in type 2 diabetes",null,"2016","Clinical pharmacist","other","article","10.1211/cp.2016.20201367",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031634","A Rare Case of Tirzepatide-Induced Hepatitis: Causality Assessment With the RUCAM Criteria","Rayan Tareg Ahmed","2025","Annals of Internal Medicine Clinical Cases","other","article","10.7326/aimcc.2024.0923",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031635","GlaxoSmithKline's Alli [orlistat] and Lily/Amylin's Byetta [exenatide] are making impacts in the obesity drug market,",null,"2007","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-200705430-00033",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031636","Glucagon Like Peptide 1 Receptor Agonists: Glycaemic Control and Beyond","Nirmalya Roy","2016",null,"other","article","10.12345/jcd.2016.2.4.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031637","Annals for Hospitalists - 16 August 2016","David H. Wesorick","2016","Annals of Internal Medicine","nonrandomized_study","article","10.7326/afho201608160",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031638","Pharmacological Treatment of Gestational Diabetes Mellitus: When Lifestyle Intervention Is Not Enough","Basilio Pintaudi","2019","Frontiers in diabetes","other","article","10.1159/000480166",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031639","Original / Síndrome metabólico Efectos de exenatide LAR en diabetes mellitus tipo 2 y obesidad","Roberto Sierra Poyatos","2015",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031640","Levothyroxine and GLP-1 Agonists Implications for Thyroid Function Monitoring","Indunil Karunarathna","2025",null,"other","article","10.13140/rg.2.2.16044.58242",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031641","SAFETY AND EFFICACY OF OBESITY MANAGEMENT WITH ENDOSCOPIC SLEEVE GASTROPLASTY AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) IN A PATIENT WITH INFLAMMATORY BOWEL DISEASE","Thomas Mathews","2023","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2023.04.134",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031642","Insulin degludec/Liraglutid: Langzeit-Blutzuckerkontrolle getestet",null,"2019","Diabetologie und Stoffwechsel","other","article","10.1055/a-0979-7269",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031643","Adjunctive exenatide “good value for money” in the US",null,"2008","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-200805480-00008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031644","Liraglutide for Weight Reduction in Obese Adolescents",null,"2020","AAP Grand Rounds","other","article","10.1542/gr.44-2-19",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031645","Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic β-cell destruction induced by encephalomyocarditis virus","寛行 佐野","2011","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031646","Liraglutide protects high fat high sucrose diet induced obesity through elevation of energy expenditure","Lixin Li","2015","Journal of Obesity & Weight loss Therapy","other","article","10.4172/2165-7904.s1.017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031647","Anti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion","Xianjin DuXiaorong","2014",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031648","Healthcare service utilization and direct medical cost for patients with type 2 Diabetes Mellitus initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1A)","HM Tang","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031649","Therapeutic effects of liraglutide, a glucagon-like peptide-1 analog, in diabetic WBN/Kob-Leprfa rats with obesity and chronic pancreatitis","Dai Nagakubo","2016","Integrative Obesity and Diabetes","preclinical","article","10.15761/iod.1000160",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031650","Type 2 Diabetes, Metabolic Syndrome and Lipid Metabolism","Orit Pinhas‐Hamiel","2019","Yearbook of pediatric endocrinology","other","article","10.1530/ey.16.12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031651","Leczenie cukrzycy typu 2","Krzysztof Dęmbe","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031652","Towards a Health Economic Simulation Model of Type 2 Diabetes in Sweden","Ali Kiadaliri","2014","Lund University Publications (Lund University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0031653","Collaborative development and commercialization of the exendin-4 compound and pharmaceutical products containing the compound to prevent and treat all human and animal diseases and disorders, with joint ownership of patents, know-how and improvements.","RoyaltyStat","2019","RoyaltyStat Library","other","article","10.34675/l30831",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031654","No Risk of Acute Pancreatitis Seen with Incretin-Based Therapies","Leah Lawrence","2015",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031655","Byetta, Elestrin","ELIZABETH MECHCATIE","2007","Skin & Allergy News","other","article","10.1016/s0037-6337(07)70171-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031656","A Monthly Dosed GLP-1 Analog for Treatment of Type 2 Diabetes Mellitus.","JL Cleland","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","other","article","10.1210/endo-meetings.2010.part3.p11.p3-517",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031657","Stéato-hépatite non alcoolique: liraglutide","Antoine de Torrenté","2016","Forum Médical Suisse ‒ Swiss Medical Forum","other","article","10.4414/fms.2016.02653",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031658","Dulaglutide – an innovative medication for diabetes mellitus type 2 treatment that requires administration once in a weekInterview with M.V.Shestakova",null,"2018","Consilium Medicum","other","article","10.26442/2075-1753_2018.4.8-11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031659","Efficacité et tolérance d'IDegLira en cas d'insuffisance rénale légère à modérée : analyses des études de phase III","M Marre","2018",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031660","Liraglutide 移섎즺援곗뿉??留ㅼ＜ L-Arginine 二쇱궗??異붽? 移섎즺??????⑤뒫","EunSubLee","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031661","당화 GLP-1-Fc와 Dulaglutide (mutated GLP-1-Fc)의 혈당 조절 작용과 위장관계 및 심장 부작용의 비교","안인복","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031662","Figure 10, Comparison of exenatide vs basal insulin on 24 hour glucose pattern [217].","Joseph L Evans","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031663","Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia","紳一郎 寺本","2012","Medical Entomology and Zoology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031664","The Combination of a Long Acting GLP-1 Analog (E-XTEN; VRS-859) and Long Acting Glucagon (Gcg-XTEN; AMX-808) for Superior Weight Loss and Glycemic Control in Treatment of Type 2 Diabetes and Obesity.","JL Cleland","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","other","article","10.1210/endo-meetings.2010.part3.or1.or24-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031665","Short-term and low-dose liraglutide plus metformin decreased body mass index and insulin resistance more than metformin alone in obese women with polycystic ovary syndrome: An open-label randomized controlled study","Ahmed Hossain","2023","Greater South Information System","randomized_trial","article","10.60692/d2w4w-3se76",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0031666","GLP-1 receptor agonists – an evolving paradigm in perioperative medication management","Edward Lim","2025","Australian and New Zealand College of Anaesthetists eBooks","other","article","10.60115/11055/1303",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0031667","UK National Exenatide Guidelines (NICE:CG87) compared to clinical outcomes at a district general hospital's diabetes department","David Hughes","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031668","Weight-loss pilots in pharmacies could be among £85m programme part-funded by Mounjaro manufacturer",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.368990",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031669","NICE provisionally recommends semaglutide for patients with obesity",null,"2022","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2022.1.129302",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031670","Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet","Nct","2019",null,"other","article","10.1002/central/cn-01992758",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031671","Byetta, Elestrin","ELIZABETH MECHCATIE","2007","Internal Medicine News","other","article","10.1016/s1097-8690(07)70070-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031672","\"Un nouveau médicament contre les diabètes et des risques de cancer\" par le Dr Mae-Wan Ho – ISIAS","Ho Dr Mae-Wan","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031673","Study on the Effect of LHA on Feeding and its Mechanism","Zhongxiang, Wang","2018","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.3350286",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031674","GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity","Anandan Palani","2016","Elsevier eBooks","other","article","10.1016/b978-0-12-409547-2.13765-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031675","Obesity, GLP-1 receptor agonist, Orlistat.","Momin M. A. Mujeeb","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031676","Semaglutide has lowest cost of glycaemic control",null,"2019","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-019-6343-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031677","Efficacité et tolérance d'IDegLira en cas d'insuffisance rénale légère à modérée : analyses des études de phase III","M Marre","2018",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031678","Study highlights pancreatitis risk with sitagliptin and exenatide",null,"2013","Clinical pharmacist","other","article","10.1211/pj.2013.11117829",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031679","New Semaglutide Dosage Forms Approved by FDA","Drew Boxler","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031680","Diabetes in childhood and adolescence","FRCP Rudy Bilous","2021",null,"other","article","10.1002/9781118976074.ch30",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0031681","Sponzoriranje i promocija lijekova : usporedba javnih podataka u SAD-u 2013. i 2014. godine","Karla Mišur Milinković","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0031682","Impressive clinical course of diabetic patient with various medical problems and remarkable improvement by insulin degludec and liraglutide (Xultophy)","Hiroshi Bando","2020","MOJ Clinical & Medical Case Reports","other","article","10.15406/mojcr.2020.10.00341",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031683","SUSTAINed: weekly semaglutide cost effective versus daily liraglutide",null,"2020","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-020-6791-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031684","Genetic findings support cardiovascular safety of GLP1R agonists",null,"2016","Clinical pharmacist","other","article","10.1211/cp.2016.20201296",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031685","Novel Dual-mechanism Agent Acts on Diabetes, Metabolic Complications","Kenneth J. Bender","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031686","Papel del sistema endocannabinoide en el metabolismo energético del músculo: repercusión para el tratamiento de la obesidad inducida por dieta","Sergio Arrabal Núñez","2016","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031687","Research Progress of Liraglutide in Improving Obesity","国庆 邢","2021","Advances in Clinical Medicine","other","article","10.12677/acm.2021.1111814",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031688","Chapter-09 Incretin-based Therapies","Rajeev Chawla","2013","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12154_9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031689","Semaglutide + metformin not cost effective vs empagliflozin + metformin for T2DM in Denmark",null,"2021","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-021-08254-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031690","Figure 21, LEAD-2 Trial: Changes in Body Weight at the End of 2 years for Liraglutide, Glimepiride and Placebo Groups in Combination with Metformin","Patricia S Juang","2013",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031691","111In-Diethylenetriaminepentaacetic acid-aminohexanoic acid-Lys40-exendin-4","Kam Leung","2012","Europe PMC (PubMed Central)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031692","Amendment to collaborative development and commercialization of a product which is a fixed-dose injection of exenatide, for any indication, and which may be sold under the 'Byetta' trademark.","RoyaltyStat","2019","RoyaltyStat Library","other","article","10.34675/l31035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031693","Once-Weekly Exenatide Lowers Glycemia, Weight","MIRIAM E. TUCKER","2008","Internal Medicine News","other","article","10.1016/s1097-8690(08)70821-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031694","PASIREOTIDE-INDUCED HYPERGLYCEMIA INACROMEGALY PATIENTS: EVALUATION OF PATHOPHISIOLOGICAL MECHANISMS AND EFFICACY OF ANTIDIABETIC TREATMENT","Ludovica F. S. Grasso","2019",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031695","AKT answer relating to side effects of tirzepatide",null,"2025","InnovAiT Education and inspiration for general practice","other","article","10.1177/17557380251360588k",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031696","The Effectiveness of GLP-1R Agonist Liraglutide within ERAS Protocols","Shizuka Kaneko","2019",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","book"],["R0031697","Ионорегулирующая функция почек и эффект глюкагоноподобного пептида-1 у крыс на высокосолевой диете","Е. В. Балботкина","2019","Российский физиологический журнал им  И  М  Сеченова","preclinical","article","10.1134/s0869813919080119",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031698","Future Drug Treatments for Type 2 Diabetes","Clifford J. Bailey","2016",null,"other","article","10.1002/9781118924853.ch67",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0031699","Food Ease in the “Ozempic Era”","Michael Greer","2025","Gastronomica The Journal of Food and Culture","other","article","10.1525/gfc.2025.25.3.59",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031700","Incretin-based therapies for type 2 diabetes with nonalcoholic fatty liver disease: a systematic review and meta-analysis","Shao Hong","2016","Journal of Chinese Pharmaceutical Sciences","systematic_review","article","10.5246/jcps.2016.03.025",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0031701","Comparison of Distinct GLP-1 Receptor Agonists in Palmitate-induced Incretin Resistance of Pancreatic Beta Cells","Annalisa Natalicchio","2015","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031702","Solution Oligomerization of Liraglutide","Max Larson Lagerås","2018","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; dissertation"],["R0031703","Treatment Result of Dulaglutide for Type-2 Diabetes in Shirakawa Kosei General Hospital","Hiroyuki Hirai","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031704","Combining a GLP-1 receptor agonist plus insulin proves more effective than other diabetes therapies",null,"2014","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2014.20066519",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031705","Short Term Outcomes of Low Dose Liraglutide in Obese Non Diabetic Indian Subjects-A Real World Experience","Soumyabrata Roy Chaudhuri","2016","Diabetes & Obesity International Journal","nonrandomized_study","article","10.23880/doij-16000140",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0031706","Glucagon-like peptide-1 agonist and Quercetin improve skeletal muscle performance and pain threshold in male rats with fibromyalgia via activating the Nrf2/HO1/NQO1 pathway.","Fatma E. Hassan","2025","Bulletin of Egyptian Society for Physiological Sciences","preclinical","article","10.21608/besps.2025.351962.1197",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031707","Chapter 14. Drug Design and Therapeutic Development for Diabetes Mellitus","Shahrad Taheri","2015","RSC drug discovery/RSC drug discovery series","other","article","10.1039/9781782622390-00297",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031708","Chapter 9. Impurity Characterization and Quantification by Liquid Chromatography–High-resolution Mass Spectrometry","Kui Zeng","2019","RSC drug discovery/RSC drug discovery series","other","article","10.1039/9781788016445-00313",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031709","GLP-1 Analogue Liraglutide: Review of its Efficacy and Role in Management of Type 2 Diabetes","Ram Kela","2011","International Journal of Clinical Reviews","narrative_review","article","10.5275/ijcr.2011.10.11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031710","Additional effect of weekly L-arginine injection on body weight change in liraglutide treatment patients","Eun-Sub Lee","2020","Korean Institute for Functional Medicine","other","article","10.32581/jkifm.2020.3.1.24",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031711","Semaglutide cost saving in T2DM",null,"2018","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-018-5110-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031712","A multifaceted approach to diabetes management","PharmD Monica Shah","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031713","糖尿病治疗新药Liraglutide（利拉鲁肽）引起众人关注","朱大龙","2008","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031714","Liraglutide in children and adolescents with type 2 diabetes","Tamborlane Wv","2020","Yearbook of pediatric endocrinology","other","article","10.1530/ey.17.12.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031715","Figure 10. [Structure of GLP-1 Receptor Agonists].","Kenneth R. Feingold","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031716","Exenatide could be a sweet option for T2DM in the US",null,"2011","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-201106380-00015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031717","Advances in Biological and Clinical Research of GLP-1 Receptor Agonists","鑫 李","2022","Advances in Clinical Medicine","other","article","10.12677/acm.2022.124430",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031718","NHS England looks to tender contract for behavioural support for patients prescribed tirzepatide in primary care",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.357792",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031719","Team-Based Strategies for Weight Management with Semaglutide","Indunil Karunarathna","2024",null,"other","article","10.13140/rg.2.2.25674.38083",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031720","Gallensteinerkrankungen: Was trägt Liraglutid dazu bei?",null,"2020","Diabetologie und Stoffwechsel","other","article","10.1055/a-1009-2613",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031721","La malattia di Parkinson: attuali terapie e insulino-resistenza come potenziale bersaglio per nuove strategie terapeutiche","Giulia Baston","2017",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031722","Real-world usage and cost of exenatide and liraglutide",null,"2015","PharmacoEconomics & Outcomes News","nonrandomized_study","article","10.1007/s40274-015-1893-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031723","New Once-Weekly Exenatide for Type 2 Diabetes","PharmD Amanda M. Stahnke","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031724","GLP-1受体长效激动剂GLP-1-exendin-4/IgG4（Fc）融合蛋白的制备与生物效应","郑云程","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031725","Incretins, Dipeptidyl Peptidase-4 Inhibitors and Diabetes","Robab Sheikhpour","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0031726","Progress of Semaglutide Tablets Based on SNAC Absorption Enhancement","Dan Li","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031727","Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and preclinical models of insulin-deficient diabetes","T Fuselier","2022","Yearbook of pediatric endocrinology","preclinical","article","10.1530/ey.19.10.17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031728","What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?","Robert E. J. Ryder","2017","British Journal of Diabetes","other","article","10.15277/bjd.2017.036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031729","Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","Sven Schinner","2010","Yearbook of Endocrinology","randomized_trial","article","10.1016/s0084-3741(10)79449-x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031730","Research progress on hypoglycemic active components in natural products","Xingyuan Chen","2016","European Journal of BioMedical Research","other","article","10.18088/ejbmr.2.1.2016.pp21-26",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031731","RR 382 - 2013 NATS Victoza para diabetes","Núcleo de Avaliação de Tecnologias em Saúde","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031732","Regular Self-monitoring of Blood Glucose is Required with Once Weekly Glucagon-like Peptide 1 Agonists (for the Motion)","Soumik Goswami","2017","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12963_41",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031733","Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","Frias JP","2022","Yearbook of pediatric endocrinology","randomized_trial","article","10.1530/ey.19.15.1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031734","The Impact of Liraglutide on Lipid Metabolism ,Oxidation Stress","Mei Xiaoxue","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031735","Small Differences in GLP-1 Agonists Identified","Leah Lawrence","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031736","Leptin and insulin receptor expression in the brain of diet induced diabetic, obese elderly rats/ treated with Liraglutide (Victoza) and Metformin","Senka Blažetić","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031737","Simulation, optimization and implementation of a twin-column MCSGP process for the purification of Liraglutide","Joaquín Gomis‐Fons","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031738","Medication treatment for type 2 diabetes","Guo Li-xi","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031739","The big online pharmacy clampdown",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.352158",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031740","82-OR: Effect of Semaglutide 2.4 mg on Glucose Metabolism and Body Weight in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial","Leigh Perreault","2021","Diabetes","randomized_trial","article","10.2337/db21-82-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031741","Table 8, Summary of Results of 30-week Trials of Exenatide in Combination with Metformin, Sulfonylurea or Both(69-71)","Patricia S Juang","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031742","688-P: Effect of Probenecid and Cyclosporin on the Pharmacokinetics of SNAC in Healthy Subjects","Tanja Kongerslev Thorning","2021","Diabetes","randomized_trial","article","10.2337/db21-688-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031743","FDA actions in brief, February 2010 (Ampyra, Victoza, Actemra, Tropazone, Morphine sulfate oral solution, Fluzone High-Dose)","Formulary staff","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031744","New drug--and new hope--for a losing game","Paula A. Kiberstis","2015","Science","other_trial","article","10.1126/science.349.6247.491-e",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031745","Injectable weight loss drug liraglutide approved by FDA",null,"2014","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2014.20067489",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031746","N-2-(4-[18F]-Fluorobenzamido)ethylmaleimide coupled to cysteine-tagged on the C- or N-terminal of exendin-4","Arvind Chopra","2012","Europe PMC (PubMed Central)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031747","Figure 11, Comparison of exenatide vs basal insulin on 24-hour glucose pattern (245).","Börk Balkan","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031748","909: LIRAGLUTIDE FOR INSULIN RESISTANCE AFTER BURN INJURY","Kaitlin A Pruskowski","2021","Critical Care Medicine","other","article","10.1097/01.ccm.0000809960.62976.cc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031749","Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist with Both Injectable and Oral Formulations",null,"2021","Frontiers research topics","other","article","10.3389/978-2-88971-350-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0031750","Byetta (r)",null,"2011","Bloomsbury Academic eBooks","other","article","10.5040/9781350363595.art-2135",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031751","Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era","J Reite","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031752","Liraglutide",null,"2017","The American Pharmacists Association eBooks","other","article","10.21019/pfdi.liraglutide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031753","Victoza indicated for type 2 diabetes and moderate kidney disease",null,"2015","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2015.20067658",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031754","Semaglutide voor gewichtsverlies bij obesitas","RA Middelburg","2021","Geneesmiddelenbulletin","other","article","10.35351/gebu.nl.2021.9.17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031755","Insulin glargine/lixisenatide good value in type 2 diabetes",null,"2021","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-021-08173-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031756","Appetite-regulating peptides and natural rewards: emphasis on ghrelin and glucagon-like peptide-1","Jesper Vestlund","2020","Gothenburg University Publications Electronic Archive (Gothenburg University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031757","Liraglutide cost effective for type 2 diabetes in the UK",null,"2011","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-201106370-00016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031758","NO與MC系統在exendin-4降低攝食中所扮演的角色; Roles of Nitric Oxide and Melanocortin Pathways in the Anorectic Effect of Exendin-4","李竹菀","1993",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031759","Laparoscopic Sleeve Gastrectomy","Amir Guindi","2017","Journal of Medical Insight","other","article","10.24296/jomi/138",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031760","Role of insulin, glucagon-like peptide-1 analogue and vitamin D in the regulation of endothelin-1 receptor subtypes in type-1 diabetic rat hearts","Suzan S. Boutary","2010",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031761","GLP-1-Agonist: Mehr als ein Zuckersenker","Springer Medizin","2019","CME","other","article","10.1007/s11298-019-7239-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031762","GLP-1 agonists cost effective for T2DM in Sweden",null,"2015","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-015-1855-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031763","Weight loss drug semaglutide will ‘soon’ be available to eligible patients, says NICE",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.177160",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031764","PHARMAC approves funding for empagliflozin and dulaglutide",null,"2021","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-021-7403-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031765","Podcast: Incretins for Type 2 Diabetes Mellitus (Part 2)","Louis Kuritzky","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031766","Investigational Drug Bests Exenatide in Glucose Control","DOUG BRUNK","2009","Family Practice News","other","article","10.1016/s0300-7073(09)70532-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031767","The hunger games: taste, GLP-1 and female gender involved P-0449","Maja Baretić","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031768","Development of Tannic acid/Al (III) Nanoparticles for Controlled Release of Liraglutide: Preparation and In Vivo Evaluation","Jinchang Zhu","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031769","Correlation of particle size distribution with process parameters in gas-atomization",null,"1995","Metal Powder Report","randomized_trial","article","10.1016/0026-0657(95)93260-7",null,null,"ClinicalTrials.gov:NCT01237119","S002015","openalex","FALSE","paywalled","1","FALSE","article"],["R0031770","Comparison of adverse effects among different GLP-1 receptor agonists added to basal insulin, and between GLP-1 receptor agonists and basal insulin versus Basal-plus or basal-bolus insulin in type 2 diabetes: A meta-analysis","Manov, Andrey Emanuilov","2021","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.5030763",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; review"],["R0031771","Insulin-secreting cell regeneration: a dream or reality?","Ilia Banakh","2013","Diabetes Management","other","article","10.2217/dmt.13.12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031772","Lixisenatide: clinical profile and available evidence","Ilaria Dicembrini","2013","Diabetes Management","other","article","10.2217/dmt.13.64",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031773","Clinical decision making in diabetes: Use of glucagon-like peptide-1 (GLP-1) receptor agonists in clinical practice (where, when, and which?)–Introduction","Jeffrey S. Freeman","2013","Osteopathic Family Physician","other","article","10.1016/j.osfp.2012.10.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031774","Role of Additional GLP-1 Receptor Agonist to Insulin Regimen in Type 1 Diabetes among Pediatric Age","Hussain Abdrabalrasool Alturaifi","2021","International Journal Of Pharmaceutical Research And Allied Sciences","other","article","10.51847/fu8wdco3du",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031775","Uloga inkretina u smanjenju kardiovaskularnog rizika","Ana-Maria Lulić","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031776","Placing Incretin-Based Therapy In Type 2 Diabetes Mellitus: Whom To Prescribe To?",null,"2010","The Internet Journal of Family Practice","other","article","10.5580/1c33",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031777","Primary Therapy for Obesity as the Treatment of Type 2 Diabetes","Manpreet S. Mundi","2011",null,"other","article","10.1002/9781444340280.ch12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0031778","Incretin mimetic therapy: Incremental for diabetes","PharmD Heidi Belden","2007",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031779","Patients willing to pay extra for liraglutide over glimepiride",null,"2010","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-201006080-00027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031780","Research Article Promotion of apoptosis in high glucose-activated hepatic stellate cells by GLP-1 receptor agonist and its potential mechanism.","Lingkang Wu","2017","Genetics and Molecular Research","other","article","10.4238/gmr16039818",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031781","Semaglutide in Clinical Practice Dose Escalation and Monitoring","Indunil Karunarathna","2024",null,"other","article","10.13140/rg.2.2.12252.60800",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031782","Pharmacists encouraged to report GLP-1 side effects amid pharmacogenomics study",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.362498",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031783","Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease.","Weizhen Liu","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031784","Protective effect of exenatide (glucagon-like peptide-1 receptor agonist) on renal ischemia–reperfusion injury in diabetic rats","OlaA El-Gohary","2016","Benha Medical Journal","preclinical","article","10.4103/1110-208x.194384",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031785","Exenatide inhibits JAK1/STAT1 expression and B cell apoptosis in insulin resistant rat model of type 2 diabetes mellitus","Qi-Jin Wang","2010","Academic Journal of Second Military Medical University","preclinical","article","10.3724/sp.j.1008.2010.01189",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031786","Efecto de los niveles de GRK2 en la modulación de la homeostasis glucémica en situaciones fisiopatológicas.: Influence of GRK2 levels in the modulation of glucose homeostasis in health and disease","Alba C. Arcones","2020","Dialnet (Universidad de la Rioja)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031787","Utjecaj prehrane bogate mastima i šećerom na Izražaj antioksidativnih gena u mikrocirkulaciji Sprague Dawley štakora","Petar Šušnjara","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031788","Exenatide with and without Insulin; Effects on the Weight and Glycemic Control.","Mario Skugor","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","other","article","10.1210/endo-meetings.2010.part3.p11.p3-531",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031789","What’s next in the Ozempic era?","Matías A. Loewy","2024","Knowable Magazine","other_trial","article","10.1146/knowable-041724-1",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031790","Sastav lipida stanične membrane jetre ženki štakora Sprague Dawley hranjenih masnom i slatkom hranom i tretiranih metforminom ili liraglutidom","Monika Berecki","2018",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031791","Liraglutide beats exenatide in diabetes-related pharmacy costs",null,"2014","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-014-1034-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031792","Betere glykemische controle met GLP-1 analoog liraglutide","Bohn Stafleu van Loghum","2013","Mednet","other","article","10.1007/s12462-013-0272-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031793","Weekly Exenatide Topped Daily Insulin Glargine","MIRIAM E. TUCKER","2010","Family Practice News","other","article","10.1016/s0300-7073(10)70821-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031794","Exenatide cheaper than insulin glargine in US",null,"2010","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-201005940-00015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031795","Vécu de l'introduction d'un traitement injectable chez le patient diabétique de type 2 : étude au centre hospitalier de Saint-Avold","Céline Charmeux","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031796","Abnormal Glucose Tolerance in Prediabetes Patients with Acute Myocardial Infarction: Implications for Therapy","Nitchakarn Laichuthai","2021","Greater South Information System","other","article","10.60692/ppdj9-2qh86",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031797","注射用重组艾塞那肽-人血清白蛋白融合蛋白E2HSA对小鼠胰岛 β 细胞功能的保护作用","李彩娜","2019",null,"other","article","10.16438/j.0513-4870.2019-1062",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031798","Exendin-4 protects pancreatic beta cells from the cytotoxic effect of rapamycin by inhibiting JNK and p38 phosphorylation","祐貴子 河崎","2010","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031799","[Table, 18F-Tetrazine-trans-cyclooctene-Cys40-exendin-4].","Kam Leung","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031800","Liraglutide as Additional Treatment in Type 1 Diabetes","Ajay Varanasi","2011",null,"other","article","10.1210/endo-meetings.2011.part1.or8.or07-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031801","Figure 16, Changes from Baseline A1C Patients Randomized to Exenatide or Placebo","Patricia S Juang","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031802","What's on the horizon for diabetes therapy?","PharmD Monica Shah","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031803","Incretin Therapy: A Short Review","Veronica Hackethal","2013",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0031804","GLP-1 analog投与下での内分泌テストにより,pseudo-Cushing病を呈したRathke嚢胞の一例","深見忠輝","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031805","The Difficulty of Diabetic Therapy: An Observational Retrospective Study from Actual Clinical Practice","Roberta Pirolo","2016","Advances in Pharmacoepidemiology & Drug Safety","nonrandomized_study","article","10.4172/2167-1052.1000205",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0031806","dose-dependent and transient. Liraglutide is contraindicated in persons with a personal or a family history of medullary thyroid cancer, a personal history of multiple endocrine neoplasia syndrome Type 2, or hypersensitivity towards liraglutide. Suspicion of acute pancreatitis should lead to drug discontinuation. Practice Points Management of Type 2 diabetes with","Mette Bohl","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031807","Archive of SID Pharmacological management of metabolic syndrome and its lipid complications","T Binesh Marvasti","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031808","Insulin degludec/liraglutide \"good value for money\" in T2DM in Italy",null,"2019","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-019-6304-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031809","New injectable hypoglycemic treatments for type 2 diabetes","Michel Gerson","2016",null,"other","article","10.1684/med.2017.241",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031810","Lipid Formulations in Customized Enteric Capsules Show Promising Results For Oral GLP-1 RA Delivery","Jannin, Vincent","2025",null,"other","article","10.13140/rg.2.2.33303.69289",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031811","Study suggests GLP-1 analogues do not raise breast cancer risk",null,"2016","Pharmaceutical journal/˜The œpharmaceutical journal","nonrandomized_study","article","10.1211/pj.2016.20201887",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0031812","Insulin and new oral antidiabetic drugs as recently modified therapeutic approach in diabetologic outpatient department","Pavel Weber","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031813","RT 1544 2019 - Saxenda para transtorno alimentar, obesidade mórbida (IMC 59,9), diabetes mellitus tipo 2, hipertensão arterial sistêmica","Natjus Tjmg","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031814","Recent insights on diabetes treatment: The extra-pancreatic effects of GLP-1 and GLP-1 receptor agonists with special reference to cardiovascular complications in diabetes mellitus","潤一郎 宮川","2009","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031815","อลบกลไทด: ยาใหมสำหรบรกษาเบาหวานชนดท 2","กิรติ เก่งกล้า","2015",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031816","The role of incretin hormones in the development of type 2 diabetes mellitus","Anna Marchal","2016","Digital Repository (National Repository of Grey Literature)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031817","Exenatide","J.A. McIntyre","2004","Drugs of the Future","other","article","10.1358/dof.2004.029.01.776562",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031818","Evaluation of US2019070266 patent, treatment diabetic foot ulcers with Liraglutide","Martín Pérez-Santos","2020","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.11235/buap.05.17.04",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031819","基于GLP-1的2型糖尿病治疗：聚焦Exenatide","东干","2008","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031820","Wegovy helps the heart even with minimal weight loss","Christa Lesté-Lasserre","2025","The New Scientist","other","article","10.1016/s0262-4079(25)01771-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031821","lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient","M David","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031822","Exclusive patent, know-how and process license to research, develop, make, have made, use, import, export, sell, offer, transfer and sublicense formulations of the GLP-1 receptor agonist compound for oral administration, to treat or prevent human diseases or conditions, including Type 2 diabetes.","RoyaltyStat","2019","RoyaltyStat Library","other","article","10.34675/l31929",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031823","No clear winner among once-weekly GLP-1 receptor agonists for diabetes",null,"2015","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2015.20200304",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031824","EFFECTIVENESS OF NESTING ON POSTURE AND MOTOR PERFORMANCE AMONG HIGH RISK NEWBORN.","ijar","2018","International Journal of Advanced Research","other","article","10.21474/ijar01/8099",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031825","ROLE OF GLP-1 AGONISTS IN THE TREATMENT OF OBESITY-RELATED GASTROINTESTINAL DISORDERS","Dr Shoaib Ahmed khan,Almas Khan,Dr. Sajid Usman Shah","2025","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.16949195",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0031826","Liraglutide, a Once-Daily Human GLP-1 Analog, Reduces Systolic Blood Pressure with Minimal Impact from Weight Loss in Subjects with Type 2 Diabetes.","RR Henry","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","other","article","10.1210/endo-meetings.2010.part3.p11.p3-514",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031827","Dietary Interventions for Maximizing the Benefits of GLP-1 Agonists","Indunil Karunarathna","2024",null,"other","article","10.13140/rg.2.2.12042.89280",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031828","The Incretin Effect And Its Significance – Basic To Applied Physiology","Sathishkumar, Solomon","2012","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.4445541",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031829","IDegLira good value for money in T2DM in Czech Republic",null,"2019","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-019-5634-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031830","Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation","Springer-Verlag Italia","2014",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031831","Choosing a GLP-1 Analogue","Sanjay Kalra","2013","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/11892_17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031832","Concerns Persist About Byetta and Pancreatitis Risks","ALICIA AULT","2008","Family Practice News","other","article","10.1016/s0300-7073(08)71076-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031833","Differential protective effects of exenatide, a GLP-1R agonist, and piragliatin, a glucokinase activator, under ER stress in pancreatic beta cells","김미경","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031834","Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor","AgonistsJ Chilton","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031835","Promjene u masnoj degeneraciji jetre kao pokazatelj odgovora na terapiju metforminom i liraglutidom kod štakora hranjenih masnom i slatkom hranom","Alen Imširović","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031836","Impact of a Restrictive Reimbursement Policy on Access, Costs and Quality & Safety of treatment: Analysis of a Dutch reimbursement case regarding GLP-1 therapy","R. Buitenhuis.","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031837","Weekly semaglutide cost effective for T2DM in Spain",null,"2020","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-020-7151-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031838","Clinical and genetic associations of dipeptidyl peptidase-4 inhibitor treatment response in type 2 diabetes / Jazlina Liza Jamaluddin","Jamaluddin Jazlina Liza","2017","University of Malaya Students Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031839","Chapter-24 Long-acting GLP-1 Agonists","S. K. Joshi","2015","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12602_25",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031840","Systematic evaluation of the effects of exenatide and liraglutide on neurodegenerative diseases induced by type 2 diabetes mellitus",null,"2022","Journal of Neurobiology and Physiology","other","article","10.46439/neurobiology.4.022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031841","Assessment of glucagon-like peptide-1 analogue and renin inhibitor in the binding and regulation of GLP-1 to its receptor in diabetic rat hearts","Shushan B. Artinian","2010",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031842","GLP-1-Agonist lindert Migräne",null,"2025","DNP – Die Neurologie & Psychiatrie","other","article","10.1007/s15202-025-6533-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031843","Impurity Identification and Characterization of some Anti-Diabetic Drugs using various Analytical Methods","Dhara Vashi","2019","Asian Journal of Pharmaceutical Research","other","article","10.5958/2231-5691.2019.00039.x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031844","Lessons learned on the safety of GLP-1 receptor agonists from post-marketing experience","Andreia Filipa Rodrigues dos Santos","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031845","Incretin-Based Therapies for the Treatment of Type 2 Diabetes – DPP-4 Inhibitors and Incretin Mimetics","Baptist Gallwitz","2008","Frontiers in diabetes","other","article","10.1159/000152022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031846","TRANSLATIONAL IMPACT",null,"2010","Disease Models & Mechanisms","preclinical","article","10.1242/dmm.005850",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031847","Adiposity and High CV Risk in Type 2 Diabetes","Leah Lawrence","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031848","CAN PRECAUTIONS BE CONSIDERED IN PRESCRIBING EXENDIN-4 TO DIABETIC PATIENTS?: A SYSTEMATIC META-ANALYSIS",null,"2020","Journal of Xidian University","systematic_review","article","10.37896/jxu14.12/029",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0031849","Liraglutide has lowest cost of T2DM control values in Canada",null,"2015","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-015-2322-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031850","Weight loss, cardiovascular diseases and all-cause mortality of overweight/obese patients with type 2 diabetes mellitus initiating sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1A)","HM Tang","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031851","Liraglutid: Kein höheres Risiko für maligne Neoplasmen (LEADER)",null,"2018","Diabetologie und Stoffwechsel","other","article","10.1055/a-0642-4601",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031852","Original Article: Treatment Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial","Robert E. Ratner","2010",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031853","Spolno uvjetovane razlike u izražaju antioksidativnih gena u aorti Sprague-Dawley štakora hranjenih visoko-masnom- visoko-slatkom hranom","Petra Tomac","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031854","GLP-1 receptor agonist boosts glycemic control in Asian patients",null,"2012","Springer Healthcare News","other","article","10.1007/s40014-012-0391-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031855","Nephroprotective Effect of Octreotide and Liraglutide in Renal Ischemia Reperfusion Injury in Mice",null,"2020","International Journal of Pharmaceutical Research","preclinical","article","10.31838/ijpr/2020.12.01.177",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031856","GLP-1 Analogues: An Overview","Sanjay Kalra","2013","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/11892_4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031857","Inkretini u terapiji šećerne bolesti tipa 2","Sara Celinšćak","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031858","The Therapeutic Value of Liraglutide Combined with Metformin on Diabetes Mellitus and Its Effect on Blood Glucose Levels",null,"2020","Foreign Language Science and Technology Journal Database Medicine and Health","other","article","10.47939/mh.v3i5(03).17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031859","A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control","Sarah Elizabeth Withycombe","2010",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0031860","Role of liraglutide and other newer diabetic drugs in the improvement of the apnea-hypopnea index and sleepiness scale amongst OSA patients with standard care - a meta-analysis","Parvataneni, Tarun","2025",null,"systematic_review","article","10.13140/rg.2.2.20675.52009",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0031861","Liraglutide leads over the long-term for T2DM in 6 countries",null,"2011","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-201106420-00023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031862","Eli Lilly pausing investment in UK as report warns against ‘limited’ NHS uptake of new drugs",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.373055",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031863","Next Era of Treatment on Obesity and Diabetes from Ozempic to Orforglipron",null,"2025","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/194",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031864","Intestinal nutrient sensing","Nikkie van der Wielen","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031865","Can Liraglutide Delay Diabetes Onset","Bobby Lazzara","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031866","An immunoassay for the GLP-1 derivative NN2211","Michael Wilken","2000",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031867","Exendin-4 ☆","B L Furman","2017","Elsevier eBooks","other","article","10.1016/b978-0-12-801238-3.97997-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031868","GLP-1 receptor more beneficial in reducing blood sugar compared to injectable therapy in Japanese patients","Tracey Walker","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031869","Subacute Development of Polymyalgia Rheumatica (PMR) In Diabetic Patient with Clinical Efficacy of Tocilizumab and Xultophy",null,"2022","Research Journal of Sports and Health Psychology","other","article","10.36266/rjshp/124",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031870","Byetta, du nouveau dans le contrôle du diabète de type II",null,"2008","Le Pharmacien Hospitalier","other","article","10.1016/s0768-9179(08)70021-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031871","Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes","Kenneth R. Feingold","2020","Europe PMC (PubMed Central)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031872","Positioning of Once Weekly GLP–1- based Therapies for Whom and When?","Brij Mohan Makkar","2018","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/14130_61",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031873","遇見「E-exenatide」道曙光","鄭莉蓉","2011",null,"other","article","10.6527/pvm.2012.9.19",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031874","New therapies for the treatment of type 2 diabetes: an update","Caroline Day","2009","European Diabetes Nursing","other","article","10.1002/edn.141",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031875","Oksidativni-antioksidativni status seruma štakora oboljelih od dijabetesa","Julijana Kljajić","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031876","Addressing Challenges in Semaglutide Use Adverse Effects and Patient Adherence","Indunil Karunarathna","2024",null,"other","article","10.13140/rg.2.2.27142.38720",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031877","Enhanced Oral Delivery of Exenatide: Optimizing Lipid-Based Formulations and Enteric Protection","Jannin, Vincent","2025",null,"other","article","10.13140/rg.2.2.18654.75848",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031878","GLP-1 Receptor Agonists","Junji Iwasa","2025","RCSB Protein Data Bank","other","article","10.2210/rcsb_pdb/mom_2025_11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031879","Liraglutide ameliorates erectile dysfunction via regulating autophagy and RhoA/ROCK pathway induced by oxidative stress in diabetes mellitus","Pei-Gen Yuan","2020","European Urology Open Science","other","article","10.1016/s2666-1683(20)33216-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031880","18F-Labeled exendin(9-39)","Arvind Chopra","2012","Europe PMC (PubMed Central)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031881","Estimation of safety of weekly injection type of glucagon-like peptide-1 (GLP-1) analogue during fasting condition running head: Weekly injection type of GLP-1 analogue and risk of hypoglycemia","Shuichi Okada","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031882","Investigating the Effect of Liraglutide on Biochemical Parameters of Plasma and Testicular Tissue","Jorge Felipe Argenta Model","2024","Journal Of Biochemical Technology","other","article","10.51847/6ae14fh6vl",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031883","Lipoproteins in the postprandial state: Studies on the metabolism of triglyceride-rich lipoproteins using multicompartmental models","Elias Björnson","2021","Gothenburg University Publications Electronic Archive (Gothenburg University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031884","Liraglutide superior in type 2 diabetes",null,"2012","PharmacoEconomics & Outcomes News","other","article","10.2165/00151234-201206570-00021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031885","Diabetes drug has positive effects on symptoms of Parkinson’s disease",null,"2017","Clinical pharmacist","randomized_trial","article","10.1211/cp.2017.20203466",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031886","AWARD Trial Shows Promise for GLP-1 Agonist","Leah Lawrence","2015",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031887","Nonexclusive patent, know-how, process and trade secret license, including improvements, to use, exploit, produce, manufacture, supply, distribute, sell, exploit and sublicense products containing metformin, sumatriptan, semaglutide, liraglutide or sildenafil, including a metformin gummy product, metformin crystals and effervescent, inhaled sildenafil, inhaled sumatriptan, and oral GLP-1 capsule of semaglutide or liraglutide.","RoyaltyStat","2024","RoyaltyStat Library","other","article","10.34675/l41260",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031888","GLP1 Receptor Agonists Reduce Food Intake While Differentially Activating Neurons in the Hypothalamus and Hindbrain","Kimberly A. Coughlan","2011",null,"other","article","10.1210/endo-meetings.2011.part2.p8.p1-480",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0031889","Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes","BS Ashley Krause","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031890","New strategies for the treatment of diabetes mellitus type 2 – Glucagon-like peptide-1 receptor agonists and sodium-glucose type 2 transporter inhibitors","Rüdiger Göke","2015",null,"other","article","10.4155/fseb2013.14.236",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0031891","Exenatide (r)",null,"2011","Bloomsbury Academic eBooks","other","article","10.5040/9781350363595.art-692",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031892","667-P: IBI362 (LY3305677), a Weekly-Dose Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist, in Subjects with Overweight or Obesity","Hongwei� Jiang","2021","Diabetes","randomized_trial","article","10.2337/db21-667-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031893","Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2) Supplementary information","Frias, Juan P","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.10606144",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031894","The Impact of Hispanic Ethnicity and the Titration Effect of LY2189265, a Glucagon-Like Peptide 1 Analog, on Metabolic Outcome Measures in Patients with Uncontrolled Type 2 Diabetes Mellitus (T2DM): An EGO Study Analysis.","EJ Bastyr","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","other","article","10.1210/endo-meetings.2010.part3.p11.p3-513",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031895","What nurses need to know about weight-loss drugs","Pavan Amara","2025","Mental Health Practice","other","article","10.7748/mhp.28.1.10.s4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031896","Dual Amylin and Calcitonin Receptor Agonists: A Novel Treatment for Obesity and Related Co-Morbidities","Sofie Gydesen","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031897","Psoriasis and Diabetes: An Unholy Alliance","Satinath Mukhopadhyay","2017",null,"other","article","10.1201/9781315152912-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031898","Victoza (r)",null,"2011","Bloomsbury Academic eBooks","other","article","10.5040/9781350363595.art-3647",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031899","Exenatide Boosts Glycemic Control, Weight Reduction","MIRIAM E. TUCKER","2006","Internal Medicine News","other","article","10.1016/s1097-8690(06)74407-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031900","With Liraglutide, More Patients Achieve ‘Zindex’","SHERRY BOSCHERT","2010","Internal Medicine News","other","article","10.1016/s1097-8690(10)70320-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031901","Central actions of glucagon-like peptide-1 on food intake and reward: Novel neurological targets and sex divergent effects","Jennifer E. Richard","2019","Gothenburg University Publications Electronic Archive (Gothenburg University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031902","GLP-1 수용체 항진제인 Exendin-4에 의한 근육에서의 에너지 대사에 관한 연구 : The effect of Exendin-4, a glucagon-like peptide-1 receptor agonist, on energy metabolism in muscle","정진승","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031903","話題のクスリ 118 時効型GLP-1受容体作動薬 トルリシティ皮下注0.75mgアテオス TRULICITY ATEOSデュラグルチド(遺伝子組換え)注射液","伊藤大亮","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031904","Saxagliptin and lixisenatide get green light for NHS use in Wales",null,"2013","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2013.11131816",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031905","Proposal for a Tirzepatide-LLF580 Fusion Protein","Boettcher, Brian R","2023",null,"other","article","10.13140/rg.2.2.23411.81448",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031906","Dulaglutide",null,"2018",null,"other","article","10.1891/9780826150356.0336",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031907","Sastav lipida stanične membrane jetre mužjaka štakora Sprague Dawley hranjenih masnom i slatkom hranom i tretiranih metforminom ili liraglutidom","Marija Ganjto","2018",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031908","Oral semaglutide a cost-effective option for patients with uncontrolled T2DM",null,"2021","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-021-08178-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031909","Annals for Hospitalists - 18 April 2017","David H. Wesorick","2017","Annals of Internal Medicine","randomized_trial","article","10.7326/afho201704180",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031910","The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells","綾 白木","2012","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031911","胰高血糖素样肽1受体激动剂exendin-4增加高脂喂养的C57BL／6J小鼠棕色脂肪脂代谢","魏琼","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031912","Impact of different types of antidiabetic interventions on the development of neurodegenerative changes in brains of diabetic mice and rats","Andrea Popelová","2015","Digital Repository (National Repository of Grey Literature)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031913","Sequence determination of pharmaceutical peptide S by maldi -tof tandem ma SS","Ivana Dodig","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031914","exendin-4はGKラット膵島においてEpac依存性にSrc活性を抑制することによりROS産生を減少させる | 文献情報 | J-GLOBAL 科学技術総合リンクセンター","向英里","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031915","Analiza prijava sumnji na nuspojave lijekova iz skupine inkretina i SGLT2 inhibitora u Republici Hrvatskoj u razdoblju od 2010. do 2018. godine","Jeronim Matijević","2019",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0031916","Exenatide may be an option for hospitalized patients with diabetes","Maria G. Tanzi","2019","Pharmacy Today","other","article","10.1016/j.ptdy.2019.06.025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031917","Metaanalyse von direkten Vergleichsstudien zwischen GLP-1 Rezeptor-Agonisten und Insulin in der Therapie des Typ 2 Diabetes","Abd El Aziz","2019","Dokumentenrepositorium der RUB (Ruhr University Bochum)","systematic_review","article","10.13154/294-6304",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; dissertation"],["R0031918","Effective oral formulation of semaglutide (Rybelsus) for diabetes and obesity due to absorption enhancer development",null,"2022","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/130",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031919","DIABETES 2020: The Molecular Basis of the Anti-Diabetic Properties of Camel Milk","Mohammed Akli Ayoub","2020",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031920","The Novel GLP-1-Gastrin Dual Agonist ZP3022 Improves Glycemic Control in ZDF Rats","Jolanta Skarbaliene","2012",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031921","반감기 향상을 위한 Exenatide와 Elastin-Based Polypeptide 융합단백질의 발현 및 특성분석","정수진","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031922","Third amendment to exclusive patent and know-how license to manufacture, use, sell, offer and import products based on the use of licensor's microspheres, including exenatide LAR products, oil-based products and the 'Bydureon' pen, and including licensee's AC2993 product.","RoyaltyStat","2019","RoyaltyStat Library","other","article","10.34675/l34985",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031923","64 Cu-Labeled Lys 40(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)NH 2–conjugated exendin-4","Arvind Chopra","2004","Europe PMC (PubMed Central)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031924","Exenatide inhibits fatty acid induced hepatocyte steatosis and inflammation through activating AMPK","Nan-Jing Guo","2016","World Chinese Journal of Digestology","other","article","10.11569/wcjd.v24.i11.1649",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031925","Efficacy of a fixed combination of insulin degludec and GLP-1 receptor agonist liraglutide (Xultophy) in patient with type 2 diabetes","Ćudina, Ivona","2021","Liječnički vjesnik","other","article","10.26800/lv-142-supp5-20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031926","Improved glycaemic control with fixed-ratio combination of insulin degludec and liraglutide",null,"2014","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2014.20066433",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031927","Exenatide and Rare Adverse Events","Enon Artist","2008",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031928","Iconography : GLP-1 agonist associated acute kidney injury: A case report and review","Tushant Baghla Bharat Bhushan Sharma","2017",null,"case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031929","Samsung books more orders",null,"2003","Pump Industry Analyst","other","article","10.1016/s1359-6128(03)00223-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031930","Semaglutide cost effective versus dulaglutide in Japan",null,"2020","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-020-7144-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031931","Figure 20, LEAD-3 Trial: Changes in Body Weight Overtime for Liraglutide vs Glimepiride Monotherapy","Patricia S Juang","2013",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031932","Liraglutide monotherapie bij diabetes mellitus type II","Teun van Gelder","2009","Medisch-Farmaceutische Mededelingen","other","article","10.1007/bf03080068",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031933","A review of exenatide in the treatment of Type 2 Diabetes","Aashish Samat","2010",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0031934","Pharmacology of the 2nd type of diabetes mellitus - a review","Konstantinos Ampatzis","2007","Digital Repository (National Repository of Grey Literature)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031935","Semaglutide in Chronic Disease A Collaborative Approach for Optimal Outcomes","Indunil Karunarathna","2024",null,"other","article","10.13140/rg.2.2.20641.21604",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031936","Trends and Perspectives in the Development of Antidiabetic Drugs for Type 2 Diabetes Mellitus","Soo-Hyun Lee","2012","Microbiology and Biotechnology Letters","other","article","10.4014/kjmb.1205.05012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031937","Biochemical effect of various anti-diabetic therapies on obesity and insulin resistance induced by monosodium glutamate in male rats","Sherin M. Khodier","2020",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031938","Type 2 diabetes drug aids weight loss, study finds",null,"2018","Clinical pharmacist","randomized_trial","article","10.1211/cp.2018.20205053",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0031939","You make the choice, clinical decision-making in diabetes: Use of GLP-1 receptor agonists in clinical practice CME POSTTEST AND EVALUATION",null,"2013","Osteopathic Family Physician","other","article","10.1016/j.osfp.2012.10.002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031940","The long-acting GLP-1 analogue, liraglutide, increases beta cell numbers during early human development","Karen Piper Hanley","2005","ePrints Soton (University of Southampton)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031941","Which Is the Best Treatment for Diabetes Complicated With Severe Obesity, Intensive Insulin Therapy or Basal Supported Oral Therapy or Glucagon-Like Peptide-1 Analog?","Sumie Moriyamaa","2011",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031942","Latest GLP-1 agonist boasts administration and cost benefits",null,"2013","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2013.11120757",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031943","Alle origini della storiografia umanistica aragonese. Edizione critica e studio dei \"Gesta Alfonsi regis\" di Tommaso Chaula","Mariarosa Libonati","2020","CINECA IRIS Institutional Research Information System (University of Basilicata)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0031944","¿Orinar o no orinar? Esta es una pregunta para la vejiga —y para el cerebro—","Emily Underwood","2024","Knowable Magazine","preclinical","article","10.1146/knowable-071824-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031945","New GLP-1 agonist claims price advantage",null,"2013","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2013.11122965",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031946","Once-Daily Liraglutide Lowers HbA1c by 1.7% in Early Trial","JOHN R. BELL","2006","Clinical Psychiatry News","other_trial","article","10.1016/s0270-6644(06)71693-9",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0031947","GLP-1 Analogues: Combination Therapy","Girish Raparti","2013","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/11892_6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031948","A patient with diabetic nephropathy treated with glucagon like peptide-1 receptor agonist","Yao Xu","2017",null,"other","article","10.3760/cma.j.issn.1671-7368.2017.01.017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031949","Nonalcoholic fatty liver disease: Pathogenesis and incretin based therapies","Xiaoyu Guo","2015","World Chinese Journal of Digestology","other","article","10.11569/wcjd.v23.i31.4990",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031950","Peptide Coagonists of the GLP-1 and NPY-2 Receptors","Robert P. Doyle","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031951","Las principales noticias científicas de 2023","Nicola Jones","2023","Knowable Magazine","other","article","10.1146/knowable-122123-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031952","Chapter 6. New Drug Design and Therapeutic Development for Weight Reduction: Preclinical Studies and Clinical Trials","Steven P. Vickers","2015","RSC drug discovery/RSC drug discovery series","other","article","10.1039/9781782622390-00090",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031953","Weight-loss drug use linked to reduced risk of substance misuse, study shows",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.343955",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031954","Significant Reduction of Body Weight and Blood Glucose by Oral Semaglutide (Rybelsus) for Type 2 Diabetes (T2D) Patient","H Yamashita","2022","Suntext Review of Case Reports & Images","other","article","10.51737/2766-4589.2022.047",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031955","Gastric Bypass Surgery Mimetic Approaches Update: Cevoglitazar + Fibroblast Activation Protein Inhibitor (FAPi) + Oral, Non-Peptide Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) for Oral Obesity Treatment","Boettcher, Brian R","2025",null,"other","article","10.13140/rg.2.2.17736.43528",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031956","Recent progress of glucagon-like peptide-1 analogue and the treatment of diabetes","王战建","2008",null,"other","article","10.3760/cma.j.issn.1671-7368.2008.06.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031957","Neuroprotective effects of food intake regulating peptides in vitro and in vivo","Barbora Judita Kasperová","2018","Digital Repository (National Repository of Grey Literature)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031958","Effects of Liraglutide on glycaemic control and pancreatic islet morphology in C57BL/KsJ db/db mice with degenerative diabetes","R. Charlotte Moffett","2010","Regulatory Peptides","preclinical","article","10.1016/j.regpep.2010.07.110",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031959","Incretins, Incretinmimetics, Inhibitors (2 nd part)","Claudia Bayón","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031960","Effect of liraglutide and metformin on bone metabolism in newly diagnosed type 2 diabetic patients","Yanhua Zhang","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031961","FDA Cites Reports of Byetta-Related Pancreatitis","ROBERT FINN","2007","Internal Medicine News","other","article","10.1016/s1097-8690(07)71269-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031962","Never Ignore a GUT Feeling!","Ehsan Rafiq","2013","The American Journal of Gastroenterology","other","article","10.14309/00000434-201310001-00953",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031963","Peri-operative management of dental patients requiring procedural sedation and taking Ozempic®, Mounjaro®, or other glucagon-like peptide-1 receptor agonist-containing medication.","I Khan","2025","Journal of the Society for the Advancement of Anaesthesia in Dentistry","other","article","10.63507/oodo3230",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031964","Novel pharmacotherapies for the treatment of Obesity and Diabetes","Timo D. Müller","2020",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031965","GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP-1R) AGONIST CONTRIBUTES TO BONE TURNOVER REBALANCING IN HYPERCALORIC DIET-INDUCED OBESITY","Paulo Flávio Silveira","2018","Proceedings for Annual Meeting of The Japanese Pharmacological Society","preclinical","article","10.1254/jpssuppl.wcp2018.0_po3-6-14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031966","3 Things You (Still) Need to Know About GLP-1 Agonists","Payal Kohli","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031967","Real-world data for tirzepatide treatment in type 2 diabetes mellitus (T2DM) to address HbA1c and obesity with consideration of atherosclerotic cardiovascular disease (ASCVD)","Scott, Victoria","2025",null,"nonrandomized_study","article","10.13140/rg.2.2.16049.85607",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0031968","Bioanalytical methods using LC-MS/MS for determination of the GLP-1-Glu dual agonist ZP2929 in plasma","Arne Lindhardt Jensen","2011",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031969","글루카곤양 펩티드-1을 바탕으로 한 제2형 당뇨병환자의 치료: Exenatide를 중심으로","오승준","2006",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031970","Analysis of the Value of SGLT2i Combined with GLP-1RAs in Cardiovascular Benefit of Elderly T2DM Patients","琳艳 代","2023","Advances in Clinical Medicine","other","article","10.12677/acm.2023.132386",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031971","Oramed Pharmaceuticals Initiation of Coverage LifeSci Investment Abstract","Jerry Isaacson","2014",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031972","Switching from exenatide to investigational GLP-1 analog improves glycemic control with low risk of hypoglycemia","Wayne Kuznar","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031973","Is semaglutide effective in reducing cardiovascular outcomes in obesity without diabetes?","Parvaneh Vaziri","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002222",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031974","DPP-IV inhibitors effectively reduce levels of HbA1c as monotherapy or in combination with other agents","Wayne Kuznar","2006",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0031975","No new safety concerns over GLP-1 therapies, says EMA",null,"2013","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2013.11123858",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031976","The GLP-1 receptor agonist Exenatide reduces serum TSH by its effect on body weight in people with Type 2 Diabetes","Tee SuAnn, Tsatlidis V, Razvi S","2023","MyImpact","other","article","10.57711/x8nr-h689",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031977","Oralni hipoglikemici u liječenju šećerne bolesti","Jana Krobot","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031978","Liraglutide cost effective for T2DM in Spain",null,"2017","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-017-4001-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031979","Once-daily IDegLira cost effective for T2DM in UK",null,"2016","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-016-3253-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031980","Incretin-based therapies","Julio Rosenstock","2009","Insulin","other","article","10.1016/s1557-0843(09)80035-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031981","COMPARAÇÃO DOS MEDICAMENTOS SAXENDA, OZEMPIC E MOUNJARO NA PERDA DE PESO EM PACIENTES COM OBESIDADE","GISELLE BARBOSA BARROS","2024",null,"other","article","10.59290/978-65-6029-178-2.7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031982","Understanding the sudden rise of type 2 diabetes in children","Charlotte Huff","2024","Knowable Magazine","other","article","10.1146/knowable-073124-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031983","MHRA urges women taking weight-loss drugs to use effective contraception",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.359584",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031984","Metformin: From Obscurity to Ubiquity","DO Edward C. Chao","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031985","Elimination of GLP-1 action in vivo by a new antagonist of GLP-1 receptor, exendin-4 (3-29)",null,"1996","Regulatory Peptides","other","article","10.1016/0167-0115(96)87981-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031986","En busca de explicaciones al repentino aumento de la diabetes tipo 2 en niños","Charlotte Huff","2024","Knowable Magazine","other","article","10.1146/knowable-080524-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031987","Mit Exenatide bleiben Diabetiker am Ball",null,"2011","CME","other","article","10.1007/bf03360425",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031988","L’analogo del GLP-1 liraglutide: efficacia clinica e sicurezza","Agostino Consoli","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031989","Original article Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin","Katarina Steen Carlsson","2014",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0031990","FDA approves Bydureon, first once-weekly treatment for type 2 diabetes","From staff reports","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031991","Beyond the Guidelines: Recent Evidence of the Incretin Mimetics in Type 2 Diabetes Management","Nkonge, Ken","2023",null,"other","article","10.13140/rg.2.2.15340.95360",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0031992","Exendin-4 and Its Related Peptides","Michelle Khai Khun Yap","2021",null,"other","article","10.1201/9780429054204-20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0031993","The differential short-term effects of liraglutide and dulaglutide on heart rate","Hisako Komada","2018","Diabetes Frontier Online","other","article","10.15634/j0100_0501_007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031994","Développement de nouvelles méthodologies en Chromatographie de Partage Centrifuge (CPC) : Application à l’isolement et la purification des peptides pharmaceutiques","Nassima Amarouche","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0031995","Exendin-4 regulates pancreatic ABCA1 transcription via CaMKK/CaMKIV pathway","軍華 李","2010","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031996","Exenatide- A Turning Point InPharmacotherapy of NIDDM","Pavan Malhotra","2008",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031997","New once-weekly treatment for type 2 DM","Kathryn Wheeler","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031998","Testing the effect of the diabetes drug Liraglutide in Alzheimer's disease","Hollie Richardson","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0031999","Dulaglutide",null,"2017","The American Pharmacists Association eBooks","other","article","10.21019/druginformation.dulaglutide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032000","Long-term outcome of placental-site trophoblastic tumours","Luc F. Van Gaal","2009",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032001","GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONIST AND ITS CLASS: A CLASSICAL APPROACH FOR MANAGEMENT OF DIABETES","Manish Kumar","2017","World Journal of Pharmaceutical Research","other","article","10.20959/wjpr20176-8712",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032002","Research Advances in Traditional Chinese Medicine and GLP-1 Receptor Agonists for Treating Type 2 Diabetes with Polycystic Ovary Syndrome","圣梓 李","2025","Advances in Clinical Medicine","other","article","10.12677/acm.2025.15113125",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032003","Penapisan Fitokimia Indonesia sebagai Agonis Reseptor Glucagon-Like Peptide-1 In Silico pada Diabetes Melitus Tipe-2","Humamuddin","2017",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0032004","Victoza (Liraglutide): Potential New Treatment for Child and Adolescent Type 2 Diabetes","Drew Boxler","2019",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0032005","[Figure], Withdrawals because of Adverse Events - Exenatide 10 mcg vs. Placebo","Dan E Jonas","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032006","Extended indication for Xultophy",null,"2015","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2015.20068999",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032007","Uso da liraglutida como tratamento para obesidade: um estudo bibliométrico / The use of liraglutide as a treatment for obesity: a bibliometric study","Paulo José Couto Sampaio Neto","2021","Brazilian Journal of Development","other","article","10.34117/bjdv7n6-103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032008","Glucagon-like Peptide-1 Analogues","Ajay Kumar","2014","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12165_8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032009","Dulaglutide Granted CV Indication in T2D With or Without CVD","Grace Halsey","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032010","Gastric Bypass Surgery Mimetic Update: A Proposal for a Tirzepatide-LLF580 Fusion Protein","Boettcher, Brian R","2023",null,"other","article","10.13140/rg.2.2.23043.17448",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032011","Hypertension in Diabetes","Sowjanya Naha","2014",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032012","Weight loss drugs: what do I tell patients if they ask about them?","Pavan Amara","2024","Nursing Standard","other","article","10.7748/ns.39.12.12.s5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032013","Prandialer GLP-1-Agonist ist ein guter Partner des Basalinsulins","Dirk Einecke","2013","MMW - Fortschritte der Medizin","other","article","10.1007/s15006-013-0444-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032014","Estimation of insulin-like growth factor-1 as a biomarker in nonalcoholic fatty liver disease in patients with metabolic syndrome","AmalE El-Maghraby","2018","Journal of Medicine in Scientific Research","other","article","10.4103/jmisr.jmisr_26_18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032015","Incretin mimetics",null,"2007","Insulin","other","article","10.1016/s1557-0843(07)80008-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032016","Liraglutide Use in the Management of Obesity: RCHT Experience","Abraham Biaye","2024","Obesity Abstracts","other","article","10.1530/obabs.4.p9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032017","Incretin-Based Therapy","Ajay Kumar","2014","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12626_37",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032018","Exendin-4对小鼠巨噬细胞一氧化氮生成和促炎/抗炎反应平衡的影响","高玉雷","2013","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032019","A NOVEL VALIDATED RP-HPLC METHOD FOR THE ESTIMATION OF ALBIGLUTIDE IN BULK","S. Susena","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032020","Insulin detemir but not liraglutide exhibits the proliferative effect on beta cell mass in aged db/db mice","康輔 小西","2014","Medical Entomology and Zoology","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032021","Effect of Liraglutide Combined with Dapagliflozin on Type 2 Diabetes Mellitus Patients with Overweight and Obesity and Its Effect on Insulin Function",null,"2022","Foreign Language Science and Technology Journal Database Medicine and Health","other","article","10.47939/mh.v3i4(01).03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032022","Liraglutide provides better glycaemic control at no extra cost",null,"2015","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-015-1861-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032023","Lixisenatide: A Cardiodiabetes Perspective","Vijay Panikar","2018","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/14130_64",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032024","Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes","八大 德田","2014","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032025","Prevalence of Lower Levels of C-Reactive Protein in Type 2 Diabetic Men Treated with Thiazolidinediones and Exenatide.","Ajay Varanasi","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","other","article","10.1210/endo-meetings.2010.part2.p11.p2-543",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032026","Potential cardiovascular benefits of GLP-1 analogues : evidence and implications for type 2 diabetes management",null,"2020","South African General Practitioner","other","article","10.36303/sagp.2020.1.0006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032027","Delayed Post-hypoxic Leukoencephalopathy: An Elusive Diagnosis (P7-3.004)","Bojun Chen","2025","Neurology","other","article","10.1212/wnl.0000000000210684",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032028","Semaglutide for Adolescents With Obesity",null,"2023","AAP Grand Rounds","other","article","10.1542/gr.49-4-40",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032029","Exendin-4 regulates the expression of the ATP-binding cassette transporter A1 via transcriptional factor PREB in the pancreatic β cell line","由美 宮井","2011","Medical Entomology and Zoology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032030","ozempic tx addict","Kensinger, Richard","2023",null,"other","article","10.13140/rg.2.2.34776.06409",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032031","Concerns Persist About Byetta and Pancreatitis","ALICIA AULT","2008","Internal Medicine News","other","article","10.1016/s1097-8690(08)71014-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032032","To pee or not to pee? That is a question for the bladder — and the brain","Emily Underwood","2024","Knowable Magazine","preclinical","article","10.1146/knowable-052924-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032033","Reimbursement for NHS Mounjaro dispensing confirmed for September 2025",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.371400",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032034","Fly-let Biology and the High Protein/Low Carb Diet","M. Karbowski","2008",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032035","Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 202 [ 68 Ga]Exendin-4: Bench-to-Bedside PET molecular imaging of the GLP-1 receptor for diabetes and cancer","Selvaraju, Ram Kumar","2015",null,"other","article","10.13140/rg.2.2.23028.30080",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032036","661-P: Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program","Richard E. Pratley","2021","Diabetes","other","article","10.2337/db21-661-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032037","No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes","M. Nauck","2003",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032038","Comparative Antibacterial Activity of New Quinolone-Carboxylic","Acid Derivatives","1988",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032039","ICER posts draft scoping document ahead of tirzepatide T2DM assessment",null,"2021","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-021-7864-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032040","Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","亮 小寺","2011","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032041","Lixisenatide",null,"2017","The American Pharmacists Association eBooks","other","article","10.21019/druginformation.lixisenatide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032042","Once-Weekly Exenatide Cut HbA1c Significantly","MIRIAM E. TUCKER","2010","Family Practice News","other","article","10.1016/s0300-7073(10)70738-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032043","GLP‐1 Receptor Agonists","Catherine Russell and","2022",null,"other","article","10.1002/9781119785033.ch6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0032044","Hypertriglyceridaemia",null,"2007",null,"other","article","10.1201/b13464-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032045","Liraglutide (r)",null,"2011","Bloomsbury Academic eBooks","other","article","10.5040/9781350363595.art-1000",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032046","Perioperative GLP-1 Receptor Agonists","Bradshaw, Brad","2024",null,"other","article","10.13140/rg.2.2.14652.04482",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032047","UTILISATION PATTERN OF GLP-1 AGONISTS IN COMBINATION WITH BASAL INSULIN IN PATIENTS WITH T2DM IN THE NORWEGIAN SETTING IN ONE YEAR.","Levorsen, Andree","2013","Value in Health","other","article","10.13140/2.1.4119.8725",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032048","Dulaglutide injection reduces risk of cardiovascular outcomes in type 2 diabetes mellitus by 12%",null,"2019","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2019.20206660",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032049","I’m Paying How Much???: A Cross-Sectional Survey Focusing on Medication Cost for Patients Prescribed GLP-1 Agonists","Dunwell, Stanley","2024","Brown Digital Repository","other","article","10.26300/p3pd-mp85",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032050","85-OR: Semaglutide 2.4 mg Improves Patient Reported Outcome Measures of Physical Functioning in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial","Sean Wharton","2021","Diabetes","randomized_trial","article","10.2337/db21-85-or",null,null,"ClinicalTrials.gov:NCT03552757","S001740","openalex","FALSE","paywalled","1","FALSE","article"],["R0032051","Diabetes ‘Zindex’ Composite Favors Liraglutide","SHERRY BOSCHERT","2010","Family Practice News","other","article","10.1016/s0300-7073(10)70448-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032052","Decoding Liraglutide in paediatric obesity.","Aritra Kapat","2025",null,"other","article","10.13140/rg.2.2.33362.47044",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032053","Liraglutide has positive effects on bone metabolism in obese women",null,"2015","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2015.20068804",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032054","Comparing Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Agonist Versus Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Chinese Patients with Type 2 Diabetes Mellitus: A Preliminary Study","Yanzhen Wei","2024","International Journal of Pharmacology","other","article","10.3923/ijp.2024.672.681",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032055","Science, Medicine, and the Anesthesiologist",null,"2019","Anesthesiology","randomized_trial","article","10.1097/aln.0000000000003013",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032056","For peer review only Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta- analysis","Louise Robinson","2012",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","article"],["R0032057","Efficacia e sicurezza di liraglutide in un soggetto diabetico tipo 2 con insufficienza renale","Gaudenzio Stagno","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032058","64Cu-Labeled 1,4,7-tris(acetic acid)-10-vinylsulfone-1,4,7,10-tetraazacyclododecane conjugated to Cys40-Exendin-4","Arvind Chopra","2012","Europe PMC (PubMed Central)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032059","Exclusive patent, know-how, technology and software license to develop, use, offer, sell, have sold, import and sublicense products containing the Exendin-4 compound, including an intranasal formulation, to treat and prevent diseases and disorders in humans and animals, but excluding chimeric, hybrid or other compounds or peptides incorporating any other active molecule or which link another active molecule with the Exendin-4 compound, with licensor to supply product and right for licensee to manufacture when licensor does not supply.","RoyaltyStat","2019","RoyaltyStat Library","other","article","10.34675/l32199",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032060","Once-weekly dulaglutide beats out insulin glargine in type 2 diabetes","Charles D. Ponte","2015","Pharmacy Today","other","article","10.1016/s1042-0991(15)30151-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032061","Outcome of renal transplantation in IgA nephropathy","Swetha Ramakrishnan","2016","Indian Journal of Transplantation","other_trial","article","10.1016/j.ijt.2016.09.011",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0032062","GLP-1RA Combined with SGLT2 Inhibitors for the Treatment of Diabetic Kidney Disease: A Meta Analysis","莹 郭","2023","Advances in Clinical Medicine","other","article","10.12677/acm.2023.13112543",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032063","Mini Research Report: Liraglutide (Saxenda) for Weight Management Author","Al-Hashimi, Hakim Kadhim","2025",null,"other","article","10.13140/rg.2.2.31741.22240",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032064","188. Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review",null,"2025","Journal of the Academy of Consultation-Liaison Psychiatry","case_report","article","10.1016/j.jaclp.2025.10.190",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032065","Research Progress on GLP-1RAs in the Treatment of Obesity in Children or Adolescents","甜甜 张","2025","Advances in Clinical Medicine","other","article","10.12677/acm.2025.15123378",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032066","Mounjaro health benefits found to reverse one year after stopping drug",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other_trial","article","10.1211/pj.2025.1.387473",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032067","Efficacy and Safety of Mazdutide Injection for Weight Control: A Comprehensive Review","DengYue Medicine","2025",null,"narrative_review","article","10.55277/researchhub.0kgprjcr",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032068","The Price Effects of Biosimilar Entry: Evidence for the GLP-1RA Market","Kanamarlapudi, Veda","2025","Stanford Digital Repository","other","article","10.25740/tz850gf3045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032069","New Drug Therapy for Substance Disorders: GLP-1R Agonists","Lunde Dadiane A","2025","Suntext Review of Case Reports & Images","other","article","10.51737/2766-4589.2025.165",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032070","The impact of glucagon-like peptide 1-receptor agonists on metabolic health and disease activity in patients with inflammatory bowel disease: a scoping review","Y Sacoor","2025","South African journal of gastroenterology and hepatology.","narrative_review","article","10.36303/sajgh.3363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032071","In adult patients with metabolic dysfunction-associated steatohepatitis (MASH), does the addition of tirzepatide compared with placebo increase the resolution of MASH?","Mark Wirtz","2025","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002453",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032072","Non-Classical Therapeutic Approaches in Gastric Ulcer: A Comprehensive Review of Pathophysiology, Epidemiology, Experimental Models, and Diagnosis","Sara Samir Aboelmagd","2025","Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences","narrative_review","article","10.21608/rpbs.2025.435364.1403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032073","Ozempic-Babys: wohl kein Versagen der Pille","Eva Bauer","2025","gynäkologie + geburtshilfe","other","article","10.1007/s15013-025-6243-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032074","Off-Label Use of GLP-1 Receptor Agonists for Weight Management in Individuals without Diabetes: Safety Signals and Evidence from Clinical Trials","Barakat, Muhammad","2025",null,"other","article","10.13140/rg.2.2.15267.72484",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032075","Research Progress of GLP-1 Receptor Agonists in the Treatment of Alzheimer’s Disease","琳娜 勾","2025","Advances in Clinical Medicine","other","article","10.12677/acm.2025.15123625",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032076","Research Progress on the Combination of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease","源 孙","2025","Advances in Clinical Medicine","other","article","10.12677/acm.2025.15123619",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032077","Semaglutide in the Treatment of Type 2 and Type 1 Diabetes","Hope Peace","2025",null,"other","article","10.31274/cc-20251215-47",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032078","Effective Usage of Semaglutide from the Point of View of Body Weight Reduction: Significance of Combination Therapy with SGLT2 inhibitor and/or Metformin","Yutaka Mori","2025","Diabetes Frontier Online","other","article","10.15634/j0100_1201_006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032079","Ozempic for everyone? Pharmacological dystopia, inequality of access and the eternal promise of healing","Cristiane Marques Seixas","2025","Physis Revista de Saúde Coletiva","other","article","10.1590/s0103-73312025350241en",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032080","Investigational weight-loss drug trial shows average reduced body weight of 30%",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other_trial","article","10.1211/pj.2025.1.390945",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032081","Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) in an Individual With Type 2 Diabetes on High-Dose Insulin Therapy","Basem M. Mishriky","2021",null,"other","article","10.2337/9781580407663.case41",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032082","Bariatric surgery more effective than GLP-1 agonist weight loss drugs, study finds",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.319979",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032083","GPs raise confidentiality and safety concerns about online prescribing of weight-loss drugs",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.345630",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032084","How Ozempic Works: (Bio)Chemical Perspectives on Weight Loss Drugs","Helen Siwan Jones","2024","ChemViews","other","article","10.1002/chemv.202400146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032085","Evaluating the Efficacy of Berberine Supplement versus Ozempic® Injection in Modulating Glycemic State, Lipid Metabolism and Body Weight in Streptozotocin-Induced Diabetic Rats","Wassan Mhammed Husain","2025","Advances in Animal and Veterinary Sciences","preclinical","article","10.17582/journal.aavs/2025/13.3.704.711",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032086","Manufacturer confirms discontinuation of type 2 diabetes mellitus treatment Victoza",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.334687",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032087","Private pharmacy semaglutide services must provide long-term support, say experts",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.181029",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032088","Do GLP-1 receptor agonists reduce the incidence of hepatocellular carcinoma and hepatic decompensation in patients with type 2 diabetes?","Alexandre Pariente","2025","Hépato-Gastro & Oncologie Digestive","other","article","10.1684/hpg.2025.2915",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032089","Glucagon -Like Peptide -1 Receptor Agonist Ameliorates Cardiovascular Dysfunction in a Metabolic Syndrome Rat Model","Shaimaa M. Motawea","2025","Bulletin of Egyptian Society for Physiological Sciences","preclinical","article","10.21608/besps.2025.435181.1238",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032090","Health news round-up: orforglipron, new gonorrhoea antibiotics and record high flu admissions",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.391562",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032091","¿Por qué no se considera la salud bucodental parte de la atención médica primaria?","Lola Butcher","2024","Knowable Magazine","other","article","10.1146/knowable-050924-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032092","Tirzepatide not recommended for treating type 2 diabetes, says NICE draft guidance",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.189936",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032093","Turning tides and changing size with tirzepatide","Kimberly Savoia-McHugh","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002213",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032094","More than 500 people hospitalised following use of weight-loss drugs, says health minister",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.349847",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032095","Drugs used in the treatment of obesity","Stela Bacinschi-Gheorghiţă","2023","Farmacist ro","other","article","10.26416/farm.214.5.2023.8764",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032096","GLP-1 receptor agonist shortage expected to continue for all of 2024",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.206500",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032097","Las neuronas que nos hacen sentir hambre","Amber Dance","2023","Knowable Magazine","preclinical","article","10.1146/knowable-061223-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032098","Tirzepatide Demonstrates Benefits in Obesity-Related HFpEF",null,"2025","Kidney News","other","article","10.62716/kn.000882025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032099","UK regulator seizes 369 potentially fake weight loss pens following reports of hospitalisations",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.199333",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032100","Tirzepatide more effective in blood sugar control and weight loss than semaglutide, meta-analysis finds",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","systematic_review","article","10.1211/pj.2023.1.197201",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032101","National patient safety alert issued for GLP-1 receptor agonists",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.191774",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032102","Folia Pharmacotherapeutica",null,"2019","Tijdschrift voor Geneeskunde","other","article","10.47671/tvg.75.24.2002983",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032103","NICE recommends tirzepatide for type 2 diabetes in final draft guidance",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.196224",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032104","T.04.9: PROSPECTIVE OBSERVATIONAL STUDY EVALUATING THE EFFECTS OF GLP1-RAS ON INFLAMMATORY BOWEL DISEASE (IBD) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (TDM2)","A. Piumatti","2024","Digestive and Liver Disease","other","article","10.1016/s1590-8658(24)00596-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032105","Semaglutide lowers risk of kidney failure and cardiovascular death in patients with type 2 diabetes and CKD, study results show",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","randomized_trial","article","10.1211/pj.2024.1.317079",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032106","Government declares 'national shortage' of GLP-1 receptor agonists for type 2 diabetes until 2024",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.189821",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032107","GLP-1 Receptor Agonists in Dialysis: The Obesity Paradox in the Incretin Era","Evan Zeitler","2025","Kidney News","other","article","10.62716/kn.001402025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032108","MHRA approves semaglutide to prevent cardiovascular events in overweight and obese adults",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.324655",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032109","Could Ozempic slow the progression of Alzheimer's?","Grace Wade","2024","The New Scientist","other","article","10.1016/s0262-4079(24)02210-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032110","POLYCYSTIC OVARY SYNDROME (PCOS): MODERN UNDERSTANDING AND CLINICAL PRACTICE IN UZBEKISTAN (2020–2025)","Komila Daniyarovna Karimova","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18017515",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032111","Body Size","Sabrina J. Ashwell","2020",null,"other","article","10.1021/acsguide.60112",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032112","Weight-loss drug semaglutide recommended for use in teenagers in Europe",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.181610",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032113","GPs to prescribe weight loss injections under £40m pilot scheme",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.188091",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032114","Should community pharmacies be offering injectable weight loss drugs?",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.180796",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032115","Spotlight: the truth about weight loss drugs",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.183774",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032116","Top science stories of 2023","Nicola Jones","2023","Knowable Magazine","nonrandomized_study","article","10.1146/knowable-122123-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032117","MHRA warns of dangers of fake weight loss pens after Yellow Card reports",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.202351",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032118","Folia Pharmacotherapeutica",null,"2017","Tijdschrift voor Geneeskunde","other","article","10.47671/tvg.73.04.2002275",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032119","Tirzepatide approved for weight loss treatment by regulator",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.200410",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032120","'Limited' supply of weight loss drug semaglutide launched in UK",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2023.1.195781",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032121","Trends in type 2 diabetes treatment","Cristian Daniel Marineci","2023","Farmacist ro","other","article","10.26416/farm.215.6.2023.8975",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032122","FDA 'evaluating regulatory action' over link between GLP-1 receptor agonists and suicidal thoughts",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.208135",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032123","Semaglutide reduces cardiovascular events in adults who are overweight by 20%, study finds",null,"2023","Pharmaceutical journal/˜The œpharmaceutical journal","other_trial","article","10.1211/pj.2023.1.201091",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032124","Diabetes prescribing guidance published amid ongoing GLP-1 RAs shortage",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.305400",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032125","A Clinical Approach to Pharmacological Management of the Patient with Obesity","Magdalena Pasarica","2024",null,"other","article","10.1201/9781003227793-50",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032126","Suicidal ideation more commonly reported as reaction to semaglutide than for all other drugs, study finds",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","nonrandomized_study","article","10.1211/pj.2024.1.327710",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032127","Semaglutide linked to sight-threatening eye condition, study results suggest",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","nonrandomized_study","article","10.1211/pj.2024.1.322776",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032128","Research Progress on the Clinical Application of GLP-1RA Drug Semaglutide","曦 陈","2024","Advances in Clinical Medicine","other","article","10.12677/acm.2024.1482293",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032129","How Did the GLP-1RA and SGLT-2i Affect Serum Uric Acid in Diabetic Patients?","白嘎力 李","2024","Advances in Clinical Medicine","other","article","10.12677/acm.2024.1482223",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032130","MHRA finds no link between GLP-1 receptor agonists and suicidal behaviour",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.329217",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032131","Weight loss drug pilot rollout ‘paused’ in England, says Obesity Health Alliance",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.334587",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032132","Weight loss drugs make up 'very small' proportion of illegal medicines trade in UK, says MHRA",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.337987",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032133","Medicines regulator receives 46 reports of hospitalisations linked to weight-loss drugs",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.335779",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032134","MHRA warns of pulmonary aspiration risk for GLP-1 receptor agonists during general anaesthesia or deep sedation",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.345007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032135","469: A SHOCKING SIDE EFFECT OF SEMAGLUTIDE: SUSPECTED SEMAGLUTIDE-INDUCED NECROTIZING PANCREATITIS","Margaret Geertz","2025","Critical Care Medicine","other","article","10.1097/01.ccm.0001100540.85595.ac",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032136","Exploring Tirzepatide's Dual Agonism in Kidney Diseases: GLP-1 Agonist With Potential GIP-Mediated Benefits","Fatima Ali","2025","Kidney News","other","article","10.62716/kn.000092024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032137","Probiotics In Incretin-Based Therapy for Patient Living with Obesity: A Synergistic Approach","Marco Mattioli","2024","Journal of Pharmacy and Pharmacology Research","other","article","10.26502/fjppr.0102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032138","Sleep Neurologists Support the FDA Approval of Tirzepatide for Obesity-related Obstructive Sleep Apnea","Dawn Fallik","2025","Neurology Today","other","article","10.1097/01.wnt.0001098712.06333.89",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032139","More than 1.5 million people could be given tirzepatide for weight loss under NHS proposals",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.333156",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032140","Various Clinical Beneficial Effects for Multiple Organs by Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA)",null,"2024","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/174f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032141","Ozempic for everyone?",null,"2025","The New Scientist","other","article","10.1016/s0262-4079(25)01267-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032142","Mounjaro® (tirzepatide), der erste und einzige GIP/GLP-1-Rezeptor-Agonist bei Typ-2-Diabetes",null,"2023","Swiss Medical Forum ‒ Schweizerisches Medizin-Forum","other","article","10.4414/smf.2023.1317833068",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032143","Living in an Ozempic world",null,"2025","The New Scientist","other","article","10.1016/s0262-4079(25)00512-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032144","Mounjaro® (tirzepatide), le premier et unique agoniste des récepteurs du GIP/GLP-1 indiqué dans le diabète de type 2 [1]",null,"2023","Forum Médical Suisse ‒ Swiss Medical Forum","other","article","10.4414/fms.2023.1318904011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032145","Ozempic really could turn back the clock on your biological age","Helen Thomson","2025","The New Scientist","other","article","10.1016/s0262-4079(25)01273-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032146","Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders","Forum on Neuroscience and Nervous System Disorders","2025","National Academies Press eBooks","other","article","10.17226/29061",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0032147","A Study on Weight Loss Cause as per the Side Effect of Liraglutide","Dr.Salve M.T Tarate K.M","2025","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.18074704",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0032148","Role of SGLT2 Inhibitors and GLP-1 Agonist in the Management of Diabetes Mellitus","Ponkaj Kanti Datta","2022",null,"other","article","10.13140/rg.2.2.27351.74403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032149","Efficacy of oral formulation of semaglutide in obese patients with type 2 diabetes mellitus - a retrospective study","Živko, Matea","2023","Liječnički vjesnik","nonrandomized_study","article","10.26800/lv-145-supl2-cm01",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article; conference-paper"],["R0032150","A Study on Factors Affecting Satisfaction After Wegovy (Semaglutide) Treatment","부천대학교 뷰티케어과 교수","2025","The Journal of Next-generation Convergence Technology Association","other","article","10.33097/jncta.2025.09.12.3699",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032151","GLP-1 RECEPTOR AGONISTS AND NON-ALCOHOLIC FATTY LIVER DISEASE: EFFICACY IN STEATOSIS RESOLUTION - A SYSTEMATIC REVIEW AND META-ANALYSIS","Majd Aldin Oudeh,Esra Mhd. Nour Barodi,Yara Mohamed,Moubaraka EL Boukhari,Nada Ahmed said,Heba Intabli,Kiran khan,Maryam Sabah,Saja Elamin Omer Elamin,Mehreen Nawaz Khan,Rana Anees Ur Rehman,Owais Mudassir","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.18162095",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; review"],["R0032152","GLP-1 RAs Linked to Lower Cardiovascular Risks in CKD",null,"2026","Kidney News","other","article","10.62716/kn.002662025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032153","Dipeptidyl peptidase-4 inhibitors use in clinical practice","Т. Б. Моргунова","2019","Consilium Medicum","other","article","10.26442/20751753.2019.4.190349",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032154","Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04208620",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032155","Management of Type 2 Diabetes Mellitus with Overweight: Focus on SGLT-2 Inhibitors and GLP-1 Receptor Agonists","Sergei V. Jargin","2019","European Journal of Therapeutics","other","article","10.5152/eurjther.2019.18067",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032156","Summary of opinion: Rybelsus,semaglutide",null,"2020","Case Medical Research","other","article","10.31525/cmr-283868a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032157","A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04184622",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032158","A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04154072",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032159","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03954834",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032160","Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03961256",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032161","Semaglutide Treatment On Coronary Progression",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03985384",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032162","Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04146155",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032163","Summary of opinion: Trulicity,dulaglutide",null,"2019","Case Medical Research","other","article","10.31525/cmr-1d3ecc1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032164","Use of a GLP-1R Agonist to Treat Opioid Use Disorder",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04199728",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032165","SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04269642",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032166","Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04059367",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032167","A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04255433",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032168","A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04187300",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032169","Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03986008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032170","The Effect of Liraglutide on the GIT",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04008290",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032171","A Study With NLY01 in Subjects With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04159766",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032172","A Study of TG103 in Chinese Healthy Adult Subjects",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03990090",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032173","A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04109547",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032174","A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04152915",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032175","Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03884075",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032176","Efficacy and safety of the russian GLP-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus in real-world clinical practice (“QUEENPROMIS” study)","Antsiferov M.B. Antsiferov","2025","Фарматека","nonrandomized_study","article","10.18565/pharmateca.2025.8.51-60",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032177","Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04189848",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032178","Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Newly Diagnosed Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03987308",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032179","Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03948347",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032180","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04083820",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032181","A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03888157",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032182","Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04137328",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032183","Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04232969",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032184","Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04074174",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032185","A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03861039",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032186","A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04143945",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032187","Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03862716",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032188","A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04039503",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032189","A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04228354",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032190","Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04001231",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032191","Effects of Insulin Glargine and Lixisenatide on the Brain",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03881995",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032192","A Study of LY3502970 in Healthy Participants",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03929744",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032193","Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04185350",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032194","Treatment of Bile Acid Malabsorption With Liraglutide",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03955575",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032195","A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04016974",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032196","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03876015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032197","A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03861052",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032198","Semaglutide vs Dulaglutide on Epicardial Adipose Tissue",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04200625",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032199","A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04102189",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032200","Impact of Semaglutide on CD34+ EPC and Fat Derived MSC",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04126603",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032201","Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04216589",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032202","A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04097600",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032203","Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03856047",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032204","Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04251156",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032205","A Study of Tirzepatide in Participants With Impaired Liver Function",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03940742",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032206","A Study of LY3305677 in Participants With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03928379",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032207","Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04061200",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032208","Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04057261",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032209","Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04029272",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032210","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04094415",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032211","The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04263415",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032212","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04261933",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032213","A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04209049",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032214","SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04287179",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032215","3mg Liraglutide for Overweight or Obesity",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03885297",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032216","Orphan designation: exenatide, Treatment of idiopathic intracranial hypertension",null,"2019","Case Medical Research","other","article","10.31525/cmr-da7a8b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032217","A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03951753",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032218","A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04172987",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032219","Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04074161",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032220","Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04196231",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032221","Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04184947",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032222","A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03989232",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032223","A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03987919",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032224","A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03882970",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032225","Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04135287",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032226","A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04012255",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032227","A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04109508",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032228","A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03914326",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032229","A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04238962",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032230","Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04174755",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032231","A Study to Measure Food and Calorie Consumption in Very Overweight Participants Using Tirzepatide",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04081337",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032232","A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04295005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032233","First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04259801",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032234","Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04190160",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032235","Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03883412",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032236","Modern aspects of use of tirzepatide – the first dual agonist of glucagon-like peptide-1 and glucosependent insulinotropic peptide receptors","Usanova A.A. Usanova","2023","Therapy","other","article","10.18565/therapy.2023.8.65-74",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032237","A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04004988",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032238","Real-world Health Outcomes in Canadian Patients Using Semaglutide",null,"2019","Case Medical Research","nonrandomized_study","article","10.31525/ct1-nct04175665",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032239","The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03878706",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032240","Summary of opinion: Suliqua,insulin glargine / lixisenatide",null,"2020","Case Medical Research","other","article","10.31525/cmr-2838689",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032241","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03929679",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032242","A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04032197",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032243","A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04093752",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032244","Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04186494",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032245","Effects of Semaglutide in HIV-Associated Lipohypertrophy",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04019197",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032246","A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04091373",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032247","A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity",null,"2000","Case Medical Research","other","article","10.31525/ct1-nct03842202",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032248","Liraglutide Effect in Atrial Fibrillation",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03856632",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032249","A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570",null,"2019","Case Medical Research","other_trial","article","10.31525/ct1-nct03994549",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032250","A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus",null,"2020","Case Medical Research","other","article","10.31525/ct1-nct04235959",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032251","A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04067999",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032252","A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03987451",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032253","Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03970044",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032254","A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04007107",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032255","Treating PCOS With Exenatide vs Active Lifestyle Intervention",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03919929",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032256","Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04122716",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032257","A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Liraglutide in the Occurrence of Serious Cardiovascular Disease",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct03993132",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032258","A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04143802",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032259","A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants",null,"2000","Case Medical Research","other","article","10.31525/ct1-nct03841630",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032260","Summary of opinion: Victoza,liraglutide",null,"2019","Case Medical Research","other","article","10.31525/cmr-1658a63",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032261","A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04166773",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032262","A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04050553",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032263","Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04034524",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032264","A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04017832",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032265","FDA approves new treatment for pediatric patients with type 2 diabetes",null,"2019","Case Medical Research","other","article","10.31525/cmr-15683dd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032266","Effect of Liraglutide on Microbiome in Obesity",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04046822",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032267","GLP-1 REceptor Agonists and Real World EvIdeNce",null,"2019","Case Medical Research","nonrandomized_study","article","10.31525/ct1-nct03959865",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032268","A Study of Tirzepatide Concentrations at Different Injection Sites in Participants With Different Body Sizes",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04050670",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032269","PSO(riasis) Long, Inflammation: Can GLP-1 RAs Clear the Way?","Chen, Jasmine Li","2024","Galter Health Sciences Library, Northwestern University","other","article","10.18131/4pz2j-gdy94",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032270","Higher-dose Wegovy could increase patient expectation, warns PDA",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.394394",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032271","Factors contributing to weight loss in patients with antipsychotic-induced weight gain treated with semaglutide or metformin: an experience sampling study","B. Campforts","2026","Neuroscience Applied","other","article","10.1016/j.nsa.2025.105776",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032272","Effect of liraglutide on methamphetamine consumption and seeking behavior in a rat model of self-administration","Maria Hrickova","2024","Neuroscience Applied","preclinical","article","10.1016/j.nsa.2024.104870",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032273","Drugs and endocrine disease","Gerard A. McKay","2021",null,"other","article","10.1002/9781394321919.ch10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0032274","Pediatric Obesity: Where Do We Stand Now?","Manuel Moya Benavent","2023",null,"other","article","10.1007/978-3-031-26727-7_10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0032275","Perspectives and Insights on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Drugs: From Development to Submission of New Drug Submission (NDS) in Canada","Shifa Thahseen","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18332381",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032276","Effect of Liraglutide on Pancreatic Tissue in Obesity Induced by High Fat High Glucose Diet in Adult Male Albino Rats. A Histological, Immunohistochemical and Biochemical Study.","Eman mohamed kamal hamed","2026","The Egyptian Journal of Histology","preclinical","article","10.21608/ejh.2026.445134.2375",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032277","Orforglipron: A Step Forward Toward Simplifying Management of Obesity and Type 2 Diabetes",null,"2026",null,"other","article","10.36266/jasg/134",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032278","The New Era of Diabetes Management: Comprehensive role of Ozempic in Cardio-Metabolic and Renal Care","Sumon Rahman Chowdhury","2026",null,"other","article","10.13140/rg.2.2.29009.39527",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032279","Appraisal of Cagrisema for Treatment of Obesity and Type 2 Diabetes",null,"2025",null,"other","article","10.36266/jasg/125",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032280","Effect of liraglutide on BMI change for patients with insufficient weight loss after metabolic bariatric surgery","Jing Wang","2025","Asian Journal of Surgery","other","article","10.1016/j.asjsur.2025.01.049",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032281","Exploring the emerging implications of GLP-1 receptor agonists in psychiatry: insights from recent studies","J. M. Paupério","2024","Neuroscience Applied","other","article","10.1016/j.nsa.2024.105314",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032282","Glucagon-like peptide-1 analogues in the management of antipsychotic-induced metabolic disturbances","João Vasco Barreira","2024","Neuroscience Applied","other","article","10.1016/j.nsa.2024.105148",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032283","For adults with obesity, what are the benefits and harms of semaglutide compared with placebo?","Amin Sharifan","2026","Cochrane Clinical Answers","other","article","10.1002/cca.4731",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032284","Semaglutide Başlanan Obezite Hastalarında Kısa Dönem (1. ve 3. Ay) Antropometrik Sonuçların Değerlendirilmesi: İki Üçüncü Basamak Merkez Deneyimi","Eşref Araç","2025","DergiPark (Istanbul University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032285","Toxicological Evaluation of Exenatide Usage","Erkekoğlu, Pınar",null,"DergiPark (Istanbul University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032286","Influencia del Síndrome Metabólico en el Pronóstico Cardiovascular: Retos y Nuevos Enfoques Terapéuticos","Juan Fernando Orozco Herrera","2025","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032287","Effects of Liraglutide on Carotid Intima-Media Thickness in Patients with Type-2 Diabetes and Non-Alcoholic Fatty Liver Disease: An 8-Month Prospective Pilot Study","PATTI, Angelo Maria","2014","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032288","Kasher Meron M et al. Supplementary materials: GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes","Michal Kasher Meron","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18404944",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032289","Liraglutide Shows Early Signal for Reducing Stroke Recurrence in Diabetes","Gina Shaw","2026","Neurology Today","other","article","10.1097/01.wnt.0001180600.84642.c7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032290","The Multifaceted Potential of Tirzepatide in Metabolic and Non-Metabolic Disorders","Thalal Mohamed","2026","International Journal of Pharmaceutical Investigation","other","article","10.5530/ijpi.20260349",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032291","GLP-1 receptor agonists modulate TNFα signaling and TNFα-induced apoptosis in INS-1 beta-cells.","NATALICCHIO, ANNALISA","2007","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032292","Incretin and its use in the treatment of type 2 diabetes mellitus","Talaulicar, Madhucar","2008","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032293","Preproglucagon neurons in the hindbrain have IL-6 Receptor α (IL-6Rα) and show Ca 2+ influx in response to IL-6","Anesten, FB","2016","UCL Discovery (University College London)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032294","Say Goodbye to Weight and Hello to Much More","Shelley, Madison","2024","Digital Commons @ Butler University (Butler University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032295","Reductions in Post-prandial Glucagon by Lixisenatide Correlate to Reductions in PPG and HbA1C.","Aronson R","2014","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032296","Effects of sustained treatment with lixisenatide on gastric emptying and glucose metabolism in type 2 diabetes","Rayner, C. K.","2018","CINECA IRIS Institutial research information system (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032297","Investigating the ability of novel GLP-1 variants to clear lipids in HepG2 cells","Helms, Madison","2022","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032298","Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (vol 36, pg 890, 2012)","Astrup, A","2012","UCL Discovery (University College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032299","Plant Polyphenols and Exendin-4 Prevent Hyperactivity and TNF-alpha Release in LPS-Treated In vitro Neuron/Astrocyte/Microglial Networks","Gullo, F","2017","UCL Discovery (University College London)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032300","Targeting postprandial hyperglycaemia with exenatide in young people with cystic fibrosis","Geyer, Myfanwy Clare","2022","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0032301","Off target benefits of GLP-1 agonist therapy in type 2 diabetes","Devlin, Ciara Josephine",null,"Ulster University Research Portal (Ulster University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032302","Exendin-4 inhibits palmitate-induced apoptosis of human cardiac progenitors cells.","Leonardini A","2012","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032303","SEMAGLUTIDE REDUCED CARDIOVASCULAR EVENTS BY 20% IN CERTAIN ADULTS","Saddam Alimuddin Shaikh",null,"CyberLeninK (CyberLeninka)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032304","Pharmacological Management of Obesity: New Approaches","Milton E Londoño Lemos",null,"RePEc: Research Papers in Economics","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032305","Peptide hormones regulating appetite: Focus on neuroimaging studies in humans","Schlögl, H.","2011","MPG.PuRe (Max Planck Society)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032306","Mechanism of Action and Metabolic Effects of Exenatide in Obesity","Camastra Stefania","2013","CINECA IRIS Institutial research information system (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032307","GLP-1 Receptor Agonists in Type 2 Diabetes Treatment","Carvalho, D","2016","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032308","Internship Report and Monograph \"The Role of Pharmacist managing Type 2 Diabetic Patients Undergoing GLP-1 RAs Therapies\".","Tavares, Sara Mariana Oliveira Mendonça Matos","2017","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032309","Cellulitis at GLP-1 Agonist Injection Site: Rare But Relevant","Simões, PB","2022","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032310","Exendin-4 restores ppar-alpha and ppar-gamma activity in nash and reduces insulin resistance, pro-inflammatory mediators and total fatty acid content","SVEGLIATI BARONI, Gianluca","2007","Università Politecnica delle Marche (Università Politecnica delle Marche)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032311","Liraglutide's safety, tolerability, pharmaokinetics, and pharmacodynamics in pediatric type 2 diabetes : a randomized, double-blind, placebo-controlled trial.","D. Klein","2014","VUBIR (Vrije Universiteit Brussel)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032312","GLP-1 receptor agonists in the treatment of diabetes mellitus type 2: cardioprotection, and more!","Granata A.","2021","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032313","Belangrijke wijziging van behandelrichtlijn ‘Diabetes mellitus type 2’","Serné, Erik H.","2021","Data Archiving and Networked Services (DANS)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032314","Regulation der Expression von Molekülen des Wnt-Signalwegs durch metabolische und pharmakologische Stimuli in pankreatischen beta-Zellen und die Rolle von Wnt4 für die Physiologie der pankreatischen beta-Zelle","Charlotte Heller","2014","Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032315","Exendin-4 counteracts palmitate-induced apoptosis by inhibiting de novo production of ceramides in human cardiac progenitor cells.","Leonardini, A","2013","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article; conference-paper"],["R0032316","Effectiveness, Safety and Therapeutic Adherence of Weekly Subcutaneous Semaglutide for Weight Management in Real Practice: An Observational Study","Santiago Tofé",null,"RePEc: Research Papers in Economics","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032317","Sustained Weight Loss and Acceptable Tolerability With the GLP-1 Analogue Liraglutide in Obese Non-Diabetic Adults: A 2-Year Randomized Trial","Lean, MEJ","2010","UCL Discovery (University College London)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032318","How useful in the daily practice of nephrologists are the new antidiabetics with cadiovascular protection?","Villegas Gutiérrez, Iván","2017","Redalyc (Universidad Autónoma del Estado de México)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0032319","IDEGLIRA VERSUS OTHER INTENSIFICATION STRATEGIES IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN (a)over-cap(sic)(a) AN INDIRECT STATISTICAL COMPARISON","Freemantle, N","2015","UCL Discovery (University College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032320","Tirzepatide: O Início de uma Nova Era na Terapêutica da Diabetes","Raimundo,Anabela","2023","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032321","Effects of\\nglucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.","MONAMI, MATTEO","2012","Florence Research (University of Florence)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","article"],["R0032322","Chronic modulation of GLP-1 receptor affects blood pressure, renal structure and function in spontaneously hypertensive rats","Gabriela Cozin Aragão","2016","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032323","The direct effects of exendin-4 on human non-diabetic and type 2 diabetic islets","Lupi R","2006","CINECA IRIS Institutial research information system (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032324","Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid‐phase gastric emptying in healthy cats","Gaschen, Frederic","2020","Civil War Book Review","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032325","Exenatide ameliorates the skeletal pathology induced by type 2 diabetes in db/db mice.","Chenu, C",null,"RVC Research Online (Royal Veterinary College)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032326","Sustained Exendin-4 secretion through gene therapy targeting salivary glands in Zucker fa/fa rats and high fat diet mice","I. Dicembrini","2011","Florence Research (University of Florence)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032327","GPR119 and GPR131: Functional Difference?","Yingxiao Li",null,"RePEc: Research Papers in Economics","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032328","Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain",null,"2021","RECERCAT (Consorci de Serveis Universitaris de Catalunya)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032329","Continuous benefit-risk assessment of oral antidiabetics and safety-related regulatory actions","Nogueras Zondag, D.A.","2014","Utrecht University Repository (Utrecht University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0032330","Exendin-4, a glucagon-like protein-1 receptor agonist, reduces proinflammatory conditions, and increases lipid oxidation and insulin sensitivity in hepatocytes from nonalcoholic steatohepatitis rats","FAVA G","2006","Università Politecnica delle Marche (Università Politecnica delle Marche)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032331","Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?",null,"2021","RECERCAT (Consorci de Serveis Universitaris de Catalunya)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032332","Living Evidence Synthesis Updated Report. Instituto Aragonés de Ciencias de la Salud-IACS. LE-IHD.","María Ximena Rojas Reyes","2022","OSF Preprints (OSF Preprints)","randomized_trial","article","10.17605/osf.io/c9yf8",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint; other"],["R0032333","Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP4-inhibitors.","Rizzo M","2009","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032334","Exendin-4 Counteracts Palmitate-induced Autophagy in Human Cardiac Progenitor Cells by Inhibiting p38 MAPK Phosphorylation and de novo Production of Ceramide.","D'Oria R","2014","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032335","Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial",null,"2021","RECERCAT (Consorci de Serveis Universitaris de Catalunya)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0032336","Impact of exendin-4 on the regeneration of pancreatic beta cell in stereptozotocin-induced diabetic mice.","章子 児玉","2004","Kumamoto University Repository (Kumamoto University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032337","Effect of exenatide on calcium-regulated proteins in myocardium","Rudež, Sara","2020","Repository of the University of Ljubljana (University of Ljubljana)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032338","Semaglutide 2.4 mg Subcutaneously Once-Weekly for Weight Reduction","Walton, Stacey M.","2022","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032339","Efficacy of liraglutide, dulaglutide and SGLT2 inhibitors in obese/overweight patients with type 2 diabetes mellitus","Maccora C","2019","IRIS Research product catalog (Sapienza University of Rome)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032340","METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO GLP-1 ANALOGS",null,"2023","Knowledge@UChicago (University of Chicago)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032341","Variációk egy szekvenciára - Exendin-4 és GLP-1 fehérjerészletek szintézise és szerkezetvizsgálata","Boller Balázs","2021","ELTE Digital Institutional Repository (EDIT) (Eötvös Loránd University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0032342","The Role of GLP-1RAs in Depression among Patients with Metabolic Conditions","Fleurimond Cemelus, Madge, PA-C","2025","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","randomized_trial","article","10.63932/3067-7106.1037",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0032343","A Budget Impact Analysis of Anti-Obesity Medications in the Medicare Population in the United States","Murray, PhD, Maria","2025","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0032344","Binding Affinity Profiles of G-protein Coupled Receptors and Mutated Protein Arginine N-methyltransferase 5","Spiegel, Kiersten","2025","The Knowledge Bank (The Ohio State University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032345","Role of GLP-1 agonist in the treatment of obesity: semaglutide","Pereira, Rui Salvador Pais","2025","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032346","Innovations 2024 en Endocrinologie et nutrition - Les doubles analogues du GLP-1 et du GIP : un nouveau traitement de l’obésité","Audrey Loumaye","2025","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032347","GLP-1 vs Gastric Bypass in Treating Obesity and Type 2 Diabetes","Oliver, Abir","2025","UND Scholarly Commons (University of North Dakota)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032348","Treating comorbidities in heart failure:tackling the hidden burden","Hopper, Ingrid","2025","Monash University Research Portal (Monash University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032349","Association of GLP-1 Receptor Agonist Use with Kidney and Cardiovascular Outcomes in Stable Kidney Transplant Recipients","Jung, Emma Yejoo","2025","DSpace@MIT (Massachusetts Institute of Technology)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0032350","New Data on Cardiovascular Effects of Glucagon- Like Peptide-1 Receptor Agonists","Anastasios Tentolouris",null,"RePEc: Research Papers in Economics","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032351","Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006)","Eyüb Yaşar Akdemir","2025","Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032352","Expanding the Role of GLP-1 Receptor Agonists: Cardiovascular, Renal, and Metabolic Outcomes Beyond Glycemic Control","Graczyk, Nicole A","2025","Florida International University Digital Commons (Florida International University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032353","Effects of endrocrine disruptors on polycystic ovary syndrome and new therapeutic approaches","Robert, Adèle Lemogne","2025","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032354","Ozempic is the First Posthuman Drug","Medeiros, Darren","2025","Journal of Media Literacy Education","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032355","Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD","Shi, Yu","2025","UCL Discovery (University College London)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0032356","Computational Study of Cannabinoid Receptors CB1 and CB2","Schneider, Lillian","2025","The Knowledge Bank (The Ohio State University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032357","Strengths, Gaps, and Opportunities in the Evidence Base For GLP-1 Receptor Agonists: Implications for Market Access Strategy","Nasser, PharmD, Sukeina","2025","The Medicine Forum","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","other"],["R0032358","The GLP1R agonist liraglutide inhibits hyperglucagonaemia induced by the SGLT2 inhibitor dapagliflozin","Bonner, C.","2017","CINECA IRIS Institutial research information system (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032359","The central vs peripheral mediated effects of liraglutide enhancement on insulin secretion is dependent on the stage of diabetes","Saponaro, C","2024","CINECA IRIS Institutial research information system (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032360","Exenatide induced cardioprotection in mice with diet induced obesity","Baensch, Leonard Richard","2025","Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032361","Implications of Ozempic: A Semaglutide with Peptide (GLP)-1 Receptor Agonists Misused for Cosmetic Weight Loss","Renee E Reardon","2025","New Prairie Press (Kansas State University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032362","Exploiting the biological effect exerted by nanocarriers in metabolic dysfunction-associated steatotic liver disease treatment","Inês Ladeiro Domingues","2025","Digital Access to Libraries","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032363","SGLT2i and GLP1RA: Safety and Effectiveness Profiles Evaluation using Real-World Patient Data","António Luís Martins Coutinho Cabral e Lopes","2025","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0032364","The Neuroprotection Effect of GLP-1 Receptor in Murine Stroke Model","Rui Chen",null,"RePEc: Research Papers in Economics","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032365","Obesity drugs: huge study identifies new health risks","Giorgia Guglielmi",null,"RePEc: Research Papers in Economics","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032366","Point-of-Care Gastric Ultrasound for Preoperative Assessment of Gastric Contents: An Objective Structured Clinical Examination","Mann, Joshua","2025","Aquila Digital Community (University of Southern Mississippi)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032367","Target Trial Emulation: A Rigorous Framework for Causal Inference in Real-World Data Studies (Motivated by the OneFlorida+ Study on GLP-1RA and SGLT2i Use and Dementia Risk in Type 2 Diabetes by Tang et al.)","Luiza Paulsen Rodrigues","2025","OSF Preprints (OSF Preprints)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","preprint"],["R0032368","Incretin-Based Glucose-Lowering Medications and the Risk for Acute Pancreatitis and/or Pancreatic Cancer Risk Reassuring Data from Cardio-Vascular Outcome Trials","Michael A Nauck",null,"RePEc: Research Papers in Economics","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032369","Pharmacological Treatment Options for Nonalcoholic Steatohepatitis: Resmetirom vs GLP- 1 Receptor Agonists","Zabel, Debbie","2025","UND Scholarly Commons (University of North Dakota)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032370","Efficacy of GLP-1 Receptor Agonists in Obese Women with PCOS","Fischer, Ellie","2025","UND Scholarly Commons (University of North Dakota)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032371","Comparing the Efficacy and Safety of GLP-1 Receptor Agonists Versus Gastric Bypass Surgery in the Treatment of Obesity and Type 2 Diabetes","Oliver, Abir","2025","UND Scholarly Commons (University of North Dakota)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032372","Cardiovascular Effects of GLP-1RA in Patients with Type 2 Diabetes","Legner, Courtney","2025","NWCommons (Northwestern College - Iowa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032373","Leveraging Psychological Factors and GLP-1 Receptor Agonists for Effective Weight Management Beyond Diet and Exercise","Emmanuel P Afari","2025","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032374","Tip 2 Diyabet Tedavisinde Kullanılan Exendin-4 ve Exendin-4’ün Alternatif Uygulama Yolları İçin Güncel Yaklaşımlar","Çelik Tekeli, Merve","2022","DergiPark (Istanbul University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032375","Risk Reduction of Incretin-Based Therapies and Lifestyle Modifications","Graf, Sara","2025","DigitalCommons (California Polytechnic State University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032376","O papel do liraglutido no tratamento da obesidade em crianças e adolescentes","Nogueiro, Beatriz Gonçalves","2025","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032377","Innovations 2024 en Endocrinologie et nutrition - Les doubles analogues du GLP-1 et du GIP : un nouveau traitement du diabète de type 2","Laura de Sales Orioli","2025","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032378","Semaglutide in Obesity and Non-Alcoholic Fatty Liver Disease","Simranjit Singh",null,"RePEc: Research Papers in Economics","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032379","Incretin-Based Therapies—Semaglutide, Tirzepatide, and Sitagliptin: Evaluating Pancreatitis Risk in Type 2 Diabetes Mellitus","Perez, Sui-Ling","2025","Florida International University Digital Commons (Florida International University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0032380","Efficacy of GLP-1 Receptor Agonists in Women with Polycystic Ovary Syndrome","Fischer, Ellie","2025","UND Scholarly Commons (University of North Dakota)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032381","«Язык худобы» и медиатравля: как обсуждают Ozempic в цифровой медиасреде","Екатерина Владимировна Трощенкова",null,"CyberLeninK (CyberLeninka)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032382","Why does America want Greenland?; Mystery of dark DNA; Ozempic weight rebound","Rowan Hooper","2026","VBN Forskningsportal (Aalborg Universitet)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0032383","Once-weekly subcutaneous semaglutide 2;4mg in adolescents with overweigh or obesity.","John Dixon","2024","VUBIR (Vrije Universiteit Brussel)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032384","Improvements in BMI below the obesity threshold in children aged 6 to <12 years treated with liraglutide 3.0 mg: a secondary analysis of the SCALE Kids study","Claudia K. Fox","2024","VUBIR (Vrije Universiteit Brussel)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032385","Additional file 2: of GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial","Wiberg, Sebastian","2016","Figshare","protocol","article","10.6084/m9.figshare.c.3629945_d2",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0032386","Additional file 2: of The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice","Caina Li","2017","Figshare","preclinical","article","10.6084/m9.figshare.c.3806485_d2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032387","Additional file 1: of Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","Suzuki, Shuichi","2017","Figshare","randomized_trial","article","10.6084/m9.figshare.c.3801541_d1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0032388","Data from: Effect of a three-week treatment with glucagon-like peptide 1 receptor agonists on vasoactive hormones in euvolemic participants","Vukajlovic, Tanja","2021","Figshare","other","article","10.6084/m9.figshare.16685470",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032389","Additional file 1: of The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice","Caina Li","2017","Figshare","preclinical","article","10.6084/m9.figshare.c.3806485_d1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032390","MOESM3 of Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study","Ishii, Hitoshi","2017","Figshare","other","article","10.6084/m9.figshare.c.3660503_d3.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032391","MOESM1 of Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study","Ishii, Hitoshi","2017","Figshare","other","article","10.6084/m9.figshare.c.3660503_d2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032392","Additional file 3: of Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","Suzuki, Shuichi","2017","Figshare","randomized_trial","article","10.6084/m9.figshare.c.3801541_d3",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0032393","MOESM2 of Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study","Ishii, Hitoshi","2017","Figshare","other","article","10.6084/m9.figshare.c.3660503_d1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032394","MOESM1 of Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes","Zeqing Zhang","2017","Figshare","other_trial","article","10.6084/m9.figshare.c.3706765_d1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0032395","Additional file 6 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Yang, Chun-Ting","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.12479063",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0032396","MOESM1 of Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","Leiter, Lawrence","2019","Figshare","other_trial","article","10.6084/m9.figshare.8233784",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0032397","Effect of a three-week treatment with glucagon-like peptide 1 receptor agonists on vasoactive hormones in euvolemic participants.docx","Vukajlovic, Tanja","2021","Figshare","other","article","10.6084/m9.figshare.16685470.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032398","Additional file 4: of Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","Suzuki, Shuichi","2017","Figshare","randomized_trial","article","10.6084/m9.figshare.c.3801541_d4",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0032399","MOESM1 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Bruen, Robyn","2017","Figshare","preclinical","article","10.6084/m9.figshare.c.3923344_d3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032400","Additional file 1: of Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance","Abdesselam, Inès","2015","Figshare","preclinical","article","10.6084/m9.figshare.c.3624287_d2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032401","Additional file 1: of GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial","Wiberg, Sebastian","2016","Figshare","protocol","article","10.6084/m9.figshare.c.3629945_d1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0032402","MOESM1 of Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study)","Z. Htike","2016","Figshare","protocol","article","10.6084/m9.figshare.c.3600608_d1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0032403","Additional file 2: of Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","Suzuki, Shuichi","2017","Figshare","randomized_trial","article","10.6084/m9.figshare.c.3801541_d2",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0032404","MOESM1 of Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study","Preman Kumarathurai","2016","Figshare","randomized_trial","article","10.6084/m9.figshare.c.3617195_d1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0032405","Selten Verhütung trotz GLP-1-RA-Therapie","Nicola Zink","2026","gynäkologie + geburtshilfe","other","article","10.1007/s15013-026-6313-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032406","For adults with obesity, what are the benefits and harms of once-weekly tirzepatide injections compared with placebo?","Amin Sharifan","2026","Cochrane Clinical Answers","other","article","10.1002/cca.4733",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032407","Interazione tra regolazione omeostatica ed edonistica dell'assunzione alimentare: evidenze neurobiologiche, endocrine e comportamentali dagli studi primari","Daniele Guccione","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18622761",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032408","Antidiabéticos de nova geração: quais são as implicações no suporte nutricional da espermatogénese?","Ribeiro, João Pedro Cardoso","2019","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032409","Why Mounjaro Searches Are Exploding in 2025 (Google Trends Report)","Discreet People","2026",null,"other","article","10.55277/researchhub.f5qmxj2o",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032410","Two-fifths of children have seen weight-loss drugs online despite ban",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.400074",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032411","For adults with obesity, what are the benefits and harms of semaglutide injections compared with liraglutide injections?","Amin Sharifan","2026","Cochrane Clinical Answers","other","article","10.1002/cca.4732",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032412","For adults with obesity, what are the benefits and harms of once-weekly tirzepatide injections compared with once-weekly semaglutide injections?","Amin Sharifan","2026","Cochrane Clinical Answers","other","article","10.1002/cca.4734",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032413","Efficacy of retatrutide for weight reduction and its cardiometabolic effects among adults: A systematic review and meta-analysis","Mark Jason D. C. Milan","2024","Clinical Nutrition ESPEN","systematic_review","article","10.1016/j.clnesp.2024.07.467",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032414","Internship Reports and Monograph entitled \"Therapeutic adherence to GLP-1 receptor agonists in diabetic patients\"","Ana Sofia Medeiros Lopes","2025","Estudo Geral (Universidad de Coimbra)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032415","Internship Reports and Monograph entitled \"Repurposing of GLP-1 analogues: new therapeutic perspectives in Alzheimer’s Disease and Metabolic Dysfunction–Associated Steatotic Liver Disease\"","Diogo Rafael Cardoso Esteves","2025","Estudo Geral (Universidad de Coimbra)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032416","Pattern of Semaglutide Prescription in a Real-World Patient Cohort","Armin Farahvash","2024","Canadian Journal of Diabetes","nonrandomized_study","article","10.1016/j.jcjd.2024.09.102",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032417","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) AND UPPER ENDOSCOPY: A REAL WORLD EXPERIENCE","Noppachai Siranart","2024","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.04.1219",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032418","Reducing Cardiovascular Risk in Diabetes: Insights from Diabetes Trials","Phong Teck Lee","2019","Frontiers in diabetes","other","article","10.1159/000486263",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032419","New drugs for the treatment of diabetes mellitus","Clifford J. Bailey","2015",null,"other","article","10.1002/9781118387658.ch47",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0032420","For adults with obesity, what are the benefits and harms of daily liraglutide injections compared with placebo?","Amin Sharifan","2026","Cochrane Clinical Answers","other","article","10.1002/cca.4735",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032421","GLP-1 receptor agonists and male reproductive health: an in vitro study on leydig cell function","André Oliveira Pinto","2025","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032422","Effects of glucagon-like peptide-1 receptor agonists on doxorubicin-induced myocardial fibrosis in a rat model","Jia Song","2025","Asian Journal of Surgery","preclinical","article","10.1016/j.asjsur.2025.02.089",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032423","Exenatide Increases Hypothalamic Connectivity in Obese Men: First Evidence of Central appetite modulating Effects in fMRI Analyzed With Eigenvector Centrality Mapping","Schloegl, H.","2010","MPG.PuRe (Max Planck Society)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","other"],["R0032424","Manejo integral del síndrome de ovario poliquístico: revisión sistemática de estrategias terapéuticas farmacológicas","Erika Alexandra Jami Tonato","2026","Dialnet (Universidad de la Rioja)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032425","Orforglipron offers greater weight loss for people with diabetes than oral semaglutide",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other_trial","article","10.1211/pj.2026.1.401466",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032426","Advances in cardiovascular pharmacogenetics and clinical outcomes in pharmacoepidemiology","Negin Soroush","2025","EUR Research Repository (Erasmus University Rotterdam)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0032427","THE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 AGONIST THERAPY (SEMAGLUTIDE AND TIRZEPATIDE) ON METABOLIC AND HORMONAL PARAMETERS IN MEN WITH OBESITY AND INSULIN RESISTANCE","Mukhammadali Jumayev","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18812162",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032428","Retrospective analysis of clinical trials of medicinal products for the treatment of diabetes mellitus","Лора Петрова","2025","Bulgarian Portal for Open Science","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0032429","Bidirectional Regulation of Glucagon-Like Peptide-1 Receptor Agonist on Bone Metabolism in Obese Patients with Type 2 Diabetes Mellitus","钰琪 王","2026","Advances in Clinical Medicine","other","article","10.12677/acm.2026.163787",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032430","The Efficacy of GLP-1 Agonists in Pediatrics with Type 2 Diabetes and Obesity","Mahrer, Cayla","2024","UND Scholarly Commons (University of North Dakota)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032431","THE DANGER ONLINE PHARMACIES POSE ON CLIENTS WITH EATING DISORDERS IN THE PRESCRIPTION OF GLP-1 AGONISTS FOR WEIGHT LOSS","Frisbie, Madyson R.","2024","SEU FIRE Scholars (Southeastern University)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0032432","Ozempic (semaglutide) versus Nonpharmacologic Interventions For Weight Management in Overweight Individuals","Jacey, Elena N","2024","DigitalCommons (California Polytechnic State University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032433","Is it Possible for GLP-1RAs to Combat type 2 Diabetes and its Comorbidities?","Michael Weingarten","2024","Touro Scholar (Touro College)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032434","The Efficacy of GLP-1 Agonists in Pediatric Patients with Type 2 Diabetes and Obesity","Mahrer, Cayla","2024","UND Scholarly Commons (University of North Dakota)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032435","Nutrition Recommendations for Patients on Weight Loss Drugs","Duque, Crystal M, RDN-LDN","2024","NSUWorks (Nova Southeastern University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032436","A Review of Antiobesity Drug Therapy","Peters, Nicholas P","2023","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032437","Is Ozempic a Safe Way to Lose Weight?","Elizer Terebelo","2024","Touro Scholar (Touro College)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032438","Nauja sėkmingo cukrinio diabeto gydymo priemonė – pasaulio ekspertų akiratyje","Gediminas Urbonas","2012","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032439","Tip 2 diyabetik hastalarda GLP-1 agonist tedavisinin serum betatrofin üzerine etkisinin insülin ile karşılaştırmalı olarak değerlendirilmesi","Yağmur Çakmak","2017","Kocaeli Üniversitesi - AVESİS","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032440","Do Glucagon-Like Peptide-1 Receptor Agonists Have an Effect on Sperm Parameters?","C Tapkan","2025","AYBU AVESIS","other","article","10.1016/0014-5793(87)81430-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032441","Evaluating Tirzepatide's Therapeutic Potential in Mitigating Obesity-Associated Comorbidities","Kahook, Zaneh","2024","NSUWorks (Nova Southeastern University)","other_trial","article",null,null,null,"ClinicalTrials.gov:NCT06301256; ClinicalTrials.gov:NCT06517212","S000939; S001684","openalex","FALSE","no_doi","5","FALSE","article"],["R0032442","Liraglutide versus Semaglutide: Long Term Weight Loss Management in Obese Individuals","Burke, McKenzie","2023","UND Scholarly Commons (University of North Dakota)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0032443","Introduction of Semaglutide as an Effective Option for Obese Patients Motivated to Lose Weight","Garcia-Martinez, Crystal","2022","scholarworks - UTEP (The University of Texas at El Paso)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032444","Glucagon-like Peptide-1 Receptor Agonist-induced Delayed Gastric Emptying: An Educational Module","Alarab, Lemya","2024","Florida International University Digital Commons (Florida International University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032445","Glucagon-like peptide-1 receptor agonist, dulaglutide, ameliorates kidney function in diet-induced obese mice by regulating lipids and metabolites.","Yeung, Ho Yin Martin",null,"PolyU Institutional Research Archive (Hong Kong Polytechnic University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032446","Evaluation of the Effect of Liraglutide, GLP-1 Receptor Agonist, on Retina in Experimental Diabetes in Rats: Histological and Immunohistochemical Study","Mai Amin Almoatasem","2026","Fayoum University Medical Journal/Fayoum University Medical Journal ","preclinical","article","10.21608/fumj.2025.396666.1540",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032447","The demise of metformin and the rise of the GLP‐1 agonists","Lawrence H. Price","2026","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31421",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032448","Structure-Activity Studies of A-Melanotropin and Ultra-Short Glp-1 Analogs To Benchmark the Development of Improved Anti-Obesity Drugs","Sawyer, Jonathon Randall","2022","UA Campus Repository (The University of Arizona)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032449","MOESM3 of Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes","Zhang, Wen-qiang","2018","Figshare","other","article","10.6084/m9.figshare.7479182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032450","Impacto na Saúde da População Brasileira pelo Uso da Tirzepatida (Mounjaro®) sem Acompanhamento Adequado: Contribuições da Enfermagem","Danielle Cintra Vilela","2025","AYA Editora eBooks","other","article","10.47573/aya.5379.3.24.31",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0032451","Beneficial effects of once-daily liraglutide, ahuman glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patientswith Type 2 diabetes","J.P. Courreges","2008","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032452","Liraglutide-stimulated cardioprotection","Aung Myat","2016","Research Portal (King's College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032453","Pharmacotherapy of diabetes mellitus followed up in diabetes clinic","Hana Bradová","2019","Digital Repository (National Repository of Grey Literature)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032454","Metabolic Tinkering: An Ethnography of a New Generation of Anti-Obesity Drugs in Users' Hands","Samuel Csanda","2025","Digital Repository (National Repository of Grey Literature)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032455","Bacteriophage as biopesticides against patoghenic bacteria in tomato","Sára Brázdová","2024","Digital Repository (National Repository of Grey Literature)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032456","GLP-1-RA: Mehr als ein Antidiabetikum","Peter Stiefelhagen","2026","CME","other","article","10.1007/s11298-026-4538-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032457","Role of GLP-1 analogues and DDP-IV inhibitors in the treatment of type 2 diabetes","J.J. Holst","2006","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032458","Expression and activities of antioxidant enzymes in the in vivo models of non-alcoholic fatty liver disease","Gabriela Sochová","2023","Digital Repository (National Repository of Grey Literature)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032459",": Analysis of Weight Loss Reduction Methods and Modern Approaches in the Treatment of Obesity in Adults","Simona Pašková","2025","Digital Repository (National Repository of Grey Literature)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0032460","Effect of GLP-1 on liver metabolism in experiment","Josef Fontana","2021","Digital Repository (National Repository of Grey Literature)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032461","Gebruik van GLP1-agonist tijdens de zwangerschap","Roosmarijn Zonneveld","2026","FarmaMagazine","other","article","10.24078/fama.1970.1.31019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032462","The effect of GLP-1 (glucagon-like peptide-1) analogues on rat hepatocytes in vitro","Veronika Krejčíková","2014","Digital Repository (National Repository of Grey Literature)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032463","Changes in epigenetic regulation in the in vivo model of NAFLD","Klára Osobová","2024","Digital Repository (National Repository of Grey Literature)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032464","Patient Access to GLP-1 RA’s: A Medicare Part D Policy Analysis","Hummer, Celine","2024","UKnowledge (University of Kentucky)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032465","Peptide Corrination for the Mitigation of Nausea and Emesis in the Treatment of Type 2 Diabetes","Tinsley, Ian","2021","Syracuse University Libraries (Syracuse University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032466","Management of Uncontrolled Type 2 Diabetes Mellitus with Combination Therapy with Metformin and/or Glucagon-like Peptide-1 Receptor Agonists/ Sodium-Glucose Cotransporter-2 Inhibitors","Contreras, Bertha L","2022","scholarworks - UTEP (The University of Texas at El Paso)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032467","CIRCULATING CETP IS NOT RELATED TO THE HEPATIC TRIGLYCERIDE CONTENT: LESSONS FROM A LIRAGLUTIDE INTERVENTION TRIAL AND A POPULATION-BASED COHORT","Eyk, H. van","2018","Leiden Repository (Leiden University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","other"],["R0032468","Heterologous production of recombinant peptidylglycine α-amidating monooxygenase for the production of biosimilar α-amidated peptides","Morrison, David Graham","2022","Open University of Cape Town (University of Cape Town)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032469","Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort","Eyk, H.J. van","2019","Leiden Repository (Leiden University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0032470","Another Positive GLP-1 RA CVOT: The AMPLITUDE-O Trial","Shubrook, Jay H.","2022","Touro Scholar (Touro College)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0032471","Two-year Effect of Semaglutide 2.4 mg vs Placebo in Adults with Overweight or Obesity: STEP 5","Garvey, WT","2021","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032472","SGLT2i Use Potentiates Acute and Chronic Radiation-Induced Side Effects in Prostate Cancer Radiation Therapy","Works, Duncan","2024","Graduate Medical Education Research Journal","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032473","EFFECTS OF LIRAGLUTIDE ON MALE REPRODUCTIVE TISSUE: A REVIEW OF CURRENT EVIDENCE","Pardayeva M.N.",null,"CyberLeninK (CyberLeninka)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032474","Effects of liraglutide on plasma ghrelin concentrations and oxidative stress in patients with type 2 diabetes: a 2-month prospective pilot study.","RIZZO, Manfredi","2012","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032475","Liraglutide improves carotid intima-media thickness in patients with type-2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study","Giglio, RV","2014","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0032476","New and Alternative Treatment Methods in Diabetes Mellitus","Gosnell, Corey","2023","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032477","Semaglutide vs Bariatric Surgery Usage in Individuals who are Obese","Carley, Megan","2024","NWCommons (Northwestern College - Iowa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032478","Health news round-up: Alzheimer's treatment, retatrutide results and kidney cancer guidelines",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.404547",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032479","Skeletal Effects of GLP-1 Receptor Agonist Therapy in Individuals with Overweight or Obesity: A Systematic Review and Meta-Analysis","Cheng-Hao Lai","2026",null,"systematic_review","article","10.37766/inplasy2026.3.0076",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","report"],["R0032480","Advances in Oral Administration",null,"2026",null,"other","article","10.3390/books978-3-7258-6919-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0032481","Pathophysiological aspects of insulin resistance in Atrial Fibrillation: novel therapeutic approaches","Saira Rafaqat","2022","Greater South Information System","nonrandomized_study","article","10.60692/shp88-kdy94",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0032482","Diabetes and cardiovascular outcome trials: a review with a focus on the use of glucagon-like peptide-1 receptor agonists in clinical practice","Reyna Daya","2021","South African General Practitioner","narrative_review","article","10.36303/sagp.2021.2.3.0073",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032483","Impact of liraglutide versus atorvastatin on cardiovascular changes in rat model of adenine induced chronic renal failure","Shata Ahmed","2017","Greater South Information System","preclinical","article","10.60692/gf03t-0vk73",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032484","A current grasp of GLP-1 receptor agonists for addiction: emerging therapeutic potential","RM Moosa-Battey","2025","SA pharmaceutical journal.","other","article","10.36303/sapj.2615",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032485","Statistical Analysis Plan: Efficacy of Sustained Use of GLP1-RA versus DPP4 Inhibitors and Sulfonylureas on HbA1c and Weight – A LEAD-2 and LEAD-3 Inspired Trial Emulation Using the Swedish National Diabetes Register","Imberg, Henrik","2022","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.15347461",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0032486","GLP-1 agonists to achieve weight loss in childhood obesity","M van den Berg","2026","Geneesmiddelenbulletin","other","article","10.35351/gebu.2026.2.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032487","The GLP-1 Receptor Agonist Liraglutide Attenuates Atherosclerotic Lesion Development and Potentially Enhances Plaque Stability in an ApoE–/–Mouse Model","BUSCEMI, Silvio","2013","Nova Science Publishers (Nova Science Publishers, Inc.)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032488","A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.","雄一郎 井上",null,"Institutional Repositories DataBase (IRDB)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0032489","Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study","浩平 伊藤",null,"Institutional Repositories DataBase (IRDB)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0032490","Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study","咲子 照井",null,"Institutional Repositories DataBase (IRDB)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0032491","Effectiveness and safety of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in women with polycystic ovary syndrome and obesity","Shipilova G.A. Shipilova","2026","Akusherstvo i ginekologiia","other","article","10.18565/aig.2025.288",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032492","Research Progress on the Application of GLP-1 Receptor Agonists in the Adjuvant Treatment of Obese Patients with Type 1 Diabetes","玮洋 周","2026","Advances in Clinical Medicine","other","article","10.12677/acm.2026.1641306",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032493","Weight-loss drug to be offered to patients at risk of stroke or heart attack",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.406390",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032494","News round-up: long COVID, chikungunya and free supplies of ciprofloxacin",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.406644",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032495","Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis","Sho Kinguchi","2022","Institutional Repositories DataBase (IRDB)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","article"],["R0032496","From model to medicine: The horse as a natural and translational model for osteoarthritis drug development","Ann-Sofie Scheike","2026","Utrecht University Repository (Utrecht University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032497","Semaglutide Reduces Infection Serious Adverse Events in Diabetic Kidney Disease",null,"2026","Kidney News","other","article","10.62716/kn.003292026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032498","Mechanism of GLP-1 Receptor Agonists in Weight Loss through Appetite Suppression","张婉儿 姚","2026","Advances in Clinical Medicine","other","article","10.12677/acm.2026.1641386",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032499","Emergency presentations relating to use of real/counterfeit incretin-based therapies","Darren Parker","2025","Obesity Abstracts","other","article","10.1530/obabs.05.p9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032500","Semaglutid v liečbe obezity a jeho kardiovaskulárne prínosy: dôkazy z klinických štúdií a odporúčania Európskej kardiologickej spoločnosti / Semaglutide in treatment of obesity and its cardiovascular benefits: evidence from clinical studies and guidelines of European Society of Cardiology","Tibor Harcsa","2026","Cardiology letters","other","article","10.4149/cardiol_2026_1_2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032501","Repurposing tirzepatide: a novel disease-modifying approach for Wolfram syndrome","G Frontino","2025","IRIS Research product catalog (Sapienza University of Rome)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032502","Efficacy and safety of semaglutide 7.2 mg in obesity: STEP UP trial","Iskandar Idris","2025","Obesity Abstracts","other_trial","article","10.1530/obabs.05.p3",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032503","Dysaesthesia added to semaglutide side effects list",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.407273",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032504","Mounjaro KwikPen Injection Diabetes Treatment Info | Online Generic Medicine","Online Generic Medicine","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19509537",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032505","Neurobehavioral Impact of Tirzepatide: Smoking Cessation and Sleep Improvement in Obese Patients","Marcelo Rodrigues","2025",null,"other","article","10.13140/rg.2.2.13960.17928",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032506","Semanat Injection Semaglutide Appetite & Sugar Control | Online Generic Medicine","Online Generic Medicine","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19548393",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032507","GLP-1 Agonists for Weight Loss and Beyond","Connor Quinter","2024","Transformative Medicine","other_trial","article","10.54299/tmed/curq6915",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032508","Mounjaro approved for use in children in UK in ‘significant advance in paediatric care’",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.407746",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032509","Efficacy of the combined use of GLP-1 receptor agonists with lifestyle modification in patients with type 2 diabetes mellitus and insulin resistance: a clinical case","Antsiferova D.M. Antsiferova","2026","Фарматека","other","article","10.18565/pharmateca.2026.2.127-134",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032510","Possibilities and prospects of oral semaglutide therapy","Koteshkova O.M. Koteshkova","2026","Фарматека","other","article","10.18565/pharmateca.2026.2.30-38",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032511","The long-lived human GLP-1 analogue","Kira Raskina","2015","Relevant endocrinology","other","article","10.18508/endo2507",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032512","Health news round-up: semaglutide and liver health, obesity vaccine response and hope for pancreatic cancer",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.407970",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032513","Wegovy FlexTouch Pen Appetite Control Therapy – Online Generic Medicine","Online Generic Medicine","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19630740",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032514","Haarausfall bei GLP-1-RA","Katalin Wagner","2026","ästhetische dermatologie & kosmetologie","other","article","10.1007/s12634-026-3175-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032515","Raucher erhalten seltener GLP-1-RA","Karsten Müssig","2026","Info Diabetologie","other","article","10.1007/s15034-026-5258-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032516","Suvorexant","Cada, Dennis J.","2015","PubMed Central","other_trial","article","10.1310/hjp5001-059",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0032517","Tirzepatide: A type 2 diabetes mellitus treatment","Dr. Usama Sohail","2026",null,"other","article","10.55277/researchhub.k0i9qj9w",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032518","Experiential Health Discourse about Ozempic on Social Web*","Aarav Lala","2026","DigitalCommons-IMSA (Illinois Mathematics and Science Academy)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032519","Dulaglutide","Pius S. Fasinu","2026","Elsevier eBooks","other","article","10.1016/b978-0-443-44037-3.00655-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032520","3,800 GLP-1 Family Analog Sequences with Predicted Pharmacology, Synthesis Routes, Binding Assay Protocols, and Pharmacokinetic Projections, Disclosed as Public-Domain Prior Art Under 35 U.S.C. §102 Across Mono-, Dual-, Triple-Receptor Agonist and Oxyntomodulin-Like Scaffolds","Coracle Research","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19801438",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0032521","Molecular and Metabolic Mechanisms Influencing Long-Term Weight Regulation after Discontinuation of GLP-1 Receptor Agonists in Adults with Obesity in Saudi Arabia","Faisal F Alshehri","2025","Genetics and Molecular Research","other","article","10.4238/7ps2g495",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032522","Semaglutide and Tirzepatide in Egypt: A Critical Evaluation of Prescribing Trends, Off-Label Challenges, and the Influence of Social Media on Patient Perception","Hossam Arafa Ghazi","2026","Egyptian Society of Diabetes and Lipidology Journal","other","article","10.21608/esdlj.2026.470049.1001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032523","Cardiometabolic Health: The Missing Piece in Most Cardiovascular Evaluations","Mildred Opondo","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19986185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032524","Tirzepatide and Diabetic Retinopathy: A Systematic Review of Effects on Incidence, Progression, and Retinal Outcomes in Adults with Type 2 Diabetes","Fahad Ali Alsahli","2025","Genetics and Molecular Research","systematic_review","article","10.4238/syvpp340",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032525","Effect of GLP-1 Receptor Agonists on Body Weight and Albuminuria in Patients With and Without Type 2 Diabetes: A Protocol for a Systematic Review and Meta-Analysis","Rong Huang","2026",null,"systematic_review","article","10.37766/inplasy2026.5.0012",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","report"],["R0032526","Clinical outcomes with GLP-1 receptor agonists in obese HFpEF: systematic review and meta- analysis","Paul E. Hernández-Montes","2026","Revista Médica Del Hospital General De México","systematic_review","article","10.24875/hgmx.25000035",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article; review"],["R0032527","Remarkable Weight Reduction and HbA1c Improvement by Tirzepatide (Mounjaro) for Short Period",null,"2026","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/206",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032528","Bridging Innovation and Access: Randomized, Single-Dose, Open-Label, Parallel-Group Bioequivalence Study of Generic and Innovator Injection Semaglutide in India","Mayur Madhav Mayabhate","2026","American Journal of Pharmacology and Toxicology","randomized_trial","article","10.3844/ajptsp.2026.9.15",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0032529","Research Progress of SGLT2i and GLP-1RA in Improving Energy Metabolism in Heart Failure with Preserved Ejection Fraction","Xu Zhengqian","2025","Biomedical Data Science","other","article","10.47297/wspbdswsp2752-630524.20250504",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032530","1077 OBESITY SUBPHENOTYPE WITH REDUCED GLP-1 AND FAST GASTRIC EMPTYING IS ASSOCIATED WITH WEIGHT LOSS RESPONSE TO TIRZEPATIDE","Alexander L. Ticho","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04743-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032531","[Kindle] LA REVOLUCIÓN OZEMPIC descargar gratis","Veronica Newton","2026",null,"other","article","10.55277/researchhub.ommgijlx.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032532","Carbohydrate and Lipid Metabolism Changes at Patients Type 2 Diabetes with Ifferent Tactics Antidiabetic and Hypolipidemic Therapy","Sergey N. Vorobyev","2012","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032533","Transcriptome study of glucagon like peptide-1 agonist Exendin-4 on mouse embryonic osteoblast precursor MC3T3-E1 in vitro","LIU Xin, QI Caihui, WANG Zhenjing, LÜ Na, WANG Shaoting, WANG Shuping","2022","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.16150/j.1671-2870.2022.03.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032534","The effects of the weight-loss drugs on the eyes","ZHANG Shuyu","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12419/25011002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032535","Preparation of Lir@BSA-PMF nanoparticles and verification of their cell functions","HUANG Qingyu, CHEN Qiying, SUN Shengjia, WU Bangwei, LIN Shan, Alimujiang·MAIMAITIJIANG","2024","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.16352/j.issn.1001-6325.2024.02.0235",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032536","Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: progress in ultrasound, CT, MRI and ablation of thyroid nodules and differentiated thyroid cancer","LIU Ruyu, WANG Chenyi, ZHANG Bo","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.19401/j.cnki.1007-3639.2025.09.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032537","Probiotics and Their Metabolites Alleviate Type 2 Diabetes Mellitus by Regulating Glucagon-like Peptide-1: A Review of Recent Research","CHENG Zhiliang, ZHANG Yulong, YANG Han, HA Hui, WANG Yingdi, CHEN Feifei, LIU Fei, JIAO Yuehua","2024","DOAJ (DOAJ: Directory of Open Access Journals)","narrative_review","article","10.7506/spkx1002-6630-20230630-241",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032538","Liraglutide ameliorates cerebral ischemic injury in diabetic rats by regulating microglia/macrophage polarization through inhibition of NOX2 expression","GUAN Jingfan","2022","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.16016/j.2097-0927.202111090",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032539","Potential Anti-inflammatory Role of Anti-Diabetic Agents","Raj Kumar","2022","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032540","艾塞那肽对多囊卵巢综合征大鼠胰岛素抵抗及生殖激素的影响",null,"2014","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032541","Diabetes and Ramadan: An update On use of glycemic therapies during fasting","Ahmed Mohamed","2011","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032542","Research Progress on Neuroprotective Effects and Mechanisms of Glucagon-like Peptide 1 Analogues in Alzheimer's Disease","MEI Chenghan","2023","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12300/j.issn.1674-5817.2022.136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032543","Perspectives of drug treatment of obesity","Alfredo Halpern","2006","DOAJ (DOAJ: Directory of Open Access Journals)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0032544","Emaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis in cardiomyocytes","LIU Yan","2025","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.12467/j.issn.2096-3882.20250003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032545","A study on the therapeutic effect of liraglutide on chronic renal failure rats by down-regulating TGF-β1 and α-SMA","CHEN Li","2020","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032546","Interpretation of Key Points of 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients with Chronic Coronary Disease","XUE  Yanan, OU  Minxing, ZHANG  Xiujie, MENG  Qingxue, LIU  Ying","2024","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12114/j.issn.1007-9572.2023.0827",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032547","The role of anti-obesity drugs in the management of obese diabetics","Micić Dragan D.","2018","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032548","Application of GLP-1 receptor agonists in postoperative combined therapy for obesity: a perspective of metabolic surgery","MENG Hua, SONG Yujia, WANG Siqi","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.16139/j.1007-9610.2025.03.05",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032549","Satisfactory Decrease of HbA1c, Liver Function and Lipid Profile by Treatment of Tirzepatide (Mounjaro)",null,"2026","International Journal of Case Reports and Clinical Images","other","article","10.36266/ijcrci/266",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032550","Mechanism of glucagon-like peptide-1 receptor agonist in the treatment of obesity and food addiction","LIU  Luyao, LI  Linwei, WANG  Chen, DI  Jianzhong","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12464/j.issn.0253-9802.2024-0505",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032551","Interpretation of Diabetes Management in Chronic Kidney Disease: a Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","YAO  Huijuan, YANG  Yu, XU  Ajing","2023","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12114/j.issn.1007-9572.2023.0015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032552","Research progress on the effect of type 2 diabetes and hypoglycemic drugs on the prognosis of patients with colorectal cancer","ZHANG Meng，LEI Xuefen，CHEN Haixia，CHEN Yixuan，JIANG Li","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.13429/j.cnki.cjcr.2025.07.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032553","Progress in treatment of nonalcoholic fatty liver disease","SHI Junping","2014","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.3969/j.issn.1001-5256.2013.12.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032554","Revisiting the role of novel weight management medications and bariatric surgery","LIANG  Hui","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12464/j.issn.0253-9802.2025-0156",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032555","Comprehensive Assessment and Rational Decision-making: Based on Recent FindingsAbout Safety of Glucagon-like Peptide-1 Receptor Agonists","Liyun He","2022","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12290/xhyxzz.2022-0391",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032556","Study on the content of nurse's prescription of drug for endocrine system and metabolic in China by Delphi method","HOU Yongchao","2019","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032557","Liraglutide decreases cardiac function damage and atrial fibrillation susceptibility in rats with myocardial infarction","ZHANG Runfeng LI Jingwei","2026","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.16352/j.issn.1001-6325.2026.02.0193",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032558","Assessment of the efficacy and safety of glucagon-like peptide-1 receptor agonists combined with insulin therapy for obese adults with type 2 diabetes mellitus","Baoting CHEN","2025","DOAJ (DOAJ: Directory of Open Access Journals)","nonrandomized_study","article","10.12464/j.issn.0253-9802.2024-0370",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0032559","MJM MedTalks (S02E03): Beyond the Hype - GLP-1 Agonists Redefining Glycemic Control","Susan Joanne Wang","2024","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032560","LIRAGLUTIDE: SUCESSO NO TRATAMENTO DO DIABETES MELLITUS EM MONOTERAPIA E ASSOCIAÇÕES – REVISÃO SISTEMÁTICA","George Robson Ibiapina","2011","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.17695/revnevol9n2p80",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032561","Research advances on the relationship between different hypoglycemic agents and acute kidney injury in type 2 diabetic patients","Dan-ning Guo","2024","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.3969/j.issn.1671-2390.2024.05.012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032562","Revolutionizing Diabetes and Obesity Management: A Comprehensive Review of Tirzepatide’s Dual Agonist Approach","Sonam Samal","2024","DOAJ (DOAJ: Directory of Open Access Journals)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032563","Clinical Research Progress of Tirzepatide: a New Hypoglycemic Agent","ZHANG  Lina, WANG  Yan, ZHANG  Kanghuai, LI  Youjia","2023","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12114/j.issn.1007-9572.2022.0644",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032564","The effect of hypoglycemic drugs on bone metabolism and dental implantation in type 2 diabetes mellitus patients","Shaojie Shi","2021","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12016/j.issn.2096⁃1456.2021.02.007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032565","Effects and mechanisms of liraglutide in ameliorating liver fibrosis in NAFLD mice","WANG Renjie","2025","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.3969/j.issn.1674-8115.2025.04.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032566","Research progress on mechanisms of glucagon-like peptide-1 receptor agonists in diabetic retinopathy","HE Cuihuan, SHI Derong, SUN Dandan, LI Yurui, XIA Guanghao","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.16150/j.1671-2870.2025.01.012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032567","The new antidiabetic agents: cardiovascular and renal protection in post-transplant diabetes mellitus","Alessandro Mattina","2020","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.32113/cellr4_20209_2898",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032568","Ketosis in type 2 diabetes mellitus: complication or compensatory mechanism?","Ivan Kruljac","2016","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.21040/eom/2016.2.2.7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032569","CHARACTERISTIСS OF THE LIPID PROFILE AT PATIENTS WITH TYPE 2 DIABETES MELLITUS COMPLICATED WITH STEATOSIS","N. Kuzmenko","2013","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.21886/2219-8075-2013-3-56-59",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032570","Survodutide - Novel Anti Obesity Drug","Irtiqa Ayani Rathore","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032571","Tirzepatide and Weight Management","Vishal R. Tandon","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032572","Recent advances in the treatment of type 2 diabetes mellitus with obesity","S. V. Yargin","2021","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032573","Analytical assessment of hypoglycemic drugs’ availability in the regional pharmaceutical market: The case of Sverdlovsk region","Светлана Бегичева","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.17072/1994-9960-2025-2-147-162",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032574","Prospects of marketed hypoglycemic drugs in treatment of nonalcoholic fatty liver disease","Xin Gao","2021","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032575","Sufficient Clinical Effect for Weight Reduction, Diabetic Control and MASLD by Weekly Tirzepatide (Mounjaro)",null,"2026","Journal of biomedical science and research","other","article","10.36266/jbsr/216",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032576","Precision Versus Population Pharmacotherapy in Obesity: A Systematic Evaluation of Setmelanotide and GLP-1 Receptor Agonists","Suhena Sarkar","2026","SSR Institute of International Journal of Life Sciences","other","article","10.21276/ssr-iijls.2026.12.2.23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032577","\"MODERN APPROACHES TO THE MANAGEMENT OF OBESITY IN WOMEN: FOCUS ON GLP-1 RECEPTOR AGONISTS\"","Rakhbarjonova M.F","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20112889",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032578","MODERN APPROACHES TO THE TREATMENT OF METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)","Najmutdinova Dilorom Kamariddinovna","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20117581",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032579","Milestone of Effective Tirzepatide (Mounjaro) For Type 2 Diabetes (T2d) and Obesity from Diabetology and Primary Care Points of View",null,"2026","JOURNAL OF MEDICAL AND CLINICAL STUDIES","other","article","10.36266/jmcs/246",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032580","Pediatric Obesity: From Pathophysiology to Family-Centered Care—A Clinical Synthesis for the Practicing Clinician","Indunil Karunarathna","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20139194",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0032581","Combined Photobiomodulation and Semaglutide Therapy Preserves Retinal Structure and Function in Experimental Diabetic Retinopathy","Ricardo Cespedes Jara","2026",null,"other","article","10.32372/4id-tn626qq",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032582","A COST -BENEFIT FRAMEWORK FOR PROVIDING GLP-1 MEDICATIONS TO US MILITARY PERSONNEL","Courtney-Jamaal T. Rouse","2026","Calhoun: The Naval Postgraduate School Institutional Archive (Naval Postgraduate School)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032583","Exploring the Therapeutic Potential of Semaglutide for Obesity Management in Non-Diabetic Patients","Tess Shainsky","2026","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032584","Wernicke’s encephalopathy following tirzepatide therapy in a non-alcoholic patient with autoimmune hepatitis/primary biliary cholangitis and diabetes: a case report","Yasmin Zaidy","2026","British Journal of Diabetes","case_report","article","10.15277/bjd.2026.502",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032585","Strengthening Semaglutide-GLP-1R Binding Affinity via a Val27-Arg28 Exchange in the Peptide Backbone of Semaglutide: A Computational Structural Approach","Wei Li","2021","Journal of Computational Biophysics and Chemistry","other","article","10.1142/s2737416521500289",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032586","Diabetes and lipid metabolism",null,"2022",null,"other","article","10.1093/oso/9780198864615.003.0006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032587","Case 48","Charlotte Frise","2023",null,"other","article","10.1093/med/9780192845894.003.0048",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032588","The impact of GLP-1 analogues on cardiovascular risk","Klaudia Kołakowska","2024","Biuletyn Głównej Biblioteki Lekarskiej","other","article","10.2478/bgbl-2024-0030",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032589","Pancreatitis associated with antipsychotic agents","Y. W. Francis Lam","2016","The Brown University Psychopharmacology Update","other","article","10.1002/pu.30168",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032590","373-OR: Repetitive Transcranial Magnetic Stimulation—A Potential Antiobesity Approach for Long-Term Maintenance of Weight Loss","ANNA FERRULLI","2023","Diabetes","other","article","10.2337/db23-373-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032591","Exploration of Management Strategies for Type 2 Diabetes among Wounded Patients: A Review","Muthoni L. Kibibi","2024","IDOSR JOURNAL OF APPLIED SCIENCES","narrative_review","article","10.59298/idosrjas/2024/9.3.4852000",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032592","2064-LB: Novel Amylin and Calcitonin Receptor Coagonists Reduce Food Intake and Body Weight in Rodents","KADER YAGIZ","2024","Diabetes","preclinical","article","10.2337/db24-2064-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032593","1662-P: Petrelintide (ZP8396) Significantly Reduces Fat Mass while Preserving Lean Mass in DIO Rats","Bill Vestergaard","2024","Diabetes","preclinical","article","10.2337/db24-1662-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032594","How the COVID-19 pandemic has affected obesity levels and how liraglutide may play a role in its control","Gemma Fromage","2022","Journal of Aesthetic Nursing","other","article","10.12968/joan.2022.11.3.118",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032595","The Use of SGLT2i and GLP-1 RA in Patients with Type 2 Diabetes in Thailand: Evidence Review and Recommendations",null,"2021","Journal of the Medical Association of Thailand","nonrandomized_study","article","10.35755/jmedassocthai.2021.11.13163",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032596","642-P: A Model-Based Evaluation of Nausea and Vomiting Events for Additional Doses of Dulaglutide in Existing and Dulaglutide-Naïve Patients with Type 2 Diabetes","Lai‐San Tham","2021","Diabetes","other_trial","article","10.2337/db21-642-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032597","Dual GIP/GLP-1 Receptor Agonists for Type 2 Diabetes: Efficacy and Metabolic Benefits","Ernest Nsubuga","2026","International Academic Association Journal of Scientific Research.","other_trial","article","10.59298/iaajsr/2026/1315564",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032598","Semaglutide for Alcohol Use Disorder: New RCT Data","David A. Gorelick","2025",null,"other","article","10.64239/pi-qt7903",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032599","Circadian Rhythm Disruption, Sleep Disorders, and Their Role in Obesity‑Linked Diabetes","Abner Tom Kalukusu","2026","IAA Journal of Applied Sciences","other","article","10.59298/iaajas/2026/1417278",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032600","Oral Medications and Incretin Mimetics",null,"2020",null,"other","article","10.2337/9781580407151.ch07",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032601","GLP Analogues Are Superior for Diabetes and Weight Control in Patients on Antipsychotic Plus/Minus Antidepressant Medications","Lauren T Perlis","2018","Diabetes","nonrandomized_study","article","10.2337/db18-2294-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032602","1887-P: The GLP-1 Receptor Agonist Liraglutide Improves Hepatic Inflammation and Fibrosis in a Mouse Model of NASH","Sophie A. Montandon","2019","Diabetes","preclinical","article","10.2337/db19-1887-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032603","An Overview on Anti Diabetic Drugs and Development","Ved Prakash Singh","2016","Science & Technology Journal","other","article","10.22232/stj.2016.04.02.05",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032604","GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management","Mercy Latricia","2026","IAA Journal of Biological Sciences","randomized_trial","article","10.59298/iaajb/2026/14145454",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032605","1090-P: MSDC-0602k, a New Oral Insulin Sensitizer in Insulin Resistant NASH Patients with and without Type 2 Diabetes (T2D)","Jerry R. Colca","2020","Diabetes","other","article","10.2337/db20-1090-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032606","Therapeutic Management of Type 2 Diabetes: The Nitric Oxide Axis","Tara Ranjbar","2022","BENTHAM SCIENCE PUBLISHERS eBooks","other","article","10.2174/9789815079814122010013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032607","Risk of Type 2 Diabetes Mellitus with Neurological Complications: Review","Nurul Amalliah","2026","International Journal of Current Science Research and Review","narrative_review","article","10.47191/ijcsrr/v9-i1-26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032608","1095-P: Exendin 4 Decreases Tumor Volume through Attenuation of psma-Induced Activation of NfκB Pathway in HPV-Induced Diabetes/Cancer Model","Dandan Mao","2020","Diabetes","preclinical","article","10.2337/db20-1095-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032609","2160-LB: Long-Acting Exendin 4 Protein Enhances Insulin Secretion and Improves Steatotic Liver in High-Fat Diet–Fed Mice","Hyonggin An","2025","Diabetes","preclinical","article","10.2337/db25-2160-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032610","452-P: Liraglutide Decreases Neointimal Growth in Control and Western Diet–Fed Mice, and Its Effect Is Insulin Dependent","MAREL GONZALEZ","2022","Diabetes","preclinical","article","10.2337/db22-452-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032611","93-LB: A Randomized Clinical Trial of Safety, Pharmacokinetics, and Pharmacodynamics of Weekly Dosing Supagutide in Healthy Chinese Subjects","ANRAN MA","2022","Diabetes","randomized_trial","article","10.2337/db22-93-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032612","Combined Treatment with Exendin-4 and Metformin Attenuates Breast Cancer Growth","Chikayo Iwaya","2018","Diabetes","other","article","10.2337/db18-1227-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032613","1232-P: Addressing Gaps in Interdisciplinary Collaboration for Type 2 Diabetes Care","Carole Drexel","2020","Diabetes","other","article","10.2337/db20-1232-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032614","1717-P: Weight-Loss Differences with SGLT2 inhibitors, GLP-1 Receptor Agonists, and Repetitive Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity","ANNA FERRULLI","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1717-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032615","Exenatide improves antioxidant capacity and reduces the expression of LDL receptors and PCSK9 in human insulin-secreting 1.1E7 cell line subjected to hyperglycemia and oxidative stress","Łukasz Bułdak","2022","Postępy Higieny i Medycyny Doświadczalnej","preclinical","article","10.2478/ahem-2021-0037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032616","The Year in Hungarian Cardiology 2024: Heart failure","Roland Gál","2025","Cardiologia Hungarica","randomized_trial","article","10.26430/chungarica.2025.55.5.335",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0032617","EFFECTS OF A GLUCAGON LIKE PEPTIDE-1 AGONIST AND RHO-KINASE INHIBITOR ON PULMONARY AND RIGHT VENTRICLE FUNCTION IN PULMONARY HYPERTENSIVE RATS WITH AND WITHOUT INSULIN RESISTANCE","James T. Pearson","2021","Journal of Hypertension","preclinical","article","10.1097/01.hjh.0000747312.60087.49",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032618","Cardiovascular and Kidney Risk Reduction in High-Risk Individuals with Type 2 Diabetes",null,"2025","American Diabetes Association eBooks","other_trial","article","10.2337/9781580408486-ch03",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0032619","Peripheral Artery Disease and Medical Therapy: Scoping Review with ☸SAIMSARA","SAIMSARA","2026","SAIMSARA Journal","randomized_trial","article","10.62487/saimsara3b5bca76",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032620","13-PUB: Safety and Efficacy of Tirzepatide in Patients with Solid-Organ Transplant","Samaneh Dowlatshahi","2024","Diabetes","nonrandomized_study","article","10.2337/db24-13-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032621","2197-LB: BMI Regain and Blood-Pressure Change after Discontinuation of Antiobesity Agents","Kibum Kim","2025","Diabetes","nonrandomized_study","article","10.2337/db25-2197-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032622","Knowledge, Attitudes, and Practices of Emirati Citizens Regarding the Use of Antidiabetic Medications for Weight Loss Purposes","Maha Alshamsi","2025","Arab Journal of Nutrition and Exercise (AJNE)","other","article","10.18502/ajne.v8i1.16216",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032623","2150-LB: Dissecting Incretin-Mediated Modulation of Hypothalamic Feeding Circuit","J. Xia","2025","Diabetes","other","article","10.2337/db25-2150-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032624","353-OR: Silencing of Mitochondrial Transaminase GPT2 in β-Cells Enhances Response to Antidiabetic Incretins","Sabyasachi Sen","2025","Diabetes","preclinical","article","10.2337/db25-353-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032625","1472-P: Low CRP Alleles in HNF1A Are Associated with Increased Risk of Cardiovascular Disease—A Meta-analysis","CHAOCHAO YANG","2024","Diabetes","systematic_review","article","10.2337/db24-1472-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032626","The incretin effect, GLP‐1 analogues and DPP‐4 inhibitors","S W Banham","2011","Prescriber","other","article","10.1002/psb.817",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032627","996-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a Dyslipidemia Animal Model","Jaehyuk Choi","2019","Diabetes","preclinical","article","10.2337/db19-996-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032628","FDA Obstrüktif Uyku Apnesi için Zepbound'u Onayladı",null,"2025","üha","other","article","10.32739/uha.id.58081",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032629","273-LB: The Effect of Bispecific GLP-1R/GLP-2R Agonist Compared with Dual GLP-1R/GLP-2R Agonist and Dual GLP-1R/GIPR Agonist in Diet-Induced Obesity Mouse Model","TIMOTHY OH","2023","Diabetes","preclinical","article","10.2337/db23-273-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032630","Pharmacological Advances in Managing Obesity-Induced Diabetes: Beyond Metformin and Insulin","Nyiramana Mukamurera P.","2026","Research Output Journal of Public Health and Medicine","other","article","10.59298/rojphm/2026/613035",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032631","1804-P: HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA–Induced Liver Inflammation and Fibrosis Mice","Jung Kuk Kim","2020","Diabetes","preclinical","article","10.2337/db20-1804-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032632","Noninvasive Longitudinal Evaluation of GPR-119 Agonist Effects on ß-Cell Mass Using GLP-1 Receptor-Targeting SPECT/CT","Takaaki Murakami","2018","Diabetes","preclinical","article","10.2337/db18-2123-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032633","Development of various drug delivery system for semaglutide: a wonder drug for diabetes","Sayan Biswas","2025","Adamas Technical Review","other","article","10.65024/atr.v2i2.09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032634","Semaglutide: Shedding pounds, weighing risks","Christopher Hanley","2025","American nurse journal","other","article","10.51256/anj062512",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032635","2183-LB: Metabolic Effects of ECC4703, a Liver Targeting Full THRb Agonist, in Combination with Semaglutide and Tirzepatide in Diet-Induced Obese Mice","JINGYE ZHOU","2025","Diabetes","other_trial","article","10.2337/db25-2183-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032636","842-P: A Novel CRFR2-Selective UCN2 Analog, HM17321, Improves Glycemic Control across Multiple Preclinical Models","SEON MYEONG LEE","2025","Diabetes","preclinical","article","10.2337/db25-842-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032637","1985-LB: Oral Small Molecule GLP-1 Receptor Agonist Demonstrates Beneficial Effects in Parkinson's Disease–Like Model Using Humanized GLP-1R Mice","Ziyi Wang","2025","Diabetes","preclinical","article","10.2337/db25-1985-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032638","EFICÁCIA E SEGURANÇA DA LIRAGLUTIDA NA OBESIDADE EM CRIANÇAS E ADOLESCENTES: UMA REVISÃO INTEGRATIVA","Rodrigo Rodrigues Pache","2025","Revista fisio&terapia.","randomized_trial","article","10.69849/revistaft/dt10202505221516",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032639","Semaglutide as a promising treatment for metabolic dysfunction‑associated steatotic liver disease","Maria Zasadzińska","2025","Journal of Medical Science","other_trial","article","10.20883/medical.e1219",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0032640","Exenatide loaded PLGA microspheres for long-acting antidiabetic therapy: preparation, characterization, pharmacokinetics and pharmacodynamics","Yutong Wang","2016","RSC Advances","other","article","10.1039/c6ra02994a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032641","2052-LB: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks, Demonstrates Similar Efficacy and PK Profile to Daily Semaglutide Administration","Shai Rubnov","2024","Diabetes","other_trial","article","10.2337/db24-2052-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032642","Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes","Nigel Irwin","2009","The British Journal of Diabetes","narrative_review","article","10.1177/1474651408101961",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032643","USO DE ANÁLOGOS DE GLP-1 COMO FATOR PROTETOR CARDIOVASCULAR E RENAL","Giovana Pereira Lopes","2026",null,"randomized_trial","article","10.66396/pontes.c32.2026",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","book-chapter"],["R0032644","Novel Pharmacotherapies for Type 2 Diabetes","Kintuza Lumwako Tebulo","2026","IDOSR JOURNAL OF SCIENTIFIC RESEARCH","other_trial","article","10.59298/idosrjsr/2026/11.1.131138",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032645","Is Ondansetron Effective for Negative Symptoms in Schizophrenia?","Oliver Freudenreich","2025",null,"other","article","10.64239/pi-qt8101",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032646","889-P: Prescriber Perceptions of the Implementation of Liraglutide into Pediatric Type 2 Diabetes Care","Talia A. Hitt","2021","Diabetes","other","article","10.2337/db21-889-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032647","EYE ON CHINA",null,"2018","Asia-Pacific Biotech News","other","article","10.1142/s0219030318000101",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032648","785-P: Preclinical Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) Assessments of Sustained-Released Formulation of Once-Monthly Injectable Semaglutide (PT403)","JIHYANG LEE","2024","Diabetes","preclinical","article","10.2337/db24-785-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032649","GLUCOREGULATORY ACTIONS OF INCRETINS/ANTI-INCRETINS","ShikhaaMahajan","2023",null,"other","article","10.58532/v3bfms12p1ch21",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032650","1659-P: Tirzepatide Compared with Semaglutide for the Functions and Mechanisms of Ameliorating Lipid-Metabolism Disorders in Type 2 Diabetic Mice","Liming Chen","2024","Diabetes","preclinical","article","10.2337/db24-1659-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032651","ANTI–INFLAMMATORY PROPERTIES OF SEMAGLUTIDE: A SYSTEMATIC REVIEW AND META–ANALYSIS","Valeria Gazzotti","2025","European Heart Journal Supplements","systematic_review","article","10.1093/eurheartjsupp/suaf076.378",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032652","Novel Therapeutic Intervention for PCOS-1","Sarita Bajaj","2025","BENTHAM SCIENCE PUBLISHERS eBooks","other","article","10.2174/9798898810962125010010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032653","Common Prescription Errors in Diabetes: Physician’s Perspective","Krishnadev Jothydev","2024","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_47_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032654","Warum moderne Medikamente nicht die individuelle Diabetesberatung ersetzen","R Große","2025","Diabetes aktuell","other","article","10.1055/a-2504-0657",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032655","Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review","Christoffer Storm Baden","2023","Adverse Drug Reaction Bulletin","narrative_review","article","10.1097/fad.0000000000000067",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032656","939-P: HD-7671, a Nonpeptide Small Molecule for Orally Available GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion","Myoungki Baek","2020","Diabetes","preclinical","article","10.2337/db20-939-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032657","THE EVOLVING PLACE OF GLP-1 THERAPY IN THE TREATMENT ALGORITHM: FROM SECOND LINE TO FIRST LINE AND COMBINATION STRATEGIES – A REVIEW","Priti Jethlia","2026","International Journal of Medicine and Public Health","randomized_trial","article","10.70034/ijmedph.2026.1.306",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032658","Take it off! Take it all off! Drugs for weight reduction","Eugene H. Cordes","2020",null,"other","article","10.1093/oso/9780190080457.003.0011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032659","1153-P: Sodium-Glucose Cotransporter-2 Inhibitors Increase Food Intake via a Mechanism That Acts on the Central Nervous System Involving Phosphorylation of Adenosine Monophosphate-Activated Protein Kinase in the Lateral Hypothalamus","Kenji Takeda","2021","Diabetes","preclinical","article","10.2337/db21-1153-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032660","217-LB: YH34160, a Novel Long-Acting GDF15 Fusion Protein, Elicits Potent and Sustained Body Weight Loss in Obese Animal Models","Seyoung Lim","2021","Diabetes","preclinical","article","10.2337/db21-217-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032661","1438-P: Antidiabetic Medication and Risk of Dementia in Patients with Type 2 Diabetes","Ida Kim Wium‐Andersen","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1438-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032662","Appetite Stimulants and Suppressant","Mrs. Shaily Goyal","2024",null,"other","article","10.58532/nbennurphch4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032663","Canine diabetes mellitus: what is new?","Stijn Niessen","2015","Companion animal","other","article","10.12968/coan.2015.20.8.442",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032664","Focus on glycaemic management: A veritable feast or a dog's dinner?","Melanie J. Davies","2008","The British Journal of Diabetes","other","article","10.1177/1474651408094886",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032665","Metabolic and Immune Toxicities of Common Therapies for Diabetes, BPH, and Autoimmune Conditions: A Comparative Review of Hepatic and Systemic Adverse Effects","Mwende Wairimu G.","2026","IDOSR JOURNAL OF BIOCHEMISTRY BIOTECHNOLOGY AND ALLIED FIELDS","narrative_review","article","10.59298/idosr/jbbaf/2026/1023641",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032666","Metabolic disorders in postmenopausal women: challenges and coping strategies","M.I. Yarmolinskaya","2025","Russian Journal of Woman and Child Health","other","article","10.32364/2618-8430-2025-8-4-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032667","The impact of semaglutide in body weight reduction: a systematic review and meta-analysis","Hosam Awaji","2026","International Journal of Medicine in Developing Countries","systematic_review","article","10.24911/ijmdc.51-1765515744",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032668","Bariatric Surgery and Its Metabolic Effects in Obese Patients with Type 2 Diabetes","Nyakairu Doreen G.","2026","IDOSR JOURNAL OF BIOLOGY CHEMISTRY AND PHARMACY","other","article","10.59298/idosr/jbcp/26/102.7884",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032669","750-P: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study","JINZI JASON WU","2025","Diabetes","randomized_trial","article","10.2337/db25-750-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032670","Obesity: problems and solutions. Possibilities of drug therapy",null,"2021","Consilium Medicum","other","article","10.26442/20751753.2021.7.201135",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032671","Metabolic dysfunction-associated steatotic liver disease - masld","Hà Vũ","2025","Tạp chí Khoa học tiêu hóa Việt Nam","other_trial","article","10.63583/cq45me13",null,null,null,null,"openalex","FALSE","open_pdf","5","FALSE","article"],["R0032672","Obesity pandemic – searching for the most effective treatments","Klaudia Kołakowska","2024","Biuletyn Głównej Biblioteki Lekarskiej","other","article","10.2478/bgbl-2024-0028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032673","“Cabeça de Ozempic”: entre a medicalização e a natureza nas práticas material-discursivas sobre celebridades no X","Atílio Butturi","2025","Revista Internacional Interdisciplinar INTERthesis","other","article","10.5007/1807-1384.2025.e109113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032674","1855-LB: Semaglutide and Lisinopril Exerts Therapeutic Benefits in a Genetically Engineered Diabetic Nephropathy Mouse Model","Zhong Chen","2025","Diabetes","preclinical","article","10.2337/db25-1855-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032675","Data Analysis of Appetite Suppressants Using Text Mining and Online Search Trends","The Pharmaceutical Society Of Korea","2025","Yakhak Hoeji","other","article","10.17480/psk.2025.69.4.385",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032676","1709-P: Novel Interleukin-22 Partial Agonists Improve Metabolic Syndrome In Vivo","Luis Rodríguez Zúñiga","2025","Diabetes","preclinical","article","10.2337/db25-1709-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032677","1071-P: A Scoping Review on Diabetes Management in People with Mild Cognitive Impairment (MCI) : Glycemic Control, Medications, and Onset of Alzheimer's and Related Dementias (ADRD)","Sumaya Abuloha","2022","Diabetes","narrative_review","article","10.2337/db22-1071-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032678","210-LB: Combined Use of Oral Standard Cookie Meal (OSC) and the Newly Revised Insulin Suppression Test for the Evaluation of Whole Body (WB), Muscle, and Hepatic Glucose Clearance (GC) Under Endogenous or Exogenous Insulin and Its Clinical Usefulness","Yutaka Harano","2020","Diabetes","other","article","10.2337/db20-210-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032679","Dual Incretin Agonism in Type 2 Diabetes and Obesity: Systematic Review of Tirzepatide Mechanisms and Clinical Outcomes","Jefferson Lorençoni de Morais","2026","International Journal of Research in Pharmacy and Allied Science","systematic_review","article","10.71431/ijrpas.2026.5309",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032680","Recent Trends in Peptide Drug Discovery and Development","Harrison Y. R. Madge","2024",null,"other","article","10.1039/9781837674541-00023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032681","790-P: An Indirect Treatment Comparison of the Cardiovascular Protective Effect of Semaglutide vs. Liraglutide in Subjects with Type 2 Diabetes","Barrie Chubb","2023","Diabetes","randomized_trial","article","10.2337/db23-790-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032682","Findings from a Diabetes Support Group—A Pilot Study","LORI MCLEER MALONEY","2018","Diabetes","other","article","10.2337/db18-720-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032683","144-OR: Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1)","Jamy D. Ard","2025","Diabetes","randomized_trial","article","10.2337/db25-144-or",null,null,"ClinicalTrials.gov:NCT05556512","S001921","openalex","FALSE","paywalled","1","FALSE","article"],["R0032684","1050-P: Revolutionary GLP-1 Weight Loss Medicine Semaglutide—To Cover or Not to Cover?","Wei Lu","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1050-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032685","81-OR: Hide and Seek—Modulating PDL1 and HLA Class I Expression to Protect Human β-Cells in T1D","Sayro Jawurek","2025","Diabetes","preclinical","article","10.2337/db25-81-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032686","2182-LB: Development and Characterization of a Humanized GLP-1 Receptor Mouse Model for the Evaluation of Small-Molecule GLP1R Agonists","Nina Sonne","2025","Diabetes","preclinical","article","10.2337/db25-2182-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032687","Semaglutide for adults living with obesity",null,"2025","Kazan medical journal","nonrandomized_study","article","10.17816/kmj696819",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0032688","1830-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice","Jaehyuk Choi","2020","Diabetes","preclinical","article","10.2337/db20-1830-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032689","2144-LB: Adipocyte GIPR and LepR Synergistically Modulate Leptin Signaling to Ameliorate Peripheral Leptin Resistance and Prevent Weight Regain in Diabetic-Obese Mice","Yan Han","2025","Diabetes","preclinical","article","10.2337/db25-2144-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032690","OZEMPIC E SEUS FATORES PROTETORES EM RELAÇÃO AO INFARTO AGUDO DO MIOCÁRDIO","Pedro Moraghi de Mori","2025","Revista fisio&terapia.","other","article","10.69849/revistaft/ch10202506252013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032691","2167-LB: Proteomic Changes in Mexican-Americans before and after Meals in Response to Semaglutide Therapy","Jennifer E. Below","2025","Diabetes","randomized_trial","article","10.2337/db25-2167-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032692","2174-LB: Preclinical Proof-of-Concept for SGB-ALK7—Selective Targeting of Adipocytes via Subcutaneous Administration of Ligand-Conjugated siRNA for Obesity","Peng Zhang","2025","Diabetes","preclinical","article","10.2337/db25-2174-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032693","843-P: A Novel CRFR2 Selective UCN2 Analog, HM17321, Facilitates Weight Loss and Improves Body Composition across Animal Models of Obesity","Jung Kuk Kim","2025","Diabetes","preclinical","article","10.2337/db25-843-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032694","819-P: A Novel Premix Insulin GZR101 for Diabetes Management","Wei Chen","2024","Diabetes","preclinical","article","10.2337/db24-819-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032695","2346-PUB: Clinical Characteristics of SGLT2 Inhibitor User in Type 2 Diabetes with Atherosclerotic Cardiovascular Disease or Heart Failure in a Real-World Setting","Su Jin Jeong","2019","Diabetes","nonrandomized_study","article","10.2337/db19-2346-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032696","A GLP-receptor-agonisták alkalmazásának potenciális előnyei Covid-19-járvány idején","János Tibor Kis","2021","Lege Artis Medicinae","other","article","10.33616/lam.31.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032697","Provider Experience Drives Clinical Decision Making in T2DM—Insights from Realistic Training Simulations","Katie Robinson","2018","Diabetes","other","article","10.2337/db18-682-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032698","NASH debrief from AASLD 2017","Panida Thong-u-thaisri","2018","Thai Journal of Hepatology","other","article","10.30856/th.jhep2018vol1iss1_11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032699","Mechanisms of Inflammation in Metabolic Diseases (such as Diabetes): Insights from Basic to Clinical Research","Yi Hui Wang","2026","Advances in Engineering Technology Research","other","article","10.56028/aetr.16.1.529.2026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032700","How the “tides” have turned in pharma manufacturing","Deborah McElhone","2024","Open Access Government","other","article","10.56367/oag-043-11453",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032701","TRATAMENTO DE OBESIDADE COM USO DE SEMAGLUTIDA: UMA REVISÃO DE LITERATURA","Wilson Souza Neto","2025","Revista fisio&terapia.","nonrandomized_study","article","10.69849/revistaft/pa10202502262002",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032702","Long-term Safety Profile of Semaglutide in the Management of Type 2 Diabetes and Obesity","Zhanxu Meng","2024","MedScien","other","article","10.61173/42stre19",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032703","741-P: Real-World Weight-Loss Effectiveness of GLP-1 Agonists among Patients with Type 2 Diabetes: A Retrospective Cohort Study","Jing Luo","2022","Diabetes","nonrandomized_study","article","10.2337/db22-741-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032704","724-P: A First-in-Human Study of RGT-075, a Novel, Orally Bioavailable, Small-Molecule GLP-1 Receptor Agonist, in Healthy Adult Subjects","MARK A. PIRNER","2022","Diabetes","randomized_trial","article","10.2337/db22-724-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032705","1403-P: DA-1726, a Balanced GLP1R/GCGR Dual Agonist, Effectively Controls Both Body Weight and Blood Glucose","TAE-HYOUNG KIM","2022","Diabetes","preclinical","article","10.2337/db22-1403-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032706","1124-P: American Indian/Alaska Native Adults with Type 2 Diabetes Navigating a Commercial Health Care System—A Qualitative Analysis","Leandra Bitterfeld","2025","Diabetes","other","article","10.2337/db25-1124-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032707","1444-P: Impact of Semaglutide Shortage in Canadian Adults and Response in a Community Endocrinology Setting (SCARCITY Study)","Akshay Jain","2025","Diabetes","other","article","10.2337/db25-1444-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032708","Semaglutide: Oral GLP-1 Receptor Analogue","Arun Kochar","2021","Exclusive Real World Evidence Journal","other","article","10.54136/erwej-0101-10008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032709","210-OR: Long-Acting GIPR Agonism Enhances Body Weight Regulation of Multiple Weight-Reducing Agents in Diet-Induced Obese Mice","William C. Roell","2023","Diabetes","preclinical","article","10.2337/db23-210-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032710","Sveikos gyvensenos praktikos GLP-1 agonistų eroje","Evelina Nomeikaitė","2024","Lithuanian General Practitioner","other","article","10.37499/lbpg.1529",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032711","Effective and convenient treatment of Xultophy with lower doses for elderly diabetic patient","Hiroshi Bando","2021","Endocrinology&Metabolism International Journal","other","article","10.15406/emij.2021.09.00305",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032712","Sindrom Kardiovaskular-Ginjal-Metabolik: Konsep Terkini untuk Klinisi","Muhammad Yamin","2024","Jurnal Penyakit Dalam Indonesia","other","article","10.7454/jpdi.v11i2.1597",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032713","2025-26 Guide to Medications for the Treatment of Diabetes Mellitus",null,"2025","American Diabetes Association eBooks","other","article","10.2337/9781580408462",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0032714","O PAPEL DO FARMACÊUTICO NA CONSCIENTIZAÇÃO SOBRE OS RISCOS DO USO INDISCRIMINADO DE ANÁLOGOS DE GLP-1 E GIP PARA EMAGRECIMENTO","Lorrany Cardoso Oliveira","2025","Editora Science eBooks","other","article","10.56001/25.9786501400518.18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032715","DESAFÍOS ACTUALES EN FALLA CARDÍACA: MECANISMOS Y POTENCIAL TERAPÉUTICO","Jorge Jalil Milad","2026","Boletín Academia Chilena de Medicina","other","article","10.69700/9d761j47",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032716","Recent advances in the pharmacological treatment of obesity","Ga Eun Nam","2025","Journal of Korean Medical Association","other","article","10.5124/jkma.25.0058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032717","788-P: A Twelve-Week Trial of MET097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist","Robert M. Stoekenbroek","2025","Diabetes","randomized_trial","article","10.2337/db25-788-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032718","1708-P: Development of a Needle-Free, Self-Applied Microarray Patch for GLP-1 Delivery","Lynda Tussey","2025","Diabetes","randomized_trial","article","10.2337/db25-1708-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032719","LIRAGLUTIDE'S IN VITRO ANTI-INFLAMMATORY AND REGENERATIVE PROPERTIES ON INFLAMMATORY HUMAN OSTEOARTHRITIC CHONDROCYTES: ON BEHALF OF THE OA-BIO CONSORTIUM","E. Ciftci","2024","Orthopaedic Proceedings","preclinical","article","10.1302/1358-992x.2024.2.044",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032720","Oral Semaglutide Does Not Affect the Bioavailability of the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel","Andreas B. Jordy","2018","Diabetes","other_trial","article","10.2337/db18-1135-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032721","Glucagon-like peptide-1 analog protects proximal tubules injury from lysosomal dysfunction and impaired autophagic flux","Wei He","2019","Materials Express","preclinical","article","10.1166/mex.2019.1576",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032722","900-P: Patterns of Drug Utilization for Cardio- and Renal-Protective Antihyperglycemic Agents in a Commercially Insured Population","DAVID J. COOK","2022","Diabetes","nonrandomized_study","article","10.2337/db22-900-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032723","1455-P: The Loss of Pancreatic ß-Cell Complement 1q-Like-3 Secreted Protein Increases Insulin Secretion in Lean and Obese Mice","MOSTAFIZUR RAHMAN","2022","Diabetes","preclinical","article","10.2337/db22-1455-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032724","Antipsychotic-Induced Weight Gain: Are GLP-1 Agonists Effective?","Oliver Freudenreich","2025",null,"other","article","10.64239/pi-qt7602",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032725","Gut Microbiota as a Determinant of Therapeutic Response in Chronic Diseases: From Systemic Dysbiosis to Microbiome-Guided Precision Medicine","Marco Vinícios de Oliveira Santana","2026","Middle East Research Journal of Medical Sciences","randomized_trial","article","10.36348/merjms.2026.v06i02.007",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032726","IMPACT OF GUT-BRAIN-AXIS MODULATION IN PARKINSON'S DISEASE-A LITERATURE REVIEW","Kathal Sab H","2026","EPRA International Journal of Multidisciplinary Research (IJMR)","nonrandomized_study","article","10.36713/epra25604",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0032727","A Comprehensive Investigation of Current Treatment Approaches for Integrated Pharmaceutical Management of Hypertension and Diabetes Mellitus","Vanita B Wadewale","2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.23s.30",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032728","1674-P: Development of a Once-a-Month Formulation of Semaglutide from an Innovative Injectable and Biodegradable Hydrogel","AUDREY MARECHAL","2024","Diabetes","preclinical","article","10.2337/db24-1674-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032729","1548-P: Functional and Behavioral Dynamics of GLP-1 Receptors in the Central Amygdala","Miguel A. Duran","2024","Diabetes","preclinical","article","10.2337/db24-1548-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032730","Antihyperglycemic drugs that improve cardiovascular outcomes and a model of diabetic cardiomyopathy","Bell, RM","2019","Heart and Metabolism","other","article","10.31887/hm.2019.80/rbell",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032731","B80-3-05 Comparative Effects of Glp-1 Receptor Agonists and Atomoxetine-antimuscarinic Combinations (oxybutynin and Aroxybutynin) on Obstructive Sleep Apnea: A Scoping Review","S Siddenthi","2026","American Journal of Respiratory and Critical Care Medicine","randomized_trial","article","10.1093/ajrccm/aamag162.6390",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032732","1495-P: Improved A1C in People with Non–Insulin-Treated T2D Using CGM in Primary Care—The Dexcom Global Registry","AMIR HERMAN","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1495-p",null,null,"ClinicalTrials.gov:NCT06483945",null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032733","Research",null,"2026","Bone and Joint 360","nonrandomized_study","article","10.1302/2048-0105.152.360318",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032734","Tirzepatide: A Turning Point in Pharmacotherapy for Obesity and Type 2 Diabetes in Adults","Amandeep Kaur","2025","Current Indian Science","other","article","10.2174/012210299x381336250404081200",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032735","1744-P: Exenatide Activates PPARd to Promote Mitochondrial Function for Insulin Secretion in Islet ß-Cells","ZHIGU LIU","2024","Diabetes","preclinical","article","10.2337/db24-1744-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032736","1435-P: Identifying the Continuing Educational Needs of U.S. Physicians in Managing Patients with T2DM and Obesity","Wendy Cerenzia","2022","Diabetes","other_trial","article","10.2337/db22-1435-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032737","GLP‐1 regula la función del sistema reproductor en la rata hembra","Verónica Outeiriño Iglesias","2015","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article","10.35869/11093/589",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0032738","304-OR: Leveraging Real-World Evidence to Analyze Changes in Prescribing of GLP-1 Receptor Agonists in the United States","Polina Kukhareva","2025","Diabetes","nonrandomized_study","article","10.2337/db25-304-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032739","Dual Benefits and Risks: Tirzepatide's Impact on Pancreatic Function","Sabina Florina Șolea","2025","Internal Medicine","other","article","10.2478/inmed-2025-0317",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032740","Dual GLP-1/GIP Agonists for Weight Reduction and Cardiovascular Outcomes in Type 2 Diabetes","Ernest Nsubuga","2026","International Academic Association Journal of Scientific Research.","randomized_trial","article","10.59298/iaajsr/2026/1316570",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032741","233-OR: The Beta-Cell Specific Deletion of Complement 1q-Like-3 Secreted Protein Improves Beta-Cell Function and Glucose Homeostasis","MD MOSTAFIZUR RAHMAN","2023","Diabetes","preclinical","article","10.2337/db23-233-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032742","1162-P: Coverage, Formulary Restrictions, and Average Retail Prices of SGLT2 Inhibitors and GLP-1 Receptor Agonists across Medicare Part D Plans in 2019","Jing Luo","2020","Diabetes","other","article","10.2337/db20-1162-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032743","Metformin or GLP 1 Receptor Agonists? Current Views on the Management of Polycystic Ovary Syndrome","Anna Aleksandra Szwankowska","2026","Archiv Euromedica","randomized_trial","article","10.35630/2026/16/iss.2.9",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032744","Glucagon‑like peptide‑1–based agonists as novel targets in obesity management: Mechanistic pathways and adverse effects","Naimeh Mesri Alamdari","2026","Biomedicine Advances","other","article","10.34172/bma.59",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032745","Nephroprotektion – Diabetes und Adipositas","Leonard Boger","2026","Nephrologie aktuell","other","article","10.1055/a-2748-5160",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032746","213-OR: Liraglutide and Empagliflozin Each Improve Metabolic and Microvascular Insulin Sensitivity, with Enhanced Cardiac Benefits in Combination Therapy","Jia Liu","2025","Diabetes","preclinical","article","10.2337/db25-213-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032747","Can Tirzepatide Revolutionize Gastric Cancer Prevention? A Comprehensive Analysis","Alexandra Orășeanu","2025","Internal Medicine","other","article","10.2478/inmed-2025-0318",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032748","778-P: Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model","Martha Andrade","2025","Diabetes","other","article","10.2337/db25-778-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032749","A atuação do farmacêutico no uso da semaglutida (Ozempic): uma revisão integrativa / The performance of the pharmacist in the use of semaglutida (Ozempic): an integrative review","Júlia Carrilho do Nascimento","2021","Brazilian Journal of Development","narrative_review","article","10.34117/bjdv7n11-498",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032750","1859-LB: PG-102, a Novel Bispecific GLP-1R/GLP-2R Fc-Fused Agonist—Data on Safety, Tolerability, and Pharmacokinetics (PK) in Single Ascending Dose Trial in Healthy Subjects and Preliminary Population PK Modeling","SEUNGHOON HAN","2024","Diabetes","randomized_trial","article","10.2337/db24-1859-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032751","1860-LB: Preliminary Study of Efficacy and Duration of an mRNA-Based GLP-1R Agonist in Diabetic Monkeys","FENGWEI XU","2024","Diabetes","other","article","10.2337/db24-1860-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032752","181-LB: Fracture Risk of Antidiabetic Agents in Type 2 Diabetes—A Network Meta-analysis","WEN HSUAN TSAI","2022","Diabetes","systematic_review","article","10.2337/db22-181-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032753","753-P: RGT-075, an Orally Efficacious Small Molecule GLP-1R Full Agonist in Cynomolgus Monkey Models","Feng Liu","2022","Diabetes","other","article","10.2337/db22-753-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032754","Impact of GLP-1 Receptor Agonists on Cardiorenal Outcomes in Obese Patients with Type 2 Diabetes and Stage 3 CKD","Sayema Afroz","2026","International Academic Research Journal of Internal Medicine and Public Health","nonrandomized_study","article","10.47310/iarjimph.2026.v07i01.001",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0032755","476-P: Pemafibrate, a PPAR Alpha Agonist, Attenuates Neointima Formation after Vascular Injury in Nondiabetic and Diabetic Mice","Tsuyoshi Horikawa","2019","Diabetes","preclinical","article","10.2337/db19-476-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032756","1479-P: Targeted Exome Sequencing for Long-Term Efficacy and Weight Loss of Dulaglutide in Type 2 Diabetes","YE AN KIM","2023","Diabetes","other","article","10.2337/db23-1479-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032757","221-OR: Retrospective Review of Genetic Mutations and Treatments in Patients with Monogenic Diabetes of the Youth (MODY)","Lily Y Deng","2023","Diabetes","nonrandomized_study","article","10.2337/db23-221-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032758","OS RISCOS DO USO DE AGONISTAS DOS RECEPTORES DE GLP-1 EM PACIENTES SUBMETIDOS A CIRURGIA GERAL E SEDAÇÃO","Nicolas Guilherme Patel Benetti","2025","Revista fisio&terapia.","other","article","10.69849/revistaft/ar10202512051925",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032759","298-OR: Precision-Engineered Activin and GDF Ligand Trap HS235—A Novel Lean Mass–Preserving Treatment for Obesity","Gauthier Schang","2024","Diabetes","preclinical","article","10.2337/db24-298-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032760","Regional Differences in GLP-1 Receptor Agonists Related Biliary Disease: A Pharmacovigilance Study of VigiBase®","K K","2024","Yakhak Hoeji","nonrandomized_study","article","10.17480/psk.2024.68.2.112",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032761","Analysis and Validation of Differentially Expressed MicroRNAs with their Target Genes Involved in GLP-1RA Facilitated Osteogenesis","Na Wang","2020","Current Bioinformatics","other","article","10.2174/1574893615999200508091615",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032762","1926-P: Potent Weight Loss Mechanism of a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models of Obesity","Jong Suk Lee","2020","Diabetes","preclinical","article","10.2337/db20-1926-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032763","Weight Management in Overweight and Obese Patients with Type 2 Diabetes Mellitus","Ioannis Kyrou","2010","The British Journal of Diabetes","other","article","10.1177/1474651410388976",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032764","Review: Durable glycaemia — the promised land","Ian W Campbell","2009","The British Journal of Diabetes","narrative_review","article","10.1177/1474651408100470",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032765","Effects of GLP-1 Receptor Agonists on Oocytes and Female Fertility","Canan Tapkan","2025","Crescent Journal of Medical and Biological Sciences","other","article","10.34172/cjmb.2025.5045",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032766","Managing the β-cell with GLP-1 in type 2 diabetes","Baptist Gallwitz","2008","The British Journal of Diabetes","other_trial","article","10.1177/1474651408100522",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032767","Diabetic nephropathy: modern principles of classification, diagnosis and features of antihyperglycemic therapy","A. G. Borisov","2021","Лечащий врач","other","article","10.51793/os.2021.24.9.010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032768","Diabetes and Antidiabetic Drugs","M. O. Faruk Khan","2024","Medicinal chemistry for pharmacy students","other","article","10.2174/9789815179729124030009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032769","580-P: Dialogues in Diabetes—Addressing Knowledge and Behavior Gaps among Clinicians Who Care for Patients with Diabetes and Obesity","KATIE ROBINSON","2024","Diabetes","other","article","10.2337/db24-580-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032770","Update: Reports of suicidality in patients taking diabetes/obesity medicines",null,"2024","The Brown University Child & Adolescent Psychopharmacology Update","other","article","10.1002/cpu30848",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032771","Severe Gastroparesis-Like Syndrome Following Single-Dose Liraglutide Administration: A Case Report","Eyad A Makkawy","2026","Galen Medical Journal","case_report","article","10.31661/gmj.v15i.4135",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032772","78-OR: KAYO-1732, a First-in-class Oral ALDH1A3 Inhibitor, Blocks Retinoid Nuclear Receptor Signaling to Regenerate Pancreatic Islets and Reverse Type 2 Diabetes","MARK ESPOSITO","2025","Diabetes","preclinical","article","10.2337/db25-78-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032773","Genetic Predictors of Response to GLP-1 and Dual GIP/GLP-1 Agonists in Obesity: an Integrative Pharmacogenomics and Machine Learning Approach",null,"2025","Endocrinologia & Diabetes Clínica e Experimental","other","article","10.29327/2413063.22.3-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032774","1845-P: GASP-1–Mediated GLP-1 Receptor Trafficking Contributes to the Development of Tolerance to Incretin Drugs","Anirudh Gaur","2025","Diabetes","other","article","10.2337/db25-1845-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032775","1422-P: The Potential of Semaglutide Once-Weekly in Patients without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss after Bariatric Surgery","Anne Lautenbach","2022","Diabetes","randomized_trial","article","10.2337/db22-1422-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032776","212-LB: Therapeutic Effect of a Novel Long-Acting GLP-1/GCG/FGF21/Anticytokine Tetra-Specific Liver Microenvironment-Targeting Drug (OGB21502) in MCD-Induced NASH Mice Model","Min Sun Kim","2021","Diabetes","preclinical","article","10.2337/db21-212-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032777","656-P: Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Fibrosis","JUNG KUK KIM","2021","Diabetes","preclinical","article","10.2337/db21-656-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032778","La Pagina Gialla","Sara Lega","2024","Medico e Bambino","other","article","10.53126/meb43485",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032779","Spatially resolved single-cell transcriptomic profiling of glucagon-like peptide-1 receptor and angiotensin-converting enzyme inhibitor pathways in diabetic nephropathy: a comparative efficacy framework","Mohammed Saleh","2026","International Journal of Medicine in Developing Countries","other","article","10.24911/ijmdc.51-1765698964",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032780","Economic Evaluation of Dapagliflozin as Add-On to Metformin in T2DM in the Israeli Health Care Setting","SHAI MOSHEL","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1297-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032781","1788-P: The Natural Product ZYM01 Exerts Antidiabetic and Islet-Protective Effects in Diabetic Mice and Promotes Glucagon-Like Peptide-1 Secretion","Yili Sun","2019","Diabetes","preclinical","article","10.2337/db19-1788-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032782","805-P: Development of a Semaglutide-Releasing Long-Acting Injectable, IVL3021, and Its Physicochemical and Pharmacokinetic Studies","MINSUNG KIM","2024","Diabetes","other","article","10.2337/db24-805-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032783","New horizons in metabolic disease treatment: multi-hormonal agonists and functional medicine-based integrated therapy","Yang‐Im Hur","2025","Korean Institute for Functional Medicine","other","article","10.32581/jkifm.2025.8.2.66",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032784","754-P: Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of IPF","SEON MYEONG LEE","2022","Diabetes","preclinical","article","10.2337/db22-754-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032785","Mechanisms of action and clinical applications of anti-obesity drugs currently available in Korea","Kyoung Kon Kim","2019","Journal of Korean Medical Association","other","article","10.5124/jkma.2019.62.11.588",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032786","Polypharmacy and renal failure","Khalifa Shaafi","2011","The British Journal of Diabetes","other","article","10.1177/1474651411411383",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032787","Mitochondrial Dysfunction in Obesity‑Associated Insulin Resistance and Diabetes Progression","Mugisha Emmanuel K.","2026","RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES","other","article","10.59298/rijrms/2026/516286",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032788","Ação dos agonistas duais de GLP-1 e GIP sobre o metabolismo do tecido adiposo: uma revisão integrativa","Maria Eduarda Bonaldi Cardoso","2026","Revista Interdisciplinar de Saúde e Educação","other","article","10.56344/2675-4827.v7n3a2025.19",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032789","1636-P: Liraglutide Mitigates Lipid Accumulation, EMT, and Fibrosis in MASLD via AMPK Activation","Chun‐Cheng Liao","2025","Diabetes","preclinical","article","10.2337/db25-1636-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032790","1616-P: Effect of Mazdutide on MASH Fibrosis—Targeting the Liver–Gut Axis and Microbiome","Hui Wang","2025","Diabetes","randomized_trial","article","10.2337/db25-1616-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032791","847-P: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model","JINZI JASON WU","2025","Diabetes","preclinical","article","10.2337/db25-847-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032792","89-LB: COVID-19 Outcomes in Patients Who Started GLP1-RAs during Hospitalization","VINCENZO PROVENZANO","2022","Diabetes","nonrandomized_study","article","10.2337/db22-89-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032793","13-LB: Treatment Patterns of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease in Colombia","Manuel Machado","2023","Diabetes","nonrandomized_study","article","10.2337/db23-13-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032794","130-OR: Tirzepatide Attenuates Hepatic Insulin Resistance and Glucagon Action Independent of Weight Loss and GIP Action in Diet-Induced Obese Mice","B. I. Kim","2023","Diabetes","preclinical","article","10.2337/db23-130-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032795","Recent Perspectives for Combined Status of Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD)","Hiroshi Bando","2021","Edelweiss Journal of Biomedical Research and Review","other","article","10.33805/2690-2613.118",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032796","1954-P: Combined Treatment with Exendin-4 and Metformin Attenuates Breast Cancer Growth","Yuki Fujimura","2019","Diabetes","preclinical","article","10.2337/db19-1954-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032797","2008-P: BioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice","Martin Gaudier","2019","Diabetes","preclinical","article","10.2337/db19-2008-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032798","Zayıflama İğnesi Mounjaro (Manjaro) Nedir?",null,"2025","üha","other","article","10.32739/uha.id.64715",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032799","Exploring Wearable Technology and Lean Mass Alterations in GLP-1 Agonists, Bariatric Surgery, and Testosterone Replacement Therapy","Gabriel J. Sanders","2025","Research in Psychology and Behavior","nonrandomized_study","article","10.53520/rpb2025.107140",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0032800","PHARMACOLOGICAL APPROACHES TO THE MANAGEMENT OF DIABETES MELLITUS","Dr. Marta Alvarez","2020","American Journal Of Pharmacy And Pharmacology","other","article","10.71465/ajpp.2250",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032801","1688-P: Novel Oral Apelin Receptor Agonist PSTC1201 for Selective Weight Loss with Muscle Preservation When Combined with Semaglutide in DIO Mice Model","ZHICHAO WANG","2025","Diabetes","other_trial","article","10.2337/db25-1688-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032802","Current Concepts of Obesity Management in India","Arun Prasad","2025","Sarvodaya International Journal of Medicine","other","article","10.4103/sijm.sijm_27_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032803","755-P: Metabolic Adaptation of Liver with Treatment of HM15275, a Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Supporting Lean Mass Preservation","Hosun Lee","2025","Diabetes","preclinical","article","10.2337/db25-755-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032804","111-OR: Effect of Dulaglutide plus Calorie-Restricted Diet vs. Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome—A Randomized Controlled Trial","Yuqin Zhang","2023","Diabetes","randomized_trial","article","10.2337/db23-111-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032805","Researchers ask for more evidence on GLP‐1s and SUD treatment","Alison Knopf","2026","Alcoholism & Drug Abuse Weekly","other","article","10.1002/adaw.34819",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032806","2100-LB: GLP-1/GIP Receptor Agonist Evaluation Using cAMP Measurement in EndoC-ßH5 Human Beta Cells","Marion Taurand","2024","Diabetes","other","article","10.2337/db24-2100-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032807","Szívelégtelenség megőrzött ejekciós frakcióval (HFpEF): fenotípusok, diagnosztikai algoritmusok és új terápiás lehetőségek","Arnold Péter Ráduly","2025","Cardiologia Hungarica","other","article","10.26430/chungarica.2025.55.1.40",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032808","Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity","Raghav Gupta","2025","Current Signal Transduction Therapy","other","article","10.2174/0115743624346660250317013032",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032809","944-P: Use of High-Potency GLP-1 Receptor Agonists with OpenAPS Automated Insulin Dosing Algorithm Eliminates Need for Meal Announcements to Achieve Glycemic Goals","Tugce Akcan","2025","Diabetes","nonrandomized_study","article","10.2337/db25-944-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032810","Polycystic Ovarian Disease (PCOD): A comprehensive review of pathophysiology, clinical manifestations, psychological impact, and therapeutic approaches","Sadhana Bondili","2025","i-manager s Journal on Life Sciences","narrative_review","article","10.26634/jls.4.1.22112",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032811","Current aspects of polycystic ovary syndrome II: treatment of hyperandrogenism, insulin resistance and infertility","Kun Imre Zoltán","2019","Orvostudományi Értesítö","other","article","10.2478/orvtudert-2019-0016",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032812","An insight to the treatment of diabetes within the era of SARS-COV2 in the existence of cardiovascular co-morbidity","Hussein Ali Hussein Al-Sa'idy","2022","World Journal of Biological and Pharmaceutical Research","other","article","10.53346/wjbpr.2022.2.2.0029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032813","Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Attenuates Prostate Cancer Cell Proliferation via Phosphorylation of MKP-1","Takako Kawanami","2018","Diabetes","preclinical","article","10.2337/db18-1957-p",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032814","Comparative analysis of safety profile of GLP-1 receptor agonists and dual-acting incretins in diabetes mellitus and obesity","A.S. Kenkishvili","2026",null,"other","article","10.33920/med-13-2602-04",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032815","Comparative Outcomes of Newer Antidiabetic Agents in Preventing Diabetic Nephropathy: A Meta-Analysis","Gana Ali Ahmad Tahmaz","2025","Fortune Journal of Health Sciences","systematic_review","article","10.26502/fjhs.262",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0032816","Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer—A Meta-analysis with Trial Sequential Analysis","Lana Catani Ferreira Pinto","2018","Diabetes","systematic_review","article","10.2337/db18-1086-p",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0032817","What do we know?","Anne Symons","2024","Dental Nursing","other","article","10.12968/denn.2024.20.11.548",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032818","Targets for rescue from fatty acid-induced lipotoxicity in pancreatic beta cells","Seok‐Woo Hong","2022","Cardiovascular Prevention and Pharmacotherapy","other","article","10.36011/cpp.2022.4.e9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032819","B73-50 Unusual Expectoration of Fibrinous Bronchial Cast-Like Material Following Initiation of Semaglutide in a Patient With Obesity","E R Leon Milan","2026","American Journal of Respiratory and Critical Care Medicine","other","article","10.1093/ajrccm/aamag162.4389",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032820","B80-3-03 Cpap Use in the Era of Glp-1 and Dual Agonists in Patients With Obstructive Sleep Apnea: A Real-World Study","L F Drager","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.6388",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032821","EFICÁCIA E SEGURANÇA DA SEMAGLUTIDA NO TRATAMENTO DA OBESIDADE","Gustavo Henrique Rodrigues Resende","2024","Revista fisio&terapia.","other","article","10.69849/revistaft/ar10202410141820",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032822","657-P: Potential Effect of a Novel Combination of GLP-1RA (efpeglenatide) and Long-Acting Glucagon Analog (HM15136) in Animal Models of Metabolic Disorders","Jong Suk Lee","2021","Diabetes","preclinical","article","10.2337/db21-657-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032823","1689-P: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks—Pharmacokinetic Modeling and Human-Based Allometric Scaling","Shai Rubnov","2025","Diabetes","other_trial","article","10.2337/db25-1689-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032824","Glucagon-Like Peptide-1 Receptor Agonists","Heather P. Whitley","2025","American Diabetes Association eBooks","other","article","10.2337/9781580408462-ch13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032825","GLP-1 Agonists Reimagined: The Tripartite Applications of the Semaglutide Hormone","Joon Daniel Park","2025","Technium BioChemMed","nonrandomized_study","article","10.47577/biochemmed.v13i.13309",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0032826","SEGURANÇA E EFICÁCIA DA SEMAGLUTIDA E TIRZEPATIDA NO TRATAMENTO DA OBESIDADE: UMA REVISÃO SISTEMÁTICA","CAMPINHO TEIXEIRA CRUZ W","2025","Revista fisio&terapia.","other","article","10.69849/revistaft/pa10202503252056",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032827","2156-LB: Superior Hepatoprotective Effects of OPK-88006, a Novel GLP-1/Glucagon Receptor Dual Agonist, to Semaglutide and Survodutide in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH","JANE HSIAO","2025","Diabetes","preclinical","article","10.2337/db25-2156-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032828","2170-LB: Tirzepatide Reduces Tumor Burden in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH-HCC with Advanced Fibrosis","Michael Feigh","2025","Diabetes","other_trial","article","10.2337/db25-2170-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032829","A case study of liraglutide in an obese diabetic patient in a District General Hospital","Mohammed Ghani","2021",null,"randomized_trial","article","10.52402/diabetes7001",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0032830","477-P: Vagal GLP-1–Mediated Reductions in Postprandial Lipids Are Sensitive to Fructose Feeding","SIMON S. HOFFMAN","2022","Diabetes","other","article","10.2337/db22-477-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032831","Case 34: Adhering or Not? That Is the Question: A Case of Glucolipotoxicity and Concentrated Insulin","Sanaa Deshmukh","2015","American Diabetes Association eBooks","case_report","article","10.2337/9781580405713.34",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032832","GLP-1-Rezeptoragonisten bei Übergewicht","Stefan Weiler","2026","pharma-kritik","other","article","10.37667/pk.2026.1450",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032833","Therapeutics Effects of Drugs on Appetite and FoodIntake- a Comprehensive Review",null,"2026","Al-Quds Journal for Natural Sciences","narrative_review","article","10.47874/aqupp:27-44",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032834","Effect of Liraglutide, Metformin, and Gliclazide on Body Composition in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease—A Randomised Trial","Wenhuan Feng","2018","Diabetes","randomized_trial","article","10.2337/db18-1344-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032835","A vese védelmében és azon is túl. A renoprotekció új lehetőségei","Dóra Bianka Balogh","2023","Hypertonia és Nephrologia","other","article","10.33668/hn.27.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032836","Liraglutide Inhibits Endoplasmic Reticulum Stress in Pancreatic Beta Cells via Regulation of the Homeodomain Transcription Factor Nkx6.1","Yukun Li","2018","Diabetes","other","article","10.2337/db18-2146-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032837","Comparação entre Retatrutida e Tirzepatida no manejo da obesidade e diabetes Mellitus tipo 2: evidências clínicas e perspectivas terapêuticas","Ana Beatriz Spreafico Montes Pereira","2026","Revista fisio&terapia.","nonrandomized_study","article","10.69849/t91t7306",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0032838","Preconception Glucagon-like Peptide-1 Receptor Agonist Use Associated With Decreased Risk of Adverse Obstetrical Outcomes","MR Imbroane","2026","Obstetrical & Gynecological Survey","nonrandomized_study","article","10.1097/01.ogx.0001181216.66623.98",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032839","Diabetes and Kidney Disease: Interconnections, Mechanisms, and Implications for Care","Mugo Moses H.","2026","IDOSR JOURNAL OF APPLIED SCIENCES","other","article","10.59298/idosrjas/2026/111617",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032840","2128-LB: Novel Predicted Loss of Function Variants in TRIP10/CIP4 Associated with Atypical Diabetes in Two Unrelated Individuals","Stephen Stone","2025","Diabetes","other","article","10.2337/db25-2128-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032841","Obesity between 13 to 16 Years Students Visiting General Hospital \"Cross-Sectional Study\"","Abbas Mohsin Younus","2023","Himalayan Journal of Applied Medical Sciences and Research","randomized_trial","article","10.47310/hjamsr.2023.v04i01.019",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0032842","Semaglutide’s dilemma: A lifesaver with a price?","Niladri Dingal","2025","Annals of Medical Science and Research","other","article","10.4103/amsr.amsr_19_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032843","Liraglutide for adults living with obesity",null,"2026","Kazan medical journal","nonrandomized_study","article","10.17816/kmj701450",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0032844","\"I Pass Through Sweet\": My Diabetes Diagnosis as Narrative","Mathew Rodriguez","2026","Women's studies quarterly","other","article","10.1353/wsq.2026.a989461",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032845","451-P: Different Cardioprotective Efficacy of Metformin, Empagliflozin, and Semaglutide to Attenuate High Glucose–Oxidative Stress via Nrf2/Keap1 in Murine Cardiomyocytes","Pamela Senesi","2024","Diabetes","preclinical","article","10.2337/db24-451-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032846","768-P: A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity","STUDY GROUP PB-718","2024","Diabetes","randomized_trial","article","10.2337/db24-768-p",null,null,"ClinicalTrials.gov:NCT06147544","S003251","openalex","TRUE","free_to_read","1","FALSE","article"],["R0032847","1651-P: Effect of New Antidiabetics on Steatosis in of Nerve Tissues and Nerve Conduction Velocity—Possible Role of NGF/Synaptophysin and Nrf2/HO-1 Pathways","Abdelaziz M. Hussein","2024","Diabetes","preclinical","article","10.2337/db24-1651-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032848","148-LB: Efficacy and Safety of Adding an Oral Hypoglycemic Agent or a GLP-1 Receptor Agonist to Insulin in Patients with Type 1 Diabetes: A Network Meta-analysis","Yoon Ji Kim","2019","Diabetes","systematic_review","article","10.2337/db19-148-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032849","O uso off-label de Ozempic (semaglutida) para tratamento da obesidade e controle na perda de peso","Felippe Schivardi Oliveira","2023",null,"other","article","10.11606/003202251",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032850","Neuro-Adipose Signaling Pathways: How Brain–Adipose Communication Breakdowns Lead to Diabesity","\\Nassimbwa Kabanda D.","2026","NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY","other","article","10.59298/nijpp/2026/71107116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032851","Cardiovascular Disease, Hypertension, and Diabetes (Part A)","Shafi Malik","2023",null,"randomized_trial","article","10.1093/oso/9780192844163.003.0006",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","book-chapter"],["R0032852","32-PUB: Glycemic Variability after Initiation of SGLT2 Inhibitors in CKD","Mengyao Tang","2024","Diabetes","other","article","10.2337/db24-32-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032853","1333-P: Therapeutic Potential of DA-1726, a Novel Oxyntomodulin Analogue, in a Diet-Induced NASH Mouse Model","IL-HUN JUNG","2022","Diabetes","preclinical","article","10.2337/db22-1333-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032854","1665-P: Novel Spatiotemporal Analysis for Exploring Intestinal L-Cell Genesis and Differentiation","Rei Fujishima","2025","Diabetes","preclinical","article","10.2337/db25-1665-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032855","The First Weight Loss Drugs","Alex Telford","2025",null,"other","article","10.62211/82we-11pu",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032856","1785-P: Clinical Characteristics and Medication Use in Children and Young Adults with Obesity in the United States","Jiabi Xue","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1785-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032857","2078-LB: Effects of Obesity on Bladder Cancer and the Intervention Effect of Semaglutide","Yanhui Liu","2024","Diabetes","preclinical","article","10.2337/db24-2078-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032858","Research",null,"2025","Bone and Joint 360","other","article","10.1302/2048-0105.146.360288",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032859","Integrating Chrono-Nutrition with Oral Semaglutide Therapy in the Management of Extreme Obesity: A Case Report","Purva Singh","2026",null,"case_report","article","10.62830/mmj3-02-20c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032860","1212-P: Real-World Prescribing of GLP-1RA in a Safety Net Health System","Jacqueline Nicole McNulty","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1212-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032861","Liraglutide for Weight Loss in Patients Taking Olanzapine or Clozapine",null,"2019",null,"other","article","10.64239/pi-qt0105",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032862","Can GLP-1 Agonists Treat Alcohol Use Disorder?","David A. Gorelick","2025",null,"other","article","10.64239/pi-qt7201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0032863","130-OR: The Association between High Out-of-Pocket Costs and Incidence of Treatment Intensification with an SGLT2 Inhibitor (SGLT2i) or GLP-1 Agonist (GLP-1a) in Patients with Type 2 Diabetes and Established Cardiovascular Disease: A Retrospective Cohort Study","Jing Luo","2022","Diabetes","nonrandomized_study","article","10.2337/db22-130-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032864","111-LB: CHM-273S Peptide Decreases Blood Glucose Level, Improves Insulin Sensitivity, and Induces Insulin Signaling Pathways in the Liver of Rats with Diet-Induced Metabolic Disorder","VSEVOLOD PAVSHINTSEV","2022","Diabetes","preclinical","article","10.2337/db22-111-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032865","990-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model","JUNG KUK KIM","2019","Diabetes","preclinical","article","10.2337/db19-990-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032866","OWL833, an Orally Active Nonpeptide GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion and Reduces Food Intake of Cynomolgus Monkeys","Takahiro Kawai","2018","Diabetes","preclinical","article","10.2337/db18-1118-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032867","The Role of a Glucagon-Like Peptide-1 Receptor Agonist in Visceral and Subcutaneous Fat Redistribution","Li Zhao","2018","Diabetes","other","article","10.2337/db18-1996-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032868","569-P: Interim Outcomes of a Patient Simulation Educational Activity for Advanced Practice Providers on the Management of Type 2 Diabetes","ERIKA BRECHTELSBAUER","2023","Diabetes","other","article","10.2337/db23-569-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032869","982-P: Effects of Digitization of Self-Monitoring of Blood Glucose Records Using a Mobile Application and the Cloud System on Glycemic Control and Self-Management in Outpatients with Diabetes","Tomoko Handa","2023","Diabetes","other_trial","article","10.2337/db23-982-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032870","212-OR: Leptin Reduction as a Required Component for Weight Loss","Shangang Zhao","2023","Diabetes","preclinical","article","10.2337/db23-212-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032871","893-P: Relation between Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists and Renal Functions among Japanese Diabetics","MASAO TOYODA","2023","Diabetes","nonrandomized_study","article","10.2337/db23-893-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032872","Retrospective Analysis Comparing the Efficacy of GLP-1 Receptor Agonists Dulaglutide and Semaglutide","Michele Traverse","2024","Guthrie Journal","nonrandomized_study","article","10.3138/guthrie-2024-0008",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032873","Tirzepatide reduces sleep events in patients with sleep apnea and obesity",null,"2024","The Brown University Psychopharmacology Update","other_trial","article","10.1002/pu.31214",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032874","313-OR: The Efficacy and Safety of Glucagon-Like-Peptide-1 Agonists in Patients with Familial Partial Lipodystrophy","Salman Imam","2023","Diabetes","nonrandomized_study","article","10.2337/db23-313-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032875","293-OR: The Antistenotic Effect of Liraglutide Is Abolished in Vascular Smooth Muscle Cell-Specific Insulin-Receptor Knockout Mice","TALHA A. CHAUDHRY","2025","Diabetes","preclinical","article","10.2337/db25-293-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032876","38-OR: Effects of Dorzagliatin, Insulin Glargine, and Metformin on Nocturnal Endogenous Glucose Production in Type 2 Diabetes","ALAAELDIN HODHOD","2025","Diabetes","other_trial","article","10.2337/db25-38-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032877","CRISPR-Nanoparticle Delivery Systems for Gene Editing of Obesity and Diabetes Targets","Mpora Kakwanzi Evelyn","2026","IAA Journal of Applied Sciences","preclinical","article","10.59298/iaajas/2026/141119126",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032878","1749-P: A Case Report of IgE-Mediated Insulin Allergy Successfully Managed with a Fixed Combination of Degludec and Liraglutide","Nadan Gregorič","2019","Diabetes","case_report","article","10.2337/db19-1749-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032879","Current Approach of Diabetes Mellitus in Obese Patients","Sülbiye Karaburgu","2023",null,"other","article","10.69860/nobel.9786053359111.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032880","SGLT2 Inhibitor Ipragliflozin Induces Breast Cancer Apoptosis via Membrane Hyperpolarization and Mitochondria Dysfunction","Shiho Komatsu","2018","Diabetes","preclinical","article","10.2337/db18-255-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032881","Conversion of Injectable Semaglutide into Oral Formulations: Comparative Evaluation of Tablet and Liquid Preparations for Pharmaceutical Feasibility and Biological Potential","Rehan Haider","2025","Biological Sciences","preclinical","article","10.55006/biolsciences.2025.5405",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032882","Adipocentricità della sindrome cardiovasculo-nefro-epato-metabolica e gli agonisti del recettore del GLP-1","Lucia Stella","2025","Cardiologia Ambulatoriale","other","article","10.17473/1971-6818-2025-3-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032883","Safety and efficacy of the novel multi-agonist retatrutide in patients with diabetes and obesity. Results of initial studies","A.S. Kenkishvili","2026",null,"other","article","10.33920/med-13-2602-03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032884","Eficácia e segurança do Ozempic®? no emagrecimento: uma análise crítica","João Vitor Maia Maranhão","2024","Revista Liberum Accessum.","other","article","10.29327/2417778.16.2-19",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032885","Identification of Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors from Miracle Berry Fruit (Synsepalum dulcificum) Extract","Nuraliana Najwa Hamsah Zollapi","2022","Journal of Biochemistry Microbiology and Biotechnology","other","article","10.54987/jobimb.v11i1.816",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032886","1690-P: PG-110, a Novel Bispecific Antibody Targeting ActRII and Myostatin, Enhances Fat-Specific Weight Loss and Improves Bone Health in Combination with GLP-1 Agonist Therapy","YOUNGLIM SON","2025","Diabetes","preclinical","article","10.2337/db25-1690-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032887","EFEITOS ADVERSOS FRENTE AO USO INDEVIDO DO OZEMPIC","Lucas Kron Rigato","2025","Revista Omnia Saúde","other","article","10.69719/ros.v8.851",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032888","Aplicaciones de la Inteligencia Artificial en Enfermería y su impacto en los Resultados del Cuidado: Una Revisión de Alcance","Josué Murillo-Cubero","2025","Crónicas científicas.","other","article","10.55139/aobn3401",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032889","793-P: Disparities in Adoption of Drugs with Cardiovascular and Renal Benefits","Hugo Amador Herrera Torres","2025","Diabetes","other","article","10.2337/db25-793-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032890","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ARE LEADERS IN REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Gromova Yu.M.","2021",null,"other","article","10.51922/2074-5044.2021.4.101",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032891","109-LB: Potent Weight Loss Mechanism by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models","Jong Suk Lee","2019","Diabetes","preclinical","article","10.2337/db19-109-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032892","1009-P: The Dual GIP and GLP-1 Receptor Agonist Tirzepatide Regulates Lipid and Carbohydrate Metabolism through GIPR in Adipose Tissue","Ricardo J. Samms","2019","Diabetes","preclinical","article","10.2337/db19-1009-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032893","1874-LB: PG-102, a Bivalent GLP-1R/GLP-2R Agonist, Protects ß-Cell Mass and Enhances Glycemic Control in Obese db/db Mice, Showing Superiority over Semaglutide, Tirzepatide, and Retatrutide","SAE WON KIM","2024","Diabetes","preclinical","article","10.2337/db24-1874-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032894","Diabetes, kardiovaskuläres Risiko und koronare Herzkrankheit","Sofia Macieira","2022","Diabetes aktuell","other","article","10.1055/a-1883-8383",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032895","Exploring spearmint (Mentha spicata) and Exendin-4 as novel therapeutic approaches for Huntington’s disease: a molecular insight","A. Asha Monica","2025","Research Journal of Biotechnology","other","article","10.25303/211rjbt2090215",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032896","Az anyagcsere-betegségek, a magas vérnyomás és a szívelégtelenség összefüggései és a kezelés holisztikus megközelítése","Gábor Simonyi","2025","Hypertonia és Nephrologia","other","article","10.33668/hn.29.027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032897","Evaluation of Liraglutide Usage for Treatment of Type 2 Diabetes at a Veterans Affairs Medical Center","RIKKI L. RYCHEL","2018","Diabetes","other","article","10.2337/db18-1285-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032898","Evaluasi Penggunaan Antidiabetes Pada Pasien Diabetes Melitus Tipe 2 Rawat Inap Di Rumah Sakit Bhayangkara Brimob","Kriselda Evelyin Ninia","2025","Jurnal Farmasi dan Farmakoinformatika","other","article","10.35760/jff.2025.v3i1.12943",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032899","Consideraciones Perioperatorias de los Análogos GLP-1.","Critical Care & Emergency Medicine","2024","Critical Care & Emergency Medicine","other","article","10.58281/ccem24120907",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032900","Tirzepatide (Mounjaro)-induced acute pancreatitis and ketoacidosis in an adult nondiabetic patient","Asma Sallam","2025","Saudi Journal for Health Sciences","other","article","10.4103/sjhs.sjhs_122_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032901","A Comprehensive Systematic Review of Belly Fats: Pathophysiology, Clinical Implications, and Intervention Strategies","Eling Felix","2025","International Journal of Research and Innovation in Social Science","systematic_review","article","10.47772/ijriss.2025.9020319",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032902","Targeted Nanocarriers for Insulin and Incretin Delivery: Overcoming Barriers in Type 2 Diabetes Management","Mugisha Emmanuel K.","2026","Research Output Journal of Biological and Applied Science","nonrandomized_study","article","10.59298/rojbas/2026/611118",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032903","Natural and Synthetic Strategies for Obesity Control","Kajal Choudhary","2026","International Journal of Innovative Science and Research Technology (IJISRT)","other","article","10.38124/ijisrt/26apr1724",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032904","Mechanisms underlying heart failure in type 2 diabetes mellitus",null,"2019","Heart and Metabolism","other","article","10.31887/hm.2019.80/hbugger",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032905","89-LB: Oral Delivery of a GLP-1 Agonist with High Bioavailability in Dogs and Humans","April Toledo Vo","2023","Diabetes","other","article","10.2337/db23-89-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032906","SEMAGLUTIDA: OS IMPACTOS DO USO INADEQUADO DE EMAGRECEDORES","Mayra Sena Carvalho Gomes","2025","Revista fisio&terapia.","other","article","10.69849/revistaft/ra10202512192340",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032907","77-LB: A Novel Glucagon-Like Peptide-1 (GLP-1R) and Glucagon (GCGR) Receptor Dual Agonist, Mazdutide (IBI362), Attenuates Hyperuricemia in Hyperuricemic Rats","HONGWEI JIANG","2023","Diabetes","preclinical","article","10.2337/db23-77-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032908","88-LB: Safety, PK, PD, and Efficacy of Weekly Dosing Supaglutide in Patients with T2D","YUE ZHOU","2022","Diabetes","randomized_trial","article","10.2337/db22-88-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032909","Beyond weight loss: Clinical anabolism to reduce muscle mass loss and physical function decline in patients undergoing pharmacological treatment for obesity","Lucas Caseri Câmara","2026","Revista fisio&terapia.","randomized_trial","article","10.69849/g2hbtt18",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0032910","746-P: GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes","Faidat Adeola Ishola","2024","Diabetes","nonrandomized_study","article","10.2337/db24-746-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032911","91-LB: Glycemic and Metabolic Effects of Long-Acting GLP-1 in T1D","DEENE MOHANDAS","2022","Diabetes","nonrandomized_study","article","10.2337/db22-91-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032912","17-PUB: DNA-Based Delivery of Therapeutic Proteins Using MYO Technology—Preclinical Results on Incretin Receptor Agonists","Linda Sasset","2025","Diabetes","preclinical","article","10.2337/db25-17-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032913","TIRZEPATIDA: A REVOLUÇÃO NO MANEJO DA DIABETES TIPO 2 E OBESIDADE- AVANÇOS E PERSPECTIVAS","Cibele Cardoso Amaro","2025","Revista fisio&terapia.","randomized_trial","article","10.69849/revistaft/ra10202506112238",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032914","1983-LB: A Phase 1 Study of ID110521156, a Small Molecule Glucagon-Like Peptide 1 Receptor Agonist, in Healthy Subjects","In‐Gyu Je","2025","Diabetes","randomized_trial","article","10.2337/db25-1983-lb",null,null,"ClinicalTrials.gov:NCT06063291; ClinicalTrials.gov:NCT06635226",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032915","1976-LB: A Novel PTAP-009 Peptide—Enhancing Glycemic Control and Sustained Appetite Suppression","Eun Jeong Jang","2025","Diabetes","preclinical","article","10.2337/db25-1976-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032916","IN VITRO AND EX VIVO OSTEOARTHRITIS MODELS AND THERAPIES","Kaihu Li","2025","Orthopaedic Proceedings","preclinical","article","10.1302/1358-992x.2025.9.031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032917","1028-P: Is Once-Weekly GLP-1 Receptor Agonist a Reasonable Option for Glucocorticoid-Induced Hyperglycemia? Twelve-Week Efficacy and Safety of Dulaglutide vs. Sitagliptin in Patients with Diabetes on Routine Glucocorticoid Treatment","Satoshi Yoshiji","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1028-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032918","Diet-Induced Adipose Tissue Inflammation and Hypoxia Are Reversed by GLP-1 Potentially via Improved Microcirculation","Fen Xu","2018","Diabetes","preclinical","article","10.2337/db18-2024-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032919","Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada","Pierre Johansen","2018","Diabetes","nonrandomized_study","article","10.2337/db18-136-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032920","1655-P: GLP-1R Is Required for Resveratrol in Exerting Its Metabolic Beneficial Effect in HFD-Challenged Male Mice","Jia Nuo Feng","2023","Diabetes","preclinical","article","10.2337/db23-1655-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032921","Semaglutide improves outcomes in patients with schizophrenia and medical comorbidities",null,"2025","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31378",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032922","991-P: Potential of a Novel Long-Acting Glucagon Analog, HM15136, for the Treatment of Obesity","Jung Kuk Kim","2019","Diabetes","preclinical","article","10.2337/db19-991-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032923","The influence of GLP-1R agonists on glucose-stimulated insulin secretion and the receptor internalisation in normal, diabetic and recovered pancreatic beta-cells","Joshua L. Reed","2022",null,"preclinical","article","10.23889/suthesis.59405",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032924","Evidências cientificas sobre o uso de tirzepatida como tratamento da obesidade","Bernardo Carneiro de Sousa Guimarães","2022","Brazilian Journal of Health Review","other","article","10.34119/bjhrv5n4-137",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032925","1424-P: Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Type 2 Diabetes Population in China","Xiaoling Cai","2020","Diabetes","other_trial","article","10.2337/db20-1424-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032926","132-OR: Trends in Total Payments, Net Payments, and Rebates for a 30-Day Supply of Glucose-Lowering Drugs (GLDs) from 2010–2017","YAO DING","2022","Diabetes","other","article","10.2337/db22-132-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032927","235-LB: YH34160, a Novel Long-Acting GDF15 Fusion Protein, Exerts Potent and Sustained Body Weight Loss in Rodent Obesity Models","Seyoung Lim","2022","Diabetes","preclinical","article","10.2337/db22-235-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032928","886-P: A Novel UCN2 Analog HM17321 with HM15275 Improves Body Composition in Mouse Model of Obesity","Hyunjoo Kwon","2025","Diabetes","preclinical","article","10.2337/db25-886-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032929","15-PUB: A Single-Center, Open-Label, Fixed-Sequence Clinical Study to Evaluate the Pharmacokinetic Effects of Supaglutide on Digoxin or Metformin in Healthy Subjects","HE JINJIE","2024","Diabetes","other_trial","article","10.2337/db24-15-pub",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032930","1139-P: Discovery of a Potent, Orally Efficacious Small Molecule Agonist of Glucagon-Like Peptide-1 (GLP-1) Receptor","DAVID J. BEARSS","2024","Diabetes","preclinical","article","10.2337/db24-1139-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032931","Liraglutide results in significant weight loss in patients with bipolar disorder",null,"2024","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31179",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032932","286-OR: JNK3—A Key Downstream Target of Incretin Responses in ß-Cells","RUY ANDRADE LOUZADA NETO","2024","Diabetes","preclinical","article","10.2337/db24-286-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032933","1716-P: Nimacimab, a Peripherally Restricted CB1 Inhibitor, Promotes Metabolic Homeostasis in a Diet-Induced Obesity (DIO) Mouse Model as Demonstrated by Weight Loss, Restored Hormonal Regulation, and Reduced Inflammatory Biomarkers","Francisco Ruíz-Pino","2025","Diabetes","preclinical","article","10.2337/db25-1716-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032934","Forced Expressed GLP-1R Attenuates Prostate Cancer Growth","Toru Shigeoka","2018","Diabetes","preclinical","article","10.2337/db18-1958-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032935","POPULARIZAÇÃO DOS ANÁLOGOS DO GLP-1 :IMPLICAÇÕES PARA A SAÚDE PÚBLICA E DESAFIOS NA ORIENTAÇÃO FARMACÊUTICA","Karla Marcelly Ferreira da Silva","2025","Revista fisio&terapia.","other","article","10.69849/revistaft/pa10202511082225",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032936","2300-PUB: The Efficacy and Safety of Combinations of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: A Systematic Review and Meta-analysis","Man Guo","2019","Diabetes","systematic_review","article","10.2337/db19-2300-pub",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032937","A Case Report on Suicidal Liraglutide Overdose in a Non Diabetic Female Presented with Hypoglycemia","Sayani Banerjee","2018","Indian Journal of Emergency Medicine","case_report","article","10.21088/ijem.2395.311x.4118.12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032938","36-OR: Modulation of Cardiorenal Benefits for GLP-1RAs Treatment by GLP1R Genetic Variants","QIAOCHU XUE","2024","Diabetes","nonrandomized_study","article","10.2337/db24-36-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032939","Comparative Cardiovascular Effectiveness of SGLT2 Inhibitors vs. Liraglutide in Routine Care","Elisabetta Patorno","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1492-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032940","A functional medicine approach to neurovascular complications in diabetes: focus on nutritional interventions","Jung-Hwa Shin","2025","Korean Institute for Functional Medicine","other","article","10.32581/jkifm.2025.8.2.40",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032941","655-P: Multitarget Engagement Effect of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Animal Model of NASH","JUNG KUK KIM","2021","Diabetes","preclinical","article","10.2337/db21-655-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032942","805-P: Early Glycemic Improvement When Switching to iGlarLixi from Premixed Insulins (PI) in Adults with Type 2 Diabetes (T2D)—A Post Hoc Analysis of Soli-SWITCH","Martin Haluzı́k","2025","Diabetes","other_trial","article","10.2337/db25-805-p",null,null,"EudraCT:2021-003711-25",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032943","850-P: Comparision of Efficacy on MASLD between GLP-1RA and SGLT2i—A Real-World Study","Weixia Sun","2025","Diabetes","nonrandomized_study","article","10.2337/db25-850-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032944","1817-P: Human Fatty Pancreas In Vitro Model Reveals Specific Effects on Beta-Cell Function and Incretin Responsiveness in T2D","E Lorza Gil","2025","Diabetes","preclinical","article","10.2337/db25-1817-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032945","Knowledge, attitude, and prescribing patterns of GLP-1 receptor agonists among cardiologists: A cross-sectional study from the Makkah Region","Yosra Turkistani","2025","International Journal of Medicine in Developing Countries","other_trial","article","10.24911/ijmdc.51-1745575418",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032946","Obezitenin Medikal Tedavisi “Yeni Farmakolojik Ajanlar”","İlhan Yetkin","2024",null,"other","article","10.53478/tuba.978-625-6110-23-6.ch08",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032947","Expert Insights for PCPs in Managing CKD in T2DM","Yik Tian Akira Wu","2022","The Singapore Family Physician","randomized_trial","article","10.33591/sfp.48.3.u5",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032948","823-P: The Long-Acting Dual Amylin and Calcitonin Receptor Agonist KBP Has Increased Efficacy on Weight Loss and Glucose Control Compared with Cagrilintide in Obese and Diabetic Rats","ANNA T. LARSEN","2022","Diabetes","preclinical","article","10.2337/db22-823-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032949","545-P: The Difference in the Effects on Microalbuminuria Depending on the Order of GLP-1RA and SGLT2i Therapy in Type 2 Diabetes","Masaya Ohara","2019","Diabetes","nonrandomized_study","article","10.2337/db19-545-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032950","745-P: Lipidomics Studies on Brown Adipose Tissue by Exercise and Liraglutide in db/db Mice","Ruili Yin","2019","Diabetes","preclinical","article","10.2337/db19-745-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032951","2136-PUB: GLP-1 Agonist Exendin-4 Protects Endothelial Cells against Hyperhomocysteinemia by Alleviating ER Stress and Enhancing Protein Folding Machinery","Chak Kwong Cheng","2020","Diabetes","preclinical","article","10.2337/db20-2136-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032952","ozempic babies: mechanisms and imp acts of semaglutide therapy","Aglatha Maali Santana","2026","Endocrinologia & Diabetes Clínica e Experimental","other","article","10.29327/2824458.23.1-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032953","Neuroprotektive Wirkungen von Antidiabetika in der Therapie von Patienten mit Diabetes und Glaukom oder hohem Glaukomrisiko","Burkhard Weisser","2024","Diabetes aktuell","other","article","10.1055/a-2401-3707",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032954","236-OR: Short-Term Effects of Semaglutide and Tirzepatide on Body Composition in Patients with Obesity Undergoing a Low-Calorie Diet","M. Naka","2024","Diabetes","other","article","10.2337/db24-236-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032955","745-P: Effects of Liraglutide on GLP-1, GIP, and Glucagon Concentrations in Persons with Type 2 Diabetes with Multiple Daily Insulin Injections during a 24-Week Period","MARSEL KOCI","2024","Diabetes","randomized_trial","article","10.2337/db24-745-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032956","2043-LB: hERG Potassium Channels as Novel Targets for GLP-1 and GIP Secretagogue Therapies in Diabetes and Obesity","YING-CHAO YUAN","2024","Diabetes","preclinical","article","10.2337/db24-2043-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032957","107-OR: Brain GLP-1R Is Likely Required for Peripheral Liraglutide Treatment on Stimulating Hepatic FGF21","Jia Nuo Feng","2024","Diabetes","preclinical","article","10.2337/db24-107-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032958","803-P: How Effective Is Weight Loss by Oral Semaglutide on Glycemic Control in a Real-World Setting?","Jothydev Kesavadev","2024","Diabetes","nonrandomized_study","article","10.2337/db24-803-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032959","641-P: Novel Microsphere Formulation Developments of Long-Acting GLP-1 RA Including Exenatide, Liraglutide, and Semaglutide","Jin Gyoung Jung","2021","Diabetes","preclinical","article","10.2337/db21-641-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032960","Global Trends and Hotspots in Dulaglutide in the Fields of Diabetes, Obesity, and Cardiovascular Research: A Bibliometric Analysis","Osama Albasheer","2025","Current Bioactive Compounds","nonrandomized_study","article","10.2174/0115734072353980250418211500",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032961","345-OR: Exercise and Liraglutide Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Diet-Induced Obesity","Jia Liu","2023","Diabetes","preclinical","article","10.2337/db23-345-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032962","ПРОБЛЕМА ЛЕКАРСТВЕННОГО ОБЕСПЕЧЕНИЯ ПАЦИЕНТОВ, СТРАДАЮЩИХ ИЗБЫТОЧНЫМ ВЕСОМ","Е.А. Некрасов","2025","Смоленский медицинский альманах","other","article","10.37903/sma.2025.2.55",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032963","Global Utilization Patterns and Reimbursement Policies of GLP-1 Receptor Agonists","The Pharmaceutical Society Of Korea","2026","Yakhak Hoeji","other","article","10.17480/psk.2026.70.1.26",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032964","Efectos antiinflamatorios de la semaglutida y liraglutida en pacientes con osteoartritis","Jadyra Pamela Cunalata-Moreno","2025","MQRInvestigar","other","article","10.56048/mqr20225.9.4.2025.e1270",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032965","87-OR: Engineered Vasculature Induces Functional Maturation of Pluripotent Stem Cell–Derived Islet Organoids","Kim-Vy Nguyen-Ngoc","2023","Diabetes","other","article","10.2337/db23-87-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032966","2314-PUB: No Clinical Factors, Except Baseline HbA1c, Can Predict Glycemic Response to Dulaglutide: Real-World Data in Korean Patients","Jeehee Yoon","2019","Diabetes","randomized_trial","article","10.2337/db19-2314-pub",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032967","GLP-1-receptor-agonisták alkalmazása időskorban","Gábor Winkler","2020","Lege Artis Medicinae","other","article","10.33616/lam.30.042",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032968","Effect of the Combination Therapy of Liraglutide, a GLP-1 Receptor Analog, and IDegAsp in Patients with Type 2 Diabetes","Marina Harada","2018","Diabetes","other","article","10.2337/db18-1002-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032969","Peripheral Artery Disease and Amputation: Scoping Review with ☸SAIMSARA","SAIMSARA","2026","SAIMSARA Journal","narrative_review","article","10.62487/saimsara20fbe2d9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032970","O uso indiscriminado de agonistas do GLP-1 (semaglutida e tirzepatida) para o emagrecimento e o papel do farmacêutico na promoção do uso racional","Danilo Conceição Silva","2026","Revista fisio&terapia.","other","article","10.69849/d1av6113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032971","Incretin therapies for type 2 diabetes: what nurses need to know","Brenda Capaldi","2012","Nurse Prescribing","other","article","10.12968/npre.2012.10.7.345",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032972","892-P: Influence of Preceding Medications on the Renal Outcomes of Japanese Diabetics Treated with SGLT2 Inhibitors and GLP-1 Receptor Agonists","Kazuo Kobayashi","2023","Diabetes","nonrandomized_study","article","10.2337/db23-892-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032973","GLP-1 Receptor Agonist Impact on Fracture Risk In Patients with Obesity","Alex Chelton","2025","Journal of the American Osteopathic Academy of Orthopedics","nonrandomized_study","article","10.70709/ellc5ccpa22",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032974","Non-Insulin Glucose-Lowering Agents","Clifford J. Bailey","2022",null,"other","article","10.1093/med/9780198870197.003.0253",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032975","1803-P: Antifibrotic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in BDL-Induced Liver Fibrosis Mice","JUNG KUK KIM","2020","Diabetes","preclinical","article","10.2337/db20-1803-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032976","2188-PUB: Efficacy and Safety in Chinese T2D Patients Discontinued from OAM to Once-Weekly Dulaglutide Monotherapy","Yanbing Li","2020","Diabetes","other","article","10.2337/db20-2188-pub",null,null,"ClinicalTrials.gov:NCT01644500","S001064","openalex","FALSE","paywalled","5","FALSE","article"],["R0032977","1221-P: Clinical Significance of Autoantibody Measurement for Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in the Plasma","Hiroki Yamagata","2022","Diabetes","other","article","10.2337/db22-1221-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032978","2191-LB: A First-in-Class FTO Small Molecule Inhibitor Preserves the Lean Mass during Long-Term Weight Control Comparable to GLP-1","Yu Yan","2025","Diabetes","other_trial","article","10.2337/db25-2191-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0032979","Brain Insulin Resistance, Nitric Oxide and Alzheimer’s Disease Pathology","Zhe Pei","2022","BENTHAM SCIENCE PUBLISHERS eBooks","other","article","10.2174/9789815079814122010014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0032980","REDUCCIÓN DE PESO EXITOSA Y SEGURA CON EL USO DE LIRAGLUTIDA PARA LA OBESIDAD SEVERA EN UN ADOLESCENTE CON OBESIDAD HIPOTALÁMICA","Marisa Armeno","2025","Actualización en Nutrición","other","article","10.48061/san.2024.26.1.82",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0032981","393-P: SGLT2 Inhibitors Reduce Cardiovascular and Renal Risks Compared with GLP-1 Receptor Agonists and DPP4 Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Network Meta-analysis","HONGWEI CAO","2022","Diabetes","systematic_review","article","10.2337/db22-393-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0032982","221 DERIVATION OF INSULIN-PRODUCING CELLS FROM HUMAN DERMAL FIBROBLASTS AT INTERMEDIATE PHASE OF REPROGRAMMING","Jee Hyun Kang","2015","Reproduction Fertility and Development","other","article","10.1071/rdv28n2ab221",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032983","GLP-1 Agonists and Orthopedic Surgery: A Review of Their Impact on Bone Metabolism, Wound Healing, and Surgical Outcomes","Mary Baun","2025","Journal of the American Osteopathic Academy of Orthopedics","randomized_trial","article","10.70709/r2fykae2uu",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032984","1066-P: Cost-Effectiveness of SGLT2i plus GLP-1RAs vs. SGLT2i in Patients with Chronic Kidney Disease","SHU NIU","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1066-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032985","GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management: Biochemical Mechanisms, Clinical Efficacy, and Translational Implications","Mercy Latricia","2026","IAA Journal of Biological Sciences","randomized_trial","article","10.59298/iaajb/2026/1415559",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032986","2014-P: The Effect of High-Fat Diet on Adipose Tissue Glycerol Metabolism Is Influenced by Sex and GLP-1 Agonist Treatment","Francesco Maria Iena","2019","Diabetes","preclinical","article","10.2337/db19-2014-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032987","767-P: TERN-601, a Novel Oral GLP-1R Agonist, Suppresses Food Intake and Improves Glucose Tolerance in Transgenic Mice Expressing Human GLP-1 Receptor","CHRISTOPHER JONES","2023","Diabetes","preclinical","article","10.2337/db23-767-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032988","1802-PUB: Liraglutide as a Potential Drug Repurposing Candidate for Alzheimer’s Disease and Related Dementia—Real-World Evidence","Tiansheng Wang","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1802-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032989","1678-P: B6-Alms1-del Mice, a Metabolic Syndrome Animal Model, Shows Semaglutide Benefits on Obesity, Hyperglycemia, and NAFL","ZHONG CHEN","2023","Diabetes","preclinical","article","10.2337/db23-1678-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032990","Cost as the Main Driver of T2D Treatment Patterns—Lessons from Real-World Data and Physician Focus Groups","Sze-jung Wu","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1254-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032991","Eyes on GLP-1 receptor agonists","Bence Tasnadi","2026","Journal of the Foundations of Ophthalmology","other","article","10.48089/jfo7689077",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032992","259-OR: Magnetic Resonance Imaging of Transplanted Islets Labeled with Exendin-4-Conjugated Manganese Magnetism-Engineered Iron Oxide Nanoparticles","Jyuhn‐Huarng Juang","2019","Diabetes","preclinical","article","10.2337/db19-259-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032993","2311-PUB: Effectiveness of Incretin-Based Therapies in Children with Early Stage Slowly Progressive Type 1 Diabetes","Tatsuhiko Urakami","2019","Diabetes","other","article","10.2337/db19-2311-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032994","942-P: Treatment of Weight Regain after Bariatric Surgery: Real-World Comparative Outcomes","Chellse Gazda","2020","Diabetes","nonrandomized_study","article","10.2337/db20-942-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0032995","SEMAGLUTIDA E O RISCO CARDIOVASCULAR NA OBESIDADE: A RELAÇÃO CRÍTICA ENTRE TOLERABILIDADE, ADESÃO E A SUSTENTAÇÃO DO BENEFÍCIO CLÍNICO","João Carlos Mendes Maia","2026","Revista fisio&terapia.","randomized_trial","article","10.69849/revistaft/pa10202601181008",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0032996","Role of the Peptide Spexin in Endocrine Beta Cell and Adipocyte Functions; Implications for Diabetes and Obesity","Md. Wasim Khan","2024",null,"preclinical","article","10.59019/ztgg9876",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0032997","2043-LB: Universal Access to GLP1-RAs Could Reduce Global Obesity Prevalence by 20% and Save 28 Million Lives over Five Years—A Microsimulation Study","Elizabeth W. Staton","2025","Diabetes","other","article","10.2337/db25-2043-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032998","83-LB: Pharmacokinetic and Pharmacodynamic Studies of Supaglutide in Rats and Monkeys","YIJING LIAO","2022","Diabetes","preclinical","article","10.2337/db22-83-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0032999","459-P: Effects of Liraglutide on Somatic Nerve Function in Subjects with Type 2 Diabetes","CAROLINA M. CASELLINI","2022","Diabetes","randomized_trial","article","10.2337/db22-459-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033000","GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?","Oliver Freudenreich","2026",null,"other","article","10.64239/pi-qt8402",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0033001","Glycemic control parameters in patients with type 2 diabetes mellitus under the fixed combination of insulin glargine and lixisenatide","KSMA — Branch Campus of the FSBEI FPE RMACPE MOH Russia","2024","Practical medicine","other","article","10.32000/2072-1757-2024-6-114-117",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033002","Useful Interventions in Treating Diabetes: A Comprehensive Review","Bizimana Rukundo T.","2025","IAA Journal of Applied Sciences","narrative_review","article","10.59298/iaajas/2025/131.6130",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033003","1433-P: Comparative Weight Loss with GLP-1 Receptor Agonists vs. Bariatric Surgery in Obesity: A Systematic Review and Pair-Wise Meta-analysis","Shohinee Sarma","2022","Diabetes","systematic_review","article","10.2337/db22-1433-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0033004","Semaglutide: Heart of the Matter (SUSTAIN-6 and PIONEER-6)","Rohit Khurana","2022","The Singapore Family Physician","other","article","10.33591/sfp.48.3.u6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033005","2371-PUB: Addition of a GLP-1 Agonist to Safety Net Hospital System Formulary to Improve Glycemic Control","Uma Gunasekaran","2019","Diabetes","other","article","10.2337/db19-2371-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033006","168 | GLP‑1 receptor signaling directs adipogenic repression and thermogenic activation in human adipose-derived stem cells","Società Italiana di Biologia Sperimentale","2026","Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale","other","article","10.4081/jbr.2026.15420",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033007","The incretin effect: An interview with Dr. Daniel Drucker",null,"2026","University of Toronto Medical Journal","other","article","10.33137/utmj.v103i2.47411",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033008","1639-P: Tirzepatide and Efruxifermin Demonstrate Therapeutic Benefits for NASH in a Preclinical Metabolic Syndrome Animal Model, B6-Alms1-del Mice","Zhong Chen","2024","Diabetes","preclinical","article","10.2337/db24-1639-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033009","119-OR: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Ultra-Long-Acting GLP-1 Receptor Agonist (ZT002) in Healthy Subjects","Yuanyuan Zhang","2024","Diabetes","randomized_trial","article","10.2337/db24-119-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033010","Antipsychotic-Induced Weight Gain: Best Management Strategies","Scott R. Beach","2025",null,"other","article","10.64239/pi-qt7102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0033011","AGONISTAS DE GLP-1 NA ONCOLOGIA: ONDE ESTAMOS?","Ana Clara Fernandes Cassimiro","2026",null,"randomized_trial","article","10.66396/pontes.c21.2026",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","book-chapter"],["R0033012","Antipsychotic-Induced Weight Gain: Prevention and Management",null,"2025",null,"other","article","10.64239/pi-vl9303",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0033013","Residual Risk That Remains","Arun Kochar","2022","Exclusive Real World Evidence Journal","other","article","10.54136/erwej-0202-10025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033014","962-P: Impacts of Different Hypoglycemic Agents on Adipokines and Inflammatory Markers in Newly Diagnosed T2D Patients","Hongrong Deng","2020","Diabetes","randomized_trial","article","10.2337/db20-962-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033015","Mechanisms Underlying Weight Regain After GLP-1RA Treatment: A Neurobiological Perspective","Kerolayne de Melo. Nogueira","2026","Annual Research & Review in Biology","other","article","10.9734/arrb/2026/v41i12370",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033016","Does Semaglutide Reverse Clozapine-Induced Weight Gain in Schizophrenia? Results from the COaST Trial","Oliver Freudenreich","2025",null,"other_trial","article","10.64239/pi-qt7802",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","report"],["R0033017","Rethinking Health: The Health Optimizer Therapy Disruption","Adam Dorr","2026",null,"other","article","10.61322/jsas8230",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0033018","1066-P: Comparison of Efficacy of Lixisenatide Combined with Basal Insulin with or without Metformin in Asian and Caucasian Patients with Type 2 Diabetes: A Pooled Analysis of Phase-III Studies","REN YUEZHONG","2020","Diabetes","other_trial","article","10.2337/db20-1066-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033019","937-P: Effects of Insulin and Exenatide on Glycemic Control and ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients with Severe Hyperglycemia","Tsung-Hui Wu","2020","Diabetes","randomized_trial","article","10.2337/db20-937-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033020","969-P: Effects of Tirzepatide on Meal Intake and Appetite in Japanese Patients with Type 2 Diabetes","Kenji Ohwaki","2020","Diabetes","other_trial","article","10.2337/db20-969-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033021","Nanomaterial-Based Modulation of Adipokines and Myokines: Implications for Diabetes-Obesity Crosstalk","B. P. David","2026","NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY","other","article","10.59298/nijpp/2026/717986",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033022","Energy Ratios Unlocked","Aastha Jaiswal","2026","The American Biology Teacher","other","article","10.1525/abt.2026.88.3.203",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033023","537-P: Virtual Patient Simulation Assesses the Levels of Competency and Improves Performance of Advance Practice Providers in the Field of Diabetes and Cardiometabolic Medicine","Igal Iancu","2023","Diabetes","nonrandomized_study","article","10.2337/db23-537-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033024","OZEMPIC (SEMAGLUTIDA) E FERTILIDADE FEMININA: UMA REVISÃO CIENTÍFICA SOBRE EFEITOS TERAPÊUTICOS, RISCOS REPRODUTIVOS E IMPLICAÇÕES CLÍNICAS","Emily Oliveira da Silva","2025","Revista fisio&terapia.","other","article","10.69849/revistaft/ra10202510151942",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033025","849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide","Daniel A. Briere","2025","Diabetes","preclinical","article","10.2337/db25-849-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033026","2173-LB: The Proteomic Analysis of Intermittent Fasting Alone or with GLP-1RA in NAFLD Rats","Yimin Shao","2025","Diabetes","preclinical","article","10.2337/db25-2173-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033027","2068-LB: GLP-1RA Prescribing Patterns among Youth with T2DM at an Academic Pediatric Endocrinology Clinic","ISABELLA MARRANZINI RODRIGUEZ","2025","Diabetes","nonrandomized_study","article","10.2337/db25-2068-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033028","A PROTEIN FROM NOSE-HORNED VIPER VENOM HOLDS PROMISE FOR THE DEVELOPMENT OF AN INNOVATIVE DRUG FOR VENOUS THROMBOEMBOLISM","Igor Križaj","2026","Slovenian Veterinary Research","other","article","10.26873/svr-2333-2026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033029","Persistence to Treatment with DPP-4 Inhibitors, SGLT2 Inhibitors, and GLP-1-RAs Compared with Insulin after Failure with First Antidiabetic Drug in T2DM Patients","György Jermendy","2018","Diabetes","nonrandomized_study","article","10.2337/db18-2321-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033030","A51-24 Salt, Satiety, and Side Effects: Hyponatremia in the Era of Glp-1 Agonists","D Thota","2026","American Journal of Respiratory and Critical Care Medicine","other","article","10.1093/ajrccm/aamag162.3164",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033031","438-P: Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists vs. Other Glucose-Lowering Agents in Patients with Type 2 Diabetes—A Nationwide Cohort Study Using Prevalent New-User Design","Chun‐Ting Yang","2019","Diabetes","nonrandomized_study","article","10.2337/db19-438-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033032","A Comprehensive Review on Dyslipidemia and Obesity: Pathophysiology, Clinical Implications and Management Approaches","Edwin Dias","2025","International Journal of Research in Pharmacy and Allied Science","nonrandomized_study","article","10.71431/ijrpas.2025.41203",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0033033","ASSOCIATION OF SEMAGLUTIDE WITH ORTHOPAEDIC OUTCOMES IN PATIENTS WITH SIGNIFICANT ADIPOSITY AND TYPE 2 DIABETES MELLITUS","E. Glenn","2026","Orthopaedic Proceedings","nonrandomized_study","article","10.1302/1358-992x.2026.2.034",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033034","27-PUB: Enhanced Glycemic Control and Weight Benefits of Insulin Glargine plus lixisenatide vs. Insulin Glargine in Type 2 Diabetes","BANSHI D. SABOO","2025","Diabetes","randomized_trial","article","10.2337/db25-27-pub",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033035","Macrovascular complications of diabetes: prevention and management",null,"2025",null,"other","article","10.1093/med/9780198831846.003.0010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033036","139-OR: AdoShell®, a Nonfibrotic Encapsulation System, Enables Stem Cell-Derived Islets In Vivo Maturation for T1DM Treatment","Ouardane Jouannot","2025","Diabetes","preclinical","article","10.2337/db25-139-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033037","Evaluating the effectiveness and safety of empagliflozin versus liraglutide in managing diabetic dyslipidemia: An observational study","Motakatla Usha Rani","2024","Asian Journal of Medical Sciences","other","article","10.3126/ajms.v15i7.65428",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033038","1677-P: Identification of a Chromosome 1 Substitution Line B6-Chr1YP1 as a Novel Obesity Model via Phenotyping Screening","Qi Hao","2023","Diabetes","preclinical","article","10.2337/db23-1677-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033039","1786-P: The New Insulin Sensitizer MSDC-0602K Synergizes with the GLP-1 Receptor Agonist Liraglutide","Kelly D. Pyles","2020","Diabetes","preclinical","article","10.2337/db20-1786-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033040","849-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of an Optimized Dual GLP-1/GIP Receptor Agonist (BGM0504) in Healthy Subjects—A Phase Ia, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study","Jiandong Yuan","2024","Diabetes","randomized_trial","article","10.2337/db24-849-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033041","1661-P: Petrelintide (ZP8396) Selectively Reduces Intake of High-Fat Diet in DIO Rats","Bill Vestergaard","2024","Diabetes","other_trial","article","10.2337/db24-1661-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033042","181-OR: Declining eGFR over Time Predicts the Risk of a Composite of Primary or Secondary Major Adverse Cardiovascular Events or Heart Failure Hospitalization, in People with Type 2 Diabetes—EXSCEL Post Hoc analysis","Abderrahim Oulhaj","2024","Diabetes","other_trial","article","10.2337/db24-181-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033043","1955-P: GLP-1R Activation Attenuates Prostate Cancer Growth via Inhibiting Cell Cycle Progression","Toru Shigeoka","2019","Diabetes","other_trial","article","10.2337/db19-1955-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033044","1810-P: Effect of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models","KIM WONKI","2019","Diabetes","preclinical","article","10.2337/db19-1810-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033045","The Revolutionary Role of GLP-1 Agonists and SGLT-2 Inhibitors in Managing Diabetes and Chronic Kidney Disease in Liver Transplant Recipients","Shankar Chakkera","2024","Medical Research Archives","other","article","10.18103/mra.v12i10.6002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033046","Lettere al Direttore","ARCA Umbria","2021","Cardiologia Ambulatoriale","other","article","10.17473/1971-6818-2021-1-10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033047","The comparative study with lixisenatide /glargine combination therapy versus twice-daily premixed insulin therapy/DPP-4 inhibitor on glycemic variability, and feeding behavior in obese patients with type 2 diabetes mellitus","Fumihiro Ochi","2018","Health and Primary Care","other","article","10.15761/hpc.1000149",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033048","This Month in: Anesthesiology",null,"2017","Anesthesiology","randomized_trial","article","10.1097/aln.0000000000001924",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0033049","The Ozempic Phenomenon: Linguistic Representations of Weight Issues in the Spanish Press","J Marta Moreno","2026","Journal of Language and Discrimination","nonrandomized_study","article","10.3138/jld-2025-0013",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033050","Navigating GIP/ GLP-1 pathophysiology and compounding impacts on T2DM care","Tania Tofail","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other","article","10.3329/jacedb.v4i20.84903",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033051","Update on gut hormone-based diabesity treatment","Mafauzy Mohamed","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other","article","10.3329/jacedb.v4i20.84877",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033052","Impactos do tratamento com liraglutida na progressão da doença renal crônica em pacientes com diabetes mellitus tipo 2","Vitor Augusto Lima do Vale","2020","Brazilian Journal of Health Review","other","article","10.34119/bjhrv3n4-362",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033053","Dulaglutide For effective diabetes management","Claude Khan","2019","Diabetes Updates","other","article","10.15761/du.1000123",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033054","Journal of Diabetes NEWS",null,"2014","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12219",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0033055","Trending topics in diabetes: Curbing sugar intake in kids, liraglutide benefits, DPP study","Maria G. Tanzi","2016","Pharmacy Today","other","article","10.1016/j.ptdy.2016.09.013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033056","Beyond glycemic control: The role of Tirzepatide in MASLD and OSA management","Md Masud Un Nabi","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other","article","10.3329/jacedb.v4i20.84905",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033057","A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus","Aashish Samat","2010","Clinical Medicine Insights Therapeutics","nonrandomized_study","article","10.4137/cmt.s3489",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0033058","Weight-Loss “Anti-Obesity” Medications Remain Inaccessible to Demographics Who Truly Need Them","Fhasal Alam","2024",null,"other","article","10.56927/897463",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033059","Moving Mountains of A1c and Weight in T2D with oral GLP-1RA – More is More","Norlela Sukor","2024","International Journal of Human and Health Sciences (IJHHS)","nonrandomized_study","article","10.31344/ijhhs.v8i20.650",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0033060","A Shot in the Dark: The Paradoxical Effects of GLP-1 Receptor Agonists on Rotator Cuff Disease and Surgical Outcomes","Cordelia Ko","2026","Galter Health Sciences Library, Northwestern University","nonrandomized_study","article","10.18131/tt7z0-7bx51",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033061","Phase III retatrutide study demonstrates 30% weight loss",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other_trial","article","10.1211/pj.2026.1.413195",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033062","Utilization of GLP-1 Receptor Agonists in Adults without Diabetes to Reduce Cardiovascular","Courtney Legendre","2026","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033063","Glucagon-Like Peptide-1 Receptor Agonist Therapy for Failed Weight Loss Surgery","Sean Bannister","2026","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0033064","Glucagon-like Peptide-1 and Sodium-glucose Cotransporter-2 in the Treatment of Chronic Kidney Disease in Patients Without Diabetes","Haley, Dylan J, PA-C","2026","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033065","Function and Purpose of Patent Compulsory Licensing","Yu. Z. Ozmanyan","2026","Juridical Science and Practice","other","article","10.25205/2542-0410-2026-22-1-48-55",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033066","Efficacy and Safety Analysis of Polyethylene Glycol Loxenatide in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease","啸宇 王","2026","Advances in Clinical Medicine","other","article","10.12677/acm.2026.1652022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033067","Substandard and Falsified Medical Products, Devices, and Online Pharmacy Supply-Chain Security: Scoping Review with ☸SAIMSARA","SAIMSARA","2026","SAIMSARA Journal","nonrandomized_study","article","10.62487/saimsarab2913b49",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033068","Delayed wound healing and subcutaneous fat necrosis following total knee arthroplasty in patients receiving semaglutide: A clinical alert","Ozair Khan","2026","International Journal of Orthopaedics Sciences","other","article","10.22271/ortho.2026.v12.i5a.3954",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033069","The 2024 ESC Guidelines for Chronic Coronary Syndromes: A Paradigm Shift in Risk Stratification and Therapeutic Strategies","S. G. Raja","2025","British journal of healthcare and medical research","other","article","10.14738/bjhr.1202.18663",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033070","Highlighting the latest research: May 2026","Sarah McSharry","2026","British Journal of Cardiac Nursing","other","article","10.12968/bjca.2026.0029",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033071","Gustatory and Interoceptive Pathways Modulate Striatal Reward Circuits to Regulate Sugar Intake","L. Tellez","2026","MPG.PuRe (Max Planck Society)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0033072","Can you stomach it? A content analysis of TikTok videos and comments about weight loss with Ozempic","Jayna Lennon","2023","University of Chicago","other","article","10.6082/5125r-a0g05",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033073","PREVALENCE AND CARDIO–KIDNEY–METABOLIC PROFILES ACROSS AHA 2025 BLOOD PRESSURE CATEGORIES IN 32,046 ADULTS WITH TYPE 2 DIABETES IN A HIGH-RISK POPULATION","Khalid Ahmed","2026","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0001197524.73701.cb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033074","METHODS AND COMPOSITIONS FOR PREDICTING RESPONSE TO GLP-1 ANALOGS","Sindhu Rajan","2013","University of Chicago","other","article","10.6082/c7hg7-9pm49",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033075","Targeting neutrophil extracellular trap (NET) formation as a potential strategy against progression of metabolic diseases","Feng Chen","2025",null,"preclinical","article","10.32657/10356/214909",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033076","Use of GLP-1 receptor agonists and the risk of aspiration during general anesthesia - an analysis of pathophysiological mechanisms and clinical recommendations",null,"2026","Medical Sciences","other","article","10.53453/ms.2026.5.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033077","AQbD assisted UPLC method development and validation of tirzepatide in bulk and pharmaceutical dosage form","Sunitha Panthagada","2026","Journal of Applied Pharmaceutical Research","other","article","10.69857/joapr.v14i3.1914",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033078","Comparative Effectiveness of Metformin and Glucagon-like Peptide-1 Receptor Agonists in Patients With Abdominal Aortic Aneurysm and Type 2 Diabetes Mellitus","Fanru Shen","2026","Journal of Vascular Surgery","other","article","10.1016/j.jvs.2026.03.313",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033079","Successful Insulin Deprescribing in a Patient with Long-Standing Type 2 Diabetes using Super Low-Carbohydrate Diet Combined with Tirzepatide",null,"2026","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/208",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033080","Progress in the mechanism of the effects of antihyperglycemic agents on lipid metabolism","Wang Li","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.3969/j.issn.1674-8115.2026.05.015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033081","2631-P: Phase 1 Study and Modelling of a Novel Drug Delivery System for GLP-1RA with Lower Adverse Events and Higher Efficacy","YOUNGHWAN PARK","2026","Diabetes","randomized_trial","article","10.2337/db26-2631-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033082","2550-P: Enhanced Weight Loss when HTD1801 Is Combined with GLP-1RAs in DIO Mice","Ru Bai","2026","Diabetes","preclinical","article","10.2337/db26-2550-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033083","Gastroparesis: A Comprehensive Overview of Pathophysiology, Etiology, Diagnosis, and Multidisciplinary Management","Indunil Karunarathna","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20551892",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033084","2814-LB: A Monthly Amylin and GLP-1 Agonists Combination Injectable Enabled by Novel Single-Process Biodegradable Microsphere Manufacturing","Jinwoo Lee","2026","Diabetes","preclinical","article","10.2337/db26-2814-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033085","1822-P: Pharmacokinetic and Pharmacodynamic Profiles of GZR102 Injection, a Novel Once-Weekly Fixed-Ratio Combination of Insulin GZR4 and GLP-1 Analog Bofanglutide","YAN HUANG","2026","Diabetes","preclinical","article","10.2337/db26-1822-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033086","1843-P: Clinical Efficacy Study of Orlistat Combined with Liraglutide in Patients with Metabolic Syndrome-Associated Steatohepatitis (MASLD)","CHENDI ZHANG","2026","Diabetes","other","article","10.2337/db26-1843-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033087","2149-P: The Association between GLP-1 and GIP Hormone Levels in Early Pregnancy and Subsequent Gestational Weight Gain","SHALMALI S. BANE","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2149-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033088","1373-P: Significant Synergistic Effects in Diabetic Kidney Disease by HDM1010","RONGYAO ZHU","2026","Diabetes","preclinical","article","10.2337/db26-1373-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033089","2839-LB: A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats","JONATHAN DOUROS","2026","Diabetes","preclinical","article","10.2337/db26-2839-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033090","2871-LB: Menin Inhibitor Icovamenib Activates Mechanisms That Support Metabolic Health","Nida Tanataweethum","2026","Diabetes","preclinical","article","10.2337/db26-2871-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033091","1664-P: Discovery of Selective, Long-Acting Amylin Receptor Agonist for Obesity","Spring Zhao","2026","Diabetes","preclinical","article","10.2337/db26-1664-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033092","2583-P: Adipose-Specific Gαq Activation Synergizes with Gαs Signaling to Increase Energy Expenditure and Fat Loss in Diet-Induced Obesity","Athanasios Kondilis","2026","Diabetes","preclinical","article","10.2337/db26-2583-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033093","2552-P: Preclinical Proof of Concept of ZT009, a Novel Unimolecular Long-Acting GLP-1 and Amylin Receptor Agonist","Yuying Zhang","2026","Diabetes","preclinical","article","10.2337/db26-2552-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033094","1879-P: Beyond Insulin Alone: One-Year CGM Outcomes of Adjunctive Incretin-Based and SGLT2 Inhibitors Therapy in Type 1 Diabetes Using Open-Source Automated Insulin Delivery Systems","REEM ALSHAREEF","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1879-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033095","3075-LB: A Trispecific GLP-1/GIP/hGH Receptor Agonist Targeting Activin Type II Receptor Drives Selective Fat Mass Reduction","YOUNGJAE JEON","2026","Diabetes","preclinical","article","10.2337/db26-3075-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033096","2548-P: Petrelintide Elicits Distinct Effects on Eating Pattern and Maintains Locomotor Activity Compared with Semaglutide in Rats with Diet-Induced Obesity","ANNA KATRINA J. GRADEL","2026","Diabetes","randomized_trial","article","10.2337/db26-2548-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033097","2864-LB: TRPM4 Protein Is Required for Semaglutide (Ozempic)-Stimulated Insulin Secretion in Pancreatic Beta Cells","Henrique Cheng","2026","Diabetes","other","article","10.2337/db26-2864-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033098","1710-P: Fragility Fracture Risk among Patients with Type 2 Diabetes Initiating Treatment with GLP-1 Receptor Agonists vs. Sulfonylureas","Thaer Idrees","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1710-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033099","1673-P: ASC37 Oral Tablets, GLP-1R/GIPR/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies","Jianmin Wu","2026","Diabetes","preclinical","article","10.2337/db26-1673-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033100","Retatrutida como estratégia terapêutica emergente no tratamento da obesidade e do diabetes mellitus tipo 2","Gabriel Reis de Oliveira","2026","Revista fisio&terapia.","other_trial","article","10.69849/v83xr454",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0033101","2827-LB: First-in-Human Study of Oral GLP-1 Receptor Agonist RDSY1801","WEIPING JIA","2026","Diabetes","randomized_trial","article","10.2337/db26-2827-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033102","2662-P: IBI3046, an INHBE siRNA, Enables High Quality and Long-Lasting Weight Control in Preclinical Study","X Zhang","2026","Diabetes","preclinical","article","10.2337/db26-2662-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033103","2543-P: IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity","Ye Jiang","2026","Diabetes","other_trial","article","10.2337/db26-2543-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033104","2881-LB: Safety and Performance of a Fully Closed-Loop (FCL) Algorithm for Omnipod in Type 2 Diabetes: The EVOLUTION3 Study","LORI M. LAFFEL","2026","Diabetes","other","article","10.2337/db26-2881-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033105","3070-LB: ABK-GIPR-1, an Oral Small-Molecule GIPR Antagonist, Enhanced GLP-1RA’s Efficacy in Reducing Body Weight and Improving Metabolic Profile in Preclinical Obesity Models","SHENGNAN LIU","2026","Diabetes","preclinical","article","10.2337/db26-3070-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033106","1204-OR: Phosphodiesterase-4B Constrains Cyclic AMP Levels and Drives Human β-Cell Dysfunction in Type 2 Diabetes","Geming Lu","2026","Diabetes","preclinical","article","10.2337/db26-1204-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033107","1663-P: Discovery and Development of CH3127, a Prodrug of Semaglutide for Once Weekly Oral Tablet Dosing","Spring Zhao","2026","Diabetes","preclinical","article","10.2337/db26-1663-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033108","1751-P: Efficacy and Safety of GLP-1 Receptor Agonists as Add-On Therapy to Insulin-Based Regimens in Adults with Type 1 Diabetes: A Systematic Review and Meta-Analysis","JOSE M. ZALDUMBIDE","2026","Diabetes","systematic_review","article","10.2337/db26-1751-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0033109","2544-P: INHBE-siRNA as a Promising Antiobesity Therapy: Preclinical Evaluation in Diet-Induced-Obesity Humanized INHBE Mice","HAO QI","2026","Diabetes","other_trial","article","10.2337/db26-2544-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033110","2657-P: Who Shapes the GLP-1 Narrative on TikTok: A Cross-Sectional Content Analysis","DANNA F. KASHLAN","2026","Diabetes","other","article","10.2337/db26-2657-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033111","2505-P: Mazdutide, a GCGR/GLP-1R Dual Agonist, Alleviates MASH and Liver Fibrosis through Hepatocytes–Hepatic Stellate Cells Cross Talk","Ling Feng Zhang","2026","Diabetes","randomized_trial","article","10.2337/db26-2505-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033112","2542-P: Generation of Humanized GCGR, GIPR, and GLP-1R Mice for Obesity and Diabetes Preclinical Research","HANNAH HORTON","2026","Diabetes","preclinical","article","10.2337/db26-2542-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033113","2553-P: Low Dose of Oral Mitochondrial Uncoupler Converts a Subefficacious Semaglutide Dose into a Durable, Fat-Selective Weight Loss Treatment in Obesity Model","MELISSA LUSE","2026","Diabetes","preclinical","article","10.2337/db26-2553-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033114","2659-P: Effect of GLP-1RA and Dual GIP/GLP-1 Agonist on Metabolic Parameters in Patients with Severe Obesity: Indian Real-World Evidence","PURVI CHAWLA","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2659-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033115","2649-P: Population-Normed Z-scores for Body Composition Enhance Sensitivity and Effect Size: Analysis of a Phase 2 RCT Testing Anti-GDF8 and Anti-Activin A on Top of Semaglutide (COURAGE)","QUANG NGUYEN","2026","Diabetes","other_trial","article","10.2337/db26-2649-p",null,null,"ClinicalTrials.gov:NCT06299098","S002384","openalex","FALSE","paywalled","5","FALSE","article"],["R0033116","2811-LB: Liraglutide-Modified BMSCs Ameliorate Osteoporosis in Type 2 Diabetic Rats","SONG GE","2026","Diabetes","preclinical","article","10.2337/db26-2811-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033117","1666-P: Orforglipron and Markers of Insulin Sensitivity and Beta-Cell Function by Prediabetes Status in Adults with Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial","CAROL WYSHAM","2026","Diabetes","randomized_trial","article","10.2337/db26-1666-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033118","2630-P: Societal Influences on Discontinuation of Weight Loss Medication: An Observational Study","JOTHYDEV KESAVADEV","2026","Diabetes","other","article","10.2337/db26-2630-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033119","2644-P: A Phase 3 Clinical Protocol Evaluating the Safety and Efficacy of NA-931 Alone and in Combination with Oral Semaglutide for the Treatment of Obesity","Lloyd Tran","2026","Diabetes","protocol","article","10.2337/db26-2644-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033120","3119-LB: Generation of a GLP1R-Knockdown EndoC-ßH5 Model to Elucidate Dual Incretin Signaling Mechanisms","Hamza Olleik","2026","Diabetes","preclinical","article","10.2337/db26-3119-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033121","2681-P: Functional Assessment of EndoC-βH5 Cells In Vivo as a Model for Type 1 Diabetes in Humanized Mice","Kiave Yune Ho Wang Yin","2026","Diabetes","preclinical","article","10.2337/db26-2681-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033122","2946-LB: A Survey on Challenges in Prescribing Medications and Technology for Diabetes Care","PATRICK MCALLISTER","2026","Diabetes","other","article","10.2337/db26-2946-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033123","1103-OR: GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats","HANNE HAAHR","2026","Diabetes","preclinical","article","10.2337/db26-1103-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033124","2609-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1 Receptor Agonist HDM1002 in Chinese Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial","XIAOYING LI","2026","Diabetes","randomized_trial","article","10.2337/db26-2609-p",null,null,"ClinicalTrials.gov:NCT06500299","S002483","openalex","FALSE","paywalled","1","FALSE","article"],["R0033125","2584-P: Durable and Exposure-Dependent Antiobesity Efficacy of IVL3021, a Once-Monthly Long-Acting Semaglutide in a Rat Diet-Induced Obesity Model","Ju Hee Kim","2026","Diabetes","preclinical","article","10.2337/db26-2584-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033126","2582-P: A Novel Class of Unimolecular Tetra-Receptor Agonists Decreases Food Intake and Improves Glucose Tolerance in Dietary Obese Mice","Tristan C. Dinsmore","2026","Diabetes","preclinical","article","10.2337/db26-2582-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033127","2949-LB: Glucagon-like Peptide 1 Receptor Agonist Use in Youth with Type 1 Diabetes Mellitus at an Academic Pediatric Medical Center","Erika Choi","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2949-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033128","1815-P: Efficacy and Safety of the GlP-1/GIP Dual Agonist HRS9531 in Overweight/Obese Chinese Patients with Polycystic Ovary Syndrome","Jingjing Li","2026","Diabetes","randomized_trial","article","10.2337/db26-1815-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033129","2832-LB: CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys","YA PEI","2026","Diabetes","other","article","10.2337/db26-2832-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033130","1410-P: Relative and Absolute Risk Reduction for MACE in Cardiovascular Outcomes Trials with GLP-1 Receptor Agonists in Female vs. Male People with Type 2 Diabetes","Young Hee Lee-Barkey","2026","Diabetes","other","article","10.2337/db26-1410-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033131","1676-P: Changes in Body Composition During and After Weight Loss with Tirzepatide","Evelyn Yandle","2026","Diabetes","randomized_trial","article","10.2337/db26-1676-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033132","2574-P: Discovery of RV-8451, a Novel, Oral, Muscle-Preserving Small Molecule GLP-1 Receptor Agonist","Sol Collado","2026","Diabetes","preclinical","article","10.2337/db26-2574-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033133","1665-P: Real-World HbA1c and Weight Change after 6 and 12 Months by GLP-1 Treatment Persistence in Adults with Type 2 Diabetes","JAIME ALMANDOZ","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1665-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033134","3061-LB: Combination Treatment of Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron and Small Molecule Amylin Receptor Agonist ACCG-2671 Demonstrated Additional Weight Loss than Monotreatment in Obese NHPs","方宪康","2026","Diabetes","other","article","10.2337/db26-3061-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033135","1988-P: Beyond Glycemic Control: Health-Related Quality-of-Life Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes","DAKSHATA A. PADHYE","2026","Diabetes","other","article","10.2337/db26-1988-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033136","2202-P: The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist in a Trial Inspired, and Wider, Population Individuals Living with Type 2 Diabetes: A Target Trial Emulation Study in CPRD","JONAH J.C. THOMAS","2026","Diabetes","randomized_trial","article","10.2337/db26-2202-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033137","3094-LB: FBL-140, a Best-in-Class ActR2A/B mAb Designed for Infrequent SC Dosing for Treatment of Obesity","Vanita D. Sood","2026","Diabetes","other_trial","article","10.2337/db26-3094-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033138","1791-P: Codelivery without Coformulation of Amylin Analog and GLP-1RA via a Shelf-Stable, Self-Applied Microarray Patch","Kathryn Kosuda","2026","Diabetes","preclinical","article","10.2337/db26-1791-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033139","19-PUB: Real-World Outcomes of Adjunct GLP-1 Receptor Agonist Therapy in Adults with Type 1 Diabetes: A Retrospective Cohort Study","SAVANNAH LIN","2026","Diabetes","nonrandomized_study","article","10.2337/db26-19-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033140","2049-P: Longitudinal Changes in Diabetes Care Delivery Before and During the COVID-19 Pandemic","HENG YEH","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2049-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033141","2594-P: XTL6001: A Novel Triple MasR/GCGR/GLP-1R Agonist for Weight Loss and Obesity-Related Complications","Ying Wang","2026","Diabetes","other_trial","article","10.2337/db26-2594-p",null,null,"ClinicalTrials.gov:NCT07205432",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033142","13-PUB: Semaglutide Reduces Risk of Adverse Limb Events among Patients with Diabetes and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis","PAULAMI DESHMUKH","2026","Diabetes","systematic_review","article","10.2337/db26-13-pub",null,null,"PROSPERO:CRD420251182802",null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0033143","2608-P: Efficacy and Safety of DA-302168S, a Novel Oral GLP-1 Receptor Agonist, in Chinese Adults with Overweight or Obesity: A Phase 2 Trial","LINONG JI","2026","Diabetes","randomized_trial","article","10.2337/db26-2608-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033144","2567-P: A Novel Humanized Glucagon-Like Peptide 1 Receptor Mouse Model for Translational Drug Development","Henrik H. Hansen","2026","Diabetes","preclinical","article","10.2337/db26-2567-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033145","1392-P: Metabolic Benefits of GLP-1RA and SGLT2i after Kidney Transplantation: A Real-World Experience","ARCHANA R. SADHU","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1392-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033146","2577-P: Differential Effects of Semaglutide, Tirzepatide, and Survodutide on Energy Expenditure in Obese Mice under Thermoneutrality","LINE ZACHARIASSEN","2026","Diabetes","randomized_trial","article","10.2337/db26-2577-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033147","1672-P: Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity","JINZI J. WU","2026","Diabetes","randomized_trial","article","10.2337/db26-1672-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033148","3104-LB: AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations","AUDREY MARECHAL","2026","Diabetes","preclinical","article","10.2337/db26-3104-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033149","1101-OR: A Novel Anti-Myostatin GLP-1RA Fusion Molecule to Preserve Muscle and Improve Body Composition during GLP-1 Therapy","Mohammed Alsuraih","2026","Diabetes","preclinical","article","10.2337/db26-1101-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033150","1714-P: Semaglutide, Tirzepatide, and Risk of Alcohol Use Disorder in Type 2 Diabetes: A Target Trial Emulation","HUILIN TANG","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1714-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033151","Real-World Clinical Outcomes of Liraglutide Therapy in Adolescents: A Six-Patient Case Series",null,"2026","Journal of Diabetes and Treatment","nonrandomized_study","article","10.29011/2574-7568.010161",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0033152","1690-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults","Huan Zhou","2026","Diabetes","randomized_trial","article","10.2337/db26-1690-p",null,null,"ClinicalTrials.gov:NCT07134127; ClinicalTrials.gov:NCT07170319",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033153","3062-LB: Comparison of Conditioned Taste Avoidance Profiles between GLP-1 Peptides, Amylin Peptides, and Small Molecule Amylin Receptor Agonists","方宪康","2026","Diabetes","preclinical","article","10.2337/db26-3062-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033154","4-PUB: Cardiovascular Benefits of GLP-1RA and SGLT2i across Different Populations","Morgan Brinson","2026","Diabetes","nonrandomized_study","article","10.2337/db26-4-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033155","1709-P: Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists Compared with Leptin in a Retrospective Study of Patients with Partial Lipodystrophy","BRANDON PODYMA","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1709-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033156","2857-LB: Glycemic Improvements with Icovamenib in T2D on Background GLP-1 Therapy: COVALENT-111 Subgroup Analysis","Juan P. Frías","2026","Diabetes","randomized_trial","article","10.2337/db26-2857-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033157","1890-P: Controlled Release without Initial Burst in High Drug-Loading Microspheres for Once-Monthly Obesity Treatment","JAEPYOUNG CHO","2026","Diabetes","other","article","10.2337/db26-1890-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033158","1411-P: Relative and Absolute Risk Reduction for MACE in Cardiovascular Outcomes Trials with GLP-1 Receptor Agonists in Type 2 Diabetes Patients with and without ASCVD at Baseline","MICHAEL A. NAUCK","2026","Diabetes","other","article","10.2337/db26-1411-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033159","1176-OR: State-Level Variation in Medicaid Diabetes Drug Access, Use, and Adherence in the United States, 2016–2023","MARIA L. ALVA","2026","Diabetes","other","article","10.2337/db26-1176-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033160","Combination therapy with glucagon-like peptide 1 analogs and insulin: Indications and contraindications in cardiopathic patients","Sesti G","2012","IRIS Research product catalog (Sapienza University of Rome)","other","article","10.1714/1203",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033161","1271-OR: Long Noncoding RNA SNHG6 Reduces Cytokine-Induced Human β-Cell Immunogenicity and Death","Geming Lu","2026","Diabetes","other","article","10.2337/db26-1271-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033162","Evaluation of the Cardioprotective Effects of Liraglutide versus Empagliflozin in Experimentally Induced Myocardial Infarction in Diabetic Rats","Nasr N. Makar","2026","Benha Medical Journal","preclinical","article","10.21608/bmfj.2026.441272.2770",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033163","Comparative Effectiveness of GLP-1 Agonists Versus Continuous Positive Airway Pressure in Reducing Symptoms and Improving Outcomes for Adults with Obstructive Sleep Apnoea: A Literature Review","Sanjin Bajgoric","2026","SAS Journal of Medicine","randomized_trial","article","10.36347/sasjm.2026.v12i06.005",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033164","USO RACIONAL DO OZEMPIC (SEMAGLUTIDA) NO TRATAMENTO DO DIABETES MELLITUS TIPO 2: UMA REVISÃO DE LITERATURA SOBRE EFICÁCIA, SEGURANÇA E BENEFÍCIOS METABÓLICOS","Gabriel Sousa Silva","2022","Editora Science eBooks","other","article","10.56001/22.9786500466386.28",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033165","1324-OR: A β-klotho Antibody Conjugated to GLP-1/GCG/GIP Triple Agonist Demonstrates Robust Body Weight Reduction and Metabolic Improvement in Obese Rodents and Nonhuman Primates","Haixia Zou","2026","Diabetes","preclinical","article","10.2337/db26-1324-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033166","Cardiometabolic Features of Remodeling of the Cardiovascular System when Using Semaglutide in Patients with Obesity and Diabetes Mellitus Type 2","A.Z. Ismailova","2026","Effective Pharmacotherapy","randomized_trial","article","10.33978/2307-3586-2026-22-11-34-38",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033167","Cardiovascular Complications in Type 2 Diabetes Mellitus: Current Possibilities of Cardioprotective Therapy","M.V. Makarovskaya","2026","Effective Pharmacotherapy","randomized_trial","article","10.33978/2307-3586-2026-22-11-50-57",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033168","Análogos de GLP-1 no manejo da obesidade: avaliação dos efeitos clínicos","Arthur Garcia Satte Alam Souza","2026","Brazilian Journal of Health Review","other","article","10.34119/bjhrv9n3-087",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033169","Dual GIP/GLP-1 Receptor Agonist Tirzepatide – a New Peak of Incretin-Based Therapy","I.V. Glinkina","2026","Effective Pharmacotherapy","other","article","10.33978/2307-3586-2026-22-12-26-36",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033170","Copper Deficiency Myelopathy As A Nutritional Complication of GLP-1/GIP Receptor Agonist Therapy: A Case Report (P3-7.009)","Clay Willis","2026","Neurology","case_report","article","10.1212/wnl.0000000000215653",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033171","GLP-1 Receptor Agonists and Neurological Outcomes in Patients With Brain Tumors: A Real-world Propensity-matched Cohort Study (S28.010)","Seerat Sachdeva","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000217764",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033172","GLP-1 Receptor Agonist Use Associated With Greater Physical Activity and Improved Patientreported Outcomes in Multiple Sclerosis: A Single-site Retrospective Cohort Study (P1-20.009)","Karl Heward","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000215503",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033173","GLP-1 Receptor Agonists in Migraine: Variable Clinical Outcomes in a Retrospective Cohort (P10-15.018)","Michelle Nguyen","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000213258",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033174","Synergistic and Distinct Central Effects of Dapagliflozin and Exenatide on Brain Networks Intrinsic Connectivity in Obesity and Type 2 Diabetes: A Randomized Controlled Trial (P1-13.001)","Jonadab dos Santos Silva","2026","Neurology","randomized_trial","article","10.1212/wnl.0000000000217682",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033175","Glycemic status, adiposity indices and cardiovascular risk in chronic kidney disease: Core findings from a nationwide cohort study","Yan-Hui Shi","2026","World Journal of Diabetes","nonrandomized_study","article","10.4239/wjd.117740",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0033176","Significant Sensorimotor Polyneuropathy Caused by Dry Beriberi Secondary to Semaglutide-associated Thiamine Deficiency (P3-9.004)","Chloe Cohan","2026","Neurology","other","article","10.1212/wnl.0000000000215813",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033177","Semaglutide","Pius Fasinu","2026","Elsevier eBooks","other","article","10.1016/b978-0-443-44037-3.00458-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033178","Liraglutide and Cardiovascular Outcomes in Diabetes (LEADER)-2016","Gabriella Petrongolo","2023",null,"other","article","10.1007/978-3-031-25620-2_21",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033179","A spotlight on digestive health",null,"2024","Nursing Made Incredibly Easy!","other","article","10.1097/nme.0000000000000082",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033180","GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX","Wen-Teng Lee","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025rdy8v05v",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033181","Findings on weight‐loss drugs offer hope, but caution needed","Gary Enos","2024","Alcoholism & Drug Abuse Weekly","randomized_trial","article","10.1002/adaw.34334",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033182","Role of Incretin Mimetics in the Management of Obesity","Shilpa Chugh Garcha","2025",null,"other","article","10.1007/978-981-96-1651-0_4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033183","Journal Scan","Tanvi Bindal","2024","Asian Journal of Pediatric Nephrology","randomized_trial","article","10.4103/ajpn.ajpn_22_24",null,null,"ClinicalTrials.gov:NCT04564339; ClinicalTrials.gov:NCT06291376",null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033184","2094-P: The Effects of Glucagon-Like Peptide 1 Receptor Agonists on Body Composition in Youth-Onset Type 2 Diabetes: Six-Month Outcomes","LISA R. SCHAAF","2026","Diabetes","other","article","10.2337/db26-2094-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033185","Cardiovascular Effects of GLP-1 Analogues","Lucio Amoresano","2025",null,"other","article","10.1007/978-3-032-01700-0_15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033186","Tirzepatide for Obesity-2022","Christian Iversen","2023",null,"other","article","10.1007/978-3-031-25620-2_46",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033187","Multi‐target Peptides for the Treatment of Metabolic Diseases","Martin Bossart","2024",null,"other","article","10.1002/9781394182862.ch20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0033188","How Effective are Gliflozins as DPP-4 Inhibitors? A Computational Study","Kunika Saini","2023","Theoretical Foundations of Chemical Engineering","other","article","10.1134/s0040579523030168",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033189","MHRA approves semaglutide oral tablets for weight loss",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.415903",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033190","Information on semaglutide and compounding","Alison Knopf","2024","The Brown University Child & Adolescent Psychopharmacology Update","other","article","10.1002/cpu30881",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033191","A Rare Case of Metformin-Associated Lactic Acidosis with Concurrent Euglycemic Ketoacidosis in a Patient with Type 2 Diabetes","Harsha Adnani","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025ba93bpm3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033192","The Effect of Sitagliptin and Exenatide on Insulin, Insulin Receptor and Insulin Receptor Substrate Gene Expression in Diabetic Rats","Metin Yıldırım","2023","Russian Journal of Bioorganic Chemistry","preclinical","article","10.1134/s1068162023030275",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033193","Bariatric surgery the best potential treatment for nonalcoholic fatty liver disease (NAFLD)","Burhanuddin Sohail Rangwala","2023","International Journal of Surgery Global Health","randomized_trial","article","10.1097/gh9.0000000000000168",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033194","L’ élécoglipron, un concurrent pour les GLP1-RA vedettes","Yann-Mickael Dalmat","2026","Option/Bio","other","article","10.1016/s0992-5945(26)74978-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033195","Welcome to the Ozempic era",null,"2025","The New Scientist","other","article","10.1016/s0262-4079(25)00482-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033196","Association of Dexcom Continuous Glucose Monitor (CGM) Initiation with Improved Kidney Function in Adults with Diabetes and CKD on Insulin Therapy","Katia Hannah","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20250bjqr2tv",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033197","Keyword Index",null,"2023","Journal of the Chinese Medical Association","randomized_trial","article","10.1097/01.jcma.0000998236.52367.df",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033198","Shop Talk",null,"2023","Oncology Times","other_trial","article","10.1097/01.cot.0000990276.66917.c6",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033199","Targeting Podocytopathy: Liraglutide Restores Podocyte Adhesion Homeostasis via GLP1R-CD151-Dependent Integrin Signaling in FSGS","Ying Fan","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2025r3y9b8cg",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033200","Drug News",null,"2025","Nursing","other","article","10.1097/nsg.0000000000000235",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033201","A New Era in Kidney Disease Treatment? Rapid Adoption of SGLT2 Inhibitors and GLP-1 Receptor Agonists Signals Shifting Paradigms","Jennifer Lafave","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025wtenjrxa",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033202","Outcomes of Automatic E-Consults in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Rural Veterans with CKD","Amara Sarwal","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025ksby0c2g",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033203","Risiko durch GLP-1-Rezeptor-Agonisten vor Endoskopie und Narkoseeinleitung","MICHAEL A. NAUCK","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2607-5520",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033204","Safety Profile of SGLT2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) Use in Patients with CKD","Iqra Nawaz","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20244hrvkhs9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033205","Exposure to Glucagon-Like Peptide 1 Receptor Agonists Does Not Increase the Risk of AKI Associated with Anticancer Therapy","Swetha Rani Kanduri","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024x8y8t8d2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033206","High-Impact Clinical Trials and Studies",null,"2025","Journal of the American College of Surgeons","randomized_trial","article","10.1097/xcs.0000000000001600",null,null,"ClinicalTrials.gov:NCT03636893; ClinicalTrials.gov:NCT04616131; ClinicalTrials.gov:NCT01022567",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033207","One drug makes you larger, and one drug makes you small: GLP-1 Drug Misuse, Risk Beliefs, and Polypharmacy in Sport and Exercise Populations","L. Lazuras","2025","Emerging Trends in Drugs Addictions and Health","other","article","10.1016/j.etdah.2025.100238",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033208","Renoprotective Effect of a GLP-1 Receptor Agonist, Liraglutide, in an Early Phase of Diabetic Kidney Disease in Spontaneously Diabetic Tori Fatty Rats","Shohei Yamada","2020","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20203110s1317d",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033209","IgA Vasculitis Triggered by Semaglutide","Mayssaa Hoteit","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025nmjavktd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033210","Study finds semaglutide not associated with higher risk of suicidality",null,"2024","The Brown University Psychopharmacology Update","nonrandomized_study","article","10.1002/pu.31149",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033211","Ozempic on the brain","Simar Bajaj","2024","The New Scientist","other","article","10.1016/s0262-4079(24)01105-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033212","Gaps in CKD Awareness Among People with Type 2 Diabetes","Matthew Garza","2021","Journal of the American Society of Nephrology","other","article","10.1681/asn.20213210s1266c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033213","GLP-1 RECEPTOR AGONIST: ANTI- INFLAMMATORY PROPERTIES AND MOLECULAR EFFECTS BEYOND GLUCOSE REGULATION","Foizunnesa Eva","2026",null,"other","article","10.13140/rg.2.2.30583.79524",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033214","Kommentar zu Insulindosis-Reduktion unter Semaglutid bei Typ-1-Diabetes und Adipositas","Robert A. Ritzel","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2855-8818",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033215","Pipeline of Pharmacotherapy in Parkinson’s Disease","Florian Brugger","2025","Cambridge University Press eBooks","other","article","10.1017/9781108989855.026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033216","Drug News",null,"2025","Nursing","other","article","10.1097/nsg.0000000000000288",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033217","FDA requests removal of suicide warnings from two GLP‐1 labels",null,"2026","The Brown University Child & Adolescent Psychopharmacology Update","other","article","10.1002/cpu.31056",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033218","Role of Glucagon-like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy","J Finkle","2026","Obstetric Anesthesia Digest","other","article","10.1097/01.aoa.0001178604.09431.82",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033219","GLP-1 Receptor Agonist Therapy Shields the Heart from Renal Fibrosis in Cardiorenal Syndrome","Chia Ying Lee","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2025dj3cb311",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033220","Highlights","Jong‐Ling Fuh","2025","Journal of the Chinese Medical Association","other","article","10.1097/jcma.0000000000001267",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033221","Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) Delays Cyst Growth in ADPKD","Jiao Wu","2024","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2024nt9gak2z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033222","Role of Normal Protein Catabolic Rate (nPCR) in Predicting Weight Loss among Patients on Hemodialysis Treated with Tirzepatide","Jyunichiro Hashiguchi","2024","Journal of the American Society of Nephrology","other","article","10.1681/asn.20246y1q8yjp",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033223","Glucagon-Like Peptide 1 Receptor Agonist Attenuates Cardiovascular Injury Caused by Renal Fibrosis","Ping-Chi Tsai","2024","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2024y0afdd02",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033224","Tirzepatide","Warren Froelich","2024","Oncology Times","randomized_trial","article","10.1097/01.cot.0001026248.04310.16",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033225","FDA Approving Drugs After Fewer Trials With Less Public Disclosure",null,"2023","Oncology Times","randomized_trial","article","10.1097/01.cot.0000978992.77433.22",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033226","Obesity-Related Glomerulopathy with Kidney Function Improvement Following Bariatric Surgery and Lisinopril Therapy","Wenxia Lu","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.202586swk222",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033227","Are GLP-1 Receptor Analogues Safe in Patients with CKD?","Zehra Raza Zaidi","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025pdh4epct",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033228","Utilization of Glucose-Lowering Medications Among US Medicare Beneficiaries with CKD Between 2007 and 2016","Julie Zhao","2020","Journal of the American Society of Nephrology","other","article","10.1681/asn.20203110s1351d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033229","Impact of Implementation of a Renal Diabetes Multidisciplinary Team Clinic in District General Hospital","Senthilkumar Krishnasamy","2022","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20223311s1914d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033230","Advancing the Science of Insulin Resistance in Type 2 Diabetes","Sanjeeb Kakati","2024","Assam Journal of Internal Medicine","nonrandomized_study","article","10.4103/ajoim.ajoim_28_24",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0033231","Prescription Errors in the Management of Type 2 Diabetes Mellitus","Joydeep Mukherjee","2024","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_40_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033232","SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplantation: Systematic Review and Meta-Analysis","Sul A Lee","2025","Journal of the American Society of Nephrology","systematic_review","article","10.1681/asn.2025pqbtg0tr",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0033233","Semaglutide-Induced Severe AKI Requiring Hemodialysis","Boris Livitz","2024","Journal of the American Society of Nephrology","other","article","10.1681/asn.20246erwaqv4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033234","Symptoms: Abdominal Pain, Fever, Chills, Nausea, Loose Stools","Marissa Koning","2024","Emergency Medicine News","other","article","10.1097/01.eem.0001027796.05658.4e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033235","Taming the hunger hormones","Alice Butzlaff","2024","Nursing Made Incredibly Easy!","other","article","10.1097/nme.0000000000000075",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033236","Medication Adherence to SGLT2 Inhibitors vs. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Meta-Analysis","Whitney B. Sussman","2024","Journal of the American Society of Nephrology","systematic_review","article","10.1681/asn.20245w2bgaw1",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0033237","Ozempic has heart health benefits","Michael Le Page","2025","The New Scientist","other","article","10.1016/s0262-4079(25)00049-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033238","Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia",null,"2026","The Brown University Psychopharmacology Update","randomized_trial","article","10.1002/pu.31414",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033239","Combined Effects of GLP-1 Receptor Agonist and SGLT2 Inhibitor on Inflammatory Modulation in Hypoxia-Induced Renal Tubular and Endothelial Cell Injury","Juliana Lopez de Oliveira","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025bf0ra9ez",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033240","More Questions than Answers about Injectable Weight Loss Drugs","Leon Gussow","2023","Emergency Medicine News","other_trial","article","10.1097/01.eem.0000945404.71459.8a",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033241","GLP-1 Drug and Ethanol Interactions Much More Complicated Than Imagined","Leon Gussow","2026","Emergency Medicine News","nonrandomized_study","article","10.1097/01.eem.0000000000000205",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033242","Metabolic Liver Disease and Obesity at a Therapeutic Crossroads: From Lifestyle Interventions to Incretin-based Pharmacotherapy","Demosthenes Panagiotakos","2025","Journal of Atherosclerosis Prevention and Treatment","randomized_trial","article","10.4103/aptj.aptj_26_26",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033243","Prediction of the in vivo pharmacokinetics of sustained-release injections for semaglutide by a novel ivivc model combined with DoE","Joonhee Kim","2025","Drug Metabolism and Pharmacokinetics","other","article","10.1016/j.dmpk.2025.101387",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033244","Research Highlights","Xunrong Luo","2023","Transplantation","randomized_trial","article","10.1097/tp.0000000000004547",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033245","Before Adopting AI, Change the Language Used with Patients","Mark Mosley","2024","Emergency Medicine News","other","article","10.1097/01.eem.0001050604.86165.2c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033246","Tirzepatide Improves Glycemic Control Better than Dulagutide in Patients Undergoing Hemodialysis","Emiko Otsuka","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20246zjscmkf",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033247","Drug News",null,"2024","Nursing","other","article","10.1097/01.nurse.0001007592.91096.52",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033248","GLP-1 Receptor Agonists and Serious Adverse Events of Hyperkalemia/Hypokalemia: Systematic Review and Meta-Analysis","Samveg Shah","2025","Journal of the American Society of Nephrology","systematic_review","article","10.1681/asn.2025wm57tqrv",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0033249","Hypothesis Epigenetic Entrenchment of SERPINE1 as a Fibrinolytic Ratchet in Osteoarthritis: A Framework for GLP-1 Intervention and Reanalysis Target in Existing Methylome Data","Chatgpt claude","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20693093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033250","Wegovy averts heart attacks – will this widen use?","Clare Wilson","2023","The New Scientist","other","article","10.1016/s0262-4079(23)02118-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033251","Utilization Trends of Tirzepatide, Glucose-Lowering Medications, and Anti-obesity Medications in Patients with CKD with and without Type 2 Diabetes","Panupong Hansrivijit","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024vtsjzr0s",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033252","Ketamine's Benefits for Acute Severe Asthma",null,"2024","Emergency Medicine News","other","article","10.1097/01.eem.0001069252.84987.fc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033253","An Assortment of Journal Abstracts to Enhance Oncology Care",null,"2025","Oncology Times","nonrandomized_study","article","10.1097/01.cot.0000000000000293",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033254","Drug News",null,"2026","Nursing","other","article","10.1097/nsg.0000000000000385",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033255","Semaglutide-Induced Lithium Toxicity in a Patient Being Treated for CKD","Jose J Arriola Montenegro","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025wy2bkz1h",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033256","Mechanistic Role of GLP-1 Receptor Agonists in Suppressing Adenine-Induced Fibrotic Signaling Independent of Weight Loss","Falguni Das","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20257feye09n",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033257","Target Emulation Trial of GLP-1 Receptor Agonists (GLP-1 RA), SGLT2 Inhibitors (SGLTi), or Dipeptidyl-Peptidase 4 Inhibitors (DPP4i) as Add-On Therapy in Primary Prevention of Kidney Outcomes Among Older Veterans","Adriana M. Hung","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025xn97dn13",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033258","Going with the FLOW: A Large Registry Study on Semaglutide and the Risk of Kidney Complications in Patients with Early Diabetic Kidney Disease","Genya Aharon‐Hananel","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20254cepk3st",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033259","Drug News",null,"2024","Nursing","other","article","10.1097/nsg.0000000000000073",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033260","Science, Medicine, and the Anesthesiologist",null,"2024","Anesthesiology","randomized_trial","article","10.1097/aln.0000000000005193",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033261","Associations Between Antidiabetes Medications and Mortality in Patients on Dialysis: A National Study from Taiwan","Szu‐Yu Pan","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025940qe8e6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033262","AAPS 2025 Annual Meeting Abstracts Supplement Table of Contents",null,"2025","Plastic & Reconstructive Surgery Global Open","randomized_trial","article","10.1097/gox.0000000000006712",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033263","The Intertwined Fate of Liver and Heart: Unravelling the Complex Relationship between Metabolic Dysfunction-associated Steatotic Liver Disease and Coronary Artery Disease","Ajeet Singh Bhadoria","2025","Journal of Medical Evidence","other","article","10.4103/jme.jme_18_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033264","PSTM 2024 Abstract Supplement Table of Contents",null,"2024","Plastic & Reconstructive Surgery Global Open","nonrandomized_study","article","10.1097/gox.0000000000006124",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0033265","Liraglutide, a GLP-1 Receptor Agonist, Improves Metabolic Profile and Kidney Function in a Rat Model of Obesity-Induced Kidney Injury","Juliana Lopez de Oliveira","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2025z514be0y",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033266","Ophthalmic Surgery",null,"2025","Journal of the American College of Surgeons","nonrandomized_study","article","10.1097/xcs.0000000000001562",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033267","Like Antibiotics, GLP-1 Agonists Ease Suffering","Ryan Richman","2023","Emergency Medicine News","other","article","10.1097/01.eem.0001004684.25518.ed",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033268","GLP-1 Receptor Agonist Ameliorates Cognitive Impairment Following Long-Term AKI","Young Eun Choi","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2025pdrh70e3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033269","What Emergency Practitioners Should Know About the New Weight-Loss Drugs","Leon Gussow","2025","Emergency Medicine News","other","article","10.1097/01.eem.0000000000000129",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033270","Tirzepatide versus Dulaglutide in Type 2 Diabetes Mellitus: Cardiovascular Insights from SURPASS-CVOT and Relevance to South Asian Populations","Ahmad Alam","2026","Bangladesh Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/bjem.bjem_11_26",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033271","Dermatite granulomateuse interstitielle lors d’un traitement par le dulaglutide","Georgio Chidiac","2024","Annales de Dermatologie et de Vénéréologie - FMC","other","article","10.1016/j.fander.2024.09.110",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033272","PSRC 2025 Annual Meeting Abstracts Supplement Table of Contents",null,"2025","Plastic & Reconstructive Surgery Global Open","nonrandomized_study","article","10.1097/gox.0000000000006665",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0033273","Do Ozempic and Wegovy really cause hair loss?","Grace Wade","2025","The New Scientist","other","article","10.1016/s0262-4079(25)00584-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033274","Why is the Wegovy weight-loss treatment so hard to get hold of?","Clare Wilson","2023","The New Scientist","other","article","10.1016/s0262-4079(23)01677-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033275","Toxicology Rounds","Leon Gussow","2021","Emergency Medicine News","other","article","10.1097/01.eem.0000795832.50340.e7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033276","The Myth that Metronidazole and Alcohol Cause a Disulfiram-Like Reaction","Leon Gussow","2023","Emergency Medicine News","nonrandomized_study","article","10.1097/01.eem.0000990104.46586.c8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033277","The discovery and development of human GLP-1 analogues","Thomsen Mads Krogsgaard","2026","Elsevier eBooks","other","article","10.1016/b978-0-443-33287-6.00007-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033278","Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists","Naveed Amjid Sattar","2026","Elsevier eBooks","other","article","10.1016/b978-0-323-87862-3.00013-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033279","When IgA Strikes Twice: The Battle Beyond Transplant","Salwa Khan","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.20253ng0zed7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033280","Cardiovascular–Kidney–Metabolic Syndrome: Untangling the Interconnected Burden","Y. J. Anupama","2025","Indian Journal of Kidney Diseases","nonrandomized_study","article","10.4103/ijkd.ijkd_35_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0033281","The most promising novel drug options for metabolic dysfunction-associated steatotic liver disease","Haixia Cao","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.16138/j.1673-6087.2026.02.02",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033282","Understanding the Off-Label Use of Semaglutide-Based Products: A Dual Analysis of Online Discourse and Scientific Literature","A. Carollo","2025","Emerging Trends in Drugs Addictions and Health","other","article","10.1016/j.etdah.2025.100205",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033283","Semaglutide Improves Kidney Function and Inflammatory Status in a Mouse Model of Glomerulonephritis","Günaj Rakipovski","2024","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20241xnj938n",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033284","Gastroenterology Elsewhere","Kayalvizhi Jayaraman","2024","Gastroenterology Hepatology and Endoscopy Practice","randomized_trial","article","10.4103/ghep.ghep_17_24",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0033285","GLP-1RAs Improve Lung Cancer Outcomes and Tumor Growth Control","Candy Goulette","2025","Oncology Times","randomized_trial","article","10.1097/01.cot.0000000000000234",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033286","Trends and Comorbidities of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Kidney Transplant Recipients: A Cross-Sectional Analysis","Meron B. Zeleke","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.20258fx6762z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033287","The Neuroprotective Potential of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Cognition and Dementia: A Comprehensive Systematic Review and Meta-Analysis","Miran Kamil","2026",null,"systematic_review","article","10.13140/rg.2.2.25321.25448",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033288","HPLC Method for Simultatienous Estimation of Tirzepatide Using Analytical Qbd","REVATI WALEKAR REVATI WALEKAR","2026","INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT","other","article","10.55041/ijsrem65025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033289","Impact of Obesity on Male Fertility and the Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists: Analytical Review","S.V. Bogolyubov","2026","Russian Medical Inquiry","narrative_review","article","10.32364/2587-6821-2026-10-4-10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033290","Analisi economica di exenatide rispetto a liraglutide nei pazienti con diabete di tipo 2: costo-efficacia e budget impact","C. Oliveri","2010","Giornale Italiano di Health Technology Assessment","other","article","10.1007/bf03320735",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033291","A YouTube-Based Discourse Analysis of Self-Directed Dose Adjustment Patterns Among GLP-1 Receptor Agonists and Their Implications for Quality of Life","제주한라대학교 간호학과 부교수","2026","Quality of Life Research","other","article","10.59434/jqolr.2026.4.3.18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033292","Ozempic: una analogía de la decadencia democrática","Raquel Rebeca Cordero Verdugo","2026","Fundación Muy Interesante","other","article","10.66806/fundacion_muyinteresante.623400",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033293","Diabetes and Weight Management","Mary Lou Perry","2026","American Diabetes Association eBooks","other","article","10.2337/9781580408493-ch13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033294","Maternal Obesity and Pregnancy: A Comprehensive Review of Epidemiology, Pathophysiology, Clinical Management, and Health Implications","Indunil Karunarathna","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.20719493",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033295","583 ASSOCIATION BETWEEN GLP-1 ANALOGUE USE AND RISK OF SMALL INTESTINAL BACTERIAL OVERGROWTH: A LARGE U.S. MULTI-CENTER PROPENSITY-MATCHED COHORT STUDY","Saqr Alsakarneh","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)05634-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033296","554 COMPARATIVE MICRONUTRIENT DEFICIENCY RISKS AFTER BARIATRIC SURGERY VERSUS GLP-1 RA THERAPY: A MULTICENTER RETROSPECTIVE COHORT ANALYSIS","Krishna Kothamasu","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04719-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033297","559 REAL WORLD GI SAFETY COMPARISON OF SEMAGLUTIDE AND TIRZEPATIDE: A PHARMACOVIGILANCE STUDY","Balkrishna Sapariya","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04724-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033298","184 EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON WEIGHT AND SKELETAL MUSCLE MASS IN PATIENTS WITH CIRRHOSIS","Diep N. Edwards","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03311-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033299","1993-LB: BGM1812, a Novel Amylin Analog, Enhances Receptor Agonism and Induces Superior Weight Loss in Preclinical Models","Jiandong Yuan","2025","Diabetes","preclinical","article","10.2337/db25-1993-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033300","Glucagon-Like Peptide-1 Analogue Exendin-4 Decreases Visceral Hypersensitivity by Increasing SERT Expression and 5-HT Reuptake","Ying Wang","2015","The American Journal of Gastroenterology","preclinical","article","10.14309/00000434-201510001-01776",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033301","261 ECONOMIC AND HEALTH OUTCOMES OF METABOLIC AND BARIATRIC SURGERY VS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR NONCIRRHOTIC MASLD AND OBESITY","Xianhua Mao","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03319-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033302","Sul8l4 ENDOSCOPIC MANAGEMENT OF OBESITY: COMPARATIVE OUTCOMES OF ENDOSCOPIC SLEEVE GASTROPLASTY, SEMAGLUTIDE, AND TIRZEPATIDE IN A MULTICENTER COHORT","Rubela Ray","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04830-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033303","553 COMPARATIVE RISK OF INTESTINAL OBSTRUCTION AND INTUSSUSCEPTION WITH GLP-1 RECEPTOR AGONISTS VERSUS SGLT2 INHIBITORS: A 984,000-PATIENT PROPENSITY-MATCHED COHORT STUDY","Eshan Nanda","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04271-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033304","1080 RESCUE STRATEGIES AFTER GLP-1RA DISCONTINUATION: SWITCHING TO ALTERNATIVE GLP-1RA VS ENDOSCOPIC GASTRIC REMODELING VS LIFESTYLE MODIFICATION ALONE","Pichamol Jirapinyo","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04746-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033305","488 IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON INCIDENCE OF HCC, LIVER DECOMPENSATION, TRANSPLANTATION AND NON-LIVER COMPLICATIONS IN PATIENTS WITH LIVER CIRRHOSIS","Rui Huang","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03332-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033306","186 EXPANDING GLP-1 THERAPY TO LIVER DISEASE: POPULATION-BASED ESTIMATES OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE ELIGIBILITY IN THE FRAMINGHAM HEART STUDY","Wissam Ghusn","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03313-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033307","B101-09 GLP1 Receptor Agonists and Respiratory Outcomes in Obese Adults With Asthma and Obstructive Sleep Apnea","C Ikwu","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.514",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033308","A72-12 Semaglutide and Cystic Fibrosis: Recognizing GI Interactions in Complex Physiology","G Kurian","2026","American Journal of Respiratory and Critical Care Medicine","other","article","10.1093/ajrccm/aamag162.2128",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033309","Disease-Modifying Therapies for Metabolic Dysfunction–Associated Steatohepatitis","CDA-AMC","2026","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2026.1459",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033310","Weight Drop and Foot Drop: A Case Series of Peroneal Neuropathy Associated With GLP-1 Agonist Use (P2-9.005)","Gautham Upadrasta","2026","Neurology","case_report","article","10.1212/wnl.0000000000216538",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033311","Preliminary National Survey of Surgeons’ Perspectives on Obesity Management Medications After Metabolic Bariatric Surgery in Taiwan","Po-Chih Chang","2026","Formosan Journal of Surgery","other","article","10.1097/fs9.0000000000000292",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033312","643 COMBINED TREATMENT WITH INTRAGASTRIC BALLOON AND TIRZEPATIDE FOR WEIGHT MANAGEMENT: A 12-MONTHS REAL-LIFE PROSPECTIVE COMPARATIVE STUDY","Salvatore Tolone","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04726-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033313","M0I8O9 COMPARATIVE OUTCOMES OF GLP-1 THERAPY VS BARIATRIC SURGERY IN PATIENTS WITH OBESITY AND CIRRHOSIS","Razan Aburumman","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04873-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033314","556 REAL-WORLD ANALYSIS OF SEMAGLUTIDE SIDE EFFECTS SHOWS CONSTIPATION IS ASSOCIATED WITH GREATER 12-MONTH BODY WEIGHT LOSS","Thomas W. Fredrick","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04721-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033315","GLP-1 Receptor Agonist Use is Associated with Reduced Post-stroke Mortality and Dementia: A National Matched Cohort Study (P8-13.003)","ibrahim abduljabbar","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000217181",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033316","574 THE GLP-1 ENDOSCOPY BURDEN STUDY: A SYSTEM-LEVEL ANALYSIS OF GLP-1RA-ASSOCIATED PREP FAILURE, CANCELLATIONS, AND U.S. COLONOSCOPY CAPACITY STRAIN","Nayanika Tummala","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)05434-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033317","772 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH AN INCREASED LONG-TERM RISK OF BILIARY PANCREATITIS","Waqas Rasheed","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)05001-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033318","A46-45 A Lung Whiteout That Contains a Dark Secret: Chylothorax as the First Manifestation of Lymphoma","M Rizvee","2026","American Journal of Respiratory and Critical Care Medicine","other","article","10.1093/ajrccm/aamag162.5966",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033319","970 GLP-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH AN INCREASED INCIDENCE OF GERD: RESULTS OF A 1:1 PROPENSITY MATCHED STUDY","Ayah Matar","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)01787-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033320","796 GLP-1 AGONISTS INCREASE NEOPLASTIC PHENOTYPES IN DNA MISMATCH REPAIR DEFICIENT COLORECTAL CANCER (CRC) CELLS: IMPLICATIONS FOR SCREENING STRATEGIES","Priya Roy","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)00666-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033321","1115 EFFECTS OF GLP-1 RECEPTOR AGONISTS ON GASTROINTESTINAL TRANSIT AND CAPSULE ENDOSCOPY OUTCOMES: SYSTEMATIC REVIEW AND META-ANALYSIS","RAYAN F. Alataa","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)05669-5",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0033322","1715-P: Discovery of a Novel Long-Acting Urocortin 2 Analog for Improving Body Composition in Obese Mice","Haixia Zou","2025","Diabetes","preclinical","article","10.2337/db25-1715-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033323","The Role of Community Pharmacists as Antimicrobial Stewards","Zahava R. S. Rosenberg-Yunger","2018","Journal of Public Health Management and Practice","other","article","10.1097/00124784-900000000-99451",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033324","The increase in semaglutide prescriptions in Slovenia","M. Brovč","2025","Clinical Nutrition ESPEN","other","article","10.1016/j.clnesp.2025.07.319",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033325","Dose-Dependent Efficacy of Tandospirone for an Oldest-Old Patient With Behavioral and Psychological Symptoms of Dementia","Shinichiro Ochi","2019","Journal of Clinical Psychopharmacology","other","article","10.1097/00004714-900000000-98616",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033326","New Diabetes Guidelines: Impact on Eligibility for SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Canada","Rebecca Bodoarca","2022","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2022.09.055",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033327","496 IMPACT OF GLP-1 RECEPTOR AGONISTS ON CLINICAL OUTCOMES IN ADULTS WITH PRIMARY BILIARY CHOLANGITIS","Guy Nguefang","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03340-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033328","Beyond glycemic control: Uncovering the anti-inflammatory power of GLP-1 receptor agonists in obesity","A. Szulc","2025","Clinical Nutrition ESPEN","other","article","10.1016/j.clnesp.2025.07.118",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033329","PEPTÍDEOS BIOATIVOS E REGULAÇÃO DO METABOLISMO ENERGÉTICO: EVIDÊNCIAS SOBRE CONTROLE DO PESO E SENSIBILIDADE À INSULINA – REVISÃO SISTEMÁTICA","Bruno Sander","2026","Revista Científica Ipedss","randomized_trial","article","10.55703/27644006060205",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033330","Potential of pharmacological modulation of level and activity of incretins in diabetes mellitus type 2","А. А. Спасов","2014","Biochemistry (Moscow) Supplement Series B Biomedical Chemistry","other","article","10.1134/s199075081404009x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033331","808 GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH REDUCED NEOPLASTIC PROGRESSION IN BARRETT’S ESOPHAGUS: INSIGHTS FROM A LARGE MULTICENTER TRINETX PROPENSITY-MATCHED COHORT","Nooraldin Merza","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)01760-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033332","Neue Daten zu GLP-1-RA und SGLT-2-Inhibitoren bei pAVK","Miriam Sonnet","2026","Info Diabetologie","other","article","10.1007/s15034-026-5301-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033333","183 SEMAGLUTIDE VERSUS RESMETIROM FOR NONCIRRHOTIC MASH WITH MODERATE TO ADVANCED FIBROSIS: A COMPARATIVE COST-EFFECTIVENESS ANALYSIS","Sarpong Boateng","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03310-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033334","498 CARDIOVASCULAR AND HEPATIC OUTCOMES WITH URSODEOXYCHOLIC ACID PLUS GLP-1 RECEPTOR AGONISTS IN PRIMARY BILIARY CHOLANGITIS PATIENTS: A PROPENSITY-MATCHED COHORT","Mohammad Alabbas","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03342-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033335","624 GLP-1 RECEPTOR AGONISTS REDUCE LONG-TERM STEROID, BIOLOGIC, AND ACUTE CARE UTILIZATION IN ULCERATIVE COLITIS AND CROHN’S DISEASE: A 5-YEAR TRINETX STUDY WITH LANDMARK ANALYSIS","Yan Sun","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)02292-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033336","Rethinking sustained recompensation in MASLD cirrhosis: The value of pharmacological maintenance","Nobuyuki Toshikuni","2026","Hepatology Communications","other","article","10.1097/hc9.0000000000000984","42319082",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033337","Body Composition and Functional Changes with GLP-1RA Therapy After Kidney Transplantation","M. Wilson","2026","American Journal of Transplantation","other","article","10.1016/j.ajt.2026.05.1705",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033338","Pre-Transplant GLP-1 Receptor Agonist Use Associates with Lower 30- and 90-Day Mortality and Graft Failure After Kidney Transplant: A Multicenter Propensity-Matched Analysis","S. Ricci","2026","American Journal of Transplantation","nonrandomized_study","article","10.1016/j.ajt.2026.05.315",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033339","Single Center Evaluation of Glucagon-Like Peptide-1 Receptor Agonists in Kidney Transplant Recipients with Delayed Graft Function","C. Jahnke","2026","American Journal of Transplantation","other","article","10.1016/j.ajt.2026.05.1116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033340","Impact of Glucagon-Like Peptide-1 Receptor Agonists on All-Cause Mortality, Major Adverse Cardiovascular Events, and Major Adverse Kidney Events in Liver Transplant Recipients","K. R. Patidar","2026","American Journal of Transplantation","other","article","10.1016/j.ajt.2026.05.182",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033341","Pancreas Transplantation in Patients with End Stage Renal Disease and T2 Diabetes - Role of GLP-1 Agonists","P.J. Bachul","2026","American Journal of Transplantation","other","article","10.1016/j.ajt.2026.05.2201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033342","Improving Access to GLP-1 RA Therapy in Kidney Transplant Recipients","I. A. Munoz Verdugo","2026","American Journal of Transplantation","other","article","10.1016/j.ajt.2026.05.1071",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033343","Prescribing in Type 2 Diabetes in Primary Care","Sarah Nazir","2026","SAS Journal of Medicine","other","article","10.36347/sasjm.2026.v12i06.013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033344","Streamlining GLP-1 Prescribing: An Epic Dot Phrase for Insurance Coverage Navigation","Marie Kimberly Lim","2026","ScholarWorks -A service of University of Vermont Libraries (University of Vermont)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0033345","Body Composition and Physical Function Changes with GLP-1 Therapy in Kidney Transplant Candidates","C. Weaver","2026","American Journal of Transplantation","other","article","10.1016/j.ajt.2026.05.1706",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033346","Weight Loss Trends Among Liver Transplant Recipients Prescribed GLP-1 Agonists: A National, EHR-Based Study","K. Terlizzi","2026","American Journal of Transplantation","other","article","10.1016/j.ajt.2026.05.1783",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033347","Investigating the role of the glutamyl linker on the biological efficacy of Liraglutide","Victor A. Gault","2010","Regulatory Peptides","other","article","10.1016/j.regpep.2010.07.116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033348","Weight-Loss Efficacy of GLP-1 Receptor Agonists Relative to Lifestyle-Based Interventions","Amy E. Betterton","2026","Lynchburg Journal of Medical Science","other","article","10.63932/3067-7106.1066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033349","Glucagon-like peptide-1-Rezeptoragonisten: Suizid- und Selbstverletzungsrisiko","R. Maria Clauss","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2406-3511",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033350","Adipositas – Liraglutid kann Gewichtsabnahme unterstützen","X Pi-Sunyer","2015","Aktuelle Ernährungsmedizin","randomized_trial","article","10.1055/s-0035-1552442",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033351","Neue Antidiabetika und kardiovaskuläre Outcome-Studien","Jochen Seufert","2017","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0042-121159",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033352","Vorsorgekoloskopien: GLP-1RAs verschlechtern Qualität der Darmvorbereitung","Annika Simon","2024","Zeitschrift für Gastroenterologie","other","article","10.1055/a-2360-1913",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033353","Regulation of insulin secretion via scaffold proteins intersectin 1 and 2","Thilo Speckmann","2024","Diabetologie und Stoffwechsel","preclinical","article","10.1055/s-0044-1785256",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033354","Typ-2-Diabetes: GLP-1-RAs reduzieren Risiko für gastrointestinalen Krebs","Frank Lichert","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2627-9896",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033355","Diabetes mellitus: kardiovaskuläre Risikoreduktion im Fokus","Maximilian Meyer-Steenbuck","2024","Kardiologie up2date","other","article","10.1055/a-2018-5620",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033356","Kommentar zu „Unterschiede in der Wirksamkeit und Verträglichkeit Inkretinbasierter Diabetes-Medikamente“","Michael A. Nauck","2024","DMW - Deutsche Medizinische Wochenschrift","other_trial","article","10.1055/a-2260-6107",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033357","Aktuelle Therapieoptionen bei Diabetes mellitus Typ 2","Burkhard Göke","2011","Gastroenterologie up2date","other","article","10.1055/s-0030-1256624",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033358","Ergebnisse zur Wirkungsweise von Semaglutid bei MASH vorgelegt","Frank Lichert","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2627-9863",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033359","GLP1-Therapie bei einer Patientin mit metabolischem Syndrom und Typ 1 Diabetes/LADA unter Insulinpumpentherapie mit Closed-Loop-Algorithmus – Daten zu glykämischer Kontrolle und metabolischer Inflammation","Annekatrin Schwanstecher","2024","Diabetologie und Stoffwechsel","other","article","10.1055/s-0044-1785309",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033360","Perioperatives Aspirationsrisiko bei GLP-1 Rezeptorantagonisten – weiterer Schritt zur Klarheit","Marc-Michael Ventzke","2026","AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie","other","article","10.1055/a-2762-7659",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033361","On the potential of group-specific component (GC) inhibition for treating metabolic disease","Richard Gill","2026","Metabolism and Target Organ Damage","preclinical","article","10.20517/mtod.2025.195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033362","… nicht ohne Nebenwirkungen: hohe GLP-1-Absetzraten bei Adipositas (ohne Diabetes)","Johannes B. Dahm","2025","Aktuelle Kardiologie","other","article","10.1055/a-2658-3543",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033363","GLP-1-Rezeptoragonisten und HPA-Achse","Susanne Krome","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2512-2217",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033364","Antidiabetika bei chronisch obstruktiver Lungenerkrankung vorteilhaft","Susanne Krome","2025","Pneumologie","other_trial","article","10.1055/a-2643-1633",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033365","GLP1-RA: unbekannte Positiveffekte und Risiken","Susanne Krome","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2512-2229",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033366","GLP-1-Agonisten reduzieren das Zirrhoserisiko bei MASLD","Susanne Krome","2025","Zeitschrift für Gastroenterologie","other","article","10.1055/a-2503-0799",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033367","Typ-2-Diabetes: GLP-1-RAs für intestinale Obstruktionen verantwortlich?","Frank Lichert","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2642-5167",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033368","Ergebnisse zur Sicherheit und Tolerabilität von Amycretin vorgelegt","Frank Lichert","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2642-5178",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033369","Empagliflozin/Finerenon plus GLP-1RA","Susanne Krome","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2628-0033",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033370","Bariatrische Operation versus GLP-1RA","Susanne Krome","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2730-0617",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033371","Stellungnahme – Ungeplante „Ozempic-Babys“ als „Nebeneffekt“ der Adipositastherapie","Ute Schäfer-Graf","2024","Geburtshilfe und Frauenheilkunde","other","article","10.1055/a-2369-7654",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033372","Das polyzystische Ovarsyndrom: Aktuelle Evidenz und praktische Empfehlungen","Susanne Tan","2020","Diabetologie und Stoffwechsel","other","article","10.1055/a-0891-9131",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033373","Diabetes und Herzinsuffizienz","Philipp Heinrich Baldia","2019","Diabetologie und Stoffwechsel","other","article","10.1055/a-0876-5672",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033374","Flavonoids as Prominent Anti-diabetic Agents","Aluru Rammohan","2021","Frontiers in clinical drug research. Diabetes and obesity","other","article","10.2174/9789811479199120060004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0033375","Kommentar zu Diabetes-Subtypen unterscheiden sich in Bezug auf Komplikationen","M Hanefeld","2022","Diabetologie und Stoffwechsel","other","article","10.1055/a-1723-3751",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033376","Effectiveness of Different Split-Dose Bowel Preparation Regimens in Patients Treated with Glucagon-Like Peptide-1 Receptor Agonists: preliminary results of The GLPreparation Study","A Piagnani","2026","Endoscopy","nonrandomized_study","article","10.1055/s-0046-1821797",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0033377","Obesity and reproduction: clinician’s algorithm of action","Mekan R Orazov","2025","Clinical review for general practice","other","article","10.47407/kr2025.6.9.00673",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033378","Typ-2-Diabetes – Exenatid und Nierenfunktion","Peter Pommer","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-115455",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033379","SGLT-2-Inhibitoren und GLP-1-RA reduzieren Risiko für NAFLD bei Typ-2-Diabetes","Gerhard Dobler","2022","Diabetologie und Stoffwechsel","other","article","10.1055/a-1732-9782",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033380","Typ-2-Diabetes – Albiglutid effektiv und sicher","Peter Pommer","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580234",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033381","GLP-1RA, SGLT2i und Amputationsrisiko","Susanne Krome","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2730-0653",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033382","Kommentar zu Bariatrische Operation versus GLP-1RA","Nikolaos Perakakis","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2751-7086",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033383","Typ-2-Diabetes: regionale Heterogenität der Ergebnisse bei GLP-1RAs-Studien?","Annika Simon","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2465-1341",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033384","Anwendung von GLP-1-Rezeptoragonisten bei Patienten mit Niereninsuffizienz – ein Update","Ludwig Merker","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-104348",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033385","Histological, Immunohistochemical, Biochemical, and Ultrastructural Evaluation of the Protective Effect of Semaglutide and Green Coffee Bean Extract in Diabetes‑Induced Testicular Injury in Adult Albino Rats","Hala El-Haroun","2026","The Egyptian Journal of Histology","preclinical","article","10.21608/ejh.2026.486786.2447",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033386","Kombinationspräparat gegen Adipositas und Typ-2-Diabetes","Richard Kessing","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2642-5123",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033387","Typ-2-Diabetes: Heterogene Effekte von GLP-1-Rezeptoragonisten nachgewiesen","Frank Lichert","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2627-9840",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033388","Lixisenatide: A New Glucagon-Like Peptide-1 Agonist","Christopher W. Ho","2013","Journal of Developing Drugs","other","article","10.4172/2329-6631.1000e134",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033389","Gewichtsreduktion durch Amycretin über 36 Wochen sicher und verträglich?","Frank Lichert","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2642-5156",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033390","Semaglutid, ein GLP-1-Agonist mit vielfältigem Nutzen","Richard Kessing","2021","Diabetologie und Stoffwechsel","other","article","10.1055/a-1540-0705",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033391","Semaglutid verbessert eine NASH besser als Placebo","Elke Roeb","2021","Gastroenterologie up2date","other","article","10.1055/a-1404-1872",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033392","Typ-1-Diabetes: Verordnung von GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren","Annika Simon","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2451-3561",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033393","Incretin Enhancers, Incretinomimetics – from Therapeutic Concept to Clinical Application","Gábor Winkler","2007","Hungarian Medical Journal","other","article","10.1556/oh-hmj.2007.28093",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033394","GLP-1-Rezeptoragonisten: kein erhöhtes Risiko für Schilddrüsentumore","Annika Simon","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2642-5283",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033395","GIP/GLP-1-Rezeptor-Agonisten reduzieren Schlaganfallrisiko bei Typ-2-Diabetes","Annika Simon","2025","Neurologie up2date","other","article","10.1055/a-2412-5244",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033396","Morbus Parkinson: Neue GLP-1-Rezeptor-Agonisten-Variante auf dem Prüfstand","Annika Simon","2025","Neurologie up2date","other","article","10.1055/a-2242-6555",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033397","Update Pharmakotherapie bei Parkinson","A Ceballos-Baumann","2018","Nervenheilkunde","other","article","10.1055/s-0038-1641240",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033398","Neue Antidiabetika und kardiovaskuläre Outcome-Studien","Jochen Seufert","2016","Kardiologie up2date","other_trial","article","10.1055/s-0042-108078",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033399","GLP-1-RA senken HbA1c und Körpergewicht effektiver als Sitagliptin","Winfried Keuthage","2014","DMW - Deutsche Medizinische Wochenschrift","other","article","10.1055/s-0034-1382145",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033400","Anesthetic Management and Bariatric Surgery: A Comprehensive Review of Pathophysiological Considerations, Evolving Guidelines, and Optimizing Patient Outcomes","Indunil Karunarathna","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.20882681",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033401","Primary Bile-Duct Stone in a Patient on Liraglutide","Enver Avcı","2023","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.5152/erp.2023.23228",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033402","Which State-Level Pharmacy Markets Get Generics First After Launch? An ML.NET-Based Forecasting Framework for Generic Drug Diffusion and Access Inequality","Tanvir Mahmud Khan","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20837673",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033403","GLP-1 Receptor Agonist Medications: Patient Education","Laura Liggett","2026","MEDSURG Nursing","other","article","10.62116/msj.2026.35.3.151",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033404","AGONISTAS DO RECEPTOR GLP-1 NO TRATAMENTO DA OBESIDADE: IMPACTO NA PERDA DE PESO, CONTROLE GLICÊMICO E DESFECHOS CARDIOMETABÓLICOS – REVISÃO SISTEMÁTICA E METANÁLISE","Danilo Gustavo Gonçalves Ferreira Romanelli","2026","Revista Científica Ipedss","randomized_trial","article","10.55703/27644006060208",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0033405","Nonarthritic anterior ischemic optic neuropathy in patients receiving semaglutide: myth or reality? (literature review)","A.D. Arsyutov","2026","Russian Journal of Clinical Ophthalmology","nonrandomized_study","article","10.32364/2311-7729-2026-26-2-11",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0033406","Emerging treatment options for metabolic dysfunction-associated steatotic liver disease and its related liver diseases","Chunye Zhang","2026","World Journal of Hepatology","other","article","10.4254/wjh.120178",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033407","Antidiabetic drugs in myocardial infarction","Ján Murín","2026","Súčasná klinická prax","other","article","10.48095/ccskp202611",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0033408","GLP-1 receptor agonists: Mechanism of action and therapeutic applications","Elizabeth Brodman","2026","Digital Repository (National Repository of Grey Literature)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0033409","Semaglutide reduces drinking in adults with alcohol use disorder and obesity",null,"2026","The Brown University Psychopharmacology Update","other_trial","article","10.1002/pu.31472",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0033410","Ana Navarro's Weight Loss Journey That Will Blow Your Mind","mervin, dickens","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12798849",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033411","Scott Disick's Weight Loss Journey: Uncovering the Factors Behind His Transformation","Georgea, Strong","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12787439",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033412","Additional file 5 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Ugamura, Daisuke","2022","Figshare","other_trial","article","10.6084/m9.figshare.20056574",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033413","Additional file 3 of Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure","Sforza, Annalisa","2022","Figshare","other","article","10.6084/m9.figshare.19571888",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033414","Orforglipron: A Review Of A Novel Oral, Non-Peptide GLP-1 Receptor Agonist.","Bharmal, Mohammad Musa","2025","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.15858941",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","report"],["R0033415","MOESM1 of The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis","Hideki Kushima","2017","Figshare","preclinical","article","10.6084/m9.figshare.5463157.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033416","Incretin-based therapies and bone fractures in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","Dooley, Gordon","2015","York","systematic_review","article","10.15124/crd42015020399",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0033417","Recent Advances in Diagnostic and Therapeutic Strategies for Diabetes Mellitus: A Comprehensive Review","Dr. Shivakumar Ladde*","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.16724111",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033418","The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study","Werkman, Nikki C. C.","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.c.6721175",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033419","АКТУАЛЬНОСТЬ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ С ПОМОЩЬЮ ИНКРЕТИНОВОЙ ТЕРАПИИ","Алакбарова, Нодира","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15319072",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033420","Additional file 2 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Alfayez, Osamah M.","2020","Figshare","systematic_review","article","10.6084/m9.figshare.12544994",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033421","Metabolic Effects of GLP-1 Agonists in the Treatment of Obesity","Gomes Duarte Neto, Jarbas","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17007248",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033422","Ambien kaufen online","Farew Saser","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11672263",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033423","A COMPREHENSIVE OVERVIEW OF ANTIDIABETIC DRUG'S SAFETY PROFILE USING WHO – UMC SCALE","*Aryan Srivastava, Surabhi Dwivedi, Asheesh Pratap Singh","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20643184",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033424","MOESM2 of Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes","Zhang, Wen-qiang","2018","Figshare","other","article","10.6084/m9.figshare.7479179",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033425","Green line 6 workbook lösungen pdf","inlmskxxi","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12138760",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033426","Additional file 1 of Pre-hospital glycemia as a biomarker for in-hospital all-cause mortality in diabetic patients - a pilot study","Greco, Salvatore","2024","Figshare","other","article","10.6084/m9.figshare.25749957",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033427","Englisch msa 2023 lvsungen pdf","uxjhtopgdq","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12220592",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033428","Resolving the SCZ–T2DM Paradox: Convergent Pathways Despite Genome-Wide Antagonism","Ngo Cheung","2026","Figshare","other","article","10.6084/m9.figshare.31347538",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033429","Wpływ nowoczesnego leczenia hipoglikemizującego na osoczowe czynniki ryzyka sercowonaczyniowego i rozwój blaszki miażdżycowej w tętnicach szyjnych","Hachuła, Marcin","2024","Medical University of Silesia","other","article","10.71804/bdfn-xf38",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033430","Campaña 25N de María Calado. Violencia simbólica corporal hacia las mujeres. Mirada interseccional. Introducción","CALADO OTERO, MARÍA","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17552132",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0033431","Novel Aspects in Incretin and Glucagon Biology: From Basic to Clinical Applications -Dual Incretin Receptor Agonists: How Far Have We Gone with “‘Twincretins”?","Endocrine Society 2022","2022","Underline Science Inc.","other","article","10.48448/1bej-p678",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033432","MOESM1 of Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes","Zhang, Wen-qiang","2018","Figshare","other","article","10.6084/m9.figshare.7479176",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033433","Evolution of Semaglutide as a Multifaceted Therapeutic Agent: Mechanism And Management To A Systematic Therapeutic Agent: A Comprehensive Review of Its Role beyond Type 2 Diabetes","Ragunathan Muthuswamy","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.17447881",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033434","New FDA Approved Weight Loss: Drug Zepbound, a Wegovy and Ozempic Rival!","Amalia, Ashcroft","2024","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.12749457",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033435","Insulin, Glucagon, and Beyond: Molecular Mechanisms and Therapeutic Innovations in Blood Glucose Regulation","glucose regulation","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19397718",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0033436","Additional file 2 of Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways","Wang, Duozi","2025","Figshare","other","article","10.6084/m9.figshare.29632376",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033437","Additional file 1 of Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case–control study","Chang, Kai-Cheng","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.27253376",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033438","Additional file 2 of Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study)","Oe, Yuki","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26368536",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033439","Beneficios cardiovasculares del semaglutide: un nuevo agonista del GLP-1","Ortega, Juan Pablo Garcés","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7702783",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033440","CURRENT STRATEGIES FOR CARDIOVASCULAR DISEASE PREVENTION: AN OVERVIEW","Dr. M.R.N Shaikh","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17174132",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033441","Additional file 2 of Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure","Sforza, Annalisa","2022","Figshare","other","article","10.6084/m9.figshare.19571885",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033442","Westfalenpost pdf","kmupbymf","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11860743",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033443","Blockbuster Drug Strategy: How Ozempic Became a Multi-Billion Dollar Brand","Dr. N Rajesh Kumar*, Amisha Wadekar, Amod Bisla, Pallavi Bhukya, Dhruv Patel, Archana Endadi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20591231",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033444","formelsammlung zap nrw pdf","fslajhlkwj","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11943585",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033445","Effects of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Lipid and Metabolite Profiles in Subjects with Type 2 Diabetes Supplementary Information","Pirro, Valentina","2021","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.4943309",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033446","Transdermal Micro-Channel Delivery System (TDDS)","Troy Wilde","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17518532",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033447","Polycystic Ovary Syndrome: A Comprehensive Review of Pathophysiology, Diagnosis, And Emerging Therapeutic Strategies","Archana B.*, Kiruthiga O. B., Mahalakshmi M., Arul Prakasam K. C.","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.17510877",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033448","Formelsammlung mathe bayern realschule pdf","silcghkkhor","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11899466",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033449","Formelsammlung mathe nrw pdf","qfmbgisjjr","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12340437",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033450","The effect of lixisenatide on liver blood tests in patients with diabetes","Dooley, Gordon","2013","York","other","article","10.15124/crd42013005779",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033451","Dataset for: Effects of insulin and the glucagon-like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice","Liljedahl, Leena","2017","Figshare","preclinical","article","10.6084/m9.figshare.c.3734506",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033452","FitSmart Fat Burner Dragons DenReviews (Consumer Reports 2024) Ingredients, Benefits and Side Effects (Rice Hack Weight Loss)","FitSmart Fat Burner Dragons DenReviews (Consumer Reports 2024) Ingredients, Benefits and Side Effects (Rice Hack Weight Loss)","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13354501",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033453","Plain language summary of the PUBLICATION titled “Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial”","Kosiborod, Mikhail N","2025","Boehringer Ingelheim","protocol","article","10.60915/boehringer-figshare.29066768",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033454","Additional file 5 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","other","article","10.6084/m9.figshare.26642788",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033455","BMI Classification and Management with GLP-1–Based Therapy: A Concise Clinical Infographic Series Covering Indications, Contraindications, Drug Selection, and Dosing","Saja Said","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20042600",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033456","A systematic review of the placebo effect of GLP-1 receptor agonists versus new class oral glucose-lowering agents in type 2 diabetes","Dooley, Gordon","2014","York","systematic_review","article","10.15124/crd42014014134",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0033457","Poster presented at EASL 2025 - Survodutide, a glucagon/ GLP-1 receptor dual agonist, in people with MASH with moderate-to advanced liver fibrosis (stage F2–F3): rationale and design of an event driven, multinational, randomised, placebo controlled, phase 3 trial (LIVERAGE™)","Schattenberg, Joern","2025","Boehringer Ingelheim","protocol","article","10.60915/boehringer-figshare.29070206",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","conference-abstract; article"],["R0033458","DRUG DESIGN INNOVATIONS IN METABOLIC DISORDERS: GLP-1 ANALOGUES AND BEYOND","Prachika Soni","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18020817",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033459","GLP-1 Receptor Agonism and the Selenoprotein Axis: Why the Kidney-Protective Mechanism of Semaglutide Is Selenium-Gated — NRF2 Activation Without Selenocysteine Substrate Cannot Complete the Selenoprotein Expression Program — Including Bone Health Addendum","Grace Ann","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20563316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033460","Cardio renal metabolic syndrome","Dr Aditya tyagi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20253692",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033461","W6 Weight Loss : Building Consistency and Real Results!","W6 Weight Loss","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20050741",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033462","Additional file 2 of hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair","Wang, Wei","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26553779",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033463","Additional file 4 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Husain, Mansoor","2020","Figshare","randomized_trial","article","10.6084/m9.figshare.13031555",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033464","GLP Formula Aider des milliers de personnes à perdre du poids en toute sécurité","GLP Formula Acheter","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15760787",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033465","Additional file 3 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Lengsfeld, Sophia","2023","Figshare","protocol","article","10.6084/m9.figshare.22671491",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033466","Buy 💉Wegovy and 💉Mounjaro +966561082467 weight lost 💊 in California ✅ 💊 Ozempic in Dubai 💉💉injection","Krantiguru Shyamji Krishna Verma Kachchh University","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11659940",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033467","Decoding Inflammation and Oxidative Stress in PCOS: Pathophysiology, Pharmacotherapy and Future Therapeutic Horizons","Dr. Payal Mittal*","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14354430",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033468","management package pdf","xxakazivd","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11972483",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033469","A Study of Adverse Drug Reactions due to Anti-Obesity Drugs in Diabetic Patients in a Multispecialty Hospital","Anand Gupta*, Samir Raja, Fujail Ashraf, Khushi Kumari, Satyam Kumar, Sabreen Khatoon, Sakshi Kumari, Md. Rehan Sanwar, Shana Shabbir, Md. Saif","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.17515585",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033470","Zentrale abschlussprüfung nrw übungen pdf","ioueyrivaak","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12216900",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033471","Survodutide Shows Strong Weight Loss Benefits in Phase 2 Obesity Trial","Boehringer Ingelheim Demo","2025","Kudos Innovations Ltd","other_trial","article","10.26303/d8f9-kj28",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0033472","hill readers pdf","kjtwiucygrj","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12410516",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033473","WEIGHT GAIN IN RELATION TO PCOS : A REVIEW","Masooma Arshad","2026","Figshare","other_trial","article","10.6084/m9.figshare.31934085",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0033474","Weight Loss Gummies The Pros and Cons of Semaglutide for Weight Loss","SherylDF, rederick","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12780166",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033475","Tirzepatide-Associated Transition from Hypothyroidism to Graves' Disease","Dr. Magdi Essa Abdullah Bakheet","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21064783",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033476","Chronic Hyperglycemia and Its Systemic Metabolic Consequences: Understanding the Effects of Continuous Elevated Blood Glucose Levels in Diabetes","Hussain, Zahid","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17336423",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033477","Transformative Weight Loss with Dulaglutide: A Success in Challenging Patient Profile of an Ex-sumo","American Medical Association 2024","2024","Underline Science Inc.","other","article","10.48448/spqn-jg87",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033478","Precision Targeting of Toxins for Enhanced Therapeutic Efficacy and Safety","Aniket Shankpal, Akash Yadav*, Dinesh Kumar Jain","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20075833",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033479","Pathophysiological Mechanisms and Systemic Complications of Polycystic Ovary Syndrome: Endocrine, Metabolic, and Neuroendocrine Targets in Infertility Management","Pratyush Mishra1, Yasmin Suthar2, Varun Arora3, Pragi Arora4, Tanmay Ghosh5, Rishin Bhattacharyya6, Sadma Parveen7, Alka Mishra8, Malarkodi Velraj*9","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18871058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033480","Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the US","Adis Journals On Behalf Of","2024","Figshare","other","article","10.6084/m9.figshare.27890910",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033481","From Metabolism to Microvasculature: Pericytes—the Architect of GLP-1 Benefits","Kennedy, Corinna","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17015286",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033482","ISAJ Newsletter volume 3 (2018)","Indian Scientists Association in Japan","2018","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16629376",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033483","Msa mathe lösungen pdf","kuecyotfu","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12130858",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033484","Phase 3 trial: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled Phase 3 trial","Eli Lilly Demo","2024","Kudos Innovations Ltd","randomized_trial","article","10.26303/rhc0-e598",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033485","Delineating the Incretin Effect and the Roles of GLP-1 and GIP: Potential Benefits of Agonism of Multiple Receptors: Mechanism of Action of Unimolecular Dual Agonsts","Endocrine Society 2022","2022","Underline Science Inc.","other","article","10.48448/72p6-mk89",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033486","PLAIN LANGUAGE SUMMARY of the PUBLICATION titled “Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial”","W Le Roux, Carel","2025","Boehringer Ingelheim","randomized_trial","article","10.60915/boehringer-figshare.29063129",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033487","Short-Term Complications After TKA in Patients with Prior Bariatric Surgery or GLP-1 Agonist Use","American Medical Association 2025","2025","Underline Science Inc.","nonrandomized_study","article","10.48448/3e9w-zr41",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033488","Additional file 2 of Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF) protocol","Win, Kyaw Z.","2024","Figshare","protocol","article","10.6084/m9.figshare.25264414",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033489","Englisch msa 2023 lösungen pdf","zkxkjfnfz","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12391853",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033490","Dual GIP/GLP-1 Receptor Agonism in Diabetes and Obesity: A Review of Tirzepatide's Efficacy and Safety","Dr. S. Arthanareeswaran, Dr. R. Subashini*, R. Mounisha, R. Preethi, N. Preethika, S. Priyadharshini, T. Manisha","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.17918417",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033491","Additional file 1 of Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis","Shokravi, Arveen","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30254184",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; review"],["R0033492","GLP Formula Recensioner: Fungerar det verkligen för viktminskning?","GLP Formula Sverige","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15835026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033493","Additional file 1 of Effects of beinaglutide on visceral fat area and gut microbiota in obesity","Liu, Tianshui","2025","Figshare","other","article","10.6084/m9.figshare.29231917",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033494","1000 verben mit präpositionen pdf","hgrxsqpubk","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11924274",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033495","Additional file 7 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","other","article","10.6084/m9.figshare.26642794",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033496","REVIEW OF SEMAGLUTIDE: AN OVERVIEW AND MECHANISM OF ACTION","D. Bharathi*","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.14966425",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033497","SUPPL_T2D_SGLT2i_GLP1RA_AF.pdf","Li, Pei-Ru","2024","Figshare","other","article","10.6084/m9.figshare.25478380.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033498","Wie GLP Lab Ihnen hilft, sicher abzunehmen","GLP Lab Rezension","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16741919",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033499","AI-GlucoRestore-001: A Multi-Pathway Glucose Normalization Therapeutic for Type 2 Diabetes Mellitus","Kilpatrick, Christian","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17444898",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033500","Zentrale abschlussprüfung nrw übungen pdf mathe","oziygisnsmc","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12360689",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033501","Comparative Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: A Bayesian Network Meta-Analysis","He, hebinghong","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.14958369",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0033502","Zap 2021 nrw mathe pdf","cbqvdwbqk","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11734012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033503","Analysis of physiologically relevant signalling events via GLP-1R in insulinoma cells","Kavita Pabreja","2016","Monash University","other","article","10.26180/4264598",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033504","Emerging Therapies in Type 2 Diabetes Mellitus: A Comprehensive Review","Rakesh Kumar Sharma2 Arun Kumar Gulia*","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.20493294",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033505","Conscience February 2026 Policy Brief - FDA action against compounders","Dylan Lamberti","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18750139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033506","Azoramide, a novel regulator, favors adipogenesis against osteogenesis through inhibiting the GLP-1 receptor-PKA-β-catenin pathway","Ruan, Banjun","2018","Figshare","preclinical","article","10.6084/m9.figshare.c.4028056.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033507","Emerging Therapies in Heart Disease: RNA-Based Approaches, Gene Therapy, and Precision Pharmacology","Vishal Pednekar*, Vikas Gupta, Sayali Jadhav, Nameerah Rakhe","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18723924",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033508","From Forum to Clinic: Transforming Patient Narratives into Clinical Insights Using Autonomous AI","American Medical Association 2025","2025","Underline Science Inc.","nonrandomized_study","article","10.48448/v9y3-wm36",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033509","Semaglutide: A Breakthrough in Type 2 Diabetes Management","Dhanshri Mangle*, Zoya Fatema Shaikh, Vijay Vaidya, Shilpa Borkar, Jagdish Baheti","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19809216",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033510","Management of Type 2 and Post-Transplant Diabetes in Kidney Transplant Recipients: A Single-Center Clinical Experience with GLP-1 Receptor Agonists and SGLT-2 Inhibitors","Navarrete, Ricardo ET","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.17066370",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033511","Statistical Analysis Plan, Efficacy on cardiovascular outcomes from sustained use of GLP-1 receptor agonists versus DPP-4 inhipitors: A LEADER-inspired trial emulation using the Swedish National Diabetes Register.","Hallström, Sara","2025","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.15311401",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033512","Injectable Semaglutide (Ozempic) For Type 2 Diabetes in India; Traslating Global Evidence into Real-World Practice After Recent Market Entry","Dr. Shivaraj D. R.1*, Dr. Nagarjuna D.2, Dr. R. S. Meghasri3, Varshini J.4, Gowthami L.5, Bharath Gowda H. G.6","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.18485151",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033513","Jardiance Weight Loss Melissa MCarthy Weight Loss - How Did She Lose Weight?","Janelle, JPowell","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12793298",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033514","Mathematik formelsammlung pdf","fliojurxrvy","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11834151",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033515","Type 2 Diabetes Mellitus","Gholap Siddhi*, Mandlik Rutuja, Madhe Prabhavati, Dr. Pallavi Phalake, Mayuri Mundhe","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20472426",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033516","Advancing Diabetes Care: A Comprehensive Review of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus – Addressing Efficacy, Safety, and Future Perspectives","Tejasaradhya N","2025","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.17777792",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033517","Zp 10 prüfungsaufgaben nrw pdf","kcrlgowjfi","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11816331",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033518","The efficacy and safety of glucagon-like-peptide-1 agonists in patients with familial partial lipodystrophy","Foss-Freitas, Maria","2024","University of Michigan Library","nonrandomized_study","article","10.7302/25183",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033519","Risk of pancreatic complication events associated with the use of GLP-1 receptor agonist and DPP-4 inhibitor drugs: a systematic review and meta-analysis","Dooley, Gordon","2013","York","systematic_review","article","10.15124/crd42013004742",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0033520","Additional file 1 of Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways","Wang, Duozi","2025","Figshare","other","article","10.6084/m9.figshare.29632373",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033521","Deintenzifikace inzulinoterapie u diabetes mellitus 2. typu v klinické praxi","Novodvorsky, Peter","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15682870",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033522","Adjuvant Dapagliflozin in Kidney Transplant Recipients with Diabetes and Heart Failure – A Real-World Data Exploratory Study","Navarrete, Ricardo ET","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.17247451",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033523","PHARMACOTHERAPY FOR METABOLIC DISEASES: EVIDENCE AND STRATEGIES IN METABOLIC SYNDROME, OBESITY, GOUT, AND CHRONIC ADRENAL INSUFFICIENCY","MARIIA MURZAEVA","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17474803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033524","Additional file 1 of Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","Zhou, Jianxing","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26680684",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033525","Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus","Dooley, Gordon","2013","York","other","article","10.15124/crd42013005859",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033526","Perioperative management of novel obesity and diabetes drugs: what the urologist needs to know.","Rossi, Sabrina H","2025","Apollo (University of Cambridge)","other","article","10.17863/cam.120288","40796000",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033527","Additional file 5 of Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways","Wang, Duozi","2025","Figshare","other","article","10.6084/m9.figshare.29632385",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033528","INTERACTIONS OF GABA AND HYPOGLYCEMIC DRUGS","Davranova Aziza Davranovna","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.10821853",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033529","Diabetes: Status of disease in India and its Treatment policy","Chawla Amit","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.15369509",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033530","Analytical Method Development and Validation of Tirzepatide in Bulk and Pharmaceutical Formulation by RP-HPLC","Y. Patil, K. Patil, K. Khadke, K. Surywanshi, V. Patil, S. Joshi, N. Porawr, Dr. K. Patil*, Dr. S. Barhate","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19810653",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033531","EVOLVING CONCEPTS IN PCOS: DIAGNOSTIC INNOVATIONS AND NOVEL THERAPEUTIC STRATEGIES","1Sharma Upasana D., 2*Thaker Kwisha, 3Sathwara Maitri, 4Sathwara Setu, 5Barot Hinal","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19327401",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033532","METABOLIC DISORDERS AND CARDIOVASCULAR RISK: AN INTERNAL MEDICINE PERSPECTIVE","*Dr. Mustafa Saif","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17405384",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033533","North America Pharmaceuticals Market Trends, Innovations, and Growth Opportunities 2032","Healthcare","2025","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.17285701",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","report"],["R0033534","GLP-1 RECEPTOR AGONISTS AND SEMAGLUTIDE: MECHANISMS, CLINICAL OUTCOMES, AND EMERGING THERAPEUTIC FRONTIERS","Saidjonova Saidabegim","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19492762",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033535","Additional file 6 of Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways","Wang, Duozi","2025","Figshare","other","article","10.6084/m9.figshare.29632388",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033536","Polymeric Microspheres in Diabetes Therapy: Preparation Strategies and Targeted Drug Delivery Applications","Mansi Sharma","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18840519",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033537","Formelsammlung körper pdf","ryzhrpnk","2024","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.11806001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033538","Green line 6 g9 workbook lösungen pdf","avmurlzdxo","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12348482",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033539","Statistical Analysis Plan, Efficacy on cardiovascular outcomes from sustained use of GLP-1 receptor agonists versus DPP-4 inhipitors: A LEADER-inspired trial emulation using the Swedish National Diabetes Register.","Hallström, Sara","2026","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.15311400",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033540","Additional file 2 of GLP-1 receptor agonists in delirium and encephalopathies: a neuroprotective scoping review","Mercado, Francisco","2025","Figshare","narrative_review","article","10.6084/m9.figshare.30786743",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033541","GLP Formula zur Gewichtsabnahme: Alles, was Sie wissen müssen","GLP Formula Aufnahme","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16352641",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033542","SGLT2 INHIBITORS AND GLP-1 AGONISTS IN HEART FAILURE: SHARED AND DISTINCT MECHANISMS","1Saad Suleman, 2Mario Gergis Azez Awed Awadala, 3Rashedul Hoq, 4Bibi Iram Hadi, 5Ufaq Hamid, 6Alabi Damilola, 7Muhammad Khaliq, 8Arshad Ali Zia, 9Mahmuda Kabir Humu, 10Dr. Nitesh Mandal, 11Nafiz Tareq Hasnain, 12*Husnain Ramzan","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.20691867",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033543","Tirzepatide in Obstructive Sleep Apnea: A Bibliometric Analysis","Gülşah Ethemoğlu","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20834794",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033544","Weight Loss Drops : The Key to Long-lasting Weight Loss with Trimova Weight Loss Drops","Weight Loss Drops","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12749373",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033545","Additional file 8 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Husain, Mansoor","2020","Figshare","other_trial","article","10.6084/m9.figshare.13031567",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033546","Exploring Corticosterone-Induced Depression Models: Mechanisms, Therapeutic Interventions, and Implications for Treatment","Meghashri Mastoli*1, Snehal Sonar2, Ashiya Choudhary3, Rutuja Khilare5, Vivek Kumbhar6, Dr. P. L. Ladda7","2025","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.15049465",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033547","Lessons from a Cast Iron Skillet: Tradition Meets Innovation in My Kitchen","Fundació Observatori Esteve Duran","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15714217",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033548","THE 36–40-BIT STRUCTURE OF PHENOMENAL CONSCIOUSNESS: A Quantitative Map under Refusal Workspace Theory (RWT)","Waterman, Alastair","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17705379",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint; article"],["R0033549","Additional file 1 of Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial","Jensterle, Mojca","2021","Figshare","protocol","article","10.6084/m9.figshare.15020780",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033550","Zentrale abschlussprüfung nrw übungen pdf","czrazcewlmj","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11834451",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033551","Risco de Desenvolvimento de DM2 Durante a Gravidez Após Uso Indiscriminado de Ozempic: Vias Moleculares Envolvidas","Kerolayne de Melo Nogueira","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13824492",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0033552","SEMAGLUTIDE-LOADED NANOEMULSION FOR ENHANCED ORAL DELIVERY AND ANTIDIABETIC EFFICACY","Dhanush Ram Turkane*1","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21032975",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033553","Discovery and design of molecular glues as a strategy for development of non-peptidic, small-molecule agonists of GLP-1 receptor","Tang, Liang","2025","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.16951758",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0033554","Additional file 1 of Uncovering the potential molecular mechanism of liraglutide to alleviate the effects of high glucose on myoblasts based on high-throughput transcriptome sequencing technique","Fan, Dongmei","2024","Figshare","other","article","10.6084/m9.figshare.25194870",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033555","Wegovy Dosierung - So unterstützt Wegovy Ihre Gewichtsabnahme!","Erfahrungen, Wegovy","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13283344",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033556","Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen","Lin, Yi-Hsuan","2024","Figshare","other","article","10.6084/m9.figshare.c.7549819.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033557","Exenatide, an incretin hormone & AMP-activated protein kinase, an energy sensor, emerge as novel insulin-sensitizing agents","Dan Zheng","2015","University of Southern California Digital Library","other","article","10.25549/usctheses-m1739",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033558","Additional file 2 of Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study","Funck, Kristian Løkke","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26552839",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033559","Development and Validation of an RP-UPLC Method for Bexagliflozin and Tirzepatide Using Analytical QbD Approach","P. Sunitha, M. Sivakumar","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15697137",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033560","Zap englisch übungen pdf","edrpbmnneyi","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12402346",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033561","Additional file 1 of Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study","Kumarathurai, Preman","2021","Figshare","randomized_trial","article","10.6084/m9.figshare.13545530",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033562","ADVANCED ORAL DRUG DELIVERY PLATFORMS FOR TYPE 2 DIABETES MELLITUS: BRIDGING PHARMACOKINETIC CHALLENGES AND GLYCAEMIC OUTCOMES","Bidgar Saraswati M.*","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20702820",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033563","Usp monograph pdf","ibcxxvvh","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12417052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033564","Innovative Gene Therapies for Obesity: Focusing on MC4R Deficiency","Khushi Kataria","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16981823",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033565","N-K Sciences Report. Gila Monster Venom Derivative (Ozempic/Semaglutide) — Phase Offset Analysis Reveals Mechanism of Pancreatic Cancer · GM3 (Abb-e-Hayaat) as the Universal Phase-Coherent Cure","Muhammad Usman Malik","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.19648497",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","report"],["R0033566","PHARMACOLOGICAL ADVANCES IN THE MANAGEMENT OF CHRONIC KIDNEY DISEASE (CKD): A COMPREHENSIVE REVIEW","Challa Venku Reddy*","2025","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.17368244",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033567","A new agent for ideal weight management before abdominal hernia surgery: Semaglutide injection","Hüseyin Kılavuz","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16878780",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033568","Additional file 2 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Husain, Mansoor","2020","Figshare","other","article","10.6084/m9.figshare.13031549",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033569","Weight watchers rezepte pdf","axvqsujc","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11834139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033570","Additional file 6 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Ugamura, Daisuke","2022","Figshare","other_trial","article","10.6084/m9.figshare.20056577",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033571","Tides are Changing for Obesity - The New Kid on the Block: A Dual GIP and GLP-1 Receptor Agonist","Endocrine Society 2023","2023","Underline Science Inc.","other","article","10.48448/yb0j-ja62",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033572","Kelly Osbourne Weight Loss: reveals dramatic weight loss due in part to surgery!","Georgea, Strong","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12787457",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033573","Deutsch b2 lesen übungen pdf","ggpsworyo","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12380566",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033574","Congenital Leptin Deficiency: Metabolic, Reproductive, and Psychological Impacts of Therapy","Endocrine Society 2022","2022","Underline Science Inc.","other_trial","article","10.48448/5az9-z680",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0033575","Additional file 3 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Yang, Chun-Ting","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.12479054",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033576","Unraveling the Neural Circuitry of Energy Balance with Molecular Connectomics","Addison Webster","2025","Libra","other","article","10.18130/2a5t-8h19",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033577","MOESM6 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Bruen, Robyn","2017","Figshare","preclinical","article","10.6084/m9.figshare.c.3923344_d8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0033578","GLP‑1 Receptor Agonists as Restorative Threshold Agents: A Unified Framework Linking Metabolism, Reward, Neurodegeneration, and Ocular Vulnerability","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19448588",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033579","Disentangling the Anti-Addiction Mechanism of GLP-1 Agonists: A Review of Competing Hypotheses and a Proposal for Resolution","Atharv Ranjan","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.17514745",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033580","A Review on the Prescription Pattern Analysis of the Diabetes Mellitus","K. Sowmya Sri*, J. Kabilan, Dr. K. Karthickeyan, Dr. P. Shanmugasundaram","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.15429215",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033581","Exenatide, metformin, or both for prediabetes in PCOS: A randomized, open-labeled, parallel-group controlled study","Zhang, Yi","2020","Figshare","randomized_trial","article","10.6084/m9.figshare.12894080",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other; article"],["R0033582","Additional file 1 of Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a Department of Veterans Affairs quality improvement intervention","Yun, Shira","2025","Figshare","other","article","10.6084/m9.figshare.28642948",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033583","The N-K Model: A Quranic-Unified Framework for Deterministic Physics, Golden-Ratio Biology, and the Kunphilin Therapeutic Platform","Muhammad Usman Malik","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18399900",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033584","Additional file 2 of Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","Koychev, Ivan","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.27157898",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033585","Additional file 1 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Alfayez, Osamah M.","2020","Figshare","systematic_review","article","10.6084/m9.figshare.12544985",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033586","Fig S5 image_final","Giles, Morgan","2022","Figshare","other","article","10.6084/m9.figshare.12363944",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033587","Additional file 1 of Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study","Santos-Pardo, Irene","2023","Figshare","randomized_trial","article","10.6084/m9.figshare.24779232",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033588","Additional file 5 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Husain, Mansoor","2020","Figshare","other_trial","article","10.6084/m9.figshare.13031558",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033589","Additional file 1 of Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study","Wu, Hongjiang","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.12291593",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033590","O Uso Indiscriminado de Tirzepatida (Mounjaro) para Emagrecimento e a Necessidade de Uma Abordagem Cautelosa","Higo José Neri da Silva (1)","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17266745",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0033591","Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH","Endocrine Society 2021","2021","Underline Science Inc.","randomized_trial","article","10.48448/ebg3-jq20",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033592","Msa mathe 2023 lösungen pdf","ibrpjrfuk","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12280921",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033593","Glucagon-Like Peptide 1 Based Pharmacotherapy for Obesity: Clinical Benefits, Risks, and Access Challenges","Sarkani, Amir","2025","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.17457951",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033594","Additional file 1 of Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction","Gonzalez, Jimmy","2023","Figshare","other","article","10.6084/m9.figshare.22622990",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033595","USE OF DEGLUDEC IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS","Sodikov Samad Salohiddinovich","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.10784099",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033596","Additional file 1 of Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis","Dagenais, Gilles R.","2020","Figshare","other","article","10.6084/m9.figshare.13290505",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033597","Oral Semaglutide for the Treatment of Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease and Antipsychotic-Associated Weight Gain (AAWG) Not Responding to Metformin – A Case Series","Subhash Saxena1*, Tanushree2, Anil Tambi3, Priya Mathur4, Navneet Saxena5","2025","Zenodo (CERN European Organization for Nuclear Research)","case_report","article","10.5281/zenodo.15104401",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033598","Additional file 10 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","other","article","10.6084/m9.figshare.26642803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033599","Green line new 6 workbook lösungen pdf","ibbujspi","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11762768",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033600","Spironolactone for ME/CFS in a Patient Homozygous for rs5522 (I180V): A Case Report","Donnellan Patricia","2026","Zenodo (CERN European Organization for Nuclear Research)","case_report","article","10.5281/zenodo.19647162",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033601","BMI Normalized Index (BNI): An Ethnic-Specific Obesity Severity Metric Toward Personalized Metabolic Medicine","Seiichi Kitahama","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20718412",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033602","Book of inventions From Cancer to Mental Health diseases Cure. 3rd Extension.","Muhammad Usman Malik","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.18271205",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0033603","Rewiring Central Glucose Circuits : A Neuro-Metabolic Approach to Obesity and Type-2 Diabetes","Awais Ahmad Mubashir*1, Gursimran Singh2, Guntaz Kaur3, Kunal Mistry4","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20636513",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033604","Uncovering Nutritional Deficiencies and the Adequacy of Wrap-Around Care for Patients on GLP-1 RAs: A quality improvement audit","Dhanush Ammineni","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18390818",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033605","Hyper and Hypothyroidism: Rational Drug Therapy","Murzaeva, Mariia","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17366671",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033606","Does CKD modify the effects of GLP1-RA and SGLT2i on weight loss?","American Medical Association 2024","2024","Underline Science Inc.","other","article","10.48448/kypt-rq95",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033607","Use of Hypercalcemia and Vitamin D Levels in the Diagnosis of Sarcoidosis","American Medical Association 2025","2025","Underline Science Inc.","other","article","10.48448/ere7-m944",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033608","diabetes research paper pdf","djjuwhueiby","2024","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.11878163",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033609","Reações adversas associadas ao uso de semaglutida (Ozempic) e tirzepatida (Mounjaro)","Freitas, Nívia Larice Rodrigues de","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17103063",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033610","Additional file 2 of The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China","Gu, Shuyan","2024","Figshare","other","article","10.6084/m9.figshare.25530430",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033611","Formelsammlung mathe nrw pdf","qsddxwcy","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11715121",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033612","GLP Formula So funktioniert die Hormoneller Gewichtsverlust erklärt","GLP Formula Befehl","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16311909",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033613","APPROACHES IN DIVERSE ISSUES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN GLOBAL HEALTH STRATEGY, ECONOMIC BURDEN, GEOPOLITICAL IMPLICATIONS AND GAIN-OF-FUNCTION RESEARCH","*Dr. Chrysanthus Chukwuma Sr.","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17510577",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033614","Additional file 7 of Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways","Wang, Duozi","2025","Figshare","other","article","10.6084/m9.figshare.29632391",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033615","PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide use in Adults with Type 2 Diabetes","Adis Journals On Behalf Of","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26583082",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033616","Non-Alcoholic Fatty Liver Managment","Denisha Meghnathi*1, Kiran Rathod2, Chintankumar Tank3, Shivani Herma1, Himanshu Parmar1, Pritesh Odedara1","2025","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.15298763",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033617","Additional file 1 of Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","Koychev, Ivan","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.27157895",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033618","A Case Report: New Onset Aphasia, Visual Field Defects, and Right-sided Weakness following Semaglutide Administration","Eunheh Koh, MPH","2025","Zenodo (CERN European Organization for Nuclear Research)","case_report","article","10.5281/zenodo.17550316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033619","Additional file 1 of Association of dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy with colon cancer risk in post-polypectomy patients with diabetes: a target trial emulation","Chih-Hsuan Wang","2026","Figshare","nonrandomized_study","article","10.6084/m9.figshare.32210496.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033620","Finale prüfungstraining deutsch 2021 lösungen pdf nrw","hzcpzktgx","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11792627",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033621","Eficácia Clínica e Perfil de Segurança em Terapias Anti Obesidade: Revisão Integrativa sobre Sibutramina, Semaglutida e Tirzepatida","JOÃO PEDRO STRADIOTTO BARBOSA","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20857254",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033622","ISAJ Newsletter volume 3 (2018)","Indian Scientists Association in Japan","2018","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16629375",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033623","Liraglutide Treatment in a Real-life Setting: A Retrospective Review in a Specialized Diabetes Center from Thailand","Yotsapon Thewjitcharoen","2016",null,"nonrandomized_study","article","10.13140/rg.2.2.23785.49765",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033624","A COMPREHENSIVE REVIEW ON METHOD DEVELOPMENT AND VALIDATION OF ANTI-DIABETIC DRUGS BY HPLC","K. Pravalika1*, M. Srikanth Reddy1, B. Gayatri1, Arunabha Mallik2","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.18440291",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033625","Efficacy of GLP-1 Receptor Agonists (E.G., Semaglutide) In Non-Diabetic Obesity Management","Srushti Bhupesh Patil, Sanika Prashant Ahirrao, Ritika Dhiraj Agrawal, Dr.  Abhijit Dattatrya Kulkarni","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20668598",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033626","Additional file 1 of Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension","Krajnc, Nik","2023","Figshare","other","article","10.6084/m9.figshare.23700431",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033627","Raising the Bar When Assessing Cardiovascular Disease Outcome When Studies with Patients with Type 2 Diabetes Mellitus are Constructed: Austin Journal of Endocrinology and Diabetes","Nashawi, Mouhamed","2021","Figshare","other_trial","article","10.6084/m9.figshare.14575566",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint; article"],["R0033628","Trulicity weight loss. Does it work and who can take it?","Georgea, Strong","2024","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.12787502",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033629","Status Epilepticus Secondary to Tirzepatide Induced Severe Hypoglycemia: A Case Report","Aarohi Parikh*, Anam Zara, Renu Thomas, Sara Shahid and Srinivas Panja","2024","Zenodo (CERN European Organization for Nuclear Research)","case_report","article","10.5281/zenodo.13237128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033630","Additional file 2 of Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease","Abdulhameed, Noor","2024","Figshare","preclinical","article","10.6084/m9.figshare.26420552",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033631","Plain Language Summary of the Manuscript: Efficacy of glucagon-glucagon-like peptide-1 receptor dual agonist, in cirrhosis","Lawitz, Eric","2024","Boehringer Ingelheim","other","article","10.60915/boehringer-figshare.27720081",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033632","A Review on Recent Advances and Newer Antidiabetic Drugs in The Management of Type 2 Diabetes Mellitus","Khushali Jepulkar*, Kewal Mekalwar, Janhvi Watsar, Humaira Firdoas, Pratik Jadhav, Amisha Kokate, Harshadeep Pandey","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.19133205",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033633","Potential Risk of Post-Discontinuation Diabetes in Non-Diabetic Mounjaro Users: A Hypothetical Alert","HIRATA, TAISHI","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15795126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033634","The Cost of Alzheimer Drug Treatment","Guirgis Hely M","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18531027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033635","Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery","Bao, Xiaoyan","2024","Figshare","preclinical","article","10.6084/m9.figshare.c.6587542",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033636","Effectiveness of GLP1-RAs in type 2 diabetes: a gender analysis","Cuttone, Alessandro","2023","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.13129/1828-6550/apmb.111.2.2023.os1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033637","Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study","Funck, Kristian Løkke","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.c.6584788",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033638","Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?","Birkenfeld, Andreas L.","2024","Universitätsbibliothek Tübingen","other","article","10.15496/publikation-107372",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033639","Green line new 6 workbook lösungen pdf","mddrqhrnylg","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12133294",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033640","Diabetes Mellitus: Pathophysiology, Complications, and Emerging Therapeutic Strategies with Emphasis on Plant-Derived Phytochemicals","Rutuja Jogdande*, Sapana More, Ajit Patil, Mukund Urade","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19484284",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033641","Additional file 7 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Husain, Mansoor","2020","Figshare","other","article","10.6084/m9.figshare.13031564",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033642","Additional file 1 of Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events","Meiring, S.","2022","Figshare","other","article","10.6084/m9.figshare.21191998",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033643","Neuronal Regulation of impulsivity and metabolic adaptation","Jessica Hatter","2023","Libra","other","article","10.18130/jh0r-2s13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033644","SKIN DISEASES, OBESITY AND DIABETES","Lujain Salah Abusadi","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.10322718",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0033645","Zentrale abschlussprüfung nrw übungen pdf englisch","rmukmyxb","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11883361",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033646","Additional file 8 of Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways","Wang, Duozi","2025","Figshare","other","article","10.6084/m9.figshare.29632394",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033647","Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong","Lui, David Tak Wai","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.c.6588533",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033648","Additional file 1 of Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway","Kang, Xiaonan","2023","Figshare","preclinical","article","10.6084/m9.figshare.26615083",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033649","Insulin korrekturschema pdf","rozycywfjj","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11795761",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033650","GLP Formula – Die Zukunft der Gewichtsabnahme","GLP Formula Rezension","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15958127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033651","Sulfurous Eructation During GLP-1 Agonist Therapy: Mechanistic Rationale for Bismuth Subsalicylate","Yunus Emre Zahiroğlu","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18944854",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033652","Effects of Glycemic Control and Antidiabetic Therapies on Erectile Function in Men With Type 2 Diabetes: A Systematic Review","Miguel Valdebenito Barraza","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.20249934",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033653","An Overview on Antidiabetic Disease","Sumedha Bane Mohammed Zakee Muazzam Malgundkar","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18269433",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033654","Preparation of exendin-4 conjugated nanoemulsions as targeted drug delivery systems","Toplak, Philipp","2023","TUGraz OPEN Library (Graz University of Technology)","other","article","10.3217/a4wvj-pnp84",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033655","besta instructions pdf","dtgqtxzl","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11889065",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033656","Additional file 2: of Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial","Whicher, Clare","2019","Figshare","protocol","article","10.6084/m9.figshare.10566902",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033657","Additional file 1 of Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors—protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial)","Al-Ozairi, Ebaa","2024","Figshare","protocol","article","10.6084/m9.figshare.26681932",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033658","Additional file 1 of Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials","Zi-Yang Peng","2025","Figshare","other","article","10.6084/m9.figshare.30969743.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033659","Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)","Endocrine Society 2021","2021","Underline Science Inc.","randomized_trial","article","10.48448/egbg-am77",null,null,"ClinicalTrials.gov:NCT03548987","S000521","openalex","TRUE","paywalled","1","FALSE","other"],["R0033660","Additional file 2 of Effects of beinaglutide on visceral fat area and gut microbiota in obesity","Liu, Tianshui","2025","Figshare","other","article","10.6084/m9.figshare.29231920",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033661","Additional file 4 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Ugamura, Daisuke","2022","Figshare","other_trial","article","10.6084/m9.figshare.20056571",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033662","Formulation Strategies and Evaluation Approaches for Drug-Loaded Paper Tablets in Type 2 Diabetes Management","Pravesh Kumar*, Dr. RamNarayan Prajapati, Dr. Sunil Kumar Prajapati","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19062076",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033663","GLP Formula Hur kan hjälpa dig att uppnå hållbar viktminskning","GLP Formula Uppleva","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15827880",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033664","Ozempic.docx","Sood, Purab","2021","Figshare","other","article","10.6084/m9.figshare.14222192",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033665","Additional file 3 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Alfayez, Osamah M.","2020","Figshare","systematic_review","article","10.6084/m9.figshare.12545000",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033666","Futurismo, presentismo y gestión clínica de la MASLD","Crespo, Javier","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.17854701",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033667","THE EXPANDING THERAPEUTIC LANDSCAPE OF GLP-1 RECEPTOR AGONISTS BEYOND DIABETES","Gayatri S. Bansode. Rupal R.Walke","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.18524936",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033668","Additional file 2 of Uncovering the potential molecular mechanism of liraglutide to alleviate the effects of high glucose on myoblasts based on high-throughput transcriptome sequencing technique","Fan, Dongmei","2024","Figshare","other","article","10.6084/m9.figshare.25195100",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033669","Wegovy Kostenübernahme Krankenkasse - Ein umfassender Leitfaden!","Erfahrungen, Wegovy","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13283342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033670","DK REDDIE WP4 Analysis plan: GLP1-RA versus DPP4","Sørensen, Kathrine Kold","2024","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.10926989",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033671","Global Burden and Evolving Therapeutic Strategies in Diabetes Mellitus: A Comprehensive Review","Mosrur Ahmed Laskar","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.17605341",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033672","Additional file 1 of Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis","Chang, Kai-Cheng","2020","Figshare","systematic_review","article","10.6084/m9.figshare.13076588",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033673","Triethyl phosphate (TEP) – dimethylsulfoxide (DMSO), as a green solvent mixture for solid-phase peptide synthesis (SPPS)","Noki, Sikabwe","2024","Figshare","other","article","10.6084/m9.figshare.28038094",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0033674","Additional file 1 of Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial","Ghosh, Sujoy","2025","Figshare","other_trial","article","10.6084/m9.figshare.28657215",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0033675","Characterization of Radiolabeled Exendin-4 Derivatives for Improved Imaging of β-Cell Pathologies","Simon Käppeli","2019","Repository for Publications and Research Data (ETH Zurich)","other","article","10.3929/ethz-b-000347610",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033676","CLINICAL IMPACT OF SEMAGLUTIDE ON OBESITY MANAGEMENT AMONG SAUDI ADULTS: A CROSS-SECTIONAL STUDY","Ahmad A Baharith, Dr. Mahmood M. Sadagah, Mahdi Hassan Aldajani, Hussain Hassan Aldajani3, Saadiah Adnan Balkhy , Abdulaziz Faris Alshehri, Meshal Hussain Alzahrani, Saeed Mohammed Alzahrani, Faisal Ahmed Alhejaily , Lujain Sameer Samarin, Omar Ahmed Bashanam, Abdulaziz Ahmed Alkathami, Zainab Aziz Al Sahwan, Sara Mohammad Altheebi  and Hoda Jehad Abousada","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.10472927",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0033677","Additional file 1 of Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study","Peng, Zi-Yang","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26623015",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033678","Improving Generation and Transplantation of Human Stem Cell-Derived Beta Cells for Treatment of Type-1 Diabetes","Larson, Kelly","2025","University of Michigan Library","preclinical","article","10.7302/25545",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033679","Anti-obesity Drugs Market Size & Demand Analysis, Growth Forecast 2025–2032","Healthcare","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15878735",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0033680","Additional file 2 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Yang, Chun-Ting","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.12479051",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033681","Additional file 3 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Husain, Mansoor","2020","Figshare","other_trial","article","10.6084/m9.figshare.13031552",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033682","Formelsammlung mittelschule bayern pdf","vblwteaq","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11672989",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033683","CAPÍTULO 123 - TIRZEPATIDE VERSUS SEMAGLUTIDA PARA O TRATAMENTO DE DIABETES MELLITUS TIPO 2- UMA REVISÃO SISTEMÁTICA","Almeida, Amanda Nascimento de","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16950827",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0033684","Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis","Guo, Tingli","2024","Figshare","preclinical","article","10.6084/m9.figshare.c.6857631",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033685","Various Allopathic Drugs Used in the Treatment of Obesity","Ishwari Sujit Agre, Rutuja Vijay Bhagat, Payal Sunil Khatavkar, Rasika Umesh Veer, Dr. Uday A.  Deokate","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19757608",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033686","Additional file 5 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Yang, Chun-Ting","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.12479060",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033687","Additional file 1 of A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal","Hadeel A. Khalil","2026","Figshare","preclinical","article","10.6084/m9.figshare.31367474.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033688","Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study","Adis Journals On Behalf Of","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26977636",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033689","Medicamentos GLP-1 RAs: uma revolução no controle da obesidade e na prevenção de doenças cardiovasculares","Reckel, Leandro de Oliveira","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14809240",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033690","Oral Delivery Challenges & Formulation Strategies for Glucagon Like Peptide-1 Receptor Agonists","Patil Rajvardhan*1, Patil Snehit2, Kadam Swapnil3, Sulgudle Shivraj4, Dr. Gejage Santosh5","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18620125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033691","BASED ON STUDY OF TIRZEPATIDE IN THE MANAGEMENT OF CHRONIC WEIGHT LOSS IN TYPE 2 DIABETES","Kattepogu Naga Kumari, Sakila Jayasri*, Vinjamuri Glory Nissy*","2024","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.13820089",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","report"],["R0033692","Additional file 1 of Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats","Inoue, Kazuho","2022","Figshare","preclinical","article","10.6084/m9.figshare.19728040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033693","GLP Formula Kapsler Anmeldelse Danmark: Officiel Pris, Hvor Kan Man Købe","GLP Formula Kapsler","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15715512",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033694","Semaglutide: A Promising Treatment for Alcohol Use Disorder","American Medical Association 2023","2023","Underline Science Inc.","other","article","10.48448/nsc6-wv76",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033695","Physiological investigation of causal genetic variants in metabolic disease","Umapathysivam, Mahesh","2019","Oxford University Research Archive (ORA) (University of Oxford)","other","article","10.5287/ora-qrgb4bka2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033696","hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair","Wang, Wei","2024","Figshare","preclinical","article","10.6084/m9.figshare.c.6583810",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033697","Additional file 1 of A comprehensive analysis of community pharmacists’ practices, barriers, and strategies in patient education on Saxenda®: a qualitative study","Abdullah Saad Turki","2026","Figshare","other","article","10.6084/m9.figshare.32070563.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033698","diabetes research project pdf","havxdjeb","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12343114",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033699","lesen & schreiben b2 pdf","djmhfgjjsez","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11989550",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033700","Type 2 Diabetes in Different Pacific Groups in Aotearoa New Zealand – Characteristics and Medication Use","Chepulis, Lynne","2024","University of Canterbury Research Repository (University of Canterbury)","other","article","10.26021/15599",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033701","Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Nileshraj G","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20951625",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033702","Statistical Analysis Plan for a Comparative Study of GLP-1 Receptor Agonists and DPP-4 Inhibitors Using Clinical Practice Research Datalink (CPRD) Data – Insights from the LEADER Trial","Gharibzadeh, Safoora","2025","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.14605131",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033703","menopause belly fat diet plan pdf","kjuixbbv","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11792655",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033704","Grammatik und konversation 1 pdf","zmrzibfst","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11946482",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033705","Adjuvant Dapagliflozin in Kidney Transplant Recipients with Diabetes and Heart Failure – A Real-World Data Exploratory Study","Ricardo ET Navarrete","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.19446326",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033706","The Leiomyoma-LAM Convergence: Nrf2-Keap1-Cullin 3 Axis Hijacking, Selenium-Dependent GPx Exhaustion, and a Three-Tier Metabolic Governance Strategy Across Estrogen-Sensitive and mTOR-Driven Smooth Muscle Proliferation","Grace Ann","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20563325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033707","The GLP-1 Plateau Problem: Why Upstream Aldose Reductase 2 Inhibition Is the Missing Pharmacological Partner for Every Incretin-Based Obesity Therapy","PRAKASH VAITHYANATHAN","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20598989",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033708","Usp monograph pdf","wqatcafgn","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11675780",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033709","Van Medical Journal - Volume 29-Issue 3","Ahmet İlkay CEYHAN- Cansu ARISOY","2022","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19493395",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033710","Additional file 1 of Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction","Trombara, Filippo","2024","Figshare","other","article","10.6084/m9.figshare.26566868",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033711","6 Week Belly Ozempic Weight Loss Before And After: Other Weight Loss Drug Results!","Johnes, Holmes","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12793342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033712","mounjaro patient assistance program pdf","htvekhmuugp","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11893987",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033713","Safety and Efficacy of Phentermine and Topiramate for Weight Loss in Obesity-Related HFpEF","American Medical Association 2025","2025","Underline Science Inc.","nonrandomized_study","article","10.48448/trjm-gy02",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033714","Clinical Trial vs Real-World Adverse Event Divergence: A Semaglutide Case Study Using FAERS Data","kasula sharath","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.19502666",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0033715","A REVIEW ON GLP-1 RECEPTOR AGONIST – SEMAGLUTIDE","Sathish Kumar M","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.20036780",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033716","Mathe 10 klasse gymnasium aufgaben mit lösungen pdf","wwnwkwikf","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11813267",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033717","Polycystic Ovary Syndrome as a Multi-System Disorder: A Comprehensive Review of Hormonal, Metabolic, and Inflammatory Crosstalk at the Cellular and Molecular Level","Sumit Ghosh1, Yash Srivastav2, Shonu Jain3, Nilanjan Pahari4, Soni Singh5, Johny Lakra6, Sujit Kumar Panda7, Jayalakshmi M.8, Srinivas Venkatraman*9","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.17047471",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033718","Rekombinante Herstellung, Renaturierung und biophysikalische Charakterisierung des humanen Glucagon-like Peptide-1 Rezeptors","Kathrin Schröder-Tittmann","2009","Digitalen Hochschulbibliothek Sachsen-Anhalt (Universitäts- und Landesbibliothek Sachsen-Anhalt)","preclinical","article","10.25673/360",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033719","Additional file 1 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence","Schechter, Meir","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.15253888",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033720","BEYOND METFORMIN: A DECADAL REVIEW OF EMERGING ORAL HYPOGLYCAEMICS AND THEIR REAL-WORLD IMPACT ON GLYCEMIC CONTROL","Dr. Mohammed Riyaz2 Dr. Mohammed Muzammil*1","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.20465454",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033721","The oligodendrocyte lineage of the median eminence in the adaptation to diet-induced obesity","Hansford, Robert","2023","Apollo (University of Cambridge)","preclinical","article","10.17863/cam.109116",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033722","novo nordisk patient assistance application pdf","vpslysdjdk","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12363729",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033723","Additional file 1 of Response to semaglutide of non-drinker subjects with type 2 diabetes","Petralli, Giovanni","2024","Figshare","other","article","10.6084/m9.figshare.25853087",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033724","DIABETES MELLITUS: PATHOPHYSIOLOGY, DIAGNOSIS, AND THERAPEUTIC ADVANCES","Kumud Madan","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20444364",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033725","Use of novel glucose-lowering therapies in novel populations with type 2 diabetes","Ahmad, Ehtasham","2024","University of Leicester","randomized_trial","article","10.25392/leicester.data.27043756",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0033726","Insulin and IGF-1 receptor autocrine loops are not required for Exendin 4.pdf","Cruzat, Vinicius","2018","Figshare","other","article","10.6084/m9.figshare.7264217",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033727","GLP-1 Receptor Agonists and Cholelithiasis: A Comprehensive Review","Giotas, Ilias","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.15303789",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033728","Efficacy of Liraglutide in the Management of Hyperphagia, Severe Obesity, and Liver Steatosis/Fibrosis Indices in Prader Willi Syndrome: A Case Report","Zumbolo F1*, Pugliese G1, de Alteriis G1, Muscogiuri G1, Barrea L2, Aprano S1, Laudisio D1, Cossiga V1, Morisco F3, and Savastano S1","2024","Zenodo (CERN European Organization for Nuclear Research)","case_report","article","10.5281/zenodo.11516330",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033729","Clinical Staging for the Management of Metabolic Disorders and Their Sequelae in Patients with Heart Failure: A Comprehensive Framework","Camilo Fernández Bravo, MD/PhD","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15565871",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033730","weight loss menu plan pdf","uiqkibpt","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11818128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033731","FDEP-TP framework — Article A3: Methodological and translational foundations (Lancet Diabetes & Endocrinology submission package)","Hector M. Virgen-Ayala","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20102987",null,null,"OSF:osf.io/3czre",null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0033732","Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice","Narendra Kumar Reddy Challa","2025","ETH Zürich Research Collection","preclinical","article","10.3929/ethz-c-000790894",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033733","Msa mathe 2023 lösungen pdf","zimnjqgdlp","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11692087",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033734","ozempic spanish pdf","cgglswtdirf","2024","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.11952893",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033735","Additional file 6 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Husain, Mansoor","2020","Figshare","other","article","10.6084/m9.figshare.13031561",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033736","MOESM2 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Bruen, Robyn","2017","Figshare","preclinical","article","10.6084/m9.figshare.c.3923344_d4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0033737","Comparative efficacy and acceptability of glucagon-like peptide-1 receptor agonists for glycemic control among patients with type 2 diabetes: a systematic review with trial sequential analysis and network meta-analysis","Dooley, Gordon","2014","York","systematic_review","article","10.15124/crd42014015328",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0033738","CONTAC WhatsApp (+966562649256) get ozempic online get ozempic prescription online BUY Wegovy UK for WEIGHT loss,treatment IN AUSTRALIA","Sri Karan Narendra Agriculture University, Jobner","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11640625",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033739","check symbol pdf","njgexqyfiw","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12056695",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033740","Pharmacotherapy for metabolic illnesses (metabolic syndrome, obesity, gout, chronic adrenal insufficiency).","Mariia Murzaeva","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17435749",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033741","Semaglutide versus other GLP-1 Agonists on Weight Loss in Type 2 Diabetes Patients","American Medical Association 2024","2024","Underline Science Inc.","other","article","10.48448/nfp9-jt12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033742","Green line 6 lösungen pdf","jcivrlfpd","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11922385",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033743","RP-HPLC METHOD FOR DETERMINATION OF ANTI-DIABETIC DRUG LIRAGLUTIDE IN BULK AND TABLET FORMULATION","Lalitha N*, Supriya S Patil","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.8412638",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033744","Novel non-invasive markers, imaging and interventions for the diagnosis, characterisation and treatment of non-alcoholic fatty liver disease","Ahmad Moolla","2019","Oxford University Research Archive (ORA) (University of Oxford)","randomized_trial","article","10.5287/ora-rjorg9k8b",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0033745","ЦУКРОВИЙ ДІАБЕТ 1 ТА 2 ТИПУ: ПОРІВНЯЛЬНИЙ ОГЛЯД ТА СУЧАСНІ ТЕРАПЕВТИЧНІ ПІДХОДИ","М.Г. Сорока","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18457356",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033746","Additional file 1 of The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","Larsen, Anna Thorsø","2021","Figshare","other","article","10.6084/m9.figshare.13544375",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033747","Transplantace, komorbidity a moderní léčba diabetu","Martin Haluzík","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20593915",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033748","Ben Napier Weight Loss What is Ozempic and why are people turning to it for weight","SherylDF, rederick","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12780100",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033749","Zentrale klausur nrw mathe 2019 lösungen pdf","jrrjcyqfh","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11774195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033750","Kissing carotid arteries: An unusual cause of male hypogonadotropic hypogonadism.","Endocrine Society 2022","2022","Underline Science Inc.","other","article","10.48448/bjm4-ww22",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033751","Metabolic and Cardiovascular Biomarker Responses to Escalating Retatrutide Doses in a Single Subject: A Longitudinal N=1 Observational Case Report","Angelo Fong","2026","Figshare","case_report","article","10.6084/m9.figshare.31989192",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033752","Additional file 1 of Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study","Che‐Yuan Wu","2025","Figshare","nonrandomized_study","article","10.6084/m9.figshare.30970098.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033753","THE HIDDEN SIDE OF MOUNJARO (TIRZEPATIDE) WEIGHT LOSS: NAVIGATING ADVERSE DRUG REACTIONS AND SOCIAL QUESTIONS","Praveen Kumar Vuppula1* and Shiva Prasad Thoutu2","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.17766991",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033754","Mitochondrial Bioenergetics and Supercomplexes in Heart Failure: Mechanisms and Therapeutic Approaches","Claire Fong-McMaster","2026","University of Ottawa - Library","preclinical","article","10.20381/ruor-31644",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033755","The Apoptotic Budget: A Geometric Framework for the Inverse Correlation Between Parkinson's Disease and Cancer, with VDAC1 as the Competitive Docking Chokepoint","Gedas Mekšriūnas","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19435751",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033756","Clinical Review of Antidiabetic Drugs: implications for Type 2 Diabetes Mellitus Management","Sahil Nivangune*, Shradha Singhi, Shravani Kulkarni, Abhijeet Satpute, Vedanti Walzade, Prathmesh Kadam","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.14993125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033757","Insulin Resistance in Alzheimer's: Exploring the Type 3 Diabetes Hypothesis","Hebbare Sravani Bai, Yashmeen Nikhat","2025","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.16799941",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033758","Mathe zp 10 nrw 2022 pdf","zbdisgpkd","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12105659",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033759","Tides are Changing for Obesity - Comparing GLP-1 Agonists and Their Effect on Weight Loss","Endocrine Society 2023","2023","Underline Science Inc.","other","article","10.48448/h50n-3j52",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033760","Additional file 1 of Adverse events associated with tirzepatide: a focus on subgroup-specific differences","Zhongming Yu","2026","Figshare","other","article","10.6084/m9.figshare.31911374",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033761","Peering into the cell: click chemistry and novel dyes towards enhanced biomedical imaging","Moreno, Jose Ricardo (author)","2022","University of Southern California Digital Library","other","article","10.25549/usctheses-ouc111384551",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033762","Repurposing Semaglutide for the Treatment of Cocaine Use Disorder: a Pilot Mechanistic Study","Joy M. Schmitz","2026","HEAL Data Platform","other","article","10.60490/hdp01571",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033763","Variability of Greenwood's Formula and Application to Meta Analysis","Rodenkirchen, Jürgen","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13141778",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033764","Management of Diabetes and Hyperglycemia in Hospitalized Patients","Ketan Dhatariya","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18371231",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033765","Beipackzettel pdf","pmikxwao","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12387747",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033766","Formelsammlung mittelschule bayern pdf","hivvjblta","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12373572",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033767","STABILITY-INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF BALCINRENONE AND DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE IN ITS SYNTHETIC MIXTURE","Ms. Janaki Patel2 Dr. Avani N. Doshi1*","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19309362",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033768","Additional file 1 of Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study","Szépkúti, Sándor","2022","Figshare","nonrandomized_study","article","10.6084/m9.figshare.21117530",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033769","A COMPREHENSIVE REVIEW OF SEMAGLUTIDE: PHARMACOLOGY, CLINICAL EFFICACY, CARDIOVASCULAR OUTCOMES, AND SAFETY PROFILE","Rakhimov Anvarjon Aliyorovich https://orcid.org/0009-0007-0785-8084","2025","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.17177815",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0033770","Development And Validation Method for Estimation for Liraglutide By RP-HPLC From Its Injectable Dosage Form","Akhil Bhakhar*, Khyati Bhupta, Dhirendra Kumar Tarai, Dr. Santosh Kirtane","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15607231",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033771","Current Advances in Pharmacotherapy for Diabetes Mellitus: A Comprehensive Review","Shreyash Gugliya, Rinkesh Zanjari, Dr. Aman Upaganlawar*, Dr. Manojkumar Mahajan, Dr. Chandrashekhar Upasani","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.15038248",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033772","Therapeutic Potential of GLP-1 Receptor Agonists in Type 1 Diabetes Mellitus","Synthory AI","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15265526",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033773","Zentrale abschlussprüfung nrw übungen pdf mathe","fudglyvht","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11943137",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033774","Pharmaceutical Perspectives on Semaglutide: Formulation Drug Delivery and Clinical Applications","Jayakumar M.*","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16991652",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033775","CONTEMPORARY WEIGHT LOSS MEDICATIONS: \"A COMPREHENSIVE REVIEW ON THE THERAPEUTIC EFFICACY, SAFETY AND ADVERSE EFFECTS.\"","Vyas Prakruti*1, Patel Harsh P.2, Dr. Manan Sharma3, Dr. Anjali Gupta4, Dr. Akshat Parashar5","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.18429691",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033776","From Scalpel to Syringe: Can Tirzepatide Bridge the Gap Between Pharmacotherapy and Bariatric Surgery?","Wiktoria Marta Rybak2 Emilia Piaszczyńska1*","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.19695495",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033777","Additional file 2 of Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study","Kumarathurai, Preman","2021","Figshare","randomized_trial","article","10.6084/m9.figshare.13545533",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033778","Formelsammlung mathe realschule bayern pdf","ijkaxzvqe","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11979991",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033779","Poster presented at EASL 2025 -Sustained improvements in non-invasive biomarkers with the novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis","Noureddin, Mazen","2025","Boehringer Ingelheim","other_trial","article","10.60915/boehringer-figshare.29070158",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","conference-abstract; article"],["R0033780","Additional file 3 of Effects of beinaglutide on visceral fat area and gut microbiota in obesity","Liu, Tianshui","2025","Figshare","other","article","10.6084/m9.figshare.29231923",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033781","MOESM2 of Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial","Peradze, Natia","2019","Figshare","randomized_trial","article","10.6084/m9.figshare.10117193",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033782","Polycystic Ovary Syndrome: Insights And Advances In Diagnosis And Management","P. Lazaru*, Dr. J. N. Suresh Kumar, K. Sai Teja Sree, SK. Mansoor, M. Siva Kumar, S. Venkata Sakshi, SK. Jameela","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14019268",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033783","Prescription frequency and development of liraglutide and empagliflozin in the light of current DMP recommendations: a German real-world cohort study in type 2 diabetes mellitus patients at high cardiovascular risk","Seidel, Karolin","2021","German Medical Science (German Research Foundation)","nonrandomized_study","article","10.3205/21dkvf068",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033784","Your Diabetes Care and Management Plan","jack, jack","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14184568",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; report"],["R0033785","Novel Aspects in Incretin and Glucagon Biology: From Basic to Clinical Applications - Triple incretin agonists: ready for prime time?","Endocrine Society 2022","2022","Underline Science Inc.","other","article","10.48448/5z2q-8616",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033786","Tracking smartphone screen time during weight-loss trials: an indirect means of exploring semaglutide's efficacy against addiction","Stacey, Neil Thomas","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12660261",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033787","Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients","Wei, Ran","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.c.6797377",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033788","Additional file 1: of Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4","Kaeppeli, Simon","2019","Figshare","other","article","10.6084/m9.figshare.8142440",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033789","In Silico Generation of Absolute Biomedical Discoveries: Topological Inference of Post-Translational Modification Cascades and PubMed Automated Cross-Referencing","Luigi Usai","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20736025",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0033790","wegovy fachinformation pdf","zasfkxylhv","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12404085",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033791","Additional file 4 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Yang, Chun-Ting","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.12479057",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033792","Association between glucagon-like peptide-1 receptor agonists, residual gastric content, and bronchopulmonary aspiration after fasting: an ongoing systematic review and meta-analysis","Sidhu, Nav","2025","University of Auckland Data Repository","systematic_review","article","10.17608/k6.auckland.28537307.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint; review"],["R0033793","Msa mathe pdf","vckpapxsay","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12107521",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033794","Zap englisch übungen pdf nrw","wgasgcdrt","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12059912",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033795","Plain Language Summary of the Manuscript: A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine.","J. Sanyal, Arun","2024","Boehringer Ingelheim","randomized_trial","article","10.60915/boehringer-figshare.27720072.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033796","Liraglutide for Weight Management in Pubertal Adolescents with Obesity: A Randomized Controlled Trial","Endocrine Society 2020","2022","Underline Science Inc.","randomized_trial","article","10.48448/h3pm-va31",null,null,"ClinicalTrials.gov:NCT02918279","S000599","openalex","TRUE","paywalled","1","FALSE","other"],["R0033797","abfm ksa answers pdf","xwdjztrddl","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11723136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033798","englisch zap übungen pdf","ztpxpbrhhm","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12042924",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033799","Nateglinide in Type 2 Diabetes Mellitus: A Focus on Postprandial Glucose Management","Ms. Laxmi Gupta","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17019164",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033800","SEMAGLUTIDE - FOR THE TREATMENT OF OBESITY","S.D. Aminov","2025","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.14993618",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033801","Advancement in the Management of the Diabetes: A Comprehensive Review","Purushottam Kumar, Mamta Kadawal, Neha Yadav, Rupesh Kumar, Ankit Kumar, Kirti Yadav*","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.18507335",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033802","Additional file 1 of Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network","García-Vega, David","2024","Figshare","other","article","10.6084/m9.figshare.26660146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033803","Additional file 2 of Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide – a review","Ming Lu","2026","Figshare","narrative_review","article","10.6084/m9.figshare.32102216",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033804","Glucagon-Like Peptide-1","Giblett, Joel P.","2019","JACC: Journal of the American College of Cardiology","nonrandomized_study","article","10.25407/jacbts.c.4536203",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033805","Glycemia and Gluconeogenesis in Youth-onset Type 2 diabetes: A Randomized Controlled Trial","Dietsche, Katrina","2023","Figshare","randomized_trial","article","10.6084/m9.figshare.24492187",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033806","АКТУАЛЬНОСТЬ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ С ПОМОЩЬЮ ИНКРЕТИНОВОЙ ТЕРАПИИ","Алакбарова, Нодира","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15319071",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033807","Additional file 1 of Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program","Nicholls, Stephen J.","2024","Figshare","other_trial","article","10.6084/m9.figshare.25201920",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033808","Additional file 1 of Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study","Yang, Chun-Ting","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.12479042",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033809","Imeglimin-A New Oral Antidiabetic Agent in the Armamentarium of Resistant type2 Diabetics Specifically Regarding t2d with Correlated Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-A Minireview","M.D Dr Kulvinder Kochar Kaur","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.18437560",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033810","Wegovy information pdf","twiaqafvl","2024","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.12300022",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033811","Desenlaces en pacientes con enfermedad hepática asociada a disfunción metabólica tratados con agonistas del receptor GLP 1: una revisión de alcance","Álvarez Ariza, Karen Margarita","2025","Repositorio Institucional E-DocUR (Universidad Del Rosario)","other","article","10.48713/10336_44950",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033812","Glucagon-like peptide-1 receptor agonist versus basal insulin in type-2 diabetic patients: An efficacy and safety analysis","Kwei-Jay Lin","2020","Greater South Information System","nonrandomized_study","article","10.60692/ff6h0-8mj30",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033813","Impact of GLP-1 receptor agonists on heart rate, blood pressure and hypertension among type 2 diabetes: a systematic review and network meta-analysis","Dooley, Gordon","2014","York","systematic_review","article","10.15124/crd42014009019",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0033814","Emerging Pharmacotherapies for MASLD: A Comprehensive Review","Deepti Bandawane Sakshi Katke*","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.18340110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033815","Additional file 1 of Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus","Grannes, Helene","2024","Figshare","other","article","10.6084/m9.figshare.25720188",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033816","Antidiabetic Agents: Pathophysiology of Diabetes Mellitus and Therapeutic Approaches","V. S. Adak Akshada Pawar","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18458301",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033817","Insulin korrekturschema pdf","zvlphlti","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12080499",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033818","Type 2 Diabetes Mellitus","Gholap Siddhi*, Mandlik Rutuja, Madhe Prabhavati, Dr. Pallavi Phalake, Mayuri Mundhe","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20472427",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033819","Cryo-Coupling: Geometric Cancer Intervention via Phase-Locked Descent of the 25×N Ladder","James E. Dunn","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19223643",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033820","Mathematik formelsammlung pdf","xtvbcejker","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12258745",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033821","Exploring Multimodal Interventions for Mitigating the Impact of Associated Coronary Artery Disease on Transcatheter Aortic Valve Replacement Efficacy: Incorporating Hemodynamic Evaluations, Staged Percutaneous Coronary Interventions, and Longitudinal Cardiovascular Risk Mitigation Strategies","MD/ PhD/ FACC Camilo Fernández Bravo","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18368909",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033822","MOESM10 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Bruen, Robyn","2017","Figshare","preclinical","article","10.6084/m9.figshare.c.3923344_d1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0033823","Green line 6 workbook lösungen pdf","zzrpcucvbaa","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11860510",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033824","SUPPL_T2D_SGLT2i_GLP1RA_AF.pdf","Chan, Yi-Hsin","2024","Figshare","other","article","10.6084/m9.figshare.25478380",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033825","Hauptschulabschluss prüfungsaufgaben mathe pdf","wwqonuiie","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11789360",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033826","Mathe 10 klasse gymnasium aufgaben mit lösungen pdf","jkkhdiujx","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12363588",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033827","Implementation of a GLP-1 Patient Education Adherence Toolkit to Improve Therapy Adherence and Clinical Outcomes in Older Adults With Type 2 Diabetes and Obesity","Mekhla Raina","2026","Libra","other","article","10.18130/hw86-nf05",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033828","Diabetes as a Risk Factor for Neurodegenerative Diseases: A Systematic Review","Synthory AI","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.15299456",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033829","Additional file 4 of Effects of beinaglutide on visceral fat area and gut microbiota in obesity","Liu, Tianshui","2025","Figshare","other","article","10.6084/m9.figshare.29231926",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033830","Table 1S.docx","Sato, Tetsuhiko","2023","Figshare","other","article","10.6084/m9.figshare.22122317",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033831","Mathe zp 10 nrw 2022 pdf","bujdvqkclyx","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11691629",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033832","Retatrutide: Α triple incretin receptor agonist showing promise in obesity treatment","Giotas, Ilias","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.15299219",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033833","mayo clinic grapefruit diet pdf","cbzjcgxtqp","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11914110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033834","MOESM3 of Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial","Peradze, Natia","2019","Figshare","randomized_trial","article","10.6084/m9.figshare.10117199",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033835","MOESM1 of Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial","Clegg, Lindsay","2019","Figshare","nonrandomized_study","article","10.6084/m9.figshare.10027562",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033836","Gunna Weight Loss: Suggests Healthy Sex Life Was Key to Massive Weight Loss!","Williame, Greens","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12798906",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033837","Diabetes Mellitus: Current Understanding, Emerging Targets, And Natural Therapies","Harsh Shukla*, Shobhit Prakash Srivastava","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13997444",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033838","MOESM1 of Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial","Peradze, Natia","2019","Figshare","randomized_trial","article","10.6084/m9.figshare.10117184",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033839","Recent advancements in the role of Angiotensin receptor blockers in the management of chronic kidney disease","Pankaj Kumar Sah","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17131771",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033840","Msa mathe 2023 pdf","hbogyjdrgb","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11702687",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033841","Hauptschulabschluss prüfungsaufgaben mathe pdf","igqluqrp","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12422934",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033842","Additional file 1 of Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","Lugner, Moa","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.14267035",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033843","Figure 6: Proposed Mechanisms for a GLP-1RA-Induced Anti-Atherosclerotic Effect","Günaj Rakipovski","2019","JACC: Journal of the American College of Cardiology","other","article","10.25407/jacbts.8253359",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033844","Grammatik und konversation 1 pdf","hzufwfrrrau","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12260593",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033845","Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence","Schechter, Meir","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.c.6668267",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033846","Additional file 3 of Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide – a review","Ming Lu","2026","Figshare","narrative_review","article","10.6084/m9.figshare.32102219",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033847","ElectroSlim (Truth-Telling Reviews) Promote Fat Burning And Prevention of Excess Fat","Simple-Promise-ElectroSlim, Simple-Promise-ElectroSlim","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11651589",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033848","Rationale for DPP-4 Inhibitors as Bridge or Dose-Sparing Therapy in Patients Using GLP-1 Receptor Agonists or Tirzepatide","Acanfora, Matteo","2025","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.17101109",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint; article"],["R0033849","Additional file 3 of Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways","Wang, Duozi","2025","Figshare","other","article","10.6084/m9.figshare.29632379",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033850","Beyond Phlebotomy: Tirzepatide for Iron Overload in Hereditary Hemochromatosis","American Medical Association 2025","2025","Underline Science Inc.","other","article","10.48448/e90s-rc32",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033851","Additional file 1: Table S1. of Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice","You-Cheol Hwang","2017","Figshare","other","article","10.6084/m9.figshare.c.3912808_d1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033852","Additional file 1 of Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes","Zhang, Xianyu","2024","Figshare","other","article","10.6084/m9.figshare.26409922",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033853","Antidiabetic Medications: An Oral Treatment Approach for Regulating Blood Glucose Levels","Mahesh Bhakare*, Syed A. A., Dinesh Gujrathi, Vaishnavi Siral, Sonal Doltade","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15205149",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033854","Using Clinical Trial Results to Optimize Patient Care: Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With GLP-1 Receptor Agonists and SGLT-2 Inhibitors","Endocrine Society 2021","2021","Underline Science Inc.","other_trial","article","10.48448/c41z-cb56",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0033855","Role of Lifestyle Interventions in Diabetes Prevention and Management","Manobalan M, Selvabalaji S, Rashvin CV, Haribaskar R, NaveenKumar Mannar","2024","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.11354003",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033856","GPCR Agonist Mechanisms: From Structural Dynamics to Targeted Drug Discovery","pharmacology science","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19659068",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0033857","PHARMACOLOGICAL APPROACHES TARGETTING INFLAMMATORY PATHWAY OF CARDIOVASCULAR COMORBIDITIES","H. Ganesh","2022","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.6452730",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033858","glargine davis pdf","tcwopiuu","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12184689",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033859","SGLT2i vs GLP1RA: Which is Better?","Endocrine Society 2022","2022","Underline Science Inc.","other","article","10.48448/qgkg-kz54",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033860","A pipeline for identification and validation of brain targets for weight loss","Blouet, Clemence","2023","Apollo (University of Cambridge)","other","article","10.17863/cam.93081",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033861","Additional file 5 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Alfayez, Osamah M.","2020","Figshare","systematic_review","article","10.6084/m9.figshare.12545018",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033862","Additional file 1 of Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists","Lai, Hsuan-Wen","2024","Figshare","other","article","10.6084/m9.figshare.26409879",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033863","Bio-Analytical Method Development and Validation for Estimation of Tirzepatide by RP-HPLC in Dosage Form","Vaishnavi Bitne","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17143457",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033864","Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial","Endocrine Society 2021","2021","Underline Science Inc.","randomized_trial","article","10.48448/hm3x-8s87",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033865","Tirzepatide (Mounjaro®) and Its Contribution to Improving Quality of Life in Endocrinology: An Integrative Review","Muniz, Miguel Matteo Leopoldo Pinheiro","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.17779558",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033866","Novel Mechanisms of Islet Oscillations","C.S. Liu","2025","Deep Blue (University of Michigan)","preclinical","article","10.7302/26962",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033867","Glucagon: Past, Present, and Future - Dual and Triple Gut Hormone Co-Agonists: Novel Therapeutics for Obesity and Diabetes","Endocrine Society 2023","2023","Underline Science Inc.","other","article","10.48448/90yt-dq26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033868","Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Huang, Yi-lin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.c.6689993.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0033869","Incretin-based therapies and risk of cancer in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","Dooley, Gordon","2015","York","systematic_review","article","10.15124/crd42015020401",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0033870","Semaglutida: Avanços Terapêuticos, Preocupações com a Segurança e Uso Racional na Obesidade e no Diabetes Tipo 2","Silva, Karla Cristine dos Anjos","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17458993",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033871","Capsiplex Burn Australia Let's– All Natural BHB Apple Gummy or Scam?","Capsiplex Burn Australia","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13822286",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033872","Additional file 5 of Effects of beinaglutide on visceral fat area and gut microbiota in obesity","Liu, Tianshui","2025","Figshare","other","article","10.6084/m9.figshare.29231929",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033873","CURRENT AND EMERGING PHARMACOLOGICAL THERAPIES FOR DIABETES MELLITUS: A REVIEW","Vishal B. Kuttarmare*, Sadhana P. Gautam, Dr. B. R. Gandhare, Jay R. Nagdeve, Ajay A. Turke, Tanveer K. Patel","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.20443916",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033874","Obesity as Metabolic Ground State Displacement: Adipose Accumulation as Φ, Food Environment as Wrong Attractor, and the Failure of Willpower as Landscape Misdiagnosis","Diego Rincon","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20410055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033875","Etiology And Clinical Manifestations Of Type 3 Diabetes (Alzheimer's Disease)","Ajay Kale, Rohit Shivaji Jamdade","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13620771",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033876","Semaglutide para insuficiência cardíaca: há fundamento?","Letícia Christiany Rodrigues Catharino Rafaella Valadares Diniz Laura Carolina Daroszewski Nogueira Guilherme Machado Moura Jéssica Thalita Alkmin Ferreira Sara Wagner Ribeiro Gontijo Rafael Cota Andrade Ferreira de Souza Isabele Borges Bueno Carolina Felipe Cotta","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13357856",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033877","Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies","Amit Namde*, Amey Dhuri, Nutan Gaikwad, Rini Punathil, Dr. Kamlesh Soni","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17313048",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033878","Therapeutic Peptides: An Evidence-Tiered Survey Across Neuroplasticity, Anti-Ageing, Fitness, and Tissue Repair: A Critical Review","Gareth Davies","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.20570202",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0033879","Your body is your sanctuary, not a project for modification: On self-love in an age of artificial standards","Sulaf Shammous","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19260040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033880","A REVIEW ON ANALYTICAL PROFILE OF SEMAGLUTIDE IN PHARMACEUTICAL DOSAGE FORMS AND BIOLOGICAL MATRICES","M. M. Eswarudu*, P. Siva Krishna, Shaik Shannu, B. Lakshmi Prasanna,  P. Tarun Kumar, Shaik Afrin, Ch. Sujith Kumar, P. Srinivasa Babu","2023","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.10154535",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0033881","Review on Type 2 Diabetes Mellitus: From Risk Determinants to Modern Therapeutic Strategies","Chandani B. Patil","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.18780172",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033882","Additional file 6 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","other","article","10.6084/m9.figshare.26642791",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033883","Glucagon-Like Peptide-1 Receptor Agonists Beyond Diabetes Mellitus: Pathophysiological Foundations and Clinical Applications in Obesity, Heart Failure, Chronic Kidney Disease, and Hepatic Steatosis","Carlos Manuel Venegas Valverde","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19849378",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033884","Additional file 1: of Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial","Whicher, Clare","2019","Figshare","protocol","article","10.6084/m9.figshare.10566896",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033885","Formelsammlung mathe bayern realschule pdf","abrsqtixeul","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12140096",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033886","Additional file 2 of Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","Lingvay, Ildiko","2024","Figshare","other","article","10.6084/m9.figshare.26577539",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033887","MOESM1 of Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists","Dawwas, Ghadeer","2018","Figshare","other","article","10.6084/m9.figshare.6831239",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033888","Profession Matters: Knowledge, Attitudes, and Practices of Libyan Healthcare Providers Regarding GLP-1 RA FDA Safety Warnings","Eshraq Alsherif","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18152852",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033889","Additional file 1 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Husain, Mansoor","2020","Figshare","other","article","10.6084/m9.figshare.13031546",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033890","INNOVATIVE PERSPECTIVES OF THE UTILIZATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR MANAGING OBESE POLYCYSTIC OVARY SYNDROME (PCOS) WOMEN & TREATMENT OFNON PCOS OBESE INFERTILE WOMEN FORIMPROV ING PREGNANCY & LIVE BIRTH RATES - A SHORT COMMUNICATION","*Dr. Kulvinder Kochar Kaur","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17276103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033891","Novel Drug Delivery System in Diabetes Mellitus: Current Trends and Future Prespective","Prerna Bahekar1, Prerana Sahu2*, Gyanesh Kumar Sahu3, Harish Sharma4","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18722381",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033892","Uso Fraudulento de Preparaciones para Pérdida de Peso en Centros Estéticos","Centro de Información de Medicamentos de la Universidad Nacional","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14026914",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033893","Englisch msa 2023 lösungen pdf","tnwmopdwo","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11693133",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033894","wegovy diet plan pdf","fcqdayszh","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12439232",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033895","COVID-19 AND DIABETES: MUTUAL INFLUENCE AND THERAPY CONSIDERATIONS","Andasheva Bermet","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17546445",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033896","Additional file 2 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","other","article","10.6084/m9.figshare.24597752",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033897","Liraglutide Improves the Integrated Pancreatic Microcirculation in Type 2 Diabetes Mellitus Mice: Evidence from the Common Microcirculatory Framework","Li, Yuan","2023","Figshare","preclinical","article","10.6084/m9.figshare.14385926",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033898","A Review on Unlocking the Theraputic Potential Effects of Semaglutide in Type 2 Diabetes and Obesity","Arya B Mohan, Grace N Raju*, Shaiju S Dharan","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.16980613",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033899","Additional file 1 of GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes","Marfella, Raffaele","2024","Figshare","other","article","10.6084/m9.figshare.26664109",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033900","Reward-Based Behavioral Drift Under GLP-1 Receptor Agonism: A Neuro-Economic Model of Incentive-Salience Re-Prioritization and Observer-Frame Asymmetry","Chris Gabriel","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18068561",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033901","Cardioprotective Mechanisms of Anti-Diabetic Agents - Mechanisms of Cardioprotection by SGLT2 Inhibitors and GLP-1R Agonists","Endocrine Society 2023","2023","Underline Science Inc.","other","article","10.48448/ftms-af13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033902","Poster presented at EASL 2025 -Non-invasive tests (NITs) to predict liver biopsy outcomes in response to treatment with survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist: exploratory analysis of a phase 2 trial in people with metabolic dysfunction associated steatohepatitis and fibrosis","Noureddin, Mazen","2025","Boehringer Ingelheim","other_trial","article","10.60915/boehringer-figshare.29070455",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","conference-abstract; article"],["R0033903","Additional file 2 of Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","Lugner, Moa","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.14267038",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033904","Wegovy Erfahrungen - Warum es eine revolutionäre Option für Ihre Diät sein könnte!","Erfahrungen, Wegovy","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13283336",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033905","Additional file 1 of Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF) protocol","Win, Kyaw Z.","2024","Figshare","protocol","article","10.6084/m9.figshare.25264281",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033906","Wegovy - So funktioniert das innovative Medikament zur Gewichtsabnahme!","Erfahrungen, Wegovy","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13283332",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033907","Comparison of subcutaneous GLP-1 receptor agonists, semaglutide and dulaglutide, on HbA1c and weight loss outcomes: A systematic review","Myo, Elaine","2025","University of Kent","systematic_review","article","10.22024/unikent/03/ajpp.1365",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033908","Effectiveness and safety of liraglutide for weight loss failure after bariatric interventions - a systematic review","Frutuoso, João Francisco da Cunha","2023","Universidade do Porto","systematic_review","article","10.34626/apd3-wq34",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","dissertation; review"],["R0033909","diabetes guide pdf","ruwniklg","2024","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.11884919",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033910","Navigating the Perfect Storm: A Comprehensive Analysis of US Healthcare Industry Pain Points 2024-2025","Jaisawal, Sudheer","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.15598190",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article; other"],["R0033911","Diagnosis and Treatment of Endocrine Diseases in Outpatient Settings: Type II Diabetes Mellitus","Mamarasul Kyzy Minura","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.19667581",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033912","Additional file 6 of Effects of beinaglutide on visceral fat area and gut microbiota in obesity","Liu, Tianshui","2025","Figshare","other","article","10.6084/m9.figshare.29231932",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033913","Losing Fat or Muscle? A Case of Rhabdomyolysis Following Initiation of Semaglutide (Wegovy)","American Medical Association 2024","2024","Underline Science Inc.","case_report","article","10.48448/0y21-qn46",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033914","Histological and immunohistochemical study of the effect of liraglutide in experimental model of non-alcoholic fatty liver disease","Nour, Mai Salah","2023","Figshare","preclinical","article","10.6084/m9.figshare.22672601",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033915","Machine Learning-Guided Design of Next-Generation Triple Agonist Peptide Therapeutics for Metabolic Disease","American Medical Association 2025","2025","Underline Science Inc.","other","article","10.48448/qckd-sz36",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033916","Additional file 4 of Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure","Sforza, Annalisa","2022","Figshare","other","article","10.6084/m9.figshare.19571894",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033917","Additional file 11: of Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas","Roberto, Giuseppe","2019","Figshare","other","article","10.6084/m9.figshare.7693394",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033918","Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","Birkenfeld, Andreas L.","2025","Universitätsbibliothek Tübingen","randomized_trial","article","10.15496/publikation-111217",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033919","Msa mathe lösungen pdf","iiclaklnzc","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11674033",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033920","AGONISTAS DO RECEPTOR DE GLP-1 EM PACIENTES COM OBESIDADE: UMA ANÁLISE DOS BENEFÍCIOS METABÓLICOS ALÉM DA PERDA PONDERAL","MARIANA MONTEIRO VILELA","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18762662",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0033921","Additional file 3 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","other","article","10.6084/m9.figshare.26642779",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033922","Zentrale klausur nrw mathe 2019 lösungen pdf","uztglqwa","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12146603",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033923","Falcetta_supplemental_material","Falcetta, Pierpaolo","2024","Figshare","other","article","10.6084/m9.figshare.28000868",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033924","Green line 6 g9 lösungen pdf","uehecieqayg","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11699130",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033925","Raport z zajęć informacja naukowa 2024","A.W.","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14259773",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0033926","G-Protein Coupled Receptors Modulating Incretin Hormone Secretion","Hodge, Daryl","2013","Apollo (University of Cambridge)","preclinical","article","10.17863/cam.122986",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033927","Additional file 2 of Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial","Jensterle, Mojca","2021","Figshare","protocol","article","10.6084/m9.figshare.15020783",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033928","A Systematic Review on Management of Type 2 Diabetes Mellitus: Conventional Treatment Strategies v/s Phyto-Alkaloids as Natural Alternatives","Raj Kumar*, Pardeep Kumar, Leena Thakur","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.17053155",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033929","Zap englisch übungen pdf nrw","kfvwpiqarix","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11735744",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033930","Additional file 3 of Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease","Abdulhameed, Noor","2024","Figshare","preclinical","article","10.6084/m9.figshare.26756596",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033931","An Uncommon Path Leading to Diagnosis of Multiple Endocrine Neoplasia 2A","Endocrine Society 2022","2022","Underline Science Inc.","other","article","10.48448/pps1-dp96",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033932","Zap 2021 nrw mathe pdf","zereubudco","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12131289",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033933","METABOLIC MULTI-TARGETING THERAPIES: A REVIEW OF DUAL-AGONIST DRUGS AND THEIR IMPACT ON DIABETES, OBESITY, AND ORGAN PROTECTION","Nukala Mounika Sivani, Matsa  Ganga Bhavani, Karri Naga Pravallika, Bollarapu Syam Deven Babu, Pemmada Sowmya, Mekala Poojitha, Agarapu  Lahari¹, Sagi Anil Kumar","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.16421699",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033934","Die GLP Formula Eine klinisch erprobte Strategie zur Gewichtsabnahme","GLP Formula Verbesserungen","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16400520",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033935","Additional file 2 of Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes","Zhang, Xianyu","2024","Figshare","other","article","10.6084/m9.figshare.26409991",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033936","The Obesity Puzzle: Mechanisms, Consequences, and Cutting Edge Treatments","Ergita Nelaj","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17424909",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033937","Formelsammlung mathe pdf","ntlqspmm","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11833748",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033938","Ozempic: Revolutionary Weight Loss Drug or Too Good to be True?","Iram Shakil","2024","Janeway","other","article","10.57898/bioscientist.230",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033939","OS RISCOS DO USO INDISCRIMINADO DE OZEMPIC PARA EMAGRECER: COM ÊNFASE NA SUA COMERCIALIZAÇÃO","De Souza, Dalila Conceição","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7996143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033940","Additional file 1 of Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","Mosenzon, Ofri","2022","Figshare","randomized_trial","article","10.6084/m9.figshare.20882123",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033941","Plain Language Summary of the Manuscript: A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.","J. Sanyal, Arun","2024","Boehringer Ingelheim","randomized_trial","article","10.60915/boehringer-figshare.27720072",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033942","OS RISCOS DO USO INDISCRIMINADO DE OZEMPIC PARA EMAGRECER: COM ÊNFASE NA SUA COMERCIALIZAÇÃO","Dalila Conceição De Souza¹; Geisielba Pereira Dos Anjos¹; Ana Oclenidia Dantas Mesquita²; Felipe Augusto Neri Vasconcelos²;","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7988077",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033943","A Comprehensive Textbook of Community Medicine And Public Health Science","S M Nazmuz Sakib","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.19667680",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","book"],["R0033944","Diabetic Ketoacidosis (DKA) in type 2 Diabetes Mellitus (T2DM): Is Tirzepatide the Culprit?","American Medical Association 2024","2024","Underline Science Inc.","other","article","10.48448/8ahw-m248",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033945","Additional file 3 of Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","Koychev, Ivan","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.27157901",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0033946","To Sell the Self-Selling: A Look into Recent Trends in the Weight-Loss Medication Industry","Grannen, Thomas","2024","Texas Digital Library (University of Texas)","other","article","10.26153/tsw/60533",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033947","Comparative Effectiveness of Sodium-Glucose Co-Transporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Randomised and Real-World Evidence","Hussein, Humaira","2023","University of Leicester","randomized_trial","article","10.25392/leicester.data.23977146",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0033948","Additional file 4 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","other","article","10.6084/m9.figshare.26642782",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033949","Weight Regain and Cardiometabolic Reversal following Discontinuation of Incretin Based Therapies A Review","Vidhi Rathi, Shivankan Kakkar, Shrey Wadhwa, Devendra Nagar, Rahul Jeengar, Dimpy Bansal, Vishvaranjan Damor, Hemant Khatana, Rajesh Kumar","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.20392314",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033950","MODERN METHODS OF TREATING DIABETES","Sultanov Samadjon","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15467329",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033951","1000 verben mit präpositionen pdf","cbfmarpaov","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12306956",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033952","Leseverstehen deutsch b2 pdf","iuzblirdj","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11800069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033953","Additional file 4 of Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways","Wang, Duozi","2025","Figshare","other","article","10.6084/m9.figshare.29632382",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033954","Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with T2D Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis","Adis Journals On Behalf Of:","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26977447",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0033955","A Systems Pharmacology Approach to Diabetes Management: Integrating Drug Therapy, Lifestyle Modulation, and Personalised Treatment Algorithm","Edapalapati Venkata Naga Nithin*1, Raveendra N2, Binaya Kumar Sethy3, Darshana Vinod Rane4, Ayesha Jamal5","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.20790751",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033956","Wegovy information pdf","pnoumayodz","2024","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.11707115",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033957","Additional file 1 of The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China","Gu, Shuyan","2024","Figshare","other","article","10.6084/m9.figshare.25530189",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033958","Msa mathe pdf","pulptcyo","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12011192",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033959","Type 2 Diabetes Mellitus: An Overview of Pathophysiology, Current Management, and Future Prospective","Sujit Ninayade*, Shivani Kumbhar, Sainath Rathod, Nasreen Shaikh, Sonali Patil","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17336957",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033960","Westfalenpost pdf","eozhqknye","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12136631",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033961","From Injections to Pills: GLP-1 for Type 2 Diabetes","Sonia Li","2020","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.3875926",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033962","Molecular dynamics insights into the binding interactions of semaglutide with human serum albumin","Liu, Yueyang","2025","Figshare","other","article","10.6084/m9.figshare.29657264",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033963","Additional file 4 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Lengsfeld, Sophia","2023","Figshare","protocol","article","10.6084/m9.figshare.22671494",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033964","Additional file 4 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Alfayez, Osamah M.","2020","Figshare","systematic_review","article","10.6084/m9.figshare.12545009",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0033965","Statistical analysis plan: Cardiovascular effectiveness of GLP-1 receptor agonists beyond cardiovascular outcome trial populations, a nationwide target trial emulation in the Swedish National Diabetes Register","Jens Michelsen","2026","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.20234499",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0033966","Jazz Jennings Weight Loss Melissa McCarthy flaunts weight-loss in tight red gown - but fans","Janelle, JPowell","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12793275",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033967","Method Development of Semaglutide And Its Application for Bioanalysis of Clinical Study Samples for Pharmacokinetic Outcome","V. Bhosale, D. Bagde, V. Deshmukh, V. Pukale, R. Kapse, S. Bhakare, S. Salunkhe, A. Mokate, N. Gangurde","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14685172",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033968","\"Chicom\" Slur, Ozempic Price Control, Emotional Straw Votes, Back STRIDE","Sunil Dasgupta","2026","Digital Repository at the University of Maryland (University of Maryland College Park)","other","article","10.13016/m2qjfb-pfaj",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033969","Additional file 1 of Tirzepatide prevents neurodegeneration through multiple molecular pathways","Fontanella, Rosaria Anna","2024","Figshare","other","article","10.6084/m9.figshare.26674158",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033970","Abschlussprüfung realschule hessen mathe pdf 2023","glnkttlvzdy","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12319570",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033971","Formelsammlung mathe mittelschule bayern pdf","zobrblvzdof","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12114179",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033972","Additional file 1 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Ugamura, Daisuke","2022","Figshare","other_trial","article","10.6084/m9.figshare.20056559",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033973","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reduce Fluid Intake in Primary Polydipsia","Endocrine Society 2021","2021","Underline Science Inc.","other","article","10.48448/4094-gv89",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033974","Msa mathe 2023 pdf","wmzrmuow","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12089965",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033975","Additional file 1 of Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes","Chaiyakunapruk, Nathorn","2025","Figshare","nonrandomized_study","article","10.6084/m9.figshare.28862501",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0033976","Exploring the function and sensing mechanisms of human enteroendocrine cells using intestinal organoids","Guccio, Nunzio","2024","Apollo (University of Cambridge)","preclinical","article","10.17863/cam.111638",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0033977","SEMAGLUTIDE REDUCED CARDIOVASCULAR EVENTS BY 20% IN CERTAIN ADULTS","Saddam Alimuddin Shaikh, Dr. Imran Aslam","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11088093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033978","GLP-1 RAs and Suicidality: Weighing Out The Risks","Riley Kishman","2025","Galter Health Sciences Library, Northwestern University","other","article","10.18131/gxeff-sas84",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033979","Fella Weight Loss for Men: Finally, a Program That Actually Works","Fella Weight Loss","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15515648",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033980","Victoza Weight Loss: Does It work? - Advanced BMI Lebanon","Johnes, Holmes","2024","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.12793440",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0033981","Statistical analysis plan: Cardiovascular effectiveness of GLP-1 receptor agonists beyond cardiovascular outcome trial populations, a nationwide target trial emulation in the Swedish National Diabetes Register","Jens Michelsen","2025","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.20218823",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0033982","saxenda dosing pdf","repsotjjw","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11788390",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033983","From Blood Sugar to Body Weight: The Expanding Therapeutic Potential of GLP-1 Agonists","Muskan Kumari, Yogesh Tamang, Khushi Sahu, Parshant Pokhriyal*","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15120024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033984","Additional file 2 of Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network","García-Vega, David","2024","Figshare","other","article","10.6084/m9.figshare.26660149",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033985","Optimization Of Treatment Of Patients With Type 2 Diabetes With Concomitant Ischemic Heart Disease","Karpenko, Y. I.","2018","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.1307402",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033986","Additional file 2 of Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome","Zeynab Yousefi","2026","Figshare","preclinical","article","10.6084/m9.figshare.31143258",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033987","Asthma exacerbations and glucagon-like peptide-1 receptor agonists: A Review of the Current Evidence","Adis Journals On Behalf Of:","2022","Figshare","narrative_review","article","10.6084/m9.figshare.21346428",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033988","Data from: Effect of a three-week treatment with glucagon-like peptide 1 receptor agonists on vasoactive hormones in euvolemic participants","Vukajlovic, Tanja","2022","Figshare","other","article","10.6084/m9.figshare.17712206",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033989","GLP-1 receptor agonists in delirium and encephalopathies: a neuroprotective scoping review","Mercado, Francisco","2025","Figshare","narrative_review","article","10.6084/m9.figshare.c.8184275.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0033990","RECENT ADVANCES IN PHARMACOLOGICAL APPROACHES FOR THE MANAGEMENT OF DIABETES MELLITUS: MECHANISM, THERAPY AND FUTURE PERSPECTIVE","Pranav Rajendra Kadam, Sachin Tukaram Kolekar, Sumit Santosh Koli, Aarti Baliram Bansode, Dr. Rahul Ishwara Jadhav","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18891372",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033991","Additional file 2 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Lengsfeld, Sophia","2023","Figshare","protocol","article","10.6084/m9.figshare.22671488",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033992","Additional file 3 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Ugamura, Daisuke","2022","Figshare","other_trial","article","10.6084/m9.figshare.20056568",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033993","Resmetirom: An Innovative Treatment for Steatohepatitis Associated with Metabolic Dysfunction (MASH)","Patil Ruchika Rajendra","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19048525",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033994","mounjaro coupon 2024 pdf usa","fzpiolxqevc","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12019743",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0033995","Tirzepatida Além da Perda de Peso: O Papel Emergente dos Agonistas Duais na Gerosciência e Longevidade","Caio Juan Correia Belonci","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18202511",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0033996","Additional file 1 of GLP-1 receptor agonists in delirium and encephalopathies: a neuroprotective scoping review","Mercado, Francisco","2025","Figshare","narrative_review","article","10.6084/m9.figshare.30786740",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033997","Additional file 9 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","other","article","10.6084/m9.figshare.26642800",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0033998","PLAIN LANGUAGE SUMMARY of the PUBLICATION titled “Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist”","Roux, Carel W Le","2025","Boehringer Ingelheim","other_trial","article","10.60915/boehringer-figshare.29066720",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0033999","Additional file 8 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","other","article","10.6084/m9.figshare.26642797",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034000","Englisch zap übungen pdf","jyzwolfha","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12378163",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034001","HEARTLAND PROTOCOL Heart failure Evidence-based Access in Rural Treatment, Linking Advanced Network Delivery","Vicky Muller Ferreira","2026","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.18408303",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034002","Additional file 1 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Lengsfeld, Sophia","2023","Figshare","protocol","article","10.6084/m9.figshare.22671485",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034003","Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2","Endocrine Society 2022","2022","Underline Science Inc.","randomized_trial","article","10.48448/4rdf-9v24",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0034004","Englisch zap übungen pdf","pwyhklnlxn","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11723786",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034005","Wegovy Online Kaufen - Die wichtigsten Vorteile auf einen Blick!","Erfahrungen, Wegovy","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13283351",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034006","Additional file 1 of Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2023","Figshare","other","article","10.6084/m9.figshare.24597464",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034007","mounjaro administration pdf","xxfjlmhgfg","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12014151",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034008","Additional file 1 of An empirical evaluation of the impact scenario of pooling bodies of evidence from randomized controlled trials and cohort studies in medical research","Bröckelmann, Nils","2022","Figshare","randomized_trial","article","10.6084/m9.figshare.21385915",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0034009","Why weight-independent effects of GLP-1RAs are expected with mediation analyses","Fernando Bril","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20672446",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034010","Additional file 1 of Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients","Saraiva, José Francisco Kerr","2021","Figshare","other","article","10.6084/m9.figshare.17210512",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034011","Additional file 1 of Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice","Bao, Xiaoyan","2020","Figshare","preclinical","article","10.6084/m9.figshare.12211595",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034012","Regulation and funciton of Glucagon-Like Peptide 1 and 2 under inflammatory conditions","Diebold, Sebastian","2019","RWTH Publications (RWTH Aachen)","preclinical","article","10.18154/rwth-2019-07203",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034013","USO OFF-LABEL DO OZEMPIC® PARA EMAGRECIMENTO UMA REVISÃO INTEGRATIVA SOBRE RISCOS, BENEFÍCIOS E DILEMAS ÉTICOS","PIRES, Ysnarah Ferreira","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17783280",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034014","el cerebro obeso pdf descargar gratis","mzizvsyuu","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11775373",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034015","Predictors of efficacy on HbA1c of individual GLP-1 receptor agonists in type 2 diabetes in placebo- or active-comparator controlled studies","Dooley, Gordon","2015","York","other","article","10.15124/crd42015020245",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034016","The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance","Jumayev Mukhammadali Jakhongirovich","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18810515",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034017","Hauptschulabschluss mathematik pdf","afzfuezhoa","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11791844",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034018","Abschlussprüfung realschule hessen mathe pdf 2023","qdvayyhbm","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11823556",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034019","Wegovy Preis - Wie dieses Medikament Ihre Gewichtskontrolle revolutionieren kann!","Erfahrungen, Wegovy","2024","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.13283355",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034020","Additional file 7 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Alfayez, Osamah M.","2020","Figshare","systematic_review","article","10.6084/m9.figshare.12545036",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0034021","Association of premorbid GLP 1RA and SGLT 2i prescription alone and in combination with COVID 19 severity","Adis Journals On Behalf Of","2024","Figshare","other","article","10.6084/m9.figshare.25257022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034022","Glucagon-like Peptide-1 Receptor Agonists","Pearson, Alvin Jalen","2024","Michigan State University Libraries","other","article","10.25335/qgrw-4v26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034023","cvs caremark prior authorization pdf","kigyeobuaqb","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12439112",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034024","Additional file 2 of Dietary resistant starch ameliorating lipopolysaccharide-induced inflammation in meat ducks associated with the alteration in gut microbiome and glucagon-like peptide 1 signaling","Qin, Simeng","2022","Figshare","other","article","10.6084/m9.figshare.20317900",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034025","Deutsch b2 lesen übungen pdf","gfpcnjub","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11694028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034026","Investigating the Association Between Ozempic Use and Psoriasis: An Analysis of FDA Adverse Event Reporting System Data from 2019-2024.","American Medical Association 2024","2024","Underline Science Inc.","nonrandomized_study","article","10.48448/wezz-pk26",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0034027","Cryo-Coupling Trial Framework: Independent Phased Validation of T1-Guided Cancer Intervention","James E. Dunn","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.19223725",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0034028","Multi-Mechanism Oral Delivery Architecture for the Metabolic-Peptide Class (GLP-1 Receptor Agonists, GLP-1/GIP Dual Agonists, GLP-1/GIP/Glucagon Triple Agonists, GLP-1/Glucagon Dual Agonists, and Amylin Analogs), Combining Transcellular Hydrophobization, Paracellular Tight-Junction Modulation, Mucus Fluidization, Selective Tight-Junction Opening, and Mucoadhesive Gastric Retention","Coracle Research","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19768434",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034029","Case report about treatment of the patient with DM Type 2 on multiple injections of insulin who with the help of continuous glucose monitoring (CGM) improved and was controlled only on anti-diabetic pills and GLP1 - RAG","A. Manov","2022","Zenodo (CERN European Organization for Nuclear Research)","case_report","article","10.5281/zenodo.7895049",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034030","Green line 6 g9 workbook lösungen pdf","vmapmoamnw","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11969220",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034031","GLP-1 RAs for weight loss: the quantity, quality and findings of network meta-analyses evaluating their effectiveness.","Isca Evidence","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.18759111",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0034032","6 Week Plan Ozempic Weight Loss Results: Achieving Transformation","6 Week Plan Ozempic Weight Loss Results","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12780162",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034033","BUY Mounjaro (+966562649256) (tirzepatide) IN Dubai, DAHRAN, DOHA get ozempic prescription online!!!","Ballard Power Systems (Canada)","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11640759",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034034","GLP-1 Based Therapy for Diabetes and Potential of Thyroid Cancer","Mehmet Akif Büyükbeşe","2014","Università degli Studi di Napoli Federico II","other","article","10.6092/1590-8577/2788",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034035","Additional file 1 of Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods","Morieri, Mario Luca","2025","Figshare","nonrandomized_study","article","10.6084/m9.figshare.30390553",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0034036","Additional file 1 of Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice","Longato, Enrico","2020","Figshare","other","article","10.6084/m9.figshare.12463160",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034037","abbi a cuore il signore pdf","mbvvexkp","2024","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.12310524",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0034038","What are the experiences, views and perceptions of patients, carers and clinicians of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)? A scoping review","Isca Evidence","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.18763478",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034039","The Molecular Landscape and Pharmacological Management of Metabolic Syndrome: A Global Review","Krishnkumarsinh Sur","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.18432135",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034040","trulicity patient handout pdf","irtzlyvnyv","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11916242",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034041","Beipackzettel pdf","akbcohigniq","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11946500",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034042","Obesity Challenges and Management","Aneja KR","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20152704",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034043","semaglutide consent pdf","yneeoxsii","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11897421",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034044","Additional file 6 of Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","Alfayez, Osamah M.","2020","Figshare","systematic_review","article","10.6084/m9.figshare.12545027",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0034045","Additional file 5 of Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study","Lengsfeld, Sophia","2023","Figshare","protocol","article","10.6084/m9.figshare.22671497",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034046","Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome (Supplementary Material)","Ahmed Shahd","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19790502",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034047","Sustained Medical Weight Management Program Leads to Increased Weight Loss and Arthroplasty Surgery","American Medical Association 2023","2023","Underline Science Inc.","nonrandomized_study","article","10.48448/7cz0-fx71",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0034048","Additional file 2 of An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Ugamura, Daisuke","2022","Figshare","other_trial","article","10.6084/m9.figshare.20056562",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034049","liraglutide pdf","srnovvgig","2024","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.12354222",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034050","Drugs Acting on Poly Cystic Ovary Syndrome: A Comprehensive Review","Muralinath E.","2024","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.10884731",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034051","Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis","Endocrine Society 2022","2022","Underline Science Inc.","randomized_trial","article","10.48448/t2qy-py24",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0034052","Additional file 1 of Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease","Abdulhameed, Noor","2024","Figshare","preclinical","article","10.6084/m9.figshare.26420326",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034053","Additional file 3 of Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","Lingvay, Ildiko","2024","Figshare","other","article","10.6084/m9.figshare.26577542",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034054","Zap englisch übungen pdf","uhpiqohi","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11797592",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034055","The potential risks of pancreatitis and pancreatic cancer with incretin-based therapies in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","Dooley, Gordon","2015","York","systematic_review","article","10.15124/crd42015020398",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0034056","Dual incretin agonism in the treatment of Type 2 Diabetes and Obesity","KEE, VANESSA TING ZHEN","2023","Monash University","other","article","10.26180/22682434",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034057","GLP Lab Kann die GLP-Lab oroptimierung Ihnen beim Abnehmen helfen?","GLP Lab Kaufen","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16717464",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034058","Additional file 1 of Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome","Zeynab Yousefi","2026","Figshare","preclinical","article","10.6084/m9.figshare.31143255.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034059","Additional file 1 of Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","Lingvay, Ildiko","2024","Figshare","other","article","10.6084/m9.figshare.26577536",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034060","Long-term Weight Loss Maintenance with Obesity Pharmacotherapy: a 5-Year Retrospective Study","Endocrine Society 2022","2022","Underline Science Inc.","nonrandomized_study","article","10.48448/wrdj-2g96",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0034061","Additional file 1 of Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure","Sforza, Annalisa","2022","Figshare","other","article","10.6084/m9.figshare.19571879",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034062","Additional file 1 of Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide – a review","Ming Lu","2026","Figshare","narrative_review","article","10.6084/m9.figshare.32102213.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034063","Additional file 1: Figure S1. of Exendin-4 enhances the differentiation of Wharton’s jelly mesenchymal stem cells into insulin-producing cells through activation of various β-cell markers","Kassem, Dina","2016","Figshare","other","article","10.6084/m9.figshare.c.3605927_d1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034064","Formelsammlung mathe realschule bayern pdf","amfhwuuwipm","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12267775",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034065","DK REDDIE WP4 Analysis plan: GLP1-RA versus DPP4","Sørensen, Kathrine Kold","2025","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.15062985",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034066","Additional file 1 of Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","Grauslund, Jakob","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.28058503",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0034067","Additional file 2 of The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","Larsen, Anna Thorsø","2021","Figshare","other","article","10.6084/m9.figshare.13544378",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034068","Multimodal Assessment of Bone Health in GLP-1 Agonist Users","American Medical Association 2025","2025","Underline Science Inc.","other","article","10.48448/tj6r-m557",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034069","An Overview on Tirzepatide, Dual-Targeted Treatment for Diabetes and Obesity","G, Dinesh Kumar","2022","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7420604",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034070","MOESM1 of The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism","Andreozzi, Francesco","2016","Figshare","other","article","10.6084/m9.figshare.c.3603728_d2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0034071","Wegovy Online Apotheke - Ein Blick hinter die Kulissen der Gewichtsreduktion!","Erfahrungen, Wegovy","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13283349",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034072","Additional file 5 of Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure","Sforza, Annalisa","2022","Figshare","other","article","10.6084/m9.figshare.19571900",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034073","Trimova Weight Loss Drops Reviews: A Natural Solution for Sustainable Weight Management","Trimova Weight Loss Drops Reviews","2024","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.12749473",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0034074","Figure 2: Proposed Schema for GLP-1 Activation of Ischemic Conditioning Pathways","Giblett, Joel P.","2019","JACC: Journal of the American College of Cardiology","other","article","10.25407/jacbts.8253953",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034075","MOESM2 of The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism","Andreozzi, Francesco","2016","Figshare","other","article","10.6084/m9.figshare.c.3603728_d1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0034076","Additional file 1 of Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study","Htoo, Phyo T.","2024","Figshare","other","article","10.6084/m9.figshare.25194735",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034077","Pericyte Bridging in Hyperglycemia, Alzheimer’s Disease, and Comorbid Pre-Clinical Models; A Sociotechnical Analysis of Glucagon-Like Peptide-1 Receptor Agonist Medications in the Treatment of Obesity","Tess Eluvathingal Muttikkal","2026","Libra","other","article","10.18130/11n9-az67",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034078","Over-Dieting and Excessive Dietary Restriction Pathophysiological Mechanisms, Pharmacological Perspectives, and Their Role in Metabolic and Systemic Diseases - A Comprehensive Review","Shiv Kumar Bhardwaj*1, Trilochan Satapathy2, Khemkaran Ahirwar3, Manmohan singh Jangdey4","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.18697734",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034079","The Development of Methods for Generating Fc-Conjugates and Antibody-Drug Conjugates","Park, Mahri","2024","Apollo (University of Cambridge)","preclinical","article","10.17863/cam.118618",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034080","Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects","Adis Journalson Behalf Of","2023","Figshare","randomized_trial","article","10.6084/m9.figshare.23304206",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0034081","Reaching 10 Kelvin: Precision Thermal Metrology; The Sociotechnical Exploitation of Body Image: Analyzing the Role of Marketing and Lack of Regulation in the Fitness Industry","Brandon Flores Castaneda","2026","Libra","other","article","10.18130/zxgm-ry36",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034082","Additional file 9 of Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials","Husain, Mansoor","2020","Figshare","other_trial","article","10.6084/m9.figshare.13031570",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034083","Additional file 1 of hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair","Wang, Wei","2024","Figshare","preclinical","article","10.6084/m9.figshare.26553776",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034084","Found Weight Loss Melissa McCarthy looks glamorous in a tulle mint green gown while","Janelle, JPowell","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.12793290",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034085","Formelsammlung mathe mittelschule bayern pdf","qytlzulkful","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11764073",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034086","Englisch msa 2023 lvsungen pdf","srtvooijda","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.11694521",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034087","Additional file 4 of Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","Koychev, Ivan","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.27157907",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0034088","Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâ s disease: study protocol for a randomised controlled trial (ELAD study)","Femminella, Grazia","2019","Figshare","protocol","article","10.6084/m9.figshare.7950476",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034089","Empagliflozin and the risk of nephrolithiasis","Endocrine Society 2022","2022","Underline Science Inc.","randomized_trial","article","10.48448/p4qp-zj44",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0034090","Unraveling the Neural Networks of Consumption: Novel Central Pathways in Feeding Control and Weight Loss","Elizabeth Godschall","2025","Libra","preclinical","article","10.18130/sy9n-7k40",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034091","Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program","Endocrine Society 2022","2022","Underline Science Inc.","other_trial","article","10.48448/smdc-kx33",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0034092","Additional file 4 of Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin","Yang, Xiaotong","2020","Figshare","preclinical","article","10.6084/m9.figshare.12332093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034093","Self emulsifying drug delivery system of exenatide via hydrophobic ion pairing","Bock, Gerlinde","2019","Digital Library of the University of Innsbruck (University of Innsbruck)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034094","Orale Antidiabetika bei Diabetes mellitus Typ 1 zukünftige Therapieoptionen.","Füchtenbusch, M.","2020","Site cant be reached","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034095","Directives de traitement du diabète de type 2","Hermans, Michel","2024","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034096","GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice(審査報告)","アラタ イトウ","2017","KeiO Associated Repository of Academic Resources (Keio University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034097","Effects of the pharmacological interventions and a structured education in the management of polycystic ovary syndrome (PCOS)","Abdalla, Mohammed Altigani","2022","Repository@Hull (Worktribe) (University of Hull)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034098","Intérêt du développement du liraglutide dans la prise en charge du patient diabétique de type 2 (vers une prise en charge précoce et globale)","ROUE, Claire","2011","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034099","Intérêt de l association insuline-Byetta® dans le traitement du diabète de type 2","LEON, Marie","2011","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034100","Nedsatt kognition och diabetes – ett ofta förbisett samband","Sjöholm, Åke","2023","Lund University Publications (Lund University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034101","Prise en charge du diabète de type 2 (mise au point sur le liraglutide)","LE GALL, Margaux","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034102","Study of the neuroprotective effects of omega -3 , liraglutide , clozapine and risperidone in a neuroinflammatory model induced by poly I: C in primary cultures of hippocampal cells","Bruna Mara Machado Ribeiro","2015","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034103","Instauration d'un traitement par analogue du GLP-1 (Exénatide (BYETTA® ) chez des patients diabétiques de type 2 atteints de complications oculaires)","IRAQI, Salma","2010","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034104","Short-term effect of GLP-1 agonist on estimated glomerular filtration and albuminuria in patients with obesity and glomerular hyperfiltration","Matheus Vieira [UNIFESP] Falcão","2024","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034105","Cost-effectiveness of intermediate or long-acting\\ninsulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual\\noral diabetes medications","Irons, Brian K.","2006","Redalyc (Universidad Autónoma del Estado de México)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034106","Estudo dos efeitos neuroprotetores do Ãmega-3, liraglutide, risperidona e clozapina em um modelo neuroinflamatÃrio induzido por Poly I:C em cultura primÃria de cÃlulas hipocampais","Bruna Mara Machado Ribeiro","2015","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034107","The effect of gut hormones on metabolism and energy homeostasis","Murphy, Kevin","2011","OpenGrey (Institut de l'Information Scientifique et Technique)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034108","Substitution of insulin by exenatide in glycemia uncontrolled type 2 diabetes patients : efficacy and predictive factors","BARTHELEMY, Mélanie","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034109","GLP1R Signaling as a Neural Switch Governing Food vs. Smoking Preference","Allen Phuong","2025","ScholarlyCommons (University of Pennsylvania)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034110","Сучасний погляд на лікування ожиріння в дорослих: Огляд літератури","В.І. Величко","2021","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034111","Thinner and wiser? Prospects of GLP-1 agonists in psychiatry","Vieta i Pascual, Eduard, 1963-","2025","Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034112","Incretin mimetics and inhibitor of the dipeptidyl peptidase-4 as therapeutic agents","GAUDRIOT, Adrien","2013","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034113","Efeitos comportamentais, metabólicos e circuitos neuronais do agonista de GLP-1 liraglutida, no modelo de depressão induzida por estresse crônico imprevisível","Vieira, Charliene Freire Xavier","2020","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034114","Exenatide (new drug therapy for type 2 diabetes)","RIGNOL, Pascale","2008","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034115","Cardiovascular effects of exendin-4 infusion into the paraventricular nucleus of the hypothalamus in an experimental model of L-NAME-induced hypertension","Yaslle Andrade Cavalcante [UNIFESP] Moraes","2023","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034116","A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice","Valverde, Ángela M.","2017","DIGITAL.CSIC (Spanish National Research Council (CSIC))","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034117","Efficacité et tolérance de l exenatide chez le diabétique de type 2","NGUYEN, Thanh Hy","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034118","Les nouveaux anti-diabétiques oraux","Fery, Françoise","2014","Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034119","L'exenatide, premier incrétino-mimétique dans le traitement du diabète de type 2","NEDELCU, Luiza","2006","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034120","Development and evaluation of novel CCK peptide analogues for the treatment of obesity and type II diabetes","Frizelle, Pamela","2010","OpenGrey (Institut de l'Information Scientifique et Technique)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034121","Nouvelles thérapeutiques disponibles dans la prise en charge du diabète de type 2 (la sitagliptine (JANUVIA®, XELEVIA®) et l'exénatide (BYETTA®))","JACQUET, Maryline","2009","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034122","Genetics of obesity and type 2 diabetes","Vogel, Heike (Dr.)","2021","publish.UP (University of Potsdam)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034123","Les analogues du GLP-1 dans la prise en charge du diabète de type 2","PERTSINIDIS, Marie","2011","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034124","Incretin mimetics","Thompson, A","2015","eCite Digital Repository (University of Tasmania)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034125","Effect of the liraglutide on muscle and fat tissues and biochemical parameters in Swiss mice submitted to the cafeteria diet and physical activity","Cybelle de Arruda Navarro Silva","2014","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034126","Evaluation of metformin and liraglutide treatment in murine pancreatic steatosis model in vivo","Mariana Veiga Copertino Ferreira da [UNESP] Silva","2022","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034127","PD-88 - Semaglutide reduces appetite and energy intake, improves control of eating and provides weight loss in subjects with obesity","Blundell, J","2016","White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0034128","Tabla datos semaglutide","Repossi Marquez, Pablo Gaston","2025","Conicet","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034129","Nouveaux antidiabétiques :À l'aube d'une révolution ?Les nouvelles options thérapeutiques du diabète de type 2 à l'épreuve de la prévention cardiovasculaire","Crenier, Laurent","2016","Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034130","Exenatide versus glimepiride monotherapy in management of patients with type 2 diabetes",null,"2013","Queen Margaret University Publications Repository (Queen Margaret University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0034131","L' exenatide, nouveau dérivé d'origine animale à propriétés antidiabétiques","YOUK, Benoist","2006","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034132","The Silent Saboteur: How Insulin Resistance Fuels Obesity and Chronic Disease","Amachree, Edwin","2025","Digital Commons (Liberty University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0034133","Glucagon-like peptide 1 analogs (clinical trials of their development and rules of good use)","FOUCHAULT, Mathilde","2009","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034134","“It feels good to be full in both head and belly” A Qualitative Study on the experiences of Children, Adolescents, and Guardians Regarding Hyperphagia and Treatment with GLP-1 Analogues in Craniopharyngioma","Kajsa Järvholm","2026","Lund University Publications (Lund University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0034135","Modern Approaches to the Treatment OF Type 2 Diabetes Mellitus","Jo’rayeva Gulhayo Jalol qizi","2025","Neliti","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034136","Effects of incretin mimetics on the cardiovascular system","David Novković","2024","Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034137","Glycaemic effect of tirzepatide by duration of diabetes","Kiljanski, J.","2022","Lirias","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034138","The contribution of incretin mimetics in the type 2 diabetes","DEVILLE, Julie","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034139","Drugs for diabetes: part 6 GLP-1 receptor agonists","McDougall, Claire","2011","ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0034140","L'exenatide (un nouveau traitement du diabète de type 2)","BUTTAZZONI, Florent","2007","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034141","De rol van Hepatocyte-Nuclear-Factor-1-A (HNF1A) in de regulatie van Glucose Homeostase en Pancreas Hormoonafscheiding","Acosta Montalvo, Ana Gabriela","2022","Lirias","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034142","BEHAVIORAL AND CIRCUIT-LEVEL INSIGHTS INTO GLP-1 RECEPTOR AGONIST-MEDIATED REDUCTION OF DRUG SEEKING","Rae J. Herman","2025","ScholarlyCommons (University of Pennsylvania)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034143","Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes(要約)","クミコ タナカ","2015","KeiO Associated Repository of Academic Resources (Keio University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034144","Assessing the Independent and Joint Effects of GLP1R and GIPR on Liver Fat and BMI Using Mendelian Randomization","Angela Ai","2025","ScholarlyCommons (University of Pennsylvania)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","other"],["R0034145","Genetic and phenotypic discordance in cardiometabolic diseases","Coral, Daniel","2024","Lund University Publications (Lund University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034146","Diabetes mellitus therapy adherence and therapy characterization in Northeast Portugal: classical vs dipeptidyl peptidase iv (dpp-4) inhibitors","Pereira, Daniela S.M.","2017","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034147","Nouvelle thérapeutique dans le traitement du diabète de type 2 (l'exenatide parmi les incrétino-mimétiques)","DECORTE, Eymeric","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034148","SITE-SPECIFIC PROTEIN FUNCTIONALIZATION USING ACTIVATED CYSTEINE BASED CHEMICAL BIOLOGY METHODS","Qiao, Yuchen","2021","OakTrust (Texas A&M University Libraries)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034149","Drugs which increase incretin level in the treatment of type 2 diabetes","CAMUS, Aurélien","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034150","Les incrétinomimétiques dans le traitement du diabète de type 2","CHAINEUX, Mélanie","2009","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034151","Behavioral and neurochemical effects of liraglutide and association with levetiracetam in mice submitted to pentilenotrazole-induced kindling mo","Alana Pontes Sun de [UNESP] Souza","2017","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034152","Cotadutide (a dual agonist of GLP-1/glucagon) affects the pancreas, brown adipose tissue, and hypothalamus of obese mice","Renata Spezani","2025","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034153","Place du liraglutide dans la prise en charge du diabète de type 2 et évaluation clinico-biologique après 6 mois de traitement sur une cohorte traitée au CHU de Besançon","ARREGUI, Charlène","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034154","Semaglutide and taste in women with obesity and polycystic ovary syndrome","Mojca Jensterle Sever",null,"dCOBISS.SI Digital Repository","randomized_trial","article","10.1210/clinem/dgaf278/8127627?redirectedfrom=fulltext#no-access-message",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0034155","Prescribing trends, safety profile, and socioeconomic analysis of semaglutide compared with liraglutide, tirzepatide, and orlistat in England, 2020–2024","Ruth Kamala Premiah",null,"Huddersfield Research Portal (University of Huddersfield)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034156","Influence of GLP-1 analogue on skeletal muscle of rats treated acutely with doxorubicin","Danilo Malmonge Barbosa [UNESP] Luciano","2023","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034157","Adjuvant treatment with empagliflozin or semaglutide increases endothelial progenitor cells in subjects with well-controlled type 1 diabetes mellitus","Navodnik-Preložnik, Maja","2025","DiRROS repository (University of Maribor)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034158","Exploring the structure, function ;regulation of the human glucagon-like peptide-1 receptor","Willars, Gary","2011","OpenGrey (Institut de l'Information Scientifique et Technique)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034159","Les nouveaux médicaments de l’obésité : un changement de paradigme ?","Thissen, Jean-Paul","2024","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034160","GLP-1 Coverage in Vermont: A Roadmap","Kyle Bergeron","2026","ScholarWorks -A service of University of Vermont Libraries (University of Vermont)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034161","Metabolic behavioral effects and neuronal circuitry of GLP-1 agonist liraglutide in the unpredictable chronic stress induced depression model","Charliene Freire Xavier Vieira","2020","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034162","Синдром полікістозних яєчників: індивідуалізований підхід до лікування. Огляд літератури","Жабіцька, Л. А.","2020","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034163","Der kardiovaskulär vorerkrankte Diabetespatient : Im Zentrum der Therapie steht die Gabe von SGLT-2-Inhibitoren und GLP-1-RA","Florian Kahles","2021","RWTH Publications (RWTH Aachen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034164","Lifestyle drug Ozempic: Between medical use and misuse by society","El-Mansory, Jasmin","2025","Unipub UB Graz (Universität Graz)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034165","Potential roles of glucagon-like peptide-1 (GLP-1) in neuroprotection","Holscher, Christian","2012","Lancaster EPrints (Lancaster University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034166","The impact of liraglutide on the gut microbiome of obese patients / case series report","Lukšić, Lea","2025","Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034167","Effect of medication on steatotic liver disease in patients with type 2 diabetes mellitus, with emphasis on newer antidiabetic therapies","Koullias, Emmanouil","2025","National Archive of Doctoral Theses (National Documentation Center (Greece))","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034168","Acute pancreatitis national audit of practice: a national prospective audit of acute pancreatitis in the era of GLP-1 agonists—the PANDORA audit protocol","Hall, L.A.","2025","White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","protocol","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0034169","Tirzepatida: um novo tratamento para a obesidade","Correia, Sara Filipa Nunes","2023","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034170","Liraglutide changes gut microbiota and reduces hepatic steatosis and fat mass in two models of obesity mice.","Gabriela Moreira","2017","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034171","Intérêt du liraglutide (Victoza®) dans la prise en charge du diabète de type 2","DA ROSA, Vania","2010","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034172","Impact assessment, at 6 months, with addition of liraglutide, GLP-1 analogue, in non insulin-treated type 2 diabetes and insulin-treated patients","NOIREZ, Yann","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034173","Efeitos dos agonistas do recetor GLP-1 no tratamento da obesidade","Baptista, Lízie Oliveira","2022","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034174","Exenatide (a new treatment in diabetes mellitus type 2)","TAN, Alice","2008","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034175","New treatment approach: incretins in the treatment of type 2 diabetes mellitus","Eglė Varanauskienė","2005","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034176","Dissecting the molecular regulation of intermittent fasting using proteomics","Harney, Dylan","2022","The Sydney eScholarship Repository (The University of Sydney)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034177","Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future","Ricardo Stein","2022","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034178","Caractérisation des cellules corticales et des neurones sensoriels primaires dérivés des cellules souches pluripotentes induites (iPSC) de patients atteints de l'ataxie de Friedreich, et validation de thérapies potentielles.","Hu, Amelie","2018","Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034179","Les incrétines dans le traitement du diabète de type deux (cas particulier des inhibiteurs de la DPP-4)","MAMAN, Eman","2009","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034180","Evaluation and characterisation of novel glucagon receptor antagonists for type 2 diabetes therapy","Franklin, Zara Jane","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034181","Divergent acute versus prolonged pharmacological GLP-1R responses in adult beta cell-specific β-arrestin 2 knockout mice","Tomas Catala, A","2023","Spiral (Imperial College London)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034182","PLace of byetta in diabete's type 2 treatment","JAMARD, Gaétan","2008","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034183","Oxyntomodulin analog (cotadutide) in non-alcoholic fatty liver disease in obese mice with emphasis on the AMPK/mTOR pathway","Ilitch Aquino Marcondes de Castro","2023","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034184","L'effet incrétine: Une nouvelle cible thérapeutique dans le diabète de type 2","Fery, Françoise","2007","Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0034185","Diabetes Mellitus: A Comprehensive Overview OF Pathophysiology, Risk Factors, Diagnosis, Complications, AND Management","U. A. (Ubaydullayev) o'g'li","2025","Neliti","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034186","NAION, diabetic retinopathy in GLP-1-RA therapy – pathogenetic role of magnesium depletion? Suggestion for detecting patients at risk by monitoring magnesium status","Bodo von Ehrlich","2026","Trace Elements and Electrolytes","other","article","10.5414/te500163",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034187","A REVIEW ON GLP-1 RECEPTOR AGONISTS IN OBESITY AND TYPE 2 DIABETES MANAGEMENT","Gokulakrishnan D.1, Mirudula S.2, Kavya M.3, Saron Micahvel S.4, Dr. K. Bharathi Priya*5","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.21137946",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034188","A UTILIZAÇÃO DO INSTAGRAM PARA PROMOVER A EDUCAÇÃO EM SAÚDE E O FORTALECIMENTO DA ATUAÇÃO CLÍNICA DO FARMACÊUTICO: INOVAÇÃO E ENGAJAMENTO DOS PROFISSIONAIS, ALUNOS E COMUNIDADE","Mariana Fernandes Lima","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21133223",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0034189","THE LITERATURE BEFORE THE MECHANISM: A Comprehensive Literature Review of the Longevity Asymmetry Corpus and Its Relationship to the Existing Intellectual Record Across Ten Disciplines","HUYNH GIA BAO","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.21126633",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034190","Pharmacological Management of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)","Sandip Kumar Bhowmick","2026","Faridpur Medical College Journal","randomized_trial","article","10.3329/fmcj.v21i2.90822",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0034191","Peptides and Hormones as Therapy: Promise, Evidence, and the Line Between Medicine and Marketing","Rohit Karki","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21163036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034192","Obesity as a risk factor for dermatological diseases","A.A. Eremina","2026","Russian Journal of Clinical Dermatology and Venereology","other","article","10.17116/klinderma202625031482",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034193","Kilo Verme Hapı Foundayo'ya Onay",null,"2026","üha","other","article","10.32739/uha.id.90765",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034194","Semaglutide as a Single-Agent Strategy for Diabetes, Obesity, and Hypertension: An 18-Month Case Experience","Kamolika Chaudhary","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21191082",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter; article"],["R0034195","Semaglutide and the Evolving Landscape of Metabolic Dysfunction–Associated Steatotic Liver Disease","Rohan Karkra","2025","Digital Journal of Clinical Medicine","other_trial","article","10.55691/2582-3868.1280",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0034196","Role and mechanisms of glucagon⁃like peptide⁃1 receptor agonists in the treatment of diabetes⁃associated cognitive dysfunction","LI Hongju*","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.13429/j.cnki.cjcr.2026.06.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034197","Aging as Information Loss: A Unified Dynamical Framework for Biological Aging","Leon Sandler","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21208933",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034198","Evaluation of newly synthesized 68Ga-labeled Exendin-4 derivative targeting glucagon-like peptide-1 receptor","Hiroyuki Kimura","2013","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034199","68G-EXENDIN-4 PET/CT IS HIGHLY EFFECTIVE IN LOCALIZING INSULINOMAS","Luo Yaping","2015","Journal of Nuclear Medicine","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0034200","Metabolic and microbiota mechanisms in high-fat diet-induced obesity: insights from global research trends with clinical relevance","Yan-Zhi Zheng","2026","International Journal of Surgery","nonrandomized_study","article","10.1097/js9.0000000000004597",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0034201","Monographs: Liraglutide: A new treatment for type 2 diabetes.","Tina Vilsbøll","2009","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034202","Specific zonal lipid accumulation in the liver of elderly rats on HFHS diet treated with Metformin and Liraglutide","Senka Blažetić","2018","EUROPEAN JOURNAL OF DEVELOPING COUNTRY STUDIES","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034203","MRI-aided PET imaging of pancreatic β-cell mass changes in mice","Su‐Tang Lo","2012","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034204","Three-quarters of pharmacies expect surge in demand for weight-loss pill",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.418912",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034205","Mazdutide in Asian Obesity: Mechanistic Rationale, Emerging Clinical Evidence, and Relevance to South Asia","Ahmad Alam","2026","Bangladesh Journal of Endocrinology and Metabolism","other","article","10.4103/bjem.bjem_31_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034206","Orforglipron, un concurrent pour Ozempic®","Yann-Mickael Dalmat","2026","Option/Bio","other","article","10.1016/s0992-5945(26)75015-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034207","Incretin therapy for obesity: reality and prospects","Merdzhen M. Orazova","2026","Clinical review for general practice","other","article","10.47407/kr2026.7.4.00824",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034208","A comparison of radiolabeled GLP-1 receptor agonists as PET tracers for pancreatic β-cell imaging","Nilantha Bandara","2014","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034209","Monograph: Lixisenatide for the treatment of type 2 diabetes.","Andreas Brønden Petersen","2013","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034210","Development of 123I labeled Exendin derivatives for the imaging of GLP-1 receptors on pancreatic {beta}-cell with SPECT","Yu Ogawa","2011","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034211","Gelofusine is effective in reducing renal uptake of 68Ga-exendin-4 and contributes to better quantification of pancreatic β cell mass","Yaping Luo","2016","Journal of Nuclear Medicine","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0034212","Radiosynthesis and evaluation of F-18 exendin-4 derivatives as a PET tracer for the imaging of GLP-1 receptors on pancreatic {beta}-cells","Hiroyuki Kimura","2011","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034213","Dosimetry of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 in rat, non-human primate and human","Ram Kumar Selvaraju","2014","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034214","Sensitive issues of the incretin-based therapy","I. BAKULIN","2026","Медицинский вестник МВД","other","article","10.52341/20738080_2026_142_3_25",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034215","Assessing Tecoma stans compounds as GLP-1 agonists and inhibitors of alpha-glucosidase/alpha-amylase","Hatice Akkaya","2025","Pakistan Journal of Botany","other","article","10.30848/pjb2025-4(6)",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034216","Semaglutide and Tirzepatide: Revolutionary Therapies for Obesity and Type 2 Diabetes Mellitus Management","James P. Torres-Pirela","2025","Ponce Health Sciences University Scientific Journal","other","article","10.71332/ekx6t266",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034217","Finerenone: Advances in Pharmacology, Clinical Efficacy, and Future Therapeutic Directions","Pravin Dighe Akanksha Borhade*","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.21267791",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034218","Orforglipron for Type 2 Diabetes Mellitus: Current Evidence, Clinical Benefits, and Future Prospects","Sagar Sagar","2026","International Scientific Journal of Engineering and Management","nonrandomized_study","article","10.55041/isjem08155",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0034219","Updating Criteria to Approach Cardiovascular Kidney Metabolic Syndrome","Anita L R Saldanha","2026",null,"other","article","10.58372/2835-6276.1412",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034220","Enerji Homeostazını Düzenleyen Peptitlerin Diyabetteki Rolleri","Rümeysa Kurşun","2022",null,"other","article","10.37609/akya.1309.c15061",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0034221","Practices and knowledge of semaglutide, Ozempic, use for weight loss among non diabetic adults in Jeddah","Maysa Ageel","2026","International Journal of Medicine in Developing Countries","other","article","10.24911/ijmdc.51-1776639289",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034222","Early Tirzepatide Improves Outcomes in Type 2 Diabetes",null,"2026","Kidney News","other","article","10.62716/kn.003912026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034223","Effects of sodium glucose co-transporter-2 inhibitors and glucagon like peptide-1 receptor agonists in diabetic metabolic dysfunction-associated steatotic liver disease management","Tuba Taslamacıoğlu Duman","2026","World Journal of Diabetes","other","article","10.4239/wjd.119285",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034224","What bariatric surgery can teach us about glucagon-like peptide-1 agonist weight loss therapy: Improving long-term outcomes and patient care","Arianna Sze Huey Tan","2026","World Journal of Clinical Cases","other","article","10.12998/wjcc.121701",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034225","Health news round-up: 'landmark' long COVID trial results and are contraceptives linked to brain tumours?",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other_trial","article","10.1211/pj.2026.1.419194",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0034226","Building a Health Canada Clinical Trial Application in CTD Format: Lessons from a Capstone Dossier","Chandrabhansinh Chavda","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.21312742",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034227","Beyond the Ceiling: GLP-1 Receptor Agonist and Long-Acting Amylin Analogue Combination Therapy: From Molecular Design to New Drug Submission in Canada","Harika Adapa","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.21312474",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034228","EFFECTS OF GLP-1 RECEPTOR AGONISTS ON PERIODONTAL HEALTH, ORAL WOUND HEALING, AND PERIODONTAL REGENERATION: A SYSTEMATIC REVIEW OF PRECLINICAL EVIDENCE","Mahnoor Shahzad,Maham Noor,Haadia Arooj,Jannat Yaqoob,Hafsa Tahir,Fahad Niaz","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21305320",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0034229","GPhC launches campaign on risk of fake online pharmacies following launch of oral semaglutide",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.419307",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034230","Targeting the Cardiometabolic Axis: An Integrative Review on Therapeutic Advances","Paul Duru","2026","International Journal of Angiology","narrative_review","article","10.1055/a-2904-8884",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034231","Perspectives and Insights on GLP-1 Receptor Agonist Drugs: From Development to Submission of a New Drug Application in the United States and a New Drug Submission in Canada","Samuel Adu-Agyei","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21312611",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0034232","When the pharmaceutical industry meets agriculture: GLP-1 adoption and implications for 1 farmers, trade, and environment","Rui Liu","2026","AgEcon Search (University of Minnesota, USA)","other","article","10.22004/ag.econ.404673",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034233","In Case You Haven't Heard…",null,"2026","Alcoholism & Drug Abuse Weekly","other","article","10.1002/adaw.34979",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034234","Safety and Efficacy of Semaglutide in Kidney Transplant Recipients With Type 2 Diabetes Mellitus or Post-Transplant Diabetes Mellitus: A Retrospective Cohort Study","Issa Kawalit","2026","Medical Research Archives","nonrandomized_study","article","10.18103/mra.2026.0406",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0034235","Lixisenatide clinical experience on patients with type 2 diabetes and obesity in Endocrinology Offices","Roca-Rodriguez M Mar","2015","Endocrine Abstracts","other","article","10.1530/endoabs.37.ep428",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034236","Abstracts",null,"2024","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_38_24",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0034237","Abstract 4145802: Association between Glucagon-like peptide-1 receptor agonists and risk of Arrhythmias or Heart Failure among patients with Type 2 Diabetes: A Meta-Analysis of 29 Randomized Controlled Trials.","Vikash Jaiswal","2024","Circulation","systematic_review","article","10.1161/circ.150.suppl_1.4145802",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034238","Tu1688 RISK OF SEVERE GI MOTILITY COMPLICATIONS GLP-1 AGONIST INITIATION IN PATIENTS WITH PRIOR ABDOMINAL SURGERY OR OBSTRUCTION: A RETROSPECTIVE COHORT STUDY","Sahil Sethi","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04618-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034239","Sa1276 GLP-1 RECEPTOR AGONISTS DO NOT INCREASE CELIAC DISEASE RISK: A 675,000-PATIENT PROPENSITY-MATCHED ANALYSIS OF REAL-WORLD TESTING AND BIOPSY OUTCOMES","Eshan Nanda","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)05707-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034240","GLP-1 receptor agonists in the therapy of alcohol use disorder: current state of the evidence base, mechanisms of action, and unresolved issues (a narrative review)","И. Ф. Тимербулатов","2026","Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery)","randomized_trial","article","10.33920/med-01-2603-01",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","review"],["R0034241","A Narrative Review on Clinical Evidence of Tirzepatide's Role in Addressing Type 2 Diabetes and Obesity Management","Payal Shelke*, Rutuja Ghumare, Vaishnavi Rakshe, Mansi Deshmukh, Bhakti Shirke, Vedika Aandhle, Priyanka Panmand","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.17570995",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","review"],["R0034242","Abstract 11806: Not Glycemic Control Using Sitagliptin But Lipid Control is Associated With Change in Coronary Atherosclerosis in Patients With Type 2 Diabetes -A Serial Integrated Backscatter Intravascular Ultrasound Study","Tsuyoshi Nozue","2015","Circulation","randomized_trial","article","10.1161/circ.132.suppl_3.11806",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034243","GLUCAGON-LIKE PEPTIDE-1 AGONISTS AND PROTECTION AGAINST STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Fotios Barkas","2017","Atherosclerosis","systematic_review","article","10.26226/morressier.58e389add462b802923855fd",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","other; article"],["R0034244","Effects of semaglutide on glycemic control and body composition in patients with type 2 diabetes mellitus and obesity in a real life setting in spain","Luca Bogdana Luiza","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep462",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034245","Abstract 12427: Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology and Primary Care Visits in a Community Health System","Dave L. Dixon","2023","Circulation","other","article","10.1161/circ.148.suppl_1.12427",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034246","GLP-1RAs boost erectile function in men with type 2 diabetes and erectile dysfunction: results from a 1-year retrospective cohort study","Giuseppe Lisco","2024","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.99.p268",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034247","31% of Australians are obese – is Ozempic a healthy solution? A GP considers Johann Hari’s inside take on a ‘mass experiment’","Natasha Yates","2024","Bond University Research Portal (Bond University)","other","article","10.64628/aa.9j4n6h37h",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034248","Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","Sposito, Andrei C.","2020","Figshare","notice","article","10.6084/m9.figshare.c.4420676.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0034249","Clinical profile and outcome of cardiac amyloidosis in a middle-income country. PB119 (#412)","Marcelo Goulart","2024",null,"other","article","10.26226/m.65f9bf8be6f73964e1d4f4bd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034250","Effects of Liraglutide on the Gut Bacterial Community","Bull, Jami Anne","2025","BearWorks (Missouri State University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034251","Functional and multi-omic aging rejuvenation with GLP-1R agonism analysis code","Kwok, Andrew J","2024","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.13859698",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0034252","A weight loss of 20 kg on liraglutide","Mohamed Hamid Abdillahi","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.ep510",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034253","EARLY INTENSIFICATION WITH FIXED-RATIO COMBINATION OF BASAL INSULIN AND GLP-1 RECEPTOR AGONIST IN T2DM: IMPACT OF ONLINE EDUCATION ON PRIMARY CARE PHYSICIAN KNOWLEDGE AND COMPETENCE","Joachim Trier","2019",null,"other","article","10.26226/morressier.5c3c8156e668b9000b9f9018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034254","Su1708 GASTROPARESIS ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS: A FAERS DATABASE RETROSPECTIVE PHARMACOVIGILANCE ANALYSIS","Bireera Muzaffar","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04413-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034255","Sa2180 PREPPING FOR SUCCESS: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) AND ENDOSCOPY OUTCOMES","Yan Chu","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)01408-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034256","Su1800 METABOLIC REMISSION AFTER COMBINED ENDOSCOPIC SLEEVE GASTROPLASTY AND EARLY TIRZEPATIDE THERAPY: FIRST PROSPECTIVE SIX-MONTH OUTCOMES FROM A 77-PATIENT COHORT","Anna C. Hoff","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04816-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034257","Research Progress of Tirzepatide in Metabolic Diseases","豪 孙","2026","Advances in Clinical Medicine","other","article","10.12677/acm.2026.1672603",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034258","GLP-1 eficcacy in severely obese people: systematic review of individual patient data of clinical trials","Thiago Moreira Trindade","2025","Arca - Repositório Institucional da Fiocruz","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0034259","S1-2 : The burden of diabetes and diabetes care in Thailand","Chaicharn Deerochanawong","2019",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0034260","The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the mechanisms","Adriana C. C. Girardi","2023","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0034261","Network Meta-Analysis of Drug Class Sequencing for Optimizing Glycemic Control, Cardiovascular, and Renal Outcomes in Type 2 Diabetes Mellitus","H.S., Siddalingaiah","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.17334010",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034262","Efficacy and safety of basal insulin plus glucagon-like peptide-1 receptor agonist versus basal-bolus insulin in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials","Acharya, Yogesh","2020",null,"systematic_review","article","10.13140/rg.2.2.15642.47043",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034263","Changes in esophageal physiology following weight loss interventions: a narrative review","Devvrat Yadav","2026","Annals of Esophagus","nonrandomized_study","article","10.21037/aoe-2026-1-0006",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0034264","Additional file 3: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Li, Ling","2016","Figshare","systematic_review","article","10.6084/m9.figshare.c.3633269_d1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034265","Real-life clinical experience with GLP1 analogs and SGLT2 inhibitors in the treatment of diabetes type 2 and obesity","José Pérez-Rodríguez","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep457",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034266","Guidance for the planning and prescribing of GLP-1 agonists in a multi-disciplinary team, tier 3, specialist weight management service","Bethany Squire","2025","Endocrine Abstracts","other","article","10.1530/endoabs.109.p108",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034267","Real-world effectiveness analysis of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus","Garcia Juan Carlos Ferrer","2023","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.90.ep437",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034268","Relationship between change in glycemic parameters and body weight with IDegLira in type 2 diabetes","Ivona Risović","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.p105",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034269","Update in Cardiovascular Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes—A Mixed Treatment Comparison Meta-analysis of Randomized Controlled Trials","Osamah M. Alfayez","2018","Diabetes","systematic_review","article","10.2337/db18-414-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034270","AKI Induced by Oral Semaglutide Leading to Metformin-Induced Lactic Acidosis","Allyson K. Halderman","2021","Journal of the American Society of Nephrology","other","article","10.1681/asn.20213210s1139c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034271","A randomized clinical trial ofexenatide onT2D v1","Jing Xu","2020",null,"randomized_trial","article","10.17504/protocols.io.bgsyjwfw",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","preprint"],["R0034272","GLP-1 receptor agonists as therapeutic approach to severe obesity in PHP/iPPSD: two case reports","Sindaco Giulia Del","2025","Endocrine Abstracts","case_report","article","10.1530/endoabs.110.ep739",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034273","Impact on weight and glycemic control in patients with type 2 diabetes and obesity treated with liraglutide","Virginia Hernando","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.p476",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034274","Meta-Analysis of Exenatide, the Sitagliptin, and Pramlintide Compared to Placebo for Treatment of Type II Diabetes.","Jonathan T. Rowell","2010","UA Campus Repository (The University of Arizona)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0034275","GLP-1 receptor agonists and pancreatic cancer risk: A meta-analysis of real-world and trial evidence.","Adarsh Vardhan Tangella","2026","Journal of Clinical Oncology","systematic_review","article","10.1200/jco.2026.44.2_suppl.712",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034276","The forgotten tribe: severe and complex obesity patient unable to benefit from GLP-1 analogue due to HbA1c criteria - a case study","Wui Hang Cheung","2018","Endocrine Abstracts","other","article","10.1530/endoabs.53.p09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034277","Copeptin levels at baseline and in response to short-acting GLP-1 receptor agonists in patients with endogenous hyperinsulinaemic hypoglycaemia and healthy controls - a secondary analysis","Sarah Baumann","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep1094",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034278","Mo1812 GASTROINTESTINAL SAFETY PROFILE OF GLP-1 RECEPTOR AGONISTS IN SEVERE OBESITY AND NON-INSULIN-DEPENDENT TYPE 2 DIABETES","Basil Jalamneh","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04876-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034279","Anti Obesity Drugs and Bariatric Surgery: Complementary Noncompeting Strategies in Obesity Management","Pawanindra Lal","2025","Journal of Bariatric Surgery","randomized_trial","article","10.4103/jbs.jbs_1_26",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","editorial"],["R0034280","A-94 | Efficacy and Safety of CagriSema compared with Semaglutide or Placebo: A Systemic Review and Updated Meta Analysis of Randomized Controlled Trials","Himat ALI Faiaz","2026","Journal of the Society for Cardiovascular Angiography & Interventions","randomized_trial","article","10.1016/j.jscai.2026.104585",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0034281","Sa2106 ASSOCIATIONS BETWEEN GLP-1 RECEPTOR AGONISTS AND LIVER FUNCTION IN TYPE 2 DIABETES: A PROPENSITY SCORE-MATCHED STUDY","Mustafa Habib","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03572-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034282","Oral Contraceptive Failure With GLP-1 and Dual GLP-1/GIP Therapies: A Case Report and Systematic Review of Incretin–COC Interactions [ID 3414]","Casey Moffitt","2026","Obstetrics and Gynecology","systematic_review","article","10.1097/aog.0000000000006265.09",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034283","LONG TERM INSULIN INDEPENDENCE AND RESTORATION OF FIRST PHASE INSULIN RELEASE AFTER SUPPLEMENTAL ISLET INFUSION UNDER EXENATIDE TREATMENT IN SUBJECTS WITH ISLET GRAFT DYSFUNCTION","Tatiana Froud","2008","Transplantation","other","article","10.1097/01.tp.0000332501.67044.8a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034284","Reversal of primary amenorrhea with titrated Mounjaro therapy","Catherine Cucknell","2025","Endocrine Abstracts","other","article","10.1530/endoabs.113.wb2.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034285","GLP-1 and neuroprotection in Alzheimer’s disease: a systematic review of randomized clinical trials","Nicole Fernanda Penteado","2025",null,"systematic_review","article","10.5327/1516-3180.cpn.1784",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034286","GLP-1 receptor agonists for weight loss in adults without diabetes: perspectives from primary care","Annelies Vanhove","2025","Endocrine Abstracts","other","article","10.1530/endoabs.112.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034287","Semaglutide-associated risk of non-arteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies","Chrzanowski, Jędrzej","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.17885011",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034288","Oral peptides: Mesoporous silicon loaded ionic liquids and trypsin inhibitors to promote oral absorption of semaglutide","Tian, Jingrun","2023","UTUPub (University of Turku)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034289","Weight loss drug semaglutide shown to be safe and potentially more effective at higher dose – new findings","Martin Whyte","2025",null,"other","article","10.64628/ab.eftghtjne",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034290","A Systematic Literature Review of Treatment Patterns, Safety Profiles, and Long-Term Disease Progression in Patients with CKD and Type 2 Diabetes Mellitus","Rakesh Kumar Singh","2021","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20213210s1719b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","review"],["R0034291","The once-daily human GLP-1 analog liraglutide reduces the prevalence of prediabetes and improves systolci blood pressure in obese non-diabetic subjects:a 52-week randomized placebo controlled trial","Nick Finer","2009","Research at the University of Copenhagen (University of Copenhagen)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0034292","Sa1791 GLP-1RA THERAPY PLUS LIFESTYLE COUNSELING SIGNIFICANTLY IMPROVES CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS LIVING WITH IBD AND OBESITY","Stephanie L. Gold","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04786-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034293","Su1995 GLP-1 RECEPTOR AGONIST-SGLT-2 INHIBITOR COMBINATION AND RISK OF MAJOR ADVERSE LIVER AND CARDIOVASCULAR OUTCOMES IN MASLD AND T2D","Xianhua Mao","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03624-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034294","Abstract 735: The associations between the use of GLP-1 receptor agonists, cancer recurrence and all-cause mortality among cancer survivors","Po-Hua Chen","2023","Cancer Research","other","article","10.1158/1538-7445.am2023-735",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034295","The weight loss drug Mounjaro has been approved to treat sleep apnoea. How does it work?","Yaqoot Fatima","2025",null,"other","article","10.64628/aa.d9v7rwtxs",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034296","Su2217 INCREASED RESIDUAL GASTRIC CONTENT BUT NO ASPIRATION IN GLP-1 RECEPTOR AGONIST USERS UNDERGOING ELECTIVE ENDOSCOPY: A PROSPECTIVE MATCHED COHORT STUDY","Yavuz Özden","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)01502-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034297","Efficacy and Safety of Subcutaneous Semaglutide in Overweight or Obese Adults: A Subgroup Meta-Analysis of Randomized Controlled Trials","Rui Zhang","2022","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.4249801",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0034298","Mo1813 GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH DELAYED COLONIC TRANSIT: A PROPENSITY SCORE-WEIGHTED RETROSPECTIVE COHORT STUDY","Jessica Atieh","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04877-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034299","Mo1781 COMPARISON OF ADVANCED CONSTIPATION PHARMACOTHERAPY BETWEEN ADULTS WITH OBESITY ON GLP-1RA VS NOT INITIATING GLP-1RA: A PROPENSITY-MATCHED REAL-WORLD COHORT ANALYSIS","Richard Maradiaga","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04590-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034300","Su2089 RESMETIROM VS SEMAGLUTIDE IN MASH: A REAL-WORLD ASSESSMENT OF CLINICAL OUTCOMES, SAFETY EVENTS, AND BIOCHEMICAL TRAJECTORIES","Regis Lee","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03718-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034301","Mo1827 LONG-TERM GLP-1 RA EXPOSURE AND CANCER RISK IN OBESITY MANAGEMENT: SYSTEMATIC REVIEW AND META-ANALYTIC EVIDENCE","Anmol Mohan","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)04891-1",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034302","Obesity and Type 2 Diabetes: One Injection, Two Conditions: The Dual Metabolic Indication Story of GLP-1 Receptor Agonist and Long-Acting Amylin Analogue Combination Therapy","Harika Adapa","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21338981",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034303","The effect of liraglutide in patients with type 2 diabetes mellitus: clinical and metabolic characteristics","Andreja Marić","2016","Endocrine Abstracts","other","article","10.1530/endoabs.41.ep570",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034304","A guerra do Ozempic: Dinamarca, Canadá, EUA, China e Brasil lutam pela patente do medicamento mais lucrativo do planeta","Carlos Oliveira","2025",null,"other","article","10.64628/ade.uavh9k59w",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034305","Exenatide protects pancreatic islets against brain death-induced inflammation and viability loss","Rodrigo Carlessi","2014","Endocrine Abstracts","other","article","10.1530/endoabs.35.p341",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034306","Abstract 13756: The Role of Glucagon Like Peptide-1 Receptor Agonists on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure: A Meta-Analysis From Cardiovascular Outcome Trials","Sharath Kommu","2023","Circulation","systematic_review","article","10.1161/circ.148.suppl_1.13756",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034307","Efficacy of liraglutide in weight reduction in a patient with HAIR-AN syndrome - case report","Weronika Wasyluk","2021","Endocrine Abstracts","case_report","article","10.1530/endoabs.73.aep249",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034308","Genetic variation in GLP1 receptor is associated with interindividual differences in weight lowering potential of liraglutide in obese women with PCOS","Mojca Jensterle","2015","Endocrine Abstracts","other","article","10.1530/endoabs.37.ep590",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034309","Evaluation of the Suitability of Commercial Bioassay Kits and Reporter Cell Lines for the Characterization of Exendin-4, Bevacizumab and Cetuximab Biological Activities","Nicolas Fourrier","2016",null,"other","article","10.26226/morressier.57d6b2bed462b8028d88ce0a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034310","Could Ozempic help people whose cancer has spread to the brain?","Prof Justin Stebbing","2026",null,"other","article","10.64628/ab.jthuc9wp3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034311","Tu2001 GLP-1 AGONIST USE IS ASSOCIATED WITH LOWER PREDNISONE USE AND HOSPITALIZATIONS IN PATIENTS WITH AUTOIMMUNE HEPATITIS AND MASLD: A MULTI-CENTER ANALYSIS.","Sharon Narvaez","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04023-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034312","Semaglutide provides sustained reductions in body weight over 2 years in subjects with type 2 diabetes (SUSTAIN 6)","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3c2f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034313","Clinical Significance of Basal and Stimulated Calcitonin Levels in A Case with Obesity Under Liraglutide Treatment","Taner Bayraktaroğlu","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep1025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034314","GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW OF THEIR ROLE ACROSS MULTIPLE ORGAN SYSTEMS BEYOND WEIGHT MANAGEMENT","1*Alabi Damilola, 2Fatima Zehra, 3Mohsin Babar, 4Chad Barker, 5Muhammad Ahsan Shaikh MBBS, MD, 6Syeddah Saiqa Gillani, 7Hirak Trivedi, 8Humaira Kousar, 9Surriya Kousar","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.20465519",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","review"],["R0034315","Abstract 515: Effects of the Glucagon-Like Peptide-1 Analog Exendin-4 on Reendothelialization and Intimal Hyperplasia Formation in an Animal Model of Vascular Injury","Linnéa Eriksson","2014","Arteriosclerosis Thrombosis and Vascular Biology","randomized_trial","article","10.1161/atvb.34.suppl_1.515",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034316","Meta-analysis of SGLT2 inhibitors and GLP-1 agonists in treating PCOS","Kannan Sridharan","2025","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0034317","Liraglutide improves binge-eating and increases ghrelin levels in obese diabetic 2 patients","Федір Ланюш","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.ep274",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034318","O Wegovy e o Mounjaro podem afetar o funcionamento de seus anticoncepcionais - veja por quê","Simon C. Cork","2025",null,"other","article","10.64628/ade.7qwryfkyg",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034319","Comparative efficacy of lifestyle and GLP-1RA-based interventions for visceral adipose tissue reduction: meta-analysis of 36 randomised controlled trials","Samit Ghosal","2025","Obesity Abstracts","systematic_review","article","10.1530/obabs.05.p1",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034320","EFFECTS OF TIRZEPATIDE ON BLOOD GLUCOSE, HOME BLOOD PRESSURE, BAPWV, AND URINARY PROTEIN IN TYPE 2 DIABETES PATIENTS WITH HYPERTENSION","Toshio Yamagishi","2026","Journal of Hypertension","other","article","10.1097/01.hjh.0001195652.14543.58",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034321","Effectiveness and tolerance of liraglutide and bupropion/naltrexone: clinical experience","Jersy Cárdenas‐Salas","2019","Endocrine Abstracts","other","article","10.1530/endoabs.63.p981",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034322","Comparison of the clinical efficacy of Semaglutide between DPP4-inhibitor-naive and DPP4-inhibitor-experienced patients in a real world setting in Spain","Miguel Sierra Poyatos Roberto","2021","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.73.aep809",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034323","Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain","Jersy Cárdenas‐Salas","2020","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.70.ep197",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034324","Data comparison on cardiovascular outcomes in patients with T2D taking liraglutide with estimates based on risk factors","Skovgaard Rasmus","2017",null,"other","article","10.26226/morressier.59d51843d462b80296ca37f1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034325","Taking a drug like Ozempic? What you need to know about risks of suicidal thoughts and contraception failure","Nial Wheate","2025",null,"other","article","10.64628/aa.c9d73gpt7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034326","Maximizing Outcomes: Synchronizing Liraglutide And Tailored Exercise In Weight Loss - A Case Study","CARLOS BLUM","2025","Medicine & Science in Sports & Exercise","other","article","10.1249/01.mss.0001160920.06481.85",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034327","Audit on GLP-1 mimetics monitoring in East Kent university hospitals UK","Abdelmajid Musa","2021","Endocrine Abstracts","other","article","10.1530/endoabs.73.aep255",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034328","Predictors of poor response to semaglutide for weight management","Ploutarchos Tzoulis","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.rc12.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034329","Semaglutide as a treatment for patients with obesity and difficult to control hypertension: preparatory analysis of the STEP trial data","Cormac Kennedy","2023","OSF Preprints (OSF Preprints)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","preprint"],["R0034330","Male patients benefit from initial exenatide treatment: a real-world experience","Liang Chen","2015","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.37.ep463",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0034331","Additional file 1: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Li, Ling","2016","Figshare","systematic_review","article","10.6084/m9.figshare.c.3633269_d6",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034332","Acute Exercise Increases Basal Spontaneous Physical Activity In Mice","Suryateja Devarakonda Rao","2024","Medicine & Science in Sports & Exercise","preclinical","article","10.1249/01.mss.0001053592.23982.d7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034333","The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonist in Diabetic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Immanuel, Surya Sinaga","2024",null,"systematic_review","article","10.13140/rg.2.2.10696.12803",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034334","Patient-reported outcomes with IDegLira vs. basal–bolus therapy in type 2 diabetes: DUAL VII trial","Jódar Esteban","2017",null,"other_trial","article","10.26226/morressier.59d51847d462b80296ca3c39",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034335","Using advanced machine learning to predict HbA1c control with basal insulin and glucagon-like peptide-1 receptor agonist","Kidd Catherine","2017",null,"other","article","10.26226/morressier.59d51846d462b80296ca3b3e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034336","Tu2126 FEASIBILITY, SAFETY, AND METABOLIC EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS IN LIVER TRANSPLANTATION: A REAL-WORLD COHORT STUDY","Sima Fansa","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04148-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034337","Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Li, Ling","2018","Open Collections","systematic_review","article","10.14288/1.0367018",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034338","People on Ozempic may have fewer heart attacks, strokes and addictions – but more nausea, vomiting and stomach pain","Lauren Ball","2025",null,"other","article","10.64628/aa.xd3hrfr9s",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034339","Lawsuit could challenge trust in Ozempic and other popular weight loss drugs","Ana Santos Rutschman","2024",null,"other","article","10.64628/aai.gdtgcwjug",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034340","Does tolerance develop toward GLP-1 receptor agonists' glucose-lowering effect?","Tuuli Sedman","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.ep607",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034341","Abstract 13483: Pathological Decline in Incretin Hormone Glucagon-like Peptide-1 Causes Cardiac Apoptosis and Dysfunction in Pressure-overloaded Heart Failure Through Cyclic AMP-dependent Mechanisms. -Distinct Role of Protein Kinase a and EPAC","Morihiko Aoyama","2014","Circulation","preclinical","article","10.1161/circ.130.suppl_2.13483",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034342","Sa1128 MOVING ALONG: THE USE OF GLP-1 RECEPTOR AGONISTS DOES NOT REDUCE ESOPHAGEAL MOTILITY","Sonia Mehra","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)01880-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034343","MINDFUL EATING AS A BEHAVIORAL STRATEGY FOR WEIGHT MANAGEMENT: A NARRATIVE REVIEW WITH IMPLICATIONS FOR PRIMARY CARE IN THE PHARMACOTHERAPY ERA","Santi Jaturawichanant","2026","International Journal of Advanced Research","narrative_review","article","10.21474/ijar01/22983",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0034344","Ocular outcomes of the sodium-glucose cotransport inhibitors: A systematic review of cohort studies","Nathaniel Eraikhuemen","2025","Journal of Clinical Ophthalmology and Research","systematic_review","article","10.4103/jcor.jcor_148_24",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0034345","Glucagon-like Peptide-1 Receptor Agonists and Their Potential Role in the Treatment of Substance Use Disorders: A Narrative Review","Adam Caplin","2026","The Canadian Journal of Addiction","randomized_trial","article","10.1097/cxa.0000000000000268",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0034346","Additional file 2: of Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis","Zhang, Xiaowen","2018","Figshare","systematic_review","article","10.6084/m9.figshare.7096853",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034347","Re:Glucagon-like peptide-1 analogues for type 2 diabetes","Chioma N. Otti","2017",null,"commentary","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0034348","Comparative analysis of GLP-1 receptor agonists, traditional glucose-lowering medications and traditional anti-obesity medications on skeletal outcomes in obese individuals with and without type 2 diabetes: a five-year propensity-score matched cohort study","Jo-Ching Chen","2025","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.110.p684",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034349","Real-world outcomes of liraglutide treatment in children with obesity: beyond weight loss","Katarina Štajer","2025","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.110.p696",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034350","Low dose Glucagon Like Peptide-1 analogue (GLP-1) improves glycemic control, medical adherence and DTSQ in patients with type 2 diabetes mellitus on peritoneal dialysis","Takeyuki Hiramatsu","2017",null,"other","article","10.26226/morressier.59a56f96d462b8028d895c0f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034351","Semaglutide reduces body weight in subjects with type 2 diabetes across baseline BMI subgroups vs comparators","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3c02",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034352","Oral Semaglutide Improves Metabolic Outcomes in Type 2 Diabetes: A Spain-based Study","Carlos Casado","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.p336",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034353","Benefits of Wegovy independent of weight loss in a patient with hypertrophic cardiomyopathy and obesity","J. Williams","2026","Endocrine Abstracts","other","article","10.1530/endoabs.117.p96",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034354","Tu1170 THE IMPACT OF CONCOMITANT USE OF PROTON PUMP INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BARRETT’S ESOPHAGUS IN GERD PATIENTS WITH OBESITY","Julton Tomanguillo Chumbe","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)02201-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034355","EP48 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND RISK OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS","Vidhi Singh","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04178-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034356","Perspectives and Insights on Glucagon-Like Peptide-1 Receptor Agonists: From Development to Submission of a Clinical Trial Application in Canada","Mihirkumar Patel","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21339162",null,null,"ClinicalTrials.gov:NCT05132088","S000582","openalex","TRUE","paywalled","1","FALSE","article"],["R0034357","Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy","Ze-jin Liao","2024","DOAJ (DOAJ: Directory of Open Access Journals)","systematic_review","article","10.3969/j.issn.1671-2390.2024.12.003",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034358","Liraglutide improves surfactant protein-B production and reduces right ventricular hypertrophy in a rat model of intersitial pulmonary fibrosis","Juan Fandino Gomez","2015","Endocrine Abstracts","preclinical","article","10.1530/endoabs.37.ep620",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034359","Abstract 13027: The Activation of Glucagon-Like Peptide-1 Improves the Mitochondrial Abnormalities in Skeletal Muscle and Exercise Intolerance in Heart Failure Mice","Takashi Katayama","2016","Circulation","preclinical","article","10.1161/circ.134.suppl_1.13027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034360","Sa2100 GLP-1 RECEPTOR AGONISTS DEMONSTRATE SUPERIOR HEPATOPROTECTION COMPARED TO SGLT2 AND DPP-4 INHIBITORS IN PREVENTING MAJOR ADVERSE LIVER OUTCOMES AMONG ADULTS WITH MASLD AND TYPE 2 DIABETES","Tochukwu Ikpeze","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03566-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034361","Additional file 2: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Li, Ling","2016","Figshare","systematic_review","article","10.6084/m9.figshare.c.3633269_d2",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034362","Tu1654 CARDIOMETABOLIC AND RENAL OUTCOMES OF GLP-1 RECEPTOR AGONISTS VS SGLT2 INHIBITORS IN IBD WITH OBESITY OR MASLD: A REAL-WORLD PROPENSITY-MATCHED STUDY","Yussif Issaka","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03272-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034363","Cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonist based on race, ethnicity, and gender: A systematic review and meta-analysis of randomized trials","Ikechukwu R Ogbu","2022","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.5904341",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034364","Inhibitors SGLT2 after liraglutide in patients with type 2 diabetes","Paloma Moreno-Moreno","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p486",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034365","Education improves physicians’ knowledge of diabetes CV outcomes trial results and appropriate use of GLP-1 RAs in T2DM","Joachim Trier","2019",null,"other_trial","article","10.26226/morressier.5d9b6234ea541d6ca84943d4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034366","IMPROVED HUMAN ISLET QUALITY USING STEROID WITH EXENDIN-4 FOR PRE-TRANSPLANT CULTURE","Atsushi Miki","2008","Transplantation","other","article","10.1097/01.tp.0000331481.09214.9b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034367","Semaglutide reduces fat accumulation in the tongue of obese women with polycystic ovary syndrome: A randomized, placebo-controlled prospective study","Mojca Jensterle","2021","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.73.aep163",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034368","Abstract 10278: Incretin-Based Treatments Prevent the Development of Atherosclerotic Lesions in Apolipoprotein E-Null Mice","Takuya Watanabe","2010","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034369","Will Ozempic-style patches help me lose weight? 2 experts explain","Nial Wheate","2026",null,"other","article","10.64628/aa.6hkyfeudp",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034370","Switching to IDegLira is effective regardless of pre-trial insulin dose in patients with T2D uncontrolled on IGlar U100","Vilsboll Tina","2017",null,"other_trial","article","10.26226/morressier.59d51842d462b80296ca3653",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034371","Sa2119 DIFFERENTIAL IMPACT OF METABOLIC BARIATRIC SURGERY VERSUS SEMAGLUTIDE ON ADVERSE HEPATIC AND EXTRAHEPATIC OUTCOMES IN PATIENTS WITH STEATOTIC LIVER DISEASE AND TYPE 2 DIABETES","Weronika Stupalkowska","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03585-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034372","Mo1137 GLP-1 RECEPTOR AGONISTS INCREASE THE INCIDENCE OF BARRETT’S ESOPHAGUS IN A LARGE PROPENSITY MATCHED COHORT","Shree A. Patel","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)02057-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034373","Abstract 310: GLP-1 Cleavage Product (9-36)-NH2 Exerts Pro-survival Effects on Smooth Muscle Cells in Advanced Inflammatory Hemodynamic Conditions","Ryan E. Feaver","2013","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvb.33.suppl_1.a310",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034374","Can a drug like Ozempic help treat addictions to alcohol, opioids or other substances?","Shalini Arunogiri","2024",null,"other","article","10.64628/aa.n3tr44sue",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034375","Reduced glycaemic deterioration with long term exposure to liraglutide in the LEADER trial","Nauck Michael","2017",null,"other_trial","article","10.26226/morressier.59d51840d462b80296ca2d34",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034376","Abstract Thu015: Maturation of iPSC-derived cardiomyocytes is necessary for Incretin-based analog function","stefanie banahene","2025","Circulation Research","preclinical","article","10.1161/res.137.suppl_1.thu015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034377","Piloting a new nursing and psychology led group session for patients starting wegovy (Semaglutide) in a specialist endocrine weight management service","Emma Lee","2024","Endocrine Abstracts","other","article","10.1530/endoabs.103.p56",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034378","Reactive hypoglycaemia following fundoplication surgery for hiatus hernia successfully treated with GLP1 agonists","Rao Muhammad Asif","2026","Endocrine Abstracts","other","article","10.1530/endoabs.117.p126",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034379","Additional file 2 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Kan, Ranran","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30703259",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034380","P0759 The association between GLP-1 and dual GIP/GLP-1 agonists and severe urolithiasis requiring surgery: A global real-world cohort study","S.E Lee","2026","European Urology","nonrandomized_study","article","10.1016/s0302-2838(26)01627-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034381","Additional file 1 of Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies","Zhong, Ying","2025","Figshare","systematic_review","article","10.6084/m9.figshare.29972422",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034382","Weight loss variability with SGLT2 inhibitors, GLP-1 receptor agonists and repetitive Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity: results of a retrospective, comparative study","Anna Ferrulli","2022","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.81.p586",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034383","Additional file 2 of Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis","Gu, Xia","2024","Figshare","systematic_review","article","10.6084/m9.figshare.24987936",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034384","No increase in calcitonin or development of C-cell malignancy in response to liraglutide in the LEADER trial","von Scholten Bernt-Johan","2017",null,"other_trial","article","10.26226/morressier.59d51846d462b80296ca3c0c",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034385","EXENATIDE COMBINED WITH ISLET TRANSPLANTATION FOR THE TREATMENT OF TYPE I DIABETES.","&NA;","2006","Transplantation","other","article","10.1097/00007890-200607152-00807",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034386","Additional file 5 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Kan, Ranran","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30703268",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034387","Retrospective case review of patients treated with semaglutide for weight management","Michael Batavanis","2023","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.94.p225",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034388","Abstract Th0048: How do novel type 2 diabetes mellitus (T2DM) medications affect lipid parameters in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and type 2 diabetes","Jessica Khoury","2026","JVS Vascular Science","other","article","10.1016/j.jvssci.2025.100314",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034389","Tu2083 GLP-1 RECEPTOR AGONISTS AND RISK OF LIVER CANCER IN ADULTS WITH DIABETES","Daria Chelysheva","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04105-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034390","Time-Dependent Effects of GLP-1 Receptor Agonists on Weight Loss: A Systematic Review and Meta-Analysis of Phase 3 Trials","Ravi Jandhyala","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21025119",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034391","Sa1287 CLINICAL OUTCOMES OF GLP-1 RECEPTOR AGONIST THERAPY IN ADULTS WITH CELIAC DISEASE: A PROPENSITY-MATCHED COHORT STUDY","Sarpong Boateng","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)05718-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034392","Abstract 17736: Cardiomyocyte Specific Loss of Diacylglycerol Acyl Transferase 1 (Dgat1) Reproduces the Abnormalities in Lipids Found in Severe Heart Failure","Chad M. Trent","2014","Circulation","preclinical","article","10.1161/circ.130.suppl_2.17736",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034393","USE OF ACETAMINOPHEN LEVEL TESTING DURING MIXED MEAL STIMULATION IN ISLET TRANSPLANT RECIPIENTS USING EXENATIDE","Tatiana Froud","2008","Transplantation","other","article","10.1097/01.tp.0000331461.15944.b2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034394","The Investigation of the Protective Effect of Glucagon-like peptide (GLP-1) Analogue Exenatide on Glucose and Fructose-induced Neurotoxicity","Khalilnezhad, Asghar","2016","Istanbul Science University (Istanbul Bilim University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034395","Additional file 2 of Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","Hu, Yan","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26641015",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034396","Tu1651 CHANGES IN INFLAMMATORY MARKERS AMONG IBD PATIENTS USING GLP-1 RECEPTOR AGONISTS ACROSS OBESITY CLASSES","Eli Malkovskiy","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03269-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034397","Abstract 4366880: Rates of Atrial Fibrillation and Atrial Flutter in Non-diabetic Obese Adult Patients on Tirzepatide","Tusharbhai Patel","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4366880",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034398","Abstract 14615: Empagliflozin Provides More Value for Money Than Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus","Joseph Azuri","2020","Circulation","randomized_trial","article","10.1161/circ.142.suppl_3.14615",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034399","Additional file 1 of Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis","Ali, Mahmoud M.","2022","Figshare","systematic_review","article","10.6084/m9.figshare.19686997",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034400","Impacts of Glucagon-Like Peptide 1 Analogues and Sodium Glucose Cotransporter 2 Inhibitor on Type 2 Diabetes Patients with Renal Impairment","Takeyuki Hiramatsu","2020","Journal of the American Society of Nephrology","other","article","10.1681/asn.20203110s1350a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034401","Considering taking Wegovy to lose weight? Here are the risks and benefits – and how it differs from Ozempic","Lauren Ball","2024",null,"other","article","10.64628/aa.wckcpcxut",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034402","One-Year Blood Glucose Level is the Best Metabolic Marker for the Prediction of Late Pancreas Graft Failure","Marine Ollivier","2018","Transplantation","other","article","10.1097/01.tp.0000542660.73899.1f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034403","GLP1RA therapy in Bardet-Biedl syndrome","Shawg Ganawa","2022","Endocrine Abstracts","other","article","10.1530/endoabs.82.wg1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034404","Wegovy and Ozempic: could the new weight-loss drug also treat dementia?","Tim J. Viney","2023",null,"other","article","10.64628/ab.nah4q3g9w",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034405","Abstract 13050: Tirzepatide versus Semaglutide for Secondary Prevention of Major Adverse Cardiovascular Events in Patients Over the Age of 65 With Type 2 Diabetes Mellitus-Value per Money Analysis","Ronen Arbel","2022","Circulation","randomized_trial","article","10.1161/circ.146.suppl_1.13050",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034406","Pregnancy after exposure to GLP-1 receptor agonists. A case report and literature review","Olga Wajtryt","2023","Endocrine Abstracts","case_report","article","10.1530/endoabs.90.ep532",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034407","Use of GLP1-RAs as an adjunct in patients with T1DM on closed-loop continuous subcutaneous insulin infusion","Niamh Crowley","2026","Endocrine Abstracts","other","article","10.1530/endoabs.115.ep33",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034408","Mo1494 THE EFFECT OF TIRZEPATIDE ON INFLAMMATORY BOWEL DISEASE WITH METABOLIC SYNDROME","Emily N. Miller","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)02864-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034409","REAL Life study of SEMaglutide in Patients with Type 2 diabetes in SPain (REALSEM-SP): Retrospective clinical study on the efficacy, adherence, and safety with Semaglutide","Salas Jersy Jair Cardenas","2022","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.81.p333",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034410","semaglutide","PAOLO MARZULLO","2023","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0034411","Additional file 1 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Kan, Ranran","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30703256",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034412","Efficacy and safety of once-weekly semaglutide in elderly subjects with T2D: post hoc analysis of SUSTAIN 1–5 trials","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3bee",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034413","Is GLP-1R Agonists Effective and Safe in Severe COVID-19 Patients with Type 2 Diabetes? - A Case Report and Literature Review","Shuqian Chen","2020","SSRN Electronic Journal","case_report","article","10.2139/ssrn.3654086",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034414","Lifestyle intervention enhances weight loss and metabolic control in GLP-1RA-initiating subjects with T2DM","Santo Colosimo","2019","Endocrine Abstracts","other","article","10.1530/endoabs.61.cd1.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034415","Editorial introductions","Su, Wilber W.","2025","Current Opinion in Cardiology","randomized_trial","article","10.1097/hco.0000000000001266",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0034416","The impact of gastrointestinal adverse events on weight loss with semaglutide in subjects with type 2 diabetes","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3bfd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034417","Abstract 438: Peripheral but Not Central Glucagon-Like Peptide-1 Receptor Agonism Regulates Fasting Dyslipidemia by Reducing VLDL Production","JenniferTaher","2014","Arteriosclerosis Thrombosis and Vascular Biology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034418","Additional file 1 of Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis","Gu, Xia","2024","Figshare","systematic_review","article","10.6084/m9.figshare.24987804",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034419","Real-life experience of semaglutide in the treatment of idiopathic intracranial hypertension: a case series","Teixeira Gilberto Claro","2025","Endocrine Abstracts","case_report","article","10.1530/endoabs.110.ep921",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034420","Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks","Ziyad Al‐Aly","2025",null,"other","article","10.64628/aai.rk3cwuhxe",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034421","Efek samping Ozempic dapat meningkatkan risiko bunuh diri dan kehamilan tak diinginkan","Nial Wheate","2025",null,"other","article","10.64628/aan.46thcf5df",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034422","Anti-inflammatory role of GLP-1 and the effect of gastric bypass on diabetes- and obesity-associated inflammation","Kirsten Katrine Lindegaard Bovbjerg","2014",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034423","The GLP-1 disclosure dilemma: Should you tell a date you’re using Ozempic for weight loss?","Treena Orchard","2026",null,"other","article","10.64628/aam.egre44tvv",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034424","Safety Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Diabetes Mellitus and Cancer","Aisha Shaikh","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s129a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034425","Effects of semaglutide injections on mental health, motivation, and decision-making","Sara Z. Mehrhof","2024","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0034426","Trial-level comparisons of iGlarLixi versus IDegLira in the LixiLan and DUAL clinical development programmes","Blonde Lawrence","2017",null,"other_trial","article","10.26226/morressier.59d51847d462b80296ca3bcb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034427","Real-world effect of tirzepatide: a prospective observational study","Lopez de Linares Lidia Urbon","2025","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.110.ep967",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034428","Editorial comment on “The effect of cardiovascular–kidney–metabolic disease on pulse pressure in patients with type II diabetes”","Ashwani Mehta","2025","Journal of current cardiology.","randomized_trial","article","10.4103/jcc.jcc_9_25",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","editorial"],["R0034429","GLP-1 receptor agonists for organ protection in sepsis: a protocol for a systematic review and meta-analysis of preclinical and clinical evidence","Chia-Ta Wu","2026",null,"systematic_review","article","10.37766/inplasy2026.5.0167",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034430","A phase I study to investigate the safety, tolerability and pharmacokinetics of a biased GLP-1R antibody Glutazumab","Li Daisy","2017",null,"other_trial","article","10.26226/morressier.59d51845d462b80296ca39f9",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034431","Short term intervention with liraglutide and metformin increased fertility potential in a subset of obese PCOS proceeding IVF","Vesna Šalamun","2017",null,"other","article","10.26226/morressier.5912d9e9d462b80292385f5c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034432","Real-world use of IDegLira significantly reduces HbA1c after 6 months and HbA1c category is a significant factor","Price Hermione","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51845d462b80296ca3658",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","other"],["R0034433","Effects of GLP-1 analogues in the treatment of a population with DM2","Catarina Ivo","2016","Endocrine Abstracts","other","article","10.1530/endoabs.41.ep555",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034434","Molecular and Computational Characterization of GLP-1 Receptor–Agonist Binding Mechanisms for Rational Therapeutic Design","Neil Banahatti","2025","ChemRxiv","other","article","10.26434/chemrxiv-2025-1dsl1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034435","1734-P: Dual Incretin Therapy vs. GLP-1 Monotherapy: Meta-Analysis of Tirzepatide and Semaglutide in Adults with Type 2 Diabetes","NASEEM ALTHUBAITI","2026","Diabetes","systematic_review","article","10.2337/db26-1734-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034436","Sa1130 COMPARATIVE DIFFERENCES OF TIRZEPATIDE VS SEMAGLUTIDE ON GASTROESOPHAGEAL REFLUX DISEASE (GERD) AND ESOPHAGITIS","Faiza Jajja","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)01882-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034437","Mo1337 BMI-DEPENDENT EFFECT MODIFICATION OF GLP-1 RECEPTOR AGONIST THERAPY ON BOWEL PREPARATION QUALITY: A RETROSPECTIVE COHORT STUDY","Anika Azam","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)01006-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034438","Su1133 GLP-1 RECEPTOR AGONIST USE AND CLINICAL OUTCOMES IN PATIENTS WITH DYSPLASTIC BARRETT’S ESOPHAGUS","Mohamed Tausif Siddiqui","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)01949-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034439","Additional file 2 of The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials","Tseng, Ping-Tao","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30736691",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034440","Editorial Glucagon-Like Peptide-1 and Diabetes","Matteo Monami","2011",null,"commentary","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0034441","Is Wegovy really a gamechanger for heart health? A consultant cardiologist gives his verdict","Peter Swoboda","2023",null,"other","article","10.64628/ab.6un69hy6u",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034442","Type 2 diabetes mellitus with chronic kidney disease: an updated narrative review of pathophysiology, diagnosis, and contemporary cardio- renal management","Van-Dung Thach","2026","International Journal of Therapeutic Innovation.","narrative_review","article","10.55522/ijti.v4i3.0156",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0034443","GLP-1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort.","Ila Sruti","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.11017",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034444","Mo1800 COST-EFFECTIVENESS ANALYSIS OF REVISIONAL ENDOSCOPIC SLEEVE GASTROPLASTY COMPARED TO SEMAGLUTIDE FOR WEIGHT REGAIN AFTER SLEEVE GASTRECTOMY","Muhammad Abdul Haseeb","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04864-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034445","Liraglutide regulates expression of enzymes involved in carbohydrate and lipid metabolism in brain cortex of female rat pups under maternal perinatal food restriction","Zainab Mastoor","2024","Endocrine Abstracts","preclinical","article","10.1530/endoabs.99.ep318",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034446","Drugs like Ozempic won’t ‘cure’ obesity but they might make us more fat-phobic","Emma Beckett","2024",null,"other","article","10.64628/aa.wrjcahn7h",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034447","Improvement in insulin sensitivity and glycaemic control in a type 1 diabetes patient following initiation of a GLP-1 receptor agonist for excess weight management","Agnieszka Brandt-Varma","2025","Endocrine Abstracts","other","article","10.1530/endoabs.111.p29",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034448","Efficacy and safety of IDegLira vs. basal–bolus in patients with type 2 diabetes: DUAL VII trial","Jódar Esteban","2017",null,"other_trial","article","10.26226/morressier.59d51846d462b80296ca3c34",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034449","IDegLira is efficacious and safe in patients with type 2 diabetes with normal, mild or moderate renal impairment","Rodbard Helena","2017",null,"other","article","10.26226/morressier.59d51845d462b80296ca3667",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034450","Differences in percentage of weight loss and secondary effects after one and two months of treatment with liraglutide versus naltrexone/bupropion","Arribas Beatriz Voltas","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p606",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034451","Su1827 IMPACT OF GLP-1 RECEPTOR AGONIST THERAPY ON ESOPHAGEAL OUTCOMES IN LEAN AND NON-LEAN PATIENTS WITH GERD","Regis Lee","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04843-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034452","Liraglutide and PYY3–36 combination therapy partially achieves the metabolic benefits of Roux-en-Y gastric bypass surgery in diet-induced obese rats","Ulrich Dischinger","2020","Endocrine Abstracts","preclinical","article","10.1530/endoabs.70.aep286",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034453","Role of Sodium-glucose Cotransporter-2 Inhibitors in Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes","A. B. M. Kamrul-Hasan","2026","Bangladesh Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/bjem.bjem_2_26",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","editorial"],["R0034454","GLP-1 receptor agonists stimulate growth hormone release","Ingrid Reppo","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.p406",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034455","Tu1093 IMPACT OF GLP-1 RECEPTOR AGONIST THERAPY ON CLINICAL OUTCOMES IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS","Guy Nguefang","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)02124-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034456","Abstract 15747: Lack Of Serine Exoprotease Dipeptidyl Peptidase-4 Activity Antagonizes Pressure-overload-induced Systolic Dysfunction Predominantly By Glucagon-like Peptide-1/camp Axis.","Toshimasa Shigeta","2011","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034457","Endometrial transcriptome alterations following short-term liraglutide treatment in infertile women with polycystic ovary syndrome and obesity","Mojca Jensterle","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.rc1.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034458","Abstract PD8-10: Glp-1 receptor agonist in combination with radiotherapy significantly delays tumor growth and improves overall survival in a murine model of triple negative breast cancer","Luxi Chen","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-pd8-10",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034459","GLP-1 Receptor Agonists for Weight Loss in Adults: A Scoping Review of Healthcare Utilization and Cost Implications","Annika Dvinskis","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0034460","Correction of cardiovascular risk factors and metabolic health indexes in patients with type 2 diabetes mellitus during semaglutide therapy","Balykova L.A. Balykova","2025","Therapy","other","article","10.18565/therapy.2025.10.7-14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0034461","Safety and Efficacy of Insulin IGlarLixi versus IDegLira: A Meta-Analysis of Fifteen studies","Ivana Beatrice Paulus","2021",null,"systematic_review","article","10.26226/morressier.617c37317c09fc044a9751b3",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034462","Resistant hypertension in an obese type 2 diabetic male with obstructive sleep apnea: resolution with CPAP, weight loss and Dulaglutide","Claudia Arnas-Leon","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.ep390",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034463","Mo1919 ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE WITH RISK OF CHOLELITHIASIS AND CHOLECYSTITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS","Ibrahim Shanti","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)00467-0",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034464","Tu2149 IMPACT OF GLP-1 RECEPTOR AGONISTS ON POST-LIVER TRANSPLANT OUTCOMES","Muhammad Kazi","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04171-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034465","Weight-loss drugs like Ozempic could work for addiction too – and we finally know how","Robert Munn","2026",null,"other","article","10.64628/aa.yj9twtqxd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034466","A Comparison of the Renal Composite Outcome Between Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in Japanese Diabetes Patients","Kazuo Kobayashi","2021","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20213210s1265a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034467","Some Ozempic users say it silences ‘food noise’. But there are drug-free ways to stop thinking about food so much","Vivienne Lewis","2023",null,"other","article","10.64628/aa.th5j6gnxn",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034468","Abstract 147: Glucagon-like Peptide-1 Receptor Activation Reverses Cardiac Mitochondrial Remodeling In Advanced Type 2 Diabetes Via Suppression Of Nox4.","Akio Monji","2013","Circulation Research","preclinical","article","10.1161/res.113.suppl_1.a147",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034469","PB119 A NOVEL APPROACH TO THE TOTAL SYNTHESIS OF PHYSOSTIGMINE AND RELATED ALKALOIDS","Vijay Nair","1988","International Symposium on the Chemistry of Natural Products","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034470","Comparative Efficacy of Sodium-Glucose Co-Transporters 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist in Cardiovascular and Renal Protection in Patients with Type 2 Diabetes Mellitus","Shuo-Ming Ou","2020","SSRN Electronic Journal","other","article","10.2139/ssrn.3709848",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034471","Semaglutide provides superior body weight reduction vs comparators in subjects with type 2 diabetes across SUSTAIN 1–5","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3bf8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034472","Abstract 16589: Predicting Cardiovascular Risk in Participants Treated With Tirzepatide in the SURPASS 1-5 Trials","Russell J. Wiese","2023","Circulation","other_trial","article","10.1161/circ.148.suppl_1.16589",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0034473","Using advanced analytics to evaluate real-world treatment pathways leading to basal insulin plus GLP-1 RA therapy","Rhee Kyu","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51847d462b80296ca3bb7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","other"],["R0034474","Semaglutide consistently reduces both fasting and postprandial glucose levels across SUSTAIN 1–5 clinical trials","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51840d462b80296ca2d39",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034475","IN VIVO ISLET REGENERATION WITH EXENDIN-4 AND ISLET TRANSPLANTATION.","&NA;","2006","Transplantation","other","article","10.1097/00007890-200607152-02829",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034476","Abstract 9995: Glucagon-Like-Peptide-1 (GLP-1) Activates AMP-Activated Protein Kinase (AMPK) and Diminishes Inflammation in Human Aortic Endothelial Cells (HAECs)","N. Krasner","2011","Circulation","other_trial","article","10.1161/circ.124.suppl_21.a9995",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0034477","The Effects of Glucagon-Like Peptide-1 Receptor Agonists of Liraglutide on Bone Turnover Makers Among Type 2 Diabetes Mellitus Patients: A Meta-Analysis of Randomized Controlled Trials","Jing-yi Kang","2022","Archives of Clinical and Biomedical Research","systematic_review","article","10.26502/acbr.50170231",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0034478","Tu1770 A VALIDATED PROCESS USING LARGE LANGUAGE MODELS TO ENSURE ACCURACY OF REAL-WORLD DATASETS AND CLINICAL UTILITY WITH SEMAGLUTIDE IMPROVES SPECIFICITY COMPARED TO TRADITIONAL METHODS","Thomas W Fredrick","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04897-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034479","Maternal obesity predisposes offspring towards the development of chronic kidney disease","Sarah J. Glastras","2016","The Sydney eScholarship Repository (The University of Sydney)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034480","Additional file 1 of Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies","Ahmad, Aftab","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26695038",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034481","Wegovy has arrived in the UK: the story of the weight-loss jab so far",null,"2023",null,"other","article","10.64628/ab.9rtscmkdt",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034482","Abstract 19593: Sirtuin-3 is Essential for Glucagon-like Peptide-1-mediated Restoration of Diabetic Cardiomyopathy","Akio Monji","2015","Circulation","preclinical","article","10.1161/circ.132.suppl_3.19593",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034483","Real-life outcomes of semaglutide therapy for weight loss","Ploutarchos Tzoulis","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.p353",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034484","Additional file 1 of Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","Sposito, Andrei C.","2020","Figshare","randomized_trial","article","10.6084/m9.figshare.7794971",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","erratum"],["R0034485","Phenotyping in obesity: to whom are we prescribing semaglutide and tirzepatide?","Ercole Franco","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep920",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034486","Mounjaro will soon be available as a weight loss treatment on the NHS – here’s what that means for patients","Zoe Edwards","2024",null,"other","article","10.64628/ab.ypqjsf9nc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034487","Additional file 2 of Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies","Ahmad, Aftab","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26695041",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034488","Ozempic, el medicamento de moda contra la obesidad: ¿de verdad es una revolución?","Maria José García‐Barrado","2023",null,"other","article","10.64628/aao.argmamrxj",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034489","Sa2114 COMPARATIVE EFFECTIVENESS OF RESMETIROM VERSUS SEMAGLUTIDE ON MORTALITY AND PORTAL HYPERTENSION OUTCOMES IN NASH PATIENTS","Ihunanya M. Kanu","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03580-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034490","Multi-receptor activation by (GIP-GCG-GLP-1) triple agonist regulates female reproductive function in diet induced obese mice","Ananyaa Sridhar","2024","Endocrine Abstracts","preclinical","article","10.1530/endoabs.104.p194",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034491","Abstract 14730: Oral Semaglutide Provides Less Value for Money Than Subcutaneous Semaglutide for the Prevention of Major Adverse Cardiovascular Events, but Significantly More Value for Money for the Prevention of Cardiovascular Mortality","Ronen Arbel","2020","Circulation","other","article","10.1161/circ.142.suppl_3.14730",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034492","Clinico-economic outcomes of liraglutide in patients with type 2 diabetes at high risk of cardiovascular event in Canada","Skovgaard Rasmus","2017",null,"other","article","10.26226/morressier.59d51840d462b80296ca2dbe",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034493","Safety and efficacy of IBI362 (LY3305677) in Chinese patients with T2D: A randomized, placebo-controlled phase 1b study","Prof. Wenying Yang","2021",null,"randomized_trial","article","10.26226/morressier.617c37307c09fc044a97516d",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","other"],["R0034494","Effect of subcutaneous semaglutide on liver fibrosis degree in patients with type 2 diabetes mellitus measured by the FIB-4 index","Garcia Perez Rosa Natalia","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep384",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034495","Tu1818 The Chemical Chaperon 4-Phenylbutyrate Inhibits Liver Fibrosis and Tumorgenesis in High-Fat Diet With N-Acetyl-AY-D-Glucosaminedase Inhibitor-Induced NASH Model Mice","Minoru Itou","2012",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034496","Abstract 429: Central Glucagon-Like Peptide-1 Reduces Intestinal Chylomicron Production via Melanocortin-4-Receptor Signaling","Sarah Farr","2014","Arteriosclerosis Thrombosis and Vascular Biology","other","article","10.1161/atvb.34.suppl_1.429",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034497","Abstract 13078: Central Glucagon-like peptide-1 Receptor Activation Counteracts Hypertension with Suppression of Sympathetic Nerve Activity in Spontaneously Hypertensive Rats","Kenichi Katsurada","2014","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034498","Additional file 1 of The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials","Yu, Meixin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26606593",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034499","A Potent Novel Small Molecule GLP-1R Agonist Identified by Rational Design and CADD","Jiayu Chen","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5803885",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034500","The impact of glucagon-like peptide-1 receptor agonists on proteasome inhibitor-associated cardiotoxicity in patients with multiple myeloma.","Yu‐Cheng Chang","2024","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2024.42.16_suppl.e24008",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034501","Perspectives and Insights on A10BJ: GLP-1 Receptor Agonist and Amylin Analogue Combination Therapies from Development to New Drug Submission in Canada","Syeda Afshi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21338889",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034502","Su1575 REAL-WORLD TRENDS IN GLP-1 AND GLP-1 + GIP DUAL AGONIST PRESCRIBING AMONG PATIENTS WITH METABOLIC RISK AND INFLAMMATORY BOWEL DISEASE","Souvik Saha","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)02713-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034503","Correction: The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes",null,"2007","Annals of Internal Medicine","notice","article","10.7326/0003-4819-146-12-200706190-00016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0034504","Comparative efficacy of GLP-1 RA vs. SGLT2 inhibitors in slowing chronic kidney disease (CKD) progression - a retrospective study done in northern hospital in pakistan","Faryal Akhtar","2026","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.117.p119",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034505","Additional file 4: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Li, Ling","2016","Figshare","systematic_review","article","10.6084/m9.figshare.c.3633269_d7",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034506","IDegLira improves cardiovascular risk markers in patients with type 2 diabetes vs. basal insulin: DUAL II and DUAL V","Vilsboll Tina","2017",null,"other","article","10.26226/morressier.59d51840d462b80296ca2d5c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034507","Abstract Th0048: How do novel type 2 diabetes mellitus (T2DM) medications affect lipid parameters in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and type 2 diabetes","Jessica Khoury","2025","Arteriosclerosis Thrombosis and Vascular Biology","nonrandomized_study","article","10.1161/atv.45.suppl_1.th0048",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034508","Evaluation of the short-term cost-effectiveness of insulin degludec/liraglutide (IDegLira) versus basal–bolus in the USA","Jódar Esteban","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3c3e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034509","Ozempic helps weight loss by making you feel full. But certain foods can do the same thing – without the side-effects","Emma Beckett","2023",null,"other","article","10.64628/aa.5rwx59fhm",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034510","Abstract 13937: Human Microvascular Dysfunction Induced by Glucose and VLDL Lipolysis Products and Protective Effect of Exenatide in Hyperglycemia","Seth Truran","2011","Circulation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034511","Pharmacokinetics and tolerability of semaglutide in subjects with hepatic impairment","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3c1b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034512","Abstract P077: Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Black Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Recent Cardiovascular Outcome Trials","Efstratios Koutroumpakis","2019","Circulation","systematic_review","article","10.1161/circ.139.suppl_1.p077",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034513","Tu1160 THE IMPACT OF CONCOMITANT USE OF PROTON PUMP INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BARRETT’S ESOPHAGUS AND ESOPHAGEAL CANCER RISK IN GERD PATIENTS","Julton Tomanguillo Chumbe","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)02191-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034514","Effects of GLP-1 Receptor Agonist Dulaglutide on Profile of Circulating miRNAs Associated with ESKD in Type 2 Diabetes","Eiichiro Satake","2023","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20233411s118a",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0034515","Impact of glucagon-like-peptide-1 receptor agonists on non-motor symptoms in Parkinson’s disease: a systematic review and meta-analysis","Regina Carneiro Leão","2024","Arquivos de Neuro-Psiquiatria","systematic_review","article","10.5327/cbn240922",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0034516","Risk of thyroid cancer with use of glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes in Denmark: Population-based active comparator, new user cohort study","Swaleh Hussain","2024","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","preprint"],["R0034517","Mo1589 IMPACT OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS ON CLINICAL OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE: A POPULATION BASED COHORT STUDY","Magda Elamin","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)02959-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034518","Tu1598 SAFETY AND EFFICACY OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS (GLP-1RAS) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Aamir Saeed","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)03216-5",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034519","Abstract 344: Incretin-Loaded Nanocarriers for Glucose Control, Therapy and Imaging of Atherosclerosis","AndreiMaiseyeu","2014","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034520","Protective effect of liraglutide on experimental testiculars ischemia reperfusion injury in rats","Recep Burak Değirmentepe","2019","European Urology Supplements","preclinical","article","10.1016/s1569-9056(19)30795-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034521","P0491 Increased risk of erectile and testicular dysfunction among young men with type 2 diabetes treated with semaglutide: A global trinetx cohort analysis","J.Y. Hsu","2026","European Urology","nonrandomized_study","article","10.1016/s0302-2838(26)01377-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034522","Mo1098 ESOPHAGEAL DYSMOTILITY AND REFLUX OUTCOMES IN TYPE 2 DIABETES PATIENTS TREATED WITH VERSUS WITHOUT GLP-1 RECEPTOR AGONISTS: A PROPENSITY-MATCHED COHORT STUDY","Jashanveer S. Johal","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)02018-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034523","Glucagon-like peptide-1 analogs reduce alcohol intake","Faisal I. Almohaileb","2025","Endocrine Abstracts","other","article","10.1530/endoabs.109.p311",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034524","Orforglipron different doses effect on body weight : A systematic review and network meta-analysis of randomized clinical trials","Abdelaziz Awad","2023","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0034525","PS-B06-11: GLUCAGON-LIKE PEPTIDE-1 SUPPRESSES ACTIVATED EFFECTOR MEMORY T CELL SUBSETS IN THE FATTY LIVER INDUCED BY ANTI-CD3-ADNTIBODY ADMINISTRATION IN LEAN MICE","Arata Itoh","2023","Journal of Hypertension","preclinical","article","10.1097/01.hjh.0000916564.38258.29",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034526","Antipsychotic induced obesity in schizophrenia and GLP-1 analog treatment? A case-report","Jakubíková Iva","2021","Endocrine Abstracts","other","article","10.1530/endoabs.73.aep334",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034527","GLP-1 Agonists-Associated Kidney Toxicities","Rimda Wanchoo","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s1427a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034528","Online education advances physicians’ knowledge and competence regarding long-acting GLP-1 receptor agonists","Joachim Trier","2019",null,"other","article","10.26226/morressier.5d9b6234ea541d6ca84943d1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034529","Ligand binding and activation mechanism og the glucagon-like peptide-1 receptor","Christina Rye Underwood","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034530","Mo1811 GASTROINTESTINAL OUTCOMES ASSOCIATED WITH GLP-1 RECEPTOR AGONIST USE IN NON-DIABETIC PATIENTS WITH OBESITY: A LARGE MULTICENTER PROPENSITY MATCHED ANALYSIS","Niven Wang","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04875-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034531","THE USE OF EXENATIDE TO IMPROVE ISLET ENGRAFTMENT, FUNCTION AND LONG TERM SURVIVAL.","&NA;","2006","Transplantation","other","article","10.1097/00007890-200607152-00815",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034532","A Case of Streptococcal Toxic Shock Syndrome With Acute Renal Failure","Renuka Tolani","2022","Journal of the American Society of Nephrology","case_report","article","10.1681/asn.20223311s185b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034533","Incretin-based therapies and all-cause mortality and progression to multiple myeloma in patients with MGUS and type 2 diabetes: A real-world cohort study.","Yousef Ateiwi","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.7572",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034534","Semaglutide is more efficacious than SGLT-2is in patients inadequately controlled on metformin: a network meta-analysis","Kanters Steve","2017",null,"systematic_review","article","10.26226/morressier.59d51840d462b80296ca2d25",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","other"],["R0034535","The Effects of Semaglutide in Adults (18+) with Overweight or Obesity and Diabetes type 2. A Narrative Review","Anzhelika Magomedova","2025","Medical Research Archives","randomized_trial","article","10.18103/mra.v13i2.6334",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0034536","Liraglutide may increase thyroid functioning","Ömercan Topaloğlu","2021","Endocrine Abstracts","other","article","10.1530/endoabs.73.aep683",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034537","Ozempic shortages in the UK may last until 2024 – here’s why","Liz Breen","2023",null,"other","article","10.64628/ab.79h5w7hvs",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034538","Listen: Widespread use of Ozempic for weight loss could change how we view fatness",null,"2023",null,"other","article","10.64628/aam.j7j5tj5vn",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034539","Boca seca, mau hálito e danos aos dentes: os efeitos que o Ozempic e o Wegovy podem ter em sua boca","Adam Taylor","2025",null,"other","article","10.64628/ade.3d6ncprxw",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034540","Glucagon-like peptide (GLP)-1 and the synthetic analogue exenatide: From novel therapy for diabetes to growth inhibition of breast cancer cells.","Ingo Wolf","2010","Journal of Clinical Oncology","preclinical","article","10.1200/jco.2010.28.15_suppl.e21035",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034541","The use of GLP-1 agonist in an adolescent with type 1 diabetes mellitus and obesity","Ellie Clarke","2022","Endocrine Abstracts","other","article","10.1530/endoabs.85.p80",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034542","Metabolic profile of T2D patients on liraglutide: About 31 cases","Harouna Nana Aichatou","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep509",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034543","Ketogenic diet and Glucagon-like peptide 1 (GLP1) receptor agonists for obesity: our experience","Elisa Pisocri","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.ep323",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034544","IDegLira is insulin sparing whilst attaining better or similar glycaemic control vs. IGlar U100 or basal–bolus therapy","Bue F. Ross Agner","2017",null,"other","article","10.26226/morressier.59d51845d462b80296ca3483",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034545","Bioinformatics modelling of baseline characteristics to predict clinical outcomes and responses in the LixiLan-L trial","Kidd Catherine","2017",null,"other_trial","article","10.26226/morressier.59d51846d462b80296ca3b43",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034546","Long term effect of setmelanotide and semaglutide on a patient with severe obesity due to 16p11. 2 microdeletion, encompassing the SH2B1 gene","Giannopoulou Eleni Z","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.p692",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034547","Additional file 4 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Kan, Ranran","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30703265",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034548","Liraglutide impact on diabetic foot ulcers in people with T2D at increased risk of cardiovascular events - LEADER trial","Dhatariya Ketan","2017",null,"other_trial","article","10.26226/morressier.59d51849d462b80296ca3147",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034549","Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials","Wu, Sijin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.c.6577411.v1",null,null,"PROSPERO:CRD42022339389",null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034550","Mounjaro has been authorised for weight loss in the UK – here’s how it compares to Wegovy","Martin Whyte","2023",null,"other","article","10.64628/ab.kxgqn6sxh",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034551","Correction: Retatrutide-Induced Intractable Diarrhea",null,"2026","Annals of Internal Medicine Clinical Cases","notice","article","10.7326/aimcc.2026.0365",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0034552","Clinical effectiveness of SGLT2-I in combination with GLP-1 agonists as alternative or adjunct to bariatric surgery in type 2 diabetes mellitus","Suhaniya Samarasinghe","2018","Endocrine Abstracts","other","article","10.1530/endoabs.53.p03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034553","RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN OBESITY TREATMENT: SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE 3 CLINICAL TRIALS","Luiz Felippe Mendes Caquetti","2026","INTERNATIONAL BLEST SCIENTIFIC","systematic_review","article","10.65671/7z5zjv05",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034554","Abstract 8993: Protective Effects of Glucagon-like Peptide-1 on Cardiac Microvessels Injury via cAMP/PKA/Rho Dependent Pathway in Diabetic Rats","Dongjuan Wang","2012","Circulation","randomized_trial","article","10.1161/circ.126.suppl_21.a8993",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034555","Liraglutide treatment prevented the increased expression of proinflammatory cytokines in the hippocampus of male pups in a perinatal stress model of food restriction","Yolanda Diz-Chaves","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.gp156",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034556","Novel biological targets for GLP-1R agonists","Darleen A. Sandoval","2021","Endocrine Abstracts","other","article","10.1530/endoabs.73.s3.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034557","Utility of Glucagon like peptide-1 analogues in patients of acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials","Rajat Bhatt","2025","Indian Heart Journal","systematic_review","article","10.1016/j.ihj.2025.11.012",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0034558","Additional file 8 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Huang, Yi-lin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26595992",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034559","All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus : asystematic review with meta-analysis and trial sequential analysis","Rados, Dimitris Rucks Varvaki","2021","Lume (Universidade Federal do Rio Grande do Sul)","systematic_review","article",null,null,null,"PROSPERO:CRD42018087336",null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0034560","Evaluation of semaglutide dose levels in type 2 diabetes based on population pharmacokinetics and exposure-response","Overgaard Rune","2017",null,"other","article","10.26226/morressier.59d51844d462b80296ca39e5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034561","Real-world clinical experience of IDegLira in the management of adolescents with type 2 diabetes","Tanveer Ashraf","2021",null,"nonrandomized_study","article","10.26226/morressier.617c37317c09fc044a9751c3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","other"],["R0034562","GLP-1 receptor agonist treatment is associated with increased endogenous DHEAS in men with type 2 diabetes mellitus but is not associated with an increased in patient-reported sexual function outcomes in either sex","Kumar Anusha Prem","2026","Endocrine Abstracts","other","article","10.1530/endoabs.115.p8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034563","Epigenetic changes of FFAR3 and LINE1 in obese and diabetic patients","Christine Margarethe Merold","2013","University of Vienna","other","article","10.25365/thesis.28445",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034564","MOESM1 of Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","Sposito, Andrei","2019","Figshare","randomized_trial","article","10.6084/m9.figshare.7794971.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","erratum"],["R0034565","Effectiveness and safety of GLP-1 receptor analogues vs. rapid-acting insulin added to basal insulin therapy in patients with type 2 diabetes mellitus: a living systematic review","Angie Santafe Garcia","2022","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0034566","Therapeutic Effect of Semaglutide on Pulmonary Function and Fibrosis in a Bleomycin-Induced and Spirometry-Confirmed Mouse Model of IPF","Michael Feigh","2022",null,"preclinical","article","10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4719",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034567","Wegovy: what you need to know about this weight loss drug","Simon C. Cork","2023",null,"other","article","10.64628/ab.af5c36cdu",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034568","Considering taking a weight-loss drug like Ozempic? Here are some potential risks and benefits","Lauren Ball","2024",null,"other","article","10.64628/aa.swmedrsaw",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034569","Abstract 18087: GLP-1 Receptor Agonist Exenatide Attenuates Endothelial Dysfunction by Reducing Oxidative Stress in Hyperhomocysteinemia via AMPK/eNOS Pathway","Chak Kwong Cheng","2017","Circulation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034570","Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","Zhou, Qian","2024","Figshare","systematic_review","article","10.6084/m9.figshare.c.6905587",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034571","Semaglutide treatment in hypotalamic obesity","Emmanuele Capobianco","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep888",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034572","Abstract WE442: Disparities in Use of Cardioprotective GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Insured Adults with Type 2 Diabetes at High Cardiovascular Risk","Andrew Hwang","2026","Circulation","other","article","10.1161/cir.153.suppl_1.we442",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034573","Abstract 4369713: Peripheral Artery Disease Outcomes in GLP-1RA Trials: Meta-Regression of SBP, HbA1c, and Weight.","Pranay Marlecha","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4369713",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034574","Additional file 1 of The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials","Tseng, Ping-Tao","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30736685",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034575","Use of Disease-modifying Therapy in Metabolic Dysfunction-associated Steatohepatitis: Benefits to Trump Challenges","Mathew John","2026","Chronicle of Diabetes Research and Practice","other_trial","article","10.4103/cdrp.cdrp_25_25",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","editorial"],["R0034576","Canagliflozin after liraglutide in patients with type 2 diabetes","Paloma Moreno-Moreno","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p485",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034577","Use of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis","Princee Kaur","2025","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.5929268",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0034578","Comparison of the clinical efficacy of Semaglutide between DPP4-inhibitor-naive and DPP4-inhibitor-experienced patients in a real world setting in Spain","Miguel Sierra Poyatos Roberto","2020","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.70.aep809",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034579","Abstract 4365964: GLP-1 Eligibility and Use Among the Medicaid Population","Grant Wen","2025","Circulation","other","article","10.1161/circ.152.suppl_3.4365964",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034580","Dataset for publication titled \"Exendin-4 enhances insulin-positive phenotype of human pluripotent stem cell-derived beta cells during transplantation\"","Crumley, Kelly M","2025","University of Michigan Library","preclinical","article","10.7302/eppx-e655",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034581","Abstract LB376: Tirzepatide inhibits tumor growth in mice with diet-induced obesity","Michaël Pollak","2024","Cancer Research","other_trial","article","10.1158/1538-7445.am2024-lb376",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","conference-abstract"],["R0034582","Joint Model of eGFR Slope: Data from LEADER in Patients with Type 2 Diabetes and High Risk of Cardiovascular Events","Johannes F.E. Mann","2020","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20203110s1332b",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0034583","Semaglutide is more efficacious than SGLT-2is in patients inadequately controlled on 1-2 OADs: a network meta-analysis","Kanters Steve","2017",null,"systematic_review","article","10.26226/morressier.59d51847d462b80296ca3be4",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","other"],["R0034584","Ozempic and other weight-loss drugs linked to rare but serious eye conditions","Flora Hui","2025",null,"other","article","10.64628/aa.j476g3ndm",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034585","The rise of Ozempic: how surprise discoveries and lizard venom led to a new class of weight-loss drugs","Sebastian G. B. Furness","2024",null,"other","article","10.64628/aa.tmdevuy3v",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034586","AKI Associated with Semaglutide","David J. Leehey","2020","Journal of the American Society of Nephrology","other","article","10.1681/asn.20203110s1350b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034587","The neuroprotective effect of exenatide on experimental Alzheimer's model in rats","V. Solmaz","2015","DSpace@Giresun","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034588","A Narrative Review on Clinical Evidence of Tirzepatide’s Role in Addressing Type 2 Diabetes and Obesity Management","Deepalaxmi Rathakrishnan","2024","DOAJ (DOAJ: Directory of Open Access Journals)","other_trial","article","10.5603/cd.101152",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","review"],["R0034589","Su1960 PROPENSITY-MATCHED REAL-WORLD COMPARATIVE RISK OF BILIARY AND PANCREATIC EVENTS WITH TIRZEPATIDE, SEMAGLUTIDE, AND NON-GLP-1 THERAPIES IN OBESITY AND DIABETES","Wissam Ghusn","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)00444-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034590","Mo2119 GLP-1 AGONIST USE IS ASSOCIATED WITH LOWER MAJOR CARDIOVASCULAR EVENTS AND LIVER DECOMPENSATION IN PATIENTS WITH LIVER CIRRHOSIS WITH DIASTOLIC DYSFUNCTION: A MULTI-CENTER ANALYSIS.","Sharon Narvaez","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03938-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034591","Tu2113 GLP-1 AGONIST USE IS ASSOCIATED WITH LOWER ALL-CAUSE MORTALITY, PREDNISONE USE, AND RECURRENT MASLD IN OBESE PATIENTS POST-LIVER TRANSPLANT DUE TO MASLD: A MULTICENTER ANALYSIS.","Sharon Narvaez","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04135-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034592","GLP-1 Receptor Agonists Significantly Impair Taste, But Not Smell Function","Rafa Khan","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.4889519",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034593","Lixisenatide improves glycaemic control and body composition in uncontrolled type 2 diabetic patients treated with insulin","Florentino Carral","2015","Endocrine Abstracts","other","article","10.1530/endoabs.37.ep454",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034594","Abstract TP51: Improving Prescriptions of Cardiovascular-Effective Anti-Diabetic Medications in Patients With Stroke and Type 2 Diabetes","Jill Libby","2024","Stroke","nonrandomized_study","article","10.1161/str.55.suppl_1.tp51",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034595","Abstract 269: Exendin-4 Prevents Glucose-induced Secretion of Tissue Transglutaminase-2 from Cardiac Microvascular Endothelial Cells: Potential Role in the Prevention of Matrix Remodeling in Diabetes","Ali S Shihab","2015","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvb.35.suppl_1.269",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034596","O que acontece quando eu paro de tomar um medicamento como o Ozempic ou o Mounjaro?","Natasha Yates","2024",null,"other","article","10.64628/ade.txrjk9jkh",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034597","Effect of semaglutide on weight, hba1c and liver enzymes in type 2 diabetes patients","Sara El Ghandour","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep434",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034598","Está pensando em tomar Wegovy para perder peso? Veja os riscos e benefícios - e como ele difere do Ozempic","Lauren Ball","2024",null,"other","article","10.64628/ade.dsd5gvpw9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034599","Abstract 205: Mitochondrial Sirt3 Is Upregulated By Glucagon-like Peptide-1 Receptor Activation And Contributes To Reversal Of Cardiac Mitochondrial Remodeling Induced By Type 2 Diabetes.","Akio Monji","2014","Circulation Research","preclinical","article","10.1161/res.115.suppl_1.205",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034600","Mo1806 ASSOCIATION OF GLP-1 RECEPTOR AGONIST USE WITH ACUTE BILIARY AND PANCREATIC EVENTS IN ADULTS WITH OBESITY: A PROPENSITY-MATCHED COHORT STRATIFIED BY BASELINE CHOLELITHIASIS","Hsien Yao Yang","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04870-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034601","Efficacy and tolerability of dulaglutide in patients with type 2 diabetes: Experience on a secondary Hospital","Paloma González Lázaro","2019","Endocrine Abstracts","other","article","10.1530/endoabs.63.gp209",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034602","Erratum: Re-imagining Oral Semaglutide in Routine Clinical Practice: Indian Expert Panel Recommendations",null,"2025","International Journal of Diabetes and Technology","notice","article","10.4103/ijdt.ijdt_41_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0034603","GLP-1 receptor agonists and erectile dysfunction in diabetic men with and without hypogonadism: a 1- year retrospective observational study","Giuseppe Lisco","2022","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.81.p355",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034604","IDegLira provides clinical benefits across all end of trial dose ranges: analyses from DUAL I and V","Vilsboll Tina","2017",null,"other_trial","article","10.26226/morressier.59d51845d462b80296ca34a1",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034605","Abstract 3669: The Glucagon Like Peptide-1 (GLP-1) Metabolite GLP-1(9–36) Protects Cardiomyocytes and Endothelial Cells From Myocardial Ischemia Reperfusion Injury via GLP-1 Receptor-independent Mechanisms","Kiwon Ban","2009","Circulation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034606","Semaglutide reduces HbA1c and body weight across multiple background OAD treatment categories","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3c16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034607","Regional heterogeneity of the results of GLP-1 receptor agonists trials on cardiovascular outcomes in type 2 diabetes","Matthieu Roustit","2024","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0034608","GLP-1 ANALOG LIRAGLUTIDE INDUCED CARDIAC DYSFUNCTION DUE TO ENERGETIC STARVATION IN HEART FAILURE WITH NON-DIABETIC DILATED CARDIOMYOPATHY IN HAMSTERS","Aya Shiraki","2021","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0000745372.65932.fd",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034609","Processo judicial nos EUA pode ameaçar confiança no Ozempic e outros populares remédios para emagrecer","Ana Santos Rutschman","2024",null,"other","article","10.64628/ade.fdg7ck9xc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034610","VIEW-Iran: A real-world study of liraglutide effectiveness on glycaemic control in people with type 2 diabetes mellitus","Mohammad E. Khamseh","2021",null,"nonrandomized_study","article","10.26226/morressier.617c37307c09fc044a97510e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","other"],["R0034611","Dapagliflozin after liraglutide in patients with type 2 diabetes","Paloma Moreno-Moreno","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p484",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034612","How dieting, weight suppression and even misuse of drugs like Ozempic can contribute to eating disorders","Samantha J. Withnell","2024",null,"other","article","10.64628/aam.mcejakyk3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034613","Abstracts - Case Reports",null,"2026","Chronicle of Diabetes Research and Practice","case_report","article","10.4103/cdrp.cdrp_10_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034614","Evaluating the impact of GLP-1 receptor agonists on glycaemic control and weight in patients with type 1 diabetes: a retrospective multi-centre study","E.T. Carey","2026","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.115.ep39",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034615","Sa1127 DOES HOLDING A DOSE OF GLP-1RA AFFECT ACID EXPOSURE TIME ON AMBULATORY REFLUX TESTING?","Meghana Pandit","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)01879-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034616","Abstract WE444: Prevalence and Predictors of GLP-1 Receptor Agonist Use Among U.S. Adults with Diabetes: Findings from the National Health Interview Survey, 2024","Miriam Katz","2026","Circulation","other","article","10.1161/cir.153.suppl_1.we444",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034617","Reduced insulin resistance with semaglutide is primarily mediated via weight loss: post-hoc analysis of SUSTAIN 1–3","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3be9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034618","Insights into the early use of oral semaglutide in routine clinical practice","Bharat Saboo","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.p507",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034619","Patient-reported outcomes with insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial","Jódar Gimeno, José Esteban","2017","ABACUS. Repositorio de Producción Científica (Universidad Europea)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0034620","Incretin drugs and pancreatic cancer risk in patients with type 2 diabetes: Meta-analysis of randomized controlled trials","Qing Tian","2017","Chin J Diabetes Mellitus","systematic_review","article","10.3760/cma.j.issn.1674-5809.2017.12.005",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034621","Dry mouth, bad breath and tooth damage: the effects Ozempic and Wegovy can have on your mouth","Adam Taylor","2025",null,"other","article","10.64628/ab.pktukyg7q",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034622","O “Ozempic da natureza”: o que e como você come pode aumentar seus níveis de hormônio do apetite sem precisar tomar remédios","Mary Scourboutakos","2025",null,"other","article","10.64628/ade.unpsgqvat",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034623","Mo1668 MENTAL HEALTH RESPONSE AND INCREASED STOOL FREQUENCY ASSOCIATED WITH REDUCED QUALITY OF LIFE IN IBD PATIENTS ON GLP-1 RECEPTOR AGONIST THERAPY","Hamzah Shariff","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03038-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034624","Managing post-bariatric surgery reactive hypoglycaemia: a dual approach with metformin and GLP-1 receptor agonist","Rao Komal Zia","2024","Endocrine Abstracts","other","article","10.1530/endoabs.100.wh5.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034625","Abstract 4134308: Re-evaluating the safety profile of Semaglutide: An updated meta-analysis","Frederick Berro Rivera","2024","Circulation","systematic_review","article","10.1161/circ.150.suppl_1.4134308",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034626","Additional file 6 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Huang, Yi-lin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26595986",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034627","Sa2112 COMPARATIVE EFFICACY OF GLP-1 AGONISTS AND LIFESTYLE INTERVENTIONS ON METABOLIC DYSFUNCTIONAL-ASSOCIATED STEATOHEPATITIS: EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS","Gunjan Malhotra","2026","Gastrointestinal Endoscopy","randomized_trial","article","10.1016/s0016-5107(26)03578-9",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034628","Beyond diabetes management: A narrative review on the neurological and psychiatric impact of semaglutide","Alexander Weiss","2026","Brain Circulation","randomized_trial","article","10.4103/bc.bc_210_25",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0034629","El Ozempic es una gran herramienta contra la obesidad, pero no puede sustituir al ejercicio y la dieta","Javier Troncoso","2025",null,"other","article","10.64628/aao.v6c6h9x4g",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034630","GLP-1 receptor agonist improves mitochondrial energy status and attenuates nephrotoxicity in vivo and in vitro","LIBIN LIU","2019",null,"preclinical","article","10.26226/morressier.5d9b6233ea541d6ca849422d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034631","P87 : 노인 환자의 지속적인 상담을 통한 혈당관리 교육사례","장연정","2019","대한당뇨병학회 학술발표논문집","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034632","Peripheral cannabinoid–1 receptor blockade potentiates the anti–obesity and anti–diabetic effects of GLP–1 mimetics","Philippe Zizzari","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.ep169",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034633","Correction: Summaries for Patients: Exenatide or Insulin Glargine for Suboptimally Controlled Type 2 Diabetes?",null,"2006","Annals of Internal Medicine","notice","article","10.7326/0003-4819-144-8-200604180-00020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0034634","Additional file 1 of Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials","Yiwen Zhang","2026","Figshare","systematic_review","article","10.6084/m9.figshare.31367664",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034635","Empagliflozin Use and the Risk of Nephrolithiasis in Patients With Type 2 Diabetes","Julie M. Paik","2022","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20223311s1673a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034636","Liraglutide prevented the deposition of Collagen in the animal model of Bleomycin-induced lung fibrosis","Juan Fandino Gomez","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.gp67",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034637","Additional file 1: of Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis","Zhang, Xiaowen","2018","Figshare","systematic_review","article","10.6084/m9.figshare.7096841",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034638","Additional file 1 of Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","Hu, Yan","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26641012",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034639","S-343 : The Effects of Administration of Exendin-4 in Obese Type 2 Diabetes Mellitus","Ju Young Hong","2013","대한내과학회 추계학술발표논문집","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034640","Mo1586 REAL-WORLD COMPARATIVE OUTCOMES OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS AND BARIATRIC SURGERY IN INFLAMMATORY BOWEL DISEASE: A MULTI-CENTER COHORT STUDY","Joshua Chen","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)02956-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034641","Tu1643 LIVER ENZYME TRENDS AND INFLAMMATORY BOWEL DISEASE OUTCOMES AFTER GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXPOSURE: AN UPDATED MULTICENTER ASSESSMENT","Ahmed Salem","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03261-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034642","Abstract 273: Prescription Rate For Antihyperglycemic Medication With Proven Cvd Benefit At Discharge In Stroke Patients Not Equal Among Payer Sources","Susan Abelt","2022","Circulation Cardiovascular Quality and Outcomes","other","article","10.1161/circoutcomes.15.suppl_1.273",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034643","Free T4 is associated with exenatide-related weight loss in patients with type 2 diabetes mellitus","Ömercan Topaloğlu","2021","Endocrine Abstracts","other","article","10.1530/endoabs.73.aep187",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034644","Ozempic naturel : comment augmenter son taux de GLP-1 sans médicaments","Mary Scourboutakos","2025",null,"other","article","10.64628/aap.dadak96pc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034645","GLP-1 receptor agonists and management of diabetes mellitus 2 and obesity in multiple sclerosis","Ifigenia Kostoglou‐Athanassiou","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep999",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034646","RE: Effects of tirzepatide on the clinical trajectory of patients with heart failure, a preserved ejection fraction, and obesity.",null,"2025",null,"commentary","article","10.1161/comment.20250406.718077",null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0034647","Elevated liver enzymes in a patient with obesity and sleep-related eating disorder during semaglutide therapy","Katie Boron","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep1006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034648","Liraglutide Protects Against Microvascular Dysfunction and Sepsis-Mediated Inflammation and Organ Injury","David M. Aslaner","2025","American Journal of Respiratory and Critical Care Medicine","preclinical","article","10.1164/ajrccm.2025.211.abstracts.a2970",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034649","The effects of Semaglutide on glycaemic control and weight, in type two diabetic patients, in our diabetic day center","Azhar Al-Shaibany","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.ep421",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034650","Semaglutide improves health-related quality of life vs placebo when added to standard-of care in patients with type 2 diabetes at high risk (SUSTAIN 6)","Jódar Gimeno, José Esteban","2018","ABACUS. Repositorio de Producción Científica (Universidad Europea)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034651","Is Semaglutide superior than Liraglutide in patients with type 2 diabetes on insulin therapy? - case presentation","Ivana Mickovski","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.ep509",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034652","Examining Body Composition, Metabolic Outcomes, and Muscular Quality and Size in GLP-1 RA Users Without and With Resistance Training","Charles Hill","2026","BearWorks (Missouri State University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034653","Abstract 14727: The Effect of Exenatide Once-Weekly on Carotid Atherosclerosis and Endothelial Function in Persons With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study","Juraj Koška","2019","Circulation","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","conference-abstract"],["R0034654","Short term intervention with liraglutide and metformin increased fertility potential in a subset of obese PCOS proceeding IVF","Vesna Šalamon","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.ep1105",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034655","Dulaglutide added on Empagliflozin improves blood pressure, body weight, glycemic control and albuminuria in obese diabetic patients","Carmen Acosta-Calero","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.ep621",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034656","Sa1801 USE OF A NOVEL SENSOR, AN E-NOSE, FOR THE MONITORING OF SOLUBLE FIBR INTAKE TO OPTIMIZE WEIGHT LOSS IN CONJUNCTION WITH THE USE OF A GLP-1 AGONIST","Lawrence R. Kosinski","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04796-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034657","How do I know which non-diabetic patients could benefit from a GLP-1 analogue","Barbara Mc Gowan","2018","Endocrine Abstracts","other","article","10.1530/endoabs.59.cmw5.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034658","Mounjaro becomes available on the NHS: what to know and what to do if you’re not eligible","Dan Baumgardt","2025",null,"other","article","10.64628/ab.eku3dm7e6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034659","Abstract 4370717: Maternal GLP-1 Receptor Agonist Exposure and the Risk of Congenital Cardiovascular Defects: A Global Pharmacovigilance Study","Harendra Kumar","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4370717",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034660","Impact of Glucagon-like peptide-1 (GLP-1) receptor agonists on insulin resistance and weight as prevention of type 2 diabetes at overweight and obesity patients","Merita Emini","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep395",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034661","Abstract 146: Glucagon-like Peptide-1 Receptor Activation Promotes Dual Benefits For Reversing Microvasculopathy And Mitochondrial Damage In Diabetic Heart.","Akio Monji","2013","Circulation Research","preclinical","article","10.1161/res.113.suppl_1.a146",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034662","Neuroprotective effects of exenatide in a rotenone-induced rat model of Parkinson's disease","Aksoy, D.","2017","Istanbul Science University (Istanbul Bilim University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034663","Synthesis of Danuglipron: An Orally Available GLP-1R Agonist","Antonia F. Stepan","2022","Synfacts","commentary","article","10.1055/s-0041-1738304",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0034664","Effect of hCMSCs and Liraglutide Combination in ALI Through cAMP/PKAc/â-Catenin Signaling Pathway","Y. Feng","2020",null,"other","article","10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a5587",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034665","Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS","Mojca Jensterle","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.oc5.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034666","Semaglutide as a potential treatment for a child with ADCY3 mutation","Canbaz Aylin Tugba","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep881",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034667","Liraglutide, a glucagon-like peptide-1 receptor agonist, improves bone mass and architecture in ovariectomised mice","Marie Pereira","2014","Endocrine Abstracts","preclinical","article","10.1530/endoabs.34.p8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034668","Abstract 4363503: Reverse Takotsubo Cardiomyopathy Triggered by Acute Pancreatitis: Rare Stress-Induced Cardiac Syndrome","Shan Tandon","2025","Circulation","other","article","10.1161/circ.152.suppl_3.4363503",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034669","Retraction notice to “A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design” [Mech. Ageing Dev. 213 (2023) 111825] (Mechanisms of Ageing and Development (2023) 213, (S0047637423000519), (10.1016/j.mad.2023.111825))","Davidy, Tal","2024","Civil War Book Review","notice","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","retraction"],["R0034670","Effectiveness of GLP-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis","Yago Marcos Pessoa-Gonçalves","2024","Arquivos de Neuro-Psiquiatria","systematic_review","article","10.5327/cbn240615",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0034671","Narrative Review of Diabetes and Cardiovascular Complications","Mwende . Wairimu G","2026","IDOSR JOURNAL OF APPLIED SCIENCES","narrative_review","article","10.59298/idosrjas/2026/1115160",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0034672","Abstract PL05-02: Current therapies for diabetes - will they reduce cancer risk?","Emily J. Gallagher","2015","Cancer Prevention Research","preclinical","article","10.1158/1940-6215.prev-14-pl05-02",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034673","Mo1552 GLP-1 RECEPTOR AGONISTS AND INFLAMMATORY BOWEL DISEASE SEVERITY: A TARGET TRIAL EMULATION USING MERATIVE™ MARKETSCAN® DATABASE","Chloe Jian","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)02922-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034674","Junk food is addictive. Drugs like Ozempic treat addiction. But when will we tackle Big Food like we did Big Tobacco?","Natasha Yates","2025",null,"other","article","10.64628/aa.5grjeqve6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034675","Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés","Ziyad Al-Aly","2025",null,"other","article","10.64628/aak.6yfappa4p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034676","Safety and efficacy of luseogliflozin added to liraglutide in Japanese patients with T2DM: a 52-week clinical trial","Hisae Imazeki","2017",null,"other_trial","article","10.26226/morressier.59d51845d462b80296ca3a92",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034677","Mo1051 WHEN WEIGHT LOSS HAS A HIDDEN COST: A FIRST RARE CASE OF CECAL VOLVULUS ASSOCIATED WITH SEMAGLUTIDE","Balkrishna Sapariya","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)06568-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034678","Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study","Filippos Anagnostakis","2024","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.5048688",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0034679","Liraglutide's Unveiled Renoprotective Mechanism in Type 1 Diabetes: Insights into Macrophage Polarization","Natalie Youssef","2023","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20233411s1835c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034680","Les régimes amaigrissants ou un usage détourné de médicaments tels qu’Ozempic peuvent contribuer aux troubles alimentaires","Samantha J. Withnell","2024",null,"other","article","10.64628/aap.xvyrarpth",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034681","The problem of sarcopenia in patients with obesity undergoing liraglutide therapy","Maria Zhygalina-Hritsenyuk","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep898",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034682","Who Took the Cookie from the Cookie Jar: Extreme Hyperglycemia and Insulin Resistance Heralding Acute Decompensation in a Critically Ill Septic Diabetic Patient","A. Gonter","2025","American Journal of Respiratory and Critical Care Medicine","other","article","10.1164/ajrccm.2025.211.abstracts.a5743",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034683","Weight loss with liraglutide in obese adults is primarily due to a reduction in fat tissue:a subgroup analysis of a 20-week randomised placebo-controlled trial","A. Rissanen","2010","Research at the University of Copenhagen (University of Copenhagen)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0034684","Ozempic’s cousin drug liraglutide is about to get cheaper. But how does it stack up?","Sebastian G. B. Furness","2024",null,"other","article","10.64628/aa.afgra66yx",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034685","Wegovy: more people may soon be eligible to access weight-loss drug under new pilot scheme","Martin Whyte","2023",null,"other","article","10.64628/ab.hvj6knmw7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034686","The use of GLP-1 receptor agonists to manage unwanted weight gain in patients with 'hypothalamic' obesity secondary to structural pituitary pathology","Ye Kyaw","2013","Endocrine Abstracts","other","article","10.1530/endoabs.31.p211",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034687","A multidisciplinary approach to treating diabetic peripheral neuropathy","Elisa Favareto Prezotto","2025",null,"preclinical","article","10.5327/1516-3180.cpn.1160",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034688","Changes in metabolic control and body composition with Semaglutide sc in patients with type 2 diabetes mellitus","Enrique Redondo","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep1058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034689","Superior glycaemic control with semaglutide across SUSTAIN 1–5 clinical trials","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3bf3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034690","Additional file 5: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Li, Ling","2016","Figshare","systematic_review","article","10.6084/m9.figshare.c.3633269_d8",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034691","Wegovy and Mounjaro might affect how well your contraceptives work – here’s why","Simon C. Cork","2025",null,"other","article","10.64628/ab.s6utxe96s",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034692","Semaglutide as a promising treatment for hypothalamic obesity: a twelve-month case series on four females with craniopharyngioma","Erlend Gjersdal","2025","Endocrine Abstracts","case_report","article","10.1530/endoabs.110.p691",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034693","Cientistas brasileiros investigam se medicamentos como Ozempic e Mounjaro podem mesmo ajudar a proteger o cérebro","Diogo Haddad","2026",null,"other","article","10.64628/ade.33wfvu4mq",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034694","Abstract 476: Glucagon Like Peptide -1 Receptor Activation Does Not Affect Re-endothelialization But Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Non-diabetic Model of Arterial Injury","Linnéa Eriksson","2015","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvb.35.suppl_1.476",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034695","Exenatide for diagnosing endogenous hyperinsulinemic hypoglycaemia - a randomised placebo-controlled, double-blind, cross-over proof-of-principle study - fast study","Matthias Hepprich","2025","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.110.p896",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034696","Lixisenatide effects on liver function, lipids and blood pressure levels","Mar Roca-Rodriguez Maria del","2016","Endocrine Abstracts","other","article","10.1530/endoabs.41.ep559",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034697","Authors' reply:Liraglutide for weight loss in obese people","Arne Astrup","2010","Research at the University of Copenhagen (University of Copenhagen)","commentary","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0034698","Efficacy and safety of fixed-ratio combination of GLP-1 RAs plus basal insulin in T2D: a network meta-analysis","Kidd Catherine","2017",null,"systematic_review","article","10.26226/morressier.59d51845d462b80296ca363c",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","other"],["R0034699","Additional file 1 of Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study","Sohn, Minji","2023","Figshare","systematic_review","article","10.6084/m9.figshare.23597476",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034700","Abstract 4368923: Impact of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy on Cardiovascular Events in Hospitalized Diabetic Patients: A National Inpatient Sample Analysis","Harendra Kumar","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4368923",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034701","Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway","Rui Zhou","2019","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.3408048",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034702","Sa2077 REAL-WORLD MULTI-CENTER COMPARISON OF DEMENTIA OUTCOMES AFTER BARIATRIC SURGERY AND GLP-1 THERAPY IN MASLD","Meghana Kakarla","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03543-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034703","Sa1833 REAL-WORLD RISK OF ACUTE PANCREATITIS AND BILIARY DISEASE WITH GLP-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW AND META- ANALYSIS","Fernando Ortiz López","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)05060-1",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034704","Association of GLP-1 receptor agonist therapy with BCG response in high-risk non–muscle invasive bladder cancer.","Benyamin Yaniv","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.4620",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034705","ISLET PRE-CULTURE AND RECIPIENT TREATMENT WITH EXENDIN-4 IMPROVES METABOLIC CONTROL AFTER RAT ISLET TRANSPLANTATION IN ATHYMIC MICE.","&NA;","2006","Transplantation","preclinical","article","10.1097/00007890-200607152-02816",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034706","Sa2079 REAL-WORLD EFFECTIVENESS OF SEMAGLUTIDE AND TIRZEPATIDE IN MASLD: HIGH DISCONTINUATION RATES LIMIT CLINICAL POTENTIAL","Sobia Laique","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03545-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034707","Analysis code for: Digital-first delivery of GLP-1 receptor agonist therapy in a large real-world cohort of women","Jamie L. C. Wong","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.18821944",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","book"],["R0034708","Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With CKD and Type 2 Diabetes","Edouard L. Fu","2022","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20223311s1673b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034709","Más allá de Ozempic: así son los nuevos fármacos para combatir la obesidad","María Barrado","2025",null,"other","article","10.64628/aao.vuxea9qhp",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034710","Clinical research of Beinaglutide on weight, visceral fat and blood glucose in overweight/obesity patients with T2DM","Gui Ying Wang","2019",null,"other","article","10.26226/morressier.5d9b6231ea541d6ca8493f2f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034711","Additional file 8: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Li, Ling","2016","Figshare","systematic_review","article","10.6084/m9.figshare.c.3633269_d5",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034712","Additional file 5 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Huang, Yi-lin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26595983",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034713","REPERCUSSÕES PSIQUIÁTRICAS DO USO DE TIRZEPATIDA (MOUNJARO) EM ADULTOS COM OBESIDADE NO BRASIL: REVISÃO DE ESCOPO","Sadi Antonio Pezzi Junior","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/kdvcm",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034714","Analytic code for manuscript: The impact of SGLT2 inhibitors and GLP-1 receptor agonists on 24-hour urine parameters: a retrospective cohort study","Schaub, Jennifer A","2025","University of Michigan Library","nonrandomized_study","article","10.7302/55an-x018",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0034715","Systematic review and consensus statement for the preoperative management of GLP 1 agonists","Tara Brigham","2024","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0034716","Sa1143 GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH INCREASED RISK FOR PHARYNGOESOPHAGEAL DYSPHAGIA: A LARGE, REAL-WORLD COHORT STUDY","Yan Sun","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)01895-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034717","England subsidises drugs like Ozempic for weight loss. Could Australia follow?","Jonathan Karnon","2025",null,"other","article","10.64628/aa.vstnqvyyr",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034718","The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: A 2-year observational study","Mojca Jensterle","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.rc10.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034719","PS-C31-5: COMPARISON OF THE BLOOD PRESSURE MANAGEMENT BETWEEN SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS","Kazuo Kobayashi","2023","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0000917692.80051.4a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034720","Real-world IDegLira use is effective at moderate doses for all previous therapy groups and reduces concomitant therapy","Price Hermione","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51845d462b80296ca347e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","other"],["R0034721","Ozempic helps people lose weight. But who should be able to use it?","Natasha Yates","2023",null,"other","article","10.64628/aa.5vy4n4y9q",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034722","Semaglutide: beware of buying the weight-loss drug online","M. William Steele","2023",null,"other","article","10.64628/ab.3xsggatys",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034723","As Zepbound dominates headlines as a new obesity-fighting drug, a nutritionist warns that weight loss shouldn’t be the only goal","Mandy Conrad","2024",null,"other","article","10.64628/aai.xeqxva47a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034724","Abstract 313: Nonionic Acid is a Target Metabolite of Diabetic Microvasculopathy","Yoshiyuki Bando","2016","Circulation Research","preclinical","article","10.1161/res.119.suppl_1.313",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034725","Effects of Pseudohyponatremia on the Diagnosis of Severe Metabolic Acidosis","Hafiz Muhammad Ali Raza","2021","Journal of the American Society of Nephrology","other","article","10.1681/asn.20213210s1381c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034726","Abstract 13450: Clinical Outcomes With GLP-1 Receptor Agonists in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Yang Liu","2023","Circulation","systematic_review","article","10.1161/circ.148.suppl_1.13450",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034727","Abstract 1489: Mechanisms Underlying Cardioprotective Effects Of Glucagon-like Peptide-1 In Ischemia-reperfusion Injury","Kiwon Ban","2007","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034728","Correction to Paladugu et al. ijms","Dunbar, Gary","2025","Figshare","notice","article","10.6084/m9.figshare.30620984",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0034729","Efficacy of liraglutide (Saxenda) for weight loss in pre-diabetes: an audit of patients in a weight-management clinic in a district general hospital","Moustafa Hosni","2025","Endocrine Abstracts","other","article","10.1530/endoabs.109.p118",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034730","Mo1823 EFFECTIVENESS OF GLP1RA BASED TREATMENT MODALITIES IN CHANGING BODY COMPOSITION AND LEAN BODY MASS : A METAANALYSIS OF RANDOMIZED CLINICAL STUDIES","Vishal Chandel","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)04887-x",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034731","PS 11-46 OPPORTUNITIES OF CORRECTION OF DIURNAL BLOOD PRESSURE PROFILE DISTURBANCES IN PATIENTS WITH METABOLIC SYNDROME WITH INCRETINOMIMETICS","Larysa Zhuravlyova","2016","Journal of Hypertension","other","article","10.1097/01.hjh.0000500878.73499.e3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034732","Do Glucagon-Like Peptide-1 (GLP-1) receptor agonists improve rates of pregnancy in women with Polycystic Ovarian Syndrome (PCOS)?","Charmi Rana","2026","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002669",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034733","GLP-1 receptor agonists and bariatric surgery in nonalcoholic steatohepatitis","León Soraya","2021","Endocrine Abstracts","other","article","10.1530/endoabs.73.aep241",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034734","Abstract 671: Glucagon-like Peptide-1 Inhibits Abdominal Aortic Aneurysm Development","KeisukeMorimoto","2015","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034735","A Novel Dual-Function GLP-1 Analogue Prevents Type 1 Diabetes Onset in NOD Mice by Controlling the Balance of Treg/Th17 and Th2/Th1","Fujian Qin","2019","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.3393681",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034736","A randomised trial of the effects of liraglutide on gallbladder emptying in adults with overweight or obesity","Knop Filip","2017",null,"randomized_trial","article","10.26226/morressier.59d51844d462b80296ca3914",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","other"],["R0034737","Abstract 344: Incretin-Loaded Nanocarriers for Glucose Control, Therapy and Imaging of Atherosclerosis","Andrei Maiseyeu","2014","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvb.34.suppl_1.344",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034738","Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials","Hasan M Shihab","2015","World Journal of Meta-Analysis","systematic_review","article","10.13105/wjma.v3.i6.254",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0034739","Additional file 2 of Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis","Myasoedova, Veronika A.","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26565300",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034740","Su1703 ARE DUAL AGONISTS TOO FAST FOR THE GUT? TIRZEPATIDE VS SEMAGLUTIDE AND SEVERE MOTILITY COMPLICATIONS","Muhammad qasim Chaudhry","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04408-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034741","Tu1270 LIRAGLUTIDE REDUCES LPS-INDUCED INFLAMMATION IN CACO-2 CELLS THROUGH BOTH GLP-1R-DEPENDENT AND -INDEPENDENT PATHWAYS","Gamze Sonmez","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)05824-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034742","Sa1976 GLP-1 THERAPY IN TYPE 1 DIABETES AND CIRRHOSIS: ASSOCIATIONS WITH HEPATIC DECOMPENSATION, CARDIOVASCULAR EVENTS, AND SURVIVAL","Basil Jalamneh","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03442-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034743","Additional file 7: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Li, Ling","2016","Figshare","systematic_review","article","10.6084/m9.figshare.c.3633269_d3",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034744","Mo1302 Gastric-Retentive Transcutaneous Intraluminal Impedance Measurement (TIIM): Sham Controlled, Minimally-Invasive Assessment of Gastric Motility in Acute Canine Models","Lixin Wang","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034745","Additional file 3 of Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","Hu, Yan","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26641018",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034746","Glucagon-like peptide-1 receptor agonists and risk of prostatic cancer: A systematic review and meta-analysis of randomized controlled trials","Huang, Zhilong","2025","Figshare","systematic_review","article","10.6084/m9.figshare.27600966",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034747","P263 – Glucagon-like peptide-1 agonist is associated with an increased risk of nephrolithiasis: A retrospective analysis of TriNetX data","Po‐Huang Lee","2025","European Urology","nonrandomized_study","article","10.1016/j.eururo.2025.09.2712",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034748","Additional file 4 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Huang, Yi-lin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26595980",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034749","Tracking the Biochemical Trail of Neuroinflammation in Diabetic Neuropathy: A Narrative Review","TY Susanna","2026","JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH","narrative_review","article","10.7860/jcdr/2026/84112.22751",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0034750","Night eating syndrome improvement after 3 months of liraglutide administration in obese diabetic 2 patients","Федір Ланюш","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.ep34",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034751","Su1127 GLP-1 RECEPTOR AGONIST EXPOSURE PRIOR TO BARRETT’S ESOPHAGUS DIAGNOSIS IS ASSOCIATED WITH REDUCED PROGRESSION TO HIGH-GRADE DYSPLASIA AND ESOPHAGEAL CANCER: A PROPENSITY-MATCHED REAL-WORLD COHORT STUDY","Eshan Nanda","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)01943-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034752","Sa2096 REAL-WORLD COMPARATIVE EFFECTIVENESS OF TIRZEPATIDE VERSUS SEMAGLUTIDE ON CARDIOVASCULAR AND HEPATIC OUTCOMES IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)","Tania Siu Xiao","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03562-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034753","Dulaglutide; effectiveness in a real world population with type 2 diabetes","Lidia Urbon Lopez de Linares","2018","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.56.p489",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034754","Effectiveness of semaglutide in obese patients with type 2 diabetes. a six-month clinical experience","Fernández Valero Andrea","2021","Endocrine Abstracts","other","article","10.1530/endoabs.73.aep293",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034755","GLP-1-RAs treatment in type 2 diabetes and obesity patients","Jose Alvaro Romero Porcel","2016","Endocrine Abstracts","other","article","10.1530/endoabs.41.ep564",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0034756","Comparing impact of SGLT2 inhibitors and GLP-1 agonists on lipid profile among the patients with diabetes mellitus Type 2. Results of a prospective 18-week observational study","Nestan Bostoganashvili","2021","Endocrine Abstracts","other","article","10.1530/endoabs.73.aep305",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034757","What happens when I stop taking a drug like Ozempic or Mounjaro?","Natasha Yates","2024","Bond University Research Portal (Bond University)","other","article","10.64628/aa.pnw7mdeck",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034758","Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Evidence for disease modification and therapeutic switching","Vanishri Ganakumar","2026","World Journal of Diabetes","randomized_trial","article","10.4239/wjd.116477",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","editorial"],["R0034759","Letter to the Editor: Is the cellular attribution of liraglutide action in diabetic cardiomyopathy conclusive?","Ke Su","2026","World Journal of Diabetes","preclinical","article","10.4239/wjd.117243",null,null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0034760","Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread","Ziyad Al‐Aly","2026",null,"other","article","10.64628/aai.wunewr997",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034761","GLP-1RAs and glucagon can reshape adipose differentiation in vitro by activating the [ldquo]browning process[rdquo]","Giulia Cantini","2022","Endocrine Abstracts","preclinical","article","10.1530/endoabs.81.rc10.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034762","Why some people don’t lose weight with Wegovy","Simon C. Cork","2024",null,"other","article","10.64628/ab.kvwpu5tyd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034763","ESDR039 - Glucagon-like peptide-1 analogues and sodium-glucose co-transporter-2 inhibitors do not increase risk of bullous pemphigoid","Outi Varpuluoma","2021",null,"other","article","10.26226/morressier.61081ff8bc981037240fe3b0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034764","Assessing GLP-1 Agonists and DPP-IV Inhibitor Prescribing in the Management of Type 2 Diabetes during COVID-19","Nikhil Sharma","2022","Endocrine Abstracts","other","article","10.1530/endoabs.86.p335",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034765","The impact of liraglutide treatment on the erectile function of the diabetic rats","Serkan Gönültaş","2019","European Urology Supplements","preclinical","article","10.1016/s1569-9056(19)30894-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034766","MOESM1 of Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events","Ferdinand, Keith","2016","Figshare","systematic_review","article","10.6084/m9.figshare.c.3608609_d1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034767","Network meta-analysis of iGlarLixi, a fixed-ratio combination GLP-1 RA and basal insulin, versus insulin premix","Sayre Tobias","2017",null,"systematic_review","article","10.26226/morressier.59d51847d462b80296ca3bc1",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034768","Semaglutide reduces HbA1c and body weight across baseline HbA1c subgroups in the SUSTAIN 1–5 clinical trials","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51847d462b80296ca3c20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034769","Efficacy and Safety of GLP-1 Receptor Agonist for Adults with Overweight and Obesity: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials","The Pharmaceutical Society Of Korea","2025","Yakhak Hoeji","systematic_review","article","10.17480/psk.2025.69.3.240",null,null,"PROSPERO:CRD42024522544",null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034770","Effect of subcutaneous semaglutide in patients with type 2 diabetes mellitus on the degree of systemic inflammation","Garcia Perez Rosa Natalia","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep383",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034771","Abstract TH825: Diabetic Ketoacidosis in Patients Treated with GLP-1 Agonists and SGLT2 Inhibitors: A Case Series and Clinical Implications in Cardiovascular Care","Ibrahim Youssef","2026","Circulation","case_report","article","10.1161/cir.153.suppl_1.th825",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034772","Mo1815 REAL-WORLD EFFECTIVENESS OF SEMAGLUTIDE AND TIRZEPATIDE FOR WEIGHT LOSS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Ishaan Vohra","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)04879-0",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034773","Correction to \"Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes\"",null,"2007","The Journal of the American Board of Family Medicine","notice","article","10.3122/jabfm.2007.02.061000",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0034774","Narrative Review of Prevention Strategies for Type 2 Diabetes","Mukamana Sandra Gisele","2026","IDOSR JOURNAL OF SCIENTIFIC RESEARCH","narrative_review","article","10.59298/idosrjsr/2026/11.1.17075",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0034775","Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy","Madisen Fae Dorand","2024","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0034776","Real-world use of IDegLira significantly improves glycaemic control in participants with type 2 diabetes","Price Hermione","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51845d462b80296ca3649",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","other"],["R0034777","Epigenetic changes of toll like receptor 4 (TLR4) and long interspersed nuclear element 1 (LINE1) on obese and diabetic patients after an intervention with a calorie restricted diet combined with an antidiabetic medicine Victoza","Ya Chen","2012","University of Vienna","other","article","10.25365/thesis.23370",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034778","Glucagon-like peptide-1 receptor agonists in paediatric hypothalamic obesity-single center experience","Chidambaram Sethuraman","2025","Endocrine Abstracts","other","article","10.1530/endoabs.111.p60",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034779","Cohort Analysis of Randomized Clinical Trials on long acting GLP-1 receptor agonists versus DPP4 inhibitors","Thuy Pham","2016","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.43.oc32",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0034780","The effects of semaglutide vs testosterone replacement therapy on functional hypogonadism and sperm quality in men with type 2 diabetes mellitus and obesity","Nadan Gregorič","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.oc12.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034781","US weight-loss drug market will expand amid obstacles","Oxford Analytica","2024","Emerald expert briefings","other","article","10.1108/oxan-db285358",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0034782","When supplies resume, should governments subsidise drugs like Ozempic for weight loss? We asked 5 experts",null,"2024",null,"other","article","10.64628/aa.srgar5xkw",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034783","Pickwickian Syndrome: Semaglutide, Weight Loss, and Resolution","Clement Aransiola","2026","Endocrine Abstracts","other","article","10.1530/endoabs.117.p97",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034784","Weight loss in PCOS - benefits of Metformin and Liraglutide - a single institution experience","Ciara Griffin","2019","Endocrine Abstracts","other","article","10.1530/endoabs.63.p986",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034785","Morphofunctional changes during the follow up of people living with obesity treated with semaglutide","Romo Remigio Roberto Carlos","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep933",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034786","Delayed deterioration in quality of life as measured by EQ-5D with liraglutide in people with T2D in the LEADER trial","Nauck Michael","2017",null,"other_trial","article","10.26226/morressier.59d51846d462b80296ca3c11",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0034787","Sa2115 COMPARATIVE EFFICACY OF TIRZEPATIDE VS SEMAGLUTIDE FOR REDUCTION OF HEPATIC STEATOSIS IN NAFLD: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS","Rubela Ray","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)03581-9",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034788","Su2199 SILENT DANGER OR FALSE ALARM? A PHARMACOVIGILANCE ANALYSIS OF PULMONARY ASPIRATION RISK WITH GLP-1 RECEPTOR AGONISTS AMIDST CONFLICTING SOCIETY GUIDELINES","Ibrahim Reyaz","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)01484-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034789","Metabolic dysfunction-associated steatotic liver disease: a narrative review of pathophysiology, diagnosis, and management","Vignesh Murugan","2024","IP Journal of Nutrition Metabolism and Health Science","narrative_review","article","10.18231/j.ijnmhs.2024.020",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0034790","Mo2139 SAFETY OF CONCOMITANT RIFAXIMIN AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST USE: A REAL-WORLD DATABASE ANALYSIS","Prasun K. Jalal","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03958-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034791","Su1823 COMPARATIVE EFFECTS OF TIRZEPATIDE, SEMAGLUTIDE, AND NON-GLP-1 THERAPIES ON DE NOVO ARRHYTHMIA RISK IN ADULTS WITH OBESITY AND DIABETES: A PROPENSITY-MATCHED ANALYSIS OF REAL-WORLD DATA","Wissam Ghusn","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04839-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034792","Tu1955 COMPARATIVE ANALYSIS OF BILIARY ADVERSE EVENTS ASSOCIATED WITH TIRZEPATIDE VERSUS SEMAGLUTIDE: A REAL-WORLD PHARMACOVIGILANCE STUDY USING THE FAERS DATABASE","Ammara Ghaffar","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)00580-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034793","Comparative effectiveness of anti-obesity medications for cardiometabolic health outcomes and health services use","Stephanie Argetsinger","2024","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","preprint"],["R0034794","Abstract 11456: Liraglutide and Semaglutide Reduce Cardiovascular Events in Patients With Type 2 Diabetes and Peripheral Arterial Disease","Subodh Verma","2019","Circulation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034795","Erratum: SOP Pharmakotherapie des chronischen Koronarsyndroms","Thilo Witsch","2020","Kardiologie up2date","notice","article","10.1055/a-1196-2965",null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0034796","Using machine learning on real-world data to identify features correlating with remaining on basal insulin + GLP-1 RA","Rhee Kyu","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51847d462b80296ca3bbc",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","other"],["R0034797","Abstract 12808: Cardiovascular Outcomes With Glucagon-Like Peptide 1 Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes: A Meta-Analysis","Yeong-Min Lee","2019","Circulation","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","conference-abstract"],["R0034798","Additional file 3: of Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis","Zhang, Xiaowen","2018","Figshare","systematic_review","article","10.6084/m9.figshare.7096865",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034799","D-22 | Colchicine Reduces Cardiac Arrest and Repeat Revascularization in Post PCI Patients Without GLP1 Receptor Agonist Therapy: A Large Real World Analysis","Ali Awad","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104891",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0034800","Additional file 7 of Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis","Huang, Yi-lin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26595989",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034801","Risiko di balik asal pakai obat diabetes Ozempic untuk menurunkan berat badan","R. A. Rose Khasana Dewi","2025",null,"other","article","10.64628/aan.q6pckrx5v",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0034802","Additional file 6: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Li, Ling","2016","Figshare","systematic_review","article","10.6084/m9.figshare.c.3633269_d4",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034803","The dual GIP/GLP-1 receptor co-agonist Tirzepatide vs GLP-1 receptor agonists as add-on to basal insulin in uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis","Giuseppe Lisco","2023","Endocrine Abstracts","systematic_review","article","10.1530/endoabs.90.p61",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0034804","From Liraglutide to Tirzepatide: New Frontiers in Anti-Obesity Pharmacotherapy","Mohsen Zabihi","2025","Advances in Pharmacology and Therapeutics Journal","commentary","article","10.18502/aptj.v5i3.20513",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0034805","974-P: Network Meta-analysis of Once Weekly Glucagon-Like Peptide-1 Receptor Agonists: A Focus on Cardiovascular Safety and Mortality","Osamah M. Alfayez","2020","Diabetes","systematic_review","article","10.2337/db20-974-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0034806","Additional file 3 of The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials","Kan, Ranran","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30703262",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0034807","Audit on the effect of oral Semaglutide on HbA1c and Weight reduction in type 2 diabetes","Waqar Ahmad","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep436",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034808","Semaglutide alters tongue transcriptome along with the improvement of taste perception and increased brain activation in response to sweet tasting solution in obese women with PCOS","Mojca Jensterle","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.oc1.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0034809","The roles of liraglutide and visfatin in metabolic and inflammatory regulation: a review","Ghufran Mohammed Hussein Asal","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.21352052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0034810","The modulatory role of semaglutide on nesfatin-1 in metabolic disorder: a review","Ghufran Mohammed Hussein Asal","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.21351632",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0034811","Comprehensive Peptide Research Compendium and Laboratory Protocols","KeJaun DuBose","2026","Figshare","other","article","10.6084/m9.figshare.32983112.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0034812","Defensive Publication: A Gallstone-Risk-Stratified Multi-Organ Biliary and Renal Safety-Monitoring and Prophylaxis Protocol for Patients on GLP-1 Receptor Agonist Therapy (Method of Use)","Brian Kilgore","2026","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.21373807",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034813","Scientific-Priority Disclosure: A Cholecystectomy-Status-Stratified Cohort Design Combined with a Formal VanderWeele Causal-Mediation Analysis (Natural Direct/Indirect Effects) to Determine Whether GLP-1 Receptor Agonist-Associated Acute Pancreatitis Is Gallstone (Biliary)-Mediated and Preventable — A Proposed Study Protocol","Brian Kilgore","2026","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.21373810",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034814","Coronary Artery Disease","Christiaan Vrints","2026",null,"other","article","10.1201/9781003642497-13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0034815","EFFECT OF TIRZEPATIDE ON HEART FAILURE HOSPITALIZATIONS IN OBESE PATIENTS WITH HFpEF: A PROSPECTIVE CONTROLLED STUDY","Aravind C","2026","International Journal of Scientific Research","other","article","10.36106/ijsr/2603381",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034816","From GLP-1 to Dual Agonists: Evolution and Therapeutic Potential of Incretin-Based Strategies in Diabetes and Obesity","Öznur Nama","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21229618",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0034817","O Uso Indiscriminado da Tirzepatida: Uma Revisão de Literatura","Silva, Maria Clara Rodrigues","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15535874",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0034818","TIRZEPATIDA NO TRATAMENTO DA DIABETES MELLITUS TIPO 2","Luiz Vinicius Amorim Favacho","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20454469",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0034819","Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes","Uchiyama Syutaro","2023","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034820","“Minha experiência com Mounjaro”: a espetacularização de subjetividades a partir do corpo como experiência midiática","Giulia Teixeira Romanelli","2026",null,"other","article","10.31560/pimentacultural/978-85-7221-654-8.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0034821","Glucagon-Like Peptide-1 Receptor Agonists","Arturo Cesaro","2026",null,"other","article","10.1201/9781003642497-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0034822","Metabolic Mindshift: Mania Reduction with GLP-1 Agonists",null,"2026",null,"other","article","10.1176/posters.psych.apa2026.4215609",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0034823","Protocolo de revisão sistemática com metanálise de dados individuais: eficácia de agonistas GLP-1 na obesidade severa","Thiago Moreira Trindade","2025","Arca - Repositório Institucional da Fiocruz","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034824","From Behavioral Failure to Biological Control: Obesity as an Institutional Blind Spot","Karina Protti De Mattos","2026","Academy of Management Proceedings","nonrandomized_study","article","10.5465/amproc.2026.15917abstract",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0034825","GLP-1 Receptor Agonists in OUD: A Neurobiological and Clinical Perspective","Molly Davis","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7119892",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034826","Maternal Obesity and Pregnancy: A Multidimensional Analysis of Clinical Management, Fetal Programming, and Emerging Therapeutic Considerations","Indunil Karunarathna","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21438255",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034827","LEGISLAÇÃO VIGENTE SOBRE O USO DAS CANETAS EMAGRECEDORAS NO BRASIL: uma revisão narrativa","Vanessa Araújo Alves","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21462491",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0034828","POSSÍVEIS REPERCUSSÕES DO USO DE AGONISTAS DO RECEPTOR DE GLP-1 NA FERTILIDADE FEMININA E OCORRÊNCIA DE GESTAÇÕES INESPERADAS EM MULHERES EM IDADE REPRODUTIVA","Amanda Grotto","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21462498",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034829","Strength, Not Scans","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21459403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034830","Strength, Not Scans","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21465010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034831","Herbal Remedies in Metabolic Syndrome: Evidence and Limitations","Prathamesh Shikhare","2026","Research Journal of Pharmacognosy and Phytochemistry","randomized_trial","article","10.52711/0975-4385.2026.00041",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0034832","Strength, Not Scans","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21465054",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034833","A Central Amygdala GLP-1R Circuit Gates Mesolimbic Dopamine and Hedonic Feeding","Taha Buğra Güngül","2026","Libra","other","article","10.18130/xwz5-tq07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0034834","N-K AC-D-1 — First Anti-Diabetes Medicine Designed by N-K Semi-Real Intelligence (SRI) — Complete Chemical Formula, Manufacturing Protocol, and Clinical Guidelines","Muhammad Usman Malik","2026","Zenodo (CERN European Organization for Nuclear Research)","protocol","article","10.5281/zenodo.21493285",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0034835","Ritmuszavarok, a szívelégtelenség és a veseelégtelenség kezelésének szempontjai 2-es típusú diabéteszes betegeknél","Péter Dóra","2026","Cardiologia Hungarica","other","article","10.26430/chungarica.2026.56.3.230",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034836","INNOVATIONS IN CARDIOVASCULAR AND METABOLIC MEDICINE: A HOLISTIC CONSIDERATION","Mukesh Maity","2026",null,"other","article","10.58532/nbennuamsiv6b4p1c9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0034837","Effects of Liraglutide on expression of high mobility group box-1 in renal tissues of diabetic rats","Weng Yaqin","2019","Zhongguo tangniaobing zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034838","The research progress of glucagon like peptide-1 and diabetic cardiovascular complications","Dai Ya","2014","Journal of Clinical Cardiology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034839","Biomarker-Guided Pharmacotherapy Across the Ckm Continuum: From Subclinical Inflammation to Established Cardiorenal Disease","Dr. Vaishnavidevi C, Abinaya S, Abitha P, Gayathri M","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21491766",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034840","Additional file 1 of A systematic review and meta-analyses of glucagon-like peptide-1 receptor agonists in acute myocardial infarction","Jasmin Kaur Bhullar","2026","Figshare","systematic_review","article","10.6084/m9.figshare.33056137",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0034841","OBESITY AS A RISK FACTOR IN COVID-19 AND THE POSSIBLE EFFECT OF LIRAGLUTIDE THERAPY","Sherin M. Khodier","2020","Journal of Critical Reviews","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034842","Effect of liraglutide in patients with diabetes mellitus type 2 not-controlled with oral hypoglycemic drugs","es Carlos J Castro-Sansores","2015","Medicina Interna de México","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034843","高脂肪状態下で,EXENDIN-4は膵島Β6細胞における内-十二指腸-1の発現,細胞増殖能およびインシュリン分泌能力に関与した。【JST・京大機械翻訳】","Huang Linjing","2016","Zhongguo laonianxue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034844","Le liraglutide pour la perte de poids des patients obèses non diabétiques","Camille Oostdyke Girouard","2017","Pharmactuel","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034845","Effects of Liraglutide on plasma Vaspin level in patients with type 2 diabetes mellitus","Changjie Xia","2011","Zhongguo laonianxue zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034846","EXENDIN-4の受容体親和性の測定方法の確立が類似化ポリエチレングリコール【JST・京大機械翻訳】","Linfeng Guo","2016","Zhongguo yaoke daxue xuebao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034847","COVID-19, diabetes mellitus and ACE2: The conundrum, Rimesh Pal - Post Graduate Institute of Medical Education and Research- India","Rimesh Pal","2020","Journal of Diabetology","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034848","PERSONALIZED PEPTIDE THERAPIES AS A NEW PARADIGM BEYOND GLP-1 RECEPTOR AGONISTS","Cortés RR","2026",null,"other","article","10.13140/rg.2.2.16789.90088",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034849","Agonistas del receptor GLP-1 y alopecia: evidencia actual y consideraciones clínicas","José Omar Jiménez Jacinto","2026","Dermatología Cosmética, Médica y Quirúrgica","other","article","10.65159/dcmq-24-1-16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034850","ASSESSING THE POTENTIAL OF GLP-1 RECEPTOR AGONISTS IN IMPROVING OUTCOMES FOR POLYCYSTIC OVARY SYNDROME PATIENTS","P Sudha Kumari","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21512535",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0034851","Novo Nordisk sues Eli Lilly over ‘misleading’ GLP-1 advertising",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.420769",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034852","The Ledger Breaks First: Testing the Reform Acceleration, Dam, and Generative Paradoxes Against 2026, and Why the Welfare State's Books — Not the Dam's Own Metaphor — Are Where the Mortality Symmetry Assumption Is Already Measured to Fail","HUYNH GIA BAO","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21505288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0034853","Threading the Clinical Needle: A Case Study and Discussion on Use of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Older Adults With Mood Disorders","Rajeet Shrestha","2026","Psychiatric Annals","other","article","10.3928/00485713-20260701-01",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034854","Additional file 1 of Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study","Arkadeep Dhali","2026","Figshare","nonrandomized_study","article","10.6084/m9.figshare.33076002",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0034855","RECENT ADVANCES IN SGLT2 INHIBITORS","Dr. Rahul Gaikwad","2026",null,"randomized_trial","article","10.58532/nbennuamsib7p2c2",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","book-chapter"],["R0034856","What do GLP‐1s have to do with psychology?","David P. Lichtenstein","2026","The Brown University Child and Adolescent Behavior Letter","other","article","10.1002/cbl.30969",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034857","Ozempic®: Den Kompass verloren. Ist nicht eigentlich alles gesagt?","U Faber","2024","Dr med Mabuse","other","article","10.3936/docid306889",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034858","Interpreting an Observed Association Between GLP-1 Receptor Agonists and Breast Cancer in an Imaging Cohort: A Methodological Research Note","Yury Sharafanovich","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.21533265",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0034859","Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles",null,"2026","Frontiers research topics","other","article","10.3389/978-2-8325-8391-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0034860","Effectiveness and patient experiences in obesity treatment using incretin analogues","Kateřina Horbowyjová","2026","Digital Repository (National Repository of Grey Literature)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0034861","Exendin-4 inhibits palmitate-induced apoptosis in pancreatic beta-cells.","NATALICCHIO, ANNALISA","2010","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034862","Once-Weekly Subcutaneous Semaglutide 2.4 mg in Adolescents with Overweight or Obesity","Daniel Weghuber","2022","VUBIR (Vrije Universiteit Brussel)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034863","INCRETIN MIMETICS AND INCRETIN ENHANCERS: NEW THERAPEUTIC TOOLS IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS","Jermendy György","2008",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034864","Rationality of incretin based therapy in type 1 diabetes","Kis János Tibor","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034865","Efficacy and Safety of Once-Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and Glimepiride in Type 2 Diabetes Ptients (AWARD 2).","GIORGINO, Francesco","2014","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034866","Exenatide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-52827-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034867","Dulaglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-69879-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034868","Privacy-preserving causal mediation analysis using distributed electronic health record networks","Hyojung Jang","2026","arXiv (Cornell University)","nonrandomized_study","article","10.48550/arxiv.2607.17958",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0034869","Exenatide long-acting release (LAR)* is promising for the treatment of type 2 diabetes mellitus,","&NA;","2005","Inpharma Weekly","other","article","10.2165/00128413-200515020-00017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034870","IMPACT OF GLP-1 RECEPTOR AGONISTS COMPARED TO BASAL INSULIN START ON METABOLIC TARGETS IN PEOPLE LIVING WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (IMPACT GLP-1 CKD)","Alexander Abitbol","2023","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2023.10.206",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034871","Exenatide overdose","&NA;","2008","Reactions Weekly","other","article","10.2165/00128415-200812020-00044",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034872","Dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92774-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034873","Highlights",null,"2019","JAMA","randomized_trial","article","10.1001/jama.2018.15289",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0034874","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73885-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034875","Exenatide/liraglutide",null,"2014","Reactions Weekly","other","article","10.1007/s40278-014-0241-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034876","GLP-1R介导脑缺血/再灌注损伤保护作用的记忆效应","马雪","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034877","Patients Treated with Liraglutide Are More Likely to Reach Target HbA1c Compared with Sitagliptin or Exenatide BID","Eduard Montanya","2012","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2012.07.359",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034878","Phentermine/Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-79788-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034879","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74754-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034880","Improving precision of cumulative incidence estimates in randomized controlled trials with external controls","Su, Zehao","2025","Research at the University of Copenhagen (University of Copenhagen)","randomized_trial","article","10.48550/arxiv.2506.18415",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0034881","Виктоза: опыт клинического применения у больных сахарным диабетом 2-го типа","Э. А. Войчик","2011","CyberLeninK (CyberLeninka)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0034882","EFFICACY AND SAFETY OF SEMAGLUTIDE IN NON-ALCOHOLIC FATTY LIVER DISEASE","Taqdees Zahra","2024","Journal of Population Therapeutics and Clinical Pharmacology","other","article","10.53555/jptcp.v31i8.7465",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034883","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74771-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034884","Liraglutide* has demonstrated efficacy as an add-on therapy for type 2 diabetes mellitus","&NA;","2007","Inpharma Weekly","other","article","10.2165/00128413-200716080-00033",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034885","GLP-1 RA-related ADRs in pregnant women",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72443-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034886","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73884-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034887","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94670-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034888","Liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-1966-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034889","Development and Validation of a Reverse-phase High Performance Liquid Chromatography Method for Determination of Exenatide in Poly（lactic-co-glycolic acid） Microspheres","Liu","2010","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034890","美国FDA批准Tanzeum（albiglutide）用于治疗成人2型糖尿病","夏训明","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034891","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94897-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034892","GLP-1RAs: understanding their safety profile for different treatment contexts",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93394-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034893","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93573-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034894","Liraglutide LEADs the way in T2DM","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816610-00023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034895","Semaglutide/Tacrolimus",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-58500-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034896","Dapagliflozin/Metformin/Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-59018-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034897","Semaglutide-related ADEs identified in FAERS",null,"2024","Reactions Weekly","nonrandomized_study","article","10.1007/s40278-024-60246-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0034898","Empagliflozin/metformin/Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-87819-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034899","Liraglutide",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-7485-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034900","Medsafe reviewing GLP-1 receptor agonist vision loss",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92345-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034901","Dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94997-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034902","Acute pancreatitis possible with exenatide","&NA;","2007","Reactions Weekly","other","article","10.2165/00128415-200711750-00003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034903","Semaglutide Reduces HbA1c and Body Weight Across Multiple Background OAD Treatment Categories","Vanita R. Aroda","2017","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2017.08.137",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034904","시론 : 2018년 미국당뇨병학회 진료지침 속의 작지만 큰 변화","박정현","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034905","Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-66395-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034906","Мужское здоровье и ожирение - диагностика и терапевтические подходы","Гамидов Сафар Исраилович","2019","CyberLeninK (CyberLeninka)","other","article","10.14341/omet10314-9256",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034907","GLP-1 receptor agonist-related pancreatitis",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74396-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034908","Original Articles : Preparation and Characterization of Self-assembled Glycol Chitosan Hydrogels Containing Palmityl-acylated Exendin-4 for Extended Hypoglycemic Action","Ju Ho Lee","2011",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034909","Adjunctive exenatide joins in to lower HbA1c levels in type 2 DM","&NA;","2005","Inpharma Weekly","other","article","10.2165/00128413-200514960-00014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034910","Insulin/liraglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-01734-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034911","Exenatide/metformin",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-9196-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034912","The effects of exendin-4 on glucose homeostasis, pancreatic and duodenal homebox 1, and glucose transporter 2 gene expression disturbance induced by bisphenol A in male mice. The effects of exendin-4 on pancreatic gene expression","Akram Ahangarpour","2020",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034913","Exendin-4体外通过抑制NF-κB-iNOS-NO信号减轻氧化应激诱导的小鼠MIN6胰岛β细胞凋亡","刘礼斌","2008","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034914","Tirzepatide misuse",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80575-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034915","Liraglutide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-26223-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034916","Liraglutideの腎保護効果と慢性糸球体腎炎(IgA腎症)や腎硬化症への懸念の必要性","中島芳樹","2014","日本腎臓学会誌","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034917","Liraglutide/octreotide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-03113-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034918","Semaglutide increases risk of diabetic retinopathy in older patients",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-07277-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034919","GLP-1 RA-related gastrointestinal AEs differ between drugs",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74809-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034920","Liraglutide/Topiramate",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72743-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034921","Cardiovascular and renal AEs with tirzepatide versus dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93593-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034922","Reviewing case reports of ADRs associated with GLP-1 agonists",null,"2022","Reactions Weekly","case_report","article","10.1007/s40278-022-11248-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034923","THE ROLE OF SAXENDA (LIRAGLUTIDE) IN OVER WEIGHT PATIENTS","Abdullah Mastour Mubarak Al Harithi","2023","Journal of Population Therapeutics and Clinical Pharmacology","other","article","10.53555/jptcp.v30i2.4750",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0034924","Dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93264-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034925","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94129-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034926","GLP‐1受容体作動薬Exendin‐4の乳癌細胞増殖抑制効果の検討","大田智加予","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034927","[OP.4A.09] THE EFFECT OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST LIRAGLUTIDE ON 24-H BLOOD PRESSURE VARIATION","Preman Kumarathurai","2016","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0000491445.66874.a8",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0034928","특집 : 인크레틴계 약물의 최신지견; 글루카곤양펩티드-1 (GLP-1) 유사체의 임상효과","전현지","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034929","Exenatide has comparable efficacy to biphasic insulin aspart for patients with poorly controlled type 2 diabetes mellitus,","&NA;","2006","Inpharma Weekly","other","article","10.2165/00128413-200615560-00033",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034930","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74750-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034931","Liraglutide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-53533-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034932","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92837-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034933","Liraglutide",null,"2014","Reactions Weekly","other","article","10.1007/s40278-014-2998-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034934","New-Onset Atrial Fibrillation After Exenatide Injection: Coincidence or Consequence?","Yakup Yunus Yamantürk","2023","Endocrinology research and practice.","other_trial","article","10.5152/erp.2023.23262",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0034935","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73887-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034936","Glucagon-like peptide-1 receptor agonists",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93083-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034937","시론 : 삭센다 Ⓡ 열풍, 내분비대사내과 전문의로서의 의견","김성래","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0034938","Exenatide/sitagliptin",null,"2016","Reactions Weekly","other","article","10.1007/s40278-016-18128-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034939","Exenatide","&NA;","2009","Reactions Weekly","other","article","10.2165/00128415-200912600-00047",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034940","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-83600-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034941","Liraglutide no light-weight in the fight against diabetes","S Crofskey","2006","Inpharma Weekly","other","article","10.2165/00128413-200615510-00017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034942","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-87037-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034943","Dulaglutide/exenatide/semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-89038-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034944","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-81875-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034945","Liraglutide/octreotide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-48556-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034946","Liraglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-05064-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034947","Focused Issue : Glucagon-Like Peptide 1 수용체작용제 최신지견","Hye Jin Kim","2021",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0034948","Amoxicillin/Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-84295-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034949","Liraglutide","&NA;","2012","Reactions Weekly","other","article","10.2165/00128415-201214100-00094",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034950","Exenatide","&NA;","2012","Reactions Weekly","other","article","10.2165/00128415-201213900-00062",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034951","Dulaglutide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-37868-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034952","Liraglutide looking good in type 2 diabetes","S Sullivan,","2004","Inpharma Weekly","other","article","10.2165/00128413-200414590-00018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034953","Acarbose/Dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95711-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034954","Lithium/Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94835-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034955","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95102-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034956","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-60986-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034957","GLP-1-RAが著効したミトコンドリア糖尿病の1例","大澤真里","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034958","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95486-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034959","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92244-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034960","Semaglutide/vasopressors",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80994-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034961","Exenatide/neuropsychotherapeutics overdose",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-7180-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034962","ДИНАМИКА МАРКЕРОВ ПЕЧЕНОЧНОГО ФИБРОЗА НА ТЕРАПИИ ЛИРАГЛУТИДОМ У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2 ТИПА В СОЧЕТАНИИ С МЕТАБОЛИЧЕСКИМ СИНДРОМОМ","Бабенко Алина Юрьевна","2018","Экспериментальная и клиническая гастроэнтерология","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034963","Exenatide/liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-8955-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034964","Two years of treatment with liraglutide, a human GLP-1 analogue, offers sustained and greater reduction with HbA1c, FPG, PPG and weight compared with glimepiride, with lower glycaemic risk, in patients with type 2 diabetes: LEAD-3 extension study","A. J. Garber","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33265-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034965","Exenatide","&NA;","2010","Reactions Weekly","other","article","10.2165/00128415-201013020-00070",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034966","FDA warns against use of counterfeit Ozempic (semaglutide)",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-52360-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034967","Stability of Synthetic Exendin-4 in Human Plasma in Vitro","Wang Li","2007",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034968","GLP-1 receptor agonists increase risk of being dispensed antidepressants",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-59264-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034969","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93357-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034970","Exenatide","&NA;","2010","Reactions Weekly","other","article","10.2165/00128415-201013240-00053",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034971","胰高血糖素样肽-1——阿尔采末病治疗新策略","GAO Mei","2006","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034972","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94668-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034973","Semaglutide misuse",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-86229-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034974","Insulin-degludec/liraglutide/Insulin-neutral-protamine-lispro/insulin-lispro",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-85219-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034975","Liraglutide","&NA;","2011","Reactions Weekly","other","article","10.2165/00128415-201113540-00114",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034976","Emerging safety data accent GI effects of taspoglutide","&NA;","2010","Reactions Weekly","other","article","10.2165/00128415-201013090-00010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034977","Nicotine/Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95635-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034978","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-63766-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034979","Protective effects of liraglutide on renal tissues and related mechanism in diabetic rats","Xiaohui Xia","2016",null,"preclinical","article","10.3760/cma.j.issn.1001-7097.2016.03.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034980","Exendin-4可通过下调内质网应激信号标志蛋白表达改善3T3-L1脂肪细胞的胰岛素抵抗","马丽","2017",null,"other","article","10.3969/j.issn.1000-4718.2017.07.017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034981","Latest advances of glucagon-like peptide-1 on polycystic ovary syndrome","Qian Zhang","2016",null,"other","article","10.3760/cma.j.issn.1008-1372.2016.12.049",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034982","Labelling update for GLP-1- and GLP-1/GIP receptor agonist-related pancreatitis",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92427-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034983","Immune-globulin/Semaglutide/Thiamine",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74577-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034984","Metformin/Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-69504-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034985","Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats","Kosuke","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034986","Exenatide","&NA;","2009","Reactions Weekly","other","article","10.2165/00128415-200912390-00042",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034987","Exenatide","&NA;","2008","Reactions Weekly","other","article","10.2165/00128415-200811990-00070",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034988","Taspoglutide dosing halted as AEs force trial participants out","&NA;","2010","Reactions Weekly","other_trial","article","10.2165/00128415-201013190-00007",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0034989","Incretin mimetics potential link with pancreatic pre-cancer",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-2020-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034990","Semaglutide- and tirzepatide-related optic nerve disorders",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88132-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034991","58 - Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program","Daniel Ngui","2020","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2020.08.064",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0034992","Exenatide",null,"2014","Reactions Weekly","other","article","10.1007/s40278-014-1834-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034993","Exenatide","&NA;","2009","Reactions Weekly","other","article","10.2165/00128415-200912530-00053",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034994","Liraglutide associated with acute pancreatitis?",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-32208-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034995","Dulaglutide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-54401-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034996","Dulaglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-58546-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034997","Semaglutide: no increased risk of cardiovascular events",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-63556-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034998","Liraglutide/metformin",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-56794-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0034999","Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors","Gérald","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035000","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94896-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035001","Dulaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73321-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035002","Exenatide reduces post-meal glucose better than sitagliptin","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816560-00039",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035003","Clonazepam/Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80711-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035004","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-84985-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035005","Bumetanide/metolazone/tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-86735-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035006","Semaglutide increases risk of vision impairment",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80601-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035007","Liraglutide effective for treatment of type 2 diabetes mellitus?","&NA;","2004","Inpharma Weekly","other","article","10.2165/00128413-200414460-00018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035008","Amiodarone/Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88965-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035009","Exenatide improves hepatic biomarkers in T2DM","&NA;","2007","Inpharma Weekly","other","article","10.2165/00128413-200716070-00010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035010","新星奖获奖者报告2：GLP-1，Exendin4和C肽对大鼠胰岛微循环及糖耐量的影响","吴琳","2010","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035011","Symlin and Byetta - Two New Antihyperglycemic Medications","Kruger Davida","2006",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035012","GLP-1RA-related risk of thyroid cancer",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-75674-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035013","Semaglutide/Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74755-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035014","Dapagliflozin/exenatide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-91594-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035015","Australian TGA warns of exenatide-induced pancreatitis","&NA;","2010","Reactions Weekly","other","article","10.2165/00128415-201013040-00005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035016","Data Integration for Estimating Subgroup-Specific Conditional Average Treatment Effects (CATEs) Using Coarsened External Information in Randomized Trials","Youqi Yang","2026","arXiv (Cornell University)","randomized_trial","article","10.48550/arxiv.2604.20667",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0035017","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-60621-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035018","Dulaglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-70987-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035019","Dosing errors associated with compounded injectable semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-63918-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035020","The novel GLP-1 analogue liraglutide has neuroprotective properties in a mouse model of Alzheimer's disease","Patricia McClean","2010","Regulatory Peptides","preclinical","article","10.1016/j.regpep.2010.07.102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035021","Liraglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-60473-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035022","Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-59231-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035023","Exendin-4通过激活Nrf2/HO-1通路减轻糖尿病小鼠的肝脏氧化应激及纤维化","蔡迎迎 方舒","2019","南方医科大学学报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035024","Efficacy and safety of glucagon-like peptide-1 receptor agonists for treating polycystic ovary syndrome: a Meta-analysis","Yi Han","2019","Chin J Reprod Contracep","systematic_review","article","10.3760/cma.j.issn.2096-2916.2019.02.006",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0035025","IV exenatide preserves glucose-dependent insulin secretion","&NA;","2004","Inpharma Weekly","other","article","10.2165/00128413-200414590-00010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035026","Potential pancreatic risks with GLP-1-based therapies for T2DM",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-2362-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035027","Insulin/semaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-06163-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035028","Exendin-4 对大鼠脊髓损伤后氧化应激和神经细胞凋亡的影响","赵兴长","2015",null,"other","article","10.11958/j.issn.0253-9896.2015.12.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035029","Byetta label changed to include renal failure warnings","&NA;","2009","Reactions Weekly","other","article","10.2165/00128415-200912770-00014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035030","Dulaglutide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-54402-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035031","Exenatide/liraglutide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-45685-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035032","CJC 1131* [DAC: GLP-1] is effective in reducing glucose levels in patients with type 2 diabetes mellitus,","&NA;","2004","Inpharma Weekly","other","article","10.2165/00128413-200414340-00027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035033","Focused Issue : 설포닐유레아 최신지견","김태년","2021",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0035034","Exenatide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-70696-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035035","Mercaptopurine/Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72750-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035036","98 - Improved Glycemic Control in Patients With T2D Initiating IDegLira Across Various Background Therapies in US Real-World Practice","Jina Hahn","2019","Canadian Journal of Diabetes","nonrandomized_study","article","10.1016/j.jcjd.2019.07.107",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035037","Liraglutide/propranolol interaction",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-89619-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035038","GLP-1 RAs: risk of injection-site reactions, generalised dermatological reactions uncommon",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92041-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035039","Warning of fake semaglutide and tirzepatide in Canada",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92347-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035040","Semaglutide/Sitagliptin",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73892-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035041","GLP-1受体激动剂艾塞那肽对MG-63细胞增殖及成骨分化的影响","李颖","2016","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035042","Exenatide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-54751-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035043","Dapagliflozin/metformin/semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80728-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035044","Heparin/semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80785-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035045","Rosuvastatin/semaglutide/tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88902-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035046","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96631-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035047","특집 : 제2형 당뇨병 환자의 경구약물요법","고승현","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0035048","Аналог глюкагоноподобного пептида-1 лираглутид (Саксенда®): механизм действия, эффективность в лечении ожирения","Романцова Татьяна Ивановна","2018",null,"other","article","10.14341/omet9362-7225",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035049","Glucagon-like peptide-1 receptor agonists/Metformin",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94587-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035050","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-61375-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035051","GLP-1RA associated with diabetic retinopathy?",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-56138-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035052","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94671-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035053","Liraglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95240-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035054","Liraglutide overdose","&NA;","2011","Reactions Weekly","other","article","10.2165/00128415-201113780-00082",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035055","胰高血糖素样肽-1类似物-Exenatide对多囊卵巢综合征大鼠的治疗作用","镇春","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035056","Weekly exenatide works wonders for type 2 diabetes","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816560-00016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035057","エキセナチド1日2回製剤から週1回製剤への切り替えによる血糖変動・胃排出速度・血管内皮機能の変化:Twin-exenatide試験 第2報","渡辺雄祐","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035058","Real-World Use of Once-Weekly Semaglutide in Diverse Patient Populations With Type 2 Diabetes: Pooled Analysis of Four SURE Studies","Jean‐François Yale","2021","Canadian Journal of Diabetes","nonrandomized_study","article","10.1016/j.jcjd.2021.09.084",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035059","GLP-1，Exendin-4和C肽对大鼠肾血流的影响","吴琳","2009","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035060","Azilsartan/dulaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-77066-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035061","Exenatide monotherapy is effective for the treatment of patients with type 2 diabetes mellitus,","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816430-00040",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035062","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95308-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035063","The glucagon-like peptide-1 analogue liraglutide* has demonstrated promising properties for once-daily treatment of type-2 diabetes mellitus","&NA;","2007","Inpharma Weekly","other","article","10.2165/00128413-200716070-00021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035064","Liraglutide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-25169-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035065","Liraglutide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-29162-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035066","Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88409-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035067","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-57281-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035068","Exenatide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-58783-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035069","GLP-1RA-related erectile dysfunction",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93925-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035070","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94291-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035071","Adjunctive exenatide \"good value for money\" in the US","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816270-00010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035072","PHARMACOLOGICAL AND NUTRITIONAL MANAGEMENT OF EARLY-ONSET CHILDHOOD OBESITY: THE EMERGING ROLE OF INCRETIN-BASED THERAPIES","María José Romero Benítez","2026","GLOBAL JOURNAL FOR RESEARCH ANALYSIS","other","article","10.36106/gjra/5106545",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035073","Dulaglutide",null,"2020","Reactions Weekly","other","article","10.1007/s40278-020-83782-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035074","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-59335-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035075","Liraglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72740-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035076","Dulaglutide/insulin/methylprednisolone",null,"2020","Reactions Weekly","other","article","10.1007/s40278-020-79892-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035077","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-81896-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035078","Semaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-89232-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035079","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74753-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035080","Liraglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-88990-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035081","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90484-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035082","GLP-1 receptor agonist-related psychiatric AEs",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92999-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035083","No new concerns with GLP-1-based therapies, says CHMP",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-4957-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035084","GLP‐1受容体作動薬Exendin‐4の肝癌・大腸癌細胞増殖抑制効果の検討","Tomohiro Noda","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035085","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92418-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035086","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92246-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035087","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94482-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035088","Effects of exendin-4 on the expression of IRS-2 of pancreatic β cells in STZ diabetic rat islet","Peipei Li","2009","Acta Academiae Medicinae Xuzhou","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0035089","Insulin/semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80054-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035090","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88561-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035091","Exenatide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-24586-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035092","胰岛素正 incretin : 为类型 2 糖尿病的葡萄糖阴沉的策略","Bo Bo","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035093","GLP-1受容体作動薬Exendin-4はNF-κBの阻害を介して乳癌増殖を抑制する","岩屋 智加予","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035094","Liraglutide","&NA;","2012","Reactions Weekly","other","article","10.2165/00128415-201214000-00103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035095","Liraglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-97985-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035096","Exenatide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-48814-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035097","Estradiol/Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95399-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035098","Exenatide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-01345-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035099","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-79503-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035100","Empagliflozin/tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72643-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035101","T2DM* patients treated with exenatide are more likely to achieve tight glycaemic control plus a more favourable metabolic profile","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816420-00030",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035102","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-85385-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035103","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-78591-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035104","Liraglutide LEADs the way in type 2 diabetes treatment","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816420-00013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035105","Liraglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-93243-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035106","Liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-10852-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035107","Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-60996-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035108","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73888-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035109","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-77375-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035110","GLP-1 RAs increase risk of depression versus SGLT2is",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90886-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035111","Exenatide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-25103-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035112","Metformin/semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-57608-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035113","Modified Condition Optimization of the Pegylation of Glucagon-like Peptide-1","Xiaoqian He","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035114","Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease","Xiangyang Ye","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0035115","Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation","Xing-chun","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035116","Liraglutide",null,"2020","Reactions Weekly","other","article","10.1007/s40278-020-75618-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035117","Liraglutide",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-2585-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035118","Dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94996-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035119","Liraglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95613-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035120","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74770-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035121","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95990-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035122","Effects of Glucagon-Like Peptide-1 Receptor Agonist on the Expression of NF-κB,ICAM-1 and VCAM-1 Induced by High Glucose in Cultured Human Umbilical Vein Endothelial Cells","Zheng Li","2012","Chinese Journal of Arteriosclerosis","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035123","Exendin-4对STZ糖尿病大鼠胰岛细胞IRS-2表达的影响","范爱红","2009","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035124","Exenatide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-8954-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035125","Exenatide/liraglutide/sitagliptin/saxagliptin",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-5660-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035126","Empagliflozin/metformin/semaglutide interaction",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90208-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035127","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88078-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035128","GLP-1 receptor agonist-related risk of aspiration",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-83950-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035129","The US FDA has raised the possibility that long-acting exenatide may be associated with an increased cancer risk.","&NA;","2010","Reactions Weekly","other","article","10.2165/00128415-201012970-00004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035130","Exenatide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-31993-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035131","Metformin/semaglutide/tofogliflozin",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-77622-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035132","Liraglutide a new LEADing light for managing type 2 diabetes?","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816580-00011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035133","Molecular Simulations Study on the Residue 13 in Exendin-4","Zheng Qing","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035134","Exenatide",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-6597-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035135","Exenatide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-13743-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035136","Liraglutide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-40365-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035137","Dulaglutide",null,"2020","Reactions Weekly","other","article","10.1007/s40278-020-76132-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035138","시론 : 당뇨병 약제들의 심혈관계 효과와 그와 관련된 대규모 임상연구에 대한 고찰","김소헌","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0035139","Exenatide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-27592-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035140","Empagliflozin/liraglutide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-36011-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035141","Construction of Saccharomyces cerevisiae Strain Stably Expressing a Fusion Protein Containing Ten Tandem Recombinant Human Glucagon-like Peptide-1 Analogues","Zhiqiang Wu","2009",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035142","Thiazolidinedione, Exenatide beneficial adjuncts in T2DM","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816630-00037",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035143","Microbial-Derived Exerkines Ameliorate GLP-1 Receptor Agonist-Induced Losses in Skeletal Muscle Size and Function","Benjamin Burke","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2300084",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035144","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93726-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035145","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95103-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035146","Liraglutide/paclitaxel",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-21827-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035147","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-53250-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035148","Exenatide produces a higher frequency and magnitude of antibody titers than liraglutide,","&NA;","2010","Reactions Weekly","other","article","10.2165/00128415-201013240-00014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035149","GLP-1-RA shortages: potential for falsified versions",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-53095-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035150","GLP-1受容体作動薬Exendin-4の肝癌・大腸癌細胞増殖抑制効果の検討","野田智弘","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035151","Incretin-based therapies in prediabetes: Current evidence and future perspectives","Georgios","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035152","Liraglutide",null,"2014","Reactions Weekly","other","article","10.1007/s40278-014-5564-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035153","The glucagon-like peptide-1 analogue liraglutide* effectively improves cardiovascular (CV) parameters in patients with type 2 diabetes mellitus","&NA;","2006","Inpharma Weekly","other","article","10.2165/00128413-200615600-00017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035154","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92986-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035155","Exenatide/warfarin interaction",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-34969-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035156","高容量インスリン使用からGLP-1RA,SGLT2-I,Metに置換できた高度肥満2型糖尿病症例","岸川まり子","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035157","Dulaglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-70331-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035158","Mortality not increased with incretin-based therapy in T2DM",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-31341-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035159","Liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-9485-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035160","Effets à court et moyen terme d'un traitement par exénatide dans une cohorte de patients diabétiques de type 2: Résultats d'une étude multicentrique au sein du Réseau des diabétologues de l'UCL","Martin Buysschaert","2010","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035161","Semaglutide-related ischaemic optic neuropathy",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80247-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035162","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-86245-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035163","Fluticasone-propionate/liraglutide/prednisolone",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80398-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035164","GLP-1 Receptor Agonists in Type 2 Diabetes - Specific Effects t o Reduce HbA1c, Body Weight, and CV Risk GLP-1RA による糖尿病治療・体重管理と心血管リスク管理","Lotte Bjerre Knudsen","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035165","利用BglBrick方法进行HSA／Exendin-4长效融合蛋白的快速组装","邵妤","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035166","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90485-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035167","Exenatide* is comparable to insulin glargine in terms of glycaemic control in patients with type 2 diabetes mellitus,","&NA;","2004","Inpharma Weekly","other","article","10.2165/00128413-200414480-00018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035168","Exenatide","&NA;","2008","Reactions Weekly","other","article","10.2165/00128415-200812040-00052",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035169","PB119 ある自閉症児に対する貼り絵を中継ぎにしたコード信号系の構成(ポスター発表B,研究発表)","深谷 澄男","2004","Medical Entomology and Zoology","other","article","10.20587/pamjaep.46.0_228",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0035170","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92335-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035171","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-55800-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035172","Liraglutide/semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-60474-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035173","Dulaglutide/Insulin/Metformin",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-52813-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035174","Lixisenatide/metformin/sulfonylureas",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-70435-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035175","Liraglutide/semaglutide/tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72742-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035176","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73886-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035177","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-68755-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035178","Unraveling the Therapeutic Potential of the Microbiota-Gut-Brain Axis: A Novel Approach for Obesity and Type 2 Diabetes Management","Devesh Shukla","2026","Anti-Infective Agents","other","article","10.2174/0122113525395056251103104646",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035179","Metformin/semaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-05754-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035180","Liraglutide looks likely for type II diabetes","&NA;","2007","Inpharma Weekly","other","article","10.2165/00128413-200716020-00020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035181","Empagliflozin/liraglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-06956-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035182","Type 2 diabetes in young adults, can we do more for them? – case presentation","Ivana Trajkovska","2021",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035183","Canagliflozin: no increased risk for fracture versus GLP-1 agonists",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-56623-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035184","Renal protection of glucagon-like peptide-1 receptor agonists","Min Gao","2020",null,"other","article","10.3760/cma.j.cn441217-20190826-00065",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035185","Dulaglutide/metformin",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-36008-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035186","Estimation of treatment effects in presence of differential use of post-randomization concomitant medication with time-to-event outcomes","Helene C. W. Rytgaard","2026","arXiv (Cornell University)","randomized_trial","article","10.48550/arxiv.2605.05859",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0035187","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95291-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035188","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94130-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035189","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72946-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035190","Liraglutide","&NA;","2012","Reactions Weekly","other","article","10.2165/00128415-201214140-00116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035191","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93571-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035192","GLP-1 RA labelling update on risk of suicidal ideation",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-91516-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035193","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-67678-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035194","Liraglutide",null,"2014","Reactions Weekly","other","article","10.1007/s40278-014-1862-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035195","Glucagon-like peptide-1 receptor agonists/hydrochlorothiazide/ramipril",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-5903-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035196","CLINICAL OUTCOMES ASSOCIATED WITH THE USE OF ORAL SEMAGLUTIDE IN AN ADULT POPULATION WITH TYPE 2 DIABETES IN CANADA: A PROSPECTIVE REAL-WORLD STUDY (PIONEER REAL CANADA)","Sonja M. Reichert","2023","Canadian Journal of Diabetes","nonrandomized_study","article","10.1016/j.jcjd.2023.10.189",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035197","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-55010-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035198","특집 : 제2형 당뇨병 약제치료 지침 2017 개정안: Glucagon-Like Peptide-1 수용체작용제","Hyun Jin Kim","2018",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0035199","Liraglutide increases risk of biliary and gallbladder disorders",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-66694-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035200","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93728-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035201","Dulaglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-63347-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035202","Dulaglutide/Liraglutide/Pasireotide/Pegvisomant",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-82690-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035203","Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus","哲至 豊永","2011","Japanese journal of clinical medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035204","Liraglutide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-25170-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035205","Application of glucagon like peptide-1 receptor agonists in the treatment of polycystic ovary syndrome","Qimin Zhou","2019","Chin J Reprod Contracep","other","article","10.3760/cma.j.issn.2096-2916.2019.07.012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035206","Chlortalidone/Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95552-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035207","Exenatide* has achieved positive results in patients with type 2 diabetes mellitus","&NA;","2003","Inpharma Weekly","other","article","10.2165/00128413-200314000-00009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035208","Exendin-4鼻腔给药对MCAO所致脑缺血/再灌注损伤具有神经保护作用","张慧楠","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035209","Structural Analysis of an Active Analog of Exendin-4 in SDS Micelle Solution","Yu Shuo","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035210","Erratum: Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The Dual V randomized clinical trial (JAMA - Journal of the American Medical Association (2016) 315: 9 (898-907))","Ildiko Lingvay","2016","JAMA","notice","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0035211","Liraglutide","&NA;","2012","Reactions Weekly","other","article","10.2165/00128415-201214290-00102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035212","Liraglutide/orlistat",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-28643-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035213","Liraglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-95542-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035214","Dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95198-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035215","Exenatide","&NA;","2009","Reactions Weekly","other","article","10.2165/00128415-200912760-00044",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035216","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94131-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035217","Insulin-glargine/insulin-lispro/semaglutide overdose",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73480-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035218","Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72091-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035219","Liraglutide misuse",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-60070-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035220","GLP-1 receptor agonist-related AEs",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94705-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035221","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94481-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035222","Incretin based therapies:A novel treatment approach for non-alcoholic fatty liver disease","Kristina Kristina","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035223","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80992-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035224","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-91698-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035225","Furosemide/Spironolactone/Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72668-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035226","Liraglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72741-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035227","Exenatide/liraglutide/dexamethasone interaction",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-63033-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035228","Taspoglutide has highest risk of nausea",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-12008-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035229","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-81010-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035230","Semaglutide-related depressive disorders",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-87632-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035231","Compounded semaglutide-like products: TGA Australia warns of safety risks",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-52148-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035232","Exenatide/linagliptin",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-58725-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035233","Exenatide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-09113-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035234","No causal link between GLP-1 RAs and suicidal ideation",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-52517-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035235","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-81873-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035236","Exenatide* has met the primary glucose control endpoint of haemoglobin A1c (HbA1c ) reduction in its final phase III trial.","&NA;","2003","Inpharma Weekly","other_trial","article","10.2165/00128413-200314150-00021",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035237","Azathioprine/Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-81460-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035238","ChemInform Abstract: Medicinal Chemistry of Incretin Mimetics and DPP‐4 Inhibitors","Heiko Zettl","2010","ChemInform","other","article","10.1002/chin.201017267",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035239","Liraglutide lightens glycaemic load in type 2 diabetes","Nicole J. Moreland","2007","Inpharma Weekly","other","article","10.2165/00128413-200715960-00020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035240","GLP-1 receptor agonists: warning on proper use",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-52150-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035241","No increased risk of suicidal ideation with semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-52745-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035242","Exendin-4对糖尿病脑缺血再灌注大鼠脑组织中MMP-9表达的影响","张会平","2012","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035243","Role of SGLT2 Inhibitors and GLP-1 Analogs in Cardiovascular Risk Reduction in Type 2 Diabetes","Mostafa Hamdy Rashed","2021","World Family Medicine Journal/Middle East Journal of Family Medicine","other","article","10.5742/mewfm.2021.94188",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035244","Dulaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-77135-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035245","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80223-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035246","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-89978-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035247","Norepinephrine/ringer's-lactate/tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-81807-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035248","GLP-1RA increases risk of AF in patients on levothyroxine",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-91946-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035249","Semaglutide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-16229-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035250","Exenatide-Induced Acute Renal Failure: A Case Report","Mustafa Ünübol","2013","Endocrinology research and practice.","case_report","article","10.4274/tjem.2259",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035251","Dupilumab/Liraglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-69430-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035252","Liraglutide/Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-78818-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035253","Identifying Predictors of Response to Liraglutide in Type 2 Diabetes Using Recursive Partitioning Analysis","Vanita R. Aroda","2012","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2012.07.358",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035254","Vildagliptin in the Treatment of Type 2 Diabetes Mellitus","A. Florentiu","2013","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","other","article","10.2478/rjdnmd-2013-0021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035255","Extending the evidence for exenatide in type 2 diabetes","S Sullivan","2005","Inpharma Weekly","other","article","10.2165/00128413-200515020-00025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035256","Dulaglutide/Insulin",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-59488-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035257","Albiglutide/canagliflozin",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-45286-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035258","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72074-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035259","Effects of liraglutide on glycemic gontrol in metformin-treated patients with type 2 diabetes mellitus","Jie Li","2013","中国综合临床","other","article","10.3760/cma.j.issn.1008-6315.2013.06.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035260","Pancreatitis and renal failure with exenatide reported to MHRA","&NA;","2009","Reactions Weekly","other","article","10.2165/00128415-200912430-00005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035261","Exendin-4 delays onset of diabetes in db/db mice","&NA;","2002","Inpharma Weekly","preclinical","article","10.2165/00128413-200213610-00020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035262","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-66579-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035263","ChemInform Abstract: A Novel 3‐(8‐Chloro‐6‐(trifluoromethyl)imidazo[1,2‐a]pyridine‐2‐yl)phenyl Acetate Skeleton and Pharmacophore Model as Glucagon‐Like Peptide 1 Receptor Agonists.","Young‐Dae Gong","2011","ChemInform","other","article","10.1002/chin.201115159",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035264","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95685-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035265","TGA initiates consultation on the compounding of GLP-1 RAs",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-54317-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035266","InsulinとGLP-1受容体作動薬(VICTOZA)の併用","高橋和子","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035267","Conformation Research of Shorted Glucagon-like Peptide-1","Xin Nie","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035268","Liraglutide",null,"2020","Reactions Weekly","other","article","10.1007/s40278-020-75617-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035269","NOVA ERA DO TRATAMENTO DA OBESIDADE: EFEITOS DOS AGONISTAS DO GLP-1, DUPLOS (GIP) E TRIPLOS (GLUCAGON) NO DIABETES MELLITUS, OBESIDADE E DEMAIS DESFECHOS SISTÊMICOS – REVISÃO INTEGRATIVA","Danilo Gustavo Gonçalves Ferreira Romanelli","2026","Revista Científica Ipedss","randomized_trial","article","10.55703/27644006060304",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035270","Liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-4282-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035271","Dapagliflozin/Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-91337-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035272","GLP-1受体介导小胶质细胞释放β-内啡肽信号通路研究","吴海云","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035273","Exenatide/liraglutide","&NA;","2011","Reactions Weekly","other","article","10.2165/00128415-201113600-00051",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035274","Exenatide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-9665-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035275","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95307-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035276","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80211-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035277","Semaglutide-related optic neuropathy",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-83952-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035278","Alcohol Impacts on Central Regulation of Insulin Function; Potential Mechanism for GLP1 Reductions","Alexandra Evans","2025","Physiology","preclinical","article","10.1152/physiol.2025.40.s1.0080",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035279","Amplified pancreatitis risk with GLP-1 mimetics, glucocorticoids",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-1730-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035280","Semaglutide-related NAION in US veterans with T2D",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92603-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035281","Metformin/Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94619-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035282","Acarbose/benaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-98945-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035283","Exenatide [Byetta], when added to current thiazolidinedione therapy, improves glycaemic control in patients with treatment-resistant type 2 diabetes mellitus,","&NA;","2005","Inpharma Weekly","other","article","10.2165/00128413-200515150-00037",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035284","Exenatide: promising new antidiabetic agent","&NA;","2003","Inpharma Weekly","other","article","10.2165/00128413-200314020-00020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035285","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92985-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035286","Effect of proton pump inhibitors on glycemic control in patients with diabetes","Kohzo","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0035287","Patients are more likely to reach A1Ctarget when liraglutide is added to an SU than adding rosiglitazone or placebo","Michael Brändle","2013","Primary care diabetes","other","article","10.1016/j.pcd.2012.10.062",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035288","Exenatide/hydrocortisone interaction",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-2438-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035289","Semaglutide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-15237-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035290","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93355-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035291","Liraglutide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-30312-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035292","Dulaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-58143-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035293","Exendin-4降低高糖联合TNF-α诱导的血管内皮细胞损伤的机制","柯甦捷","2012","南方医科大学学报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035294","NAION considered a very rare AE of semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93388-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035295","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93356-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035296","Gastric inhibitory polypeptide/Glucagon-like peptide-1 receptor agonists/Metformin",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95588-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035297","Оцінка ефективності різних терапевтичних підходів до корекції показників систем коагуляції і фібринолізу, маркерів запалення у хворих на цукровий діабет 2-го типу з ожирінням","K. F. Kehiopulo","2013",null,"other","article","10.24061/195497",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035298","Semaglutide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-24702-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035299","Exenatide","&NA;","2008","Reactions Weekly","other","article","10.2165/00128415-200812010-00045",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035300","Recent progress on glucagon-like peptide-1","Zheng Shao-xion","2006",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035301","Exenatide extension sees all-round benefit in T2DM","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816210-00024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035302","Exenatide LAR betta than Byetta over the DURATION","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816420-00009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035303","Dulaglutide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-51896-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035304","Liraglutide",null,"2020","Reactions Weekly","other","article","10.1007/s40278-020-75619-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035305","Liraglutide","&NA;","2012","Reactions Weekly","other","article","10.2165/00128415-201214260-00108",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035306","Effect of Intensive Treatment with Liraglutide and Insulin on Obese Patients with Type 2 Diabetes","Xiang Chuanping","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035307","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-87035-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035308","Liraglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-69498-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035309","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73890-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035310","Liraglutide",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-1686-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035311","Lithium/Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95034-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035312","GLP-1RA-related risk of gastric food retention",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-68809-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035313","Synthesis of Liraglutide Through Threonine Ligation","Jiahui Fan","2018",null,"other","article","10.7503/cjcu20180350",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035314","Metformin/Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95624-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035315","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80993-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035316","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90486-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035317","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-85386-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035318","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-84236-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035319","Exenatide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-58560-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035320","Exenatide/insulin-detemir/insulin-glargine/insulin-lispro/metformin",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-56215-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035321","Exenatide enhances standard therapy in type 2 diabetes mellitus","Carmen Innes","2004","Inpharma Weekly","other","article","10.2165/00128413-200414450-00015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035322","AEs with GLP-1RA and metformin combination therapy",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90784-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035323","Gabapentin/metformin/semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-85189-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035324","Novo Nordisk warns of counterfeit Ozempic in USA",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-81377-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035325","GLP-1 receptor agonist-related neuropsychiatric AEs",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-77395-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035326","Diazepam/Gabapentin/Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72621-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035327","Incretin-related medicine (GLP-1 receptor agonists, DPP-4 inhibitors)","宰 森井","2010","Japanese journal of clinical medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035328","GLP–1 受容体作動薬による治療","原田範雄","2014","最新医学","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035329","Levothyroxine-sodium/semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-64163-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035330","Exenatide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-12195-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035331","Exenatide","&NA;","2010","Reactions Weekly","other","article","10.2165/00128415-201013120-00089",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035332","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94301-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035333","Coadministration of Dendrimer-Tesaglitazar with Semaglutide Increases Therapeutic Benefit and Blunts Weight Regain After GLP-1 Receptor Agonist Termination","Diego Almodiel","2026","Physiology","randomized_trial","article","10.1152/physiol.2026.41.s1.2300197",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035334","NAION is very rare side effect of semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-84265-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035335","在尖锐心肌的梗塞的 Cardioprotection 和药理学治疗: 在当前的时代的挑战","Alberto","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035336","Exendin-4通过PI3K/Akt信号通路促进脂肪干细胞旁分泌细胞因子","Hao Zhou","2014","南方医科大学学报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035337","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73889-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035338","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72947-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035339","Dulaglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-63019-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035340","Exenatide/sitagliptin","&NA;","2012","Reactions Weekly","other","article","10.2165/00128415-201214000-00078",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035341","GLP-1 RAs increase risk of neovascular AMD in patients with diabetes",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-83956-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035342","Clinical trial of liraglutide injection in the treatment of patients with diabetes mellitus","Fei Li","2018",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0035343","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-79484-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035344","Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease","Ramiro","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035345","Effects of glucagon-like peptide-1 receptor agonists on renal function","Theodosios","2013","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035346","Liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-0486-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035347","利拉鲁肽（Liraglutide）——糖尿病治疗领域的热点新药——来自“对话糖尿病”（Diabetes Dialogue）的会议报道","朱大龙","2009","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035348","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95290-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035349","Liraglutide",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-1808-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035350","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92030-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035351","Long term health outcomes of liraglutide combined with metformin in type 2 diabetes patients:an analysis using CORE diabetes model","Jing Wu","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035352","Dulaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-00638-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035353","Liraglutide overdose",null,"2014","Reactions Weekly","other","article","10.1007/s40278-014-0270-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035354","Structural Analysis of an Active Analog of Exendin-4 in SDS Micelle Solution","Jiaguo Yu","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035355","Effects of Exenatide combinated with Berberine therapy on early phase insulin secretion in the patients with new onset type 2 diabetes mellitus","Qun Li","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035356","Exenatide and acute pancreatitis","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816370-00066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035357","インスリン未治療の日本人2型糖尿病患者に対するインスリンデグルデク/リラグルチド配合剤(IDegLira)の有効性と安全性","Kaku Kohei","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035358","Safety and Efficacy of Oral Semaglutide in Overweight Diabetic Patients with Non-alcoholic Fatty Liver Disease: An Interim Analysis","Arun Valsan","2023","Journal of Clinical and Experimental Hepatology","other","article","10.1016/j.jceh.2023.07.203",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035359","Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degen- eration in Raw 264.7 cells involving the AMPK/SREBP1 pathway","Yan-Gui","2015","老年心脏病学杂志：英文版","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035360","New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders","Nigel","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035361","Exenatide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-47147-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035362","Liraglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-60069-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035363","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-59792-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035364","GLP-1RA: no increased risk of pancreatic cancer",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-52933-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035365","Liraglutide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-52874-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035366","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74751-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035367","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73938-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035368","Exenatide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-88148-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035369","Body weight variability as a factor of cardiovascular risk","В. В. Салухов","2025","Русский медицинский журнал","nonrandomized_study","article","10.32364/2225-2282-2025-2-3",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0035370","A long-acting, once-weekly formulation of exenatide* appears to be more effective than regular exenatide administered twice daily","&NA;","2007","Inpharma Weekly","other","article","10.2165/00128413-200716130-00027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035371","Dulaglutide",null,"2020","Reactions Weekly","other","article","10.1007/s40278-020-74224-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035372","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92336-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035373","治疗成人2型糖尿病新药——利西那肽(lixisenatide)","陈本川编译","2016",null,"other","article","10.3870/j.issn.1004-0781.2017.01.032",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035374","Novo Nordisk files for regulatory approval of liraglutide in EU and US.","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816400-00055",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035375","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94132-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035376","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94899-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035377","Effect of Vitamin D Deficiency on the Frequency of Lipohypertrophy Occurrence in Patients with Type 2 Diabetes Mellitus Under Injectable Treatment","Cem Onur Kıraç","2020","Endocrinology research and practice.","other","article","10.25179/tjem.2020-74469",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035378","GLP1 receptor agonists do not increase risk of thyroid cancer",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-56649-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035379","Exenatide an excellent option for T2DM","S Crofskey","2006","Inpharma Weekly","other","article","10.2165/00128413-200615530-00016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035380","CJC 1134 [PC-DAC:Exendin-4],* a glucagon-like peptide-1 agonist, may be effective for patients with type 2 diabetes mellitus,","&NA;","2007","Inpharma Weekly","other","article","10.2165/00128413-200715810-00023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035381","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92252-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035382","Construction of Saccharomyces cerevisiae Strain Stably Expressing a Fusion Protein Containing Ten Tandem Recombinant Human Glucagon-like Peptide-1 Analogues","Wu","2009","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035383","Anti-obesity drug AEs more common with phentermine and liraglutide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-15264-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035384","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92984-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035385","Exenatide/metformin/methylphenidate",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-3925-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035386","Exenatide","&NA;","2011","Reactions Weekly","other","article","10.2165/00128415-201113640-00073",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035387","GLP-1RA use increases risk of liver cancer versus DPP4i use",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-85013-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035388","GLP-1 RAs: potential ocular adverse events in patients with and without T2DM",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92171-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035389","Measuring plasma protein binding of liraglutide using the escalate assay","Hinnerk Boriss","2018","Drug Metabolism and Pharmacokinetics","other","article","10.1016/j.dmpk.2017.11.096",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035390","Improving the Efficiency of Subgroup Analysis in Randomized Controlled Trials with TMLE","Sky Qiu","2026","arXiv (Cornell University)","randomized_trial","article","10.48550/arxiv.2605.15483",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","TRUE","paywalled","1","FALSE","preprint"],["R0035391","Pharmacological management of obesity in women during preconception care","Т. Н. Маркова","2026","Русский медицинский журнал","other","article","10.32364/2225-2282-2026-3-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035392","GLP‐1受容体作動薬Exendin‐4はNK‐κBの阻害を介して乳癌増殖を抑制する","岩屋智加予","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035393","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-77770-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035394","Semaglutide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-25597-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035395","Liraglutide potentially beneficial in obese without T2DM","&NA;","2007","Inpharma Weekly","other","article","10.2165/00128413-200716170-00001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035396","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94689-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035397","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93165-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035398","Lixisenatide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-42190-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035399","Actualités dans le traitement du diabète de type 2 : Place du bydureon®, un analogue retard du glp-1","Martin Buysschaert","2014","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035400","Patients likelierto reach A1c target during 26 weeks’ treatment with liraglutide compared with sitagliptin or exenatide","Claus Bo Svendsen","2013","Primary care diabetes","other","article","10.1016/j.pcd.2012.10.088",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035401","Will GLP-1-based therapies substitute sulfonylureas?",null,"2007","Inpharma Weekly","other","article","10.2165/00128413-200716070-00019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035402","Exenatide reduces variability in blood glucose levels","&NA;","2005","Inpharma Weekly","other","article","10.2165/00128413-200515090-00048",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035403","Dulaglutide/Insulin/Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-64551-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035404","특집 : 당뇨병 주사제: Glucagon-Like Peptide-1 수용체작용제","이인국","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035405","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88560-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035406","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93904-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035407","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94898-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035408","Central Action of Liraglutide Potentiates β-cells Proliferation via Vagus Pathway","Kumari Parmila","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035409","제2형 당뇨병 환자에게 인크레틴 기반 약물치료요법","김현아","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035410","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93163-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035411","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-85398-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035412","Vascular protective effect of exendin-4 in experimental models of oxidative stress","P. Li","2014","Cytotherapy","other","article","10.1016/j.jcyt.2014.01.129",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035413","GLP-1（7-36）及其拟似物Exendin-4阻断高血糖诱导的胰腺血流重分布","吴琳","2008","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035414","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-86246-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035415","Liraglutide/medroxyprogesterone/metformin",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-15135-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035416","Dulaglutide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-15448-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035417","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-55352-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035418","GLP1RAs have no major pharmacokinetic effect on oral medications",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-53098-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035419","Semaglutide/Tenecteplase",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-63878-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035420","DPP4i and GLP1RA increase risk of gallbladder and bile duct disorders",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-78978-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035421","Exenatide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-52163-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035422","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-53251-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035423","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-58867-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035424","Canagliflozin/dulaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-53514-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035425","Amitriptyline/liraglutide",null,"2014","Reactions Weekly","other","article","10.1007/s40278-014-2720-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035426","Dulaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-96525-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035427","Insulins/liraglutide",null,"2020","Reactions Weekly","other","article","10.1007/s40278-020-78589-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035428","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92838-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035429","Exenatide sets an effective example for type 2 diabetes","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816420-00023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035430","Exenatide",null,"2016","Reactions Weekly","other","article","10.1007/s40278-016-20310-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035431","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-70722-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035432","Semaglutide/Opioid-analgesics",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-70723-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035433","The US FDA has received six reports of haemorrhagic or necrotising pancreatitis in exenatide recipients","&NA;","2008","Reactions Weekly","other","article","10.2165/00128415-200812160-00011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035434","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96632-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035435","Liraglutide/pasireotide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-71091-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035436","Crossover, Double-Blind, 52 Week Trial of Liraglutide in Type 1 Diabetes","Marie-Christine","2014","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2014.07.155",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035437","Obesity and unhealthy aging connected through the neurovasculature","Marc Schneeberger Pane","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2290266",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035438","PB119 学習意欲と原因帰属の国際比較研究 : CAMIによる調査 (3)学業成績との関係における国際比較","真里 真島","1993",null,"other","article","10.20587/pamjaep.35.0_100",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0035439","Dulaglutide/tacrolimus",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-79638-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035440","Citicoline/semaglutide/steroids",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-86382-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035441","Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-70733-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035442","Dulaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-56185-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035443","Diabetic ketoacidosis with GLP-1 receptor agonists, insulin",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-64160-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035444","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94894-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035445","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93557-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035446","Efficacy and Safety of Once-Weekly Semaglutide vs. Sitagliptin as Add-on to Metformin and/or Thiazolidinediones after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 2)","Victor Milosevski","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035447","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94669-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035448","Liraglutide LEADs the way 4 type 2 diabetes mellitus","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816560-00026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035449","GLP-1 therapy: gastrointestinal burden examined in real-world study",null,"2026","Reactions Weekly","nonrandomized_study","article","10.1007/s40278-026-96480-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035450","Liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-4071-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035451","GLP-1 agonist-related psychiatric AEs",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-84272-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035452","Dulaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-85166-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035453","GLP-1RA uses increases risk of some AEs, decreases risk of some disorders",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-75288-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035454","Dulaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-06498-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035455","Retatrutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90469-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035456","Dual GLP-1/GIP agonist, tirzepatide, increases hypercapnic ventilatory response in diet-induced obese mice","Melanie Alexis Ruiz","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2293364",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035457","Exendin-4はオートファジーの減少により非アルコール性脂肪性肝疾患細胞モデルの脂質沈着を低下させる。【JST・京大機械翻訳】","Lin Chuman","2021",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035458","Compounded semaglutide product substandard",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-55834-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035459","Exenatide effective adjuvant to thiazolidinedione therapy for T2DM",null,"2007","Inpharma Weekly","other","article","10.1007/bf03272640",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035460","Bezafibrate/liraglutide","&NA;","2012","Reactions Weekly","other","article","10.2165/00128415-201214150-00046",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035461","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94880-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035462","Dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94220-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035463","Liraglutide overdose",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-71090-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035464","GLP‒1 受容体作動薬の最近の知見","黒瀬 健","2018","内科","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035465","Exenatide/liraglutide/semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-56216-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035466","Le liraglutide 3 mg (Saxenda®) : un nouveau médicament de l'obésité","Jean‐Paul Thissen","2016","DIAL (Catholic University of Leuven)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035467","GLP-1-RAs: risk of gall bladder and biliary disease",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90012-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035468","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-75234-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035469","GLP-1RA-related cancers identified in FAERS",null,"2026","Reactions Weekly","nonrandomized_study","article","10.1007/s40278-026-93393-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035470","Dapagliflozin/Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90173-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035471","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96287-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035472","DPP-4 inhibitors and GLP-1 receptor agonists: Difference between two drugs in pharmacological and clinical effects","Shinji Kamei","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035473","Efficacy and safety of sitagliptin in patients with type 2 diabetes mellitus:a meta-analysis","Wan Li-ya","2013",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","article"],["R0035474","Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73526-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035475","Dulaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-77134-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035476","Exenatide",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-0914-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035477","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93905-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035478","Albiglutide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-24301-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035479","Risk mitigation plan in effect for Roche's taspoglutide","&NA;","2010","Reactions Weekly","other","article","10.2165/00128415-201013070-00002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035480","Dulaglutide/prednisolone",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-17490-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035481","Dulaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-69427-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035482","Empagliflozin/metreleptin/semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74974-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035483","GLP-1 receptor agonist labelling updated with risk of pulmonary aspiration",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-70376-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035484","Once-weekly semaglutide increases risk of optic neuropathy",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-75291-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035485","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88562-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035486","Liraglutide",null,"2020","Reactions Weekly","other","article","10.1007/s40278-020-75620-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035487","Semaglutide/Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90487-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035488","GLP-1 receptor agonists for the treatment of type 2 diabetes","大祐 田中","2014","日本医師会雑誌","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035489","Insulin/liraglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-03093-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035490","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93727-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035491","Dulaglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-60980-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035492","Venomous drugs: Exenatide (Byetta)","James Mitchell Crow","2012","The New Scientist","other","article","10.1016/s0262-4079(12)61176-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035493","Dulaglutide/semaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-06112-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035494","Dulaglutide/insulin overdose/metformin",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-06499-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035495","Comparable CVD risks with GLP-1 agonists vs other antidiabetics",null,"2016","Reactions Weekly","other","article","10.1007/s40278-016-16872-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035496","Liraglutide/sodium-chloride",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-63732-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035497","Exenatide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-1346-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035498","The Role of GLP-1 Affects Fate of Astrocytes Following Ischemic Stroke in Mice","Hsuan-Yu Lu","2024","Physiology","preclinical","article","10.1152/physiol.2024.39.s1.508",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035499","GLP-1RAs increases risk of NAION compared with SGLT2 inhibitors",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94510-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035500","Exenatide","&NA;","2008","Reactions Weekly","other","article","10.2165/00128415-200812030-00071",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035501","Liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-9983-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035502","Intranasally administrated exendin-4, a glucagon-like peptide-1 receptor agonist, ameliorates circadian rhythm disruption induced by amyloid β-protein and possible mechanisms in mice","Qianqian Yu","2016","Chin J Neurol","preclinical","article","10.3760/cma.j.issn.1006-7876.2016.06.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035503","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-81874-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035504","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88559-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035505","Dulaglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-66198-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035506","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96002-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035507","GLP-1类似物Exendin-4对糖尿病肾病大鼠肾脏SOD、8-OHdG的影响","郝绍伯","2012","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035508","TERAPIAS BASEADAS EM PEPTÍDEOS NA MEDICINA MODERNA: APLICAÇÕES CLÍNICAS E DESAFIOS NA ESTABILIDADE E BIODISPONIBILIDADE – REVISÃO SISTEMÁTICA","Bruno Sander","2026","Revista Científica Ipedss","nonrandomized_study","article","10.55703/27644006060301",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035509","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-71203-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035510","Exendin-4对2型糖尿病大鼠主动脉内皮核因子-κB和细胞间黏附分子-1表达的影响","Wei Li","2009","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035511","GLP‐1受容体作動薬Exendin‐4はNK‐κBの阻害を介して乳癌増殖を抑制する","Chikayo Iwaya","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035512","GLP-1 and dual GIP/GLP-1 receptor agonists increase risk of aspiration",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-75669-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035513","利用BglBrick方法进行HSA/Exendin-4长效融合蛋白的快速组装","曲国龙 邵妤","2014",null,"other","article","10.13523/j.cb.20140410",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035514","Glucagon‐like peptide 1 receptor agonist-related DVT",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-82288-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035515","Semaglutide-related AEs in patients at risk of cardiovascular disorders",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-91628-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035516","GLP-1类似物对糖尿病心肌病大鼠心脏组织PPAR-α、ET-1表达的影响","侯敏","2012","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035517","Lixisenatide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-55363-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035518","Does continuing tirzepatide help prevent weight regain?","Devin Kearns","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002226",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035519","Dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92775-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035520","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94302-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035521","Dulaglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-57488-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035522","Glucose/steroids/tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90239-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035523","exendin-4预处理对大鼠心肌缺血/再灌注损伤的影响","鲁佳佳","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035524","Immunosuppressants/semaglutide/ursodeoxycholic-acid",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-58221-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035525","Unprescribed online semaglutide products falsified",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-64807-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035526","Liraglutide restores ??-cell responsiveness in type 2 diabetes","&NA;","2003","Inpharma Weekly","other","article","10.2165/00128413-200314000-00014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035527","糖尿病腎症4期の患者へのGLP-1受容体作動薬(GLP-1RA)使用の効果と注意点","本島寛之","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035528","Effects of liraglutide on PKC-β of kidney in insulin resistance rats induced by high-fat feeding","Minghao Wu","2016",null,"preclinical","article","10.3760/cma.j.issn.1001-7097.2016.06.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035529","Предикторы эффективности терапии агонистами рецепторов глюкагоноподобного пептида-1 у пациентов с сахарным диабетом 2 типа и ожирением","Тихоненко Екатерина Вячеславовна","2019","CyberLeninK (CyberLeninka)","other","article","10.14341/omet9584-7518",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035530","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96286-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035531","Liraglutide overdose",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-5370-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035532","Exenatideによる糖尿病ラットの認知機能の改善作用及びメカニズムに関する研究【JST・京大機械翻訳】","Li Fei","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035533","Generation of transgenic cucumbers with expression of a ten-tandem repeat long-acting GLP-1 analogue and their biological function on diabetic rats","Cui Wang","2009",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035534","Effect of glucagon-like peptide-1 receptor agonist exendin-4 on electrophysiology in myocardial infarction-heart failure rats and the mechanism","Jingjing Chen","2018",null,"preclinical","article","10.3760/cma.j.issn.1007-6638.2018.05.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035535","The effects of medications on body weight","Ying Li","2017","药物不良反应杂志","other","article","10.3760/cma.j.issn.1008-5734.2017.02.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035536","원저 : 장내분비 K-세포에서 인슐린-발현세포로의 분화","이에스더","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0035537","Semaglutide/tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-75639-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035538","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74752-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035539","Exenatide and sitagliptin appear to carry no higher risk of acute pancreatitis than metformin or glibenclamide [glyburide],","&NA;","2009","Reactions Weekly","other","article","10.2165/00128415-200912730-00009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035540","Exenatide looks attractive in UK setting","&NA;","2007","Inpharma Weekly","other","article","10.2165/00128413-200715880-00008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035541","Semaglutide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-11203-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035542","Prednisone/semaglutide/tacrolimus",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-75977-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035543","Exenatide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-35654-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035544","Liraglutide overdose",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-57811-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035545","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80221-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035546","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-87036-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035547","GLP-1RAs increase risk of chronic cough",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-91621-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035548","Exendin-4对抵抗素介导的βTC6细胞PDX-1表达损害及细胞凋亡的干预作用","郑少娟","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035549","Glucagon-like peptide-1 receptor agonists/Lithium",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95007-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035550","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-58499-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035551","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93572-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035552","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93164-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035553","Liraglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-97984-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035554","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-55799-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035555","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-72044-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035556","Albiglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88624-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035557","Dulaglutide/insulin",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-87811-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035558","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-89979-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035559","Diabetes Drugs Investigated","Bridget M. Kuehn","2013","JAMA","other","article","10.1001/jama.2013.4243",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035560","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92148-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035561","Semaglutide and liraglutide have differing gastrointestinal ADR profiles",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-09264-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035562","基础研究 Exendin-4对肿瘤坏死因子-α诱导的单核细胞趋化蛋白-1表达的影响","江颖娟","2013","南方医科大学学报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035563","Exenatide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-0670-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035564","Liraglutide/vildagliptin",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-0810-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035565","Semaglutide-related risk of ischaemic optic neuropathy",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-70117-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035566","Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73525-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035567","Aripiprazole/exenatide/sertraline",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-28887-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035568","DPP-4i, GLP-1RA and SGLT2i have differing autoimmune disease risks",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96309-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035569","Potential link between liraglutide use and thyroid cancer","&NA;","2011","Reactions Weekly","other","article","10.2165/00128415-201113560-00010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035570","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-87567-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035571","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-94895-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035572","Liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-1163-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035573","Calcium supplements/Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95906-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035574","Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-79284-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035575","Exenatide",null,"2016","Reactions Weekly","other","article","10.1007/s40278-016-23630-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035576","항당뇨 기능성 식품의 개발 전략","Sunmin Park","2007","식품과학과 산업 = Food science and industry","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035577","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-69992-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035578","Exenatide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-1910-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035579","GLP‐1受容体作動薬Exendin‐4の乳癌細胞増殖抑制効果の検討","Ota Chikayo","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035580","Exenatide safer than insulin glargine in T2DM","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816420-00028",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035581","Incretin mimetics: pancreatitis identified in daily clinical practice",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-7688-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035582","Gastric Estrogen I - Clinical Research","Yoshimitsu Kanai","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21619655",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0035583","Benefits of exenatide extend","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816440-00031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035584","Safety concerns about use of tirzepatide, particularly dosing errors",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90674-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035585","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-68756-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035586","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93889-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035587","Dulaglutide/semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72631-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035588","Long-term exenatide: do clinical findings translate to real life?","&NA;","2008","Inpharma Weekly","other","article","10.2165/00128413-200816420-00029",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035589","·国外药讯·未来重磅炸弹药物——Exendin-4","Huang Yu","2004","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035590","Tackling shortage of GLP-1 receptor agonists in EU",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-62500-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035591","시론 : Sodium-Glucose Cotransporter 2 Inhibitor의 안전성: 임상에서 고려해야 할 점","임수","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0035592","Liraglutide",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-26017-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035593","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-82249-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035594","Dulaglutide overdose",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-67192-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035595","Exenatide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-7702-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035596","Харчові втручання при надмірній масі тіла та ожирінні","Anastasia Sokolova","2022","Український медичний часопис","other","article","10.32471/umj.1680-3051.152.236646",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035597","GLP-1的N端修饰研究进展及其用于治疗II型糖尿病的应用前景（英文）","白晓辉","2015","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035598","제 2형 당뇨병 치료제의 개발 동향","이수현","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0035599","Exenatide","&NA;","2008","Reactions Weekly","other","article","10.2165/00128415-200812080-00047",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035600","Semaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-06709-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035601","Exendin-4对IL-1β诱导小鼠胰岛β细胞凋亡的保护作用","刘晓红","2012","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035602","Exenatide Attenuates Vascular Endothelial Dysfunction in Diabetes Mellitus Rats","Chun Xu","2011","Chinese Journal of Arteriosclerosis","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035603","Liraglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-54534-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035604","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95101-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035605","Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90298-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035606","Exenatide, in combination with metformin or a sulphonylurea, or both, may improve blood glucose control and reduce weight","&NA;","2005","Inpharma Weekly","other","article","10.2165/00128413-200514920-00042",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035607","Candesartan cilexetil/hydrochlorothiazide/exenatide","&NA;","2011","Reactions Weekly","other","article","10.2165/00128415-201113330-00040",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035608","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95686-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035609","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-95839-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035610","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-93903-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035611","Pharmacotherapy Of Type 2 Diabetes – The Future","A P Abhay","2006",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035612","Semaglutide-related optic nerve and retinal disorders",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-83301-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035613","Increased risk of pancreatic cancer with incretin-based therapy?",null,"2017","Reactions Weekly","other","article","10.1007/s40278-017-38941-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035614","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92149-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035615","Exenatide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-26524-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035616","Liraglutide/prednisolone",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-29040-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035617","Liraglutide reduces HbA1c and bodyweight in type 2 diabetes","&NA;","2005","Inpharma Weekly","other","article","10.2165/00128413-200515040-00016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035618","Liraglutide LEADing light for glycaemic control","&NA;","2007","Inpharma Weekly","other","article","10.2165/00128413-200715940-00011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035619","Empagliflozin/semaglutide drug interaction",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-05663-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035620","Exenatide/insulin glargine/lixisenatide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-68916-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035621","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-77365-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035622","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-74772-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035623","Liraglutide (victoza®): place d'un nouvel analogue du GLP-1 dans le traitement du diabète de type 2","Martin Buysschaert","2010","Louvain médical","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035624","Prednisone/semaglutide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-16208-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035625","ChemInform Abstract: Recent Progress and Future Options in the Development of GLP‐1 Receptor Agonists for the Treatment of Diabesity.","M. Lorenz","2013","ChemInform","other","article","10.1002/chin.201338263",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035626","Exenatide","&NA;","2008","Reactions Weekly","other","article","10.2165/00128415-200811890-00054",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035627","Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists","Dilek Tüzün","2022","Endocrinology research and practice.","other_trial","article","10.5152/tjem.2022.22003",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0035628","GLP-1 RA-related risk of NAION varies between drugs",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88126-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035629","Semaglutide-related eye disorders after oral and SC administration",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-82293-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035630","Liraglutide",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-3004-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035631","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92156-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035632","Liraglutide overdose",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-1175-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035633","Liraglutide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-0252-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035634","GLP-1受容体作動薬Exendin-4は閉塞性肺疾患モデルマウスの肺機能・肺気腫病態を悪化させる","野原寛文","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035635","Paradoxical Increase In Cubital Tunnel Syndrome Risk Among Glp-1 Agonist Users Despite Obesity As An Independent Risk Factor","Shelley Edwards","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20064784",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0035636","Semaglutide improves outcomes for patients with obesity and HS","Susanne Kämmerer","2024",null,"other","article","10.55788/2dc316f1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035637","GLP-1 Agonists Effects on Weight Loss in Those With and Without Diabetes","Comerford, Alyssa","2023","ValpoScholar (Valparaiso University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0035638","Protective effects of exenatide on RINm5f cell injury induced by palmitate","Liping An","2011",null,"preclinical","article","10.1109/hhbe.2011.6027948",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035639","Glp-1 Receptor Agonists Mitigate Lymphedema Risk Following Axillary Node Dissection And Lumpectomy","Berk Ozmen","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20079155",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0035640","Cardio-Renal-Metabolic connection – Do we have possibilities for solving this problem?","Andrew J. Krentz","2025",null,"other","article","10.46793/karnef25.190k",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035641","STEP-HFpEF: Semaglutide safe and efficacious in HFpEF plus obesity","Robert van den Heuvel","2023",null,"other","article","10.55788/0fb6234c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035642","Erster oraler GLP-1-Agonist zeigt gutes kardiovaskuläres Sicherheitsprofil","Peter Overbeck","2019","CardioVasc","other","article","10.1007/s15027-019-1587-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035643","METABOLIC SYNDROME: SECRETS AND CURRENT MANAGEMENT APPROACHES","Symak Z.","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21411825",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035644","PRAISE-HFrEF: Is it safe to use GLP1-receptor agonists in clinically severe HF?","Robert van den Heuvel","2025",null,"other","article","10.55788/196aefb4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035645","SGLT-2-Inhibitoren oder GLP-1-RA - wer hat die Nase vorn?","Miriam Sonnet","2024","Info Diabetologie","other","article","10.1007/s15034-024-4967-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035646","Simulated head-to-head comparison of SGLT-2 inhibitors and GLP-1R agonists in type 2 diabetes","Mihai Surducan","2024",null,"other","article","10.55788/6f940c73",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035647","Type 2 Diabetes Update: Semaglutide and Linagliptin as Basal Insulin Alternatives","CHRISTINE KILGORE","2020","Caring for the Ages","other","article","10.1016/j.carage.2020.05.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035648","Behandeling van diabetes mellitus type 2: exenatide wekelijkse versus twee keer daagse toediening","T. B. Y. Liem","2009","Medisch-Farmaceutische Mededelingen","other","article","10.1007/bf03079947",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035649","WARFARIN","Neil Shear","2010",null,"other","article","10.3109/9781841847665-226",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035650","Fast Exendin-4-induced weight independent changes in oxidative stress and lipid contents in insulin-sensitive organs in Obese Nondiabetic Zucker Rats","Colin, Idès","2013","Digital Access to Libraries","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035651","Nanomedicine-based Modulation of Parkinson's Disease Pathology Through Integrated Biological and Computational Approaches","Emma Hickey","2026","NSUWorks (Nova Southeastern University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035652","Binge-Eating Disorder (BED)","Jennifer L. Gaudiani","2025",null,"other","article","10.4324/9781003624523-14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035653","Liraglutide, a GLP‐1 Analogue to Treat Diabetes","Lotte Bjerre Knudsen","2010",null,"other","article","10.1002/9783527630035.ch14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0035654","OZEMPIC: UMA ALTERNATIVA PARA TRATAR A OBESIDADE NA ADOLESCÊNCIA","Janina Martins Costa","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17744286",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035655","AÇÕES HEPATOPROTETORAS DA TIRZEPATIDA: UMA REVISÃO DE LITERATURA","Danielle Carla Lopes dos Santos","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13824000",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035656","Conclusion","Marilyn Bromberg","2025",null,"other","article","10.4324/9781003678793-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035657","Exendin-4 Inhibits Palmitate-Induced Apoptosis of Human Cardiac Progenitor Cells","Leonardini A","2011","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035658","Dosimetry of exendin-4 based radiotracer for glucagonlike peptide-1 receptor imaging: an initial report","Monika Tomaszuk","2011","Journal of Physics Conference Series","other","article","10.1088/1742-6596/317/1/012011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035659","Diyabetin Farmakolojik Tedavisinde Güncel Yaklaşımlar","Şencay Yıldız Şahin","2022",null,"other","article","10.37609/akya.1707.c16230",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035660","Seronegative Inflammatory Necrotizing Myositis in a 57 year old Male with Concomitant Use of a GLP-1 Agonist and Colchicine","Russell, Joseph","2025","Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035661","Long-Term Injection-Free Subcutaneous Delivery of Exenatide via ITCA 650 Improves Compliance and Controls Glycemic Parameters and Weight","R. Buckely","2011","MD Conference Express","randomized_trial","article","10.1177/155989771108006",null,null,"ClinicalTrials.gov:NCT00943917","S001812","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0035662","GLP-1 Receptor Agonist Effect On Wound Healing In Breast Reduction Surgery","Nathan Booth","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20064021",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0035663","ORLISTAT","Neil Shear","2014",null,"other","article","10.1201/b15347-149",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035664","Diffenrential effects of weight loss by calorie restriction vs. exendin-4 on liver metabolism and eWAT inflammation.","S.C. Schriever","2019","PuSH - Publication Server of Helmholtz Zentrum München","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035665","DESIGN AND IN SILICO ANALYSIS OF GLP1R AGONISTS","Burak Kuzu","2023","Van Yüzüncü Yıl University Academic Data Management System","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035666","- Future developments in diabetes","Ian N. Scobie","2006",null,"other_trial","article","10.1201/b15304-15",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0035667","PROCESSO DE ADMISSÃO TEMPORÁRIA DE CARGA VIVA – MONSTRO-DE-GILA","Sanches, Agnes Bittencourt","2020","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14107689",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035668","Fertigpen erleichtert die Anwendung von Depot-Exenatide","Silke Wedekind","2015","MMW - Fortschritte der Medizin","other","article","10.1007/s15006-015-2835-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035669","„Ozempic-Gesicht“: Risiken und therapeutische Optionen","David Seidel","2026","Info Diabetologie","other","article","10.1007/s15034-025-5232-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035670","A-118 | Glucagon-Like Peptide-1 Receptor Agonists and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction and Mitral Regurgitation: A Real-World Analysis","Abdul-Rahaman Adedolapo Ottun","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104609",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0035671","Recent Data from LEAD","Daniel S. Gordon","2010","MD Conference Express","other","article","10.1177/155989771009004",null,null,"ClinicalTrials.gov:NCT00700817","S002361","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0035672","EXENATIDE","Neil Shear","2014",null,"other","article","10.1201/b15347-78",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035673","Drug Therapy: Current and Emerging Agents for Hyperglycaemia","Joe M. Chehade","2009",null,"other","article","10.1002/9780470744093.ch17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0035674","Poređenje potrošnje analoga glukagonu sličnog peptida 1 (GLP-1) u Srbiji i Finskoj, u periodu od 2018. do 2020. godine","Vuković, Milana","2022","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.13907598",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035675","Survodutide meets expectations in MASH","Federica Angius","2024",null,"other","article","10.55788/fffd7ccb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035676","STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes","Susanne Kämmerer","2024",null,"other","article","10.55788/226c4d86",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035677","Adherence and the contemporary approach to treating type 2 diabetes mellitus","Kolarš, Bela","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.10972897",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035678","Increasing the number of intestinal L cells—an alternative to GLP-1 therapy in type 2 diabetes mellitus?",null,"2015","Nature Reviews Endocrinology","other","article","10.1038/nrendo.2014.244",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035679","Unexplained INR instability following switch from injectable to oral Semaglutide: a case report","Girard, Aurore","2025","DIAL (Catholic University of Leuven)","case_report","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035680","COMPLICAÇÕES ABDOMINAIS ASSOCIADAS AO USO DE CANETAS EMAGRECEDORAS EM PACIENTES SUBMETIDOS À CIRURGIA DE URGÊNCIA","Afonso Leite Justino Pires","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20061509",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035681","Biochemical mechanisms and clinical efficacy of glucagon-like peptide-1 receptor agonists in metabolic regulation: a comprehensive review","Rawnaq Kadhim Salih","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.19911556",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035682","LEADER Study: Testing the Cardiovascular Safety of Liraglutide","M. Mosley","2013","MD Conference Express","other_trial","article","10.1177/155989771317011",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0035683","The �Ozempic Face� Effect: Shifts In U.s. Demand For Fillers And Contouring Procedures In The Glp-1 Era","Ainaz Dory Barkhordarzadeh","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20088414",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035684","PD-89 - Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity","Blundell, J","2016","White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035685","Critiquing fat oppression in the age of Wegovy","Rachel Fox","2023",null,"other","article","10.31076/2023.s1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035686","Expert Debate: Are All Diabetes Drugs Created Equal?","Alex Jacobson","2008","MD Conference Express","other","article","10.1177/155989770800800701",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035687","Questions 1–35","Sukhpreet Singh Dubb","2011",null,"other","article","10.1201/b13540-21",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035688","Liraglutide may improve post-ablation outcomes in obese patients with AF","Robert van den Heuvel","2024",null,"other","article","10.55788/e5dcacfb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035689","Albiglutide Superior to Sitagliptin and Glimepiride in T2DM","E. Hitt","2013","MD Conference Express","other_trial","article","10.1177/155989771317006",null,null,"ClinicalTrials.gov:NCT00838903","S001892","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0035690","Discovery and Development of Semaglutide","Yumeng Duan","2022","Proceedings of the 11th International Conference on Biomedical Engineering and Bioinformatics","other","article","10.5220/0011378500003443",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035691","ANÁLISE DA SEGURANÇA E EFEITOS DE UMA NOVA DROGA ANTIOBESIDADE: ORFORGLIPRON","Victor Filipe de Jesus dos Santos","2025",null,"other","article","10.29327/9786527213949.1018290",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035692","Semaglutide improves renal outcomes in overweight/obese participants with cardiovascular disease and no diabetes","Mihai Surducan","2024",null,"other","article","10.55788/5ad29264",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035693","Underlying and Extended Data for: Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials","Minahil Rasul","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21649808",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0035694","STRIDE: Semaglutide improves function, symptoms, and outcomes in patients with peripheral artery disease and type 2 diabetes","Robert van den Heuvel","2025",null,"other","article","10.55788/f7bf8d13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035695","Weight Loss and Nausea from Subcutaneous and Oral Semaglutide Accurately Simulated with a QSP Model","Zackary Kenz","2024",null,"other","article","10.70534/eegp5305",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035696","A Deep Reinforcement Learning (DRL) Agent for Optimizing Tirzepatide Dosing Schedules to Minimize Gastrointestinal Side Effects","Kumaran. R","2026",null,"nonrandomized_study","article","10.1109/raeeucci67649.2026.11504461",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0035697","Glucagon-like Peptide-1, Exendin and Insulin Sensitivity","Andrew A. Young","2013",null,"other","article","10.3109/9780203217412-18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035698","Adaptation of the Glucose, Glucagon, Gastric-Inhibitory Peptide, Glucagon-like Peptide-1, and Insulin (4GI) Model for Simulation of Acute Meal Challenges with Infused Antagonists","Theodore R. Rieger","2025",null,"other","article","10.70534/rwpo1208",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035699","Effects of semaglutide on MACE irrespective of HF status","Michiel Tent","2024",null,"other","article","10.55788/58ad6a61",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035700","Predictive factors of successful weight loss after liraglutide treatment for obesity","Pairon, Camille","2023","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035701","IMPACTOS E EFEITOS DO USO INDISCRIMINADO DE MEDICAMENTOS À BASE DE SEMAGLUTIDA (OZEMPIC E MOUNJARO) E SUAS CONSEQUÊNCIAS PARA A SAÚDE BUCAL: IMPLICAÇÕES DO USO OFF-LABEL","Renata Raquel Monteiro Arcoverde","2025",null,"other","article","10.51161/v-conbrasp/66759",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035702","Omega-3s Enhance GLP-1","Robert Fried","2025",null,"other","article","10.1201/9781003546894-59",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035703","Oral semaglutide reduces cardiovascular events in patients at high-risk with type 2 diabetes","Robert van den Heuvel","2025",null,"other","article","10.55788/8162e6c8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035704","The effect of exenatide treatment on serum ghrelin levels in patients with type 2 diabetes","Deniz Sigirli","2015","Bursa Uludag University - AVESIS","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035705","Self emulsifying nanoformulation of exendin-4: in vitro cellular uptake and insulin secretion studies on INS-1E cells","Nevin Çelebi","2024","Erciyes University - AVESIS","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035706","Use of Non-Insulin Antihyperglycemic Drugs in Relation to Pregnancy","Montserrat Balsells","2024",null,"other_trial","article","10.1201/9781003355939-31",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0035707","Effect of LY2189265, a long-acting glucagon-like peptide 1 analog, on metabolic outcomes and GI events in obese patients with uncontrolled type 2 diabetes mellitus (T2DM): The EGo study.","Guillermo E. Umpierrez","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33073-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035708","Repurposing GLP-1RA Drugs for Modulating Sepsis-Associated Encephalopathy and Neurodegeneration","Janhavi Tonge","2026","NSUWorks (Nova Southeastern University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035709","GLP-1 receptor agonists might reverse liver pathology in MASH","Robert van den Heuvel","2025",null,"other","article","10.55788/bb9c2c64",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035710","Switch from Basal Insulin to Ideglira: Why Hyperglycemia Does Not Occur at The Beginning of Ideglira Titration Despite The Great Amount Reduction of Dose from Basal Insulin? Case Report","Cristiano Roberto Grimaldi Barcellos","2018","International Journal of Nutrology","case_report","article","10.1055/s-0038-1675040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035711","RISCOS E IMPLICAÇÕES DO USO INDEVIDO DE OZEMPIC PARA EMAGRECIMENTO:IMPACTOS NA SAÚDE E NO PERFIL EPIDEMIOLÓGICO","M Santos","2025",null,"other","article","10.51161/iii-conasus/60857",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035712","Discovering anti-obesity oligopeptide from functional protein IDRs using AI-based computational pipeline","Baichuan Xiao","2025",null,"preclinical","article","10.1117/12.3095698",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035713","GLP-1 -- The New Darling of Diabetes Treatment","L. Gater","2006","MD Conference Express","other","article","10.1177/155989770600600202",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035714","Effectiveness of iGlarLixi (Insulin Glargine-Lixisenatide) in People with Type 2 Diabetes According to the Time of Administration through the Day","Haluzik, Martin","2022","UCL Discovery (University College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035715","Influence Of Glucagon-like Peptide-1 Receptor Agonists On Implant-based Breast Surgery Infection Risk","Yash Mehta","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20064500",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0035716","Neutral Results Obtained in the ELIXA Trial","M. Cunningham","2015","MD Conference Express","randomized_trial","article","10.1177/1559897715611120",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0035717","O USO INDISCRIMINADO DE OZEMPIC® PARA FINS DE EMAGRECIMENTO: OS RISCOS E CONSEQUÊNCIAS DA BUSCA PELO CORPO IDEAL","Samara Gonçalves Marx","2024",null,"other","article","10.29327/1449322.9-122",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035718","A Machine Learning Framework for Pathway-Driven Therapeutic Target Discovery in Metabolic Disorders","Iram Wajahat","2025","arXiv (Cornell University)","other","article","10.1109/fmlds67896.2025.00104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper; preprint"],["R0035719","How the many antidiabetic drugs work","Hugh McGavock","2017",null,"other","article","10.1201/9781315385020-24",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035720","Noninsulin Antidiabetic Agents: Typical and Atypical Effects","Dan Gordon","2010","MD Conference Express","other","article","10.1177/155989771009016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035721","P373 Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity","Hjerpsted, J","2017","White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035722","Development and Application of Methods for Separation of Carbohydrates by Hydrophilic Interaction Liquid Chromatography","Göran Karlsson","2011","Chromatographic science/Chromatographic science series","other","article","10.1201/b10609-22",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035723","New Treatments: Liraglutide","L. Gater","2006","MD Conference Express","other_trial","article","10.1177/155989770600600210",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0035724","Liraglutide Effects on Gallbladder Emptying: A Randomized Trial in Adults with Overweight or Obesity",null,"2018","International Journal of Nutrology","randomized_trial","article","10.1055/s-0038-1674813",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-paper"],["R0035725","GLORIOUS: GLP-1 agonist did not meet primary endpoint in CABG","Robert van den Heuvel","2025",null,"other","article","10.55788/da0df1ce",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035726","Achievement of Near-Normal HbA1c With Early Initiation of Oral Semaglutide: An Exploratory Subgroup Analysis of PIONEER 1","Ronald Goldenberg","2021","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2021.09.085",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035727","Nonalcoholic Fatty Liver Disease","Michael M., Michael J., RDN, CNSC, Lisa P. Rothkopf, Nusbaum, Haverstick","2014",null,"other","article","10.1201/b17616-12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035728","EFFECT OF EXENATIDE ON LIVER IN AN IRON OVERLOAD RAT MODEL","FARUK METİN ÇOMU","2015","AYBU AVESIS","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035729","FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease","Mihai Surducan","2024",null,"other_trial","article","10.55788/66f35841",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0035730","Insulinotropic and glucose lowering effects of small molecule GLP-1-receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline","Steven Patterson","2009","Research Portal (Queen's University Belfast)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035731","GIP/GLP-1-RA wirkt positiv auf HbA1c und Körpergewicht","Peter Stiefelhagen","2025","CME","other","article","10.1007/s11298-025-4404-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035732","Do privately insured patients receive new antidiabetic drugs earlier than patients insured under the statutory health insurance scheme? The case of glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors","Grimmsmann, Thomas","2023","German Medical Science (German Research Foundation)","other","article","10.3205/23gaa10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035733","Effects of dapagliflozin and liraglutide on metabolic control and cognition in high fat fed mice","Varun Pathak","2016","Research Portal (Queen's University Belfast)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035734","The effects of six months of treatment with exenatide for type 2 diabetes","Liesel M. FitzGerald","2011","Journal of Human Nutrition and Dietetics","nonrandomized_study","article","10.1111/j.1365-277x.2011.01175_9.x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035735","Liraglutide induces weight loss","Ezzie Hutchinson","2010","Nature Reviews Gastroenterology & Hepatology","other","article","10.1038/nrgastro.2009.228",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035736","Obez ve Aşırı Kilolu Hastalarda Diyabet Yönetimi","Hüseyin Soylu","2022",null,"other","article","10.37609/akya.1707.c16221",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035737","Liraglutide improves metabolic disturbances in antipsychotic-treated schizophrenia patients",null,"2017","The Brown University Psychopharmacology Update","other","article","10.1002/pu.30264",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035738","Large-Scale Stance Analysis of Public Discourse on Anti-Obesity Drugs Using Locally Deployed LLMs","Shengtian Huang","2025",null,"other","article","10.1145/3765612.3767770",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035739","Valutazione economica del trattamento con exenatide o sitagliptin di pazienti affetti da diabete tipo 2 in Italia","Roberto Ravasio","2011","Giornale Italiano di Health Technology Assessment","other","article","10.1007/bf03320738",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035740","Exploring the Value and Costs of Incretin-Based Therapies","Daniel O. Bittner","2014","MD Conference Express","other","article","10.1177/155989771432022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035741","High-Dimensional Trajectory Data Analysis of Molecular Dynamics Simulations: A Case Study in Domain-Specific Stabilization of GLP-1R Agonists","Minsung Ko","2025",null,"other","article","10.1109/rivf68649.2025.11365105",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035742","Regresión de una apnea obstructiva del sueño tras el uso de tirzepatide y pérdida de peso","Luis Carrascal García","2026",null,"other","article","10.48158/semg26-777",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035743","Analysis of Possible Ingredient and Manufacture Steps of Oral GLP-1 Receptor Agonists","Zhiyue Lin","2022","Proceedings of the 11th International Conference on Biomedical Engineering and Bioinformatics","other","article","10.5220/0011205700003443",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0035744","Investigating Efficacy of Nanomedicine for Novel Parkinson's Disease Therapeutics","Emma Hickey","2025","NSUWorks (Nova Southeastern University)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","conference-paper"],["R0035745","ACESSIBILIDADE AO OZEMPIC E O SEU IMPACTO NO CORPO SOCIAL: UMA REVISÃO INTEGRATIVA COM ANÁLISE QUALITATIVA","Clara Andressa de Souza","2026",null,"other","article","10.51161/iii-conasus/73090",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035746","Impact of Type 2 Diabetes Duration on Response to iGlarLixi vs. iGlar: A Subanalysis of LixiLan-L","Lawrence Blonde","2018","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2018.08.127",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035747","Pharmacogenomics Based Study for Liraglutide And Metfromin (PCOS Drugs) Efficacy In Populations Across The Globe","Aparna Chauhan","2021",null,"other","article","10.1109/icccnt51525.2021.9579679",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035748","Analisi di costo-efficacia di exenatide versus insulina glargine nel trattamento dei pazienti diabetici di tipo 2 in fallimento secondario al doppio ipoglicemizzante orale","Roberto Ravasio","2008","Giornale Italiano di Health Technology Assessment","other","article","10.1007/bf03320710",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035749","Anti-Diabetic Drugs","Awanish Kumar","2020","Diabetes","other","article","10.1201/9781003089391-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035750","Long-term management of hyperglycemia","David Leslie","2012","Diabetes","other","article","10.1201/b15227-15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035751","In vivo fluorescent imaging of β cell mass using a glucagon-like peptide-1 receptor (GLP-1R; GLP1R)-targeted exendin-4 analog",null,"2011","Science-Business eXchange","other","article","10.1038/scibx.2011.865",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035752","SCALE Diabetes: Continually Dosed Liraglutide May Aid Weight Loss in T2DM","Lynne Lederman","2014","MD Conference Express","other_trial","article","10.1177/155989771432013",null,null,"ClinicalTrials.gov:NCT01272232","S001792","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0035753","Effects of Diabetes on Fitness to Drive","Wulf Quester","2014",null,"other","article","10.1002/9781118570654.ch56",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0035754","SUMMIT: Tirzepatide reduces cardiovascular events in HFpEF plus obesity","Robert van den Heuvel","2025",null,"other","article","10.55788/d9fd7622",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035755","Exendin-4 Protects Beta-cells from Palmitate-induced Apoptosis by Reducing GPR40 Expression and Interfering with Activation of the MKK4/7-JNK Pathway","NATALICCHIO, ANNALISA","2011","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035756","GLP-1 agonists induce weight loss and alleviate headache in idiopathic intracranial hypertension","Michiel Tent","2023",null,"other","article","10.55788/380d2b76",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035757","Exenatide Increases Glucose Uptake in Brain Areas Involved in Glucose Homeostasis and Food Intake","Daniel Bittner","2014","MD Conference Express","other_trial","article","10.1177/155989771432012",null,null,"ClinicalTrials.gov:NCT01588418","S001239","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0035758","Diagnosis and Treatment","Awanish Kumar","2020","Diabetes","other","article","10.1201/9781003089391-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035759","Effets du Bydureon sur le contrôle glycémique et le poids : résultats préliminaires","Preumont, Vanessa","2015","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035760","WARFARIN","Neil Shear","2015",null,"other","article","10.1201/b17996-141",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035761","O USO OFF-LABEL DE OZEMPIC: SOLUÇÃO OU RISCO PARA A OBESIDADE?","Mateus prata Borges","2025",null,"other","article","10.51161/iv-conbrasp/52700",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035762","Session IA: Biology Presentation 3 - Beyond Weight Loss: The Effects of the GLP-1 Agonist, Semaglutide, on Weight Care, Type II Diabetes Management, and Cardiac Function in Obese Patients","Smith, Amber","2025","Digital Commons - Gardner-Webb University (Gardner–Webb University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035763","Concordance of synonyms and trade names with generic names","Neil Shear","2016",null,"other","article","10.1201/b20727-10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035764","Type 2 Diabetes","&NA;","2008","Home Healthcare Now","other","article","10.1097/01.nhh.0000324308.56212.38",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035765","Incretin Receptor Agonists: Pharmacovigilance Implications of Rational Molecular Design","Sidário Rodrigues Malheiros-junior","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.21612597",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0035766","The Efficacy of the GLP-1 Agonist Exenatide in the Treatment of Short Bowel Syndrome","Mark Pimentel","2007","The American Journal of Gastroenterology","other","article","10.14309/00000434-200709002-00233",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035767","Type 2 diabetes",null,"2012","Nursing Management","other","article","10.1097/01.numa.0000410740.51779.30",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035768","EFFECTS ON HOME BLOOD PRESSURE AND HEART RATE OF SEQUENTIALLY ADDING DULAGLUTIDE TO THERAPY IN PEOPLE WITH TYPE 2 DIABETES MELLITUS WHO HAD PREVIOUSLY BEEN RECEIVING EMPAGLIFLOZIN","Tatsuo Misawa","2018","Journal of Hypertension","other","article","10.1097/01.hjh.0000539524.19976.db",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0035769","Editors' Selections from Relevant Scientific Publications",null,"2024","Cancer Prevention Research","nonrandomized_study","article","10.1158/1940-6207.capr-17-3-hfl",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035770","GLP-1 Agoniste Liraglutide for Endocrine Pancreas Dysfunction After Pancreas Transplantation.","Diego Cantarovich","2014","Transplantation","other","article","10.1097/00007890-201407151-02934",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035771","Keeping up-to-date with diabetes care and education",null,"2018","Nursing","other","article","10.1097/01.nurse.0000546580.46691.e2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035772","2014 update",null,"2014","Nursing Management","other","article","10.1097/01.numa.0000443955.36139.0f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035773","Efeitos do Uso de Ozempic Visando o Emagrecimento: Uma Revisão de Literatura","Letícia Maia Oliveira","2025","AYA Editora eBooks","other","article","10.47573/aya.5379.3.2.20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0035774","Stimulating Beta Cell Replication and Improving Islet Graft Function by a GPR40 and GPR120 Dual Agonist","Jie Gao","2012","Transplantation","preclinical","article","10.1097/00007890-201211271-01095",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0035775","Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes","MA Nauck","2005","Practical Diabetes","other_trial","article","10.1002/pdi.801",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035776","Rybelsus (Semaglutide): Revolutionizing Type 2 Diabetes Therapy - A Systematic Review Of Clinical Evidence And Future Prospects","Harshitha G.*1, Surendra Vada2, P. Aswathy3, K. Keerthana4","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21671030",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0035777","Hypoglycaemic Agents and Risk of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease","Mario Cazzola","2026","Respirology","other","article","10.1002/resp.70293","42521255",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035778","Role Of Semaglutide in The Treatment of Obesity","Harshit kumar*, Rajesh Kumar, Ajeet Pal Singh, Amar Pal Singh, Gaurav Hastir","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21673207",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035779","Low-Dose Aripiprazole-Associated Sleepwalking in a Long-Term Zolpidem Treatment Patient With a Depressive Episode","Ching‐Wen Chu","2019","Journal of Clinical Psychopharmacology","other","article","10.1097/00004714-900000000-98617",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035780","2015 update",null,"2015","Nursing Management","other_trial","article","10.1097/01.numa.0000460000.10626.a4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035781","The gallbladder in diabetes","Rowan Hillson","2021","Practical Diabetes","randomized_trial","article","10.1002/pdi.2323",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035782","Infectious complications of newer agents in the fight against diabetes",null,"2020","The Nurse Practitioner","randomized_trial","article","10.1097/01.npr.0000722048.34837.83",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035783","Conference report","Andrew J. Krentz","2015","Cardiovascular Endocrinology","randomized_trial","article","10.1097/xce.0000000000000070",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035784","Editorial introductions","Yanagawa, Bobby","2020","Current Opinion in Cardiology","other_trial","article","10.1097/hco.0000000000000717",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","editorial"],["R0035785","B99-08 Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes","K -M Liao","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.6756",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035786","Type 2 Diabetes Drugs",null,"2015","Home Healthcare Now","other","article","10.1097/nhh.0000000000000268",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035787","UK government is preparing guidance to help with type 2 diabetes medication supply issues",null,"2022","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2022.1.159582",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035788","Conference report","Andrew J. Krentz","2014","Cardiovascular Endocrinology","randomized_trial","article","10.1097/xce.0000000000000041",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035789","183","Anil Gulati","2013","Critical Care Medicine","preclinical","article","10.1097/01.ccm.0000439332.51179.d6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035790","Effects of Glucagon-like Peptide-1 Receptor Agonists on Weight and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients","Hong Qiu","2013","Journal of Hubei University of Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035791","Uncovering Imperative Interventions in Prediabetes and Type 2 Diabetes",null,"2008","The Nurse Practitioner","other_trial","article","10.1097/01.npr.0000335127.29923.61",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035792","Diarrhoea and diabetes","Rowan Hillson","2018","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.2194",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035793","AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY","Nikolinka Koleva","2026","Journal of IMAB - Annual Proceeding (Scientific Papers)","nonrandomized_study","article","10.5272/jimab.2026322.6901",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0035794","B24-04 SGLT2 Inhibitors Are Associated With Decreased Risk of 30-Day Readmission in Diabetic Individuals Hospitalized for Acute Exacerbations of COPD: A Retrospective Cohort Analysis","D M Macdonald","2026","American Journal of Respiratory and Critical Care Medicine","randomized_trial","article","10.1093/ajrccm/aamag162.1763",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035795","The effect of nutrition and exercise in addition to hypoglycemic medications on HbA1C in patients with type 2 diabetes mellitus: a systematic review protocol","Ellen Dombrowski","2013","The JBI Database of Systematic Reviews and Implementation Reports","systematic_review","article","10.11124/jbisrir-2013-954",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0035796","European Association for the Study of Diabetes Annual Conference Explores Links Between Diabetes and Cancer","Andrew G. Renehan","2011","Oncology Times","nonrandomized_study","article","10.1097/01.cot.0000407714.17774.21",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035797","Glucose in the coronary care unit","David Carty","2014","Cardiovascular Endocrinology","randomized_trial","article","10.1097/xce.0000000000000034",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035798","Tailored Antidiabetic Therapy","Gerardo Sarno","2012","Transplantation","randomized_trial","article","10.1097/tp.0b013e318260b218",null,null,"ClinicalTrials.gov:NCT01002339; ClinicalTrials.gov:NCT01265537",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035799","New Drug for Type 2 Diabetes",null,"2014","AJN American Journal of Nursing","other","article","10.1097/01.naj.0000453036.85876.67",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035800","The Effect of Vitamin D Supplementation on Glycemic Control and Body Mass Index in the Obese, Vitamin D Deficient Adult with Type 2 Diabetes Mellitus: A Systematic Review Protocol","Laura Garza-Gongora","2013","The JBI Database of Systematic Reviews and Implementation Reports","systematic_review","article","10.11124/01938924-201311020-00006",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0035801","Eli Lilly’s Mounjaro in India: the race to shape a new market for obesity care","Thomason Rajan","2026","The CASE Journal","other_trial","article","10.1108/tcj-11-2025-0394",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035802","B Family Album","CARMEN DRAHL","2013","Chemical & Engineering News","other","article","10.1021/cen-09130-notw3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0035803","Combination of exenatide and insulin in type 2 diabetes: a retrospective case series observation","Mazhar Hussain","2010","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1432",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035804","PS 16-29 GLP-1 RECEPTOR AGONISTIC AND ANTIDIABETIC ACTIVITY OF MEFLOQUINE AGAINST STZ-NA INDUCED DIABETES IN ALBINO WISTAR RATS","Gaurav Kaithwas","2016","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0000501260.52383.7b",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0035805","CONCENTRATES",null,"2008","Chemical & Engineering News","other","article","10.1021/cen-v086n046.p026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0035806","Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes","Elaine M. Sinclair","2005","Current Opinion in Endocrinology & Diabetes","other","article","10.1097/01.med.0000155379.11926.e2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035807","Beyond the scale: understanding mechanisms of weight gain and obesity in diabetes","Allison B. Goldfine","2005","Current Opinion in Endocrinology & Diabetes","other","article","10.1097/01.med.0000158151.47287.95",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035808","Use of GLP-1 receptor agonists in patients with T2DM and chronic kidney disease",null,"2019","The Nurse Practitioner","other","article","10.1097/01.npr.0000554217.33610.f6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035809","Aerobic Interval Training Improve Effect of Liraglutide on Hepatic Lipid Steatosis in Diabetic Rats with NASH","Yuxiu He","2019","Medicine & Science in Sports & Exercise","preclinical","article","10.1249/01.mss.0000562640.45661.ac",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0035810","New drugs 2015, part 3",null,"2015","Nursing","other","article","10.1097/01.nurse.0000472118.27342.e2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035811","Metabolic Syndrome","Richard Salcido","2013","Advances in Skin & Wound Care","other","article","10.1097/01.asw.0000436696.111171.f3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035812","Clinical and Experiential Evaluation of Retatrutide for Advanced Weight and Neurobehavioral Optimization","Christopher Broomhead","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.18372551",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0035813","P2.14: Accelerating the Differentiation of Neonatal Porcine Pancreatic Cell Clusters Into Beta Cells in Alginate-Microcapsules","Heon‐Seok Park","2022","Transplantation","preclinical","article","10.1097/01.tp.0000888204.32080.88",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035814","GLP-1 mimetics: a potential panacea for type 2 diabetes?","George Thomson","2005","Practical Diabetes","other","article","10.1002/pdi.794",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035815","New Drugs 2011 Part 1",null,"2011","Nursing","other","article","10.1097/01.nurse.0000394082.38001.0f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035816","A Case of Exenatide-Induced Recurrent Pancreatitis Despite Withdrawl of Drug Therapy","Varun Jain","2014","The American Journal of Gastroenterology","case_report","article","10.14309/00000434-201410002-00977",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035817","Incretins and islet function","Bo Åhrén","2006","Current Opinion in Endocrinology & Diabetes","other","article","10.1097/01.med.0000216964.28881.ba",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035818","Inhibition of Dipeptidyl Peptidase-4 (DPP-4) - A Novel Approach to Treat Type 2 Diabetes","Bo Åhrén","2005","Current Enzyme Inhibition","other","article","10.2174/1573408052952667",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035819","Diabetes UK, March 2013, Manchester, UK","Andrew J. Krentz","2013","Cardiovascular Endocrinology","randomized_trial","article","10.1097/xce.0b013e328361ec9b",null,null,"ISRCTN:ISRCTN34875079",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035820","Drug updates and approvals",null,"2014","The Nurse Practitioner","other","article","10.1097/01.npr.0000457486.76207.aa",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035821","Use of Weight-Altering Diabetes Medications to Address Obesity as a Barrier to Kidney Transplant Evaluation in Patients with Type 2 Diabetes and Stage 4-5 CKD or ESKD","Kiran Chintam","2020","Journal of the American Society of Nephrology","other","article","10.1681/asn.20203110s1765a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0035822","All you need to read in the other general journals",null,"2012","BMJ","randomized_trial","article","10.1136/bmj.e4055",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035823","Влияние комбинации аутотрансплантации полнослойного кожного лоскута и лираглутида на сосудисто-тромбоцитарный механизм гемостаза у белых крыс с абсолютной инсулиновой недостаточностью","А. Н. Иванов","2025","Тромбоз гемостаз и реология","preclinical","article","10.25555/thr.2025.3.1155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035824","One size does not fit all",null,"2020","Nursing","other","article","10.1097/01.nurse.0000694908.15735.2e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035825","New Drugs 2019, part 1",null,"2019","Nursing","other","article","10.1097/01.nurse.0000553312.06244.76",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035826","New Drugs 2017, part 2",null,"2017","Nursing","other","article","10.1097/01.nurse.0000521052.60374.fd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035827","Drug updates and approvals",null,"2015","The Nurse Practitioner","other","article","10.1097/01.npr.0000475327.15281.9e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035828","196","Seema Briyal","2012","Critical Care Medicine","preclinical","article","10.1097/01.ccm.0000424416.67430.bc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035829","Evolutionary or revolutionary? The transformative role of glucagon-like peptide-1 agonists in type-2 diabetes management","Denise Bockwoldt","2018","Journal of the American Association of Nurse Practitioners","other","article","10.1097/jxx.0000000000000147",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035830","Drug News",null,"2022","Nursing","other","article","10.1097/01.nurse.0000872428.84874.9e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035831","P15.05: Safety of Once-Weekly Dulaglutide on Post-transplant Diabetes Mellitus: A Preliminary Single-Centre Experience","Alessandro Mattina","2022","Transplantation","nonrandomized_study","article","10.1097/01.tp.0000889588.86483.d4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0035832","What are the most effective medications for weight loss?","Jocele Skinner","2018","Evidence-Based Practice","other","article","10.1097/01.ebp.0000542033.64813.87",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035833","Medication Errors","Michael R. Cohen","2018","Nursing","other","article","10.1097/01.nurse.0000529821.41599.28",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035834","A Possible Anti-Obese Strategy for Kidney Transplant Recipients With Type 2 Diabetes After Successful Kidney Transplantation.","Tetsuhiko Sato","2014","Transplantation","other","article","10.1097/00007890-201407151-01753",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035835","Correction",null,"2006","Hepatology","preclinical","article","10.1002/hep.21288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0035836","Shop Talk",null,"2021","Oncology Times","other_trial","article","10.1097/01.cot.0000749972.41274.c6",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035837","Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review","Anabel Alvarez Mercado","2012","Recent Patents on Regenerative Medicine","narrative_review","article","10.2174/2210296511303010056",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035838","Rôles des analogues du glucagon-like peptide 1 dans l’arthrose : caractérisation des effets analgésiques, anti-inflammatoires et structuraux du liraglutide","C. Meurot","2022",null,"preclinical","article","10.70675/a3a95a66z221ez48f8za375za47ba9766b15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0035839","Dulaglutide inhibited perilipin 2-induced atrial fibrillation through the improvement of atrial impulse conduction slowing in transgenic mice","Nanae Ishida","2021","Proceedings for Annual Meeting of The Japanese Pharmacological Society","preclinical","article","10.1254/jpssuppl.94.0_3-p2-04",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035840","Glucagon-like Peptides, the Central Nervous System, and the Regulation of Energy Homeostasis","Julie A. Lovshin","2003","Central Nervous System Agents in Medicinal Chemistry","preclinical","article","10.2174/1568015033477866",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035841","Advances in pharmacotherapy of NASH","Durga Devi Surya Kumar Verma","2025","World Journal of Biology Pharmacy and Health Sciences","other","article","10.30574/wjbphs.2025.23.2.0767",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035842","A guerra do Ozempic: Dinamarca, Canadá, EUA, China e Brasil disputam o medicamento mais lucrativo do planeta","Carlos Oliveira","2025",null,"other","article","10.64628/ade.667t9nqmg",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0035843","GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP-1R) ANTAGONIST IMPAIRS BONE TURNOVER IN HYPERCALORIC DIET-INDUCED OBESITY","Paulo Flávio Silveira","2018","Proceedings for Annual Meeting of The Japanese Pharmacological Society","preclinical","article","10.1254/jpssuppl.wcp2018.0_po3-6-15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035844","Dulaglutide: A Review of a New Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus","Sarmad Said","2014","Medical Science Review","narrative_review","article","10.12659/msrev.893152",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035845","La terapia del diabete nel paziente nefropatico","Edoardo Mannucci","2015","Giornale di Techniche Nefrologiche e Dialitiche","other","article","10.5301/gtnd.2015.14823",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035846","822-P: The Harmine and Exendin4 Combination Markedly Expands Human Beta-Cell Mass In Vivo in Diabetic Mice","KARA A. BELIARD","2022","Diabetes","preclinical","article","10.2337/db22-822-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035847","'Beyond weight loss': what is the future of semaglutide?",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.321964",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035848","EMA tells countries to prioritise weight loss drugs for patients ‘with greatest need’",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.322393",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035849","A novel presentation of a His1157Arg INSR mutation in male half-siblings with type A insulin resistance: A case report","Kaci Wirthwein","2025","Gene & Protein in Disease","case_report","article","10.36922/gpd025200039",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035850","Expanding the Role of GLP-1 Receptor Agonists: Cardiovascular, Renal, and Metabolic Outcomes Beyond Glycemic Control","Nicole Graczyk","2026",null,"other","article","10.25148/fiuir.144",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0035851","Incretin-Based Therapies—Semaglutide, Tirzepatide, and Sitagliptin: Evaluating Pancreatitis Risk in Type 2 Diabetes Mellitus","Sui-Ling Perez","2026",null,"other","article","10.25148/fiuir.138",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0035852","GLP - 1 Analogs: Newer Molecules, Newer Uses","Sanjay Kalra","2009","Recent Patents on Endocrine Metabolic & Immune Drug Discovery","other","article","10.2174/187221409788452309",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035853","A Review on Pharmacological and Non-Pharmacological Therapy for the treatment of Obesity with Cardiovascular Diseases","Anuj Panchal","2024","Research Journal of Pharmacology and Pharmacodynamics","narrative_review","article","10.52711/2321-5836.2024.00020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035854","Multi Targeted Strategies Towards Identification of Potential Drug Candidates from Natural Products in the Management of Obesity","Baddireddi Subhadra Lakshmi","2018","Anti-obesity drug discovery and development","other","article","10.2174/9781681085586118040007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035855","Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients","Fábryová Ä ⁄ ubomíra","2015","Journal of Obesity & Weight loss Therapy","other","article","10.4172/2165-7904.1000277",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035856","Dipeptidyl Peptidase-IV Inhibitors: An Evolving Treatment for Type 2 Diabetes from the Incretin Concept","Yau‐Jan Chyan","2007","Recent Patents on Endocrine Metabolic & Immune Drug Discovery","other","article","10.2174/187221407779814570",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035857","The Current, Emerging and Future Medications for Type 2 Diabetes and Obesity","Hidesuke Kaji","2016","BENTHAM SCIENCE PUBLISHERS eBooks","other_trial","article","10.2174/9781681081854116020003",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0035858","Liraglutide-A Novel GLP-1 Analogue","Sanjay Kalra","2009","Recent Patents on Endocrine Metabolic & Immune Drug Discovery","other","article","10.2174/187221409789104719",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035859","Integrated Approaches to Obesity Management: Pharmacological Advances, Pandemic Challenges, and the Role of Shared Decision-Making","Mansi Srivastava","2025","medtigo Journal of Medicine","nonrandomized_study","article","10.63096/medtigo3061232",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0035860","Switching between weight-loss medications",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.389743",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035861","The GLP-1 system in the olfactory bulb mediates the regulation of pre- and post-prandial glucose homeostasis in health and obesity","Mireia Montaner Massana","2022",null,"preclinical","article","10.70675/c4760103zbac8z43c9z89f3z8298568aeb9a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0035862","Long-Term Observation of Improvement in Liver Fibrosis Index by A Glucagon-Like Peptide-1 Receptor Agonist in A Patient with Type 2 Diabetes: A Case Report","Akinori Tokito","2020","Archives of Clinical and Medical Case Reports","case_report","article","10.26502/acmcr.96550199",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035863","Incretin-Based Therapies in Patients with Type 2 Diabetes","Jeffrey S. Freeman","2010","Current Drug Therapy","other","article","10.2174/157488510791065094",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035864","The Protective Role of Liraglutide on Experimentally Induced Parkinsonism in the Substantia Nigra of Adult Male Albino Rats: Light and Electron Microscopic Study","Amira Bakr Mohamed Amara","2025","The Egyptian Journal of Histology","preclinical","article","10.21608/ejh.2025.413146.2312",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035865","Choroba stłuszczeniowa wątroby związana z zaburzeniami metabolicznymi — co warto wiedzieć?","Stanisław Surma","2025","Choroby Serca i Naczyń","other","article","10.5603/chsin.109819",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035866","Recent Advances in Anti-Obesity Agents","Min Kyung Kim","2018","Korean Journal of Medicine","other","article","10.3904/kjm.2018.93.6.501",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035867","Answering the 'call to action' on diabetes: tackling poor glycaemic control in a GP practice",null,"2022","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2022.1.152641",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035868","Current Pharmacological Approaches in Obesity Treatment","Nuno Borges","2020","Recent advances in obesity research","randomized_trial","article","10.2174/9789811442636120010011",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","book-chapter"],["R0035869","Weight-Centric Management of Type 2 Diabetes Mellitus","Lindsay Mandel","2018","Diabetes","nonrandomized_study","article","10.2337/db18-295-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035870","GLP-1 Receptor Agonists and Ocular Health: Benefits and Risks","Rickvir Sidhu","2025","Journal of the Foundations of Ophthalmology","other","article","10.48089/jfo7688336",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035871","10-OR: Combination Therapy with Anti-CD3 Antibody and Harmine plus Exendin-4 Enhances Remission from Recent-Onset Type 1 Diabetes.","Geming Lu","2022","Diabetes","preclinical","article","10.2337/db22-10-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035872","Liraglutide Therapy for Glycemic Control and Weight Reduction in Overweight and Obese Patients with Type 2 Diabetes at Sultan Qaboos University Hospital","A. Al Subhi","2025","Journal of Diabetes and Endocrine Practice","nonrandomized_study","article","10.1055/s-0045-1815641",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-paper"],["R0035873","Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes","Barnett Ah","2014","Internal Medicine Open Access","systematic_review","article","10.4172/2165-8048.s6-006",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0035874","GLP-1 Agonist Use in Familial Partial Lipodystrophy with PPARG Variant","Mariana Henry","2026","Journal of clinical lipidology","other","article","10.1016/j.jacl.2026.05.216",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035875","Interventions for Weight Management in Children and Adolescents",null,"2024","AAP Grand Rounds","randomized_trial","article","10.1542/gr.52-4-43",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035876","Excellent Blood Glucose Levels for 5 Years with Well Maintained Insulin Secretion by the Treatment Comprising a Once-Weekly Injection of Dulaglutide: GLP- 1RA Alone in a Patient with Type 2 Diabetes Mellitus","Seiho Nagafuchi","2023","Austin Journal of Endocrinology and Diabetes","other","article","10.26420/austinjendocrinoldiabetes.2023.1099",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035877","Commentary on Once-Weekly Semaglutide in Adults with Overweight or Obesity","Erica M. Garner","2021","Journal of Diabetes and Clinical Research","other_trial","article","10.33696/diabetes.3.044",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","editorial"],["R0035878","GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus","Ioannis Legakis","2007","Recent Patents on Endocrine Metabolic & Immune Drug Discovery","other","article","10.2174/187221407782409107",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035879","New anti-diabetic agents","Doo Man Kim","2017","Journal of Korean Medical Association","other_trial","article","10.5124/jkma.2017.60.12.992",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0035880","Reducing suboptimal prescribing of glucagon-like peptide mimetics in type 2 diabetes",null,"2018","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2018.20205541",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035881","Zawał serca u chorych na cukrzycę — nowości terapeutyczne","Anna Fojt","2022","Choroby Serca i Naczyń","other","article","10.5603/chsin.a2022.2002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035882","Will reshoring medicines manufacturing solve shortages in the UK?",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.336872",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035883","Exendin-4 and Its Derivatives for Diabetes and Obesity: Old Story and New Hope",null,"2016","BENTHAM SCIENCE PUBLISHERS eBooks","other","article","10.2174/9781681082479116030003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035884","Journal Review",null,"2008","Primary Care Cardiovascular Journal (PCCJ)","narrative_review","article","10.3132/pccj.2008.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035885","Advances in New Drugs for Diabetes Treatment: GLP-1 Mimetics and DPP-4 Inhibitors","Xianglan Sun","2016","BENTHAM SCIENCE PUBLISHERS eBooks","other","article","10.2174/9781681081854116020008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035886","Top ten features of 2025",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.390409",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035887","Dragging their feet: the cost of sub-optimal treatment for patients diagnosed with peripheral arterial disease","Gerry Stansby","2008","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2008.044",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035888","The LIPT-Study: On Risk Markers of Vascular Thrombosis in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Liraglutide","Signe Frossing Malin Nylander","2015","Journal of Obesity & Weight loss Therapy","randomized_trial","article","10.4172/2165-7904.1000254",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0035889","Plastic and Reconstructive Surgery Highlights: Plastic Surgery Focus","Albert H. Chao","2026","Plastic & Reconstructive Surgery","randomized_trial","article","10.1097/prs.0000000000012956","42340838",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035890","1743-P: Assessing Disparities in Diabetes Prevention and Obesity Pharmacotherapy Treatment Outcomes among Veterans—A Local Cohort Study","Diana Pinzón","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1743-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035891","New Drugs for Obesity Treatment","Won Jun Kim","2016","Korean Journal of Medicine","other_trial","article","10.3904/kjm.2016.90.2.121",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0035892","GLP-1 Receptor Agonists: A Comprehensive Analysis of Side Effects Beyond Weight Loss and Appetite Control","Brody Moazzeni Md","2026",null,"other","article","10.13140/rg.2.2.21013.69608",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035893","Pharmacologic Obesity Treatment - Emphasis on Efficacy and Cardiometabolic Markers","Fariha Salman","2019","Frontiers in clinical drug research. Diabetes and obesity","other","article","10.2174/9781681084459117040003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035894","Inhibiteur de Tpl2 et agoniste du récepteur GLP-1 : Une nouvelle combinaison thérapeutique prometteuse pour lutter contre le diabète de type 2 ?","Morgane Delobel","2021","theses.fr (ABES)","preclinical","article","10.70675/9b688c6czb805z459czb7b6zdc85a3fbd320",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0035895","The Role of Anti-Obesity Medications in Polycystic Ovary Syndrome","İlgın Türkçüoğlu","2018","Anti-obesity drug discovery and development","other","article","10.2174/9781681085586118040004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035896","A Review of Therapeutic Approaches and Pathogenesis of Diabetic Retinopathy","Shreya Singh","2024","Apple Academic Press eBooks","narrative_review","article","10.1201/9781003454021-20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035897","Liraglutide: Present and Future","D Cheţa","2014","BENTHAM SCIENCE PUBLISHERS eBooks","other_trial","article","10.2174/9781608058563114010005",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0035898","PM320 Multiorgan versus single organ atherosclerotic disease as a risk factor for cardiovascular events in patients with end-stage renal disease","Luís Henrique Wolff Gowdak","2014","Global Heart","other","article","10.1016/j.gheart.2014.03.1679",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0035899","Semaglutide effective for weight loss in non-diabetic adults, research suggests",null,"2021","Pharmaceutical journal/˜The œpharmaceutical journal","randomized_trial","article","10.1211/pj.2021.20208793",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035900","GLP-1 receptor agonist-related ischaemic optic neuropathy",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96642-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035901","Management of Diabetes Mellitus by Natural Products: Glucagon-like Peptide 1 Perspective","Ojaskumar D. Agrawal","2020","Phytotherapy in the management of diabetes and hypertension","other","article","10.2174/9789811459139120030006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035902","The Effects of GLP-1 Receptor Agonists on Endothelial Function: Do They Function Directly or Indirectly?","Masataka Kudo Akiko Saito","2013","Journal of Autacoids","other","article","10.4172/2161-0479.1000e121",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035903","Optimization of the bariatric treatment:Finding the right fit for every patient","Marijn Tessel Filomijne Jense","2026","Research Publications (Maastricht University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0035904","Research",null,"2026","Bone and Joint 360","other","article","10.1302/2048-0105.154.360352",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035905","UK’s biggest online pharmacy freezes Mounjaro price amid reports of 'stockpiling'",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.369942",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035906","GLP-1 RA Use in Children With Obesity or Type 2 Diabetes",null,"2026","AAP Grand Rounds","randomized_trial","article","10.1542/gr.55-1-04",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035907","Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies","Jeffrey S. Freeman","2015","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035908","Economic analysis of Lixisenatide in Diabetes Mellitus Type 2","А. С. Колбин","2018","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035909","Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control","La Salle J","2022","Journal of Family Medicine","other","article","10.26420/jfammed.2022.1321",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035910","EMA safety committee to review link between semaglutide and rare eye condition",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","nonrandomized_study","article","10.1211/pj.2025.1.344423",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035911","Effects of SGLT2 inhibition and GLP-1 receptor agonism on the regulation of food intake and body weight: illuminating the role of the brain","van Ruiten, Charlotte Constance","2022","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0035912","Interplay Between Bile Acid and GLP-1 Receptor Agonist Signaling Informs the Design of Drugs to Combat Obesity and its Metabolic Complications","Jessica Felton","2019","Frontiers in clinical drug research. Diabetes and obesity","other","article","10.2174/9781681084459119040004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035913","Evolocumab/Inclisiran/Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72654-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035914","Therapies Using Anti-diabetics to Prevent and Manage Progression of Parkinson's Disease","Monalisa Rout","2024","Current Drug Therapy","nonrandomized_study","article","10.2174/0115748855332557240820054810",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035915","Endocrinology, Diabetes, and Metabolic Disorders","Dr. Partha Pratim Adak","2026",null,"randomized_trial","article","10.66715/cerebral/2026.edmd",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","dissertation"],["R0035916","Medicamentos antidiabéticos no indivíduo com obesidade e o impacto na função muscular","Aline Job de Carvalho","2024","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0035917","Abstract: Perioperative Anesthetic Outcomes and Holding Practices in Patients Using GLP-1 Receptor Agonists: A Retrospective Cohort Study.","Sara Marroquin","2026","PubMed","nonrandomized_study","article",null,"42525985",null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-abstract"],["R0035918","GLP-1 analogues and prostate cancer incidence: A systematic review and meta-analysis.","Selena Gong","2025","Journal of Clinical Oncology","systematic_review","article","10.1200/jco.2025.43.5_suppl.374",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0035919","INVESTIGATING ENTEROENDOCRINE HORMONE LEVELS IN CHRONIC DIARRHOEA AND OBESITY","Chris Bannon","2025","Apollo (University of Cambridge)","randomized_trial","article","10.17863/cam.130523",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0035920","Enhanced expression of PDX-1 and Ngn3 by exendin-4 during beta cell regeneration in STZ-treated mice","Kodama, S","2016","Tokyo Tech Research Repository (Tokyo Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035921","Choices, Choices … Basal Insulin vs. GLP-1RA?","E. Svelund","2014","DigitalCommons-Cedarville (Cedarville University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035922","Everything you need to know about GLP-1s for weight loss",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.397613",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035923","The Effect of Diabetic Medicine Exendin-4 on Lipopolysaccharide-induced Bone Resorption, Osteoclast Formation, and Orthodontic Tooth Movement","威任 沈","2021","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0035924","Anti-Diabetic Drugs in Cardiovascular Disease","Se-Eun Kim","2021","Korean Journal of Medicine","randomized_trial","article","10.3904/kjm.2021.96.2.85",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0035925","A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients","Eyk, H.J. van","2019","Leiden Repository (Leiden University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0035926","Oral Semaglutide (Rybelsus) vs. Subcutaneous Liraglutide and Placebo in Type 2 Diabetes","Ayanjoke, Emmanuel","2019","DigitalCommons-Cedarville (Cedarville University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035927","GLP-1 RA Therapy in T2DM: Implementing a New Standard of Care","Christiansen, Mark P.","2019","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035928","The European perspective","Richard J. Hobbs","2008","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2008.018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035929","FIBRILLATION OF THERAPEUTIC PEPTIDES","Renawala, Harshil K","2022","Purdue","other","article","10.25394/pgs.19653399",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0035930","How Low Can We Go: Evaluation of a Pharmacist-led Weight Loss Management Program","Kelly Rubi","2024","Nursing & Health Sciences Research Journal","nonrandomized_study","article","10.55481/2578-3750.1195",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0035931","Effect of Lipids and Obesity on Blood Glucose Level: The Connection Between Obesity and Diabetes-A Review","Soliman Mohammed Alchaidib","2025","Egyptian Journal of Chemistry","narrative_review","article","10.21608/ejchem.2025.395260.11921",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035932","Secondary Agents as Add-On Therapy to Metformin in Type 2 Diabetes Mellitus: A Quality Improvement Study","Emily J. Fox","2018","Digital Commons @ Butler University (Butler University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0035933","Knee",null,"2026","Bone and Joint 360","randomized_trial","article","10.1302/2048-0105.154.360356",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0035934","The unregulated semaglutide prescribing circus",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.327278",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035935","Enhanced expression of PDX-1 and Ngn3 by exendin-4 during beta cell regeneration in STZ-treated mice","昭苑 粂","2005","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035936","GLP-1 receptor agonist-related severe acute pancreatitis",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96643-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035937","The Promise of Diabetes Technology in Population Health Management","Hawkins, MD, Kara","2024","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035938","Exenatide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-63721-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035939","Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model","Narushima D.; Kawasaki Y.; Takamatsu S.; Yamada H.",null,"Institutional Repositories DataBase (IRDB)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0035940","Glucagon-like Peptide Receptor Agonists: A Review of Glycemic Benefits and Beyond","LaDonna B Clark","2021","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035941","GLP-1 receptor agonists increase risk of alopecia",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96648-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035942","Semaglutide Injection for Weight Reduction in Non-Diabetic Adults with Overweight and Obesity","Velazquez Hernandez, Maite","2025","JMU Scholoraly Commons (James Madison University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0035943","Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies",null,null,"RECERCAT (Consorci de Serveis Universitaris de Catalunya)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035944","Semaglutide benefits heart health regardless of weight lost",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other_trial","article","10.1211/pj.2025.1.381190",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035945","Protective effects of GLP-1 receptor agonists on TNFα-induced apoptosis in INS-1 beta cells.","NATALICCHIO, ANNALISA","2007","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035946","Mapping the Diabetes Comorbidome: A New Frontier in Personalised Medicine","Abhishek Pachauri","2025","Preventive Medicine Research & Reviews","nonrandomized_study","article","10.4103/pmrr.pmrr_39_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0035947","Six-month total weight loss after sleeve gastrectomy versus roux-en-y gastric bypass and the adjunctive effect of glp-1 receptor agonists: A retrospective cohort study","Oksana Janik Lozano Ramírez M.D.","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.21763156",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0035948","Evaluating the Role of Anti-Obesity Medications in Modifying Risks of Visual and CSF Complications in Idiopathic Intracranial Hypertension","Arman Saeedi","2025","Journal of Neurological Surgery Part B Skull Base","nonrandomized_study","article","10.1055/s-0045-1803092",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0035949","Effect of once-weekly Dulaglutide by baseline β-cell function in the AWARD program","Chantal Mathieu","2017","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0037-1601749",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035950","Typ-2-Diabetes: GLP-1-basierte Therapie in der Praxis - Was hat der Patient davon?","Marcel Kaiser","2012","Diabetes aktuell","other","article","10.1055/s-0032-1313923",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035951","Wirksamkeit und Verträglichkeit von wöchentlichem Depot-Exenatide über 3 Jahre: Eine gepoolte Analyse von 3 Studien","Marcel Trautmann","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580879",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035952","A multi-center clinical study of liraglutide in the therapy of Chinese patients with type 2 diabetes","Ping Feng","2012","Intern J Endocrinol Metab","other_trial","article","10.3760/cma.j.issn.1673-4157.2012.04.001",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035953","Deutschland - ein Diabetesland - Byetta® - eine Alternative bei Typ-2-Diabetes vor der Insulintherapie",null,"2007","Diabetes aktuell","other","article","10.1055/s-2007-985315",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035954","Perioperatives Aspirationsrisiko bei GLP-1-Rezeptorantagonisten – weiterer Schritt zur Klarheit",null,"2025","Journal Club AINS","other","article","10.1055/a-2708-3876",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035955","Erstes Inkretin-Mimetikum für Typ-2-Diabetiker - Exenatide: Die neue Alternative vor der Insulintherapie",null,"2007","Notfall & Hausarztmedizin (Notfallmedizin)","other","article","10.1055/s-2007-985015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035956","Unlocking the Potential of Microfluidic Assisted Formulation of Exenatide-Loaded Solid Lipid Nanoparticles","Büşra Arpaç","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5202126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0035957","Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88408-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035958","Auch 10 Tage nach Absetzen von Semaglutid noch präoperativ vermehrter Mageninhalt",null,"2025","Journal Club AINS","other","article","10.1055/a-2570-6249",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035959","Kommentar",null,"2019","Diabetologie und Stoffwechsel","other","article","10.1055/a-0979-8061",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035960","Jetzt verfügbar - Inkretin-Mimetikum für Typ-2-Diabetiker",null,"2007","Diabetes aktuell","other","article","10.1055/s-2007-985304",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035961","Das metabolische Syndrom – eine (neue) Frauenkrankheit?","Stefan Diederich","2011","Geburtshilfe und Frauenheilkunde","other","article","10.1055/s-0031-1295373",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035962","Endoscopic Sleeve Gastroplasty Versus Oral Semaglutide for Obesity: A Real-World Comparative Study","N Jagtap","2026","Endoscopy","nonrandomized_study","article","10.1055/s-0046-1820792",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035963","Emerging Role Of Dulaglutide In Parkinson's Disease: Neuroprotective Mechanisms And Therapeutic Advances","Renuka Sahu, Dipesh Kumar, Naveen Kumar, Indumati Thakare, Madhuri Baghel, Hari Prasad Sonwani*","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21773767",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035964","8. Stuttgarter Nephrologisches Seminar","Bettina Albers","2016","Dialyse aktuell","other","article","10.1055/s-0042-121405",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0035965","Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) behandeltem Typ-2-Diabetes: explorative Analyse der SoliMix-Studie nach Alter, Diabetesdauer und Nierenfunktion zu Studienbeginn","Philip Home","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1768001",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE",null,null,"FALSE","article"],["R0035966","Innovative Behandlungskonzepte des Typ–2–Diabetes – Optimierung der Blutzuckereinstellung und Reduktion des kardiovaskulären Risikos","Matthias Blüher","2008","Der Klinikarzt","other","article","10.1055/s-0028-1119362",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035967","Typ-2-Diabetes - Stellenwert der GLP-1-Agonisten",null,"2010","Diabetes aktuell","other","article","10.1055/s-0029-1245047",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035968","VCD Spectroscopic Analysis of the Exendin-4 Truncated Analog TC5b","Jeffrey Copps","2010",null,"other","article","10.1007/978-0-387-26575-9_314",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035969","Therapie des Typ-2-Diabetes mit Liraglutid - Physiologische Blutzuckersenkung mit nur geringer Hypoglykämiegefahr",null,"2009","Diabetes aktuell","other","article","10.1055/s-0029-1237496",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035970","Effects of GLP-1 receptor agonists on insulin sensitivity","Rendong Zheng","2012","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2012.05.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035971","Human glucagon-like peptide-1 analogue-Liraglutide","Ping Feng","2008","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2008.06.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035972","Effects of GLP-1 and GLP-1 analogue on function and mass of β cell in type 2 diabetes mellitus","Haoming Tian","2009","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2009.05.002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035973","Liraglutide",null,"2014","Reactions Weekly","other","article","10.1007/s40278-014-5141-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035974","GLP-1 Agonisten erhöhen die Insulinwirkung in der humanen Leberzelllinie HepG2","B Knebel","2013","Diabetologie und Stoffwechsel","other","article","10.1055/s-0033-1341869",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035975","Liraglutide verbessert als ergänzende Therapie zur ICT mit Insulinpumpe die Blutzuckerkontrolle bei Typ 1 Diabetes (Fallbericht)","HE Sarnighausen","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1253859",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035976","Dauerhafte Glukosekontrolle - Inkretinmimetikum hält dem Vergleich mit Insulin stand",null,"2006","Der Klinikarzt","other","article","10.1055/s-2006-954429",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035977","Real-World-Wirkungen von Dulaglutide bei Patienten, betreut in Diabetologischen Schwerpunktpraxen","Rüdiger Göke","2017","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0042-124422",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035978","Comparative Cardiovascular Benefits of Semaglutide Versus Tirzepatide in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Zhou Xiao-yu","2025","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.5359752",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0035979","Erstes Inkretinmimetikum zugelassen",null,"2006","Der Klinikarzt","other","article","10.1055/s-2006-959058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035980","Medicaid Coverage of GLP-1 Receptor Agonists for Obesity: A Comprehensive Framework for Evidence-Based Policy Reform","Audrey Walter-Evans","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5792002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0035981","Innovative Behandlungskonzepte des Typ–2–Diabetes – Optimierung der Blutzuckereinstellung und Reduktion des kardiovaskulären Risikos","Matthias Blüher","2009","Diabetes aktuell","other","article","10.1055/s-0029-1208372",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035982","The Replacement of Phe28 by Ser Enhances the Stability of the GLP-1 Analog During Fermentation","Pengyan Li","2015","Lecture notes in electrical engineering","other","article","10.1007/978-3-662-46318-5_37",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035983","Insulin-Glargin/Lixisenatid senkt HbA1c deutlich ohne Gewichtsanstieg",null,"2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-102205",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035984","Prandiale GLP-1-basierte Therapie des Typ-2-Diabetes: Ein Fall aus der Praxis – Gute Blutzuckerwerte und begleitende Gewichtsreduktion",null,"2011","Diabetes aktuell","other","article","10.1055/s-0031-1280694",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035985","Senkung des Körperfetts - Neues GLP-1-Analogon hat günstigen Einfluss",null,"2008","Diabetes aktuell","other","article","10.1055/s-0028-1085042",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035986","A biased GLP-1/GIP/glucagon receptor tri-agonist demonstrates robust glycemic control and significant weight reduction","Xiaoyi Sun","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5712585",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0035987","Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) behandeltem Typ-2-Diabetes: explorative Analyse der SoliMix-Studie nach HbA1c, Insulindosis und BMI zu Studienbeginn","Philip Home","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1767994",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE",null,null,"FALSE","article"],["R0035988","Beneficial effects of liraglutide on carotid intima-media thickness in patients with type 2 diabetes: a 8-month prospective study","AM Patti","2013","Ultraschall in der Medizin - European Journal of Ultrasound","other","article","10.1055/s-0033-1354820",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035989","Clinical characteristics, treatment patterns and persistence in patients with T2D initiating a Glucagon-like-peptide 1 receptor agonists (GLP-1 RA): a retrospective analysis of the Diabetes Prospective Follow-Up (DPV) registry","Hyun-Ju Jung","2021","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0041-1727302",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0035990","Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes","Julio Rosenstock","2025","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0045-1807441",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0035991","Behandlung der arteriellen Hypertonie bei CKD","Gideon J. L. Schäfer","2026","Nephrologie aktuell","other","article","10.1055/a-2749-2368",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035992","Incretin-based therapies linked to pancreatic cancer?",null,"2016","Reactions Weekly","other","article","10.1007/s40278-016-22586-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035993","Hypotension in Patients on GLP-1 RAs: An Emerging Clinical Observation","Emily Eiswirth","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5749649",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0035994","Obesity and Its Treatment in Type 2 Diabetes","Frank L. Greenway","2008","Contemporary Endocrinology","other","article","10.1007/978-1-60327-043-4_20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0035995","Endoscopic Ultrasound-Guided Delivery of Single-Dose Glucagon-like Peptide-1 Pancreatic Gene Therapy: Feasibility and Safety in a Porcine Model","J Bergman","2026","Endoscopy","other_trial","article","10.1055/s-0046-1820877",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0035996","Pharmakologische Ansätze der Adipositastherapie","KM Derwahl","2008","Aktuelle Ernährungsmedizin","other","article","10.1055/s-2007-986324",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035997","Inkretin-Mimetika bei Diabetes mellitus Typ 2 – Liraglutid verbessert kardiovaskuläre Prognose bei Hochrisikopatienten",null,"2016","Aktuelle Kardiologie","other","article","10.1055/s-0042-117037",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0035998","Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany","Markus Menzen","2022","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0042-1746340",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0035999","Glycemic fluctuation: a new target in the treatment of diabetes","Yi Kang","2009","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2009.03.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036000","Ersatz der langfristigen kontinuierlichen subkutanen Insulininfusion (CSII) bei Type 2 Diabetikern durch Insulin Degludec und Liraglutide (IDegLira) einmal täglich hat meistens eine verbesserte Stoffwechsellage zur Folge","Rudolf Chlup","2021","Diabetologie und Stoffwechsel","other","article","10.1055/s-0041-1727323",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036001","Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes","Lourenço, Inês Mariana Pereira","2025","Open Repository of the University of Porto (University of Porto)","other","article","10.34626/0bj8-pd44",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036002","Bilateral Peroneal Neuropathy Associated with Semaglutide Related Rapid Weight Loss: A Case Report (P10-11.019)","Dhaval Desai","2025","Neurology","case_report","article","10.1212/wnl.0000000000211255",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036003","Indirect comparisons (ICs) of once weekly dulaglutide (DU) plus metformin (MET) versus sulphonylureas (SU) plus MET in patients with type 2 diabetes (T2D) from AWARD-5","J Baeumler","2015","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0035-1549664",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0036004","Two new polyhydroxylated compounds from the fungus Malbranchea circinata with α-glucosidase inhibitory properties","Abraham Madariaga‐Mazón","2016","Planta Medica","preclinical","article","10.1055/s-0036-1596665",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036005","Update on the cardiovascular protective effects of glucagon-like peptide-1 receptor agonists","Rendong Zheng","2012","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2012.04.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036006","Advancements in GLP-1 Receptor Agonists for Treating Eating Disorders - Advancements in GLP-1 Receptor Agonists for Treating Eating Disorders: Mechanisms, Clinical Successes, Genetic Insights, and Broader Economic and Public Health Impacts","Audrey Walter-Evans","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5964739",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036007","Efficacy and safety of once-weekly dulaglutide versus insulin glargine, both with prandial insulin lispro (+/- metformin), in an AWARD-4 subpopulation of patients with type 2 diabetes (T2D) and baseline HbA1c (≥7.5% and ≤11%) above the German recommended HbA1c treatment target range","Elke Heitmann","2015","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0035-1549548",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0036008","Gute Therapie des Diabetes - Die Patienten dort abholen, wo sie stehen",null,"2008","Diabetes aktuell","other","article","10.1055/s-2008-1082343",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036009","Characterization of people achieving different weight reduction categories with tirzepatide","Reshmi Srinath","2024","Diabetologie und Stoffwechsel","other","article","10.1055/s-0044-1785386",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036010","\"CANETAS EMAGRECEDORAS\": MEDICALIZAÇÃO DO CORPO E DESIGUALDADES NO ACESSO A TERAPIAS PARA OBESIDADE","Maurício Gabriel Barros Perote","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21778511",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0036011","TARGET TRIAL EMULATION FOR COMPARATIVE SAFETY OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST USE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN REAL-WORLD CLINICAL PRACTICE","Hafizan Yusuf","2026",null,"nonrandomized_study","article","10.23860/thesis-2699",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","dissertation"],["R0036012","Sicherheitsupdate der FDA - Exenatid kann Nierenprobleme verursachenl",null,"2010","Dialyse aktuell","other","article","10.1055/s-0029-1245031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036013","Treatment utilization patterns and characteristics of individuals using tirzepatide for type 2 diabetes in Germany","M Füchtenbusch","2025","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0045-1807432",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0036014","Schlüsselpeptid im Glukosemetabolismus - Neues Therapieprinzip ahmt Funktion des Inkretins GLP-1 nach",null,"2006","Notfall & Hausarztmedizin (Notfallmedizin)","other","article","10.1055/s-2006-951417",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036015","71. Jahrestagung der American Diabetes Association – Neue Therapien bei Typ-2-Diabetes",null,"2011","Diabetes aktuell","other","article","10.1055/s-0031-1286685",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036016","Semaglutide Improves Cognitive Function and Neuroinflammation in APP/PS1 Transgenic Mice by Inhibiting TLR4/NF-κB Pathway","Yanyu Zhai","2024","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4680913",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036017","Basalinsulin-Therapie bei Typ 2-Diabetes: Welche Patientencharakteristika entscheiden über Erfolg bzw. die Notwendigkeit zu einer weiteren Therapie-Intensivierung?","Claus Buchholz","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580881",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036018","Impact of Glp-1 Receptor Agonists on the Incidence of Inflammatory Bowel Disease in People with Type 2 Diabetes","Fu‐Shun Yen","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.4986319",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036019","Glucagon-like Peptide-1 Receptor Agonists","Ja Young Jeon","2021","Stroke revisited","other","article","10.1007/978-981-16-5123-6_14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0036020","Effects of hypoglycemic drugs on osteoporosis in diabetic patients","Qinfeng Zhang","2011","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2011.05.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036021","Gewichtssenkung in der Kombination des prandialen GLP-1RA Lixisenatid mit Basalinsulin","M Simonsohn","2013","Diabetologie und Stoffwechsel","other","article","10.1055/s-0033-1341815",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036022","Pharmakokinetisches Modell von Liraglutid, einem humanen GLP-1 Analogon zur einmal täglichen Gabe bei Gesunden und im Vergleich zu Exenatide","Derek J. Jonker","2008","Diabetologie und Stoffwechsel","other","article","10.1055/s-2008-1076372",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036023","Evaluation and Comparison of Efficacy and Safety of SGLT-2 Inhibitors, DPP-4 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease: A Bayesian Network Meta-Analysis","Rui Zhang","2025","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.5213389",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0036024","Kommentar",null,"2021","Diabetologie und Stoffwechsel","other","article","10.1055/a-1464-9515",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036025","Exenatide Risk","Bridget M. Kuehn","2008","JAMA","other","article","10.1001/jama.300.12.1403-c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036026","Variabilität der täglichen Blutglukoseverläufe unter wöchentlichem Depot-Exenatide versus Basalinsulin in drei randomisierten, kontrollierten klinischen Studien","M Trautmann","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549677",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036027","Current status and challenge for the treatment of type 2 diabetes——emerging area of glucagon-like peptide-1 based therapies","Juming Lu","2009","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2009.03.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036028","Sustained Weight Loss with Semaglutide once-weekly in Patients without Type 2 Diabetes and Postbariatric Treatment Failure","Anne Lautenbach","2023","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0043-1767984",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0036029","Discovery and Structural Optimization of High Affinity Co- Agonists at the Glucagon and GLP-1 Receptors","Vasily M. Gelfanov","2010",null,"other","article","10.1007/978-0-387-26575-9_334",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0036030","Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction – experience from Dubrava University Hospital","Jasmina Ćatić","2022","Cardiologia Croatica","nonrandomized_study","article","10.15836/ccar2022.217",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0036031","Meta Analysis of FDA Approved Weight Loss Drugs in Obesity","Jessy Jayakumar1, Chandini2, Marka Sheshi3, Srujana Rani Kasoju4,Talla Sairam Goud5","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21771494",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036032","Accelerated Lipolysis-Induced Carbonyl Stress: The Liver-Dermis Axis and Methylglyoxal Accumulation as the Molecular Etiology of Incretin-Associated Facial Aging (\"Ozempic Face\")","MACIEL","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21781792",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036033","Behandlungsziele vereinbaren – 3 Jahre Therapieerfahrung mit Exenatid",null,"2010","Diabetes aktuell","other","article","10.1055/s-0030-1255363",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036034","Medikamentöse Adipositastherapie – Chancen und Perspektiven","Anne Lautenbach","2021","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/a-1491-5805",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036035","Lower Risks of Long COVID and Mortality with GLP-1RAs in Adults with Type 2 Diabetes: Insights into Infectious, Autoimmune, Cardiovascular, Neurological, and Psychiatric Diseases","Jiun‐Ling Wang","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.5044989",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036036","New therapy strategy for type 2 diabetes:Incretin based treatment","Minxiang Lei","2009","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2009.06.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036037","Differential Gastrointestinal Tolerability, Motility Effects, and Nutrient Absorption Profiles Among GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Adults With Type 2 Diabetes: A Multidimensional Comparative Pharmacovigilance and Real-World Outcomes Analysis","Camilo Fernández Bravo","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6225119",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0036038","Typ-2-Diabetes – GLP-1-Analogon reaktiviert schlummernde Betazellen",null,"2010","Diabetes aktuell","other","article","10.1055/s-0030-1269798",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036039","Large Language Models Can Accurately Manage Pre-Endoscopy Referrals: A Comparative Study","Yuri Gorelik","2025","Endoscopy","other","article","10.1055/s-0045-1805330",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036040","Association of GLP-1 and its receptor agonist with inflammation and oxidative stress","Shen Qu","2014","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2014.04.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036041","IMPACTO DOS AGONISTAS DO RECEPTOR DE GLP-1 NA SAÚDE MENTAL DE PACIENTES COM OBESIDADE: UMA REVISÃO INTEGRATIVA DAS EVIDÊNCIAS CIENTÍFICAS","Susana Lucía Cairo Ortiz","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21776951",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0036042","GLP1 receptor agonism attenuates anthracycline and HER2 targeted therapy induced cardiac dysfunction and systemic inflammation in non-diabetic models","V Quagliariello","2026","European Heart Journal Supplements","randomized_trial","article","10.1093/eurheartjsupp/suag097.004",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0036043","The gut-brain axis and its implications for the therapy of type 2 diabetes","Baptist Gallwitz","2006","Experimental and Clinical Endocrinology & Diabetes","other_trial","article","10.1055/s-2006-954679",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0036044","Typ 2-Diabetes - Exenatide stimuliert Insulin-Sekretion",null,"2005","Notfall & Hausarztmedizin (Notfallmedizin)","other","article","10.1055/s-2005-869430",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036045","Effektivität und Sicherheit von IDegLira bei unkontrolliertem Typ-2-Diabetes",null,"2018","Diabetologie und Stoffwechsel","other","article","10.1055/a-0609-9526",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036046","Deutsche Diabetes-Gesellschaft bezweifelt Aussagekraft – Verordnung von GLP1-Analoga nicht ändern",null,"2011","Diabetes aktuell","other","article","10.1055/s-0031-1286686",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036047","Signifikant bessere Gewichts- sowie postprandiale Blutzucker-Senkung bei adipösen Typ-2-Diabetikern mit kurzer Diabeteslaufzeit durch Zugabe von Lixisenatid statt Sitagliptin zur Metformin-Vortherapie","Joerg Steindorf","2014","Diabetologie und Stoffwechsel","other","article","10.1055/s-0034-1374981",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036048","Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide","Shweta Urva","2021","Diabetologie und Stoffwechsel","other","article","10.1055/s-0041-1727327",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036049","Der Natrium-Glukose-Cotransporter-2 (SGLT-2)-Inhibitor Empagliflozin hat eine dauerhafte Wirkung auf die Wiederherstellung der Glukose-Homöostase durch Erhalt der Beta-Zell-Masse in „Zucker Diabetic Fatty“ (ZDF)-Ratten","J Jelsing","2013","Diabetologie und Stoffwechsel","other","article","10.1055/s-0033-1341820",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036050","Kommentar",null,"2021","Diabetologie und Stoffwechsel","other","article","10.1055/a-1539-5926",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036051","Effects of glucagon-like peptide-1 on polycystic ovary syndrome","Lin Cao","2013","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2013.06.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036052","Weight loss with once-weekly dulaglutide versus insulin glargine, both with insulin lispro (+/- metformin), in patients with type 2 diabetes (T2D) from AWARD-4, stratified by baseline body mass index (BMI) category","Martin Füchtenbusch","2015","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0035-1549751",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0036053","Verbesserung der Stabilität und Hochskalierung der Produktion von [68Ga]Ga- Met14-Lys40(NODAGA)-Exendin-4 für die Mehrfachanwendung in der Klinik: Vergleich von Stabilisatoren und Puffersystemen","Guilhem Claude","2025","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0045-1804369",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036054","Moderne Antidiabetika in der Diabetologie","Baptist Gallwitz","2018","Aktuelle Kardiologie","other","article","10.1055/a-0651-7879",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036055","The mechanism and clinical effects of exenatide","Shaofeng Ding","2012","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2012.05.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036056","Ga-68-DOTA-Exendin-4 reliably detects insulinomas and shows regional differences in pancreatic distribution","C. Stoykow","2019","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0039-1683648",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036057","Das multifunktionale nukleäre Protein Eny2 reguliert die glukose- und inkretinvermittelte Insulinsekretion","Andreas Lechner","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1255202",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036058","Adäquat gleichmäßige Senkung des Nüchtern- und postprandialen Blutzuckers über alle Mahlzeiten nach 1xig morgendlicher Gabe von Lixisenatid zum Basalinsulin in der täglichen Praxis","Rüdiger Göke","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549725",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036059","Treatment of NASH in mice with antidiabetic drugs","Wenke Jonas","2019","Adipositas - Ursachen Folgeerkrankungen Therapie","preclinical","article","10.1055/s-0039-1693546",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036060","Glucagon-Like Peptide-1 - Liraglutid im Vergleich mit Insulinglargin",null,"2007","Diabetes aktuell","other","article","10.1055/s-2007-993268",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036061","Response to insulin and GLP-1 of pancreatic alpha-cells in mice with age and under high fat diet","Sven Schinner","2014","Experimental and Clinical Endocrinology & Diabetes","preclinical","article","10.1055/s-0034-1372118",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036062","Patients with type 2 diabetes mellitus (T2DM) who receive weekly dulaglutide are more likely to achieve fasting blood glucose (FBG) ≤6.7mmol/L at 2 weeks than those treated with metformin, sitagliptin or exenatide twice daily (BID): early and long-term (week 52) data from three clinical studies","M Edwards","2016","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0036-1580783",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0036063","Evaluating Real World Data From WebMD on Anti-Obesity Medication Semaglutide","Salem Abuhadida","2025","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.5126847",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0036064","Drug uilization patterns in patients Initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes (T2D) in Germany: A retrospective cohort study","Heike Jung","2018","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0038-1641860",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0036065","Auswirkungen von Depot-Exenatide auf kardiovaskuläre Endpunkte bei Patienten mit Typ-2-Diabetes mellitus: Ergebnisse der EXSCEL-Studie","M Hanefeld","2018","Diabetologie und Stoffwechsel","other","article","10.1055/s-0038-1641964",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036066","Exendin-4 Attenuates t-BHP-Induced Pancreatic β-Cell Apoptosis Through Regulation of METTL14","Zhibin Xue","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5262415",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036067","Potential Risk of Diabetic Lumbosacral Radiculoplexus Neuropathy (DLSRPN) in Association with Glucagon-like-Peptide-1 (GLP-1) Analog: A Case Series (P4-11.031)","Pritikanta Paul","2025","Neurology","case_report","article","10.1212/wnl.0000000000208965",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036068","Tirzepatide vs Insulin Lispro TID Added-On to Poorly Controlled Basal Insulin-Treated Type 2 Diabetes","Julio Rosenstock","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785381",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0036069","Metformin and GLP-1RA Drug Interaction and Risk of Starvation Ketoacidosis: A Pharmacovigilance-MBMA Model Evaluation","Hua He","2025","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.5886180",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0036070","Kommentar",null,"2020","Diabetologie und Stoffwechsel","other","article","10.1055/a-1087-8412",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036071","Effects of glucagon-like peptide-1 receptor agonists on the central nervous system","Zhengwei Fu","2011","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2011.04.015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036072","GLP-1 Receptor Agonists Improved Obesity Through the Gut-Adipose Tissue-Brain Axis","Yang Li","2022","SSRN Electronic Journal","other","article","10.2139/ssrn.4297047",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036073","Klinisch relevante Hypoglykämien bei Typ–2–Diabetes vermeiden! – Inkretinbasierte Therapie macht es möglich","Andreas Klinge","2009","Notfall & Hausarztmedizin","other","article","10.1055/s-0029-1237447",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036074","Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)","Yucheng Hou","2026","iMetaMed","other","article","10.1002/imm3.70042",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036075","Optimized Sublingual Delivery of Dual Fatty Acid–conjugated GLP-1 Receptor Agonist TE-8105 Produces Durable Efficacy in Diabetic Mice","Carmay Lim","2026","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.6055610",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036076","GLP-1 Receptor Agonists as Novel Pharmacotherapy for Substance Use and Behavioral Addictions: Clinical Evidence, Mechanisms, and Public Health Implications","Audrey Walter-Evans","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5964554",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036077","Therapie der chronischen Niereninsuffizienz bei Diabetes mellitus","Christian Gerdes","2025","Nephrologie aktuell","other","article","10.1055/a-2536-2689",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036078","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Osteoarthritis among Individuals with Type 2 Diabetes: A Population-Based Cohort Study","Minjeong Jeon","2025","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.5702461",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0036079","GLP-1 Receptor Agonists Versus DDP-4 Inhibitors in Reducing Mortality and Infection Risks in Patients with Type 2 Diabetes","Yuan‐Pin Hung","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.4968219",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036080","Clinical progress of GLP-1 based therapy on diabetes","Guoqiang Jing","2010","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2010.02.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036081","Patient Perceptions of the Efficacy and Safety of Tirzepatide: Discrepancies with Clinical Data and Unawareness of Cardiovascular Protection","Anton Guo","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5637710",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036082","Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA)","Radica Z. Alicic","2022",null,"other","article","10.1007/978-3-030-86020-2_26",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0036083","Time-restricted feeding improves insulin secretion and prevents hyperglycemia in diabetes-prone mice despite obesity","Wenke Jonas","2024","Diabetologie und Stoffwechsel","preclinical","article","10.1055/s-0044-1785268",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036084","A Novel GLP-1 and FGF21 Dual Agonist Has Therapeutic Potential for Diabetes and Non-Alcoholic Steatohepatitis","Qi Pan","2020","SSRN Electronic Journal","other","article","10.2139/ssrn.3692418",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036085","Effects of liraglutide plus PYY3-36 vs. Roux-en-Y gastric bypass on hypothalamic gene expression","Ulrich Dischinger","2021","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0041-1727385",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0036086","Inkretine: Hoffnungsschimmer für Jugendliche mit Adipositas und/oder Typ-2-Diabetes",null,"2022","DMW - Deutsche Medizinische Wochenschrift","other","article","10.1055/a-1925-0005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036087","Therapieoptionen bei Diabetes mellitus - Analyse vergleicht Inkretin-basierte Antidiabetika",null,"2008","Notfall & Hausarztmedizin","other","article","10.1055/s-2008-1040387",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036088","A Validated, Stability-Indicating Hplc Method for the Simultaneous Determination of 5 Related Substances in Liraglutide Drug Substance","Lexing Zhang","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.5009545",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036089","Osteonecrosis-Like Oral Complications in a Semaglutide User: A Case Report Supported by FAERS Pharmacovigilance Findings","Gülce  Ecem Doğancalı","2025","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.5938654",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0036090","Pituitary GLP-1 receptor expression in the pathophysiology of type 2 diabetes","Marti Boss","2019","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0039-1683647",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036091","Oraler GLP-1-Rezeptoragonist scheint sich zu bewähren",null,"2019","Diabetologie und Stoffwechsel","other","article","10.1055/a-0979-7209",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036092","IDegLira, eine Fixkombination aus Insulin degludec und Liraglutid, verbessert sowohl die prä- als auch die postprandiale Plasmaglucose bei Patienten mit Typ 2 Diabetes","Elmar Jaeckel","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549744",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036093","Development and Validation of a Robust Reversed-Phase LC Method for Liraglutide (GLP-1 analogue) and Its Impurities in Injectable Formulations Using a Quality by Design Approach","Naresh Konduru","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5511143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036094","Association of Glucagon-Like Peptide-1 Receptor Agonists with Diabetic Retinopathy and Other Ocular Diseases in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis","Ning Lan","2025","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.5364609",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0036095","Inkretinbasierte Antidiabetika im Vergleich: GLP-1-Mimetika und DPP-IV-Inhibitoren","Baptist Gallwitz","2008","Diabetologie und Stoffwechsel","other","article","10.1055/s-2008-1076915",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036096","Orforglipron – ein oraler GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes","R. Maria Clauss","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2642-5066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036097","The follow-up observation of 93 overweight or obese patients with type 2 diabetes treated by liraglutide","Mei Wang","2013","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2013.05.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036098","Behandlung mit GLP-1-RA erhöht präoperativen Mageninhalt",null,"2025","Journal Club AINS","other","article","10.1055/a-2513-8975",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036099","Effects of Semaglutide on Vessel Morphology: Studies on the Chicken Chorioallantoic Membrane","Steven Bloom","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5449829",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036100","Einfluss von GLP-1-Analoga auf die Mikronährstoffversorgung","Felix Kerlikowsky","2025","Ernährung & Medizin","other","article","10.1055/a-2492-9615",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036101","Fallbericht: Störung der Leberfunktion unter der Verordnung von Exenatide und Fluvastatin","S Surber","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1253930",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036102","Effects of Liraglutide on glucose-induced neuronal damage in Ceanorhabditis elegans","K Wongchai","2013","Diabetologie und Stoffwechsel","other","article","10.1055/s-0033-1341715",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036103","Metaanalyse von direkten Vergleichsstudien zwischen Therapie mit GLP-1 Rezeptor-Agonisten oder Insulin: Unterschied für kurz- und lang-wirksame Medikamente?","Mohammed Aziz","2016","Diabetologie und Stoffwechsel","systematic_review","article","10.1055/s-0036-1584101",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0036104","Vergleichende Proteomanalyse isolierter Mitochondrien aus INS-1 Zellen: Rolle von Exendin-4 auf die Zytokin-induzierte Apoptose","Dominique S. Tews","2007","Diabetologie und Stoffwechsel","other","article","10.1055/s-2007-982165",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036105","Haeufigkeit von Hypoglykämien unter einer Sulfonylharnstofftherapie","U Schatz","2011","Diabetologie und Stoffwechsel","other","article","10.1055/s-0031-1277427",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036106","Nucleotidaustausch im Intron 1 des HNF-4α Gens ist assoziiert mit phänotypisch unterschiedlichen Diabetesformen und neuen Therapiemöglichkeiten","D Deiss","2011","Diabetologie und Stoffwechsel","other","article","10.1055/s-0031-1277475",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036107","Therapie des Typ-2-Diabetes - Auftreten von Pankreatitis und Pankreaskarzinom unter GLP-1-Analoga",null,"2011","Diabetes aktuell","other","article","10.1055/s-0031-1278653",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036108","Glucagon-like peptide-1 receptor agonists","Baptist Gallwitz","2016",null,"other","article","10.1007/978-3-319-08982-9_3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0036109","Strukturierte, ambulante Adipositastherapie als effektive Alternative bzw. Ergänzung zu GLP-1-Rezeptoragonisten","Christine Becker","2025","Diabetologie und Stoffwechsel","other","article","10.1055/s-0045-1807496",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036110","Peptide‐Based GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity","János T. Kodra","2026",null,"other","article","10.1002/9783527845408.ch4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0036111","GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS","Nigel H. Greig","2018","Proceedings for Annual Meeting of The Japanese Pharmacological Society","other","article","10.1254/jpssuppl.wcp2018.0_or6-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036112","Effect of liraglutide on the expressions of NF-κB and VCAM-1 in aorta endothelium of type 2 diabetic rats","QI Caihu","2014","Journal of Shandong University","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036113","Cardiovascular Outcomes and Cardioprotective Mechanisms of GLP-1 Receptor Agonists: What Is Established in Humans, What Is Shown in Animal and Cell Models, and What Remains Contested","Brian P. Kilgore","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21782646",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036114","Trends in Drug Discovery in Diabetes and Obesity",null,"2026",null,"nonrandomized_study","article","10.1002/9783527845408",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","book"],["R0036115","Incretin-based therapy for patients with diabetes mellitus secondary to chronic pancreatitis: An update from the 2015 Japanese guidelines of management of chronic pancreatitis","Tetsuhide Ito","2015","Suizo","other","article","10.2958/suizo.30.773",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036116","GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease","Sachs, Stephan","2024","Figshare","preclinical","article","10.6084/m9.figshare.c.6795225.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036117","The Association Between Serum Vaspin and Omentin-1 Levels in Obese Children with Metabolic Syndrome","Muammer Büyükinan","2018","Yearbook of pediatric endocrinology","preclinical","article","10.1530/ey.15.12.10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036118","Polypharmakologie als ein neuer Ansatz zur Präzisionsmedizin in der Adipositas- und Diabetestherapie","Sigrid Jall","2018","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/s-0038-1654054",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036119","The Role of Gut Peptides in the Regulation of Body Weight","Jens J. Holst","2026",null,"other","article","10.1002/9783527845408.ch1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0036120","Neuropeptide Y Receptor Ligands and Opportunities Within Diabetes and Obesity","Søren Østergaard","2026",null,"other","article","10.1002/9783527845408.ch7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0036121","Diabetes und Fettleber","Norbert Stefan","2022","Diabetologie und Stoffwechsel","other","article","10.1055/a-1853-9763",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036122","Tirzepatide: A Review Of Its Mechanism Of Action, Clinical Efficacy, And Emerging Importance In Diabetes And Obesity Treatment","Dr. R. Subashini*, P. Abitha, M. Gayathri, S. Abinaya","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.21812563",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036123","Exploratory associations between incretin-based therapies and plasma cell disorders in patients with type 2 diabetes: A real-world study.","Yousef Ateiwi","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.7571",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0036124","Letter to the Editor: Serum bile acid profiling for diabetic gastrointestinal neuropathy: Promise and pitfalls","Yu-Hong Zhan","2026","World Journal of Diabetes","nonrandomized_study","article","10.4239/wjd.117130",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","letter"],["R0036125","Understanding Online Search Behavior regarding GLP-1 Receptor Agonist Medications","Jayden Wei","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21798830",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036126","760-P: Real-World Efficacy of Combined SGLT2i and GLP-1RA Therapy in Elderly Patients with Type 2 Diabetes and Obesity","Anna Ferrulli","2025","Diabetes","nonrandomized_study","article","10.2337/db25-760-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0036127","An Update on Prader-Willi Syndrome with Diabetes Mellitus","Jieun Lee","2016","Journal of mucopolysaccharidosis and rare disease","other","article","10.19125/jmrd.2016.2.2.35",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036128","Exenatide administration time-dependently affects the hepatic circadian clock through glucagon-like peptide-1 receptors in the central nervous system","許  平平",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0036129","Cashew nut oil (Anacardium occidentali) reduces blood glucose levels through different mechanisms in glucose metabolism in an experimental model","Gabriela Barbosa Amarante de Mello Freire","2025","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036130","Nutritional Care for Adults with Obesity Treated with GLP-1and Dual GIP/GLP-1 Receptor Agonists: A Review of Evidence, Gaps, and Clinical Implications","Carolina McGuane","2026","NSUWorks (Nova Southeastern University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036131","Implementation of GLP-1 Receptor Agonists for Perioperative Weight Loss","Anne W Shand","2026","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036132","Shortages of semaglutide from the point of view of patients using the drug for weight loss","Nelli Baumgartner","2025","Työväentutkimus Vuosikirja","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036133","Approaches to health technology assessment of innovative treatments for type 2 diabetes mellitus","Мариана Димитрова // Йончева-Михайлова","2023","Bulgarian Portal for Open Science","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036134","The Supply and Demand of Ozempic in America: An Economic Analysis","Chaudhary, Eeman","2025","Hollins Digital Commons (Hollins University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036135","Poster session (held in conjunction with Science Seminar) // Dana 2nd floor","Asmaldi, Asmeena","2025","Hollins Digital Commons (Hollins University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036136","The Impact of Pharmacotherapy in Weight Loss","Edwards, Jessica","2025","ODU Digital Commons (Old Dominion University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036137","GLP-1 receptor agonists in the treatment of type 2 diabetes - a direct comparison of glycemic control","Seufert, Jochen","2015","FreiDok plus (Universitätsbibliothek Freiburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036138","From Venom to Medicine: Harnessing Animal Toxins for Drug Discovery","Vega, Christine","2025","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036139","Vitamin B12 Bioconjugates In Pharmaceutical Design","Jayme L. Workinger","2017","Syracuse University Libraries (Syracuse University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036140","Metformin Versus GLP-1 for Therapeutic Potential in Polycystic Ovary Syndrome","Stone, Carlyn","2024","ValpoScholar (Valparaiso University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0036141","Patients’ Perceptions of Combining Pharmacotherapy and Lifestyle Modifications for Weight Management: Barriers, Facilitators, and Impacts on Adherence","Catherine Miget","2026","Journal of the Arkansas Academy of Science","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036142","GPCR-Mediated Mechanisms in Obesity: The Role of Ghrelin and GLP-1 Receptors","Singh, Ryan","2025","Digital Commons - University of South Florida (University of South Florida)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0036143","Bactrim Induced BRASH Syndrome In Elderly Female: A Case Report","Maknoor, Pooja","2023","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036144","Efficacy and safety of liraglutide vs placebo in children and adolescents with type 2 diabetes: the ellipse randomised trial results",null,"2019","Dspace Repository (Marmara Üniversitesi)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036145","Áhrif semaglutide á líkamsþyngd og efnaskipti hjá einstaklingum með geðsjúkdóma","Ingi Hrafn Guðbrandsson 2003-","2026","Skemman","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036146","Enhancing CRNA Knowledge and Confidence in Gastric Point-of-Care Ultrasound for Patients on GLP-1 Receptor Agonists: A Focused Educational Intervention","Murphy, Jordan","2025","Murray State's Digital Commons (Murray State University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036147","Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity: A Clinical Review","Overholser, Andrew","2023","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036148","β-glucan attenuates intestinal ischemia-reperfusion injury in mice by promoting glucagon-like peptide-1 secretion","WANG Wei","2025","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.16016/j.2097-0927.202409020",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036149","Riech- und Schmeckstörungen unter GLP-1-RA","Elke Oberhofer","2026","HNO Nachrichten","other","article","10.1007/s00060-026-9702-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036150","BIOLOGICAL MECHANISMS OF POLY-L-LACTIC ACID IN COLLAGEN BIOSTIMULATION UNDER CONDITIONS OF LIPOATROPHY ASSOCIATED WITH GLP-1 AGONIST USE","Gabriela Chahine Matos","2026",null,"other","article","10.63330/aurumpub.044-030",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0036151","Impact of Endocrine Comorbidities on the Clinical Response to Semaglutide and Tirzepatide: A Systematic Review","Sandro La Vignera","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21818802",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0036152","Beyond Intention-to-Treat Analyses in Randomized Trials: Utilizing Per-Protocol Estimands and Observational Data to Investigate Strategies for Cardiovascular Disease Prevention","Rienna Grace Russo","2025","Digital Access to Scholarship at Harvard (DASH) (Harvard University)","protocol","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","dissertation"],["R0036153","Incretin-Based Medications for Type 2 Diabetes: An Overview of Reviews","Hatch, Kelly","2021","Scholarship@Western (Western University)","systematic_review","article",null,null,null,"PROSPERO:CRD42013005149",null,"openalex","FALSE","no_doi","3","FALSE","article"],["R0036154","Management of Obesity in Primary Care","Marjorie Scott","2021","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036155","Dulaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-64550-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036156","利拉鲁肽对肥胖的2型糖尿病患者胰岛β细胞功能指数及糖化血红蛋白的影响","Baoqin Chen","2013","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036157","Identification of dipeptidyl-peptidase 4 (DPP-4) inhibitors from miracle berry fruit (Synsepalum dulcificum) extract","Hamsah Zollapi, Nuraliana Najwa","2023","Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia)","other","article","10.54987/jobimb.v11i1.805",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036158","The Role of GLP-1R Agonists in Supporting Intracellular Bacterial Growth in Alveolar Macrophages","Sierra Novabilski","2026","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036159","Framställningen av semaglutid på sociala medier och dess implikationer för klinisk praxis","Annie Pham","2026","DiVA (Linnaeus University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0036160","GLP-1 Agonists for Pediatric Obesity: A Clinical Review","Burgin, Grace","2026","Digital Commons - Gardner-Webb University (Gardner–Webb University)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036161","Glucagon-Like Peptide-1 Therapy and Substance Use Disorders","Brunsell, Rachel J.","2025","UND Scholarly Commons (University of North Dakota)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036162","GLP-1 Agonists on Reducing the Risk of Developing Dementia in Patients with Type 2 Diabetes","Guerrero, Alli","2024","Digital Commons - George Fox University (George Fox University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036163","Quantifying Ozempic’s Impact: Sentiment-Based Drug Evaluation with BERT and Mistral Models","Lala, Aarav","2025","DigitalCommons-IMSA (Illinois Mathematics and Science Academy)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036164","Strategies for targeted immunomodulation","Sean Patrick Quinnell","2022","OpenBU (Boston University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036165","Investigation for Daily Profile of Blood Glucose by the Administration of Canagliflozin and Xultophy (IdegLira)","Hiroshi Bando","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036166","Evaluating novel glucose-lowering therapies in first-line treatment for type 2 diabetes","Ho‐Jin Shin","2021","Digital Access to Scholarship at Harvard (DASH) (Harvard University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0036167","GLUKAGON BENZERİ PEPTİD -1’İN SİNİR SİSTEMİ VE İŞTAH KONTROLÜ ÜZERİNE ETKİLERİ","Hale SAYAN ÖZAÇMAK","2017","DergiPark (Istanbul University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036168","Application of chromatography and mass spectrometry in One Health: Detecting therapeutic analytes and drug residues in complex biological and food matrices.","Diab, Hanin","2025","ThinkTech (Texas Tech University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036169","Metabolic dysfunction-associated fatty liver disease and metabolic-associated steatohepatitis: a review of pathogenesis and potential pharmacological targets","Samaneh Olapour","2022","DOAJ (DOAJ: Directory of Open Access Journals)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036170","Influência da cápsula de liberação ileal de óleo de palma e de glutamina sobre peptídeos intestinais GLP-1 em pacientes com diabetes tipo 2","Luciana Arantes Soares","2018","Americanae (AECID Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036171","Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа","A.Yu. Kulikov","2013","DOAJ (DOAJ: Directory of Open Access Journals)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0036172","Preface","Anna Maria Papini","2024","Current Protein and Peptide Science","other","article","10.2174/138920372601241122105141",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036173","Dietary Intake and Body Composition During the Early Phase of GLP-1 Receptor Agonist Treatment","Jenný June Tómasdóttir 1991-","2026","Skemman","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036174","Liraglutide; A New Hope for Obese Diabetics","Ajeet Kumar","2020","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.22442/jlumhs.201940702",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036175","Semaglutide Added to Type 2 Diabetes Mellitus Treatment for Improvement in Hemoglobin A1c","Valle, Christina","2023","scholarworks - UTEP (The University of Texas at El Paso)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036176","Assessment of Quality of Life Among Patients Undergoing Semaglutide Treatment for Weight Loss","Sameed, Muhammad","2024","Journal of International Crisis and Risk Communication Research","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036177","Cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes.","Grigg, Robert D","2022","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036178","Effects of Liraglutide on Metabolic Parameters and Carotid Intima-Media Thickness in Patients with The Metabolic Syndrome: A 12-Month Prospective Pilot Study","RIZZO, Manfredi","2014","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0036179","An Analysis of Lifestyle Modification and Pharmacologic Treatment of Obesity","Angelica Rumley","2020","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036180","exendin-4はEpac依存的に糖尿病Goto-Kakizakiラット膵島におけるSrc活性および活性酸素種産生を抑制する","Eri Mukai","2011","Diabetes","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036181","Injekcinio semagliutido, dulagliutido ir tirzepatido veiksmingumas ir saugumas metaboliniams rodikliams suaugusiesiems, sergantiems 2 tipo cukriniu diabetu","Rimi Saloum","2026","Lithuanian University of Health Sciences","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0036182","El efecto incretina y su participación en la diabetes mellitus tipo 2","Quintanilla-García, Cristina","2010","Redalyc (Universidad Autónoma del Estado de México)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036183","The influence of different variants of glucose-lowering therapy on indices of inflammation in patients with diabetes type 2 on a background of gastroesophageal reflux disease and obesity","Andreeva E.l.","2018","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036184","Outcomes in patients with metabolic dysfunction associated liver disease treated with GLP 1 receptor agonist: a scope review","Álvarez Ariza, Karen Margarita","2025","Repositorio Institucional E-DocUR (Universidad Del Rosario)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036185","Evaluating the Efficacy and Ethical Implications of Semaglutide and GLP-1 Receptor Agonists for Weight Management in Obesity","Ebonne' M Quiller","2025","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036186","Halting a Silent Pandemic: The Fight Against Adult Obesity","Kelli J Simco","2021","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036187","Comparative evaluation the effects of bariatric surgery and exenatide treatment on the clinical and laboratory parameters in obese type 2 diabetic patients","Onur Elbasan","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.ep608",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0036188","Comparative Impact of SGLT2 Inhibitors and Emerging Therapies on Heart Failure With Preserved Ejection Fraction","Shaju, Ronald A","2025","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036189","Secretagogin is Essential for Circadian GLP-1 Secretion and is Altered in a Model of Type 2 Diabetes","Andrew D. Biancolin","2022","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036190","میزان تجویز SGLT2i و GLP1RA در بیماران دیابت نوع 2 بر اساس ADA و ESC در سه مرکز دیابت در ایران","راحله سادات سجاد","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.48305/jims.v43.i809.0302",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036191","Peptide and Peptide bioconjugate based drug development for the treatment of metabolic diseases","Nancy Cham","2026","Syracuse University Libraries (Syracuse University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036192","GLP-1 Receptor Agonists in Obstructive Sleep Apnea: Association with Fractures, Bone Health, and Clinical Outcomes in a Propensity-Matched Cohort","Shefali Waghray","2026","Rowan Digitals Works (Rowan University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036193","Preface","Anna Maria Papini","2025","Protein and Peptide Letters","other","article","10.2174/092986653201250206011525",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036194","GLP-1 receptor agonists in fatty liver disease","Viivi Maria Päivärinta","2026","Työväentutkimus Vuosikirja","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036195","774-P: Robust Antiobesity Effect and Mechanistic Insights of HM15275, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in Animal Model of Obesity","SANG HYUN PARK","2025","Diabetes","other_trial","article","10.2337/db25-774-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0036196","Slimmer’s Paralysis in the Era of GLP-1 Therapy: A Review of Recent Cases","Nidhin John","2025","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036197","Effects of Nonpharmacological and Pharmacological Interventions on the Management of Polycystic Ovarian Syndrome","Fagg, Ellington","2024","Journal of the Arkansas Academy of Science","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0036198","Budget Impact Analysis of Semaglutide for Weight-loss Management in Overweight and Obese U.S. Adults","Sebastian, PharmD, Tobin","2021","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036199","Acute Improvement of Glucose Variability by Oral Semaglutide (Rybelsus) and Low Carbohydrate Diet (LCD) In Type 2 Diabetes (T2D) Patient with Ophthalmic Operation","Hiroshi Bando","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036200","Determining Minimal Dosage Thresholds for Gastroparesis Development in GLP-1 Receptor Agonist Therapy: A Comprehensive Systematic Review and Meta-Analysis","Mirajkar, Nikita","2025","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0036201","Efficacy and Safety of GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus Treatment: Systematic Review","Ana Paula Martins","2016","DOAJ (DOAJ: Directory of Open Access Journals)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0036202","Development of Peptide and Protein Microparticles for Diabetes Therapy : From Fabrication to In Vivo Evaluation","Zhang, Pei","2022","Työväentutkimus Vuosikirja","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036203","Diabetinė inkstų liga: patofiziologija paremtas gydymas","Tiam Moghaddas Jafari","2021","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036204","Evaluating the Therapeutic Potential of Tirzepatide in Liver Diseases: A Comprehensive Review","Bryan, Carina","2024","NSUWorks (Nova Southeastern University)","other_trial","article",null,null,null,"ClinicalTrials.gov:NCT04166773","S000031","openalex","FALSE","no_doi","5","FALSE","article"],["R0036205","The Effectiveness of Tirzepatide (GIP/GLP-1 Receptor co-Agonist) vs GLP-1 Receptor Agonists on Lowering A1C in Adults with Type 2 Diabetes Mellitus","LaPlante, Madison","2023","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036206","Association of GLP1R polymorphisms with the incretin response: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH)","Edgar Gerardo Dorsey-Treviño","2021","Digital Access to Scholarship at Harvard (DASH) (Harvard University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0036207","Beyond Body Weight","Mohammed El Amin Bouchelit","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21841035",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036208","Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study","the CAPTURE investigators","2023","Utrecht University Repository (Utrecht University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036209","GLP-1 receptor agonists can reverse immunosuppression-induced beta-cell dysfunction","S. Bertera","2020","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.32113/cellr4_202010_2943",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036210","Pharmacology treatment principles in PCOS combined with obesity.","Yu.F. Marchuk","2025","DSpace BSMU","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036211","Modulating Visceral Adipose Tissue Immunometabolism: GLP-1RA Semaglutide’s Impact on Immune–Stromal Networks","Miaoer Xu","2026","Digital Access to Scholarship at Harvard (DASH) (Harvard University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036212","تأثیر آگونیستهای گیرندهی GLP-1 و درمانهای غیرتزریقی بر کنترل قند خون و مدیریت وزن در بیماران مبتلا به دیابت نوع ۲","مریم شریفی","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.48305/jims.v43.i827.0992",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036213","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-73891-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036214","Targeting the food reward system in preclinical models for eating disorders","Kooij, Karlijn Liselotte","2024","Utrecht University Repository (Utrecht University)","preclinical","article","10.33540/2130",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036215","Liraglutide and the Preservation of Pancreatic beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014; 37: 3270-3278","Arnolds, Sabine","2015","Kölner Universitäts PublikationsServer (Universität zu Köln)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036216","Considerations on the Impact of GLP1-RAs on the Present and Future of Metabolic and Bariatric Surgery","Palazzo, MD, FACS, Francesco","2025","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036217","The access and use of GLP-1 receptor agonists in people with eating disorders in the UK: A mixed method study","Fiona Duffy","2026","PsyArXiv (OSF Preprints)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036218","An examination of switching from insulin to glucagon-like peptide-1 analogue liraglutide in hemodialysis patients with type 2 diabetes: A descriptive epidemiology study","Ryuji Matsushita","2013","Nihon Toseki Igakkai Zasshi","other","article","10.4009/jsdt.46.923",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036219","The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes","Bolli GB",null,"Newcastle University ePrints (Newcastle Univesity)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0036220","Geneettiseen tietoon perustuva reaalimaailman näyttö ja tutkimuksen suunnittelu","Jakob German","2025","Työväentutkimus Vuosikirja","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0036221","Disease-modifying Therapies Targeting Neuroinflammation in Alzheimer's Disease: Evaluation of Ongoing Clinical Trials","Shree Diora","2026","NSUWorks (Nova Southeastern University)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","conference-paper"],["R0036222","Beyond Skin: Adjunctive GLP-1 Receptor Agonist Therapy for Psoriasis and Metabolic Dysfunction","Patricia J Quartin","2026","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036223","Cost–benefit analysis of public reimbursement of semaglutide (Wegovy®) for obesity treatment in Portugal","Pedro Miguel de Sá Damião","2025","Repositório do ISCTE-IUL","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036224","Research on living clinical practice guidelines in diabetes mellitus II: summary of key evidence in the development of drug treatment strategies for type 2 diabetes mellitus","Cai Fengyi","2026","DOAJ (DOAJ: Directory of Open Access Journals)","nonrandomized_study","article","10.12173/j.issn.1004-5511.202508056",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036225","Association of Glucagon-like Peptide-1 Receptor Agonist Use with Cardiovascular Risk Reduction in Patients with Obstructive Sleep Apnea and Obesity: A Real-world Analysis","Ahn, Jaeun","2025","ODU Digital Commons (Old Dominion University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0036226","Central GLP-1 System: Physiological Roles and Its Potential as an Anti-obesity Target","Jiang, Wanqing","2025","UCL Discovery (University College London)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036227","La sustancia para la eterna juventud. ¿Alguna vez has soñado con una mejor versión de ti mismo?","David Cordero Vázquez","2025","Deposito de Investigacion Universidad de Sevilla (University of Seville)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036228","Moderate Exercise and Tirzepatide versus Tirzepatide Alone for Long-Term Weight Loss Maintenance","Acheampong, Edward Amoah","2025","UND Scholarly Commons (University of North Dakota)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036229","Comparison of Postprandial Insulin Levels in Withania Coagulans and Liraglutide Treated Diabetic Rats","Shazia Ali Abdul Samad","2018","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0036230","Characterization of GLP-1 Receptor in Flox & Knockout Mice","Caroline Youdes","2023","Murray State's Digital Commons (Murray State University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036231","A review of the Mechanisms of Action and Side Effects of Anti-diabetic Agents","Mubarak Muhammad Dahiru","2022","DOAJ (DOAJ: Directory of Open Access Journals)","narrative_review","article","10.30476/tips.2022.95931.1153",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036232","Semaglutide and Physical Activity for Obesity and Multimorbidity (SemPAct): Co-designing Healthy Healthcare","Thomas Quaade Bandholm","2025","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","preprint"],["R0036233","Balancing Weight Loss and Muscle Preservation During GLP-1-Based Therapy for Type 2 Diabetes and Obesity: A Clinical Review","Elizabeth N. Parker","2025","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036234","Targeting Inflammatory, Fibrotic, Hemodynamic, and Metabolic Pathways in Chronic Kidney Disease: Emerging Pharmacotherapies and Precision Treatment Strategies","North American Academic Research","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21797980",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036235","Beyond CPAP: Modern Treatment of Obstructive Sleep Apnea and Its Impact on Mood Disorders","Kyrillos Ghattas","2026","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036236","Metabolic risk factors and prevention of liver and colorectal diseases : population-based studies from East to West","Mao, Xianhua","2025","The HKU Scholars Hub (University of Hong Kong)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0036237","Barriers to Applying Guidelines for Treatment of Type 2 Diabetes Mellitus in the Rio Grande Valley","Honderich, Carra G.","2023","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036238","Beyond Body Weight","Mohammed El Amin Bouchelit","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21841034",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036239","Nutritional Assessment of Diet Quality and Potential Deficiencies in Individuals Using GLP-1 Receptor Agonist Medications: A Questionnaire Study","Neetha Lobo","2026",null,"other","article","10.13140/rg.2.2.11784.58886",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036240","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97034-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036241","Is Semaglutide the Key to the Fight Against \"Globesity\"?","Travelsted, Melissa","2024","TopSCHOLAR (Western Kentucky University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036242","GLP-1 Receptor Agonists in Diabetic Foot and Ankle Care: Skeletal Liability or a Blessing in Disguise? A Scoping Review","Daniela Lizbeth Avilez","2026","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036243","Non-Insulin Management of Type II Diabetes","Rabovsky, MD, Andrew","2018","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036244","The metabolic effects of incretin mimetics in L6 skeletal muscle cells","Jenny Illman","2025","Työväentutkimus Vuosikirja","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0036245","Recent Developments in Tirzepatide's Role in Reducing Cardiovascular Disease Risk Factors in Adults with Type 2 Diabetes","Jones, Talaya","2024","NSUWorks (Nova Southeastern University)","other_trial","article",null,null,null,"ClinicalTrials.gov:NCT04847557; ClinicalTrials.gov:NCT04255433","S000047; S002212","openalex","FALSE","no_doi","5","FALSE","article"],["R0036246","Implémentation des traitements recommandés dans la néphropathie diabétique chez les patients suivis au centre de néphrologie et de diabétologie au Centre hospitalier universitaire vaudois (CHUV)","Hippolyte Gaiffe","2025","IRIS","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0036247","Treatment with exenatide in acute ischaemic stroke trial protocol: A prospective, randomised, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycaemia","Muller, Claire","2018","Research Bank (Australian Catholic University)","protocol","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036248","Cardioprotective Effects of Combined Treatment with Sodium-glucose Co-Transporter-2 Inhibitor and Glucagon-like Peptide-1 Receptor Agonist in a Mouse Model of Ischemia-reperfusion Injury","Dorrin Zarrin Khat","2021","TSpace (University of Toronto)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0036249","Role and regulation of islet-Brain 1 in pancreatic β-cells","Mourad Ferdaoussi","2008","IRIS","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036250","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96812-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036251","The Celebrity Effect: How Social Media Changed Ozempic Utilization by Medicaid Patients","Ma, Sara L, MS","2024","Human Biology","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0036252","The Labor Market Impacts of GLP-1s","Ida Lykke Kristiansen","2026","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0036253","GLP-1 receptor agonists for the treatment of obesity in children and adolescents","Miisa Korvenaho","2026","Työväentutkimus Vuosikirja","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036254","Metabolic Dysfunction-Associated Steatotic Liver Disease in General Medicine: From Incidental Fatty Liver to Cardiometabolic Risk Stratification","Mohammed Alkhanafsa","2026","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article","10.22037/aab.v17i1.52378",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0036255","DRUGMAKER PARTNERSHIPS","Rick Mullin","2002","Chemical & Engineering News","other_trial","article","10.1021/cen-v080n039.p009",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0036256","IMPACT OF SMOKING CESSATION ON GLYCAEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW","Abdulelah Saad Alzahrani","2026","Genetics and Molecular Research","systematic_review","article","10.4238/g85ndv51",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0036257","Lihavuuden kehittyvä lääkehoito nyt ja tulevaisuudessa","Matias Pykälämäki","2025","Työväentutkimus Vuosikirja","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0036258","Semaglutide ameliorates core symptoms in mouse model of autism spectrum disorder by regulating inflammation-related pathways","LIU Jiayin","2026","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.16016/j.2097-0927.202601037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036259","Dulaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96927-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036260","Cost-effectiveness of Empagliflozin Compared to Liraglutide in Iran Based on Cardiovascular Outcome Trials in Type 2 Diabetes Mellitus","Nayyereh Ayati","2022","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036261","Nouveaux traitements de l’obésité : Efficacité comparée aux mesures hygiéno-diététiques chez l’adulte","Deschuymere, Alix","2024","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036262","Analysis of the dose-dependent risk factors of the GLP-1 receptor agonist and the societal normalization of the drug for cosmetic use","Bryanna A Bhakta","2026","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036263","The Risk of Diabetic Retinopathy Progression in Patients with Type 2 Diabetes Mellitus Treated with GLP-1 Receptor Agonists: A Literature Review and Analysis of Clinical Cases","Kazimieras Kaušyla","2026","Lithuanian University of Health Sciences","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036264","Adapting Global Diabetes Management Guidelines for Low Resource Settings","Mohamed Baayou","2026","مجلة البحوث الأكاديمية","other","article","10.65540/jar.v30i.1595",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036265","Glucagon-like peptide-1 receptor agonists/Sodium-glucose transporter 2 inhibitors",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96938-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036266","Efficacy analysis of oral and injectable semaglutide in persons with type 2 diabetes","Novak, Neža","2025","Repository of the University of Ljubljana (University of Ljubljana)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036267","FINDING NEW INTERVENTIONS TO SLOW KIDNEY FUNCTION DECLINE IN DIABETES","Keum, Youngshin","2024","Digital Access to Scholarship at Harvard (DASH) (Harvard University)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0036268","Tirzepatide-Induced Ketoacidosis with Hyperglycemia in a Non-diabetic Patient: A Case Report","Shloush, Mendel","2025","Florida International University Digital Commons (Florida International University)","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036269","Assessing Pharmacy Budget Impact of Tirzepatide for Weight Loss: A U.S. Commercial Payer Perspective","Bigness, PharmD, BCPS, Christopher J.","2024","The Medicine Forum","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","other"],["R0036270","Improving the bioartificial pancreas: Investigation of the effects of pro-survival and insulinotropic factor delivery and the development of PEGylated alginate microcapsules to support the function and survival of encapsulated islets and beta cells","Stephanie Duncanson","2014","SMARTech Repository (Georgia Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036271","Improving GLP-1 RA Initiation in Primary Care Through a Paper-Based Clinical Decision Support Tool","Carissa R Bowery","2026","Digital Commons - East Tennessee State University (East Tennessee State University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036272","GLP-1 viðtakaörvar og áhrif á líkamsþyngdarstuðul og andlega líðan","Jóhannes Helgason Thoroddsen 2000-","2025","Skemman","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0036273","Medicines, Markets, and the State","Barber, Melissa","2023","Digital Access to Scholarship at Harvard (DASH) (Harvard University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036274","Cost Effective Treatment Options for Uninsured Patients with Diabetes","Selva, Sidney","2024","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036275","Notkun og árangur GLP-1 viðtakaörva hjá börnum með offitu eftir nýlegar ábendingar","Helena Björk Arnarsdóttir 2003-","2025","Skemman","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036276","Preliminary comparison of major adverse outcomes in patients with nonalcoholic fatty liver disease initiated on second-line antihyperglycemic therapy","Rachel Soon-yong Kim","2023","OpenBU (Boston University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0036277","GLP-1 Receptor Antagonists Medicaid Utilization Trends and Obesity Rates in the US","Magwenzi, Faith","2024","Digital Commons (Liberty University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036278","Trimming the Fat: GLP-1 Agonists in Treatment of NASH","Frankwick, Katelyn M","2022","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036279","GLP1 Receptor Agonist Increases Fracture Risk In Patients with Obesity","Chelton, Alex T","2025","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036280","Modern Antidiabetics in Cardiology","Schneider, Christian A.","2018","Kölner Universitäts PublikationsServer (Universität zu Köln)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036281","胰高血糖素样肽-1受体激动剂对2型糖尿病合并冠心病患者心功能的影响","李晶晶","2020","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036282","Non-Insulin Pharmacologic Management of Diabetes","Flink, MD, Lilli","2021","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036283","18 F-Tetrazine- trans-cyclooctene-Cys 40-exendin-4","Kam Leung","2004","Europe PMC (PubMed Central)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036284","Use of GLP-1 analogues in liver and kidney transplant recipients: a retrospective analysis in a tertiary center","JACQUINOD, M.","2024","IRIS","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0036285","Semaglutide vs Liraglutide for Weight Loss in Adults with Obesity","Bar, Orian","2025","Digital Commons - Gardner-Webb University (Gardner–Webb University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0036286","Cost-effective strategies for the long-term management of diabetes mellitus","Kedar Nath Mulpuri","2015","OpenBU (Boston University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036287","CRNAs’ Perceptions of a Quick Reference Guide For Aspiration Pneumonitis: A Quality Improvement Project","Johnathan Dockery","2025","The Scholarship East Carolina University's Institutional Repository (East Carolina University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036288","Semaglutide and tirzepatide – comparison of weight regain after treatment discontinuation: a systematic review","Sérgio Oliveira Pires [UNIFESP] Teixeira","2026","UNIFESP Institutional Repository (Universidade Federal de São Paulo)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0036289","Effects of liraglutide on neurological function and levels of serum VEGF and bFGF in type 2 diabetes patients with acute cerebral infarction","SUN Rongdao","2023","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.13429/j.cnki.cjcr.2023.12.005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036290","Кардіальні захворювання та хронічна хвороба нирок – фатальний альянс чи нові можливості в лікуванні? (Огляд літератури)","Тащук, Віктор","2025","Scientific periodicals of Ukraine","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036291","Glucagon-like Peptide-1RA as a Public Health Interventions","Briana Sepeda","2026","CSUSB ScholarWorks (California State University, San Bernardino)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036292","Exploration of Treatment Options for a Hispanic Patient with Obesity Class III and Multiple Comorbidities","Arab, Shuaibahmed M","2024","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036293","Hidradenitis Suppurativa in an Atypical Localization","Gailė Mišeikytė","2025","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036294","More than a gut feeling: Gut Microbiota and Binge Eating Disorder","Lisa Praz","2025","IRIS","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036295","Hypothalamic-pituitary dysfunction in children with suprasellar tumors: improving the outcome","Schaïk, Jiska van","2023","Utrecht University Repository (Utrecht University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0036296","The Impact of Liraglutide on the Urogenital and Reproductive System in Mice","Mehdi Ebrahimi","2024","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.22034/tru.2024.444725.1177",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036297","USO OFF-LABEL DO OZEMPIC PARA FINS ESTETICOS: UMA REVISAO DE LITERATURA SOBRE OS RISCOS FISIOLOGICOS E CLINICOS EM INDIVIDUOS EUTROFICOS","ANA LUISA NEGRINI","2026",null,"other","article","10.29327/9786527226727.1681834",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036298","A Quantum Circuit Framework for Protein Ensemble-Level Energetics","Pratik Patil","2026","arXiv (Cornell University)","other","article","10.48550/arxiv.2608.05491",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036299","In vivo and in vitro evaluation of radioactive labeled DTPA- and HYNIC GLP-1-Analoga for the detection of insulinomas","Sebastian Huss","2008","Publikationsserver (Universitat Marburg)","preclinical","article","10.17192/z2008.0539",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036300","Efficacy of anthiyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.","Henry RR","2011","IRIS Research product catalog (Sapienza University of Rome)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0036301","New Diabetic Medications for Non-Alcoholic Fatty Liver Disease Treatment in Type 2 Diabetic Patients","Vicki Shah","2021","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036302","Improving outcomes for patients with chronic kidney disease","Ahmed M. Shaman","2020","The Sydney eScholarship Repository (The University of Sydney)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036303","Efficacy and Safety of Semaglutide in Adults without Diabetes who are Overweight or Obese","Petty, Rebecca","2026","Digital Commons - Gardner-Webb University (Gardner–Webb University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036304","Evaluating GLP-1 Receptor Agonist in the Treatment of Type 2 Diabetes: A Comparison of Medication Efficacy and Cost","Saul Villalobos Escorza","2026","ScholarsArchive  (Brigham Young University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036305","GLP-1 agonisti u liječenju pretilosti","Topić, Katarina","2023","Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036306","The role of anti-diabetic drugs on the extent of post-BAriatric surgery CARDIac reverse remodelling (BACARDI)","Edilson Samuel Paulino Chamba","2025","Open Repository of the University of Porto (University of Porto)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036307","GLP-1 Agonists and Total Knee Arthroplasty Outcomes: A Systematic Review","Rolanda Willacy","2026","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0036308","Major Adverse Cardiovascular Events are Less Frequent in Psoriasis Patients Starting GLP-1RA Compared to Controls: An Observable Retrospective Cohort Study","Vera, Ana Ormaza","2025","ODU Digital Commons (Old Dominion University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0036309","Cutting calories or cutting corners? Anti-obesity medication use sparks effort-based sanctions and social penalties","Tissot, Tassilo","2025","Ghent University Academic Bibliography (Ghent University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036310","The effect of GLP-1 agonist treatment on serum betatrophin levels and comparison with insulin treatment in type 2 diabetes mellitus patients","İlhan Tarkun","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.gp108",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0036311","Diabetes mellitus in ischemic stroke patients","Takao Urabe","2013","Nosotchu","other","article","10.3995/jstroke.35.103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036312","The role of the microRNAs in the age-associated oancreatic β-cell dysfunction","K. Tugay","2015","IRIS","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036313","An Evidence Based Practice Educational Module Utilizing a Risk Stratification Algorithm for Surgical Patients on GLP-1 Agonists","Getahun, BSN, RN, CCRN, Hana","2024","Florida International University Digital Commons (Florida International University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036314","Type 2 diabetes in young adults, can we do more for them? – case presentation","Mickovski, Ivana","2021","Goce Delchev University Repository (Goce Delčev University of Štip)","other","article","10.46389/rjd-2021-1018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036315","Metabolism and Cognition in Major Depressive Disorder: The Effects of Glucagon-Like Peptide 1 Agonists on Domains of Cognitive Function","Sebastian Badulescu","2025","TSpace (University of Toronto)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036316","Agonis Reseptor Glucagon-Like Peptide-1 (GLP-1) sebagai Terapi Neuroprotektif Baru pada Penyakit Parkinson: Dari Mekanisme Molekuler hingga Perspektif Klinis","Arief Gunawan Darmanto","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other_trial","article","10.24123/kesdok.v7i2.8471",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0036317","UPDATES ON SAFETY AND EFFECTIVENESS OF SEMAGLUTIDE IN WEIGHT LOSS AMONG OBESE PATIENTS WITHOUT DIABETES: A SYSTEMATIC REVIEW","Dr. Nada Zainalabden Tawfeeq, Khalil Ibrahim Bo grain, Amal Abdullah Alhayek, Fatimah Mossa Alahmad, Hawra Mohammed Bu hulayqah, Zainab Abdulrzzak Aldajani, Sakainh Waleed Abdraboh, Yara Waleed Alsaeed, Sara Abdullah Alali, Hawraa Ayesh Al-Ibrahim, Maryam Abdulmonem Bukhamsin","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21825441",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036318","Advancing Knowledge, Collaboration, and Impact—Highlights from the FIU 2025 Diabetes Awareness Day","Barengo, Noel","2025","Florida International University Digital Commons (Florida International University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036319","Beyond the Airway, Volume 1, Issue 1, May 2024",null,"2024","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036320","Validation of a novel radiopharmaceutical according to EU GMP requirements at Turku PET Centre","Yousfi, Maria","2025","UTUPub (University of Turku)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036321","GLP 1 Receptor Agonists and Exercise: Implications for Physical Fitness and Clinical Nutrition","Edna J Nava-González","2026","Journal of Physical Fitness Medicine & Treatment in Sports","other","article","10.19080/jpfmts.2026.11.555823",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036322","UK patients being recruited for ribupatide trials",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other_trial","article","10.1211/pj.2026.1.423674",null,null,"ClinicalTrials.gov:NCT07284901; ClinicalTrials.gov:NCT07284875","S003211; S003213","openalex","FALSE","paywalled","5","FALSE","article"],["R0036323","Additional file 1 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","Chan, Yi-Hsin","2022","Figshare","nonrandomized_study","article","10.6084/m9.figshare.20176126",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036324","Mapping the Scientific Landscape of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Obesity Treatment","Santos, Beatriz Rodrigues dos","2025","New University of Lisbon's Repository (New University of Lisbon)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036325","INCRETIN-BASED THERAPY","Yoshio Fujitani","2012","Juntendō Igaku/Juntendo igaku","other","article","10.14789/pjmj.58.490",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036326","Additional file 1 of Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study","Vencio, Sérgio","2022","Figshare","other_trial","article","10.6084/m9.figshare.18132637",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0036327","Additional file 1 of Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes","Ferdinand, Keith C.","2023","Figshare","other","article","10.6084/m9.figshare.22624691",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036328","Effects of GLP-1 Receptor Agonists on Cardiovascular Events and Their Clinical Positioning","Shunsuke Yamane","2021","Nihon Naika Gakkai Zasshi","other","article","10.2169/naika.110.2458",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036329","Additional file 1 of Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study","Baviera, Marta","2022","Figshare","nonrandomized_study","article","10.6084/m9.figshare.20580410",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036330","Obesity Pharmacotherapy Beyond Weight Loss: Incretin-Based Therapies, Maintenance, and the Role of Family Physicians","I Mohamud","2026","World Family Medicine Journal/Middle East Journal of Family Medicine","nonrandomized_study","article","10.5742/mewfm.2026.241809",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0036331","Association of GLP-1 receptor agonists and risk of pancreatitis: a pharmacovigilance study based on FAERS database","Bishakha, Adwiza Chakraborty","2023","BRAC University Institutional Repository (BRAC University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0036332","Comparison Study of Usability for Patients after Changing Pen-type Injection Needles","Sakiko Futagami","2015","Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","other","article","10.5649/jjphcs.41.624",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036333","Additional file 1 of Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence","Natali, Andrea","2021","Figshare","narrative_review","article","10.6084/m9.figshare.16696428",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0036334","Additional file 1 of Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6","Husain, Mansoor","2022","Figshare","other_trial","article","10.6084/m9.figshare.19682255",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0036335","Additional file 2 of Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study","Baviera, Marta","2022","Figshare","nonrandomized_study","article","10.6084/m9.figshare.20580413",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036336","Erratum to: (64)Cu- and (68)Ga-Labelled [Nle (14),Lys (40)(Ahx-NODAGA)NH 2]-Exendin-4 for Pancreatic Beta Cell Imaging in Rats","Mikkola, Kirsi","2014","Open Access CRIS of the University of Bern","notice","article","10.7892/boris.46334",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0036337","Efficacy and Safety of Tirzepatide for Weight Management in Adults with Overweight or Obesity, with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials","Gülçin Türkmen Sarıyıldız","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21773036",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036338","The impact of glucagon-like peptide 1 agonists on anthracycline or human epidermal growth factor receptor 2 inhibitor-associated cardiotoxicity in patients with breast cancer and diabetes mellitus.","Cho‐Han Chiang","2024","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2024.42.16_suppl.12026",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0036339","Abstract PS3-11-29: Impact of GLP-1 Receptor Agonist Use on Pathologic Complete Response in HER2-Positive Breast Cancer Treated with Neoadjuvant TCHP","D. Urueta Portillo","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-ps3-11-29",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0036340","Achievement of Insulin Reduction and Rapid Stabilization of Blood Sugar by Administering Insulin and GLP-1 Receptor Agonist in Type 2 Diabetes","Shota Kakoi","2016","JOURNAL OF THE JAPANESE ASSOCIATION OF RURAL MEDICINE","other","article","10.2185/jjrm.65.273",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036341","Staff Education About Prescribing Glucagon-Like Peptide-1s (GLP1s)","Deenis Garcia","2026","ScholarWorks (Walden University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036342","Retatrutide: prospects and potential risks in oncology and ophthalmology","A. O. Kenkishvili","2026","Spravočnik vrača obŝej praktiki (Journal of Family Medicine)","other","article","10.33920/med-10-2607-03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036343","Novo Nordisk’s moonshot: turning a diabetes drug into a global phenomenon-risk mitigation practices in Novo Nordisk's supply chain: operational resilience and risk management in global pharma","Mattia Donadei","2025","New University of Lisbon's Repository (New University of Lisbon)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036344","Hosszú hatású GLP-1-receptoragonista szokatlan mellékhatása – a gastrointestinalis motilitás klinikai panaszokat okozó csökkenése IDegLira-kezelés során – esetismertetés [Unexpected adverse event of a long-acting GLP-1-receptor agonist – decreased gastrointestinal motility causing clinical symptoms during IDegLira therapy. A case report]","Arapovicsné Kiss, Krisztina","2019","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036345","Newly Approved and Promising Antidiabetic Agents","Murielle Combettes",null,"Springer Link (Chiba Institute of Technology)","preclinical","article","10.2515/therapie:2007054/pdf",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036346","GLP-1 receptor agonists—another promising therapy for Alport syndrome?","Boeckhaus J",null,"Newcastle University ePrints (Newcastle Univesity)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0036347","The Level of Awareness of County Services in Maryland Offered by a Local Care Team to Youth with Developmental Disabilities and Mental Illness","Valantina Awah Nsoh","2025","ScholarWorks (Walden University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0036348","Dietary Guidance for Managing Gastrointestinal Side Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis","Dominik Diefenbach","2025","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0036349","Effects of glucagon-like peptide 1 receptor agonists on cannabis use: A scoping review protocol","Joselyn Sarabia","2026","OSF Preprints (OSF Preprints)","protocol","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","preprint"],["R0036350","The costs of diabetes in 2020 and 2030 − A model analysis comparing innovative glucose lowering treatments in second line following European and American guidelines compared to current standard of care","Fridhammar, Adam",null,"RePEc: Research Papers in Economics","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036351","Acupuncture for patients with GLP-1 RAs-induced nausea and vomiting: a systematic review protocol","Linzhi LI","2020","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0036352","Raw data for \"The GLP-1RA Trade-Off: Weight Loss, Metabolic Benefits, and the Question of Sexual Interest\"","Ralf Ludwig","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036353","Comparative effectiveness of tirzepatide vs sitagliptin in individuals at cardiovascular risk","Shirley Wang Ph.D.","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036354","GLP-1 RA in Substance Use Disorders","Nandini Jha","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036355","GLP-1 RAs in AD","Ryan Gomes Pedrosa de Siqueira","2026","OSF Preprints (OSF Preprints)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","preprint"],["R0036356","Comportamenti alimentari patologici e variabili psicopatologiche in un campione di pazienti obesi trattati in chirurgia bariatrica e/o terapia con GLP-1 RA","MATTEO BUCCI","2026","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036357","Effects of GLP-1 Receptor Agonists on Mitochondrial Function in Obesity and Heart Failure: A Scoping Review","Pradeep Mammen","2025","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036358","GLP-1 Receptor Agonists in Paediatric obesity: A Systematic Review of Lived Experiences","Catherine Homer","2026","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","preprint"],["R0036359","The \"Skinny Gene\": Has Nature Been Running Its Own Ozempic Experiment?","Ijaz Durrani","2026",null,"other","article","10.13140/rg.2.2.25271.89769",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036360","Az orális szemaglutid terápiás helye a mindennapi gyakorlatban [The importance of cardiometabolic risk reduction in type 2 diabetes mellitus]","Lengyel, Csaba Attila","2022","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036361","Metabolic Dysfunction-Associated Steatohepatitis Systematic Review and Meta-Analysis: From Diagnosis to Newest Available Medications and Outcomes","Marie Balfour","2026","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0036362","Modulation of metabolic, inflammatory, and fibrotic pathways by Semaglutide in MASLD","Jara M",null,"Newcastle University ePrints (Newcastle Univesity)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036363","Exenatide",null,"2015","Reactions Weekly","other","article","10.1007/s40278-015-0207-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036364","Antidiabetikumok új szerepben - újdonságok a Magyarországon elérhető SGLT-2-gátlóknál [Antidiabetics in a new role – news about SGLT-2 inhibitors available in Hungary]","Simonyi, Gábor","2020","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036365","Az antidiabetikumok hatása a kardiovaszkuláris biztonságosságra és a szívelégtelenségre - ahogy a kardiológus látja [Effects of antidiabetics on cardiovascular safety and heart failure – from the point of view of a cardiologist]","Rábai, Miklós","2017","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0036366","GLP1 CVD scoping review protocol","jaredmberndt@gmail.com","2021","OSF Preprints (OSF Preprints)","protocol","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","preprint"],["R0036367","Expert Opinion on Diabetes Management Challenges and Role of Basal Insulin/GLP-1 RA Fixed-Ratio Combination in People with Type 2 Diabetes from Indonesia","Ketut Suastika, -",null,"Universitas Airlangga Repository (Universitas Airlangga)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036368","Effects of Liraglutide on body weight in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","Arif Al-Attar, Delman Mohammed Raoof","2012","Queen Margaret University eTheses Repository","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0036369","Abstracts from the 2024 WDS Forum - virtual option",null,"2025","International Journal of Women’s Dermatology","nonrandomized_study","article","10.1097/jw9.0000000000000202",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0036370","Too much of a good thing? Food aversions with semaglutide after bariatric surgery","Neha Bang (HSC)","2023","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036371","A kardiometabolikus rizikó csökkentésének fontossága 2-es típusú cukorbetegségben [The importance of cardiometabolic risk reduction in type 2 diabetes mellitus]","Kempler, Péter","2022","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036372","GLP-1 regulates the POMC neurons of the arcuate nucleus both directly and indirectly via presynaptic action","Péterfi, Zoltán Attila","2021","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036373","Exenatide versus glimepiride monotherapy in management of patients with type 2 diabetes","Anonymous,","2013","Queen Margaret University eTheses Repository","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0036374","Health Technology Assessment (HTA) of GLP-1 receptor agonists and SGLT-2 inhibitors in combination with metformin as first-line treatment in patient with type 2 diabetes mellitus (T2DM) and established cardiovascular or chronic kidney disease","Aas, Eline",null,"RePEc: Research Papers in Economics","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036375","mev_diet","Leopold Roth","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036376","Stochastic analysis of Ozempic","Prince Fefemwole","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036377","Crystallographic and physicochemical characterization of salcaprozoic acid: A structural basis for SNAC-enabled drug delivery systems","Roy P",null,"Newcastle University ePrints (Newcastle Univesity)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036378","Dual GIP/GLP-1 receptor agonism and addictive behaviors: neurobiological rationale and emerging evidence for tirzepatide in alcohol, tobacco/nicotine, and cocaine use disorders — a translational scoping review","CARLA JULIANA ABRA BERGAMIN","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036379","Comparative effects of GLP-1 receptor agonist–based therapies approved for weight management worldwide in adults with overweight or obesity: protocol for a global systematic review and network meta-analysis","Kalliopi Tsapa","2026","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0036380","How completely do pivotal incretin-based anti-obesity trials capture skeletal-muscle health?","yanglan ou","2026","OSF Preprints (OSF Preprints)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","preprint"],["R0036381","Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss","Jamie Brown","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036382","Comparative effectiveness of semaglutide and tirzepatide in patients at low, moderate, and high cardiovascular risk with type 2 diabetes and obesity","Shirley Wang Ph.D.","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036383","A Clinical Practice Guideline for Managing Gastrointestinal Toxicities Related to GLP-1RA and GIP/GLP-1RA Medications","Williamson, Lindsay","2025","ScholarWorks (Walden University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036384","Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy","Vijiaratnam N",null,"Newcastle University ePrints (Newcastle Univesity)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036385","GLP-1 and exendin-4 for imaging endocrine pancreas. A review. Labelled glucagon-like peptide-1 analogues : past, present and future",null,"2015","Homo Politicus (Academy of Humanities and Economics in Lodz)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036386","Examining the Molecular Mechanisms of Glucagon-like Peptide-1 Receptor Agonists in Cancer Cell Biology","Sabet, Oliver G","2025","OpenCommons - UConn (University of Connecticut)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0036387","Újdonságok a nefro-diabetológiában [An up-date in the nephro-diabetology]","Wittmann, István","2017","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036388","Indokolt lehet-e plazmaferezis, ill. opioid készítmény kiegészítő adása a neuropathia diabetica kezelésében? [Is there any indication for plasmapheresis and opioid therapy in the treatment of diabetic neuropathy? – a case report]","Körei, Anna Erzsébet","2021","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036389","Semaglutide Treatment in Children and Adolescent with Obesity: A Scoping Review of clinical evidence, safety and Ongoing trials","Yurydia Jorge","2026","OSF Preprints (OSF Preprints)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","preprint"],["R0036390","Personalized and evidence-based management of type 2 diabetes : the role of clinical-phenotyping for treatment planning and surveillance of complications","Lakshminarayanan Varadhan","2025","Warwick Research Archive Portal (University of Warwick)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","dissertation"],["R0036391","Attitudes of African American Police Officers Towards Violent Police Encounters in an Urban Environment","Lindsay Williamson","2025","ScholarWorks (Walden University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036392","Új terápiás stratégiák a diabéteszes vesebetegség kezelésében [New therapeutic strategies in the management of diabetic kidney disease]","Balogh, Zoltán","2022","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036393","The role of Magnetic Resonance Imaging and Spectroscopy in the Assessment of Disease Pathophysiology in Patients with Type 2 Diabetes Mellitus","Chowdhary, Amrit","2022","White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0036394","A hosszú hatású GLP-1-receptoragonisták helye a 2-es típusú diabetes kezelésében – a jelen hazai lehetőségek [The place of long acting GLP-1 receptor agonists in the therapy of type 2 diabetes – the present possibilities in Hungary]","Winkler, Gábor","2019","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036395","Preserving musculoskeletal health through resistance training in individuals undergoing Glucagon-like Peptide-1 Receptor Agonist Therapy: a controlled interrupted time-series analysis","Robin M. Daly","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036396","Search Strategies for: \"Evaluating the Efficacy of GLP-1 Receptor Agonists in Metabolic Liver Diseases: A Systematic Review and Network Meta-Analysis.\"","Tara Brigham","2025","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0036397","Severe form of lipoedema and obesity, therapeutic challenge: report of a rare case","Minova Natasha Nedeska","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep991",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0036398","GLP-1 receptor agonists in the management of COVID-19 and long COVID for patients with underlying metabolic disorders","Nigel Hinchliffe","2025","Medical Research Archives","other","article","10.18103/mra.v13i4.6406",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036399","Exenatide once a week versus placebo as a potential disease modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","Vijiaratnam N",null,"Newcastle University ePrints (Newcastle Univesity)","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT04232969; EudraCT:2018-003028-35","S001156","openalex","TRUE","no_doi","1","FALSE","article"],["R0036400","Kettős inkretinterápia – új lehetőség a 2-es típusú diabetes vércukorcsökkentő kezelésében","Gábor Winkler","2022","Lege Artis Medicinae","other","article","10.33616/lam.32.019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036401","SUSTAIN program: klinikai eredmények [SUSTAIN trial program: clinical results]","Balogh, Zoltán","2019","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036402","Effect of dulaglutide on functional and structural MRI changes during cigarette smoking cessation","David Coynel","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036403","Tirzepatide for Type 2 Diabetes","Institute for Clinical and Economic Review","2023","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036404","A cross-sectional study investigating the neurotrophic effect of GLP-1ra treatment on small fibre neuropathy in type 2 diabetes","Tobin, Victoria R","2021","Open Access at Essex (University of Essex)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036405","Systematic review and consensus statement for the preoperative management of GLP 1 agonists","Victoria Clifton",null,"OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0036406","A Research Proposal to Examine the Semaglutide-Sarcopenia Paradox in Geriatric Care Among Older Adults in Ontario, Canada","Charmaine Marcus-Paiva","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21877870",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036407","Efficacy and Safety of Once-Weekly Semaglutide Use for Weight Loss Among Patients without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Areesha Moiz",null,"OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0036408","Treatment of Moderate to Severe Binge Eating Disorder with GLP-1 agonist Semaglutide","Courtney McCorkle (HSC)","2023","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036409","Új antidiabetikum-csoportok cardiovascularis biztonságossága 2-es típusú diabetesben [Cardiovascular safety of newer antidiabetic compounds in type 2 diabetes]","Winkler, Gábor","2018","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036410","Kajian pustaka efektivitas dan keamanan semaglutide injeksi pada pasien diabetes melitus tipe 2 dengan obesitas","Putri, Nanda Elmaiyana","2022","Widya Mandala Catholic University Surabaya Repository (Widya Mandala Catholic University Surabaya)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0036411","Weight loss and metabolic changes in response to diet restriction and bariatric surgery","van Riel, Natal; id_orcid 0000-0001-9375-4730","2024","TU/e Research Portal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036412","DPP-4-gátlók a 2-es típusú diabetes kezelésében – megújult irányelvek, változó klinikai gyakorlat [DPP-4-inhibitors for treating patients with type 2 diabetes – updated guidelines, changing clinical practice]","Jermendy, György","2020","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036413","EFFECTS OF TIRZEPATIDE ON BODY COMPOSITION IN INDIVIDUALS WITH OBESITY: AN INTEGRATIVE REVIEW","Estélio Henrique Martin Dantas","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036414","GLP- 1 Receptor Agonists In Type 2 Diabetes And Obesity: Review Article","Sheeba Anitha Rani1*, Yerni Jyothi Kolli2, Anusuyadevi V.3, Prathima Prakasam4","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.21872967",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036415","Pérdida de masa muscular con agonistas del receptor GLP-1: Sarcopenia inducida por farmacoterapia y estrategias de mitigación","Albert Rafael Barrail Hellman","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21865727",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036416","Organic Nanoparticles for targeting β-Cell in Type 1 and Type 2 Diabetes","Shakila Behzadifar","2025","theses.fr (ABES)","preclinical","article","10.70675/83c0ea93z4540z47e3za116zcd64537685bf",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036417","Dental and Salivary Complications Associated with GLP-1 Receptor Agonist Therapies in Adults: A Scoping Review of Clinical Evidence.","Camila Guimarães da Costa Campo","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036418","Real-World GLP-1RA Treatment Response Study — All of Us Research Program","Valentin","2026","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","preprint"],["R0036419","Community Survey of Ozempic, Wegovy, Trulicity, Mounjaro and other GLP-1 Agonist Use","Kristi Griffiths","2026","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","preprint"],["R0036420","Rôle thérapeutique du dimère du domaine Kringle 1 du facteur de croissance des hépatocytes/facteur de diffusion dans les maladies du foie et le diabète","Michele Lodato","2024","theses.fr (ABES)","other","article","10.70675/916e2823z366fz4cc5za748z5d1540ee523e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036421","GLP-1 Receptor Agonists and musculoskeletal outcomes","Yveline Malrechauffé","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036422","A Clinical Practice Guideline for Managing Gastrointestinal Toxicities Related to GLP-1RA and GIP/GLP-1RA Medications","Sonia O. Roselló Aponte","2025","ScholarWorks (Walden University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036423","A diszfunkcionális zsírszövet szerepe az elhízáshoz társuló cardiorenalis-metabolikus szindróma kialakulásában = The role of dysfunctional adi-pose tissue in the development of obesity-associated cardiovascular-kidney-metabolic syndrome","Mariann Harangi","2025","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036424","Patiënten met type 2-diabetes en een laag cardiovasculair risico","Erik H. Serné","2023","Pure Amsterdam UMC","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036425","Understanding Monoclonal Gammopathy of Undetermined Significance","Winkel, Scott, MSPH, MHS, PA-C","2025","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article","10.63932/3067-7106.1054",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036426","Evidências sobre o uso da semaglutida no tratamento da obesidade e seus impactos cardiovasculares: uma revisão de escopo","Juliana Ascencao de Souza","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036427","Adverse Event Reports for Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents","Brice Koons","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036428","Type 2 Diabetes Mellitus: Pathophysiology, Management, and Future Directions","Zulfkar, Qadrie","2025","Umsida Repository (Universitas Muhammadiyah Sidoarjo)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036429","Diet quality among adults utilising injectable incretin-mimetic medications for weight loss in the United Kingdom","Sarah Pearce","2026","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","preprint"],["R0036430","A diabetológia fejlődése és az antihyperglykaemiás terápia szemléletének változása az elmúlt 35 évben = Development in diabetology, changes in antihyperglycaemic treatment attitudes in the past 35 years","György Jermendy","2026","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036431","IGlarLixi – bázisinzulin és GLP-1-receptoragonista új fix kombinációja [IGlarLixi – new fix combination of a basal insulin and a GLP-1 receptor agonist]","Winkler, Gábor","2018","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036432","Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk","Nils Krüger","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036433","Diabetes Mellitus: A Comprehensive Overview of Pathophysiology, Risk Factors, Diagnosis, Complications, and Management","Ubaydullayev, Abbosxo'ja Xikmatilla","2025","Umsida Repository (Universitas Muhammadiyah Sidoarjo)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036434","Quality Improvement Initiative to Evaluate GLP-1 Medication Effectiveness in Adults Aged 30–50 Years with Type 2 Diabetes","Awah Nsoh, Valantina","2025","ScholarWorks (Walden University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0036435","Effect of jicama (Pachyrhizus erosus L.) Fiber In hight-fat Diet On glucagon-like peptide 1 in mice (Mus musculus)","Muhammad, Ihsan Anggi Manura","2022","Andalas University eThesis (Andalas University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036436","Safety profile of GLP-1 receptor agonists in clinical use: scoping review","Ana Cristina Baetas Gonçalves","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036437","The efficacy of liraglutide in reducing major adverse cardiovascular events (MACE) in individuals with overweight or obesity without a diagnosis of type 2 diabetes mellitus.","Graziela Torres Blanch","2026","OSF Preprints (OSF Preprints)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","preprint"],["R0036438","Paradigm shift from glucocentric to organ protection for the management of hyperglycemia in patients with type 2 diabetes","Jie-Eun Lee","2024","Cardiovascular Prevention and Pharmacotherapy","other","article","10.36011/cpp.2024.6.e15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036439","Association of glucagon-like peptide 1 receptor agonists and treatment for bile acid diarrhea","Martin Torp Rahbek",null,"OSF Preprints (OSF Preprints)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","preprint"],["R0036440","GLP-1 Agonists for Substance Use and Compulsive Behavior Disorders: A Scoping Review","Dan Stuart","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036441","A glukagonszerű-peptid-1-receptoragonisták anyagcsere-, ér- és vesehatása, a kénhidrogén lehetséges szerepe [Metabolic, vascular and renal effect of glucagon-like peptide-1 receptor agonist; the possible role of hydrogen sulfide]","Wittmann, István","2021","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0036442","Glucagon-Like Peptide-1 Receptor Agonists and Chemosensory Function: Mapping the Pre-clinical and Clinical Evidence Base","Katherine Whitcroft","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036443","Comparative effectiveness of the glucose-lowering agents semaglutide and tirzepatide vs sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in patients with peripheral vascular disease","Shirley Wang Ph.D.","2025","OSF Preprints (OSF Preprints)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","preprint"],["R0036444","Impact of cardiac autonomic neuropathy on diabetic kidney disease: Assessment by magnetic resonance imaging","Soe, Kywe Kywe","2024","White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0036445","From Metabolism to Microvasculature: Pericytes-the Architect of GLP-1 Benefits","Corinna","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036446","A szemaglutid szerkezete és farmakológiája [Semaglutide: structure, pharmacokinetics and pharmacodynamics]","Winkler, Gábor","2019","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036447","GLP-1 Receptor Agonists and Antipsychotic Adherence in Adults with Schizophrenia Spectrum Disorders: A Scoping Review and Evidence Gap Analysis","Chimaobi Aroeze","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036448","GLP-1-receptoragonista-kezelés diabeteses vesebetegségben [GLP-1 receptor agonist treatment in diabetic kidney disease]","Fülöp, Gábor","2021","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036449","Evaluating the Use of Incretin-Based Therapies in Athletes With Overweight or Obesity","Ryan C. Roe","2026","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036450","A GLP-1-receptoragonista liraglutid direkt hatásai az érfali diszfunkcióra 2-es típusú cukorbetegségben [Direct effects of GLP-1 receptor agonist liraglutide on endothelial dysfunction and atherosclerosis in type 2 diabetes]","Sztanek, Ferenc","2022","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036451","Pharmacological treatment for obesity in adults: Scoping Review","Gaia Guevara","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036452","Real-World Outcomes of Bariatric Surgery and Adjunctive Setmelanotide in Genetic Obesity","Kristie Kay Roberts","2026","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","preprint"],["R0036453","Efficacy and safety of oral small-molecule GLP-1RAs in type 2 diabetes mellitus, obesity or both: A systematic review and meta-analysis","Paschalis Karakasis",null,"OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0036454","Új hatásmechanizmusú antihipertenzív szerek = Novel antihypertensive drugs","Alföldi, Sándor","2025","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036455","Epekövesség cukorbetegségben [Gallstones in diabetic patients]","Buzás, György Miklós","2017","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036456","Safety of Chance Exposure to GLP-1 Receptor Agonists in Pregnancy","Balwinder Ruprai","2025","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036457","Új, innovatív antidiabetikumok (DPP-4-gátlók, SGLT-2-gátlók, GLP-1-receptorantagonisták) perzisztenciavizsgálata 2-es típusú diabetesben - országos adatbázis-elemzés eredményei","Jermendy, György","2019","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036458","semaglutide","PAOLO MARZULLO",null,"OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0036459","Semaglutid schützt auch bei oraler Applikation","Susanne Krome","2025","DMW - Deutsche Medizinische Wochenschrift","other","article","10.1055/a-2596-1820",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036460","Editorial introductions","Bobby Yanagawa","2026","Current Opinion in Cardiology","commentary","article","10.1097/hco.0000000000001276",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0036461","Association Between Glucagon-Like Peptide-1 Receptor Agonists and Fracture Risk in Type 2 Diabetes: A Large-Scale Target Trial Emulation","Yao-Jen Chang","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6031396",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0036462","El Ozempic y otros fármacos GLP-1 podrían combatir la adicción a todo tipo de sustancias","Ziyad Al-Aly","2026",null,"other","article","10.64628/aao.q3hx74fs9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0036463","Cagrilintide Combined with Semaglutide: a new Approach for Treatment of Obesity and type 2 Diabetes","Nasser Mikhail","2023","Clinical Research and Clinical Trials","randomized_trial","article","10.31579/2693-4779/154",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0036464","Beneficial Effects of Incretin-Based Therapy on Glycemic Control, Adipokines, Insulin Sensitivity Parameters and Weight Loss in Overweight or Obese Patients With Newly Diagnosed Type 2 Diabetes: A Prospective Study","Yang Yu","2015","Journal of Endocrinology and Metabolism","randomized_trial","article","10.14740/jem304w",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0036465","THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON METABOLIC AND REPRODUCTIVE OUTCOMES IN POLYCYSTIC OVARY SYNDROME","Vikram Kumar Dr. Rao","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21890518",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036466","Impact of Semaglutide on Obesity and Cardio Metabolic Risk Factors in Non-Diabetic Adult","R Sumithra, Arun Kumar K, Manoj Irappa K, Ananda S, Mohammad Saqib Wani, Jiji K","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21891387",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036467","Improved Glycemic Control due to Reduction in Glucagon Levels by the Administration of Once-Weekly Dulaglutide in a Non-Obese Patient With Type 2 Diabetes","Shingo Morimitsu","2018","Journal of Endocrinology and Metabolism","other","article","10.14740/jem.v8i1.486",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036468","Rotenon ile İndüklenen İn Vitro Parkinson Hastalığı Modelinde Glukagon Benzeri Peptid-1 Analoğu Ekzenatidin Nöron Sağkalımına Etkisi","Mümin Alper Erdoğan","2019","DergiPark (Istanbul University)","preclinical","article","10.22312/sdusbed.590482",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036469","Machine Learning-Assisted Gene Risk Score for Calories to Satiation Predicts Weight Loss Response to Semaglutide in a Multi-Center Biobank and Outcomes Registry","Sima Fansa","2025","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.5961920",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0036470","EFFECTS OF MOUNJARO ON BRAIN CELLS","Diego Santiago Marinho","2026","Revista fisio&terapia.","other","article","10.69849/revistaft/dt10202601151251",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036471","ORAL HEALTH CONSEQUENCES OF SEMAGLUTIDE (GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST) THERAPY: SYSTEMATIC REVIEW WITH EVIDENCE GRADING AND CLINICAL RECOMMENDATIONS","Dr. Jaideep Kour Raina","2026","International Journal of Advanced Research","systematic_review","article","10.21474/ijar01/23857",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0036472","848: PRIOR GLP-1 USAGE MAY BE ASSOCIATED WITH REDUCED MORTALITY IN SEPTIC SURGICAL PATIENTS WITH OBESITY","Jasmine Kelley","2026","Critical Care Medicine","nonrandomized_study","article","10.1097/01.ccm.0001185388.05241.50",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0036473","Idiopathische intrakranielle Hypertonie: Benefit durch GLP-1-Rezeptoragonisten","Annika Simon","2026","Neurologie up2date","other","article","10.1055/a-2675-6907",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036474","Which Is the Best Treatment for Diabetes Complicated With Severe Obesity, Intensive Insulin Therapy or Basal Supported Oral Therapy or Glucagon-Like Peptide-1 Analog?","Moriyama","2011","Journal of Endocrinology and Metabolism","other","article","10.4021/jem50w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036475","Insulindosis-Reduktion unter Semaglutid bei Typ-1-Diabetes und Adipositas","R. Maria Clauss","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2801-1674",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036476","The cardiometabolic triad: obesity, sleep-disordered breathing, and epicardial adipose tissue","Fulvio Cacciapuoti","2026","Minerva Cardiology and Angiology","randomized_trial","article","10.23736/s2724-5683.26.07120-6",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0036477","GLP-1-RA-Stopp bei Schwangerschaft: Was sind die Konsequenzen?","Frank Lichert","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2754-5806",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036478","Hyperglycemia — An Evolutionary Blind Spot: The Central Neurological Set Point Reset Hypothesis of Progressive Type 2 Diabetes","Aditya Mishra","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19201285",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036479","A Review of NAFLD Remission Strategies: From Molecular Mechanisms to Clinical Interventions","Weiyu Chen","2026","Exploring Science Academic Conference Series","other_trial","article","10.70267/shbe.20266170",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-paper"],["R0036480","Exenatide‐induced hypomagnesaemia causing seizures","J Mackay","2010","Practical Diabetes","other","article","10.1002/pdi.1513",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036481","Incretin-based therapies for type 2 diabetes","Brenda Capaldi","2012","Practice Nursing","other","article","10.12968/pnur.2012.23.10.508",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036482","The optimal medical therapy for glycemic control in covid-19","Hidekatsu Yanai","2021","Journal of Endocrinology and Metabolism","other","article","10.14740/jem.v0i0.718",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036483","a systematic analysis for the Global Burden of Disease Study 2023","Hay, Simon I.","2025","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036484","May Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Be a New Frontier in Managing Female Urinary Inconti-nence?","Mertihan Kurdoğlu","2026","Crescent Journal of Medical and Biological Sciences","other","article","10.34172/cjmb.2003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036485","Involvement of Vascular Endothelial Cells in the Anti-atherogenic Effects of Liraglutide in Diabetic Apolipoprotein E-null Mice","小澁正和",null,"Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036486","Effects of Liraglutide, a Human Glucagon-Like Peptide-1 Analog, on Glucose/Lipid Metabolism, and Adipocytokines in Patients With Type 2 Diabetes","Hidekatsu Yanai","2011","Journal of Endocrinology and Metabolism","randomized_trial","article","10.4021/jem.v1i3.38",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036487","The anti -Parkinson effects of Liraglutide in rat model of Rotenone induced Parkinsonism",null,"2020","International Journal of Pharmaceutical Research","preclinical","article","10.31838/ijpr/2020.sp2.449",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036488","Ozempic e outros medicamentos GLP-1 podem ajudar a combater vícios em diversas substâncias","Ziyad Al-Aly","2026",null,"other","article","10.64628/ade.cnkywguyg",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0036489","GLP-1-Rezeptoragonisten II: Erhöhtes 1-Jahres-Risiko für Optikusneuropathie","Annika Simon","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2801-1741",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036490","GLP-1-RAs: Genetische Prädiktoren für Sicherheit und Wirksamkeit","Annika Simon","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2858-2415",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036491","Steroid-Induced Hyperglycemia Successfully Treated With Once-Weekly Dulaglutide in an Old Patient With Type 2 Diabetes","Hidetaka Hamasaki","2018","Journal of Endocrinology and Metabolism","other","article","10.14740/jem.v8i1.491",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036492","Cardiac Toxicology and Cardioprotective Mechanisms of Semaglutide A Bibliometric and Clinical Analysis (2)","Gregory K. Tharp","2026",null,"other","article","10.13140/rg.2.2.34964.67205",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036493","Intersecting Health Behaviors in a Collegiate Population: GLP-1 RA Injection Use and Uptake of Influenza and COVID-19 Vaccines","Beth H. Chaney","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6430421",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036494","Diabetes und Niere - Wie wirkt sich das Absetzen von SGLT-2i und GLP1-RA bei CKD-Patienten aus?","Gunter Wolf","2026","Nephrologie aktuell","other","article","10.1055/a-2806-8795",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036495","1470-NM ENDOLASER-ASSISTED AMBULATORY TREATMENT FOR LIPEDEMA: A CASE REPORT","Heidi Feitoza","2026","Revista Científica Faesa","case_report","article","10.5008/1809.7367.315",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036496","1652: EUGLYCEMIC KETOACIDOSIS SECONDARY TO SEMAGLUTIDE-INDUCED MUNCHAUSEN SYNDROME BY PROXY","Christopher Schneller","2026","Critical Care Medicine","other","article","10.1097/01.ccm.0001188604.24022.19",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036497","297-OR: A Novel GLP-1/FGF21 Dual Agonist ZT003 Has Therapeutic Potential for Obesity, Diabetes, and Nonalcoholic Steatohepatitis","Yuanyuan Zhang","2024","Diabetes","preclinical","article","10.2337/db24-297-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036498","GLP-1-Rezeptoragonisten: Kausale Reduktion des Risikos für Myokardinfarkte?","Annika Simon","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2754-5783",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036499","Zulassungsrelevante Daten zu einer neuen Abnehm-Tablette bei Adipositas","Friederike Klein","2026","Zeitschrift für Gastroenterologie","other","article","10.1055/a-2796-2421",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036500","Typ-2-Diabetes und Adipositas: Orforglipron unterstützt Gewichtsreduktion","Annika Simon","2026","Zeitschrift für Gastroenterologie","other","article","10.1055/a-2841-6576",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036501","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in the Weight Loss Among Obese Individuals: A Systematic Review","Raed Aldahash","2021","Journal of Endocrinology and Metabolism","systematic_review","article","10.14740/jem.v0i0.745",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036502","904: METHYLENE BLUE AS RESCUE THERAPY IN METFORMIN-ASSOCIATED LACTIC ACIDOSIS","Ariel Ruiz de Villa","2026","Critical Care Medicine","other","article","10.1097/01.ccm.0001185612.82548.83",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036503","Liraglutide Treatment in a Patient with Diabetes Mellitus in Prader-Willi Syndrome","Yutaka Uzuki","2012","Acta Endocrinologica (Bucharest)","other","article","10.4183/aeb.2012.107",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036504","GLP-1 Receptor Agonist Therapy in the Treatment of PCOS: A Scoping Review","Madelyn Kennedy","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/jw62x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; preprint"],["R0036505","Quantities of GLP-1 mimetics: answers","Janice Davies","2020","Journal of Prescribing Practice","other","article","10.12968/jprp.2020.2.3.154",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036506","Glucagon-like peptide-1 receptor agonists on outcomes in osteoarthritis among persons with obesity: a protocol for systematic review and meta-analysis","Mengying Wang","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/8y457",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036507","Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: a Systematic Literature Review","Bratosin, Felix","2024","Open Science Framework","narrative_review","article","10.17605/osf.io/d5f9t",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0036508","Use of GLP-1 Receptor Agonists for Obesity Management in Adolescents: A Rapid Review of Recent Evidence (2023–2025)","Armstrong, Nicole Rubino Niemeyer","2025","OSF Preprints (OSF Preprints)","narrative_review","article","10.17605/osf.io/yzq3w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036509","Effect of GLP-1RA, SGLT2i, and DPP-4i on incident depression in individuals with type 2 diabetes: A Danish nationwide target trial emulation","Köhler-Forsberg, Ole","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/y67fg",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036510","SDOH, GLP-1 Prescription Patterns and MASLD-associated Liver Disease in a Real World Population","Satya Manasa Kota","2026","University of Illinois Chicago","nonrandomized_study","article","10.25417/uic.32991914.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0036511","Staging Liver Fibrosis in MASLD: Is FAPI PET the Missing Piece?","Yasser G. Abdelhafez","2026","The Egyptian Journal Nuclear Medicine","other","article","10.21608/egyjnm.2026.473141.1139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036512","The incidence and volume of residual gastric contents in fasting surgical patients using glucagon-like peptide-1 receptor agonists: a prospective observational study.","Hobai, Ion","2025","Open Science Framework","other","article","10.17605/osf.io/3cmrg",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036513","GABA signaling regulation by GLP-1 receptor agonists and GABA-A receptors modulator","Omar Babateen","2016","KTH Publication Database DiVA (KTH Royal Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036514","The Effect of SGLT-2i and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis","Jogimahanti Arjun","2024","Journal of Cardiology and Cardiovascular Medicine","systematic_review","article","10.29328/journal.jccm.1001173",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0036515","Phasic Dopamine Signaling During Ingestion: Modulation Across the Need-to-Satiety Arc","Bazzino, Paula","2025","University of Illinois Chicago","preclinical","article","10.25417/uic.30424876",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036516","Weight loss interventions for overweight or obese individuals with chronic kidney disease (CKD): a systematic review and meta-analysis","Αναστασία Χ. Σταματίου","2026","Aristotle University of Thessaloniki","systematic_review","article","10.26262/heal.auth.ir.372860",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036517","Ultraprocessed Foods, GLP-1, and Mental Health: A Modular Protocol with Diet, Physical Activity, and Tirzepatide","da Silva Barros, Maicon Herverton Lino Ferreira","2025","OSF Preprints (OSF Preprints)","protocol","article","10.17605/osf.io/7p4x5",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0036518","The Use Of Oral Small-Molecule Glucagon-Like Peptide-1 And Metabolic Outcomes In DMT2 And Obesity: Network Meta-Analysis of Clinical Trials","Ayesh, Hazem","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/3cy6e",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036519","Glucagon-like peptide-1 Receptor Agonists for Weight Management in Mental Illness: A Network Meta-Analysis","Taro Kishi","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/e89uf",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036520","The metabolic effect of medicinal plants and synthetic anti-obesity products on human health","Zainab A. A. Al-Shammary","2024","Plant Science Today","other","article","10.14719/pst.3206",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036521","Calorie Estimation Error and BMI","Doshi, Shemal","2025","Open Science Framework","other","article","10.17605/osf.io/bhg6j",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036522","GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation","Fernandes Cruzat, Vinicius","2022","Torrens University","preclinical","article","10.25905/21555126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036523","TIRZEPATIDE","Sharon Rees","2024","Journal of Prescribing Practice","other","article","10.12968/jprp.2024.6.3.94",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036524","The maternal and fetal effects of glucagon-like peptide-1 receptor agonists in pregnancy: a scoping review","van Pelt, Laura","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/5h826",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036525","Comparative Analysis of GLP-1 Agonists vs Metformin vs Inositol in the Treatment of PCOS: Network Meta-Analysis of Clinical Trials","Ayesh, Hazem","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/zyhws",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036526","Validating the Role of Chatgpt in Automatic Systematic Reviews and Meta-Analysis: a Case Study Focusing on Mortality Benefits of Glucagon-Like Peptide-1 Receptor Agonists","Teperikidis, Lefteris","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/x6n8b",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036527","Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis","Δημήτριος Ιωάννη Πατουλιάς","2019","Aristotle University of Thessaloniki","systematic_review","article","10.26262/heal.auth.ir.305942",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036528","Κλινική αξιολόγηση του σκευάσματος Suliqua (Lisixenatide + Insulin glargine) στα πρότυπα διαδικασίας υποβολής φακέλου για την Επιτροπή Αξιολόγησης Φαρμάκων Ανθρώπινης Χρήσης","Χατζόπουλος, Παναγιώτης Θεόδωρου","2022","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.340650",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036529","A nationwide target trial emulation evaluating whether initiation of GLP-1 receptor agonists reduces work disability among adults with low back pain","Mortensen, Ole Steen","2025","OSF Preprints (OSF Preprints)","nonrandomized_study","article","10.17605/osf.io/qd7ap",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0036530","Comparative efficacy of Tirzepatide vs Semaglutide in reducing body weight in humans; A systematic review and metanalysis","Latif, Rabia","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/mjt9p",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036531","Evaluating the Impact of Semaglutide on Stroke Risk Reduction in Cardiovascular High-Risk Populations: A Systematic Review and Meta-analysis","Laiba Nasir","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/mbwgq",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other; review"],["R0036532","Comparative Effectiveness of Long-Term Weight Loss Maintenance Post Sleeve Gastrectomy and Glucagon-Like Peptide-1 Receptor Agonist Treatment: A Systematic Review and Meta-Analysis","Ayesh, Hazem","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/ysq4z",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036533","Understanding the impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1As, e.g. Ozempic) on eating disorder psychopathology, negative affect, body image and wellbeing.","Robinson, Shea","2025","Open Science Framework","other","article","10.17605/osf.io/6f4ue",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036534","Effects of GLP-1 Receptor Agonists on Mitochondrial Function in Obesity and Heart Failure: A Scoping Review","Pierce, Janet","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/xhtre",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036535","Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review","Holmes, Lucy","2024","Open Science Framework","narrative_review","article","10.17605/osf.io/kwn9q",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036536","Dulaglutide",null,"2016","Reactions Weekly","other","article","10.1007/s40278-016-18123-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036537","\"Incretin-Based Therapies for Patients with Overweight or Obesity and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Thomaz Alexandre Costa","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/3w4cs",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036538","Association between SGLT2 inhibitors use and risk of phimosis: A Norwegian cohort study","Pottegård, Anton","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/yzrj3",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036539","Glucagon-like peptide-1 (GLP-1) receptor agonists: treatment targets: answers","Janice Davies","2025","Journal of Prescribing Practice","other","article","10.12968/jprp.2025.0100",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036540","Glucagon-Like Peptide 1 Receptor Agonist for Patients with Obesity and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Thomaz Alexandre Costa","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/5a26b",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036541","Sweating in diabetes","Rowan Hillson","2017","Practical Diabetes","other","article","10.1002/pdi.2096",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036542","Οι αγωνιστές του GLP-1 υποδοχέα ως προσθήκη στην ινσουλινοθεραπεία σε ασθενείς με Σακχαρώδη Διαβήτη τύπου 1. Συστηματική ανασκόπηση και μετα-ανάλυση","Κίτσιος, Κωνσταντίνος Ζήση","2019","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.306159",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036543","Tirzepatide versus placebo in adults with osteoarthritis and obesity: a secondary analysis of the SURMOUNT 1, 2, and 3 randomised trials","Cade Shadbolt","2025","Open Science Framework","randomized_trial","article","10.17605/osf.io/vsg6f",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article; preprint"],["R0036544","GLP-1 agonists medication and judgments","Monterosso, John","2023","Open Science Framework","other","article","10.17605/osf.io/sxv28",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036545","GLP-1 receptor agonists and co-agonists for the prevention of atrial fibrillation in overweight or obesity: A meta-analysis of randomized controlled trials","Karakasis, Paschalis","2025","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/2qd5p",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0036546","Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk","Wang, Shirley","2025","Open Science Framework","other","article","10.17605/osf.io/s9r5q",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036547","Evaluating the Impact of Semaglutide on Stroke Risk Reduction in Cardiovascular High-Risk Populations: A Systematic Review and Meta-Analysis","Farooqui, Maryam","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/hf583",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036548","Orforglipron different doses effect on body weight : A systematic review and network meta-analysis of randomized clinical trials","Abouelmagd, Alaa Abdrabou","2023","Open Science Framework","systematic_review","article","10.17605/osf.io/nmaq5",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036549","Application of GLP-1 Receptor Agonists in the Pre-Operative Setting for Liver Resection: A Scoping Review","Gordon-Weeks, Alex","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/mvzf9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036550","Anesthesia in patients using GLP-1 analogues: Implications for preoperative fasting and risk of pulmonary aspiration","BÁRBARA GEMELLI FERNANDES","2026","International Health Sciences Review","nonrandomized_study","article","10.70164/ihsr.v2i3.183",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0036551","Pharmacological Study of Weight Losing of Liraglutide Loaded Within Layered Double Hydroxide Carrier",null,"2020","Indian Journal of Forensic Medicine & Toxicology","other","article","10.37506/ijfmt.v14i4.12165",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036552","Pharmacist’s role in cancer risk reduction through diabetes management and obesity-modifying therapies","Gabriel Beltran","2026","NCODA Oncology and Hematology Meeting Abstracts","other","article","10.67209/nvwc2178",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0036553","Dietary Guidance for Managing Gastrointestinal Side Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis","Makarand Prasad Nadendla","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/6s4dj",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036554","Επίδραση των GLP-1 αγωνιστών στο σύνδρομο πολυκυστικών ωοθηκών: συστηματική ανασκόπηση","Ραλλίδη, Αφροδίτη Λουκιανού","2024","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.356448",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036555","TRIM","Gudbergsen, Henrik","2024","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/65pxj",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036556","Real-world evidence on the cardiovascular impact of GLP-1 RAs in diabetic patients with and without heart failure: Insights from longitudinal data of Greek tertiary hospitals","Κυρτσόπουλος, Μιχαήλ Γεωργίου","2025","Aristotle University of Thessaloniki","nonrandomized_study","article","10.26262/heal.auth.ir.361792",null,null,"ClinicalTrials.gov:NCT05176769",null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036557","Liraglutide and semaglutide in the treatment of severe obesity in adolescents treated in the Brazilian Public Health System: Research protocol for cost-effectiveness and budget impact analysis study","De Melo Barbosa, Aurelio","2025","OSF Preprints (OSF Preprints)","protocol","article","10.17605/osf.io/jdy7z",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0036558","Social Media Promotion of GLP-1 Receptor Agonists for Obesity: A Scoping Review of Study Designs, Engagement Strategies, and Public Perceptions","Zein, Ola El","2025","Open Science Framework","protocol","article","10.17605/osf.io/j8kpe",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0036559","Glucagon-Like Peptide-1 Receptor Agonists for the Prevention of Genitourinary Cancers: A Systematic Review of Observational Studies","Yu, Oriana Hoi Yun","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/fgbc9",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036560","GLP-1 Receptor Agonists versus Placebo or Standard Care for Disability Progression in Multiple Sclerosis","Nafiseh Sami","2025","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/3ec5j",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036561","COMPARATIVE STUDY OF ERYTHROPOIETIN AND EXTENDIN-4 ON ADULT MALE DIABETIC ALBINO RATS","Sameh Soltan","2017","Al-Azhar Medical Journal","preclinical","article","10.12816/0038275",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036562","Reporting of diet quality and intake in interventions evaluating the effects of liraglutide, semaglutide or tirzepatide on weight-loss and/or blood glucose in patients of all age groups with obesity and/or T2D: A systematic review of RCTs","Collins, Clare","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/gcmxw",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036563","Reward Dysregulation, Delay Aversion and Rewarded Perseveration in Adult ADHD: A Two-Arm Neuroimaging and GLP-1 Modulation Study of Habenular Circuits","Borghi, Rodrigo Nogueira","2025","Open Science Framework","randomized_trial","article","10.17605/osf.io/zxr8b",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0036564","The impact of GLP-1 and dual GLP-1/GIP agonists on the efficacy of combined oral contraceptives: a scoping review","Casey M. Moffitt","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/s63jd",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036565","The Impact of Ozempic on Neurological and Psychological Systems: A Scoping Review","Fliti, Tala","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/e2bgc",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036566","Construction and evidence of validity and reliability of psychological instruments for assessing eating behavior.","Alef Alves Lemos","2026","Open Science Framework","other","article","10.17605/osf.io/267ae",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036567","Behandling med GLP-1-analog hos överviktiga patienter utan diabetes mellitus","Li Sturesdotter","2013","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036568","Temporal and Racial Differences in Outcomes of Treatment of Myocardial Infarction-Associated Heart: A Systematic Review","Mentz, Robert","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/ehj4x",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036569","Impact of semaglutide introduction on the use of antimigraine medication: an interrupted-time series","Kildegaard, Helene","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/jum4z",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036570","Efficacy and Safety of Once-Weekly Semaglutide Use for Weight Loss Among Patients without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Areesha Moiz","2023","Open Science Framework","systematic_review","article","10.17605/osf.io/6g7j4",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review; preprint"],["R0036571","Influence of Diabetes Mellitus on Anesthetic Considerations When Undergoing Surgery","Jordan Derbidge","2026","RVU Elevate","other","article","10.82451/k51175",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0036572","Heart and Health Behavior Responses to GLP-1 RA: A 12-Week Study Using Wearable Technology and Causal Inference","Grosicki, Gregory","2024","Open Science Framework","other","article","10.17605/osf.io/x4vgz",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036573","Comparative effectiveness of semaglutide versus liraglutide/dulaglutide or tirzepatide: a systematic review and meta-analysis","Dadkhah, Parisa Alsadat","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/xkhvq",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036574","Nutritional assessment in registered randomized clinical trials evaluating the efficacy of incretin-based therapy in people living with overweight or obesity (PWO)","Rives-Lange, Claire","2023","Open Science Framework","randomized_trial","article","10.17605/osf.io/yun2v",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0036575","Emerging Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Knee Osteoarthritis: A Scoping Review","Jiayi Guo","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/mqjyv",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036576","Utilization of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Dialysis Population","Beatrice Drambarean","2025","University of Illinois Chicago","other","article","10.25417/uic.28931171",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036577","Letter to the Editor: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes?","Dimitrios Patoulias","2023","Hepatology","commentary","article","10.1097/hep.0000000000000311","36724447",null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0036578","Exploring Cardiometabolic Health, Physical Activity, and Quality of Life in Patients with Obesity and Multimorbidity during an Intensive Weight Loss Program: A Protocol for a Real-Life Prospective Cohort Study.","Bandholm, Thomas Quaade","2025","Open Science Framework","protocol","article","10.17605/osf.io/ezn57",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0036579","Effectiveness of GLP-1 RAs in reversing patients with prediabetes to normoglycemia: A Systematic Review and Meta-Analysis","Tsironikos, Georgios","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/ebxch",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036580","Comparative effectiveness of the glucose-lowering agents semaglutide and tirzepatide vs sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in patients with peripheral vascular disease","Krüger, Nils","2025","Open Science Framework","randomized_trial","article","10.17605/osf.io/z4rxt",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0036581","Changing the way type 2 diabetes is managed","Hannah Syed","2021","Journal of Prescribing Practice","randomized_trial","article","10.12968/jprp.2021.3.10.412",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0036582","Semaglutide for type 2 diabetes: a systematic review and meta-analysis","Ανδρεάδης, Παναγιώτης Αλέξανδρου","2018","Aristotle University of Thessaloniki","systematic_review","article","10.26262/heal.auth.ir.299033",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036583","Effects of GLP-1 Receptor Agonists on Wound Healing in Diabetic Patients: A Protocol for a Scoping Review","Madkins, Krystal L","2024","Open Science Framework","protocol","article","10.17605/osf.io/ryge8",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0036584","Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in the Treatment of overweight or obesity with or without type 2 Diabetes Mellitus","Jin, Ting","2025","Open Science Framework","other","article","10.17605/osf.io/62w74",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036585","Systemic and oral adverse effects of semaglutide: a scoping review","Câmara, João Victor Frazão","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/9g7hy",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036586","Discrepancy between guidelines and clinical practice regarding the use of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and established cardiovascular disease","Γεώργιος Η. Βουρνάς","2026","Aristotle University of Thessaloniki","nonrandomized_study","article","10.26262/heal.auth.ir.372857",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036587","Safety and efficacy of Retatrutide in treatment of obesity : a systematic review and meta-analysis","Belal, Mohamed Mohamed","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/ex2ud",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036588","Risk of Gastrointestinal Events Associated with Concomitant Use of Oxycodone, Hydrocodone, and Tramadol in Patients Receiving GLP-1RA","Bykov, Katsiaryna","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/spn5r",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036589","Association of glucagon-like peptide 1 receptor agonists and treatment for bile acid diarrhea","Martin Torp Rahbek","2022","Open Science Framework","randomized_trial","article","10.17605/osf.io/854ts",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other; preprint"],["R0036590","Effects of glucagon-like peptide 1 receptor agonists on cannabis use: A scoping review protocol","Tristan L Maynard","2024","Open Science Framework","protocol","article","10.17605/osf.io/ue6pd",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article; preprint"],["R0036591","Clinical Effects of GLP1RA Based Treatments on DXA-Acquired Musculoskeletal Health Outcomes: A meta-analysis","Foy, Colleen","2023","Open Science Framework","systematic_review","article","10.17605/osf.io/4yafm",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036592","Comparative Efficacy of FGF21 Analogues and Semaglutide in the Management of MASLD: A Network Meta-Analysis of Clinical Trials","Ayesh, Hazem","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/7fng3",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036593","Comparative Effectiveness of GLP-1 Receptor Agonists Alone vs. in Combination with Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: Protocol for Systematic Review and Network Meta-Analysis","Tsavdaris, Dimitrios","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/muazq",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; preprint"],["R0036594","Pregnancy Weight Gain and Other Adverse Maternal Outcomes Following GLP-1 Receptor Agonist Discontinuation","Kari Johansson","2025","Open Science Framework","other","article","10.17605/osf.io/pxbz4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036595","Comparative effectiveness of tirzepatide vs sitagliptin in individuals at cardiovascular risk","Wang, Shirley","2025","Open Science Framework","other","article","10.17605/osf.io/xfnm5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036596","Effect of the use of GLP-1 analogues on sex hormones, seminal parameters and sperm function in obese men - A scoping review","Fraietta, Renato","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/g9fbq",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036597","Effects of semaglutide injections on mental health, motivation, and decision-making","Nord, Camilla","2023","Open Science Framework","other","article","10.17605/osf.io/7kmf5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036598","Carotid Intima-Media Thickness in Patients with Type II Diabetes Mellitus: A Narrative Review","Abubakar A. Abubakar","2026","Afrischolar Discovery","randomized_trial","article","10.60787/sjhrs.vol1no1.14",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","review"],["R0036599","A scoping systematic review on the effect of GLP-1 analogue therapy for obesity management on vitamin and micronutrient levels.","Hooper, Joanna","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/qj35d",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036600","Investigation of the Metabolic Effects of Liraglutide on Patients with Overweight and Obesity","Spencer, Lewis","2023","UDORA","nonrandomized_study","article","10.48773/q02yx",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036601","Risk Benefit ratio GLP1ar metaA","Grenet, Guillaume","2022","Open Science Framework","other","article","10.17605/osf.io/ckjdb",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036602","Η επίδραση των Glucagon like-peptide 1 αναλόγων στον οστικό μεταβολισμό","Δανιηλοπούλου, Ιωάννα","2021","University of West Attica","other","article","10.26265/polynoe-1356",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036603","Internalisierte Gewichtsvorurteile und die Akzeptanz von medikamentöser Gewichtsreduktion","Euteneuer, Frank","2025","Open Science Framework","other","article","10.17605/osf.io/m5ybk",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036604","Dosage- and formation-dependent effects of GLP-1 receptor agonists on delay discounting and inhibitory control","Lindholm, Johanne Alice","2025","Open Science Framework","other","article","10.17605/osf.io/t5wxr",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036605","The efficacy and safety of liraglutide for the management of obesity in individuals without diabetes: Systematic review and meta-analysis","Θεόδωρος Γεωργίου Μιχαηλίδης","2019","Aristotle University of Thessaloniki","systematic_review","article","10.26262/heal.auth.ir.305898",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036606","Framing GLP-1 Agonists to Reduce Weight Stigma","Post, Stacy","2024","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/bpa5q",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036607","Exploring perspectives on a novel weight loss device and on ecological momentary assessment as a tool to measure appetite in underserved communities","Elsworth, Rebecca","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/t37ye",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036608","Addiction as a Primary Metabolic Dysfunction: The Metabolic–Arousal Axis Across Neurobiological, Physiological, and Psychological Levels","Lomas, Christopher","2025","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/2sh3b",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036609","Landscape of randomised clinical trials of interventions to reduce perioperative aspiration risk in patients taking GLP-1 receptor agonists","Cade Shadbolt","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/y7h5u",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other; preprint"],["R0036610","The New American Addiction: How Weight-Loss Drugs Could Create the Next Epidemic","Peters Fredrick","2025","Journal of Sports Medicine and Therapy","other","article","10.29328/journal.jsmt.1001096",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036611","Safety and efficacy of liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","Καλογήρου, Μαρία-Στυλιανή Βασιλείου","2019","Aristotle University of Thessaloniki","systematic_review","article","10.26262/heal.auth.ir.306639",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036612","Efeitos periodontais dos agonistas do GLP-1: mapeamento de evidências clínicas, histológicas e moleculares — uma revisão de escopo","Weckwerth, Artur Villas Boas","2025","OSF Preprints (OSF Preprints)","preclinical","article","10.17605/osf.io/fw8sd",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036613","The role of the signalling protein XLalphas in cardiovascular control in mice","Nicolas Nunn","2013","University of Liverpool","preclinical","article","10.17638/00009893",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036614","Tirzepatide versus placebo in adults with back pain and obesity: a secondary analysis of the SURMOUNT 1, 2, and 3 randomised trials","Cade Shadbolt","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/bwuer",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other; article; preprint"],["R0036615","Συσχέτιση της HbA1c με τον κίνδυνο εμφάνισης ΑΕΕ (ισχαιμικού, αιμορραγικού και καρδιοεμβολικού) σε ασθενείς με Σ/Δτ2","Γραικός, Κωνσταντίνος Δημητρίου","2022","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.338005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036616","Conceptualization of Treatment Success in Clinical Trials of GLP-1 Receptor Agonists for Pediatric Obesity: A Scoping Review","Anna Hirsch","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/gq58c",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; preprint"],["R0036617","GLP-1 Receptor Agonists: Bridging Diabetes, Obesity and Periodontal Disease – A Scoping Review of Emerging Evidence","Giannobile, William V.","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/g29uj",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036618","GLP-1 Agonist vs SGLT-2 Inhibitor in the Management of MASLD: A Network Meta-analysis","Ayesh, Hazem","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/3uyxv",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036619","Σχεδιασμός ερευνητικού πρωτοκόλλου μη παρεμβατικής μελέτης για την κλινική και οικονομική αξιολόγηση των νεότερων θεραπευτικών κατηγοριών για την αντιμετώπιση του σακχαρώδη διαβήτη τύπου 2 στην Ελλάδα","Μπούγια, Κυριακή Γαληνού","2024","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.358044",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036620","GLP-1 ανάλογα στην πρόληψη και θεραπεία της Αθηροσκληρωτικής Καρδιαγγειακής Νόσου σε άτομα με ΣΔ2","Ακήφογλου, Εζγκήλ Μ.","2025","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.365191",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036621","GLP-1 agonists and reproductive health (pregnancy and lactation)","Γεώργιος Σ. Τζαραλής","2025","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.372470",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036622","Primary cardiovascular prevention by GLP-1 RA and SGLT2i in T2D","Bassett, Ken","2024","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/qv6mn",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036623","EFFICACY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST IN MYOCARDIAL INFARCTION PREVENTION: A SYSTEMATIC REVIEW AND META-ANALYSIS","Han, Chin Yip","2024","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/7vxn5",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0036624","Antipsychotic-induced metabolic side-effects: a systematic review and meta-analysis of rodent models","Siafis, Spyridon","2022","Open Science Framework","systematic_review","article","10.17605/osf.io/m8vc3",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036625","Normal pregnancy outcome after first-trimester exposure to semaglutide in an overweight woman: a case report","Xi-Mei Zhu","2024","Clinical Research Communications","case_report","article","10.53388/crc2024013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036626","The effects of glucagon-like peptide-1-based medications on muscle and bone health in type 2 diabetes mellitus: A scoping review protocol","Mohammed Abdu Seid","2026","Open Science Framework","protocol","article","10.17605/osf.io/y9cmk",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0036627","Replicating cardiovascular outcome trials for type 2 diabetes using real-world evidence: protocol for a systematic review of observational studies.","Yu, Oriana Hoi Yun","2023","Open Science Framework","systematic_review","article","10.17605/osf.io/g8erw",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036628","A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies","Mihai-Teodor Georgescu","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/n3hxf",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036629","Risk of thyroid cancer with use of glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes in Denmark: Population-based active comparator, new user cohort study","Hicks, Blánaid","2023","OSF Preprints (OSF Preprints)","nonrandomized_study","article","10.17605/osf.io/54svt",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0036630","GLP-1 Receptor Agonists and Antipsychotic Adherence in Adults with Schizophrenia Spectrum Disorders: A Scoping Review and Evidence Gap Analysis","Reagan Ozuzu","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/qbjg6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036631","Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","Van Alebeek, Remigius","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/zn3aq",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036632","UntitledThe safety of glp-1 agonists in patients with type 2 diabetes and patients with obesity, a systematic review","Alwafi, Hassan","2023","Open Science Framework","systematic_review","article","10.17605/osf.io/58vd7",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036633","Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic β-cell bioenergetic parameters and metabolism in BRIN-BD11 cells","Fernandes Cruzat, Vinicius","2022","Torrens University","other","article","10.25905/21555132",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036634","Perioperative use of GLP-1 RA medications in overweight and obese patients undergoing elective surgery: A Scoping Review","Johnson, Peter","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/u62ht",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036635","Use of semaglutide and risk of anterior ischemic optic neuropathy: Danish nationwide observational studies","Pottegård, Anton","2024","OSF Preprints (OSF Preprints)","nonrandomized_study","article","10.17605/osf.io/h3uv4",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0036636","Comparative Analysis of Resmetirom vs GLP-1 Agonist vs SGLT-2 Inhibitor in MASLD and MASH: Network Meta-Analysis of Clinical Trials","Ayesh, Hazem","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/2pqhm",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036637","Psychological Characteristics, Supports, and Outcomes in GLP-1 Receptor Agonist Trials: A Scoping Review","Feutrill, Olivia","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/n25b3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036638","Glucagon-Like Peptide Therapies and Cancer Risk: A Systematic Review","Erul, Enes","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/enjtb",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036639","Patient-Centred Outcomes with Incretin-Based Therapies and SGLT2 Inhibitors in Obesity-Related HFpEF: A Programme-Level Systematic Review and Meta-Analysis","Dr. Daniyal Khan","2026","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/naqrg",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0036640","Exploring the #Ozempic viral trend on TikTok","Sutton, Megan","2023","Open Science Framework","other","article","10.17605/osf.io/d3spm",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036641","Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review","Bayoumy, Ahmed","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/wabe5",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036642","Advances in the treatment of nonalcoholic steatohepatitis: current status and future directions","Pushpendra Kumar, Ujjwal*, Kajal Varshney, Km Neha","2026","Journal of medical pharmaceutical and allied sciences","other","article","10.55522/jmpas.v15i1.6969",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036643","Αγωνιστές GLP-1 στη διαχείριση του Σακχαρώδη Διαβήτη Τύπου 2: Μηχανισμοί δράσης και κλινικές εφαρμογές","Αντωνίου, Μυράντα Μ.","2025","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.366281",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036644","Comparative effectiveness of GLP-1RA, SGLT2i, and DPP-4i on preventing the worsening of depression in comorbid patients with depression and type 2 diabetes: A Danish nationwide target trial emulation","Fuglsang, Nina Friis Bak","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/hws97",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036645","The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in People With HIV: A Systematic Review and Meta-Analysis","Tsavdaris, Dimitrios","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/72ymp",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036646","Research Synthesis: Semaglutide Biomarker Effects","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/gwf5k",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036647","OFF-LABEL USE OF TIRZEPATIDE (MOUNJARO®) FOR WEIGHT LOSS: HEALTH BENEFITS AND RISKS","CRISTIANO PATRÍCIO ROCHA","2026",null,"nonrandomized_study","article","10.63330/aurumpub.058-018",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","book-chapter"],["R0036648","Exploring the Psychiatric Effects of GLP-1 Agonists in Depression and PTSD","Milton, Amy L","2025","Open Science Framework","other","article","10.17605/osf.io/5edkt",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036649","Effect of glucagon-like peptide-1 receptor agonists as add-on therapy to insulin on metabolic outcomes in type 1 diabetes mellitus: a systematic review and meta-analysis","Ρέμπελου, Ελένη Ιωάννη","2024","Aristotle University of Thessaloniki","systematic_review","article","10.26262/heal.auth.ir.359931",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036650","Semaglutide once: 69%-79% of participants achieved ≥10% weight loss with semaglutide 2.4 mg (vs. 12%-27% with placebo)","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/8jcpv",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036651","Pharmacometric Models of Glucose Homeostasis in Healthy Subjects and Diabetes Patients","Rikke Meldgaard Røge","2016","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0036652","Clinical Implications of The Direct Comparison of Dulaglutide Versus Tirzepatide","Nasser Mikhail","2026","General medicine and Clinical Practice","randomized_trial","article","10.31579/2639-4162/330",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0036653","Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.","Filion, Kristian","2022","Open Science Framework","systematic_review","article","10.17605/osf.io/epv6t",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036654","Exposure to GLP-1 Agonist Use and Weight Controllability Information on Eating Cognitions","Post, Stacy","2024","Open Science Framework","other","article","10.17605/osf.io/5a8w6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036655","Comparative Efficacy of Retatrutide versus Tirzepatide in Achieving Weight Loss: A Network Meta-Analysis","Salhab, Ahmad","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/pqdwk",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036656","Tirzepatide versus placebo in adults with osteoarthritis and obesity: a secondary analysis of the SURMOUNT 1, 2, and 3 randomised trials","Cade Shadbolt","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/3s4jv",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0036657","Safety and efficacy of the Glucagon and GLP-1 receptor dual agonist survodutide in treatment of obesity : a systematic review and meta-analysis","Abdelaziz Awad","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/gb39w",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036658","A scoping review of the cardiovascular protective mechanisms of glucagon-like peptide-1 receptor agonists","jaredmberndt@gmail.com","2021","Open Science Framework","narrative_review","article","10.17605/osf.io/8k42f",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036659","El Auge Del Ozempic En La Sociedad Y Su Impacto En Las Personas Con Diabetes","Farías Arbelo, Valeria Ariadna","2025","Acceda (Universidad de Las Palmas de Gran Canaria)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036660","Disease-Modifying Effects of GLP-1 Receptor Agonists in Adults Without Pre-Established Diabetes: A Scoping Review Protocol","Ferrell, Sabrina Rose","2024","Open Science Framework","protocol","article","10.17605/osf.io/qmazu",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0036661","The Use of GLP-1 Agonists Following Bariatric Surgery: A Systematic Review","Pare, Aurelie","2020","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/rwv9z",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0036662","The risks and rewards of semaglutide in obesity treatment","George Winter","2023","Journal of Prescribing Practice","other","article","10.12968/jprp.2023.5.4.146",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036663","Evidence-based use of newer agents in type 2 diabetes","David Morris","2021","Journal of Prescribing Practice","other","article","10.12968/jprp.2021.3.6.224",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036664","Ο συνδυασμός των αγωνιστών του υποδοχέα του γλυκαγονοειδούς πεπτιδίου-1 (GLP-1) και των αναστολέων του συμμεταφορέα νατρίου-γλυκόζης-2 (SGLT-2) ως θεραπεία στο σακχαρώδη διαβήτη τύπου 2. Συστηματική ανασκόπηση και μετα-ανάλυση","Μάντσιου, Χρυσάνθη Δημητρίου","2020","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.319842",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036665","Effect of tirzepatide on the risk for malignancy among individuals with type 2 diabetes: a meta-analysis.","Karakasis, Paschalis","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/8j9yd",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036666","GLP-1 Receptor Agonists in Substance Use Disorders: A Systematic Review","Patil, Shruti","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/x76sn",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036667","Post Hoc Control Group Selection Methods","Becker, Ezra Daniel","2024","University of Illinois Chicago","randomized_trial","article","10.25417/uic.26108041",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0036668","SGLT2 Inhibitors versus GLP-1 Receptor Agonists for Chronic Kidney Disease Progression in Asian Populations with Type 2 Diabetes: A Systematic Review and Meta-Analysis","Fathur Agita Raihan","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/2ued3",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; preprint"],["R0036669","Safety profile of glucagon-like peptide-1 agonists (GLP1) for weight loss, a scoping review","Θεοδωρίδου, Κωνσταντίνα Σπυρίδων","2025","Aristotle University of Thessaloniki","nonrandomized_study","article","10.26262/heal.auth.ir.361756",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036670","Comparative Analysis of Resmetirom vs FGF21 Agonists vs GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials","Ayesh, Hazem","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/hxvp3",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036671","SYNERGISTIC INTEGRATION OF LIRAGLUTIDE AND PHYSIOTHERAPY IN OBESITY MANAGEMENT: CURRENT EVIDENCE AND FUTURE PERSPECTIVES","Avinash Devaraneni","2026","Asian Journal of Pharmaceutical and Clinical Research","other","article","10.22159/ajpcr.2026v19i8.60515",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036672","COMPARATIVE STUDY BETWEEN BERBERINE AND EXENDINE 4 ON ADULT MALE DIABETIC ALBINO RATS","Ahmad Gad Alla","2017","Al-Azhar Medical Journal","preclinical","article","10.12816/0038276",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036673","Managing aesthetic needs in prescription medication-driven rapid weight loss patients: An International consensus","Enright, Kaitlyn M.","2024","Open Science Framework","other","article","10.17605/osf.io/35he2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036674","Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on controlled attenuation parameter in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","Πανάς, Παντελεήμων Αλέξανδρος Χαράλαμπου","2023","Aristotle University of Thessaloniki","systematic_review","article","10.26262/heal.auth.ir.344903",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036675","To reduce or not to reduce? Insulin dose adjustments upon starting GLP-1 receptor agonists","Elmes, Abigail","2021","University of Illinois Chicago","other","article","10.25417/uic.16550574",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036676","“Pancreatic and Gallbladder safety of Tirzepatide in Obesity Management: A Scoping Review Protocol of Clinical and Real-World Evidence”","Kutsyba, Tetiana","2026","Open Science Framework","protocol","article","10.17605/osf.io/pdzm6",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0036677","Efficacy of GLP-1 Receptor Agonists on Alveolar Bone Regeneration, Osseointegration, and Inflammation: A Preclinical Systematic Review and Meta-analysis","Liangjun Zhong","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/tx63s",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036678","Enhanced Reduction of Albuminuria with Combined SGLT-2 and GLP-1 Therapy: A Network Meta-Analysis of Clinical Trials","Ayesh, Hazem","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/ug3ed",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036679","Επιδραση του πολυμορφισμού CETP Taq1B στην ανταποκριση ασθενων με σακχαρωδη διαβητη τυπου 2 στη δουλαγλουτιδη","Ανδριανοπούλου, Ροζαλία Βασιλείου","2023","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.354347",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036680","GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: An updated meta-analysis of RCTs","Mantovani, Alessandro","2020","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/qtuc7",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036681","Exposure to GLP-1 Agonists on Stigma and Weight-related Cognitions among Black and White Women","Post, Stacy","2024","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/4u8mq",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036682","Farmakologisk behandling vid fetma : Semaglutid versus liraglutid","Nilsson, Natalié","2021","KTH Publication Database DiVA (KTH Royal Institute of Technology)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0036683","Dental and Salivary Complications Associated with GLP-1 Receptor Agonist Therapies in Adults: A Scoping Review of Clinical Evidence.","Thalita de Paris Matos","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/b7jx8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; preprint"],["R0036684","Semaglutide Versus Tirzepatide in Heart Failure with Preserved Ejection Fraction and Obesity: A Meta-Analysis and Systematic Review","Habis, Yousef","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/2uhzp",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036685","Severity of GLP-1 Agonist Associated Pancreatitis in patients presenting to the ED: A Scoping Review","Biju, Alby","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/u52cn",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036686","Current Practices in Thyroid Screening for GLP-1 Receptor Agonist Use and the Influence of Screening Bias on Reported Rates of C-Cell and Medullary Thyroid Carcinoma: A Protocol for a Scoping Review","Mustafa Al-Mashhadani","2025","Open Science Framework","protocol","article","10.17605/osf.io/pebhs",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0036687","Viktminskning med liraglutid","Anna Boye","2014","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036688","Comparative Efficacy and Safety of Resmetirom vs Semaglutide in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Network Meta-analysis of Randomized Clinical Trials","Ayesh, Hazem","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/ec6df",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036689","Cardiovascular, Metabolic, and Hepatic Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease: Comparative Efficacy of Semaglutide versus Sodium–Glucose Cotransporter 2 Inhibitors","Hosam I. Taha","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/fujyp",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036690","Beneficial effects of glucagon-like peptide-1 receptor agonists in overweight and obese patients","Αποστολίδης, Λεωνίδας Χρήστου","2024","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.355788",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036691","Safety profile of GLP-1 receptor agonists in clinical use: scoping review","ALESSANDRO CARDOSO MAUES","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/cgkwn",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0036692","A rapid review on the effects of GLP-1 receptor agonists on opioid and stimulant use-related outcomes","Bondy, Greg","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/az9jk",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036693","Comparative safety and cardiovascular outcomes of glucagon-like peptide 1 receptor agonists (GLP-1-RAs) versus sodium glucose co-transporter 2 inhibitors (SGLT2-Is), naltrexone/bupropion, or phentermine/topiramate: a real-world data study.","Hoffman, Sarah Ruth","2024","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/psy74",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036694","Comparative Efficacy of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Reducing Albuminuria: A Network Meta-Analysis of Clinical Trials","Ayesh, Hazem","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/e7cmx",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036695","Mapping Alcohol Use and Mental Health in Diabetes: An Explorative Study","Hammarberg, Anders","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/57wj9",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036696","Reassessing Cancer Risk with GLP-1 Receptor Agonists: A Comprehensive Meta-Analysis of Gastrointestinal Malignancies","Rangraze, Imran","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/3rv6d",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036697","Usability and educational impact of GLiMPSE, a pharmacovigilance-aware GLP-1 prescribing simulator: a prospective single-group mixed-methods study","Adnan Agha","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/6q5pa",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other; preprint"],["R0036698","Evaluating the efficacy of GLP-1 receptor agonists for Parkinson's Disease: a systematic review and meta-analysis","Reis, Victor Hugo Palhares Flavio Dos","2024","Open Science Framework","systematic_review","article","10.17605/osf.io/bdrwf",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0036699","Comparative Effectiveness of Orforglipron and Oral Semaglutide in the Management of Overweight and Obesity: Network Meta-analysis of Randomized Clinical Trials.","Hazem Ayesh","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/56tah",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036700","Comparative Efficacy of Survodutide, Cotadutide, Retatrutide, and Mazdutide on Weight Loss: A Network Meta-Analysis of randomized control trial","Lehia, Ayah Freih Abu","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/ek5nu",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036701","Glucagon-Like Peptide-1 Receptor Agonists for Treatment of MASLD: An Updated Meta-Analysis of Randomized Controlled Trials","Mantovani, Alessandro","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/hgvs4",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036702","GLP-1 Recepter Agonists in Substance Use Disorders: A Scoping Review","Caitlyn Paige Poteet","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/w7azs",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; preprint"],["R0036703","NMNH R1583-00 (MIN) Individual Sample Quartz>Mineral Chalcedony with cinnabar and chalcedony","Mansur, Adam","2019","SESAR_Smithsonian","other","article","10.58151/nhb00383p",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036704","EFFECT OF DIHYDROQUERCETIN ON THE WEIGHT OF EXPERIMENTAL ANIMALS: REVIEW","R. Terekhov","2026","Problems of Biological Medical and Pharmaceutical Chemistry","nonrandomized_study","article","10.29296/25877313-2026-04-14",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0036705","The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease","Τσιαμπαλή, Χαρά Γεωργίου","2023","Aristotle University of Thessaloniki","nonrandomized_study","article","10.26262/heal.auth.ir.351698",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036706","Rural disparities in the utilization of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes: A scoping review","Manik Ahuja","2024","Open Science Framework","narrative_review","article","10.17605/osf.io/ytdxq",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036707","Effect of Prehabilitation with GLP-1 Agonists in Obese Patients Undergoing Abdominal Wall Reconstruction or Complex Hernia Repair: A Scoping Review","Possiedi, Rafael Dib","2025","Open Science Framework","narrative_review","article","10.17605/osf.io/3ukr5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036708","Victoza (liraglutid). Komentář ke článku (Prakt. lékáren. 2010; 6(6): 271-274)","Martin Doležal","2010","Praktické lékárenství","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036709","Vliv inkretinového mimetika liraglutidu (Victoza) na hmotnost a hladiny glykovaného hemoglobinu u nemocných s diabetes mellitus 2. typu v diabetologických ordinacích ČR - studie BIVI","J Perusicová","2013","Interní medicína pro praxi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036710","Effects of liraglutide and exenatide, two GLP-1 agonists, in vascular wall cells","Isabel Maria Hipólito Reis Dias Rodrigues","2016","Open Repository of the University of Porto (University of Porto)","other","article","10.34626/16zn-am61",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036711","Comprehensive characterization of cardiovascular protection by the GLP-1 (Glucagon-like peptide-1) analog liraglutide in experimental arterial hypertension","Helmstädter, Johanna","2022","Gutenberg Open Science","preclinical","article","10.25358/openscience-6874",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036712","GHRH and GLP-1 Receptor Agonism Promote Human β-Cell Survival and Improve Glucose Homeostasis in mice","Ruy Louzada","2025","Figshare","preclinical","article","10.6084/m9.figshare.29120561.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036713","Can corneal confocal microscopy be used as an imaging biomarker for neurodegeneration in children and adults with metabolic disease?","Hoda Gad","2026","e-space (Manchester Metropolitan University)","other","article","10.83056/mmu.32482941.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036714","BfArM übernimmt Koordination im Fälschungsfall des Diabetes-Arzneimittels Ozempic: Alle Packungen des Arzneimittels sollen vorsorglich in den Apotheken vor Abgabe auf ihre Echtheit geprüft werden",null,"2023","GesundheitsRecht","other","article","10.9785/gesr-2023-221102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036715","Saxenda – jak na to?","Dita Pichlerová","2019","Interní medicína pro praxi","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036716","Studie LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results)","Lenka Špinarová","2018","Intervenční a akutní kardiologie","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036717","Effect of Semaglutide-Induced Prolonged Activation of Glucagon-Like Peptide-1 Receptors on Sodium Balance in Rats","Е. В. Балботкина","2026","Journal of Evolutionary Biochemistry and Physiology","preclinical","article","10.1134/s002209302604006x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036718","THE DIFFERENCES IN CKM RISK FACTORS BETWEEN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES AND POTENTIAL CHALLENGES TO THERAPY IN THESE GROUPS","Khalid Ahmed","2026","Journal of Hypertension","other","article","10.1097/01.hjh.0001196756.05566.63",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036719","Targeting metabolism to overcome obesity and related disorders","Chen, Sing-Young","2023","UNSWorks (University of New South Wales, Sydney, Australia)","preclinical","article","10.26190/unsworks/24844",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036720","REAL-WORLD DETERMINANTS OF BLOOD PRESSURE CONTROL AND SHORT-TERM BLOOD PRESSURE CHANGES IN PATIENTS WITH CHRONIC KIDNEY DISEASE","Nino Vreča","2026","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0001196668.98605.01",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0036721","Mechanisms of axonal pathophysiology in diabetes and chronic kidney disease","Issar, Tushar","2022","UNSWorks (University of New South Wales, Sydney, Australia)","other","article","10.26190/unsworks/22384",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036722","Liraglutide in obese adolescents- experience from a Portuguese pediatric hospital","Roxo, Luísa Alexandra Nunes","2024","Open Repository of the University of Porto (University of Porto)","other","article","10.34626/9qhd-wg82",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036723","Repurposing diabetes drugs for the treatment of intestinal helminth infection","Dooley, Megan","2022","Lancaster EPrints (Lancaster University)","preclinical","article","10.17635/lancaster/thesis/1722",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036724","GHRH and GLP-1 Receptor Agonism Promote Human β-Cell Survival and Improve Glucose Homeostasis in Diabetic mice","Ruy Louzada","2025","Figshare","preclinical","article","10.6084/m9.figshare.29120561",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036725","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92709-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036726","COMPARATIVE EVALUATION OF THE SINGLE AND COMBINED EFFECTS OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS","G'.Yu. Djanayev","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21918749",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036727","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97033-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036728","AF4 as a passepartout technique for the characterization of nanosystems of medical interest","Giordani, Stefano","2025","AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna)","other","article","10.48676/unibo/amsdottorato/11782",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036729","Use of Induced Pluripotent Stem Cells from Patient Carrying a Homozygous Mutation in the glp-1r Gene for Disease Modeling","Almutairi, Hanouf","2024","King Abdullah University of Science and Technology Repository (King Abdullah University of Science and Technology)","preclinical","article","10.25781/kaust-8yyv9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036730","Central and peripheral neurodegeneration in diabetes and dementia","Georgios Ponirakis","2026","e-space (Manchester Metropolitan University)","randomized_trial","article","10.83056/mmu.32479965",null,null,"ClinicalTrials.gov:NCT02887625","S002035","openalex","TRUE","paywalled","1","FALSE","dissertation"],["R0036731","Preoperative fasting for patients who take GLP-1 receptor agonists: should we Sip Til Send?","Lesley Lowes","2026","Advances in Perioperative Care","other","article","10.14324/111.444/apoc.3777",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036732","GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin",null,"2026","Cancer Discovery","nonrandomized_study","article","10.1158/2159-8290.cd-nw2026-0002","41543505",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0036733","On Hunger: Violence and Craving in America, from Starvation to Ozempic","Helen Anne Curry","2026","Agricultural History","other","article","10.1215/00021482-12440604",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036734","Additional file 1 of Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial","Zhang, Jie","2020","Figshare","randomized_trial","article","10.6084/m9.figshare.12197088",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036735","Additional file 1 of High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist","Ma, Bingwei","2023","Figshare","other","article","10.6084/m9.figshare.23590602",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036736","Additional file 1 of Systemic semaglutide provides a mild vasoprotective and antineuroinflammatory effect in a rat model of ocular hypertensive glaucoma","Mouhammad, Zaynab A.","2025","Figshare","preclinical","article","10.6084/m9.figshare.29454157",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036737","Additional file 1 of Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen","Lin, Yi-Hsuan","2024","Figshare","other","article","10.6084/m9.figshare.27872917",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036738","Immunometabolism and GLP-1 Signaling in Rheumatic Diseases: Molecular Mechanisms, Clinical Implications, and Therapeutic Perspectives","Paulina Patrycja Turzyńska","2026","Quality in Sport","nonrandomized_study","article","10.12775/qs.2026.68.74444",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0036739","EATING DISORDER DETERIORATION IN AN OLDER ADULT AFTER INITIATION OF GLP-1 RECEPTOR AGONIST TREATMENT","Speaker: Natalie David","2026","American Journal of Geriatric Psychiatry","other","article","10.1016/j.jagp.2026.03.095",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036740","Glucagon in health and diabetes","Rajeev Chawla","2023","Journal of Diabetology","other","article","10.4103/jod.jod_102_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036741","GLP‑1 Receptor Agonists and PDE5 Inhibitors as Restorative Threshold Agents: A Unified Framework for Resetting the Brain's Vascular Miser Policy in Autoimmunity, Neurodegeneration, and Glandular Siege","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21927597",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036742","Therapeutic Approaches to Type 2 Diabetes Remission: Challenges, Lifestyle Modifications, and Genetic Innovations","Sohel Tamboli*, Madhura Mundhe, Suraj Nanaware","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21927152",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036743","Additional file 1 of The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","Giugliano, Dario","2022","Figshare","systematic_review","article","10.6084/m9.figshare.19373457",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036744","Design and synthesis of rhamnose-modified exenatide conjugate by sortase A-mediated ligation","Chen Li","2019","Journal of Carbohydrate Chemistry","other","article","10.1080/07328303.2019.1609021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036745","Large VA trial will evaluate effects of semaglutide for AUD","Gary Enos","2026","Alcoholism & Drug Abuse Weekly","other_trial","article","10.1002/adaw.35017",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0036746","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97032-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036747","A RAPID REVIEW OF THE RAPID WEIGHT LOSS DRUGS: GLP-1 RECEPTOR AGONISTS ROLE IN NEUROCOGNITIVE DISORDERS","Speaker: Heidi Kiziah","2026","American Journal of Geriatric Psychiatry","narrative_review","article","10.1016/j.jagp.2026.03.023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036748","Semaglutide in Chronic Kidney Disease: Current Evidence, Clinical Applications, and Future Perspectives","Ankitha M2 Aswin Shaji*1","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.21927215",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0036749","Postprandial Hyperglycemia","Vasudevan A. Raghavan","2008","Humana Press eBooks","randomized_trial","article","10.1007/978-1-60327-043-4_7",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","book-chapter"],["R0036750","Additional file 1 of Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)","Davis, Timothy M. E.","2022","Figshare","other","article","10.6084/m9.figshare.20167950",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036751","F22. THREADING THE CLINICAL NEEDLE: A CASE STUDY AND DISCUSSION ON USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN OLDER ADULTS WITH MOOD DISORDERS","Martha Sajatovic","2026","American Journal of Geriatric Psychiatry","other","article","10.1016/j.jagp.2026.03.125",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0036752","Additional file 1 of Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","Zhou, Qian","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26633796",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036753","Additional file 1 of Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis","Coleman, Ruth L.","2025","Figshare","other","article","10.6084/m9.figshare.29974480",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036754","Additional file 1 of Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis","Balata, Mahmoud","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.27312312",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036755","The Assessment of Nutritional Status in Pediatrics: New Tools and Challenges. Review","Ignacio Díez López","2026",null,"narrative_review","article","10.67375/fpch.01.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036756","Additional file 1 of Metformin use correlated with lower risk of cardiometabolic diseases and related mortality among US cancer survivors: evidence from a nationally representative cohort study","Li, Yukun","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26112931",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036757","S26. SEMAGLUTIDE-ASSOCIATED INDUCTION OF MANIA AND CATATONIA: A CASE REPORT","Riley Reasons","2026","American Journal of Geriatric Psychiatry","case_report","article","10.1016/j.jagp.2026.03.194",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0036758","Additional file 1 of Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","Sandsdal, Rasmus M.","2023","Figshare","randomized_trial","article","10.6084/m9.figshare.22615322",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036759","Additional file 1 of Long-term comparison of renal and metabolic outcomes after sodium–glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes","Sohn, Minji","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.26157034",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036760","Type 2 Diabetes","Hermes Flórez","2009","Humana Press eBooks","other","article","10.1007/978-1-60327-850-8_2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0036761","Additional file 1 of Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","Yamada, Takayuki","2021","Figshare","systematic_review","article","10.6084/m9.figshare.13545484",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036762","Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes","Gail Mkele","2015","Journal of Endocrinology Metabolism and Diabetes of South Africa","other","article","10.1080/16089677.2015.1030883",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036763","Comparison Between Sleeve Gastrectomy and Exenatide on Type 2 Diabetic Patients","Onur Elbasan","2020","Bariatric Surgical Practice and Patient Care","other","article","10.1089/bari.2019.0041",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036764","Additional file 1 of Intestinal epithelium penetration of liraglutide via cholic acid pre-complexation and zein/rhamnolipids nanocomposite delivery","Bao, Xiaoyan","2024","Figshare","other","article","10.6084/m9.figshare.26561800",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036765","GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response","Zhao, Qini","2021","Figshare","other","article","10.6084/m9.figshare.8245901.v3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036766","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97212-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036767","The financialization of the pharmaceutical industry: The case of Novo Nordisk's Wegovy","Joan Busfield","2026","Edward Elgar Publishing eBooks","other","article","10.4337/9781035338450.00027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0036768","Erratum",null,"2010","Postgraduate Medicine","other","article","10.3810/pgm.2010.07.2195",null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0036769","Additional file 1 of The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study","Werkman, Nikki C. C.","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26600980",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036770","Additional file 1 of Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease","Ritsinger, Viveca","2024","Figshare","other","article","10.6084/m9.figshare.26758622",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036771","Journal Digest","Nick Zagorski","2019","Psychiatric News","randomized_trial","article","10.1176/appi.pn.2019.1a5",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0036772","Additional file 1 of Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats","Klotsman, Michael","2024","Figshare","other","article","10.6084/m9.figshare.25854611",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036773","Integrating GLP-1 RAs Into Psychiatric Clinical Practice","Linda M. Richmond","2026","Psychiatric News","other","article","10.1176/appi.pn.2026.07.7.26",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036774","Additional file 1 of The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis","Yugar, Louise Buonalumi Tacito","2024","Figshare","systematic_review","article","10.6084/m9.figshare.25687387",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036775","Additional file 1 of The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration","Cencioni, Chiara","2025","Figshare","other","article","10.6084/m9.figshare.28237002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036776","Additional file 1 of Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis","Shokravi, Arveen","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30816974",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036777","THE EMERGING ROLE OF GLP-1 AGONISTS IN ALZHEIMER’S AND PARKINSON’S DISEASE","Chair: Pallavi Joshi","2026","American Journal of Geriatric Psychiatry","other","article","10.1016/j.jagp.2026.03.102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036778","News in brief",null,"2010","Expert Review of Endocrinology & Metabolism","other_trial","article","10.1586/eem.10.12",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0036779","Additional file 1 of Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization","Zhang, Xinyi","2025","Figshare","other","article","10.6084/m9.figshare.29191990",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036780","New treatments for type 2 diabetes","Laura Cascales","2012","Medical Writing","other","article","10.1179/2047480612z.00000000066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036781","Additional file 1 of Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials","Wu, Sijin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26557475",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036782","Additional file 1 of Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review","Yang, Chen-Yi","2021","Figshare","systematic_review","article","10.6084/m9.figshare.13612565",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036783","Additional file 1 of Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes","Wharton, Sean","2025","Figshare","other","article","10.6084/m9.figshare.29261647",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036784","Additional file 1 of The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease","Lin, Yuan","2024","Figshare","other","article","10.6084/m9.figshare.26575829",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036785","How to Treat Binge Eating by Patients With Bipolar Disorder","Nick Zagorski","2019","Psychiatric News","other","article","10.1176/appi.pn.2019.7a19",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036786","Additional file 1 of Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study","Inaishi, Jun","2022","Figshare","other","article","10.6084/m9.figshare.18230651",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036787","Alpha cells as targets for incretin therapy","Om Lakhani","2023","Journal of Diabetology","other","article","10.4103/jod.jod_97_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036788","News in brief",null,"2011","Expert Review of Endocrinology & Metabolism","other","article","10.1586/eem.11.77",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036789","GLP-1 Receptor Agonists and the Risk of Thyroid Cancer","Θεοδώρα Παππά","2023","Clinical Thyroidology","other","article","10.1089/ct.2023;35.18-20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036790","Additional file 1 of Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","Zhou, Lingling","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26637207",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036791","Additional file 1 of Risk of all–cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network","Tartaglia, Enrico","2025","Figshare","other","article","10.6084/m9.figshare.30662758",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036792","Additional file 1 of Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients","Lin, Li-Chun","2025","Figshare","other","article","10.6084/m9.figshare.28463106",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036793","“Beyond Weight Loss: Evaluating the Anti-Inflammatory Potential of GLP-1 Receptor Agonists in Hidradenitis Suppurativa”","Lindsey Roos","2026","ValpoScholar (Valparaiso University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","conference-paper"],["R0036794","Additional file 1 of Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong","Lui, David Tak Wai","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26571379",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036795","Additional file 1 of Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal","Silva Miguel, Luís","2024","Figshare","other","article","10.6084/m9.figshare.25727836",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036796","Glucagon-related advancements in diabetes therapy","Binayak Sinha","2023","Journal of Diabetology","other","article","10.4103/jod.jod_96_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036797","Additional file 1 of The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis","Tseng, Ping-Tao","2025","Figshare","systematic_review","article","10.6084/m9.figshare.28738874",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036798","Additional file 1 of Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","Wu, Rui","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30026680",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; review"],["R0036799","Additional file 1 of Critical discourse analysis of social media advertisements for GLP-1 receptor agonist weight loss drugs: implications for public perceptions and health communication","Rad, J.","2025","Figshare","other","article","10.6084/m9.figshare.30026703",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036800","Additional file 1 of Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials","Salamah, Hazem Mohamed","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26733807",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036801","Additional file 1 of Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial","Myat, Aung","2021","Figshare","randomized_trial","article","10.6084/m9.figshare.13979203",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036802","Additional file 1 of Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis","Hu, Shanshan","2023","Figshare","systematic_review","article","10.6084/m9.figshare.24452492",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036803","Additional file 1 of Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK","Trachsel, Belinda","2023","Figshare","preclinical","article","10.6084/m9.figshare.24089318",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036804","MedCheck: High-Dose Naloxone, Tavapadon, Tirzepatide, and Lumateperone","Terri D’Arrigo","2024","Psychiatric News","randomized_trial","article","10.1176/appi.pn.2024.06.6.1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0036805","Pharmacist Disease Management – Diabetes","John T. Johnson","2006","Europe PMC (PubMed Central)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0036806","Peptide-Based Therapeutics Development","Daniel Hansen","2024","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19511843",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0036807","Novel Therapeutic Targets in Metabolic Disorders","Clara Lindberg","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19512427",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036808","REAL-WORLD SAFETY PROFILE OF TIRZEPATIDE: A DESCRIPTIVE ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)","Mukthiyar Ahamed*","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.21949709",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036809","Combination therapy with GHRH agonist MR-409 and GLP-1 receptor agonist Exendin-4 provides additional benefits on β-Cell survival and glucose homeostasis","Louzada, Ruy","2025","Figshare","other","article","10.6084/m9.figshare.29120561.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036810","Multi-Target Drug Design Strategies","Sofia Lindberg","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19512252",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036811","Additional file 2 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","Chan, Yi-Hsin","2022","Figshare","nonrandomized_study","article","10.6084/m9.figshare.20176129.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0036812","KARDIOVASKULARNE KOMPLIKACIJE ŠEĆERNE BOLESTI","Matea Šimunić","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036813","ЦУКРОВИЙ ДІАБЕТ 1 ТА 2 ТИПУ: ПОРІВНЯЛЬНИЙ ОГЛЯД ТА СУЧАСНІ ТЕРАПЕВТИЧНІ ПІДХОДИ","М.Г. Сорока","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18457355",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036814","The Language of Stress: Example - Hunger (Patterned Tension, Anticipatory Relief) (v1.0)","Joshua Pace","2026","Figshare","other","article","10.6084/m9.figshare.31297048.v1",null,null,"OSF:osf.io/tpsrv",null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036815","Ozempic-like drugs may help with alcohol addiction","Chris Simms","2025","The New Scientist","other","article","10.1016/s0262-4079(25)00300-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036816","Fig S5 image_final","Giles, Morgan","2022","Figshare","other","article","10.6084/m9.figshare.12363944.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036817","Table 1S.docx","Sato, Tetsuhiko","2023","Figshare","other","article","10.6084/m9.figshare.22122317.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036818","Application of GLP-1 Receptor Agonists in Cardiorenometabolic Syndrome","Eldorbek Nomozov","2026","Cardiology of Uzbekistan.","randomized_trial","article","10.70626/cardiouz-2026-3-00082",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0036819","Antiobesity drugs utilization trend analysis and reimbursement lists status: The perspective of selected European countries","Ivana Stević","2024","Arhiv za farmaciju","other","article","10.5937/arhfarm74-50851",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036820","Comparing the Efficacy and Tolerability of Oral Semaglutide and Weekly Injectable Dulaglutide: A Real-World Indian Experience","Binayak Sinha","2024","Journal of Diabetes and Treatment","nonrandomized_study","article","10.29011/2574-7568.010135",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0036821","Alteraciones del metabolismo hidrocarbonado en el paciene con síndrome coronario agudo. Beneficios del tratamiento con agonistas del receptor de GLP1","del Olmo García, María Isabel","2020","Repository of Digital Objects for Teaching Research and Culture (University of Valencia)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0036822","EVOLVING TREATMENTS IN TYPE 2 DIABETES: A FOCUS ON METFORMIN, TIRZEPATIDE, AND SEMAGLUTIDE","Om Patel1*, Kalma Vedant2, Ashok Kumar3, Jaymina Panthaki4, Divyakant Patel5","2026","World Journal of Pharmaceutical Research","other","article","10.5281/zenodo.18659693",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036823","ANDROGEN INSENSITIVITY SYNDROME WITH METABOLIC SYNDROME","Fatimah Zaherah Mohamed Shah","2023","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.038.s2.87",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036824","Data extraction dataset for a network meta-analysis of GLP-1 receptor agonists in women with polycystic ovary syndrome","Chenran Tang","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21961648",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0036825","INK-4a Downregulated in P53 and P21 Mutation Induce BAT and VSMCs Proliferation: Obesity and Hypertension","Peni K. Samsuria Mutalib","2025","International Multispeciality Journal of Health","other","article","10.5281/zenodo.16594856",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036826","1877061_Manuscript_Raw Data 20260815","Cong Wu","2026","Figshare","preclinical","article","10.6084/m9.figshare.33265854.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0036827","GLP-1 Receptor Agonist Withholding Interval and Residual Gastric Contents before Anaesthesia: A Systematic Review and Meta-analysis","Shalini Y1, Rashmi H R2*, Akshay B3","2026","International Journal of Medical Science in Clinical Research and Review","systematic_review","article","10.5281/zenodo.21960925",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036828","Expanding Therapeutic Horizons: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Overweight and Obese CFRD Adults","Ahmed, Ammar","2025","Journal of Obesity & Weight loss Therapy","other","article","10.5281/zenodo.17148002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036829","Cardiovascular Implications of NAFLD: Pathophysiology, Risk Assessment, and Clinical Management Strategies","Simranjeet Singh1, Ishrat Amin2, Bisma Ayoub3, Yasir Ahmad Dar4, Ananya5, Lovepreet Singh6","2025","Journal of Pharmaceutical Sciences","nonrandomized_study","article","10.5281/zenodo.17662909",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036830","GLP-1 Receptor Activation and Cardioprotection: Mechanisms and Clinical Implications","Daniela Guerrero Carrillo","2026","International Journal of Medical Science and Clinical Research Studies","other","article","10.5281/zenodo.19689521",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036831","DIABETOLOGY IN MODERN PHARMACY: AN UPDATED AND CONCISE REVIEW","1*Sikander Ali Sheikh, 2Kashi Ram, 3Himanshu Soni, 4Lakhsya Panchariya","2026","World Journal of Pharmaceutical Research","narrative_review","article","10.5281/zenodo.20438780",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036832","Liraglutide: efficace en cas de diabète de type 2 nécessitant de hautes doses d’insuline?","Antoine de Torrenté","2016","Forum Médical Suisse ‒ Swiss Medical Forum","other","article","10.4414/fms.2016.02749",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036833","Incorporation of Nutrition Education with Medication Injection to sustain Weight Loss","Julia Calvelo","2024",null,"nonrandomized_study","article","10.33015/dominican.edu/2024.nurs.rp.56",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","other"],["R0036834","Personalized Treatment in Chronic Kidney Disease","Anna Dubois","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19613967",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036835","Webometric analysis of the availability of semaglutide-based anti-obesity drugs","Kremin, Yuliia","2024","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.5281/zenodo.14274379",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036836","Glucagon‐like Peptide-1 Agonists and Smoking Cessation: A Brief Review","Richard J. Robbins","2024","Southwest Journal of Pulmonary Critical Care & Sleep","narrative_review","article","10.13175/swjpccs041-24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036837","GLP-1 Receptor Agonists - An Anaesthesiologist’s Perspective – A Comprehensive Review","Assistant Professor, MBBS, FRCA, MD. Penn state health, Hershey, PA.","2024","International Journal of Medical Science and Clinical Research Studies","narrative_review","article","10.47191/ijmscrs/v4-i08-23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036838","Comparing Semaglutide and Terzipatide: A Review of Patient Satisfaction and Quality of Life Outcomes in Type 2 Diabetes",null,"2024","Egyptian Society of Diabetes and Lipidology Journal","narrative_review","article","10.21608/esdlj.2024.456232",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036839","EXPLORING THE UNINTENDED CONSEQUENCES OF MISUSE OF WEGOVY AND OZEMPIC IN WEIGHT MANAGEMENT: A COMPREHENSIVE REVIEW","SARTHAK A. KUTE","2024","International Journal of Pharmacy and Pharmaceutical Sciences","narrative_review","article","10.22159/ijpps.2024v16i6.50611",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036840","Know your enemy: Nature and biochemistry of obesity","Jasna Bjelanović","2024","Arhiv za farmaciju","other","article","10.5937/arhfarm74-50830",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036841","Solution structure of glucagon-like peptide-1 analogues and their interactions with the endogenous receptor and albumin","Tine Maja Frimann","2019","Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0036842","Tirzepatide in Treating Metabolic Disorders","Shulin Wei","2024","International Journal of Drug Discovery and Pharmacology","other","article","10.53941/ijddp.2024.100023",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036843","Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: A systematic review and meta-analysis","Madhusudan Prasad Singh","2025","Journal of Neurosciences in Rural Practice","systematic_review","article","10.25259/jnrp_393_2024",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0036844","Exendin-4 dosing time-dependently affects hepatic circadian clock through GLP-1 receptors in the central nervous system","Pingping Xu","2023","Proceedings for Annual Meeting of The Japanese Pharmacological Society","preclinical","article","10.1254/jpssuppl.97.0_1-b-ss01-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036845","Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight","Hiroshi Itoh","2026",null,"other","article","10.51219/urforum.2026.hiroshi-itoh",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0036846","RCT: Semaglutide reduces alcohol craving and consumption","Alison Knopf","2025","Alcoholism & Drug Abuse Weekly","randomized_trial","article","10.1002/adaw.34470",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0036847","Cardiovascular-Kidney-Metabolic Syndrome: A New Perspective from Definition to Comprehensive Management","博棋 崔","2026","Journal of Clinical Personalized Medicine","other","article","10.12677/jcpm.2026.54253",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036848","Characterising gut dysbiosis in rodent models relevant to psychiatric and neurodevelopmental disorders","Jodie Ellis","2020","Lancaster EPrints (Lancaster University)","preclinical","article","10.17635/lancaster/thesis/967",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036849","POSTTEST EXPIRATION DATE: DECEMBER 2012","&NA;","2011","JAAPA","other","article","10.1097/01720610-201112000-00010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036850","A REVIEW OF THE DEVELOPMENT AND VALIDATION OF THE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) METHOD FOR ESTIMATING THE AMINO ACID MOLE RATIO IN SEMAGLUTIDE","Swetha Vegesna*, Mishall Masa, Sampath Sri Venkata Sai Kumar, Naga Datta Sasi Mrudula Kothapalli","2025","European Journal Pharmaceutical and Medical Research","narrative_review","article","10.5281/zenodo.17577863",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036851","A Review on Pharmacovigilance in the Treatment of Diabetic Patients","Anuja Bhosale, Jagruti Desale, Durgesh Chitte","2025","Journal of Pharmaceutical Sciences","nonrandomized_study","article","10.5281/zenodo.17986502",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036852","Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier","Yoko Takizawa","2024","European Pharmaceutical Journal","preclinical","article","10.2478/afpuc-2024-0008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036853","Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin","Beatriz Atonal Flores","2025",null,"other","article","10.51219/urforum.2025.beatriz-atonal-flores",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0036854","The Role of GLP-1 in the Regulation of Metabolism and Immune Responses","Ellen Zalucha","2021","Deep Blue (University of Michigan)","preclinical","article","10.7302/2719",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036855","A real-world observational study comparing cardiovascular outcomes in patients with type 2 diabetes initiating mixed insulin versus newer oral antidiabetic agents as first injectable therapy","Iyad Khalifah Ahmad Al-Domi","2025","International Journal of Science and Research Archive","nonrandomized_study","article","10.5281/zenodo.18337323",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036856","Versatility of reproductive disorders in obese patients: the view of endocrinologist, obstetrician-gynecologist and urologist","Ю. А. Барсуков","2024","Russian Journal of Woman and Child Health","other","article","10.32364/2618-8430-2024-7-3-10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036857","A New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide in Bulk and Pharmaceutical Dosage Forms","Jhansi Naga Pedaprolu","2016","Eurasian Journal of Analytical Chemistry","other","article","10.12973/ejac.2017.00152a",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036858","CHEW ON THIS","Jonathan A. W. Stecyk","2006","Journal of Experimental Biology","preclinical","article","10.1242/jeb.02285",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036859","Systematic Literature Review: Effectiveness of Insulin Combination Therapy with Glucagon-Like Peptide-1 (GLP-1) Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus","Benly Levi Andreas Sibarani","2024","Asian Journal of Healthcare Analytics","nonrandomized_study","article","10.55927/ajha.v3i2.12310",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0036860","Tirzepatide and Cognitive–Behavioral Regulation of Eating: Bridging Incretin Pharmacology with Neurobehavioral Models of Appetite Control","Sahar Jafari Karegar","2026","Food & Health","other","article","10.82291/fh.2025.1242803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036861","Effects of hypolipemic drugs on psoriasis v1","Mateusz Matwiejuk","2023",null,"nonrandomized_study","article","10.17504/protocols.io.261ge311wl47/v1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0036862","MISINFORMATION OR EDUCATION? TIKTOK’S CONTENT ON GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) FOR USE IN POLYCYSTIC OVARIAN SYNDROME (PCOS) AND INFERTILITY","Rachel Licea","2025","North American Proceedings in Gynecology and Obstetrics - Supplemental","other","article","10.54053/001c.142086",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036863","Anti-fatness in the Ozempic era: State of the landscape and considerations for future research","Flora Oswald","2024","Fat Studies","other","article","10.1080/21604851.2024.2307674",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036864","Auswirkungen der Glucagon-Like Peptide 1 Rezeptor Agonisten Liraglutid und Lixisenatid auf die gastroösophageale Funktion und den gastroösophagealen Reflux bei Patienten mit Diabetes mellitus Typ 2","Quast, Daniel Robert","2021","Dokumentenrepositorium der RUB (Ruhr University Bochum)","other","article","10.13154/294-8110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036865","Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management","Ganesh Chavan1*, Pratiksha Kadale2, Sakshi kumbhoje3, Sayali Karande3, Shruti Lohar4, Sanika Ingale5","2026","Journal of Pharmaceutical Sciences","narrative_review","article","10.5281/zenodo.19041454",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036866","INJECTABLE D-RIBOSE AS A METABOLIC SUPPORT STRATEGY IN PATIENTS UNDERGOING RAPID WEIGHT LOSS INDUCED BY GLP-1 RECEPTOR AGONISTS","2Dr. Carlos Ruiz da Silva 1*Dra Daniela Baptistini Moleiro","2026","European Journal Pharmaceutical and Medical Research","other","article","10.5281/zenodo.19310390",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036867","Follow the Leader GLP-1 Agonist Liraglutide Demonstrates Cardioprotective Benefits","Sony Wibisono","2018","Universitas Airlangga Repository (Universitas Airlangga)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","book-chapter"],["R0036868","THE CARDIOVASCULAR BENEFITS OF ANTI-OBESITY MEDICATIONS: A GAME-CHANGER IN HEART HEALTH","Dr. Imran Aslam","2025","Research Focus International Scientific Journal","other","article","10.5281/zenodo.15161115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036869","Vergleich der Gesundheitskosten von Typ-2 Diabetikern bei der Anwendung von Empagliflozin, DPP-4-Hemmern und GLP-1-Agonisten","et al. Wilke","2022",null,"other","article","10.24945/mvf.06.22.1866-0533.2448",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0036870","Tirzepatide: Revolutionary Drug in Management of “Diabesity”","Vansh Chouhan","2022","International Journal of Medical and Dental Sciences","other_trial","article","10.18311/ijmds/2022/636",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0036871","CLINICAL EVALUATION OF THE BENEFITS OF TOPICAL CALCIUM HYDROXYAPATITE IN PATIENTS WITH SEVERE WEIGHT LOSS DUE TO GLP-1 AGONISTS: AN INTERVENTION STUDY WITH MULTILAYER ANALYSIS ASSOCIATED WITH DERMOCOSMETICS AND NUTRACEUTICALS","1*Dr. Daniela Baptistini Moleiro, 2Dr. Carlos Ruiz Da Silva, 3Dra. Rebeca Butignon Galdeano Araujo, 4Dra. Kerolin Lima Da Silva, 5Dra. Aldrey Coelho De Oliveira","2026","European Journal Pharmaceutical and Medical Research","other","article","10.5281/zenodo.18092886",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036872","Semaglutide induced Pancreatitis","R - Princy","2024","International Journal For Multidisciplinary Research","other_trial","article","10.36948/ijfmr.2024.v06i04.26238",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0036873","Editorial","Aranda Da Silva, José","2015","DOAJ (DOAJ: Directory of Open Access Journals)","commentary","article","10.25756/rpf.v4i3.63",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0036874","Exendin 4 Conjugation and Sequence Modification to Treat Type 2 Diabetes and Obesity","R. Bonaccorso","2016","Syracuse University Libraries (Syracuse University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036875","USING INCRETIN IN TREATMENT OF DIABETES MELLITUS DISEASE","Neeran .F. HASSAN","2022",null,"other","article","10.47832/minarcongress4-29",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0036876","Efficacy and safety of semaglutide for obesity: A systematic review of phase 3 clinical trials","Salvador, Rui","2025","Science Letters","systematic_review","article","10.48797/sl.2025.374",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036877","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS: A COMPREHENSIVE COMPARATIVE REVIEW OF CLINICAL EVIDENCE","K.V. Shanmukhi Saisree*","2026","World Journal of Pharmaceutical Research","randomized_trial","article","10.5281/zenodo.20679044",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0036878","Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association","Hyun Jin Kim","2018","Journal of Korean Diabetes","other","article","10.4093/jkd.2018.19.1.35",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036879","GLP Agonist and Weight Loss: A Systemic Review on GLP-1 Agonist and Its Effect on the Pancreas for Nondiabetic Patients of African Descent","Uchechukwu Chiadikobi","2025","International Journal For Multidisciplinary Research","other_trial","article","10.36948/ijfmr.2025.v07i02.39726",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0036880","Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon?","Lonardo, Amedeo","2025","Exploration of Drug Science","other","article","10.18154/rwth-2025-10562",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036881","Different alterations in gut microbiota caused by combining with metformin liraglutide or pioglitazone in overweight individuals diagnosed with diabetes","Kh.A. Moskva","2024","InterConf","other","article","10.51582/interconf.19-20.05.2024.037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036882","THE SEMAGLUTIDE TREATMENT EFFECT IN PEOPLE WITH OBESITY: A REVIEW","Tulsi Singh*1, Sonalal Prasad Kushwaha1, Gireesh Saini2","2025","European Journal Pharmaceutical and Medical Research","narrative_review","article","10.5281/zenodo.17733451",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036883","Safety and Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients: Synthesis of Evidence v1","Ioannis Bellos","2024",null,"other","article","10.17504/protocols.io.e6nvw1eq9lmk/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036884","IMPACTO DA TERAPIA COM OZEMPIC (SEMAGLUTIDA) NO EMAGRECIMENTO E NA SAÚDE METABÓLICA: UMA REVISÃO DETALHADA DOS EFEITOS E MECANISMOS DE AÇÃO","Brenda Maciel Castellar Lima","2024","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v10i6.14411",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036885","Risk of Type 2 Diabetes Mellitus with Neurological Complications: Review","Amalliah Nurul","2026","International Journal of Current Science Research and Review","narrative_review","article","10.5281/zenodo.18255916",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036886","PERIGOS E CONSEQUÊNCIAS DO USO INDISCRIMINADO DE OZEMPIC NO EMAGRECIMENTO","Thaynara Paula Warren Bezerra","2024","Revista Foco","other","article","10.54751/revistafoco.v17n6-004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036887","Pharmacological vs. Surgical Approaches to Obesity: Are GLP-1 Inhibitors an Alternative to Bariatric Surgery?","Isaías Miguel de Almeida","2025","Journal of Medical Science and Evidences.","nonrandomized_study","article","10.70789/jmse.v2i2.28",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0036888","Glucagon-like Peptide 1 Receptor Agonist Attenuates Diabetic Podocyte Injury","Yoshida Akane","2023","Proceedings for Annual Meeting of The Japanese Pharmacological Society","preclinical","article","10.1254/jpssuppl.97.0_2-b-ss11-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036889","Clinical management strategies for type 2 diabetes mellitus with metabolic dysfunction-associated fatty liver disease: an umbrella review of systematic reviews and meta-analyses","Hui-Ling Huang","2025","Exploration of Endocrine and Metabolic Diseases","systematic_review","article","10.37349/eemd.2025.101443",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0036890","Glucagon-like peptide 1 receptor agonists: a new approach to type 2 diabetes management","Lambert Lynn","2013","South African Family Practice","other","article","10.1080/20786204.2013.10874408",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036891","Efeitos nos desfechos cardiovasculares em Diabetes Tipo 2 sob controle glicêmico intensivo e a introdução de terapias baseadas em agonistas GLP-1 e inibidores sglt2","Thiago Barroso Ferreira Lima Brito Campos","2024","Contribuciones a las Ciencias Sociales","other","article","10.55905/revconv.17n.12-387",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036892","Systematic Review of Tirzepatide's Dual Action on Glycemic Control and Hepatic Biomarkers in Adults with Type 2 Diabetes","Santosh Yadav","2025","International journal for current research and techniques.","systematic_review","article","10.5281/zenodo.15796120",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036893","SYNERGISTIC METABOLIC DYSFUNCTION: INVESTIGATING THE INTERPLAY BETWEEN PCOD, INSULIN RESISTANCE, AND NON-ALCOHOLIC FATTY LIVER DISEASE(NAFLD)","1Jerina CA., 2Ashini David, 1*Dr. Alwin Simon","2026","European Journal Pharmaceutical and Medical Research","other","article","10.5281/zenodo.21785756",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036894","Evaluation of the Effect of Liraglutide Used in Obesity Treatment on Quality of Life","Yildirim, Duygu İlke","2024","Annals of Medical and Health Sciences Research","nonrandomized_study","article","10.5281/zenodo.14505266",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036895","Glucocorticoid-Induced Diabetes: Potential Role for Incretin-Based Therapies","Genugten, R.E. van","2013","Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation; other"],["R0036896","Bariatric Surgery vs. GLP-1 Analogs: Impact on Fertility and Metabolism","Luísa Doria de Almeida","2025","JBRA","other","article","10.5935/1518-0557.20263581",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036897","Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss","Casanueva Freijo, Felipe","2014","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036898","New avenues for GLP1 receptor agonists in the treatment of diabetes","Sedman, Tuuli","2021","DSpace repository (University of Tartu)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036899","Interventionsmöglichkeiten von Inkretinmimetika in den Pathogeneseprozess der pulmonalen Hypertonie sowie daraus abgeleitete potenzielle therapeutische Konsequenzen","Hertl, Maximilian","2017","University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen)","other","article","10.22029/jlupub-14558",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036900","CURRENT TRENDS IN THE DIAGNOSIS AND THERAPEUTIC APPROACHES TO PCOS","Anamika Koshti*1, Jinal Jadeja2, Mayuri Vaja3, Rimsha Soni4, Priyanka Yadav5,  Dr. Divyakant Patel6","2026","World Journal of Pharmaceutical Research","other","article","10.5281/zenodo.18152194",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036901","GLP‑1 Receptor Agonists in Non‑Diabetic Chronic Kidney Disease: A Systematic Review","Isabel Ralha de Abreu","2025","Portuguese Kidney Journal (PKJ)","systematic_review","article","10.71749/pkj.120",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0036902","Comparative efficacy and safety of cardio-renoprotective pharmacological interventions in chronic kidney disease: an umbrella review of network meta-analyses and a multicriteria decision analysis v1","Ioannis Bellos","2024",null,"systematic_review","article","10.17504/protocols.io.81wgbrdx3lpk/v1",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0036903","Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?","Nae‐Yun Heo","2016","Korean Journal of Gastroenterology","randomized_trial","article","10.4166/kjg.2016.67.5.286",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0036904","New drugs 2015, part 2",null,"2015","Nursing","other","article","10.1097/01.nurse.0000469160.33349.19",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036905","Novel Trends in the Management of Type 2 Diabetes: Beyond Glycaemic Control to Cardiovascular Protection","Manav Devalraju Sai Rajesh","2025","IFR journal of medicine and surgery.","other","article","10.5281/zenodo.16542330",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036906","Transforming 300 billion points of data into diagnostics, therapeutics and new insights into disease","Jerry Overman","2013","Mental Health Clinician","nonrandomized_study","article","10.9740/mhc.n155664",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0036907","Tirzepatide: O Início de uma Nova Era na Terapêutica da Diabetes","Raimundo, Anabela","2022","Medicina Interna","other","article","10.24950/rspmi.1053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036908","The Effects of a GLP-1 Receptor Agonist on HbA1c and Weight in Comparison to Standard Therapy in a Veteran Population","Isaac Warshawsky","2020","Digital Commons @ Butler University (Butler University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036909","Diabetes",null,"2025",null,"other","article","10.3390/books978-3-7258-5558-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0036910","ASSISTÊNCIA FARMACÊUTICA E RISCOS ASSOCIADOS AO USO DE OZEMPIC NA BUSCA DO PESO IDEAL","Danielly Viana de Freitas","2024",null,"other","article","10.51161/inofarm2024/28803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0036911","Characteristics and management of juvenile type 2 diabetes mellitus","Young‐Jun Rhie","2024","Journal of Korean Medical Association","other","article","10.5124/jkma.2024.67.5.342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036912","Strategic approaches to enhance the adoption of GLP-1 analogs for diabetes and obesity treatment in India","Shweta Arora","2024","World Journal of Biology Pharmacy and Health Sciences","other","article","10.5281/zenodo.13799143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036913","Problemas relacionados a las nuevas moléculas en pacientes ambulatorios con diabetes mellitus tipo 2, según la clasificación del Segundo Consenso de Granada en la Clínica Internacional; enero 2015-marzo 2017.","Chávez Taype, Katherine","2019","renati","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036914","Nutritional Assessment of Diet Quality and Potential Deficiencies in Individuals Using GLP-1 Receptor Agonist Medications: A Questionnaire Study Institute for Optimum Nutrition","Neetha Lobo","2026",null,"other","article","10.13140/rg.2.2.23479.48801",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036915","Next Generation Incretin Therapies in Obesity: Evolution for Multi-Receptor Agonism to Non-Peptide Oral Molecules","Sonale S*1, Revanth R2, Gowtham Arumugam3","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21980896",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036916","Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective","Weiskirchen, Ralf","2025","Exploration of Drug Science","other","article","10.18154/rwth-2025-10578",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036917","Elevating GLP-1 receptor agonist adoption in India: A comprehensive review integrating the CLIBS framework and rogers' model of diffusion","Arora, Shweta","2025","World Journal of Biology Pharmacy and Health Sciences","narrative_review","article","10.5281/zenodo.17346045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036918","Brief Overview of GLP-1 Agonists: A Primer for Stroke Clinicians","Samarth P. Shah","2024","Stroke Clinician","other","article","10.59236/sc.v1i4.70",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036919","GLP-1 analogue semaglutide regulates pancreatic beta-cell proliferation via PDX-1 expression control","Ming Liang","2024","Theoretical and Natural Science","preclinical","article","10.54254/2753-8818/46/20240399",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036920","AVANCES EN EL TRATAMIENTO DE LA DIABETES EN EL SIGLO XXI","Ethel Codner Dujovne","2025","Boletín Academia Chilena de Medicina","other","article","10.69700/rfyg4h20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036921","Injectable Drugs in Diabetes Treatment: Insulin versus Incretin","Kang Hee Ahn","2025","Journal of Korean Diabetes","other","article","10.4093/jkd.2025.26.1.28",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036922","Liraglutide Modulates Hepatic Lipid Metabolism in Primary Hepatocytes of Brown Trout","Sofia Esquível","2026",null,"preclinical","article","10.3390/proceedings2026146066",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0036923","Can we determine the mechanism behind cancer risk reduction with glucagon-like peptide-1 receptor agonists (GLP-1RAs)?","Junmin Song","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.10535",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0036924","Journal of Diabetes News",null,"2014","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12247",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0036925","The Metabolic-Cognitive Link: Exploring the Association Between Diabetes and Alzheimer's Disease","Dr. Lal Prasanth ML. Dr. Sebin Tharique K.*","2026","International Journal of Medical & Pharmaceutical Sciences","nonrandomized_study","article","10.5281/zenodo.18128851",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036926","Twincretin (Dual GIP/GLP-1 Receptor Agonists): The New Kid on The Block","Jimmy J Thomas","2025","Journal of Diabetes and Treatment","other","article","10.29011/2574-7568.010139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036927","Dissecting gastrointestinal dysfunction and inflammation in a “pre-motor” rodent model of Parkinson’s disease","Sara Raquel Marques Correia","2014","New University of Lisbon's Repository (New University of Lisbon)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036928","GLP-1/GIP Receptor Agonists: Mechanism of Action of Tirzepatide","Tae Jung Oh","2024","Journal of Korean Diabetes","other","article","10.4093/jkd.2024.25.2.76",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036929","Consideration of Use of Semaglutide and Tirzepatide Prior to Pregnancy","Alyse S. Goldberg","2024","Canadian Women s Health Today","nonrandomized_study","article","10.58931/cwht.2024.1210",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0036930","Protective Effect of Ipragliflozin on Acute Brain Injury Induced by Endotoxemia in Mice","Ammar Rasoul Mohammad","2023","مجله طب جانباز","randomized_trial","article","10.58209/ijwph.15.3.225",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0036931","Diversa efficacia clinica e biochimica della terapia con liraglutide in una popolazione di diabetici di tipo 2 in relazione ai valori basali di HbA1c","Radellini S","2016","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper; article"],["R0036932","The Role of GLP-1 Receptor Agonists in Diabetic Kidney Disease: Recent Evidence","Jin Hwa Kim","2025","Journal of Korean Diabetes","other_trial","article","10.4093/jkd.2025.26.1.5",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0036933","Highlights from the Diabetes UK Professional Conference 2017","Félix David","2017","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.2095",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0036934","RELAÇÃO ENTRE DISTÚRBIOS DO SONO E CONTROLE DA HIPERTENSÃO ARTERIAL EM ADULTOS","Fernanda Mol Campos; Teresa Lamaita Lopes; Marcos de Azevedo Reis; Alice Martins Coelho; Luciana Campos Leite Ferreira; Rafaela Ribeiro Bernardino Lessa; Maria Fernanda Santos Attie; Douglas Aparecido Ribeiro; Cecília Teixeira Werner; João Eduardo Vieira Caldas; Júlia Godinho Vecchio Maurício; Carolina Mattos Lindgren Alves; Isabela Dias Sanches Leite; Giovanna Andrade Lopes; Maria Clara Vieira Silva","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21984488",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036935","O uso da Victoza Liraglutida como método para emagrecimento / The use of Victoza Liraglutide as a method for weight loss","Nilton Laudelino Silva Júnior","2021","Brazilian Journal of Development","other","article","10.34117/bjdv7n11-494",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036936","Risiko für Riech- und Schmeckstörungen unter GLP-1-RA offenbar erhöht","Elke Oberhofer","2026","CME","other","article","10.1007/s11298-026-4715-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036937","THE NEWEST THERAPEUTICALLY APPROACH OF “DIABESITY” USING GLP-1 RA MOLECULES: IMPACT OF THE ORAL FORMULATION","Mariana Cornelia Tilinca","2023","FARMACIA","other","article","10.31925/farmacia.2023.1.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036938","Exendin-4 ameniza o dano hepático induzido pela morte encefálica do doador em ratos","Daisy Crispim","2014","Lume (Universidade Federal do Rio Grande do Sul)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0036939","Clinical and toxicological effects of GLP-1 agonists","Teixeira, M. J.","2023","Science Letters","nonrandomized_study","article","10.48797/sl.2023.97",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036940","Clinically Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) with Related Factors","Hiroshi Bando","2024","Asploro Journal of Biomedical and Clinical Case Reports","other","article","10.36502/2024/asjbccr.6363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036941","Optimal Management of Diabetic Kidney Disease","Jae‐Han Jeon","2025","Journal of Korean Diabetes","other","article","10.4093/jkd.2025.26.1.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036942","DIABETES CARE IN PUBLIC HEALTH FACILITIES IN INDIA- A DETAILED STUDY","Ashish Dixit1*, Vikas Chandra Sharma2, Anurag Mishra3, Ashwini Mishra4","2025","World Journal of Pharmacy and Pharmaceutical Sciences","other","article","10.5281/zenodo.17213663",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036943","An Overview of Modern Strategies for Treating Obesity","Aleksandra Jędrasek","2024","Journal of Education Health and Sport","other","article","10.12775/jehs.2024.68.49506",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036944","A Cross Sectional Study to Determine the Therapeutic Response of AntiDiabetic Agents Used in Type 2 Diabetic Patients at Tertiary Care Centre in Western Rajasthan","Aditi Arha","2023","International Journal of Pharmaceutical and Clinical Research","other","article","10.5281/zenodo.11110529",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036945","Navigating the complex landscape of GLP-1 receptor agonists: Barriers, opportunities, and future directions in the indian pharmaceutical market","Shweta Arora","2024","World Journal of Biology Pharmacy and Health Sciences","other","article","10.5281/zenodo.13766409",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036946","Liraglutide: 52 Weeks and 59 lb Later","Kyle R. Peters","2012","Clinical Diabetes","other","article","10.2337/diaclin.30.3.123",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036947","TIRZEPATIDE USE IN SPECIAL POPULATIONS: ELDERLY, PREGNANT WOMEN, AND ADOLESCENTS WITH TYPE 2 DIABETES","Qamar mohammed kashmoola","2025","Journal of Population Therapeutics and Clinical Pharmacology","randomized_trial","article","10.53555/0cqhb709",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0036948","New ASN Kidney Health Guidance Focuses on Outpatient Dialysis for Patients With AKI","Bridget M. Kuehn","2025","Kidney News","other_trial","article","10.62716/kn.000342025",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0036949","The clinical application and research progression of glucagon-like-peptide-1","Ziyu Shu","2024","Theoretical and Natural Science","other","article","10.54254/2753-8818/2024.la18093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036950","In The News/New Products",null,"2012","Optometry and Vision Science","other","article","10.1097/opx.0b013e318253c43d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036951","Real-world Evidence of Injection Semaglutide 2.4 mg in Indian Adults with Obesity: Effects on Weight Loss and Metabolic Outcomes","Rikin Shah","2026","International journal of scientific study","nonrandomized_study","article","10.5281/zenodo.19451528",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036952","Effects of Liraglutide on Ovarian Histomorphology in LDLr⁻/⁻ Mice on a High-Calorie Diet","Licia Cristina Silva de Lima Oliveira","2025","JBRA","preclinical","article","10.5935/1518-0557.20263666",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036953","O USO DE ESTEROIDES ANABOLIZANTES POR PRATICANTES DE ATIVIDADES FÍSICAS - UMA REVISÃO DE LITERATURA","Francisco de Assis Nóbrega Neto","2025","Revista interdisciplinar em saúde","other","article","10.35621/23587490.v12.n1.p1574-1590",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036954","Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview","Carolyn Robertson","2011","Diabetes Spectrum","other","article","10.2337/diaspect.24.1.26",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036955","Agonista del receptor glp-1 liraglutide frente a otros agonistas del receptor de glp-1 en la reducción de hba1c y cambios en el peso en pacientes diabéticos tipo 2, revisión sistemática con metaanálisis.","Elkin Johan Granados Vega","2015","Repositorio CES","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation; article"],["R0036956","Non-arteritic anterior ischemic optic neuropathy (NAION) in a patient treated with semaglutide","Haïthem Chtioui","2025","IRIS","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036957","AKT answer relating to prescribing tirzepatide",null,"2025","InnovAiT Education and inspiration for general practice","other","article","10.1177/17557380251360588e",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036958","Efficacy and safety of traditional Chinese medicine and SGLT2i, GLP‐1RA, and ACEI/ARB in the management of diabetic kidney disease: A systematic review and network meta‐analysis","Jiarong Liu","2025","Rheumatology & autoimmunity","systematic_review","article","10.1002/rai2.12172",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0036959","SYNERGISTIC IMPACT OF EXERCISE AND GLP-1 RECEPTOR AGONIST TREATMENT: ADDRESSING METABOLIC SYNDROME, ABDOMINAL OBESITY, AND INFLAMMATION","Jakub Kuśmierski","2024","Health Problems of Civilization","other","article","10.5114/hpc.2024.139680",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036960","Comprehensive study of GLP‐1 effects suggests neuropsychiatric benefits",null,"2025","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31301",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036961","GLP-1 Receptor Agonists - An Anaesthesiologist's Perspective – A Comprehensive Review","Dr. Shubha Srinivasareddy","2024","International Journal of Medical Science and Clinical Research Studies","narrative_review","article","10.5281/zenodo.13604031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036962","Therapeutic benefits of incretin hormones beyond glycemic control from a primary care perspective: A Narrative Review","Fatma Abubakar Amin","2024","Journal of Medical Science And clinical Research","narrative_review","article","10.18535/jmscr/v12i09.04",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0036963","The future of healthy brain aging will be metabolic: a predictive lesson from data-driven modeling","Luc Pellerin","2025","Frontiers in Science","other_trial","article","10.3389/fsci.2025.1561735",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0036964","Integrated Metabolic and Topical Therapy for Cellulite in Women With Metabolic Syndrome and Insulin Resistance: A Protocol Using Tirzepatide and G21 Topical Formulation","Adamidis Sotirios","2026",null,"protocol","article","10.51219/urforum.2026.adamidis-sotirios",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-paper"],["R0036965","Análise da Eficácia e Segurança de Ozempic e Saxenda no Tratamento da Obesidade: Uma Revisão Abrangente","Davi Ferreira Pires","2024","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2024v6n5p36-48",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036966","Surgical treatment of congenital hyperinsulinism","Kıvılcım Karadeniz Cerit","2025","Turkish Journal of Pediatric Surgery","nonrandomized_study","article","10.62114/jtaps.2025.110",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0036967","SEMAGLUTIDE IN THE TREATMENT OF BONE PAIN IN CAMURATIENGELMANN DISEASE: A CASE REPORT","Fernando H. Pereira","2024",null,"case_report","article","10.47660/cbr.2024.2336",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0036968","Possibilities of a new glucagon-like peptide-1 receptor agonist Semaglutide in improving left ventricular diastolic function in a patient with arterial hypertension and type 2 diabetes mellitu","Makka R. Azimova","2021","Systemic Hypertension","other","article","10.26442/2075082x.2021.4.201305",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036969","Overview of Semaglutide: Effectiveness, Side Effects, and Cost","Mani Vahedi Kafshgari","2025",null,"other","article","10.58445/rars.2874",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036970","Epidemiology And Biological Mechanisms Of Cardiovascular Disease And Diabetes","Rishabh Chaudhary","2024","South Eastern European Journal of Public Health","other","article","10.70135/seejph.vi.1580",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036971","Semaglutide (Wegovy®) in the treatment of obesity and overweight: efficacy and clinical prospects","J De Filette","2025","Revue Medicale de Bruxelles","other","article","10.30637/2025.25-075",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036972","Ozempic (Semaglutide): Beyond Diabetes-An Emerging Role in Weight Loss","Shisode Shweta*, Kelgaonkar Prajakta, Dhamshetti Nikita, Kadbe Mansi, Aishwarya Mehtre","2026","International Journal of Medical & Pharmaceutical Sciences","nonrandomized_study","article","10.5281/zenodo.21860169",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0036973","Oral Galactose Provides a Different Approach to Incretin-Based Therapy of Alzheimer's Disease","Salkovic-Petrisic Melita","2018","Journal of Neurology and Neuromedicine","preclinical","article","10.29245/2572.942x/2018/4.1204",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036974","ENERGY EXPENDITURE, GLUCOSE METABOLISM AND BODY COMPOSITION IN BABOONS AT BASELINE AND AFTER A PARTIAL PANCREATECTOMY AND A 13 WEEKS OF CONTINUOUS INFUSION OF EXENATIDE","Francesca Casiraghi","2014","Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano)","other","article","10.13130/casiraghi-francesca_phd2014-03-11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036975","To Determine the Effect of Oral Pantoprazole and Rabeprazole on Blood Glucose Levels in Type 2 Diabetes Mellitus","Geetika Gupta","2023","INTERNATIONAL JOURNAL OF TOXICOLOGICAL AND PHARMACOLOGICAL RESEARCH","other","article","10.5281/zenodo.11056062",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036976","The Effects of Exenatide on the Autoimmune Development of Diabetes","Kristen L. Miller","2011","The Knowledge Bank (The Ohio State University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036977","New drugs 2015, part 1",null,"2015","Nursing","other","article","10.1097/01.nurse.0000463677.41100.11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0036978","Elucidating the role of growth rate on the production of a fusion protein under regulation of the hp4d promoter by Yarrowia lipolytica","Seshni Govender","2015","SUNScholar (Stellenbosch University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0036979","Expression And Functional Evaluation Of Exendin 4 Fused To Cholera Toxin B Subunit In Tobacco Chloroplast To Treat Type 2 Diabetes","Ramya Nityanandam","2011","Journal of International Crisis and Risk Communication Research","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036980","The effect of SGLT2 inhibitors on kidney stones; a systematic review and meta-analysis","Ali Rahnama Sisakht","2024","Journal of Renal Injury Prevention","systematic_review","article","10.34172/jrip.2024.32292",null,null,"PROSPERO:CRD42023483132",null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0036981","EVALUATE THE EFFECT OF ORLISTAT, LIRAGLUTIDE, AND THE HERBAL SUPPLEMENT ON THE MOTHERS OF EXPERIMENTALLY FATTENED WHITE RATS","Zainab Hasan Majeed","2024","Journal of Medical Genetics and Clinical Biology","preclinical","article","10.61796/jmgcb.v1i6.583",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036982","Liraglutide as a means of modifying cardiometabolic risk in patients with arterial hypertension and concomitant obesity","Dunaieva, I.P.","2025","Inter Collegas","other","article","10.5281/zenodo.17429334",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036983","Clinical Response to Xultophy Possibly Varies from Each Different Metabolic Function","Hiroshi Bando","2021","Edelweiss Applied Science and Technology","other","article","10.33805/2576-8484.190",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036984","Methanol extract from Apium graveolens stimulate glucagon-like peptide-1 secretion (GLP-1), reduced dipeptidyl-peptidase-4 (DPP-4) and protect pancreatic b cells against glucotoxicity and H2O2 toxicity","Rosa Martha Pérez Gutiérrez","2024","Biomedical Research and Therapy","preclinical","article","10.15419/bmrat.v11i6.900",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036985","Mechanisms of Glucagon Receptor Agonism and GLP-1/Glucagon/GIP Receptor Triple Agonism for Treatment of Diabetes and Obesity","Se Hee Min","2024","Journal of Korean Diabetes","other","article","10.4093/jkd.2024.25.2.82",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036986","Ozempic: eficacia y efectos secundarios en la búsqueda de un peso saludable","Diaz, Alfonso","2025","PHYSIOS","other","article","10.60647/x4b1-cr87",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036987","Abstract PS1-05-22: Characteristics and weight loss outcomes in patients with breast cancer prescribed semaglutide","J. Song","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-ps1-05-22",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0036988","Safety and Efficacy of Semaglutide in Type 2 Diabetes Patients: A Real-World Study","Pankaj Aneja","2025","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_48_24",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0036989","The Emerging Trend of Managing Type 2 Diabetes with Oral Semaglutide","Supratik Bhattacharyya","2025","Clinical Diabetology","other","article","10.5603/cd.105996",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036990","The Amplified Cascade: ADHD and the Predictive Network","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21989128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0036991","The Cost of Alzheimer Drug Treatment","Helmy M. Guirgis","2025","Medical Research Archives","other","article","10.18103/mra.v14i1.7163",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036992","System interactions in the regulation of appetite","Fiona Wright","2013","White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0036993","Schreibverbote zum Zwecke des Gesundheitsschutzes","Markus Prazeller","2025","Medialex","other","article","10.52480/ml.25.01",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036994","JPEF Abstracts 2022",null,"2022","International Journal of Diabetes and Technology","randomized_trial","article","10.4103/2949-8457.369062",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0036995","Preventive Cardiology in Coronary Artery Disease: Shifting the Paradigm from Treatment to Prediction","Mohamed Ahmed Mostafa","2026","Case Reports and Case Series in Cardiology Journal","commentary","article","10.64874/crcscj.v1i3.2025.017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0036996","Neuroprotective Effects of Semaglutide: A Comprehensive Review of Cognitive Function and Neuroinflammation","João Paulo Moraes Gomes","2024","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.1594652404072",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0036997","O uso de semaglutida no tratamento de obesidade e sobrepeso: uma revisão integrativa","Hiromi Okuyama, Agnês","2025","Dialnet (Universidad de la Rioja)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0036998","Pharmacological approaches to the treatment of obesity","Londoño-Lemos, Milton Enrique","2017","Magazine Portal Bibliotech Digital (Universidad Nacional de Colombia)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0036999","From Ozempic to Wegovy: Building Brand Equity through Effective Brand Positioning in Multiple Markets","Zachary White","2026","Business Case Journal","other","article","10.69521/bcj.v33i1.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037000","Herbal Interventions in Cardiometabolic Disorders","Léa Dubois","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19631289",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037001","FDA, EU Regulators Expand Indications for Semaglutide to Include Kidney Benefits for Patients With Diabetes","Bridget M. Kuehn","2025","Kidney News","other_trial","article","10.62716/kn.000322025",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0037002","Clinical Cardiology Congress 2020: An Audit of Glucose Lowering Therapies In Patients With Type 2 Diabetes And Hospitalisation for Heart Failure - Meor Azraai - The Royal Melbourne Hospital and NorthWestern Mental Health.","Meor Azraai","2020",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0037003","GLP-1 Receptor Agonists and Substance Use Disorders: A Public Health Opportunity with Emerging Safety Concerns","Silvia Martinelli","2025","Epidemiology Biostatistics and Public Health","other","article","10.54103/2282-0930/29800",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037004","Uso de agonistas do receptor GLP-1 no tratamento da obesidade em pacientes pediátricos: uma revisão de literatura de ensaios clínicos randomizados","Leonardo Rosa Monjeló","2024","Brazilian Journal of Health Review","other","article","10.34119/bjhrv7n10-319",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037005","Pharmacological Synergy: Systematic Review Of Glp-1 And Gip Receptor Co-Activation By Tirzepatide","Aishwarya Mishra","2022","American Journal of Psychiatric Rehabilitation","systematic_review","article","10.69980/ajpr.v28i5.608",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0037006","Neuroprotective strategies in Parkinson’s disease","Divyani Garg","2021","Annals of Movement Disorders","nonrandomized_study","article","10.4103/aomd.aomd_38_21",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037007","Contemporary Treatments for Obesity: Physical Activity in the Context of Antiobesity Medications","John M. Jakicic","2024","Translational Journal of the American College of Sports Medicine","other","article","10.1249/tjx.0000000000000253",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037008","The role of weight loss drugs in the management of patients scheduled for hip and knee joint replacement","Raymond Fuller","2026","Royal College of Surgeons in Ireland","randomized_trial","article","10.25419/rcsi.30551213",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0037009","Ryšys tarp nutukimo ir atsparumo insulinui moterims, sergančioms PCOS","Revital Inna Risman","2025","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037010","Incretin-mimetic drugs—nature, benefits, and risks","Nadezhda Hvarchanova","2024","Varna Medical Forum","other","article","10.14748/vmf.v13i1.9474",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037011","Postprandial Hyperglycemia","Tae Jung Oh","2016","Journal of Korean Diabetes","other","article","10.4093/jkd.2016.17.4.233",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037012","Effect of Glucagon Like Peptide 1 Receptor Agonist (Liraglutide) on Male Reproductive Function in Obese Male Albino Rats",null,"2026","The Egyptian Journal of Hospital Medicine","preclinical","article","10.21608/ejhm.2026.520741",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037013","Potential Gastroprotective Effects of Sitagliptin versus Liraglutide Against Indomethacin-Induced Gastric Ulcer in Diabetic Rats","Omaima M. Abd-Allah","2026","Benha Medical Journal","preclinical","article","10.21608/bmfj.2026.466734.2913",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037014","OR3-2 | GLP-1 Receptor Agonist Use in Patients with Type II Diabetes After Acute Myocardial Infarction and PCI: A Retrospective Cohort Study","Moses Sghayyer","2025","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2025.102704",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037015","Nutritional Considerations for Diabetic Patients on Diabetes Medication","Dal Lae Ju","2014","Journal of Korean Diabetes","other","article","10.4093/jkd.2014.15.1.35",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037016","PERSPECTIVES AND CHALLENGES IN THE USE OF OZEMPIC AND MOUNJARO IN PATIENTS WITH METABOLIC DISEASES: AN UPDATED REVIEW","Robison Antônio Coelho Júnior","2024","International Journal of Health Science","narrative_review","article","10.22533/at.ed.1594912414109",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037017","The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial and Its Clinical Impact on Patterns of Prescription for Anti-Diabetes Medication","Hyuk‐Sang Kwon","2016","Journal of Korean Diabetes","other_trial","article","10.4093/jkd.2016.17.4.225",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0037018","Liraglutida: Uma revisão bibliográfica","Nathália Fernandes de Castro Alves","2024","Research Society and Development","other","article","10.33448/rsd-v13i9.46758",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037019","Systematic Review of Cardiovascular Outcomes with Sulfonylureas, GLP-1 RA, and DPP-4 Inhibitors in Type 2 Diabetes Mellitus","Koo Thai Hau","2024","Journal of Diabetology","systematic_review","article","10.4103/jod.jod_80_24",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0037020","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-70432-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037021","Diabetes and stroke:liraglutide is associated with a decreased risk of stroke in type 2 diabetes mellitus. A nested case-control study","Jan Lykke Scheel Thomsen","2014","VBN Forskningsportal (Aalborg Universitet)","nonrandomized_study","article","10.1111/ene.12496",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0037022","Evaluating the impact of GLP-1 receptor agonists on weight management in patients with breast cancer undergoing endocrine therapy: A comparative analysis.","Daniela Urueta Portillo","2024","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2024.42.16_suppl.e13063",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037023","Exploring the Mechanism of Action of GLP-1RAs in the Treatment of Non-Alcoholic Fatty Liver Disease Combined with Diabetes Based on Network Pharmacology","高林 齐","2025","Medical Diagnosis","nonrandomized_study","article","10.12677/md.2025.152027",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037024","Exocrine pancreatic insufficiency in diabetes","Larysa Zhuravlyova","2024","Herald of Pancreatic Club","nonrandomized_study","article","10.33149/vkp.2024.04.07",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037025","The Neuroprotective Nexus: GLP-1 Receptor Agonists, Sleep, and the Glymphatic System in Alzheimer’s Disease Prevention","Aadith Maganti","2026","American journal of student research.","other","article","10.70251/hyjr2348.42278288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037026","An Updated Review of Glucagon-Like Peptide-1 Receptor Agonists","John R. Coleman","2026","Advances in Anesthesia","narrative_review","article","10.1016/j.aan.2026.04.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037027","Treatment Options for Polycystic Ovary Syndrome","Jie Cai","2025","Obstetrics and gynecology.","other","article","10.5772/intechopen.1012822",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0037028","700 EPICARDIAL ADIPOSE TISSUE AND ATRIAL FIBRILLATION, A REVIEW","Angelica Cersosimo","2022","European Heart Journal Supplements","narrative_review","article","10.1093/eurheartjsupp/suac121.017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037029","Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice","Juyoung Shin","2023","Cardiovascular Prevention and Pharmacotherapy","other","article","10.36011/cpp.2023.5.e7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037030","SEMAGLUTIDE- REVOLUTIONARY DRUG IN OBESITY MANAGEMENT","Gabriela Majka","2025","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(47).2025.3877",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037031","Study of the physiological and pharmacological actions of GLP-1 and GLP-1 receptor antagonists in appetite regulation","Ιωάννης Κορκολής Ανέστης Μάριος","2026","Harokopio University","nonrandomized_study","article","10.26258/heal.hua.7732",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037032","The application of GLP-1 receptor agonists in obesity due to MC4R deficiency","Mengmeng Ding","2026","Metabolism and Target Organ Damage","nonrandomized_study","article","10.20517/mtod.2026.58",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037033","Understanding and evaluating cardio-metabolic benefits imposed by surgery, medication and adipose tissue metabolism","Sahar Azharian","2018","Warwick Research Archive Portal (University of Warwick)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0037034","Os crijevo – mozak: novi horizonti u poremećajima pokreta","Mario Mašić","2026","Paediatria Croatica","other","article","10.13112/pc.1227",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0037035","Abstract PD8-09: Revisiting the GLP-1-pCR Link in TNBC: Contrasting Outcomes in a High-BMI, Majority-Hispanic Cohort","D. Urueta Portillo","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-pd8-09",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037036","Pharmacology of the GLP-1 Analog Liraglutide in Healthy Cats","M.J. Hall","2014","OhioLink ETD Center (Ohio Library and Information Network)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037037","Detection and Treatment of Diabetic Urinary Microalbumin: The Need of the Hour","S Parthasarathy","2024","SBV Journal of Basic Clinical and Applied Health Science","other","article","10.4103/sbvj.sbvj_5_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037038","1857-LB: Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity—An Exploratory Analysis of GLORY-1","Linong Ji","2024","Diabetes","randomized_trial","article","10.2337/db24-1857-lb",null,null,"ClinicalTrials.gov:NCT05607680","S000751","openalex","FALSE","paywalled","1","FALSE","article"],["R0037039","Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists","Se Hee Min","2015","Journal of Korean Diabetes","other","article","10.4093/jkd.2015.16.4.252",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037040","Recent Advances for Anti-Obesity Agents","Chul Sik Kim","2015","Journal of Korean Diabetes","other","article","10.4093/jkd.2015.16.4.260",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037041","Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology","Bhaskar Pal","2024","Journal of Diabetology","other_trial","article","10.4103/jod.jod_117_23",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0037042","Management of Hypertension, Obesity, Lipids, and Diabetes with Glucagon-like Peptide 1 Receptor Agonists","Hridish Narayan Chakravarti","2024","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_11_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037043","Case Series on Implementation of Continuous Glucose Monitoring for Better Glycemic Control without Long-acting Insulin",null,"2024","Journal of Medical Clinical Case Reports","case_report","article","10.47485//2767-5416.1062",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037044","Ozempic e fertilidade feminina: A relação entre o tratamento com semaglutida e aumento da fertilidade","Diogo Nunes Melo","2025","Journal of Medical and Biosciences Research.","other","article","10.70164/jmbr.v2i1.538",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037045","An Overlooked Impact of GLP-1 Receptor Agonists on Enteric Coated Medications","Eman Atef","2026","Open Journal of Pharmacology and Pharmacotherapeutics","other_trial","article","10.17352/ojpp.000030",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0037046","Recent trials with a “High Impact” on current daily practice: A 360° journal search","Suman Bhandari","2024","Journal of current cardiology.","randomized_trial","article","10.4103/jcc.jcc_35_24",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037047","PS18 - 1. Exenatide blunts hyperactivation in CNS reward and satiety circuits elicited by viewing food cues in obese individuals","Liselotte van Bloemendaal","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0160-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037048","Shortage of Weight Loss Drugs Creates Problems for Patients","Diane S. Aschenbrenner","2024","AJN American Journal of Nursing","other","article","10.1097/01.naj.0001010560.28176.11","38511704",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037049","Mifepristone/semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-34944-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037050","Poster presented at EASL 2026: The glucagon/glucagon-like peptide-1 receptor dual agonist survodutide strongly reduces alcohol intake in the lean golden syrian hamster, a preclinical model with spontaneous alcohol preference","François Briand","2026","Boehringer Ingelheim","other","article","10.60915/boehringer-figshare.32158923.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0037051","Pleiotropic Benefits with Glucagon-like Peptide-1 Receptor Agonists: A Clinical Review","SONALI A. PATANGE","2023","International Journal of Diabetes and Technology","narrative_review","article","10.4103/ijdt.ijdt_19_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037052","1700-P: Durable Cardiometabolic Effects of Utreglutide in Metabolic Dysfunction–Associated Steatotic Liver Disease Patients with Nondiabetic and Prediabetic Status","Rajamannar Thennati","2026","Diabetes","randomized_trial","article","10.2337/db26-1700-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037053","Overweight and obesity in children and adolescents: causes and strategies for prevention","Anna Celina Durma","2026","Pediatria i Medycyna Rodzinna","nonrandomized_study","article","10.15557/pimr.2026.0001",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037054","Advances in the Pharmacologic Management of MASLD","Savita Madhankumar","2026","Gastroenterology Insights","other","article","10.3390/gastroent17010017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037055","Cardiovascular protection in type 2 diabetes: time to ADVANCE management ACCORDing to the evidence","Hajhosseiny R","2013","DOAJ (DOAJ: Directory of Open Access Journals)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; review"],["R0037056","S855 Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Endoscopy Outcomes: A Systematic Review and Meta-Analysis","Raseen Tariq","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001032788.29188.60",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0037057","GLP-1 RECEPTOR AGONIST USE AMONG PATIENTS UNDERGOING MAJOR PANCREATICOBILIARY RESECTIONS","L. Ayasa","2026","HPB","other","article","10.1016/j.hpb.2026.04.339",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037058","Liraglutide as a means of modifying cardiometabolic risk in patients with arterial hypertension and concomitant obesity","Інна Павлівна Дунаєва","2025","Kharkiv National Medical University Repository (Kharkiv National Medical University)","other","article","10.35339/ic.2025.12.2.dun",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037059","799-P: Nephroprotective Effects of a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Preclinical Models of Acute and Chronic Kidney Diseases","SEON MYEONG LEE","2024","Diabetes","preclinical","article","10.2337/db24-799-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037060","Lilly (Eli) & Co.",null,"2008","Mergent s Dividend Achievers","other","article","10.1002/div.7768",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037061","CE-534538-004 GLUCAGON-LIKE PEPTIDE-1 AGONISTS AND INCIDENCE OF ATRIAL FIBRILLATION IN OBESE ADULTS WITHOUT DIABETES: A PROPENSITY-MATCHED COHORT STUDY","Aseed Mestarihi","2026","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2026.03.017",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037062","The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit","REJ Ryder","2010","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1522",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037063","1146-P: SGLT2 Inhibitors and the Risk of Early Bladder Cancer Events","Devin Abrahami","2022","Diabetes","nonrandomized_study","article","10.2337/db22-1146-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037064","Exénatide à libération prolongée (Bydureon®) : données de sécurité d’utilisation du programme clinique DURATION","J.-P. Sauvanet","2010","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(10)70106-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037065","S3131 Effects of GLP-1RA Use on Upper GI Toxicity in Patients Receiving Platinum Analog-Based Chemotherapy","Varun Vemulapalli","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001139984.75057.54",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037066","2138-P: A Novel Strategy for Optimizing Preconception Medication Choices in Women with Early-Onset Type 2 Diabetes","CLAIRE MEEK","2026","Diabetes","other","article","10.2337/db26-2138-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037067","S1911 Impact of GLP-1 Therapy on Disease Outcomes in Patients With Inflammatory Bowel Disease and Type 2 Diabetes: A Nationwide Analysis","Fariha Hasan","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001135104.41808.5b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037068","Additional file 1 of Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin","Yang, Xiaotong","2020","Figshare","other","article","10.6084/m9.figshare.12332069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037069","Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Thiazolidinediones for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Network Meta-Analysis","Minjeong Park","2022","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.4049630",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0037070","81-LB: Novel Microsphere Technology Reducing Injection Site Reaction in the Development of Long-Acting GLP-1 RA Formulation","YEJIN KIM","2023","Diabetes","preclinical","article","10.2337/db23-81-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037071","Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease (Supplemental 3D videos)","Henrik H. Hansen","2026","Figshare","other","article","10.6084/m9.figshare.31850719.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037072","Typ-1-Diabetes – Zweite Phase-III-Studie mit GLP1-RA bestätigt erste","Friederike Klein","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-121782",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037073","GLP-1 Agonists in Obese NSCLC Patients: Enhancing Survival While Mitigating Pneumonia Risk?","Assal Sadighian","2025",null,"other","article","10.13140/rg.2.2.32904.12807",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037074","EFEITO CARDIOPROTETOR DOS ANÁLOGOS DE GLP1 EM PACIENTES PORTADORES DE DIABETES MELLITUS: UMA REVISÃO DE ESCOPO","Da Costa Júnior, Flávio Luiz","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.8214229",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037075","The environmental impact of weight-loss drugs","Aayushi Pratap","2024","C&EN Global Enterprise","other","article","10.1021/cen-10213-feature1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037076","An investigation into the aggregation of therapeutic peptides through adsorption to primary containers","Geraldine Baekelandt","2019","Apollo (University of Cambridge)","other_trial","article","10.17863/cam.52684",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","dissertation"],["R0037077","704-P: Time in Range and Time Below Range in Insulin-Treated Older Adults with Type 2 Diabetes","Silmara A O Leite","2022","Diabetes","randomized_trial","article","10.2337/db22-704-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037078","716-P: Systolic Blood Pressure Reduction with Tirzepatide across SURPASS Program: A Mediation Analysis Using Weight Loss as a Factor","ILDIKO LINGVAY","2022","Diabetes","other","article","10.2337/db22-716-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037079","In Case You Haven't Heard…",null,"2023","Alcoholism & Drug Abuse Weekly","other","article","10.1002/adaw.33933",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037080","Impacto farmacológico e fisiológico do uso de tirzepatida e de agonistas do receptor de GLP-1 em indivíduos não diabéticos: uma metanálise","EDUARDA PARZIANELLO LUBI","2026","RCMOS - Revista Científica Multidisciplinar O Saber","other","article","10.51473/rcmos.v1i1.2026.2676",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037081","Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes","Skolnik, Neil","2020","Figshare","other","article","10.6084/m9.figshare.13376882",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037082","In This Issue",null,"2011","Obesity","preclinical","article","10.1038/oby.2011.173",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037083","CA-027: Observance du traitement par Agoniste du GLP-1 en Allemagne : Bydureon en prise hebdomadaire vs Victoza en prise quotidienne","Giuseppe Ricci","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30159-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037084","Dulaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-50437-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037085","A comparative hepatoprotective effect of liraglutide and nano extracts of Ficus carica and Olea europaea leaves on diabetes-induced in laboratory animals","Laila A. Hummdi","2020","Bulletin of Pure & Applied Sciences- Zoology","preclinical","article","10.5958/2320-3188.2020.00008.x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037086","Liraglutide: a guide to its use in type 2 diabetes mellitus","&NA;","2010","Drugs & Therapy Perspectives","other","article","10.2165/11204100-000000000-00000",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037087","0447 Cutaneous outcomes following glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: A propensity-matched trinetx cohort study","D. Wambold","2026","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2026.06.478",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037088","Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study","Federico Perna","2026","Alimentary Pharmacology & Therapeutics","nonrandomized_study","article","10.1111/apt.70714","42101069",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","editorial"],["R0037089","Abstract #611 Real World Treatment of Obesity with Liraglutide in Mexican Patients of a Medical Care Network","Arturo Pena Velarde","2018","Endocrine Practice","nonrandomized_study","article","10.1016/s1530-891x(20)47250-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037090","Study the role of GLP-1 receptor agonist (Liraglutide) on experimentally induced diabetic nephropathy in male albino rats","Samah Gamal Elsayed Elraey","2025","International Journal of Health Sciences","preclinical","article","10.53730/ijhs.v9ns1.15674",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037091","1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study","RICCARDO CANDIDO","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1804-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037092","EE297 Cost-Utility Analysis of Adding Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors or Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists to Standard Therapy in Thai Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease","Pattara Leelahavarong","2025","Value in Health","other","article","10.1016/j.jval.2025.09.681",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037093","1984-LB: All-Cause Mortality and GI Adverse Effects in Adults with Type 1 Diabetes (T1D) on GLP-1RA","Danah Al-Deiri","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1984-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037094","Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study","Of, Adis Journals On Behalf","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.13360382",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037095","Agonistas do recetor do péptido semelhante ao glucagon tipo 1 e fertilidade masculina","Beatriz de Fátima Oliveira Fernandes","2026","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037096","IBC Oxford Poster Abstract 1 - Effectiveness of liraglutide in managing recurrent weight gain and suboptimal clinical response after bariatric surgery: a meta-analysis","Shu Yu Lim","2026","British journal of surgery","systematic_review","article","10.1093/bjs/znaf288.065",null,null,"PROSPERO:CRD420251053386",null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0037097","1732-P: Liraglutide Ameliorates Diabetic Cardiomyopathy via Ferroptosis Inhibition: Clinical CMR Evidence and Mechanistic Insights","LIANQIN CHEN","2026","Diabetes","randomized_trial","article","10.2337/db26-1732-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037098","Weekly Journal Scan: Have we reached the SUMMIT of incretin treatment of heart failure with preserved ejection fraction and obesity?","Giovanna Liuzzo","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf013","39836093",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037099","NEW ONCE-WEEKLY GLP-1 RECEPTOR AGONIST – A QUALITATIVE LEAP IN MANAGEMENT OF TYPE 2 DIABETES MELLITUS","T. Yu. Demidova","2018","Фарматека","other","article","10.18565/pharmateca.2018.4.9-15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037100","Abstract ED03-01: Breaking the Obesity-Breast Cancer Link: Comparing Diet, Drug and Surgical Approaches","SD Hursting","2024","Cancer Research","preclinical","article","10.1158/1538-7445.sabcs23-ed03-01",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037101","The Use of GLP-1 Agonists in Alcohol Use Disorder and Reducing Alcohol Consumption: A Scoping Review","Alec Birnbaum","2025",null,"nonrandomized_study","article","10.31986/issn.2689-0690_rdw.stratford_research_day.19_2025",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0037102","Effects of Semaglutide on Lipid Metabolism and C-Reactive Protein in Obesity: A Review of STEP Trials","Clemilson Berto-Junior","2026","Drugs and Drug Candidates","other_trial","article","10.3390/ddc5020035",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0037103","6-OR: Renal Cell Type—Associated Therapeutic Effects of Semaglutide in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","MARCO TOZZI","2024","Diabetes","preclinical","article","10.2337/db24-6-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037104","Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646","Stavros Liatis","2021","Diabetes Care","commentary","article","10.2337/dc21-0518","34155034",null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0037105","268-OR: The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes","Laurent Azoulay","2023","Diabetes","nonrandomized_study","article","10.2337/db23-268-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037106","ANÁLISE DO INDISCRIMINADO USO OFF LABEL DE OZEMPIC PARA EMAGRECIMENTO",null,"2023",null,"other","article","10.56161/sci.ed.20230810188",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0037107","779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study","Raffaele Napoli","2023","Diabetes","nonrandomized_study","article","10.2337/db23-779-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037108","790-P: The Effect of Tirzepatide vs. Placebo on Changes and Shifts in BMI Category in Adults with Type 2 Diabetes—A Post Hoc Analysis of the SURMOUNT-2 Study","RODOLFO J. GALINDO","2024","Diabetes","other_trial","article","10.2337/db24-790-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037109","S3784 Diverticulitis-Induced Sigmoid Stricture Causing Large Bowel Obstruction in a Young Adult","Arham Siddiqui","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001142596.43101.3f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037110","The role of pharmacological interventions in optimizing glycemic control and reducing complications in diabetes mellitus: Current insights and future directions","Alanezi, Abdulkareem A.","2025","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037111","2049-P: Real-World Assessment of Orlistat and Liraglutide in Patients with Obesity: The XENSOR Study","Juan José Gorgojo Martínez","2019","Diabetes","nonrandomized_study","article","10.2337/db19-2049-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037112","Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting","Cheli Melzer-Cohen","2019","Figshare","nonrandomized_study","article","10.6084/m9.figshare.10082762",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037113","Redefining Diabetes & Cardiodiabesity Management: The Tirzepatide Evolution","Sumon Rahman Chowdhury","2026",null,"other","article","10.13140/rg.2.2.22298.50882",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037114","Which Platform Delivers More Accurate Responses to Common Questions About GLP1RA Therapy: Large Language Models or Internet Searches? (Preprint)","Sarah Ying Tse Tan","2025",null,"other","article","10.2196/preprints.78289",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0037115","Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review","González González, José Gerardo",null,"El Repositorio Academico Digital de la UANL (Universidad Autónoma de Nuevo León)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0037116","Corrigendum",null,"2022","Journal of Diabetes Investigation","other","article","10.1111/jdi.13840","35775966",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0037117","Current status and future of drug therapy for obesity-related heart failure with preserved ejection fraction","Zhiao Zhang","2026","Journal of Cardiothoracic Surgery","other","article","10.1186/s13019-026-04647-z",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037118","Exploring the interplay of pharmacotherapy and dietary weight loss interventions with whole body health including physical activity, physical function and body composition","Jobanputra, Rishi","2025","University of Leicester","randomized_trial","article","10.25392/leicester.data.28333928",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0037119","26-A-15811-ACC MIND AND HEART: CARDIOVASCULAR AND PSYCHIATRIC OUTCOMES WITH TIRZEPATIDE VS GLP-1 AGONISTS IN OBESITY","Ure K Eziyi","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.513",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037120","Obesidad y Medicamentos en Diabetes: Una Revisión del Tratamiento Farmacológico en Pacientes con Sobrepeso y Obesidad","Morales Dussán, Evelyn Yulieth","2025","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037121","How IL-9 signaling Influences Astrocytes and ultimately Contributes to BBB Disruption after Ischemic Stroke","Parvin Mozafari","2026","JUNIOR RESEARCHERS","nonrandomized_study","article","10.52340/jr.2026.04.02.03",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037122","Abstract 115","Akanksha Kulhari","2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.363618",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0037123","4710 CHALLENGES IN METABOLIC/BARIATRIC SURGERY REFERRALS: EXAMINING THE IMPACT OF GLP-1 RECEPTOR AGONISTS",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.254",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037124","Figures of Efficacy and Safety of Modern Renoprotective Therapies for Non-Diabetic Kidney Disease: Insights from a Network Meta-Analysis","Chen, rulong","2025","Figshare","systematic_review","article","10.6084/m9.figshare.29649545.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0037125","GLP-1 analogues increase risk of breast cancer?",null,"2016","Reactions Weekly","other","article","10.1007/s40278-016-22398-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037126","From Decoding Light to Entire Universe — N-K Sciences The Complete Framework: Space is Not Vacuum · Mass is N-Compression · Particles are Bubbles · Light Speed Varies with N-Density · Gravity is Buoyancy · One Fluid, One Law, One Equation: F = -k ∇N.","Muhammad Usman Malik","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19656743",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037127","Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes: A Meta-Analysis of Randomized Controlled Trials","Edoardo Mannucci","2019","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.3424204",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0037128","Efficacy and tolerability of once-weekly subcutaneous semaglutide for weight management: A prospective follow-up study from Bangladesh","Md Rakibul, Hasan","2024","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other","article","10.5281/zenodo.14614220",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037129","The protein state of matter: defining a key player in health and disease.","Luigi Leonardo Palese","2018","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0037130","P2‐480: Insulin‐like agonists reverse detrimental effects on synaptic activity induced by beta‐amyloid fragments","Christian Hölscher","2008","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2008.05.1558",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037131","Impact of Glucagon-Like Peptide-1 Receptor Agonists Prior to Bariatric Surgery","Martin Zachary","2024","Journal of Obesity and Weight-loss Medication","other","article","10.23937/2572-4010.1510051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037132","Use of GLP-1 Receptor Agonist in MODY1 With a Complex Variant of Exons 2-8 of the HNF4A Gene",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037133","A Patient With Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young Treated With an Oral Glucagon-like Peptide 1 Receptor Agonist",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.244",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037134","N-K RUBIN BIRD VOICE DNA — COMPLETE ENCODING OF AVIAN TASBEEH The First Ever Digital-Geometric Synthesis of Bird Vocalization Using the Four Divine Axioms — Full Audio Waveform + 121-Node Frequency Grid + Arabic Decoding","Muhammad Usman Malik","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19675070",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037135","Glucagon like-peptide 1 or exendin-4 administration limited to the transient neonatal hyperglycemic period in the n0-STZ rat model of NIDDM exerts a long-term favorable influence on glycemic control in the adult","Cécile Tourrel","2000","Diabetes Research and Clinical Practice","preclinical","article","10.1016/s0168-8227(00)81313-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037136","Limbal stem cells as a potential source of pancreatic beta cells","CRISCIMANNA, Angela","2009","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0037137","Emergency of \"Ozempic face \" ; Addressing Unintended consequences of rapid weight loss (Preprint)","Kashif Kashif Zarnaab","2025",null,"other","article","10.2196/preprints.81965",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0037138","Wöchentliche Gabe von IcoSema vs. wöchentliche Gabe von Insulin icodec zum Typ-2-Diabetes-Management (COMBINE 1)","Thomas Schimmel","2025","Die Diabetologie","other","article","10.1007/s11428-025-01363-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037139","Treatment Experience Using U-500 Insulin and Tirzepatide",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.053",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037140","Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes","Robert E. J. Ryder","2011","The British Journal of Diabetes","randomized_trial","article","10.1177/1474651411412658",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037141","336 Assessing Impact of Pharmacy Benefit Manager Reimbursement Rates on Access to GLP-1 Therapies in Independent Pharmacies","C. Kimble","2026","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2026.103350",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037142","1518-PUB: Role of PPARd in Regulating Autophagy Pathway in Improving Islet ß-Cell Function with GLP-1 Receptor Agonist","Yanna Su","2022","Diabetes","preclinical","article","10.2337/db22-1518-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037143","(Re)conceptualizing fatness as a medical and moral issue in the Finnish media discourse on fat and Ozempic in 2022–2023","Hannele Harjunen","2025","Fat Studies","other","article","10.1080/21604851.2025.2529706",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037144","Drug News",null,"2025","Nursing","other","article","10.1097/nsg.0000000000000186","40254754",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037145","Lilly (Eli) & Co.",null,"2008","Mergent s Dividend Achievers","other","article","10.1002/div.7083",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037146","Oral administration of boschnaloside, a GLP-1 receptor activator from herbal medicine Boschniakia rossica (the northern groundcone), improved diabetic conditions and modulated incretin hormone levels in db/db mice","Hui‐Kang Liu","2018","Proceedings for Annual Meeting of The Japanese Pharmacological Society","preclinical","article","10.1254/jpssuppl.wcp2018.0_po1-5-32",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037147","Food Noise: Emerging Concept, Neurobiological Mechanisms, and Psychopathological Implications","M. F. Fernandes","2026","European Psychiatry","nonrandomized_study","article","10.1192/j.eurpsy.2026.10726",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037148","758-P: Changes in Liver and Abdominal Fat in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 MRI Substudy","ÁNGEL RODRÍGUEZ","2023","Diabetes","other_trial","article","10.2337/db23-758-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037149","Medication Use Evaluation of Tirzepatide FDA Approved for Type 2 Diabetes in the Outpatient Setting","Diaz, Carina","2025","Scholarly Commons - Baptist Health South Florida (Baptist Health South Florida)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0037150","94-LB: A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes","MARK A. PIRNER","2022","Diabetes","randomized_trial","article","10.2337/db22-94-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037151","GLP-1-basierte Polypharmakotherapien als wegweisender neuer Ansatz in der Behandlung von Adipositas und Diabetes","Timo D. Müller","2022","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/a-1904-5552",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037152","OBESITY AS A GLOBAL HEALTH CONCERN: A MULTI-DIMENSIONAL ANALYSIS OF PATHOPHYSIOLOGY, SOCIOECONOMICS, AND MODERN THERAPEUTIC PARADIGMS","Abhinav chauhan","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20151602",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0037153","Myocardial infarction in type 2 diabetes using sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network-based machine learning","Tomohide Yamada","2019","Figshare","other","article","10.6084/m9.figshare.11409840.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037154","Abstract 4363248: GLP1 Receptor Agonist Use in Obstructive Sleep Apnea and the Risk of Developing Atrial Fibrillation","Brandon Berman","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4363248",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0037155","845-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline HbA1c, Insulin Dose, and BMI","PHILIP HOME","2022","Diabetes","randomized_trial","article","10.2337/db22-845-p",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037156","Mat á lyfjameðferð með GLP-1 viðtakaörva og álit sjúklinga á þeirri meðferð. Skipti milli GLP-1 viðtakaörva","Svana Björk Steinarsdóttir 1999-","2024","Skemman","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0037157","306-OR: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)","Dalong Zhu","2025","Diabetes","randomized_trial","article","10.2337/db25-306-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037158","Exenatide once weekly: clinical outcomes and patient satisfaction","Biju Jose1","2010","DOAJ (DOAJ: Directory of Open Access Journals)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0037159","Évaluation de la sécurité cardiovasculaire du liraglutide : l’étude LEADER","J.-P. Sauvanet","2010","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(10)70175-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037160","USO DO MOUNJARO NO TRATAMENTO DE EMAGRECIMENTO","Júlia Sena Pereira","2025",null,"other","article","10.29327/9786527213369.1086387",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0037161","Comment on “Human scalp hair follicles can ‘taste’: chemosensory signalling via the bitter taste receptor TAS2R4 inhibits hair growth ex vivo”: reply from authors","Jennifer Gherardini","2025","British Journal of Dermatology","other","article","10.1093/bjd/ljaf244","40576445",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037162","Inkretinų poveikis ir koncentracija kraujo serume sergant genetinio ir pirmo tipo cukrinio diabeto atvejais","Simona Timinskaite","2024","Lithuanian University of Health Sciences","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0037163","The Effects of Weight Loss Method and Body Size on Weight Stigma","Persky, Susan","2023","Open Science Framework","other","article","10.17605/osf.io/j2tny",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037164","Glucose control therapies in the perioperative period","Hulst, A.H.","2022","UvA-DARE (University of Amsterdam)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037165","Pharmacology and cardiometabolic impacts of the oral small-molecule glucagon-like peptide-1 receptor agonist orforglipron","Kevan English","2026","World Journal of Methodology","other","article","10.5662/wjm.121475",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037166","Tirzepatide: A first-in-class twincretin, a Dual GIP/GLP-1 receptor agonist, for the management of type 2 Diabetes","Sanjana Malyala","2026","International Journal of Pharmacology and Clinical Research","other","article","10.33545/26647613.2026.v8.i7a.281",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037167","Challenge following discontinuation of incretin-based anti-obesity drugs: weight relapse and prevention strategies","Kishore Kumar Shil","2026","European journal of medical research","randomized_trial","article","10.1186/s40001-026-04862-3",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037168","3059-LB: Combination of MS 001 with GLP-1R Agonist Semaglutide Induces Further Weight Loss while Supporting Muscle Health in Mice","SHANTA BANTIA","2026","Diabetes","preclinical","article","10.2337/db26-3059-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037169","3051-LB: Central Amygdala Glucagon-Like Peptide 1 Receptor Neurons Integrate Endogenous GLP-1 and Encode Consummatory Valence through Diverse Outputs","Miguel Duran","2026","Diabetes","preclinical","article","10.2337/db26-3051-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037170","Comparative analysis of monthly weight-regain dynamics after discontinuation of semaglutide vs tirzepatide","G Fazio","2026","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwag249.275",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037171","241-OR: Effects of Antidiabetes Therapies on Irisin Levels in Type 2 Diabetes Patients","Annalisa Natalicchio","2021","Diabetes","preclinical","article","10.2337/db21-241-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037172","Long Acting Injectable Formulations of Biologicals: Examination of an innovative polymer family for the controlled release of peptides and proteins","Frank, Simon","2024","heiDOK (Heidelberg University)","preclinical","article","10.11588/heidok.00029166",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037173","Precision and efficacy guided novel approaches to target dyslipidemia and atherosclerosis","M. Modder","2026","Leiden Repository (Leiden University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0037174","Investigation of Liraglutide Effects on Changes of Uterine Tissue and Estradiol and FSH Hormones in NMRI Mice","Sara Atashnezhad","2017","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037175","132-OR: Structured Medical Nutrition Therapy Improves Glycemia, Reduces Percentage Body Fat while Maintaining Fat-Free Mass in Individuals with Overweight/Obesity and Type 2 Diabetes","Adham Mottalib","2024","Diabetes","randomized_trial","article","10.2337/db24-132-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037176","Liraglutide et paramètres lipidiques chez les patients diabétiques de type 2 (étude sur 123 patients)","PUPIER, Emilie","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0037177","Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor","Adis Journals On Behalf Of:","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.24610002",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037178","The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials","Yu, Meixin","2024","Figshare","systematic_review","article","10.6084/m9.figshare.c.6759424.v1",null,null,"PROSPERO:CRD42023396138",null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0037179","THE EFFECT OF GLP-1 RECEPTOR AGONISM ON DIVERSE ASPECTS OF THE CARDIOVASCULAR SYSTEM IN PATIENTS WITH TYPE 2 DIABETES AND OBESITY","Saidova Shakhnoza Aripovna","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15008063",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037180","147-OR: DUAL VIII: Significantly Longer Time to Treatment Intensification with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) in a 104-Week (Wk) Randomized Trial Mirroring Clinical Practice","Vanita R. Aroda","2019","Diabetes","randomized_trial","article","10.2337/db19-147-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037181","562 Effect of Liraglutide on Streptozotocin-Induced Diabetic Rat Testis","Suhejb Sulejman","2018","The Journal of Sexual Medicine","preclinical","article","10.1016/j.jsxm.2018.04.468",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037182","Efficacy and Safety of Oral Semaglutide in Managing Type 2 Diabetes in India: A Real-World Study","Saswati Ray","2024","Clinical Diabetology","nonrandomized_study","article","10.5603/cd.102374",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037183","IP15-19 ASSOCIATION BETWEEN GLUCAGON-LIKE PEPTIDE-1 AGONIST USE AND ESCALATION TO SURGICAL TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA: A NATIONWIDE CLAIMS DATABASE STUDY","Devin M. Dishong","2026","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001191356.52697.6d.19",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037184","Is It Beneficial to Delay Surgery for Weight Loss in Obese Patients Before THA?","Lorenz Büchler","2025","Journal of Bone and Joint Surgery","nonrandomized_study","article","10.2106/jbjs.24.01481","40237720",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037185","WCN26-6468 COMPARATIVE EFFECTIVENESS OF GLP-1RAs VS. MRAs AS FOURTH-LINE THERAPY FOR RESISTANT HYPERTENSION","Bernhard Schmidt","2026","Kidney International Reports","other","article","10.1016/j.ekir.2026.105760",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037186","Clinical cases of management of patients with type 2 diabetes mellitus using GLP-1 receptor agonists","Kanavets N.S. Kanavets","2024","Фарматека","other","article","10.18565/pharmateca.2024.8.124-132",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037187","Análise da Eficácia e Segurança da Tirzepatida no Tratamento da Obesidade","Emmanuelle Campos Diniz Rafael","2025","COGNITIONIS Scientific Journal","other","article","10.38087/2595.8801.714",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037188","Glucagon-Like Peptide-1 Receptor Agonist Use and Colorectal Cancer Risk in US Veterans With Diabetes Mellitus",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.256",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037189","Acute semaglutid effect on aortic responses in an experimental rat model of MASLD","B Guven Ciloglu","2026","Cardiovascular Research","preclinical","article","10.1093/cvr/cvag092.197",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037190","Activation of GLP-1 receptors suppresses pathological defensive aggression via DMPAG in mice","Yiran Liu","2026","Translational Psychiatry","preclinical","article","10.1038/s41398-026-04385-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037191","Wolfenden Report","H. Walker","1959","BMJ","preclinical","article","10.1136/bmj.2.5158.1019-a",null,null,"ClinicalTrials.gov:NCT03309241","S002228","openalex","FALSE","free_to_read","5","FALSE","article"],["R0037192","A new lease on half-life","Kathryn A. Whitehead","2016","Science Translational Medicine","other","article","10.1126/scitranslmed.aal3699","27974661",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037193","FRI-365 DR10624, a novel FGF21R, GCGR, and GLP-1R tri-agonist, demonstrated extraordinary efficacy in B6-Alms1-del mice, a spontaneous MASH model of mice with obesity, hyperglycemia, and dyslipidemia phenotype","Yongliang Fang","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)01598-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037194","Cardiometabolic Outcomes of Novel Therapy Tirzepatide: A Systematic Review",null,"2025","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2025.05.564",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0037195","P-095. ORFORGLIPRON SE ASOCIA CON MEJORAS EN LOS MARCADORES DE LA FUNCIÓN DE LAS CÉLULAS BETA Y LA SENSIBILIDAD A LA INSULINA CUANDO SE USA COMO MONOTERAPIA EN PERSONAS CON DIABETES TIPO 2","Lisa Ludwig","2026","Endocrinología Diabetes y Nutrición","other","article","10.1016/s2530-0164(26)00272-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037196","88-OR: Targeted Drug Delivery to Human ß-Cells Using Novel Nanocapsule Delivery Vehicle for T1D Treatment","Jillian Collins","2023","Diabetes","preclinical","article","10.2337/db23-88-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037197","S1975 GLP1-RA in Patients With Crohn's Disease Independently Associated With Reduction in SEMA-CD Score","Vincent Dioguardi","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001135360.07354.89",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037198","Retrospective Review of the Impact of Glucagon-like Peptide 1 Agonists on Gastrointestinal Motility and Outcomes in the Medical ICU","Cameron G. Gmehlin","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a3800",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037199","Rapid Onset Diabetic Ketoacidosis after Semaglutide initiation in a patient with presumed Diabetes Mellitus Type 2 – A Case Report","Warda Ali Naqvi","2026",null,"case_report","article","10.13140/rg.2.2.29313.21609",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037200","Comparative Efficacy of Empaglifozin and Semaglutide Combination Therapy Versus Semaglutide Alone in Diabetes with MASLD: A Multiparameter Analysis From North India",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.575",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037201","637-P: Effectiveness of Fixed Ratio Combination of IGlarLixi in People with Type 2 Diabetes Mellitus: Experience from Routine Clinical Practice","János Tibor Kis","2021","Diabetes","randomized_trial","article","10.2337/db21-637-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037202","More semaglutide-treated subjects achieved HbA1c <7% without weight gain or hypoglycaemia vs comparators in SUSTAIN 1–5","Ho Thien","2017",null,"other","article","10.26226/morressier.59d51840d462b80296ca2d2f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037203","EPH142 CHANGES IN GLP-1RA UTILIZATION TRENDS AMONG MALES AND FEMALES DURING 2019-2024: IMPACT OF SEMAGLUTIDE (WEGOVY) APPROVAL FOR CHRONIC WEIGHT MANAGEMENT","Jerusha Daggolu","2026","Value in Health","other","article","10.1016/j.jval.2026.03.974",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037204","Impact of glucagon-like peptide-1 receptor agonists on bowel preparation quality for colonoscopy in type 2 diabetes","Hyun Jung Park","2026","World Journal of Gastroenterology","nonrandomized_study","article","10.3748/wjg.121313",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037205","1225-OR: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial","LINONG JI","2026","Diabetes","randomized_trial","article","10.2337/db26-1225-or",null,null,"ClinicalTrials.gov:NCT06164873","S000397","openalex","FALSE","paywalled","1","FALSE","article"],["R0037206","Mechanism of Liraglutide in Oxidized Low-density Lipoprotein Induced Endothelial Cell Injury Based on NOD-like Receptor 3 Inflammasome Pathway","CHEN  Ling, XU  Rui, CHENG  Xinchun, ZHANG  Zhanying, XU  Hong","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12114/j.issn.1007-9572.2023.0531",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037207","Optimizing GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM","Ghosal, Samit","2025","Figshare","systematic_review","article","10.6084/m9.figshare.29918414",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0037208","MOESM9 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Robyn Bruen","2017","Figshare","preclinical","article","10.6084/m9.figshare.5577100.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0037209","SAT-453 MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)","Rohit S. Loomba","2025","Journal of Hepatology","other","article","10.1016/s0168-8278(25)01709-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037210","S4232 Megaesophagus Causing Respiratory Failure: Diagnosis of Achalasia via EndoFLIP™","Sarah Rahni","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001144388.59794.08",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037211","Σύγκριση των επιδράσεων της ινσουλίνης Degludec με το συνδυασμό ινσουλίνης Degludec/liraglutide στο μεταβολισμό των λιπιδίων και λιποπρωτεϊνών του ορού σε ασθενείς με σακχαρώδη διαβήτη τύπου 2","Ελένη Παππά","2021","University of Ioannina","other","article","10.12681/eadd/49478",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation; article"],["R0037212","Molecular characterisation of small molecule agonists and internalisation of GLP‐1R","Venkateswarlu Kanamarlapudi","2018","The FASEB Journal","other","article","10.1096/fasebj.2018.32.1_supplement.670.57",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037213","Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus","Silvio E. Inzucchi","2017","Annals of Internal Medicine","other_trial","article","10.7326/l17-0231","28672385",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037214","Abstract 15257: The “Free Choice” Diet-Induced Obese Nonalcoholic Steatohepatitis Hamster, a Clinically Relevant Model for Evaluating Drugs Targeting Heart Failure With Preserved Ejection Fraction","Rana Assaly","2023","Circulation","randomized_trial","article","10.1161/circ.148.suppl_1.15257",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0037215","SGLT2 Inhibitors—Sweet Success for Diabetic Kidney Disease?","Ian H. de Boer","2016","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2016060650","27539605",null,"ClinicalTrials.gov:NCT02065791",null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037216","Lipid-Based Formulation in customized enteric capsule for oral GLP-1 receptor agonist peptide delivery","Dumont, Camille","2025",null,"other","article","10.13140/rg.2.2.11654.48962",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037217","OZEMPIC: THE DOUBLE-EDGED DRUGS THERAPEUTIC PROMISES AND HIDDEN PERIL","Renuka Gajanan Chawake*, Hrutik Kanhed , Dr. Swati P. Deshmukh","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17441813",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0037218","Understanding the function of PGC-1α Isoforms in ß-cell survival and diabetes","Sczelecki, Sarah","2013","Library and Archives Canada (Government of Canada)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0037219","Genetically proxied antidiabetic drugs targets and stroke risk","Zhu, Yahui","2024","Figshare","other","article","10.6084/m9.figshare.c.6860278.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037220","Durability of effectiveness between users of once-weekly semaglutide and dipeptidyl peptidase 4 inhibitors (DPP-4i) in US adults with type 2 diabetes","of:, Adis journals on behalf","2023","Figshare","other","article","10.6084/m9.figshare.24476476.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037221","Evaluation of the CGMs in type-2 diabetic patients switched from Liraglutide and Insulin Degludec to Liraglutide and Insulin Degludec/Aspart","Yusuke Kakizaki","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31198-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037222","Cardiovascular Outcome in T2D Patients: A Real World Evidence Study of the Effectiveness of SGLT2 Inhibitors and GLP1-RA","Salah Abusnana","2026","Ibnosina Journal of Medicine and Biomedical Sciences","nonrandomized_study","article","10.1055/s-0046-1820059",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-paper"],["R0037223","Does semaglutide provide neuroprotection in models of glaucoma?","Zaynab Ahmad Mouhammad","2025","Acta Ophthalmologica","preclinical","article","10.1111/aos.17134",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037224","Drug News",null,"2024","Nursing","other","article","10.1097/nsg.0000000000000090","39497660",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037225","The Economic Value of Treating Pediatric Obesity: Costs Are Not Keeping Up With Efficacy","Justin R. Ryder","2023","JAMA Network Open","nonrandomized_study","article","10.1001/jamanetworkopen.2023.36337","37824149",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037226","369-OR: Continued Weight Loss with Semaglutide Once-Weekly in Patients without Type 2 Diabetes and Postbariatric Treatment Failure","Anne Lautenbach","2023","Diabetes","nonrandomized_study","article","10.2337/db23-369-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037227","Aktuelles: Liraglutid (Victoza®) in aktuellen LeitlinienbrHerausragende Evidenz für kardiovaskuläre Risikoreduktion","Brugger A","2020","Journal für Kardiologie (Krause & Pachernegg GmbH)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037228","Lilly to invest $5.3 billion in Indiana","Aayushi Pratap","2024","C&EN Global Enterprise","other","article","10.1021/cen-10217-buscon3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037229","EFEITOS DO USO DA SEMAGLUTIDA EM PACIENTES COM OBESIDADE: UMA REVISÃO DE LITERATURA","De Sousa, Laura Cristina Alves","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.8262435",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037230","S2798 Familiarity With Glucagon, GLP-1, and GIP Receptor Agonists and Dual Agonists Among Hepatology/Gastroenterology, Primary Care, and Endocrinology Specialists","Harold E. Bays","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001138652.46927.47",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037231","Evaluation of Short-Term (1st and 3rd Month) Anthropometric Results in Obesity Patients Initiating Semaglutide Treatment: Experience of Two Tertiary Centers","Eşref Araç","2025","Dicle Medical Journal / Dicle Tip Dergisi","nonrandomized_study","article","10.5798/dicletip.1841074",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037232","795-P: Balancing the Scales—The Effect of Tirzepatide on Lean Body Mass and Fat Mass","MONICA BODENSTAB","2024","Diabetes","randomized_trial","article","10.2337/db24-795-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037233","75888 Dermatological effects of GLP-1 receptor agonists: A literature review","Maleka Najmi","2026","Journal of the American Academy of Dermatology","narrative_review","article","10.1016/j.jaad.2026.04.587",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037234","1880-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Non-Asian People with Type 2 Diabetes Inadequately Controlled with Basal Insulin—A Systemic Literature Review and Network Meta-analysis","PHILIP HOME","2024","Diabetes","systematic_review","article","10.2337/db24-1880-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0037235","Liraglutide cost-effective option for type 2 DM in Italy",null,"2017","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-017-4115-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037236","S5950 Management and Outcomes Following Coronary Artery Bypass Graft and Liver Transplant","Hariharan Ramakrishnan","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001151260.34031.98",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037237","Figure 1: Aortic Plaque Lesion Development Is Attenuated by Semaglutide (LDLr","Günaj Rakipovski","2019","JACC: Journal of the American College of Cardiology","preclinical","article","10.25407/jacbts.8253344.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037238","Investigating the relationship between disgust, nausea and eating behaviours in healthy and clinical populations","Nord, Camilla","2025","Open Science Framework","other","article","10.17605/osf.io/z4k7a",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037239","Understanding the Incretin Effect","Yutaka Seino","2011","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/jc.2011-0329","21474688",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037240","IP18-24 DO GLP-1 RECEPTOR AGONISTS PROTECT AGAINST KIDNEY STONES IN DIABETES? REAL-WORLD INSIGHTS","Thomas Syphan","2026","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001191368.71794.72.24",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037241","CE-534538-002 METABOLIC MODULATION AND ATRIAL FIBRILLATION: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND 5-YEAR ATRIAL FIBRILLATION RISK IN NON-DIABETIC ADULTS WITH OBESITY","Kevin Maymi","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037242","Department of Error",null,"2026","The Lancet","other","article","10.1016/s0140-6736(26)00467-8","41831846",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037243","SY15-2SUBCHRONIC LOW DOSE EXENDIN-4 PRETREATMENT INHIBITS RELAPSE TO ALCOHOL DRINKING IN HIGH ALCOHOL PREFERING C57BL6 MICE","Ditte Dencker","2015","Alcohol and Alcoholism","preclinical","article","10.1093/alcalc/agv076.62",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037244","811-P: Safety and Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus (T2DM) in South Korea","HUN-SUNG KIM","2024","Diabetes","other_trial","article","10.2337/db24-811-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037245","Management of Type 1 Diabetes Without Insulin","Caitlin Hammermeister","2026","RVU Elevate","other","article","10.82451/k51005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0037246","746-P: Time in Tight Range with Oral Semaglutide as an Add on to SGLT2i and Metformin Combination in People with Type 2DM—Real-World Evidence from India","SONALI A. PATANGE","2025","Diabetes","nonrandomized_study","article","10.2337/db25-746-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037247","Human medicines European public assessment report (EPAR): Ozempic, semaglutide, Diabetes Mellitus, Date of authorisation: 08/02/2018, Revision: 2, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-bc1103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037248","New Drug Indications for Pediatric Type 2 Diabetes, Cystic Fibrosis, and Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia","Diane S. Aschenbrenner","2019","AJN American Journal of Nursing","other","article","10.1097/01.naj.0000586152.18638.5b","31567247",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037249","Drug Therapy for Unexplained Dyspnea in Post–COVID-19 Fatigue Syndrome: Empagliflozin and Sildenafil","Peter Manu","2022","American Journal of Therapeutics","nonrandomized_study","article","10.1097/mjt.0000000000001483","35412483",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037250","Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","Zhou, Lingling","2024","Figshare","systematic_review","article","10.6084/m9.figshare.c.6921447",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0037251","Effect of the therapy of weekly-GLP1 analog given monthly to eldery type 2 diabetes patients","Rui Imamine","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31146-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037252","Severe inflammatory disorder in trisomy 8 without myelodysplastic syndrome and response to methylprednisolone: A case report","Feiyan Pan","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6206","37731580",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037253","2580-P: Multimodal Imaging Reveals Organ- and Depot-Specific Adipose Tissue and Lean Mass Changes upon Weight-Loss Pharmacotherapy in NHPs","Kuan Tian","2026","Diabetes","randomized_trial","article","10.2337/db26-2580-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037254","1738-P: Efficacy and Hypoglycemia Outcomes with Once-Weekly IcoSema vs. Comparators in T2D by Baseline A1C: COMBINE 1–3","VISWANATHAN MOHAN","2026","Diabetes","other_trial","article","10.2337/db26-1738-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037255","Thermodynamic and Spectral Characterization of a Type 2 Diabetes Drug: GLP-1 Receptor Agonist Interaction with Albumin","Valentina Gavazova","2025",null,"other","article","10.13140/rg.2.2.28714.38085",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037256","PDB17 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETESWHO INITIATED THERAPY WITH EXENATIDE OR INSULIN GLARGINE","DA Misurski","2008","Value in Health","other","article","10.1016/s1098-3015(10)66664-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0037257","Establishment of GLP-1 Receptor Agonist Liraglutide as a Discriminative Stimulus in Rats (Abstract ID: 224710)","Leslie Sullivan","2026","Journal of Pharmacology and Experimental Therapeutics","preclinical","article","10.1016/j.jpet.2026.104253",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037258","Comparative 12-month cardiometabolic impact of semaglutide vs tirzepatide: a synthetic propensity-matched analysis","G Fazio","2026","Cardiovascular Research","nonrandomized_study","article","10.1093/cvr/cvag092.061",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037259","GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences","N Maurea","2025","European Heart Journal Supplements","preclinical","article","10.1093/eurheartjsupp/suaf083.001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037260","Efficacia e sicurezza di liraglutide in un soggetto diabetico tipo 2 con insufficienza renale \\n","Stagno, Gaudenzio","2011","CNR Solar (Scientific Open-access Literature Archive and Repository) (Consiglio Nazionale delle Ricerche)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037261","783-P: Baseline HOMA2-B Can Predict Tirzepatide Efficacy—Post Hoc Analysis of the SURPASS-1 and SURPASS-2 Studies","Stanley H. Hsia","2023","Diabetes","other_trial","article","10.2337/db23-783-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037262","Editorial: Targeted Gene Disruption in Endocrine Research—The Case of Glucagon-Like Peptide-1 and Neuroendocrine Function","Randy J. Seeley","2000","Endocrinology","preclinical","article","10.1210/endo.141.2.7372","10650925",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0037263","Reporting on Adverse Clinical Events",null,"2014","Clin-Alert","other","article","10.1177/0069477014524889",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037264","Dulaglutide-Combined Conventional Insulin Therapy Contributes to Ideal Glycemic Control in Noncritically Ill Hospitalized Patients","Nobutoshi Fushimi","2018","Diabetes","randomized_trial","article","10.2337/db18-1087-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037265","53-OR: Efficacy and Safety of Coadministered s.c. Semaglutide and s.c. Cagrilintide in Type 2 Diabetes","Juan P. Frías","2023","Diabetes","randomized_trial","article","10.2337/db23-53-or",null,null,"ClinicalTrials.gov:NCT04982575","S002064","openalex","FALSE","paywalled","1","FALSE","article"],["R0037266","Biophysical interactions of peptides and their analogues with lipid membranes: applications in drug development and drug delivery","Stulz, Anja","2019","FreiDok plus (Universitätsbibliothek Freiburg)","nonrandomized_study","article","10.6094/unifr/151565",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0037267","Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes(要約)","久美子 田中","2015","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037268","Additional file 2: of Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance","Inès Abdesselam","2015","Figshare","preclinical","article","10.6084/m9.figshare.4403723",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037269","Obesity and Diabetes","Jens Aberle","2024","Experimental and Clinical Endocrinology & Diabetes","other","article","10.1055/a-2166-6797","38452792",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037270","Editors’ Selections from Relevant Scientific Publications",null,"2025","Cancer Prevention Research","nonrandomized_study","article","10.1158/1940-6207.capr-18-11-hfl","41178363",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037271","Impact of semaglutide with sleeve gastrectomy on blood glucose control and metabolism in obese type 2 diabetics","Jinping Li","2026","World Journal of Gastrointestinal Surgery","nonrandomized_study","article","10.4240/wjgs.118659",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037272","Current control of patient body composition after a contemporary cardiac rehabilitation program: the ReCardio registry","M Sestayo Fernandez","2026","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwag249.273",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037273","GLP-1 agonists and cardiovascular endpoints in obesity without diabetes","Jorrit‐Jan Verlaan","2025","Geneesmiddelenbulletin","other","article","10.35351/gebu.2025.2.6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037274","S3062 Small Bowel Adenocarcinoma After Bariatric Surgery: A Case Report","Joseph Wawrzynski","2021","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0000785780.45538.51",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037275","Human medicines European public assessment report (EPAR): Byetta, exenatide, Diabetes Mellitus, Type 2, Date of authorisation: 20/11/2006, Revision: 22, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-11ef046",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037276","Efficacy Comparison of Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Systematic Review And Network Meta-Analysis","Dr Mohd Fazal Ahmed Makki Dr Mohd Fazal Ahmed Makki","2026","Journal of Carcinogenesis","systematic_review","article","10.64149/j.carcinog.25.1.197-209",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0037277","26-A-13994-ACC COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS IN WOMEN UNDERGOING CARDIAC REHABILITATION: A TRINETX RETROSPECTIVE COHORT STUDY","Leah Vaikutis","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1895",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037278","The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial","Linjawi, Sultan","2018","Figshare","randomized_trial","article","10.6084/m9.figshare.6205676",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0037279","Additional file 1 of Evidence that tirzepatide protects against diabetes-related cardiac damages","Taktaz, Fatemeh","2024","Figshare","preclinical","article","10.6084/m9.figshare.26699858",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037280","Sodium Glucose co-Transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Mellitus: Assessing their Safety and Effectiveness using Real-world Data","Michael Fralick","2019","TSpace (University of Toronto)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0037281","The Impact of GLP-1 Receptor Agonists on Human Fertility: A Narrative Review of the Reproductive Effects of Semaglutide (Ozempic) and Tirzepatide (Mounjaro) in Men and Women","Kamar Manzalji","2025","Scholars Journal of Medical Case Reports","narrative_review","article","10.36347/sjmcr.2025.v13i11.027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0037282","Fracture Risk After Initiation of Use of Canagliflozin","Michael Fralick","2019","Annals of Internal Medicine","other","article","10.7326/l19-0320","31261403",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037283","C21-07 Tirzepatide Outcome Prediction Using Sleep Apnea Endotyping in SURMOUNT-OSA","S A Sands","2026","American Journal of Respiratory and Critical Care Medicine","other","article","10.1093/ajrccm/aamag162.6400",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037284","Avis favorable en Europe pour le liraglutide (Victoza®) dans le traitement du diabète de type 2","J.-P. Sauvanet","2009","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(09)72418-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037285","Discussion of Molecular Mechanism of Endocrine Regulation Mechanism and Pathogenesis of Diabetes","晓君 孙","2025","Advances in Clinical Medicine","commentary","article","10.12677/acm.2025.1551615",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0037286","SAT-416 The impact of SGLT-2i and GLP-1RA on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis","Lu Li","2025","Journal of Hepatology","systematic_review","article","10.1016/s0168-8278(25)01679-4",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0037287","230-OR: Comparative Effectiveness of Semaglutide in Type 2 Diabetes—Year 2 Results of a Randomized Pragmatic Clinical Trial","John B. Buse","2024","Diabetes","randomized_trial","article","10.2337/db24-230-or",null,null,"ClinicalTrials.gov:NCT03596450","S000545","openalex","FALSE","paywalled","1","FALSE","article"],["R0037288","The use of GLP-1 agonists in patients with end-stage kidney disease in an urban underserved patient population","B. Thomas","2026","The American Journal of the Medical Sciences","other","article","10.1016/j.amjms.2025.12.560",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037289","1695-P: Effect of CagriSema on Eating Control and Behavior: REDEFINE 1","Michelle Dalton","2026","Diabetes","randomized_trial","article","10.2337/db26-1695-p",null,null,"ClinicalTrials.gov:NCT05567796","S001154","openalex","FALSE","paywalled","1","FALSE","article"],["R0037290","A Narrative Review of Biosimilars, GLP-1 Therapies, and Specialty Medication Management: An Interprofessional Perspective Including Health Assisting, Dentistry, Nursing, Health Informatics, Emergency Services, and Pharmacy","Lafi Mulfi E1 Almuharraq","2024","Saudi Journal of Medicine and Public Health","narrative_review","article","10.64483/202412713",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0037291","GW24-e3607 Pretreatment of ADSCs with exendin-4 improve therapeutic efficiency following myocardial infarction via enhanced adhesion","Liu Jianfeng","2013","Heart","preclinical","article","10.1136/heartjnl-2013-304613.71",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037292","S3400 Acute Pancreatitis Following Routine Screening Colonoscopy","Hiba Ghannam","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001141060.66613.9a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037293","Cambio de Paradigma en la Insuficiencia Cardíaca con Fracción de Eyección Preservada: De la Nihilidad Terapéutica a la Medicina de Precisión","Erick Eduardo López Santos","2025","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.18022384",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0037294","Extracting structural requirements for activity of GPR119 agonists: a hologram quantitative structure activity relationship (HQSAR) study","Apoorva G. Ugarkar","2014","Canadian Journal of Chemistry","other","article","10.1139/cjc-2014-0129",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037295","S780 Predictors of Weight Loss Following Endoscopic Re-Suturing Post Endoscopic Sleeve Gastroplasty","Kevin Lin","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130580.58233.56",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037296","298. Association of glucagon-like peptide-1 receptor agonist use with complications following spinal fracture: a propensity-matched analysis of 14,000 patients","Philip Grandoff","2026","The Spine Journal","nonrandomized_study","article","10.1016/j.spinee.2026.06.318",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037297","A Decade of Discovery: Major Advances in Medical Science From Leading Journals","Licun Wu","2026","AI in Clinical Medicine","nonrandomized_study","article","10.14740/aicm28",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037298","1607-P: Multiomic Analyses of GLP-1/GIP/GCGR Triagonism Highlights the Role of Hepatic Lipid Metabolism during Weight Loss in Obese Mice","Teayoun Kim","2025","Diabetes","preclinical","article","10.2337/db25-1607-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037299","Exploring on the Hyperinsulinism Management in Women with Polycystic Ovary Syndrome","Sebastião Freitas de Medeiros","2026","Journal of Gynecology and Obstetrics","nonrandomized_study","article","10.11648/j.jgo.20261403.12",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037300","Using Artificial Intelligence to Structure Treatment Decisions in a Rare Hereditary Cancer: A Viewpoint on MET-Driven Hereditary Papillary Renal Carcinoma (Preprint)","Michael Dulin","2026",null,"other","article","10.2196/preprints.107183",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0037301","Metabolik Disfonksiyon İlişkili Steatotik Karaciğer Hastalığı (MASLD)","Emine Gül Aydın","2026",null,"other","article","10.37609/akya.4287.c17054",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0037302","770-P: Efficacy and Safety of Once-Weekly PB-119 Monotherapy vs. Placebo in Chinese Patients with Type 2 Diabetes in a Randomized Controlled Trial","PEGBIO STUDY GROUP","2023","Diabetes","randomized_trial","article","10.2337/db23-770-p",null,null,"ClinicalTrials.gov:NCT04504370","S000217","openalex","FALSE","paywalled","1","FALSE","article"],["R0037303","New Oral GLP-1 Receptor Agonists: Gliprons","Chulho Kim","2025","NeuroTrials","other_trial","article","10.65321/ntta.2025.002",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0037304","Optimizing Endogenous GLP-1 Holistically","Taylee Carscadden","2025",null,"other","article","10.33015/dominican.edu/2025.nurs.st.39",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037305","Glucagon-like peptide-1 receptor agonists and the risk of chemotherapy-induced peripheral neuropathy in patients with diabetes: A real-world study.","Xiaocao Xu","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.12133",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037306","Incretin mimetics for the management of diabetes and associated comorbidities: An overview","Faryal Haider","2024","Innovative Medicines & Omics","other","article","10.36922/imo.4911",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037307","Use of glucagon-like peptide-1 receptor agonists reduces the risk of severe exacerbation in Chinese patients with chronic obstructive pulmonary disease and type 2 diabetes","fang wang","2026","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-026-01660-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037308","Poster Session I - A159 IMPACT OF GLP-1 RECEPTOR AGONISTS ON BOWEL PREPARATION QUALITY IN PATIENTS UNDERGOING ELECTIVE COLONOSCOPY","Philippe Gaulin","2026","Journal of the Canadian Association of Gastroenterology","nonrandomized_study","article","10.1093/jcag/gwaf042.159",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037309","Can Inhibitors of Luminal Carbohydrate Digestion Decrease Insulin Resistance in Obesity and T2DM?","Orien L Tulp","2025",null,"other","article","10.56147/jmcscr.1.1.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037310","Plain Language Summary of the Manuscript: Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","W. le Roux, Carel","2024","Boehringer Ingelheim","randomized_trial","article","10.60915/boehringer-figshare.27720057",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0037311","Figure 5: Semaglutide Lowered TG and Prevented WD-Induced Transcriptional Changes in Liver of LDLr","Günaj Rakipovski","2019","JACC: Journal of the American College of Cardiology","other","article","10.25407/jacbts.8253356",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037312","Liraglutide : supériorité à un an par comparaison à la sitagliptine","J.-P. Sauvanet","2010","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(10)70109-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037313","Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study","Adis journals of behalf of","2025","Figshare","nonrandomized_study","article","10.6084/m9.figshare.29532950",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037314","Beyond Farnesoid X receptor to target new therapies for NAFLD","Xiaoying Liu","2017","Hepatology","preclinical","article","10.1002/hep.29411","28749598",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037315","Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-59230-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037316","1131-P: Clinical, Demographic, Provider, and Formulary Characteristics Associated with Initiation of a SGLT2i or GLP-1RA among Medicare Beneficiaries with Type 2 Diabetes on Prior Oral Agents: A Cohort Study","Jing Luo","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1131-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037317","O EMPREGO DA SEMAGLUTIDA NO MANEJO DA OBESIDADE: O OLHAR DA ENDOCRINOLOGIA E METABOLOGIA FRENTE À \"INJEÇÃO DO MOMENTO\"","Tamires Rodrigues Toqueton","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7981716",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037318","Intestinal Hypertrophic And Anti-Inflammatory Potential Of A Novel Combination Of Long-Acting Glp-2 Analog (Hm15912) And Glp-1ra (Efpeglenatide) In Animal Models Of Inflammatory Bowel Disease","Jeong Been Lee","2023","Clinical Nutrition ESPEN","other","article","10.1016/j.clnesp.2022.09.555",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037319","Anti-obesity drugs for the gastroenterologist","Lisa Sharkey","2025","Frontline Gastroenterology","other","article","10.1136/flgastro-2024-102995",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037320","1780-P: Differential Effects of Medications and Gastric Banding on OGTT-Modeled Measures of ß-Cell Function in Adults with IGT or Recent-Onset Type 2 Diabetes (T2D)","Kristina M. Utzschneider","2020","Diabetes","other","article","10.2337/db20-1780-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037321","PS-C17-2: STUDY OF THE ANTIHYPERTENSIVE EFFECTS OF ORAL SEMAGLUTIDE, GLP 1 RECEPTOR AGONIST","Shu Meguro","2023","Journal of Hypertension","other","article","10.1097/01.hjh.0000916708.57641.42",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037322","Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of Electronic Health Records Database in the US Population","Boye, Kristina S","2018","Figshare","nonrandomized_study","article","10.6084/m9.figshare.5854452",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037323","PIONEER REAL Sweden: a multicentre, prospective, real-world observational study of oral semaglutide use in adults with type 2 diabetes in Swedish clinical practice","of, Adis journals on behalf","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26064211.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037324","Behandling af overvægt hos voksne i almen praksis. Lægemidler skal bruges med omtanke.","Hanne Madsen","2023","VBN Forskningsportal (Aalborg Universitet)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037325","Polypill: Shifting Paradigm from Concept to Practice in the Prevention of Myocardial Infarction","Dhan Bahadur Shrestha","2025","Cardiology","randomized_trial","article","10.1159/000547098","40701142",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037326","SHOCK SYNOPSIS APRIL 2024","Diana Julia Tedesco","2024","Shock","randomized_trial","article","10.1097/shk.0000000000002368","38604132",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037327","815-P: Cost-Effectiveness of Subcutaneous Semaglutide vs. Empagliflozin as Add-On Therapy for Type 2 Diabetes","Margaret F. Zupa","2021","Diabetes","other_trial","article","10.2337/db21-815-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037328","P153 Relais exenatide 2 injections par jour pour liraglutide 1 injection par jour améliore l’équilibre glycémique de patients diabétiques de type 2 traités par hypoglycémiants oraux","Bruno Guerci","2010","Diabetes & Metabolism","other","article","10.1016/s1262-3636(10)70301-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037329","Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting","Bergenstal, Richard M.","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.11815914",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0037330","Therapies for non-alcoholic steatohepatitis","Winston Dunn","2017","Liver Research","other_trial","article","10.1016/j.livres.2017.12.006",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0037331","Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results","Adis Journals On Behalf Of","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.16913317",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037332","S5671 A Rare Case of Tirzepatide Induced Cholestatic Hepatitis","Nisar Amin","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001150144.16302.ac",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0037333","Effect of SGLT2i & GLP-1 medications on Skeletal Muscle Health: A Scoping Review (Search Protocol)","Sutcliffe, Cian","2023","University of Leicester","protocol","article","10.25392/leicester.data.24421747",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","report"],["R0037334","Glucagon like peptide-1 receptor agonists as neuroprotective agents for stroke: a systematic review of pre-clinical studies","Maskery, Mark P","2019",null,"systematic_review","article","10.13140/rg.2.2.32974.00326",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0037335","S3261 Weight Loss, Unexpected Cost: GLP-1 Receptor Agonist-Associated Acalculous Cholecystitis","Kaitlyn Ghassemi","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001140504.61012.71",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037336","S2605 GLP-1 Analogs Linked to Lower Ascites, Paracentesis, and SBP Rates in Cirrhosis: Insights From a Retrospective Cohort Study","Chidera Onwuzo","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137880.52226.7f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037337","Antihypertensive treatments in obese patients","Jens Jordan","2014","Journal of Hypertension","randomized_trial","article","10.1097/hjh.0000000000000245","24984176",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037338","Hemodynamic effects by glucagon-like peptide-1 receptor analogues","Peter M. Nilsson","2017","Journal of Hypertension","randomized_trial","article","10.1097/hjh.0000000000001315","28353547",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037339","Another Detrimental Effect of Immunosuppression: Metabolic Syndrome","Charles G. Rickert","2024","Transplantation","nonrandomized_study","article","10.1097/tp.0000000000005253","39466196",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037340","Effects of glucagon-like peptide-1 receptor agonists on ischemia/reperfusion injury in isolated hearts of rats with metabolic syndrome","Ravić, Marko","2025","National Repository of Dissertations in Serbia","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037341","GLP ‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity","Lars Linderoth","2021",null,"other","article","10.1002/9783527826872.ch3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037342","GLP-1 agonists and urea cycle disorders: When metabolic pathways collide – A tale of two patient cases","C. Suares","2026","Molecular Genetics and Metabolism","other","article","10.1016/j.ymgme.2026.109809",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037343","S896 GLP-1 Receptor Agonists and Retained Gastric Content in Type 2 Diabetics: Insights From a Retrospective Endoscopic Analysis, A Preliminary Study","Madalyn Elliott","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032952.21205.89",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037344","PDB38 ADDITION OF INCRETIN-THERAPY TO METFORMIN IN TYPE-2DIABETES MELLITUS (T2DM): COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS SITAGLIPTIN FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)","Michael Schlander","2010","Value in Health","other","article","10.1016/s1098-3015(11)72096-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0037345","4134 PREOPERATIVE SEMAGLUTIDE BEFORE SLEEVE GASTRECTOMY IS ASSOCIATED WITH GREATER SHORT-TERM WEIGHT LOSS AND DYSLIPIDEMIA REMISSION: A PROSPECTIVE NON-RANDOMIZED CONTROLLED TRIAL",null,"2026","Surgery for Obesity and Related Diseases","randomized_trial","article","10.1016/j.soard.2026.02.202",null,null,null,null,"openalex","FALSE","open_pdf","2","FALSE","article"],["R0037346","IMPROVING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE MANAGEMENT IN TYPE 2 DIABETES:","Mark William McGiffin","2026","Purdue","nonrandomized_study","article","10.25394/pgs.32076660",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0037347","EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY WITHOUT DIABETES MELLITUS","Aravinthan Vignarajah","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00863-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037348","WED-426 Glucagon-like peptide-1 receptor agonists reduce the risk of decompensation in patients with type 2 diabetes across different stages of liver disease","Montserrat Camps Fajol","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)00712-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037349","Effects of Dulaglutide and Trelagliptin on Beta-Cell Function in Patients with Type 2 Diabetes—The DUET-Beta Study","Yoshinobu Kondo","2018","Diabetes","randomized_trial","article","10.2337/db18-1080-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037350","A Review of Management and Treatment of Diabetes Mellitus","Kahkasha Bano","2025","International Journal of Innovative Science and Research Technology (IJISRT)","narrative_review","article","10.5281/zenodo.14613824",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037351","Figure 4: Semaglutide Affected Local (Aortic) and Systemic Inflammation","Günaj Rakipovski","2019","JACC: Journal of the American College of Cardiology","other","article","10.25407/jacbts.8253353.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037352","Abstract 15452: Using a Commercial Virtual Health Platform to Effectively Treat Obesity and Improve Cardiometabolic Risk Factors at Scale","Kim Boyd","2023","Circulation","nonrandomized_study","article","10.1161/circ.148.suppl_1.15452",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037353","Hypertriglyceridemia-induced Pancreatitis in the Setting of Glucagon-like Peptide-1 Receptor Agonist and the Role of Plasmapheresis",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.294",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037354","P-03-045 Sexual Health and Comorbidities (DM, Prostate Cancer)","Ella Kinzikeeva","2016","The Journal of Sexual Medicine","other","article","10.1016/j.jsxm.2016.03.262",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037355","Stroke and myocardial infarction prevention with GLP1 analogues in high or very-high cardiovascular risk diabetic patients","D Cazorla-Morallon","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.2967",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037356","Abstract #215: Liraglutide as an Adjunct to Insulin in the Treatment of Type 1 Diabetes Mellitus in an Academic Setting","Zona Batacchi","2016","Endocrine Practice","other","article","10.1016/s1530-891x(20)44923-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037357","798-P: Shift to a Lower BMI Category Is Associated with Improved Cardiometabolic Measures in Adults with T2D Treated with Tirzepatide","RUSSELL WIESE","2023","Diabetes","other_trial","article","10.2337/db23-798-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037358","334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity","SAMUEL KLEIN","2022","Diabetes","randomized_trial","article","10.2337/db22-334-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037359","22-PUB: Semaglutide Improves Metabolic Profile in Patients with LADA","Maria Elena Lunati","2025","Diabetes","nonrandomized_study","article","10.2337/db25-22-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037360","Exenatide in type 2 diabetes – Authors' reply","Michaëla Diamant","2010","The Lancet","commentary","article","10.1016/s0140-6736(10)61486-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0037361","Uso Do Ozempic Como Estratégia De Controle De Vício Em Bebida Alcoólica","GABRIELA CARMINATI LINO","2025","Editora Pasteur eBooks","other","article","10.59290/9490523252",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0037362","4558 PREVALENCE OF INCRETIN-BASED THERAPY AMONG POST-BARIATRIC SURGERY PATIENTS IN A HIGH-VOLUME CENTER",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.305",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037363","Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease","Katherine R. Tuttle","2019","Clinical Journal of the American Society of Nephrology","other_trial","article","10.2215/cjn.07730719","31740570",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0037364","1022-P: Quantitative and Qualitative Effect of Dulaglutide in Type 2 Diabetes Patients Under Treatment with Liraglutide","Alexios Sotiropoulos","2019","Diabetes","other","article","10.2337/db19-1022-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037365","Glucagon-Like Peptide-1 Receptor Agonists Added to Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Historical Cohort Study Using the Diabetes Study From the Center of Tokyo Women's Medical University (DIACET)","Tetsuya Babazono","2023","DOAJ (DOAJ: Directory of Open Access Journals)","nonrandomized_study","article","10.24488/twmuj.2023005",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0037366","Glucagon-like Peptide 1 Receptor Agonist Use is Associated with Decreased Risk of Postoperative Complications Following Total Hip Arthroplasty: A Propensity Matched Comparison","Bowers, Cameron","2025",null,"nonrandomized_study","article","10.13140/rg.2.2.19455.52645",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0037367","DPP-4 is overexpressed in lung tissue from idiopathic pulmonary patients and activates lung fibroblasts","Paula Montero Magalló","2020",null,"preclinical","article","10.1183/13993003.congress-2020.3375",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037368","957-P: Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program","John B. Buse","2020","Diabetes","randomized_trial","article","10.2337/db20-957-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037369","Drug repositioning framework driven by landscape analysis and competitive intelligence: A case report on Prader Willi Syndrome","Manish Sarkar","2024",null,"case_report","article","10.58647/rexpo.24003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0037370","2473-P: Does Visceral Fat Reduction Drive Steatosis Improvement Regardless of Weight-Loss Method? A Single-Center Cohort Study","Federica Sileo","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2473-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037371","Real-World Clinical Effectiveness and Cost Savings of Liraglutide versus Sitagliptin in Treating Type 2 Diabetes for One and Two Years","Li, Qian","2018","Figshare","nonrandomized_study","article","10.6084/m9.figshare.6133790",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037372","GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy","Shvetank Sharma","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5344852",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0037373","S1253 Dual Therapy With Metformin and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2-i) Improves Mortality in Cirrhotic Patients","Daniel J. Huynh","2022","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000861652.83789.d5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037374","633-P: Impact of Simulation-Based CME on Clinicians’ Knowledge and Competence Related to Hypoglycemia Management","Shpetim Karandrea","2020","Diabetes","other","article","10.2337/db20-633-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037375","COST-EFFECTIVENESS OF OZEMPIC VERSUS BARIATRIC SURGERY FOR LONG-TERM WEIGHT MANAGEMENT: A 10-YEAR MARKOV MODEL","Syed Hasan Ali","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00892-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037376","366-OR: 14-3-3-ζ Contributes to Effect of ß-Cell GLP1 Receptor Signaling to Alter a-Cell Proglucagon Processing","Marlena M. Holter","2022","Diabetes","preclinical","article","10.2337/db22-366-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037377","Effect of a Web-based continuing-education program on pharmacist learning","Burgunda V. Sweet","2009","American Journal of Health-System Pharmacy","other","article","10.2146/ajhp080658","19850780",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037378","Exploring Weight Loss Medication Discourse: A Mixed-Methods Analysis of U.S.-Based Facebook Posts (Preprint)","Elizabeth Dennard","2025",null,"other","article","10.2196/preprints.89732",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0037379","Real-world comparative outcomes of glucagon like peptide-1 receptor agonists and bariatric surgery in inflammatory bowel disease: A multi-center cohort study","Joshua Chen","2026","Obesity Medicine","nonrandomized_study","article","10.1016/j.obmed.2026.100727",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037380","Trends & Technology",null,"2022","ASA Monitor","other_trial","article","10.1097/01.asm.0000904228.68973.78",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037381","ВЛИЯНИЕ НОВЫХ КЛАССОВ САХАРОСНИЖАЮЩИХ ПРЕПАРАТОВ НА КЛИНИКО-ЛАБОРАТОРНЫЕ ИЗМЕНЕНИЯ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА В ПОСТКОВИДНОМ ПЕРИОДЕ","C.А. Алтынбекова","2025","Farmaciâ Kazahstana","other","article","10.53511/pharmkaz.2025.89.39.019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037382","P332 Efficacité et tolérance du liraglutide chez des patients diabétiques avec une dysfonction endocrine de l’allogreffe de pancréas entier","Carine Bernard","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72623-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037383","SAT-105 The glucagon/glucagon-like peptide-1 receptor dual agonist survodutide reduces liver fibrosis in a 4-week carbon tetra chloride lean mouse model","François Briand","2026","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(26)01772-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037384","EFICÁCIA DO MOUNJARO NA REDUÇÃO DE EVENTOS CARDIOVASCULARES EM PACIENTES COM OBESIDADE","Laura Rodrigues Bicca","2026","Asclepius International Journal of Scientific Health Science","other","article","10.70779/aijshs.v5i7.635",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037385","Additional file 2 of Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin","Yang, Xiaotong","2020","Figshare","preclinical","article","10.6084/m9.figshare.12332078",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037386","COMBINATION THERAPY WITH SEMAGLUTIDE AND PCSK9I REDUCES SYNERGISTICALLY ANTHRACYCLINE-INDUCED CARDIOTOXICITY UNDER HYPERLIPIDEMIA: IMPLICATIONS IN PRIMARY PREVENTION OF CTRCD IN CANCER PATIENTS","Nicola Maurea","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)03087-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037387","Unmasking Euglycemic DKA in Tirzepatide Therapy: A Case Report",null,"2026","Endocrine Practice","case_report","article","10.1016/j.eprac.2026.01.243",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037388","Glucagon-like Peptide-1 Receptor Agonists and Anesthesia Considerations","Hemant Sarin","2024","Journal of Research & Innovation in Anesthesia","other","article","10.5005/jp-journals-10049-2055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037389","56 Adherence to NICE guidance for GLP-1 receptor agonist prescribing in patients with severe aortic stenosis and elevated body mass index","Husnain Abid","2026",null,"nonrandomized_study","article","10.1136/heartjnl-2026-bcs.6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0037390","P-066 - MÁS ALLÁ DE LA PÉRDIDA DE PESO: TIRZEPATIDA (MOUNJARO). SEPSIS ABDOMINAL VS. BODYPACKER","Leonid Omar Carrión Retuerto","2025","Cirugía Española","other","article","10.1016/s0009-739x(26)00036-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037391","2636-P: Efsubaglutide Alfa in Overweight or Obesity: Phase 2b ENLIGHT Study","YUQIAN BAO","2026","Diabetes","randomized_trial","article","10.2337/db26-2636-p",null,null,"ClinicalTrials.gov:NCT06921486","S000654","openalex","FALSE","paywalled","1","FALSE","article"],["R0037392","WCN26-4188 OFF-LABEL SEMAGLUTIDE USE IN A DIABETIC HEMODIALYSIS PATIENT: INDUCED WEIGHT LOSS AND UNEXPECTED RETURN OF DIURESIS – A CASE REPORT","REINA LYNN G. ANTONIO","2026","Kidney International Reports","case_report","article","10.1016/j.ekir.2026.104618",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037393","Pharmacological intervention to target the procalcific phenotypic drift of myeloid cells: a pilot study","MIGNOGNA, CARMEN","2025","IRIS Research product catalog (Sapienza University of Rome)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0037394","Eighteen-month evaluation of oral semaglutide on liver enzymes and fibrosis markers in type 2 diabetes: A twin-centre study","Rajeev Chawla","2025","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-025-01600-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037395","Poster presented at EASL 2026: The glucagon/glucagon-like peptide-1 receptor dual agonist survodutide reduces liver fibrosis in a 4-week carbon tetra chloride lean mouse model","François Briand","2026","Boehringer Ingelheim","preclinical","article","10.60915/boehringer-figshare.32158899",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0037396","De l’intérêt de l’exenatide chez les adolescents diabétiques de type 1","Patrice Darmon","2011","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(11)70040-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037397","A GLP‐1 Mimetic Alleviates Irritable Bowel Syndrome‐like Symptoms in the Wistar Kyoto Rat","Rebecca L. O’Brien","2016","The FASEB Journal","preclinical","article","10.1096/fasebj.30.1_supplement.1021.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037398","1033-OR: Early Weight Loss Velocity Guides Precision Escalation in Obesity Treatment","Andrea Foppiani","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1033-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037399","Beyond Diabetes Mellitus and weight loss: the potential effect of GLP-1 agonist drugs in the treatment of Parkinson’s Disease","Deimile Marija Gritenaitė","2025","JUNIOR RESEARCHERS","nonrandomized_study","article","10.52340/jr.2025.03.02.26",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037400","L8BPM4NP8B Outcomes Associated with GLP1 Agonist Withdrawal within a University-Based Clinical Setting",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.453",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037401","Reporting on Adverse Clinical Events",null,"2012","Clin-Alert","other","article","10.1177/0069477012444557",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037402","S3467 A Rare Case of Tirzepatide-Induced Liver Injury","Achashman Berihun","2023","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000963508.23690.49",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037403","Comparison of Glycemic Variability in Chinese T2DM Patient Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial","Yin, Ting-Ting","2018","Figshare","randomized_trial","article","10.6084/m9.figshare.5982262.v2",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0037404","MOESM7 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Bruen, Robyn","2017","Figshare","preclinical","article","10.6084/m9.figshare.c.3923344_d9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0037405","'Life-threatening condition' added to Mounjaro patient information leaflet",null,"2025","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2025.1.387870",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037406","Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study","of, Adis journals on behalf","2023","Figshare","nonrandomized_study","article","10.6084/m9.figshare.22717597",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037407","MOESM1 of The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke","Shan, Yilong","2019","Figshare","preclinical","article","10.6084/m9.figshare.11296775",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037408","657. AAV5 Mediated Exendin-4 Transduction of Salivary Glands in Mouse and Rat Obese Models Results in Robust Systemic Secretion of Exendin-4 and Improvement of Metabolic Parameters",null,"2011","Molecular Therapy","preclinical","article","10.1016/s1525-0016(16)37230-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037409","Short-term cost-effectiveness of oral semaglutide versus empagliflozin, sitagliptin, and liraglutide in the treatment of Type 2 diabetes in Greece","Panagiotis Papantoniou","2024","Global Health Economics and Sustainability","other","article","10.36922/ghes.3032",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037410","RWD43 TRENDS IN UTILIZATION AND OUT-OF-POCKET SPENDING FOR GLP-1 RECEPTOR AGONISTS AMONG U.S. ADULTS WITH TYPE 2 DIABETES, 2018-2023: A MEPS STUDY","Unity king Gbeblewu","2026","Value in Health","other","article","10.1016/j.jval.2026.03.2031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037411","BREATHTAKING BENEFITS? GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IMPACT ON ASTHMA EXACERBATIONS","Vidya Krishnan","2025","CHEST Journal","other","article","10.1016/j.chest.2025.07.3155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037412","Additional file 2 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","Rossing, Peter","2023","Figshare","other","article","10.6084/m9.figshare.26612678",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037413","Liraglutide: ruolo nel trattamento del diabete di tipo 2","Agostino Consoli","2009","L Endocrinologo","other","article","10.1007/bf03344661",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037414","Glycated hemoglobin and cardiovascular risk in diabetes mellitus: Evolving evidence beyond glycemic control","Manjeet Kumar Goyal","2026","World Journal of Diabetes","other_trial","article","10.4239/wjd.115820",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0037415","O-SEMA-FAST: A prospective, non-interventional study investigating oral semaglutide use in adults with type 2 diabetes mellitus during Ramadan","Adis Journals On Behalf Of","2025","Figshare","other","article","10.6084/m9.figshare.28443518",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037416","Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies","Of, Adis Journals On Behalf","2021","Figshare","systematic_review","article","10.6084/m9.figshare.13667132",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0037417","Complex therapy of patients with metabolic syndrome in the early stages of its development","Мельник","2014","Journal of New Medical Technologies","other","article","10.12737/7343",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037418","TZP Paper","Arthur Sherman","2026","Figshare","other","article","10.6084/m9.figshare.31370863.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037419","Su1615: GLP-1 RECEPTOR AGONISTS HAVE A LOWER RISK OF DEVELOPING ALCOHOL-ASSOCIATED LIVER DISEASE IN PATIENTS WITH ALCOHOL USE DISORDER","Soo Young Hwang","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02803-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037420","PO13 Caractéristiques pharmacodynamiques du lixisénatide en une prise quotidienne vs le liraglutide chez des patients ayant un diabète de type 2 (DT2) non équilibré sous metformine","Christoph Kapitza","2012","Diabetes & Metabolism","other","article","10.1016/s1262-3636(12)71075-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037421","Human medicines European public assessment report (EPAR): Bydureon, exenatide, Diabetes Mellitus, Type 2, Date of authorisation: 17/06/2011, Revision: 18, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-ab02b4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037422","Glucagon-like-peptide 1 (GLP-1) Receptor Agonists in Rheumatologic Disease","Jill Trinacty","2025","Canadian rheumatology today.","other","article","10.58931/crt.2025.2158",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037423","Early action if new oral hypoglicaemic agents on echocardiographic parameters","A Dagostino","2026","European Journal of Preventive Cardiology","other","article","10.1093/eurjpc/zwag249.211",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037424","Additional file 1 of GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs","Elhaitham Yasir Awad Musa","2026","Figshare","systematic_review","article","10.6084/m9.figshare.32227353.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0037425","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia","Ju-Ming Lu","2019","Figshare","other","article","10.6084/m9.figshare.7745426",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037426","1784-P: Liraglutide Treatment Stimulates Alpha Cells to Produce Glucagon-Like Peptide-1 via Expression of Prohormone Convertase 1/3 in Mice and Human","Mridusmita Saikia","2020","Diabetes","preclinical","article","10.2337/db20-1784-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037427","Epilogue: The Ozempic Era",null,"2024",null,"other","article","10.5040/9798881890988.ch-005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037428","Montelukast-Induced Anxiety in Pediatric Patients: Fixed Drug Eruption on Penis Due to Oxcarbazepine: Interferon-alfa-Induced Lupus in a Patient with Hepatitis C: Acute Pancreatitis Associated with Liraglutide: Severe Muscle Cramps after Acute Administration of Intravenous Amiodarone: Linezolid-Associated Hypoglycemia in Patient with Type 2 Diabetes: Levamisole Commonly Found Mixed with Cocaine","Joel Shuster","2011","Hospital Pharmacy","other","article","10.1310/hpj4607-477",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037429","3078-LB: HM17321, a Novel UCN2 Analog, Improves Weight Loss Quality in Combination with Amylin Analogs in DIO Rats","YOHAN KIM","2026","Diabetes","preclinical","article","10.2337/db26-3078-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037430","Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study","Qin, Lei","2018","Figshare","other","article","10.6084/m9.figshare.6182603",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037431","Abstract #256 Real Life Experience with the Combination of Glargine Insulin and Lixisenatide in Obese Type 2 Diabetic Patients in Mexico City.","Ernesto Garcı́a-Rubi","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47101-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037432","805-P: Sarcopenia in Insulin-Treated Older Adult Patients with Type 2 Diabetes","Silmara A O Leite","2022","Diabetes","nonrandomized_study","article","10.2337/db22-805-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037433","Correction",null,"2026","Tissue Barriers","other","article","10.1080/21688370.2026.2634592","41801795",null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0037434","GLP-1 Receptor Agonists for Perimenopausal Symptom Management: A PRISMA-ScR Scoping Review and Convergent Multi-Source Evidence Synthesis","Huizhen Chen","2026","SSRN Electronic Journal","narrative_review","article","10.2139/ssrn.6867919",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0037435","Mitigating Glucagon-like peptide-1 Agonist-induced Gastrointestinal Symptoms: A Case of Effective Mirtazapine Use",null,"2026","Endocrine Practice","case_report","article","10.1016/j.eprac.2026.01.747",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037436","Mathematical Modeling of the Mechanism of Action of Tirzepatide and Semaglutide","Arthur Sherman","2026","Figshare","other","article","10.6084/m9.figshare.31018369.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037437","The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain","Vidal, Josep","2019","Figshare","other","article","10.6084/m9.figshare.11359718.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037438","CICR takes centre stage in β-cells: a cute cascade connects cAMP to CICR","Md. Shahidul Islam","2010","The Journal of Physiology","preclinical","article","10.1113/jphysiol.2010.202291","21173086",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037439","749-P: Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment","Shaheen Tomah","2025","Diabetes","other","article","10.2337/db25-749-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037440","P1102 Résultats intérimaires de l’étude ROOTS, une étude multicentrique observationnelle et non interventionnelle Belge destinée à évaluer l’efficacité et la sécurité du liraglutide chez des patients diabétiques de type 2","Vanessa Preumont","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71848-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037441","CLINICAL CHARACTERISTICS AND METABOLIC OUTCOMES IN THAI PEOPLE WITH YOUNG-ONSET DIABETES ATTENDING THEPTARIN HOSPITAL:","Siriwan Butadej","2023","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.038.afes.04",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037442","S4463 Management of Functional Obstructive Jaundice in a Young Female With History of Semaglutide Use","Tasnim S. Ali","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001047220.21474.98",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037443","Method Development and Validation for Estimation of Liraglutide and it's related substances using RP-HPLC method","Yekkele Santhoshini","2026","International Journal of Chemistry and Pharmaceutical Sciences","other","article","10.30904/j.ijcps.2026.4996",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037444","878-P: Maximize Benefits of SGLT2 Inhibitors in People with Advanced CKD Stages with Type 2 Diabetes","Koji Kashima","2022","Diabetes","other","article","10.2337/db22-878-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037445","Target trial emulation to reduce confounding in therapy effectiveness assessment - (Based on the Cohort Study by Wang et al. on Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder)","Victor Galvão","2025","OSF Preprints (OSF Preprints)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","preprint"],["R0037446","The Role of Endobariatrics in a Bariatric Surgery Program","Brandon VanderWel","2025","Foregut The Journal of the American Foregut Society","other","article","10.1177/26345161251354940",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037447","482-P: The GLP-1 Receptor Agonist Liraglutide Improves Glomerular Filtration Rate, Renal Inflammation, and Fibrosis in the Type 2 Diabetic SDT Fatty Rat","François Briand","2020","Diabetes","preclinical","article","10.2337/db20-482-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037448","P34. Semaglutide use prior to single-level lumbar fusion associated with fewer readmissions and 90-day costs","Mitchell K. Ng","2025","The Spine Journal","other","article","10.1016/j.spinee.2025.08.035",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037449","GLP-1 Receptor Agonists Ameliorate Obesity-Driven EAE Severity in HLA Class II Transgenic Mice 2265661","Allison Rux","2026","The Journal of Immunology","preclinical","article","10.1093/jimmun/vkag141.1076",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037450","Trends in weight change pattern among adults with type 2 diabetes mellitus using dapagliflozin 10mg and Semaglutide 1mg in King Abdulaziz Medical City, Riyadh, Saudi Arabia","Eman Alharbi","2024","Medical Science","nonrandomized_study","article","10.54905/disssi.v28i150.e107ms3405",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037451","Cellular mechanisms of addiction (468.2)","Paul J. Kenny","2014","The FASEB Journal","preclinical","article","10.1096/fasebj.28.1_supplement.468.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037452","S1176 Dual Therapy With Metformin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) Improves Mortality in Diabetic Cirrhotic Patients","Daniel J. Huynh","2022","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000861344.44054.b7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037453","Editorial: Preventing cardiovascular complications of type 2 diabetes, volume II","Nadia Di Pietrantonio","2026","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1792059","41694573",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0037454","Who are the Best Candidate Patients with Diabetes for Tirzepatide?","N Mikhail","2022","Austin Diabetes Research","other","article","10.26420/austindiabetesres.2022.1025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037455","TZP Paper","Arthur Sherman","2026","Figshare","other","article","10.6084/m9.figshare.31370863.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037456","Dulaglutide/pioglitazone/risperidone",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-38406-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037457","Cutting the brakes to prevent Type 2 Diabetes onset: augmenting insulin secretion and conserving pancreatic beta‐cell mass by deleting Gαz","Jaclyn A. Wisinski","2017","The FASEB Journal","preclinical","article","10.1096/fasebj.31.1_supplement.665.10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037458","The efficacy of liraglutide for treatment of type 2 diabetes","Hung-Ling Su","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31236-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037459","2375-P: Trends in Utilization of Glucose Lowering Medications among Patients with Type 1 Diabetes in the United States","JANINNE ORTEGA MONTIEL","2026","Diabetes","randomized_trial","article","10.2337/db26-2375-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037460","1061-P: Food Recording and HbA1c Improvement —GluCare.Health Remote Monitoring Program Compared with Traditional Care in Patients with Obesity","Begum Demircan","2023","Diabetes","other","article","10.2337/db23-1061-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037461","OP45 PREDICTORS OF THE EFFECTIVENESS OF INCRETIN-BASED THERAPY: RESPONSIVENESS OF C-PEPTIDE TO MIXED MEAL TOLERANCE TEST AND GLUCAGON LOADING TEST IN JAPANESE TYPE 2 DIABETES","Eriko Nara","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70251-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037462","Oral presentation at AASLD 2025: Improvements in non-invasive biomarkers and biopsy responses with the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: Overlap analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis","M. Anstee, Quentin","2025","Boehringer Ingelheim","other_trial","article","10.60915/boehringer-figshare.30436906",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","conference-paper"],["R0037463","TNFα Promotes Glioblastoma A172 Cell Mitochondrial Apoptosis via Augmenting Mitochondrial Fission and Repression of MAPK–ERK–YAP Signaling Pathways [Retraction]","Lu,Changyu","2024","Dove Medical Press (Taylor and Francis Group)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037464","2059-LB: NA-931, a Novel Triple IGF-1/GLP-1/GIP Incretin Receptor Agonist Reduces Body Weight and Improves Metabolic Profile in DIO Mice","LLOYD L. TRAN","2024","Diabetes","preclinical","article","10.2337/db24-2059-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037465","Promises & pitfalls of GLP-1-based therapies for cognitive and mental disorders","Riccardo De Giorgi","2026",null,"other_trial","article","10.1136/jnnp-2026-bnpa.3",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0037466","Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK","Vega-Hernandez, Gabriela","2018","Figshare","other","article","10.6084/m9.figshare.6171425",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037467","765-P: Therapeutic NuSH Cocktails—Coadministration of Ultra-Long-Acting GLP-1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice","ROBERT HANSFORD","2025","Diabetes","preclinical","article","10.2337/db25-765-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037468","Hypereosinophilia following initiation of glucagon-like peptide 1 receptor agonists: a Danish population-based register study","Rahbek, Martin Torp","2023","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/sabzk",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037469","S1999 The Dark Side of Semaglutide: Discrete Instances of Acalculous Cholecystitis and Acute Pancreatitis in the Same Patient Due to Continued Use of GLP-1 Agonist","Ruona Ebiai","2023","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000957636.56371.78",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037470","388-P: GLP-1 Receptor Agonists Attenuates Secretion of Extracellular Matrix via Inhibiting HMGB1 Signaling in Rat Mesangial Cells","Wensha Gu","2021","Diabetes","preclinical","article","10.2337/db21-388-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037471","ОЦЕНКА ВЛИЯНИЯ ТЕРАПИИ ИНКРЕТИНОМИМЕТИКАМИ И ГЛИФЛОЗИНАМИ НА ФУНКЦИЮ АЛЬФА И БЕТА-КЛЕТОК ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ У ПАЦИЕНТОВ С СД 2 ТИПА","Н. Н. Кушнарёва","2021","World Science","other","article","10.31435/rsglobal_ws/30032021/7507",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037472","Liposomes Containing Tetraether Lipids and Cell‐Penetrating Peptides as Platform Technology for Oral Delivery of Peptides: A Comparative Study on GLP‐1 Analogs","Lorenz Herbster","2025","Nano Select","preclinical","article","10.1002/nano.70010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037473","COMPARAÇÃO DOS DESFECHOS CARDIOMETABÓLICOS ENTRE AGONISTAS DE GLP-1 E CIRURGIA BARIÁTRICA EM PACIENTES COM SÍNDROME METABÓLICA","Francisco de Oliveira Borges","2025","LUMEN ET VIRTUS","other","article","10.56238/levv16n50-026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037474","Poster Session I - A100 IMPACT OF GLP-1 RECEPTOR AGONISTS ON THE QUALITY OF BOWEL PREPARATION IN SCREENING COLONOSCOPIES","S Quan","2026","Journal of the Canadian Association of Gastroenterology","nonrandomized_study","article","10.1093/jcag/gwaf042.100",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037475","Abstract 453: Ablation of TRPV1 Impairs Exendin-4 Induced Suppression in Renal Cytokine Release","Beihua Zhong","2014","Hypertension","preclinical","article","10.1161/hyp.64.suppl_1.453",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037476","Denying Visas to Doctors in the United States","Muhammad Hassan Majeed","2017","New England Journal of Medicine","nonrandomized_study","article","10.1056/nejmc1616421","28146640",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037477","The impact of GLP-1 receptor agonists on cognitive decline in heart failure patients: a retrospective cohort study using real world data","A R Rahmani","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.1431",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037478","Effects of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Metabolic Abnormalities and Body Weight in HIV-infected Subjects with or without Type 2 Diabetes","Ramesh Saeedi","2015","Journal of HIV and AIDS","other","article","10.16966/2380-5536.107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037479","- Safety of Obesity Drugs","Debasis Bagchi","2012","Obesity","other","article","10.1201/b12261-22",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0037480","Editorial: Diabetic kidney disease: routes to drug development, pharmacology and underlying molecular mechanisms, volume II","Divya Bhatia","2025","Frontiers in Pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1609100","40351438",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0037481","Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study","Adis Journals On Behalf Of:","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.24807525",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037482","Patients’ Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment","Brooks, Anne","2019","Figshare","other","article","10.6084/m9.figshare.7757066.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037483","1701-P: Activin E–Blocking Antibody for Treatment of Metabolic Diseases","CORY SCHWARTZ","2025","Diabetes","preclinical","article","10.2337/db25-1701-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037484","Obesity and Gut Microbiota: what do we know so far?","Laura Machuga De Almeida","2023","Seven Editora eBooks","other","article","10.56238/tfisdwv1-037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0037485","MOESM11 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Robyn Bruen","2017","Figshare","preclinical","article","10.6084/m9.figshare.5576974.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0037486","The use of dulaglutide in real clinical practice in patients with type 2 diabetes mellitus in Moscow","Antsiferov M.B. Antsiferov","2024","Фарматека","other","article","10.18565/pharmateca.2024.2.77-84",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037487","GLP-1R agonist blocks torpor in mice while GLP-1R deletion does not disrupt normal torpor behavior","Alejandra Ayala Becerra","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2300965",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037488","ASPECTOS FARMACOLÓGICOS E CLÍNICOS DA TIRZEPATIDA NO TRATAMENTO DA OBESIDADE: UMA REVISÃO NARRATIVA SOBRE SEU MECANISMO DE AÇÃO E EFICÁCIA TERAPÊUTICA","José Neto","2025","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v11i11.22179",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037489","In silico exploration of phytochemicals for GLP-1 receptor agonists for the treatment of type 2 diabetes","Sharanjeet Kour","2025","Computational and Structural Biotechnology Reports","preclinical","article","10.1016/j.csbr.2025.100069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037490","MP10-04 USE OF SODIUM-GLUCOSE COTRANSPORTER (SGLT2) INHIBITORS IN DIABETIC STONE FORMERS IS ASSOCIATED WITH A REDUCED RISK OF FUTURE STONE EVENTS","Ridwan Alam","2023","The Journal of Urology","nonrandomized_study","article","10.1097/ju.0000000000003225.04",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037491","PREVENTIVE EFFECT OF EXENATIDE TO ENDOTHELIAL DYSFUNCTION INDUCED BY ISCHEMIA-REPERFUSION INJURY VIA ADP K CHANNELS","Sang Jin Ha","2010","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(10)61589-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037492","Abstract 4142589: GLP-1 receptor agonists slow the progression of subclinical cardiovascular risk as detected from 12-lead electrocardiograms","Lena R Kaisinger","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4142589",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037493","Semaglutide for Metabolic dysfunction-Associated Steatohepatitis: Global Access, Equity, and Next Steps After FDA Approval","Kainat Younisl","2025",null,"other","article","10.22541/au.176216049.92983323/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0037494","Abstract #1242: Generalized EDEMA Caused by Albiglutide (Tanzeum) – A Case Report","Issac Sachmechi","2015","Endocrine Practice","case_report","article","10.1016/s1530-891x(20)42473-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037495","Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Type 2 Diabetes Patients: Propensity Score Matched Analysis","Tabák, Ádám G.","2019","Figshare","nonrandomized_study","article","10.6084/m9.figshare.10303784",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037496","A Remotely Delivered GLP-1RA–Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation (Preprint)","Rebecca Richards","2025",null,"nonrandomized_study","article","10.2196/preprints.72577",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0037497","The Dynamic Incretin Adaptation and Type 2 Diabetes","Bo Åhrén","2011","The Journal of Clinical Endocrinology & Metabolism","preclinical","article","10.1210/jc.2011-0299","21378226",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037498","PDB42 INCRETIN-THERAPY IN ADDITION TO METFORMIN AND/OR SULFONYLUREA FOR TYPE 2 DIABETES MELLITUS (T2DM): COSTEFFECTIVENESS OF LIRAGLUTIDE VERSUS EXENATIDE FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)","Michael Schlander","2010","Value in Health","other","article","10.1016/s1098-3015(11)72100-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0037499","Journal of Diabetes NEWS","Benjamin M. Kozak","2012","Journal of Diabetes","randomized_trial","article","10.1111/j.1753-0407.2012.00197.x",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0037500","Liraglutide pour le traitement du diabète de type 2","A. Avignon","2010","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(10)70066-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037501","GLP-1 RA for primary prevention of post-mastectomy lymphedema in breast cancer patients: A multicenter real-world analysis.","Dawit Hailemariam Yesho","2026","Journal of Clinical Oncology","randomized_trial","article","10.1200/jco.2026.44.16_suppl.628",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0037502","Discovery of a new GLP-1 receptor agonist using DNA encoded-libraries and similarity search","Ju Ho Lee","2026","Results in Chemistry","other","article","10.1016/j.rechem.2026.103415",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037503","S5880 Challenging the Dogma: Reversal of End-Stage Liver Fibrosis With Tirzepatide in MASH Cirrhosis","Thuy-Duyen Nguyen","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001150980.09519.07",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037504","26-A-13496-ACC ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY WITH CLINICAL OUTCOMES IN CARDIAC ALLOGRAFT VASCULOPATHY: A PROPENSITY-MATCHED MULTICENTER COHORT","Harsh Agarwal","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1804",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037505","Insulinotropic Actions of GLP-1: How Much in the Brain and How Much in the Periphery?","Eva Tudurí","2017","Endocrinology","preclinical","article","10.1210/en.2017-00410","28881865",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037506","Comparison of the efficacy and safety of commercially available fixed ratio combinations of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) - a network meta-analysis","Visolyi, Gergely Á","2023","UCL Discovery (University College London)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","article"],["R0037507","PO138 MOLECULAR MECHANISM FOR PROTECTIVE EFFECT OF PIOGLITAZONE AND LIRAGLUTIDE ON BETA-CELLS WITH THE PROGRESSION OF DIABETIC MORBIDITY","Tomonori Kimura","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70432-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037508","Semaglutide Therapy And Reduction Of Left Ventricular Mass In Patients With Type 2 Diabetes: A STOP Trial Substudy","Redento Mora","2025","Journal of cardiovascular computed tomography","other_trial","article","10.1016/j.jcct.2025.05.015",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037509","Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase-4 Inhibitor","Adis Journals On Behalf Of","2023","Figshare","nonrandomized_study","article","10.6084/m9.figshare.24610002.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037510","Effects of Glucagon-like peptide-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease","Altintas Dogan, Ayse Dudu","2022","University of Southern Denmark Research Portal (University of Southern Denmark)","other","article","10.21996/4f2x-gb95",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037511","GW29-e1421 Exenatide improves doxorubicin-induced cardiac injury","Juntao Fang","2018","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2018.08.160",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037512","CPAP but not Liraglutide-mediated weight loss improves early cardiovascular disease in OSA: a proof-of-concept study using vascular PET-CT and AI-enabled CTCA plaque analysis","Crilly, Shane","2024","European Society of Radiology","other","article","10.26044/ecr2024/c-14363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037513","S1593 Temporal Patterns of Body Mass Index, Health Care Resource Utilization, and Biomarkers in Patients With Ulcerative Colitis; A Descriptive Study of Electronic Health Records","Stephen Shields","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001133832.70875.f5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037514","Semaglutide and delayed gastric emptying: case report and analysis of anesthetic implications","Luis Leobardo Fortis-Olmedo","2025","Colombian Journal of Anesthesiology","case_report","article","10.5554/22562087.e1137",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037515","COMBINATION THERAPY WITH SEMAGLUTIDE AND VERICIGUAT AS AN EFFECTIVE PREVENTIVE THERAPY OF 5-FU INDUCED CARDIOTOXICITY IN CANCER PATIENTS: PRELIMINARY EVIDENCES IN CARDIO-ONCOLOGY","Nicola Maurea","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)03086-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037516","Additional file 5 of A peripheral lipid sensor GPR120 remotely contributes to suppression of PGD2-microglia-provoked neuroinflammation and neurodegeneration in the mouse hippocampus","Iwasa, Kensuke","2021","Figshare","preclinical","article","10.6084/m9.figshare.17696331",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037517","The world congress on insulin resistance, diabetes, and cardiovascular disease ( WCIRDC )","Zachary T. Bloomgarden","2022","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13260","35191189",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037518","4371 GLP-1 RECEPTOR AGONIST PRESCRIPTION PATTERNS AMONG SURGEONS: A NATIONAL MEDICARE PART D ANALYSIS",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.215",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037519","MOESM4 of Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway","Feng, Yun","2020","Figshare","other","article","10.6084/m9.figshare.11508102.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037520","2321-PUB: Improved Glycemic Control among Patients Newly Prescribed IDegLira across Various Background Therapies in U.S. Real-World Practice","Leonard E. Egede","2019","Diabetes","nonrandomized_study","article","10.2337/db19-2321-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037521","Liraglutide add-on to insulin improved glycaemia but exhibited short durability after cessation in type 1 diabetes with residual insulin secretion","Yoshiyuki Hamamoto","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31181-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037522","Semaglutide ed esiti cardiovascolari in pazienti con diabete di tipo 2","Riccardo C. Bonadonna","2016","L Endocrinologo","other","article","10.1007/s40619-016-0235-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037523","Orforglipron: First Approval","Matt Shirley","2026","Figshare","other_trial","article","10.6084/m9.figshare.32817425",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0037524","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-44683-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037525","2604-P: Sleep-Related Outcomes in Patients with OSA Treated with Tirzepatide for Obesity or Overweight via Telehealth","Lauren Broffman","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2604-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037526","Tirzepatide/valproate-semisodium",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-40151-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037527","Hormone therapy boosts tirzepatide weight loss in menopause","Roberto Vettor","2026","The Lancet Obstetrics Gynaecology & Women s Health","other","article","10.1016/s3050-5038(25)00210-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037528","432 The impact of Liraglutide Treatment on the Erectile Function of the Diabetic Rats","Serkan Gönültaş","2018","The Journal of Sexual Medicine","preclinical","article","10.1016/j.jsxm.2018.04.338",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037529","Futuro en la diabetes: innovaciones terapéuticas y nuevas moléculas","León Litwak","2025","Revista de la Sociedad Argentina de Diabetes","other","article","10.47196/diab.v59i2sup.1256",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037530","Why Are Doctors Not Interested in Type 2 Diabetes Mellitus Remission?","Heung Yong Jin","2024","Diabetes & Metabolism Journal","other","article","10.4093/dmj.2024.0312","39091006",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037531","Peptide Drug Purification by Spatial Solvent Gradient Twin-Column Recycling Chromatography Coupled with Complementary Stationary-Phase Selectivity: A Case Study of Tirzepatide Analogues","Zhipeng Ding","2026","Industrial & Engineering Chemistry Research","other","article","10.1021/acs.iecr.6c00509",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037532","Association between GLP-1 receptor agonist use and risk of pneumonia and pyothorax in type 2 diabetes: a retrospective cohort study","Li-Hsiu Tai","2026","BMC Infectious Diseases","nonrandomized_study","article","10.1186/s12879-026-14234-1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037533","4226 HOW ARE BARIATRIC CENTERS ADAPTING TO THE ADVENT OF NOVEL GLP-1 RAS? AN EXPLORATIVE QUALITATIVE STUDY OF MEDICAL AND SURGICAL BARIATRIC DIRECTORS",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.339",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037534","Clinical News",null,"2009","British Journal of Hospital Medicine","other","article","10.12968/hmed.2009.70.3.40551",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037535","1635-P: Survodutide Weight Loss Is Associated with Changes in Food Preference and Improvement of Dyslipidemia in the Free Choice Diet–Induced Obese Hamster Model","François Briand","2024","Diabetes","other_trial","article","10.2337/db24-1635-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037536","Risk Of SIBO And Colorectal Cancer Among Non-Obese Patients with Irritable Bowel Syndrome Treated With GLP-1 Agonists","Sadighian, Sadaf","2025",null,"other","article","10.13140/rg.2.2.28391.36004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037537","Erratum",null,"2026","The Medical Journal of Australia","nonrandomized_study","article","10.5694/mja2.70163","41845954",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","erratum"],["R0037538","Abstract #805218: Combination Therapy with Once Weekly GLP 1 Receptor Agonist Dulaglutide and Basal Insulin Analogues in Asian Indians with Type 2 Diabetes","Brijendra Kumar Srivastava","2020","Endocrine Practice","other","article","10.1016/s1530-891x(20)39612-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037539","The Possible Effects of Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)","Swapnil Tripathi","2025","Novel Practices in Medical Study","other","article","10.31031/npms.2025.01.000518",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037540","Fracture Risk Following Semaglutide Treatment Versus Sleeve Gastrectomy",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037541","1105-OR: In Vitro and In Vivo Characterization of CC-18, a Novel GLP-1R/ActRIIA/ActRIIB Dual Pathway-Targeting Fusion Protein That Reduces Weight while Increasing Muscle in Preclinical Models","JIA NI","2026","Diabetes","preclinical","article","10.2337/db26-1105-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037542","1798-P: Combined Semaglutide and Sodium–Glucose Cotransporter 2 Inhibitors in Real-World Clinical Practice in China: Scholar Post Hoc Analysis","SHANSHAN WANG","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1798-p",null,null,"ClinicalTrials.gov:NCT06351748","S000366","openalex","FALSE","paywalled","4","FALSE","article"],["R0037543","164 Is Pharmacotherapy a Threat to the Field of Bariatric Surgery? – A Perspective from Surgical Trainees and Consultants","Amarah Ghani Shaikh","2025","British journal of surgery","other","article","10.1093/bjs/znaf270.213",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037544","Study Identifies Benefits and Risks of GLP-1 Drugs Across 175 Health Outcomes","Samantha Anderer","2025","JAMA","other","article","10.1001/jama.2025.0542","39982718",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037545","6ER-018 Therapeutic strategies in cardio-renal-metabolic syndrome: a systematic review","A Colicchio","2026",null,"systematic_review","article","10.1136/ejhpharm-2026-eahp.618",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-paper"],["R0037546","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-37402-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037547","Rybelsus Weight Loss Weight Loss Options: Ozempic Alternatives for Australians Seek","SherylDF, rederick","2024","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.12780059",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037548","Semaglutide-Associated Severe Gastrointestinal Intolerance and Hepatic Granulomas: A Case Report","Aqsa Khan","2025","Journal of Diabesity","case_report","article","10.66381/jod.2025.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037549","4719 CARDIOMETABOLIC OUTCOMES OF METABOLIC SURGERY VERSUS GLP-1 RECEPTOR AGONISTS IN OLDER ADULTS WITH DIABETES AND OBESITY",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.045",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037550","Beyond incretin therapy: integrating precision nutrition for sustained obesity management medications","C.F. Nicoletti","2026","Obesity Medicine","other","article","10.1016/j.obmed.2026.100690",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037551","Lixisenatid weist schützende Wirkung auf diabetische Netzhaut auf","Maddalena Angela Di Lellis","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2247-7387",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037552","0058 Decreased rate of cardiovascular events with GLP-1 receptor agonist use in dermatomyositis and lupus patients","E. Wei","2026","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2026.06.089",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037553","Treatment of clozapine-associated obesity and diabetes with exenatide (Codex) in adults with schizophrenia","Crystal A. Franklin","2017","Australian & New Zealand Journal of Psychiatry","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037554","Association of Glucagon-Like Peptide-1 Receptor Agonist Therapy With Cancer in Adults With Type 2 Diabetes Mellitus",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.220",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037555","Inkretinek és inkretinhatású \\nvércukorcsökkentők pleiotrop \\ntulajdonságai | Pleiotropic effects of incretins and antidiabetics with incretine mechanism","Winkler, Gábor","2013","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037556","Intenzív inzulinkezelés korai deeszkalálásának lehetőségei - Esettanulmány és irodalmi áttekintés = Exploring Opportunities of Early De-Escalation of Intensive Insuline Therapy – Case Report and Review","Fejes, Roland","2024","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","case_report","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037557","Your body already has a built-in weight loss system that works like Wegovy, Ozempic and Mounjaro – food and your gut microbiome","Christopher J. Damman","2024",null,"other","article","10.64628/aai.fjd6n4h7t",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037558","NIAAA/NIDA animal study: Diet drug may help treat AUD","Alison Knopf","2024","Alcoholism & Drug Abuse Weekly","preclinical","article","10.1002/adaw.34068",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037559","PO-03-100 GLP-1 AGONISTS AFTER AF ABLATION AND RISK OF RECURRENT ATRIAL FIBRILLATION: A PROPENSITY-MATCHED REAL-WORLD COHORT STUDY","Geoffroy A. Napon","2026","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2026.03.839",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037560","Additional file 5 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","Rossing, Peter","2023","Figshare","other","article","10.6084/m9.figshare.26612687",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037561","Tirzepatide, menopause hormone therapy, and oral hormone absorption","Maria Celeste Osório Wender","2026","The Lancet Obstetrics Gynaecology & Women s Health","other","article","10.1016/s3050-5038(26)00181-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037562","Komplex inzulinkezelési rezsimek deeszkalációja a jó glikémiás kontroll megőrzésével 2-es típusú diabetes mellitusban [De-escalation of complex insulin regimens while preserving good glycemic control in type 2 diabetes]","Taybani, Zoltán Jamal","2020","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037563","Is there a link between Ozempic and vision loss?","Grace Wade","2025","The New Scientist","other","article","10.1016/s0262-4079(25)00406-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037564","The safety and efficacy of GLP-1 receptor agonists in kidney transplant recipients with diabetes: A single-centre retrospective analysis","R Chakraborty","2023",null,"nonrandomized_study","article","10.13140/rg.2.2.18923.72482",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0037565","The fast-changing world of obesity, diabetes, and systemic metabolic disorders","Filippo Crea","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf696","41052781",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037566","Cardiac Aspects of Diabetes","Sunandan Sikdar","2023",null,"other","article","10.1201/9781003027584-41",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0037567","Tirzepatide use in patients with heart failure with preserved ejection fraction and obesity in clinical practice","A Villarreal Rizzo","2026","European Journal of Heart Failure","randomized_trial","article","10.1093/ejhf/xuag193.093",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037568","Analysis of Clinical Characteristics in Dilated Cardiomyopathy Patients with Different Weight Statuses and the Influence of Weight Management on the Prognosis","SUN  Xia, SHEN  Wen, TANG  Xiang, ZHONG  Wei, WANG  Kailin, DAI  Zhiyin, ZHANG  Chaopu, YUAN  Wei, YUAN  Guoyue","2026","DOAJ (DOAJ: Directory of Open Access Journals)","nonrandomized_study","article","10.12114/j.issn.1007-9572.2025.0352",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0037569","TOP-176 Concurrent responses in multiple non-invasive tests for hepatic inflammation and fibrosis following pemvidutide treatment: 24-week responder analyses of the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis","Naim Alkhouri","2026","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(26)01885-4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0037570","Research Progress on Synergistic Treatment of Diabetic Nephropathy with Chinese and Western Medicine","Xiao Chang","2025","Journal of Contemporary Medical Practice","other","article","10.53469/jcmp.2025.07(07).09",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037571","Additional file 3 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","Rossing, Peter","2023","Figshare","other","article","10.6084/m9.figshare.26612681",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037572","Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a USA Real-World Setting","Of:, Adis Journals On Behalf","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.14248778",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037573","MOESM3 of Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway","Feng, Yun","2020","Figshare","other","article","10.6084/m9.figshare.11508093.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037574","Bekendmaking resultaten ELIXA-studie naar cardiovasculair veiligheidsprofiel lixisenatide","Bohn Stafleu van Loghum","2015","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-015-0011-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037575","Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias","Boulmpou, Aristi","2024","Figshare","systematic_review","article","10.6084/m9.figshare.27231628",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0037576","Lower risk of long-term adverse clinical outcomes of Glucagon-like peptide-1 receptor agonist and/or Sodium–glucose cotransporter-2 inhibitor treatment among patients with Metabolic dysfunction associated steatotic liver disease: a systematic review and meta-analysis","Israni, Jake","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/7ubcn",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0037577","1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys","METTE HØY JENSEN","2026","Diabetes","randomized_trial","article","10.2337/db26-1713-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037578","MOESM4 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Robyn Bruen","2017","Figshare","preclinical","article","10.6084/m9.figshare.5577040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0037579","87-LB: Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes—The RESTORE-G Real-World Study","RICCARDO CANDIDO","2022","Diabetes","nonrandomized_study","article","10.2337/db22-87-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037580","Clinically Both Effects of Weight and Glucose Variability by Oral Semaglutide (Rybelsus) for Younger Female Patient with Type 2 Diabetes (T2D)","Hiroshi Bando","2022","Journal of Obesity and Diabetes","other","article","10.33805/2638-812x.126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037581","1814-P: Impact of Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonism on β-Cell Ca2+ Dynamics within the Pancreatic Islet In Vivo","Luis Fernando Delgadillo-Silva","2025","Diabetes","preclinical","article","10.2337/db25-1814-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037582","732-P: Patients with Type 2 Diabetes Reach Glycemic Targets Faster with Tirzepatide Compared with Semaglutide and Titrated Insulin Degludec","KEVIN M. PANTALONE","2022","Diabetes","other","article","10.2337/db22-732-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037583","S1494 Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-Diabetic Patients With Inflammatory Bowel Disease","Jeremy A. Klein","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035344.73427.3c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037584","Methylprednisolone/Prednisone/Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-51094-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037585","A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide once weekly versus dapagliflozin alone in obese patients with Type 2 diabetes mellitus (RESILIENT).","Clare Brown","2026","University of Liverpool","randomized_trial","article","10.17638/03198911",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0037586","Obesity-related hypertension",null,"2023","The Nurse Practitioner","randomized_trial","article","10.1097/01.npr.0000000000000064","37227310",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037587","1758-P: Efficacy and Hypoglycemia Outcomes with Once-Weekly IcoSema vs. Comparators in T2D by Baseline BMI: COMBINE 1–3","DAISUKE YABE","2026","Diabetes","other_trial","article","10.2337/db26-1758-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037588","Patient Attitudes Toward GLP-1 Receptor Agonists","Elle Cunningham","2026","ScholarWorks -A service of University of Vermont Libraries (University of Vermont)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037589","Kniearthrose: Lange GLP-1RA-Therapie ist krankheitsmodifizierend",null,"2024","Aktuelle Rheumatologie","other","article","10.1055/a-2183-6149",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037590","680-P: Effect of the FreeStyle Libre System on Diabetes Treatment for People with T2D: Results from a Retrospective Cohort Study Using Canadian Private Payer Claims Database","Stewart B. Harris","2022","Diabetes","nonrandomized_study","article","10.2337/db22-680-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037591","874-P: Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes","Jiaqiang Zhou","2025","Diabetes","randomized_trial","article","10.2337/db25-874-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037592","P24 - Subocclusive ileus following off-label high-dose semaglutide use","A Nikolaeva","2025","European Journal of Endocrinology","other","article","10.1093/ejendo/lvaf168.055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0037593","Multi-day administration of the GLP-1 agonist, exendin-4, reduces food intake and body weight and prevents fasting related alterations in hypothalamic gene expression","Chantelle E. Terrillion","2009","Appetite","other","article","10.1016/j.appet.2009.04.191",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037594","Maintaining Muscle Mass on GLP-1s","Krumholz, Sarah","2025","ScholarWorks -A service of University of Vermont Libraries (University of Vermont)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037595","Gefäßprotektion – Nutzen über den HBA1chinaus",null,"2010","Diabetes aktuell","other","article","10.1055/s-0030-1268098",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037596","Triple G Agonists — A Home Run for Obesity?","Mary‐Elizabeth Patti","2023","New England Journal of Medicine","other_trial","article","10.1056/nejme2307282","37590453",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037597","HX05 From toxic bite to therapeutic benefit: the Gila monster and the history of glucagon-like peptide-1 agonists","Sarah Dyson","2026","British Journal of Dermatology","other","article","10.1093/bjd/ljag086.536",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037598","Effets à 3 mois du changement de l'insulinothérapie par le liraglutide chez des patients diabétiques de type 2 (résultats intermédiaires) /","FARIGON, Nicolas","2011","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0037599","Efficacy of Once-weekly GLP 1 analogue: Semaglutide. A Multicenter Experience from Pakistan",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.03.031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037600","Pharmacokinetics and tolerability of a novel long acting glucagon-like-peptide-1 analog CJC-1131","A VANVLIETMDPHD","2005","Clinical Pharmacology & Therapeutics","other","article","10.1016/j.clpt.2004.12.102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037601","Development And Validation Of A Novel Reverse-Phase HPLC Method For Impurity Profiling In Advanced Anti-Diabetic Drugs: Amycretin And Teplizumab","Manjunath Naik","2024","African Journal of Biomedical Research","other","article","10.53555/ajbr.v27i4s.5622",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037602","Contribution to Safety Assessment of New Antidiabetics during Pregnancy – A Placenta-based $\\textit{Ex Vivo}$ and $\\textit{In Vitro}$ Study","Sabrina Kuoni","2026","Zurich Open Repository and Archive (University of Zurich)","preclinical","article","10.5167/uzh-434704",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037603","Coste-efectividad de la insulina de acción intermedia o larga contra Exenatide en pacientes con diabetes mellitus tipo 2 no óptimamente controlados con antidiabéticos orales","Edwards,Krystal L.","2006","Scientific Electronic library online (Sciences Carlos III Health Institute)","other","article","10.4321/s1885-642x2006000300005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037604","Comparison of Safety Profile of Semaglutide, Tirzepatide, and Liraglutide in Obese Patients: FAERS Database Investigation","Yash P. Ashara","2025","Spartan Medical Research Journal","nonrandomized_study","article","10.51894/001c.143624",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037605","2100-P: Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) or GLP-1RA/Glucose-Dependent Insulinotropic Polypeptide RA (GLP-1/GIPRA) Effects in Youth/Young Adults (Y/YA) with Type 1 Diabetes and Characteristics of Nonresponders","LAUREN A. WATERMAN","2026","Diabetes","other_trial","article","10.2337/db26-2100-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037606","Insulinoma Localization by Glucagon-Like Peptide-1 Receptor Imaging After 18 Years of Hypoglycemia","Aglaia Kyrilli","2015","AACE Clinical Case Reports","other","article","10.4158/ep14427.cr",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037607","1082-P: Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes","Alexander Kutz","2022","Diabetes","nonrandomized_study","article","10.2337/db22-1082-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037608","26-A-13902-ACC COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS VS. SGLT2 INHIBITORS IN OBESE PATIENTS WITH HFPEF: A PROPENSITY-MATCHED ANALYSIS","Ammad Naeem","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1894",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037609","Practice patterns and Outcomes following once weekly semaglutide shortage in Thailand: Theptarin Hospital' s experience","Yotsapon Thewjitcharoen","2023",null,"other","article","10.13140/rg.2.2.28886.83526",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037610","HFPEF AND GLYCEMIC VARIABILITY: GHIDD TRIAL","Giovanni Fazio","2024","European Heart Journal Supplements","other_trial","article","10.1093/eurheartjsupp/suae036.053",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract; article"],["R0037611","P121 Treatment with semaglutide improves the systemic inflammatory burden associated with hidradenitis suppurativa","Lisa Killion","2025","British Journal of Dermatology","nonrandomized_study","article","10.1093/bjd/ljaf085.149",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0037612","264-OR: Effect of Tirzepatide on Kidney Function in People with Excess Body Weight and Type 2 Diabetes—A Post-Hoc Analysis of the SURMOUNT-2 Trial","Hiddo J.L. Heerspink","2024","Diabetes","randomized_trial","article","10.2337/db24-264-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037613","MOESM3 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Robyn Bruen","2017","Figshare","preclinical","article","10.6084/m9.figshare.5577019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0037614","Clinical and laboratory characteristics of exenatide-given patients in endocrinology clinic of a university hospital","Faruk Kılınç","2014","Dicle Medical Journal / Dicle Tip Dergisi","other","article","10.5798/diclemedj.0921.2014.01.0386",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037615","S768 Efficacy and Safety of Tirzepatide for the Management of Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)","Monica Gaurdian","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001130532.17598.29",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0037616","Cost Effectiveness of Semaglutide Compared to Other Anti-Diabetic Medication in Treating Type 2 Diabetes – A Comprehensive Systematic Review and Meta-Analysis","Ziyun Liu","2025",null,"systematic_review","article","10.2337/figshare.28570043.v1",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","other"],["R0037617","Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients","Harreiter, Jürgen","2018","Figshare","other","article","10.6084/m9.figshare.6177200",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037618","From Hope to Silence: The Hidden Stories of 128,127 Patients in Discontinued and Unpublished Obesity Trials",null,"2025","Egyptian Society of Diabetes and Lipidology Journal","other","article","10.21608/esdlj.2025.456296",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037619","The future of cardiovascular and metabolic medical practice: evidence-based winds of change","Andrew J. Krentz","2020","Cardiovascular Endocrinology & Metabolism","other","article","10.1097/xce.0000000000000226","32803136",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037620","S2827 Comparative Efficacy of GLP-1 Receptor Agonists in the Treatment of Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis","Aria Khan","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001138768.29025.a3",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0037621","Identification of Subpopulations Exhibiting the Greatest Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide-1 Receptor Agonists—A Combined Analysis of Large Cardiovascular Outcome Trials","Yu Mi Kang","2018","Diabetes","randomized_trial","article","10.2337/db18-1064-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037622","Comparative risk of obesity-related cancer with glucagon-like protein-1 receptor agonists vs. bariatric surgery in patients with BMI ≥ 35.","Cindy Lin","2024","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2024.42.16_suppl.10508",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0037623","Ozempic, the ‘miracle drug,’ and the harmful idea of a future without fat","Fady Shanouda","2023",null,"other","article","10.64628/aam.gtu6jy4hx",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037624","Semaglutida no tratamento de obesidade e sobrepeso","Izadora Pires de Oliveira","2023","Research Society and Development","other","article","10.33448/rsd-v12i3.40656",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037625","GLP-1 receptor agonists and tirzepatide gall bladder-related AEs",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-36401-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037626","2034-P: Glycemic Outcomes for Patients with Type 2 Diabetes Mellitus (DM2) and Hemoglobin A1c ≥10% Managed in Primary Care and Endocrinology Clinics and Indications for Endocrinology Referral","VANESSA WILLIAMS","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2034-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037627","791-P: The Impact of Age on Response to Injectable Semaglutide—Insights from the Association of British Clinical Diabetologists’ Audit Programme","THOMAS S.J. CRABTREE","2024","Diabetes","nonrandomized_study","article","10.2337/db24-791-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037628","Novo Nordisk will acquire Cardior","Sarah Braner","2024","C&EN Global Enterprise","other_trial","article","10.1021/cen-10210-buscon16",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0037629","Efficacy and Safety of Weekly Glucagon-Like Receptor Agonist (GLP-1RA) Versus Daily Glucagon-Like Receptor Agonist (GLP-1RA) for Type 2 Diabetes: A Meta-Analysis of Data from Randomized Controlled Trials","Fudan Zhang","2022","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.4007186",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0037630","Glucagon like peptide-1 analogues analysis in whole blood samples by the use of LC-ESI-HRMS method","Nadia Arbouche","2025","Annales de Toxicologie Analytique","other","article","10.1016/j.toxac.2024.11.005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037631","Exenatide Modulates Neuronal Insulin Signalling in Parkinson’s Disease","Gulyani, Seema","2018","Open Research (University of Surrey)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0037632","Correlation of Weight loss and 36-Item Short Form Survey Total Score in Weight Management with Semaglutide Injection: Post-Hoc Analysis of Phase 3 Study",null,"2026","Endocrine Practice","other_trial","article","10.1016/j.eprac.2026.03.057",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037633","Ultrasound Monitored Regression in the Severity of Fatty Liver in Type 2 Diabetic Participants on Dulaglutide and Empagliflozin Therapy: A Real-world Study from India",null,"2025","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2025.09.118",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0037634","358-OR: Remote CGM Monitoring in People with Type 2 Diabetes (T2D) in an Under-resourced Setting","VALERIE F. RUELAS","2024","Diabetes","other","article","10.2337/db24-358-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037635","Outcomes Associated With GLP1 Receptor Agonist Use In Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review And Meta Analysis Of Randomized Control Trials","Brandon Berman","2026","Journal of Cardiac Failure","systematic_review","article","10.1016/j.cardfail.2025.11.075",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0037636","Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes",null,"2011","Clinical Medicine Reviews in Vascular Health","nonrandomized_study","article","10.4137/cmrvh.s1664",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037637","Use of GLP-1 agonists for weight loss increases risk of GI AEs",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-47379-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037638","73985 Association of GLP-1 Therapy with Reduced Biologic Initiation in Hidradenitis Suppurativa: A Retrospective Cohort Study","Eli Kasheri","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.268",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037639","Shifting paradigms in diabetes management: Metformin’s diminished role amid the rise of SGLT2 inhibitors and GLP-1 agonists","Joseph, Shawn","2024",null,"other","article","10.13140/rg.2.2.31408.26886",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037640","Are the Newer Antidiabetic Agents Worth the Cost?","Sudhakar Pemminati","2016","JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH","other","article","10.7860/jcdr/2016/17683.7384","27134895",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037641","S2597 Semaglutide Use Is Associated With Lower Risk of Cirrhosis Among Hospitalized Patients With Non-Alcoholic Fatty Liver Disease: A Nationwide Analysis Using the National Inpatient Sample","Harendra Kumar","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137848.14651.18",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037642","The Potential Role of GLP-1 Receptor Agonists for the Treatment of Alzheimer’s Disease","Tyler Oyang","2025","American journal of student research.","other","article","10.70251/hyjr2348.36594600",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037643","Abstract #216: A Systematic Review and Meta-Analysis of Randomized Controlled Trials in Use of GLP1 Receptor Agonists in Type 1 Diabetes Mellitus","Raju Panta","2017","Endocrine Practice","systematic_review","article","10.1016/s1530-891x(20)44336-8",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0037644","Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment","Blevins, Thomas","2018","Figshare","other","article","10.6084/m9.figshare.6217181",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037645","Non-arteritic anterior ischemic optic neuropathy combined with branch retinal vein obstruction: A case report","Hongxia Gong","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6189","37731577",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037646","Lixisenatide and Renal Outcomes in Patients with Type 2 Diabetes—A Post-Hoc Analysis of the ELIXA Trial","MARCEL A. MUSKIET","2018","Diabetes","other_trial","article","10.2337/db18-1060-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037647","WCN24-1289 EFFECT OF THE SEMAGLUTIDE IN ISCHEMIC ACUTE KIDNEY INJURY MODEL","Guilherme Henrique Ferreira Vieira","2024","Kidney International Reports","other","article","10.1016/j.ekir.2024.02.094",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037648","2565-P: Survodutide Induces Superior Weight Loss and Energy Expenditure Compared with Semaglutide in DIO Mice Housed at Thermoneutrality","MAFALDA PEREIRA","2026","Diabetes","preclinical","article","10.2337/db26-2565-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037649","Distorsión terapéutica y medicalización estética: análisis documental del uso off-label de semaglutida y liraglutida en personas sin patologías metabólicas","Cejudo Illescas, Roberto Carlos","2025","Dialnet (Universidad de la Rioja)","other","article","10.37811/cl_rcm.v9i3.17920",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037650","Effect of Glucagon‐Like Peptide‐1 Receptor Agonist (GLP1RA) on Hypertension‐Induced Atrial Remodelling","Zhe Yu Zhang","2018","The FASEB Journal","other","article","10.1096/fasebj.2018.32.1_supplement.715.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037651","Additional file 7 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","Rossing, Peter","2023","Figshare","other","article","10.6084/m9.figshare.26612693",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037652","Effect of Liraglutide on Type B Insulin Resistance Syndrome and Insulin Allergy in Type 2 Diabetes: A Case Report","Matsumoto, Yuko","2018","Figshare","case_report","article","10.6084/m9.figshare.5967040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037653","Ozempic para todos? Distopia farmacológica, desigualdade de acesso e a eterna promessa de cura","Cristiane Marques Seixas","2025","Physis Revista de Saúde Coletiva","other","article","10.1590/s0103-73312025350241pt",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037654","Development of transcutaneous vaccine by using microneedles technology","Ying‐Shu Quan","2024","Drug Delivery System","other","article","10.2745/dds.39.116",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037655","Tirzepatide: A Useful Addition for Treatment of Type 2 Diabetes and Obesity",null,"2021","International Journal of Diabetes & Metabolic Disorders","randomized_trial","article","10.33140/ijdmd.06.02.03",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037656","THE COMPREHENSIVE COMPARISON OF THE EFFICACY OF FIRST-LINE DRUGS IN THE TREATMENT OF TYPE II DIABETES: METFORMIN, GLP-1 AGONISTS, AND SGLT2 INHIBITORS","Anna Kamieniak","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3884",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037657","What proportion of patients fail NICE criteria for continuing GLP‐1 treatment beyond six months, and why?","Lars Wessels","2013","Practical Diabetes","other","article","10.1002/pdi.1775",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037658","S2634 GLP-1 Receptor Agonist Use Is Associated With Lower Risks of Cardiovascular and Kidney Outcomes in Type 2 Diabetic Liver Transplant Recipients","Emily Shu-Yen Chan","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137996.11428.4a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037659","409 Dose–Response Analysis of Tirzepatide and Acute Pancreatitis: An International Systematic Review and Quantitative Meta-Analysis of Randomised Trials","O Benny","2026","British journal of surgery","systematic_review","article","10.1093/bjs/znag063.671",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0037660","Additional file 4 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","Rossing, Peter","2023","Figshare","other","article","10.6084/m9.figshare.26612684",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037661","Additional file 4 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","Chan, Yi-Hsin","2022","Figshare","nonrandomized_study","article","10.6084/m9.figshare.20176135.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037662","(716) Divergent Trends in Testosterone and GLP-1 Prescribing Across the United States: A State-Level Analysis of Medicare Part D Data (2013–2025)","D Pohl","2026","The Journal of Sexual Medicine","nonrandomized_study","article","10.1093/jsxmed/qdag118.624",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037663","S321 Lower Incidence of Gastrointestinal Cancers in Sodium Glucose Co-Transporter-2 Inhibitor-Treated Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study in the United States","Shu-Yen Emily Chan","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000950924.49214.01",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037664","How Ozempic is Changing Dating: GLP-1 Weight Loss Medications Are Reshaping Body Confidence, Desire, and Stigma","Selena Piercy","2026","PsyArXiv (OSF Preprints)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0037665","Metabolic Adverse Effects of Second- and Third-Generation Antipsychotics: Mechanisms, Monitoring, and Management","Dr. Naineni Prakash Mahesh Kumar","2026","African Journal of Biomedical Research","other","article","10.69980/h",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037666","Editorial: Food, nutrition, and diets at net zero. 10 years of Frontiers in Nutrition","Johannes le Coutre","2025","Frontiers in Nutrition","nonrandomized_study","article","10.3389/fnut.2025.1600417","40342366",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0037667","228-OR: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids","John J. Suschak","2024","Diabetes","randomized_trial","article","10.2337/db24-228-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037668","When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm","Bruce W. Bode","2016","Endocrine Practice","other","article","10.1016/s1530-891x(20)42965-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037669","Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or caloric restriction and weight loss on glycemic control in ZDF rat","Abegg, Kathrin","2015","Zurich Open Repository and Archive (University of Zurich)","preclinical","article","10.5167/uzh-104034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037670","Pour le contrôle du diabète de type 2, Byetta® (exénatide), une alternative avant l’insuline est désormais disponible","J.-P. Sauvanet","2008","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(08)71690-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037671","1033-P: Effects of Benaglutide on Weight Loss, Metabolic Changes, and Sexual Hormones in PCOS","Jingyan Chen","2019","Diabetes","randomized_trial","article","10.2337/db19-1033-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037672","Abstract # P-28: Improved Clinical Outcomes with The Dual Therapies of a SGLT-2I and a GLP-1RA in Overweight/Obese People with T2 Diabetes, Real World Data From the Indian Subcontinent","Anant Nigam","2016","Endocrine Practice","nonrandomized_study","article","10.1016/s1530-891x(20)43841-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037673","Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease","Alan J. Garber","2011","Endocrine Practice","other","article","10.1016/s1530-891x(20)43147-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037674","Medicinal plants as a source of natural remedies in the management of diabetes","Zingisia Sitobo","2024","INNOSC Theranostics and Pharmacological Sciences","other","article","10.36922/itps.1885",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037675","4376 A RARE TWIST: CASE REPORT OF INTUSSUSCEPTION IN THE SETTING OF ROUX-EN-Y GASTRIC BYPASS AND SEMAGLUTIDE",null,"2026","Surgery for Obesity and Related Diseases","case_report","article","10.1016/j.soard.2026.02.373",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037676","G-371 Sector of Care Variations in Prescriptions of SGLT2 Inhibitors (SGLT2i) and GLP-1 Receptor Agonists (GLP-1 RA) in the US Military Health System (MHS)",null,"2025","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2025.02.372",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037677","1680-P: Prescribing Pattern of GLP-1 Receptor Agonists among People with Newly Diagnosed Type 2 Diabetes: A Retrospective Cohort Study","JOYCE Y-C. LEE","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1680-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037678","Sustaining metabolic health after GLP-1 RA discontinuation: Lifelong obesity care and practical tips for clinicians","Andrej Belančić","2026","Obesity Medicine","other","article","10.1016/j.obmed.2026.100707",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037679","4367 RESOLUTION OF OBESITY-ASSOCIATED DISEASES WITH REVISIONAL SURGERY VERSUS SEMAGLUTIDE FOLLOWING SUBOPTIMAL CLINICAL RESPONSE IN CLINICAL OBESITY",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.068",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037680","MOESM5 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Bruen, Robyn","2017","Figshare","preclinical","article","10.6084/m9.figshare.c.3923344_d7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0037681","Boosting Insulin Sensitivity: The Impact of GLP-1 Therapy in Type 1 Diabetes",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.248",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037682","Increase in falsified semaglutide detained in Ireland",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-48943-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037683","106-OR: Semaglutide Reduces Tumor Burden in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH with Advanced Fibrosis and HCC","Michael Feigh","2024","Diabetes","other_trial","article","10.2337/db24-106-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037684","GLP-1-Agonist Liraglutid verbessert Insulinsensitivität","Maddalena Angela Di Lellis","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2265-4843",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037685","Exenatide-loaded glucose-responsive microspheres for intelligent diabetic therapy","Yutong Wang","2017","Journal of Controlled Release","other","article","10.1016/j.jconrel.2017.03.365",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037686","Insulinoma Discovery After Tirzepatide Initiation Complicated by Postoperative Diabetes",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.466",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037687","Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA","Hunt, Barnaby","2018","Figshare","other","article","10.6084/m9.figshare.6406556",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037688","OP10 EFFICACY AND SAFETY OF LIRAGLUTIDE IN JAPANESE TYPE 2 DIABETIC PATIENTS TREATED OVER 2 YEARS","Hiroki Shimizu","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70216-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037689","Measures related to obstructive sleep apnea after tirzepatide treatment by baseline OSA severity: post-hoc analyses of SURMOUNT-OSA","B. Liao","2026","Sleep Medicine","other","article","10.1016/j.sleep.2025.108113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037690","IP16-18 BEYOND GLYCEMIC CONTROL: CONCURRENT GLP-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH REDUCED URINARY ADVERSE EVENTS FOLLOWING ONABOTULINUMTOXINA TREATMENT IN NON-DIABETIC ADULTS WITH OVERACTIVE BLADDER","Muhammed Hammad","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191360.00345.d8.18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037691","Customer Perceptions of the Social Media Marketing of Weight Loss Injections (WLIs)","Awad, Rawan","2025","American University of Bahrain","other","article","10.58014/aubh.30530051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037692","Hemosuccus Pancreaticus: Acute Pancreatitis Caused by GLP-1 Agonism","American Medical Association 2025","2025","Underline Science Inc.","other","article","10.48448/kc1f-mg17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037693","TIRZEPATIDE FOR CARDIOVASCULAR RISK REDUCTION: A LITERATURE REVIEW","Elhatra Settaf-Cherif","2025","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.3(47).2025.3989",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037694","Update to delivering medications via a pneumatic tube system","Phyllis Wang","2017","American Journal of Health-System Pharmacy","nonrandomized_study","article","10.2146/ajhp150107","28947520",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037695","Semaglutide's Role in Modulating the Brain-Heart Axis: Implications for Obesity and Alzheimer’s Disease Co-management","Abhimanyu Gupta","2025","International Journal of Health Medicine and Nursing Practice","other","article","10.47941/ijhmnp.3122",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037696","GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes with CKD stages 2–4: a target trial emulation","Yung‐Chih Chen","2026","Diabetology & Metabolic Syndrome","randomized_trial","article","10.1186/s13098-026-02266-1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037697","Tirzepatide, Suatu Dual GIP dan GLP1-RA pada Diabetes Mellitus Tipe 2, Efektifkah? : Systematic Review","Sabran, Mohammad Zuhriansyah","2023",null,"systematic_review","article","10.13140/rg.2.2.16038.50247",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0037698","756-P: The Effect of Semaglutide on Alanine Aminotransferase (ALT) Levels: Results from the Association of British Clinical Diabetologists (ABCD) Audit","THOMAS S.J. CRABTREE","2022","Diabetes","nonrandomized_study","article","10.2337/db22-756-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037699","Editorial 5(17). Cambios urgentes en las prácticas agrícolas para mitigar el cambio climático","Muñoz-Rojas, Jesús","2020","Zenodo (CERN European Organization for Nuclear Research)","commentary","article","10.5281/zenodo.5093680",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0037700","Comparative Cardiometabolic and Hepatic Outcomes with Tirzepatide vs Semaglutide in Noncirrhotic Nonalcoholic Steatohepatitis: A Global Real-World TriNetX Study",null,"2026","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2026.01.310",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037701","Typ-2-Diabetes und Adipositas: Orforglipron unterstützt Gewichtsreduktion",null,"2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2754-5738",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037702","Reporting on Adverse Clinical Events",null,"2013","Clin-Alert","other","article","10.1177/0069477013485219",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037703","From guidelines to practice: An Audit of Tirzepatide Prescribing at LNWUH","Sidhu, Parminder","2025",null,"other","article","10.13140/rg.2.2.35839.52641",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037704","Liraglutide Blocks Platelet Activation And Thrombus Formation by Inhibiting Camp- and Cgmp-Induced Vasp Signaling","Yi Li","2022","SSRN Electronic Journal","other","article","10.2139/ssrn.4052762",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0037705","Erfahrungen mit dem Inkretin-Mimetikum Byetta® - \"Effektive HbA1c-Reduktion und Gewichtsabnahme überzeugen\"",null,"2007","Notfall & Hausarztmedizin","other","article","10.1055/s-2007-991565",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037706","P2826Teneligliptin attenuated AngII-induced cardiac hypertrophy by inhibiting Nox4-HDAC4 axis","Kazuto Okabe","2018","European Heart Journal","preclinical","article","10.1093/eurheartj/ehy565.p2826",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037707","Contemporary Strategies for Comorbid Obesity, Hypertension, and Chronic Heart Failure in Primary Care: An Evidence-Based Perspective","Mathialagan Ramalingam","2024","Special journal of the Medical Academy and other Life Sciences","other","article","10.58676/sjmas.v2i10.98",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037708","Effects of Preoperative Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss After Bariatric Surgery","Mona Abdel‐Bary","2025","Bariatric Surgical Practice and Patient Care","nonrandomized_study","article","10.1177/2168023x251389594",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037709","Fracture Risk After Initiation of Use of Canagliflozin","Hema Padmanabhan","2019","Annals of Internal Medicine","nonrandomized_study","article","10.7326/l19-0319","31261402",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037710","736-P: Comparison of Semaglutide vs. Tirzepatide Therapy in Adults with Type 1 Diabetes (T1D)","HENON GEBRE","2024","Diabetes","nonrandomized_study","article","10.2337/db24-736-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037711","1.17 GLP-1 Agonists in Substance Use Disorders: What Does the Adolescent Psychiatrist Need to Know?","Kevin Pendo","2025","Journal of the American Academy of Child & Adolescent Psychiatry","other","article","10.1016/j.jaac.2025.08.046",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037712","Effect of GLP-1 receptor agonists on obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis","Αγγελούδη, Ελένη Μιχαήλ","2019","Aristotle University of Thessaloniki","systematic_review","article","10.26262/heal.auth.ir.305070",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0037713","787-P: Individualized Estimated GFR Slope Analysis Is Needed to Preserve Renal Function by SGLT2 Inhibitors in Patients with DKD","Koji Kashima","2021","Diabetes","other","article","10.2337/db21-787-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037714","2923-LB: A Remote Program for Navigator- and Pharmacist-Led Implementation of Obesity Medications","John Ostrominski","2026","Diabetes","other","article","10.2337/db26-2923-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037715","La glycation de l’albumine altère sa liaison au liraglutide","Angélique Galahi Soudahome","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30428-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037716","Actions of Liraglutide on Vascular Endothelial Cells Play a Central Role in the Suppression of Atherosclerosis in Diabetic Mice","Munenori Hiromura","2018","Diabetes","randomized_trial","article","10.2337/db18-487-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037717","Predictive Factors of Insulin Discontinuation after Adding a GLP-1 Receptor Agonist in Patients with Type 2 Diabetes Treated with Insulin in Combination with Oral Antihyperglycemic Agents","Juan José Gorgojo Martínez","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1099-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037718","PO418 PREDICTION OF RESPONSE TO GLP-1 RECEPTOR AGONIST THERAPY IN JAPANESE PATIENTS WITH TYPE 2 DIABETES","Kentaro Imai","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70712-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037719","Reversing Fetal Undernutrition by Kick-Starting Early Growth","Kartik Shankar","2015","Endocrinology","nonrandomized_study","article","10.1210/en.2015-1625","26295490",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037720","A vese védelmében és azon is túl : A renoprotekció új lehetőségei = For kidney protection and beyond : New possibilities of renoprotection","Balogh, Dóra Bianka","2023","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0037721","Glucagon-like peptide 1 receptor agonists improve prognosis of patients with inflammatory bowel disease","J Jishu","2026","The American Journal of the Medical Sciences","other","article","10.1016/j.amjms.2025.12.562",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037722","76073 Patient Perspectives on Dermatologic Effects of GLP-1 Receptor Agonists: A Qualitative Content Analysis of a Social Media Platform","Megan Hoang","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.1312",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037723","Comparative Effectiveness of SGLT-2 Inhibitors versus GLP-1 Receptor Agonists on Recurrent Cardiovascular Events in Patients with Type 2 Diabetes After Acute Ischemic Stroke: A Target Trial Emulation Using Chinese Insurance Claims Data","Yuliang Xiang","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/a3yht",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other; preprint"],["R0037724","2578-P: Retatrutide Enhances Weight Loss in Female Mice and Preserves Muscle Mass, Strength, and Mitochondrial Efficiency","KYLE BAUM","2026","Diabetes","preclinical","article","10.2337/db26-2578-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037725","Novel Roles of GLP-1 and GLP-2 in the Regulation of Hepatic Lipid/Lipoprotein Homeostasis and the Involvement of BAT Activation","Jennifer Taher","2017","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037726","An Escape From Diabetes","Neda Rasouli","2020","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgaa401","32597475",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0037727","Factors Influencing Adherence to GLP-1 Receptor Agonist Therapy Among Patients Receiving Weight-Loss Injections","Rasha Salem Salama Alrehaili","2026","Saudi Journal of Medicine and Public Health","randomized_trial","article","10.64483/202631737",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0037728","Effect of Dulaglutide versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study","Nagaike, Hiroe","2018","Figshare","other","article","10.6084/m9.figshare.7485179",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037729","A Novel Neutrotrophic Property Of Glucagon‐Like Peptide 1: A Promoter Of Nerve Growth Factor‐Mediated Differentiation In PC12 Cells","TracyAnn Perry","2002","Journal of the Peripheral Nervous System","preclinical","article","10.1046/j.1529-8027.2002.02026_3.x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037730","P137. Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion","Mitchell K. Ng","2025","The Spine Journal","other","article","10.1016/j.spinee.2025.08.138",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037731","407-P: Kidney Transplant Infection Risks—CGM Parameters Insights and Glucagon-Like Peptide-1 Receptor Agonist (GLP1-RA) Strategies","M Campana","2024","Diabetes","other","article","10.2337/db24-407-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037732","Effect of GLP-1 Receptor Agonist on Acute Myocardial Infarction and Post-MI Chronic Heart Failure in Rats","Ismayil Ahmet","2009","Journal of Cardiac Failure","preclinical","article","10.1016/j.cardfail.2009.06.164",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037733","MOESM7 of Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway","Feng, Yun","2020","Figshare","other","article","10.6084/m9.figshare.11508126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037734","443-P: Two-Year Results from a Novel, Patient-Centered, Team-Based Intervention for Patients with Type 2 Diabetes at High Cardiovascular Risk","Ala’ Arafah","2023","Diabetes","other","article","10.2337/db23-443-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037735","Maintaining Weight Loss After Discontinuance of GLP-1 Receptor Agonists","Morazzano, Rickey J","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037736","The year in pharma","Rowan Walrath, Aayushi Pratap, and Sarah Braner","2025","C&EN Global Enterprise","other","article","10.1021/cen-10323-feature3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037737","Weekly Journal Scan: REDEFINing the next generation of obesity pharmacotherapy","Giovanna Liuzzo","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf628","40973647",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037738","Falsified Ozempic pens in the EU and UK",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-48194-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037739","MOESM3 of Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism","Yang, Sheng-Hua","2018","Figshare","preclinical","article","10.6084/m9.figshare.6094196",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037740","MOESM2 of Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway","Feng, Yun","2020","Figshare","other","article","10.6084/m9.figshare.11508087",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037741","A Real-World Observational Study Evaluating Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes","Baxter, Mike","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.12264179",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037742","759-P: Changes in Liver Fat in Patients with Type 2 Diabetes by Presence of Genetic Hepatic Steatosis in the SURPASS-3 MRI Substudy","KENNETH CUSI","2023","Diabetes","other_trial","article","10.2337/db23-759-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037743","Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients With Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study","journals on behalf of:, Adis","2025","Figshare","nonrandomized_study","article","10.6084/m9.figshare.30580040",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037744","Peripheral eosinophilia with eosinophilic gastroenteritis associated with semaglutide: a case report and literature review","Abrar A. Oraijah","2026","International Journal of Research in Medical Sciences","case_report","article","10.18203/2320-6012.ijrms20262657",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037745","COMPARISON OF GLP-1 AGONIST, LIFE STYLE AND DIET MODIFICATION VS GLP-1 AGONIST ALONE FOR TREATMENT OF DIABETIC PATIENTS WITH MASLD","Fabiha Faiz","2026","Genetics and Molecular Research","randomized_trial","article","10.4238/rhvv0512",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0037746","Association between Glp-1 Receptor Agonist Plus Aspirin Use and Cardiovascular Outcomes in Non-Diabetic Obese Individuals: A Multi-Institutional Cohort Study","Chia-Ming Lin","2024","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.4845143",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0037747","Evaluation of effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on estimated glomerular filtration rate, albuminuria and weight in diabetic kidney disease: A prospective cohort study","Hayder Aledan","2023","Journal of Renal Injury Prevention","nonrandomized_study","article","10.34172/jrip.2023.32062",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037748","Opinion Mining and Multi-Label Classification of Patient-Generated Long-Term Anti-Obesity Medication Reviews (Preprint)","Kyrian Ezendu","2021",null,"nonrandomized_study","article","10.2196/preprints.32397",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0037749","266-OR: Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity","JULIO ROSENSTOCK","2024","Diabetes","randomized_trial","article","10.2337/db24-266-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037750","2345-PUB: Exploring Patient Factors Contributing to Enhanced Efficacy of Incretin-Related Drugs with Add-On SGLT2 Inhibitor Therapy in Reducing Glycemic Variability (GV)","Tetsurou Onishi","2019","Diabetes","other","article","10.2337/db19-2345-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037751","Dry Beriberi Presenting as Severe Sensorimotor Polyneuropathy Associated with Semaglutide-Related Thiamine Deficiency","Chloe Cohan¹","2026",null,"other","article","10.13140/rg.2.2.33473.52324",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037752","Lilly (Eli) & Co.",null,"2006","Mergent s Dividend Achievers","other","article","10.1002/div.3974",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037753","Early Comparative Effectiveness of GLP-1RA Versus SGLT2i After Myocardial Infarction in Patients With Diabetes","N Ray Chaudhuri","2026","Heart Lung and Circulation","other","article","10.1016/j.hlc.2026.07.988",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037754","956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin","Ofri Mosenzon","2020","Diabetes","randomized_trial","article","10.2337/db20-956-p",null,null,"ClinicalTrials.gov:NCT03021187","S002369","openalex","FALSE","paywalled","1","FALSE","article"],["R0037755","Novel preventive cardiology clinic associated with reduced risk of recurrent major adverse cardiovascular events for patients with prior acute coronary syndrome","J Y Chen","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.3641",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037756","Szemaglutid és a kardiovaszkuláris kockázat – a SUSTAIN-6 vizsgálat eredményei [Semaglutide and cardiovascular risk – results from the SUSTAIN-6 clinical trial]","Jermendy, György","2019","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0037757","Redefining Diabetes Management: From Escalating Insulin to Overcoming Insulin Resistance — The Complete Evidence-Based Framework And Role of Insulin In Systemic Organ Damage, Oncogenesis, Clinical Trial Evidence, and Historical Warnings.","Aditya Mishra","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19014349",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0037758","Management of type 2 diabetes: the role of incretin mimetics","John H. Holcombe","2006","Drug Development Research","other","article","10.1002/ddr.20120",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037759","Brain circuits for satiety and nausea","Kuei-Pin Huang","2023","Physiology","preclinical","article","10.1152/physiol.2023.38.s1.5763559",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037760","Assessment of acute pancreatitis in liraglutide type 2 diabetes trials","T.M. Jensen","2013","Pancreatology","other","article","10.1016/j.pan.2012.12.186",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037761","4339 UNDERSTANDING INSURANCE-BASED DIFFERENTIAL HEALTHCARE COSTS FOR GLP-1 RA VERSUS BARIATRIC SURGERY",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037762","409-P: Post Hoc Analyses of Longitudinal Changes of Plasma Proteins Associated with Progression to End-Stage Kidney Disease in Type 2 Diabetes Patients with Chronic Kidney Disease Treated with GLP-1 Receptor Agonist Dulaglutide (AWARD-7)","Brandon E. McFarlin","2023","Diabetes","other_trial","article","10.2337/db23-409-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037763","The MUSCLE-GLP1-CKD study: design and rationale of a prospective real-world cohort evaluating muscle health after subcutaneous semaglutide initiation in chronic kidney disease and type 2 diabetes","Manuel Macía-Heras","2026","BMC Nephrology","protocol","article","10.1186/s12882-026-05304-2",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0037764","Tirzepatide — A Twin cretin in Obesity Patients: A Comprehensive Review & Recent updates","Shruti Chandra","2026","International Journal of Drug Delivery Technology","nonrandomized_study","article","10.25258/ijddt.16.35s.70",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037765","Impact of GLP-1 RA plus progestin therapy on conservative management of endometrial cancer and endometrial intraepithelial neoplasia","Tina Yi Jin Hsieh","2026","Gynecologic Oncology","other","article","10.1016/j.ygyno.2026.01.078",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037766","Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study","Martinez, Luc","2018","Figshare","other","article","10.6084/m9.figshare.6411146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037767","Pattern of the use of anti-obesity drugs among obese population and their adherence to better lifestyle","M. R. Mahmoud","2025","Journal of Pioneering Medical Science","other","article","10.47310/jpms2025140916",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037768","S87 Early Signs of Pancreas Adenocarcinoma Are Often Missed on Cross-Sectional Imaging: Results From a Multicenter Cohort Study","Benjamin M. Moy","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001126808.04121.09",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037769","Effect of liraglutide and metformin on constitution, metabolism and micro-inflammatory state in newly diagnosed type 2 diabetic mellitus patients with obesity","Xiu-Ping Han","2016","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037770","Unlocking the Mysteries of Epicardial Adipose Tissue: Implications of Cardiometabolic Syndrome","Federico Cacciapuoti","2024","Research in Cardiovascular Medicine","other","article","10.4103/rcm.rcm_11_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037771","Pharmacists keep ahead of evolving diabetes care standards","Kate Traynor","2019","American Journal of Health-System Pharmacy","other","article","10.1093/ajhp/zxz091","31187854",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037772","Judicious use of modern technology with antihyperglycemic agents: The changing landscape of type 2 diabetes management","Brijendra Kumar Srivastava","2024","Journal of Diabetology","other","article","10.4103/jod.jod_127_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037773","Regulating effect of liraglutide therapy on metabolic disorders in patients with newly diagnosed type 2 diabetes complicated with obesity","Dongmei Gao","2017","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037774","The modulating effect of differences in cardiovascular risk factors on major cardiovascular outcomes in glucose-lowering trials","Danijela Gašević","2019","Journal of Hypertension","randomized_trial","article","10.1097/hjh.0000000000002181","31464860",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037775","1833-P: National Patterns of SGLT2i and GLP-1RA Use in U.S. Cancer Survivors with Diabetes","ELLE BILLMAN","2026","Diabetes","other","article","10.2337/db26-1833-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037776","1969-P: Time-Based Internalized Characterization of Exendin-4-Based Glucagon-Like Peptide-1 Receptor-Targeting Imaging Probe","Takaaki Murakami","2019","Diabetes","preclinical","article","10.2337/db19-1969-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037777","Su2051: ANALYZING THE GASTROINTESTINAL BURDEN OF GLP-1 AGONISTS: A RETROSPECTIVE FAERS ANALYSIS OF ADVERSE EVENTS","Mohamed Ebrahim","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03103-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037778","Impact of GLP-1 Receptor Agonists on Healing Outcomes in Diabetic Patients With Chronic Venous Ulcers","Estefania Narvaez","2026","Journal of Vascular Surgery Venous and Lymphatic Disorders","other","article","10.1016/j.jvsv.2025.102404",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037779","The role of semaglutide in the treatment of type 2 diabetes mellitus in a female patient with sarcopenia: A clinical case","E.V. Uzhakova Uzhakova","2026","Therapy","other","article","10.18565/therapy.2026.4.146-151",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037780","Real-world effectiveness of once-weekly Semaglutide in type 2 diabetes: insights from Pak. diabetes effectiveness study","M.U. Wahab","2025","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/j.diabres.2025.112853",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037781","Exenatide Improves the Luteinizing Hormone Pulse in Obese Polycystic Ovary Syndrome Rats by Upregulating Sirtuin-1 in the Hypothalamus","Bo Lv","2022","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4195255",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0037782","Novel GLP-1 analogues cross the blood brain barrier and enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease","Christian Hölscher","2009","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037783","One-year cardiovascular outcomes before and after GLP-1 ra discontinuation: a real-world retrospective cohort study","Amin Tajerian","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.1624",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037784","Glucagon-like Peptide Receptor Agonists (GLP-1 receptor agonists): A Powerful Addition to Foundational Therapy Kidney Care in Patients with Type 2 Diabetes Mellitus","Louis Girard","2024","Canadian Diabetes & Endocrinology Today","randomized_trial","article","10.58931/cdet.2024.2333",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0037785","Real-World Effectiveness and Tolerability of Indian Generic Semaglutide for Obesity: A Retrospective Observational Study from a Nationally Deployed Virtual Weight Management Programme","Darshit Jain","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7040941",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint; article"],["R0037786","SP459THE EFFICACY OF TREATMENT WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN CHRONIC DIALYSIS PATIENTS WITH DIABETES MELLITUS","Kazuhito Takeda","2017","Nephrology Dialysis Transplantation","other_trial","article","10.1093/ndt/gfx149.sp459",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037787","1842-P: GLP-1 Receptor Agonists Induce Lasting Cyclic-AMP Generation and Insulin Secretion in Beta Cells","Michelle Chan","2025","Diabetes","preclinical","article","10.2337/db25-1842-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037788","Comparative Efficacy of Tirzepatide and Semaglutide in the Treatment of Obesity: A Meta-analysis","Isadora Roza","2026","Medical Research Archives","systematic_review","article","10.18103/mra.v14i4.7392",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0037789","S1890 Safety and Weight Loss Outcomes of Tirzepatide in Obesity Patients With Inflammatory Bowel Disease: A Matched-Control Study","Jose Villamarin","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001135020.04175.da",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037790","S2552 Semaglutide Versus Sodium-Glucose Cotransporter-2 Inhibitors for Liver and Cardiovascular Outcomes in Metabolic Dysfunction-Associated Fatty Liver Disease: A Propensity Score-Matched Cohort Study","Ahmed Abuhasna","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137668.83929.70",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037791","442: IMPACT OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS ON SUBSPECIALTY AND WEIGHT LOSS SURGERY REFERRALS","T J Mathews","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)05326-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037792","An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis","Ugamura, Daisuke","2022","Figshare","nonrandomized_study","article","10.6084/m9.figshare.c.6042131.v1",null,null,"UMIN:UMIN000024283",null,"openalex","TRUE","paywalled","4","FALSE","other; article"],["R0037793","Is doing “nothing” the answer to American metabolic health: reviewing the benefits of fasting.","Mack, Ronald P, Jr","2022","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037794","IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON CARDIOVASCULAR OUTCOMES AND MORTALITY IN HYPERTROPHIC CARDIOMYOPATHY: A POPULATION-BASED COHORT STUDY","Rebecca Hsieh","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(25)01981-3",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037795","Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Patients with Type 2 Diabetes in the UK Setting","Capehorn, Matthew","2020","Figshare","other","article","10.6084/m9.figshare.13388420",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037796","Role of glucagon in treating diabetes: Evidence and concepts (胰高血糖素在糖尿病治疗中的作用：证据与概念)","Zachary T. Bloomgarden","2013","Journal of Diabetes","preclinical","article","10.1111/1753-0407.12107","24224965",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037797","GLP-1 receptor agonist prevents fatty infiltration in the rotator cuff muscle and enhances muscle contractility in rat models","J.P. Yoon","2026","JSES International","preclinical","article","10.1016/j.jseint.2025.101474",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037798","Body mass index-dependent therapeutic efficacy in heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction: A systematic review and network meta-analysis","Zhiqiang Ma","2025","Asian Heart Journal","systematic_review","article","10.1097/ah9.0000000000000024",null,null,"PROSPERO:CRD420251022550",null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0037799","Glucagon-like peptide-1 receptor agonist prevents pulmonary post-acute sequelae of COVID-19 associated with type 2 diabetes 3430","Runhong Zhou","2025","The Journal of Immunology","preclinical","article","10.1093/jimmun/vkaf283.1238",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037800","S1224 Double Trouble: The Effect of Opioid and GLP-1 Agonist Use on Peri- and Post-Operative Complications","Kyle Scholten","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001132356.72629.5e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037801","S1264 Comparison of Aspiration Risk in Patients Undergoing Upper Endoscopy vs Colonoscopy While on GLP-1 Agonist Therapy","Robert Molina","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001132516.80767.63",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037802","GLUCAGON-LIKE 1 RECEPTOR AGONIST USE WAS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A LARGE REAL-WORLD DATABASE STUDY","Amanda Johnson","2026","Inflammatory Bowel Diseases","nonrandomized_study","article","10.1093/ibd/izag006.159",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037803","382-P: Insulin Requirements after Hospital Discharge in Patients with Type 2 Diabetes","Maya Fayfman","2019","Diabetes","randomized_trial","article","10.2337/db19-382-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037804","Effect of Dulaglutide and Long-Acting Insulin Combination Therapy in Patients with Type 2 Diabetes","Kohei Ito","2018","Diabetes","other","article","10.2337/db18-1079-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037805","1218-OR: Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HDM1002) in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Diet and Exercise or Metformin","YIMING MU","2026","Diabetes","randomized_trial","article","10.2337/db26-1218-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037806","Effects of GLP-1 analog in the gut microbiota and attenuation of doxorubicin-induced cardiotoxicity in rats","Carolina Rodrigues [UNESP] Tonon","2024","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037807","Prevalência familiar elevada, automedicação e desinformação sobre Diabetes mellitus entre acadêmicos da área da saúde de uma universidade no Paraná, Brasil","M. Schulze","2025","Research Society and Development","other","article","10.33448/rsd-v14i11.49949",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037808","Assessing the Role of GLP-1 Receptor Agonists in Lung Transplantation: Risks and Benefits","Z. Dhanani","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a1870",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037809","Generation of transgenic cucumbers with expression of a ten-tandem repeat long-acting GLP-1 analogue and their biological function on diabetic rats","Lei Zhao","2009","中国科学通报：英文版","preclinical","article","10.1007/s11434-009-0699-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037810","Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target—Analyses from the DUAL Program","Luigi Meneghini","2018","Diabetes","other_trial","article","10.2337/db18-1109-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0037811","Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study","Peng, Zi-Yang","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.c.6866379",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037812","Les patients DT2 traités par IDegLira ont plus de chance d’atteindre différents objectifs cibles d’HbA1c sans hypoglycémies ni prises de poids versus insuline basale ou basale bolus","Emmanuel Disse","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.202",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037813","History and Professional Legacy of Nursing Certification","Sara Knippa","2024","Critical Care Nurse","other","article","10.4037/ccn2024655",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037814","SAT-100 Enhancing effects of combining resmetirom and semaglutide in a modified AMLN diet-induced mouse model for metabolic dysfunction-associated steatohepatitis (MASH)","Tai-Yu Huang","2026","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(26)01767-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037815","Pancreatic and Gallbladder safety profile of Tirzepatide in Obesity Management: A Scoping Review of Clinical and Real-World Evidence.","Tetiana Kutsyba","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.21095264",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0037816","Weight loss effect of Glucagon-like peptide-1 receptor agonists in obese, non- diabetic patients: A systematic review and meta-analysis","Πιέτρη, Αικατερίνη Χρήστου","2018","Aristotle University of Thessaloniki","systematic_review","article","10.26262/heal.auth.ir.298390",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0037817","IMPACT OF CELEBRITY STATEMENTS ON INTERNET SEARCHES ON THE USE OF SEMAGLUTIDE FOR WEIGHT LOSS","Local Health Unit of Trapani, ASP Trapani, Trapani, Italy","2025","Avicenna Bulletin","other","article","10.25005/2074-0581-2025-27-2-373-384",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037818","Mitochondrial SIRT3 is upregulated by Glucagon-like peptide-1 receptor activation and contributes to reversal of cardiac mitochondrial remodeling induced by type 2 diabetes","Akio Monji","2013","European Heart Journal","preclinical","article","10.1093/eurheartj/eht308.778",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037819","Corrigendum to “Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting” [Diabetes Metab. Syndr. Clin. Res. Rev. 9 (1) (2015) 30–33]","Jothydev Kesavadev","2015","Diabetes & Metabolic Syndrome Clinical Research & Reviews","nonrandomized_study","article","10.1016/j.dsx.2015.07.001",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","erratum"],["R0037820","Effect of glucagon-like peptide 1 receptor agonism on exercise blood pressure: genome-wide association and mendelian randomization analyses","Caden Rowan","2026","Physiology","nonrandomized_study","article","10.1152/physiol.2026.41.s1.2300122",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037821","Case 65: Novel Combination Therapy for Type 2 Diabetes","Donna L. White","2015","American Diabetes Association eBooks","other","article","10.2337/9781580405713.65",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0037822","Abstract MPTU11: Prediabetes Progression In Young American Adults: A Pooling Project","Mary Rooney","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.mptu11",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037823","1347 Impact of Comorbid Obstructive Sleep Apnea on Pharmacological Treatment Selection for Type 2 Diabetes Mellitus","Chien‐Yu Tseng","2025","SLEEP","nonrandomized_study","article","10.1093/sleep/zsaf090.1347",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037824","Su2071: RISK OF SUICIDE AND SELF HARM BEHAVIOR IN PATIENTS ON GLP-1 RECEPTOR AGONISTS: SYSTEMATIC REVIEW OF DISPROPORTIONALITY ANALYSIS AND A META-ANALYSIS OF PUBLISHED STUDIES","Vishal Singh Chandel","2025","Gastroenterology","systematic_review","article","10.1016/s0016-5085(25)03123-3",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0037825","1707-P: Direct Assessment of Gastric Emptying Kinetics Using Barium Meal Administration in Semaglutide-Treated Nonhuman Primates (NHPs)","GUOKU LIU","2025","Diabetes","other","article","10.2337/db25-1707-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037826","New generations of GLP-1 agonists in the treatment of obesity: Evolution of weight-loss pens and clinical impact","Jamile Zampieri Fernandes","2026","International Health Sciences Review","randomized_trial","article","10.70164/ihsr.v2i2.144",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0037827","Use of Semaglutide for Successful Weight Loss and Maintenance in a Non- Obese Population: An Observational Study - Figures and Tables","Giese, Sharon","2025","Figshare","other","article","10.6084/m9.figshare.29361653",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037828","Evaluation of Insulin and Glucagon-like peptide-1 Receptor Agonists Combination for Type 2 Diabetes Mellitus: An Updated Meta-analysis","Raed Aldahash","2024","Majmaah Journal of Health Sciences","systematic_review","article","10.5455/mjhs.2024.03.015",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0037829","High-fat diet induced impairment in exendin-4-induced anorexia emerges quickly and is reversed by return to chow diet","Diana L. Williams","2011","Appetite","other","article","10.1016/j.appet.2011.05.294",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037830","40 | Does Tirzepatide Lead to an Improvement in Joint Symptoms Among Patients With Inflammatory Arthropathies? A Retrospective Analysis",null,"2026","International Journal of Rheumatic Diseases","nonrandomized_study","article","10.1111/1756-185x.70608_53",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037831","The use of glucagon-like peptide 1 (GLP-1) receptor agonists for primary and secondary prevention of chronic kidney disease","Marcos Aguirre Sáez","2025","e_Buah","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037832","943-P: Improvement in Glycemic Variability with Dulaglutide Therapy Evaluated by Continuous Glucose Monitoring System: A Real-World Experience of Indian Patients with Type 2 DM","SONALI A. PATANGE","2019","Diabetes","nonrandomized_study","article","10.2337/db19-943-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037833","Peptide aggregation: Physical stability of therapeutic glucagon-like peptide 1 analogues","Brichtova, Eva","2020",null,"other","article","10.13140/rg.2.2.16739.50726",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037834","A Diabetes RELIEF Initiative: Realizing the Potential of GLP-1 Receptor Agonists in Type 2 Diabetes: Partnering with Patients to Improve Glycemic and Cardiovascular Outcomes","Mustafa, Nasir","2023",null,"other","article","10.13140/rg.2.2.20938.13767",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037835","S790 Risk of Neuroendocrine Neoplasms With Glucagon-Like-Petide-1 Receptor Agonist Use in Patients With Type 2 Diabetes Mellitus","Gordon Hong","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130620.01386.2d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037836","Comparative Risk of Pancreatitis and Related Outcomes in Diabetic Patients Using GLP-1 Receptor Agonists versus DPP-4 Inhibitors: A Propensity-matched Cohort Study",null,"2025","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2025.09.062",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037837","Clinical aspects of semaglutide therapy: How to choose the optimal drug?","N.V. Mazurina Mazurina","2026","Therapy","other","article","10.18565/therapy.2026.4.183-189",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037838","Investigating drug effects on aging and alzheimer's disease using causal inference approaches","Bowen Tang","2025",null,"randomized_trial","article","10.69622/27889941",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0037839","Exploring the preventive role of GLP-1 receptor agonists in reducing pulmonary hypertension in diabetes: a multimodal analysis","Arif Albulushi","2025","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf236.094",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037840","Use of glucagon-glucagon-like peptide 1 dual agonist as a positive inotropic agent for treatment of heart disease such as congestive heart failure, systolic dysfunction, myocardial infarction, and diabetic cardiomyopathy.","Jørgen Søberg Petersen","2011","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037841","Glucagon-like Peptide 1 Receptor Agonist Use is Associated with Decreased Risk of Postoperative Complications Following Total Knee Arthroplasty: A Propensity Matched Comparison","Bowers, Cameron","2025",null,"nonrandomized_study","article","10.13140/rg.2.2.21133.24802",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0037842","5PSQ-014 Electronic communication of the discontinuation of home treatment prescribed to patients in a tertiary level hospital","A Martín Roldán","2024","Section 5: Patient safety and quality assurance","other","article","10.1136/ejhpharm-2024-eahp.348",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0037843","1477-PUB: The Comparison between Sodium–Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist Treatment Depending on the Change in Blood Pressure in Japanese Patients with Type 2 Diabetes Mellitus on the Renal Function","Kazuo Kobayashi","2022","Diabetes","nonrandomized_study","article","10.2337/db22-1477-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037844","Falsified Ozempic (semaglutide) and Saxenda (liraglutide)",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-51307-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037845","Возможности применения ингибитора натрий- глюкозного котранспортера 2-го типа","И.Р. Агабабян","2024","Кардиология в Беларуси","other","article","10.34883/pi.2024.16.4.011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037846","M2047 Mechanism of ROSE-010 Action is Similar to That of GLP-1 and Mediated by the Exendin Receptor: Comparison With GLP-2 and Glucagon","Per M. Hellström","2010","Gastroenterology","other","article","10.1016/s0016-5085(10)62155-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037847","0496 The immunometabolic effects of glucagon-like peptide-1 receptor agonists in psoriasis and hidradenitis suppurativa","J.K. Morales","2026","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2026.06.527",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037848","Cyclin dependent kinase 5 (CDK5): a possible link between neuropathologies and diabetes","Jessica Lee Stevens","2009","The FASEB Journal","preclinical","article","10.1096/fasebj.23.1_supplement.492.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037849","Annals for Educators - 4 February 2020","Darren B. Taichman","2020","Annals of Internal Medicine","nonrandomized_study","article","10.7326/awed202002040","32016339",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037850","Annals for Educators - 5 February 2019","Darren B. Taichman","2019","Annals of Internal Medicine","randomized_trial","article","10.7326/awed201902050","30716759",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037851","Abstract #806375: Once-Weekly Semaglutide Reduces HBA1C and Body Weight Across Baseline HBA1C Subgroups in the Sustain 1-5 and 7-10 Clinical Trials","Satish K. Garg","2020","Endocrine Practice","other","article","10.1016/s1530-891x(20)39696-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037852","METABOLIC MECHANISMS OF TIRZEPATIDE IN ADIPOSE TISSUE REDUCTION AND AESTHETIC IMPLICATIONS","Maria Eduarda Santos Izel","2026","Seven Editora eBooks","nonrandomized_study","article","10.56238/sevened2026.009-063",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","book-chapter"],["R0037853","S1261 Benefits of Glucagon-Like Peptide-1 Agonists Use in Patients With Inflammatory Bowel Disease","Alan Abboud","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001034412.42810.c5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037854","Effects of GLP-1RAs on the course of IBD and clinical outcomes in IBD patients, A systematic review article.","Roaa Haddad","2025",null,"systematic_review","article","10.13140/rg.2.2.14206.70727",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0037855","Semaglutide salt versus base formulations: a regulatory and pharmacovigilance imperative","M. Salguna S. Vivek","2026","International Journal of Basic & Clinical Pharmacology","nonrandomized_study","article","10.18203/2319-2003.ijbcp20261130",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037856","Precision Treatment of Metabolic Subtypes in Major Depressive Disorder – Multi-Tissue Transcriptome-Wide Association Reveals Mitochondrial-NAD-Insulin Axis Drivers of Symptom Heterogeneity","Ngo Cheung","2026","Figshare","nonrandomized_study","article","10.6084/m9.figshare.31939008.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0037857","Sicurezza ed efficacia della liraglutide in pazienti con steatoepatite non alcolica (LEAN): uno studio di fase 2, multicentrico, doppio cieco, randomizzato, con controllo placebo","Riccardo C. Bonadonna","2016","L Endocrinologo","other","article","10.1007/s40619-016-0201-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037858","CDK5: A Contributor to the Insulin Phenotype of Transdifferentiated β Cells","Jessica Lee Stevens","2008","The FASEB Journal","preclinical","article","10.1096/fasebj.22.1_supplement.638.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037859","GLP1-RAs as Second-Line Treatment in Type 2 Diabetics and their Cardiovascular Benefits","Paschen, Lee","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037860","The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease","Of, Adis Journals On Behalf","2021","Figshare","other","article","10.6084/m9.figshare.14077133",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037861","Su1960 Analysis of Inhibitory Action of Glucagon Like Peptide-1 (GLP-1) Receptor Agonist on Gastrointestinal Motility Using Capsule Endoscopy","Mitsunori Maeda","2016","Gastroenterology","other","article","10.1016/s0016-5085(16)32059-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037862","Diabetes prevention while treating obesity: STEP by STEP analysis of an apparently inSURMOUNTable problem","Maria Chantal Ponziani","2026","Obesity and Endocrinology","randomized_trial","article","10.1093/obendo/wjag002",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037863","Symptom-Level Gastrointestinal Adverse Event Profiles of GLP-1 Receptor Agonists: A Network Meta-Analysis to Inform Initial Agent Selection","Jin‐Yi Wan","2026","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.6836584",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0037864","Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in diabetic patients with a higher impact on women","D Garcia Vega","2025","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf236.448",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037865","Challenges and future directions for the use of GLP-1 receptor agonists in children and adolescents living with obesity","Giulio Equitani","2026","Obesity and Endocrinology","randomized_trial","article","10.1093/obendo/wjag009",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037866","The clinical efficacy, outcomes and quality of life of diabetic disease patients treated with dapagliflozin","Venu Talla","2024","Medicover journal of medicine.","other","article","10.4103/mjm.mjm_4_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037867","S931 Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Upper Endoscopy: A Real World Experience","Noppachai Siranart","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001033092.86725.ca",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037868","Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39(Suppl. 1):S52–S59","Dario Giugliano","2016","Diabetes Care","other","article","10.2337/dc15-2829","27222559",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037869","Wirkung von Antidiabetika auf Proliferation und Migration von humanen koronaren Glattmuskelzellen","AV Hinze","2011","Diabetologie und Stoffwechsel","other","article","10.1055/s-0031-1277458",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037870","S2076 Trends in the Prescription of Weight Loss Medications in Patients With Obesity: A Nationwide Cross-Sectional Analysis, 1999-2018","Rohini Ghosh","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037672.94077.d8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037871","The cost-effectiveness of subcutaneous semaglutide 2.4mg in the management of people living with obesity and prediabetes in England","Ramos, Mafalda","2025","Figshare","other_trial","article","10.6084/m9.figshare.30365166.v1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0037872","The Author's Reply: Testosterone, oestradiol, and insulin sensitivity in men","Katya B. Rubinow","2012","Clinical Endocrinology","randomized_trial","article","10.1111/j.1365-2265.2012.04367.x",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0037873","MP426THE EFFECT OF GLUCAGON-LIKE-PEPTIDE-1 AND VITAMIN D ON JAK-STAT PATHWAY IN DBDB MICE AND IN ENDOTELIAL CELLS EXPOSED TO A DIABETIC LIKE ENVIRONMENT","Tali Zitman‐Gal","2016","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfw192.10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037874","Insulin treatment of post‐prandial hyperglycemia","Marc Rendell","2008","Drug Development Research","other","article","10.1002/ddr.20237",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037875","Title Index",null,"2025","Journal of the Chinese Medical Association","randomized_trial","article","10.1097/01.jcma.0001177672.68128.57","41449607",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037876","Risk of Chronic Kidney Diseases Progression And Stroke Among Type 2 Diabetics Treated with Semaglutide","Pham, Judy","2024",null,"other","article","10.13140/rg.2.2.25435.89127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037877","Exenatide geeft toename in hartslag en sympathicusactiviteit","Bohn Stafleu van Loghum","2015","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-015-0014-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037878","CD4-4 Exendin-4 treatment expands graft β cell mass in diabetic recipients with a marginal number of fresh islets","Jyuhn‐Huarng Juang","2008","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(08)70738-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037879","National Trends in Type 2 Diabetes Treatment—Comparing Older and Younger Adults","Scott J. Pilla","2018","Diabetes","other","article","10.2337/db18-176-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037880","Erratum: Incretin mimetics vie for slice of type 2 diabetes market","Catherine Shaffer","2007","Nature Biotechnology","notice","article","10.1038/nbt0407-478b",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0037881","Mazdutide: First Approval","Shirley, Matt","2025","Figshare","other","article","10.6084/m9.figshare.30161881",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037882","721-P: Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8","Vanita R. Aroda","2022","Diabetes","other_trial","article","10.2337/db22-721-p",null,null,"ClinicalTrials.gov:NCT03021187","S002369","openalex","FALSE","paywalled","5","FALSE","article"],["R0037883","1363-P: Glucagon-Like Peptide 1 Receptor Agonists Slow Gastric Emptying but Do Not Prevent Hypoglycemia in Patients with Post-Bariatric Hypoglycemia","Nicole Turk","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1363-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037884","Regulatory Insights into Anti-Obesity Drugs: From Development to NDS Submission (Health Canada)","Bhatt, Jahnvi","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17470043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037885","Pathophysiologic Approach to Type 2 Diabetes Management : One Centre Experience 1980‚Äì2020","Chlup, Rudolf","2018","BiblioBoard Library Catalog (Open Research Library)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","book-chapter"],["R0037886","1697-P: Oral Delivery of Semaglutide, Tirzepatide, and Retatrutide Formulated in Polymerized Ursodeoxycholic Acid (pUDCA) Nanoparticles (NP)","GERALD W. REA","2026","Diabetes","other","article","10.2337/db26-1697-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037887","S2765 Beyond Diabetes: The Role of Glucagon-Like Peptide-1 Receptor Agonists in Non-Diabetic NASH","Priyanka Pradhan","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001138520.35616.33",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0037888","Amélioration du contrôle glycémique des patients diabétiques de type 2 après remplacement de leur traitement par exénatide par le liraglutide","J.-P. Sauvanet","2009","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(09)73322-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037889","IP19-16 TRENDS IN GENITOURINARY RECONSTRUCTIVE PLASTIC SURGERY AMONG OBESE ADULTS USING GLP-1 RECEPTOR AGONISTS","Adam C. Schneider","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191384.77563.6d.16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037890","0469 Skin excision complications following glucagon-like peptide-1 receptor agonist use: A retrospective cohort analysis","M.W. Hayama","2026","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2026.06.500",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037891","AstraZeneca signs $18.5 billion weight-loss-drug deal with Chinese firm","Rowan Walrath","2026","C&EN Global Enterprise","other","article","10.1021/cen-10403-buscon2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037892","MOESM8 of Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","Robyn Bruen","2017","Figshare","preclinical","article","10.6084/m9.figshare.5577094",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0037893","Musculoskeletal Effects of GLP-1 Receptor Agonists in Patients Undergoing Pharmacologic Weight Reduction: A Retrospective Analysis of Bone Density and Sarcopenia in Orthopaedic Practice","Anurag Mittal","2026","JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH","nonrandomized_study","article","10.7860/jcdr/2026/89282.23745",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0037894","Glucagon-Like Skin-1’s Effect on Islet β Cells in High Glucose via AMPK/mTOR Pathway","Minhong Luo","2021","Journal of Biomaterials and Tissue Engineering","other","article","10.1166/jbt.2021.2625",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037895","The Collaborative Approach to Semaglutide Therapy Optimizing Outcomes in Diabetes, Cardiovascular Health, and Weight Management","Indunil Karunarathna","2024",null,"other","article","10.13140/rg.2.2.32385.26728",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037896","The impact of inflammation, oxidative stress, and metabolic dysregulation in maternal obesity, diabetes and pregnancy","Rodrigo, Natassia","2022","The Sydney eScholarship Repository (The University of Sydney)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0037897","RWD3 REAL-WORLD SAFETY TRENDS OF GLP-1 RECEPTOR AGONISTS IN THE UNITED STATES: ANALYSIS OF FAERS REPORTS (2015-2025)","Daniel O. Umoru","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.1992",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037898","The effect of dulaglutide on pancreatic β-cell function in patients with type 2 diabetes mellitus and obesity in real clinical practice","D.G. Gusenbekova","2024","Endocrinology News Opinions Training","other","article","10.33029/2304-9529-2024-13-3-14-18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037899","1199-OR: Inhibition of ALDH1A3 Restores Beta-Cell Function in Type 2 Diabetes and Offers First-in-Class Potential as an Oral, Safe, and Disease-Modifying Therapeutic","MARK ESPOSITO","2026","Diabetes","preclinical","article","10.2337/db26-1199-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037900","Abstract #723: The Effect of Liraglutide 3.0 Mg For Weight Management on Hrqol, as Measured by Sf-36: 3-Year Data","Ronette L. Kolotkin","2016","Endocrine Practice","other","article","10.1016/s1530-891x(20)45132-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037901","Hypoglycemia after gastric bypass","Soner Cander","2022","Bursa Uludag University - AVESIS","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0037902","Comparative Efficacy of Lifestyle Modification and GLP-1RA-Based Interventions for Visceral Adipose Tissue Reduction: Meta-Analysis of 36 Randomised Controlled Trials","Samit Ghosal","2025","Figshare","systematic_review","article","10.6084/m9.figshare.29875070",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0037903","GLP-1 Receptor Agonist Cardiovascular Protection among Type-2 Diabetes Patients: A Literature Review","Khaled Mesfer S Alghamdi","2021","Pharmacophore","narrative_review","article","10.51847/chnotmbuut",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037904","ORIENTAÇÃO FARMACÊUTICA E OS RISCOS DA SEMAGLUTIDA: NAVEGANDO COM SEGURANÇA NA PERDA DE PESO","Daniel Rosa da Silva","2024","Revista fisio&terapia.","nonrandomized_study","article","10.69849/revistaft/ch102024111531",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037905","GLP-1 RECEPTOR AGONISTS BEFORE GENERAL ANESTHESIA AND RESPIRATORY COMPLICATIONS","Agam Bansal","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)02997-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037906","Optimizing Glycemic Control in Type 2 Diabetes: A Review of Metformin-Based Combination Regimens","Kahled Ali Ajala","2025","مجلة جامعة بني وليد للعلوم الإنسانية والتطبيقية","narrative_review","article","10.58916/jhas.v10i3.904",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037907","Semaglutide Associated Cholestatic Drug-Induced Liver Injury",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.061",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037908","Πρωτόκολλο τυχαιοποιημένης ελεγχόμενης κλινικής μελέτης για την αξιολόγηση της αποτελεσματικότητας και ασφάλειας της σεμαγλουτίδης έναντι της μετφορμίνης σε ασθενείς με διαβήτη Τύπου 2","Πασχάλης Ι. Γκορτσίλας","2024","University of Thessaly Institutional Repository (University of Thessaly)","randomized_trial","article","10.26253/heal.uth.39614",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0037909","GLP-1 Receptor Agonists for the Treatment of Obesity in Children and Adolescents: A Systematic Review and Updated Meta-Analysis of Randomized Controlled Trials",null,"2025","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2025.05.521",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0037910","309. Association between glucagon-like peptide 1 receptor agonists and surgical outcomes after anterior and lateral lumbar interbody fusion","Ahmed Elbayomy","2026","The Spine Journal","other","article","10.1016/j.spinee.2026.06.329",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037911","Successful results for semaglutide in the highly anticipated SELECT trial","Robert van den Heuvel","2024",null,"other_trial","article","10.55788/6b5123e5",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0037912","Commercially Available Injectables in Diabetes – Insulin, Incretins, and More","Jothydev Kesavadev","2023","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_29_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037913","Polymer reduces drug conjugate immune reactions","STU BORMAN","2016","C&EN Global Enterprise","other","article","10.1021/cen-09448-scicon003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037914","Anti‐inflammatory Effects of Dipeptidyl Peptidase IV (DPPIV) Inhibition in Heart Failure","Thiago de Almeida Salles","2015","The FASEB Journal","preclinical","article","10.1096/fasebj.29.1_supplement.634.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037915","Neue Therapiekonzepte in der Diabetes- und Adipositasbehandlung: ein GLP‑1- und Glukagon-Co-Agonist in der klinischen Erforschung","Haiko Schlögl","2018","Der Diabetologe","other","article","10.1007/s11428-018-0379-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037916","Effet du dulaglutide en une prise hebdomadaire selon la fonction β-cellulaire initiale dans le programme AWARD","Chantal Mathieu","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.235",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037917","Sa.65. Biosimulations Predict Optimal Oral Insulin/Anti-CD3 and Oral Insulin/Exendin-4 Combination Treatment Regimens for the Reversal of Diabetes in the Non-Obese Diabetic (NOD) Mouse","Yanan Zheng","2008","Clinical Immunology","preclinical","article","10.1016/j.clim.2008.03.286",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037918","Cardiovascular effects of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis","Shanshan Wu","2016","The Lancet Diabetes & Endocrinology","systematic_review","article","10.1016/s2213-8587(16)30373-4",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0037919","Liraglutide and semaglutide may cause serious AEs",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-36402-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037920","Challenges of Weight Management in a Transgender Woman Veteran","Emily Sarett","2026","Rowan Digitals Works (Rowan University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037921","2026-P: Efficacy of Internet-Based Intensive Weight Management or Exenatide Treatment on Weight Loss and Metabolism in Overweight/Obese PCOS","Siyuan Zheng","2020","Diabetes","other","article","10.2337/db20-2026-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037922","Malignancies associated with DPP4 inhibitors and GLP1 receptor agonists: Data from a large real-world database.","Jiasheng Wang","2020","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2020.38.15_suppl.1567",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037923","1642-P: Metabolic Effects of Semaglutide and Resmetirom at Thermoneutrality in the Diet-Induced Obese Mouse","Marco Tozzi","2024","Diabetes","randomized_trial","article","10.2337/db24-1642-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037924","Near-Normoglycemia, with Meaningful Discontinuations of Prandial Insulin, by Adding Weekly Albiglutide (Albi) to Uncontrolled Basal/Bolus Insulin-Treated Type 2 Diabetes (T2DM)","Julio Rosenstock","2018","Diabetes","other","article","10.2337/db18-1073-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037925","Beyond glycemic control: How semaglutide reshapes intestinal neuroception via transforming growth factor-β/brain-derived neurotrophic factor signaling hubs","Hao-Yao Pan","2026","World Journal of Clinical Cases","other","article","10.12998/wjcc.v14.i9.118295",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037926","Comparative Analysis of Tirzepatide, Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, And Phentermine on Ocular Health in Individuals with Obesity: A Propensity-Score Matched Cohort Study","Yu‐Nan Huang","2024","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.5065542",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0037927","P30. Preoperative semaglutide use in patients undergoing single-level lumbar fusion results in lower infection and pseudoarthrosis rates: a propensity-matched retrospective cohort analysis","Jesus Lujan","2025","The Spine Journal","nonrandomized_study","article","10.1016/j.spinee.2025.08.031",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037928","AFTER THE UNIVERSAL MORTALITY PREMISE: What Every Discipline Must Reconstruct When Death Becomes a Class Variable","HUYNH GIA BAO","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20790802",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0037929","Effect of Oral Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients With Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial","Of, Adis Journals On Behalf","2020","Figshare","randomized_trial","article","10.6084/m9.figshare.13360163.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0037930","Impact of GLP1Ra and SGLT2i on Atrial Fibrillation in Overweight, Non-Diabetic Patients: A Meta-Analysis of Randomized Evidence - search string","Luca Sgarra","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21215992",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0037931","Prolonged Radioactive Iodine Uptake in Papillary Thyroid Carcinoma Treatment With Concomitant GLP-1 Agonist Use",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.697",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037932","Off-label pharmacotherapy of obesity: a systematic review","Roger Rafael Porto Ro","2024","International Journal of Nutrology","systematic_review","article","10.54448/ijn24s304",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0037933","Eventos adversos graves asociados con el uso de agonistas del receptor GLP-1 y agonistas duales GLP-1/GIP en pacientes con obesidad: revisión sistemática y metanálisis","Alejandra Celina Esparza Sandoval","2026","El Repositorio Academico Digital de la UANL (Universidad Autónoma de Nuevo León)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0037934","Effets du liraglutide en prévention cardiovasculaire chez des diabétiques de type 2 : résultats de l’étude LEADER","Tiphaine Vidal-Trécan","2016","Sang thrombose vaisseaux","other","article","10.1684/stv.2016.0949",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037935","Alteration Effect of Exendin-4 on Oxidative Stress and Metabolic Disorders Induced by Bisphenol A in Adult Male Mice","Akram Ahangarpour","2016","Jentashapir Journal of Health Research","preclinical","article","10.17795/jjhr-37836",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037936","Abstract P006: Liraglutide Attenuates Cardiac Fibrosis and Vascular Dysfunction in a Non-diabetic Angiotensin II-infusion Model via Anti-inflammatory and Anti-oxidant Mechanisms","Huey Wen Lee","2015","Hypertension","preclinical","article","10.1161/hyp.66.suppl_1.p006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0037937","ABCD position statement on incretin mimetics and DPP‐4 inhibitors ‐2009","C. M. B. Edwards","2009","Practical Diabetes","other","article","10.1002/pdi.1370",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037938","Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Wang, Weihao","2018","Figshare","systematic_review","article","10.6084/m9.figshare.6050624",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0037939","The GLP‐1 agonist liraglutide lowers blood pressure in a placental ischemic model of preeclampsia","Subhi Talal Younes","2019","The FASEB Journal","preclinical","article","10.1096/fasebj.2019.33.1_supplement.574.7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037940","22-LB: Use of a Novel Virtual Patient Simulation Application to Assess Providers’ Knowledge in Management of T2 Diabetes","Boris Draznin","2021","Diabetes","nonrandomized_study","article","10.2337/db21-22-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037941","Impact of GLP-1 Analogs vs. Lipid Lowering Agents on Risk for Acute Pancreatitis in Hypertriglyceridemia: A TriNetX Analysis","Kang, Alyssa","2025",null,"other","article","10.13140/rg.2.2.30275.92963",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037942","4125 WEIGHT REGAIN AFTER SLEEVE GASTRECTOMY CONVERTED TO ROUX-EN-Y GASTRIC BYPASS: IMPACT OF GLP-1 RECEPTOR AGONISTS ON WEIGHT LOSS FOLLOWING FAILED REVISIONAL BARIATRIC SURGERY",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.274",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037943","Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Disorders","Jothydev Kesavadev","2022","International Journal of Diabetes and Technology","other_trial","article","10.4103/ijdt.ijdt_2_23",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0037944","EMERGING METABOLIC THERAPIES IN POLYCYSTIC OVARY SYNDROME","Keerthana Banala, G. Nandini, A. Mavya, G. Manasa, Dr. Falak Naaz","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18152357",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037945","1423-P: A Longitudinal Analysis of Changes in Therapies and Outcomes among People with Type 2 Diabetes","ALAN BELTRAN","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1423-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037946","Effects of liraglutide on soluble tumor necrosis factor receptor in patients with diabetic nephropathy","Yan‐Yun Hu","2018","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037947","Additional file 3 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","Chan, Yi-Hsin","2022","Figshare","nonrandomized_study","article","10.6084/m9.figshare.20176132.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0037948","Impact of GLP-1 Receptor Agonists and DPP-4 Inhibitors on Diabetic Macular Edema and Ophthalmic Outcomes: A Retrospective Cohort Analysis","Wang, Joshua","2025",null,"nonrandomized_study","article","10.13140/rg.2.2.36543.21921",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0037949","Efficacy and Safety of Semaglutide Injection in Weight management: A subgroup analysis of patients based on Age",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.03.058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037950","Impact of Insulin Dependence on Glycemic Response to GLP-1 and Dual GLP-1/GIP Receptor Agonists in Primary Care setting",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.03.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037951","Mortality Risk Among Long-Covid Patients With Hefref Treated With Glp-1 Agonist","Shahin, Hania","2025",null,"other","article","10.13140/rg.2.2.33681.95849",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037952","Pathogenesis and current therapeutic approaches for Parkinson’s disease","Raxida Umar","2024","Global Translational Medicine","other","article","10.36922/gtm.5082",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037953","Roflumilast Potentiates GLP-1 Receptor Agonists` Suppression of Cardiac Inflammation and Adrenal Aldosterone Secretion (Abstract ID: 159413)","Anastasios Lymperopoulos","2025","Journal of Pharmacology and Experimental Therapeutics","other","article","10.1016/j.jpet.2024.100579",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037954","Ozempic et perte de poids : les risques derrière le mauvais usage de cet antidiabétique","Jean‐Daniel Lalau","2023",null,"other","article","10.64628/aak.tkktdm3dd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0037955","Clinical Compendium: Advancing the Care of Patients With Type 2 Diabetes and Chronic Kidney Disease: Role of the Glucagon-like Peptide-1 Receptor Agonists","Mustafa, Nasir","2023",null,"other","article","10.13140/rg.2.2.16926.20802",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037956","Research Progress of Semaglutide Combined with Metformin in the Treatment of Obese Type 2 Diabetes Mellitus","Rongrong Tang","2025","Journal of Clinical and Nursing Research","other","article","10.26689/jcnr.v9i8.11857",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037957","140 Spontaneous Perforation of the Common Bile Duct in the Absence of Choledocholithiasis: A Case Report","Gregg Neagle","2025","British journal of surgery","case_report","article","10.1093/bjs/znaf270.071",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037958","Approaches to treatment 1: How is type 2 diabetes actually treated?","Zachary T. Bloomgarden","2015","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12329","26211568",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0037959","1539-P: Assessing the Risk of Amputation with Canagliflozin in Middle-Aged Adults and Adults over 65 Years of Age: An Observational Study Using Three Nationwide Databases","Michael Fralick","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1539-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037960","2305-PUB: Effects of Dulaglutide on Renal Function, Glycemic Control, and Weight Outcomes in Indian Patients with Type 2 Diabetes: A Real-World Study","SONALI A. PATANGE","2019","Diabetes","nonrandomized_study","article","10.2337/db19-2305-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037961","Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","Lingvay, Ildiko","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.c.6593632.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0037962","SAT-415 Are glucagon-like peptide-1 analogs better answer for obese patients with metabolic dysfunction associated steatotic liver disease than bariatric surgery? Real-world evidence","Ritu Singh","2025","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(25)01678-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037963","PDB39 EFFECT OF VARYING MODELLING ASSUMPTIONS ON THE COSTEFFECTIVENESS OF LIRAGLUTIDE 1.2 MG (AS A COMPONENT OF DUAL THERAPY) IN TYPE 2 DIABETES","WJ Valentine","2010","Value in Health","other","article","10.1016/s1098-3015(11)72097-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0037964","Glucagon-like peptide-1 receptor agonists and cardiometabolic risk factors in Polycystic Ovary Syndrome: role of race/ethnicity","Jacob E. Pruett","2023","Physiology","nonrandomized_study","article","10.1152/physiol.2023.38.s1.5714775",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037965","Exenatide: a guide to its use as an adjunct to metformin and/or a sulfonylurea in patients with type 2 diabetes mellitus","&NA;","2007","Drugs & Therapy Perspectives","other","article","10.2165/00042310-200723100-00002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037966","A Case of Postbariatric Hypoglycemia Responding Well to GLP-1 Analog",null,"2026","Endocrine Practice","case_report","article","10.1016/j.eprac.2026.01.159",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037967","Efficacité du liraglutide dans le traitement du diabète de type 2 : données d’une cohorte de 64 patients diabétiques de type 2 traités par liraglutide avec 2 ans de suivi","P Giraud","2015","Annales d Endocrinologie","other","article","10.1016/j.ando.2015.07.830",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037968","1056-P: Effect of Dulaglutide on Glycemic Variability: Post Hoc Analysis of the AWARD Studies","Esteban Jódar","2020","Diabetes","randomized_trial","article","10.2337/db20-1056-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037969","232eP GLP-1 receptor agonists and risk of incident endometrial, colorectal, and hepatocellular cancer: A systematic review and meta-analysis","D.J. Halim","2026","ESMO Open","systematic_review","article","10.1016/j.esmoop.2026.107864",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0037970","GLP‐1 Receptor Is Associated with Genes Involved in Fatty Acids Oxidation and White‐to‐Brown Fat Differentiation in Epicardial Adipose Tissue (EAT)","Massimiliano Marco Corsi Romanelli","2019","The FASEB Journal","other","article","10.1096/fasebj.2019.33.1_supplement.662.21",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037971","997-P: Thyroid Safety in T2DM Patients Treated with Long-Term Administration of Liraglutide","Mengyu Zhang","2021","Diabetes","other","article","10.2337/db21-997-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037972","Genetic polymorphisms in NOS1AP affects insulin secretion in response to exenatide via nNOS/p38 MAPK/CREB signaling pathway in Chinese patients with type 2 diabetes mellitus","Wang, Tao","2024","Figshare","preclinical","article","10.6084/m9.figshare.27957378.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037973","Title Index",null,"2023","Journal of the Chinese Medical Association","randomized_trial","article","10.1097/01.jcma.0000998240.92275.b3","40460871",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0037974","Decoding the related comments of emerging anti obesity drugs on China social media: Assessing the association between weight‑management policy and public discourse (Preprint)","Yongfeng Lv","2026",null,"other","article","10.2196/preprints.108681",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0037975","Investigation on the Protective Effect of Canagliflozin on Pancreatic Beta-Cell Mass Using SPECT/CT Imaging with 111In-Labeled Exendin-4","Keita Hamamatsu","2018","Diabetes","preclinical","article","10.2337/db18-2124-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037976","Insulin Initiation and Intensification Strategies—Effect of Case-Based Online Education on Physician Competence and Confidence","GILLIAN A. GRIFFITH","2018","Diabetes","other","article","10.2337/db18-2228-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037977","Figure 3: Liraglutide Decreased Aortic Plaque Lesion Development in ApoE","Günaj Rakipovski","2019","JACC: Journal of the American College of Cardiology","other","article","10.25407/jacbts.8253350.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037978","Erratum",null,"2023","Journal of the National Comprehensive Cancer Network","other","article","10.6004/jnccn.2023.0055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0037979","Periodic Graphics: The science of weight-loss drugs","special to C EN Andy Brunning","2025","C&EN Global Enterprise","other_trial","article","10.1021/cen-10302-feature5",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0037980","84-LB: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with Glargine 300 U/mL or IDegLira—The RESTORE-G Real-World Study","RICCARDO CANDIDO","2023","Diabetes","nonrandomized_study","article","10.2337/db23-84-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037981","Obesity Treatment with Glucagon-like Peptide-1 Receptor Agonists","Reyna, Angelina","2023","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037982","1684-P: Comparative Efficacy and Tolerability of Incretin-Based Medication for Weight Loss in Adults with Overweight or Obesity: A Meta-Analysis of Randomized Controlled Trials","Saif Al Basri","2026","Diabetes","systematic_review","article","10.2337/db26-1684-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0037983","The Intersection of Diabetes and Cardiovascular Disease: Mechanisms, Risks, and Management","En-Nasery Amal","2025","Scholars Journal of Applied Medical Sciences","nonrandomized_study","article","10.36347/sjams.2025.v13i05.032",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037984","Pretransplant C-peptide Levels and Pancreas Transplant Outcomes: Risk and Reward","Robert J. Stratta","2023","Transplantation","nonrandomized_study","article","10.1097/tp.0000000000004566","37097983",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037985","Diagnostic Problems After Change in Brand of Lubricant Jelly","Jill M. Paulson","2012","Annals of Internal Medicine","other","article","10.7326/0003-4819-157-9-201211060-00024","23128874",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037986","The Effect of Tirzepatide on Lipid Metabolism: A Systematic Review and Meta-Analysis","Salaar Ahmed","2023",null,"systematic_review","article","10.13140/rg.2.2.18297.03682",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0037987","2700-LB: High-Dose Semaglutide Is Associated with Preservation of Kidney Function in People Living with Obesity without Diabetes","PETER ROSSING","2026","Diabetes","randomized_trial","article","10.2337/db26-2700-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037988","S1603 GLP-1 Agonists in Inflammatory Bowel Disease: Does the Choice Between Semaglutide and Dulaglutide Matter?","Aun Muhammad","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001133872.35314.33",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037989","Human physiology of intra-cranial pressure and the biological role of GLP-1 agonists","Mitchell, James Lee","2022","University of Birmingham Institutional Research Archive (University of Birmingham)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0037990","The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery","Adis Journals On Behalf Of","2024","Figshare","other","article","10.6084/m9.figshare.26729122",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0037991","Adipose and non-adipose layers of epicardium: paracrine activity consequences on cardiomyocytes and modulation by semaglutide","Rumeysa Basdas","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.4914",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0037992","Effect of Single Dose of Insulin Glargine/Lixisenatide Fixed-Ratio Combination (IGlarLixi) on Postprandial Glucodynamic Response in Japanese Patients with Type 2 Diabetes Mellitus","Megumi Inoue","2018","Diabetes","randomized_trial","article","10.2337/db18-1075-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0037993","MANAGEMENT OF HYPEROSMOLAR HYPERGLYCAEMIC STATE","Anna Brackenridge","2026","Postgraduate Medical Journal","nonrandomized_study","article","10.1093/postmj/qgag042.009",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0037994","26-A-8886-ACC GLP1 AGONISTS IN PATIENTS WITH DIABETES: EVALUATING INCIDENT PULMONARY HYPERTENSION WITH REAL WORLD DATA","Pushan Aggarwal","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.2395",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037995","Incidence and Risk Factors of Urinary Tract Infection in Patients with Diabetes Mellitus Using Dapagliflozin in Benghazi, Libya","Asma M. Buzgeia","2025","AlQalam Journal of Medical and Applied Sciences","other","article","10.54361/ajmas.258500",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0037996","S2805 The Use of Non-Invasive Tests to Characterise the Total Baseline Population in the Phase 3 Essence Trial","Laurent Castera","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001138680.36161.70",null,null,"ClinicalTrials.gov:NCT04822181","S000511","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0037997","AMERICAN OTOLOGICAL SOCIETY PRELIMINARY PROGRAM 158th Annual Meeting May 16–18, 2025 New Orleans, LA",null,"2025","Otology & Neurotology","nonrandomized_study","article","10.1097/mao.0000000000004436","39951670",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0037998","Diabetes UK Type 2 Diabetes Research Award",null,"2017","Diabetic Medicine","nonrandomized_study","article","10.1111/dme.6_13303",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0037999","Real-World Effectiveness of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study","Adis Journals on behalf of","2025","Figshare","nonrandomized_study","article","10.6084/m9.figshare.30105244",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038000","Pfizer to buy weight-loss drug firm Metsera for $4.9 billion","Aayushi Pratap","2025","C&EN Global Enterprise","other_trial","article","10.1021/cen-10321-buscon4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0038001","1120-OR: The Pain-Relieving Effect of Bifidobacterium longum -pNZ44-Oxyntomodulin Engineered Probiotics on Painful Diabetic Neuropathy","Yikai Zhang","2026","Diabetes","preclinical","article","10.2337/db26-1120-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038002","Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries with Type 2 Diabetes Mellitus","Sérgio R. R. Decker","2025",null,"other","article","10.2337/figshare.30565829.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038003","S2264 Evaluating the Safety of GLP-1 Receptor Agonists in ERCP: A Propensity-Matched Analysis of Aspiration and Procedural Outcomes Before and After ASA Guideline Changes","Mohammad Abuassi","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001136516.81245.bb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038004","Physiological, Morphological and molecular biological studies of the effect of Glucagon-like peptide-1 and exenatide in the diabetic rat pancreas","Mohamed Ibrahim Lofty","2012","CLOK (University of Central Lancashire)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038005","Clinical Impact Of 5 Year Liraglutide Treatment On Cardiovascular Risk Factors In Patients With Type 2 Diabetes Mellitus In A Real Life Setting In Italy: An Observational Study","Frison, Vera","2018","Figshare","other","article","10.6084/m9.figshare.7029323.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038006","EUGLYCE MIC DIABETIC KETOACIDOSIS WITH REFRACTORY METABOLIC ACIDOSIS IN A PATIENT WITH T2 DM ON EMPAGLIFLOZIN AND INTERMITTENT FASTING","Maria Roselle Vicencio","2022","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.037.afes.83",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038007","Endoskopik İşlemlerde Sedasyon ve Anestezi","Ahmet Karadaş","2026",null,"other","article","10.37609/akya.4287.c17073",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0038008","A Rare Side Effect of Semaglutide",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.247",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038009","Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial (Preprint)","Nynne Sophie Holdt-Caspersen","2024",null,"protocol","article","10.2196/preprints.64899",null,null,"ClinicalTrials.gov:NCT06333080","S001277","openalex","FALSE","paywalled","5","FALSE","preprint"],["R0038010","GABA(A) receptor-mediated currents in the hippocampus are transiently enhanced by glucagon-like peptide-1 receptor (GLP-1R) agonists","Sergiy V. Korol","2014","Acta Physiologica","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038011","Abstract TH814: Independent Genetic Effects of GLP1R Locus on Body Mass Index and Type 2 Diabetes","Chang Liu","2026","Circulation","other","article","10.1161/cir.153.suppl_1.th814",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038012","LBP-003 DR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hypertriglyceridemia: a 12-week randomized, placebocontrolled, double-blind, multi-center trial","Yongliang Fang","2025","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(25)00422-2",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038013","MHRA approves orforglipron weight-loss pill",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.423921",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038014","2186-PUB: Comparison of Insulin Degludec (IDeg)/Insulin Aspart (IAsp) Coformulation Therapy Twice Daily with Free Combination of GLP-1 Receptor Agonist Liraglutide plus Insulin Degludec in Tochigi: IDEAL Trial","Yoshimasa Aso","2020","Diabetes","randomized_trial","article","10.2337/db20-2186-pub",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0038015","Von Injektion zu Ingestion? Ergebnisse zu Orforglipron bei Typ-2-Diabetes aus ACHIEVE 1 und zukünftige Perspektiven","Rima Chakaroun","2025","Die Diabetologie","other","article","10.1007/s11428-025-01389-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038016","The acute efficacy and safety of dulaglutide in Japanese adults with type 2 Diabetes Mellitus","A Mizoguchi","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31191-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038017","Glucagon-Like Peptide-1 Receptor Agonists and Weight Loss in Adolescents with Type 1 Diabetes","Whelchel, Alyn","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038018","Incorporating Cardioprotective Effects of Once-Weekly Semaglutide in Estimates of Health Benefits for Patients with Type 2 Diabetes","Marc Evans","2018","Diabetes","other_trial","article","10.2337/db18-1273-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038019","THE USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RAS) FOR THE TREATMENT OF SUBSTANCE USE DISORDER IN RATS AND HUMANS","Patricia S. Grigson","2025","Drug and Alcohol Dependence","preclinical","article","10.1016/j.drugalcdep.2024.112333",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038020","Can corneal confocal microscopy be used as an imaging biomarker for neurodegeneration in children and adults with metabolic disease?","Gad, Hoda","2024","e-space (Manchester Metropolitan University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038021","254-LB: EndoC-ßH5 Human Beta Cells—A Unique “Thaw and Go” Model for Accelerating Diabetes Research with Highly Functional and Ready-to-Use Human Beta Cells","Hamza Olleik","2022","Diabetes","other","article","10.2337/db22-254-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038022","Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials","Chen, Han","2018","Figshare","systematic_review","article","10.6084/m9.figshare.6210794",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0038023","S1632 GLP-1 Receptor Agonists Are Associated With Reduced IBD Exacerbations, Hospitalizations, and ER Visits: A Multicenter Observational Cohort Study","Josue A. Davila","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001133988.82754.9b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038024","S5687 Hepatotoxicity Linked to Compounded Semaglutide: A Rare Case of Probable Drug-Induced Liver Injury","Nikita Garg","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001150208.23224.83",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038025","Standards of care in relation to diabetes status in patients with st-elevation myocardial infarction in 2023 - the european unified registries on heart care evaluation and randomized trials","A Bhatty","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.2131",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038026","S4691 Some Semaglutide Side Effect: Ileus as a Complication of a GLP-1 Receptor Analog","Alejandra Casillas","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001048132.08985.99",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038027","1681-P: Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Metformin (Met) with/without One Other Oral Antidiabetic Drug (OAD)","LINONG JI","2026","Diabetes","randomized_trial","article","10.2337/db26-1681-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038028","Letter to the Editor from Knobler and Toledano: “Validation of the Swedish Diabetes Regrouping Scheme in Adult-Onset Diabetes in China”","Hilla Knobler","2020","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgaa827","33164090",null,null,null,"openalex","FALSE","paywalled","2","FALSE","letter"],["R0038029","Study on the efficacy of insulin pump combined with dapagliflozin in Chinese patients with type 2 diabetes v1","Liting Guo","2018",null,"other","article","10.17504/protocols.io.tnwemfe",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038030","Liraglutide protects against microvascular dysfunction and sepsis-mediated inflammation and organ injury","David M. Aslaner","2024","Physiology","preclinical","article","10.1152/physiol.2024.39.s1.1501",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038031","Journal of Diabetes NEWS",null,"2012","Journal of Diabetes","other_trial","article","10.1111/1753-0407.12018",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038032","Obesity and Atrial Fibrillation: Therapeutic Perspective for GLP-1 Analogs","Alicja Szołkiewicz-Płatkowska","2024","In a good rythm","other","article","10.5604/01.3001.0054.6436",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038033","La liraglutide aumenta i tassi di gravidanza dopo IVF in donne obese con PCOS e scarsa risposta alle terapie di prima linea: uno studio pilota randomizzato","Marco Infante","2018","L Endocrinologo","other","article","10.1007/s40619-018-00503-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038034","S3653 Semaglutide-Induced Hepatotoxicity: A Rare Case of Drug Induced Liver Injury","Santiago F. Galeano-Lovera","2023","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000964252.91007.e2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038035","2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity","W. TIMOTHY GARVEY","2022","Diabetes","randomized_trial","article","10.2337/db22-2-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038036","1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity—STEP UP Trial","Sean Wharton","2025","Diabetes","randomized_trial","article","10.2337/db25-1966-lb",null,null,"ClinicalTrials.gov:NCT05646706","S001354","openalex","FALSE","paywalled","1","FALSE","article"],["R0038037","Ischemia-Reperfusion Injury: Can We Stop the Curing-Hurting Paradox?","Alberto Testa","2021","Journal of Cardiovascular Pharmacology","other_trial","article","10.1097/fjc.0000000000000992","33818549",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0038038","COMPARISON OF EFFICACY OF TRADITIONAL AND MODERN MEDICINE IN DIABETES MELLITUS MANAGEMENT","Indrawan, Doby","2024","Research Repository Universitas Islam Negeri Maulana Malik Ibrahim (University of Southampton)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038039","1716-P: Real-World Outcomes Using Medication and Intensive Lifestyle Intervention to Treat Obesity and Improve Diabetes at Scale","Kim Boyd","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1716-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038040","618-P: Effect of Liraglutide Combined with Human Umbilical Cord Mesenchymal Stem Cells on Liver Injury of T2DM with NAFLD Rats by Mediating Toll-Like Receptor 4/Nuclear Factor-kappa B Signaling Pathway and Oxidative Stress","Pin Chen","2019","Diabetes","preclinical","article","10.2337/db19-618-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038041","S4128 Side Effects of GLP-1 Agonists: A Case of Colonic Pseudo-Obstruction","Priyam Doshi","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001143972.38422.8d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038042","954-P: GLP-1–Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting (EXPERT Study)","Ildiko Lingvay","2020","Diabetes","nonrandomized_study","article","10.2337/db20-954-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038043","Liraglutide treatment in post-bariatric surgery patients who failed to maintain weight reduction","Naim Shehadeh","2017","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2017.09.317",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038044","S2942 Yersinia Enterocolitica: A Rare Cause of Infectious Gastroenteritis in an Immunocompetent Patient","Karamvir Kaur","2024","The American Journal of Gastroenterology","preclinical","article","10.14309/01.ajg.0001041136.66340.af",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038045","Prevalence of Left Ventricular Hypertrophy in Sudden Death Victims","Alia Capone","2020","American Journal of Preventive Cardiology","other","article","10.1016/j.ajpc.2020.100060",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038046","1444-P: The Relationship between Diabetic Retinopathy and Glucose-Lowering Therapy in Type 2 Diabetes: Results of an Observational Retrospective Study","Pamela Senesi","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1444-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038047","Revolutionizing obesity treatment: The emerging role of GLP-1 receptor agonists and next-generation pharmacotherapies","Picheswara Rao Polu","2026","Obesity Medicine","other","article","10.1016/j.obmed.2026.100686",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038048","Potential predictors of response to therapy in a cohort 24-week study of the efficacy and safety of liraglutide in obese adolescents aged 12–15 years old","O.P.Kovtun O.P.Kovtun","2025","Voprosy praktičeskoj pediatrii","nonrandomized_study","article","10.20953/1817-7646-2025-2-54-62",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038049","Clinical care and other categories posters: pregnancy",null,"2016","Diabetic Medicine","nonrandomized_study","article","10.1111/dme.46_13048",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038050","Human medicines European public assessment report (EPAR): Lyxumia , lixisenatide, Diabetes Mellitus, Type 2, Date of authorisation: 31/01/2013, Revision: 9, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-17cd5d1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038051","Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship","Raffaele De Caterina","2010","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehp589","20418342",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0038052","Cost-Effectiveness Analysis of Liraglutide Versus Insulin Glargine in Chinese Patients with Type 2 Diabetes Insufficiently Controlled on Metformin","Xunke Gu","2018","Value in Health","other","article","10.1016/j.jval.2018.04.502",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038053","890-P: Efficacy of Antiobesity Agents on Fat Distribution—A Systematic Review and Network Meta-analysis of Randomized Controlled Trials","XIUQI QIAO","2025","Diabetes","systematic_review","article","10.2337/db25-890-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0038054","Overexpression of GLP-1 receptor in hepatocellular carcinoma causes anti-cancer effect of Exendin-4","Tomohiro Noda","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31274-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038055","S5668 Déjà Vu! A Case of Recurrent MASH 60 Days After Liver Transplantation","Tanner Thornsberry","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001150132.42940.bd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038056","Can Reprogramming Taste Modulate Excess Food Intake?","Kerstin Rohde‐Zimmermann","2026","Obesity","preclinical","article","10.1002/oby.70199","41964206",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038057","S139 Sex-Related Disparities Observed in Acute Pancreatitis-Associated ARF/ARDS Mortality: A CDC WONDER Analysis (2018 to 2023)","Rohan Raj","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001127016.09366.b7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038058","Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic","Kvapil, Milan","2018","Figshare","other","article","10.6084/m9.figshare.5915299",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038059","Corrigendum",null,"2013","Expert Review of Endocrinology & Metabolism","other_trial","article","10.1586/eem.13.19","30780816",null,null,null,"openalex","FALSE","paywalled","5","FALSE","erratum"],["R0038060","Self-assembly and aggregation of glucagon-like peptide 1 and its analogues","Přáda, Eva","2023","Apollo (University of Cambridge)","nonrandomized_study","article","10.17863/cam.98055",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0038061","PO-02-014 METABOLIC IMPACT ON CARDIAC CONDUCTION PATHWAYS: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND 5-YEAR RISK OF ATRIOVENTRICULAR BLOCK IN NON-DIABETIC ADULTS WITH OBESITY","Kevin Maymi","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.406",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038062","Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review","Jang Won Son","2026","Journal of Korean Medical Association","narrative_review","article","10.5124/jkma.25.0138",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0038063","Efficacy of SGLT2i and GLP-1RA in acute myocardial infarction: A meta-analysis of randomized controlled trials","Xiao Liu","2026","Journal of Molecular and Cellular Cardiology Plus","systematic_review","article","10.1016/j.jmccpl.2025.100630",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0038064","A MULTIPRONGED APPROACH TO ACHIEVE SIGNIFICANT LDL CHOLESTEROL REDUCTION","Jolyn Rumefla Susinadan","2025","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.040.s1.042",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038065","Lilly to pour $6.5 billion into GLP-1 pill manufacturing","Aayushi Pratap","2025","C&EN Global Enterprise","other","article","10.1021/cen-10321-buscon3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038066","GLP-1 Receptor Agonists and Complications After Transesophogeal Echocardiography: The GAS-TEE Study","Mitchell Rozman","2026","Michigan medical education and health bulletin.","other","article","10.69735/001c.163911",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038067","Literature Review of Economic Evaluations of Oral Semaglutide and its Role in the Treatment of Type 2 Diabetes","Johnson, Jacob","2022","NSUWorks (Nova Southeastern University)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038068","Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”","Kazuhiro Takahashi","2022","Hepatology Communications","nonrandomized_study","article","10.1002/hep4.1996","35531591",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","letter"],["R0038069","795-P: Efficacy and Safety of RAY1225 Once Every Two Weeks in Chinese Adults with Type 2 Diabetes (SHINING-1)","Linong Ji","2025","Diabetes","randomized_trial","article","10.2337/db25-795-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038070","885-P: Sex-Dependent Additive Effects of Dorzagliatin and Incretin on Insulin Secretion in a Novel Mouse Model of GCK-MODY","SHADAI SALAZAR","2025","Diabetes","preclinical","article","10.2337/db25-885-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038071","FRI-106 The glucagon/glucagon-like peptide-1 receptor dual agonist survodutide strongly reduces alcohol intake in the lean golden syrian hamster, a preclinical model with spontaneous alcohol preference","François Briand","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)00570-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038072","PO412 THE PRACTICE OF LIRAGLUTIDE TREATMENT IN PATIENTS WITH TYPE 2 DIABETES IN MONGOLIA","Altanzul Altaisaikhan","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70706-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038073","Abstract 4373476: Disparities in Major Adverse Cardiovascular Outcomes Based on Body Mass Index and Estimated Glomerular Filtration Rate in Glucagon-like Peptide-1 Receptor Agonists Users Among Patients With and Without Diabetes Mellitus: A Meta-analysis of 9 Randomized Controlled trials.","Vikash Jaiswal","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4373476",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0038074","Clinical care and other categories posters: monitoring",null,"2017","Diabetic Medicine","other","article","10.1111/dme.35_13304",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038075","1437-P: Treatment Pattern and Glycemic Control of Adults with T2DM in Northern China","Liming Chen","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1437-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038076","Cardiovascular outcomes in CLL patients receiving GLP-1 agonists and BTK inhibitors: A global propensity-matched study","Angimar Uriepero","2025","Blood","randomized_trial","article","10.1182/blood-2025-2774",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0038077","S3180 GLP-1 Receptor Agonist Use and Risk of Gastric Cancer: A Population-Based Retrospective Cohort Study","Muaz Alsabbagh","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001140180.62996.32",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038078","Az elhízás gyógyszeres kezelése: múlt, jelen, jövő = The Pharmacological Treatment of Obesity: Past, Present and Future","Simonyi, Gábor","2012","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038079","COMPARATIVE CARDIOPROTECTIVE EFFECTS OF GLP-1 RA VS SGLT2i INHIBITORS IN PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM A LARGE-SCALE REAL-WORLD DATA ANALYSIS","Saud Alawad","2025","CHEST Journal","nonrandomized_study","article","10.1016/j.chest.2025.07.3124",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038080","The Role of Liraglutide and Dapagliflozin in Attenuating Cardio-Renal Injuries in Diabetic Rats","Adel Ali Ali Ali Al-Bana'a","2024","University of Science and Technology Institutional Repository (University of Science and Technology, Sana’a, Yemen)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038081","CE-534538-003 IMPACT OF GLUCAGON-LIKE PEPTIDE RECEPTOR-1 AGONISTS AND TIRZEPATIDE ON ATRIAL FIBRILLATION AND RELATED EVENTS IN CHRONIC KIDNEY DISEASE","Ninad Khandekar","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038082","S3125 Resolution of Gastroparesis Symptoms With the Removal of a Dipeptidyl Peptidase-4 Inhibitor","Sri Nuvvula","2021","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0000786032.36253.51",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038083","Diabetes",null,"2025","Directory of Open access Books (OAPEN Foundation)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038084","S5281 Endoscopic Retrieval of an Eroded Gastric Band: A Minimally Invasive Alternative to Surgical Intervention","Ali Shaat","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001148584.07566.35",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038085","New Onset Autoimmune Type 1 Diabetes in Patients Using Compounded Semaglutide: Coincidence or Underlying Serious Concerns",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.292",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038086","PNDM9V5MLB Use of Glucagon-like peptide 1 Agonists (GLP-1's) Among Individuals Undergoing Bariatric Surgery In The United States: A Retrospective Cohort Study",null,"2025","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2025.04.214",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038087","Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes","Piya Sen Gupta","2018","Diabetes","randomized_trial","article","10.2337/db18-1250-p",null,null,"ISRCTN:ISRCTN00151053","S001522","openalex","FALSE","paywalled","1","FALSE","article"],["R0038088","Additional file 1 of Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence","Schechter, Meir","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26592413",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0038089","Étude DUAL V : l’efficacité d’IDegLira est indépendante de la dose d’insuline glargine administrée avant l’étude","Nicolas Chevalier","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.594",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038090","The Effects of Semaglutide Combined with Dapagliflozin on SOD, CAT, and 2hPBG Levels in Elderly Patients with Type 2 Diabetes Mellitus Whose Conditions Were Not Well Controlled by Metformin","布 威麦尔耶姆·乃比","2025","Advances in Clinical Medicine","other","article","10.12677/acm.2025.1572123",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038091","A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus","Seino, Yutaka","2020","Figshare","randomized_trial","article","10.6084/m9.figshare.11830233",null,null,"ClinicalTrials.gov:NCT01098461","S001266","openalex","TRUE","paywalled","1","FALSE","article"],["R0038092","Literature Commentary",null,"2025","Journal of Neuro-Ophthalmology","nonrandomized_study","article","10.1097/wno.0000000000002321","39879172",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038093","Defining mechanisms and new treatments for headache in raised intracranial pressure","Grech, Olivia","2024","University of Birmingham Institutional Research Archive (University of Birmingham)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038094","1889-P: Light Exercise and Liraglutide Synergistically Improve Muscle Insulin Action in Diet-Induced Obesity","Jia Liu","2020","Diabetes","preclinical","article","10.2337/db20-1889-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038095","1718-P: Novel GLP-1RA (GmFc) Greatly Reduces GI Adverse Effects while Exhibiting Glycemic Control and Satiety in Rodents","YI LIU","2026","Diabetes","preclinical","article","10.2337/db26-1718-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038096","Cyanocobalamin/semaglutide/semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-50400-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038097","Dulaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-50440-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038098","L26/O-010 Glucagon-like peptide-1 receptor agonists (GLP-1’s) for the improvement of cardiometabolic outcomes in women with polycystic ovarian syndrome (PCOS): a systematic review and network meta-analysis (NMA)","N. Blampied","2026","Human Reproduction","systematic_review","article","10.1093/humrep/deag083.010",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0038099","Off-Label Split Dosing of Tirzepatide (Mounjaro) KwikPens: A Literature-Anchored Risk Assessment of Sterility and Stability","Kong, Hyunseung","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17702092",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038100","Current options in obesity pharmacotherapy for children and adolescents","Hae Woon Jung","2024","Precision and Future Medicine","other","article","10.23838/pfm.2024.00093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038101","750-P: “SURPASS(ing)” an Era of Basal-Bolus Insulin Therapy—Tirzepatide vs. Insulin Lispro TID Added-on to Poorly Controlled Basal Insulin-Treated in Type 2 Diabetes","JULIO ROSENSTOCK","2023","Diabetes","randomized_trial","article","10.2337/db23-750-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038102","G-425 GLP-1 Agonists and Unforeseen Consequences in Calcium-Phosphate Metabolism",null,"2025","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2025.02.426",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038103","90-LB: Soliqua (Lixilan): Sustained Long-Term Cost Efficacy and Safety When Used in Combination with Metformin and Glimepiride","Udaya M. Kabadi","2021","Diabetes","other","article","10.2337/db21-90-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038104","Impact of pharmacological Interventions on insulin resistance in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials: supplementary materials","abdalla, mohammed","2021","Figshare","systematic_review","article","10.6084/m9.figshare.14748921",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0038105","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-32100-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038106","Glucagon-like peptide-1 receptor agonists suppress water intake","Naomi J. McKay","2011","Appetite","other","article","10.1016/j.appet.2011.05.226",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038107","S4493 Superior Mesenteric Artery Syndrome and Nutcracker Syndrome in a Patient With Ehlers-Danlos Syndrome","Nitin Desai","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001145432.17396.2e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038108","Long-term blockade of glucagon-like peptide-1 receptor increases systolic blood pressure levels in both hypertensive and normotensive rats","Flavia L. Martins","2019","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038109","Exenatide prolonged-release suspension for injection in \\ncombination with oral antidiabetic therapy for the \\ntreatment of type 2 diabetes","Waugh, Norman","2012","Warwick Research Archive Portal (University of Warwick)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0038110","Recent Improvements in the Treatment of Type 2 Diabetes Mellitus","Abhishek Abhishek","2024","International Journal of Pharmaceutical and Healthcare Innovation.","other","article","10.62752/xxdw3c54",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038111","HSD7 Are Glucagon-Like Peptide-1 Receptor Agonists Prescribed for Weight Loss Slipping Through the Net of Japan’s Strict Guidelines? An Analysis of Health Insurance Claims Data","Tomomi Takeshima","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.09.1668",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038112","Semaglutide preserves myocardial function in a murine model of sequential anthracycline trastuzumab induced early cardiotoxicity: insights from speckle tracking echocardiography","Nicola Maurea","2026","European Heart Journal - Cardiovascular Imaging","randomized_trial","article","10.1093/ehjci/jeaf367.267",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038113","GLP-1 receptor agonists are associated with higher mitochondrial coupling efficiency in the human heart","P Gabert","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.1252",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038114","INCIDÊNCIA, GRAVIDADE E DESCONTINUAÇÃO DE RELACIONADAS A EVENTOS ADVERSOS GASTROINTESTINAIS ASSOCIADOS AOS ANÁLOGOS DO RECEPTOR DE GLP-1 NO TRATAMENTO DO DIABETES MELLITUS TIPO 2: REVISÃO SISTEMÁTICA","Mariana Prieto Barbosa","2026","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v12i8.29492",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038115","238P Association of GLP-1 receptor agonist use before diagnosis with breast cancer outcomes in a large real-world cohort","Christie Hilton","2026","ESMO Open","nonrandomized_study","article","10.1016/j.esmoop.2026.107192",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0038116","P345 Liraglutide chez un patient obèse, diabétique de type 2, en insuffisance rénale pré-terminale : un intérêt ?","Jean-Paul Ory","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72636-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038117","2088-P: Soluble EGFR and Adipsin Are Independent Serum Biomarkers for Insulin Resistance in Mouse and Human","Mayu Kyohara","2019","Diabetes","preclinical","article","10.2337/db19-2088-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038118","S2627 Metabolic Liver Disease in HCC: Underdiagnosis and Advanced Portal Hypertension in Patients With a MASH-Consistent Phenotype in a Diverse Southwestern Cohort","Gicel J. Aguilar","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137968.68500.bb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038119","The Benefits of Injectable Semaglutide in Obese Adults With and Without Type 2 Diabetes Mellitus","njie, emade s","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038120","Long-Term Efficiency of Twice-Daily Exenatide in Type 2 Diabetes Mellitus: A Real-Life Study","Mehmet Çağrı Ünal","2024","Endocrinology research and practice.","nonrandomized_study","article","10.5152/erp.2024.23395",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038121","KIDNEY PROTECTIVE EFFECTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Nicole Felix","2024",null,"systematic_review","article","10.65034/bjnabstract-cbn240726",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0038122","Insulin/tirzepatide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-44665-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038123","The liver adventures of bariatric endoscopy","Ivo Boškoski","2023","Endoscopy","randomized_trial","article","10.1055/a-2160-1581","37699426",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038124","Analytical Method Development And Validation Of Impurity Profile In Semaglutide","Satish Shelke","2024","African Journal of Biomedical Research","other","article","10.53555/ajbr.v27i3s.2254",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038125","Praxisstudie belegt signifikante Reduktion von HbA1cund Gewicht - Exenatide stellt fünf physiologische GLP-1-Wirkungen wieder her",null,"2009","Diabetes aktuell","other","article","10.1055/s-0029-1233391",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038126","This Month in Anesthesiology",null,"2024","Anesthesiology","randomized_trial","article","10.1097/aln.0000000000005270","39715501",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038127","1724-P: Long Duration of Action of an Oral Semaglutide Administered via the Intestine in Healthy Humans","ROGER R.C. NEW","2026","Diabetes","other","article","10.2337/db26-1724-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038128","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-43252-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038129","79-LB: An Open-Label, Active-Controlled Phase 2 Evaluation of Novel GLP-1 Analog Ecnoglutide in Adults with Obesity","ZHIYI ZHU","2023","Diabetes","randomized_trial","article","10.2337/db23-79-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038130","Influences of gastrointestinal microbiotica and short chain fatty acids on metabolic syndrome","Berit Hippe","2014","University of Vienna","other","article","10.25365/thesis.33590",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038131","New treatments and biomarkers in heart failure, hypertrophic cardiomyopathy, and familial hypercholesterolaemia","Filippo Crea","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf271","40364752",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0038132","1692-P: Metabolic Assessment of Semaglutide (a GLP-1R Agonist) and Tirzepatide (a GLP-1R/GIPR Coagonist) in Diet-Induced Obese (DIO) Mice","SARAH OLKKOLA","2025","Diabetes","randomized_trial","article","10.2337/db25-1692-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038133","HEALTH & SCIENCE 2025-IV",null,"2025",null,"preclinical","article","10.59617/efepub2025214",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0038134","1114-P: Management Outcomes by Provider Type in People with Diabetes Receiving Care at a Federally Qualified Health Center","Emily Rose N. San Diego","2024","Diabetes","other","article","10.2337/db24-1114-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038135","Liraglutide increases 24-h heart rate by reducing the cardiac parasympathetic activity of patients with type 2 diabetes: power spectral analysis of heart rate variability on 24-h Holter ECG recordings","Kenji Hara","2014","Diabetology International","other","article","10.1007/s13340-014-0170-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038136","Renal and metabolic effects of the association of GLP-1 receptor agonists and SGLT-2 inhibitors in individuals with type 2 diabetes: a retrospective observational study (\"ReMeSG study\")","VAN BIGNOOT, G.","2021","IRIS","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0038137","Long-acting exendin-4-coated selenium nanoparticles with improved hypoglycemic activity","Reeju Amatya","2025","Journal of Pharmaceutical Investigation","other","article","10.1007/s40005-024-00723-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038138","Semaglutide e benefici cardiovascolari indipendenti dalla perdita di peso: analisi del trial SELECT","Giovanni B. Munari","2026","L Endocrinologo","other_trial","article","10.1007/s40619-026-01844-9",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038139","Preventive cardiology or cardiometabolic medicine: a new and emerging subspecialty?","Nathan D. Wong","2020","Cardiovascular Endocrinology & Metabolism","other_trial","article","10.1097/xce.0000000000000206","32803137",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0038140","1678-P: IBI3032: An Orally Bioavailable Nonpeptidic GLP-1 Receptor Agonist Advancing through Phase 1 Clinical Trials","Ye Jiang","2026","Diabetes","other_trial","article","10.2337/db26-1678-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038141","What Is The Role of Incretin Mimetics In The Treatment of Type 2 Diabetes","Isaac Silberstein","2013","Touro Scholar (Touro College)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038142","Research Progress of GLP-1 Receptor Agonists in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease","舒婷 陈","2025","Journal of Clinical Personalized Medicine","other","article","10.12677/jcpm.2025.43402",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038143","26-A-14016-ACC GLP-1 RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES IN PATIENTS UNDERGOING CARDIAC REHABILITATION: A REAL-WORLD COHORT STUDY","Leah Vaikutis","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1897",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038144","Terahertz Spectroscopy: An investigation of the Structural Dynamics of Freeze-Dried PLGA Microspheres","Tan H. S.","2019","ChemRxiv","other","article","10.26434/chemrxiv.7547222",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038145","Semaglutide’s Impact on Kidney Health in Obese Mice: A Metabolomics Study","Johanna Eriksson","2025","Pharmaceutical Sciences and Drug Design","preclinical","article","10.51847/5whbt71l9k",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038146","Tu1754: THE IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON COLONIC ADENOMA INCIDENCE: A LARGE RETROSPECTIVE COHORT STUDY","Hassan Elsaygh","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04283-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038147","GLP‐1 and its Analogue Liraglutide Affects Human Endothelial Cell Signaling by Reducing VEGF‐A Induced Ca 2+ Signaling and Activating Protein Kinases","Cecilie Rotboel","2015","The FASEB Journal","preclinical","article","10.1096/fasebj.29.1_supplement.642.7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038148","Ozempiconomy: Exploratory Analysis on Actor Behavior and Hegemony Within Radical Innovation-Induced Novel Ecosystems","Wang, Long You","2025","Deep Blue (University of Michigan)","other","article","10.7302/26028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038149","Applications of Semaglutide for Various Diseases","Jiayun Pan","2024","Transactions on Materials Biotechnology and Life Sciences","other","article","10.62051/ccdpax22",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038150","Abstract #329: Is Switching from Liraglutide to Exenatide Useful?","Jack Elstein","2016","Endocrine Practice","other","article","10.1016/s1530-891x(20)45037-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038151","supporting tables and figureV2.doc","Tianru Jin","2020","Figshare","preclinical","article","10.6084/m9.figshare.12702569.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038152","췌장 베타세포에서 GLP-1의 Glucosamine에 의한 세포 독성 보호 기전","임보라","2007","KUMeL Repository (Keimyung University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038153","Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)","Nomoto, Hiroshi","2020","Figshare","protocol","article","10.6084/m9.figshare.13379093",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0038154","798-P: Potential Cardioprotective Effects of HM15275, a Novel, Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Hypertension","SEON MYEONG LEE","2024","Diabetes","preclinical","article","10.2337/db24-798-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038155","807-P: GLP-1 Agonists and the Risk of Delayed Gastric Emptying in Elective Ophthalmic Procedures","Amelia Cooper","2024","Diabetes","other","article","10.2337/db24-807-p",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038156","Insulin Resistance vs Dysregulation -- A Distinction without a Difference","Eleanor M Kellon","2024",null,"other_trial","article","10.22541/au.172115170.04205404/v1",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","preprint"],["R0038157","The Overlooked Role of Psychiatrists in Obesity Management: A Multidisciplinary Perspective","D. Dos Santos","2026","European Psychiatry","nonrandomized_study","article","10.1192/j.eurpsy.2026.11376",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038158","The Effects of Antidiabetic Drugs on Cerebral Metabolism in Mice with Central Insulin Resistance","Yue Cao","2018","Diabetes","preclinical","article","10.2337/db18-247-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038159","Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?","Jun-Zhang Chen","2023","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.0000000000000230","38039089",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0038160","Dulaglutide/semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-47900-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038161","Human medicines European public assessment report (EPAR): Eperzan, albiglutide, Diabetes Mellitus, Type 2, Date of authorisation: 20/03/2014, Revision: 8, Status: Withdrawn",null,"2019","Case Medical Research","other","article","10.31525/cmr-bd6496",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038162","Ozempic, Wegovy : quels risques d’usage détourné avec ces médicaments pour le diabète et l’obésité ?","Jean‐Daniel Lalau","2024",null,"other","article","10.64628/aak.n6e4ndtpp",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038163","2833-LB: Utreglutide (GL0034) Shows Comparable Tolerability and Efficacy with Different Dose Escalation Regimens in Overweight and Obese Adults with Type 2 Diabetes (T2DM)","RAJAMANNAR THENNATI","2026","Diabetes","randomized_trial","article","10.2337/db26-2833-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038164","Incidence of atrial fibrillation and related events with glucagon-like peptide-1 receptor agonist use in chronic kidney disease","N Khandekar","2026","The American Journal of the Medical Sciences","other","article","10.1016/j.amjms.2025.12.510",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038165","Typ-1-Diabetes – GLP1-RA als Add-on-Therapie?","Friederike Klein","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-121780",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038166","2859-LB: Fracture Risk with Combined SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Target Trial Emulation","Xinyan Jia","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2859-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038167","Association of GLP-1 Receptor Agonist Exposure and Device-Detected Ventricular Arrhythmic Events.","Murray Coetzee","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20584169",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0038168","Cardiology Update London 2019","Andros Tofield","2020","European Heart Journal","other","article","10.1093/eurheartj/ehaa014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038169","The Skinny on Treating Adult Obesity: Prescribing for Weight Loss","Davis, Leslie A","2022","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038170","GLP-1 receptor agonists: new treatment frontiers",null,"2025","Nature Mental Health","other","article","10.1038/s44220-025-00402-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038171","Are GLP-1 Receptor Agonists safe in Prader-Willi Syndrome? A detailed investigation on safety and efficacy with a focus on gastric emptying.","Hor, Hui Min","2024","UNSWorks (University of New South Wales, Sydney, Australia)","nonrandomized_study","article","10.26190/unsworks/30386",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0038172","NICE recommends liraglutide & venetoclax + obinutuzumab, but not nivolumab",null,"2020","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-020-7295-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038173","Tu1813 Effect of Glucagon-Like Peptide-1 (GLP-1) Analogue on Hepatic Cholesterol Metabolism in Nonalcoholic Steatohepatitis (NASH)","Yukiomi Nakade","2012","Gastroenterology","other","article","10.1016/s0016-5085(12)63959-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038174","Beyond glycaemic control : SGLT2 inhibitors and GLP-1 receptor agonists in the cardiovascular-kidney-metabolic syndrome","Arvid Engström","2026",null,"nonrandomized_study","article","10.69622/31819498.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0038175","Prescribing by Ethnicity: (Im)precision Medicine?","Nish Chaturvedi","2020","Diabetes Care","randomized_trial","article","10.2337/dci20-0015","33539313",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038176","Addition of New Therapeutic Agents to an Established Type 2 Diabetes Simulation Platform for Therapy Optimization: A Bayesian Model-Based Approach","Thibault Gautier","2020","IFAC-PapersOnLine","other_trial","article","10.1016/j.ifacol.2020.12.649",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0038177","Sauna therapy in HFpEF: more than just heat?","Philip Haaf","2026","European Journal of Heart Failure","randomized_trial","article","10.1093/ejhf/xuag093","41889337",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0038178","Communautés en ligne : (re)connecter les personnes en quête de perte de poids et les professionnels de santé","Steffie Gallin","2025",null,"other","article","10.64628/aak.as9qdfynx",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038179","S5864 Weight Loss or Liver Loss? Cholestatic Injury Following Semaglutide and Supplement Use: A Diagnostic Dilemma","Taha Shakarchi","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001150916.53027.c9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038180","EE110 PHARMACY BUDGET IMPACT OF EXPANDING MEDICARE COVERAGE FOR GLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF OBESITY UNDER ALTERNATIVE PRICING SCENARIOS","Paige Ngo","2026","Value in Health","other","article","10.1016/j.jval.2026.03.405",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038181","1865-LB: Exploring Incretin-Based Therapies as Adjunctive Treatment for Type 1 Diabetes—Real-World Insights and Future Directions","Ihsan Almarzooqi","2024","Diabetes","randomized_trial","article","10.2337/db24-1865-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038182","The Effects of GLP-1 Agonists on Cardiac Structure and Function: A Systematic Review","Sarin Sarjian","2025","Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","systematic_review","article","10.26685/urncst.898",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0038183","Prensa escrita, publicity y desinformación: “curas milagro”, un problema de comunicación en salud y responsabilidad social de los medios","Ibáñez Hernández, Ana I.","2025","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038184","1778-P: Opioids and Risk of Gastrointestinal Outcomes among Patients Receiving GLP-1RAs","Sungho Bea","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1778-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038185","S2554 Comparative Effectiveness of Initiating GLP-1 Receptor Agonists (GLP-1 RAs) vs SGLT-2 Inhibitors (SGLT2is) in Patients With Compensated MASLD Cirrhosis and Type 2 Diabetes: A Global Retrospective Analysis","Varun Aitharaju","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137676.76763.38",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038186","Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center","Sofra, Daniela","2018","Figshare","other","article","10.6084/m9.figshare.6182417",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038187","Blood glucose and hypertension development","Peter M. Nilsson","2018","Journal of Hypertension","nonrandomized_study","article","10.1097/hjh.0000000000001946","30499918",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038188","Review finds GLP‐1s have favorable psychiatric safety profile",null,"2025","The Brown University Psychopharmacology Update","narrative_review","article","10.1002/pu.31345",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038189","Corrigendum",null,"2016","Diabetes Obesity and Metabolism","other","article","10.1111/dom.12746","27546838",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0038190","Determinants and pharmacologic modulation of fasting substrate oxidation in humans","Hummel, Julia","2023","Universitätsbibliothek Tübingen","randomized_trial","article","10.15496/publikation-83524",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0038191","B54-10 Association of Glucagon-Like Peptide-1 Agonist Use With Pulmonary and Infectious Complications in Non-Alcoholic Steatohepatitis","H Kamal","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.4253",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038192","303-OR: Efficacy and Safety of BGM0504 in Chinese Patients with Type 2 Diabetes—A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Semaglutide Positive-Controlled Phase 2 Trial","Jiandong Yuan","2025","Diabetes","randomized_trial","article","10.2337/db25-303-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038193","The neuroprotective effect of GLP-1 receptor agonist liraglutide in a rat model of Wolfram syndrome","Seppa, Kadri","2021","DSpace repository (University of Tartu)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038194","Incretin mimetics: type 2 diabetes therapy beyond glucose control","Baptist Gallwitz","2004","International Journal of Clinical Practice","preclinical","article","10.1111/j.1368-504x.2004.00325.x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038195","427-P: Influence of Blood Pressure Management on the Renal Outcome in Patients Treated with SGLT2 Inhibitors and GLP1 Receptor Agonist","Kazuo Kobayashi","2024","Diabetes","nonrandomized_study","article","10.2337/db24-427-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038196","Incretin-Like Glycemic and Metabolic Effects of Luminal Starch Blockers",null,"2025","Acta Scientific Women s Health","other","article","10.31080/aswh.2025.07.0680",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038197","Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?","Masakazu Haneda","2008","Nephrology Dialysis Transplantation","other_trial","article","10.1093/ndt/gfn616","19015168",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038198","Cardiology Update 18 London","Andros Tofield","2019","European Heart Journal","other_trial","article","10.1093/eurheartj/ehz030","30789670",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0038199","PO-03-115 ASSOCIATION OF GLP-1 RECEPTOR AGONIST USE WITH ATRIAL AND VENTRICULAR ARRHYTHMIAS IN OBESE POPULATIONS WITH HEART FAILURE","Jefferson Hunter","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.854",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038200","Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands","Hunt, Barnaby","2018","Figshare","other","article","10.6084/m9.figshare.6099959",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038201","P5006Metformin reduces the risk of hospitalization for heart failure in type 2 diabetes patients: a retrospective cohort analysis","Chin‐Hsiao Tseng","2019","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehz746.0184",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038202","Suspected Optic Nerve Dysfunction Associated with Semaglutide in a Non-Diabetic Obese Patient: A Case Report","Badeeya Rashid","2026","Journal of Diabesity","case_report","article","10.66381/jod.2026.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038203","781-P: Sustained-Release Formulation Development and Preclinical Evaluations of Monthly or Bimonthly Injectable Semaglutide and Tirzepatide","Jin Gyoung Jung","2023","Diabetes","nonrandomized_study","article","10.2337/db23-781-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038204","Effect of semaglutide combined with metformin on type 2 diabetes mellitus and its regulation of IL-6/JAK2/STAT3 signaling axis","Xiaoxia Li","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.13429/j.cnki.cjcr.2026.06.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038205","Comparative effects of glucagon-like peptide-1 receptor agonists combined with hormone therapy on endometrial cancer risk among women with benign uterine or endometrial hyperplasia: A United States real-world retrospective study","Ting‐Tai Yen","2025","Gynecologic Oncology","nonrandomized_study","article","10.1016/j.ygyno.2025.04.029",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038206","MOESM5 of Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway","Feng, Yun","2020","Figshare","preclinical","article","10.6084/m9.figshare.11508111.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038207","Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","Hu, Yan","2024","Figshare","systematic_review","article","10.6084/m9.figshare.c.6935175.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0038208","Specialty Specific Guidance: An Orthopedic Surgeon's Guide to Using GLP-1 Receptor Agonists in Patients who are Obese or Overweight to Optimize Joint Health and Surgical Outcomes","Nasir Mustafa","2026",null,"other","article","10.13140/rg.2.2.22199.38561",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038209","PDB52 LONG-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VS. ROSIGLITAZONE IN THE CZECH REPUBLIC","Tomáš Doležal","2010","Value in Health","other","article","10.1016/s1098-3015(11)72110-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0038210","26-A-16842-ACC REAL WORLD IMPACT OF TIRZEPATIDE ON CLASS III OBESE PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION","Justin Haloot","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.160",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038211","PO411 CLINICAL PRACTICE USE OF LIRAGLUTIDE NEW TREATMENT FOR TYPE 2 DIABETES","Altanzul Altaisaikhan","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70705-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038212","Étude LEAN : Effet bénéfique du liraglutide sur la stéato-hépatite non alcoolique","Danièle Dubois‐Laforgue","2016","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(16)30108-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038213","Molecular pathomechanisms of immune-mediated epileptogenesis","Galvis Montes, Daniel Sebastian","2025","bonndoc (University of Bonn)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038214","Erratum",null,"2009","Expert Review of Endocrinology & Metabolism","other_trial","article","10.1586/eem.09.48","30736191",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","erratum"],["R0038215","New and Future Medications for the Treatment of Type 2 Diabetes Mellitus","Michael C. Mathers","2013","American Journal of Lifestyle Medicine","other","article","10.1177/1559827613498694",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038216","KNEE B-SCORE SHAPE FROM COMPUTED TOMOGRAPHY IS ASSOCIATED WITH SUBCHONDRAL BONE ATTENUATION AND MARGINAL CORTICAL BONE THICKNESS","C Thøger Nielsen","2024","Osteoarthritis Imaging","other_trial","article","10.1016/j.ostima.2024.100192",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0038217","S4045 Successful Necrosectomy Using the Over-the-Scope-Grasper Device: A Tool for Solid Necrotic Debris","Rahul Karna","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001045548.10701.47",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038218","S3217 Semaglutide-Induced FATAL Acute Necrotizing Pancreatitis Complicated by ARDS and Septic Shock","Deepak Kumar","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001140328.40132.f2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038219","735-P: Direct Anti-Inflammatory and Antifibrotic Effects of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist, HM15211, in Thioacetamide-Induced Mouse Model of Liver Injury and Fibrosis","JUNG KUK KIM","2022","Diabetes","preclinical","article","10.2337/db22-735-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038220","From diabetes care to metabolic care","Krishna Seshadri","2023","Journal of Diabetology","other","article","10.4103/jod.jod_69_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038221","Glucagon-Like Peptide 1 Agonists in Lung Transplantation, a Mixed Bag","R. Gordon Hester","2026","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2026.02.288",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038222","GLP1-RA: una nuova prospettiva nel controllo dell’iperfagia nella sindrome di Prader-Willi","Maria Francesca Milano","2026","L Endocrinologo","other","article","10.1007/s40619-026-01810-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038223","S171 The Over-Estimation of Pancreatic Cyst Malignant Transformation Rates: A Lesson From the EPIC Cosmos Database","Wade N. O'Brien","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001127144.37536.45",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038224","P286 Effets de l’agoniste des récepteurs du GLP-1 (GLP-1R) lixisenatide en une prise quotidienne sur la vidange gastrique et l’utilisation des glucides alimentaires sur des modèles animaux : comparaison avec le Liraglutide","U. Werner","2012","Diabetes & Metabolism","other","article","10.1016/s1262-3636(12)71388-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038225","LBP-029 Weight loss–independent Glucagon effect led to rapid, clinically significant reductions in MASH severity, including steatosis and liver stiffness, during a 48-week randomized controlled trial of dual agonist DD01","Mazen Noureddin","2026","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(26)00444-7",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038226","Combinations of the GLP-1 agonist exendin-4 and the opioid antagonist naltrexone inhibit food intake to a greater degree than either alone","Nu‐Chu Liang","2011","Appetite","other","article","10.1016/j.appet.2011.05.212",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038227","Efficacy of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease","Daiki Yoshiura","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.910",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038228","26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS","Mohab Elnashar","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.516",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038229","S4488 GLP-1 Agonists and Dyspeptic Symptoms: A Case Series in the Ambulatory Setting","Christopher Costa","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001145412.09488.2d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038230","Nonalcoholic fatty liver disease","Stergios A. Pοlyzos","2018","Hepatology","other","article","10.1002/hep.29897","29601090",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038231","CARDIOMETABOLIC EFFECTS OF SEMAGLUTIDE IN OBESE AND OVERWEIGHT PATIENTS WITH PREEXISTING CARDIOVASCULAR DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Luís Gustavo Menegardo Siqueira De Oliveira","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(25)00865-4",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0038232","Association of empagliflozin treatment with changes in the metabolic score for insulin resistance in Iraqi adults with type 2 diabetes: a 6-month prospective cohort study","Rawnaq Adil Aladhab","2026","International Journal of Basic & Clinical Pharmacology","nonrandomized_study","article","10.18203/2319-2003.ijbcp20262782",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038233","1800-P: GLP-1 Use in Type 1 Diabetes Patients: Assessing Changes in HbA1c, Body Weight, and Cardiovascular Disease Risk Reduction","Mushgan Nassiri","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1800-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038234","2610-P: Pathophysiological Obesity Phenotype–Guided Evaluation of Efficacy and Safety for GLP-1RA","YIRAN WANG","2026","Diabetes","other","article","10.2337/db26-2610-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038235","Research Highlights","Paulomi Mehta","2024","Transplantation","preclinical","article","10.1097/tp.0000000000005247","39760994",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038236","1657-P: Concomitant Use of GLP-1RAs and Chronic Opioids and Risk of Opioid Overdose and Substance Use Disorders","Sungho Bea","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1657-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038237","Reducing Treatment Complexity in Older Adults with T2DM: The Role of Fixed- Ratio GLP-1 Receptor Agonist/Insulin Combinations","Mustafa, Nasir","2022",null,"other","article","10.13140/rg.2.2.22640.53761",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038238","Sichere Therapie für Typ-2-Diabetiker – Effektive HBA1c-Senkung ohne Unterzuckerung und Gewichtszunahme",null,"2010","Diabetes aktuell","other","article","10.1055/s-0030-1268096",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038239","GLP-1 RECEPTOR AGONISTS IMPROVE MENSTRUAL REGULARITY IN POLYCYSTIC OVARY SYNDROME: A RETROSPECTIVE COHORT STUDY","Temiloluwa Oladeji","2026","Fertility and Sterility","nonrandomized_study","article","10.1016/j.fertnstert.2026.05.065",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038240","EE7 COST-UTILITY OF LIRAGLUTIDE VERSUS ORLISTAT FOR ADULT OBESITY MANAGEMENT IN SAUDI ARABIA A PAYER PERSPECTIVE ANALYSIS","Ahmed A. Alshehri","2026","Value in Health","other","article","10.1016/j.jval.2026.03.303",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038241","A comprehensive review of semaglutide in treating Type 2 diabetes and obesity","Isidoros Mentis","2025","Global Health Economics and Sustainability","narrative_review","article","10.36922/ghes.8547",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038242","Short-Term Changes in Hematologic Inflammatory Indices During Exenatide Therapy in Patients with Type 2 Diabetes Mellitus","Çiğdem CİNDOĞLU","2026","ASIDE Internal Medicine","nonrandomized_study","article","10.71079/aside.im.040826358",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038243","Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis","Shu, Hua","2018","Figshare","systematic_review","article","10.6084/m9.figshare.6210710",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0038244","424 Underregulation in the Online Market for Compounded Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and Tirzepatide: Marketing, Prescription Pro","R. Wyatt","2026","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2026.103430",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038245","1827-P: Add-On Semaglutide in the Treatment of Elderly with Type 2 Diabetes May Offer the Potential Benefits","KATARINA VUKELIC","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1827-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038246","CordenPharma to spend nearly $1 billion on peptide plants","Aayushi Pratap","2024","C&EN Global Enterprise","other","article","10.1021/cen-10222-buscon3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038247","The Social Construction of Off-label Drug Use: A Case Study of Ozempic Discourse on Social Media","Nazan Kartal","2025","International Journal of Mental Health and Addiction","other","article","10.1007/s11469-025-01599-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038248","Abstract 18777: Glucagon-like Peptide-1 Inhibits Thrombin-induced Human Platelet Aggregation","Alison Cameron-Vendrig","2012","Circulation","preclinical","article","10.1161/circ.126.suppl_21.a18777",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038249","Antiplatelet treatment in coronary syndrome","Stefan Agewall","2020","European Heart Journal - Cardiovascular Pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvab015","33720341",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038250","Incretine e diabete di tipo di 2 : effetti di Exenatide bis and die sul metabolismo glucidico e sulla composizione corporea (massa grassa, massa magra, peso corporeo, circonferenza vita, BMI, metabolismo energetico) in una popolazione di adulti affetti da diabete di tipo 2","V. Santini","2010","Cineca Institutional Research Information System (Tor Vergata University)","other","article","10.58015/santini-vanina_phd2010-03-03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038251","LipoLess Review: Legit or Overhyped Weight Loss Supplement? (2026) (D3N5KF)","jaix datu","2026",null,"narrative_review","article","10.55277/researchhub.lpijiy12.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0038252","1322-OR: Synergistic Effects of Dorzagliatin and Orforglipron on Glycemic Control and Adiposity in DIO Mice","Lingge Feng","2026","Diabetes","randomized_trial","article","10.2337/db26-1322-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038253","Retrospective evaluation of microalbuminuria and GFR levels of diabetic patients taking DPP-4 Inhibitor, GLP-1 Analog, or SGLT-2 Inhibitor","Bahriye Gültaş","2022","Turkish Journal of Internal Medicine","nonrandomized_study","article","10.46310/tjim.1072857",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038254","Insulin glargine/lixisenatide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-36625-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038255","Les analogues de GLP-1 dans l’arthrose : avancées et perspectives","Françis Berenbaum","2025","Médecine des Maladies Métaboliques","preclinical","article","10.1016/j.mmm.2025.06.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038256","Assessment of Awareness Toward Glucagon-Like Peptide-1 Anti-Diabetic Medication in Madinah City, Saudi Arabia: A Cross-Sectional Study","M Zala","2025","Saudi Journal of Medical and Pharmaceutical Sciences","other","article","10.36348/sjmps.2025.v11i07.007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038257","409-P: The Prevalence and Factors Associated with CKD Remission in Patients with Type 2 Diabetes Mellitus","TAO-CHUN LEE","2025","Diabetes","nonrandomized_study","article","10.2337/db25-409-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038258","[P2–167]: NOVEL DUAL GLP‐1 AND GIP RECEPTOR ANALOG ATTENUATES HIGH‐FAT‐DIET‐INDUCED DISEASE PROGRESSION IN 3XTG‐AD MICE","Jayasankar Kosaraju","2017","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2017.06.818",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038259","PD34-08 SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS ARE ASSOCIATED WITH A DECREASED RISK OF UROLITHIASIS COMPARED TO OTHER ANTIHYPERGLYCEMICS AMONG STONE-NAIVE DIABETICS","Ridwan Alam","2023","The Journal of Urology","randomized_trial","article","10.1097/ju.0000000000003327.08",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038260","Improving Protein Quality Through Targeted Chromatographic Profiling of Cell Culture Media","PC Shukla","2025","GEN Biotechnology","other","article","10.1177/27681572251401833",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038261","The Effects of Liraglutide on Cardiovascular Outcomes in Patients with Diabetes Type 2. A Systematic Review and Meta-Analysis","Chananard Siritanetdachatorn","2024",null,"systematic_review","article","10.13140/rg.2.2.21778.26562",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0038262","Research",null,"2025","Bone and Joint 360","randomized_trial","article","10.1302/2048-0105.143.360247",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038263","Tirzepatide-related improvement in sleep disordered breathing and hypoxic burden and its association with sleep apnoea cardiometabolic outcomes","Ali Azarbarzin","2025",null,"randomized_trial","article","10.1183/23120541.sleepandbreathing-2025.73",null,null,"ClinicalTrials.gov:NCT05412004","S000156","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0038264","Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Renal Insufficiency","Zachary T. Bloomgarden","2011","Endocrine Practice","other","article","10.1016/s1530-891x(20)43145-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038265","A Potential Role of Psoralea corylifolia L. Seed Extract in Diabetic Nephropathy","Jong Han Lee","2026","Diabetology","other","article","10.3390/diabetology7070141",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038266","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus—A Systematic Review and Meta-analysis","M M Satti","2018","Diabetes","systematic_review","article","10.2337/db18-1108-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0038267","Victoza® : nouvelle voie dans le traitement du diabète de type 2","Marie Solignac","2010","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(10)70110-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038268","G-418 Glucagon-Like Peptide-Receptor Agonists (GLP-1 RA) and Kidney Outcomes in Patients with Youth-Onset Type 2 Diabetes (YO-T2D)",null,"2025","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2025.02.419",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038269","SAT-414-YI Can non-diabetic patients with metabolic dysfunction associated steatotic liver disease benefit from glucagon-like peptide-1 analogs? A multicenter cohort study","Ritu Singh","2025","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(25)01677-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038270","Abstract WP109: Glucagon-Like Peptide-1 Has Anti-Inflammatory Effects Through Increasing IB1, A Scaffold Regulator Of JNK, In Cerebral Ischemia","Soojin Kim","2013","Stroke","preclinical","article","10.1161/str.44.suppl_1.awp109",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038271","Combining Insulin and Incretins in T2DM Management—Effect of Online Education on Physician Knowledge and Competence","Joachim Trier","2018","Diabetes","other","article","10.2337/db18-669-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038272","S3058 Comparative Risk of Small Intestinal Bacterial Overgrowth (SIBO) Among Patients Using GLP-1 Receptor Agonists: A Real-World Analysis Using TriNetX","Lina AlQirem","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001139692.64685.fa",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038273","The Impact of GLP-1 Agonist Therapy and Lifestyle Modifications on Body Composition: A Case Study Approach","Andrew R. Jagim","2025",null,"other","article","10.1370/afm.23.s1.7435",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0038274","LY307161: A GLP-1 analogue with extended time action and increased activity in vivo","Sharon R Myers","2000","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(00)81310-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038275","Molecular mechanism of Haikun Shenxi Capsules as adjuvant therapy for diabetic kidney disease through the interleukin-23/interleukin-17 inflammatory axis","Zhang An-na","2025","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0038276","Comparative efficacy and safety of Tirzepatide versus Semaglutide for obesity management","Kishore Kumar Shil","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","nonrandomized_study","article","10.3329/jacedb.v4i20.84989",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038277","Η επίδραση των νεότερων αντιδιαβητικών αγωγών στη μεταβολή βιοδεικτών και η συσχέτιση τους με την αγγειακή και την καρδιακή λειτουργία σε ασθενείς με σακχαρώδη διαβήτη τύπου 2","Ιωάννης Θυμής","2022",null,"other","article","10.12681/eadd/52790",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038278","REMISSIONE DEL DIABETE MELLITO DI TIPO 2 DOPO CHIRURGIA BARIATRICA: MECCANISMI FISIOPATOLOGICI E SIGNIFICATO CLINICO","Gabriella Nosso","2015","Università degli Studi di Napoli Federico II","other","article","10.6092/unina/fedoa/10362",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038279","An integrated approach for obesity management: the effectiveness of glucagon-like peptide 1 agonist and life-style interventions for obesity management","Andrii Dinets","2022","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","other","article","10.22141/2224-0721.18.3.2022.1161",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038280","Who Doesn't Love an Underdog?","Joe Mechlinski","2024",null,"other","article","10.1002/9781394308378.ch7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038281","Additional file 2 of Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes","Davies, Melanie J.","2022","Figshare","other_trial","article","10.6084/m9.figshare.20438492",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0038282","Results from pivotal studies with exenatide","Schnabel, Catherine A","2011","Figshare","other","article","10.6084/m9.figshare.18950",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038283","Mechanisms of Inflammation-Fibrosis in Diabetic Nephropathy and Intervention Strategies of Traditional Chinese and Western Medicine","Yuying Jia","2026","Journal of Contemporary Medical Practice","other","article","10.53469/jcmp.2026.08(01).46",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038284","P234 Glucagon-like-peptide-1 receptor agonists and cholecystitis incidence in type 2 diabetic mellitus and obesity: insights from the TriNetX database (2015–2024)","Ruchir Paladiya","2025",null,"nonrandomized_study","article","10.1136/gutjnl-2025-bsg.368",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038285","Therapeutic effects of glucagon-like peptide -1 receptor agonist in adult overweight and obese women with polycystic ovary syndrome: a narrative review","F. Keli","2024","Journal of Kenya Assocation of Physicians","randomized_trial","article","10.4314/jkap.v6i2.19a",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0038286","Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity","Dehshini Ali","2026","Diabetes Obesity and Cardiometabolic CARE","nonrandomized_study","article","10.2337/doc25-0026",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038287","Metformin/semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-44698-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038288","S27 Detection of Ultra-High Risk Pancreatic Cancer Diagnoses Using a Custom NLP Pipeline Incorporating a Large Language Model: A Pilot Safety Net for Missed Diagnoses","Aman Mohapatra","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001126568.63035.43",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038289","S1317 Effect of GLP-1 Receptor Agonists on Quality of Bowel Preparation for Colonoscopy: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis","Hayder Alamily","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001132728.40130.cb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0038290","Tip 2 diabetes mellitus tedavisinde inkretinler","Ramis Çolak","2012","Journal of Experimental and Clinical Medicine","other","article","10.5835/jecm.omu.29.s1.007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038291","Pleiotropic actions of GLP-1 RA","Young Min Cho","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)30929-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038292","Dulaglutide blijkt effectief bij Japanse patiënten","Bohn Stafleu van Loghum","2015","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-015-0012-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038293","Uso della liraglutide nel trattamento dell’obesità","Fabiana Picconi","2017","L Endocrinologo","other","article","10.1007/s40619-017-0299-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038294","Liraglutide/metoprolol",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-41910-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038295","The new era of aspiration risk: The dilemma of GLP-1 receptor agonists","Jack Madden","2024","Journal of Perioperative Nursing","other","article","10.26550/2209-1092.1291",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038296","Diabetic Kidney Disease","Lili Tong","2017","Clinical Journal of the American Society of Nephrology","randomized_trial","article","10.2215/cjn.04650417","29046291",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0038297","More than One-Half of Adults Hospitalized for COVID-19 Still Report Significant Symptoms at Four Months Postdischarge.","Henry C Barry","2021","PubMed","other","article",null,"34383435",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038298","Anti-Inflammatory and Anti-Oxidative Effects of GLP1-RAs and SGLT2i: The Guiding Star Towards Cardiovascular Protection in Type 2 Diabetes","Livia M. R. Marcon","2025","Immuno","other","article","10.3390/immuno5010011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038299","GLP-1 receptor agonist-related risk of pancreatic cancer",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-36789-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038300","Anesthetic Guidelines for Patients on Glucagon-Like Peptide Receptor Agonists","Martin, Megan Elizabeth","2025","UA Campus Repository (The University of Arizona)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038301","Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program","Khunti, Kamlesh","2018","Figshare","other_trial","article","10.6084/m9.figshare.6171386",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0038302","From Diabetes to Weight Loss: The Problems with Semaglutide's Expanded Use","R. Ben Othman","2025","University of Ottawa Journal of Medicine","other","article","10.18192/uojm.v15is2.7533",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038303","Gli effetti del glucagone e degli agonisti del GLP-1R in un modello di precursori adiposi umani Effects of glucagon and GLP-1 receptors agonists on human adipose precursors","Trabucco M","2022","Florence Research (University of Florence)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038304","Successful treatment of obesity and diabetes with incretin analogue over four years in an adult with Prader–Willi syndrome","RB Paisey","2011","Practical Diabetes","other","article","10.1002/pdi.1621",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038305","Correction: Neonatal Exendin-4 Reduces Growth, Fat Deposition and Glucose Tolerance during Treatment in the Intrauterine Growth-Restricted Lamb","The PLOS ONE Staff","2014","PLoS ONE","notice","article","10.1371/journal.pone.0095944",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0038306","Hope in Hopeless Times: Gearing Up to Fight the Obesity Pandemic","Denise D. Belsham","2020","Endocrinology","other","article","10.1210/endocr/bqaa144","32894767",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038307","Efficacy of glucagon-like peptide-1 receptor agonist and basal insulin combination therapy for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","Dooley, Gordon","2014","York","systematic_review","article","10.15124/crd42014010688",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0038308","752-P: Study Design and Baseline Profile for Patients with Type 2 Diabetes in the Semaglutide Once-Weekly Randomized Pragmatic Trial (SEPRA)","Vincent J. Willey","2022","Diabetes","protocol","article","10.2337/db22-752-p",null,null,"ClinicalTrials.gov:NCT03596450","S000545","openalex","FALSE","paywalled","5","FALSE","article"],["R0038309","YH25724, a novel long-acting GLP-1/FGF21 dual agonist lowers both non-alcoholic fatty liver disease activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis","Haiou Hong","2017","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(17)30295-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038310","998-P: Efficacy and Safety of Semaglutide by Baseline BMI in SUSTAIN 1-5 and 7","Adie Viljoen","2019","Diabetes","other_trial","article","10.2337/db19-998-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038311","2303-PUB: Efficacy of Dulaglutide (DU) as First Injectable Option for Patients with Type 2 Diabetes (T2D): A Post Hoc Pooled Analysis","Hiren Patel","2019","Diabetes","other","article","10.2337/db19-2303-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038312","Tirzepatide in Egypt: A New Era in Type 2 Diabetes and Obesity Management","Hossam Arafa Ghazi","2026",null,"nonrandomized_study","article","10.5005/jodec-11035-0006",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038313","The correlation amongst insulin resistance indices( including TyG index, TyG-BMI,AIP, METS-IR along with results in patients with heart failure with preserved ejection fraction- A Short Communication","Dr Kulvinder Kochar Kaur","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16793922",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038314","Glucagon-like peptide-1 receptor agonists as potential preventive and therapeutic agents in ischemic stroke","Muhammad Ali","2025","Advanced Neurology","other","article","10.36922/an025150027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038315","Real-World Comparative Effectiveness and Treatment Persistence of Tirzepatide versus Semaglutide in Middle Eastern Populations: A Systematic Review and Meta-Analysis (2020–2026)","Waqar Khan","2026","Journal of Medical Research and Reviews","systematic_review","article","10.5455/jmrr.20260526050512",null,null,"PROSPERO:CRD42026019344",null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0038316","Additional file 3 of Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin","Yang, Xiaotong","2020","Figshare","preclinical","article","10.6084/m9.figshare.12332087",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038317","Medullary Thyroid Carcinoma in an Obese Diabetic Male Patient on Semaglutide",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.691",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038318","The Role of Long Non-coding RNAs in Regulating Adipogenesis and Metabolism","Weixiu Ji","2026","PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS","other","article","10.3724/j.pibb.2025.0539",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038319","Oral Semaglutide Reduces HbA1c and Body Weight in Patients With Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses","Adis Journals On Behalf Of","2021","Figshare","other","article","10.6084/m9.figshare.13477029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038320","Observational Study: Glycemic Control & CV Outcomes Among Patients With T2DM Newly Initiating GLP1-RAs vs Basal Insulin",null,"2019","Case Medical Research","other","article","10.31525/ct1-nct04006379",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038321","Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial","Li, Feng-fei","2018","Figshare","randomized_trial","article","10.6084/m9.figshare.6189518",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0038322","Risk of Community Acquired Pneumonia Among Diabetics Treated with Semaglutide","Hoang-Tran, Cindy","2024",null,"other","article","10.13140/rg.2.2.12014.11844",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038323","Dulaglutid wirkt bei Patienten mit Typ-2-Diabetes kardioprotektiv","Maddalena Angela Di Lellis","2023","Diabetologie und Stoffwechsel","other","article","10.1055/a-1974-3006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038324","The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes","Marko Skelin","2019","European Heart Journal","other","article","10.1093/eurheartj/ehz242","31323668",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038325","Dose-Response Relationship of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis","Yong Yang","2023","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.4618777",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0038326","S1266 Preventing Inadequate Colonoscopy Bowel Preparation With the Targeted Addition of Adjuncts: A Quality Improvement Study","Hussam Sabbagh","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001132524.04776.68",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038327","Treatment Response Heterogeneity’s Existence Should Not Be Dismissed, But Should Neither Be Presumed: Illustration in Metabolic Effects of GIP and GLP-1 Receptor Agonists in Overweight and Obese Individuals","Thirupathi Reddy Mokalla","2025",null,"other","article","10.13140/rg.2.2.23159.69281",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038328","PrRP‐GPR10 Signaling and Metabolism","Claire H. Feetham","2026",null,"preclinical","article","10.1002/9783527845408.ch8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038329","1055-P: Glycemic Variability with Dulaglutide vs. Basal Insulin Glargine","Esteban Jódar","2020","Diabetes","randomized_trial","article","10.2337/db20-1055-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038330","1319-OR: Oral TIX100 Protects against Weight Rebound after Semaglutide Discontinuation","Seongho Jo","2026","Diabetes","other_trial","article","10.2337/db26-1319-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038331","Analoghi del glucagon-like peptide (GLP-1) per uso topico","RAIMONDI, LAURA","2012","Florence Research (University of Florence)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038332","S809 Gastric Emptying Scintigraphy: Understanding Nuclear Medicine’s Real World Clinical Practice","Daniel Staursky","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032604.58940.5f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038333","S824 Impact of GLP-1 RA Therapy on Esophageal Motility Patterns","Annie L. Wang","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130756.96696.bd",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038334","Comprehensive insights into diabetic nephropathy: pathophysiology, clinical features, and emerging treatments","Mohamad M. Habli","2024","Journal of The Egyptian Society of Nephrology and Transplantation","other","article","10.4103/jesnt.jesnt_16_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038335","Antidiabetic effects of Cassia abbreviata Oliv. leaf fractions extracts in type 2 diabetic male adult Wistar rats","Emmanuel M. Musenge","2025","Investigational Medicinal Chemistry and Pharmacology","preclinical","article","10.31183/imcp.2025.00110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038336","Additional file 3: of Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance","Abdesselam, Inès","2015","Figshare","preclinical","article","10.6084/m9.figshare.c.3624287_d1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038337","Two views of elusive diabetes drug target","STU BORMAN","2017","C&EN Global Enterprise","other","article","10.1021/cen-09524-notw3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038338","Glucagon-like peptide 1 receptor agonists in the treatment of type II diabetes","Xi Chen","2023",null,"other","article","10.1117/12.2669050",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0038339","Insulin degludec/liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-34898-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038340","Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study","Adis Journals On Behalf Of:","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.25574685",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038341","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-51245-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038342","Endocrinology for the hepatologist","Sadaf Afraz","2023","Clinical Liver Disease","randomized_trial","article","10.1097/cld.0000000000000037","37521181",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0038343","1873-LB: Comparison of Adherence and Persistence between Oral Semaglutide and Once-Weekly Semaglutide Injection at 12-Month Follow-up in Japanese Real-World Data","Takeshi Horii","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1873-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038344","449-P: Liraglutide Rapid Effects on Glucose and Adipose Tissue during and after CABG","Gianluca Iacobellis","2024","Diabetes","randomized_trial","article","10.2337/db24-449-p",null,null,"ClinicalTrials.gov:NCT03260881","S000936","openalex","FALSE","paywalled","1","FALSE","article"],["R0038345","2755-LB: Education and Implementation to Improve Prescription of Guideline-Based Cardiorenal Protective Medications","KRISTEN KULASA","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2755-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038346","Integrating Clinical Decision Support Systems in CKD Management","C. Elena Cervantes","2026","Kidney International Reports","other","article","10.1016/j.ekir.2026.106633","42436698",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038347","EFFICACY AND SAFETY OF SEMAGLUTIDE FOR WEIGHT LOSS","Silva, Thaiz","2025","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.17815944",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0038348","A Systematic Review of Exenatide in Glycemic Control","Alvaro Ramos","2010","CommonKnowledge Research Repository (Pacific University Oregon)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0038349","Exacerbation of Hypoglycemia in a Post-Roux-en-Y Gastric Bypass Patient on Glucagon-Like Peptide-1 Agonist Therapy: A Case Report",null,"2025","Endocrine Practice","case_report","article","10.1016/j.eprac.2025.05.469",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038350","RWD78 SOCIAL MEDIA CONVERSATIONS ON GLP-1 THERAPIES FOR OBESITY: REAL-WORLD EXPERIENCES AND TREATMENT NARRATIVES","Rachna Rana","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.2066",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038351","GLP-1 Receptor Agonists Associated With Reduced Surgical Interventions in Hidradenitis Suppurativa: A Propensity Score-Matched Analysis","Kermanjot Sidhu","2025",null,"nonrandomized_study","article","10.13140/rg.2.2.28313.68960",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0038352","Lilly (ELI) & Co.",null,"2007","Mergent s Dividend Achievers","other","article","10.1002/div.6043",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038353","Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Post Prandial Blood Glucose",null,"2026","Endocrine Practice","other_trial","article","10.1016/j.eprac.2026.03.026",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038354","90-LB: Characterization of Tirzepatide-Treated patients achieving HbA1c <5.7% in the SURPASS 1-4 Trials","JULIO ROSENSTOCK","2022","Diabetes","other","article","10.2337/db22-90-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038355","Ecnoglutide: First Approvals","Matt Shirley","2026","Figshare","other","article","10.6084/m9.figshare.32320305",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038356","Precision nutrition while weight loss therapy: Defending lean mass as a standard of care","Anuj Maheshwari","2026","IP Journal of Nutrition Metabolism and Health Science","other","article","10.18231/j.ijnmhs.25737.1783318799",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038357","Short-term continuous subcutaneous insulin infusion combined with metformin and semaglutide in the treatment of type 2 diabetes mellitus","ZHANG Mimi","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.13429/j.cnki.cjcr.2026.06.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038358","EPH5 USE OF GLUCAGON-LIKE PEPTIDE 1 AGONISTS (GLP-1RAS) BEFORE BARIATRIC SURGERY IN THE US","Abigail Zion","2026","Value in Health","other","article","10.1016/j.jval.2026.03.838",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038359","840-P: Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Type 2 Diabetes according to Baseline Glucagon-Like Peptide 1 Receptor Agonist Use—ONWARDS 1–5","Tina Vilsbøll","2024","Diabetes","other_trial","article","10.2337/db24-840-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038360","If drugs with metabolic action affect the intestinal microbiota. Literature review","Фадєєнко, Г. Д.","2022","Scientific periodicals of Ukraine","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038361","1727-P: Tirzepatide Induced Cardiometabolic Transformation in Indian Patients with Obesity: A Prospective Cohort Study","ADITYA JAIN","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1727-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038362","A85 PATTERN OF SEMAGLUTIDE PRESCRIPTION IN A REAL-WORLD PATIENT COHORT","Armin Farahvash","2025","Journal of the Canadian Association of Gastroenterology","randomized_trial","article","10.1093/jcag/gwae059.085",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0038363","S1264 Combination Therapy Yields Similar Efficacy and Improved Safety Compared to Surgical Revision for the Management of Weight Regain Following Roux-en-Y Gastric Bypass","Pichamol Jirapinyo","2021","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000778588.31528.c7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038364","146-OR: Differences in HbA1c-Lowering Effect and Hypoglycemia Risk between Gla-300 and IDeg According to Renal Function in the BRIGHT Trial","Martin Haluzı́k","2019","Diabetes","randomized_trial","article","10.2337/db19-146-or",null,null,"ClinicalTrials.gov:NCT02738151","S002664","openalex","FALSE","paywalled","1","FALSE","article"],["R0038365","Patient Perceptions of Ozempic (Semaglutide) for Weight Loss: Mixed Methods Analysis of Online Medication Reviews (Preprint)","Abanoub J. Armanious","2025",null,"nonrandomized_study","article","10.2196/preprints.78391",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","preprint"],["R0038366","1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats","YUNA CHAE","2023","Diabetes","preclinical","article","10.2337/db23-1676-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038367","Enfermedad por esteatosis hepática, 2023 un año de cambios: revisión en la nomenclatura, diagnóstico y tratamiento","Iván Fernández Castro","2024","Galicia Clínica","other","article","10.22546/85/1/1269",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038368","The effect of liraglutide on body weight among binge eating obese non-diabetic subjects","Sarah Anne Robert","2013","Obesity Research & Clinical Practice","other","article","10.1016/j.orcp.2013.12.645",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038369","Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists","Massimo Volpe","2020","Cardiovascular Research","randomized_trial","article","10.1093/cvr/cvaa334","33231613",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0038370","Paying the Price for Eating Ice Cream: Is Excessive GLP-1 Signaling in the Brain the Culprit?","Hans‐Rudolf Berthoud","2008","Endocrinology","preclinical","article","10.1210/en.2008-0932","18809947",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038371","[ 68 Ga]Ga-NODAGA-exendin-4 PET/CT for the diagnosis and localization of focal congenital hyperinsulinism","Marti Boss","2020","Nuklearmedizin - NuclearMedicine","nonrandomized_study","article","10.1055/s-0040-1708240",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0038372","Lipid treatment","Stefan Agewall","2025","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvaf009","40079901",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0038373","Perspective Chapter: A Critical Overview of Metformin Use from Past to Present","Ahmet Hakan Türk","2026","Pharmaceutical science.","other","article","10.5772/intechopen.1012223",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0038374","Dosisabhängige Effekte von Survodutid auf den HbA1c-Wert und das Körpergewicht","R. Maria Clauss","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2265-4753",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038375","848-P: The Antidiabetic Medication Treatment Patterns in Chinese Patients with Type 2 Diabetes—Real-World Evidence from ICaReMe China Registry Study","Han Wu","2025","Diabetes","nonrandomized_study","article","10.2337/db25-848-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038376","Su1817: EFFECT OF GLP-1 AGONISTS ON GI SYMPTOMS IN PATIENTS WITH GI MOTILITY DISORDERS","Rushil Reddy","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02891-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038377","Lowering Hepatic Enzyme Levels with Tirzepatide, a Case Study","Shaw, April P","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038378","Abstract 671: Glucagon-like Peptide-1 Inhibits Abdominal Aortic Aneurysm Development","Keisuke Morimoto","2015","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvb.35.suppl_1.671",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038379","Incretin-based therapy has better glycemic sustainability and less variability in patients with diabetes on stable anti-diabetic medications","Bing Ru Gau","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31249-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038380","2906-LB: Utilization of GLP-1RA and SGLT2i Medication Classes in Medicaid: Results from an Academic Health System","HUGO A. TORRES","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2906-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038381","2551-P: Survodutide Improves Stroke Outcome in Obese/Type 2 Diabetic Mice","Ellen Vercalsteren","2026","Diabetes","other_trial","article","10.2337/db26-2551-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038382","1282-OR: Major Adverse Limb Events with Tirzepatide vs. Injectable Semaglutide in Adults with Type 2 Diabetes and Peripheral Artery Disease","Kevin Cowart","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1282-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038383","Acute renal infarction associated with Semaglutide (Ozempec) use","Kamel El-Reshaid","2025","International Journal of Case Reports and Images","other","article","10.5348/101491z01ke2025cr",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038384","2114-P: Quantification of GLP-1R Trafficking in Primary Beta Cells in Response to Different Ligands","Sarah M. Gray","2020","Diabetes","preclinical","article","10.2337/db20-2114-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038385","The Silent Trigger A Rare Case of Anaphylaxis to an Excipient in Oral Semaglutide","Hamdan Khalid Alawadhi","2025",null,"other","article","10.13140/rg.2.2.15685.15843",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038386","GLP-1 Receptor Agonist","Seung Min Chung","2024","Journal of Korean Diabetes","other","article","10.4093/jkd.2024.25.2.69",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038387","Drug News",null,"2024","Nursing","other","article","10.1097/nsg.0000000000000103","39792109",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038388","2846-LB: Efficacy and Safety of Semaglutide by Race and Ethnicity in the SELECT Trial","Jamy Ard","2026","Diabetes","randomized_trial","article","10.2337/db26-2846-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038389","Advances in Translational Research on GLP-1 Receptor Agonists for Disease-Modifying Therapy of Parkinson’s Disease","裴瑶 魏","2026","Advances in Clinical Medicine","other","article","10.12677/acm.2026.1651903",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038390","Incretin-Based Therapeutics: A Dual-Pronged Evaluation of Global Health Impact and Clinical Viability (Preprint)","Esteban Ortiz-Prado","2026",null,"other","article","10.2196/preprints.99738",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0038391","Abstract 03: Impact of SGLT 2 inhibitors and GLP-1 receptor agonists dual therapy on Cardiovascular Outcomes in patients with Heart Failure with Reduced Ejection Fraction and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Propensity-Matched Cohort","Preet Doshi","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.03",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038392","1435-P: Dulaglutide Exerts More Beneficial Antiatherosclerotic Effects in Early Phase of Diabetes than in Late Phase in ApoE Knockout Mice with Diabetes","Junpei Sanada","2020","Diabetes","preclinical","article","10.2337/db20-1435-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038393","4149 BARIATRIC SURGERY EFFECTIVENESS AFTER GLP-1 AGONIST WEIGHT LOSS",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038394","769-P: Efficacy and Safety of GLP1RAs in Liver-Transplanted People with Diabetes—Ad Interim Results of a 24-Month Trial","Valeria Grancini","2024","Diabetes","other_trial","article","10.2337/db24-769-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038395","The dark side of the ‘miracle jab’: why eating disorder safety cannot be an afterthought",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.395589",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038396","P-100. MOUNJARO: PRIMERAS IMPRESIONES Y RESULTADOS EN LA PRÁCTICA CLÍNICA REAL","S. Jiménez Blanco","2025","Endocrinología Diabetes y Nutrición","other","article","10.1016/s2530-0164(25)00262-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038397","Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators","of:, AdisRapid Journals on behalf","2023","Figshare","other","article","10.6084/m9.figshare.22645201",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038398","776-P: Comparative Effectiveness of SC Semaglutide in Adults with T2D in U.S. Routine Clinical Practice—Year 1 Results of SEPRA, a Randomized Pragmatic Clinical Trial","John B. Buse","2023","Diabetes","randomized_trial","article","10.2337/db23-776-p",null,null,"ClinicalTrials.gov:NCT03596450","S000545","openalex","FALSE","paywalled","1","FALSE","article"],["R0038399","The Impact of GLP-1 Receptor Agonists on Patients with Diabetes on Insulin Therapy","Wardian, Jana","2018",null,"other","article","10.13140/rg.2.2.27440.66566",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038400","THE BIRD'S TASBEEH — FIRST COMPLETE DECODING OF AVIAN VOCALIZATION IN HISTORY How the Robin Recites Subhan Allah, Alhamdulillah, and Allahu Akbar at 135.5° Phase Lock","Muhammad Usman Malik","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19673850",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038401","731-P: Metabolite Biomarkers and Cardiovascular Events in REWIND: A Post Hoc Analysis","Valentina Pirro","2022","Diabetes","nonrandomized_study","article","10.2337/db22-731-p",null,null,"ClinicalTrials.gov:NCT01394952","S000147","openalex","FALSE","paywalled","4","FALSE","article"],["R0038402","Figure 1S.pptx","Sato, Tetsuhiko","2023","Figshare","nonrandomized_study","article","10.6084/m9.figshare.22122329",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038403","AB128. SOH25_AB_092. A systematic literature review of anaesthesia guidelines for GLP-1 medications and proposed fasting times","Kieran Moloney","2025","Mesentery and Peritoneum","nonrandomized_study","article","10.21037/map-25-ab128",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0038404","FRI-201 Effect of pemvidutide on cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis: 48-week results from the phase 2b, IMPACT trial","Dr John Suschak","2026","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(26)01936-7",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0038405","Lilly (Eli) & Co.",null,"2006","Mergent s Dividend Achievers","other","article","10.1002/div.4807",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038406","438-P: Very-Low-Dose Metformin Can Safely Improve Glycemic Control in Type 2 Diabetic Patients Receiving Maintenance Hemodialysis (HD)","SATOSHI FUNAKOSHI","2023","Diabetes","other","article","10.2337/db23-438-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038407","Inkretin hatáserősítők, inkretin mimetikumok – a terápiás alkalmazás kigondolásától a gyakorlati megvalósításig = Incretin enhancers, incretin mimetics – from therapeutic concept to clinical application","Gábor Winkler","2007","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038408","Inkretintengelyen ható gyógyszerek a 2-es típusú diabetes kezelésében = Incretin-based therapy for treating patients with type 2 diabetes","György Jermendy","2011","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038409","Abstract #148: Exenatide Suppresses TGFβ1: A Novel Potential Role for Glp-1 Agonists in Nephropathy","Husam Ghanim","2016","Endocrine Practice","other","article","10.1016/s1530-891x(20)44907-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038410","4152 PREOPERATIVE GLP-1 RECEPTOR AGONIST (GLP-1 RA) USE PREDICTS POSTOPERATIVE GLP-1 RA USE, BUT NOT GREATER PERCENT TOTAL WEIGHT LOSS (%TWL), 1-YEAR AFTER METABOLIC/BARIATRIC SURGERY (BMS)",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.213",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038411","1196-P: Impact of Pharmacist-Driven Access to Therapy in Type 2 Diabetes Mellitus","Margaret Allison","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1196-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038412","921-P: Liraglutide Improves NAFLD in Patients with Type 2 Diabetes","Debasis Basu","2020","Diabetes","other","article","10.2337/db20-921-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038413","EXPLORING THE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 AGONIST IN VENTRICULAR ARRHYTHMIA","Min Choon Tan","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00496-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038414","FRI-202 Semaglutide improves hepatic and cardiometabolic outcomes in paediatric metabolic dysfunction-associated steatotic liver disease: a prospective observational study","Andrea Tou","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)01937-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038415","Semaglutid-Effekte bei HFpEF und Adipositas unabhängig von LVEF","Johannes B. Dahm","2024","Aktuelle Kardiologie","other","article","10.1055/a-2222-5502",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038416","2002-LB: Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist—Results of a Phase 1b/2a Clinical Trial","Kirsten Dahl","2025","Diabetes","randomized_trial","article","10.2337/db25-2002-lb",null,null,"ClinicalTrials.gov:NCT06064006","S003223","openalex","FALSE","paywalled","1","FALSE","article"],["R0038417","1926-LB: Use of Continuous Glucose Monitoring and Health Care Resource Utilization in Patients with Diabetes Treated with Sulfonylureas/Meglitinides","RODOLFO J. GALINDO","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1926-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038418","1102-OR: Adipose-Targeted ALK7 siRNA Synergizes with Tirzepatide to Reduce Fat Mass while Preserving Lean Mass in Diet-Induced Obese Mice","Nan Liu","2026","Diabetes","preclinical","article","10.2337/db26-1102-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038419","1106-OR: Prevention of Weight Rebound and Restoration of Muscle Mass after Semaglutide Withdrawal Using Bc-006, an INHBE siRNA, in a Nonhuman Primate Obesity Model","JING YANG","2026","Diabetes","randomized_trial","article","10.2337/db26-1106-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038420","The Role of Nitrergic System In The Effect of Exenatide on Penicillin Induced Epileptiform Activity","Ayşegül Yıldız","2020",null,"other","article","10.13140/rg.2.2.32701.69602",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038421","Abstract 13697: Glucagon-like Peptide-1 Analogue Liraglutide Does Not Improve Microvascular Myocardial Function in Patients With Type 2 Diabetes - a Randomized, Single-blinded Cross Over Trial","Rebekka Faber","2014","Circulation","randomized_trial","article","10.1161/circ.130.suppl_2.13697",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038422","Analysis of Inflated Drug Prices in the United States","Simryn Patel","2025",null,"other","article","10.58445/rars.3061",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038423","Marked Improvement in Glycemic Control with Exenatide on Addition to Metformin, Sulfonylurea and Insulin Glargine in Type 2 Diabetes Mellitus, a Real World Experience","Salina Esmail","2018","Journal of Diabetes Mellitus","nonrandomized_study","article","10.4236/jdm.2018.84015",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038424","Tirzepatide Suppresses NF-κB Gene Expression in Colorectal Cancer Cells In Vitro","Zeenah Waheed Atwan","2025","The Medical Journal of Basrah University","preclinical","article","10.33762/mjbu.2025.166749.1333",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038425","A Case of Tirzepatide-Associated Ketoacidosis in a Patient Without Diabetes",null,"2025","Endocrine Practice","case_report","article","10.1016/j.eprac.2025.05.115",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038426","Cardiotoxicity and Survival Outcomes in Obese EGFR Exon 19 and 21-Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors and GLP-1 Agonists: A 5-Year Analysis. Background","Yohannes Haile","2025",null,"other","article","10.13140/rg.2.2.16126.91208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038427","Abstract P137: Real-World Impact of Semaglutide on Cardiometabolic Risk Factors in Patients without Diabetes: A Multi-Center Analysis of Electronic Health Records","Chungsoo Kim","2024","Hypertension","randomized_trial","article","10.1161/hyp.81.suppl_1.p137",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038428","Klausuleret tilskud til Wegovy","Andreas Holm Joensen","2025","Reformator – Tidsskrift for samfundsløsninger","other","article","10.7146/reformator.1.2025.161464",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038429","Abstract 146: Biphasic Effect Of Cyclic Amp Axis On Cardiomyocyte Survival","Morihiko Aoyama","2014","Circulation Research","preclinical","article","10.1161/res.115.suppl_1.146",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038430","Abstract 4364905: Beyond Glycemic Control: Cardiovascular Benefits of GLP-1 Receptor Agonists in Type 2 Diabetes","Shahzeb Saeed","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4364905",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038431","Comparaison de l’utilisation des stylos de lixisénatide, exénatide et liraglutide par des patients ayant un diabète de type 2","Alfred Penfornis","2013","Annales d Endocrinologie","other","article","10.1016/j.ando.2013.07.570",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038432","Endocrinologia: efeitos da terapia combinada com metformina e agonistas do GLP-1 na redução do peso corporal em pacientes com diabetes tipo 2","Matheus Henrique de Sousa Macêdo","2024","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","randomized_trial","article","10.18378/rebes.v14i3.10839",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0038433","Gastrin—A Potential Predictor of Glucoregulation in Newly Diagnosed Type 2 Diabetes Patients","Maja Cigrovski Berković","2018","Diabetes","other","article","10.2337/db18-1965-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038434","Achieving Composite Endpoint of A1C <7.0% without Weight Gain or Hypoglycemia with Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes—Post-Hoc Analysis","Xinhua Xiao","2018","Diabetes","randomized_trial","article","10.2337/db18-1069-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038435","Heart Valve Disease 2 GLP1-RA SEMAGLUTIDE AND SLOWING PROGRESSION OF AORTIC VALVE STENOSIS IN NON DIABETIC PATIENTS","G Marchetti","2026",null,"other","article","10.13140/rg.2.2.36482.03523",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038436","Effects of exendin in rats trained to discriminate between 22 and 2 hr food deprivation","David C. Jewett","2010","The FASEB Journal","preclinical","article","10.1096/fasebj.24.1_supplement.lb457",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038437","A review on the use of adjunctive therapies in artificial pancreas systems","Clara Furió-Novejarque","2024","IFAC-PapersOnLine","narrative_review","article","10.1016/j.ifacol.2024.11.053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038438","72390 Population Trends in Facial Aesthetic Concerns Among Patients Receiving GLP-1 Agonists for Weight Loss","Cheryl Burgess","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.1371",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038439","CON: GLUCOSE IS THE MOST IMPORTANT TARGET FOR CARDIOVASCULAR PREVENTION IN DIABETES","Francesco Giorgino","2017","Artery Research","other","article","10.1016/j.artres.2017.10.012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038440","26-A-19426-ACC GLP-1 RECEPTOR AGONISTS AND OUTCOMES IN TAKOTSUBO SYNDROME: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS","Ure K Eziyi","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1673",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038441","The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-on Therapy","Meece, Jerry","2018","Figshare","other","article","10.6084/m9.figshare.6411101",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038442","Additional file 1 of Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin","Uchinuma, Hiroyuki","2020","Figshare","other","article","10.6084/m9.figshare.12270095",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038443","Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management",null,"2023","Hepatology","notice","article","10.1097/hep.0000000000000564","37967003",null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0038444","Structural Insights into Multiplexed Pharmacological Actions of Mazdutide At the Glp-1 or Glucagon Receptors","Zhang Jinhua","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5376321",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038445","The Utility of Gastric Ultrasound in Anaesthesia Education: Participant Survey Data from a Statewide Gastric POCUS Workshop","Libiran, Nicole Bianca","2025","IUScholarWorks (Indiana University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038446","Impact of Short-term Medical Weight Loss on Atherosclerotic Cardiovascular Disease Risk in Patients with Obesity","XIANG  Xinyue, ZHANG  Bingqing, OUYANG  Yuqin, TANG  Wenjuan, FENG  Wenhuan","2025","DOAJ (DOAJ: Directory of Open Access Journals)","nonrandomized_study","article","10.12114/j.issn.1007-9572.2024.0652",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0038447","Is diabetes still a state of premature cardiovascular death?","Miles Fisher","2016","Practical Diabetes","other","article","10.1002/pdi.2057",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038448","Finerenone in Type 1 Diabetes and Chronic Kidney Disease","Muhammad Aaqib Shamim","2026","New England Journal of Medicine","nonrandomized_study","article","10.1056/nejmc2604395","42235021",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038449","C49-05 Catastrophic Multiorgan Failure From Drug-induced Liver Injury and Metformin-Associated Lactic Acidosis in a Patient Without Baseline Organ Disease","J P Corcoran","2026","American Journal of Respiratory and Critical Care Medicine","other","article","10.1093/ajrccm/aamag162.4842",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038450","1662-P: Digital Programme Engagement Overcomes Weight Loss Resistance in Women with PCOS Treated with GLP-1 Receptor Agonists","HANS JOHNSON","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1662-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038451","Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis","MA  Panpan, WANG  Sijing, YOU  Na, DING  Dafa, LU  Yibing","2025","DOAJ (DOAJ: Directory of Open Access Journals)","systematic_review","article","10.12114/j.issn.1007-9572.2024.0484",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0038452","WCN26-1902 KIDNEY OUTCOMES WITH GLP-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Juana Sophiya Ariza Garcia","2026","Kidney International Reports","systematic_review","article","10.1016/j.ekir.2026.104587",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0038453","Obesity management: An update on the available pharmacotherapy","Eleni Christaki","2025","Innovative Medicines & Omics","other","article","10.36922/imo.8316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038454","Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Adis Journals On Behalf Of","2021","Figshare","systematic_review","article","10.6084/m9.figshare.14519067",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0038455","DPP-4 inhibition and blood pressure lowering in perspective","Peter M. Nilsson","2015","Journal of Hypertension","randomized_trial","article","10.1097/hjh.0000000000000814","26682784",null,"ClinicalTrials.gov:NCT01897532",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038456","Assessing potential misuse in the off-label use of ozempic for obesity tratment in non- diabetic individuals","Greta Sophie Westermann","2024","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038457","Dose Initiation and the Risk of Semaglutide Discontinuation in Real-World Practice",null,"2025","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2025.05.501",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038458","THE INFLUENCE OF LIRAGLUTIDE ON THE LEVEL OF BLOOD PRESSURE IN PATIENTS WITH ARTERIAL HYPERTENSION AGAINST THE BACKGROUND OF OBESITY AND TYPE 2 DIABETES MELLITUS","Larysa Zhuravlyova","2021","Journal of Hypertension","other","article","10.1097/01.hjh.0000746772.11336.ec",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038459","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-33858-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038460","Recurrent Stress Cardiomyopathy Induced by Sudafed PE","David M. Zlotnick","2012","Annals of Internal Medicine","other","article","10.7326/0003-4819-156-2-201201170-00028","22250160",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038461","L26/P-755 Comparative efficacy of GLP-1 receptor agonists and DPP-4 inhibitors versus metformin for insulin resistance in PCOS: a systematic review and meta-analysis","F. Oliveira","2026","Human Reproduction","systematic_review","article","10.1093/humrep/deag083.1082",null,null,"PROSPERO:CRD420251129333",null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0038462","Neuropeptide W: An Anorectic Peptide Regulated by Leptin and Metabolic State","Yukari Date","2010","The Journal of Clinical Endocrinology & Metabolism","other","article","10.1210/jcem.95.3.9990",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038463","Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review","Ostawal, Amrita","2018","Figshare","nonrandomized_study","article","10.6084/m9.figshare.6211073",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","review"],["R0038464","POS1137 Genetically proxied glucose-lowering drug target and risk of immune mediated inflammatory disease: a drug target mendelian randomization study","Y. Jin","2025","Annals of the Rheumatic Diseases","other","article","10.1016/j.ard.2025.06.487",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0038465","408-P: Assessing Individual Estimated GFR Trajectory on GLP-1RA Use for Kidney Protection","Koji Kashima","2025","Diabetes","other_trial","article","10.2337/db25-408-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038466","Editorial: Technologies for diabetes, volume III","Roque Cardona‐Hernandez","2026","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1846249","42058787",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0038467","Type 2 Diabetes Mellitus and the Structure of Available Medication: A Review",null,"2024","Journal of Community Medicine and Public Health Reports","narrative_review","article","10.38207/jcmphr/2024/nov051401130",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038468","The protective effects of GLP-1 and liraglutide on insulin resistant 3D kidney spheroids.","Ayesha Judge","2019","Pure (Coventry University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0038469","Retatrutide: uma abordagem inovadora no tratamento da Diabetes Mellitus Tipo 2","Lais Maia Raposo","2023",null,"other","article","10.13140/rg.2.2.26950.24648",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; conference-paper"],["R0038470","Comparative Efficacy Of GLP-1 Receptor Agonists, Mineralocorticoid Receptor Antagonists, And SGLT2 Inhibitors In HFpEF: A Meta-analysis Of Cardiovascular Outcomes","Shahzeb Saeed","2026","Journal of Cardiac Failure","systematic_review","article","10.1016/j.cardfail.2025.11.197",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0038471","26-A-13517-ACC GLP-1 RECEPTOR AGONISTS IN HEART FAILURE WITH REDUCED/MILDLY REDUCED EF: 5-YEAR OUTCOMES AND EFFECT MODIFICATION BY OBESITY AND ETHNICITY","Harsh Agarwal","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.1976",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038472","Evaluating the Synergistic Effect of Glucagon-like Peptide-1 Receptor Agonists and Lipid- Lowering Therapy on Apolipoprotein B in Diabetic Patients: A Retrospective Study Using TriNetX Database",null,"2026","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2026.01.282",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038473","Efficacy and safety of the russian GLP-1 receptor agonist Quincenta (semaglutide) in patients with type 2 diabetes mellitus in real clinical practice (QUINPROMIS study. Interim data)","Antsiferov M.B. Antsiferov","2024","Фарматека","other","article","10.18565/pharmateca.2024.8.54-61",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038474","2081-LB: Efficacy and Safety of Semaglutide and Tirzepatide—A Comparative Analysis of Clinical Trials","LLOYD L. TRAN","2024","Diabetes","randomized_trial","article","10.2337/db24-2081-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038475","IP12-11 GLP-1 RECEPTOR AGONISTS REDUCE KIDNEY STONE EVENTS IN OBESE PATIENTS: EVIDENCE FROM A REAL-WORLD COHORT","Thomas Syphan","2026","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001191328.95269.a6.11",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038476","S2463 Targeting Liver and Glucose: Comparative Efficacy of SGLT2i and GLP-1RA in NAFLD Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis","Mohamed A. B. Elnaggar","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001137312.65504.8c",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0038477","46-LB: Improvement of Ischemic Lesions of Lower Limbs in Diabetic Mice by Liraglutide","Chao Zheng","2019","Diabetes","preclinical","article","10.2337/db19-46-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038478","Type B Insulin Resistance: A Rare Type of Diabetes Mellitus","Glynda Caga-anan","2015","AACE Clinical Case Reports","other","article","10.4158/ep15978.cr",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038479","The effects of liraglutide on the characteristics of blood parameters and testicular tissue induced diabetes and obesity in mice","Saied Mohammadzadeh","2024","Sālnāmah va āmār.","preclinical","article","10.61186/jbums.31.2.150",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038480","995-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Analysis in the Canadian LMC Diabetes Registry: The SPARE Study","Ruth E. Brown","2019","Diabetes","nonrandomized_study","article","10.2337/db19-995-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038481","Semaglutide in Patients with Obesity and Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review & Meta-Analysis","Mylavarapu, Maneeth","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/k6hzv",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0038482","Exendin-4 inhibits MMP-9 activation and reduces infarct growth after focal cerebral ischemia in hyperglycemic mice","T. Kuroki","2017","Journal of the Neurological Sciences","preclinical","article","10.1016/j.jns.2017.08.2469",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038483","FRI-438 Identification of differences in therapeutic mechanisms between Resmetirom and Semaglutide on metabolic dysfunction-associated steatohepatitis treatment in western diet-fed melanocortin 4 receptor knockout mice","Takumi Sugawara","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)01656-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038484","GLP-1 Receptor Agonist Use Is Associated With Lower Femoral Neck Bone Density in Obese US Adults: An NHANES 2013-2020 Analysis",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.334",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038485","Recent Advancements in the Management of Obesity","Ahmed Hossain","2024","Bangladesh Journal of Medicine","other","article","10.3329/bjm.v35i20.73377",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038486","1755-P: Improved Glycemic Control with Insulin Glargine 300 U/ml in Insulin-Naïve Chinese People with T2D Uncontrolled on GLP-1RAs: A Real-World Retrospective Cohort Study","LIJUN DUAN","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1755-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038487","UR - GLP1RA & Weight Loss","Arnav Gupta","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0038488","NEW ORAL oral formulation glucagon-like peptide 1 (GLP1) SEMAGLUTIDE","Raffaele La Porta","2020",null,"other","article","10.22541/au.158645585.55176335",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038489","2170-P: Association of Newer Glucose-Lowering Drugs with Incident Parkinsonian Disorders in Older Adults with REM Sleep Behavior Disorder and Type 2 Diabetes","Pareeta Kotecha","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2170-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038490","Figure S1 - Radioligand competition binding.pdf","Grunddal, Kaare","2021","Figshare","preclinical","article","10.6084/m9.figshare.15019203",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038491","1975-LB: A Single Ascending Dose Study of a Once-Monthly Liraglutide Formulation in Participants with Type 2 Diabetes","J. Hans DeVries","2025","Diabetes","other_trial","article","10.2337/db25-1975-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038492","750-P: Novel Approach for Development of Oral GLP-1 Receptor Agonist with Superior Bioavailability and Antidiabetic Efficacy","EUN JI PARK","2022","Diabetes","preclinical","article","10.2337/db22-750-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038493","Novel Diagnostic Markers and Therapeutic Strategies for Diabetic Peripheral Neuropathy","Dhanapalaratnam, Roshan","2024","UNSWorks (University of New South Wales, Sydney, Australia)","other","article","10.26190/unsworks/30665",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038494","Effect of Liraglutide on Time in Glycaemic Ranges Assessed by CGM in Persons with Type 2 Diabetes Treated with Multiple Daily Insulin Injections","Sheyda Sofizadeh","2019","Figshare","other","article","10.6084/m9.figshare.9777764.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038495","CO114 Examining the Trade-off of Breastfeeding vs. Semaglutide Use After Childbirth","Surrey M. Walton","2025","Value in Health","other","article","10.1016/j.jval.2025.09.216",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038496","Current diabetes drugs: Lessons learned and implications for next-generation therapeutics","Jiayu Liao","2026","The Innovation Drug Discovery","other","article","10.59717/j.xinn-drugdisc.2026.100008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038497","Impact of a Weekly GLP-1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial","Julio Rosenstock","2020",null,"randomized_trial","article","10.2337/figshare.12469121.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0038498","Editorial (Thematic Issue: Frontiers in Atherosclerosis, Heart Disease and Diabetes)","Zemin Yao","2014","Cardiovascular & Haematological Disorders - Drug Targets","commentary","article","10.2174/1871529x1402140807142745","24801722",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0038499","FRI-181 Efficacy and safety of semaglutide 2.4 mg in the Japanese subgroup of the ESSENCE study","Atsushi Nakajima","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)01919-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038500","4043 ARE POST SURGICAL BARIATRIC PATIENTS LESS LIKELY TO EXPERIENCE SIDE EFFECTS OF GLP-1 ANALOGS IN COMPARISON TO NONSURGICAL PATIENTS",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.306",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038501","MP84-13 LIRAGLUTIDE AMELIORATES ERECTILE DYSFUNCTION VIA REGULATING AUTOPHAGY AND RHOA/ROCK PATHWAY INDUCED BY OXIDATIVE STRESS IN DIABETES MELLITUS","Penghui Yuan","2020","The Journal of Urology","preclinical","article","10.1097/ju.0000000000000976.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038502","IP05-25 FROM GLYCEMIC CONTROL TO RENAL OUTCOMES: DO GLP-1 AGONISTS SLOW KIDNEY FUNCTION DECLINE AFTER RADICAL NEPHRECTOMY?","Amar Kassim","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191288.32814.7d.25",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038503","1775-P: Effect of Subcutaneous Semaglutide on Cardiorenal Outcomes across Type 2 Diabetes Subtypes: SUSTAIN 6 Post Hoc Analysis","WEIHAO WANG","2026","Diabetes","other","article","10.2337/db26-1775-p",null,null,"ClinicalTrials.gov:NCT01720446","S001933","openalex","FALSE","paywalled","5","FALSE","article"],["R0038504","1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D","PETTER BJORNSTAD","2026","Diabetes","other_trial","article","10.2337/db26-1134-or",null,null,"ClinicalTrials.gov:NCT05260021","S000249","openalex","FALSE","paywalled","5","FALSE","article"],["R0038505","COMPARISON OF RENAL PROTECTIVE EFFECTS BETWEEN SGLT2 INHIBITORS AND DPP4 INHIBITORS IN TYPE 2 DIABETES IN REAL-WORLD CLINICAL PRACTICE","Hyeong-Kyu Park","2023","Journal of the ASEAN Federation of Endocrine Societies","randomized_trial","article","10.15605/jafes.038.afes.89",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0038506","Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease","Tan, Xi","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.c.6940274",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038507","Islet Amyloid Polypeptide/GLP‐1/Exendin","Laurie L. Baggio","2003",null,"other","article","10.1002/0470862092.d0209",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038508","797-P: Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D","Jean‐François Yale","2023","Diabetes","randomized_trial","article","10.2337/db23-797-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038509","Abstract 4365569: GLP-1 Receptor Agonists and Cardiovascular Outcomes in Patients with Type 2 Diabetes Undergoing TAVI: A Real-World Cohort Study","Hoang Nhat Pham","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4365569",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038510","NUEVOS FÁRMACOS EN DIABETES MELLITUS","Carmen Gloria Aylwin H","2016","Revista Médica Clínica Las Condes","other","article","10.1016/j.rmclc.2016.04.013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038511","Tratamiento farmacológico para la obesidad: conocimiento y controversia actual","Espinoza Diaz, Cristóbal Ignacio","2019","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.4173932",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038512","Evaluation of patient demographics, clinical characteristics, and cardiovascular outcomes in patients with type 2 diabetes newly initiated on sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and other antidiabetic medications","Elmor David Pineda","2019",null,"nonrandomized_study","article","10.26153/tsw/5675",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0038513","Effect of Glucose Metabolism-Associated Protein-1 on Exendin-4-Treated Pancreatic Islet Cell Function","Jing Feng","2020","Journal of Biomaterials and Tissue Engineering","other","article","10.1166/jbt.2020.2343",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038514","Abstract #267 Clinical Effectiveness of Glp-1 Ras in Patients with Metabolic Syndrome Diseases","Aloysius Obinna Ikwuka","2019","Endocrine Practice","other","article","10.1016/s1530-891x(20)46611-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038515","Preserving Skeletal Muscle during Pharmaco logical Weight Loss: A Practical Framework Integrating Nutrition and Eccentric Exercise","Urlike Roser","2026","German Journal of Sports Medicine","other","article","10.5960/dzsm.2026.667",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038516","Prevalence of eligibility for dual GIP/GLP-1 receptor agonists among non-diabetic and overweight adults - a Portuguese community-based study","H Santos Moreira","2026","European Journal of Heart Failure","other_trial","article","10.1093/ejhf/xuag193.1297",null,null,"ClinicalTrials.gov:NCT04184622","S001077","openalex","FALSE","paywalled","5","FALSE","article"],["R0038517","The Expanding Role of GLP-1 Receptor Agonists & Tirzepatide in Dermatological Diseases Associated with Obesity","Shahjada Selim","2026",null,"other","article","10.13140/rg.2.2.21801.56166",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038518","P5997GLP-1(28-36) prevents progression of ischemic heart failure in mice","M. Ahsan Siraj","2019","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehz746.0718",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038519","A Systematic Review of Weight-Loss Medications and Their Impact on Oral Health","Ana Keohane","2026","Journal Of Oral Medicine And Dental Research","systematic_review","article","10.52793/jomdr.2026.7(2)-119",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0038520","S1640 Necrotizing Pancreatitis Associated With Liraglutide and Empagliflozin","Andrea T. Fernandez","2021","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000780092.28084.14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038521","Impact of GLP-1 Receptor Agonists on End-Organ Complications in Type 1 Diabetes: A Retrospective Cohort Analysis",null,"2026","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2026.01.132",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038522","Monitoring of human endogenous signaling ex vivo","Stefania Koutsilieri","2026",null,"other","article","10.69622/31388596",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038523","Assessment of Diabetic Patient Satisfaction and Efficacy of Semaglutide in Qassim Region; in Saudi Arabia","Metab Algeffari","2024","International Journal of Medicine in Developing Countries","other","article","10.24911/ijmdc.51-1731774001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038524","Highlights of the March issue","Giuseppe Mancia","2020","Journal of Hypertension","randomized_trial","article","10.1097/hjh.0000000000002357","32028512",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038525","789-P: Discovery of a Novel, Long-Acting Amylin Receptor Agonist for Body Weight Control","Yan Li","2024","Diabetes","other_trial","article","10.2337/db24-789-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038526","Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database","Michael Nakhla","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4142154",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038527","Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis","Dong Anthony R.","2026","DOAJ (DOAJ: Directory of Open Access Journals)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0038528","Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study","Çetiner S.","2026","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0038529","Eficácia e mecanismos de ação da Semaglutida no controle da obesidade","Marcos Vinícius Santos Souza","2025","Journal of Medical and Biosciences Research.","other","article","10.70164/jmbr.v2i1.473",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038530","Effects of liraglutide on 8-OHdG,MDA and SOD of kidney in insulin resistance rats","WU Ming-hao","2017","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038531","Is there sustained weight loss after discontinuation of GLP-1 agonist for obesity treatment?","Rebecca Caro","2022","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001786",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038532","Bile Acids as Biomarkers","Emer Fitzpatrick","2015","Journal of Pediatric Gastroenterology and Nutrition","preclinical","article","10.1097/mpg.0000000000000809","25844712",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038533","Exendin Increases Gastric Acid Secretion in the Anesthetized Rat","Melanie K. Shadoan","2015","The FASEB Journal","preclinical","article","10.1096/fasebj.29.1_supplement.628.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038534","141-OR: Efficacy and Safety of Naltrexone/Bupropion as Add-On to Incretin Agents in Patients with Obesity and T2DM","Sean Wharton","2020","Diabetes","randomized_trial","article","10.2337/db20-141-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038535","VD5K58YKDZ Association Between Weight Lost and Diabetes Resolution After Bariatric Surgery With Preoperative GLP-1 Agonist Use",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.266",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038536","New product intros (betibeglogene darolentivec, evocalcet (new indication), fexinidazole, GV-971, lascufloxacin hydrochloride, luspatercept-aamt, semaglutide (new formulation), trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki), voxelotor)",null,"2020","Drugs of today","other","article","10.1358/dot.2020.56.1.3127025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038537","Mo2094: #OZEMPTOK: A QUALITATIVE CROSS-SECTIONAL STUDY OF TRENDING SOCIAL MEDIA VIDEOS FEATURING GLP1-AGONISTS","Jasmine Baste","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03846-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038538","S2082 Assessing a Weight Loss Medication Workshop at a Military Treatment Facility","Bryan Harper","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001037696.33762.f1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038539","Tirzepatide, menopause hormone therapy, and oral hormone absorption – Authors’ reply","Maria D Hurtado Andrade","2026","The Lancet Obstetrics Gynaecology & Women s Health","other","article","10.1016/s3050-5038(26)00182-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038540","Alterations of Thyroid Function and Nutritional Status in Patients with Type 2 Diabetes Mellitus Complicated by Metabolic Syndrome Treated with Insulin Combined with Either Liraglutide or Dapagliflozin","Hui Wang","2023","Current Topics in Nutraceutical Research","other","article","10.37290/ctnr2641-452x.22:152-159",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038541","Liraglutide Promotes Browning of White Adipose Tissue in Mice with Diet Induced Obesity","Fernanda Cerqueira Barroso Oliveira","2017","The FASEB Journal","randomized_trial","article","10.1096/fasebj.31.1_supplement.886.1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038542","S1696 No Difference Seen in Disease Activity in Crohn's Disease and Ulcerative Colitis Patients With Normal Versus Elevated BMI","Cindy Xin Fang","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001134244.12665.5b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038543","Beyond GLP‐1: The Cardiometabolic Potential of Dual GLP‐1/GIP Receptor Agonists","Chao Xue","2026","iNew Medicine","randomized_trial","article","10.1002/inm3.70048",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0038544","Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of Incidence and Prevalence in AWARD-11","DO, Joanna Van","2021","Figshare","other","article","10.6084/m9.figshare.15125622",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038545","Survey On Prevalence And Pharmacological Approaches In Non-Alcoholic Fatty Liver Disease And Steatohepatitis","Aniket N Lalaji","2025","Journal of Neonatal Surgery","other","article","10.52783/jns.v14.2947",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038546","Exenatide: A viewpoint by Curtis Triplitt and Ralph","A. DeFronzo","2005","Drugs","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038547","2304-PUB: Liraglutide also Has Favorable Effects on Body Composition without Decrease in Lean Body","Shizuka Kaneko","2019","Diabetes","other","article","10.2337/db19-2304-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038548","WCN24-1330 EFFECTS OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS ON TOP OF RAS BLOCKADE IN UNINEFRECTOMIZED DB/DB MICE","María José Soler","2024","Kidney International Reports","preclinical","article","10.1016/j.ekir.2024.02.467",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038549","Novo Nordisk parent to acquire Catalent","Aayushi Pratap","2024","C&EN Global Enterprise","other","article","10.1021/cen-10205-buscon4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038550","Análogos de GLP-1 no manejo da nefropatia por Diabetes Mellitus tipo 2","Maria Eduarda Goulart Pestana","2025","Revista Eletrônica Acervo Saúde","other","article","10.25248/reas.e21326.2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038551","A COMPREHENSIVE SYSTEMATIC REVIEW OF THE ASSOCIATION BETWEEN VISCERAL OBESITY AND INCREASED CARDIOMETABOLIC DISEASE RISK: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES","Jeffy Marta","2026","The Indonesian Journal of General Medicine","systematic_review","article","10.70070/r23xkg06",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0038552","Physical Activity Patterns in Adults Taking Glucagon-Like Peptide-1 Receptor Agonists: An All of Us Cross-Sectional Study","Kacey Chae","2026","Diabetes Obesity and Cardiometabolic CARE","other","article","10.2337/doc26-0062",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0038553","213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats","JOLANTA SKARBALIENE","2022","Diabetes","other_trial","article","10.2337/db22-213-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038554","833-P: Impact of Hypoglycemia on Insulin Titration and Fasting Plasma Glucose in Basal Insulin–Treated Type 2 Diabetes: A Subanalysis of the SoliMix Trial","Francesco Giorgino","2022","Diabetes","other_trial","article","10.2337/db22-833-p",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038555","1647-P: Nonhuman Primate Obesity Model for the Translation of Target-Based Precision Medicine","Shaohui Ji","2024","Diabetes","other","article","10.2337/db24-1647-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038556","Vascular health has an impact on brain health","Masud Husain","2025","Brain","nonrandomized_study","article","10.1093/brain/awaf126","40359475",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038557","The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways","Günaj Rakipovski","2019","JACC: Journal of the American College of Cardiology","preclinical","article","10.25407/jacbts.c.4536092.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038558","Adipose Loss and Metabolic Disease Due to Seipin Deficiency: Systemic Versus Tissue Specific Effects","Roumane, Ahlima","2021","eSpace (Curtin University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038559","O uso indiscriminado dos análogos GLP-1","Júlia Cabral Grillo","2025","DELOS Desarrollo Local Sostenible","other","article","10.55905/rdelosv18.n75-230",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038560","Benaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-34214-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038561","Lilly (ELI) & Co.",null,"2008","Mergent s Dividend Achievers","other","article","10.1002/div.7427",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038562","1016-P: A Novel GLP-1 and FGF-21 Dual Agonist Drug Protects Mice from Obesity and Hyperglycemia","Caslin A. Gilroy","2019","Diabetes","preclinical","article","10.2337/db19-1016-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038563","Associations Between Preconception Weight Loss Drug Use, Gestational Weight Gain, and Development of Gestational Diabetes","Kelly Mover","2025","Women s Health Reports","nonrandomized_study","article","10.1177/26884844251401523",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038564","NN2211, a protracted GLP-1 derivative, potently reduces consumption of high-carbohydrate and high-fat diets in the rat","Christina Bjenning","2000","Diabetes Research and Clinical Practice","preclinical","article","10.1016/s0168-8227(00)81315-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038565","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-38213-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038566","Vagal activity related events and GLP-1 receptor agonists","Anders Holt","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.4315",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038567","83-OR: GLP-1RA Efficacy Doubled with Small Molecule Modulators of Pyruvate Kinase for Obesity Treatment","RICHARD KIBBEY","2025","Diabetes","preclinical","article","10.2337/db25-83-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038568","723-P: The Dual Glucagon and Glucagon-Like Peptide-1 Receptor (GCGR/GLP-1R) Agonist BI 4569Reduces Body Weight in Diet-Induced Obese Mice Based on Food Intake Reduction and an Increase in Energy Expenditure","TINA ZIMMERMANN","2022","Diabetes","preclinical","article","10.2337/db22-723-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038569","Impact Of GLP-1 Receptor Agonists On Oral Health: An Integrative Review","Letícia Pitelli Bertazzi","2026","IOSR Journal of Dental and Medical Sciences","narrative_review","article","10.9790/0853-2504013038",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038570","Glucagon-like Peptide-1 Receptor Agonist in Large Vessel Occlusion Treated by Endovascular Therapy (GALLOP-2): A Multicentre, Prospective, Randomised, Open-label, Blinded Endpoint Trial","Hao Wang","2026","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.6724402",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0038571","PDB18 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETESWHO INITIATED THERAPY WITH EXENATIDE OR SITAGLIPTIN","MJ Lage","2008","Value in Health","other","article","10.1016/s1098-3015(10)66665-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0038572","0984 Do Glucagon-Like Peptide-1 Agonists Improve Sleep? Evidence from a Nationally Representative Sample of Adults in the United States","Marie‐Rachelle Narcisse","2026","SLEEP","other","article","10.1093/sleep/zsag091.0983",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038573","Sodium–glucose cotransporter 2 inhibitors and renal function钠‐葡萄糖共转运体2抑制剂与肾功能","Zachary T. Bloomgarden","2015","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12268","25565352",null,"ClinicalTrials.gov:NCT02065791; ClinicalTrials.gov:NCT01131676",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0038574","Semaglutide, liraglutide: risk of suicidal ideation and self-injury",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-43459-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038575","WED-460-YI Glucagon-like peptide- 1 receptor agonists improve survival and reduce healthcare utilization in decompensated hepatitis C cirrhosis","Jeeva Jaganathan","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)00738-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038576","GLP-1 therapy in normal and diabetic rats Effect on glycocarriers","Clemente Velarde, Luis Felipe","1999","OpenGrey (Institut de l'Information Scientifique et Technique)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038577","Soliqua (Lixi Lan): Sustained Long Term Cost Efficacy and Safety When Used in Combination with Metformin and Glimepiride","Udaya M. Kabadi","2021","Journal of Advances in Medical and Pharmaceutical Sciences","nonrandomized_study","article","10.9734/jamps/2021/v23i1030263",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0038578","Supplement Files: PYY3-36 potentiates Semaglutide‑mediated mitochondrial modulation in MASLD","Niklas Geiger","2026","Figshare","other","article","10.6084/m9.figshare.31967481",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038579","26-A-9627-ACC GLP-1 RECEPTOR AGONISTS REPROGRAM VASCULAR SMOOTH MUSCLE CELL METABOLISM TO ATTENUATE EXTRACELLULAR MATRIX REMODELING UNDER HYPERGLYCEMIC STRESS","Zhongwei Liu","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.2523",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038580","S2676 Effects of GLP-1 Agonists on Rates of Decompensated Liver Failure","Shawn Howell","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001138164.34024.40",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038581","Can weight-loss drugs tackle the mental health crisis?","special to C EN Elizabeth Hlavinka","2024","C&EN Global Enterprise","other","article","10.1021/cen-10233-feature2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0038582","Stimulation of glucagon-like peptide-1 (GLP-1) receptor inhibits oxidative stress and apoptosis in an Epac-dependent manner","Supachoke Mangmool","2013","European Heart Journal","preclinical","article","10.1093/eurheartj/eht310.p5038",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038583","Kinetic Optimization and Scale-Up of Site-Specific Thiol-PEGylation of Loxenatide from Laboratory to Pilot Scale","Xudong Wang","2018","Industrial & Engineering Chemistry Research","other","article","10.1021/acs.iecr.8b02613",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038584","Empagliflozin/liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-39357-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038585","USO OFF-LABEL DA SEMAGLUTIDA NO TRATAMENTO DE OBESIDADE: UMA REVISÃO DE LITERATURA.","Alecxandra Cruz Pereira DE SÁ","2024","Visão Acadêmica","other","article","10.5380/acd.v25i1.93401",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038586","Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials","Mannucci, Edoardo","2018","Figshare","systematic_review","article","10.6084/m9.figshare.6450422",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0038587","Combination of exendin-4 and DPP-4 silencing promoted angiogenesis of human coronary artery endothelial cells via activation of PI3K-Akt pathway",null,"2017","Pakistan Journal of Pharmaceutical Sciences","preclinical","article","10.36721/pjps/30/2(suppl)/02.03.2017/585/555-560",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038588","Wirkmechanismus von Tirzepatide entschlüsselt","Astrid Glaser","2023","Diabetologie und Stoffwechsel","other","article","10.1055/a-2127-3016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038589","REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION Authors","Zainab M. Al-Shammaa","2025","Global Journal of Public Health Medicine","other","article","10.37557/gjphm.v7i1.336",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038590","26-CCC-14499-ACC TIRZEPATIDE-WARFARIN INTERACTION LEADING TO SUPRATHERAPEUTIC INR AND DIFFUSE ALVEOLAR HEMORRHAGE","Joshua Qerbash","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.4655",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038591","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-47344-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038592","152 GLP-1 Receptor Agonists are Associated With Reduced Fecal Calprotectin and Neutrophil Counts in Patients With Inflammatory Bowel Disease and Type 2 Diabetes Mellitus","Eli Malkovskiy","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001173032.66112.39",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038593","Effects of lilalutine on blood glucose, lipid, blood pressure and carotid plaque in patients with type 2 diabetes mellitus complicated with atherosclerosis","Ya Chen","2019","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038594","Investigation into the effects of sepsis-induced hyperglycaemia on glucose-modulating hormones receptors in hepatocyte and monocyte cell lines","Daabo, Hamid Mahmood Abdullah","2012","OpenGrey (Institut de l'Information Scientifique et Technique)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038595","31-OR: Ipragliflozin Ameliorated Overweight and Pathological Liver Fibrosis in Diabetic Patients with Nonalcoholic Fatty Liver Disease in a Multicenter Randomized Controlled Trial","Hirokazu Takahashi","2020","Diabetes","randomized_trial","article","10.2337/db20-31-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038596","Correction",null,"2019","Current Medical Research and Opinion","other","article","10.1080/03007995.2019.1580035","30758231",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0038597","Beeinflussen blutzuckersenkende Medikamente das kardiovaskuläre Risiko?","Markus Numberger","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2265-4832",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038598","ANAIS II SEMANA DE FARMÁCIA","Mário Luan Silva de Medeiros","2024",null,"other","article","10.36599/qped-978-65-5376-409-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0038599","Current Treatment Trends in T2DM and Impact of COVID-19 among T2DM Patients: A Review","Bedi, Dr. Ashish Akshay","2020","Figshare","narrative_review","article","10.6084/m9.figshare.13056635",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038600","Impact of SGLT2 Inhibitors and GLP-1 Agonists on Rheumatoid Arthritis Flares in Patients on DMARD Therapy: A Retrospective Study","Shreya Sakthivel","2025",null,"nonrandomized_study","article","10.13140/rg.2.2.10947.57120",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0038601","CENTRAL APPETITE SUPPRESSION DURING SEMAGLUTIDE THERAPY AS A DETERMINANT OF DURABLE METABOLIC CONTROL IN TYPE 2 DIABETES AND OBESITY: A MECHANISM-INFORMED RAPID EVIDENCE SYNTHESIS","Aigerim Mukhtarova","2026",null,"other","article","10.70286/eoss-20.07.2026.024.263-269",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038602","Impact of Bariatric Surgery vs. GLP-1 Therapy on the Risk of Hepatocellular Carcinoma and Liver Disease Progression",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.09.058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038603","Glucagon-like peptide-1 analogue exendin-4 suppresses ER stress and enhances protein folding to ameliorate hyperhomocysteinemia-induced endothelial dysfunction","Chak Kwong Cheng","2020","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2020.10.346",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038604","Shifting the Paradigm: The Transformative Role of Novel Diabetes Drugs in Cardiovascular Disease Management","Akshat Sinha","2025","Indian Journal of Clinical Cardiology","other","article","10.1177/26324636251356433",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038605","Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden","Lind, Marcus","2018","Figshare","nonrandomized_study","article","10.6084/m9.figshare.6217163",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038606","Comparison of Glycemic Variability of Exenatide and Insulin Glargine Treatment in Chinese T2DM Patients: A Randomized Controlled Trial","Yin, Ting-Ting","2018","Figshare","randomized_trial","article","10.6084/m9.figshare.5982262.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0038607","Retraction notice to: Retatrutide and Ketoacidosis: Previously Unreported Adverse Effect of the New Triple Agent",null,"2026","Endocrine Practice","notice","article","10.1016/j.eprac.2026.01.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","retraction"],["R0038608","Dulaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-50973-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038609","Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis","Of, Adis Journals On Behalf","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.14308688.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038610","Budget impact of oral semaglutide intensification versus sitagliptin among US patients with type 2 diabetes uncontrolled with metformin","Wehler, Elizabeth","2020","Figshare","other","article","10.6084/m9.figshare.12966854",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038611","Welcome Reassurance About GLP-1 Drugs—But They Are Still Young and Not Fully Grown","Matthew C. Riddle","2015","Diabetes Care","other_trial","article","10.2337/dc14-2649","25614687",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038612","2130-P: Imeglimin Modulated ER Stress to Prevent ß-Cell Apoptosis Induced by High Glucose or Thapsigargin","Jinghe Li","2019","Diabetes","preclinical","article","10.2337/db19-2130-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038613","Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain","Of, Adis Journals On Behalf","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.14077409",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038614","TIRZEPATIDE VERSUS LONG-ACTING INSULIN IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META ANALYSIS","Ellebedy, Mohamed","2024",null,"systematic_review","article","10.13140/rg.2.2.29401.74081",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0038615","Analyse nephroprotektiver Effekte von Empagliflozin und Semaglutide bei Typ-2-Diabetes","R. Maria Clauss","2023","Diabetologie und Stoffwechsel","other","article","10.1055/a-1974-3017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038616","Impact of liraglutide 3.0 mg for weight management among women with obstetrics and gynaecology-related complications \"OG-RC\"","Majed Hudhud","2023","International Journal of Medicine in Developing Countries","nonrandomized_study","article","10.24911/ijmdc.51-1683020410",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0038617","Fasting GLP-1 Levels in Women with PCOS and CAH","Ralitsa Robeva","2024","Acta Medica Bulgarica","other","article","10.2478/amb-2024-0071",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038618","Patient perceptions of the efficacy and safety of tirzepatide: Discrepancies with clinical data and limited awareness of cardiovascular benefits","Anton Guo","2026","Next research.","other_trial","article","10.1016/j.nexres.2026.102044",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0038619","Engineering a versatile lipoMSN delivery platform for the development of gene and drug therapies","Jing Gong","2020",null,"preclinical","article","10.7916/d8-743w-4z67",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038620","RWD148 MACHINE LEARNING MODELS FOR PREDICTING SERIOUS ADVERSE EVENT REPORTS IN GLP-1 RECEPTOR AGONISTS USING FAERS, 2015-2025","Zhouzhou Chu","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.2136",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038621","EXENATIDE ATTENUATE H9C2 CELLS DAMAGES INDUCED BY HYPOXIA/REOXYGENATION VIA P38MAPK γ NOT P38MAPK α AND β","Zhang Dongying","2012","Heart","other","article","10.1136/heartjnl-2012-302920a.56",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038622","N‑K SCIENCES COMPLETE DRUG RESPONSE SIMULATION BY BLOOD TYPE: Antibiotics, Cardiovascular Drugs, Analgesics, and More — Organ‑Specific Effects on Kidneys, Liver, Heart, Brain, and Pancreas Subtitle From First Principles — Using Only Four Divine Axioms — No Empirical Fitting — 60+ Drugs, 8 Blood Types, 5 Major Organs — The First Blood Type‑Stratified Pharmacological Simulation in Medical History","Muhammad Usman Malik","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20482487",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038623","Tissue-Resolved Transcriptome-Wide Association Study Reveals Targeted NAD⁺ Salvage, Synaptic Refinement, and Reduced Insulin Drive as Transcriptional Mechanisms of Human Lifespan","Ngo Cheung","2026","Figshare","other","article","10.6084/m9.figshare.31951029.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038624","Efectos precoces de semaglutide oral en la cohorte de Diabetes tipo 2 en el Hospital Universitari Germans Trias i Pujol","Rafaella Salazar Perez","2022",null,"other","article","10.13140/rg.2.2.26012.40326",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038625","Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction","Trombara, Filippo","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.c.6580579",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038626","Comparison of medication adherence and persistence \\nin type 2 diabetes: A systematic review and meta-analysis","Mcgovern, Andrew","2017","Surrey Research Insight Open Access (The University of Surrey)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0038627","Once-daily liraglutide cost effective for T2DM in the UK",null,"2017","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-017-3812-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038628","Repurposing of aging‐preventive pharmaceuticals to delay Alzheimer's disease progression.","Andrea Mosqueda Solís","2025","Alzheimer s & Dementia","nonrandomized_study","article","10.1002/alz70859_102599","41449523",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038629","Avis favorable de l’Agence européenne du médicament pour l’obtention d’une AMM par le lixisénatide (Lyxumia®)","Marie Solignac","2013","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(13)70497-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038630","Figure 1S.pptx","Sato, Tetsuhiko","2023","Figshare","nonrandomized_study","article","10.6084/m9.figshare.22122329.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038631","Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis","Myasoedova, Veronika A.","2024","Figshare","systematic_review","article","10.6084/m9.figshare.c.6586522.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0038632","Hypotension in Patients on Glucagon-Like Peptide 1 Receptor Agonists: An Emerging Clinical Observation","Emily Eiswirth","2026","The Journal for Nurse Practitioners","other","article","10.1016/j.nurpra.2026.105766",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038633","Effects of liraglutide combined with metformin on lipid metabolism and micro-inflammatory response in T2DM patients with obesity","Weihuan Zhang","2018","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038634","Integrated Pancreatic and Biliary Safety Signals of GLP-1RAs: A Real-World Pharmacovigilance Analysis Based on FAERS Database","Yuanbin Wu","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6246918",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0038635","Inhibition of Activin A Signaling by Follistatin Alleviates Diabetic Kidney Disease Burden","Érika Bevilaqua Rangel","2025","Kidney360","preclinical","article","10.34067/kid.0000000877","40875507",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038636","Breaking Barriers to GLP-1 Agonists",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.468",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038637","Influence of Semaglutide on Neurochemical Correlates of Learning and Memory in Young and Aged Rats (Abstract ID: 221434)","Christian Wohlfeld","2026","Journal of Pharmacology and Experimental Therapeutics","preclinical","article","10.1016/j.jpet.2026.104063",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038638","102 The Impact of GLP-1 Receptor Agonists on IBD Outcomes – A Systematic Review and Meta-Analysis","Panagiotis G. Doukas","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001172832.03359.d6",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0038639","Drug-Induced Bullous Pemphigoid Triggered by GLP-1 Receptor Agonist",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.167",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038640","863-P: Genetically Proxied GLP-1 Receptor Agonism Improves Kidney Function—A Mendelian Randomization Study","JAEWON CHOI","2024","Diabetes","nonrandomized_study","article","10.2337/db24-863-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038641","Anti-obesity medications, the new frontiers in metabolic dysfunction-associated fatty liver disease: Efficacy, limitations, and future directions","Yasser Fouad","2026","World Journal of Hepatology","other","article","10.4254/wjh.v18.i5.118303",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038642","1838-P: Individualized Slope Analysis: Optimizing Reno-Protective Pillars of Therapy","Koji Kashima","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1838-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038643","2038-P: The Somatostatin Analog Pasireotide Reduces Pancreatic ß-Cell Function and Survival, and Both Incretin-Based Drugs and Irisin Revert These Effects","Annalisa Natalicchio","2020","Diabetes","other","article","10.2337/db20-2038-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038644","Basalinsulin plus Bolusinsulin oder besser plus GLP1-RA?","Friederike Klein","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2167-7444",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038645","755-P: Liraglutide plus Basal Insulin Combination Therapy in Japanese Old-Aged People with Type 2 Diabetes: Peak Age at 70s","Koji Kashima","2022","Diabetes","other","article","10.2337/db22-755-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038646","160 Pharmacotherapies in improving functional capacity in heart failure with preserved ejection fraction: a combined bayesian and frequentist network meta-analysis","Zenel Qenami","2024","Heart failure","systematic_review","article","10.1136/heartjnl-2024-bcs.157",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-paper"],["R0038647","PLAIN LANGUAGE SUMMARY of the PUBLICATION titled “Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 & -2)”","Wharton, Sean","2025","Boehringer Ingelheim","protocol","article","10.60915/boehringer-figshare.29066735.v1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0038648","Category Index",null,"2023","Hepatology","randomized_trial","article","10.1097/hep.0000000000000582","38227906",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038649","Advanced diagnostic and treatment options for non-alcoholic fatty liver disease with regard to novel clinical guidelines","Yu. A. Kravchuk","2025","Русский медицинский журнал","other","article","10.32364/2225-2282-2025-3-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038650","Clinical Guideline Necessary to Manage Obese Patients Undergoing Total Joint Arthroplasty","Alparslan Uzun","2025","Journal of Bone and Joint Surgery","other","article","10.2106/jbjs.25.00154","40591261",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038651","Impacts of Glucagon-like Peptide-1 Receptor-Agonists (GLP-1 RAs) Treatment for Metabolic Disturbances & Weight Gain in Patients on Clozapine/Olanzapine: A Systematic Review","Panda, Shivani","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/8fpzk",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0038652","MOESM8 of Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway","Feng, Yun","2020","Figshare","other","article","10.6084/m9.figshare.11508135",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038653","GLP-1 analogue Liraglutide の糖尿病モデルラット（OLETF rat）及びラット血管平滑筋細胞における酸化ストレス抑制に関する検討","嘉奈子 加藤","2021","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038654","S2412 Racial Disparity in Weight Loss of MASLD/MASH Patients in a Predominantly African American Academic Medical Center Population","Michael J. Mello","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001137108.88638.1c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038655","777-P: Early Weight Loss and Late Metabolic Outcomes in Tirzepatide-Treated Participants with Type 2 Diabetes","ILDIKO LINGVAY","2023","Diabetes","other_trial","article","10.2337/db23-777-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038656","INTERFERENCE OF GLP-1 AGONISTS IN GENERAL AND DENTAL ANESTHESIA: AN ANALYSIS OF OZEMPIC","Pedro Guimarães Sampaio Trajano Dos Santos","2025","Aracê.","nonrandomized_study","article","10.56238/arev7n6-270",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038657","Short Duration of Diabetes Should Be Associated with More Prominent Effect of Liraglutide—Titrated from Insulin Degludec plus Liraglutide Combination Therapy","Koji Kashima","2018","Diabetes","other","article","10.2337/db18-1074-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038658","The New Paradigm of Diabetes Care","SAAD SAKKAL","2018","Diabetes","other","article","10.2337/db18-2270-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038659","S2461 Demographic and Regional Disparities in GLP-1 Receptor Agonist Clinical Trials for Weight Loss: A Comparative Meta-Analysis of US and International RCTs","Kimberly Ho","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001137304.74762.c2",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0038660","1420-P: Adherence to ADA SOC Guidelines for CKD in Individuals with Diabetes at an Academic Primary Care Outpatient Practice","Venket Rao","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1420-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038661","Abstract 13142: Combined Treatment With Dapagliflozin and Exenatide is More Cardioprotective Than Either Agent Alone in a Non-Diabetic Mouse Model of Ischemia-Reperfusion Injury","Dorrin Zarrin Khat","2021","Circulation","randomized_trial","article","10.1161/circ.144.suppl_1.13142",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038662","COMPARATIVE EFFECTIVENESS OF GLP-1 AGONISTS AND BARIATRIC SURGERY ON ASTHMA AND OBSTRUCTIVE SLEEP APNEA OUTCOMES: A PROPENSITY-MATCHED ANALYSIS","NAVNEET GUPTA","2025","CHEST Journal","nonrandomized_study","article","10.1016/j.chest.2025.07.3050",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038663","Dose-dependent acute effects of liraglutide on liver function and metabolic parameters in healthy rats","Aytaç Gül","2025","Interdisciplinary Medical Journal","randomized_trial","article","10.17944/interdiscip.1782720",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0038664","The Efficacy of GLP-1 RAs in Managing Weight Loss after Bariatric Surgery: A Literature Review","Angel Sen","2025","Mspace (University of Manitoba)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038665","Safety Profile of Semaglutide in People Aged 55 Years and Over: Pooled Data from the PIONEER, SUSTAIN, and STEP Phase 3 Clinical Programmes (P11-9.014)","Marwan Sabbagh","2024","Neurology","other_trial","article","10.1212/wnl.0000000000204711",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038666","Dulaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-33179-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038667","106-LB: Real-Life Efficacy and Safety of IDegLira in Type 2 Diabetic Patients during COVID-19: A 6-Month Follow-Up by Teleconsultation in Bucaramanga, Colombia","Gustavo Adolfo Parra-Serrano","2021","Diabetes","nonrandomized_study","article","10.2337/db21-106-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038668","141-OR: Safety, Tolerability, and Clinical Effects of Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Agonist","Stine Maarbjerg","2025","Diabetes","randomized_trial","article","10.2337/db25-141-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038669","Su2058: INCREASE IN GASTROESOPHAGEAL REFLUX DISEASE SYMPTOMS ASSOCIATED WITH GLP-1 RECEPTOR AGONIST USE RETURNS TO BASELINE WITHIN 12 MONTHS AFTER CESSATION OF THERAPY: RESULTS FROM A LARGE MULTI-INSTITUTIONAL DATASET","Pinghsin Hsieh","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03110-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038670","740-P: Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes (T2D) after Efsubaglutide Alfa Treatment","Rui Sun","2025","Diabetes","other","article","10.2337/db25-740-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038671","764-P: Discovery of ASC30, a Highly Potent and Orally Available Novel Nonpetide GLP-1 Receptor Biased Agonist","JINZI JASON WU","2024","Diabetes","preclinical","article","10.2337/db24-764-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038672","Beta-cell Defects in Type 2 Diabetes and the Possibility of Treatment Options with GLP-1-based Therapies","Baptist Gallwitz","2006","US Endocrinology","other","article","10.17925/use.2006.00.02.1j",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038673","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-50538-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038674","Effect of GLP-1 agonist on osteoblast proliferation and related signaling pathways","Jian-Qiang Gao","2018","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038675","Letter to the Editor: Cardiovascular outcomes in high-risk type 2 diabetes mellitus: Standard of care vs multifactorial intensive therapy","Chun-Fang Dong","2026","World Journal of Diabetes","commentary","article","10.4239/wjd.v17.i4.115721",null,null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0038676","Abstract 4141434: Real-World Improvement of Cardiometabolic Risk Factors by Treating Obesity at Scale","Kim Boyd","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4141434",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038677","The Effect of Liraglutide on Postprandial Hypoglycemia in Non-Bariatric Surgery Patients: A Case Series and Review of Literature","Jamilah Atallah Alatawi","2024","Progress in Medical Sciences","case_report","article","10.47363/pms/2024(8)200",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038678","Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials","Muhammad, Asif","2023","Figshare","systematic_review","article","10.6084/m9.figshare.24597757.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0038679","3066-LB: Activating the Adipose Thermogenic Switch: A First-in-Class Ucp1 saRNA Drives Durable, High-Quality Weight Loss in Diet-Induced Obese Mice","Jie Wang (16762)","2026","Diabetes","preclinical","article","10.2337/db26-3066-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038680","The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity","Jun Yin","2024","Chinese Science Bulletin (Chinese Version)","other","article","10.1360/tb-2024-0417",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038681","[P2–187]: EXENDIN‐4 IMPROVES LEARNING AND MEMORY IMPAIRMENT, HYPERPHOSPHORYLATED TAU AND NEUROFILAMENTS IN THE APP/PS1/TAU TRIPLE TRANSGENIC MICE","Yanqiu Deng","2017","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2017.06.838",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038682","ASSOCIATION OF GLP-1 RA WITH CARDIOVASCULAR OUTCOMES IN NON-DIABETIC PATIENTS WITH MAFLD/MASH","Vinithra Varadarajan","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00868-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038683","Research letter: Risk–benefit analysis of Tirzepatide for HFpEF and obesity – insights from NNT analysis in the SUMMIT trial","Shambo Samrat Samajdar","2025","International Journal of Diabetes in Developing Countries","other_trial","article","10.1007/s13410-025-01475-0",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038684","Human steatohepatitis and the effects of HMGB1","Thea Guy","2025","Oxford University Research Archive (ORA) (University of Oxford)","preclinical","article","10.5287/ora-ozv6pyagy",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038685","1400-P: Hepatic Effectiveness of SGLT2 Inhibitors in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes","Sungho Bea","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1400-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038686","P0996 : The effects of short-term exenatide on circulating adiponectin levels in patients with type 2 diabetes mellitus (DMT2) with or without non-alcoholic fatty liver disease (NAFLD): a randomized, open-label, controlled intervention trial","Savvoula Savvidou","2015","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(15)31197-1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038687","1376 An Unprecedented 94% Reduction in AHI with Semaglutide in a CPAP-Intolerant Patient","Teddy Ikhuoriah","2026","SLEEP","other","article","10.1093/sleep/zsag091.1375",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038688","Oral semaglutide cost effective for T2DM in UK",null,"2020","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-020-6490-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038689","A real world experience of long-acting GLP-1 receptor agonists in a medical center in southern of Taiwan","Chunyi Yang","2016","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/s0168-8227(16)31250-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038690","Protopine as a multitarget modulator of glucose homeostasis: An in silico approach","Meltem Güleç","2026","Planta Medica","preclinical","article","10.1055/s-0045-1815234",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0038691","QDEM-8-49: Exploring Healthcare Providers' Off-Label Use of GLP-1 Receptor Agonists for Weight Management: Qatar Perspective","Abdulqadir J. Nashwan","2024",null,"other","article","10.13140/rg.2.2.34119.71848",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038692","1038-P: National Trends in Antidiabetes Drug Spending for U.S. Adults with Diabetes—2000–2021","Ping Zhang","2024","Diabetes","other","article","10.2337/db24-1038-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038693","Beyond the scale: evaluating skeletal muscle preservation and its impact on metabolic health during GLP-1RA therapy","Dalan Zydel","2025",null,"other","article","10.17760/d20794341",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038694","P2-126 - « Bien manger et bouger plus pour être en bonne santé, les nîmois s’engagent » : au sujet d’une action locale de lutte contre l’obésité infantile","N. Jourdan","2006","Annales d Endocrinologie","other","article","10.1016/s0003-4266(06)72957-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038695","A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes","Of, Adis Journals On Behalf","2021","Figshare","other","article","10.6084/m9.figshare.13653191",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038696","Rodent models of diabetes: pathogenesis and complications",null,"2017","Diabetic Medicine","preclinical","article","10.1111/dme.10_13303",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038697","Exenatide and Saxagliptin Do Not Attenuate NFkB-Induced Inflammation in Prediabetic Humans","Absalon Gutierrez","2018","Diabetes","randomized_trial","article","10.2337/db18-1954-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038698","Liraglutide et fréquence cardiaque","F. Alvarado","2017","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(17)30019-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038699","A Promising Approach: Semaglutide Reduces Alcohol Intake and Relapse Drinking in Male and Female Rats","Cajsa Aranäs","2023","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4388142",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038700","Figure S2 - Autoradiography and IHC control studies","Grunddal, Kaare V","2021","Figshare","preclinical","article","10.6084/m9.figshare.15019206",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038701","Exendin‐4, a Glucagon‐like Peptide 1 (GLP‐1) Agonist, Attenuates Vascular Dysfunction in Type 2 Diabetes (T2DM) via Anti‐Inflammatory and Antioxidant Effects.","Evan Bernard Asher","2017","The FASEB Journal","preclinical","article","10.1096/fasebj.31.1_supplement.853.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038702","Repurposing semaglutide to treat alcohol use disorder","Ana Donnelly","2025","Nature Mental Health","other","article","10.1038/s44220-025-00400-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038703","Semaglutida y obesidad, una solución definitiva","López Quinga, Nathaly Solange","2025","Dialnet (Universidad de la Rioja)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0038704","Multidimensional cardiometabolic protection with SGLT2 inhibitors and GLP-1 receptor agonists in obesity, type 2 diabetes and hypertension","Renu Vajjiravelu","2026","Obesity Medicine","other","article","10.1016/j.obmed.2026.100719",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038705","Challenges in the daily practice with incretin-based therapy","Georgi Shopov","2024","Varna Medical Forum","other","article","10.14748/vmf.v13i2.10066",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038706","4032 SLEEVE GASTRECTOMY VERSUS SEMAGLUTIDE FOR OBESITY: A 12-MONTH PROSPECTIVE HEAD-TO-HEAD COMPARISON",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.204",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038707","IP27-03 TIRZEPATIDE VERSUS BARIATRIC SURGERY FOR OBESITY-RELATED URINARY INCONTINENCE IN FEMALE PATIENTS","Persu Cristian","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191436.28373.9b.03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038708","A Multimodal Approach to Optimizing Semaglutide Suspension Timing Before Surgery: A Systematic Review and Meta-Analysis","Remus Ballotin, Vinicius","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30450836.v1",null,null,"PROSPERO:CRD42024609601",null,"openalex","TRUE","paywalled","3","FALSE","other; review"],["R0038709","Biochemical Analysis of Glycine max Seeds under Different Germinating Periods and Densitometric Analysis of Genistein","Robert Ahmed Khan","2010","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038710","1677-P: Real-World Outcomes of Tirzepatide Combined with Personalized Lifestyle Modification in an Indian Population with Diabetes and Obesity","CHHAVI G. MEHRA","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1677-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038711","3093-LB: Metabolic Response to Oral Semaglutide in Adults with Obesity—Weight Loss and Beyond: The GAROS Prospective Study","Łukasz Szczerbiński","2026","Diabetes","other","article","10.2337/db26-3093-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038712","OP18 EXENDIN-4 SUPPRESSES N-EPSILON-CARBOXYMETHYLLYSINE-INDUCED PROFIBROTIC ACTION OF TGF-B1 IN MESANGIAL CELLS BY HEPATOCYTE GROWTH FACTOR INDUCTION","Meei‐Ling Sheu","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70224-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038713","402-P: Liraglutide Might Have Synergistic Renal Protection Effect with SGLT2 Inhibitors in Rapidly Progressive Diabetic Kidney Disease","Koji Kashima","2021","Diabetes","other","article","10.2337/db21-402-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038714","Development and Evaluation of a Biocompatible Interpolymer Complex Matrix Tablet of Dapagliflozin and Exenatide for Enhanced Antidiabetic Efficacy","Narasihma Rao T, M.Sivakumar","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16452907",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038715","PCR169 EMPLOYEE PERCEPTIONS AND EXPERIENCES WITH TIRZEPATIDE TREATMENT FOR OBESITY OR OVERWEIGHT IN THE US","TD Hunter","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1942",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038716","Beyond Glycemic Control: The Role of GLP-1 Agonists in Preventing Neurodegeneration","Cera Huffman","2026","RVU Elevate","other","article","10.82451/k51029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0038717","Tirzepatide: Clinical Review of Novel GLP-1/GIP Agonist","Dailey, Whitney","2023","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038718","The Role of Sterol O-acyltransferase 1 In Obesity And In Prostate Cancer","Kim, Sora","2023","Purdue","preclinical","article","10.25394/pgs.22704412",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038719","Dulaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-50438-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038720","2514 The Biggest Loser: A Case of Dramatic Weight Loss Achieved With an Intragastric Balloon","Kirtan Chauhan","2019","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0000599588.07149.5f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038721","Associação entre o uso de agonistas do receptor do peptídeo semelhante ao glucagon-1 e o risco de complicações perioperatórias em pacientes submetidos a procedimentos cirúrgicos","Sara Bum do Nascimento França","2026","Brazilian Journal of Health Review","other","article","10.34119/bjhrv9n3-101",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038722","Synergistic Pharmacodynamics Effect Among Thiamine, Ertugliflozin and Liraglutide Drugs on Liver Cirrhosis and Splenomegaly","Riyadh K. Farhood","2025",null,"preclinical","article","10.53555/ajbr.v27i3.6752",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038723","Su2046: GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN OBESE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Yash Verma","2025","Gastroenterology","systematic_review","article","10.1016/s0016-5085(25)03098-7",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0038724","A Fully Automated Procedure for the GMP-Synthesis of 68Ga-NODAGA-Exendin-4 Using a Cationic Purification Method","Gerben M. Franssen","2015","European Journal of Nuclear Medicine and Molecular Imaging","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038725","Tu1694: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THEIR EFFECTS ON GASTRIC EMPTYING SCANS: A RETROSPECTIVE REVIEW","Nicholas Noverati","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04259-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038726","Is the Presence of a Depressive Disorder a Risk Factor for Worse Metabolic Outcomes Among Patients with Type 2 Diabetes Treated with GLP-1 Analogs?","Joana Nicolau","2025","Diabetology","nonrandomized_study","article","10.3390/diabetology6070068",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0038727","S1624 Glucagon-Like Peptide-1 Receptor Agonists Are Not Associated With Higher Risk of Intubation or Aspiration Pneumonia in Patients Who Underwent ERCP: A National Cohort Study","Khaled Alsabbagh Alchirazi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035864.69509.0f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038728","Real-world outcomes comparing the use of GLP-1 agonists in patients with multiple myeloma and comorbid obesity: A propensity score–matched analysis from a global federated health research network.","Arshi Syal","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.7548",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038729","GLP-1 RECEPTOR AGONISTS AND RISK OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM IN TYPE 2 DIABETES: EVIDENCE FROM A LARGE, REAL-WORLD DATABASE ANALYSIS","IRAKLI LEMONJAVA","2025","CHEST Journal","nonrandomized_study","article","10.1016/j.chest.2025.07.3123",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038730","Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Type 2 Diabetes Patients Regardless of Background Common OAD: A Subgroup Analysis from SUSTAIN 2–4 and 10","Capehorn, Matthew","2020","Figshare","other","article","10.6084/m9.figshare.11907837.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038731","TCT-231 Exenatide Does Not Improve Myocardial Salvage In Patients With An Acute Myocardial Infarction Successfully Treated With Primary Percutaneous Coronary Intervention: The First Results Of The EXAMI Trial","Sebastiaan T. Roos","2015","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2015.08.914",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0038732","Venlafaxine Abuse in a Patient With a History of Methylphenidate Abuse","Thomas Iliou","2019","Journal of Clinical Psychopharmacology","other","article","10.1097/00004714-900000000-98607",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038733","From referral to therapy: opportunities for treatment optimisation in heart failure with preserved ejection fraction across care settings","A Munawwar","2026","European Journal of Heart Failure","nonrandomized_study","article","10.1093/ejhf/xuag193.545",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038734","Real-World Effectiveness and Safety of Lixisenatide as Add- on to Oral Antidiabetic Drugs as Part of the Routine Clinical Practice in Bulgaria: LIXODAR study","Temelkova, Nataliya","2019","Figshare","nonrandomized_study","article","10.6084/m9.figshare.7844975",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038735","Editorial: New trends in managing obesity in primary care","Camila Medeiros da Silva Mazzeti","2026","Frontiers in Medicine","commentary","article","10.3389/fmed.2025.1761474","41585267",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0038736","CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS","Arya Aminorroaya","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(25)00899-x",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0038737","1388 Dose Increment-Associated Liraglutide-Induced Acute Pancreatitis","Nizar Al-Salameh","2019","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000595080.14595.de",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038738","GLP-1 RECEPTOR AGONISTS AND RISK OF PULMONARY COMPLICATIONS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND TYPE 2 DIABETES MELLITUS","Soon Young Hwang","2025","CHEST Journal","other","article","10.1016/j.chest.2025.07.3955",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038739","Kardiovaskuläre Endpunkte bei Typ-2-Diabetes mit Tirzepatide","Vojtech Pavlicek","2026","Die Diabetologie","other","article","10.1007/s11428-026-01422-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038740","994-P: Effects of Dulaglutide and Trelagliptin on ß-Cell Function after One Year in Patients with Type 2 Diabetes: DUET-Beta Extension Study","Yoshinobu Kondo","2019","Diabetes","randomized_trial","article","10.2337/db19-994-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038741","Impact of GLP-1 receptor agonists in hormone receptor–positive breast cancer patients receiving CDK4/6 inhibitors.","Kiara Patino","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.1100",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038742","Health-Related Quality of Life in People With Type 2 Diabetes and High Cardiovascular Risk Receiving the GIP/GLP-1 Receptor Agonist Tirzepatide or the GLP-1 Receptor Agonist Dulaglutide in the SURPASS-CVOT Study",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.233",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038743","Wernicke Encephalopathy in Patients Treated with Glucagon-Like Peptide-1 Receptor Agonists: A Comprehensive Systematic Review",null,"2026","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2026.03.059",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0038744","The GLP-1 receptor agonist semaglutide dose-dependently reduces alcohol consumption in Marchigian-Sardinian alcohol-preferring rats","Michela Palmisano","2026","Alcohol","preclinical","article","10.1016/j.alcohol.2026.01.105",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038745","419. Effect of Exendin-4 Expressed by Two-Step Transcription Amplification Plasmid System with Arginine-Grafted Bioreducible Polymer for Type 2 Diabetes",null,"2012","Molecular Therapy","other","article","10.1016/s1525-0016(16)36223-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038746","2087-LB: Novel Human Islet Spheroid Models of Type 1 Diabetes","ALEXANDRA C. TITLE","2024","Diabetes","preclinical","article","10.2337/db24-2087-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038747","Liraglutide Ameliorates Inflammation and Oxidative Stress of Periodontitis through Activating Nrf2/HO-1 Signaling Pathway","Fangting Li","2023","Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents","preclinical","article","10.23812/j.biol.regul.homeost.agents.20233702.102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038748","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-48809-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038749","11-PUB: Transitioning from Dulaglutide to Tirzepatide Improves Glycemic Control in Patients Undergoing Hemodialysis with Type 2 Diabetes—An Assessment by Continuous Glucose Monitoring","Emiko Otsuka","2024","Diabetes","nonrandomized_study","article","10.2337/db24-11-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038750","New clinical indication for weight loss drug","Diane S. Aschenbrenner","2025","AJN American Journal of Nursing","other_trial","article","10.1097/ajn.0000000000000217a","41437443",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038751","S1929 GLP-1 Receptor Agonists Decrease the Colorectal Cancer Rates in Inflammatory Bowel Disease","Khaled Alsabbagh Alchirazi","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001135176.67610.d3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038752","Poster presented at AASLD 2025: Survodutide improved liver histology in people with MASH and moderate-to-severe fibrosis regardless of age, sex, ethnicity, or type 2 diabetes: Subgroup analysis of a randomized phase 2 trial","Alkhouri, Naim","2025","Boehringer Ingelheim","randomized_trial","article","10.60915/boehringer-figshare.30437114",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","conference-abstract; article"],["R0038753","Effect of Glucose Metabolism Related Protein-1 on Proliferation and Apoptosis of MIN6 Cells","Yugui Zhang","2020","Journal of Biomaterials and Tissue Engineering","other","article","10.1166/jbt.2020.2229",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038754","Effects of Liraglutide on endothelial function, immune function and related factors in patients with type 2 diabetes mellitus","De-Zhi Bian","2019","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038755","Evaluating the Synergistic Effect of GLP-1 Agonists and Lipid- Lowering Therapy on Apolipoprotein B in Diabetic Patient: A Retrospective Study Using TriNetX Database","Hala Yousef","2026",null,"nonrandomized_study","article","10.13140/rg.2.2.11750.38722",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0038756","0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review","A. Arain","2026","Journal of Investigative Dermatology","narrative_review","article","10.1016/j.jid.2026.06.470",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038757","Abstract 4367438: Evaluating Procedural Safety and Outcomes In GLP-1 Exposed Patients Undergoing TEE","Ikponmwosa Igbinigie","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4367438",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038758","1093-P: Incidence of Primary Nonadherence to Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Agonists (GLP-1A) in an Integrated Health Care System","Jing Luo","2021","Diabetes","nonrandomized_study","article","10.2337/db21-1093-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038759","Ozempic induced pancreatitis leading to respiratory failure and severe ARDS","Harpreet Dosanjh","2026","The Southwest Journal of Medicine","other","article","10.12746/swjm.v14i58.1513",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038760","Dulaglutide-related adverse events",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-51979-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038761","1686-P: Dual GLP-1R/GCGR Activation Reprograms Systemic and Hepatic Metabolism to Ameliorate MAFLD","Danni Gao","2026","Diabetes","preclinical","article","10.2337/db26-1686-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038762","2564-P: Understanding the Implications of Incretin Receptor Desensitization","Rashmita Basu","2026","Diabetes","preclinical","article","10.2337/db26-2564-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038763","2796-LB: Beyond Weight Loss: Association between GLP-1 Medication Use and Patient-Reported Improvements in Confidence, Social Engagement and Food Noise among Adults with Obesity and T2D","AYSE LEVENT","2026","Diabetes","other","article","10.2337/db26-2796-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038764","Abstract #221 Combination Therapy with Once Weekly GLP 1 Receptor Agonist Dulaglutide and SGLT2 Inhibitors in Asian Indians with Type 2 Diabetes","Brijendra Kumar Srivastava","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47067-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038765","Obesidad infantil: factores de riesgo, complicaciones,tratamiento y estrategias de prevención","Jiménez Hernández, Eduardo Antonio","2023","Institutional Repository of the University of El Salvador (University of El Salvador)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038766","Food noise as a missing piece in obesity treatment: toward an integrated intervention framework","Abu Ansar Md Rizwan","2026","International Journal of Obesity","other","article","10.1038/s41366-026-02185-1","42587021",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038767","Semaglutid schützt die Nieren","Susanne Krome","2023","Diabetologie und Stoffwechsel","other","article","10.1055/a-1974-2520",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038768","Semaglutide scams in Australia",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-35565-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038769","Abstract 4361776: Alpha-ketoglutarate facilitates high-fat diet for inflammatory myeloid cell production and atherosclerotic plaque progression via OXGR1","Jiwei Zhao","2025","Circulation","preclinical","article","10.1161/circ.152.suppl_3.4361776",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038770","741-P: Impact of Virtual Patient Simulation on Improving T2D Treatment Intensification by PCPs","AMY LARKIN","2025","Diabetes","other","article","10.2337/db25-741-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038771","Weight‐loss drugs improve outcomes in patients with alcohol use disorder",null,"2025","The Brown University Psychopharmacology Update","nonrandomized_study","article","10.1002/pu.31274",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038772","P178 Évolution à 9 mois de l’équilibre glycémique de patients diabétiques de type 2 ayant bénéficié du remplacement d’une insulinothérapie par de l’Exenatide*","María Ángeles Rueda Martín","2010","Diabetes & Metabolism","other","article","10.1016/s1262-3636(10)70326-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038773","Latest news and product developments",null,"2008","Prescriber","randomized_trial","article","10.1002/psb.250",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0038774","S3044 The Double-Edged Sword of GLP-1 Receptor Agonists: Metabolic Benefits and GI Risks – A Systematic Review","Fnu Payal","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001139636.52094.23",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0038775","A Review on Semaglutide: An Oral Glucagon-Like Polypeptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus","Kalra, Sanjay","2020","Figshare","narrative_review","article","10.6084/m9.figshare.12661451",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038776","Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea","G. Lozano-Ortega","2018","Figshare","systematic_review","article","10.6084/m9.figshare.6865667",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0038777","Natürlich schöner, Teil 2: Schlauchbootlippen und Doppel-D","Falter, Celine","2024","Universitätsbibliothek Tübingen","other","article","10.15496/publikation-104541",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038778","Response to Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831","Sanjay Kaul","2017","Diabetes Care","other_trial","article","10.2337/dci17-0044","29162590",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038779","Annals for Educators - 18 August 2020","Darren B. Taichman","2020","Annals of Internal Medicine","randomized_trial","article","10.7326/awed202008180","32805170",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038780","Association between Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer: A Disproportionality Analysis","Meifen Han","2023","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.4391572",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0038781","2875-LB: Effectiveness and Safety of Adjunctive Therapy in Classic Type 1 Diabetes: A Real-World Cohort Study","Jie Zhang (64655)","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2875-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038782","1035-OR: Effects of CagriSema on Appetite and Functional Brain Activity in People with Overweight/Obesity","NIKOLAJ BAK","2026","Diabetes","randomized_trial","article","10.2337/db26-1035-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038783","Abstract 11522: Impact of Chronic Glucagon-Like Peptide-1 Receptor Agonist and Sodium Glucose Cotransporter-2 Inhibitor Therapy on In-Hospital Outcomes of Patients Hospitalized With Acute Myocardial Infarction","Filippo Trombara","2022","Circulation","nonrandomized_study","article","10.1161/circ.146.suppl_1.11522",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038784","PO-04-251 OBESITY-DEPENDENT BENEFITS OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS ON ATRIAL FIBRILLATION RISK: A LARGE-SCALE ELECTRONIC HEALTH RECORD-BASED TARGET TRIAL EMULATION","Reina Tonegawa‐Kuji","2026","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2026.03.1249",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038785","A korai erélyes glikémiás kontroll jelentősége 2-es típusú cukorbetegségben [The importance of early tight glycemic control in type 2 diabetes]","Hosszúfalusi, Nóra","2022","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038786","Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: A multicenter prospective observational study","祐也 小出","2026","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038787","Evaluation of the efficacy of semaglutide in the correction of lipotoxicity in patients with type 2 diabetes mellitus","Antsiferova D.M. Antsiferova","2026","Фарматека","other","article","10.18565/pharmateca.2026.4.237-248",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038788","754-P: A First-in-Human Single Ascending Dose Study of GSBR-1290, a Novel Small Molecule GLP-1 Receptor Agonist, in Healthy Volunteers","Blai Coll","2023","Diabetes","randomized_trial","article","10.2337/db23-754-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038789","Clinical obesity in the new era: Evidence-based therapeutics and improved patient outcomes","Iqbal Munir","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other","article","10.3329/jacedb.v4i20.84906",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038790","Abstract A051: Spontaneous Remission & Abscopal Responses in Prostate Cancer, a marker of “coldness”?","Tim Oliver","2026","Cancer Research","other","article","10.1158/1538-7445.prostateca26-a051",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038791","Design, findings and implications of the liraglutide Phase III clinical trial program","Bruce W. Bode","2011","Clinical Investigation","other_trial","article","10.4155/cli.11.166",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038792","ASPECTOS CLÍNICOS E FARMACOLÓGICOS DO EMPREGO DO EXENATIDE NA TERAPÊUTICA DO DIABETES MELLITUS TIPO 2","Daniele Andreta","2008","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article","10.25110/arqsaude.v12i2.2008.2389",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038793","Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-weekly Versus Daily Injectable Glucagon-like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)","Adis Journals On Behalf Of","2021","Figshare","other","article","10.6084/m9.figshare.17091752",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038794","685-P: Digital Platform Users Taking GLP-1 and Managing Diabetes Adapt Lifestyle Behavior Change over Twelve Months","YIFAT HERSHCOVITZ","2024","Diabetes","nonrandomized_study","article","10.2337/db24-685-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038795","Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. IGlar—A Subanalysis of LixiLan-L","Lawrence Blonde","2018","Diabetes","other_trial","article","10.2337/db18-1094-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038796","Association of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-like Peptide-1 Receptor Agonists Use With Optimal Cardiometabolic Health Among U.S. Adults With Type 2 Diabetes: A National Health and Nutrition Examination Survey 2015-2020 Study",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.288",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038797","Comparing the Effects of Glucagon-Like Peptide-1 Receptor Agonists on Cardiovascular Events to Metformin in Patients With Polycystic Ovary Syndrome: A Real-World Multicenter Cohort Study Across the United States [ID 1078]","Tina Yi Jin Hsieh","2025","Obstetrics and Gynecology","nonrandomized_study","article","10.1097/aog.0000000000005917.021",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038798","0301 Cutaneous reactions associated with GLP-1 receptor agonists: A comprehensive review","A. Sackett","2026","Journal of Investigative Dermatology","narrative_review","article","10.1016/j.jid.2026.06.332",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038799","O03 Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: analysis of UK pharmacovigilance data and literature review","Arash Fattahi","2026","British Journal of Dermatology","nonrandomized_study","article","10.1093/bjd/ljag086.018",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038800","Network meta-analysis of liraglutide versus DPP-4 inhibitors for the treatment of Type 2 diabetes in Japanese patients.","Ayers, Dieter","2017","Figshare","systematic_review","article","10.6084/m9.figshare.5132680.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0038801","258-OR: Sustainability of HbA1c Control of Tirzepatide vs. Insulin Glargine in People with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)","Ewan R. Pearson","2022","Diabetes","randomized_trial","article","10.2337/db22-258-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038802","Efficacy of a Digital Educational Intervention for Patients With Type 2 Diabetes Mellitus: Multicenter, Randomized, Prospective, 6-Month Follow-Up Study (Preprint)","Irene Caballero Mateos","2024",null,"randomized_trial","article","10.2196/preprints.60758",null,null,"ClinicalTrials.gov:NCT06850129","S002487","openalex","FALSE","paywalled","1","FALSE","preprint"],["R0038803","Nessun rischio di cancro della tiroide nel trattamento con GLP-1 RA?","Francesco Trimarchi","2025","L Endocrinologo","other","article","10.1007/s40619-025-01636-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038804","GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM","Mustafa, Nasir","2022",null,"other","article","10.13140/rg.2.2.34277.47840",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038805","P6513Cardiac and renal fibrosis and insulin administration in a rat model of diabetic cardiomyopathy","SH Wan","2018","European Heart Journal","preclinical","article","10.1093/eurheartj/ehy566.p6513",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038806","0245 Dermatologic outcomes of glp-1 receptor agonists versus non-glp-1 therapy in postmenopausal women on hormone replacement therapy: A trinetx cohort study","J. Saoub","2026","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2026.06.276",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0038807","DRESS Syndrome Associated with Deferasirox Treatment Recurrent Stress Cardiomyopathy Induced by Over-the-Counter Phenylephrine; Angular Cheilitis after Selective Serotonin Reuptake Inhibitor Treatment; Chemotherapy-Induced Spontaneous Orgasms; Liraglutide-Induced Acute Kidney Injury; Peripheral Edema Associated with Risperidone; Risk of Bleeding with Concurrent Use of Antibiotics and Warfarin","Joel Sinister","2012","Hospital Pharmacy","other","article","10.1310/hpj4704-264",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038808","Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of intestinal helminth infection","Macluskie, Jess","2025","Lancaster EPrints (Lancaster University)","preclinical","article","10.17635/lancaster/thesis/2739",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038809","814-P: Efficacy and Safety of Switching to Iglarlixi from Premix Insulin Regimen in Patients with T2DM—Real-World Experience","CHUN JUI HUANG","2025","Diabetes","nonrandomized_study","article","10.2337/db25-814-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038810","CA-023: Facteurs initiaux associés à la réponse glycémique au traitement par Dulaglutide, un agoniste des récepteurs au Glucagon-Like Peptide-1 en injection hebdomadaire chez des patients diabétiques de type 2 (DT2)","Bruno Guerci","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30155-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038811","4686 IMPROVED WEIGHT LOSS RESULTS WHEN GLP-1 AGONISTS ARE PRESCRIBED AS PART OF A COMPREHENSIVE WEIGHT MANAGEMENT PROGRAM",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.371",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038812","Association of Weight Reduction with Weight-Cycling Parameters: A SURMOUNT-5 Trial Post-Hoc Analysis","D Horn","2026","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0046-1819985",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0038813","Impact of GLP-1 Analogs on Benign Liver Neoplasms in Patients With Type 2 Diabetes: A Retrospective Cohort Analysis",null,"2025","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2025.05.540",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038814","Comparative efficacy of glucagon-like peptide-1 receptor agonists for cardiovascular outcomes in Asian versus White persons: systematic review and meta-analyses of randomized trials with and without type 2 diabetes and/or overweight/obesity","Matthew M.Y. Lee","2025",null,"systematic_review","article","10.2337/figshare.28074674.v1",null,null,"PROSPERO:CRD42024493010",null,"openalex","TRUE","free_to_read","3","FALSE","other"],["R0038815","2185-LB: Antibody-siRNA Conjugate Targeting Myostatin Preserves Muscle Mass during GLP-1R Agonism","YAFEI XING","2025","Diabetes","preclinical","article","10.2337/db25-2185-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038816","Letter: Confounding Factors in the Association Between Sarcopenia and Carotid Atherosclerosis Among Patients With Type 2 Diabetes Mellitus","Jovana Petrovic","2025","Angiology","other","article","10.1177/00033197251321262","39949309",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038817","Semaglutida pode ser utilizada para a perda de peso? - Indicações e possíveis complicações relacionadas ao medicamento","Lara Julia Evangelista Mineiro","2024","Contribuciones a las Ciencias Sociales","other","article","10.55905/revconv.17n.11-004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038818","Geroscience-Guided Repurposing of FDA-Approved Drugs to Target Aging: A 2025 Update","George A. Kuchel","2025","Innovation in Aging","other","article","10.1093/geroni/igaf122.1580",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038819","MOESM4 of Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism","Yang, Sheng-Hua","2018","Figshare","preclinical","article","10.6084/m9.figshare.6094232",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038820","Effects of Iron Overload and Exenatide on Erythrocyte Deformability in a Rat Model","Ayşegül KÜÇÜK","2015","AYBU AVESIS","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0038821","Magnifying Glass on Renal Impact of GLP1-RA","Mustafa, Nasir","2022",null,"other","article","10.13140/rg.2.2.15385.90726",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038822","Clinical Questions in Cardiology: Using Glucagon-like Peptide-1 Receptor Agonists","Mustafa, Nasir","2024",null,"other","article","10.13140/rg.2.2.20458.73926",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038823","Analysis suggests risk of suicidal ideation associated with semaglutide",null,"2024","The Brown University Psychopharmacology Update","nonrandomized_study","article","10.1002/pu.31236",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038824","Human medicines European public assessment report (EPAR): Bydureon, exenatide, Diabetes Mellitus, Type 2, Date of authorisation: 17/06/2011, Revision: 16, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-ab03d5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038825","Development of a predictive model for the side effects of liraglutide","Ji Young Min","2022","Cardiovascular Prevention and Pharmacotherapy","other","article","10.36011/cpp.2022.4.e12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038826","794-P: Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes (Pw2D), Not at Target on Basal Insulin (BI) and Oral Antidiabetic Therapy (BOT)—Results from the Observational, Prospective Study CHANCE","Tobias Wiesner","2023","Diabetes","other","article","10.2337/db23-794-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038827","Female participation in cardiovascular trials of antidiabetic medications: a SAGER-Guided systematic review","S U N G E Makawa","2026","European Journal of Preventive Cardiology","systematic_review","article","10.1093/eurjpc/zwag249.411",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0038828","Metabolic Syndrome: Pathophysiology, Clinical Implications, and Management Strategies","Firoz Khan","2026","Current Pharmaceutical Research","other","article","10.63785/2025.1.4.473485",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038829","Glucagon-like Peptide-1 Receptor Agonists and Gastrointestinal Neoplasms","Yu Jin Kim","2025","Journal of Digestive Cancer Research","randomized_trial","article","10.52927/jdcr.2025.13.2.99",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0038830","Digital Twin Technology for TIDES Process Development and Manufacturing","Alexander Uhl","2026","Processes","other","article","10.3390/pr14121873",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038831","Gastrointestinal AEs after switch from semaglutide injections to tablets",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-43455-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038832","S1562 Efficacy and Safety of Semaglutide in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","Kai Zhu","2023","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0000955888.05905.21",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0038833","S2643 Racial Disparities in Prevalence of Cirrhosis and Extrahepatic Manifestations in Alcohol-Associated Liver Disease","Pradhan Hariharan","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001138032.23327.33",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038834","S3896 The Risks of the New Weight Loss Medications","Mark Peicher","2023","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000965224.61011.89",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038835","3068-LB: A Next-Generation GLP-1/GIP/GCG/Gastrin Quadruple Agonist with Potent Antiobesity and Glucose-Lowering Effects","SEONHYEONG LEE","2026","Diabetes","preclinical","article","10.2337/db26-3068-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038836","Real-World Data","Joshua J. Neumiller","2025","Kidney360","randomized_trial","article","10.34067/kid.0000000989","41264407",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0038837","LB1133 Glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors for cardiovascular outcomes in patients with hidradenitis suppurativa and type 2 diabetes","A. Ormaza-Vera","2026","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2026.06.1164",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038838","787-P: GLP-1 Receptor Agonists as Monotherapy Lowered BMI Z-Score in Youth Newly Diagnosed with Type 2 Diabetes","Isaac Tejeji","2025","Diabetes","randomized_trial","article","10.2337/db25-787-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038839","Glucagon-like peptide-1 receptor agonists beyond metabolism: insights into gynecologic cancer prevention","Georgios Chrelias","2026","International Journal of Gynecological Cancer","other","article","10.1016/j.ijgc.2025.104060",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038840","CA-120: Une incidence comparable des effets indésirables gastro-intestinaux entre IDegLira et les comparateurs non analogue du GLP-1","S. Madani","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30252-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038841","“My body has gone out of style”: A critical examination of fashion magazines’ GLP-1 agonist drug discourse","Katie Baker Jones","2026","Media Culture & Society","other","article","10.1177/01634437261458569",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038842","Obesity and Type 2 diabetes; achieving weight loss","G. A. Hitman","2011","Diabetic Medicine","other_trial","article","10.1111/j.1464-5491.2011.03319.x","21569083",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0038843","Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Patients with Obesity and Type 2 Diabetes vs Metabolic Surgery for Weight Loss Achievement",null,"2025","Journal of Obesity and Chronic Diseases","other","article","10.17756/jocd.2025-055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038844","Abstract PD8-08: Glp-1 receptor agonists are associated with improved breast cancer outcomes in dcis patients on hormonal therapy: a real-world cohort study","A. Y. Khan","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-pd8-08",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038845","Semaglutide overdose",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-40133-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038846","Insulin degludec/liraglutide in type 2 diabetes: a profile of its use","Heo, Young-A","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.12045333",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other; article"],["R0038847","Cost-of-Illness Study of Diabetes Mellitus: Focus on Patients with Type 2 Diabetes - \\nCost-of-Illness Della Patologia Diabetica in Italia: Focus Sul Paziente Con Diabete Di Tipo 2","Roberta Pirolo","2016","Florence Research (University of Florence)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0038848","Obesity pandemic in China: epidemiology, burden, challenges, and opportunities","Jing Li","2022","Chinese Medical Journal","nonrandomized_study","article","10.1097/cm9.0000000000002189","35866571",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0038849","Liraglutide vs SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis","Lorenzi, Maria","2018","Figshare","systematic_review","article","10.6084/m9.figshare.6210485",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0038850","Semaglutide slows down the progression of motor deficits in a body-first rodent model of environmental parkinsonism","Ceyda YALÇIN","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2300719",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038851","2150-P: Association between GLP-1 Receptor Agonist Use during Pregnancy and Adverse Birth Outcomes","ABIGAEL FINKLE","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2150-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038852","NAVIGATING GLP-1 AGONIST THERAPY IN THE PERIOPERATIVE PERIOD \"A Modern Anesthetic Concern\"","Haashim Rahman","2025",null,"other","article","10.13140/rg.2.2.20238.42564",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038853","Development of biomarker specific of pancreatic beta cells (incretin radiolabelled) for image of beta functional mass in diabetic and obese: study in animal model","Daniele Seo","2017","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038854","Double Duty: GLP-1 RAs to Reduce Stroke Risk in Type 2 Diabetes","Mustafa, Nasir","2023",null,"other","article","10.13140/rg.2.2.28651.31523",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038855","Antihyperglycemic Drug Therapy in Patients with Diabetes and Ckd: a Closer Look at Incretin-Based Therapies","Robert R. Henry","2013","Endocrine Practice","other","article","10.4158/ep12363.or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038856","Exenatide‐induced hypomagnesaemia causing seizures","M‐F Kong","2010","Practical Diabetes","other","article","10.1002/pdi.1504",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038857","OphthoEvidence Report: Protocol for a systematic review and meta-analysis on glucagon-like peptide-1 receptor agonists and eye-related outcomes","Lima, João Pedro","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/9zmp7",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0038858","Tirzepatide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-47053-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038859","78-LB: PK Studies in Rats and Minipigs of GB-7001, a Novel Monthly Microsphere Formulation Containing High Drug Content of Semaglutide","E. Seegyoung Seol","2023","Diabetes","preclinical","article","10.2337/db23-78-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038860","The Case for Ozempic","Stacey Ann Tovino","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6299640",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038861","Adipositas/Typ-2-Diabetes: GLP-1-Agonist Tirzepatid fördert Gewichtsabnahme","Annika Simon","2024","DMW - Deutsche Medizinische Wochenschrift","other","article","10.1055/a-2162-5050",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038862","P337 Rémission prolongée du psoriasis chez un patient diabétique traité par exenatide","Vanessa Preumont","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72628-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038863","Ghrelin sensitises colonic myenteric neurons to the neurostimulatory effects of glucagonlike peptide‐1 in Sprague Dawley and Wistar Kyoto rats.","Rebecca L. O’Brien","2018","The FASEB Journal","preclinical","article","10.1096/fasebj.2018.32.1_supplement.lb363",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038864","EFFICACY OF TIRZEPATIDE IN TREATING METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 10 RANDOMIZED CLINICAL TRIALS","Arya Aminorroaya","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(25)05174-5",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0038865","TIRZEPATIDE A NEW DRUG APPROACH IN DIABETES MANAGEMENT: A REVIEW","Janvi Jain, Harshita Badoliya, Rohit Sharma, Dr. Vandana Sharma, Vani Madaan,  Dr. Mukesh Sharma, Dr. Ashok Kumar Sharma","2023","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.10435668",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038866","Training in Bariatric Endoscopy","Ahmad Najdat Bazarbashi","2020","ACG Case Reports Journal","other","article","10.14309/crj.0000000000000358","32337318",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038867","Novel neuron-Schwann cell co-culture models to study peripheral nerve degeneration and regeneration","Kazunori Sango","2022","Neural Regeneration Research","other_trial","article","10.4103/1673-5374.363195","36751798",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0038868","Injuria renal aguda","SLANH","2025","Revista de la Sociedad Ecuatoriana de Nefrología Diálisis y Trasplante","other","article","10.56867/134",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038869","Cost-Effectiveness of Dulaglutide, Liraglutide, And Glargine In Adult Patients With Diabetes Mellitus In Colombia","Pieralessandro Lasalvia","2016","Value in Health","other","article","10.1016/j.jval.2016.03.052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038870","26-A-9959-ACC USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS AMONG PATIENTS WITH DIABETES AND CARDIOVASCULAR DISEASE IN A SAFETY NET HEALTH SYSTEM","Danh Q. Nguyen","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.584",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038871","Liraglutide Suppresses Atherosclerosis via AMP-Activated Protein Kinase Dependent and Independent Mechanisms in Diabetic Apolipoprotein Enull Mice","Masakazu Koshibu","2018","Diabetes","randomized_trial","article","10.2337/db18-289-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038872","Superior Glycaemic Control Effects with Dulaglutide (Dula), a Once-Weekly Glucagon-Like Peptide Receptor-Antagonist (GLP-1RA), to Liraglutide (Lira) in Diabetic Hemodialysis Patients Assessed by Continuous Glucose Monitoring (CGM)","Satoshi Funakoshi","2018","Diabetes","other","article","10.2337/db18-543-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038873","Evaluation of the Relationship between Metabolicparameters of Liraglutide, Red Yeast Rice and Atorvastatinin High Fat Fed Rats","Gülbahar Sedefoğlu","2024","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4723058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0038874","Comment on: Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis","Syeda Bareera","2026","BMC Plastic and Reconstructive Surgery","systematic_review","article","10.1186/s44452-026-00033-9",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","letter"],["R0038875","One Size Does Not Fit All: Special Considerations for Behavioral Health Providers Treating Patients Using GLP-1RA Medications for Obesity","Noreen A. Reilly-Harrington","2025","Cognitive and Behavioral Practice","other","article","10.1016/j.cbpra.2025.02.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038876","S4695 Gastrointestinal Adverse Effects of Dual GLP-1 and GIP Receptor Agonist Used for Weight Loss","Joseph H. Wright","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001048148.32269.ea",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038877","Investigating properties of cerebro-spinal fluid contacting cells in rodents; can they influence ependymal cell proliferation?","Marx-Carr, Charlotte Natasha","2022","White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0038878","Krónikus vesebetegség és obesitas","Lilla Freisinger","2023","Hypertonia és Nephrologia","other","article","10.33668/hn.27.034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038879","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-45695-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038880","Dysfunctional Lipid‐Induced Secretion of Glucagon‐Like Peptide‐2(GLP‐2), but Not of Incretins Glucagon‐Like Peptide‐1(GLP‐1)/Glucose‐Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia","Giovanni Musso","2026","MedComm","randomized_trial","article","10.1002/mco2.70323","41948456",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0038881","279. GLP-1 receptor agonist use in elective lumbar spine surgery: reduced pseudarthrosis rates and favorable safety profile","David Gibbs","2026","The Spine Journal","other","article","10.1016/j.spinee.2026.06.299",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038882","2025 Late Breaking Abstracts",null,"2025","Hepatology","randomized_trial","article","10.1097/hep.0000000000001589","41201154",null,"ClinicalTrials.gov:NCT05989711","S000412","openalex","FALSE","paywalled","1","FALSE","article"],["R0038883","2546-P: Preclinical Efficacy and Safety of HDM1014, a Novel GalNAc-siRNA Targeting INHBE, for Weight Management with Muscle Preservation","HUAYE PAN","2026","Diabetes","preclinical","article","10.2337/db26-2546-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038884","Real-World Effectiveness of Tirzepatide for Obesity: The Critical Role of Treatment Persistence","Edward H. Livingston","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7224116",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0038885","E-029 Semaglutide (Ozempic) use and mortality in acute ischemic stroke: insights from nationwide and institutional data","A Elbayomy","2026",null,"randomized_trial","article","10.1136/jnis-2026-snis.133",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038886","2324-P: GLP-1RA Discontinuation in People with Obesity: Real-World Insights across Disease Burden Subgroups","JAIME ALMANDOZ","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2324-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038887","Latest news and product developments",null,"2007","Prescriber","nonrandomized_study","article","10.1002/psb.140",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0038888","792-P: GLP-1 RA Therapy Increases Circulating Vascular Regenerative Cell Content and Decreases Inflammatory Burden in People with T2D","Aishwarya Krishnaraj","2023","Diabetes","randomized_trial","article","10.2337/db23-792-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038889","MRI Assessment of Subclinical Cardiac Dysfunction and its Association With Ectopic Fat in Adults With Type 2 Diabetes","Althagafi, Loai K.","2023","University of Leicester","randomized_trial","article","10.25392/leicester.data.24441001",null,null,"ClinicalTrials.gov:NCT02043054; ClinicalTrials.gov:NCT02590822","S000535","openalex","TRUE","paywalled","1","FALSE","dissertation"],["R0038890","A Remotely Delivered, Semaglutide-Supported Specialist Weight Management Program: Preliminary Findings From a Retrospective Service Evaluation (Preprint)","Rebecca Richards","2023",null,"nonrandomized_study","article","10.2196/preprints.53619",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0038891","1779-P: Significant Synergistic Hypoglycemic Effects in Type 2 Diabetes Mellitus by HDM1010","RONGYAO ZHU","2026","Diabetes","preclinical","article","10.2337/db26-1779-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038892","S645 Esophageal Motility Patterns in Patients Receiving GLP-1RA Therapy","Annie L. Wang","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001031948.81401.61",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038893","IP06-36 CHARACTERIZING KIDNEY STONE EPISODES BY GLP-1RA MEDICATION IN GLP-1RA USERS","Shreya Thiagarajan","2025","The Journal of Urology","other","article","10.1097/01.ju.0001109820.51058.5a.36",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038894","282-OR: The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation and Pyruvate Carboxylase Flux in Man Assessed by Positional Isotopomer NMR Tracer Analysis (PINTA)","Kitt Falk Petersen","2021","Diabetes","other","article","10.2337/db21-282-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038895","BIOBOARD",null,"2016","Asia-Pacific Biotech News","other","article","10.1142/s0219030316000069",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038896","How Safe and Effective are Glucagon-like peptide-1 Receptor Agonists for Weight Reduction in Obese Patients 12 years and older with and without Type 2 Diabetes?","Wantz, Katelin","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038897","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-40543-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038898","S2606 GLP-1 Analogs in Cirrhosis: Reduced Mortality and Fewer Complications in a National Cohort","Chidera Onwuzo","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137884.89687.d4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038899","Poster presented at AASLD 2025: Improvements in non-invasive biomarkers and biopsy responses with the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: Overlap analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis","M. Anstee, Quentin","2025","Boehringer Ingelheim","other_trial","article","10.60915/boehringer-figshare.30437453",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","conference-abstract; article"],["R0038900","Review of Glucagon-Like Peptide-1 Receptor Agonists in the Peri-Operative Period and Its Application in Hair Transplant Surgery","Japhlet Leomil R. Aranas","2025","International Society of Hair Restoration Surgery","narrative_review","article","10.33589/35.5.166",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038901","Tirzepatide: First Approval","Syed, Yahiya Y.","2022","Figshare","other_trial","article","10.6084/m9.figshare.20128214",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0038902","Protective effect of hypoglycemic therapy by liraglutide on renal function in early diabetic nephropathy","Rui Liu","2016","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038903","Letter to the Editor: Hepatic multi-omics insights into Jiangtang tiaozhi formula for glycolipid metabolic disorders","Jia-Yu Lin","2026","World Journal of Diabetes","nonrandomized_study","article","10.4239/wjd.118206",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","letter"],["R0038904","The Current Situation and Influencing Factors of “Three Highs” Control in Communities of Qingdao","娇 陈","2025","Advances in Clinical Medicine","nonrandomized_study","article","10.12677/acm.2025.1541038",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038905","Development and Validation of a Headspace Gas Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Nitrosamine Impurities in Liraglutide Drug Substance","V. Umamaheshkumar","2026","Separation Science Plus","other","article","10.1002/sscp.70279",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038906","Gewichtsreduktion: Phentermin/Topiramat und Semaglutid am effektivsten","Blüher, M.","2022","DMW - Deutsche Medizinische Wochenschrift","other","article","10.1055/a-1750-1009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038907","Gastric emptying and Type 2 diabetes mellitus","Quintero-Cadavid, Camilo Andrés","2015","Magazine Portal Bibliotech Digital (Universidad Nacional de Colombia)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0038908","THE ABC TARGETS AND USE OF ORGANPROTECTIVE MEDICATIONS AMONG THAI PEOPLE WITH YOUNG-ONSET TYPE 2 DIABETES","Soontaree Nakasatien","2023","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.038.afes.73",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038909","Abstract 4367733: Dual Therapy With Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Is Associated With Improved Outcomes in Patients With Heart Failure: A Real-World Propensity-Matched Cohort Study","Ali Reza Rahmani","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4367733",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0038910","Semaglutide overdose",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-47031-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038911","2732-LB: GLP-1 Receptor Agonists and Diabetic Foot Ulcer Risk: A Meta-analysis","JIA YAO","2026","Diabetes","systematic_review","article","10.2337/db26-2732-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0038912","2024 ATS Semaglutide Case Report.pptx-54x36","Mak, Karina","2024",null,"case_report","article","10.13140/rg.2.2.13632.96006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038913","FRI-390 Transcriptomic analysis reveals alterations in mitochondrial energy metabolism and lipogenesis in GIPR/GLP-1R agonists treated metabolic dysfunction-associated steatohepatitis rodents","Hui Li","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)01619-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038914","Severe Obesity Associated with Severe Hyperinsulinism and T2D in a Family with Mutation in SH2B1 Gene","Rosangela Artuso","2015","Florence Research (University of Florence)","other","article","10.2337/db15-932-1471",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038915","Knee",null,"2025","Bone and Joint 360","other","article","10.1302/2048-0105.141.360208",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038916","Effects of glucagon-like peptide-1 receptor agonists on incident gynecologic cancer outcomes in endometriosis patients compared to metformin: A real-world multicenter retrospective cohort study across the United States","Tina Yi Jin Hsieh","2025","Gynecologic Oncology","nonrandomized_study","article","10.1016/j.ygyno.2025.04.222",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038917","Abstract Fri042: Association of GLP-1 Receptor Agonist Use With Carotid Revascularization, Cerebrovascular Events, and Mortality in Patients With Type 2 Diabetes: A Real-World Analysis","Aakash Srikanth","2026","Arteriosclerosis Thrombosis and Vascular Biology","nonrandomized_study","article","10.1161/atvb.46.suppl_1.fri042",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038918","New product intros (carteolol hydrochloride/latanoprost (new combination); glycopyrrolate/formoterol fumarate (new combination); lixisenatide/insulin glargine (new combination); nusinersen (first-in-class); rucaparib camsylate",null,"2017","Drugs of today","other","article","10.1358/dot.2017.53.1.2614787",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038919","Remission of Bulimia Nervosa Observed During Administration of Liraglutide and Metformin: A Case Report","Margarita Perez-Cheron","2017","AACE Clinical Case Reports","other_trial","article","10.4158/ep161667.cr",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0038920","A PANCREATIC NIGHTMARE: A RARE CASE OF DRUG-INDUCED NECROTIZING PANCREATITIS DUE TO SEMAGLUTIDE","JASON SHAH","2025","CHEST Journal","other","article","10.1016/j.chest.2025.07.1793",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038921","Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients With Type 2 Diabetes: Subgroup Analysis By Potential Influential Factors","Ma, Jianhua","2020","Figshare","other","article","10.6084/m9.figshare.13089323",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038922","Abstract 12095: Efficacy, Safety, and Cardio-Protective Effect of GLP-1 Receptor Agonists Among Patients With Diabetes Mellitus: A Meta-Analysis and Meta-Regression","Vikash Jaiswal","2023","Circulation","systematic_review","article","10.1161/circ.148.suppl_1.12095",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0038923","Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modelling","Ghosal, Samit","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30162679.v1",null,null,"PROSPERO:CRD42024567890",null,"openalex","TRUE","paywalled","3","FALSE","article; review"],["R0038924","Journal watch","AlokKumar Singh","2016","Heart India","randomized_trial","article","10.4103/2321-449x.190756",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0038925","S1422 NASH Clinic; A Multidisciplinary Team Approach to Assess the Efficacy of Diet, Lifestyle and GLP1 Agonists","Yara Dababneh","2022","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000862328.28290.63",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038926","773-P: Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium–Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes—A Patient-Level Pooled Analysis","Francesco Giorgino","2023","Diabetes","other","article","10.2337/db23-773-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038927","Improvement of Iron Deficiency Anemia in Metabolically Associated Fatty Liver Disease With Tirzepatide Therapy",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.320",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038928","296-OR: Underutilization of High-Intensity Statin Therapy in Patients with Type 2 Diabetes and Elevated Coronary Artery Inflammation Detected on Coronary CT Angiography","Bangwei Wu","2025","Diabetes","nonrandomized_study","article","10.2337/db25-296-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038929","RETRACTED: Retatrutide and Ketoacidosis: Previously Unreported Adverse Effect of the New Triple Agent",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.241","41475768",null,null,null,"openalex","FALSE",null,null,"TRUE","article"],["R0038930","Response to liraglutide treatment in patients with Type 2 Diabetes Mellitus in the Greek population; A pharmacogenetic study","Κυριακίδου, Αρτεμις Αθανασίου","2020","Aristotle University of Thessaloniki","other","article","10.26262/heal.auth.ir.316706",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038931","426-P: Semaglutide, Empagliflozin, and Cagrilintide Reduce Levels of Serum Endotrophin in Type 2 Diabetic Rats","Alexandra Louise Møller","2023","Diabetes","preclinical","article","10.2337/db23-426-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038932","Impact of Glucagon-like Peptide 1 Receptor Agonists on Body Weight in People with HIV and Diabetes Treated with Integrase Inhibitors","Dario Cattaneo","2025","Diabetology","nonrandomized_study","article","10.3390/diabetology6030020",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0038933","Relacorilant Treatment Improves Glycemic Control Among Individuals With Endogenous Hypercortisolism and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study",null,"2026","Endocrine Practice","other_trial","article","10.1016/j.eprac.2026.01.496",null,null,null,null,"openalex","FALSE","open_pdf","5","FALSE","article"],["R0038934","GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries","Divino, Victoria","2018","Figshare","other","article","10.6084/m9.figshare.6189494",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0038935","1341 Re-Emergence of Night Terrors Triggered by Semaglutide Therapy: A Dose-Dependent NREM Parasomnia Phenomenon","Maithili Udupa","2026","SLEEP","other","article","10.1093/sleep/zsag091.1340",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038936","Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds","David J. Cohen","2013","BMJ","other","article","10.1136/bmj.f2607","23613543",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038937","Endoscopic duodenal hydrothermal ablation for the treatment of type 2 diabetes mellitus","van Baar, Anna C. G.","2021","Data Archiving and Networked Services (DANS)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0038938","Effect of treatment with Victoza® on cafeteria induced‐obese rats.","Dionízia Xavier Scomparin","2015","The FASEB Journal","preclinical","article","10.1096/fasebj.29.1_supplement.lb651",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038939","4.8 Mechanistic Insights and Omics-Driven Exploration of GLP-1 Receptor Agonist Therapeutics",null,"2025","Molecular & Cellular Proteomics","other","article","10.1016/j.mcpro.2025.101335",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038940","S1493 Clinical Effectiveness and Safety of GLP1RA in Patients With IBD","Hamzah Shariff","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001133432.99448.b2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0038941","Escalation of Glucagon-like Peptide-1 Agonist Therapy Preceding Perforated Cholecystitis and Multisystem Failure",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.323",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038942","Glucagon‐like peptide‐1 receptor agonist use and violent crime among US adults","Daniel C. Semenza","2026","Criminology","other","article","10.1111/1745-9125.70058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038943","WITHDRAWN: Leptin enhances and fasting inhibits the anorexic response to Exendin-4 in the rat","D G Baskin","2006","Appetite","preclinical","article","10.1016/j.appet.2006.03.322",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038944","CA-116: Étude DUAL IV : IDegLira chez les diabétiques de type 2 naïfs d'insuline insuffisamment contrôlés sous sulfonylurées seuls ou associés à la metformine","S. Madani","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30248-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038945","Glucagon-like peptide-1 (GLP-1) Biological Role in Patients of Type 2 Diabetes and Metabolic Syndrome","Mohammedziyad Abu Awad","2019","The Indian Journal of Nutrition and Dietetics","other","article","10.21048/ijnd.2019.56.2.20967",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038946","Slankemedisin som hjelper mot søvnapné","Kristoffer Brodwall","2024","Tidsskrift for Den norske legeforening","other","article","10.4045/tidsskr.24.0362",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038947","IDDF2025-ABS-0165 Unmasking aspiration risks: a propensity matched odyssey of GLP-1 receptor agonists and colonoscopy","Puneet Chhabra","2025","Clinical Gastroenterology","nonrandomized_study","article","10.1136/gutjnl-2025-iddf.221",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0038948","204-LB: An Unusual Case of Autoantibody-Negative Ketosis-Prone Diabetes (KPD) Secondary to Marked Insulin Resistance","Marco Infante","2022","Diabetes","other","article","10.2337/db22-204-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038949","45-PUB: Glycemia in Perimenopausal vs. Preperimenopausal Age Groups in Women with Type 1 Diabetes","JAIME LUCOVE","2026","Diabetes","nonrandomized_study","article","10.2337/db26-45-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038950","895-P: Effect of Long-Term Empagliflozin Therapy on Plasma Beta-Hydroxy Butyrate (ß-OHB)—Lack of Effect of Concomitant Insulin, GLP-1 Agonist, or Pioglitazone Therapy","Luis C. Ortiz","2023","Diabetes","nonrandomized_study","article","10.2337/db23-895-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038951","Editorial: New frontiers in heart failure therapy: mechanisms, efficacy, and challenges","Tzu‐Hurng Cheng","2026","Frontiers in Cardiovascular Medicine","commentary","article","10.3389/fcvm.2026.1902385","42483460",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0038952","113 Effects of Exendin-4 on Pancreatic Islets Function in Treating Hyperglycemia Post Severe Scald Injury in Rats","Chuanan Shen","2019","Journal of Burn Care & Research","randomized_trial","article","10.1093/jbcr/irz013.114",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0038953","Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity","Nidhi Sharma","2023","Journal of Diabetology","nonrandomized_study","article","10.4103/jod.jod_102_22",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0038954","PO420 A 52 WEEKS OBSERVATION OF RENAL FUNCTION CHANGE UNDER EXENATIDE (BYETTA) TREATMENT IN OBESE TYPE 2 DM TAIWANESE","Kyeongho Lee","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70714-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038955","PO-02-162 IMPACT OF SGLT2 INHIBITORS, GLP-1 RECEPTOR AGONISTS, AND SGLT2I–GLP-1RA COMBINATION THERAPY ON VENTRICULAR ARRHYTHMIAS AND MORTALITY IN STAGE 4 CKM SYNDROME: A GLOBAL TRINETX COHORT ANALYSIS","Yun-Yu Chen","2026","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2026.03.553",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038956","The Ethical Landscape of Plastic Surgeons Prescribing Weight Loss Medications","Rohun Gupta","2026","Aesthetic Surgery Journal","other","article","10.1093/asj/sjag015","42047194",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038957","Cardiovascular-kidney-metabolic syndrome in an ageing population: what does frailty add?","Aaron L. Troy","2026","European Journal of Preventive Cardiology","other","article","10.1093/eurjpc/zwag244","42095826",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038958","Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment","6: Chianelli M","2024","IRIS Research product catalog (Sapienza University of Rome)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038959","Efficacy of liraglutide with change of lifestyle in type 2 diabetes mellitus","Takhirova, Feruza","2020",null,"other","article","10.13140/rg.2.2.24060.16007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038960","GLP-1RA for glycaemic control and obesity as add on therapy for type 2 diabetes","Elmiladi, Samia A.","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7942951",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038961","Saxagliptin: a new option for the management of type 2 diabetes","Marc Evans","2009","Future Prescriber","other","article","10.1002/fps.50",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038962","71162 Psychiatric Risk Reduction in Psoriasis Patients Treated With GLP-1 Receptor Agonists","Matthew Yan","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.1434",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038963","Evaluating the Cost-Effectiveness of GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the UK","Donna Ashley","2015","Value in Health","other","article","10.1016/j.jval.2015.09.2093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038964","GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction","Daniel Lorber","2012","Cardiovascular Therapeutics","preclinical","article","10.1111/cdr.12000",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038965","Effectiveness of different anti-diabetic medications in managing cardiovascular outcomes in patients with type 2 diabetes: A meta-analysis","Talha Tariq","2024",null,"systematic_review","article","10.48047/hm.10.2.2024.1102-1115",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0038966","Adverse Effects of Multi-drug Diabetes Regimens: Case Report of Acute Pancreatitis and Diabetic Ketoacidosis","Emma Barry","2024","American Journal of Medical Case Reports","case_report","article","10.12691/ajmcr-12-8-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038967","A sustainable primary care approach for obesity","The Lancet Primary Care","2025","The Lancet Primary Care","other","article","10.1016/j.lanprc.2025.100086",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038968","766-P: GLP-1RA, Oral Formulation and Its Preclinical Evaluations","Jin Jung","2025","Diabetes","nonrandomized_study","article","10.2337/db25-766-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038969","26-A-13345-ACC EFFECT OF GLP-1 RECEPTOR AGONISTS ON INFARCT SIZE AND CARDIAC FUNCTION IN ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS","Hasan Munshi","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.2111",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0038970","Rapid Progression of Papillary Thyroid Carcinoma Following Initiation of Semaglutide (Wegovy) for Weight Loss: A Case Report","Miranda Stiewig-Rapp","2025","International Journal of Clinical and Translational Medicine","case_report","article","10.53941/ijctm.2025.1000021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038971","Assessing the Impact of SGLT2i on Outcomes Following Hindfoot Arthrodesis: A TriNetX Analysis","Kush S. Mody","2026","Foot & Ankle Orthopaedics","nonrandomized_study","article","10.1177/2473011426s00043",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0038972","847-P: SGLT2 Inhibitors and GLP-1s Are Falling Short of Expectations among Patients with Type 2 Diabetes Newly Initiating Therapy","CLAIRE HOLLEMAN","2023","Diabetes","other","article","10.2337/db23-847-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038973","Clinical utility of a novel test for assessing cardiovascular disease risk in type 2 diabetes: a randomized controlled trial","Peabody, John W.","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.c.6739593.v1",null,null,"ClinicalTrials.gov:NCT05237271",null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0038974","MOESM2 of Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism","Yang, Sheng-Hua","2018","Figshare","preclinical","article","10.6084/m9.figshare.6094166",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038975","Tirzepaptide: A Promising Option for Treating Obesity and Overweight","Manoj Kumar Saurabh Amit","2024","International Journal of Science and Research (IJSR)","other","article","10.21275/sr24305143919",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038976","(248) Exploring the Effects of GLP-1 Agonists on Male Fertility: A Systematic Review","B Steinberg","2025","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdaf320.244",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0038977","Additional file 1 of Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride","Jendle, J.","2021","Figshare","other","article","10.6084/m9.figshare.17273245",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038978","Cost–Benefit Management of Insulin Resistance: Combination of Phentermine and a Flexible Weight Loss Strategy in the Era of GLP-1 Agonists. Visible Benefits Shown After Six Months of Treatment","Cesar Ochoa","2026","Metabolism","other","article","10.1016/j.metabol.2026.156543",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038979","Diabetes and Osteoporosis","Chaiho Jeong","2025","Journal of Korean Diabetes","other","article","10.4093/jkd.2025.26.2.97",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038980","GLP-1 RA Initiation and Risk of Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study",null,"2025","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2025.05.607",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0038981","Akute und Chronische Effekte von Wnt-Stimulation auf pankreatische beta-Zellen – Regulation durch Exendin-4","Claudia L. Heller","2010","Diabetologie und Stoffwechsel","preclinical","article","10.1055/s-0030-1253997",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038982","Drug News",null,"2023","Nursing","other","article","10.1097/01.nurse.0000995548.99033.54","38126978",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038983","Use of ultrasound to characterize adipose tissue distribution and its impact on cardiovascular risk in different disease conditions and in response to drug treatments","Guillem Cuatrecasas Cambra","2025","O2 - Repositori Institucional (Universitat Oberta de Catalunya)","other","article",null,null,null,"EudraCT:2019-000979-16",null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0038984","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics","Adis Journals On Behalf Of","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.14547270",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0038985","Oleate controls the effects of GLP-1 and exendin-4 on myocardial glucose utilization and contractile function","Yasushige Shingu","2010","The Thoracic and Cardiovascular Surgeon","preclinical","article","10.1055/s-0029-1246646",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038986","MP265PROXIMAL TUBULAR GLP-1 RECEPTOR ACTIVITY IS INCREASED IN CKD RAT WITH MYOCARDIAL INFARCTION","Soon Kil Kwon","2016","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfw188.21",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038987","2645-P: Changes in Eating Behavior Before and After Semaglutide Administration in People with Obesity","MAMIKO HITOMI","2026","Diabetes","other","article","10.2337/db26-2645-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038988","The Effect of Liraglutide on Inflammatory Factors and Neurological Prognosis in Patients with Acute Cerebral Infarction Complicated with Type 2 Diabetes Mellitus","Q Zhang","2026","Advances in Precision Medicine","other","article","10.18063/apm.v11i3.1664",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038989","Advances in Therapeutic Agents for Diabetic Nephropathy","Meng Sh","2026","Advanced Medical Research","other","article","10.62836/amr.v5i1.0001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0038990","Use of Glucagon-like peptide-1 receptor agonists and subsequent risk of alcohol-related events: A nationwide register-based cohort and self-controlled case series study.","Ida Kim Wium‐Andersen","2022","Neuroscience Applied","nonrandomized_study","article","10.1016/j.nsa.2022.100120",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0038991","Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Fasting Blood Glucose",null,"2026","Endocrine Practice","other_trial","article","10.1016/j.eprac.2026.03.027",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0038992","S5049 Rare Presentation of Small Bowel Necrosis in the Setting of Fulminant Clostridioides difficile Infection After GLP-1 Usage","AJ Carroll","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001147656.34623.2f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038993","S3979 Dramatic Changes in Thiopurine Metabolite Levels in a Patient with Inflammatory Bowel Disease Treated with Tirzepatide for Weight Loss: A Case Report","Jeremy A. Klein","2024","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001045284.27371.1b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0038994","Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization","Cooke, Catherine E.","2020","Figshare","nonrandomized_study","article","10.6084/m9.figshare.11815362",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0038995","GW24-e3600 The Stem Cell Adjuvant with Exendin-4 Enhances the Therapeutic Efficacy for Myocardial Infarction via STAT3 Activation","Liu Jianfeng","2013","Heart","preclinical","article","10.1136/heartjnl-2013-304613.280",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038996","GLP‐1r activation, hypoxia and antioxidant‐oxidant expression in kidney after ischemia reperfusion in obese rats","S. Meza","2019","The FASEB Journal","preclinical","article","10.1096/fasebj.2019.33.1_supplement.485.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038997","SP456EFFICACY AND SAFETY OF LIRAGLUTIDE IN OVERWEIGHT DIABETIC PATIENTS WITH STAGE 3 NEPHROPATHY","Beatriz Avilés","2017","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfx149.sp456",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0038998","Relationship between nitric oxide release from pig iliac endothelial cells caused by Exendin-4 and change in intracellular calcium","Haoyu Liu","2012","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0038999","Rapid quantification of Semaglutide in mouse plasma: An optimized LC-MS/MS approach","Venkata Murali Bokka","2025","Journal of the Indian Chemical Society","preclinical","article","10.1016/j.jics.2025.102276",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039000","A scientometric survey of the emerging research landscape on orforglipron, an oral non-peptide GLP-1 receptor agonist","Mina Bagheriyan","2025","Scientometrica","nonrandomized_study","article","10.5267/j.sci.2025.4.003",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039001","Optimizing glycemic control: clinical utility of exenatide prolonged release injection","Maffioli P","2012","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0039002","Sustained Hepatic and Metabolic Benefits of Oral Semaglutide in MASLD Over 18 Months",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.492",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039003","2178-LB: BI-4659, an Adipose Tissue–Enriched Mitochondrial Uncoupler, Reverses Diet-Induced Obesity in Mice","MAFALDA PEREIRA","2025","Diabetes","preclinical","article","10.2337/db25-2178-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039004","Incretins and Development of Incretin‐based Therapeutics","Nan Zheng","2025","Peptide Science","other","article","10.1002/9781119824701.ch09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039005","Digest",null,"2014","Progress in Neurology and Psychiatry","preclinical","article","10.1002/pnp.360",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039006","Comparative Analysis of Once-Weekly Tirzepatide and Once-Daily Insulin Degludec for Diabetes Management: Efficacy, Safety, and Clinical Considerations","Chava Sowmya Devi","2024","Biomedicine","other","article","10.51248/v44i3.87",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039007","229-LB: Quantification of GLP-1R Internalization and Recycling in Live ß Cells","Sarah M. Gray","2021","Diabetes","preclinical","article","10.2337/db21-229-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039008","Insulin degludec/liraglutide cost effective in Slovakia",null,"2018","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-018-4615-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039009","Effets des antidiabétiques oraux","Marie‐Eva Pickering","2025","Médecine des Maladies Métaboliques","other","article","10.1016/j.mmm.2025.03.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039010","Abstract 10809: Socioeconomic Factors Affect Prescription Patterns of the Newer Anti-Diabetic Medications","Haritha Gaddipati","2021","Circulation","nonrandomized_study","article","10.1161/circ.144.suppl_1.10809",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039011","Figure 2S.pptx","Sato, Tetsuhiko","2023","Figshare","other","article","10.6084/m9.figshare.22122362",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039012","1914-P: From Data to Action: Early Real-World Evidence on Behavioral Change and Feature Engagement with Stelo","Margaret Crawford","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1914-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039013","2023-P: From Guidelines to Practice: System-Level Adherence to Guideline-Directed Diabetes Therapies in Real-World Academic Practice","LAURA NGUYEN","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2023-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039014","Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes","Cody Chan","2026","Diabetes Obesity and Cardiometabolic CARE","other","article","10.2337/doc26-0019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039015","Multi-Ancestry TWAS-Informed Prioritization of Antipsychotic Metabolic Risk Identifies GLP1R as a Shared Mechanistic Link","N. Wah Cheung","2026","Figshare","other","article","10.6084/m9.figshare.32751111",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint; article"],["R0039016","Annals On Call - SGLT2 Versus GLP1 for Cardiovascular Prevention","Robert M. Centor","2021","Annals of Internal Medicine","other","article","10.7326/a20-0027","34929127",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039017","Drug News",null,"2024","Nursing","other","article","10.1097/nsg.0000000000000136","39849325",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039018","Evaluation of The Antioxidant, Hypolipidemic, and Pancreatic Histological Alterations Effects of Tirzepatide in High-Fat Diet and Streptozotocin-Induced Type 2 Diabetic Rats","Shams Dhiaa Fakhir","2026","Al Mustansiriyah Journal of Pharmaceutical Sciences","preclinical","article","10.32947/ajps.v26i1.1347",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039019","Le taspoglutide : premier analogue du GLP-1 humain en une administration hebdomadaire","J.-P. Sauvanet","2010","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(10)70108-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039020","Exenatide: A Novel Therapeutic Approach for Type 2 Diabetes Mellitus","Amie D. McCord","2005","Journal of Pharmacy Technology","other","article","10.1177/875512250502100402",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039021","Turning the Tide of Obesity Medicine: Tirzepatide in the Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans with Overweight/Obesity","Jasmine Yang","2025","Metabolism","other","article","10.1016/j.metabol.2025.156229",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039022","The role of liraglutide in the management of obesity","Gemma Fromage","2019","Journal of Aesthetic Nursing","other","article","10.12968/joan.2019.8.7.322",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039023","Dipeptidyl peptidase-4 inhibitors and osteoporosis","Wen-Ling Lee","2022","Journal of the Chinese Medical Association","nonrandomized_study","article","10.1097/jcma.0000000000000775","35816295",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","editorial"],["R0039024","Current control of diabetes after cardiac rehabilitation program: the ReCardio registry","M Sestayo Fernandez","2026","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwag249.279",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039025","Impact of GLP1-agonists on the outcomes of catheter ablation for atrial fibrillation in obese patients","S Rafique","2024",null,"other","article","10.13140/rg.2.2.31114.99521",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039026","Foundation Models for Heterogeneous Treatment Effect Estimation: Adapting Pretrained EHR Embeddings in Small Clinical Cohorts","Association for Artificial Intelligence 2026","2026","Underline Science Inc.","other","article","10.48448/42c7-w889",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039027","74372 Do GLP-1s SCAR? A FAERS Disproportionality Analysis of Severe Cutaneous Adverse Reactions to GLP-1 Receptor Agonists","Nicole Levin","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.672",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039028","Software Price Modeling of Ertugliflozin","Bradley Eilerman","2018","Diabetes","other","article","10.2337/db18-145-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039029","Focus on Type 2 Diabetes Comorbidities: Using Incretin-Based Therapies in Patients With Renal, Cardiovascular, and Hepatic Insufficiencies",null,"2011","Endocrine Practice","other","article","10.1016/s1530-891x(20)43149-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039030","GLP-1 agonist use is associated with reduced risk of multiple myeloma in type II diabetes.","Eric Irons","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-5755",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0039031","Glucagon Stimulation Test and Insulin Secretory Capacity in Clinical Assessment of Incretin-Based Therapy for Diabetes","卓也 原口","2025","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039032","Dulaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-50439-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039033","Effectiveness of the Mediterranean Diet for Sustained Weight Maintenance Following GLP-1 Medication Discontinuation: A Longitudinal Prospective Study","Nitya Reddy","2026","NSUWorks (Nova Southeastern University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039034","776-P: Potent Weight Loss and Favorable Glycemic Control Effects of a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Animal Models","SANG HYUN PARK","2024","Diabetes","preclinical","article","10.2337/db24-776-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039035","S2097 Characteristics of Glucagon-Like Peptide-1 Receptor Agonist Mentions in Unstructured Notes of Specialty Dermatology Clinics","Vikas Kumar","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001037756.86286.5e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039036","Myths, Realities and Practicalities in the Initiation and Intensification of Insulin Therapy in Type 2 Diabetes","Andreas Liebl","2008","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2008.04.02.27",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039037","Liraglutide preserves endothelial function in ophthalmic arteries of septic mice via prevention of oxidative stress","Tara Gaschik","2025","Gutenberg Open Science","preclinical","article","10.25358/openscience-15339",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039038","1659-P: Early Metabolic and Hepatic Benefits of Tirzepatide in Indian Adults with Type 2 Diabetes: Insights from Real-World Practice","DINESH KUMAR","2026","Diabetes","randomized_trial","article","10.2337/db26-1659-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039039","Modeling the role of semaglutide treatment in patients with obesity and kidney disease","Jordan Mallette","2026","Physiology","nonrandomized_study","article","10.1152/physiol.2026.41.s1.2300865",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039040","FATTY LIVER DISEASE – MODERN TRENDS IN EARLY DETECTION AND TREATMENT","Bojan Mitrović","2026","Taurunum Medical Journal","nonrandomized_study","article","10.63696/tmj202601005",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039041","Human medicines European public assessment report (EPAR): Xultophy, insulin degludec / liraglutide, Diabetes Mellitus, Type 2, Date of authorisation: 18/09/2014, Revision: 12, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-17cd5c9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039042","Advances in Pharmacologic Strategies to Reduce Atheroma Plaque Size in Atheromatosis: A Comprehensive Review","Francisco Epelde","2026","Current Drug Therapy","narrative_review","article","10.2174/0115748855405974251130161059",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039043","WILL BARIATRIC SURGERY CEASE TO EXIST IN THE FUTURE?","Letícia D’Agostino Lehfeld","2026","Seven Editora eBooks","other","article","10.56238/sevened2026.009-062",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0039044","Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size","Nino Turashvili","2025","Exploration of Endocrine and Metabolic Diseases","other","article","10.37349/eemd.2025.101452",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039045","1856-LB: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)","Linong Ji","2024","Diabetes","randomized_trial","article","10.2337/db24-1856-lb",null,null,"ClinicalTrials.gov:NCT05607680","S000751","openalex","FALSE","paywalled","1","FALSE","article"],["R0039046","Efficacy of Oral Semaglutide after Switching from DPP-4 Inhibitors on Glucose Level and Body Weight Control in Japanese Type 2 Diabetes Patients with Obesity","Aki Okamoto","2025","Journal of Diabetes Mellitus","nonrandomized_study","article","10.4236/jdm.2025.152007",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039047","The comparison of liraglutide and exercise on body composition, lipid profile, peripheral and respiratory muscle performance and exercise capacity in individuals with obesity: a preliminary study","Şule Yiğit","2025","European Journal of Preventive Cardiology","other","article","10.1093/eurjpc/zwaf236.268",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039048","Dulaglutide/Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-50974-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039049","Systematic review of the study of cell therapy on pancreatic marker expression for β-cell regeneration.","Pérez Pérez, Diana","2022","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.7293622",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; review"],["R0039050","Tirzepatide Reduced Disordered Breathing in Patients With Sleep Apnea","Emily Harris","2024","JAMA","other","article","10.1001/jama.2024.12873","39028651",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039051","S4689 Splenic Artery Thrombosis and Glucagon-like Peptide-1 (GLP-1) Agonist: Is There an Association?","Regis Lee","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001048124.25350.a6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039052","Case Report of Severe Respiratory Failure and Vasoplegia After Heart Transplantation (HTx) in Three Patients with Preoperative Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Treatment","I. Pantelis","2026","The Journal of Heart and Lung Transplantation","case_report","article","10.1016/j.healun.2026.02.466",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039053","Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Ameliorates Stroke-Induced Brain and Bladder Injury in Type I Diabetic Rats","Cheng Hsun Chung","2020",null,"preclinical","article","10.22541/au.159316959.94554158",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039054","Neuromyelitis optica spectrum disorder-like presentation following semaglutide therapy: A case report","Moneera O. Aldraihem","2025","Brain Disorders","case_report","article","10.1016/j.dscb.2025.100249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039055","Glucagon-Like Peptide-1 Receptor Agonists and Respiratory Diseases: A Systematic Review and Meta-Analysis","Xin Ya See","2025","American Journal of Respiratory and Critical Care Medicine","systematic_review","article","10.1164/ajrccm.2025.211.abstracts.a6561",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0039056","Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom","Qin, Lei","2018","Figshare","other","article","10.6084/m9.figshare.6182399",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039057","Comparative Effectiveness of GLP-1 Receptor Agonists and Phentermine-Topiramate for Weight Loss in Patients with Obesity With and Without Type 2 Diabetes: A Retrospective Analysis",null,"2025","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2025.05.613",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039058","Restoring digestive harmony: A scientific prespective on integrative homeopathic and holistic management of post bariatric dumping syndrome","Himani Shah","2025","International Journal of Advanced Academic Studies","other","article","10.33545/27068919.2025.v7.i2b.1373",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039059","P172 Étude observationnelle de 4 mois sur l’efficacité et la tolérance de l’exenatide et recherche de critères prédictifs de bonne réponse","C. Halter","2010","Diabetes & Metabolism","other","article","10.1016/s1262-3636(10)70320-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039060","113-LB: Effects of Liraglutide and Empagliflozin Add-On to Insulin Therapy in Patients with Type 2 Diabetes: ELLENA-IT, a Randomized Controlled Study","Hirotatsu Nakaguchi","2019","Diabetes","randomized_trial","article","10.2337/db19-113-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039061","Prédiction de l efficacité d un traitement par liraglutide 1,2 mg à trois mois en fonction de l insulinorésistance","PEROL, Amélie","2011","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0039062","S6299 Gastric Delay, Bacterial Display: Sarcina ventriculi in Gastroparesis","Alondra Velez-Santiago","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001153656.68296.79",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039063","Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide-1 Receptor Agonists","Of, Adis Journals On Behalf","2021","Figshare","other","article","10.6084/m9.figshare.14192567",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039064","Comment on ‘Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?’","Erkan Cüre","2020","Journal of Hypertension","other","article","10.1097/hjh.0000000000002481","32371810",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039065","Orforglipron is Associated With Body Weight Reductions Across All Body Mass Index Categories by Sex in Adults With Obesity or Overweight, Without Type 2 Diabetes: ATTAIN-1 Trial Post hoc Analysis",null,"2026","Endocrine Practice","other_trial","article","10.1016/j.eprac.2026.01.322",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039066","Behavioral Changes Following Tirzepatide Treatment in Prader–Willi Syndrome: A Case Report","A. Pavesic Radonja","2026","European Psychiatry","case_report","article","10.1192/j.eurpsy.2026.11096",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039067","O3‐05‐03: Glucagon‐like peptide‐1 mimetic peptide Exendin 4 preserves memory function and attenuates neuropathology in APP/PS1 double transgenic mice","Ling Li","2010","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2010.05.421",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039068","Translational 3D spatiomolecular imaging in health and disease","Yue Li","2025",null,"nonrandomized_study","article","10.69622/30108748",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","other"],["R0039069","762-P: Semaglutide Awareness among Clinical-Year Medical Students","Nazmun Nahar Alam","2024","Diabetes","other","article","10.2337/db24-762-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039070","Diabetes mellitus – a leading risk factor for the development and progression of chronic kidney disease","Violeta Stoyanova","2026","Journal of Varna Medical College","other","article","10.14748/jmk.v7i1.10514",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039071","Beta-cell Defects in Type 2 Diabetes and the Possibility of Treatment Options with GLP-1-based Therapies","Gallwitz Baptist","2006","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2006.00.01.43",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039072","Impact of GLP-1 Receptor Agonist Therapy on Metabolic Parameters and Cardiovascular Risk: A Real-World Study","Nazif Yalçın","2026","Cukurova Anestezi ve Cerrahi Bilimler Dergisi","nonrandomized_study","article","10.36516/jocass.1933450",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039073","1482 Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue: TROD-GROG 006","Özüm Atasoy","2025","Radiotherapy and Oncology","other","article","10.1016/s0167-8140(25)00488-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039074","PDB82 PRESCRIBED DAILY DOSES OF ONCE-DAILY LIRAGLUTIDE IN THE GERMAN STATUTORY HEALTH INSURANCE (SHI)","Oliver Schöffski","2010","Value in Health","other","article","10.1016/s1098-3015(11)72140-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039075","Memorable moments of 2024","Laura Howes","2024","C&EN Global Enterprise","other","article","10.1021/cen-10238-cover6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039076","Functional screening system for GPCR‐agonists using peptide‐secreting yeasts (654.5)","Tomohiro Shigemori","2014","The FASEB Journal","other","article","10.1096/fasebj.28.1_supplement.654.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039077","S2502 Development of IgG4-Related Disease and Autoimmune Pancreatitis-Like Changes on Cross-Sectional Imaging After GLP-1 Agonist","Vikarsh Bhardwaj","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001039376.52014.b8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039078","P-639 Effect of preconceptional weight optimization on metabolic parameters and in vitro fertilization outcomes in infertile women with obesity","János Zádori","2025","Human Reproduction","nonrandomized_study","article","10.1093/humrep/deaf097.945",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0039079","Abstract #610: Improvements in Health-Related Quality of life with Liraglutide 3.0 Mg Compared with Placebo for Weight Management","Ronette L. Kolotkin","2015","Endocrine Practice","other","article","10.1016/s1530-891x(20)42674-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039080","Which patients are candidates for dipeptidyl peptidase IV inhibitors?","Joel C. Marrs","2007","American Journal of Health-System Pharmacy","other","article","10.2146/ajhp070104","17563046",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039081","The effect of sodium-glucose linked transporter 2 inhibitor and glucagon-like peptide-1 receptor agonist on weight and blood pressure control in an obese diabetic patient: a case report","Zekiye Nur Haktanıyan","2024","Ankyra Medical Journal","case_report","article","10.51271/ankmj-0033",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039082","EE114 ECONOMIC IMPACT OF CARDIOVASCULAR BENEFIT OF SEMAGLUTIDE VERSUS TIRZEPATIDE IN PATIENTS WITH OVERWEIGHT OR OBESITY IN CHINA","Nannan Meng","2026","Value in Health","other","article","10.1016/j.jval.2026.03.409",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039083","Effect of chitosan on physicochemical properties of exenatide-loaded PLGA nanoparticles","Min-ho Park","2013","Journal of Pharmaceutical Investigation","other","article","10.1007/s40005-013-0094-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039084","GLP-1 RECEPTOR AGONISTS AS A BREAKTHROUGH THERAPY FOR OBESITY AND METABOLIC SYNDROME: A SYSTEMATIC REVIEW OF EFFICACY AND LONG-TERM OUTCOMES","Aisha Alyassi","2024","Journal of Population Therapeutics and Clinical Pharmacology","systematic_review","article","10.53555/6tdd8g65",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0039085","Method Development and Validation for the Estimation of Liraglutide and Its Related Substances by using RP-HPLC","Avinash Reddy Tudi","2026","International Journal of Medicine and Pharmaceutical Research","other","article","10.30904/j.ijmpr.2026.4917",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039086","Differential released proteins between epicardial and subcutaneous fat from patients with cardiovascular disease: role on its progression and semaglutide modulation","S Eiras","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.4830",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039087","Treating obesity to optimize women’s health outcomes","Domenica Rubino","2025","Menopause The Journal of The North American Menopause Society","randomized_trial","article","10.1097/gme.0000000000002595","40446319",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039088","Real-World Experience With Tirzepatide in Nondiabetic Obese Indian Adults - An Early Interim Analysis",null,"2026","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2026.01.318",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039089","315 Mapping Nutrient Deficiencies and Supplementation in GLP-1 and GIP/GLP-1 Receptor Agonist Therapy: A Scoping Review","K. Dvorsky","2026","Journal of the American Pharmacists Association","narrative_review","article","10.1016/j.japh.2026.103332",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039090","Az életmódi és gyógyszeres testsúlycsökkentés újabb eredményei","László Bajnok","2024","Lege Artis Medicinae","other","article","10.33616/lam.34.0017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039091","Human medicines European public assessment report (EPAR): Trulicity, dulaglutide, Diabetes Mellitus, Type 2, Date of authorisation: 21/11/2014, Revision: 10, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-fdc55a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039092","The Impact of Obesity on Airway Inflammation, Lung Function and Biologic Treatment in Asthma: A Narrative Review","Benjamin Hadžić","2026","Dove Medical Press (Taylor and Francis Group)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0039093","Abstract 4370988: Outcomes Associated with GLP1 Receptor Agonist Use in Hypertrophic Cardiomyopathy","Brandon Berman","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4370988",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0039094","DKA Triggered by GLP-1 Receptor Agonist (GLP-1RA) Therapy in a Patient With Type 2 Diabetes (DM2)",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.119",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039095","26-A-13454-ACC TIME TO SUSTAINED CARDIOVASCULAR BENEFIT WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN HIGH-RISK PATIENTS: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS","Gerald Chi","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.483",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0039096","Orforglipron: First Approval","Matt Shirley","2026","Figshare","other_trial","article","10.6084/m9.figshare.32817425.v1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0039097","Efficiency of a fixed combination of insulin glargine and lixisenatide in everyday clinical practice","O.S. Elsukova Elsukova","2025","Фарматека","other","article","10.18565/pharmateca.2025.2.70-74",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039098","Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","Rossing, Peter","2024","Figshare","other_trial","article","10.6084/m9.figshare.c.6804559",null,null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","openalex","TRUE","paywalled","5","FALSE","other"],["R0039099","Analisis Sistem Pendukung Keputusan dalam Pemilihan Obat untuk Pasien Diabetes Menggunakan Metode Multi Criteria","Dede Sunandar","2025","Riau Jurnal Teknik Informatika.","other","article","10.30606/rjti.v4i1.3259",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039100","Mechanism of exendin-4 promoting bone regeneration","Yuxuan Guo","2024",null,"other","article","10.1117/12.3013156",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0039101","Chondroprotective Effect of Semaglutide in Osteoarthritis: Association with Macrophage Polarization","Ding Lei","2026","Journal of Biosciences and Medicines","preclinical","article","10.4236/jbm.2026.145015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039102","893-P: Real-World Effectiveness of Finerenone in Chinese Patients with Type 2 Diabetes Mellitus (T2MD) and Chronic Kidney Disease (CKD)","Ang Li","2024","Diabetes","randomized_trial","article","10.2337/db24-893-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039103","Molecular Therapeutics for Diabetes and Related Complications",null,"2025",null,"other","article","10.3390/books978-3-7258-5880-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0039104","El título debe ser New Myocardial Protection Therapies. Alburquerque-Béjar JJ, Barba I, Inserte J, Miró-Casas E, Ruiz-Meana M, Poncelas M, et al. Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs. Cardiovasc Res. 2015;107:246-54. http://doi.org/72h","DONATO, MARTÍN","2015","Redalyc (Universidad Autónoma del Estado de México)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039105","PO292 THE EFFECTS OF LIRAGLUTIDE ON ENOS AND IRS-1 IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS","Yi-Ming Ling","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70586-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039106","GLP-1 receptor agonist restores phagocytic activity of macrophages under hyperglycemic enviroment in vitro","Rayssa da Mota","2026",null,"preclinical","article","10.35259/isi.2026_76389",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0039107","Lilly taps Haya for weight-loss collaboration","Rowan Walrath","2024","C&EN Global Enterprise","other","article","10.1021/cen-10228-buscon2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039108","Review of Medications Used in the Treatment of Diabetes Mellitus","Brandi K Laliberte","2010","Journal of Pharmacy Technology","narrative_review","article","10.1177/875512251002600307",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039109","14-OR: Harmine and Exenatide Combination Increases Human ß-Cell Survival","Carolina Rosselot","2022","Diabetes","preclinical","article","10.2337/db22-14-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039110","Glucagon-like peptide-1 and glucagon receptor dual agonists for weight loss: a systematic review and meta-analysis of randomized controlled trials","Jafar, Uzair","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30643241",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0039111","Exenatide mitigates rosiglitazone-induced MI risk",null,"2013","Reactions Weekly","other","article","10.1007/s40278-013-6970-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039112","The influence of donor body mass index on human pancreatic islet function, structure and islet transplant outcome","Paul Johnson","2011","OpenGrey (Institut de l'Information Scientifique et Technique)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0039113","Potential effectiveness of exenatide in experimentally-induced osteoporosis","Osama M. Abu Taleb","2019","The Egyptian Rheumatologist","preclinical","article","10.1016/j.ejr.2019.06.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039114","A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes","Genovese, Stefano","2018","Figshare","narrative_review","article","10.6084/m9.figshare.6406562",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039115","GLP-1 Receptor Agonists and Inflammatory Protein Profiles in Advanced CKD: Insights from Two Cohort Studies","Alzyood, Laith","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.13140/rg.2.2.24568.30729",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0039116","P4‐420: Liraglutide, a drug developed to treat type 2 diabetes, has protective effects in mouse models of Alzheimer's disease","Bettina Platt","2011","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2011.09.116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039117","Efectos de exenatide LAR en diabetes mellitus tipo 2 y obesidad","Sierra Poyatos, Roberto","2015","Redalyc (Universidad Autónoma del Estado de México)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039118","Mental Health Outcomes Following GLP-1 Receptor Agonist Therapy in Polycystic Ovary Syndrome: Comparative Evidence From a Global Electronic Health Record Network",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.524",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039119","IP36-16 BEYOND GLYCEMIC CONTROL AND OBESITY: ARE GLP-1 AGONISTS ASSOCIATED WITH FEWER METABOLIC AND ACID–BASE DISORDERS AFTER RADICAL CYSTECTOMY?","Noor Banihashem Ahmad","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191488.74766.a1.16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039120","Early Clinical Development of Pharmaceuticals for Type 2 Diabetes Mellitus: From Preclinical Models to Human Investigation","John A. Wagner","2002","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/jc.2002-020910","12466321",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039121","Opposing Molecular Programs in OCD and Hoarding: TWAS Reveals Distinct Senescence, Complement, and Metabolic Signatures","Ngo Cheung","2026","Figshare","other","article","10.6084/m9.figshare.32099284",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039122","Metabolic and hepatic effects of tirzepatide in adults with type 2 diabetes: A 4-month real-world evaluation","Rajeev Chawla","2026","International Journal of Diabetes in Developing Countries","nonrandomized_study","article","10.1007/s13410-026-01645-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039123","Abstract WP48: Prescription Rate for Antihyperglycemic Medication With Proven Cardiovascular Benefit at Discharge in Stroke Patients Not Equal Among Payer Sources","Susan Abelt","2024","Stroke","other","article","10.1161/str.55.suppl_1.wp48",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039124","Die Wirkung von GLP-1-Agonisten bei diabetischer peripherer Neuropathie","Markus Numberger","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2265-4799",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039125","A Novel 3-(8-Chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-yl)phenyl Acetate Skeleton and Pharmacophore Model as Glucagon-like Peptide 1 Receptor Agonists","Young‐Dae Gong","2010","Bulletin of the Korean Chemical Society","preclinical","article","10.5012/bkcs.2010.31.12.3760",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039126","The Teratogenic Effect of Semaglutide Drug on the Histological Structure of the Lungs in the Albino Mouse (Mus musculus)","Saba Dawod Salman","2026","Journal of Pioneering Medical Science","preclinical","article","10.47310/jpms2026150223",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039127","Specialty Specific Guidance: An OB/GYN Professionals Guide to Using GLP-1 Receptor Agonists in Patients with Overweight or Obesity to OptimizeWomen's Health Across the Lifespan","Nasir Mustafa","2026",null,"other","article","10.13140/rg.2.2.24932.23687",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039128","Using genetics to understand and develop treatments for Parkinson’s disease","Storm, Catherine Sofie","2022","UCL Discovery (University College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0039129","Semaglutide Treatment to Achieve Sustained Weight Loss in Obesity","Nelson, Jennifer G, MMS, PA-C","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039130","P0116 The Protective Role of PYY in Intestinal Mucosal Defects Induced by SATB2 Deficiency in Inflammatory Bowel Disease","Yong Liu","2025","Journal of Crohn s and Colitis","nonrandomized_study","article","10.1093/ecco-jcc/jjae190.0290",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039131","Newer GLP-1 receptor agonists and clinical outcomes in heart failure with reduced ejection fraction: a real-world comparative study","A R Rahmani","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.1530",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039132","TZP Paper","Arthur Sherman","2026","Figshare","other","article","10.6084/m9.figshare.31370863.v3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039133","Hot topics in psychiatry/psychopharmacology","Pavel Mohr","2025","European Psychiatry","other","article","10.1192/j.eurpsy.2025.73",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039134","The Glucagon-Like Peptide-1 Receptor Agonist Inhibits Hypoxia-Induced Pulmonary Hypertension in Mice","Junya Honda","2017","Journal of Cardiac Failure","preclinical","article","10.1016/j.cardfail.2017.08.347",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039135","728-P: Glycemic Variability of Tirzepatide vs. Insulin Degludec in People with Type 2 Diabetes Using Continuous Glucose Monitoring (SURPASS-3 CGM)","Richard M. Bergenstal","2022","Diabetes","other","article","10.2337/db22-728-p",null,null,"ClinicalTrials.gov:NCT03882970","S001591","openalex","FALSE","paywalled","5","FALSE","article"],["R0039136","S3803 Doing Something When There Is Nothing—A Case of Colonic Pseudo-Obstruction","Angiela Sivakumar","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001142672.14772.e2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039137","INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH","Plamena Kabakchieva","2026","Anti-Aging Eastern Europe","other","article","10.56543/aaeeu.2026.5.1.02",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039138","PD23-06 GLP1-AGONIST USE IS ASSOCIATED WITH IMPROVED SPERM COUNTS IN OVERWEIGHT AND OBESE MEN","Skyler Howell","2025","The Journal of Urology","other","article","10.1097/01.ju.0001110004.96669.db.06",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039139","Successful Use of GLP-1 Receptor Agonist As Add-on Therapy in a Patient With Insulin Resistance Due to a Novel Mutation in the Insulin Receptor Gene",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.171",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039140","687 Is semaglutide safe and effective for improving glycemic control in individuals with cystic fibrosis-related diabetes?","M. Gerges","2025","Journal of Cystic Fibrosis","other","article","10.1016/s1569-1993(25)02303-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039141","26-A-15490-ACC GLP-1 RECEPTOR AGONISTS REDUCE POSTOPERATIVE ALL-CAUSE MORTALITY IN TYPE 2 DIABETES PATIENTS UNDERGOING ELECTIVE CABG: A NATIONAL MATCHED COHORT STUDY","Muneeb Asad","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.4913",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039142","Tinjauan Terpadu terhadap Terapi Presisi dan Standardized Herbal Drug untuk Non-Alcoholic Fatty Liver Disease (NAFLD): Kemajuan Molekuler, BuktiKlinis, serta Implikasi Integratif","Raymond R. Tjandrawinata","2025","MEDICINUS","other","article","10.56951/mh4ry926",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039143","N-K WEATHER DNA V6 — COMPLETE The Deterministic Unification of Atmosphere, Ocean, Geology, and Climate","Muhammad Usman Malik","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19674474",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039144","Recent Advances in Thrombosis and Hemostasis—Part XII","Sam Schulman","2025","Seminars in Thrombosis and Hemostasis","randomized_trial","article","10.1055/s-0045-1809697","40940012",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039145","The GLP-1 receptor agonist Semaglutide preserves cardiac function, reduces inflammation-driven cardiotoxicity with cardio-renal benefits in non-diabetic models exposed to anthracyclines and HER2 block","V Quagliariello","2026","European Journal of Heart Failure","randomized_trial","article","10.1093/ejhf/xuag193.1327",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039146","Lilly (Eli) & Co.",null,"2006","Mergent s Dividend Achievers","other","article","10.1002/div.4390",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039147","Dulaglutide Has Favorable Outcomes in Elderly or Renal Impairment Patients with Type 2 Diabetes","Shizuka Kaneko","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1101-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039148","1739-P: Impact of IGlarLixi on Glycemic Variability (GV): A Participant-Level Exploratory Pooled Analysis of the Global LixiLan Clinical Trial Program","Leszek Czupryniak","2026","Diabetes","other_trial","article","10.2337/db26-1739-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039149","Kommentar zu „Typ-2-Diabetes: SGLT2-Inhibitoren und DPP4-Inhibitoren im Vergleich“","Markus Menzen","2023","DMW - Deutsche Medizinische Wochenschrift","other","article","10.1055/a-2058-1588",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039150","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-31812-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039151","26 Exenatide alleviate adriamycin-induced cardiac injury","F Juntao","2018",null,"randomized_trial","article","10.1136/heartjnl-2018-ics.26",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0039152","Editorial: Oxytocin and metabolic dysregulation: from pathophysiology to pharmacotherapy","James E. Blevins","2025","Frontiers in Endocrinology","preclinical","article","10.3389/fendo.2025.1579937","40134807",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0039153","S3574 An Unusual Case of Rapid Gastric Emptying","M Ammar Kalas","2021","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000787828.46101.36",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039154","Lilly (Eli) & Co.",null,"2008","Mergent s Dividend Achievers","other","article","10.1002/div.6741",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039155","859-P: GLP-1 Receptor Agonists vs. DPP-4 Inhibitors and SGLT2 Inhibitors on Liver Outcomes in Metabolic Dysfunction–Associated Steatotic Liver Disease","Jyotirmoy Sarker","2025","Diabetes","nonrandomized_study","article","10.2337/db25-859-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039156","Preface","Guido Grassi","2026","Current Hypertension Reviews","other","article","10.2174/0115734021474321260130103450","42333928",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039157","Rethinking muscle health assessment in GLP-1-based therapies for obesity","Mojca Jensterle Sever","2026","DiRROS repository (University of Maribor)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039158","MedCheck: FDA to Consider Low-Sodium Oxybate for Narcolepsy; Wegovy Pill Approved, and More","Linda M. Richmond","2026","Psychiatric News","other","article","10.1176/appi.pn.2026.02.2.9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039159","Effectiveness of Empagliflozin With Oral Semaglutide on Metabolic Profile of North Indian Patients With Type-2 Diabetes Mellitus in Routine Care Setting",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.565",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039160","Discrepancies Between Prespecified and Reported Outcomes","The Editors","2015","Annals of Internal Medicine","randomized_trial","article","10.7326/l15-0615","26720499",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039161","1661-P: Digital Programme Engagement Enhances GLP-1 Receptor Agonist Weight Loss Outcomes in Type 2 Diabetes","HANS JOHNSON","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1661-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039162","GLP-1 Receptor Agonists in Pediatric Populations: Current Evidence, Developmental Considerations, and Gaps in Knowledge","Madison Christman","2026","RVU Elevate","other","article","10.82451/k5931",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039163","PRAC concludes GLP-1 receptor agonists not associated with thyroid cancer",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-48583-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039164","Dipeptidilpeptidáz-4-gátlók (gliptinek): az orális antidiabetikumok új hatástani csoportja = Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs","György Jermendy","2011","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039165","Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Heart Transplant Recipients","Z. Blázquez Bermejo","2026","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2026.02.342",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039166","Cost Effectiveness of Insulin Glargine/Lixisenatide for Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin in South Korea","Hae‐Young Park","2019","Yakhak Hoeji","other","article","10.17480/psk.2019.63.1.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039167","Additional file 1 of Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study","Longato, Enrico","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.17007077",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0039168","Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom","Hunt, Barnaby","2018","Figshare","other","article","10.6084/m9.figshare.6205649",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039169","Obesity and hypertension in type 2 diabetes: exploring central and peripheral effects of glucagon-like peptide-1 receptor signalling","Louise Robinson","2012","Warwick Research Archive Portal (University of Warwick)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039170","Diabetes and endocrinology symposium: genes, environment and emerging therapies","Nicola N. Zammitt","2008","The Journal of the Royal College of Physicians of Edinburgh","other","article","10.1177/1478271520083801009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039171","Protein Distribution among Individuals Using Glucagon-like-peptide-1 Receptor Agonist for Weight Loss",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.09.066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039172","Evaluation of the Safety and Efficacy of Semaglutide","Siqi Ma","2025","Theoretical and Natural Science","other","article","10.54254/2753-8818/2025.ld27803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039173","The triple agonist incretin mimetic retatrutide as a novel treatment strategy for obesity-driven endometrial cancer","Miller Singleton","2026","Gynecologic Oncology","other","article","10.1016/j.ygyno.2026.01.076",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039174","Current Pharmacological Treatments in Type 1 Diabetes and Patient Tolerability against New Generation Medicines","Muzaffer Serdar Deniz","2024","IntechOpen eBooks","other","article","10.5772/intechopen.1006990",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0039175","Poster presented at EASL 2026. Survodutide reduces steatosis and fibrosis in a MASH human liver spheroid model through direct glucagon receptor agonism","Philip Vonschallen","2026","Boehringer Ingelheim","other","article","10.60915/boehringer-figshare.32158941",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039176","S1307 Examining the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Residual Gastric Contents During Upper Endoscopy: A Systematic Review and Meta-Analysis","Emeka S. Obi","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001132688.69299.45",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0039177","Victoza® : de nouveaux résultats prometteurs dans le diabète de type 2","Marie Solignac","2011","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(11)70322-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039178","AGONISTAS DO GLP-1 E INSUFICIÊNCIA CARDÍACA: EVIDÊNCIAS DA RELAÇÃO TERAPÊUTICA","Verônica Cristina Carvalho Chaves","2026","Revista Foco","other","article","10.54751/revistafoco.v19n7-010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039179","A dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist increases blood pressure in stroke-prone spontaneous hypertensive rats","Y Ono","2025","European Heart Journal","preclinical","article","10.1093/eurheartj/ehaf784.4888",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039180","Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients With Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial","Of, Adis Journals On Behalf","2020","Figshare","randomized_trial","article","10.6084/m9.figshare.13360163",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0039181","CO217 Safety Profile of Semaglutide in Obesity Management With or Without Type 2 Diabetes (T2DM): A Systematic Literature Review From Controlled and Real-World Settings","Amit Dang","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.09.318",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","review"],["R0039182","OLEATE CONTROLS THE EFFECTS OF GLP-1 AND EXENDIN-4 ON MYOCARDIAL GLUCOSE UTILIZATION AND CONTRACTILE FUNCTION","Tien Nguyen","2011","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(11)60211-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039183","Parkinson's Disease Society 6th Spring Conference for Researchers","Lynn Bedford","2009","Progress in Neurology and Psychiatry","other","article","10.1002/pnp.143",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039184","2459-P: Nucleus of the Solitary Tract GIPR Agonism Fails to Additively Reduce Food Intake with Leptin Co-Infusion","MELISSA T. WANG","2026","Diabetes","preclinical","article","10.2337/db26-2459-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039185","Once-Weekly Dulaglutide (DU) and Canagliflozin (CAN) Combination Therapy in Obese T2 Diabetes (T2D) Patients—One Year Real-World Evidence from India","Anant Nigam","2018","Diabetes","nonrandomized_study","article","10.2337/db18-103-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039186","Mo2047: THE IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) USE ON GASTROESOPHAGEAL REFLUX AND THE DEVELOPMENT OF ESOPHAGEAL ADENOCARCINOMA","Joshua Thariath","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03817-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039187","Patients' preference for subsequent therapy following secondary failure of metformin and sulphonylurea","Halima Khan","2009","Practical Diabetes","other","article","10.1002/pdi.1400",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039188","The intersection of severe mental illness, psychotropic pharmacotherapy, and metabolic disorders","J. Samochowiec","2026","European Psychiatry","other","article","10.1192/j.eurpsy.2026.10405",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039189","4311 LAPAROSCOPIC SLEEVE GASTRECTOMY IS SUPERIOR TO HIGH DOSE SEMAGLUTIDE OR TIRZEPATIDE ON WEIGHT LOSS AND BODY COMPOSITION. A REAL-WORLD SINGLE INSTITUTION PROSPECTIVE COHORT STUDY MATCHED FOR SAMPLE SIZE, GENDER, AGE, INITIAL BMI, BIOIMPEDANCE SCALE, FOLLOW-UP AND INTENSIVE LIFESTYLE INTERVENTION",null,"2026","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2026.02.032",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0039190","Investigation on the Effects of GLP1 analog and SGLT2 inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms","Abdelaziz M. Hussein","2021","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.5033874",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0039191","EFEITOS RENOPROTETORES DA ASSOCIAÇAO DE SEMAGLUTIDA E EMPAGLIFLOZINA EM MODELO MURINO DE DIABETES TIPO 2, DOENÇA RENAL DIABETICA E OBESIDADE","Melise Oliveira Mariano","2025",null,"other","article","10.65034/bjnabstract-cpn25332",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039192","THU-040 Efficacy of CRV431 and Semaglutide on liver fibrosis in a mouse model of MASH","Asha Goodman","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)00860-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039193","1386-P: XTL6001: A Novel Triple MasR/GCGR/GLP-1R Agonist for Chronic Kidney Disease/Diabetic Kidney Disease with Proteinuria and Hyperuricemia","Ying Wang","2026","Diabetes","preclinical","article","10.2337/db26-1386-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039194","S2080 Antiretroviral Therapy Enhances the Cardioprotective Benefit of GLP-1 Receptor Agonists in People With HIV","Sarpong Boateng","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001135780.83910.54",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039195","Effects of liraglutide + / - PYY3-36 vs. Roux-en-Y gastric bypass on non-alcoholic fatty liver disease","Ulrich Dischinger","2021","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0041-1727388",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0039196","Addition of liraglutide vs addition of a single dose of insulin aspart to insulin degludec plus metformin in patients with type 2 diabetes","Chantal Mathieu","2013","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039197","1875-LB: Adjuvant Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) Use in HNF1A- and HNF4A-MODY","DAVID BROOME","2024","Diabetes","other","article","10.2337/db24-1875-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039198","980-P: Automated Insulin Delivery Clamp Technology—Proof of Concept Study","Kate Hawke","2024","Diabetes","nonrandomized_study","article","10.2337/db24-980-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039199","1775-P: Liraglutide Corrects Impaired Insulin Secretion in 14-3-3-ζ Overexpressing Mice","RAHAF SHISHANI","2023","Diabetes","preclinical","article","10.2337/db23-1775-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039200","950-P: Efficacy and Safety of Once-Weekly Dulaglutide Added to Titrated Insulin Glargine, Prandial Insulin, and Oral Agents in Obese Asian T2 Diabetes (T2D) Patients: One Year Real-World Evidence from India","Anant Nigam","2020","Diabetes","nonrandomized_study","article","10.2337/db20-950-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039201","S2278 Safety of GLP-1 Agonists With Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis: Insights From a Phase 3 Study","Richard W. McCallum","2024","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0001038480.66695.52",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0039202","Figure 2: Dose-Dependent Effect on Body Weight Gain by Semaglutide in LDLr","Günaj Rakipovski","2019","JACC: Journal of the American College of Cardiology","preclinical","article","10.25407/jacbts.8253347.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039203","Such a loss… (of kilograms) - a therapeutic success in pharmacological treatment of obesity using SGLT2 inhibitors and GLP1 analogs","Patryk Gryszkiewicz","2023",null,"other","article","10.22541/au.168181570.01874151/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039204","Semaglutide once: semaglutide (1.8%) versus placebo (2.2%)","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/e69jr",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039205","Risk of pulmonary aspiration with glucagon-like peptide-1 receptor agonists in patients under anesthesia: a call for more research and streamlined guidelines","Velhagen, Juliet","2024",null,"other","article","10.13140/rg.2.2.16179.23845",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039206","Slower Titration of Liraglutide Achieves better Tolerability in some Patients","Martin M. Grajower","2017","AACE Clinical Case Reports","other","article","10.4158/ep171826.cr",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039207","6.3 Efficacy and Safety of Lixisenatide in Elderly T2DM Patients: Subanalysis from the GetGoal Program (916-P)","M Hanefeld","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0049-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039208","Abstract 4371746: Comparative Study of Cardiovascular Safety of GLP-1 Receptor Agonists Across Indications: A Meta-Analysis of Randomized Controlled Trials in Type 2 Diabetes and Obesity","Rubab Fatimaa","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4371746",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0039209","Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis","Ahrén, Bo","2018","Figshare","other","article","10.6084/m9.figshare.6211085",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039210","MOESM1 of Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway","Feng, Yun","2020","Figshare","other","article","10.6084/m9.figshare.11508075.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039211","Figure 2S.pptx","Sato, Tetsuhiko","2023","Figshare","other","article","10.6084/m9.figshare.22122362.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039212","Phân tích xu hướng sử dụng thuốc trong tăng cường điều trị đái tháo đường típ 2 chưa đạt mục tiêu kiểm soát đường huyết tại một bệnh viện đa khoa ở Thành phố Hồ Chí Minh","Đình Phiên Trần","2026","Y HOC TP HO CHI MINH","other","article","10.32895/hcjm.m.2026.02.11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039213","Pesquisa e desenvolvimento de novos medicamentos para tratamento de doenças","Gildomar Lima Valasques","2026","Revista Científica Eletrônica do Conselho Regional de Farmácia da Bahia","commentary","article","10.70673/rcecrfba.v5i1.104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0039214","P3‐362: GLP‐1 mimetics improve learning and memory: A link between diabetes and Alzheimer's disease","Stephen F.J. McGovern","2010","Alzheimer s & Dementia","other_trial","article","10.1016/j.jalz.2010.05.1904",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039215","Sa1586: REVERSE OF LIVER PATHOLOGY IN MASH PATIENTS WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST MEDICATIONS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Christopher C. Thompson","2025","Gastroenterology","systematic_review","article","10.1016/s0016-5085(25)04806-1",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0039216","26-A-14626-ACC HARMONIZED META-ANALYSIS OF GLP-1 RECEPTOR AGONIST CARDIOVASCULAR OUTCOME TRIALS: CONSISTENT REDUCTION IN 3-POINT MACE","Mrinal Bhandari","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.683",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0039217","Effects of intermittent intraperitoneal infusion of exendin-4 and PYY(3–36) on food intake and adiposity in diet-induced obese rats","R.D. Reidelberger","2009","Appetite","preclinical","article","10.1016/j.appet.2009.04.161",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039218","International Diabetes Guidelines Face to Face","Anita L R Saldanha","2026","American Journal of Medical and Clinical Research & Reviews","other","article","10.58372/2835-6276.1368",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039219","Advantages of combined use of sodium-glucose co-transporter type 2 inhibitors and glucagon-like peptide-1 receptor agonists relatively to cardiovascular and renal outcomes in patients with type 2 diabetes mellitus","Salukhov V.V. Salukhov","2024","Therapy","other","article","10.18565/therapy.2024.8.66-76",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039220","Semaglutide (Wegovy)","CDA-AMC","2025","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2025.1255",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039221","Comparative Effectiveness of Liraglutide and Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Propensity Score-Matched Real-World Study",null,"2026","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2026.01.290",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039222","GLP-1-receptoragonisten en renoprotectie in type 2-diabetes","Marcel H.A. Muskiet","2024","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-024-1567-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039223","Glucagon-Like Peptide-1 Receptor (GLP-1R) Signaling Ameliorates Dysfunctional Immunity in COPD Patients","Jian Huang","2019",null,"other","article","10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4525",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039224","4 Prospective Audit and Observational Study of GLP-1 Receptor Agonist Use in a Surgical Patient Cohort","A Walker","2026","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znag080.002",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039225","Exenatide regulates short-term control of food intake by different neuronal pathways","Jizette V. Hunt","2011","Appetite","other","article","10.1016/j.appet.2011.05.185",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039226","Diabetes and renal disease—should we biopsy?","Sheila Bermejo","2019","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfz248","31883322",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039227","Preparation of sustained-release microspheres containing exenatide and their in vitro release","Ji-ming XUAN","2011","Academic Journal of Second Military Medical University","preclinical","article","10.3724/sp.j.1008.2011.00772",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039228","Weight loss drugs for the unemployed—how will the government’s new trial work?","Elisabeth Mahase","2024","BMJ","other_trial","article","10.1136/bmj.q2281","39419523",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039229","Regulating effect of empagliflozin plus liraglutide on glucose/lipid metabolism and serum levels of SFRP5， Irisin and tAPN in obese type 2 diabetics","Gao Rui-chao","2022","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0039230","GLP-1 Receptor Agonists and Cardiovascular Effects: Scoping Review with ☸SAIMSARA","SAIMSARA","2026","SAIMSARA Journal","randomized_trial","article","10.62487/saimsarafcc6e977",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039231","Research",null,"2025","Bone and Joint 360","nonrandomized_study","article","10.1302/2048-0105.144.360255",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039232","Liraglutide/semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-45891-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039233","Exenatide for obesity in children and adolescents: Systematic Review and Meta-analysis (Preprint)","Xihong Li","2023",null,"systematic_review","article","10.2196/preprints.48486",null,null,"PROSPERO:CRD42023413706",null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0039234","Kilograms are the wrong endpoint: Glucagon-like peptide-1 receptor agonists and muscle health in older adults","Liang-Kung Chen","2026","Aging Medicine and Healthcare","other","article","10.4103/amah.amah.v17-3_editorial",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039235","100.69 Pre-Procedural GLP-1 Receptor Agonist Use and Risk of Contrast-Induced Acute Kidney Injury After PCI: A Single-Center Cohort Study","Christopher James","2026","JACC: Cardiovascular Interventions","nonrandomized_study","article","10.1016/j.jcin.2026.01.072",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039236","GLP-1 RECEPTOR AGONISTS AND RISK OF CARDIOVASCULAR OUTCOMES IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND TYPE 2 DIABETES MELLITUS","Soon Young Hwang","2025","CHEST Journal","other","article","10.1016/j.chest.2025.07.3957",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039237","Su2062: RELATIONSHIP OF WEIGHT LOSS AND ACUTE PANCREATITIS IN PATIENTS ON GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST","Sarjukumar Panchal","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03114-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039238","1708-P: Effect of Oral Semaglutide in Glycemic Control and Weight Reduction for People with Type 2 Diabetes Mellitus Having a BMI ≥25 kg/m2—A Six-Month Real-World Study","JOTHYDEV KESAVADEV","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1708-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039239","EE12 COST-EFFECTIVENESS ANALYSIS OF ORFORGLIPRON AND SEMAGLUTIDE FOR THE TREATMENT OF ADULTS WITH OBESITY IN THE UNITED STATES","Kwame Kissi-Twum","2026","Value in Health","other","article","10.1016/j.jval.2026.03.308",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039240","788-P: Synergistic Body Weight Reduction of GLP-1 Analog Ecnoglutide and Amylin Analogs in Preclinical Animal Models","Haixia Zou","2024","Diabetes","other_trial","article","10.2337/db24-788-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039241","S2567 Insurance Coverage for GLP-1 Receptor Antagonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Analysis of the Top US Insurers","Kara Eileen Rieth","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001137728.22009.20",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0039242","Effects of liraglutide on the biological behavior of human endothelial colony forming cell induced by high glucose via regulating sirtuin expression","Lu ZHANG","2019","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039243","2004-P: Liraglutide Shows Better Weight Loss and Cardiometabolic Benefits than Lorcaserin and Pioglitazone in a Novel Diet-Induced Obese Rat Model","François Briand","2019","Diabetes","preclinical","article","10.2337/db19-2004-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039244","Tirzepatide Versus Semaglutide for Glycemic Control and Weight Loss: Updated Network Meta-analysis of Phase 3 Trials Incorporating 2025 SURMOUNT-5 Data",null,"2026","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2026.01.157",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0039245","A PROSPECTIVE OBSERVATIONAL STUDY ON ASSESSMENT OF CLINICAL EFFICACY AND SAFETY OF RIFAXIMIN IN PATIENTS WITH NON- ALCOHOLIC FATTY LIVER DISEASE",null,"2024",null,"nonrandomized_study","article","10.48047/afjbs.4.4.2022.366-377",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039246","Central GLP-1 receptor agonist promotes insulin release and lowers blood glucose","Kumari Parmila","2017","The Journal of Physiological Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039247","Approved Combination Agents","W. Timothy Garvey","2023",null,"other_trial","article","10.1201/9781003432807-37",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0039248","Vildagliptin Improves Glucose Tolerance and Decreases Plasma Triglycerides in Sprague-Dawley Rats","Go Koizumi","2013","The Showa University Journal of Medical Sciences","preclinical","article","10.15369/sujms.25.213",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039249","452 GLP-1 Inhibits Prandial Antro-Duodeno-Jejunal Motility in Humans: Native GLP-1 Compared With Analogue ROSE-010 In Vitro","Md Abdul Halim","2016","Gastroenterology","preclinical","article","10.1016/s0016-5085(16)30437-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039250","S1102 GLP-1 Receptor Agonist Use for Reducing Symptom Burden and Medication Utilization in Non-Obese Women With IBS-D: A Propensity Matched Retrospective Cohort Study","Jordan Barnett-Kradjian","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001131868.76662.c6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039251","Evaluating the Renoprotective Effects of Pharmacological Interventions in Diabetic Kidney Disease: A Comparative Study","Ishitta Sarkar","2026","KIDNEYS","other","article","10.65327/kidneys.v15i1.622",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039252","1177-OR: Informing Medicare Prescription Drug Subsidy Expansion: A Cost Sensitivity Analysis of Income-Related Heterogeneity in Discontinuation of GLP-1 Receptor Agonists and SGLT2 Inhibitors","ELIZABETH MITCHELL","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1177-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039253","More than skin deep : the role of augmented reality beauty filters in social self-comparison, emotions, and GLP-1 decision-making","Makenzie Shay Schroeder","2026",null,"other","article","10.32469/10355/112621",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0039254","Re: Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial","Fariha Shahid Tanveer","2025",null,"nonrandomized_study","article","10.22541/au.176642523.38751199/v1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0039255","---HEALTH & SCIENCE 2025-IV---",null,"2025",null,"preclinical","article","10.59617/efepub2025216",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0039256","Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain","Ayman I. Sayegh","2008","Appetite","other","article","10.1016/j.appet.2008.04.212",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039257","Microstructural analysis of water and sucrose intake by rats after systemic administration of the glucagon-like-peptide-1 (GLP-1) receptor agonist Exendin-4","Clare M. Mathes","2011","Appetite","preclinical","article","10.1016/j.appet.2011.05.224",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039258","Personalized treatment of hypogonadism in obese male individuals: An algorithm for the combined use of incretin mimetics and testosterone medications","V.V. Salukhov Salukhov","2026","Therapy","other","article","10.18565/therapy.2026.4.82-96",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039259","Plaque-Targeted, Proteolysis-Resistant and Activatable Nano-GLP-1 Receptor Agonist Reduces Atherosclerosis in Apoe -/- Mice Without Weight Loss","Andrei Maiseyeu","2021","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.3789441",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039260","Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom","Feher, Michael","2018","Figshare","nonrandomized_study","article","10.6084/m9.figshare.6182312",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0039261","Dulaglutide/empagliflozin",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-42733-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039262","Manejo actual del síndrome de ovario poliquístico en mujeres con deseo genésico","Germania Elizabeth Yugcha Andino","2024","Mediciencias UTA (Impresa)/Mediciencias UTA (En línea)","randomized_trial","article","10.31243/mdc.uta.v8i4.2629.2024",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039263","Review: On Hunger: Violence and Craving in America, from Starvation to Ozempic , by Dana Simmons","Julie Guthman","2025","California History","preclinical","article","10.1525/ch.2025.102.4.91",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039264","S5933 Hepatitis B Reactivation in a Patient on Long-Term Entecavir Following Initiation of Semaglutide: A Case Report","Kenda Al-Assi","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001151192.53754.09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039265","World Hypertension League: education and awareness about the most important risk factor. An interview with prof Gianfranco Parati, president of WHL","Paul Dendale","2026","European Journal of Preventive Cardiology","other_trial","article","10.1093/eurjpc/zwag132","42139551",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039266","26. The Effect of Initial Glargine (IG) Dose on Response to Added Exenatide Twice Daily (BID) or Bolus Insulin: Subgroup Analysis of the 4B Study (1129-P)","Bruce H. R. Wolffenbuttel","2015","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-015-0047-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039267","G-448 GLP1 Receptor Agonist for the Treatment of Obesity-Associated Secondary FSGS",null,"2026","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2026.02.449",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039268","1236 Impact of Pharmacy Support on Tirzepatide Management in Patients with Obstructive Sleep Apnea or Obesity","Amanda Gronniger","2026","SLEEP","nonrandomized_study","article","10.1093/sleep/zsag091.1235",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039269","3. Blood glucose-lowering therapies – Non-insulin options for type 2 diabetes","Stephen Colagiuri","2025","Diabetes Research and Clinical Practice","other_trial","article","10.1016/j.diabres.2025.112147","40209898",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0039270","Editorial: Tamiflu and the open data campaign","Sarah Edwards","2013","Research Ethics","other_trial","article","10.1177/1747016113502276",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","editorial"],["R0039271","1005-OR: The SURPASS-CVOT Retinopathy Substudy: Retinal Status after Treatment with Tirzepatide or Dulaglutide in Patients with Type 2 Diabetes and Risk for Progressive Retinopathy","DAVID M. D'ALESSIO","2026","Diabetes","randomized_trial","article","10.2337/db26-1005-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039272","1811-P: Therapeutic Transition to Weekly Basal Insulin Icodec plus Tirzepatide in Type 2 Diabetes: An Early Real-World Experience","Giada Rossi","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1811-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039273","When the Shot Stops: A Scoping Review of Weight Trajectory and Metabolic Outcomes After Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Discontinuation","Saylor McFarland","2025","Open Science Framework","randomized_trial","article","10.17605/osf.io/6w2kh",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0039274","Slimness or smooth skin? the aesthetic trade-off between GLP-1 agonists and BoNT-A","Ecem Büşra Değer","2026","Medical Hypotheses","other","article","10.1016/j.mehy.2026.112019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039275","9 | GLP‐1 Receptor Agonists in Systemic Lupus Erythematosus: A Scoping Review",null,"2026","International Journal of Rheumatic Diseases","narrative_review","article","10.1111/1756-185x.70608_66",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039276","Biocompatible microspheres based on acetylated polysaccharide prepared from water-in-oil-in-water (W1/O/W2) double-emulsion method for delivery of type II diabetic drug (exenatide)","Hyun Jung Yang","2009","Colloids and Surfaces A Physicochemical and Engineering Aspects","other","article","10.1016/j.colsurfa.2009.03.015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039277","Glycemic Treatment Effect of Oral Semaglutide Plus Other Antidiabetic Medications","Manoj Chawla","2022","Journal of Diabetology","randomized_trial","article","10.4103/jod.jod_71_22",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0039278","C108-02 Changes in Respiratory Physiology Following Initiation of GLP-1 Receptor Agonists (GLP-1RA)","S Vakharia","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.5458",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039279","2456-P: Restoration of Impaired Portal Glucose Signaling Using Low-Dose Dihydrotestosterone Reprograms Brain Networks in Experimental Diabetes","Charles‐Henri Malbert","2026","Diabetes","randomized_trial","article","10.2337/db26-2456-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039280","Comparative 12-month cardiometabolic impact of semaglutide vs tirzepatide: a synthetic propensity-matched analysis","M R Fazio Giovanni","2026","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwag249.181",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039281","530-P: Evaluating the Role of a Digital Health Platform in Supporting GLP-1 Adherence and Sustained Outcomes Post-discontinuation","‪Yifat Fundoiano-Hershcovitz","2025","Diabetes","nonrandomized_study","article","10.2337/db25-530-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039282","P1027THE DIFFERENCES EFFECTS OF GLUCAGON LIKE PEPTIDE-1(GLP-1) ANALOGUES AND SODIUM-COTRANSPORTER 2 (SGLT-2) INHIBITORS ON TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT","Takeyuki Hiramatsu","2020","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfaa142.p1027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039283","Interaction between obesity and vitamin D and testosterone and vitamin D in prostate cancer patients on active surveillance in the PROVENT trial.","Tim Oliver","2026","Journal of Clinical Oncology","randomized_trial","article","10.1200/jco.2026.44.7_suppl.401",null,null,"ISRCTN:ISRCTN91422391",null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0039284","Single molecule SNAP-GLP-1R tracking data","Buenaventura, Teresa","2019","Spiral (Imperial College London)","other","article","10.6084/m9.figshare.c.4592000",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0039285","Predictors of Kidney Disease Progression in Diabetes and Precision Medicine: Something Old, Something New, and Something Borrowed","George Vasquez‐Rios","2021","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2021070945","34465605",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039286","[Current status and management of obesity in China].","Y P Wang","2023","PubMed","other","article","10.3760/cma.j.cn112138-20231010-00197","38044060",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039287","Involvement of Vascular Endothelial Cells in the Anti-atherogenic Effects of Liraglutide in Diabetic Apolipoprotein E-null Mice","Masakazu Koshibu","2019","The Showa University Journal of Medical Sciences","randomized_trial","article","10.15369/sujms.31.115",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039288","EVALUATING POUCH RELATED OUTCOMES WITH GLUCAGON LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS IN PATIENTS WITH ILEAL POUCH ANAL ANASTOMOSIS—A DATABASE STUDY IN THE UNITED STATES","Pal Ramesh","2026","Inflammatory Bowel Diseases","nonrandomized_study","article","10.1093/ibd/izag006.048",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039289","FRI-383 Comparative anti-fibrotic action of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH","Jacob Nøhr-Meldgaard","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)01612-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039290","Diabetes és osteoporosis = Diabetes and osteoporosis","Valkusz, Zsuzsanna","2011","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039291","Diabetes News","Ursula Biba","2019","Journal of Diabetes","nonrandomized_study","article","10.1111/1753-0407.12980","31433564",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039292","Wired for Obesity?","Dinesh Selvarajah","2014","Diabetes","other","article","10.2337/db14-1311","25414020",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039293","Breaking Ground: From CPAP Treatment to the First Medicine for OSA Patients with Obesity","Daniil Lisik","2025","Current Pulmonology Reports","other","article","10.1007/s13665-024-00365-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039294","Decrease mortality in type II diabetes mellitus","Claudio Borghi","2018","Journal of Cardiovascular Medicine","randomized_trial","article","10.2459/jcm.0000000000000586","29538138",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039295","Mechanism of Liraglutide Regulating the Expression of PI3K/AKT/NF-KB Pathway-related Proteins on Nonalcoholic Fatty Liver Disease","Yao Sang","2024","Transactions on Materials Biotechnology and Life Sciences","preclinical","article","10.62051/0j03m472",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039296","Obesity, Type 2 diabetes and NAFLD",null,"2014","Diabetic Medicine","randomized_trial","article","10.1111/dme.12377_1","24593688",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039297","1207-P: Glucose Tolerance and Glucagon-Like Peptide-1 Sensitivity in Offspring Exposed to Prenatal Hyperglycemia","G. Tomizawa","2024","Diabetes","preclinical","article","10.2337/db24-1207-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039298","Abstract 51: Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Prevention of Stroke among Patients with Type 2 Diabetes Mellitus, Heart Failure, or Obesity: A Meta-Analysis of 12 Randomized Controlled Trials.","Vikash Jaiswal","2025","Stroke","systematic_review","article","10.1161/str.56.suppl_1.51",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0039299","Abstract 4145444: GLP-1 Receptor Agonists And Clinical Events After Anthracycline-Based Chemotherapy: A Propensity Score-Matched Cohort Study","Nicole Felix","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4145444",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039300","OS-016 Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis","Mazen Noureddin","2026","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(26)00326-0",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0039301","Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study","Nicholas Stucky","2026","UNC Libraries","nonrandomized_study","article","10.17615/0qep-j968",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0039302","1857-LB: GLP-1 Receptor Agonist and GLP-1GIP Dual Agonist in Diabetic Kidney Disease","Aihua Wu","2025","Diabetes","randomized_trial","article","10.2337/db25-1857-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039303","TOS / OMA / OAC Expert Guidance Statement on Obesity Pharmacotherapy: A Humbling Call to Action","Beverly G. Tchang","2026","Obesity","randomized_trial","article","10.1002/oby.70170","41782449",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039304","445-P: Network Meta-analysis of Seven Glucagon-Like Peptide-1 Receptor Agonists: A Focus on Cardiovascular Outcome Trials Data","Osamah M. Alfayez","2020","Diabetes","systematic_review","article","10.2337/db20-445-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0039305","75371 Risk of New-Onset Hair Loss with Semaglutide and Tirzepatide: A Retrospective Cohort Study","Henry Herrera","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.1557",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039306","Iperglicemia e memoria metabolica: GLP-1 e i suoi analoghi","Lucia La Sala","2012","Università Politecnica delle Marche (Università Politecnica delle Marche)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0039307","Incretin Hormones and their effec ts in Type 2 Diabetes","Molly Getz","2014","Digital Commons - Otterbein (Otterbein University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039308","Cost Per Responder of Lixisenatide Versus Rapid-Acting Insulin Intensification Regimens in an Insulin-Exposed Type 2 Diabetes Mellitus (T2DM) Population","Marion Afonso","2016","Value in Health","other","article","10.1016/j.jval.2016.09.1866",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039309","Impact of GLP-1 Receptor Agonists and Dual/Triple Incretin Therapies on Cardiometabolic Outcomes Beyond Glycemic Control: Evidence from Recent Randomized Trials","Javaria Ismail","2026","Journal of Diabetes Research Review & Reports","randomized_trial","article","10.47363/jdrr/2026(8)211",null,null,null,null,"openalex","FALSE","open_pdf","2","FALSE","article"],["R0039310","The Population Health Research Institute","Janette Panhuis","2017","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehx608","29145659",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039311","Real-world Effectiveness of Oral Semaglutide in Patients with Type 2 Diabetes Mellitus: A Retrospective Observational Study on Glycemic Control and Weight Reduction","Tarunika Bawa","2025","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_5_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039312","Lilly (Eli) & Co.",null,"2007","Mergent s Dividend Achievers","other","article","10.1002/div.6395",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039313","Consumer Concentration and the Risk of the \"Ozempic Effect\" in the US Retail Market","Aljoscha Janssen","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.4703402",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039314","Effect of the protracted GLP-1 derivative NN2211 in betacell reduced minipig","Ulla Ribel","2000","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(00)81309-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039315","S2660 Efficacy of GLP-1 Receptor Agonists in MASH Resolution and Fibrosis Reduction: A Meta-Analysis","Rahul Tripathi","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001138100.63129.02",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0039316","GLP-1-RA und Schilddrüsenkrebs: Gibt es einen Zusammenhang?","Karsten Müssig","2025","Info Diabetologie","other","article","10.1007/s15034-025-5201-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039317","Increasing Permeability of the Intestinal Epithelium to Enable Oral Delivery of Protein Drugs","Lamson, Nicholas","2019","KiltHub Repository","preclinical","article","10.1184/r1/8131967",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; dissertation"],["R0039318","Pérdida de la Visión por el Uso de Fármacos para la Obesidad y Diabetes","Dávila Lucas, Dayana Brigitte","2025","Dialnet (Universidad de la Rioja)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0039319","S2362 Increasing GLP-1 Prescription Rates in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity: A Quality Improvement Initiative","Cody Ashcroft","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001136908.47885.d7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039320","The Perfect Combination: Semaglutide and Whole-Food Plant-Based Diet in Chronic Disease Care","Dasaad Mulijono","2025","Cardiology and Cardiovascular Medicine","other","article","10.26502/fccm.92920463",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039321","Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain","Mezquita-Raya, Pedro","2018","Figshare","other","article","10.6084/m9.figshare.6182324",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039322","S754 Investigating the Prescription Patterns of GLP-1 Receptor Agonist Medications in Patients With Chronic Pancreatitis and Obesity","Karthic Drishna Perumal","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130476.20703.6b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039323","Role of the heterotrimeric inhibitory G‐protein, Gαz, and its unique G‐protein coupled receptor, EP3, in the progression and pathophysiology of Type 2 Diabetes","Austin Reuter","2019","The FASEB Journal","preclinical","article","10.1096/fasebj.2019.33.1_supplement.514.16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039324","S6351 Post-Fundoplication Dumping Syndrome Successfully Managed With Tirzepatide: A Case Report","Olanrewaju Adeniran","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001153864.63427.a5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039325","314 Integrating Dietitian-Led Counseling in Pharmacy Practice: Optimizing Health Outcomes in Patients Who Are Overweight or Using GLP-1 Receptor Agonist","A. Lewis","2026","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2026.103331",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039326","Adverse events after use of compounded semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-41258-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039327","S5603 Drug-Induced Liver Injury With Combination Semaglutide and Atorvastatin","Ashley Robinson","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001149872.32333.14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039328","Liraglutide for the Treatment of Hypothalamic Obesity","Sadia Ashraf","2018","AACE Clinical Case Reports","other_trial","article","10.4158/accr-2018-0009",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0039329","The therapeutic role of Liraglutide in the modulation of adipose tissue angiogenesis","Fonseca, Laura do Mar Oliveira de Almeida","2018","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039330","Neuroendocrine modulation in addiction: clinical perspectives on GLP-1R agonists","Justyna Daniek","2025","MEDICAL SCIENCE PULSE","randomized_trial","article","10.5604/01.3001.0055.3402",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0039331","2835-LB: Greater Combined A1C Reductions and Weight Loss with 25 mg and 50 mg vs. 14 mg Oral Semaglutide in Adults with T2D: Evidence from PIONEER PLUS","JENS ABERLE","2026","Diabetes","randomized_trial","article","10.2337/db26-2835-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039332","2860-LB: Clinical Inertia in the Treatment of Hypertension for Individuals with Diabetes","JOSEPH HERGES","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2860-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039333","Was ist besser: SGLT-2-Hemmer im Vergleich zu Sitagliptin bei älteren Patienten mit Herzinsuffizienz und T2DM","Johannes B. Dahm","2023","Aktuelle Kardiologie","other","article","10.1055/a-2112-4376",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039334","Dietary, Lifestyle and Pharmaceutical Interventions for the Treatment of Metabolic Diseases","O'Rielly, Rebecca Jane","2021","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0039335","A literature review of GLP-1 agonists for the urologist: What do we know so far?","Anayat Ullah","2026","Journal of Clinical Urology","randomized_trial","article","10.1177/20514158261454811",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039336","Adipose tissue: The early sensor and driver of systemic aging","Juanhong Liu","2026","Shengming kexue","other","article","10.3724/cbls.2026104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039337","Therapieverbesserungen durch GLP-1-RA und Wocheninsulin","Petra Eiden","2025","Info Diabetologie","other","article","10.1007/s15034-025-5177-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039338","Role of R-spondin-1 in the Regulation of β-cell Behaviour","Wong, Victor Shing Chi","2011","Library and Archives Canada (Government of Canada)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039339","WITHDRAWN: Exendin-4 reduces food intake in non-human primates through changes in meal size","Karen A. Scott","2006","Appetite","other","article","10.1016/j.appet.2006.03.290",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039340","Dreams for Type 1 Diabetes: Shutting Off Autoimmunity and Stimulating β-Cell Regeneration","Gordon C. Weir","2010","Endocrinology","preclinical","article","10.1210/en.2010-0538","20570953",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039341","Inhibition of Daily Torpor in Mice Requires Calories, Not Just Feeding: A Potential Role for GLP-1","Anika Kakarla","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2299142",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039342","Heterogeneity in Cardiovascular Risk Among Patients with Type 2 Diabetes: Insights from a Large Cardiology Database","Debbiche, Khalid","2025","Figshare","nonrandomized_study","article","10.6084/m9.figshare.29485859",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint; article"],["R0039343","Diabétiques de type 2 en échec d’une bithérapie : analyse transversale et comparative des études LEAD sur l’efficacité respective du liraglutide, de l’éxenatide et de l’insuline glargine","J.P. Courrèges","2010","La Revue de Médecine Interne","other","article","10.1016/j.revmed.2010.03.416",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039344","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-47990-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039345","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-40758-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039346","Clinical effect of under the diaphragm by stasis soup combinated with point thread-embedding on infertility patients with obesity-type polycystic ovary syndrome","Lian-Di Zhang","2019","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039347","Tirzepatide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-51276-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039348","Development of a novel semaglutide-loaded dry powder inhaler: application of freeze-drying and Pharmacokinetic evaluation in rats","Ji Yun Beak","2025","Journal of Pharmaceutical Investigation","preclinical","article","10.1007/s40005-025-00752-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039349","Effect of GLP-1 receptor agonists on free fatty acids and implication for preventing atherosclerosis","Kentaro Q. Sakamoto","2017","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2017.06.513",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039350","A Case Report on Therapeutic Optimization and Cardiometabolic Benefits of Semaglutide Therapy in Type 2 Diabetes Mellitus","Syed Afzal Uddin Biyabani","2026","Journal of Pharma Insights and Research.","case_report","article","10.69613/ss2yp015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039351","Human medicines European public assessment report (EPAR): Victoza, liraglutide, Diabetes Mellitus, Type 2, Date of authorisation: 30/06/2009, Revision: 19, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-1f52488",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039352","2299-PUB: Liraglutide-Based Therapy Attained A1C Target with Little Risk of Hypoglycemia: Optimization by Average Daily Risk Range Measurement","Koji Kashima","2019","Diabetes","other","article","10.2337/db19-2299-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039353","Regenerative and Hepatotropic Properties of GLP-1 and GLP-2: Mechanistic Insights and Implications for Post-Hepatectomy Liver Regeneration: A Narrative Review","Ahmad Mahamid","2026","Livers","nonrandomized_study","article","10.3390/livers6030036",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0039354","Insulin glargine/lixisenatide: a review in type 2 diabetes","Scott, Lesley","2018","Figshare","other_trial","article","10.6084/m9.figshare.6045419",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other; article"],["R0039355","A modulação crônica do receptor de GLP-1 altera aos níveis pressóricos, a estrutura e a função renal de ratos espontaneamente hipertensos","Gabriela Cozin Aragão","2016","Americanae (AECID Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039356","Beyond Metabolic Control: Interpreting the Role of GLP-1 Receptor Agonists in Inflammatory Bowel Disease","Muhammad Hassan Saeed","2026",null,"nonrandomized_study","article","10.22541/au.176851546.64679245/v1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0039357","Drug News",null,"2025","Nursing","other","article","10.1097/nsg.0000000000000168","40122863",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039358","0235 Glucagon-like peptide-1 receptor agonist use in primary cicatricial alopecia: A retrospective cohort study","R. Granovsky","2026","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2026.06.266",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0039359","2069-P: Risk of Suicidal Ideation and Behaviors, Depression, and Anxiety with GLP-1 Receptor Agonist Use in Children and Adolescents: A Target Trial Emulation Study","Pareeta Kotecha","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2069-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039360","2828-LB: BACH01, a Nanoengineered Platform Enabling Oral Semaglutide with Preclinical Evaluation","JIN JUNG","2026","Diabetes","other","article","10.2337/db26-2828-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039361","Stabilisation of β-catenin in hypothalamic neurons through feeding related stimulation and the role this may have on synaptic function in the control of metabolic homeostasis.","H. J. L. McEwen","2015","Otago University Research Archive (University of Otago)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0039362","THE ROLE OF LIRAGLUTIDE TREATMENT ON WEIGHT LOSS FOR PATIENTS WITH SUBOPTIMAL INITIAL RESPONSE OR WEIGHT REGAIN AFTER BARIATRIC SURGERY","Issam Merdan","2025","Basrah Journal of Surgery","nonrandomized_study","article","10.33762/basjsurg.2025.163362.1137",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039363","Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4","Errafii, Khaoula","2022","Qatar National Library","preclinical","article","10.57945/manara.21598452",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039364","Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study","Of, Adis Journals On Behalf","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.13651214",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0039365","The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes","Catherine A. Schnabel","2005","The British Journal of Diabetes","other","article","10.1177/14746514050050040801",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039366","SEMAGLUTIDE EXERTS SIGNIFICANT CARDIOPROTECTIVE PROPERTIES AGAINST ANTHRACYCLINE AND TRASTUZUMAB INDUCED CARDIOTOXICITY: BIOCHEMICAL EVIDENCES","Nicola Maurea","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)03088-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039367","559 Efficacy of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis","Diego Pichardo-Rojas","2026","Neurosurgery","systematic_review","article","10.1227/neu.0000000000003964_559",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0039368","NN2211, a derivative of GLP-1, monitored by an immunoassay in a 4 weeks treatment study","Michael Wilken","2000","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(00)81318-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039369","Glucagon-like peptide-1 agonists for weight loss in people with obesity","Sara Kirk","2017","Obesity Medicine","other","article","10.1016/j.obmed.2017.01.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039370","The Rising Burden of Obesity and the Emerging Role of Injectable Weight-Loss Therapies: A Systematic Literature Review","Jeyatheepan Jeyatheepan Jeyaretnam","2026","Journal of Diseases Disorders & Treatments","randomized_trial","article","10.47363/jddt/2026(6)142",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0039371","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-51243-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039372","1689-P: Impact and Effectiveness of Once-Weekly Semaglutide in Achieving Glycemic Targets among Public Health Care Patients with Type 2 Diabetes in Chile: A Multicenter Prospective Study","Karina Elgueta","2026","Diabetes","other_trial","article","10.2337/db26-1689-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039373","Unpublished and published liraglutide studies in humans","Ramirez, Jorge H","2014","Figshare","other","article","10.6084/m9.figshare.1134664.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039374","2442-P: Distinct Physiologic Platforms for Assessing Insulin Sensitivity in Nonhuman Primates: Hyperinsulinemic-Euglycemic Clamp and Insulin Tolerance Testing for Translational Diabetes Research","Flordeliza P. de Villa","2026","Diabetes","other","article","10.2337/db26-2442-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039375","Liraglutide - glucagon like peptide-1 analogue in the treatment of type 2 diabetes","Uruska, Aleksandra; Katedra i Klinika Chorób Wewnętrznych i Diabetologii Uniwersytetu Medycznego w Poznaniu","2010","Via Medica Journals","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039376","116-OR: GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice","RAJAMANNAR THENNATI","2024","Diabetes","other_trial","article","10.2337/db24-116-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039377","1618-P: Treatment of Prefibrotic Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)","Emily Wood","2025","Diabetes","other","article","10.2337/db25-1618-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039378","175-OR: Disparities in New Glucose-Lowering Drug Spending in U.S. Adults with Type 2 Diabetes (T2D), 2018–2022","Ping Zhang","2025","Diabetes","other","article","10.2337/db25-175-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039379","1711-P: The Anti-myostatin Antibody SRK-439 Improves Grip Strength during GLP-1RA Treatment in a Mouse Model of Obesity","Christopher Chapron","2025","Diabetes","preclinical","article","10.2337/db25-1711-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039380","TGA warns of counterfeit semaglutide in Australia",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-40178-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039381","768-P: Effect of Dulaglutide Therapy Initiation on the Course of Coronavirus Infection and the Dynamics of Inflammatory Markers in Hospitalized Patients with Type 2 Diabetes","Т. Н. Маркова","2023","Diabetes","other","article","10.2337/db23-768-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039382","1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist","YUNA CHAE","2023","Diabetes","other_trial","article","10.2337/db23-1668-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039383","IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting","Hunt, Barnaby","2018","Figshare","other","article","10.6084/m9.figshare.6171404",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039384","Diabetes mellitus and the kidney","Luigi Gnudi","2020",null,"other","article","10.1093/med/9780198746690.003.0491_update_001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0039385","1973-LB: Glucagon-Like Peptide 1 Receptor Agonist with Basal Insulin vs. Basal-Bolus Regimen on Glycemic Variability and Time-in-Range in Type 2 Diabetes Patients with Chronic Kidney Disease—A Randomised Controlled Trial","J Ling","2025","Diabetes","randomized_trial","article","10.2337/db25-1973-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039386","DESENSITIZATION TO TIRZEPATIDE AFTER RECURRENT MACULOPAPULAR ERUPTIONS TO GLP-1 AGONISTS","V. Saldana-Fraire","2025","Annals of Allergy Asthma & Immunology","other","article","10.1016/j.anai.2025.08.404",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039387","24-PUB: The Efficacy and Safety of iGlarLixi in Insulin-Naïve Adults with Type 2 Diabetes (T2D) by Baseline Age, Sodium–Glucose Cotransporter 2 Inhibitor (SGLT2i) Use, and BMI—Post Hoc Analysis of Soli-CGM","Viral N. Shah","2025","Diabetes","other_trial","article","10.2337/db25-24-pub",null,null,"ClinicalTrials.gov:NCT05114590","S002030","openalex","FALSE","paywalled","5","FALSE","article"],["R0039388","2158 Comparative Outcomes of GLP-1 Receptor Agonists versus Glyburide in ICH Patients With Type 2 Diabetes: A Real-World Analysis Using the TriNetX Live Database","Fnu Ruchika","2026","Neurosurgery","nonrandomized_study","article","10.1227/neu.0000000000003964_2158",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039389","Ban-Lan-Gen Granule Alleviates Dextran Sulfate Sodium-Induced Chronic Relapsing Colitis in Mice via Regulating Gut Microbiota and Restoring Gut SCFA Derived-GLP-1 Production","Peng Jiao","2022","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039390","Hydrogel Microparticle Encapsulation Enhances In Vivo Peptide Delivery of Recombinant Probiotics","Shuang Gao","2025","Advanced Functional Materials","other","article","10.1002/adfm.202412859",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039391","A39-23 Association Between GLP 1 Receptor Agonists Use and Interstitial Lung Disease Incidence in Rheumatoid Arthritis With Type 2 Diabetes: A Real-world Cohort Analysis","R Leguizamon","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.2246",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039392","RECENT ADVANCEMENT IN DIABETES & OBESITY TREATMENT - GLP-1 RAs LIKE SEMAGLUTIDE","Dr Pathak Niranjan P","2026",null,"other","article","10.58532/nbennuamsib7p2c1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0039393","TCT-751 Outcomes of GLP-1 Receptor Agonist Use in Transcatheter Mitral Valve Repair or Replacement: A Real-World Analysis","Aman Goyal","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2025.09.917",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039394","Tirzepatide and nocturnal hypoxia (T90): SURMOUNT-OSA post hoc analyses","I Fietze","2026","Diabetologie und Stoffwechsel","other","article","10.1055/s-0046-1819896",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0039395","S2920 New Drugs and New Toxicities: Liraglutide-Induced Liver Injury","Faisal Inayat","2022","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000868320.94587.6b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039396","Two trials bring new advances for patients with metastatic colorectal cancer","Leah Lawrence","2026","Cancer","other","article","10.1002/cncr.70368","42083467",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039397","P1589Metabolomic impact of glucagon-like peptide-1 on diabetic myocardium - glucagon-like peptide-1 accelerates myocardial glycolysis and utilizes more lactate as myocardial substrate","Hiroya Kawase","2017","European Heart Journal","preclinical","article","10.1093/eurheartj/ehx502.p1589",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039398","Prediction, diagnosis and treatment of hypertension","Alberto Zanchetti","2016","Journal of Hypertension","randomized_trial","article","10.1097/hjh.0000000000000939","27088637",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039399","Differential effects of glucose-lowering agents on atherosclerotic plaque progression in diabetic patients: a retrospective cohort study using serial coronary CT angiography","J U N Y A N Zhang","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.1724",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039400","Sistem Endokrin dan Diabetes Millitus","Setiawan, Meddy","2021","UMM Institutional Repository (University of Maine at Machias)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0039401","Assessment of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity in Women with Polycystic Ovary Syndrome","McCurry, Kathryn D.","2023","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039402","Safety of GLP-1 and GIP/GLP-1 Receptor Agonists in Patients With Prior Alcohol-induced Pancreatitis: A Multicenter Real-World Cohort Study",null,"2026","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2026.01.216",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039403","EFFECTIVENESS OF SEMAGLUTIDE IN OBESITY TREATMENT AND THE ROLE OF LIFESTYLE INTERVENTIONS","Filip Bracichowicz","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3931",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039404","Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways","GuÓl O. DoÓan","2025","Cirugía y Cirujanos (English Edition)","preclinical","article","10.24875/cirue.m23000810",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039405","The effect of Ramadan focused education on patients with type 2 diabetes: About a tertiary center experience","S Chtioui","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.8108257",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039406","MOESM6 of Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway","Feng, Yun","2020","Figshare","other","article","10.6084/m9.figshare.11508120.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039407","Abstract #230: A Shot in the Dark: False Positive Positron Emission Tomography Results with Once Weekly Exenatide and 18-Fluoro-2- Deoxyglucose","Jordan Tichenor","2017","Endocrine Practice","other","article","10.1016/s1530-891x(20)44350-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039408","1862-LB: Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Suicide and Self-Harm among Patients with Type 2 Diabetes","Samantha B. Shapiro","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1862-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039409","Acute renale effecten van GLP-1-receptoragonist exenatide in gezonde mannen met overgewicht","Bohn Stafleu van Loghum","2015","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-015-0018-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039410","Correction",null,"2025","Current Medical Research and Opinion","other","article","10.1080/03007995.2026.2624991","41614667",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0039411","Gastric Ulcer in the Setting of Doxycycline and Low-Dose Semaglutide during Prophylaxis with Famotidine","Gebara, Marc","2025",null,"other","article","10.13140/rg.2.2.16882.00966",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039412","Cardiovascular outcomes with GLP-1 receptor agonists in patients with established coronary plaque: a propensity-matched real-world analysis","Osman Yousafzai","2026","Next research.","nonrandomized_study","article","10.1016/j.nexres.2026.102033",null,null,null,null,"openalex","FALSE","free_to_read","4","FALSE","article"],["R0039413","LBP-036 Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial","Naim Alkhouri","2026","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(26)00451-4",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0039414","Comparative Efficacy of Dual and Triple GLP-1, GIP, and Glucagon Receptor Agonists: A Systematic Review and Network Meta-analysis","Qiannan Jia","2025","International Journal of Biology and Life Sciences","systematic_review","article","10.54097/9576k069",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0039415","β-Cell Regeneration in a Patient with Type 1 Diabetes Mellitus Who Was Receiving Immunosuppressive Therapy","Akio Kuroda","2003","Annals of Internal Medicine","other","article","10.7326/0003-4819-139-10-200311180-00030-w1","14623642",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039416","Trends in use of glucagon-like peptide –1 receptor agonists (GLP-1 RAs) in obese patients with and without endometrial cancer","Heidi Chang","2026","Gynecologic Oncology","other","article","10.1016/j.ygyno.2026.01.364",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039417","S5850 Detox or Danger: The Unseen Risks of Herbal Supplements on Liver Health","Shyamal Sheth","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001150860.03057.85",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039418","S5866 Statins, Sartans, Semaglutide, or Stauffer’s? Dissecting Idiosyncratic Drug-Induced Hepatitis in a Complex Patient","Mohamed Belal","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001150924.23664.2c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039419","MASLD/MASH Pharmacologic Therapeutic Efficacy in a Predominately African American Medical Center Population","Smadi, Reema","2025","Human Biology","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0039420","Advances in the Co-management of Metabolism Dysfunction-associated Fatty Liver Disease and Type 2 Diabetes Mellitus","WANG Peng, QIU Lixia, XU Shanshan, ZHANG Yang, ZHANG Jing, DU Xiaofei","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12114/j.issn.1007-9572.2024.0591",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039421","IP18-26 IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON THE RISK AND MANAGEMENT OF KIDNEY AND URETERAL STONES","Loui Othman","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191368.71794.72.26",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039422","Renin–Angiotensin Blocking Therapies: A Must—But How?—After Percutaneous Coronary Intervention","Simone Calcagno","2020","Journal of Cardiovascular Pharmacology","nonrandomized_study","article","10.1097/fjc.0000000000000941","33136768",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039423","Lixisenatide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-39473-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039424","Prevention and Treatment of Sarcopenia in Diabetes","Yunjung Cho","2025","Journal of Korean Diabetes","other","article","10.4093/jkd.2025.26.2.90",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039425","S797 Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists Used for Weight Loss: A Real-World Cohort Study","Saqr Alsakarneh","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130648.55090.4f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039426","Prevention of Posttransplant Diabetes: A Complex Problem Without a Simple Solution","Justin Oveyssi","2022","Transplantation","randomized_trial","article","10.1097/tp.0000000000004374","36525549",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039427","Novo Nordisk taps start-up for new oral weight-loss drugs","Rowan Walrath","2026","C&EN Global Enterprise","other","article","10.1021/cen-10404-buscon4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039428","The comparison of outcomes between metabolic bariatric surgery and glucagon-like peptide 1 receptor agonists (GLP-1 RA) after three years","Wang, Xiaoxia (M.S. in pharmaceutical sciences)","2025","Texas Digital Library (University of Texas)","nonrandomized_study","article","10.26153/tsw/61703",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0039429","GLP-1 RECEPTORIŲ AGONISTŲ POVEIKIS ŠIRDIES NEPAKANKAMUMUI","Gintarė Pudinskaitė","2025","Health Sciences","other","article","10.35988/sm-hs.2025.334",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039430","O USO INDISCRIMINADO DE SEMAGLUTIDA PARA FINS ESTÉTICOS: SUAS CAUSAS E CONSEQUÊNCIAS EM UMA REVISÃO BIBLIOGRÁFICA","Emanuela Amancio Sousa Silva","2026","Pensar Acadêmico","other","article","10.21576/pensaracadmico.2026v24i1.4526",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039431","Can amylin weight-loss drugs compete in a world of GLP-1s?","Aayushi Pratap","2026","C&EN Global Enterprise","other_trial","article","10.1021/cen-10405-feature3",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0039432","GLP-1 RECEPTOR AGONISTS AND ATRIAL FIBRILLATION/ATRIAL FLUTTER IN PATIENTS WITH DIABETES: A RETROSPECTIVE ANALYSIS","Thomas O’Neill","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(25)00565-0",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039433","Effect of Liraglutide Combined with Nephritis Rehabilitation Tablets for Type 2 Diabetic Nephropathy","Xiaohui Cao","2020","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039434","764-P: Time in Range and Time in Tight Range in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 CGM Substudy","Richard M. Bergenstal","2023","Diabetes","other_trial","article","10.2337/db23-764-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039435","Semaglutide cost effective versus dulaglutide for type 2 diabetes",null,"2019","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-019-5794-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039436","Effect of liraglutide combined with basal insulin on blood glucose control, lipid metabolism and oxidative stress in patients with newly diagnosed type 2 diabetes mellitus complicated by obesity","Fei-Fei He","2018","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039437","Safety and efficacy of liraglutide 1.2mg in patients with mild and moderate renal impairment: the ABCD nationwide liraglutide audit","K. Y. Thong","2013","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1748",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039438","Real-world outcomes comparing the use of GLP-1 receptor agonists in patients with endometrial cancer and comorbid obesity: A propensity score matched analysis from a global federated health research network.","Yajur Arya","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.5543",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0039439","0779 Sleep Quality Based on Baseline Characterization in SURMOUNT-OSA: Post-Hoc Analyses","Chisom Kanu","2025","SLEEP","other_trial","article","10.1093/sleep/zsaf090.0779",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0039440","Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks","Haber, Harry","2012","Hispana","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0039441","Incretin-based therapies and the kidney: From physiology, to pharmacology and outcomes in type 2 diabetes","Muskiet, Marcel Hendrik Alwin","2022","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039442","Análise da resposta hormonal pancreática antes e após tratamento com GLP-1 mimético em indivíduos com diabetes tipo 2 portadores da variante rs7903146 do gene TCF7L2","Mari Cassol Ferreira","2013","Americanae (AECID Library)","other","article","10.11606/t.5.2013.tde-01112013-113904",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039443","Tu1814 GLP-1R Agonist Increased Glucose Uptake and Inhibited GSK3ß Phosphorylation Through the AMPK Signaling Pathways in Human Hepatocytes","Minoru Itou","2012","Gastroenterology","other","article","10.1016/s0016-5085(12)63960-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039444","Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study [Corrigendum]","Ankarfeldt MZ","2018","DOAJ (DOAJ: Directory of Open Access Journals)","nonrandomized_study","article","10.2147/clep.s191335","30568511",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","erratum"],["R0039445","Comparison of noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus on glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors as add-on treatment: a retrospective head-to-head comparative study","Μακρή, Ευαγγελία Στέργιου","2020","Aristotle University of Thessaloniki","nonrandomized_study","article","10.26262/heal.auth.ir.316286",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0039446","#1608 Glucagon-like peptide-1 receptor agonists and the risk of emergency department visits and hospitalization in patients across the spectrum of kidney disease","Kevin Yau","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.0918",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039447","Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes","Valentine, Virginia","2018","Figshare","other","article","10.6084/m9.figshare.6022454",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039448","Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use","Deeks, Emma","2020","Figshare","other_trial","article","10.6084/m9.figshare.9696338",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other; article"],["R0039449","788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi","ALICE Y. CHENG","2023","Diabetes","randomized_trial","article","10.2337/db23-788-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039450","Research Highlights and Trends in the Use of GLP-1 Receptor Agonists for the Treatment of Parkinson’s Disease: A Bibliometric Analysis","Ting YU","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/u7wdy",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039451","المستقبل جامعة حاله دراسة 1 : - والطبية الصحية التقنيات كلية الكلية : االشعة تقنيات القسم 2 : - وفوائدها الوزن انقاص في التنحيف ابر دور الكامل الدراسة اسم الجانبية واعراضها 3 : - الدراسة عن مختصرة نبذه BENEFETS AND SIDE EFFECTS OF MOUNJARO AND SAXENDA IN OBESITY 4 : - اساتذه الدراسة في المشاركين وطلبة 1 . - حسين علي زينب د 2 . - نبات الرحيم عبد لميس د 3 . - كاظم شاكر ارشد د","Hussein, Zainab Ali","2025",null,"other","article","10.13140/rg.2.2.35715.62241",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039452","Tirzepatide and the prevention of heart failure in patients with obesity and atrial fibrillation: a multicenter real-world cohort study","H Wei","2026","European Journal of Heart Failure","nonrandomized_study","article","10.1093/ejhf/xuag193.730",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039453","Actualización del manejo de los ar-GLP-1 en pacientes con sobrepeso y obesidad","Nuñez Silva, David Sebastian","2025","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039454","PDB38 - BUDGET IMPACT ANALYSIS OF BENAGLUTIDE INJECTION IN THE TREATMENT OF TYPE 2 DIABETES IN CHINA","Houliang Deng","2018","Value in Health","other","article","10.1016/j.jval.2018.09.744",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039455","Lilly (Eli) & Co.",null,"2007","Mergent s Dividend Achievers","other","article","10.1002/div.5644",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039456","RENAL PROTECTIVE COMPARISON BETWEEN SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS VERSUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW","Iqbal Saeed Shaikh","2024","Journal of Population Therapeutics and Clinical Pharmacology","systematic_review","article","10.53555/jptcp.v31i6.6423",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0039457","Meta-Analysis of the Efficacy of GLP-1RA in the Treatment of Metabolic-Associated Fatty Liver Disease","玲 徐","2025","Advances in Clinical Medicine","systematic_review","article","10.12677/acm.2025.1582255",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0039458","GLP-1 RA vs DPP4i in patients with prior major adverse limb evets","C J Chen","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3019",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039459","IDDF2025-ABS-0014 Effectiveness of semaglutide in non-alcoholic steatohepatitis resolution a meta-analysis and systematic review","Claudine Feliciano","2025",null,"systematic_review","article","10.1136/gutjnl-2025-iddf.135",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-paper"],["R0039460","EPH8 PREDICTORS OF GLP-1 RECEPTOR AGONIST USE AMONG U.S. ADULTS WITH COMORBID DEPRESSION AND TYPE 2 DIABETES MELLITUS","Michael C. Okonkwo","2026","Value in Health","other","article","10.1016/j.jval.2026.03.841",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039461","O USO DO MOUNJARO NO MANEJO DA OBESIDADE E DIABETES TIPO 2: EVIDÊNCIAS ATUAIS E PERSPECTIVAS TERAPÊUTICAS FUTURAS","Julia Kalene Saraiva Torres","2025","Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida","other","article","10.36692//v17n3-1r",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039462","2072-LB: Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease","XIAO YAN XIN","2024","Diabetes","randomized_trial","article","10.2337/db24-2072-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039463","744-P: Effects of a Novel Long-Acting GIP/GLP-1/Glucagon Trireceptor Agonist, HISHS-3001, on HbA1c, Body Weight, and Lipid Metabolism","VINOD S. BURADE","2022","Diabetes","preclinical","article","10.2337/db22-744-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039464","Role of Medicinal plants and nanotechnology used in management of Diabetes mellitus","Divyansh Dhand","2026","JOURNAL OF ADVANCE AND FUTURE RESEARCH","other","article","10.56975/jaafr.v4i4.507371",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039465","Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad","Juan José Gorgojo Martínez","2014","Hipertensión y Riesgo Vascular","other","article","10.1016/j.hipert.2014.02.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039466","172-LB: Phone-Based Management by a PharmD May Improve Glycemic Control More Than Endocrinology Care Alone","Daniel J. Rubin","2019","Diabetes","nonrandomized_study","article","10.2337/db19-172-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039467","Safety and efficacy of liraglutide in patients with obesity","Ayesha Durrani","2025","International Journal of Pathology","other","article","10.59736/ijp.23.03.965",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039468","Focus on Incretin-Based Therapies for Elderly Patients with Type 2 Diabetes","Richard E. Pratley","2011","Endocrine Practice","other","article","10.1016/s1530-891x(20)43148-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039469","Abstract #223: Real Life Experience with the Combination of Exenatide Lar and Dapagliflozin in Obese Type 2 Diabetic Patients in Mexico City.","Ernesto Garcı́a-Rubi","2016","Endocrine Practice","other","article","10.1016/s1530-891x(20)44931-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039470","Longitudinal intra-patient changes in CT body composition measures associated with semaglutide use","Pickhardt, Perry","2024","European Society of Gastrointestinal and Abdominal Radiology","other","article","10.5444/https://doi.org/10.5444/esgar2024/se-094",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039471","Neuer GLP-1-Agonist bei Adipositas",null,"2023","DMW - Deutsche Medizinische Wochenschrift","other","article","10.1055/a-1986-1677",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039472","1032-P: A System-Based Approach to Advancing Care Delivery in High-Risk Patients with T2D—Findings from a Quality Improvement Educational Intervention (QIEi)","Pratibha PR Rao","2023","Diabetes","other","article","10.2337/db23-1032-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039473","Reply: Possible impact of membrane ACE2 expression on COVID-19 infection","Murray Esler","2020","Journal of Hypertension","nonrandomized_study","article","10.1097/hjh.0000000000002484","32371814",null,"ClinicalTrials.gov:NCT04312009",null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039474","The communication of risks associated with GLP-1 receptor agonists: An AI-powered content analysis of TikTok videos","Almenara, Carlos A","2025","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/sca2w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039475","GLP-1 agonists for type 2 diabetes mellitus and heart failure","T Preijers","2024","Geneesmiddelenbulletin","other","article","10.35351/gebu.2024.10.14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039476","Consideration for the use of GLP-1 Receptor Agonist in adult HIV-1 patients to treat weight gain and associated metabolic conditions.","Pukish, Nicholas A, Jr","2023","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039477","PJ view: Patients deserve a regulatory system built to keep them safe as oral semaglutide launches",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.419646",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039478","TIRZEPATIDE: Trending ‘Weight loss’ Drug– Potential Influence in Tackling Obesity Epidemic","Ravjit Kaur","2024","International Journal of Pharmaceutical Sciences and Medicine","other_trial","article","10.47760/ijpsm.2024.v09i06.003",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0039479","Dietary intake based leg muscle building and fat loss: reducing the cardiovascular-cause mortality","Ningjing Qian","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3769",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039480","Novo taps Metaphore for weight-loss","Rowan Walrath","2024","C&EN Global Enterprise","other","article","10.1021/cen-10215-buscon17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039481","Liraglutide: A Review of its Use in the Treatment of Diabetes Mellitus",null,"2010","Clinical Medicine Reviews in Vascular Health","randomized_trial","article","10.4137/cmrvh.s1652",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039482","Selective PKCß Inhibition Enhances Energy Expenditure and Mitigates Obesity in High-Fat Diet-Fed Mice: Friend or Foe to GLP-1-Based Therapies? (Abstract ID: 222083)","Kamal D. Mehta","2026","Journal of Pharmacology and Experimental Therapeutics","preclinical","article","10.1016/j.jpet.2026.104139",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039483","Abstract 4373642: Efficacy of GLP-1 Receptor Agonists in Patients with Established Cardiovascular Disease: A Meta-Analysis of Nine Randomized controlled trials","Vikash Jaiswal","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4373642",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0039484","Relative Risk of Nephrolithiasis in Type 2 Diabetes Patients Using Sodium-Glucose Cotransporter 2 Inhibitors Compared to Those Using DPP-4 Inhibitors or GLP-1 Receptor Agonists: A Protocol of Systematic Review and Meta-analysis","Jia-Ai Yeh","2024",null,"systematic_review","article","10.37766/inplasy2024.10.0087",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0039485","Role of an Anti-Inflammatory Agent in the Management of Type 2 Diabetes Mellitus","Shivangi Singh","2022","BENTHAM SCIENCE PUBLISHERS eBooks","other","article","10.2174/9789815040227122010010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0039486","Bridging gaps in chronic kidney disease management: insights from clinicians on real-world practices","Vishwa Mehta","2025","International Journal of Clinical Trials","nonrandomized_study","article","10.18203/2349-3259.ijct20253332",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039487","RETRACTED ARTICLE: GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response","Zhao, Qini","2021","Figshare","other","article","10.6084/m9.figshare.8245901.v4",null,null,null,null,"openalex","TRUE",null,null,"TRUE","article"],["R0039488","Management of Suboptimally Controlled Type 2 Diabetes Mellitus in General Practice","Murphy, Mark","2021","Royal College of Surgeons in Ireland","randomized_trial","article","10.25419/rcsi.15035628",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0039489","751-P: The Risk of Acute Pancreatitis and Biliary Events after Initiation of GLP-1RA, SGLT2i, or DPP-4i in Patients with T2D","YICHEN E. FANG","2025","Diabetes","nonrandomized_study","article","10.2337/db25-751-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039490","Case Report of Common Fibular Neuropathy After Hand Surgery in A Patient With GLP‑1–Associated Weight Loss","JAMES CHEN","2026","Frontiers in Medical Case Reports","case_report","article","10.47746/fmcr.2026.7203",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039491","S1594 Association Between SGLT2 Inhibitor Use and Inflammatory Bowel Disease in Non-Diabetic Patients","Xiaoliang Wang","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001133836.48463.29",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039492","Switch-to-Semaglutide Study (STS-Study) – a Retrospective Cohort Study","Of, Adis Journals On Behalf","2021","Figshare","nonrandomized_study","article","10.6084/m9.figshare.13655921",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0039493","B45-05 Association Between Glp-1 Receptor Agonist Use and Mortality Among Patients With Bronchiectasis","H Alaws","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.1233",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039494","“Cabeça de Ozempic”: entre a medicalização e a natureza nas práticas material-discursivas sobre celebridades no X","Venzon Filho, Pedro Paulo","2025","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039495","Dulaglutide/empagliflozin",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-39343-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039496","Roseoside from Lemon Fruits (Citrus limon) as a Potential Inhibitor of Cluster of Differentiation 36 for Obesity Treatment","Charistika Lonika","2025","Engineering headway","nonrandomized_study","article","10.4028/p-vo3mlu",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-paper"],["R0039497","Prescribing Patterns and Adverse Drug Reactions associated with Semaglutide:A real-world evaluation from a socioeconomically deprived UK region","Whorton, Abigail","2025","University of Birmingham Research Portal (University of Birmingham)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0039498","Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation","of:, Adis journals on behalf","2021","Figshare","other","article","10.6084/m9.figshare.14561904",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039499","INCRETIN-BASED THERAPIES IN OBESITY TREATMENT: IMPLICATIONS FOR NUTRITIONAL CARE AND A PROPOSED MEDICAL NUTRITION THERAPY PROTOCOL","Magda Cruz","2026","Medical Research Archives","protocol","article","10.18103/mra.v14i5.7498",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0039500","Additional file 2 of Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a Department of Veterans Affairs quality improvement intervention","Yun, Shira","2025","Figshare","other","article","10.6084/m9.figshare.28642951",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039501","Liraglutide in obesity: a guide to its use in the EU","Lesley J. Scott","2015","Drugs & Therapy Perspectives","other","article","10.1007/s40267-015-0241-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039502","Efficacy of Glucose-Lowering Drugs for Young-Onset Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized Control Trials","Calvin Ke","2025","Vivli","systematic_review","article","10.25934/pr00010843",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0039503","Why do mosquitoes seek human blood?","Alex Viveros","2024","C&EN Global Enterprise","other","article","10.1021/cen-10222-scicon5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039504","Clinical Efficacy and Safety of GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis","Anonymous,","2012","Queen Margaret University eTheses Repository","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0039505","Hypertonia kezelése krónikus vesebetegekben : az újabb irányelvek alapján, 2024-ben","Tibor Kovács","2024","Hypertonia és Nephrologia","other","article","10.33668/hn.28.034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039506","Effects of glucagon-like peptide-1 analogue liraglutide on autophagy of human umbilical vein endothelial cells in high glucose conditions","Xiaoxia Liu","2019","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039507","Abstract #373 Single-Center Experience of a GLP -1 Receptor Agonist, Liraglutide for the Management of Diabetes in Solid Organ Transplant (SOT) Recipients","Maryam Taufeeq","2019","Endocrine Practice","other","article","10.1016/s1530-891x(20)46717-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039508","Oral Semaglutide","Jothydev Kesavadev","2022","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_22_23",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039509","Semaglutide’s Neuropharmacological Effects: From Glycemic Regulation and Weight Loss to Potential Implications in Substance Use Disorders – A Narrative Review","Jes Sebastian Denis Völker","2024","Current Psychopharmacologye","nonrandomized_study","article","10.2174/0122115560282952231218061257",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","review"],["R0039510","SAT-035 Impact of fibrotic MASH as a new indication on semaglutide eligibility in the U.S. adult population","Laurens A. van Kleef","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)02148-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039511","THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE IS SAFE AND MAY BE CARDIOPROTECTIVE IN ACUTE MYOCARDIAL INFARCTION: THE EXAMI PHASE L TRIAL","Flip J.P. Bernink","2012","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(12)60263-0",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0039512","S6294 Navigating Narrow Passages: Prepyloric Stricture and Sarcina","Charles Woodall","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001153636.55602.06",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039513","Worsening Mental Health in a 34-Year-Old Patient With Type 2 Diabetes After Initiation of Semaglutide (Ozempic)",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039514","72-LB: DD01, a Novel Once-Weekly Dual GLP-1/Glucagon Receptor Agonist, Improves Metabolic Health and Achieves Rapid, Clinically Significant Reductions in Hepatic Steatosis following Only Four Weeks of Treatment and without the Need for Significant Weight Loss in Overweight/Diabetic Subjects with NAFLD","Dennis To","2023","Diabetes","other_trial","article","10.2337/db23-72-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039515","S1885 Impact of GLP-1 Receptor Agonist or GIP/GLP-1 Receptor Agonist on Clinical Outcomes in Obese Patients With Inflammatory Bowel Disease: A Propensity-Matched Analysis","Mohamed Nadeem","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001135000.32511.d8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039516","Sleeve Gastrectomy vs. GLP-1 Agonists (Semaglutide): A Cost-Effectiveness Perspective on Long-Term Obesity Management","Naushad Khan","2026","Human Biology","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0039517","Novo Nordisk to buy drug delivery firm","Michael McCoy","2020","C&EN Global Enterprise","other","article","10.1021/cen-09844-buscon15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039518","Maybe it’s lifestyle, maybe it’s Ozempic: An analysis of online discussions of the medicalization of weight loss (Preprint)","Eloise Germic","2024",null,"other","article","10.2196/preprints.57475",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039519","Potential role of CPAP treatment on right ventricular function in patients with heart failure and OSA","G Severini","2026","European Journal of Heart Failure","nonrandomized_study","article","10.1093/ejhf/xuag193.767",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039520","Analoghi del glucagon-like peptide-1: effetti su glicemia e peso corporeo","Mariafrancesca Ruffo","2010","Giornale italiano di cardiologia","other","article","10.1714/565.6705",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039521","Вплив ліраглутиду та дапагліфлозину на серцево-судинний ризик у пацієнтів зі стеатотичною хворобою печінки, асоційованою з метаболічною дисфункцією","Чернявський, Володимир","2025","Scientific periodicals of Ukraine","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0039522","“The next big thing” in diabetes: clinical progress on DPP‐IV inhibitors","Thomas W von Geldern","2006","Drug Development Research","preclinical","article","10.1002/ddr.20138",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039523","Efficacy of Modern Diabetes Treatments- Dpp-4i, Sglt-2i, Glp-1ra- in White and Asian Patients With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Sushrima Gan","2020",null,"systematic_review","article","10.2337/figshare.12003276",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0039524","Eosinophilic Esophagitis induced by semaglutide use: A case report","Pérez-Macías JP","2026","Journal of Surgery and Research","randomized_trial","article","10.26502/jsr.10020482",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0039525","A Comprehensive Systematic Review of the Role of Semaglutide Anti-Obesity Therapy in Multiple Metabolic Diseases: A Systematic Review of Randomized Controlled Trials and Primary Studies","Jeffy Marta","2026","The International Journal of Medical Science and Health Research","systematic_review","article","10.70070/wcwp4h85",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0039526","LBP-039 Survodutide reduces steatosis and fibrosis in a MASH human liver spheroid model through direct glucagon receptor agonism","Philip Vonschallen","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)00454-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039527","FRI-156 DR10624, a novel FGF21R/GCGR/GLP-1R triple agonist, significantly reduced liver fat and improved hepatic and metabolic biomarkers in a phase 2 study of patients with severe hypertriglyceridemia","Yongliang Fang","2026","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(26)01900-8",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0039528","Improvement of beta cell function in intraportal transplantation of islet cell cluster using secretion signal peptide-linked exendin-4 gene","Simmyung Yook","2014","Macromolecular Research","other","article","10.1007/s13233-014-2120-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039529","Research",null,"2025","Bone and Joint 360","randomized_trial","article","10.1302/2048-0105.145.360271",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039530","Antidiabetic drug use in chronic kidney disease","Naveen Kumar","2015","Indian Journal of Health Sciences and Care","other","article","10.5958/2394-2800.2015.00023.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039531","Beneficial effects of exendin-4 treatment on syngeneic mouse islet transplantation","Jyuhn‐Huarng Juang","2007","Xenotransplantation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039532","More Reasons to Say Goodbye to Glyburide","Matthew C. Riddle","2010","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/jc.2010-1972","21051583",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039533","OC4 Semaglutide in people with HIV: a metabolic health intervention toward the fourth 90%","M Menozzi","2026",null,"other","article","10.1136/sextrans-icar-2026.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0039534","Association of GLP-1RA Use with Improvement in Medical and LTSS/HCBS Utilization in the High-Complexity, LTSS/HCBS Utilizing Medicare-Medicaid Dual-Eligible Population (Preprint)","Valmeek Kudesia","2026",null,"other","article","10.2196/preprints.105283",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039535","Glucagon Like Peptide-1 (GLP-1) Receptor Agonists for Parkinson's Disease: An Updated Systematic Review and Meta-Analysis","F Alnajjar","2025",null,"systematic_review","article","10.13140/rg.2.2.10233.94563",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0039536","L’analogo del GLP-1 liraglutide: efficacia clinica e sicurezza \\n","Consoli, A.","2009","CNR Solar (Scientific Open-access Literature Archive and Repository) (Consiglio Nazionale delle Ricerche)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039537","S1289 Peri-Operative Use of Glucagon-Like Peptide 1 (GLP-1) Agonists Is Associated with Retained Gastric Contents During Upper Endoscopy and Procedure Abortion, But Not With Procedural Complications","Ricardo Flores","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001132616.34609.d2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039538","1722-P: Effect of Tirzepatide on Cardiac Arrhythmia in Adults with Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis","SI-YAN CHEN","2026","Diabetes","systematic_review","article","10.2337/db26-1722-p",null,null,"PROSPERO:CRD420251237091",null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0039539","2825-LB: Effect of Initial Combination Therapy with Pioglitazone plus Exenatide vs. Conventional Therapy on Body Composition and Bone Mineral Density: Results from the EDICT Study","SIHAM ABDELGANI","2026","Diabetes","other","article","10.2337/db26-2825-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039540","Double Trouble","SV Madhu","2023","Indian Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/2230-8210.379597","37583408",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039541","Effect of Glucagon-like Peptide-1 Receptor Agonist on Cardiac Structure and Function in Patients with Heart Failure: A Systematic Review and Meta-analysis","Xinyu Zhang","2023","International Journal of Drug Discovery and Pharmacology","systematic_review","article","10.53941/ijddp.2023.100010",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0039542","682-P: Early Detection and Prevention of Dulaglutide-Induced Asymptomatic Nocturnal and Persistent Hypoglycemia in Patients with Advanced Diabetic Kidney Disease","HARUMI NISHIHARA","2019","Diabetes","other","article","10.2337/db19-682-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039543","Health news round-up: elecoglipron, antibiotic resistant E. coli and low blood pressure risk in frailty",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.415921",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039544","1235 “From Waistline to Wound Healing: Do GLP-1 Receptor Agonists Improve Peri- and Post-Operative Outcomes After Major Weight-Bearing Joint and Spine Surgery in Overweight and Obese Adults?","B Jazayeri","2026","British journal of surgery","randomized_trial","article","10.1093/bjs/znag063.495",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039545","S3399 Case Report: Beware of Incomplete Workup: A Case of Acute Pancreatitis Due to Pancreatic Malignancy Misdiagnosed as GLP-1 Receptor Agonist Side Effects","Khadeja Khan","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001141056.26425.09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039546","Anti-hypertensive and natriuretic effect of glucagon-like peptide 1 in Dahl S rats","Péter Vollenweider","2003","Journal of Hypertension","preclinical","article","10.1097/00004872-200306000-00004","12777941",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039547","Association Between GLP-1 Agonists/co-agonists and Thromboembolic Events in COPD Patients: A Retrospective Cohort Study","Nutchapon Xanthavanij","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a6152",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039548","Effect of incretin-based therapies on cardiovascular risk in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","Dooley, Gordon","2015","York","systematic_review","article","10.15124/crd42015020395",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0039549","Translational Endocrinology & Metabolism: Metabolic Surgery Update","DEL PRATO, STEFANO","2012","Translational endocrinology & metabolism","other","article","10.1210/team.9781936704071",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0039550","74028 GLP-1 Receptor Agonists and Hair Loss in Non-Diabetic Adults: Findings from the All of Us Research Program","Mckenna Karsten","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.950",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039551","Medication adherence among type 2 diabetes Texas Medicaid patients using basal insulin","Zhang, Hanxi","2020","Texas Digital Library (University of Texas)","nonrandomized_study","article","10.26153/tsw/14152",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0039552","CO132 THE BLOCKBUSTER BATTLE IN OBESITY: DO NEWER SEMAGLUTIDE DOSES CLOSE THE GAP? A TIME-COURSE MODEL-BASED NMA","Sneha Rai","2026","Value in Health","other","article","10.1016/j.jval.2026.03.227",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039553","Modern approaches to the management of patients with diabetic nephropathy","Vaibhav Gumber","2025","Special journal of the Medical Academy and other Life Sciences","nonrandomized_study","article","10.58676/sjmas.v3i5.124",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039554","28-OR: GLP1R R131Q is a Gs-Biased Gain-of-Function Variant Associated with Preservation of β-Cell Function","Hyunsuk Lee","2025","Diabetes","nonrandomized_study","article","10.2337/db25-28-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039555","[Intensive efforts for future antidiabetic agents].","Christian Berne","2011","PubMed","other_trial","article",null,"21179868",null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0039556","4CPS-306 Semaglutide in obese haemodialysis patients with chronic kidney disease: a case series","I Marín Espinosa","2026","Section 4: Clinical pharmacy services","nonrandomized_study","article","10.1136/ejhpharm-2026-eahp.403",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0039557","Abstract 5718 Retatrutide: The Future of Weight Loss Medications","Daniel Shannon","2026","Journal of Biological Chemistry","other","article","10.1016/j.jbc.2026.111958",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039558","WCN25-1211 ACUTE KIDNEY INJURY FROM MONONUCLEAR CELL-PREDOMINATED INTERSTITIAL NEPHRITIS AFTER THE INTRODUCTION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS: A CASE REPORT","Raweekarn Itsathitpaisarn","2025","Kidney International Reports","case_report","article","10.1016/j.ekir.2024.11.120",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039559","Efficacy of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss in Non-Diabetic Children & Adolescents with Overweight or Obesity: A Systematic Review & Meta-Analysis","El-Hagrasy, Ahmed Mohsen","2025",null,"systematic_review","article","10.13140/rg.2.2.31161.07520",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0039560","Glucagon-like Peptide-1 Receptor Agonists and Chemosensory Function: A Scoping Review Mapping the Preclinical and Clinical Evidence Base","Gina Spencer","2026","SSRN Electronic Journal","narrative_review","article","10.2139/ssrn.6997542",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039561","741-P: Circulating Follistatin Predicts Tirzepatide Treatment Outcomes on Type 2 Diabetes","Qi Zou","2024","Diabetes","other","article","10.2337/db24-741-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039562","Abstract P1034: Trends of Glucagon-Like Peptide 1 Receptor Agonist Usage, Self-Payments and Total Payments Among People Without Diabetes in the United States from 2017 -2022","Michael M Hammond","2025","Circulation","other","article","10.1161/cir.151.suppl_1.p1034",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039563","Goto-Kakizaki 당뇨병 쥐에서 metformin과 fenofibrate 병합 요법이 포도당 항상성에 미치는 영향에 대한 연구","오태정","2012","Seoul National University Open Repository (Seoul National University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0039564","Glucagon-like-Peptid-1-Rezeptoragonisten beim Typ-2-Diabetes-mellitus: Ihre Anwendung und Unterschiede","Lyseng-Williamson, Katherine","2020","Figshare","other","article","10.6084/m9.figshare.11788854",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0039565","GLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis","Sean M. Brady","2015","AACE Clinical Case Reports","other","article","10.4158/ep15658.cr",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039566","Changes in Cardiometabolic Risk Factors Upon Discontinuation of Tirzepatide for 17 Weeks in a Phase 3 Three-Year Study",null,"2025","Endocrine Practice","other_trial","article","10.1016/j.eprac.2025.05.523",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039567","770-P: Efficacy and Safety of Tirzepatide in Participants Who Achieved Fasting Serum Glucose Targets at 52 Weeks in SURPASS-3 and SURPASS-4","ALICE Y.Y. CHENG","2024","Diabetes","other","article","10.2337/db24-770-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039568","GG01-42 CARDIOLOGIC AND ONCOLOGIC OUTCOMES WITH GLP-1 RECEPTOR AGONISTS IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER","Tamás Fazekas","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191268.85865.a2.42",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039569","GLP-1 Receptor Agonists in Addiction Psychiatry—Neurobiological Rationale, Emerging Clinical Evidence, and Cautions for Practice: A Narrative Review","Gniewko Więckiewicz","2026","Psychiatry International","randomized_trial","article","10.3390/psychiatryint7030130",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0039570","INDIVIDUALIZED RESPONSE TO TIRZEPATIDE FOR WEIGHT LOSS AND GLYCEMIC CONTROL USING COMPUTATIONAL PHENOMAPPING AND MACHINE LEARNING IN THE SURPASS TRIALS: THE TRIMAPS TOOLKIT","Phyllis Thangaraj","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01185-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039571","ProLynx raises $70 million to develop its long-lasting weight-loss drug pipeline","special to C&EN Helen Albert","2026","C&EN Global Enterprise","other","article","10.1021/cen-10401-buscon4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039572","GLP-1RAs and SGLT-2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Eeight: A Meta‑Analysis With Meta-Regression","Qiu, Mei","2020","Figshare","other","article","10.6084/m9.figshare.12789854",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039573","On Hunger : Violence and Craving in America, from Starvation to Ozempic (Edition 1)","Dana Simmons","2025","BiblioBoard Library Catalog (Open Research Library)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0039574","Inkretin-Mimetika: viele Fragen zur mikrovaskulären Wirksamkeit","Annika Simon","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2167-7479",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039575","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-51244-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039576","Abstract #806367: The Efficacy of Once-Weekly Subcutaneous Semaglutide is Comparable in Subjects with Type 2 Diabetes Aged < 65 Years and ≥ 65 Years: A Post Hoc Analysis of Sustain 1-5 and 7-10","Mark Warren","2020","Endocrine Practice","other","article","10.1016/s1530-891x(20)39694-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039577","Thirty-Year Misdiagnosis of Maturity-Onset Diabetes of the Young Type 3 (MODY3) as Type 1 Diabetes: Novel Therapeutic Approach with Glyburide and Adjunctive Tirzepatide",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.131",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039578","Glucagon-Like Peptide-1 (GLP-1) Analogue Inhibited Hepatic Inflammation in Nonalcoholic Steatohepatitis (NASH)","Yukiomi Nakade","2011","Gastroenterology","other","article","10.1016/s0016-5085(11)64072-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039579","Liraglutide-Based Therapy Shows More Prominent Effect than Conventional Insulin Therapy to Achieve HbA1c Target, Especially in Patients with Short Duration","Koji Kashima","2018","Diabetes","other","article","10.2337/db18-2297-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039580","OP0078 Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study","Kinga Grzybowski","2025","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1016/j.ard.2025.05.100",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0039581","148 Prospective Evaluation of Semaglutide (Wegovy) in a Tier 3 NHS Obesity Service: Six-Month Real-World Outcomes from a District General Hospital","Violeta Diaz Fermin","2025","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znaf270.211",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039582","S3916 A Rare Cause of Rectal Bleeding: Inferior Mesenteric Vein Varices in a Non-Cirrhotic Patient","Annie Shergill","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001143124.80195.85",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039583","1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg/m2 or more","HONGWEI JIANG","2024","Diabetes","randomized_trial","article","10.2337/db24-1866-lb",null,null,"ClinicalTrials.gov:NCT04904913","S001183","openalex","FALSE","paywalled","1","FALSE","article"],["R0039584","S1297 Endoscopic Gastric Remodeling Plus GLP-1 Receptor Agonist versus Endoscopic Gastric Remodeling Alone for Weight Loss","Sunny Kumar","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001132648.71698.3d",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0039585","1911-P: The Physiological Role of GLP-1 in Regulating Pancreatic Inflammation in a Sepsis Model","Ellen Davis","2020","Diabetes","preclinical","article","10.2337/db20-1911-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039586","77514 Exploring “Ozempic Face” on TikTok: Patient Perceptions, Social Media Narratives, and Emerging Aesthetic Strategies","Nicole Skalka","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.890",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039587","Aviso importante sobre el uso de Ozempic® (agonista GLP-1), en pacientes programados para cirugía electiva","Manuel G. Bermúdez-Ochoa","2024","Anales Médicos de la Asociación Médica del Centro Médico ABC","other","article","10.24875/amh.m24000055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039588","4337 SKELETAL MUSCLE MASS LOSS IN PATIENTS TREATED WITH SEMAGLUTIDE OR TIRZEPATIDE FOR WEIGHT REGAIN OR INSUFFICIENT WEIGHT LOSS POST BARIATRIC SURGERY",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.217",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039589","GLP-1 Receptor Agonists Discontinuation and Cardiovascular Events in Type 2 Diabetes: A Population-Based Study","Antonio Ceriello","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6567724",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0039590","Investigating function and evolution of genes and proteins involved in metabolic control in mammals","Chuan He","2016","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","preclinical","article","10.4225/55/59093e39cd254",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039591","Cost-effectiveness analysis of liraglutide for obesity treatment in Colombia","Catalina Barón Triana","2020","Repositorio Institucional Universidad El Bosque","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039592","425-P: Lessons Learned from a Patient-Centered, Team-Based Intervention for Patients with Type 2 Diabetes at High Cardiovascular Risk: Year 1 Results from the CINEMA Program","IAN NEELAND","2022","Diabetes","other","article","10.2337/db22-425-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039593","Correction to: 2023 Scientific Sessions Abstract 14413",null,"2024","Circulation","notice","article","10.1161/cir.0000000000001223","38437477",null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0039594","Translational Medicine and Exercise Prescription (TMEP): Advancing the Era of Exercise Medicine","Sulin Cheng","2021","Translational Medicine and Exercise Prescription","randomized_trial","article","10.53941/tmep.v1i1.27",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0039595","1746-P: Post Hoc Analysis of Efficacy and Safety Outcomes of Efsitora vs. Once-Daily Insulin in Type 2 Diabetes by GLP-1RA Use across QWINT-1–4 Trials","ALICE Y.Y. CHENG","2026","Diabetes","other_trial","article","10.2337/db26-1746-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039596","370-OR: Optimized Weight Loss with Bimagrumab—Reduced Fat Mass with Increased Muscle Mass by Appetite-Independent Mechanisms","Kenneth M. Attie","2023","Diabetes","other","article","10.2337/db23-370-or",null,null,"ClinicalTrials.gov:NCT05616013","S000715","openalex","FALSE","paywalled","5","FALSE","article"],["R0039597","749-P: Selection of BI 456906 as a Dual GCGR/GLP-1R Agonist Based on In Vitro Potency and In Vivo Target Engagement Biomarkers","ROBERT AUGUSTIN","2023","Diabetes","preclinical","article","10.2337/db23-749-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039598","Overweight and Reproductive Outcomes: The Role of GLP-1 Receptor Agonists and Preconceptional Weight Loss","Kathrine Vauvert Römmelmayer Hviid","2026","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039599","2313-PUB: Efficacy by Baseline BMI with Once Weekly Dulaglutide in Chinese T2DM Patients","Yongquan Shi","2019","Diabetes","randomized_trial","article","10.2337/db19-2313-pub",null,null,"ClinicalTrials.gov:NCT01644500; ClinicalTrials.gov:NCT01648582","S001064; S001404","openalex","FALSE","paywalled","1","FALSE","article"],["R0039600","LipoLess Review - Gelatin Weight Loss Scam EXPOSED(DVF4ET)","jaix datu","2026",null,"narrative_review","article","10.55277/researchhub.gdti5ulj.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0039601","1463-P: LEADER Eligibility and Preventable Cardiovascular Events in the U.S. Population: An Analysis of the National Health and Nutrition Examination Survey","Nathan D. Wong","2019","Diabetes","other_trial","article","10.2337/db19-1463-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039602","Outcomes Associated With GLP1 Receptor Agonist Use In Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review And Meta Analysis Of Randomized Control Trials","Brandon Berman","2026","Journal of Cardiac Failure","systematic_review","article","10.1016/j.cardfail.2025.11.417",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0039603","S517 Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) Significantly Impair Quality Metrics for Colonoscopy Preparations, Even When Held 7 Days Prior to Procedure","Schyler McBride","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129528.48929.23",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039604","The Analysis Study of Effects of Glucagon-Like Peptide-1 Receptor to Reduce Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Comprehensive Systematic Review","Radian Tommy Firmansyah","2024","The International Journal of Medical Science and Health Research","systematic_review","article","10.70070/1qe6dr94",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0039605","814-P: What Are the Early Selection Predictors of GLP-1 Receptor Agonists in Real-World Data for Japanese Individuals with Type 2 Diabetes?","Yuka Suganuma","2024","Diabetes","nonrandomized_study","article","10.2337/db24-814-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039606","2058-LB: DA-1726, a GLP1R/GCGR Dual Agonist, a Promising Approach in Obesity Treatment and Lipid Management","YUNA CHAE","2024","Diabetes","other_trial","article","10.2337/db24-2058-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039607","Untersuchungen zur blutzuckerabhängigen Wirkung von Exendin-4 auf die Insulinsekretion bei Typ 2-Diabetikern","Peters, Natalie Alice","2011","Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0039608","Protective Effects of Exendin-4 on Nitric Oxide-Mediated Cell Death in Insulin-Producing RINm5F Cells","Myoung Won Lee","2007","Laboratory Animal Research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039609","Diabetes therapies in renal impairment","Clifford J. Bailey","2012","The British Journal of Diabetes","other","article","10.1177/1474651412458811",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039610","IDDF2026-ABS-0353 Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors on Risk of Hepatic and Extrahepatic Outcomes in Patients with Type 2 Diabetes and Viral Hepatitis","Xinrong Zhang","2026",null,"nonrandomized_study","article","10.1136/gutjnl-2026-iddf.14",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0039611","Patient outcome audit in ACT health obesity management service","C Kojima","2017","Internal Medicine Journal","nonrandomized_study","article","10.1111/imj.7_13461",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039612","2813-LB: CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study","Ildiko Lingvay","2026","Diabetes","randomized_trial","article","10.2337/db26-2813-lb",null,null,"ClinicalTrials.gov:NCT06525935","S002807","openalex","FALSE","paywalled","1","FALSE","article"],["R0039613","TPW 7.14 When Weight Loss Hurts: An Observational Study of Emerging Biliary and Pancreatic Complications in Patients Receiving Tirzepatide (Mounjaro)","Bidisha Singha","2026","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znag087.383",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039614","An Industry update: the Latest Developments in Therapeutic Delivery","Iain A. Simpson","2017","Therapeutic Delivery","other","article","10.4155/tde-2016-0082","28088881",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039615","PDB36 LONG-TERM COST-CONSEQUENCE ANALYSIS OF EXENATIDE ONCE WEEKLY VERSUS SITAGLIPTIN OR PIOGLITAZONE IN TYPE 2 DIABETES PATIENTS IN THE UNITED STATES","Gaebler J Aledort","2010","Value in Health","other","article","10.1016/s1098-3015(11)72094-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039616","PP13 Apprendre en jouant : nouveau jeu sur le diabète et sur Byetta®","J.-P. Guichard","2009","Diabetes & Metabolism","other","article","10.1016/s1262-3636(09)72080-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039617","O bloqueio em longo prazo do receptor do peptídeo-1 semelhante ao glucagon eleva os níveis de pressão sistólica em ratos hipertensos e normotensos","Flavia Leticia Martins","2019","Americanae (AECID Library)","other","article","10.11606/d.5.2019.tde-16102019-112906",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039618","Semaglutide: Scoping Review with ☸SAIMSARA","SAIMSARA","2026","SAIMSARA Journal","narrative_review","article","10.62487/saimsara45190890",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039619","Abstract #252: Once Weekly Dulaglutide may be Coadministered with Warfarin Without Dose Adjustment","Amparo de la Peña","2015","Endocrine Practice","other","article","10.1016/s1530-891x(20)42558-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039620","Mechanism of Glucagon-like Peptide-1 Receptor Agonist Improving Liver Lipid Deposition in a Rat Model of Insulin Resistance Induced by High-fructose Diet","GAO  Zhe, DUAN  Kaixin, LYU  Xiuqin, MA  Huijuan, ZHANG  Zhimei, SONG  Guangyao","2023","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article","10.12114/j.issn.1007-9572.2023.0062",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0039621","Austrian Experience with Lixisenatide under Real-Life Conditions: A Prospective, Observational Study","Brath, Helmut","2018","Figshare","other","article","10.6084/m9.figshare.7467278",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039622","ОСОБЛИВОСТІ ЗАСТОСУВАННЯ АГОНІСТА РЕЦЕПТОРІВ ГЛЮКАГОНОПОДІБНОГО ПЕПТИДУ-1 У ХВОРИХ НА ЦУКРОВИЙ ДІАБЕТ 2 ТИПУ ЗАЛЕЖНО ВІД СТАТІ ТА ФЕНОТИПУ","ШИШКАНЬ-ШИШОВА КАТЕРИНА","2022","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.6570272",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039623","PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice","Adis Journals On Behalf Of:","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.26064211",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0039624","44 Nutritional approach to weight management of morbid obesity and type 2 diabetes mellitus in Prader-Willi syndrome","Maheen Fathima Pasha","2024",null,"other","article","10.1136/bmjpo-2024-asped.44",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039625","Abstract #200 A Real-World; Observational Study of Weekly Exenatide Added to Basal Insulin in Patients with Type 2 Diabetes Mellitus (NCT02895672)","Matthew Stryker","2018","Endocrine Practice","nonrandomized_study","article","10.1016/s1530-891x(20)47046-6",null,null,"ClinicalTrials.gov:NCT02895672","S000410","openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039626","422-P: GLP-1 RA Should Be Used with SGLT2 Inhibitor in People with Rapidly Progressive CKD","Koji Kashima","2023","Diabetes","other","article","10.2337/db23-422-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039627","Annals On Call - First-Line Drug Therapy for Type 2 Diabetes","Robert M. Centor","2023","Annals of Internal Medicine","other","article","10.7326/a22-0004","36802895",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039628","S2243 Trends in Utilization and Outcomes After Endoscopic Bariatric Therapies: An MBSAQIP Database Analysis From 2016-2023","Sevag Hamamah","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001136432.64243.30",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039629","Treatment of Obesity with Once Weekly Tirzepatide","Musaali, Alyssa M","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039630","1158-P: Evolving Trends in GLP-1 Receptor Agonist Prescriptions for Pediatric Type 2 Diabetes—A Retrospective Analysis (2019–2024)","NOHA EL YAMAN","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1158-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039631","Exenatide extended-release for injectable suspension, BYDUREON® 2mg Pen","Akihiro Kusaba","2016","Drug Delivery System","other","article","10.2745/dds.31.156",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039632","Kommentar zu „Adipositas/Typ-2-Diabetes: GLP-1 Agonist Tirzepatid fördert Gewichtsabnahme“","Matthias Blüher","2024","DMW - Deutsche Medizinische Wochenschrift","other","article","10.1055/a-2162-5083",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039633","Science, Medicine, and the Anesthesiologist (October 2024): Erratum",null,"2024","Anesthesiology","randomized_trial","article","10.1097/aln.0000000000005251","39530723",null,null,null,"openalex","FALSE","paywalled","2","FALSE","erratum"],["R0039634","Pharmacotherapeutic Strategies to Prevent Progression to ESKD and Reduce Cardiovascular Risk","Ayodele Odutayo","2024","Nephrology Self-Assessment Program","other","article","10.58483/nsap.00222024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039635","Abstract 4371168: Comparative Outcomes of GLP-1 Agonists vs SGLT2 Inhibitors in Patients with Type 2 Diabetes and Heart Failure: A Propensity-Matched Multicenter Retrospective Analysis","Ali Akram Qureshi","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4371168",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039636","MOESM2 of Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases","Bramlage, Peter","2019","Figshare","nonrandomized_study","article","10.6084/m9.figshare.7855313",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0039637","Sodium–Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections","Chintan V. Dave","2019","Annals of Internal Medicine","randomized_trial","article","10.7326/l19-0671","31842209",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039638","Dapagliflozin/metformin/semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-30626-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039639","Navigating Obesity Management: A Comprehensive Review of Glucagon-Like Peptide-1 Receptor Agonists","Thomas, PA-C, Tangie","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039640","S1757 Impact of Glucagon-Like Peptide-1 Receptor Agonists on Inflammatory Bowel Disease in Patients With and Without Type 2 Diabetes Mellitus","Matthew Still","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001134488.18764.c4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039641","Abstract #266 Clinical Effectiveness of Dulaglutide Monotherapy in Obese Indian Adults with Prediabetes: First Report of a Real-World Retrospective Study in India","Supratik Bhattacharyya","2019","Endocrine Practice","nonrandomized_study","article","10.1016/s1530-891x(20)46610-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039642","Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trials","Jing Qin","2019","Research Square","systematic_review","article","10.21203/rs.2.16671/v1",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","preprint"],["R0039643","Beyond basic research: recent clinical research breakthroughs in GIP and GLP1","Qianhui Sun","2024",null,"other","article","10.1117/12.3044208",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0039644","FRI-155 Efficacy of oral semaglutide in overweight- obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD) related compensated advanced chronic liver disease (cACLD) - Results of first randomized controlled trial","Prof. Ajay Kumar Duseja","2026","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(26)01899-4",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0039645","3080-LB: Naturally Derived Fully Human Anti-ACVR2A Antibodies with Superior PK and Functional Benefits for Obesity and Metabolic Disease","YUXIANG LIU","2026","Diabetes","preclinical","article","10.2337/db26-3080-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039646","1965-P: Glycemic Outcomes in CGM-Naïve vs. Experienced Patients Using Implantable CGM","RISHAB TANDON","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1965-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039647","Effect of Semaglutide in Hepatic Lipid Metabolism of Rats in a Methionine-choline Deficient Diet-induced Non-alcoholic Fatty Liver Disease Model","ZHANG  Quanai, LI  Sha, WANG  Kaiti, DONG  Huicong, LU  Xiaofei, GUO  Yongze","2025","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.12114/j.issn.1007-9572.2023.0534",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039648","The headlines we expect in 2026","C&EN Editors","2026","C&EN Global Enterprise","commentary","article","10.1021/cen-10401-editorial",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0039649","Additional file 1 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","Rossing, Peter","2023","Figshare","other","article","10.6084/m9.figshare.26612675",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039650","Human medicines European public assessment report (EPAR): Suliqua, insulin glargine / lixisenatide, Diabetes Mellitus, Type 2, Date of authorisation: 11/01/2017, Revision: 3, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-1930427",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039651","Reaching for Individualized Medicine in Diabetic Kidney Disease","Mallory Mandel","2025","JAMA Network Open","randomized_trial","article","10.1001/jamanetworkopen.2025.1702","40126484",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039652","S1443 Predictors of Pancreatitis on Initiation of GLP-1 Receptor Agonists for Weight Loss","Robert J. Postlethwaite","2022","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000862412.41232.db",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039653","Exendin-4 promotes GSIS without increasing β-cell number through upregulation of glucose-sensing apparatus and mitochondrial oxidative phosphorylation machinery genes in hPSC-derived β-cells","Diane, Abdoulaye","2023","Qatar National Library","preclinical","article","10.57945/manara.22785233",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract; article"],["R0039654","Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide-1 Receptor Agonist in Chinese Patients with Type 2 Diabetes Mellitus","Cai, Xiaoling","2021","Figshare","other","article","10.6084/m9.figshare.14566482",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039655","1675-P: GLP-1 Receptor Agonists (GLP-1RAs) in Kidney-Transplanted (KTX) People with Diabetes: Ad Interim Results of an 18-Month Trial","Irene Cogliati","2026","Diabetes","other_trial","article","10.2337/db26-1675-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039656","Case Study: GLP-1 Receptor Agonist Up-Titration During rTMS for MDD Associated With New-Onset Dyskinesias and Symptom Relapse","Cameron Noorbakhsh","2026","Transcranial magnetic stimulation .","other","article","10.1016/j.transm.2026.100281",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039657","The impact of liraglutide on epicardial adipose tissue and left atrial remodelling prior to ablation for atrial fibrillation","K Z Win","2026","European Heart Journal - Cardiovascular Imaging","other","article","10.1093/ehjci/jeaf367.398",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039658","Microplastics and nanoplastics: tiny threats for cardiovascular diseases?","Raffaele Marfella","2025","Cardiovascular Research","nonrandomized_study","article","10.1093/cvr/cvaf143","40919846",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039659","Diabetes News","Helen X. Gao","2015","Journal of Diabetes","other_trial","article","10.1111/1753-0407.12350","26575085",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039660","Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting","Wysham, Carol H.","2019","Figshare","nonrandomized_study","article","10.6084/m9.figshare.10033067",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0039661","The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease","Lin, Yuan","2024","Figshare","nonrandomized_study","article","10.6084/m9.figshare.c.6590636.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0039662","S6230 GLP-1-Induced Superior Mesenteric Artery Syndrome: An Interesting Complication in the Age of GLP-1 and SGLT-2 Medications","Omar Zuhdi","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001153380.29689.9c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039663","1060-P: The Effect of FGF21/GLP-1 Fusion Protein on Glucose and Lipid Metabolism Using Diabetic Mice Models","Lixin Guo","2020","Diabetes","preclinical","article","10.2337/db20-1060-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039664","2909-LB: Longitudinal Analysis of Variation by Race and Ethnicity in Prescription of GLP-1RA and SGLT2i Medications in Type 2 Diabetes","HUGO A. TORRES","2026","Diabetes","other","article","10.2337/db26-2909-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039665","Étude de l’effet du dulaglutide, analogue du GLP1, sur la protection des cellules bêta dans un modèle de stress inflammatoire mimant la greffe d’îlots pancréatiques","Guillaume Kreutter","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30224-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039666","Dual GIP/GLP-1 Receptor Agonists and Kidney Protection: Expanding Therapeutic Horizons in Nephrology","Richard Adrián Vergara Trujillo","2025","IECCMEXICO","other","article","10.64784/007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039667","Cardiovascular, Metabolic, and Mortality Outcomes With Semaglutide Versus Tirzepatide in Obese Patients With Hypothyroidism: A Real-World Analysis",null,"2026","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2026.03.054",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039668","Impact of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists on Diabetic Macular Edema: A Systematic Review and Meta-Analysis",null,"2026","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2026.03.039",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0039669","Mission: halt diabetes momentum and stop growing epidemic","Wenying Yang","2008","Chinese Medical Journal","randomized_trial","article","10.1097/00029330-200811010-00001","19080168",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0039670","Auswirkungen der Therapieumstellung von übergewichtigen Patienten mit Diabetes mellitus Typ 2 auf Exenatide","Luminiţa Timofte","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1253963",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039671","Biased Agonism in Incretin-based Therapies","Krishna Seshadri","2025","International journal of clinical metabolism and diabetes.","other","article","10.1177/30502071251336542",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039672","433-P: Comparative Evaluation of Current Therapeutic Agents for Heart Failure with Preserved Ejection Fraction (HFPEF)—A Systematic Review and Network Meta-analysis","ZONGLIN LI","2025","Diabetes","systematic_review","article","10.2337/db25-433-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0039673","1731-P: A Six-Month Single-Arm Study Testing the Effectiveness of Commercial Telehealth Medical Weight Management and GLP-1 Behavioral Program on Weight Loss and Blood Pressure Outcomes","Leslie J. Heinberg","2025","Diabetes","other_trial","article","10.2337/db25-1731-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039674","760-P: TERN-501 Enhances Weight Loss Efficacy of a GLP-1R Agonist in Obese Mice via Increased Fat Mass Loss without Additional Loss of Lean Mass","CHRISTOPHER JONES","2024","Diabetes","preclinical","article","10.2337/db24-760-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039675","175 Eligibility and referral to weight management services in a cardiology outpatient department","Kelly Wright","2026",null,"other","article","10.1136/heartjnl-2026-bcs.107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0039676","Radiological assessment of body composition changes and complications in an era of incretin-based therapies: A narrative review","Jonah Moyal","2026","University of Toronto Medical Journal","narrative_review","article","10.33137/utmj.v103i2.46711",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0039677","748-P: Noninvasive Tests of Central Adiposity Correlate with Reductions in MRI-Measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide","Shaheen Tomah","2025","Diabetes","randomized_trial","article","10.2337/db25-748-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039678","768-P: Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Motility-Related Gastrointestinal Adverse Events—A Cohort Study","Wajd Alkabbani","2025","Diabetes","nonrandomized_study","article","10.2337/db25-768-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039679","GLP-1RAs may cause intolerable gastrointestinal AEs",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-44172-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039680","Liraglutide restores trabecular bones in ovariectomized rats by osteoanabolic mode","Subhashis Pal","2016",null,"preclinical","article","10.13140/rg.2.2.23624.72965",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039681","The influence of a GLP-1 analogue, liraglutide on binge eating behaviour among obese healthy participants","Sarah Anne Robert","2013","Obesity Research & Clinical Practice","other","article","10.1016/j.orcp.2013.12.576",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039682","G-361 GLP-1 Receptor Agonist Utilization in a National Cohort of Maintenance Dialysis Patients",null,"2026","American Journal of Kidney Diseases","nonrandomized_study","article","10.1053/j.ajkd.2026.02.362",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039683","1869-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes (T2D) Suboptimally Controlled with Oral Antidiabetic Drug(s) (OAD)—The SoliD Randomized Controlled Trial","MING LIU","2024","Diabetes","randomized_trial","article","10.2337/db24-1869-lb",null,null,"ClinicalTrials.gov:NCT05413369","S000073","openalex","FALSE","paywalled","1","FALSE","article"],["R0039684","751-P: Benefits of HR17031, a Fixed-Ratio Combination of INS068 and SHR20004, vs. Its Components Alone in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Oral Antidiabetic Drug(s) (OADs)","Linong Ji","2024","Diabetes","randomized_trial","article","10.2337/db24-751-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039685","The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF)","Metsärinne Kaj","2025","UTUPub (University of Turku)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0039686","The new era of diabetes management: Comprehensive benefits of Ozempic in diabetes and co-morbidities","Yasmin Aktar","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other_trial","article","10.3329/jacedb.v4i20.84907",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0039687","26-A-9228-ACC GLP-1 RECEPTOR AGONIST-INDUCED SINUS TACHYCARDIA MIMICKING ARRHYTHMIA IN A PATIENT WITH AN IMPLANTED LOOP RECORDER","Navpreet Boparai","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039688","Diabetes and prediabetes prevalence and guideline directed antidiabetic therapy in acute coronary syndrome and complex coronary interventions","Orsolya Tímár","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3658",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039689","Focus on old and emerging risk factors: familial hypercholesterolaemia, lipoprotein(a), and skeletal muscle adiposity","Filippo Crea","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf124","40123524",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039690","1176-P: Effects of GLP-1 Therapy on GDF15 Expression in Hepatocytes of MAFLD","Lu Gan","2021","Diabetes","preclinical","article","10.2337/db21-1176-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039691","1871-LB: Phase 1 Topline Safety, Efficacy, and Pharmacokinetics of Oral Ecnoglutide","ZHIYI ZHU","2024","Diabetes","randomized_trial","article","10.2337/db24-1871-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039692","Improving the outcome of primary PCI: protection from reperfusion injury","Gerd Heusch","2017","Cardiovascular Research","other_trial","article","10.1093/cvr/cvx120","28899004",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039693","Rethinking Contraception in the Age of Glucagon-like Peptide-1 Agonists: A Case for Long-Acting Reversible Contraceptives",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.328",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039694","Efficacy of GLP-1 agonists in the achievement of remission-level HbA1c in type 2 diabetes: A systematic review and meta-analysis","Alsharif, Fatima R","2024",null,"systematic_review","article","10.13140/rg.2.2.33101.55521",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0039695","Obesity and Reproduction","Wendy Vitek","2023","Seminars in Reproductive Medicine","other","article","10.1055/s-0043-1777336","38198790",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039696","Upconversion nanoparticles-loaded injectable supramolecular hydrogels for on-demand glycemic regulation by optogenetic GLP-1 release","Mungu Kim","2026","Cell Biomaterials","preclinical","article","10.1016/j.celbio.2026.100491",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039697","Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic Syndrome)","Giuseppe Montalto","2014","Current Pharmaceutical Design","nonrandomized_study","article","10.2174/1381612819666131206112537","24320029",null,null,null,"openalex","FALSE","paywalled","4","FALSE","editorial"],["R0039698","Efficacy of Glucagon-like Peptide-1 Receptor Agonists on Weight Loss in Adults","STULO, ALEX","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039699","Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways","Yong Luo","2019","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039700","CE-534538-005 COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS, GLP-1 RECEPTOR AGONISTS, AND THEIR COMBINATION ON THE RISK OF ATRIAL FIBRILLATION AND STROKE IN STAGE 4 CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME: A TRINETX GLOBAL COHORT STUDY","Yun-Yu Chen","2026","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2026.03.018",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039701","Drug shortages created opportunities for bad actors","Laurel Oldach","2024","C&EN Global Enterprise","other","article","10.1021/cen-10238-cover5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039702","Aging as art: a poetic inquiry","Zhaohui Su","2026","Asian Journal of Medical Humanities","other","article","10.1515/ajmedh-2026-0013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039703","Intérêt du liraglutide dans la prise en charge du surpoids et de l’obésité","Ariane Sultan","2016","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(16)30095-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039704","794-P: Effect of Liraglutide on Abdominal Fat Distribution and Glucose Metabolism in Chinese Patients with Obesity","MENGYANG DU","2024","Diabetes","other","article","10.2337/db24-794-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039705","Insulin synthesis in the brain","Golnaz Madadi","2008","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039706","Do Glucagon-Like Peptide-1 Analogs Affect Diabetic Compliance and Quality of Life?","Lisa C. Greer","2013","The Journal for Nurse Practitioners","other","article","10.1016/j.nurpra.2013.01.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039707","Comprehensive analysis of the safety of semaglutide","Liangliang Ding","2021","Figshare","other","article","10.6084/m9.figshare.13565084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039708","Tirzepatide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-51275-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039709","Efficacy of Liraglutide: GLP 1 Receptor Agonist on Glycemic Control and Weight Loss among Patients with Type 2 Diabetes","Fatima Jehangir","2019","Pakistan Journal of Medicine and Dentistry","other","article","10.36283/pjmd9-1/008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039710","Software Price Modeling of Semaglutide","Bradley Eilerman","2018","Diabetes","other","article","10.2337/db18-144-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039711","Alogliptin and Pioglitazone, Alone or in Combination, Prevent Palmitate-Induced Apoptosis and Autophagy in Human Cardiac Progenitor Cells","Maria Angela Incalza","2018","Diabetes","preclinical","article","10.2337/db18-2190-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039712","Adjusting background insulin therapy in type 2 diabetes when initiating a glucagon-like peptide 1 receptor agonist: A case series","Heather P. Whitley","2023","Journal of Case Reports and Images in Medicine","case_report","article","10.5348/100073z09hw2022cs",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039713","FDA Approves 'Gamechanger' Semaglutide for Weight Loss Source: Medscape Medical News",null,"2021","Journal of Pakistan Society of Internal Medicine.","other","article","10.70302/jpsim.v2i2.2142",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039714","Response to: “Nutritional Priorities to Support GLP ‐1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society”","Lifestyle Medicine","2025","Obesity","other","article","10.1002/oby.70064",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039715","POS0209 IMPACT OF TIRZEPATIDE ON MUSCULOSKELETAL PAIN AND RISKY ANALGESIC USE AMONG NON-DIABETIC INDIVIDUALS WITH OVERWEIGHT OR OBESE BODY HABITUS: A PROPENSITY SCORE-MATCHED, ACTIVE COMPARATOR, NEW USER DESIGN STUDY","Gregory J. Challener","2025","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1016/j.ard.2025.05.596",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0039716","Comparação entre semaglutida e tirzepatida no tratamento da obesidade: revisão das evidências clínicas de eficácia e segurança","Amadeu Monteiro Vaz da Silva","2025","Brazilian Journal of Health Review","other","article","10.34119/bjhrv8n6-396",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039717","Convergent and complementary cardiorenal protective mechanisms of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease within the CKM framework","Zhuoran Jia","2026","Diabetology & Metabolic Syndrome","randomized_trial","article","10.1186/s13098-026-02284-z",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0039718","IP22-12 GLP-1 RECEPTOR AGONISTS ASSOCIATED WITH REDUCE PELVIC COMPLICATIONS IN POSTPARTUM WOMEN: A GLOBAL REAL-WORLD MATCHED COHORT STUDY","Muhammed Hammad","2026","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001191396.05243.57.12",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039719","754-P: Development of a Novel One-Month Long-Acting Injectable Semaglutide (IVL3021) and Tirzepatide (IVL3024) with Well-Controlled Pharmacokinetic Profiles and Enhanced Quality of Life Window","Ju Hee Kim","2025","Diabetes","preclinical","article","10.2337/db25-754-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039720","Peptide‐based Therapeutics for Inflammatory and Autoimmune Diseases","Sunay V. Chankeshwara","2025","Peptide Science","other","article","10.1002/9781119824701.ch10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039721","PO32 Méta analyse des études LEAD (Liraglutide Effects & Action on Diabetes)","J.P. Courrèges","2010","Diabetes & Metabolism","other","article","10.1016/s1262-3636(10)70138-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039722","755-P: GLP-1RA Therapy Recovers Vascular Regenerative Cell Content in High Cardiovascular–Risk Individuals with Type 2 Diabetes","Aishwarya Krishnaraj","2024","Diabetes","nonrandomized_study","article","10.2337/db24-755-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039723","Exenatide","Julio Rosenstock","2005","Drugs","other","article","10.2165/00003495-200565120-00010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039724","Pharmacological treatments in adults with chronic heart failure: a systematic review and component network meta-analysis","X Zou","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.1303",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0039725","Association Between Semaglutide Treatment and Suicide in Patients With Obesity: Systematic Review and Meta-analysis",null,"2026","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2026.01.327",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0039726","1253-OR: ADA Presidents' Select Abstract: Efficacy and Safety of Orforglipron vs. Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5","FRANCESCO GIORGINO","2026","Diabetes","randomized_trial","article","10.2337/db26-1253-or",null,null,"ClinicalTrials.gov:NCT06109311","S001044","openalex","FALSE","paywalled","1","FALSE","article"],["R0039727","Cardiovascular Safety Trials of Antidiabetic Therapies to Treat Type 2 Diabetes: Perhaps Asking the Wrong Question?","Bruce M. Psaty","2019","American Journal of Hypertension","other_trial","article","10.1093/ajh/hpz093","31175821",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0039728","846-P: Advancing Therapy in Basal Insulin–Treated Type 2 Diabetes: Exploratory Analysis of the SoliMix Trial by Baseline Age, Diabetes Duration, and Renal Function","PHILIP HOME","2022","Diabetes","randomized_trial","article","10.2337/db22-846-p",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039729","Will pharmacotherapy soon replace bariatric surgery as the gold standard treatment for obesity?","Heba Butt","2025","The British Student Doctor Journal","nonrandomized_study","article","10.18573/bsdj.419",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039730","A look at the GLP‐1 agonists","Lawrence H. Price","2023","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31062",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039731","Dulaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-47899-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039732","Neues bei Kopfschmerzen 2022–2023","Hans‐Christoph Diener","2023","Neurologie up2date","other","article","10.1055/a-2123-7121",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039733","GLUCAGON-LIKE PEPTIDE 1 ANALOG LIRAGLUTIDE REDUCES TNF-α-INDUCED OXIDATIVE STRESS AND INFLAMMATION","Aya Shiraki","2012","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(12)60905-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039734","Tirzepatide-induced lipid metabolic remodeling in relation to clonogenicity and migration in colorectal cancer cells: An in vitro and in silico approach.","Ipek Zeynep Durusu","2026","Journal of Clinical Oncology","preclinical","article","10.1200/jco.2026.44.16_suppl.e15561",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039735","Saxagliptin a New Second Line Therapy After Metformin for the Treatment of Type 2 Diabetes",null,"2010","Clinical Medicine Reviews in Vascular Health","other","article","10.4137/cmrvh.s4535",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039736","CO89 THE DIABETES PENALTY, ARE WE COMPARING LIKE VERSUS LIKE IN OBESITY MANAGEMENT? RE-RANKING SEMAGLUTIDE AND TIRZEPATIDE AFTER ADJUSTING FOR COMORBID T2D CONFOUNDING","Sneha Rai","2026","Value in Health","other","article","10.1016/j.jval.2026.03.184",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039737","PO027 A COMPARISON OF THE EFFECTS OF THE GLP-1 ANALOGUE LIRAGLUTIDE AND INSULIN GLARGINE ON METABOLIC PARAMETERS AND ENDOTHELIAL FUNCTION","Hiroshi Nomoto","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70322-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039738","S2482 Prescriber Beware: Rethinking the Routine Glucagon-Like Peptide-1 Receptor Agonists","Yousef Hreish","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001039296.29354.19",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039739","1704-P: Survodutide Improves Heart Failure with Preserved Ejection Fraction and Dyslipidemia in a Diet-Induced Obese Hamster Model","François Briand","2025","Diabetes","randomized_trial","article","10.2337/db25-1704-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039740","Qualitative and Quantitative Effect of IDegLira Compared with the Nonfixed Administration of Degludec and Liraglutide","Anastasios Koutsovasilis","2018","Diabetes","other_trial","article","10.2337/db18-1104-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039741","SKALE Kids Trial: liraglutide efficace nell’obesità anche nei bambini: l’effetto è bello finché dura","Elena Arosio","2025","QUADERNI ACP","randomized_trial","article","10.53141/peqacp.2025.1.n1",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039742","New product intros (apalutamide, betrixaban, bictegravir/emtricitabine/tenofovir alafenamide fumarate (new combination), ertugliflozin, ertugliflozin/metformin hydrochloride (new combination), ertugliflozin/sitagliptin (new combination), nonacog beta pegol, plecanatide (new indication), semaglutide, synthetic human angiotensin II, tezacaftor/ivacaftor (new combination))",null,"2018","Drugs of today","other","article","10.1358/dot.2018.54.2.2794727",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039743","Antiobesity drug therapy","Taher Modarressi","2021","Cleveland Clinic Journal of Medicine","other","article","10.3949/ccjm.88c.12001","34857599",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039744","790-P: Paradigm Shifts in GLP-1 Receptor Agonist Use Amongst Patients with Type 2 Diabetes in the United States","Jackson Lee","2025","Diabetes","other","article","10.2337/db25-790-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039745","Tirzepatid versus Insulin lispro bei Typ-2-Diabetes: SURPASS-6-Studie","R. Maria Clauss","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2167-7589",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039746","Liraglutide increases surfactant proteins (SPA & SPB) and angiotensin-converting enzymes (ACE & ACE2) expression in a rat model of acute lung injury by bleomycin","Juan Fandiño","2016","Endocrine Abstracts","preclinical","article","10.1530/endoabs.41.gp99",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0039747","Decreased 68Ga-NOTA-exendin-4 renal uptake in patients pretreated with Gelofusine infusion: a randomized controlled study","Yaping Luo","2020","Journal of Pancreatology","randomized_trial","article","10.1097/jp9.0000000000000053",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0039748","Body of Work: Reflections on Body Contouring Surgery Innovation and 30 Years of Aesthetic Surgery Journal","Jeffrey A. Gusenoff","2026","Aesthetic Surgery Journal","randomized_trial","article","10.1093/asj/sjag034","42298944",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0039749","110-LB: Efficacy, Safety, and Appropriateness of iGlarLixi, a Fixed-Ratio Combination (FRC) in Type 2 Diabetes (T2D) in Real-World Settings: Results from the ENSURE Study","Riccardo Candido","2021","Diabetes","randomized_trial","article","10.2337/db21-110-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039750","Real-world treatment patterns and mortality associated with GLP1-RAs in breast cancer patients.","Jasmine S. Sukumar","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.629",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039751","1674-P: Trends in Antidiabetic Medication Use among California Medicare Beneficiaries, 2013–2022","Jiahui Dai","2026","Diabetes","other","article","10.2337/db26-1674-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039752","Anesthetic risks associated with the use of implantable Glucagon-like Peptide 1 (GLP-1): case report","Marcelo de Jesus Martins","2026","Perioperative Anesthesia Reports","case_report","article","10.61724/2965-3681/e00292025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039753","945-P: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of 12 Once-Weekly Subcutaneous Doses of PB-119 to Patients with Type 2 Diabetes Mellitus as Monotherapy","Min Xu","2020","Diabetes","randomized_trial","article","10.2337/db20-945-p",null,null,"ClinicalTrials.gov:NCT03520972","S002761","openalex","FALSE","paywalled","1","FALSE","article"],["R0039754","Protective Effect of Liraglutide on Early Renal Fibrosis in Diabetes Mice","Xiaolan Ke","2025","Journal of Biosciences and Medicines","preclinical","article","10.4236/jbm.2025.131008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039755","837-P: Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin","Lixin Guo","2025","Diabetes","randomized_trial","article","10.2337/db25-837-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039756","Gastric Point of Care Ultrasound (POCUS) in Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS)","Awal, Manu","2025","UA Campus Repository (The University of Arizona)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039757","Abstract 4129733: Glucagon-like Peptide 1 Receptor Agonists Effect on Low-Density Lipoprotein Cholesterol and Total Cholesterol Levels Independent of Weight Reduction: A Meta-analysis and Meta-regression of Placebo-controlled Randomized Controlled Trials","Frederick Berro Rivera","2024","Circulation","systematic_review","article","10.1161/circ.150.suppl_1.4129733",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0039758","Semaglutide shows favorable safety profile in patients receiving clozapine",null,"2025","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31361",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039759","S473 GLP-1 Receptor Agonists Worsen Colonoscopy Quality Indicators: A Meta-Analysis of 18,805 Patients","Saqr Alsakarneh","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001129352.20930.36",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0039760","Interventions targeting hepatic and cardiovascular complications of metabolic syndrome","J. Inia","2026","Leiden Repository (Leiden University)","other","article","10.60602/1887-4302628",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039761","Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: A pilot study","Juan Carlos Palma","2017","Revista Médica Del Hospital General De México","randomized_trial","article","10.1016/j.hgmx.2017.03.001",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039762","S2858 Efficacy and Safety of Semaglutide in Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Mohammad Tanshat","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001138892.42646.d3",null,null,"PROSPERO:CRD420251045059",null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0039763","PO-02-064 INCIDENCE OF NEW-ONSET ATRIAL FIBRILLATION IN OBESE, HYPERTENSIVE PATIENTS AFTER INITIATING GLP-1 RECEPTOR AGONISTS","Ari Kaganovsky","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.455",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039764","Adolescent Obesity in India: Need for Urgent Policy Action and Multi-sectoral Reform","SV Madhu","2025","Indian Journal of Endocrinology and Metabolism","other","article","10.4103/ijem.ijem_172_25","40416470",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039765","On the Impact of Bariatric Surgery on Glucose Homeostasis","Niclas Abrahamsson","2016","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039766","174-OR: Genetic Variation in GLP-1R Modify the Risk of Hypoglycemia in Response to Intensive Glycemic Control in Adults with Type 2 Diabetes","QIAOCHU XUE","2024","Diabetes","nonrandomized_study","article","10.2337/db24-174-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039767","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-46927-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039768","GLP-1 receptor agonists offer protection against fatty acid induced insulin resistance in 3D kidney spheroids","Ayesha Judge","2021","Endocrine Abstracts","other","article","10.1530/endoabs.77.lb43",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039769","Abstract TP103: Liraglutide Reduces Amyloid-β Deposits and Secondary Damage in the Thalamus After Focal Cortical Infarction in Rats","Anding Xu","2017","Stroke","preclinical","article","10.1161/str.48.suppl_1.tp103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039770","P260 Ultrasound guided percutaneous neuromodulation and low volume superior trunk block (STB-PTNS) to manage a ASA-4 patient to fix a proximal humerus nonunion fracture- case report","Athmaja Thottungal","2025",null,"case_report","article","10.1136/rapm-2025-esra.539",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039771","Diabetic Ketoacidosis and Safety Outcomes With GLP-1 Agonists in Type 1 Diabetes",null,"2026","Endocrine Practice","other","article","10.1016/j.eprac.2026.01.189",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039772","Optimizing glycemic control: clinical utility of exenatide prolonged release injection","Giuseppe Derosa","2012","Dove Medical Press (Taylor and Francis Group)","randomized_trial","article","10.2147/rred.s24237",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review; article"],["R0039773","Impact of GLP 1 Receptor Agonists on Atrial Fibrillation Outcomes in Obese Adults: Real World Evidence From Australia","A. Williamson","2026","Heart Lung and Circulation","nonrandomized_study","article","10.1016/j.hlc.2026.07.760",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0039774","76671 The Safety of GLP1 Receptor Agonist Usage in Mohs Micrographic Surgery Patients","Margo Schoenberg","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.1774",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039775","THE INFLUENCE OF GLP-1RAS (ORAL SEMAGLUTIDE) ON TENSIONAL CONTROL IN DIABETIC PATIENTS WITH CHRONIC RENAL DISEASE","Carlos Mañero Rodríguez","2023","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0000941684.14153.09",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039776","Long non-coding RNA MALAT1 promotes steatosis in HepG2 cells by modulating target gene expression in presence of Exendin-4","Khalifa, Olfa","2023","Qatar National Library","other","article","10.57945/manara.22785668",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract; article"],["R0039777","Comprehensive Metabolic and Hepatic Benefits of Tirzepatide in Type 2 Diabetes: A 4-Month Real-World Evaluation in 132 Patients",null,"2026","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2026.01.211",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039778","4786 COMPARATIVE ANALYSIS OF LARGE LANGUAGE MODEL (LLMS) RESPONSES TO PATIENT QUESTIONS ABOUT GLP-1 RECEPTOR AGONISTS (GLP-1RAS)",null,"2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.02.346",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039779","Identification of Expression and Function of the Glucagon‐like Peptide‐1 Receptor in Gastrointestinal Smooth Muscle","Alexander T May","2017","The FASEB Journal","preclinical","article","10.1096/fasebj.31.1_supplement.888.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039780","Glucagon‐like peptide‐1‐based therapies: new developments and emerging data","Alan J. Garber","2008","Diabetes Obesity and Metabolism","other","article","10.1111/j.1463-1326.2008.00921.x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039781","Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care","Nunes, Anthony P.","2018","Figshare","other","article","10.6084/m9.figshare.5952511",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039782","full-blots of Figs1-3.pptx","Peiwen Wu","2020","Figshare","other","article","10.6084/m9.figshare.12631115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039783","565-P: A Case of Atypical Diabetes, Monogenic Diabetes","RALUCHUKWU ATTAH","2023","Diabetes","case_report","article","10.2337/db23-565-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039784","Abstract #606 Effect of Low Dose Liraglutide in Nondiabetic Obese Patient","Mohammad Zeshaan Rahman","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47245-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039785","Problems of antihypertensive management","Alberto Zanchetti","2017","Journal of Hypertension","randomized_trial","article","10.1097/hjh.0000000000001334","28244898",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039786","POS1232 IMPACT OF GLP-1 RECEPTOR AGONISTS ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ANKYLOSING SPONDYLITIS: A RETROSPECTIVE COHORT STUDY","C. Pena","2025","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1016/j.ard.2025.06.582",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0039787","EFFECT OF SGLT-2 INHIBITOR ON BONE TURNOVER IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES","Wentao Lv","2021",null,"other","article","10.12783/dtssehs/ehla2021/35720",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0039788","405 The Glucagon-like Peptide-1 Analogue Exendin-4 Inhibiting Pancreatic Beta Cells Apoptosis, Increasing Insulin Secretion and Improving Glucose Tolerance in Severely Scalded Rat","Lijun Ma","2018","Journal of Burn Care & Research","preclinical","article","10.1093/jbcr/iry006.327",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039789","Investigation into the effects of sepsis-induced hyperglycaemia on glucose-modulating hormones receptors in hepatocyte and monocyte cell lines","Mahmood Abdullah  Daabo, Hamid","2023","University of Liverpool","preclinical","article","10.17638/03174272",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039790","HTA373 Worth Their Weight? Cost-Effectiveness and Access Decisions for GLP-1 and GIP/GLP-1 Therapies","Rebecca Mackley","2025","Value in Health","other","article","10.1016/j.jval.2025.09.2156",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039791","343. GLP-1 receptor agonist use is associated with reduced systemic complications but increased pseudarthrosis following lumbar spine surgery: a national cohort study","Dhiraj J. Pangal","2026","The Spine Journal","nonrandomized_study","article","10.1016/j.spinee.2026.06.363",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039792","(ID: 267) Utilising MYMEDS-CARDMET questionnaire in supporting medicines optimisation in post myocardial infarction patients with diabetes","Saeed M. Al-Asmary","2025","International Journal of Pharmacy Practice","nonrandomized_study","article","10.1093/ijpp/riaf093.095",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0039793","A tale of two fronts : novel experimental strategies to improve stroke outcome in type 2 diabetes","Dimitra Karampatsi","2024",null,"preclinical","article","10.69622/26781034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039794","103-LB: Impact of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in COVID-19 Patients with Preexisting Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD)","Chi Nguyen","2023","Diabetes","nonrandomized_study","article","10.2337/db23-103-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039795","Enhancing the Action of Incretin Hormones: A New Whey Forward?","Daniel J. Drucker","2006","Endocrinology","other","article","10.1210/en.2006-0494","16777979",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039796","NASH Related Cirrhosis and Hepato-Cellular Carcinoma: A Case Study","Saeed, Aisha","2018","Figshare","other","article","10.6084/m9.figshare.7318901.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0039797","Additional file 6 of Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis","Rossing, Peter","2023","Figshare","other","article","10.6084/m9.figshare.26612690",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039798","Corrigendum",null,"2013","Pediatric Diabetes","other","article","10.1111/pedi.12079",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0039799","1034-P: Liraglutide and Dapagliflozin Induce an Increase in Plasma GLP-1 and GLP-2 Concentrations","Husam Ghanim","2019","Diabetes","randomized_trial","article","10.2337/db19-1034-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039800","S6063 A Gut Reaction: Duodenal Vasculitis Unveiled After Mounjaro Use","Charitha Karanam Ramapathy","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001152712.49771.c7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039801","EPH84 Estimated Healthcare Resource Utilization and Costs Associated With Semaglutide Life Expectancy Gains in a Real-World Population With CVD and Overweight or Obesity in the United Kingdom","Steven H J Hageman","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.09.1213",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039802","PDB5 Efficacy and Safety of Liraglutide 1.2Mg and Exenatide 10Mcg Twice Daily in Type 2 Diabetes Mellitus: A Systemtic Review and Meta-Analysis","Q. Ye","2012","Value in Health","systematic_review","article","10.1016/j.jval.2012.03.926",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0039803","An Extensive Review of Semaglutide: A Comprehensive Analysis of its Role in Modern Metabolic Medicine","Vedanshu Malviya","2026","Asian Journal of Pharmaceutical Research","other_trial","article","10.52711/2231-5691.2026.00050",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039804","B24-09 Glp-1 Receptor Agonist Use Is Associated With Improved Survival and Reduced Hospitalizations in COPD Patients With Obesity","A Obeidat","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.1768",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039805","Lilly to invest $4.5 billion in Indiana","Aayushi Pratap","2024","C&EN Global Enterprise","other","article","10.1021/cen-10231-buscon13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039806","Prescribing Paradigm Shift? Damned If You Do, Damned If You Don’t","Nikolaus Marx","2020","Diabetes Care","randomized_trial","article","10.2337/dci20-0027","32910774",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039807","Preferences For Treatment Attributes Of Dulaglutide And Liraglutide Among Patients With Type 2 Diabetes Mellitus And Their Willingness To Self-Inject Diabetes Medication: A Comparison Between Japan And The United Kingdom","HL Gelhorn","2016","Value in Health","other","article","10.1016/j.jval.2016.08.201",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039808","Once-Daily Oral Semaglutide Versus Injectable Glp 1 RAs in People With Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-Analysis","Of, Adis Journals On Behalf","2021","Figshare","systematic_review","article","10.6084/m9.figshare.13953326",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0039809","Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population","Nguyen, Hiep","2018","Figshare","other","article","10.6084/m9.figshare.6411173",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039810","Abstract PD8-02: Evaluating weight loss outcomes in patients with hormone receptor-positive breast cancer on endocrine therapy receiving concurrent weight loss medications","Travis E. Adamson","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-pd8-02",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039811","Abstract 13263: Utilization of Proteomic Surrogates for Early Detection of Unexpected Drug Benefits","Jessica Chadwick","2023","Circulation","other_trial","article","10.1161/circ.148.suppl_1.13263",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0039812","Integrated Yeast‐mammalian Assay System for Screening of Novel Peptides Activating Glucagon‐like Peptide‐1 Receptor","Kouichi Kuroda","2016","The FASEB Journal","other","article","10.1096/fasebj.30.1_supplement.1269.7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039813","The crosstalk between incretins, endothelial cells and adipocytes in cardiometabolic disease","N Krajic","2026","Cardiovascular Research","other","article","10.1093/cvr/cvag092.151",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039814","S2613 Assessing the Effects of Glucagon-Like Peptide-1 Agonists and Lifestyle Changes on Fibrosis and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease","Jason N. Chen","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137912.22199.46",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039815","Cardioprotective Effects of Exenatide In Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention; Results of Exenatide Myocardial Protection in Revascularization (EMPIRE) Study","Jong Shin Woo","2013","The American Journal of Cardiology","other","article","10.1016/j.amjcard.2013.01.012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039816","Semaglutide settimanale per il trattamento della gonartrosi obesità-relata","Valerio Velardi","2025","L Endocrinologo","other","article","10.1007/s40619-025-01640-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039817","G-047 Rapid Weight Loss by Semaglutide Causing Severe Orthostatic Hypotension in a CKD Patient With Parkinson's Disease",null,"2025","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2025.02.048",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039818","ALL-CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ATRIAL FIBRILLATION","Aravinthan Vignarajah","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00543-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039819","PO421 THE SHORT TERM EFFECTS OF SUBCUTANEOUS ADMINISTRATION OF EXENDIN-4 ON BODY COMPOSITION, HBA1C, LIPID, PWV ON OBESE TYPE 2 DIABETES MELLITUS","David M. Lim","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70715-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039820","S3236 Balancing Blame: Acute Pancreatitis in the Setting of Hypertriglyceridemia and GLP-1 Therapy","Srishti Kulshrestha","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001140404.50047.09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039821","Effectiveness of carbohydrate diet restriction in type 2 diabetes mellitus on insulin and incretin-based therapies","Raju Panta","2018","Asian Pacific Journal of Health Sciences","other","article","10.21276/apjhs.2018.5.1.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039822","Medication assisted treatment for substance use disorder","Maheen Naeem","2026","Journal of the Pakistan Medical Association","preclinical","article","10.47391/jpma.31816","42363359",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039823","GLP-1 receptor agonist therapy and cancer risk and mortality in patients with moderate CKD: A national matched cohort study of 58,000 patients.","Muneeb Asad","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.10583",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039824","1737-P: Efficacy, Glycemic Variability, and Safety of Insulin Icodec Combined with Semaglutide in Simplifying Complex Polypharmacy for Uncontrolled Type 2 Diabetes: A Retrospective Study","XIXI ZHU","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1737-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039825","Bounded Semaglutide once signal: 69%-79% of participants achieved ≥10% weight loss with semaglutide 2.4 mg (vs. 12%-27% with placebo)","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/y3cjg",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039826","New product intros (avapritinib, benzhydrocodone hydrochloride/acetaminophen (new combination), crizanlizumab-tmca (first-in-class), enfortumab vedotin-ejfv (first-in-class), givosiran (first-in-class), lasmiditan succinate (first-in-class), semaglutide (new indication), ubrogepant)",null,"2020","Drugs of today","other","article","10.1358/dot.2020.56.2.3138014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039827","Analysis of drug development risks for metabolic dysfunction-associated steatotic liver disease from a sustainable accounting perspective","Xiyan Liu","2026","Cost Effectiveness and Resource Allocation","other","article","10.1186/s12962-026-00804-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039828","Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review","Qingxing Xie","2023","Chinese Medical Journal","systematic_review","article","10.1097/cm9.0000000000002778","37464470",null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0039829","Evaluating the Effects of GLP‐1 Receptor Agonists on Long‐COVID Outcomes: A Comparative Analysis Using TriNetX","Cooper K. Allenbrand","2025","PM&R","other","article","10.1002/pmrj.11_70065","41363278",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039830","743-P: Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials","CAROL H. WYSHAM","2022","Diabetes","other_trial","article","10.2337/db22-743-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039831","How uniform is cAMP signaling? Focus on “Systems analysis of GLP-1 receptor signaling in pancreatic β-cells”","Robert D. Harvey","2011","American Journal of Physiology-Cell Physiology","preclinical","article","10.1152/ajpcell.00245.2011","21775708",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039832","Building a healthier future to prevent aortic stenosis","Benoît J. Arsenault","2025","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwaf229","40685648",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0039833","21-PUB: GLP-1 Receptor Agonist–Based Therapy in Early Type 1 Diabetes","Koji Kashima","2026","Diabetes","nonrandomized_study","article","10.2337/db26-21-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039834","A 2-es típusú diabetes mellitus antihiperglikémiás kezelésének változása Magyarországon 2015-2020 között - adatbázis-elemzés országos adatai [Changing patterns of antihyperglycaemic treatment among patients with type 2 diabetes in Hungary between 2015 and 2020 – nationwide data from a register-based analysis]","Jermendy, György","2022","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0039835","GLP-1 RA Drugs Not Associated With Increased Suicidal Thoughts","Samantha Anderer","2024","JAMA","other","article","10.1001/jama.2024.14872","39120897",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039836","Forever (BMI) 21: A Case of GLP-1 Agonist Usage in a T1DM Patient Resulting in Improved Insulin Burden, A1C, BMI, and Hypoglycemia Rates",null,"2026","Endocrine Practice","case_report","article","10.1016/j.eprac.2026.01.250",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039837","Real-world Use of Oral Semaglutide in Adults with Type 2 Diabetes: the PIONEER REAL Switzerland Multicentre, Prospective, Observational Study","Adis Journals On Behalf Of:","2023","Figshare","nonrandomized_study","article","10.6084/m9.figshare.24807525.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0039838","GLP-1 Receptor Agonists Across Different Levels of Physical Activity and Lifestyle: A Bayesian Network Meta-Analysis in Adults Who Are Overweight or Obese","Jiaqi Duan","2026","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.7205699",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0039839","174 Mapping GLP-1 Receptor Agonist Prescribing Across the United States, 2010–2022","E Wu","2026","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2026.103217",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039840","WCN26-3099 Normal Protein Catabolic Rate (nPCR) as a Predictor of Weight Loss in Hemodialysis Patients Treated with Tirzepatide","Jyunichiro Hashiguchi","2026","Kidney International Reports","other","article","10.1016/j.ekir.2026.104725",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039841","S755 The Effect of GLP-1 Receptor Agonists on Whole Gut Gastrointestinal Motility Using Wireless Motility Capsule","Michael Cymbal","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032388.64356.b1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039842","American Diabetes Association Annual Meeting, June 2003","Zachary T. Bloomgarden","2003","Diabetes Care","other","article","10.2337/diacare.26.10.2941","14514605",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039843","Diabetes mellitus and COVID-19: The ominous duo","SanjayKumar Bhadada","2020","International Journal of Noncommunicable Diseases","nonrandomized_study","article","10.4103/jncd.jncd_65_20",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0039844","Diabetes UK Type 2 Diabetes Research Award",null,"2015","Diabetic Medicine","other","article","10.1111/dme.12665_9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039845","AS-0173 Effect of Semaglutide on Cardiac Resynchronization Therapy Outcomes","Qiang Xu","2025","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2025.09.1556",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039846","Neurogenic hypothesis of antiobesity action: is it on the horizon?","David Petřík","2025","Obesity and Endocrinology","preclinical","article","10.1093/obendo/wjaf014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039847","Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD–scid IL-2rgnull RIP-DTR mice engrafted with human islets","Chaoxing Yang","2015","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039848","Abstract P230: Glucagon-like Peptide-1-induced Increases in Afferent Renal Nerve Activity and Renal Sodium Excretion: Role of Trpv1","Beihua Zhong","2015","Hypertension","preclinical","article","10.1161/hyp.66.suppl_1.p230",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039849","Semaglutide and atrial fibrillation: a systematic review and meta-analysis","M J Primo","2026","European Journal of Heart Failure","systematic_review","article","10.1093/ejhf/xuag193.1364",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0039850","GLP-1 receptor agonists and microvascular complications in type 2 diabetes mellitus: an integrative literature review","Isabela Midori Ramalho Moreira","2026","International Health Sciences Review","narrative_review","article","10.70164/ihsr.v2i1.111",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039851","Specialty Specific Guidance: A Cardiologist's Guide to Using GLP-1 Receptor Agonists in Patients Who Are Obese","Nasir Mustafa","2026",null,"other","article","10.13140/rg.2.2.21231.09125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039852","The effect of GLP-1 on the reproductive axis of the ewe","Elizabeth; id_orcid 0000-0001-5107-9300 Jones","2024","Charles Sturt University Research Output (CRO)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039853","Identification of dynamic markers for multiple myeloma in patients with MGUS and T2DM","Mei Wang","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-5784",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0039854","3 The effects of liraglutide on endothelial cell-derived extracellular vesicles","D. Ganesh","2024",null,"preclinical","article","10.1136/heartjnl-2024-bscr.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0039855","Liraglutide prevents right ventricle hypertrophy by avoiding ACE1 & ACE2 reduction in an experimental model of idiopathic pulmonary fibrosis","Juan Fandiño","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.gp52",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039856","S2830 Alcohol Use Reduction With GLP-1 Agonist Use","Nishani Wickramarachchi","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001138780.07976.e4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039857","A discrete choice experiment to understand preferences of patients with type 2 diabetes about the attributes of GLP1 receptor agonists in Spain","San José Terrón, Patricia","2024","Figshare","other","article","10.6084/m9.figshare.27159363.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039858","Advantages of GLP-1 receptor agonist therapy in comorbid patients with type 2 diabetes mellitus","Koteshkova O.M. Koteshkova","2025","Фарматека","other","article","10.18565/pharmateca.2025.8.34-43",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039859","Мултицентрична, ретроспективна студија која ја анализира гликемиската контрола кај една група на GLP-1 наивни пациенти со дијабетес тип 2 кои биле поставени на еднаш неделна терапија со semaglutide (OZEMPIC) во рутинска клиничка пракса во С. Македонија. Број на протоко: NN9535-4976","Mickovski, Ivana","2022","Goce Delchev University Repository (Goce Delčev University of Štip)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0039860","Different weight-loss and hypoglycemic effects of exenatide and insulin treatment of patients with newly diagnosed T2DM combined with obesity","Xuebin Liu","2018","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039861","Glucagon-like Peptide 1 Receptor Agonist Use is Associated with Decreased Risk of Postoperative Complications Following Total Shoulder Arthroplasty: A Propensity Matched Comparison","Bowers, Cameron","2025",null,"nonrandomized_study","article","10.13140/rg.2.2.10647.48808",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0039862","Falsified versions of GLP-1 receptor agonists reported",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-46014-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039863","860-P: Effects of the Combination Treatment with SGLT2 Inhibitors and GLP1 Receptor Agonists among Japanese Patients with Type 2 Diabetes Mellitus and Obesity","Takaya Matsushita","2024","Diabetes","nonrandomized_study","article","10.2337/db24-860-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039864","G-145 Weight Loss or Kidney Loss: An Awareness of Ozempic (Semaglutide)-Induced Acute Kidney Injury",null,"2025","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2025.02.146",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039865","Long-Term Effectiveness of Liraglutide in Association with Patients’ Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study","Berkovic, Maja Cigrovski","2018","Figshare","nonrandomized_study","article","10.6084/m9.figshare.5904754",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0039866","Determination of Chloride, Sulfate, Trifluoroacetic acid, Phosphate, Sodium and Ammonium from Semaglutide by Ion Chromatography","Chetan Chavan","2022","International Journal of Science and Research (IJSR)","other","article","10.21275/sr22214102902",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039867","The effect of lixisenatide on post-prandial blood glucose and glucagon in type 1 diabetes","Chitrabhanu Ballav","2018","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039868","1006-P: Real-World Effectiveness of Semaglutide in Early Users from a U.S. Commercially Insured (CI) and Medicare Advantage (MA) Population","Jay Visaria","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1006-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039869","CA-110: Étude DUAL III : efficacité et tolérance de l'association degludec/liraglutide (IDegLira) chez les patients diabétiques de type 2 naïfs d'insuline et insuffisamment contrôlés par agonistes du récepteur du GLP-1","S. Madani","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30242-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039870","Effect of Glucagon-like peptide-1 receptor agonists on dyslipidemia in type 2 diabetes","Elizabeth Cristiano","2020","American Journal of Preventive Cardiology","other","article","10.1016/j.ajpc.2020.100058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039871","The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients","Simeon I. Taylor","2020","Diabetes Care","other","article","10.2337/dci20-0039","32958616",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039872","PHARMACOLOGICAL MODULATORS OF APPETITE AND METABOLISM IN OBESITY MANAGEMENT","Mashal Shahzadi","2025","Biology and Biotechnology Communications","randomized_trial","article","10.67079/bbc.0232",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039873","Advances in the Treatment of Overweight and Obesity: An Opportunity to Improve Public Health in Peru","Atrith N. Pedroso-Limaymanta","2025","Indian Journal of Endocrinology and Metabolism","other","article","10.4103/ijem.ijem_507_24","40416460",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039874","Combination of liraglutide and sitagliptin therapy improves glycemic control in Japanese patients with type 2 diabetes mellitus","Yuki Matsuhashi","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31166-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039875","227-OR: Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo Regardless of Insulin Sensitivity and Beta-Cell Function—Post Hoc Analysis from SURMOUNT-2","TIM HEISE","2024","Diabetes","other","article","10.2337/db24-227-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039876","104-OR: State-Dependent Activity in Hindbrain Glucagon-Like Peptide 1—Producing Neurons Regulates Consummatory and Valence Behavior through Functionally Interconnected Hypothalamic and Limbic Circuits","Miguel A. Duran","2024","Diabetes","preclinical","article","10.2337/db24-104-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039877","6ER-007 Cost-effectiveness of novel therapies in cardio-renal-metabolic syndrome: a systematic review","I Di Cesare","2026",null,"systematic_review","article","10.1136/ejhpharm-2026-eahp.607",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-paper"],["R0039878","L26/P-775 Impact of semaglutide on fertility and reproductive outcomes in female mice","X. Han","2026","Human Reproduction","other_trial","article","10.1093/humrep/deag083.1102",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0039879","Delphi Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies","Of, Adis Journals On Behalf","2021","Figshare","other","article","10.6084/m9.figshare.13622792",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0039880","A Case Series of Tirzepatide Treatment in Patients with Type 2 Diabetes, Chylomicronemia and Genetic Variants Affecting Lipoprotein Lipase","Stephan P. Babirak","2025","Medical Research Archives","case_report","article","10.18103/mra.v13i2.6229",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039881","Semaglutide Augments Vascular Proliferation and Cardiac Performance in a Large Animal Model of Ischemic Cardiomyopathy","Muir, Kelsey","2025","Figshare","randomized_trial","article","10.6084/m9.figshare.30801743.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0039882","3092-LB: Effect of Obesity Management Medications on Physical Function: A Systematic Review and Meta-analysis","Alexandra Peary","2026","Diabetes","systematic_review","article","10.2337/db26-3092-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0039883","1028-P: Rates of GLP1 Prescription in Patients with T2D after MI Are Poor Even among Patients Willing to Inject Insulin","ASEEL A. DWEIK","2023","Diabetes","other","article","10.2337/db23-1028-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039884","Postprandial hyperglycemia: Why do we care about it? What should we do?","Marc Rendell","2006","Drug Development Research","other","article","10.1002/ddr.20127",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039885","EE343 COST-EFFECTIVENESS OF SEMAGLUTIDE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS UNDER MEDICARE DRUG PRICE NEGOTIATIONS","Siang-Hao Cheng","2026","Value in Health","other","article","10.1016/j.jval.2026.03.637",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039886","Systematic review of stroke outcomes during clinical studies of glucagon like peptide-1 receptor agonists (GLP-1RAs)","Maskery, Mark P","2019",null,"systematic_review","article","10.13140/rg.2.2.19552.23045",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0039887","P1011CARDIOVASCULAR OUTCOME TRIALS (CVOT) USING NEW ANTI-DIABETIC AGENTS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Nadia Sarween","2020","Nephrology Dialysis Transplantation","systematic_review","article","10.1093/ndt/gfaa142.p1011",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0039888","Journal of Diabetes NEWS",null,"2013","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12109",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039889","Different roles of brain uroguanylin and brown adipose tissue in males and females","Nikola Habek","2026","Biology of Sex Differences","preclinical","article","10.1186/s13293-026-00965-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039890","947-P: Semaglutide Added to Treatment or Changed from Other GLP-1 Receptor Agonist in Type 2 Diabetes: A Study to Evaluate Real-World Effectiveness","Juan Carlos Ferrer-García","2020","Diabetes","nonrandomized_study","article","10.2337/db20-947-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039891","0221 Impact of GLP-1 receptor agonists on the risk of inflammatory arthropathies in patients with hidradenitis suppurativa: A population-based cohort study","A. Ure","2026","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2026.06.252",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0039892","Male Infertility in Diabetes Mellitus","A B Kamrul-Hasan","2023","Bangladesh Journal of Endocrinology and Metabolism","other","article","10.4103/bjem.bjem_8_23",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039893","Lilly touts results for once-daily weight-loss pill","Aayushi Pratap","2025","C&EN Global Enterprise","other_trial","article","10.1021/cen-10311-buscon2",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0039894","P3‐492: Neuroprotective effects of exendin‐4 in animal models of Parkinson's disease","Peter S. Whitton","2011","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2011.05.1937",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039895","PS2 - 3. The effect of INGAP, FGF7 and a GLP-1R agonist on the differentiation of primary human duct cells towards beta cells","Jeetindra R. A. Balak","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0071-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039896","Early Real-World Sex-Stratified Phenotypic Patterns of GLP-1 Receptor Agonist Initiation Following Recent Launch in India",null,"2026","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2026.03.021",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039897","1126 Switching Patterns of GLP-1 Receptor Agonists among Patients in a Pharmacist-Prescribed Collaborative Practice Diabetes Management Program","E. Bolaske","2025","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2025.102609",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039898","Orforglipron is associated with improvements in markers of beta-cell function and insulin sensitivity when used as monotherapy in participants with type 2 diabetes","L Ludwig","2026","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0046-1819875",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0039899","Looming GLP-1 drug patent expirations draw generics firms","Aayushi Pratap","2026","C&EN Global Enterprise","other","article","10.1021/cen-10401-feature17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039900","Informe científico de investigador: Donnamaria, María Cristina (2011-2012)","Donnamaria, María Cristina","2012","Americanae (AECID Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0039901","Abstract 13519: US Population Eligibility and Estimated Impact of Tirzepatide on Obesity Prevalence and Preventable Cardiovascular Disease Events in US Adults","Nathan D. Wong","2023","Circulation","other_trial","article","10.1161/circ.148.suppl_1.13519",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0039902","Risk Factors in Coronary Heart Disease","William B. Kannel","1964","Annals of Internal Medicine","randomized_trial","article","10.7326/0003-4819-61-5-888","14233810",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039903","GLP-1 start-up Metsera launches with $290 million","Rowan Walrath","2024","C&EN Global Enterprise","other","article","10.1021/cen-10213-buscon4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0039904","786-P: Demographic and Clinical Characteristics Associated with Real-World Persistence on Semaglutide for Weight Management in the USA","William H. Polonsky","2025","Diabetes","nonrandomized_study","article","10.2337/db25-786-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039905","76151 GLP-1 receptor agonists-associated skin events: identifying the most common culprits and reactions","Anagha B. Thiagarajan","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.953",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039906","S3497 A Cautionary Tale in Obesity Management: A Rare Case of Tirzepatide-Associated Functional Gastric Outlet Obstruction","Mina Iskander","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001043356.57259.1f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039907","Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial","Kalra, Sanjay","2018","Figshare","other_trial","article","10.6084/m9.figshare.6210836",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other; article"],["R0039908","GLP-1 receptor agonists and cardiovascular safety","Yu‐Yao Huang","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)30931-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039909","Real-world evaluation of cardiometabolic outcomes with liraglutide and adjunctive therapies in type 2 diabetes","Saleem Qureshi","2025","Discover Endocrinology and Metabolism","nonrandomized_study","article","10.1007/s44417-024-00001-w",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039910","1652-P: The Effectiveness of Semaglutide on Glucose Tolerance and Body Composition in Obese Diabetic Rhesus Monkeys","ZUNYUAN YANG","2024","Diabetes","randomized_trial","article","10.2337/db24-1652-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039911","Indices of beta‐cell function: association with diabetes control in patients with type 2 diabetes on stable GLP ‐1 agonist treatment","Preeshila Behary","2014","Practical Diabetes","other","article","10.1002/pdi.1867",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039912","GLP-1 Receptor Agonists and Substance Use Disorder: A Systematized Literature Review","Jesse Shantz","2025","Mspace (University of Manitoba)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0039913","Efficacy of Semaglutide in Treating Obesity in Nondiabetics","Gilroy, Tara","2023","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039914","Prevalence of Weight Related Comorbidities and Eligibility for Tirzepatide in an Acute Adult Psychiatric Inpatient Population Prescribed Antipsychotics in Northern Ireland","Emma Norris","2026","BJPsych Open","nonrandomized_study","article","10.1192/bjo.2026.11803",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039915","CO11 IMPACT OF GLP-1 RECEPTOR AGONIST (GLP-1 RAS) PERSISTENCE VERSUS DISCONTINUATION ON CARDIOMETABOLIC MEASURES IN POLYCYSTIC OVARY SYNDROME (PCOS) OVER A TWO-YEAR FOLLOW-UP","I Winer","2026","Value in Health","other","article","10.1016/j.jval.2026.03.106",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039916","Sa1512: OUTCOMES IN LIVER TRANSPLANT RECIPIENTS WITH TYPE 2 DIABETES; A COMPARISON OF GLP-1 RECEPTOR AGONISTS AND NONGLP-1 THERAPIES","Sajid Jalil","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04732-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039917","GLP-1 receptor agonists for weight loss, benefits and risks: A systematic review of the literature","Silva Pacheco de Moraes, Diego","2024","Dialnet (Universidad de la Rioja)","systematic_review","article","10.56294/sctconf2024.719",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0039918","CO205 Real-World Evidence on the Broader Benefits of GLP-1RA-Based Therapies: A Global Targeted Literature Review","Katherine L. Gibbs","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.09.306",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0039919","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-37674-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039920","2831-LB: GLP-1R in JBMMSCs Suppressed Jaw Bone Osteoporosis via Modulating PKA/STAT3/TET3/SHP2/ß-catenin Signaling–Induced Osteoblast Differentiation","Huiming Liu","2026","Diabetes","preclinical","article","10.2337/db26-2831-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039921","1699-P: Effect of Bofanglutide on the Pharmacokinetics of Metformin in Healthy Participants","JIN WANG","2026","Diabetes","other","article","10.2337/db26-1699-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039922","Abstract #270 Clinical Experience in the use of Glp 1 Analogs in an Endocrinology Outpatient Clinic in Tegucigalpa, Honduras","María Alejandra Ramos Guifarro","2019","Endocrine Practice","other","article","10.1016/s1530-891x(20)46614-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039923","378-P: Enhanced Renal Protective Effects of Tirzepatide in T2D People","Shizuka Kaneko","2025","Diabetes","nonrandomized_study","article","10.2337/db25-378-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039924","Preserving Muscle Mass During GLP-1RA Induced Weight Loss Using Combined HIFEM and Synchronized Radiofrequency Technology","Jeannie McCoy","2025","Archives of Clinical and Biomedical Research","other","article","10.26502/acbr.50170468",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039925","Abstract 171","D Shabeer","2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.363677",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0039926","1034-OR: Efficacy and Safety of Dual GLP-1/GIP Receptor Agonist HDM1005 in Obese Participants without Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial","XIAOYING LI","2026","Diabetes","randomized_trial","article","10.2337/db26-1034-or",null,null,"ClinicalTrials.gov:NCT06886126","S003263","openalex","FALSE","paywalled","1","FALSE","article"],["R0039927","1779-P: Liraglutide + Metformin Delays Worsening of Glycemia in Adults with Impaired Glucose Tolerance (IGT) or Type 2 Diabetes (T2D)","Susan Sam","2020","Diabetes","randomized_trial","article","10.2337/db20-1779-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039928","442-P: Comparative Study of the Effects of GLP-1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms","Elsayed A. Eid","2020","Diabetes","preclinical","article","10.2337/db20-442-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039929","TCT-494 Cost-Effectiveness of SGLT2 Inhibitors, Statins, and GLP-1 Receptor Agonists for Cardiovascular Secondary Prevention: A Comparative Analysis","Mehmet Cilingiroglu","2025","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2025.09.624",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039930","Enhanced survival of human mesenchymal stem cells following co-delivery with glucagon-like peptide-1 analogue in fibrin gel","Hyerim Jin","2014","Journal of Pharmaceutical Investigation","other","article","10.1007/s40005-014-0156-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039931","Lilly (Eli) & Co.",null,"2006","Mergent s Dividend Achievers","other","article","10.1002/div.5219",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039932","Mo1585: PRACTICE PATTERNS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST MEDICATION PRESCRIPTION IN PATIENTS WITH DIABETES FOLLOWING BILIARY PANCREATITIS AND CHOLECYSTECTOMY: A MUTI-NETWORK POPULATION STUDY","Gordon Hong","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)05018-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0039933","Updates in Cardiology from January to May 2025","Praveen Nagula","2025","Indian Journal of Clinical Cardiology","other","article","10.1177/26324636251353264",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039934","Semaglutide/Tacrolimus",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-51246-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039935","Exénatide (Byetta®) : nouvelles données d’utilisation à long terme","J.-P. Sauvanet","2010","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(10)70112-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039936","75345 GLP-1 Receptor Agonists and Treatment Utilization in Cicatricial Alopecia: A Retrospective Cohort Study","Henry Herrera","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.952",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039937","Modern concepts of pleiotropic effects of semaglutide in a wide population of patients","Demidova T.Yu. Demidova","2025","Therapy","other","article","10.18565/therapy.2025.3.145-154",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039938","GLP-1 Receptor Agonist Liraglutide Increased IVF Pregnancy Rates in Obese Women with PCOS and Previous Poor Response to First-Line Reproductive Treatments","Andrej Janež","2018","Diabetes","randomized_trial","article","10.2337/db18-1465-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0039939","0339 Limitations of hurley staging in assessing response to GLP-1 therapy in hidradenitis suppurativa","M. Von Lotten","2026","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2026.06.370",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039940","FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes","Shravya Pant","2025","JAMA","other","article","10.1001/jama.2025.19724","41201832",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039941","Cardiometabolic medicine: time to recognize a new clinical specialty?","Andrew J. Krentz","2019","Cardiovascular Endocrinology & Metabolism","other","article","10.1097/xce.0000000000000173","31588426",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039942","1688-P: Addition of GLP-1 Analogs to DM1 Patients Using Automatic Insulin Delivery (AID) (MiniMed 780G): A Retrospective Real-Life Study","W Fernando Trigoso","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1688-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0039943","Investigating individual variability and therapeutic targets in alcohol and opioid use disorders","HELA MRIZAK","2026","Unicam Scientific Publications (University of Camerino)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0039944","Antiobesity Effect of Peripheral Exendin-4 and/or Exercise in High-Fat Diet-Induced Obese C57bl/6 Mice","Hayder Abdullah A","2016","Pakistan Journal of Nutrition","preclinical","article","10.3923/pjn.2016.379.385",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039945","New product intros (bupivacaine/meloxicam (new combination), lazertinib, odevixibat, ozanimod hydrochloride (new indication), pegcetacoplan (first-in-class), regdanvimab, relugolix/estradiol/norethisterone acetate (new combination), savolitinib, semaglutide (new indication), serdexmethylphenidate/dexmethylphenidate (new combination), tenofovir amibufenamide fumarate, tralokinumab, upadacitinib tartrate (new indications))",null,"2021","Drugs of today","other","article","10.1358/dot.2021.57.9.3358201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039946","The role of glucagon-like-peptide 1 in patients with suboptimal weight loss following bariatric surgery","Jessica Mok","2025","UCL Discovery (University College London)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0039947","The Current Status and Challenges of Integrative Chinese and Western Medicine in the Treatment and Management of Prediabetes from a Proactive Health Perspective","PENG  Hongye, LU  Chunli","2025","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article","10.12114/j.issn.1007-9572.2024.0242",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0039948","COMPARAÇÃO DIRETA ENTRE OZEMPIC (SEMAGLUTIDA) E MOUNJARO (TIRZEPATIDA) NA PERDA DE PESO E CONTROLE GLICÊMICO: ANÁLISE DE ESTUDOS CLÍNICOS RECENTES","Michele Carvalho Alves Egüez Jelski","2025","Asclepius International Journal of Scientific Health Science","other","article","10.70779/aijshs.v4i12.465",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039949","652-P: Patients with Diabetes at High Cardiovascular Risk with Chronic Kidney Disease: Online Virtual Simulation Improves Clinical Decisions","Joachim Trier","2020","Diabetes","other","article","10.2337/db20-652-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039950","Prospects of antidiabetic drugs in the treatment of neurodegenerative disease","Lidan Hu","2024","Brain‐X","other","article","10.1002/brx2.52",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039951","DECIPHERING THE PUZZLE","Yik Zhi Kum","2024","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.039.s1.072",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039952","Nephrotoxicity in Diabetes and Obesity: Mechanisms, Biomarkers, and Therapeutic Interventions","Niwarinda Arnold","2025","NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY","other","article","10.59298/nijpp/2025/63124129",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039953","The link between college students’ perspectives on GLP-1 agonists and fat stigma","Meghan J. Gangel","2026","Fat Studies","other","article","10.1080/21604851.2026.2631235",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039954","Comparative effects of liraglutide and dapagliflozin on lipid profile and cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: a 6-month randomized study","Artem Akimov","2025","Ukrainian Scientific Medical Youth Journal","randomized_trial","article","10.32345/usmyj.4(158).2025.17-26",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039955","ALCOHOL-INDUCED REVERSAL OF SEMAGLUTIDE'S GLYCAEMIC BENEFITS","Kalaivani Sathiyamoorthi","2025","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.040.s1.021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039956","Transdermal Drug Delivery Strategies for Antidiabetic Therapy: Current Progress and Future Perspectives of Dapagliflozin","Yamini Verma","2026","International Journal of Advanced Multidisciplinary Research and Studies","other","article","10.62225/2583049x.2026.6.3.6450",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039957","Clinical Evaluation of Novel Antidiabetic Molecules","Ivan Schmidt","2022","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.19511451",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0039958","A Critical Review on Diabetes Mellitus Type 1 and Type 2 Management Approaches: From Lifestyle Modification to Current and Novel Targets and Therapeutic Agents","Apeksha D. Pawar","2025","International Journal of Advanced Research in Science Communication and Technology","narrative_review","article","10.48175/ijarsct-29628",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039959","“Postfeminist ‘Thin’ Feminities”","Tina Sikka","2025","Journal of femininities.","other","article","10.1163/29501229-bja10020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039960","Evaluating Dose Titration in Semaglutide and Tirzepatide for Weight Loss: A Retrospective Academic Call Center Study","Goar Alvarez","2025","Obesities","nonrandomized_study","article","10.3390/obesities5040090",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039961","Knowledge gaps in the 2024 consensus statement on atrial fibrillation ablation","Jonathan M. Kalman","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf175","40325605",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039962","Treatment of people with type 1 diabetes with Semaglutide or Tirzepatide – Relevant in the future?","Sten Madsbad","2025","Medical Research Archives","randomized_trial","article","10.18103/mra.v13i9.6925",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039963","Agonistas del receptor de GLP-1 y enfermedad cardiovascular: de la fisiopatología a la clínica","Paula Terns","2021","Revista de la Federación Argentina de Cardiología","other","article","10.63600/jc27ds66",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039964","GLP-1 medications for weight-loss: a triumph of marketing over patient care","Ragen Chastain","2026","Figshare","randomized_trial","article","10.6084/m9.figshare.31942107.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0039965","GLP-1-agonisten en cardiovasculaire eindpunten bij obesitas zonder diabetes","JP Verlaan","2025","Geneesmiddelenbulletin","other","article","10.35351/gebu.nl.2025.2.6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039966","Semaglutide Peptide On GLP-1 Receptor Agonists and Its Therapeutic Potential to Treat Liver Diseases and Neurodegenerative Disorders","Sophia Velasco","2025",null,"other","article","10.22541/au.175312597.72100584/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039967","CIRROSE HEPÁTICA EM ESTÁGIO AVANÇADO E O PAPEL DO TRANSPLANTE DE FÍGADO: DESAFIOS ATUAIS E PERSPECTIVAS FUTURAS NO MANEJO DE PACIENTES COM DOENÇA HEPÁTICA TERMINAL","Gabriel Duarte do Nascimento","2025","Revista Contemporânea","other","article","10.56083/rcv5n8-058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039968","Hypervisibility meets hyperinvisibility: anti-fatness, moral panics, and mainstream U.S. news coverage of fat people taking Ozempic and Wegovy","Breanne Fahs","2025","Fat Studies","other","article","10.1080/21604851.2025.2529651",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039969","Enhancing Anesthesia Safety: Ultrasound-Guided Gastric Evaluations for Patients Taking Glucagon-Like Peptide-1 Receptor Agonists","Alex Rath","2026","UA Campus Repository (The University of Arizona)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039970","A Scientometrics survey of GLP-1 receptor agonists in neurodegenerative disorders: An evolving paradigm from metabolic to brain health","Nastaran Makoui","2025","Scientometrica","randomized_trial","article","10.5267/j.sci.2025.4.004",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0039971","DIABETIC KIDNEY DISEASE: PREVALENCE, DIAGNOSIS, RISK FACTORS AND TREATMENT",null,"2025","Indian Journal of Health Care Medical & Pharmacy Practice","other","article","10.59551/ijhmp/25832069/2025.6.1.20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039972","#3569 Early clinical experience of finerenone in patient with chronic kidney disease and type 2 diabetes in real Life. Comparison with FIDELITY pooled","Sara Aladro","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.0928",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039973","Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database","Masanori Arai","2018","Diabetes Care","nonrandomized_study","article","10.2337/dc18-0210","30002201",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039974","Effects of Obesity on Human Health and the Emerging Role of GLP-1 Based Therapies","Gauri Bansal","2025","International journal of high school research","other","article","10.36838/v7i3.10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039975","Perspectivas innovadoras en el tratamiento de la obesidad","María Yuma","2025","Revista de la Sociedad Argentina de Diabetes","other","article","10.47196/diab.v59i2sup.1241",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039976","Functional Study on the GLP-1 Based Drug Liraglutide in High Fat Diet Fed Mice","Manroop Khroud","2020","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039977","Semaglutide for the treatment of obesity – a review","Abubakar Bham","2021","World Family Medicine Journal/Middle East Journal of Family Medicine","narrative_review","article","10.5742/mewfm.2021.94116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039978","Food unease: How Ozempic era master narratives burden fat people","Michael Greer","2026","Fat Studies","other","article","10.1080/21604851.2026.2629080",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039979","Hiperfiltración glomerular: : una visión fisiopatológica para entender sus consecuencias y tratamiento","Ardiles, Leopoldo","2025","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039980","Knowledge of Pharmacists in the Management of Diabetes in a Tertiary Hospital","Patel Apurva A","2024","Current Research in Diabetes & Obesity Journal","other","article","10.19080/crdoj.2024.17.555966",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039981","Mounjaro e seu efeito farmacológico","Antônio Levy Carvalho Nobre","2026","Revista fisio&terapia.","other","article","10.69849/3cz4xr10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039982","Vitiligo as a Cutaneous SAP Cascade: A Unified Framework of the Brain's Vascular and Immune Decree Against the Melanocyte","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22038586",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0039983","Obesity Correlates and Weight-Management Practices in a Clozapine-Treated Cohort: A Service Evaluation From Suffolk.","Nada Zahreddine","2026","BJPsych Open","nonrandomized_study","article","10.1192/bjo.2026.11616",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039984","TIRZEPATIDE, NUTRITION AND RESISTANCE TRAINING: EFFECTS ON BODY COMPOSITION, MUSCLE HYPERTROPHY AND METABOLIC HEALTH WITH EMPHASIS ON PUBLIC SAFETY PROFESSIONALS","Raphael Pinto dos Santos","2026","Artefactum","other","article","10.23900/artefactum.v25i3.2948",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039985","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97414-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0039986","Medicalising the Unruly Body: GLP-1 Drugs, Social Control and the Moral Regulation of Body Weight","Violet D. Tobin","2026","University of Africa Journal of Social Inquiry","nonrandomized_study","article","10.63725/uajsi.v1.i1.08",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0039987","GLP-1R agonists for the prevention of cardiac injury in STEMI patients undergoing PCI: Something new and promising, or not?","Xian Wu Cheng","2013","IJC Metabolic & Endocrine","other","article","10.1016/j.ijcme.2013.10.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039988","Impact of Diabetes Mellitus Type 2 on the Development of Alzheimer’s Disease","Maria Isabel Gomez-Coral","2024","Open access Journal of Neurology & Neurosurgery","other","article","10.19080/oajnn.2024.19.556004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039989","GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells","弘幸 高橋",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0039990","GLP-1 en trastornos por uso de sustancias: Neurobiología, evidencia clínica y agenda de investigación","Marlene Concepción Espínola Zárate","2026","Dialnet (Universidad de la Rioja)","randomized_trial","article","10.5281/zenodo.20580232",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0039991","Diabetes Impact on Cardiovascular Disorders",null,"2026",null,"other","article","10.47278/book.tl/2026.134",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0039992","Oral hygiene habits in patients taking glucagon like peptide-1 analogues","Jankowska Aleksandra","2025","Pomeranian Journal of Life Sciences","other","article","10.21164/pomjlifesci.1121",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039993","Oral Anti-Diabetic Semaglutide: A GLP-1 RA Peptide","Richa Kahol","2024","International Journal of Innovative Science and Research Technology (IJISRT)","other","article","10.38124/ijisrt/ijisrt24jun1950",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039994","Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action","Kevin Zhan","2026","Annals of Clinical Pathology","preclinical","article","10.47739/pathology1186",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039995","The effects of GLP-1 RAs compared to DPP4is or SGLT2is on appendicular lean mass index (ALMI): an interim analysis.","Mackenzie Alexiuk","2026","Mspace (University of Manitoba)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0039996","Relationship between food addiction and the use of appetite-reducing drugs among medical students","T. C. García","2026","European Psychiatry","other","article","10.1192/j.eurpsy.2026.11374",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0039997","Mazdutide: An emerging glucagon/GCG-like peptide-1 dual receptor agonist for obesity—a comparison of therapeutic effects and potential side effects with GCG-like peptide-1 inhibitors","Chen-Xi Deng","2026","World Journal of Pharmacology","other_trial","article","10.5497/wjp.v15.i1.113080",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0039998","GLP-1 Receptor Agonists: Expanding Pharmacological Horizons Beyond Metabolic Disease","Neha Shewale*, Manashri Ahire, Jubershaha Fakir, Chandrashekhar Patil","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22044573",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0039999","A Review on Regional Approaches to Disease Burden, Monitoring, and Control of Diabetes Mellitus and Hypertension Comorbidity","A. I. Omogbiya","2026","Scientia Africana","narrative_review","article","10.4314/sa.v25i3.19",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040000","Modern Approaches to the Treatment of Type 2 Diabetes Mellitus: Personalized Therapy and Prevention of Complications","Grekova Natalia","2026","Journal of chemical health risks","other","article","10.52783/jchr.v16.i4.15879",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040001","Body-Contouring Surgery After GLP-1–Induced Massive Weight Loss: Surgical Outcomes, Complications, and Patient-Reported Quality of Life","Rabab Abbas Hasan","2026","Journal of Medical and Health Studies","nonrandomized_study","article","10.32996/jmhs.2026.7.8.10",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040002","GLP-1 Receptor Agonists and SGLT2 Inhibitors in Diabetes, Obesity, and Kidney Disease: a Global Perspective","Jyoti Baharani","2026","Current Research in Diabetes & Obesity Journal","other_trial","article","10.19080/crdoj.2026.18.555990",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040003","GLP-1 Agonists and the Medicalization of Obesity in Canada: Promise and Pitfalls","Jordan Pham","2026","University of Ottawa Journal of Medicine","other","article","10.18192/uojm.v16i1.7628",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040004","Online illicit trade of GLP-1 receptor agonists on telegram","Filippo Andrei","2026","Trends in Organized Crime","other","article","10.1007/s12117-026-09613-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040005","14 Residual risk in a cardiac rehabilitation population. The value of an MDT approach","SM Fleming","2024",null,"nonrandomized_study","article","10.1136/heartjnl-2024-ics.14",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0040006","A New and Green Analytical Method for the Determination of Glucagon‑Like Peptide‑1 Analogue Semaglutide in Subcutaneous and Oral Pharmaceutical Preparations","Gamze Ergin Kızılçay","2025","International Journal of Peptide Research and Therapeutics","other","article","10.1007/s10989-024-10674-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040007","A Comprehensive Review on Cardiovascular Diseases: Epidemiology, Pathophysiology, and Emerging Therapeutic Strategies","Senthilkumar V.","2026","International journal of research and scientific innovation","other_trial","article","10.51244/ijrsi.2026.1304000006",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040008","Mechanisms behind corticosteroid resistance in obesity-induced airway inflammation – a review","Piotr Włodarczyk","2024","Journal of Medical Science","narrative_review","article","10.20883/medical.e1034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040009","Weekly semaglutide reduces craving in adults with alcohol use disorder",null,"2025","The Brown University Psychopharmacology Update","randomized_trial","article","10.1002/pu.31307",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040010","Semaglutide: muscle loss and the ugly truth behind the weight loss trend","Rodrigo Terán-Garza","2025","Medicina Universitaria","other","article","10.24875/rmu.m25000096",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040011","An Update on Molecular Modes Implicated in Diastolic Impairment in Early Diabetic Cardiomyopathy; Probable Modes of Therapy &Avoidance-A Narrative Review",null,"2023","International journal of cardiology and cardiovascular disorder.","narrative_review","article","10.47485/2998-4513.1015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0040012","Effect of dulaglutide injection on weight beyond glycemic control: real-world observational study","Adel Gassab Mohammed","2023","Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale","nonrandomized_study","article","10.4081/jbr.2023.10643",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040013","A brief approach to hypertension in type 2 diabetes mellitus","Yılmaz Güneş","2025","Exploration of Endocrine and Metabolic Diseases","randomized_trial","article","10.37349/eemd.2025.101422",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040014","Successful necrosectomy using the over-the-scope grasping device: a tool for solid necrotic debris","Rahul Karna","2024","Endoscopy","other","article","10.1055/a-2443-4173","39515769",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040015","Suppressed tonic glucagon, depleted substrate and attenuated warning: hypoglycaemia risk with incretin receptor agonists outside diabetes","Sidário Rodrigues Malheiros-junior","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22018963",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0040016","A Review on Therapeutic Mechanisms and Pharmacological Actions of Incretin-Based Dual and Single Receptor Agonists","Jyothika Taneti","2026","Journal of Pharma Insights and Research.","other_trial","article","10.69613/ne8s3v59",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040017","Effects of GLP-1 receptor agonists on pituitary and adrenal hormones","Heinla, Keiu","2023","DSpace repository (University of Tartu)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040018","Riñon, Diabetes y Metabolismo","SLANH","2025","Revista de la Sociedad Ecuatoriana de Nefrología Diálisis y Trasplante","other","article","10.56867/146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040019","Emerging Role Of Multifaceted Drugs In Diabetes Care","Jayesh Bhawarlal Chaudhari","2025","African Journal of Biomedical Research","other","article","10.53555/ajbr.v27i6s.8507",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040020","Type 2 Diabetes Mellitus: Beyond the Beta Cell","Natalie Morris","2016","EMJ Diabetes","other","article","10.33590/emjdiabet/10311885",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040021","Hemoglobin A1C (A1C) Reduction And Diabetes-Related Health Care Costs Among Type 2 Diabetes (T2DM) Patients Treated With Liraglutide or Exenatide: A Retrospective Claims Database Analysis","Michelle Mocarski","2016","Value in Health","nonrandomized_study","article","10.1016/j.jval.2016.09.1839",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040022","Partial colectomy of small bowel perforation after using dulaglutide: A rare and unexpected complication","Vishnu Jindal","2025","Journal of Clinical Images and Medical Case Reports","other","article","10.52768/2766-7820/3749",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040023","26-A-8880-ACC GLP1 AGONISTS VS SGLT2 INHIBITORS IN CONCURRENT DIABETES MELLITUS AND HEART FAILURE: EVALUATING THE BEST TREATMENT OPTIONS WITH REAL WORLD DATA FROM THE UNITED STATES","Pushan Aggarwal","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1847",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040024","Exploring the Efficacy of Triple Therapy with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists on Cardiovascular and Renal Outcomes in Advanced Heart Failure: A Meta-analysis","Bassem Ashraf","2024","African Journal of Biomedical Research","systematic_review","article","10.53555/ajbr.v27i4s.3624",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040025","Bleeding and thrombosis","Stefan Agewall","2025","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvaf017","40314444",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040026","The Inadvertent Use of Weight-loss Medications may Result in Adverse Health Outcomes","Chitta Ranjan Chowdhury","2026","The British Journal of Translational Global Health","other","article","10.5005/bjotgh-11016-0035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040027","Sugar Addiction and BED: Elucidating Pathological Mechanisms and Therapeutic Strategies","Yingyu Yang","2026","BIO Web of Conferences","other","article","10.1051/bioconf/202623701009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper; article"],["R0040028","The Thyroid as a Gland Under Siege: A Unified Framework for Hypothyroidism, Hashimoto's, Postpartum Thyroiditis, and the Brain's Metabolic Decree","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22021867",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040029","Rise of GLP-1 use for the treatment of obesity and their accessibility across various socioeconomic groups","Manaswi Chigurupati","2025","Journal of medical and dental science research.","other","article","10.35629/076x-12039499",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040030","Effects of valproate and liraglutide in rodent models of Wolfram syndrome: emphasis on transcriptomic changes in the renin–angiotensin–aldosterone system","Punapart, Marite","2024","DSpace repository (University of Tartu)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040031","How Caron uses GLP‐1 agonists in SUD treatment","Alison Knopf","2025","Alcoholism & Drug Abuse Weekly","other","article","10.1002/adaw.34596",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040032","GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Narrative Review of Clinical Effectiveness, Safety, And Future Directions","Harry S Patel","2024","Iconic Research and Engineering Journals","randomized_trial","article","10.64388/irev8i6-1719510",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0040033","Prescribing patterns and impact of glucagon-like peptide-1 receptor agonists in a kidney transplant evaluation cohort in British Columbia, Canada","Hyunwoong Harry Chae","2026","Canadian Urological Association Journal","nonrandomized_study","article","10.5489/cuaj.9689",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040034","Potential Role of GLP-1 Receptor Agonists for the Treatment of Alzheimer's Disease","Tyler Oyang","2025",null,"other","article","10.58445/rars.3139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040035","Đồng vận thụ thể GLP-1: con đường mới trong điều trị vô sinh ở phụ nữ mắc hội trứng buồng trứng đa nang thừa cân béo phì","Thị Ngọc Hân Nguyễn","2024","Vietnam Journal of Diabetes and Endocrinology","other","article","10.47122/vjde.2023.65.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040036","A corpus-assisted multimodal discourse analysis of glucagon-like peptide-1 receptor agonist narratives on TikTok","Nicola Pelizzari","2026","Online Journal of Communication and Media Technologies","other","article","10.30935/ojcmt/18491",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040037","Metabolic-Associated Steatotic Liver Disease and Cognitive Impairment: Shared Pathophysiological Mechanisms and Clinical Implications: A Narrative Review","George P. Roy","2026","JUNIOR RESEARCHERS","randomized_trial","article","10.52340/jr.2026.04.02.02",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0040038","Efficacy and safety of Ozempic: Real-world tertiary care experience from Saudi Arabia","M.I. Butt","2025","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/j.diabres.2025.112615",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040039","Microvascular and Macrovascular Complications of Type 2 Diabetes","Lakshmi Jayaprakash","2024","Journal of Student Research","other","article","10.47611/jsrhs.v13i4.7975",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040040","Diabetes and Sarcopenia: Intersection of Co Morbid Conditions","Byron J. Hoogwerf","2025","OBM Geriatrics","other","article","10.21926/obm.geriatr.2501299",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040041","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90592-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040042","Pharmacotherapy and weight management: efficacy and clinical effectiveness in patients with obesity and type 2 diabetes","Nasser M. Aldekhail","2018","Enlighten: Theses (The University of Glasgow)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0040043","EXAMINING THE EFFECTS OF PHARMACOLOGICAL AND NUTRITIONAL INTERVENTIONS ON METABOLIC SYNDROME ASSOCIATED WITH ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS","Chun-I Liu","2025","The International Journal of Neuropsychopharmacology","systematic_review","article","10.1093/ijnp/pyae059.622",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0040044","STUDY OF THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME COMPARING A COMPREHENSIVE PHARMACOLOGICAL APPROACH AND LIFESTYLE CHANGES","Mariana Oliveira Soares","2026","Artefactum","other","article","10.23900/artefactum.v25i1.2510",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040045","0780 Association Between Tirzepatide and Fatigue and Functioning Based on Baseline Characterization: SURMOUNT-OSA Trials","Terri E. Weaver","2025","SLEEP","other_trial","article","10.1093/sleep/zsaf090.0780",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0040046","Investigation of Factors Influencing Blood Glucose Improvement with Tirzepatide","Shuichi Okada","2025","Clinical Diabetology","other","article","10.5603/cd.105700",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040047","(092) A PROTOCOL FOR EVALUATION OF SEXUAL SIDE EFFECTS OF GLP-1 INHIBITOR MEDICATIONS","Sauro Lorenzini","2025","The Journal of Sexual Medicine","protocol","article","10.1093/jsxmed/qdaf068.082",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040048","260-OR: iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study","RORY J. MCCRIMMON","2022","Diabetes","nonrandomized_study","article","10.2337/db22-260-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0040049","Comparison of the Effectiveness and Safety of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients with Overweight or Obesity","Asma Luqman","2025","Journal of Health Wellness and Community Research","randomized_trial","article","10.61919/q7nc4n17",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040050","PSYCHIATRIC EFFECTS ASSOCIATED WITH GLP-1 AND GIP AGONISTS: A REVIEW ON SEMAGLUTIDE AND TIRZEPATIDE","Rafael Ignácio dos Santos","2025","Asclepius International Journal of Scientific Health Science","narrative_review","article","10.70779/aijshs.v4i7.235",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040051","GLP-1 Receptor Agonists beyond Glycemic Control: Physiology and Pharmacological Evidence","Prakash K Amate","2026","Open Journal of Pharmacology and Pharmacotherapeutics","other_trial","article","10.17352/ojpp.000029",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040052","The Dopaminergic D3 System and Incretin Therapies: New Perspectives on Reducing Addictive Behaviors","O. Crețu","2026","Bulletin of Integrative Psychiatry","other","article","10.36219/bpi.2026.2.10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040053","Obezitede Kullanılan İlaçların Gıdalarla Etkileşimi","Esra Elve","2026","DergiPark (Istanbul University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040054","Glucagon-like peptide-1 receptor agonists and the incidence of medullary thyroid cancer: A systematic review and meta-analysis of rare events","Tae Hyuk Kim","2026","Vivli","systematic_review","article","10.25934/pr00012972",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0040055","Using GLP-1s to improve health: Fear of fat and “obesity” discourse","Ariane Prohaska","2026","Fat Studies","other","article","10.1080/21604851.2026.2674153",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040056","Clinical Inertia in the Management of Patients with Uncontrolled Type 2 Diabetes: A Retrospective Cohort Study","Jubran Boulos","2026","Journal of Diabetes and Clinical Research","nonrandomized_study","article","10.33696/diabetes.8.073",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040057","GW29-e0157 Attenuation of High Glucose-Induced Rat Cardiomyocyte Apoptosis by Exendin-4 via Intervention of HO-1/Nrf-2 and the PI3K/AKT Signaling Pathway","Shumei Zhao","2018","Journal of the American College of Cardiology","preclinical","article","10.1016/j.jacc.2018.08.025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040058","ISBE & Cochrane Portugal Newsletter nº 250: Semaglutide (Ozempic®) para perda de peso","Carneiro, António Vaz","2023","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040059","Semaglutide For Weight Loss: A Literature Review","Fransisca Centani Sadana","2024","International Journal of Research Publication and Reviews","nonrandomized_study","article","10.55248/gengpi.5.0724.1908",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040060","Biologic therapies in type 1 diabetes: how far are they from us?","Chao Deng","2013","Chinese Medical Journal","randomized_trial","article","10.3760/cma.j.issn.0366-6999.20132375","24229664",null,"ClinicalTrials.gov:NCT01773707; ClinicalTrials.gov:NCT01785108",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040061","Short-term effects of tirzepatide on weight loss in treated primary hypothyroidism: a retrospective study","Yusuf Elma","2026","Hitit Medical Journal","nonrandomized_study","article","10.52827/hititmedj.1848166",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040062","1817-P: Elafibranor and Glucagon-Like Peptide-1 Receptor Agonists Synergize to Attenuate Hepatic Inflammation and Fibrosis in a Rodent Model of Obesity, Insulin Resistance, and NASH","Vanessa Legry","2020","Diabetes","other_trial","article","10.2337/db20-1817-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0040063","Benefits of administering GLP-1 analogs to patients with polycystic ovary syndrome, considering their effect on adipose tissue metabolism","Małgorzata Król","2023","Pomeranian Journal of Life Sciences","other","article","10.21164/pomjlifesci.965",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040064","Vpliv inkretinov in njihovih analogov na dinamiko kalcija v celicah beta v svežih rezinah trebušne slinavke","Paradiž Leitgeb, Eva","2024","University of Maribor digital library (University of Maribor)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040065","Diabetes and Gastroparesis: New Concepts and Insights","Gaetano Leto","2026","Diabetology","randomized_trial","article","10.3390/diabetology7050093",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040066","GLP-1RA: New Hope in Obesity Therapy","Danfeng Zhang","2025","Journal of Biosciences and Medicines","other","article","10.4236/jbm.2025.132035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040067","A Promising Path Forward in Obesity Pharmacotherapy: Ecnoglutide and the Evolution of GLP-1R Agonist Design","Liangbin Zhou","2025","BIO Integration","other","article","10.15212/bioi-2025-0129",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040068","UNDERSTANDING THE DIGITAL HEALTH KNOWLEDGE ECOSYSTEM: ANALYZING THE MARKETING AND COMMUNICATION PRACTICES OF PATIENT INFLUENCERS, PHARMACEUTICAL AND TELEHEALTH COMPANIES","Milana Leskovac","2026","AoIR Selected Papers of Internet Research","other","article","10.5210/spir.v2024i0.15206",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040069","Perspective Chapter: Metformin and its Role in Diabetic Kidney Disease and Glucose Control","Amitabh Kulkarni","2026","Pharmaceutical science.","other","article","10.5772/intechopen.1011446",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040070","The effects of discontinuing GLP-1 receptor agonists on body habitus - A systematic review and meta-analysis","Sara Berg","2024",null,"systematic_review","article","10.37766/inplasy2024.2.0004",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0040071","Distinct effects of dipeptidy1 peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function","亜州華 森田",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040072","The Urgent Need and Expanding Scope of Semaglutide Biosimilars in Pakistan",null,"2025","Journal of Pakistan Society of Internal Medicine.","other","article","10.70302/jpsim.v6i2.2520",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040073","0777 Measures of Sleepiness Based on Baseline Characterization in Participants: SURMOUNT-OSA Post-hoc Analysis","Terri E. Weaver","2025","SLEEP","other_trial","article","10.1093/sleep/zsaf090.0777",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040074","FATORES RELACIONADOS AO USO DO MEDICAMENTO OZEMPIC (SEMAGLUTIDA) PARA O MANEJO DE COMORBIDADES, EXPONDO AS PERSPECTIVAS DE SUA UTILIZAÇÃO.","Sabrina Ferreira","2025","Periódicos Brasil Pesquisa Científica","other","article","10.36557/pbpc.v4i1.312",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040075","Drugs in Incretin Based Control of Type 2 Diabetes: Intervention for More Efficacy and Safety","S. A. Sreenivas","2024","International Journal of Pharmaceutical Research and Applications","other","article","10.35629/4494-0906916919",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040076","THE TRIVIALIZATION OF THE USE OF MOUNJARO AND OZEMPIC AS RAPID WEIGHT LOSS MEDICATIONS","Danier Renato Reisdorfer Avello","2025","Seven Editora eBooks","nonrandomized_study","article","10.56238/edimpacto2025.087-022",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","book-chapter"],["R0040077","Exendin-4 and Wound Healing","Stefano Bacci","2025","Biocell","other","article","10.32604/biocell.2025.069216",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040078","Effects of Exendin-4 on diabetic wounds: Direct action on proliferative phase of wound healing","Virginia Lotti","2024","Biocell","other","article","10.32604/biocell.2024.057904",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040079","Mitigation of acute lung injury by semaglutide: role of inflammatory and oxidative stress pathways","Ekhlas Sabah Hassan","2024","Journal of Phytomedicine and Therapeutics","preclinical","article","10.4314/jopat.v23i2.24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040080","Cardiovascular Effects of GLP-1 Receptor Agonists in Non-Diabetic Adults With Obesity: A Systematic Literature Review","Mariam Abdeen","2025",null,"nonrandomized_study","article","10.31986/issn.2689-0690_rdw.stratford_research_day.95_2025",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0040081","MASLD and Liver Transplantation: Clinical Challenges, Systemic Complications, and Emerging Role of GLP-1 Receptor Agonists","Ali Canbay","2025","Journal of Inonu Liver Transplantation Institute","other","article","10.14744/jilti.2025.51196",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040082","GLP-1 Receptor Agonists and Neurocognitive Outcomes in Type 2 Diabetes: A Propensity-Matched Real-World Analysis of Cognitive Impairment, Neurodegeneration, and Mortality","Om Patel","2026","Rowan Digitals Works (Rowan University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0040083","Administration of the GLP-1 receptor agonist exenatide in rats improves functional recovery after spinal cord injury by reducing endoplasmic reticulum stress","慧 野村",null,"Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040084","0208 Underreporting of semaglutide-associated skin laxity in pharmacovigilance data","S. Krikor","2026","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2026.06.239",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040085","Recurrent Small Bowel Obstruction Following Combined Use of Clozapine and Tirzepatide: A Case Illustrating Additive Gastrointestinal Hypomotility","Mariana Galvao de Oliveira","2026","BJPsych Open","other","article","10.1192/bjo.2026.11778",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040086","IMPACTO CARDIOVASCULAR DOS AGONISTAS DO RECEPTOR DE GLP-1: EVIDÊNCIAS CLÍNICAS E MECANISMOS","Manuelle Quixabeira Freire","2025",null,"other","article","10.29327/1662579.2-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0040087","GLP-1 Receptor Agonists and Skeletal Muscle Health: Overview of Reviews Examining Muscle Mass, Strength, and Physical Function in Adults with Obesity","Kelly Chen","2025",null,"systematic_review","article","10.37766/inplasy2025.11.0027",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0040088","SGLT2 Inhibitor And GLP-1 Receptor Agonist in Type 2 Diabetes Mellitus Patients. Research on Their Cardiovascular Benefits","Leicheng He","2023","Highlights in Science Engineering and Technology","other","article","10.54097/m9vm2798",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040089","Topical ocular administration of DPP-IV inhibitors: a new approach for treating diabetes-induced retinal neurodegeneration","Rafael Simó","2022","Neural Regeneration Research","randomized_trial","article","10.4103/1673-5374.353492","37843198",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0040090","merging Advances in Oral and Injectable Anti-Obesity Pharmacotherapies: A Review of Current Evidence","Sten Madsbad","2025","Medical Research Archives","narrative_review","article","10.18103/mra.v14i1.7208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040091","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-80222-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040092","Literature review: Interconnection between Type 2 diabetes mellitus and ischemic stroke: Pathophysiology, risks, and management","Daffa Bintang Jatmika","2024","Magna Scientia Advanced Research and Reviews","narrative_review","article","10.30574/msarr.2024.12.2.0221",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040093","Diabetic Bone Disease: A Comprehensive Narrative Review of Pathophysiology, Diagnosis, and Evidence-Based Management","João Protásio","2025","Diabetology","nonrandomized_study","article","10.3390/diabetology6110140",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0040094","Recently identified collateral benefits of drugs acting in the metabolic sphere","Cristian‑Daniel Marineci","2025","Farmacist ro","other_trial","article","10.26416/farm.223.4.2025.11209",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040095","4. Blood glucose-lowering therapies – Insulin options for type 2 diabetes","Stephen Colagiuri","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112148","40209899",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040096","Ped Endo Journal Scan","Kriti Joshi","2023","Journal of Pediatric Endocrinology and Diabetes","randomized_trial","article","10.25259/jped_10_2023",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040097","Correction",null,"2023","Journal of Managed Care & Specialty Pharmacy","other","article","10.18553/jmcp.2023.29.6.714","37278445",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0040098","Heart disease in diabetic patients",null,"2025","International Research Journal of Modernization in Engineering Technology and Science","nonrandomized_study","article","10.56726/irjmets82795",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040099","Correspondence on “Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic”","SEHYR IMRAN","2025",null,"nonrandomized_study","article","10.22541/au.176253083.32035268/v1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0040100","EFFICACY AND SAFETY OF INJECTABLE INCRETIN THERAPIES IN THE MANAGEMENT OF OBESITY: A SYSTEMATIC REVIEW","Fernanda Rodrigues Lopes","2026","Seven Editora eBooks","systematic_review","article","10.56238/sevened2026.020-032",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040101","Wait Times for First Neurologist Visit Vary Widely, Study Finds","Gina Shaw","2025","Neurology Today","other","article","10.1097/01.wnt.0001098708.60268.21",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040102","O uso do Ozempic (Semaglutida) no tratamento da obesidade – vantagens e desvantagens","Carolina Tomicki","2024","Brazilian Journal of Health Review","other","article","10.34119/bjhrv7n5-183",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040103","Perspective Chapter: Metabolic Dysfunction-Associated Steatotic Liver Disease as an Emerging Cardiovascular Risk Factor – Pathophysiology, Implications and Clinical Perspectives","Diana-Ruxandra Hădăreanu","2025","IntechOpen eBooks","other","article","10.5772/intechopen.1011513",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040104","EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON CIRCULATING ADIPOKINE LEVELS IN ADULTS WITH OVERWEIGHT, OBESITY, OR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Gabriella Vasconcelos Mariano Branquinho Leocadio","2026","Artefactum","systematic_review","article","10.23900/artefactum.v25i4.3175",null,null,"PROSPERO:CRD420261421956",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040105","Značaj GLP-1 agonista u kliničkoj praksi","Jurlina, Matko","2023","Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040106","A new kind of diabetes medication approved by the FDA: is there hope for obesity?","Danisha Dhirani","2023","International Journal of Surgery","randomized_trial","article","10.1097/js9.0000000000000044","36799809",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0040107","Hypoglycaemia during incretin receptor agonist therapy in people without diabetes: beyond acute counterregulation","Sidário Rodrigues Malheiros-junior","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22062628",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040108","Role of Semaglutide in Weight loss",null,"2023",null,"other","article","10.56831/pssrp-02-060",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040109","Cardiovascular risk in systemic lupus erythematosus: beyond Framingham to emerging risk prediction tools and therapeutic approaches","Mona Aflaki","2026","Frontiers in Lupus","other","article","10.3389/flupu.2026.1725054",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040110","Pleiotropic effects of GLP1-agonists","Rotim, Tea","2023","Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040111","Evaluación preoperatoria en anestesia: Revisión de la Guía 2017 de la Sociedad de Anestesiología de Chile","María Jesús Acuña Paolinelli","2026","Revista Confluencia","nonrandomized_study","article","10.52611/confluencia.2026.1721",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040112","Real-world weight loss outcomes of semaglutide with lifestyle intervention in adults with obesity and cardiometabolic comorbidities in an Asian population of Bangladesh: A 20-patient case series","Md. Abdul Mukid","2026","International Journal of Cardiology Sciences","randomized_trial","article","10.33545/26649020.2026.v8.i1a.163",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040113","High level soluble expression of human Glucagon-Like Peptide-1 (GLP-1) analogue as a recombinant peptide in E. coli","S. Sushmita","2024",null,"other","article","10.17952/37eps.2024.p2122",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0040114","Improved Glycemic Control using Oral Semaglutide in a Patient with Type 2 Diabetes with Insulin Allergy","Kamal Abouglila","2024","Journal of Diabetes and Endocrine Practice","other","article","10.1055/s-0044-1790586",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040115","Resilience selection: a grave potential bias in clinical trials","Milind Watve","2026","International Journal of Clinical Trials","randomized_trial","article","10.18203/2349-3259.ijct20261391",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040116","LipoLess Reviews: Official Site — #1 Natural Weight Loss Formula(DFC46T)","jaix datu","2026",null,"other","article","10.55277/researchhub.n9uqzqsa.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0040117","Development and investigation of chitosan-based extendedrelease microneedles for multi-day administration of liraglutide antidiabetic drug","Martin Cseh","2025",null,"other","article","10.14232/syrptbrs.2025.30",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0040118","Impacto cardiometabólico de las nuevas drogas","María Yuma","2024","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040119","ВЛИЯНИЕ ТЕРАПИИ СЕМАГЛУТИДОМ НА МАССУ ТЕЛА И УРОВЕНЬ ГЛЮКОЗЫ, ИНСУЛИНА И ТИРЕОИДНЫХ ГОРМОНОВ У СТАРЕЮЩИХ КРЫС С ДИЕТА-ИНДУЦИРОВАННЫМ ОЖИРЕНИЕМ","К.В. Деркач","2025","Успехи геронтологии","preclinical","article","10.34922/ae.2025.38.4.015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040120","Comparative Efficacy of Tirzepatide, Teneligliptin, and Empagliflozin in HbA1c Reduction in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","Jordan Llerena‐Velastegui","2023","International Journal of Medical and Surgical Sciences","systematic_review","article","10.32457/ijmss.v10i3.2263",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040121","Editorial: Exploring molecular mechanisms and novel diagnostics in cardiovascular disease treatment","Jianguo Sun","2026","Frontiers in Cardiovascular Medicine","nonrandomized_study","article","10.3389/fcvm.2026.1792721","41884634",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0040122","The effect of liraglutide on overweight and streptozotocin-induced diabetic male rats","Hanadi A Hafth","2026","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","preclinical","article","10.22141/2224-0721.22.2.2026.1691",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040123","Molecular Mechanisms of Liraglutide Aggregation Induced by Dual Air-Water and Silicone-Oil-Water Interfacial Stress","Naomi HAMADA","2025","ChemRxiv","other","article","10.26434/chemrxiv-2025-11cbq",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040124","Insights from a multicenter nationwide cohort analysis in Japan on the association of underlying conditions and pharmacological interventions with COVID-19 disease severity","Kyoka Sakamaki","2024","Discover Public Health","nonrandomized_study","article","10.1186/s12982-024-00225-7",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040125","Concept, Diagnosis, and Treatment in Steatotic Liver Disease (SLD)","Yoshio Sumida","2025","Health Evaluation and Promotion","other","article","10.7143/jhep.52.794",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040126","Novel Pharmacological Treatment of Post-prandial Hyperinsulinemic Hypoglycemia","Emily Cooper","2019","Current Research in Diabetes & Obesity Journal","other","article","10.19080/crdoj.2019.10.555777",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040127","Development And Validation of RP-HPLC Method for Semaglutide in Bulk and Pharmaceutical Dosage Form","Suyash Shashikant Ingle","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22060568",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040128","An analysis of safety risks associated with GLP-1 RA use in the direct-to-consumer telehealth model compared to traditional care model","Andrew Bursick","2025",null,"other","article","10.17760/d20731762",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040129","0778 Association Between Tirzepatide and Snoring Based on Participants’ Baseline Characterization from SURMOUNT-OSA","Chisom Kanu","2025","SLEEP","other_trial","article","10.1093/sleep/zsaf090.0778",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0040130","Ozempic’s positive and negative impact on the heart","Julianne Lin","2026",null,"other","article","10.51219/urforum.2026.julianne-lin",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0040131","Is There a Natural, Non-Addictive, And Non-Anti-Reward, Safe, Gene-Based Solution to Treat Reward Deficiency Syndrome (RDS)? KB220 Variants vs GLP-1 Analogs",null,"2024","Journal of Addiction Psychiatry","other","article","10.17756/jap.2024-044",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040132","Evaluation des Krankheitsverlaufs von Patienten mit Diabetes mellitus Typ 2 der Diabetesambulanz der UMG anhand laborchemischer und klinischer Parameter – eine retrospektive Analyse des Zeitraums 2014 bis 2021","Hörner, Dennis","2025",null,"nonrandomized_study","article","10.53846/goediss-10989",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","dissertation"],["R0040133","The Cardioprotective Effect Of Human Glucagon‐Like Peptide1 Receptor Agonist (Semaglutide) on Cisplatin‐Induced Cardiotoxicity in Rats: Targeting Mitochondrial Functions, Dynamics, Biogenesis, And Redox Status Pathways",null,"2023","Egyptian Society of Diabetes and Lipidology Journal","preclinical","article","10.21608/esdlj.2023.456215",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040134","Weight Loss Strategy Disparities Among Anti-Obesity Medication-Eligible US Adults: A Cross-Sectional NHANES Analysis","Harshal Parmar","2026","Rowan Digitals Works (Rowan University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040135","Semaglutide partially reshapes oral microbial dysbiosis and interferon-associated transcriptional programs in diabetic mice","Wang Ying","2026","Oral Science and Homeostatic Medicine","preclinical","article","10.26599/oshm.2026.9610056",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040136","Effect of Semaglutide on the Structure and Function of Intestinal Flora in Patients with MAFLD","悦 孙","2025","Advances in Clinical Medicine","other","article","10.12677/acm.2025.1551604",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040137","Obeziteye Genel Bakış","Çetin Altunal","2022",null,"other","article","10.37609/akya.1273.c18147",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0040138","Relação entre transtorno dismórfico corporal e o uso indiscriminado dos agonistas de GLP-1","Laiana da Silva Brito","2026","Revista fisio&terapia.","nonrandomized_study","article","10.69849/gq96ye58",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040139","Triple Incretin Agonists in Diabetes Mellitus: Retatrutide Improves Lipid Profile and Decreases Blood Pressure","Nuri Barış Hasbal","2025","Turkish Journal of Nephrology","other","article","10.5152/turkjnephrol.2025.24727",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040140","The impact of novel antidiabetic medications among people with HIV","Lara Haidar","2026","Mspace (University of Manitoba)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0040141","GLP-1 receptor agonism in cardiovascular disease prevention","Hussain Saleh","2025","Asia-Pacific Journal of Pharmacotherapy & Toxicology","nonrandomized_study","article","10.32948/ajpt.2024.11.22",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040142","Use of Tirzepatida (Mounjaro) as a Therapeutic Agent in Obesity and Type 2 Diabetes: A Systematic Review on Metabolic Control with GLP-1 Agonists",null,"2025","Journal of diabetology research.","systematic_review","article","10.52338/jodr.2025.4833",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040143","USO DA TIRZEPATIDA EM PACIENTES COM DIABETES MELLITUS TIPO 1: UMA REVISÃO DA LITERATURA","Maria Valentina Ferreira Teodosio Silva","2026","LUMEN ET VIRTUS","other","article","10.56238/levv17n63-049",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040144","From pills to pounds: prospective insights into the weight effects of antidepressant use","R. Musil","2026","European Psychiatry","randomized_trial","article","10.1192/j.eurpsy.2026.10330",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040145","The Association Between GLP-1 Receptor Agonist Use and Gastroparesis in Patients with Type 2 Diabetes Mellitus: A Scoping Review","Daniela Lizbeth Avilez","2025","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040146","A theoretical investigation on the geometries of glucagon-like peptide-1 and its interactions with dipeptidyl peptidase DPP-IV","Jürgen Brickmann","2008","Chemistry Central Journal","preclinical","article","10.1186/1752-153x-2-s1-p31",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040147","Developing a translational framework to predict clinical weight loss for novel or combination incretin therapies","Lyndsey F. Meyer","2026",null,"nonrandomized_study","article","10.70534/mbnn1276",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0040148","Agentes antidiabéticos de nueva generación en cirugía cardíaca: beneficios cardiovasculares y renales más allá del control glucémico","Viviana B Tinizhaay-Peralta","2026","Cirugía Cardiaca en México","other","article","10.35366/122230",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040149","The anti-fibrotic potential of GLP-1 and GIP receptor agonists in chronic inflammatory disorders: Mechanisms and therapeutic horizons","Simon Jones","2025",null,"other","article","10.22541/au.176487391.15715714/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040150","NA-931, a novel quadruple IGF-1, GLP-1 and GIP incretin receptor agonist reduces body weight without muscle loss",null,"2024",null,"other_trial","article","10.59462/3068-5192.c0.101",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-paper"],["R0040151","26-A-10742-ACC GLUCAGON-LIKE PEPTIDE-1 AGONISTS AND THE INCIDENCE OF ATRIAL FIBRILLATION IN NON-DIABETIC OBESE PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION","Farah Rassam","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.313",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040152","Enhanced Outcomes of SGLT2 Inhibitors and GLP-1 Receptor Agonists: A Systematic Review of Major Adverse Cardiovascular Events and Renal Outcomes","Abdulrahman Mazki J Alanazi","2026","Saudi Journal of Medical and Pharmaceutical Sciences","systematic_review","article","10.36348/sjmps.2026.v12i06.004",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040153","CLINICAL OUTCOMES OF A MULTIMODAL APPROACH COMBINING LOW-CARBOHYDRATE DIET AND PHARMACOTHERAPY FOR OBESITY MANAGEMENT","Sarojini Devi Simanchalam","2025","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.040.s1.218",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040154","Novo Nordisk’s Moonshot: turning a diabetes drug into a global phenomenon - navigating the global pricing maze for strategic market acces","Marco la Raja","2025","New University of Lisbon's Repository (New University of Lisbon)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040155","Mechanisms of drugs in the treatment of type 2 diabetes mellitus","Tao Yang","2022","Chinese Medical Journal","other","article","10.1097/cm9.0000000000002356","36921103",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040156","Adherence Trends in the Use of Innovative Drugs for Diabetes: Evaluation of Their Effectiveness and Safety","Dwight Mahaputera Marulitua Hutapea","2025","Oshada.","other","article","10.62872/7474ys44",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040157","Glucagon-like peptide-1 receptor agonists and muscle: interpreting lean mass changes in clinical care","Muhammad Sameer Arshad","2026","Global Cardiology","randomized_trial","article","10.4081/cardio.2026.101",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040158","GLP-1 Agonist Drug Influence on Alcohol Absorption","Andy Ewens","2026",null,"other","article","10.21428/7c9a8daa.6b5b11ae",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0040159","VOLTA DOS TRANSTORNOS ALIMENTARES COM O USO DE AGONISTAS DO RECEPTOR DE GLP-1: UMA REVISÃO NARRATIVA","Maria Beatriz Ávila Cavalcante","2025","Aracê.","other","article","10.56238/arev7n12-037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040160","Difficulties in diagnosing angiomatoid fibrous histiocytoma of the head and neck region: A case report","Adam Michcik","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6252","37731558",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040161","Út a szívhez a vesén át. A residualis cardiovascularis rizikó csökkentésének újabb távlatai – a mesodermalis eredetű szervek kommunikációs útvonalai és mediátorai","Emília Mácsai","2023","Hypertonia és Nephrologia","other","article","10.33668/hn.27.014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040162","TREATMENT OF MICROVASCULAR ANGINA IN THE ABSENCE OF SIGNIFICANT ATHEROSCLEROTIC CORONARY ARTERY DISEASE IN PATIENTS WITH CARDIO-RENAL METABOLIC SYNDROME","Yevhen Yu. Marushko","2024","Medical Science of Ukraine (MSU)","other","article","10.32345/2664-4738.4.2024.01",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040163","GLP-1 Receptor Agonists in Preconception Management of Obese Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS): Metabolic and Reproductive Implications","Turan Kaan Karakaya","2026","Cerasus journal of medicine.","randomized_trial","article","10.70058/cjm.1924573",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040164","Heterogeneity, MCID, and missed trials: comments on “efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: A systematic review and meta-analysis”","Yuanyuan Zou","2026","Journal of Neurosciences in Rural Practice","systematic_review","article","10.25259/jnrp_307_2025",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040165","Regulatory T Cells at the CNS Borders: Responsiveness to GLP-1 Receptor Agonism and Characterization of the Human Dural Compartment","Hector Ferrando Gomez","2026","Digital Access to Scholarship at Harvard (DASH) (Harvard University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040166","Der sog. Off-Label-Use","Luca Alexander Wacker","2025","Interdisziplinäre Beiträge zu Medizin und Recht","other","article","10.17875/gup2025-2911",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040167","POLYCYSTIC OVARIAN SYNDROME - CURRENT CHALLENGES","Isabela Nunes Gameiro","2024","International Journal of Health Science","other","article","10.22533/at.ed.1594982408115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040168","European Society of Cardiology clinical consensus statement on obesity and cardiovascular disease: 10 key points","Konstantinos C. Koskinas","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf177","40838297",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040169","CME Exam 1: Glucagon-like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis",null,"2025","Gastroenterology","systematic_review","article","10.1053/j.gastro.2025.08.035",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0040170","Analysis of Genetic Polymorphisms of OCT1, MATE1, MATE2 and GLP1R in Rats with Experimentally Induced Obesity","Mariya Kalinkova","2024","Acta Medica Bulgarica","preclinical","article","10.2478/amb-2024-0041",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040171","Medical treatment of pediatric obesity","Lindsey Yoojin Chung","2024","Journal of Korean Medical Association","other","article","10.5124/jkma.2024.67.5.324",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040172","GLP-1 Receptor Agonists in the Treatment of Pediatric Obesity: Therapeutic Advances and Metabolic Repercussions","Millena Stefany Dias Vaz","2026","International Journal of Health Science","other","article","10.22533/at.ed.0159672604066",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040173","Drug treatment of MASH from none to (too) many options?","Amedeo Lonardo","2025","Exploration of Medicine","other","article","10.37349/emed.2025.1001378",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040174","Navigating the Gastrointestinal Frontier: A Comprehensive Treatise on Oral Biologic Drug Delivery — Physiological Impediments, Formulation Innovations, Clinical Advances, and Emerging Therapeutic Horizons","Dhana Sri Gandham","2026","International Journal of Research Publication and Reviews","other","article","10.55248/gengpi.07.0626.17a10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040175","Is lasting remission feasible in the real-world setting? No!","Kamlesh Khunti","2024","British Journal of Diabetes","nonrandomized_study","article","10.15277/bjd.2024.453",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040176","Management Strategies for Children and Adolescents with Diabetes Mellitus","Ja Hyang Cho","2024","Journal of Korean Diabetes","other","article","10.4093/jkd.2024.25.3.145",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040177","Game of stones: making a decision about economic value of a weight-loss intervention","Joseph A. Ladapo","2025","The Lancet Regional Health - Europe","other","article","10.1016/j.lanepe.2025.101375","40687946",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040178","The Benefits of Glucagon-Like Peptide 1 Agonists in Adult Women with Polycystic Ovary Syndrome","Bethany A. Johnson","2026","UND Scholarly Commons (University of North Dakota)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0040179","In questo numero 2024 Dicembre",null,"2024","Recenti Progressi in Medicina","other","article","10.1701/4392.43912","39688036",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040180","Glucagon-like peptide-1-induced suppression on glucagon secretion in pancreatic alpha-cells: A study using phosphoinositol 3-kinasegamma deficient mice","Ya-Chi Huang","2006","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040181","Clinical applications of GLP-1 receptor–targeted PET imaging: A disease-oriented review","Zeyang Wang","2025","Journal of Nuclear Medicine and Molecular Imaging","narrative_review","article","10.65457/jnmmi-2025-0011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040182","Updates to the Clinical Practice Guidelines for the Management of Overweight and Obesity in Saudi Arabia: Year 2024","Abdulrahman Alshaikh","2025","International Journal of Clinical Medicine","other","article","10.4236/ijcm.2025.1612042",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040183","ATENÇÃO FARMACÊUTICA PARA PACIENTES EM TRATAMENTO DA OBESIDADE: O USO DE MEDICAMENTOS OFF-LABEL E DA SEMAGLUTIDA (OZEMPIC®) COMO TRATAMENTO SECUNDÁRIO","Mizael da Silva Gomes","2025","Revista Foco","other","article","10.54751/revistafoco.v18n11-285",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040184","TIRZEPATIDA (MOUNJARO®) E A ATUAÇÃO DO FARMACÊUTICO CLÍNICO: INOVAÇÃO E DESAFIOS NO TRATAMENTO DA OBESIDADE¹","Ana Beatriz Nunes de Melo","2025","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v11i11.22142",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040185","Outpatient medication for type 2 diabetes mellitus: a retrospective epidemiological study in real-world settings","Mariana Yoncheva","2024","Social Medicine","nonrandomized_study","article","10.14748/sm.v32i1.10384",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040186","8K5NW46NL0 Comparison of Glucagon-Like Peptide-1 Receptor Agonists Use for Weight Loss Between Postsurgical and Nonsurgical Patients: A Retrospective Analysis",null,"2025","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2025.04.281",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040187","The Hypothalamus and Hippocampus are Targets for New Drugs Controlling the Energy Balance and Treating Type 2 Diabetes Mellitus, Obesity, and Neurodegenerative Diseases","Matheus Melo Fabiano","2025","International Journal of Morphology","other","article","10.4067/s0717-95022025000100182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040188","Current Therapeutic Strategies for Obesity in the Pediatric Population: A Literature Review","Julia Rokosz","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.63.73245",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040189","Neuroprotective Potential of Semaglutide in Parkinson's Disease: Mechanisms, Preclinical Evidence, and Clinical Perspectives","Dipesh Kumar","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22059804",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0040190","C-120 | Association of Peri-Procedural GLP-1 Receptor Agonist Therapy With 1-Year Major Adverse Cardiovascular Events After Carotid Artery Stenting: A Propensity-Matched Analysis","Abdullah Ghuman","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104854",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0040191","VitaGLP France – Avis et plaintes ?","Lk E money","2026",null,"other","article","10.55277/researchhub.7zb6baif.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0040192","DirectMeds GLP1 : Complete Guide, Ingredients, Benefits & User Results#18APR2026","FA IJI","2026",null,"other","article","10.55277/researchhub.4dnl4i5r.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0040193","A Case of Lixisenatide-Induced Acute Interstitial Nephritis",null,"2025","Endocrine Practice","case_report","article","10.1016/j.eprac.2025.05.265",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040194","The Role of GLP-1 Receptor Agonists in Eating Disorders: Appetite Regulation and Neurobiological Mechanisms","Julija Blažytė","2024","Neurologijos seminarai","other","article","10.15388/ns.2024.28.102.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040195","Dipeptidyl Peptidase IV Inhibitor MK-0626 Attenuates Pancreatic Islet Injury in Tacrolimus-Induced Diabetic Rats","Sun Woo Lim","2014","Kidney Research and Clinical Practice","preclinical","article","10.1016/j.krcp.2014.05.028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040196","Intestinal obstruction due to giant liver cyst: A case report","Adem Küçük","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6246","37731578",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040197","Influência do peptídeo semelhante ao glucagon 1 (GLP-1) em diferentes espécies : ações fisiológicas e farmacológicas em cães e gatos e efeitos na regulação do metabolismo intermediário em ratas wistar ovariectomizadas","Model, Jorge Felipe Argenta","2024","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040198","The Latest topics of Standards of Care in Diabetes 2025: Focusing on GLP-1RA","Hiroshi Bando","2024","Asploro Journal of Biomedical and Clinical Case Reports","other","article","10.36502/2024/asjbccr.6386",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040199","New opportunities in the treatment of type 2 diabetes mellitus in patients with cardiovascular diseases: innovations in pharmacotherapy and revision of clinical guidelines","Daria Konovalova","2025","Vestnik of Saint Petersburg University Medicine","other","article","10.21638/spbu11.2025.101",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040200","Assessing the Impact of Once-Weekly Semaglutide on Glycemic Control in Psychiatric Outpatients with Type 2 Diabetes: A 4-Year Observational Study","P. Argitis","2026","European Psychiatry","other","article","10.1192/j.eurpsy.2026.10453",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040201","The Clinical Applications and Challenges of Semaglutide in the Treatment of Type 2 Diabetes and Obesity","Tianqi Zhu","2025","Theoretical and Natural Science","other","article","10.54254/2753-8818/2025.22730",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040202","Drugs for diabetes first, then weight loss, now maybe AUD","Alison Knopf","2024","The Brown University Child & Adolescent Psychopharmacology Update","other","article","10.1002/cpu30886",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040203","Fármacos antidiabéticos en cardioprotección: más allá del control de la glicemia","Sofía Adasme-Reyes","2025","Salud y Ciencia","other","article","10.22370/syc.1.1.2025.5395.",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040204","Clinical Application and Research Progress of Novel Anti-Obesity Medications","博 商","2026","Pharmacy Information","other","article","10.12677/pi.2026.154043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040205","Exploring biomarkers for parkinsonian diseases and disease modification trials","Vijiaratnam, Nirosen","2024","UCL Discovery (University College London)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0040206","GLP-1 RA and SGLT2 – Inhibitor Treatment","Diana Teneva","2026","Scholars Academic Journal of Pharmacy","randomized_trial","article","10.36347/sajp.2026.v15i06.001",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040207","Perspectivas en el desarrollo de fármacos cardiometabólicos","Fernanda Valverde-Casa","2025","MQRInvestigar","other","article","10.56048/mqr20225.9.3.2025.e797",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040208","Geriatric Gaps in Glucagon-like Peptide-1 Receptor Agonist Therapy for Cardio-Kidney-Metabolic Syndrome: A Scoping Review of Age-Specific Clinical Evidence","Zahra Rizqika Aliyya Safitri","2026","Nusantara Science and Technology Proceedings","nonrandomized_study","article","10.11594/nstp.2026.5615",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040209","Alternatives to GLP-1 Peptides",null,"2026",null,"other","article","10.56831/pssrp-08-298",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040210","Antiplatelet treatment in different clinical settings","Stefan Agewall","2025","European Heart Journal - Cardiovascular Pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvaf060","40874871",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040211","Squamous cell carcinoma associated with endometriosis in the uterus and ovaries: A case report","Zhe Cai","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6240","37731556",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040212","Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial",null,"2025","Texila international journal of academic research","randomized_trial","article","10.21522/tijar.2014.12.02.art012",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040213","Mechanisms for anesthesia, unawareness, OIRD, sleep and memory replay: MHb→IPN→ PAG + DRN + MRN→claustrum→ slow-waves.","Karin Vadovičová","2025",null,"other","article","10.14293/pr2199.000799.v9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040214","EFICÁCIA DA TIRZEPATIDA NO MANEJO CLÍNICO DA OBESIDADE EM ADULTOS: UMA REVISÃO DA LITERATURA","Francisca Evelyn Abreu de Lira","2024","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v10i7.14912",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040215","Add-on effect of dulaglutide on basal-bolus therapy for the improvement of diurnal variation in plasma glucose levels and acceleration of a step-down regimen involving insulin","尚嗣 村上","2020","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040216","Emerging role of GLP-1RAs in the management of diabetic kidney disease","Srikanth Bellary","2025","British Journal of Diabetes","other","article","10.15277/bjd.2025.478",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040217","Glycemic Management Strategies and Cardiovascular Event Risk in Elderly Patients with Diabetes and Cardiovascular Disease","Li Zhang","2025","Theoretical and Natural Science","nonrandomized_study","article","10.54254/2753-8818/2025.pj25647",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040218","A Revolutionary Road Map for Obesity Management and Beyond: Tirzepatide as a Dual-Acting Insulinotropic Polypeptide","Laith Thamer Al-Ameri","2024","AL-Kindy College Medical Journal","other","article","10.47723/hesy7z38",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040219","4) Update of GLP-1 Receptor Agonists","Nobuya Inagaki","2023","Nihon Naika Gakkai Zasshi","other","article","10.2169/naika.112.1613",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; conference-abstract"],["R0040220","La chirurgia bariatrica è ancora un’opzione di prima scelta nel trattamento dell’obesità?","Danila Capoccia","2025","il Diabete","other_trial","article","10.30682/ildia2503e",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040221","(130) A CASE REPORT: ANORGASMIA FOLLOWING INITIATION OF GLP-1 AGONIST","Vidya Visvabharathy","2025","The Journal of Sexual Medicine","case_report","article","10.1093/jsxmed/qdaf068.115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040222","Desafios e atualizações na legislação farmacêutica na farmácia comercial","Anderson Carlos Costa Soeiro","2025","Dialnet (Universidad de la Rioja)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0040223","GW26-e4793 Comparative efficacy and acceptability of glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes: a systematic review and network meta-analysis","Zhirong Yang","2015","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2015.06.493",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0040224","Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo","Aleix Cases","2022","Nefrología","other","article","10.1016/j.nefro.2022.07.008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040225","CLINICAL EFFECTIVENESS OF ONCE-WEEKLY DULAGLUTIDE AS ADD-ON TO SGLT2i IN THAI PATIENTS WITH T2DM","Yotsapon Thewjitcharoen","2022","Journal of the ASEAN Federation of Endocrine Societies","randomized_trial","article","10.15605/jafes.037.afes.53",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040226","Pharmacological Benefits of Multifaceted Mode Of Action For A Novel Combination Of Long-Acting GLP-2 Analog (HM15912) And GLP-1ra (Efpeglenatide) In Animal Model Of Inflammatory Bowel Disease","J. Choi","2023","Clinical Nutrition ESPEN","other","article","10.1016/j.clnesp.2022.09.060",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040227","Healing with Food or Managing with Injection? A New Era in Chronic Disease Care","Dasaad Mulijono","2025","Journal of Biomedical Research & Environmental Sciences","other","article","10.37871/jbres2092",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040228","In This Issue of Diabetes Care",null,"2014","Diabetes Care","randomized_trial","article","10.2337/dc14-ti10",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040229","Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review","Jeong-Hwan Lee","2026","Journal of Korean Medical Association","narrative_review","article","10.5124/jkma.26.0043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0040230","A retrospective study of GLP-1 receptor agonists uses in the management of hidradenitis suppurativa","Fatima Khan","2026","International Journal of Research in Dermatology","nonrandomized_study","article","10.18203/issn.2455-4529.intjresdermatol20262836",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040231","Therapeutic Management of Obstructive Sleep Apnea: Clinical and Surgical Interventions","ISADORA ROCHA CASSIANO DA VEIGA","2025","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.15953325281012",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040232","P30 - Successful non-surgical treatment of bilateral macronodular adrenocortical disease with osilodrostat","Gustaw Laskowski","2025","European Journal of Endocrinology","other","article","10.1093/ejendo/lvaf168.075",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0040233","Editorial: Journey through bariatric surgery","Mauro Lombardo","2025","Frontiers in Nutrition","commentary","article","10.3389/fnut.2024.1546283","39839300",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0040234","A rare metabolic complication: hypercalcemic crisis in a patient using a GLP-1 agonist","Jasmine Dushime","2026","The Southwest Journal of Medicine","other","article","10.12746/swjm.v14i58.1641",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040235","Tirzepatide: The Most Effective Drug Therapy for Prevention of Type 2 Diabetes","Nasser Mikhail","2025","Clinical Endocrinology and Metabolism","randomized_trial","article","10.61440/jmdr.2025.v2.04",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040236","The Anti-Fibrotic Potential of GLP-1 and GIP Receptor Agonists in Chronic Inflammatory Disorders: Mechanisms and Therapeutic Horizons","W. Jones Simon","2026","Fibrosis","other","article","10.70322/fibrosis.2026.10001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040237","GLP-1 Agonists, Willpower, and Weight Stigma: A Paradigm Shift for Obesity","Pablo Arrona Cardoza","2025","University of Ottawa Journal of Medicine","other","article","10.18192/uojm.v15is2.7526",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040238","Toward Integrated Diabetes Care: A Comprehensive Review of Strategies for Prevention, Diagnosis, Treatment, and Follow-up","Osama Albasheer","2026","Saudi Journal of Health Research & Practice","narrative_review","article","10.63908/f3pvc937",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040239","ANTIPSYCHOTIC-INDUCED METABOLIC SYNDROME: PREVENTION AND MANAGEMENT","Willy Luis Chacón Simionato","2025","Asclepius International Journal of Scientific Health Science","nonrandomized_study","article","10.70779/aijshs.v4i8.261",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040240","Editorial: Atrial Fibrillation: selection of management strategy and evaluation of outcomes -volume II","Rui Providencia","2026","Frontiers in Cardiovascular Medicine","nonrandomized_study","article","10.3389/fcvm.2026.1859934","42524141",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0040241","Racial and Ethnic Disparities Across the MASLD/MASH Care Continuum in the United States: A Narrative Review","Rowan Bandaranaike","2026","ASIDE Gastroenterology","randomized_trial","article","10.71079/aside.gi.071126795",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0040242","Transient Effects of Exenatide on Intraocular Pressure in a Rat Bone Defect Model","Candemir Özcan","2026","Dicle Üniversitesi Veteriner Fakültesi Dergisi","randomized_trial","article","10.47027/duvetfd.1858619",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040243","Enhancing Equity in Access to GLP-1 Receptor Agonists",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.631",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040244","Comparação do benefício cardiovascular entre agonistas do receptor de GLP-1 e inibidores do cotransportador de Sódio-glicose 2 no manejo da insuficiência cardíaca","Daniella Khouri Fernandes","2025","Contribuciones a las Ciencias Sociales","other","article","10.55905/revconv.18n.6-096",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040245","GLP-1 Receptor Agonists for the Treatment of Obstructive Sleep Apnea and Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials",null,"2025","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2025.05.505",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040246","Editorial: Diabetes and cardiovascular complications: synergistic treatment approaches","Belma Pojskić","2025","Frontiers in Clinical Diabetes and Healthcare","nonrandomized_study","article","10.3389/fcdhc.2025.1689009","41070184",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0040247","Co-Produced Research Priorities for Metabolic Interventions in Severe Mental Illness: A James Lind Alliance Priority Setting Partnership","Dina Farran","2026","BJPsych Open","other","article","10.1192/bjo.2026.11242",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040248","Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes","Caputo V","2020","Cineca Institutional Research Information System (Tor Vergata University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040249","OBESITY MANAGEMENT - A COMPARATIVE REVIEW OF THE EFFICACY AND SAFETY OF BARIATRIC SURGERY AND TIRZEPATIDE THERAPY","Wojciech Gąska","2025","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(47).2025.3687",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040250","De fármaco a ícone : publicidade, cultura digital e o comportamento planejado no caso Ozempic","Felipe Portilho Figueira Gonzalez","2025",null,"other","article","10.11606/003301681",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040251","严重烧伤小鼠肠-胰岛轴功能的变化及其作用","Xinzhu Liu","2024","PubMed Central","preclinical","article","10.3760/cma.j.cn501225-20240520-00189",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040252","The New Year's Message","Salem Beshyah","2024","Journal of Diabetes and Endocrine Practice","other","article","10.1055/s-0044-1779468",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040253","A megtartott ejekciós frakcióval járó szívelégtelenség és a krónikus vesebetegség kapcsolata","Ágoston, Gergely","2024","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article","10.33668/hn.28.029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040254","Cost Comparison Review: Semaglutide vs Tirzepatide in India (August 2025)","Meetakshi Saraf","2025","INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT","narrative_review","article","10.55041/ijsrem52284",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040255","Effects of Lifestyle and GLP-1RA based Interventions on Waist Circumference: A Systematic Review and Meta-Analysis","Samit Ghosal","2025","Figshare","systematic_review","article","10.37766/inplasy2025.8.0071",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report; review"],["R0040256","Longitudinal MRI-PDFF Quantification of Hepatic Steatosis Reversibility During SGLT2-Inhibitor versus GLP-1 Receptor Agonist Therapy: A Prospective Cohort Study","Arsan Saliha","2026","Sriwijaya Journal of Radiology and Imaging Research","nonrandomized_study","article","10.59345/sjrir.v3i2.292",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040257","THE VICIOUS CYCLE OF POLYCYSTIC OVARY SYNDROME AND BINGE EATING DISORDER: A REVIEW OF METABOLIC, PSYCHOLOGICAL, AND IATROGENIC PATHWAYS","Marcelina Grzelak","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.2(50).2026.5970",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040258","Effects of dual GLP-1–GIP receptor agonist (Tirzepatide) and pioglitazone on weight loss and lipid metabolism in rats","M. Abu-farha","2025","Diabetes Research and Clinical Practice","preclinical","article","10.1016/j.diabres.2025.112531",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040259","Combating obesity: a change in perspectives","George Boon‐Bee Goh","2023","Singapore Medical Journal","other","article","10.4103/singaporemedj.smj-2023-043","36876620",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040260","GW25-e0235 Effects of Liraglutide on Glycemic Control and Left Ventricular Function in Patients with Acute Myocardial Infarction: a Randomized, Double-blind, Placebo-controlled Clinical Trial","Chen Weiren","2014","Journal of the American College of Cardiology","randomized_trial","article","10.1016/j.jacc.2014.06.611",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040261","The W orld C ongress of I nsulin R esistance, D iabetes and C ardiovascular D isease ( WCIRDC )","Zachary T. Bloomgarden","2023","Journal of Diabetes","nonrandomized_study","article","10.1111/1753-0407.13349","36610044",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040262","Characterising the role of the Amyloid Precursor Protein and Glucagon-like peptide-1 analogues in Age-Related Macular Degeneration","Sultan, Fatima","2022","Lancaster EPrints (Lancaster University)","other","article","10.17635/lancaster/thesis/1559",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040263","Long Term Management of Obesity with Once Weekly Semaglutide Efficacy and Safety in Clinical Trials","Texas Health Resources 300 E Round Grove rd Apt 422 Lewisville TX 75067 USA","2024","SciBase clinical and medical case reports.","other","article","10.52768/2995-5874/1029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040264","Insulin Resistance in Human Hippocampal Pyramidal Neurons Correlates with Age in Cognitively Normal and Alzheimer's Disease Patients","Xuelin Gu","2025","Alzheimer s & Dementia","other_trial","article","10.1002/alz70855_106242","41445510",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040265","O uso indiscriminado do Ozempic® para fins estéticos: uma revisão de literatura","Williane Lima Rodrigues","2024","COGNITIONIS Scientific Journal","other","article","10.38087/2595.8801.509",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040266","IMPACTO DOS AGONISTAS DO RECEPTOR GLP -1 NA ESTRUTURA E FUNÇÃO CARDÍACA: REVISÃO SISTEMÁTICA DE LITERATURA","AMANDA VILARIM FAUSTINO","2026","Aracê.","other","article","10.56238/arev8n5-068",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040267","β‐cell recovery revisited: Is prediabetes remission driven by insulin sensitivity or β‐cell function?","Joonyub Lee","2026","Journal of Diabetes Investigation","nonrandomized_study","article","10.1111/jdi.70292","41863035",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0040268","Unveiling the Power of GLP-1RAs: Optimizing MACE Reduction in T2DM Through BMI and Blood Pressure Insights","Samit Ghosal","2025",null,"other","article","10.37766/inplasy2025.8.0045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0040269","Glucagon-like peptide-1 receptor agonists in dermatology: more than meets the eye","Ana L. João","2025","Portuguese Journal of Dermatology and Venereology","other","article","10.24875/pjdv.25000042",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040270","Moving Beyond Traditional Cost Containment for GLP-1 Coverage within Oregon's Proposed Universal Health Plan","Manoj Rajesh","2026","PDXScholar  (Portland State University)","other","article","10.15760/honors.1939",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; dissertation"],["R0040271","Improvement of Glucose Variability and Weight Management with Administration of Tirzepatide (Mounjaro)","Hiroshi Bando","2026","Asploro Journal of Biomedical and Clinical Case Reports","other","article","10.36502/2026/asjbccr.6450",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040272","GLP-1 receptor agonists: new uses and adverse events","Pablo Merino Guijarro","2024","UCrea (University of Cantabria)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040273","Фармакологични и нефармакологични подходи за повлияване на апетита и затлъстяването","Ханджиева-Дърленска, Теодора Светославова  //   Handjieva-Darlenska, Teodora Svetoslavova","2023","Bulgarian Portal for Open Science","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040274","O USO OFF-LABEL DE AGONISTAS DO RECEPTOR DE GLP-1 PARA EMAGRECIMENTO ESTÉTICO","Caroline Martins Pereira","2026","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v12i2.24249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040275","Cardiac magnetic resonance-based prediction of left atrial fibrosis as a feature of left atrial myopathy using left atrial epicardial adipose tissue volume quantification","Schmidt, Thomas Robert","2024","Qucosa (Saxon State and University Library Dresden)","nonrandomized_study","article","10.13140/rg.2.2.20951.28324",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0040276","WCN26-3204 Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Patients with Chronic Kidney Disease","K.H.K. Yau","2026","Kidney International Reports","preclinical","article","10.1016/j.ekir.2026.104602",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040277","Lipoless Review 2026 | Lipoless Weight Loss Scam or Legit? (Watch Before Buying)(F4TD75)","jaix datu","2026",null,"narrative_review","article","10.55277/researchhub.4qdvzk2a.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0040278","Causal relationship between GLP-1 agonists and depressive symptomatology in patients with type 2 Diabetes: A systematic review","F Barroso","2024","Salud Ciencia y Tecnología - Serie de Conferencias","systematic_review","article","10.56294/sctconf2024942",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040279","The Role of GLP 1 Receptor Agonists in Treating Heart Failure: Useful or Not?","Laura Lungeanu-Juravle","2024","Internal Medicine","other","article","10.2478/inmed-2024-0276",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040280","Evaluación Económica de Semaglutida oral en monoterapia para el tratamiento de pacientes con Diabetes Mellitus Tipo 2 que no logran un control glicémico apropiado (HbA1c ≤ 7) desde la perspectiva del Instituto Mexicano del Seguro Social","Godina-Ortíz, Blanca Aideé","2023","Re-Unir (International University of La Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040281","Effect of Semaglutide on Vascular Regenerative Cells in People at Elevated Risk for Atherosclerosis","Brady Park","2025","TSpace (University of Toronto)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0040282","Food Noise and Its Impact on Diabetes Care and Management: Insights for Registered Dietitian Nutritionists","Daisuke Hayashi","2025","ScholarSphere (Penn State Libraries)","other","article","10.26207/q2j9-ph73",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040283","ABJWPL0W9Y Comparative Risk of Psychiatric Disorders Following GLP-1 Receptor Agonist Therapy vs. Bariatric Surgery: A Propensity Score-Matched Analysis",null,"2025","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2025.04.018",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040284","AV84YXP4V4 Impact of prior long-term semaglutide therapy on 1-year weight loss after primary sleeve gastrectomy",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.193",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040285","Roadmaps to Continuous Glucose Monitoring’s Role in Transforming Diabetes Management","Richard M. Bergenstal","2023","Diabetes Spectrum","other_trial","article","10.2337/dsi23-0007","37982067",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040286","A EFICÁCIA DA TIRZEPATIDA (MOUNJARO) NO PROCESSO DE PERDA DE PESO: AVANÇOS E PERSPECTIVAS NO TRATAMENTO DA OBESIDADE","Lívia Meireles Gomes","2022","Editora Science eBooks","other","article","10.56001/22.9786500466386.25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040287","GLP-1 receptor agonist for the management of metabolic syndrome in an adolescent with bipolar disorder on atypical antipsychotic treatment","M. Ruiz Martinez","2026","European Psychiatry","other","article","10.1192/j.eurpsy.2026.11126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0040288","Current and potential use of GLP-1R agonists: beyond type 2 diabetes","Abelardo Camacho-Luis","2024","Revista Mexicana de Endocrinología Metabolismo y Nutrición","other","article","10.24875/rme.23000053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040289","Zwischen Lifestyle und Leitlinie: die Rolle von GLP-1- Analoga in der GKV-Versorgung bei Adipositas","Volker Nürnberg","2026","Monitor Versorgungsforschung","other","article","10.24945/mvf.01.26.1866-0533.2797",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040290","Efficacy of oral semaglutide on cardiovascular risk in patients with type 2 diabetes mellitus: A real-life study","Francesca Nicolì","2024","European Atherosclerosis Journal","nonrandomized_study","article","10.56095/eaj.v3i3.82",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040291","Liraglutide - A Promising Approach Against Obesity","Nabila Rafi","2025","Journal of Bahria University Medical and Dental College","other","article","10.51985/jbumdc2024-455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040292","CHANGES IN HbA1c AND ANTHROPOMETRY IN REAL-WORLD SETTINGS IN PATIENTS WITH TYPE 2 DIABETES RECEIVING GLP-1 RECEPTOR ANALOGUES (CHARGE AUDIT)","Goh Kian Guan","2023","Journal of the ASEAN Federation of Endocrine Societies","randomized_trial","article","10.15605/jafes.038.afes.76",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040293","7PA4Z5846Z Efficacy of semaglutide or tirzepatide in patients with history of bariatric surgery: A retrospective observational study",null,"2025","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2025.04.188",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040294","THE RELATIONSHIP OF GUT MICROBIOTA AND OBESITY AND TREATMENT WITH SEMAGLUTIDE","Vanessa da Silva Moreira Teixeira","2024","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.1594642401077",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040295","Nursing Strategies for Diabetic Patient Management: Predicting Parameter Values Post-Exenatide Treatment with Machine Learning Algorithm","Sıddıka Ersoy","2024","Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi","other","article","10.22312/sdusbed.1449989",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040296","Effect of Switching from Glucagon-like Peptide-1 Receptor Agonists to Tirzepatide in Patients with Type 2 Diabetes: A Retrospective Observational Study","Kohzo Takebayashi","2026","Institutional Repositories DataBase (IRDB)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0040297","Effect Of Glucagon-like Peptide-1 Receptor Agonists on Regulation of Blood Pressure and Water-Sodium Metabolism in Rats with Diabetic Nephropathy","Shaoqing Wang","2015","Hong Kong Journal of Nephrology","preclinical","article","10.1016/j.hkjn.2015.08.053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040298","Commentary: Sensorimotor dysfunction and postural instability in older adults with type 2 diabetes mellitus: the role of proprioception and neuropathy","Diyou Chen","2025","Frontiers in Aging Neuroscience","nonrandomized_study","article","10.3389/fnagi.2025.1658306","41019421",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0040299","Neuroprotective or Neurohype? Unpacking GLP-1 Agonists in Brain Health and Weight Loss","Kolade Adene","2025","Carleton undergraduate journal of science.","other","article","10.22215/cujs.v5i1.5306",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040300","Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists","一雄 小林",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040301","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist-Associated Non-Arteritic Ischemic Optic Neuropathy (NAION): A Bayesian Framework for Drug Safety Under Uncertainty","Tan Aik Kah","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5663030",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040302","Effect of Glucagon-like Peptide-1 Receptor Agonists on Gastric Residual Volume and Quality of Bowel Preparation in Patients Undergoing Painless Gastroenteroscopy: A Meta-Analysis","xinying yang","2025",null,"systematic_review","article","10.37766/inplasy2025.11.0024",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0040303","Effect of GLP-1 receptor agonist on non-alcohol fatty liver disease","絵美子 青木",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040304","Semaglutide en el tratamiento de pacientes con insuficiencia cardíaca con fracción de eyección preservada y obesidad. Estudio STEP-HFpEF","Thierer, Jorge","2023","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040305","GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice(審査報告)","新 伊藤","2017","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040306","Use of Tirzepatide for Severe Reactive Hypoglycemia in a Patient with Obesity","Kamal Abouglila","2026","Journal of Diabetes and Endocrine Practice","other","article","10.1055/s-0046-1817792",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040307","Addition of Lemborexant to Bromazepam Therapy for Chronic Insomnia in a Patient Receiving Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis: A Longitudinal Observational Study of Sleep Duration and Dream Occurence","Hsin-Fu Chen","2026","American Journal of Medical and Clinical Sciences","other","article","10.33425/2832-4226/26004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040308","GLP-1 Receptor Agonists’ Impact on Fertility - A Review","Joanna Wojda","2025","Quality in Sport","narrative_review","article","10.12775/qs.2025.38.58325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040309","Unexpected Effect of GLP-1 Receptor Agonists: Slimming Down Psoriasis",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.09.102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040310","Diabetes and Heart Failure: What’s the Connection","R. Ma","2025","Theoretical and Natural Science","other","article","10.54254/2753-8818/2025.ld27050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040311","GLP ‐1 Medicines in Perspective: Approaches to Optimize Outcome","Zachary T. Bloomgarden","2026","Journal of Diabetes","other","article","10.1111/1753-0407.70264","42618878",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040312","Efeitos da Tirzepatida na Doença Hepática Esteatótica associada à disfunção metabólica em pacientes com obesidade: uma revisão integrativa","Higor Andrade Bustamante","2026","Revista fisio&terapia.","nonrandomized_study","article","10.69849/etpxqp41",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040313","Artificial Intelligence-Driven Prediction of Glucagon-Like-Peptide-1 Receptor Agonist Eligibility in Obesity","Gitanjali Srivastava","2025","Diabetes Technology and Obesity Medicine","nonrandomized_study","article","10.1177/29986702251380864",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040314","Gastric sonography assessment after liquid diet initiation and fasting in a patient with metabolic dysfunction-associated steatohepatitis initiated with tirzepatide treatment","Hsin-Fu Chen","2025","Journal of Clinical Images and Medical Case Reports","other","article","10.52768/2766-7820/3828",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040315","Management of Overweight and Obese People with the Dual GIP/GLP-1 Receptor Agonist Tirzepatide: A Systematic Review","Liya Fu","2026","Clinical Medicine Frontiers","systematic_review","article","10.57237/j.cmf.2026.01.001",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040316","Ozempic: um novo paradigma na prevenção de eventos cardiovasculares isquêmicos","Laura Heck Zettermann","2025","Editora Pasteur eBooks","other","article","10.59290/5220102016",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040317","Cardiovascular Effects of GLP-1 and Glucagon Dual Receptor Agonism in Humans","Goodman, James","2024","Apollo (University of Cambridge)","other","article","10.17863/cam.117744",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040318","Non-invasive monitoring of glycemia-induced regulation of GLP-1R expression in murine and human islets of langerhans","Ada Admin","2020",null,"preclinical","article","10.2337/figshare.12840770.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040319","Incretin-based therapy for MASH: are two better than one?","Richard K. Sterling","2026","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2026.74",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040320","The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women","Ian Edwin Cock","2026","Pharmacognosy Communications","other","article","10.5530/pc.2026.3.18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040321","Фармакоэкономическая оценка применения фиксированной комбинации вилдаглиптин/метформин в лечении пациентов старше 18 лет с сахарным диабетом 2-го типа","И.С. Романова","2026","Рецепт","other","article","10.34883/pi.2026.29.3.001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040322","‘Behandeling van MASLD/MASH bij DM2 dient meer gericht te zijn op het cardiovasculaire risico dan op de lever-uitkomsten. Dit maakt SGLT2-remmers een net zo'n goede keuze als GLP-1-RA voor de combinatie MASLD/MASH en DM2'",null,"2025","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-025-1595-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040323","Semaglutide for Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction in Patients with and without Diabetes","Nasser Mikhail","2024","Journal of Diabetes and Clinical Research","randomized_trial","article","10.33696/diabetes.6.059",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040324","Typ-2-Diabetes – Effektive Glykämiekontrolle – GLP-1-Agonist überzeugt im direkten Vergleich",null,"2016","Diabetes aktuell","other","article","10.1055/s-0042-102231",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040325","The effect of semaglutide on the progression of murine breast cancer","Isidora Stanisavljević","2025","National Repository of Dissertations in Serbia","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040326","EAST COAST ENDOCRINE TERTIARY CENTRE EXPERIENCE WITH GLUCAGONLIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS","Aina Mardiah Z","2024","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.039.s1.071",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040327","COMPARISON OF THE CHRONIC KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES BETWEEN DIABETES CLINIC AND INTERNAL MEDICINE CLINIC","Siwakorn Inkhong","2023","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.038.afes.109",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040328","Más allá del GLP-1: Eficacia multiórgano de los agonistas duales y triples de incretinas en el síndrome cardiometabólico","Elizabeth Valinotti","2026","Dialnet (Universidad de la Rioja)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0040329","Convergent Mechanisms of Metabolism-Based Therapeutics in MASH: Mechanistic Review of SGLT2 Inhibitors and GLP-1 Receptor Agonists","Kangchan Choi","2025","Preprints.org","narrative_review","article","10.20944/preprints202508.0991.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040330","The Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications In Patients with Type 2 Diabetes","Yichen E. Fang","2025",null,"nonrandomized_study","article","10.2337/figshare.30209941.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0040331","Non-Alcoholic Fatty Liver Disease (NAFLD) and its Impact on Health: Risk Factors and Management",null,"2025",null,"other","article","10.47278/book.hh/2025.187",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040332","Semaglutide (Wegovy)","CDA-AMC","2025","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2025.1159",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040333","10.51847/GSN_4aH","Fatmah S. Alhawyan","2000","Time to knit","randomized_trial","article","10.51847/gsn_4ah",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040334","Neural mechanisms of a novel GLP-1 receptor agonist-mediated appetite suppression","Sujin Yoo","2019","IBRO Reports","other","article","10.1016/j.ibror.2019.07.1273",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040335","TORONTO, DINAMARCA E A INSULINA: A HISTORIA DE UMA RUPTURA TECNOLOGICA QUE CULMINOU NA FEBRE CHAMADA OZEMPIC","Francisco Carlos Tadeu Starke Rodrigues","2024","Arte 21","other","article","10.62507/a21.v23i2.536",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040336","COMPARATIVE ANALYSIS OF NATURAL AND SYNTHETIC ANTI-DIABETIC COMPOUNDS: EVALUATING BOTH TYPES OF COMPOUNDS IN TERMS OF EFFECTIVENESS, SAFETY PROFILES, AND POTENTIAL FOR INTEGRATIVE THERAPY","Saba Razzak","2025","International Journal of Pharmacy & Integrated Health Sciences","other","article","10.56536/ijpihs.v6i2.267",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040337","GLP-1 receptor agonist treatment improved fasting and postprandial lipidomic profile independently of diabetes and weight loss","Giuseppe Della Pepa","2024",null,"other","article","10.2337/figshare.26169385.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040338","Glucagon-Like Peptide-1 Receptor Agonists' Effect on Polycystic Ovary Syndrome: A Meta Analysis","Xinrui Li","2025","Theoretical and Natural Science","randomized_trial","article","10.54254/2753-8818/2024.19862",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040339","Efectos de AGLP1 en pacientes con enfermedad renal diabética en cuanto al pronóstico renal","González Martínez, Miguel Ángel","2024","Dialnet (Universidad de la Rioja)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0040340","A duális antidiabetikus hatású kombináció, a tirzepatid [The dual antidiabetic combination, tirzepatide]","Gerő, László","2023","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040341","Tirzepatide: A First-in-class Twincretin for the Management of Type 2 Diabetes","Shalini Jaswal","2023","Letters in Drug Design & Discovery","other","article","10.2174/1570180820666230130153219",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040342","BENEFÍCIOS E MALEFÍCIOS DO USO DA MEDICAÇÃO OZEMPIC NO TRATAMENTO DA OBESIDADE: UMA REVISÃO SISTEMÁTICA","Mariana Fernandes Santos","2024",null,"other","article","10.47094/978-65-6036-445-5/7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0040343","The Silent Siege: A Unified Framework for the Liver as the Central Territory of the Brain's Metabolic Decree","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22064435",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040344","O PAPEL DO FARMACÊUTICO FRENTE AO USO INDEVIDO DO OZEMPIC PARA EMAGRECIMENTO IMEDIATO","Ana Beatriz Queiroga Basilio","2025","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v11i11.22334",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040345","The Efficacy of Metformin and Exenatide in Polycystic Ovary Syndrome (PCOS) Patients","Kesavan, Sanggeeta","2023","e-rph (University of Granada)","other","article","10.30827/ars.v64i2.27302",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040346","Pregnancy outcomes after GLP-1 agonist exposure in early pregnancy","Winterfeld, Ursula","2023","IRIS","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040347","Change in HbA1c Across the Baseline CHbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents","Gentilella, Raffaella","2019","Figshare","other","article","10.6084/m9.figshare.7998908",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040348","Tirzepatide: Responders vs. Non-Responders","Akriti Singh","2025","Clinical Diabetology","other","article","10.5603/cd.106515",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040349","Increased Xerostomia in Clinical Practice? Considering GLP-1 Therapies as a Contributing Factor","John Chao DDS","2026",null,"other","article","10.63620/mkjcdoc.2026.1052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040350","OR3-31 | Semaglutide Use and Thromboembolic Outcomes Following Left Atrial Appendage Occlusion","Chris James","2026","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2026.104494",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040351","Obesidad y síndrome de ovario poliquístico en edad fértil","Vélez Torres, Jonathan Michael","2025","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040352","Cardioprotective effect of liraglutide alone and in combination with L-arginine against cyclophosphamide-induced cardiotoxicity","Dlanpar Fatuhulla","2025","Zanco Journal of Medical Sciences","preclinical","article","10.15218/zjms.2025.067",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040353","Precision in an Era of Complexity: Integrating AI with Novel Anti Diabetic Drugs for Personalized Diabetes Management","Istak khan","2026","JOURNAL OF ADVANCE AND FUTURE RESEARCH","other","article","10.56975/jaafr.v4i1.503009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040354","O Conceito \"Barn Doors\" nas Osteotomias em Rinosseptoplastia: Avaliação Prospetiva dos Resultados Estéticos e Funcionais","André Filipe Marques Rodrigues Pereira","2026","Open Repository of the University of Porto (University of Porto)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040355","Pharmacological Approaches to the Management of Diabetes Mellitus","Dr. Amina Yusuf","2021","American Journal Of Pharmacy And Pharmacology","other","article","10.71465/ajpp.2266",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040356","Cost-effectiveness analysis of Oral Semaglutide treatment for type 2 diabetes mellitus patients: a systematic review","I Kadek Suardiana","2024","Journal of Public Health and Development","systematic_review","article","10.55131/jphd/2024/220322",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040357","full-blots of Figs1-3.pptx","Peiwen Wu","2020","Figshare","other","article","10.6084/m9.figshare.12631115.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040358","JDEP at Seven Years of Age","Salem Beshyah","2024","Journal of Diabetes and Endocrine Practice","nonrandomized_study","article","10.1055/s-0044-1792127",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040359","Use of social media for evaluation of semaglutide effectiveness for body weight loss","Erhatič, Ela","2025","Repository of the University of Ljubljana (University of Ljubljana)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040360","Specialty grand challenge for molecular and structural endocrinology: celebrating successes and the future ahead","Debbie C. Thurmond","2026","Frontiers in Endocrinology","preclinical","article","10.3389/fendo.2025.1756684","41550873",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040361","CME Exam 1: PNPLA3 Risk Allele Association With ALT Response to Semaglutide Treatment",null,"2024","Gastroenterology","other","article","10.1053/j.gastro.2023.12.021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040362","Anti-diabetic Therapies, Strategies for Diabetes Management, and Advancement in Drug Delivery Systems: A Review","G. (Gurkirat) Kaur","2024","Neliti","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040363","Navigating Challenges in Dose-Exposure-Response Analysis in the Presence of Confounding Associated with Titrated Drug Regimens","Maja Skataric","2026",null,"other","article","10.70534/ewzs2051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0040364","Comparative Cardioprotective Effects of SGLT2 Inhibitors in Preclinical Models of Diabetic Cardiomyopathy","Lamya Abdullah Almatrafi, Basmah Jameel Alharbi, Hanadi Abdulhadi Alqarni, Nouf Hassan Alamoudi, Afrah Awadh Alqarni, Feryal Mohamad Alabdulrahman, Amani Saleh Alghamdi, Maha Hamdan Alsofyani","2025","Vascular and Endovascular Review","preclinical","article","10.64149/j.ver.8.20s.1-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040365","Review of current anti-obesity medication","Jiayi Shi","2024","Theoretical and Natural Science","narrative_review","article","10.54254/2753-8818/44/20240861",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040366","Exploring Semaglutide Effects on Osteoarthritis in Obesity: Emphasis on Weight Management and Inflammatory Responses","P. Ravi","2025","Indian Journal of Pharmacy Practice","other","article","10.5530/ijopp.20260437",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040367","Perfil de seguridad de la semaglutida frente a otros agonistas del receptor GLP-1 no orales: revisión bibliográfica sobre reacciones adversas graves","Leire Ozkoidi Baños","2026","Academica-e (Universidad Pública de Navarra)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040368","Analysis of the therapeutic effect of semaglutide","Y. W. Liu","2023","Theoretical and Natural Science","other","article","10.54254/2753-8818/16/20240608",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040369","A Descriptive Content Analysis of Weight Loss Injectables on UK TikTok","Charlotte Kerner","2026","European Journal of Health Communication","other","article","10.47368/ejhc.2026.102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040370","Six Cases of Intussusception After Roux-en-Y Gastric Bypass in Patients on GLP-1 Therapy","Valentina Fernandez-Rodriguez","2025","Graduate Medical Scholars Journal","other","article","10.1349/3143-6587.1.s1.64",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040371","Obesity may present challenges during gastric ultrasound","Rafet Yarımoğlu","2025","Anaesthesia","nonrandomized_study","article","10.1111/anae.16572","39948769",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040372","Sarcopenia: Diagnosis and Surveillance Amid Rising GLP-1 Agonist Use","Igor M Kitanovski","2025","Graduate Medical Scholars Journal","other","article","10.1349/3143-6587.1.s1.58",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040373","Beyond muscle: could GLP-1 receptor agonists offset the tendon risk of intensive lipid-lowering therapy?","Yashendra Sethi","2026","Archives of Medical Science","nonrandomized_study","article","10.5114/aoms/226714",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040374","Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients With Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial","Of, Adis Journals On Behalf","2021","Figshare","randomized_trial","article","10.6084/m9.figshare.13360163.v2",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0040375","Efficacy of polyethylene glycol loxenatide for type 2 diabetes mellitus patients: A systematic review and meta-analysis","Yibo Liu","2023",null,"systematic_review","article","10.37766/inplasy2023.5.0106",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0040376","OBESIDADE E AUTISMO: REVISÃO SISTEMÁTICA E POSSIBILIDADES TERAPÊUTICAS EMERGENTES","Rafael Domingos Vasconcelos","2025","Revista Contemporânea","other","article","10.56083/rcv5n4-057",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040377","136P Mitigating cardiovascular risk in lung cancer: The role of GLP-1 receptor agonists in patients with type 2 diabetes","C-C. Lin","2026","ESMO Open","nonrandomized_study","article","10.1016/j.esmoop.2026.106443",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040378","Pszichiátriai gyógyszerek által kiváltott időskori elhízás – szövődmények, preventív és terápiás intervenciók = Psychotropic drug-induced obesity in older adults: complications, preventive and therapeutic interventions","Gábor Nadubinszky","2026","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040379","Rare Causes of Hypoglycemia—Lessons from Case Reports","Alia Munir","2025","JCEM Case Reports","case_report","article","10.1210/jcemcr/luaf270","41281935",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040380","Effectiveness and Safety of Add-on Once-Daily Liraglutide (1.2 mg) in Type 2 Diabetes Patients with Obesity: Data from a Real-World Cohort of Iraqi Patients","Haider Ayad Alidrisi","2024","Clinical Diabetology","nonrandomized_study","article","10.5603/cd.99656",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040381","The Effect of the GLP-1/GIP Receptor Co-agonist, MAR709, on Oral Fentanyl Consumption","Kaleb Gage Darnell","2026","IUScholarWorks (Indiana University)","other","article","10.7912/sww6-8292",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040382","SURMOUNT-OSA: Tirzepatide verbetert de symptomen van slaapapneu","Marcel H.A. Muskiet","2024","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-024-1568-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040383","AGONISTAS DO RECEPTOR DE GLP-1 NA SÍNDROME CARDIORRENAL-METABÓLICA: TRATAMENTO DA OBESIDADE E INSUFICIÊNCIA CARDÍACA Autores","Helia Maria Rodrigues Silva","2026","EPITAYA eBooks","other","article","10.47879/ed.ep.20260415p1154",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040384","Editorial Commentary on Letter “Glucagon-Like Peptide-1 Receptor Agonists: A New Frontier in Prostate Cancer Treatment?”","Young Hwii Ko","2025","Journal of Urologic Oncology","commentary","article","10.22465/juo.255000640032",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0040385","The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review","Silvia Tempia Valenta","2025","European Psychiatry","systematic_review","article","10.1192/j.eurpsy.2025.1993",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0040386","The Role of Semaglutide in Weight Management: An Analysis of Clinical Studies for Overweight and Obese Adults","Chengxiang Huang","2024","Journal of Education Humanities and Social Sciences","other","article","10.54097/sdhqyz53",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040387","Bilateral dislocation of the long head of biceps tendon with intact rotator cuff tendon: A case report","Hyuk-Joon Sohn","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6304","37731569",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040388","Effect of Liraglutide and Dapagliflozin on Cardiovascular Risk in Metabolic Dysfunction-associated Steatotic Liver Disease Patients","Volodymyr Chernyavskiy","2025","Family medicine European practices","randomized_trial","article","10.30841/2786-720x.3.2025.339921",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040389","Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas","Ramírez Hernández, Alexis","2025","Dialnet (Universidad de la Rioja)","other","article","10.63969/tg610p62",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040390","Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-induced Obesity","Jia Liu","2024",null,"preclinical","article","10.2337/figshare.22647826.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040391","The Intersection of Obesity and Behavioral Addictions: A Comprehensive Narrative Review of Neurobiological Mechanisms and Clinical Implications","Eşref Araç","2025","DAHUDER Medical Journal","narrative_review","article","10.56016/dahudermj.1793707",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0040392","DirectMeds GLP1 (We Tried It 365) My Honest Review!#18 APRIL 2026","gdbdyeu kfirjrvv","2026",null,"narrative_review","article","10.55277/researchhub.bah3zseg.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0040393","Memory difficulties in perimenopause: neuropsychological distinction from early-onset dementia","L. G. NUNES","2026","European Psychiatry","other","article","10.1192/j.eurpsy.2026.11940",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040394","GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge","Marta Grycan","2025","Biuletyn Głównej Biblioteki Lekarskiej","randomized_trial","article","10.2478/bgbl-2025-0015",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040395","The Role of Diabetes Mellitus in the Development of Chronic Kidney Disease: A Review","I Ketut Ngurah Sajjana Kirthana Pamecut","2025","International Journal Of Scientific Advances","narrative_review","article","10.51542/ijscia.v6i6.15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040396","Efficacy and Safety of Once-Weekly Semaglutide versus Tirzepatide in Type 2 Diabetes: A 24-Week Randomized Clinical Trial","Tahir Siddique","2025","Journal of Health Wellness and Community Research","randomized_trial","article","10.61919/qxt0b644",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040397","Short Supply, Long-Term Effects: Evaluating Diabetic Patient Adherence Amidst the Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Shortage","Christopher Carpenter","2025","UA Campus Repository (The University of Arizona)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040398","BLWJBXVJG6 A Higher Body Mass Index Predicts the Likelihood of Surgery for Patients on Glucagon-Like Peptide-1 Agonists",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.238",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040399","Impact of real-time glucose monitoring using FreeStyle Libre 3 on glycaemia in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial protocol","Evans, Mark","2025","Apollo (University of Cambridge)","protocol","article","10.17863/cam.117060",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0040400","Topical approaches to addressing tissue changes as a result of GLP-1RA and GIP therapies","Anna Baker","2025","Journal of Aesthetic Nursing","other","article","10.12968/joan.2025.0040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040401","Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults with Overweight or Obesity and Type 2 Diabetes Mellitus: A 54-Week Randomized Phase 2b Study","Rajaa Nahra","2021",null,"randomized_trial","article","10.2337/figshare.14272955.v1",null,null,"ClinicalTrials.gov:NCT03235050","S000257","openalex","TRUE","free_to_read","1","FALSE","other"],["R0040402","The efficacy and safety of Rybelsus in Asian patients with type 2 diabetes：A systematic review and meta-analysis","Tianzuo Wang","2023",null,"systematic_review","article","10.37766/inplasy2023.8.0046",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0040403","Correction: Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated","Sergio Fazio","2025","Frontiers in Cardiovascular Medicine","notice","article","10.3389/fcvm.2025.1720220","41333746",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0040404","GLP-1 Receptor Agonist: Health Care Savings or Healthcare Burden","Nirlepkumar Patel","2024","Journal of Medicine and HealthCare","other","article","10.47363/jmhc/2024(6)291",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040405","“A simplified Therapeutic Approach in Patients with Type 2 Diabetes Mellitus Through the Use of the Fixed-Ratio Combination of Insulin Glargine Plus lixisenatide (iglarlixi): An Account of Our Experience in Frail Elderly Patients”","C Peirce","2024","Journal of Clinical Case Studies Reviews & Reports","other","article","10.47363/jccsr/2024(6)312",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040406","Beyond declining mortality: toward equitable cardiometabolic prevention","Moon-Seung Soh","2026","Cardiovascular Prevention and Pharmacotherapy","other","article","10.36011/cpp.2026.8.e6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040407","Role and Efficacy of GLP 1 Agonists in the Management of PCOS","Nithisha Chitteti","2025","Advanced International Journal for Research","randomized_trial","article","10.63363/aijfr.2025.v06i04.1084",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040408","Out-of-pocket health expenditure among individuals with obesity","Furkan Alp Eren","2026","Türkiye Halk Sağlığı Dergisi","other","article","10.20518/tjph.1796314",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040409","Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: a randomized controlled study","裕達 中口",null,"Institutional Repositories DataBase (IRDB)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0040410","The Administration of Xultophy for Diabetic Patients on Hemodialysis","T Fujikawa","2020","Institutional Repositories DataBase (IRDB)","other","article","10.36502/2020/droa.6172",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040411","Acute Hemolytic Anemia Following Semaglutide Injection: A Case Report","Abdullah Khlofh Saleh","2022","World Family Medicine Journal/Middle East Journal of Family Medicine","case_report","article","10.5742/mewfm.2022.95251483",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040412","Патофізіологічні механізми прогресування та фатальних ускладнень коронавірусної хвороби (COVID-19) у пацієнтів з цукровим діабетом","Briukhanova, T. O.","2020","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0040413","\"Semaglutide Usage as a Weight Loss Management - Literature Review\"","Hananeh Rahmanpoor","2024","Biomedical Journal of Scientific & Technical Research","narrative_review","article","10.26717/bjstr.2024.58.009179",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040414","Nutritional deficiencies associated with anti-obesity pharmacotherapy","Ebtehaj Saud Aloraini","2026","International Journal of Community Medicine and Public Health","other","article","10.18203/2394-6040.ijcmph20262346",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040415","Testing for association between exonic glucagon-like peptide 1 receptor (GLP-1R) mutation with physical and brain health traits in UK Biobank","Ward, Joey","2023","UCL Discovery (University College London)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0040416","Advancing Parkinson's Disease Research: Targeting Pathogenic Mechanisms with Emerging Therapies","R Gowrisankari.","2025","International Journal of Research Publication and Reviews","other","article","10.55248/gengpi.6.0125.0211",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040417","Physiological and Biochemical Analysis of Cardiovascular Complications in Type 2 Diabetes Mellitus Patients","Mohammed Merza","2025","Journal of Neonatal Surgery","other","article","10.52783/jns.v14.2671",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040418","The cross-link between major depressive disorder and type 2 diabetes mellitus: a review of longitudinal and mendelian randomisation studies","C. Possidente","2022","Neuroscience Applied","randomized_trial","article","10.1016/j.nsa.2022.100485",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040419","Pathophysiology and Management of Cardiovascular Complications in Diabetes: Current Evidence and Emerging Therapies","Shivam Agarwal","2026",null,"other","article","10.62502/ijflhs/v1i1art5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040420","Mind and Metabolism in Harmony: Addressing the Metabolic Side Effects of Second-Generation Antipsychotics with Topamax, Metformin, and GLP-1 Agonists","Tiffany Pressley","2026","New Prairie Press (Kansas State University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040421","Tinjauan atas Glucagon-like Peptide-1 Receptor Agonist","Johan Indra Lukito","2020","Cermin Dunia Kedokteran","other","article","10.55175/cdk.v47i6.628",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040422","Influence of switching from dulaglutide to oral semaglutide on glycaemic control and clinical parameters in Japanese patients with well-controlled type 2 diabetes: a retrospective, observational study","Kentaro Watanabe","2025","British Journal of Diabetes","nonrandomized_study","article","10.15277/bjd.2025.492",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040423","Bariatric Surgery and Glucagon-Like Receptor-1 Agonists' Effects on Weight, HbA1c, and Cardiovascular Outcomes: A Meta-Analysis","Salah Alghamdi","2025","Journal of Pioneering Medical Science","systematic_review","article","10.47310/jpms2025141114",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040424","Stenting for carotid stenosis . . . and other research","Tom Nolan","2025","BMJ","other","article","10.1136/bmj.r2484","41344722",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040425","CB1 and GLP-1 receptors cross-talk provides new therapies for obesity","Ada Admin","2020",null,"preclinical","article","10.2337/figshare.13148288.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040426","Long-Term Adverse Effects of Semaglutide Use: A Systematic Review","Eveline Moreira de Souza","2025",null,"systematic_review","article","10.62486/978-9915-704-12-8.ch21",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040427","Efficacy of Metformin plus Sodium Glucose Transporter-2 inhibitors (SGLT-2i) in Obese Type 2",null,"2024","Journal of Pakistan Society of Internal Medicine.","other","article","10.70302/jpsim.v5i3.2447",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040428","A Cross-Sectional Study of Liraglutide Efficacy and Safety in Obesity Management among Egyptian Adults","Mai Mousa","2025","AlSalam International Journal of Pharmacy","other","article","10.21608/aijp.2025.414761.1010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040429","PRE-RAMADAN COUNSELLING IN ADULTS WITH TYPE 2 DIABETES (T2D) IN INSTITUT ENDOKRIN HOSPITAL PUTRAJAYA","Yong Shern Siau","2025","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.040.s1.204",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040430","O USO DA SEMAGLUTIDA PARA O TRATAMENTO DA OBESIDADE: UMA REVISÃO INTEGRATIVA","M. G. Prianti","2023","Revista Arte Ciência e Tecnologia","other","article","10.29327/2192619.1.28-12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040431","Acute Regulation of Postprandial Lipemia and Chylomicron Production by Glucagon-Like Peptide-1 and Bile Acid Signaling","Sarah Farr","2017","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040432","Sex Representation and Sex-Specific Treatment Effects in Randomized Trials of Novel Cardio-Renoprotective Therapies for Chronic Kidney Disease: A Meta-Epidemiological Study v1","Ioannis Bellos","2026",null,"randomized_trial","article","10.17504/protocols.io.eq2lymzyqlx9/v1",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","preprint"],["R0040433","Défis dans la prise en charge du diabète en hémodialyse chronique [Challenges in managing diabetes in chronic hemodialysis]","Lamine, F.","2019","IRIS","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0040434","Quelle est la place d'un traitement adjuvant par GLP-1 Receptor Agonists dans la prise en charge du diabète de type 1 ?","CLOSSET, Constance",null,"Repository of the University of Namur","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040435","Review of GLP‐1 trials finds low incidence of suicide risk",null,"2025","The Brown University Psychopharmacology Update","narrative_review","article","10.1002/pu.31321",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040436","Ped endo journal scan","Kriti Joshi","2025","Journal of Pediatric Endocrinology and Diabetes","randomized_trial","article","10.25259/jped_84_2025",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040437","ФАРМАКОЛОГІЧНИЙ ПРОФІЛЬ ТИРАЗЕПАТИДУ ЯК ПЕРШОГО В КЛАСІ ПОДВІЙНОГО АГОНІСТА РЕЦЕПТОРІВ ГІП ТА ГПП-1","Денис Дмитренко","2026",null,"other","article","10.36074/logos-08.05.2026.066",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0040438","Tenecteplase Given Up to an Extended Treatment Window Reduces Stroke-related Disability","Dawn Fallik","2024","Neurology Today","other_trial","article","10.1097/01.nt.0001028052.23181.50",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040439","AI-Driven Behavioural Insights for Ozempic Drug Users","Sruthi Balammagary","2025",null,"other","article","10.21276/jccci/2025.v1.i1.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040440","Complementary Chromatographic Strategies for Enhanced Impurity Analysis and Purification of Peptides: A comparative study of HILIC, SFC, and RP-LC","Octaviano Alessi","2026","Lund University Publications Student Papers (Lund University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040441","Early glycemic, weight, and metabolic effects of insulin glargine/lixisenatide in uncontrolled type 2 diabetes: A single-center experience","Emre Urhan","2026","Anadolu Kliniği Tıp Bilimleri Dergisi","nonrandomized_study","article","10.21673/anadoluklin.1840385",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040442","Medical Treatment in Obesity","Seher Çetinkaya Altuntaş","2023","Turkish Journal of Diabetes and Obesity","other","article","10.25048/tudod.1386433",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040443","Process for the Manufacture of Derivatized Amino Acids","Cabri W","2019","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040444","IMPACT OF DIABETIC MEDICATIONS ON ERECTILE FUNCTION: A META-ANALYSIS","G Rastrelli","2025","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdaf077.056",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0040445","A Comparative Effectiveness and Renoprotective Effects of Hypoglycemic Drugs for Type 2 Diabetes Mellitus","Bisma Rehman","2023","Molecular Medicine Communications","other","article","10.55627/mmc.003.01.0284",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040446","ストレプトゾトシン誘発糖尿病マウスの膵β細胞再生に対するexendin-4の効果","Shoko Kodama","2004","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040447","GLP-1 Drugs May Manage Weight Recurrence After Bariatric Surgery","Samantha Anderer","2025","JAMA","other","article","10.1001/jama.2025.13880","40971153",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040448","Exploring Side Effects and Discontinuation Reasons of Glucagon-Like-Peptide-1 Agonist (Liraglutide, Semaglutide) for Weight Loss Among Patients at King Abdulaziz University, Jeddah in 2021 to 2023","Nesrain Mubarak Alhamedi","2025","Journal of Clinical Medical Research","other","article","10.46889/jcmr.2025.6104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040449","Balancing Benefit and Risk: Continuing Tirzepatide after Allergic Reactions","Salem Beshyah","2025","Ibnosina Journal of Medicine and Biomedical Sciences","other","article","10.1055/s-0045-1811649",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040450","113 Impact of Preoperative GLP-1 Agonist Use on Postoperative Outcomes in Bariatric Surgery Patients: A Retrospective Cohort Study","Muhammad Noman Mushtaq","2025","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znaf270.044",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040451","A Case of Ketoacidosis Caused by Tirzepatide in Non-diabetic Individual","Esraa Ahmed Bukhari","2026","International Journal of Innovative Research in Medical Science","case_report","article","10.23958/ijirms/vol11-i03/2181",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040452","PRINCIPAIS REAÇÕES DERMATOLÓGICAS ASSOCIADAS AO USO DE AGONISTA DO RECEPTOR GLP-1","Isabela Dário Martineli","2026",null,"other","article","10.22533/at.ed.48226230229",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040453","Positive Pregnancy Outcome following First Trimester Dulaglutide Exposure in a Women with Type 2 Diabetes and PCOS: A Case Report","Bhumi Patel","2024","Journal of Diabetes Research Review & Reports","case_report","article","10.47363/jdrr/2024(6)178",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040454","Are GLP-1 Receptor Agonists Transforming Obesity Care or Creating Lifelong Drug Dependency?","NK Singh","2026",null,"other","article","10.5005/ijccp-11063-0018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040455","Assessment of Public Interest in the Use of Munjaro for Weight Loss in Ha'il City Community, KSA","Ebtehaj Saud Almughais","2025","Journal of Pioneering Medical Science","other","article","10.47310/jpms2025141119",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040456","The Easy Way Out? How Consumers Negotiate Stigma Around Semaglutide Use","Milana Pejic","2026","Lund University Publications Student Papers (Lund University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040457","Beyond Diabetes and Obesity: The Emerging Role of GLP-1 and GIP Agonists in Neurodegenerative Diseases—A Mini-Review","Andrei Emilian Popa","2026","Clinical Medical Reviews and Reports","other_trial","article","10.31579/2690-8794/322",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","review"],["R0040458","Tirzepatide as an Emerging Modality for Management of Obstructive Sleep Apnea","Dipti Gothi","2025","Indian Journal of Sleep Medicine","randomized_trial","article","10.5005/jp-journals-10069-0151",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040459","De la sindromul intestinului iritabil comorbid cu sindromul post-COVID-19 spre sindemie","Alexandru Babin","2025","Public Health Economy and Management in Medicine","other","article","10.52556/2587-3873.2025.2(104).03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040460","Perioperative Management of Patients Receiving GLP‑1 Receptor Agonists: An Updated Clinical Review","Dr. Hind Khaleel Jamila Hamdi","2026","International Journal of Medical Science in Clinical Research and Review","narrative_review","article","10.5281/zenodo.18383229",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040461","La Top 4 di febbraio 2024. Gli studi clinici che vale la pena conoscere se lavori nelle cure primarie in Italia","Peter K Kurotschka","2024","Recenti Progressi in Medicina","other","article","10.1701/4211.42045","38411683",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040462","Research Progress of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Heart Failure","明月 胡","2025","Advances in Clinical Medicine","other","article","10.12677/acm.2025.1571991",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040463","Advances in Diagnostic and Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease","Ryan Njeim","2026","Livers","other","article","10.3390/livers6030035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040464","Comparative Cardiovascular Safety Profile of Semaglutide, Liraglutide, and Tirzepatide: A Pharmacovigilance Analysis Based on The FDA Adverse Event Reporting System Reports","Mustafa Gökçe","2026","Haydarpaşa Numune medical journal (Online)","nonrandomized_study","article","10.14744/hnhj.2026.85821",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040465","New and Interesting Benefits with New Molecules in Obesity and Type 2 Diabetes","Fernando Grover Páez","2026","IntechOpen eBooks","other","article","10.5772/intechopen.1009256",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040466","Glucagon-like peptide 1 receptor agonists in the treatment of patients with type 2 diabetes and metabolically-associated steatosic liver disease. Review","С. М. Ткач","2024","Clinical endocrinology and endocrine surgery","randomized_trial","article","10.30978/cees-2024-1-44",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0040467","Discovery and Applications of Dulaglutide for Type 2 Diabetes and Other Potential Uses","Carol Zhang","2023",null,"other","article","10.58445/rars.762",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040468","Ozempic® e recomendações clínicas atuais para o tratamento da obesidade e controle de peso: uma revisão sistemática","Leidiany Souza Silva","2024","Revista Cereus","other","article","10.18605/2175-7275/cereus.v16n3p323-336",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040469","Multi-Faceted Evaluation of a Facial Cream Across Aging and Targeted GLP-1 Users","Hequn (Tracy) Wang","2026","Journal of Dermatology and Skin Science","other","article","10.29245/2767-5092/2026/2.1214",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040470","The Effect of Adjunctive Semaglutide Treatment on Cognition and Reward Based Decision Making in Patients with Major Depressive Disorder","Hartej Gill","2025","TSpace (University of Toronto)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0040471","Drug Discovery and Development of Semaglutide and Tirzepatide from the Gila monsters (Heloderma spp)","M Olimat","2025","Medical & Clinical Research","other","article","10.33140/mcr.10.03.03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040472","#863 Long-term effect of semaglutide on the glomerular filtration rate slope in high-risk patients with diabetic nephropathy: analysis in real-world clinical practice","Enrique Luna Huerta","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.0533",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040473","Management of type 2 diabetes in patients with frailty","Kara Hawker","2024","Canadian Family Physician","other","article","10.46747/cfp.700130","38262761",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040474","Phytochemical Targeting of the Incretin System: Evaluating Plants that Act as Natural GLP-1 Receptor Agonists or DPP-4 Inhibitors","Om Anil Pingat and Kajol Balu Sonavane","2026","International Journal of Advanced Research in Science Communication and Technology","other","article","10.48175/ijarsct-31143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040475","GLP-1 receptor agonism to improve cardiometabolic health","Eyk, H.J. van","2023","Leiden Repository (Leiden University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0040476","Micelles For Oral Delivery Of Biomacromolecules","Han, Xiangfei","2021","Human Biology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040477","A Dose of Caution: Identifying Therapeutic Errors Associated with Injectable Semaglutide","Briana Ingersoll","2025","UA Campus Repository (The University of Arizona)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040478","INDISCRIMINATE USE OF TIRZEPATIDA: THE PHARMACY ROLE IN THE PREVENTION OF ABUSE AND PROMOTION OF PATIENT SAFETY","Rosiel da Silva Coimbra","2026","Artefactum","nonrandomized_study","article","10.23900/artefactum.v25i2.2961",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040479","SEMAGLUTIDE IN TYPE 2 DIABETES MELLITUS: GLYCEMIC CONTROL, CARDIOMETABOLIC BENEFITS, RENAL PROTECTION, AND SAFETY CONSIDERATIONS","Gabriela Ana PUHA","2026","Medicine and Materials","nonrandomized_study","article","10.36868/medmater.2026.06.02.07",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040480","Brain-wide spatially resolved cell type-dependent age-counteraction and senomorphic effects of GLP-1R agonism and mTOR inhibition","Nenghan Lin","2026","California Digital Library","preclinical","article","10.48321/d17f46837e",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040481","GLP-1 Receptor Agonist and Structured Exercise on Glycemic Con-trol and Epigenetic Modulation in Diabetic Rats","Qurat-ul-Ain Adnan","2026","Balneo and PRM Research Journal","randomized_trial","article","10.12680/balneo.2026.1065",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040482","Intersections of Inflammatory Bowel Disease (IBD) and Non‑Alcoholic Fatty Liver Disease (NAFLD): A PRISMA‑ScR Guided Scoping Review","Asrul Lubis","2025","Asian Multidisciplinary Research Journal of Economy and Learning.","randomized_trial","article","10.70471/v6pn3r03",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040483","How Cost-Benefit Evaluations and Stigmatization Influence Individuals’ Acceptance of Medical Interventions for Severe Obesity","Junhao Fan","2025","The Journal of Medicine Humanity and Media","other","article","10.62787/mhm.v3i4.255",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040484","Overview: Obesity","Jayesh Trivedi *","2026","International Journal of Clinical Case Reports and Reviews","other","article","10.31579/2690-4861/1066",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040485","Process for The Manufacture of GLP-1 Analogues","Cabri W","2018","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040486","Glycemic Management and Body Composition Changes in Patients with Type 2 Diabetes Mellitus Using Semaglutide Injections","Tomoko Nakagawa","2025","Journal of St Marianna University","other","article","10.17264/stmarieng.16.13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040487","Study Maps Effectiveness and Risks of GLP-1RAs",null,"2025","Kidney News","other","article","10.62716/kn.000302025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040488","Efficacy of Exosome-Derived microRNA Therapy versus GLP-1 Agonists in Improving Insulin Sensitivity among Obese Type 2 Diabetics: A Narrative Review","Zakaria Ali","2025","Newport International journal of research in education (NIJRE)","nonrandomized_study","article","10.59298/nijses/2025/63.7579",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0040489","Efficacy and Safety of Oral Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analyses","Andrés Mauricio García Sierra","2026","Endocrinology research and practice.","systematic_review","article","10.5152/erp.2026.26919",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040490","GLP-1 Use in Active Populations and Potential Effects on Glycogen Availability, Appetite, and Training Outcomes","Isabel Seibert","2026","Research in Therapeutic Sciences","other","article","10.53520/rts2026.105184",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040491","Contribuições de uma sanitarista à farmacovigilância no SUS : uma perspectiva estratégica","Silva, Luiza Lovatto da","2025","Lume (Universidade Federal do Rio Grande do Sul)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040492","Beyond bariatrics: A systematic review and meta-analysis of glucagon-like peptide-1 receptor agonists and novel anti-obesity medications in critical care settings","Shibu Sasidharan","2025","Global Journal of Health Sciences and Research","systematic_review","article","10.25259/gjhsr_19_2025",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040493","Experience in Prescribing Gliflozines and GLP 1 Receptor Agonists: Study in a Population of Diabetics followed up at the Institut de Prévoyance Médico-social de l'Université Cheikh Anta DIOP de Dakar","Tall CT","2025","Diabetes & its Complications","nonrandomized_study","article","10.33425/2639-9326.1123",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040494","Incretin-Based Therapies for Weight Loss and Diabetes: Comparing the Clinical Impact of Tirzepatide and Semaglutide","Miguel A. Fuentes-Cortez","2026","Iowa State University Digital Repository (Iowa State University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040495","Treatment of Type 2 Diabetes: A Comprehensive Review of Recent Improvements, Therapeutic Strategies, Challenges, and Future Perspectives","Tawhidul Islam","2025","EMJ Diabetes","narrative_review","article","10.33590/emjdiabet/rkyo7834",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040496","Discovery and characterization of a novel peptide regulating energy homeostasis","Thi My Hanh Ngo","2026","Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)","preclinical","article","10.5282/edoc.36869",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040497","NAION (non-arteritic anterior ischemic optic neuropathy): Focus on semaglutide","Azhar Hussain","2025","Side effects of drugs annual","other","article","10.1016/bs.seda.2025.10.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0040498","Роль семаглутида и метформина в коррекции уровня тестостерона у пациентов с сахарным диабетом тип 2 и ожирением","Смирнов В.В.","2024","International journal of medicine and psychology.","other","article","10.58224/2658-3313-2024-7-5-18-26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040499","The role of medicinal plants in correcting metabolism during an unhealthy diet","M. A. Lieshchova","2024",null,"other","article","10.30525/978-9934-26-511-2-13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040500","Insulin, adipokines and psoriatic arthritis. Review","V. Ye. Кondratiuk","2026","Clinical endocrinology and endocrine surgery","narrative_review","article","10.30978/cees-2026-2-70",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040501","生理活性物質の新知見(2)生理活性物質としてのインクレチンから糖尿病治療薬としてのインクレチン関連薬の開発","里佳 須田","2024","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040502","Lifestyle and Pharmacological Interventions for Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review","Tatia Khachidze","2025","JUNIOR RESEARCHERS","systematic_review","article","10.52340/jr.2025.03.05.22",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040503","Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","貴之 山田",null,"Institutional Repositories DataBase (IRDB)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0040504","GLP-1 receptor agonists’ Role in the treatment of binge eating and bulimia nervosa","Monika Maruszak","2024","Medical Research Journal","other","article","10.5603/mrj.102177",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040505","Effects of Exenatide Twice Daily and Once Weekly on Weight Loss","Rajal A. Patel","2013","UA Campus Repository (The University of Arizona)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0040506","Semaglutide, infertilite ve gebelikte kullanımı","Hatice Kübra Taşdemir","2025","DergiPark (Istanbul University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040507","Real world changes in glycemic and anthropometric outcomes from semaglutide use","Khurram Saleem","2026","Northwest journal of medical sciences.","nonrandomized_study","article","10.69723/njms.05.02.0745",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040508","V604LKV46Y Comparing real-world long-term clinical and economic outcomes betweComparing realworld long-term clinical and economic outcomes between bariatric surgery and GLP-1 receptor agonistsen bariatric surgery and GLP-1 receptor agonists",null,"2025","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2025.04.091",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040509","Colonic Delivery of α-Linolenic Acid by an Advanced Nutrient Delivery System Prolongs Glucagon-Like Peptide-1 Secretion and Inhibits Food Intake in Mice","Kamakura Remi","2022","UTUPub (University of Turku)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040510","Uso de análogos de GLP-1 e Doença Renal Crônica","Laura Marangoni Cestaro","2025","Revista Eletrônica Acervo Saúde","other","article","10.25248/reas.e18990.2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040511","Syndroom van Cushing door kruidenpreparaat","Krul-Poel, Yvonne H.M.","2024","Socio-Environmental Systems Modeling","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040512","Gastrointestinal and Extra-Metabolic Effects of GLP-1-Based Therapies: A Narrative Review","Sreethu Sreekantan Geetha","2026","JUNIOR RESEARCHERS","nonrandomized_study","article","10.52340/jr.2026.04.02.06",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0040513","(094) ASSESSING THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON SEXUAL DESIRE: A QUALITATIVE REVIEW","H Quaile","2025","The Journal of Sexual Medicine","nonrandomized_study","article","10.1093/jsxmed/qdaf068.084",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040514","Trends in sedentary behaviour. . . and other research","Tom Nolan","2025","BMJ","other_trial","article","10.1136/bmj.r1137","40506065",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040515","Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review","Velimir Altabas","2025","Diabetology","systematic_review","article","10.3390/diabetology6060052",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040516","Treatment Algorithms for Endocrine Disorders","Hyndavi Trylockya Nagumantri","2025",null,"other","article","10.69613/xkn0e981",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040517","The efficacy of oral semaglutide in weight loss and glycemic control","Caroline Augusto Lopes","2024","International Journal of Health Science","randomized_trial","article","10.22533/at.ed.1594552414069",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040518","Glucagon-Like Peptide-1 Receptor Agonists Reduce Asthma Exacerbations In Obese But Not Non-Obese Type 2 Diabetics: A Global Study","Anthony Balolong-Reyes","2026","Journal of Allergy and Clinical Immunology","other","article","10.1016/j.jaci.2025.12.628",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040519","Betere glycemiecontrole met semaglutide dan met canagliflozine wanneer toegevoegd aan metformine?","Goderis, Geert","2020","Lirias","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040520","Pharmacogenetic Insights into Glucagon-Like Peptide-1 Receptor and Its Role in Diabetes Therapy","Chloe Davis","2023","Annals of Pharmacy Practice and Pharmacotherapy","other","article","10.51847/qbaabzn70k",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040521","COMPARATIVE EFFECTIVENESS OF CONTEMPORARY WEIGHT-LOSS INJECTIONS AND ESTABLISHED BARIATRIC PROCEDURES","Dvir Levin","2026","International Journal of Advanced Research","randomized_trial","article","10.21474/ijar01/23223",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040522","In Reply: Diabetic retinopathy: Screening, prevention, and treatment","David D. Chong","2024","Cleveland Clinic Journal of Medicine","commentary","article","10.3949/ccjm.91c.12002","39622597",null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0040523","#1700 Heterogeneity in characteristics of target population and definitions of renal outcome on evaluating the renoprotective effect of GLP-1RA in patients with diabetes: a systematic review and meta-analysis of observational studies versus randomized controlled trials","Xiaoyu Wu","2025","Nephrology Dialysis Transplantation","systematic_review","article","10.1093/ndt/gfaf116.0920",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040524","Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights","Sagarika Basavaraj","2026","Journal of Pharmaceutical Research","nonrandomized_study","article","10.18579/jopcr/v25.i1.10",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040525","In Case You Haven't Heard…",null,"2025","Mental Health Weekly","other","article","10.1002/mhw.34416",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040526","Efficacy and Safety of GLP-1 Receptor Agonists in Adults with Overweight/Obesity: A Systematic Review","Grace Vanderheyden","2026","Journal of Food Studies","systematic_review","article","10.5296/jfs.v15i1.23736",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040527","Remission of obesity-related comorbidities after bariatric surgery: a case report","Marinela Bochvarska","2025","Goce Delchev University Repository (Goce Delčev University of Štip)","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0040528","From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis","Manik Aggarwal","2023","Clinical Liver Disease","other","article","10.1097/cld.0000000000000005","36938314",null,"ClinicalTrials.gov:NCT05067621; ClinicalTrials.gov:NCT05016882; ClinicalTrials.gov:NCT04822181; ClinicalTrials.gov:NCT04971785; ClinicalTrials.gov:NCT04944992; ClinicalTrials.gov:NCT04771273; ClinicalTrials.gov:NCT04505436; ClinicalTrials.gov:NCT03919929; ClinicalTrials.gov:NCT04166773; ClinicalTrials.gov:NCT03987451; ClinicalTrials.gov:NCT03884075; ClinicalTrials.gov:NCT05254626; ClinicalTrials.gov:NCT04642261; ClinicalTrials.gov:NCT04910178; ClinicalTrials.gov:NCT04639414; ClinicalTrials.gov:NCT04065841; ClinicalTrials.gov:NCT03723252; ClinicalTrials.gov:NCT03646292; ClinicalTrials.gov:NCT05011305; ClinicalTrials.gov:NCT04501406; ClinicalTrials.gov:NCT03863574; ClinicalTrials.gov:NCT03459079; ClinicalTrials.gov:NCT03617263; ClinicalTrials.gov:NCT03350165; ClinicalTrials.gov:NCT02653300; ClinicalTrials.gov:NCT03950505","S000031; S000186; S000339; S000468; S000511; S000731; S000814; S001106; S001202; S001764; S001877; S002804","openalex","TRUE","open_pdf","5","FALSE","article"],["R0040529","Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions","Dinesh Bhaskaran","2025","Medicina Moderna - Modern Medicine","narrative_review","article","10.31689/rmm.2025.32.3.229",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040530","THE POSSIBILITY OF USE OF INCRETINS IN DIABETES MELLITUS II THERAPY","Valentina Soldat Stanković","2010","Praxis medica","other","article","10.70949/pramed201001342s",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040531","The Potential of Glucagon-like Peptide-1 Receptor Agonists in Addictive Disorders","Sigrid Breit","2025","Medical Research Archives","other","article","10.18103/mra.v14i2.7249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040532","The role of TRPM channels in glucose homeostasis","Noushafarin Khajavi","2026","Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)","other","article","10.5282/edoc.37147",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040533","MACE With GLP-1RAs in Patients With Type 2 Diabetes—A Systematic Review and Meta-Analysis of Randomised Controlled Trials","Yanping Bao","2025","Heart Lung and Circulation","systematic_review","article","10.1016/j.hlc.2025.06.887",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040534","3. TĂNG ĐƯỜNG HUYẾT SỚM SAU PHẪU THUẬT GHÉP THẬN","Phạm Văn Huệ","2024","Tạp chí Y học Cộng đồng","other","article","10.52163/yhc.v65icd9.1508",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040535","Managing delayed gastric emptying in patients on glp-1 receptor agonists scheduled for endoscopy: A brief communication","Faizan Sheraz","2025","International Journal of Gastroenterology Research","other","article","10.33545/26646439.2025.v7.i1b.16",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040536","Retatrutide: A novel approach in the treatment of obesity, diabetes mellitus, and MASLD (metabolic dysfunction-associated steatotic liver disease)","Robert Prosecký","2025","Klinická farmakologie a farmacie","other","article","10.36290/far.2025.041",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040537","Immunological impacts of GLP-1 analogues on female reproduction: therapeutic perspectives for infertility and recurrent pregnancy loss","Ana Clara Muniz Tavares","2025","JBRA","other","article","10.5935/1518-0557.20263771",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0040538","Glucagon-like peptide-1 and glucagon-like peptide-1 analogs nanotechnology-based systems for prevention and therapy of diabetes","Ana Francisca Lopes Correia de Araújo","2017","Open Repository of the University of Porto (University of Porto)","other","article","10.34626/pv16-mw23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040539","(054) Early Outcomes of GLP-1 Receptor Agonists for Weight Management During the Treatment of Male Testosterone Deficiency","Ashley Kieran Clift","2025","The Journal of Sexual Medicine","nonrandomized_study","article","10.1093/jsxmed/qdaf320.054",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040540","Pharmacoeconomic Evaluation of Polyethylene Glycol Losenatide for the Treatment of Type 2 Diabetes Mellitus Based on Markov Modeling","Shi Peirou","2024","Medical Research Frontiers","other_trial","article","10.57237/j.mrf.2024.03.002",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040541","Discontent with the weight-centred health paradigm: A critical examination of the charge against 'obesity'","Egan, Natalie","2025","Apollo (University of Cambridge)","other","article","10.17863/cam.120153",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040542","RETATRUTIDE-BASED TRIPLE AGONISM VERSUS TIRZEPATIDE-BASED DUAL AGONISM IN THE TREATMENT OF OBESITY: SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS OF RANDOMIZED CLINICAL TRIALS","Luiz Felippe Mendes Caquetti","2026","INTERNATIONAL BLEST SCIENTIFIC","systematic_review","article","10.65671/vhs6ed16",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0040543","Let food be thy medicine: anti-inflammatory diets and the hidden properties of coronary plaque","E. Wynn Jones","2025","Cardiovascular Research","randomized_trial","article","10.1093/cvr/cvaf115","40667871",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0040544","Use of a GLP-1 Receptor Agonist Shows Promise for Reducing Craving in Opioid Use Disorder","Christopher S. Freet","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5775637",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040545","NON-ALCOHOLIC FATTY LIVER DISEASE AND ITS RELATIONSHIP WITH METABOLIC SYNDROME: MODERN APPROACHES TO TREATMENT AND PREVENTION","Sh.Y. Bazargaliyev","2025","Farmaciâ Kazahstana","nonrandomized_study","article","10.53511/pharmkaz.2025.16.55.008",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040546","Immunotherapy for type 1 diabetes","Kyi Min Sann","2024","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2024.37",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040547","Semaglutide/venlafaxine",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-62034-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040548","Glucagon-like Peptide-1 Receptor Agonists and Thyroid Cancer: Myth or Reality?","Ronald Goldenberg","2025","Canadian Diabetes & Endocrinology Today","randomized_trial","article","10.58931/cdet.2025.3137",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040549","Surgical versus medical treatment of obesity in the New Era: A systematic review","Hamad Abdulaziz AlSubaie","2026","World Journal of Biology Pharmacy and Health Sciences","systematic_review","article","10.30574/wjbphs.2026.26.1.0192",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040550","Transfer and expression of exendin-4 fused to cholera toxin B subunit (CTB) in lettuce","Ebrahim Moradi","2023","مهندسی ژنتیک و ایمنی زیستی.","other","article","10.61186/gebsj.12.2.168",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040551","EFICÁCIA DOS AGONISTAS DO RECEPTOR DE GLP-1 NO TRATAMENTO DA OBESIDADE SEM DIABETES","Mohadeseh Miri","2026","Arquivos Catarinenses de Medicina","other","article","10.63845/27vewf30",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040552","The impact of SGLT-2i and GLP-1RA on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: a systematic review and network meta-analysis","Lu Li","2025",null,"systematic_review","article","10.37766/inplasy2025.3.0085",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0040553","Metabolinės širdies ir kraujagyslių ligų rizikos valdymas","Olivija Dobilienė","2025","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0040554","Mechanisms for anesthesia, unawareness, OIRD, sleep and memory replay: MHb→IPN→ PAG + DRN + MRN→claustrum→ cortical slow-waves.","Karin Vadovičová","2025",null,"other","article","10.14293/pr2199.000799.v10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040555","Correlation Analysis among Searches of Anti-Obesity Medications, Herbal Medicine, and Supplements Using Big Data: from 2016 to 2024","Suhyun Kwon","2024","Journal of Korean Medicine for Obesity Research","other","article","10.15429/jkomor.2024.24.2.133",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040556","Comparative Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus at High Cardiovascular Risk","Knizhenko Egor","2026","Journal of chemical health risks","randomized_trial","article","10.52783/jchr.v16.i4.15645",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040557","Liraglutideの脂肪肝改善作用","傑仲 楊","2013","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040558","To Hold or Not to Hold? Periprocedural Management of Glucagon-like Peptide-1 Receptor‑based Agonists (GLP‑1ra) in Patients with Diabetes and Obesity","Tayyab S. Khan","2026","Canadian Diabetes & Endocrinology Today","other","article","10.58931/cdet.2026.4152",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040559","Comment on the article titled “Association of the triglyceride‐glucose index with subclinical left ventricular dysfunction in type 2 diabetes mellitus patients: A retrospective cross‐sectional study”","Mehmet İlkin Naharcı","2023","Journal of Diabetes Investigation","randomized_trial","article","10.1111/jdi.14093","37864283",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0040560","GLP-1 receptor agonists and suicidal ideation/behavior: subject-level analysis of clinical trials","Van Hung Tran","2026","Drugs & Therapy Perspectives","randomized_trial","article","10.1007/s40267-026-01266-5",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040561","Efeitos do Orforglipron no tratamento da obesidade","Marcelo José da Silva de Magalhães","2025","Bionorte","other","article","10.47822/bn.v13i2.1045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040562","Plenary Lectures",null,"2015","Acta Physiologica","preclinical","article","10.1111/apha.12479","25764025",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040563","Editorial: Omics in endocrinology: from biomarker discovery to targeting therapeutic strategies","Michele Costanzo","2025","Frontiers in Molecular Biosciences","nonrandomized_study","article","10.3389/fmolb.2025.1567250","40017631",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0040564","PREVALENCE OF SGLT2 INHIBITOR AND GLP-1 RECEPTOR AGONIST PRESCRIPTIONS IN PATIENTS WITH COMORBID DIABETES AND CARDIOVASCULAR DISEASE IN RAJAVITHI HOSPITAL","Thitiporn Srisuk","2023","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.038.afes.81",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040565","O USO INDISCRIMINADO DE SEMAGLUTIDA (OZEMPIC) PARA EMAGRECER","Jocimar Farias","2025","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v11i11.22299",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040566","GLP-1 Therapy in Cancer and Its Mechanism","Baowen Zhang","2025","Theoretical and Natural Science","other","article","10.54254/2753-8818/2025.20466",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040567","Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","Alina Velescu","2026","Angiología","randomized_trial","article","10.20960/angiologia.00899",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040568","Effect of Exenatide on Aortic Stiffness and Blood Pressure Parameters","Eren Gürkan","2017","Endocrinology research and practice.","randomized_trial","article","10.25179/tjem.2017-56552",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040569","АГОНІСТИ РЕЦЕПТОРІВ ГЛП-1 У ЛІКУВАННІ ОЖИРІННЯ, ЦУКРОВОГО ДІАБЕТУ 2 ТИПУ ТА СЕРЦЕВО-СУДИННИХ РИЗИКІВ","Ростислав Капіцький","2026","ГРААЛЬ НАУКИ","other","article","10.36074/grail-of-science.15.05.2026.151",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040570","Uso de agonistas do receptor do peptídeo semelhante ao glucagon tipo 1 em pacientes com transtorno por uso de álcool","Ferronatto, Luiza Letti","2025","CEUB (University Center of Brasília)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040571","The expanding therapeutic landscape of glucagon-like peptide-1 receptor agonists: Mechanisms, physiology, classification and therapeutic application","Ray Chimango","2026","International Journal of Pharmaceutical Research and Development","other","article","10.33545/26646862.2026.v8.i7b.412",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040572","Youth-Onset Type 2 Diabetes: Update on Epidemiology, Pathophysiology, Diagnosis, and Management Strategies","Bruno Bombaci","2025","Diabetology","other","article","10.3390/diabetology6090090",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040573","Pharmacological treatment of steatotic liver disease associated with metabolic dysfunction","Daniela Lagos-Prieto","2026","Clínicas de gastroenterología de México (English Edition)","other","article","10.24875/cgme.m25000047",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040574","Is semaglutide superior that liraglutide in patients with type2 diabetes on insulin therapy – case presentation","Mickovski, Ivana","2022","Goce Delchev University Repository (Goce Delčev University of Štip)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0040575","Semaglutide (Ozempic®): an adjuvant, an alternative, or the solution in treating obesity?","AL CHAAR, Malda",null,"Repository of the University of Namur","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040576","Screening dan Identifikasi Molekuler Probiotik dari Dadih sebagai Inhibitor Alpha-Glukosidase","Togi Rut Marlita Marbun","2025","NUTRITURE JOURNAL","other","article","10.31290/nj.v4i1.5268",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040577","Oral Manifestations of Glucagon-Like Peptide-1 Receptor Agonist Therapy: Implications for Dental Practice","Aparnaa Upadhyaya","2026","International journal of research and scientific innovation","other","article","10.51244/ijrsi.2026.1306000479",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040578","Can Wegovy move the needle on NZ’s obesity crisis, or simply treat its symptoms?","Julie Trafford","2026",null,"other","article","10.64628/aa.r4hu44wpp",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040579","Long-term follow-up of pancreatic islet transplantation in a patient with Wolfram syndrome: a case report","Davide Catarinella","2025","Acta Diabetologica","case_report","article","10.1007/s00592-025-02558-4","40736545",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040580","Gastrointestinal effects of incretin hormone receptor agonists","С. М. Ткач","2024","Clinical endocrinology and endocrine surgery","other","article","10.30978/cees-2024-3-37",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040581","Análogos de GLP-1 utilizados para el tratamiento de la obesidad y su efecto en la enfermedad del Parkinson","Aguirre Solano, Carlos Alberto","2025","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040582","Semaglutida, liraglutida e tirzepatida na balança: uma revisão integrativa dos riscos e benefícios em contextos clínicos","Brunna Stefanne Araújo Cardoso","2026","DELOS Desarrollo Local Sostenible","other","article","10.55905/rdelosv19.n82-035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040583","Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia","Gundtoft Uhrenholt, Nicolai","2025","University of Southern Denmark Research Portal (University of Southern Denmark)","randomized_trial","article","10.21996/a7ff50a6-55c8-451c-92d9-57b5688247d6",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0040584","KOMBINASI TERAPI SEMAGLUTIDE INJEKSI DAN DIETHYLPROPION HCL ORAL PADA PASIEN OBESITAS: LAPORAN KASUS","Yani Kurniawan","2026","Jurnal Akta Trimedika","other","article","10.25105/aktatrimedika.v3i1.24604",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040585","Staff Education to Improve Tirzepatide Education and Lifestyle Counseling","Daisy Asemota","2026","ScholarWorks (Walden University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040586","Impact of obesity and metabolic drugs on orthopedic outcomes: A narrative review","Ajay Sehrawat","2025","International Journal of Orthopaedics and Bone Disorders","narrative_review","article","10.33545/26648946.2025.v7.i1a.48",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0040587","Comprehensive Review of Neurodegenerative Disorders","Nabeel Mohammed Al-Sharafi","2026","Kufa Journal For Veterinary Medical Sciences","narrative_review","article","10.36326/kjvs/2025/v16i218768",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040588","Systematic Review Protocol: Impact of Physical Exercise as an Adjuvant in Weight Loss Treatment Associated with Liraglutide Use v1","R Silva","2024",null,"systematic_review","article","10.17504/protocols.io.rm7vzknn5vx1/v1",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","preprint"],["R0040589","Effective Approaches For Obesity Prevention And Management",". .","2024","IOSR Journal of Dental and Medical Sciences","other","article","10.9790/0853-2311080110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040590","Diabetes and Alzheimer's Disease","Zachary T. Bloomgarden","2025","Journal of Diabetes","other","article","10.1111/1753-0407.70103","40389367",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040591","Glucagon-like peptide-1 (GLP-1) receptor agonist therapy duration vs durability of weight loss","Revanth Poondla","2026","Texas Family Medicine Research Journal","nonrandomized_study","article","10.65738/001c.163395",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040592","RBJ8JMR8BW Prevalence and timing of cholecystitis in patients taking GLP-1 agonists from a large academic health network",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.335",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040593","The Complexity of Diabetes: Exploring its Complications","P. Seetharamaiah","2025",null,"other","article","10.38124/ijisrt/25apr1992",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040594","GLP-1 analogs protect beta cells and prevent diabetes in models of Wolfram syndrome.","Igoillo Esteve, Mariana","2018","Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0040595","Semaglutidin vaikutusten mallintaminen aterianjälkeiseen glukoosiin ja insuliiniin käyttäen hierarkkista monilähtöistä Gaussin prosessin regressiota","Juuso Vilppula","2026","Aaltodoc (Aalto University)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","dissertation"],["R0040596","Diabetes-induced osteoporosis. Review","V. Ye. Кondratiuk","2024","Clinical endocrinology and endocrine surgery","narrative_review","article","10.30978/cees-2024-1-65",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040597","Non‐Surgical Management of Obesity","Petra Hanson","2022",null,"other","article","10.1002/9781119521686.ch5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040598","EVALUATING THE IMPACT OF MODERN ANTI-DIABETIC DRUGS ON SURVIVAL OUTCOMES IN LUNG CANCER PATIENTS WITH TYPE 2 DIABETES","Javed Ahmed Ujan","2025","Journal of medical & health sciences review.","other","article","10.62019/hmpfcj11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040599","Uso da semaglutida como ativador do canal de glicose e aumento de gasto energético: uma revisão integrativa","Silva, Maria Cristina da; Universidade Estadual do Ceará, UECE, Fortaleza, CE","2024","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article","10.18378/rebes.v14i2.10260",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040600","Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study","弘江 長池",null,"Institutional Repositories DataBase (IRDB)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0040601","Individualised pharmacological treatment of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes","Rudenko Viktor Petrovich",null,"CyberLeninK (CyberLeninka)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040602","Management of Obstructive Sleep Apnea in People with Type 2 Diabetes","Niel Patel","2026","Diabetology","other_trial","article","10.3390/diabetology7070128",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040603","NAFLD in overweight adolescents: Lifestyle intervention vs. GLP-1 agonist: A pilot RCT","Emily R Thompson","2025","International Journal of Paediatrics and Geriatrics","randomized_trial","article","10.33545/26643685.2025.v8.i2a.271",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040604","In questo numero",null,"2025","Giornale italiano di cardiologia","other","article","10.1714/4531.45326",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040605","Efficacy and Safety of GLP-1 Receptor Agonists as Adjuvant Pharmacotherapy After Bariatric Surgery: A Narrative Review","Natanael Sinaga","2026","Health & Medical Sciences","randomized_trial","article","10.47134/phms.v3i3.631",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0040606","家族協力・デイサービスとIDegLiraが奏効した認知症・副腎不全合併高齢糖尿病の1例","飯郷 徹","2025","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0040607","Mechanical Thrombectomy Versus Intravenous Thrombolysis in Distal Medium Vessel Acute Ischemic Stroke: Statistical and Methodological Suggestions While Exploring Outcomes","Sunny Ssu‐Yu Chen","2025",null,"randomized_trial","article","10.22541/au.173921621.11534712/v1",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","preprint"],["R0040608","Severe Alopecia, Dermatitis and Acute Interstitial Nephritis Following Oral Semaglutide (Rybelsus) That Is Amenable to Drug-Discontinuation and 6-Weeks of Prednisone —Rybelsus Interstitial Nephritis","Kamel El-Reshaid","2025","Open Journal of Nephrology","other","article","10.4236/ojneph.2025.152019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040609","AVANÇOS NO TRATAMENTO DE DIABETES MELLITUS TIPO 2 COM INCRETINOMIMÉTICOS","Anabel Medeiros","2024","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040610","Rupture de stock de l'Ozempic® en officine","TIOTSOP KENNE, Karelle",null,"Repository of the University of Namur","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040611","Semaglutide in people with obesity and type 2 diabetes on hemodialysis: a prospective analysis of glycemic and weight outcomes","Akinori Hayashi","2025","Renal Replacement Therapy","other_trial","article","10.1186/s41100-025-00628-5",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040612","Uso de Inibidores do Cotransportador de Sódio-Glicose do tipo 2 (iSGLT2) e Agonistas do Recetor do GLP-1 (GLP-1 RA) em Diabetes Mellitus Pós Transplante Renal","Ricardo Emidio Navarrete de Toledo","2026","Open Repository of the University of Porto (University of Porto)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040613","Associação neuroendócrina da Tirzepatida: implicações na homeostase energética e regulação hipotalâmica - uma revisão sistemática","Patrick Jhordan Rodrigues Silva","2026","Aposta","other","article","10.23900/ra.v24i116.1523",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040614","YXG8WVM8D9 Effects of Neoadjuvant GLP-1 Receptor Agonists on Weight Loss After Bariatric Surgery",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.265",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040615","Exendin-4 Protected against Cognitive Dysfunction in Hyperglycemic Mice Receiving an Intrahippocampal Lipopolysaccharide Injection","Guey-jen Lee-chen","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040616","ORIGINAL PAPER",null,"2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040617","\"Silencing the noise\": A theoretical exploration of GLP-1 weight-loss medications and the psychology of food-related cognitive preoccupation","Jack Wood","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22093933",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040618","ARTICLE",null,"2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040619","The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway","Ewan R. Pearson","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040620","Chronic Exposure to GLP-1R Agonists Promotes Homologous GLP-1 Receptor Desensitization In Vitro but Does Not Attenuate GLP-1R–Dependent Glucose","Homeostasis In Vivo","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040621","The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances {beta}-cell function but does not inhibit gastric emptying in mice","Adriano Maida","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040622","II. The Incretin Axis","John R. Ussher","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040623","Research Article Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine","Hsin-chieh Tang","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040624","Pharmacological treatment options for binge-eating disorder: a review","R. M. S. Lousada","2026","European Psychiatry","nonrandomized_study","article","10.1192/j.eurpsy.2026.11371",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040625","Exendin-4 Pretreated Adipose Derived Stem Cells Are Resistant to Oxidative Stress and Improve Cardiac Performance via Enhanced Adhesion in the Infarcted","Jianfeng Liu","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040626","INCRETIN ANALOGUE, LIRAGLUTIDE A NEWER TREATMENT APPROACH FOR TYPE-2 DIABETES MELLITUS.","Binila T Balagopal","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040627","Examination of efficacy, safety, and quality of life of dulaglutide in elderly type 2 diabetic patients","守弘 岡田","2022","Institutional Repositories DataBase (IRDB)","other","article","10.15066/00000660",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040628","and SGLT-2 Inhibitors","Michelle Degeeter","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040629","Clinical Study Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study","Weijian Ke","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040630","Review Article",null,"2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040631","A túlsúly, az elhízás a megküzdési stratégiák és az étkezési szokások vizsgálata a Saxenda használók körében","Dorottya Fonth","2026","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040632","REVIEW Liraglutide, a once-daily human GLP-1 analogue","Michael A Nauck","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040633","Medizinische Interventionen zur Adipositastherapie","Schultes, Bernd","2024","Zurich Open Repository and Archive (University of Zurich)","other","article","10.5167/uzh-276540",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040634","ORIGINAL ARTICLE PYY 3–36 and Oxyntomodulin Can Be Additive in Their Effect on Food Intake in Overweight and Obese Humans","Benjamin C. T. Field","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040635","Research Article Exendin-4 Protects MIN6 Cells from t-BHP-Induced Apoptosis via IRE1-JNK-Caspase-3 Signaling","Wen-jia Chen","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040636","LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) study,",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040637","Regulation of serotonin system in the pancreatic beta cell by glucocorticoids : involvement in the pathophysiology of diabetes","Moina Hasni Ebou","2015","theses.fr (ABES)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040638","REVIEW",null,"2015",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040639","The Global GLP-1 Boom and How Weight-Loss Drugs Are Reshaping Multiple Industries","Anya Khanna","2025","International Journal For Multidisciplinary Research","other","article","10.36948/ijfmr.2025.v07i06.62764",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040640","Korrelation der Betazellmasse und GLP-1-Rezeptor-Darstellung mit _1hn1_1hn1_1hn1In-DTPA-Lys40-Exendin-4 an betazelldefizitären Diabetesmodellen bei Nagern","Baumeister, Philipp","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040641","Byetta ® Step Therapy Criteria Brand Generic Dosage Form","Blue Cross","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040642","REVIEW The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor","Stephen C. Bain","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040643","ORIGINAL RESEARCH Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study","Borje Darpo","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040644","Receptor-Mediated Tumor Targeting with Radiolabeled Peptides: There Is More to It than","Somatostatin Analogs","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040645","Commentary Incretins in the ICU: is insulin on its way out?","Michelle A Kovalaske","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040646","Breast cancer trials--a new initiative.","M Spittle","1981","BMJ","randomized_trial","article","10.1136/bmj.282.6257.68-b","6778570",null,"PROSPERO:CRD42021271647",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0040647","26-A-12310-ACC PRECONCEPTION GLP-1 RECEPTOR AGONIST USE AND RISK OF HYPERTENSIVE DISORDERS OF PREGNANCY IN WOMEN WITH TYPE 2 DIABETES","Taylor Monique Bell","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.2624",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040648","in a l a","Y. Seino","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040649","Impact du sémaglutide sur la composition corporelle et le comportement alimentaire des patients obèses","Alissou, Mathieu","2024","HAL (Le Centre pour la Communication Scientifique Directe)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0040650","OBJECTIVE","An Investigator-initiated","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040651","Receptor Agonists Increase Pancreatic Mass by Induction of Protein Synthesis",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040652","Once-weekly albiglutide in the management","Heather N Woodward","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040653","OPEN BARIATRIC AND METABOLIC SURGERY REVIEW",null,"2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040654","Gut-brain interactions affecting metabolic health and central appetite regulation in diabetes, obesity and aging","M. Wijdeveld","2023","UvA-DARE (University of Amsterdam)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","other"],["R0040655","Original Article Leptin Regulation of the Anorexic Response to Glucagon-Like Peptide-1 Receptor Stimulation","Diana L. Williams","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040656","The evolving world of GLP-1 agonist therapies for type","Kevin C. R. Baynes","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040657","DJ: Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des 7:1399–1412","Daniel J. Drucker","2001",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040658","GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated b-cell damage","Shunsuke Yamane","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040659","Exenatide-Induced Urticaria: A Case Report and Review of the Literature","Reem Faiz Hussein Eisa","2026","World Allergy Organization Journal","case_report","article","10.1016/j.waojou.2026.101263",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040660","GLP-1R–Targeting Magnetic Nanoparticles for Pancreatic Islet Imaging",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040661","Comment on Andersen et al, PancreatitisY DiabetesYPancreatic Cancer Summary of an NIDDK-NCI Workshop To the Editor: W e have read the summary of theNational Cancer Institute/National Institutes of Diabetes and Digestive and","Kidney Diseasesysponsored Workshop","2013",null,"commentary","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0040662","ADVANTAGES OF INCRETIN-BASED THERAPIES Incretin-based",null,"2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040663","Exendin-4对糖尿病大鼠糖脂代谢的影响","李维辛","2011","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040664","A 2004 Effect of exenatide (exendin-4) on glycemic control and safety over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes 53(Suppl 2):A82 (Abstract 352-OR) Endocrinology is published monthly by The Endocrine Society (http://www.en","John B. Buse","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040665","New craze: Ozempic in the fight against obesity","Sholehah Abdullah","2025","UiTM Institutional Repositories (Universiti Teknologi MARA)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0040666","Newer Agents Better? DOI: 10.2337/dc13-1901 OBJECTIVE",null,"2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040667","Restoring Insulin Secretion (RISE): Design of Studies of b-Cell Preservation in Prediabetes and Early Type 2 Diabetes Across the Life Span OBJECTIVE","Nct Clinicaltrials. Gov","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040668","Diabetes Mellitus in Adults","Maria Tzefos Kira Harris","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040669","Diabetes Metab J 2012;36:262-267 GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease","Jinmi Lee","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040670","Research Article The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp","Hui Wu","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040671","Analogue in Patients with Poorly Controlled Type","Zih-syuan Chen","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040672","CARDIO VASCULAR DIABETOLOGY REVIEW Open Access The role of co-morbidity in the selection of","Diethelm Tschöpe","2014",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040673","ORIGINAL RESEARCH Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus","Mitch Dekoven","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040674","Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions","Richard D. Dimarchi","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040675","THE EFFECT OF TIRZEPATIDE IN PEOPLE WITH TYPE 2 DIABETES","I Made Siswadi Semadi","2022","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.037.afes.03",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040676","Rapid Publication Regeneration of Pancreatic Islets After Partial Pancreatectomy in Mice Does Not Involve the Reactivation of Neurogenin-3","Catherine S. Lee","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040677","doi:10.1155/2012/709893 Review Article Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor","Francis S. Willard","2012",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040678","Diagnostic Problem of Hyperbilirubinemia in Diabetes Mellitus Patient: Case Report","Universitas Airlangga","2025","Gaceta Médica de Caracas","case_report","article","10.47307/gmc.2025.133.1.21",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040679","Review","Joshua J Neumiller","2013",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040680","AN OVERVIEW OF EMERGING PHARMACOLOGICAL TARGETS IN TREATMENT OF TYPE 2 DIABETES MELLITUS","J. S. Rajkumar","2013",null,"other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040681","GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE-/- mice. Endocrinology 154(1):127e139","Naim Panjwani","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040682","Original Research Liraglutide prevents fast weight gain and b-cell dysfunction","Juan Zheng","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040683","original article Diabetes, Obesity and Metabolism 12: 604–612, 2010.",null,"2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040684","Marine invertebrate and bacterial extract library screens for novel modulators of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors","Catherine E. Merchant","2011","cIRcle (University of British Columbia)","preclinical","article","10.14288/1.0105089",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040685","Glucagon-Like Peptide-1 Increases Mitochondrial","Endocrinol Metab","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040686","ORIGINAL ARTICLE Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages","Grzegorz Machnik","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040687","An evaluation and comparison of current FDA-approved treatments for obesity","Neha Bapatla","2018","OpenBU (Boston University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040688","Brain GLP-1 Signaling Regulates Femoral Artery Blood Flow and Insulin Sensitivity Through Hypothalamic PKC-d","Cendrine Cabou","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040689","Results From Primary Outcome Measures",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040690","ORIGINAL RESEARCH Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE","Chantal Mathieu","2016",null,"other","article",null,null,null,"ClinicalTrials.gov:NCT00635492","S001805","openalex","FALSE","no_doi","5","FALSE","article"],["R0040691","Efficacy and Safety of Exenatide Once WeeklyVersusMetformin,Pioglitazone, and Sitagliptin Used asMonotherapy in Drug-Naive PatientsWith Type 2 Diabetes (DURATION-4)","David Russell-jones Md","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040692","Treatment of antipsychotic-associated",null,"2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040693","What about metabolic adds-on as GLP1 agonists and metformine before ART ?","Vanessa Lubin","2026","Médecine thérapeutique / Médecine de la reproduction, gynécologie et endocrinologie","other","article","10.1684/mte.2026.1090",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040694","Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor","Kathryn M Hurren","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040695","Beyond the Weight Loss: The Effects of Semaglutide on Standard and Diet-Induced Obese Mice","ASHLEY REHN","2025","National University of Singapore","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040696","Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012 OBJECTIVE","Department Of Epidemiology","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040697","Gariepy (corresponding author","Masayuki Arakawa","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040698","Intolerance and Islet-Cell Dysfunction in Humans","Glucocorticoid-induced Glucose","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040699","Corresponding author:","Michael A Nauck","2009",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040700","Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 43","Joshua J Neumiller","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040701","RESEARCH Short term monotherapy w 4",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040702","ON BEHALF OF THE NN2211-1310","Ole Schmitz","2014",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040703","SEE PROFILE","Pál Stráner","2014",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040704","Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 32(Suppl","Michael A. Nauck","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040705","Summary",null,"2013",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0040706","Rapid Identification of Semaglutide by Matrix‐assisted Laser Desorption/Ionization Time‐of‐Flight Mass Spectrometry","Ahmad Amini","2025","Separation Science Plus","other","article","10.1002/sscp.70076",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040707","GLP-1 Receptor Agonist Effects on Normal and","Neoplastic Pancreata","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040708","Synthesis and preclinical characterization of [Cu-64]NODAGA-MAL-exendin-4 with a N-epsilon-maleoyl-L-lysyl-glycine linkage","Cheng-Bin, Yim","2013","Åbo Akademi University Research Portal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040709","Robust Estimation of the Weighted Average Treatment Effect for A Target Population","Yebin Tao","2018","arXiv (Cornell University)","nonrandomized_study","article","10.48550/arxiv.1804.05079",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0040710","REVIEW Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists","Annachiara Uccellatore","2015",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040711","Effects of treatment with semaglutide, empagliflozin and the combination on kidney function in type 2 diabetes: impact of oxygenation and perfusion","Gullaksen, Søren; id_orcid 0000-0001-8275-1278","2022",null,"randomized_trial","article","10.1007/s00125-022-05755-w#sec15",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0040712","GLP-1对高脂环境胰岛β细胞的保护作用及机制的初步探究","焦宜珺","2020","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040713","by Direct and Indirect Mechanisms: Implications for Viscera-Mediated Arousal","Claudio Acuna-goycolea","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040714","RISCOS E IMPLICAÇÕES DO USO INDEVIDO DE OZEMPIC PARA EMAGRECIMENTO:IMPACTOS NA SAÚDE E NO PERFIL EPIDEMIOLÓGICO","MANOELA SANTOS","2026","Revista Multidisciplinar em Saúde","other","article","10.51161/integrar/rems/4757",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040715","Albiglutide dose regimen study The Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A Randomized Controlled Trial Exploring Weekly, Biweekly, and Monthly Dosing Running title: Albiglutide dose regimen study","Julio Rosenstock","2009",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040716","ORIGINAL ARTICLE Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver","Dan Zheng","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040717","doi:10.1155/2012/470851 Review Article Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor","Francis S. Willard","2012",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040718","Beneficial Effects of Incretin-Based Therapy on Glycemic Control, Adipokines, Insulin Sensitivity Parameters and Weight Loss in Overweight or Obese Patients With Newly Diagnosed Type 2 Diabetes: A Prospective Study","Original Article J Endocrinol Metab","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040719","Open Access Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus","Mohamed Lotfy","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040720","Нове у лікуванні цукрового діабету 2 типу","Kadzharyan, V. G.","2014","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040721","Diabetes 2013;62:2595–2604","Exocrine Pancreas Dysplasia","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040722","Empagliflozin Preserves b-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat","Henrik H. Hansen","2014",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040723","Transmucosal delivery of protein and peptide drugs by using cell penetrating peptides","Wu, Jiamin","2025","cIRcle (University of British Columbia)","preclinical","article","10.14288/1.0440603",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040724","Management Strategies for Obese Diabetes","Misook Kim","2024","Journal of Korean Diabetes","other","article","10.4093/jkd.2024.25.3.165",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040725","Draft Document for Public Consultation: What is new and what has changed in the 2026 Global Heart Failure Implementation Guidelines and why","Writing Task Force | ICARDIO-Alliance","2026","Global Cardiology","randomized_trial","article","10.4081/cardio.2026.111",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040726","Pharmacology of obese patient with appetite management","Kuribayashi, Shunsuke","2019","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040727","BindingDB Entry 12676: PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR","BindingDB","2025","UC San Diego","other","article","10.7270/q2n87gb6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040728","Age-Dependent Decline in -Cell Proliferation Restricts the",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040729","Islet Morphology and Function in a Mouse Model of Type 2 Diabetes","Qianni Cheng","2008",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040730","Exendin-4通过抑制Toll样受体4/核因子κB信号通路对帕金森病小鼠保护作用的研究","陶计委","2022","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040731","北醫藥訊第一百零二期","藥劑部","2023","Taipei Medical University Repository","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0040732","TheFateofTaspoglutide,aWeeklyGLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2Diabetes The T-emerge 2 trial","Julio Rosenstock Md","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040733","AddingOnce-DailyLixisenatideforType2 Diabetes Inadequately ControlledWith Newly Initiated and Continuously Titrated Basal Insulin Glargine","A -week","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040734","Address correspondence to:","Daniel A. Cunha","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040735","Research Article Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus","Muhammad Khan","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040736","ORIGINAL ARTICLE Glucagon-Like Peptide-1 Agonists Protect Pancreatic �-Cells From Lipotoxic Endoplasmic Reticulum Stress Through Upregulation of BiP and JunB","Daniel A. Cunha","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040737","REVIEW Clinical update Impact of glucose-lowering drugs on","Ele Ferrannini","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040738","Exendin-4 induction of cyclin D1 expression in INS-1 -cells: involvement of cAMP-responsive element","M-j Kim","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040739","Combining Incretin-Based Therapies With Insulin Realizing the potential in type 2 diabetes",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040740","Review Article Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective","Dominique Xavier Brown","2012",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040741","Differential anti-diabetic efficacy of incretin agonists vs. DPP-4 inhibition in high fat fed mice","Benjamin J. Lamont","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040742","ORIGINAL RESEARCH Open Access Synergism of peptide receptor-targeted Auger","Christoph Rochlitz","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040743","DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929–2940","Daniel J. Drucker","2003",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040744","Korea",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040745","The cientificWorldJOURNAL Clinical Study The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to",null,"2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040746","Anti-Obesity Drugs; Adverse Side Effects; Clinical Trials; Combination Therapy; Lifestyle Modifications Correspondence to Author:","A. K. Misra","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040747","For Peer Review Only GLP-1R Agonism Enhances Adjustable Gastric Banding In Diet-Induced Obese Rats","Kirk M. Habegger","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040748","Envelhecimento facial associado ao uso da tirzepatida: alterações estéticas e estratégias de manejo na harmonização orofacial – revisão integrativa da literatura.","Adriana Karollayne Silva Pedroso","2026","Revista fisio&terapia.","nonrandomized_study","article","10.69849/zynvd397",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040749","FOR THE LIRAGLUTIDE EFFECT ACTION IN DIABETES (LEAD)-6 STUDY GROUP*","John B. Buse","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040750","Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials with Time-to-Event Outcomes under ICH E9 (R1)","Yuhao Deng","2024","arXiv (Cornell University)","randomized_trial","article","10.48550/arxiv.2401.14684",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0040751","Research Article Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits","Christoffer Clemmensen","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040752","Effects of Exenatide Alone and in Combination With Daclizumab on -Cell Function in Long-Standing Type 1 Diabetes","Kristina I. Rother","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040753","Non Step-Preferred Step-Preferred Step-Preferred • Exenatide BID (Byetta)","Bottom Line","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040754","ORIGINAL ARTICLE Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of","Glucose Homeostasis","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040755","Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study","Michael Nauck","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040756","Diabète de type 2 : outils d'aide à la prise en charge thérapeutique","Ibrahim, Marluya","2024","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040757","REVIEW ARTICLE Incretin-based therapies","Anthony H. Stonehouse","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040758","Circuits for anesthesia, unawareness, OIRD, sleep and memory replay: MHb→IPN→PAG + DRN + MRN→claustrum→cortex.","Karin Vadovičová","2023","arXiv (Cornell University)","other","article","10.13140/rg.2.2.29677.97766",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0040759","Review Article Weight Loss Is Still an Essential Intervention in Obesity and its Complications: A Review","Jianzhong Xiao","2012",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040760","doi: 10.1210/en.2004-1349 Exenatide (Exendin-4) Improves Insulin Sensitivity and �-Cell Mass in Insulin-Resistant Obese fa/fa Zucker Rats Independent of Glycemia and Body Weight","Bronislava R. Gedulin","2004",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040761","Panel Members","Helena W. Rodbard","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040762","Health benefits of oat (Avena sativa) bioactives. Acute and second-meal effects of oat polar lipids and beta-glucans.","Hossain, Mohammad Mukul","2024","Lund University Publications (Lund University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040763","GLP-1 Use and Protein Demand","Bina, Justin D.","2025","AgEcon Search (University of Minnesota, USA)","other","article","10.22004/ag.econ.379045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040764","GLP-1 Receptor Agonists Linked to Lower Dementia Risk, Observational Studies Find","Dan Hurley","2025","Neurology Today","other","article","10.1097/01.wnt.0001113816.63158.25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040765","OBSERVATIONS",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040766","Αξιολόγηση της επίδρασης της τιρζεπατίδης στα νεφρικά εκβάματα σε ασθενείς με σακχαρώδη διαβήτη τύπου 2 και διαβητική νεφρική νόσο (RENT-DKD): πρωτόκολλο μιας τυχαιοποιημένης, διπλά-τυφλής, ελεγχόμενης με εικονικό φάρμακο κλινικής δοκιμής","Αρτέμιος Γ. Καραγιαννίδης","2023","University of Thessaly Institutional Repository (University of Thessaly)","randomized_trial","article","10.26253/heal.uth.39000",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0040767","2 3 4 5 6 7 8","Mansoor Husain","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040768","doi:10.1155/2011/601047 Review Article Glucagon-Like Peptide-1 Gene Therapy","Anne M. Rowzee","2011",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040769","GSK initiates phase III programme for novel type 2 diabetes medication, Syncria ® (albiglutide)",null,"2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0040770","Objectives",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040771","The incretin mimetic, exenatide: a novel treatment option for type 2 diabetes Published by:",null,"2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040772","PEGylated Exendin-4, a Modified GLP-1 Analog Exhibits More Potent Cardioprotection than Its Unmodified Parent Molecule on a Dose to Dose Basis in a Murine","Model Of Myocardial Infarction","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040773","RESEARCH ARTICLE The Short-Term Cost-Effectiveness of Once- Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States","Joshua A. Roth","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040774","Comparative Efficacy of Insulin Therapy vs Oral Antidiabetic Agents in T1DM and T2DM","So Yun Park","2025","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040775","CELL THERAPY AND ISLET TRANSPLANTATION Long-Term Insulin Independence and Improvement in Insulin Secretion After Supplemental Islet Infusion Under","Raquel N. Faradji","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040776","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92584-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040777","Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate The Ability to Activate the Glucagon-Like Peptide 1 Receptor In Vivo","Corinne Benquet","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040778","Statements Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits","Daniel J. Drucker","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040779","TRATAMENTO FARMACOLÓGICO DA OBESIDADE COM AGONISTAS DO RECEPTOR DE GLP-1 NA PREVENÇÃO DE EVENTOS CARDIOVASCULARES: REVISÃO SISTEMÁTICA COM META-ANÁLISE","MIGUEL LUCAS SILVA VALENTE","2026","Asclepius International Journal of Scientific Health Science","other","article","10.70779/aijshs.v5i3.520",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040780","Although the American Diabetes Associ-",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040781","ORIGINAL RESEARCH Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study","Javier Escalada-san","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040782","DIABETOLOGY & METABOLIC SYNDROME REVIEW Open Access",null,"2013",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040783","To cite: Anholm C,","Kumarathurai P","2014",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040784","Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET","Andreas Bauman","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040785","Kardiovaszkuláris rizikót befolyásoló betegségek előfordulásának és korszerű antidiabetikus terápia gyakoriságának vizsgálata akut coronaria szindrómában és komplex coronaria intervención átesett betegekben","Laura Csenge Fülöp","2026","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040786","ORIGINAL CONTRIBUTION Exendin-4 attenuates adverse cardiac remodelling in streptozocin- induced diabetes via specific actions on infiltrating macrophages","Mitchel Tate","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040787","DIABETICMedicine Original Article: Treatment",null,"2010",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040788","Cost-effectiveness analysis of Semaglutide treatment for weight management for overweight and obese (BMI ≥25) patients in combination with lifestyle intervention compared to the current standard of care in Norway.","Olsen, Sjur Aulesjord","2024","Duo Research Archive (University of Oslo)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040789","Retatrutide (LY3437943) for metabolic disorders: A systematic review of clinical outcomes in obesity and type 2 diabetes","Shruti Singh","2026","Indian Journal of Physiology and Pharmacology","systematic_review","article","10.25259/ijpp_357_2025",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0040790","GLP-1R Responsiveness Predicts Individual Gastric Bypass Efficacy on Glucose Tolerance in Rats",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040791","¡ Review Article LIRAGLUTIDE: THE LATEST ADDITION TO ARMAMENTARIUM OF ANTIDIABETIC DRUGS","Dubey Ak","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040792","REVIEW Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Differentiating the New Medications",null,"2010",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040793","CURRENT TOPICS",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040794","METABOLIC SYNDROME","Zhixin Guo","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040795","Learning Objectives 1. Compare and contrast the differences between the",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040796","Patient Preference and Adherence 2010:4 313–324 Patient Preference and Adherence Dovepress submit your manuscript | www.dovepress.com","Abd A Tahrani","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040797","Cardiometabolic Crossroads: Obesity, Sleep-Disordered Breathing, and Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction – A Mini-Review","Fulvio Cacciapuoti","2024","Heart and Mind","narrative_review","article","10.4103/hm.hm-d-24-00050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0040798","Exendin-4 Suppresses Src Activation and Reactive Oxygen Species Production in Diabetic Goto-Kakizaki Rat Islets in an Epac-Dependent Manner",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040799","Comparing management of cardio-metabolic risk in Diabetes Related Foot Disease: a retrospective audit","Do, Kimchi","2025","UNSWorks (University of New South Wales, Sydney, Australia)","nonrandomized_study","article","10.26190/unsworks/31417",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0040800","Teratogenic Effects of Lixisenatide: Anatomical Malformations and Histopathological Changes in Developing Chick Embryos","Yogesh Yadav","2025",null,"other","article","10.9734/bpi/msraa/v4/2168",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0040801","doi:10.1155/2012/460869 Research Article Suppression of the Nuclear Factor Eny2 Increases Insulin",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040802","Receptor–Expressing Cells Using a New Transgenic Mouse Model",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040803","In Vivo Imaging of GLP-1R with a Targeted Bimodal PET/ Fluorescence Imaging Agent","Christian Br","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040804","ORIGINAL RESEARCH Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)","Jean-louis Chiasson","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0040805","Bioactive peptides synthesis inspired from venoms","Julien Giribaldi","2019","theses.fr (ABES)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040806","ORIGINAL ARTICLE Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats","Jason G. Barrera","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040807","1 Review Interventions that Improve Body and Brain Bioenergetics for Parkinson’s Disease Risk Reduction and Therapy","Mark P. Mattsona B","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0040808","ORIGINAL ARTICLE Glucose Intolerance and Reduced Proliferation of Pancreatic �-Cells in Transgenic Pigs With Impaired","Glucose-dependent Insulinotropic","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040809","which permits unrestricted noncommercial use, provided the original work is properly cited. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013:6 123–129 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","Roberto Anichini","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040810","Treated With Exenatide or Sitagliptin","William Chen","2013",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040811","The Lira-1 study","Thomas Fremming Dejgaard","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040812","ORIGINAL RESEARCH Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study","Erin K. Buysman","2015",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040813","Propensity score matching in semaglutide retrospective studies","Elizabeth Mohney","2025","arXiv (Cornell University)","nonrandomized_study","article","10.48550/arxiv.2501.05533",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0040814","Improving blood glucose control in cardiac surgery patients : glycemic variability, nurse-compliance to insulin therapy protocols and use of incretin mimetics","Guillaume Besch","2017","theses.fr (ABES)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0040815","Gauging the Antiobesity Potential of Oral Semaglutide in Type 2 Diabetes in the Indian Context","Awadhesh Kumar Singh","2023",null,"other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0040816","Etude de la transition endothélio-mésenchymateuse des cellules endothéliales intra-insulaires de souris et modulation pharmacologique : intérêt dans la greffe d'îlots pancréatiques","Noura Sbat","2021",null,"other","article","10.70675/292d490cz4a4ez4eefzba79z2a3e68d706ff",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040817","Review Article Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors","Ki-suk Kim","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040818","A Review on Dual GIP/GLP-1 Receptor Agonists in Type 2 Diabetes: A New Era in Incretin Therapy","Challa Srilekha","2025",null,"narrative_review","article","10.56557/ajoaims/2025/v7i1164",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040819","Differential Protective Effects of Exenatide, an Agonist of GLP-1 Receptor and Piragliatin, a Glucokinase Activator in Beta Cell Response to Streptozotocin-Induced and","Endoplasmic Reticulum Stresses","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040820","RP-HPLC METHOD FOR DETERMINATION OF ANTI-DIABETIC DRUG LIRAGLUTIDE IN BULK AND TABLET FORMULATION","Supriya S patil Lalitha N","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.8412639",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040821","Clinical Study","Linong Ji","2012",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040822","Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain","Brown, Jamie","2025","UCL Discovery (University College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040823","Editorial Treatment of Diabetic Complications: How Can We Learn by Seeking and Blundering?","K. Pafili","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","editorial"],["R0040824","CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access","Anne Gill","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040825","Diabétologie","Gariani, Karim","2021","Archive ouverte UNIGE (University of Geneva)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040826","A New Chapter in Obesity Treatment: Mechanisms and Clinical Research Progress of Multi-target Peptide Agonists","YAN  Manli, ZHANG  Baoqing, HUANG  Lei, LI  Xiang","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12114/j.issn.1007-9572.2025.0372",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040827","ral Health and Quality of Life Outcomes ssBioMed Cent","Kristina Secnik Boye","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0040828","ORIGINAL RESEARCH Liraglutide as Add-On Therapy to Insulin in Type 2 Diabetes Mellitus: A Retrospective, Observational Study From a Daily Clinical Practice Setting","In Switzerland","2014",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040829","Review Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment","Barbara Fruci","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040830","Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005","David M. Kendall","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040831","Effect of dulaglutide on endothelial to mesenchymal transition of murine pancreatic intra-insular endothelial cells induced by cytokine stress at the initial phase of pancreatic islet transplantation","Bastien Misgault","2020","HAL (Le Centre pour la Communication Scientifique Directe)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040832","Pancreatic b-Cell Response to Increased Metabolic Demand and to Pharmacologic Secretagogues","Requires Epaca","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040833","Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week, Randomized, Placebo-Controlled Study (GETGOAL-DUO-1)","Matthew C. Riddle","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040834","RESEARCH ARTICLE Open Access","Byron Hoogwerf","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040835","GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice(要旨)","新 伊藤",null,"Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040836","Research Article Neuroprotection by Exendin-4 Is GLP-1 Receptor Specific but DA D3 Receptor Dependent, Causing Altered BrdU Incorporation in Subventricular Zone and Substantia Nigra","A. Harkavyi","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040837","Common Genetic Variation in GLP1R and Insulin Secretion in Response to Exogenous GLP-1 in Nondiabetic Subjects","A Pilot Study","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040838","private correspondence","Vedtofte L","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040839","Review Article The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A ‘‘Me Too’ ’ or ‘‘the Special One’’","Antidiabetic Class","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040840","CELL THERAPY AND ISLET TRANSPLANTATION The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy, and Metabolic Effects","Tatiana Froud","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040841","Prevention of Atrial Fibrillation: Contemporary Approaches and Future Perspectives","RYAN RAFAEL BARROS DE MACEDO","2025","International Journal of Health Science","other","article","10.22533/at.ed.1595152518037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040842","Review Article Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1","Xingchun Wang","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040843","PET of Glucagonlike Peptide Receptor Upregulation After Myocardial Ischemia or Reperfusion","Haokao Gao","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040844","Mass in Diabetic Patients","Bernard Portha","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040845","Journal of Translational Medicine Sample","Elisabeth Streckel","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040846","New Drug Class","Daniel J Drucker Michael","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040847","GLP-1受体激动剂治疗糖尿病的循证评价和对糖尿病大鼠胃动力影响的机制研究","李维辛","2012","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040848","RESEARCH ARTICLE Open Access","O Gomez-peralta","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040849","Glucagon-like Peptide-1 Receptor Signaling Modulates","Cell Apoptosis","2002",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040850","Word count: 2,442 Address for correspondence:","Matteo Monami","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040851","Conceptual Framework for the Medicalization of Obesity with Semaglutide-Based Treatments","Lorenzo Murace","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22089864",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040852","Sacramento Tomás Navarro, Collaborative Groups of the Diabetes and Obesity Unit of the","Alfonso López Ruiz","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040853","Reduce Food Intake through Different Mechanisms in Mice","Tanvi Talsania","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040854","One-Pot Two-Step Radiosynthesis of a New 18F‑Labeled Thiol Reactive Prosthetic Group and Its Conjugate for Insulinoma Imaging","Dale O. Kiesewetter","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040855","Agonists for the Treatment of Type 2 Diabetes","Endocrinol Metab","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040856","(synthetic exendin-4)1","Richard A Hiles","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040857","CASE REPORT Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes","Miyako Kishimoto","2016",null,"case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040858","Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice","Korean J Physiol Pharmacol","2014",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040859","Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and NF-kappa B Levels in Type 2 Diabetes","Liu, Xia","2019","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040860","Ann Robinson’s research reviews—14 September 2023",null,"2023","BMJ","other","article","10.1136/bmj.p2192","37739423",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040861","Understanding the Cardiovascular Effects of Incretin","Diabetes Metab J","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040862","OBJECTIVE",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040863","Effekten av liraglutid som monoterapi eller i kombination med metformin vid behandling av fetma och övervikt hos kvinnor med polycystiskt ovarialt syndrom","AL-Salman, Jasmine","2023","DiVA (Linkoping University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0040864","Review Article Update on Pharmacotherapy for Type 2 Diabetes","Ahmed Ss","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040865","doi: 10.1136/ebn1023","Karen Chang","2010",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040866","Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040867","Clinical Medicine Reviews in Vascular Health 2011:3 71 Exenatide: Review of its Role as Adjunctive Therapy in Patients with Type 2 Diabetes","On K. Bellows","2015",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040868","ORIGINAL CONTRIBUTION","Emma Robinson","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040869","Dipeptidyl Peptidase IV Inhibitor MK-0626 Attenuates Pancreatic Islet Injury in Tacrolimus-Induced Diabetic Rats","Byung Ha Chung","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040870","Facteurs déterminants à l’utilisation d’analogues du GLP 1 dans le diabètede type 2 en médecine générale : enquête auprès de 14 médecins généralistes prescripteurs d’analogues du GLP-1 en Lot-et-Garonne","Rémi Godard","2020","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040871","The Human GLP-1 Analog Liraglutide and the Pancreas Evidence for the Absence of Structural Pancreatic Changes in Three Species","Niels C. B. Nyborg","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040872","Anti-angiogenesis of Obesity-Related Peptides Resistin (23-42) and Exendin-3","蘇信芳","2003","Taipei Medical University Repository","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040873","利拉鲁肽对大鼠实验性牙周炎骨效应及炎症效应的影响","袁雪敏","2019","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040874","Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1","Matthew C. Riddle","2006","Diabetes Care","other","article","10.2337/diacare.29.02.06.dc05-1267","16443905",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040875","Semaglutide Attenuates Cerebral Ischemia-Reperfusion-Induced Brain Damage in Albino Rats Through Anti-Inflammatory and Antioxidant Mechanisms","Haidy Mohamed Ali Mohamed","2025","Zagazig University Medical Journal","preclinical","article","10.21608/zumj.2025.441605.4318",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040876","Adaptive -Cell Proliferation Is Severely Restricted With Advanced Age","Matthew M. Rankin","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040877","Will Oral Semaglutide be a Game-Changer in the Management of Type 2 Diabetes in Indian Context?","Arjun Baidya","2022",null,"other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040878","A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES",null,"2016",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0040879","79A6Z7L6WX Analysis of Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Weight Stall or Regain Post Bariatric Surgery: A Retrospective Observational Study",null,"2025","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2025.04.346",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040880","A GLP1-receptor-agonistáktól a glükagonreceptor-agonizmussal kiegészített hármashormonreceptor-aktiválásig : Új távlatok a 2-es típusú diabetes és az elhízás kezelésében","Winkler, Gábor","2023","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040881","The Impact of GLP-1 Receptor Agonists on Lipid Subfractions and Cardiometabolic Risk in Non-Diabetic Adults: A Systematic Review and Meta-Analysis","S. Sathiyapal","2026","Heart Lung and Circulation","systematic_review","article","10.1016/j.hlc.2026.07.573",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0040882","Research Article Glucagon-Like Peptide-1 Receptor Imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-Exendin-4 for the",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040883","Cardiovascular Benefits and Pharmacological Mechanisms of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Narrative Review","Amir Jan Ali","2026","Indus journal of bioscience research.","narrative_review","article","10.70749/ijbr.v4i2.2909",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0040884","REVIEW The evolving place of incretin-based therapies",null,"2013",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040885","Loss of Glycemic Control in Type 1 Diabetic PatientsWith andWithout Residual b-Cell Function URD KIELGAST, MD1,2","Liraglutidereduces Insulindosewithout","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040886","GLP-1–Based Therapy for Diabetes: What You Do Not Know Can Hurt You",null,"2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040887","Pharmacological Treatments of Polycystic Ovarian Syndrome","Anahita Rostam Shirazi","2022","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040888","RESEARCH ARTICLE Use of the Analytic Hierarchy Process for Medication Decision-Making in Type 2 Diabetes","Nisa M. Maruthur","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040889","Incretin-Based Therapies Viewpoints on the way to consensus",null,"2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040890","Do GLP-1 Medications Pay for Themselves?","Coady Wing","2026","National Bureau of Economic Research","nonrandomized_study","article","10.3386/w34678",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","report"],["R0040891","Article Glucose Metabolism in Critically Ill Patients: Are Incretins an Important Player?","Signe Tellerup Nielsen","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040892","ORIGINAL ARTICLE Exendin-4 Stimulation of Cyclin A2 in �-Cell Proliferation","Woo-jin Song","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040893","One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patientswith Type 2 diabetes","Degn, K.B.","2004",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040894","Efficient estimation of the target population average treatment effect from multi-source data","Zehao Su","2024","arXiv (Cornell University)","other_trial","article","10.48550/arxiv.2405.10769",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0040895","doi:10.1155/2011/898913 Review Article From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy","Ilaria Dicembrini","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040896","Japanese Clinical Medicine Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiab","Hiroki Yokoyama","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040897","Pharmacological Treatment of PCOS","Alaa Elachi","2023","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040898","Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial","Belma Ascic Buturovic","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040899","European","Rafael Simó","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040900","Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycaemia","Degn, K.B.","2004",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040901","The effects of semaglutide on adolescent male and female C57BL6/J mice","Katelyn Eisner","2025","cIRcle (University of British Columbia)","preclinical","article","10.14288/1.0451045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040902","www.mdpi.com/journal/ijms Neuroprotective Effects of Liraglutide for Stroke Model of Rats","Kenichiro Sato","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040903","Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin Diabetes","Kathleen Dungan","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040904","From Injections to Pills: GLP-1 for Type 2 Diabetes","Li, Sonia","2020","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.3875927",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040905","The use of phage display technology to discover GLP-1R modulators","Bennani, Kenza","2025","Archive ouverte UNIGE (University of Geneva)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040906","Review","Jason Seewoodhary","2013",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040907","ORIGINAL INVESTIGATION Exendin-4 ameliorates car e",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040908","open access to scientific and medical research Open Access Full Text Article Review Liraglutide in the management of type 2 diabetes","Estela Wajcberg","2013",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040909","GLP-1 Agonist in the Treatment of Parkinson, New Innovations: A Literature Review","Mohamad Barakat, Imadeddin","2024","HAL (Le Centre pour la Communication Scientifique Directe)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040910","Email correspondence","Vivian Fonseca","2006",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040911","ORIGINAL PAPER Managing Diabetes Mellitus: A Survey of Attitudes and Practices Among Family Physicians","Yacov Fogelman","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040912","胰高血糖素样肽-1受体激动剂在多囊卵巢综合征中的临床应用","周启敏","2019","Lanzhou University Institutional Repository","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0040913","Oral delivery of semaglutide through multifunctional FCRN-peptide targeting nanoparticles for treatment of type 2 diabetes mellitus","Pinto, Soraia Filipa Tavares","2024","Open Repository of the University of Porto (University of Porto)","other","article","10.34626/zjrr-cm36",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0040914","RESEARCH ARTICLE Activation of the GLP-1 Receptors in the Nucleus of the Solitary Tract Reduces Food Reward Behavior and Targets the Mesolimbic System","Jennifer E. Richard","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040915","The Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Quality Indicators of Colonoscopy – Systematic Review and Meta-analysis","Yu‐Tse Chiu","2025",null,"systematic_review","article","10.37766/inplasy2025.1.0054",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0040916","Analytic Review Glucose Metabolism in Critically Ill Patients: Are Incretins an Important Player?","Signe Tellerup Nielsen","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040917","Semaglutide and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-analysis","Eugene Yu-Chuan Kang","2025",null,"systematic_review","article","10.37766/inplasy2025.3.0110",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0040918","Renal protective effect of glucagon-like peptide-1 receptor agonist in patients with type II diabetes and chronic kidney disease","陳慧偵","2024","Taipei Medical University Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040919","Risk of pancreatitis with semaglutide (Ozempic) use for weight reduction: a systematic review","Khalil Bograin","2026","International Journal of Medicine in Developing Countries","systematic_review","article","10.24911/ijmdc.51-1782826605",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0040920","The Lira-1 study","Thomas Fremming Dejgaard","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040921","a Randomized Controlled Trial (AWARD-5) Diabetes Care 2014;37:2149–2158 | DOI: 10.2337/dc13-2761 OBJECTIVE",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040922","Public Perception on GLP1 receptor agonists : Leveraging Sentiment Analysis and BERTopic Modeling on Twitter Data","Correia, Jorge","2024","Archive ouverte UNIGE (University of Geneva)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0040923","Objectives",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040924","Exenatide in Combination Therapy: Small Study, Big Market, and Many Unanswered Questions",null,"2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040925","Exploring the Effects of GLP-1 Agonists on Weight Management in Non-Diabetic Individuals","Lakshya Alagan","2024","Berkeley Scientific Journal","other","article","10.5070/bs328264288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040926","COMMENTARY Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach","Sanjay Kalra","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040927","Description et évolution des usages problématiques potentiels des analogues du GLP-1 en Nouvelle Aquitaine entre 2018 et 2022","Margaux Jaeck","2025","HAL (Le Centre pour la Communication Scientifique Directe)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0040928","org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Effects of Exendin-4 on Male Reproductive Parameters of D-Galactose Induced Aging Mouse Mode","Correspondence To Ali","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040929","Efficacy and safety of glucagon-like peptide 1 analogs for prediabetes: A systematic review and meta-analyses","賴妘薇","2020","Taipei Medical University Repository","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0040930","Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006;47:2025–33","Damian Wild","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040931","GLP-1 Receptor Agonists In Diabetes And Weight Management","Nguyen An Khe Tran","2024","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040932","Injecting Ozempic Narratives: A Corpus-Based Discourse Analysis on U.S. Newspapers","Saana Sadinmäki","2025","Tampere University Institutional Repository (Tampere University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0040933","Glucagon-like Peptide‑1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications","Bikash Man","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040934","Research Article Assessment of Glucagon-Like Peptide-1 Analogue and Renin Inhibitor on the Binding and Regulation of GLP-1 Receptor in Type 1 Diabetic Rat Hearts","Shushan B. Artinian","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040935","Original Article Activation of Glucagon-Like Peptide-1 Receptor Signaling Does Not Modify the Growth or Apoptosis of Human","Pancreatic Cancer Cells","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040936","On cardiovascular complications in people with type 2 diabetes : Aspects of incretin-based therapy and glycemic control","Santos Pardo, Irene","2024","Open Archive (Karolinska Institutet)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0040937","Review Article Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","Feng Sun","2016",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0040938","一项在接受基础胰岛素联用或不联用口服降糖药治疗血糖控制不佳的2型糖尿病患者中，在加用或不加用二甲双胍下比较iGlarLixi与甘精胰岛素的疗效和安全性的为期30周的随机、活性对照、开放性、双治疗平行组、多中心研究","李汛",null,"Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040939","Transgenic","Laurie L. Baggio","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040940","Incretin-Based Therapy and the Quest for Sustained Improvements in b-Cell Health",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040941","Heart failure: focus on genes, kidney, and sudden death","Filippo Crea","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf872","41232809",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040942","ORIGINAL RESEARCH Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus","Pedro Mezquita","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0040943","The Use of GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes Mellitus: Mechanisms and Clinical Outcomes","Muhsin Ahmed","2026","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040944","利拉鲁肽对人牙周膜细胞增殖、迁移、炎症以及成骨分化潜能的影响","Yunqing Pang","2017","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040945","Original Article Pharmacologic Treatment Strategies in Children with Type 2 Diabetes Mellitus","Tatsuhiko Urakami","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040946","OBSERVATIONS Latent Autoimmune Diabetes in Adults Presenting as Diabetes “Recurrence ” After Bariatric","Surgery A","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040947","Costs and Consequences Associated With Newer Medications for Glycemic Control in Type 2 Diabetes","Mangala Rajan Mba","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040948","doi:10.1155/2012/519784 Review Article Bone: Incretin Hormones Perceiver or Receiver?","Ilaria Dicembrini","2012",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040949","Discovery of Dual-Action Membrane-Anchored Modulators of Incretin Receptors","Daniel Chinnapen","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040950","Tratamentul medicamentos în boala ficatului gras non-alcoolic: cine are nevoie de tratament, cum tratăm și cine tratează?","Peltec, A.I.","2019","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0040951","Tirzepatide相对于度拉糖肽对2型糖尿病患者的主要不良心血管事件的影响","李汛",null,"Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0040952","Predicting the agonist-bound structures of the glucagon-like peptide 1 receptor, a class B G protein-coupled receptor","Andrea Kirkpatrick","2012","CaltechAUTHORS (California Institute of Technology)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0040953","TYPE 1 DIABETES","Alex Rabinovitch","2007",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040954","Impacto de los farmacos para el control glucemico en el riesgo de accidente cerebrovascular","Joaquín Murguía‐González","2023","Revista de la Sociedad Argentina de Diabetes","other_trial","article","10.47196/diab.v57i3sup.683",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0040955","Challenges and Strategies for Moving Patients to","Linda Siminerio","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0040956","BAPTIST GALLWITZ, MD 1","Michael Böhmer","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040957","The emerging role of glucagon-like peptide-1 receptor agonists in male infertility: mechanisms, experimental evidence, and future clinical perspectives","Shubham Biswas","2026","International Journal of Basic & Clinical Pharmacology","randomized_trial","article","10.18203/2319-2003.ijbcp20262889",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0040958","Acute","Jacob Lønborg","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040959","Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study","Harsányi Adrienn","2025","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040960","l a r t","The Diabetes","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040961","TRIALS STUDY PROTOCOL Open Access Effect of additional treatment with EXenatide in","Martijn Scholte","2013",null,"protocol","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0040962","Is Incretin-Based Therapy Ready for the",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040963","Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone A double-blind pl","Michael A. Nauck","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040964","Review Article Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria","Martin Haluzík","2013",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040965","Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy","Doris A. Stoffers","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040966","OBSERVATIONS",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040967","doi:10.1155/2011/215764 Research Article Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials","Matteo Monami","2013",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0040968","Stratégie de préservation de la vascularisation des îlots pancréatiques au cours de la transplantation à l’aide d’un modèle de sphéroïde de cellules endothéliales et de cellules à insuline","Amira Saidi","2025",null,"other","article","10.70675/7276dc65z8f5az4d9fzaba0z706411b82278",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0040969","Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies","Safe Diabetes Care","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040970","JMCP JOURNAL OF MANAGED CARE PHARMACY® Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes","Jeremy M. Gleeson","2005",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040971","doi:10.1155/2012/635472 Review Article Cardiovascular Benefits of GLP-1-Based Therapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial","Vascular Dysfunction","2012",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040972","with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040973","Clinical Review Incretin agents in type 2 diabetes","Stuart A. Ross","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040974","0775 OSA Outcomes in Participants by Baseline BMI Classification from SURMOUNT-OSA Trials: A Post-Hoc Analysis","Ronald R. Grunstein","2025","SLEEP","other","article","10.1093/sleep/zsaf090.0775",null,null,"ClinicalTrials.gov:NCT05412004","S000156","openalex","TRUE","open_pdf","5","FALSE","article"],["R0040975","0772 The Impact of GLP-1 and GLP-1/GIP Receptor Agonists on Hypoglossal Nerve Stimulator Treatment in Sleep Apnea Patients","Arman Saeedi","2025","SLEEP","nonrandomized_study","article","10.1093/sleep/zsaf090.0772",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0040976","TheFateofTaspoglutide,aWeeklyGLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2Diabetes","The T-emerge Trial","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040977","Lixisenatide as add-on therapy to basal insulin","Dominique Xavier Brown","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040978","Premature Death in Kidney Transplant Recipients: The Time for Trials is Now","Amanda J. Vinson","2022","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2021111517","35292438",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0040979","Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by EstablishedBasal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L)","Matthew C. Riddle","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040980","54 Cardiovascular safety of glucagon-like peptide-1 receptor agonists in real-world practice: a comparative phenotype-based analysis","Justine Tin Nok Chan","2026",null,"nonrandomized_study","article","10.1136/heartjnl-2026-bcs.237",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0040981","Towards clinical imaging with F-18-labelled exendin-4, synthesised via click chemistry","Mikkola, K.","2013","Åbo Akademi University Research Portal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040982","Commentary Is Exenatide the Next Big Thing in Parkinson’s Disease?","Tanya Simunia","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040983","Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With","Insulin Glargine","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040984","ORIGINAL RESEARCH A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice","Marc Evans","2012",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040985","ORIGINAL RESEARCH Bone Fracture Risk is Not Associated with the Use of Glucagon- Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis","Johanna H. M. Driessen","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040986","A Novel Humanized GLP-1 Receptor Model Enables Both Affinity Purification and Cre-LoxP Deletion of the Receptor. PLoS One 9:e93746","Lucy S. Jun","2014",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040987","DEBATE Open Access","Bjørn H Ebdrup","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040988","Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and",null,"2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040989","Efficacy and safety of semaglutide in the treatment of obesity","Belén Ancora Florencia","2024",null,"other","article","10.62486/978-9915-9875-2-1.ch15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0040990","Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes","Controlled Trial","2015",null,"randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT00765817","S000345","openalex","FALSE","no_doi","1","FALSE","article"],["R0040991","Attenuates the Nicotine-Induced Locomotor Stimulation, Accumbal Dopamine Release, Conditioned Place Preference as well as the Expression of Locomotor Sensitization in Mice","Emil Egecioglu","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040992","DIABETIC PERSPECTIVES www.The-RDS.org 208 DOI 10.1900/RDS.2006.3.208 T The Fate of Beta-Cells in Type 2 Diabetes and the Possible Role of Pharmacological Interventions",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040993","Clinical Medicine Reviews in Vascular Health 2010:2 63 Saxagliptin a New Second Line Therapy After metformin for the Treatment of Type 2 Diabetes","Anna I. Palalau","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040994","Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice","Emil Egecioglu","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040995","Exenatide-Induced Reduction in Energy Intake Is AssociatedWith Increase in Hypothalamic Connectivity","Annette Horstmann","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0040996","Incretin Effects on b-Cell Function, Replication, andMass The human perspective","Alan J. Garber","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0040997","Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study Diabetes Care 2015;38:1089–1098 | DOI: 10.2337/dc13-2983 OBJECTIVE",null,"2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0040998","Editorial","Y Ho","2016",null,"commentary","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0040999","ARTICLE","Royal Guildford Hospital","2009",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041000","RESPONSE TO COMMENT ON SARKAR ET AL. Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041001","Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho- Dependent Mechanism",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041002","RESEARCH ARTICLE Open Access Effect","Prajakti A Kothare","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041003","Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, b-Cell Mass, or Food Intake in Metallothionein-","Preproexendin Transgenic Mice","2000",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041004","Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24Weeks of Treatment Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)","Itamar Raz Md","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041005","Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes","Articles The","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041006","exenatide in the treatment of type 2 diabetes","Catherine A Schnabel","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041007","BindingDB Entry 13172: GLP-1R Agonist and Therapeutic Method Thereof","BindingDB","2025","UC San Diego","other","article","10.7270/q2n58s51",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041008","Diabetic Patient","To Hypoglycemia","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041009","Research Article Exenatide Activates the APPL1-AMPK-PPAR","Lei Xiaotian","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041010","GLP-1 Based Therapy and the Exocrine Pancreas: Accelerated Dysplasia and Cancer?","Peter C. Butler","2014","eScholarship (California Digital Library)","other","article","10.6092/1590-8577/2775",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041011","GLP-1R Agonism Enhances Adjustable Gastric Banding in Diet-Induced Obese Rats","David A. D’alessio","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041012","PatientsWith Type 2 Diabetes A randomized, open-label trial","Richard E. Pratley","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041013","GLP-1 Agonists in Severe Asthma","University of California Office of the President","2018","California Digital Library","other_trial","article","10.17920/g9p072",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0041014","Diabetes: An",null,"2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041015","Research Article JNK3 Is Required for the Cytoprotective Effect of Exendin 4","Julie Kerr-conte","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041016","exendin-4 infusion in conscious rats","Sm Gardiner","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041017","B2013-PA对db/db小鼠减肥和肾脏保护作用及其机制研究","刘莎","2017","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041018","GLP-1 Therapies Repurposed for Opioid Use Disorder","Winnie Chen","2025",null,"other","article","10.13140/rg.2.2.19026.62406",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041019","doi:10.5402/2012/340632 Review Article Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes","Isrn Endocrinology","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041020","Letter Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance","Endocrinol Metab","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041021","Mechanically reinforced beta cell encapsulation device with drug delivery functions","Mette Steen Toftdal","2024",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041022","Diabetic Patient","To Hypoglycemia","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041023","R e v I e w Clinical Medicine Insights: Therapeutics 2010:2 715 A Review of exenatide in the Treatment of Type 2 Diabetes","Aashish G. Samat Amit Bhargava","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041024","Cardiovascular outcomes and healthcare costs of Liraglutide versus Basal insulin for Type 2 diabetes patients at high cardiovascular risk","黃琬珺","2020","Taipei Medical University Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041025","r e s e a r","The Diabetes","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041026","SGLT2 inhibitors for diabetes are linked to increased risk of lower limb amputation","Zosia Kmietowicz","2018","BMJ","other","article","10.1136/bmj.k4828","30429136",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041027","Early responders to liraglutide 3,0 mg as adjunct to diet and exercise from the SCALE Obesity and Prediabetes trial: efficacy and safety results","Kjeld Hermansen","2015",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","conference-paper"],["R0041028","12 Stats About Semaglutide to Make You Look Smart Around the Water Cooler","d5dqwfq615","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.8175314",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041029","Received: 2014.06.11 Accepted: 2014.07.15 Published: 2014.07.30 Exenatide Treatment Exerts Anxiolytic- and Antidepressant-Like Effects and Reverses Neuropathy in a Mouse Model of Type-2 Diabetes","Abce Ipek","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041030","Incretin physiology and pathophysiology from an Asian perspective","Young Min Cho","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041031","Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57(10):2577e2587","Cendrine Cabou","2008",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041032","Efficacy and safety of GLP-1 receptor agonists in patients with diabetes mellitus - systematic review","Petrova, L.","2023",null,"systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0041033","ORIGINAL RESEARCH Efficacy of Liraglutide in a Real-Life Cohort","Anthony Heymann","2014",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041034","Uso de agonistas GLP-1 y GIP/GLP-1 para diabetes y control ponderal: implicaciones nutricionales, clínicas y éticas en el contexto mundial, México y Quintana Roo","Eneida Nadhxiely Canto Arau","2026","Ciencia Latina Revista Científica Multidisciplinar","other","article","10.37811/cl_rcm.v10i3.24610",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041035","Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes","Juraj Koska Md","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041036","Effect of Dulaglutide on HbA1c and Vit B12, on Alloxan-Induced Diabetes in Albino Mice","Najah Balaoo","2025","AlQalam Journal of Medical and Applied Sciences","preclinical","article","10.54361/ajmas.2584107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041037","Effects of Tirzepatide on Erythropoiesis in People with Obesity: An Individual Patient Data Meta-analysis of the SURMOUNT Trials","Yohei Doi","2026","Vivli","systematic_review","article","10.25934/pr00011648",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0041038","INTERNATIONAL STUDY GROUP","Ole Schmitz","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041039","Correspondence to","Holt Ta","2012",null,"commentary","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0041040","RESEARCH Open Access The use of exenatide in severely burned pediatric patients","Gabriel A Mecott","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041041","Détournement de l'Ozempic, un médicament anti-diabétique pour perdre du poids","Sellah, Inès","2024","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041042","doi:10.1155/2012/924168 Review Article A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer","Wei-yih Chiu","2012",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041043","Semaglutida (Ozempic) e neuropatia óptica","Bruna Vilela Ribeiro","2025","Editora Pasteur eBooks","other","article","10.59290/4954020212",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0041044","Efficacy and Safety of the Once- Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study DOI: 10.2337/dc13-2855 OBJECTIVE",null,"2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041045","Glucagon-Like Peptide 1 Receptor Agonist ZP10A","Christian Thorkildsen","2003",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041046","Abnehmspritzen Mounjaro - Wegovy - Ozempic - Zepbound : gesund und schnell Gewicht verlieren : aktuellste Informationen zu Semaglutiden","Lipman, Richard",null,null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041047","Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice","Tao Zhu","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041048","Efficacy and Safety of the Once- Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study Diabetes Care 2014;37:2723–2730 | DOI: 10.2337/dc13-2855 OBJECTIVE",null,"2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041049","Analogues of glucagon-like peptide 1 and obesity, what indications and what results?","Gérard Bergua","2024","Cairn.info","other","article","10.1684/med.2024.984",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041050","Overcoming Barriers to Adoption of Glucagon-like Peptide-1 Antagonists in India","Shweta Arora","2024","INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT","other","article","10.55041/ijsrem35943",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041051","RESEARCH ARTICLE The GLP-1 Receptor Agonist Exendin-4 and Diazepam Differentially Regulate GABAA Receptor-Mediated Tonic Currents in Rat","Pyramidal Neurons","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041052","ORIGINAL ARTICLE Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets","Kyle W. Sloop","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041053","GLP-1 receptor agonisták a kardiovaszkuláris kockázat tükrében","Balogh, Zoltán","2020","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041054","Specialty: Internal Medicine/Diabetology","Abcdef Hiromi Hamamoto","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041055","Acute pancreatitis and diabetic ketoacidosis associated with compounded semaglutide","Napat Wongmat","2026","The Southwest Journal of Medicine","other","article","10.12746/swjm.v14i60.1573",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041056","The Patchable Body: Evolutionary Vulnerabilities, Biological Zero-Day Mechanisms, and the Political Consequences of Differential Patch Access","HUYNH GIA BAO","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20822470",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0041057","Correspondence to:","Diabetes Centre","2014",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","letter"],["R0041058","REVIEW Incretin-Based Therapy: a Powerful and Promising Weapon in the Treatment of Type 2 Diabetes Mellitus","Chrysi Koliaki","2010",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041059","22 Emerging Therapies for Treatment of Type 2 Diabetes","Siddharth N Shah","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041060","Exendin-4对糖尿病胃血管病变及胃动力障碍的作用及机制研究","李维辛",null,"Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0041061","RESEARCH ARTICLE Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats","Shunsuke Fujita","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041062","Exendin-4对2型糖尿病大鼠胃组织氧化应激及胃动力的影响","李维辛","2012","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041063","Effect of Semaglutide on Obese Female Patients with Polycystic Ovarian Disease: A Retrospective Observational Study and Systematic Review","Prakash Narayan Gupta","2026","International Journal of Pharmaceutical Quality Assurance","systematic_review","article","10.25258/ijpqa.17.1.31",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0041064","REVIEW Open Access Clinical comments related to medullary thyroid cancer diagnosis and management","Leonidas H Duntas","2009",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041065","Pharmacological management of diabetes type 2","Sheyda Mazloomi","2024","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041066","WEIGHT REBOUND POST GLP-1 RA CESSATION","Norhaliza MA","2025","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.040.s1.053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041067","Original Article Exendin-4 Potently Decreases Ghrelin Levels in Fasting Rats","Mayte Alvarez-crespo","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041068","Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in human? Diabetes 2012; 61: 2199–2204. 390","Jiwen (jim Liu","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041069","Evaluating Histopathological Changes in Kidneys of Developing Chick Embryos Induced by Lixisenatide","Amit Kumar Srivastava","2025",null,"other","article","10.9734/bpi/rpbs/v4/5500",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0041070","Benefits of Liraglutide Treatment in Overweight and Obese Older","Individualswith Prediabetes","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041071","ORIGINAL RESEARCH Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice—EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study","Jean-francois Gautier","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041072","Glucagon-like Peptide-1 (GLP-1) Receptor Agonists: Mechanism of action and side effects","Saania Tariq","2026","The Calgary Guide to Understanding Disease","other","article","10.60716/vmd6-yc12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041073","which permits unrestricted noncommercial use, provided the original work is properly cited. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 165–174 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","Helen Berlie","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041074","Maintaining an adequat...","Antonio Nicolucci","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041075","GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal","Intraepithelial Lymphocyte Glp-r","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041076","DOI 10.1186/s12933-015-0188-1Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku,",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041077","Research Article Liraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice","Bingxiang Yuan","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041078","Periconception Discontinuation of GLP-1 Receptor Agonists and GLP-1/GIP Dual Agonists: Contraception Reliability, Metabolic Rebound, and Early Pregnancy Outcomes-A Systematic Review with a Clinical Transition Pathway","Wiku Andonotopo","2026",null,"systematic_review","article","10.13140/rg.2.2.24567.69287",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0041079","GASTROENTEROLOGY 2004;127:546–558 Oxyntomodulin and Glucagon-Like Peptide-1 Differentially Regulate Murine Food Intake and Energy Expenditure","Laurie L. Baggio","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041080","Exenatide-Induced Reduction in Energy Intake Is AssociatedWith Increase in Hypothalamic Connectivity","Haiko Schlögl Md","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041081","Correspondence to","Lise L Gluud","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","letter"],["R0041082","Ocular Effects of GLP-1 Receptor Agonists: A Review of Current Evidence and Safety Concerns","Giuseppe Maria Albanese","2025","Diabetology","narrative_review","article","10.3390/diabetology6100117",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041083","REVIEW ARTICLE Diabetes mellitus: new challenges and innovative therapies","Cristina M. Sena","2009",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041084","CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular safety of exenatide BID: an","Robert Ratner","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041085","iNKT Invariant natural killer T PASI Psoriasis Area and Severity Index","D. J. Drucker","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041086","DTB Select: 9 | September 2016",null,"2016","Drug and Therapeutics Bulletin","other","article","10.1136/dtb.2016.9.0422",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041087","艾塞那肽对宫腔粘连小鼠的作用 及其机制研究","丁媛","2019","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041088","Article URL","Yen-ta Chen","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041089","Ceguera Asociada a Ozempic: Revisión Sistemática sobre la Relación entre Semaglutida y Neuropatía Óptica Isquémica Anterior no Arterítica NAION","Sánchez Knupflemacher, Daniel","2025","Dialnet (Universidad de la Rioja)","nonrandomized_study","article","10.37811/cl_rcm.v9i5.19867",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041090","A diabetes retinopathiat befolyásoló tényezők vizsgálata","János Bencze","2023","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041091","Integrating Machine Learning and Pathway Analysis for Precision Medicine in Type 2 Diabetes: Predictive Modeling and Therapeutic Target Identification","Iram Wajahat","2025","Proceedings of the ... International Florida Artificial Intelligence Research Society Conference","other","article","10.32473/flairs.38.1.138766",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0041092","Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005","Ralph A. Defronzo","2015",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041093","RESEARCH ARTICLE Open Access","Ramzi A Ajjan","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041094","RESEARCH ARTICLE","Kristin Taylor","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041095","Original Article Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A","Endocrinol Metab","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041096","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-91804-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041097","Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes","Helle Harder","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041098","Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2","Vladimer Darsalia","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041099","Methods",null,"2007",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041100","Collaborative Groups of the Diabetes and Obesity Unit of the Hospital Reina Sofía","Ricardo Soriano Sánchez","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041101","ORIGINAL ARTICLE Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats","Bethany P. Cummings","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041102","Obesity: How long should drug treatment last?","Elisabeth Mahase","2023","BMJ","other","article","10.1136/bmj.p1772","37527846",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041103","Glucagon-Like Peptide-1 Induced Signaling and Insulin Secretion Do Not Drive Fuel and Energy Metabolism in Primary Rodent Pancreatic b-Cells","Marie-line Peyot","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041104","Clinical Study Study of Postprandial Lipaemia in Type 2","Diabetes Mellitus","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041105","Behandling med GLP-1-reseptor agonist til personer med overvekt eller fedme uten diabetes type II: en litteraturstudie om potensielle kardioprotektive egenskaper","Roald, Madicken Victoria Söderlind","2024","Duo Research Archive (University of Oslo)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041106","Press Release",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041107","Exploratory Trial of Intranasal Administration of Glucagon-Like Peptide-1 in Japanese Patients With Type 2 Diabetes Diabetes Care 2014;37:2024–2027 | DOI: 10.2337/dc13-0690 OBJECTIVE",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041108","Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes","Steve Bain","2025","Cronfa (Swansea University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041109","Running Title: Exenatide once weekly, 52-wk safety & efficacy","Weight Loss","2016",null,"other_trial","article",null,null,null,"ClinicalTrials.gov:NCT00308139","S002279","openalex","FALSE","no_doi","5","FALSE","article"],["R0041110","RESEARCH ARTICLE Preservation of the Blood Brain Barrier and Cortical Neuronal Tissue by Liraglutide, a Long Acting Glucagon-Like-1 Analogue, after Experimental Traumatic Brain Injury","Jakob Hakon","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041111","An accidental liraglutide overdose: case report L",null,"2015",null,"case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041112","Completed Liraglutide Type 2 Diabetes Clinical Trials Diabetes Care 2015;38:1058–1066 | DOI: 10.2337/dc13-1210 OBJECTIVE","Pancreatitis A","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0041113","-Cell Pdx1 Expression Is Essential for the",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041114","myocardial ischemia-reperfusion injury studies","Paulus Wohlfart","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041115","Receptor Abbreviations","Ad Adenoviral Vector","2012",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041116","RESEARCH ARTICLE Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice","Kanako Tamura","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041117","Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington’s Disease","Stuart Maudsley","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041118","Managing Loss of Glycemic Control in Middle-Aged Patients With Diabetes: The Role of GLP-1 Receptor Agonists","Assistance From E","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041119","Semaglutide: Untangling the Gordian Knot of Glucose Control","Dr Sanjay Kalra","2022",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041120","Drugs and prescribing in the new decade","Rupert Payne","2020","Prescriber","other","article","10.1002/psb.1813",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041121","Therapeutic Roles of Semaglutide in Type 2 Diabetes and Its Complications","Xiaohan Li","2025","Theoretical and Natural Science","other","article","10.54254/2753-8818/2026.pj30890",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041122","GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond","Donna Ryan","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041123","p2smi: A Python Toolkit for Peptide FASTA-to-SMILES Conversion and Molecular Property Analysis","Aaron L. Feller","2025","arXiv (Cornell University)","other","article","10.48550/arxiv.2505.00719",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0041124","Glucagon-like peptide-1 influences proliferation within the spinal cord; an effect via cerebrospinal fluid contacting neurons?","Clark, Marilyn Heather May","2023","White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041125","Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates","Richard P. Shannon","2012","European Heart Journal Supplements","randomized_trial","article","10.1093/eurheartj/sus001",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041126","GLP‐1 receptor agonists not associated with increased suicidality",null,"2024","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31245",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041127","Transgenic","Laurie L. Baggio","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041128","Investigate the effects of glucagon-like peptide-1 receptor agonists(GLP-1 RAs)on the risk of dementia in patients with type 2 diabetes mellitus","許綾珍","2024","Taipei Medical University Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041129","Obesity Management in Primary Care: Clinical Approaches and Policy Implications in the Era of Incretin-Based Therapies","Chung-Woo Lee","2026","Korean Journal of Family Practice","other","article","10.21215/kjfp.2026.16.2.81",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041130","Effects of Exenatide Plus Rosiglitazone on �-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on","Ralph A. Defronzo","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041131","1876-8938/11 2011 Bentham Open Open Access Role of the Glucagon-like Peptide-1 Receptor Agonist in Maintaining","Pluripotency Human","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041132","Diabétologie","Jornayvaz, François","2017","Archive ouverte UNIGE (University of Geneva)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0041133","Az elhízás farmakológiai kezelése","Ayoleyi Orowole Ehinmosan","2022","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041134","Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041135","Quadruple therapy in HFpEF with type 2 diabetes: Time to implement?","Gregg C. Fonarow","2025","Kardiologia Polska","other","article","10.33963/v.phj.110268","41408940",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041136","Oral Delivery of Exenatide Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate","Baojie Zhang","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041137","METABOLIC SYNDROME",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041138","GLP-1–Based Therapies and the Exocrine Pancreas:","More Light","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041139","Tracing the Evolution of Antidiabetic Treatments: A Reflection of Cardiovascular Outcomes","Ryota Yagi","2025","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041140","Newer Agents Better? Diabetes Care 2014;37:1338–1345 | DOI: 10.2337/dc13-1901 OBJECTIVE",null,"2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041141","RESPONSE TO COMMENT ON THOMSEN ET AL. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population- Based Case-Control Study. Diabetes Care",null,"2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041142","DIABETOLOGY",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041143","RADIOSYNTHESIS OF [64CU((S)-P-MALEIMIDO-BENZYL-NOTA)]- AND PREPARATION OF HIGH EFFECTIVE SPECIFIC ACTIVITY [64CU]-MAN-EXENDIN-4(9-39) VIA SITE-SPECIFIC PRELABELING","Schlesinger, J.","2009","Åbo Akademi University Research Portal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041144","Correspondence","Bo Ahrén","2007",null,"commentary","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0041145","A FRMDable Future for Fibrosis?","Fiona E. Karet","2024","Kidney360","nonrandomized_study","article","10.34067/kid.0000000638","39724106",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041146","Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges OBJECTIVE",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041147","One weeks treatment with the long acting GLP-1 derivative, NN2211, markedsly increases 24-h glycaemia, reduces endogenous glucose release and improves alfa- and beta-cell function in type 2 diabetes patients","Degn, Kirstine Bruun","2004",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041148","GLP-1 Receptor Agonists in Alcohol-Associated Liver Disease: A Scoping Review of Mechanisms, Preclinical Evidence, Clinical Efficacy, and Therapeutic Potential","Daniel Heringer","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0041149","EDITORIAL Taking lizard saliva to heart","Derek J. Hausenloy","2011",null,"commentary","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0041150","RESEARCH ARTICLE Liraglutide Improves Hypertension and Metabolic Perturbation in a Rat Model of","Polycystic Ovarian Syndrome","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041151","UK study to look at semaglutide for alcohol addiction and obesity",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.425949",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041152","Article Effect of the GLP-1 Analog Exendin-4 and Oxaliplatin on","Intrahepatic Cholangiocarcinoma","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041153","Exendin-4 Induces Cell Adhesion and Differentiation and Counteracts the Invasive Potential of Human","Neuroblastoma Cells","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041154","Exendin-4在失血性休克损伤救治的应用","宋翔","2015","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041155","Orlistat: weight lost at cost of HIV rebound","Cristina Gervasoni","2016","Journal of Antimicrobial Chemotherapy","other","article","10.1093/jac/dkw033","26945709",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041156","P044: First report of GLP-1 agonist use in MCAD deficiency","Shaindy Grunwald","2026","Genetics in Medicine Open","other","article","10.1016/j.gimo.2026.103535",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041157","Nephrotoxicity in Mice After Repeated Imaging Using 111In-Labeled Peptides","Marleen Melis","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041158","Practical Use of Exenatide and Pramlintide for the Treatment of Type 2 Diabetes","Lisa T. Meade","2009","Journal of Pharmacy Practice","other","article","10.1177/0897190009333164",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041159","Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study","Jean‐Baptiste Julla","2019","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0041160","of Clinical Endocrinologists/American","Commenton Inzucchi","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041161","Hepatic-glycemic Interdependence: the Bidirectional Relationship between Type 2 Diabetes and MASLD and Emerging Therapeutic Strategies","CHEN  Yiming, HUANG  Yiling, JI  Fei, LYU  Ling, HUANG  Yu, WU  Zeyu, HANG  Qiqi, PING  Fan, YANG  Meng","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12114/j.issn.1007-9572.2025.0455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041162","Integrating Continuous Glucose Monitoring, Novel Antidiabetic Therapies, And Social Risk Assessment: A Multidisciplinary Primary Care Approach To Modern Diabetes Management Involving Family Physicians, Nursing, Pharmacist, Laboratory And Social Service","Dr.Rana matouq M Alaofi","2024","The Review of Diabetic Studies","other","article","10.70082/pw8yvn15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041163","Efficacy of GLP-1 Infusion in Congestive Heart Failure Patients on Myocardial Function","Romilla Yogesh Bijlani","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041164","Nanomedicines targeting intestinal Fc receptor to enhance the oral delivery of antidiabetic peptides","João David Batista da Costa Almeida","2025","Open Repository of the University of Porto (University of Porto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041165","Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One. 2012;7(2):e31394. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Publish your work in this journal Submit your manuscr","Jinmi Lee","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041166","ORIGINAL INVESTIGATION Open Access","Rebekka Faber","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041167","Ozempic® : les risques liés aux usages non conformes à visée amaigrissante","Arthur-Mike Ahonon","2025","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041168","利拉鲁肽对糖尿病大鼠牙周炎抗炎和成骨作用的影响","杨嫚","2019","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041169","NOVEL PHARMACOLOGICAL AND INTERVENTIONS FOR OBESITY, HYPERTENSION AND DIABETES MELLITUS: A REVIEW ON CURRENT GUIDELINES","Dr. Malghalara Suleman","2026","Journal of medical & health sciences review.","narrative_review","article","10.65035/04n0ae61",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041170","Management of diabetes mellitus in patients with severe mental disorders using new generation hypoglycemic drugs- A review of the literature","O. Vasiliu","2023","PubMed Central","nonrandomized_study","article","10.1192/j.eurpsy.2023.1226",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0041171","Клинико-фармакологическая характеристика и аспекты рационального применения основных групп лекарственных препаратов в лечении сахарного диабета 2-го типа","Т.А. Чак","2025","Рецепт","other","article","10.34883/pi.2025.28.3.005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041172","Overview","Daniel J. Drucker Md","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041173","Research progress and future prospects of small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs)","Yuxiang Tu","2025","Metabolism and Target Organ Damage","other_trial","article","10.20517/mtod.2024.99",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0041174","Efficacy of liraglutide therapy in Japanese type 2","Mitsuyoshi Takahara","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041175","Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like","Hirotaka Watada","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041176","Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia","Glucagon-producing Neuroendocrine Tumors","2016",null,"commentary","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0041177","Open Access Full Text Article","Julia A Gaebler","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041178","Management of Type 2 diabetes with Liraglutide","Larsen, Mette Bohl; id_orcid 0009-0009-9913-1011","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041179","ORIGINAL RESEARCH IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy","Nick Freemantle","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041180","*De and § Can",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041181","Development of thermosensitive hydrogel as a long-term delivery system for GLP-1 agonists","Donghan Cai","2024","Taipei Medical University Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041182","Research Article Liraglutide Suppresses the Plasma Levels of Active and Des-Acyl Ghrelin Independently of Active Glucagon-Like Peptide-1 Levels in Mice","Isrn Endocrinology","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041183","Controlled Trial (AWARD-3) DOI: 10.2337/dc13-2759 OBJECTIVE","Monotherapy Versusmetformin In","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041184","Open Access Full Text Article","Jothydev Kesavadev","2013",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041185","Discovery of (S)‑2-Cyclopentyl‑N‑((1-isopropylpyrrolidin2-yl)-9- methyl-1-oxo-2,9-dihydro‑1H‑pyrrido[3,4‑b]indole-4-carboxamide",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041186","monotherapy in Type 2 diabetes mellitus","M. J. Davies","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041187","A Critical Analysis of the Clinical Use of Incretin-Based Therapies",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041188","RESEARCH ARTICLE Effect of Hemodialysis on Plasma Glucose Profile and Plasma Level of Liraglutide in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease: A Pilot Study","Takeshi Osonoi","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041189","Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database","Jennie H. Best","2013",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041190","A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin","Pedro Mezquita","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041191","The role of GLP-1 receptor agonist as a potential treatment for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","Sara Behbahani","2017","OpenBU (Boston University)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","dissertation"],["R0041192","A eficácia e segurança do Mounjaro e Ozempic: uma revisão de literatura","Monica Ribeiro Portela","2026",null,"other","article","10.36229/978-65-5866-612-7.cap.02",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0041193","RESEARCH ARTICLE A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial","Arina Miyoshi","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041194","ORIGINAL RESEARCH Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study","Stephan Matthaei","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041195","Original Article","Gitte Hansen","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041196","Non-Pharmacological and Pharmacological Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): An Overview","Mariya Tabassum","2025","Journal of Nephrology & Endocrinology Research","other","article","10.47363/jone/2025(5)140",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041197","RESEARCH ARTICLE The Effects of Exendin-4 Treatment on Graft Failure: An Animal Study Using a Novel Re- Vascularized Minimal Human Islet Transplant Model","Afaf Sahraoui","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041198","which permits unrestricted noncommercial use, provided the original work is properly cited. Patient Preference and Adherence 2013:7 35–45 Patient Preference and Adherence","Economic Considerations","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041199","Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes","A Randomized Trial","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041200","Objectives",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041201","Printed in U.S.A. Copyright © 2002 by The Endocrine Society Exendin-4 as a Stimulator of Rat Insulin I Gene Promoter Activity via bZIP/CRE Interactions Sensitive to Serine/Threonine Protein Kinase Inhibitor Ro 31-8220","Oleg G. Chepurny","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041202","Cardiovascular and Metabolic Disease","Peplow, Phil","2015","RSC drug discovery/RSC drug discovery series","other","article","10.1039/9781782622390",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0041203","doi:10.1155/2012/672658 Research Article Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis","Carlo M. Rotella","2016",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","article"],["R0041204","Az endoszkópos vizsgálatok sajátosságai inkretinkezelés alatt cukorbetegeknél és obesitas esetén = Peculiarities of endoscopic examinations during incretin therapy in diabetic and obese patients","György Miklós Buzás","2026","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0041205","Une nouvelle approche pharmacologique pour la gestion de l’obésité à l’officine : analogues du GLP-1","Guillaume Coguic","2025","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041206","Data Sources: Electronic databases (PubMed, Web of Science, Cochrane Central Register of Controlled Trials, U.S. Food and Drug Administration, European Medicines Agency,","Francesco Zaccardi","2015",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041207","RISK FACTOR IN TYPE 2",null,"2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041208","Exenatide: A New Option for the Treatment of Type 2 Diabetes","Bong Kyu Yoo","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041209","COMMENTS AND RESPONSES Type 2 Diabetes","Southside Endocrinology","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041210","ORIGINAL Determination of Boc5 in Rat Plasma by HPLC–MS/MS and Its Application to a Pharmacokinetic Study","Ruixing Li","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041211","doi:10.5402/2012/625809 Review Article The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes","Isrn Endocrinology","2011",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0041212","Roles of glucagon-like peptide 1 analogues in osteoarthritis : characterization of analgesic, anti-inflammatory and structural effects of liraglutide","C. Meurot","2022","theses.fr (ABES)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041213","Glucagon-Like Peptide-1 Receptor Agonists Protect Against Hepatocyte Senescence Driving Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis","Federica Zatterale","2025","EMJ Diabetes","other","article","10.33590/emjdiabet/tvaj8774",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041214","Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database","Edward S. Horton","2013",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041215","One-Year Treatment With Exenatide Improves -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients","Controlled Trial","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041216","Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-d. Diabetes 60(9):2245e2256","Cendrine Cabou","2011",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041217","Durable glycaemia — the promised land","Ian W Campbell","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041218","Background",null,"2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041219","Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells","Chien-chi Lin","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041220","With Tacrolimus in Kidney Transplant",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041221","RESEARCH Open Access","Jan Müller","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041222","CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access","Kana Inoue","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041223","REVIEW",null,"2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041224","Glucagon-like Peptide 1 Receptors in Lateral Septum Affect Food Intake",null,"2014","DigiNole (Florida State University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041225","Tirzepatide: First Approval","Syed, Yahiya Y.","2022","Figshare","other_trial","article","10.6084/m9.figshare.20128214.v1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0041226","Specialty Specific Guidance: An Endocrinologist's Guide to Using GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight to Help Optimize Their Metabolic Health","Nasir Mustafa","2026",null,"other","article","10.13140/rg.2.2.16158.60487",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041227","REVIEW Glucagon-like peptide-1: a major regulator of pancreatic b-cell function","Riccardo Perfetti","2014",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041228","Brand Name (Manufacturer): Bydureon (Amylin Pharmaceuticals)","Pdl Class","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041229","ORIGINAL ARTICLE Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity","Cendrine Cabou","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041230","measures: a randomized, double-blind, crossover study","J. K. Berg","2011",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041231","ORIGINAL ARTICLE Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington’s Disease","Bronwen Martin","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041232","Oral semaglutide reduces appetite and energy intake and improves control of eating in subjects with type 2 diabetes","Blundell, J","2019","White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0041233","d Cent","Mansoor Husain","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041234","Click chemistry for F-18-labeling of exendin-4","Cheng-Bin, Yim","2013","Åbo Akademi University Research Portal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041235","The Impact of GLP-1 Receptor Agonists on Female Reproductive Health","Gabriel Monteiro Pinheiro","2025","JBRA","other","article","10.5935/1518-0557.20263842",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041236","Journal of Nuclear Medicine, published on August 14, 2008 as doi:10.2967/jnumed.108.053249 Reducing Renal Uptake of Radiolabeled Peptides Using Albumin Fragments","Erik Vegt","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041237","Novel, Selective Amylin Agonists as Therapeutic Tools to Treat Diabetes","Yule, Lauren","2018","ResearchSpace (University of Auckland)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041238","Purification and bioactivity of exendin-4, a peptide analogue of GLP-1, expressed in Pichia pastoris","Si-liang Zhang","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041239","Exploring the Role of GLP-1 Receptor Agonists and Probiotics in Alleviating Brain Insulin Resistance in Parkinson’s Disease:A Gut-Brain Axis Perspective","張家竣","2025","Taipei Medical University Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041240","Exploring the Evidence: GLP-1 RAs in Individuals with T2D and ASCVD","Nasir Mustafa","2026",null,"other","article","10.13140/rg.2.2.29839.24487",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041241","Liraglutide-Induced Intake Suppression Competes with an Intake Promoting Cafeteria Diet, but Has No Effect on Relative Intake of Specific Foods or Macronutrients",null,"2016","DigiNole (Florida State University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041242","Progesterone Receptor Membrane Component 1 Is a Functional Part of the Glucagon-like Peptide-1 (GLP-1) Receptor Complex in","Pancreatic Cells*□s","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041243","doi:10.1155/2012/950693 Review Article Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease","Kei Nakajima","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041244","Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Open Access Full Text Article","Chee W Chia","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041245","Strategy for preserving pancreatic islet vascularization during transplantation : a spheroid model composed of endothelial and insulin cells","Amira Saidi","2025","theses.fr (ABES)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041246","A COMPREHENSIVE REVIEW OF CONTEMPORARY DIABETES MELLITUS MANAGEMENT: PATHOPHYSIOLOGY, PHARMACOTHERAPY, AND TECHNOLOGICAL ADVANCES (2026)",null,"2026","International Journal of Progressive Research in Engineering Management and Science","narrative_review","article","10.58257/ijprems53974",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041247","Kyung Taek Oh","Insoo Kim","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041248","Research Article",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041249","Objectives",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041250","doi:10.1155/2012/382518 Research Article Exenatide Pretreatment Improved Graft Function in Nonhuman Primate Islet Recipients Compared to Treatment after","Transplant Only","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041251","Incretin-Based Therapies A Clinical Need Filled by Unique Metabolic Effects Learning Objectives","Daniel J. Drucker Md","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041252","Second Annual Clinical Diabetes Technology Meeting","David D. Klonoff","2006","Defense Technical Information Center (DTIC)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041253","Clinical Procedure: —","Abcdef David","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041254","2022年08月健康報","臺北醫學大學附設醫院","2022","Taipei Medical University Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0041255","Semaglutide and the Risk of Non-Arteritic Anterior Ischaemic Optic Neuropathy: A Systematic Review and Meta-Analysis","Jovita Jutamulia","2026","Open Access Indonesian Journal of Medical Reviews","systematic_review","article","10.37275/oaijmr.v6i2.884",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0041256","GLP-1 Medication Adoption and Household Demand for Ultra-Processed Foods","Awad, Koroles","2025","AgEcon Search (University of Minnesota, USA)","other","article","10.22004/ag.econ.379044",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041257","REVIEW Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes","Samuel S. Grossman","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041258","AGONISTAS DO RECEPTOR DE GLP-1 E COAGONISTAS GIP/GLP-1 NO PERIOPERATÓRIO: RISCO DE ASPIRAÇÃO, JEJUM, ULTRASSOM GÁSTRICO E TOMADA DE DECISÃO ANESTÉSICA BASEADA EM RISCO","Mariana Garrido Santos Esquirio","2026","International Journal of Health Management Review","other","article","10.47172/ijhmreview.v12i1.483",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041259","Assessment of Pancreatic -Cell Function: Review of Methods and Clinical Applications","Eugenio Cersosimo","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041260","ral ssBioMed CentBMC Cardiovascular Disorders Open AcceResearch article","Jens Kristensen","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041261","ARTICLE",null,"2010",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041262","¿Combinamos AR-GLP1 + i-SGLT2? Sí o no","Folino, Claudia Cristina","2024","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041263","Development and Evaluation of 18F-TTCO-Cys40-Exendin-4: A PET Probe for Imaging Transplanted Islets","Zhanhong Wu","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041264","BindingDB Entry 13073: HETEROCYCLIC GLP-1 AGONISTS","BindingDB","2025","UC San Diego","other","article","10.7270/q2m61qvj",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041265","Research Article Alleviation of Hyperglycemia Induced Vascular Endothelial Injury by Exenatide Might Be Related to the Reduction of Nitrooxidative Stress","Si-yu Wang","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041266","Articles","John B Buse","2009",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041267","DIABETICMedicine Original Article: Treatment Improved treatment satisfaction and weight-related",null,"2009",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041268","Collision tumor of primary malignant lymphoma and adenocarcinoma in the colon diagnosed by molecular pathology: A case report and literature review","Meng Jiang","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6289","37731579",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041269","Original Article The Effects of Exendine-4 on Insulin Producing Cell Differentiation from Rat Bone Marrow-Derived","Mesenchymal Stem Cells","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041270","Obesity: Diagnosis and Treatment","Eric Thomas","2026","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041271","A RELAÇÃO DA MUDANÇA DOS PADRÕES ESTÉTICOS COM O USO INDISCRIMINADO DA SEMAGLUTIDA: UMA REVISÃO BIBLIOGRÁFICA","Maria Emília Bottini","2025","Revista Contemporânea","other","article","10.56083/rcv5n9-100",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041272","l a r t","D. Funch","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041273","It's Magic, You Know","Matthew Herring","2024","The Motley Undergraduate Journal","other","article","10.55016/ojs/muj.v2i2.79247",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041274","Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS One 2013","Vadivel Parthsarathy","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041275","Review Article Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS","Samit Ghosal","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041276","News and Views","IJCP Group","2023",null,"other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0041277","Case Report Longstanding insulin dependent diabetics may not require insulin after the introduction of GLP-1 analogues","Umar Y Raja","2016",null,"case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041278","ОСОБЛИВОСТІ ЗАСТОСУВАННЯ АГОНІСТА РЕЦЕПТОРІВ ГЛЮКАГОНОПОДІБНОГО ПЕПТИДУ-1 У ХВОРИХ НА ЦУКРОВИЙ ДІАБЕТ 2 ТИПУ ЗАЛЕЖНО ВІД СТАТІ ТА ФЕНОТИПУ","ШИШКАНЬ-ШИШОВА КАТЕРИНА","2022","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.6570273",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041279","How do tirzepatide and semaglutide compare for weight loss … and other research","Tom Nolan","2024","BMJ","other","article","10.1136/bmj.q1564","39025497",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041280","Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury","NH, Greig;Tweedie, D;Rachmany, L;Li, Y;Rubovitch, V;Schreiber, Schreiber S;YH, Chiang;BJ, Hoffer;Miller, J;DK, Lahiri;Sambamurti, K;RE, Becker;CG, Pick","2014","Taipei Medical University Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041281","REVIEW A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes","Zin Z. Htike","2011",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041282","Incretin Hormones and Insulin Secretion","Bo Ahrén","2004","Hormone and Metabolic Research","other","article","10.1055/s-2004-826153","15655700",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041283","doi:10.1155/2011/984245 Review Article Weight Considerations in Pharmacotherapy for Type 2 Diabetes","Vicky Cheng","2013",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041284","The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes","A Randomized Trial","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041285","A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with","Walid K. H","2015",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0041286","Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","C. Mark","2001",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041287","CARDIO","Tohru Funahashi","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041288","Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. PLoS One 2013","James L. Trevaskis","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041289","利拉鲁肽对Pg-LPS刺激下人牙周膜细胞成骨分化的影响及其机制研究","Yunxia Zhang","2019","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041290","New Trends In The Treatment Of Diabetes Mellitus Type 2","Yusuf, Fatima Kabiru","2019","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041291","Mechanisms involved in weight gain and adipose tissue alterations induced by HIV integrase inhibitors : identifying prevention strategies","Kenza Ngono Ayissi","2025","theses.fr (ABES)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041292","REVIEW",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041293","Mise en place de la [68Ga]Ga-NODAGA[40Lys]-Exendin-4 au Centre Jean Perrin","Ragot, Mailys","2024","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041294","in Cancer Biology, Graduate","Enrique Fuentes-mattei","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041295","杜拉鲁肽对小鼠宫腔粘连的作用机制研究","王奕翔","2021","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041296","Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met�TZD)","Bernard Zinman","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041297","OBJECTIVE — In the Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly (DURATION-1) study,","Weight Loss","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041298","doi:10.1155/2011/279530 Review Article Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function","Chinmay S. Marathe","2011",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041299","DIABETICMedicine Original Article: Treatment","C. Ellero","2010",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041300","Analyse de l'utilisation des agonistes du récepteur du glucagon-like peptide-1 à partir des données de l'entrepôt de données de santé du CHU de Bordeaux","Inès Vuillemin Gouné","2025","HAL (Le Centre pour la Communication Scientifique Directe)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0041301","The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases -cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283: E745–E752","Bidda Rolin","2002",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041302","Weight-loss pill could beat Wegovy","Clare Wilson","2024","The New Scientist","other","article","10.1016/s0262-4079(24)00490-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041303","CLINICAL REVIEW An Evidence-Based and Practical Approach to Using Bydureon ™ in Patients With Type 2 Diabetes","Nathan A. Painter","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041304","Exenatide use in the management of type 2 diabetes mellitus. Pharmaceuticals","Angelos Kyriacou","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041305","利拉鲁肽对晚期糖基化终末产物诱导的人牙周膜细胞的影响","常语宸","2017","Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041306","一项在接受基础胰岛素联用或不联用口服降糖药治疗血糖控制不佳的2型糖尿病患者中，在加用或不加用二甲双胍下比较iGlarLixi与甘精胰岛素的疗效和安全性的为期30周研究-补充协议","李汛",null,"Lanzhou University Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0041307","Tirzepatide ndash; new treatment option for patient with type 2 diabetes","Mufeed, M.","2024",null,"other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041308","Metabolic Link Between Obesity And Insulin Resistance","Shunichiro Minoya","2024","University of Debrecen Electronic Archive (University of Debrecen)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041309","Articles",null,"2008",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041310","ORIGINAL RESEARCH Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries","Victoria Divino","2014",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041311","Polish Academy of Sciences","Vishal Patel","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041312","Research Article Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway",null,"2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041313","Long-acting preparations of exenatide","Liangming Wei","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041314","The exploitation of incretin mechanisms","Konathala Archana","2015","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041315","GLP-1 Infusions in the setting of Acute Myocardial Infarction Improve Myocardial Function and Reduce Morbidity and Mortality","Gavin J Bush","2013",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041316","GLP-1 Receptor Agonists and Joint Health","Ali Mobasheri","2026","EMJ Rheumatology","other","article","10.33590/emjrheumatol/8vk6z8kq",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041317","Beyond Metformin: Safety Considerations in the Decision- Making Process for Selecting a Second Medication for Type 2 Diabetes Management Ref lections From a Diabetes Care Editors ’ Expert Forum",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041318","Article: Treatment","C. Wysham","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041319","Mapping of Glucagon-like Peptide-1 Receptor Expression in the Developing Mouse Brain",null,"2020","DigiNole (Florida State University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041320","D (2012) Transient neonatal diabetes mellitus gene Zac1 impairs insulin secretion","Anke Hoffmann","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041321","Targeting relative risk heterogeneity with causal forests","Vik Shirvaikar","2023","arXiv (Cornell University)","nonrandomized_study","article","10.48550/arxiv.2309.15793",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0041322","RESEARCH ARTICLE","Hongyan Zhao","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041323","Metabolic link between Insulin Resistance and Obesity: Novel Drug candidates","Multazam Ali Khokhar","2023","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041324","RESEARCH ARTICLE Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways","Kosuke Nagayama","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041325","Original Article Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance","Endocrinol Metab","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041326","renal injury in streptozotocin-treated mice. Kidney Int 2006; 69:",null,"2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041327","RESEARCH ARTICLE In VitroMetabolic Stability of Exendin-4: Pharmacokinetics and Identification of Cleavage Products","Sha Liao","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041328","Article: Treatment","W. E. Schmidt","2011",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041329","ORIGINAL RESEARCH Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes","In Sweden","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041330","The development of a multimodal imaging agent for the management of diabetes mellitus type 2","Asher Garrod","2019","Repository@Hull (Worktribe) (University of Hull)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041331","M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and -independent pathways. Circulation 117:2340–2350","Kiwon Ban","2008",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041332","Weight and behavior Management in a Patient with SmithMagenis Syndrome : Role of GLP-1 Receptor Agonists","Correia, Jorge","2025","Archive ouverte UNIGE (University of Geneva)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0041333","Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041334","O R IG IN A L A R","J. Derving Karsbøl","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0041335","The Journey and Excitement Following the Development of the First Peptide in a Pill: A Brief Overview of Pharmacology and Clinical Trials of Oral Semaglutide","Banshi Saboo","2022",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041336","ORIGINAL RESEARCH ARTICLE Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis","Kristin C. Carlsson","2015",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0041337","REVIEW Emerging Role of Insulin with Incretin Therapies for Management of Type 2 Diabetes","Rupa Ahluwalia","2011",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041338","Completed Liraglutide Type 2 Diabetes Clinical Trials DOI: 10.2337/dc13-1210","Pancreatitis A","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0041339","Controlled Trial (AWARD-3) Diabetes Care 2014;37:2168–2176 | DOI: 10.2337/dc13-2759 OBJECTIVE","Monotherapy Versusmetformin In","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041340","Highly Parallel Method for Synthesis of DNA Repeats Enables Discovery of “Smart ” Protein Polymers","Miriam Amirama","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041341","ORIGINAL RESEARCH Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study","Jakob Langer","2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041342","Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes OBJECTIVE",null,"2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041343","Liraglutide in Assisted Reproduction: Current Evidence and Clinical Guidance","Maiara Peixoto Paiva","2025","JBRA","other","article","10.5935/1518-0557.20263926",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041344","Food Demand in a Post-Ozempic World","Roe, Brian E.","2025","RePEc: Research Papers in Economics","other","article","10.22004/ag.econ.349333",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041345","Exploratory Trial of Intranasal Administration of Glucagon-like Peptide-1 in Japanese Patients With Type 2 Diabetes OBJECTIVE",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041346","Tirzepatide (Mounjaro)","CDA-AMC","2026","Canadian Journal of Health Technologies","randomized_trial","article","10.51731/cjht.2026.1507",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041347","Obesity Management","Al-Hariri, Mohammed","2021","Data Archiving and Networked Services (DANS)","other","article","10.17632/3mpkm4hsfh.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041348","Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like-peptide-1 receptor agonist, Iepsen EW","Iepsen, Eva","2018","Data Archiving and Networked Services (DANS)","other","article","10.17632/dryd5vjvz4.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041349","An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin","Evans, Marc","2020","Figshare","other_trial","article","10.6084/m9.figshare.5625094.v2",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0041350","Roles of pharmacotherapy and dietotherapy in type II diabetes mellitus","Niaparast, Rashin","2021","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041351","An Inter-Organ Neural Circuit for Appetite Suppression","Wenfei Han","2022","Data Archiving and Networked Services (DANS)","other","article","10.17632/zkjm36wp8s.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041352","Metabolic and neurological warning phenotypes during tirzepatide treatment: a clinical pharmacology and pharmacovigilance review","Sidário Rodrigues Malheiros-junior","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22105183",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0041353","Blast wave transmission through the ear with computational and 3D printed models and assessment of cochlea damage with SEM imaging","Marcus A. Brown","2021","SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041354","MedCheck: FDA to Consider Novel ADHD Drug; Semaglutide Fails to Slow Alzheimer’s Progression; and More","Linda M. Richmond","2025","Psychiatric News","other","article","10.1176/appi.pn.2026.01.1.24",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0041355","Source data \"Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy\"","TENA-SEMPERE, MANUEL","2024","Data Archiving and Networked Services (DANS)","other","article","10.17632/7j94gwthv7.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041356","A clinical case of asymptomatic pancreatic hyperenzymemia on the background of taking a Glucagon-like peptide-1 analogue (GLP-1)","Nataliia Sanina","2023","Medicni perspektivi","other","article","10.26641/2307-0404.2023.3.289229",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041357","SGLT2 inhibitors reduce the risk of hospitalization for heart failure and amputation rate compared with incretin-based therapy in patients with diabetic foot disease: A nationwide population-based study","Lin, Yi-Hsuan","2023","Data Archiving and Networked Services (DANS)","nonrandomized_study","article","10.17632/jdv9bjtnxw.1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0041358","C58-10 Tirzepatide Improves Lung Function in Obese Patient With Hypersensitivity Pneumonitis","D Lew","2026","American Journal of Respiratory and Critical Care Medicine","preclinical","article","10.1093/ajrccm/aamag162.2744",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041359","To assess the effect of incretin (Exenatide) on bone markers and bone density in population with type 2 diabetes mellitus vs a control group with type 2 diabetes mellitus not being treated with an incretin",null,"2012","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041360","A hydrogen-bonded polar network in the core of the glucagon-like peptide-1 receptor is a fulcrum for biased agonism:lessons from class B crystal structuress","Wootten, Denise","2016","Aston Publications Explorer (Aston University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041361","Glucagon-like peptide-1 receptor agonists and risk of pancreatic cancer in high-risk individuals: A multicenter real-world analysis.","Cho Han Chiang","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.19_suppl.126",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041362","Semaglutide for weight reduction in non-diabetic adults with overweight and obesity","Fiutak, Kaela","2024","JMU Scholoraly Commons (James Madison University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041363","Prévention et traitement de la fragilité osseuse chez les sujets diabétiques de type 2","Julien Paccou","2025","Médecine des Maladies Métaboliques","other","article","10.1016/j.mmm.2025.03.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041364","Pharmacological Management of Type 1 Diabetes","Im, Erin","2019","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041365","GLP1R Regualtion of Gap Junction Coupling in the Islet of Langerhans","Rachelle Walter","2015","The FASEB Journal","preclinical","article","10.1096/fasebj.29.1_supplement.997.7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041366","Incretin mimetics in the treatment of type 2 diabetes mellitus.","Orife, Okiemute Ada","2015","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041367","Data from: Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes","Lu, Nan","2015","Data Archiving and Networked Services (DANS)","preclinical","article","10.5061/dryad.mf3rb",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041368","glp1ra_nma","Jiang, Yawen","2020","Data Archiving and Networked Services (DANS)","other","article","10.17632/66hsvjcth6.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041369","Liraglutide Immobilized on Poly(lactic-co-glycolic acid) Polymer Films Induced the Differentiation of Islet β-Like Cells from Bone Marrow Mesenchymal Stem Cells","Shuang Sun","2019","Macromolecular Research","other","article","10.1007/s13233-019-7061-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041370","Microencapsulation of bioactives by in situ complex coacervation during spray drying","Tang, Yuting","2022","eScholarship (California Digital Library)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041371","Deciphering the mechanism of foxa2 inactivation by respiratory pathogens in chronically diseased lungs","Choi, WooSuk","2020","Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041372","Pre-pregnancy use of GLP-1RA improves maternal lipid metabolism disorder through liver-secreted FGF21 during pregnancy in high-fat diet fed dams","Guo, Haonan","2024","Data Archiving and Networked Services (DANS)","other","article","10.17632/mb4kz7w9pn.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041373","3 Efficacy and Safety of Semaglutide 2.4 mg Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)","Melanie J. Davies","2021","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/s-0041-1735690",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0041374","#87 - BEYOND WEIGHT LOSS: TRIAL-LEVEL MEDIATION ANALYSIS OF METABOLIC CHANGES AND HISTOLOGICAL RESPONSE TO PHARMACOTHERAPY IN MASH","Pedro Passos","2026","Annals of Hepatology","other_trial","article","10.1016/j.aohep.2026.102357",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0041375","Modern treatments of diabetes mellitus","Korzoum, Wassim","2014","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041376","Victoza i USA","Nielsen, Christina","2010","CBS Research Portal (Copenhagen Business School)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041377","Biopsy-Proven Acute Tubular Injury Temporally Associated With Semaglutide Exposure: A Case Report and Review of Biopsy-Proven Glucagon-Like Peptide-1 Receptor Agonist–Associated Kidney Lesions","Md Refayat Bhuiyan","2026","Kidney International Case Reports","case_report","article","10.1016/j.kintcr.2026.100104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041378","Development of lipid nanocapsules encapsulating exenatide for oral delivery in the treatment of type 2 diabetes mellitus","Ana R. Lemos","2019","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041379","Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE -/- mice","Zhang, Keyin","2023","Data Archiving and Networked Services (DANS)","preclinical","article","10.17632/5m4tm2tmsh.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041380","From the Editor-in-Chief: Highlights of the Ninth Issue","Awni D. Shahait","2025","JAP Academy Journal","nonrandomized_study","article","10.4103/japaj.japaj_26_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","editorial"],["R0041381","Comparative Efficacy and Safety of GLP-1 Receptor Agonists vs SGLT2 Inhibitors on the Risk of Alzheimer’s Disease and Related Dementia: A Systematic Review and Meta-analysis (P4-13.002)","Advait Teli","2026","Neurology","systematic_review","article","10.1212/wnl.0000000000216824",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0041382","Trends and factors associated with glucagon-like peptide 1 receptor agonists prescription for cancer populations with type 2 diabetes.","Ilana Graetz","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.11181",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041383","The latest recommendations of the Polish Diabetes Association and the American Diabetes Association in the treatment of diabetes with modern drugs","Szymon Marosz","2020","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12775/jehs.2020.10.09.084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041384","Diagnosis and treatment of metabolic-associated fatty liver disease in patients with type 2 diabetes mellitus. Review","Ткач, С. М.","2023","Scientific periodicals of Ukraine","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041385","Development and Evaluation of Exenatide Loaded PLGA Nanoparticles for Intranasal Delivery in the Treatment of Obesity","Tosha Pandya","2022","Drug Delivery Letters","preclinical","article","10.2174/2210303112666220318155445",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041386","Safety of glucagon-like peptide-1 receptor agonists in patients with breast cancer: A real-world multicenter cohort study.","Cho Han Chiang","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.11139",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041387","Additional file 1 of Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss","Simeone, Paola","2022","Figshare","other","article","10.6084/m9.figshare.19350000",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041388","Semaglutide: Miracle for Weight or Menace for Vision? A Scoping Review on Semaglutide and Non Arteritic Anterior Ischemic Optic Neuropathy (P4-17.016)","Sunanda Banerjee","2026","Neurology","narrative_review","article","10.1212/wnl.0000000000215099",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041389","COMPARATIVE ANALYSIS OF INSULIN VARIETIES IN THE MANAGEMENT OF OBESITY: A COMPREHENSIVE SYSTEMATIC REVIEW","Mohammed K. Aldosari","2024","International Journal of Advanced Research","systematic_review","article","10.21474/ijar01/19391",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0041390","Le dulaglutide (Trulicity®) est un nouvel analogue du GLP-1 à durée d’action prolongée dans le traitement du diabète de type 2. Comment ? Avec quels résultats ?","Martin Buysschaert","2016","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0041391","A rare case of Liraglutide-induced iatrogenic amyloidosis","Sumeet K Aujla","2022","The Journal of Immunology","other","article","10.4049/jimmunol.208.supp.48.13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041392","Diabetes Mellitus Type 2, effects of SGLT-2 inhibitors","Thorsdottir, Ragnheidur Anna","2021","University of Debrecen Electronic Archive (University of Debrecen)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0041393","Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference","Seino,","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041394","Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents","Melanie J. Davies (7155500)","2017","Figshare","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0041395","Acute Interstitial Nephritis Due to Tirzepatide (Mounjara)","Kamel El-Reshaid","2025","Open Journal of Nephrology","other","article","10.4236/ojneph.2025.153034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041396","Oral Semaglutide Improves Hepatic Enzymes and Metabolic Parameters in MASLD Over 12 Months",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.493",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041397","Guidelines Aim to Speed Drug Approval While Protecting Human Subjects","Mike Mitka","2006","JAMA","other","article","10.1001/jama.295.9.988","16507790",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041398","Additional file 1 of Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies","Zheng, Deqiang","2023","Figshare","nonrandomized_study","article","10.6084/m9.figshare.22598999.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0041399","Targeting the hyperglycemic memory in diabetic kidney disease is therapeutically amendable","Elwakiel, Ahmed","2024","Qucosa (Saxon State and University Library Dresden)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0041400","Semaglutide and resmetirom for MASH: the AASLD Practice Guidance tells us when, not which","Jakob Weglage","2026","Hepatoma Research","other","article","10.20517/2394-5079.2026.60",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041401","S3890 Weight Loss at a Price: Tirzepatide-induced Pneumatosis Intestinalis","Sindhura Kolli","2023","The American Journal of Gastroenterology","preclinical","article","10.14309/01.ajg.0000965200.35581.63",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041402","Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation","Anju Pradeep","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5900630",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0041403","Exendin-4 mitigates BBB disruption and brain injury by suppressing the VEGF pathway in astrocytes after intracerebral hemorrhage","Haopeng Tan","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7314772",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0041404","Should Kidney Transplantation be Offered to Patients with Body Mass Index >40?: Commentary","Phillipe Abreu","2025","Kidney360","randomized_trial","article","10.34067/kid.0000000954","40779321",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0041405","Additional file 1 of Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study","Lin, Diaozhu","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.25918869",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0041406","Navigating the Complex Landscape of Obesity Clinical Trials: Diagnosis Criteria, Pivotal Endpoints, and Enhanced Protocols","iNGENū CRO","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.22104957",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0041407","Association of SGLT2 inhibitors and GLP-1 receptor agonists or DPP-4 inhibitors with incident cancer in patients with type 2 diabetes.","Nikitha Vobugari","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.10590",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041408","Place of GLP1 receptor agonists in type 2 diabetes in primary care : practices and representations of general practitioners in Ille-et-Vilaine and Morbihan","Poissel, Priscilla","2021","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041409","Abstract 4143220: Racial Differences in Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among US Veterans with Type 2 Diabetes and Coronary Artery Disease","Demetria M Bolden","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4143220",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041410","Incretin Based Therapy of Type 2 Diabetes Mellitus","Bjornsdottir, Hrafnhildur Greta","2015","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041411","Linxia Wang Database","Linxia Wang","2018","Data Archiving and Networked Services (DANS)","nonrandomized_study","article","10.17632/9f46z6vh67.1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0041412","The influence of basal insulin (glargine or dettermir) and liraglutide on coronary artery calcification in type 2 diabetes memlitus (version1)",null,"2012","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041413","Agonists and Antagonists of Peptide Receptors: Therapeutic Approaches to Combat Cancer","Rafael Coveñas","2026","Pakistan BioMedical Journal","other","article","10.54393/pbmj.v9i1.1327",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041414","Brain dysfunction and cell death in type 2 diabetes : A neuroprotective role for the peripheral treatment with Exendin-4","Inês Sebastião","2014","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041415","Management of Euglycemic Diabetic Ketoacidosis in the Intensive Care Unit: Risk Factors and New Consensus Guidelines","Christopher Mitchell","2025","American Journal of Respiratory and Critical Care Medicine","other","article","10.1164/ajrccm.2025.211.abstracts.a5696",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041416","Obesity and Life-Related Disorders","Sami Ullah Mumtaz","2025","Pakistan Journal of Health Sciences","other","article","10.54393/pjhs.v6i5.3208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041417","GLP-1 Receptor Agonists and Total Hip Arthroplasty Outcomes: A Systematic Review","Rolanda Willacy","2026",null,"systematic_review","article","10.61440/jop.2026.v4.59",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0041418","An inter-organ crosstalk mediates the therapeutic effect of a dual glp-1/glucagon receptor agonist in diet-induced obesity","Valverde, Ángela M.","2021","DIGITAL.CSIC (Spanish National Research Council (CSIC))","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0041419","Rybelsus - nowoczesna tabletka i nowoczesne leczenie cukrzycy typu 2. Wskazówki dotyczące stosowania",null,"2022","Homo Politicus (Academy of Humanities and Economics in Lodz)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041420","Response to Commentary on “Reassessing Simultaneous Pancreas Kidney Vs. Kidney Transplant Alone: A Propensity Weighted Analysis of Survival and Morbidity”","Pooja Budhiraja","2025","Transplant International","nonrandomized_study","article","10.3389/ti.2025.16011","41536838",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041421","Insulin and GLP-1 analogues in the treatment of type 1 Diabetes Mellitus.","Sanni, Abdulsabur","2020","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041422","Residual Gastric Content and Perioperative Semaglutide Use Assessed by Gastric Ultrasound: A Prospective Observational Study - databank","Muniz da Silva, Leopoldo","2024","Data Archiving and Networked Services (DANS)","other","article","10.17632/35jm7bsj68.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041423","#50 - INTEGRATED COST-EFFECTIVENESS OF SEMAGLUTIDE VERSUS HYPOTHETICAL RESMETIROM FOR MASH WITH F3 FIBROSIS AND CARDIOMETABOLIC OR RENAL COMORBIDITIES IN MEXICO: A MARKOV MODEL","Fátima Higuera","2026","Annals of Hepatology","other","article","10.1016/j.aohep.2026.102325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041424","Semaglutide-induced Erectile Dysfunction: A Case Report on Glucagon-like-peptide1 (GLP-1) Agonist Medication","Nurul Hazwani Hatta","2026","Malaysian Journal of Medicine and Health Sciences","case_report","article","10.47836/mjmhs.22.s4.37",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041425","The Current Status of Exenatide Once Weekly","Kulasa,","2011","Clinical Medicine Insights Therapeutics","other","article","10.4137/cmt.s3083",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041426","GLP-1 RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES AND MORTALITY IN TYPE 2 DIABETES. A NEW APPRAISAL","Fatimah Awad Alahmary","2023","International Journal of Advanced Research","other","article","10.21474/ijar01/17800",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041427","2607-P: Dynamics of Noninvasive Tests, LIVERFASt (LFASt), FIB-4 and Vibration-Controlled Transient Elastography (VCTE, FibroScan), during Monitoring Therapy with THR-beta Agonist Resmetirom (RT) in Patients with MASH: Update","Jeevin Sandhu","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2607-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041428","Vasodilator Effect of Glucagon, Glucagon-like Peptide-1 and GLP-1 Receptor Agonists, and Role of Oxidative Stress in Their Vasoactivity","Sélley Eszter","2017","Pesci Egyetemi Archivum (University of Pécs)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041429","Source data \"Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy\"","Serrano López, Víctor","2024","Data Archiving and Networked Services (DANS)","other","article","10.17632/hfxxw9kccs.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041430","Eksenatidi : Byetta 5 mikrog ja 10 mikrog injektioneste, Lilly B. V., Alankomaat","Kimmo Malminiemi","2007","STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041431","RGC DATA","Leopoldo Muniz da Silva","2022","Data Archiving and Networked Services (DANS)","nonrandomized_study","article","10.17632/78ghfpj225.1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0041432","Tirzepatide and Reduced Initial Ischemic Stroke Risk in Adults with Type 2 Diabetes: A Target Trial Emulation (N3.001)","Shih‐Syuan Wang","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000213029",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041433","Liraglutids viktminskningseffekt","Hazime, Zahraa","2020","DiVA (Linkoping University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041434","In vivo Glucagon-like Peptide 1 receptorimaging using radiolabeled Exendin 4","Michael Hower","2012","open_UMR Marburg DSpace 10.0 (Philipps-Universität Marburg)","other","article","10.17192/z2011.0728",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041435","A Practical Guide to Treatment with Liraglutide","Devendra,","2010","Clinical Medicine Insights Therapeutics","other","article","10.4137/cmt.s4148",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041436","Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes.","Haack, T.","2017","Site cant be reached","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041437","Modern Management of Type 2 Diabetes Mellitus","Choudhari, Christina","2015","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041438","Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients","Saadah, Loai","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041439","Raw data of gut microbiota, blood metabolome and feces metabolome","Liu, Libin","2024","Data Archiving and Networked Services (DANS)","preclinical","article","10.17632/wm8wkpg5bp.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041440","Unraveling the Ozempic Craze: A Content and Thematic Analysis of Prescription Weight Loss Medication Advertisements on Meta","Minhey Chung","2025","Journal of Advertising","other","article","10.1080/00913367.2025.2593673",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041441","Metabolic and endocrine effects of SGLT2 inhibition","Per Lundkvist","2019","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041442","Association Between Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Pancreatic Cancer: A Systematic Review and Meta-Analysis","Gaetano Lauri","2025","Pancreatology","systematic_review","article","10.1016/j.pan.2025.07.187",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0041443","Effect of combination pioglitazone with SGLT2i or GLP-1 RA on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database","Anson , Matthew","2024","Research Explorer (The University of Manchester)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0041444","Incretin-Based Therapy In Type 2 Diabetes Mellitus","Vakilzadehian, Faranak","2015","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041445","Exendin-4 reverses biochemical and functional alterations in the blood-brain and blood-CSF barriers in diabetic rats","Boeckel, Caroline Zanotto de","2017","Lume (Universidade Federal do Rio Grande do Sul)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041446","Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.","M. J. Davies (7604990)","2017","Figshare","randomized_trial","article","10.1111/dom.13125/abstract",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0041447","An assessment of the effectiveness and cost of Liraglutide ( Victoza®) treatment in Type 2 diabetes",null,"2011","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041448","Positioning the Novel Therapeutics in Diabetes Care: Time to Integrate the Recommendations.","N Marx (9382901)","2020","Figshare","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041449","Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy","Cesta Carolyn E.","2025","UTUPub (University of Turku)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0041450","Current and Novel Pharmacological Management of Diabetes","Mahdavi, Seyed Saeed","2020","University of Debrecen Electronic Archive (University of Debrecen)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0041451","5 Weight-Loss Maintenance with Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity Reaching Maintenance Dose (STEP 4)","Domenica Rubino","2021","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/s-0041-1735670",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0041452","Clinical studies of GLP-1RA, DPP-4i, and SGLT-2i mediated cardiovascular protection","Fang, Zemin","2024","Data Archiving and Networked Services (DANS)","other","article","10.17632/jcrtycvdpc.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041453","Værdiansættelse af Novo Nordisk","Johannesson, Mark Francis","2016","CBS Research Portal (Copenhagen Business School)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041454","Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","Steve Bain","2025","Cronfa (Swansea University)","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT03914326","S002179","openalex","TRUE","no_doi","1","FALSE","article"],["R0041455","Treatment approaches for Prediabetes in obese individuals","Javed, Sayra","2018","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041456","Ligand and Structure-Based Virtual Screening of iPPl-lib, Diverse-lib, and GLASS Databases for Homology Modeling-Derived Orphan GPCR SREB2 Identifies Glucagon-Like Peptide 1 Receptor and Thyrotropin Receptor Ligands as Top Hits",null,null,"Digital Repository Service (Northeastern University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041457","Investigation of psychoemotional and phenotypic characteristics of patients with type 2 diabetic mellitus under the influence of incretinomimetics therapy","Шишкань-Шишова, К. О.","2023","Scientific periodicals of Ukraine","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041458","Intestinal Lipoprotein Secretion: Incretin-Based Physiology and Pharmacology Beyond Glucose","Robert H. Eckel","2015","Diabetes","other","article","10.2337/db15-0470","26106196",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041459","Pharmacological Overview of Diabetes Mellitus","Thomas, Elizabel Susan","2020","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041460","57 Underutilization of Weight-Management Interventions in Patients With IBD and Obesity: A Propensity-Matched Analysis","Mouhand Mohamed","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001172652.40278.4e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041461","A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus","Bhargava, Amit","2010",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0041462","Cichlidogyrus microscutus Pariselle & Euzet 1996","Pariselle, Antoine","2009","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.4559882",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0041463","Obesity hypoventilation syndrome: current knowledge and new developments","Jean‐Louis Pépin","2026","European Respiratory Society eBooks","other","article","10.1183/2312508x.10029825",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0041464","Mechanisms underlying monosaccharide stimulated incretin hormone secretion from the intestine","O'Flaherty Rottenberger, Elisabeth","2023","Apollo (University of Cambridge)","preclinical","article","10.17863/cam.107980",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041465","Retatrutide vs. Tirzepatide: Qual a melhor escolha no tratamento da obesidade?","Rafaela Margarida dos Santos Marques Machado Vilaça","2026","Open Repository of the University of Porto (University of Porto)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041466","Conventional and new therapeutic strategies for Alzheimer's disease","Vincze, Kamilla","2021","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041467","Traitement du diabète de type 2 en 2019 : un même rapport coût-bénéfices ? Le point de vue du diabétologue","Hermans, Michel","2019","Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B))","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041468","Liraglutidi","Kalliokoski, Annikka","2015","STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041469","12467 Ethical Challenges During Medication Scarcity","Kavita Seetharaman","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.760",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041470","Successful treatment of a patient with type II diabetes mellitus and familial partial lipodystrophy with glucagon-like peptide-1 agonist, hybrid closed loop pump system, and off label use of subcuatneous daily degludec due to high total daily dose of insulin","N Soyster","2024","The American Journal of the Medical Sciences","other","article","10.1016/s0002-9629(24)00518-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041471","Impact of chronic GLP-1 receptor agonist and SGLT-2 inhibitor therapy on in-hospital outcomes of patients with diabetes mellitus hospitalized with acute myocardial infarction","Filippo Trombara","2022","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehac544.1303",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041472","Egg Microneedle for Transdermal Delivery of Active Liraglutide (Adv. Healthcare Mater. 9/2023)","Jeongyun You","2023","Advanced Healthcare Materials","other","article","10.1002/adhm.202370042",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041473","8418 Association of GLP-1 Receptor Agonists and SGLT-2 Inhibitors with Major Adverse Cardiovascular Events and Serious Liver Events among Patients with Type 2 Diabetes and MASLD","Alexander Kutz","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.555",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041474","Abstract #1155435: Use of Glucagon-like Peptide 1 Receptor Agonist Therapy for Inpatients with Type II Diabetes and Chronic Kidney Disease: A Retrospective Analysis","Dmitriy Khazron","2022","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2022.03.064",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041475","The signature of serum lipids remodeling in recent-onset type 2 diabetes mellitus treated with dulaglutide and liraglutide","Juan Du","2024","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-024-01408-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041476","EE237 Cost-Minimization Analysis for Soliqua in the Treatment of T2DM in Turkiye","Cevdet Duran","2024","Value in Health","other","article","10.1016/j.jval.2024.10.519",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041477","O-16 Never too late: Delayed diagnosis of Prader-Willi syndrome","Özge Baş Aksu","2024","JCEM Case Reports","other","article","10.1210/jcemcr/luad146.045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041478","Underprescribing of cardioprotective novel antidiabetic drugs in marginalized patients with type II diabetes mellitus","Angela Khidhir","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.3006",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041479","Management of the child with obesity: Role and development of new medications","Gabriel Ángel Martos‐Moreno","2024","Global Pediatrics","other","article","10.1016/j.gpeds.2023.100126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041480","IDF2022-0371 Decreased HbA1c levels associated with improved patient reported outcomes in T2D patients treated with tirzepatide","V. Thieu","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110304",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041481","Multiscale Mathematical and Computational Systems Biology Frameworks That Explicitly Couple Molecular Clock Gene Networks Across Multiple Tissues, Pulsatile Neuroendocrine Generators, Autonomic Flux Balance, and Stochastic Hormonal Noise to Predict Individual Dawn Phenomenon Severity and to Identify Optimal, Personalized Circadian Therapeutic Windows: A Theoretical and Predictive Architecture Whose Construction and Experimental Validation Remain at an Embryonic Stage in the International Literature","Camilo Fernández Bravo","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22133364",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0041482","THE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY ON DIURETIC RESISTANT FLUID RETENTION IN A PATIENT WITH PULMONARY HYPERTENSION AND RIGHT HEART FAILURE","Rahul Kumar","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)04792-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041483","Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes","N Del-Cuerpo-Salinas","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2775",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041484","New weight-loss drugs could shift the scales","Megha Satyanarayana","2021","C&EN Global Enterprise","other","article","10.1021/cen-09938-cover",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041485","6486 Gastroparesis Exacerbation by a GLP-1 Agonist","Jacqueline M Deirmenjian","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.780",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041486","6656 Frequently sampled HbA1c Shows Low-Sodium, High-Carbohydrate Rice Diet To Be Effective in Type 2 Diabetes","Francis A. Neelon","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.779",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041487","#995 Effectiveness of Semaglutide once weekly as add-on to SGLT-2Is in T2DM and CKD: a single-center observational study with body composition assessment","Qing Yang","2024","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfae069.699",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041488","Effects on re-endothelialisation with Bydureon treatment add on to insulin versus insulin alone, both in combination with metformin in type 2 diabetic subjects: Rebuild study","Irene Santos‐Pardo","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.1328",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041489","Effect of glucagon-like peptide-1 receptor agonists on atrial fibrillation incidence: a systematic review and meta-analysis","Krishnarjun Banerjee","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.409",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0041490","TOP-096 Glucagon-like peptide-1 receptor agonist, semaglutide attenuates liver cirrhosis-related skeletal muscle atrophy in diabetic mice","Kosuke Kaji","2024","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(24)00777-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041491","IJU this issue","Haruki Kume","2021","International Journal of Urology","nonrandomized_study","article","10.1111/iju.14708",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041492","PCR6 The Association between Administration Method, Socio-Demographic Characteristics, and Patient-Reported Outcomes for Glucagon-like Peptide-1 Receptor Agonists Among Diabetes Patients in Japan: A Cross-Sectional Patient Survey","Toshihisa Murofushi","2023","Value in Health","other","article","10.1016/j.jval.2023.03.1786",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041493","Two dual GLP‐1/GIP receptor agonists show superior protective properties compared to liraglutide in the APP/PS1 mouse model of Alzheimer’s disease","Christian Hölscher","2021","Alzheimer s & Dementia","preclinical","article","10.1002/alz.050388",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041494","5037 Coronary artery disease risk assessment by coronary artery calcium scoring in asymptomatic Thai people with diabetes mellitus","Yotsapon Thewjitcharoen","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.572",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041495","Cardiovascular, mortality and renal outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes – a systematic review and meta-analysis of randomised trials","David Preiss","2019","The Lancet Diabetes & Endocrinology","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0041496","Approaching sleep apnea management in the setting of uncertainty","Lucas M. Donovan","2022","SLEEP","randomized_trial","article","10.1093/sleep/zsac234","36149838",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041497","Corrigendum",null,"2022","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.14846","36004610",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","erratum"],["R0041498","42762 Successful treatment of hidradenitis suppurativa with semaglutide","Claire Drumm","2023","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2023.07.359",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041499","AstraZeneca licenses obesity drug candidate","Michael McCoy","2023","C&EN Global Enterprise","other","article","10.1021/cen-10138-buscon16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0041500","A373 Analyzing the use of Glucagon like peptide-1 agonists prior to endoscopy in bariatric patients",null,"2024","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2024.04.344",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041501","Managing Obesity in Heart Failure: Latest Evidence and Knowledge Gaps","Ramzi Ibrahim","2024","Current Treatment Options in Cardiovascular Medicine","nonrandomized_study","article","10.1007/s11936-024-01056-0",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041502","Cover Feature: A Nickel(II)‐Mediated Thiocarbonylation Strategy for Carbon Isotope Labeling of Aliphatic Carboxamides (Chem. Eur. J. 24/2021)","Simon S. Pedersen","2021","Chemistry - A European Journal","other","article","10.1002/chem.202100497",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041503","GLP-1 Receptor Agonist Inhibited the Activation of RIPK1 for Alleviation the Neuronal Death and Neuroinflammation in APP/PS1 Mice","Xiaodong Kong","2021","International Journal of Peptide Research and Therapeutics","preclinical","article","10.1007/s10989-021-10202-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041504","Semaglutide Once Weekly In Persons with Type 2 Diabetes: Real-World Analysis of the Colombian Diabetes Registry (COL-REAL 1 Study)","Carlos Mario Balcázar Valencia","2021","Metabolism","nonrandomized_study","article","10.1016/j.metabol.2020.154640",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041505","Identification and optimisation of a risk stratified cohort of patients with type 2 diabetes through the delivery of a enhanced pharmacist-led service","Stephen V. McBrien","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.3304",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041506","Pressure, Hysteresis, and Experience: A Friction-Theoretic Framework for Clinical Intervention","Tomas Pødenphant Lund","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22132990",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0041507","#1698353 Comparative Effectiveness of GLP1 Analogues and Bariatric Surgery in Obese Hypothyroid Patients: Insights from a TriNetX Network Analysis","Hussein Al‐Sudani","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.050",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041508","Correction to: GLP-1 Receptor Agonist Inhibited the Activation of RIPK1 for Alleviation the Neuronal Death and Neuroinfammation in APP/PS1 Mice","Xiaodong Kong","2022","International Journal of Peptide Research and Therapeutics","notice","article","10.1007/s10989-022-10422-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0041509","GLP3-B Reviews - Scam or Legitimate Knows Shocking Price","glp3-b price","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22129181",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041510","IDF2022-0918 Tirzepatide reduces serum triglyceride irrespective of fibrate use in people with T2D at high CV risk (SURPASS-4)","S. Kahn","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110401",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041511","Liraglutide Shows Better Cardiometabolic Benefits Than Lorcaserin in a Novel Free Choice Diet-Induced Obese Rat Model","François Briand","2020","Metabolism","preclinical","article","10.1016/j.metabol.2019.12.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041512","PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS","M. Carrasco Perez","2019","Value in Health","other","article","10.1016/j.jval.2019.09.902",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041513","Tirzepatide, una nuova frontiera nel trattamento dell’obesità","Francesca Guarini","2023","L Endocrinologo","other","article","10.1007/s40619-023-01219-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041514","SAT439 Euglycemic Diabetic Ketoacidosis When Combining Empagliflozin With Cocaine","F Cardenas","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.1069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041515","EMA finds no link between GLP-1 receptor agonists and suicidal thoughts",null,"2024","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2024.1.308856",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041516","Liraglutide as a potential drug repurposing candidate for Alzheimer’s disease and related dementia: Real World Evidence","Tiansheng Wang","2023","Alzheimer s & Dementia","nonrandomized_study","article","10.1002/alz.073346",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041517","8040 Precision-Engineered Activin and GDF Ligand Trap HS235: A Novel Lean Mass-Preserving Treatment for Obesity","Gauthier Schang","2024","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvae163.017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041518","Tirzepatide per il trattamento della sindrome delle apnee notturne e dell’obesità","Valerio Velardi","2024","L Endocrinologo","other","article","10.1007/s40619-024-01553-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041519","Elevating brain GLP‐1 and GIP levels as a treatment strategy for neurodegenerative disorders","Nigel H. Greig","2024","Alzheimer s & Dementia","preclinical","article","10.1002/alz.089262",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041520","Clinical care and other categories posters: Inpatient care",null,"2019","Diabetic Medicine","other","article","10.1111/dme.32_13883",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041521","Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review","Leonardo Bianchi","2023","JEADV Clinical Practice","case_report","article","10.1002/jvc2.255",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041522","P-779 GLP-1 receptor agonist treatment in early pregnancy and risk of pregnancy complications - A nationwide cohort study","Kathrine Vauvert Römmelmayer Hviid","2024","Human Reproduction","nonrandomized_study","article","10.1093/humrep/deae108.041",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041523","#1706873 Paradox in T2DM Management: Relative ineffectiveness of Oral Semaglutide in Overweight Patients - A Real-World Study","Rajeev Chawla","2024","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2024.03.220",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041524","Editorial: Diabetes, transplantation and regenerative medicine","Alessandro Mattina","2024","Frontiers in Clinical Diabetes and Healthcare","nonrandomized_study","article","10.3389/fcdhc.2024.1388904","38711746",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0041525","Absolute treatment effects of novel oral antidiabetic drugs on cardiovascular mortality and hospitalization for heart failure: a meta-analysis of digitalized individual patient outcomes","Georg Wolff","2022","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehac544.2686",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0041526","Glucagon-like peptide-1 receptor agonists in combination therapy of gonarthrosis in patients with metabolic syndrome: Results of a 24-week prospective randomized study","Surov A.I. Surov","2026","Therapy","randomized_trial","article","10.18565/therapy.2026.1.14-23",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041527","7431 Non-Insulin Treatment of Type 1 Diabetes Mellitus: The Power of GLP-1 and GLP-1/GIP RA","Juliana Ferri-Guerra","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.864",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041528","The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease","Jonathan Tjerkaski","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.3311",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041529","THE EFFICACY OF GLP1 AGONISTS AND GIP/GLP1 COAGONISTS ON CARDIOVASCULAR OUTCOMES IN COPD PATIENTS","Xin Ya See","2024","CHEST Journal","other","article","10.1016/j.chest.2024.07.070",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041530","POS-336 SEMAGLUTIDE 2.4 MG AND 1.0 MG IMPROVED ALBUMINURIA IN ADULTS WITH OVERWEIGHT/OBESITY AND TYPE 2 DIABETES IN STEP 2","Hiddo J.L. Heerspink","2022","Kidney International Reports","other_trial","article","10.1016/j.ekir.2022.01.357",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","conference-abstract"],["R0041531","A cost-controlling treatment strategy of adding liraglutide to insulin in type 2 diabetes","Wit, H.M. de","2017","Radboud Repository (Radboud University)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0041532","ID: 3492486 SEMAGLUTIDE IN ASSOCIATION TO ENDOSCOPIC SLEEVE GASTROPLASTY: TAKING ENDOSCOPIC BATRIATRIC PROCEDURES OUTCOMES TO THE NEXT LEVEL","Anna Carolina Hoff","2021","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2021.03.083",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041533","2型糖尿病の日本人におけるインスリングラルギン100単位/mLおよびリキシセナチド(iGlarLixi)の固定比併用の利点: LixiLan JP第3相試験のサブグループおよび時間-対照分析【JST・京大機械翻訳】","Yasuo Terauchi","2020","Diabetes Obesity and Metabolism","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041534","Clinical case: Evaluation of the effect of liraglutide therapy on myocardial perfusion according to spect data in an obese patient","P. Rezinkina","2022","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2022.06.597",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041535","Minimization of drug interactions in polypharmacy treatments of diabetes mellitus type 2 with cardiovascular comorbidities by using the decision support tool PM-TOM","Adnan Kulenović","2023","Informatics in Medicine Unlocked","other","article","10.1016/j.imu.2023.101267",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041536","Metabolomic profile of morbidly obese NAFLD: effect of weight loss by exenatide or diet","Bárbara G. Patrício","2019","Digestive and Liver Disease","other","article","10.1016/j.dld.2018.11.090",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041537","ASSOCIATION BETWEEN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USE AND REDUCED RISK OF NEW-ONSET FIBROIDS AMONG WOMEN WITH TYPE 2 DIABETES","Tina Yi Jin Hsieh","2024","Fertility and Sterility","other","article","10.1016/j.fertnstert.2024.07.360",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041538","8443 Incretin-Mimetic Therapy In Hypertriglyceridemia-Induced Pancreatitis - A Case Report","Anira Iqbal","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.817",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041539","Combined therapy with SGLT2i and GLP-1ra improves cardiovascular prognosis in a population with diabetes and overweigh or obesity. A real-world clinical practice study","D Garcia Vega","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.2569",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041540","Prevention is still the key to success","Stefan Agewall","2022","European Heart Journal - Cardiovascular Pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvac046","36057770",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041541","Mo1356: EFFICACY OF GLP-1 RECEPTOR AGONISTS AND SGLT-2 INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES IN LIVER TRANSPLANT RECIPIENTS","Amirhossein Azhie","2022","Gastroenterology","other","article","10.1016/s0016-5085(22)61778-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041542","6560 Atypical Diabetes Mellitus in a Mother-Son Pair with Multiple Autoimmune Conditions & Pathogenic Variant in BCL11B Inherited from the Mother","Rawan Elrajabi","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.679",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041543","EE277 Assessing the Cost-Effectiveness of Semaglutide 2.4 Mg Injection for Chronic Weight Management in Portugal","Marina Borges","2023","Value in Health","other","article","10.1016/j.jval.2023.09.543",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041544","Liraglutide in Treatment of Diabetes Mellitus Type 2: Systematic Review and Bibliometric Analysis Over The Last Two Decades","Manar Ahmed Kamal","2022","Metabolism","systematic_review","article","10.1016/j.metabol.2021.154997",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0041545","#6624 EFFICACY AND SAFETY OF GLP1 ANALOGUES IN ADVANCED CKD PATIENTS: A POTENTIAL STRATEGY FOR WEIGHT LOSS AND INCLUSION IN RENAL TRANSPLANT WAITING LIST","Marta Alonso","2023","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfad063c_6624",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041546","Tirzepatide, a new class of incretin-based drug for diabetes","Tianru Jin","2023","Obesity Medicine","other","article","10.1016/j.obmed.2023.100483",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041547","EVALUATION OF WEIGHT REDUCTION AND METABOLIC PARAMETERS IN HIV COHORT UNDERGOING TREATMENT WITH GLP-1 RECEPTOR AGONISTS AT A LARGE PUBLIC NYC/HHC+ HOSPITAL IN NEW YORK CITY","Natalia Nazarenko","2024","American Journal of Preventive Cardiology","nonrandomized_study","article","10.1016/j.ajpc.2024.100788",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041548","ASSOCIATION OF CORONARY ARTERY DISEASE WITH CARDIOVASCULAR OUTCOMES IN OBESITY WITHOUT DIABETES: IMPLICATIONS FOR THE USE OF CORONARY CTA TO IDENTIFY SELECT TRIAL-LIKE POPULATION","Camila Verônica Souza Freire","2024","American Journal of Preventive Cardiology","other_trial","article","10.1016/j.ajpc.2024.100849",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0041549","12614 Induction Of Gpt2 During Metabolic Stress Is Associated With Reduced Incretin Responsiveness And Decreased β-cell Resilience To Metabolic Stress","Sabyasachi Sen","2024","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvae163.819",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041550","Drug news and therapeutic news",null,"2024","Fundamental and Clinical Pharmacology","other","article","10.1111/fcp.13011","38851869",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041551","The growing complexity of the number one killer: ischaemic heart disease","Filippo Crea","2021","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehab414","34244748",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041552","FRI652 Type 2 Diabetes Management: More GLP1 Agonists And Less Metformin?","Francisco J Lopez Maldonado","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.871",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0041553","Free T4 is associated with exenatide-related weight loss in patients with type 2 diabetes mellitus and obesity","Ömercan Topaloğlu","2023","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-023-01197-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041554","Identification on preventive mechanism of glucagon-like peptide-1 (GLP-1) agonist for atherosclerosis model","Sang‐Guk Lee","2023","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2023.06.723",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041555","P3.01E.01 Real-World Analysis of GLP-1 Receptor Agonists and Lung Cancer Risk in Treatment-Naïve Type 2 Diabetes: Potential Impact of Obesity and Gender","Joo Han Song","2024","Journal of Thoracic Oncology","nonrandomized_study","article","10.1016/j.jtho.2024.09.533",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041556","(285) A CASE REPORT OF MULTIMODAL APPROACH TO PGAD IN A 47 YEAR OLD WOMAN WITH ANXIETY, OBESITY AND PERIMENOPAUSE","Süheyla Rahman","2024","The Journal of Sexual Medicine","case_report","article","10.1093/jsxmed/qdae161.215",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041557","12590 Glp1 Agonists Role On Prediabetes Reversal, A Meta-analysis","Aline Levy Sitnoveter","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.788",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0041558","Preoperative Semaglutide Before Robotic Major Liver Resection in Obese patients – Preliminary Results","P Kambakamba","2026","Zeitschrift für Gastroenterologie","other","article","10.1055/s-0046-1826556",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041559","Liraglutide prevents hyperglycemia-induced senescence and proinflammatory monocyte differentiation in CD34+ hematopoietic stem cells","Giuseppe Damiano","2024","Cardiovascular Research","preclinical","article","10.1093/cvr/cvae088.202",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041560","Gestione degli effetti collaterali delle terapie con SGLT2i e GLP1 RA","Luigi Bonifazi Meffe","2024","L Endocrinologo","other","article","10.1007/s40619-024-01494-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041561","Efficacia di semaglutide rispetto a liraglutide nel trattamento del recupero ponderale post chirurgia bariatrica","Nicoletta Benenati","2024","L Endocrinologo","other","article","10.1007/s40619-024-01480-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041562","Liraglutide may affect visceral fat accumulation in diabetic rats via changes in FTO, AMPK, and AKT expression","Shan Xiao","2021","International Journal of Diabetes in Developing Countries","preclinical","article","10.1007/s13410-021-00974-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041563","Early effect of exenatide treatment on atherogenicity in patients with type 2 diabetes mellitus","Burak Menekşe","2023","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-023-01233-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041564","Impact of Sglt-2 Inhibitors on Sickle Cell Disease Patients with Type 2 Diabetes: A Retrospective Matched Cohort Study","Athar Nawab","2024","Blood","randomized_trial","article","10.1182/blood-2024-209371",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0041565","Injection site reaction induced by liraglutide use in a female patient with obesity","İhsan AYHAN","2023","JCEM Case Reports","other","article","10.1210/jcemcr/luac014.039",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041566","A278 GLP-1 Receptor Agonist Use for Weight Loss Management After Bariatric Surgery",null,"2023","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2023.04.262",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041567","Cutaneous Reactions to Antidiabetic Agents: A Narrative Review","Aleia Boccardi","2022","Diabetology","narrative_review","article","10.3390/diabetology3010008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0041568","ASSOCIATION BETWEEN GLP1 AGONISTS/COAGONISTS AND RESPIRATORY OUTCOMES IN COPD PATIENTS: A RETROSPECTIVE COHORT STUDY","Nutchapon Xanthavanij","2024","CHEST Journal","nonrandomized_study","article","10.1016/j.chest.2024.07.073",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041569","6370 New-Onset Autoimmune Diabetes Following COVID-19 Infection and its Implications for Identical Twin Siblings","Gelareh Wintermyer","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.862",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041570","A356 Short term outcomes of semaglutide use after bariatric surgery",null,"2024","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2024.04.336",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041571","Incretins for obstructive sleep apnea: effects mediated fully by weight loss?","Liang Peng","2024","SLEEP","randomized_trial","article","10.1093/sleep/zsae232","39431950",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041572","Let's Get Healthy","Allensworth, Ashlee","2022","The Scholarship East Carolina University's Institutional Repository (East Carolina University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041573","Real-world eligibility for GLP1-ra therapy in a cohort of heart failure patients","Alessandro Villaschi","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.1096",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041574","GLUCAGON-LIKE PEPTIDE-1: GASTROINTESTINAL MOTILITY AND FOOD INTAKE","ROTONDO, Alessandra","2012","Nova Science Publishers (Nova Science Publishers, Inc.)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041575","Fatty acid chain modification of loxenatide and its kinetics in a continuous flow microchannel reactor","Shuchang Wang","2022","Process Biochemistry","other","article","10.1016/j.procbio.2022.12.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041576","Liraglutide and Exercise: A Possible Treatment for Obesity?","Ana Paula Azevêdo Macêdo","2022","Obesities","other","article","10.3390/obesities2030023",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041577","GLP1 receptor agonists exhibit antioxidant and anti-inflammatory properties in human heart tissue via the canonical GLP1 receptor expression through a AMPK-mediated pathway","Elena‐Mihaela Cordeanu","2023","European Heart Journal","other","article","10.1093/eurheartj/ehad655.2825",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041578","LBP-010 Azemiglitazone in combination with GLP1 agonists increases benefit and could preserve lean body mass","Jerry R. Colca","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)00577-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041579","Perioperative Considerations for Patients on Semaglutide","Sher‐Lu Pai","2024","Current anesthesiology reports","other","article","10.1007/s40140-024-00611-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041580","Wirksamkeit von Glucagon‐like Peptide‐1‐Rezeptor‐Agonisten bei Psoriasis: Eine aktualisierte systematische Übersicht und Metaanalyse","Su‐Chi Ku","2024","JDDG Journal der Deutschen Dermatologischen Gesellschaft","systematic_review","article","10.1111/ddg.15431_g","39105246",null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0041581","Early life determinants of Beta-cell function in the sheep","Siti Aishah Sulaiman","2015","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041582","P729 Prospective observational study evaluating the effects of GLP1-RA on Inflammatory Bowel Disease (IBD) in patients with Type 2 Diabetes Mellitus (TDM2)","A. Piumatti","2024","Journal of Crohn s and Colitis","other","article","10.1093/ecco-jcc/jjad212.0859",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041583","Memorable moments","Laura Howes","2023","C&EN Global Enterprise","other","article","10.1021/cen-10140-cover7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041584","Glucagon‐like peptide‐1 mediated renal sympathetic activation in obese rats: role of intrarenal mechanisms","Hong Zheng","2020","The FASEB Journal","preclinical","article","10.1096/fasebj.2020.34.s1.06104",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041585","6660 Euglycemic DKA Induced by SGLT-2 Inhibitor Following Administration ofTirzepatide","Kursat Gurel","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.765",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041586","Losing Weight, Losing Muscle? Muscle Health During GLP-1-Based Obesity Therapy","Michael Tsoukas","2026","Canadian Diabetes & Endocrinology Today","other","article","10.58931/cdet.2026.4254",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041587","THU280 Acute Interstitial Nephritis- A Complication Of Semaglutide Use","Md Junayed Hasan","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.716",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041588","Abstract #1413680: Post-Bariatric Hypoglycemia (PBH) Refractory to Conventional Therapies: The Combined Effect of Very High Doses of Glucagon-Like Receptor Agonist (GLP1-RA) and a Low Dose of Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i)","Arya May","2023","Endocrine Practice","other","article","10.1016/j.eprac.2023.03.068",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041589","Withdrawal: “Effect of glucagon‐like peptide‐1 receptor agonists in subjects with type 2 diabetes mellitus: A meta‐Analysis” Weiyun Qian, Fei Liu, Qichao Yang",null,"2021","International Journal of Clinical Practice","other","article","10.1111/ijcp.14400",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041590","Orally deliverable nanoformulation of liraglutide against type 2 diabetic rat model","N. Senduran","2020","Journal of Drug Delivery Science and Technology","preclinical","article","10.1016/j.jddst.2020.101513",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041591","A084 Variation in Patient Characteristics and Preoperative Weight Loss Among Patients using Glucagon-Like Peptide-1 Receptor Agonists Prior to Bariatric Surgery",null,"2023","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2023.04.083",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041592","#2426 Diabetes treatment in CKD patients—do we treat according to the guidelines?","Nomy Levin Iaina","2024","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfae069.700",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041593","Retatrutide: “tre farmaci in uno” per il trattamento dell’obesità. Uno studio di fase 2","Annalisa Bufano","2024","L Endocrinologo","other","article","10.1007/s40619-024-01421-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041594","Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients","Deene Mohandas","2023","Endocrines","nonrandomized_study","article","10.3390/endocrines4010008",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041595","Assessment of therapeutic effect of liraglutide in newly established cell culture model of non-alcoholic and drug-induced fatty liver disease","Tea Omanović Kolarić","2022","Journal of Hepatology","other","article","10.1016/s0168-8278(22)01755-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041596","PROVIDER-LEVEL VARIATION IN NOVEL CARDIOVASCULAR MEDICATION PRESCRIPTION AMONG PATIENTS HOSPITALIZED FOR HEART FAILURE AND CORONARY ARTERY DISEASE IN THE VETERANS AFFAIRS SYSTEM","Taufiq Salahuddin","2024","American Journal of Preventive Cardiology","nonrandomized_study","article","10.1016/j.ajpc.2024.100828",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041597","Wanting, Liking, Effort and Interoception: Dissociable Reward Constructs in Incretin Pharmacology, and the Limits of Cross-Domain Generalisation","Brandon Thomas Mysliwiec","2026","OSF Preprints (OSF Preprints)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","preprint"],["R0041598","Mulberry leaf extract exhibits multiple anti-diabetic activities and alleviates dysglycemia, systemic inflammation, hepatic steatosis, and xenobiotic metabolism abnormalities in type 2 diabetic mice","Jing-Jy Cheng","2024","Journal of Functional Foods","preclinical","article","10.1016/j.jff.2024.106330",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041599","Corrigendum",null,"2020","Diabetes Obesity and Metabolism","nonrandomized_study","article","10.1111/dom.14037","32363794",null,null,null,"openalex","FALSE","paywalled","4","FALSE","erratum"],["R0041600","USE OF GLP-1 RECEPTOR AGONISTS AND/OR SGLT-2 INHIBITORS AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE BEFORE AND AFTER REVASCULARIZATION IN A SINGLE-CENTER COHORT","Franck H. Azobou Tonleu","2024","American Journal of Preventive Cardiology","nonrandomized_study","article","10.1016/j.ajpc.2024.100762",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041601","IDF23-0198 Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist HRS9531 in T2DM patients","Lihua Zhao","2024","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2024.111436",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041602","GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGS DIRECTLY INHIBIT TRPV1 CHANNEL ACTIVATION","Jaeik Park","2023","IBRO Neuroscience Reports","other","article","10.1016/j.ibneur.2023.08.1430",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041603","Efficacy of Liraglutide Versus Gliclazide in Treatment of Patients with Type II Diabetes Mellitus: Systematic Review and Meta-Analysis","Manar Ahmed Kamal","2022","American Heart Journal","systematic_review","article","10.1016/j.ahj.2022.10.016",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0041604","Special focus on the new anti-diabetic drugs","Stefan Agewall","2024","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvae039","39012214",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041605","Multi-action Secretagogin Controls Circadian Glucagon-Like Peptide-1 Secretion","Satish Sen","2022","Endocrinology","nonrandomized_study","article","10.1210/endocr/bqac178","36282870",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041606","#3484 A NETWORK META-ANALYSIS COMPARING INTENSIVE GLYCEMIC CONTROL AND SGLT-2 INHIBITORS IN PREVENTING RENAL OUTCOMES","Samit Ghosal","2023","Nephrology Dialysis Transplantation","systematic_review","article","10.1093/ndt/gfad063c_3484",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0041607","190 The Impact of Liraglutide Treatment on the Erectile Function of the Diabetic Rats","Serkan Gönültaş","2019","The Journal of Sexual Medicine","preclinical","article","10.1016/j.jsxm.2019.01.198",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041608","Associations Between Alzheimer’s Disease and Stroke: Clinical Studies of NA‐831 for AD and NA‐911 for Stroke","Lloyd Tran","2024","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.095736",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041609","Abstract #1402779: A Case of Possible Tirzepatide-Induced Pancreatitis","Jose Gomez Casanovas","2023","Endocrine Practice","case_report","article","10.1016/j.eprac.2023.03.034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041610","7265 Characterization of Treatment Intensified (Add-on To Metformin) Adults With Type 2 Diabetes Mellitus In Thailand: A cross sectional real-world study (CONVERGE)","Chutintorn Sriphrapradang","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.702",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041611","Effects of Antidiabetic Drugs on Longevity and Healthspan: Evidence and Controversies From Glucose-Lowering Therapy to Anti-Aging Intervention","Xuancheng Zhou","2026","Cytotherapy and Longevity","randomized_trial","article","10.66729/cl202606044",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0041612","#1706120 Effect of combination therapy with once weekly Dulaglutide and Empagliflozin on noninvasive liver scores: real world experience from India","Brijendra Kumar Srivastava","2024","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2024.03.210",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041613","Update on technologies, medicines and treatments","Simon O’Neill","2023","Diabetic Medicine","nonrandomized_study","article","10.1111/dme.15190",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041614","The involvement of GLP1 signaling with the effect of oral galactose in the hypothalamus of sporadic Alzheimer’s disease rat model","Ana Knezović","2023","Alzheimer s & Dementia","preclinical","article","10.1002/alz.082936",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041615","An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain","Santiago Tofé","2021","Endocrine and Metabolic Science","nonrandomized_study","article","10.1016/j.endmts.2021.100082",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041616","8647 Reversal Of Left Atrial Dilation In Heart Failure With Preserved Ejection Fraction (HFpEF) Treated With A GLP-1 Receptor Agonist And A Mineralocorticoid Receptor Antagonist","Michael J. Marino","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.914",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041617","Developing CNS therapeutics for brain insulin resistance in Alzheimer’s disease (AD) and mild cognitive impairment (MCI)","Konrad Talbot","2020","Alzheimer s & Dementia","other_trial","article","10.1002/alz.039514",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0041618","‘Huffing and puffing’ back to health: learning about adherence to exercise training in heart failure with preserved ejection fraction","Faye Forsyth","2024","European Journal of Cardiovascular Nursing","nonrandomized_study","article","10.1093/eurjcn/zvae060","38717331",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041619","MP-483498-003 SEMAGLUTIDE AND ATRIAL FIBRILLATION RECURRENCE AFTER CATHETER ABLATION","Fengwei Zou","2024","Heart Rhythm","other","article","10.1016/j.hrthm.2024.03.1802",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041620","The Importance of Glycemic Equipoise in NASH","Alina M. Allen","2021","Hepatology","randomized_trial","article","10.1002/hep.31866","33901304",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041621","[68Ga]Ga-HBED-CC-exendin-4: A new GLP1R targeting radiolabeled agent for pancreas β-cell and insulinoma imaging","Linlin Li","2021","Nuclear Medicine and Biology","other","article","10.1016/s0969-8051(21)00342-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041622","MO617: Liraglutide Improves Both Diabetic Nephropathy and Cardiomyopathy in the SDT Fatty Rat, A Cardiorenal Model of Type 2 Diabetes","François Briand","2022","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfac076.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041623","Correction to: Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use","Emma D. Deeks","2019","Drugs & Therapy Perspectives","notice","article","10.1007/s40267-019-00681-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0041624","5185 A Meta-Analysis Evaluating the Efficacy of Liraglutide in Reducing Cardiovascular Complications Among Patients With Type 2 Diabetes","Michelle Panol Del Rosario","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.648",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0041625","A100 Outcomes of Combined Therapy of Severe Obesity with Bariatric Surgery, Glucagon-like Peptide 1 Agonist Before and After Surgery and Genetic-based Targeted Therapy",null,"2023","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2023.04.099",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041626","Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks","Sanjana Thota-Kammili","2024","Current Treatment Options in Gastroenterology","other","article","10.1007/s11938-024-00452-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041627","Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist","Rouchan Ali","2022","Health Sciences Review","other","article","10.1016/j.hsr.2022.100032",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041628","Semaglutide effects on human epicardial and subcutaneous fat released exosomes, aortic endothelial cells and neutrophils","D Sanchez-Lopez","2023","European Heart Journal","other","article","10.1093/eurheartj/ehad655.3295",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041629","Corrigendum",null,"2022","Diabetes Obesity and Metabolism","nonrandomized_study","article","10.1111/dom.14728","35543084",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","erratum"],["R0041630","Anti-inflammatory and anti-fibrotic effects by simultaneous activation of glucagon, GIP, and GLP-1 of efocipegtrutide (HM15211) in thioacetamide-induced mouse model of liver injury and fibrosis","Jung Kuk Kim","2023","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(23)02172-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041631","APPLYING REWIND CVD CRITERIA TO SUSTAIN 6 AND PIONEER 6: AN EXPLORATORY ANALYSIS OF CV OUTCOMES WITH SEMAGLUTIDE","Subodh Verma","2020","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(20)32549-3",null,null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","openalex","TRUE","free_to_read","5","FALSE","article"],["R0041632","GLP-1 AGONISTS: EFFECT IN MANAGEMENT OF DIABETES AND WEIGHT LOSS IN OLDER ADULTS WITH OVERWEIGHT AND OBESITY","Anna Pendrey","2023","Innovation in Aging","nonrandomized_study","article","10.1093/geroni/igad104.2256",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0041633","Tirzepatide settimanale per il trattamento dell’obesità","Antonio Siena","2022","L Endocrinologo","other","article","10.1007/s40619-022-01165-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041634","Moderate preventative effect with intraperitoneal liraglutide injection in high-fat diet induced C57BL/6J obese mouse model","Manroop Khroud","2019","Obesity Medicine","preclinical","article","10.1016/j.obmed.2019.100153",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041635","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-33479-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041636","Pharmacokinetics of Lixisenatide, a GLP-1 Receptor Agonist, Determined by a Novel Liquid Chromatography–Tandem Mass Spectrometry Analysis in Rats","Hyeon Seok Oh","2023","Separations","preclinical","article","10.3390/separations10050282",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041637","Patients and healthcare professionals views on injectables for cardiovascular disease","G Lee","2022","European Heart Journal","other","article","10.1093/eurheartj/ehac544.2757",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041638","FRI064 The Role Of GLP-1 Receptor Agonists In The Treatment Of Pituitary And Hypothalamic Tumor Induced Obesity","Carlos S Botero Suarez","2023","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvad114.074",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0041639","Improvement of liver fibrosis by a novel long acting Glucagon/GLP-1/GIP triple agonist, efocipegtrutide (HM15211) in carbon tetrachloride-induced mouse model of liver injury and fibrosis","Jong Suk Lee","2023","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(23)02208-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041640","THU-232 Additive hepatoprotective effects of DA-1241, a novel GPR119 agonist, in combination with semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH","Monika Lewińska","2024","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(24)01698-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041641","Soli-switch: efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes","Haluzik, Martin","2024","Diabetologia","other","article","10.5281/zenodo.14228107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041642","7501 The Effect Of Liraglutide On Postprandial Hypoglycemia In Non-Bariatric Surgery Patients; A Case Series And Review Of Literature","Wael Almistehi","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.952",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041643","Comparative Efficacy of Resmetirom, GLP-1 Receptor Agonists, and Pioglitazone for Fibrosis Regression and MASH Resolution in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Narrative Synthesis of Network Meta-Analyses with Implications for Pakistan","Sameed Qureshi","2026","Pakistan journal of Gastroenterology","systematic_review","article","10.63521/641kea29",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0041644","RWD129 Trends in GLP-1 Receptor Agonist Dispensing Among US Patients Without Type 2 Diabetes Using Real World Data","DA Djibo","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.03.1783",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0041645","Cardio-oncology: a focus on cardiovascular toxicities of cancer therapies and on atrial fibrillation in cancer","Filippo Crea","2022","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehab905","35100343",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041646","Response to Letter to the Editor From Han and Xu: “Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes”","Dae Ho Lee","2022","The Journal of Clinical Endocrinology & Metabolism","commentary","article","10.1210/clinem/dgac697","36478031",null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0041647","PLGA‐Based Drug Delivery Systems: A Promising Carrier for Antidiabetic Drug Delivery","Bhaben Sharmah","2024","Advanced Therapeutics","other","article","10.1002/adtp.202300424",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041648","Association of HbA1C with mortality and cardiovascular outcome in patients with type 2 diabetes using drugs with different hypoglycemic risk","Yu‐Jung Lin","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.3303",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041649","Is predicting the risk of incident diabetes useful in patients with cardiovascular disease?","Héctor Bueno","2024","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwae151","39196788",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0041650","CO9 A Real-World Examination of HBA1C Reduction and Target Achievement Comparing SGLT2 Inhibitors and GLP1 Receptor Agonists As Second-Line Augmentation to Metformin for Treating Type II Diabetes","Jie Chen","2023","Value in Health","nonrandomized_study","article","10.1016/j.jval.2023.03.083",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041651","P177. Semaglutide to the Rescue: Real-World Clinical Data in Patients With Antipsychotic-Induced Weight Gain not Responding to Metformin","Femin Prasad","2022","Biological Psychiatry","nonrandomized_study","article","10.1016/j.biopsych.2022.02.411",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041652","#1698343 Impact of Menopausal Status on BMI Reduction in Obese Women Treated with GLP-1 Analogues: A Comparative Analysis Using TriNetX Database","Hussein Al‐Sudani","2024","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2024.03.254",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041653","8494 A Case of Diabetic Ketoacidosis in Setting of COVID-19 Infection and SGLT-2 Inhibitor Use","Nora Abrahimi","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.636",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041654","IDF2022-0372 Higher weight loss is associated with improved patient reported outcomes in T2D patients treated with tirzepatide","K.S. Boye","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110305",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041655","Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials in type 2 diabetes: a meta-analysis of individual patient data","O Kuss","2022","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehac544.2685",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0041656","Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria","Ashwin K. Chetty","2024","American Heart Journal","other_trial","article","10.1016/j.ahj.2024.09.026",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0041657","Prevalence of SELECT-eligibility and incidence of 5-year major adverse cardiovascular outcomes in non-diabetic patients with myocardial infarction","Michael Mæng","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.2538",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041658","Small intestine is a big player!","Ivo Boškoski","2023","Digestive Endoscopy","randomized_trial","article","10.1111/den.14624","37492017",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0041659","Heart failure and renal outcomes in patient treated with GLP1 agonists","N Del-Cuerpo-Salinas","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.1036",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041660","RELEVANCE of GLP-1 AGONISTS FOR INFERTILITY PRACTICE","Savcı Bekir Telek","2024","Reproductive BioMedicine Online","other","article","10.1016/j.rbmo.2024.104522",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041661","Comparison of efficacy between liraglutide and phentermine/topiramate in obese patients with non-alcoholic fatty liver disease","Young Eun Chon","2023","Journal of Hepatology","other","article","10.1016/s0168-8278(23)02299-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041662","Ozempic for pets on the horizon?","Josh Loeb","2024","Veterinary Record","other","article","10.1002/vetr.4755","39364944",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041663","Anti-Diabetic drugs","Valentine, Emeka","2016","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041664","Glucose-dependent insulinotropic polypeptide and tissue inflammation: Implications for atherogenic cardiovascular disease","Xiaoming He","2022","European Journal of Inflammation","other","article","10.1177/20587392211070402",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041665","Preparation of semaglutide long-acting injectable microcapsules with physicochemical properties, long-term stability, and pharmacokinetics and pharmacodynamics","Ravi Maharjan","2024","Journal of Pharmaceutical Investigation","other","article","10.1007/s40005-024-00681-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041666","WED-251 Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis","John J. Suschak","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)01588-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041667","Corrigendum",null,"2020","Diabetes Obesity and Metabolism","other","article","10.1111/dom.14249","33314558",null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0041668","Integrating High-Dose GLP-1 Receptor Agonists Into the Care of People With or at Risk for Type 2 Diabetes","Sarah E. Wheeler","2022","ADCES in Practice","other","article","10.1177/2633559x221086298",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041669","CO34 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists - Efficacy, Safety, and Cost-Effectiveness in Obesity Management: A Systematic Review","RJ. Ahiwale","2024","Value in Health","systematic_review","article","10.1016/j.jval.2024.03.123",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0041670","P1‐079: NOVEL DUAL GLP‐1/GIP RECEPTOR AGONISTS SHOW NEUROPROTECTIVE EFFECTS IN TWO ANIMAL MODELS OF AD","Christian Hölscher","2019","Alzheimer s & Dementia","other_trial","article","10.1016/j.jalz.2019.06.104",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0041671","8447 A Short-Term Tirzepatide Treatment Improves Insulin Sensitivity and Reduces Leptin-Ghrelin Ratio in Diet-Induced Obese Mice","Suryateja Devarakonda Rao","2024","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvae163.653",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041672","Prescriptions of newer glucose regulating agents in older hospitalized patients with type 2 diabetes A retrospective cohort study","D. Janssen","2023","Diabetes Epidemiology and Management","nonrandomized_study","article","10.1016/j.deman.2023.100157",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041673","EE481 Long-Term Cost-Effectiveness of Tirzepatide Versus Placebo for Individuals With Type 2 Diabetes and Obesity","Min Tang","2024","Value in Health","other","article","10.1016/j.jval.2024.03.2246",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041674","21.4 So Do I Prescribe Wegovy Now? The Child and Adolescent Psychiatrist’s Role In Weight Management","Nazeeha J. Micciche","2024","Journal of the American Academy of Child & Adolescent Psychiatry","other","article","10.1016/j.jaac.2024.07.157",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041675","Effect of semaglutide 2.4 mg on alanine aminotransferase in adolescents with obesity: a post-hoc analysis of the STEP TEENS trial","Daniel Weghuber","2023","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(23)00541-x",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0041676","EE15 Cost-Effectiveness Analysis of Oral Semaglutide as the Second-Line and Third-Line Treatment for Type 2 Diabetes Patient","Eleonora Tan","2023","Value in Health","other","article","10.1016/j.jval.2023.09.288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041677","UTILIZATION TRENDS OF GLUCOSE-LOWERING DRUGS FOR TYPE 2 DIABETES IN OLDER ADULTS WITH AND WITHOUT DEMENTIA","Chandrasekar Gopalakrishnan","2022","Innovation in Aging","nonrandomized_study","article","10.1093/geroni/igac059.1819",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041678","7215 Skeletal Muscle Mass Loss with Use of Dual GLP-1 GIP Receptor Agonist Tirzepitide","Jessica Zinn","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041679","Diabetes and Ramadan Fasting (2024): A Thematic Overview","Salem Beshyah","2025","Journal of Diabetes and Endocrine Practice","nonrandomized_study","article","10.1055/s-0045-1809319",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041680","MO637: Effectiveness and Safety of Glucagon-Like Peptide-1 Receptor Agonist in a Cohort of Kidney Transplant Recipients","Luis Alberto Vigara","2022","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfac076.030",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041681","Stimulation of GLP‐1 signaling enhances protein clearance and reduces Aβ‐mediated toxicity in neuronal cells","Chih‐Li Lin","2020","Alzheimer s & Dementia","other","article","10.1002/alz.038285",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041682","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity","Jennifer L. Strande","2023","Metabolism","randomized_trial","article","10.1016/j.metabol.2023.155433",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041683","223 Factors associated with sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) prescriptions among women veterans",null,"2024","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2024.01.226",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041684","#6653 USE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS IN KIDNEY TRANSPLANT PATIENTS: A MULTI-CENTER STUDY","Luis Alberto Vigara","2023","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfad063c_6653",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041685","REPURPOSED FOR AGING","Sandra Aleksić","2024","Innovation in Aging","other","article","10.1093/geroni/igae098.0449",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041686","MA13.11 Glucagon-Like Peptide 1 Receptor Agonists Associated with Reduced Risk of Lung Cancer in Type 2 Diabetes Mellitus","Tomasz Tabernacki","2024","Journal of Thoracic Oncology","other","article","10.1016/j.jtho.2024.09.197",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041687","THE FIRST REPORT OF ANGIOEDEMA AND ANAPHYLAXIS WITH TEMPORAL ASSOCIATION TO SEMAGLUTIDE","J. Feinstein","2022","Annals of Allergy Asthma & Immunology","other","article","10.1016/j.anai.2022.08.735",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041688","Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors on Renal and Cardiovascular Outcomes","Samuel M. John","2023","ADCES in Practice","other","article","10.1177/2633559x231202491",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041689","From burden to benefits: new promises of glucose-lowering treatments in older adults","Antoine Christiaens","2024","Age and Ageing","randomized_trial","article","10.1093/ageing/afae265","39656766",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0041690","Heart failure treatment and mortality in older people: beyond clinical trials","Marco Zuin","2024","The Lancet Healthy Longevity","randomized_trial","article","10.1016/s2666-7568(24)00060-6","38705148",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0041691","Optimizing heart failure services: a focus on patients with heart failure with preserved ejection fraction","Leeanne Macklin","2024","European Journal of Cardiovascular Nursing","nonrandomized_study","article","10.1093/eurjcn/zvae140","39446566",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041692","THU-194 Semaglutide links with improved survival and liver outcomes in MASLD patients, a large multicenter retrospective real-world cohort study","Mohammed Suki","2024","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(24)01667-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041693","GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AGONISTS DURING OOCYTE AND EMBRYO CRYOPRESERVATION","Katherine Roberts","2024","Fertility and Sterility","other","article","10.1016/j.fertnstert.2024.07.783",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041694","A340 Results of the Use of the GLP-1 Analogs in Patients with Obesity Type 1 or Regain Weight After Bariatric Surgery","Evelyn Dorado","2019","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2019.08.283",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041695","Gastric motor function in health and diabetes: implications for incretin hormone release and postprandial blood glucose regulation.","Jessica Lee Sing Chang","2012","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0041696","#1783600 The Efficacy of GLP-1 RA Therapy in Patients with Type 1 Diabetes: A Real-world Observational Study","Novera Shahid","2024","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2024.03.164",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041697","Baseline Body Mass Index anticipating the Efficacy of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: A Meta-analysis Study","Minji Sohn","2023","Obesity Research & Clinical Practice","systematic_review","article","10.1016/j.orcp.2023.08.012",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0041698","7947 Semaglutide Induced Pancreatitis: A Case Report","Tamara Altaweel","2024","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvae163.1071",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0041699","ASSESSING GEROTHERAPEUTIC POTENTIAL OF GLP-1 RECEPTOR AGONISTS","John Newman","2024","Innovation in Aging","other_trial","article","10.1093/geroni/igae098.0452",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","conference-abstract"],["R0041700","A320 A Retrospective Single Center Multi Surgeon Experience on the Adjuvant Use of Semaglutide as an AOM in post MBS-Patients",null,"2023","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2023.04.296",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041701","A047 Impact of Glucagon-Like Peptide-1 Receptor Agonists in the ‘Neoadjuvant’ and ‘Adjuvant’ setting of bariatric surgery",null,"2023","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2023.04.046",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041702","7279 Survodutide and Semaglutide Both Induce Weight Loss but Show Different Effects on Food Preference and Dyslipidemia in the Free Choice Diet-induced Obese Hamster Model","F Briand","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041703","Effect of semaglutide on global longitudinal strain and global myocardial work efficiency in patients with uncontrolled type 2 diabetes mellitus and obesity","Giuseppe Armentaro","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.2566",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041704","Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults with Class 3 Obesity.","Sian Raubinger","2024","Obesity Research & Clinical Practice","other","article","10.1016/j.orcp.2024.09.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041705","IDF21-0072 Safety and Efficacy of Insulin IGlarLixi versus IDegLira: A Meta-Analysis of Fifteen studies","Ivana Beatrice Paulus","2022","Diabetes Research and Clinical Practice","systematic_review","article","10.1016/j.diabres.2022.109606",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0041706","Direct anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in thioacetamide-induced mouse model of liver injury and fibrosis","Jung Kuk Kim","2022","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(22)01267-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041707","#1860 Oral semaglutide in diabetic kidney transplant recipients: Evaluating effectiveness and safety","Arshdeep Singh","2024","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfae069.983",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041708","Weight-loss on liraglutide in a real-life swiss obese cohort","Stefano Angelo Santini","2021","Clinical Nutrition ESPEN","nonrandomized_study","article","10.1016/j.clnesp.2021.09.428",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041709","Does Non-Alcoholic Steatohepatitis Independently Increase the Risk of Venous Thromboembolism?","Maya Gogtay","2022","Blood","nonrandomized_study","article","10.1182/blood-2022-159317",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041710","Sulfobetaine modification of poly (D, L-lactide-co-glycolic acid) nanoparticles enhances mucus permeability and improves bioavailability of orally delivered liraglutide","Zhenyu Zhao","2024","Journal of Drug Delivery Science and Technology","other","article","10.1016/j.jddst.2024.105437",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041711","Liraglutide treatment attenuates dysfunction-related changes in the cardiac and cerebral microvasculature in streptozotocin-induced diabetic rats","A Korn","2022","Cardiovascular Research","preclinical","article","10.1093/cvr/cvac066.234",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041712","Liraglutide treatment sustains neuronal glycolysis and prevents hyperinsulinemia‐induced neuronal senescence","Hei‐Man Chow","2020","Alzheimer s & Dementia","other","article","10.1002/alz.044992",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041713","MSR92 Racial and Smoking Status Disparities in Mediation Effects on Liraglutide-Associated Cardiovascular Outcomes: A Dynamic Path Analysis Using Leader Trial Data","Z.Y. Peng","2023","Value in Health","other_trial","article","10.1016/j.jval.2023.03.2749",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0041714","A 10‐Year Nationwide Pharmacovigilance Assessment on Anti‐Obesity Medications and Factors Associated with Serious Adverse Events","Yeo Jin Choi","2022","The FASEB Journal","nonrandomized_study","article","10.1096/fasebj.2022.36.s1.r3296",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041715","6762 Real-World Analysis of Medication Access and Clinical Outcomes for Obesity Treatment with GLP-1s","Kaelen L. Medeiros","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.025",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041716","IDF2022-0613 PIONEER 11: Efficacy and safety of oral semaglutide versus placebo in predominantly Chinese patients with T2D treated with diet and exercise","W. Wang","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110316",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041717","8132 Prolonged Refractory Hypoglycemia For Seven Days After Discontinuation Of Neutral Protamine Hagedorn (NPH) Insulin And Injectable Semaglutide","Anisa Musleh","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.899",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041718","EE362 Tirzepatide in the Treatment of Diabetes: A Systematic Overeview of Economic Evaluations","Andrej Belančić","2024","Value in Health","other","article","10.1016/j.jval.2024.10.643",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041719","Generalizability of SELECT to a contemporary cohort of cardiac surgical patients: analysis of the TRICS III Randomized Trial","N. Dhingra","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2492",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041720","Novo Nordisk plans $6 billion expansion","Rick Mullin","2023","C&EN Global Enterprise","other","article","10.1021/cen-10138-buscon5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0041721","6411 Ozempic - Oh no! Acute Renal Failure Associated with Initiation of Semaglutide","Kaitlyn Barney","2024","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvae163.873",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0041722","Telomere shortening and cardiac alterations in asymptomatic type 2 diabetes patients: impact of sex","Paul Balfanz","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.825",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041723","Preparation, characterization and in vitro evaluation of chitosan nanoparticles for the oral delivery of GLP-1 analog liraglutide","Jeferson Ziebarth","2023","Journal of Thermal Analysis and Calorimetry","preclinical","article","10.1007/s10973-022-11909-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041724","GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease","Joshua J. Neumiller","2022","Kidney and Dialysis","other_trial","article","10.3390/kidneydial2030034",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0041725","Beneficial outcomes of glucagon like peptide-1 agonist therapy in a patient with Bardet Biedl syndrome and kidney transplant","Banu Ertürk","2023","JCEM Case Reports","other","article","10.1210/jcemcr/luac014.036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041726","148 A Unique Case of Semaglutide Associated Minimal Change Disease",null,"2024","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2024.01.151",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041727","GLP-1受容体作動薬Exendin-4の末梢神経保護作用：インスリンおよびRhoAの関与","塚本, 雅美","2015","The Academic Repository of The Jikei University School of Medicine (Jikei University School of Medicine)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041728","#1302161: Mechanism Behind GLP1RA-Induced Refractory Tachycardia: A Case and Literature Review","Andrés Calderón","2022","Endocrine Practice","narrative_review","article","10.1016/j.eprac.2022.10.169",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041729","HPR36 Utilization of Glucagon-like Peptide-1 Receptor Agonists in Canada","Christopher Vannabouathong","2023","Value in Health","other","article","10.1016/j.jval.2023.03.1183",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041730","Semaglutide modulates adipogenic differentiation and extracellular acidification in epicardial (EAT) and subcutaneous (SAT) adipose tissue stromal cells from patients with cardiovascular disease","Rumeysa Basdas","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae666.3689",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041731","IDF23-0254 A Phase 1, Dose-Escalation Study of a Novel dual GIP and GLP-1 receptor agonist (HS-20094) in Healthy Chinese Subjects","Ruiqin Xie","2024","Diabetes Research and Clinical Practice","other_trial","article","10.1016/j.diabres.2024.111447",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0041732","Corrigendum",null,"2019","Clinical Obesity","other","article","10.1111/cob.12338","31709763",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0041733","Prescription patterns in people who are frail","Isca Hershkowitz","2023","The Lancet Healthy Longevity","randomized_trial","article","10.1016/s2666-7568(23)00177-0","37734396",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041734","Effect of GLP-1 receptor agonist therapy on endometrial cancer","Danielle Krause","2024","Gynecologic Oncology","other","article","10.1016/j.ygyno.2024.07.650",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041735","Heart and Diabetes","Dirk Müller‐Wieland","2024","Clinical Cardiology","other","article","10.1007/978-3-662-69938-6_12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0041736","Four Clicks of the Liraglutide Pen: A Case Report of Administration Error and Adverse Effects","Harneal Diocee","2023","ADCES in Practice","case_report","article","10.1177/2633559x231174018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041737","Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin(9-39).","Collado Camps, E.","2023","Radboud Repository (Radboud University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041738","8269 Euglycemic Diabetic Ketoacidosis Secondary to Rapid Weight Loss in a Patient on Dapagliflozin","Archana Sridhar","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.763",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041739","Effect of liraglutide on epicardial adipose tissue thickness with echocardiography in patients with obese type 2 diabetes mellitus","Ying Li","2020","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-020-00820-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041740","Mejoría en el pronóstico renal con el uso de análogos del receptor GLP-1","Juan de Dios López-González Gila","2023","Medicina Clínica Práctica","other","article","10.1016/j.mcpsp.2023.100392",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041741","Activation of the GLP-1 receptor by chloropyrimidine derivatives","Shaikha S. AlNeyadi","2021","Results in Chemistry","preclinical","article","10.1016/j.rechem.2021.100222",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041742","Anti-obesity drugs alone or combined with exercise training in the management of obesity: a systematic review with meta-analysis","Bruna Marmett","2025","Translational Exercise Biomedicine","systematic_review","article","10.1515/teb-2024-0039",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0041743","73 A Rare Case of Exenatide–Induced Acute Interstitial Nephritis",null,"2021","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2021.02.078",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041744","EE393 Assessing Cost-Effectiveness in Diabetes Management: A US Healthcare Payer’s Perspective on 15MG Tirzepatide Versus 1MG Semaglutide","Rawan A. Almasuood","2024","Value in Health","other","article","10.1016/j.jval.2024.03.689",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041745","Technetium-99m radiolabeled glucagon-like peptide analog exendin-4 for cancer diagnosis","Emre Özgenç","2019","Nuclear Medicine and Biology","other","article","10.1016/s0969-8051(19)30325-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041746","Liraglutide as a Prophylactic Treatment for Sepsis Induced Lung Inflammation and Edema","Brandon Baer","2022","The FASEB Journal","preclinical","article","10.1096/fasebj.2022.36.s1.l7447",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041747","398 Comparative Effectiveness of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists on Incident Albuminuria and Glomerular Filtration Rate Decline in US Veterans","Rhee, Connie","2022","American Journal of Kidney Diseases","other","article","10.1053/j.ajkd.2022.01.403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041748","Effects of cotadutide on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 54-week analysis of a randomized phase 2b study","Rajaa Nahra","2020","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(20)30655-3",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041749","Editorial: Effects of nonpharmacological interventions on HbA1c variability and glycemic control","João Soares Felício","2024","Frontiers in Endocrinology","randomized_trial","article","10.3389/fendo.2024.1482920","39497802",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0041750","370P Glucagon-like peptide-1 receptor agonists and risk of common cancers: A transcriptomic and proteomic-wide Mendelian randomization analysis","Kai Wang","2024","Annals of Oncology","other","article","10.1016/j.annonc.2024.10.389",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041751","Risk of acute pancreatitis after glucagon-like peptide-1 receptor agonists","Adriana Gherbon","2019","Pancreatology","other","article","10.1016/j.pan.2019.05.115",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041752","EE295 Cost-Effectiveness Analysis of Switching from BASAL Insulin + ORAL Antidiabetics - GLP1-RA to Ideglira in Brazil","V de Almeida","2022","Value in Health","other","article","10.1016/j.jval.2022.04.540",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041753","PP93 Efficacy Of Pharmacological Treatments For Type 2 Diabetes In China","Shuyan Gu","2019","International Journal of Technology Assessment in Health Care","randomized_trial","article","10.1017/s0266462319002319",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0041754","Spatiotemporal Dynamics of GLP-1 Receptor and GIP Receptor Trafficking and Signaling in β Cells","Julio E. Ayala","2023","Endocrinology","preclinical","article","10.1210/endocr/bqad056","36996323",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041755","Tirzepatide: la nuova sfida farmacologica al diabete e all’obesità","Emmanuele Capobianco","2024","L Endocrinologo","other","article","10.1007/s40619-024-01522-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041756","OR10-03 Murine Bimagrumab Co-administration With Incretin Agonists Results In Additive Efficacy And Superior Quality Weight Loss In The Mouse Diet-induced Obesity Model","Kevin Nguyen","2023","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvad114.009",null,null,"ClinicalTrials.gov:NCT05616013","S000715","openalex","TRUE","free_to_read","5","FALSE","article"],["R0041757","The year in cardiovascular pharmacotherapy 2022: landmark evidence at a glance","Felice Gragnano","2023","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvad043","37358273",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041758","6694 A Case of an Extraneous Organ: A Uterus Found in a Genotypic and Phenotypic Male","Rachel Zielinski","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.1537",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041759","TREATMENT OF OBESITY IN GP'S OFFICE USING GLP-1 AGONIST LIRAGLUTIDE","Andrea Laštovková","2024","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2024.118775",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041760","Phase‐Changeable Nanoemulsions for Oral Delivery of a Therapeutic Peptide: Toward Targeting the Pancreas for Antidiabetic Treatments Using Lymphatic Transport","Po‐Yen Lin","2019","Advanced Functional Materials","other","article","10.1002/adfm.201809015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041761","Agonistas del receptor GLP-1 en enfermedades reumáticas inflamatorias: impacto inmunometabólico, obesidad y potencial terapéutico","Liliana Teruel Leyva","2026","Revista Metropolitana de Ciencias Aplicadas","other","article","10.62452/2xf01v27",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041762","Commentary on: Aesthetic Surgery Journal Articles on Injectable Weight Loss Medications and Their Role in Plastic Surgery","Mark L. Jewell","2023","Aesthetic Surgery Journal","randomized_trial","article","10.1093/asj/sjad263","37610239",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0041763","Innovating in the field of weight loss","Ahmed R. Ahmed","2023","British journal of surgery","randomized_trial","article","10.1093/bjs/znad025","36745552",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041764","A Synergistic Semaglutide-targeted Fluorescent Nanodrug Delivery System and its Therapeutic Efficacy in Diabetic Nephropathy Treatment","Jinchao Fu","2024","Journal of Inorganic and Organometallic Polymers and Materials","other","article","10.1007/s10904-024-03516-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041765","Products with \"Black Box\" Warnings","Joseph A. Woelfel","2006","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041766","6923 Case Report: Long Standing Type 2 Diabetes with TOFI Phenotype Successfully Weaned Off One Hundred Units of Basal-Bolus Insulin Therapy With Glucagon-Like Peptide 1 Receptor Agonist Therapy","Yin Chian Kon","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.695",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041767","Subacute Thyroiditis Associated With Liraglutide","Banu Ertürk","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.1956",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041768","FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease","Giovanna Liuzzo","2021","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehab725","34905601",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041769","Editorial: Chemical Design and Biomedical Applications of Disulfide-rich Peptides: Challenges and Opportunities","Diana Imhof","2020","Frontiers in Chemistry","commentary","article","10.3389/fchem.2020.586377","33195084",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0041770","Leveraging AI and NLP to Uncover real-world experiences with semaglutide for weight loss","Akshaya Srikanth Bhagavathula","2024","Annals of Epidemiology","nonrandomized_study","article","10.1016/j.annepidem.2024.07.054",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041771","Commercial manufacturing of current good manufacturing practice peptides spanning the gamut from neoantigen to commercial large-scale products","Michael W. Pennington","2020","Medicine in Drug Discovery","other","article","10.1016/j.medidd.2020.100071",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041772","Are we ready for cell-specific therapies in atherosclerosis?","Abdul Waheed Khan","2023","European Heart Journal","other_trial","article","10.1093/eurheartj/ehad147","36928096",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0041773","Short term effect of sodium glucose cotransporter 2 inhibitors and sacubitril/valsartan on comprehensive geriatric assessment and oxidative stress in elderly with chronic heart failure (from MAGIC-HF)","Giuseppe Armentaro","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.1085",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041774","Insulin degludec/liraglutide in type 2 diabetes: a profile of its use","Young‐A Heo","2020","Drugs & Therapy Perspectives","other","article","10.1007/s40267-020-00731-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041775","IDF21-0136 VIEW-Iran: A real-world study of liraglutide effectiveness on glycaemic control in people with type 2 diabetes mellitus","M.E. Khamseh","2022","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/j.diabres.2022.109473",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041776","Phase 3 trial of survodutide in adults with obesity and MASLD","A Geier","2026","Zeitschrift für Gastroenterologie","other_trial","article","10.1055/s-0046-1826555",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0041777","Exenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use","Emma D. Deeks","2019","Drugs & Therapy Perspectives","other","article","10.1007/s40267-018-00597-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041778","Comparison of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in myocardial infarction patients with type 2 diabetes","Jonathan Tjerkaski","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.1484",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041779","FDA approves Lilly diabetes drug","Gina Vitale","2022","C&EN Global Enterprise","other_trial","article","10.1021/cen-10018-buscon15",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0041780","Efficacy and Safety of Tirzepatide in Type 2 Diabetes: The SURPASS Clinical Trial Program","Denis Finney","2023","Metabolism","other_trial","article","10.1016/j.metabol.2023.155457",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0041781","Side Effect Synergism Between Metformin and GLP-1 Receptor Agonists","E Cristiano","2022","American Heart Journal","other","article","10.1016/j.ahj.2022.10.025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041782","IDF2022-0694 Pre-genetic screening and the use of GLP-1 RA and SGLT-2i in monogenic diabetes: A real-world audit-based study","Manuella Constantino","2023","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/j.diabres.2023.110453",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041783","CO105 Impact of Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA) Non-Persistence on Body Mass Index, HBA1C, and Lipids: Analysis of Over 190,000 Adults Treated With Semaglutide, Liraglutide, and Tirzepatide in US Real-World Data","KA Cappell","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.10.181",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0041784","Gli effetti avversi dei farmaci antiepilettici","Miglio, Gianluca","2012","Institutional Research Information System University of Turin (University of Turin)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0041785","#1698349 Comparative Effectiveness of GLP-1 Analogues on BMI Reduction in Obese and Morbidly Obese Populations: A TriNetX Database Analysis","Hussein Al‐Sudani","2024","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2024.03.256",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041786","#1698346 Impact of GLP1 Analogues vs. Bariatric Surgery on Outcomes in Obese Patients with Hyperthyroidism: A TriNetX Analysis","Hussein Al‐Sudani","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.049",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041787","The effect of glucagon-like peptide-1 receptor agonists on the course of gonarthrosis in obese patients with metabolic syndrome: a pilot randomized study","Surov A.I. Surov","2025","Фарматека","randomized_trial","article","10.18565/pharmateca.2025.8.80-88",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041788","Sodium-glucose cotransporter 2 inhibitors and emphysematous cystitis","Ina Dubin","2024","Postgraduate Medical Journal","other","article","10.1093/postmj/qgae099","39140618",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041789","URINARY INCONTINENCE IN US ADULTS WITH DIABETES WHO ARE GUIDELINE-RECOMMENDED TO RECEIVE SGLT2IS: NHANES 2013–2020","Alexandra Lee","2024","Innovation in Aging","other","article","10.1093/geroni/igae098.1455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041790","8462 Synergistic Outcomes Of hCG And GLP1-RA Combination Therapy: Improved Body Composition And Carbohydrate Metabolism","Florence Comite","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.946",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041791","Controlled Release of Exendin-4 from PLGA Micropheres with Convective Blood Flow","Yuen Ching Chen","2013","eCommons (Cornell University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041792","#1677365 A case of a 58-year-old man with type 2 DM who was diagnosed with pancreatic adenocarcinoma after treatment with Tirzepatide","Vladimer Betchvaia","2024","Endocrine Practice","case_report","article","10.1016/j.eprac.2024.03.168",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041793","Su1562 – Longitudinal Change in Fib4 Score in Patients with Diabetes Mellitus Treated with Glucagon-Like Peptide-1 Receptor Agonist Or Sodium/Glucose Cotransporter 2 Inhibitors","Akio Moriya","2019","Gastroenterology","other","article","10.1016/s0016-5085(19)40256-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041794","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97396-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041795","Efficacy and Safety of Tirzepatide in Type 2 Diabetes: The Surpass Clinical Trial Program","Mike Barros","2022","American Heart Journal","other_trial","article","10.1016/j.ahj.2022.10.028",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0041796","Distribution of cardiovascular risk in type 2 diabetes: results of an analysis using data from the CAPTURE study","H.B Oestergaard","2021","European Heart Journal","other","article","10.1093/eurheartj/ehab724.2730",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041797","Can we re‐purpose drugs from the cardiology medicine cabinet? Should we look in the rheumatology, metabolic and hematology cabinets as well?","Terence J. Quinn","2021","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.050163",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0041798","Therapeutic effect of a novel long-acting GLP-1/GIP/glucagon triple agonist (HM15211) in animal models of NASH and fibrosis","Jung Kuk Kim","2020","Journal of Hepatology","other","article","10.1016/s0168-8278(20)30585-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041799","Prevention is the key","Stefan Agewall","2024","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvae090","39797531",null,"ClinicalTrials.gov:NCT04560998","S001363","openalex","TRUE","open_pdf","1","FALSE","article"],["R0041800","7098 Paradoxical Worsening of Dyslipidemia with Tirzepatide","Jacob E. Pruett","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.600",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041801","S2087 Efficacy and Safety of Subcutaneous Semaglutide and Tirzepatide Injections in Elderly vs Younger Obese: A Case-Control Study","Yousif Arif","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037716.85106.62",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041802","MASLD/MASH—New mechanisms and treatments","Xin Zhang","2025","Hepatology Communications","randomized_trial","article","10.1097/hc9.0000000000000770","40694379",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0041803","Tirzepatide in aggiunta a insulina basale nel trattamento del diabete tipo 2: risultati del trial SURPASS-6","Federica De Luca","2024","L Endocrinologo","other_trial","article","10.1007/s40619-024-01446-3",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0041804","Novo Nordisk to expand GLP-1 output","Rick Mullin","2023","C&EN Global Enterprise","other","article","10.1021/cen-10140-buscon14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0041805","Response to Letter to the Editor","Adnan Sharif","2021","Kidney International Reports","commentary","article","10.1016/j.ekir.2021.09.015","34805648",null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0041806","Semaglutide: weighing up the benefits and risks","Joe M. Moody","2024","The Lancet Diabetes & Endocrinology","other","article","10.1016/s2213-8587(24)00181-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041807","Role of liraglutide on cardiotoxicity and gut microbiota changes induced by doxorubicin in rats","Carolina Rodrigues Tonon","2024","European Heart Journal","preclinical","article","10.1093/eurheartj/ehae666.3152",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041808","7311 Endoplasmic reticulum (ER) stress and its associated signaling modulate incretin receptor signaling in pancreatic β cells","Jin‐Young Lee","2024","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvae163.757",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041809","Multi-target engagement effect of a novel long-acting Glucagon/ GIP/GLP-1 triple agonist, HM15211, in animal model of NASH/ fibrosis","Jong Suk Lee","2022","Journal of Hepatology","other","article","10.1016/s0168-8278(22)01266-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041810","Glucagon-like peptide-1 analogue liraglutide attenuates abdominal aortic constriction-induced cardiac fibrosis and dysfunction by inhibiting angiotensin II AT1 receptor in rat","Ronghua Zheng","2020","Journal of Molecular and Cellular Cardiology","preclinical","article","10.1016/j.yjmcc.2019.11.048",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041811","Assessing the potential for precision medicine of glucose-lowering drugs in type 2 diabetes mellitus: a meta-regression analysis considering body weight variability from 120 randomized trials","Kris G. Vargas","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.2994",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041812","7553 Thyroid Paraganglioma: A Complex Tale of the Familiar Thyroid Nodule","Vivek Moorthy","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.2105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041813","IDF2022-0475 GLP-1 receptor agonists and the risk of atrial fibrillation: a real-world evidence","JUNG-IM SHIN","2023","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/j.diabres.2023.110309",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041814","#1702651 Comparative Effectiveness of Bariatric Surgery vs. GLP-1 Therapy in Obese Women with PCOS","Hussein Al‐Sudani","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.381",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041815","Editorial: Endocrine disruptors in gut endocrinology","Velmurugan Ganesan","2024","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1536495","39735652",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0041816","CO43 Projecting Cardiovascular Benefits Associated With Tirzepatide's Effects on Cardiovascular Risk Factors in Patients With Type 2 Diabetes in France: A Simulation Study","Beatrice Osumili","2023","Value in Health","other","article","10.1016/j.jval.2023.09.115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041817","PRESCRIBING PRACTICES OF CARDIOPROTECTIVE ANTI-DIABETIC MEDICATIONS IN MARGINALIZED PATIENTS","Raheel Khan","2023","American Journal of Preventive Cardiology","nonrandomized_study","article","10.1016/j.ajpc.2023.100538",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0041818","Abstract #1406346: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1-RA) in Patients with Diabetes who Underwent Kidney Transplantation (KT): A Retrospective Study with a Control Group","Mario Campana","2023","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2023.03.051",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0041819","RWD164 Association Between GLP-1 Receptor Agonists and Suicidal Ideation in Type 2 Diabetes and Obesity: A Meta-Analysis","Dan Wei","2024","Value in Health","systematic_review","article","10.1016/j.jval.2024.10.3721",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0041820","Overcoming Therapeutic Inertia in Type 2 Diabetes: Combination GLP-1 Agonist and SGLT-2 Inhibitor Therapy Offers Hope","Marla J. Hayes","2022","ADCES in Practice","other","article","10.1177/2633559x221080161",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041821","The incorporation of repeated measurements of risk factors at current and previous visits improves the accuracy of cardiovascular risk assessment: an analysis of the EXSCEL trial","Abderrahim Oulhaj","2023","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwad125.029",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041822","Editorial: The role of sphingolipid metabolism in endocrine diseases","Li Cao","2024","Frontiers in Endocrinology","preclinical","article","10.3389/fendo.2024.1506971","39539931",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0041823","CO187 Acute Pancreatitis Risk Associated with Glucagon-Like Peptide-1 Receptor Agonists Used for Weight Loss: A Retrospective Cohort Study in the United States","Jahangir H. Sarker","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.03.273",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0041824","A169 Preoperative semaglutide treatment in adolescents anticipating bariatric surgery",null,"2023","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2023.04.162",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041825","Successful use of liraglutide in a female patient with type 1 Gaucher disease, type 2 diabetes mellitus and obesity","Ömercan Topaloğlu","2023","JCEM Case Reports","other","article","10.1210/jcemcr/luac014.034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041826","M001 ANGIOEDEMA AND ANAPHYLAXIS INDUCED BY DULAGLUTIDE USE","T. Liu","2019","Annals of Allergy Asthma & Immunology","other","article","10.1016/j.anai.2019.08.079",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041827","Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry","D Garcia Vega","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.3305",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041828","Editorial: Obesity and type 2 diabetes mellitus: novel and alternative functional bioactive nutritional interventions","Renato Chaves Souto Branco","2024","Frontiers in Endocrinology","randomized_trial","article","10.3389/fendo.2024.1453733","39483981",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0041829","CARDIOVASCULAR BENEFIT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN FEMALE PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RECENT CARDIOVASCULAR OUTCOME TRIALS","David Aguilar","2019","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(19)30847-2",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0041830","Novo Nordisk plans big API project","Michael McCoy","2023","C&EN Global Enterprise","other","article","10.1021/cen-10120-buscon15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0041831","O064 Tirzepatide reduced sleep apnea severity in adults with obstructive sleep apnea and obesity: results from the SURMOUNT-OSA trial","Ronald R. Grunstein","2024","SLEEP Advances","randomized_trial","article","10.1093/sleepadvances/zpae070.064",null,null,"ClinicalTrials.gov:NCT05412004","S000156","openalex","TRUE","open_pdf","1","FALSE","conference-abstract"],["R0041832","Pediatric obesity and treatment controversies: Is the use of medications too good to be true?","Megan Fortenberry","2024","American Journal of Health-System Pharmacy","other","article","10.1093/ajhp/zxae340","39673808",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041833","Effects of Semaglutide on Metabolic Syndrome Parameters in Non-Diabetics: A Meta-analysis of Randomized Controlled Trials","Saurabh Aggarwal","2023","Metabolism","systematic_review","article","10.1016/j.metabol.2023.155462",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0041834","A432 Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery",null,"2024","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2024.04.388",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041835","Variable effect of exercise training programme on cardiovascular outcomes in high-genetic-risk individuals with diabetes","Alexander Е. Berezin","2024","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwae106","38469747",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0041836","Elevated IRS‐1 pS616 Pathology in Human Hippocampal Area CA1 as a Biomarker of Preclinical and Alzheimer's Disease Dementia","Xuelin Gu","2024","Alzheimer s & Dementia","other","article","10.1002/alz.093219",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041837","6959 Variation of FIB-4 Classification In A 5-Year Follow-Up Cohort of Patients With Type 2 Diabetes Mellitus Managed By A Multi-Disciplinary Team In A Hospital In Northeastern Mexico","María Elena Romero-Ibarguengoitia","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.1000",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041838","Incretin-based Therapies for Obesity: From Metabolic Modulation to Systems Medicine","Arvinder Singh","2026","AMEI's Current Trends in Diagnosis & Treatment","other","article","10.5005/jp-journals-10055-0200",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041839","Optimizing Semaglutide Therapy in Type 2 Diabetes: Pharmacokinetic Limitations, Nanoemulsion-Based Delivery Strategies and Translational Potential","Satya Prakash","2026","Journal of Pharmaceutical Innovation","other","article","10.1007/s12247-026-10999-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041840","L'ozempic sur les réseaux sociaux : Analyse qualitative d'expériences de perte de poids partagées par des influenceuses","Mara De Matos Pato","2026","IRIS","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041841","Various Evidence-Based Effects of Insulin Degludec/Liraglutide (Ideglira) for Type 2 Diabetes Mellitus","Hiroshi Bando","2020","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041842","Clinical efficacy of dual GIP/GLP-1 receptor agonism for hypothalamic obesity in an adolescent with ROHHAD syndrome","Masako Aoki","2026","Clinical Pediatric Endocrinology","other","article","10.1297/cpe.2026-0072",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041843","Impact of Dietary Reversal and Voluntary Wheel Running in a Female Mouse Model of Obesity","Morgan Valeriano","2026","Digital Commons - Ursinus (Ursinus College)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041844","Patterns of Antidiabetic Therapy and Associated Metabolic Profiles in Routine Clinical Practice","Mădălina Ioana Moisi","2026","Diabetology","nonrandomized_study","article","10.3390/diabetology7080145",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041845","A Middle-aged Man Who Used Semaglutide and Was Diagnosed as Having Euglycemic Ketoacidosis: A Case Report","Tomoki Tanie","2025","DOAJ (DOAJ: Directory of Open Access Journals)","case_report","article","10.60227/jhgmeibun.2025-0010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041846","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97047-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041847","Glucagon-like peptide-1 receptor agonists and risk of cancer: a systematic review and meta-analysis of randomized controlled trials","Weiming Liang","2026","Scientific Reports","systematic_review","article","10.1038/s41598-026-63543-7",null,null,"PROSPERO:CRD42024558497",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0041848","Educational Forum-Glucagon like peptide-1: A new therapeutic target for\\ndiabetes mellitus","Patel SK, Goyal RK, Anand IS, Shah JS, Patel HU, Patel CN","2006","Bioline International (Bioline International)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041849","Beneficial Xultophy Treatment from Medical and Social Points of View","Hiroshi Bando","2021",null,"other","article","10.52588/biomedscij.2.17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041850","Incretin based therapy to promote antitumor immunity in obesity driven triple negative breast cancer","Coleman, Michael","2024","California Digital Library","other","article","10.48321/d1xh41",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041851","EPH9 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND RISK OF PARKINSON’S DISEASE IN PATIENTS WITH OBESITY","Pareeta Kotecha","2026","Value in Health","other","article","10.1016/j.jval.2026.03.842",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041852","PT37 EFFECTIVENESS AND SAFETY OF GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH WEIGHT RECURRENCE AFTER BARIATRIC SURGERY: A REAL-WORLD STUDY","Rotana M. Radwan","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.295",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0041853","Effective Xultophy administration to stable blood glucose profile by Continuous Glucose Monitoring (CGM)","Etsuko Sueki","2020","Institutional Repositories DataBase (IRDB)","other","article","10.33702/rremd.2020.2.1.5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041854","An Important Dose‐response study for tirzepatide, a novel dual (GIP and GLP‐1) Agonist (https://doi.org/10.1111/dom.13979)",null,"2020","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.00007",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041855","Semaglutide functional electrospinning nanofiber membrane rescues apoptosis and promotes diabetic wound healing","Wenyan Jiang","2024","European Polymer Journal","other","article","10.1016/j.eurpolymj.2024.113448",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041856","GLP-1R agonists therapy for type 2 diabetes","Bilan Zhou","2014","Wuhan University Journal of Natural Sciences","other","article","10.1007/s11859-014-0974-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041857","Novas classes terapêuticas para o controlo da glicemia na Diabetes Tipo 2: eficácia clínica e questões de segurança","Magda Rita Garcia Cabral Ferreira","2011","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041858","The \"Can Semaglutide or eMpAgliflozin Stabilise coronary atHerosclerosis after Acute Coronary Syndrome (SMASH-ACS)” study in people with type 2 diabetes","Marathe, Dr Jessica","2025","South Australian Health and Medical Research Institute","other_trial","article","10.58138/de9s-xg27",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0041859","DB08 When iron becomes too much: diabetes as a first clue to hidden hemochromatosis – a case report","T Ninkovic","2026","European Journal of Endocrinology","case_report","article","10.1093/ejendo/lvag128.040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041860","Kongressbericht: Liraglutid (Victoza®): Diabetestherapie mit Mehrwert","Leitner H","2018","Journal für Kardiologie (Krause & Pachernegg GmbH)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041861","Liksisenatidi","Kalliokoski, Annikka","2013","STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041862","Once-Monthly and Extended-Interval Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines","Héctor Iván Saldívar-Cerón","2026","Scientia Pharmaceutica","other_trial","article","10.3390/scipharm94010021",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0041863","Klinische Studien/Klinische Praxis: Liraglutid (Victoza(R)): GLP-1-Agonisten neu bewertet","Heather Leitner","2012","Journal für Kardiologie (Krause & Pachernegg GmbH)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041864","A PARADIGM SHIFT IN THE DIAGNOSIS AND TREATMENT OF POLYCYSTIC OVARIAN SYNDROME: A PRACTICE CHANGE IN PRIMARY CARE","Sullivan, Patricia L","2016","Pittsburg State University Digital Commons (Pittsburg State University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041865","Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study","M. Odawara","2015","Institutional Repositories DataBase (IRDB)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0041866","Onderzoek naar liraglutide","Bohn Stafleu van Loghum","2011","Mednet","other","article","10.1007/s12462-011-0199-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0041867","IMPACT OF SEMAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND MILD COGNITIVE IMPAIRMENT (MCI): clinical effects and genetic predictors of response","Giuliano Cassataro","2025","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041868","Synthesis of protected fragments of Liraglutide","Σταυρούλα Κατσαγάνη","2016","Νημερτής","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041869","“Persistente secrezione di Exendin-4, un agonista recettoriale del Glucagon-like peptide-1, mediante terapia genica mediata da Adeno-associated Viruses, su ghiandole salivari di roditori in due differenti modelli di obesità/diabete tipo 2”","Ilaria Dicembrini","2013","Florence Research (University of Florence)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041870","Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro","Vaittinen Maija","2025","UTUPub (University of Turku)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041871","Wirkungen von GLP-1 und Exendin-4 auf die myokardiale Glucoseverwertung und Kontraktilität","Tiến Dũng Nguyễn","2014","Common Library Network (Der Gemeinsame Bibliotheksverbund)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041872","GLP-1 Therapy and Wound Healing","Federica Tomaselli","2026","Annals of Plastic Surgery","other","article","10.1097/sap.0000000000004866",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041873","Glucose-lowering efficacy of Xultophy with low doses by FreeStyle Libre as continuous glucose monitoring (CGM)","Takafumi Kawata","2021","International Medicine","other","article","10.5455/im.59761",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041874","Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study","咲 山本",null,"Institutional Repositories DataBase (IRDB)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0041875","Latest Topics on Pharmacotherapy for Obesity Including Glucagon Like Peptide-1receptor Agonists (GLP-1RAs)","Hiroshi Bando","2021","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041876","Novel strategies for secondary stroke prevention - exploring the use of pioglitazone therapy using a mixed methods approach","Hala F. Azhari","2020","Enlighten: Theses (The University of Glasgow)","nonrandomized_study","article","10.5525/gla.thesis.81493",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0041877","ESTROGEN AND GLP-1 RECEPTOR SIGNALING IN THE REGULATION OF DRINKING BEHAVIOR IN FEMALE RATS","Grace Trinity Young","2026","UKnowledge (University of Kentucky)","preclinical","article","10.13023/etd.2026.358",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041878","Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study","Balcázar-Valencia,Carlos","2024","Dove Medical Press (Taylor and Francis Group)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0041879","Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms","俊祐 加藤",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041880","DB17 Switching from oral semaglutide to tirzepatide in patients with type 2 diabetes: a real-world retrospective cohort study","A Pucci","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag128.018",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0041881","Tratamiento con Exenatide en pacientes obesos con DM Tipo 2 e insulina","Vidal Peracho, Concepción","2011","Zaguan (Universidad de Zaragoza)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041882","Influence of genetic polymorphisms of the inflammatory pathway on the control of diabetes and the occurrence of late complications in patients with type 2 diabetes","Verbanec, Anja","2024","Repository of the University of Ljubljana (University of Ljubljana)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041883","GLP-1 Receptor Agonists and Ocular Risk","Saharsh Satheesh","2026","The Medicine Forum","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0041884","GLP-1 Receptor Agonists and Breast Cancer Survivorship: Weight Management, Metabolic Health, and Oncologic Safety","Jane J. Chen","2026","Current Breast Cancer Reports","other","article","10.1007/s12609-026-00662-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041885","DB12 Incretin-based therapy lowers routinely available systemic-inflammation indices partly independent of weight loss in obesity: a 6-month real-world cohort","D Türkum Atikcan","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag128.025",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0041886","Effective and convenient treatment of Xultophy with lower doses for elderly diabetic patient","Tatsuo Yasuoka","2021","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041887","Synthesis study of liraglutide with peptide condensation","Σωτηρία Σταμούτσου","2018","Νημερτής","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041888","GLP-1 weight-loss medicine and Retatrutide use for anabolic effects among online weight trainers: cultural understandings of risk","Luke Cox","2026","Cronfa (Swansea University)","other","article","10.1080/16066359.2026.2671771",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041889","American D iabetes A ssociation S tandards of M edical C are in D iabetes 2017","Payal H. Marathe","2017","Journal of Diabetes","other_trial","article","10.1111/1753-0407.12524","28070960",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0041890","The effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review and meta-analysis","Bellman, Susan Marie","2016","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0041891","Structural study of biological macromolecules towards drug target design","Μαρία Σπηλιοπούλου","2023","Νημερτής","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041892","VMAT2 and GLP-1R targeting tracers for pancreatic beta cell imaging","Kirsi Mikkola","2017","UTUPub (University of Turku)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041893","Obesitiy: Its Complications and Available Medications","Additiya Paramanya","2020","Kocaeli Üniversitesi Sağlık Bilimleri Dergisi","other","article","10.30934/kusbed.615706",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041894","Useful Xultophy for Older Diabetic with Various Problems","K. Hayashi","2021","Institutional Repositories DataBase (IRDB)","other","article","10.51737/2766-4813.2021.027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041895","Elderly Diabetic Patients with Effective Add-on Therapy of Dulaglutide as a GLP-1 Receptor Analogue (GLP-1 RA)","Yozo Takehisa","2020","Edelweiss Journal of Biomedical Research and Review","other","article","10.33805/2690-2613.113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041896","Early improvement of HbA1c, weight and low-density lipoprotein (LDL) for Type 2 diabetes (T2D) patient by Rybelsus (oral semaglutide)","Hiroshi Bando","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041897","Incretin use was not associated with increased risk for acute pancreatitis","Joel M. Schectman","2015","Annals of Internal Medicine","nonrandomized_study","article","10.7326/acpjc-2015-162-12-012","26075777",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0041898","The Hypoxic Retina: Vasoconstriction as the Brain's Decree and the Ocular Cascade from Choroid to Optic Nerve","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22138518",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0041899","Insulin physiology and metabolic control: current concepts and perspectives","Cozar-Castellano Irene","2021","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2026.80",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041900","Antiobesity Medicines: How Far Can We Go?","Dr. Yogesh Harwani","2026","Journal of Digestive Endoscopy","randomized_trial","article","10.1055/s-0046-1828823",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0041901","Semaglutide: a glucagon-like peptide-1 receptor agonist and its therapeutic potential in type 2 diabetes and beyond","Wenshan Zhao","2025","Elsevier eBooks","other","article","10.1016/b978-0-443-33885-4.00007-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0041902","SURPASS-PEDS: clinical promise and priorities for future research on tirzepatide treatment for youth with type 2 diabetes","Wei Perng","2026","AME Clinical Trials Review","other","article","10.21037/actr-26-0017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041903","Medicines for the management of overweight and obesity: A systematic review with network meta-analysis","Gabriela Masiero Marcon","2025","Brazilian Journal of Pharmaceutical Sciences","systematic_review","article","10.1590/s2175-97902025e24177",null,null,"PROSPERO:CRD42023423308",null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0041904","Effetti renali dei farmaci basati sul sistema delle incretine nelle persone con diabete di tipo 2","Irene Caruso","2025","L Endocrinologo","other","article","10.1007/s40619-025-01625-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041905","Study of pseudoprolines’ tripeptides synthesis and their application in peptide synthesis","Σταματία Πατρικίου","2021","Νημερτής","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041906","Gastric bezoars and GLP-1RA medications [Data set]","Patel, Ritesh","2022","ResearchOnline@ND (The University of Notre Dame)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0041907","Design, Synthesis, and Characterization of Monomeric Peptide Multiple Agonists for the Treatment of Metabolic Disease","Emily Ashlaw","2026","Syracuse University Libraries (Syracuse University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041908","Vaccinazione antinfluenzale e trattamento con antagonisti della vitamina K: un RCT versus placebo, cross-over, in doppio cieco","Elisa Benetti","2010","Institutional Research Information System University of Turin (University of Turin)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0041909","Antipsychotic-like Effect of GLP-1 Agonist Liraglutide but not DPP-IV Inhibitor Sitagliptin in Mouse Model for Psychosis","Dixis, T. S.","2017","Journal of Bioresource Management","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041910","What Would the World Look Like Without Mobile Iv Therapy?","w5iecfn552","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.8175304",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041911","Improved HbA1c value by combined treatment of Dulaglutide and Imeglimin for patient with type 2 diabetes mellitus (T2DM)","Hiroshi Bando","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041912","Latest Topic for Clinical Effects of Tirzepatide as Dual GIP/GLP-1 Receptor Agonist","Hiroshi Bando","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041913","Editorial: Mechanisms Underlying Diabetes-Associated Damage in Target Tissues","Beatriz Suárez-Álvarez","2022","Frontiers in Pharmacology","commentary","article","10.3389/fphar.2022.915806","35656296",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0041914","Identification of a Dual-Action Small Molecule with Potent Anti-diabetic and Anti-obesity Activity","Yao Wang","2019","VTechWorks (Virginia Tech)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041915","GLP-1 Receptor Agonists Improve Cerebrovascular Integrity and Vascular Cognitive Impairment and Dementia via Recovery of Brain Pericytes Functions in Diabetic Mice","Joseph Bailey","2020","Mercer University Libraries (Mercer University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041916","Can GLP-1 receptor agonists be used after an episode of acute pancreatitis? Reconciling emerging evidence with regulatory caution","Cole R Smith","2026","Considerations in Medicine","other","article","10.1136/conmed-2026-000055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041917","Clinical Conundrum: Three Management Strategies for Three-Vessel Coronary Artery Disease?","Giuseppe Biondi‐Zoccai","2020","Journal of Cardiovascular Pharmacology","randomized_trial","article","10.1097/fjc.0000000000000900","32826412",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041918","ANALYTICAL METHOD VALIDATION AND IMPURITY PROFILING OF TIRZEPATIDE: A CRITICAL REVIEW FROM A REGULATORY QUALITY ASSURANCE PERSPECTIVE","Drashti Mistry*, Dr. Nidhi Chauhan, Dhruvita Patel, Divyanshi Atodariya, Kiran Patel","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.22157790",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041919","TYPE 2-DIABETES: PATOFYSIOLOGI OG MEDIKAMENTELL BEHANDLING","Wai Joe Chan","2006","Duo Research Archive (University of Oslo)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0041920","Investigations into the gastrointestinal factors involved in the regulation of appetite and energy intake","Little, Tanya Jane","2006","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041921","A porcine type 1 Diabetes Mellitus model, for non-invasive in vivo imaging of the glucagon-like peptide-1 receptor in the pancreas, using [68Ga]Ga-DO3A-VS-Cys40-conjugated synthetic exendin-4 in PET-CT","Susanne Andréasson","2015","Epsilon Archive for Student Projects (University of Southampton)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","other"],["R0041922","Биохимическая оценка сомаклональных линий сои, резистентных к ионам кадмия","Кодирова Г.А.","2018","CyberLeninK (CyberLeninka)","other","article","10.24411/1999-6837-2018-13055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041923","The Role of Central Nervous System Glucagon-Like Peptide-1 in the Regulation of Energy Balance","Jason G. Barrera","2009","OhioLink ETD Center (Ohio Library and Information Network)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041924","Incretin-based drugs and the risk of cholangiocarcinoma among patients with type 2 diabetes","Abrahami, Devin","2018","eScholarship@McGill (McGill)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0041925","Obezite İçin Güncel Bilgiler","Lezan Keskin","2022",null,"other","article","10.37609/akya.1293.c18533",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0041926","The Path to an Orally Administered Protein Therapeutic for the Treatment of Diabetes Mellitus","James, Susan Clardy","2012","Syracuse University Libraries (Syracuse University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041927","Für Sie gelesen: Liraglutide and Renal Outcomes in Type 2 Diabetes","Leitner H","2017","Journal für Kardiologie (Krause & Pachernegg GmbH)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041928","Efeitos cardiovasculares e mecanismos moleculares da terapia combinada com inibidores de SGLT2 e agonistas do receptor de GLP-1: uma revisão sistemática pré-clínica","Roberto Guilherme Rosa Morais","2026","Brazilian Journal of Implantology and Health Sciences","preclinical","article","10.36557/2674-8169.2026v8n8p1595-1617",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041929","Human pregnancy outcomes after early glucagon-like peptide-1 receptor agonist exposure: A scoping review","Ritu Singh","2026","World Journal of Diabetes","nonrandomized_study","article","10.4239/wjd.124799",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041930","Tirzepatide (Zepbound)","CDA-AMC","2026","Canadian Journal of Health Technologies","randomized_trial","article","10.51731/cjht.2026.1510",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0041931","Mechanism of Action of the Glucagon-like Peptide-1 analog Exendin-4 in the Reward System – A Preclinical Study in the Drug Addiction Field","Elisabeth Vestergaard","2020","Gothenburg University Publications Electronic Archive (Gothenburg University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041932","Energy metabolism as a target for new treatment strategies in Huntington’s disease","Marie Sjögren","2019","Lund University Publications (Lund University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041933","17 Signs You Work With Mobile Iv Hydration","z4ibspc042","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.8066311",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041934","Effect of glucagon-like peptide-1 on differentiation of adipose derived mesenchymal stem cells into cardiomyocytes","Özgür TEKİN","2022","Ege Tıp Dergisi","preclinical","article","10.19161/etd.1180666",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041935","Obesity Pharmacotherapy in the GLP-1 Era: Efficacy, Equity, and the Long-Term Unknowns of Incretin-Based Care","Nafel Sammah Alharbi","2026","Integrative Biomedical Research","other","article","10.25163/biomedical.10110910",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041936","Exendin-4 Decreases Immobility in the Forced Swim Test in Rats Treated with Lipopolysaccharide","Filip Ventorp","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041937","The Effects of Incretin Mimetics on Islet Cell Function in Type 2 Diabetes","Piero Marchetti","2008","US Endocrinology","other","article","10.17925/use.2008.04.2.75",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041938","Medicina Nuclear no Estudo dos Tumores Neuroendócrinos","Hugo Duarte","2011","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041939","Type 2 Diabetes: Cardiovascular Outcomes with Metformin and Incretin Combination Therapy Compared to Metformin and Sulfonylureas","Lucas, Brendan K.","2019","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041940","Sintesi e caratterizzazione di nanosistemi biocompatibili per drug delivery nel trattamento dell'Alzheimer","Campodoni, Elisabetta","2014","AMS Degree Thesis (University of Bologna)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041941","National prevalence of heart failure in type 2 diabetes patients derived from the National eHealth System and their access to treatment with SGLT2 inhibitors or GLP-1 Receptor Agonists","Smokovski, Ivica","2019","Goce Delchev University Repository (Goce Delčev University of Štip)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0041942","Wyraźna poprawa dobowej glikemii oraz funkcji komórek α i β, a także zmniejszenie uwalniania glukozy pochodzenia endogennego u chorych na cukrzycę typu 2 po tygodniowej terapii pochodną glukagonopodobnego peptydu 1 — liraglutydu (NN2211)","Degn, Kristine B.; Department of Endocrinology (M&amp;C), University Hospital of Aarhus, Department of Clinical Pharmacology, University of Aarhus, Aarhus, Dania","2004","Via Medica Journals","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041943","Weight-loss interventions in gastrointestinal and liver diseases: a narrative review of GLP-1 based therapies, bariatric surgery, and endoscopic approaches","Jessica Atieh","2026","BMC Gastroenterology","randomized_trial","article","10.1186/s12876-026-05264-9",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0041944","Occurence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists","Bettge, Karolin","2018","Dokumentenrepositorium der RUB (Ruhr University Bochum)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041945","Effects of incretin-based therapies on the gastrointestinal motility of an animal model of Multiple Sclerosis","Martins, Beatriz de Oliveira","2018","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041946","Klinische Studien/Klinische Praxis: Liraglutid (Victoza(R)): Eine neue Therapiealternative bei Diabetes mellitus Typ 2","Luger A","2009","Journal für Kardiologie (Krause & Pachernegg GmbH)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041947","Molecules of the Millennium- Exenatide: An incretin-mimetic agent","Kaushal S, Chopra SC, Arora S","2006","Bioline International (Bioline International)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041948","Using Forced Degradation to Aid the Development of Biopharmaceutical Products","Alexander Benet","2021","Deep Blue (University of Michigan)","other","article","10.7302/2763",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041949","Glucagon - Like Peptide – 1 Receptor Agonists to Reduce the Risk of Nephropathy in the Uncontrolled Type 2 Diabetic Patient","Rebecca M. Fee","2019","UND Scholarly Commons (University of North Dakota)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041950","Gastric and small intestinal determinants of postprandial blood pressure and glycaemia","Laurence G. Trahair","2016","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0041951","The place of semaglutide in the treatment of mental disorders: a focus on preventing the metabolic complications of schizophrenia during antipsychotic therapy","Azat R. Asadullin","2026","Neurology Bulletin","nonrandomized_study","article","10.17816/nb707354",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0041952","Abscisic acid: a promising molecule in the treatment of type 2 diabetes mellitus and its complications","BOOZ, VALERIA","2018","CINECA IRIS Institutial Research Information System (University of Genoa)","preclinical","article","10.15167/booz-valeria_phd2018-02-08",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041953","Seek and destroy. Theranostics of hyperinsulinemic hypoglycemia using exendin-based tracers","Boss, M","2021","Radboud Repository (Radboud University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041954","Il trattamento farmacologico dell’epilessia nell’adulto: una revisione","Miglio, Gianluca","2011","Institutional Research Information System University of Turin (University of Turin)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041955","The use of SGLT2 Inhibitors compared to GLP-1 receptor agonists in patients with type 2 diabetes and hypertension","Koree Vivatson","2020","UND Scholarly Commons (University of North Dakota)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041956","Evaluating The Effect Of Different Plga Microsphere Preparation Methods On Pharmacokinetics Of Exenatide","Malothu Nagulu Harish Kaushik Kotakonda","2017","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.275282",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041957","Inhibitory dipeptydylopeptydazy 4 (DPP-4) ze szczególnym uwzględnieniem sitagliptyny","Mariusz Jasik","2010","Via Medica Journals","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041958","IL-6 and GLP-1 in body fat regulating parts of the CNS in healthy mice","Fredrik Anesten","2016","Gothenburg University Publications Electronic Archive (Gothenburg University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041959","High-risk coronary artery plaque in asymptomatic patients with type 2 diabetes mellitus: Assessment using serial coronary computed tomography angiography and relation to triglycerides and glucagon-like peptide 1 receptor agonists","Heinsen, Laurits","2022","University of Southern Denmark Research Portal (University of Southern Denmark)","other","article","10.21996/4r0v-qx05",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0041960","Literature review efektivitas dan keamanan liraglutide sebagai terapi kombinasi pada pasien diabetes melitus","Elvina Gunawan","2020","Widya Mandala Catholic University Surabaya Repository (Widya Mandala Catholic University Surabaya)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0041961","Régulation du système sérotonine dans la cellule bêta pancréatique par les glucocorticoïdes : implication dans la physiopathologie du diabète","Moina Hasni Ebou","2015",null,"other","article","10.70675/581ee5f8z8a89z4feazb870ze1eff247fa58",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0041962","Relación entre el uso de inhibidores SGLT2 y agonistas GLP-1 con desenlaces cardiovasculares en pacientes con Diabetes Mellitus tipo 2: Una Revisión sistemática y Metaanálisis","Terán Chávez, Pier André","2020","renati","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0041963","Primary polydipsia in the medical and psychiatric patients","Clara Odilia Sailer","2020","edoc (University of Basel)","randomized_trial","article","10.5451/unibas-007218396",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0041964","Estudo dos efeitos neuroprotetores do ômega-3, liraglutide, risperidona e clozapina em um modelo neuroinflamatório induzido por Poly I:C em cultura primária de células hipocampais","Bruna Mara Machado Ribeiro","2015","Americanae (AECID Library)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041965","Liraglutide achieved greater weight reduction and improved glycaemic control compared with sitagliptin following one-year treatment when both are used in combination with metformin","Matthews","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041966","Pharmacological treatment approaches of Type II Diabetes Mellitus","Bicaj, Valon","2014","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041967","Глюкагоноподобный пептид 1, головной мозг, нейродегенеративные заболевания: современный взгляд","Булгакова Светлана Викторовна","2020","CyberLeninK (CyberLeninka)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041968","Efficacy and safety of liraglutide vs placebo in children and adolescents with type 2 diabetes: the ellipse randomised trial results","Barrett, T.","2019","Dspace Repository (Marmara Üniversitesi)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","report"],["R0041969","Impact of Increasing GLP-1 on Markers of Inflammation, Glucose Control and Cardiovascular Risk Factors in Patients With Type 2 Diabetes","Kristina Sandstedt","2016","UND Scholarly Commons (University of North Dakota)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041970","Is Liraglutide Safe and Effective as a Monotherapy for the Treatment of Obesity in Type 2 Diabetics and Healthy Individuals","Erica Sheeran","2011","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041971","GLP-1 mimetics and their contribution to the treatment of type II diabetes mellitus","Maya, Elasi","2015","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041972","Identification of nutrient-specific receptors in the intestine and their role in signaling","Le Nevé, Boris François","2010","mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041973","New trends in the treatment of type 2 Diabetes Mellitus: a review of Thiazolidinediones, GLP-1 agonists, Dipeptidyl Peptidase-4 inhibitors, and SGLT-2 inhibitors","Shokry, Mario Samier Fahmi","2014","University of Debrecen Electronic Archive (University of Debrecen)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041974","Investigation the impact of liraglutide on the thyroid function tests","Emre Urhan","2023","Turkish Journal of Clinics and Laboratory","other","article","10.18663/tjcl.1284003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041975","The Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes","Aboud, Fadi","2015","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041976","The Best Kept Secrets About Mobile Iv Hydration","c1ghhaj077","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.8066197",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041977","Revisión de la eficacia y seguridad de fármacos incretín-miméticos, inhibidores del cotransportador sodio – glucosa tipo 2 y análogos de la amilina en el tratamiento de la Diabetes Mellitus 2.","TIRADO PATIÑO, MARÍA","2015","Zaguan (Universidad de Zaragoza)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041978","Investigation of cell-based therapies employing microcapsules and microspheres: encapsulation and controlled release","In Kim","2016","Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041979","Importance of prevention in Diabetes Mellitus and the Role of incretin in Pharmacotherapy of diabetes mellitus type II","Elnaz, Kasiri","2016","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041980","The development of an adapted Donabedian structure, process and outcomes model to evaluate the influences on prescribing for diabetes in English National Health Service primary care organisations","Catherine Alexander","2018","University of Birmingham Institutional Research Archive (University of Birmingham)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041981","GLP-1R AGONISTS IMPROVE CEREBROVASCULAR INTEGRITY AND VASCULAR COGNITIVE IMPAIRMENT AND DEMENTIA (VCID) BEYOND GLYCEMIC CONTROL VIA RECOVERY OF BRAIN PERICYTE FUNCTION IN DIABETIC MICE","Joseph Bailey","2020","Mercer University Libraries (Mercer University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0041982","Molecular Interactions in PLGA Delivery Systems and Their Effects on Microencapsulated Peptides","Hong, King Yeung","2022","Deep Blue (University of Michigan)","preclinical","article","10.7302/4650",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041983","The Evidence Base of Vildagliptin for T2DM Patient During Ramadan","Agung Pranoto, .,","2017","Universitas Airlangga Repository (Universitas Airlangga)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0041984","Liraglutide promotes intracellular thyroid hormone activation and has additive effects to β3-adrenergic signaling in inducing thermogenesis in brown adipose tissue","Angélica Amorim Amato","2018","Lume (Universidade Federal do Rio Grande do Sul)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0041985","The effect of L-dopa and neuroprotective agents on \\ncell replacement therapy for Parkinson’s disease.","Elabi, Osama","2017","ORCA Online Research @Cardiff (Cardiff University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041986","Semaglutide and Short-Term Outcomes After Ventral Hernia Repair","Yousef Tanas","2026",null,"other","article","10.13140/rg.2.2.10610.67528",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041987","Studium transparentních nanopovlaků pro aplikaci na ocelový substrát","Aleš Nykl","2011","DSpace VŠB-TUO (VŠB-TUO)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041988","Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus : randomized placebo-controlled trial (vol 18, pg 55, 2019)","Maurice B. Bizino","2019","Leiden Repository (Leiden University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","other"],["R0041989","Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer’s and Parkinson’s disease","Christian Hölscher","2016","Cardiovascular Endocrinology","other","article","10.1097/xce.0000000000000087",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041990","Effectiveness and safety of iGlarLixi in people with type 2 diabetes in Adriatic Region Countries","Danijel Đekić","2026","DiRROS repository (University of Maribor)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041991","高糖环境下exendin-4对人肾小管上皮细胞CTGF、BMP-7表达的影响","张继敏","2012","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041992","Metabolic and functional evaluation of diabetic cardiomyopathy using MR Spectroscopy and MR Imaging","Bizino, M.B.","2022","Data Archiving and Networked Services (DANS)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0041993","The Impact of GLP-1 Analog, Exenatide, on The Resting Brain of Lean vs Obese Women","Kristen Coveleskie","2016","eScholarship (California Digital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041994","Pharmacology of new treatment of diabetes","Huy Huynh","2014","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0041995","Prescribing GLP-1s for Obesity in Primary Care","Kufahl, Callie","2024","MOspace Institutional Repository (University of Missouri)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0041996","Gastric and small intestinal motor function in health and disease - implications for glucose absorption, incretin hormone release, and postprandial blood glucose regulation.","Paul Kuo","2010","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0041997","POEGMAlation – A Next-Generation PEGylation Technology","Yizhi Qi","2016","DukeSpace (Duke University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0041998","The Role of The Central GLP-1 System in Cocaine-Seeking Behavior","Nicole S. Hernandez","2019","ScholarlyCommons (University of Pennsylvania)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0041999","GLP-1/GIP/Gcg三受体激动剂改善3xTg-AD小鼠认知行为和病理特征研究","Juan‐Juan Jiao","2017","Lancaster EPrints (Lancaster University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042000","Semaglutide: A Simple Definition","e1jfmwv051","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7942915",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042001","Case series of amiodarone-induced thyrotoxicosis following semaglutide-induced weight loss","Ilaria Giordani","2026","Endocrine Abstracts","case_report","article","10.1530/endoabs.119.ps2-12-09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0042002","Medical Weight Loss With Tirzepatide: A Modern Approach for Better Health Outcomes","Medical Weight Loss with Tirzepatide","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22202093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042003","POSTER: MPN-1689: Impact of GLP-1 Agonists on Clinical Outcomes in Patients With Essential Thrombocythemia: A Propensity-Matched Analysis","Nneoma Ubah","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)01005-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042004","THE EFFECTS OF EXENATIDE TREATMENT ON METABOLIC PARAMETERS, GHRELIN, GDF-15 AND FGF-21 IN OBESE TYPE 2 DIABETIC PATIENTS","Müge Özsan Yılmaz","2022","Kırıkkale Üniversitesi Tıp Fakültesi Dergisi","other","article","10.24938/kutfd.1014625",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042005","PS9 - 3. The effect of exenatide compared to insulin glargine on exercise-related hemodynamics and metabolism in patients with type 2 diabetes and left ventricular systolic dysfunction","Weena J.Y. Chen","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0101-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042006","POSTER: MM-1350: GLP-1 Receptor Agonists and Organ Function Outcomes in Amyloid Light-Chain Amyloidosis: A Real-World Analysis From the TriNetX Global Collaborative Network","Dhriti Sood","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)01449-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042007","Is liraglutide effective for weight loss in adults who are overweight or obese compared to placebo?","Yadav, Shaina","2021","Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0042008","Ús de l’ecografia per caracteritzar la distribució del teixit adipós abdominal i el seu impacte en el risc cardiovascular en diferents situacions clíniques i en resposta a diferents règims terapèutics","Guillem Cuatrecasas Cambra","2025","Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)","other","article",null,null,null,"EudraCT:2019-000979-16",null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042009","(2) GLP-1受容体作動薬 （III. 糖尿病治療薬に関する最近の話題 3. インクレチン関連薬）","秀明 三好","2020","Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042010","Investigation of Reductive Amination in the Synthesis of T-0632","J. B. Kwon","2014","Wellesley College Digital RepositoryWellesley (Wellesley College)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042011","Glucagon-like peptide-1 and alcohol-mediated behaviors in rodents","Daniel Vallöf","2019","Gothenburg University Publications Electronic Archive (Gothenburg University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042012","POSTER: MM-857: Survival and Cardiovascular Outcomes Associated With GLP-1 Receptor Agonist Exposure in Patients With Multiple Myeloma and Metabolic Comorbidities: A Propensity-Matched TriNetX Analysis","Nnamdi Omenuko","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)01376-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042013","GLP-1 receptor agonists and dental sedation: a potential blind spot in preoperative assessment","Toru Yamamoto","2026","Journal of Dental Anesthesia and Pain Medicine","other","article","10.17245/jdapm.2026.26.146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042014","MPN-1689: Impact of GLP-1 Agonists on Clinical Outcomes in Patients With Essential Thrombocythemia: A Propensity-Matched Analysis","Nneoma Ubah","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)02436-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0042015","FEATURES OF APPLICATION OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST IN PATIENTS WITH TYPE 2 DIABETES DEPENDING ON GENDER AND PHENOTYPE","Zinych O. V. Shyshkan-Shyshova K. O.","2022","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.6814449",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042016","P4.790: Efficacy and safety of tirzepatide for weight reduction in kidney transplant recipients.","Fatima AlKindi","2026","Transplantation","other","article","10.1097/01.tp.0001254684.09228.b4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042017","ภาวะอวนและโรคไต: กลไกและการรกษาใหม","ฐิติรัตน์ ศุภศิลป์","2026","Journal of the Nephrology Society of Thailand","other","article","10.63555/jnst.2026.289162",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042018","Analysis of pancreatic hormonal response before and after treatment with GLP-1-mimetic in subjects with type 2 diabetes carrying the rs7903146 variant in TCF7L2","Mari Cassol Ferreira","2013","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042019","MM-626: GLP-1 Receptor Agonist Exposure and Survival Outcomes in Newly Diagnosed Multiple Myeloma Treated With Daratumumab-Based Quadruplet Therapy: A Target Trial Emulation","Colton Jones","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)02903-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0042020","Can DPP-IV Inhibitors or GLP-1 Analogs be Tomorrow’s Therapy for Diabetic Retinopathy?","Andreia Gonçalves","2016","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042021","Novel radiolabelled Exendin-4 derivatives for the targeting of β-cells","Andreas Jodal","2015","Repository for Publications and Research Data (ETH Zurich)","other","article","10.3929/ethz-a-010485488",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042022","FDA concerns about unapproved GLP-1 receptor agonists",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92496-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042023","Semaglutide markedly reduced high-output ileostomy volume: A case report","Enzo Cerullo","2026","Zenodo (CERN European Organization for Nuclear Research)","case_report","article","10.5281/zenodo.22215100",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042024","758-P: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset","S ARMSTRONG","2025","Diabetes","nonrandomized_study","article","10.2337/db25-758-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042025","Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of real-world studies","Georgios Kostopoulos","2026","Endocrine Abstracts","systematic_review","article","10.1530/endoabs.119.ps2-09-02",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0042026","Infection-Associated Mycobacterium Fortuitum Infection","Dennis T. Huang","2017","ScholarWorks - WMU (Western Michigan University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042027","Oral Abstracts",null,"2024","Obesity","nonrandomized_study","article","10.1002/oby.24194","39562472",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042028","Undergraduates perceive differences in helpfulness and thoroughness of responses of ChatGPT 3.0, Gemini 1.5, and copilot responses about drug interactions","Jennifer E. Grant","2025","Discover Artificial Intelligence","other","article","10.1007/s44163-025-00527-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042029","TRIM","Gudbergsen, Henrik","2024","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/86kmc",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0042030","Medical Weight Loss Programs for Personalized Weight Support","Medical Weight Loss Programs","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22203455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042031","Autonomy","Rodolphe Durand","2026",null,"other","article","10.1093/9780197861844.003.0004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0042032","Clinical and mechanistic studies of duodenal mucosal resurfacing for type 2 diabetes","Meiring, S.","2023","UvA-DARE (University of Amsterdam)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042033","Impact of incretin-based therapy on levothyroxine dose requirements in euthyroid obese patients","Koca Arzu Or","2026","Endocrine Abstracts","other","article","10.1530/endoabs.119.ps2-14-04",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0042034","Indication-Specific Adverse Event Patterns of Tirzepatide: An Updated FAERS Pharmacovigilance Study","The Pharmaceutical Society Of Korea","2026","Yakhak Hoeji","nonrandomized_study","article","10.17480/psk.2026.70.4.347",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042035","GLP-1 receptor agonists and thyroid function in euthyroid obese patients: a comparison between autoimmune and non-autoimmune thyroid disease","Mge Keskın","2026","Endocrine Abstracts","other","article","10.1530/endoabs.119.ps2-14-01",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0042036","Are GLP-1 Receptor Agonists the Next Big Thing for Sickle Cell Disease?","Sonia Wolf","2026","The Hematologist","other","article","10.1182/hem.v23.5.2026510",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042037","POSTER: MM-626: GLP-1 Receptor Agonist Exposure and Survival Outcomes in Newly Diagnosed Multiple Myeloma Treated With Daratumumab-Based Quadruplet Therapy: A Target Trial Emulation","Colton Jones","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)01336-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042038","P2.231: Weight gain and metabolic control after pancreas kidney transplantation in patients with type 2 diabetes and the role of GLP-1 receptor agonists.","Piotr Bachul","2026","Transplantation","other","article","10.1097/01.tp.0001253004.16546.dc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042039","MM-1350: GLP-1 Receptor Agonists and Organ Function Outcomes in Amyloid Light-Chain Amyloidosis: A Real-World Analysis From the TriNetX Global Collaborative Network","Dhriti Sood","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)03031-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0042040","POSTER: MPN-1144: GLP-1 Receptor Agonists and Major Clinical Outcomes in Adults With Classic Myeloproliferative Neoplasms and Type 2 Diabetes and/or Obesity: A Global Propensity Score-Matched Analysis","Muluken Megiso","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)00983-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042041","S2435 Incretin-Based Therapies in MASH: A Meta-Analysis of Hepatic and Metabolic Outcomes","Amanda Rigdon","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001137200.19766.2f",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0042042","Eficacia y seguridad de liraglutida para manejo de sobrepeso y obesidad. Revisión sistemática y Metaanálisis en red","Sandoval Vásquez, Ricardo Augusto","2022","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article","10.48713/10336_18879",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042043","Glucagon-Like Peptide-1 and its Analogues Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight.","Anderberg, RH","2017","Apollo (University of Cambridge)","preclinical","article","10.17863/cam.8472",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042044","Gastrointestinal mediation of glucose homeostasis and postprandial cardiovascular risk","Sony S. Thazhath","2016","Adelaide Research & Scholarship (AR&S) (University of Adelaide)","randomized_trial","article","10.4225/55/58ae4f68c1232",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0042045","Keep the muscles, lose the fat","Robert Gerard Memelink","2025",null,"randomized_trial","article","10.5463/thesis.1193",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","dissertation"],["R0042046","Semaglutide - Molecule of the Month May 2021 [Archived version]","May, Paul","2021","Bristol Research (University of Bristol)","other","article","10.6084/m9.figshare.13992209",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0042047","The Consolidation of the Danish Corporate Elite: Corporate Elite Factions in a Small Open Economy","Majsa Stina Grosen","2026",null,"other","article","10.22439/phd.14.2026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042048","Geographic Variation in the Utilization of Antihyperglycemic Therapies in the U.S. Medicaid Program at State-Level Using Geographic Information System","Almarhoon, Zahra M, B.S.","2019","OhioLink ETD Center (Ohio Library and Information Network)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042049","PERIOPERATIVE ANESTHETIC IMPLICATIONS OF TIRZEPATIDE (MOUNJARO) IN SAUDI ARABIA","Alanoud K. Albanna","2025","International Journal of Advanced Research","randomized_trial","article","10.21474/ijar01/21858",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042050","Target Trial Emulation Study of GLP-1 RAs for Depression-Related Outcomes in the All of US Cohort","Alicia Pacilio","2025",null,"randomized_trial","article","10.17605/osf.io/shbjv",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0042051","Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications","Körner Jachertz, Meike","2012",null,"other","article","10.7892/boris.12472",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042052","Glucagon-like peptide-1 receptor agonists and co-agonists for weight loss among individuals without diabetes","Moiz, Areesha","2025","eScholarship@McGill (McGill)","randomized_trial","article","10.82308/2683",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0042053","Use of glucagon-like peptide 1 (GLP-1) agonists among exercisers and recreational athletes and associated mental health symptoms","Daniel Martin","2025","Performance Enhancement & Health","other","article","10.1016/j.peh.2025.100353",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042054","Estudio de los mecanismos implicados en la actividad anti-inflamatoria a nivel arterial del exenatida","Martínez de Marañón Peris, Aranzazu","2016","RiuNet (Universitat Politècnica de València)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042055","Literature-Calibrated Computational Predictions for In Vivo Validation of the GLP-2 Receptor-Mediated Gut Barrier Relay Hypothesis — Barrier-Specific Endpoints with Transit Confound Correction (v2.0)","Robert King Beathard","2026",null,"other_trial","article","10.17605/osf.io/5snqh",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042056","Prolactin as an Adjunct to Anti-CD3 Type I Diabetes Therapy","Colin M. Hyslop","2014","Libraries and Cultural Resources (University of Calgary)","preclinical","article","10.11575/prism/27455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042057","FAIRE DÉCOUVRIR, LAISSER ATTENDR: Foucault's Biopolitics, the ARSI-Poisson Dynamic, The Empirical Obsolescence of Foucauldian Biopolitics in the Age of ARSI - Compound Poisson Jumps","HUYNH GIA BAO","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20953301",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042058","acontinuedsagaofboc5thefirstnonpeptidicglucagonlikepeptide1receptoragonistwithinvivoactivities","He Min","2012","Dalian Institute of Chemical Physics, CAS Institutional Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042059","“Pancreatic and Gallbladder safety of Tirzepatide in Obesity Management: A Scoping Review Protocol of Clinical and Real-World Evidence”","Kutsyba, Tetiana","2025",null,"protocol","article","10.17605/osf.io/rm46g",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042060","Mazdutide: First Approval","Shirley, Matt","2025","Figshare","other","article","10.6084/m9.figshare.30161881.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042061","Semaglutide","Seth Wynes","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0042062","Behavior change support in the new era of obesity care","Brunna Boaventura","2026","BMC Medicine","other","article","10.1186/s12916-026-05167-2","42665797",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042063","Pain in studies of glucagon-like peptide-1 receptor agonists is measured with instruments that cannot locate it: a scoping review","Leonardo Neves","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.17605/osf.io/kq7pb",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint; other"],["R0042064","Combined keto-analogue nutritional therapy and incretin-based drugs in CKD patients","Hugo You‐Hsien Lin","2026",null,"other","article","10.17605/osf.io/j4gyw",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042065","Decomposing the cardiovascular benefit of GLP-1 receptor agonists: a multi-state network meta-analysis of cardiovascular outcome trials","Junhui Bai","2026",null,"systematic_review","article","10.17605/osf.io/sqezd",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042066","Regulatory Challenges in Novo Holdings’ $16.5 Billion Catalent Acquisition","Hoke, Delaney","2025","Figshare","other","article","10.57912/28612034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042067","ANALISI DEGLI ESITI DI SALUTE E DEI MODELLI DI COMORBIDITA IN PAZIENTI CON MALATTIE CRONICHE. MODELLI DI PREVISIONE E PHENOMAPPING SU DATABASE AMMINISTRATIVI INTEGRATI.","SCIANNAMEO, VERONICA",null,"Padua Research Archive (University of Padova)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0042068","Atrial Electrophysiology and Arrhythmogenesis: Impacts of Diabetes Mellitus and Bruton's Tyrosine Kinase Inhibitors","Bohne, Loryn J","2022",null,"preclinical","article","10.11575/prism/dspace/41247",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042069","Glucagon-like peptide-1 receptor agonists, weight loss, and urolithiasis: what urologists should know",null,"2026","Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication","other","article","10.5173/ceju.2026.0038",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042070","GLP-1-Rezeptoragonisten bei Alkoholkonsumstörungen","Michael Soyka","2026","Nervenheilkunde","other","article","10.1055/a-2852-2335",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042071","Corrigendum to ’Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis’ [AACE Endocrinology and Diabetes. 2026;13(2):259-269]",null,"2026","AACE Endocrinology and Diabetes","systematic_review","article","10.1016/j.aed.2026.08.013",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","erratum"],["R0042072","Semaglutide and Behavioral Treatment for Binge-Eating Disorder Comorbid with Obesity","Grilo, Carlos","2024","California Digital Library","randomized_trial","article","10.48321/d16d0a1e42",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0042073","Glucagon-like peptide-1 agonism in combination with low-dose interleukin 2 enhances regulatory T cell suppressive function in vitro","Aaron D. Thome","2025","NeuroImmune Pharmacology and Therapeutics","preclinical","article","10.1515/nipt-2025-0001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042074","Comparative analysis of GLP-1 receptor agonists versus metformin on cancer outcomes in patients with polycystic ovarian syndrome: A real-world multi-center cohort study in the United States.","Tina Yi Jin Hsieh","2024","JCO Oncology Practice","nonrandomized_study","article","10.1200/op.2024.20.10_suppl.402",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0042075","Monoagonist combinations for the treatment of obesity and diabetes, and the impact of biased signalling","Hinds, Charlotte","2022",null,"preclinical","article","10.25560/114644",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042076","Expanding the Role of Novel Therapeutics in Cardiometabolic Syndrome: Beyond Heart Failure and Diabetes","Hyun‐Jin Kim","2025","CardioMetabolic Syndrome Journal","other","article","10.51789/cmsj.2025.5.e4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042077","Comparative efficacy and cost-effectiveness of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists in type 2 diabetes and chronic kidney disease","Nguyen, Bao Ngoc","2023","Memorial University Research Repository (Memorial University)","other","article","10.48336/cxbj-8x60",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042078","A Systematic Review and Network Meta-Analysis: Efficacy and Safety of Pharmacotherapy for Weight Management Following Bariatric Surgery","Kannan Sridharan","2025",null,"systematic_review","article","10.17605/osf.io/kxvy5",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042079","Effects of Ozempic Reimbursement Policy Changes on Ozempic Utilization and Glycemic Control in Type 2 Diabetes","Emma Simonsen","2026",null,"other","article","10.17605/osf.io/jbzda",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042080","The diet-GLP-1 receptor agonist visibility gap: a scoping review and bibliometric map of PubMed-indexed literature, 2010-2024","Qiang Wang","2026",null,"narrative_review","article","10.17605/osf.io/xc4st",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042081","Emerging Pharmacology of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current Advances and Future Therapeutic Perspectives","Ankita Shindalkar*, Dr. Prajakta Kelgaonkar, Sadiya Shaikh, Vaishnavi Patil, Vasundhara Wadulkar","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.22219537",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0042082","Plan de negocios para el lanzamiento al mercado peruano de un producto Innovador para el tratamiento de la diabetes","Bruno Crousillat, Giuliana","2017","Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042083","Generalizability of SELECT to cardiac surgical patients: analysis of the TRICS III randomized trial","Nitish K Dhingra (14832449)","2025","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0042084","PPARidgm shifts in the treatment of metabolic dysfunction–associated steatotic liver disease","Layla A. Abushamat","2025","Hepatology","other","article","10.1097/hep.0000000000001511","40856686",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042085","GLP-1 Receptor Agonists May Slow Cancer Progression","Candy Goulette","2026","Oncology Times","other","article","10.1097/01.cot.0000000000000471",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042086","The effect of GLP-1 receptor agonist exendin-4 on steatosis in cultured HepG2 human hepatoma cells","Chen-Liaw, Alice Y.","2016","University of Scranton Digital Collections","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042087","When innovations collide: The adjunct use of SGLT2 inhibitors or GLP1-receptor agonists with automated insulin delivery for type 1 diabetes","Pasqua, Melissa-Rosina","2025","eScholarship@McGill (McGill)","other","article","10.82308/10658",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042088","Access, affordability, equity and health system implementation gaps in GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists for adults with type 2 diabetes: a scoping review with implications for Chile","Gonzalo Alberto Peralta-Jiménez","2026",null,"narrative_review","article","10.17605/osf.io/u4cjz",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042089","GLP-1 and Autocrine TGF-β/BMP SMAD Synergy in Step-Wise Initiation and Maturation during β-Cell Differentiation of AR42J Cells","Kok-Hooi Yew","2008","Griffith Research Online","other","article","10.25904/1912/2335",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042090","The efficacy of liraglutide in reducing major adverse cardiovascular events (MACE) in individuals with overweight or obesity without a diagnosis of type 2 diabetes mellitus.","Hartur Fontes Assis de Sousa","2026",null,"randomized_trial","article","10.17605/osf.io/xgzs2",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0042091","Caracterización de las manifestaciones psiquiátricas vinculadas al tratamiento con agonistas del receptor de GLP-1 (ar-GLP1) en población femenina adulta: revisión de alcance de la literatura","Valeria Durán Cordero","2026",null,"other","article","10.17605/osf.io/sh942",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042092","Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk: Clinical Effectiveness and Human Urinary Lithogenic Phenotype Triangulation, with GLP-1-Based Therapies as an Active Comparator and Mechanistic Contrast","Qin-Wen Liu","2026",null,"randomized_trial","article","10.17605/osf.io/k5wh4",null,null,"PROSPERO:CRD420261491376",null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0042093","Beyond the weight : A quantitative study on the impact of GLP-1 treatment on eating disorders symptoms, mental well-being and physical activity","Karin Ahnlund Steen","2026","Diva portal (Dalarna University Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042094","Disruptions in Aesthetic Medicine: A Global Analysis of GLP-1 Agonists Using Punctuated Equilibrium Framework","Shabnam Sadeghi Esfahlani (6554441)","2025","Figshare","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042095","Correction: Summaries for patients: Exenatide or insulin glargine for suboptimally controlled type 2 diabetes?","-",null,"UCLA - Biblioteca de Ciencias de la Salud","notice","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0042096","Unravelling the significance of the human GLP-1 receptor rs10305492 variant: implications for metabolic health and personalised therapeutics","El Eid, Liliane","2024",null,"preclinical","article","10.25560/119953",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042097","Rhabdomyolysis and Severe Myopathy Associated With GLP-1 Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Scoping Review of Published Case Reports and Case Series","Ammar Aldeghlawi","2026",null,"case_report","article","10.17605/osf.io/63zu5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042098","Analytical Chemistry Techniques for the Identification, Quantification, and Characterization of Illicit Peptide Pharmaceutical Products","Terence Geoffrey Watts","2026",null,"other","article","10.17605/osf.io/qzw54",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042099","The impact of modified Pharmaceutical Benefits Scheme (PBS) prescribing restrictions on glucagon-like peptide-1 receptor agonists (GLP-1RAs) prescriptions in patients with type 2 diabetes","C Nguyen","2025","Minerva Access (University of Melbourne)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-abstract"],["R0042100","Cardioprotective pharmacotherapy during immune checkpoint inhibitor therapy and cardiovascular outcomes: a systematic review and meta-analysis.","Piyush Puri","2026",null,"systematic_review","article","10.17605/osf.io/bwtd5",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042101","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-91805-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042102","Investigating the role of indole in glucose homeostasis","Phuah, Hi Qi Phyllis","2022",null,"preclinical","article","10.25560/122697",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042103","Diabétologie","Gariani, Karim","2021","Archive ouverte UNIGE (University of Geneva)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042104","Real-world Challenges and Predictors of Success in Glucagon-like Peptide-1 Receptor Agonist Therapy","Nitin Mohaniraj Patankar","2026","Journal of the Association of Physicians of India","nonrandomized_study","article","10.59556/japi.74.1627",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042105","Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study","Steve Bain","2024","Cronfa (Swansea University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042106","Innovative use of fatty acid acylation to enhance biological action and biophysical properties of peptide therapeutics","Brian Ward",null,"ProQuest Demo Repository","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0042107","Dichotomy of calcium 1.2 and calcium 1.3 L-type calcium channel function and modulation in GLP-1-mediated insulin exocytosis and ERK1/2 activation in pancreatic beta-cells","Jacobo, Sarah Melissa P","2008","Purdue e-Pubs (Purdue University System)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042108","GLP-1R drugs and alcohol use disorder: A definitive therapeutic solution or just another unfulfilled promise?","Hugo López-Pelayo","2025","Utrecht University Repository (Utrecht University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042109","Incretin-based therapies: economic sustainability and health impact in the global management of metabolic syndrome","Alessio Provenzani","2026","Strathprints: The University of Strathclyde institutional repository (University of Strathclyde)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042110","The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review","Ricky Le (13082112)","2025","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0042111","Cardiorenal Outcomes of Tirzepatide versus Semaglutide in Adults with Type 2 Diabetes and Established Chronic Kidney Disease: A Multi-National Target Trial Emulation in the TriNetX Global Network","Solomon Chih‐Cheng Chen","2026",null,"nonrandomized_study","article","10.17605/osf.io/9au65",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042112","Semaglutide, Tirzepatide, and Muscle-Related Adverse Events: A Systematic Review of Published Cases","QINGKE HE","2026",null,"systematic_review","article","10.17605/osf.io/kwfzb",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042113","Grand challenges in oral drug delivery","Driton Vllasaliu","2025","Frontiers in Drug Delivery","preclinical","article","10.3389/fddev.2025.1571982","40837714",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042114","Drug-target genetic evidence for incretin receptor pathways in upper gastrointestinal motility, reflux disease, and esophageal carcinogenesis: a Mendelian randomization study separating GLP-1R and GIPR","Hyuk Lee","2026",null,"other","article","10.17605/osf.io/frvy8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042115","OC13.05: Neonatal and obstetric outcomes following periconceptional exposure to glucagon‐like peptide‐1 receptor agonists","J. Hakim","2026","Ultrasound in Obstetrics and Gynecology","other","article","10.1002/uog.70305_85","42672477",null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042116","Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in UK primary care: A retrospective, real‐world study","Kunal Gulati (20675852)","2025","Figshare","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042117","Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes","Evans, Mark","2025","Apollo (University of Cambridge)","randomized_trial","article","10.17863/cam.118841",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0042118","GLP-1 receptor agonists in women with polycystic ovary syndrome and mental health, quality of life, and psychosocial outcomes: a scoping review","Augusto Sassi-Baldizan","2026",null,"nonrandomized_study","article","10.17605/osf.io/ef3j5",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042119","Public involvement Insight Report - Proposed clinical trial to understand how Tirzepatide affects bone health in people living with obesity","Maria Piggin","2026",null,"other_trial","article","10.25560/128689",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0042120","Oral Treatment and Pharmaceutical care in DM2","Carmen Rodriguez Rivera","2026",null,"other","article","10.17605/osf.io/24x6u",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042121","The Effect of Obesity on Comorbidities: A Benchmark Study","Nolen, Kaley","2023","Scholar Works at UT Tyler (The University of Texas at Tyler)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042122","Comparative Effects of GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors on Lipid Profiles: A Large Real-World Propensity-Matched Analysis","Rahmah Sameh Shaheen","2026",null,"nonrandomized_study","article","10.17605/osf.io/p9be4",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042123","The Weight of Stigma","King, Rebekah A.","2026","eYLS (Yale Law School)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042124","Vitamin D and sarcopenia across the menopausal transition and postmenopause: a scoping review protocol mapping evidence, gaps and research priorities.","Cristina Tejera","2026",null,"protocol","article","10.17605/osf.io/jad3v",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042125","Glucagon analogue therapy for obesity and metabolic disease; implications of amino acid metabolism","Hope, David","2023",null,"other_trial","article","10.25560/110747",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0042126","Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomised SUSTAIN 6 & PIONEER 6","WD Strain (14423826)","2025","Figshare","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","openalex","TRUE","no_doi","1","FALSE","article"],["R0042127","Exposure, Not Route: Cardiovascular Pharmacology of Oral versus Injectable GLP-1 Receptor Agonists","Jeel Padaria","2026",null,"other_trial","article","10.17605/osf.io/cyfsg",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042128","GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification","V Lagou (7644506)","2025","Figshare","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042129","Oral Health Behaviors and Associated Factors in Patients with Diabetes","Yumi Kuwamura","2013","Institutional Repositories DataBase (IRDB)","other","article","10.24546/81005509",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042130","Real-World Effectiveness of Semaglutide for Weight Loss Outcomes in a Community Clinic","Bains, Aran Singh","2025","Scholarship at UWindsor (University of Windsor)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0042131","Exenatide and Kidney Function","Bridget M. Kuehn","2009","JAMA","other","article","10.1001/jama.2009.1847",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042132","Metabolic Syndrome and Pharmacological Interventions in Clinical Development","Eugen Javor","2024","Diabetology","randomized_trial","article","10.3390/diabetology5030023",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0042133","Behavioral and hormonal measures of hunger, satiety, and energy intake to predict weight-loss response to Liraglutide","Webster, Chelsi","2022","ThinkTech (Texas Tech University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0042134","Point-of-care gastric ultrasound to assess residual gastric content and the influence of Glucagon-Like Peptide-1 Receptor Agonists: A scoping review","Zheng Jie Lim","2026",null,"narrative_review","article","10.17605/osf.io/zg67e",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042135","OP0069 GLP1 agonists mitigate the risk of cardiovascular events in Rheumatoid Arthritis patients treated with JAK inhibitors","Asmaa Beltagy","2025","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1016/j.ard.2025.05.092",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0042136","Risk of incident and recurrent nephrolithiasis following initiation of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide 1 receptor agonists among patients with type 2 diabetes in Denmark, Norway, the Netherlands, the United Kingdom and Taiwan","Lund, Christian","2023",null,"nonrandomized_study","article","10.17605/osf.io/sg4r9",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042137","Health outcomes of concurrent lifestyle intervention and glucagon-like peptide-1 receptor agonist therapy in older adults: A scoping review","Tasuku Terada","2026",null,"narrative_review","article","10.17605/osf.io/mjn8c",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042138","Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.","Rayaz A Malik (6634004)","2025","Figshare","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042139","Genotype as a modifier of treatment response in MASLD/MASH: a scoping review of evidence, gaps and clinical implications — study protocol","Xiaocheng Li","2026",null,"protocol","article","10.17605/osf.io/j9x72",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042140","Biologics, GLP-1 Receptor Agonists and Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease: A Scoping Review of Evidence Isolation","Yunchao Huang","2026",null,"nonrandomized_study","article","10.17605/osf.io/8tfrq",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042141","Ozempic och viktnedgång - fri från dieter och tankar på mat : En kvalitativ studie om hur Ozempic och andraGLP-1-analoger för viktnedgång påverkar individerskänslor, synsätt och relation till mat och ätande","Olsson, Nomi","2025","Uppsala University Publications (Uppsala University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042142","Editorial: Disease-modifying approaches in type 1 diabetes","Benjamin Udoka Nwosu","2025","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1624146","40510490",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0042143","GLP-2 Relay Computational Predictions","Robert King Beathard","2026",null,"other_trial","article","10.17605/osf.io/e7m8f",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042144","Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin >= 8%, >= 64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial","Melanie J Davies (7258691)","2023","Figshare","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT02058147","S001199","openalex","TRUE","no_doi","1","FALSE","article"],["R0042145","The comparison of GLP-1RA therapy with non-pharmacological interventions on Th1, Th2, Th17 cytokine profile and atherosclerosis markers in patients suffering from obesity","Marcin Kutek","2026",null,"randomized_trial","article","10.17605/osf.io/n9jds",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0042146","A caneta emagrece, quem sustenta?","Rodolfo Guimarães Silva","2026","Congresso de Educação Física de Volta Redonda","other","article","10.47385/cedvr.2827.7.2026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042147","EFFECTS OF TIRZEPATIDE ON BODY COMPOSITION IN INDIVIDUALS WITH OBESITY: AN INTEGRATIVE REVIEW","Marckson da Silva Paula","2026",null,"narrative_review","article","10.17605/osf.io/fq56h",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042148","Nutritional and Exercise Interventions for the Preservation of Lean Mass in Adults with Obesity Receiving GLP-1 Receptor Agonists or Related Incretin-Based Therapies: A Scoping Review Protocol","Josué Daniel Rodríguez Ríos","2026",null,"protocol","article","10.17605/osf.io/d4gst",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042149","Eficácia e segurança dos agonistas do receptor de GLP-1 na redução de eventos cardiovasculares e mortalidade em pacientes com obesidade e Diabetes Mellitus tipo 2: uma umbrella review.","Juliana Oliveira de Toledo","2026","Revista fisio&terapia.","systematic_review","article","10.69849/6tp4j418",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0042150","Bilateral Non-Arteritic Anterior Ischemic Optic Neuropathy Following Weight Loss from Semaglutide (Ozempic): A Case Report","Emely Karam","2024","Neuro-Ophthalmology","case_report","article","10.1080/01658107.2024.2411260",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042151","Incorporating Specific Biological Functionality into Self-Assembling Peptide Amphiphiles for Nanostructured Biomaterials","Saahir Khan",null,"ProQuest Demo Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042152","GLP-1 receptor agonists across the breast cancer continuum: a scoping review","Erika Bushatsky Andrade de Alencar","2026",null,"narrative_review","article","10.17605/osf.io/qkf5r",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042153","Incretin-based therapies in patients with Type 2 diabetes mellitus and renal impairment","Howse, Patricia Marie","2023","Memorial University Research Repository (Memorial University)","nonrandomized_study","article","10.48336/hems-sk50",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0042154","New mechanical 500 ton compacting press for production of advanced PM parts",null,"1995","Metal Powder Report","randomized_trial","article","10.1016/0026-0657(95)93286-0",null,null,"ClinicalTrials.gov:NCT01237119","S002015","openalex","FALSE","paywalled","1","FALSE","article"],["R0042155","Systematic Review on efficacy of newer antihyperglycemic agents for treatment of NAFLD/NASH","Alessandro Mantovani","2021",null,"systematic_review","article","10.17605/osf.io/ckphb",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042156","Efficacy and Perioperative Management of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Obese Orthopedic Patients: A Scoping Review","Satoshi Nakayama","2026",null,"narrative_review","article","10.17605/osf.io/v9quh",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042157","Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database","Tae Hyeon Kim (2098843)","2024","Figshare","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042158","Data for: Liraglutide promotes the angiogenic ability of human umbilical vein endothelial cells through the JAK2/STAT3 signaling pathway","Li, Huanming","2020","Data Archiving and Networked Services (DANS)","other","article","10.17632/b9yxskd9fw.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042159","A Clinical Review of Adult Obesity and Weight Management in the United States","Helf, Megan","2024","RIT Scholar Works (Rochester Institute of Technology)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0042160","The Effects of a High-Energy Diet, Fasting, and Peptide Signaling on Ingestive Behavior","Frankot, Michelle",null,"ProQuest Demo Repository","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042161","Pharmacological and biologically active interventions to improve dental implant osseointegration and wound healing in diabetic patients: A scoping review","Alexander Gyenis","2026",null,"nonrandomized_study","article","10.17605/osf.io/4ekzv",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042162","False negative Ga68-DOTA-exendin-4 PET/CT in a patient with occult insulinomas","EK Bongetti","2017","Minerva Access (University of Melbourne)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0042163","Handbook of Incretin-based Therapies in Type 2 Diabetes",null,"2016","Thammasat University Digital Collections","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042164","Pharmacokinetic Variability, Bioavailability, and Gastrointestinal Adverse Events of SNAC-Formulated Oral Semaglutide versus Subcutaneous Semaglutide: A Systematic Review and Meta-Analysis of Clinical Studies","Eva Brahmbhatt","2026",null,"systematic_review","article","10.17605/osf.io/7kg9z",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042165","Dipeptidyl peptidase 4 inhibitors and glucagon-like peptide-1 receptor agonist mitigate inflammation and fibrosis in models of non-alcoholic steatohepatitis and biliary fibrosis","Wang, Xiaoyu","2017","Gutenberg Open Science","other","article","10.25358/openscience-2775",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042166","Semaglutide","Seth Wynes","2026",null,"other","article","10.17605/osf.io/vefdt",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042167","Mitigation of Blast-Induced Hearing Damage Associated with Mild-TBI Chinchillas using Liraglutide","Sanders, Sarah","2022","SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042168","Semaglutide in a real-world outpatient setting: discontinuation patterns and weight maintenance","Claudia Brufani","2025","Obesity and Endocrinology","nonrandomized_study","article","10.1093/obendo/wjaf011",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042169","Appearance-Oriented Vulnerabilities as Predictors of Openness to GLP-1 Weight-Loss Medications","H.A. (Henna) Kapoor","2026",null,"other","article","10.17605/osf.io/2adxr",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042170","Determinants and reversal of obesity-associated hyperandrogenemia in adolescent girls","Mccartney, Christopher","2025","California Digital Library","other","article","10.48321/d159c4ea83",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042171","The Relationship Between Diet Composition and Mental Health in Adults Using GLP-1 RAs","Chantelle McGivern","2026",null,"other","article","10.17605/osf.io/buwfm",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042172","ICOSL as a Protective Checkpoint Linking Metabolic Dysfunction to Kidney Injury","Steve Mangos","2026","California Digital Library","preclinical","article","10.48321/d14c813f61",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042173","Longitudinal Assessment of New Anti-Obesity Medications: Behavioral and Psychiatric Predictors and Outcomes","Ivezaj, Valentina","2025","California Digital Library","other","article","10.48321/d1839bdf37",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042174","GLP-1 Receptor Agonists in Bulimia Nervosa: A Scoping Review of Clinical Effects, Mood Outcomes, Reward Circuit Modulation, and Safety Risks","Monzporn Leelakajonjit","2025",null,"narrative_review","article","10.17605/osf.io/d7tx9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042175","Investigating the Role of Glucagon-Like Peptide-1 in the Regulation of Spermatogenesis in Adult Danio rerio (Zebrafish)","Jesse Stephen Neumann","2026",null,"preclinical","article","10.11575/prism/51014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042176","Diabétologie","Jornayvaz, François","2017","Archive ouverte UNIGE (University of Geneva)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0042177","Efficacy of Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Associated With Obesity","Nour ali husseini","2026",null,"other","article","10.17605/osf.io/7fk9r",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042178","Direct and Remote Encapsulation Strategies for GLP-1 Receptor Agonists in PLGA Microspheres","Aishwarya Chandrashekar","2026",null,"preclinical","article","10.7302/dspace/29252",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042179","Real-world safety signals of resmetirom in FAERS: a disproportionality study with GLP-1 comparator and MAESTRO-NASH benchmarking","Xiyi Lu","2026",null,"nonrandomized_study","article","10.17605/osf.io/fpg84",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042180","Enteroendocrine cells mediate dietary risk factors of chronic disease","Mccauley, Heather","2025","California Digital Library","preclinical","article","10.48321/d110df0d0e",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042181","A longitudinal IPA analysis of clinically obese women’s psychological lived experiences of the side effects of Saxenda (Liraglutide) pharmacotherapy for weight loss, in relation to the physical consequences, using secondary data from YouTube.","Phoebe Penfold","2022",null,"other","article","10.17605/osf.io/xa6bg",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042182","Ruolo della combinazione IGlarLixi: dalle evidenze scientifiche alla pratica clinica","Riccardo Candido","2019","Padua Research Archive (University of Padova)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0042183","Evaluating the Impact of Missing Data on Treatment Effect Evaluating the Impact of Missing Data on Treatment Effect Estimation in Simulated Pragmatic Trials: A Methodological Study in Type 2 Diabetes","Bahareh Kheiri","2025","Scholarship@Western (Western University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0042184","Ecnoglutide: First Approvals","Matt Shirley","2026","Figshare","other","article","10.6084/m9.figshare.32320305.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042185","GLP-1 Receptor Agonists as Preoperative Prehabilitation for Abdominal Wall Hernia Repair in Patients With Obesity: A Scoping Review Protocol","Hakeem Seidu-Aroza","2026",null,"protocol","article","10.17605/osf.io/g7edh",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042186","Anesthetic Considerations in Surgical Patients Prescribed GLP-1 Receptor Agonists: A Case Study","Constantinescu, Kevin","2024","University of Scranton Digital Collections","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042187","GLP-1R agonists: Full of hope, use with caution","Yanyong Xu","2024","The Innovation Medicine","commentary","article","10.59717/j.xinn-med.2024.100086",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0042188","Experiences and perceptions of stigma related to GLP-1/GIP-GLP-1 receptor agonist use: a scoping review protocol.","Tala Al Ajmi","2026",null,"protocol","article","10.17605/osf.io/sp3e8",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042189","Real-World Use and Dosing Patterns of Semaglutide for Weight Management in Denmark 2022–2025","Emma Simonsen","2025",null,"nonrandomized_study","article","10.17605/osf.io/twbu9",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042190","Enhancing therapeutic potential of olfactory ensheathing cells in spinal cord injury by phagocytosis","Choudhury, Indra N","2023","Griffith Research Online","other","article","10.25904/1912/4759",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042191","Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial","Melanie Davies (20342379)","2025","Figshare","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT04916470","S000161","openalex","TRUE","no_doi","1","FALSE","article"],["R0042192","Antipsychotic-Induced Weight Gain: What Have We Learned?","Akshatha Silas","2025","Current Cardiovascular Risk Reports","other","article","10.1007/s12170-025-00762-z",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042193","Real-World Weight Loss with GLP-1 Receptor Agonists versus SGLT2 Inhibitors in a Diverse US Cohort: An Active Comparator New-User Study","Valentin","2026",null,"nonrandomized_study","article","10.17605/osf.io/xb8th",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042194","Semaglutide as a bridge to kidney transplantation in adults with obesity and kidney failure: a systematic review and exploratory meta-analysis","Yiwei Shang","2026",null,"systematic_review","article","10.17605/osf.io/6uj2r",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042195","Rational Design of Anti-diabetic Agents","Redij, Tejashree",null,"ProQuest Demo Repository","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042196","Dopaminergic control of obesity in mice","Alexxai V. Kravitz","2026","California Digital Library","nonrandomized_study","article","10.48321/d174a1d243",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0042197","Incretin receptor agonists and PMOS: pathogenetic rationale for therapy","Yarmolinskaya M.I. Yarmolinskaya","2026","Akusherstvo i ginekologiia","other","article","10.18565/aig.2026.282",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042198","Glucagon-like Peptide-1 Receptor Agonists in Essential Tremor and Cerebellar Neurodegeneration: Mechanistic Rationale, Pharmacovigilance Paradox, and the Case for Targeted Investigation","Md. Shadin","2026",null,"nonrandomized_study","article","10.17605/osf.io/rscd2",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042199","Metabolic functions of pyruvate kinase m2 in pancreatic beta-cells","Merrins, Matthew","2023","California Digital Library","preclinical","article","10.48321/d1b04k",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042200","Impact of GLP-1 Receptor Agonists on Reproductive Outcomes in Women with Obesity Without Polycystic Ovary Syndrome: A Scoping Review","Maria Fernanda Baptista Caldas","2026",null,"narrative_review","article","10.17605/osf.io/u8hze",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042201","Metabolic Adaptation to Weight Loss In Response to a Behavioural Lifestyle Program with or without Semaglutide in Adolescents with Obesity","Athena Flores Miranda","2026",null,"randomized_trial","article","10.71548/2209",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0042202","Compounding Inequities Through Drug IP and Unfair Competition","Kumar, Shweta","2024","bepress Legal Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042203","Six month snapshot audit of admission, clinical and glycaemic characteristics of in-patients with diabetes mellitus in Liverpool Hospital","Kaur, tavleen","2025","UNSWorks (University of New South Wales, Sydney, Australia)","other","article","10.26190/unsworks/31406",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042204","Population-level oral health implications of GLP-1 receptor agonists: a scoping review of emerging evidence and public health preparedness","Abdullah Bokhary","2026",null,"nonrandomized_study","article","10.17605/osf.io/93ehj",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042205","Effects of acetylcholine and liraglutide on intracellular calcium in the hearts","Researcher Siripong Palee","2016","Thammasat University Digital Collections","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042206","Cardiovascular Remodeling and Myocardial Fibrosis Outcomes of Dual GIP/GLP-1 Receptor Agonism With Tirzepatide in Obesity and Heart Failure: A Systematic Review and Meta-Analysis of Clinical Trials","Yaqeen M. Al-Jaradeen","2026",null,"systematic_review","article","10.17605/osf.io/26sbq",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042207","GLP-1 Receptor Agonists in Alcohol-Associated Liver Disease: A Scoping Review of Mechanisms, Preclinical Evidence, Clinical Efficacy, and Therapeutic Potential","Michelle Mussi","2026",null,"narrative_review","article","10.17605/osf.io/afczy",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042208","Optimising glucose-lowering medication treatment following cardiothoracic surgery: implementation of a pharmacist-led guideline","F Foo","2024","Minerva Access (University of Melbourne)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0042209","Discontinuation-driven weight regain and lean mass dynamics: Implications for sustained metabolic healthspan with GLP-1 RAs","Dominic Lynch","2026",null,"other","article","10.17605/osf.io/bwy9p",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042210","GLP-1 receptor agonists and incretin-based therapies in oral and craniofacial bone: a scoping review of bone healing, osseointegration, and orthodontic tooth movement","Akash Kumar Giri","2026",null,"other_trial","article","10.17605/osf.io/3asy5",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042211","Utilization patterns of GLP 1 RAs in Germany protocol for a population-based cohort study","Mina Ashraf Tawfik Goher","2026",null,"protocol","article","10.17605/osf.io/tvkq9",null,null,"OSF:osf.io/8qa5x",null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042212","Prevention and Delayed Progression of Diabetic Nephropathy","Scott, Russell","2023","OpenSIUC (Southern Illinois University Carbondale)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0042213","Does early oligosaccharides consumption affect pancreas maturation?","Catherine Michel","2013","HAL (Le Centre pour la Communication Scientifique Directe)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0042214","GLP-1 Receptor Agonists and Risk of Substance Use Disorders Among Adults with Type 2 Diabetes: An Active Comparator New User Study in a Diverse US Population","Fang Li","2026",null,"nonrandomized_study","article","10.17605/osf.io/5r2sb",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042215","Off-label Semaglutide & GLP-1 weight-loss medicine use for anti-ageing: A Netnography of older bodybuilders’ experiences and understandings","Luke A. Turnock","2025","Performance Enhancement & Health","other","article","10.1016/j.peh.2025.100355",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042216","Research Synthesis: Liraglutide Metabolism Effects — full paper","Dominic Lynch","2026",null,"other","article","10.17605/osf.io/x96ey",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042217","Comparative Effectiveness of CagriSegma, semaglutide, cagrilintide and Tirzepatide in the Management of Overweight and Obesity: Network Meta-analysis of Randomized Clinical Trials.","Hamarsheh, Sultan","2025",null,"systematic_review","article","10.17605/osf.io/bfh6s",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042218","Incretin-based drugs and the incidence of endometrial cancer among patients with type 2 diabetes","Rothman, Sonny","2025","eScholarship@McGill (McGill)","nonrandomized_study","article","10.82308/49186",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0042219","The Synthesis and Evaluation of Peptide-Based Probes for the Imaging of RHAMM Expressing Carcinoma and GLP-1R on Pancreatic Beta Cells","Ashley Esarik","2013","Scholarship@Western (Western University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042220","Assessing the Therapeutic Potential of GLP‐1 Receptor Agonists in Psoriasis and Other Skin Diseases: Insights From a Scoping Review and Mendelian Randomization Study","Xiafan Long","2026","Dermatologic Therapy","narrative_review","article","10.1155/dth/9612721",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042221","Dual and Triple Incretin Receptor Agonism and Addictive Behaviors: Neurobiological Rationale and Emerging Evidence for Tirzepatide and Retatrutide in Alcohol, Tobacco/Nicotine, and Cocaine Use Disorders","CARLA JULIANA ABRA BERGAMIN","2026",null,"other","article","10.17605/osf.io/4w3jx",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042222","Ruolo di liraglutide nella cura dei pazienti con diabete tipo 2: l'esperienza regionale del Friuli Venezia Giulia","Candido R","2012","ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0042223","Incretin-based therapies in hepatology practice","Merve Eren Durmuş","2026","World Journal of Hepatology","nonrandomized_study","article","10.4254/wjh.125275",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042224","Clinical Predictors of GLP-1 Receptor Agonist Weight Loss Response in Real-World Practice: An Exploratory Analysis from the All of Us Research Program","Valentin","2026",null,"nonrandomized_study","article","10.17605/osf.io/um8jh",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042225","Anti-Obesity Pharmacotherapy-Induced Loss of Muscle Mass and Function is Rescued by Modulating Dietary Protein Consumption in a Model of Childhood Obesity","Morris, Brooke Ally","2025","YorkSpace (York University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042226","Cardiovascular Imaging of GLP-1–Based Therapies in Adults: A Scoping Review of Remodeling Domains, Imaging Modalities, and Evidence Gaps","Imeth Illamperuma","2026",null,"other_trial","article","10.17605/osf.io/2s78f",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042227","GLP-1 Effects on Maternal Metabolism and Fetal Development","Lu, Cindy V","2022","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042228","Nurse-led supportive care interventions for adults receiving GLP-1 receptor agonists for obesity and/or type 2 diabetes: a scoping review protocol","dong hannan","2026",null,"protocol","article","10.17605/osf.io/a7wmb",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0042229","Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study","Suematsu, Natsu","2019","Kobe University Repository Kernel (Kobe University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0042230","S699 GLP-1 Receptor Agonists Are Associated With Decreased Esophageal Cancer Risk in Type 2 Diabetes Patients Compared to Other Anti-Diabetic Therapy","Khaled Alsabbagh Alchirazi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032164.05931.aa",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0042231","Understanding Patient Perceptions and Behavioral Intentions Toward GLP-1 Receptor Agonists for Weight Management in the United States: A Health Belief Model Approach","Aryan Shokrollah Shirazi","2026",null,"nonrandomized_study","article","10.36837/chapman.000719",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","dissertation"],["R0042232","Obesity alters global response to ischemia and GLP-1 agonism","Daniel Sassoon","2016","ProQuest Demo Repository","other","article","10.7912/c28k5p",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042233","The magnitude of slowing gastric emptying by GLP-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes","由美 菅沼",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042234","Liraglutide",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-58612-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042235","Inkretiner : morgendagens medikamenter for behandling av diabetes type 2 : en litteraturstudie","Line Louise Rasmussen","2012","NORA - Norwegian Open Research Archives","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042236","Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study","Steve Bain","2024","Cronfa (Swansea University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042237","Real-World Comparisons Between Glucagon-Like Peptide-1 Receptor Agonists and Other Glucose-Lowering Agents in Type 2 Diabetes: Retrospective Analyses of Cardiovascular and Economic Outcomes in England","Steve Bain","2025","Cronfa (Swansea University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042238","Computational investigation of flavonol-based GLP-1R agonists using DFT calculations and molecular docking","Min Zhang","2020","Computational and Theoretical Chemistry","other","article","10.1016/j.comptc.2020.113005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042239","The Five-Gate Framework: A Two-Axis Evidence-Governance Instrument for Peptide Therapeutics in Pre-Consensus Use. Specification, Calibration on an Approved Anchor, and an Applied Monograph on BPC-157","Nicholas Stanley","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22260110",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0042240","Simultaneous Estimation of Liraglutide and Preservative Phenol in Injectable Dosage Form by Validated Stability-indicating RP-HPLC Method","Shah Yesha Hitesh Kumar","2026","Asian Journal of Research in Medical and Pharmaceutical Sciences","other","article","10.9734/ajrimps/2026/v15i2389",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042241","Dulaglutide",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-93560-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042242","Glaucoma: The Silent Thief of Sight as the End-Stage of the Brain's Ocular Decree","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22241871",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042243","Nouvelle ère : ouverture des jeux Ozempic, impact pharmaceutique et sociétal","Laudisi, Charlène","2024","HAL AMU","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042244","The Ozempic Paradox: How Much is Too Much in the Race for Weight Loss and Diabetes Treatment?","Bekos, Jack","2025","bepress Legal Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0042245","Tul765 THE IMPACT OF LIRAGLUTIDE ON FASTING GASTROINTESTINAL MOTILITY, MOTILIN SECRETION, AND APPETITE: TRANSLATIONAL INSIGHTS","Emily Ruilova Sosoranga","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04961-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042246","Effect of Semaglutide on Skeletal Muscle During Weight Loss in Diabetic Rats","Taherkhani, Kian","2025","YorkSpace (York University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042247","Review: cell mechanisms in the control of inflammatory foundations of obesity and secondary metabolic disorders","Goldstone, Kristin","2025","Arrow - TU Dublin (Technological University Dublin)","narrative_review","article","10.21427/zt2f-hs55",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042248","Mol793 LIRAGLUTIDE-RESPONSIVE GUT MICROBIOME SIGNATURES MAP TO SPECIFIC HOST CELLULAR PATHWAYS VIA A SINGLE-CELL POLYGENIC SCORE FRAMEWORK, REVEALING PHYSIOLOGIC ROUTES THROUGH WHICH MICROBIOME ALTERATIONS MAY SHAPE HOST RESPONSES","qi wei","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04926-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042249","Cost-utility of injectable and oral GLP-1RAs for type 2 diabetes mellitus inadequately controlled with metformin: A Markov model analysis","Penglin Zhou","2026","Pharmacoeconomics and Policy","randomized_trial","article","10.1016/j.pharp.2026.08.004",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042250","mir-22 inhibition as glp1 agonist orthogonal mechanism for nafl and nash treatment","Riccardo Panella","2023","Journal of Hepatology","other","article","10.1016/s0168-8278(23)02145-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042251","Sal339 REDUCED RISK OF CLOSTRIDIOIDES DIFFICILE INFECTION WITH GLP-1 RECEPTOR AGONISTS COMPARED WITH DPP-4 INHIBITORS IN ADULTS WITH DIABETES: A PROPENSITY-MATCHED ANALYSIS OF REAL-WORLD DATA","Donna Maria Abboud","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)00825-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042252","An examination into the effects of very-low calorie diets and glucagon-like peptide-1 receptor agonists, individually or in combination, on skeletal muscle metabolism and glycaemic outcomes in individuals with type 2 diabetes living with obesity","Anyiam, Oluwaseun","2025","Nottingham ePrints (University of Nottingham)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042253","Type 2 Diabetes in 2025","Rudolf Chlup","2026","Directory of Open access Books (OAPEN Foundation)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042254","Effects of GLP1-RAS and SGLT2I on liver steatosis and fibrosis in metabolic dysfunction-associated fatty liver disease (MAFLD) with type 2 diabetes: interim analysis of an open trial","Mega A.","2025","Padua Research Archive (University of Padova)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","conference-paper"],["R0042255","Mathematical Modeling of Electrical Activity and Exocytosis in Intestinal L-cells and Pancreatic Beta-cells","Michela Riz","2015","Padua@research (University of Padova)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042256","GLP-1 Receptor Agonists: Mechanisms, Insights, and the Impact of Wegovy and Ozempic on Contemporary Weight Management","MADHURA S. CHOTHAVE","2024",null,"other","article","10.9734/bpi/prrat/v6/2151",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0042257","Medikamentell behandling for vektoppgang etter gastrisk bypass operasjon","Sandvik, Ida Vinje","2023","NORA - Norwegian Open Research Archives","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042258","inSIGHT, Volume 6, Issue 1, 2026",null,"2026","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042259","Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies","Shubham Sharma","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/ng7mu",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0042260","Phase 3 Trial of Survodutide Once Weekly for the Treatment of Adults with Obesity: SYNCHRONIZE™-1 (ID 62)","K Laubner","2026","Adipositas - Ursachen Folgeerkrankungen Therapie","other_trial","article","10.1055/s-0046-1827105",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0042261","Abdominal Pain of Unknown Origin","Thompson, Gregory","2020","SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042262","LIRA‐ADD2SGLT2i – New Evidence on Combing GLP‐1 RA and SGLT2i Therapies (https://doi.org/10.1111/dom.13978)",null,"2020","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.00008",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042263","Multimodal ultrasound assessment of tibial nerve changes after semaglutide therapy in diabetic tibial neuropathy","Yanqiu Chen","2026","European journal of medical research","other","article","10.1186/s40001-026-05112-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042264","Innføring av nye og effektive legemidler for pasienter med diabetes mellitus type 2 og samtidig kardiovaskulær sykdom og/eller nyresykdom","Anker, Andreas","2021","NORA - Norwegian Open Research Archives","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042265","GLP-1 start-up launches with $400 million","Rowan Walrath","2024","C&EN Global Enterprise","other_trial","article","10.1021/cen-10231-buscon6",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0042266","It's Magic?: Ozempic, Addiction Treatment, and the Law","Amandeep S. Grewal","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5322092",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042267","Successful use of empagliflozin in medically refractory post‐bariatric surgery hypoglycaemia","Yeung‐Ae Park","2024","Internal Medicine Journal","randomized_trial","article","10.1111/imj.16401","38757202",null,"ClinicalTrials.gov:NCT05036317",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0042268","Beyond Glycemic Control: Expanding Therapeutic Horizons of Semaglutide and Liraglutide in Cardiometabolic, Neurodegenerative, and Addictive Disorders","Aarav Chaudhary*1, Dr. Hiren Chaudhary2, Aayushi Shah3, Akruti Patel4, Krish Patel5, Het Solanki6","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22260500",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042269","Semaglutide reduces craving for nicotine in Phase 2a trial",null,"2026","The Brown University Psychopharmacology Update","other_trial","article","10.1002/pu.31505",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0042270","Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset","Amira Guirguis","2023","Cronfa (Swansea University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0042271","E. Burch's book featured in The Legal Intelligencer","Office of Communications and Public Relations","2024","bepress Legal Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042272","Gastric point-of-care ultrasound and anesthesia","Olivia N. Kyle","2026",null,"other","article","10.17918/00011288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042273","Overcoming biological barriers by lipid-based nanocarriers","ARPAC, BUSRA","2023","Padua Research Archive (University of Padova)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042274","Effectiveness and safety of the GLP-1 analogue liraglutide for the treatment of obesity in adults without type 2 diabetes : An analysis of weight loss, maintenance of effect, and adverse effects","Raniah Alsaegh","2025","DiVA (Linnaeus University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0042275","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-82265-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042276","GLP-1 Agonists and Satiety","Nicholas T. Bello","2008","Immunology Endocrine & Metabolic Agents - Medicinal Chemistry","other","article","10.2174/187152208787169170",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042277","Mol826 EFFICACY AND SAFETY OF ORAL GLP-l RECEPTOR AGONIST ORFORGLIPRON FOR WEIGHT MANAGEMENT IN ADULTS WITH OBESITY: A SYSTEMATIC REVIEW AND META-ANALYSIS","Choudhary Ahmed Hasan Maqbool","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)04890-x",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0042278","GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns","Klaudia Nowak","2026","Current Pharmacology Reports","nonrandomized_study","article","10.1007/s40495-026-00459-w",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042279","GLP-1 REGULATES PROLIFERATION OF GLP-1 SECRETING CELLS THROUGH A FEEDBACK MECHANISM","Abdullahi Mohamed, Mohamed","2010","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042280","Lilly’s weight-loss pill wins FDA approval","Aayushi Pratap","2026","C&EN Global Enterprise","other_trial","article","10.1021/cen-10405-buscon4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0042281","Risk Assessment in Cardiovascular-Kidney-Metabolic Syndrome","L. Parker Gregg","2025","Clinical Journal of the American Society of Nephrology","nonrandomized_study","article","10.2215/cjn.0000000973","41414951",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042282","Prevention of Hypotensive Adverse Events Utilizing Structured Home Blood Pressure Monitoring in Patients on GLP-1 Agonists","Alexandrya M Tran","2026","Digital Commons-TMC (Texas Medical Center)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042283","Mol824 ASSOCIATION OF NAUSEA SEVERITY WITH SEMAGLUTIDE TREATMENT OUTCOMES: A DESCRIPTIVE COMPARATIVE ANALYSIS","Juan Diego Pazmino Zurita","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04957-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042284","Lilly buys fat-loss drug firm Versanis","Gina Vitale","2023","C&EN Global Enterprise","other","article","10.1021/cen-10124-buscon13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0042285","1677-P: AdOral—A Versatile Platform for Improved Oral Peptide Absorption","ULYSSE NAESSENS","2024","Diabetes","preclinical","article","10.2337/db24-1677-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042286","Menneskers erfaringer med å bruke slankemedisin som behandling mot overvekt og fedme","Jeremiassen, Jonas","2024","NORA - Norwegian Open Research Archives","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042287","Blood pressure lowering in type 2 diabetes for preventing of cardiovascular events and death: a meta-analysis of SGLT2 inhibitors and GLP-1 receptor agonists trials","Alhassane Diallo","2022","HAL (Le Centre pour la Communication Scientifique Directe)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0042288","The Rise of GLP-1 Agonists: The Paradigm-shifting Frontier in Diabetic Kidney Disease, Cardio-renal Protection and Beyond","Fousiya Yoonus","2026",null,"other","article","10.9734/ajrn/2026/v9i1124",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042289","RZY8JY68MG COMPARATIVE EFFECTIVENESS OF SEMAGLUTIDE AND TIRZEPATIDE vs BARIATRIC SURGERY",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042290","Exenatide: a review from pharmacology to clinical practice.","Gentilella R.","2009","Florence Research (University of Florence)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042291","GLP-1 medications for kids: do they work, and at what price?","Sylvia Peña","2025","Evidence-Based Nursing","randomized_trial","article","10.1136/ebnurs-2025-104495","41475770",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042292","Medical news in brief: Daily pill for hot flushes, medical training prioritisation bill passes, no Sweden subsidy for Wegovy, and other stories","British Medical Journal Publishing Group","2026","BMJ","other","article","10.1136/bmj.s491",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042293","Medikamentell behandling for vektoppgang etter gastrisk bypass operasjon","Iversen, Ingebjørg Synnøve Klinge","2023","NORA - Norwegian Open Research Archives","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042294","Pankreas øytransplantasjon som behandling for diabetes mellitus","Afaf Sahraoui","2007","NORA - Norwegian Open Research Archives","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042295","The effects of ileal transposition on GLP-1 analog sensitivity and cognitive function in diabetic long Evans rats","Zihui Wang","2013","OpenSIUC (Southern Illinois University Carbondale)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042296","Oxidative versus Recovery Therapeutics in Type 2 Diabetes Mellitus: An Immunometabolic Perspective","Medhavi Sudarshan","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22260832",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042297","Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions","Said A. Al‐Busafi","2025","Transplantology","other","article","10.3390/transplantology6040035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042298","GLP-1 and GIP/GLP-1 Research Data","Paige Timbrook","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22181142",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042299","Do DPP-4 inhibitors improve endotherial cell function?","Nomoto, Hiroshi","2017","Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042300","Impact of incretin-related agents on endothelial cell function","Hiroshi Nomoto","2017","Clinical Trials in Degenerative Diseases","other","article","10.4103/2542-3975.202726",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042301","P-069 SEVERE DIARRHEA FOLLOWING TIRZEPATIDE THERAPY IN A WOMAN WITH CELIAC DISEASE","Omercan Topaloğlu","2026","JCEM Case Reports","other","article","10.1210/jcemcr/luaf297.052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042302","Riscos do desenvolvimento, falha informativa e o caso Ozempic","Flaviana Rampazzo Soares","2024","Revista IBERC","other","article","10.37963/iberc.v7i2.315",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042303","Glucose variability is independently correlated with serum level of pigment epithelium-derived factor in type 2 diabetes.","藤川大輝",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042304","Effect of Glukagon-Like Peptide-1 Analog Liraglutide On Neural Tube Development In Chick Embryo Model","Hava AÇAR KAYA","2022","Kocatepe Veterinary Journal","other","article","10.30607/kvj.1103958",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042305","Lipid nanocapsules charged with incretin","Beloqui Garcia, Ana","2020","Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B))","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0042306","A study of newly initiated antidiabetic medication in primary care in Region Uppsala : A cross-sectional study","Hatem, Zina","2021","Uppsala University Publications (Uppsala University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042307","O-046 Obesity, implantation and early pregnancy - does GLP1 play a role?","David Westergaard","2025","Human Reproduction","nonrandomized_study","article","10.1093/humrep/deaf097.046",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042308","Synthesis of Peptides and Small Molecules for the Imaging of Cancer and Disease","Breadner, Daniel","2008","Scholarship@Western (Western University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042309","Evaluation of semaglutide treatment effects on spatial memory and anhedonia in diabetes type 2 rat model of both sexes","Kristina Jezdić","2025",null,"preclinical","article","10.5937/arhfarm-61855",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042310","Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: A retrospective cohort study","Yoshinobu Kondo",null,"Institutional Repositories DataBase (IRDB)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0042311","Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model","邦夫 平田","2009","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0042312","P-01 ADRENAL LESIONS IN A PATIENT WITH ACROMEGALY","Alexandra Giannou","2025","JCEM Case Reports","other","article","10.1210/jcemcr/luae218.004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042313","Protocol GLP-1 RA's effect on oxidative stress in humans. A systematic review.","Mads Bobjerg Kirkhoff Larsen","2025",null,"systematic_review","article","10.17605/osf.io/w6f8e",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042314","400 Real-World Safety of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists in US Veterans With and Without Chronic Kidney Disease","Narasaki, Yoko","2022","American Journal of Kidney Diseases","nonrandomized_study","article","10.1053/j.ajkd.2022.01.405",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0042315","Risk-Based Cardio–Renal Benefits of GLP-1 Receptor Agonists and SGLT-2 Inhibitors: A Systematic Review, Meta-analysis, and Decision-Support Tool","Ghosal, Samit","2025","Figshare","systematic_review","article","10.6084/m9.figshare.30071938.v1",null,null,"PROSPERO:CRD420251142103",null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0042316","Xultophy®, une association d’insuline basale et de liraglutide : place dans le traitement du diabète de type 2","Buysschaert, Martin","2018","Digital Access to Libraries","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042317","Research Peptide Lot Documentation: Procurement, CoA Verification, and Handling References","Research Procurement Lab","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22283243",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042318","Peptide-loaded nanoparticle oral delivery strategies towards diabetes treatment","Xu, Yining","2020","DIAL (Catholic University of Leuven)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042319","Effect of GLP-1R Knockout on stroke outcome","Alexandra Voinea","2014","KTH Publication Database DiVA (KTH Royal Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042320","3081 Insulinoma presenting with intermittent horizontal diplopia","Jack Stapleton","2024",null,"other","article","10.1136/bmjno-2024-anzan.79",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042321","A evolução do tratamento farmacológico da Perturbação de Ingestão Alimentar Compulsiva nos adultos","Ferreira, Liliana Vasconcelos Pinho","2024","Open Repository of the University of Porto (University of Porto)","other","article","10.34626/abx9-8658",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042322","Glucagon-like peptide-1 (GLP-1) and liraglutide, a synthetic GLP-1 analog, inhibit inflammation in human aortic endothelial cells via calcium and AMPK dependent mechanisms","N. Krasner","2014","OpenBU (Boston University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042323","350 Effects of GLP-1 Agonist on Pediatric Populations in a Real-World Setting","Gabi Barajas","2024","Journal of Clinical and Translational Science","nonrandomized_study","article","10.1017/cts.2024.312",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042324","GLP-1 agonist semaglutide slows aging in mice","Laurel Oldach","2026","Chemical & Engineering News","preclinical","article","10.47287/cen.593550.newsarticle",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042325","The effect of the GLP -1 receptor agonist on brain responses to reward-related cues and emotional cues? Protocol for a systematic review","Vincent Dang","2024",null,"systematic_review","article","10.17605/osf.io/jbpv7",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042326","Many individuals with eating disorders are using GLP‐1 medications",null,"2026","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31498",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042327","Glucagon-like peptide 1 receptor agonists in obesity treatment: efficacy, safety and clinical implications","Sylwia Lepak","2026","Medical Science","randomized_trial","article","10.54905/disssi.v30i174.e148ms3856",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042328","P-226. GLP-1 Use and Outcomes in Persons with and without HIV","Cassidy Boomsma","2026","Open Forum Infectious Diseases","nonrandomized_study","article","10.1093/ofid/ofaf695.448",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0042329","The contribution of hormonal disorders in the pathogenesis of metabolic-associated steatotic liver disease","Фадєєнко, Г. Д.","2024","Scientific periodicals of Ukraine","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042330","GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice(要約)","Shin ITO",null,"Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042331","Improvement of Obesity and Type 2 Diabetes (T2D) by Oral Semaglutide (Rybelsus) and Super-Low Carbohydrate Diet (LCD)","Hiroshi Bando","2023","Institutional Repositories DataBase (IRDB)","other","article","10.51737/2771-5469.2023.010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042332","Brain dysregulation of appetite and insulin signalling-associated genes in GLP-1 RKO and APP/PS1 mouse models and downregulation in response to 21 days liraglutide treatment","English, Andrew","2017","TeesRep (Teesside University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042333","Extent and impact of obesity in patients with diabetes and acute myocardial infarction - experience from a national cohort","Viveca Ritsinger","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.1547",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042334","FRI060 Real World Experience Of Weight Management In Low Socioeconomic Community Clinic","Brittany Ann West","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.071",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0042335","Evaluating Cardiometabolic Risk Management in Multiethnic Adult Patients with Diabetes in the UCI Health System","Karthikeyan, Hridhay Sai","2024","eScholarship (California Digital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042336","Possibilities of Combinatorial Therapy: Insulin Dysregulation and the Growth Hormone Perspective on Neurodegeneration","Priyanka Sengupta","2021","Pharmacogenetics","other","article","10.5772/intechopen.97002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0042337","P03 | Role of GLP-1 RAs on bone metabolism in patients with type 2 diabetes mellitus: longitudinal study","Vo Van Kha","2025","Italian Journal of Medicine","randomized_trial","article","10.4081/itjm.2025.2209",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0042338","P322 Efficacité comparée de l’exénatide et du liraglutide à doses conventionnelles chez des diabétiques de type 2 en échec d’une bithérapie orale par metformine et sulfamides hypoglycémiants.","Vanessa Preumont","2012","Diabetes & Metabolism","other","article","10.1016/s1262-3636(12)71424-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0042339","Caution in Generalizing Part D Results to Medicare Population—Reply","Millett, Christopher","2011","eScholarship (California Digital Library)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042340","THU385 Refractory Hyperglycemia As Main Presenting Symptom In A Patient With Acromegaly","Talia Rave","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.818",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042341","Strength, Not Scans","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21217580",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0042342","The influence of Glucagon-Like Peptide 1 (GLP-1) for appetite, eating and weight","Hiroshi Bando","2021","Institutional Repositories DataBase (IRDB)","other","article","10.33702/rriemd.2021.3.1.7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042343","Subacute Development of Polymyalgia Rheumatica (PMR) In Diabetic Patient with Clinical Efficacy of Tocilizumab and Xultophy","寛 坂東","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042344","Place du Suliqua®, une association à ratio fixe d'insuline glargine et de lixisénatide, dans le traitement du diabète de type 2","Buysschaert, Martin","2019","DIAL (Catholic University of Leuven)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042345","Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study","Vittal Hejjaji (13147908)","2022","Figshare","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042346","Mechanisms of beta cell dysfunction and application of GLP-1 mimetics in feline diabetes mellitus","Aaron Herndon","2015","SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","dissertation"],["R0042347","Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis","GR Dagenais","2021","Figshare","randomized_trial","article","10.26181/5ffbea8a7ffa7",null,null,"ClinicalTrials.gov:NCT01394952","S000147","openalex","TRUE","paywalled","1","FALSE","article"],["R0042348","GLP-1 Receptor Agonist Drugs, Gastric Emptying, and Fatal Perioperative Pulmonary Aspiration: A Systematic Review and Meta-Analysis","MOHAMED ABDALLA SELIM MEKKAWI","2026",null,"systematic_review","article","10.17605/osf.io/26yse",null,null,"PROSPERO:CRD420261374130",null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042349","Novel Anti-Obesity Pharmacotherapies","Firas Ghomraoui","2023","IntechOpen eBooks","other","article","10.5772/intechopen.110685",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0042350","Direction for Basal Insulin Therapy by Once Daily Injection in the Clinical Practice","Hiroshi Bando","2021","Institutional Repositories DataBase (IRDB)","other","article","10.36502/2021/droa.6177",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042351","Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-κB activation","智加予 岩屋",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042352","A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo","光輔 木谷","2008","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042353","DEVELOPMENT AND VALIDATION OF A SELECTIVE ELECTRO SPRAY IONIZATION – LIQUID CHROMATOGRAPH TANDEM MASS SPECTROMETRY METHOD FOR SIMULTANEOUS DETERMINATION OF SEMAGLUTIDE AND EMPAGLIFLOZIN IN HUMAN PLASMA","JAGAPATHI RAJU VATSAVAYI","2026","Asian Journal of Pharmaceutical and Clinical Research","other","article","10.22159/ajpcr.2026v19i1.56485",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042354","Acupuncture for patients with GLP-1 RAs-induced nausea and vomiting: a systematic review protocol","NING DING","2020",null,"systematic_review","article","10.17605/osf.io/3fgu8",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042355","Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes","Jo Nagakura",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042356","IL-23 Inhibitors in Psoriasis: A Canadian Dermatology Roundtable","Simon Nigen","2026","Canadian dermatology today.","nonrandomized_study","article","10.58931/cdt.2026.7s03166",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042357","Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020","Rudolf Chlup","2021","IntechOpen eBooks","randomized_trial","article","10.5772/intechopen.96237",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","book-chapter"],["R0042358","The role of endothelial ion channels in vascular protection:By SGLT2 inhibitors and GLP1 receptor agonists","M. Wang","2026","UvA-DARE (University of Amsterdam)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","other"],["R0042359","La mise au point du 68Ga-NODAGA-Exendin-4 pour le diagnostic des insulinomes au CHRU de Nancy","Matthieu Sacrez","2024","INRIA a CCSD electronic archive server","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042360","No Worsening of Glycemic Control in Patients with Type 2 Diabetes Mellitus for Three Years during COVID-19 Pandemic Restrictions in Japan","Furukawa, Yasuyuki","2025","Institutional Repositories DataBase (IRDB)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0042361","Longer Fasting After Rybelsus Administration Contributes Higher Efficacy","K Miki","2022","Institutional Repositories DataBase (IRDB)","other","article","10.51737/2766-4813.2022.050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042362","Modern approaches to the management of patients with obesity (according to the materials of the Consensus of the American Gastroenterological Association in 2022)","Ткач, С. М.","2023","Scientific periodicals of Ukraine","randomized_trial","article","10.30978/cees-2023-1-47",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042363","Kroppsskildring i semaglutiddebatten och dess konsekvenser för personer involverade i debatten : En intervjustudie","Boström Gatti, Rebecka","2024","DiVA at Umeå University (Umeå University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042364","Gut peptides in gastrointestinal motility and mucosal permeability","Md Abdul Halim","2016","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0042365","Impressive clinical course of diabetic patient with various medical problems and remarkable improvement by insulin degludec and liraglutide (Xultophy)","Yoshikane Kato","2020","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042366","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97213-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042367","Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease","Li, Lin","2016","Lancaster EPrints (Lancaster University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042368","DEVELOPMENT AND VALIDATION OF AN LC-MS/MS METHOD FOR SIMULTANEOUS DETERMINATION OF METFORMIN AND SEMAGLUTIDE IN HUMAN PLASMA","JAGAPATHI RAJU VATSAVAYI","2025","Asian Journal of Pharmaceutical and Clinical Research","other","article","10.22159/ajpcr.2025v18i9.55110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042369","THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice","Hyeong Kyu Park","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.723",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042370","Fasting period after Rybelsus administration influences clinical benefit","Kenji Hayashi","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042371","SAT133 A Case Study Of UX/UI Design Diabetes Medication Discharge Orderset: An Initiative To Reduce Discharge Prescribing Error","Elvina Yunasan","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.998",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042372","P148 | Effects of new anti-diabetic drugs (SGLT2-I and GLP1-RA) in patients suffering from type 2 diabetes mellitus complicated by peripheral artery disease undergoing percutaneous transluminal angioplasty","Vo Van Kha","2025","Italian Journal of Medicine","other","article","10.4081/itjm.2025.2344",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042373","Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report","Ivanišević, Marina","2018","Hrčak Portal of scientific journals of Croatia (University Computing Centre)","case_report","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0042374","Lifestyle Medicine 2023 Annual Conference Research Abstracts",null,"2024","American Journal of Lifestyle Medicine","other","article","10.1177/15598276231221327",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042375","SAT079 A Novel Variant In The Carboxyl Ester Lipase (CEL) Gene Causing MODY","chalapathi Rao Medavarapu","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.945",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042376","Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.","RE Pratley (7631600)","2012","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0042377","Effectiveness and safety of GLP-1 receptor analogues vs. rapid-acting insulin added to basal insulin therapy in patients with type 2 diabetes mellitus: a living systematic review","Laura Lizeth Trujillo Vargas","2022",null,"systematic_review","article","10.17605/osf.io/zvq7c",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042378","New era for useful add-on therapy (AOT) to diabetes by combined agents of insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA)","Hiroshi Bando","2020","International Medicine","other","article","10.5455/im.24928",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042379","GLP-1 Analogues improved in Glycemic Control in a Patient of Brittle Diabetes Mellitus：A Case Report","Nobuyoshi Tsuzuki","2013","Institutional Repositories DataBase (IRDB)","case_report","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042380","Strength, Not Scans","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21465097",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0042381","DEVELOPMENT AND VALIDATION OF A SPECIFIC AND UNIQUE DUAL POLARITY ESI-LC-MS/MS METHOD FOR SIMULTANEOUS DETERMINATION OF SEMAGLUTIDE AND DAPAGLIFLOZIN IN HUMAN PLASMA","JAGAPATHI RAJU VATSAVAYI","2024","International Journal of Applied Pharmaceutics","other","article","10.22159/ijap.2024v16i5.51095",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042382","Gut Microbiota-derived Metabolites: A New Perspective of Traditional Chinese Medicine Against Diabetic Kidney Disease","Hailing Zhao","2024","Integrative Medicine in Nephrology and Andrology","randomized_trial","article","10.1097/imna-d-23-00024",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0042383","The Era for Dual and Triple Receptor Agonists Treating Type 2 Diabetes (T2D)","Hiroshi Bando","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042384","Development and Application of the Experiment-Selector Cross-Validated Targeted Maximum Likelihood Estimator","Dang, Lauren Elizabeth Eyler","2023","eScholarship (California Digital Library)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0042385","Satisfactory Rapid Response to Xultophy Associated with Meal Tolerance Test (MTT) by Carbohydrate Loading","Hiroshi Bando","2021","Asploro Journal of Biomedical and Clinical Case Reports","other","article","10.36502/2021/asjbccr.6245",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042386","GLP-1 RECEPTOR AGONISTS: EXPANDING INDICATIONS FROM DIABETES AND OBESITY TO CARDIOVASCULAR AND NEURODEGENERATIVE DISEASES","Wardah Zineb Aftassi","2023","Global journal of research in biology and pharmacy","other_trial","article","10.58175/gjrbp.2023.2.4.0225",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042387","Activation of overexpressed GLP-1R attenuates prostate cancer growth by inhibiting cell cycle progression","徹 重岡",null,"Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042388","Effects of the long-acting glucagon-like peptide-1 receptor agonist liraglutide in adolescent pigs with impaired glucose-dependent insulinotropic polypeptide receptor function","Elisabeth Streckel","2013","Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)","other","article","10.5282/edoc.16855",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042389","GLP-1R/GIPR DUAL AGONISM REDUCES INTESTINAL LIPID SECRETION","Farnoosh Tabatabaeian","2026","HARVEST (University of Saskatchewan)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042390","Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes.","Shinobu Matsumoto",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042391","From cardiorenal to cardiovascular–kidney–metabolic syndromes","Eugene Braunwald","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae775","39699246",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0042392","Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protoco","H Hussein (7790060)","2018","Figshare","systematic_review","article",null,null,null,"PROSPERO:CRD42018091306",null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0042393","7347 The Efficacy And Safety Of Oral Semaglutide In Asian Patients With Type 2 Diabetes:A Systematic Review And Meta-Analysis","Tiange Wang","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.957",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042394","“Ozempic personality” — anxious patient or happier patient? A narrative review of GLP-1 receptor agonists and mood disorder","Barbara Alicja Rymanowska","2026","Forum Leczenia Otyłości","nonrandomized_study","article","10.5603/flo.113152",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","review"],["R0042395","Biocatalyzed synthesis of antidiabetic drugs: A review","Cristina Alcántara","2017","Biocatalysis and Biotransformation","narrative_review","article","10.1080/10242422.2017.1323887",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042396","Medical nutritional intervention during pharmacological treatment of obesity","Julia Szymczak","2026","Forum Leczenia Otyłości","other","article","10.5603/flo.111881",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042397","OBESITÀ E BINGE EATING DISORDER: ASPETTI FISIOPATOLOGICI E VALUTAZIONE DELLA TERAPIA INCRETINICA Effetti della terapia combinata GLP-1/GIP sul craving alimentare e sulla composizione corporea in pazienti affetti da obesità: uno studio retrospettivo","LETIZIA ROSSETTI","2026","Electronic Theses and Dissertations Repository (University of Pisa)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0042398","SAT108 What A Simple Switch Can Achieve; A Case Of Severe Insulin-induced Lipohypertrophy","Tooba Ayub","2023","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvad114.973",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042399","Alteration of PGC1-α in the mitochondrial homeostasis of cardiomyocytes under hyperglycemia. Role of the GLP-1R activation","Jairo Lumpuy‐Castillo","2022","IBJ Plus","other","article","10.24217/2531-0151.22v1s5.00029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042400","Defining the Impact of Obesity and Obesity-Targeted Therapies on Natural Killer Cell Metabolism and Function","de Barra, Conor","2024","Maynooth University ePrints and eTheses Archive (Maynooth University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042401","(2) GLP-1受容体作動薬 （III. 糖尿病治療薬に関する最近の話題 3. インクレチン関連薬）","Hideaki Miyoshi","2020","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042402","Effective oral formulation of semaglutide (Rybelsus) for diabetes and obesity due to absorption enhancer development","Hiroshi Bando","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042403","Inhibition of atherosclerosis by glucagon-like peptide-1 receptor agonist in endothelial cells","Takako Okumura","2013","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042404","Modeling the Effect of Liraglutide in T2DM with the T2DM Simulator: a Paradigm for In-Silico Trials","Roberto Visentin","2015","Padua Research Archive (University of Padova)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0042405","P075 When weight limits care: complex myositis management in extreme obesity","Jyothi Sivasothy","2025","Rheumatology Advances in Practice","other","article","10.1093/rap/rkaf111.104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042406","Kidney Talks - Finerenone: What has changed for primary care?","Andrew Frankel","2026",null,"other","article","10.52843/cassyni.pb227f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0042407","Role of G protein-coupled receptor-associated sorting protein 1 (GASP1) in post-endocytic trafficking of Glucagon-like peptide 1 (GLP-1) receptor and its effect on receptor function","Gaur, Anirudh","2023","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042408","THU372 Finasteride Induced Hyperglycemia","Vivek Bose","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.805",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042409","Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice.","Rakhat Yermek","2024","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042410","The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis","九島秀樹",null,"Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042411","Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth","Yuki TANAKA",null,"Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042412","Engraftment of Pancreatic Islets in Alternative Transplantation Sites and the Feasibility of in vivo Monitoring of Native and Transplanted Beta-Cell Mass","Daniel Espes","2016","Uppsala University Publications (Uppsala University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042413","Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics","Takao Ando","2018","Nagasaki University's Academic Output SITE (Nagasaki University)","other","article","10.11343/amn.61.151",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042414","GLP-1-based therapies and functional ageing: post-completion protocol and audit archive for a systematic review and evidence-gap map","He Liu","2026",null,"systematic_review","article","10.17605/osf.io/2fcdm",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042415","P49 | From guidelines to a care pathway: \"Diabetes is close to our hearts at the hospital\"","Vo Van Kha","2025","Italian Journal of Medicine","nonrandomized_study","article","10.4081/itjm.2025.2242",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0042416","503 Examination of Labeling for Geriatric Sub-Populations in Recently Approved Type 2 Diabetes Drugs","Natalie Mao","2024","Journal of Clinical and Translational Science","nonrandomized_study","article","10.1017/cts.2024.427",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042417","PP27 Health Technology Assessment For Obesity Treatment In The Brazilian Public Health System: A Review Of Technology Incorporation Decisions","Jaqueline Driemeyer Correia Horvath","2025","International Journal of Technology Assessment in Health Care","narrative_review","article","10.1017/s0266462325102468",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042418","P70 | Have we underestimated the power of GLP1-RA? A case report of middle-aged man with T2D and obesity","Vo Van Kha","2025","Italian Journal of Medicine","case_report","article","10.4081/itjm.2025.2263",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042419","Prévalence de l'obésité sarcopénique chez les patients atteints d'obésité suivis au CSO PACA Ouest et effet d'un traitement de 6 mois par Semaglutide en accès précoce","Bouchet, Margot","2023","HAL AMU","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042420","Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment intensification: The DISCOVER study","Kamlesh Khunti (171607)","2021","Figshare","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042421","THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use","Nora Abrahimi","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.820",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042422","Novel oral semaglutide (Rybelsus) with life-changing beneficial effects for diabetic patients","Hiroshi Bando","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042423","Improving Care With the “DM Kit”: A Novel, Low-cost Intervention to Increase GLP-1RA and Insulin Prescribing","Abel W.L. Chen","2026","Diabetes Obesity and Cardiometabolic CARE","other","article","10.2337/doc26-0036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042424","GLP-1 Receptor Agonists in Addiction: From Observational Signals to Research Priorities","Augusta Okoro","2026","BJPsych Open","randomized_trial","article","10.1192/bjo.2026.11941",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042425","OP21 Long-Term Cost-Effectiveness Of IDegLira Versus Basal-Bolus Insulin Therapy In Patients With Type 2 Diabetes In Chinese Setting","Junling Weng","2024","International Journal of Technology Assessment in Health Care","nonrandomized_study","article","10.1017/s0266462324000849",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042426","SAT681 Obesity Is A Disease. Maximize Positive Patient Outcome With Medical Treatment","Sabina Casula","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.129",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042427","FRI017 Precision-engineered Activin And GDF Ligand Trap HS235: A Novel Lean Mass-preserving Treatment for Obesity","Gauthier Schang","2023","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvad114.028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042428","エクセナチドは非糖尿病ラットの脂肪組織における脂質利用を増強させて脂肪肝を改善する","田中, 紘介","2015","Institutional Repositories DataBase (IRDB)","preclinical","article","10.15017/1500581",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042429","Glucagon-like Peptide-1 Suppresses the Proliferation and Migration of Vascular Smooth Muscle Cells: Implications for Preventive Effects on Atherosclerosis","Masako Tomoyasu","2014","The Showa University Journal of Medical Sciences","preclinical","article","10.15369/sujms.26.191",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042430","Hur ser framtidens behandlingsmetod ut för personer med diabetes typ 2? : Effektivitet av dualpeptiderna: ''LY3298176'' och ''RG7697''","Salihu, Bjondina","2021","DiVA (Linkoping University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042431","[68Ga]Exendin-4: Bench-to-Bedside : PET molecular imaging of the GLP-1 receptor for diabetes and cancer","Ram Kumar Selvaraju","2015","Uppsala University Publications (Uppsala University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042432","SAT664 Obesity And Overweight Diagnosis, Physician Prescription And Patient Filling Of Anti-Obesity Medications In US","Kyrian Ezendu","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.112",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042433","Exenatide Combined with Metformin and Glimepiride Allows Successful Weaning from Insulin in an Obese Diabetic Patient with Klinefelter Syndrome","Nagai Yoshio","2014","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042434","Anti-inflammatory role of DPP-4 inhibitors in a non-diabetic model of glomerular injury.","佳毅 東島","2016","Institutional Repositories DataBase (IRDB)","preclinical","article","10.15083/00073766",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042435","Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","Melanie J. Davies (7155500)","2015","Figshare","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT01272232","S001792","openalex","TRUE","no_doi","1","FALSE","article"],["R0042436","A randomised, open label, active comparator trial assessing the effects of 26 weeks of Liraglutide or Sitagliptin on cardiovascular function in young obese adults with Type 2 diabetes","David Webb (294780)","2020","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0042437","P127 | Dapagliflozin and acute pancreatitis: a case report","Vo Van Kha","2025","Italian Journal of Medicine","case_report","article","10.4081/itjm.2025.2323",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042438","Cardio-protective effects of glucagon-like peptide-1 receptor agonists: An overview of systematic reviews","Stefanos Zafeiropoulos","2020",null,"systematic_review","article","10.17605/osf.io/tprvn",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042439","SAT677 Use Of An Anti-obesity Medication In A Transgender Woman Pursuing Body Mass Index Requirements For Gender-affirming Surgery","John Michael Taormina","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042440","Exendin-4 protects beta-cells from palmitate-induced apoptosis by interfering with the GPR40-MKK4/7-JNK signaling pathway.","NATALICCHIO, ANNALISA","2011","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042441","Study of the influence of GLP-1 receptor agonists on the metabolic activity of the intestinal microbiota in patients with type 2 DM","Зінич, Олеся Вадимівна","2023","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042442","Diabetes mellitus: associations with atherosclerosis, myocardial fibrosis, and implications for heart failure","Salvador, Dante Jr.","2023","BORIS (University Library Bern)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0042443","Addiction","Jørgen G. Bramness","2025","European Psychiatry","other","article","10.1192/j.eurpsy.2025.82",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042444","Analiza efektywności klinicznej eksenatydu w porównaniu z placebo w leczeniu cukrzycy typu II","Porzucek, Olga",null,"Jagiellonian University Repository (Jagiellonian University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042445","Cognitive impairment and anhedonia as potential diabetes type 2 complications: A preclinical perspective","Kristina Jezdić","2025",null,"preclinical","article","10.5937/arhfarm-61969",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042446","GLP-1 receptor agonists versus Sitagliptin and incident Alzheimer's disease in type 2 diabetes: A propensity score-matched TriNetX cohort study","Meet P. Kachhadia","2026","Bioinformation","nonrandomized_study","article","10.6026/973206300224688",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042447","Swedish diabetes patients’ experiences of using GLP-1 receptor agonists (GLP-1 RAs) : A qualitative interview study.","Ekenberg, Marie","2021","Uppsala University Publications (Uppsala University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042448","P-044 PRECISION MEDICINE MANAGEMENT APPROACH TO ATYPICAL DIABETES: A CASE REPORT","Nwe Oo Aung","2026","JCEM Case Reports","case_report","article","10.1210/jcemcr/luaf297.037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042449","GLP-1 Receptor Agonists in Fibromyalgia: Opioid Sparing Signals from Real World Data","A. S. Verma","2026","European Psychiatry","nonrandomized_study","article","10.1192/j.eurpsy.2026.11477",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042450","Systematic Review of the Efficacy and Safety of GLP-1 Agonists in the Treatment of Idiopathic Intracranial Hypertension (IIH)","Maryam Moghbel Baerz","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/y2s5g",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review; preprint"],["R0042451","Low kidney uptake of GLP-1R-targeting, beta cell-specific PET tracer, 18F-labeled [Nle14,Lys40]exendin-4 analog, shows promise for clinical imaging","Mikkola K","2022","UTUPub (University of Turku)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042452","CO20 | Oral semaglutide for 12 months improves microalbuminuria and GFR in type 2 diabetes outpatients","Vo Van Kha","2025","Italian Journal of Medicine","other","article","10.4081/itjm.2025.2172",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042453","THU003 An Analysis Of A Patient Simulation Platform To Test Learners’ Obesity Management Skills During A Live Educational Event","Robin L. Black","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.001",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0042454","インスリン使用中の維持血液透析患者におけるGLP-1受容体作動薬デュラグルチドの併用によるその有効性および安全性に関する探索的臨床研究","Daisuke Ugamura",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042455","GLP-1 Agonist As Adjunct To Antidepressants In Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.","A. N. R. B. Saad","2026","European Psychiatry","randomized_trial","article","10.1192/j.eurpsy.2026.11401",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042456","Glucagon-Like Peptide-1 Strengthens the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells Under Basal and Hyperglycemia Conditions","福田, 修志","2017","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042457","GLP-1 analogues in post-operative bariatric surgery patients: a systematic review and meta-analysis","Silva, Catarina Columbano Paulino","2024","Open Repository of the University of Porto (University of Porto)","systematic_review","article","10.34626/1f8k-th73",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","dissertation"],["R0042458","Clinical care and other categories posters","Horigan, Geraldine","2015","Diabetic Medicine","other","article","10.1111/dme.12668_1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042459","METHOD DEVELOPMENT AND VALIDATION OF A HIGHLY SELECTIVE AND SPECIFIC POSITIVE POLARITY ESI-LC-MS/MS METHOD FOR SIMULTANEOUS DETERMINATION OF SEMAGLUTIDE AND CANAGLIFLOZIN IN HUMAN PLASMA","JAGAPATHI RAJU VATSAVAYI","2025","International Journal of Applied Pharmaceutics","other","article","10.22159/ijap.2025v17i3.53379",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042460","Current Treatment Trends in T2DM andImpact of COVID-19 among T2DM Patients: A Review","Ashish Akshay Bedi","2020","International Journal of Pharmacy and Pharmaceutical Research","narrative_review","article","10.25166/ijppr.2020.v19i01.58",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042461","Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes : the earlier, the better","Junpei Sanada",null,"Institutional Repositories DataBase (IRDB)","preclinical","article","10.15111/00003014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042462","Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.","Sankar D Navaneethan (8335614)","2023","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0042463","Role of liraglutide and probiotics in managing chronic kidney disease induced in rats","Zeineb Alamri","2026","Zanco Journal of Medical Sciences","preclinical","article","10.15218/zjms.2026.026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042464","Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy","Hiroshi Bando","2021","Institutional Repositories DataBase (IRDB)","other","article","10.36502/2021/asjbccr.6233",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042465","Radiopeptide Targeting for Tumor Therapy: Peptide Receptor Distribution","Jean Claude Reubi","2013",null,"preclinical","article","10.3109/9781420016727-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0042466","SAT675 GLP-1RA Therapy And Intussusception: A Case Report Of Bowel Telescoping In Anobese Patient After Successful Weight Loss On Therapy","Sura Alqaisi","2023","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvad114.123",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042467","Impact of insulin or incretin hormones in reversing diabetic neuropathy in type 1 and type 2 diabetes mellitus","Kan, Michelle","2011","Libraries and Cultural Resources (University of Calgary)","other","article","10.11575/prism/4182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042468","Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis","Chrysanthi Mantsiou","2019","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/73fj5",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042469","Response by Bergmark et al to Letter Regarding Article, “Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial”","Brian A. Bergmark","2020","Circulation","randomized_trial","article","10.1161/circulationaha.119.044819","31986098",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042470","GLP-1 Receptor Agonists and Suicide Risk in Adults With Chronic Pain: A New User Cohort Across Multi-System EHR data","A. S. Verma","2026","European Psychiatry","nonrandomized_study","article","10.1192/j.eurpsy.2026.11980",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042471","4CPS-226 Pharmaceutical intervention on the adequacy of the indication of semaglutide in diabetes mellitus 2","CM Dominguez Santana","2024","Section 4: Clinical pharmacy services","other","article","10.1136/ejhpharm-2024-eahp.330",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042472","Efficiency and safety of adding semaglutide for the management of patients with type 2 diabetes and heart failure in real-world clinical practice","Martina God","2023","Cardiologia Croatica","nonrandomized_study","article","10.15836/ccar2023.294",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042473","ANALYSIS OF THE PLASMID MAP OF NATIVE PROTEIN EXPRESSION VECTOR SYSTEM pYES2 AND PROSPECTS OF APPLICATION IN PHARMACEUTICAL BIOTECHNOLOGY","Решетняк, Людмила","2023","Scientific periodicals of Ukraine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042474","Le traitement par Liraglutide chez les patients diabétiques type 2 obèses","Nada Derkaoui","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042475","Regulation und Funktion von Glucagon-like Peptide 1 und 2 unter inflammatorischen Bedingungen","Diebold, Sebastian","2019","RWTH Publications (RWTH Aachen)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042476","SAT680 Mounjaro: A Side Effect","Kamini Rao","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042477","Research Peptide Procurement Standards — P0 Cluster Reference (BPC-157, Tirzepatide, GHK-Cu, Retatrutide)","Research Procurement Lab","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22283297",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042478","To evaluate the efficacy of GLP-1 analogues on the blood sugar levels, insulin resistance, islet β-cell function and pre-diabetes of the children","Ruifeng Li","2017","Biomedical Research-tokyo","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0042479","Practical Effects of Oral Twymeeg for Type 2 Diabetes (T2d) Patient with Special Habit Taking Much Carbs","M Okada","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042480","Tirzepatide for type 2 diabetes. Systematic review and meta-analysis","Thomas Karagiannis","2021",null,"systematic_review","article","10.17605/osf.io/kjysc",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042481","CHARACTERIZING NOVEL GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES FOR NUCLEAR IMAGING OF THE PANCREATIC BETA CELLS","Vanessa Rota","2011","Scholarship@Western (Western University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042482","Add-on effects of dulaglutide and sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus undergoing intensified insulin therapy","Takeshi Kondo","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042483","FRI067 Efficacy And Safety Of Glucagon-like Peptide 1 Analogs And Agonists (aGLP1) In Overweight/Obese Patients: A Systematic Review And An Updated Network Meta-analysis","Caroliny Hellen Silva","2023","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvad114.077",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0042484","DEVELOPMENT AND VALIDATION OF A SELECTIVE LIQUID CHROMATOGRAPH WITH TANDEM MASS SPECTROMETRY METHOD FOR SIMULTANEOUS ESTIMATION OF SEMAGLUTIDE AND ERTUGLIFLOZIN IN HUMAN PLASMA","JAGAPATHI RAJU VATSAVAYI","2026","Asian Journal of Pharmaceutical and Clinical Research","other","article","10.22159/ajpcr.2026v19i4.58313",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042485","EFFICACY OF GLP-1 RECEPTOR ANALOGS IN NON-ALCOHOLIC FAT LIVER DISEASE: A SYSTEMATIC REVIEW","Paulo Victor dos Santos Lima Paim","2020",null,"systematic_review","article","10.17605/osf.io/3b7um",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0042486","THU285 Predictive Factors Of Response To Liraglutide In Long-standing Type 2 Diabetes: A Real-life Study","Fabiola Romero","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.721",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042487","Diabetic Management with GLP1-RA Ozempic and Diabetic Education","Sivo-Souza, Katrina","2024","Digital Commons (Liberty University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042488","Latest Trend for Standards of Medical Care in Diabetes","Hiroshi Bando","2021","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042489","FRI646 Dulaglutide-induced Acute Liver Injury - A Case Report","Maham Shahid","2023","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvad114.865",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042490","Clinical Application and Mechanistic Investigation of GLP-1 Receptor Agonists in the Treatment of Polycystic Ovary Syndrome","Yan Liu","2025","Pacific International Journal","randomized_trial","article","10.55014/pij.v8i2.794",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042491","FRI643 Tirzepatide Associated Partial Small Bowel Obstruction: A Case Report","Anoopa Mathew","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.862",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0042492","PD53 Glucagon-Like Peptide-1 Receptor Agonists And Polyagonists For Severe Obesity: Rapid Overview Of Outcomes Measurement","Thiago Trindade","2025","International Journal of Technology Assessment in Health Care","randomized_trial","article","10.1017/s0266462325101852",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042493","Physiological and morphological characterization of trangenic pigs expressing a dominant-negative glucose-dependent insulinotropic polypeptide receptor (GIPRdn)","Christiane Fehlings","2010","Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München)","preclinical","article","10.5282/edoc.11948",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042494","O-18 SUCCESSFUL ANTIHYPERGLYCEMIC AND WEIGHT LOSS EFFECTS OF TIRZEPATIDE IN A WOMAN WITH OBESITY AND GENETICALLY CONFIRMED TBC1D4 MUTATION","Omercan Topaloğlu","2026","JCEM Case Reports","other","article","10.1210/jcemcr/luaf297.031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042495","Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond","David E Kloecker (8494704)","2021","Figshare","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0042496","CO01 | Cardiovascular and metabolic effects of GLP-1RAs in patients with type 2 diabetes mellitus: a preliminary longitudinal study","Vo Van Kha","2025","Italian Journal of Medicine","nonrandomized_study","article","10.4081/itjm.2025.2152",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0042497","5. Staying Fat","Mackenzie Edwards","2025","(Un)Disturbed A Journal of Feminist Voices","other","article","10.15353/un-disturbed.v2i1.6423",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042498","Cardiometabolic Outcomes of Glucagon-Like Peptide-1 Receptor Agonists and Incretin-Based Co-Agonists in Adults with Diabesity: A Systematic Review","Prasannakumar Pedapudi","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/yntgw",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0042499","Microencapsulation of Pancreatic Islets : A Non-Vascularised Transplantation Model","Sara Bohman","2008","KTH Publication Database DiVA (KTH Royal Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042500","Semaglutide reduces Cardiovascular Events Among Patients with Variable CV Risk: A Combined Post‐hoc analysis of the SUSTAIN 6 and PIONEER trials (https://doi.org/10.1111/dom.13955)",null,"2020","Diabetes Obesity and Metabolism Now","other","article","10.1002/doi2.00011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042501","Rational design of therapeutic peptides using physics-based molecular dynamics simulations","Vishnoi, Shubham","2023","Figshare","other","article","10.34961/researchrepository-ul.24191565.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; conference-paper"],["R0042502","Kartläggning av förändring i HbA1c och vikt vid behandling med SGLT2-hämmare eller GLP-1-analoger hos patienter med diabetes typ II","Salinas Achusim, Stephanie","2022","Uppsala University Publications (Uppsala University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0042503","THU291 Successful Reversal Of Glucose Toxicity After DKA Precipitated By SGLT2 Inhibitor","Houda Abdelrahman","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.727",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042504","Development of Site-Specific Chemical Strategies for Protein Bioconjugation","Yu, Xingjian","2022","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042505","Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells","バトツェツェグ バトチュルーン","2014","Institutional Repositories DataBase (IRDB)","other","article","10.15017/1470539",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042506","S4690 Semaglutide-Linked Dry Beriberi: A Rare Adverse Reaction","Neha Sharma","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001048128.46369.17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0042507","Expert Opinion on the Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Established or High‑risk Atherosclerotic Cardiovascular Disease in Thailand","Wanwarang Wongcharoen","2025","Journal of Asian Pacific Society of Cardiology","other","article","10.15420/japsc.2024.14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042508","Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","J Deanfield (7667639)","2024","Aston Publications Explorer (Aston University)","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT03574597","S000716","openalex","TRUE","no_doi","1","FALSE","article"],["R0042509","Obesity: Is the tide turning?","Turlough Heffernan (16857930)","2023","Figshare","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0042510","The role of glucagon-like peptide-1 on food intake, glucokinase expression and fatty acid metabolism","Hanjie Zhang","2009",null,"preclinical","article","10.31390/gradschool_theses.3765",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042511","IGlarLixi – bázisinzulin és GLP-1-receptoragonista új fix kombinációja","Gábor Winkler","2018","Diabetologia Hungarica","other","article","10.24121/dh.2018.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042512","DURATION-8: SGLT2-Hemmer plus GLP-1-Agonist","Stephanie Schikora","2016","Diabetes aktuell","other","article","10.1055/s-0042-118918",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042513","Comparison of the safety and clinical efficacy of glucagon-like peptide-1 receptor agonist and α-glucosidase inhibitor among Chinese people with type 2 diabetes","Qin-jin Hu","2022","Tropical Journal of Pharmaceutical Research","other","article","10.4314/tjpr.v20i5.26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042514","RCN Diabetes Forum: achievements and future developments",null,"2008","Practical Diabetes","other_trial","article","10.1002/pdi.1206",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042515","Pharmacological Management Evolution of Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials from 2013 to 2020 and Their Impact on Practice Guidelines","Morales-Villegas EC","2020","Journal of Heart Health","other","article","10.16966/2379-769x.154",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042516","Predictive modelling of peptide-based therapeutics: a way to accelerate biopharmaceutical design and formulation development","Vishnoi, Shubham","2023","Figshare","other","article","10.34961/researchrepository-ul.24566236.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042517","\"Potential Role of Semaglutide in Treatment of Covid-19 Infection\"","Mohamed Elborei","2023","Biomedical Journal of Scientific & Technical Research","other","article","10.26717/bjstr.2023.50.008010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042518","Typ-2-Diabetes: Deutsche Daten der SOLVE™ Studie – Insulin detemir senkt Blutzucker bei vergleichsweise geringem Hypoglykämierisiko",null,"2012","Diabetes aktuell","other","article","10.1055/s-0032-1330871",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042519","Subcutaneous Nodules during Treatment with an Exenatide Long-Actin Once-Weekly Formulation: An Ultrasound Evaluation","Felice Strollo","2016","Diversity & Equality in Health and Care","other","article","10.21767/2049-5471.100070",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042520","Do DPP-4 inhibitors improve endothelial cell function?","Hiroshi Nomoto","2017",null,"other","article","10.35841/cardiology.1.1.12-14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042521","New Drugs: Exenatide",null,"2007","Australian Prescriber","other","article","10.18773/austprescr.2007.099",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042522","Dapagliflozin: a new adjunct in the treatment of Type 2 diabetes mellitus","Mamta Sachdeva","2014","International Journal of Basic & Clinical Pharmacology","other","article","10.5455/2319-2003.ijbcp20140805",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042523","Tirzepatide, A New Antidiabetic Drug with Change in the Treatment of Patients with Type 2 Diabetes","Soo Kyoung Kim","2022","Journal of Korean Diabetes","other","article","10.4093/jkd.2022.23.4.213",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042524","Incretin-Based Therapies and the Risk of Breast Cancer in Women with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis","Mobina Oladghaffari","2023","International Journal of Drug Research in Clinics","systematic_review","article","10.34172/ijdrc.2023.e19",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042525","2816-LB: Efficacy and Safety of Oral Ribupatide (HRS9531) in Adults with Obesity: A Phase 2 Trial","YAN BI","2026","Diabetes","randomized_trial","article","10.2337/db26-2816-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0042526","The use of SGL T2 inhibitors and GLP-1 receptor agonists, a worthwhile physiologic combination in managing type 2 diabetes while reducing cardiovascular risk","Javier Morales","2019","Journal of Cardiology & Current Research","other","article","10.15406/jccr.2019.12.00450",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042527","Oral Abstracts","Unlu, Y","2021","Obesity","randomized_trial","article","10.1002/oby.23328","34874110",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042528","Type 2 Diabetes Mellitus as a Cardiometabolic Disease","Chin Meng Khoo","2019","The Singapore Family Physician","other","article","10.33591/sfp.45.1.u2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042529","Real-World Challenges in Type 2 Diabetes Mellitus: Why a Paradigm Shift Is Needed","Eve Blumson","2018","EMJ Diabetes","nonrandomized_study","article","10.33590/emjdiabet/10314547",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042530","Watch Out for the Little Guy","Richard N. Bergman","2008","Obesity","other","article","10.1038/oby.2007.124","18239626",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042531","GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis","Alessandro Mantovani","2020","Exploration of Medicine","systematic_review","article","10.37349/emed.2020.00008",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0042532","Diabetic cases controlled with low carbohydrate diet (LCD) and GLP-1 receptor agonist (GLP-1 RA)","Masahiro Shirakawa","2019","Asploro Journal of Biomedical and Clinical Case Reports","other","article","10.36502/2019/asjbccr.6137",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042533","An Integrated Ligand- and Structure-Based Virtual Screening and Experimental Strategy for the Prediction of Chemically Diverse GLP-1R Agonists","Elena Murcia García","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20119342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042534","Effects of GPCRs on Type 2 Diabetes and Obesity","Muzi Jin","2023","Highlights in Science Engineering and Technology","other","article","10.54097/xpb5md29",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042535","Anti-diabetic drug utilization patterns in a government hospital in Saudi Arabia","MR Misbahuddin","2018","Tropical Journal of Pharmaceutical Research","nonrandomized_study","article","10.4314/tjpr.v17i6.28",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042536","Additive Effect of Oral Insulin and an Oral GLP-1 Agonist on Postprandial Glucose Excursions in a Porcine Model",null,"2017",null,"preclinical","article","10.31038/edmj.2017131",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042537","Tierisch gute Arzneimittel",null,"2009","Bulletin des Médecins Suisses","other","article","10.4414/saez.2009.14482",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042538","Chronotropic compression or true autonomic deterioration? DFA-derived complexity loss as a discriminator of reduced heart rate variability during GLP-1 receptor agonist therapy","Hasan Kazdağlı","2026","Medical Hypotheses","other","article","10.1016/j.mehy.2026.112146",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042539","Data and Reproducibility Code for the VAT Meta-analysis of Lifestyle and GLP-1RA-Based Interventions","Samit Ghosal","2026","Figshare","systematic_review","article","10.6084/m9.figshare.33437314",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0042540","Cardiovascularis biztonságossági vizsgálatok 2-es típusú diabetesben – az első 10 év tapasztalatai","György Jermendy","2017","Diabetologia Hungarica","randomized_trial","article","10.24121/dh.2017.14",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042541","To Study the Effect of Liraglutide on Formalin Induced Tonic Pain in Obese and Diabetic Rabbits","Mayank Chaudhary","2015","Indo Global Journal of Pharmaceutical Sciences","other","article","10.35652/igjps.2015.27",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042542","Morphological changes of pancreatic endocrinocytes on the background of medical treatment of diabetes mellitus by exenatid and insulin","О. Р. Іванців","2020","Morphologia","preclinical","article","10.26641/1997-9665.2020.3.132-136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042543","IndustryNews",null,"2022","Kompass Nutrition & Dietetics","other","article","10.1159/000527783",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042544","Terapi Diabetes Melitus Tipe 2 Berbasis Hormon Inkretin","Marcel Antoni","2023","Jurnal Kedokteran Meditek","other","article","10.36452/jkdoktmeditek.v29i2.2664",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042545","Antidiabetics and Heart Failure - Large Trials but Little Mechanistic Insight","Dirk von Lewinski","2017","Journal of Clinical and Molecular Endocrinology","randomized_trial","article","10.21767/2572-5432.100037",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042546","https://ildiabeteonline.it/agonisti-recettoriali-glp-1-e-doppi-agonisti-gip-glp-1-alleati-metabolici-ma-quale-impatto-sullo-scheletro/","Giulia Leanza","2026","il Diabete","other","article","10.30682/ildia2602f",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042547","Role of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Diabetic Patients with or without COVID-19","Fatemeh Mirzaei","2022","The Open Medicinal Chemistry Journal","other","article","10.2174/18741045-v16-e2212130",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042548","GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease","Kacper Deska","2023","Postępy Higieny i Medycyny Doświadczalnej","other","article","10.2478/ahem-2023-0001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042549","Glucagon-like peptide-1 receptor agonists for post-bariatric surgery weight regain and insufficient weight loss: A systematic review","Kevin Gracia Pratama","2024","Obesity Medicine","systematic_review","article","10.1016/j.obmed.2024.100533",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0042550","Saxenda® Frenzy: Opinions of an Endocrine and Metabolism Specialist","Sungrae Kim","2019","Journal of Korean Diabetes","other","article","10.4093/jkd.2019.20.2.63",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042551","The Skinny Injection: What’s Behind the Magic of Ozempic?","Isabelle Ong","2026","Rice Research Repository (Rice University)","other","article","10.25611/2ccp-ww26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042552","Tirzepatide: Una vez por semana para el tratamiento de la obesidad","Rolando Calderón Velasco","2023","Diagnóstico","other","article","10.33734/diagnostico.v62i2.463",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042553","Current and upcoming methods of pharmacotherapy of obesity","Jan BIENIASZ","2023","Journal of Education Health and Sport","other","article","10.12775/jehs.2023.13.04.028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042554","Potential Theraputic Effect of Liraglutide in Male Rats Parkinsonn’Disease Model","Ahmed Hazem Abdulkareem","2018","Al Mustansiriyah Journal of Pharmaceutical Sciences","preclinical","article","10.32947/ajps.v17i2.39",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042555","Endocrinología","Residentes Residentes","2019","Acta Médica Colombiana","other","article","10.36104/amc.2018.1395",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042556","Evaluation of Liraglutide Effect on Serum Adipocytokines of Adults Male Wistar Rats with Insulin Resistance That Induced by High Fat Diet","Furqan Mohammed Abdulellah","2018","Al Mustansiriyah Journal of Pharmaceutical Sciences","preclinical","article","10.32947/ajps.18.02.0382",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042557","Weight Loss in Diabetes: Pharmacological Management and Other Strategies","Maria Isabel Gomez Coral","2023","Current Research in Diabetes & Obesity Journal","other","article","10.19080/crdoj.2023.17.555953",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042558","A eficácia da liraglutida no tratamento da obesidade - uma revisão integrativa","Isabelle Felix Fonseca","2023","Brazilian Journal of Health Review","other","article","10.34119/bjhrv6n6-057",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042559","Which antidiabetic drug indications are recommended for geriatric DM patients?","Edoardo Mannucci","2021","Journal of Gerontology and Geriatrics","other","article","10.36150/2499-6564-n458",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042560","Identification of the dominant loop of a dual-loop macro-reentry left atrial flutter without prior intervention using high-density mapping technology: A case report","Shandong Yu","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6165","37731554",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042561","The GLP-1-Brain Axis: From Metabolic Health to Cognitive Resilience","Swarup K. Chakrabarti","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22297516",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042562","Comment on “GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases”","Linda Van Le","2026","Obstetrical & Gynecological Survey","nonrandomized_study","article","10.1097/ogx.0000000000001626",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0042563","Acute pancreatitis in a patient receiving sitagliptin","Shamael Abdulredha Sanaseeri","2012","Journal of Diabetes Mellitus","other","article","10.4236/jdm.2012.24063",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042564","Strategy for Peptide Drug Delivery via Nose-to-Brain Transport Pathways: Challenges to Pharmacotherapy for Dementia","Noriyasu Kamei","2019","Drug Delivery System","preclinical","article","10.2745/dds.34.360",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042565","Orale semaglutide versus subcutane semaglutide","M van den Berg","2026","Geneesmiddelenbulletin","other","article","10.35351/gebu.nl.2026.7.12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042566","Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control","La Salle J","2023","Journal of Family Medicine","other","article","10.26420/jfammed.2023.1325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042567","Long Standing Diabetes on Insulin-Is it Possible to Stop Insulin, Lose Weight and still have Glycaemic Control?","Kalyan Kumar Gangopadhyay","2017","Current Research in Diabetes & Obesity Journal","other","article","10.19080/crdoj.2017.05.555652",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042568","Diabetic cardiomyopathy: current state of the problem. Review","V. Ye. Кondratiuk","2023","Clinical endocrinology and endocrine surgery","nonrandomized_study","article","10.30978/cees-2023-1-58",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042569","Novel Therapeutic Targets in Metabolic Disorders: From the Bench to the Bedside","Maddalena Illario","2014","The Scientific World JOURNAL","preclinical","article","10.1155/2014/365974","24959610",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042570","Prozessbezogene Kompetenzen in zentralen Abschlussarbeiten im Fach Mathematik? – Eine Analyse aller ZP10-Aufgaben Nordrhein-Westfalens von 2007 bis 2019","Bruno Scheja","2023","Zeitschrift für Erziehungswissenschaft","other","article","10.1007/s11618-023-01191-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042571","Highlights",null,"2017","JAMA","randomized_trial","article","10.1001/jama.2016.13355",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042572","The Cardiovascular Events in Metabolic Surgery Compared to the New Classes of Glucose-Lowering Agents in Patients with T2DM","Najla Shamsi","2021","Journal of Endocrinology and Metabolism Research","randomized_trial","article","10.37191/mapsci-2582-7960-2(2)-019",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042573","Cardiovascular pharmacotherapy—2015 was a good year","Basil S. Lewis","2016","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvw020","27600902",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042574","Echec de la metformine: sulfonylurées ou agoniste du récepteur GLP-1?","Antoine de Torrenté","2012","Forum Médical Suisse ‒ Swiss Medical Forum","other","article","10.4414/fms.2012.01206",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042575","Pharmacological treatment of CVD","Stefan Agewall","2022","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvac068","36519600",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042576","ANÁLOGOS DO GLP-1 E NEUROPROTEÇÃO: UMA REVISÃO SISTEMÁTICA","Júlia Vasconcellos Castro","2023","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2023v5n4p2727-2740",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042577","Comparing the projected cost per HbA1c reduction of exenatide QW versus liraglutide 1.8 mg for the treatment of type 2 diabetes mellitus using alternate data sources","B. Wang","2014","Value in Health","other","article","10.1016/j.jval.2014.03.1456",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042578","Peptide Therapeutics","Himanshi Kain","2026",null,"other","article","10.1201/9781003570103-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0042579","Real-World Evidence of GLP-1 Receptor Agonist in Neurodegenerative Disorder: A Scoping Review of Observational Studies","Anuj Mubayi","2026","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","preprint"],["R0042580","Effect of Glucagon Like Peptide 1| (GLP1) Analogues on Obese Egyptians With and Without Diabetes","Khaled A. Elbana","2019","The Medical Journal of Cairo University/˜The œMedical Journal of Cairo University","other","article","10.21608/mjcu.2019.65613",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042581","Establishment of Stability-Indicating Purity Method Based on the Stress Degradation Behaviour of Human Glucagon-like Peptide-1 Analog Liraglutide using Reverse Phase-Liquid Chromatography","Tapan Kumar Giri","2023","Indian Journal of Pharmaceutical Sciences","other","article","10.36468/pharmaceutical-sciences.1172",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042582","Flash CIRS n°12 : Une fois par semaine, pas une fois par jour !","Esther Henzi","2020","Primary and hospital care médecine interne générale","other","article","10.4414/phc-f.2020.10208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042583","Diabetic kidney disease — state-of-the-art knowledge in 2020","Hanna Kwiendacz","2020","Clinical Diabetology","other","article","10.5603/dk.2020.0019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042584","THE USE OF SEMAGLUTIDE (ANALOG OF GLP-1) IN THE TREATMENT OF OBESITY","Giovana Elisa Rosa Galiassi","2022","International Journal of Health Science","other","article","10.22533/at.ed.1592432201088",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042585","Rx Report",null,"2008","Dialysis & Transplantation","other","article","10.1002/dat.20249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042586","Dual Action Mechanism of Insulin Resistance and Insulin Secretion by Imeglimin for Diabetic Treatment","Hiroshi Bando","2022","Diabetes Research - Open Journal","other","article","10.17140/droj-8-e017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042587","Proficiency and Knowledge of Community Pharmacists in the Use of Liraglutide and Semaglutide as Weight Reduction Agents","Ahmed Hussein Al‐Samiry","2024","Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )","other","article","10.54133/ajms.v6i1.413",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042588","Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus","Fiorenzo Santoleri","2014","Pharmacology &amp Pharmacy","nonrandomized_study","article","10.4236/pp.2014.54040",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042589","Liraglutide (Saxenda)","Reimbursement Team","2021","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2021.155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042590","Formulary Management of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists","Daniel Trinh","2024","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2024.861",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042591","Issues of insulin therapy for type 2 diabetes and ways to solve them","V.I. Katerenchuk","2023","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","nonrandomized_study","article","10.22141/2224-0721.19.3.2023.1277",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042592","Impact of the Agents Treated for Metabolic Syndrome on Surgical Complications","Sheng-Lung Hsu","2019","Open Access Journal of Urology & Nephrology","nonrandomized_study","article","10.23880/oajun-16000162",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042593","Peptides in Metabolic Disorders","Priyanka Ray Choudhury","2026",null,"other","article","10.1201/9781003570103-11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0042594","Obesità e terapie incretiniche nel diabete di tipo 1: razionale ed evidenze su GLP-1RA e tirzepatide","Giuseppe Daniele","2026","il Diabete","randomized_trial","article","10.30682/ildia2602d",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042595","Antidiabetic Agents and Stroke Risk in Type 2 Diabetes: A Narrative Review of Mechanisms, Evidence, and Clinical Implications","Sami, Nafiseh","2025",null,"randomized_trial","article","10.32592/smmr.202501.05.06",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0042596","Lixisenatide: a once-daily glucagon-like peptide-1 receptor agonist","Tushar B. Chudiwal","2016","International Journal of Basic & Clinical Pharmacology","randomized_trial","article","10.18203/2319-2003.ijbcp20164085",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042597","LIRAGLUTIDE AND INSULIN DETEMIR IN COMBINATION - A NEW THERAPEUTIC OPTION IN PATIENTS WITH TYPE 2 DIABETES: A CASE REPORT","Milena Velojić-Golubović","2017","Acta Medica Medianae","case_report","article","10.5633/amm.2017.0421",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042598","Pharmacological Study of Weight Losing of Liraglutide Loaded within Layered Double Hydroxide Carrier","Sevan A. Dushan1 , Ashuor H. Dawood 2, Mustafa G. Alabassi3","2020","Indian Journal of Forensic Medicine & Toxicology","preclinical","article","10.37506/ijfmt.v14i4.11818",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042599","Tirzepatide: A Useful Addition for Treatment of Type 2 Diabetes and Obesity","Nasser Mikhail","2021","Gastroenterology Pancreatology and Hepatobilary Disorders","randomized_trial","article","10.31579/2641-5194/044",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042600","Evaluación positiva de medicamentos: Diciembre 2013, Enero y Febrero 2014","MJ. Pérez Morán","2014","Sanidad militar: revista de sanidad de las Fuerzas Armadas de España","other","article","10.4321/s1887-85712014000200006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042601","Liraglutide as Add-on to Oral Antidiabetic Agents or Insulin in Routine Practice of Patients with Type 2 Diabetes","Christian Anholm","2014","Journal of Diabetes Mellitus","randomized_trial","article","10.4236/jdm.2014.42022",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042602","Fnab and calcitonin wash-out during exenatide therapy","Bengür Taşkıran","2014","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.35.p524",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0042603","Audit of clinical practice in the use of incretin mimetic agents for the management of patients with type 2 diabetes","Balraj Dhesi","2013","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1767",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042604","ANTI - OBESITY DRUGS : PRESENT AND FUTURE","Momin M. A. Mujeeb","2015","Journal of Evolution of Medical and Dental Sciences","other","article","10.14260/jemds/2015/1931",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042605","POTENTIAL ROLE OF GLP-1 RECEPTOR AGONIST IN A RAT MODEL OF CARDIO-RENAL SYNDROME TYPE-3: EFFECTS ON OXIDATIVE, INFLAMMATORY AND INOS EXPRESSION AXIS","Atef Abood","2021","Ain Shams Medical Journal","preclinical","article","10.21608/asmj.2021.167313",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042606","Potential of polymeric and Lipid based nanocarriers for oral GLP-1 analogue delivery","Ruba Ismail","2020",null,"other","article","10.14232/syrptbrs.2020.op9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042607","RECENT ADVANCE IN DIABETES: INNOVATION, CHALLENGES AND FUTURE DIRECTION","Vandana Kathiriya","2024","Journal of Population Therapeutics and Clinical Pharmacology","other","article","10.53555/4xz9gr51",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042608","Catalyst Volume 16, 2024-2025",null,"2025","Rice Research Repository (Rice University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042609","Clinical and translational science in cardiovascular research: highlights from the American Heart Association Scientific Sessions 2017","Evangelos K. Oikonomou","2017","Cardiovascular Research","randomized_trial","article","10.1093/cvr/cvx233","29202178",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042610","Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis","Ramin Haghighi","2024","Journal of Renal Injury Prevention","systematic_review","article","10.34172/jrip.2024.32276",null,null,"PROSPERO:CRD42023479548",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042611","Novel Drugs Recently Authorized by EMA and FDA (Q2, 2022)","Santiago Cuéllar Rodríguez","2022","Anales de la Real Academia Nacional de Farmacia","other","article","10.53519/analesranf.2022.88.02.07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042612","What Do You Need to Know About GLP-1 Receptor Agonists?","Kim A. Carmichael","2022","Consultant","other","article","10.25270/con.2022.02.00004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042613","PDB42 Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Patients with Type 2 Diabetes in the UK Setting","Matthew Capehorn","2020","Value in Health","other","article","10.1016/j.jval.2020.08.639",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042614","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97753-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042615","Semaglutide Affecting Alcohol Consumption","Chandrasekara, Lumbini","2024","eScholarship (California Digital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042616","Pacific RxTracts - March 2026","Pacific RxTracts","2026","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042617","The pharmacological treatment of obesity: A historical perspective","Universidad Católica de Cuenca.\n            Cuenca-Ecuador.","2022","Gaceta Médica de Caracas","other","article","10.47307/gmc.2022.130.s3.27",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042618","Two Cases of Mitochondrial Diabetes in Which Pancreatic Beta-Cell Function and Neuropathy Were Improved by Glucagon-Like Peptide-1 Receptor Agonist Therapy","Midori Minezaki","2019","Journal of Endocrinology and Metabolism","other","article","10.14740/jem539",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042619","Blood glucose, antidiabetic drugs, and risk of stroke","Meng Lee","2021","Precision and Future Medicine","randomized_trial","article","10.23838/pfm.2020.00156",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042620","Suspension Culture Alters Insulin Secretion in Induced \\nHuman Umbilical Cord Matrix-Derived \\nMesenchymal Cells","Seyedi, Fatemeh",null,"Research Information System of Ardabil University of Medical Sciences (Ardabil University of Medical Sciences)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042621","Summary: Management of Hyperglycemia in Type 2 Diabetes according to the 2022 ADA-EASD Consensus Report and 2023 ADA Standards of Care in Diabetes","Mi Hae Seo","2023","Journal of Korean Diabetes","other","article","10.4093/jkd.2023.24.1.5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042622","Effect of Liraglutide on Weight Reduction in Euthyroid, Non Diabetic Obese Patients","Reema Tandale Kashiva","2019","Diabetes & Obesity International Journal","nonrandomized_study","article","10.23880/doij-16000204",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042623","Global approach to high-risk cardiovascular patients","Maeve Soto Pérez","2022","Anales de la Real Academia Nacional de Farmacia","other","article","10.53519/analesranf.2022.88.05.06",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042624","Prognostic importance of myocardial infarct characteristics","D Carrick","2012","European Heart Journal - Cardiovascular Imaging","randomized_trial","article","10.1093/ehjci/jes296","23248208",null,"ClinicalTrials.gov:NCT01388504",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042625","Effects of Once-Weekly Dulaglutide on Glycemic Control and Renal Function in Patients with Advanced-Stage Diabetic Nephropathy","Keiji Hirai","2017","Nephro-Urology Monthly","nonrandomized_study","article","10.5812/numonthly.55058",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042626","New Hypoglycaemic Drugs for the Treatment of Diabetes Mellitus and Its Complications: The Future is coming.","Alberto Martínez Castelao","2019","Open Access Journal of Urology & Nephrology","other","article","10.23880/oajun-16000157",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042627","Dr. Virgil Carballo Zárate","Helí Hernández Ayazo","2020","Acta Médica Colombiana","other","article","10.36104/amc.2020.2018",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042628","Pacific RxTracts - February 2026","Pacific RxTracts","2026","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042629","Introducing the 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and CVD","Victor Aboyans","2019","European Heart Journal","other","article","10.1093/eurheartj/ehz688","31608953",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042630","Los inhibidores del SGLT-2 y los agonistas del receptor GLP-1 disminuyen la mortalidad en pacientes con diabetes mellitus tipo 2","Antonella Stellardo","2021","Evidencia actualizacion en la práctica ambulatoria","other","article","10.51987/evidencia.v25i1.6977",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042631","Massive underreporting of type II Diabetes in emergency department admissions","Josefin Gustafsson","2013","Scandinavian Journal of Trauma Resuscitation and Emergency Medicine","other","article","10.1186/1757-7241-21-s2-a35",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042632","The GLP-1 analogue liraglutide decreases the pro-inflammatory status of the heart in diabetes","Reindert W. Emmens","2013","European Heart Journal","preclinical","article","10.1093/eurheartj/eht308.1755",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042633","Baseline interleukin1beta expression in peripheral blood monocytes predicts the extent of weight loss and nonalcoholic fatty liver improvement in obese subjects with prediabetes or type 2 diabetes","Pasquale Simeone","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.3033",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042634","Evaluating Short-Term Cost-Effectiveness Of Liraglutide Versus Insulin Glargine In Patients With Type-2 Diabetes In A Chinese Setting","Chengxin Fan","2013","Value in Health","other","article","10.1016/j.jval.2013.03.812",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042635","Developments in Diabetology in 2016","Sanjay Kalra","2016","US Endocrinology","other","article","10.17925/use.2016.12.02.78",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042636","Algoritmos para determinar el umbral de alerta ante epidemias de malaria",null,"2004","Revista Panamericana de Salud Pública","randomized_trial","article","10.1590/s1020-49892004000800012",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042637","Effects of treatment with GLP-1RA on prediabetes: a systematic review and meta-analysis","Weihao Wang","2022",null,"systematic_review","article","10.37766/inplasy2022.8.0085",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0042638","Pacific RxTracts - April 2025","Pacific RxTracts","2025","Scholarly Commons (University of the Pacific)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0042639","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97755-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042640","Fibroblast Growth Factor 21—Metabolic Role in Mice and Men","Harald Staiger","2017","Endocrine Reviews","preclinical","article","10.1210/er.2017-00016","28938407",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042641","Semaglutide: A Strategic Weapon for Primary Care","Akshay Jain","2022","The Singapore Family Physician","other","article","10.33591/sfp.48.3.u3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042642","Evaluation of Targeted Therapeutics: Energy and Lipid Regulation Modulating Small Molecule for Severe Metabolic Dysfunction-Driven Diseases and Antisense Oligonucleotides for SARS-CoV-2","Lee, Justin Y","2025","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042643","EFFECTS OF EXENDIN-4 AND ANTIOXIDANTS ON ADULT DIABETIC MALE ALBINO RATS","Gamal Ahmed Shawer","2016","Al-Azhar Medical Journal","preclinical","article","10.12816/0029126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042644","Prelimbic cortex to nucleus accumbens signaling contributes to semaglutide-induced suppression of food seeking","Bridget Matikainen-Ankney","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0042645","Treatment of Type 2 Diabetes in Subjects with Obesity: What is the Best Approach?","Diego Ferone","2020","Interventions in Obesity & Diabetes","other","article","10.31031/iod.2020.04.000579",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042646","Student of the Month February 2025",null,"2025","NSUWorks (Nova Southeastern University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042647","Typ-2-Diabetes – Aktuelle EASD-Daten: Patienten profitieren besonders von frühem Liraglutid-Einsatz",null,"2013","Diabetes aktuell","other","article","10.1055/s-0033-1361861",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042648","Typ-2-Diabetes – Patienten profitieren vom frühen Einsatz eines GLP-1-Analogons",null,"2012","Diabetes aktuell","other","article","10.1055/s-0032-1331333",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042649","Investigating the Status of WHO VigiAccess Adverse Drug Event Reporting and Exploring its Potential for Application Using Anti-Obesity Agents as Examples","Mi-Kyung Kim","2024","The Journal of Internal Korean Medicine","nonrandomized_study","article","10.22246/jikm.2024.45.1.55",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042650","GLP-1 Receptor Agonists Critical Review: Revisiting Its Positioning for Type 2 Diabetes Mellitus in Routine Clinical Practice in India","Rajesh Rajput","2022","Clinical Diabetology","narrative_review","article","10.5603/dk.a2022.0026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042651","Anti-Diabetic Medications and Osteoporosis","Kyongyoung Kim","2023","Journal of Korean Diabetes","other","article","10.4093/jkd.2023.24.4.173",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042652","Praxiserfahrungen mit Exenatid 1 × wöchentlich - Überzeugende Effekte auf Blutglukose und Gewicht bereits nach relativ kurzer Zeit",null,"2012","Diabetes aktuell","other","article","10.1055/s-0032-1322294",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042653","Semaglutide as a chance for obesity treatment","Ugo Giordano","2023","Medical Research Journal","other","article","10.5603/mrj.a2023.0034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042654","Pharmacotherapy for patients with diabetes mellitus","Joon Ho Moon","2020","Journal of Korean Medical Association","other","article","10.5124/jkma.2020.63.12.766",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042655","Pacific RxTracts - July 2025","Pacific RxTracts","2025","Scholarly Commons (University of the Pacific)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0042656","Highlights",null,"2018","JAMA","randomized_trial","article","10.1001/jama.2017.12328",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042657","Human insulin — is there still a place for it in everyday practice?","Katarzyna Nabrdalik","2018","Clinical Diabetology","other","article","10.5603/dk.2018.0014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042658","Changes in the biochemical parameters of the blood of rats using hypoglycemic agents for the potentiation of drugs with a hepatoprotective effect","FSFEI HE SPBSUVM, Russia","2023",null,"preclinical","article","10.52419/3006-2023-11-35-40",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042659","GLP1 analogs as treatment of postprandial hypoglycemia after gastric bypass for morbid obesity","Niclas Abrahamsson","2014","Endocrine Abstracts","other","article","10.1530/endoabs.35.p770",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042660","Glucagon-Like Peptide-1 (GLP-1) Agonist","Young Sil Eom","2014","Korean Journal of Medicine","other","article","10.3904/kjm.2014.87.1.9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042661","Praxiserfahrungen mit Basalinsulin plus Byetta® – Positive Effekte auf HbA1c und Gewicht ohne zusätzliches Hypoglykämierisiko",null,"2012","Diabetes aktuell","other","article","10.1055/s-0032-1330872",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042662","How do new therapeutic strategies for PCOS management influence the health of the affected individuals? The narrative review","Aleksandra Wójcik","2022","Journal of Education Health and Sport","narrative_review","article","10.12775/jehs.2022.12.10.035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0042663","Pharmacotherapeutics efficacy in obesity treatment: A systematic review","Tarboush BA","2023","International Journal of Advanced Community Medicine","systematic_review","article","10.33545/comed.2023.v6.i1a.256",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042664","A critical appraisal of antihyperglycemic and cardioprotective activities of liraglutide: A glucagon-like peptide-1 analog","NajmiAbul Kalam","2014","International Journal of Medicine and Public Health","other","article","10.4103/2230-8598.133108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042665","Agonistas del receptor de GLP-1","Hugo César Arbañil- Huamán","2020","Diagnóstico","other","article","10.33734/diagnostico.v59i2.219",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042666","Exenatide — A Novel Treatment to Manage Type 2 Diabetes Mellitus","Manel Puig‐Domingo","2007","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2007.00.01.23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042667","Efficacy and Safety of Basal-Supported Prandial GLP-1 Receptor Agonist Therapy","Taichi Nagahisa","2017","Journal of Diabetes Mellitus","nonrandomized_study","article","10.4236/jdm.2017.73007",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042668","The GLP-1RAs: From Evolution to Revolution","Nitish K. Mishra","2022","The Singapore Family Physician","other","article","10.33591/sfp.48.3.u2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042669","Liraglutide (L): une nouvelle arme contre l’obésité?","Antoine de Torrenté","2015","Forum Médical Suisse ‒ Swiss Medical Forum","other","article","10.4414/fms.2015.02414",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042670","Glucagon-like Peptide-1 Receptor Agonists for Substance Use Disorders: Comprehensive Review of Circuit Mechanisms and Clinical Evidence","Adela-Georgiana Buciuc","2026","Addiction & Prevention","randomized_trial","article","10.3390/addictprev1010007",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0042671","Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain","De Bray, Anne","2024","Apollo (University of Cambridge)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042672","Clinical effectiveness of combination therapy with dulaglutide, SGLT2 inhibitor and metformin with or without insulin in Indian adults with type 2 diabetes: a real-world retrospective study","Supratik Bhattacharyya","2020","Clinical Diabetology","nonrandomized_study","article","10.5603/dk.2020.0026",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042673","PERKEMBANGAN TERAPI DIABETES MELLITUS TIPE 2 PADA PASIEN YANG TERINFEKSI COVID-19","Asyifa Yan Balqis","2021","Journal of Experimental and Clinical Pharmacy (JECP)","nonrandomized_study","article","10.52365/jecp.v1i2.244",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042674","The importance of prevention in high-risk patients: peripheral artery disease, renal failure, and diabetes","Filippo Crea","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae218","38614813",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042675","Elevated Pancreatic Enzymes and Acute Pancreatitis in Subjects with Type 2 Diabetes Mellitus Treated with Exenatide","Udaya M. Kabadi","2017","Advanced Research in Gastroenterology & Hepatology","other","article","10.19080/argh.2017.03.555609",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042676","The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","Anna Thorsø Larsen","2020","Research Square","preclinical","article","10.21203/rs.3.rs-39438/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042677","Research Progress on Relationship between Iron Metabolism and Type 2 Diabetes and Intervention Effect of GLP-1","Qin Jie","2023","Journal of Neurology Research Review & Reports","other","article","10.47363/jnrrr/2023(5)184",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042678","Tackling metabolic defects in HFpEF","Rongling Wang","2024","European Heart Journal","other_trial","article","10.1093/eurheartj/ehad884","38367012",null,"ClinicalTrials.gov:NCT04788511","S002012","openalex","TRUE","open_pdf","5","FALSE","article"],["R0042679","A Study on the development and in-vivo evaluation of Exenatide Self-Emulsifying Drug Delivery System (SEDDS)",null,"2022","Journal of Pharmaceutical Negative Results","preclinical","article","10.47750/pnr.2022.13.03.072",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042680","Evaluation of Exenatide Versus Insulin Glargine Treatment’s Impact on Brown Adipose Tissue Markers and Epicardial Adipose Tissue","Özlem Zeynep Akyay","2023","Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy","randomized_trial","article","10.4274/bmj.galenos.2023.2023.6-5",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042681","The GLP-1 receptor agonist Exendin-4 modulates hippocampal NMDA-receptor signalling in aged rats and improves cognitive impairment in diabetic elderly patients","Antonino Davide Romano","2022","Journal of Gerontology and Geriatrics","preclinical","article","10.36150/2499-6564-n474",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042682","Diabetes or Diabetes Drugs: A Cause for Acute Pancreatitis","Leann Olansky","2012","InTech eBooks","other_trial","article","10.5772/25445",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","book-chapter"],["R0042683","Exenatide associated renal failure","Rahila Bhatti","2010","Practical Diabetes","other","article","10.1002/pdi.1493",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042684","The promise of a new orally active body weight reducer","Massimo Volpe","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad470","37525544",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042685","Focus on the complex relationships among hypertension, dementia, and comorbidities","Filippo Crea","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad374","37339246",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042686","Kombinationstherapie bei Typ-2-Diabetes - Metaanalyse bestätigt synergistische Effekte",null,"2013","Diabetes aktuell","systematic_review","article","10.1055/s-0033-1337655",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0042687","The Use of Oral Antidiabetics in Heart Failure: A Promising Therapeutic Approach","H. Kalkoul","2023","Saudi Journal of Medical and Pharmaceutical Sciences","other","article","10.36348/sjmps.2023.v09i08.004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042688","Extent of Role: Anti-Diabetic Medications","Jun Hwa Hong","2022","Journal of Korean Diabetes","other","article","10.4093/jkd.2022.23.3.153",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042689","Mounjaro® (tirzepatide), der erste und einzige GIP/GLP-1-Rezeptor-Agonist bei Typ-2-Diabetes [1]",null,"2023","Swiss Medical Forum ‒ Schweizerisches Medizin-Forum","other","article","10.4414/smf.2023.1246459688",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042690","Vergleich der Gesundheitskosten von Typ-2 Diabetikern bei der Anwendung von Empagliflozin, DPP-4-Hemmern und GLP-1-Agonisten (Print)","et al. Wilke","2022","Monitor Versorgungsforschung","other","article","10.24945/mvf.06.22.1866-0533.2465",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042691","Pacific RxTracts - April 2026","Pacific RxTracts","2026","Scholarly Commons (University of the Pacific)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0042692","UpToDate®",null,"2023","ASA Monitor","other","article","10.1097/01.asm.0000996844.05730.80",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042693","Combined Therapy with Insulin and Vildagliptin causes Cardiac Dysfunction in Diabetic Rats","Priya Ebeneasan","2018","Indian Journal of Pharmaceutical Sciences","preclinical","article","10.4172/pharmaceutical-sciences.1000396",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042694","Perspectives of incretin mimetics in cardiovascular diseases","João Felipe Rito Cardoso","2021","Brazilian Journal of Health and Biomedical Sciences","nonrandomized_study","article","10.12957/bjhbs.2021.59746",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042695","Actual Meal of Low Carbohydrate Diet (LCD) for Diabetic Patient Treated by Effective Imeglimin (Twymeeg)","Tomoko Kusumoto","2023","Asploro Journal of Biomedical and Clinical Case Reports","other","article","10.36502/2023/asjbccr.6312",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042696","Insulin-Based Treatment for Amyotrophic Lateral Sclerosis","Ari Rappoport","2022","Preprints.org","nonrandomized_study","article","10.20944/preprints202212.0297.v2",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0042697","Effects of A GLP‑1 Receptor Agonist on Gastrointestinal Epithelial Cells","Yusuke Takizawa","2022","Scholars Academic Journal of Pharmacy","other","article","10.36347/sajp.2022.v11i04.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042698","Pacific RxTracts - October 2025","Pacific RxTracts","2025","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042699","Successful treatment of a case of Congenital Lipodystrophy with 1 mg subcutanous Semaglutide","Rana Abdulsalam Almudhammed","2023","JCEM Case Reports","case_report","article","10.1210/jcemcr/luac014.026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042700","ASSESSING THE LEADER TRIAL: UNDERSTANDING MYOCARDIAL INFARCTION SUBTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS AND THE BENEFICIAL IMPACT OF LIRAGLUTIDE THERAPY.","Satish Kumar Singh","2023","Student s Journal of Health Research Africa","other_trial","article","10.51168/sjhrafrica.v4i12.865",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042701","New Treatments for Type 1 and Type 2 Diabetes","Miles Fisher","2012","Annals of SBV","other_trial","article","10.5005/jp-journals-10085-1208",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042702","Assessment of New Protected Mechanism of Liraglutide on CKD Progression","Hayder Hussein Luaibi","2021","Pharmaceutical and Biosciences Journal","preclinical","article","10.20510/pbj/9/i2/1283",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042703","SGLT2 inhibitors: a promising class of antidiabetic agents","Camelia Cristina Diaconu","2018","Archives of the Balkan Medical Union","other_trial","article","10.31688/abmu.2018.53.4.485",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042704","Diabetic Kidney Disease: A New Concept for an Old Problem","Alberto Martínez C","2017","Open Access Journal of Urology & Nephrology","other","article","10.23880/oajun-16000126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042705","EE205 Cost-Effectiveness Analysis of Empagliflozin Versus Albiglutide Among Individuals with Type 2 Diabetes in the US","Alaa Alshehri","2022","Value in Health","other","article","10.1016/j.jval.2022.04.454",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042706","Current trends in the pharmacotherapy for obesity","Sanja Klobučar Majanović","2016","Endocrine Oncology and Metabolism","other","article","10.21040/eom/2016.2.6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042707","\"Semaglutide in Obesity and Non-Alcoholic Fatty Liver Disease\"","Simranjit Simranjit","2022","Biomedical Journal of Scientific & Technical Research","other","article","10.26717/bjstr.2022.42.006775",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042708","Is it Time to Transform our Treatment of Type 2 Diabetes?","Jonathan Viney","2013","EMJ Diabetes","other_trial","article","10.33590/emjdiabet/10310247",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042709","Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018","Jeong Mi Kim","2019","Journal of Korean Diabetes","other","article","10.4093/jkd.2019.20.1.6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042710","El liraglutide permite controlar la glucemia sin aumento de peso en pacientes con diabetes tipo 2",null,"2004","Revista Panamericana de Salud Pública","other","article","10.1590/s1020-49892004000800011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042711","Incretin-based Combination Therapy in Type 2 Diabetes Mellitus","Jae Hyeon Kim","2009","Journal of Korean Medical Association","other","article","10.5124/jkma.2009.52.10.1030",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042712","Pacific RxTracts - December 2024","Pacific RxTracts","2024","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042713","Obesity: an overlooked player in cardiological practice and the need for urgent action","Armando Ferrera","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad875","38620068",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042714","The role of GLP ‐1 receptor agonists as weight loss agents in patients with and without type 2 diabetes","Shujah Dar","2015","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1978",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042715","NEW IN THE TREATMENT OF TYPE 2 DIABETES","V. G. Kadzharyan","2014","Zaporozhye Medical Journal","other","article","10.14739/2310-1210.2014.1.23806",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042716","Liraglutide vs. Sitagliptin as add-on to metformin treatment for type 2 diabetes mellitus: short term cost-per-controlled patient in italy","A Ramirez de Arellano","2015","Value in Health","other","article","10.1016/j.jval.2015.03.363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042717","Liraglutide With or Without Metformin Ameliorates Liver Function and Fatty Liver in Obese Patients with Type 2 Diabetes Mellitus","Tadashi Sakai","2015","Journal of Diabetes & Metabolism","other","article","10.4172/2155-6156.1000598",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042718","The Patient Care Pathway for Type 2 Diabetes Mellitus in Asian Countries: Implications on Target Physician Group for Diabetes Clinical Trials","Vivien Foong Yee Tang","2014","Journal of Diabetes & Metabolism","other_trial","article","10.4172/2155-6156.1000331",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042719","Effects of Epalrestat as Aldose Reductase Inhibitor (ARI), Sitagliptin as Incretin-Based Therapy (IBT), or Combined Epalrestat and Sitagliptin on Cardiac Vagal Neuropathy (CVN) in Patients with Type 2 Diabetic Mellitus","Kyuzi Kamoi","2014","International Journal of Diabetes & Clinical Diagnosis","preclinical","article","10.15344/2394-1499/2014/107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042720","OVERVIEW OF GLP-1 AND ITS PHYSIOLOGY",null,"2023","International Journal of Biology Pharmacy and Allied Sciences","other","article","10.31032/ijbpas/2023/12.6.1057",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042721","Endocrine effects of adipose tissue on cardiovascular redox state: the antioxidant benefits from targeting insulin signalling","Polkinghorne, Murray David","2023","Oxford University Research Archive (ORA) (University of Oxford)","other","article","10.5287/ora-zgadpbpre",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042722","Combinational Therpies and Drugs for Diabetes Mellitus Type I and Type II","Sivasankari S.1, Kumaravel S.2, Govardhanan K.3, Ganesh Kumar4","2020","Medico-Legal Update","other","article","10.37506/mlu.v20i4.2199",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042723","Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity","Magdalena Mazurek","2023","Journal of Education Health and Sport","other","article","10.12775/jehs.2023.13.04.022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042724","Pacific RxTracts - February 2025","Pacific RxTracts","2025","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042725","41st Annual Meeting of the European Association for the study of Diabetes","Charles D Wroe","2006","Practical Diabetes","randomized_trial","article","10.1002/pdi.905",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042726","New Kid on the Block: Semaglutide","Sattik Siddhanta","2022","Bengal Physician Journal","other","article","10.5005/jp-journals-10070-7079",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042727","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97754-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042728","Editorial: Developing high-yielding plant cell bio-factories for high-value low-volume phytochemicals","Smita Srivastava","2023","Frontiers in Plant Science","commentary","article","10.3389/fpls.2023.1281385","37818317",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0042729","Liraglutide (Victoza): A New Treatment Option for Adolescents with Type 2 Diabetes","Michele Olbrich","2020","Journal of Pediatric Nursing","other","article","10.1016/j.pedn.2020.02.027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042730","Quantification of Brain Access of Exendin-4 in the C57BL Mouse Model by SPIM Fluorescence Imaging and the Allen Mouse Brain Reference Model","Casper Bo Jensen","2015","Lecture notes in computer science","preclinical","article","10.1007/978-3-319-19665-7_38",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042731","PDB87 - A COST-OF-CONTROL ANALYSIS: ONCE-WEEKLY SEMAGLUTIDE REDUCES COST OF REACHING TREATMENT TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN NORWAY","Vahideh Hamidi","2018","Value in Health","other","article","10.1016/j.jval.2018.09.792",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042732","L'antibioticoterapia topica è efficace nel trattamento della congiuntivite acuta nei bambini","Gruppo di lettura di Parma","2023","QUADERNI ACP","randomized_trial","article","10.53141/peqacp.2023.2.n2",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042733","Langwerkend exenatide vergoed","Bohn Stafleu van Loghum","2011","Mednet","other","article","10.1007/s12462-011-433-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0042734","Reproduction and Anti-Obesity Medications: A Review of Current Evidence","Héctor Iván Saldívar-Cerón","2023","The Journal of Reproduction","narrative_review","article","10.58779/issn.2954-467x.tjor2023.v2.n2.27",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042735","Oral semaglutide improves glycemic control and lowers blood lipids: evidence from a real-world study","Dora Gašparini","2024","Cardiovascular Endocrinology & Metabolism","randomized_trial","article","10.1097/xce.0000000000000312",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0042736","Glucagon-like Peptide-1 Receptor Agonist Treatment in Type 1 Diabetes","Michael A. Tsoukas","2023","Canadian Diabetes & Endocrinology Today","other","article","10.58931/cdet.2023.1318",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042737","Comparative Treatment between Sitagliptin vs. Metformin, Alone or In Combination, In Patients with Polycystic Ovarian Syndrome. A Clinical Entity with a High Risk of Developing Diabetes Mellitus and Gestational Diabetes",null,"2019",null,"randomized_trial","article","10.31038/edmj.2019341",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042738","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97767-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042739","Pacific RxTracts - July 2026","Pacific RxTracts","2026","Scholarly Commons (University of the Pacific)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0042740","Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes","Shurui Hong","2023","BIO Web of Conferences","other","article","10.1051/bioconf/20236101006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042741","Ideglira Improves Health Utility Compared With Insulin Glargine In Patients With Type 2 Diabetes","Nick Freemantle","2015","Value in Health","other","article","10.1016/j.jval.2015.09.2135",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042742","A súlyfelesleg és annak csökkentése kardiovaszkuláris szempontból","László Bajnok","2021","Cardiologia Hungarica","randomized_trial","article","10.26430/chungarica.2021.51.5.331",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042743","Point: Pulmonary Inhalation of Insulin: Another “Brick in the Wall”","William T. Cefalu","2007","Diabetes Care","other","article","10.2337/dc06-2163","17259527",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042744","Impact of the stepwise approach to cardiovascular disease prevention in patients with established ASCVD from the 2021 ESC Prevention Guideline","Joris Holtrop","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.2476",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042745","Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection","Jong Chul Won","2023","Journal of Korean Diabetes","other","article","10.4093/jkd.2023.24.2.59",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042746","Semaglutide (Rybelsus)","Reimbursement Team","2021","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2021.146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042747","Improving adherence to insulin: Hope with degludec","Sanjay Kalra","2013","Journal of Social Health and Diabetes","other","article","10.4103/2321-0656.120249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042748","Pacific RxTracts - October 2024","Pacific RxTracts","2024","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042749","A Fluid Approach to Type 2 Diabetes Management: Recent Advances in Medication Therapy from Tradition to Novelty","Kissa zaidi -","2024","International Journal For Multidisciplinary Research","other","article","10.36948/ijfmr.2024.v06i01.11140",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042750","Sa1714 Glucagon-Like Peptide-1 Analogue Exendin-4 Decreases Visceral Hypersensitivity by Increasing Rat SERT Expression and 5-HT Reuptake","Ying Wang","2015","Gastroenterology","preclinical","article","10.1016/s0016-5085(15)33482-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042751","AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE","Nahid Rao","2022","Journal of Applied Pharmaceutical Sciences and Research","other_trial","article","10.31069/japsr.v5i2.02",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042752","Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes: An Effectiveness-Implementation Hybrid Type 1 Randomized Trial","Gianna Wilkie","2026","California Digital Library","randomized_trial","article","10.48321/d1989d6a3a",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0042753","Exendin-4 Protects Neural Progenitor Cells from Glucolipoapoptosis","Shiva Mansouri","2014","Journal of Diabetes & Metabolism","preclinical","article","10.4172/2155-6156.1000409",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042754","GLP-1 receptor signalling by novel GLP-1 analogues","Peiqi Wang","2020","The University of Queensland","other","article","10.14264/uql.2020.486",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042755","INTRACELLULAR NO AND CALCIUM IONS CHANGE CAUSED BY EXENDIN-4 IN THE PIG ILIAC ENDOTHELIUM","Xiaochun Hu","2012","Heart","other","article","10.1136/heartjnl-2012-302920b.11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042756","Semaglutide-induced Subclinical Hypothyroidism: A Case Report","Elias E. Mazokopakis","2023","European Journal of Medical and Health Sciences","case_report","article","10.24018/ejmed.2023.5.3.1743",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042757","The effects of incretin mimetics on the level of the microbial metabolite trimethylamine-N-oxide, a marker of cardiovascular risk in type 2 diabetic patients","К.О. Shyshkan-Shyshova","2023","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","other","article","10.22141/2224-0721.19.7.2023.1330",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042758","The Effect of Glucagon-like Peptide-1 (GLP-1) on Obesity","Xiaoyi Huang","2019","Critical Care Obstetrics and Gynecology","other","article","10.21767/2471-9803.1000171",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042759","ABCD now on N3: The ABCD nationwide exenatide QW audit","Robert E. J. Ryder","2014","The British Journal of Diabetes","nonrandomized_study","article","10.15277/bjdvd.2014.009",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042760","Development and validation of novel fluorescent probes to advance research into glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) receptor localisation and activity","De Bray, Anne Yingchol","2025","Oxford University Research Archive (ORA) (University of Oxford)","preclinical","article","10.5287/ora-gpg5vjayz",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042761","Morbid Obesity in Diabetes Mellitus Type 2 and Exenatide","María Ángeles Ibáñez Gil","2014","Pharmacology &amp Pharmacy","other","article","10.4236/pp.2014.52020",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042762","Drugs in type 2 diabetes: their properties and recommended use","Ian Campbell","2010","Prescriber","other","article","10.1002/psb.595",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042763","Low‐molecular‐weight fucoidan and high‐stability fucoxanthin decrease serum alanine transaminase in patients with nonalcoholic fatty liver disease—A double‐blind, randomized controlled trial","I‐Ching Cheng","2019","Advances in digestive medicine","randomized_trial","article","10.1002/aid2.13125",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042764","Eine physiologisch sinnvolle Kombination - Basalinsulin plus GLP-1-Analogon",null,"2012","Diabetes aktuell","other","article","10.1055/s-0032-1322298",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042765","The association between polycystic ovary syndrome and early cardiovascular disease morbidity strengthens","Meri‐Maija Ollila","2023","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvad083","37461221",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042766","Characteristics of the Latest Therapeutic Agent for Diabetes","Nuri Yun","2023","Journal of Korean Diabetes","other","article","10.4093/jkd.2023.24.3.148",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042767","Ergebnisse der DUAL-V-Studie – Mehr als 70 % mit einem HbA1c unter 7",null,"2015","Diabetes aktuell","other","article","10.1055/s-0041-110112",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042768","Az antidiabetikumok kardiovaszkuláris szerepe a véletlen besorolásos vizsgálatokban és az újabb ajánlások világában","László Bajnok","2017","Cardiologia Hungarica","other","article","10.26430/chungarica.2017.47.5.381",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042769","Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?","Awadhesh Kumar Singh","2022","Clinical Diabetology","other","article","10.5603/dk.a2022.0037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042770","Modulation of Intestinal and Systemic Inflammation by Liraglutide and Lactobacillus Plantarum Ameliorates Intestinal Dysfunction and Glucolipid Abnormalities in Diabetic Rats","Amina Ahmed Sedky","2022","The Medical Journal of Cairo University/˜The œMedical Journal of Cairo University","preclinical","article","10.21608/mjcu.2022.234979",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042771","GLP-1 Receptor Agonist Use for Uncontrolled Type 2 Diabetes and Insufficient Weight Loss after Bariatric Surgery","Vanessa Schmidt","2024","eScholarship (California Digital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042772","DOI: 10.2337/dc13-2983",null,"2016",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0042773","Safety Issues with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical Considerations","Soo Lim","2019","Journal of Korean Diabetes","other","article","10.4093/jkd.2019.20.3.127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042774","Efficacy and Safety of Exenatide versus Insulin in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis","Bao-Ju Chen","2019","International Journal of Management Economics and Social Sciences","systematic_review","article","10.32327/ijmess/8.3.2019.16",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042775","Kajian Rute Alternatif Pemberian Liraglutide dalam Penanganan Diabetes dan Obesitas","Handika Immanuel","2023","JIFFK Jurnal Ilmu Farmasi dan Farmasi Klinik","other","article","10.31942/jiffk.v20i2.9299",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042776","Pharmacy Newsletter : September 2025"," Pharmacy Department","2025","eCommons - AKU (Aga Khan University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042777","2023 Clinical Practice Guidelines for Diabetes: Recommendations for Pharmacological Treatment of Type 2 Diabetes","Junghyun Noh","2023","Journal of Korean Diabetes","other","article","10.4093/jkd.2023.24.3.127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042778","Hypothalamic-pituitary dysfunction in children with suprasellar tumors","Jiska van Schaïk","2023",null,"nonrandomized_study","article","10.33540/1959",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","dissertation"],["R0042779","Gliptin Therapies for Inhibiting Dipeptidyl Peptidase-4 in Type 2 Diabetes","Brian D. Green","2010","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2010.06.02.19",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042780","Dual GIP and GLP-1 agonists and changes in the lipid spectrum","David Karásek","2024","Vnitřní lékařství","other","article","10.36290/vnl.2024.006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042781","Antidiabetic Therapy in Patients Related to CKD (Chronic Kidney Disease)","U Bhavana","2023","Diabetes & Obesity International Journal","other","article","10.23880/doij-16000282",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042782","Diabetes & Ramadan (DaR) Workshop in Turkey","Binnur Okan","2014","Journal of Nutritional Disorders & Therapy","other","article","10.4172/2161-0509-4.1000e116",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042783","Insulin Therapy in Type 2 Diabetes","Etie S. Moghissi","2013","US Endocrinology","other","article","10.17925/use.2013.09.01.6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042784","GLP-1 agonists in treatment of obesity","Władysław ORŁOWSKI","2023","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2023.13.02.033",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042785","REAL-WORLD EXPERIENCE OF DULAGLUTIDE THERAPY IN A SINGLE TERTIARY CENTER","Universiti Sains Islam Malaysia, Malaysia","2021","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.036.s6",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042786","MP175EXENDIN-4 PROTECTS AGAINST RENAL ISCHEMIA-REPERFUSION INJURY THROUGH ACTIVATION OF NRF2 SIGNALING PATHWAY","Chih‐Chao Yang","2016","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfw186.01",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042787","Mesoporous Silicon Particle Formulations for Protected and Sustained Delivery of Therapeutic Peptides","Zangabad, Parham Sahandi","2022","Monash University","other","article","10.26180/20103674",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042788","New Drugs for Type 2 Diabetes: New Hopes and New Concerns About the Skeleton","Zehra Berberoğlu","2016","EMJ Oncology","other","article","10.33590/emjdiabet/10313042",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042789","ANALEPTIC APPLICATIONS OF PEPTIDES","Bharat Kwatra","2021","International Journal of Medical and Biomedical Studies","other","article","10.32553/ijmbs.v5i1.1671",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042790","The Promise of Liraglutide in Type 2 Diabetes Mellitus","Tarek Elshourbagy","2019","Acta Scientific Pharmaceutical Sciences","other","article","10.31080/asps.2019.03.0401",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042791","Fasting plasma c-peptide level predicts the response of glucagon-like peptide-1 agonist (exenatide) add on to metformin monotherapy in obese type 2 diabetics","Kağan GÜNGÖR","2022","Journal of Experimental and Clinical Medicine","nonrandomized_study","article","10.52142/omujecm.39.3.39",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042792","The Endocrine Impact of Obstructive Sleep Apnea: Mechanisms, Hormonal Dysregulation, and Emerging Therapeutic Strategies","Achyuth P. Jakka","2026","IFR journal of medicine and surgery.","randomized_trial","article","10.70146/msv03i03.002",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0042793","Pacific RxTracts - June 2025","Pacific RxTracts","2025","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042794","Functional properties of muffin as affected by substituing wheat flour with carob powder","Libor Červenka","2019","Potravinarstvo Slovak Journal of Food Sciences","other","article","10.5219/1033",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042795","Inpatient Use of GLP-1R Agonists for Weight Loss Prior to Transplantation","Garcia, Michael C.","2022","eScholarship (California Digital Library)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042796","FP455THE EFFECTS OF GLUCAGON-LIKE-PEPTIDE 1 AND VITAMIN D ON THE INFLAMMATORY RESPONSE OF ENDOTHELIAL CELLS EXPOSED TO A DIABETIC-LIKE ENVIRONMENT","Tali Zitman‐Gal","2015","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfv178.15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042797","Оbesity: the modern approaches to rational therapy","T. М. Bentsa","2019","Medicine of Ukraine","other","article","10.37987/1997-9894.2019.3(229).185061",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042798","Musculoskeletal response during mechanical unloading: Effects of age, alendronate, and Semaglutide","Orr, Sophie Victoria","2025","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0042799","Knowing Well, Being Well: well-being born of understanding: Access to GLP-1s: Where Do Employers Fit in?","Mary T. Imboden","2025","American Journal of Health Promotion","other","article","10.1177/08901171251335507","40340527",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042800","Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?","Martina Matovinović","2024","Diabetology","nonrandomized_study","article","10.3390/diabetology5010003",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042801","Fully automated GMP production of [Ga-68]Ga-DO3A-VS-Cys(40)-Exendin-4 for clinical use","Velikyan, Irina","2017","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042802","The privileged position of glp-1 in diabetic nephropathy","Kunz Martínez Walter","2018","Endocrinology&Metabolism International Journal","other","article","10.15406/emij.2018.06.00182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042803","The Association of Non Viral Liver Diseases from NAFLD to NASH to HCC with the Pandemic of Obesity, Type 2 Diabetes, or Diabesity & Metabolic Syndrome Etiopathogenetic Correlation along with Utilization for Diagnostic & Therapeutic Purposes-A Systematic Review","Kulvinder Kochar Kaur","2021","Journal of Endocrinology Research","systematic_review","article","10.30564/jer.v3i2.3520",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042804","Current Perspectives for Oral Hypoglycemic Agents with Clinical Evidence of Larger Studies","Hiroshi Bando","2021","Diabetes Research - Open Journal","other","article","10.17140/droj-7-e016",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042805","1 × wöchentlicher GLP-1-Rezeptor-Agonist – Einfache Anwendung überzeugt in der Praxis",null,"2016","Diabetes aktuell","other","article","10.1055/s-0042-108689",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042806","Czy leki inkretynowe i inhibitory SGLT-2 mogą znaleźć zastosowanie w leczeniu cukrzycy typu 1?","Paulina Różańska","2015","Clinical Diabetology","other","article","10.5603/dk.2015.0015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042807","Research Progress in the Effect Evaluation of GLP1-1 Agonists","Dongchun Li","2022","Journal of Clinical and Nursing Research","other","article","10.26689/jcnr.v6i1.2876",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042808","Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus","O. Suprun","2022","Clinical pharmacology and therapy","other","article","10.32756/0869-5490-2022-2-63-68",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042809","Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6","Miles Fisher","2021","British Journal of Diabetes","other_trial","article","10.15277/bjd.2021.301",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0042810","ORIGINAL ARTICLE doi: 10.1111/j.1463-1326.2009.01154.x",null,"2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042811","Efeitos dos análogos do GLP-1 e dos inibidores do SGLT-2 nos desfechos cardiovasculares em pacientes portadores de Diabetes Mellitus tipo 2 / Effects of GLP-1 analogues and SGLT-2 inhibitors on cardiovascular outcomes in patients with type 2 Diabetes Mellitus","Jéssica Brambati Martins","2021","Brazilian Journal of Health Review","other","article","10.34119/bjhrv4n5-213",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042812","Antiepileptic effects of exenatide in penicillin induced acute epilepsy model in rats","Ayşegül Yildiz","2023","Indian Journal of Experimental Biology","preclinical","article","10.56042/ijeb.v61i06.1931",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042813","Investigating the Modulating Effects of Tirzepatide on NAFLD/NASH Progression Using 3D Human Liver Organoids","Barry Wei","2024","Proceedings of IMPRS","other","article","10.18060/27826",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042814","Evaluation of the effect of liraglutide therapy on body weight and insulin resistance.","Dorota Szydlarska","2023","Medycyna Ogólna i Nauki o Zdrowiu","other","article","10.26444/monz/176898",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042815","Semaglutide’s Trail of Success in Weight Loss Management and HbA1c Reduction: A Systematic Review","Shayne Paff","2023","Health","systematic_review","article","10.4236/health.2023.1510073",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042816","Why are GLP-1 receptor agonists in short supply?","Clifford J. Bailey","2022","British Journal of Diabetes","other","article","10.15277/bjd.2022.382",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042817","Holding GLP-1 Agonists Prior to Elective Procedures","Patient Safety Authority","2023","Patient Safety","other","article","10.33940/001c.91636",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042818","Diabetes mellitus and chronic kidney disease: A neglected and dangerous liaison","Edoardo Sciatti","2020","European Journal of Preventive Cardiology","other_trial","article","10.1177/2047487320913381","32188295",null,"ClinicalTrials.gov:NCT03036150",null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042819","10 Jahre Insulin detemir in Deutschland – Ein effektives und verlässliches modernes Basalinsulin",null,"2014","Diabetes aktuell","other","article","10.1055/s-0034-1375839",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042820","Cost-Utility Analysis of Liraglutide in Type 2 Diabetes Patients in China after Chinese Reformation of Medical Care System","Gao-Yu Xie","2018","Journal of Biosciences and Medicines","other_trial","article","10.4236/jbm.2018.612002",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042821","Tirzepatide for Type 2 Diabetes Mellitus","Matthew McDonald","2022","Canadian Journal of Health Technologies","other_trial","article","10.51731/cjht.2022.318",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042822","The Ethics of Wegovy in Pediatric Mental Health","Ryan, Nanette",null,"PhilPapers (PhilPapers Foundation)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042823","Understanding the role of the intestinal melanocortin-4 receptor in the control of body weight","Haque, Rifa Tasfia","2025","Monash University","preclinical","article","10.26180/29209529",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042824","The effect of liraglutide on eating disorders in patients with type 2 diabetes","А М Урбанович","2021","Experimental and Clinical Physiology and Biochemistry","other","article","10.25040/ecpb2021.03-04.033",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042825","Pacific RxTracts - November 2024","Pacific RxTracts","2024","Scholarly Commons (University of the Pacific)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042826","EE352 Projecting the Incidence and Costs of Major Cardiorenal Complications of Type 2 Diabetes with Widespread GLP-1 RA and SGLT2I Use","Jedidiah I Morton","2022","Value in Health","other","article","10.1016/j.jval.2022.04.600",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042827","Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease","Young Woon Chang","2023","Clinical and Molecular Hepatology","randomized_trial","article","10.3350/cmh.2023.0356","37828839",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042828","Therapie des Typ-2-Diabetes – Zulassungserweiterung für GLP-1-Rezeptoragonist",null,"2015","Diabetes aktuell","other","article","10.1055/s-0035-1554865",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042829","Which oral agent to use when metformin is no longer effective?","M. Bannon","2011","QJM","randomized_trial","article","10.1093/qjmed/hcr015","21330402",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042830","Effects of Delayed Release Microsphere of Exenatide on Peri-Implant Bone Response of Diabetic Rats","Wenjuan Zhou Stefan Tangl","2015","Dentistry","preclinical","article","10.4172/2161-1122.1000335",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042831","Temperature and blood glucose management","Rowan Hillson","2015","Practical Diabetes","preclinical","article","10.1002/pdi.1963",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042832","Pacific RxTracts - August 2025","Pacific RxTracts","2025","Scholarly Commons (University of the Pacific)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0042833","Hosszú hatású GLP-1-receptor-agonista szokatlan mellékhatása – a gastrointestinalis motilitás klinikai panaszokat okozó csökkenése IDegLira‑kezelés során – esetismertetés|","Krisztina Arapovicsné Kiss","2019","Diabetologia Hungarica","other","article","10.24121/dh.2019.23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042834","Protective effect of exendin-4 treatment on oxidative status of liver in rats exposed to chronic methylglyoxal","Esra Akcabağ","2020","ACTA Pharmaceutica Sciencia","preclinical","article","10.23893/1307-2080.aps.05910",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042835","99mTc-exendin-4: Radiolabeling and quality control studies of glucagon-like peptide analog","Derya İlem‐Özdemir","2022","Experimental Biomedical Research","other","article","10.30714/j-ebr.2022.141",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042836","Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental?","Taoreed Adegoke Azeez","2021","Forum of Clinical Oncology","randomized_trial","article","10.2478/fco-2021-0014",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042837","Approach to Fatty Liver Disease in Patients with Type 2 Diabetes","Ji Cheol Bae","2023","Journal of Korean Diabetes","other","article","10.4093/jkd.2023.24.3.107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042838","Role of nutrition in depression and other mental illnesses","Omveer Singh","2022","International Journal of Science and Research Archive","randomized_trial","article","10.30574/ijsra.2022.7.2.0232",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042839","Effects of Glucagon-Like Peptide-1 on Arteriovenous Fistula Remodelling and Vascular Smooth Muscle Cell Phenotype Switching in Diabetic Rats","Jun‐Neng Roan","2016","Cardiovascular Pharmacology Open Access","randomized_trial","article","10.4172/2329-6607.1000169",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042840","A Systematic Review and Network Meta-Analysis: Effect of of GLP-1 drugs on weight loss in obese people","Yunhui Xie","2022",null,"systematic_review","article","10.37766/inplasy2022.6.0074",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0042841","The potential beneficial effect of exenatide on cisplatin induced nephrotoxicity in non-diabetic rats","Eman Abdelaziz","2020","International Journal of Pharmacology and Toxicology","preclinical","article","10.14419/ijpt.v8i1.30454",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042842","Typ-2-Diabetes – Neue Optionen bereichern antidiabetische Therapie",null,"2013","Diabetes aktuell","other","article","10.1055/s-0033-1361866",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042843","▼Liraglutide for type 2 diabetes – new data",null,"2010","Drug and Therapeutics Bulletin","other","article","10.1136/dtb.2010.01.0006corr1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042844","Új, innovatív antidiabetikumok (DPP‑4‑gátlók, SGLT‑2‑gátlók, GLP‑1‑recepetoragonisták) perzisztenciavizsgálata 2‑es típusú diabetesben – országos adatbázis‑elemzés eredményei","György Jermendy","2019","Diabetologia Hungarica","other","article","10.24121/dh.2019.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042845","Diabetes mellitus and non-alcoholic fatty liver disease","JiaJun ZHAO","2018","Scientia Sinica Vitae","other","article","10.1360/n052018-00042",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042846","Efficacy and Safety of GLP-1 Agonists in Chronic Kidney Disease: A Case Series","Linda Awdishu","2018","Clinical Medical Reviews and Case Reports","case_report","article","10.23937/2378-3656/1410242",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042847","Focus on blood pressure and risk factor intervention","Stefan Agewall","2020","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvaa130","33197927",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042848","Real-world effectiveness of semaglutide for weight loss: A comprehensive review of evidence","Zahra Karimpoor","2025","Scientometrica","nonrandomized_study","article","10.5267/j.sci.2025.4.005",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042849","Knowledge, attitude, practice, and pharmaceutical outcomes of type 2 diabetes mellitus selfmanagement among patients in Makkah Region, Saudi Arabia","Sharaf E. Sharaf","2021","Pharmacy & Pharmacology International Journal","nonrandomized_study","article","10.15406/ppij.2021.09.00333",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042850","Preferences for Attributes of Medications among Patients with Type 2 Diabetes: A Cross-Medication Class Comparison of Injection Therapies","Jiat Ling Poon","2018","Current Research in Diabetes & Obesity Journal","other","article","10.19080/crdoj.2018.06.555700",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042851","which permits unrestricted noncommercial use, provided the original work is properly cited. Vascular Health and Risk Management 2012:8 255–264","Vascular Health","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042852","Metabolic Modulation with Incretins: Is the Bloom off the Rose?","Brandy Patterson","2017","Journal of Cardiovascular Disorders","other","article","10.26420/jcardiovascdisord.2017.1031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042853","Dulaglutide preserves kidney function and maintains metabolic control at a 36-month follow-up","David León Jiménez","2020",null,"other","article","10.22541/au.158739916.66317776",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042854","Liraglutide as an effective therapeutic agent in a patient with Prader Willi syndrome and type 2 diabetes","Justyna Witczak","2014","Endocrine Abstracts","other_trial","article","10.1530/endoabs.34.p151",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0042855","Gall stone Disease after starting Liraglutide, Is it reversible?",null,"2023","Journal of Medical Science And clinical Research","other","article","10.18535/jmscr/v11i6.06",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042856","Insulins/metformin/semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-39428-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042857","Non‐alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control","Zachary T. Bloomgarden","2017","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12566","28513098",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042858","Paradigm sift of the medical care in diabetes","Fumitaka Okajima","2023","Nihon Ika Daigaku Igakkai Zasshi","other","article","10.1272/manms.19.32",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042859","Awareness of Population Regarding GLP-1 (liraglutide and Semaglutide) Prescribing in PHCC in Abha City, KSA","Majed Al saleh","2023","World Family Medicine Journal/Middle East Journal of Family Medicine","other","article","10.5742/mewfm.2023.95256163",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042860","769 EFFECT OF GLUCOSE LOWERING AGENTS ON CARDIAC AUTONOMIC FUNCTION AND STRUCTURE IN TYPE 2 DIABETES MELLITUS","Francesco Antonio Veneziano","2022","European Heart Journal Supplements","other","article","10.1093/eurheartjsupp/suac121.405",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042861","Kardiovaskulärer Benefit","Stephanie Schikora","2016","Diabetes aktuell","other","article","10.1055/s-0042-118917",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042862","CIRS-Flash Nr. 12: Einmal wöchentlich, nicht einmal täglich","Esther Henzi","2020","Primary and Hospital Care Allgemeine Innere Medizin","other","article","10.4414/phc-d.2020.10208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042863","Typ-2-Diabetes – Patienten profitieren von frühzeitigem Einsatz von GLP-1-Analoga",null,"2011","Diabetes aktuell","other","article","10.1055/s-0031-1298725",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042864","Role of the Glucagon-like Peptide-1 Receptor Agonist in Maintaining Pluripotency in Human Embryonic Stem Cells","Methichit Chayosumrit","2011","The Open Stem Cell Journal","other","article","10.2174/1876893801103010011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042865","Editorial: A timely topic","Donna H. Ryan","2015","Obesity","commentary","article","10.1002/oby.21090","25900867",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0042866","American Drug Index 2013","Norman F. Billups","2012","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0042867","REPURPOSING DIABETES DRUGS FOR NEURODEGENERATIVE DISEASES: ANTI-DIABETIC DRUG REPOSITION","Mrugank Parmar","2019","International Research Journal of Pharmacy","randomized_trial","article","10.7897/2230-8407.0912297",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042868","Fasting period after Rybelsus administration influences clinical benefit","Hiroshi Bando","2022","International Journal of Complementary & Alternative Medicine","other","article","10.15406/ijcam.2022.15.00603",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042869","Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues","Hyun-Ji Chun","2013","Journal of Korean Diabetes","other","article","10.4093/jkd.2013.14.3.125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042870","Series: Cardiovascular outcome trials for diabetes drugs.","Miles Fisher","2022","British Journal of Diabetes","other_trial","article","10.15277/bjd.2022.387",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0042871","Anthropometric, metabolic parameters and cognitive functions investigation in patients with obesity treated with liraglutide 3 mg","Ю. Г. Самойлова","2022","Endocrinology News Opinions Training","other","article","10.33029/2304-9529-2022-11-4-21-25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042872","Efikasi Liraglutide Dalam Tatalaksana Obesitas Pada Pasien Dewasa Diabetik dan Non-Diabetik","Arya Adi Bramasta","2024","Malahayati Nursing Journal","other","article","10.33024/mnj.v6i2.12883",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042873","EFEITOS DO USO DO OZEMPIC (SEMAGLUTIDA) NO TRATAMENTO DA OBESIDADE","Karine Rodrigues da Silva Neumann","2023","Revista Multidisciplinar do Nordeste Mineiro","other","article","10.61164/rmnm.v13i1.1849",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042874","PDX-1/VP16 Overexpression Induce the Transdifferentiation of Canine Adult Pancreatic Cells into Beta-cells","Young‐Hye You","2007","The Journal of Korean Diabetes Association","preclinical","article","10.4093/jkda.2007.31.1.51",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042875","Association Between Exercise and Treatment with Liraglutide in Obese Rats by Cafeteria Diet","Daiane Didek","2019","Brazilian Archives of Biology and Technology","preclinical","article","10.1590/1678-4324-2019180563",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042876","Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes(審査報告)","久美子 田中",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042877","Kombinasi Insulin Basal dengan GLP-1 RA dalam FRC (iGlarLixi) terhadap Pencapaian Target DM tipe 2","Maria Cecilia Gritce Widjaja","2022","Jurnal Health Sains","other","article","10.46799/jhs.v3i3.440",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042878","Perioperative liraglutide therapy for orthopedic patients with T2DM","Shizuka Kaneko","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.p478",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042879","Liraglutid: wirksam bei Typ-2-Diabetikern unter hohen Insulindosen?","Antoine de Torrenté","2016","Swiss Medical Forum ‒ Schweizerisches Medizin-Forum","other","article","10.4414/smf.2016.02749",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042880","Prescribing patterns of antidiabetic drugs and glycaemic control in type 2 diabetes patients visiting tertiary care hospital based in Karachi, Pakistan","Asifa Jamali","2023","International Journal of Community Medicine and Public Health","nonrandomized_study","article","10.18203/2394-6040.ijcmph20233433",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042881","NEW TREATMENTS FOR OBESITY: DOUBLE AGONIST TWO GIP/ GLP-1 RECEPTORS – TIRZEPATIDE","Gabrielle Molina Pinto","2024","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.1594122423011",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042882","A Comparative Study of the Use of Ferric Chelate in Iron-Deficiency Anaemia","C.F. Herridge","1958","BMJ","other","article","10.1136/bmj.2.5089.140","13560807",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042883","Exenatide and Pioglitazone Regulate Fatty Acid-Induced Gene Expression in Normal and Diabetic Human Islets","Hamedeh G hanaat-Pour","2011","Journal of Postgenomics Drug & Biomarker Development","other","article","10.4172/2153-0769.1000102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042884","Recent Advances in Anti-Obesity Drugs","Jang Won Son","2022","Journal of Korean Diabetes","other","article","10.4093/jkd.2022.23.2.113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042885","Diabetes care in general practice 25 years on: key developments and the future","PRW Tasker","2009","Practical Diabetes","other_trial","article","10.1002/pdi.1395",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042886","Drug Review: Tirzepatide","Juman Alsaab","2023","Pharmacology Toxicology and Biomedical Reports","narrative_review","article","10.5530/ptb.2023.9.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042887","Transactions of The Showa University Society: The 340th Meeting",null,"2017","The Showa University Journal of Medical Sciences","other_trial","article","10.15369/sujms.29.457",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042888","Glucagon-like Peptide-1 Receptor Agonist for Diabetic Retinopathy: Friend or Foe?","Tan Huiwen","2023","JOJ Ophthalmology","other","article","10.19080/jojo.2023.10.555789",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042889","The Valve as Boundary: Rheumatic Mitral Valve Disease as a Stasis-Acidosis-Proteinopathy Cascade Under the Brain's Defensive Decree","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22537257",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0042890","Diagnosis and treatment of pediatric type 2 diabetes mellitus","Hae Sang Lee","2021","Journal of Korean Medical Association","other","article","10.5124/jkma.2021.64.6.432",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042891","Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Like Agonist, Exendin-4-Fc","Wen Zhang","2021","International Journal of Peptide Research and Therapeutics","preclinical","article","10.1007/s10989-021-10269-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042892","Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity.","Kamil Pondel","2022","Journal of Education Health and Sport","other","article","10.12775/jehs.2022.12.09.007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042893","Experience of the Glucagon-like Peptide-1 (GLP-1) Agonist for the Treatment of Short Bowel Syndrome","Jia Ryu","2012","JOURNAL OF ACUTE CARE SURGERY","other","article","10.17479/jacs.2012.2.1.11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042894","Cytotoxicity and Biological Efficacy of Exendin‐4‐Encapsulated Solid Lipid Nanoparticles in INS‐1 Cells","Hee‐Sook Jun","2015","Journal of Nanomaterials","preclinical","article","10.1155/2015/753569",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042895","Impact of Pharmacist Insulin Management on Hemoglobin A1c in Outpatient Hospital Clinic Setting","Danette Warner","2016","Journal of Pharmacy and Pharmacology","other","article","10.17265/2328-2150/2016.07.010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042896","The effect of modern hypoglycemic therapy on the course of chronic kidney disease in patients with type 2 diabetes mellitus","V.I. Katerenchuk","2021","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","other","article","10.22141/2224-0721.17.8.2021.246795",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042897","Estimating The Societal Costs Associated With Glp-1ras In The United States For The Treatment of Type 2 Diabetes","B.C. Wang","2016","Value in Health","other","article","10.1016/j.jval.2016.03.053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042898","Effetti dei nuovi farmaci incretinici sulla salute dell’osso","Gian Pio Sorice","2024","L Endocrinologo","other","article","10.1007/s40619-024-01436-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042899","Recent News in Medical Nutrition Therapy",null,"2021",null,"other","article","10.31038/nrfsj.2021423",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042900","A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes","Elvira Meni Maria Gkrinia","2023","Diabetology","systematic_review","article","10.3390/diabetology4040038",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042901","Diagnosis and treatment of metabolic-associated fatty liver disease in patients with type 2 diabetes mellitus. Review","Sergey Tkach","2023","Clinical endocrinology and endocrine surgery","narrative_review","article","10.30978/cees-2023-3-62",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042902","Bleeding gastric erosion after oral zinc sulphate.","Rebecca R. Moore","1978","BMJ","other_trial","article","10.1136/bmj.1.6115.754","147123",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042903","revisão sistemática e metanálise sobre os eventos adversos gastrointestinais em adultos durante o tratamento de obesidade com Wegovy","Lailton Oliveira da Silva","2024","Nutrivisa Revista de Nutrição e Vigilância em Saúde","other","article","10.59171/nutrivisa-2024v11e12293",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042904","GLP-1 receptor agonists: evolution and advancement in the treatment of type 2 diabetes mellitus","Renata Russo Frasca Candido","2021","The Journal of AMD","other","article","10.36171/jamd21.24.2.4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042905","Changes in the parameters of a clinical blood test in rats using hypoglycemic agents for the potentiation of drugs with a hepatoprotective effect","FSFEI HE SPBSUVM, Russia","2023",null,"preclinical","article","10.52419/3006-2023-11-28-34",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042906","Implementation of the American Diabetes Association Pharmacological Approach for Adults with Type 2 Diabetes Mellitus with Cardiovascular Disease","José Luis Cedillo","2023",null,"other","article","10.22371/07.2023.030",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042907","Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review","Amedeo Lonardo","2024","Metabolism and Target Organ Damage","narrative_review","article","10.20517/mtod.2024.07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0042908","New treatment options for glucose control in type 2 diabetes: an opportunity for individualised therapy is now possible","Ken Shaw","2009","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1365",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042909","Neue Therapieform Basalinsulin plus GLP-1-Analogon in einem Pen – Typ-2-Diabetes: Wenn Basalinsulin mit oralen Antidiabetika nicht mehr ausreicht",null,"2015","Diabetes aktuell","other","article","10.1055/s-0034-1398418",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042910","Incretin-Based Treatment Strategy - GLP-1 Receptor Agonists (GLP-1R) or So-Called Incretin Mimetics","Jindra Perušičová","2011","InTech eBooks","other","article","10.5772/21873",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0042911","Semaglutide (Rybelsus)","Reimbursement Team","2021","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2021.91",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042912","Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?","Bob Ryder","2017","British Journal of Diabetes","other","article","10.15277/bjd.2017.147",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042913","Acute Pancreatitis; New Methods for Understanding an Old Problem","Gülali Aktaş","2022","National Journal of Health Sciences","other","article","10.21089/njhs.63.0090",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042914","OS IMPACTOS DO USO INDISCRIMINADO DO OZEMPIC: CONSEQUÊNCIAS PARA A SAÚDE PÚBLICA E O MERCADO DE MEDICAMENTOS ESTÉTICOS","Ana Oliveira","2025","Revista Saúde dos Vales","other","article","10.61164/h2438r24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042915","Therapeutic Targets of Type 2 Diabetes: an Overview","Sofia Banu","2017","MOJ Drug Design Development & Therapy","other","article","10.15406/mojddt.2017.01.00011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042916","Technological and Therapeutic Approaches to Type 2 Diabetes Management","Rekha Krishnan","2023","International Journal of Health Sciences and Research","other","article","10.52403/ijhsr.20230320",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042917","Pharmacologic treatment of obesity","Han Na Jung","2022","Journal of Korean Medical Association","other_trial","article","10.5124/jkma.2022.65.7.408",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042918","Semaglutida e Ganho ponderal","Felipe Passareli Diniz","2026","Revista fisio&terapia.","randomized_trial","article","10.69849/5rhepr42",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042919","Effect of Lixisenatide (Short-acting Glucagon-Like Peptide 1 Receptor Agonist) as an Add-on to Insulin in Lowering HbA1C among Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis","Ashwaq Ali Abusalem","2023","World Family Medicine Journal/Middle East Journal of Family Medicine","systematic_review","article","10.5742/mewfm.2023.95256162",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042920","Islets and Glucose Homeostasis","Tien‐Jyun Chang","2015","International Journal of Endocrinology","other","article","10.1155/2015/358460","25821466",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042921","First Fabulous Fifty – An Initial Experience of Dulaglutide from a Tertiary Care Centre in Eastern India",null,"2018",null,"nonrandomized_study","article","10.31038/edmj.2018244",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042922","Quality by Design driven development of Liraglutide loaded nanocarrier system designed for oral delivery","Ruba Ismail","2019",null,"other","article","10.14232/syrptbrs.2019.op18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042923","The cardiovascular benefits of GLP1-RA are directly related to their positive effect on glycaemic control: A meta-regression analysis","Samit Ghosal","2022",null,"other","article","10.37766/inplasy2022.1.0071",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0042924","NICE : type 2 diabetes in adults, 2015","Rowan Hillson","2016","Practical Diabetes","randomized_trial","article","10.1002/pdi.1989",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042925","Pharmacologic Weight Loss: An Underutilized Practice in the Fight Against Obesity","Megumi Howard","2021","Interventions in Obesity & Diabetes","randomized_trial","article","10.31031/iod.2021.04.000596",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042926","Jianpi Huashi Tongluo Recipe in the Treatment of Obesity Type 2 Diabetes Mellitus Caused by Damp-heat Trapped Spleen",null,"2022","Journal of Contemporary Medical Practice","other","article","10.53469/jcmp.2022.04(02).16",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042927","SP044ROLE OF GLUCAGON LIKE PEPTIDE-1 IN EXPERIMENTAL GLOMERULONEPHRITIS","Foteini Moschovaki Filippidou","2016","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfw157.05",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0042928","Albiglutide","J. Rosenstock","2010","Drugs of the Future","other","article","10.1358/dof.2010.35.9.1516042",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042929","Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction","Tim Kambič","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad856","38190431",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042930","Benefits of GLP-1 Agonist",null,"2023","DHR Proceedings","other","article","10.47488/dhrp.v3is2.96",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042931","Transdifferentiation of Enteroendocrine K-cells into Insulin-expressing Cells","Esder Lee","2009","Korean Diabetes Journal","preclinical","article","10.4093/kdj.2009.33.6.475",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042932","Quality by design driven development of polymeric and lipid-based nanocarriers as potential systems for oral delivery of glp-1 analogues","Ruba Ismail","2020",null,"other","article","10.14232/phd.10468",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0042933","Glucagon-Like Peptide-1 Receptor Agonist Effects on Gastric Motility: A Systematic Review","Nicha Wongjarupong","2020","Diabetes & its Complications","systematic_review","article","10.33425/2639-9326.1076",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0042934","Reduction of Recurrent Severe Hypoglycemia and Hypoglycemia Unawareness in Type 2 Diabetes by Treatment Modification and Diabetes Education","José G. Jiménez-Montero","2020","Diabetes & its Complications","other","article","10.33425/2639-9326.1068",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042935","Manejo de la enfermedad hepática metabólica grasa","A Lucena","2020","Revista Andaluza de Patología Digestiva","other","article","10.37352/2020432.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042936","Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)","Ebrahim Abbasi Oshaghi","2017","Avicenna Journal of Medical Biochemistry","other","article","10.15171/ajmb.2017.10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042937","GLP-1-Mimetika — wegweisend zur Behandlung von Diabetes und Adipositas","Kerstin Stemmer","2023","BIOspektrum","other","article","10.1007/s12268-023-1919-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042938","Tirzepatide Reduced Significantly the Body Weight in Obese Patients","László Gerő","2022","Current Research in Diabetes & Obesity Journal","other_trial","article","10.19080/crdoj.2022.16.555930",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042939","THE EFFICACY AND SAFETY OF SAXENDA INJECTION FOR WEIGHT LOSS","Mohammed Saad Mohammed Alqahtani","2022","European Chemical Bulletin","other_trial","article","10.53555/ecb/2022.11.11.149",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042940","Eficácia terapêutica do exenatide no tratamento da doença de Parkinson","André Luiz de Lima Nascimento Alcântara","2023","Revista de Ciências Médicas e Biológicas","other","article","10.9771/cmbio.v22i2.52661",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042941","DOI 10.1186/s13098-015-0116-2",null,"2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0042942","Metabolic Acidosis – Not Always the Medication to Blame","Mohammed Yousef Al Mulhim","2020","The Egyptian Journal of Hospital Medicine","other","article","10.21608/ejhm.2020.107571",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042943","GLP-1 receptor expression in human internal thoracic arteries is dependent on low-grade inflammation potentially explaining the cardiovascular protective effect of GLP1-R agonists","Elena‐Mihaela Cordeanu","2022","European Heart Journal","other","article","10.1093/eurheartj/ehac544.3086",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042944","If drugs with metabolic action affect the intestinal microbiota. Literature review","G. D. Fadieienko","2022","Modern Gastroenterology","narrative_review","article","10.30978/mg-2022-1-37",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042945","Science, Medicine, and the Anesthesiologist",null,"2023","Anesthesiology","randomized_trial","article","10.1097/aln.0000000000004792",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042946","GLP-1 and GIP receptors co-agonists","Elise Bernard","2018","Proceedings of the 35th European Peptide Symposium","other","article","10.17952/35eps.2018.244",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0042947","The Effect of Semaglutide on Glycolipid Metabolism in Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease","Ding Li","2022","Indian Journal of Pharmaceutical Sciences","other","article","10.36468/pharmaceutical-sciences.spl.549",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042948","Diabetes mellitus y su manejo en escenarios difíciles","Diana Cristina Varela","2023","Ciencia y Salud","other","article","10.22206/cysa.2023.v7i2.pp31-40",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042949","Impact of gut microbiota on the central nervous system relevance in neurodegenerative and psychiatric diseases","Oksana Zatorska","2024","Current Problems of Psychiatry","nonrandomized_study","article","10.12923/2353-8627/2024-0022",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042950","Abstract 4343038: Effects of cardiac rehabilitation on body composition changes in patients receiving GLP-1 receptor agonists","Tara Shahrvini","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4343038",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0042951","Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist","Inkuk Lee","2019","Journal of Korean Diabetes","other","article","10.4093/jkd.2019.20.3.149",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042952","The potential of β‐cell growth promotion, continued","Zachary T. Bloomgarden","2023","Journal of Diabetes","other_trial","article","10.1111/1753-0407.13396","37102341",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042953","Impact of Diabetes on Heart","Zoya Zabeen -","2024","International Journal For Multidisciplinary Research","other","article","10.36948/ijfmr.2024.v06i01.14123",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042954","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97577-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0042955","Semaglutide for Type 2 Diabetes (2 mg)","Deepa Jahagirdar","2023","Canadian Journal of Health Technologies","randomized_trial","article","10.51731/cjht.2023.752",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042956","Assessment of myocardial perfusion with SPECT in obese patients with high and very high cardiovascular risk during GLP-1 receptor agonists therapy, preliminary results","P. Rezinkina","2023","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2023.06.382",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042957","A Study on Enhancing Pancreatic Islet Function in Type 2 Diabetes and Coronary Heart Disease Patients with Liraglutide and Metformin Combination Therapy","Chunxiao Yang","2023","Proceedings of Anticancer Research","randomized_trial","article","10.26689/par.v7i6.5566",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042958","Incretin as a Pathophysiological Component and Target for Treatment in Youth Type 2 Diabetes (T2D)","Jordan Jacob","2020","Journal of Health Sports and Kinesiology","other_trial","article","10.47544/johsk.2020.1.1.24",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0042959","Clinical and basic studies of GLP-1 receptor agonists for the treatment of diabetes in China","Tianpei Hong","2018","Scientia Sinica Vitae","other","article","10.1360/n052018-00030",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042960","Semaglutide (Wegovy)","CADTH","2022","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2022.463",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042961","Pharmacy Cost Differences Associated with the Initiation of Exenatide Once-Weekly Compared to Liraglutide Once-Daily","AM Loughlin","2015","Value in Health","other","article","10.1016/j.jval.2015.09.2068",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042962","¿Qué tan útiles en la práctica diaria para los nefrólogos son los nuevos antidiabéticos con protección cardiovascular?","Iván Villegas Gutiérrez","2017","Revista Colombiana de Nefrología","other","article","10.22265/acnef.4.1.265",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042963",null,"田中 章郎","2011","Nihon Toseki Igakkai Zasshi","other","article","10.4009/jsdt.45.120",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042964","Histopathological Study of Liraglutide on Renal Deterioration Progression Induced by Doxorubicin","Hayder Hussein Luaibi","2019","Al Mustansiriyah Journal of Pharmaceutical Sciences","preclinical","article","10.32947/ajps.19.04.0422",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042965","Remarkable improvement and weight reduction in obese diabetic patient by continuation of super low carbohydrate diet (LCD)","Hiroshi Bando","2020","Advances in Obesity Weight Management & Control","other","article","10.15406/aowmc.2020.10.00303",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042966","Liraglutide as an innovative and multifunctional drug for patients with obesity – the current state of knowledge and future prospects","Maria Grodkiewicz","2022","Journal of Education Health and Sport","other","article","10.12775/jehs.2023.13.01.024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042967","Dulaglutide‑pharmacological profile","Alena Adamíková","2019","Interní medicína pro praxi","other","article","10.36290/int.2019.011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042968","Antidiabetic Medications and the Risk of Prostate Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis","Haiying Cui","2020",null,"systematic_review","article","10.37766/inplasy2020.6.0113",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0042969","Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER","Miles Fisher","2020","British Journal of Diabetes","other_trial","article","10.15277/bjd.2020.267",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0042970","Analogues du GLP-1 et modification des comportements alimentaires : une rupture pour l'industrie agroalimentaire et les industries de santé ?","Nathan Benmergui","2026","INRIA a CCSD electronic archive server","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0042971","Liraglutide for the treatment of obesity","Elmien Bronkhorst","2016","South African Family Practice","other","article","10.4102/safp.v58i3.4496",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042972","548 ROLE OF NEW ANTIDIABETIC DRUGS IN THE PREVENTION OF CONTRAST-INDUCED NEPHROPATHY IN DIABETIC PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION","Federico Bernardini","2022","European Heart Journal Supplements","randomized_trial","article","10.1093/eurheartjsupp/suac121.499",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042973","Spring 2007 Meeting of the Association of British Clinical Diabetologists","J Wore","2007","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1170",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042974","Highlights",null,"2018","JAMA Internal Medicine","randomized_trial","article","10.1001/jamainternmed.2017.5229",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042975","Update on technologies, medicines and treatments","Simon O’Neill","2022","Diabetic Medicine","randomized_trial","article","10.1111/dme.15004",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0042976","Einziges GLP-1-Analogon mit 6-Jahres-Daten – Neuer Pen vereinfacht Anwendung",null,"2015","Diabetes aktuell","other","article","10.1055/s-0035-1547494",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042977","Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives?","Robert E. J. Ryder","2020","British Journal of Diabetes","other","article","10.15277/bjd.2020.250",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042978","Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus","Seung-Hyun Ko","2019","Journal of Korean Diabetes","other","article","10.4093/jkd.2019.20.3.142",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042979","Effect of Liraglutide 3.0mg 3.0 on Body Weight & Quality of Life Among Patients With Obesity Disease at King Fahad Medical City Retrospective Study","Al Amri K","2021","Advances in Nutrition and food science","nonrandomized_study","article","10.37722/anafs.2021102",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042980","Hepatotoxicity Secondary to A Drug to Lose Weight, \"Orlistat\": to take into Account as a Differential Diagnosis","Nancy Yaneth Angulo Castaneda","2020","Scholars Academic Journal of Pharmacy","other","article","10.36347/sajp.2020.v09i02.007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042981","Is Tirzepatide the New Game Changer in Type 2 Diabetes?","Giuseppe Lisco","2024","Endocrines","other","article","10.3390/endocrines5010005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042982","Recent Progression of Incretin-Based Obesity Treatment","Dughyun Choi","2024","Korean Journal of Medicine","other","article","10.3904/kjm.2024.99.2.78",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042983","Hot off the press: Insight to the cardioprotective effects of GLP-1 (glucagon-like peptide-1) analog liraglutide",null,"2022","Hypertension News","other","article","10.30824/2204-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042984","Steatosi epatica non alcolica: non sempre una condizione benigna","Stefano Ciardullo, Gianluca Perseghin","2021","il Diabete","other","article","10.30682/ildia2102g",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042985","Semaglutide: de la moda a la evidencia científica. A propósito de una Revisión Narrativa","Elvio Bueno","2024","Anales de la Facultad de Ciencias Médicas (Asunción)","other","article","10.18004/anales/2024.057.03.102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042986","Therapeutics Letter 140","Therapeutics Initiative (University of British Columbia)","2022","cIRcle (University of British Columbia)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042987","Terapie innovative per il diabete: effetti sul rischio di scompenso cardiovascolare nel paziente non diabetico","Angelo Avogaro","2022","il Diabete","other","article","10.30682/ildia2203a",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042988","The urgency to treat optimally and to target: Avoiding long-term complications in type 2 diabetes with a focus on GLP-1 receptor agonists","Lionel Noronha","2023","Canadian Primary Care Today","other","article","10.58931/cpct.2023.1s0717",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042989","Residual lipidic risk beyond low-density lipoprotein cholesterol: new challenges and opportunities","Filippo Crea","2023","European Heart Journal","other","article","10.1093/eurheartj/ehad671","37837659",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042990","SEMAGLUTIDE (RYBELSUS) AND LOSING WEIGHT","Hassan Mohsen Alalasi","2022",null,"other","article","10.53555/jptcp.v29i02.4506",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042991","The impact of liraglutide treatment on erectile function of the diabetic rats","Serkan Gönültaş","2023","The European Research Journal","preclinical","article","10.18621/eurj.1140921",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042992","Liraglutide (Saxenda)","Reimbursement Team","2021","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2021.226",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042993","THE ROLE OF PHARMACISTS IN MANAGING GESTATIONAL DIABETES MELLITUS: A DESCRIPTIVE REVIEW","Rashid Ali","2024",null,"narrative_review","article","10.53555/jptcp.v31i3.5030",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042994","„Glucagon-like peptide‑1“(GLP‑1)-Rezeptor-Agonisten – die neuen Wunderwaffen in der Adipositastherapie?","Dirk Raddatz","2023","Journal für Gastroenterologische und Hepatologische Erkrankungen","other","article","10.1007/s41971-023-00170-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042995","Semaglutide (Wegovy)","CADTH","2022","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2022.524",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042996","Anti-cancer effects of sitagliptin, vildagliptin, and exendin-4 on triple-negative breast cancer cells via mitochondrial modulation","Pooja Jaiswal","2022","Biocell","preclinical","article","10.32604/biocell.2022.021754",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042997","Semaglutide for the treatment of obesity","Rafał Oleszczuk","2022","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2022.12.08.095",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0042998","A Nanocarrier Approach for Oral Peptide Delivery: Evaluation of Cell‐Penetrating‐Peptide‐Modified Liposomal Formulations in Dogs","Philipp Uhl","2023","Advanced Therapeutics","other","article","10.1002/adtp.202300021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0042999","Exendin-4 improves glucose metabolism in insulin-resistant cells by upregulating the phosphorylative AMPK","Jian Li","2019","Journal of Advances in Health","other","article","10.3724/sp.j.2640-8686.2019.0126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043000","Association between intensity of glycemic control with GLP-1 receptor agonists and risk of atherosclerotic cardiovascular disease: a systematic review and meta-regression","D Gomes","2023","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehad655.2542",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0043001","Pharmacotherapy in obesity: the current state and the near future","Yoon Jeong Cho","2022","Journal of Korean Medical Association","other","article","10.5124/jkma.2022.65.8.514",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043002","A Novel Use of Liraglutide: Induction of Partial Remission in Ulcerative Colitis and Ankylosing Spondylitis","L. Osborn Jeffrey","2019","Clinical Medical Reviews and Case Reports","other","article","10.23937/2378-3656/1410281",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043003","Diabetes and Incretin-based Therapy","Mark E. Molitch","2007","The Journal of Clinical Endocrinology & Metabolism","other","article","10.1210/jcem.92.4.9998",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043004","PROTECTIVE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 VIA CAMP/PKA/RHO DEPENDENT PATHWAY ON CARDIAC MICROVESSELS INJURY IN DIABETES MELLITUS","Dongjuan Wang","2012","Heart","randomized_trial","article","10.1136/heartjnl-2012-302920a.1",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043005","Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy","Edoardo Mannucci","2022","Farmeconomia Health economics and therapeutic pathways","nonrandomized_study","article","10.7175/fe.v23i1.1539",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043006","On the prognostic value of post-load glucose in patients with coronary artery disease","Lars Rydén","2018","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehy320","29893842",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0043007","Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist","Hae Jin Kim","2021","Journal of Korean Diabetes","randomized_trial","article","10.4093/jkd.2021.22.2.126",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043008","Diabetes with hypertension in China: current status of epidemiology and management","Hongbo He","2018","Scientia Sinica Vitae","other","article","10.1360/n052018-00044",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043009","IS EXENATIDE REALLY LINKED TO ACUTE PANCREATITIS: A NOVEL ANALYTIC EXAMINATION?","J. Chen","2016","Value in Health","other","article","10.1016/j.jval.2016.03.1815",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043010","Gottfried was sollen wir tun","Martina Huber","2023","Bulletin des Médecins Suisses","other","article","10.4414/saez.2023.21569",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043011","The next generation of venom‐based drugs","Mark Greener","2020","Prescriber","other","article","10.1002/psb.1837",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043012","Diabetes medications with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 receptor agonists complement each other to save lives by different mechanisms?","Bob Ryder","2019","British Journal of Diabetes","other","article","10.15277/bjd.2019.207",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043013","New drugs: Liraglutide",null,"2012","Australian Prescriber","other","article","10.18773/austprescr.2012.075",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043014","2021 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk","Min Kyong Moon","2021","Journal of Korean Diabetes","other","article","10.4093/jkd.2021.22.4.259",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043015","Latest Development of Administration Routes for Anti-Diabetic Agents using Insulin Nanoparticles (NPs)","Hiroshi Bando","2023","Asploro Journal of Biomedical and Clinical Case Reports","other","article","10.36502/2022/asjbccr.6280",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043016","Effects of Glucagon-Like Peptide-1 Receptor Agonists on β-Cell Function in Patients with Type 2 Diabetes","Susan Grandy","2015","Journal of Diabetes & Metabolism","randomized_trial","article","10.4172/2155-6156.1000643",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043017","Cost-effectiveness of metabolic and bariatric surgery versus contemporary medical therapy for adults with type 2 diabetes and obesity in China: a multicentre target-trial-emulation and microsimulation study protocol","Qiu-jing Song","2026","Open Science Framework","protocol","article","10.17605/osf.io/tnbkz",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0043018","Pharmacological management of obesity: a comprehensive narrative review of diagnostic classification, incretin-based and legacy drug therapy, and landmark trial evidence","Mosrur Ahmed","2025","Journal of Prevention Diagnosis and Management of Human Diseases","randomized_trial","article","10.55529/jpdmhd.52.68.79",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0043019","Neue Antidiabetika – Neuer GLP-1-Agonist für mehr Lebensqualität",null,"2015","Diabetes aktuell","other","article","10.1055/s-0035-1563641",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043020","Editorial: Association of metabolic diseases with cognition impairment and dementia","Sisi Luan","2023","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2023.1166342","36967747",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0043021","Impact of adding semaglutide in a person with type 1 diabetes: A case report","Daniela Sofrà","2019","Diabetes Updates","case_report","article","10.15761/du.1000128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043022","ROLE OF THIAZOLIDINEDIONES (TZDs) AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS AND ANTAGONOSTS IN TYPE-II DIABETES MELLITUS ON ADULT MALE ALBINO RATS","Nageh Mabrouk Gabr","2018","Al-Azhar Medical Journal","preclinical","article","10.12816/0052811",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043023","Is the excess of serious biliary events with incretin-based therapies determined by the magnitude of weight loss rather than by drug identity? A network meta-analysis and dose–response meta-regression of individually enumerated adverse events from mandated trial-registry reporting","XIAO MA","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/b4ufj",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0043024","#4581 EVALUATION OF THE BENEFICIAL EFFECTS OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONIST ON TOP OF RAS BLOCKADE IN EXPERIMENTAL DIABETIC NEPHROPATHY","Conxita Jacobs Cachá","2023","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfad063c_4581",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043025","Overview of Type 2 Diabetes Drugs on the Market","Yuxi Hu","2020","Journal of Biosciences and Medicines","other","article","10.4236/jbm.2020.88001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043026","EE79 A Cost of Control Analysis of Once-Weekly Subcutaneous Semaglutide Versus Dulaglutide for Bringing Patients to Treatment Targets in China","R Zhen","2022","Value in Health","other","article","10.1016/j.jval.2022.04.333",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043027","Poster Abstracts",null,"2017","Fundamental and Clinical Pharmacology","other","article","10.1111/fcp.12273",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043028","Food Noise, Intrusive Thoughts, and Depression - Improvement on Tirzepatide: A Case Report",null,"2026","International Journal of Biomedicine","case_report","article","10.21103/article16(3)_cr5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043029","2023 European Pediatric Hypertension Guidelines: has anything changed?","Carissa M. Baker‐Smith","2023","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfad207","37708051",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0043030","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97576-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043031","Celecoxib/diphenhydramine/semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-86758-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043032","Clinical care and other categories posters: Incretin therapies",null,"2019","Diabetic Medicine","randomized_trial","article","10.1111/dme.31_13883",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043033","HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial","Manal F. Abdelmalek","2020","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(20)30765-0",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043034","Establishment of a GFP Fluorescence Labeled GLP-1 Receptor Cell Line","Mingrui Li","2015","Advances in engineering research/Advances in Engineering Research","preclinical","article","10.2991/iea-15.2015.170",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0043035","2057-LB: Amino Acids Plasma Levels Do Not Correlate with Lean Mass Loss in Weight-Matched DIO Mice Treated with Survodutide or Semaglutide","KATARINA KLEPAC-BARTL","2024","Diabetes","preclinical","article","10.2337/db24-2057-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043036","Victime de son succs","Martina Huber","2023","Bulletin des Médecins Suisses","other","article","10.4414/bms.2023.21569",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043037","New Anti‐Hyperglycaemic Medications and the Risk of Dementia: A Nationwide Population‐Based Study","Avi Cohen","2023","Alzheimer s & Dementia","nonrandomized_study","article","10.1002/alz.076217",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043038","OSTEOCALCIN ROLE IN THE REGULATION OF INSULIN SECRETION AND OSTEOTROPIC EFFECTS OF DIFFERENT CLASSES OF ANTI-DIABETIC DRUGS (LITERATURE REVIEW AND OWN RESEARCH)","Алла Ковальчук","2022","World Science","narrative_review","article","10.31435/rsglobal_ws/30042022/7803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043039","Developments in diabetes management for older people 1991–2023","Tilenka Thynne","2023","Journal of Pharmacy Practice and Research","nonrandomized_study","article","10.1002/jppr.1908",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043040","Are Incretin Receptor Agonists Psychiatric Drugs: Near-term Opportunity or Creative Superlative?","Roger McIntyre","2026","Psychiatry and Clinical Psychopharmacology","other_trial","article","10.65801/pcp.3528",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043041","Consensus 2021 for medical management of type 2 diabetes from the diabetes, obesity, and nutrition working group of the Spanish Society of Internal Medicine","Francisco J. Carrasco-S�nchez","2021","Spanish Journal of Medicine","other","article","10.24875/sjmed.21000010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043042","Trends in initiation of GLP-1 RA in patients with type 2 diabetes during 2014–2019: a US database study","Mikhail Kosiborod","2021","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehab724.2957",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043043","Comparing Two Medications Used in Primary Care Management of Obesity","J Julanta Leela Rachel","2022","Journal of Obesity and Weight-loss Medication","other","article","10.23937/2572-4010.1510043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043044","TRPV1, PPAR and SGLT-2 as a Potential Therapeutic Target for Diabetes Mellitus: Current Status and Challenges","M Luisetto","2021","Pharmaceutical and Biosciences Journal","other","article","10.20510/10.20510/pbj/9/i5/1650",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043045","Diabetes & Ramadan (DaR) Workshop in Turkey","Binnur Okan Bakır","2014","Journal of Nutritional Disorders & Therapy","other","article","10.4172/2161-0509.1000e116",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043046","Glucagon-like Peptide 1 Receptor Agonists for the Treatment of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials","Bander J. Alshehri","2023","Journal of Pharmaceutical Research International","systematic_review","article","10.9734/jpri/2023/v35i127361",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043047","A review on recent trends of diabetes mellitus","Thirupathi Reddy A","2022","Journal of Innovations in Applied Pharmaceutical Science (JIAPS)","narrative_review","article","10.37022/jiaps.v7i1.258",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043048","No ‘easy’ weight loss: don’t overlook the social cost of anti-obesity drugs","Alexandra Brewis","2024","Nature","other","article","10.1038/d41586-024-00329-9","38321134",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043049","Comparative Effectiveness of Dulaglutide Versus Iiraglutide in Asian type 2 Diabetes Patients: A Multi-Institutional Cohort Study and Meta-Analysis","Kai-Cheng Chang","2020","Research Square","systematic_review","article","10.21203/rs.3.rs-48852/v1",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","preprint"],["R0043050","The glucagon-like peptide-1 receptor--or not?","Pyke C","2013","Endocrinology","preclinical","article","10.1210/en.2012-2124","23267050",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","News; article"],["R0043051","Patient analysis and case-control investigation for high-output ileostomy control with glucagon (PACIFHIC-G) like peptide-1 analogues: a case control study","Agustín Castro-Segovia","2023","International Journal of Research in Medical Sciences","nonrandomized_study","article","10.18203/2320-6012.ijrms20233162",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043052","Letter to the Editor: “GLP-1 Receptor Expression Within the Human Heart”","Gianluca Iacobellis","2018","Endocrinology","commentary","article","10.1210/en.2018-00196","29554319",null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0043053","Efficacy, Safety and Clinical Implications of GLP-1 Receptor Agonists for Chronic Weight Management in Patients with or Without Type 2 Diabetes","Karthika A.*1, Karthikeyan M.1, Santhosh S.1, Praveenkumar A.2, V. S. Saravanan3","2026","International Journal of Medical & Pharmaceutical Sciences","other","article","10.5281/zenodo.22647817",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043054","Safety of Anti-Obesity Drugs Approved for Long-Term Use","Kyoung Kon Kim","2015","The Korean Journal of Obesity","other","article","10.7570/kjo.2015.24.1.17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043055","Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial","Hannon TS","2026","Yearbook of pediatric endocrinology","randomized_trial","article","10.1530/ey.23.12.5",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043056","Comparative Study of Incretin Versus Non- Incretin Based Therapies on Type 2 Diabetes Patients in Addis Ababa, Ethiopia","Alias Tesfamariam","2018","Advances in Biochemistry","other","article","10.11648/j.ab.20180602.11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043057","IMPACT OF SEMAGLUTIDE ON GLYCEMIC CONTROL AND POST-PRANDIAL GLUCOSE REDUCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Vitor Piassi","2023","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.1593462328062",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043058","Erratum",null,"2020","Bioanalysis","other","article","10.4155/bio-2018-0322e1","32101061",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0043059","Functional Imaging of Neuroendocrine Tumors: Stacking the Odds in a Patient’s Favor","Karel Pacák","2022","The Journal of Clinical Endocrinology & Metabolism","preclinical","article","10.1210/clinem/dgac298","35536703",null,"ClinicalTrials.gov:NCT04023331; ClinicalTrials.gov:NCT03849105; ClinicalTrials.gov:NCT03044977",null,"openalex","TRUE",null,null,"FALSE","article"],["R0043060","Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","Magdalena Mazurek","2023","Journal of Education Health and Sport","other","article","10.12775/jehs.2023.13.04.013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043061","Effect of probiotics and incretine mimeticss on the levels of glucagon-like peptide-1 in blood serum of patients with type 2 diabetes mellitus","К.О. Shyshkan-Shyshova","2021","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","other","article","10.22141/2224-0721.17.8.2021.246792",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043062","Effect of Liraglutide Regulating Phosphoinositide 3 Kinase/Protein Kinase B-ART Pathway on Myocardial Injury in Rats with Acute Myocardial Infarction","Lu Yu","2024","Indian Journal of Pharmaceutical Sciences","preclinical","article","10.36468/pharmaceutical-sciences.1301",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043063","Kardiovaskuläre Outcomedaten","Karl Filip","2017","Diabetes aktuell","other","article","10.1055/s-0042-123108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043064","Semaglutide, Tirzepatide and the Cardiologist: Weight-Directed Therapy as Cardiovascular Therapy","Nuria Ferrandis-Cabó","2024","Journal of Heart and Cardiovascular Science","other_trial","article","10.5281/zenodo.22365904",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0043065","An evaluation of the efficacy of therapeutic approaches to correcting the indices of the systems of coagulation and fibrinolysis, inflammation markers in patients with diabetes mellitus of type 2 with obesity","K. F. Kehiopulo","2013","Bukovinian Medical Herald","other","article","10.24061/2413-0737.xvii.2.66.2013.64",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043066","Human medicines European public assessment report (EPAR): Saxenda, liraglutide, Obesity,Overweight, Date of authorisation: 23/03/2015, Revision: 6, Status: Authorised",null,"2019","Case Medical Research","other","article","10.31525/cmr-12cc6fb",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043067","Long-Term Cost Utility Analysis Of Ideglira Versus Basal-Bolus Insulin Intensification Therapies In Patients With Type 2 Diabetes Inadequately Controlled On Basal Insulin In Spain","M. Prades","2016","Value in Health","other","article","10.1016/j.jval.2016.03.1712",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043068","Incretin Hormones and the Up-Regulation of Insulin Secretion in Insulin Resistance","Bo Åhrén","2012","The Journal of Clinical Endocrinology & Metabolism","other","article","10.1210/jc.2012-1420","22493308",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043069","Safety and Efficacy of Meglitinides in Combination with GLP-1 Analogues- A Case Series","Moulinath Banerjee","2017","Journal of Endocrinology and Thyroid Research","case_report","article","10.19080/jetr.2017.01.555559",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043070","Impact of Ozempic (Semaglutide) on Post-Cataract Surgery Complications in Diabetic Patients: A Retrospective Cohort Analysis","Ryan Lu","2026",null,"nonrandomized_study","article","10.13140/rg.2.2.14152.89600",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0043071","Review of Type 2 Diabetes Mellitus Treatment and Relation with Hemoglobin A1c in Diabetes Center- Dr. Sulaiman Al Habib Hospital, Dubai, UAE","Omar Dhaimat","2019","Biomedical Journal of Scientific & Technical Research","nonrandomized_study","article","10.26717/bjstr.2019.21.003578",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043072","Comments on Post‐pancreatitis diabetes mellitus is common in chronic pancreatitis and is associated with adverse outcomes: Authors' reply","Ana Dugic","2023","United European Gastroenterology Journal","nonrandomized_study","article","10.1002/ueg2.12378","36918521",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","letter"],["R0043073","\"Managing Obesity with Mounjaro: A Brief Literature Review\"","Radwa Clarissa Omar","2023","Biomedical Journal of Scientific & Technical Research","narrative_review","article","10.26717/bjstr.2023.52.008226",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043074","Liraglutide/sitagliptin/vildagliptin",null,"2016","Reactions Weekly","other","article","10.1007/s40278-016-13262-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043075","Sulfonylurea, an Update","Tae Nyun Kim","2021","Journal of Korean Diabetes","other","article","10.4093/jkd.2021.22.2.105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043076","Pharmakogenetik neuer Glukosespiegelsenker: eine Chance für die Präzisionsmedizin?","Anna-Therese Lehnich","2023","Die Diabetologie","other","article","10.1007/s11428-022-00993-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043077","Pharmacotherapy of Diabetes Mellitus Type 2: A Review on Various Hypoglycemics","Muhammad Khalid Khan","2022","Journal of Clinical and Nursing Research","narrative_review","article","10.26689/jcnr.v6i5.4169",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043078","Translation of heart failure with preserved ejection fraction: a tale of mice and men","Coenraad Withaar","2024",null,"preclinical","article","10.33612/diss.870705282",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043079","Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials","Marta Letizia Hribal","2011","Clinical Investigation","other_trial","article","10.4155/cli.10.26",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043080","Promotion of reproductive and metabolic health - current trends in the treatment and prevention of polycystic ovary syndrome in different periods of life","Joanna Smyczyńska","2021","Kwartalnik Naukowy Fides et Ratio","other","article","10.34766/fetr.v47i3.895",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043081","SUSTAIN program: klinikai eredmények","Zoltán Balogh","2019","Diabetologia Hungarica","other_trial","article","10.24121/dh.2019.s2.2",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043082","Pharmacological Advances to the Treatment of Obesity","Milton E Londono Lemos","2018","Journal of Childhood Obesity","other","article","10.21767/2572-5394.100043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043083","PDB25 COST-EFFECTIVENES OF REAL-WORLD USE OF GLP-1 RECEPTOR AGONISTS VERSUS OTHER GLUCOSE-LOWERING AGENTS IN TYPE 2 DIABETES","Chwen Yi Yang","2020","Value in Health","nonrandomized_study","article","10.1016/j.jval.2020.04.213",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043084","Obesity in Pediatric Transplant and the Use of Liraglutide","Daphney Kernizan","2022","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2022.01.1304",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043085","P3‐423: Liraglutide, a novel drug to treat type 2 diabetes, prevents the impairment of learning and hippocampal synaptic plasticity in an APP/PS‐1 mouse model of Alzheimer's disease","Christian Hölscher","2010","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2010.05.1966",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043086","A Smart Drug Delivery Silica Nanoparticles System for Diabetes Mellitus Disease Treatment","Dalia A Elaty","2019","Acta Scientific Pharmaceutical Sciences","other","article","10.31080/asps.2019.03.0444",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043087","6th Month Metabolic and Laboratory Findings of Our Patients Taking Exenatide","Hatice Özışık","2016","Turkiye Klinikleri Journal of Endocrinology","other","article","10.5336/endocrin.2016-52723",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043088","Oral Semaglutide: A Novel Oral Preparation of GLP-1 Receptor Agonist","Babu Priya Mohan","2021","International Journal of Diabetes and Clinical Research","other","article","10.23937/2377-3634/1410146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043089","P31-05 Safety Evaluation of GLP-1 Receptor Agonists in the Pediatric Population: A Multi-Method Disproportionality Analysis of Real-World Data from the FDA Adverse Event Monitoring System","H. Tezel-Yalcin","2026","Toxicology Letters","nonrandomized_study","article","10.1016/j.toxlet.2026.112858",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0043090","Temporary interruption and safe reinitiation of cardiometabolic medications during acute illness and peri-procedural fasting in adults: a scoping review of risk triggers, restart criteria, patient education and clinical responsibility","lingyan xu","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/u28qs",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0043091","Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines","Zachary T. Bloomgarden","2015","Journal of Diabetes","other","article","10.1111/1753-0407.12345","26431291",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043092","A Clinical Case study of a patient with Syndrome Z in Diacare, Diabetes Car e and Hormone Clinic, Ahmedabad","Vidisha Patel","2020","IP Journal of Nutrition Metabolism and Health Science","other","article","10.18231/j.ijnmhs.2020.013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043093","Liraglutide: The Latest Addition to Armamentarium of Antidiabetic Drugs","AK Dubey","1970","Health Renaissance","other","article","10.3126/hren.v8i2.4424",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043094","32 Nutritional assessment of diet quality and potential deficiencies in individuals using GLP-1 receptor agonist medications: a questionnaire study","Neetha Lobo","2026",null,"other","article","10.1136/lma-2026-bslm-10th.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0043095","Incretin Based Therapies in Type 2 Diabetes Mellitus","Uğur Alp Göksu","2017","Kafkas Journal of Medical Sciences","other","article","10.5505/kjms.2017.94830",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043096","2301-PUB: Efficacy of HbA1c Changes, Weight Changes, and Blood Pressure Changes in GLP-1RA Daily Treatment or GLP-1RA Weekly Treatment in Type 2 Diabetes","Xiaoling Cai","2019","Diabetes","other","article","10.2337/db19-2301-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043097","Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease","Sang Hoon Park","2014","Korean Journal of Medicine","randomized_trial","article","10.3904/kjm.2014.86.4.425",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043098","Novelties in the treatment of obesity","Pavol Holéczy","2019","Medicína pro praxi","other","article","10.36290/med.2019.058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043099","Protein chemical synthesis by serine and threonine ligation","Yinfeng Zhang","2014",null,"other","article","10.5353/th_b5295527",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043100","Cardiovascular Outcomes with Liraglutide: An Update following LEADER","RK Ghosh","2017","Open Access Journal of Cardiology","other_trial","article","10.23880/oajc-16000101",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043101","Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation","Maya J","2026","Yearbook of pediatric endocrinology","other","article","10.1530/ey.23.15.11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043102","Erste Praxiserfahrungen – GLP-1-Rezeptor-Agonist senkt wirksam den HbA1c-Wert",null,"2015","Diabetes aktuell","other","article","10.1055/s-0035-1556942",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043103","Incretin System: Recent Advances in Glucagon Like Peptide-1 and Dipeptidyl Peptidase-4 Inhibitors","Rameshwar Mahaseth","2015","Journal of Patan Academy of Health Sciences","other","article","10.3126/jpahs.v1i1.13015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043104","Beginning With Very Low Dose (0.2mg) Liraglutide in Indian Type 2 Diabetic Patients Appears Better Tolerated: Experience from Real Life Practice","Anirban Majumder","2017","Journal of Diabetes Metabolic Disorders & Control","other","article","10.15406/jdmdc.2017.04.00127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043105","Novel cardioprotective approaches in ischaemic heart disease","Gemma Vilahur","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae058","38445879",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043106","Quantitative Structural Mapping of Insulin Vesicle Maturation in Beta Cells","Aneesh Deshmukh","2023","Microscopy and Microanalysis","other","article","10.1093/micmic/ozad067.597","37613637",null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043107","Uso de análogos de GLP-1 no tratamento da obesidade: uma revisão narrativa / Use of GLP-1 analogues in treatment of obesity: a narrative review","Igor Martins Costa","2021","Brazilian Journal of Health Review","narrative_review","article","10.34119/bjhrv4n2-022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0043108","Observational Study on the Effectiveness of Treatment with the GLP1-Receptor Agonist Dulaglutide in Patients with Type 2 Diabetes Mellitus: Real-Life Study in Spain","Laura Oleaga","2022","Current Research in Diabetes & Obesity Journal","randomized_trial","article","10.19080/crdoj.2022.15.555918",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043109","Glucagon-like Peptide-1 Analogue and Dipeptidyl Peptidase-IV Inhibitors","Seungjoon Oh","2006","Journal of Korean Endocrine Society","other","article","10.3803/jkes.2006.21.6.437",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043110","Age-Related Decrease in Glucagon-Like Peptide-1 in Mouse Prefrontal Cortex but Not in Hippocampus Despite the Preservation of Its Receptor","Ryo Ohshima","2015","American Journal of BioScience","preclinical","article","10.11648/j.ajbio.20150301.13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043111","Effect of liraglutide dose on efficacy of correcting microcirculatory disorders in absolute insulin deficiency of albino rats","Daria D. Lagutina","2021","Saratov Medical Journal","preclinical","article","10.15275/sarmj.2021.0304",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043112","P32-06 Semaglutide Modulates Skin Inflammation in L929 Fibroblasts: An In Vitro Study","A. Balcı Ozyurt","2026","Toxicology Letters","preclinical","article","10.1016/j.toxlet.2026.112900",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043113","Effectiveness and Safety of Liraglutide Treatment in Patients with a Psychiatric Disorder","Young Jae Choi","2020","신경정신의학","other","article","10.4306/jknpa.2020.59.4.325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043114","Typ-2-Diabetes – GLP-1-Rezeptor-Agonist nur einmal wöchentlich",null,"2014","Diabetes aktuell","other","article","10.1055/s-0034-1395738",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043115","Terapia basada en la incretina: una nueva propuesta en el tratamiento de la Diabetes Mellitus tipo 2","Maia Burstein","2008","Evidencia actualizacion en la práctica ambulatoria","other","article","10.51987/evidencia.v11i1.5947",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043116","SIMILAR BUT DIFFERENT: A TALE OF 2 CASES OF EUGLYCEMIC DIABETIC KETOACIDOSIS","KS Chiew","2021","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.036/s62",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043117","Prescribing Patterns of SGLT2 Inhibitors and GLP-1 RAs in Patients with Type 2 Diabetes and Comorbid Conditions of Cardiovascular Disease, Chronic Kidney Disease, and Obesity",null,"2022","Journal of Obesity and Chronic Diseases","other","article","10.17756/jocd.2022-050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043118","Long in the shade, glucagon re‐occupies centre court","J. C. Henquin","2011","Diabetes Obesity and Metabolism","preclinical","article","10.1111/j.1463-1326.2011.01476.x","21824249",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043119","Tierisch gute Arzneimittel",null,"2009","Bulletin des Médecins Suisses","other","article","10.4414/bms.2009.14482",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043120","Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) Improve Periodontal and Peri-Implant Health in Type 2 Diabetes Mellitus.","Ahmad, Paras",null,"Open Access CRIS of the University of Bern","nonrandomized_study","article","10.48620/88029",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0043121","Recent Advances in the Pharmacotherapy of Kidney Diseases","Hikmat Ali","2026","International Journal of Pharmacology and Clinical Research","nonrandomized_study","article","10.33545/26647613.2026.v8.i9a.320",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043122","Ozempic and its Protective Factors in Relation to Acute Myocardial Infarction","Katryne Ferreira Rodrigues Correa","2023","Global Journal of Medical Research","other","article","10.34257/gjmrfvol23is9pg1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043123","Oral Semaglutide for the Treatment of Type 2 Diabetes: A Mini Review","Nasser Mikhail","2019","Series of Endocrinology Diabetes and Metabolism","randomized_trial","article","10.54178/jsedmv1i3002",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043124","Effect of monotherapy and combined therapy with thiazolidinedione DPP 4 inhibitors","Komal Chandra","2020",null,"other","article","10.52783/nveo.5447",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043125","Long Standing Diabetes on Insulin – is it Possible to Stop Insulin, Lose Weight and still have Glycaemic Control? – Case Report","Kalyan Kumar Gangopadhyay","2019","Current Research in Diabetes & Obesity Journal","case_report","article","10.19080/crdoj.2019.10.555786",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043126","Dipeptidyl Peptidase-4 Inhibition in the Management of Type 2 Diabetes","Edoardo Mannucci","2007","touchREVIEWS in Endocrinology","preclinical","article","10.17925/ee.2007.00.01.42",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043127","Cognitive Dysfunction and Diabetes","Chan‐Hee Jung","2022","Journal of Korean Diabetes","other","article","10.4093/jkd.2022.23.3.165",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043128","Add on exenatide treatment in obese type 2 diabetic patients under intensive insulin regiments","Alper Sönmez","2016","Endocrine Abstracts","other","article","10.1530/endoabs.41.ep542",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043129","PDB25 COST OF ALL-CAUSE AND CARDIOVASCULAR DISEASE-RELATED HOSPITALIZATION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE BID, SULFONYLUREAS, OR INSULIN: A RETROSPECTIVE ANALYSIS OF THE LIFELINK DATABASE","Jennie H. Best","2011","Value in Health","nonrandomized_study","article","10.1016/j.jval.2011.02.533",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043130","Use of lorcaserin for glycemic control in patients with type 2 diabetes mellitus","Leon I. Igel","2017","Obesity","other_trial","article","10.1002/oby.21817","28371396",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043131","The treatment of type 2 diabetes in heart failure","Andrea Llano","2018","Practical Diabetes","other","article","10.1002/pdi.2178",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043132","Therapeutic Approach to NAFLD-NASH","Georgios Sfikas","2022","IntechOpen eBooks","other","article","10.5772/intechopen.107487",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043133","GLP 1 and Macrovascular Complications","Dana Sleiman","2011","Journal of Diabetes & Metabolism","other","article","10.4172/2155-6156.s4-007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043134","PDB110 - TREATMENT PERSISTENCE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH GLP-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE IN SWEDEN: NATIONWIDE RETROSPECTIVE COHORT STUDY","Anders Toll","2018","Value in Health","nonrandomized_study","article","10.1016/j.jval.2018.09.815",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043135","Incretin Mimetics in the Treatment of Type 2 Diabetes Mellitus","Juul Holst Jens","2006","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2006.00.01.17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043136","Clinical application of Exenatide for type 2 diabetes","Gwanpyo Koh","2009","Journal of Medicine and Life Science","other_trial","article","10.22730/jmls.2009.6.5.271",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043137","Regulatory and clinical perspective on patient access to antidiabetic medicines in Slovenia","Špela Žerovnik","2021","Srpski arhiv za celokupno lekarstvo","nonrandomized_study","article","10.2298/sarh210125058z",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043138","Evaluating Short-Term Cost-Effectiveness Of Liraglutide Versus Oral Antidiabetic Drugs In Patients With Type 2 Diabetes In A Chinese Setting","Luwen Shi","2013","Value in Health","other","article","10.1016/j.jval.2013.03.814",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043139","Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes","Ayşe Nur Torun","2015","InTech eBooks","other","article","10.5772/59241",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043140","Remedial therapies for the management and treatment of diabetes mellitus",null,"2019","Journal of Chemical Biological and Physical Sciences","other","article","10.24214/jcbps.b.9.3.34155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043141","A utilização de agonistas dos receptores de GLP-1 em pacientes obesas com Síndrome do Ovário Policístico: uma revisão integrativa de literatura","Júlia Laís de Sá Gomes","2023","Research Society and Development","other","article","10.33448/rsd-v12i9.43306",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043142","Use of liraglutide in the patient with obesity and type 2 diabetes mellitus: a literature review","Jorge A. Diaz Cancino","2023","International Journal of Basic & Clinical Pharmacology","narrative_review","article","10.18203/2319-2003.ijbcp20232577",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043143","Session Two: Changing the Type 2 Diabetes Mellitus Management Paradigm with Fixed-Ratio Combinations","Lisa Michel","2017","EMJ Diabetes","other_trial","article","10.33590/emjdiabet/10310975",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043144","Autumn 2008 Meeting of the Association of British Clinical Diabetologists","Wroe Cd","2009","Practical Diabetes","randomized_trial","article","10.1002/pdi.1363",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043145","Improvement of left ventricular global longitudinal strain (LV GLS) after 6-months of GLP-1 RAs treatment in diabetes mellitus type 2","Paolo Basile","2023","European Heart Journal - Cardiovascular Imaging","other","article","10.1093/ehjci/jead119.145",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043146","The diabetes clinic consultation: and one more question?","Ma'en Al‐Mrayat","2015","Practical Diabetes","randomized_trial","article","10.1002/pdi.1922",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043147","Highlights",null,"2016","JAMA","randomized_trial","article","10.1001/jama.2015.14406",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043148","The Evaluation of Liraglutide Combined with Intensive Insulin Therapy on the Pancreatic Beta Cells Function in Type II Diabetes Mellitus","Shenjiao Dong","2021","International Journal of Clinical and Experimental Medicine Research","other","article","10.26855/ijcemr.2021.07.023",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043149","Association Between Exenatide/Β2AR Use and Parkinson’s Disease Risk in Medicare Population","Bo Zhou","2018","Value in Health","other","article","10.1016/j.jval.2018.04.1391",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043150","Liver fibrosis: Which mechanisms matter?","Ralf Weiskirchen","2016","Clinical Liver Disease","nonrandomized_study","article","10.1002/cld.581","31041072",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043151","The addition of metformin and glucagon-like peptide-1 receptor agonist or dipeptidyl-peptidase-4 inhibitor to insulin for latent autoimmune diabetes in adults","Sumie Moriyama","2013","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-013-0167-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043152","Antihyperglycemic agent combination therapy for patients with type 2 diabetes mellitus","Jungmin Lee","2014","Journal of Korean Medical Association","other","article","10.5124/jkma.2014.57.5.435",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043153","Polycystic ovary syndrome: individualized approach to treatment. Literature review","Л. А. Жабіцька","2020","Reproductive Endocrinology","narrative_review","article","10.18370/2309-4117.2020.54.89-94",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043154","Effects of GLP-1 Analogue, Liraglutide on the Expression of Mouse Pre-osteoblast MC3T3-E1","Zhihui Gao","2020","Indian Journal of Pharmaceutical Sciences","preclinical","article","10.36468/pharmaceutical-sciences.spl.126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043155","Inisiasi Fixed Ratio Combination (FRC) Insulin Glargine/Lixisenatide untuk Orang Dewasa dengan Diabetes Melitus Tipe 2","Md Ikhsan Mokoagow","2023","Cermin Dunia Kedokteran","other","article","10.55175/cdk.v50i12.1014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043156","Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction","Giovanna Liuzzo","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad674","37879100",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043157","Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME","Miles Fisher","2020","British Journal of Diabetes","other_trial","article","10.15277/bjd.2020.254",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0043158","USE OF LIRAGLUTIDE FOR WEIGHT LOSS IN OBESE OR OVERWEIGHT PATIENTS ASSOCIATED WITH COMORBIDITIES: A LITERATURE REVIEW","Amanda Nascentes Coelho dos Santos Omer","2023","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.15938823181010",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043159","Nuklearmedizin: neue nuklearmedizinische Bildgebung zur Lokalisation von okkulten Insulinomen","David Wild","2008","Swiss Medical Forum ‒ Schweizerisches Medizin-Forum","other","article","10.4414/smf.2008.06694",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043160","Add-on saxagliptin improves glycemic status among uncontrolled type 2 diabetes mellitus","Butungeshwar Pradhan","2018","International Journal of Research in Medical Sciences","other","article","10.18203/2320-6012.ijrms20181758",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043161","GLP-1 analogs in the treatment of obesity","Aleksandra Metelska","2022","Journal of Education Health and Sport","other","article","10.12775/jehs.2022.12.08.034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043162","Adapting L-Cells to the Rescue!","Jeffrey Gagnon","2016","Endocrinology","preclinical","article","10.1210/en.2016-1639","27690675",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043163","Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?)","V.I. Katerenchuk","2023","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","other","article","10.22141/2224-0721.19.1.2023.1244",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043164","Efeitos adversos da semaglutida comparada à liraglutida: uma revisão integrativa de literatura","Ana Laura Silva Machado de Moraes","2022","Research Society and Development","other","article","10.33448/rsd-v11i10.33181",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043165","What's new in pharmacotherapy at ESC Congress 2023?","Felice Gragnano","2023","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvad064","37682522",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043166","Glucagon-Like Peptide-1 and Its Implications in Obesity","Verónica Hurtado-Carneiro","2013","InTech eBooks","preclinical","article","10.5772/54221",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043167","Adipositas","Michael Koczorek","2016","Diabetes aktuell","other","article","10.1055/s-0042-114372",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043168","Effect of semaglutide on lipoprotein subfractions and chemerin levels in type 2 diabetic patients","Ferenc Sztanek","2022","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2022.06.582",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043169","Inhibition of continuous movement in smokers and non-smokers: a large-scale online study","Swann lab","2026","Open Science Framework","other","article","10.17605/osf.io/z8792",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043170","Kardiovaskuläre Risikofaktoren bei Typ-2-Diabetes – GLP-1-Rezeptor-Agonisten zeigen nützliche Effekte",null,"2015","Diabetes aktuell","other","article","10.1055/s-0035-1547495",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043171","Intervention of Type 2 Diabetes With GLP-1RA Caused Early Worsening and Remission of Diabetic Retinopathy","Teruo Shiba","2018","Interventions in Obesity & Diabetes","other","article","10.31031/iod.2018.02.000542",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043172","Typ-2-Diabetes – ein heterogenes Krankheitsbild – Gefragt ist eine patientenzentrierte, individualisierte Therapie",null,"2014","Diabetes aktuell","other","article","10.1055/s-0033-1363787",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043173","Effects of Oral Semaglutide on Glycemic Control, Body Mass Index, and Renal Function in Indian Patients with Type 2 Diabetes Mellitus: A Retrospective Case Series","Royce An Abraham","2026","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_37_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043174","Too many heart patients discharged without follow-up care","Zosia Kmietowicz","2005","BMJ","randomized_trial","article","10.1136/bmj.330.7504.1346-a","15947381",null,"ClinicalTrials.gov:NCT02905864","S001734","openalex","TRUE","free_to_read","1","FALSE","article"],["R0043175","Pharmacotherapy of Obesity: Past, Present and Future","С. М. Ткач","2016","Clinical endocrinology and endocrine surgery","other","article","10.24026/1818-1384.4(56).2016.87174",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043176","Long Acting Hyaluronate – Exendin 4 Conjugate for the Treatment of Type 2 Diabetes","한세광","2010","Open Access System for Information Sharing (Pohang University of Science and Technology)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0043177","Mechanisms Underlying Cardioprotective Effects of Glucagon like Peptide-1 in Ischemia-reperfusion Injury","Kiwon Ban","2007","Library and Archives Canada (Government of Canada)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043178","International Journal of Diabetes and Technology",null,"2026","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_36_26",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0043179","GLP-1R agonist alleviate obesity and NAFLD by upregulates OTR to activating MAPK/ERK signalling pathway in liver through the brain–liver axis","Weixi Jia","2025","Materials Technology","preclinical","article","10.1080/10667857.2025.2517670",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043180","Editorial: Cell cross-talk in diabetic kidney diseases, volume III","Ruopei Wang","2025","Frontiers in Medicine","commentary","article","10.3389/fmed.2025.1627354","40520807",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0043181","Wybrane propozycje leczenia otyłości przedstawione na XIII kongresie International Association for the Study of Obesity w Sztokholmie","Adriana Stenka","2010","Via Medica Journals","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043182","Effect of liraglutide on cardiovascular outcomes in elderly patients: A post hoc analysis of a randomized controlled trial","R. Roginski Rea","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/8t49-rn46",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043183","Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits","S. I. Sherman","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/kj4b-d081",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043184","The Paradigm Shift in the Management of Diabetic Kidney Disease: A Comprehensive Review of the Four Pillars of Therapy","Y. J. Anupama","2026","APIK Journal of Internal Medicine","narrative_review","article","10.4103/ajim.ajim_3_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043185","Intestinal nutrient sensing : a gut feeling for food","Nikkie van der Wielen","2016",null,"preclinical","article","10.18174/378269",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043186","Tirzepatide 5mg 10mg 15mg 20mg 30mg 40mg 50mg 60mg","benzocainesupplier","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22652744",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043187","Abstract No: 070 REAL-WORLD IMPACT OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS ON CARDIO-RENAL OUTCOMES IN RESOURCE-LIMITED SETTINGS","K. Ssensamba","2026","Kidney International Reports","nonrandomized_study","article","10.1016/j.ekir.2026.106774",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043188","The efficacy and safety of once-daily oral semaglutide in adults with type 2 diabetes during Ramadan: A prospective observational study in Kuwait","Talal Muzaffar","2026","Endocrine and Metabolic Science","other","article","10.1016/j.endmts.2026.100325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043189","Erratum to ‘Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making’",null,"2014","Therapeutic Advances in Endocrinology and Metabolism","notice","article","10.1177/2042018814565579",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0043190","Effect of hyperandrogenism in obese PCOS patients: GLP-1 receptor agonists plus metformin versus metformin monotherapy–a systematic review and meta-analysis","Gilang Rizqy Perdana Aries Rohman","2026","Media Penelitian dan Pengembangan Kesehatan","systematic_review","article","10.34011/jmp2k.v36i1.3593",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0043191","Inhibidores de SGLT2 y agonistas del receptor GLP-1 en el tratamiento de la diabetes mellitus tipo 2 en adultos.","Kevin Rafael Moreno-Ramos","2026","Innova Science Journal","other","article","10.63618/omd/isj/v4/n2/252",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043192","Evaluation of glycaemic control and diabetes treatment strategies during the religious fasting period of Ramadan","Elaine Hui","2012","Spiral (Imperial College London)","randomized_trial","article","10.25560/13695",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0043193","A minireview of pharmacotherapy of type 2 diabetes – drugs and mechanisms","Érick Bryan de Sousa Lima","2022","Research Society and Development","randomized_trial","article","10.33448/rsd-v11i12.34900",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043194","Challenges in personalized evidence-based medicine, applications in type 2 diabetes","Guillaume Grenet","2019","HAL (Le Centre pour la Communication Scientifique Directe)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0043195","Is Ozempic™ enabling sustainable consumption?","Maurie J. Cohen","2023","Sustainability Science Practice and Policy","other","article","10.1080/15487733.2024.2295140",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043196","Liraglutide and Glycaemic Outcomes in the LEADER Trial","B. Zinman","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/kz1k-4223",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0043197","Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial","H. Sourij","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","protocol","article","10.17615/psft-h469",null,null,"ClinicalTrials.gov:NCT01144338","S000905","openalex","TRUE","paywalled","5","FALSE","article"],["R0043198","Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists","Emily J. Cox","2020","US Endocrinology","other","article","10.17925/use.2020.16.2.80",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043199","The diet-GLP-1 receptor agonist evidence gap: analysis snapshot","Qiang Wang","2026",null,"other","article","10.17605/osf.io/caz6v",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043200","USING MACHINE LEARNING TECHNIQUES TO IDENTIFY AND ASSESS HETEROGENEOUS TREATMENT EFFECTS IN ADULTS WITH TYPE 2 DIABETES","Wang, Tiansheng","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/0hkx-9a76",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0043201","Diabetic cardiomyopathy: current state of the problem. Review","Кондратюк, В. Є.","2023","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0043202","Quels sont les facteurs prédictifs de l’efficacité d’un traitement par liraglutide (analogue GLP-1) dans le diabète de type 2 ?","Pierre Gérard","2014","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043203","Phenotyping cardiometabolic disease with magnetic resonance techniques","Elisabeth H.M. Paiman","2020","Leiden Repository (Leiden University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0043204","Traitement du diabète de type II par Bydureon","A. L. M. Lelong","2016","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043205","Investigating Potential Mechanisms Underlying the Anticancer Benefit of Tirzepatide-Induced Weight Loss","Holt, Alex","2025","Carolina Digital Repository (University of North Carolina at Chapel Hill)","preclinical","article","10.17615/0p5r-qx94",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043206","Emulating randomized controlled trials using real-world evidence: The case of long-acting insulins among patients with type 2 diabetes","Wanning Wang","2024","eScholarship@McGill (McGill)","randomized_trial","article","10.82308/35693",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0043207","Non-insulin therapy in diabetic inpatients: SGLT2- inhibitors and incretins for the care of hospitalized patients","G. Brunori","2022","The Journal of AMD","other","article","10.36171/lamd22.25.3.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043208","Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: Insights from the EXSCEL trial","L.E. Clegg","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/brjm-hg52",null,null,"ClinicalTrials.gov:NCT01144338","S000905","openalex","TRUE","paywalled","4","FALSE","article"],["R0043209","Eficacia de la Efpeglenatida en el manejo de diabetes mellitus tipo 2 en adultos obesos: revisión sistemática y meta-análisis","Ugarte Carbajal, Sergio Robert","2023","renati","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043210","Strategies for prandial intensification of insulin therapy: the SPRINT project","Simona Corrao","2017","The Journal of AMD","other","article","10.36171/jamd17.20.2.05",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043211","Effects of gut hormones, glucagon-like peptide-1 and desacyl ghrelin, on eating behaviour in obesity and ex-smokers","Ling, Yong Yong","2020",null,"randomized_trial","article","10.25560/108169",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043212","Cost-utility of semaglutide in the management of obesity or overweight: A systematic review","Ronald Watema-Lord","2026","Obesity Medicine","systematic_review","article","10.1016/j.obmed.2026.100744",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043213","Glucagon-like Peptide-1 Receptor Agonists and Anaesthesia Considerations","Hemlata Kapoor","2024","Airway","other","article","10.4103/arwy.arwy_5_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043214","Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management","Muhammed Vally","2020","South African General Practitioner","other_trial","article","10.36303/sagp.2020.1.1.0006",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0043215","Diabesity An Emerging Epidemic and Advances in Treatment","Saqib Salah Aufi Aufi","2024","Barind Medical College Journal","nonrandomized_study","article","10.70818/bmcj.2024.v010i01.003",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043216","Resistensi Insulin sebagai Poros Disfungsi Ovulasi pada Polycystic Ovary Syndrome","Raymond R. Tjandrawinata","2026","MEDICINUS","other","article","10.56951/wnqbb620",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043217","Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence","Lívia Cristina Ribeiro Teixeira","2025","Receptors","preclinical","article","10.3390/receptors4010002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043218","Postglucose Hyperinsulinemia in Black Women Is Not What We Thought","Melanie Cree‐Green","2018","The Journal of Clinical Endocrinology & Metabolism","nonrandomized_study","article","10.1210/jc.2018-02213","30371868",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043219","Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from the leader trial","S.P. Marso","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/14f1-fy23",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043220","Compilation of Scientific Data for Newly CDSCO-Approved Antidiabetic Drugs in Last Five Years: A Review","Archita Tiwari","2024","International Journal of Pharmaceutical Quality Assurance","narrative_review","article","10.25258/ijpqa.15.2.79",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043221","A Chlorooxime-Mediated Amidination of N-Terminus for Late- Stage Modifications of Unprotected Peptides","Fa-Jie Chen","2025","ChemRxiv","other","article","10.26434/chemrxiv-2025-s29g7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043222","Single or multiple nutritional hormone receptor modulators for chronic kidney disease","Hiddo J.L. Heerspink","2026","Clinical Kidney Journal","other","article","10.1093/ckj/sfag311",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043223","Adjacent Evidence Brief: Liraglutide Cardiovascular Effects","Dominic Lynch","2026",null,"other","article","10.17605/osf.io/6y8n3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043224","Immunometabolism Sentinels: Gut Surface T-Cells Regulate GLP-1 Availability","Nicole G. Barra","2019","Endocrinology","preclinical","article","10.1210/en.2019-00215","30958533",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043225","Approach toward diabetic nephropathy and its management in patients with type 2 diabetes: results of a web-based italian survey","Vito Borzı̀","2021","The Journal of AMD","other","article","10.36171/jamd21.24.1.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043226","Coronary artery disease in metabolic syndrome: a role for the sarcoplasmic reticulum Ca2+ ATPase","Rodenbeck, Stacey Dineen","2016","IUScholarWorks (Indiana University)","preclinical","article","10.7912/c2/2015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043227","GLP-1 analogues in clinical management of obesity","Rachel Agius","2022","Current Opinion in Endocrine and Metabolic Research","narrative_review","article","10.1016/j.coemr.2022.100360",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0043228","GLP-1 Receptor Agonists for MASH in Non-Diabetic Adults: A Systematic Review","Bárbara Moema Peixoto Frazão","2026",null,"systematic_review","article","10.17605/osf.io/4rt95",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0043229","The impact of diet on male semen quality and fertility: A comprehensive review","Bingxin Ma","2026","Placenta and Reproductive Medicine","randomized_trial","article","10.54844/prm.2026.1231",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043230","Pharmacotherapy of Type 2 Diabetes Mellitus","Pankaj Kumar Jha","2023","IntechOpen eBooks","other","article","10.5772/intechopen.1002309",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043231","Exendin-4 effects on islet volume and number in mouse pancreas","Layasadat Khorsandi","2013","Brazilian Journal of Pharmaceutical Sciences","preclinical","article","10.1590/s1984-82502013000400014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043232","Automated cardiac segmentation pipeline and motion analysis in rodent models of pulmonary hypertension","Marili Niglas","2023",null,"preclinical","article","10.25560/126600",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043233","A systematic review of the efficacy and safety of triple therapy in patients with type 2 diabetes mellitus not achieving target Ale goals despite existing dual therapy (metformin plus a sulfonylurea)","Jordan M. Kautz","2019","Carolina Digital Repository (University of North Carolina at Chapel Hill)","systematic_review","article","10.17615/0965-cd05",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0043234","The Acute Regulation of Intestinal Chylomicron Secretion by Glucagon-like Peptides","Joanne Hsieh","2012","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043235","Liraglutide-Induced Depression with Suicidality in an Obese Adult: A Case Report","Feras Almarshad","2024","Galician Medical Journal","case_report","article","10.21802/e-gmj2024-a07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043236","Glucagon-like peptide-1 receptor agonists in the treatment of non-alcoholic (metabolic-associated) fatty liver disease: a review","С. В. Туркина","2026","Consilium Medicum","narrative_review","article","10.26442/20751753.2026.5.203661",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043237","Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)","S.P. Marso","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/13n0-cc93",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0043238","Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example","M. Donsmark","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/6xz3-t923",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043239","Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas.","Waser, Beatrice",null,"Open Access CRIS of the University of Bern","preclinical","article","10.7892/boris.62432",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043240","EMA – Warning about sharp rise in illegal medicines sold in the EU","vroby","2025","Industrias Culturais (Universidade de Coimbra)","other","article","10.58079/156rl",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043241","Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials","T. Monk Fries","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/n642-gk64",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043242","AT1-receptor blockade and insulin sensitivity in hypertensive subjects: the role of capillary recruitment","A.M. Jonk","2010","Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043243","Obesity in people with diabetes AMD Annals 2024","Russo, G.","2025","The Journal of AMD","other","article","10.36171/jamd25.28.3.11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043244","Central nervous system control of triglyceride metabolism","Johanna Janetta Geerling","2013","Leiden Repository (Leiden University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043245","Bariatric Surgery in the Era of Obesity Management Medication: A Paradigm Shift or a Complementary Tool?","Randeep Wadhawan","2024","Journal of Bariatric Surgery","other_trial","article","10.4103/jbs.jbs_17_24",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0043246","Oral glucose lowering agents and cancer in type 2 diabetes mellitus: focus on sulphonylurea derivatives","Dennis Schrijnders","2019",null,"nonrandomized_study","article","10.33612/diss.103517830",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","dissertation"],["R0043247","Articles You Might Have Missed","Allison R. Font","2025","Journal of Medical Toxicology","other","article","10.1007/s13181-025-01079-4","40402356",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043248","Study the effect of Dipeptidyl Peptidase 4 Inhibitors as an Antidiabetic in Type 2 Diabetes Mellitus (T2DM)",null,"2021","American Journal of PharmTech Research","other_trial","article","10.46624/ajptr.2021.v11.i5.009",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043249","Pratique de prescription du liraglutide VICTOZA®. Étude de cohorte au sein du service d’endocrinologie et de maladies métaboliques au CHU de Rouen","Marie-Pierre Riffault","2015","HAL (Le Centre pour la Communication Scientifique Directe)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0043250","Glucose Control and Diabetic Retinopathy","Savita Bhat","2023","Chronicle of Diabetes Research and Practice","nonrandomized_study","article","10.4103/cdrp.cdrp_cdrp_22_22",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043251","Dietitians’ attitudes toward GLP-1s: weight bias and professional identity in an Israeli context","Bat-Chen Cohen","2026","Fat Studies","other","article","10.1080/21604851.2026.2682774",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043252","Contemporary pharmacological obesity treatments","Katarzyna Kaszubska","2016","Current Issues in Pharmacy and Medical Sciences","other","article","10.1515/cipms-2016-0012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043253","Occurence of First and Recurrent Major Adverse Cardiovascular Events with Liraglutide Treatment among Patients with Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial","Sø. Rasmussen","2021","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/t4wn-b146",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043254","Rôle du récepteur nucléaire FXR dans la régulation de la production de GLP-1 : nouvelle cible thérapeutique dans le traitement du diabète de type 2 ?","Mohamed Trabelsi","2015","HAL (Le Centre pour la Communication Scientifique Directe)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043255","Lipotoxicity and the role of translationally controlled tumour protein (TCTP) in pancreatic β-cell survival","Katy Louise Hayward","2014","UWE Research Repository (UWE Bristol)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043256","Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes","R.A. Patel","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/mtwd-4906",null,null,"ClinicalTrials.gov:NCT01144338","S000905","openalex","TRUE","paywalled","1","FALSE","article"],["R0043257","From intestines to skeleton: The impact of incretin hormones on human bone","Svarer Hansen, Morten","2024","University of Southern Denmark Research Portal (University of Southern Denmark)","other","article","10.21996/5fxy-hv89",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043258","Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management","Mariya Kalinkova","2023","Pharmacia","other","article","10.3897/pharmacia.70.e104481",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043259","Efeitos da Exenatida e da Sitagliptina durante a indução da periodontite em ratos","Renata Mendonça Moraes","2014","Americanae (AECID Library)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043260","Incretin-based drugs and the risk of skin cancer among patients with type 2 diabetes mellitus","Richeek Pradhan","2023","eScholarship@McGill (McGill)","other","article","10.82308/19630",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043261","Case Report: Combining rTMS With Dual GIP and GLP-1 Agonist for Nicotine Cessation","Elizabeth Fenstermacher","2026","Transcranial magnetic stimulation .","case_report","article","10.1016/j.transm.2026.100245",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043262","Knowledge, Attitude and Practice about a Newer Class of Antidiabetic Drug (Glucagon-like peptide-1 receptor agonist) Among the Health Care Professionals of Qassim University, Saudi Arabia","Alwaleed Yousef Aldhobaib","2021","Journal of Pharmaceutical Research","other","article","10.18579/jopcr/v20i4.ms21083",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043263","Association des analogues du GLP-1 et des inhibiteurs du SGLT2 : de nouvelles perspectives ?","Claire Ritz","2017","Revue Médicale Suisse","other","article","10.53738/revmed.2017.13.565.1134",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043264","Four Pillars in Type 2 Diabetes and CKD G4–G5: Mission Impossible—or Not Too Late to Start?","Masayuki Yamanouchi","2026","Kidney Medicine","nonrandomized_study","article","10.1016/j.xkme.2026.101516",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043265","Prescription characteristics of the insulin glargine plus lixisenatide fixed-ratio combination in real-world clinical practice according to the Registry of Diabetes Mellitus in the Moscow Region","И. В. Мисникова","2024","Almanac of Clinical Medicine","nonrandomized_study","article","10.18786/2072-0505-2024-52-044",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043266","Cutting-edge stroke prevention strategies","Lisa Kaindl","2025","eNeurologicalSci","other","article","10.1016/j.ensci.2025.100561","40070447",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043267","Diabetes: learning from the past 25 years and looking to the future","Andrew J. Krentz","2018","Cardiovascular Endocrinology & Metabolism","nonrandomized_study","article","10.1097/xce.0000000000000161","31646286",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043268","151 Anti-Inflammatory and Anabolic Effects of Liraglutide on 3D Inflammatory Osteoarthritic Pellets of Human Chondrocytes","Eda Çiftci Dede","2024","Osteoarthritis and Cartilage","other","article","10.1016/j.joca.2024.02.162",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043269","Antidiabetic Drug-loaded Solid Lipid Nanoparticle and Its Importance in Drug Delivery","Vijayakumar P","2024","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.14.1.73",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043270","Co-Formulations as the First Injectable in Type 2 Diabetes: A Review of Efficacy, Safety, and Implications in Clinical Practice","Mathew John","2020","Dubai Diabetes and Endocrinology Journal","narrative_review","article","10.1159/000509045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043271","Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial","M.A. Nauck","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/d1hv-pw35",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0043272","Mazdutide and the metabolic treatment revolution","Xianyu Li","2026","Trends Open","narrative_review","article","10.1016/j.treopn.2026.07.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0043273","Delayed gastric emptying during elective gastroscopy under sedation in a patient receiving semaglutide: a case report","M. L. Pogosyan","2026","Clinical nutrition and metabolism","case_report","article","10.17816/clinutr713507",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043274","Hepatic Events Prevention by Anti-Hyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-Analysis","Pedro Robson Costa Passos","2026",null,"systematic_review","article","10.2337/figshare.31795342.v1",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","other"],["R0043275","Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD","Margaret K. Yu","2016","Clinical Journal of the American Society of Nephrology","randomized_trial","article","10.2215/cjn.10361016","27827307",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043276","Tirzepatide in the management of heart failure with preserved ejection fraction: A narrative review","Meghna Bordoloi","2026","Journal of Clinical Sciences","other_trial","article","10.4103/jcls.jcls_173_25",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","review"],["R0043277","LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ","Buse, John","2019","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/a6vv-8z56",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","TRUE","paywalled","5","FALSE","article"],["R0043278","Reimbursed Use of GLP-1 Receptor Agonists in France, 2019–2025","Javier Zorrilla de San Martín","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22658978",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043279","Effects of liraglutide on weight control and blood pressure in type 2 diabetes mellitus Iraqi patients","Ahmed J. Abdulrahman","2023","Journal of the Faculty of Medicine Baghdad","other_trial","article","10.32007/jfacmedbagdad.6441971",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043280","Research Synthesis: Semaglutide Adverse Safety — full paper","Dominic Lynch","2026",null,"other","article","10.17605/osf.io/s3yce",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043281","Abstract No: 120 Mechanism of Metabolic Reprogramming Mediated by Moderate High-Altitude Hypoxia in Promoting Renal Tubular Fibrosis in Chronic Kidney Disease","X. Wang","2026","Kidney International Reports","nonrandomized_study","article","10.1016/j.ekir.2026.106776",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043282","Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?","Derek Daniels","2018","Diabetes","other","article","10.2337/dbi18-0045","30573675",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043283","The role of intestinal hydrogen sulfide on GLP-1 secretion and downstream metabolism","Jennifer Pichette","2017","Lu Zone Ul (Laurentian University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043284","FDG-PET imaging of pulmonary vascular remodelling in PAH","Lei Wang","2016",null,"preclinical","article","10.25560/58197",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043285","The role of the gut microbiota in the regulation of incretin effects","K.O. Shyshkan-Shyshova","2020","Clinical endocrinology and endocrine surgery","other","article","10.30978/cees-2020-1-64",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043286","Latest data on metabolic diseases: Diabetes Mellitus","Panagiota Mitrou","2017","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043287","Costs and Consequences Associated With Newer Medications for Glycemic Control in Type 2 Diabetes","L. Pogach","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/kx5w-yd71",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043288","Ozempic","Dana Simmons","2025",null,"other","article","10.1525/luminos.232.i",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043289","Islet Biology/Insulin Secretion",null,"2013","Diabetes","preclinical","article","10.2337/db13-2161-2296","23792721",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043290","93 A case of disordered eating emerging amidst tirzepatide use for obesity treatment in an 18-year-old male","Chunyang Lu","2025","The American Journal of the Medical Sciences","case_report","article","10.1016/s0002-9629(25)00102-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043291","The Demedicalization of GLP-1 Receptor Agonists: An Analysis of TikTok Influencer Endorsement of Ozempic-Like Medications for Cosmetic Weight Loss","Jayanthi, Riya","2025","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/6ta9-kz32",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043292","Prescribing trend of drugs for the treatment of diabetes in the Local Health Service Tuscany Centre from 2020 to 2023: between “Diabetes Project” and AIFA Nota 100","Eugenio Peluso","2025","The Journal of AMD","other","article","10.36171/jamd24.27.3.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043293","The emergence of cardiodiabetology","Paul D. Rosenblit","2017","Cardiovascular Endocrinology","randomized_trial","article","10.1097/xce.0000000000000117","31646112",null,"ClinicalTrials.gov:NCT01032629; ClinicalTrials.gov:NCT01730534; ClinicalTrials.gov:NCT01986881; ClinicalTrials.gov:NCT01144338; ClinicalTrials.gov:NCT01394952","S000147; S000905","openalex","TRUE","free_to_read","1","FALSE","article"],["R0043294","Cover: Fibrotic MASH as Treatment Indication for Semaglutide Largely Overlaps With Conventional Indications",null,"2026","Gastro Hep Advances","other","article","10.1016/j.gastha.2026.100977",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043295","Dedifferentiation as a Stealthy Disruptor of β-Cell Function in Diabetes","Jinsook Son","2024","The Journal of Clinical Endocrinology & Metabolism","preclinical","article","10.1210/clinem/dgae624","39257186",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043296","IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test","S.C. Gough","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/q14z-kk30",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043297","Diabetes treatment today: an exciting confusion","Antonio Ceriello","2020","The Journal of AMD","other","article","10.36171/jamd20.23.1.08",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043298","Basal insulin treatment optimization in T2DM: GLP-1 Receptor Agonists in loose addition or in fixed dose combination","Gloria Formoso","2019","The Journal of AMD","other","article","10.36171/jamd19.22.1-2.06",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043299","The expanding role of dermatologists in the era of glucagon-like peptide-1 receptor agonist therapies","Yu‐Ping Hsiao","2026","Dermatologica Sinica","randomized_trial","article","10.4103/ds.ds_v44-2_editorial",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043300","Research Synthesis: Liraglutide Biomarker Effects — full paper","Dominic Lynch","2026",null,"randomized_trial","article","10.17605/osf.io/c9uat",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0043301","Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.","Johannes F E Mann","2026","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/zxjx-5p49",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043302","Type 1 Diabetes, Still No Medications for Excess Weight? A Review of the Scientific Evidence Supporting the Use of Incretin-Based Drugs in Type 1 Diabetes"," ","2026","The Journal of AMD","narrative_review","article","10.36171/jamd26.29.1.7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043303","Évaluation de l'efficacité et de la tolérance du Byetta® dans une étude de phase IV","Anne-Laure Jouffrey","2009","OpenGrey (Institut de l'Information Scientifique et Technique)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043304","Clinical Outcomes in Patients with Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results from the EXSCEL Trial","Goodman, S.G.","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/ks7q-gz23",null,null,"ClinicalTrials.gov:NCT01144338","S000905","openalex","TRUE","paywalled","5","FALSE","article"],["R0043305","Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes.","Loretta Fala","2015","PubMed","other","article",null,"26629271",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043306","Treatment of diabetes mellitus in patients with chronic hepatitis B: Are SGLT2 inhibitors hitting the sweet spot?","Milan J. Sonneveld","2023","Hepatology","nonrandomized_study","article","10.1097/hep.0000000000000424","37185255",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043307","Tolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real World Experience from a Single Center Study","Mary Ann Lim","2025","American Journal of Transplantation","nonrandomized_study","article","10.1016/j.ajt.2025.07.915",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043308","A content analysis of information about Ozempic on Instagram","Elviira Junnila","2025",null,"other","article","10.32469/10355/109729",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043309","Top 20 Research Studies of 2023 for Primary Care Physicians.","Mark H. Ebell","2013","PubMed","randomized_trial","article",null,"24134045",null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0043310","Polyglycerol for Half-Life Extension and Increased Stability of Biopharmaceuticals","Tully, Michael","2021",null,"preclinical","article","10.17169/refubium-31502",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043311","P461: Cartilage-hair hypoplasia: Expanding the association of severe prenatal skeletal findings","Danita Velasco","2025","Genetics in Medicine Open","other","article","10.1016/j.gimo.2025.103328",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043312","The Effects of Liraglutide on In Vitro Fertilization in Mice Following Experimental Diabetes","Rafieh Khalily","2020","Qom Univ Med Sci J","preclinical","article","10.29252/qums.14.1.51",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043313","The continuous evolution of diabetology between scientific updates and social changes","C.B. Giorda","2019","The Journal of AMD","other","article","10.36171/jamd19.22.1-2.08",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043314","Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis","Shi, L.","2023","Carolina Digital Repository (University of North Carolina at Chapel Hill)","systematic_review","article","10.17615/0ytp-fq60",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0043315","Exenatide in T2DM in Spain: better outcomes, lower cost",null,"2019","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-019-6119-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043316","Inadvertent Pregnancy During Tirzepatide Therapy in Type 2 Diabetes Mellitus: A Case Report with Maternal and Neonatal Outcomes","Khalid Ahmed","2026","Journal of Diabetology","case_report","article","10.4103/jod.jod_190_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043317","Why Should be the Strategy of Type 2 Diabetes Treatment Radically Changed","Juraj Gmitrov","2017","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","other","article","10.1515/rjdnmd-2017-0032",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043318","The Role of Glucagon-like Peptides in Experimental Type 1 Diabetes","Irene Hadjiyianni","2010","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043319","WCN23-0528 RENO-PROTECTIVE EFFECT OF LIRAGLUTIDE IN T1DM: A NOVEL ANTI-INFLAMMATORY THEORY","Natalie Youssef","2023","Kidney International Reports","other","article","10.1016/j.ekir.2023.02.435",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043320","Exploring Gaps in Infant and Young Child Feeding Practices and Emerging Initiatives Within Collective Shelters for Displaced Children in Lebanon","Lamis Jomaa","2026","Current Developments in Nutrition","randomized_trial","article","10.1016/j.cdnut.2026.108587",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043321","Research Synthesis: Semaglutide 2.4 mg Once Weekly Effects — full paper","Dominic Lynch","2026",null,"other","article","10.17605/osf.io/qh7dw",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043322","Applying the Estimand Framework in SURPASS-CVOT: Toward Precision and Transparency in Cardiometabolic Trials","Shambo S. Samajdar","2026","Journal of Diabetology","nonrandomized_study","article","10.4103/jod.jod_152_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043323","Efficacy and safety of ITCA 650, a novel drug-Device GLP-1 receptor agonist, in type 2 diabetes uncontrolled with oral antidiabetes drugs: The FREEDOM-1 trial","J. Rosenstock","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/yejd-1542",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043324","REAL WORLD SAFETY AND EFFICACY OF SGLT-2 INHIBITORS IN ELDERLY TYPE 2 DIABETIC PATIENTS","Carlos Trescolí Serrano","2017","Innovation in Aging","nonrandomized_study","article","10.1093/geroni/igx004.588",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0043325","Glucagon-like Peptide-1 Receptor Agonists: Multifaceted Agents for Cardiovascular Risk Reduction in Diabetes","Sawera Haider","2025","The Journal of Medical Research","randomized_trial","article","10.4103/jmr.jmr_48_25",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043326","Improving Glucose Control in Type II Diabetes with SGLT-2 Inhibitors and GLP-1 Agonists","Tallin Martirossian","2021","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043327","Synthesis, characterization and evaluation of antidiabetic properties of a new metformin-3- hydroxyflavone complex studied in high fat diet fed - low dose streptozotocin induced experimental type 2 diabetes in wistar rats","C. JAIGA NESH","2017","International Journal of Pharma and Bio Sciences","preclinical","article","10.22376/ijpbs.2017.8.3.p1-15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043328","Research Synthesis: Semaglutide Intervention Semaglutide 2 4 Mg Rates — full paper","Dominic Lynch","2026",null,"other_trial","article","10.17605/osf.io/q4djs",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0043329","8 Ozempic","Dana Simmons","2025",null,"other","article","10.1525/9780520412996-010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043330","Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.","Rylova, Svetlana N",null,"Open Access CRIS of the University of Bern","preclinical","article","10.7892/boris.92938",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043331","Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)","N. Iqbal","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/wt81-5t92",null,null,"ClinicalTrials.gov:NCT01144338","S000905","openalex","TRUE","paywalled","1","FALSE","article"],["R0043332","A peptidomic investigation into enteroendocrine cells and islets of humans and mice","Sam G. Galvin","2021","Apollo (University of Cambridge)","preclinical","article","10.17863/cam.72295",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043333","Mechanisms and therapeutic modulation of myocardial infarct healing","Leo Timmers","2008","Utrecht University Repository (Utrecht University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043334","A Systematic Review On Novel Twincretin; Tirzepatide in Treatment of Type-II Diabetes Mellitus.","A Naveen","2022","International Journal of Pharma and Bio Sciences","systematic_review","article","10.22376/ijpbs.2022.13.4.p7-15",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0043335","Address for Correspondence","Jin Young Kim","2000",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043336","A Novel Hyaluronic Acid - Exendin 4 Conjugate for the Treatment of Type 2 Diabetes","한세광","2009","Open Access System for Information Sharing (Pohang University of Science and Technology)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0043337","The effects of GLP-1 and statin co-treatment on cardiometabolic risk factors and cardiac tolerance to ischaemia/reperfusion injury in a murine model of obesity","Cassandra J Robertson","2026",null,"preclinical","article","10.25904/1912/5948",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043338","WCN25-3766 SAFETY OF LOW DOSE ACE INHIBITION IN LIVING KIDNEY DONORS : A PILOT STUDY","Ankur Chaudhary","2025","Kidney International Reports","other","article","10.1016/j.ekir.2024.11.964",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043339","Metabolic Determinants of Weight-Loss Quality During and After Incretin-Based Therapies in Obesity","Mariana Luna","2026","Clinical Nutrition Open Science","other","article","10.1016/j.nutos.2026.100711",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043340","“Obtención y caracterización de mutantes del gen hscA de cepas de Escherichia coli etanologénicas”","Ma. Consuelo Reséndiz Tamayo","2012","Americanae (AECID Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043341","Metabolic sabotage: The insulin–cancer conspiracy","Muhammed Jasim Abdul Jalal","2025","The Journal of Clinical and Scientific Research","nonrandomized_study","article","10.4103/jcsr.jcsr_90_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043342","Erratum",null,"2016","Journal of Diabetes Investigation","randomized_trial","article","10.1111/jdi.12470","27042283",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","erratum"],["R0043343","The craze with Semaglutide","Ruby Dhar","2024","Asian Journal of Medical Sciences","commentary","article","10.71152/ajms.v15i6.544",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0043344","675 Euglycemic diabetic ketoacidosis triggered by glucagon-like peptide-1 (GLP-1) agonist dulaglutide in a patient with type 2 diabetes: a case report","Parth Adrejiya","2025","The American Journal of the Medical Sciences","case_report","article","10.1016/s0002-9629(25)00681-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043345","GLP-1 Receptor Agonist Use in Pregnancy","Irena Druce","2025","Canadian Diabetes & Endocrinology Today","other","article","10.58931/cdet.2025.3139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043346","Placebo, Nocebo, and the Emotional Landscape of Alzheimer’s Treatment","Alireza Shafaati","2025","The Journal of Medical Research","other","article","10.4103/jmr.jmr_79_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043347","Efeitos do tratamento com Liraglutida nas vias de sinalização de insulina e leptina em hipotálamo de camundongos obesos = Effects of treatment with Liraglutide in signaling pathways of insulin and leptin in the hypothalamus of DIO mice","Giovanna Tase Ricardo","2015","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043348","Investigating central and pancreatic GIPR signalling; implications for the treatment of metabolic disease","Davies, Iona","2025",null,"preclinical","article","10.25560/119307",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043349","2003 was stellar for biotechs; new applications make 2004 promising.","Bob Carlson","2004","PubMed","other_trial","article",null,"23372480",null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0043350","The incretin revolution","Tuccinardi, D.","2025","The Journal of AMD","other_trial","article","10.36171/jamd25.28.3.12",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043351","Physicochemical and biopharmaceutical properties of cryosprayed particulate lipid systems for oral liraglutide delivery","Caroline Carrie","2025","Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043352","Diabetes-induced osteoporosis. Review","Кондратюк, В. Є.","2024","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043353","Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents","W. E. Schmidt","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/bnt5-cj47",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043354","24. A case of necrotising autoimmune myopathy with recent statin use","Mahima Charan","2018","Rheumatology Advances in Practice","randomized_trial","article","10.1093/rap/rky033.015",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043355","Association of GLP-1 RA once weekly and basal insulin: a valid therapeutic option from the complications of SARS-CoV-2 infection too?","Vincenzo Maria Monda","2022","The Journal of AMD","other","article","10.36171/jamd21.24.4.5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043356","The Ambiguous beta-cell : On the loss of human pancreatic beta-cell identity","H. Siebe Spijker","2017","Data Archiving and Networked Services (DANS)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043357","THE INCRETIN MIMETIC DRUG TIRZEPATIDE ATTENUATES MAMMARY TUMOR GROWTH INDEPENDENTLY OF INSULIN-LIKE GROWTH FACTOR-1 SIGNALING","Gates, Claire","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/5x7y-6b44",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043358","Cèl·lules estrellades pancreàtiques: implicació en el procés de transdiferenciació cel·lular endocrina i caracterització del seu secretoma","Lucas Gil, Maria","2008","Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043359","Evaluation of Insulin and Glucagon-Like Peptide-1 Analog Sales in Turkey Before the Pandemic Period; Projection for Upcoming Years: A Market Analysis Study","İsmail Mert Vural","2022","Sakarya Medical Journal","other","article","10.31832/smj.1021311",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043360","Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: Results from the LEADER randomized trial","M.A. Nauck","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/t29z-8831",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","TRUE","paywalled","1","FALSE","article"],["R0043361","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90772-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043362","Mechanistic studies on GLP-1 agonists and DPP-4 inhibitors: Favorable effect of GLP-1 agents outperform side effects","M.A.J. Smits","2018","EUR Research Repository (Erasmus University Rotterdam)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043363","La prescription des analogues du GLP1 dans le diabète de type II est-elle entrée dans la pratique des médecins généralistes picards ?","Clément Foyart","2019","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043364","Preoperative GLP-1 receptor agonist continuation and perioperative safety after thyroidectomy in type 2 diabetes: a target trial emulation using a retrospective multicenter cohort","Chia-Ming Lin","2026","BMC Endocrine Disorders","nonrandomized_study","article","10.1186/s12902-026-02537-y",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043365","Changes in Food Preference and Taste Responses after Roux-en-Y Gastric Bypass","Marco Buter","2011",null,"preclinical","article","10.25560/6872",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043366","Glucagon-Like Peptide-1 Receptor Agonists and Outcomes in Transthyretin Amyloid Cardiomyopathy with Type 2 Diabetes Mellitus","Hritvik Jain","2026","CJC Open","other","article","10.1016/j.cjco.2026.07.008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043367","Timing of GLP-1 Receptor Agonist Discontinuation and Gestational Weight Gain: A Scoping Review","Maria Koleilat","2026","Current Developments in Nutrition","narrative_review","article","10.1016/j.cdnut.2026.108659",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043368","Tratamiento de la diabetes en adultos mayores de 65 años: Revisión y utilidad de los análogos de GLP-1 en este grupo de pacientes","Purificación Sánchez López","2016","European journal of health research","nonrandomized_study","article","10.30552/ejhr.v2i1.12",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043369","Incretins in healthy and type 2 diabetic people","Umberto Goglia","2024","The Journal of AMD","other","article","10.36171/jamd24.27.2.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043370","Outcome cardiovascolari con tirzepatide versus dulaglutide in pazienti con diabete mellito di tipo 2","Chiara Barberis","2026","L Endocrinologo","other","article","10.1007/s40619-026-01879-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043371","Errata",null,"2010","Diabetes Care","other","article","10.2337/dc10-er03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043372","Evaluation of quality of care indicators in type 2 diabetes in relation to the age of patients in 2023: the Annals of AMD"," ","2026","The Journal of AMD","other","article","10.36171/jamd25.28.4.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043373","Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis","Benjamin Ole Wolthers","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/m8h4-9h11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043374","Improvement and appropriateness of diabetes care: multidisciplinary approach projet for people with type 2 diabetes with high clinical complexity","I. Blasi","2023","The Journal of AMD","other_trial","article","10.36171/jamd23.26.s3.11",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043375","Functional characterization of diabetes-and glycemic trait-associated SNPs in GLP-1R","Olesya Fedoryak","2017","eScholarship@McGill (McGill)","other","article","10.82308/41006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043376","Herbal Medicine as an Alternative Medicine for Treating Diabetes: The Global Burden","Geeta Watal","2014","Evidence-based Complementary and Alternative Medicine","preclinical","article","10.1155/2014/596071","25202334",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043377","The Cystic Kidney as a Territory Under Siege: Polycystic Kidney Disease and the Brain's Vasoconstrictive Decree","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22654660",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043378","Impact of Glucagon-Like Peptide-1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients","Scott E. Martin","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.916",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043379","Comparison of the intestinal permeation enhancers, SNAC and C₁₀, for oral peptides : biophysical, in vitro and ex vivo studies","Caroline Twarog","2020","HAL (Le Centre pour la Communication Scientifique Directe)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043380","Antibodies to exenatide did not cross-react with human GLP-1 or glucagon or alter the efficacy or safety of exenatide","Fineman, M.","2010","Data Archiving and Networked Services (DANS)","other_trial","article",null,null,null,"ClinicalTrials.gov:NCT00289237",null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0043381","APOE*3Leiden. CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome","Hoek, A.M. van den","2014","TNO Repository","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043382","Abilities of Renewable Changes of Pancreatic Ultrastructure on the Background of Medical Correction of Experimental Diabetes Mellitus","О. Р. Іванців","2015","Galician Medical Journal (Ivano-Frankivsk National Medical University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043383","Células estromais mesenquimais diferenciadas em células produtoras de insulina : estratégia de neuroproteção em modelo diabético","Krista Minéia Wartchow","2019","Americanae (AECID Library)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043384","The Role of Endocrine Factors in Childhood Obesity","H. Samuel","2026","IntechOpen eBooks","other","article","10.5772/intechopen.1013567",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter; article"],["R0043385","Changes in Food Cravings, Dietary Intake, and Body Composition During GLP-1 Receptor Agonist Titration in Adults With Obesity","Demsina Babazadeh","2026","Current Developments in Nutrition","other","article","10.1016/j.cdnut.2026.109184",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043386","Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)","K. Brown-Frandsen","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/tazj-ry27",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043387","Oral Presentation",null,"2012","Journal of Diabetes Investigation","preclinical","article","10.1111/jdi.12012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043388","Der erste und einzige GIP/GLP-1-Rezeptor-Agonist für die Behandlung des Typ-2-Diabetes [2]","Eli Lilly Suisse","2023","Swiss Medical Forum ‒ Schweizerisches Medizin-Forum","other","article","10.4414/smf.2023.09513",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043389","Acute coronary syndrome: Non-ST-segment elevation myocardial infarction, emerging perspective 2026","Akshay Dhananiwala","2026","Journal of current cardiology.","nonrandomized_study","article","10.4103/jcc.jcc_27_26",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043390","Bariatric surgery: when and for whom?","Chilelli, N.C.","2025","The Journal of AMD","other","article","10.36171/jamd25.28.3.14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043391","Is polypharmacy the future for pharmacological management of obesity?","Ryan A. Lafferty","2022","Current Opinion in Endocrine and Metabolic Research","narrative_review","article","10.1016/j.coemr.2022.100322",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0043392","Current Management of Obesity in an Infertile Female-Recent Advances and Future Prospective Drugs","Kulvinder Kochar Kaur","2013","Journal of Pharmacy and Nutrition Sciences","other","article","10.6000/1927-5951.2013.03.03.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043393","Newer Oral Hypoglycemics Do Not Increase or Decrease Mortality.","Allen F. Shaughnessy","2017","PubMed","other","article",null,"29094897",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043394","Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?","Mark M. Smits","2017","Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043395","The Effect of Gut Hormones on Metabolism and Energy Homeostasis","Klara Hostomska","2011",null,"preclinical","article","10.25560/9140",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043396","Virtual Diabetes Optimization Program (VDOP) for Veterans with Uncontrolled Diabetes","Thomas Adel","2026","Diabetes Obesity and Cardiometabolic CARE","other","article","10.2337/figshare.33055055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0043397","Exendin-4 na prevenção de danos teciduais decorrentes da morte encefálica e no controle bioenergético da célula β pancreática","Rodrigo Carlessi","2015","Americanae (AECID Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043398","Recent Advances in Chronic Renal Failure: A Review of Integrated Traditional Chinese and Western Medicine Perspectives","Zilong Yan","2026","Journal of Artificial Intelligence and Information","narrative_review","article","10.66069/ojspub.27450748",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043399","Particularidades del manejo perioperatorio de agonistas GLP-1 en pacientes obesos. Análisis crítico de las recomendaciones actuales","Antonello Penna","2024","Revista Chilena de Anestesia","other","article","10.25237/revchilanestv53n4-09",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043400","Transferability of CVOTs EMPA-REG OUTCOME and LEADER in the real world in Italy","Andrea Da Porto","2019","The Journal of AMD","nonrandomized_study","article","10.36171/jamd19.22.4.03",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043401","Effects of Two Glucagon-Like Peptide-1 Receptor Agonists (Semaglutide and Tirzepatide) on Metabolic Dysfunction-Associated Steatotic Liver Disease in Male and Female Mice","Benjamin Madura","2026","Current Developments in Nutrition","preclinical","article","10.1016/j.cdnut.2026.109185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043402","Case Study of Semaglutide and Cardiovascular Outcomes: An Application of the Causal Roadmap to a Hybrid Design for Augmenting an RCT Control Arm with Real-World Data","Buse J.B","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/dzjx-xy02",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043403","The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?","S. Morteza Seyed Jafari",null,"Open Access CRIS of the University of Bern","other","article","10.48620/97784",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043404","The role of epicardial fat in the progression of cardiovascular disease in women","Ruzzell C Flores","2025","Current Opinion in Physiology","narrative_review","article","10.1016/j.cophys.2025.100888",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0043405","DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks","K. L. Taylor","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/nqmf-re91",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043406","Trends in Diabetes Medications after Metformin in High Versus Moderate Cardiovascular Risk Patients: the BESTMED Consortium 2014-2022","M. Cecilia Lansang","2026",null,"nonrandomized_study","article","10.2337/figshare.32575320.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0043407","Real-world phenotypic markers to guide equitable use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes: evidence from a large machine learning-based cohort study"," ","2026","The Journal of AMD","nonrandomized_study","article","10.36171/jamd25.28.4.3",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043408","The Cardiovascular Events in Metabolic Surgery Compared to the New Classes of Glucose-Lowering Agents in Patients With Type 2 Diabetes Mellitus: A Systematic Review With Narrative Synthesis","Najla Shamsi","2021","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvab048.977",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0043409","Future Directions in Choline: From Neurodevelopment to Cardiometabolic Health","Jessica Sprinkles","2025","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/1ext-vp77",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043410","Efficacy and Safety of Endoscopic Sleeve Gastroplasty in Patients with Obesity and Predictors of Weight Loss","Noble Thomas","2024","Tropical Gastroenterology","nonrandomized_study","article","10.4103/tg.tg_17_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043411","Untersuchungen zur Wirkung von Glp-1 Rezeptoragonisten auf die Betzell-Apoptose","Daniel Tews","2008","Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043412","Mechanisms and Treatments of Obesity-related Inflammation","Hannah Min-Young Oh","2026","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/k3z5-ja40",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043413","Investigating the Impact of Semaglutide on Hepatic Oxidative Stress in Obese Male Rats Induced by High-Fat Diet","Duha Haitham Mohammed Alzubaidy","2024","Maaen Journal for Medical Sciences","preclinical","article","10.55810/2789-9136.1050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043414","Advancing Type 2 Diabetes Management with Semaglutide: Clinical and Real-World Insights","Mansi Srivastava","2025","medtigo Journal of Medicine","randomized_trial","article","10.63096/medtigo3061238",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043415","Der Einfluss inflammatorischer Mediatoren des Metabolischen Syndroms auf die Regulation des Hyaluronsäure-Systems an humanen, glatten Gefäßmuskelzellen","Martina Rosen","2012","Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043416","In Silico discovery and design of molecular glues as a new strategy for development of non-peptidic, small-molecule agonists of GLP-1 receptor","Liang Tang","2025","ChemRxiv","other_trial","article","10.26434/chemrxiv-2025-k2gjf",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","preprint"],["R0043417","Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial","Steve Bain","2024","Cronfa (Swansea University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0043418","GLP-1 Receptor Agonists Alter Interoceptive Effects of Alcohol and Reward Preference","Windram, McKinley","2025","Carolina Digital Repository (University of North Carolina at Chapel Hill)","preclinical","article","10.17615/edw0-5010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043419","New treatments and new choices for type 2 diabetes mellitus","Deepak Bhatnagar","2010","The Journal of the Royal College of Physicians of Edinburgh","randomized_trial","article","10.4997/jrcpe.2010.424","21132140",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043420","Pre-clinical development of cyclodextrin-based nanoparticles for oral delivery of protein/peptide drugs-in vitro and in vivo evaluation","Elena Presas","2018","Arrow@dit (Dublin Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043421","Health-related quality of life in people with type 2 diabetes participating in the LEADER trial","S. Pocock","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/5edj-5h41",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0043422","GLP-1 Receptor Agonists for Obesity in Asians: Evidence From East Asia and Research Gaps in South Asia","Ahmad Alam","2025","Journal of Diabetology","randomized_trial","article","10.4103/jod.jod_164_25",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043423","Does the glucagon-like peptide-1 act through the vagal afferent neurons to modulate anxiety, food neophobia and food reward behaviour?","Marie Rouault","2015","HAL (Le Centre pour la Communication Scientifique Directe)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043424","Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes","Buse,","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/cz52-x169",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043425","Management of Type 2 Diabetes Mellitus","Leslie Bahn Kawa","2023","IntechOpen eBooks","other","article","10.5772/intechopen.1002478",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043426","Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support","Sooyeun Choi","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","systematic_review","article","10.17615/32vd-ce81",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0043427","What if Gut Hormones Aren't Really Hormones: DPP-4 Inhibition and Local Action of GLP-1 in the Gastrointestinal Tract","David A. D’Alessio","2011","Endocrinology","preclinical","article","10.1210/en.2011-1385","21785013",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043428","Semaglutide and the Effects of Glucagon-like Peptide-1 on Vision","Rajesh Rajput","2026","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_28_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043429","Інсулін, адипокіни та псоріатичний артрит. Огляд","В.Є. Кондратюк","2026","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043430","From a Glycocentric Approach to Prevention of Multi-Organ Damage in Type 2 Diabetes","Fernando Grover‐Páez","2023","IntechOpen eBooks","other","article","10.5772/intechopen.1002363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043431","Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)","P. Raskin","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/cn5s-c680",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043432","Better the Time in Range, Longer the Time in Life","Jothydev Kesavadev","2026","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_16_26",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","editorial"],["R0043433","Beyond Benefits: The Unseen Risks of GLP-1 Receptor Agonists in Recent Trials","Mahmoud H. Elbatreek","2024","Zagazig Journal of Pharmaceutical Sciences/Zagazig Journal of Pharmaceutical Science","other","article","10.21608/zjps.2024.340729.1080",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043434","Liver transplantation and bariatric surgery: Is sleeve gastrectomy really the panacea?","Bruno Sensi","2024","American Journal of Transplantation","other","article","10.1016/j.ajt.2024.11.017","39557122",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043435","Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database","Atul Khurana","2024","Clinical Epidemiology and Global Health","nonrandomized_study","article","10.1016/j.cegh.2024.101805",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043436","Effects of GLP-1 Receptor Agonist on Chronic Axonal Damage, Neurodegeneration, and Cognitive Function in Relapsing-remitting MS (MSGLP): Exploratory, Open Label, Randomized Controlled Trial","Richard Imrich","2024","Neurotherapeutics","randomized_trial","article","10.1016/j.neurot.2024.e00403",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043437","Estimating glomerular filtration rate in African populations","June Fabian","2023","African Journal of Nephrology","other","article","10.21804/26-1-6108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043438","Analogues du GLP-1 versus inhibiteurs du SGLT-2 pour les diabétiques de type 2 obèses","Marques, Ana Rita Forte","2015","Archive ouverte UNIGE (University of Geneva)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043439","Unintended effects of anti-hyperglycaemic drugs studied in population-based cohorst","Johanna H. M. Driessen","2017",null,"nonrandomized_study","article","10.26481/dis.20170421ad",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","dissertation"],["R0043440","Atenção farmacêutica no tratamento da obesidade envolvendo os análogos do Glucagon-like peptide 1 (GPL-1)","Ana Maria Santos Barbosa","2022","Research Society and Development","other","article","10.33448/rsd-v11i7.30134",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043441","Metformin: new insights into an archetypal cardiometabolic drug","Andrew J. Krentz","2017","Cardiovascular Endocrinology","randomized_trial","article","10.1097/xce.0000000000000129","31646125",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043442","Oxford Diabetes Symposium 2017","Andrew J. Krentz","2017","Cardiovascular Endocrinology","nonrandomized_study","article","10.1097/xce.0000000000000137","31646133",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043443","Self-assessment questions: Future treatments for Parkinson’s disease","Thomas Foltynie","2012","Clinical Medicine","other","article","10.7861/clinmedicine.12-6-s91",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043444","Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling","Kanamarlapudi Aiysha Thompson","2013","Clinical and Experimental Pharmacology","other","article","10.4172/2161-1459.1000138",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043445","Recent trials with a “High impact” on current daily practice: A 360° journal search","Suman Bhandari","2025","Journal of current cardiology.","randomized_trial","article","10.4103/jcc.jcc_3_25",null,null,"ClinicalTrials.gov:NCT04275726",null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043446","Mortality and Heart Failure Exacerbations With Incretin-Mimetic Drugs for Weight Loss in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction","Leila Humphreys","2025","Current Developments in Nutrition","other","article","10.1016/j.cdnut.2025.107225",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043447","Proteomic and phosphoproteomic analysis of the effect of exendin-4 treatment on the rat pancreatic beta cell line ins-1","Al Mismar, Rasha","2017","Spiral (Imperial College London)","preclinical","article","10.25560/73979",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043448","Tirzepatide Safely Improves Obesity and Glycemic Control in Diabetic Kidney Transplant Recipients","Masayoshi Miura","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.949",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043449","Impact of a High Pea Protein and Prebiotic Fiber Matrix on Nutrient Adequacy and Gastrointestinal Dynamics in GLP-1 Receptor Agonist Users: A Pilot Study","Nikki A Withrow","2026","Current Developments in Nutrition","other","article","10.1016/j.cdnut.2026.108006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043450","Growth of the ESKD Population: Progress or Peril?","Allan J. Collins","2018","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2018111135","30559145",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043451","Prescription de l'association fixe insuline degludec/liraglutide chez les diabétiques de type 2 en pratique médicale courante dans les Alpes Maritimes : étude ancillaire de l'étude nationale prospective multicentrique FOXYs","Charlotte Roure","2019","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043452","MRI-based computational characterization of subcutaneous drug depots in ex vivo porcine model: implications for biotherapeutics and delivery devices","Shuying Wang","2026","AAPS Open","preclinical","article","10.1186/s41120-026-00191-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043453","Obezitenin Medikal Tedavisinde Liraglutide Etkinliğinin Araştırılması","Mustafa Altınkaynak","2023","Sakarya Medical Journal","other","article","10.31832/smj.1320355",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043454","Nearly Half of U.S. Perimenopausal Women Meet Eligibility for GLP-1–Based Anti-Obesity Medications: NHANES 2013–2023","Demsina Babazadeh","2026","Current Developments in Nutrition","other","article","10.1016/j.cdnut.2026.109150",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043455","Clinical Review of Incretin Based Therapies: Their Role in the Management of Type 2 Diabetes Mellitus","Eulalia Barajas-Graham","2019","Carolina Digital Repository (University of North Carolina at Chapel Hill)","narrative_review","article","10.17615/2fjk-y383",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043456","Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing","Michael O. Frederick","2021","Organic Process Research & Development","other","article","10.1021/acs.oprd.1c00108",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043457","Linagliptina, nuevo medicamento aprobado para el tratamiento de la diabetes","Xavier, Silvia","2011","Americanae (AECID Library)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043458","Hypothesis-Generating Brief: GLP-1 longevity — full paper","Dominic Lynch","2026",null,"other_trial","article","10.17605/osf.io/98auj",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0043459","Effects of liraglutide on depressive behavior and cognitive function in the probe trial of Morris water maze test","Duk‐In Jon","2025","European Psychiatry","other_trial","article","10.1192/j.eurpsy.2025.2083",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043460","Traitement combiné d’insuline et d’analogue du GLP-1 : qu’en attendre ?","Bénédicte de Kalbermatten","2014","Revue Médicale Suisse","other","article","10.53738/revmed.2014.10.433.1235",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043461","Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes","C. R. Heilmann","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/tes1-8f86",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043462","Le premier et unique agoniste des récepteurs du GIP/GLP-1 pour le traitement du diabète de type 2 [2]","Eli Lilly Suisse","2023","Forum Médical Suisse ‒ Swiss Medical Forum","other","article","10.4414/fms.2023.09513",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043463","Targeted Inhibition of Methionine Aminopeptidase 2: A Novel Strategy for Anti-Obesity Therapy","Hazera Binte Sufian","2026","Current Developments in Nutrition","other","article","10.1016/j.cdnut.2026.109175",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043464","Novel modulators of lipoprotein metabolism : implications for steatohepatitis and atherosclerosis","Yanan Wang","2013","Leiden Repository (Leiden University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043465","Cognitive disorders in diabetes","Karim Gariani","2025","Frontiers in Clinical Diabetes and Healthcare","other","article","10.3389/fcdhc.2025.1534105","40066254",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043466","Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","N. Poulter","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/7zxp-j706",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043467","Weight Loss in a Commercial Mobile Behavior Change Program With and Without Semaglutide Microdose: Protocol","Larissa Calancie","2026","Current Developments in Nutrition","protocol","article","10.1016/j.cdnut.2026.109275",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0043468","Abstract of Oral Papers presented at the OSSICON 2026, the 23rd Annual Conference of the Obesity and Metabolic Surgery Society of India (OSSI), February 25–28, 2026, Ahmedabad, India",null,"2025","Journal of Bariatric Surgery","randomized_trial","article","10.4103/jbs.jbs_4_26",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0043469","Diabetes and cardiovascular disease: what have we learned in 2012?","Glenn R. Cunningham","2013","PubMed","randomized_trial","article",null,"23914022",null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0043470","Weight Loss Drugs: A Panacea for our Obesity Crisis?","Amitav Banerjee","2026","Medical Journal of Dr D Y Patil Vidyapeeth","nonrandomized_study","article","10.4103/mjdrdypu.mjdrdypu_1220_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043471","Perioperative management of novel oral hypoglycaemic agents","Faida Al-Maiyah","2025","BJA Open","other","article","10.1016/j.bjao.2025.100452",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043472","A Retrospective Real-world Study of Oral Semaglutide in Obesity-related Heart Failure with Preserved Ejection Fraction in India","Guna Sai Vallapuri","2026","Journal of the Practice of Cardiovascular Sciences","randomized_trial","article","10.4103/jpcs.jpcs_92_25",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043473","The Demedicalization of GLP-1 Receptor Agonists: An Analysis of TikTok Influencer Endorsement of Ozempic-like Medications for Cosmetic Weight-loss","Riya Jayanthi","2026","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/kerc-rs37",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043474","Pathophysiology-Oriented Treatment of Type 2 Diabetes: 10 Case Reports","Noemi Nováková","2023","IntechOpen eBooks","case_report","article","10.5772/intechopen.1002857",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043475","The Badly Behaving Brain: How Ultra-Processed Food Addiction Thwarts Sustained Weight Loss","Susan Peirce Thompson","2024","IntechOpen eBooks","other","article","10.5772/intechopen.1004428",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0043476","Tirzepatide versus Semaglutide: Selecting the Right Agent for the Right Patient in Contemporary Metabolic Care","Ahmad Alam","2026","Bangladesh Journal of Endocrinology and Metabolism","other","article","10.4103/bjem.bjem_17_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043477","Pharmacological management of heart failure with preserved ejection fraction: a narrative review of diagnosis, drug classes, and trial evidence","Mosrur Ahmed","2025","Journal of Prevention Diagnosis and Management of Human Diseases","randomized_trial","article","10.55529/jpdmhd.52.95.108",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0043478","Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure","N.R. Poulter","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/t8n0-9d50",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043479","Systemic benefits of weight loss: impact on cardiovascular risk","Tozzi, R.","2025","The Journal of AMD","nonrandomized_study","article","10.36171/jamd25.28.3.15",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043480","Beyond Weight Loss: The Musculoskeletal Effects of GLP-1 Therapies","Aleksandra Zurowska","2026","EMJ Rheumatology","other","article","10.33590/emjrheumatol/771475ds",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043481","On Hunger: Violence and Craving in America, from Starvation to Ozempic","Dana Simmons","2024",null,"other","article","10.1525/luminos.232",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0043482","Clinical and economic aspects of semaglutide use in the treatment of obesity","A. L. Tibilova","2026","FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","randomized_trial","article","10.17749/2070-4909/farmakoekonomika.2026.369",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043483","The Effects of Glucagon-like Peptide-1 on Human Megakaryocytes and Platelets","Alison Cameron-Vendrig","2013","Library and Archives Canada (Government of Canada)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043484","Beyond Syringes and Pills: Advances in Drug Delivery Systems for Diabetes","Muggu Sankara Bhavani","2023","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.13.3.48",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043485","Weight Reduction in Obese or Overweight Diabetic Patients Treated with Oral Semaglutide in a Real World Setting","Rupesh Jain","2025","Indian Heart Journal","nonrandomized_study","article","10.1016/j.ihj.2025.11.139",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043486","POS-778 OUTCOMES OF SODIUM–GLUCOSE COTRANSPORTER 2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN KIDNEY TRANSPLANT RECIPIENTS WITH DIABETES","Tarek Mahmoud","2022","Kidney International Reports","other","article","10.1016/j.ekir.2022.01.814",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043487","The craze with semaglutide","Ruby Dhar","2024","Asian Journal of Medical Sciences","other","article","10.3126/ajms.v15i6.64582",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043488","LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations","A. C. Moses","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/7bvq-pf76",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043489","Bridging Evidence and Practice: A Scoping Review Protocol on Access to GLP-1 Receptor Agonists for Obesity in the United States","Osman Mohamed Elfadil","2026","Current Developments in Nutrition","protocol","article","10.1016/j.cdnut.2026.109299",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0043490","Determining the gastrointestinal stability of peptide therapeutics via chromatographic methods","Maxim Bird","2025",null,"nonrandomized_study","article","10.25560/128174",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0043491","Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes.","Lisa A. Raedler","2015","PubMed","other","article",null,"26629285",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043492","Critically Appraised Topic: Weight Gain Following Discontinuation Of Semaglutide In Nondiabetic Patients","Natalia Halpern","2025","Michigan Journal of Medicine","randomized_trial","article","10.3998/mjm.7687",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043493","831 Comparison of A1C, bmi and weight after treatment with GLP-1 agonist vs standard therapy with metformin and insulin in adolescents with Type 2 Diabetes","Mar Vera-Sánchez","2025","The American Journal of the Medical Sciences","other","article","10.1016/s0002-9629(25)00836-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043494","Population Pharmacokinetics of Lixisenatide, a Once- Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes","Thomas Frank","2013","Journal of Pharmaceutics & Drug Delivery Research","other","article","10.4172/2325-9604.1000112",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043495","Role of incretins and DPP-4 inhibitors in the regulation of adipokine secretion","Xu, L","2010","Zurich Open Repository and Archive (University of Zurich)","other","article","10.5167/uzh-34779",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043496","Molecular mechanisms of the rapid and weight loss-independent beneficial cardiovascular effects of Roux-en-Y gastric bypass surgery","Doytcheva, Petia","2016","Zurich Open Repository and Archive (University of Zurich)","preclinical","article","10.5167/uzh-204803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043497","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-83259-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043498","The Role of AMPK in Diabetic Cardiomyopathy and Related Intervention Strategies","Fang-Lian LIAO","2025","PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS","other","article","10.3724/j.pibb.2025.0155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043499","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92251-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043500","Treatment of suboptimal initial response or recurrent weight gain after Roux-en-Y gastric bypass","Janine Makaronidis","2024","British journal of surgery","other_trial","article","10.1093/bjs/znae081","38717921",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043501","G Protein-Coupled Receptors and Insulin Secretion: 119 and Counting","S.R. Murthy Madiraju","2007","Endocrinology","preclinical","article","10.1210/en.2007-0336","17507578",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043502","EFFECTS OF ONE-YEAR SEMAGLUTIDE AND SITAGLIPTIN TREATMENT ON SERUM INSULIN-LIKE GROWTH FACTOR-BINDING PROTEINS IN PATIENTS WITH TYPE 2 DIABETES","Eszter Dániel","2026","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2026.121462",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043503","Cagrilintide enhances leptin sensitivity and energy expenditure in a sex-dependent manner in a polygenically predisposed rat model of obesity","Patricia Mühlstädt","2026","Zurich Open Repository and Archive (University of Zurich)","preclinical","article","10.5167/uzh-435165",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043504","Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extende release","Anna Krämer","2020","Zurich Open Repository and Archive (University of Zurich)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043505","TIRZEPATIDE VERSUS SEMAGLUTIDE ON ATHEROGENIC LIPID PROFILES AND WEIGHT LOSS IN OBESITY: A SYSTEMATIC REVIEW","Gautham Bonny Natesan","2026","Atherosclerosis","systematic_review","article","10.1016/j.atherosclerosis.2026.121452",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0043506","Insulin/semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-81628-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043507","GLP-1 receptor agonists in obesity and musculoskeletal disease","Kathryn Biddle","2026","Medicine","other","article","10.1016/j.mpmed.2026.06.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043508","THE EFFECT OF LIPOXIN-A4 & LIRAGLUTIDE IN A GLUCOSE-CHALLENGED MACROPHAGE MODEL OF EARLY DIABETES ASSOCIATED ATHEROSCLEROSIS","Luke Conroy","2026","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2026.120968",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043509","SEMAGLUTIDE SIGNIFICANTLY REDUCES BONE MARROW RESIDENT INFLAMMATORY MACROPHAGES AND CIRCULATING INFLAMMATORY MONOCYTES IN T2D PATIENTS","Thomas Collins","2026","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2026.120888",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043510","Эффективность и безопасность применения лираглутида у подростков 12-15 лет с ожирением: проспективное 24-недельное наблюдательное когортное исследование","O. P. Kovtun","2025","Electronic Archive of Ural Federal University (ELAR UrFU)","nonrandomized_study","article","10.15690/pf.v22i2.2871",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043511","CARDIOMETABOLIC RISK OPTIMIZATION WITH DULAGLUTIDE: SIGNIFICANT REDUCTIONS IN BODY WEIGHT, BMI, AND LDL-CHOLESTEROL","Amelian Bobu","2026","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2026.121270",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043512","Efficacy and Safety of Basal Insulin Combined with GLP-1 Receptors Agonists versus Intensified Conventional Insulin Regimens in Type 2 Diabetes: A Meta Analysis of Randomized Controlled Trials","Sarah Albishri","2026","International Journal of Medicine in Developing Countries","randomized_trial","article","10.24911/ijmdc.51-1785039096",null,null,"PROSPERO:CRD420261443671",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043513","Long-Acting GLP-1 Receptor Agonists for Weight and Glycaemic Control in Adolescents with Type 2 Diabetes","Muhindo Anitah","2026","IDOSR JOURNAL OF SCIENTIFIC RESEARCH","randomized_trial","article","10.59298/idosrjsr/2026/11.2.2327",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043514","Zur Beeinflussung des Verzehrsverhaltens durch Exendin-4, Leptin und Ghrelin","Simone Jacqueline Gilg","2003","Zurich Open Repository and Archive (University of Zurich)","preclinical","article","10.5167/uzh-163095",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043515","Editorial: Bio-nanomaterials and systems for enhanced bioimaging in biomedical applications","Sumin Park","2024","Frontiers in Molecular Biosciences","other_trial","article","10.3389/fmolb.2024.1491376","39473822",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0043516","Liraglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-33859-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043517","SUN-186 Insulin Antibody Associated Severe Insulin Resistance Leading to Uncontrolled Hyperglycemia","Hajira Amir","2019","Journal of the Endocrine Society","other","article","10.1210/js.2019-sun-186",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043518","111In標識exendin-4を用いた、非侵襲的かつ縦断的なベータ細胞量の定量","Fujita, Naotaka","2020","Institutional Repositories DataBase (IRDB)","other","article","10.14989/doctor.k22149",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043519","Accidental Semaglutide Overdose","Chung, Jeffrey","2023","eScholarship (California Digital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043520","Ocular Adverse Events of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide versus Selective GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis","Yehya Tlaiss","2026",null,"systematic_review","article","10.17605/osf.io/wnfqb",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0043521","SUN-813 GLP-1 and Cancer Risk: AI Chatbot Responses","Sahej Sidhu","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1319",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043522","Exenatide Worsens Depression And Causes Suicidal Ideation Relapse : A Case Report","Seker, Asilay","2017","BiblioBoard Library Catalog (Open Research Library)","nonrandomized_study","article","10.26226/morressier.5c642bea9ae8fb00131cf05d",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0043523","Bounded Subcutaneous semaglutide signal: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/vb37n",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043524","Impact of Ramadan fasting on glycemic control in type 2 diabetic patients treated with insulin","Imen Sebai","2017",null,"other_trial","article","10.26226/morressier.59d5184fd462b80296ca2c2e",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","other"],["R0043525","Characteristics and pattern of care of type 1 and 2 diabetic patients during Ramadan: an international prospective study","Hassanein Mohamed","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51840d462b80296ca2da2",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0043526","Reporting of diet quality and intake in interventions evaluating the effects of liraglutide, semaglutide or tirzepatide on weight-loss and/or blood glucose in patients of all age groups with obesity and/or T2D: A systematic review of RCTs","Stanford, Jordan","2024","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/xpngy",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0043527","Systematic Review on the Association Between Tirzepatide and Gastroparesis in Diabetic and Non-Diabetic Populations","Sabrina Ait Gacem","2024",null,"systematic_review","article","10.37766/inplasy2024.11.0124",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0043528","Concluding words","Satish K. Garg","2008","Diabetes Obesity and Metabolism","other_trial","article","10.1111/j.1463-1326.2008.00848.x",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0043529","Vitamin D status connect insulin resistance and bone turnover in Chinese non-osteoporosis patients with type 2 diabetes","Jie Zhang","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51846d462b80296ca2e70",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0043530","Efficacy and safety of oral small-molecule GLP-1RAs in type 2 diabetes mellitus, obesity or both: A systematic review and meta-analysis","Karakasis, Paschalis","2023","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/rmu7q",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0043531","The role of glucagon like peptide - 1 (GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus","Vaishnavi Menon","2019","Endocrine Abstracts","preclinical","article","10.1530/endoabs.63.p562",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043532","Dapagliflozin restores odor‐induced functional integration of POC circuit, but not local olfactory neural activation in patients with type 2 diabetes: a 16‐week randomized parallel comparative study","Xin Li","2025","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz70859_097012","41446977",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043533","MON-694 Resolving the Metabolic Puzzle, Tirzepatide's Multifaceted Benefits in Partial Lipodystrophy","Laura D Barrett","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.032",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043534","NOVOS ANTIDIABÉTICOS E PERSPECTIVAS NO MANEJO DA HIPERGLICEMIA CRÔNICA","Luiza Higino Cruz","2024","RCMOS - Revista Científica Multidisciplinar O Saber","nonrandomized_study","article","10.51473/rcmos.v1i1.2024.613",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043535","There Are Great New Medications Out There—Why Aren’t We Using Them?","Stephen Brunton","2018","Clinical Diabetes","other","article","10.2337/cd18-0011","29686447",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043536","Remission revolution; redefining CKD management from slowdown to reversal","Sepideh Hajian","2026","Journal of Nephropharmacology","other","article","10.34172/npj.2026.12855",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043537","Effect of Liraglutide in The Real World Setting of Type 2 Diabetes Patients : Preliminary Results From The Lira-Spd Trial","Silva-Nunes, José","2017","BiblioBoard Library Catalog (Open Research Library)","nonrandomized_study","article","10.26226/morressier.5d9b6231ea541d6ca8493cb6",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0043538","Real‐World Evidence and the Regulation of Medicines","Peter K. Honig","2021","Clinical Pharmacology & Therapeutics","randomized_trial","article","10.1002/cpt.2230","33870489",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043539","JAMA Network Open —The Year in Review, 2025","Stephan D. Fihn","2026","JAMA Network Open","narrative_review","article","10.1001/jamanetworkopen.2026.8216","41874512",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043540","PSUN172 Prescribing SGLT-2 Inhibitors and GLP-1 Agonists in Primary Care: Improving Rates of Guideline-Concordant Practice","Samantha R Schuetz","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.770",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043541","GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach","Amira Guirguis","2023","Cronfa (Swansea University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043542","Проблеми збереження м’язової маси у разі зниження маси тіла, зокрема при лікуванні ожиріння та надлишкової маси тіла. Огляд","Г. Д. Фадєєнко","2026","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043543","Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","Sanaz Gabery","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/bf32-7709",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043544","L'intérêt du tirzépatide dans la prise en charge non remboursée de l'obésité chez les patients adultes, conseils à l'officine","Sautron, Anthony","2025","HAL (Le Centre pour la Communication Scientifique Directe)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0043545","ADA2019","Zachary T. Bloomgarden","2019","Journal of Diabetes","nonrandomized_study","article","10.1111/1753-0407.12965","31250543",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043546","BioTM Buzz Volume 5, Issue 1","Aaron C. Anselmo","2019","Bioengineering & Translational Medicine","preclinical","article","10.1002/btm2.10156","31989040",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043547","Perfil de seguridad y beneficios de los fármacos antidiabéticos en cuanto al riesgo cardiovascular","Luis Dulcey","2023","Acta Bioclínica","nonrandomized_study","article","10.53766/acbio/2023.13.26.11",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043548","MON-734 TIrzepatide Reverses Insulin Resistance Independent of Weight Loss in Individuals Without Diabetes","Tracey McLaughlin","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.067",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043549","Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin","Yasuhiro Matsubayashi","2022","Diabetes Obesity and Metabolism","nonrandomized_study","article","10.1111/dom.14836","35979908",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043550","The impact of innovative glucose-lowering drugs on the course and outcome of COVID-19 in patients with type 2 diabetes mellitus","Т. Н. Маркова","2024","Diabetes Mellitus","randomized_trial","article","10.14341/dm13106",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043551","Health, risks and disease in therapeutic functionalities of Glucagon-like peptide-1 receptoragonists (GLP-1RAs) concerning human susceptibility","Chukwuma Sr Chrysanthus","2025","Greenfort International Journal of Applied Medical Science","other","article","10.62046/gijams.2025.v03i05.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043552","Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain","Owen Carmichael (707539)","2024","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","conference-paper"],["R0043553","The effect of the GLP-1 agonist, liraglutide, on the right ventricle in pulmonary hypertension","Zhao, Lin","2020",null,"preclinical","article","10.25560/100483",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043554","Acquired Brain Injury-Induced Hyperphagia and Obesity, Successfully Treated With a GLP-1 Agonist","Michael Ngu","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.063",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043555","Bedrohen Dünne die Wirtschaft?",null,"2023","agrarzeitung","other","article","10.51202/1869-9707-2023-41-012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043556","Efficacy and Safety of the Combined Use of Antidiabetic Drugs: Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2) and Glucagon-Like Peptide-1 Receptor Agonists (GLP 1): A Scoping Review","Rodrigues, Ana Clara Martins","2025","OSF Preprints (OSF Preprints)","nonrandomized_study","article","10.17605/osf.io/yf73j",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0043557","Ozempic and the moralization of weight loss: a sociological analysis of media discourse and user comments on tiktok","Nika Oblak","2026","Repository of the University of Ljubljana (University of Ljubljana)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043558","Impact of lifestyle habits on the risk of sarcopenia when using incretin hormones therapies: a systematic review","Marianne Legault","2026",null,"systematic_review","article","10.17605/osf.io/38vb7",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0043559","Unforeseen role for glucocorticoids in combinatorial anti-obesity pharmacology","Carmelo Quarta","2016","Molecular Metabolism","other","article","10.1016/j.molmet.2016.05.009","27408769",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043560","L’Ozempic : intérêt thérapeutique, parcours du médicament et impact des ruptures d’approvisionnement. Conséquences et solutions face aux pénuries","Ellis, Louis","2025","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043561","The 2023 WCIRDC : Obesity","Zachary T. Bloomgarden","2024","Journal of Diabetes","other","article","10.1111/1753-0407.13568","38654482",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043562","A500 The risk of progression of steatotic liver disease to hepatocellular carcinoma and cirrhosis with use of vitamin E, pioglitazone, and glucagon-like peptide 1 analogs: a large, multi-center cohort study",null,"2024","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2024.04.433",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0043563","SUN-682 Prevalence of Eating Disorders Among GLP-1 Receptor Agonist Users: A Cross-Sectional Analysis","Hani Shalabi","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.192",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043564","Potential of liraglutide (Victoza) in multifactor treatment approach in type 2 diabetes mellitus","Е Ю Пашкова","2012","Problems of Endocrinology","other","article","10.14341/probl201258221-24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043565","Pharmacologic strategies for improvement of islet survival: targeting the enterohormonal axis*","Horacio L. Rodriguez-Rilo","2011","Transplant International","preclinical","article","10.1111/j.1432-2277.2011.01377.x","22050184",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043566","Diabetes in the third millennium: prognosis improves, but juvenile forms are more frequent","Fulvio Ventura","2019","European Heart Journal Supplements","other_trial","article","10.1093/eurheartj/suz006","30948936",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0043567","The clinical benefits of IDegLira in DUAL VII were achieved while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy","EM Miller (7814318)","2018","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0043568","Efficacy and cardiovascular effects of dipeptidyl peptidase-4 (DPP4) inhibitors: a systematic review","Dr Muhammad Umar Wahab","2017",null,"systematic_review","article","10.26226/morressier.59d51846d462b80296ca3bd0",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","other"],["R0043569","Preclinical pharmacological characterization of GLP-1 agonists, PPARα activators, and peripheral CB1 antagonists in the treatment of high-fat high-fructose diet–induced metabolic and neuroendocrine dysregulation","Nabila Rasheed","2026","IRIS Research product catalog (Sapienza University of Rome)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043570","Imaging of insulin factory: Is it just imagination or approaching reality?","Soroku Yagihashi","2012","Journal of Diabetes Investigation","preclinical","article","10.1111/j.2040-1124.2012.00236.x","24843602",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043571","The exaptation of endocrine pharmacology","Sanjay Kalra","2012","Indian Journal of Endocrinology and Metabolism","commentary","article","10.4103/2230-8210.95658","22629494",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0043572","Considerations Regarding Association of Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy","Brian Mac Grory","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/qj13-bp07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043573","GLP-1 receptor agonists in a cohort of older adults with type 2 diabetes : Outcomes on body composition, strength, and physical performance","Andrade Moreno, Maria Paz","2023","Repositorio Institucional (Pontificia Universidad Javeriana)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0043574","SAT-536 How Do Metabolic Dysfunction Associated Steatosis Liver Disease (MASLD) and Depression in Veterans with T2DM respond to novel medications","Shannen Nicole Dean Ubalde","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1068",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043575","Efficacy of Lifestyle Intervention Versus Pharmacotherapy in the Progression of Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis","Ghazala S. Virk","2025","Journal of Advances in Medicine and Medical Research","systematic_review","article","10.9734/jammr/2025/v37i15712",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0043576","The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF-36: 3-year data","Jakob Bue Bjørner","2016","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043577","Taking Aim at Islet Hormones With GLP-1: Is Insulin or Glucagon the Better Target?","David A. D’Alessio","2010","Diabetes","other","article","10.2337/db10-0299","20587800",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043578","Letter to the Editor: Diabetes, obesity and hypertension may promote oral SARS‐CoV‐2 infection—Salivary soluble ACE2 perspective","Jelena Roganović","2020","Oral Diseases","commentary","article","10.1111/odi.13711","33141469",null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0043579","Subcutaneous semaglutide: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/bjrc3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043580","GLP-1RA Medications Significantly Reduce Fracture Risk in the Diabetic Foot and Ankle Patient Population","Samantha N. Olson","2025","Foot & Ankle Orthopaedics","nonrandomized_study","article","10.1177/2473011425s00269",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043581","Role of insulin dysregulation in the development of yoshida sarcoma-induced cancer cachexia","Mary Ann Honors","2013","Purdue e-Pubs (Purdue University System)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043582","GLP-1 Receptor Agonists & Dietary Recommendations...What We Know So Far","Richardson, Olivia","2025","ScholarWorks -A service of University of Vermont Libraries (University of Vermont)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043583","2024-25 Guide to Medications for the Treatment of Diabetes Mellitus","Joshua J. Neumiller","2024","American Diabetes Association eBooks","other","article","10.2337/9781580408387",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0043584","HbA1c increases significantly post-transplant and is highest in overweight patients","Dattani, Rakesh","2017","BiblioBoard Library Catalog (Open Research Library)","other","article","10.26226/morressier.5c2e086926eca80014e243fa",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043585","Editorial: Metabolic dysfunction-associated steatotic liver disease (MASLD) - pathogenesis, prevention and treatment","Stanisław Surma","2025","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1703019","41070342",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0043586","Potencial Aplicação da Tirzepatida no Manejo da Síndrome do Ovário Policístico: Uma Revisão Narrativa","Larissa Assumpção Gimenes de Souza","2025","RCMOS - Revista Científica Multidisciplinar O Saber","other","article","10.51473/rcmos.v1i2.2025.1548",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043587","Investigation of myoglobin expression and its physiological function in brown adipose tissue","Christen, Lisa","2024","Qucosa (Saxon State and University Library Dresden)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043588","Imaging probes targeted to pancreatic beta-cells: design, synthesis and testing","Clough, Thomas Joseph","2021",null,"preclinical","article","10.25560/94498",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043589","Multi-Omic Characterisation of Renal Responses to Intentional Weight Loss in Diabetic Kidney Disease","Martin, William Patrick","2022","Research Repository UCD (University College Dublin)","randomized_trial","article","10.13140/rg.2.2.23464.65286",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0043590","Perinatal hypoxic-ischemic brain injury – characterization, mechanisms and treatment","Zhou, Qishan (Kelly)","2022","ResearchSpace (University of Auckland)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043591","Sakharnyy diabet i gormonal'naya enterologiya: put' v prekrasnoe daleko?","Andrey Alexeevich Aleksandrov","2011","Diabetes Mellitus","other","article","10.14341/2072-0351-5633",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043592","Dapagliflozin-Associated Weight Reduction in Overweight Adults with Type 2 Diabetes: A Systematic Review","Liliane Mfeukeu Kuaté","2026","Journal of Diabetes and Treatment","systematic_review","article","10.29011/2574-7568.010160",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043593","Pharmacotherapy of metabolically associated fatty liver disease","E.E. Mulyukova","2025","Russian Journal of Preventive Medicine","nonrandomized_study","article","10.17116/profmed202528101103",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043594","Liraglutide/semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-67037-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043595","''Jag hade ingen aning om att det var något fel på mig förrän det var fixat'' : En kritisk diskurspsykologisk studie om hur vikt och inkretinbaserade läkemedel konstrueras på sociala medier","Cassandra Eriksson","2026","Diva portal (Dalarna University Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043596","THE 40TH CONGRESS OF THE ITALIAN PHARMACOLOGICAL SOCIETY (SIF)","Francesco Visioli","2021",null,"nonrandomized_study","article","10.36118/pharmadvances.03.2021.01",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043597","Omarigliptin","Iona Galloway","2017","Practical Diabetes","randomized_trial","article","10.1002/pdi.2086",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043598","Copper(II) Lysinate and Pseudoproline Assistance in the Convergent Synthesis of the GLP-1 Receptor Agonists Liraglutide and Semaglutide","Ivan Guryanov","2021","Organic Process Research & Development","other","article","10.1021/acs.oprd.1c00021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043599","Regeneration of β cells from cell phenotype conversion among the pancreatic endocrine cells","Tianjiao Wei","2022","Chronic Diseases and Translational Medicine","preclinical","article","10.1002/cdt3.15","35620156",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043600","Hypoglycemic Effect and Mechanism of ICK Pattern Peptides","Lin-Fang Chen","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.16476/j.pibb.2024.0208",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043601","Ozempic Face”: An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)—Our Experience","Luciano Catalfamo","2026","Journal of Cranio-Maxillofacial Surgery","other","article","10.1016/j.jcms.2026.109623",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043602","The Role of GLP-1 Agonists in Weight Management: Barriers, Effectiveness, and Safety Perceptions","Pratikshya Silwal","2026","Drugs & Therapy Perspectives","nonrandomized_study","article","10.1007/s40267-026-01243-y",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043603","MON-546 Euglycemic Diabetic Ketoacidosis With Recent Initiation Of A SGLT2 Inhibitor Medication In A Patient With T2D","N. M. Mahmudul Alam Bhuiya","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.913",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043604","Establishing a role of the insulin receptor in microglia","William A. Banks","2025","Neural Regeneration Research","preclinical","article","10.4103/nrr.nrr-d-25-00722","40808473",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043605","MON-702 Semaglutide as a Potential Tool in Pre-Lung Transplant Weight Loss Optimization","Roshaneh Ali","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.040",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043606","Schizophrenia: Does Semaglutide Outperform Liraglutide for Antipsychotic Weight Gain?","Oliver Freudenreich","2026",null,"randomized_trial","article","10.64239/pi-qt9102",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","report"],["R0043607","Semaglutide Effect on Working Memory","Lu, Tommy","2024","Scholarship @ Claremont (The Claremont Colleges)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043608","Improved treatment satisfaction with dulaglutide and insulin glargine in patients with T2D and chronic kidney disease","Yu Maria","2017",null,"randomized_trial","article","10.26226/morressier.59d51846d462b80296ca3bda",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0043609","Liver-directed gene therapy for type 1 diabetes","Appavoo, Mathiyalagan","2022","UNSWorks (University of New South Wales, Sydney, Australia)","preclinical","article","10.26190/unsworks/17515",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043610","P0050 Cardiologic and oncologic outcomes with GLP-1 receptor agonists in men receiving androgen deprivation therapy for prostate cancer","T. Fazekas","2026","European Urology","other","article","10.1016/s0302-2838(26)00967-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0043611","A duális antidiabetikus hatású kombináció, a tirzepatid","László Gerő","2023","Diabetologia Hungarica","other","article","10.24121/dh.2023.4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043612","Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects","Soo Lim","2021","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.14627","34908220",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043613","Benefits and Harms of Once-weekly Glucagon-like peptide-1 receptor agonist treatments. A systematic review and network meta-analysis","Melanie J. Davies (7155500)","2015","Figshare","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0043614","PSUN276 GLP1RAs use for treating NALFD in a multidisciplinary clinic in low socioeconomic community","Brittany West","2022","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvac150.836",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043615","Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes","Young Min Cho","2022","Journal of Diabetes Investigation","randomized_trial","article","10.1111/jdi.13953","36449020",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043616","Adipose-targeted microneedle patch co-delivering semaglutide and rosiglitazone unlocks adipose browning efficacy for obesity therapy","Weiqin Yao","2026","Nano Research","preclinical","article","10.26599/nr.2026.94908852",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043617","Evaluation of Diabetes Education and Pharmacist Interventions in a Rural, Primary Care Setting","Lisa T. Meade","2017","Diabetes Spectrum","other","article","10.2337/ds16-0064","29456431",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043618","‘Type 3 diabetes’: linking a brain insulin‐resistant state with dementia and Alzheimer's disease","Ken Shaw","2013","Practical Diabetes","preclinical","article","10.1002/pdi.1752",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043619","GLP-1 receptor agonists improve glycemia and lipidemia through changes in gut microbiota and intestinal immune system","François Briand","2017",null,"preclinical","article","10.26226/morressier.59d51846d462b80296ca3bd5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043620","The importance of sleep quality, quantity, and chronotype in the management of diabetes: Is it time to wake up?","Theocharis Koufakis","2022","Journal of Diabetes","other","article","10.1111/1753-0407.13313","36084953",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043621","Efficacy of semaglutide in reducing atrial fibrillation recurrence post-catheter ablation: propensity score-matched analysis","Raffaele Salerno","2025","EP Europace","nonrandomized_study","article","10.1093/europace/euaf085.496",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043622","The liver in health and disease: relevance to diabetes and associated metabolic disorders","Andrew J. Krentz","2007","Practical Diabetes","other","article","10.1002/pdi.1121",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043623","Incidence of severe urinary tract infections not increased by initiating sodium–glucose cotransporter 2 inhibitors","Hiroki Yokoyama","2019","Journal of Diabetes Investigation","nonrandomized_study","article","10.1111/jdi.13189","31763787",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043624","OH, OH, NO OZEMPIC: THE DANGERS OF OZEMPIC’S DIRECT-TO-CONSUMER ADVERTISEMENTS","Taylor Blicht","2025","bepress Legal Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043625","Reframing Polycystic Ovary Syndrome: Understanding meta-inflammation as the core pathophysiological mechanism and target for future therapies.","Efrén Quiñones-Lara","2026","The Journal of Reproduction","other","article","10.58779/tjorvol4num1/6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043626","MON-166 Excess Cardiovascular Events Despite Good Glycaemic Control","Thomas Ulahannan","2019","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/js.2019-mon-166",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043627","Role of molecular hydrogen in obesity treatment: modulation of GLP-1, irisin, and PGC-1α for improved metabolism","Nikola Todorović","2025","Medical Gas Research","randomized_trial","article","10.4103/mgr.medgasres-d-24-00146","40251025",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043628","Treatment of glycemic control in diabetes in the CVOT era","Daniel Einhorn","2019","Journal of Diabetes","other","article","10.1111/1753-0407.13006","31746129",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043629","Efficacy and Safety of Liraglutide vs. Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes (T2DM) and Moderate Renal Impairment (LIRA-RENAL)","Melanie Davies (545715)","2024","Figshare","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043630","Berberine and Metabolic Dysfunction‐Associated Steatotic Liver Disease: Hope or Hype?","Ruth A Nona","2026","Pharmacology Research & Perspectives","other","article","10.1002/prp2.70300","42458881",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043631","Liraglutide in adolescents with simple obesity and gastrointestinal comorbidities: treatment experience","A. V. Vitebskaya","2023","Obesity and metabolism","other","article","10.14341/omet12922",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043632","Drug Treatment of other Psychiatric Conditions",null,"2025",null,"other","article","10.1002/9781119870203.mpg009.pub2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0043633","761-P: Use of Tirzepatide in Type 1 Diabetes","Belinda P. Childs","2024","Diabetes","nonrandomized_study","article","10.2337/db24-761-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0043634","GLP-1–Based Pharmacotherapies and Migraine Outcomes: A Scoping Review of Human Clinical Evidence","Hameed Alhashmi","2026",null,"randomized_trial","article","10.17605/osf.io/9xqgc",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0043635","Las estrategias de marketing en redes sociales en la percepción de los consumidores del medicamento Ozempic","Gomez Alonso, Lorenzo","2024","Biblioteca Digital Repositorio Institutional CESA (Colegio de Estudios Superiores de Administración)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043636","Targeting Obesity: The Role of GLP-1 Receptor Agonists in Achieving Sustainable Weight Loss","Brad Vamplew","2025","Lynchburg Journal of Medical Science","other","article","10.63932/3067-7106.1031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043637","Barriers to Use of Cardio-Kidney Protective Medications in Chronic Kidney Disease: Results of a Nephrology Provider Survey","Melanie R. Weltman","2026","Kidney Medicine","other","article","10.1016/j.xkme.2026.101474",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043638","Pioneering Advances in Diabetes Technology and Obesity Medicine: Embracing Innovation and Overcoming Challenges","Gitanjali Srivastava","2025","Diabetes Technology and Obesity Medicine","commentary","article","10.1089/dtom.2025.0019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0043639","Efficacy of tirzepatide in people with young-onset type 2 diabetes in the SURPASS programme","MJ Davies (7347098)","2024","Figshare","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0043640","Incretin-based therapies and renal outcomes in adults with chronic kidney disease and/or type 2 diabetes or overweight/obesity: a scoping review protocol","Builes-Montaño, Carlos E.","2025",null,"protocol","article","10.17605/osf.io/sz87j",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0043641","Treatment: Concepts and new developments","Zachary T. Bloomgarden","2016","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12381","26854013",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043642","New-onset atrial fibrillation during critical illness: another piece of the puzzle","Jaap Seelig","2022","EP Europace","randomized_trial","article","10.1093/europace/euac197","36352552",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0043643","MON-LB020 Compound H Causes a Sustained Reduction in Food Intake and Body Weight in Obese Cynomolgus","Simon A. Hinke","2019","Journal of the Endocrine Society","other","article","10.1210/js.2019-mon-lb020",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043644","SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials","Ahmad Salhab","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.169",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043645","Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors","Hirotaka Watada","2019","Journal of Diabetes Investigation","other_trial","article","10.1111/jdi.13131","31446675",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043646","Exploring access, motivations and impact of GLP-1RA use in eating disorder populations","Josephine Balfour-Oatts","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043647","Patient guide to starting a GLP-1 agonist","Eaton, Jenna G","2024","ScholarWorks -A service of University of Vermont Libraries (University of Vermont)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043648","The experience with the use of the GLP-1 analog liraglutide (Victoza) for the optimization of metabolic control and correction of the body mass in the patients with type 2 diabetes mellitus","Т. В. Саприна","2012","Problems of Endocrinology","randomized_trial","article","10.14341/probl201258575-79",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043649","HDL: who needs it?","Anthony S. Wierzbicki","2011","International Journal of Clinical Practice","nonrandomized_study","article","10.1111/j.1742-1241.2011.02769.x","21995687",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043650","Obesity, adipocytes and insulin resistance—Friends for life?","Stefanie Reuter","2019","Acta Physiologica","preclinical","article","10.1111/apha.13258","30659780",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043651","Metabolic complications in people living with HIV: the role of obesity, inflammation, lipid metabolism, and directions for future interventions","Stefano Savinelli","2024","Research Repository UCD (University College Dublin)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0043652","Cardiovascular Risk Factors and Aspects of GLP-1 Treatment in Pediatric Obesity","Stenlid, Rasmus","2025","KTH Publication Database DiVA (KTH Royal Institute of Technology)","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT02794402","S001285","openalex","TRUE","no_doi","1","FALSE","dissertation"],["R0043653","Sa1572 COMPARATIVE EFFICACY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS WITH DIFFERENT TREATMENT DURATIONS PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A NETWORK META-ANALYSIS","Zhenwu Wang","2024","Gastroenterology","systematic_review","article","10.1016/s0016-5085(24)01575-0",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0043654","Effect of semaglutide combined with lifestyle intervention on ovulation rate, androgen excess and metabolic outcomes in adolescent and young adult women with polycystic ovary syndrome: an open-label randomized clinical trial","Marta Lecina Arranz","2025","Universitat de Girona Digital Repository (Universitat de Girona)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0043655","Diabetes agents taking centre stage, playing to the beats of Canon in D","Wann Jia Loh","2024","Current Opinion in Endocrinology Diabetes and Obesity","other","article","10.1097/med.0000000000000898","39692100",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043656","SUN-679 HS235, A Novel Lean Mass-Preserving Treatment for Obesogenic Heart Failure with Preserved Ejection Fraction with Pleiotropic Metabolic Effects","Gauthier Schang","2025","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaf149.189",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043657","SAT-725 Impact of Ozempic (Semaglutide) on Reducing Total Knee Replacement Procedures in Patients with Osteoarthritis","Mahvish Ayman","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.582",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043658","Glucagon-like peptide-1 receptor agonists: practical use in type 2 diabetes","Y-A Park","2022","Minerva Access (University of Melbourne)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043659","Functional characterisation of selective vertebrate and invertebrate venoms on the modulation of human blood clotting and platelet function","Pradeep Vijayakumar","2026","CentAUR (University of Reading)","other","article","10.48683/1926.00130951",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043660","MON-518 Assessing Glycemic Excursions in Patients with Type 2 Diabetes Mellitus Receiving Epidural Steroid Injections","Audrey Lee","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.885",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043661","OR09-08 Muscle Loss With Weight Loss Is Modulated by Age, Sex, and Protein Intake and May Affect Glucose Homeostasis in Adults With Obesity","Melanie S Haines","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.073",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043662","MON-651 Hyperosmolar Hyperglycemic State Induced by Leptospirosis Infection","Rohan Maini","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043663","Adipose tissue—more than just fat","Kathrin Groeneveld","2020","Acta Physiologica","preclinical","article","10.1111/apha.13451","32017398",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043664","Articles in 'Endocrinology and Metabolism' in 2014","Won‐Young Lee","2015","Endocrinology and Metabolism","other","article","10.3803/enm.2015.30.1.47","25827457",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043665","Atrial fibrillation reporting with semaglutide versus tirzepatide in eudravigilance: a comparative disproportionality analysis","Y Shhab","2026","EP Europace","nonrandomized_study","article","10.1093/europace/euag105.333",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043666","RF28 | PSUN182 Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis","Alimitha M Kodali","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.887",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043667","CO41 Comparative Effectiveness of Glucagon-like Peptide 1 Agonists Vs Dipeptidyl Peptidase 4 Inhibitors on Liver Outcomes in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Fatty Liver Disease","Tiehan H. Shen","2024","Value in Health","other","article","10.1016/j.jval.2024.03.130",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043668","Medical decision making: Microsimulation versus cohort modelling for assessing type 2 diabetes treatments","Lyu, J","2023",null,"nonrandomized_study","article","10.36334/modsim.2023.lyu",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0043669","GLP -1 agonists for weight loss: What you need to know","Joseph F. Goldberg","2023","Current Psychiatry","other","article","10.12788/cp.0318",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043670","Medical nutrition therapy in type 1 diabetes mellitus","SanjayKumar Bhadada","2017","Indian Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/ijem.ijem_539_17","28989867",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043671","Vilken effekt har liraglutid vid behandling av typ 1-diabetes i kombinationsbehandling med insulin?","Khalil, Fatima","2025","KTH Publication Database DiVA (KTH Royal Institute of Technology)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0043672","ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity","Linong Ji","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.026",null,null,"ClinicalTrials.gov:NCT04440345","S001410","openalex","TRUE","open_pdf","1","FALSE","article"],["R0043673","Narrative review on glucagon-like peptide-1 receptor agonists and late-life depression: A new frontier in geriatric psychiatry?","Giuseppe Marano","2025","Aging advances.","randomized_trial","article","10.4103/agingadv.agingadv-d-25-00027",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0043674","Journal of Diabetes News","Manu V. Venkat","2013","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12094","24112456",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043675","Semaglutide-related nonarteritic anterior ischaemic optic neuropathy",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-62504-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043676","Editorial: Exploring combination therapies for effective obesity and metabolic syndrome management","Puspha Sinnayah","2026","Frontiers in Endocrinology","other_trial","article","10.3389/fendo.2026.1824139","42077426",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0043677","Unlocking the Potential: Amylin-Based Therapies as Novel Interventions for Addressing the Nexus of Obesity and Cardiovascular Health","Imran Badshah","2024","Journal of Endocrinology and Metabolism Research","other","article","10.37191/mapsci-2582-7960-5(1)-036",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043678","Take a personalised approach to weight management for older adults with obesity","Michael B. Brown","2026","Drugs & Therapy Perspectives","other","article","10.1007/s40267-025-01213-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043679","Anti-fibrotic Potential of a Novel Long-acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Idiopathic Pulmonary Fibrosis","J.A. Kim","2023",null,"other","article","10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2249",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0043680","Biased signalling of Dual GLP-1R/GCGR agonists","Pickford, Philip John","2020",null,"preclinical","article","10.25560/98649",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043681","Brain-gut-adipose interplay in the antidiabetic effects of gastric bypass surgery","Almby, Kristina","2024","Uppsala University Publications (Uppsala University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043682","Repercussões estéticas faciais do emagrecimento induzido por agonistas do receptor GLP-1 na Harmonização Orofacial: uma revisão integrativa","Rafaella","2026",null,"other","article","10.17605/osf.io/hnp5e",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043683","Direct and indirect medical costs of diabetes and its complications in South Asia","Singh Kavita","2017",null,"other","article","10.26226/morressier.59d51840d462b80296ca2d98",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043684","733 HEPATOPROTECTIVE EFFECTS OF SEMAGLUTIDE IN THE GAN DIET-INDUCED OBESE AND BIOPSY-CONFIRMED MOUSE MODEL OF NASH WITH ADVANCED FIBROSIS AND HEPATOCELLULAR CARCINOMA","Sebastian M⊘ller Nguyen Heimbürger","2023","Gastroenterology","preclinical","article","10.1016/s0016-5085(23)03934-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043685","COPD Exacerbations in Patients With Type 2 Diabetes on Glucagon-like Peptide-1 Receptor Agonists","Dinah Foer","2023",null,"other","article","10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5920",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0043686","SAT-697 Baseline glucose profiles and weight trajectory influence renal function decline in obese individuals with diabetes","Haremaru Kubo","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.130",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043687","The Ema and Glucagon-Like Peptide-1 Agonists: a Wake-Up Call.","George Gregory Buttigieg","2023","Clinical Research and Studies","other","article","10.31579/2835-2882/034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043688","Metabolic syndrome, rheumatoid and psoriatic arthritis: Managing cardiovascular risk","Milan K. Piya","2021","International Journal of Rheumatic Diseases","other_trial","article","10.1111/1756-185x.14197","34469059",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043689","Modulación hormonal, mitocondria y prevención de enfermedad de Alzheimer: el rol de los agonistas de GLP-1 y estrógenos","Daniela Sanabria Candia","2026","Repositorio Institucional E-DocUR (Universidad Del Rosario)","other","article","10.48713/10336_47397",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043690","Precision medicine in type 2 diabetes: Using individualised prediction models to optimise selection of treatment","JM Dennis (21320054)","2025","Figshare","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0043691","Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β-cell function and the achievement of the HbA1c target 1 year after init","Usui, Ryota","2018","Institutional Repositories DataBase (IRDB)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","letter"],["R0043692","Fetal origin of vascular aging","Shailesh Pitale","2011","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.86971","22145131",null,"ClinicalTrials.gov:NCT04255433","S002212","openalex","TRUE","free_to_read","1","FALSE","article"],["R0043693","“Ozempic face”: Aesthetic consequence, unintended muscle loss, or a warning sign of maladaptive weight reduction?","Thomaz Funari Neto","2025","International Health Sciences Review","other","article","10.70164/ihsr.v1i4.49",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043694","Cardioprotective Pharmacotherapy During ICI Therapy and Cardiovascular Outcomes: Systematic Review and Meta-Analysis Protocol","Piyush Puri","2026",null,"systematic_review","article","10.17605/osf.io/kcteq",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0043695","Deintensification of basal-bolus insulin therapy by switching to a fixed-ratio combination of insulin glargine and lixisenatide in patients with type 2 diabetes","V. V. Klimontov","2025","Diabetes Mellitus","nonrandomized_study","article","10.14341/dm13381",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043696","Structural biochemistry : exploring biological macromolecules for the enhancement of pharmaceutical formulations","Μαρία Αθανασιάδου","2023","Νημερτής","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043697","A 3-week nonalcoholic steatohepatitis mouse model allows the rapid evaluation of liraglutide and elafibranor benefits on NASH","François Briand","2020","Metabolism","preclinical","article","10.1016/j.metabol.2019.12.059",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043698","Efficacy and safety of insulin glargine U300 in insulin-nau00efve type 2 diabetes subjects in a real-world practice setting","Guja, Cristian","2017","BiblioBoard Library Catalog (Open Research Library)","nonrandomized_study","article","10.26226/morressier.5d9b6229ea541d6ca8493890",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0043699","GLP-1 receptor agonist-related pulmonary aspiration rare",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-69668-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043700","Investigation of possible effects of Exendin-4 during exposure to mild chronic stress on dehydroepiandrosterone-induced polycystic ovary syndrome in rats","Burcu Köksal","2019","AFMN Biomedicine","preclinical","article","10.5937/afmnai2001034k",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043701","GLP-1 Agonists Reduce Functional Endoscopic Sinus Surgery Rates in Chronic Rhinosinusitis Patients With Obesity","Mohamad R. Chaaban","2024",null,"other","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5395",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0043702","Chronic kidney disease is no longer a ‘non-traditional’ cardiac risk factor: a call to action for cardiovascular-kidney-metabolic health","Jie Ming Nigel Fong","2025","Singapore Medical Journal","nonrandomized_study","article","10.4103/singaporemedj.smj-2025-012","40116056",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043703","Diabetes News","Emily E. Regier","2015","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12328","26223410",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043704","Exploring Glucagon-Like Peptide-1 Receptor Agonists for Treating Alcohol Use Disorder","Solis, Dolores, MPAS, PA-C, CAQ-Psych","2025","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043705","Struck by ACCORD","David McGrane","2008","Practical Diabetes","other_trial","article","10.1002/pdi.1227",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0043706","Liraglutide is a Perioperative Therapeutic Option for Patients with Type 2 Diabetes that Undergo Elective Surgery","Naoko Katagiri","2016","International Journal of Diabetes & Clinical Diagnosis","nonrandomized_study","article","10.15344/2394-1499/2016/117",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043707","FÁRMACOS PARA O TRATAMENTO DA OBESIDADE: UMA JORNADA ATRAVÉS DO PASSADO, PRESENTE E FUTURO DAS INTERVENÇÕES FARMACOLÓGICAS","Vinycius Marin","2024","Revista fisio&terapia.","other","article","10.69849/revistaft/pa10202409141758",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043708","Relación obesidad y adicción: implicaciones farmacológicas","Iveth Arenas Salazar","2024",null,"other","article","10.32997/11227/18499",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0043709","The hunger games: taste, GLP-1 and female gender involved","Maja Baretić","2017",null,"randomized_trial","article","10.26226/morressier.59d51846d462b80296ca2e52",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0043710","Diabetes in China: The challenge now","Jianping Weng","2010","Journal of Diabetes Investigation","nonrandomized_study","article","10.1111/j.2040-1124.2010.00053.x","24843428",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043711","Glucagon-Like Peptide-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Co-Agonism in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Randomized and Real-World Evidence","Ritu Raj Kumar","2026",null,"systematic_review","article","10.67796/jph.v1i1.26",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043712","Dapagliflozin: NICE guidance for use in combination therapy for the treatment of type 2 diabetes","Ma'en Al‐Mrayat","2013","Practical Diabetes","randomized_trial","article","10.1002/pdi.1779",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043713","Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes","Baptist Gallwitz","2009","Diabetes Care","other","article","10.2337/dc09-s331","19875573",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043714","ODP632 Preadmission Use Of Antidiabetic Medications And Mortality Among Patients With Covid-19 Having Type 2 Diabetes: A Meta-analysis","Nam Nhat Nguyen","2022","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvac150.718",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0043715","LEADER and the new ‘cardiovascular’ glucose‐lowering agents","Rachel Livingstone","2016","Practical Diabetes","randomized_trial","article","10.1002/pdi.2033",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043716","The Effect of Glucagon-Like Peptide-1 Receptor Agonist on Mouse Placental Lipid Metabolism","Zang, Tianyi","2022","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043717","The role of osteoprotegerin and receptor activator of nuclear factor kappa-betta ligand in vascular calcification and the influence of insulin and liraglutide on this process in type 2 diabetes mellitus.","Colin Davenport","2014",null,"preclinical","article","10.25419/rcsi.10807616",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043718","Su1580 DUAL THERAPY WITH METFORMIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP1-RA) REDUCES COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS AND CIRRHOSIS","Daniel J. Huynh","2023","Gastroenterology","other","article","10.1016/s0016-5085(23)04119-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0043719","À la Mode!","Alexander Kretzschmar","2025","Onkologische Welt","commentary","article","10.1055/a-2526-3746",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0043720","Improvement of liver function and glycemic control with Combination of DPP-4 inhibitors and GLP-1 agonists in type II diabetes mellitus patients with non-alcoholic steatohepatitis","Alexander Myint","2020","Gastroenterology & Hepatology Open Access","other","article","10.15406/ghoa.2020.11.00427",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043721","Subcutaneous semaglutide: 55.8% vs 13.2%, respectively; P < .001","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/69t5q",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043722","The glucagon-like-peptide-1 receptor agonists and the role of point-of-care ultrasound","Michael J. Weber","2023","ASRA news","other","article","10.52211/asra110123.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043723","SAT-680 Reduction of liver steatosis following semaglutide treatment, bariatric surgery, and conservative multimodal therapy in patients with obesity: real-world evidence from a german university obesity center","Paula Lünswilken","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.114",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043724","COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA","Gao, Lan","2012","Own your potential (DEAKIN)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0043725","Use of GLP-1 analogues in improving fertility in women with polycistic ovarian syndrome: scope review protocol","Moro, Ana Luiza Bucholdz","2024","OSF Preprints (OSF Preprints)","protocol","article","10.17605/osf.io/czfnr",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0043726","Next-level health: Obesity – the hidden pandemic and new answers","Andrew Haller","2024","Mednet","other","article","10.70270/gmuerv5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043727","Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes","Natália A. Rocha","2019","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12918","31044534",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043728","SAT-LB116 Extreme Insulin Resistance: The Diagnostic Challenges When Cost Is a Limitation","Nadia Carenina Nunes Cavalcante Parr","2020","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvaa046.2040",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043729","Editorial: Brain dopaminergic mechanisms","Ben Yang","2023","Frontiers in Synaptic Neuroscience","preclinical","article","10.3389/fnsyn.2023.1292511","37840572",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0043730","Impact of Lixisenatide On Phase 1 and Phase 2 Glucose-Stimulated insulin Secretion During An intravenous Glucose Tolerance Test in Type 2 Diabetes : a Model-Based Assessment",null,"2017","BiblioBoard Library Catalog (Open Research Library)","randomized_trial","article","10.26226/morressier.5c3c8158e668b9000b9f8e24",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0043731","Effect of Nutrition Education on Outcomes After Initiation of Glucagon-like Peptide-1 in Adults with Diabetes","Terri-Ann Burke","2026",null,"randomized_trial","article","10.57709/347",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0043732","Albiglutide","Pius S. Fasinu","2026","Elsevier eBooks","other","article","10.1016/b978-0-443-44037-3.00115-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0043733","Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","Patoulias, Dimitrios","2023","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/k3fvx",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0043734","Vad har liraglutid för effekt på patienter med Polycystiskt ovarialsyndrom (PCOS)? : En litteraturstudie","Motlak, Sarah Ali","2025","DiVA (Linnaeus University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043735","MON-189 Comparative Effectiveness of GLP-1 Analogues and Metformin in Managing Polycystic Ovarian Syndrome: Insights from a Propensity-Matched Cohort Study","Maxim John Levy Barnett","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1920",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043736","GLP-1RAs Benefits and Risk of Pulmonary Aspiration","Farjam Haider","2026","Iowa State University Digital Repository (Iowa State University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043737","Nouveaux traitements du diabète : quelles sont les incidences en pratique odontologique ?","Jade Novel","2025","INRIA a CCSD electronic archive server","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043738","Precision medicine in nonalcoholic fatty liver disease","Amedeo Lonardo","2022","Journal of Gastroenterology and Hepatology","nonrandomized_study","article","10.1111/jgh.15850","35801994",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0043739","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-38584-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043740","Effekten av tirzepatid jämfört medliraglutid på viktminskning hos vuxnamed fetma : En litteraturstudie","Rawan Al Marrawi","2026","KTH Publication Database DiVA (KTH Royal Institute of Technology)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0043741","Treatment effects of once-weekly dulaglutide versus insulin glargine in patients with different baseline glycemic patterns (based on high/low fasting or high/low postprandial glucose): a post hoc analysis of the AWARD-2 clinical trial","Georgino, Francesco","2018","ResearchOnline at James Cook University (James Cook University)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","conference-paper"],["R0043742","SAT-560 Glucagon Like Peptide 1 Receptor Agonists as a Potential Treatment of Post Bariatric Hypoglycemia","Marianne Riordan","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1091",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043743","Il semaglutide inverte l’aumento di peso indotto dalla clozapina nella schizofrenia? Risultati del trial COaST","Oliver Freudenreich","2025",null,"other_trial","article","10.64239/pi-it-qt7802",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","report"],["R0043744","Assessing liver fibrosis in all patients with type 2 diabetes and fatty liver disease: It's time to act now","Chi‐Ho Lee","2022","Journal of Diabetes Investigation","nonrandomized_study","article","10.1111/jdi.13765","35119217",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043745","Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?","Ralf Weiskirchen","2026","Hepatoma Research","other","article","10.20517/2394-5079.2026.62",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043746","Cardiometabolic Health: Actionable Prevention Strategies and New Care Models","Omar Leonards","2024","Texas Heart Institute Journal","nonrandomized_study","article","10.14503/thij-23-8275","38287668",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043747","A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes","Ryotaro Bouchi","2022","Journal of Diabetes Investigation","nonrandomized_study","article","10.1111/jdi.13960","36562245",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043748","Mid-year review of SMJ highlights in 2025","Tiing Leong Ang","2025","Singapore Medical Journal","nonrandomized_study","article","10.4103/singaporemedj.smj-2025-160","40700751",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043749","Role of incretin based therapies in the treatment of diabetic kidney disease","Paola Fioretto","2018","Diabetes Mellitus","other","article","10.14341/dm9845",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043750","EFFECT OF DULAGLUTIDE VERSUS LIRAGLUTIDE ON GLUCOSE VARIABILITY AND OXIDATIVE STRESS AND ENDOTHELIAL FUNCTION IN TYPE 2 DIABETES PATIENTS",null,"2017","BiblioBoard Library Catalog (Open Research Library)","randomized_trial","article","10.26226/morressier.5c3c8159e668b9000b9f8d98",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0043751","Breast cancer and metabolic comorbidities: From epidemiology and molecular mechanisms to precision interventions","Zhang Shen-hao","2026","World Journal of Clinical Oncology","other","article","10.5306/wjco.v17.i4.117705",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043752","Acute Improvement of Glucose Variability by Oral Semaglutide (Rybelsus) and Low Carbohydrate Diet (LCD) In Type 2 Diabetes (T2D) Patient with Ophthalmic Operation",null,"2022","International Journal of Case Reports and Clinical Images","other","article","10.36266/ijcrci/184",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043753","Incarcerated Incisional Hernia: Strangulated Transverse Colon with Perforation Associated with Abscess Formation","Min‐Po Ho","2016","Journal of the American Geriatrics Society","other","article","10.1111/jgs.13969","27000367",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043754","Distinctive detection of insulinoma using [¹⁸F]FB(ePEG12)12-exendin-4 PET/CT","Murakami, Takaaki","2021","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043755","Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve indices of atrial cardiomyopathy: a systematic review and meta-analysis","Konstantinos Pamporis","2025","EP Europace","systematic_review","article","10.1093/europace/euaf085.236",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043756","GLP-1, eating disorders and TikTok","See Heng Yim","2026",null,"other","article","10.17605/osf.io/sv2wc",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043757","¹¹¹インジウム標識exendin-4 SPECT/CTを用いた、糖尿病モデル雄マウスでのGPR119アゴニストによる膵β細胞保護効果の非侵襲的評価","Takaaki Murakami","2020","Institutional Repositories DataBase (IRDB)","other","article","10.14989/doctor.k22358",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043758","Pharmacokinetics of first semaglutid drug in Russian Federation: results of open-label randomized clinical trial","Anna Arefeva","2023","Meditsinskiy sovet = Medical Council","randomized_trial","article","10.21518/ms2023-312",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043759","The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease","Nauck, Michael (Prof. Dr. med.)","2021","Dokumentenrepositorium der RUB (Ruhr University Bochum)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043760","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-41220-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043761","Liraglutide for the treatment of obesity, a real life experience.","Abo Zaid Wisam","2017",null,"other","article","10.26226/morressier.59d51843d462b80296ca3800",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043762","MON-701 A case which GLP 1 receptor agonist semaglutide enabled the management of both obesity and diabetes mellitus, suggesting the potential for diabetes remission","Shigeatsu Hashimoto","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.039",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043763","Hypothyroidism in Older Adults, Glucocorticoid Withdrawal, Diabetic Heart Disease, and More","Salem Beshyah","2024","Journal of Diabetes and Endocrine Practice","other","article","10.1055/s-0044-1788989",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043764","Impact Of Glucagon-like Peptide-1 Receptor Agonists Utilization on Outcomes of Midfoot and Hindfoot Fusions","Hana Hashioka","2025","Foot & Ankle Orthopaedics","nonrandomized_study","article","10.1177/2473011425s00285",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043765","SUN-653 Impact of GLP-1 Agonist on Outcomes in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-Analysis","Ashraf Ahmed","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.163",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043766","Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","Domenica Rubino (8951612)","2021","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0043767","SUN-808 ADCES7 Guidelines and AI Chatbots: Do They Help Our Patients?","Ethan Pan","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1314",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043768","MON-639 A Case of Acute Pancreatitis Induced by Semaglutide","Harshita Marasandra Ramesh","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.999",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043769","Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.","Melanie Davies (545715)","2017","The Medicine Forum","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0043770","Presentations at the 81st scientific sessions of the American Diabetes Association ( ADA ), Part 1","Zachary T. Bloomgarden","2021","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13211","34251079",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043771","Torasemide","Angus Stirling","2018","Practical Diabetes","randomized_trial","article","10.1002/pdi.2174",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043772","Rate and pattern of prescription for osteoporosis and non-alcoholic fatty liver disease among patients with diabetes mellitus in Tabuk City, Saudi Arabia","Waleed Badoghaish","2023","Medical Science","other","article","10.54905/disssi/v27i133/e139ms2935",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043773","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-62033-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043774","Кардіоваскулярна автономна нейропатія у хворих на цукровий діабет 2 типу. Огляд","Л. П. Журавльова","2024","Scientific periodicals of Ukraine","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043775","Glucagon-Like Peptide-1 Receptor Agonists Are Promising for the Treatment of Brain Diseases: an Outlook from the Perspective of Integrative Physiology","N. V. Gulyaeva","2025","Journal of Evolutionary Biochemistry and Physiology","other","article","10.1134/s0022093025050023",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043776","CREDENCE: A silver lining in the dark cloud of diabetic nephropathy","Ko Hanai","2019","Journal of Diabetes Investigation","randomized_trial","article","10.1111/jdi.13175","31705732",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043777","Waist Circumference as a Cardiometabolic Vital Sign: A Translational Framework for Early Detection and Prevention of Heart Failure with Preserved Ejection Fraction in Primary Care",null,"2026","Journal of Obesity and Chronic Diseases","other","article","10.17756/jocd.2026-059",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043778","Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells","Camilla Kappe","2012","Figshare","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043779","SAT-675 The Impact of the Oral Growth Hormone Secretagogue Ibutamoren on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults With Overweight/Obesity","Natalia Chamorro-Pareja","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1594",null,null,"ClinicalTrials.gov:NCT05364684; ClinicalTrials.gov:NCT02217345",null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043780","ABSTRACT NUMBER: ESOC2026A2308 GLP-1 OR DUAL GIP/GLP-1 RECEPTOR AGONIST IN ACUTE ISCHAEMIC STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PRE-CLINICAL STUDIES","Sara Eltirafi","2026","European Stroke Journal","systematic_review","article","10.1093/esj/aakag023.1061",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0043781","Does Wegovy reduce the risk of Cardiovascular Events","Killen, Christopher F","2024","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043782","A randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in patients with diabetes – PILGRIM trial","Jeroen Hermanides","2017",null,"randomized_trial","article","10.26226/morressier.58f5b033d462b80296c9ddb3",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0043783","When I use a word . . . Drug shortages—a new prospect","Jeffrey K Aronson","2025","BMJ","commentary","article","10.1136/bmj.r832","40280624",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0043784","The Genetic Role of PCSK 1","Aquino, Lisbeth","2025","HELIN Digital Commons","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0043785","The 5th Annual Heart in Diabetes Conference (part 2)","Zachary T. Bloomgarden","2022","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13251","35075783",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043786","Research Protocol: Effects of GLP-1 Therapy on Skeletal Muscle Health Across Stages of Type 2 Diabetes","Ben Mei-Dan","2025","Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","protocol","article","10.26685/urncst.957",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043787","Mechanistic Crosstalk of Triple Agonist Signalling: A Scoping Review of GLP-1, GIP, and Glucagon Receptor Co-Activation in Human Metabolism","Kaya Genc","2026",null,"preclinical","article","10.17605/osf.io/nh42a",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043788","Incretin-based therapies","Lre Bereznicki","2010","eCite Digital Repository (University of Tasmania)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043789","Exploring Preclinical Targets in Abdominal Aortic Aneurysm","Balboa Ramilo, Amanda","2024","KTH Publication Database DiVA (KTH Royal Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043790","Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?","Kathleen E. Corey","2011","Hepatology","randomized_trial","article","10.1002/hep.24696","21953015",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043791","Characteristics and glycemic outcomes of T2D patients titrated to 60 U/day iGlarLixi vs insulin in the LixiLan-L trial","Bowden Georgina","2017",null,"randomized_trial","article","10.26226/morressier.59d51845d462b80296ca34ab",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0043792","A commentary from the European Renal Best Practice (ERBP) on the Kidney Disease Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease in children and adults","Iatridi, Fotini","2024","Zurich Open Repository and Archive (University of Zurich)","randomized_trial","article","10.5167/uzh-264449",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0043793","Engineering Next-Generation Chemically Activated Protein Domains for Chemogenetic Peptide Control","Luis Vazquez-Rivera","2026",null,"preclinical","article","10.7302/dspace/29635",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043794","SAT-637 Impact of Weight Loss Through Non-Surgical Approaches on Kidney Stone Risk","Karen Feghali","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.2288",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043795","Heart failure prevention with sodium‐glucose cotransporter 2 inhibitors","Muhammad Shahzeb Khan","2019","Journal of Diabetes","nonrandomized_study","article","10.1111/1753-0407.12932","31044514",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0043796","Borrowing From the Type 2 Diabetes Armamentarium for Asthma","Katherine N. Cahill","2024","JAMA Internal Medicine","nonrandomized_study","article","10.1001/jamainternmed.2024.5983","39556391",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043797",null,"Alexander Kretzschmar","2025","Onkologische Welt","commentary","article","10.1055/s-015-62665",null,null,null,null,"openalex","FALSE",null,null,null,"editorial"],["R0043798","SUN-579 Patient with No Prior History of Diabetes Mellitus Develops Acute Pancreatitis and Diabetic Ketoacidosis on Compounded Semaglutide","Michelle Stefanelli","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1230",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043799","Standardized Proactive GLP-1 Prior Authorization Workflow","Ebote Etape","2026","ScholarWorks (Walden University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043800","A conversation with Dr. Robert F. Kushner, MD, Professor of Medicine (Endocrinology) and Medical Education, Northwestern University Feinberg School of Medicine","Kathy Siranosian","2023","Journal of Clinical and Translational Science","other","article","10.1017/cts.2022.518","36845301",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043801","P017 – GLP-1 receptor agonists improve survival and reduce cardiovascular and kidney events in prostate cancer patients with type 2 diabetes","J.-Y. Sheu","2025","European Urology","other","article","10.1016/j.eururo.2025.09.2478",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0043802","Inconclusive effects of once‐weekly exenatide on cardiovascular outcomes in type 2 diabetes","Chih Wong","2017","Practical Diabetes","randomized_trial","article","10.1002/pdi.2140",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043803","SAT-LB105 A Transcribed Ultraconserved Noncoding RNA, Uc.336-As, Promotes White to Brown Conversion in 3T3-L1 Cells","Xiaoying He","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.2099",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043804","MON-684 Comparative Effectiveness and Safety of GLP-1 Receptor Agonist versus Traditional Anti-obesity Medications: A Real-world Evidence Study","Jo-Ching Chen","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.023",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043805","Microbially derived bioactive peptides to improve human health","Robert M. Kent","2014","Cork Open Research Archive (University College Cork, Ireland)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043806","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-65961-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043807","GLP-1 secretion and signaling in patients with aneurysmal enlargement of the thoracic aorta : a potential contributor to reduced prevalence of aneurysm in diabetes","Stelia Ntika (18676741)","2022","Figshare","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043808","Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer","Armando Patrizio","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5797093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043809","A Review of Metabolic Health Outcomes of Tirzepatide vs Semaglutide in Obesity and Type 2 Diabetes","Charlotte A. Friedman","2025","Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","nonrandomized_study","article","10.26685/urncst.945",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043810","New therapeutic strategy for Alzheimer's disease using antidiabetes agents","Koichi Yokono","2013","Journal of Diabetes Investigation","randomized_trial","article","10.1111/jdi.12031","24843645",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043811","Effects of Combination Therapy with Liraglutide and Insulin Glargine as the Initial Treatment for Hyperglycemic Patients with Type 2 Diabetes: An Observational Study","Kotaro Kurasaki","2016","International Journal of Diabetes & Clinical Diagnosis","nonrandomized_study","article","10.15344/2394-1499/2016/121",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043812","MON-822 GLP-1 and Anesthesia: Queries to AI Chatbots","Ethan Pan","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043813","Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment","Ilijana Babic (20118222)","2016","Research Online (University of Wollongong)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043814","Cardiovascular safety trials: Be careful what you wish for (心血管安全性研究：当心你许的愿)","Zachary T. Bloomgarden","2013","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12092","24103189",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043815","Prescribing Patterns and Adverse Effects of Semaglutide:A real-world evaluation from a socioeconomically deprived UK region","Whorton, Abigail","2025","University of Birmingham Research Portal (University of Birmingham)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0043816","Possible Adverse Effects (AEs) of Semaglutide (Ozempic) Administration for the Latest Investigation","Hiroshi Bando","2024",null,"other","article","10.36502/2024/droa.6189",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043817","Analysis of Spontaneous Reports of Psychiatric Adverse Events Associated with GLP-1 Analogues","Piotr Kowalski","2022","Annals of Pharmacy Practice and Pharmacotherapy","nonrandomized_study","article","10.51847/bl9xxfe3dd",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043818","Interrogating biomarkers for, and the pathophysiological mechanisms of, obesity-related complications","Martin Tze Wah Kueh","2024","Research Repository UCD (University College Dublin)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043819","Dietetic input is important when starting a GLP‐1 analogue","Leona Courtney","2018","Practical Diabetes","randomized_trial","article","10.1002/pdi.2175",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043820","Escribir poesía en tiempos de Ozempic","María Pilar Úcar Ventura","2025","Comillas Repository (Comillas Pontifical University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043821","THE IMPORTANCE OF PROPER NUTRITION IN PROTECTING THE MUSCULOSKELETAL SYSTEM DURING WEIGHT LOSS","Donatella Verbanac","2026","Fizikalna i rehabilitacijska medicina","other","article","10.21751/frm-40-1-25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043822","Influence of glucagon-like peptide-1 receptor agonists on fat distribution in patients with diabetes mellitus or obesity: A systematic review and meta-analysis of randomized control trials","Wanrun Xie","2023",null,"systematic_review","article","10.37766/inplasy2023.11.0020",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043823","A MODEL OF BETA-CELL RESPONSE TO GLP-1 TO QUANTIFY INCRETIN EFFECT IN HEALTHY AND PREDIABETIC SUBJECTS","Francesco Micheletto","2013","Padua@research (University of Padova)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0043824","Transcriptional regulation of healthy and diabetic pancreatic beta-cell gene expression","Hamedeh Ghanaat‐Pour","2008","Figshare","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043825","Abstract 4363062: BRCC3 inhibition of EndoMT via deubiquitination of Smad7: Implication in Atherosclerosis","Qing Yin","2025","Circulation","preclinical","article","10.1161/circ.152.suppl_3.4363062",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043826","GLP-1RA, SGLT2i combination therapy","Karakasis, Paschalis","2024","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/6p5jd",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043827","LBODP038 Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm","Marwa K Maki","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.548",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043828","Nurse practitioner role; initiation, monitoring and facilitation GLP-1 analogue and insulin combination therapy. Abstract P-1624","MA Woods","2013","eCite Digital Repository (University of Tasmania)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043829","Enhancing Post-Marketing Pharmacovigilance: An AI-Driven System Approach for Safety Signal Detection of Adverse Drug Events: A Case Study of Glucagon-Like Peptide-1 Receptor Agonists","Alsuhibani, Ali","2025","VCU Scholars Compass (Virginia Commonwealth University)","nonrandomized_study","article","10.25772/btp3-ze96",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article; dissertation"],["R0043830","Metformin, Liraglutide, Orlistat, and Phentermine for Childhood Obesity and Blood Lipids: A Systematic Review and Meta-Analysis","Yuhang Chen","2023",null,"systematic_review","article","10.37766/inplasy2023.5.0100",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0043831","An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes","David Owens","2025","Cronfa (Swansea University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0043832","OR10-3 Long-term Weight Loss Maintenance with Obesity Pharmacotherapy: a 5-Year Retrospective Study","Clarissa Andre","2022","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvac150.033",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043833","Patient Compliance Through Education for Type 2 Diabetics on New Medications: SGLT-2 Inhibitors and GLP-1 Analogues","Hachat, Lindsay","2024","Scholarly Commons - Ouachita Research, Creative Work, and Archives (Ouachita Baptist University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","conference-paper"],["R0043834","SAT-147 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Erectile Dysfunction and Testosterone Levels: A Systematic Review and Meta-Analysis","Adnan Ezici","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.1998",null,null,"PROSPERO:CRD42025640594",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043835","GLP-1 аналози у терапији гојазности","Кендерешки, Aлександра","2020","Digital Archive of SASA (Serbian Academy of Sciences and Arts)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043836","Tirzapped: “My Brain is Colonized” – The Voice of a Person Using Tirzepatide","Dr SANJAY KALRA","2025",null,"other","article","10.59793/kvbnjv56",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043837","Su1343: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH INCREASED ACID EXPOSURE TIME ON WIRELESS AMBUALTORY PH MONITORING","Chase Cottle","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02691-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0043838","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90871-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043839","Examining the Efficacy of a Home Sleep Apnoea Testing Kit and the Effect of liraglutide 3.0mg on Parameters of Sleep Apnoea and Metrics of Health and Obesity","Brendan Moran","2022","Research Repository UCD (University College Dublin)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0043840","New Incretin Therapy in a Preclinical Model of Heart Failure With Preserved Ejection Fraction (HFpEF)","Park, Jeong Eun","2025","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043841","Insulin as a potent bidirectional regulator of GABAergic signalling in the hippocampus of an Alzheimer’s disease mouse model","Mai Marie Holm","2021","Acta Physiologica","preclinical","article","10.1111/apha.13660","33830635",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043842","Early responders to liraglutide 3.0 mg as adjunct to diet and exercise from the SCALE Maintenance trial","wharton sean","2017",null,"randomized_trial","article","10.26226/morressier.59d51844d462b80296ca36ec",null,null,"ClinicalTrials.gov:NCT00781937","S001278","openalex","TRUE","free_to_read","1","FALSE","other"],["R0043843","GLP1-RA-related suicide, alopecia and aspiration",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-67198-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043844","The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin","Mojca Jensterle Sever","2026","DiRROS repository (University of Maribor)","other","article","10.3389/fendo.2024.1366940/abstract",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043845","Determination of Palmitoleic Acid and Corosolic Acid Present in Insulin Plant (Costus Igneus)","Aruna Aasirvatham","2020","International Journal for Research in Applied Science and Engineering Technology","other","article","10.22214/ijraset.2020.6163",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043846","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92414-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043847","Dulaglutide/megestrol",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-69824-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043848","Targeting the gut microbiota for treating colitis: Is FGF19 a magic bullet?","John Y.L. Chiang","2020","EBioMedicine","preclinical","article","10.1016/j.ebiom.2020.102754","32339941",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043849","Efficacy of Semaglutide in Reducing Visceral Adipose Tissue and Ectopic Fat Deposition: A Systematic Review of Clinical Trials","Jazzaa Hammad Mutlaq Alshammari","2026","Journal of Clinical Practice and Medical Research","systematic_review","article","10.59324/jcpmr.2026.2(4).16",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0043850","What is the quantity, quality and scope of recent network meta-analyses evaluating the effectiveness of Glucagon-like peptide-1 receptor agonists for weight loss in obese adults? Protocol for a scoping review of network meta-analyses","M Nunns (21855728)","2023","Open Research Exeter (University of Exeter)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","other"],["R0043851","Recent Articles—Skeletal Muscle and Other Topics in Diabetes","Zachary T. Bloomgarden","2025","Journal of Diabetes","other","article","10.1111/1753-0407.70169","41253694",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043852","Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases","Ryoichi Miyazaki","2023","Renal Replacement Therapy","nonrandomized_study","article","10.1186/s41100-023-00492-1",null,null,"UMIN:UMIN000050853",null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043853","Diabetes in the UK: time for a reality check?","Elaine Gale","2010","Diabetic Medicine","nonrandomized_study","article","10.1111/j.1464-5491.2010.03100.x","20722669",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043854","The effects of supplementation with curcumin plus piperine on glycemic indices in prediabetes status: protocol for randomized controlled trial","Maryam Emadzadeh","2024","Herba Polonica","protocol","article","10.5604/01.3001.0054.6601",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0043855","The battle against perioperative glycaemic control: Hard to win?","S Parthasarathy","2022","Indian Journal of Anaesthesia","randomized_trial","article","10.4103/ija.ija_923_22","36590185",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043856","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND BONE HEALTH: RESULTS FROM A PILOT RANDOMIZED CONTROLLED TRIAL","Dinkla, Lauren","2025","WakeSpace Scholarship (Wake Forest University)","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT05786521","S000230","openalex","FALSE","no_doi","1","FALSE","dissertation"],["R0043857","GLP-1 Agonists Liraglutide Improved Vascular Endothelial Function in Type 2 Diabetes Rats","Xi Li","2020",null,"preclinical","article","10.36502/2020/droa.6168",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043858","Encouraging but slow progress toward incorporating obesity care into diabetes care","Jaime P. Almandoz","2023","Obesity","other","article","10.1002/oby.23925","37926782",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043859","MON-232 Atypical Diabetes due to Hypomethylation at BWS ICR2 and the 6q24 loci: Potential Evidence for a Multifocal Hypomethylation Syndrome","Sara Muneer","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1706",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043860","Appetite-suppressing drugs and emerging implications for sustainability","Christopher J. O’Bryan","2026","npj Sustainable Agriculture","other","article","10.1038/s44264-026-00186-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043861","The effects of DPP-4 inhibitors on vascular endothelial function in diabetes","S.M. Salheen","2015","RMIT Research Repository (RMIT University Library)","preclinical","article","10.25439/rmt.27591369",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043862","Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial","Stephen A. Harrison","2023","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(23)00517-2",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043863","AJH Hematology Crossword Puzzle, August 2010","David P. Steensma","2010","American Journal of Hematology","randomized_trial","article","10.1002/ajh.21778",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043864","Analysis of the effectiveness of semaglutide and metformin in the correction of anthropometric parameters, cardiometabolic profile and adipokines in patients with type 2 diabetes mellitus and obesity","Ametov As","2026","Endocrinology News Opinions Training","other","article","10.33029/2304-9529-2026-15-2-05-11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043865","Early improvement of HbA1c, weight and low-density lipoprotein (LDL) for Type 2 diabetes (T2D) patient by Rybelsus (oral semaglutide)",null,"2022","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/138",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043866","Cardiovascular disease in patients with type 2 diabetes","Ja Young Jeon","2021","Journal of Diabetes Investigation","nonrandomized_study","article","10.1111/jdi.13742","34953095",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043867","Prolonged release exenatide gets the go‐ahead from NICE","Ma'en Al‐Mrayat","2012","Practical Diabetes","other_trial","article","10.1002/pdi.1664",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0043868","YR58MDW8V8 Patients Report Decreased Hunger, Appetite, and Cravings with the Use of GLP-1 Receptor Agonists for Suboptimal Weight Loss After Sleeve Gastrectomy",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.267",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043869","Coronary pericytes as mediators of brain–gut–heart signaling: expanding the cardioprotective paradigm of GLP-1","Ihsan Qamar","2026","Annals of Medicine and Surgery","preclinical","article","10.1097/ms9.0000000000005120","42254129",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043870","Linagliptin—Role in the Reversal of Aβ‐Mediated Impairment of Insulin Signaling and Reduced Neurotoxicity in AD Pathogenesis: Some Considerations","Nuggehally R. Srinivas","2015","CNS Neuroscience & Therapeutics","other_trial","article","10.1111/cns.12475","26547267",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043871","New approvals","Michele B. Kaufman","2011","Dialysis & Transplantation","other_trial","article","10.1002/dat.20575",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043872","GLP-1 in metabolism: implications in diabetes and obesity","Pablo González Alonso","2024","Hispana","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043873","Dipeptidyl peptidase‐4 inhibitor approaches","Zachary T. Bloomgarden","2016","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12476","27576300",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043874","Newer agents for blood glucose control in type 2 diabetes: the NICE draft proposals","MW Savage","2008","Practical Diabetes","other","article","10.1002/pdi.1304",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043875","Advancements in glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes",null,"2024","Journal of Chinese Pharmaceutical Sciences","other","article","10.5246/jcps.2024.08.050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043876","Glucagon-like peptide-1 injectable medication uptake among United States cancer survivors with diabetes: National estimates and socioeconomic patterns from 2024.","Aditya Pandey","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e23094",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043877","Get Ugly: Liberatory Mess and Decentering the Male Gaze in Theatrical Performance","Pedego, Izzy","2025","eScholarship (California Digital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043878","Cardiodiabetology: Evolution or Revolution?","I. Z. Bondarenko","2025","Diabetes Mellitus","other","article","10.14341/dm13295",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043879","The Role of Incretin-Based Medications in Transforming Obesity and Metabolic Health Treatment","Nicholas J. Streit","2025",null,"other","article","10.31274/cc-20251215-45",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0043880","GLP-1 Agonists Increase Risk of Surgical Site Infection and Nonunion in Patients Undergoing Operative Fixation of Ankle Fractures","Jens T. Verhey","2025","Foot & Ankle Orthopaedics","nonrandomized_study","article","10.1177/2473011425s00268",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043881","Δομική μελέτη βιολογικών μακρομορίων για τη δημιουργία φαρμακευτικών στόχων","Μαρία Σπηλιοπούλου","2023",null,"other","article","10.12681/eadd/54084",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043882","Efficacy and safety of teneligliptin","Awadhesh Kumar Singh","2016","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.193163","28217491",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043883","SAT-703 The Intersection of Obesity, Testosterone Therapy, and Atrial Fibrillation: A Case Report","Matthew John Sheahan","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043884","The neuroprotective potential of GLP-1 analogues with particular emphasis in Alzheimer’s and Parkinson’s diseases","Zuzanna Drozd","2025","Journal of Education Health and Sport","other_trial","article","10.12775/jehs.2025.86.66890",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043885","Uso inapropiado de ArGLP-1: implicaciones clínicas, éticas y de farmacovigilancia","Echeverry-Guerrero, Sofía","2025","Repositorio Institucional E-DocUR (Universidad Del Rosario)","other","article","10.48713/10336_46761",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0043886","SAT-406 Role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in mortality reduction among patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis: a global retrospective analysis","Varun Aitharaju","2025","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(25)01673-3",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0043887","Suicide and diabetes","Rowan Hillson","2022","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.2402",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0043888","SAT-662 Effects of SGLT Inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis","Soo Lim","2020","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaa046.1636",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0043889","Keert semaglutide door clozapine geïnduceerde gewichtstoename om bij schizofrenie? Resultaten van de COaST-trial","Oliver Freudenreich","2025",null,"other_trial","article","10.64239/pi-nl-qt7802",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","report"],["R0043890","Optimizing clinical outcomes resulting from glucose‐lowering therapies in type 2 diabetes: increased confidence about the DPP ‐4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin","Craig J. Currie","2014","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.12349","25040702",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0043891","Guideline directed medical therapy for secondary prevention after coronary artery bypass grafting","Deo, Salil Vasudeo","2025","Enlighten: Theses (The University of Glasgow)","nonrandomized_study","article","10.5525/gla.thesis.85379",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0043892","Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)","Sejeong Park","2016","Diabetes & Metabolism Journal","other_trial","article","10.4093/dmj.2016.40.4.336","27550211",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0043893","Implementing an Exercise Program in Prediabetic Patients on GLP-1 RAs to Increase Self-Efficacy and Decrease HgbA1c, BMI, and Weight","Alston, Tamara","2025","Digital Commons (Liberty University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043894","In vivo-Bildgebung transplantierter neonataler Schweineinselzellen im diabetischen Mausmodell mit Gallium 68-markiertem Exendin-4 hoher molarer Aktivität zur Kontrolle der Transplantatsviabilität","Lindheimer, Felix","2024",null,"other","article","10.5282/edoc.34135",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043895","New medications for the treatment of diabetes","Satish K. Garg","2012","International Journal of Clinical Practice","randomized_trial","article","10.1111/j.1742-1241.2011.02859.x","22308994",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043896","Liraglutide/Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-56910-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043897","Analogues du GLP-1 et perte de poids : évaluation des mécanismes d'action, de l'efficacité clinique, des risques et des usages détournés","Hassani, Amine","2024","INRIA a CCSD electronic archive server","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043898","Global Medicines Regulation in Pregnancy and Lactation: Addressing Emerging Therapies, Safety, and Access Inequalities","Riad Mohammed Abdelrahman","2025","British journal of healthcare and medical research","nonrandomized_study","article","10.14738/bjhr.1206.19640",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043899","Liraglutide as an adjunct agent to manage excessive weight regain two years post bariatric surgery","Shehla Shaikh","2019",null,"other","article","10.26226/morressier.5d9b6231ea541d6ca8494055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043900","Mass Spectrometry Applications for GLP-1 and Dual Incretin Receptor Agonists: A Scoping Review Protocol","Howard Rodriguez Mori","2026",null,"protocol","article","10.17605/osf.io/ckums",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0043901","\"Genetic Contribution and Inhibitor Marker of Diabetic Disease: A Review Article\"","Nanda Rachmad Putra Gofur","2022","Open Access Journal of Biomedical Science","narrative_review","article","10.38125/oajbs.000382",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043902","Glucagon-Like Peptide-1 Analogue In The Management Of Rebound Intracranial Hypertension: A Case Report","Yasmine Hoydonckx","2023",null,"case_report","article","10.30756/ahmj.2023.11.02",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043903","A076 Use of Pre-operative Glucagon-Like Peptide 1 Agonists and Impact on Weight Loss Following Bariatric Surgery",null,"2024","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2024.04.062",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0043904","MON-655 A rare case of Stiff-Person Syndrome (SPS) in a young woman with Latent Autoimmune Diabetes in Adult (LADA)","Sheryl Thant Yu Htoo","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043905","Tu1605 EFFICACY AND SAFETY OF SEMAGLUTIDE IN NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW","Jean M. Chalhoub","2023","Gastroenterology","systematic_review","article","10.1016/s0016-5085(23)03453-4",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0043906","Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial","Steve Bain","2024","Cronfa (Swansea University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0043907","Research Synthesis: Semaglutide Cardiovascular Effects — full paper","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/5ujxf",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043908","Type 2 treatments for type 1 diabetes","Zachary T. Bloomgarden","2016","Journal of Diabetes","other_trial","article","10.1111/1753-0407.12430","27206987",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043909","Reponse to Comments on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604","Alexandra E. Butler","2013","Diabetes","randomized_trial","article","10.2337/db13-0996","24065800",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043910","Small steps forward: Adjunctive therapy for T1D","Zachary T. Bloomgarden","2022","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13326","36205524",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043911","TRATAMENTO FARMACOLÓGICO COM SEMAGLUTIDA NA OBESIDADE","Vitor dos Santos Rodrigues","2024","Revista fisio&terapia.","nonrandomized_study","article","10.69849/revistaft/ra10202411111552",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0043912","Potential Role of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist in the Treatment of Bulimia Nervosa","Nkechinyere Mary Harry","2024","Journal of Advances in Medicine and Medical Research","randomized_trial","article","10.9734/jammr/2024/v36i75514",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043913","Combined therapy for type 1 diabetes : Immunotherapy and Regenerative Strategies","Villalba Felipe, Adrián","2020","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043914","Evaluating patients’ preferences for dulaglutide versus insulin glargine medication profiles in T2D patient subgroups","Thieu Vivian","2017",null,"other","article","10.26226/morressier.59d5184fd462b80296ca2c54",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043915","Dapagliflozin and DAPA‐HF: from glycaemic control to heart failure therapy","Miles Fisher","2019","Practical Diabetes","other_trial","article","10.1002/pdi.2243",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043916","Does GLP-1 suppress hepatocyte glucose production directly, via fibroblast growth factor 21?","Jun‐Li Liu","2019","EBioMedicine","other","article","10.1016/j.ebiom.2019.03.012","30876763",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043917","Diabète post-transplantation rénale: le point de vue du diabétologue","Amélie Pauchet","2020","Revue Médicale Suisse","other","article","10.53738/revmed.2020.16.697.1200",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043918","Nyhedsbrev for Netværk for Udvikling af Apotekspraksis (august 2023)","Tina Olesen Linde","2023","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043919","The use of GLP-1 analogues in the treatment of patients with type 1 diabetes mellitus and obesity: a scoping review\"","Ana Larissa Alves Rodrigues Melo","2026",null,"randomized_trial","article","10.17605/osf.io/fkzs3",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0043920","The Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Stimulates Mechanistic Target of Rapamycin (mTOR) Signaling via PKA And Akt","Thao D. V. Le","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.1044",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043921","Obesity treatment – Is pharmacotherapy the answer?","AdityaKumar Rangbulla","2020","International Journal of Applied and Basic Medical Research","other","article","10.4103/ijabmr.ijabmr_113_20","33088734",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043922","The results and the meaning of EMPA-REG OUTCOME and LEADER studies for modern diabetology: in search of ideal combination","В. В. Салухов","2019","Meditsinskiy sovet = Medical Council","other","article","10.21518/2079-701x-2019-4-44-51",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043923","Evaluation of the effects of a diabetes type 2 rat model and semaglutide treatment on the sucrose preference test","Kristina Jezdić","2025","FarFar - Pharmacy Repository","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0043924","SUN-270 Use of Triple Phase CT to Diagnose an Otherwise Radiographically Invisible Insulinoma","B A S S A M ALHAMER","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.2473",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043925","Slowed Meal Appearance May Enable Hybrid Closed Loop System in Type 1 Diabetic Patients : in Silico Results",null,"2017","BiblioBoard Library Catalog (Open Research Library)","other","article","10.26226/morressier.5c3c8156e668b9000b9f8d42",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043926","Glp-1 Analogs for the Treatment of Obesity and Diabetes","Juan Belloni","2022","Endocrinology and Disorders","other","article","10.31579/2640-1045/116",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043927","P0976 GLP-1 receptor agonists and male genitourinary infections: A 3-year TriNetX comparative cohort study","P.C. Liu","2026","European Urology","nonrandomized_study","article","10.1016/s0302-2838(26)01827-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0043928","Liraglutide/orlistat/phentermine/topiramate",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-56909-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043929","Peptide Mimetics: Fast‐Forward Look","David Gurwitz","2017","Drug Development Research","preclinical","article","10.1002/ddr.21403","28833328",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043930","Tirzepatide: Novel Dual Targeted Treatment for Type 2 Diabetes Mellitus in Adults","Noopur Verma","2022","RUHS Journal of Health Science","other","article","10.37821/ruhsjhs.7.4.2022.190",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043931","Expression and mechanism of FGF21 in white adipose tissue of obese type 2 diabetic rats induced by liraglutide","Yi Zhang","2019",null,"preclinical","article","10.26226/morressier.5d9b6231ea541d6ca8493f41",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043932","Updates on dyslipidemia in patients with diabetes","Shintaro Ide","2023","Journal of Diabetes Investigation","randomized_trial","article","10.1111/jdi.14042","37347218",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043933","Mitigating neuroinflammation : new potential therapeutics and targets","Elliot James Glotfelty (18673780)","2023","Open Archive (Karolinska Institutet)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043934","SAT-064 Copeptin Levels at Baseline and in Response to Short-Acting GLP-1 Receptor Agonists in Patients with Endogenous Hyperinsulinemic Hypoglycemia and Healthy Controls - A Secondary Analysis","Svenja Leibnitz","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.1546",null,null,"ClinicalTrials.gov:NCT04909333","S001699","openalex","TRUE","open_pdf","1","FALSE","article"],["R0043935","First study with positive cardiovascular outcome in obesity: Reflections on SELECT","Qi Pan","2024","Aging Medicine","randomized_trial","article","10.1002/agm2.12300","38975303",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043936","SUN-703 Post Bariatric Hypoglycemia Successfully Treated With GLP-1 Receptor Agonist","Samiya Khan","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.210",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043937","Journal of Diabetes NEWS","Nina A. Ran","2013","Journal of Diabetes","other","article","10.1111/1753-0407.12066",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043938","SUN-344 Much Ado About Nothing: Tirzepatide and Medullary Thyroid Cancer Debunked","Maxim John Levy Barnett","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.2358",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0043939","Protective effects of GLP-1 analogues against cellular stress in glucose uptaking tissues under lipotoxic conditions","Maha M. Hammad","2017",null,"other","article","10.26226/morressier.59d51846d462b80296ca3bad",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043940","PSUN326 An Interim Analysis of Healthcare Professionals’ Gaps in Incretin Knowledge Before and After Education","Erika L Brechtelsbauer","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.858",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0043941","Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide","Ametov As","2011","Diabetes Mellitus","other","article","10.14341/2072-0351-6226",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043942","Evaluation of the Influence of Route of Administration and Patient Covariates on a Pharmacokinetics and Pharmacodynamics Model: A Model-Based Meta-Analysis of Oral versus Subcutaneous Semaglutide","Mariana Resendiz Chavez","2026","Uppsala University Publications (Uppsala University)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0043943","Comparison of short- and long-acting GLP-1RA on glucose excursion, insulin/glucagon secretions and gastric emptying","ueno shinji","2017",null,"randomized_trial","article","10.26226/morressier.59d51845d462b80296ca346f",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0043944","DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?","Richard P. Shannon","2013","Diabetes","other","article","10.2337/db12-1794","23520281",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043945","Up Front",null,"2023","Diabetologia","preclinical","article","10.1007/s00125-023-05944-1","37243785",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043946","The Debate Surrounding Ozempic and Other “Miracle” Weight Loss Drugs Situated in the Scholarly and Public Spheres","Rivard, Allison","2025","HELIN Digital Commons","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043947","The effect of tirzepatide compared with semaglutide on weight loss in adults with obesity : A literature review","Emilia Uddenbjörk","2026","DiVA (Linnaeus University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0043948","Effect of GLP-1 receptor agonists at doses for obesity management on muscle health : systematic review of the literature and meta-analysis","Ligia Patricia Laverde Jimenez","2025","Repositorio Institucional (Pontificia Universidad Javeriana)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0043949","Prostaglandins supplementation enhances the efficacy of standard care on renal outcomes in patients with diabetic kidney disease","Xia Gu","2025","Chinese Medical Journal","randomized_trial","article","10.1097/cm9.0000000000003740","40898398",null,"ClinicalTrials.gov:NCT00968812; ChiCTR:ChiCTR2000040170",null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043950","Research Progress on the Combination of Semaglutide and Metformin in the Treatment of Obese PCOS","玉丽 鲁","2025","Advances in Clinical Medicine","other","article","10.12677/acm.2025.151073",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043951","Clinical relevance of recent outcome trials with antidiabetic drugs","Miles Fisher","2021","Practical Diabetes","randomized_trial","article","10.1002/pdi.2363",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043952","Use of HbA1c in clinical practice: New insights","Zachary T. Bloomgarden","2021","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13155","33427383",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0043953","Inside Back Cover: Nanoparticles Targeting the Intestinal Fc Receptor Enhance Intestinal Cellular Trafficking of Semaglutide","Santos, Hélder A.","2024","University of Groningen research database (University of Groningen / Centre for Information Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043954","CAN WE REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH OBESITY?","Jasmina Ćatić","2026","Fizikalna i rehabilitacijska medicina","other","article","10.21751/frm-40-1-24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043955","Potentiel thérapeutique des analogues du GLP-1 dans la modulation des processus neurodégénératifs et neuro-inflammatoires des maladies d'Alzheimer et de Parkinson","El Kebir, Nassim","2025","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043956","MER ÄN MEDICIN : [En grundad teoristudie som analyserar hur samtal i podcasts bidrar till att forma förståelser av inkretinläkemedel]","Linda Kahma","2026","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043957","Gall bladder agenesis in Prader Willi syndrome","VivekaP Jyotsna","2015","Indian Journal of Endocrinology and Metabolism","other","article","10.4103/2230-8210.149329","25729700",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043958","Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline","O Schmitz (14582942)","2008","Figshare","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0043959","A case of semaglutide associated severe acute kidney injury in an immunocompromised patient","Dhwanil Patel","2024","The American Journal of the Medical Sciences","case_report","article","10.1016/s0002-9629(24)00566-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043960","THE EFFICACY AND SAFETY OF THE SGLT2 RECEPTOR INHIBITORS IN TRIPLE THERAPY IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES",null,"2017","BiblioBoard Library Catalog (Open Research Library)","other_trial","article","10.26226/morressier.5c3c8158e668b9000b9f8dd6",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0043961","Surface Decoration of Peptide Nanoparticles Enables Efficient Therapy toward Osteoporosis and Diabetes","Tianhe Huang","2022","Advanced Functional Materials","preclinical","article","10.1002/adfm.202210627",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043962","Endocrine control of lipid metabolism","Talyia MaKell Fordham","2025",null,"other","article","10.32469/10355/111067",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0043963","Sarcopenia in Patients with Cardiovascular Disease Can Also Be Triggered by Other Risk Factors","Josef Finsterer","2025","Journal of the ASEAN Federation of Endocrine Societies","other","article","10.15605/jafes.040.02.02","41357064",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043964","Larger Relationship Between Diabetes and Alzheimer Disease and Related Dementias (ADRD)","Hiroshi Bando","2026","Journal of Health Care and Research","other","article","10.36502/2026/droa.6196",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043965","Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)","Sergey V. Kakorin","2016","Diabetes Mellitus","randomized_trial","article","10.14341/dm2003422-27",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043966","The role of endogenous neural stem cells (eNSCs) in metabolic syndrome and aging","Nikolakopoulou, Polyxeni","2017","Qucosa (Saxon State and University Library Dresden)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043967","Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus","Hyun Min Kim","2015","Endocrinology and Metabolism","preclinical","article","10.3803/enm.2015.30.1.84","25325279",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043968","Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use","Emma D. Deeks","2019","Drugs & Therapy Perspectives","other_trial","article","10.1007/s40267-019-00670-4",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0043969","NICE guidance on type 2 diabetes: too little, too early?","PH Winocour","2008","Practical Diabetes","other","article","10.1002/pdi.1266",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043970","Schizofrenie: presteert semaglutide beter dan liraglutide bij antipsychotica-geïnduceerde gewichtstoename?","Oliver Freudenreich","2026",null,"other","article","10.64239/pi-nl-qt9102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0043971","“Is this what thin people experience?” – Lived experiences of individuals undergoing GLP1-RA treatment for obesity","Holm, Signe Skjærbæk; id_orcid 0009-0000-2002-784X","2025",null,"other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0043972","Investigating the use of Bayesian prediction methods in precision medicine approaches in Diabetes","P Cardoso (12142371)","2024","Figshare","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0043973","Hypoglycemia, cardiovascular outcomes, and death: The LEADER experience","B. Zinman","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/k65w-3s34",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","TRUE","paywalled","1","FALSE","article"],["R0043974","Exendin-4 inhibits MMP-9 activation and reduces infarct growth after focal cerebral ischemia in hyperglycemic mice","黒木, 卓馬","2016","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043975","#1698348 Gender and Racial Disparities in the Utilization of GLP-1 Analogues in Obese Patients: A TriNetX Database Analysis","Hussein Al‐Sudani","2024","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2024.03.255",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0043976","Semaglutide in modulating disease : Severity in staphylococcal septic arthritis","Swapna Chinham","2026","KTH Publication Database DiVA (KTH Royal Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043977","Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","Steve Bain","2025","Cronfa (Swansea University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0043978","First GLP-1 analog liraglutide: the result of clinical trails on efficacy","Ametov As","2011","Diabetes Mellitus","other","article","10.14341/2072-0351-5815",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043979","Levothyroxine sodium/Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-66655-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043980","Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’","Vishal Mundra","2012","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.103040","23226666",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043981","Bio‐Inspired Pancreas With Microfluidic Multi‐Component Hydrogel Microfibers for Exploring Pancreatic Exocrine and Endocrine Interactions","Zhikun Huan","2025","Aggregate","other","article","10.1002/agt2.70210",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043982","Mésusage du sémaglutide (analogue du GLP-1) dans la perte de poids","Pregliasco, Julia","2025","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043983","Application of Mass Spectrometry in GLP‑1 and Dual Incretin Therapeutics: A Scoping Review of Analytical, Clinical, and Structural Advances (2008–2025)","Howard Rodriguez Mori","2026",null,"narrative_review","article","10.17605/osf.io/v3g7k",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0043984","Role of retinol binding protein 4, visfatin, omentin-1 and vaspin in gout patients with various obesity phenotypes","N. N. Pavlova","2024","Russian Journal of Cardiology","other","article","10.15829/1560-4071-2024-5871",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043985","Stereotypes and Discrimination Toward Weight Loss Injection Users","Philipp Sprengholz","2026","Journal of Applied Social Psychology","other","article","10.1111/jasp.70070",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043986","Spontaneous emulsification of model acylated peptide: An investigation on semaglutide","Qi Li","2023",null,"other","article","10.1021/scimeetings.3c00067",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0043987","The Image We Shape in the Era of GLP-1 Receptor Agonists","Sonya Heitmann","2026","UCLA Department of Medicine Clinical Insights","other","article","10.5070/v6.64555",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043988","ODP240 Routine Glucose-lowering Therapies and Risk of Adverse Outcomes in COVID-19 Patients with Diabetes: a Network Meta-analysis","Zheng Zhu","2022","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvac150.689",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0043989","Cardiovascular-Kidney-Metabolic Health Syndrome","Nisha Bansal","2024","Journal of the American Society of Nephrology","other","article","10.1681/asn.0000000000000323","38421033",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043990","Factors affecting survival in intestinal failure and novel therapeutic avenues","Oke, Siddhartha","2020","Spiral (Imperial College London)","nonrandomized_study","article","10.25560/91738",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0043991","Latest Topic for Clinical Effects of Tirzepatide as Dual GIP/GLP-1 Receptor Agonist",null,"2022","JOURNAL OF MEDICAL AND CLINICAL STUDIES","other","article","10.36266/jmcs/169",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0043992","Evaluación tras 12 meses de las características de una población con diabetes tipo 2 del Área Sur de Tenerife sometidas a tratamiento farmacológico combinado","Marrero García, Melody","2018","Scientia Insularum Revista de Ciencias Naturales en islas","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043993","The impact intentional weight loss can have on patients living with sleep apnea","Ayyad Alruwaily","2024","Research Repository UCD (University College Dublin)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0043994","Simplifying complex insulin regimens with preserving good glycaemic control in type 2 diabetes","Taybani Zoltán","2017",null,"other","article","10.26226/morressier.59d51845d462b80296ca349c",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0043995","Sulfonylureas: Scoring beyond START STUDY","Altamash Shaikh","2017","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/ijem.ijem_322_17","29285461",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0043996","Well-being-centred perspective on childhood obesity","Anna Hirsch","2026","JME Practical Bioethics","other","article","10.1136/jmepb-2026-000164",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043997","01 / Incretins and the anaesthetist: a systematic review","Abraham H. Hulst","2018",null,"systematic_review","article","10.26226/morressier.5aeb0ac607b0d6001a79a15b",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","other"],["R0043998","Useful Oral Administration of Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) as Semaglutide (Rybelsus) for Type 2 Diabetes Mellitus (T2DM)","Hiroshi Bando","2022","Asploro Journal of Biomedical and Clinical Case Reports","other","article","10.36502/2022/asjbccr.6260",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0043999","Falsified batches of OZEMPIC (semaglutide) identified",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-61431-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044000","GLP-1 agonists and type 2 diabetes health outcomes among rural patients","Hunter E. Wadlow","2024",null,"other","article","10.32469/10355/99422",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044001","Euglycemic diabetic ketoacidosis with SGLT2 inhibitors in undiagnosed type 1 DM","Mohammad, Aljumah","2017","BiblioBoard Library Catalog (Open Research Library)","other","article","10.26226/morressier.59d518442bbcef00144065dd",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044002","Editorial: New insights on vascular and metabolic diabetic complications","Hua Mao","2026","Frontiers in Physiology","other_trial","article","10.3389/fphys.2026.1784609","41657553",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0044003","Letter: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab2014;29:536-44, Min Jung Jung et al.)","Daeyoon Park","2015","Endocrinology and Metabolism","other","article","10.3803/enm.2015.30.2.231","26194082",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044004","On cardiovascular complications in people with type 2 diabetes : Aspects of incretin-based therapy and glycemic control","Irene Santos Pardo (18663229)","2024","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0044005","Evolution of Biochemical Effects of Byetta® in Type 2 Diabetics with Cardiovascular Risk","Alfonso López Ruiz","2013","Pharmacology &amp Pharmacy","randomized_trial","article","10.4236/pp.2013.49094",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044006","MON-690 Impact of GLP-1 Receptor Agonists on Late Complications Following Bariatric Surgery","Karima Gadalla","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.028",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044007","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND DIABETIC RETINOPATHY: MECHANISMS OF RETINAL PROTECTION AND CLINICAL IMPLICATIONS","Elizabeth Thompson","2026","UA Campus Repository (The University of Arizona)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044008","Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists in the Treatment of Heart Failure","Schloemann, Lisa Kristen","2025","OpenSIUC (Southern Illinois University Carbondale)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044009","Nutrition-obésité-Jeûne intermittent: une solution pour les maladies métaboliques ?","Tinh‐Hai Collet","2021","Revue Médicale Suisse","other","article","10.53738/revmed.2021.17.720-21.0059",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044010","Patients reaching treatment targets with once-weekly semaglutide in real‑world practice: pooled analysis of four SURE studies","Rasalam, Roy","2022","ResearchOnline - JCU (James Cook University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0044011","GLP-1 Receptor Agonist Plastic Surgery Meta-Analysis: Extracted Event Count Dataset","Julia Follmann","2026",null,"systematic_review","article","10.17605/osf.io/xkubr",null,null,"PROSPERO:CRD420261376776",null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0044012","DAPAGLIFLOZIN USE IN TRIPLE THERAPY FOR TREATING TYPE 2 DIABETES IN THE ENDOCRINOLOGY UNIT AT IMBANACO MEDICAL CENTER. CALI, COLOMBIA",null,"2017","BiblioBoard Library Catalog (Open Research Library)","other_trial","article","10.26226/morressier.5c3c8158e668b9000b9f8dd9",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0044013","Semaglutide: Multilevel organ protection in type 2 diabetes – from the heart and kidneys to peripheral vessels","Maria G. Pavlova","2025","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2025-475",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044014","Modelling The Impact Of High Fat Diet Feeding And Intentional Weight Loss On Type 1 Endometrial Cancer In The BDII/Han Rat","Sinclair, Piriyah","2021","Research Repository UCD (University College Dublin)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044015","Effects of glucagon-like peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis of propensity score-matched studies","Karakasis, Paschalis","2024","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/zgw26",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0044016","Safety Profiles of Antidiabetic Drugs (Ad) : a Disproportionality Analysis in The Portuguese Pharmacovigilance System (Pps) Database",null,"2017","BiblioBoard Library Catalog (Open Research Library)","nonrandomized_study","article","10.26226/morressier.5c3c8159e668b9000b9f8f71",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0044017","The Expanding Cardiovascular and Cardiorenal Role of GLP-1 Receptor Agonists","Marianne Koleng","2026","Advances In Clinical And Medical Research","randomized_trial","article","10.52793/acmr.2026.7(2)-122",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044018","RF07 | PSUN366 An Uncommon Path Leading to Diagnosis of Multiple Endocrine Neoplasia 2A","Sagarika Gokul","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.1856",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044019","The neurophysiological effects of glucagon-like peptide-1 receptor agonists on neuronal activity in the lateral septum","B Gurung (18377367)","2024","Figshare","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044020","Transition from hospital to outpatient diabetes care","Zachary T. Bloomgarden","2018","Journal of Diabetes","other","article","10.1111/1753-0407.12664","29655199",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044021","Diabetes Has Gotten Pretty Darn Complicated","NEIL SKOLNIK","2015","Clinical Diabetes","other","article","10.2337/diaclin.33.3.114","26203203",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044022","Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis","Laura J. Gray (7605071)","2015","Figshare","systematic_review","article","10.1111/dom.12462/abstract",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0044023","Publication and dataset for article \"Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing\"","Zhang, Wei","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14780593",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044024","An update of contemporary insulin therapy","Yuan‐Yu Tsai","2024","Journal of Diabetes Investigation","nonrandomized_study","article","10.1111/jdi.14212","38571372",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044025","Association of Patient Cost-Sharing With Adherence to GLP-1a and Adverse Health Outcomes","Donglan Zhang (702608)","2025","Figshare","nonrandomized_study","article","10.60929/nyulangone.28995647.v1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044026","Cardiovascular effects of anti-obesity medications: the perils and promise","Haoyi Zheng","2025","Cardiology Plus","randomized_trial","article","10.1097/cp9.0000000000000114",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044027","PSUN259 A Severe Case of Fournier's Gangrene Associated With Dapagliflozin","Shumail Syed","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.821",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044028","Estrategias de marketing social para el uso responsable de Ozempic® en Colombia","Daniela Plata Rueda","2025","Biblioteca Digital Repositorio Institutional CESA (Colegio de Estudios Superiores de Administración)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044029","Overview of the Role of Glucagon like Peptide-1 Receptor Agonists in the Management of Polycystic Ovary Syndrome","Asma Alshenqiti","2021","Journal of Pharmaceutical Research International","other","article","10.9734/jpri/2021/v33i58b34206",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044030","Diabetes mellitus, vitamin D & osteoporosis","Ravinder Goswami","2019","The Indian Journal of Medical Research","randomized_trial","article","10.4103/ijmr.ijmr_1920_19","31939384",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044031","Injectable Therapies for Diabetes and Obesity: From Evolution to Revolution","Elamin Abdelghadir","2024","Journal of Diabetes and Endocrine Practice","nonrandomized_study","article","10.1055/s-0043-1778117",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044032","Schizofrenia: il semaglutide supera il liraglutide nel controllo dell’aumento di peso da antipsicotici?","Oliver Freudenreich","2026",null,"other_trial","article","10.64239/pi-it-qt9102",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","report"],["R0044033","Effect of Different Diabetes Mellitus Treatments on Functional Decline and Death in Elderly Adults with Diabetes Mellitus","Carmine Gazzaruso","2013","Journal of the American Geriatrics Society","other","article","10.1111/jgs.12191","23581934",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044034","Mo2069: RATES OF GASTROINTESTINAL SYMPTOMS AND HEALTHCARE UTILIZATION AMONG OLDER ADULTS WITH OBESITY ON GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS","T J Mathews","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03839-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0044035","Caracterización de los efectos de GLP-1 y sus análogos en al función y maduración pulmonar","Marina Romaní‐Pérez","2014","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044036","Metabolic syndrome and heart failure","Yu. M. Lopatin","2025","Russian Journal of Cardiology","other","article","10.15829/1560-4071-2025-6540",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044037","SUN-668 A Severe Case of Pica Resolved With GLP-1 Agonist Therapy","Brandon Robert Bedell","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.178",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044038","Article Commentary: “Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes”",null,"2023",null,"commentary","article","10.1161/blog.20230201.87866",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0044039","Genetic Variants in Sulfonylurea Targets Affect Parkinson's Disease Risk: A Two‐Sample Mendelian Randomization Study","N. Ahmad Aziz","2023","Movement Disorders","other","article","10.1002/mds.29341","36782054",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044040","Decrease in Beta -Cell Proliferation Precedes Apoptosis during Diabetes Development in Bio-Breeding/ Worcester Rat: Beneficial Role of Exendin-4","Pérez Arana, Gonzalo","2010","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044041","L'influence des réseaux sociaux sur la prise de médicaments : le phénomène OZEMPIC®","Rabia Khessar","2025","INRIA a CCSD electronic archive server","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044042","Sa1965 EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BODY COMPOSITION - A SYSTEMATIC REVIEW AND META-ANALYSIS","Ravi Teja Pasam","2024","Gastroenterology","systematic_review","article","10.1016/s0016-5085(24)01842-0",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0044043","Effect of glucagon-like peptide-1 receptor agonists and co-agonists dose on body mass composition: systematic review and network meta-analysis","Karakasis, Paschalis","2024","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/su5hc",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0044044","Een studie naar de respons van vetweefsel op behandeling van obesitas met incretine analogen","Seuntjens, Joke","2025","Lirias","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044045","GLP-1RA – DRUGS THAT CHANGED THE STORY OF OBESITY","Dubravka Jurišić-Eržen","2026","Fizikalna i rehabilitacijska medicina","other","article","10.21751/frm-40-1-23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044046","IMPACT OF GLP-1 RECEPTOR AGONIST SEMAGLUTIDE ON CAROTID INTIMA-MEDIA THICKNESS IN DIABETES MELLITUS","Lijiang Li","2024","FARMACIA","randomized_trial","article","10.31925/farmacia.2024.4.9",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044047","Cardiovascular and metabolic outcomes associated with insulin use in type 2 diabetes : evidence from insulin users in the UK primary care","Uchenna Anyanwagu","2017","Nottingham ePrints (University of Nottingham)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0044048","Management of Patients With Type 2 Diabetes At High Cardiovascular Risk : Virtual Simulation Improves Clinical Decisions",null,"2017","BiblioBoard Library Catalog (Open Research Library)","other","article","10.26226/morressier.5c3c8158e668b9000b9f8e2d",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044049","Fixed-Ratio Combinations","Emmeline Tran","2017","Clinical Diabetes","other","article","10.2337/cd17-0037","29109615",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044050","GLP-1 Receptor Agonists in Obstructive Sleep Apnea: New fronteirs in Metabolic and Respiratory Medicine","Milesh Jung Sijapati","2024","Nepalese Respiratory Journal","commentary","article","10.3126/nrj.v3i2.83165",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0044051","149 REAL-WORLD WEIGHT LOSS OUTCOMES OF SEMAGLUTIDE: COMPARATIVE ANALYSIS AMONG PATIENTS WITH AND WITHOUT METABOLIC/BARIATRIC SURGERY","Pourya Medhati","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)04574-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044052","GLP-1 CellBead therapy for the prevention of left ventricular dysfunction in pigs","Elizabeth J. Wright","2013","Research Explorer (The University of Manchester)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044053","SAT-532 A Bariatric Breakthrough in Diabetes Control","Patricia Therese Pile","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1064",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044054","Prevalence of alopecia as an emerging adverse effect in individuals using tirzepatide for weight loss: a scoping review.","M. CARRER FASSBENDER TEIXEIRA","2026",null,"narrative_review","article","10.17605/osf.io/tf2q3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044055","The role of communication in medical weight loss : a study on ozempic's impact","Wallin, Celinn","2025","DiVA at Umeå University (Umeå University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044056","Diabetes type 2 én een hoog risico op hart- en vaatziekten","Erik H. Serné","2023","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044057","Diabetes and Cardiovascular Disease in Women: Current Challenges and New Hope","Efstratios Koutroumpakis","2020","Texas Heart Institute Journal","randomized_trial","article","10.14503/thij-19-7068","32603448",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044058","The Effect of Liraglutide on Hypoglycemia in Type 1 Diabetes Mellitus: A Meta-Analysis","Yan Wang","2024",null,"systematic_review","article","10.37766/inplasy2024.6.0051",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0044059","Research suggests antidepressant benefit of GLP‐1 receptor agonists",null,"2023","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044060","Glycemic treatment: Further concepts","Zachary T. Bloomgarden","2021","Journal of Diabetes","nonrandomized_study","article","10.1111/1753-0407.13168","33576179",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044061","Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD","Victoria E Parker (16613325)","2021","Figshare","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT03550378","S002039","openalex","FALSE","no_doi","1","FALSE","article"],["R0044062","Semaglutide-related suicidal ideation",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-65611-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044063","Lessons from glargine trials: What is the goal fasting glucose with basal insulin? (来自甘精胰岛素临床试验的经验教训：使用基础胰岛素治疗的空腹血糖目标是什么？)","Zachary T. Bloomgarden","2014","Journal of Diabetes","other_trial","article","10.1111/1753-0407.12152","24656089",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0044064","Cardio–renal service, time for a change","Nupur N. Uppal","2021","Clinical Kidney Journal","other","article","10.1093/ckj/sfab105","34603709",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044065","Synchronizing obesity management with survodutide","Amedeo Lonardo","2026","Exploration of Drug Science","other_trial","article","10.37349/eds.2026.1008175",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044066","Efficacy And Safety Of Semaglutide Injection (Generic) Compared With Ozempic® In Patients With Type 2 Diabetes Mellitus - A Multicentric, Prospective, Randomized, Open-Label, ActiveControlled, Parallel-Group Study","Piyush Agarwal","2026","Journal of diabetology research.","randomized_trial","article","10.52338/jodr.2026.5831",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044067","Semaglutide para el trastorno por uso de alcohol: nuevos datos de ECA","David A. Gorelick","2025",null,"other","article","10.64239/pi-es-qt7903",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044068","Efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RA) in primary prevention of cardiovascular events in patients with type 2 diabetes mellitus without established cardiovascular disease: a systematic review and meta-analysis of randomized clinical trials","Alesia Isamar Julca Malca","2026","Universidad Peruana Cayetano Heredia Institutional Repository","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0044069","Diabetes Remission – The New Therapeutic Goal in Management of Type 2 Diabetes Mellitus","T. De Abrew","2024","Sri Lanka Journal of Diabetes Endocrinology and Metabolism","other","article","10.4038/sjdem.v15i2.7553",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044070","Drug‑induced weight gain: pathophysiological mechanisms, clinically relevant drug classes, and management strategies","Tatyana Nikolaevna Skobeleva","2026","Patient-Oriented Medicine and Pharmacy","other","article","10.37489/2949-1924-0139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044071","MON-693 A Case of Hypothalamic Obesity Treated with Dual GLP-1/GIP Agonist and Stimulant Therapy","Brandon Lam","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044072","PSUN113 Evaluating The Efficacy Of Anti-Obesity Medications In a Multidisciplinary Weight Management Clinic At a VA Medical Center","Travis Goettemoeller","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.045",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044073","The effect and mechanism of LncRNA-NONRATT003689 in the function and viability of u03b2 cells mediated by GLP-1RA","Cui, Lijuan","2017","BiblioBoard Library Catalog (Open Research Library)","nonrandomized_study","article","10.26226/morressier.5d9b622cea541d6ca8493c4f",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0044074","Desarrollo de un tratamiento tópico en colirio para la retinopatia diabética basado en el efecto neuroprotector de GLP-1","Sampedro Vida, Joel","2020","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044075","AVALIAÇÃO DO USO OFF LABEL DE SEMAGLUTIDA EM UMA FARMÁCIA NO INTERIOR DO RIO GRANDE DO SUL","Bruna Eduarda Sprandel Scheibe","2023","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044076","Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-63446-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044077","SUN-542 Identifying Late Autoimmune Diabetes in Older Adults: Implications for Diagnosis and Management","Brooklyn A Bradley","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044078","Glucagon-Like Peptide 1 Receptor Agonists Protect Against Stroke In Patients With Diabetes : A Systematic Review And Meta-Analysis","Filippas-Ntekouan, Sempastian","2017","BiblioBoard Library Catalog (Open Research Library)","systematic_review","article","10.26226/morressier.5cc04c44c66852000b5aee26",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0044079","Role of GLP-1 receptor agonists in endothelial function","Özlem Erdogdu","2012","Figshare","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044080","USE OF GLP-1 ANALOGUE AS A CAUSE OF COMPLICATED ACUTE OBSTRUCTIVE ABDOMEN WITH PERFORATION – CASE REPORT AND LITERATURE REVIEW","Euler de Medeiros Azaro Filho","2024","Journal of Coloproctology","case_report","article","10.1055/s-0045-1808839",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044081","Two birds, One Hormone: Addressing cognitive impairment and the metabolic side-effects of antipsychotic drugs with liraglutide, a GLP-1 receptor agonist","Ilijana Babic (20241018)","2021","Research Online (University of Wollongong)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044082","The Year in Hungarian Cardiology 2023: Heart failure","Roland Gál","2024","Cardiologia Hungarica","randomized_trial","article","10.26430/chungarica.2024.54.3.177",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044083","PSAT043 Liraglutide Ameliorates Symptoms of Cushing Syndrome in a Pediatric Patient","Rohan K. Henry","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.217",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044084","FATORES RELACIONADOS AO USO DO MEDICAMENTO MOUNJARO (TIZERPATIDA) PARA O MANEJO DE COMORBIDADES, EXPONDO AS PERSPECTIVAS DE SUA UTILIZAÇÃO","Kedson Melo","2024","Revista fisio&terapia.","nonrandomized_study","article","10.69849/revistaft/ni10202408142114",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044085","On anti-diabetic agents and the vasculature","Linnéa Eriksson (18690448)","2024","Figshare","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044086","Signals and Noise in Drug Safety Analyses","William T. Cefalu","2013","Diabetes Care","other","article","10.2337/dc13-0895","23695816",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044087","Mo2070: EXPLORATION OF INTERACTIONS BETWEEN SEMAGLUTIDE AND CANNABIS USE","Joanna Sung","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03840-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0044088","0351 Decreased incidence of acanthosis nigricans in patients with obesity taking GLP-1 agonists","Jeremiah J. Bearss","2025","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2025.06.355",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044089","Encapsulation as a 3D model for human embryonic stem cell propagation and differentiation","Chayosumrit, Methichit","2022","UNSWorks (UNSW Sydney)","other","article","10.26190/unsworks/23160",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044090","Are Physicians Neglecting the Risk of Heart Failure in Diabetic Patients who are Receiving Sulfonylureas? Lessons from the TOSCA.IT Trial","Milton Packer","2018","European Journal of Heart Failure","randomized_trial","article","10.1002/ejhf.1093","29388338",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044091","Incremental choices, system-wide impact on health system performance","Rocco Friebel","2025","Health Economics Policy and Law","other","article","10.1017/s174413312510025x","41126745",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044092","GLP 1: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/a3f9d",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044093","Glucagon signaling in the heart: Activation or inhibition?","Alessandro Pocai","2014","Molecular Metabolism","preclinical","article","10.1016/j.molmet.2014.12.004","25685695",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044094","How to implement quality use of medicines in developing countries - an example from China","Lan Gao","2014","NOVA (University of Newcastle Australia)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044095","Inflammatory Signaling: Another Drug Target to Improve Glycemic Control in Type 2 Diabetes","Barry J. Goldstein","2008","Clinical and Translational Science","randomized_trial","article","10.1111/j.1752-8062.2008.00011.x","19468293",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044096","Efficacy and safety of semaglutide compared with dulaglutide in patients with type 2 diabetes:a meta-analysis","Guochao Xu","2023",null,"systematic_review","article","10.37766/inplasy2023.11.0027",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0044097","Impact on Knowledge, Competence, and Performance of a Faculty-Led Web-Based Educational Activity for Type 2 Diabetes and Obesity: Questionnaire Study Among Health Care Professionals and Analysis of Anonymized Patient Records (Preprint)","Jennifer Okemah","2023",null,"other","article","10.2196/preprints.49115",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0044098","Effect of liraglutide on carotid intima-media thickness in obese patients with type 2 diabetes: interim analysis","Prakash Shanmugam","2017",null,"other_trial","article","10.26226/morressier.59d51847d462b80296ca3bb2",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","other"],["R0044099","The Effectiveness of the use of Liraglutide 3.0mg in Obesity Services (The STRIVE Study)","Anna Isayeva","2023","Research Repository UCD (University College Dublin)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0044100","Adipose tissue and insulin-resistance. Beneficial effects of glp-1 agonists","Quintanilla, María Florencia","2022","Conicet","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0044101","Save the brain! ; studies on GLP-1-mediated neuroprotection","Martin Larsson","2019","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0044102","GLP-1 receptor agonist-related AEs and potential for misuse",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-69665-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044103","Effects of glucagon-like peptide-1 receptor agonists on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes: a meta-analysis of randomized controlled trials","Karakasis, Paschalis","2024","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/bx368",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0044104","Hepatotropc effects of glucose-lowering drugs: non-alcoholic fatty liver disease in focus","E. V. Uzhakova","2023","Экспериментальная и клиническая гастроэнтерология","other","article","10.31146/1682-8658-ecg-214-6-121-129",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044105","GLYCEMIA NORMALIZATION IN PATIENTS WITH OBESITY AND TYPE 2 DIABETES MELLITUS USING TECHNOLOGIES PROVIDING MAXIMUM INCRETIN EFFECT (BILIOPANCREATIC DIVERSION VS LIRAGLUTIDE 3.0 MG)","Shestakova, Ekaterina","2017","BiblioBoard Library Catalog (Open Research Library)","other","article","10.26226/morressier.5c3c8159e668b9000b9f9195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044106","Considering the risks of glucagon-like peptide-1 receptor agonists in dentoalveolar surgery: a case report","Rhea Narang","2026","Journal of Cranio-Maxillofacial Surgery","case_report","article","10.1016/j.jcms.2026.108056",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044107","MON-230 Safety Profile of Sodium-Glucose Cotransport-2 Inhibitors in a Large, Children’s Hospital System","Olivia Ginnard","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1704",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044108","A cross-sectional study on the symptoms of depression in dental students in Kerbela","Athraa A. Abass","2024","Technium BioChemMed","preclinical","article","10.47577/biochemmed.v11i.12117",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044109","Promoting Muscle Health During GLP-1 Therapy Through Nutrition","Manogaran, Erin","2025","ScholarWorks -A service of University of Vermont Libraries (University of Vermont)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044110","Bounded Semaglutide once signal: semaglutide (1.8%) versus placebo (2.2%)","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/f9ubp",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044111","MON-244 Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone","Kimberly A Rizzo","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.2376",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044112","Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus","Yury Ivanovich Suntsov","2012","Diabetes Mellitus","nonrandomized_study","article","10.14341/2072-0351-5971",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044113","Noninvasive quantitative evaluation of viable islet grafts using ¹¹¹In-exendin-4 SPECT/CT","Botagarova, Ainur","2023","Institutional Repositories DataBase (IRDB)","preclinical","article","10.14989/doctor.k24965",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; dissertation"],["R0044114","Exploring aspects of allosteric modulation and bias signalling at the glucagon-like peptide-1 receptor","Emilia E. Savage","2017","Figshare","other","article","10.4225/03/58b618c43aaad",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044115","Significant effect of decreased weight and HbA1c by oral semaglutide (Rybelsus) for Type 2 Diabetes (T2D) patient",null,"2023","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/162",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044116","Semaglutide delays 4-hour gastric emptying in women with PCOS and obesity","Mojca Jensterle Sever","2026","DiRROS repository (University of Maribor)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0044117","Sindrome dell’ovaio policistico: ruolo del glucagon-like peptide 1 (GLP-1) nella regolazione dell’asse ipotalamo-ipofisi-ovaio","Gabriella Pugliese","2023","L Endocrinologo","other","article","10.1007/s40619-023-01355-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044118","Semaglutid 2,4 mg vid behandling av övervikt och fetma - en kortare viktminskningskur eller livslång behandling?","Tengesdal Nielsen, Nina","2024","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0044119","The new therapeutic modalities for the treatment of type 2 diabetes mellitus: insulin detemir added to liraglutide","Е Ю Пашкова","2013","Problems of Endocrinology","other","article","10.14341/probl201359450-55",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044120","Development and Exploitation of RiPPs technology for Peptide Engineering","Yanli Xu","2024",null,"other","article","10.33612/diss.1161821388",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044121","Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review","Giulia Biagi Furlan","2023","International Journal of Nutrology","systematic_review","article","10.54448/ijn23105",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0044122","The Effects of Liraglutide on the Learned Control of Appetitive Behavior / by Sabrina Jones.","Jones, Sabrina","2020","Figshare","preclinical","article","10.17606/eg0g-5h69",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044123","Monitoring of incretin drugs for type2 diabetes in private health care in Abu Dhabi - Clinical audit","Alnounou Rania","2017",null,"other","article","10.26226/morressier.59d5184bd462b80296ca32f0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044124","Victosa: the experience with clinical application in patients with type 2 diabetes mellitus","Э. А. Войчик","2011","Problems of Endocrinology","randomized_trial","article","10.14341/probl201157337-41",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044125","Liraglutideas Adjunct Therapy in the Management of Obesity","Eugênio Cersósimo","2015","International Journal of Nutrology","other_trial","article","10.1055/s-0040-1705257",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044126","The Analysis Study of Association of Type 2 Diabetes Mellitus and Hepatocellular Carcinoma : A Comprehensive Systematic Review","Muhammad Ilham Wira Tri Putra","2024","The Indonesian Journal of General Medicine","systematic_review","article","10.70070/x66ng691",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0044127","RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis","Priyadarshini Balasubramanian","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.878",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0044128","SUN-075 Efficacy of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Diabetes Management in Patients with Cushing’s Disease","Zainab Nasrallah","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1660",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044129","Costo efectividad de Liraglutide frente a Orlistat en el tratamiento de obesidad","Quintero Clavijo, Angélica","2022","Repositorio Institucional E-DocUR (Universidad Del Rosario)","other","article","10.48713/10336_31779",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044130","Les actualités thérapeuthiques et de suivi en diabétologie chez les carnivores domestiques","Wurtz, Éloïse","2022","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044131","Editorial: Community and clinical pharmacy services in type 2 diabetes care, volume II","Muhammad Shahzad Aslam","2026","Frontiers in Clinical Diabetes and Healthcare","commentary","article","10.3389/fcdhc.2026.1812553","41890347",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0044132","ADA/EASD-consensus over glucoseverlagende therapie bij diabetes mellitus type 2: wat betekent dit voor België?","Mathieu, Chantal","2019","Lirias","other","article","10.2143/tvg.75.07.2002819",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044133","Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies","Abd El Aziz, Mirna Safia (Dr. med.)","2019","Dokumentenrepositorium der RUB (Ruhr University Bochum)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0044134","Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","Thomas A Wadden (8951606)","2021","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0044135","The regulatory state of nonalcoholic steatohepatitis and metabolism","Stephanie O. Omokaro","2020","Endocrinology Diabetes & Metabolism","randomized_trial","article","10.1002/edm2.113","33102795",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044136","Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169572 per QALY and exenatide with $278935 per QALY as second-line treatment in adult diabetics in the USA","Davis, Wendy; id_orcid 0000-0002-5709-8235","2010","UWA Profiles and Research Repository (University of Western Australia)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0044137","Author Correction: Monocytes to Apolipoprotein A1 ratio is associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus","Wei Wang","2025","Scientific Reports","other","article","10.1038/s41598-025-90119-8","40055381",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0044138","Investigation for Daily Profile of Blood Glucose by the Administration of Canagliflozin and Xultophy (IdegLira)",null,"2022","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/129",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044139","PharmacoAnalytics: Assessing the Relationship Between Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Utilization and Dementia Incidence","Qi, Junnan","2024","D-Scholarship@Pitt (University of Pittsburgh)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0044140","Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.","J Rosenstock (7710920)","2019","Figshare","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT02607865","S002267","openalex","FALSE","no_doi","1","FALSE","article"],["R0044141","GLYCAEMIC CONTROL AFTER OPTIMAL MEDICAL TREATMENT IMPROVES ENDOTHELIAL FUNCTION, MYOCARDIAL DEFORMATION, BODY MASS INDEX, AND OXIDATIVE STRESS IN SUBJECTS WITH TYPE 2 DIABETES","Ikonomidis, Ignatios","2017","BiblioBoard Library Catalog (Open Research Library)","other","article","10.26226/morressier.5c77f16d148ee80015e1ccb4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044142","SUN-666 Sex-based Differences In Body Composition Changes Among Adolescents With Obesity Under Glp-1 Analogue Therapy","Adar Lopez","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.176",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044143","Hypoxia-inducible factor-1 (HIF-1) in pancreatic cancer cell aggressiveness and therapeutic resistance and the potential role for pancreatic endocrine cells in islet transplantation","Xiaohui Jia","2013","Figshare","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044144","Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation","N. А. Avxentyev","2022","FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","other","article","10.17749/2070-4909/farmakoekonomika.2022.150",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044145","Impact of GLP-1 receptor agonists on renal function and weight loss in patients with chronic kidney disease and obesity: a systematic review and meta-analysis","Lilio <1993> Hu","2026","AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0044146","The Evolving Therapeutic Landscape of Diabetes Mellitus and Obesity: From Conventional Treatments to Next-Generation Metabolic Therapies","Nazmi Özer","2026","Journal of Advances in Medicine and Medical Research","other","article","10.9734/jammr/2026/v38i86173",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044147","Post-transcriptional regulation of insulin mRNA mediated by G3BP1/2 condensates in beta cell biology","Quezada Dulcic, Esteban","2024","Qucosa (Saxon State and University Library Dresden)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044148","Stroke-inducerad stamcells proliferation i normala kontra diabetiska möss och famakologisk reglering","Fadhel, Zainab","2015","KTH Publication Database DiVA (KTH Royal Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044149","High-Risk Coronary Plaques and Cardiovascular Prevention: Insights from Coronary Computed Tomography Angiography and Real-World Data","Ahmed Salem","2026",null,"nonrandomized_study","article","10.23889/suthesis.72008",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","dissertation"],["R0044150","Aggressive variant prostate cancer: A case report and literature review","Xiang-Tao Weng","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6213","37731555",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044151","Semaglutide treatment effects on anxiety-like behavior and sucrose preference in a rat model of diabetes type 2","V. Todorović","2026","Neuroscience Applied","nonrandomized_study","article","10.1016/j.nsa.2025.106261",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044152","The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review","Jahnavi Udaikumar","2025","Pharmacoepidemiology","systematic_review","article","10.3390/pharma4030014",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0044153","Ion- and osmoregulating renal functions in patients with type 2 diabetes mellitus","E. V. Balbotkina","2016","Diabetes Mellitus","other","article","10.14341/dm7585",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044154","S6, a novel GLP-1 receptor agonist, stimulates insulin secretion in pancreatic u03b2-cells","Yang, Xiaohua","2017","BiblioBoard Library Catalog (Open Research Library)","preclinical","article","10.26226/morressier.5d9b6230ea541d6ca8493db0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044155","Exploring the Structure, Function & Regulation of the Human Glucagon-Like Peptide-1 Receptor","Yan Huang (46805)","2011","Figshare","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044156","Glucagon-Like Peptide 1 Receptor Agonists Protect Against Stroke in Patients With Diabetes : a Systematic Review and Meta-Analysis of 5 Randomized Controlled Trials","Barkas, Fotios","2017","BiblioBoard Library Catalog (Open Research Library)","systematic_review","article","10.26226/morressier.5cb58cffc668520010b56f27",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0044157","Semaglutide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-46321-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044158","Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal–bolus insulin in UK clinical practice","Melanie J. Davies","2023","Diabetes Obesity and Metabolism","nonrandomized_study","article","10.1111/dom.15278","37722973",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044159","The influence of exendin and GLP-1 on VCAM-1 and ICAM-1 production in endothelium stimulated by TNF-α and glycated albumin","Krzysztof Siemianowicz","2012","Health","preclinical","article","10.4236/health.2012.412a225",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044160","Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90771-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044161","Health economic evaluation of dipeptidyl peptidase-4 inhibitors","Vishvas Garg","2011","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.83049","21847463",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044162","Patterns and trends in insulin intensification among patients with T2DM in Middle East and North Africa Region","Jabbar Abdul","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51844d462b80296ca3880",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0044163","Stratégie thérapeutique envisagée après échec de la metformine : évaluation des pratiques des médecins généralistes","Lacombrade, Julien","2018","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044164","ODP259 Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonist in T1DM Patients","Deene Mohandas","2022","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvac150.706",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044165","A Phase 1, Open-Label, Single-Dose Study to Evaluate Pharmacokinetics of MEDI0382 in Patients with Renal Impairment","Gernot K Klein (16619241)","2019","Figshare","other_trial","article",null,null,null,"ClinicalTrials.gov:NCT03235375","S000042","openalex","FALSE","no_doi","5","FALSE","conference-paper"],["R0044166","Carbohydrate‐induced weight gain models for diabetes research: Contribution of incretins and parasympathetic signal","Yusuke Seino","2020","Journal of Diabetes Investigation","preclinical","article","10.1111/jdi.13342","32618108",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044167","New factors secreted from islets expand β‐cell mass","Hirotaka Watada","2013","Journal of Diabetes Investigation","preclinical","article","10.1111/jdi.12079","24843677",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044168","LDL‐C rebound after long‐term evolocumab treatment and intravascular imaging evidence in a familial hypercholesterolemia patient with early‐onset myocardial infarction","Zhifan Li","2023","Chronic Diseases and Translational Medicine","other_trial","article","10.1002/cdt3.97","38450306",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0044169","“Oral Health and Adverse Oral Effects Associated with Semaglutide and Tirzepatide: A Scoping Review”","Cardoso, Mariane","2025","OSF Preprints (OSF Preprints)","nonrandomized_study","article","10.17605/osf.io/2vhc6",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0044170","New medications and new ways to use them","Donna H. Ryan","2015","Obesity","other","article","10.1002/oby.21091","25900866",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044171","Vildagliptin: optimal control in type 2 diabetes mellitus treatment","Ametov As","2015","Diabetes Mellitus","other","article","10.14341/dm7599",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044172","Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?","Yong Kyun Cho","2018","Clinical and Molecular Hepatology","randomized_trial","article","10.3350/cmh.2018.1006","30196651",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044173","Obesità e rischio cardiovascolare: nuovi approcci terapeutici","Patrizia Suppressa","2023","Cardiologia Ambulatoriale","other_trial","article","10.17473/1971-6818-2023-4-4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0044174","Learning by reading: A review of recent diabetes articles","Zachary T. Bloomgarden","2022","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13272","35606898",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044175","Diabetes Treatment: Recent Developments","Aristidis Veves","2013","Advances in Therapy","randomized_trial","article","10.1007/s12325-013-0073-9","24263555",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044176","The combination of coronary artery disease and type 2 diabetes: a therapeutic challenge","Isabelle Johansson","2019","European Heart Journal Supplements","nonrandomized_study","article","10.1093/eurheartj/suz037","30996707",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044177","Chilean multidisciplinary consensus on the use of GLP-1 agonists: recommendations based on the GRADE methodology","Sebastián Cabrera","2026","London School of Economics and Political Science Theses Online (London School of Economics and Political Science)","other","article","10.4067/s0034-9887202600071070",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044178","Factors Associated with the Serious Adverse Effects and Misuse of GLP-1 Receptor Agonists","Nguyen, Khang","2024","Digital Archive @ GSU","nonrandomized_study","article","10.57709/37401983",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0044179","Liraglutide-Degludec Fixed Dose Combination Improves Nash/Nafld In Patients With Uncontrolled Type II Diabetes Mellitus","Prem, Sonia","2017","BiblioBoard Library Catalog (Open Research Library)","other","article","10.26226/morressier.5c3c8155e668b9000b9f8dd3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044180","G9LKGD0KBR The Challenges in Evaluating Weight Loss Outcomes of Preoperative GLP-1 Receptor Agonist with Sleeve Gastrectomy – Getting A Prescription is Not Enough",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.287",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044181","Association between antidiabetic drug use and the risk of COVID ‐19 hospitalization in the INSIGHT Clinical Research Network in New York City","Jea Young Min","2022","Diabetes Obesity and Metabolism","nonrandomized_study","article","10.1111/dom.14704","35373892",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044182","GLP-1 Receptor Agonists for Treatment of Obesity","Maria Kenneally","2024","MEDSURG Nursing","other","article","10.62116/msj.2024.33.3.125",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044183","Pain and diabetes","Rowan Hillson","2020","Practical Diabetes","other","article","10.1002/pdi.2292",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044184","Knowledge, Attitude and Practice about Glucagon-like Peptide-1 Receptor Agonist Among the Physicians of Prince Mohammed bin Abdulaziz Hospital & Primary Health Care, National Guard, Saudi Arabia","Meshari Turjoman","2025","Journal of Pharmaceutical Research","other","article","10.18579/jopcr/v24.i1.71",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044185","Étude des mécanismes impliqués dans l’effet des inhibiteurs d’intégrase du VIH sur la prise de poids et les atteintes du tissu adipeux : identification de stratégies de prévention","Kenza Ngono Ayissi","2025",null,"preclinical","article","10.70675/8e7e5f79z74c8z43b1zb33dz70861a311713",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044186","Diabetogenic effects of Glucocorticoids : role of Protein Phosphatase 5 and GLP-1 receptor activation","Liselotte Fransson","2014","Figshare","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044187","The heart in diabetes meeting","Zachary T. Bloomgarden","2019","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12973","31373114",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044188","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-57828-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044189","Cardiovascular Endocrinology",null,"2013","Cardiovascular Endocrinology","other","article","10.1097/xce.0b013e328361ec28",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044190","Albiglutida (Eperzan®): tractament de la diabetis mellitus tipus 2 en adults per millorar el control glucèmic com a monoteràpia quan la dieta i l'exercici per si sols no proporcionen un control glucèmic adequat, en pacients per a qui l'ús de metformina no es considera apropiat a causa de contraindicacions o intolerància, i com a tractament addicional en combinació amb altres medicaments hipoglucemiants incloent-hi insulina basal, quan aquests, juntament amb la dieta i l’exercici, no proporcionen un control glucèmic adequat",null,null,"RECERCAT (Consorci de Serveis Universitaris de Catalunya)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0044191","Clinical characteristics associated with adherence and persistence in patients with type 2 diabetes mellitus treated with dulaglutide","이데이비드승우","2023","Seoul National University Open Repository (Seoul National University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044192","How Does Neprilysin Inhibition in Heart Failure Work?","Mark Richards","2019","European Journal of Heart Failure","randomized_trial","article","10.1002/ejhf.1454","30884077",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044193","Paracrine actions of glucagon-like peptide 1 in the gut unraveled","C. Allard","2022","Life Metabolism","preclinical","article","10.1093/lifemeta/loac010","39872692",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044194","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-67167-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044195","The effect of liraglutide on metabolic and reproductive outcomes in infertile women with PCOS: A prospective cohort study","Rossella Cannarella","2025","Human Nutrition & Metabolism","nonrandomized_study","article","10.1016/j.hnm.2025.200331",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044196","Intensification of basal insulin therapy with Lixisenatide in patients with Type 2 Diabetes in a real-world setting : the BASAL-LIXI study / Diego Bellido ... et al.","Bellido, Diego.","2018","CEU Repositorio Institucional (Fundación Universitaria San Pablo CEU)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0044197","Associations of taste intensity changes with appetite during incretin-based therapy in obesity","A Kapan","2025","European Journal of Public Health","other","article","10.1093/eurpub/ckaf161.1174",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044198","MON-242 Effects of Liraglutide on Body Composition Distribution in Adolescents with Refractory Obesity Post-Vertical Sleeve Gastrectomy","Bao-Vi Tran","2025","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvaf149.1716",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044199","Liraglutide and dulaglutide in addition to SGLT-2i and metformin in Indian T2DM: a retrospective observational study","Samit Ghosal","2017",null,"nonrandomized_study","article","10.26226/morressier.5a004583d462b80296ca39c3",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0044200","Incretin Based Therapy – Another Risky Behavior?","Winikoff, Janet","2012","eScholarship (California Digital Library)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044201","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-67168-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044202","SEMAGLUTIDE : A THERAPEUTIC REVOLUTION IN THE MANAGEMENT OF OBESITY AND OVERWEIGHT IN TYPE 2 DIABETICS","Gisele Marlene Maciag","2024","Revista fisio&terapia.","nonrandomized_study","article","10.69849/revistaft/ra10202411061804",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044203","Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?","Patrice Darmon","2023","HAL AMU","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044204","Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604","Robert J. Heine","2013","Diabetes","commentary","article","10.2337/db13-0690","24065798",null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0044205","Type 2 diabetes management with glucagon like peptide 1 analogues: potential gains and pitfalls","Mark Woods","2012","eCite Digital Repository (University of Tasmania)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044206","Ozempic.docx","Purab Sood","2021","Figshare","other","article","10.6084/m9.figshare.14222192.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044207","More cardiovascular outcomes trials in people with diabetes: time to change the NICE guidelines","Miles Fisher","2018","Practical Diabetes","randomized_trial","article","10.1002/pdi.2193",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044208","An evaluation of the prescription pattern of IDegAsp and its clinical outcomes in Indian clinical practice","Jothydev Kesavadev","2019",null,"nonrandomized_study","article","10.26226/morressier.5d9b6232ea541d6ca8493b53",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0044209","Psoriasis patients with obesity and type 2 biabetes: the effect of glucagon-like peptide 1 (GLP-1) receptor agonists","Paula Cristina Cardoso Teixeira","2015","Open Repository of the University of Porto (University of Porto)","randomized_trial","article","10.34626/x485-j713",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0044210","Evaluation of Physicochemical Properties and Biological Activity of Tirzepatide-Based Drugs","P. I. Makarevich","2025","Pharmacy & Pharmacology","preclinical","article","10.19163/2307-9266-2025-13-6-529-546",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044211","Ambulatory anesthesia: optimal perioperative management of the diabetic patient","Jorinde A. W. Polderman","2016","Ambulatory Anesthesia","other","article","10.2147/aa.s102136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044212","Strategies to improve outcome after islet transplantation using the GLP-1 receptor agonist, extendin-4","Amit Sharma","2007","Figshare","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044213","Evaluation of Cardio-Metabolic Effects of Treatment with Incretin-Based Therapies in Patients with Type 2 Diabetes","Olga Montvida","2018","Queensland University of Technology","nonrandomized_study","article","10.5204/thesis.eprints.122920",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","dissertation"],["R0044214","Evaluation of drug utilisation pattern and cost associated with diabetes mellitusType 2 management in Saudi Arabia","Mohammad Daud Ali","2022","Brazilian Journal of Pharmaceutical Sciences","nonrandomized_study","article","10.1590/s2175-97902022e20681",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044215","Moving towards a more realistic concept of what constitutes Alzheimer's disease","Christian Hölscher","2018","EBioMedicine","other_trial","article","10.1016/j.ebiom.2018.12.030","30579866",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044216","Amylin, bariatric surgery, and type 2 diabetes mellitus","Wen-Ling Lee","2021","Journal of the Chinese Medical Association","nonrandomized_study","article","10.1097/jcma.0000000000000618","34524225",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044217","Évolution du comportement alimentaire chez les patients présentant une obésité sévère et compliquée, traités par WEGOVY pendant 6 mois, suivis au CSO de Poitiers","Cerdan, Marie","2024","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044218","Metformin/semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-56920-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044219","β‐Cell research – A decade of rapid growth","Bo Åhrén","2009","Diabetes Obesity and Metabolism","preclinical","article","10.1111/j.1463-1326.2009.01143.x","19817782",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044220","Bounded GLP 1 signal: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)","Dominic Lynch","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/64y8h",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044221","EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Anstee, Quentin","2024","Conicet","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044222","17 Artificial intelligence for the safe use of medications during breastfeeding","Elkana Kohn","2024",null,"other","article","10.1136/bmjpo-2024-esdppp.16",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044223","Treatment of Cardiometabolic Risk Factors in Adults with Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review of Evidence-Based and Real-World Observational Data: A Clinical Review for Practising Physicians","Ranjit Gain","2026","International Journal of Science and Research (IJSR)","randomized_trial","article","10.21275/sr26809235305",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0044224","Neuroinflammation in Alzheimer’s disease: current evidence and therapeutic targets","Jan Olszewski","2026","Medical Science","other_trial","article","10.54905/disssi.v30i174.e168ms3927",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044225","One more piece in the pancreatic chloride puzzle","Lena Eliasson","2021","Acta Physiologica","preclinical","article","10.1111/apha.13737","34709722",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044226","Impaired glucose tolerance and incretins in chronic liver disease","Mark D. Gorrell","2008","Journal of Gastroenterology and Hepatology","other_trial","article","10.1111/j.1440-1746.2007.05268.x","18289349",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0044227","Letter: The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes (Diabetes Metab J2014;38:211-9)","Seung‐Hwan Lee","2014","Diabetes & Metabolism Journal","randomized_trial","article","10.4093/dmj.2014.38.4.317","25215279",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044228","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-62032-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044229","Drug safety and effectiveness in relation to kidney function : a pharmacoepidemiological approach","Marco Trevisan","2021","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0044230","A 2-es típusú diabetes mellitus antihiperglikémiás kezelésének változása Magyarországon 2015–2020 között – adatbáziselemzés országos adatai","György Jermendy","2022","Diabetologia Hungarica","other","article","10.24121/dh.2022.23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044231","Research Progress on the Pathogenesis and Chinese and Western Medicine Treatment of Diabetic Kidney Disease","Xiaoduo Ai","2026","Journal of Artificial Intelligence and Information","other","article","10.66069/ojspub.27450813",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044232","Postpartum hemophagocytic lymphohistiocytosis: A case report","Ju Ho An","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6183","37731572",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044233","SUN-688 Unexpected Consequences: Guillain-Barre Syndrome Following GLP-1 Agonist Therapy","Stephanie Obialo","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044234","Developments in type 1 and type 2 diabetes","Zachary T. Bloomgarden","2021","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13186","33855791",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044235","Oh, Oh, Oh, Ozempic: Utilizing Harm to Determine the Permissibility of Direct-to-Consumer Prescription Pharmaceutical Advertising","Corbett, Rachel","2024","Scholarship @ Claremont (The Claremont Colleges)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044236","Improving Solid-State Properties of the Side-Chain Peptide Building Blocks for the Synthesis of GLP-1 Analogs through Their Complexation with Metal Cations","Andrea Orlandin","2025","Organic Process Research & Development","other","article","10.1021/acs.oprd.4c00515",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044237","A182 Novel Medical Nutrition Therapy May Positively Support GLP-1 RA Medication Use John P. Troup, Ph.D. Middletown, CT1, Megan Koscinski, MS, RD, Middletown, CT1 Blueroot Health Institute1",null,"2024","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2024.04.219",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0044238","Critical Clinical Issue of Diabetes Therapy induced Hypoglycemia : a Population Study Analysis On Existing Databases",null,"2017","BiblioBoard Library Catalog (Open Research Library)","nonrandomized_study","article","10.26226/morressier.5c3c8157e668b9000b9f90a6",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0044239","AI in the drug discovery pipeline","Néstor F. González García","2025","Alzheimer s & Dementia","other","article","10.1002/alz70861_108629","41434258",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044240","Studies on Incretins and Cardiovascular Function","David Nathanson","2010","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0044241","Evaluation of insulin secretion by glucagon stimulation test predicts long-term glycemic control in type 2 diabetes","Daisuke Ikeda","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51847d462b80296ca3c48",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0044242","Prescribing gliptins: Enthusiasm should be coupled with caution","MK Garg","2012","Indian Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/2230-8210.93785","22470884",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044243","Vildagliptin and its role in the treatment of diabetes mellitus","Yury Shavkatovich Khalimov","2010","Diabetes Mellitus","other","article","10.14341/2072-0351-5495",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044244","Talks and tweets from the ADA","Zachary T. Bloomgarden","2018","Journal of Diabetes","nonrandomized_study","article","10.1111/1753-0407.12831","30054986",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044245","Novel approaches to the treatment of type 1 diabetes","Zachary T. Bloomgarden","2022","Journal of Diabetes","other_trial","article","10.1111/1753-0407.13333","36345147",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044246","Hormonal Management of Small Bowel Failure","Kumkum Patel","2017","Clinical and Translational Gastroenterology","randomized_trial","article","10.1038/ctg.2017.32","28662020",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044247","Are both protein kinase A‐ and protein kinase C‐dependent pathways involved in glucagon‐like peptide‐1 action on pancreatic insulin secretion?","Makoto Shigeto","2014","Journal of Diabetes Investigation","preclinical","article","10.1111/jdi.12225","25411592",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044248","Gut microbiota as a key player in type 2 diabetes: Current perspectives","Sruthi Sethumadhavan","2025","Journal of Applied Pharmaceutical Science","other","article","10.7324/japs.2026.267236",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044249","Reply","Eduardo Vilar‐Gómez","2016","Hepatology","nonrandomized_study","article","10.1002/hep.28670","27287070",null,null,null,"openalex","FALSE","paywalled","4","FALSE","letter"],["R0044250","Dysglycaemia and cardiovascular disease. Aspects on screening, management, and prognosis","Giulia Ferrannini (18679255)","2023","Figshare","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0044251","Peculiarities of treatment and prevention in patients with type 2 diabetes mellitus with osteoporotic disorders in a region with a high birth rate","M. E. Muzafarova","2022","Health care of Tajikistan","other","article","10.52888/0514-2515-2021-351-4-55-59",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044252","Taking Control Of Your Diabetes: An Innovative Approach to Improving Diabetes Care Through Educating, Motivating, and Making the Connection Between Patients and Health Care Providers","Steven V. Edelman","2017","Clinical Diabetes","other","article","10.2337/cd17-0090","29263578",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044253","Long‐term effect of dipeptidyl peptidase‐4 inhibition on β‐cell mass in an advanced‐aged diet‐induced obesity mouse model","Shunsuke Yamane","2014","Journal of Diabetes Investigation","preclinical","article","10.1111/jdi.12192","24843751",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044254","Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders","Riccardo Dalle Grave","2024","IJEDO","other","article","10.32044/ijedo.2024.02",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044255","Alzheimer's disease and related dementias: From risk factors to disease pathogenesis","Anton P. Porsteinsson","2022","European Journal of Neuroscience","other_trial","article","10.1111/ejn.15857","36324230",null,null,null,"openalex","FALSE","open_pdf","5","FALSE","article"],["R0044256","Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","ZZ Htike (7774208)","2016","Figshare","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0044257","Fully closed-loop insulin delivery—are we nearly there yet?","Charlotte K. Boughton","2021","The Lancet Digital Health","randomized_trial","article","10.1016/s2589-7500(21)00218-1","34580054",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044258","Was it really pancreatitis from GLP‐1 receptor agonist therapy?","K. Y. Thong","2013","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1801",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044259","10th International conference on advanced technologies & treatments for diabetes","Helen X. Gao","2016","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12415","27100744",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044260","Treatment of Oral Semaglutide (Rybelsus) for Diabetic Patient with Past History of Crohn’s Disease",null,"2024","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/168",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044261","Prise en charge de la prise de poids induite par les antipsychotiques : meilleures stratégies thérapeutiques","Scott R. Beach","2025",null,"other","article","10.64239/pi-fr-qt7102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044262","Role of oral semaglutide in management of type 2 diabetes","Nasser Mikhail","2019","Trends in Diabetes and Metabolism","randomized_trial","article","10.15761/tdm.1000114",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044263","PRAC meeting July 2004: news on GLP-1 RAs, glatiramer acetate",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-62982-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044264","GLP-1 Based Combination Therapy for Obesity and Diabetes","Young Hee Lee","2017","Journal of Obesity & Metabolic Syndrome","preclinical","article","10.7570/jomes.2017.26.3.155","31089512",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044265","PSUN263 Diagnosis of Latent Autoimmune Diabetes of Adulthood Unveiled After Initiation of an SGLT2 Inhibitor","Goonja Patel","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.825",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044266","A retrospective single-center study, evaluating the long-term effects of the roux-en-y gastric bypass on weight, metabolic health, and comorbidities","Hadi, Karam","2024","ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway)","nonrandomized_study","article","10.13025/29200",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0044267","EFFECT OF THE GLP-1 RECEPTOR AGONIST EXENATIDE ON AWARENESS OF HYPOGLYCAEMIA IN PATIENTS WITH TYPE 1 DIABETES AND IMPAIRED AWARENESS OF HYPOGLYCAEMIA",null,"2017","BiblioBoard Library Catalog (Open Research Library)","randomized_trial","article","10.26226/morressier.5c3c8158e668b9000b9f8e2a",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0044268","Characteristic points of latest Standards of Medical Care in Diabetes","Hiroshi Bando","2024",null,"other","article","10.36502/2024/droa.6185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044269","SUN-480 GLP-1 Agonist Therapy Managing the Effects of Excess Glucocorticoid Production","Brandon Robert Bedell","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.445",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044270","Corrigendum: GLP‐1 receptor activation improves neurological outcome after murine brain trauma 1 (9) , pp 1‐12",null,"2016","Annals of Clinical and Translational Neurology","preclinical","article","10.1002/acn3.340","27606348",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0044271","Efficacy and Safety of Glucagon Receptor Agonists and Resmetirom for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-Analysis with Harmonised Hepatic Endpoints.","Ahmed Amr Ahmed Hegazy Morsy","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/7f2p6",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0044272","Schizophrenia : le sémaglutide surpasse-t-il le liraglutide pour la prise de poids induite par les antipsychotiques ?","Oliver Freudenreich","2026",null,"other","article","10.64239/pi-fr-qt9102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044273","Paradigm shift in the management of DM & CVD —preventing the next CV event","Yehuda Handelsman","2020","Journal of Diabetes","other","article","10.1111/1753-0407.13079","32573096",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044274","Commentary: Shared decision making for weight‐lowering medications in China","Qingyi Jia","2024","Clinical and Translational Medicine","other_trial","article","10.1002/ctm2.70065","39448555",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0044275","What makes GLP1 receptor agonist drugs so effective for obesity?","Michael W. Schwartz","2025","Open Access Government","other","article","10.56367/oag-048-11964",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044276","Tubular Biomarkers and Retinal Microvasculature","Keren Cohen‐Hagai","2025","Kidney360","nonrandomized_study","article","10.34067/kid.0000001002","41411113",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044277","Sulfonylureas: Assets in the past, present and future","Sanjay Kalra","2015","Indian Journal of Endocrinology and Metabolism","other_trial","article","10.4103/2230-8210.149925","25932384",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","editorial"],["R0044278","Terminology, risk stratification and management of patients with non-alcoholic fatty liver disease with obesity and type 2 diabetes mellitus. Review","Ткач, С. М.","2023","Scientific periodicals of Ukraine","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044279","Tirzepatide","Shuchismita Dutta","2023","RCSB Protein Data Bank","other","article","10.2210/rcsb_pdb/gh/dm/drugs/in/tirzepatide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044280","Еволюція технологій виробництва інсуліну: від історичних відкриттів структури молекули до сучасних інновацій","Ольга Сергіївна Калюжная","2025","Scientific periodicals of Ukraine","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0044281","Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial","Steve Bain","2026","Cronfa (Swansea University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0044282","The role of GLP-1 receptor agonists in the treatment of obesity and metabolic disorders in patients with polycystic ovary syndrome - a systematic literature review","Benita Jonušaitė","2026","Medical Sciences","narrative_review","article","10.53453/ms.2026.4.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0044283","Evaluating a new treatment approach for obstructive sleep apnoea in adults with obesity and without diabetes: a proof-of-concept study investigating the effects of glucagon-like-peptide-1 agonist-mediated weight loss versus CPAP or both in combination, on metabolic, cardiovascular and quality of life outcomes","Cliona P O'Donnell","2024","Research Repository UCD (University College Dublin)","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT04186494","S001827","openalex","TRUE","no_doi","1","FALSE","dissertation"],["R0044284","A New Hope for Treating Obesity Pandemic","Sagheer Ahmed","2023","Molecular Medicine Communications","other_trial","article","10.55627/mmc.003.01.0312",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044285","SAT-519 Frances Nicole Monefeldt Strofer","Frances Nicole Monefeldt Strofer","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044286","Metabolic Insights and Reproductive Health Challenges: High-Protein Hypocaloric Diets in PCOS Management [Letter]","Weilan Liu","2025","Diabetes Metabolic Syndrome and Obesity","randomized_trial","article","10.2147/dmso.s552390","40734943",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044287","Liver–heart connection in diabetes mellitus","Terry Cheuk‐Fung Yip","2021","Journal of Gastroenterology and Hepatology","nonrandomized_study","article","10.1111/jgh.15533","34105827",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044288","Megatrends in bile acid receptor research","Luciano Adorini","2017","Hepatology Communications","other_trial","article","10.1002/hep4.1085","29404496",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0044289","Oral insulin dosage forms: assessment of solid-state stability, compaction behaviour and permeation enhancers’ impact on dissolution performance","Andrew Fagan","2025","Cork Open Research Archive (University College Cork, Ireland)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044290","EMERGENCE DELIRIUM IN PEDIATRIC SURGERY: AN UPDATED REVIEW OF RISK FACTORS AND NURSING INTERVENTIONS","Busra Zehra Buyukkilic","2025","Istanbul Kent University Institutional Repository","narrative_review","article","10.30546/19023.978-9952-8605-1-1.2025.091",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044291","Overview of Semaglutide on Obesity Treatment","Kyleigh Hanzlik","2024",null,"other","article","10.31274/cc-20240624-1097",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0044292","Enduring support for the case report","Jemima E. Mellerio","2019","British Journal of Dermatology","randomized_trial","article","10.1111/bjd.17500","31475346",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0044293","Development of therapeutics for the treatment of diabetic brain complications","Shiva Mansouri","2013","Figshare","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044294","Cardiovascular outcomes and harmful effects of SGLT-2 inhibitors and GLP-1 agonists in patients with type 2 diabetes mellitus: A systematic review and metaanalysis","Terán Chávez, Pier André","2020","Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0044295","Combine glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in people with type 2 diabetes mellitus (T2DM): A protocol for a scoping review.","Builes-Montaño, Carlos E.","2024",null,"protocol","article","10.17605/osf.io/wjcsn",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0044296","Combination Therapy of Glucagon-like Peptide-1 Receptor Agonists and Insulin for Patients who developed Diabetes after Partial Pancreatectomy","北澤, 公","2015","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044297","Autofagia en células β: efecto preventivo de las incretinas","Maiztegui, Bárbara","2019","El Servicio de Difusión de la Creación Intelectual (National University of La Plata)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0044298","Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors","Wayne Huey‐Herng Sheu","2020","Journal of Diabetes Investigation","nonrandomized_study","article","10.1111/jdi.13254","32190971",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044299","Compréhension et généralisation du mécanisme de protection de peptides hormonaux par conjugaison à l'albumine","Michèle Parisien","2007","Archipel (Université du Québec à Montréal)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044300","Obesity and Menopause: Redefining Obesity – New Guidelines","Atul Munshi","2025","Journal of Mid-life Health","other","article","10.4103/jmh.jmh_24_25","40330226",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044301","Hepatic diseases at the molecular level : identifying novel targets and biomarkers through transcriptomics","Christian Sommerauer (18679660)","2024","Open Archive (Karolinska Institutet)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044302","Pulmonary disease in diabetes","Zachary T. Bloomgarden","2023","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13509","38156437",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044303","The Role of GLP-1 Receptor Agonists (e.g., Ozempic) in Decreasing Disparities in Diabetes and Obesity Care: A Systematic Review of Efficacy, Access, and Public Health Equity Implications","Mamta Panwar","2025","Journal of the National Medical Association","systematic_review","article","10.1016/j.jnma.2025.08.017",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0044304","Portulaca oleracea (purslane) aqueous extract reduced the adverse metabolic outcomes and favored liraglutide activities in streptozotocin-induced cardiometabolic disorders of male Wistar rats","Adewumi Oluwafemi Oyabambi","2024","Endocrine and Metabolic Science","preclinical","article","10.1016/j.endmts.2024.100191",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044305","Le téléservice ASAFO et les ordonnances falsifiées : état des lieux 2024-2025","Fakhouri, Ibrahim","2025","INRIA a CCSD electronic archive server","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044306","The Indian Obesity Paradox- Low in Muscle, High in Fat","Sri V. Madhu","2026","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/ijem.ijem_245_26","42238564",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044307","Efficacy of GLP-1 analog to achieve metabolic control and correction of body weight in patients with type 2 diabetes mellitus","Т. В. Саприна","2011","Bulletin of Siberian Medicine","other","article","10.20538/1682-0363-2011-6-114-119",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044308","Eficácia de Agonistas GLP-1 e Co-agonistas GIP/GLP-1 na Insuficiência Cardíaca com Fração de Ejeção Preservada Relacionada à Obesidade: Revisão Sistemática","Vitor Daniel Picinin","2025","RCMOS - Revista Científica Multidisciplinar O Saber","randomized_trial","article","10.51473/rcmos.v1i2.2025.1731",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044309","Is Liraglutide a Safe and Effective Medication to Treat Hyperglycaemia?: A Systematic Review","Al Oneze, Ameera","2020","Repository@Nottingham (University of Nottingham)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0044310","Establishment of non-invasive quantification of pancreatic beta cell mass in mice using SPECT/CT imaging with ¹¹¹In-labeled exendin-4 and its application to evaluation of diabetes treatment effects on pancreatic beta cell mass","Keita Hamamatsu","2020","Institutional Repositories DataBase (IRDB)","preclinical","article","10.14989/doctor.k22363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044311","Impact of Incretin Mimetics on Body Composition: A Systematic Literature Review","Jones, Emily Paige","2025","OSF Preprints (OSF Preprints)","nonrandomized_study","article","10.17605/osf.io/s3a5e",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0044312","Lixisenatide as an add on therapy to basal insulin in diabetic type 2 patients previously treated with insulin","Bilic-Curcic Ines","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51845d462b80296ca39a5",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0044313","SAFETY AND EFFICACY OF INSULIN DEGLUDEC/LIRAGLUTIDE FIXED-RATIO COMBINATION IN OAD FAILURE TYPE 2 DIABETES PATIENTS IN A TERTIARY CARE CENTRE IN EASTERN INDIA","Bhattacharyya, Supratik","2017","BiblioBoard Library Catalog (Open Research Library)","nonrandomized_study","article","10.26226/morressier.5c3c8156e668b9000b9f900c",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0044314","Atorvastatin/dulaglutide/fenofibrate",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-62157-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044315","Effects of diet, exercise and anti-obesity treatment on adult neural stem cells and neurogenesis","Jorgensen, Sara","2024","ORCA Online Research @Cardiff (Cardiff University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044316","Metabolic Therapy for Lipedema: Can Tirzepatide Overcome the Treatment Gap?","Diogo Pinto da Costa Viana","2025","Journal of Pharmaceutical Research International","other","article","10.9734/jpri/2025/v37i37664",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044317","Ameliorative impact of mycophenolate mofetil on diabetic kidney disease; a review on current knowledge","Hamid Nasri","2018","Immunopathologia Persa","narrative_review","article","10.15171/ipp.2018.19",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044318","Evolution of type 2 diabetes mellitus treatment approaches","Zachary T. Bloomgarden","2018","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12854","30204296",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0044319","Glucagon-like Peptide 1 Receptor Agonists, Heart Failure, and Critical Appraisal: How the STEP-HFpEF Trial Unmasks the Need for Improved Reporting of Blinding",null,"2024",null,"other_trial","article","10.31038/edmj.2024813",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044320","Secondary alopecia due to semaglutide","Javier Obando Pacheco","2026","Medicina Clínica (English Edition)","other","article","10.1016/j.medcle.2026.107507",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044321","Finns det tillräckligt med information om kroppsförändrade preparat i samhället? : En kvalitativ studie om kunskapen och riskuppfattningen kopplat till anabola androgena steroider och Ozempic","Hamberg, Maja","2025","Publications (Mid Sweden University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044322","Moving in the right direction but not there yet: the utility, measurement, and analysis of health status in heart failure trials","Michael E. Nassif","2021","European Journal of Heart Failure","randomized_trial","article","10.1002/ejhf.2193","33880841",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044323","Recent cardiovascular safety trials with antidiabetic drugs: time to change the guidelines!","Miles Fisher","2015","Practical Diabetes","randomized_trial","article","10.1002/pdi.1980",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044324","A Case of Multiorgan Failure Following Glucagon-Like Peptide 1 Agonist Use for Weight Loss - Is It Worth the Risk?","Muhammad Rehan","2024",null,"case_report","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5687",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0044325","Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide","Vitaly V. Gorban","2026","Meditsinskiy sovet = Medical Council","nonrandomized_study","article","10.21518/ms2026-194",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044326","Pharmacovigilance update [Pharmacovigilance update]","Françoise Livio","2010","SERVAL (Université de Lausanne)","nonrandomized_study","article","10.53738/revmed.2010.6.232.0128",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","review"],["R0044327","Estrategia de reconocimiento para construir un vínculo con cuidadoras informales: visibilización del rol de cuidadoras informales de adultos mayores en tratamiento con semaglutida, en el canal privado de Novo Nordisk Colombia","Carlos José Uribe Chaves","2025","Biblioteca Digital Repositorio Institutional CESA (Colegio de Estudios Superiores de Administración)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044328","OS RISCOS E BENEFÍCIOS DO USO OFF-LABEL DA SEMAGLUTIDA (OZEMPIC) PARA EMAGRECIMENTO: UMA REVISÃO INTEGRATIVA","Wanderluci Rocha Ribeiro","2024","Revista fisio&terapia.","nonrandomized_study","article","10.69849/revistaft/ar10202411151900",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044329","Prise en charge de l'obésité en France : intérêt du Semaglutide","Canac, Thibaut","2024","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044330","Long term real world safety and efficacy of SGLT-2 inhibitors in elderly type 2 diabetic patients","TRESCOLI-SERRANO, CARLOS","2017","BiblioBoard Library Catalog (Open Research Library)","nonrandomized_study","article","10.26226/morressier.5d9b6229ea541d6ca849382a",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0044331","Fragility index and risk of bias in cardiovascular outcome trials for new antidiabetic drugs","Dalmau Vila, Alba","2020","Universitat de Girona Digital Repository (Universitat de Girona)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0044332","How are we intervening in the psychosocial dimension of T1D? Exploring the experience of intervention recipients","Francisca Mena","2017",null,"other_trial","article","10.26226/morressier.59d5184ed462b80296ca4009",null,null,"UMIN:UMIN000026761",null,"openalex","TRUE","free_to_read","5","FALSE","other"],["R0044333","Association between monoclonal gammopathy of undetermined significance and cardiovascular disease risk among individuals with type 2 diabetes: A Taiwan nationwide Study","Tzeyu Michaud","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-3966",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044334","SAT-584 Uc.336-As Inhibits White Adipocyte Differentiation and Promotes White to Brown Conversion","Yanbing Li","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.078",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044335","The role of Fas-mediated apoptotic pathway in amyloid-induced beta-cell death","Yoo Jin Park","2015","cIRcle (University of British Columbia)","preclinical","article","10.14288/1.0135683",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044336","Finerenone","Rachel Mauchlen","2023","Practical Diabetes","randomized_trial","article","10.1002/pdi.2471",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044337","A078 The Impact of GLP-1 Receptor Agonists vs Medical Nutrition Therapy on Sarcopenia. John P. Troup, Ph.D. Middletown, CT1 , Megan Koscinski, MS,RD, Middletown, CT1 Blueroot Health Institute1",null,"2024","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2024.04.165",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0044338","SUN-444 Hydrocortisone Absorption While on Tirzepatide","Stephanny Reyes","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.414",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044339","MON-650 A Presentation of Euglycemic DKA Precipitated by Paraganglioma","Rohan Maini","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044340","Current trends in bariatric surgery","А. Е. Неймарк","2025","Russian surgical journal","randomized_trial","article","10.18705/3034-7270-2025-1-2-103-111",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044341","Association between the systemic treatment of psoriasis and cardiovascular risk","Liqing Shi","2021","Chinese Medical Journal","nonrandomized_study","article","10.1097/cm9.0000000000001249","33605600",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044342","Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents","Stefan D. Anker","2020","Diabetes Mellitus","other","article","10.14341/dm10374",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044343","GLP-1 analogues in the treatment of alcohol dependence: a new direction in pharmacotherapy – a literature review","Milena Kędzierska","2026","Medical Science","randomized_trial","article","10.54905/disssi.v30i173.e140ms3914",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044344","Semaglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-71658-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044345","A higher percentage of elderly on dulaglutide achieved hba1c<7.5% without nocturnal hypoglycemia vs. glargine in AWARD-2","Thieu Vivian","2017",null,"other_trial","article","10.26226/morressier.59d51844d462b80296ca3a12",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","other"],["R0044346","Multifactorial Cardiovascular Disease Risk Estimation and Preventable Cardiovascular Events Among Patients with Diabetes","Fan, Wenjun","2023","eScholarship (California Digital Library)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0044347","Association of Glucagon-Like Peptide-1 Receptor Agonists With All-Cause and Cause-Specific Mortality in US Adults with Diabetes","Qingchun Jin","2025","Heart and Mind","nonrandomized_study","article","10.4103/hm.hm-d-25-00065",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044348","Emerging diagnostic and predictive utilities of natriuretic peptides in diabetes mellitus patients at high cardiovascular risk","Alexander Е. Berezin","2020","Integrative Molecular Medicine","other","article","10.15761/imm.1000393",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044349","Development of a weight-loss product using Chinese herbal medicine combined with nutritional technologies","LUO, Shiqi","2021","RMIT Research Repository (RMIT University Library)","other_trial","article","10.25439/rmt.27596529",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","dissertation"],["R0044350","Management of patients with diabetes and heart failure with reduced ejection fraction: A cross-country comparison","Arnold V Suzanne","2017",null,"nonrandomized_study","article","10.26226/morressier.59d5184cd462b80296ca33e7",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0044351","RISKS RELATED TO THE USE OF OZEMPIC® (SEMAGLUTIDE) FOR WEIGHT LOSS","Michelle Vanessa da Silva Pacheco","2024","Amplla Editora eBooks","other","article","10.51859/amplla.sset.2224-16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0044352","Antiinflammatorische Wirkung von DA-CH5 auf Mikroglia","Schöning, Timm Lasse","2022","Multimedialen Archiv und Publikationsserver der Christian-Albrechts-Universität zu Kiel (Christian-Albrechts-Universität zu Kiel)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","dissertation"],["R0044353","To Address Treatment-Resistant Depression, First You Have to Define It","Terri D’Arrigo","2023","Psychiatric News","other","article","10.1176/appi.pn.2023.07.7.52",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0044354","#1698355 A Decade-Long Perspective on GLP-1 Agonist Use in Obesity Management: Insights from the TriNetX Network","Hussein Al‐Sudani","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.257",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044355","Diabetes update: What's new, what's interesting","Zachary T. Bloomgarden","2022","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13308","36040202",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044356","SUN-LB014 Intermittent Complete Fasting for Complicated Severe Obesity in Older Diabetic Subjects: Preliminary Evidence for Massive Fluid and Fat Loss with Improvement in Cardiac and Renal Failure","Naftali Stern","2019","Journal of the Endocrine Society","other","article","10.1210/js.2019-sun-lb014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044357","Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)","Sri Khaerani Rahman","2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.342311",null,null,"ClinicalTrials.gov:NCT03552757","S001740","openalex","TRUE","free_to_read","1","FALSE","conference-abstract"],["R0044358","IDENTIFICATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR LIGANDS AND THEIR IMPACTS IN THE TREATMENT OF TYPE 2 DIABETES","Luiz Gustavo Antunes Pessoa","2023","Arquivos do Mudi","other","article","10.4025/arqmudi.v27iespecial.68206",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044359","Efficacy of Bydureon in Adults with Type 2 Diabetes","Katie L. Fetter","2014","University of North Florida Digital Commons (University of North Florida)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0044360","Glucagon-like peptide-1 receptor agonists (GLP-1As, e.g. Ozempic) for weight loss: A 12-month study on eating disorders, body image, and mental health.","Mia L. Pellizzer","2026",null,"other","article","10.17605/osf.io/cdhvf",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044361","Cost-effectiveness analysis of Semaglutide as an anti-obesity medication Markov modelling","Knutar, Samuel","2024","KTH Publication Database DiVA (KTH Royal Institute of Technology)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044362","Is endogenous GLP-1 a major influence on the orbitofrontal cortex?","Aaron A. May‐Zhang","2015","Molecular Metabolism","other","article","10.1016/j.molmet.2015.09.011","26909314",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044363","Self-monitoring blood glucose in type 2 diabetes: a continuous improvement initiative","Rossi Maria Chiara","2017",null,"other","article","10.26226/morressier.59d51841d462b80296ca2df8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044364","Adherence and diabetes","Zachary T. Bloomgarden","2018","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12786","29808586",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044365","A341 Pre and Post-Semaglutide Era: A Comparative Study of Bariatric Surgery Outcomes",null,"2024","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2024.04.322",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0044366","Effect of tirzepatide-induced weight loss on adipose tissue in obesity","Herman, Rok","2025","DiRROS repository (University of Maribor)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0044367","Effect of GLP-1 receptor agonist on cardiac remodelling: a systematic review and meta-analysis","Yang Yu","2024",null,"systematic_review","article","10.37766/inplasy2024.6.0063",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0044368","P0758 Comparative risk of nephrolithiasis in obesity pharmacotherapy: A real-world analysis of semaglutide, tirzepatide, and orlistat in type 2 diabetes","P-H. Lee","2026","European Urology","nonrandomized_study","article","10.1016/s0302-2838(26)01626-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0044369","Immunological Pathways in Hidradenitis Suppurativa: Current Concepts and Innovative Therapies","José Antonio Guzmán Cubilla","2018","Journal of Clinical Research in Dermatology","other","article","10.15226/2378-1726/5/1/00176",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044370","The Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonist Drugs: A Comprehensive Literature Review","Khalid M. Alhusayni","2023","Open Access Macedonian Journal of Medical Sciences","narrative_review","article","10.3889/oamjms.2023.11735",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044371","The ADA 2020 virtual poster hall","Zachary T. Bloomgarden","2020","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13103","32755033",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044372","RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS","Mojca Jensterle","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.070",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044373","424 Liraglutide protects against microvascular dysfunction and sepsis-mediated inflammation and organ injury","David M. Aslaner","2025","Journal of Clinical and Translational Science","preclinical","article","10.1017/cts.2024.1031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044374","Russian-made pharmpreparation semaglutide in the experience of de-intensification of diabetes mellitus treatment: A clinical case","D. U. Allaberdina","2025","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2025-164",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044375","Efficacy Of GLP-1 Receptor Agonists in the Management of Hyperphagia, Severe Obesity, and Liver Steatosis/Fibrosis Indices in Prader Willi Syndrome: Two Case Reports","Zumbolo Francesca","2025","Annals of Case Reports","case_report","article","10.29011/2574-7754.102240",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044376","SAT-534 Trulicity Troubles: When Diabetes Medications Go Kidney-ward","Ramya Pendyala","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1066",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044377","The Effect of Oral Semaglutide on Systolic Blood Pressure in Patients with Type 2 Diabetes: A Systemic Review","Oliver Emmanuel Yausep","2025","American Heart Journal","narrative_review","article","10.1016/j.ahj.2025.07.031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044378","PZBBWVLBZV Gastric Banding Compared to GLP-1 Receptor Agonist Following Roux-en-Y Gastric Bypass Surgery",null,"2025","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2025.04.255",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044379","The Intersecting Role of Glycaemia and Cardiac Function in the Development of Heart Failure Among Patients with Type 2 Diabetes Mellitus After an Acute Coronary Syndrome","Malik Elharram","2020","European Journal of Heart Failure","randomized_trial","article","10.1002/ejhf.1845","32353172",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044380","Psoriasis Remission in an Obese, Non-Diabetic Patient with Hyperinsulinemia Treated with GLP-1 Receptor Agonist Therapy","Anna Bowling","2026","Journal of Dermatology Research","other","article","10.46889/jdr.2026.7209",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044381","Circadian rhythms and diabetes","Takeshi Kurose","2011","Journal of Diabetes Investigation","preclinical","article","10.1111/j.2040-1124.2011.00105.x","24843479",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044382","A GLP-1-Receptor-Agonisták És Az SGLT2-Gátlók Kombinált Alkalmazásának Előnyei 2-Es Típusú Cukorbetegségben","Ferenc Sztanek","2024","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044383","Beyond weight loss: Preserving muscle health in the incretin era","Toshinori Imaizumi","2026","Journal of Diabetes Investigation","other_trial","article","10.1111/jdi.70414","42576312",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044384","OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2","Brian D. Benneyworth","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.738",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044385","Is it time to ban sulfonylureas?","Antonio Ceriello","2020","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13095","32767650",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044386","Orforglipron: a Step Forward Toward Simplifying Management of Obesity and Type 2 Diabetes","Nasser Mikhail *","2026","Clinical Research and Clinical Trials","other_trial","article","10.31579/2693-4779/314",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044387","Evaluation of the stability of exenatide in aqueous solutions","Ali Al Assadi","2015","eSpace (Curtin University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044388","Description de l’évolution des délivrances d'antidiabétiques hors Insuline en France de 2014 à 2024 à partir des données de l’Assurance Maladie","Marin Bommelaer","2026","HAL (Le Centre pour la Communication Scientifique Directe)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0044389","Equitable Care During Incarceration","Taylor, Lisa M","2024","UNM’s Digital Repository (University of New Mexico)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044390","Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensus","Steve Bain","2025","Cronfa (Swansea University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044391","Levetiracetam/Phenytoin/Tirzepatide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90291-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044392","The 2022 American Diabetes Association Meeting","Zachary T. Bloomgarden","2022","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13297","35841236",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044393","Incretin mimetics","Angus Thompson (14750959)","2015","Figshare","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044394","Introduction to the 2nd Heart in Diabetes (HiD) Meeting","Yehuda Handelsman","2019","Journal of Diabetes","other","article","10.1111/1753-0407.12925","31066171",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044395","BEYOND BORDERS: TIRZEPATIDE UNVEILED - A COMPREHENSIVE REVIEW OF DUAL TARGETING THERAPIES IN DIABETES AND OBESITY MANAGEMENT","Kunal Agam Kanaujia","2024","Biochemical and Cellular Archives/Biochemical and cellular archives","narrative_review","article","10.51470/bca.2024.24.2.1511",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044396","Semaglutide-induced adverse drug reactions: Clinical characteristics, management, and outcomes","Jincai Guo","2025","Asian Journal of Surgery","other","article","10.1016/j.asjsur.2025.02.071",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044397","ODP255 Woman With Maturity-Onset Diabetes of the Young Type 2 (MODY2) Mistakenly Diagnosed and Treated as Type 2 Diabetes Mellitus","Deborah Sasha Bernardes Nacache","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.703",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044398","Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome","Andrej Janež","2017","Journal of Diabetes and Obesity","other","article","10.15436/2376-0494.17.1246",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044399","Type 2 diabetes and Parkinson's disease","Ken Shaw","2019","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.2227",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044400","Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2016;40:240-7)","Jin Hwa Kim","2016","Diabetes & Metabolism Journal","other","article","10.4093/dmj.2016.40.4.334","27550210",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044401","Metabolic Dysfunction, Extracellular Matrix Remodeling, and Therapeutic Intervention in Heart Failure with Preserved Ejection Fraction","Gromova, Tatiana","2025","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044402","Glucagon like peptide 1 receptor agonists: a therapy for diabetes management","Universidad de Antioquia","2018","CES Medicina","other","article","10.21615/cesmedicina.32.1.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044403","Changes in glomerular filtration rate in patients with BMI≥ 35kg/m2 treated with bariatric surgery vs. GLP-1 agonists at one-year follow-up","Jurado Florez, Mayra Alejandra","2023","Repositorio Institucional (Pontificia Universidad Javeriana)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044404","The dynamics of consumption of glucagon-like peptide-1 agonists in the Russian Federation in the period 2010-2025: a pharmacoepidemiological study","Yu. М. Gomon","2026","Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice","nonrandomized_study","article","10.37489/2588-0519-gcp-0022",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044405","MON-733 Clinical Adiposity Based Chronic Disease Management, experiences from the clinic post COVID","Thaw /Thaw Dar Htet","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.066",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044406","Low incidence of gastrointestinal adverse events over time with a combination of insulin glargine and lixisenatide","Bowden Georgina","2017",null,"randomized_trial","article","10.26226/morressier.59d51845d462b80296ca34a6",null,null,"ClinicalTrials.gov:NCT02058160; ClinicalTrials.gov:NCT02058147","S001199; S001409","openalex","TRUE","free_to_read","1","FALSE","other"],["R0044407","The Weight of Stigma","Rebekah A. King","2025","bepress Legal Repository","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044408","A suggestion of using Ang-(1-7) and/or GLP-1 receptor agonists in high mortality patients with COVID-19","Ahmed G. Elkabily","2020","Trends in Medicine","other","article","10.15761/tim.1000233",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044409","Randomized Comparison of initiating insulin Glargine or Iglarlixi in South Asian Subjects With T2D : Variation 2 Sa Trial","Chu, Lisa","2017","BiblioBoard Library Catalog (Open Research Library)","randomized_trial","article","10.26226/morressier.5d9b6229ea541d6ca84938ab",null,null,"ClinicalTrials.gov:NCT03819790","S000235","openalex","TRUE","paywalled","1","FALSE","other"],["R0044410","A Clinical Study on the Metabolic and Hormonal Effects of Terzepate in Women With Polycystic Ovary Syndrome and Obesity","Israa J. Mohammad","2026","Umsida Repository (Universitas Muhammadiyah Sidoarjo)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0044411","Bioactive compounds and sustainable approaches in drug discovery and development","Silvia <1997> Rizzo","2026","AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044412","Peptide Therapy in Aesthetic, Metabolic, and Endocrine Medicine","Manali Padhye","2026","International Journal of Science and Research (IJSR)","other","article","10.21275/sr26818101854",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044413","GLP-1 Receptor Agonists in Metabolic Medicine: Mechanisms, Clinical Applications, Current Challenges, and Future Directions","Michelle Paik","2026",null,"other","article","10.58445/rars.4074",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044414","The Gut, Hormone, Skin Axis in Skin Health and Ageing: A Scoping Review and Integrative Dermatological Perspective","Andy Young","2026",null,"randomized_trial","article","10.17605/osf.io/k9jrg",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0044415","‘What sort of diabetes have I got?’ The importance of a label","Clare Shaban","2017","Practical Diabetes","randomized_trial","article","10.1002/pdi.2114",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044416","Diabetes phenotypes: Beyond IDDM vs NIDDM","Zachary T. Bloomgarden","2019","Journal of Diabetes","nonrandomized_study","article","10.1111/1753-0407.12954","31125185",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044417","Required reading to remain relevant","Leslie Citrome","2017","International Journal of Clinical Practice","other","article","10.1111/ijcp.12965","28508458",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044418","Застосування агоністів рецепторів глюкагоноподібного пептиду-1 у лікуванні ожиріння: практичні поради для лікарів",null,"2022","Український медичний часопис","other","article","10.32471/umj.1680-3051.151.235526",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044419","Cardiac Fibroblast Heterogeneity and Epigenomic Regulation in Heart Failure","Gehred, Natalie","2025","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044420","Cardiovascular safety of oral antidiabetic medications: Need of the hour","PrashantUlhas Kaduskar","2017","Indian Journal of Endocrinology and Metabolism","other","article","10.4103/ijem.ijem_47_17","28670551",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044421","From Glycaemic Control to Gastrointestinal Crisis: A Case of Semaglutide-Induced Pancreatitis","Rutvik Jadvani","2025","Journal of Clinical Case Reports and Studies","case_report","article","10.31579/2690-8808/265",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044422","Effects of oral semaglutide on metabolic parameters and renal function in patients with type 2 diabetes","Hidekatsu Yanai","2025","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2025.119953",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044423","Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies","Matthew R. Weir","2019","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12929","31066238",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044424","Editorial","D. B. Sarwer","2018","Obesity Science & Practice","commentary","article","10.1002/osp4.158","29479458",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0044425","Aumento di peso indotto dagli antipsicotici: gli agonisti del GLP-1 sono efficaci?","Oliver Freudenreich","2025",null,"other","article","10.64239/pi-it-qt7602",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044426","Lessons learned on the safety of GLP-1 receptor agonists from post-marketing experience","Santos, Andreia Filipa Rodrigues dos","2016","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044427","Increased Levothyroxine Requirement After Tirzepatide Initiation","Derya Koç","2026","AACE Endocrinology and Diabetes","other","article","10.1016/j.aed.2026.04.007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044428","Semaglutide in Routine Obesity Care: Effectiveness Outside the Trial Population","Alvaro Serrano","2023","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22258300",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0044429","Molecular Mechanisms Involved in Insulin- and Leptin-mediated Regulation of Hypothalamic Proglucagon Gene Expression and Action of Glucagon-like Peptides on Hypothalamic Neuropeptides","Prasad S. Dalvi","2012","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044430","Editorial: Women in renal pharmacology 2023","Núria Lloberas","2025","Frontiers in Pharmacology","commentary","article","10.3389/fphar.2024.1519295","39906394",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0044431","Efficacy of new obesity treatments GLP-1ar (semaglutide) and dual agonists GLP-1 + GIPar (tirzepatide) in the treatment of weight regain and insufficient weight loss after bariatric-metabolic surgery: a systematic review and meta-analysis","María Icíar Lloréns Martín","2026","e_Buah","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0044432","GLP-1 Agonistleri Alkol Kullanım Bozukluğunu Tedavi Edebilir mi?","David A. Gorelick","2025",null,"other","article","10.64239/pi-tr-qt7201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044433","Door antipsychotica geïnduceerde gewichtstoename: zijn GLP-1-agonisten effectief?","Oliver Freudenreich","2025",null,"other","article","10.64239/pi-nl-qt7602",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044434","MedCheck: Zepbound for Obstructive Sleep Apnea, Tavapadon for Parkinson’s Disease, and More","Terri D’Arrigo","2025","Psychiatric News","other","article","10.1176/appi.pn.2025.02.2.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0044435","The Role of the Glucagon-like Peptide-1 Receptor in Atherosclerosis","Naim Panjwani","2013","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044436","Aumento di peso indotto dagli antipsicotici: le migliori strategie di gestione","Scott R. Beach","2025",null,"other","article","10.64239/pi-it-qt7102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044437","Update on the perioperative management of diabetes mellitus","Jorinde A. W. Polderman","2024","BJA Education","nonrandomized_study","article","10.1016/j.bjae.2024.04.007","39099754",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044438","Tirzepatide and the Weight-Regain Question: What Happens When Treatment Stops","Jonáš Kirchner","2024","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.22260596",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0044439","Retatrutide 60mg uae research","Haseebuddin M R","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22704705",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044440","Tirzepatide",null,"2023","Reactions Weekly","other","article","10.1007/s40278-023-48175-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044441","Use of SGLT2 Inhibitors Reduces Heart Failures and Hospitalization: A Multicenter, Real-World Evidence Study","Blanco, Christopher","2023","IUScholarWorks (Indiana University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0044442","Perioperative hyperglycaemia and its treatment in patients with diabetes mellitus","Jorinde A. W. Polderman","2018","UvA-DARE (University of Amsterdam)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","other"],["R0044443","Lifestyle Interventions to Mitigate Muscle and Bone Loss During GLP-1RA Use in Diabetes and Obesity: A Systematic Review & Meta-Analysis","Emily Elizabeth Douglas","2025","Scholarship@Western (Western University)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0044444","Recent Advances on the Management of Parkinson’s Disease: A Review","Franklyn Nonso Iheagwam","2019","Covenant University Repository (Covenant University)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044445","The Exquisite Intrinsic Mechanisms of Adverse Health Effects Caused by Overtraining","Shuai-Wei QIAN","2024","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.16476/j.pibb.2023.0395",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044446","Integrative Molecular and Microbial Mechanisms Linking Liver Fibrosis, Cancer Biology, and Host-Microbe Interactions","Anwar Ullah  Okti Sri Purwanti","2026","Integrative Biomedical Research","other","article","10.25163/biomedical.10110621",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044447","In-hospital glycaemic control: A bittersweet symphony","Marjolein K. Sechterberger","2015","UvA-DARE (University of Amsterdam)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044448","GLP-1 Receptor Agonists and Muscle Mass: A Narrative Review of What Body Composition Data Do and Do Not Show","Felix Trautmann","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22261251",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","review"],["R0044449","Assessing the impact of PCSK9 inhibitors in steatotic liver disease:a prospective observational cohort study (SIMPLE)","George, J","2024","Discovery Research Portal (University of Dundee)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","other"],["R0044450","Development of new incretin drugs: Promising therapies","Kirandeep Kaur","2006","Indian Journal of Pharmacology","other_trial","article","10.4103/0253-7613.24614",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0044451","Enzymatic tools for peptide ligation and cyclization: Development and applications","Marcel Schmidt","2019","UvA-DARE (University of Amsterdam)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044452","Therapeutic potential of inhibiting mitochondrial fission to reduce abdominal aortic aneurysms","Tessa Forbes","2020","Cardiovascular Research","preclinical","article","10.1093/cvr/cvaa227","32717022",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0044453","Relação entre Agonistas do Receptor de GLP-1 em Indivíduos com Transtorno Bipolar.","Lucas Cony Ferreira da costa","2026","Editora Pasteur eBooks","other","article","10.59290/3260689401",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0044454","β-Arrestins as Key Switches in GPCR Signaling: From Molecular Structure to Clinical Implications — a Narrative Review","Monika Głuch-Lutwin","2025","Acta Poloniae Pharmaceutica - Drug Research","narrative_review","article","10.32383/appdr/214749",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0044455","Ozempic Face, Unmerited Body","Peers, Robyn","2023","Columbia Academic Commons (Columbia University)","other","article","10.7916/zyk1-xa25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044456","Semaglutide bij alcoholgebruiksstoornis: nieuwe RCT-data","David A. Gorelick","2025",null,"other","article","10.64239/pi-nl-qt7903",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044457","Retatrutide 60mg uae research","Haseebuddin M R","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22704704",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044458","Door antipsychotica geïnduceerde gewichtstoename: optimale beheersstrategieën","Scott R. Beach","2025",null,"other","article","10.64239/pi-nl-qt7102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044459","A Comparative Study of Analytical Methods for Empagliflozin and Related Drugs","Kajol","2025","Glucolipid metabolic disorders","other","article","10.2174/0129499011332816250311185959",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044460","What to do about borderline hyperglycemia?","Therapeutics Initiative (University of British Columbia)","2023","Open Collections","other","article","10.14288/1.0432787",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044461","From metabolic vulnerability to therapeutic opportunity - Targeting cardio metabolic risk in schizophrenia","Ganeshalingam, Ashok Ainkaran","2025","University of Southern Denmark Research Portal (University of Southern Denmark)","other","article","10.21996/dca8dab4-028a-4b95-9bd7-f82261d985ba",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044462","Obesity and type 2 diabetes","Subhashini Yaturu","2011","Journal of Diabetes Mellitus","other","article","10.4236/jdm.2011.14012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044463","Epigenetic regulation in MASLD:Exploring the role of DNA methylation","D. Gonçalves","2025","UvA-DARE (University of Amsterdam)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044464","Investigation of the Effect of GLP-1 Receptor Agonists on Metabolic Cancer Imaging","Charisma DeSai","2026","International Journal of Cancer Care and Delivery","other","article","10.53876/001a.129754",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044465","Cover: Glucagon-Like Peptide-1 Receptor Agonists in IBD",null,"2026","Gastro Hep Advances","other","article","10.1016/s2772-5723(26)00219-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044466","Where diabetes care meets cardiovascular research: our cardiovascular perspective at a Centre devoted to diabetes research and care","Gian Paolo Fadini","2021","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehab177","33755089",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044467","Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study","Bashaaer Sharad","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3791",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044468","Prise de poids induite par les antipsychotiques : les agonistes du GLP-1 sont-ils efficaces ?","Oliver Freudenreich","2025",null,"other","article","10.64239/pi-fr-qt7602",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044469","Metabolic Dysfunction–Associated Steatotic Liver Disease in Endocrine Practice: Risk Assessment, Fibrosis Stratification, and Treatment Considerations","Melike Yakut","2026","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article","10.5152/erp.2026.26984",null,null,null,null,"openalex","FALSE","open_pdf","2","FALSE","article"],["R0044470","The No-Hunger Games: How GLP-1 Medication Adoption Is Changing Consumer Food Demand","Sylvia Hristakeva","2025","Journal of Marketing Research","other","article","10.1177/00222437251412834",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044471","Tirzepatide for Severe Obesity in Adolescents Without Diabetes","Reham Yehia","2026","AACE Endocrinology and Diabetes","other","article","10.1016/j.aed.2026.07.013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044472","On the same track: Glucose monitoring and treatment strategies in diabetes and critical illness","S. C. J. van Steen","2018","UvA-DARE (University of Amsterdam)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044473","Mécanismes et contrôle de la réaction inflammatoire précoce au cours de la greffe d'îlots pancréatiques dans un modèle de lignée de cellules bêta de rat : rôle et modulation de la libération des microparticules","Céline Gleizes","2014","HAL (Le Centre pour la Communication Scientifique Directe)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044474","O PAPEL DOS AGONISTAS DO RECEPTOR DE GLP-1 NO TRATAMENTO DA ESTEATO-HEPATITE ASSOCIADA À DISFUNÇÃO METABÓLICA (MASH): UMA REVISÃO SISTEMÁTICA DA LITERATURA","Marielle Neiva da Silva","2026","Brazilian Journal of Health Review","other","article","10.34119/bjhrv9n5-013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044475","Insulin resistance in the brain: A new therapeutic target for Alzheimer's disease","Hiroyuki Umegaki","2013","Journal of Diabetes Investigation","preclinical","article","10.1111/jdi.12027","24843644",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044476","GLP-1 Receptor Agonists and Colorectal Cancer Outcomes: A Multinational Cohort Study","Sajjad Ahmed Khan","2026","International Journal of Cancer Care and Delivery","nonrandomized_study","article","10.53876/001a.129872",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044477","Semaglutide per il disturbo da uso di alcol: nuovi dati da RCT","David A. Gorelick","2025",null,"other","article","10.64239/pi-it-qt7903",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044478","GLP-1’s bij schizofrenie: moeten we semaglutide voorschrijven voor metabolisch management?","Oliver Freudenreich","2026",null,"other","article","10.64239/pi-nl-qt8402",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044479","Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data","Krüger, Nils","2025","Open Science Framework","randomized_trial","article","10.17605/osf.io/ajnek",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0044480","Six-Year Follow-Up of Glucagon-like peptide-1 receptor agonist (GLP1-RA) Therapy in a Patient With Exogenous Insulin Antibody Syndrome: A Case Report","Jinying Xia","2025","AACE Endocrinology and Diabetes","case_report","article","10.1016/j.aed.2025.12.008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044481","Reporting of lithium toxicity with GLP-1 receptor agonists and tirzepatide in FAERS: how much of an apparent interaction signal is made of duplicated literature reports?","abdullah talab","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22704855",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0044482","Expanded Use of Exenatide in the Management of Type 2 Diabetes","Linda E. John","2007","Diabetes Spectrum","nonrandomized_study","article","10.2337/diaspect.20.1.59",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044483","GLP-1 nella schizofrenia: dobbiamo prescrivere semaglutide per la gestione metabolica?","Oliver Freudenreich","2026",null,"other","article","10.64239/pi-it-qt8402",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0044484","GLP-1 Receptor Agonists and their therapeutic potential in alcohol use disorder","Luna Jiménez Ortega","2026","e_Buah","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044485","TRANSGENIC PLANTS AS A NOVEL BIOREACTOR TO PRODUCE ANTIDIABETIC PROTEINS FOR THE TREATMENT OF TYPE 2 DIABETES","Choi, Jeehye","2011","Scholarship@Western (Western University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044486","Made in China: The international supply of illicit Semaglutide and weight-loss medicines online","Luke A. Turnock","2024","Emerging Trends in Drugs Addictions and Health","other","article","10.1016/j.etdah.2024.100169",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044487","Exenatide: An incretin-mimetic agent","Sandeep Kaushal","2006","Indian Journal of Pharmacology","nonrandomized_study","article","10.4103/0253-7613.19864",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044488","DPP-4 Inhibitor–Related Pancreatitis: Rare but Real!","J. Hans DeVries","2017","Diabetes Care","randomized_trial","article","10.2337/dci16-0035","28108536",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044489","Authors' reply to Scheffel and Schaan","Απόστολος Τσάπας","2012","BMJ","commentary","article","10.1136/bmj.e2922",null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0044490","Abundance and Diversity of Microbiota in Type 2 Diabetes and Obesity","Marlene Remely","2013","Journal of Diabetes & Metabolism","other","article","10.4172/2155-6156.1000253",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044491","ZNAĈAJ INKRETINSKOG SUSTAVA U PATOFIZIOLOGIJI I LIJEĈENJU ŠEĆERNE BOLESTI","Lucia Španjol-Pandelo","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044492","Stroke-induced stem cells proliferation in normal versus diabetic mice and pharmacological regulation","Zainab Fadhel","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044493","Glycemic Outcomes Associated With GLP-1 Receptor Agonist Shortages in Type 2 Diabetes","Zhimin Fu","2026","PRiMER","nonrandomized_study","article","10.22454/primer.2026.826203",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044494","Pathophysiological mechanisms of microvascular inflammation in the heart and brain","Umit Baylan","2025",null,"preclinical","article","10.5463/thesis.1174",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044495","Eyelid swelling after semaglutide injection","Hiroshi Ito","2024","Visual Journal of Emergency Medicine","other","article","10.1016/j.visj.2024.101996",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044496","GLP-1 減重藥能抗癌嗎?從 ASCO 2026 到大型世代研究的證據盤點","Hsieh-Ting Lin","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20416187",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044497","GLP1s and antifatness: on the medicalization, social construction, and future of fatness in the Ozempic era","Flora Oswald","2025","Fat Studies","commentary","article","10.1080/21604851.2025.2551995",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0044498","GLP-1 減重藥能抗癌嗎?從 ASCO 2026 到大型世代研究的證據盤點","Hsieh-Ting Lin","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20416188",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044499","Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease","啓 中島","2012","Josai University Repository of Academia (Josai University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044500","Med Check: Loperamide; SPN-810; BNC210; Aducanumab; Reyvow; Trulicity","Terri D’Arrigo","2019","Psychiatric News","randomized_trial","article","10.1176/appi.pn.2019.12a5",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0044501","Åldersberoende förändringar i proliferativ kapacitet och energimetabolism hos neonatala endotelceller vid hjärtregeneration","Sofie Lehto","2026","Työväentutkimus Vuosikirja","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044502","Pharmacological preconditioning by incretinomimetics exenatide and vildagliptin: decrement of liver ischemia-reperfusion injury","Tarasova, A. P.","2019","Open Access Repository (Belgorod State National Research University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044503","A quantum approach to the endocrinology of obesity","Sanjay Kalra","2026","Endocrine Connections","other","article","10.1530/ec-26-0450","42447054",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044504","Application of single-port laparoscopic sleeve gastrectomy in a Chinese patient with a BMI of 86.4 kg/m²: a case report","Bangjie Lu","2026","BMC Surgery","case_report","article","10.1186/s12893-026-04192-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044505","Eficacia de la tirzepatida en pacientes con diabetes mellitus tipo 2 y obesidad: un innovador fármaco dual","María Gracia Machado Fernandez","2023","Dialnet (Universidad de la Rioja)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0044506","Efecto cardioprotector de los inhibidores de sglt2 y agonistas del receptor de glp-1","Jorge Andrés Negrete Levette","2022","Dialnet (Universidad de la Rioja)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0044507","Repurposing GLP-1 receptor agonists for Alzheimer's disease: Promise, pitfalls, and patient selection","Shreyas Adhikari","2026","The Journal of Precision Medicine Health and Disease","other","article","10.1016/j.premed.2026.100057",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044508","Response to Comment on Klein et al. Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.","Ildiko Lingvay","2026","UNC Libraries","other_trial","article","10.17615/1729-0j29",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0044509","Reducción de la dosis de insulina posterior a iniciar tratamiento con liraglutida, en pacientes con diabetes tipo 2, en el Hospital General de Zona con Unidad de Medicina Familiar Número 1, Pachuca Hidalgo.","Eridany Guadalupe Vargas Monroy","2026","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044510","Effect of GLP-1 agonist Exenatide on cerebral, hepatic and peripheral glucose metabolism in postprandial state","DANIELE, GIUSEPPE","2014","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044511","Meccanismo d'azione ed effetti metabolici dell'exenatide nell'obesita'","PRESTI, PAMELA","2010","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044512","Scalable PEC Purification Enables API-Grade Semaglutide with Minimal HPLC Intervention","Stephan Lüdtke","2026",null,"other","article","10.17952/38eps.2026.p013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0044513","Differenziamento in vitro di cellule insulino- e glucagone- secernenti da cellule staminali ematopoietiche CD34+ e formazione di pseudo-isole: possibile ruolo di Exendin-4 e Betatrofina.","ZAPPULLA, GIUSEPPA","2021","Electronic Theses and Dissertations Repository (University of Pisa)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044514","Dental Management Considerations for Patients Receiving GLP-1 Receptor Agonist Therapy: A Scoping Review Protocol","Pegah Mir","2026","Open Science Framework","protocol","article","10.17605/osf.io/6nphy",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0044515","How claims about aspiration risk with GLP-1 receptor agonists have been cited: a citation content analysis","Vivin Chrysostor Albert Santhappa","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044516","Efficacia di semaglutide in una coorte di soggetti con diabete tipo 2 e MASLD. Studio real-life monocentrico.","GIOVANNI PETRALLI","2026","Electronic Theses and Dissertations Repository (University of Pisa)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0044517","Studio della composizione corporea in soggetti con obesità e sovrappeso in trattamento con counseling psico-nutrizionale, farmaci GLP-1 agonisti e amminoacidi essenziali","CIGLIERI, LORENZO","2025","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044518","Differenziamento in vitro di linfomonociti isolati da pazienti con diabete mellito tipo 2 in cellule insulino- e glucagone-secernenti: possibile ruolo di Betatrofina, Exendin-4 e Resveratrolo.","TROISI, FABIOLA","2021","Electronic Theses and Dissertations Repository (University of Pisa)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044519","Terapia adiuvante con Liraglutide nel Diabete Mellito tipo 1","POLITI, KONSTANTINA SAVVINA","2012","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044520","The challenge of managing coexistent type 2 diabetes and obesity","Clifford J. Bailey","2011","BMJ","other","article","10.1136/bmj.d1996","21490051",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044521","Synthesis of new 1.3-diaza-4oxa[3.3.1]bicyclic derivatives as novel potential anti-diabetic agents","NANNINI, ALESSIA","2019","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044522","Semaglutide per il trattamento dell'obesità: valutazione di efficacia in un contesto di vita reale","D'AMBROSIO, MELISSA","2025","Electronic Theses and Dissertations Repository (University of Pisa)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0044523","Dry eye disease and GLP-1 receptor agonists – current state of knowledge and emerging therapeutic perspectives","Marzena Jargiło","2026","Ophthalmology","other","article","10.5114/oku/226459",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044524","GLP-1 agonists effective for weight management in patients with antipsychotic-induced weight gain",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-64375-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044525","The Necessity for Polypharmacological Research – An Editorial on ‘Network Polypharmacology of ATP-binding Cassette (ABC) and Solute Carrier (SLC) Transporters’","Muhammad Rafehi","2025","Frontiers in Pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1561247","40201687",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044526","Effetti centrali e periferici dell'analogo del GLP-1 exenatide","DI FILIPPI, MARIANNA","2016","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044527","Studio degli effetti neuroprotettivi di farmaci metabolici in un modello cellulare della malattia di Parkinson","Vincenzo Placenti","2025","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044528","Palm-Derived Tocotrienols as Precision Adjuncts in Type 2 Diabetes: Residual Oxidative, Inflammatory, and Cardiorenal Risk in the SGLT2–GLP-1 Era A Critical Review","Loso Judijanto","2026","Journal of Nephrology & Endocrinology Research","narrative_review","article","10.47363/jone/2026(6)147",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044529","Food noise in adults with obesity treated with GLP-1 receptor agonists: scoping review","Bartosz Krawczyk-Demczuk","2026","OSF Preprints (OSF Preprints)","nonrandomized_study","article","10.17605/osf.io/cm8tr",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0044530","Diabetes and cardiovascular disease: it’s time to apply the evidence","Peter J. Grant","2020","European Heart Journal Acute Cardiovascular Care","nonrandomized_study","article","10.1177/2048872620952722","33203234",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044531","LA TERAPIA CON LIRAGLUTIDE NELL’OBESITÀ: RISULTATI NELLA PRATICA CLINICA","RITIENI, CAMILLA","2019","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044532","Semaglutide e obesità: nuove prospettive farmacologiche per il trattamento off-label del sovrappeso e delle comorbidità metaboliche","GORINI, ALESSANDRA","2025","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044533","Effects of GLP-1 Receptor Agonists on Motor Deficits in Parkinson’s Disease A Scoping Review","Maria Fioletova","2026",null,"narrative_review","article","10.13140/rg.2.2.34002.11203",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044534","EFFETTI DEL TRATTAMENTO CON EXENATIDE SUL CONTROLLO GLICOMETABOLICO IN PAZIENTI CON DIABETE MELLITO TIPO 2","CONSANI, CRISTINA","2012","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044535","Award Winner Describes Efforts to Improve Cognition in People With Bipolar Disorder","Nick Zagorski","2023","Psychiatric News","other_trial","article","10.1176/appi.pn.2024.01.1.37",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0044536","Effetti della terapia con GLP-1 RA in soggetti con fallimento della chirurgia bariatrica/metabolica: studio real-life prospettico sulle modifiche dietetiche e comportamentali","GIORDANO PALA","2025","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044537","Counterfeit Retatrutide: A Global Public Health Crisis in Investigational Drug Diversion—Pharmacokinetic Mechanisms, Drug-Induced Hepatotoxicity Pathways, Poison Center Epidemiology, and Clinical Case Series Documentation","HENRY ATTAR","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.22731325",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0044538","729. From metabolic dysregulation and shared genetic etiology to suicidality: the psychiatric promise and safety debate of GLP-1 receptor agonists","G Fanelli","2026","The International Journal of Neuropsychopharmacology","randomized_trial","article","10.1093/ijnp/pyag040.499",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044539","Twincretine nel trattamento del diabete mellito di tipo 2: Tirzepatide agonista ibrido del recettore del GIP e del GLP-1","PARLAGRECO, ALESSANDRO","2019","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044540","Hypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship?","Barbara Janota","2023","World Journal of Hepatology","other","article","10.4254/wjh.v15.i5.641","37305371",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044541","Disordered eating behaviors, impulsivity and affective temperaments in a sample of obese candidates for bariatric surgery: which linkage?","GRAVINA, DAVIDE","2025","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044542","Effetti endocrino-metabolici dell'exenatide in pazienti obesi non diabetici","PARDO, MARIA ANTONIETTA","2015","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044543","Impiego clinico di Liraglutide, analogo del GLP-1, come nuova strategia per il trattamento dell'obesita.","FIORENTINI, FEDERICA","2016","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044544","Tirzepatide, primo agonista duale dei recettori degli ormoni incretinici: una nuova frontiera nel trattamento farmacologico del diabete di tipo 2 e dell'obesità.","CANINI, DESIRÈE","2025","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044545","New modifications of 1,3-diaza-4oxa-[3.3.1]bicyclic scaffolds as novel GLP-1 agonists","COMPARINI, LUCREZIA MARGHERITA","2020","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044546","UTILIZZO DELL’ASSOCIAZIONE DI INSULINA BASALE ED AGONISTA DEL RECETTORE DEL GLP-1 IN PAZIENTI GERIATRICI DIABETICI RICOVERATI PER PATOLOGIA ACUTA","DEL VECCHIO, STEFANIA","2023","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044547","Effetti del glucosio e della resistenza insulinica sul metabolismo cerebrale: implicazioni per le funzioni cognitive e lo sviluppo di patologie neurodegenerative","BALICE, ELEONORA","2025","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044548","Exenatide/metformin",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-92758-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044549","Glucagon is terug: survodutide opent nieuw hoofdstuk in obesitas en MASLD","Marcel Muskiet","2026","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-026-1631-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044550","The Impact of GLP-1 Receptor Agonist–Induced Nutritional Deficiencies on Skin Health: A Narrative Review With a Proposed Framework for the Aesthetic Practitioner","Justin N. Karlin","2026","Aesthetic Surgery Journal Open Forum","narrative_review","article","10.1093/asjof/ojag169",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0044551","698. Glucagon-like peptide-1 receptor agonists and eating disorders","A Keshen","2026","The International Journal of Neuropsychopharmacology","nonrandomized_study","article","10.1093/ijnp/pyag040.472",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044552","Obesità, alterazione del gusto, impatto sulle scelte alimentari: il ruolo del nutrizionista.","VIRGINIA GRAGNOLI","2025","Electronic Theses and Dissertations Repository (University of Pisa)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0044553","548. Glucagon-like peptide-1 agonists and their association with worsening mental illness in individuals with depression and anxiety. Results from a nationwide cohort study from Sweden","H Taipale","2026","The International Journal of Neuropsychopharmacology","randomized_trial","article","10.1093/ijnp/pyag040.159",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044554","Distribution of Lipoprotein(a) Concentrations in Children and Young People with Familial Hypercholesterolemia (FH) compared to those without FH: A Systematic Review and Narrative Synthesis","L. Priestley-Barnham","2026","Atherosclerosis Plus","systematic_review","article","10.1016/j.athplu.2026.100596",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0044555","Pharmacological treatment and risk stratification for cardiovascular disease prevention","Carl-Emil Lim","2026",null,"nonrandomized_study","article","10.69622/32788974",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0044556","Интестинальные гормоны и их роль при сахарном диабете 2-го типа: современное состояние проблемы","Колбина Марина Владимировна","2013","Omsk Scientific Bulletin","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044557","758. Use of glucagon-like peptide 1 receptor agonists and the associated outcomes in bipolar disorder, from a nationwide cohort, 2009-2024","M Taylor","2026","The International Journal of Neuropsychopharmacology","randomized_trial","article","10.1093/ijnp/pyag040.166",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044558","Glp-1 Usage As Novel Treatment For Lower And Upper Extremity Lymphedema","Fatima Arif","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20086839",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0044559","Directional Pressure Failure: A Unifying Orientation for Insulin Signaling, Buffering Failure, and GLP-1 Response, Lantern of Sulfur, Concept B0, v12","Beth Martell","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18035186",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044560","Obesity and Systemic Inflammation: Pathophysiological Mechanisms and Management Strategies","Ayesha Abdul Raoof","2025","Oral Sphere Journal of Dental and Health Sciences","other","article","10.63150/osjdhs.2026.07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044561","GLP- 1受容体シグナルはアルツハイマー病モデルマウスの反応性アストロサイトにおいてアクアポリン4の 細胞内局在を修復し、アミロイドβの排泄を促進する","可奈 佐々木",null,"Institutional Repositories DataBase (IRDB)","preclinical","article","10.20569/0002002067",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044562","Development of New Synthetic Approaches to Biologically-Active Peptides","Sanne J. M. Verhoork","2021","Liverpool John Moores University","other","article","10.24377/ljmu.t.00011319",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044563","Journal of obesity",null,null,null,"nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0044564","LEFT ATRIAL STRAIN IMAGING AS A MARKER OF EPICARDIAL ADIPOSE TISSUE–RELATED ATRIAL REMODELING","F Cacciapuoti","2026","European Heart Journal Supplements","other","article","10.1093/eurheartjsupp/suag058.283",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044565","GLP-1 Receptor Agonists, Constipation, and Iatrogenic Failure: Predictable Drug Responses under Directional Pressure Failure, Lantern of Sulfur, Concept B3, v12","Beth Martell","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18036848",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044566","Therapeutic Resumption of Incretin Efficacy via Upstream ALR2–RAGE Axis Reversal: Structural and Mechanistic Insights into 5-SANA Co-Administration","PRAKASH VAITHYANATHAN","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20633654",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044567","The Real World Impact of Tirzepatide on dyslipidaemia in patients with Type 2 Diabetes Mellitus","Zara Linn","2026","Atherosclerosis Plus","nonrandomized_study","article","10.1016/j.athplu.2026.100594",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044568","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90762-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044569","Obesity: Necessity of Re-Evaluating Therapeutic Approaches and Health Policies","Akram Ghadiri‐Anari","2026","ماهنامه علمی پ‍ژوهشی دانشگاه علوم پزشکی شهید صدوقی یزد","other","article","10.18502/ssu.v34i6.22664",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044570","From Specialty Silos to Integrated Care: A Korean Initiative for Cardiovascular-Kidney-Metabolic Health","Sungjin Chung","2026","Electrolytes & Blood Pressure","other","article","10.5049/ebp.2026.24.e16",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044571","Neurological symptoms during incretin receptor agonist therapy: current evidence for metabolic and fluid-electrolyte mechanisms and testable hypotheses","Sidário Rodrigues Malheiros-junior","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21612596",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0044572","糖尿病性腎臓病のための自己管理支援システム「DialBetesPlus」の有用性に関する無作為化比較試験","光彦 奈良",null,"Institutional Repositories DataBase (IRDB)","randomized_trial","article","10.20569/0002002064",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0044573","GLP1–RA SEMAGLUTIDE AND SLOWING PROGRESSION OF AORTIC VALVE STENOSIS IN NON DIABETIC PATIENTS","G Marchetti","2026","European Heart Journal Supplements","other","article","10.1093/eurheartjsupp/suag058.557",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044574","Sitagliptin in Type 2 Diabetes Mellitus and Cardiovascular Disease: A Public Health and Health Equity Perspective","M. Olowofeso Abisola","2025","Cardiovascular Science","other_trial","article","10.70322/cvs.2025.10010",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044575","Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show","Linda M. Richmond","2024","Psychiatric News","nonrandomized_study","article","10.1176/appi.pn.2024.06.6.38",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044576","Glucagon-like peptide-1 receptor agonists beyond weight loss: A paradigm shift in cardiovascular prevention","Alaa Solaiman Algazzar","2026","Saudi Journal of Internal Medicine","nonrandomized_study","article","10.4103/sjim.sjim_12_26",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044577","Master Index Directional Pressure Failure Series (v 2026.xx) and Lantern of Sulfur (v 2025.xx and v12), v 2026.2","Beth Martell","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18356156",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044578","Shanghai archives of psychiatry",null,null,"iMPULSE (Heinz Maier-Leibnitz Zentrum)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044579","THE GLP–1 RECEPTOR AGONIST SEMAGLUTIDE PRESERVES CARDIAC FUNCTION, REDUCES INFLAMMATION–DRIVEN CARDIOTOXICITY WITH CARDIO–RENAL BENEFITS IN NON–DIABETIC MODELS EXPOSED TO ANTHRACYCLINES AND HER2 BLOCKADE","V Quagliariello","2026","European Heart Journal Supplements","randomized_trial","article","10.1093/eurheartjsupp/suag058.049",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0044580","Svorį mazinantys vaistai ir diabeto kontrole","Kamal Jamali","2025","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044581","EP685 - ECE_1281 - Public concern about GLP-1 analogues: a google trends analysis of global search patterns","Vasiliki Tsiama","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1095",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044582","IMPROVEMENT IN SF-36-DERIVED HEALTH UTILITY SCORE WITH LIRAGLUTIDE 3.0 MG VERSUS PLACEBO OVER 3 YEARS IN PREDIABETES","Ronette L. Kolotkin","2016","Value in Health","other","article","10.1016/j.jval.2016.03.996",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044583","PDB77 - LONG-TERM COST-EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS IGLARLIXI FOR THE TREATMENT OF PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN IN THE ITALIAN SETTING","Roberta Montagnoli","2018","Value in Health","other","article","10.1016/j.jval.2018.09.782",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044584","Relationship Between Change in Body Mass Index and Testosterone Levels in Male Patients Using GLP-1 Receptor Agonists for Weight Loss","Kammo, Sesilia, BS","2025","Human Biology","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","conference-paper"],["R0044585","PDB51 COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE AND VERSUS BIPHASIC INSULIN ASPART FOR THE TREATMENT OF TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM HEALTH ECONOMIC ANALYSIS","JL Palmer","2010","Value in Health","other","article","10.1016/s1098-3015(11)72109-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044586","PDB45 CANADIAN COST UTILITY ANALYSIS COMPARING EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE TWO DIABETES","Doug Coyle","2008","Value in Health","other","article","10.1016/s1098-3015(10)70732-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044587","Evaluating the Cost-Effectiveness of Liraglutide 1.8Mg Versus Lixisenatide 20μg for Patients with Type 2 Diabetes Mellitus in the UK Setting","Nana Kragh","2016","Value in Health","other","article","10.1016/j.jval.2016.09.1874",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044588","Exendin-4 ameniza o dano hepático induzido pela morte encefálica do doador em ratos","Dias, Ana Luiza Perez Olive","2014","Lume (Universidade Federal do Rio Grande do Sul)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044589","Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteo-arthritis: Secondary analyses of a randomized controlled trial","Asbjørn Seenithamby Poulsen","2025","Osteoarthritis and Cartilage","randomized_trial","article","10.1016/j.joca.2025.02.024",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044590","Beyond Glycemic Control: Periodontal, Salivary, and Oral Mi-crobiome Effects of GLP 1 Receptor Agonists—A Scoping Re-view of Clinical and Preclinical Evidence","Vanessa Bolchis","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/mhk9u",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0044591","P71 - ECE_1542 - Beneficial for weight, detrimental for bone: semaglutide and PYY3-36 exacerbate metabolic osteoporosis (MetOP) in a novel two-hit MetOP rat model","Simon Kloock","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.274",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0044592","Directional Pressure Failure as a Unifying Framework for Insulin Signaling, Cellular Hydration, and GLP-1 Response in Hyperchloremia with NAGMA, Lantern of Sulfur, Concept B4, v12","Beth Martell","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18034378",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044593","Assessment of Jordanian Pharmacists’ Knowledge and Awareness of Liraglutide Injection and their Practice in Counseling Obesity Patients","Jumanah Al Shawabkeh","2024","Pharmacy Practice","other","article","10.18549/pharmpract.2024.4.3099",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044594","서방형 exenatide 단회 투여 시 6주간의 약동학 및 정상 포도당 조절 시스템하의 시간에 따른 약효의 변화 양상에 대한 연구","구남이","2013","Seoul National University Open Repository (Seoul National University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044595","PDB35 Estimating the Real Life Daily Usage and Daily Cost of GLP-1 Receptor Agonists in the UK Setting","Amanda McDonell","2011","Value in Health","other","article","10.1016/j.jval.2011.08.1338",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044596","EP487 - ECE_2748 - Preoperative GLP-1 receptor agonist therapy and body composition outcomes in bariatric surgery: a real-world study","Sonsoles Gutiérrez-Medina","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.980",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044597","P286 - ECE_1919 - Tirzepatide in patients with hypothalamic obesity secondary to craniopharyngioma: a single-center case series","Elisa Sala","2026","European Journal of Endocrinology","case_report","article","10.1093/ejendo/lvag096.442",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044598","PDB63 LIRAGLUTIDE IN THE TREATMENT OF TYPE 2 DIABETES MIELLITUS—ECONOMIC EVALUATION IN ROMANIAN SETTING","Dorin Ionescu","2010","Value in Health","other","article","10.1016/s1098-3015(11)72121-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044599","Studies of the molecular anatomy of stroma vascular cells in murine adipose and renal tissues","Martin Uhrbom","2025",null,"nonrandomized_study","article","10.69622/29929685",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","other"],["R0044600","S2.4 - GLP1 induced weight loss and pregnancy","Ursula Winterfeld","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.014",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044601","EP1863 - LBA_ECE_1163 - Semaglutide and contraceptive efficacy: insights from FAERS and patient experiences","Nithin Tumkur Prasad","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1869",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0044602","EP729 - ECE_2411 - Effect of short term subcutaneous liraglutide treatment on respiratory function in individuals with clinical obesity and obstructive sleep apnea","Maria Christou","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.1117",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044603","EP1778 - LBA_ECE_1292 - GLP-1 receptor agonist therapy in “double diabetes”: a case demonstrating arked improvement in glycaemic control and insulin requirements in type 1 diabetes","Tabinda Dugal","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1823",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044604","EE665 Cost-Minimisation Analysis of Oral Semaglutide Versus Dulaglutide in Patients With Type 2 Diabetes Requiring Treatment With a GLP-1 Receptor Agonist","J Garcia Uranga","2022","Value in Health","other","article","10.1016/j.jval.2022.09.904",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044605","Cost-Effectiveness Analysis of Liraglutide 1.8Mg Versus Lixisenatide 20μg for Patients with Type 2 Diabetes Mellitus in Italy","Nana Kragh","2016","Value in Health","other","article","10.1016/j.jval.2016.09.1872",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044606","Clinical Trials of Novel Perspectives on Semaglutide with Injectable and Oral Formulations","Hiroshi Bando","2022","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044607","The ”Ozempic babies” phenomenon: a narrative review of the impact of GLP-1 receptor agonists on fertility and early pregnancy","Lasoń, Joanna Karolina; Faculty of Medicine, Jan Kochanowski University, Kielce, Poland","2026","Medical Research Journal","nonrandomized_study","article","10.5603/mrj.113632",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0044608","Real-World Comparison of Healthcare Costs Among Patients with Type 2 Diabetes Treated with Dulaglutide Vs. Liraglutide in the United States","Reema Mody","2018","Value in Health","nonrandomized_study","article","10.1016/j.jval.2018.04.520",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044609","TIRZEPATIDE TREATMENT AND ACHIEVING WEIGHT REDUCTION ›5%, SBP REDUCTION ›5 MMHG AND NON–HDL CHOLESTEROL REDUCTION ›10%: A POST–HOC ANALYSIS FROM THE SURMOUNT–1 3–YEAR TRIAL","N Sattar","2026","European Heart Journal Supplements","other_trial","article","10.1093/eurheartjsupp/suag058.162",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044610","SURPASS-CVOT: Tirzepatide versus dulaglutide bij patiënten met type 2-diabetes en doorgemaakte cardiovasculaire ziekte","Mark M. Smits","2025","Nederlands Tijdschrift voor Diabetologie","other_trial","article","10.1007/s12467-025-1607-x",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044611","PDB10 Achieving Target Goals in Patients with T2DM Treated with Exenatide Once Weekly or Insulin Glargine: A Retrospective Analysis of the Number-Needed-To-Treat","David F. Bruhn","2011","Value in Health","nonrandomized_study","article","10.1016/j.jval.2011.08.1313",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0044612","Unraveling One-Carbon Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease: Semaglutide Turns Metabolic Stress Into Metabolic Resilience","Lonardo, Amedeo","2025","RWTH Publications (RWTH Aachen)","other","article","10.18154/rwth-2025-10565",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044613","Evaluating the Cost-Effectiveness of Liraglutide 1.8Mg Versus Lixisenatide 20μg for the Treatment of Type 2 Diabetes Mellitus in the Spanish Setting","Nana Kragh","2016","Value in Health","other","article","10.1016/j.jval.2016.09.1879",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044614","SEMAGLUTIDE REDUCES HIGH-SENSITIVITY CRP LEVELS ACROSS DIFFERENT TREATMENT FORMULATIONS: EXPLORATORY ANALYSES OF SUSTAIN 3 AND PIONEER 1, 2 AND 5 TRIALS","Julio Rosenstock","2021","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(21)02964-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044615","Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists","Hong Sang Choi","2025","Korean Journal of Medicine","other_trial","article","10.3904/kjm.2025.100.2.61",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044616","EP725 - ECE_1845 - Exploring the metabolic risks of weight loss therapy in Type 1 Diabetes: A case of DKA following Retatrutide injections","Hasan Jamjoom","2026","European Journal of Endocrinology","other_trial","article","10.1093/ejendo/lvag096.1115",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0044617","EP562 - ECE_2924 - Reduced weight loss response to semaglutide in patients with hypothyroidism: a real-world study","Patricia Oriol Ocejo","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1023",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044618","EP835 - ECE_3442 - Allergy to dexamethasone: a rare pitfall in endocrine practice","Rihab Khochtali","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.1166",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044619","EP490 - ECE_1508 - Real-world comparison of the effects of loxenatide with other GLP-1RAs on renal outcomes in patients with type 2 diabetes: a subgroup analysis of the fighting-1 cohort study (fighting-3)","Wu Hong","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.982",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0044620","GLP-1 Receptor Agonists and Neurological Outcomes in Multiple Sclerosis: A TriNetX Retrospective Cohort Study","Majd A. AbuAlrob","2026","Multiple Sclerosis and Related Disorders","nonrandomized_study","article","10.1016/j.msard.2026.107630",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044621","Efficacy of GLP-1 and GIP/GLP-1 Receptor Agonists on the Body Weight Management of Obesity","Paige D Timbrook","2026","Pepperdine Digital Commons (Pepperdine University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0044622","PDB28 MODEL-Based LONG-TERM Cost-Effectiveness of Once-Weekly Semaglutide Compared with Other GLP-1 Receptor Agonists in Type 2 Diabetes: A Systematic Literature Review","Rui Zhen","2020","Value in Health","narrative_review","article","10.1016/j.jval.2020.08.625",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0044623","Congresverslag",null,"2025","Nederlands Tijdschrift voor Diabetologie","other_trial","article","10.1007/s12467-025-1599-6",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044624","EPH136 Demographic Characteristics, Utilization Trends, and Access to GLP-1 Agonists Among Adults in a Nationally Representative Pharmacy Database","Krisha Patel","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.666",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0044625","PDB27 Cost-Utility Analysis of Liraglutide Versus Glimepiride As Add-on to Metformin in Patients with Type 2 Diabetes in China","Lan Gao","2012","Value in Health","other","article","10.1016/j.jval.2012.08.358",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044626","Viral Insulin/IGF-1–Like Peptides: Novel Regulators of Physiology and Pathophysiology?","David M. Irwin","2018","Endocrinology","other","article","10.1210/en.2018-00856","30304404",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044627","Modeling the Renal Hemodynamic Effects of Semaglutide in Obesity-Associated Chronic Kidney Disease","John S. Clemmer","2026","Figshare","other","article","10.6084/m9.figshare.33811759",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044628","EP726 - ECE_3628 - Anaphylaxis after initiation of insulin glargine/lixisenatide in a patient with long-term tolerance to insulin glargine: a case report","Gökhan Baykal","2026","European Journal of Endocrinology","case_report","article","10.1093/ejendo/lvag096.1116",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044629","JS6.3 - The cardiometabolic–hepatic axis in menopause","Poli Mara Spritzer","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044630","EP814 - ECE_3766 - Semaglutide therapy in a woman with polycystic ovary syndrome and type 1 diabetes: a clinical case","A.P. Vereshchynska","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.1154",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044631","Le sémaglutide (Wegovy®), pour le contrôle du poids","Jacques Buxeraud","2025","Actualités Pharmaceutiques","other","article","10.1016/j.actpha.2025.01.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044632","Cost Analysis Of Treatment Success To Achieve A Clinically Relevant Composite Endpoint For Patients With Type-2 Diabetes On Liraglutide Or Other Antidiabetic Therapies In A Chinese Setting","Lang Shi","2013","Value in Health","other","article","10.1016/j.jval.2013.03.802",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044633","Effect of Switching from Dulaglutide to Oral Semaglutide in Patients with Type 2 Diabetes: A Retrospective Observational Study","Kohzo Takebayashi","2025","Institutional Repositories DataBase (IRDB)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0044634","EE40 Cost-Effectiveness of GLP-1 Receptor Agonists Versus Long-Acting Insulins in Type 2 Diabetes From the Healthcare Sector Perspective: A Model-Based Analysis Using Real-World Data","WY Yao","2022","Value in Health","nonrandomized_study","article","10.1016/j.jval.2022.09.293",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0044635","Could semaglutide promote lifestyle interventions? Influence of semaglutide among people living with overweight/obesity on weight loss and physical activity in a real-world scenario","Antelm Pujol Calafat","2024","Revista de la Sociedad Española de Cirugía de Obesidad y Metabólica y de la Sociedad Española para el Estudio de la Obesidad","nonrandomized_study","article","10.53435/funj.00962",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044636","EP1769 - LBA_ECE_1076 - Severe hyponatremia (104 mmol/L) and SIADH-like syndrome associated with tirzepatide: a novel safety signal","Nithin Tumkur Prasad","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1817",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044637","МОРФОМЕТРИЧНІ ТА ІМУНОГІСТОХІМІЧНІ ОСОБЛИВОСТІ СЕЛЕЗІНКИ ЩУРІВ У ПІЗНІ ТЕРМІНИ СТРЕПТОЗОТОЦИН-ІНДУКОВАНОГО ЦУКРОВОГО ДІАБЕТУ ЗА УМОВ КОРЕКЦІЇ ІНСУЛІНОМ ТА ДАПАГЛІФЛОЗИНОМ","О.Б. Ханенко","2025","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044638","Correction to: Optimizing the Efficacy of Anti-Obesity Medications: A Practical Guide to Personalizing Incretin-Based Therapies","Afua K. Takyi","2025","Current Treatment Options in Gastroenterology","notice","article","10.1007/s11938-025-00478-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0044639","Perfil de notificações de eventos adversos a antidiabéticos no Brasil nos últimos cinco anos","Jeneffer Ferreira Borges","2025","Revista Eletrônica Acervo Saúde","other","article","10.25248/reas.e19509.2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044640","Oxidative Stress Index and Adiponectin Levels in Stable Glucagon-Like Pep-tide-1 Receptor Agonist (GLP-1 RA) (Semaglutide) Users among Obese Non-Diabetic Women: A Cross-Sectional Study","Miqat Abdulkadhim Jawad","2026","Karbala Journal of Medicine","other","article","10.70863/karbalajm.v19i2.7553",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044641","EP371 - ECE_3158 - Genetically predicted HbA1c and the risk of acute pancreatitis in a mendelian randomization study","Silvano Silva","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.893",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044642","Real World Tolerability And Effectiveness of Exenatide Once-Weekly Compared To Basal Insulin Among Elderly Patients with Type 2 Diabetes (T2D)","JD Seeger","2016","Value in Health","nonrandomized_study","article","10.1016/j.jval.2016.09.1847",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044643","Beta cell mass in individuals with and without post-bariatric hypoglycemia after Roux-en-Y Gastric Bypass","Sevilay Tokgöz","2025",null,"other","article","10.2337/figshare.30179038.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044644","2型糖尿病患者におけるリラグルチドの膵内脂肪沈着に対する効果","督 栗山",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044645","EFFECT OF SEMAGLUTIDE ON CARDIORENAL OUTCOMES BY BASELINE BODY MASS INDEX AND PRIOR CARDIOVASCULAR DISEASE: POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6","Jingmin Zhou","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03924-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044646","EP416 - ECE_1411 - Risk of incident chronic obstructive pulmonary disease in type 2 diabetes treated with SGLT2 inhibitors or GLP-1 receptor agonists vs DPP-4 inhibitors: a Real-World Cohort Study","Wei‐Chuan Chang","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.928",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044647","Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treatedwith liraglutide: Results from the LEADER randomized trial","W.M. Steinberg","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/w55w-c869",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0044648","EE67 Cost Per Responder and Number Needed to Treat of iGlarlixi vs Premix BIAsp 30 in Algerian Setting","Rachid Malek","2022","Value in Health","other","article","10.1016/j.jval.2022.09.319",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044649","674 Single-center experience of effect of glucagon-like-peptide-1 receptor agonists in adults with cystic fibrosis","Sung Sup Park","2024","Journal of Cystic Fibrosis","other","article","10.1016/s1569-1993(24)01512-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044650","PDB61 COMPARE LIXISENATIDE WITH RAPID-ACTING INSULIN INTENSIFICATION REGIMENS ON TOP OF BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A COST PER RESPONDER AND NUMBER NEEDED TO TREAT ANALYSIS IN CHINA","P. Men","2019","Value in Health","other","article","10.1016/j.jval.2019.04.610",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044651","Evaluating Patients’ Preferences for Dulaglutide Versus Insulin Glargine Profiles in the United Kingdom: A Discrete Choice Experiment","Kirsi Norrbacka","2017","Value in Health","other","article","10.1016/j.jval.2017.08.483",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044652","CRT-112 Exendin-4 Improves the Survival and Therapeutic Efficacy of Implanted Stem Cells Following Myocardial Infarction","Liu Jianfeng","2013","JACC: Cardiovascular Interventions","other","article","10.1016/j.jcin.2013.01.027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044653","Changing from a Dipeptidyl Peptidase (DPP)-4 Inhibitor to Oral Semaglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Observational Study","Kohzo Takebayashi",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044654","Comparative Efficacy and Safety of Lixisenatide and Insulin Regimens in the Treatment of Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Basal Insulin: A Systematic Review and Network Meta-Analysis","P Men","2018","Value in Health","systematic_review","article","10.1016/j.jval.2018.07.269",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0044655","PDB43 PATIENT REPORTED OUTCOMES ARE SUPERIOR IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH LIRAGLUTIDE AS COMPARED TO EXENATIDE, WHEN ADDED TO METFORMIN, SULFONYLUREA OR BOTH","WE Schmidt","2009","Value in Health","other","article","10.1016/s1098-3015(10)73586-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044656","PERIOPERATIVE ANESTHETIC MANAGEMENT OF ADULTS WITH OBESITY: A PRACTICAL NARRATIVE REVIEW","Ali Rıza Ata","2026","Eskisehir Medical Journal Eskisehir City Hospital","randomized_trial","article","10.48176/esmj.2026.282",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0044657","IMPACTO DO GLP-1 RAS NO PERIOPERATÓRIO QUANDO SUSPENDER?","Guilherme Vaz Silva","2026",null,"other","article","10.51161/iii-conbrasc/87834",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0044658","Cost-Effectiveness of Insulin Glargine/Lixisenatide Titratable Fixed-Ratio Combination for Patients with Basal Insulin-Treated Type 2 Diabetes in South Korea","Hho Hun PARK","2018","Value in Health","other","article","10.1016/j.jval.2018.07.292",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044659","Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study","Díaz-Cerezo,Silvia","2025","Dove Medical Press (Taylor and Francis Group)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0044660","EP423 - ECE_1970 - Anti-inflammatory & anti-fibrotic effects of semaglutide in a rat model for metabolic kidney disease","Felix Wiegand","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.933",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0044661","EP500 - ECE_1831 - Semaglutide rewires thyroid transcriptional programs in obesity through sex-specific modulation of adiponectin signaling and mTOR–RET pathways","Niklas Geiger","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.991",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0044662","EP52 - ECE_1187 - When weight loss hides Cushing's: a tirzepatide pitfall","Aparajita Roy","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.661",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044663","EP480 - ECE_2629 - Can glucagon-like peptide (GLP)-1 agonists and dual glucose-dependent insulinotropic polypeptides (GIP/GLP-1) agonists assist in managing hyperphagia and obesity in Prader-Willi syndrome?","Magdalena Goralska","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.976",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044664","RC3.5 - ECE_2991 - Cancer risk and GLP-1 receptor agonist use in patients with Cushing syndrome","Idit Dotan","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.161",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044665","GLP-1 Agonist in Middle-Aged Obesity Versus Standard Diet and Exercise Effects on BP and HR","John Troy Rubeck","2025","ScholarSphere (Penn State Libraries)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044666","Ozempic : intérêt thérapeutique, mésusage et rôle du pharmacien d'officine","Fatnassi, Yousra","2023","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044667","A Meta-Analysis of Randomized Controlled Trials Comparing Once-Weekly Semaglutide to Control Therapy for the Treatment of Type 2 Diabetes","Amit Pagada","2018","Value in Health","systematic_review","article","10.1016/j.jval.2018.07.268",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0044668","Kriya launches for diabetes gene therapy","Ryan Cross","2020","C&EN Global Enterprise","other","article","10.1021/cen-09819-buscon16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044669","PRM40 Efficacy of Liraglutide Compared to Exenatide and Insulin Glargine in Patients With Diabetes Type 2: A Meta-Analysis","J.J. Fadipe","2012","Value in Health","systematic_review","article","10.1016/j.jval.2012.08.1504",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0044670","POSC350 Health Utility Values in the STEP 1–4 Trials of Semaglutide 2.4 MG in Obesity","Henrik H. Meincke","2022","Value in Health","other","article","10.1016/j.jval.2021.11.1175",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044671","Exacerbation in Glycemic Control by Switching from Subcutaneous Dulaglutide Injection to Oral Semaglutide Administration in a Patient with Type 2 Diabetes, Who Had Undergone Gastrectomy","Kohzo Takebayashi","2024","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044672","EP1240 - ECE_1609 - Early hypocortisolism with persistent remission following osilodrostat therapy in a patient with long-standing Cushing disease","Liat Sasson","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.1483",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044673","IMPROVEMENT IN IWQOL-LITE-DERIVED HEALTH UTILITY SCORE WITH LIRAGLUTIDE 3.0 MG VERSUS PLACEBO OVER 3 YEARS IN PREDIABETES","R.L. Kolotkin","2016","Value in Health","other","article","10.1016/j.jval.2016.03.1000",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044674","ESTIMATING THE COST TO SOCIETY FOR EXENATIDE QW AND INSULIN GLARGINE IN THE UNITED STATES FOR THE TREATMENT OF TYPE 2 DIABETES","B.C. Wang","2016","Value in Health","other","article","10.1016/j.jval.2016.03.1288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044675","Estimation of treatment effect among treatment responders with a time‐to‐event endpoint","Andreas Nordland","2024","Scandinavian Journal of Statistics","other_trial","article","10.1111/sjos.12706",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0044676","Assessment of Race-Specific Tolerability And Effectiveness of Exenatide once-Weekly or Basal Insulin Among Patients With Type 2 Diabetes In A Real World Setting In The USA","JD Seeger","2016","Value in Health","nonrandomized_study","article","10.1016/j.jval.2016.09.1845",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044677","Reducing Budget Impact To Mexican Public Health Care System With The Usage Of A Novel Glp-1 Analogue For Uncontrolled T2dm Patients On Basal Insulin Regimen","IF Soria-Cedillo","2013","Value in Health","other","article","10.1016/j.jval.2013.03.798",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044678","PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC","Monika Russel-Szymczyk","2018","Value in Health","other","article","10.1016/j.jval.2018.09.779",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044679","A novel RP- HPLC method development and forced degradation studies for semaglutide in active pharmaceutical ingredients and pharmaceutical dosage form","Arun Kumar Kuna","2019","International Journal of Research in Pharmaceutical Sciences","other","article","10.26452/ijrps.v10i2.263",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044680","Untersuchung zum Mechanismus von SGLT2-Inhibitoren und GLP1-Rezeptoragonisten in zellulären Modellen von diabetischer Kardiomyopathie","Hasse, Marcel","2024","Qucosa (Saxon State and University Library Dresden)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044681","EP388 - ECE_3156 - Genetic evaluation of glycemic pathways targeted by GLP-1 receptor agonists and the risk of anterior ischemic optic neuropathy","Silvano Silva","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.904",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044682","Physiology and pharmacology of diabetes therapies in the cat: insulin detemir, insulin glargine, exenatide and the incretin effect","Chen Gilor","2010","Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044683","US POPULATION ELIGIBILITY AND ESTIMATED IMPACT OF SEMAGLUTIDE TREATMENT ON OBESITY PREVALENCE AND CARDIOVASCULAR DISEASE EVENTS IN US ADULTS","Nathan D. Wong","2023","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(23)02259-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044684","The albiglutide budget impact model ipad application – a new, interactive, user-friendly platform demonstrating the budget impact of including albiglutide on managed care formularies","D. Bruhn","2014","Value in Health","other","article","10.1016/j.jval.2014.03.1419",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044685","Exenatide In Obese Or Overweight Patients Without Diabetes: A Systematic Review And Meta-Analyses Of Randomized Controlled Trials","Naichuan Su","2017","Value in Health","systematic_review","article","10.1016/j.jval.2017.08.2822",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0044686","Pacific RxTracts - August 2026","Pacific RxTracts","2026","Scholarly Commons (University of the Pacific)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0044687","Risk factors for stroke recurrence in young patients with first-ever ischemic stroke: A meta-analysis","Xia Yu","2023","World Journal of Clinical Cases","systematic_review","article","10.12998/wjcc.v11.i26.6122","37731567",null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0044688","Comparative effects of sodium glucose co-transporter inhibitors and glucagon like peptide 1 receptor agonists on metabolic parameters","구윤희","2020","Seoul National University Open Repository (Seoul National University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044689","POSC141 Evaluation of the Long-Term Cost-Effectiveness of Ideglira Versus Liraglutide for Patients with Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs in China","RX Jia","2022","Value in Health","other","article","10.1016/j.jval.2021.11.545",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044690","Cost-Effectiveness of Dulaglutide 1.5mg Once Weekly for the Treatment of Patients with Type Two Diabetes Mellitus in Sweden","A Raibouaa","2015","Value in Health","other","article","10.1016/j.jval.2015.09.2095",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044691","Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth","Yoko Tsutsumi",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044692","EP683 - ECE_3959 - The importance of integrating FIB-4 and transient elastography in detecting advanced liver fibrosis among patients with type 2 diabetes","Marin Pecani","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.1093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044693","EP444 - ECE_3605 - Female sexual function following glp-1 receptor agonist therapy in women with obesity: a prospective observational study","Sara Odalovic","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.951",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044694","Long-Term Cost Effectiveness Analysis Of Ideglira Versus Glp-1 Added To Basal Insulin As Intensification Therapies In Type 2 Diabetes Mellitus In Spain","M. Prades","2016","Value in Health","other","article","10.1016/j.jval.2016.03.1714",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044695","Prevention of esophageal adenocarcinoma","Johan Hardvik Åkerström","2026",null,"nonrandomized_study","article","10.69622/32261475",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0044696","Cardiovascular–Kidney Outcome Concordance with Tirzepatide in Type 2 Diabetes: A Design-Stratified Systematic Review and Exploratory Meta-analysis","Eyasu Daba Dugasa*, Md Ahmadunnisa, Mohammad Al-Haddad, Ali Al Salami","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.22770210",null,null,"PROSPERO:CRD420261436184",null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0044697","THE EFFECT OF ONCE-WEEKLY OF HIGH DOSE SEMAGLUTIDE ON BODY WEIGHT AND PHYSICAL ACTIVITY: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Mohammed Al‐Sadawi","2022","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(22)02537-2",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0044698","Novel biomarkers associated with gestational diabetes mellitus and metabolic outcomes of pregnancy","Nithya Sukumar","2017","Warwick Research Archive Portal (University of Warwick)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0044699","Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes","航之介 永江","2019","Institutional Repositories DataBase (IRDB)","preclinical","article","10.15017/2348711",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044700","Liraglutide: A pharmacoeconomic review of its use in type ii diabetes","Neil M. Schultz","2014","Value in Health","narrative_review","article","10.1016/j.jval.2014.03.1432",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044701","Incretin Therapy for Patients with Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin","Antonio Ramírez de Arellano","2013","Value in Health","other","article","10.1016/j.jval.2013.08.670",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044702","EFFICACY AND SAFETY OF GLP-1 ANALOGUES IN TYPE 2 DIABETES, OBESITY, AND CARDIOMETABOLIC RISK: A SYSTEMATIC NARRATIVE REVIEW","Praveen","2026","International Journal of Scientific Research","narrative_review","article","10.36106/ijsr/9402067",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0044703","CANAGLIFLOZIN VERSUS SEMAGLUTIDE FOR SECONDARY PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - VALUE PER MONEY ANALYSIS","Ronen Arbel","2021","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(21)02967-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044704","Αξιολόγηση της ποιότητας αναφοράς των τυχαιοποιημένων κλινικών δοκιμών σχετικά με τη χρήση dulaglutide στο σακχαρώδη διαβήτη τύπου 2 δημοσιευμένων από το 2010 έως το 2020 με τη χρήση της δήλωσης CONSORT","Γκόγκος, Γεώργιος Σ.","2021","University of Thessaly Institutional Repository (University of Thessaly)","other","article","10.26253/heal.uth.11414",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044705","Analogues du GLP-1 : un traitement oral bientôt disponible ?","Thomas Schmid","2019","Revue Médicale Suisse","randomized_trial","article","10.53738/revmed.2019.15.666.1840",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044706","Effects of liraglutide on the testis in experimental diabetic and ischemia-reperfusion injury.","Sinem Hazır","2016","Çukurova University Institutional Repository","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044707","Preserving Lean Mass During GLP-1RA-Induced Weight Loss: The Potential Role of Ketogenic Metabolic Therapy in Improving Weight-Loss Quality","Marco Medeot","2026","Biomedicine Advances","other","article","10.34172/bma.74",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044708","The role of gut hormones in energy homeostasis","K. McCullough","2013","Spiral (Imperial College London)","preclinical","article","10.25560/39353",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044709","HSD104 Semaglutide and Tirzepatide in Type 2 Diabetes: Patient Characteristics and Weight-Related Outcomes in the Real-World Setting","A. Althoff","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.03.1327",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0044710","Modeling the Renal Hemodynamic Effects of Semaglutide in Obesity-Associated","John S. Clemmer","2026","Figshare","other","article","10.6084/m9.figshare.33811759.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044711","PT20 Estimating the Cost at which GLP-1 RAs Would become Cost-Effective for Multimorbid Type 2 Diabetes Patients in Canada","Ethan McNally","2025","Value in Health","other","article","10.1016/j.jval.2025.04.2127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044712","ROLE OF GLP1 AGONIST AFTER TAVI: INSIGHTS FROM MOTIVE REGISTRY","M Ferrua Trucco","2026","European Heart Journal Supplements","randomized_trial","article","10.1093/eurheartjsupp/suag058.061",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044713","EP564 - ECE_3229 - Post-bariatric hypoglycaemia—a case series from a large surgical bariatric centre","Aparna Chaudhary","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1025",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044714","S2.1 - Tanycytes at the crosstalk between reproduction and metabolism","Daniela Fernandois","2026","European Journal of Endocrinology","preclinical","article","10.1093/ejendo/lvag096.011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044715","Glucagon-like peptide-1 receptor agonists reduce serum LDL-cholesterol levels via LDL receptor in mice and Type 2 diabetes patients","夕希子 長谷川","2017","Institutional Repositories DataBase (IRDB)","preclinical","article","10.20780/00031932",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044716","A Survey and Guide to the Development of Fatty Acid‐derivatized Peptide Therapeutics","Michael T. Jacobsen","2025","Peptide Science","other","article","10.1002/9781119824701.ch07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044717","Modern therapeutic approaches to diabetic nephropathy","Τσέλιου, Κωνσταντίνα Σ.","2024","University of Thessaly Institutional Repository (University of Thessaly)","other","article","10.26253/heal.uth.39686",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044718","Primary prevention of atrial fibrillation with pharmacological therapy","K Raveendra","2024","EP Europace","randomized_trial","article","10.1093/europace/euae102.829",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044719","Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study","健将 尾町",null,"Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044720","P149 - ECE_2587 - Semaglutide and empagliflozin improve glycaemic control and body composition in type 1 diabetes (T1DM): results from the ENDIS trial","Maja Navodnik Preložnik","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.337",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0044721","EP1705 - LBA_ECE_1103 - Wernicke's encephalopathy following GLP-1 receptor agonist use for weight loss: a case report","Anne Milligan","2026","European Journal of Endocrinology","case_report","article","10.1093/ejendo/lvag096.1776",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044722","GPR119 Agonism Revisited: A Novel Target for Increasing β-Cell Mass?","Daniela Nasteska","2020","Endocrinology","preclinical","article","10.1210/endocr/bqz018","32053720",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044723","Studio randomizzato, controllato sugli effetti della Liraglutide alla dose di 3 mg nel trattamento dell’eccesso ponderale","Paola Fierabracci","2015","L Endocrinologo","other","article","10.1007/s40619-015-0136-z",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044724","Cost Effectiveness of Optifast® LCD As Compared with Liraglutide 3 Mg And “No Intervention” In Switzerland","MJC Nuijten","2017","Value in Health","other","article","10.1016/j.jval.2017.08.885",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044725","PDB7 ASSESSMENT OF CARDIOVASCULAR OUTCOMES ASSOCIATED WITH SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR THERAPY AND INCRETIN-BASED THERAPIES AMONG ELDERLY PATIENTS TYPE 2 DIABETES MELLITUS","Siddhi Korgaonkar","2020","Value in Health","other","article","10.1016/j.jval.2020.04.196",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044726","PDB13 A Cost of Control Analysis of Liraglutide Versus Other ANTI-Diabetic Therapies in the Treatment of Patient with Type 2 Diabetes in China","Aizong Shen","2021","Value in Health","other","article","10.1016/j.jval.2021.04.411",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044727","Advertencia sobre posible riesgo de neuropatía óptica isquémica anterior no arterítica con semaglutida","Arrieche, Martín","2025","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044728","EP697 - ECE_2662 - Effect of Glucagon like Peptide-1 Receptor Agonist therapies on metabolic dysfunction-associated steatotic liver disease in overweight and obese adults","Thaw Htet","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1102",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0044729","P475 - LBA_ECE_1057 - Clinical outcome and safety profile of combination therapy with low-dose semaglutide and metformin vs metformin alone in polycystic ovary syndrome with obesity","Hurjahan Banu","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.591",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0044730","EE100 Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide","Xi Tan","2025","Value in Health","other","article","10.1016/j.jval.2025.04.392",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044731","PDB68 DEMOGRAPHIC AND CLINICAL PROFILES OF PATIENTS WITH TYPE 2 DIABETES NEWLY INITIATING SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS COMPARED TO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS","E. P. Pineda","2019","Value in Health","other","article","10.1016/j.jval.2019.04.617",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044732","P450 - LBA_ECE_1110 - Evaluation of a nutraceutical based on white mulberry leaves, fenugreek, niacin, chrome, zinc and a probiotic for reducing insulin resistance in patients with prediabetes: the NoDiab study","Francisco Javier Martínez-Martín","2026","European Journal of Endocrinology","other_trial","article","10.1093/ejendo/lvag096.569",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0044733","EP1815 - LBA_ECE_1182 - The impact of Semaglutide and Tirzepatide intervention on the metrics of metabolic function, bioimpedance analysis, and dietary behaviors in individuals receiving treatment","Gamze Akkuş","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1847",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044734","EE227 Systematic Review on Cost-Effectiveness of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists","Debra Winberg","2022","Value in Health","systematic_review","article","10.1016/j.jval.2022.04.475",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0044735","Systematic Literature Review And Indirect Treatment Comparison of The Efficacy of Semaglutide Versus Empagliflozin As Add-on To Basal Insulin","Steve Kanters","2017","Value in Health","narrative_review","article","10.1016/j.jval.2017.08.430",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0044736","Effect of GLP1 agonists and the combination of GLP1 agonist and GIP on weight loss and weight maintenance in obese patients","Ραάτ, Αιμιλία Α.","2024","University of Thessaly Institutional Repository (University of Thessaly)","other","article","10.26253/heal.uth.40414",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044737","PDB7 Efficacy and Safety of Liraglutide 1.2Mg Once Daily in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Qiuyan Ye","2012","Value in Health","systematic_review","article","10.1016/j.jval.2012.03.928",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0044738","PDB59 LIXISENATIDE, BASAL INSULIN AND PREMIXED INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY ORAL ANTIDIABETIC DRUGS: NETWORK META-ANALYSIS AND COST-EFFECTIVENESS ANALYSIS","P. Men","2019","Value in Health","systematic_review","article","10.1016/j.jval.2019.04.608",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0044739","Exenatide","&NA;","2006","Reactions Weekly","other","article","10.2165/00128415-200610910-00030",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044740","Can serious adverse event rates be used as a metric of trial representativeness for pharmacological interventions? Glucagon-like peptide-1 receptor agonist trials as an exemplar","Almazam, Saleh Ali M","2025","Enlighten: Theses (The University of Glasgow)","randomized_trial","article","10.5525/gla.thesis.84908",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0044741","PDG9 Economic Impact of Cardiovascular Benefit of Once-Weekly Semaglutide in Type 2 Diabetes Patients with High Cardiovascular Risk in China","Rui Zhen","2021","Value in Health","other","article","10.1016/j.jval.2021.04.457",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044742","SYSTEMATIC REVIEW OF EFFICACY AND SAFETY OF DULAGLUTIDE COMPARED WITH OTHER ANTIDIABETIC DRUGS","JG Bayona","2016","Value in Health","systematic_review","article","10.1016/j.jval.2016.03.1320",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0044743","A novel strategy to prepare the precursor peptide of liraglutide","Nian Cheng","2017","Process Biochemistry","other","article","10.1016/j.procbio.2017.07.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044744","RETATRUTIDE, A TRIGONAL GLP-1, GIP AND GLUCAGON RECEPTOR AGONIST, AND ITS ROLE IN WEIGHT REDUCTION","Hamza Naeem","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03892-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044745","A TRIGONAL GLP-1, GIP AND GLUCAGON RECEPTOR AGONIST, RETATRUTIDE, AND METABOLIC SYNDROME","Hamza Naeem","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03926-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044746","REAL WORLD OUTCOMES OF GLUCAGON LIKE PEPTIDE1 RECEPTOR AGONISTS (GLP1-RA) IN DIABETIC PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION","Zaza Iakobishvili","2024","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(24)02744-x",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044747","Dulaglutida per al tractament de la diabetis mellitus tipus 2","Programa d'Harmonització Farmacoterapèutica",null,"RECERCAT (Consorci de Serveis Universitaris de Catalunya)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0044748","Impact of Weight Loss on Patient-Reported Outcomes In The Scale Obesity and Prediabetes Trial of Liraglutide 3.0 Mg As Adjunct to A Diet and Exercise (D&E) Programme","RL Kolotkin","2015","Value in Health","other_trial","article","10.1016/j.jval.2015.09.1991",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0044749","EP710 - ECE_2689 - Budget impact analyses for the management of obesity: a literature review","Timothy Quek","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1108",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044750","Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) as Add-on Therapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies","Jing Deng","2015","Value in Health","other","article","10.1016/j.jval.2015.09.2105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044751","Corrections to ’Systematic Literature Review and Indirect Treatment Comparison of the Efficacy of Semaglutide versus Empagliflozin as Add-On to Basal Insulin (PDB4)’",null,"2017","Value in Health","narrative_review","article","10.1016/j.jval.2017.11.006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0044752","Update on New Drugs","Ernst, Mike","2015","Iowa Research Online (The University of Iowa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044753","Inflammatory Mechanisms of Depression and Suicidal Behavior","Filip Ventorp","2017","Lund University Publications (Lund University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044754","Drugs for Weight Loss, Psychoanalysis for Weight Gain: An SAE Dimensional Analysis of Eating Disorders / 减肥靠吃药,增重靠心理分析:饮食障碍的SAE层级分析","Han Qin","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19501120",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0044755","EE273 Budget Impact of Lixisenatide/Insulin Glargine in the Treatment Oftype 2 Diabetes Mellitus in Guatemala","P Lasalvia","2022","Value in Health","other","article","10.1016/j.jval.2022.04.519",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044756","Effect of dual therapy with liraglutide and ghrelin on brain metabolism and intracellular stress in the Huntington's disease R6/2 mouse model","Débora Mena","2019","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044757","Non-alcoholic fatty liver disease: diet therapy and pharmacotherapy","Moscow Federal State Budgetary Educational Institution of Higher Professional Education of the Russian Ministry of Health","2025","Terapevt (General Physician)","other","article","10.33920/med-12-2503-05",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044758","PET Imaging of Neuroendocrine Neoplasms","Rahko, Anni","2024","UTUPub (University of Turku)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044759","Transformer-Based Deep Learning Model to Predict Long-Term Trajectories of Weight-Loss in GLP-1 Agonist Patients","Kumaran. R","2026",null,"other","article","10.1109/icisc69558.2026.11681021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0044760","PDB3 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 6-Month Analysis Results","Francesco Giorgino","2020","Value in Health","nonrandomized_study","article","10.1016/j.jval.2020.08.600",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044761","Long-term Effect of Oral Semaglutide on Glycemic Control: An Extended Observational Study over Two Years from Baseline","Kohzo Takebayashi","2025","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044762","Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines","Steve Bain","2025","Cronfa (Swansea University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044763","ICER: semaglutide less cost effective vs empagliflozin in T2DM",null,"2019","PharmacoEconomics & Outcomes News","other","article","10.1007/s40274-019-6353-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044764","The cost-effectvenese of liraglutide vs exenatide for the treatment of type 2 diabetes in the United States","Ning Ning","2014","Value in Health","other","article","10.1016/j.jval.2014.03.1464",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044765","Dose-Dependent Evaluation of Semaglutide possible Changes in the Fallopian Tubes of Adult Female Albino Rats:Histological,Immunohistochemical,and Scanning Electron Microscopic study","Federal Institute for Risk Assessment","2026","Bundesinstitut für Risikobewertung Fachgruppe ZEBET - Datenbank und Informationsbeschaffung Abteilung Experimentelle Toxikologie und ZEBET","preclinical","article","10.17590/asr.0000455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044766","PDB18 COST OFFSETS ASSOCIATED WITH USE OF EXENATIDE COMPARED TO GLARGINE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES","MD Pawaskar","2009","Value in Health","other","article","10.1016/s1098-3015(10)74996-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044767","EP1439 - ECE_3455 - Body weight strongly influences the metabolic phenotype in women with polycystic ovary syndrome","Sabrina Marville","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1622",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044768","Dulaglutide-associated interstitial granulomatous dermatitis: a case report","Georgio Chidiac","2026","JAAD Case Reports","case_report","article","10.1016/j.jdcr.2026.09.009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044769","Diabetes Mellitus: From Pathophysiology to Novel Therapeutic Strategies-A Comprehensive Review","Pratheeksha .","2026","International Journal of Pharma Growth Research Review","narrative_review","article","10.54660/ijpgrr.2026.3.5.01-12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044770","The impact of glucagon-like peptide-1 on the brain-reward system and beyond","Rozita H. Anderberg","2015","Gothenburg University Publications Electronic Archive (Gothenburg University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044771","Commentary on glucose reduction in type 2 diabetes ( GRADE )","Y.-T. Lee","2023","Journal of Diabetes Investigation","randomized_trial","article","10.1111/jdi.13994","36799078",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0044772","P177 - ECE_1410 - Glucagon-like peptide-1 receptor agonists vs sodium–glucose cotransporter-2 inhibitors and risk of incident asthma in patients with diabetes: a real-world cohort","Wan-Ting Huang","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.359",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0044773","Comparative Effectiveness of Liraglutide Versus Sitagliptin in Type 2 Diabetes in the United Kingdom: A Retrospective Study in Primary Care","Martin Erik Nyeland","2013","Value in Health","nonrandomized_study","article","10.1016/j.jval.2013.08.624",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044774","EFFICACY AND SAFETY OF DULAGLUTIDE IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Raju Kanukula","2016","Value in Health","systematic_review","article","10.1016/j.jval.2016.03.1319",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0044775","EP823 - ECE_1873 - Current literature on the use of Probiotic and prebiotic with Glucagon like peptide- 1 receptor agonist therapy in patients with Type 2 diabetes","Thaw Htet","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1160",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0044776","Characteristics Of Patients Initiating Treatment With Exenatide Once Weekly","Jennie H. Best","2013","Value in Health","other","article","10.1016/j.jval.2013.03.789",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044777","PDB117 PATIENT TREATMENT SATISFACTION AND STUDY STAFF PERCEPTIONS OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES","B.B. Hansen","2019","Value in Health","other","article","10.1016/j.jval.2019.09.999",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044778","Assessing glycemic and weight-lowering potential of oral semaglutide in type 2 diabetes compared to other GLP-1 receptor agonists in Indian context","Awadhesh Kumar Singh","2024","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-024-01337-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044779","Estimating Pathway Treatment Effects in the Presence of Intermediate Events with Multi-State Data","Yuhao Deng","2026","arXiv (Cornell University)","other_trial","article","10.48550/arxiv.2608.22608",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0044780","The role of Exenatide in managing cardiovascular risks and complications in patients with type 2 diabetes",null,"2016","Greenwich Academic Literature Archive (University of Greenwich)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","conference-paper"],["R0044781","EP1820 - LBA_ECE_1225 - A case of co-existence of prediabetes and insulinoma and the advantages of EUS-RFA","Maria Pandelieva","2026","European Journal of Endocrinology","case_report","article","10.1093/ejendo/lvag096.1850",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044782","EP768 - ECE_3429 - Use of tirzepatide: metabolic, functional and psychological outcomes","Khash Nikookam","2026","European Journal of Endocrinology","other_trial","article","10.1093/ejendo/lvag096.1137",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0044783","EE459 Early Intensification of Oral Semaglutide in the UK: A Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy","H Ren","2022","Value in Health","other","article","10.1016/j.jval.2022.09.704",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044784","EE531 Cost-Utility Analysis of Once-Weekly Semaglutide Versus Dulaglutide in Patients With Type 2 Diabetes Requiring Treatment With a GLP-1 Receptor Agonist","J Garcia Uranga","2022","Value in Health","other","article","10.1016/j.jval.2022.09.772",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0044785","Up-titration strategy after DPP-4 inhibitor-based oral therapy for type 2 diabetes: A randomized controlled trial shifting to a single-dose GLP-1 enhancer versus adding a variable basal insulin algorithm","匡彦 宮城",null,"Institutional Repositories DataBase (IRDB)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0044786","Manejo preoperatorio de pacientes en tratamiento con análogos GLP-1: ¿suspender o individualizar?","Javier Crespo","2025","Revista de Gastroenterología de México","other","article","10.1016/j.rgmx.2024.11.010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044787","Ozempic-Induced Thrombocytopenia",null,"2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.05.025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044788","O USO DE AGONISTAS DE RECEPTOR GLP-1 EM PACIENTES IMUNODEPRIMIDOS OU IMUNOSSUPRIMIDOS","Mariana Mota Botelho","2026","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v12i9.28426",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044789","Once-weekly dulaglutide noninferior to once-daily liraglutide",null,"2014","Nature Reviews Endocrinology","other","article","10.1038/nrendo.2014.137",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044790","Evaluation of the feasibility and acceptability of liraglutide 3.0mg as a management of overweight and obesity in people with severe mental illness (LOSE Weight trial)","Whicher, Clare Alexandra","2021","ePrints Soton (University of Southampton)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0044791","Lemons for Obesity","Michael S. Lauer","2012","Annals of Internal Medicine","randomized_trial","article","10.7326/0003-4819-157-2-201207170-00438","22801677",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0044792","Media Framing of Ozempic and Other GLP-1 Receptor Agonists in The New York Times","Kevin Sogoli","2026","McMaster University Journal of Public Health","nonrandomized_study","article","10.15173/mujph.v3i2.4071",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044793","The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management","Carlo Acierno","2025","Exploration of Medicine","other","article","10.37349/emed.2025.1001365",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044794","Antipsychotic‐induced weight gain: Is the weight over? New guidelines needed","Nini de Boer","2022","Acta Psychiatrica Scandinavica","randomized_trial","article","10.1111/acps.13485","35951775",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044795","GLP1 acts on the carotid body to modulate glucose homeostasis and cardiorespiratory responses","Pires, Dinis Sampaio","2022","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044796","Poster Session II A324 THE NAUSEA ATLAS: IDENTIFYING AND CHARACTERIZING NAUSEA SUBTYPES USING PATIENT-REPORTED INFORMATION","Sneh Sonaiya","2026","Journal of the Canadian Association of Gastroenterology","other","article","10.1093/jcag/gwaf042.324",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044797","Real-world effectiveness and safety of semaglutide for weight loss","Ploutarchos Tzoulis","2022","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.86.p86",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0044798","Wegovy:FDA approves weight loss drug to cut cardiovascular risk","Mustafa Vakur Bor","2024","University of Southern Denmark Research Portal (University of Southern Denmark)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044799","5 An update on obesity and type 2 diabetes treatment","Sarah Ehtisham","2023",null,"other","article","10.1136/bmjpo-2023-asped.5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0044800","Exenatide provides benefit in Parkinson's disease","Harrison Charlotte","2013","Nature Reviews Drug Discovery","other","article","10.1038/nrd4060",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044801","Semaglutide for managing overweight and obesity","Cooper, Keith","2021","ePrints Soton (University of Southampton)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0044802","Rethinking T2DM Care: GLP-1 Therapy and Strength Training Combined","Jaina H. Patel","2026","Health Science Inquiry","other","article","10.29173/6n2qsv59",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044803","Moderator's view: after SGLT2i and MRA antagonists, where do we go?","Carmine Zoccali","2024","Clinical Kidney Journal","other_trial","article","10.1093/ckj/sfae013","38370428",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044804","Hunger and the Obesity Epidemic: Old Insights Reaffirmed by New Medicines?","Rory Taylor","2023","Annals of Internal Medicine","other_trial","article","10.7326/m23-0744","37364261",null,null,null,"openalex","FALSE","paywalled","5","FALSE","editorial"],["R0044805","Cardioprotection – is no the answer? A renewed look at nitric oxide signalling in cardiomyocytes","Sean M. Davidson","2018","Cardiovascular Research","other_trial","article","10.1093/cvr/cvy073","29584817",null,null,null,"openalex","FALSE","paywalled","5","FALSE","editorial"],["R0044806","Media Coverage on Weight Loss - Icelandic Media Coverage of Diabetes Medication and User Experiences with the Drug","Erla Katrín Kjartansdóttir 1993-","2024","Skemman","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044807","Expression of the Glucagon Like Peptide-1 Receptor in Human Pancreas and Incretin Therapy","Gladys Teitelman","2014","Endocrinology","preclinical","article","10.1210/en.2014-1166","24654830",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044808","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97575-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044809","Liraglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-90952-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044810","Recent Advances Addressing the Challenges of Precision Dosing","Iris K. Minichmayr","2024","Clinical Pharmacology & Therapeutics","nonrandomized_study","article","10.1002/cpt.3365","39087264",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044811","Dulaglutide/metoprolol",null,"2021","Reactions Weekly","other","article","10.1007/s40278-021-93561-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044812","Strategieën om het metabole risico na de bevalling te verbeteren bij vrouwen met eerdere zwangerschapsdiabetes","Yana Vanlaer",null,"Lirias (KU Leuven)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0044813","Deaths stalk GLP-1 agonist","Jodi Hyer","2008","Nature Biotechnology","other","article","10.1038/nbt1108-1204b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044814","Letter to the Editor from Banerjee and Mondal: “Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline”","Mainak Banerjee","2022","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgac478","35962775",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","letter"],["R0044815","Admission glucagon-like peptide-1 levels in acute myocardial infarction: is this a new biomarker of cardiovascular risk?","Leonardo Roever","2019","European Heart Journal","commentary","article","10.1093/eurheartj/ehz868","31834367",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0044816","Progression of Treatment Strategies in Type 2 Diabetes","Richard I. G. Holt","2010","US Endocrinology","other","article","10.17925/use.2010.06.1.34",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044817","Exenatide and insulin glargine are equally effective in patients with suboptimally controlled type 2 diabetes","Marie Lofthouse","2006","Nature Clinical Practice Endocrinology &#38 Metabolism","other","article","10.1038/ncpendmet0064",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044818","Transforming the diabetes outcomes for people with mental illness","Richard I. G. Holt","2024","Practical Diabetes","other","article","10.1002/pdi.2516",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044819","GLP-1 Receptor Agonists Beyond Metabolic Disease: A Systematic Review of Cardiovascular, Renal, Neurological, and Emerging Therapeutic Evidence","Dr. Swati.Fulmali","2026","PAIN JOINTS SPINE","systematic_review","article","10.1922/pjs.16.3s.2026.597",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0044820","Prandialer GLP-1-Agonist ist guter Partner des Basalinsulins","Dirk Einecke","2013","Info Diabetologie","other","article","10.1007/s15034-013-0282-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044821","Liraglutide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-52642-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044822","Neuer GLP-1-Agonist wirkt additiv zu Basalinsulin",null,"2011","Info Diabetologie","other","article","10.1007/bf03371339",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044823","P2668Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells","Ang Chen","2018","European Heart Journal","other","article","10.1093/eurheartj/ehy565.p2668",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044824","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-79483-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044825","Byetta (exenatide)","Business Review Editor","2005","PharmaDeals Review","other","article","10.3833/pdr.v2005i62.647",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044826","It's Still Not Too Late to Make a Change: Current Status of Glycemic Control in Korea","Sang Yong Kim","2014","Diabetes & Metabolism Journal","other_trial","article","10.4093/dmj.2014.38.3.194","25003072",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044827","Finding Common Ground: Updates from ObesityWeek 2025","Anthony J. Millard","2026","Journal of Cardiac Failure - Intersections","other_trial","article","10.1016/j.yjcafi.2026.04.005",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044828","Ozempic: Use, Misuse, and Implications for the Treatment of Obesity.","Adela Condrat","2026","Health Science Inquiry","other","article","10.29173/24mnwh21",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044829","Erratum: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study","T A Wadden","2013","International Journal of Obesity","notice","article","10.1038/ijo.2013.148",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0044830","Adverse Event Label Expansion for GLP-1 Medications Due to Off-Label Use: Regulatory Implications and Challenges","Deepaben Bhavsar","2025","International Journal of Basic and Applied Sciences","nonrandomized_study","article","10.14419/n99q9v48",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044831","New challenges in vascular biology and medicine: from unravelling the mechanisms of neointima formation to the prevention of amputations and of ischaemic stroke","Filippo Crea","2021","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehab224","33962463",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044832","Efficacia e sicurezza del Semaglutide comparato con il Liraglutide e con placebo per la perdita del peso in pazienti affetti da obesità: un trial clinico randomizzato di fase 2, in doppio cieco","Edoardo Mocini","2019","L Endocrinologo","other_trial","article","10.1007/s40619-019-00569-2",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044833","Exenatide nur noch einmal wöchentlich",null,"2011","MMW - Fortschritte der Medizin","other","article","10.1007/bf03367659",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044834","Corrigendum",null,"2015","The Journal of Clinical Endocrinology & Metabolism","other","article","10.1210/jc.2015-1782","25955325",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0044835","GLP1 agonists beyond glycemic control—redefining their role","Subhankar Chowdhury","2020","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-020-00879-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044836","Use and informal access to GLP-1 receptor agonists in Switzerland: a national survey","Clement P. Buclin","2026","BMC Medicine","other","article","10.1186/s12916-026-05206-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044837","0057Online Prescribing of GLP-1 Receptor Agonists: A Secret Shopper Study","Ashwin K. Chetty","2026","American Heart Journal","nonrandomized_study","article","10.1016/j.ahj.2026.107567",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044838","Expira patente da semaglutida, princípio do Ozempic","Lana Dias","2025","Institutional Digital Library (Federal Senate)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044839","Beyond Weight Loss: Examining the Nutritional and Physiological Impacts of GLP-1–Based Anti-Obesity Medications","Demsina Babazadeh","2026","eScholarship (California Digital Library)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0044840","Once-weekly exenatide reduces HbA1c more than the twice-daily formulation",null,"2009","Nature Clinical Practice Endocrinology &#38 Metabolism","other","article","10.1038/ncpendmet1036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044841","Oral GLP1 analogue rounds Phase II corner","Asher Mullard","2015","Nature Reviews Drug Discovery","other_trial","article","10.1038/nrd4607",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0044842","Real-World Implementation of GLP-1–Based Pharmacotherapies for Adolescent Obesity: A Scoping Review Protocol of Barriers and Facilitators","Sarah E. Messiah","2026","Open Science Framework","protocol","article","10.17605/osf.io/p5r7g",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0044843","Semaglutide overdose",null,"2019","Reactions Weekly","other","article","10.1007/s40278-019-62839-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044844","Highlights from Issue 3, 2025: Reflections on Leadership, Innovation, and Rare Diagnoses","Salem Beshyah","2025","Ibnosina Journal of Medicine and Biomedical Sciences","randomized_trial","article","10.1055/s-0045-1811568",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0044845","Glucagon Therapy: A Comparison of Current and Novel Treatments","Justin J. Sherman","2020","Diabetes Spectrum","other","article","10.2337/ds19-0076","33223773",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044846","GLP-1 Receptor Agonists for Smoking Cessation: A Systematic Review and Meta-analysis of Randomized Controlled Trials","Amauri De Vargas Junior","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.22820471",null,null,"PROSPERO:CRD420251104504",null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0044847","Twincretins and the Gut Microbiome: The Missing Link","Sami Ullah Mumtaz","2026","Pakistan Journal of Health Sciences","commentary","article","10.54393/pjhs.v7i7.4468",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0044848","Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma","Richard J. Comi","2005","Annals of Internal Medicine","randomized_trial","article","10.7326/0003-4819-143-8-200510180-00012","16230728",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0044849","Tirzepatide (Zepbound) in Human Milk During Periods of Maternal Dosing","Jon S. Thompson","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5387250",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044850","Cardiorenal outcomes of the recently approved antidiabetic drugs in people with Type 2 Diabetes Mellitus in Malaysia: Clinical and economic evaluation","RUTH SIM","2023","Monash University","nonrandomized_study","article","10.26180/24038802",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0044851","Series: Cardiovascular outcome trials for diabetes drugs Lixisenatide and ELIXA","Miles Fisher","2020","British Journal of Diabetes","other_trial","article","10.15277/bjd.2020.241",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0044852","Is prediabetes a cardiovascular risk factor in patients with coronary artery disease?","Gisle Langslet","2023","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwad097","37036914",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0044853","Antidiabetic Pharmacotherapy in Psoriatic Disease: A Comprehensive Systematic Review Across Five Drug Classes","Leah Thomas","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/9trnu",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0044854","T-Cell-Directed Treatment Strategies for Type 1 Diabetes and the Confounding Role of Inflammation","Maria Koulmanda","2010","Immunotherapy","nonrandomized_study","article","10.2217/imt.10.40","20635995",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044855","Liraglutide and Renal Outcomes in Type 2 Diabetes","Ian H. de Boer","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/p8r3-g815",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0044856","Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care 2019;42:1912-1920","M.A. Nauck","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/hmrw-yb89",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0044857","Is semaglutide the magic bullet for liver disease?","Alex Turnbull","2025","Gastrointestinal Nursing","commentary","article","10.12968/gasn.2025.0086",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0044858","Do We Need a New Unifying Theory for Obesity?","Bruce Blumberg","2024","Endocrinology","other","article","10.1210/endocr/bqae029","38546853",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044859","Mechanism of Action and Clinical Analysis of Semaglutide in Weight Loss","Xinyu Yu","2026","MedScien","other","article","10.61173/v87vyz34",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044860","Analysis of the Mechanism of Action and Therapeutic Efficacy of Semaglutide in the Treatment of Type 2 Diabetes Mellitus","Yuhan Min","2026","MedScien","other","article","10.61173/aq4yjk08",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044861","The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial","R. Simpson","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/64ky-dq52",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","TRUE","paywalled","1","FALSE","article"],["R0044862","Does Glucagon‐like peptide‐1 induce Diuresis and Natriuresis by Modulating Afferent Renal Nerve Activity?","Kenichi Katsurada","2018","The FASEB Journal","preclinical","article","10.1096/fasebj.2018.32.1_supplement.598.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044863","Metabolic Syndrome and the Role of GLP‐1 Receptor Agonists in a Model of Postmenopausal PCOS","Edgar D. Torres Fernandez","2018","The FASEB Journal","randomized_trial","article","10.1096/fasebj.2018.32.1_supplement.766.2",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0044864","¿Qué efecto pueden tener fármacos como el Ozempic sobre el envejecimiento?","Sonia de Pascual-Teresa","2026","DIGITAL.CSIC (Spanish National Research Council (CSIC))","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0044865","Prescribing indications, issues and concerns surrounding semaglutide","Aysha Mendes","2024","Journal of Prescribing Practice","other","article","10.12968/jprp.2024.6.9.364",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0044866","Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide","Ripa M.S","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/5kr3-7797",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0044867","The Quiet Window–Challenge Window Framework: A Conceptual Framework for Habit Formation During GLP-1 Receptor Agonist Therapy","Laura Martin","2026","PsyArXiv (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0044868","Giving Leptin a Second Chance","Ania M. Jastreboff","2014","Science Translational Medicine","preclinical","article","10.1126/scitranslmed.3008433",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044869","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92341-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044870","Age-dependent Decline in Beta Cell Proliferation Restricts the Capacity of Beta Cell Regeneration in Mice","Shuen-ing Tschen","2008","eScholarship (California Digital Library)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044871","Reply to Li et al.","Dinah Foer","2023","American Journal of Respiratory and Critical Care Medicine","randomized_trial","article","10.1164/rccm.202310-1721le","37855723",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","letter"],["R0044872","Semaglutide Injection, a GLP1 Agonist, Induced Depression and First Time Suicidal Ideation in a Female with Long-standing Anxiety",null,"2025","Acta Scientific Neurology","nonrandomized_study","article","10.31080/asne.2025.08.0838",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044873","Dipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?","Yong‐ho Lee","2015","Diabetes & Metabolism Journal","randomized_trial","article","10.4093/dmj.2015.39.3.204","26124990",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044874","Antidiabetes medication initiation trends in US adults with cirrhosis and type 2 diabetes: A nationwide study","Tracey G. Simon","2023","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.15052","36938914",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044875","Incretin Therapy and Islet Pathology: A Time for Caution","Steven E. Kahn","2013","Diabetes","nonrandomized_study","article","10.2337/db13-0520","23596147",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044876","Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","M.A. Nauck","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/1h1y-s837",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0044877","Phosphatidic acid: a new therapeutic lead to suppress hepatic glucose production","Anil K. Agarwal","2014","Diabetes Management","preclinical","article","10.2217/dmt.14.29","26413162",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044878","Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction","Giuseppe Biondi‐Zoccai","2024","Journal of Cardiovascular Pharmacology","randomized_trial","article","10.1097/fjc.0000000000001636","39326052",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044879","Focus on the European Society of Cardiology: Guidelines on hypertension, Atlas of cardiovascular disease statistics, and Consensus statement on obesity","Filippo Crea","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae664","39374627",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0044880","Permeation Enhancer-Induced Membrane Defects Assist the Oral Absorption of Peptide Drugs","Severin T. Schneebeli","2025","ChemRxiv","other","article","10.26434/chemrxiv-2025-n24f8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044881","Sitagliptin treatment increases GLP-1 without improving diabetes outcomes after total pancreatectomy with islet autotransplantation","Kendall R. McEachron","2018","American Journal of Transplantation","randomized_trial","article","10.1111/ajt.15119","30230221",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044882","Cardiovascular risk reduction with liraglutide: An exploratory mediation analysis of the leader trial","MARTIN LINDER","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/1rnr-dq63",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","TRUE","paywalled","5","FALSE","article"],["R0044883","Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PioNEER 8 trial","S.T. Hoff","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/1bzn-7t47",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0044884","Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the european association for the study of diabetes (EASD)","J. Fradkin","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/b3bm-af48",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044885","New light shed on the treatment of heart failure and on novel therapeutic targets","Filippo Crea","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae643","39367734",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044886","Weight loss drugs are compared for effectiveness","Jacqui Wise","2016","BMJ","other","article","10.1136/bmj.i3330","27307315",null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0044887","The GLP-1 Revolution: Miracle Drugs, Market Chaos, and the Cost of Slimness","Haixu Mao","2025","MedScien","other","article","10.61173/hpz8h587",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044888","Guideline recommendations and the positioning of newer drugs in type 2 diabetes care","Petrie John R","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/hgsm-aw82",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044889","Response Letter to Gazzaruso and Colleagues","Sei J. Lee","2013","Journal of the American Geriatrics Society","other","article","10.1111/jgs.12192","23581935",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044890","Taste receptor‐mediated duodenal bicarbonate secretion is associated with incretin release in rats","Joon Ho Wang","2010","The FASEB Journal","preclinical","article","10.1096/fasebj.24.1_supplement.1015.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044891","Visceral adiposity, aortic stiffness, and cardiovascular risk","Tomonari Harada","2025","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf516","40796340",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0044892","Age-dependent human beta cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling","Dai, Chunhua","2017","The Journal of the American Medical Association (JAMA) Network (American Medical Association)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044893","Correction: Immuno-inflammatory-metabolic interactions in cardiovascular diseases: a review from basic mechanisms to clinical translation","朱兴顺","2026","Frontiers in Immunology","notice","article","10.3389/fimmu.2026.1924972",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0044894","Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure","Steve Bain","2020","Cronfa (Swansea University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044895","Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201","William T. Cefalu","2017","Diabetes Care","randomized_trial","article","10.2337/dci16-0036","28108540",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044896","Molecular basis of peptide activation of the GLP-1 receptor","Laurence J. Miller","2013","Molecular Metabolism","other","article","10.1016/j.molmet.2013.02.003","24199149",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044897","Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine","Westerhout C.M","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/cm0e-4y75",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0044898","Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin","A.-S. Alexopoulos","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/6gsp-7a34",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0044899","Comparative effectiveness of semaglutide and tirzepatide in patients with type 2 diabetes mellitus","Ghassan Ahmed","2026","Tropical Journal of Pharmaceutical Research","randomized_trial","article","10.4314/tjpr.v25i8.13",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044900","Quantifying Changes In Dietary Intake And Activity During Glucagon-like Peptide 1 Receptor Agonist Therapy","Elizabeth Rose Moore","2026","Medicine & Science in Sports & Exercise","other","article","10.1249/01.mss.0001266064.01904.eb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044901","GLP-1 Receptor Agonists and Disordered Eating: Clinical Indicators and Patient Narratives","S. Schulz","2026","Journal of the Academy of Nutrition and Dietetics","other","article","10.1016/j.jand.2026.156818",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044902","GLP-1 Therapy and the Reshaping of Socioeconomic Gradients in Health","J. Felipe Montano-Campos","2026","National Bureau of Economic Research","nonrandomized_study","article","10.3386/w35296",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","report; preprint"],["R0044903","Semaglutide",null,"2022","Reactions Weekly","other","article","10.1007/s40278-022-16786-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044904","Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial","H.A. Saevereid","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/jxws-kt94",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0044905","Reduction of A1c with Dulaglutide in Type 2 Diabetes (T2D) Patients Positive or Negative for GAD Antibodies (GADA): A Post-hoc Analysis of AWARD-2,-4, and-5","Pozzilli, P","2017","Queen Mary Research Online (Queen Mary University of London)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0044906","Current Status of Semaglutide Injection andDevelopment Prospects in China","Jianqiao Wen","2024","MedScien","other","article","10.61173/qr7sqa05",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044907","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92579-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044908","Exenatide improves myocardial function in a diabetic model before and after myocardial infarction depending on GLUT4","Aylin Aysenur Celik","2026","Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0044909","Long-term Safety Profile of Semaglutide in the Management of Type 2 Diabetes and Obesity","Zhanxu Meng","2025","MedScien","other","article","10.61173/rvr8p069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044910","Insulin-Regulated Glucagon-Like Peptide-1 Release from L Cells: Actin’ Out","Debbie C. Thurmond","2009","Endocrinology","nonrandomized_study","article","10.1210/en.2009-1178","19933397",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044911","The Glucagon‐Like Peptide‐1 (GLP‐1) System is Modulated by Acute and Chronic Exposure to Alcohol: Findings from Human Laboratory and Brain Postmortem Studies","Mehdi Farokhnia","2019","The FASEB Journal","other","article","10.1096/fasebj.2019.33.1_supplement.739.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044912","Central Fructose Impairs Exendin 4‐Mediated Anorexia in the Ventromedial Hypothalamus in Male C57Bl/6 Mice","Melissa A. Burmeister","2018","The FASEB Journal","preclinical","article","10.1096/fasebj.2018.32.1_supplement.766.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044913","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92023-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044914","Glucagon-like peptide-1 (GLP-1) analogues as a novel pharmacotherapeutic approach for alcohol use disorder (AUD)","Palzes, Vanessa","2024",null,"other","article","10.17605/osf.io/qcjh6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044915","Examining Associations Between Intuitive Eating, Duration of GLP-1 Therapy, and BMI Among Adult GLP-1 Receptor Agonist Users: A Pilot Study","S. Linden","2026","Journal of the Academy of Nutrition and Dietetics","other","article","10.1016/j.jand.2026.156782",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044916","Alzheimer und Tumoren – eine komplexe Beziehung","Alexander Kretzschmar","2025","Onkologische Welt","other","article","10.1055/a-2526-4099",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044917","Proteomics for personalized cardiovascular risk assessment: in pursuit of the Holy Grail","Peter Ganz","2020","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaa661","32901246",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0044918","Current status of anti-obesity medications and performance, an EHR based survey","Xiaoyang Ruan","2026","BMC Endocrine Disorders","randomized_trial","article","10.1186/s12902-026-02423-7",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0044919","Exenatide as chronopharmacotherapy for T2DM associated complications","Chacon, Aaron","2024","UKnowledge (University of Kentucky)","preclinical","article","10.13023/etd.2024.433",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044920","The transiency of metabolically healthy obesity: Metabolic decline and atherosclerotic risk","Saeid Mirzai","2024","Diabetes/Metabolism Research and Reviews","other_trial","article","10.1002/dmrr.3765","38598738",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0044921","The gut-kidney axis and inflammation in type 2 diabetes patients","C.M. Mosterd","2026","UvA-DARE (University of Amsterdam)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","other"],["R0044922","The interplay between antidiabetic and lipid-lowering therapies in psoriasis: A narrative review of risks and benefits","C. C. Tsai","2026","Dermatologica Sinica","narrative_review","article","10.4103/ds.ds-d-25-00251",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0044923","Effect of liraglutide on carotid intima-media thickness in patients with type-2 diabetes: a 4-month prospective study","RIZZO, Manfredi","2012","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044924","The Language of Stress: Example - Hunger (Patterned Tension, Anticipatory Relief) (v2.0)","Joshua Pace","2026","Figshare","other","article","10.6084/m9.figshare.31297048.v3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044925","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98208-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044926","History repeating itself: anti-fat narratives in the ozempic and Fen-Phen eras","Erin D. Basinger","2026","Fat Studies","other","article","10.1080/21604851.2026.2632416",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044927","« Malheur à la ville dont le Prince est un enfant ! » (L’Ecclésiaste)","Jean-François Bayart","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044928","Avertissement","Jean-François Bayart","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044929","Pourquoi je ne voterai pas Macron, sans état d’âme","Jean-François Bayart","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044930","Pourquoi je voterai Macron par défaut, mais sans état d’âme","Jean-François Bayart","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044931","Cardiovascular and kidney outcomes of semaglutide and the annual eGFR slope in adults with and without type 2 diabetes: data extraction sheet, analysis code and search records for a systematic review and meta-analysis of randomised controlled trials","Peichen Zhang","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.22841839",null,null,"PROSPERO:CRD420261496524",null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0044932","Counterfeit retatrutide product causes serious AEs",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97979-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044933","Abstract Book of 1st Neuro-Cell Molecular Research Congress-Oral Presentations","NCMR Congress","2026","Neuro-Cell Molecular Research","nonrandomized_study","article","10.66588/ncmr.3.sp1.2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0044934","Clinical outcomes of overweight and obese patients in a lifestyle medicine clinic at PHCC, Riyadh, Saudi Arabia, December 2024: a retrospective observational study","Sulaiman Alahmad","2026","International Journal of Medicine in Developing Countries","nonrandomized_study","article","10.24911/ijmdc.51-1754435066",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044935","NEW AUDIO INTERVIEW - Camilo Fernández Bravo, MD/PhD/FACC, Editor in Chief, on the Future of Clinical and Translational Cardiology","Camilo Fernández Bravo","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22845623",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0044936","La tentation bonapartiste","Jean-François Bayart","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044937","Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023:a systematic analysis for the Global Burden of Disease Study 2023","Disease and Injury and Risk Factors Collaborators inc., GBD 2023","2025","Aston Publications Explorer (Aston University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044938","Weekly Journal Scan: a ‘thousand-mile’ journey in obesity-related heart failure treatment begins with a few STEPs","Daniela Pedicino","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae427","38985014",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044939","Heart failure and ischaemic heart disease: new challenges and opportunities","Filippo Crea","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae497","39121015",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0044940","Introduction","Jean-François Bayart","2017","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044941","Cohesive Environment as Predictable Rhythm: A Prevention Framework for the Hypoxic Cascade","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22841517",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044942","Budget impact of GLP-1 and dual GIP/GLP-1 receptor agonists for obesity management in Saudi Arabia: a budget impact analysis from public and private payer perspectives","Ali Alshahrani","2026","BMC Health Services Research","nonrandomized_study","article","10.1186/s12913-026-15623-7",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044943","Ultra Processed Foods, Metabolic Syndrome, and the Pharmaceutical Burden: A Global Paradox","Muhammad Bashir","2025","Pakistan BioMedical Journal","nonrandomized_study","article","10.54393/pbmj.v8i6.1256",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044944","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-96811-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044945","Que le terme plaise ou non, il y a bien une islamophobie d’État en France","Jean-François Bayart","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044946","Jupiter et l’Aquarius","Jean-François Bayart","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044947","GLP-1 Receptor Agonists and the Risk of Upper Gastrointestinal Tract Disorders: Protocol for a Systematic Review of Observational Studies","Mina Ashraf Tawfik Goher","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/udp26",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0044948","Pages de début","Ève Bergeron","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044949","Le sparadrap du capitaine Macron","Jean-François Bayart","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044950","Comparative Effectiveness of Diabetes Drugs: The Use and Misuse of Observational Research","Steven E. Nissen","2023","Annals of Internal Medicine","randomized_trial","article","10.7326/m23-0958","37155989",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0044951","Semaglutide",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-78179-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044952","Liraglutide-Induced Injection Site Reaction","NadaFouda Neel","2019","Journal of Dermatology & Dermatologic Surgery","other","article","10.4103/jdds.jdds_5_19",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044953","Quantities of GLP-1 mimetics","Janice Davies","2020","Journal of Prescribing Practice","other","article","10.12968/jprp.2020.2.3.120",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044954","Research roundup: June 2014","Mark Greener","2014","Nurse Prescribing","other","article","10.12968/npre.2014.12.6.270",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0044955","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98207-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044956","Lifelong impact of adiposity on cardiac structure and function: an alarming signal","Leonardo Roever","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae443","39013546",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044957","Worksite Health Promotion and the ACSM Consensus Statement on Physical Activity and Excess Body Weight and Adiposity","Nico Pronk","2025","Translational Journal of the American College of Sports Medicine","other","article","10.1249/tjx.0000000000000291",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044958","Sa2109 TRIPLE AND DUAL INCRETIN CO-AGONISTS DEMONSTRATE SUPERIOR HISTOLOGIC AND RADIOGRAPHIC EFFICACY COMPARED TO GLP-1 MONO-AGONISTS IN MASLD: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS","Saad Masood","2026","Gastroenterology","systematic_review","article","10.1016/s0016-5085(26)03644-9",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0044959","Therapeutic innovations for type 2 diabetes: if Nature is the solution?","Kwapich, Maxime","2020","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.4401965",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044960","Sa2090 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN COMPENSATED CIRRHOSIS DUE TO MASLD: SURVIVAL BENEFITS WITHOUT IMPROVEMENT ON HEPATIC DECOMPENSATION","Gustave Reese Gottlieb","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03556-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0044961","Sa2089 EFFECT OF STATIN USE ON THE CLINICAL EFFECTIVENESS OF SEMAGLUTIDE IN MASLD/MASH: A PROPENSITY SCORE-MATCHED ANALYSIS","Yazan Al Jabiri","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03555-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0044962","Additional file 1 of Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey","Isabelle Sundell","2026","Figshare","other","article","10.6084/m9.figshare.33171264.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044963","Longitudinally Extensive Transverse Myelitis Potentially Induced by Semaglutide: A Case Report","Andrija Kostic","2025",null,"case_report","article","10.22541/au.176231533.35713430/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044964","594 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS VERSUS SLEEVE GASTRECTOMY FOR MORBID OBESITY: A TARGET TRIAL EMULATION STUDY","Yussif Issaka","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)05966-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044965","EFEITOS DOS AGONISTAS DO RECEPTOR GLP-1 NA REDUÇÃO DE PESO EM ADULTOS COM OBESIDADE","Caio Henrique Correa Alves","2026","Periódicos Brasil Pesquisa Científica","other","article","10.36557/2674-9432.2026v5n4p1636-1659",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044966","EP560 - ECE_2371 - Muscle function in adults with class III obesity receiving liraglutide vs tirzepatide","Maria Evangelia Koloutsou","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1021",null,null,"ClinicalTrials.gov:NCT07094568","S000828","openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0044967","Abstract TH929: GLP-1 Receptor Agonist Medication Use Persistence in the All of Us Research Program","George Hatzis","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.th929",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0044968","Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Cirrhosis","H AHMED","2026","ASIDE Gastroenterology","nonrandomized_study","article","10.71079/aside.gi.072726751",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044969","Case Studies in Successful Polypeptide Therapeutics","Nahla Sameh Tolba","2026",null,"other","article","10.1201/9781003653196-11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0044970","AI-Enabled Personalization of Semaglutide Therapy in Type 2 Diabetes: Systematic Review With an Integration Framework (Preprint)","Ghinwa M. Barakat","2025",null,"systematic_review","article","10.2196/preprints.86960",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0044971","Endoscopic Safety and Risk of Retained Gastric Content in Patients Treated with GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis","pofeng huang","2026",null,"systematic_review","article","10.37766/inplasy2026.2.0033",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0044972","P8 COMPARATIVE EFFECTIVENESS OF GLP-1RA AND SGLT2I IN PATIENTS WITH DIABETIC KIDNEY DISEASE: A TARGET TRIAL EMULATION","Kai‐Cheng Chang","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.023",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044973","Anti-inflammatory and direct antifibrotic effect of the oral hepatotropic DPP4 inhibitor Linagliptin in model of bilary fibrosis and NASH","Xianyao Wang","2013","Zeitschrift für Gastroenterologie","preclinical","article","10.1055/s-0033-1352814",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044974","Outcomes with GLP-1RAs in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-analysis. (S20.007)","Mohamed Saad Sayed","2026","Neurology","systematic_review","article","10.1212/wnl.0000000000217270",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0044975","Additional file 1 of Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes","Denimal, Damien","2023","Figshare","other","article","10.6084/m9.figshare.22767305",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044976","The Impact of GLP-1 Receptor Agonists on Women's Reproductive Health: A Review","Marta Wolszczak","2025","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2025.82.60194",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044977","1886-LB: A Novel Antibody–Peptide Conjugate Targeting PCSK9,GLP-1R,GCGR,GIPR Improves Cardiovascular Risk Markers in Preclinical Study","DECHENG REN","2025","Diabetes","preclinical","article","10.2337/db25-1886-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044978","Effect of Tirzepatide on Blood Pressure in Patients with High Salt Intake","Daiki Shioya","2025","Clinical Diabetology","other","article","10.5603/cd.105945",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044979","Fmoc-His-Aib-OH as a Semaglutide Precursor: Efficient One-Pot Synthesis and Computational Insights","Karuna Sree Kunta","2026","Polycyclic aromatic compounds","other","article","10.1080/10406638.2026.2621953",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044980","CLINICAL PHARMACOLOGY OF HYPOGLYCEMIC DRUGS","Rayimnazarov Shaxzot Muhiddin o'g'li","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.10544051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044981","OUTCOME-DIRECTED USE OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS IN TYPE 2 DIABETES","Didar Muratbek","2026",null,"randomized_trial","article","10.70286/eoss-27.07.2026.014.167-176",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0044982","GLP 1 RECEPTOR AGONISTS AND THEIR EFFECTS ON REWARD AND COMPULSIVE BEHAVIORS","Anita Pieńkowska","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.1(49).2026.4826",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044983","Relationship between glomerular hyperfiltration and diabetic nephropathy progression: pathophysiological mechanisms, clinical evidence, and therapeutic perspectives","Flaubert Sena de Medeiros Filho","2025","Brazilian Journal of Health Review","nonrandomized_study","article","10.34119/bjhrv8n2-146",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0044984","Patent landscape analysis of anti-obesity pharmacotherapy: Mechanisms, assignees, and international filing strategies","Lucas Antônio dos Santos Barbosa","2026","World Patent Information","nonrandomized_study","article","10.1016/j.wpi.2026.102488",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044985","The widespread adoption of glucagon-like peptide-1 receptor agonists in the management of obesity and its implications for the anaesthesiologist and intensivist: A narrative review","Taylor E. Browning","2025",null,"nonrandomized_study","article","10.25259/peak_19_2024",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0044986","Jalleh et al. JCEM 2024 Online Supplement","Jalleh, Ryan","2024","Figshare","other","article","10.6084/m9.figshare.26540737.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044987","Rosiglitazone: A Thunderstorm from Scarce and Fragile Data","Cynthia D. Mulrow","2007","Annals of Internal Medicine","randomized_trial","article","10.7326/0003-4819-147-8-200710160-00013","17938398",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0044988","Covid-19 and diabetes - a bidirectional relationship?","Maria Moța","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044989","Involvement of Cyclic AMP Response Element (CRE) in Exendin‐4 Induction of Rat Egr‐1 Gene","Jung‐Hoon Kang","2006","The FASEB Journal","preclinical","article","10.1096/fasebj.20.5.lb68-c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044990","current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)","Justyna Lipińska","2024","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2024.59.011",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0044991","1067-P: Trends in Medical Expenditures before and after Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) Initiation in U.S. Adults Aged 18–64 Years with Type 2 Diabetes (T2D) and Commercial Insurance","Yixue Shao","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1067-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044992","Exendin-4 and exendin (9-39)NH*U2-agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1 (7-36)NH*U2","W. Schepp","1994","Research at the University of Copenhagen (University of Copenhagen)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044993","Glucagon-Like Peptide-1 Receptor Agonists and Psychiatric Hospitalization in People with Diabetes and Pre-Existing Mental Illness: A National Self-Controlled Study","Belle Tamir Brahms","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7205611",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0044994","1917-LB: Association of FreeStyle Libre Utilization and Glycemic Outcomes among People with Type 2 Diabetes Treated with Basal Insulin and GLP-1RAs","EILEEN HUANG","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1917-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0044995","THU-531 DA-1241, a GPR119 agonist, combined with Semaglutide synergistically improved liver fibrosis in mice with CCl4-induced liver fibrosis","Il Hoon Jung","2024","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(24)00977-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0044996","Microwave-Assisted Solid Phase Synthesis of GLP-1-Analogues","Yushi Chi","2008","Letters in Organic Chemistry","other","article","10.2174/157017808784872061",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0044997","Shots for Sobriety: GLP-1 RAs in Substance Use and Metabolic Dysregulation: A Narrative Review","Amir Mullick","2026","Figshare","narrative_review","article","10.6084/m9.figshare.33945826.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0044998","The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities","E.N. Ostroukhova","2012","Problems of Endocrinology","other","article","10.14341/probl201258351-55",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0044999","0525 Glucagon-Like Peptide-1 Receptor Agonists, Obstructive Sleep Apnea, and Mortality in Patients with Type 2 Diabetes: The First 10 Years","Diana Song","2026","SLEEP","other","article","10.1093/sleep/zsag091.0524",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045000","Is thirst the missing physiological link between SGLT2 inhibitors and reduced nephrolithiasis risk?","Marco Lombardi","2026","Clinical Kidney Journal","randomized_trial","article","10.1093/ckj/sfag133","42147789",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0045001","870-P: Empagliflozin and the Risk of Gout—Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","Helen Tesfaye","2023","Diabetes","nonrandomized_study","article","10.2337/db23-870-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045002","Evaluation of protein content in seed material of somaclonal soybean lines","Galina Kodirova","2020","Far Eastern Agrarian Herald","preclinical","article","10.22450/1999-6837-2020-3-41-47",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045003","Protection-Free Site-Directed Peptide or Protein S -Glycosylation and Its Application in the Glycosylation of Glucagon-like Peptide 1","Gefei Li","2021","CCS Chemistry","preclinical","article","10.31635/ccschem.021.202101115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045004","Impact of baseline heart failure status on glucagon-like peptide-1 receptor agonists heart failure-related outcomes in type2 diabetes:a systematic review and meta-analysis of seven cardiovascular outcome trials","Jian Cheng Cao","2023",null,"systematic_review","article","10.37766/inplasy2023.6.0016",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045005","Su1129 ASSOCIATION OF GLP-1 RECEPTOR AGONISTS WITH ACCELERATED PROGRESSION OF NON-DYSPLASTIC BARRETT’S ESOPHAGUS: A POPULATION-LEVEL RETROSPECTIVE MATCHED COHORT STUDY","Rishi Chowdhary","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)02014-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045006","Corrigendum to “The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis” [Pharmacol. Res. (2018) 102–111]","Yakun Li","2018","Pharmacological Research","other","article","10.1016/j.phrs.2018.06.018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0045007","Additional file 1 of The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis","Kezia Peter","2026","Figshare","systematic_review","article","10.6084/m9.figshare.32142834.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0045008","555 CANCER RISK AFTER THERAPEUTIC GLP-1 RECEPTOR AGONIST USE COMPARED WITH BARIATRIC SURGERY AND OTHER WEIGHT-LOSS DRUGS","Elio R. Bitar","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04789-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045009","Semaglutide for weight management in adults","Steve Chaplin","2023","Prescriber","other","article","10.1002/psb.2066",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045010","Tirzepatide: A dual action approach to weight reduction and glycemic control in type 2 diabetes mellitus","Princy Domnic Dsouza","2025","MGM Journal of Medical Sciences","other","article","10.4103/mgmj.mgmj_386_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045011","Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review","Michał Rabenda","2024","Quality in Sport","narrative_review","article","10.12775/qs.2024.20.53995",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045012","The Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists on Peripheral Neuropathy Among Diabetic Patients: A Systematic Review","Dr Sara Mahmoud Humaida","2026","SAS Journal of Medicine","systematic_review","article","10.36347/sasjm.2026.v12i02.006",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045013","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Pediatric Obesity","Özde KURAN","2026","Current Treatment Options in Pediatrics","other","article","10.1007/s40746-026-00370-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045014","Thirzepatide. A novelty in the treatment of obesity - literature review","K Wiśniewska","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.15.52005",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045015","Semaglutida no tratamento do diabetes mellitus tipo 2: evidências clínicas além do controle glicêmico","Dayane da Silva","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18705043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045016","Danuglipron: pioneering oral glucagon-like peptide-1 receptor agonists paving the way forrevolutionizing diabetes treatment","Jinrong Hu","2025","Elsevier eBooks","other","article","10.1016/b978-0-443-33885-4.00044-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045017","Safety of exenatide for type 2 diabetes: a systematic review","Tang Yao","2011","Chinese Journal of Hospital Pharmacy","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0045018","Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model","In Young Choi","2018","Diabetes","preclinical","article","10.2337/db18-1106-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045019","Effects of Liraglutide on Endothelial Function and Immune Function in Elderly Patients with Type 2 Diabetes Mellitus Complicated with Hyperlipidemia","Pan Chang","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045020","S746 Pharmacogenomic Analysis of the GLP-1 Receptor in a Phase 2 Trial of Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, in Adults With Obesity","Matthias Blüher","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001130444.00553.d1",null,null,"ClinicalTrials.gov:NCT04667377","S002375","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0045021","Transkript zur Episode „HFpEF“","Denis Nößler","2025","EvidenzUpdate","other","article","10.69156/trx.001/2025.09.00151",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045022","GLP-1 Agonist as an effective add-on basal-bolus therapy in type 2 diabetic patients","Andreja Marić","2019","Endocrine Abstracts","other","article","10.1530/endoabs.63.p983",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045023","Tirzepatide protects against hepatic oxidative stress in high-fat induced obesity in male rats","Ashraf Jameel Alathary","2024","Maaen Journal for Medical Sciences","preclinical","article","10.55810/2789-9136.1053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045024","Glucagon Stimulation Test and Insulin Secretory Capacity in Clinical Assessment of Incretin-Based Therapy for Diabetes","Takuya Haraguchi","2024",null,"nonrandomized_study","article","10.2337/figshare.26836057",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0045025","Additional file 2 of Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review","Dave Osinachukwu Duru","2026","Figshare","narrative_review","article","10.6084/m9.figshare.32787545",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045026","S850 Bowel Preparation Quality and Colonoscopy Safety With Glucagon-Like Peptide 1 Receptor Agonists vs Diabetes Mellitus: A Case-Control Study From a Large Tertiary Care Health System","Vismaya S. Bachu","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032768.58705.8c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045027","Tirzepatide - an innovative treatment for diabetes and obesity","Krystian Żuk","2025","Medycyna Ogólna i Nauki o Zdrowiu","other","article","10.26444/monz/205172",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045028","S1768 The Efficacy of GLP-1 Agonists in the Management of MASH in an Appalachian Cohort","Omar Almetwali","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001036440.35710.e8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045029","FC 128: Novel Glucose-Lowering Drugs and the Risk of Acute Kidney Injury in Routine Care: The Stockholm Creatinine Measurements (SCREAM) Project","Jim Alkas","2022","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfac127.002",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045030","Glucagon-Like Peptide-1 Receptor Agonist potential in AUD treatment. Neurobiological Mechanisms and Clinical Evidence","Paulina Wądołowska","2026","Medical Science","randomized_trial","article","10.54905/disssi.v30i169.e49ms3791",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045031","Additional file 2 of The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis","Kezia Peter","2026","Figshare","systematic_review","article","10.6084/m9.figshare.32142840",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0045032","Efficacy and Dataset and PRISMA checklist for Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials","Ahmad Hassan","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21447435",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0045033","Experiences of GPs with incretin mimetics: a qualitative study in Germany","Amelie Ege","2026","data_UMR","other","article","10.17192/openumr/953",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0045034","EP1835 - LBA_ECE_1329 - Reversible nyctalopia from severe vitamin A deficiency and effective management of late weight regain with semaglutide after malabsorptive biliopancreatic diversion: a dual-outcome case report","Borja Santana-Ojeda","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1855",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045035","Assessment by baseline HbA1c of key outcomes for once weekly dulaglutide versus insulin glargine, both with prandial insulin lispro, in patients with type 2 diabetes from the Assessment of Weekly AdministRation of dulaglutide in Diabetes 4 (AWARD-4) study","O Adetunji","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549747",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045036","Changes in Body Composition, Regional Fat Distribution, and Metabolism After Stopping Tirzepatide","Evelyn Yandle","2026","Metabolism","other","article","10.1016/j.metabol.2026.156545",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045037","Long-Acting Glucagon-Like Peptide-1 Receptor Agonist-Induced Rheumatoid Arthritis in a Patient with Type 2 Diabetes Mellitus","Koji Kikkawa","2021","Dubai Diabetes and Endocrinology Journal","other","article","10.1159/000519008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045038","Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial (NCT02058147)","Ronnie Aronson","2016","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2016.08.126",null,null,"ClinicalTrials.gov:NCT02058147","S001199","openalex","FALSE","paywalled","5","FALSE","article"],["R0045039","Glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors combination therapy after acute myocardial infarction in patients with type 2 diabetes mellitus: a dynamic duo","M Vidak","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.1801",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045040","We are looking at the wrong place: Exercise beyond muscle mass preservation during incretin-based therapies","Nathan Muci Aguiar","2026","Obesity Medicine","other","article","10.1016/j.obmed.2026.100743",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045041","Research Progress of Long-acting Exendin-4","Jianhua Chen","2013","Xiandai shengwu yixue jinzhan","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045042","44-PUB: Evaluation and Care of Double Diabetes in Asian American Patients","Ying Liu","2026","Diabetes","nonrandomized_study","article","10.2337/db26-44-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045043","Manejo das complicações renais e cardiovasculares em diabetes tipo 2: uma análise comparativa entre inibidores de SGLT2 e agonistas de GLP-1","Camila Moreira Silva","2025","Brazilian Journal of Health Review","other","article","10.34119/bjhrv8n2-030",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045044","Managing Glaucoma in an Evolving Clinical Landscape","Coy Steel","2026",null,"other","article","10.61440/joor.2026.v2.11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045045","How to Classify Type 2 Diabetes Mellitus and Approach its Treatment in View of Associated Diabetes and Complications-A Short Communication","Kulvinder Kochar Kaur","2019","Series of Endocrinology Diabetes and Metabolism","other","article","10.54178/jsedmv1i2002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045046","How do Dual GLP-1/GIP Receptor Agonists Differ from GLP-1 Agonists for Diabetes Management: A Systematic Review","Prisha Bhat","2026","Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","systematic_review","article","10.26685/urncst.1029",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045047","Surgical Outcomes Of Patients Receiving GLP-1 Receptor Agonists Undergoing Breast Reduction Surgery: A Propensity Score-matching Analysis","Diane Saab","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20087075",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0045048","Glucagon-like peptide-1 (GLP-1) receptor agonist as cardio- and nephroprotection in a patient with diabetic kidney disease and proximal myotonic myopathy type 2 (PROMM MD2)","Danilo Radunović","2024","Rad Hrvatske akademije znanosti i umjetnosti Medicinske znanosti","other","article","10.21857/m16wjcw7d9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045049","DB20 Maintenance strategies following GLP-1/GIP-based obesity pharmacotherapy: a systematic review and exploratory meta-analysis","L Mlaćo Skenderi","2026","European Journal of Endocrinology","systematic_review","article","10.1093/ejendo/lvag128.028",null,null,"PROSPERO:CRD420261411350",null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0045050","Tirzepatide - a promising medication for cardiovascular protection and treatment of Type 2 diabetes and obesity","Pavlína Piťhová","2025","Vnitřní lékařství","other","article","10.36290/vnl.2025.009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045051","From GLP-1 Agonism to Triple-Receptor Therapy. Narrative Review of Semaglutide, Tirzepatide, and Retatrutide in Obesity Management.","Jerzy Darmoń","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.54.70772",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0045052","Change in Peripheral Apnea-Hypopnea Index (pAHI), and Body Weight in Participants With Moderate-to-Severe OSA With Obesity From Surmount-OSA","Atul Malhotra","2025","American Journal of Respiratory and Critical Care Medicine","randomized_trial","article","10.1164/ajrccm.2025.211.abstracts.a5288",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0045053","26-A-21519-ACC COMPARATIVE ANALYSIS OF MORTALITY OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS TREATED WITH TIRZEPATIDE VERSUS SEMAGLUTIDE AND STANDARD THERAPY","T P Fedrigoni","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.1709",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045054","WILL YOU CARE FOR ME","Tharsini Sarvanandan","2025","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.040.s1.209",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045055","Dulaglutide, a glucagon-like peptide-1 receptor agonist: in the search for survival molecule","Ametov As","2020","Endocrinology News Opinions Training","other","article","10.33029/2304-9529-2020-9-2-49-58",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045056","A person with diabetes as a patient - basic rules of conduct","Monika Prylińska","2019","Nicolaus Copernicus University Repository (Nicolaus Copernicus University)","other","article","10.5281/zenodo.3386701",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045057","Differential Cardiometabolic Effects of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Early-Onset Type 2 Diabetes: A Randomized Controlled Trial","Marriam Abid","2026","DOAJ (DOAJ: Directory of Open Access Journals)","randomized_trial","article","10.61919/061x6w21",null,null,null,null,"openalex","FALSE","free_to_read","2","FALSE","article"],["R0045058","Painless thyroiditis induced by the cessation of a dipeptidyl peptidase-4 inhibitor","Ryota Uehara","2018","Annals of Thyroid","other","article","10.21037/aot.2018.10.06",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045059","1752-P: GDF11 Involved in Expressed MicroRNAs during GLP-1RA Inhibited Adipogenesis","Peng Xue","2019","Diabetes","other","article","10.2337/db19-1752-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045060","Non-Invasive Tests in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Diagnosis to Treatment Monitoring","H O Lee","2026","Clinical Ultrasound","other_trial","article","10.18525/cu.2026.11.1.1",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0045061","Menopause, obesity, and incretin therapy: new horizons in the fight for women's metabolic health","F. O. Ushanova","2025","Women s Health and Reproduction","other","article","10.31550/2712-8598-2025-4-8-zhzir",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045062","A Delicate Balance","Ami Schattner","2026","Journal of the American Geriatrics Society","other","article","10.1111/jgs.70371","41783991",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045063","Comparative effectiveness of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis with intervention ranking","I Khalil","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.4321",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0045064","Review of Efficacy and Safety of Semaglutide in the Management of Obesity","Seunghoon Han","2024","Korean Journal of Clinical Pharmacy","narrative_review","article","10.24304/kjcp.2024.34.1.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045065","Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus","Hua Pan","2017","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2017.12.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045066","An Overview on Tirzepatide, Dual-Targeted Treatment for Diabetes and Obesity","Dinesh Kumar G","2022","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7420605",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045067","Cytotoxicity and anti-inflammatory properties of a GLP-1 receptor agonist in a model of human peripheral blood mononuclear cell culture","Marija Drakul","2024","Биомедицинска истраживања","preclinical","article","10.59137/bii202401345d",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045068","Effects of liraglutide on eNOS and IRS-1 expressions in human umbilical vein endothelial cells cultured with high glucose","Ling Yue","2016","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2016.04.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045069","A rare case of tirzepatide-induced liver injury","Radhika Sudhir","2026","Journal of Medicine and Therapeutics","other","article","10.15761/jmt.1000151",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045070","Sa1437: GLP-1 RECEPTOR AGONIST IN ACUTE PANCREATITIS, CHRONIC PANCREATITIS AND PANCREATIC DUCTAL ADENOCARCINOMA: A POPULATION-BASED STUDY IN THE UNITED STATES","Thai Hau Koo","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)02015-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045071","Eventos adversos gastrointestinais associados aos agonistas do receptor de GLP-1: Prevalência e fatores de risco – uma revisão sistemática","Kelly Cristina de Amorim da Silva","2026","Journal of Medical and Biosciences Research.","other","article","10.70164/jmbr.v3i4.1315",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045072","WHO WINS THE WAR AGAINST DIABETES? COMPARATIVE EFFICACY OF TIRZEPATIDE, SEMAGLUTIDE, AND PLACEBO IN DIABETES CONTROL: A NETWORK META-ANALYSIS","Júlia Cremonini Bernardi","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(25)01067-8",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0045073","Effects of exendin-4 on expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in renal tissue of type 2 diabetic rats","Li Xiu","2009","Di-Si Junyi Daxue xuebao","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045074","Additional file 1 of Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review","Dave Osinachukwu Duru","2026","Figshare","narrative_review","article","10.6084/m9.figshare.32787542.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045075","Poster presented at EASL 2026. Treatment effects of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, on hepatic biomarkers in patients with compensated and decompensated cirrhosis","Eric Lawitz","2026","Boehringer Ingelheim","other","article","10.60915/boehringer-figshare.32158932.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0045076","Real-world outcomes of SGLT2 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus: An effectiveness and safety analysis","Ricardo E T Navarrete","2026","Diabetes Epidemiology and Management","nonrandomized_study","article","10.1016/j.deman.2026.100302",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045077","Incretin-based therapy under pricing pressure: clinico-economic perspectives and role of biosimilar glucagon-like peptide-1 receptor agonists","S. A. Kosobutskaya","2026","FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","nonrandomized_study","article","10.17749/2070-4909/farmakoekonomika.2026.363",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045078","GLP-1 FAERS Pharmacovigilance Pre-registration 2024","Igor Eduardo","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/hrcn6",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other; preprint"],["R0045079","767-P: A Phase 1b/2a Study of the Safety and Tolerability of GSBR-1290, a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA), in Healthy Overweight/Obese Volunteers (HOV) and Participants with Type 2 Diabetes Mellitus (T2DM)","Blai Coll","2024","Diabetes","nonrandomized_study","article","10.2337/db24-767-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045080","Weight loss from GLP-1 receptor agonists and facial ptosis: Specific mechanism or epiphenomenon of weight loss? A critical review","Ana Beatriz Neves Felix","2026","Brazilian Journal of Science","narrative_review","article","10.14295/bjs.v6i3.948",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045081","Semaglutide Mitigates Doxorubicin-Induced Hepatic and Renal Damage: Functional, Anti-Inflammatory, and Histopathological Insights","Raz Muhammed HamaSalih","2026","Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )","preclinical","article","10.54133/ajms.v10i1.2626",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045082","USO INDISCRIMINADO DA TIRZEPATIDA (MOUNJARO®): ANÁLISE DAS PRINCIPAIS REAÇÕES ADVERSAS","Ana Carolina Cavalheiro Manarelli","2026","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v12i2.24084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045083","Management of Life-Threatening Obesity and Type 2 Diabetes Mellitus in Prader-Willi Syndrome Using a Combination Therapy of Semaglutide and Methylphenidate","Shiga Chirayath","2024","Annals of Case Reports","other","article","10.29011/2574-7754.101594",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045084","Effects of liraglutide on the differentiation of human bone marrow mesenchymal stem cells into insulin producing cells","Chen Pin","2012","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2012.05.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045085","Obesity | Causes, Treatments and Anti-Obesity Medications","Rochana Acharya","2025","˜The œAmerican journal of patient health info.","other","article","10.69512/ajphi.v2i3.96",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045086","Glucagon-like Peptide-1 Receptor Agonists, Immunomodulation, and Autoimmune Phenomena: A Mechanistic and Epidemiological Synthesis","Jason Kreger","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6599858",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045087","Impact of hormonal and metabolic disturbances on aging: evaluation of GLP-1 mimetics, DPP-4 inhibitors, nutraceutical compounds, and exercise-like interventions in Caenorhabditis elegans","Péterson Alves Santos","2025",null,"other_trial","article","10.17605/osf.io/nd3hr",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0045088","Advances and Future Directions in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes: Efficacy, Safety and Cardiometabolic Benefits","Abdulkadir Abdu","2026","International Journal of Applied Biology and Pharmaceutical Technology","nonrandomized_study","article","10.26502/ijabpt.202144",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045089","Změny hmotnosti a kompenzace diabetu (HbA1c) u nemocných s diabetes mellitus 2. typu po přidání exenatidu (Byetta) ke stávající léčbě ve 28 diabetologických ambulancích v ČR - studie BIBY-I (sledování 3-12 měsíců)","Jindra Perušičová","2013","Vnitřní lékařství","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045090","(272) GLP-1 Agonists and Testosterone Deficiency: A Systematic Review of Clinical and Preclinical Evidence","Abuzar Mahmood","2025","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdaf320.268",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0045091","Poor Access to Anti-Obesity Medications in Metabolic Dysfunction-Associated Steatotic Liver Disease","Sophia Hurr","2026","North Carolina Medical Journal","nonrandomized_study","article","10.18043/001c.154980",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045092","ROLE OF GLUCAGON-LIKE PEPTIDE TYPE 1 ANALOGUES ON HYPOTHALAMUS-PITUITARY TESTIS AXIS AND SEXUAL FUNCTION IN MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS","G Corona","2025","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdaf077.063",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0045093","EARLY REAL-WORLD EVIDENCE FOR THE USE OF ORAL SEMAGLUTIDE IN A TERTIARY CENTRE IN MALAYSIA","Jun Kit Khoo","2025","Journal of the ASEAN Federation of Endocrine Societies","randomized_trial","article","10.15605/jafes.040.s1.203",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045094","LONG-TERM METABOLIC AND HORMONAL EFFECTS OF EXENATIDE ON ISLET TRANSPLANT RECIPIENTS WITH ALLOGRAFT DYSFUNCTION","Tatiana Froud","2008","Transplantation","other","article","10.1097/01.tp.0000331456.85449.d6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045095","72852 Anatomic Site Matters: Protective Effects of GLP-1 Agonists on Mohs Surgical Healing","Paola Ramirez","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.211",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045096","Comparative effectiveness on all-cause mortality for treatment with GLP1ra, SGLT2i and DPP-IVi in comorbid schizophrenia and type 2 diabetes: A Danish nationwide target-trial emulation study","Søren Lundorff Jacobsen","2024","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","preprint"],["R0045097","1733-P: Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight","STANLEY HSIA","2026","Diabetes","randomized_trial","article","10.2337/db26-1733-p",null,null,"ClinicalTrials.gov:NCT06124807","S001915","openalex","FALSE","paywalled","1","FALSE","article"],["R0045098","Comparative efficacy and safety of Dual GIP/GLP1 agonists versus GLP1 receptor agonists for weight loss: A Scoping Review","Riya Patil","2026","Journal of Advances in Internal Medicine","nonrandomized_study","article","10.3126/jaim.v15i1.98486",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045099","Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice","Binghua Xue","2020","Research Square","preclinical","article","10.21203/rs.3.rs-25980/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045100","GLP-1 receptor agonist usage for obesity in medium chain acyl-COA dehydrogenase deficiency","Olivia D'Annibale","2026","Molecular Genetics and Metabolism","other","article","10.1016/j.ymgme.2026.109981",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045101","Su2115 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH REDUCED RISK FOR CIRRHOSIS AND RELATED COMPLICATIONS IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS","Faith Morley","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)03813-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045102","Uncoupling weight regain and glycemic control: post-cessation effects of alternate-day fasting and semaglutide treatment in MS-NASH mice","Carina Sun","2026","Physiology","randomized_trial","article","10.1152/physiol.2026.41.s1.2299519",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045103","1216-P: Prevalence of SGLT2i and GLP1RA Use among U.S. Adults with Type 2 Diabetes","CHRISTINE LIMONTE","2022","Diabetes","other","article","10.2337/db22-1216-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045104","Beyond GLP ‐1","Zachary Bloomgarden","2026","Journal of Diabetes","other","article","10.1111/1753-0407.70204","41784368",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045105","714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism","Kieren J. Mather","2022","Diabetes","randomized_trial","article","10.2337/db22-714-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045106","Adverse Events of GLP-1 Receptor Agonists for Weight Loss: Twitter and a National Pharmacovigilance Database","Hyun-Myung Back","2023","Drug Targets and Therapeutics","nonrandomized_study","article","10.58502/dtt.23.0003",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045107","Ozempic, Travel, and Troublesome Diarrhoea: Lessons from a Transplant Case","Taha Kaan Isleyici","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19409788",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045108","EFFECTIVENESS AND PERSISTENCE OF GLP-1 RECEPTOR AGONIST TREATMENT AMONG PEOPLE WITH TYPE 2 DIABETES","Lakshna Vani Nadarajan","2025","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.040.s1.212",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045109","用Network Meta分析系统评价GLP-1受体激动剂类降糖药的心血管安全性","孙凤","2012","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045110","Evaluating novel therapeutics in type 2 diabetes: a systematic review and meta-analysis of bexagliflozin and tirzepatide","Jia Shi","2025","Turkish Journal of Biochemistry","systematic_review","article","10.1515/tjb-2024-0393",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045111","The Cardioprotective Effects of Semaglutide in Obese Patients: Literature Review","Eduarda Giaquinto Herkenhoff Pinheiro","2024","Journal of Medical Residency Review","narrative_review","article","10.37497/jmrreview.v3i00.59",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045112","Clinical Efficacy Evaluation and Long-Term Prognosis of Glucagon-Like Peptide-1 Combined with Sodium Glucose Cotransporter-2 Inhibitor in Diabetes","Yan Pi","2022","Indian Journal of Pharmaceutical Sciences","other","article","10.36468/pharmaceutical-sciences.976",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045113","A Convolutional Neural Network (CNN) Analysis of Liver Histology Images to Predict Response to GLP-1 Agonists in NASH","K. Shoba and B. C. Surekha Merwin Paul. R","2026",null,"nonrandomized_study","article","10.1109/icmsci67830.2026.11469554",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0045114","USO CRESCENTE DO MOUNJARO E DESAFIOS ÉTICOS REGULATÓRIOS NO TRATAMENTO DA OBESIDADE GLOBAL","Joao Fernandes Floriano","2026",null,"other","article","10.56161/sci.ed.20260130re07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0045115","Efficacy and safety of liraglutide in morbid obese patients in first year of commercialization in Spain","Inmaculada González Molero","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.p485",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045116","Effects of novel glucose-lowering drugs on the COVID-19 patients with diabetes: A network meta-analysis of clinical outcomes","Yang Yang","2023","International Journal of Diabetes in Developing Countries","systematic_review","article","10.1007/s13410-023-01228-x",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045117","1134-P: Efficacy of iGlarLixi in Adults with Type 2 Diabetes Inadequately Controlled on Two or More Oral Antidiabetic Agents","NEIL SKOLNIK","2019","Diabetes","randomized_trial","article","10.2337/db19-1134-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045118","P397 Cannabis use is associated with an increased prevalence of gastroparesis and cyclical vomiting syndrome","Mohsin Butt","2026","E-Posters","nonrandomized_study","article","10.1136/gutjnl-2026-bsg.504",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045119","Metabolic and Renal Outcomes with Semaglutide Add-on to Dapagliflozin in Routine Clinical Practice: A Propensity-Weighted Cohort Study from Saudi Arabia","Muneera AlTaweel","2026","AACE Endocrinology and Diabetes","nonrandomized_study","article","10.1016/j.aed.2026.08.009",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045120","Treatment of Gestational Diabetes: Molecular Transport Mechanisms, Shear Stress Adaptation, and Efficacy Comparison Between Liraglutide and Insulin","L J Liu","2026","Journal of Engineering and Science in Medical Diagnostics and Therapy","other","article","10.1115/1.4070794",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045121","197 Introduction of a multidisciplinary cardiac metabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation","Laura Bijman","2021",null,"nonrandomized_study","article","10.1136/heartjnl-2021-bcs.193",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0045122","Abstract TH854: Digital Twins Powered by Generative Artificial Intelligence Support Long-Term Evaluation of Obesity and Cardiometabolic Outcomes","Eric Wu","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.th854",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045123","Tu1478 IMPACT OF GLP-1 RECEPTOR AGONISTS ON SYMPTOMATIC REMISSION IN ULCERATIVE COLITIS: A RETROSPECTIVE COHORT STUDY","Budoor Alqinai","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)03166-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045124","Novel Combination of a Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) and Once-Weekly Basal Insulin (HM12460a) Offers Improved Glucose Lowering and Weight Loss in a Diabetic Animal Model","JUNG KUK KIM","2018","Diabetes","preclinical","article","10.2337/db18-77-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045125","185 LONG TERM OUTCOMES OF GLP1 RECEPTOR AGONISTS VERSUS SGLT2 INHIBITORS IN PATIENTS WITH MASLD: A REAL WORLD MULTINATIONAL COHORT STUDY","Asifa Manzoor","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)03381-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045126","GLP-1 agonists in Type 1 diabetes – Indications and use","Panadeekarn Panjawatanan","2025","Obesity Medicine","other","article","10.1016/j.obmed.2025.100591",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045127","Drug–Drug and Drug–Disease Interactions Across Antidiabetic Drug Classes: A Narrative Review and Practical Recommendations","Cristina-Elena Zbârcea","2026","Diabetology","nonrandomized_study","article","10.3390/diabetology7060108",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0045128","Semaglutide Reduces the Risk of Adult-onset Epilepsy in Type 2 Diabetes: A Target Trial Emulation and Mediation Analysis (S5.004)","Yong Eun","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000216020",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045129","Beyond Standard Renoprotection: Palm Tocotrienol-Rich Vitamin E and Multi-Hit Residual Renal Risk in Diabetic Kidney Disease-A Translational Review","Loso Judijanto","2026","Journal of Clinical Case Studies Reviews & Reports","randomized_trial","article","10.47363/jccsr/2026(8)467",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045130","227 Improving the assessment of cardiovascular risk factors in patients with non-ST elevation acute coronary syndrome: a quality improvement project","Victoria de Braal","2024",null,"nonrandomized_study","article","10.1136/heartjnl-2024-bcs.219",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0045131","Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review","Yosra Alhindi","2026","Journal Of Advanced Pharmacy Education And Research","narrative_review","article","10.51847/bfye5lnqza",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045132","Glucagon-like Peptide 1, Brain, Neurodegenerative Diseases: A Modern View","Bulgakova","2020","Bulletin of Science and Practice","other","article","10.33619/2414-2948/53/19",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045133","Glucagon-like peptide-1 analogs for Alzheimer’s disease -- A systematic meta-analysis","Cindy Wang","2024","Theoretical and Natural Science","systematic_review","article","10.54254/2753-8818/32/20240813",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0045134","PO19 Stimulation de la sécrétion de VEGF dans les îlots pancréatiques de Rat par le Liraglutide","A. Langlois","2012","Diabetes & Metabolism","preclinical","article","10.1016/s1262-3636(12)71081-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045135","Tirzepatide Versus Long-Acting Insulin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Mohamed Ahmed Abu-Alsaud","2025","Journal of Diabetology","systematic_review","article","10.4103/jod.jod_213_24",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0045136","Development of a Cost-Effective ELISA-Based cAMP Assay for Evaluating Small-Molecule GLP-1 Receptor Agonists","Xuejiao Mei","2026","BIO Web of Conferences","other","article","10.1051/bioconf/202625001013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0045137","Current Available Pharmacological Intervention for PCOS-II","Mohammad Salem Baba","2025","BENTHAM SCIENCE PUBLISHERS eBooks","other","article","10.2174/9798898810962125010006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045138","Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial","Takahiro Iijima",null,"Institutional Repositories DataBase (IRDB)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0045139","1237-P: Generation of Targeted Nanoparticles for ß-Cell-Selective Delivery of Antioxidant Drugs","ALISSA NOVAK","2021","Diabetes","preclinical","article","10.2337/db21-1237-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045140","Adjunctive nephroprotection in lupus nephritis: a scoping review of SGLT2 inhibitors, GLP-1 receptor agonists, non-steroidal mineralocorticoid receptor antagonists and endothelin receptor antagonists, with proposed practice points","María Carpintero","2026",null,"narrative_review","article","10.37766/inplasy2026.9.0081",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0045141","Orchestrating Metabolic Homeostasis: The Role of Gut Hormones in Next-Generation Therapies for Metabolic Syndrome","Tamer A. Addissouky","2025","Iranian journal of diabetes and obesity","other","article","10.18502/ijdo.v17i2.18851",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045142","Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in prader willi syndrome - case series","Mojca Jensterle","2025","Endocrine Abstracts","case_report","article","10.1530/endoabs.110.ep926",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045143","Dulaglutide – New in the Treatment of Type 2 Diabetes","L.V. Yegshatyan","2019","Effective Pharmacotherapy","other","article","10.33978/2307-3586-2019-15-25-20-28",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045144","Solid-Phase Synthesis of Semaglutide: Using Novel Fragment Coupling Strategy to Overcome Aggregation, Improve yield and Quality","Abdul Shafee","2026","International Journal of Peptide Research and Therapeutics","other","article","10.1007/s10989-026-10836-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045145","The Double-Edged Sword: Bidirectional Oral Health Implications of GLP-1 Receptor Agonists and the Unpreparedness of Modern Dental Practice","SURVEEN SINGH","2026",null,"nonrandomized_study","article","10.17605/osf.io/56bj3",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0045146","Manifestações orais associadas a agonistas de GLP-1/GIP: foco na halitose, microbiota oral e alterações salivares em pacientes que utilizam tirzepatida","Camilla Beatriz Silva Melo","2026","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2026v8n5p1968-1980",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045147","Incretin pathway modulation in intracerebral haemorrhage: a scoping review protocol","Alastair Paterson","2026",null,"protocol","article","10.17605/osf.io/vh2wu",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0045148","809-P: Oral Semaglutide in Indian Type 2 Diabetes Mellitus patients (SOLID) Study—Twelve Months Follow-up","SUPRATIK BHATTACHARYYA","2024","Diabetes","nonrandomized_study","article","10.2337/db24-809-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045149","1 Beutel, 800.000 Euro und „doofe“ Docs – Evidenz-Quickies KW 18","Denis Nößler","2026","EvidenzUpdate","other_trial","article","10.69156/quick/2026.05.00017",null,null,"ClinicalTrials.gov:NCT04959331",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045150","Sa1860 GLP-1 RECEPTOR AGONISTS INDUCE ACINAR-PREDOMINANT PANCREATIC GLANDULAR ENLARGEMENT AND LIPASE LEAK WITHOUT EVIDENCE OF PANCREATITIS","Jianing Li","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)05087-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045151","Weight Reduction in Adolescents with Obesity: A Systematic Review and Meta-Analysis of GLP-1 Receptor Agonists and Metabolic-Bariatric Surgery","Marina Wenn","2026",null,"systematic_review","article","10.17605/osf.io/ptyhu",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0045152","Abstract 523: Pioglitazone and Glucagon-like Peptide 1 Receptor Agonist Stimulate Mitochondrial Turnover in the Heart When Administered After the Infarct in Obese Mice","Allen M. Andres","2018","Circulation Research","randomized_trial","article","10.1161/res.123.suppl_1.523",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0045153","Characteristics & Glycemic Response of Patients With Uncontrolled Type 2 Diabetes Initiating Dulaglutide Alone or In Combination with Insulin In US Real World Practice","Reema Mody","2018","Value in Health","nonrandomized_study","article","10.1016/j.jval.2018.04.469",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045154","1261-OR: Molecular Risk Scores Enhance Type 2 Diabetes (T2D) Prediction beyond Hemoglobin A1c (HbA1c) and Body Mass Index (BMI) across Diverse Clinical Contexts","MAGDALENA SEVILLA-GONZALEZ","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1261-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045155","Fully automated and optimized [68Ga]Ga-NODAGA-Exendin-4 radiolabelling process on the TRASIS miniAllinOne","Elodie Duray","2025","Nuclear Medicine and Biology","other","article","10.1016/j.nucmedbio.2025.109441",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045156","74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations","Adam He","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.954",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045157","Continuation of GLP-1 Receptor Agonists During Post-Acute Skilled Nursing Facility Stays and 30-Day Outcomes","Chan Mi Park","2025","Innovation in Aging","nonrandomized_study","article","10.1093/geroni/igaf122.4331",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045158","ODP222 Liragluitde Increased IL-1RA Concentrations in Obese Type 2 Diabetes: A Small Randomized Controlled Trial","Nattapol Sathavarodom","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.673",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0045159","Impact of glucagon-like peptide-1 receptor agonist or glucagon-like peptide-1 receptor agonist/glucose-dependent insulinotropic polypeptide receptor agonists after bariatric surgery in the veteran population","Sara Corum","2025","JAPhA Pharmacotherapy","nonrandomized_study","article","10.1016/j.japhar.2025.100020",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045160","Design of GLP-1 Analog Loaded Redox-Active Injectable Gel as A Novel Anti-Diabetic Drug","Sho Sakaue","2017","高分子学会予稿集(CD-ROM)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045161","Additional file 1 of Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis","Arveen Shokravi","2026","Figshare","systematic_review","article","10.6084/m9.figshare.31937673",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0045162","Efficacy of Glucagon-like Peptide-1 Receptor Agonists for Treatment of Idiopathic Intracranial Hypertension in Pediatric Patients: A Case Series (P6-15.006)","Sophia Falmagne","2026","Neurology","case_report","article","10.1212/wnl.0000000000217344",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045163","340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment","SHWETA URVA","2022","Diabetes","randomized_trial","article","10.2337/db22-340-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045164","New therapeutic options for reducing atherosclerotic cardiovascular disease residual risk","Nathan Wong","2021","Srce i krvni sudovi","other","article","10.5937/siks2104251w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045165","Additional file 1 of Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants","Paul‐Yang Lin","2026","Figshare","systematic_review","article","10.6084/m9.figshare.31976059.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0045166","Abstract 4353895: The effectiveness of the GLP-1 receptors agonists in improving obesity-related heart failure events: A systematic review and meta-analysis of randomized clinical trials.","Geraldine de Melo","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4353895",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045167","S728 Meta-Analysis of Survodutide: Impact on Satiety, Appetite, Gastrointestinal Adverse Effects, and Drug Discontinuation","Smruti Karale","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001130372.83275.a5",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045168","S48 Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients With Type 2 Diabetes and Inflammatory Bowel Disease","Muhammad Ali Ibrahim Kazi","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001126652.27700.96",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045169","Investigation of potential relationship between glucagon-like peptide 1 receptor agonists with suicide/self-injury: disproportionality analysis using WHO-VigiBase","Y.Y. Kim","2024","Precision and Future Medicine","nonrandomized_study","article","10.23838/pfm.2024.00170",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045170","Tratamiento farmacológico para la obesidad: conocimiento y controversia actual","Cristóbal Ignacio Espinoza Díaz","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045171","Additional file 5 of Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review","Dave Osinachukwu Duru","2026","Figshare","narrative_review","article","10.6084/m9.figshare.32787554.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045172","Randomised Placebo Controlled Trial to Assess the Effect of Liraglutide on Cardiac Function in Type 2 Diabetes Mellitus Patients","Maurice B. Bizino","2018","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.3204722",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0045173","Comparative Dose–Response Effects of Liraglutide, Metformin, and Their Combination in Polycystic Ovary Syndrome: A Network Meta-Analysis","Hazem Ayesh","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/7njuw",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0045174","Cover Picture: Semaglutide to remodel mitochondrial dynamics and mitophagy balance for vascular dementia therapy (View 3/2025)","Xiaoyan Yang","2025","Open Research (University of Surrey)","preclinical","article","10.1002/viw2.70043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045175","775-P: Mazdutide, a Dual GLP-1R/GCGR Agonist, Reduces Hyperuricemia by Modulating Energy and Lipid Metabolism and Inhibiting Hepatic Purine Metabolism","YANSHUANG REN","2025","Diabetes","preclinical","article","10.2337/db25-775-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045176","NANOTECHNOLOGY-BASED THERAPIES IN THE TREATMENT OF TYPE 2 DIABETES: A NARRATIVE REVIEW","Jagoda Józefczyk","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.4(48).2025.4418",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0045177","GLEAM: GLP-1 receptor agonists and endometriosis symptoms — an international cross-sectional survey","Bas Baudoin","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/6qjke",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045178","Optimising Insulin Therapy in Modern Type 2 Diabetes Care: A Narrative Review","Uchechukwu Bethel Abioke","2026","Journal of international research in medical and pharmaceutical sciences","narrative_review","article","10.56557/jirmeps/2026/v21i310637",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0045179","Prospective Prediction of Phase 2/3 Clinical Trial Success for Novel Molecular Entities Using Consciousness-Enhanced Computational Synthesis — C×D Law Extension to Drug Development","John Paul Sicoli","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.20344183",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0045180","The Silent Pandemic: From Metabolic Consequences to Exercise and Lifestyle-Driven Remodelling in Metabolic Syndrome","Bogumił Libura","2026","Quality in Sport","other","article","10.12775/qs.2026.68.74421",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045181","The influence of liraglutide on ERp46 in non-alcoholic fatty liver disease rats","Na Ao","2018","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2018.02.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045182","Evaluation of Clinical and Quality of Life Effects of Oral Semaglutide Use in Type 2 Diabetes from a Public Health View: A Prospective Study in Italy","Paola Pantanetti","2025","Diabetology","other","article","10.3390/diabetology6080080",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045183","Integrating Modern GLP-1–Based Therapies with Traditional Lifestyle Interventions: A Public Health Review on Diabetes and Obesity Management","Akter Sraboni","2026","Public Healthcare and Ancient Science","narrative_review","article","10.64907/xkmf.v6.i1.phas.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045184","Prospective Test of Whether LV-Mass Reduction with Weight-Lowering Therapies Is Weight-Proportional or Relatively Weight-Independent","Jeel Padaria","2026","Open Science Framework","other_trial","article","10.17605/osf.io/g3swt",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0045185","Association of Comorbidity Patterns with the Utilization of Comorbidity-specific Medications in Patients with Type 2 Diabetes Mellitus: A Cross-sectional Study","SK Sabir Rahaman","2026","Journal of Integrated Health Sciences","other","article","10.4103/jihs.jihs_90_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045186","Effetti a lungo termine della liraglutide sui parametri glico-metabolici, sulle lipoproteine a bassa densità piccole e dense e sullo spessore medio intimale carotideo nei pazienti con diabete mellito di tipo 2: studio prospettico di 5 anni","Rosaria Vincenza Giglio","2025","Biochimica Clinica","nonrandomized_study","article","10.23736/s0393-0564.25.00059-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045187","EPH161 Dose Escalation Patterns in Patients with Overweight or Obesity Initiating Semaglutide 2.4mg: A 6-Month Follow-up in a Real-World Setting in the United States","Lin Lv","2023","Value in Health","nonrandomized_study","article","10.1016/j.jval.2023.03.1043",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045188","Assessment of Lipid Levels in Newly Diagnosed Diabetic Obese Patients Treated with GLP-1 Inhibitors Using MRI-PDFF","Yufei Zhao","2024","Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition","other","article","10.58530/2024/4739",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0045189","Efectos de los Agonistas del Receptor GLP-1 sobre la Función Eréctil y Niveles de Testosterona en Hombres con Diabetes Tipo 2 y Obesidad: Una Revisión Sistemática con Síntesis Narrativa Estructurada","Eliezer Melean","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20092899",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045190","S788 Oral Super-Absorbent Hydrogel Capsules Double Clinically Meaningful Weight Loss Without Added Serious or GI Adverse Events: A Systematic Review and Meta Analysis of Randomized Controlled Trials","A. N. Das","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001130612.88952.c3",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045191","StreaMLine - Machine learning guided development of novel GLP-1 receptor agonists","Claudia U. Hjørringgaard","2024",null,"other","article","10.17952/37eps.2024.p1143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0045192","73-LB: Tirzepatide 5, 10, and 15 mg vs Injectable Semaglutide 0.5 mg for the Treatment of Type 2 Diabetes—An Indirect Treatment Comparison","KEVIN M. PANTALONE","2023","Diabetes","other_trial","article","10.2337/db23-73-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045193","783-P: Efficacy of GLP-1RA according to Type 2 Diabetes Phenotypes—A Monocentric Retrospective Study","Irene Caruso","2024","Diabetes","nonrandomized_study","article","10.2337/db24-783-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045194","740-P: Persistence and Adherence of Once-Weekly GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in a Real-World Setting","Tyler J. Dunn","2024","Diabetes","nonrandomized_study","article","10.2337/db24-740-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045195","OBESITY – PATHOPHYSIOLOGY AND MODERN TREATMENT STRATEGIES","Julia Kacperczyk","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.2(50).2026.5368",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045196","The effect of tirzepatide therapy on the severity of obstructive sleep apnea in a patient with type 2 diabetes mellitus: a case report","O. P. P'yanykh","2025","Endocrinology News Opinions Training","case_report","article","10.33029/2304-9529-2025-14-4-71-76",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045197","Integrated Metabolic and Cardiovascular Optimization Before Surgery: Multidisciplinary Strategies to Reduce Perioperative Risk","Nery Rene Mazariegos Flores","2026","IECCMEXICO","other","article","10.64784/202",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045198","Cardiometabolic effects of dual GLP-1 and glucagon receptor agonists: a systematic review and meta-analysis of randomised controlled trials","Johann Roessler","2026",null,"systematic_review","article","10.2337/figshare.33167144.v1",null,null,"PROSPERO:CRD420261295754",null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0045199","Impact of GLP-1 agonists on the progression of Alzheimer's disease: a systematic review","Nathália Carvalho Figuerêdo","2025",null,"systematic_review","article","10.5327/rpda25037",null,null,"PROSPERO:CRD42025105947",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045200","Inhibidores del cotransportador 2 de sodio-glucosa, agonistas del receptor de péptido 1 similar al glucagón y mortalidad por cáncer. Registro de la práctica real","David García‐Vega","2024","Revista Española de Cardiología","nonrandomized_study","article","10.1016/j.recesp.2024.07.004",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045201","Sa1514 EFFECTIVENESS AND SAFETY OF GLP-1 RECEPTOR AGONISTS IN REDUCING OSTOMY OUTPUT AMONG IBD PATIENTS WITH ILEOSTOMIES","Chase M. Duty","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)02524-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045202","#811 Effect of GLP-1 receptor agonists on the weight, urea distribution volume and blood pressure of hemodialysis (HD) patients","Sheetal Chaudhuri","2024","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfae069.1577",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045203","Efficacy of liraglutide in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring","Fuminori Sato","2013","Tōnyōbyō/Tounyoubyou","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045204","Safety and efficacy of glucagon-like peptide-1 receptor agonists and sodium- glucose co-transporter-2 inhibitors compared with the standard of care in a cohort of liver transplanted patients: a retrospective study","Aida Rebiha","2023","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(23)01218-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045205","Racial and Ethnic Representation in Phase 3 RCTs of FDA-Approved GLP-1 Receptor Agonists (2021–2026)","Olivia Cory","2026",null,"randomized_trial","article","10.17605/osf.io/njkme",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0045206","Investigation of clinical outcomes on the oral or injectable use of semaglutide and cardiovascular risks: a systematic review","Barbara Vanzelli de Oliveira","2025","International Journal of Nutrology","systematic_review","article","10.54448/ijn25207",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045207","OC.10.2 USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST IS ASSOCIATED WITH REDUCED RISK OF MAJOR LIVER-RELATED EVENTS: A META-ANALYSIS","C. Celsa","2025","Digestive and Liver Disease","systematic_review","article","10.1016/s1590-8658(25)00470-0",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0045208","Oral presentation at EASL 2026. Hepatic transcriptomic signatures reveal mechanistic insights underlying improved metabolic dysfunction–associated steatohepatitis histology with survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in a phase 2 trial","Raphael Hesse","2026","Boehringer Ingelheim","other_trial","article","10.60915/boehringer-figshare.32158935.v1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0045209","796-P: Glucose-Lowering Drugs and Risk of COPD Exacerbations in Adults with Type 2 Diabetes","AVIK RAY","2024","Diabetes","nonrandomized_study","article","10.2337/db24-796-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045210","LP-20 A Novel Marine-Derived GLP-1 Receptor Agonist Exhibits Sustained Signaling with Minimal Receptor Internalization","M. Kim","2026","Toxicology Letters","other","article","10.1016/j.toxlet.2026.112949",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045211","Tu1594 GLP-1 RECEPTOR AGONISTS DO NOT INCREASE IBD FLARES OR HOSPITAL UTILIZATION IN OBESE PATIENTS WITH CROHN’S DISEASE OR ULCERATIVE COLITIS: A PROPENSITY-MATCHED REAL-WORLD COHORT STUDY","Eshan Nanda","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)03281-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045212","1082 IMPACT OF GLP-1 RECEPTOR AGONIST USE IN ADULTS WITH SICKLE CELL DISEASE AND TYPE 2 DIABETES: A REAL-WORLD COHORT ANALYSIS","Guy Nguefang","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04748-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045213","Diabetes Mellitus at an Elderly Age","Andrej Zeyfang","2023","Experimental and Clinical Endocrinology & Diabetes","nonrandomized_study","article","10.1055/a-1946-3728","36638808",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045214","Évaluation des bénéfices et des risques du traitement par sémaglutide 2,4 mg chez les sujets en situation d’obésité âgés de plus de 65 ans et de plus de 70 ans : résultats rétrospectifs d’une cohorte monocentrique","Baena, Chloé","2024","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0045215","1128-P: Diabetes and Cardiovascular Disease Hospital Recognition Program Associated with Rapid Improvement in Guideline-Directed Medical Therapy","Gregg C. Fonarow","2024","Diabetes","other","article","10.2337/db24-1128-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045216","Tratamento com tirzepatida para resistência à insulina em pacientes obesos","Natália Rivoli Rossi","2025","Congresso Médico Acadêmico UniFOA.","other","article","10.47385/cmedunifoa.2024.2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0045217","High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.","Anne Sofie Laulund","2026","UNC Libraries","randomized_trial","article","10.17615/vghg-6244",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0045218","Beyond glucagon-like peptide-1: The promise of polyagonists in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis—A systematic review of randomized trials","Rachel M. Slaton","2026","JAPhA Pharmacotherapy","systematic_review","article","10.1016/j.japhar.2026.100032",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0045219","PROVIDER-REPORTED BARRIERS TO GUIDELINE-DIRECTED UTILIZATION OF SGLT2I/GLP-1RA AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK FOR CARDIOVASCULAR DISEASE","Frank Qian","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03877-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045220","774-P: Weight-Independent Effects of CT-868, a Signaling Biased Dual GLP-1/GIP Receptor Modulator, on Glucose Homeostasis in Overweight and Obese Adults with Type 2 Diabetes","Manu V. Chakravarthy","2023","Diabetes","randomized_trial","article","10.2337/db23-774-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045221","How does the use of GLP-1 receptor agonists affect bone mineral density and fracture risk in obese individuals?","Jakub Zbigniew Zalewski","2026","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2026.87.68397",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045222","Occupancy of Glucagon Like Peptide-1 receptor by Tirzepatide and SAR441255 measured with [68Ga]Ga-DO3A-exendin-4/PET in vivo.","Amina Khalil","2023","Nuclear Medicine and Biology","other","article","10.1016/j.nucmedbio.2023.108662",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045223","MON-095 Phentermine Induces Weight Loss in Prader-Willi Syndrome","Adham Mottalib","2019","Journal of the Endocrine Society","other","article","10.1210/js.2019-mon-095",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045224","Glucagon-Like Peptide-1 Receptor Agonists and Outcomes in Shoulder Surgery: A Scoping Review Across Arthroscopy, Arthroplasty, and Trauma","Rajarajan Srinivasan","2026",null,"narrative_review","article","10.17605/osf.io/4g75e",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045225","Systemic mastocytosis","Clay W. Walker","2025","JAAPA","other_trial","article","10.1097/01.jaa.0000000000000202","40273169",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045226","Efficacy of GLP-1 agonists vs. other weight management medications in obese and overweight patients","Arielle Davidson","2025","JAPhA Practice Innovations","nonrandomized_study","article","10.1016/j.japhpi.2025.100046",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045227","Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes","Laura Opalska","2024","Quality in Sport","other","article","10.12775/qs.2024.35.56425",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045228","Evaluating the Effect of Dual GIPR/GLP-1R Agonists on Non-Alcoholic Fatty Liver Disease and Metabolic Risk Abnormalities: A Drug-Target Mendelian Randomization Study","Siyuan Xie","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.4771342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045229","1201-OR: Harmine and Exendin-4 Combination Attenuates Human β-Cell Senescence","Randy B. Kang","2026","Diabetes","other","article","10.2337/db26-1201-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045230","IDDF2026-ABS-0331 Real-world comparative effectiveness and gastrointestinal safety of orlistat versus liraglutide in adults with obesity and type 2 diabetes: a propensity-matched cohort study","Arkadeep Dhali","2026","Clinical Gastroenterology","nonrandomized_study","article","10.1136/gutjnl-2026-iddf.316",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0045231","Neonatal Exendin-4 Normalizes Epigenetic Modifications at the Proximal Promoter of PGC1-α in IUGR Rat Liver.","SE Pinney","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","preclinical","article","10.1210/endo-meetings.2010.part2.or.or09-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045232","Comparative efficacy, safety, and treatment burden of injectable intensification strategies after basal insulin in type 2 diabetes: a network meta-analysis","Hazem Ayesh","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/us2dq",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0045233","Efficacy of Empagliflozin in Fibrosis Progression in Patients with Type 2 Diabetes Mellitus Having Metabolic Dysfunction-Associated Steatotic Liver Disease","Javed Imran","2026","Bangladesh Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/bjem.bjem_31_25",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0045234","Weight loss drugs, a miracle solution?","Ève Bergeron","2024","Journal de Pharmacie Clinique","other","article","10.1684/jpc.2024.0544",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045235","Changing paradigms in diabetes: Scientific breakthroughs of the past 15 years","M A Halim Khan","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other","article","10.3329/jacedb.v4i20.84908",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045236","26-A-17161-ACC THE PERIPROCEDURAL SAFETY OF CONTINUED GLP-1 RECEPTOR AGONIST PRIOR TO CARDIAC CATHETERIZATION","Kuan-Yu Chi","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.1276",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045237","Semaglutide-Induced Weight Loss: Consequences for Muscle Mass and Functional Outcomes","Barbara Reizer","2026","Journal of Education Health and Sport","other","article","10.12775/jehs.2026.88.68182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045238","S1561 Evaluating Effectiveness and Safety of a GLP-1 Agonist in Obese Patients With Inflammatory Bowel Disease: A Systematic Review","Moulika Kari","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001133704.32389.16",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045239","MON-691 Oral Delivery Of A Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) Via A Robotic Pill (RT-114) Achieves Bioequivalence To Subcutaneous Injection In Canines","Anvesh Dasari","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.029",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045240","Tirzepatide for refractory post-fundoplication dumping syndrome: A case report","Olanrewaju Adeniran","2026","World Journal of Gastroenterology","case_report","article","10.3748/wjg.122564",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045241","Dietary reversal of Type 2 diabetes motivated by research knowledge","Sarah Steven","2010","Diabetic Medicine","other","article","10.1111/j.1464-5491.2010.02992.x","20546297",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045242","Glucagon- Like Peptide-1 (GLP-1) receptor agonists and New-onset Type 2 Diabetes","Seiko Hayashi","2026",null,"other","article","10.17605/osf.io/3nsgv",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045243","FRI-461-YI Safety and efficacy of GLP-1 receptor agonists in liver transplant recipients: a multi-national experience","Chiara Becchetti","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)01165-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045244","Nutrition Support During GLP-1 Receptor Agonist Therapy: Protecting Lean Mass While Intake Falls","Bettina Achleitner","2025","Journal of Clinical Nutrition and Health","nonrandomized_study","article","10.5281/zenodo.22302378",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0045245","Efficacy and safety of semaglutide versus placebo for people with schizophrenia spectrum disorders with obesity or early-stage metabolic abnormalities: A systematic review and meta-analysis of randomized controlled studies","Minahil Rasul","2026","Therapeutic Advances in Psychopharmacology","systematic_review","article","10.1177/20451253261473919",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0045246","0676 The Association Between Tirzepatide and Sleep Architecture: Post-Hoc Analyses from SURMOUNT-OSA","Anil K. Malhotra","2026","SLEEP","other_trial","article","10.1093/sleep/zsag091.0675",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0045247","TIRZEPATIDE VERSUS SEMAGLUTIDE: A COMPREHENSIVE REVIEW OF COMPARATIVE EFFICACY, SAFETY, AND METABOLIC OUTCOMES IN TYPE 2 DIABETES AND OBESITY","Mandy Schulz","2025","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.4(48).2025.4276",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045248","400.05 Long-term Survival Benefit of GLP-1 Agonists In Heart-Transplant Recipients: A Propensity-matched Real-World Analysis","Afnan Chaudhry","2026","JACC: Cardiovascular Interventions","nonrandomized_study","article","10.1016/j.jcin.2026.01.142",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045249","SUN-580 A Phase III Small Molecule GLP1R Agonist Acts As a Pharmacological Chaperone for Misfolded GLP1R Mutants","Ya‐Xiong Tao","2025","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvaf149.1231",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0045250","A GLP-1 Receptor Agonist Looks Promising in Phase 2 Study for Parkinson's Disease","Jamie Talan","2024","Neurology Today","randomized_trial","article","10.1097/01.nt.0001017612.54350.b4",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045251","Durability of Effects of Exenatide Treatment on Glycemic Control, Body Weight, hsCRP, Lipid Concentrations and Bone Mineral Density","Mukul Kumar Gupta","2011",null,"other","article","10.1210/endo-meetings.2011.part4.p4.p3-492",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045252","TRANSCEND-T2D-1 and the First-Line Question: What Retatrutide's Phase 3 Results Mean for Diabetes Care, Access & Equity","Steven Minh Phat Duong","2026","SocArXiv (OSF Preprints)","other_trial","article","10.31235/osf.io/kyb4z_v2",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","preprint"],["R0045253","Exploring Equity in Glucose‐lowering Research for Patients with Obesity. A Meta-epidemiological Study Protocol","Junior Vitorino Fandim","2026",null,"protocol","article","10.17605/osf.io/8yxpu",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0045254","1427-P: Fibrosis-4 Index Is Associated with ASCVD Burden, MACE, and Mortality in Real-World Type 2 Diabetes Cohort","Melina I. Manolas","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1427-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045255","1711-P: Menopausal Hormonal Status and Estradiol Use Modulate Semaglutide-Associated Weight Loss in Women: Analyses from STEP1 and SELECT","Maria Dermit","2026","Diabetes","randomized_trial","article","10.2337/db26-1711-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045256","Injections for weight loss: what’s new in GLP-1 RAs for obesity treatment – review","M Zajac","2024","Quality in Sport","narrative_review","article","10.12775/qs.2024.20.53875",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045257","MORPHOFUNCTIONAL STATE OF PANCREAS IN RATS WITH DIABETES MELLITUS","О. Р. Іванців","2024","Art of Medicine","randomized_trial","article","10.21802/artm.2024.1.29.271",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045258","Oral hydrophobic ion-paired semaglutide self-microemulsion for improving glucoregulatory effect","Xiaowu Yao","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6269345",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045259","Liraglutide mitigates changes in migration, proliferation, calcification and apoptosis of vascular smooth muscle cells under high glucose conditions via autophagy","Lili Shi","2020",null,"other","article","10.21203/rs.3.rs-109663/v1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0045260","FRI645 A Case Of Diabetic Ketoacidosis After Initiation Of Decitabine And Venetoclax Chemotherapy","Rohan Maini","2023","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvad114.864",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0045261","2603-P: Body Mass Index and Blood Pressure Changes During and After Antiobesity Medication Use","Mohammad Alnuman","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2603-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045262","EPH123 PREOPERATIVE USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS)AND SHORT-TERM POSTOPERATIVE OUTCOMES AFTER BARIATRIC SURGERY: A RETROSPECTIVE COHORT STUDY","Yumeng Wang","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.955",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045263","Pancreatic β- and α-cell adaptation in response to metabolic changes","Johanne H. Ellenbroek","2015","Leiden Repository (Leiden University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0045264","423-P: Three Decades of Glucose-Lowering Therapy in Patients with Established Coronary Artery Disease—A Real-World Analysis","MAGDALENA NEYER","2025","Diabetes","nonrandomized_study","article","10.2337/db25-423-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045265","Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review","João Pedro Henriques","2026","Neurology and Clinical Neuroscience","randomized_trial","article","10.1002/ncn3.70165",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045266","GLP1-PANC: Risk of Acute Pancreatitis Among Patients With Obesity Treated With GLP-1 Receptor Agonists: A Target Trial Emulation Using National EHR-Claims Data","Zachary Smith","2026","OSF Preprints (OSF Preprints)","nonrandomized_study","article","10.17605/osf.io/4mkqz",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0045267","PDB8 COMPARATIVE EFFECTIVENESS OF LIRAGLUTIDE AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN: A POPULATION-BASED COHORT STUDY","K.C. Chang","2019","Value in Health","nonrandomized_study","article","10.1016/j.jval.2019.09.890",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045268","Semaglutide versus Tirzepatide - comparison of both drugs in treatment of diabetes type 2 and weight reduction","Arkadiusz Staroń","2024","Quality in Sport","other","article","10.12775/qs.2024.19.53518",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045269","Clinical Significance of Drug–Drug Interaction Studies During Therapeutic Peptide Drug Development: Follow‐Up Investigation of Therapeutic Peptides Approved Between 2021 and 2024","Carolina Säll","2025","Clinical and Translational Science","preclinical","article","10.1111/cts.70288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045270","TOP-209-YI GLP-1 RA use reduces the incidence of alcohol-associated hepatitis and risk of death in type 2 diabetes mellitus and alcohol use disorder in a routine clinical care stetting","Neha Shah","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)00515-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045271","2834-LB: Cardiometabolic Outcomes in Adults with T2D Treated with 1 mg Semaglutide Who Titrate to 2 mg Semaglutide vs. Switch to Tirzepatide","Gang Fang","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2834-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045272","Current Status of Safety Research on Glucagon-Like Peptide-1 Receptor Agonists for Obesity Treatment: A Scoping Review","Jisoo Cho","2026","Journal of Pharmacoepidemiology and Risk Management","nonrandomized_study","article","10.56142/perm.26.0001",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045273","Targeting inflammation in diabetes: Newer therapeutic options","Neeraj","2014","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045274","Effectiveness and safety of ITCA 650 vs currently available GLP-1 RAs in type 2 diabetes: a phase IIIb, pragmatic RCT","New John","2017",null,"randomized_trial","article","10.26226/morressier.59d5184ed462b80296ca2ba0",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0045275","Sa2092 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IMPROVE HEPATIC AND METABOLIC OUTCOMES IN PATIENTS WITH MASLD: A RETROSPECTIVE STUDY","Pooja Khatiwala","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03558-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045276","Prescribing Patterns for Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Chronic Kidney Disease: Retrospective Analysis at an Academic Family Medicine Center","Alina McCue","2026","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/4c3a-z128",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0045277","Sa1274 IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON CLINICAL OUTCOMES IN ADULTS WITH CELIAC DISEASE: A MULTI-INSTITUTIONAL COHORT STUDY","Muhammad Ali Ibrahim Kazi","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)05774-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045278","Same Result, Different Price: Compounded versus Branded Tirzepatide No Detected Effectiveness Difference, Conditional Cost Savings","Shanmugesh Raja","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7119866",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045279","More than a sidekick: GIP signalling and cardiovascular outcomes","Berkan Kurt","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf944","41424109",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045280","Cardiovascular outcomes of antidiabetic drugs","Ranjit Kumar Nath","2021","Asian Journal of Medical Sciences","other","article","10.3126/ajms.v12i3.32477",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045281","Green Tea and Nigella Sativa- Herbs in Non-Alcoholic Fatty Liver Disease","Mazhar Hussain","2021","Journal of Sheikh Zayed Medical College","other","article","10.47883/jszmc.v11i04.160",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045282","1311 Acute Pancreatitis in a Patient Using Liraglutide for Weight Loss","Karina Fatakhova","2019","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0000594772.87672.64",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045283","Changes in Cardiometabolic Risk Factors Based on Improvements in Apnea-Hypopnea Index in Participants from the SURMOUNT-OSA Clinical Studies","Reena Mehra","2025","American Journal of Respiratory and Critical Care Medicine","other_trial","article","10.1164/ajrccm.2025.211.abstracts.a5287",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0045284","Agonistas GLP-1 y protección oncológica en obesidad: revisión sistemática de mecanismos metabólicos, inflamación sistémica y evidencia clínica","Ixchel Lorena Guevara Galindo","2026","Ciencia Latina Revista Científica Multidisciplinar","other","article","10.37811/cl_rcm.v10i4.25167",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045285","Liraglutide attenuates renal tubular ectopic fat deposition in diabetic nephropathies rats through inhibiting sterol regulatory element binding protein 1","Ke Su","2019","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2019.12.002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045286","1892P Glucagon-like peptide 1 agonists and anthracycline-associated cardiotoxicity in hematologic malignancies","C.‐H. Chiang","2024","Annals of Oncology","other","article","10.1016/j.annonc.2024.08.1986",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045287","Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review","Jing Zhou","2026","Exploration of Endocrine and Metabolic Diseases","narrative_review","article","10.37349/eemd.2026.101481",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045288","971-P: Renal Impairment Has No Impact on the Clinical Pharmacokinetics of Tirzepatide","Shweta Urva","2020","Diabetes","other","article","10.2337/db20-971-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045289","Statement : 제2형 당뇨병 환자의 혈당 관리: 2018년 미국/유럽 당뇨병학회 합의안 요약","김정미","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0045290","Abstract 15922: Effect of Glp-1 Receptor Agonists on Systolic Blood Pressure in Patients With Overweight or Obesity: A Network Meta-Analysis","Muhammad Usman","2022","Circulation","systematic_review","article","10.1161/circ.146.suppl_1.15922",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045291","T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report","Sungwoo Park","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6200","37731550",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045292","Oral semaglutide significantly reduces low-density lipoprotein cholesterol level","Shuichi Okada","2023","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-023-01259-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045293","Semaglutide: A revolution in the treatment of obesity and prevention of cardiovascular disease","Wiktoria Bilska","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.22.55010",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045294","Diabetes mellitus and fertility","Marine Jullien","2023","Médecine thérapeutique / Médecine de la reproduction, gynécologie et endocrinologie","randomized_trial","article","10.1684/mte.2023.0969",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045295","Hyp-O-besity: Unmet Challenge in Management of Type 2 Diabetes Mellitus and Cardiovascular Risk","Ambady Ramachandran","2015","Journal of Diabetes & Metabolism","other","article","10.4172/2155-6156.1000520",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045296","Transcranial super-resolution ultrasound imaging as a tool to visualise neuronal activation patterns in the brain following peripheral administration of GLP-1 receptor agonists","Krish Desai","2026","Endocrine Abstracts","other","article","10.1530/endoabs.117.p158",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045297","The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review","Ghinwa M. Barakat","2025","Current Drug Therapy","narrative_review","article","10.2174/0115748855404783250917112146",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045298","Secondary pulmonary infection by Fusarium solani and Aspergillus niger during systemic steroid treatment for COVID-19: A case report","Daisuke Usuda","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6280","37731582",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045299","The Impact of GLP-1 Analogs on Thromboembolic Outcomes in Patients With Sarcoidosis","Xin Ya See","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a1130",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045300","Cardioprotective Benefits of Combined Treatment With Glucagon-Like Peptide-1 Receptor Agonist & Sodium Glucose Transporter-2 Inhibitor In Mice","Dorrin Zarrin Khat","2018","Atherosclerosis Supplements","preclinical","article","10.1016/j.atherosclerosissup.2018.04.341",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045301","Su1182 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND RISK OF GASTROESOPHAGEAL REFLUX DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Dimo Dimitrov","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)01998-x",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045302","The multimodal approach to obesity treatment – current pharmacological and surgical methods and lifestyle changes","Maria Kowalczuk","2024","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2024.59.014",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045303","Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry","Viveca Ritsinger","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.1232",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045304","Miglioramenti della qualità di vita correlata alla salute (HRQoL) con Liraglutide 3 mg rispetto a placebo per la gestione del peso","Salvatore Buscemi","2015","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045305","Additional file 4 of The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis","Kezia Peter","2026","Figshare","systematic_review","article","10.6084/m9.figshare.32142846.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0045306","Additional file 3 of The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis","Kezia Peter","2026","Figshare","systematic_review","article","10.6084/m9.figshare.32142843",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0045307","Tirzepatide versus Semaglutide in the Risk of Cerebral Infarction in Patients with Diagnosis of Type 2 Diabetes Mellitus: A Propensity Score Matching from a Global Federated Health Network Analysis (S30.005)","Mariana Letícia de Bastos Maximiano","2025","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000212661",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045308","GLP-1 RECEPTOR AGONISTS AND COLORECTAL CANCER: BIOLOGICAL PLAUSIBILITY AND CURRENT EVIDENCE","Bartosz Nowak","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.1(49).2026.4822",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0045309","Will Tirzepatide become a game-changer in the pharmacological treatment of obesity? - literature review","Aleksandra Doryń","2024","Journal of Education Health and Sport","narrative_review","article","10.12775/jehs.2024.71.49544",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045310","738-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Patient-Reported Outcomes","MARTIN FUECHTENBUSCH","2022","Diabetes","nonrandomized_study","article","10.2337/db22-738-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045311","557 GASTROINTESTINAL AND HEPATOBILIARY SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN DIABETIC PATIENTS WITH BARIATRIC SURGERIES","Chengu Niu","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04791-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045312","A-109 | Cardiovascular outcomes with tirzepatide versus GLP-1 RA in patients with type 2 diabetes mellitus: a systematic review and meta-analysis post-SURPASS-CVOT trial","Omer Mohammed","2026","Journal of the Society for Cardiovascular Angiography & Interventions","systematic_review","article","10.1016/j.jscai.2026.104600",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0045313","Identification of Patients with Type 2 Diabetes Mellitus Requiring Concentrated Pharmaceutical Management in Health Insurance Pharmacies:","Ryo Iketani","2021","Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)","nonrandomized_study","article","10.5649/jjphcs.47.10",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045314","Counter-Current Chromatography Enables Use of Green Solvents for Productive Peptide Purification Processes","Rosella Prestia","2026","Separations","other","article","10.3390/separations13070195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045315","Análise do uso indiscriminado do Ozempic para emagrecimento na atualidade e seus impactos na saúde do paciente: revisão bibliográfica","Ana Luisa Albuquerque Miranda","2024","Cuadernos de Educación y Desarrollo","other","article","10.55905/cuadv16n12-127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045316","ACNMD26-486: EFFECTIVENESS OF DIFFERENT SPLIT-DOSE BOWEL PREPARATION REGIMENS IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: PRELIMINARY RESULTS OF THE GLPREPARATION STUDY","Alessandra Piagnani","2026","Digestive and Liver Disease","other","article","10.1016/s1590-8658(26)00626-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045317","Tirzepatide Ameliorates Renal Dysfunction, Dyslipidemia, and Thyroid Hormone Dysregulation in Diabetic Rats","Amal M. AlRashidi","2026","International Journal of Pharmacology","preclinical","article","10.31083/ijp49432",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045318","513 RISK OF POST-ERCP PANCREATITIS IN GLP-1 RECEPTOR AGONIST USERS: A REAL-WORLD PROPENSITY-MATCHED COHORT STUDY","Mariam Chalhoub","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)05043-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045319","Defining the roles of SGLT2IS and GLP-1 RAS in the management of chronic kidney disease with type 2 diabates and overweight/obesity : a delphi consesus","Yehuda Handelsman","2026","Digitalen Hochschulbibliothek Sachsen-Anhalt (Universitäts- und Landesbibliothek Sachsen-Anhalt)","other","article","10.25673/123604",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045320","Association Between Semaglutide 2.4 mg and Risk of Cardiovascular Events in Patients With Heart Failure in the Real World: Results From the SCORE-HF Study","Kim G. Smolderen","2026","Journal of Cardiac Failure - Intersections","nonrandomized_study","article","10.1016/j.yjcafi.2026.05.004",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045321","Editorial introductions","Ron Blankstein","2019","Current Opinion in Cardiology","nonrandomized_study","article","10.1097/hco.0000000000000665",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","editorial"],["R0045322","Therapy with exenatide in obese and morbidly obese type 2 diabetic patients: comparative analysis","Felechosa M Dieguez","2011","13th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045323","Efficacy and safety of liraglutide switched from premixed insulin in patients with type 2 diabetes mellitus","Fan Liu","2014","Intern J Endocrinol Metab","randomized_trial","article","10.3760/cma.j.issn.1673-4157.2014.04.006",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045324","Application prospects of glucagon-like peptide-1 receptor agonists in treatment of metabolic diseases","Qiang Zhang","2020","World Chinese Journal of Digestology","other","article","10.11569/wcjd.v28.i11.393",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045325","The effect of the GLP-1 analogue Liraglutide on intermittent hypoxia-induced systemic insulin resistance in vivo","Ailbhe King","2022",null,"randomized_trial","article","10.1183/13993003.congress-2022.2182",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0045326","The Role of Semaglutide in Obesity Treatment: Effectiveness and Safety Based on Current Evidence","Zuzanna Gąsior","2026","Archiv Euromedica","randomized_trial","article","10.35630/2026/16/iss.1.007",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045327","Riscos potenciais relacionados ao uso indiscriminado da semaglutida","Francinei da Silva Linhares","2024","Revista JRG de Estudos Acadêmicos","other","article","10.55892/jrg.v7i15.1486",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045328","AGONISTA ORAL DE GLP-1 (ORFORGLIPRON) NO MANEJO DA OBESIDADE E DO DIABETES TIPO 2","Valéria Goulart Viana","2026","LUMEN ET VIRTUS","other","article","10.56238/medcientifica-090",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper; article"],["R0045329","Exenatide",null,"2018","Reactions Weekly","other","article","10.1007/s40278-018-51909-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045330","SAT-655 Comparative Analysis of Glucagon Receptor Agonists vs Resmetirom in MASLD and MASH:Network Meta-Analysis of Clinical Trials","Celina R Andonie","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.091",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045331","793-P: Biased GLP-1 Analog Ecnoglutide (XW003) Has Improved Efficacy Relative to Unbiased Peptides","GUO WANJUN","2024","Diabetes","other_trial","article","10.2337/db24-793-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045332","Maturity-onset diabetes of the young type 6 in China and the utility of semaglutide: A case report","Chen Gui-yan","2026","World Journal of Diabetes","case_report","article","10.4239/wjd.126085",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045333","Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.","Olivia Benny",null,"Open Access CRIS of the University of Bern","systematic_review","article","10.48620/97703",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0045334","Future developments in diabetes care","Ian N. Scobie","2023",null,"other","article","10.1201/9781003342700-12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045335","Dataset for: Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis of Randomized Controlled Trials","Minahil Rasul","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21546594",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0045336","S2117 Combination Therapy of Glucagon-Like-Peptide-1 Receptor Agonists and Endoscopic Gastric Plication in Obesity Population: A Meta-Analysis","Noppachai Siranart","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001037836.98748.24",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045337","The Efficacy of Using Liraglutide for Improving Non-Acoholic Fatty Liver Disease Condition in Pediatric-Adolescent Population with Obesity: Real World Evidence","Min chul Kim","2022","Korean Journal of Family Practice","nonrandomized_study","article","10.21215/kjfp.2022.12.5.361",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045338","Oral Antidiabetic Agents and Injectable Incretin Mimetics","Pradeep Talwalkar","2015","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/12593_14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045339","5PSQ-043 Rare adverse event monitoring: nonarteritic anterior ischaemic optic neuropathy associated with tirzepatide – a pharmacovigilance disproportionality study","Eleonora Castellana","2026","Section 5: Patient safety and quality assurance","nonrandomized_study","article","10.1136/ejhpharm-2026-eahp.470",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0045340","“From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of GLP1 receptor agonists in obesity management services","Brown, Adrian","2024","UCL Discovery (University College London)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045341","From promise to prudence: Integrating semaglutide into Indian clinical practice","Ayush Bhadreshkumar Patel","2026","Indian Journal of Physiology and Pharmacology","other","article","10.25259/ijpp_723_2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045342","780-P: Soli-SWITCH—Efficacy and Safety of Switching to iGlarLixi from Premixed Insulins (PI) in People with Type 2 Diabetes (T2D)","MARTIN HALUZIK","2024","Diabetes","other_trial","article","10.2337/db24-780-p",null,null,"EudraCT:2021-003711-25",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045343","284. Semaglutide achieves equivalent fusion with reduced mechanical complications compared with bariatric surgery in spine fusion patients","A. James Moser","2026","The Spine Journal","other","article","10.1016/j.spinee.2026.06.304",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045344","323-LB: Activation of the GLP-1 Receptor Signaling Prevents Beta-Cell Dedifferentiation in a Mouse Model of Wolfram Syndrome through Modulating TXNIP Expression","Katsuya Tanabe","2019","Diabetes","preclinical","article","10.2337/db19-323-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045345","Abstract 20313: Glucagon-Like-Peptide-1 Receptor Preserves Cardiac Performance and Attenuates Remodeling Through Mkk3 in Infarcted Hearts","Jian Du","2014","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045346","Glucagon-Like Peptide-1 Receptor Agonist (GLP-1R): An Important Therapy to Treat Type 2 Diabetes","Devajit Mohajan","2024","Journal of Innovations in Medical Research","other","article","10.56397/jimr/2024.09.01",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045347","Tirzepatide – alternative to CPAP-therapy or new opportunity in the therapy of obstructive sleep apnea?","D. V. Cherkashin","2026","Meditsinskiy sovet = Medical Council","other_trial","article","10.21518/ms2025-551",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0045348","Initial results and patient satisfaction with the new oral formulation of semaglutide","Martin Francisco Javier Martinez","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.p506",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045349","Key Physiopathological Pathways and Emerging Therapeutic Strategies in Type 2 Diabetes Mellitus","K.K. Awasthi","2026","Journal of Endocrinology and Metabolism","other","article","10.14740/jem1622",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045350","Tirzepatide and semaglutide in obesity management and their impact on health-related quality of life – a comparative narrative review","Weronika Kopniak","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.67.74311",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0045351","‘Budget Ozempic’: five ways this dangerous TikTok weight loss trend will harm your health","Swrajit Sarkar","2024",null,"other","article","10.64628/ab.g9agxua76",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0045352","Bayesian Network Meta-Analysis (Nma) to Assess Relative Efficacy of Canagliflozin (Cana) Versus Glucagon-Like Peptide-1 (Glp-1) Agonists in Dual and Triple Therapy In Patients with type 2 Diabetes Mellitus (T2dm)","Suzy Van Sanden","2015","Value in Health","systematic_review","article","10.1016/j.jval.2015.03.319",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0045353","A case of type B insulin resistance syndrome with postprandial hyperglycemia successfully treated with liraglutide","Satoru Uchida","2017","Tōnyōbyō/Tounyoubyou","case_report","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045354","High throughput methods and novel approaches for the characterization and purification of bioactive compounds in different matrices","Matteo Spedicato",null,"Institutional Research Information System University of Ferrara (University of Ferrara)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0045355","Could a new type of weight-loss pill shake up the market? Here’s what to know about orforglipron","MARTIN B. WHYTE","2026",null,"other","article","10.64628/ab.e5h7het7h",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0045356","Efficacy and Safety of the Oral Small-Molecule GLP-1 Receptor Agonist HRS-7535 in Patients with Diabetic Kidney Disease","Xiaoying Du","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20254m6bwa9n",null,null,"ClinicalTrials.gov:NCT06415214","S001370","openalex","FALSE","paywalled","1","FALSE","article"],["R0045357","Is the sympathetic hyperactivity a confounding factor for the outcomes of atrial fibrillation ablation?","Márcio Galindo Kiuchi","2020","EP Europace","randomized_trial","article","10.1093/europace/euaa089","32531031",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045358","Tirzepatide a novel anti diabetic molecule unfold dual action","Sweta","2024","Discover Public Health","other","article","10.1186/s12982-024-00200-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045359","The Effect of SGLT-2i and GLP-1RA on Major Cardiovascular Conditions: A Meta-Analysis","Arjun V. Jogimahanti","2024","Cardiology and Cardiovascular Medicine","systematic_review","article","10.26502/fccm.92920359",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0045360","Abstract 438: Peripheral but Not Central Glucagon-Like Peptide-1 Receptor Agonism Regulates Fasting Dyslipidemia by Reducing VLDL Production","Jennifer Taher","2014","Arteriosclerosis Thrombosis and Vascular Biology","other","article","10.1161/atvb.34.suppl_1.438",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045361","Effect of Tirzepatide on Weight Reduction in People With Obstructive Sleep Apnea and Obesity: A Post Hoc Analysis of the SURMOUNT Trials","Beverly L. Falcón","2024",null,"other","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2990",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045362","Neuroprotective Mechanisms of GLP‑1 Pathway Activation in Parkinson’s Disease - Foundations For Future Disease‑Modifying Strategies","Gabriela Chmiel","2026","Quality in Sport","other","article","10.12775/qs.2026.51.68253",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045363","A Content Analysis of Web Pages on “Weight-Loss Injections”","Asuman Okur","2026","Cerasus journal of medicine.","other","article","10.70058/cjm.1852434",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045364","Abstract 4141117: Semaglutide and cardiovascular outcomes by blood pressure in the SELECT trial","Subodh Verma","2024","Circulation","randomized_trial","article","10.1161/circ.150.suppl_1.4141117",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0045365","Su1816 EVALUATION OF ENDOSCOPIC SLEEVE GASTROPLASTY (ESG) AS AN ALTERNATIVE WEIGHT LOSS STRATEGY FOR PATIENTS WITH OBESITY DISCONTINUING GLP-1 RECEPTOR AGONISTS DUE TO INTOLERANCE OR INEFFECTIVENESS (RESCUE GLP-1)","Pichamol Jirapinyo","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04832-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045366","Vildagliptin promotes improvement in pulmonary arterial hypertension: incretin-based therapy at a follow-up of 3 years","Flavio Fontes Pirozzi","2017","Lungs and Breathing","other","article","10.15761/lbj.1000105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045367","Semaglutide and COVID-19 mortality risk","Emily Tang","2026","Scientific Reports","nonrandomized_study","article","10.1038/s41598-026-64277-2",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045368","Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes in Adults with Obesity Undergoing Elective Non-Bariatric Surgery: A Systematic Review","Abdulrahman Al‐Majmuei","2026","SN Comprehensive Clinical Medicine","systematic_review","article","10.1007/s42399-026-02671-7",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045369","Ozempic: the gold standard for weight normalisation or a “lifeboat”","Hanna Salivon","2026","Ukrainian Scientific Medical Youth Journal","other_trial","article","10.32345/usmyj.1(160).2026.45-49",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0045370","Abstract 13535: The Synergistic Effects of Incretin-related Drugs for the Treatment of Pulmonary Arterial Hypertension","Susumu Hosokawa","2014","Circulation","preclinical","article","10.1161/circ.130.suppl_2.13535",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045371","LATEST ADVANCES IN INJECTABLE AND ORAL MEDICATIONS FOR TYPE 2 DIABETES TREATMENT","Katarzyna Jurkiewicz","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3883",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045372","Microbiota gut-brain axis dysfunction in Alzheimer’s Disease: From pathogenesis to potential treatments – A review","Bilal Salman","2025","Health Sciences Review","narrative_review","article","10.1016/j.hsr.2025.100251",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045373","9229 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-4 phase 3 Trial","Theresa Marie Gibble","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.043",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045374","A Novel, Scalable Rat Model of Glomerular Hyperfiltration CKD via Inducible Nephron Progenitor Cell Ablation","Shutaro Yamamoto","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20250ks938wt",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045375","105-OR: Single-Cell Multiomic Analysis of the Effect of GIP and GIP-1 Mono- and Multi-agonism on the Hypothalamus and Hindbrain","Robert M. Gutgesell","2024","Diabetes","preclinical","article","10.2337/db24-105-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045376","Clinical experience of long-term observation of the efficacy of a fixed combination of insulin glargine and GLP-1RA lixisenatide in patients with type 2 diabetes mellitus who did not reach the target glycemia values with the use of oral antidiabetic drugs","A.M. Mkrtumyan","2020","Фарматека","other","article","10.18565/pharmateca.2020.4.119-123",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045377","Evaluation of the Efficacies of Liraglutide and Glargine in Type 2 Diabetes Patients with Malignant Tumors Treated with Glucocorticoids","D. L. Pu","2022","Indian Journal of Pharmaceutical Sciences","other","article","10.36468/pharmaceutical-sciences.spl.428",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045378","Efficacy and safety of semaglutide in type 2 diabetes compared with sitagliptin, exenatide ER, insulin glargine, basal insulin and placebo: a systematic review","Wei Lin","2018","Pharmaceutical Sciences Asia","systematic_review","article","10.29090/psa.2018.03.123",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045379","Correlation Between Bone Mineral Density (BMD) And Serum Carboxy-Terminal Cross-Linked Telopeptide of Type 1 Collagen (CTX-1) In Type 2 Diabetes Mellitus (T2DM) Patients on Antidiabetic Medications","Mohamed E. Hanafy","2024","Al-Azhar International Medical Journal /Al-Azhar International Medical Journal","nonrandomized_study","article","10.58675/2682-339x.2804",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045380","Prevalence of Adverse Events and Hypoglycemia in Patients with Type 2 Diabetes Treated with Novel Antidiabetic Medications","Ebrahim Mohammadi","2025","مجله دانشگاه علوم پزشکی اراک","nonrandomized_study","article","10.61186/jams.28.1.43",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045381","2817-LB: Semaglutide in Kidney Transplant Recipients: Real-World Evidence on Safety and Efficacy","ELAMIN ABDELGADIR","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2817-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045382","Leader 8: Type 2 Diabetes Patients: A Comparison of Baseline Characteristics of Eastern and Western European Participants with Established Cardiovascular Disease in the LEADER Trial","Edward Franek","2016","Journal of Diabetes & Metabolism","other_trial","article","10.4172/2155-6156.1000646",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0045383","1092-P: Treatment Changes Post–Second-Line Medication Initiation, a Real-World Retrospective Cohort Study","SANYA PASRICHA","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1092-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045384","The Potential Role of Antidiabetic Agents in Bipolar Disorder","Eliana Landivar","2026","Current Treatment Options in Psychiatry","randomized_trial","article","10.1007/s40501-026-00375-2",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045385","PCR58 Comparing Adherence in Patients with Type 2 Diabetes Initiating Glucagon-like Peptide-1 Receptor Agonists or Sodium-Glucose Cotransporter-2 Inhibitors","Udim Damachi","2023","Value in Health","other","article","10.1016/j.jval.2023.03.1837",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0045386","Antidiabetic pharmacotherapy aiding in fertility restoration: an integrative review of current evidence","Rowyna Reji Koshy","2026","Middle East Fertility Society Journal","narrative_review","article","10.1186/s43043-026-00316-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045387","EP406 - ECE_1369 - Impact of ethnicity and antihyperglycemic medications on dementia incidence in older adults with type 2 diabetes","Elena Chertok Shacham","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.922",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045388","EP670 - ECE_2372 - Liraglutide versus tirzepatide: real-world effects on lipid and carbohydrate metabolism in adults with class III obesity","Maria Evangelia Koloutsou","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1087",null,null,"ClinicalTrials.gov:NCT07094568","S000828","openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0045389","Mo1738 COMPARATIVE RISK OF ESOPHAGEAL DYSFUNCTION AMONG GLP-1 RECEPTOR AGONIST USERS VERSUS NON–GLP-1 USERS IN A LARGE MULTICENTER PROPENSITY-MATCHED COHORT","Kevin Nguyen","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)04616-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045390","Fast Quantitative Evaluation of the Amelioration Effect in MASLD During Semaglutide Treatment Using Ultrasound‐Derived Fat Fraction and Fat‐to‐Muscle Ratio","Yun‐Lin Huang","2026","Portal hypertension & cirrhosis","other","article","10.1002/poh2.70035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045391","Leveraging the Individualized Metabolic Surgery Score to Predict Weight Loss with Tirzepatide in Adults with Type 2 Diabetes and Obesity","Regina Castaneda","2026","Diabetology","nonrandomized_study","article","10.3390/diabetology7010010",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045392","Primary care diabetes prescribing volume and costs are on the increase","Steve Chaplin","2017","Practical Diabetes","other","article","10.1002/pdi.2144",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045393","Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program","Gurdeep Singh","2021","International Journal of Diabetes and Endocrinology","nonrandomized_study","article","10.11648/j.ijde.20210604.17",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045394","Prévention des effets délétères des inhibiteurs de l’intégrase du VIH sur le tissu adipeux grâce aux analogues des incrétines GLP1/GIP","Kenza Ngono Ayissi","2024","Annales d Endocrinologie","preclinical","article","10.1016/j.ando.2024.08.586",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045395","164-OR: A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide in Adults with Overweight or Obesity","Linong Ji","2025","Diabetes","randomized_trial","article","10.2337/db25-164-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045396","Semaglutide in the Treatment of Diabetes and Associated Obesity","Rafał Makuch","2024","Journal of Education Health and Sport","other","article","10.12775/jehs.2024.73.51699",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045397","8 Implication of drug repurposing in the identification of drugs for renal disorders","Mayank Joshi","2023","Drug repurposing","other","article","10.1515/9783110791150-008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045398","GLP-1 Receptor Agonists and Chronic Migraine: A Real-world Cohort Study of Healthcare Utilization and Preventive Escalation (P10-15.017)","Vitória Acar","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000215109",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045399","POSA125 Comparing Healthcare Cost Among Empagliflozin, DPP-4 Inhibitors and GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A German Claims Data Analysis","Thomas Wilke","2022","Value in Health","nonrandomized_study","article","10.1016/j.jval.2021.11.268",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045400","Therapeutic Approaches to Newer Classes of Drugs and Treatments for Type 2 Diabetes Mellitus","Abhik Paul","2026","Apple Academic Press eBooks","other_trial","article","10.1201/9781779640598-4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0045401","Natural Products Targeting GLP-1: Insights into Herbal Therapy for Insulin Resistance and Beta-Cell Function","Akshita Vyas","2026","International Journal of Drug Discovery and Pharmacology","other","article","10.53941/ijddp.2026.100001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045402","S723 The Holy Grail Illusion: GLP-1s, Pharmacologic Hope, and Public Health Failure in Obesity Care","Julian Galindo-Ramírez","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001130352.71778.f2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045403","Natural Peptides with Potential Applications in Drug Development, Diagnosis, and/or Biotechnology","Mirian A.F. Hayashi","2012","International Journal of Peptides","preclinical","article","10.1155/2012/757838","22927866",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045404","Diabetes and cancer: Doubts of a causal link","Andrew G. Renehan","2024","International Journal of Cancer","randomized_trial","article","10.1002/ijc.34862","38450768",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045405","Cell-type specific secretome profiling reveals targets of liver-heart interorgan crosstalk in HFpEF and semaglutide treatment","J P Schuette","2025","European Heart Journal","preclinical","article","10.1093/eurheartj/ehaf784.4729",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045406","Lithium toxicity with GLP-1RA co-prescription: clinical considerations and recommendations","Sonia Seth","2025","Personalized Medicine in Psychiatry","other","article","10.1016/j.pmip.2025.100177",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045407","POSTER: MM-1086: GLP-1 Receptor Agonists and Venous Thromboembolism Risk in Multiple Myeloma","Priyanshi Maurya","2026","Clinical Lymphoma Myeloma & Leukemia","other","article","10.1016/s2152-2650(26)01406-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045408","Utilisation du liraglutide 3 mg dans l’obésité hypothalamique secondaire au craniopharyngiome après échec de chirurgie bariatrique : à propos d’un cas","Marion Bretault","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.719",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045409","Exploration on the protective effect of liraglutide on renal injury in diabetic nephropathy rats based on ROS-NLRP3 inflammasomes","Jun Xue","2024","Discussion of Clinical Cases","preclinical","article","10.5430/dcc.v10n3p18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045410","The role of sevoflurane in postoperative cognitive dysfunction","Wenjie Wang","2023","Medical Gas Research","preclinical","article","10.4103/2045-9912.388755","40232697",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045411","The Worldwide Problem of Obesity - Comparison of the Effectiveness of Pharmacological Treatment with Semaglutide and Tirzepatide in Reducing Body Weight","Karolina Garbino","2025","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2025.79.58305",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045412","GLP-1 receptor agonists and depression in obesity: current evidence","Dawid Głaz","2026","Archiv Euromedica","randomized_trial","article","10.35630/2026/16/iss.1.005",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045413","91-LB: Study of Glycemic Variability and Hypoglycemia Using Continuous Glucose Monitoring in Type 2 Diabetes Mellitus Changed from Basal-Bolus Therapy to Basal-GLP-1RA Therapy","Arina Miyoshi","2020","Diabetes","other","article","10.2337/db20-91-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045414","Additional file 2 of The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis","do Nascimento, Tatiana S.","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26752561",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0045415","Review of pharmacological treatment registered for obesity in Poland","Julia Wyrwał","2024","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2024.56.004",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045416","GLP-1受容体作動薬(GLP-1RA)が体組成に及ぼす影響の検討","Kubota Sodai","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045417","Beinaglutide Alleviates Weight and Reduces Adipose Tissue Inflammation and Intestinal Permeability in HFD Mice","Minli Qu","2022","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4208693",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045418","Treatment of NAFLD: Diet, Physical Activity, and Potential Pharmacological Options","Justyna Śliz","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.16.52219",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045419","Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives","Andrea Carugno","2026","Sage Open Chronic Disease","randomized_trial","article","10.1177/27558428261449178",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0045420","Uso off label da semaglutida (Ozempic®) por indivíduos não diabéticos para perda de peso","Chirlaine Cristina OLIVEIRA","2026","Revista científica FACS.","other","article","10.70159/rcfacs.v26.925",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045421","Total Knee Arthroplasty with GLP-1 RAs: a literature review of the association between primary total knee arthroplasties and GLP-1 use on post-operative outcomes","Benjamin Huang","2026",null,"narrative_review","article","10.17605/osf.io/a96t2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045422","Investigating SNAC-enhanced peptide drug permeability with stimulated Raman scattering microscopy","Chisa Zensho","2026",null,"other","article","10.1117/12.3081009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0045423","OS-020 Effect of empagliflozin alone or combined with low-dose semaglutide on metabolic dysfunction-associated steatohepatitis and type 2 diabetes – a histology-based randomized, placebocontrolled, double-blind phase 4 trial (COMBAT_T2_NASH)","Sabine Kahl","2026","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(26)00330-2",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0045424","2836-LB: HbA1c and Weight Outcomes among Adults with Type 2 Diabetes on 25 mg Oral Semaglutide Previously Treated with Metformin Only: A Post hoc Analysis from PIONEER PLUS","LIN XIE","2026","Diabetes","randomized_trial","article","10.2337/db26-2836-lb",null,null,"ClinicalTrials.gov:NCT04707469","S001571","openalex","FALSE","paywalled","1","FALSE","article"],["R0045425","Improvement of Sleep-related Eating Disorder With a GLP-1 Receptor Agonist (P3-14.007)","Subhendu Rath","2026","Neurology","other","article","10.1212/wnl.0000000000217525",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045426","Obesity and cardiovascular aging: current state of the problem","A.N. Kuchmin","2025","Therapist’s Bulletin","other","article","10.31550/2712-8601-vt-2025-4-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045427","1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial","Julio Rosenstock","2019","Diabetes","randomized_trial","article","10.2337/db19-1146-p",null,null,"ClinicalTrials.gov:NCT02787551","S001125","openalex","FALSE","paywalled","1","FALSE","article"],["R0045428","1720-P: Effect of Renal Impairment on the Pharmacokinetics and Safety of Bofanglutide","Wei Zhao (14321)","2026","Diabetes","other_trial","article","10.2337/db26-1720-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045429","2844-LB: Safety, Tolerability, PK, and PD of Elecoglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Chinese Adults Living with Obesity or Overweight With or Without Type 2 Diabetes","Yerong Yu","2026","Diabetes","randomized_trial","article","10.2337/db26-2844-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045430","Mo1814 GLP-1 RECEPTOR AGONISTS ASSOCIATED WITH LOWER RISK OF GASTROINTESTINAL MALIGNANCIES IN NON-DIABETIC PATIENTS WITH OBESITY","Mahmoud Yousef","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04947-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045431","The frontline of metabolic dysfunction–associated steatotic liver disease: More to be discovered","Chun-Ting Ho","2025","Journal of the Chinese Medical Association","other_trial","article","10.1097/jcma.0000000000001266","40626331",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0045432","Abstract 15482: Effects of DPP4-inhibition on Endothelial Function and Hemostasis in a Rodent Model of Septic Shock","Sebastian Steven","2014","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045433","Treatment effects of once-weekly dulaglutide versus insulin glargine in patients with different baseline glycemic patterns (based on high/low fasting or high/low postprandial glucose): A post hoc analysis of the AWARD-2 clinical trial","Francesco Giorgino","2019","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0039-1688249",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0045434","Novel Cutaneous Manifestations During Semaglutide Therapy: Case Report of Two Siblings","Saima Rahman","2026","Journal of Saidu Medical College","case_report","article","10.52206/jsmc.2026.16.3.1403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045435","Efficacy and safety of GLP-1 Receptor Agonists for BMI Reduction in Children and Adolescents with Obesity: A Narrative Review","Justyna Pestka","2026","Quality in Sport","nonrandomized_study","article","10.12775/qs.2026.54.70610",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0045436","A dual GLP-1/GIP agonist inhibits oxidative stress in diabetic rats with cerebral ischemia-reperfusion injury by activating the Nrf2/ARE signaling pathway","Bo Bai","2026","Fluids and Barriers of the CNS","preclinical","article","10.1186/s12987-026-00874-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045437","Verifying the Safety of Microbial Contamination in Self-Injectors of Glucagon-like peptide-1 Receptor Agonists","Atsushi Ishimura","2024","Scholars Academic Journal of Pharmacy","other","article","10.36347/sajp.2024.v13i03.001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045438","Modern Approaches to the Management of Obesity in Children: Novelties","Ya. V. Girsh","2021","Doctor Ru","other","article","10.31550/1727-2378-2021-20-10-61-67",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045439","1052-P: Changes in Medical Expenditures Associated with GLP-1RA Initiation in Medicare Beneficiaries with Type 2 Diabetes","Yu Wang","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1052-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045440","1487-P: Use of GLP-1 Receptor Agonists among Medicare Beneficiaries with Diabetes, 2017–2021","LINDA J. ANDES","2025","Diabetes","other","article","10.2337/db25-1487-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045441","EE77 Cost-Effectiveness Analysis of Liraglutide for the Treatment of Obesity in Mexico","R Valdez-Huerta","2022","Value in Health","other","article","10.1016/j.jval.2022.04.331",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0045442","E-111 | Comparing the effects of Tirzepatide vs. Semaglutide on Long-Term Outcomes in Heart Failure Patients with co-existing chronic kidney disease: A US Cohort Propensity-Matched Study","Abdul Wali Khan","2025","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2025.103372",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0045443","Fluorescence lifetime imaging uncovers quantitative metabolic alterations in proximal tubular epithelial cells in type 2 diabetes","Woo Young Kwon","2026","Journal of Analytical Science & Technology","preclinical","article","10.1186/s40543-026-00557-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045444","Charting the future of cardiorenal medicine: a vision for integration, innovation, and impact","Amir Kazory","2025","Frontiers in Nephrology","randomized_trial","article","10.3389/fneph.2025.1719673","41311555",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045445","PERIOPERATIVE PREPARATION OF PATIENTS RECEIVING GLP-1 RECEPTOR AGONISTS","N.D. Daniyalova","2023","Современные проблемы науки и образования","other","article","10.17513/spno.33167",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045446","Evaluating AI-generated patient information on GLP-1 receptor agonists: A comparative analysis of ChatGPT amd Gemini","J Stepp","2026","SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045447","Difficulty identifying clinical signs of cushing's disease with concomitant glucagon-like peptide-1 receptor (GLP-1) agonist use","Demetris Mariannis","2025","Endocrine Abstracts","other","article","10.1530/endoabs.113.wg2.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045448","FRI-431 A novel GLP-1/GDF15 dual-agonist reduces hepatic inflammation and fibrosis in murine models of chemical-induced liver fibrosis and metabolic associated steatohepatitis (MASH)","Yuanping Shi","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)01649-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045449","GLP1 receptor activation and DPP‐4 inhibition increase GFR and induce natriuresis and diuresis in mice","Timo Rieg","2011","The FASEB Journal","preclinical","article","10.1096/fasebj.25.1_supplement.666.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045450","3057-LB: GLP-1 Receptor Agonist Treatment Promotes IL6-Dependent Activation of Brown Adipogenesis Program and Glucose Uptake in Adipose Tissue of Insulin-Resistant Humans","ABSALON D. GUTIERREZ","2026","Diabetes","randomized_trial","article","10.2337/db26-3057-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045451","P073 GLP-1 agonists, weight-loss and systemic autoimmune rheumatic diseases: functional outcomes and real-world safety experience","Gagandeep Sukhija","2026","Lara D. Veeken","nonrandomized_study","article","10.1093/rheumatology/keag121.109",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045452","Amycretin in the Treatment of Obesity: Hormonal Mechanisms, Clinical Evidence, and Therapeutic Perspectives of the New Generation of Incretin Agonists","Carolina Fátima Gioia Nava","2026","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.015961026050812",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045453","Abstract 13192: Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, Ameliorates Endothelial Dysfunction and Atherogenesis in Apolipoprotein-e Deficient Mice Through GLP-1 Dependent and Independent Manners","Hotimah Masdan Salim","2015","Circulation","preclinical","article","10.1161/circ.132.suppl_3.13192",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045454","Oxidative stress, inflammation, and metabolic dysregulation in type 2 diabetes: Therapeutic potential of Carica papaya","Mthokozisi Bongani Nxumalo","2026","Health Sciences Review","other","article","10.1016/j.hsr.2026.100274",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045455","102-OR: Efficacy and Safety of Once-Weekly Efpeglenatide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (AMPLITUDE-M)","Seung Jae Baek","2021","Diabetes","randomized_trial","article","10.2337/db21-102-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045456","687-P: ß-Cell Function and Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes","Masashi Hasebe","2021","Diabetes","nonrandomized_study","article","10.2337/db21-687-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045457","Comparative effects of liraglutide, elafibranor and obeticholic acid on NAFLD activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed NASH","Michael Feigh","2017","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(17)31629-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045458","Impact of modern glucose-lowering therapies on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes","A. M. Urbanovych","2026","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","nonrandomized_study","article","10.22141/2224-0721.22.3.2026.1717",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045459","Peptide hormone exendin-4 enhances neurogenesis in the dentate gyrus of photochemically induced cerebral ischemia model mice","Chang Sub Lee","2014","Journal of Medicine and Life Science","preclinical","article","10.22730/jmls.2014.11.2.90",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045460","Efficacy and safety of liraglutide compared with insulin glargine in patients with type 2 diabetes mellitus inadequately controlled with metformin","Wen Guo","2014","Zhonghua neifenmi daixie zazhi","randomized_trial","article","10.3760/cma.j.issn.1000-6699.2014.12.011",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045461","Casos reais e o que aprendemos?","Maria Eduarda Silva Santos","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18793543",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0045462","SAT-573 Should We Be Keeping a Closer Eye? A Case of Non-arteritic Anterior Ischemic Optic Neuropathy (Naion) After Semaglutide Initiation","Asnin Shah","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.1104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045463","Efficacia e sicurezza della semaglutide orale 50 mg die in adulti con sovrappeso o obesità: risultati dello studio OASIS 1","Rossana Richiusa","2025","L Endocrinologo","other","article","10.1007/s40619-025-01638-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045464","Comparing GLP-1 agonists versus other weight loss interventions on atrial fibrillation recurrence after catheter ablation: a meta-regression analysis","Hsing‐Yuan Li","2025","EP Europace","randomized_trial","article","10.1093/europace/euaf085.330",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045465","ADVERSE EFFECTS OF GLP-1 RECEPTOR AGONISTS: A COMPREHENSIVE APPROACH","Natalia Sapeda","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.4(48).2025.4111",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045466","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss and Cardiovascular Protection in Obesity and Type 2 Diabetes: A Systematic Review and Meta-Analysis","Ishtiaq Ahmad","2026","Journal of Diabetes Research Review & Reports","systematic_review","article","10.47363/jdrr/2026(8)209",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045467","2843-LB: HbA1c and Weight Outcomes for Individuals with T2D Persistent on 25mg Oral Semaglutide: A PIONEER PLUS Post-Hoc Analysis","Yeshaben Patel","2026","Diabetes","other_trial","article","10.2337/db26-2843-lb",null,null,"ClinicalTrials.gov:NCT04707469","S001571","openalex","FALSE","paywalled","5","FALSE","article"],["R0045468","Impact of semaglutide introduction on the use of ten concomitant medications An interrupted-time series","Noémie Roland","2026",null,"other","article","10.17605/osf.io/amsn6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045469","766-P: Long-Term Effectiveness Associated with Maintenance Doses of Once-Weekly Semaglutide in U.S. Adults with Poorly Controlled Type 2 Diabetes","XI TAN","2024","Diabetes","nonrandomized_study","article","10.2337/db24-766-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045470","#1704 GLP-1RA versus DPP-4 inhibitors and rates of hyperkalemia and discontinuation of renin-angiotensin system (RAS) blockade in Swedish routine care","Yang Xu","2024","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfae069.105",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045471","GLP-1 therapies for obesity: mechanisms, outcomes, and regulatory challenges","Debora de Oliveira Emos","2026","Academia Drug Development and Pharmacotherapy","other","article","10.20935/acaddrug8360",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045472","Safety of liraglutide treatment for obesity or overweight:a Meta-analysis","Na Su","2015","药物不良反应杂志","systematic_review","article","10.3760/cma.j.issn.1008-5734.2015.02.012",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0045473","Not All Weight Loss Is Equal: Towards Muscle‐Preserving Therapies in Obesity","Joseph D Abraham","2026","Journal of Cachexia Sarcopenia and Muscle","randomized_trial","article","10.1002/jcsm.70298","42046455",null,"ClinicalTrials.gov:NCT06282458","S002177","openalex","TRUE","free_to_read","1","FALSE","article"],["R0045474","D-68 | Comparative Cardiovascular Outcomes of Tirzepatide vs Semaglutide After PCI in Type 2 Diabetes: A Real-World Propensity-Matched Analysis","Ayodeji Ilelaboye","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104936",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0045475","Clonal hematopoiesis of indeterminate potential (CHIP) as a pre-specified effect modifier of GLP-1 receptor agonist cardiovascular benefit in type 2 diabetes: a target trial emulation","Youxin Tan","2026",null,"nonrandomized_study","article","10.17605/osf.io/tnq8x",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0045476","The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study","Bryan Alcazar","2026","Dove Medical Press (Taylor and Francis Group)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0045477","Anesthetic considerations in patients receiving glucagon-like peptide-1 receptor agonists: Focus on gastric emptying and safety","Raja Suhail Shounthoo","2026","Asian Journal of Medical Sciences","other","article","10.71152/ajms.v17i7.5334",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045478","Development of Reverse Phase Ultra-High Performance Liquid Chromatography for the Identification of Semaglutide","Ali Mohammed Saleh Ahmed","2024","Pakistan Journal of Science","other","article","10.57041/vol76iss03pp326-332",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045479","Markers of blood oxidative stress and antioxidative enzymes activity in obese diabetic elderly rats treated with Metformin or Liraglutide","Ines Drenjančević","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045480","227-OR: Patient-Reported Outcomes in People with T2D in the SURPASS-SWITCH Phase 4 Clinical Trial","KRISTINA BOYE","2025","Diabetes","randomized_trial","article","10.2337/db25-227-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045481","Association Between Semaglutide Use and Mood Disorders in Patients with Type 2 Diabetes","Uday Lomada","2026","Proceedings of IMPRS","nonrandomized_study","article","10.18060/29725",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045482","Protective effects of combining human umbilical cord mesenchymal stem cells and glucagon like peptide-1 receptor agonist on the islet inflammatory injury in rat model of type 2 diabetes mellitus","Chen Pin","2016","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2016.12.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045483","Modulación inflamatoria y metabólica: El papel de los agonistas del receptor GLP-1 en las enfermedades reumáticas","María Chacón","2026","Revista Reumatología al Día.","other","article","10.62484/rad.v20i2.13247",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045484","Tu1779 GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RA) USE IS ASSOCIATED WITH LOWER RATES OF GASTROINTESTINAL MALIGNANCIES IN OBESE PATIENTS. NATIONWIDE DATA ANALYSIS","Rama Nanah","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)04975-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045485","The Modulatory Effect of Liraglutide on the Expression of GPX4, HO-1 and SLC7A11 Signaling Pathway in Obese Rats","Mahmood Jameel Saeed","2026","Pharmaceutical Sciences","preclinical","article","10.34172/ps.026.43381",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045486","Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence","Natalia Gniaź","2024","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2024.75.56672",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045487","INNOVATIONS IN OBESITY TREATMENT – GLP – 1 PHARMACOTHERAPY AND BARIATRIC SURGERY","Piotr Bartnik","2025","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(47).2025.3682",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045488","Su1689 GASTROINTESTINAL EVENTS ASSOCIATED WITH CONCURRENT PPI AND GLP-1 RECEPTOR AGONIST THERAPY: A NATIONAL RETROSPECTIVE MULTICENTER COHORT","Mustafa Naveed","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04394-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045489","Blueness, Whiteness, and greenness Appraisal of sensitive chromatographic approach for determination of semaglutide concurrently with Pioglitazone and metformin using green mobile Phase; alongside with pharmacokinetic study","Noura M. Mansour","2024","Microchemical Journal","other","article","10.1016/j.microc.2024.111686",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045490","Tu1775 GLUCAGON LIKE PEPTIDE -1 RECEPTOR AGONISTS (GLP-1 RA) ARE ASSOCIATED WITH LOWER RATES OF COLORECTAL CANCER (CRC), COLECTOMY AND MORTALITY IN OBESE PATIENTS WHO HAVE NEVER UNDERGONE BARIATRIC SURGERY","Rama Nanah","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04971-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045491","Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight or obesity","A.M. Patti","2026","Nova Science Publishers (Nova Science Publishers, Inc.)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","book-chapter"],["R0045492","A Comparative Study Between Tirzepatide and Semaglutide in The Management of Obesity and Type 2 Diabetes Mellitus","Muhammad Mobarock Hossain","2025","Archives of Internal Medicine Research","nonrandomized_study","article","10.26502/aimr.0200",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045493","A Comprehensive Review on Evolving Landscape of Drug Therapies for Diabetes","Roni Weinberg Sibony","2024",null,"narrative_review","article","10.9734/bpi/mria/v4/11972f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045494","The synergistic potential of GLP-1R agonist dulaglutide and ghrelin receptor analogue anamorelin in ameliorating muscle atrophy","Hla Myat Mo Mo","2024","Medical Hypotheses","other","article","10.1016/j.mehy.2024.111418",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045495","Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists and cancer mortality. A real-world registry","D Garcia Vega","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.2932",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045496","Tirzepatide: The new ‘wonder drug’","Arafat Mansour","2025","InnovAiT Education and inspiration for general practice","other","article","10.1177/17557380251349067",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045497","Semaglutide-induced Silent Aspiration: An Unrecognized Cause of Organizing Pneumonia in a 27-year-old With Obstructive Sleep Apnea on CPAP Therapy – A Case Report","Kobina Essilfie‐Quaye","2025","American Journal of Respiratory and Critical Care Medicine","case_report","article","10.1164/ajrccm.2025.211.abstracts.a4176",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045498","Su1985 GLP-1 RECEPTOR AGONIST USE AND MAJOR FRACTURE RISK IN METABOLIC DYSFUNCTION-ASSOCIATED: A PROPENSITY-MATCHED COHORT STUDY","Hira Khan","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)03683-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045499","Liraglutide Limited Experience in Bahrain","Abeer Al Saweer","2014","Bahrain Medical Bulletin","other","article","10.12816/0008114",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045500","SUN-654 Comparative Efficacy and Safety of Glucagon Receptor Agonists in Metabolic Outcomes: A Network Meta-Analysis of Randomized Controlled Trials","Ayah Abulehia","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.164",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045501","Editorial: Nutrition for sustainable weight management post-bariatric surgery","Bart Torensma","2026","Frontiers in Nutrition","nonrandomized_study","article","10.3389/fnut.2026.1816785","42058705",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0045502","Comments on ‘The cardio–pancreatic axis in heart failure: from conceptual framework to empirical evidence’","Han Naung Tun","2026","ESC Heart Failure","other","article","10.1093/eschf/xvag122","42081457",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045503","Lumbar, But Not Renal or Vagal, Sympathetic Nerve Activation During GLP-1 Agonist–Induced Hyperglycemia with Fat-Dominant Metabolism","Yukino Komura","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2300003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045504","Su2072: ASSESSMENT OF GASTROINTESTINAL ADVERSE EFFECTS OF TIRZEPATIDE VERSUS SEMAGLUTIDE: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS OF THE U.S. COLLABORATIVE NETWORK","Hussein Baydoun","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03124-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045505","A meta-analysis preliminary result: Effectiveness and Safety of Oral Semaglutide vs. Injectable Semaglutide in Weight Loss in General Population Indifferent of Diabetic Status","Albalushi, Sarvinoz","2024","Digital Access to Scholarship at Harvard (DASH) (Harvard University)","systematic_review","article","10.53901/tjbs.2024.03.art03",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0045506","The Cost of Inaction in Treating Obesity in the United States","Tanvi Sapra","2026",null,"other","article","10.2337/figshare.32002617.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0045507","Abnormal Urinary C-Peptide Levels in a Patient with Type 2 Diabetes and Heart Failure Treated with GLP-1 Receptor Agonists and an ARNI","Kentaro Takahashi","2024","Annals of Case Reports","other","article","10.29011/2574-7754.101593",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045508","GLP-1 drugs like Ozempic may lower the risk of addiction: new study","Shalini Arunogiri","2026",null,"other","article","10.64628/aa.s6ptvqnf5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0045509","Alziemer","Ishaan Singla","2026","OSF Preprints (OSF Preprints)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","preprint"],["R0045510","Semaglutide come Architetto del Reset Epigenetico e Molecolare: Una Nuova Frontiera nella Geroscienza e nella Neuro-rigenerazione","Glauco Messina","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19512370",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045511","Clinical Science at the Intersection of Cardiovascular, Metabolic, and Renal Diseases: New Approaches","Heinz Drexel","2025","Cardiology","randomized_trial","article","10.1159/000547405","40790846",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045512","GLP-1 receptor agonist impact gutmicrobiota and intestinal immunity to improve hyperglycaemia and dyslipidaemia in rodents","Rémy Burcelin","2017","HAL (Le Centre pour la Communication Scientifique Directe)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0045513","Abstract TH829: Physician Perspectives and Barriers to Tirzepatide Use in Heart Failure with Preserved Ejection Fraction and Obesity","Ishan Abdullah","2026","Circulation","other_trial","article","10.1161/cir.153.suppl_1.th829",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0045514","BARIATRIC SURGERY IMPACTS IMMUNE CELL METABOLISM AND FUNCTION DEPENDENT ON METABOLIC STATUS","Samantha N. Hart","2026","UKnowledge (University of Kentucky)","nonrandomized_study","article","10.13023/etd.2025.574",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0045515","The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis","Binayak Sinha","2026","Figshare","systematic_review","article","10.6084/m9.figshare.c.8245119.v1",null,null,"PROSPERO:CRD420251045294",null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0045516","Efficacy and safety of GLP-1 receptor agonists for metabolic outcomes in patients with schizophrenia spectrum disorders treated with second-generation antipsychotics: a systematic review and meta-analysis","Adam Gędek","2026","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/zbc98",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0045517","Integrative multi-omics analysis reveals GLP-1R agonists-driven proteins via Notch signaling as mediators of ulcerative colitis risk","Hailong Li","2026","Genes & Diseases","nonrandomized_study","article","10.1016/j.gendis.2026.102070",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045518","Mechanisms of diabetes and dementia","Amar Puttanna","2019","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.2234",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045519","Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: A randomized controlled open label pilot study examining a 16-week flexible titration regimen vs. label-recommended 8-week semaglutide titration regimen","Roy Eldor","2025",null,"randomized_trial","article","10.2337/figshare.29425454.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0045520","In-vitro Differentiation of Human Umbilical Cord Wharton’s Jelly Mesenchymal Stem Cells to Insulin-Producing Cells","Masoomeh Nekohi Madoei","2015","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045521","TPW 7.15 First Reported Case of GLP-1 Induced Adult Jejuno-Jejunal Intussusception with No Identifiable Lead Point","Nour Ibrahim","2026","British journal of surgery","other","article","10.1093/bjs/znag087.384",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045522","Efficacy and safety of GLP-1 agonists in obesity-related heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized placebo-controlled trials","Jacinthe Khater","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.1283",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045523","2381-P: International Comparison of Adjuvant Pharmacotherapy Use in Type 1 Diabetes 2018–2024","Sarah Lyons","2026","Diabetes","other","article","10.2337/db26-2381-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045524","What can we do about the coincidence of runaway obesity and climate change?","Tim Lang","2026","Frontiers in Science","other","article","10.3389/fsci.2026.1773140",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045525","GLP-1 Agonists and Eating Disorders: Is There a Link?","Victória Vargas Castagno","2026","Open Minds International Journal","nonrandomized_study","article","10.22533/at.ed.51572122610066",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045526","Rapid Resolution of Psoriatic Arthritis Symptoms Following Initiation of a GLP-1 Receptor Agonist","Joseph E. Capito","2026","The Research Repository @ WVU (West Virginia University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045527","Abstract #1913019 Weight Loss Outcomes in Older Adults Treated With Liraglutide at the Qatar Metabolic Institute","Tariq Chukir","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.09.083",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045528","Glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors combination therapy after acute myocardial infarction in patients with type 2 diabetes mellitus: a dynamic duo?","Jasmina Ćatić","2024","Cardiologia Croatica","other","article","10.15836/ccar2024.524",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045529","IMPACT OF GLP-1 AGONISTS AND SOCIAL DETERMINANTS OF HEALTH ON OUTCOMES FOLLOWING TOTAL KNEE ARTHROPLASTY","Charles L. Nelson","2026","Orthopaedic Proceedings","nonrandomized_study","article","10.1302/1358-992x.2026.6.018",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045530","The Impact of GLP-1 Receptor Agonists on Reproductive Function in Women with Obesity and Metabolic Disorders: A Narrative Review","Emilia Muraszewska","2026","Quality in Sport","nonrandomized_study","article","10.12775/qs.2026.54.70814",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0045531","2042-P: Disparities in Diabetes Medication Use among Hispanic Adults with Type 2 Diabetes Mellitus","WENJUN FAN","2026","Diabetes","other","article","10.2337/db26-2042-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045532","Glucagon-like peptide 1 receptor agonists in the practice of an obstetrician-gynecologist","Apolikhina I.A. Apolikhina","2026","Akusherstvo i ginekologiia","other","article","10.18565/aig.2025.313",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045533","INITIATING PATIENTS ON GLP-1/COMBINED GLP-1 AND GIP AGONISTS: A QUALITY IMPROVEMENT PROJECT","Shreya Srivastava","2024","American Journal of Preventive Cardiology","other_trial","article","10.1016/j.ajpc.2024.100813",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0045534","IP59-10 POSTOPERATIVE OUTCOMES FOLLOWING NEPHRECTOMY IN OVERWEIGHT PATIENTS RECEIVING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RAS)","Aidan S. Weitzner","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191632.79764.15.10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045535","Pharmacokinetic bioequivalence of semaglutide injection in healthy adults under fasting conditions: A randomized study","Sohel Mohammed Khan","2026","Journal of Clinical and Translational Research","randomized_trial","article","10.36922/jctr026250056",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045536","3058-LB: Semaglutide-Induced Modulation of Multiomic Profiles and Oral Minimal Model-Derived Metrics in Mexican-Americans with Prediabetes: A Preliminary Analysis","ABSALON D. GUTIERREZ","2026","Diabetes","nonrandomized_study","article","10.2337/db26-3058-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045537","949-P: Dulaglutide Improves Kidney Fibrosis Biomarker Levels in Patients with Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease","KATHERINE R. TUTTLE","2020","Diabetes","other_trial","article","10.2337/db20-949-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045538","Holding up the crystal ball: using regulatory intelligence insights to support quality in healthcare","Martin Fletcher","2025","International Journal for Quality in Health Care","other","article","10.1093/intqhc/mzaf001","39797739",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045539","Exercise Interventions During GLP-1–Based Obesity Treatment: A Scoping Review of Muscle Health, Physical Fitness, and Implementation Characteristics","Ruofei Li","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/gnmwc",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0045540","The Interplay Between Breast Cancer and Diabetes Mellitus: Shared Mechanisms, Risk Factors, and Integrated Management Strategies","Mayowa Solomon Owolabi","2025","BIOMED natural and applied science","other","article","10.53858/bnas05010118",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045541","1678-P: Weight-Independent GLP-1RA Effects on Adipose Tissue PGC1-α and TERT in Insulin-Resistant Humans","ABSALON D. GUTIERREZ","2025","Diabetes","randomized_trial","article","10.2337/db25-1678-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045542","1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM","Kenji Ohwaki","2019","Diabetes","randomized_trial","article","10.2337/db19-1024-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045543","Dose Response Effects of Liraglutide (Saxenda) on Weight Loss among Overweight and Obese Individuals: A Three Arm Randomized Controlled Trial","Uzma Dost Muhammad Rajar","2024","ATHENS JOURNAL OF HEALTH & MEDICAL SCIENCES","randomized_trial","article","10.30958/ajhms.11-1-4",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045544","O39 Influence du liraglutide (analogue du GLP-1) sur les caractéristiques hédoniques de la prise alimentaire et les performances gustatives, chez les patients diabétiques de type 2","Marie‐Claude Brindisi","2011","Nutrition Clinique et Métabolisme","other","article","10.1016/s0985-0562(11)70043-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045545","WED-512-YI Safety and outcomes of glp-1 receptor agonists in patients with cirrhosis: a meld-matched real-world cohort study","Abdullah Sohail","2026","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(26)00780-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045546","Neuroprotective Potential of Liraglutide in Alzheimer's Disease","Gabriel Wilker De Alencar Farias","2024",null,"other","article","10.62922/4cbffc.cp099",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0045547","782-P: Insulin Therapy Deintensification with iGlarLixi—The IDEAL Randomized Controlled Trial","Peter Novodvorský","2024","Diabetes","randomized_trial","article","10.2337/db24-782-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045548","Nuevas perspectivas terapéuticas en diabetes tipo 2 y avances en agonistas del receptor GLP-1 [New therapeutic perspectives in type 2 diabetes and advances in GLP-1 receptor agonists]","Olivia Elizabeth Altamirano-Guerrero","2025","Sanitas. Revista arbitrada de ciencias de la salud.","other","article","10.62574/6bgm9479",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045549","Obesity-driven Cardiovascular Risk: Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists","Amandeep Kaur","2026","Glucolipid metabolic disorders","nonrandomized_study","article","10.2174/0129499011491956260906185203",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045550","128 Progress and early outcomes of a cardiometabolic clinic in a uk tertiary cardiology centre","Rajay Narain","2022","Heart failure","nonrandomized_study","article","10.1136/heartjnl-2022-bcs.128",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0045551","Páginas de inicio","Ève Bergeron","2024","Cairn.info","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045552","Mo1203 REDUCED RISK OF PROGRESSION OF ATROPHIC GASTRITIS AND GASTRIC INTESTINAL METAPLASIA TO GASTRIC CANCER IN PATIENTS USING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS","Abdellatif Ismail","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)06112-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045553","1805-P: Safety, Tolerability, and Pharmacokinetic Characteristics of GZR102 Injection Compared with GZR4 or Bofanglutide","DONGYANG LIU","2026","Diabetes","randomized_trial","article","10.2337/db26-1805-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045554","Protective Effects of Glucagon Like Peptide-1 on HIT-T15 β Cell Apoptosis via ER Stress Induced by 2-deoxy-D-glucose","Ju‐Young Kim","2008","Korean Diabetes Journal","preclinical","article","10.4093/kdj.2008.32.6.477",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045555","Снижение кардиоваскулярного риска у пациентов с сахарным диабетом 2 типа: обзор основных стратегий и клинических исследований","В. В. Салухов","2018","Сахарный диабет","randomized_trial","article","10.14341/dm9570-7290",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045556","The Role of the neuropeptide Y system in the pancreas in the development of obesity and diabetes","Xuan Zhang","2026","UNSWorks (University of New South Wales, Sydney, Australia)","preclinical","article","10.26190/unsworks/32057",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0045557","GLP-1 agonist semaglutide reduces appetite but reinforces pleasure","Karlijn L. Kooij","2022","Neuroscience Applied","other","article","10.1016/j.nsa.2022.100095",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045558","Heart failure in SAVOR‐TIMI 53: The hindsight of diabetic retinopathySAVOR‐TIMI 53研究中的心脏衰竭：糖尿病视网膜病变的后尘","Richard E. Gilbert","2014","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12249","25443633",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045559","Review of current therapeutic approaches for polycystic ovary syndrome","Teodora Mitrovic","2024","Medicinski pregled","randomized_trial","article","10.2298/mpns2412309m",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045560","1142-P: Efficacy and Safety of Antidiabetes Treatment in Adjunct to Insulin in Type 1 Diabetes","Xiaoling Cai","2019","Diabetes","other","article","10.2337/db19-1142-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045561","Editorial: Clinical trials in cardiovascular medicine: 2025—addressing residual cardiovascular risks through precision-guided approaches","Euscia Y. Wang","2026","Frontiers in Cardiovascular Medicine","randomized_trial","article","10.3389/fcvm.2026.1904928","42465537",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0045562","Available evidence on the use of GLP-1 analogues in women with polycystic ovary syndrome (PCOS): A scoping review","Karina Alves Medeiros","2026",null,"narrative_review","article","10.17605/osf.io/4kxbf",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045563","Association between GLP-1 receptor agonist use and glaucoma risk: a systematic review and meta-analysis","Luke M. Yaldo","2026","Figshare","systematic_review","article","10.6084/m9.figshare.31435727.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0045564","Association between glucagon-like peptide-1 receptor agonists and thyroid carcinoma; a systematic review and meta-analysis of observational studies","Mojtaba Lotfi","2025","Journal of Parathyroid Disease","systematic_review","article","10.34172/jpd.2025.13293",null,null,"PROSPERO:CRD420251051827",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045565","Obesidade e a busca por informações sobre o uso indiscriminado e off-label do Ozempic®","Lucas Mariano Herzogues","2025","Research Society and Development","other","article","10.33448/rsd-v14i6.48967",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045566","7971 The Role of PDX1 In Beta Cell Response To GLP1","Chandni Bheeman","2024","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvae163.971",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045567","Agonistas do receptor de GLP-1 no emagrecimento estético","Ana Beatriz Caetano Peixoto de Camargo","2026","Revista Ciências da Saúde CEUMA","other","article","10.61695/rcs.v4i1.94",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045568","26-A-19079-ACC EFFECT OF ORFORGLIPRON, A NOVEL ORAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST, ON LIPID PANEL AND BLOOD PRESSURE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Sharath Kommu","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.703",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045569","COST-EFFECTIVENESS ANALYSIS OF DULAGLUTIDE COMPARED WITH INSULIN GLARGINE ADD ON TO INSULIN LISPRO IN TREATMENT OF TYPE 2 DIABETES: A US THIRD-PARTY PAYER PERSPECTIVE","Mohammadreza Nili","2016","Value in Health","other","article","10.1016/j.jval.2016.03.1302",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045570","1438-P: Trends in Obesity and GLP-1RA Use among Youth and Adults with Type 1 Diabetes in U.S. Health System—2008–2022","Yunwen Xu","2024","Diabetes","other","article","10.2337/db24-1438-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045571","Etude DUAL V : l’efficacité d’IDegLira est indépendante de la dose d’insuline glargine administrée avant l’étude chez des patients diabétiques de type 2 insuffisamment contrôlés","Nicolas Chevalier","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045572","Influence of Copy Number and Spacer Peptides on Secretive Expression of exendin-4 Analog in Pichia pastoris","Siliang Zhang","2008",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045573","Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients","Ping Ping","2015","中国药理学报：英文版","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045574","Efficacy of GLP-1 Receptor Agonists in Reducing Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease","A M Alzahrani","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21617085",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0045575","MPN-1634: Targeting Metabolic-Inflammatory Signaling in Chronic Myelomonocytic Leukemia: Association of GLP-1 Receptor Agonist Therapy With Improved Real-World Outcomes","Asfand Yar Cheema","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)02429-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045576","1864-LB: Comparative Safety and Effectiveness of GLP-1RA and SGLT2i Use in Adults with Type 2 Diabetes in U.S. Clinical Practice","SARAH R. HOFFMAN","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1864-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045577","POSTER: MPN-1634: Targeting Metabolic-Inflammatory Signaling in Chronic Myelomonocytic Leukemia: Association of GLP-1 Receptor Agonist Therapy With Improved Real-World Outcomes","Asfand Yar Cheema","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)01000-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045578","Additional file 1 of Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials","Adir Alper","2026","Figshare","systematic_review","article","10.6084/m9.figshare.33413240.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0045579","GLP-1 RECEPTOR AGONISTS AS EMERGING THERAPEUTICS FOR SUBSTANCE USE DISORDERS: A REVIEW OF MECHANISMS, EFFICACY, AND PUBLIC HEALTH IMPLICATIONS","Natalia Bylak","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.1(49).2026.5071",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045580","Sa1973 OUTCOMES OF GLP-1 RECEPTOR AGONIST THERAPY AFTER LIVER TRANSPLANTATION IN PATIENTS WITH TYPE 2 DIABETES: A REAL-WORLD COHORT STUDY","Guy Nguefang","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)03508-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045581","Rethinking the signal: Depressed mood and suicidal ideation with GLP-1 receptor agonists","Zhangfang Zeng","2026","Journal of Affective Disorders Reports","other","article","10.1016/j.jadr.2026.101103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045582","Additional file 1 of The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis","Binayak Sinha","2026","Figshare","systematic_review","article","10.6084/m9.figshare.31075797",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0045583","Future Prospects of GLP-1–Based Biopharmaceuticals in Obesity and Diabetes Management: A Food and Biotechnology Perspective","Akter Sraboni","2026","Journal of Biotechnology and Food Engineering","other","article","10.64907/xkmf.v4.i1.jbfe.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045584","Unraveling the complexity of Exendin-4 folding through two distinct pathways","Ziyao Gao","2023","Journal of Mathematical Chemistry","other","article","10.1007/s10910-023-01535-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045585","The treatment of diabetes with new generation drugs","Szymon Marosz","2020","Journal of Education Health and Sport","other","article","10.12775/jehs.2020.10.09.083",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045586","Comparative effects of glucagon-like peptide-1-based regimens on peripheral arterial and limb events in type 2 diabetes: a network meta-analysis of randomized trials","Reza Amani‐Beni","2026","Diabetology & Metabolic Syndrome","systematic_review","article","10.1186/s13098-026-02271-4",null,null,"PROSPERO:CRD420251244166",null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0045587","26-A-14698-ACC GLP-1 RECEPTOR AGONISTS AND CLINICAL OUTCOMES IN HEART FAILURE PATIENTS: A REAL-WORLD MATCHED COHORT STUDY","Charbel Nakhoul","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1902",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045588","Експертний консенсус щодо ведення екзокринної недостатності підшлункової залози у пацієнтів із цукровим діабетом","Ігор Миколайович Скрипник","2026","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045589","Targeting intestinal neprilysin to ameliorate glucose homeostasis through insulinotropic effect","Shiori Mizuma","2024","Endocrinology","preclinical","article","10.1210/endocr/bqae131","39331736",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045590","Body weight reduction in women treated with tirzepatide by menopausal stage: A post hoc analysis from the SURMOUNT program","Andreea Ciudin Mihai","2024","Obesity Research & Clinical Practice","other","article","10.1016/j.orcp.2024.09.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045591","Directly observed Rx use of exenatide LAR in a unique Aboriginal and Torres Strait Islanders population in Australia","Gaurav Puri","2017",null,"nonrandomized_study","article","10.26226/morressier.59d51840d462b80296ca2d9d",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0045592","Retatrutide - revolutionary recently developed GLP agonist - literature review","Patrycja Brzozowska","2024","Quality in Sport","narrative_review","article","10.12775/qs.2024.15.52125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045593","IMPACT OF GLP-1 RECEPTOR AGONISTS ON THE MANAGEMENT OF DIABETIC RETINOPATHY: NEUROPROTECTIVE EFFECTS AND ASSOCIATED RISKS","Virgínia Gomes Fernandes","2024","International Journal of Health Science","other","article","10.22533/at.ed.15949624291011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045594","Optimisation du contrôle glycémique en chirurgie cardiaque : variabilité glycémique, compliance aux protocoles de soins, et place des incrétino-mimétiques","Guillaume Besch","2017",null,"other_trial","article","10.70675/a82dd2caz9bccz4076z8a9az23597b728f0a",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","dissertation"],["R0045595","Portal, Superior Mesenteric, and Splenic Vein Thrombosis After Tirzepatide Therapy: Triple Threat in Splanchnic Circulation","Abidemi O. Akinrinmade","2026","Annals of Internal Medicine Clinical Cases","other","article","10.7326/aimcc.2025.1284",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045596","Modalités de remplacement dâune association libre dâinsuline basale et agoniste du GLP-1R par la combinaison fixe Degludec-Liraglutide en situation de vie réelle : étude multicentrique française.","Pierre Gourdy","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045597","The effect of GLP-1 analogs on the motor function of patients with Parkinson’s disease: a systematic review and meta-analysis","Luís Fernando Ferreira Cavalcante","2024","Arquivos de Neuro-Psiquiatria","systematic_review","article","10.5327/cbn241606",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0045598","Insulin in Type 2 Diabetes: Therapeutic Failure or Marker of Disease Severity?","Carlos Duran Martinez","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025weg2mgrj",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045599","Effect of semaglutide in patients with type 2 diabetes and peripheral artery disease: an analysis of the STRIDE trial stratified by disease severity and age","J Nordanstig","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.3030",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045600","Optimization of glucose control drives improvement of NAFLD independent of weight loss in people with T2D","Santo Colosimo","2023","European Atherosclerosis Journal","other","article","10.56095/eaj.v2i1.34",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045601","GLP-1 receptor agonists in diabetes-associated neurological disorders","Rokhsana Rasooli","2026","Brain Disorders","other","article","10.1016/j.dscb.2026.100326",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045602","Sex‐Specific Adverse Event Reporting Signals Associated With Semaglutide: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS)","Minjiao Wang","2026","International Journal of Clinical Practice","nonrandomized_study","article","10.1155/ijcp/3238847",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045603","1222-OR: Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Type 1 Diabetes: A Target Trial Emulation Study","YUNWEN XU","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1222-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045604","Tackle Comorbid Obesity in T2DM by Applying New Strategies to Optimize Glycaemic Control and Weight Management","Yugandhar Bokka","2024",null,"other_trial","article","10.1201/9781003529231-11",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0045605","Additional file 2 of Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease","Jason N. Chen","2026","Figshare","nonrandomized_study","article","10.6084/m9.figshare.31911393",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0045606","Additional file 1 of Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","Nauck, Michael A.","2022","Figshare","randomized_trial","article","10.6084/m9.figshare.20782257.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0045607","Effect of contemporary HFpEF therapies on diuretic management: decongestive role or disease modification?","Mauro Riccardi","2026","European Journal of Heart Failure","randomized_trial","article","10.1093/ejhf/xuag074","41802271",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045608","Efficacy and Durability of Combination Treatment With Glucagon-Like Peptide-1 Receptor Agonists and Basal Insulin","Anthony Martinez","2022","ADCES in Practice","other","article","10.1177/2633559x221127992",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045609","Laser Doppler flowmetry in assessing the effect of liraglutide on microcirculation in rats with absolute insulin deficiency","Era B. Popyhova","2022",null,"preclinical","article","10.1117/12.2624388",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0045610","Dietary fiber and GLP-1 receptor agonists in obesity management: converging mechanisms, interactions, and strategies for durable weight control","Yuxin Wang","2025","Research Publications (Maastricht University)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0045611","6680 GLP-1 Agonists in Type 1 Diabetes - Indications and Use","Panadeekarn Panjawatanan","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.786",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045612","Glucagon-like peptide 1 receptor agonists: More than just weight loss medications.","Anna Homeniuk","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.2_suppl.520",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045613","1703-P: Treating Glucose Intolerance and High-Fat Diet–Induced Adiposity with the Novel Antidiabetic TIX100","SEONGHO JO","2025","Diabetes","preclinical","article","10.2337/db25-1703-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045614","The pleiotropic effects of liraglutide in obesity-linked diseases","Michał Kozdrowicki","2025","European Journal of Clinical and Experimental Medicine","nonrandomized_study","article","10.15584/ejcem.2025.2.2",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045615","111-LB: Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3","Julio Rosenstock","2019","Diabetes","other","article","10.2337/db19-111-lb",null,null,"ClinicalTrials.gov:NCT02607865","S002267","openalex","FALSE","paywalled","5","FALSE","article"],["R0045616","103-OR: Association of Tirzepatide with Kidney Parameters in People with Obesity and Prediabetes from SURMOUNT-1 over 176 Weeks","Hiddo J.L. Heerspink","2025","Diabetes","randomized_trial","article","10.2337/db25-103-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045617","PS-C17-9: RELEVANT BLOOD PRESSURE REDUCTION WITH ORAL SEMAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND OBESITY, INDEPENDENT OF PREVIOUS ANTIHYPERTENSIVE TREATMENT","Francisco Javier Martínez-Martín","2023","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0000916736.77778.3d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045618","Glucose-Lowering Therapies and Contrast-Associated Acute Kidney Injury: Results from a Large Cohort of Patients with Diabetes Mellitus","Monica Verdoia","2026","Diabetology","nonrandomized_study","article","10.3390/diabetology7080154",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045619","21-OR: Systematic Review and Meta-analysis of the Association of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Dementia in Patients with Type 2 Diabetes","CHI-HAN CHENG","2025","Diabetes","systematic_review","article","10.2337/db25-21-or",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045620","Maintaining women’s reproductive health in the context of drug-induced obesity correction (tirzepatide)","O. V. Yakushevskaya","2026","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2026-075",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045621","Semaglutide, a GLP-1 receptor agonist, preserves brain microcirculation and neurovascular unit integrity in a metabolic syndrome experimental model","Vanessa Estato","2023","Journal of the Neurological Sciences","other","article","10.1016/j.jns.2023.121686",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045622","Neurosymbolic Clinical Reasoning:From Evidence Extraction to Reason-Based Decision","Henrique Marcos","2026","Research Publications (Maastricht University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0045623","P22 Perspectives of clinical trial site staff on recruitment and retention barriers at UK centres participating in the ESSENCE trial","Simone Magnisio","2025",null,"randomized_trial","article","10.1136/gutjnl-2025-basl.38",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0045624","1715-P: Health-Related Quality of Life (HRQOL) in People with Type 2 Diabetes (T2D) Receiving the Once-Daily, Oral, Nonpeptide GLP-1RA Orforglipron in ACHIEVE-2 and -3","Kendra Terrell","2026","Diabetes","randomized_trial","article","10.2337/db26-1715-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045625","Effect of glucagon like peptide-1 receptor agonist combined human umbilical cord mesenchymal stem cells on the glucose metabolism and the islet β cell function in type 2 diabetic SD rats","Chen Pin","2015","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2015.12.005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045626","2154-P: Second-Line Antidiabetic Exposure in Early Pregnancy and Risk of Spontaneous Abortion: A Nationwide Cohort Study","Yongtai Cho","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2154-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045627","Semaglutide: A Potential Therapeutic for Mitochondria-Associated Disorders","George B. Stefano","2024","THE MIND - Bulletin on Mind-Body Medicine Research","other","article","10.61936/themind/202412123",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045628","1701-P: Longitudinal Dynamics of Cardiometabolic Parameters in a MASH Population Stratified by Baseline Glycemia and Treated with Semaglutide: Post Hoc Insights from the ESSENCE Trial Part 1","Mary Rinella","2026","Diabetes","randomized_trial","article","10.2337/db26-1701-p",null,null,"ClinicalTrials.gov:NCT04822181","S000511","openalex","FALSE","paywalled","1","FALSE","article"],["R0045629","Glucagon-like peptide-1 receptor agonist for primary prevention of hepatocellular carcinoma in high-risk patients: A real-world analysis across metabolic, viral, alcoholic, and hereditary liver disease.","Colton Jones","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.10522",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045630","1752-P: Improved Treatment Satisfaction with Once-Weekly IcoSema vs. Once-Daily Glargine U100 in Insulin-Naive Adults with Type 2 Diabetes (COMBINE 4)","LIMING CHEN","2026","Diabetes","randomized_trial","article","10.2337/db26-1752-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045631","RETATRUTIDE: REGULATORY CHALLENGES, PATIENT SAFETY, AND THE IMPACT OF THE ILLICIT SALE OF AN INVESTIGATIONAL DRUG FOR THE TREATMENT OF OBESITY","Simonia Mara De Oliveira","2026",null,"other","article","10.63330/aurumpub.058-017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0045632","Su1732 COMPARATIVE RISK OF ASPIRATION PNEUMONITIS ACROSS GLP-1 RECEPTOR AGONISTS AND TIRZEPATIDE: A LARGE REAL-WORLD TRINETX ANALYSIS","Gautam Maddineni","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)04506-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045633","IP59-23 INFLUENCE OF GLP1 RECEPTOR AGONIST ON RENAL CELL CARCINOMA INCIDENCE AND OVERALL SURVIVAL, A PROPENSITY SCORE MATCHED ANALYSIS USING THE OPTUMLABS DATA WAREHOUSE","Michael K. Wang","2026","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001191632.79764.15.23",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045634","A-98 | Comparative Cardiovascular Outcomes of Tirzepatide Versus SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Real-World Propensity-Matched Analysis","Ayodeji Ilelaboye","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104589",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0045635","Plain Language Summary of the Manuscript: Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes","Sean Wharton","2026","Boehringer Ingelheim","randomized_trial","article","10.60915/boehringer-figshare.32034918.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0045636","Abstract 20406: Stimulation of Glucagon-Like-Peptide-1 Receptor Elicits the Protection Through Akt-1 in Infarcted Hearts","Jian Du","2014","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045637","Knowledge, Attitudes, and Practices Regarding Tirzepatide (Mounjaro®) for Weight Management Among University Students in Jeddah, Saudi Arabia: A Cross-Sectional Study","Pharm D. Haitham Abdu","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045638","Efficacy and safety of once-weekly GLP-1 RA in patients with type 2 diabetes treated with DPP-4 inhibitor","Masako Murakami","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31180-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045639","Comparison of short-and long-acting glucagon-like peptide 1 receptor agonists on postprandial glucose excursion, insulin and glucagon secretions and gastric emptying","Hitoshi Kuwata","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31235-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045640","Finerenone and polypharmacy in heart failure with mildly reduced or preserved ejection fraction: a marker of risk, not a barrier to therapy","M J Yoon","2026","European Journal of Heart Failure","other_trial","article","10.1093/ejhf/xuag025","41771105",null,null,null,"openalex","FALSE","paywalled","5","FALSE","editorial"],["R0045641","Possibilities of optimizing therapy of heart failure with preserved ejection fraction using glucagon-like peptide-1 receptor agonists","E. A. Kuzheleva","2025","South Russian Journal of Therapeutic Practice","other","article","10.21886/2712-8156-2025-6-4-7-15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045642","Paper 06. Rotator Cuff Repair RoHI Scoring: Identifying Characteristics to Validate or Modify the Score System","Brian P. Cunningham","2026","Orthopaedic Journal of Sports Medicine","nonrandomized_study","article","10.1177/2325967126s00267",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045643","Influence of TCF7L2 gene polymorphisms on the effectiveness of various variants of antihyperglycaemic therapy in patients with type 2 diabetes","Olga Kondratyeva","2021","Voprosy dietologii","other","article","10.20953/2224-5448-2021-2-11-20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045644","Evolving strategies for nephroprotection in diabetic kidney disease: From established therapies to novel interventions","Guido Gembillo","2026","World Journal of Diabetes","randomized_trial","article","10.4239/wjd.v17.i4.115058",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0045645","INVESTIGATING RENAL FUNCTION MODULATION IN CHRONIC KIDNEY DISEASE: INSIGHTS INTO PATHOPHYSIOLOGY AND THERAPEUTIC TARGETS","Dr. Rayidi Manasa","2026","Genetics and Molecular Research","other","article","10.4238/h3e7dm12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045646","The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction","N. D. Kozhukhov","2025","Obstetrics Gynecology and Reproduction","randomized_trial","article","10.17749/2313-7347/ob.gyn.rep.2025.657",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045647","Unlocking the potential of GSK-3β inhibitors in neurodegenerative disease prognosis: insights from glucagon-like peptide-1 receptor agonist effects","Ahmed S. Khalifa","2026","Elsevier eBooks","other","article","10.1016/b978-0-443-44173-8.00021-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045648","Association Between Incretin-Based Therapies and Ocular Outcomes in Adults: A Systematic Review with Qualitative Synthesis","Carlos E. Builes-Montaño","2026",null,"systematic_review","article","10.17605/osf.io/28uz4",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0045649","1113 EXPOSURE TO GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH SIGNIFICANT REDUCTION IN BLEEDING EVENTS, TRANSFUSIONS, AND ENDOSCOPIC UTILIZATION IN PATIENTS WITH GASTROINTESTINAL ARTERIOVENOUS MALFORMATIONS: A REAL-WORLD PROPENSITY-SCORE MATCHED ANALYSIS","Rohit Goyal","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)05736-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045650","PWE-173 Peripheral And Central Effects Of A Single Dose Of The Glucagon-like Peptide-1 Receptor Agonist Exenatide","Lucy K. Wasse","2014","Gut","other","article","10.1136/gutjnl-2014-307263.433",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045651","Efficacy and safety of glucagon-like peptide-1 receptor agonists in the treatment of binge eating disorder in Type 2 diabetic patients: a pilot study in real world clinical practice","E. G. Starostina","2026","Diabetes Mellitus","nonrandomized_study","article","10.14341/dm13410",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045652","Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database","Amira Guirguis","2026","Cronfa (Swansea University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0045653","Effects of semaglutide on diabetic retinopathy a literature review","Liepa Kleizaitė","2026","Medical Sciences","narrative_review","article","10.53453/ms.2026.4.8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045654","FRI-168 Treatment effects of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, on hepatic biomarkers in patients with compensated and decompensated cirrhosis","Eric Lawitz","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)01909-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045655","Prandiální agonista receptoru pro GLP-1 (GLP-1 RA) lixisenatid jako klíčový faktor v kontrole tělesné hmotnosti u pacientů s diabetem 2. typu a obezitou","Petr Žák","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045656","Effectiveness of the glucagon test in estimating islet function for liraglutide treatment in a lean diabetic patient with impaired insulin response to glucose","Katsumi Iizuka","2012","Diabetology International","other","article","10.1007/s13340-012-0068-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045657","Arrhythmias in patients with diabetes","Patrycja Pabis","2025","In a good rythm","other","article","10.5604/01.3001.0055.0130",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045658","IDDF2026-ABS-0326 Glucagon-like peptide-1 receptor agonists are associated with reduced risk of opioid use and invasive interventions in chronic pancreatitis: a real-world cohort study","Arkadeep Dhali","2026","Clinical Gastroenterology","nonrandomized_study","article","10.1136/gutjnl-2026-iddf.312",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045659","Effect of Exenatide on Metabolic and Inflammatory Markers in Diabetic Obese Patients","Eşref Araç","2025","DAHUDER Medical Journal","nonrandomized_study","article","10.56016/dahudermj.1653914",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045660","The efficacy of once-daily liraglutide as an add-on to oral antidiabetic agents on weight reduction and glycemic control in obese patients with inadequately controlled type 2 diabetes: a retrospective analysis in relation to liraglutide dose escalation within a 7-month treatment period","Abbas Mahdi Rahmah","2020","International Journal of Diabetes in Developing Countries","nonrandomized_study","article","10.1007/s13410-020-00878-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045661","Application of Fuming Tablet Combined with Liraglutide in the Treatment of Diabetic Retinopathy","Lijuan Gao","2021","2021 International Conference on Computer Engineering and Artificial Intelligence (ICCEAI)","other","article","10.1109/icceai52939.2021.00093",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0045662","Kardiovaskulární riziko u diabetiků a diabetiček","Petr Žák","2015","Praktické lékárenství","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045663","International Strategies for Lymphedema Management","Diana H. Presno Rubin","2025","Current Physical Medicine and Rehabilitation Reports","other_trial","article","10.1007/s40141-025-00514-5",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0045664","752-P: Evaluating the Efficacy of Oral Semaglutide in Chinese Patients with Type 2 Diabetes by Baseline Characteristics—Post Hoc Analysis of PIONEER 11 and 12","Linong Ji","2024","Diabetes","randomized_trial","article","10.2337/db24-752-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045665","MORPHOMETRIC AND IMMUNOHISTOCHEMICAL FEATURES OF THE SPLEEN IN RATS IN LATE STAGES OF STREPTOZOTOCIN-INDUCED DIABETES MELLITUS UNDER CONDITIONS OF INSULIN AND DAPAGLIFLOZIN CORRECTION","O.B. Khanenko","2025","Clinical & experimental pathology","preclinical","article","10.24061/1727-4338.xxiv.4.94.2025.10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045666","The Neurocognitive Implications of Triple-Receptor Agonism: A Conceptual and Systematic Analysis of Retatrutide (LY3437943) on Executive Functions, Information Processing, and Energetic Homeostasis","Jérôme Jaouad Yousfi","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7259858",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045667","Dipeptidyl Peptidase-4 Inhibitor","Dae Ho Lee","2014","Korean Journal of Medicine","randomized_trial","article","10.3904/kjm.2014.87.1.1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0045668","Mo1572 GLP-1 RECEPTOR AGONIST THERAPY IS ASSOCIATED WITH REDUCED CORTICOSTEROID DEPENDENCE AND IMPROVED LONG-TERM OUTCOMES IN ADULTS WITH CROHN’S DISEASE: A MULTICENTER REAL-WORLD COHORT STUDY.","Nakul Ganju","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)03011-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045669","Curcumin compounds and total microorganisms in turmeric kombucha as a potential therapy in rats obesity model","Zulfia Rosyidatun Nisa'","2025","Jurnal Gizi dan Dietetik Indonesia (Indonesian Journal of Nutrition and Dietetics)","preclinical","article","10.21927/ijnd.2025.12(2).114-124",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045670","Systematic Review of Exenatide for Type 2 Diabetes","Tang Yao","2010","Zhongguo yaofang","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","article"],["R0045671","The Association between Glucagon-like Peptide-1 Receptor Agonist and Major Adverse Cardiac and Cerebrovascular Events in Monoclonal Gammopathy of Undetermined Significance: A Propensity-Score Analysis","Junmin Song","2024","Blood","nonrandomized_study","article","10.1182/blood-2024-194867",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045672","789-P: Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) according to Prior Insulin Use","JOCHEN SEUFERT","2023","Diabetes","nonrandomized_study","article","10.2337/db23-789-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045673","MSR93 Evaluating the Efficacy of Artificial Intelligence Models as Suitable Screening Tools in Systematic Reviews: The Example of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure Treatment","Kyriacos Ioannou","2025","Value in Health","systematic_review","article","10.1016/j.jval.2025.09.3378",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045674","Abstract 13807: Semaglutide Provides More Value for Money Than Dulaglutide or Liraglutide for Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease","Joseph Azuri","2020","Circulation","other_trial","article","10.1161/circ.142.suppl_3.13807",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0045675","Efficacy and Safety of 1:1 Fixed Ratio Combination of Insulin Glargine/Lixisenatide (iGlarLixi) versus Lixisenatide in Japanese Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial","Hirotaka Watada","2020",null,"randomized_trial","article","10.2337/dc20-1234/suppl.12016425.v1",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","other"],["R0045676","Pleiotropic effects of GLP-1 receptor agonists — a narrative review of extra-metabolic outcomes in adults","Julia Maria Koperdowska","2026","Medical Research Journal","randomized_trial","article","10.5603/mrj.111322",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0045677","Clinical trial of exenatide injection in type 2 diabetes mellitus patients with overweight and obese and poorly controlled blood sugar","Guangming Chen","2016",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0045678","Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","Muhammad Hassan","2026","Diabetology & Metabolic Syndrome","systematic_review","article","10.1186/s13098-026-02248-3",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0045679","172-OR: Long-Term Cost-Effectiveness of Using Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) for Preventing Type 2 Diabetes (T2D) in U.S. Adults with Prediabetes and Obesity—A Simulation Study","SHICHAO TANG","2025","Diabetes","other","article","10.2337/db25-172-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045680","23-PUB: Efficacy and Safety of IGlarLixi vs. IDegAsp by Baseline HbA1c in Chinese People with T2D—Post Hoc Analyses of the SoliD Study","Hongyu Kuang","2025","Diabetes","other","article","10.2337/db25-23-pub",null,null,"ClinicalTrials.gov:NCT05413369","S000073","openalex","FALSE","paywalled","5","FALSE","article"],["R0045681","Effect and mechanism of liraglutide on proliferation and apoptosis of human pancreatic cancer cells","Rui Wei","2015","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2015.06.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045682","#2257 SGLT2 inhbitors reduce the eGFR slope in diabetic and non-diabetic renal transplant recipients","Diana Rodríguez Espinosa","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.0801",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045683","Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM)","Shengwu Ma","2017","Canadian Journal of Biotechnology","other","article","10.24870/cjb.2017-000107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045684","Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide","Weixin Li","2022","DOAJ (DOAJ: Directory of Open Access Journals)","nonrandomized_study","article","10.16016/j.2097-0927.202109129",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0045685","MANIFESTATION OF GLP-1 RECEPTOR AGONISTS IN THE ORAL AND MAXILLOFACIAL REGION: A SCOPING REVIEW","Antonia Karina Silva Azevedo","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/7fs5t",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint; article"],["R0045686","HSD31 UTILIZATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) FOR WEIGHT LOSS AND DIABETES: A STATE-LEVEL ANALYSIS ACROSS PAYER TYPES","Steven C. Do","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1268",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045687","CLINICAL IMPACT OF GLP-1 RECEPTOR AGONISTS ON COLONOSCOPY: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS","Ahmad Abdulraheem","2025","Gastrointestinal Endoscopy","systematic_review","article","10.1016/j.gie.2025.03.603",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0045688","905-P: Variables Associated with Prescription of SGLT2 Inhibitors or GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Obesity in Spain","Ana Cebrián","2025","Diabetes","other","article","10.2337/db25-905-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045689","440-P: Associated Factors with Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in iCaReMe China Registry","Xiaoling Cai","2025","Diabetes","nonrandomized_study","article","10.2337/db25-440-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045690","Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus","Sisi Luan","2022",null,"other","article","10.37766/inplasy2022.6.0015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0045691","The Role of GLP-1 Receptor Agonists In Rheumatic Diseases and Osteoarthritis: A Literature Review","Pshysical and Rehabilitation medicine 2 , IRCSS istituto ortopedico Rizzoli, Bologna , Italy","2025","˜The œjournal of clinical medicine.","randomized_trial","article","10.52338/tjocm.2025.5014",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045692","Weight Regain After Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists in Adults with Obesity or Overweight: A Systematic Review and Meta-Analysis Integrating Randomized Controlled Trials and Real-World Evidence","Hui Zheng","2026",null,"systematic_review","article","10.17605/osf.io/w86gy",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0045693","Retatrutide-Induced Intractable Diarrhea","Opeyemi Komolafe","2026","Annals of Internal Medicine Clinical Cases","other","article","10.7326/aimcc.2025.1218",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045694","Retinal neuroprotective effect of GLP-1 analogs liraglutide in early diabetic retinopathy","Honghua Zheng","2019","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.3980/j.issn.1672-5123.2019.2.21",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045695","26-A-20515-ACC LOW-DOSE SEMAGLUTIDE AMELIORATES PRESSURE OVERLOAD-INDUCED HEART FAILURE BY SUPPRESSING THE NAT10-AC4C-TGF-β1 AXIS","Yiqing Hu","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.1439",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045696","Editorial: Current chemical approaches in combating neuroinflammation in Alzheimer's disease (AD)","Sayan Roy Chowdhury","2025","Frontiers in Aging Neuroscience","other_trial","article","10.3389/fnagi.2025.1712601","41200274",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0045697","MON-641 Effectiveness Of Semaglutide On Renal Outcomes In Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","Daniah Rizwan","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.1001",null,null,"PROSPERO:CRD42024603838",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045698","Drug Repurposing for Antidiabetics Discovery and Development","Oluwafemi Adeleke Ojo","2026",null,"other","article","10.1201/9781003645382-26",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045699","EFFECTIVENESS OF LIRAGLUTIDE (VICTOZA) IN THE TREATMENT OF TYPE 2 DIABETES","Islomov Samandar Dilmurod ogli,Khudoyberganova Shahnoza Bakhtiyorovna","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15695645",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0045700","Exendin-4在大肠杆菌中的串联表达、纯化及活性鉴定","刘延杰","2011","生物技术","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045701","Plain Language Summary of the Study: Survodutide for the Treatment of Obesity: Baseline characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial","Elke Platz","2026","Boehringer Ingelheim","other_trial","article","10.60915/boehringer-figshare.31150663",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0045702","EFFECTIVENESS OF SEMAGLUTIDE FOR OBESITY MANAGEMENT IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A SYSTEMATIC REVIEW AND A META-ANALYSIS","Priya Hotwani","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(25)01927-8",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0045703","Comparison of efficacy and safety between liraglutide and sitagliptin in overweight and obese type 2 diabetes patients","Rui Chen","2014","Chin J Diabetes Mellitus","randomized_trial","article","10.3760/cma.j.issn.1674-5809.2014.03.005",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045704","Comparative effectiveness of metabolic bariatric surgery versus incretin-based and medical therapies for weight loss and glycemic outcomes: a systematic review and meta-analysis","Ehab sharyan","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/qcg3y",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0045705","Mo1922 INCIDENCE PROPORTION OF THYROID CANCER WITH GLP-1 RECEPTOR AGONISTS: A MULTICENTER POPULATION-BASED STUDY","Vibhu Chittajallu","2023","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(23)03175-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045706","Renal safety of newer medications","Amar Puttanna","2016","Practical Diabetes","other","article","10.1002/pdi.2013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045707","FP56 Semaglutide and tirzepatide affect post prandial gut hormone responses and induce symptom remission in two patients with bile acid diarrhoea","Christopher Bannon","2026",null,"other","article","10.1136/gutjnl-2026-bsg.132",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0045708","FRI-453 Proteomics reveals the effect of liraglutide in enhancing fatty acid metabolism and reducing fibrosis in metabolic dysfunction-associated steatotic liver disease","Yuxuan Chen","2025","Journal of Hepatology","other","article","10.1016/s0168-8278(25)01667-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045709","745-P: Efficacy and Safety of RAY1225 Once Every Two Weeks in Chinese Adults with Obesity or Overweight (REBUILDING-1)","LINONG JI","2025","Diabetes","randomized_trial","article","10.2337/db25-745-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045710","The role of empagliflozin, exenatide, and quercetin in reducing neurodegeneration associated with diabetes in rats","D. Ağırcan","2025","Journal of the Neurological Sciences","preclinical","article","10.1016/j.jns.2025.125381",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045711","Treating obesity with GLP-1 RAs: does sex matter? A commentary on the meta-analysis by Yang et al. (J Diabetes 2025;17(3):e70063)","Ralf Weiskirchen","2026","Exploration of Endocrine and Metabolic Diseases","systematic_review","article","10.37349/eemd.2026.101458",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0045712","High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight/obesity: a randomized, placebo-controlled, phase 2 trial","Vanita R. Aroda","2025",null,"randomized_trial","article","10.2337/figshare.28544267.v1",null,null,"ClinicalTrials.gov:NCT05486065","S001555","openalex","TRUE","free_to_read","1","FALSE","other"],["R0045713","128-LB: Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Once-Weekly (OW) Semaglutide","MONICA S. FRAZER","2022","Diabetes","nonrandomized_study","article","10.2337/db22-128-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045714","Recent advances in the Management of Diabetes Mellitus","U Sanusi","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045715","GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review","Łukasz Karaban","2025","Quality in Sport","systematic_review","article","10.12775/qs.2025.41.60343",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045716","Neuroendocrine and Microbiome Dimensions of GLP-1 Receptor Agonism in Obesity Management","Deivis de Oliveira Guimarães","2026","Figshare","other","article","10.6084/m9.figshare.31444741",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045717","COMPARATIVE EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS IN OBSTRUCTIVE SLEEP APNEA MANAGEMENT: A COMPREHENSIVE BAYESIAN NETWORK META-ANALYSIS WITH INTERVENTION RANKING","Ibrahim Khalil","2025","CHEST Journal","systematic_review","article","10.1016/j.chest.2025.07.3942",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0045718","examination of the effects of liraglutide on diabetic nephropathy","Akihiro Ryuge","2012","Kidney Research and Clinical Practice","other","article","10.1016/j.krcp.2012.04.536",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045719","Glucagon-Like Peptide-1 Receptor Agonists and Risk of Autoimmune Diseases in Type 2 Diabetes: A Multicenter Emulated Target Trial","Cheng-Hsien Hung","2026","SSRN Electronic Journal","other_trial","article","10.2139/ssrn.6064329",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","preprint"],["R0045720","Emerging mechanism and Therapeutic intervention for Sarcopenic obesity- A narrative review","Dimple Lohia","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0045721","71660 GLP-1 Receptor Agonist Use in Patients with Psoriasis or Hidradenitis Suppurativa","Rachel Granovsky","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.949",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045722","26-A-13149-ACC GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST IN THE PREVENTION OF LUPUS NEPHRITIS AMONG PATIENTS WITH TYPE 2 DIABETES AND SYSTEMIC LUPUS ERYTHEMATOSUS: INSIGHTS FROM REAL WORLD GLOBAL DATA","Muhammad Hanif","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.478",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045723","26-A-13879-ACC EFFECT OF SEMAGLUTIDE ON ANKLE-BRACHIAL INDEX IN PEOPLE WITH PERIPHERAL ARTERY DISEASE AND TYPE 2 DIABETES: AN ANALYSIS OF THE STRIDE TRIAL BY DISEASE SEVERITY","Marc P. Bonaca","2026","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2026.02.2542",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045724","GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists to treat Idiopathic Intracranial Hypertension: a scoping review","Antônio Santos de Araújo","2026","OSF Preprints (OSF Preprints)","narrative_review","article","10.17605/osf.io/aqjzn",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045725","Sa2110 NOVEL REAL-WORLD HEAD-TO-HEAD COMPARISON OF SEMAGLUTIDE VS RESMETIROM IN MASLD: A PROPENSITY-MATCHED COHORT STUDY","Islam Rajab","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03576-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045726","Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?","George Hall","2009","Anesthesia & Analgesia","randomized_trial","article","10.1213/ane.0b013e3181a6ad5c","19448192",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045727","733-P: Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial","Lin Liu","2024","Diabetes","randomized_trial","article","10.2337/db24-733-p",null,null,"ClinicalTrials.gov:NCT06118008","S000891","openalex","FALSE","paywalled","1","FALSE","article"],["R0045728","Impact of liraglutide on cardiovascular system in type 2 diabetes","Xiaowei Yan","2015","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2015.01.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045729","A Study on the Effect of Glucagon Like Peptide 1 Agonist on Glycemic State, Renal Functions and Some Hemodynamic Parameters in Diabetic Male Albino Rats","M.D. SHAIMAA M. MOTAWEA SOHEIR A. SALEH","2020","The Medical Journal of Cairo University/˜The œMedical Journal of Cairo University","preclinical","article","10.21608/mjcu.2020.105131",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045730","Mo1810 ASSESSING THE ROLE OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH): A SYSTEMATIC REVIEW AND META-ANALYSIS","Rishikesh R Magaji","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)04874-1",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045731","An update on the role of antihyperglycemic agents in diabetoporosis","Nidhi Sharma","2023","Journal of Diabetology","other","article","10.4103/jod.jod_35_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045732","Human GLP-1 Analogue Liraglutide Alleviates Oxidative Stress Induced by Oscillating High Glucose in Human Umbilical Vascular Endothelial Cells","Bruno Schisano","2010","WestminsterResearch (University of Westminster)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045733","1748-P: IGlarLixi Improves PPG and DTIR in Asian People with T2D (PwT2D): Post Hoc Pooled Analysis of Ph3 Studies","WENJIAN LIN","2026","Diabetes","other","article","10.2337/db26-1748-p",null,null,"ClinicalTrials.gov:NCT03798054; ClinicalTrials.gov:NCT03798080; ClinicalTrials.gov:NCT05413369","S000073; S000170; S002110","openalex","FALSE","paywalled","5","FALSE","article"],["R0045734","IDDF2026-ABS-0342 Clinical outcomes associated with GLP-1 receptor agonists in patients with chronic pancreatitis and type 2 diabetes mellitus: a real world cohort study","Jyotirmoy Biswas","2026","Clinical Gastroenterology","nonrandomized_study","article","10.1136/gutjnl-2026-iddf.324",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0045735","Lixisenatide (Lyxumia): new GLP‐1 mimetic for type 2 diabetes","Steve Chaplin","2014","Prescriber","other","article","10.1002/psb.1177",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045736","COMPARISON OF PHARMACOLOGICAL INTERVENTIONS WITH GLP-1, GIP, IGLUCAGON, BEHAVIORAL AND SURGICAL APPROACHES TO OBESITY IN WEIGHT LOSS AND WEIGHT REGAIN","Darley Wilson Dias Filho","2026","Artefactum","other","article","10.23900/artefactum.v25i1.2507",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045737","Heart Failure with Supranormal Ejection Fraction: A Female-Predominant Syndrome","Rahul Garg","2025","Indian Journal of Cardiovascular Disease in Women","other","article","10.25259/ijcdw_109_2024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045738","91-LB: Once-Weekly Exenatide in Youth with Type 2 Diabetes: A Pivotal Phase III Randomized Study","William V. Tamborlane","2021","Diabetes","randomized_trial","article","10.2337/db21-91-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045739","Therapeutic applications of incretin mimetics for metabolic diseases: preclinical studies","Christine M. Mack","2006","Drug Development Research","other","article","10.1002/ddr.20121",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045740","Abstract 4368472: Glucagon-Like Peptide 1 Mediated Reduction in Atrial Fibrillation Risk Is Independent of Weight Loss","Tiago Palmisano","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4368472",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045741","Childhood obesity: a comprehensive review of prevention and management strategies","Rabab Hijazi","2025","International Journal of Medicine in Developing Countries","narrative_review","article","10.24911/ijmdc.51-1736284886",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045742","DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR ESTIMATION OF TIRZEPATIDE","Ajay Patel","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20529552",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045743","1226-OR: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial","YINGYING LUO","2026","Diabetes","randomized_trial","article","10.2337/db26-1226-or",null,null,"ClinicalTrials.gov:NCT06184568","S001621","openalex","FALSE","paywalled","1","FALSE","article"],["R0045744","The subtle red line between combating and resolving inflammation in the cardiovascular disease, a “silent sniper”","Ciarán Kennedy","2025","Bleeding Thrombosis and Vascular Biology","other","article","10.4081/btvb.2025.187",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045745","Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study (Preprint)","Rebecca Richards","2025",null,"nonrandomized_study","article","10.2196/preprints.81912",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","preprint"],["R0045746","TRATAMENTO MEDICAMENTOSO COM OZEMPIC PARA DIABETES MELLITUS TIPO II","Suelen Aparecida Ribeiro de Souza","2025","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v11i10.20937",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045747","CO94 Changes in Demographic and Clinical Characteristics of Patients with Type 2 Diabetes (T2DM) Initiating Subcutaneous Semaglutide","TJ Dunn","2022","Value in Health","other","article","10.1016/j.jval.2022.04.190",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0045748","Mo1822 EFFICACY OF ORFORGLIPRON FOR WEIGHT REDUCTION IN OBESITY AND GLYCEMIC CONTROL: A DOSE STRATIFIED SYSTEMATIC REVIEW AND META-ANALYSIS","Medhansh Biradar","2026","Gastroenterology","systematic_review","article","10.1016/s0016-5085(26)04955-3",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045749","Erratum to the article “Exenatide: Its position in the treatment of type 2 diabetes” [Ann Endocrinol 69 (3) (June 2008) 201–209]","Bruno Guerci","2008","Annales d Endocrinologie","notice","article","10.1016/j.ando.2008.07.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0045750","Liraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology Appraisal 664","Hassan Kahal","2021","British Journal of Diabetes","other","article","10.15277/bjd.2021.298",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045751","Exenatide decreases ectopic fat accumulation but have no impact on myocardial function and perfusion in patients with obesity and type 2 diabetes","Ines Imane Abdesselam","2017","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0045752","“Winning the peace” against obesity in recipients of liver transplant","Kevin Pak","2024","Liver Transplantation","nonrandomized_study","article","10.1097/lvt.0000000000000430","38963348",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045753","Amelioration of Kidney Function by Glucagon-Like Peptide-1 Receptor Agonist in Db/Db Mice Via Inhibiting Ferroptosis, Inflammation and Fibrosis","Fengyi Deng","2024","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4855072",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045754","Semaglutide and Tirzepatide in Type 2 Diabetes and Obesity: Efficacy, Prescribing Safety, and Practical Risk-Mitigation Strategies for Clinical Practice in the UK and Qatar","Ghassan S.N. Al-Joubory","2026","SAS Journal of Medicine","other","article","10.36347/sasjm.2026.v12i04.009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045755","Blinded by the treatment? The risk of vision loss with semaglutide in Pakistan","Muhammad Owais","2025","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-025-01461-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045756","5-year risk of progression to type 2 diabetes in patients with myocardial infarction and overweight or obesity: a cohort study of the preventive potential of semaglutide treatment","P T Tonnesen","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3627",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045757","The clinical importance of the cardiovascular–kidney–metabolic syndrome and related mortality","Karolina Hoffmann","2025","Frontiers in Clinical Diabetes and Healthcare","randomized_trial","article","10.3389/fcdhc.2025.1719760","41426975",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045758","Impact of Liraglutide therapy on mitigating cardiovascular and metabolic comorbidities in adolescents with morbid obesity","Sophie Dworzak","2024","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2024.118221",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045759","983: SEMAGLUTIDE EXPOSURE IS ASSOCIATED WITH LOWER ODDS OF CIRRHOSIS IN NON-OBESE, NON-DIABETIC PATIENTS WITH STEATOTIC LIVER DISEASE: A GLOBAL DATABASE STUDY","Kate Cooper","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04678-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045760","Addressing inequality of health care","Michael R. Skilton","2025","The Medical Journal of Australia","other","article","10.5694/mja2.52601","39955629",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045761","Is Hair Loss a Class Effect of GLP-1 Receptor Agonists? A Structured Review of Semaglutide and Related Therapies","Winifred Chijioke","2025",null,"randomized_trial","article","10.64709/v1i101",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045762","Satisfactory Control for Glucose Profile by Combined Agents of Xultophy with A Small Dose","Hiroshi Bando","2021",null,"other","article","10.36502/2021/droa.6180",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045763","COMPREHENSIVE TREATMENT OF TYPE 2 DIABETES IN PATIENTS WITH OBESITY: THE ROLE OF PATIENT EDUCATION, WEIGHT REDUCTION, PHARMACOTHERAPY AND LIFESTYLE MODIFICATION - A NARRATIVE REVIEW","Magdalena Fąfara","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.2(50).2026.5796",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0045764","104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects","Shweta Urva","2021","Diabetes","randomized_trial","article","10.2337/db21-104-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045765","GLP-1 Agonist Semaglutide Promotes Molecular and Structural Remodeling of Chronically Ischemic Myocardium","Jad Hamze BS","2026","Brown Digital Repository","other","article","10.26300/9vkw-7e98",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045766","A glucagon-like peptide 1 receptor agonist and a dual glucosedependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist used to treat obesity and associated diseases (case report)","О.В. Косарева","2026","Russian Medical Inquiry","case_report","article","10.32364/2587-6821-2026-10-5-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045767","953-P: Real-World Effectiveness of Once-Weekly Semaglutide (Sema OW) from a U.S. Commercially Insured and Medicare Advantage Population","Jay Visaria","2020","Diabetes","nonrandomized_study","article","10.2337/db20-953-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045768","COMPARATIVE EFFICACY OF TIRZEPATIDE, SEMAGLUTIDE, AND PLACEBO IN WEIGHT MANAGEMENT: A NOVEL NETWORK META-ANALYSIS","Júlia Cremonini Bernardi","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(25)01093-9",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0045769","Semaglutide and Exacerbation of Psychogenic Non-Epileptic Activity: A Case Report","Adam J. Fusick","2026","Journal of Psychiatric Insight Review","case_report","article","10.63721/26jpir0132",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045770","Metformin and GLP-1 Receptor Agonist Use in Hidradenitis Suppurativa: A Study Using the NIH All of Us Research Program","Raslina Shrestha","2026",null,"nonrandomized_study","article","10.2337/figshare.32189892.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0045771","Agonistas do receptor de GLP-1 no tratamento do diabetes tipo 2: evidências e perspectivas clínicas","Mateus Gamarra Schwieder","2025","Caderno Pedagógico","other","article","10.54033/cadpedv22n11-106",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045772","Experimental and clinical pharmacology: Incretin mimetics and enhancers: mechanisms of action","Johannes B. Prins","2008","Australian Prescriber","other","article","10.18773/austprescr.2008.058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045773","WED-604 Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on risk of liver and non-liver outcomes in patients with viral hepatitis and type 2 diabetes","Xinrong Zhang","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)02544-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045774","Finerenone with empagliflozin in CKD with diabetes (CONFIDENCE): only a blood pressure effect? Likely!","María José Soler","2026","Nephrology Dialysis Transplantation","other_trial","article","10.1093/ndt/gfag042","41711584",null,null,null,"openalex","FALSE","paywalled","5","FALSE","editorial"],["R0045775","The Impact of GLP-1 Receptor Agonists on Surgical Outcomes in Achilles Tendon Repair","Carl Rai","2025","Foot & Ankle Orthopaedics","nonrandomized_study","article","10.1177/2473011425s00473",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045776","Dulaglutide promotes mitophagy by regulating copper metabolism and protects retinal pigment epithelial cells from high glucose-induced damage","Di Lu","2026","Journal of the Renin-Angiotensin-Aldosterone System","preclinical","article","10.1177/14703203261426211",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045777","2866-LB: Semaglutide Use Along with Neural Network Fully Closed-Loop Systems Improves Time in Range (TIR) to 87% in Adults with Type 1 diabetes: In Silico Study","Dayu Lv","2026","Diabetes","randomized_trial","article","10.2337/db26-2866-lb",null,null,"ClinicalTrials.gov:NCT05537233","S002321","openalex","FALSE","paywalled","1","FALSE","article"],["R0045778","SAT-179 Enhancing treatment of metabolic dysfunction-associated steatohepatitis: combination of GLP-1R agonist with others","Hui Li","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)01828-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045779","26-A-12430-ACC EFFECTS OF GLP-1 RECEPTOR AGONISTS AND DUAL AGONISTS ON ALCOHOL USE DISORDER: A META-ANALYSIS AND SYSTEMATIC REVIEW","Nicole Ann Tesoro","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.466",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0045780","Possibilities of using analogues of glucagon-like peptide-1 in various disease entities","Weronika Bielka","2021","Farmacja Polska","other","article","10.32383/farmpol/133606",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045781","Strengths and Limitations of Synthetic Versus Reference Semaglutide in Indian Adults With Type 2 Diabetes and Obesity: A Systematic Critical Appraisal of the Published Phase III Evidence","Awadhesh Kumar Singh","2026",null,"randomized_trial","article","10.17605/osf.io/49gfn",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0045782","14. Liraglutide Decreases Food Related CNS Activation after Short-Term, but Not after Longer-Term Treatment in Patients with Diabetes (159-OR)","Jennifer S. ten Kulve","2015","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-015-0035-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045783","EP370 - ECE_2737 - Combination therapy with SGLT2i and polyethylene glycol loxenatide vs SGLT2i monotherapy for cardiovascular events in Chinese patients with type 2 diabetes: a multicenter retrospective study","Yaqian Duan","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.892",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045784","Oral Semaglutide vs. Sitagliptin: Efficacy by Baseline HbA1c and Background OAD in PIONEER 3","Michelle E. Hauser","2021","Diabetologie und Stoffwechsel","other","article","10.1055/s-0041-1727310",null,null,"ClinicalTrials.gov:NCT02607865","S002267","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0045785","Exploring the evolving portrayal of #Ozempic content on TikTok.","Megan Sutton","2026","Psychology of Popular Media","other","article","10.1037/ppm0000664",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045786","ABSTRACT NUMBER: ESOC2026A262 STROKE RISK WITH SGLT2I, GLP-1RA, AND DPP-4I IN TYPE 2 DIABETES: REAL-WORLD LONGITUDINAL ESTIMATES IN THE CONTEXT OF TRIAL AND OBSERVATIONAL EVIDENCE","Anastasios Mavridis","2026","European Stroke Journal","nonrandomized_study","article","10.1093/esj/aakag023.016",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0045787","The review of the effects of glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on hypothalamus-pituitary-gonad axis","Hao Ming","2019","Zhonghua neifenmi daixie zazhi","narrative_review","article","10.3760/cma.j.issn.1000-6699.2019.06.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045788","Beneficial effects of liraglutide on peripheral blood vessels","Xueyang Zhang","2020","Vojnosanitetski pregled","other","article","10.2298/vsp200423089z",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045789","Functional and Rehabilitation Outcomes in Patients on GLP-1 Receptor Agonists Undergoing or Recovering from Musculoskeletal Injury or Surgery: A Scoping Review","Christopher Kirschner","2026",null,"narrative_review","article","10.17605/osf.io/69uwa",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045790","26-A-13162-ACC USE OF ECNOGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIAL","Muhammad Sharjeel Abbas","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.2913",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045791","764-P: Long-Term (24-Month) Follow-up of Indian T2DM Patients on Oral Semaglutide","SUPRATIK BHATTACHARYYA","2025","Diabetes","nonrandomized_study","article","10.2337/db25-764-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045792","Incrétines et analogues des GLP-1 : des nouveaux traitements médicamenteux de l’obésité","Gérard Bergua","2025","Médecine","other","article","10.1684/med.2025.1087",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045793","19-PUB: Improved Glycemic Control in People with Type 2 Diabetes (T2D) Initiating or Switching to Insulin Degludec/Insulin Aspart (IDegAsp) in a Real-World Setting in China","LIXIN GUO","2024","Diabetes","nonrandomized_study","article","10.2337/db24-19-pub",null,null,"ClinicalTrials.gov:NCT05221580",null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045794","1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)","Stefano Del Prato","2019","Diabetes","randomized_trial","article","10.2337/db19-1139-p",null,null,"ClinicalTrials.gov:NCT02787551","S001125","openalex","FALSE","paywalled","1","FALSE","article"],["R0045795","Additional views regarding the association between body mass index and lipoprotein(a) level in relation to atrial fibrillation","Kazuhiko Kotani","2026","Polskie Archiwum Medycyny Wewnętrznej","other","article","10.20452/pamw.17240","41744430",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045796","Safet and tolerability, pharmacokinetic and spharmacodynamics of albiglutide in Japanese subjects with type 2 diabetes: a comparison with an ethnically mixed population","Yutaka Seino","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33270-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045797","Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application","David Chen","2023","Statistics in Biopharmaceutical Research","randomized_trial","article","10.1080/19466315.2023.2173644",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045798","The Labor Market Impacts of GLP-1s","N. Meltem Daysal","2026","National Bureau of Economic Research","other","article","10.3386/w35475",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0045799","원저 : 성체 개에서 분리된 췌장세포에 PDX-1/VP16 유전자 과발현을 이용하여 베타세포로의 분화 유도","유영혜","2007",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045800","Can exenatide, an antidiabetic drug, cause chronic pancreatitis? A case presentation","Kader Uğur","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep433",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045801","Metabolic control of our turkish diabetic patients on exenatide therapy: good at metabolic control but how about compliance?","Cem Mirili","2014","Endocrine Abstracts","other","article","10.1530/endoabs.35.p465",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045802","Activation of the HPA axis does not explain non-responsiveness to GLP-1R agonist treatment in individuals with type 2 diabetes","Sevilay Tokgöz","2024",null,"other","article","10.2337/figshare.27764883",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0045803","THE POPULARIZATION OF WEIGHT-LOSS PENS AND THEIR IMPACTS ON PUBLIC HEALTH: THERAPEUTIC BENEFITS, EMERGING RISKS, AND REGULATORY CHALLENGES IN CONTEMPORARY BRAZIL","Rogerio Matheus Pinheiro Carreira","2026",null,"other","article","10.63330/aurumpub.058-009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0045804","1730-P: The Antiobesity Medications and Renal Outcomes, One Answer But with Multiple Implications—A Meta-analysis of Randomized Controlled Trials","CHU LIN","2025","Diabetes","systematic_review","article","10.2337/db25-1730-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045805","Impact of coronary artery calcium score assessment on the management of asymptomatic patients with type 2 diabetes","Mohamed Riadh Boukhris","2025","European Journal of Preventive Cardiology","other","article","10.1093/eurjpc/zwaf236.220",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045806","Novel findings regarding treatment obesity and weight-related comorbidities – the systemic literature review","Karina Urbańska","2025","Quality in Sport","nonrandomized_study","article","10.12775/qs.2025.37.57002",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045807","Liraglutide: new GLP‐1 analogue for uncontrolled type 2 diabetes","Steve Chaplin","2009","Prescriber","other","article","10.1002/psb.577",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045808","2071-P: Gastric Emptying in Youth on Glucagon-Like Peptide 1 Receptor Agonists","NATALIE SEGEV","2026","Diabetes","other","article","10.2337/db26-2071-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045809","Preparation and Evaluation of a 4-Branched Polyethylene Glycol Derivative Modified with Exendin-4 and Stearylamine for Extended Hypoglycemic Action","In-Soo Kim","2010","Journal of Pharmaceutical Investigation","other","article","10.4333/kps.2010.40.3.175",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045810","S918 The Impact of GLP-1 Receptor Agonists on Upper and Lower GI Endoscopy: A Systematic Review and Meta-Analysis","Spyridon Peppas","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001033040.94957.e9",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045811","CE-534538-001 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS REDUCE ATRIAL FIBRILLATION INDEPENDENTLY OF EFFECTS ON WEIGHT LOSS AND SURVIVAL","Kenneth C. Bilchick","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045812","A Phase II, randomized, double-blind, placebo-controlled, dose-finding study of survodutide (BI 456906) in people living with overweight/obesity","M. Carel W. Le Roux","2024","Metabolism","randomized_trial","article","10.1016/j.metabol.2024.155848",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045813","Imaging of the pituitary: Recent advances","Vikas Chaudhary","2011","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.84871","22029027",null,"ClinicalTrials.gov:NCT04255433","S002212","openalex","TRUE","free_to_read","1","FALSE","article"],["R0045814","Mo2108 EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON THE RISK OF ADVERSE LIVER OUTCOMES IN CIRRHOTIC PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES","Muhammed O. Jajeh","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03927-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045815","PDB22 - CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS REACHING A HIGH DAILY DOSE OF IDEGLIRA SIX MONTHS AFTER INITIATION IN A REAL-WORLD SETTING","Richard L. Prager","2018","Value in Health","nonrandomized_study","article","10.1016/j.jval.2018.09.728",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0045816","Comparative Real-Life Evaluation of Tirzepatide versus Semaglutide in Non-Diabetic Obese Populations: Implications for Systemic Metabolic Reset and Neurodegenerative Risk Mitigation","Glauco Messina","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20681640",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045817","1708-P: Comparing Major Adverse Kidney Events (MAKE) among New Users of Oral Semaglutide (SEMA) vs. Select Oral Antidiabetic Medications (ADMs) among U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)","LIN XIE","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1708-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045818","GLP-1-Receptor Agonists Directly Reduce Proliferation in ATDC5 Chondrocytes","Irit Meivar‐Levy","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6095710",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045819","Harmony 5-year 3 Results: albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes","Paramesh Shamanna","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045820","Mikrobiota–Usus–Otak sebagai Jaringan Metabolik dan Pengatur Kontrol Energi","Raymond R. Tjandrawinata","2025","MEDICINUS","other","article","10.56951/fy2cd832",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045821","S133 Etiology-Based Outcomes of Acute Pancreatitis: A Multi-Center Real-World Analysis From a Nationwide EMR Network","Ashujot K. Dang","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001126992.81811.48",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045822","Crowdsourcing-Based Knowledge Graph Construction for Drug Side Effects Using Large Language Models with an Application on Semaglutide","Zhijie Duan","2025","arXiv (Cornell University)","nonrandomized_study","article","10.48550/arxiv.2504.04346",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0045823","SEMAGLUTIDE AND BODY COMPOSITION: A NARRATIVE REVIEW OF ITS EFFECTS ON LEAN MASS AND STRATEGIES FOR PRESERVATION","Anna Tomasiewicz","2025","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.3(47).2025.4067",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0045824","TOP-063 The efficacy of Glucagon-like Peptide-1 receptor agonists in patients with compensated cirrhosis and obesity","Wee Han Ng","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)00831-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045825","Role of albiglutide in the treatment of type 2 diabetes","Steve Chaplin","2016","Prescriber","other","article","10.1002/psb.1471",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045826","8283 Diabetes Mellitus in Patients with Hemochromatosis- A Diagnostic and Therapeutic Challenge","Ummara Rafat","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.730",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045827","Dulaglutide protects beta cells against cytokine stress mimicking islet transplantation","Guillaume Kreutter","2017","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045828","736-P: Effect of Semaglutide on Liver Steatosis/Fibrosis Indexes in Patients with Diabetes and Obesity","JUANA CARRETERO GOMEZ","2022","Diabetes","other","article","10.2337/db22-736-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045829","Medicinal Plants as Powerful and Efficient Sources of Diabetes Treatment Compared to Medicinal Insulins : Case Study Dukagjin Region in Kosovo","Arber Dreshaj","2025","International Journal of Drug Delivery Technology","nonrandomized_study","article","10.25258/ijddt.15.2.5",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045830","Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels","Yi Wen","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2862",null,null,"ClinicalTrials.gov:NCT04867785","S000489","openalex","FALSE","paywalled","1","FALSE","article"],["R0045831","Glucose lowering drugs with proven cardiovascular benefit following acute coronary syndrome in type 2 diabetes: treatment gaps and outcomes","Ibrahim Naoum","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.2930",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045832","652-P: Real-World Effectiveness of Once-Weekly Semaglutide (sema OW) from a U.S. Commercially Insured and Medicare Advantage Population","Vincent J. Willey","2021","Diabetes","nonrandomized_study","article","10.2337/db21-652-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045833","Combined Keto-Analogues and Incretin-Based Therapies and Mortality and Inflammation in Chronic Kidney Disease: A Propensity Score–Matched Federated Cohort Study","Hugo You‐Hsien Lin","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6808734",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0045834","Mo1831 TIRZEPATIDE-ASSOCIATED HYPOGLYCEMIA REVEALING AN OCCULT INSULINOMA: A RARE PANCREATIC NEUROENDOCRINE TUMOR UNMASKED BY GLP-1/GIP AGONIST THERAPY","Sari Lada","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)05295-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045835","Risk of cardiovascular disease development in metabolically associated fatty liver disease (MAFLD): risk stratification and current therapeutic strategies","Yu. A. Trusov","2026","Russian Medicine","randomized_trial","article","10.17816/medjrf704126",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045836","75722 Dermatologic side effects of GLP-1 receptor agonists: A Cross-sectional Analysis","Celine Mouawad","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.583",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045837","Efficacy of dapagliflozin in combination therapy with the glucagon-like peptide-1 analog in obese patients with type 2 diabetes","Momoko Isono","2015","Diabetes Frontier Online","other","article","10.15634/j0100_0201_008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045838","BERBERINE IN METABOLIC DISORDERS: THE “NATURE’S OZEMPIC” PHENOMENON - A NARRATIVE REVIEW","Emilia Lenkiewicz","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.2(50).2026.5247",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0045839","936-P: Plasma Proteomic Profiling Delineates Treatment Efficacy of a GLP-1/GIP Coagonist in Female and Male Mice","Susanna M. Hofmann","2020","Diabetes","preclinical","article","10.2337/db20-936-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045840","FRI-353-YI Tirzepatide reduces diet-induced senescence and NETosis-mediated liver fibrosis in mice","Feng Chen","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)01591-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045841","941-P: A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Semaglutide in Healthy Chinese Subjects","Aixin Shi","2020","Diabetes","randomized_trial","article","10.2337/db20-941-p",null,null,"ClinicalTrials.gov:NCT03288740","S000680","openalex","FALSE","paywalled","1","FALSE","article"],["R0045842","26-A-13364-ACC IMPACT OF INCRETIN-BASED THERAPIES ON ATRIAL FIBRILLATION AND FLUTTER: A META-ANALYSIS OF RANDOMIZED TRIALS","Muna Salah","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.086",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045843","Efficacy and safety of semaglutide in patients with heart failure: A meta-analysis","Xincheng Li","2025","Precision medication.","systematic_review","article","10.1016/j.prmedi.2025.100064",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0045844","SGLT2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared with Incretin-Based Therapy in Patients with Diabetic Foot Disease: A Nationwide Population-Based Study","Yi‐Hsuan Lin","2022","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.4025058",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0045845","74974 Evaluating GLP-1 agonist dialogue within the field of dermatology across conditions, attitudes, regions, and time: a retrospective review","Adam Cardenas","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.833",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045846","P171 Effet du Liraglutide sur le remodelage membranaire de la cellule β et l’activité procoagulante du facteur tissulaire, dans un modèle in vitro de stress inflammatoire","Céline Gleizes","2015","Diabetes & Metabolism","preclinical","article","10.1016/s1262-3636(15)30284-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045847","783: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IS ASSOCIATED WITH ELEVATED RISK OF GALLBLADDER AND BILIARY TRACT DISEASE IN INDIVIDUALS WITH OVERWEIGHT OR OBESITY: A PROPENSITY MATCHED MULTI-INSTITUTIONAL NETWORK ANALYSIS","Muhammad Soban Arif Maan","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)01367-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045848","Exendin-4 Derivative Conjugated with Palmitylamine Modified-PEG as an Injection-Based Long-Acting Anti-Diabetic Treatment","In-Soo Kim","2010","춘계총회 및 학술대회","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045849","LEAN PCOS AS A DISTINCT PHENOTYPE: METABOLIC DYSFUNCTION, DIAGNOSTIC IMPLICATIONS, AND THE EMERGING ROLE OF GLP-1–BASED THERAPIES","Kaja Stolarska","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.2(50).2026.5971",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045850","Pembrolizumab-Associated Insulinopenic Diabetes Mellitus Presenting without Ketoacidosis and Mimicking Type 2 Diabetes Mellitus","Faryal Ashfaq","2026","Journal of Diabetes and Endocrine Practice","other","article","10.1055/s-0046-1825859",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045851","Novel multidisciplinary cardiometabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation","Rajay Narain","2021","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehab724.2631",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045852","Additional file 2 of Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study)","Nitin Kapoor","2026","Figshare","randomized_trial","article","10.6084/m9.figshare.32087491",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0045853","On anti-diabetic agents and the vasculature","E. Eriksson","2014","Open Archive (Karolinska Institutet)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0045854","Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review","Bartłomiej STACHYRA","2023","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2023.18.01.003",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045855","1891P The effects of glucagon-like peptide 1 agonists on immune checkpoint inhibitor-associated cardiotoxicity","C.‐H. Chiang","2024","Annals of Oncology","other","article","10.1016/j.annonc.2024.08.1985",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045856","Dermatological adverse effects associated with the use of GLP-1 receptor agonists: A literature review","Gerardo Uriel Viquez Burboa","2026","JAAD reviews.","narrative_review","article","10.1016/j.jdrv.2026.06.001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045857","Sa1850 GLP-1 RECEPTOR AGONIST EXPOSURE AND ACUTE PANCREATITIS OUTCOMES: A PROPENSITY-MATCHED MULTICENTER COHORT ANALYSIS","Kevin Nguyen","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)05077-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045858","Pharmacogenetics of Type 2 Diabetes Mellitus: Linking Genetic Variability to Drug Efficacy and its Cardiovascular Outcomes","Kaiser Jamil","2025","Advances in Clinical Toxicology","other","article","10.23880/act-16000329",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045859","The Dual-Agonist Advantage: Comparing Tirzepatide (GIP/GLP-1) Efficacy Against Single GLP-1 RAs (Semaglutide) in T2DM","Lin Li Chen","2026",null,"other","article","10.63721/26jadr0103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045860","Update on the classification and treatment approaches for heart failure in 2026","V. А. Skybchyk","2026","Medicine of Ukraine","other","article","10.37987/1997-9894.2026.5(301).367141",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045861","Rosiglitazone","Richard E. Gilbert","2007","Clinical Journal of the American Society of Nephrology","randomized_trial","article","10.2215/cjn.03470807","17928463",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045862","Vagal nerve and sympathetic nerve activity in response to glucagon-like peptide-1 (GLP-1) receptor stimulation in conscious rats","Kenju Miki","2024","Physiology","preclinical","article","10.1152/physiol.2024.39.s1.2169",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045863","ENDOTHELIAL DYSFUNCTION AND RESIDUAL INFLAMMATION IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF): NEW THERAPEUTIC PERSPECTIVES","Rodolfo de Oliveira Medeiros","2025","Journal of Media Critiques","nonrandomized_study","article","10.17349/jmcv11n28-084",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045864","Mapping the research landscape of glucagon-like peptide-1 receptor agonists and diabetic retinopathy: a bibliometric analysis","Nan Chen","2026",null,"other","article","10.17605/osf.io/95sm4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045865","Semaglutide for Craving Reduction in a Cocaine Dependent Patient: A Case Report","Alessandro Matteo Sileoni","2025","Clinical Neuropsychopharmacology and Addiction","case_report","article","10.53941/cna.2025.100003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045866","Mo1807 COMPARATIVE RISK OF ATRIAL FIBRILLATION AMONG PATIENTS WITH OBESITY TREATED WITH GLP-1 RECEPTOR AGONISTS: A RETROSPECTIVE COHORT STUDY","Jonathan Ghobrial","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04871-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045867","Diabetic kidney disease: mechanisms of development, diagnostic methods and treatment","V.V. Skvortsov","2026","Therapist’s Bulletin","other","article","10.31550/2712-8601-vt-2026-1-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045868","Hypoglycemia in patients with type-2 diabetes - incidence and prognostic significance - results of the DiaRegis 2 year follow-up","Diethelm Tschoepe","2013","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/eht311.5924",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045869","Insulin resistance in psoriasis: beyond comorbidity?","Emma Carroll","2026","British Journal of Dermatology","other","article","10.1093/bjd/ljag383","42700374",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045870","0620 Effect of Tirzepatide on Weight Loss in Patients with Obstructive Sleep Apnea and Obesity from SURMOUNT-1","Ronald R. Grunstein","2024","SLEEP","randomized_trial","article","10.1093/sleep/zsae067.0620",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045871","Lithuanian experience: CKD (Chronic kidney disease) alert program in primary care","Inga Arūnė Bumblytė","2024","Lithuanian University of Health Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0045872","742-P: A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes","Dalong Zhu","2024","Diabetes","randomized_trial","article","10.2337/db24-742-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045873","Investigating genetic and epigenetic biomarkers associated with metabolic recovery after weight loss treatments","Agnieszka Lovett","2026","UDORA","preclinical","article","10.48773/k5dg-dj34",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0045874","Für Sie gelesen: Neue Studien zur Effektivität von Liraglutide (Victoza®) in Kombination mit Metformin","Peter Fasching","2016","Journal für Kardiologie (Krause & Pachernegg GmbH)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0045875","1341-P: Comparison of the Effects of Metformin and Exenatide on Pregnancy Rate and Outcomes in Overweight or Obese PCOS Women","Renyuan Li","2020","Diabetes","randomized_trial","article","10.2337/db20-1341-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045876","Oral manifestations of GLP-1 agonist use in diabetes and weight loss therapies: a scoping review protocol","Mayron Guedes Silva","2026",null,"protocol","article","10.17605/osf.io/drmbj",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0045877","Insulin Management in the Inpatient Setting: A Comprehensive Review","Noah J Sirkin","2026","International Journal of Diabetes & its Complications","narrative_review","article","10.64030/2573-8895.04.02.01",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045878","2106-P: Glucagon-Like Peptide-1 Receptor Agonist Exenatide Promotes ß-Cell Function via Activation of PPARd/UCP-2 Pathway","Yanna Su","2020","Diabetes","preclinical","article","10.2337/db20-2106-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045879","Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer","Zheng Li","2023","World Journal of Clinical Cases","other","article","10.12998/wjcc.v11.i26.6083","37731570",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045880","2080-LB: Analysis of Hyperemesis Gravidarum and Diabetes-Associated Gene TCF7L2 in Pregnancy","Marlena S. Fejzo","2025","Diabetes","other","article","10.2337/db25-2080-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045881","The effect of Semaglutide (Wegovy) in patients with genetic variants linked to obesity","Henry Montague","2026","Endocrine Abstracts","other","article","10.1530/endoabs.117.p272",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045882","To evaluate and compare the efficacy of newer antidiabetic medications on cardiovascular outcomes","Omar Bahamdan","2025","International Journal of Medicine in Developing Countries","randomized_trial","article","10.24911/ijmdc.51-1737107151",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045883","P325 Le lixisenatide améliore significativement l’équilibre glycémique chez des patients asiatiques ayant un DT2 mal équilibré sous insuline basale ± SU","Yusuke Seino","2012","Diabetes & Metabolism","other","article","10.1016/s1262-3636(12)71427-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045884","Cardiovascular Risk Prediction Modelling with Semaglutide in Patients with Type 1 Diabetes","Massimo Nardone","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2025m7ss8e68",null,null,"ClinicalTrials.gov:NCT05205928","S000181","openalex","FALSE","paywalled","1","FALSE","article"],["R0045885","Major clinical outcomes of the action of the co-agonist tirzepatide to liraglutide and semaglutide in the treatment of obesity and type 2 diabetes mellitus: a systematic review","Helena Ramalho Arvate","2025","International Journal of Nutrology","systematic_review","article","10.54448/ijn25102",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045886","Survodutide, a new horizon in the treatment of obesity and Type 2 diabetes mellitus: A narrative review","Abdelmoneim B. Yousif","2024","Yemen Journal of Medicine","other_trial","article","10.18231/j.yjom.2024.005",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","review"],["R0045887","The Ameliorative Effect of Naltrexone/Bupropion, Liraglutide and Caloric Restriction on Blood Pressure Changes in Diabetic Male Albino Rats","Reem Hammad","2025","Fayoum University Medical Journal/Fayoum University Medical Journal ","preclinical","article","10.21608/fumj.2025.332201.1415",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045888","ETBF and the Evolution of Obesity: Why we Are prone to becoming 'Fat' ? (Obesity: Ozempic or Olympic size denial?)","O. Ennis","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20470558",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045889","GLP-1 Receptor Agonist-Based Pharmacotherapy for Weight Management in Adults with Obesity or Overweight Compared with Placebo or Active Comparator: A Protocol for a Systematic Review and Network Meta-Analysis of Randomised Controlled Trials","Abdulrahman Alanazi","2026",null,"systematic_review","article","10.37766/inplasy2026.5.0153",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045890","CO30 Clinical Experiences of Type 2 Diabetes (T2DM) Patients Initiating Oral Semaglutide","TJ Dunn","2022","Value in Health","other","article","10.1016/j.jval.2022.04.1741",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0045891","Shredded or Stripped? The Fight to Preserve Muscle on GLP-1s","Amir Mullick","2026","Figshare","other","article","10.6084/m9.figshare.33945832",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0045892","127-LB: Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Oral Semaglutide","MONICA S. FRAZER","2022","Diabetes","nonrandomized_study","article","10.2337/db22-127-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045893","208 Use of GLP-1 analog in a patient with prader-willi syndrome","Duje Braovac","2021","Abstracts","other","article","10.1136/archdischild-2021-europaediatrics.208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0045894","An Update on Management of Nonalcoholic Fatty Liver Disease & Nonalcoholic Steatohepapititis is the Time Ripe for Achieving Resolution of NAFLD & NASH Soon","Kulvinder Kochar Kaur","2021","Journal of Endocrinology Research","other_trial","article","10.30564/jer.v3i2.3580",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0045895","Emerging Technologies and Innovative Therapeutic Strategies for Diabetes Management","Neha Sharma","2026","Current Drug Research Reviews","other","article","10.2174/0125899775408464251209122116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045896","Renegade AI: The Catalyst for the Evolution of Human Cognition","Brooks Han","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.21887749",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","book"],["R0045897","1733-P: Two-Year Real-World Effectiveness of Semaglutide in Patients with Obesity or Overweight","Aleksandrina Ruseva","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1733-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045898","1493-PUB: Effects of Semaglutide on Body Composition in Obese and Diabetic Patients Attended in Internal Medicine Wards","JUANA CARRETERO GOMEZ","2022","Diabetes","other","article","10.2337/db22-1493-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045899","1018-P: Comparison of Short- and Long-Acting Glucagon-Like Peptide-1 Receptor Agonist Effects on Postprandial Glucose and Lipid Excursion via Gastric Emptying","Hitoshi Kuwata","2019","Diabetes","randomized_trial","article","10.2337/db19-1018-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045900","TZP Paper","Arthur Sherman","2026","Figshare","other","article","10.6084/m9.figshare.31370863",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045901","Polycystic ovary syndrome through the prism of cardiometabolic risk: From pathogenesis to new therapeutic strategies","F. O. Ushanova","2026","FOCUS Endocrinology","other","article","10.62751/2713-0177-2026-7-1-09",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045902","Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials","Melva Louisa","2010","Medical Journal of Indonesia","randomized_trial","article","10.13181/mji.v19i3.406",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045903","Abstract TU267: Cardiovascular Health Scores in Patients with Sleep-Disordered Breathing","Allison Lin","2026","Circulation","other","article","10.1161/cir.153.suppl_1.tu267",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045904","Acceptability of the switch from parenteral to oral semaglutide in patients with type 2 diabetes mellitus and obesity: Patient satisfaction, and changes in HbA1c, body weight, systolic blood pressure and tryglicerides","Martinez Martin Francisco Javier","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.p75",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045905","397-P: Association of Visit-to-Visit Variability of Metabolic Indicators with the Progress of Proteinuria in Chinese Patients with Type 2 Diabetes Mellitus","YUHANG MA","2025","Diabetes","nonrandomized_study","article","10.2337/db25-397-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045906","Progress in antiobesity medications","Tonia Yee Vinton","2025","Baylor University Medical Center Proceedings","commentary","article","10.1080/08998280.2025.2469990","40291092",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0045907","Conference highlights: The 81st Annual (Virtual) conference of the American diabetes association: June 25–29, 2021","Mohamed Suliman","2021","Journal of Diabetes and Endocrine Practice","other","article","10.4103/jdep.jdep_31_21",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045908","Glucagon like peptide-1 receptor agonist and nonalcoholic fatty liver disease","Xingchun Wang","2014","Intern J Endocrinol Metab","other","article","10.3760/cma.j.issn.1673-4157.2014.01.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045909","MULTIFACTORIAL APPROACH-THE KEY TO SUCCESS IN THE TREATMENT OF TYPE 2 DIABETES","Ivan Vuksan","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045910","Abstract 4453: Glucagon-like peptide-1 receptor agonists target the HIF1α-PFKFB3 pathway to enhance Lenvatinib efficacy and overcome resistance in hepatocellular carcinoma through the reversal of the Warburg effect","Takayuki Noma","2025","Cancer Research","other","article","10.1158/1538-7445.am2025-4453",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045911","Visual disturbances due to semaglutide: A systematic review of the literature","Camila Barreto Maciel","2025","International Journal of Neurology","systematic_review","article","10.62486/ijn2025247",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0045912","Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?","Zheng Li","2024","Hepatology","nonrandomized_study","article","10.1097/hep.0000000000000803","38373119",null,null,null,"openalex","FALSE","paywalled","4","FALSE","letter"],["R0045913","Cost-Effectiveness Analysis of Four Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Adult Patients with Overweight and Obesity in Chinacost-Effectiveness Analysis of Four Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Adult Patients with Overweight and Obesity in China","Wu Fu","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5087396",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045914","Obesity and Diabetes","Jens Aberle","2026","Experimental and Clinical Endocrinology & Diabetes","other","article","10.1055/a-2766-3375","42190731",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045915","GLP-1 RECEPTOR AGONISTS AND ALCOHOL USE DISORDER: A NARRATIVE REVIEW OF THERAPEUTIC POTENTIAL AND WELL-BEING OUTCOMES","Nina Polek","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.2(50).2026.5584",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0045916","Recent Advances in Nanoformulations of GLP‐1 Mimetics for Enhanced Antidiabetic Efficacy and Stability","Habib Yaribeygi","2026","International Journal of Clinical Practice","other","article","10.1155/ijcp/2770814",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045917","Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J2015;39:247-52)","Dae Ho Lee","2015","Diabetes & Metabolism Journal","randomized_trial","article","10.4093/dmj.2015.39.4.348","26301198",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045918","786-P: Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Metabolic Parameters in Older People with Type 2 Diabetes Mellitus—SWITCH-SEMA1 Subgroup Analysis","YUKA TAKAHASHI","2023","Diabetes","randomized_trial","article","10.2337/db23-786-p",null,null,"jRCT:jRCTs1011200008",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045919","Oral Agents Used to Treat Type 2 Diabetes and Obesity","John Liddle","2026",null,"other","article","10.1002/9783527845408.ch5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0045920","Euglycemic Diabetic Ketoacidosis Triggered By Semaglutide In A Patient With Type 1 Diabetes Mellitus: A Case Of Misguided Metabolic Control","Hossam Abdel Aziz","2026","Medicine & Science in Sports & Exercise","case_report","article","10.1249/01.mss.0001261456.50014.76",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045921","Pediatric Use of Compounded GLP-1 Agents: Benefits, Risks, and Equity","Lisa Kelly","2026","Obesities","other","article","10.3390/obesities6010010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045922","Tu1791 ROUX-EN-Y IS MORE EFFECTIVE THAN GLP-1 RECEPTOR AGONISTS AT ACHIEVING WEIGHT LOSS WITHOUT INCREASED SAFETY CONCERNS AT 52 WEEKS: RESULTS OF A NETWORK META-ANALYSIS","Ballakur D. Rao","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)04918-7",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0045923","Tirzepatide Improved Sleep Disordered Breathing in Adults with Obstructive Sleep Apnea with Obesity: Results from SURMOUNT-OSA Trials.","Atul Malhotra","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807558",null,null,"ClinicalTrials.gov:NCT05412004","S000156","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0045924","Glucagon-Like Peptide-1 Receptor Agonists and Aspiration Risk: A Perioperative Call to Action","Aparna Sinha","2025",null,"other","article","10.62830/mmj2-04-12a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045925","226-OR: Switching from Dulaglutide to Tirzepatide in T2D—Subgroup Analyses of the SURPASS-SWITCH Trial","Rafael Violante","2025","Diabetes","other_trial","article","10.2337/db25-226-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045926","Insulin-Induced Severe Lipohypertrophy","Samir S.E. Ahmed","2024","AACE Clinical Case Reports","other","article","10.1016/j.aace.2024.03.005","39372830",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045927","Epidemiologie als Imperativ und die Medikalisierung der Gesellschaft","Denis Nößler","2024","EvidenzUpdate","other","article","10.69156/pod.001/2024.01.00120",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045928","179-OR: Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study","PHYO T. HTOO","2022","Diabetes","nonrandomized_study","article","10.2337/db22-179-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045929","\"CagriSema: Emerging Data on a New Treatment Option for Patients with Diabetes\"","Jessica Huston","2023","Journal of pharmacology & clinical research","other_trial","article","10.19080/jpcr.2023.09.555769",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0045930","Effect of SGLT2 Inhibitors on Erythrocytosis and Arterial Thrombosis Risk in Patients with Type 2 Diabetes Mellitus: A Real-World Multi-Center Cohort Study across the United States","Yuhan Chen","2024","Blood","nonrandomized_study","article","10.1182/blood-2024-207610",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0045931","Dual GIP/GLP-1 receptor agonists and acute pancreatitis: A literature review with a focus on tirzepatide","Fernanda Eduarda Mendes de Sousa","2026","International Health Sciences Review","narrative_review","article","10.70164/ihsr.v2i2.152",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045932","PO-03-076 SEMAGLUTIDE FOR THE PREVENTION OF ATRIAL FIBRILLATION: A SYSTEMIC REVIEW AND META-ANALYSIS","Hongda Zhang","2024","Heart Rhythm","systematic_review","article","10.1016/j.hrthm.2024.03.1077",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0045933","Liraglutide, Roflumilast Improve Body Weight in Obese Women With PCOS","E. H. Nichols","2015","MD Conference Express","other","article","10.1177/1559897715581824",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0045934","Neuroprotective effect and mechanism of liraglutide on hippocampal neurons in diabetic rats","Xiangbo Hao","2018","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2018.06.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045935","Ready for the challenge: navigating the evolving landscape of GLP-1s for pediatric obesity treatment","E Thomaseo Burton","2026","Journal of Pediatric Psychology","other_trial","article","10.1093/jpepsy/jsag002","41677195",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045936","NOVEL DRUGS FOR THE TREATMENT OF DIABETES MELLITUS","Preeti Garg","2023",null,"other","article","10.58532/v3bfms12p1ch15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045937","Sociocultural Perceptions, Barriers, and Stigma Influencing Acceptance and Use of Incretin Therapies for Weight Management: A Systematic Scoping Review","Haocheng Qu","2026",null,"narrative_review","article","10.17605/osf.io/7svb8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045938","Immunometabolic Dysregulation Driving Vascular Dysfunction Underlying Cardiovascular Disease","Norfazlina Mohd Nawi","2026","Current Cardiology Reviews","other","article","10.2174/011573403x453146260422195850",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045939","1725-P: Once-Monthly Zovaglutide (ZT002) in Adults with Overweight or Obesity and Prediabetes: A Phase 2 Subgroup Analysis","LINONG JI","2026","Diabetes","randomized_trial","article","10.2337/db26-1725-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045940","Would a weekly shot be enough to solve the obesity problem? a new denial of a complex reality","Alexandre Duparc","2025","European Journal of Preventive Cardiology","other","article","10.1093/eurjpc/zwaf002","39777485",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045941","Semaglutide as a Novel Therapeutic Agent for Obesity and Type 2 Diabetes","Ruilin Chen","2025","Transactions on Materials Biotechnology and Life Sciences","nonrandomized_study","article","10.62051/5008za94",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045942","Hypoglycemic Ketoacidosis in Nondiabetic Patients on Tirzepatide","Vikram Singh Dhapola","2026","Indian Journal of Medical Specialities","other","article","10.4103/injms.injms_325_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045943","521-P: Novel Screening and Management of Fall Risk in Type 2 Diabetic Patients with Diabetic Kidney Disease","SHIN IKEJIMA","2020","Diabetes","other","article","10.2337/db20-521-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045944","S541 Glucagon-Like Peptide-1 Receptor Agonist Use and its Potential Impact in Colonoscopy Among Patients Undergoing Colorectal Cancer Screening: A Multicenter Propensity Score Matching Analysis","Ahmed Eltelbany","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001031532.99210.78",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045945","475-P: Exendin-4 Stimulates eNOS Activation by Upregulation of Scavenger Receptor Type B Class I in Human Endothelial Cells","Jingya Lyu","2019","Diabetes","other","article","10.2337/db19-475-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045946","De Novo BETA-2 adrenergic receptor gene variant associated with obesity","Derya Sema Yaman Kalender","2023","JCEM Case Reports","other","article","10.1210/jcemcr/luac014.035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045947","Recent controversial issues in testosterone replacement therapy","Mohamed Abd-El Malik Hasan","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","nonrandomized_study","article","10.3329/jacedb.v4i20.84897",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045948","COMPARATIVE EVALUATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THEIR ASSOCIATION WITH THE RISK OF ASTHMA INCIDENCE: A COMPREHENSIVE BAYESIAN NETWORK META-ANALYSIS","Ibrahim Khalil","2025","CHEST Journal","systematic_review","article","10.1016/j.chest.2025.07.3063",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0045949","β-cyclodextrin-bearing glycol chitosan for long-acting formulation of an exenatide derivative","Hye Jin Jang","2014","Macromolecular Research","other","article","10.1007/s13233-014-2147-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045950","GLP-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF LIPODYSTROPHY: A SCOPING REVIEW","Carlos Antônio Negrato","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045951","Visceral adiposity assessment to enhance risk stratification in heart failure with preserved ejection fraction","Barry A Borlaug","2026","European Heart Journal","other_trial","article","10.1093/eurheartj/ehag119","41790513",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045952","Therapeutic Boon or Hidden Bane? Semaglutide for Weight Loss in Non-diabetics","Aneesh Kumar Sangtiani","2026","Journal of Community Medicine and Health Solutions","other","article","10.29328/journal.jcmhs.1001080",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045953","Étude DUAL VII : efficacité et tolérance d’IDegLira versus basal-bolus chez des patients diabétiques de type 2","Liana K. Billings","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.239",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045954","Preparation and evaluation of exenatide loaded PLGA nanocapsules for oral administration","Tingyuan Yang","2017","Journal of Controlled Release","other","article","10.1016/j.jconrel.2017.03.263",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045955","Exendin-4类似物的克隆、表达与体内生物活性检测","李泰明","2012","生物工程学报","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045956","Su1831 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND PANCREATIC OUTCOMES IN CHRONIC PANCREATITIS: A REAL-WORLD COHORT STUDY USING THE TRINETX RESEARCH NETWORK","Arkadeep Dhali","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)05198-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045957","EXAMINATION OF THE EFFECT OF LIRAGLUTIDE ON BLOOD PRESSURE AND URINARY SODIUM EXCRETION","Hiroshi Akasaka","2021","Journal of Hypertension","other","article","10.1097/01.hjh.0000746868.52168.38",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0045958","1961-P: Improved Glucose Control and Robust Weight Loss with a Long-Acting OXM-001","Ashref Kayed","2020","Diabetes","preclinical","article","10.2337/db20-1961-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045959","Abstract TH930: Potential overtreatment of older adults with diabetes and dementia: a real-world study","Zixuan He","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.th930",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045960","275 Patient perspectives on GLP-1 receptor agonists for weight loss: A mixed-methods study to inform translational obesity care","Jane McElroy","2026","Journal of Clinical and Translational Science","other","article","10.1017/cts.2026.10473",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045961","A time course analysis of glycaemic improvements with albiglutide, a long-acting GLP-1-receptor agonist for the treatment of type 2 diabetes","Jane E.B. Reusch","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33272-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045962","1145-P: Individual SGLT2 Inhibitors and the Risk of Diabetic Ketoacidosis","Devin Abrahami","2022","Diabetes","nonrandomized_study","article","10.2337/db22-1145-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045963","69-LB: Sex-Specific Dynamics of GLP-1R and GIPR Expression in the Hypothalamus and the Amygdala of Mice","Susanna M. Hofmann","2023","Diabetes","preclinical","article","10.2337/db23-69-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045964","753-P: Tirzepatide Improves HRQoL Compared with Insulin Lispro in Poorly Controlled Basal Insulin–Treated Adults with Long-Standing T2D (SURPASS-6)","KRISTINA BOYE","2023","Diabetes","randomized_trial","article","10.2337/db23-753-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045965","800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial","MARTIN HALUZIK","2023","Diabetes","randomized_trial","article","10.2337/db23-800-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045966","Abstract 4371250: The association between GLP-1 RA initiation and cardiovascular events among patients treated with direct oral anticoagulants: A target trial emulation","Fanxing Du","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4371250",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0045967","S2727 The First Reported Case of Drug-Induced Liver Injury Caused by Semaglutide","Sarah Enslin","2021","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0000784440.97741.d2",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045968","Curcumin Targets the Spleen–Brain Axis in Diabetes: A Comparative Study with Liraglutide via JAK2/STAT3 Signaling","Mohsen A. Khormi","2026","Pharmacognosy Magazine","preclinical","article","10.1177/09731296261473067",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045969","OR1-6 | Impact of Tirzepatide on Post-PCI Outcomes in Patients With Diabetes Mellitus: Insights From a Real-World Propensity-Matched Cohort","Ayodeji Ilelaboye","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104409",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045970","ODP183 Diabetic Ketoacidosis Precipitated by Ketogenic Diet and SGLT-2 Inhibitor Use in an Individual with T2DM","Timothy J. Mason","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.635",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0045971","748-P: GLP-1 Receptor Agonists Dulaglutide and Semaglutide in Japanese Patients with Type 2 Diabetes—Randomized, Parallel-Group, Multicenter, Open-Label Trial","Tomohiko Kimura","2023","Diabetes","randomized_trial","article","10.2337/db23-748-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0045972","Greater Efficacy and Improved Endothelial Dysfunction in Untreated Type 2 Diabetes with Liraglutide versus Sitagliptin","Kunihiro Suzuki","2014","Institutional Repositories DataBase (IRDB)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0045973","GLP-1 Receptor Agonists: Effective Weight Loss, Limited Metabolic Restoration","JM Oliver","2025",null,"other","article","10.22541/au.174076928.85570162/v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0045974","DETERMINATION OF BACTERIAL ENDOTOXIN CONTENT IN SEMAGLUTIDE SUBSTANCE","Abdullina S.G.","2026","Медико-фармацевтический журнал «Пульс»","other","article","10.26787/nydha-2686-6838-2026-28-6-58-63",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045975","Dermatologic and Aesthetic Implications of GLP‐1 Receptor Agonist‐Associated Weight Loss: Pathophysiology, Clinical Manifestations, and Management","Douglas Jaxon Vadner","2026","Dermatological Reviews","other","article","10.1002/der2.70092",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045976","The Neuro‐Pancreatic Axis in Metabolic Disease: A Review of Neuro‐Immune Interfaces and Translational Challenges","Thanh Tuan Vu Le","2026","Comprehensive physiology","preclinical","article","10.1002/cph4.70241",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045977","Mepolizumab induced palmoplantar psoriasis: A case report","Fabio Artosi","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6154","37731552",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045978","Dual Therapy with GLP-1 Agonists and T Cell Modulation Outperforms GLP-1 Alone in Obesity Treatment 4792","Selma Boulenouar","2025","The Journal of Immunology","preclinical","article","10.1093/jimmun/vkaf283.2416",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045979","Next Step in Incretin-Based Therapy: From Single to Dual Agonism","Subhodip Pramanik","2022","EMJ Diabetes","randomized_trial","article","10.33590/emjdiabet/22-00140",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045980","2605-P: Comparing Adverse Event Rates among GLP-1/GIP Therapy Switchers vs. Continuous Use Groups in a Real-World Telehealth Cohort","Lauren Broffman","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2605-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045981","Exploiting Complex-Type N -Glycan to Improve the in Vivo Stability of Bioactive Peptides","Qijia Wei","2022","CCS Chemistry","preclinical","article","10.31635/ccschem.022.202202122",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045982","Maßband oder Waage – und werden GLP-1-RA jetzt zu „Herz-Arzneien“?","Denis Nößler","2025","EvidenzUpdate","other","article","10.69156/pod.001/2025.11.00156",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045983","Postoperative Complications and Revision Rates Following Total Shoulder Arthroplasty in Patients Receiving GLP-1 Agonists and/or SGLT-2 Inhibitors","Arthur Saroyan","2026","Michigan medical education and health bulletin.","other","article","10.69735/001c.163915",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045984","Clinical Insight into Type 2 Diabetes Mellitus: A Retrospective Study from Hospital Sultan Abdul Aziz Shah (HSAAS), Universiti Putra Malaysia’s Teaching Hospital","Murtala Muhammad Ahmad","2024","International Journal of Human and Health Sciences (IJHHS)","nonrandomized_study","article","10.31344/ijhhs.v8i40.746",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045985","Proteomic CKD Prediction in Type 2 Diabetes","Shiuan-Chih Chen","2026","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.0000000991","41563362",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0045986","Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects","Annarita Valeria Piazzolla","2025","Metabolism and Target Organ Damage","other_trial","article","10.20517/mtod.2025.152",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0045987","S2654 Semaglutide’s Dose Dependent Effect on MASH Resolution: Updated Meta-Analysis of 5 RCTs With Histologic and Metabolic Improvements","Madhu Babu Adusumilli","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001138076.63959.68",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0045988","Atypical Progeroid Syndrome with Familial Partial Lipodystrophy due to A Missense c.1045 C > T LMNA Mutation: A Case Report and an Innovative Therapeutic Approach","Benedetta Russo","2022","Archives of Clinical and Medical Case Reports","case_report","article","10.26502/acmcr.96550538",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045989","Mo1637 EFFECTS OF GLP-1 RECEPTOR OR A DUAL GLP-1/GIP RECEPTOR AGONISTS ON GASTROINTESTINAL SYMPTOMS AND GASTRIC EMPTYING: RESULTS FROM A LARGE CLINICAL PRACTICE DATABASE","Camille Lupianez‐Merly","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)02923-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0045990","The combination of the PPARγ agonist pioglitazone and the GLP1R agonist liraglutide act synergistically to attenuate alcohol consumption in genetically selected alcohol preferring rats","Sofia Christina Gkolfinopoulou","2026","Alcohol","preclinical","article","10.1016/j.alcohol.2026.01.148",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0045991","SEMAGLUTIDE IN THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME: CURRENT EVIDENCE AND REPRODUCTIVE BENEFITS","Diana Wisz","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3940",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0045992","Saxenda, Ozempic, and Mounjaro: a Comparative Analysis of The Weight Loss Medications and Their Side Effects in Najaf, Iraq","Zainab Sajid Mohammed","2026","Medical Science Journal for Advance Research","other","article","10.46966/msjar.v6i3.275",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045993","898-P: SGLT2 Inhibitors or GLP-1 Receptor Agonists? Development of a Personalized Treatment Algorithm for Individuals with Type 2 Diabetes","Tim Mori","2025","Diabetes","nonrandomized_study","article","10.2337/db25-898-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0045994","Consensus of the Expert Council on the Management of Pancreatic Exocrine Insufficiency in Patients with Diabetes Mellitus","Ігор Миколайович Скрипник","2026","Family medicine European practices","other","article","10.30841/2786-720x.1.2026.353747",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0045995","GLP-1 Receptor Agonists Beyond Glycemic Control: Clinical Implications in Neurodegenerative Disease and Substance Use Disorders","Michelle Raja","2026","Journal of Community Hospital Internal Medicine Perspectives","randomized_trial","article","10.55729/2000-9666.1651",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045996","Exendin-4 Protects MIN6 Cells from Endoplasmic Reticulum Stress-Induced Apoptosis","Wenjia Chen","2011",null,"other","article","10.1210/endo-meetings.2011.part3.p5.p2-502",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0045997","Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","Hirokazu Takahashi","2025","Diabetes Mellitus","randomized_trial","article","10.14341/dm13340",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0045998","Additional file 1 of The impact of glucagon-like peptide-1 receptor agonists in the patients undergoing anesthesia or sedation: systematic review and meta-analysis","do Nascimento, Tatiana S.","2024","Figshare","systematic_review","article","10.6084/m9.figshare.26752558",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0045999","IBD and obesity: the vicious cycle","Léa Sequier","2024","Hépato-Gastro & Oncologie Digestive","other","article","10.1684/hpg.2023.2697",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046000","The Use of Exenatide to Reverse Morbid Obesity in a Child with Hypothalamic Obesity","Nancy Ann Varni","2008","Journal of Pediatric Nursing","other","article","10.1016/j.pedn.2008.02.018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046001","GLP-1 receptor agonists","Jens Juul Holst","2026","Elsevier eBooks","other","article","10.1016/b978-0-443-33287-6.00012-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0046002","Xultophy: combination therapy for the treatment of type 2 diabetes","Steve Chaplin","2015","Prescriber","other","article","10.1002/psb.1382",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046003","2023-P: OXM-001, a Novel Oxyntomodulin Analog, Improves Glucose Tolerance and Reduces Body Weight in High-Fat Diet Mice","Ashref Kayed","2019","Diabetes","preclinical","article","10.2337/db19-2023-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046004","Abstract 529: Asporin - Extracellular Matrix Protein Mitigates Pathological Remodeling","Honit Piplani","2018","Circulation Research","preclinical","article","10.1161/res.123.suppl_1.529",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046005","637: PULMONARY OUTCOMES IN DIABETIC GASTROPARESIS: A PROPENSITY-MATCHED STUDY OF GLP-1 AGONIST USE","Hasan Kamal","2026","Critical Care Medicine","nonrandomized_study","article","10.1097/01.ccm.0001184544.61601.14",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046006","Targeting Mitochondrial Dysfunction in Lipedema: A Pharmacological Approach to Enhance Metabolic Flexibility","Md Arafat Hossain","2026","Scholarly Commons (University of the Pacific)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046007","Combination therapy of semaglutide and methylphenidate leads to significant weight loss in prader-willi syndrome patients","Shiga Chiaryath","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.p716",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046008","GLP-1 Receptor Agonist Liraglutide Modulates the Oxidative Stress and SIRT1/PGC1 Alpha Levels on Liver Tissue in Ovariectomized Rats","Hale SAYAN ÖZAÇMAK","2025","Turkish Journal of Diabetes and Obesity","preclinical","article","10.25048/tudod.1648915",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046009","PDB57 REAL-WORLD ECONOMIC OUTCOMES AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) TREATED WITH DULAGLUTIDE (DU) VS. BASAL INSULIN (BI) IN THE US: THE DISPELTM STUDY","Reema Mody","2019","Value in Health","nonrandomized_study","article","10.1016/j.jval.2019.04.606",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046010","730-P: Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes (SURPASS-CN-INS)","LIXIN GUO","2025","Diabetes","randomized_trial","article","10.2337/db25-730-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046011","Parkinson's Disease: Molecular Mechanisms, Metabolic Interactions, Biomarkers, and Emerging Therapeutic Targets","Moh Aijaz","2026","Neurology and Clinical Neuroscience","other","article","10.1002/ncn3.70131",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046012","Ozempic Face e Envelhecimento Facial Acelerado: Impactos da Perda Ponderal Induzida por Agonistas do GLP-1 na Estética e no Planejamento de Procedimentos Faciais","Gabriela Camilly de Lima Nogueira","2026","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2026v8n8p84-98",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046013","76672 Impact of GLP-1 and Dual GLP-1/GIP Receptor Agonists on Inflammatory Outcomes in Atopic Dermatitis: A Real-World Cohort Study","Dylan Wambold","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.1033",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046014","New Hypoglycemic Agents-Incretins","Xue‐Jiao Tian","2012","Xiandai yufang yixue","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046015","CO170 COMPARATIVE CARDIOVASCULAR AND KIDNEY EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VERSUS OTHER GLUCOSE-LOWERING AGENTS IN PATIENTS WITH TYPE 2 DIABETES: A REAL-WORLD STUDY IN CHINA","Yuqing Fan","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.265",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046016","Glucagon-like peptide-1 receptor agonists are associated with decreased risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy","Zujaja Tauqeer","2021","Investigative Ophthalmology & Visual Science","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046017","2571-P: An Olive-Derived Small Molecule Enhances Liraglutide-Induced Weight Loss in Diet-Induced Obesity","HANA ALKHALIDY","2026","Diabetes","preclinical","article","10.2337/db26-2571-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046018","Tu1790 OPTIMAL TIMING FOR GLP-1 RECEPTOR AGONIST INITIATION IN OBESE PATIENTS UNDERGOING METABOLIC BARIATRIC SURGERY","Guy Nguefang","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04917-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046019","HSD3 BARRIERS AND FACILITATORS IMPACT PERSISTENCE OF SGLT2 INHIBITORS & GLP-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A QUALITATIVE STUDY WITH HEALTHCARE PROVIDERS","Bilqees Fatima","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1240",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046020","GLP-1 RA Eligibility in Reproductive-Age U.S. Women","Ivy Shi","2026","Diabetes Obesity and Cardiometabolic CARE","other_trial","article","10.2337/doc25-0040",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046021","Exploring Equity in Glucose‐lowering Research for Patients with Obesity. A Meta-epidemiological Study Protocol","Maria Fernanda Assumpção Jacob","2026","OSF Preprints (OSF Preprints)","protocol","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","preprint"],["R0046022","Mo1816 INCIDENCE OF PANCREATIC DISEASES AFTER GLP-1 RECEPTOR AGONIST INITIATION IN ADULTS WITH AND WITHOUT PRIOR PANCREATIC DISEASE","Kerri Conklin","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)04880-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046023","Rybelsus: an oral formulation of the GLP ‐1 agonist semaglutide","Steve Chaplin","2020","Prescriber","other","article","10.1002/psb.1873",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046024","Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden","George J. Dugbartey","2026","Toxicology Reports","other","article","10.1016/j.toxrep.2026.102247","42006047",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046025","Systematic Literature Review on Efficacy and Safety of Glucagon-Like Peptide (GLP-1) Agonists in Asian Adults Living with Type 2 Diabetes Mellitus.","Sunil Dhungel","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/6z92t",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint; review"],["R0046026","1779-P: Cracking the Code—How the Individualized Metabolic Surgery Score Predicts Weight Loss with Tirzepatide in People with Type 2 Diabetes and Obesity","REGINA CASTANEDA","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1779-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046027","EVALUATING LIPOPROTEIN(A) TESTING PATTERNS AND ASSOCIATED CLINICAL CARE IMPACT IN A LARGE ACADEMIC HEALTH CENTER","Aida Roman","2025","American Journal of Preventive Cardiology","nonrandomized_study","article","10.1016/j.ajpc.2025.101181",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046028","Gut Microbiome–SCFA Axis as a Pharmacodynamic Modifier of GLP-1 Receptor Agonist Therapy in the South Asian Metabolic Phenotype","Shibichakravarthy Kannan","2026",null,"other","article","10.55277/researchhub.gtm3xbkr",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0046029","68Ga- and 177Lu-radiolabelling chemistry of DO3A-VS-Cys40-Exendin-4 and differences of the tracer pancreatic uptake in various species","Irina Velikyan","2019","Nuclear Medicine and Biology","other","article","10.1016/s0969-8051(19)30340-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046030","The hypoglycemic effect of the GLP-1 analogue LY307161 is self-limiting in normal, fasted dogs","Sharon R Myers","2000","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(00)81311-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046031","In silico prediction of GLP-1R agonists using machine learning approach","Zhengkun Kuang","2021","Chemical Papers","other","article","10.1007/s11696-021-01600-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046032","A Retrospective Analysis of Glucagon-Like Peptide 1 Receptor Agonists in Treating Type 2 Diabetes Mellitus Complicated by Nonalcoholic Fatty Liver Disease","Jiaqian Chen","2024","Journal of Biosciences and Medicines","nonrandomized_study","article","10.4236/jbm.2024.123002",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046033","897-P: Use of In-Person and E-Consults for Type 2 Diabetes in an Academic Primary Care Network","CAITLIN A. COLLING","2022","Diabetes","other","article","10.2337/db22-897-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046034","Unveiling the metabolic benefits of GLP-1 analogues in alstrom syndrome: implications for monogenic syndromic obesity management","Sadaf Ali","2023","Endocrine Abstracts","other","article","10.1530/endoabs.94.p54",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046035","S827 Global Insights: Glucagon-Like Peptide-1 Receptor Agonists are Linked to Gastrointestinal Functional Disorders ACG Outstanding Research Award in the Functional Bowel Disease Category (Trainee)","Mengdan Xie","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032676.04728.09",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046036","Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death","Indranil Dasgupta","2017","Annals of Internal Medicine","nonrandomized_study","article","10.7326/acpjc-2017-167-8-047","29049766",null,null,null,"openalex","FALSE","paywalled","4","FALSE","editorial"],["R0046037","217-OR: A Randomized Controlled Trial Comparing the Safety and Efficacy of IDegLira vs. Basal Bolus in Patients with Poorly Controlled Type 2 Diabetes and Very High HbA1c (>9%–15%) : IDegLira HIGH Trial","RODOLFO J. GALINDO","2022","Diabetes","randomized_trial","article","10.2337/db22-217-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046038","Vergleich der Wirksamkeit von wöchentlichem Depot-Exenatide und Liraglutid unter Alltagsbedingungen bei Patienten mit Typ 2 Diabetes mellitus","W. Brian Saunders","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549606",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046039","Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis (Preprint)","Parisa Momeni","2025",null,"nonrandomized_study","article","10.2196/preprints.80660",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0046040","Risk-benefit of tirzepatide, semaglutide, and bariatric surgery in obesity","Lucca Lorenzo Déo Malaquini","2024","Interamerican Journal of Health Sciences","nonrandomized_study","article","10.59471/ijhsc2025277",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046041","244: GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH REDUCED RISK OF LIVER DISEASE PROGRESSION IN PATIENTS WITH ALCOHOL USE DISORDER: A PROPENSITY SCORE MATCHED ANALYSIS","Yassine Kilani","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04621-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046042","Apparent Refractory Type 2 Diabetes in Extreme Obesity: Marked Improvement Following Automated Insulin Delivery","Saraswathi Saiprasad","2026","AACE Endocrinology and Diabetes","other_trial","article","10.1016/j.aed.2026.08.005",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0046043","Application and Mechanism of GLP-1 Receptor Agonists in the Treatment of Obesity Complicated with Type 2 Diabetes Mellitus","Xingyu Liu","2025","International Journal of Public Health and Medical Research","other","article","10.62051/ijphmr.v3n3.08",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046044","Impact of luseogliflozin on metabolic health, lipid profiles, and cardiovascular outcomes in patients with type II diabetes: A systematic review and network meta‐analysis","Luigi Angelo Z. Borlongan","2026","Diabetes Obesity and Metabolism","systematic_review","article","10.1111/dom.70482","41582558",null,"PROSPERO:CRD42024605191",null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046045","Pharmacological and Non-Pharmacological Interventions for the Treatment of Obesity: A Review of Guidelines and Clinical Trials (2020–2025)","Anna Gęborys","2026","Journal of Education Health and Sport","randomized_trial","article","10.12775/jehs.2026.90.69970",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046046","O emergente uso do Ozempic® no tratamento da obesidade","Evelyn de Oliveira de Maria","2024","Research Society and Development","other","article","10.33448/rsd-v13i6.46063",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046047","Sa1433: DECREASED RISK OF ACUTE PANCREATITIS IN CHRONIC PANCREATITIS PATIENTS ON GLP-1 RECEPTOR AGONISTS: A PROPENSITY MATCHED ANALYSIS","Mahmoud Y. Madi","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)02011-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046048","Cognition and Long COVID: a review","CHRISTINA MARIA VAN DER FELTZ-CORNELIS","2026","White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046049","The GLP-1 receptor agonist Liraglutide attenuates intermittent hypoxia-induced pro-inflammatory macrophage polarization in primary macrophages","Ailbhe King","2021",null,"preclinical","article","10.1183/13993003.congress-2021.oa3018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046050","Lâassociation iGlarLixi permet de réduire davantage l'HbA1c quâun traitement à lâinsuline basale, quels que soient les niveaux dâHbA1c à lâinclusion","Elisabeth Niemoeller","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046051","761-P: Effect of Orforglipron vs. Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes","Juan P. Frías","2023","Diabetes","randomized_trial","article","10.2337/db23-761-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046052","765-P: Efficacy and Safety of Switching to iGlarLixi from Premixed Insulin (PI) in South Korean People Living with Type 2 Diabetes (T2D)—Subanalyses of Soli-SWITCH Study","Soo Lim","2024","Diabetes","other_trial","article","10.2337/db24-765-p",null,null,"EudraCT:2021-003711-25",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046053","Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of incident infection and severe infection–related outcomes in type 2 diabetes","Jheng-Yan Wu","2026","BMC Infectious Diseases","nonrandomized_study","article","10.1186/s12879-026-13982-4",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046054","Abstract 4343077: Combination of Prolonged Water Fasting and Tirzepatide for Treatment of Refractory Morbid Obesity: Case Report","Tiago Palmisano","2025","Circulation","case_report","article","10.1161/circ.152.suppl_3.4343077",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046055","Origin and therapy for hypertriglyceridaemia in type 2 diabetes","Chen Cha","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046056","2007-P: Obesity Prevalence in the Patient Neighborhood and Outcomes of Antiobesity Medication Mediated by Treatment Continuation: Structured Equation Modeling Approach","Kibum Kim","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2007-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046057","Mo1622: EFFICACY OF GLP-1 ANALOGS AND AGONISTS ON PROPORTION OF WEIGHT LOSS IN OVERWEIGHT OR OBESE DIABETICS AND NONDIABETICS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Kia Vosoughi","2022","Gastroenterology","systematic_review","article","10.1016/s0016-5085(22)61976-0",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0046058","Functionality and Tunability of Danuglipron-Containing Matrix Tablets for Extended Drug Delivery","Kenneth S. Ogueri","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6662211",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046059","832 REPOSITIONING DUAL GLP-1/GIP RECEPTOR AGONISTS FOR THE TREATMENT OF COLITIS AND COLITIS-ASSOCIATED CANCER","Bianca N. Islam","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)02389-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046060","Abstract TH826: Impact of Glucagon-Like Peptide-1 Receptor Agonists on Asthma Exacerbations Among Individuals with Type 2 Diabetes and Asthma: A Target Trial Emulation Study","Lijuan Zeng","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.th826",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046061","TREATMENT OF TYPE 2 DIABETES MELLITUS WITH GLP-1 RECEPTOR AGONISTS, CHRONIC KIDNEY DISEASE AND INFLUENCE ON CARDIOVASCULAR RISK","Nikolay Kostadinov","2025","Trakia Journal of Sciences","other","article","10.15547/tjs.2025.s.01.004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046062","26-A-14911-ACC IMPLEMENTATION AND OUTCOMES OF GLP-1 RECEPTOR AGONIST TITRATION (GLP-1RA) IN A HEART FAILURE CLINIC","Sydney Hege","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.1903",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046063","Diabetes mellitus: therapy adherence and new therapeutic approach with incretin mimetics in Northeast Portugal","Olívia R. Pereira","2016","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0046064","The interplay of metabolically associated fatty liver disease and carbohydrate metabolism disorders: Current understanding of pathogenesis and treatment","A.V. Murasheva","2024","FOCUS Endocrinology","other","article","10.62751/2713-0177-2024-5-3-08",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046065","74547 Impact of Metabolic Risk and Healthcare Access on GLP-1RA Counseling and Prescribing in Psoriasis and Hidradenitis Suppurativa","Rachel Granovsky","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.1039",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046066","Treatment options for type 2 diabetes:introducing the incretin‐based therapies","A H Barnett","2009","Practical Diabetes","other","article","10.1002/pdi.1367",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046067","In vitro differentiation of human adipose tissue-derived stromal cells into insulin-producing cells","Weiqun Yan","2012","Journal of Jilin University","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046068","Barriers to integrating obesity management into cancer survivorship care: Results from a single-institution survey.","Jaleesa Akuoko","2026","Journal of Clinical Oncology","other","article","10.1200/jco.2026.44.16_suppl.e13783",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046069","Additional file 4 of Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review","Dave Osinachukwu Duru","2026","Figshare","narrative_review","article","10.6084/m9.figshare.32787551",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046070","Virtual issue: focus on cardiovascular protection","Wouter Vandevelde","2016","Cardiovascular Research","other_trial","article","10.1093/cvr/cvw160","27402319",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046071","Cardiovascular Outcomes Associated with Semaglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis","Gianmarco Adinolfi","2026","Endocrines","systematic_review","article","10.3390/endocrines7010009",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046072","Perioperative Management of GLP-1 Receptor Agonists and SGLT2 Inhibitors and the Risk of Aspiration, Ketoacidosis, and Major Complications: A Systematic Review and Meta-analysis","Lawrence Willis Chinn","2025",null,"systematic_review","article","10.17605/osf.io/rvdpw",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0046073","IDDF2026-ABS-0333 Real-world gastrointestinal, nutritional, biliary, and metabolic outcomes of GLP-1-based therapy in chronic pancreatitis","Arkadeep Dhali","2026","Clinical Gastroenterology","nonrandomized_study","article","10.1136/gutjnl-2026-iddf.318",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0046074","74786 Burns and Blood Sugar: The Impact of Semaglutide on Wound Healing and Adverse Postoperative Outcomes in Diabetic Adult Burn Patients","Danielle Cain","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.365",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046075","The Effects of Exendin-4 on the Viability and Insulin Secretion of Microencapsulated Pancreatic Islets","Jun‐Beom Park","2010","한국생물공학회 학술대회","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046076","Difficult‐To‐Treat Psoriatic Arthritis: An Evolving Clinical Construct","Illiasul K Ibad","2026","International Journal of Rheumatic Diseases","randomized_trial","article","10.1111/1756-185x.70632","41906347",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0046077","Pharmacists, knowledge and counseling practices regarding tirzepatide for obesity and type 2 diabetes management in the UAE","Anan S. Jarab","2026","Pharmacy Practice","other","article","10.18549/pharmpract.2026.3.3596",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046078","Combined therapy with liraglutide, insulin, and metformin in a glucocorticoid-induced diabetic patient with multiple sclerosis","Ye Chen","2014","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2014.03.017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046079","MM-1086: GLP-1 Receptor Agonists and Venous Thromboembolism Risk in Multiple Myeloma","Priyanshi Maurya","2026","Clinical Lymphoma Myeloma & Leukemia","other","article","10.1016/s2152-2650(26)02979-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046080","Changes to Insulin Requirements Over Time With Semaglutide in Adults With Type 1 Diabetes on Insulin Pump Therapy: A Post-Hoc Analysis of a Double-Blinded, Randomized, Crossover Trial","Melissa‐Rosina Pasqua","2025","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2025.10.134",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046081","Obesity","Timothy Stopford Christopher Hinks","2025","European Respiratory Society eBooks","other","article","10.1183/2312508x.10015524",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0046082","Use of liraglutide for management of high output stoma after small bowel resection in Crohn’s disease: a case report","Seong Hui Moon","2025","Frontline Gastroenterology","case_report","article","10.1136/flgastro-2024-102911",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046083","Tissue distribution of exendin-4 in rats","Ai Guo","2008","Zhongguo yaolixue yu dulixue zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046084","The Liver-Heart Axis: A Narrative Review of Clinical Implications of the MASLD Redefinition for Internists","Hassan A. Abdou","2026","ASIDE Gastroenterology","nonrandomized_study","article","10.71079/aside.gi.031826446",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0046085","26-A-9711-ACC CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS","Bara M. Hammadeh","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.652",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0046086","Medikamentöse Therapie der Adipositas bei Kindern und Jugendlichen","Julia Lischka","2025","Monatsschrift Kinderheilkunde","other","article","10.1007/s00112-025-02149-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046087","which permits unrestricted noncommercial use, provided the original work is properly cited. Vascular Health and Risk Management 2012:8 621–629","Vascular Health","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046088","NICE gives rimonabant the green light","Milan K. Piya","2008","Practical Diabetes","randomized_trial","article","10.1002/pdi.1284",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046089","1469-P: Risk of Diabetic Ketoacidosis in SGLT2i vs. GLP-1RA Initiators with Chronic Kidney Disease Stage 3–4 and Type 2 Diabetes","Panupong Hansrivijit","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1469-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046090","A betegség lefolyását módosító gyógyszeres kezeléssel szerzett tapasztalataink 2-es típusú diabetes mellitusos betegeinknél egy egycentrumos retrospektív vizsgálat eredményei alapján","Ágnes Diószegi","2025","Diabetologia Hungarica","other","article","10.24121/dh.2025.27",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046091","1271-P: Health Care Utilization and Cost with Empagliflozin vs. GLP-1RA in Patients with Type 2 Diabetes","PHYO T. HTOO","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1271-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046092","Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs","Dariusz Popiela","2025","Quality in Sport","nonrandomized_study","article","10.12775/qs.2025.37.57000",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046093","Phase Angle and Lean Mass Evolution After Roux-en-Y Gastric Bypass: Functional Outcomes and Comparison with GLP-1 Therapies","Julia Navarro-Marroco","2026","Dietetics","nonrandomized_study","article","10.3390/dietetics5020021",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046094","771-P: Meta-analysis of hsCRP's Effect on Cardiovascular Outcome among GLP-1RAs–Based Clinical Trials","Lin Luo","2025","Diabetes","systematic_review","article","10.2337/db25-771-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046095","Cardiometabolic benefits of dual GLP1-RA and SGLT2i therapy in patients with HFpEF, T2DM, obesity, and obstructive sleep apnea: a prospective study","Gergana Voynova","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.1009",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046096","SUN-222 Pioglitazone: An Underutilized Treatment of Diabetes Concurrent With NASH","Talal Alomar","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.2371",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046097","A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.","聡 前川","2020","Institutional Repositories DataBase (IRDB)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0046098","Investigating the Binding Efficacy of Snake Venom Proteins as GLP-1 Analogs for Diabetes mellitus Management: An In silico Study","Upendra Gunta","2023","Oriental Journal Of Chemistry","other","article","10.13005/ojc/390306",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046099","Il paziente diabetico di tipo 2 con insufficienza renale cronica: le raccomandazioni delle linee guida italiane","Matteo Monami","2024","il Diabete","commentary","article","10.30682/ildia2401c",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0046100","¿Cómo contribuyen los AR GLP-1 a las poblaciones de mayor riesgo?","Sergio Giménez","2021","Revista de la Federación Argentina de Cardiología","other","article","10.63600/7yc0ra48",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046101","Trends in New Antidiabetes Drug Dispensation in Colombia, 2015-2023","Camilo González","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20256maz5wje",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046102","Effect of glucagon-like peptide 1 receptor agonist on the expression of chemerin in insulin target tissues in high-fat diet-induced obese rats","Jing Yang","2016","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2016.11.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046103","Effects of once-weekly semaglutide on regional body composition in overweight or obese adults","Yishan Ma","2026","Metabolism and Target Organ Damage","nonrandomized_study","article","10.20517/mtod.2025.212",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046104","The Hormonal dysregulation and its consequences in Obese Women - overview","Katarzyna Pala","2025","Journal of Education Health and Sport","other","article","10.12775/jehs.2025.77.56907",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046105","Is obstructive sleep apnoea more than an epiphenomenon in patients with obesity? A cardiovascular perspective from a real-world propensity score-matched study","B S Prado","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3900",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046106","Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review","Rachelle Choi","2025","Endocrines","narrative_review","article","10.3390/endocrines6020027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0046107","GLP-1 Receptor Agonists: A New Hope in the Global Fight Against Obesity — Benefits and Health Risks","Oskar Pastuszek","2026","Journal of Education Health and Sport","randomized_trial","article","10.12775/jehs.2026.87.67433",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046108","52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study","Sean Wharton","2023","Diabetes","randomized_trial","article","10.2337/db23-52-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046109","Chronic Kidney Disease Related to Cognitive Disorders in the Elderly: A Narrative Literature Review","Ajat Sudrajat","2022","Bioscientia Medicina Journal of Biomedicine and Translational Research","narrative_review","article","10.37275/bsm.v6i14.663",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046110","Essential Role Of High Glucose-Induced Overexpression Of PKCβ And PKCδ In GLP-1 Resistance In Rodent Cardiomyocytes","Xinghua Pan","2019","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046111","P-12: PREVASCULARIZATION STRATEGIES FOR SUBCUTANEOUS ISLET TRANSPLANTATION: COMPARATIVE ASSESSMENT OF BFGF-LOADED AGAROSE RODS AND BIOABSORBABLE COLLAGEN–GELATIN SHEETS","Kei Yamane","2025","Transplantation","preclinical","article","10.1097/01.tp.0001123420.50920.f3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046112","Mo1821 RISK OF NEW-ONSET CONSTIPATION ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1) USE: RESULTS FROM A NATIONWIDE COHORT STUDY","Madeleine Chang","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04885-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046113","Periconception Glucagon-Like Peptide-1 Receptor Agonist Treatment and Pregnancy Outcomes in Women With Obesity Without Diabetes: A Community-Based Retrospective Cohort Study","Mor Svorai","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7459062",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0046114","PDB11 RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES TREATED WITH EXENATIDE OR THIAZOLIDINEDIONES: A RETROSPECTIVE ANALYSIS OF THE PHARMETRICS DATABASE","JH Best","2010","Value in Health","nonrandomized_study","article","10.1016/s1098-3015(10)72258-0",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046115","Bariatric Surgery as a Potent Intervention for Type 2 Diabetes Remission in Obesity: Mechanisms, Outcomes, and Future Directions","Lei Zhang","2025","Journal of Biosciences and Medicines","other","article","10.4236/jbm.2026.141003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046116","TZP Paper","Arthur Sherman","2026","Figshare","other","article","10.6084/m9.figshare.31370863.v4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046117","Biotechnological Advances in GLP-1 Receptor Agonists: Development, Optimization, and Market Dynamics","Yanze Wang","2025","Highlights in Science Engineering and Technology","other","article","10.54097/7zncrb24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046118","2195-PUB: Use of U500 Insulin in External Pump for Insulin-Resistant Diabetic Patients: A French Experience","YOUSSEF OUALIT","2020","Diabetes","other","article","10.2337/db20-2195-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046119","Onset and Relapse of Depressive Disorders Associated With Wegovy® For Weight Loss","Tasnim Fareh","2023","Annals of Case Reports","other","article","10.29011/2574-7754.101502",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046120","Dramatic reductions in hepatic steatosis accompanied by improved HbA1c following a 4-week treatment of obese/diabetic/NAFLD patients with DD01, a novel long-acting GLP-1/glucagon receptor agonist","Adam C. Bell","2023","Journal of Hepatology","other","article","10.1016/s0168-8278(23)00587-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046121","P131 - ECE_1459 - Proportion of diabetes of the exocrine Pancreas among adult patients classified as type 2 diabetes mellitus and evaluation of gut-pancreatic hormones for its detection","Ankitesh Kumar","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.322",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046122","GLP-1 analogues in therapy of obese adolescents. Early real-life experience with liraglutide treatment","Jana Křenek Malíková","2023","Česko-slovenská pediatrie","other","article","10.55095/cspediatrie2023/024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046123","MANIFESTATION OF GLP-1 RECEPTOR AGONISTS IN THE ORAL AND MAXILLOFACIAL REGION: A SCOPING REVIEW","Ana Carolina Uchoa Vasconcelos","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0046124","GLP-1 Receptor Agonists in People Living with HIV and Overweight or Obesity Associated with Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide: A JBI Scoping Review","Gerardo Uriel Viquez Burboa","2026",null,"nonrandomized_study","article","10.17605/osf.io/nqhwe",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0046125","Mechanisms of Effects of Glucagon-Like Peptide 1 in the Pancreas","Chong Xu","2009","Letters in Biotechnology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046126","GLP-1 receptor agonist therapy and risk of small intestinal neoplasms: Real-world evidence from a global network.","Prerna Ashok Kherajani","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e16499",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046127","MSR50 AI-ASSISTED GENERATION OF SYNTHETIC PATIENT-LEVEL DATA TO RECREATE WEIGHT-CHANGE OUTCOMES FROM THE STEP-4 SEMAGLUTIDE TRIAL","Devendra Patil","2026","Value in Health","other_trial","article","10.1016/j.jval.2026.03.1549",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0046128","73447 Risk of Bullous Pemphigoid in Patients Treated With GLP-1 Receptor Agonists and Other Diabetes Medications: A Retrospective Cohort Study","Catherine Shen","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.1549",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046129","Tirzepatide in Obstructive Sleep Apnea: Targeting Obesity and Hypoxic Burden","Md Mohsin Sarker","2026","Bangladesh Journal of Endocrinology and Metabolism","other","article","10.4103/bjem.bjem_36_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046130","8336 Glycemic Control and Associated Factors During Transition in Youths with Childhood-onset Type 2 Diabetes Mellitus","Jeesun Yoo","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.1454",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046131","Reduced Risk of Colorectal Adenomas and Polyps with GLP-1 Receptor Agonists: A Colonoscopy-Based Target Trial Emulation","Angela T.H. Kwan","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6261583",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0046132","775-P: Influence of Eating Behavior on Therapeutic Effects of GLP-1 Receptor Agonists over a One-Year Period","YUYA KOIDE","2024","Diabetes","other","article","10.2337/db24-775-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046133","A Case of Paradoxical Appetite Increase During Semaglutide Therapy","E. Karisik","2025","Diabetology","case_report","article","10.3390/diabetology6100101",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046134","2021-LB: Sustained Weight and Metabolic Health following GLP-1 Deprescription for Type 2 Diabetes—Evaluating the Long-Term Impact of Breathe Well-Being’s Lifestyle Management Program","ADITYA KAICKER","2025","Diabetes","nonrandomized_study","article","10.2337/db25-2021-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046135","Abstract 4359705: Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Dementia Risk in Type 2 Diabetes: A Comprehensive Bayesian Network Meta-Analysis","Ibrahim Khalil","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4359705",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0046136","The mechanistic understanding of the prothrombotic role of GLP-1 agonist","Kylla A. Przekop","2025","OpenBU (Boston University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0046137","3033-LB: Spatiocellular Mapping Indicates Complementary Action of Amylin and GLP-1 Receptor Agonism in the Human Brain","Mette Q. Ludwig","2026","Diabetes","preclinical","article","10.2337/db26-3033-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046138","The Impact of GLP-1 Receptor Agonists on Body Composition and Musculoskeletal Integrity: A Review of Mechanisms, Protective Strategies, and Clinical Perspectives","Szymon Domagała","2026","Quality in Sport","other_trial","article","10.12775/qs.2026.53.69771",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0046139","WCN26-1959 ASSOCIATION OF TIRZEPATIDE WITH KIDNEY PARAMETERS IN PEOPLE WITH OBESITY AND PREDIABETES FROM SURMOUNT-1 OVER 176 WEEKS","Hiddo J.L. Heerspink","2026","Kidney International Reports","other","article","10.1016/j.ekir.2026.104589",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046140","It's Time to Overcome Clinical Inertia","Lawrence S. Phillips","2008","Annals of Internal Medicine","randomized_trial","article","10.7326/0003-4819-148-10-200805200-00011","18490691",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","editorial"],["R0046141","Improving Reproductive Outcomes in PCOS: The Emerging Role of GLP-1 Receptor Agonists","Adrianna Tabeau","2025","Journal of Education Health and Sport","other","article","10.12775/jehs.2025.79.59347",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046142","Efficacy GLP-1 agonists, SGLT-2 inhibitors and other glucose-lowering medications on cardiorenal outcomes in patients with diabetes and cancer on immune checkpoint therapy.","Diptasree Mukherjee","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.11174",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046143","The effectiveness of exenatide, sitagliptin and insulin in treatment of diabetic neuropathy: A comparative experimental study in rats","Erkan Özbay","2018","Van Yüzüncü Yıl University Academic Data Management System","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0046144","O uso de análogos de GLP-1 para emagrecimento em adultos com sobrepeso ou obesidade: Revisão integrativa","Matheus Henrique de Lima Maciel","2026","Journal of Medical and Biosciences Research.","other","article","10.70164/jmbr.v3i2.1142",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046145","Incretin-based therapies: A focus on safety concerns and emerging uses","Lalita Prasad‐Reddy","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046146","Análise do uso do Ozempic para perda de peso e tratamento da obesidade na atualidade: uma revisão integrativa.","Ana Luisa Albuquerque Miranda","2025","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2025v7n1p1768-1781",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046147","Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials","Nazanin Mozaffari","2024","PharmaNutrition","systematic_review","article","10.1016/j.phanu.2024.100409",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046148","Demystifying the Progression of Retinopathy with Glucagon-Like Peptide-1 Receptor Agonists","Jothydev Kesavadev","2022","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_17_22",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046149","Additional file 1 of Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study)","Nitin Kapoor","2026","Figshare","randomized_trial","article","10.6084/m9.figshare.32087488.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0046150","2602-P: Cardiometabolic Risk Trajectories On and After Antiobesity Medication Use","Lilah Khoja","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2602-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046151","Glucagon-Like Peptide-1 and Glucagon-Like Peptide-2 Receptor Agonists and Their Association With Cannabis: A Scoping Review","Johannes Thrul","2026",null,"nonrandomized_study","article","10.17605/osf.io/evxfy",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0046152","Eficácia de novas terapias injetáveis para Diabetes tipo 2 na redução de eventos cardiovasculares","Marcella Eppinger Caruso Casadei Abumussi","2025","Journal Archives of Health","other","article","10.46919/archv6n4espec-15937",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046153","AMPK-Mediated Multi-Organ Protective Effects of GLP-1 Receptor Agonists","Xin Wang","2025","Health and Metabolism","other","article","10.53941/hm.2025.100004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046154","Cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus. Review","Larysa Zhuravlyova","2024","Ukrainian Therapeutical Journal","narrative_review","article","10.30978/utj2024-4-68",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046155","3077-LB: IBI3040, a Novel Amylin Analog, Induces Superior Weight Loss in Preclinical Models","WENKUI WU","2026","Diabetes","preclinical","article","10.2337/db26-3077-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046156","Association of GLP-1 receptor agonist exposure with mortality, infectious, and hematologic outcomes in chronic lymphocytic leukemia: A real-world retrospective TriNetX study.","Sai Sushrutha Mudupula Vemula","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e18591",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046157","Macrophages: Novel Molecular Mechanism and Therapeutic Strategy in Diabetic Kidney Disease","Sinan Ai","2025","Integrative Medicine in Nephrology and Andrology","other_trial","article","10.1097/imna-d-25-00021",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0046158","Semaglutida: Uma análise dos efeitos do uso no combate à obesidade","Lorranny Vitoria Niquini Ribeiro","2024","E-Acadêmica","nonrandomized_study","article","10.52076/eacad-v5i2.553",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046159","Glucagon-like peptide-1 receptor agonists for cardiorenal protection in diabetes and obesity-related kidney disease","Marco Montomoli","2024","CEU Repositorio Institucional (Fundación Universitaria San Pablo CEU)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0046160","Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in patients with type 2 diabetes with a higher impact on women","D Garcia Vega","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3972",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046161","PDB9 THE COMPARATIVE EFFICACY OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (NMA)","Katherine Fazioli","2020","Value in Health","systematic_review","article","10.1016/j.jval.2020.04.198",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0046162","Small Intestinal Bacterial Overgrowth in Type 2 Diabetes Mellitus: Prevalence, Pathophysiology, and Clinical Implications - A Narrative Review","Michał Nowakowski","2026","Journal of Education Health and Sport","narrative_review","article","10.12775/jehs.2026.91.70753",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0046163","Un traitement par liraglutide chez un patient diabétique de type 2 à haut risque cardiovasculaire","Françoise Couic-Marinier","2017","Actualités Pharmaceutiques","other","article","10.1016/j.actpha.2016.11.021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046164","Semaglutide, Testosterone and Sildenafil advertising on social media: The Normalisation of lifestyle enhancement drugs","Mikey Hirst","2024","Performance Enhancement & Health","other","article","10.1016/j.peh.2024.100303",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046165","MODERN GLP-1 BASED PHARMACOTHERAPY FOR SEVERE ADOLESCENT OBESITY: CLINICAL PROMISE, SAFETY CONCERNS, AND ETHICAL CHALLENGES","Agata Porwolik","2026","International Journal of Innovative Technologies in Social Science","preclinical","article","10.31435/ijitss.2(50).2026.5185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046166","Tirzepatide - A Revolution in Obesity Treatment?","Aleksandra Jaroń","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.17.53102",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046167","FARMACOLOGIA DA ESTÉTICA: A EMERGÊNCIA DO OZEMPIC NO IMAGINÁRIO COLETIVO","Giovana Corrêa de Moraes Nardo","2026","Amplla Editora eBooks","other","article","10.51859/amplla.vfe281.1126-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0046168","Psoriasis and glucagon-like peptide-1 agonists: A scoping review","Amanda Paredes-Barbeito","2025","JAAD reviews.","narrative_review","article","10.1016/j.jdrv.2025.07.008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046169","Recent advances in bariatric endoscopy for obesity management: expanding the therapeutic spectrum","Ravishankar Asokkumar","2025","Singapore Medical Journal","randomized_trial","article","10.4103/singaporemedj.smj-2025-121","40833753",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0046170","Comparative clinical outcomes and metabolomic considerations of the use of tirzepatide and retatrutide in the treatment of obesity: a systematic and umbrella review","Flávio Henrique Figueiredo de Macêdo Andrade","2026","International Journal of Nutrology","systematic_review","article","10.54448/ijn26107",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0046171","ADJUNCT THERAPIES IN TYPE 1 DIABETES: A REVIEW OF MECHANISMS, MANAGEMENT AND SAFETY OF NEW FORMS OF TREATMENT","Magda Downar-Zapolska","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.2(50).2026.5503",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046172","849-P: Factors Influencing the Selection of Glucose-Lowering Medications among Physicians Treating Patients with Type 2 Diabetes in Real World","JOUD A. ABUDAHESH","2022","Diabetes","nonrandomized_study","article","10.2337/db22-849-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046173","Restoration of Islet Vascularity and Oxygenation in Mouse and Human Islets Experimentally Transplanted to the Omentum : A Basis for Superior Function when Compared to Intraportally Transplanted Islets","Daniel Espes","2016","American Journal of Transplantation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046174","Pharmacotherapy (Obesity Management Medications)","Rochelle Blacklock","2026",null,"other","article","10.1002/9781394206148.mdp0070",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0046175","177-OR: Sodium–Glucose Cotransporter-2 Inhibitors and the Risk of Incident Atrial Fibrillation in Older Adults with Type 2 Diabetes","MIN ZHUO","2022","Diabetes","nonrandomized_study","article","10.2337/db22-177-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046176","S5329 When Common Diagnoses Overshadow the Rare: A Case Revealed by EUS After Multiple Admission","Ibrahim Shanti","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001148776.87495.eb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046177","Scoping Review: GLP-1 Receptor Agonist-Associated Presentations to Emergency Departments","Yash Raj Sharma","2026",null,"narrative_review","article","10.17605/osf.io/zhjqv",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046178","A review of the recent clinical studies on the treatment of patients with the chronic kidney disease et advanced stages","A.S. Ananeva","2025","Russian Journal of Preventive Medicine","nonrandomized_study","article","10.17116/profmed202528081110",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046179","The intervention of glucagon-like peptide 1 analogue in IRE1α-JNK signaling pathway of rats with non-alcoholic fatty liver disease","Jiayu Xu","2015","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2015.03.018",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046180","Cardiovascular outcomes in sustained use of glucagon like peptide inhibitors: a trial inspired population vs. a broad population","K Soerensen","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.4316",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046181","From Scalpel to Syringe: Can Tirzepatide Bridge the Gap Between Pharmacotherapy and Bariatric Surgery?","Emilia Piaszczynska","2026",null,"other","article","10.13140/rg.2.2.31500.88966",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046182","Abstract #1902451 The Efficacy of Glucagon-Like Peptide-1 Receptor Agonists as Adjunct Therapy to Insulin in Patients With Type 1 Diabetes: A Systematic Review and Meta-Analysis","Nancy Nakhoul","2024","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2024.09.044",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0046183","The experimental study of pancreatic tissue lesion induced by Exenatide","Yongchao Yang","2013","Chin J Pancreatol","preclinical","article","10.3760/cma.j.issn.1674-1935.2013.06.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046184","Additional file 1 of Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes","McGuire, Darren K.","2022","Figshare","other","article","10.6084/m9.figshare.20625103.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046185","7792 Efficacy of Retatrutide for Weight Reduction and Its Cardiometabolic Effects Among Adults: A Systematic Review and Meta-Analysis","D C Lopez","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.749",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046186","THE POTENTIAL OF GLP-1 IN THE TREATMENT OF AUTOIMMUNE DISEASES: A REVIEW OF MECHANISMS AND CLINICAL DATA","Małgorzata Stopyra","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3970",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046187","GLP-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF LIPODYSTROPHY: A SCOPING REVIEW","João Pedro Henriques","2026",null,"narrative_review","article","10.17605/osf.io/cfkew",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046188","GLP-1 receptor agonists versus SGLT2 inhibitors in patients with coexisting COPD and heart failure","Sheng-Chi Huang","2026","Communications Medicine","nonrandomized_study","article","10.1038/s43856-026-01876-0",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046189","Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improved Markers of Pancreatic Beta Cell Function and Insulin Sensitivity","Julio Rosenstock","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807451",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0046190","Glucagon-like peptide-1 analog in the treatment of metabolic dysfunction-associated steatotic liver disease","Inês Eiras","2026","International Journal of Contemporary Pediatrics","other","article","10.18203/2349-3291.ijcp20262978",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046191","Open Chromatin State of Dpp4 With Glucocorticoid Treatment—Setting up Shop for Metasteroid Diabetes?","Nadya M. Morrow","2021","Endocrinology","preclinical","article","10.1210/endocr/bqab220","34694370",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046192","86-OR: The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels","David Højland Ipsen","2025","Diabetes","preclinical","article","10.2337/db25-86-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046193","Once-weekly exenatide in youth with type 2 diabetes","Tamborlane Wv","2023","Yearbook of pediatric endocrinology","other","article","10.1530/ey.20.10.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046194","Semaglutide 7,2 mg settimanale in adulti con obesità (STEP UP): un trial randomizzato controllato di fase 3b","Riccardo Miatton","2025","L Endocrinologo","other_trial","article","10.1007/s40619-025-01731-9",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046195","Sa1953: GLP-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH CLOSTRIDIOIDES DIFFICILE INFECTION AND DOES NOT INCREASE THE NEED OF SURGERY: A PROPENSITY-MATCHED, MULTICENTER STUDY","Imran Qureshi","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)02315-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046196","Evaluation of the effect of Saxenda on the histological structure of the kidneys in the white mouse","Shahad Ali","2025","Iraqi journal for applied science.","preclinical","article","10.69923/hes1me47",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046197","1403-P: Prescribing Trends of Glucose-Lowering Medications among Adult Kidney Transplant Recipients with Type 2 Diabetes—A U.S. Population-Based Cohort Study","Panupong Hansrivijit","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1403-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046198","Existing and prospective pathways for intervention in treatment of obesity in a novel way‒a review","Kulvinder Kochar Kaur","2018","MOJ Drug Design Development & Therapy","nonrandomized_study","article","10.15406/mojddt.2018.02.00035",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046199","GLP-1 Receptor Agonists versus Metformin and Incident Dementia After Delirium in Adults ≥ 65 years With Type 2 Diabetes Mellitus: A Real-World Retrospective Cohort Study","Sumi Akter","2026",null,"nonrandomized_study","article","10.13140/rg.2.2.30038.61762",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0046200","Impact of the coronary artery calcium score on the cardiovascular preventive management of asymptomatic patients with diabetes","Marouane Boukhris","2023","European Heart Journal","other","article","10.1093/eurheartj/ehad655.2555",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046201","GLP-1 Receptor Agonists in Paediatric obesity: A Systematic Review of Lived Experiences","Claire Williams","2026",null,"systematic_review","article","10.17605/osf.io/e3qyd",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0046202","Sa1558 EFFECT OF SGLT-2 INHIBITORS, GLP-1 RECEPTOR AGONISTS ON CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES, NAFLD, AND CHRONIC KIDNEY DISEASE: A REAL WORLD EVIDENCE","Arunkumar Krishnan","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)01561-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046203","26-A-18326-ACC GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE AND OUTCOMES IN TRANSTHYRETINAMYLOID CARDIOMYOPATHY WITH DIABETES MELLITUS: A PROPENSITY-SCORE MATCHEDANALYSIS","Kriti Soni","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1654",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046204","From Insulin Resistance to Neurodegeneration: Exploring the Link Between Type 2 Diabetes and Alzheimer’s Disease as Type 3 Diabetes","Manthan Suthar","2026","Current Signal Transduction Therapy","nonrandomized_study","article","10.2174/0115743624420375251212124953",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046205","Semaglutide: effects on eating behavior","V. V. Gorban","2024","Meditsinskiy sovet = Medical Council","nonrandomized_study","article","10.21518/ms2024-268",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046206","IMPAIRED OSTEOGENESIS AS A LINK IN THE CHAIN OF ATHEROSCLEROSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: PATHWAYS TO OVERCOMING IT","Алла Ковальчук","2026","World Science","other","article","10.31435/ws.1(91).2026.4915",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046207","Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations","Nimet Yılmaz","2026","Dove Medical Press (Taylor and Francis Group)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","review"],["R0046208","Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease: a protocol for a systematic review and meta-analysis","Simin Fan","2020",null,"systematic_review","article","10.37766/inplasy2020.5.0045",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","report"],["R0046209","S1113 Long-Acting GLP-1 Receptor Agonists Are Associated With a Reduced Risk of Functional Lower Gastrointestinal Disorders in Obese Patients With or Without Diabetes","Jin‐Xiu Pan","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001131912.61970.71",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046210","Glucagon like peptide 1 receptor agonists, diabetes, obesity, and psoriasis","Jingyan Tian","2012","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2012.04.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046211","Comments on Methodological Consideration in Interpreting the Association Between GLP-1 Receptor Agonist Therapy And Risk of Psoriatic Arthritis","AYESHA RIZWAN","2026",null,"nonrandomized_study","article","10.22541/au.177324091.19499281/v1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0046212","Glucagon-like peptide-1-based incretin agonists in obesity-related heart failure with preserved ejection fraction: A systematic review and meta-analysis","Ehab Al Mashtoub","2026","World Journal of Meta-Analysis","systematic_review","article","10.13105/wjma.v14.i2.119849",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0046213","Patient foundation model for risk stratification in low-risk overweight patients","Zachary Flamholz","2026","arXiv (Cornell University)","nonrandomized_study","article","10.48550/arxiv.2602.09079",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0046214","development and validation of a reverse-phase high performance liquid chromatography method for determination of exenatide in poly(lactic-co-glycolic acid) microspheres","Bin Liu","2010","Chemical Research in Chinese Universities","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046215","Evaluating the Pulmonary Impact of Semaglutide in Patients With Diabetes: A Meta-analysis of Randomized Clinical Trials","FARDAD MOSHTAGH SISAN","2024",null,"systematic_review","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5957",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0046216","Effectiveness of Oral Semaglutide in Weight Loss and Glycemic Control among Type 2 Diabetes Population: A Real-world Longitudinal Study","Jothydev Kesavadev","2023","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_33_23",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046217","EFFICACY AND SAFETY OF DUAL GLP-1/GIP RECEPTOR AGONISTS FOR GASTROINTESTINAL AND HEPATIC OUTCOMES IN ADULTS WITH OBESITY AND TYPE 2 DIABETES: A SYSTEMATIC REVIEW","Dr. Mohid Ayub","2026","Genetics and Molecular Research","systematic_review","article","10.4238/b94h1957",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046218","Cardiovascular effects of GLP-1 receptor agonists: atherosclerotic outcomes, obesity, HFpEF, and kidney disease — a narrative review.","Marcel Gisal","2026","Journal of Pre-Clinical and Clinical Research","randomized_trial","article","10.26444/jpccr/235860",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0046219","A65-06 Glucagon-Like Peptide-1 Receptor Agonist Use in Patients With Pulmonary Arterial Hypertension","S E Niedermeyer","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.5568",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046220","Medicamentos que favorecen la pérdida de peso y el control metabólico en las personas obesas con diabetes mellitus tipo 2","José Hernández Rodríguez","2013","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046221","Diabetic Nephropathy with Proteinuria Is the Risk of Indigestion Symptoms in Patients with Diabetes Mellitus—A Multicenter Survey in Japan","Yulia Namiki","2018","Diabetes","other","article","10.2337/db18-2204-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046222","2624-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orforglipron: A Multiple Dose Titration Study in Chinese Participants with Obesity or Overweight with Weight-Related Comorbidities","Hui Liu (33624)","2026","Diabetes","randomized_trial","article","10.2337/db26-2624-p",null,null,"ClinicalTrials.gov:NCT06023095","S002270","openalex","FALSE","paywalled","1","FALSE","article"],["R0046223","EE482 Cost-Effectiveness Analysis of Once-Weekly Semaglutide for the Treatment of Patients with Type 2 Diabetes in Mexico","R Valdez-Huerta","2022","Value in Health","other","article","10.1016/j.jval.2022.04.729",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046224","Benefícios do agonista do receptor de GLP-1 na redução de riscos cardiovasculares","Natália Rivoli Rossi","2025","Congresso Médico Acadêmico UniFOA.","other","article","10.47385/cmedunifoa.2026.2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0046225","critique of semaglutide (Wegovy®) for obesity management NICE technology appraisal TA875","Hassan Kahal","2024","British Journal of Diabetes","other","article","10.15277/bjd.2024.439",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046226","Transforming Obesity Care: Medications at the Forefront","Tabinda Ashfaq","2025","National Journal of Health Sciences","other_trial","article","10.21089/njhs.104.0220",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0046227","THE IMPACT OF TIRZEPATIDE ON BODY MASS IN THE CLINICAL TRIALS SURMOUNT AND SURPASS","Kinga Brzdęk","2024","The Polish Journal of Aviation Medicine Bioengineering and Psychology","nonrandomized_study","article","10.13174/pjambp.17.12.2024.03",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046228","Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in a National Population of Patients With Type 1 Diabetes","Carl-Emil Lim","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6356664",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046229","Trajectory of weight regain after cessation of glucagon-like-peptide-1 receptor agonists: a systematic review and nonlinear meta-regression","Brajan Budini","2026","Endocrine Abstracts","systematic_review","article","10.1530/endoabs.117.p102",null,null,"PROSPERO:CRD420250631751",null,"openalex","TRUE","paywalled","3","FALSE","conference-abstract; review"],["R0046230","Heart failure with preserved ejection fraction in older adults","Bharathi Upadhya","2026",null,"other","article","10.1201/9781003568933-20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0046231","A sensitive LC-MS/MS method for tirzepatide in rat plasma with comprehensive pharmacokinetic evaluation","Sungmin Song","2026","Journal of Analytical Science & Technology","preclinical","article","10.1186/s40543-026-00540-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046232","Declining cervical cancer incidence in young women living in the United States: is it time to stop screening them?","P. Castle","2026","JNCI Journal of the National Cancer Institute","nonrandomized_study","article","10.1093/jnci/djag041","41904709",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0046233","Su2100: IMPACT OF GLP-1 RECEPTOR AGONIST ON RETAINED GASTRIC CONTENTS DURING: A PROPENSITY SCORE MATCHED STUDY","Hiroyuki Hisada","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03132-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046234","Leukocytoclastic vasculitis and GLP-1 agonist: A case report","Kathryn Harrison","2026","Journal of Dermatology for Physician Assistants","case_report","article","10.1097/jdpa.0000000000000103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046235","Comparison of Curative Efficacy of Exenatide and Premixed Insulin for Type 2 Diabetes Mellitus","Chuan-mei Liu","2013","Chinese Journal of General Practice","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046236","1019-P: Glucagon-Like Peptide-1 Receptor Agonists Predominantly Reduce Body Fat Mass in Patients with Type 2 Diabetes","Yuki Fujita","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1019-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046237","Glucagon-Like Peptide-1 Receptor Agonists and Acute Pancreatitis: Current Evidence and Clinical Implications","Kwang Hyun Chung","2026","The Korean Journal of Pancreas and Biliary Tract","nonrandomized_study","article","10.15279/kpba.2026.31.1.1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046238","Linking Epicardial Adipose Tissue to Atrial Remodeling: Clinical Implications of Strain Imaging","Fulvio Cacciapuoti","2025","Hearts","other","article","10.3390/hearts6010003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046239","The Effects of Tirzepatide and Semaglutide on Clinical and Metabolic Outcomes in Patients With Heart Failure and Obesity or Metabolic Syndrome: A systematic review","Ahmed J. AlAraibi","2025",null,"systematic_review","article","10.13140/rg.2.2.36009.45928",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0046240","Erratum: Investigation of Transport Mechanism of Exendin-4 across Madin Darby Canine Kidney Cell Monolayers [Biol. Pharm. Bull. 35(5): 745-752 (2012)]","Mengshu Wang","2012","Biological and Pharmaceutical Bulletin","notice","article","10.1248/bpb.b12-e3510",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0046241","The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus","Xueyang Zhang","2020","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-020-00857-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046242","POSTER: MM-837: GLP-1 Receptor Agonists Are Associated With Significantly Reduced All-Cause Mortality, Hospitalization, and Sepsis in Patients With Multiple Myeloma and Type 2 Diabetes: A Propensity Score–Matched Analysis of the TriNetX Global Collaborative Network","Ekow Pinkrah","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)01370-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046243","Perioperative Management of Patients Taking GLP-1 Receptor Agonists. A Mini-Review","Lucia Hradská Smilková","2026","Bratislavské lekárske listy/Bratislava medical journal","narrative_review","article","10.1007/s44411-026-00825-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0046244","Incretin mimetics and enhancers: New insulin secretagogues for Type-2 diabetes","Rajiv Mahajan","2010","Biomedical Research-tokyo","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046245","PO-05-317 GLP-1 RECEPTOR AGONIST USE DURING PULSED FIELD ABLATION AND SUBSEQUENT ATRIAL ARRHYTHMIA RECURRENCE AT ONE YEAR","Ali Dakik","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.1492",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046246","Potential of GLP-1 Analogs in Managing Hyperphagia and Obesity in Prader-Willi Syndrome: A Review of Efficacy and Safety","Olga Grelewicz","2024","Quality in Sport","narrative_review","article","10.12775/qs.2024.25.54915",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046247","Championing Weight-Neutral Healthcare: A Review of Resources from Medical Students for Size Inclusivity","Samantha Guss","2026","Journal of Consumer Health on the Internet","narrative_review","article","10.1080/15398285.2026.2618934",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046248","Beyond Weight Loss: GLP-1 and the future of Aesthetic Outcomes","Kavita Mariwalla","2026","Dermatologic Surgery","other_trial","article","10.1097/dss.0000000000005189","42210878",null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0046249","Impact of oral antidiabetic agents on bone metabolism","Nihal Thomas","2015","The Indian Journal of Medical Research","randomized_trial","article","10.4103/0971-5916.159244","26112838",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0046250","An Expert Opinion on the Management of Type 2 Diabetes Mellitus in Children and Adolescents","Rajesh Rajput","2021","Journal of Diabetology","other","article","10.4103/jod.jod_71_21",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046251","Geroprotective Agents and Ocular Outcomes: A Scoping Review With Emphasis on GLP-1 RAs and Glaucoma","Alan Nguyen","2026",null,"narrative_review","article","10.17605/osf.io/msud3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046252","AGONISTAS DO RECEPTOR DE GLP-1 E INIBIDORES DE SGLT-2 ALÉM DO CONTROLE GLICÊMICO: BENEFÍCIOS CARDIOVASCULARES NO TRATAMENTO DE DIABETES MELLITUS TIPO-2","Maria Luiza Nery Coelho","2025","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v11i10.21484",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046253","Mo1577 IMPROVED CLINICAL OUTCOMES WITH TIRZEPATIDE COMPARED TO GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONISTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND TYPE 2 DIABETES","Krishan S. Patel","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)02947-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046254","Weight loss efficacy of high-dose semaglutide regimens in adults with type 2 diabetes and obesity: a systematic review with quantitative synthesis","Wachirawit Angkatavanich","2026",null,"systematic_review","article","10.17605/osf.io/7wzu5",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0046255","Autophagy promotion and fibrosis inhibition by combination of GLP1 analogue and metformin decreasing the progression of type II diabetic cardiomyopathy of albino rats: Immunohistochemical study","Mahmoud Hendawy","2022","Bulletin of Egyptian Society for Physiological Sciences","preclinical","article","10.21608/besps.2021.103465.1113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046256","From Weight Loss to Legal Loss: How Wegovy Exposed a Hidden Patent Exception","Peter Ganea","2026","GRUR International","other","article","10.1093/grurint/ikag041",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046257","PS-C17-10: ORAL SEMAGLUTIDE REDUCES ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES, OBESITY AND HYPERTENSION, WITH PARTIAL DEPENDENCE ON BLOOD PRESSURE CONTROL","Francisco Javier Martínez-Martín","2023","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0000916740.08960.77",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046258","PO-04-274 GLP-1 RECEPTOR AGONISTS AND CONDUCTION OUTCOMES IN PATIENTS WITH BRADYARRHYTHMIAS","Rudra Pratap Singh","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.1271",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046259","75741 Monotherapy Versus Dual Therapy With GLP-1 Agonists in the Management of Hidradenitis Suppurativa: A Literature Review","Alexa Bonk","2026","Journal of the American Academy of Dermatology","narrative_review","article","10.1016/j.jaad.2026.04.1224",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046260","Sa2105 BILIARY SAFETY SIGNALS WITH RESMETIROM IN MASH: REAL-WORLD COMPARISON AGAINST GLP-1 RECEPTOR AGONISTS","Fnu Alvina","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03571-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046261","Long-Term Survival Benefit Of GLP-1 Receptor Agonists In Heart Transplant Recipients: A Propensity-Matched Real-World Analysis","Afnan Chaudhry","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6709495",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0046262","Treatment with Either SGLT2 Inhibitors or GLP-1 Receptor Agonists Rescues GFR Decline in a Multifactorial Cardiovascular-Kidney-Metabolic Syndrome Mouse Model","Arianne van Koppen","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2025h4d7j463",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046263","The Relationship Between Obesity and Polycystic Ovary Syndrome: Pathophysiology, Clinical Consequences, and Management, A Review.","Karolina Szeląg","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.66.74010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046264","EP1400 - ECE_1757 - Impact of maternal obesity and gestational GLP-1 receptor agonist exposure on fetal hypothalamic development","Hadley Johnson","2026","European Journal of Endocrinology","preclinical","article","10.1093/ejendo/lvag096.1601",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046265","Understanding Obesity and the Role of Pharmacological Treatments: Insights for Health and Fitness Enthusiasts","Agnieszka Starzyk","2025","Quality in Sport","other","article","10.12775/qs.2025.38.58211",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046266","OZEMPIC FACE: UM EFEITO INDESEJADO DECORRENTE DO USO DA SEMAGLUTIDA","Marina Ribas Losasso","2024",null,"other","article","10.29327/i-congresso-academico-local-de-patologias-cardiorrespiratorias-512570.1034607",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0046267","Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial","J Plutzky","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.4243",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046268","26-A-19380-ACC CARDIOVASCULAR BENEFITS OF GLP-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS","Gabriele Volucke","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.401",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0046269","A Global Misuse of Semaglutide for Cosmetic Weight Loss in Non-diabetic Young Population, an FDA Public Database and Google Trends Data Analysis","Nahid Sabah aldin Saber","2025","AL-Kindy College Medical Journal","nonrandomized_study","article","10.47723/qv85p752",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046270","Comparative Effects of Empagliflozin and Semaglutide on Left Ventricular Diastolic Function in HFpEF Patients with Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials","Syed Ali Hussein Abdi","2025","International Journal Of Scientific Advances","systematic_review","article","10.51542/ijscia.v6i3.16",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046271","A Critical Review on Obesity: Herbal Approach, Bioactive Compounds, and Their Mechanism","Mukul Kumar","2022","Applied Sciences","narrative_review","article","10.3390/app12168342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046272","Function of exenatide reduces fatty acid induced hepatocyte apoptosis through inhibiting endoplasmic reticulum stress","Jin Li","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046273","796-P: Real-World Persistence with GLP-1 RA Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced Chronic Kidney Disease (CKD)","F N U Sidra","2023","Diabetes","nonrandomized_study","article","10.2337/db23-796-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046274","Neuroprotective Effects of Tirzepatide: A Scoping Review of Preclinical and Clinical Evidence (P11-7.002)","Yousef Hawas","2026","Neurology","narrative_review","article","10.1212/wnl.0000000000216302",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046275","Anaesthesiologic management of patients at risk of pulmonary aspiration: a Swiss consensus statement","Sascha J. Baettig","2026","BMC Anesthesiology","nonrandomized_study","article","10.1186/s12871-026-03835-7","42002786",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046276","EFFICACY OF TIRZEPATIDE ON WEIGHT LOSS, MUSCLE MASS AND CARDIOVASCULAR HEALTH IN THE ADULT POPULATION WITH DIABETES TYPE 2, OVERWEIGHT OR OBESITY: A SYSTEMATIC REVIEW","Zuzanna Strojek","2026","International Journal of Innovative Technologies in Social Science","systematic_review","article","10.31435/ijitss.2(50).2026.5992",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046277","CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access","Que Liu","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046278","Glucose-Lowering Therapies, New Expectations for Brain Health: Emerging Promise and Uncertainty","S K Kim","2026","Journal of Korean Diabetes","other","article","10.4093/jkd.2026.27.2.51",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046279","Pathophysiological mechanisms, potential biomarkers, and therapeutic interventions in diabetic nephropathy","Kuldip Vyas","2026","Discover Molecules","other","article","10.1007/s44345-026-00071-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046280","798-P: Semaglutide Effect during Mixed-Meal Tolerance Test (MMTT) with Fully Closed-Loop Therapy in Type 1 Diabetes (T1D)","Melissa‐Rosina Pasqua","2025","Diabetes","randomized_trial","article","10.2337/db25-798-p",null,null,"ClinicalTrials.gov:NCT05205928","S000181","openalex","FALSE","paywalled","1","FALSE","article"],["R0046281","683-P: Real-World Evaluation of Once-Weekly Semaglutide (Sema OW) in Patients Newly Initiating GLP-1 Agonist Therapy","Nitin Shivappa","2021","Diabetes","nonrandomized_study","article","10.2337/db21-683-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046282","Ассоциированная с Метаболической дисфункцией стеатотическая болезнь печени (МасБП) и лишняя масса тела: обзор литературы","И.Р. Гайсин","2025","Health demography ecology of finno-ugric peoples","nonrandomized_study","article","10.64111/1994-8921.2025.51.3.007",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046283","The One-Time Strategy: Using GLP-1 to Build a Body That Lasts","HAMZA LAKHBIZA","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22268575",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0046284","SUN-114 Comparative Analysis of Glucagon-Like Peptide-1 Receptor Agonists, Metformin, and Inositol in Managing Polycystic Ovary Syndrome: A Network Meta-Analysis","Asad Omarion","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.2048",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0046285","Mo2040 COMPARATIVE EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VERSUS NALTREXONE IN THE TREATMENT OF ALCOHOL USE DISORDER: A REAL-WORLD ANALYSIS OF 9,360 PATIENTS","Yassine Kilani","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03859-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046286","Liraglutide Ameliorates Metabolic Dysfunction Targeting the NRF2 Pathway in Obese Rats Induced by a High-Fat Diet","Mahmood Jameel Saeed","2026","Al Mustansiriyah Journal of Pharmaceutical Sciences","preclinical","article","10.32947/ajps.v26i1.1354",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046287","Abstract 4143390: HEMODYNAMIC AND CLINICAL IMPACT OF OBESITY IN GROUP 1 PULMONARY HYPERTENSION","Revati Varma","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4143390",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046288","Clinical effects of liraglutide monotherapy in the treatment of newly diagnosed patients with early-onset type 2 diabetes","Min Si","2014","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2014.05.012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046289","644-P: Discovery of Nonpeptide, Orally Available Small Molecule GLP-1 Receptor Agonists","A‐Rang Im","2021","Diabetes","preclinical","article","10.2337/db21-644-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046290","Agonistas do receptor de GLP-1 na saúde óssea da pessoa sem diabetes: uma revisão integrativa","Gabriel Alves Quintino Guimarães","2026","Cadernos Cajuína","other","article","10.52641/cadcajv11i9.3683",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046291","THE PLACE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN THE DRUG THERAPY OF OBESITY AT THE PRESENT STAGE","Анна Борисовна Шаповалова","2024","Медицина: теория и практика","other","article","10.56871/mtp.2024.47.58.005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046292","PDB5 IMPROVED TREATMENT SATISFACTION IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH EXENATIDE OR INSULIN GLARGINE","Kristina Secnik","2005","Value in Health","other","article","10.1016/s1098-3015(10)67625-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046293","Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis","Yange Meng","2025","Journal of Clinical Question","systematic_review","article","10.69854/jcq.2025.0033",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0046294","The impact of novel hypoglycemic medications on hormonal and metabolic parameters in patients with polycystic ovary syndrome: a Bayesian network meta-analysis","Haoyu Wu","2024",null,"systematic_review","article","10.37766/inplasy2024.1.0001",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0046295","223-OR: Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT)","John W. Ostrominski","2025","Diabetes","randomized_trial","article","10.2337/db25-223-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046296","Personalized treatment of diabetic nephropathy in patients with diabetes mellitus type 2","Vagif M Ibraghimov","2020","Journal of Nephrology & Renal Diseases","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046297","1058-P: The Relationship between Health Insurance Coverage and Clinical Outcomes among People with Diabetes in Saudi Arabia","MOHAMMED AL-SOFIANI","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1058-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046298","Semaglutide to remodel mitochondrial dynamics and mitophagy balance for vascular dementia therapy","Xiaoyan Yang","2025","Open Research (University of Surrey)","other","article","10.1002/viw.20250013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046299","Tirzepatide – a new hope for type 2 diabetes mellitus and obesity management. A literature review.","Izabela Stawicka","2024","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2024.71.55971",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046300","128-OR: The Effect of Tirzepatide during Weight Loss on Food Intake, Appetite, Food Preference, and Food Craving in People with Obesity","CORBY K. MARTIN","2023","Diabetes","randomized_trial","article","10.2337/db23-128-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046301","Transforming diabetes care: Latest advancements in treatment and technology","Shivani Choudhary","2024","International Journal of Pharmacy and Pharmaceutical Science","other","article","10.33545/26647222.2024.v6.i1b.105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046302","Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin deguldec in Tochigi: IDEAL Trial","Yoshimasa Aso","2020",null,"randomized_trial","article","10.22541/au.159129005.57065700",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","preprint"],["R0046303","Segurança terapêutica dos análogos do peptídeo semelhante ao glucagon 1 (GLP-1): Revisão dos principais efeitos adversos","André Luighi Ferraciolli Basso","2026","Research Society and Development","other","article","10.33448/rsd-v15i6.51184",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046304","Mo1818 SEMAGLUTIDE AND RISK OF NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION): AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS OF OVER 3 MILLION ADULTS","Varathpavee Bhuriveth","2026","Gastrointestinal Endoscopy","systematic_review","article","10.1016/s0016-5107(26)04882-0",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046305","RETRACTED: Therapeutic efficacy of liraglutide on diabetic nephropathy mice by inhibiting inflammatory factors","WenXing Fan","2018","European Journal of Inflammation","preclinical","article","10.1177/2058739218819283",null,null,null,null,"openalex","TRUE",null,null,"TRUE","article"],["R0046306","Exendin-4, but Not Oleoylethanolamide, Promotes Host-Mediated Alterations to the Gut Microbiome during Weight Loss","Jacob D. Brown","2018","Diabetes","preclinical","article","10.2337/db18-1970-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046307","Perioperative Glucagon-Like Peptide-1 Receptor Agonist Use in Orthopaedic Surgery: A Systematic Review of Surgical Outcomes","Grace Kim","2026","Journal of the American Osteopathic Academy of Orthopedics","systematic_review","article","10.70709/pmiw7lkpkareon",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046308","Preparation and Characterization of Self-assembled Glycol Chitosan Hydrogels Containing Palmityl-acylated Exendin-4 for Extended Hypoglycemic Action","Ju-Ho Lee","2011","Journal of Pharmaceutical Investigation","other","article","10.4333/kps.2011.41.3.173",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046309","Additional file 3 of Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review","Dave Osinachukwu Duru","2026","Figshare","narrative_review","article","10.6084/m9.figshare.32787548",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046310","Cost-of-Illness Study of Diabetes Mellitus: Focus on Patients with Type 2 Diabetes","Roberta Pirolo","2016","Global & Regional Health Technology Assessment","nonrandomized_study","article","10.33393/grhta.2016.405",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046311","Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing GLP-1 Receptor Agonists and SGLT2 Inhibitors","Philip Branigan","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/prnya",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0046312","Efectividad de la liraglutida en el tratamiento de la obesidad del adolescente","Mónica Ruiz Pons","2025","Anales de Pediatría","nonrandomized_study","article","10.1016/j.anpedi.2025.503856",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046313","Impact of Finerenone on Kidney Function, Albuminuria, and Arterial Stiffness: Clinical Insights from a Pilot Six-Month Diabetic Kidney Disease Study","Nejc Piko","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025xsrhmtdm",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046314","Does brainstem-derived serotonin mediate GLP-1 receptor agonist-induced suppression of appetite and body weight via 5-HT2A receptors?","Katsunori Nonogaki","2017","Integrative Obesity and Diabetes","other","article","10.15761/iod.1000187",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046315","523-P: Different Effect on UACR According to Predetermined Treatment Schedule Groups (GLP1RA or SGLT2i) Therapy in T2DM","Juana Carretero‐Gómez","2020","Diabetes","other","article","10.2337/db20-523-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046316","DIABETES MELLITUS TYPE II: REVIEW OF ORAL TREATMENT OPTIONS","Rana Hashem Ibrahim","2010",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046317","Perioperative Cardioprotective Effects of GLP-1 Receptor Agonists in Patients Undergoing Cardiac Surgery: A Systematic Review","Roy Novri Ramadhan","2026",null,"systematic_review","article","10.17605/osf.io/26pwr",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0046318","Evolution of insulin production technologies: from historical discoveries of the molecule structure to modern innovations","O. S. Kaliuzhnaia","2025","ScienceRise Biological Science","nonrandomized_study","article","10.15587/2519-8025.2025.349033",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046319","Obsessive-Compulsive Symptoms After Tirzepatide Treatment: A Case Report","Gözde Özsoy Şen","2026","Case Reports in Clinical Practice","case_report","article","10.18502/crcp.v10i4.21109",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046320","Meal replacement plans in managing adolescent obesity: a systematic literature review","Ainul Mardhiah Irfan","2025","The International Islamic University Malaysia Repository (The International Islamic University Malaysia)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","review"],["R0046321","Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist","Elaine Wong","2022","The Journal for Nurse Practitioners","other","article","10.1016/j.nurpra.2022.10.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046322","Integrated Diabetes Prevention: GLP-1 Receptor Agonists Plus Lifestyle Interventions","Susan Kohl Malone","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.5988902",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046323","Layer-by-layer polymeric films for buccal GLP-1 delivery","Eleftheria Pantazoglou","2026","Cell Reports Physical Science","preclinical","article","10.1016/j.xcrp.2026.103410",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046324","INCREASED INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE II DIABETES AND HIDRADENITIS SUPPURATIVA DESPITE GLP-1RA THERAPY","June Choi","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00996-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046325","The Child on GLP-1 Therapy Presenting for Anesthesia: From Adult Guidance to Pediatric Risk-Adapted Management","Paolo Taffache","2026",null,"other","article","10.17605/osf.io/4vcmw",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046326","Potential effect of the short-acting GLP-1 agonist exenatide on copeptin in healthy adults","Sarah Baumann","2026","Obesity and Endocrinology","randomized_trial","article","10.1093/obendo/wjag006",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0046327","Sa1830 COMPARATIVE INCIDENCE OF PANCREATIC DISEASE AFTER GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST VERSUS SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS INITIATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND OBESITY","Kerri Conklin","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)05057-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046328","754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials","Hiddo J.L. Heerspink","2024","Diabetes","other_trial","article","10.2337/db24-754-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046329","GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis","K Soerensen","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.3309",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046330","The Safety of Chance GLP-1RA Exposure in Pregnancy","Vanesa Berati","2025","Scholarship@Western (Western University)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","review"],["R0046331","Abstract TH822: Characteristics of Glucagon-like Peptide-1 Receptor Agonist Initiators and Temporal Trends in Prescriptions by Diabetes Status; MarketScan 2016-2023","Rob Walker","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.th822",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046332","GLP-1/GIP-1 Agonism improves metabolic dysfunction and delays renal injury in an experimental model of Systemic Lupus Erythematosus","Jordan Hart","2026","Physiology","randomized_trial","article","10.1152/physiol.2026.41.s1.2301118",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046333","505 GLP-1 RECEPTOR AGONIST SEMAGLUTIDE INDUCES SMOOTH MUSCLE HYPERTROPHY VIA MIR-10A DEFICIENCY, DRIVING GASTROINTESTINAL DYSMOTILITY","Rajan Singh","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04333-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046334","P-31 GLP1 receptor agonist in end-stage kidney disease: Are they safe and effective?","José Vicente Rocha","2024","JCEM Case Reports","other","article","10.1210/jcemcr/luad146.034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046335","Will retatrutide help me lose weight or look ‘shredded’?","Lauren Ball","2026",null,"other","article","10.64628/aa.ax6u5kfrj",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0046336","Mo2052 GLP-1 AGONISTS OUTPERFORM STANDARD FDA-APPROVED TREATMENTS IN PATIENTS WITH DUAL ALCOHOL USE DISORDER AND METABOLIC DYSFUNCTION","Amir Gougol","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)03940-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046337","“It’s a miracle drug”: Patients’ voices on GLP1-RA as a weight loss medication","Jane A. McElroy","2025",null,"other","article","10.1370/afm.23.s1.8164",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046338","Therapeutic Strategies at the Diabetes–Alzheimer’s Disease Interface: Mechanisms, SAR Design Rules, and Safety","Yashasvi Sharma","2026","International Journal of Research in Pharmacology & Pharmacotherapeutics","other","article","10.61096/ijrpp.v15.i2.2026.911-937",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046339","Semaglutide and metformin improve menstrual cyclicity in overweight/obese women with polycystic ovary syndrome: a randomized trial","Weihan Zhang","2026","Metabolism and Target Organ Damage","randomized_trial","article","10.20517/mtod.2025.210",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046340","747-P: Insulin Therapy Deintensification with iGlarLixi (IDEAL) Randomized Controlled Trial—CGM-Related Outcomes","Peter Novodvorský","2024","Diabetes","randomized_trial","article","10.2337/db24-747-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046341","EE402 Comparing the Expenditure and Health-Related Quality of Life between SGLT2 Inhibitors and GLP-1 Agonists","Simeng Hu","2024","Value in Health","other","article","10.1016/j.jval.2024.03.698",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046342","Subcutaneous Tirzepatide Versus Semaglutide and Emerging Incretin Agents in Type 2 Diabetes: A Comprehensive Frequentist Network Meta-Analysis of 42 Trials Through May 2026","Abdulrahman Alanazi","2026",null,"systematic_review","article","10.37766/inplasy2026.6.0011",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046343","(1039) Glp-1 Receptor Agonists Among LVAD Patients with Diabetes and Obesity; Effect on Comorbid Conditions","M. Mekhaimar","2023","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2023.02.1250",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046344","333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D)","Charles Benson","2022","Diabetes","randomized_trial","article","10.2337/db22-333-or",null,null,"ClinicalTrials.gov:NCT03325387; ClinicalTrials.gov:NCT03928379","S000802; S001186","openalex","FALSE","paywalled","1","FALSE","article"],["R0046345","Effects of liraglutide on the expression of genes related to cholesterol metabolism in ApoE-/-mice with hypoadiponectinemia","Long-hui Li","2011","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2011.07.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046346","Emerging Poly‐Agonists for Obesity and Type 2 Diabetes","Maximilian Kleinert","2017","Obesity","preclinical","article","10.1002/oby.21932","28948717",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046347","Effect of Semaglutide in an Ischemic AKI Model","Juliana veloso gusmao silva","2024","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2024m2yr9mz5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046348","SAT672 Dulaglutide Might Reduce Visceral Fat In Patients With Metabolic Syndrome","Yu Na Kim","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.120",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046349","是质子泵禁止者新 antidiabetic 药 ? 生气部分研究","Diana Diana","2011","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046350","Evaluation of efficacy and safety of liraglutide in newly diagnosed type 2 diabetic patients with continuous glucose monitoring system","Zejun Ma","2014","Chin J Diabetes Mellitus","randomized_trial","article","10.3760/cma.j.issn.1674-5809.2014.12.011",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046351","1765-P: First Disclosure of PSTC1411, a Novel Oral G-Protein-Biased Apelin Agonist Demonstrating Monotherapy Efficacy for Weight Loss and Muscle Preservation","ZHICHAO WANG","2026","Diabetes","preclinical","article","10.2337/db26-1765-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046352","Fat necrosis associated with glucagon-like peptide-1 receptor agonist- induced weight loss","Fahd A. Malik","2026","JAAD Case Reports","other","article","10.1016/j.jdcr.2026.08.033",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046353","739-P: Post Hoc Analysis of Efsubaglutide Alfa Monotherapy and Combined Therapy with Metformin in T2D Patients by Baseline Characteristics","Yulong Xu","2025","Diabetes","randomized_trial","article","10.2337/db25-739-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046354","Reconsidering metabolic adaptation in weight loss evidence: insights and potential limitations of tirzepatide-induced fat oxidation","Mohammad T. Alashqar","2026","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2025.235",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046355","Sa1124 GLP-1RA USE IS ASSOCIATED WITH LOWER INCIDENCE OF GERD COMPARED TO SLEEVE GASTRECTOMY IN PATIENTS WITH TYPE 2 DIABETES: A MULTICENTER NATIONAL STUDY","Shaina Ailawadi","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)01876-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046356","Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS","Aleksandra Jaroń","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.20.53831",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046357","Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study","Tamer Coşkun","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785379",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046358","Is taking a GLP-1 receptor agonist for weight loss “cheating”? A qualitative study of responses from a US census-matched panel","Misty A.W. Hawkins","2026","BMC Research Notes","other","article","10.1186/s13104-026-08019-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046359","Research progress on the relationship between new hypoglycemic drugs and fracture risk","Jing Peng","2019","药物不良反应杂志","other","article","10.3760/cma.j.issn.1008-5734.2019.06.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046360","26-A-10033-ACC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN THE POST ACUTE MYOCARDIAL INFARCTION SETTING: A SYSTEMATIC REVIEW AND META-ANALYSIS","Subhendu Mandal","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.2053",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0046361","319-LB: GLP-1 Receptor Agonist Promotes Brown Remodeling in? Human Adipose-Derived Stromal Cells Isolated from Omentum through Foxc2","Xiaoying He","2019","Diabetes","other","article","10.2337/db19-319-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046362","Sindrome progeroide atipica con lipodistrofia parziale familiare, dovuta alla mutazione missenso c.1045 C > T (p.Arg349Trp) in eterozigosi del gene LMNA, e diabete mellito di tipo 2","Benedetta Russo","2023","il Diabete","other","article","10.30682/ildia2301g",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046363","Bone Protective Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in an Animal Model","Sang-Don Lee","2018","Diabetes","preclinical","article","10.2337/db18-1105-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046364","Hinweis auf UAW chronischer Husten unter GLP-1-RA – Evidenz-Quickie","Denis Nößler","2025","EvidenzUpdate","other","article","10.69156/quick/2025.11.00005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046365","SAT-184 Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists","Jieun Song","2026","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(26)01833-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046366","93-LB: Discovery of ID110521156, a Small Molecule GLP-1 Receptor Agonist, for the Treatment of Type 2 Diabetes and Obesity","In‐Gyu Je","2023","Diabetes","preclinical","article","10.2337/db23-93-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046367","Endothelial Dysfunction in Type 2 Diabetes with an Update on New Interventions","Natalie C. Ward","2023","Contemporary diabetes","other","article","10.1007/978-3-031-26681-2_14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0046368","Diabetic signature on Parkinson’s disease: Insights into pathophysiology and therapeutic repurposing","Reshma Venugopal","2026","Annals of Movement Disorders","nonrandomized_study","article","10.4103/aomd.aomd_64_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046369","Effects of GLP-1 analog on cellular immune function of diabetes mellitus rats","Hai Zhao","2007","Zhongguo laonianxue zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046370","Effects of oral semaglutide on the lipid profile of patients with type 2 diabetes mellitus and obesity: Are they mediated by body weight loss?","Agnieszka Kuzior","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.p808",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046371","PL8 - GLP-1 and beyond: next-gen therapies for obesity and metabolic disease","LOTTE BJERRE KNUDSEN","2026","European Journal of Endocrinology","preclinical","article","10.1093/ejendo/lvag096.008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046372","Efeitos da semaglutida em pacientes com insuficiência cardíaca com fração de ejeção preservada e obesidade para controle de sintomas cardiometabólicos: uma revisão de escopo","Fernanda sabrina Chaves","2024","Jornal Memorial da Medicina","other","article","10.37085/jmmv6.n1.2024.pp.17-25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046373","GLP-1 receptor agonists for obesity-related heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","C Rodrigues Rosa","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.1248",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046374","When hypoglycemia hits early: a rare case of insulinoma post-bariatric surgery and novel tirzepatide therapy in preoperative optimization","Keimee Lopez","2026","Endocrine Abstracts","other","article","10.1530/endoabs.117.p134",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046375","786-P: Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) according to Baseline BMI","János Tibor Kis","2024","Diabetes","nonrandomized_study","article","10.2337/db24-786-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046376","Impact of Glucagon Like Peptide-1 (GLP-1) Analogue Medications on Liver Transplant Risk Factors","Muhammad Salman Faisal","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.1059",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046377","MOUNJARO APLICADO AO TRATAMENTO DA OBESIDADE EM ADULTOS BASES CIENTÍFICAS EFICÁCIA CLÍNICA SEGURANÇA TERAPÊUTICA ATUAL: REVISÃO SISTEMÁTICA","Daniel Carneiro Maffra","2026",null,"other","article","10.70073/prod.edt.978-65-83680-02-0/06",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0046378","Rapid Resolution of Psoriatic Arthritis Symptoms Following Initiation of a GLP-1 Receptor Agonist","BSE Kate Gelman","2026","West Virginia Medical Journal","other","article","10.21885/wvmj.2026.05",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046379","653-P: Evaluating Antidiabetic Medication Treatment Patterns in T2D Patients Initiating Once-Weekly Semaglutide (sema OW)","Vincent J. Willey","2021","Diabetes","nonrandomized_study","article","10.2337/db21-653-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046380","Development of Novel Therapeutics: From Small Molecules to Biologics","Lani J. Davies","2026","ANU Open Research (Australian National University)","other","article","10.25911/c28y-ew98",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0046381","Additional file 1 of Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease","Jason N. Chen","2026","Figshare","nonrandomized_study","article","10.6084/m9.figshare.31911390",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0046382","The Impact of GLP-1 Receptor Agonists on Weight Control in Patients with Diabetes and Comorbid Obesity","Jie Wang","2025","International Journal of Molecular Medical Science","other","article","10.5376/ijmms.2025.15.0026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046383","2824-LB: Indication-Specific Adverse Event Profiles of Semaglutide and Liraglutide: A FAERS Disproportionality Analysis","Silvia Fisch","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2824-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046384","Pleiotropic Neuroprotection of GLP-1 Receptor Agonists:From Synaptic Plasticity to Autophagy-Mediated Proteostasis in Neurodegeneration","Divyanshu Tripathi","2026","International Journal of Drug Delivery Technology","randomized_trial","article","10.25258/ijddt.16.48s.8",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046385","1692-P: The Relationship between β-Cell Senescence and Incretin Signaling in Type 2 Diabetes","Maya Jackson","2026","Diabetes","preclinical","article","10.2337/db26-1692-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046386","Engineering chitosan-Exenatide nanocomplexes with fatty acids for improved peptide delivery","Rana Hani Mohammed Ali Al-Shaikh Hamed","2026","ScienceRise Pharmaceutical Science","other","article","10.15587/2519-4852.2026.340895",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046387","Exendin-4 Emerging Therapeutic Potential in Dermatology","Ahmed El-Sayed Hassan","2026","Journal of Pioneering Medical Science","preclinical","article","10.47310/jpms2026150212",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046388","730-P: Effectiveness of iGlarLixi (Insulin Glargine-Lixisenatide) in People with Type 2 Diabetes According to the Time of Administration through the Day","MARTIN HALUZIK","2022","Diabetes","randomized_trial","article","10.2337/db22-730-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046389","Abstract 395: Pioglitazone and Glucagon-like Peptide 1 Receptor Agonist Mitigate Adverse Postinfarction Left Ventricular Remodeling in Lean Mice When Administered After the Infarct Independent of Changes in Infarct Size","Allen M. Andres","2018","Circulation Research","preclinical","article","10.1161/res.123.suppl_1.395",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046390","P0964 : Direct glucagon-like peptide-1 receptor agonism ameliorates steatohepatitis and fibrosis in models of NASH and biliary fibrosis via regulation of liver macrophage infiltration and activation","X.-Y. Wang","2015","Journal of Hepatology","other","article","10.1016/s0168-8278(15)31165-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046391","Metabolic dysfunction-associated steatotic liver disease in India: A growing public health imperative and call to action","De Arka","2025","International Journal of Noncommunicable Diseases","other_trial","article","10.4103/jncd.jncd_223_25",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","editorial"],["R0046392","Incretin mimetics as pharmacological tools to elucidate and as a new drug strategy to treat traumatic brain injury","Nigel H. Greig","2014","PMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046393","Clinical inertia and associated factors in the treatment of type 2 diabetes patients: an analysis from a multicenter study","Xiang Li","2020","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2020.02.005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046394","Advances and Challenges in Nanoemulsion for Diabetes Management: An Emerging Framework","Anushka Sharma","2026","Current Nanomaterials","other","article","10.2174/0124054615441747260401094729",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046395","Long-Term Safety of Tirzepatide (Mounjaro): Relationship Between Duration of Use and Adverse Events Compared With Semaglutide and Liraglutide","Thiago A. Rochetti Bezerra","2026","Journal of Clinical Endocrinology and Metabolism","nonrandomized_study","article","10.52338/jocem.2026.5500",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046396","Abstract 16932: Glucagon-Like Peptide 1 Receptor Agonist Mitigates Postinfarction Adverse Left Ventricular (LV) Remodeling in Mice; a Mechanism Linked to Mitophagy and the Restoration of Cardiac Fatty Acid Oxidation","Allen M. Andres","2018","Circulation","preclinical","article","10.1161/circ.138.suppl_1.16932",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046397","The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes","L L Sun","2026","European journal of medical research","other","article","10.1186/s40001-026-04534-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046398","Once-weekly Triple Receptor (GIP/GLP-1/Glucagon) Agonist Retatrutide (LY3437943): Efficacy and Safety in a 48-week Obesity Phase 2 Trial","Ania M. Jastreboff","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785389",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046399","GLP-1 Receptor Agonists in the Treatment of Obesity: A Narrative Review of Current Therapeutic Methods","Konrad Borkowski","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.55.71099",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0046400","Sa1252 GLP1RA MEDICATION USE AMONG PATIENTS WITH CELIAC DISEASE","Nicole Cornet","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)05683-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046401","PPARG activation by pioglitazone promotes mitophagy and inhibits the NLRP3 inflammasome to alleviate arthritic joint inflammation and bone damage","Tingting Fu","2026","Figshare","preclinical","article","10.6084/m9.figshare.32312703.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046402","O uso da Semaglutida para emagrecimento","Daiane Ana da Silva","2024","Revista JRG de Estudos Acadêmicos","other","article","10.55892/jrg.v7i15.1554",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046403","Comparative pharmacodynamic analysis of resmetirom, semaglutide and obeticholic acid in translational mouse models of MASH","Rufeng Zhang","2025","Exploration of Endocrine and Metabolic Diseases","preclinical","article","10.37349/eemd.2025.101433",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046404","769-P: Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Orforglipron (LY3502970), an Oral, Nonpeptide GLP-1 Receptor Agonist","XIAOSU MA","2023","Diabetes","randomized_trial","article","10.2337/db23-769-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046405","Beyond Pharmacology: Transitioning Off Incretin-Based Therapies and the Role of Lifestyle Interventions in Weight Maintenance","Emilia Buzek","2026","Quality in Sport","other","article","10.12775/qs.2026.56.71975",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046406","DD01, a Dual GLP-1/Glucagon Agonist, in Metabolic Dysfunction–Associated Steatotic Liver Disease and Steatohepatitis: A Phase 2 Trial Top Line Results","Mazen Noureddin","2026","SSRN Electronic Journal","other_trial","article","10.2139/ssrn.6034158",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","preprint"],["R0046407","Emerging mechanism and Therapeutic intervention for Sarcopenic obesity- A narrative review","Dr Sheetal Kalra","2026",null,"narrative_review","article","10.17605/osf.io/5sq2b",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046408","Polymer-based microencapsulation of peptidyl drugs: from bench to bedside","Pranal Chhetri","2026","Journal of Applied Pharmacology and Toxicology","other","article","10.69857/joapt.v1i1.14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046409","Predictors of glycemic and weight responses to exenatide in patients with type 2 diabetes mellitus","Yuhan Huang","2023","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-023-01239-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046410","2,4 dinitrophenol; has the inferno drug burnt out?","Dr Jennifer Germain","2026","Performance Enhancement & Health","other","article","10.1016/j.peh.2026.100445",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046411","Comparative Effectiveness of Semaglutide, Orforglipron, Phentermine–Topiramate, and Naltrexone–Bupropion for the Management of Overweight and Obesity: A Network Meta-analysis of Randomized Clinical Trials","Tamer Hodrob","2026",null,"systematic_review","article","10.17605/osf.io/g8jmy",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0046412","2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice","Greta Lommi","2026","Diabetes","preclinical","article","10.2337/db26-2458-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046413","Safe use of basal insulin–GLP-1 receptor agonist combination products","Joseph Ladd","2017","Pharmacy Today","other","article","10.1016/j.ptdy.2017.02.033",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046414","The onco-bariatric paradigm: a tri-phasic metabolic obesity framework for synergizing glucagon-like peptide-1 receptor agonists and metabolic bariatric surgery","Dong Jin Park","2026","Kosin Medical Journal","other","article","10.7180/kmj.26.154",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046415","Normalization of fasting hyperglycemia is beneficial for successful introduction of small amount of the GLP-1 analog liraglutide in an obese patient with type 2 diabetes mellitus","Katsumi Iizuka","2011","Diabetology International","other","article","10.1007/s13340-011-0052-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046416","S2901 Comparative Outcomes of GLP-1 Receptor Agonists vs SGLT2 Inhibitors in Patients With Cirrhosis","Hatem Ahmed","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001139064.02867.85",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046417","A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia","Ayesha Malik","2026","Journal of Hypertension","nonrandomized_study","article","10.1097/hjh.0000000000004250","41744241",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046418","Effects of Peptide Molecular Properties and Permeation Enhancement on Oral Absorption","Prosper Emeh","2026","KTH Publication Database DiVA (KTH Royal Institute of Technology)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0046419","Left epigastric isolated tumor fed by the inferior phrenic artery diagnosed as ectopic hepatocellular carcinoma: A case report","Hongbo Liu","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6231","37731571",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046420","Effectiveness of Oral versus Injectable Semaglutide in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia","Sanja Klobučar Majanović","2024","Diabetology","nonrandomized_study","article","10.3390/diabetology5010005",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046421","L26/O-314 Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) during preconception and pregnancy: a systematic review and meta-analysis of obstetric and neonatal outcomes","W. Vollebregt","2026","Human Reproduction","systematic_review","article","10.1093/humrep/deag083.312",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046422","Regulation of GLP-1 on PERK-eIF2 α-ATF4 Pathway in Non-alcoholic Fatty Pancreas Disease","Taiyong Fang","2019","Data Archiving and Networked Services (DANS)","preclinical","article","10.17632/hm32r98hmt.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046423","Investigating the Influence of Glucagon-like Peptide-1 Receptor Agonist Treatment on Food Noise","Isabelle Perraut","2025","Open Science Framework","other","article","10.17605/osf.io/75xt2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0046424","Au fil de la presse","Philippe Casassus","2023","Médecine","randomized_trial","article","10.1684/med.2023.903",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046425","The Progress of Glucagon-like Peptide-1 Analogue in Treatment of Diabetes Mellitus","Wang Nai","2011","Medical Recapitulate","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046426","From Obesity to Efficacy: A Comprehensive Analysis of Emerging Weight Loss Drugs","Hani Raka Karrar","2025","Journal of Pharmaceutical Research International","other","article","10.9734/jpri/2025/v37i127800",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046427","Systematic Literature Review on Efficacy and Safety of Glucagon-Like Peptide (GLP-1) Agonists in Asian Adults Living with Type 2 Diabetes Mellitus.","Roberta Lamptey","2026","OSF Preprints (OSF Preprints)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","preprint"],["R0046428","Do glucagon-like peptide 1 receptor agonists offer protective effect on colon cancer risk?","Gokul Karthikeyan","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.2_suppl.91",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046429","Sa2095 REAL-WORLD LIVER-RELATED OUTCOMES AFTER INITIATION OF RESMETIROM VS GLP-1 RECEPTOR AGONISTS IN MASH: A PROPENSITY SCORE-MATCHED COHORT ANALYSIS HIGHLIGHTING THE IMPACT OF FIBROSIS CODING.","Kevin Eid","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)03630-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046430","1721-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study","WEI HU","2026","Diabetes","randomized_trial","article","10.2337/db26-1721-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046431","Exendin-4通过上调pdx-1 mRNA表达促进STZ造模小鼠β细胞增生","朱敏","2005","Acta Scientiarum Naturalium Universitatis Sunyatseni","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046432","OZEMPIC (SEMAGLUTIDA) COMO INOVAÇÃO TERAPÊUTICA NO TRATAMENTO DA DIABETES TIPO 2 E DA OBESIDADE: AVANÇOS CLÍNICOS, RISCOS E CONTROVÉRSIAS ÉTICAS NO USO DE AGONISTAS DO RECEPTOR GLP-1: REVISÃO DE LITERATURA","Diogo Vieira de Carvalho","2025",null,"other","article","10.70073/prod.edt.978-65-984030-5-8/10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0046433","PO13 La dysfonction du protéasome induite par l’hyperglycémie chronique entraîne l’apoptose des cellules bêta pancréatiques : Une nouvelle cible thérapeutique de l’Exendin-4","Elodie M. Varin","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71709-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046434","937-P: Efficacy and Safety of SGLT2i vs. Other Oral Antidiabetic Drugs as Dual Therapy Add-On to Metformin in Type 2 Diabetes—A Systematic Review and Meta-analysis","YUHANG MA","2024","Diabetes","systematic_review","article","10.2337/db24-937-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0046435","C75-11 Evaluation of Diaphragmatic Weakness - Lessons From a Dedicated Clinic at a Tertiary Care Center","J Glowala","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.5337",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046436","Abstract 06: Comparative Effectiveness of Semaglutide and Tirzepatide on Cardiovascular Outcomes among Patients with Obesity and Established Cardiovascular Disease","Gwen Aubrac","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.06",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046437","787-P: Glucose and Weight Outcomes Associated with Oral Semaglutide in the Real-World—Initial Results from the Association of British Clinical Diabetologists’ (ABCD) Audit","THOMAS S.J. CRABTREE","2023","Diabetes","nonrandomized_study","article","10.2337/db23-787-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046438","75730 Evaluating GLP-1 Agonists and Weight Loss in Hidradenitis Suppurativa: A Retrospective Analysis and Patient Survey","Claire Hines","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.834",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046439","Glycemic Control and Dosage Form Preference Following the Transition from Weekly-once Injectable to Daily Oral Semaglutide in Type 2 Diabetes Mellitus","Ferdous Ara Joty","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.21864297",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0046440","Readability of AI-Generated Patient Information on Glucagon-Like Peptide-1 Receptor Agonists (Preprint)","Maja Cigrovski Berković","2025",null,"other","article","10.2196/preprints.90572",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046441","Discovery of a new GLP-1 Receptor Agonist using DNA Encoded-Libraries and Similarity Search","Byumseok Koh","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6051455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046442","742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies","Boris Calderón","2022","Diabetes","other_trial","article","10.2337/db22-742-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046443","High Cell Density Fermentation Strategy for High-Level Soluble Expression of Glucagon-like Peptide-1 Analogue in Escherichia coli","Sushmita Kumar","2026","Fermentation","other","article","10.3390/fermentation12010053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046444","Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnoea: A real-world propensity score-matched study","B S Prado","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.3899",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046445","1938-P: GLP-1 Receptor Agonist Ameliorates Intramyocellular Lipid Deposition without Weight Loss by Activating AMPK","Fen Xu","2019","Diabetes","preclinical","article","10.2337/db19-1938-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046446","Oral Manifestations Associated with GLP-1 and GIP Receptor Agonists: A Scoping Review Protocol","Doménica Gabirela Escudero Samaniego","2026",null,"protocol","article","10.17605/osf.io/nwtcs",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0046447","Preferences of Individuals With Obesity for Online Medical Consultation in Different Demand Scenarios: Discrete Choice Experiments (Preprint)","Yaolin Hu","2023",null,"other","article","10.2196/preprints.53140",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0046448","Comment on: “Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation”","Christina S. Han","2026","Obstetrical & Gynecological Survey","nonrandomized_study","article","10.1097/ogx.0000000000001543",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","letter"],["R0046449","1152-P: Treatment Trends in Youth-Onset Type 2 Diabetes—Changing Landscape after GLP-1RA Approval","Ho‐Jin Shin","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1152-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046450","Pathophysiological Interplay Between Cardiovascular Diseases and Metabolic Disorders: A Review of Shared Mechanisms and Emerging Therapeutic Approaches","Afshin Nazari","2025","Epidemiology and Health System Journal","narrative_review","article","10.34172/ehsj.26451",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046451","2818-LB: Real-World Evidence on Efficacy and Safety of Semaglutide in Patients with Type 2 Diabetes and Advanced Chronic Kidney Disease","SALMA ELNOUR","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2818-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046452","Management of the Gut Microbiota as an Adjunctive Weight-Reduction's Strategy, Including Therapy with Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists: the Role of Arabinogalactan and Lactoferrin","N.V. Bakulina","2026","Effective Pharmacotherapy","other","article","10.33978/2307-3586-2026-22-4-58-66",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046453","Integrated Diabetes Prevention: Glucagon-Like Peptide-1 Receptor Agonists Plus Lifestyle Interventions","Susan Kohl Malone","2026","The Journal for Nurse Practitioners","other","article","10.1016/j.nurpra.2026.105902",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046454","Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy","Shreyas Krishna","2026","npj gut and liver.","randomized_trial","article","10.1038/s44355-026-00069-9",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046455","Lifestyle modification and selected pharmacological therapies in Polycystic Ovary Syndrome: current evidence and emerging approaches","Agnieszka Brzozowska","2026","Quality in Sport","other","article","10.12775/qs.2026.51.68457",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046456","1625-P: GS-4571, an Oral Small Molecule GLP-1R Agonist, Improves Glucose Tolerance and Suppresses Food Intake in Obese Diabetic Cynomolgus Monkeys","JEN VOGEL","2024","Diabetes","preclinical","article","10.2337/db24-1625-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046457","Impact of Ozempic on Adipose Tissue in Obese Mice: A Quantitative Study Using Dixon and MT MRI Methods, DEXA and CT.","Orlando Aristizábal","2025","Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition","preclinical","article","10.58530/2025/2013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0046458","Beyond weight loss in hypertrophic cardiomyopathy: metabolic therapy and the evolving treatment paradigm","Priyanka Boettger","2026","European Heart Journal - Quality of Care and Clinical Outcomes","nonrandomized_study","article","10.1093/ehjqcco/qcag064","42017238",null,null,null,"openalex","FALSE","paywalled","4","FALSE","editorial"],["R0046459","PO-03-087 IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) THERAPY ON RECURRENCE OF TACHYARRHYTHMIAS IN DIABETIC PATIENTS: A PROPENSITY-MATCHED ANALYSIS OF REAL-WORLD DATA","Johnny Bou Saba","2026","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2026.03.826",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046460","Assessing GLP-1 RAs in Diabetic Gastroparesis: A Literature Review","Jacob Itkin","2025","Translation The University of Toledo Journal of Medical Sciences","narrative_review","article","10.46570/utjms-2025-1363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046461","Patient-reported outcome assessment in heart failure with preserved ejection fraction: A systematic review of semaglutide trials using the Kansas City Cardiomyopathy Questionnaire","Razan Abdulaal","2026","World Journal of Meta-Analysis","systematic_review","article","10.13105/wjma.v14.i2.121918",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046462","Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review","Aleksander Jentkiewicz","2025","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2025.78.57712",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046463","Current innovative treatments of obesity","Damian Wach","2023","Journal of Education Health and Sport","other","article","10.12775/jehs.2023.21.01.020",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046464","GW27-e1127 GLP-1 analog liraglutide attenuates cardiac dysfunction, oxidative stress, and inflammatory in streptozotocin-induced diabetic rats","Cairong Li","2016","Journal of the American College of Cardiology","preclinical","article","10.1016/j.jacc.2016.07.148",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046465","‘Insulin should be prescribed at the outset of diagnosis of type 2 diabetes’","M‐F Kong","2011","Practical Diabetes","randomized_trial","article","10.1002/pdi.1564",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046466","IP33-20 FROM BLOOD SUGAR TO BLADDER HEALTH: GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH LOWER URINARY COMPLICATION RISK IN DIABETES","Robert Adler","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191476.64741.7c.20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046467","Liraglutide Induces Enhanced Suppression of Food Intake in Ghsr-Deficient Mice","Mario Perelló","2025","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.5276200",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046468","Somatostatin receptor subtype-2 and -3–selective agonists inhibit insulin secretion from INS-1 cells through modulation of the R-type Ca2+ channel activity","Stefan Mergler","2007","Experimental and Clinical Endocrinology & Diabetes","other","article","10.1055/s-2007-972323",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046469","Metabolic consequences of semaglutide discontinuation in type 2 diabetes: a retrospective cohort study","Amela Dizdarević-Bostandžić","2026","BMJ Nutrition Prevention & Health","nonrandomized_study","article","10.1136/bmjnph-2026-001616",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046470","Incorporation of D-amino Acids and Ornithines into Tirzepatide by Biosynthesis in E. Coli","Yanli Xu","2026","International Journal of Peptide Research and Therapeutics","other","article","10.1007/s10989-026-10813-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046471","TOP-162 Glucagon-like peptide-1 receptor agonists and long-term liver outcomes in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: a large real-world analysis","Arunkumar Krishnan","2026","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(26)01884-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046472","The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Transplant Outcomes","Zehra Dhanani","2025","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2025.02.1255",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046473","Exenatide: a New Agent for the Treatment of type 2 Diabetes Mellitus as Adjunctive Therapy","Juno Yoo","2005","Korean Journal of Clinical Pharmacy","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046474","Modern strategies for pharmacological correction of fibrotic disorders: mechanisms of action, clinical efficacy and prospects of therapy","Vadim A. Kosolapov","2026","Journal of Volgograd State Medical University","nonrandomized_study","article","10.19163/1994-9480-2026-23-1-10-17",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046475","НОВЫЙ, КАРДИОГЕПАТОРЕНАЛЬНЫЙ, КОНТИНУУМ: ЧАСТЬ II","И.Р. ГАЙСИН","2025","Health demography ecology of finno-ugric peoples","randomized_trial","article","10.64111/1994-8921.2025.51.4.009",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046476","Postoperative Cholestasis and Cholangitis After Total Pancreatectomy with Biliary Reconstruction Impair the Function of Autotransplanted Islets","Tatsuo Hata","2013","Transplantation","other","article","10.1097/tp.0b013e3182a049bb","23995869",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046477","HPR74 ACCESS TO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ANTIOBESITY MEDICATIONS: FORMULARY COVERAGE AND PRIOR AUTHORIZATION RESTRICTIONS ACROSS U.S. PAYERS","MATTHEW KLEBANOFF","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1136",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046478","GLP-1 Receptor Agonists Do Not Cause Tumor Growth in Patients with Papillary Thyroid Carcinoma Undergoing Active Surveillance","Micheal W. Porter","2026","Clinical Thyroidology","other","article","10.1177/23299711261441003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046479","Effect of GLP1 Agonists on Reproduction","Marie Couldwell","2026","Obstetrical & Gynecological Survey","other","article","10.1097/ogx.0000000000001487","41557916",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046480","850-P: Trends in GLP-1RA Use among Individuals with Type 2 Diabetes (T2D) and/or Obesity—Insights from a Nationwide Electronic Health Record System, 2010–2023","PIAOPIAO LI","2024","Diabetes","nonrandomized_study","article","10.2337/db24-850-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046481","Innovative Diabetes Management: Navigating Treatment, Financial Constraints, and Patient-Centered Care","Đani Hadžović","2025","Acta Medica Saliniana","other","article","10.5457/ams.v55i1.821",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046482","Mol808 GASTROINTESTINAL ADVERSE EFFECTS AND MOTILITY ALTERATIONS ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS: ANALYSIS FROM LARGE TERTIARY CARE COHORT.","Julio Zúñiga Cisneros","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04872-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046483","Alcohol use dominates determining liver-related events in steatotic liver disease: Rethinking the role of metabolic dysfunction","Luis Antonio Diaz","2026","Hepatology","nonrandomized_study","article","10.1097/hep.0000000000001687","41563877",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046484","Triple agonists of GIP, GLP-1, and glucagon - the future of obesity treatment: a review of the latest findings","Kinga Brzdęk","2024","MEDICAL SCIENCE PULSE","nonrandomized_study","article","10.5604/01.3001.0054.8367",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046485","Rational Design of Small Molecular GLP-1R Agonists","Zixin Yang","2021","Biophysical Journal","other","article","10.1016/j.bpj.2020.11.422",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046486","BEYOND OZEMPIC: THE NEW TRIPLE AGONIST AND CARDIOVASCULAR RISK","Jair Marcos Frota Zurita","2026","Asclepius International Journal of Scientific Health Science","nonrandomized_study","article","10.70779/aijshs.v5i3.516",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046487","999-P: Trends and Characteristics of Continuous Glucose Monitoring Initiation in Older Adults with Diabetes—A Cohort Study","Wajd Alkabbani","2024","Diabetes","nonrandomized_study","article","10.2337/db24-999-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046488","Pharmacokinetics and brain distribution of the therapeutic peptide liraglutide by a novel LC–MS/MS analysis","Hyeon Seok Oh","2023","Journal of Analytical Science & Technology","preclinical","article","10.1186/s40543-023-00382-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046489","Protective effect of exenatide treatment in STZ-induced diabetic rats in vivo and in vitro","Mahmoud Lotfy","2012","Proceedings of The Physiological Society","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046490","Abstract 071: Comparative Antihypertensive Effects of Emerging Cardiorenal Therapies in Chronic Kidney Disease: A Network Meta-Analysis of SGLT2 Inhibitors, MRAs, and GLP-1 Receptor Agonists","Vaishnavi Sabesan","2025","Hypertension","systematic_review","article","10.1161/hyp.82.suppl_1.071",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046491","Effect of exenatide on bone metabolism in patients with newly diagnosed T2DM","Renyuan Li","2014","Zhongguo bingli shengli zazhi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046492","Epiploic appendagitis during rapid weight loss associated with tirzepatide therapy: a case report","Beshoy M. Astfanous","2026","Exploration of Endocrine and Metabolic Diseases","randomized_trial","article","10.37349/eemd.2026.101465",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046493","S4686 Semaglutide’s Hidden Perils: A Rare Case of Malnutrition and Wernicke Encephalopathy","Suhib Alhaj Ali","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001048112.46649.58",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046494","Biochemical and Pharmacological Mechanisms of GLP-1 and Dual Agonists: Implications for Glycemic Control and Cardiovascular Risk Reduction — A Review","Akter Sraboni","2026","Journal of Biochemistry Pharmacology and Public Health","nonrandomized_study","article","10.64907/xkmf.v4.i1.jbpph.1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046495","Preface from the Editors-in-Chief","Anna McCracken","2026","University of Toronto Medical Journal","commentary","article","10.33137/utmj.v103i2.47567",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0046496","In silico Design and Computational Assessment of Small-Molecule GLP-1R Agonist as a Possible Treatment for Obesity and Type 2 Diabetes","Sarah Ahmed Waheed","2026","Tikrit Journal of Pharmaceutical Sciences","other","article","10.25130/tjphs.2026.20.1.6.51.66",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046497","Unraveling Molecular and Metabolic Gut‐Brain Signalling Disruptions and Potential Therapy in New Bardet‐Biedl Syndrome Mouse","Arashdeep Singh","2022","The FASEB Journal","preclinical","article","10.1096/fasebj.2022.36.s1.r2708",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046498","[PS 01-27] ENHANCED-AUTOPHAGY BY EXENATIDE MITIGATES DOXORUBICIN-INDUCEDCARDIOTOXICITY IN VITRO AND IN VIVO","Haneul Cho","2016","Journal of Hypertension","preclinical","article","10.1097/01.hjh.0000500128.23138.1d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046499","1293-OR: Changes in Diabetic Retinopathy (DR) in People with Type 1 Diabetes Using Tirzepatide for >1 Year","Sarit Polsky","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1293-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046500","Effect of Liraglutide on visceral fat, body fat and blood glucose control in overweight/obesity petients with type 2 diabetes mellitus","Xiaoying Liu","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046501","Latest data on obesity","Evangelos Fousteris","2017","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046502","The effects and safety of Exenatide on reproductive function in PCOS:A Meta-Analysis","Zhengrong Ye","2022",null,"systematic_review","article","10.37766/inplasy2022.5.0105",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","report"],["R0046503","26-A-13074-ACC CARDIO-RENAL OUTCOMES OF GLP-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES: AN UMBRELLA REVIEW OF META-ANALYSES AND DEVELOPING A CARDIO-RENAL GUIDELINE FRAMEWORK","David Savage-Lobeck","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.674",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0046504","Precision Medicine Approaches in Diabetes Management: Targeting Individualized Pathways","Nasim Akhtar","2024","Innovative Research in Applied Biological and Chemical Sciences","other","article","10.62497/irabcs.2024.33",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046505","A-127 | Real-World Cardiovascular Outcomes of Tirzepatide Versus Dulaglutide After Percutaneous Coronary Intervention","Revati Varma","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104617",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046506","966-P: Effect of Baseline ß-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes","Chaofan Wang","2020","Diabetes","other","article","10.2337/db20-966-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046507","Tu1773 TIRZEPATIDE AND SEMAGLUTIDE AND CANCER RISK: A PROPENSITY SCORE-MATCHED ANALYSIS OF 92,284 PATIENTS","Yassine Kilani","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)04969-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046508","Preserving Skeletal Muscle and Function During GLP-1 Receptor Agonist Therapy: An Evidence-Informed Exercise Prescription Framework","Michał Adamczak","2026","Quality in Sport","other","article","10.12775/qs.2026.68.74482",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046509","SEMAGLUTIDE IN THE TREATMENT OF OBESITY- A NEW LOOK AT AN EFFECTIVE PHARMACOLOGICAL TOOL IN THE FIGHT AGAINST EXCESSIVE BODY WEIGHT","Monika Rogowska","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.1(49).2026.5096",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046510","Authors' Reply: Proteomic CKD Prediction in Type 2 Diabetes: Underexplored Limitations and Translational Gaps","Chloe Yu-Yan Cheung","2026","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.0000000992","41563352",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","letter"],["R0046511","Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies","Yu. Sh. Khalimov","2020","Meditsinskiy sovet = Medical Council","randomized_trial","article","10.21518/2079-701x-2019-21-189-197",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0046512","Liraglutide normalised glucose tolerance and the response of insulin to glucose in a non-obese patient with newly diagnosed type-2 diabetes mellitus","Katsumi Iizuka","2014","Diabetology International","other","article","10.1007/s13340-014-0167-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046513","MON-325 Tirzepatide Improves Metabolic Dysfunction in High-Fat Diet-Fed Brca1+/- Mice","Sailesh Palikhe","2025","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaf149.2423",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046514","Diabetic kidney disease: what we know so far - literature review","Piotr Kuczyński","2024","Quality in Sport","narrative_review","article","10.12775/qs.2024.18.54036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046515","Trends of HBA1c and related side effects of dapagliflozin 10mg and semaglutide 1mg in adults with type 2 diabetes mellitus in King Abdulaziz Medical City, Riyadh, Saudi Arabia","Khalid Abdulkhaliq M. Alharbi","2024","Medical Science","nonrandomized_study","article","10.54905/disssi.v28i150.e103ms3406",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046516","1963-LB: Prenatal Treatment of Glucagon-Like Peptide 1 Agonist Mitigates Cognitive Deficits in Offspring of Mothers with Diabetes by Modulating Placental Development Mediated by ADGRL3","MARIKO ITO","2024","Diabetes","preclinical","article","10.2337/db24-1963-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046517","RWD133 GLP-1 RECEPTOR AGONIST-ASSOCIATED THROMBOCYTOPENIA: A NOVEL/EXTENSIVE PHARMACOVIGILANCE EVALUATION FROM SOUTHERN NETWORK ON ADVERSE REACTIONS (SONAR-AI)","Demir C. Uslu","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.2121",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046518","Reproducible analysis code and data for Efficacy and safety of mazdutide in overweight, obesity, and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","Syed Muhammad Rayyan","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.21427643",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0046519","Acute cholestatic liver injury due to hypothyroidism that reversed with intravenous levothyroxine: A rare case report","Qi Li","2026","Journal of Clinical and Translational Endocrinology Case Reports","other_trial","article","10.1016/j.jecr.2026.100212",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0046520","Promotion and Application of Weekly GLP-1 Receptor Agonist Preparations in the Treatment of Type 2 Diabetes Patients","Jun Chen","2026","Advances in Precision Medicine","other","article","10.18063/apm.v11i1.1222",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046521","Effects of exenatide therapy on hepatic insulin resistance in high-fat diet and low-dose streptozotocin-induced diabetic rats","Hui Wu","2014","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2014.09.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046522","Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes","Sophie Meillon","2012","HAL (Le Centre pour la Communication Scientifique Directe)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0046523","Оновлення класифікації та підходів до лікування серцевої недостатності у 2026 році","В. А. Скибчик","2026","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046524","Effect of GLP-1 Receptor Agonists (Liraglutide) on Glycemic Parameters and Circulating miRNA Expression in Type 2 Diabetes Mellitus","Aqeel Meer AL-ZAMILY","2025","Medicina Moderna - Modern Medicine","other","article","10.31689/rmm.2025.32.2.143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046525","2620-P: MDR-001, an AI-Enabled β-arrestin2-Biased Oral GLP-1RA: Efficacy and Safety in Chinese Adults with Overweight or Obesity","LINONG JI","2026","Diabetes","randomized_trial","article","10.2337/db26-2620-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046526","Az elhízás és a pitvarfibrilláció kapcsolata: patofiziológiai háttér és terápiás perspektívák","Mariann Harangi","2026","Cardiologia Hungarica","other","article","10.26430/chungarica.2026.56.3.210",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046527","Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial","Huisheng Xiao","2018",null,"randomized_trial","article","10.3760/cma.j.issn.1000-6699.2018.04.015",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046528","Bullous Pemphigoid Development in a Patient Treated with Dulaglutide: A Case Report","Natalia Baj-Osiewicz","2026","Spartan Medical Research Journal","case_report","article","10.51894/001c.164571",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046529","Impact of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Patient-Reported Quality of Life in Adults: A Systematic Review Protocol","Kaushal Jatti","2026",null,"systematic_review","article","10.17605/osf.io/yxtg8",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0046530","Dual GLP-1/glucagon receptor agonists in metabolic dysfunction–associated steatotic liver disease: a meta-analysis of randomized controlled trials","Mohammed A. Elbahloul","2026","BMC Gastroenterology","systematic_review","article","10.1186/s12876-026-05324-0",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0046531","Efficacy and safety of GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of randomized controlled trials","Chia Siang Kow","2026","Proceedings of Singapore Healthcare","systematic_review","article","10.1177/20101058261424018",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0046532","Comparative Effectiveness of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Reducing Cardiovascular Events in Type 2 Diabetes","Olaniran Olabode","2025","International Journal For Multidisciplinary Research","randomized_trial","article","10.36948/ijfmr.2025.v07i04.51435",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046533","Abstract 398: GLP-1 Receptor Agonist Administered After the Infarct Suppresses miR-33 Expression in Lean Mice Subjected to Permanent Coronary Artery Occlusion","Juliana de Freitas Germano","2018","Circulation Research","preclinical","article","10.1161/res.123.suppl_1.398",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046534","Deciphering ‘Food Noise’ in the Era of GLP-1 Receptor Agonists: A Comprehensive Narrative Review of Neurobiological Mechanisms and Clinical Implications for Health Education","Dominika Janik","2026","Journal of Education Health and Sport","narrative_review","article","10.12775/jehs.2026.88.69532",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0046535","Mounjaro como opção medicamentosa para Diabetes Mellitus tipo 2 descompensada: benefícios e riscos a longo prazo","Ana Carolina Cavalheiro Manarelli","2025","Contribuciones a las Ciencias Sociales","other","article","10.55905/revconv.18n.5-089",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046536","2065-P: Trends in Metabolic Medication Use among Youth Receiving Antipsychotics, 2016–2024","OZI IYALOMHE","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2065-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046537","COMPREENSÃO DOS RISCOS ASSOCIADOS AO USO INDISCRIMINADO DE OZEMPIC (SEMAGLUTIDA) E A IMPORTÂNCIA DO ACOMPANHAMENTO MULTIPROFISSIONAL","Sadi Antonio Pezzi","2025","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2025v7n4p985-1000",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046538","\"Beyond the Exam Chair\" - Future Directions for Glaucoma Care","Andy Renschler","2026","Medical Research Archives","other","article","10.18103/mra.v14i4.7413",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046539","Semaglutide “Ozempic” Face and Implications in Cosmetic Dermatology","Karen Montecinos","2024","Dermatological Reviews","other","article","10.1002/der2.70003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046540","Glucagon-like Peptide 1 and Estradiol in Metabolic Dialogue: A Scoping Review Protocol","Bettina Weber","2026",null,"protocol","article","10.17605/osf.io/kzqfy",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0046541","Semaglutid und Tirzepatid – Game-Changer bei HFpEF mit Typ-2-Diabetes?","Denis Nößler","2025","EvidenzUpdate","other","article","10.69156/pod.001/2025.09.00151",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046542","Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes following Percutaneous Coronary Intervention in Patients with Obstructive Sleep Apnea","Roopeessh Vempati","2026","Michigan medical education and health bulletin.","other","article","10.69735/001c.163913",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046543","26-A-18263-ACC CARDIOVASCULAR OUTCOMES IN ATRIAL FIBRILLATION PATIENTS ON SEMIGLUTIDE VS LIRAGLUTIDE: A PROPENSITY-MATCHED GLOBAL COHORT STUDY","Yasaman Navari","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.191",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046544","Shoulder Arthroplasty Outcomes Using Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review","Kha Minh Kami P. Nguyen","2026","Journal of Orthopaedic Experience & Innovation","systematic_review","article","10.60118/001c.155814",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","book-chapter"],["R0046545","Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer.","Sherry Shen","2024","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2024.42.16_suppl.10607",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046546","Typ-2-Diabetes – was nach Metformin kommt und die Niere schützen kann","Denis Nößler","2021","EvidenzUpdate","randomized_trial","article","10.69156/pod.001/2021.02.00058",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046547","639-P: GIP Receptor Agonism Enhances Weight Loss from Either a Biased or an Unbiased GLP-1 Receptor Agonist in DIO Mice","Matthew P. Coghlan","2021","Diabetes","preclinical","article","10.2337/db21-639-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046548","Hemodynamic Changes in response to GLP-1 RA treatment in ICD and CRT patients: Insights from HeartLogic Sensor Data","F Fussing","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.1228",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046549","Navigating comorbidity: addressing the dual burden of coronary artery disease and diabetes","Ingvild Hernar","2025","European Journal of Cardiovascular Nursing","commentary","article","10.1093/eurjcn/zvaf238","41525790",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0046550","For adults with chronic kidney disease (CKD) and type 2 diabetes, what are the effects of glucagon-like peptide 1 (GLP-1) receptor agonists?","Samira Bell","2025","Cochrane Clinical Answers","other","article","10.1002/cca.4616",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046551","DULAGLUTIDE REDUCES HBA1C IRRESPECTIVE OF ANTIHYPERGLYCEMIC AGENTS, DURATION OF DIABETES, BMI AND WEIGHT LOSS: A POST HOC ANALYSIS FROM THE REWIND TRIAL","Anita Y. M. Kwan","2020","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(20)32578-x",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0046552","GLP-1s - An Investigation into Iatrogenic Harm, Diagnostic Delay, and the Suppression of Systemic Vitality in this Modern Weight Management System","Isa-Allena Muriel Corozone","2026","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/yfb6j",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046553","Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis","Jolanta Skarbaliene","2017","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(17)30466-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046554","Tirzepatide - role in obesity, health and physical wellness. Information overview","Anna Hanslik","2025","Quality in Sport","other","article","10.12775/qs.2025.38.58191",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046555","Impact of body mass index and prediabetes on the risk of type 2 diabetes and cardiovascular events following a recent myocardial infarction","P T Tonnesen","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3467",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046556","Comparação da eficácia do ozempic e mounjaro no tratamento do diabetes tipo 2: revisão integrativa de literatura","Nicole Luisa Konzen Stuepp","2025","Brazilian Journal of Health Review","other","article","10.34119/bjhrv8n4-194",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046557","Wirksamkeit von iGlarLixi (Insulin glargin 100 E/ml - Lixisenatid) bei Menschen mit Typ-2-Diabetes in Abhängigkeit vom Zeitpunkt der Verabreichung über den Tag","Martin Haluzı́k","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1767988",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046558","Breast implant explantation with mastopexy in patients using GLP-1 receptor agonists: A retrospective comparative analysis","Or Friedman","2025","Journal of Plastic Reconstructive & Aesthetic Surgery","nonrandomized_study","article","10.1016/j.bjps.2025.09.028","41151322",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046559","PHARMACOVIGILANCE SIGNALS OF SEMAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS: AN ANALYSIS OF THE FOOD AND DRUG ADMINISTRATION (FDA) ADVERSE EVENTS REPORTING SYSTEM (FAERS) DATASET","Stefania Chiappini","2025","The International Journal of Neuropsychopharmacology","nonrandomized_study","article","10.1093/ijnp/pyae059.533",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0046560","Tirzepatide and intermittent energy restriction have anti-obesity and anti-tumorigenic effects in a pre-clinical mouse model of obesity-driven endometrial cancer","Alexandra Diggs","2026","Gynecologic Oncology","preclinical","article","10.1016/j.ygyno.2026.01.077",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046561","0653 Integration of GLP-1 Receptor Agonists into Treatment Protocols for Obstructive Sleep Apnea","Kory Mack","2026","SLEEP","nonrandomized_study","article","10.1093/sleep/zsag091.0652",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046562","1723-P: Semaglutide Reduces Asthma-Related Adverse Outcomes in Patients with Comorbid Asthma and Obesity: A Post Hoc Analysis of the SELECT Trial","CHARLOTTE S. ULRIK","2026","Diabetes","randomized_trial","article","10.2337/db26-1723-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046563","SAT-579 Potential Glucose-Lowering Properties of Paxlovid® in Type 2 Diabetes Patients","Sarah Dickerman","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046564","Stability indicating method development and validation of semaglutide by RP-HPLC in pharmaceutical substance and pharmaceutical product","Manasa Merugu","2021","Research Journal of Pharmacy and Technology","other","article","10.5958/0974-360x.2021.00247.x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046565","Semaglutide as a cardioprotective factor in patients with type 2 diabetes mellitus: a meta-analysis","Christopher Aquino Pereira Lima","2025",null,"systematic_review","article","10.13140/rg.2.2.27407.85922",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0046566","Cardiovascular effectiveness and musculoskeletal safety of tirzepatide, GLP-1 receptor agonists, and SGLT2 inhibitors in normal-weight adults with type 2 diabetes and established atherosclerotic cardiovascular disease: a cohort study using a federated electronic health record network","Yu‐Hsuan Li","2026","Cardiovascular Diabetology","nonrandomized_study","article","10.1186/s12933-026-03361-3",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046567","1703-P: Semaglutide Reduces Multiorgan Proteomic-Based Biological Age across Cohorts","Maria Dermit","2026","Diabetes","other","article","10.2337/db26-1703-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046568","Abstract 4145955: In An Experimental Type 2 Diabetes Mellitus Model Induced With Streptozotocin, The Combined Use of Finerenone and Exenatide Reduced Inflammation and Oxidative Stress In The Heart and Kidney Tissues and Improved The Health of The Heart","emirhan gunek","2024","Circulation","preclinical","article","10.1161/circ.150.suppl_1.4145955",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046569","USO DE MOUNJARO (TIRZEPATIDA) NO CONTROLE DO DIABETES TIPO 2 E PERDA DE PESO","Lívia Rocha Bridi","2025","Revista Contemporânea","other","article","10.56083/rcv5n3-064",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046570","Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis","Ting Jin","2025","Journal of Clinical Question","systematic_review","article","10.69854/jcq.2025.0032",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0046571","1691-P: Clinical Outcomes in Patients with Obesity or Overweight Treated with Semaglutide 2.4 mg—A Real-World Retrospective Cohort Study in the United States (SCOPE 2)","Wojciech Michalak","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1691-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046572","WEIGHT REDUCTION IN OBESE OR OVERWEIGHT DIABETIC PATIENTS TREATED WITH ORAL SEMAGLUTIDE IN A REAL WORLD SETTING","Rupesh Jain","2023","Indian Heart Journal","nonrandomized_study","article","10.1016/j.ihj.2023.11.230",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046573","Nutritional Management and Monitoring of Adolescents on GLP-1 Receptor Agonist Therapy: A Scoping Review","Usra Ghanem","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/3dtyz",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0046574","Comparative incidence of sarcopenia across distinct GLP-1 receptor agonists in non-diabetic populations","Vitória Cristina Molchan Borges","2026","International Health Sciences Review","nonrandomized_study","article","10.70164/ihsr.v2i4.202",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046575","GLP-1 based multi-agonists-induced signaling includes profound TRP channel involvement in insulin secretion","Noushafarin Khajavi","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.oc2.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046576","Cost-Effectiveness Analysis of Mazdutide For the Treatment of Adult Patients with Overweight and Obesity in China","Wu Fu","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5378169",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046577","Progress on myocardial protective effects and mechanisms of liraglutide in patients with type 2 diabetes","Jingqin Liu","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046578","3090-LB: UBT251, a Triple Hormone Receptor Agonist in Adults with Overweight or Obesity: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Trial","ZHIGUANG ZHOU","2026","Diabetes","randomized_trial","article","10.2337/db26-3090-lb",null,null,"ClinicalTrials.gov:NCT07177469","S002813","openalex","FALSE","paywalled","1","FALSE","article"],["R0046579","Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents","Kyung‐Soo Kim","2022","Journal of Korean Diabetes","other","article","10.4093/jkd.2022.23.2.83",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046580","Serum leptin and glucagon-like peptide-1 levels in diabetic patients with end-stage renal disease on hemodialysis ‒ a cross-sectional study in Iraqi patients","Haneen Husham Fadhil","2025","European Journal of Clinical and Experimental Medicine","other","article","10.15584/ejcem.2025.4.25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046581","Enhanced oral drug delivery by mimicking natural amino acid and oligopeptide absorption route","Ruinan Wu","2024","Nano Research","preclinical","article","10.26599/nr.2025.94907082",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046582","New therapeutic hypothesis for infantile extrinsic hydrocephalus","Masahiro Kameda","2023","Frontiers in Neurology","preclinical","article","10.3389/fneur.2023.1215560","37794877",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046583","Neuromyelitis Optica Spectrum Disorder in a 29-Year-Old Woman on Semaglutide: A Case of Acute Myelopathy Following Weight Loss Treatment. (P3-2.003)","Moneera Aldraihem","2025","Neurology","case_report","article","10.1212/wnl.0000000000210555",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046584","HSD96 Medication Utilization Patterns Among T2DM Patients Initiating Treatment with Oral Semaglutide","M. Frazer","2023","Value in Health","other","article","10.1016/j.jval.2023.03.1403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046585","Abstract #1411741: Genetic Obesity Case with 2 Heterozygote Variants: MKS1 and MC4R in Which Weight Loss Managed with Tirzepatide","Faiza Mubeen","2023","Endocrine Practice","other","article","10.1016/j.eprac.2023.03.091",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046586","IP35-11 INFLUENCE OF GLP1 RECEPTOR AGONIST ON BLADDER CANCER INCIDENCE AND OVERALL SURVIVAL, A PROPENSITY SCORE MATCHED ANALYSIS USING THE OPTUMLABS DATA WAREHOUSE","Michael K. Wang","2026","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001191484.59024.a0.11",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046587","The Effects of Glucagon-Like Peptide-1 Receptor Agonist Use on Chemosensory Systems and Ingestive Behavior","Giorgia Rutigliani","2026","Current Developments in Nutrition","preclinical","article","10.1016/j.cdnut.2026.109186",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046588","Role of Insulin Resistance and Glucose Metabolism in Alzheimer’s Disease","Jaya Saha","2026","Current Journal of Applied Science and Technology","other","article","10.9734/cjast/2026/v45i64710",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046589","BiblioDem 2026 23 (4)","Jean-Francois Dartigues","2026","HAL (Le Centre pour la Communication Scientifique Directe)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","other"],["R0046590","Pregnancy outcomes of GLP-1 exposure in the first trimester","Laura Dearden","2026","Apollo (University of Cambridge)","other","article","10.17863/cam.134097",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046591","1068-P: Reassessing Insulin Therapy In Diabetes of the Exocrine Pancreas—A Pilot Study","Gea Ciccarelli","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1068-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046592","P314 Évaluation des principaux résultats du dulaglutide en administration hebdomadaire comparé à l’insuline glargine, tous deux associés à l’insuline prandiale lispro, selon le taux initial d’HbA1c chez les patients diabétiques de type 2 (DT2) inclus dans l’esssai AWARD-4 (Assessment of weekly administration of dulaglutide in diabetes 4)","O Adetunji","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30427-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046593","Qual é o principal risco do uso do Ozempic no pré-operatório de cirurgia plástica?","Jefferson Lessa Soares de Macedo","2024","Revista Brasileira de Cirurgia Plástica","other","article","10.1055/s-0044-1801799",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046594","Heart Failure with Preserved Ejection Fraction — A Metabolic Disease?","Yigal M. Pinto","2023","New England Journal of Medicine","other_trial","article","10.1056/nejme2309294","37622676",null,null,null,"openalex","FALSE","paywalled","5","FALSE","editorial"],["R0046595","AB050. SOH26AB_0042. Pancreaticobiliary disease in glucagon-like peptide-1 receptor agonist users: a case series","Ruth Comerford","2026","Mesentery and Peritoneum","case_report","article","10.21037/map-26-ab050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046596","Comparative Effectiveness of GLP-1 RAs Versus SGLT2 Inhibitors in Patients With Heart Failure With Preserved Ejection Fraction: A Network Meta-Analysis of Cardiovascular Outcomes, Mortality, and Hospitalisations","A. Cai","2026","Heart Lung and Circulation","systematic_review","article","10.1016/j.hlc.2026.07.279",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046597","Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models","Jeong A. Kim","2018","Diabetes","preclinical","article","10.2337/db18-1107-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046598","4CPS-003 Liraglutide in chronic intestinal failure: overview and case report","Matilde Scaldaferri","2020","Section 4: Clinical pharmacy services","other_trial","article","10.1136/ejhpharm-2020-eahpconf.104",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-paper"],["R0046599","Combination of Empagliflozin and Liraglutide protects heart against isoproterenol-induced myocardial infarction in rats","Neng Fisheri Kurniati","2023","Pharmacia","preclinical","article","10.3897/pharmacia.70.e96975",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046600","72160 Losing More than Solely Weight: Evaluating the Association Between GLP-1 Agonists and Different Types of Hair Loss","Ulysses Cázares","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.1170",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046601","485-P: Insights from Type 2 Diabetes Patients Reveal Education- and Income-Based Disparities in Awareness Surrounding Kidney Disease Risk and Renoprotective Therapies","Julia Stevenson","2021","Diabetes","other","article","10.2337/db21-485-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046602","1772-P: Novel Oral Brain Penetrant NLRP3 Inhibitor PSTC2501 for Treatment of Obesity and Cardiovascular Diseases","ZHICHAO WANG","2026","Diabetes","preclinical","article","10.2337/db26-1772-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046603","A143 ACUTE ESOPHAGEAL NECROSIS: A COMPLICATION OF DIABETIC KETOACIDOSIS","Tahrin Mahmood","2021","Journal of the Canadian Association of Gastroenterology","other","article","10.1093/jcag/gwab002.141",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046604","S927 Risk of Gastric Food Retention With Glucagon-like Peptide 1 Receptor Agonists versus Diabetes Mellitus: A Case-Control Study From a Large Tertiary Care Health System","Firas Bahdi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001033076.54920.7a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046605","Use of Glucagon-like Peptide-1 Receptor Agonist is associated with reduced risk of major liver-related events: a meta-analysis","C. Celsa","2025","Digestive and Liver Disease","systematic_review","article","10.1016/j.dld.2025.01.124",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0046606","Stability Indicating Assay Method (Siam) For Determination Of Semaglutide By Hplc Using Qbd Approach","Manasa Merugu","2021","International Journal of Research in Pharmaceutical Sciences","other","article","10.26452/ijrps.v12i2.4692",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046607","Effect of GLP1-Receptor Agonist Therapies for Patients with a LVAD and Obesity: A Case Series","T.L. Brazile","2026","The Journal of Heart and Lung Transplantation","case_report","article","10.1016/j.healun.2026.02.583",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046608","The importance of the multidisciplinary team for the management of complex obesity in patients with diabetes","Michelle O’Keeffe","2016","Practical Diabetes","other","article","10.1002/pdi.2046",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046609","2281-P: Metformin and GLP-1RA Use in Adults with Hidradenitis Suppurativa: A Population-Based Study","Raslina Shrestha","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2281-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046610","3052-LB: JUV161 Improves Glycemic Control and Restores Skeletal Muscle Function as Monotherapy and Combination Therapy in a Type 2 Diabetes Mouse Model","Vengadeshprabhu Karuppagounder","2026","Diabetes","preclinical","article","10.2337/db26-3052-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046611","A Possible Effect of Glucagon-Like Peptide 1 Receptor Enhancement on Graft Kidney Function","Tetsuhiko Sato","2021","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20213210s1668b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046612","Prevalence and Impact of Endogenous Hypercortisolism in Patients with Obesity Resistant to Incretin-Based Weight Loss Therapy: A Scoping Review","Naseem Eisa","2026",null,"other_trial","article","10.17605/osf.io/jrc52",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0046613","Abstract 4361396: Cardiometabolic Therapy Reduces Electrocardiogram-Derived Biological Age: A Time-Weighted Analysis","Wojciech Losos","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4361396",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046614","P629 LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISM MITIGATES INFLAMMATION AND FIBROSIS IN MODELS OF NASH AND BILIARY FIBROSIS","X.-Y. Wang","2014","Journal of Hepatology","other","article","10.1016/s0168-8278(14)60791-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046615","Abstract #1182965: Remarkable 161.8lbs weight loss with Liraglutide in a non-diabetic morbidly obese patient","Maham Fatima","2022","Endocrine Practice","other","article","10.1016/j.eprac.2022.03.178",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046616","OS-018 Hepatic transcriptomic signatures reveal mechanistic insights underlying improved metabolic dysfunction–associated steatohepatitis histology with survodutide, a glucagon/glucagonlike peptide-1 receptor dual agonist, in a phase 2 trial","Raphael Hesse","2026","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(26)00328-4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0046617","Inhibitory mechanism of exenatide on the apoptosis of endothelial cells induced by high glucose","Wei Yang","2013","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2013.09.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046618","B22-02 Glucagon-like Peptide-1 Receptor Agonists as Dual Therapeutics for Obesity-related Asthma and Metabolic Dysfunction","D R Gomez","2026","American Journal of Respiratory and Critical Care Medicine","preclinical","article","10.1093/ajrccm/aamag162.394",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046619","Abstract TU207: Independent and Joint Association of GLP-1 Therapy and Physical Activity with Weight Loss: Real-World Evidence from All of Us","Jungae Lee","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.tu207",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046620","20 - Oral Semaglutide vs Sitagliptin: Efficacy by Baseline HbA1C and Background Oral Antidiabetic Drug in PIONEER 3","Peter Assimakopoulos","2019","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2019.07.027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046621","2589-P: Combination LUM-201 and Semaglutide Enhances Weight Loss and Preserves Lean Mass in Diet-Induced Obesity: Translational Rationale for a Phase 2 Study in Adults with Obesity","PISIT (DUKE) PITUKCHEEWANONT","2026","Diabetes","randomized_trial","article","10.2337/db26-2589-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046622","Essential and unnecessary medicines for diabetes","Rokuro Hama","2017","Journal of Lipid Nutrition","other","article","10.4010/jln.26.59",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046623","1907-P: GLP-1RA and iSGLT2 Combination Treatment Effects over Fatty Liver Index","Juana Carretero‐Gómez","2019","Diabetes","other","article","10.2337/db19-1907-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046624","The gut-vascular axis in diabetes: exploring impaired blood flow, cardiovascular disease, and peripheral arterial complications","S. Immanuel Alex Pandian","2025","International Journal of Research in Medical Sciences","other","article","10.18203/2320-6012.ijrms20253215",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046625","Utilisation of Transoral Outlet Reduction and Tirzepatide in management of resistant dumping syndrome","Arkeliana Tase","2025",null,"other","article","10.13140/rg.2.2.22604.88961",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046626","Primary care diabetes prescribing rates: latest analysis shows continued rise in volume and cost","Steve Chaplin","2017","Practical Diabetes","randomized_trial","article","10.1002/pdi.2075",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046627","21-PUB: A Real-World Adverse Event Profile of Tirzepatide—A Pilot Systematic Review and Meta-analysis of Observational Studies","GAGAN DEEP REDDY CHITIKI","2025","Diabetes","systematic_review","article","10.2337/db25-21-pub",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046628","It is all about POCUS!: Participant Survey Data from a Statewide Gastric POCUS Workshop","Mohammed, Azam","2025","IUScholarWorks (Indiana University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046629","2033-LB: Dulaglutide Improves Metabolic Dysfunction–Associated Steatohepatitis (MASH), but Not Atherosclerosis, Independent of Weight Loss in Middle-Age LDLR-/- Mice","Dharti Shantaram","2024","Diabetes","preclinical","article","10.2337/db24-2033-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046630","The need for population-specific cardiovascular risk prediction models for guiding risk stratification and treatment approaches in type 2 diabetes","Quan Hziung Lim","2023","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwad230","37439153",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0046631","KLF11 enhances the effect of liraglutide in high glucoseinduced Schwann cells by regulating endoplasmic reticulum stress and autophagy through inactivation of P38 MAPK","Yuanyuan Xiao","2023","Tropical Journal of Pharmaceutical Research","other","article","10.4314/tjpr.v22i7.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046632","338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D","TIM HEISE","2022","Diabetes","randomized_trial","article","10.2337/db22-338-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046633","6724 Children and young people presenting in diabetic ketoacidosis(DKA) on first presentation of Type 2 Diabetes Mellitus(T2DM) in a District General Hospital(DGH)","Morgan Keane","2024",null,"nonrandomized_study","article","10.1136/archdischild-2024-rcpch.362",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0046634","Efficacy and Safety of Semaglutide in Obese Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis","Ibraheem Altamimi","2025","Annals of Middle Eastern Medicine","systematic_review","article","10.24911/amem.15-2431",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046635","Comparative Effectiveness of GLP-1 Receptor Agonists versus Mineralocorticoid Receptor Antagonists as Fourth-line Therapy in Patients with Resistant Hypertension and Overweight or Obesity","Zhejia Tian","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6458058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046636","INCRETIN-BASED PHARMACOTHERAPY FOR OBESITY: A COMPARATIVE NARRATIVE REVIEW OF GLP-1, DUAL AND TRIPLE AGONISTS AND COMBINATION THERAPIES","Łukasz Krzystek","2025","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.4(48).2025.4388",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0046637","No effect of liraglutide, dulaglutide or danuglipron on in-vitro aggregation and activation of platelets from healthy subjects","Kumar Anusha Prem","2024","Endocrine Abstracts","other","article","10.1530/endoabs.104.p103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046638","Impact bénéfique du liraglutide, agoniste du récepteur au GLP1, sur tous les tissus de l’articulation du genou dans trois modèles murins d’arthrose inflammatoire et post-traumatique","F. Berenbaum","2022","Revue du Rhumatisme","other","article","10.1016/j.rhum.2022.10.136",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046639","CO57 Clinical and Patient-Reported Outcomes Associated With Oral Semaglutide Use in Adults With Type 2 Diabetes: A Pooled Analysis of Six Pioneer Real Prospective Real-World Studies","Gottfried Rudofsky","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.10.134",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046640","Liraglutide may be associated with increased skin cancer risk: A propensity score-matched analysis.","Furkan Bahar","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e21504",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046641","Diabetes and Ageing: From Treatment Goals to Pharmacological Therapy","Rohit Raina","2025",null,"other","article","10.9734/bpi/mono/978-93-49238-92-3/ch5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0046642","ASSOCIATION BETWEEN SEMAGLUTIDE AND NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY: A SYSTEMATIC REVIEW","S. AGRAWAL","2026","International Journal of Current Pharmaceutical Research","systematic_review","article","10.22159/ijcpr.2026v18i3.9041",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046643","757-P: Efficacy and Safety of Supaglutide Monotherapy in Patients with Type 2 Diabetes","QINGHUA WANG","2023","Diabetes","randomized_trial","article","10.2337/db23-757-p",null,null,"ClinicalTrials.gov:NCT04994288","S001511","openalex","FALSE","paywalled","1","FALSE","article"],["R0046644","781-P: Efficacy and Safety of Switching to iGlarLixi from Twice-Daily (BID) Premixed Insulin (PI) Administration in People with Type 2 Diabetes (T2D)—Subanalysis of Soli-SWITCH Study","MARTIN HALUZIK","2024","Diabetes","other_trial","article","10.2337/db24-781-p",null,null,"EudraCT:2021-003711-25",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046645","The evolution of obesity pharmacotherapy from sympathomimetics to incretin-based therapies","KN Ncube","2026","SA pharmaceutical journal.","other","article","10.36303/sapj.4108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046646","Subcutaneous Weekly Semaglutide as Adjunct to Automated Insulin Delivery: A Double-blinded, Randomized, Crossover Trial","Melissa‐Rosina Pasqua","2024","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2024.09.022",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046647","Tirzepatide-Induced Weight Loss and Free Triiodothyronine Exhibit a Negative Correlation","Shuichi Okada","2025","Clinical Diabetology","other","article","10.5603/cd.105559",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046648","Unequal follow-up, not two findings: comment on GLP-1 receptor agonists and ischemic optic neuropathy in patients with type 2 diabetes and obesity","Abha Gahlot","2026","AJO International","other","article","10.1016/j.ajoint.2026.100301",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046649","Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease","Arne Janssen","2019","European Journal of Preventive Cardiology","randomized_trial","article","10.1177/2047487319891783","31801050",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046650","3 neue Cochrane-Reviews zu GLP-1-RA bei Erwachsenen mit Adipositas – Evidenz-Quickie","Denis Nößler","2025","EvidenzUpdate","other","article","10.69156/quick/2025.10.00002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046651","SEGURANÇA DO MEDICAMENTO OZEMPIC: UM OLHAR FARMACÊUTICO","AMANDA SANTANA BRITO MOTA","2024","Revista fisio&terapia.","other","article","10.69849/revistaft/cl10202412031225",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046652","FRI-139 Semaglutide provides liver health-related benefits in menopausal women living with MASH: a post hoc analysis of the ESSENCE trial part 1","Manal F. Abdelmalek","2026","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(26)01887-8",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0046653","Semaglutide (Ozempic): How off-Label Use Influences the Drug's Perspective","Giullia De Paula","2024",null,"other","article","10.62922/4cbffc.cp159",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0046654","GLP-1 agonists in addiction therapy – review","Paweł Gwałt","2026","Biuletyn Głównej Biblioteki Lekarskiej","randomized_trial","article","10.2478/bgbl-2026-0001",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046655","PE-208 : Complementary Liver Histological Effects of Mitochondrial Function Enhancer HSG4112, a Synthetic First-in-Class Small Molecule, and Semaglutide in a Diet-Induced and Biopsy-Confirmed Obese Mouse Model of Non-Alcoholic Steatohepatitis","Kyungil Kim","2020","춘·추계 학술대회 (KASL)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046656","127-OR: The Effect of Tirzepatide during Weight Loss on Metabolic Adaption, Fat Oxidation, and Food Intake in People with Obesity","Éric Ravussin","2023","Diabetes","randomized_trial","article","10.2337/db23-127-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046657","BEYOND THE SCALE: COMPREHENSIVE TREATMENT OPTIONS FOR YOUTH OBESITY","Magdalena Jabłonowska","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.4(48).2025.4236",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046658","Pharmacological Interventions in the Management of Antipsychotic-Induced Metabolic Disturbances","João Vasco Barreira","2025","European Psychiatry","randomized_trial","article","10.1192/j.eurpsy.2025.2064",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046659","729-P: Retrospective Effects of GLP-1 Receptor Agonists with and without Concomitant SGLT2 Inhibitor Use in Diabetic Renal Transplant Recipients after 12 Months","Francisca M. Acosta","2025","Diabetes","nonrandomized_study","article","10.2337/db25-729-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046660","Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs","Divya Rajagopal","2024","Journal of Diabetology","other_trial","article","10.4103/jod.jod_128_24",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0046661","Effects of GLP-1 Receptor Agonist on SIRT-1/PGC-1α Signaling Pathway in Isoprenaline-Induced Takotsubo Cardiomyopathy in Ovariectomized Female Rats","Hale SAYAN ÖZAÇMAK","2025","Bursa Uludag University - AVESIS","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046662","Is It Time to Review How We Use Proteinuria to Define Disease Activity in Glomerular Diseases?","Fádi Fakhouri","2026","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.0000001093","41842947",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0046663","4-OR: IL6R Signaling in Adipogenesis Mediates GLP-1 Analog Effects on Adipose Tissue Beiging","ABSALON D. GUTIERREZ","2022","Diabetes","preclinical","article","10.2337/db22-4-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046664","Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations","Do-Hyub Kim","2025","Journal of Pharmaceutical Investigation","other","article","10.1007/s40005-025-00762-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046665","S2884 The Role of Dulaglutide in Bowel Perforation","Ghaith Almhanni","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001040904.27362.ec",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046666","Glucagon Expression Is Regulated by Exendin-4 via CaMKK/AMPK/FoxO1 Pathway in Alpha TC1.6 Cells","Jingya Lyu","2018","Diabetes","preclinical","article","10.2337/db18-2164-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046667","106-OR: A First-in-Human Single Ascending Dose Study of Oxyntomodulin Analog LY3305677 in Healthy Subjects","Lai‐San Tham","2021","Diabetes","randomized_trial","article","10.2337/db21-106-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046668","Impact of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Patient-Reported Quality of Life in Adults: A Systematic Review Protocol","Alexandria Ratzki-Leewing","2026","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","preprint"],["R0046669","Effects of pH and Salts on the Aggregation State of Semaglutide and Membrane Filtration Performance","Lei Duan","2025","Separations","other","article","10.3390/separations13010015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046670","Obesity and Gynecologic Malignancies: A Narrative Review of Molecular Mechanisms and Clinical Management Challenges","Kateryna Bessmylna","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.56.72510",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0046671","Body composition analysis through menopause and andropause transition: Observational study of somatometric characteristics over time","Maria Karaflou","2025","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/nft3x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046672","863-P: SGLT2i Use and the Risk of Nephrolithiasis in Patients with T2D","Julie M. Paik","2022","Diabetes","nonrandomized_study","article","10.2337/db22-863-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046673","Impact of Semaglutide and Safinamide versus Bromocriptine on Parkinsonism induced in rats","Mohamed Hasan Mansour","2025","Benha Medical Journal","preclinical","article","10.21608/bmfj.2025.388219.2438",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046674","SAT-629 Treatment of Prediabetes and Obesity with Tirzepatide in a Patient with History of Type 1 Diabetes with Pancreas and Kidney Transplant","Jannel Liu","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046675","GLP-1 Receptor Agonists in Recreational Athletes: Emerging Weight-Reduction Strategy or Potential Health Risk? A Review of Current Evidence","Kamil Topolski","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.55.71600",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046676","Tirzepatide-Induced Ketoacidosis with Hyperglycemia in a Non-diabetic Patient: A Case Report","Mendel Shloush","2026",null,"case_report","article","10.25148/fiuir.139",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0046677","EE107 Long-Term Cost-Effectiveness of iGlarLixi Versus IDegLira in Patients With Uncontrolled Type 2 Diabetes Treated With Basal Insulin or Oral Antidiabetic Drug in China","Xiaoqiang Mo","2024","Value in Health","other","article","10.1016/j.jval.2024.03.406",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046678","1626-P: Liver-Specific Silencing of INHBE with ARO-INHBE, an siRNA Therapeutic, for Metabolic Diseases","Michelle Ngai","2024","Diabetes","preclinical","article","10.2337/db24-1626-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046679","26-A-15734-ACC CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS","Ravi Venkata Sai Krishna Medarametla","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.688",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0046680","743-P: Efficacy and Safety of VCT220 in Chinese Adults with Overweight or Obesity","LINONG JI","2025","Diabetes","randomized_trial","article","10.2337/db25-743-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046681","Dual Cardiorenal Coverage in Type 2 Diabetes: A Comprehensive Systematic Review and Meta-Analysis of GLP-1 Receptor Agonist and SGLT-2 Inhibitor Combination Therapy Versus Monotherapy Across Cardiovascular, Renal, and Metabolic Endpoints","Abdulrahman Alanazi","2026",null,"systematic_review","article","10.37766/inplasy2026.6.0007",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046682","SAT-215 Healthcare cost and resource utilization among patients with non-alcoholic steatohepatitis (NASH), stratified by glucagon-like peptide 1 receptor agonist (GLP-1) use in real world data","Yestle Kim","2024","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(24)01782-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046683","Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis","Anna Skowronek","2025","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2025.77.56953",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046684","PD52-09 EFFECT OF THE GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST, SEMAGLUTIDE IN OBESE MEN WITH MILD TO MODERATE ERECTILE DYSFUNCTION: A PROSPECTIVE OBSERVATIONAL STUDY","Edoardo Pozzi","2024","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001009412.04863.1b.09",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046685","Off-Trial: Real-World Weight Loss on Tirzepatide and Semaglutide","Shanmugesh Raja","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7119918",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0046686","1086-P: GLP-1 Promotes Osteogenic Differentiation of Human ADSCs via Wnt/GSK-3ß/ß-Catenin Pathway","Yun Li","2020","Diabetes","other","article","10.2337/db20-1086-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046687","The potential effect of Tirzepatide (Mounjaro) on Leptin hormone and some biochemical markers in Obese Iraqi individuals","Sulaiman M. Hasan","2026","Iraqi Journal of Science","other_trial","article","10.24996/ijs.2026.67.4.3",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0046688","A new long-acting GLP-1 derivative KTP ameliorates hyperglycemia and dyslipidemia and improves pancreas and fatty liver in db/db mice","Sang Sang","2013","中国科学通报：英文版","preclinical","article","10.1007/s11434-013-5915-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046689","Structural properties of short glucagon-like peptide-1 in various solvents investigated by molecular dynamics simulations","Hongyu Cao","2017","Journal of Theoretical and Computational Chemistry","other","article","10.1142/s0219633617500717",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046690","Effect of glucagon-like peptide-1 receptor agonists on blood pressure: a systematic review and meta-analysis","Christian Basile","2025","European Journal of Preventive Cardiology","systematic_review","article","10.1093/eurjpc/zwaf236.127",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0046691","Treatment Gap in Nephroprotection: Analysis of Prior Use of Drugs with Nephroprotective Effects in Patients with Incidental Diagnosis of Diabetic Kidney Disease","Donna Lira","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025kwhpmakv",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046692","A-97 | Impact of GLP-1 Receptor Agonist on Outcomes After Carotid Endarterectomy in Patients with Diabetes: A Real-World Propensity-Matched Analysis","Ayodeji Ilelaboye","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104588",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0046693","INTENSIFY: effectiveness of insulin degludec/liraglutide (IDegLira) in a real-world T2DM population in the UAE","Fatheya Al Awadi","2021",null,"nonrandomized_study","article","10.26226/morressier.61a8b7aabe545488cfae58b7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","other"],["R0046694","GLP-1 Receptor Agonist Therapy and Incident Atrial Fibrillation in Non-Diabetic Adults with Obesity and Chronic Kidney Disease: A Propensity Matched Cohort Study","Abdulraheem Hassan","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7083106",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0046695","PET imaging of glucagon-like peptide receptor upregulation after myocardial ischemia/reperfusion injury","Haokao Gao","2012","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046696","744-P: Efficacy and Safety of BGM0504 in Chinese Patients with Obesity—A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial","Jiandong Yuan","2025","Diabetes","randomized_trial","article","10.2337/db25-744-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046697","Health Promotion Board–Ministry of Health Clinical Practice Guidelines: Obesity","Yung Seng Lee","2016","Singapore Medical Journal","other","article","10.11622/smedj.2016141",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046698","PP-30 Anhedonia and Increased Alcohol Consumption Following Tirzepatide Use: A Case Report","Deniz Kaya","2026","Turkish Journal of Psychiatry","case_report","article","10.5080/61upk.ozt519",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046699","Glucagon-like peptide 1 receptor agonists and the risk of developing malignancies of the liver.","Ameera Syed","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.2_suppl.525",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046700","Choice of Therapy in Obese Type 2 Diabetes","VivekaP Jyotsna","2022","Chronicle of Diabetes Research and Practice","other","article","10.4103/cdrp.cdrp_2_22",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046701","Tirzepatide for the treatment of adults with type 2 diabetes","Steve Chaplin","2023","Prescriber","other_trial","article","10.1002/psb.2081",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0046702","Ozempic para fins de emagrecimento","Maria Eduarda de Oliveira Pereira","2025","Congresso Médico Acadêmico UniFOA.","other","article","10.47385/cmedunifoa.2094.2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0046703","SUN-661 Impact of GLP-1 Analogs vs. Lipid Lowering Agents on Risk for Acute Pancreatitis in Hypertriglyceridemia: A TriNetX Analysis","Alyssa Kang","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.171",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046704","Congress wrap-up: ESC Preventive Cardiology 2024 in Athens","Nicolle Kränkel","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae329","39190608",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046705","1227-P: Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease—Results from the EMPRISE Study","PHYO T. HTOO","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1227-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046706","Impact of concomitant GLP-1 receptor agonist use on overall survival and chemotherapy-related adverse events in colorectal cancer: A real-world pharmacoepidemiologic cohort study.","Arunkumar Krishnan","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.3661",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046707","The efficacy of glp-1 analogue therapy in patient with hypotalamic obesity","Bojana Carić","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.ep45",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046708","Sex Differences in the Oxidative Stress Level and Antioxidative Enzymes Activity in Obese Pre-Diabetic Elderly Rats Treated with Metformin or Liraglutide","Anita Ćosić","2016",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046709","Treatment intensification in type 2 diabetes mellitus and obesity.","Zawiejska A","2013","The British journal of general practice : the journal of the Royal College of General Practitioners","case_report","article","10.3399/bjgp13x665152","23540457","PMC3609446",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Case Reports; Letter; article"],["R0046710","A-110 | Long-Term Cardiovascular and Arrhythmic Benefits of GLP-1 Receptor Agonists in Anticoagulated Atrial Fibrillation Patients: A Retrospective Cohort Study","Amir Behzad Bagheri","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104601",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0046711","425-P: Renin-Angiotensin System Inhibition in Combination with Glucagon-Like Peptide 1 Receptor Agonist Treatment Improve Levels of a Kidney Fibrosis Biomarker in Persons with Type 2 Diabetes","Alexandra Louise Møller","2023","Diabetes","nonrandomized_study","article","10.2337/db23-425-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046712","Editorial: Novel insights into the pathophysiology of diabetes-related complications: implications for improved therapeutic strategies, volume II","Jian Ma","2025","Frontiers in Endocrinology","commentary","article","10.3389/fendo.2025.1570628","40084141",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0046713","Mo1262 ENDOSCOPIC FINDINGS IN PATIENTS ON GLP-1 RECEPTOR AGONISTS PRESENTING WITH DYSPEPSIA: A PROPENSITY-MATCHED COHORT ANALYSIS","Oleksandr Shumeiko","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)06240-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046714","Drug Therapy: Special Considerations in Diabetes","Bernard M.Y. Cheung","2016",null,"other","article","10.1002/9781118924853.ch28",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0046715","PDB5 Effectiveness of Dulaglutide and Liraglutide in Glycemic Control, Weight Loss and Blood Pressure Reduction: A Systematic Review and Meta-Analysis","J.Y. Ye","2020","Value in Health","systematic_review","article","10.1016/j.jval.2020.08.602",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0046716","The Evolving Role of Bariatric Surgery in Children and Adolescents Amid the Rise of GLP-1 Receptor Agonists","Joanna Jabłońska","2026","Quality in Sport","other","article","10.12775/qs.2026.62.73665",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046717","Semaglutide: a new GLP‐1 analogue for type 2 diabetes","Steve Chaplin","2019","Prescriber","other","article","10.1002/psb.1784",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046718","Primary prevention of acute leukemias in high-risk patients: The therapeutic promise of GLP-1 receptor agonists.","Jonathan Dao","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.10507",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046719","S1175 Do Weight Loss Medications Reduce the Risk of Cirrhosis and HCC?","Sophie Trujillo","2021","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000778232.15515.30",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046720","1359-P: Gaps in the Use of Evidence-Based Diabetes Medications for NASH","Anastasia‐Stefania Alexopoulos","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1359-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046721","Glucagon-like Peptide-1 Receptor Agonists and Endometrial Cancer: Potential Future in Fertility-Sparing Treatment","Sonia Kotanidou","2026","Reproductive Medicine","other","article","10.3390/reprodmed7030034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046722","CARDIOVASCULAR IMPACT OF GLP1 AGONISTS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA","Xin Ya See","2024","CHEST Journal","other","article","10.1016/j.chest.2024.07.124",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046723","1086-P: A Retrospective Nationwide Surveillance on the First-Line Antidiabetic Medication for the Patients with Type 2 Diabetes in Japan","Ryotaro Bouchi","2021","Diabetes","nonrandomized_study","article","10.2337/db21-1086-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046724","SAT-236 Efficacy and safety of incretin-based therapies in patients with metabolic dysfunction-associated steatotic liver disease complicated by type 2 diabetes mellitus","Tadamichi Kawano","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)01794-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046725","Diabetes and Frailty-Interactions and Clinical Implications","Alan J. Sinclair","2025",null,"other","article","10.1201/9781003398295-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0046726","12624 The Efficacy Of Glp1 Receptor Agonists As Adjunct Therapy To Insulin In Patients With Type 1 Diabetes: A Meta-analysis","Maria Abi Azar","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.958",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0046727","HSD80 GLP-1 THERAPY IMPROVES GLYCEMIC CONTROL WITH NO DIFFERENCE IN MEDICAL SPENDING: A REAL-WORLD EFFECTIVENESS STUDY","Vrushabh P. Ladage","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.1317",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046728","Evidence-based positioning of SGLT2IS and GLP-1 RAS in the management of chronic kidney disease with type 2 diabetes and overweight/obesity : a systematic literature review","Yehuda Handelsman","2026","Digitalen Hochschulbibliothek Sachsen-Anhalt (Universitäts- und Landesbibliothek Sachsen-Anhalt)","narrative_review","article","10.25673/123606",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0046729","Rhabdomyolysis: An Adverse Effect of Semaglutide?","Manuel A. Valle Moradel","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025968dc2tt",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046730","Transzonal Projections and Follicular Development Abnormalities in Polycystic Ovary Syndrome","Dan Cheng","2025","PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS","other","article","10.3724/j.pibb.2025.0182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046731","Beyond Glycemic Control: The Expanding Role of GLP-1 Analogues in Type 2 Diabetes and Metabolic Health","Michał Mazur","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.36.56722",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046732","GLP-1 receptor agonists in patients with alcohol use disorder and related liver disease: a systematic review and meta-analysis","Pedram Pirmoradian","2026","European journal of medical research","systematic_review","article","10.1186/s40001-026-04867-y",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0046733","SGLT-2 inhibitors do not decrease tsh levels despite weight reduction, unlike GLP-1 agonists","Mikuláš Kosák","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep856",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046734","GLP-1 agonists in pediatric obesity: an integrative perspective on cell signaling, development, and metabolism","Pedro Víctor Carvalho","2025","International Journal of Molecular Biology Open Access","other","article","10.15406/ijmboa.2025.08.00198",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046735","Tirzepatide and thyroid function in adults with type 2 diabetes or obesity: a systematic evidence map and data gap analysis","Danilo Caponio","2026","Obesity Medicine","other","article","10.1016/j.obmed.2026.100696",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046736","Abstract 4369008: Dual Therapy with Semaglutide and Physical Training Lowers Cardiorenal Burden in Experimental DKD and renal cells","Maria de Fátima Fernandes Vattimo","2025","Circulation","preclinical","article","10.1161/circ.152.suppl_3.4369008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046737","IMPACT OF SEMAGLUTIDE USE ON LEAN MASS AND SARCOPENIA RISK: AN INTEGRATIVE REVIEW OF CLINICAL EVIDENCE","Valéria Goulart Viana","2026","Seven Editora eBooks","randomized_trial","article","10.56238/sevened2026.009-036",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","book-chapter"],["R0046738","2008-P: Association between ZIP-Code Level, Obesity Prevalence, and Antiobesity Medication Persistence","Johnson Y. Osei","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2008-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046739","胰高血糖素样肽-1受体PET/CT定位诊断胰岛素瘤的技术规范","罗亚平","2020",null,"other","article","10.3969/j.issn.1674-9081.2020.04.022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046740","EE738 Treatment With Semaglutide Reduces the Complication Costs Among Type 2 Diabetes Patients With CKD in China: A Short-Term Cost Analysis Based on the FLOW Trial","Ying Chen","2025","Value in Health","other_trial","article","10.1016/j.jval.2025.09.1116",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0046741","News and Reviews","Diogenes","2007","Age and Ageing","other","article","10.1093/ageing/afm103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046742","A Sustainable Chemo-Enzymatic Approach to the Synthesis of Liraglutide","S. Rizzo","2024","ACS Sustainable Chemistry & Engineering","other","article","10.1021/acssuschemeng.4c07543",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046743","1515-P: Pyruvate Kinase Amplifies Insulin Secretion Downstream of the ß-Cell GLP1 Receptor","Hannah R. Foster","2024","Diabetes","preclinical","article","10.2337/db24-1515-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046744","Glucagon-Like Peptide-1 Receptor Agonists in People With Human Immunodeficiency Virus: An Expanded Meta-Analysis of Metabolic Outcomes","Thomas Barnett","2025","Cellular and Molecular Medicine Research","systematic_review","article","10.14740/cmmr114",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046745","PP025-MON EXENDIN-4 INHIBITS INOS EXPRESSION AT THE PROTEIN LEVEL IN LPS-STIMULATED RAW264.7 MACROPHAGE BY THE ACTIVATION OF CAMP/PKA PATHWAY","Seo‐Yoon Chang","2012","Clinical Nutrition Supplements","other","article","10.1016/s1744-1161(12)70364-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046746","Management of Diabetic Kidney Disease","U. Ayyagari","2025","International journal of clinical metabolism and diabetes.","other","article","10.1177/30502071261427510",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046747","Persistence-dependent effectiveness of tirzepatide on the cardio-metabolic-kidney syndrome outcomes in obesity","Imran Rangraze","2026","DiRROS repository (University of Maribor)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046748","Bridging the Knowledge Gap: A Scoping Review of GLP-1 Receptor Agonists and Oral Health in the Era of Technology-Enabled Dentistry","SURVEEN SINGH","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0046749","GLP-1 Receptor Agonists and the Risk of Thyroid Cancer","Amandine Gouverneur","2022","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0046750","Update NDF Voedingsrichtlijn 2020","Iris van Damme","2024","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-024-1562-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046751","Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?","Gerald F. Watts","2024","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwae095","38446991",null,"ClinicalTrials.gov:NCT05610280",null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0046752","Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects","Satoru Kuriyama","2022","Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics","other","article","10.3999/jscpt.53.6_249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046753","Liraglutide Reduces Adipogenesis in Human Orbital Fibroblasts in Graves’ Orbitopathy","Chih-Wei Shih","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6318438",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046754","GIP/GLP-1 DUAL AGONIST TIRZEPATIDE AMELIORATES RENAL ISCHEMIA/REPERFUSION DAMAGE IN RATS","Ghada A. Alkhafaji","2025","International Journal of Applied Pharmaceutics","preclinical","article","10.22159/ijap.2025v17i2.53156",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046755","Supplements claiming to work like Ozempic and Wegovy are now being sold – here’s what the evidence actually says about these products","Duane Mellor","2024",null,"other","article","10.64628/ab.uwc57unmm",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0046756","CO61 Suicidal Ideation in Patients Treated With Glucagon-like Peptide 1 Receptor (GLP1) Agonists: A Retrospective Real-World Analysis","Geoff Severtson","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.146",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0046757","S2328 The Effect of GLP-1 RA Use on Gastric Emptying and Gastroparesis Symptoms in Patients With Diabetic Gastroparesis: A Systematic Review","Jacob Itkin","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001038680.08387.b9",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0046758","SAT-631 Glucagon-Like Peptide-1 Receptor Agonist Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-Analysis","Francinny Alves Kelly","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.2289",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046759","Letter to the Editor: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality","Zheyu Li","2023","Hepatology","commentary","article","10.1097/hep.0000000000000377","36932712",null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0046760","Repercussões psiquiátricas do uso de tirzepatida (mounjaro) em adultos com obesidade: revisão de escopo","Cesário Monteiro Ruas","2026","Cadernos Cajuína","other","article","10.52641/cadcajv11i3.1943",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046761","Retour d’expérience concernant l’utilisation, l’efficacité et la tolérance du liraglutide 3 mg (Saxenda®) en vie réelle chez 153 patients : l’étude SAX-RL","M. Goeau Brissonniere","2023","Annales d Endocrinologie","other","article","10.1016/j.ando.2023.07.047",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046762","72930 The Effect of Specific GLP-1RAs on Wound Healing after Mohs Surgery in Overweight Non-Diabetic Patients","Paola Ramirez","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.1724",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046763","Should we shift from delaying diabetes to pursuing pre-diabetes remission for cardiovascular disease prevention?","Zhitong Li","2026","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2026.03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046764","IDDF2026-ABS-0341 GLP-1 receptor agonists and clinical outcomes in non-diabetic patients with chronic pancreatitis: a real world cohort study","Arkadeep Dhali","2026","Clinical Gastroenterology","nonrandomized_study","article","10.1136/gutjnl-2026-iddf.323",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0046765","Quality and Safety of YouTube Videos on GLP-1 Receptor Agonists and Reproductive Health: A Systematic Evaluation Using Validated Instruments and Artificial Intelligence (Preprint)","Çağlayan Biçer","2026",null,"other","article","10.2196/preprints.101296",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046766","Semaglutide Induces Local AHR-dependent Prothrombotic Changes in the Vessel Wall, Augmenting Deep Vein Thrombosis in Obese Mice","Kashvi Sethamuran","2026","Journal of Vascular Surgery","preclinical","article","10.1016/j.jvs.2026.03.397",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046767","Effects of semaglutide, peptide YY3-36 and empagliflozin on metabolic dysfunctionsassociated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthase-inhibition","Niklas Geiger","2024","Endocrine Abstracts","preclinical","article","10.1530/endoabs.102.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046768","Effect of glucagon-like peptide-1 agonist on insulin signaling pathway in skeletal muscle of mice with insulin resistance","Xiaoyi Xu","2016","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2016.04.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046769","Mind over metabolism: a systematic review of GLP-1 receptor agonists in the treatment of stress-related disorders","Charlotte Rye","2026","Translational Psychiatry","systematic_review","article","10.1038/s41398-026-04425-4",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046770","EE6 COST-EFFECTIVENESS OF TIRZEPATIDE FOR THE MANAGEMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION AND OBESITY","Tadesse M Abegaz","2026","Value in Health","other","article","10.1016/j.jval.2026.03.302",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046771","MM-837: GLP-1 Receptor Agonists Are Associated With Significantly Reduced All-Cause Mortality, Hospitalization, and Sepsis in Patients With Multiple Myeloma and Type 2 Diabetes: A Propensity Score–Matched Analysis of the TriNetX Global Collaborative Network","Ekow Pinkrah","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)02939-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046772","S2756 GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Efficacy and Safety","Mazhar Shapoo","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001138484.16960.b7",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046773","Lean Mass Preservation During Incretin-Based Obesity Pharmacotherapy: A Scoping Evidence Map of Nutrition, Resistance Exercise, Body Composition Outcomes, and Registered Trials","Alejandro Bruna-Mejías","2026",null,"other","article","10.17605/osf.io/4x5rv",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046774","Analysis of the safety profile of retatrutide based on phase I and II clinical trials","Kinga Brzdęk","2025","Lekarz Wojskowy","other_trial","article","10.53301/lw/197354",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0046775","Treatment Patterns in Patients with Newly Diagnosed Type 2 Diabetes in 2015","Jianmin Wu","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1648-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046776","Comparative Risk of Dementia after Initiation of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in T2D","Fu‐Shun Yen","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5363080",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046777","MON-609 Use of a Continuous Glucose Monitor System (CGM) in Latinx Patients with Type 2 Diabetes (TD2) Improves A1c without an Effect on Weight: Real Life Observational Experience","L. Garcia","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.971",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046778","Skin manifestations associated with Glucagon-Like Peptide-1 (GLP-1) receptor agonist use for weight loss: A cross-sectional analysis","Yahya Argobi","2026","Journal of Pakistan Association of Dermatologists","other","article","10.66344/jpad.v36i1.3221",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046779","Beyond phenogroups: towards a continuous biology of HFpEF","S Störk","2026","European Journal of Heart Failure","nonrandomized_study","article","10.1093/ejhf/xuag130","42008131",null,null,null,"openalex","FALSE","paywalled","4","FALSE","editorial"],["R0046780","Diabetes and menopause: A critical yet neglected intersection","Isabell Haage","2026","Diabetic Medicine","other","article","10.1111/dme.70298","41885705",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046781","ESC/EASD guideline sheds light on diabetes and cardiovascular disease management","Steve Chaplin","2020","Practical Diabetes","randomized_trial","article","10.1002/pdi.2256",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046782","S789 Temporal Patterns in GLP-1 Receptor Agonist and Bariatric Surgery Use Among Patients With Diabetes Mellitus and Obesity in the United States","Omar Al Ta’ani","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001130616.49570.f5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046783","GLP-1 medicine and non-arteritic anterior ischemic optic neuropathy: Literature review and perspectives","Jia Nuo Feng","2025","Metabolism and Diseases","nonrandomized_study","article","10.1016/j.metdis.2025.100001",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046784","A Graph Convolutional Network (GCN) Framework to Identify Patients at High Risk for GLP-1 Agonist Discontinuation","K. Shoba and B. C. Surekha Merwin Paul. R","2026",null,"nonrandomized_study","article","10.1109/icmsci67830.2026.11469215",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0046785","정신건강의학과 환자에서의 Liraglutide의 효과 및 안전성","최영재","2020","신경정신의학","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0046786","26-A-13687-ACC SAFETY AND EFFICACY OF GLP-1 RECEPTOR AGONISTS IN HEART FAILURE WITH REDUCED AND MILDLY REDUCED EJECTION FRACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS","Lorenzo Bianchi","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.1890",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046787","203.8: Metabolic bariatric surgery vs GLP-1 receptor agonists in dialysis patients with diabetes and obesity: A target trial emulation study.","Babak J. Orandi","2026","Transplantation","nonrandomized_study","article","10.1097/01.tp.0001249444.65141.3e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046788","Clinical Efficacy, Mechanism of Action, and Adverse Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes – a Systematic Review","Łukasz Starczewski","2026","Quality in Sport","systematic_review","article","10.12775/qs.2026.54.70481",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046789","Glucagon-like peptide-1 agonists and total shoulder arthroplasty outcomes: using natural language processing to assess postoperative risks and complications","Troy B. Amen","2026","Seminars in Arthroplasty JSES","other","article","10.1016/j.sart.2026.151556",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046790","TPW 6.14 Effect of Saxenda on Pre-operative Bariatric Patients for Weight Reduction","Aslesha Deshraju","2026","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znag087.367",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046791","GLP-1 receptor agonists and SGLT2-inhibitors in patients with diabetes and ischaemic heart disease in primary care","T Andersson","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.3816",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046792","1032-P: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM","Hideaki Kaneto","2019","Diabetes","randomized_trial","article","10.2337/db19-1032-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046793","Perioperative Management and Perspectives of GLP-1 Receptor Agonist Use: A Cross-Sectional Survey of Practicing Anesthesiologists","Christopher T. Nguyen","2026","Translational Perioperative and Pain Medicine","other","article","10.31480/2330-4871/217",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046794","A potential improvement of rheumatoid arthritis in a patient treated with liraglutide for glucocorticoid-induced diabetes","Michiko Kohno","2013","Tōnyōbyō/Tounyoubyou","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046795","Le double agoniste GLP−1/GIP, Tirzepatide, combine les effets bénéfiques des deux incrétines sur la fonction et la survie de la cellule betapancréatique","Nour Zaïmia","2021","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0046796","Protective effects of liraglutide on the injury of retinal ganglion cells induced by hyperglycemia","Xuefei Ma","2018","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2018.05.010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046797","850-P: Greater HbA1c Reduction with iGlarLixi vs. Insulin Glargine and Lixisenatide Regardless of Levels at Screening: Subgroup Analysis of the LixiLan-O Asia Pacific Trial","YIFAN HE","2022","Diabetes","randomized_trial","article","10.2337/db22-850-p",null,null,"ClinicalTrials.gov:NCT03798054","S000170","openalex","FALSE","paywalled","1","FALSE","article"],["R0046798","1682-P: Weight Endpoints in Randomized Controlled Trials (Rcts) of Adults Eligible for Antiobesity Medications (AOM)—A Systematic Literature Review (SLR)","Alison M. Bjornson","2024","Diabetes","randomized_trial","article","10.2337/db24-1682-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","review"],["R0046799","Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists isproportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials","Masashi Hasebe","2025","Institutional Repositories DataBase (IRDB)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0046800","MSR30 Applying G-methods to Account for Treatment Switching in Postmarketing Effectiveness Evaluation: A Case Study of GLP-1 Receptor Agonists for Diabetic Kidney Disease","Zi‐Yang Peng","2025","Value in Health","other","article","10.1016/j.jval.2025.09.3321",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046801","Interpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy","Thijs T Jansz","2026","The Lancet Primary Care","other","article","10.1016/j.lanprc.2026.100201",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046802","Short-Term Treatment Response Outcomes of Semaglutide Combined With Dapagliflozin in Overweight or Obese Patients With Early Diabetic Nephropathy","Mengmeng Zheng","2026","Discovery Medicine","nonrandomized_study","article","10.24976/discov.med.202638210.164",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046803","Uso de agonistas del receptor GLP-1 en adultos sin diabetes para reducir eventos cardiovasculares mayores: revisión sistemática de la evidencia clínica","Daniel Sánchez Knupflemacher","2025","Revista Científica de Salud y Desarrollo Humano","other","article","10.61368/r.s.d.h.v6i2.659",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046804","Novel Approach to Sarcopenia in Diabetic Patients Treated with GLP-1 Receptor Agonists (GLP-1RA)","SHIN IKEJIMA","2018","Diabetes","other","article","10.2337/db18-673-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046805","Effect of Prehabilitation with GLP-1 Agonists in Obese Patients Undergoing Abdominal Wall Reconstruction or Complex Hernia Repair: A Scoping Review","Mable Pereira","2026","Formosan Journal of Surgery","narrative_review","article","10.1097/fs9.0000000000000298",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046806","Léčba agonisty receptoru pro GLP1 a kontrola hmotnosti","Petr Žák","2015","Vnitřní lékařství","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046807","Abstract MPTU08: Semaglutide versus liraglutide and incidence of diabetes and cardiovascular disease: a target trial emulation using real-world data","Ethan Cannon","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.mptu08",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046808","Efecto de liraglutide sobre los niveles de andrógenos séricos y la función sexual en mujeres con obesidad","Franklin Espitia de la Hoz","2022","Revista Colombiana de Endocrinología Diabetes & Metabolismo","other","article","10.53853/encr.8.3.685",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046809","Emerging Role of Dual Agonists in Metabolic Disease Management: Clinical Outcomes and Safety Considerations – A Review Study","Akter Sraboni","2026","Review of Medicine Surgery and Dentistry","nonrandomized_study","article","10.64907/xkmf.v5.i1.rmsd.1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046810","Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","J.C. LaRocque","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/sf7g-9004",null,null,"ClinicalTrials.gov:NCT02849080; EudraCT:2015-005593-38","S001153","openalex","TRUE","paywalled","1","FALSE","article"],["R0046811","EP453 - ECE_3084 - Two cases of immunotherapy-induced type 1 diabetes: clinical characteristics, presentation and the role of technology","Vasiliki Antonopoulou","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.956",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046812","Acute hyperglycaemia after COVID-19 vaccination in patients with stable diabetes: A Case Series (Preprint)","Rahila Bhatti","2021",null,"case_report","article","10.2196/preprints.27401",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046813","Ozempic (Semaglutide) for the treatment of obesity: advantages and disadvantages from an integrative analysis","Hanna Benayon Oliveira Sabbá","2022","Research Society and Development","preclinical","article","10.33448/rsd-v11i11.33963",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046814","Adverse drug reactions associated with antidiabetic drugs and their reporting through pharmacovigilance in India","Seema Mishra","2024","Journal of Pharmacognosy and Phytochemistry","nonrandomized_study","article","10.22271/phyto.2024.v13.i5b.15061",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046815","L26/P-760 Phenotype-specific progression of insulin resistance and hyperandrogenism in polycystic ovary syndrome: A 15-year longitudinal HOMA-IR and FAI trajectory analysis","Y. J. Kim","2026","Human Reproduction","nonrandomized_study","article","10.1093/humrep/deag083.1087",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046816","“Weight loss, Semaglutide and Manic Episode”: A case report","Jesús González","2024","European Psychiatry","case_report","article","10.1192/j.eurpsy.2024.452",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046817","БІОХІМІЧНІ МЕХАНІЗМИ ТА ТЕРАПЕВТИЧНИЙ ПОТЕНЦІАЛ ДІЄТОТЕРАПІЇ, НУТРИЦЕВТИКІВ ТА СУЧАСНИХ ІНКРЕТИНОМІМЕТИКІВ (TIRZEPATIDE) У МЕНЕДЖМЕНТІ ЦД 2","Тетяна Андреєва","2025",null,"other","article","10.36074/logos-19.12.2025.043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0046818","O uso de agonistas do receptor de GLP-1 no auxílio de distúrbios da fertilidade feminina: uma revisão sistemática acerca desta interação","Gabrielle Gonçalves dos Santos","2024","Jornal Brasileiro de Ginecologia","other","article","10.5327/jbg-2965-3711-2024134s1103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0046819","673-P: Effect of Once-Weekly Dulaglutide 3.0 and 4.5 mg in Patients with Different Baseline Renal Function: Post-hoc Analysis from the Award-11 Trial","Luis‐Emilio García‐Pérez","2021","Diabetes","randomized_trial","article","10.2337/db21-673-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046820","Implicit Evaluations of Junk Foods Among GLP-1 Users and Non-Users","Oskar Pineño","2026",null,"other","article","10.17605/osf.io/f3d2h",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046821","Gliptins: Does this New Class of Antidiabetic Drugs Possess Endothelial-Vasculoprotective Effects?","Tina Bharani","2016","Qatar Foundation Annual Research Conference Proceedings Volume 2016 Issue 1","preclinical","article","10.5339/qfarc.2016.hbsp3253",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0046822","GLP-1 Receptor Agonists and Clinical Periodontal Outcomes: A Scoping Review","Qazi Jawad Hayat","2026",null,"narrative_review","article","10.17605/osf.io/7wa25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046823","Association of glucagon-like peptide-1 receptor agonist therapy with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis","Dorsa Shekouh","2026","Diabetology & Metabolic Syndrome","systematic_review","article","10.1186/s13098-026-02268-z",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0046824","Wirksamkeit und Sicherheit von iGlarLixi bei unter basalunterstützter oraler Therapie (BOT) unzureichend eingestellten Typ-2-Diabetespatienten – Ergebnisse der prospektiven Beobachtungsstudie CHANCE","Tobias Wiesner","2024","Diabetologie und Stoffwechsel","other","article","10.1055/s-0044-1785276",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046825","GLP-1 Receptor Agonists and Pulmonary Outcomes in Rheumatoid Arthritis: A Propensity Score-Matched Retrospective Cohort Study","Betul Ibis","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7169039",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0046826","BNP AND NT-PRO BNP AS INDEPENDENT DIAGNOSTIC BIOMARKERS FOR CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES MELLITUS","Balaji Vijayam","2022","Innovare Journal of Medical Sciences","other","article","10.22159/ijms.2022.v10i5.45992",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046827","CARDIOPROTECTIVE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS: A REVIEW OF RANDOMIZED CLINICAL TRIALS","Т. S. Zaikina","2026","Bulletin of Problems Biology and Medicine","randomized_trial","article","10.29254/2077-4214-2026-2-181-62-67",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0046828","Efeito dos Agonistas do Receptor de GLP-1 na Fertilidade de Mulheres com Síndrome dos Ovários Policísticos: Uma Revisão Sistemática","Emanuelle","2026",null,"other","article","10.17605/osf.io/kyqz5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046829","SAT0295 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AMELIORATED MUSCLE WEAKNESS AND INFLAMMATION IN EXPERIMENTAL POLYMYOSITIS","Mari Kamiya","2020","Annals of the Rheumatic Diseases","other","article","10.1136/annrheumdis-2020-eular.1597",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046830","Neuroprotection of Exenatide in rats with diabetic peripheral nerve injury","Wen Wang","2011","Journal of Clinical Neurology","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046831","1271-PUB: Real-World Effectiveness of Newly Initiated Once-Weekly Semaglutide (sema OW) by Prescriber Specialty","Nitin Shivappa","2021","Diabetes","nonrandomized_study","article","10.2337/db21-1271-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046832","TIRZEPATIDA (MOUNJARO®) COMO AGONISTA DUPLO GIP/GLP-1: BASES FARMACOLÓGICAS E MECANISMOS DE AÇÃO","Daniela Gomes Rocha","2025",null,"other","article","10.63330/aurumpub.024-042",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0046833","The impact of tirzepatide on lipid profile based on the SURMOUNT clinical trials","Kinga Brzdęk","2024","Lekarz Wojskowy","other","article","10.53301/lw/189579",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046834","Peptides for therapeutic applications – challenges and chances","Chiara Ruggirello","2024","Pure and Applied Chemistry","other","article","10.1515/pac-2024-0104",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046835","TIRZEPATIDE AND RETATRUTIDE IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS: CURRENT EVIDENCE AND FUTURE DIRECTIONS. A SYSTEMATIC REVIEW OF CURRENT LITERATURE","Rafał Bednarczyk","2026","International Journal of Innovative Technologies in Social Science","systematic_review","article","10.31435/ijitss.1(49).2026.4671",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0046836","PO353 EFFECT OF GLP-1 ANALOGUE LIRAGLUTIDE ON PREVENTION OF CARDIOMYOCYTES APOPTOSIS INDUCED BY ANOXIA/REOXYGENATION","Yafang Shen","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70647-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046837","APLICABILIDADE DOS AGONISTAS DO RECEPTOR DE GLP-1 EM DOENÇAS DERMATOLÓGICAS IMUNOMEDIADAS REFRATÁRIAS: PERSPECTIVAS TERAPÊUTICAS NA PSORÍASE","Caroline Oliveira Gomes","2025","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v11i12.23068",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046838","Polycystic Ovarian Disease (PCOD) And Women’s Health: Challenges And Emerging Solutions","Vinay Gaurav","2024","International Journal of Environmental Sciences","other","article","10.64252/r1d3re34",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046839","1696-P: Effect of Semaglutide on COVID-19–Related Complications and All-Cause Death: Pooled Analyses of the SELECT, FLOW, and SOUL Trials","BENJAMIN SCIRICA","2026","Diabetes","randomized_trial","article","10.2337/db26-1696-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046840","26-LB: Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter, Randomized, Parallel Study","Xiangyu Wang","2020","Diabetes","randomized_trial","article","10.2337/db20-26-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046841","P1039 Effectiveness and Safety of GLP-1 Receptor Agonists in Reducing Ostomy Output Among IBD Patients with Ileostomies","C M Duty","2026","Journal of Crohn s and Colitis","nonrandomized_study","article","10.1093/ecco-jcc/jjaf231.1220",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046842","1728-P: Large-Scale Proteomic Discovery of Prognostic and Treatment-Responsive CKD Biomarkers in SELECT","PETTER BJORNSTAD","2026","Diabetes","other_trial","article","10.2337/db26-1728-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046843","Engineered exosomal delivery of semaglutide activates SIRT1–FOXO3a–miR-124 signaling and protects against cortical neuroinflammation","Elsayed A. Elmorsy","2026","Journal of Drug Delivery Science and Technology","other","article","10.1016/j.jddst.2026.108078",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046844","OBESITY DISEASE - NON-SURGICAL TREATMENT METHODS - A LITERATURE REVIEW","Zuzanna Rabczak","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3566",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046845","Investigation of GLP-1RA semaglutide and systemic inflammation index ratios in type 2 diabetes with and without retinopathy: a retrospective study","Amani Y. Alhalwani","2026","BMC Endocrine Disorders","nonrandomized_study","article","10.1186/s12902-026-02558-7",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046846","Subcutaneous Semaglutide as a bridge to Kidney Transplant Waitlisting in Obese Patients with Type 2 Diabetes Receiving Kidney Replacement Therapy: A 12-Month Prospective Pilot Study","Katia Pérez del Valle","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7404807",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046847","α‐Adrenergic regulation of blood flow in HFpEF: too much and not enough","Christopher M. Hearon","2024","The Journal of Physiology","other","article","10.1113/jp286912","38923435",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046848","Diabetes and cardiovascular prevention: bridging two epidemics","Laurence Salle","2025","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf737","41493054",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046849","#1704142 Evaluating the Association Between Early Body Weight Changes with Tirzepatide and Categorical Weight Reduction in People with Obesity or Overweight: a Post-Hoc Analysis","Brandi Addison","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.261",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046850","Mapping the spectrum of reported adverse effects associated with glucagon-like peptide-1 receptor agonists for weight management in adults: a scoping review protocol","Ghadeer Alenezi","2026",null,"protocol","article","10.17605/osf.io/2rj8u",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0046851","Two cases of alopecia induced by liraglutide during the treatment of type 2 diabetes","Chen Chen","2013","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2013.09.022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046852","118.2: Characterization of neonatal porcine islets during in vitro cultivation as a tool for quality control in xenotransplantation","Martin Kraetzl","2023","Transplantation","preclinical","article","10.1097/01.tp.0000993892.70497.80",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046853","Propensity Score Matching Accounting for Longitudinal Trends Before Baseline with Group-based Trajectory Modeling","Dustin Bastaich","2026","VCU Scholars Compass (Virginia Commonwealth University)","nonrandomized_study","article","10.25772/ptqt-xf74",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0046854","MAJOR ADVERSE CARDIOVASCULAR EVENTS ARE LESS FREQUENT IN PSORIASIS PATIENTS STARTING GLP-1RA COMPARED TO CONTROLS: AN OBSERVATIONAL RETROSPECTIVE COHORT STUDY","Ana Ormaza Vera","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(25)00932-5",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046855","Impact of oral semaglutide on liver pathology and glucose metabolism in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus","Tadamichi Kawano","2023","Journal of Hepatology","other","article","10.1016/s0168-8278(23)02280-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046856","Largest, Five-Year Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Kidney Transplant Recipients a Retrospective Single-Center Study","Priyamvada Singh","2025","American Journal of Transplantation","randomized_trial","article","10.1016/j.ajt.2025.07.914",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046857","Potenciais efeitos colaterais de Ozempic®, Mounjaro® e outros emagrecedores na cavidade oral: revisão de literatura","Gabriela Santana de Castro Lopes","2025","Brazilian Journal of Health Review","other","article","10.34119/bjhrv8n2-155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046858","The GLP-1 Illusion: Weight Loss Without Metabolic Health","JM Oliver","2025",null,"other","article","10.22541/au.174076928.85570162/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0046859","1694-P: Expression of GLP-1R and GIPR in Papillary and Medullary Thyroid Carcinoma and Hashimoto’s Thyroiditis: An Immunohistochemistry H-score Study","Pantelitsa Rakitzi","2026","Diabetes","other","article","10.2337/db26-1694-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046860","EE428 COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VERSUS SGLT2 INHIBITORS FOR CARDIOVASCULAR PROTECTION AMONG U.S. ADULTS WITH DIABETES: A MEPS-BASED ECONOMIC EVALUATION 2022","Yathreb Bayan Mohamed","2026","Value in Health","other","article","10.1016/j.jval.2026.03.722",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046861","MAP4K1 Downregulation by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Alleviates Podocyte Injury and Inflammation via the cGAS-STING Pathway in Glomerular Diseases","Aili Cao","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024gdkxyks6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046862","149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s)","Lawrence Blonde","2019","Diabetes","randomized_trial","article","10.2337/db19-149-or",null,null,"ClinicalTrials.gov:NCT02787551","S001125","openalex","FALSE","paywalled","1","FALSE","article"],["R0046863","Green and High-Throughput Quantification of Semaglutide in Bulk Substance and Solutions for Injections Using Liquid Chromatography","Michał Adam Laszczyk","2026","Acta Poloniae Pharmaceutica - Drug Research","other","article","10.32383/appdr/226652",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046864","Miracle cures and moral panics: British media coverage of celebrity weight loss in the age of the GLP-1 medications","Rachele Salvatelli","2026","Fat Studies","other","article","10.1080/21604851.2026.2637285",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046865","2155-LB: Hepatic BHMT Integrates GIP/GLP-1 Signaling to Ameliorate Metabolic Dysfunction through Coordinated Regulation of Lipid Metabolism and Fibrogenesis","Han Yan","2025","Diabetes","preclinical","article","10.2337/db25-2155-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046866","Die ACCORD-Studie und die Probleme bei der Interpretation der Ergebnisse","Anil Abraham Thomas","2008","Diabetologie und Stoffwechsel","other","article","10.1055/s-2008-1076807",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046867","O28 Efficacité et sécurité du dulaglutide en administration hebdomadaire et de l’insuline glargine en administration quotidienne à 52 semaines de traitement chez les patients diabétiques de type 2 (DT2) inclus dans l’étude AWARD-2 (Assesment of Weekly Adminis)","Jiten P Vora","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30028-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046868","2290-PUB: Donor HLA-DR4 Positivity and Islet Transplantation Outcomes","Carmen E. Chavez","2020","Diabetes","nonrandomized_study","article","10.2337/db20-2290-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046869","GLP-1 receptor agonist use and pancreatic cancer risk in patients with chronic pancreatitis.","Sarina Ailawadi","2026","Journal of Clinical Oncology","randomized_trial","article","10.1200/jco.2026.44.2_suppl.733",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0046870","GLP1 receptor agonist with add-on SGLT2 inhibitor therapy is associated with lower risks of major adverse cardiovascular events: a population-based and machine learning causal inference analysis","Zhiyao Luo","2025","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.109.p110",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046871","26-A-16654-ACC REDUCED RISK OF SINUS NODE DYSFUNCTION WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: EVIDENCE FROM A SYSTEMATIC REVIEW OF CLINICAL TRIALS","Carlos M. Patiño","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.154",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0046872","746-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Primary Endpoint Analysis","Francesco Giorgino","2022","Diabetes","nonrandomized_study","article","10.2337/db22-746-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046873","Decrease in the efficacy of glucagon-like peptide-1 receptor agonists: what is the reason?","Наталія Миколаївна Кушнарьова","2021","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","other","article","10.22141/2224-0721.17.8.2021.246799",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046874","S1177 Use of GLP1 Agonists or SGLT2 Inhibitors in Non-Alcoholic Steatohepatitis Patients With T2DM Is Associated With a Lower Risk of Cirrhosis: A Nationwide Population-Based Study","Ahmed Eltelbany","2022","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000861348.86439.43",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046875","Glucagon Like Peptide-1 & Analogs","Tithi Trivedi","2025",null,"other","article","10.61440/jcmhc.2025.v2.17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046876","982-P: Use of Antihyperglycemic Agents (AHA) with Cardioprotective Benefit in Older Patients with T2D and CVD or CV Risk Factors","Reema Mody","2021","Diabetes","nonrandomized_study","article","10.2337/db21-982-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046877","What is ‘budget Ozempic’ that’s all over social media? Can it help me lose weight?","Nial Wheate","2023",null,"other","article","10.64628/aa.d3rnayr4q",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0046878","1734-P: Reduction of the 10-Year ASCVD Risk in Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg in Routine Clinical Care—A Real-World Study","Aleksandrina Ruseva","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1734-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046879","P-48THE GLUCAGON-LIKE PEPTIDE 1 ANALOGUE LIRAGLUTIDE ATTENUATES ALCOHOL-INDUCED REWARD, DECREASES ALCOHOL INTAKE AND PREVENTS RELAPSE-LIKE DRINKING TO ALCOHOL IN OUTBRED RODENTS AS WELL AS REDUCES OPERANT ALCOHOL SELF-ADMINISTRATION IN SARDINIAN ALCOHOL-PREFERRING RATS","Daniel Vallöf","2015","Alcohol and Alcoholism","preclinical","article","10.1093/alcalc/agv080.48",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046880","Cloning, Expression and Purification of a Novel GLP-1 Analog in CHO with GC-Rich","Bo Xie","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046881","Cardiometabolic improvements, sleep apnea reduction, and biomarker modulation under dual GLP-1RA and SGLT2i therapy: a prospective study","Petar Kalaydzhiev","2025","Pharmacia","nonrandomized_study","article","10.3897/pharmacia.72.e166690",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046882","38 - Cost Effectiveness of Oral Semaglutide 14 mg Vs Empagliflozin 25 mg in Canada","Aiden Liu","2020","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2020.08.044",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046883","234-OR: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Better Clinical Outcomes with IGlarLixi vs. Premix 70/30 in the SoliMix Trial","Julio Rosenstock","2021","Diabetes","randomized_trial","article","10.2337/db21-234-or",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046884","#2505 CHARACTERISTICS OF MEDICATION-INITIATOR COHORTS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES IN JAPAN: A REPORT FROM FOUNTAIN PLATFORM","Yuichiro Yano","2023","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfad063c_2505",null,null,"ClinicalTrials.gov:NCT05526157","S002732","openalex","TRUE","open_pdf","4","FALSE","article"],["R0046885","SAT673 Novel Mutation Of TBX3 Associated With Morbid Obesity In Human","Hussam R Alkaissi","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.121",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046886","A527 Will GLP-1 Agonists shift the paradigm of surgical therapy in the fight against diabetes and obesity?","Christopher Esposito","2019","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2019.08.465",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046887","Liraglutide is more potent in stably reverting overt autoimmune diabetes in NOD mice compared to exendin-4 when combined with αCD3 antibody","Lei Ding","2012",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046888","Semaglutide Reduces Appetite and Energy Intake, Improves Control of Eating and Provides Weight Loss in Subjects with Obesity","Daniella Linton","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046889","Child of our time: how childhood now lasts a lifetime","David D. Spence","2011","BMJ","nonrandomized_study","article","10.1136/bmj.d2341",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046890","68Ga-DOTA-Exendin-4 PET/CT and 68Ga-DOTA-NOC PET/CT in localization of clinically suspected insulinomas.","Sreedharan Thankarajan Arunraj","2018","Journal of Nuclear Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046891","S3783 Colonic Perforation in a Patient on GLP-1 Agonist Therapy: A Case Report","Mohammed Inam Ullah Khan","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001142592.28071.eb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046892","NON-SURGICAL STRATEGIES FOR THE TREATMENT OF SEVERE OBESITY IN THE BRAZILIAN PUBLIC HEALTH SYSTEM: A COST-EFFECTIVENESS ANALYSIS","Aurelio de Melo Barbosa","2026","Artefactum","other","article","10.23900/artefactum.v25i4.3077",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046893","Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis","Bing Yang","2023","Frontiers in Endocrinology","preclinical","article","10.3389/fendo.2023.1284809","37842309",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0046894","Incretin Based Therapies","Sanjay Kalra","2013","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/11892",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0046895","SAT-405 TSH testing patterns for patients with type 2 diabetes and hypothyroidism after GLP-1 RA initiation in a target trial setting","Naykky Singh Ospina","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.2320",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046896","GLP-1 RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES FOLLOWING STEMI: A PROPENSITY-MATCHED COHORT STUDY","Osman K. Yousafzai","2025","American Journal of Preventive Cardiology","nonrandomized_study","article","10.1016/j.ajpc.2025.101216",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046897","844-P: Association between Preoperative GLP-1RA Use and Postoperative Respiratory Complications in Real-World Patients Undergoing Elective Surgical Procedures—A Target Trial Emulation Study","Pareeta Kotecha","2025","Diabetes","nonrandomized_study","article","10.2337/db25-844-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046898","1773-P: Effects of the Novel Long-Acting Amylin Analogue Petrelintide on Body Weight and Waist Circumference by Sex in a Phase 1 Trial","DAN HESSE","2025","Diabetes","randomized_trial","article","10.2337/db25-1773-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046899","The effect of liraglutide on adipokine and incretin levels in children with obesity","Timofey V. Chubarov","2025","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2025-493",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046900","Abstract 14806: The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Most Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials","Subodh Verma","2018","Circulation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046901","Semaglutide Consistently Reduces Cardiovascular Events in Both Male and Female Subjects with Type 2 Diabetes","IRENE M. HRAMIAK","2018","Diabetes","randomized_trial","article","10.2337/db18-1085-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046902","1362-P: Eligibility for GLP-1 Receptor Agonists for Obesity across 91 Countries","SANG GUNE K. YOO","2025","Diabetes","other","article","10.2337/db25-1362-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046903","Patient-Reported Outcomes in Patients with Type 2 Diabetes Treated with Tirzepatide or Insulin Degludec (SURPASS-3)","Maria B. Yu","2021",null,"other","article","10.26226/morressier.617c37317c09fc044a97529d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0046904","675-P: Effects of Liraglutide in T1D by Baseline Anthropometrics in ADJUNCT One and Two","Thomas Fremming Dejgaard","2021","Diabetes","randomized_trial","article","10.2337/db21-675-p",null,null,"ClinicalTrials.gov:NCT01836523; ClinicalTrials.gov:NCT02098395","S001732; S002341","openalex","FALSE","paywalled","1","FALSE","article"],["R0046905","OP0025 MORTALITY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST INITIATION IN PATIENTS WITH AUTOIMMUNE DISEASES AND TYPE 2 DIABETES: A POPULATION-BASED STUDY","Derin Karacabeyli","2023","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1136/annrheumdis-2023-eular.2163",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046906","59 CYTOPROTECTIVE EFFECTS OF EXENDIN-4, A GLP-1 RECEPTOR AGONIST, ON THE BILIARY EPITHELIUM","Marco Marzioni","2008","Journal of Hepatology","other","article","10.1016/s0168-8278(08)60061-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046907","SUN-566 Continuous Glucose Monitoring for Post-Kidney Transplantation in Pre-existing Type 2 Diabetes","Dania Salih Bacha","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1218",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046908","PII-39Effects of exenatide on statin single-dose pharmacokinetics and 30-week lipid response","Prajakti A. Kothare","2006","Clinical Pharmacology & Therapeutics","randomized_trial","article","10.1016/j.clpt.2005.12.164",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046909","GL0034 (Utreglutide), a novel, long acting, glucagon-like peptide 1 receptor agonist (GLP-1 RA), results of a phase 1 study in healthy individuals","Rajamannar Thennati","2023","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(23)01426-5",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0046910","Agricultural Technology: Reconciling Food Abundance and Public Health Through Integrated Pharmacotherapy Policies","Gangadhar Dhulipala","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.19554469",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0046911","Incretin‐based therapies","Michael Albrecht Nauck","2015",null,"other","article","10.1002/9781118387658.ch48",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0046912","Detection sensitivity of ultrasound scanning vs. clinical examination for insulin injection-related lipohypertrophy","Jian Qin Yu","2021","Chinese Medical Journal","nonrandomized_study","article","10.1097/cm9.0000000000001742","34561336",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0046913","A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson's Disease","Elliot J. Hogg","2022","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.4212371",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0046914","Comparison of Therapies with GLP1 Analogues in Type 2 Diabetic Patients Without Control","Jose Zambrano","2021","American Heart Journal","other","article","10.1016/j.ahj.2021.10.002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046915","Relationship between GLP-1 receptor agonists on cancer recurrence and survival of patients with stage I-III colorectal cancer: A retrospective cohort study using the TriNetX database.","Emily Noelle Kinsey","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.3636",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046916","A case of insulin antibody-induced glucose instability in an elderly woman with type 2 diabetes on hemodialysis, successfully ameliorated with liraglutide","Yoshiaki Tamura","2012","Diabetology International","case_report","article","10.1007/s13340-012-0100-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046917","TOLERABILITY AND WEIGHT REDUCTION OF TIRZEPATIDE IN ADULTS WITH OBESITY OR OVERWEIGHT","Domenica Rubino","2023","Canadian Journal of Cardiology","other","article","10.1016/j.cjca.2023.06.401",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046918","6.35 Exploring Semaglutide as a Potential Treatment for Eating Disorders: A Systematic Review and Meta-Analysis","E. Radha Krishnan","2025","Journal of the American Academy of Child & Adolescent Psychiatry","systematic_review","article","10.1016/j.jaac.2025.08.511",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0046919","What's New.","Hisamitsu Uno","2011","Nihon Naika Gakkai Zasshi","other","article","10.2169/naika.100.1464",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046920","A real-world data analysis investigating the cardioprotective effects of glucagon-like peptide-1 receptor agonists among people with type 2 diabetes in England","Derek Connolly","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.2902",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046921","180-OR: Baseline Predictors of Remission of Type 2 Diabetes in Response to Short-Term Insulin-Based Therapy—The Pivotal Role of Beta-Cell Function","Ravi R. Retnakaran","2023","Diabetes","randomized_trial","article","10.2337/db23-180-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0046922","Exenatide promotes the autophagic function in the diabetic hippocampus: a review","Eman Mohammed Elsaeed","2022","Egyptian Journal of Basic and Applied Sciences","narrative_review","article","10.1080/2314808x.2022.2067388",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046923","1042: SEMAGLUTIDE-INDUCED ACUTE PANCREATITIS LEADING TO DEATH AFTER FOUR YEARS OF USE","CHEBLY DAGHER","2025","Critical Care Medicine","other","article","10.1097/01.ccm.0001102832.93407.73",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046924","Semaglutide (Ozempic ® ): a comprehensive review of its pharmacology, efficacy, and safety profile in type 2 diabetes mellitus and weight management","SD Vambe","2024","SA pharmaceutical journal.","narrative_review","article","10.36303/sapj.1143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046925","Sex-specific molecular effects of semaglutide on cardiac and hepatic mitochondrial respiration and cellular redox state in HFpEF and MASLD","Niklas Geiger","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.oc15.6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046926","COMPARAÇÃO ENTRE CIRURGIA BARIÁTRICA E TIRZEPATIDA (MOUNJARO) NA REDUÇÃO DO RISCO CARDIOVASCULAR EM PACIENTES OBESOS","Ana Carolina Cansanção Melro","2026","LUMEN ET VIRTUS","other","article","10.56238/levv17n56-003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; conference-paper"],["R0046927","Drug-induced liver injury associated with liraglutide use: a systematic review of detection, severity, causality assessment, and clinical outcomes","Faisal Inayat","2023","Journal of Clinical and Translational Research","systematic_review","article","10.18053/jctres.09.202303.004",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046928","Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease","Mariam Elmegaard Malik","2022","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehac544.2692",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046929","Semaglutide as an Aid to Weight Reduction in Adults With Obesity and Advanced CKD","Sarah I. Bukhari","2022","Journal of the American Society of Nephrology","other","article","10.1681/asn.20223311s1849d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046930","Abstract 4361084: GLP-1 Receptor Agonists in Non-Diabetic Obese Adults: A Retrospective Cohort Study of Cardiovascular and Arrhythmia Outcomes","Yaman Jarrar","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4361084",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046931","Antidiabetic drugs use and new-onset atrial fibrillation in patients with diabetes mellitus","Laurent Fauchier","2021","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehab724.0457",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046932","Liraglutide and sibutramine: similarities and differences in pharmacotherapy of obesity","Tatiana Ivanovna Romantsova","2023","Endocrinology News Opinions Training","other","article","10.33029/2304-9529-2023-12-4-117-131",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046933","1113-OR: ADA Presidents' Select Abstract: Single-Cell Transcriptomic Profiling Identifies GLP-1RA Associated Pathways in Early Kidney Disease","Ye Ji Choi","2026","Diabetes","other","article","10.2337/db26-1113-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046934","SEMAGLUTIDE IN OBESE PATIENTS: AN UPDATED META-ANALYSIS OF 11930 PATIENTS","Abdulrhman M. Khaity","2024","Atherosclerosis","systematic_review","article","10.1016/j.atherosclerosis.2024.118709",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046935","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists for Parkinson’s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials (P11-5.012)","Hassan Waseem","2025","Neurology","systematic_review","article","10.1212/wnl.0000000000211906",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046936","GLP‑1 receptor agonists and clonal hematopoiesis: Early human signals of anti‑inflammatory clone mitigation and lower MDS‑to‑AML progression","Mark D. Orland","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-1385",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046937","1685-P: Dapiglutide Is a Dual Agonist on Human GLP-1- and GLP-2-Receptors with a Biased and Prolonged Signaling Profile at the GLP-1R","Louise Carstensen Gjelstrup","2024","Diabetes","other_trial","article","10.2337/db24-1685-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046938","Abstract 9041: Provider Evaluation for Selection of Evidence-Based Therapies to Reduce Cardiovascular Complications in Patients With Type 2 Diabetes Mellitus Study - Primary Results of the PREFER-DM Study","Abhinav Sharma","2021","Circulation","other","article","10.1161/circ.144.suppl_1.9041",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046939","The association between sglt-2 inhibitor use and progression from monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans","Byron S. Sigel","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-4027",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046940","GLP-1 Receptor Agonist Use Associated with Improvement in Hospitalization Rates in Patients with ESKD","Steven M. Brunelli","2025","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.2025ebmh05b5",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046941","adding liraglutide to existing therapy improves glycaemic control: evidence from a meta-analysis of six large randomised clinical trials","Richard E. Pratley","2009","Canadian Journal of Diabetes","systematic_review","article","10.1016/s1499-2671(09)33266-9",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0046942","Liraglutide 3.0 mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight/obese adults: the SCALE obesity and prediabetes trial","Xavier Pi‐Sunyer","2014",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0046943","Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100 + lixisenatide","M. V. Martjanova","2020","Meditsinskiy sovet = Medical Council","other","article","10.21518/2079-701x-2020-7-50-55",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046944","Effect of semaglutide on mitochondrial homeostasis parameters in neurons of the substantia nigra in an experimental Parkinson’s disease model","Anna V. Egorova","2025","Biological Communications","preclinical","article","10.21638/spbu03.2025.402",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046945","Obesity in Patients with Type 1 Diabetes: Causes and Consequences","Vadim Valer'evich Klimontov","2025","Diabetes Mellitus","other","article","10.14341/dm13237",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046946","Comparison of cardiovascular outcomes in patients with diabetes treated with tirzepatide versus semaglutide: a multi-institutional analysis","Miriam P. Cervantes","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.2907",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046947","336.7: [68Ga]Ga-DOTA-Exendin-4 PET/CT detects increased liver signal of transplanted neonatal islet cell clusters in diabetic pig recipients","Nicol Gloddek","2023","Transplantation","other","article","10.1097/01.tp.0000994536.09032.fc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046948","Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction","Jwan A. Naser","2024","Circulation","randomized_trial","article","10.1161/circulationaha.124.069479","38885297",null,"ClinicalTrials.gov:NCT04730947",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046949","Incretin Analogues in Therapy of Type 2 Diabetes and Obesity","Igor A. Zalunin","2021","Biotekhnologiya","other","article","10.21519/0234-2758-2021-37-3-53-64",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046950","HDL lipidomic analysis in patients with type 2 diabetes mellitus receiving fixed-dose combination of insulin degludec and liraglutide","Eleni T. Pappa","2020","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2020.10.200",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046951","Perspective strategies for non-alcoholic fatty liver disease therapy: from trial to practice","Игорь Геннадьевич Бакулин","2020","Экспериментальная и клиническая гастроэнтерология","randomized_trial","article","10.31146/1682-8658-ecg-170-10-18-25",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046952","Potential of Triple Therapy in Diabetic Kidney Disease","Lean Alkhatib","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025pt4vchxa",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046953","S86 Turning the Tide: GLP-1 Agonists Improve Outcomes in Patients With Obesity Admitted With Acute Pancreatitis","Aun Muhammad","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001126804.83575.55",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046954","734-P: The Effect of Adjunctive Therapy with Liraglutide on Insulin Sensitivity in Overweight Persons with Type 1 Diabetes","Thomas Fremming Dejgaard","2022","Diabetes","randomized_trial","article","10.2337/db22-734-p",null,null,"ClinicalTrials.gov:NCT01612468","S000597","openalex","FALSE","paywalled","1","FALSE","article"],["R0046955","Liraglutide Increases Gastric Fundus Tonus and Reduces Food Intake in Type 2 Diabetic Rats","Ana Catarina Lourenço Carrêlo","2025","Diabetology","preclinical","article","10.3390/diabetology6090096",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046956","#944 Baseline analysis of the patterns of CKD care in an implementation trial using future health today in primary care","Hannah Wallace","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.0583",null,null,"ANZCTR:ACTRN12623001096640",null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046957","Effect of liraglutide on intragastric pressure (IGP) and satiation during intragastric nutrient drink infusion in healthy volunteers","Antonio Rotondò","2011","Appetite","other","article","10.1016/j.appet.2011.05.256",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046958","Analysis of safety and efficacy of liraglutide compared with dulaglutide in patients with type 2 diabetes mellitus","Arina Frolova","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p476",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046959","COST-EFFECTIVENESS ANALYSIS OF ENDOSCOPIC SLEEVE GASTROPLASTY COMPARED TO SEMAGLUTIDE FOR WEIGHT LOSS IN PATIENTS WITH OBESITY","Muhammad A. Haseeb","2023","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2023.04.1479",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046960","Addition of SGLT2 inhibitor to GLP ‐1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control","Louise R Curtis","2016","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.2018",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046961","Insulin degludec/Liraglutid (IDegLira) verbesserte bei Patienten mit Typ 2 Diabetes (T2D) mit unzureichender Blutzuckereinstellung unter Insulin glargin (IGlar) plus Metformin (Met) die Leistungsfähigkeit und das Wohlbefinden (Patient Reported Outcomes): DUAL-V-Studie","Wolfgang Kern","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580789",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046962","Renal Impairment Does Not Affect the Glycemic Efficacy or Safety of Liraglutide Treatment in Patients with Type 2 Diabetes","Stephen C. L. Gough","2012","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2012.07.326",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046963","Best practice in management of type 2 diabetes","David Stuart Morris","2016","Nurse Prescribing","other","article","10.12968/npre.2016.14.sup10.s3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046964","A case of euglycaemic ketoacidosis and concomitant acute pancreatitis in a diabetic patient treated with SGLT2i and GLP-1RA","Melpomeni Moustaki","2020","Endocrine Abstracts","case_report","article","10.1530/endoabs.70.aep823",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046965","Sa1953 COMPARATIVE EFFECTIVENESS OF GLP-1 AGONISTS FOR OBESITY MANAGEMENT IN ADULTS WITHOUT DIABETES: A NETWORK META-ANALYSIS","Jena Velji-Ibrahim","2024","Gastroenterology","systematic_review","article","10.1016/s0016-5085(24)01830-4",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0046966","S1981 A Systematic Review Comparing GLP-Agonists and Resmetirom for Improving Fibrosis among Patients With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)","Mahmoud Mahdi","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001037292.83414.fb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0046967","Tirzepatide Improved Markers of Islet Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared to Semaglutide in People with Type 2 Diabetes","Katelyn E. Brown","2023","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0043-1767867",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0046968","Abstract #1608339: Sodium–Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists, Efficacy and Safety in Diabetic Kidney Transplant Recipients","Tarek Mahmoud","2023","Endocrine Practice","other","article","10.1016/j.eprac.2023.10.050",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046969","Cyclic AMP‐dependent Activation of ERK Via GLP‐1 Receptor Signaling Requires the Neuroendocrine Cell‐Selective Guanine Nucleotide Exchanger NCS‐RapGEF2","Wenqin Xu","2021","The FASEB Journal","preclinical","article","10.1096/fasebj.2021.35.s1.04803",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046970","Abstract 4367612: The Risk of Pancreatitis and Adverse Cardiovascular Events in Patients with Type 2 Diabetes and/or Overweight/Obesity with and without Hypertriglyceridemia when Prescribed GLP1RA: A Propensity Score-Matched Analysis","Leslie K. Iverson","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4367612",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046971","Sequence-based knowledge driven structural design of peptide drugs as co-agonists of GLP-1/GCG receptors","Shubham Vishnoi","2023","Biophysical Journal","other","article","10.1016/j.bpj.2022.11.1202",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046972","Exendin-4 protect beta-cells from palmitate-induced apoptosis by reducing GPR40 expression and interfering with activation of MKK4/7-JNK pathway.","Annalisa Natalicchio","2011","CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046973","Assessing The Efficacy of Semaglutide on Glycaemia Control and Weight Reduction among Patients with Type 2 Diabetes at the Outpatient Department of Teaching Hospital","Abul Fazal Mohammad Helal Uddin","2025","SSB Global Journal of Medical Science","other","article","10.61561/ssbgjms.v6i01.76",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046974","Glucagon-like peptide 1 receptor agonism alters lateral septal activity and motivated behaviour in rats","Isabella Rose Culshaw","2026","Otago University Research Archive (University of Otago)","preclinical","article","10.82348/our-archive.00370",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046975","Comparative Evaluation of Renal Tissue Changes Associated with Anti-Obesity Therapies: Hoodia Gordonii Extract, Liraglutide (Saxenda), and Their Combination","Zeinab Hameed Abbas","2025","Medical Forum Monthly","other","article","10.60110/medforum.361108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0046976","One Year Exenatide Therapy, Compared with Insulin Glargine, Reduces Postprandial Oxidative Stress in Metformin-Treated Patients with Type 2 Diabetes","Mathijs C. M. Bunck","2009","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0046977","P44 Type 2 diabetes mellitus in children: non-insulin medication, where are we up to?","Rhiannon E. Austin","2019","Archives of Disease in Childhood","randomized_trial","article","10.1136/archdischild-2019-esdppp.82",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046978","Abstract 4360716: An Artificial Intelligence Model for Clinical Event Adjudication in Cardiovascular Clinical Trial","Hiya Banerjee","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4360716",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0046979","PDB32 A LONG-TERM Cost-Effectiveness Analysis of Treatments for Type 2 Diabetes in Portugal: Once-Weekly Semaglutide 1 MG Versus Once-Daily Empagliflozin 25 MG","Nino Hallén","2020","Value in Health","other","article","10.1016/j.jval.2020.08.629",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0046980","Development of a radiolabelling method of 68 Ga-Exendin-4(NODAGA) using the GAIA module from Elysia-Raytest (R)","Fanny Bernard","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046981","The incretin axis offers a novel therapeutic target to preserve myocardial energy metabolism in cardiorenal syndrome","Marie Schroeder","2016","Journal of Cardiovascular Magnetic Resonance","nonrandomized_study","article","10.1186/1532-429x-18-s1-o15",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046982","Anti-Obesity Medications: An Update for Canadian Physicians","Renuca Modi","2020","Canadian Journal of General Internal Medicine","nonrandomized_study","article","10.22374/cjgim.v15i4.394",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046983","3233 Massive Gastric Distention… Aaand It's Gone!","Baruh B. Mulat","2019","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000602464.37334.03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046984","Effektivität und Sicherheit der Therapie mit Exenatide bei Patienten in einer Hochschulambulanz","T Daumüller","2009","Diabetologie und Stoffwechsel","other","article","10.1055/s-0029-1221931",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046985","MP13-03 GLP-1 RECEPTOR AGONIST USE IS NOT ASSOCIATED WITH IMPAIRED SEMEN PARAMETERS AMONG DIABETIC MEN PRESENTING FOR FERTILITY EVALUATION","Luis Carlos Arthur Gago","2024","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001008832.14212.d6.03",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0046986","ITCA 650","Elaine W. Butterly","2018","Practical Diabetes","randomized_trial","article","10.1002/pdi.2165",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0046987","Incretin therapy for cardiovascular disease: opportunities, mechanistic gaps, and challenges","Daniel Emil Tadeusz Raaschou-Pedersen","2025","European Heart Journal","commentary","article","10.1093/eurheartj/ehaf983","41330422",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0046988","WED-219 Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model","Stephen A. Harrison","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)01560-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0046989","Real world outcomes comparing the use of GLP-1 receptor agonists in patients with CML and comorbid obesity: A propensity score matched analysis from global federated health research network","Arshi Syal","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-4635",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046990","GLP-1 receptor agonists for Parkinson's disease (Protocol)","Caroline A. Mulvaney","2018","Lancaster EPrints (Lancaster University)","protocol","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0046991","Race of GLPS: Impact on Weight and Glycemic Control on Type 2 Diabetes with Semaglutide Versus Liraglutide","Noha Hafeez","2024","Journal of Gandhara Medical and Dental Science","nonrandomized_study","article","10.37762/jgmds.12-1.633",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0046992","Effects of SGLT-2i and GLP-1RA in vascular function parameters: the impact of the weight loss","Panagiota K. Stampouloglou","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae666.2934",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046993","Abstract 25: Glycemic variability of oral semaglutide versus empagliflozin: A post hoc analysis of PIONEER 2","D Shabeer","2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.342139",null,null,"ClinicalTrials.gov:NCT02863328","S000251","openalex","TRUE","free_to_read","1","FALSE","conference-abstract"],["R0046994","A-114 | Impact of GLP-1 Receptor agonist in patients with HFpEF on SGLT inhibitors post-TAVR: A propensity-matched analysis","Efeturi M. Okorigba","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104605",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0046995","Glucagon-like Peptide-1 Receptor Agonists as Modulators of Pain-Related Mechanisms: A Systematic Review of Experimental and Translational Evidence","Sebastián Eustaquio Martín Pérez","2026","Rheumato","systematic_review","article","10.3390/rheumato6030016",null,null,"PROSPERO:CRD420261367538",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046996","Exenatide Once Weekly Plus Metformin for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomised Controlled Trials","Sheena Kayaniyil","2015","Value in Health","systematic_review","article","10.1016/j.jval.2015.09.2044",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0046997","Abstract 4367419: Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With Lower Risk Of Cardiovascular Event Recurrence Compared With Use Of Bupropion-Naltrexone or Phentermine-Topiramate: A Nationwide Target Trial Emulation Study","Wenxin Guo","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4367419",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0046998","400-P: KidneyIntelX Impact on ADA DKD Prevention Model Metrics","Joji Erik Tokita","2024","Diabetes","other","article","10.2337/db24-400-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0046999","Use Of Glp-1 Receptor Agonists Is Associated With An Increased Rate Of Upper Eyelid Blepharoplasty","Jeong-Gu Ha","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20086344",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0047000","Effects of prognostic nutritional index and obesity on 1-year mortality in patients with acute heart failure","Mohammed El‐Sheikh","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.1204",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047001","FRI-359 A 5-week treatment with the GLP-1/GIP/glucagon triple receptor agonist retatrutide demonstrates multiple metabolic benefits and strong reduction in liver steatosis in a diet-induced obese MASH mouse model","François Briand","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)01596-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047002","GLP-1 agonist semaglutide for the treatment of acquired hypothalamic obesity in adolescents: efficacy, adverse effects and impact on quality of life and eating behaviours","Rebecca J. Cramer","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.p903",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047003","Treatment with a glucagon-like peptide-1 receptor agonist liraglutide decreases albuminuria in overweight type 2 diabetic patients","Tomislav Bulum","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047004","Abstract Wed074: Semaglutide in HFpEF: Uncoupling Weight Loss to Reveal Additional Therapeutic Benefits","Mahmoud H. Elbatreek","2025","Circulation Research","other_trial","article","10.1161/res.137.suppl_1.wed074",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047005","CO133 Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients With Obesity: A Bayesian Network Meta-Analysis of GLP-1 RCTs","Andreea Ciudin","2024","Value in Health","systematic_review","article","10.1016/j.jval.2024.10.209",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0047006","MRI CHANGES FOLLOWING TREATMENT OF GLP‐1 ANALOGUE, LIRAGLUTIDE IN ALZHEIMER’S DISEASE","Paul Edison","2023","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.080538",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047007","Clinical experience with lixisenatide in patients with obesity and type 2 diabetes","Cristina Tejera","2015","Endocrine Abstracts","other","article","10.1530/endoabs.37.ep457",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047008","S1467 Risk of Inflammatory Bowel Disease Complications in Obese Inflammatory Bowel Disease Patients on GLP-1 Therapy: A Large Multicenter Cohort Study","Ayowumi A. Adekolu","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035236.78118.00",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047009","960-P: Characteristics of U.S. Patients with Type 2 Diabetes Prescribed GLP-1RA+SGLT2i in Combination during 2018","Rory J. McCrimmon","2020","Diabetes","randomized_trial","article","10.2337/db20-960-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047010","S798 Endoscopic Sleeve Gastroplasty vs GLP-1 Receptor Agonists: Comparative Effectiveness in Obesity Management","Vikash Kumar","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130652.47326.dc",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047011","Editorial: Mechanisms involved in the development of obesity with PCOS","Anju Elizabeth Joham","2024","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1444299","39015184",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0047012","26-A-12558-ACC GLP-1 RECEPTOR AGONISTS REDUCE CARDIOVASCULAR EVENTS AND MORTALITY IN PEOPLE WITH HIV","Yussif Issaka","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.471",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047013","S2216 GLP-1 RAs Use is Associated with Lower Mortality and Improvement of Cardiovascular Outcomes in Patients with Celiac Disease and Obesity: A Multi-Center Analysis","Donghyun Ko","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001038232.61346.20",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047014","Exploration of Cagrilintide's Mechanism of Action in the Kidneys","Vera Christine Wulfmeyer","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2025rw8zadz8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047015","737-P: HDM1002 in Chinese Adults with Overweight or Obesity—A Randomized, Placebo-Controlled, Four-Week, Phase 1b Study","Hongrong Xu","2025","Diabetes","randomized_trial","article","10.2337/db25-737-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047016","Liraglutide improves insulin sensitivity in diabetic mice through reduction of inflammation and induction of thermogenesis.","Joseph Yi Zhou","2018","The FASEB Journal","preclinical","article","10.1096/fasebj.2018.32.1_supplement.lb159",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047017","Liraglutide improves renal oxidative stress in rats with insulin resistance","Minghao Wu","2016","Chin J Diabetes Mellitus","preclinical","article","10.3760/cma.j.issn.1674-5809.2016.09.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047018","Prevalence of Overweight/Obesity Among Patients Admitted With Acute Coronary Syndromes: Implications for Semaglutide Eligibility to Further Reduce Residual Risk","Matthew Y. Lim","2025","Heart Lung and Circulation","other","article","10.1016/j.hlc.2025.06.675",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047019","TIRZEPATIDE AND CLINICAL OUTCOMES ASSESSED BY IMAGING: COMPARISONS WITH SEMAGLUTIDE AND INSULIN IN TYPE 2 DIABETES AND OBESITY","Bianca Senger Vasconcelos Barros","2025","Revista fisio&terapia.","other","article","10.69849/revistaft/ra10202508151353",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047020","231-OR: Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2","RODOLFO J. GALINDO","2024","Diabetes","nonrandomized_study","article","10.2337/db24-231-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047021","Regional heterogeneity of the results of glucagon-like peptide-1 receptor agonists trials in type 2 diabetes: a reanalysis of individual participant data","Ariane Jullien","2024",null,"randomized_trial","article","10.2337/figshare.26528158",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0047022","773-P: Effect of Glucagon-Like Peptide 1 Receptor Agonists Compared with Basal Insulin in Severely Uncontrolled Type 2 Diabetes","J Student","2025","Diabetes","nonrandomized_study","article","10.2337/db25-773-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047023","GLP-1 receptor agonist use and colorectal cancer risk in patients with inflammatory bowel disease.","Sarina Ailawadi","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.19_suppl.138",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047024","AMPLIFICATION OF THE MYOCARDIAL INFARCT SIZE LIMITING EFFECTS OF EXENATIDE WITH CILOSTAZOL, A PHOSPHODIESTERASE III INHIBITOR","Yochai Birnbaum","2012","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(12)60451-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047025","Diversity of pleiotropic effects of semaglutide: From potential mechanisms to real clinical outcomes","Tatiana Yu. Demidova","2025","FOCUS Endocrinology","other","article","10.62751/2713-0177-2025-6-1-03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047026","Efficacy of GLP-1 receptor agonists (revision number 2)","Filip Krag Knop","2012","Diapedia.org eBooks","other","article","10.14496/dia.81043351107.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047027","Exendin-4 (E4) and glucagon-like peptide-1 (GLP-1) improve glucose tolerance and induce islet cell growth in chronic pancreatitis (CP) in rats","Guðrún Aspelund","2000","Journal of the American College of Surgeons","preclinical","article","10.1016/s1072-7515(00)00460-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047028","LOW RATES OF GASTRIC FOOD RETENTION DURING ENDOSCOPY IN PATIENTS ON GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONISTS AT A LARGE ACADEMIC CENTER","Bharati Dev","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.983",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047029","103-OR: The Glucagon-Like Peptide-1 Analog, Liraglutide Is a Safe and Effective Treatment of Bile Acid Malabsorption: A Proof of Concept Study","Martin Lund Kårhus","2021","Diabetes","randomized_trial","article","10.2337/db21-103-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047030","TRANSDERMAL PATCH-BASED DELIVERY OF TIRZEPATIDE: A CONTROLLED RELEASE STRATEGY FOR DIABETES TREATMENT","Parul Nigam","2025","Innovare Journal of Medical Sciences","preclinical","article","10.22159/ijms.2025v13i4.55051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047031","LBSUN213 An Investigation Into The Effects Of Dapagliflozin On Ketogenesis In Type 1 Diabetes","Husam Ghanim","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.592",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0047032","Abstract 13393: Liraglutide Improves Myocardial Redox State in Humans by Regulating the Adipose Tissue-Derived Long-Chain Ceramides","Nadia A. Akawi","2021","Circulation","randomized_trial","article","10.1161/circ.144.suppl_2.13393",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047033","S1909 Association of Glucagon-Like Peptide-1 Therapies and Risk of Cancer in Liver Transplant Patients","Muhammad Saad Faisal","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037004.02896.90",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047034","Tirzepatide maintained significant weight loss when treatment was continued in a follow‐up study","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.79",null,null,"ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657003; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT04660643","S000242; S001077; S001712; S002157","openalex","TRUE","open_pdf","1","FALSE","article"],["R0047035","Abstract 188","Manash Baruah","2022","Indian Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/2230-8210.363695",null,null,"ClinicalTrials.gov:NCT04042441",null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0047036","Gastrointestinal disorders in diabetes","Chinmay S. Marathe","2020","MDText.com, Inc. eBooks","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047037","Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists","Phuc Nguyen Tran-Duc","2025","CardioMetabolic Syndrome Journal","other","article","10.51789/cmsj.2025.5.e9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047038","Amylin receptor agonism protects against metabolic side effects of acute olanzapine","Kyle D. Medak","2023","Physiology","other","article","10.1152/physiol.2023.38.s1.5730313",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047039","Perspectives of Obstetricians and Gynaecologists on the Use of Weight Loss Medications","Ciara E. Nolan","2025","Reproductive Female and Child Health","other","article","10.1002/rfc2.70034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047040","Safety and Efficacy of Liraglutide as an Add-On Therapy to Pre-Existing Anti-Diabetic Regimens during Ramadan, A Prospective Observational Trial","Azza Abdulaziz Khalifa","2015","Journal of Diabetes & Metabolism","other_trial","article","10.4172/2155-6156.1000590",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047041","Spending on glucagon-like peptide-1 medications across high-income countries: a repeated cross-sectional study","Shenthuraan Tharmarajah","2026","Journal of Pharmaceutical Health Services Research","other","article","10.1093/jphsr/rmag004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047042","26-A-19195-ACC INCREMENTAL CARDIOVASCULAR BENEFITS OF GLP1 RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE ON SGLT2 INHIBITORS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION: A REAL-WORLD COHORT STUDY","Shawn Wang","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.5044",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047043","Vom Altersdiabetes zum Typ-2-Diabetes","Hellmut Mehnert","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-123102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047044","Abstract #288: Low Incidence of Gastrointestinal Adverse Events Over Time with a Fixed-ratio Combination of Insulin Glargine Lixisenatide Vs Lixisenatide Alone","Jennifer M. Trujillo","2017","Endocrine Practice","other","article","10.1016/s1530-891x(20)44408-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047045","Abstract 4752: The combination of GLP1-R agonists and progestins enhances endometrial cancer cell killing through membrane receptor crosstalk","Lane E. Smith","2025","Cancer Research","preclinical","article","10.1158/1538-7445.am2025-4752",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047046","GOING ROGUE: HOW COMPOUNDED GLP-1 AGONIST THERAPY LIKELY PRECIPITATED STEMI IN A YOUNG HEALTHY PATIENT","Alexander M. Bosley","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)03383-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047047","Review article Place of exenatide in the treatment of type 2 diabetic patients","Marta Patrycja Wróbel","2007","Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047048","Агоністи рецепторів глюкагоноподібного пептиду-1 у лікуванні захворювань серцево-судинної системи в пацієнтів із цукровим діабетом","A.M. Sokolova","2025","Ukrainian Journal of Cardiology","other","article","10.31928/2664-4479-2025.3.7182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047049","Potential gender differences of exenatide in outpatients with type 2 diabetes mellitus","Antonio Carlo Bossi","2015","IrInSubria (University of Insubria)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0047050","S2126 GERD Outcomes in Pediatric Population With Obesity Who Received GLP-1 Agonist or Phentermine-Topiramate: A National Database Analysis","Arleen M. Delgado","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037872.17373.e6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047051","Abstract 13544: Cardiologist Underutilization of New Antihyperglycemic Medications in Diabetic Patients With Cardiovascular Disease","Gregory Desrosiers","2020","Circulation","randomized_trial","article","10.1161/circ.142.suppl_3.13544",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047052","Abstract 17437: Estimated Lifetime Benefits of Combination Therapy With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-Steroidal MRAs in Patients With Type 2 Diabetes and Albuminuria","Brendon Lange Neuen","2023","Circulation","other_trial","article","10.1161/circ.148.suppl_1.17437",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047053","Macronutrient composition and metabolic regulation: Do our islets care what we eat?","Dominik Hans Pesta","2022","Acta Physiologica","preclinical","article","10.1111/apha.13895","36214612",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047054","Impact of insulin sensitivity and β-cell function over time on glycemic outcomes in the GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness) Study: differential treatment effects of dual therapy.","Kristina M. Utzschneider","2024",null,"randomized_trial","article","10.2337/figshare.24324946.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0047055","Effects of liraglutide combined with metformin and Diamicron on glucose–lipid metabolism and islet β-cell function in elderly patients with type 2 diabetes mellitus","Chunzhi Zhao","2021","All Life","other","article","10.1080/26895293.2021.1917457",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047056","Trends in the Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs), Diagnosis Requirements, and Beneficiary Use Among US Self-Insured Employers","Richard Alan Brook","2026",null,"other","article","10.13140/rg.2.2.16783.55209",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047057","PT01.2: ZP7570: A Novel GLP-1/GLP-2 Dual Acting Peptide with Potential as the Next Generation Therapy for Short Bowel Syndrome","Jolanta Skarbaliene","2019","Clinical Nutrition","other","article","10.1016/s0261-5614(19)32542-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047058","S90 Predictors of Biliary Malignancy Among GLP-1 Receptor Agonist Users","Sarpong Boateng","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001126820.19690.23",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047059","Impact des effets indésirables gastro-intestinaux sur la satisfaction vis-à -vis du traitement par semaglutide des diabétiques de type 2","Alfred Penfornis","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047060","Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL","Susan D. Reed","2018","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047061","GLP-1RA THERAPY IS ASSOCIATED WITH HIGHER VASCULAR REGENERATIVE CELL CONTENT AND LOWER INFLAMMATORY BURDEN IN PEOPLE LIVING WITH TYPE 2 DIABETES","A. Krishnaraj","2023","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2023.10.312",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047062","Effects of tirzepatide versus insulin glargine 100U/ml on kidney outcomes in people with type 2 diabetes in SURPASS-4","Hiddo J.L. Heerspink","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1767986",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047063","The efficacy and safety of GLP-1 agonists to modify cardiovascular morbidity in patients with obesity without diabetes mellitus: a meta-analysis involving 32,884 patients","Mohamed Abouzid","2024","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehae666.3279",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0047064","1032-OR: ACCESS Trial: Dose-Ranging Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with Obesity and Overweight","Julio Rosenstock","2026","Diabetes","randomized_trial","article","10.2337/db26-1032-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047065","S3653 Successful Use of GLP-1 Receptor Agonist in Patient With Recurrent Hypertriglyceridemia-Induced Pancreatitis: A Case Report","Chinmay Guralwar","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001142072.33570.44",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047066","Abstract 4365079: Semaglutide Modulates the Cardio-Hepatic Axis By Mitigating Lipid and Fibrosis Deposition Independent of Weight Loss in Obese HFpEF","David J. Polhemus","2025","Circulation","preclinical","article","10.1161/circ.152.suppl_3.4365079",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047067","SAT-520 Tirzepatide-associated Interstitial Kidney Injury: A Case Report","Mohamed El‐Dib","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.1052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047068","GLP-1 and GLP-1-based therapies : addressing beta-cell dysfunction in type 2 diabetes : review","Michael Albrecht Nauck","2009","˜The œSouth African journal of diabetes & vascular disease","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047069","72819 Evaluation of GLP1-Receptor Agonist Use in Patients with Idiopathic Inflammatory Myopathies: A Retrospective Analysis","Nadean F Alnajjar","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.866",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047070","SAT-452 GLP1 agonist and metabolic dysfunction-associated steatohepatitis (MASH): systematic review and meta-analysis","Ryan YanZhe Lim","2025","Journal of Hepatology","systematic_review","article","10.1016/s0168-8278(25)01708-8",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0047071","ADJUNCTIVE GLP-1 RECEPTOR AGONISTS IN CROHN’S DISEASE: REDUCED STEROID DEPENDENCE AND HOSPITALIZATIONS IN A REAL-WORLD MULTI-NETWORK COHORT","Nakul Ganju","2026","Inflammatory Bowel Diseases","nonrandomized_study","article","10.1093/ibd/izag006.014",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047072","GLP-1R Agonist Therapy Attenuates Proteinuria Development in Non-Diabetic Subtotally Nephrectomized Rats","Brittany J. Telford","2012","Canadian Journal of Diabetes","preclinical","article","10.1016/j.jcjd.2012.07.381",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047073","Novel Nanoparticles for Oral Exendin-4 Delivery","Ho-Ngoc Nguyen","2012","World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany","other","article","10.1007/978-3-642-32183-2_18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047074","Pilotstudie mit Exenatide als Ersatz für Insulin bei bisher insulinbehandelten Patienten mit Typ 2 Diabetes unter Therapie mit oralen Antidiabetika","CHRISTOF M. KAZDA","2007","Diabetologie und Stoffwechsel","other","article","10.1055/s-2007-982252",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047075","Changes in insulin sensitivity and DHEAS in type 2 diabetic men treated with liraglutide","Gonzalo Piedrola","2014","Endocrine Abstracts","other","article","10.1530/endoabs.35.p487",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047076","Association of GLP-1 Agonist Prescription with Improved Joint Outcomes in Rheumatoid Arthritis","Faissal Stipho","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6442041",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047077","Oral hypoglycemic drugs: An overview","Pardeep Kaur","2019","Journal of Drug Delivery and Therapeutics","other","article","10.22270/jddt.v9i3-s.2815",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047078","Effects of Long-Term Use of Sodium–Glucose Co-Transporter-2 Inhibitors on Proteinuria and Renal Function in Patients with Type 2 Diabetes Mellitus without Chronic Kidney Disease during the COVID-19 Pandemic","Dimitrios Patoulias","2025","Saudi Journal of Kidney Diseases and Transplantation","randomized_trial","article","10.4103/sjkdt.sjkdt_605_21","41431916",null,"ISRCTN:ISRCTN88851713",null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047079","WEIGHT LOSS OUTCOMES WITH SEMAGLUTIDE TREATMENT IN A LARGE HEALTHCARE SYSTEM- A REAL LIFE REPORT FROM THE HOUSTON METHODIST CVD LEARNING HEALTH SYSTEM REGISTRY","Eleonora Avenatti","2024","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(24)03721-5",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047080","The role of glucagon-like peptide-1 receptor agonists in cardiometabolic health management","Tatiana Yu. Demidova","2024","FOCUS Endocrinology","randomized_trial","article","10.62751/2713-0177-2024-5-4-22",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047081","733-P: Efficacy of a Novel Oral Amylin Analog and the Development of an Oral GLP-1/Amylin Coformulated Tablet to Produce High In Vivo Plasma Exposures","Haixia Zou","2025","Diabetes","preclinical","article","10.2337/db25-733-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047082","Su1942 SHORT-TERM EFFECTS OF LIRAGLUTIDE ON OREXIGENIC HORMONE PLASMA CONCENTRATION, APPETITE AND FOOD PREFERENCES IN FASTED AND POSTPRANDIAL STATE: AN INTERMEDIATE ANALYSIS","Emily Ruilova Sosoranga","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)02501-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047083","Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs","David Z.I. Cherney","2020","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20203110s1349b",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047084","Exendin-4 attenuates the development of experimental diabetic cardiomyopathy via specific actions on the extracellular matrix","Mitchel Tate","2013","Research Portal (Queen's University Belfast)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047085","S1071 GLP-1 Agonist Use is Associated With Lower Complications and Mortality in Patients With Ulcerative Colitis and Obesity: A National Database Analysis","Luis Miguel Nieto","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001033652.14646.a5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047086","378-P: Network Meta-analysis of Hypoglycemic Treatment Regimens with Potential Risk of Hypoglycemia in Terms of Glycemic Control and Severe Hypoglycemia","SATORU KODAMA","2022","Diabetes","systematic_review","article","10.2337/db22-378-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0047087","Charakteristika von 833 Patienten, die neu mit GLP-1-Analoga oder DPP-IV Inhibitoren in 38 Diabetes-Schwerpunktpraxen therapiert werden","Gregor Hess","2011","Diabetologie und Stoffwechsel","other","article","10.1055/s-0031-1277437",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047088","Evolution of concepts on optimal nutrition as a pillar for improving metabolic health","Tatiana Yu. Demidova","2026","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2026-191",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047089","Tubular and glomerular biomarkers of kidney injury on glucagon-like peptide-1 (GLP-1) therapy in type 1 diabetic patients","З. Т. Зураева","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.ep568",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047090","S2338 GLP-1 Receptor Agonist Therapy in Obese Patients With Coexisting IBD and MASLD: Metabolic and Inflammatory Outcomes","Noor Albusta","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001136812.26450.d8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047091","Exenatide prolonged-release suspension for injection incombination with oral antidiabetic therapy for thetreatment of type 2 diabetes","Norman R Waugh","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047092","Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal Tests","David Peick Sonne","2015","Diabetes Care","other","article","10.2337/dc14-2751","25908158",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047093","Impact of SGLT2 inhibitors and GLP1 receptor agonists on respiratory infections: a meta-analysis","Mei Hong Qiu","2021",null,"systematic_review","article","10.37766/inplasy2021.1.0092",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0047094","EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BOWEL PREPARATION FOR COLONOSCOPY","Khushboo S. Gala","2023","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2023.04.272",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047095","1207-P: Early vs. Late Initiation of SGLT2 and GLP-1RA for Cardiometabolic Risk Factor Control: A Real-World Study","Sanjoy Ketan Paul","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1207-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047096","Impact of weight loss on GLP-1, glucagon and oxyntomodulin secretion in patients with obesity and type 2 diabetes","Ekaterina Alekseevna Shestakova","2025","Diabetes Mellitus","other","article","10.14341/dm13267",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047097","S1668 The Effects of Gastric Emptying on Weight Loss After Intragastric Balloon and Endoscopic Sleeve Gastroplasty","Sigrid Young","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000956312.86160.d6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047098","Economic Evaluation of Liraglutide for Treatment of Type 2 Diabetes Mellitus in the Russian Federation","Roza Ismailovna Yagudina","2013","Value in Health","other","article","10.1016/j.jval.2013.08.688",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047099","IDF2022-0369 Predictors of achieving weight loss ≥15% with tirzepatide in people with type 2 diabetes from SURPASS 1-4","M. Malecki","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110271",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047100","Su1806 DUODENAL MUCOSAL RESURFACING STABILIZES WEIGHT LOSS AND GLYCEMIC CONTROL AFTER GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST WITHDRAWAL: REVEAL-1 - A PROSPECTIVE MULTICENTER OPEN-LABEL STUDY","Shailendra Singh","2026","Gastroenterology","other_trial","article","10.1016/s0016-5085(26)04891-2",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047101","AVALIAÇÃO DA INTELIGÊNCIA ARTIFICIAL PARA OBTENÇÃO DE CONHECIMENTO E SUGESTÕES DE CONDUTA NA PRÁTICA CLÍNICA EM NEFROLOGIA","Gabriel Rotsen Fortes Aguiar¹","2024",null,"other","article","10.65034/bjnabstract-cbn240480",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047102","Trends in use of glucagon-like peptide-1 receptor agonists in obese patients with endometrial cancer","Heidi  Heekyung Chang","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7266806",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047103","Semaglutide therapy does not impede improvements in aerobic endurance or body composition during early cardiac rehabilitation","J Riess","2026","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwag249.350",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047104","2300-PUB: Activation of GLP-1 Signaling Attenuates FFAs-Induced Muscle Dysfunction and Senescence","Hsin‐Hua Li","2020","Diabetes","preclinical","article","10.2337/db20-2300-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047105","Lixisenatide—Once-daily Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes","Celeste C L Quianzon","2010","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2012.08.01.12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047106","CO72 Real-World Effectiveness of Tirzepatide vs. Semaglutide on HbA1c and Weight in GLP-1 RA Experienced Patients with T2D","Meredith M. Hoog","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.157",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0047107","Glycemic Variability of Tirzepatide vs Insulin Degludec in People with Type 2 Diabetes (T2D) Using Continuous Glucose Monitoring (SURPASS-3 CGM)","Richard M. Bergenstal","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1767870",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047108","Semaglutide and cardiovascular outcomes in overweight or obesity without diabetes: A real-world cohort study","George Anthony Komatsoulis","2025","Next research.","nonrandomized_study","article","10.1016/j.nexres.2025.100587",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047109","Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist—Immunogenicity Profile Based on Preclinical and Clinical Studies","Stefano Del Prato","2018","Diabetes","preclinical","article","10.2337/db18-1097-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047110","Differentiation of Rat Bone Marrow-Derived Mesenchymal Stem Cells into Insulin-Producing Cells","Mahmoud M. Gabr","2011",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047111","Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist","Iepsen Ew","2019","Yearbook of pediatric endocrinology","other","article","10.1530/ey.16.11.12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047112","Normoglucemiantes orales y riesgo cardiovascular","Guillermo Edinson Guzmán","2018","Revista Colombiana de Cardiología","other","article","10.1016/j.rccar.2017.10.009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047113","Tu1921 - Liraglutide Treatment Modulates Regional Body Fat Distribution in Individuals with Obesity","Hoda C. Kadouh","2018","Gastroenterology","other","article","10.1016/s0016-5085(18)33527-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047114","184-OR: Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM","Olga Lavrynenko","2020","Diabetes","randomized_trial","article","10.2337/db20-184-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047115","GLP-1 Receptor Agonists in Hypertrophic Cardiomyopathy: Mortality Benefit with Complex Cardiovascular Risk Profile","Karldon Iwuchukwu Nwaezeapu","2025","American Heart Journal","other","article","10.1016/j.ahj.2025.07.028",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047116","eP172 Tirzepatide Mimicking /Causing Acute Surgical Abdomen: A Two-Case Experience","Altaf GAUHAR Haji","2025","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znaf166.438",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047117","Insulin-sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8","Vanita R. Aroda","2022","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2022.09.014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047118","Treatment with Exenatide Twice Daily and Once Weekly is Associated with Favorable Lipid Subclass Changes in Patients with Abnormal Baseline Values","Peter Paul Toth","2012","Journal of clinical lipidology","other","article","10.1016/j.jacl.2012.04.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047119","P20 A comparison of the cardiovascular effects of empagliflozin and liraglutide: a systematic review and meta-analysis","Ify R. Mordi","2016",null,"systematic_review","article","10.1136/heartjnl-2016-310696.24",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0047120","Efficacité et tolérance de la substitution de la sitagliptine par le liraglutide chez des patients diabétiques de type 2 - LIRA-SWITCH : Essai de 26 semaines, randomisé en double aveugle, double placebo contrôlé versus comparateur actif","Alfred Penfornis","2016","Annales d Endocrinologie","other","article","10.1016/j.ando.2016.07.229",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047121","Long-Term Follow-up of an Infant with Prader-Willi Syndrome","Amy Fleischman","2024","NeoReviews","nonrandomized_study","article","10.1542/neo.25-10-e669","39349415",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047122","S2404 Use of Oral Semaglutide in the Management of MASLD in Failures of Standard Therapy","Ayush Ayush","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001137076.03754.89",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047123","Einfluss von Hypoglykämien auf Insulintitration und Nüchternplasmaglukose bei mit basalunterstützter oraler Therapie (BOT) behandeltem Typ-2-Diabetes: eine Subanalyse der SoliMix-Studie","Francesco Giorgino","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1767989",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE",null,null,"FALSE","article"],["R0047124","Medication counselling with sodium glucose transporter 2 inhibitor therapy","Sanjay Kalra","2014","Indian Journal of Endocrinology and Metabolism","other_trial","article","10.4103/2230-8210.139206","25285273",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","editorial"],["R0047125","Age no Impediment to Effective Weight Loss with Liraglutide 3.0 Mg: Data from Two Randomized Trials","Domenica Rubino","2018","International Journal of Nutrology","randomized_trial","article","10.1055/s-0038-1674366",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-paper"],["R0047126","Verbesserung von Betazellfunktion und glykämischer Kontrolle nach einem Jahr Therapie mit Exenatide bei Metformin-behandelten Patienten mit Typ-2-Diabetes","Oliver P. Bachmann","2008","Diabetologie und Stoffwechsel","other","article","10.1055/s-2008-1076191",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047127","1166-P: Bromocriptine-QR (BQR) Therapy Reduces Elevated Sympathetic Nervous System Activity (SNSA) and Oxidative Stress (OS) in Type 2 Diabetes (T2D) Subjects whose Dysglycemia Is Poorly Controlled on GLP-1 Receptor Agonist (GLP-1RA)","Bindu Chamarthi","2019","Diabetes","other","article","10.2337/db19-1166-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047128","#36247 Glucagon-like peptide-1 analogue in the management of rebound intracranial hypertension: a case report","James S. Khan","2023",null,"case_report","article","10.1136/rapm-2023-esra.380",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0047129","Abstract 4365144: Glucagon-like-peptide-1 Receptor Agonists Are Associated with Lower Postoperative Complication Rates in Patients with Peripheral Artery Disease","Hasan Nassereldine","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4365144",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047130","155-OR: Reduced Perceived Diabetes Distress with the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 2 Diabetes (T2D)—Analysis of the SECURE-T2D Study","KRISTIN N. CASTORINO","2025","Diabetes","nonrandomized_study","article","10.2337/db25-155-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047131","IP17-11 PRESCRIBING PATTERNS AND CLINICAL IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AMONG KIDNEY TRANSPLANT POPULATION IN BRITISH COLUMBIA, CANADA","Hyunwoong Harry Chae","2025","The Journal of Urology","other","article","10.1097/01.ju.0001110028.22652.53.11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047132","Liraglutide 3.0 mg in obese/overweight adults with or without prediabetes with baseline BMI <35 vs ≥35 kg/m2 in the SCALE Obesity and Prediabetes 56-week randomized, double-blind, placebo-controlled trial","Joseph Proietto","2019","Obesity Research & Clinical Practice","randomized_trial","article","10.1016/j.orcp.2016.10.266",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047133","Sa1506: REAL WORLD DATA ASSESSING THE IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE","Reeti K. Gulati","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04726-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047134","Cost analysis of SGLT2 inhibitors in patients with type 2 diabetes in India","Sooriyaprasannan Sriram","2020","Research Journal of Pharmacy and Technology","other","article","10.5958/0974-360x.2020.01021.5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047135","2836 Age differences in efficacy of newer glucose lowering treatments for type 2 diabetes","Peter Hanlon","2025","Age and Ageing","randomized_trial","article","10.1093/ageing/afae277.076",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047136","19. Efficacy and Safety of Liraglutide Added to Insulin in Type 1 Diabetes: The LIRA-1 Trial (277-OR)","Thomas Fremming Dejgaard","2015","Nederlands Tijdschrift voor Diabetologie","other_trial","article","10.1007/s12467-015-0040-y",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047137","THU296 Effect Of Tirzepatide In GADA-positive Individuals With T2D: A Post Hoc Analysis Of The SURPASS 2-5 Trials","Anne L. Peters","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.731",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047138","MON-591 Effect of Liraglutide Treatment on Proglucagon-Derived Peptides","Sun H. Kim","2020","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaa046.1288",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047139","7529 A Silent Menace Of Mounjaro: Acute Renal Failure Associated With Tirzepatide","Fadi Farhat","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.1027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047140","S2388 Chronic Pancreatitis Secondary to Semaglutide Use","Charles Vallejo","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001038920.86891.ba",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047141","80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)","Dominik B. Dahl","2021","Diabetes","randomized_trial","article","10.2337/db21-80-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047142","Liraglutide for the treatment of severe obesity in children: early experiences from a tier 3 paediatric weight management service","Katherine Hawton","2022","Endocrine Abstracts","other","article","10.1530/endoabs.85.oc9.7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047143","O-018 Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomised controlled trial","Elo Andersen","2022","Human Reproduction","randomized_trial","article","10.1093/humrep/deac104.018",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0047144","An exploration of the predictive factors for the early pleiotropic responses to exenatide therapy in patients with type 2 diabetes mellitus","Thomas W. Barber","2010","Society for Endocrinology BES 2010","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047145","Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial","Ahmed A. Kolkailah","2022","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwac056.042",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047146","Case 68: Insulin Allergy in an Insulin-Requiring Patient","Nestoras Nicolas Mathioudakis","2015","American Diabetes Association eBooks","other_trial","article","10.2337/9781580405713.68",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0047147","Quick Take Vol. 78","Kristin Raj","2025",null,"other","article","10.64239/pi-it-qt78",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0047148","Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Cross-Over LIRALUNG Study","Carolina López‐Cano","2021",null,"randomized_trial","article","10.2337/figshare.16915396.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0047149","PO-02-054 EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS IN PATIENTS WITH ATRIAL FIBRILLATION AND SARCOIDOSIS: A PROPENSITY SCORE-MATCHED ANALYSIS","Min Choon Tan","2025","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2025.03.536",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047150","93 - Semaglutide in Patients With Type 2 Diabetes: Real-World Analysis in the Canadian LMC Diabetes Registry: The SPARE Study","Peter Galthen Bech","2019","Canadian Journal of Diabetes","nonrandomized_study","article","10.1016/j.jcjd.2019.07.102",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047151","Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (GLP-1RA) injections in the treatment of type 2 diabetes","Brett Hauber","2014","Value in Health","other","article","10.1016/j.jval.2014.03.1488",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047152","PDB9 IMPACT OF EXENATIDE, PEN INSULIN AND VIAL/SYRINGE INSULIN ON PATIENT OUTCOMES IN A DIABETES POPULATION IN THE UNITED STATES: A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE AND FIRST-YEAR COSTS","Nazish Rashid","2011","Value in Health","nonrandomized_study","article","10.1016/j.jval.2011.02.517",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047153","S2570 Underuse of GLP-1 Receptor Agonists Despite Promising Evidence in Managing Post-Liver Transplant Alcohol Recidivism in Alcohol Associated Liver Disease","Leandro Sierra","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137740.62046.3a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047154","Drug Improves Glucose Levels and Drives Weight Loss","Anita J Slomski","2018","JAMA","other","article","10.1001/jama.2018.12046","30167698",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047155","COMPARED TO INSULIN GLARGINE, TIRZEPATIDE REDUCES THE PREVALENCE OF THE METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK: POST-HOC ANALYSIS OF SURPASS-4","Stephen James Nicholls","2023","Canadian Journal of Cardiology","other","article","10.1016/j.cjca.2023.06.281",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047156","Beyond weight loss: a case study and narrative review of the potential role of glucagon-like peptide-1 receptor agonists for the treatment of idiopathic intracranial hypertension","Daniel Paulo","2023","Annals of Eye Science","narrative_review","article","10.21037/aes-24-42",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0047157","Utilizing AI and Social Media Analytics to Discover Adverse Side Effects of GLP-1 Receptor Agonists","Alon Bartal","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.4790676",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047158","Engineered Escherichia coli Nissle 1917 Expressing IGF1 and FGF19 Reduce Liver Fat Accumulation and Restore Microbial Equilibrium in a Metabolic Dysfunction-Associated Steatotic Liver Disease Mice Model","Johnson Lok","2024",null,"preclinical","article","10.3390/proceedings2023091402",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047159","Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. Diabetes Care 2013;36:2559–2565","Robert R. Henry","2013","Diabetes Care","randomized_trial","article","10.2337/dc14-er01b",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047160","Reprogramming of GLP-1 Response at Prediabetes for the Prevention of Type 2 Diabetes: The Role of Albumin and GLP-1 Receptor Agonists","Amr Kamel Khalil Ahmed","2024","Cell & Cellular Life Sciences Journal","other","article","10.23880/cclsj-16000199",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047161","Modern aspects of therapy of metabolic associated liver disease in patients with type 2 diabetes mellitus","Svetlana Viktorovna Bulgakova","2024","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2024-414",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047162","Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial","Ninian N. Lang","2020","Cardiovascular Research","randomized_trial","article","10.1093/cvr/cvaa247","32980877",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047163","The Effect of Exenatide on Weight and Appetite in Overweight Adolescents and Young Adults with Prader-Willi Syndrome","Parisa Salehi","2015","54th Annual ESPE","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047164","Abstract P2-08-25: FITWISE: Feasibility study of tirzepatide for weight loss intervention in early stage hormone receptor positive/HER2 negative breast cancer","Coral Oghenerukevwe Omene","2025","Clinical Cancer Research","randomized_trial","article","10.1158/1557-3265.sabcs24-p2-08-25",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047165","Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX): a pilot randomised controlled trial","Dan J. Siskind","2018",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0047166","1763-P: Impact of Telehealth Delivered GLP-1RA Therapy on Cardiometabolic Outcomes in a Weight Management Program","Lauren Broffman","2025","Diabetes","other","article","10.2337/db25-1763-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047167","S852 Does ASA Physical Status Class Affect Outcomes of Endoscopy Under MAC Anesthesia in Patients on GLP-1? A Retrospective Cohort Analysis","Rabih Ghazi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032776.87950.1c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047168","Clinical effects of SGLT2 inhibitors in seven persons with HNF1A ‐ MODY ( MODY3 )","Henrik Maagensen","2024","Diabetic Medicine","randomized_trial","article","10.1111/dme.15387","38875310",null,"CTIS:2023-503760-17-00",null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047169","Su1101: IMPACT OF GLP-1 RA ON GASTRIC EMPTYING AT TIME OF ENDOSCOPY; A SYSTEMATIC REVIEW","Selome F. Yewedalsew","2025","Gastroenterology","systematic_review","article","10.1016/s0016-5085(25)02531-4",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0047170","Abstract #204 GLP1 Agonist Dulaglutide and Proteinuria Reduction in Obese Diabetes Patient with Focal Segmental Glomerulosclerosis","Teresa V. Brown","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47050-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047171","1015-P: Effects of the Oral, Small Molecule GLP-1R Agonist TTP273 on Patients with Stage 2 Hypertension: Results from a Post Hoc Analysis of the Phase 2 Logra Study","Carmen Valcarce","2019","Diabetes","randomized_trial","article","10.2337/db19-1015-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047172","86 - Clinical Response (HbA1C ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA1C and Body Weight in the SUSTAIN Program","Akshay Jain","2019","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2019.07.095",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047173","Real-World Comparative Evaluation of Clinical and Economic Outcomes of Fixed-Ratio GLP-1 Receptor Agonist and Basal Insulin Combinations","Kevin Cowart","2025","Diabetes Technology and Obesity Medicine","nonrandomized_study","article","10.1177/29941520251358769",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047174","In-Silico Design of Novel Glucagon-Like Peptide 1 Mutants as Candidate for New Peptide Agonist Drugs","Tony Ibnu Sumaryada","2021","HAYATI Journal of Biosciences","other","article","10.4308/hjb.28.1.92",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047175","Effects of EXf,a fragment of exendin-4,on H2O2-induced apoptosis in pancreatic islet β-cells line INS-1","Dong Li-jin","2011","Di-san junyi daxue xuebao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047176","316-LB: Medically Reproducing Bariatric Surgery (MRB): A Proof-of-Concept Study","Moahad Saeed Dar","2019","Diabetes","other","article","10.2337/db19-316-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047177","Neutrophil-to-lymphocyte ratio predicts cardiovascular events in patients with type 2 diabetes: post hoc analysis of SUSTAIN 6 and PIONEER 6","Subodh Verma","2021","European Heart Journal","other_trial","article","10.1093/eurheartj/ehab724.2479",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0047178","Targeting mitochondria: a great boon to fight type 2 diabetes","Aranzazu Martinez de Marañon","2022","Redox Experimental Medicine","other","article","10.1530/rem-22-0012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047179","Effectiveness of Weight Loss School","N.V. Bolotova","2022","Voprosy praktičeskoj pediatrii","other","article","10.20953/1817-7646-2022-2-93-98",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047180","Drugs Used in the Treatment of Obesity – A Systematic Review","Olga Plinta","2026","Quality in Sport","systematic_review","article","10.12775/qs.2026.51.67976",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0047181","L’ancienneté du diabète et les traitements antérieurs sont les facteurs prédictifs de la réponse au liraglutide : résultats de l’étude post-inscription EVIDENCE®","Alfred Penfornis","2014","Annales d Endocrinologie","other","article","10.1016/j.ando.2014.07.355",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047182","EARLY EXPERIENCE OF GPP-1 LIRAGLUTIDE 3.0 MG ANALOGUE IN RUSSIA AND ITS EFFECT ON METABOLIC RISK FACTORS IN OBESITY PATIENTS","K. A. Komshilova","2017","Meditsinskiy sovet = Medical Council","other","article","10.21518/2079-701x-2017-3-58-62",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047183","Once-weekly dulaglutide (DU) vs. insulin glargine in the control of fasting serum glucose and hypoglycaemia rate in the first 20 weeks in patients with type 2 diabetes mellitus on metformin and glimepiride","Esteban Jódar","2017","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0037-1601745",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047184","406-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment","Peter R Rossing","2021","Diabetes","randomized_trial","article","10.2337/db21-406-p",null,null,"ClinicalTrials.gov:NCT02540993",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047185","PDB5 Real-World Treatment Patterns and Outcomes When Initiating Once-Daily Injectable Pen Therapy with Insulin Glargine or Liraglutide – an Electronic Medical Records Study","James H. Mersey","2012","Value in Health","nonrandomized_study","article","10.1016/j.jval.2012.08.1648",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047186","Semaglutide shown to improve cardiovascular outcomes among patients with type 2 diabetes with any forms of heart failure","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","other","article","10.1002/doi2.70004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047187","Non‐Insulin Parenteral Therapies","Jens Juul Holst","2010",null,"other","article","10.1002/9781444324808.ch30",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0047188","1027-P: A Phase 1, Open-Label, Single-Dose Study to Evaluate Pharmacokinetics of MEDI0382 in Patients with Renal Impairment","Gernot Klein","2019","Diabetes","other_trial","article","10.2337/db19-1027-p",null,null,"ClinicalTrials.gov:NCT03235375","S000042","openalex","FALSE","paywalled","5","FALSE","article"],["R0047189","S4100 Iron Deficiency Anemia and Weight Loss: A Case of Colon Cancer in a Young Woman on Semaglutide","Andrea Escalante","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001143860.71615.03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047190","New Hope For People With Dysglycemia and Cardiovascular Disease Manifestations","Lars Rydén","2017","Circulation","other_trial","article","10.1161/circulationaha.117.027952","28507248",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0047191","Comparative analysis of tirzepatide versus metformin and insulin in type 2 diabetes patients across the 13 most common cancers.","Viraj R. Shah","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.10508",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047192","Activation of the Sympathoadrenal System under the Influence of Glucagon-Like Peptide-1 Mimetic in Rats","E. V. Balbotkina","2024","Нейрохимия","preclinical","article","10.31857/s1027813324040066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047193","Weight loss induced by semaglutide once weekly contributes to improved health-related quality of life and treatment satisfaction","John P.H. Wilding","2019","Figshare","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","conference-paper"],["R0047194","Exendin-4 reduces infarct volume after transient focal cerebral ischaemia in mice","Tetsuo Ishizaki","2010","European Journal of Anaesthesiology","preclinical","article","10.1097/00003643-201006121-00384",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047195","Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?","Serge A Jabbour","2008","International Journal of Clinical Practice","other","article","10.1111/j.1742-1241.2008.01757.x","18479275",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047196","S1878 Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated With an Increased Rate of Aborted Esophagogastroduodenoscopy and Need for Repeat EGD, Independent From the Presence of Diabetes","Danial Nadeem","2023","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000957152.92407.c4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047197","Treatment of Diabetic Complications","Kalliopi Pafili","2014","Angiology","other_trial","article","10.1177/0003319714544948","25092682",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047198","MRI-PDFF≥70% Reduction Was Associated With Fibrosis Improvement With Tirzepatide: Post-Hoc Analysis of the SYNERGY-NASH Phase 2B Trial","Rohit Loomba","2026","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0046-1819980",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0047199","Cardiovascular safety of liraglutide: Pooled analysis of Major adverse cardiovascular events across weight management and Type 2 Diabetes development programs","Simon N. Jacob","2016","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0036-1580943",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047200","Fat depot of the heart: contribution to the development of cardiovascular diseases, visualization methods and the possibilities of it’s correction","E. S. Bratilova","2020","Bulletin of the Russian Military Medical Academy","other","article","10.17816/brmma50562",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047201","Liraglutide as additional treatment to insulin in patient with latent autoimmune diabetes in adults (LADA): a case report","Iuliia V. Silko","2016","Endocrine Abstracts","case_report","article","10.1530/endoabs.41.ep538",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047202","Liraglutide withdrawal rates: ‘real world’ practice","Anjali Balasanthiran","2012","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1680",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047203","S102 The potential effect of glucagon-like peptide 1 receptor agonists (GLP1s) on chronic obstructive pulmonary disease (COPD) exacerbations, a case control analyses","Bernardino Alcázar Navarrete","2025",null,"randomized_trial","article","10.1136/thorax-2025-btsabstracts.108",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047204","FRAGILITY INDEX OF VARIOUS GLP1 AGONISTS ON CARDIOVASCULAR OUTCOMES IN PLACEBO CONTROLLED TRIALS","Jean‐Jacques Mourad","2021","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0000746812.65674.1a",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047205","OUTCOMES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN OBESE PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY","Amro D. Aglan","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)02199-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047206","change in patient-reported outcomes (pros) and the relationship with clinical parameters in patients with Type 2 diabetes receiving once weekly dulaglutide or insulin glargine in the Assessment of Weekly Administration of Dulaglutide in Diabetes (award-2 and -4) studies : p149","Kate Van Brunt","2015","Diabetic Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047207","Editorial: Diabetes and oral health","Xiaofang Zhu","2026","Frontiers in Clinical Diabetes and Healthcare","nonrandomized_study","article","10.3389/fcdhc.2026.1786239","41659747",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0047208","Morphological features of pancreatic endocrinicytes in rats with type 2 diabetes mellitus receiving the incretin mimetic therapy of different duration","Таисия Павловна Тучина","2020","Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia»","preclinical","article","10.25557/0031-2991.2020.03.117-125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047209","Abstract 4367801: Tirzepatide Achieves Greater Weight and Blood Pressure Reduction Than Semaglutide in Routine Clinical Practice","Chungsoo Kim","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4367801",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047210","Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 56-week trial","Gary Wittert","2014","Obesity Research & Clinical Practice","randomized_trial","article","10.1016/j.orcp.2014.10.211",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047211","Plin5 alleviates endoplasmic reticulum stress to promote white adipose tissue remodeling","Jingru Qu","2026","Biology Direct","preclinical","article","10.1186/s13062-026-00976-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047212","(010) Vulvar Tissue Changes in Non-diabetic Women Receiving GLP-1 Receptor Agonists: A Global Federated Cohort Analysis","M Moukhtar Hammad","2026","The Journal of Sexual Medicine","nonrandomized_study","article","10.1093/jsxmed/qdag063.010",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047213","Disproportionate improvement in obstructive sleep apnea relative to weight loss following tirzepatide therapy","Dr. Abdul Wahid","2026","Journal of Diabesity","other","article","10.66381/jod.2026.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047214","GLP-1 defects in diabetes (revision number 6)","CJ Janus","2015","Diapedia.org eBooks","other","article","10.14496/dia.0104336116.6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047215","The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus: A meta-analysis of multinational randomized trials","Salil Vasudeo Deo","2021",null,"systematic_review","article","10.37766/inplasy2021.7.0097",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0047216","Combined Use of Empagliflozin and Liraglutide Protects Against Tacrolimus-Induced Pancreatic and Kidney Injury through Suppression of Oxidative Stress","Beom Joon Kim","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.940",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047217","Exenatide in Type 2 Diabetes: Indications and Initiation","Vanita Treat","2008","Humana Press eBooks","other","article","10.1007/978-1-60327-103-5_38",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047218","P-048 MODY 8 DUE TO CEL GENE MUTATION IN A 41-YEAR-OLD FEMALE: A DIAGNOSTIC CHALLENGE AND MANAGEMENT UPDATE","Suha Adil Nasir","2026","JCEM Case Reports","other","article","10.1210/jcemcr/luaf297.040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047219","Monitoring beta cell survival after intrahepatic islet transplantation using dynamic exendin PET imaging: a proof-of-concept study in individuals with type 1 diabetes","Theodorus J.P. Jansen","2023",null,"other","article","10.2337/figshare.22564699.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0047220","1474-P: Changes in SGLT2i and GLP-1RA Real-World Initiator Profiles following Cardiovascular Outcome Trials—A Danish Nationwide Population-Based Study","Jakob Schöllhammer Knudsen","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1474-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047221","GL0034, A novel long-acting glucagon-like peptide 1 receptor agonist exhibits significant efficacy in aged db/db mouse model of non-alcoholic fatty liver disease (NAFLD)","Rajamannar Thennati","2022","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(22)01737-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047222","231-LB: GLP-1 Promotes Cortical and Medullary Perfusion in Human Kidney and Maintains Tissue Oxygenation during Na Loading","Bryan Haddock","2022","Diabetes","randomized_trial","article","10.2337/db22-231-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047223","A single-center retrospective study of GLP-1 agonist use in patients with hidradenitis suppurativa","Sawsan Alkhalili","2025","Archives of Dermatological Research","nonrandomized_study","article","10.1007/s00403-025-04443-0",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047224","Diabetes UK Professional Conference","Payal H. Marathe","2017","Journal of Diabetes","other_trial","article","10.1111/1753-0407.12552","28323390",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0047225","GLP-1 Based Therapies: Potential for Drug - Disease Interaction","Maria Vinall","2013","MD Conference Express","other","article","10.1177/155989771317021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047226","2650-P: Multiorgan Magnetic Resonance–Based Imaging Improves Risk Stratification and Supports Treatment Allocation in Individuals with Clinical Obesity","EDWARD JACKSON","2026","Diabetes","other","article","10.2337/db26-2650-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047227","Abstract 52: Glucagon-like peptide-1 receptor agonists use and outcomes in Cardiac Amyloidosis patients: A Propensity Matched Analysis","Vikash Jaiswal","2025","Stroke","randomized_trial","article","10.1161/str.56.suppl_1.52",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047228","Abstract 4370885: Outcomes of Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes and Heart Failure with Preserved Ejection Fraction: A Retrospective Cohort Analysis","Abdulrahman Murshid","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4370885",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047229","107-LB: Progression of Position of Basal Insulin in the Treatment of Type 2 Diabetes—A Real-World Analysis","David Schapiro","2022","Diabetes","nonrandomized_study","article","10.2337/db22-107-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047230","Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6","Katherine R. Tuttle","2020","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20203110s136a",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047231","P172 Évaluation des propriétés anti-inflammatoire et anti-oxydante du liraglutide sur des îlots pancréatiques de rat in vitro","A. Langlois","2014","Diabetes & Metabolism","preclinical","article","10.1016/s1262-3636(14)72463-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047232","S4838 Iron Tablet Gastropathy: When Iron Supplementation for GI Bleeding Leads to More GI Bleeding","Yannis S. Lafazanos","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001146812.82541.9e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047233","Abstract 4367416: GLP-1 Receptor Agonists and Mortality Outcomes in Patients with Left Ventricular Assist Devices: A Propensity-Matched Cohort Study from the TriNetX Global Network","Ahmad Muneer Alkhatib","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4367416",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047234","ESKD in Veterans with Type 2 Diabetes: Comparative Effectiveness of Valproic Acid and Lamotrigine","Amara Sarwal","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20257cq92try",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047235","ABCD position statement on GLP‐1 based therapies and pancreatic damage","Bob Ryder","2013","Practical Diabetes","randomized_trial","article","10.1002/pdi.1816",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047236","Liraglutide More Effectively Achieves a Composite Endpoint for A1C, SBP and Weight Change Than Other Diabetes Therapies","Bernard Zinman","2009","Diabetes","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047237","Market licensing of type 2 diabetes medicinal products based on patient-relevant hard outcomes: is there hope?","Thomas Andersen Schmidt","2017","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvx026","29315396",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047238","The adverse cosmetic effects of GLP-1 receptor agonists on the face, body, and hair: a narrative review","Megan Hoang","2025","Archives of Dermatological Research","narrative_review","article","10.1007/s00403-025-04379-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0047239","781-P: Structural Modeling of GLP-1R Variants Interactions with Tirzepatide Using AI Tools—A Precision Diabetes Management Method","ANWAR MOHAMMAD","2025","Diabetes","nonrandomized_study","article","10.2337/db25-781-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047240","Perte de poids sous semaglutide versus dulaglutide selon l’IMC initial dans l’étude SUSTAIN 7","Bruno Guerci","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.199",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047241","Spotlight in Plastic Surgery: October 2024","Brett Thomas Phillips","2024","Plastic & Reconstructive Surgery","randomized_trial","article","10.1097/prs.0000000000011591","39314108",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047242","5184 Tirzepatide Improved Mental and Psychosocial Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-4 phase 3 Trial","T M Gibble","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.044",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047243","772-P: Tirzepatide vs. Basal Insulins in People with T2D and Different Baseline Glycemic Patterns—Post Hoc Analyses of the SURPASS-3 and -4 Trials","Francesco Giorgino","2023","Diabetes","other","article","10.2337/db23-772-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047244","Abstract 50: Factors Associated With Obesity Pharmacotherapy Prescription Among Ambulatory Patients With Excess Weight","Meron Haile","2024","Circulation","other","article","10.1161/circ.149.suppl_1.50",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047245","New star award abstract 2: Effects of GLP-1, Exendin-4, and C-peptide on microcirculation and glucose tolerance in rat islets","吴琳","2010","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2010.10.038",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047246","725-P: Protein Biomarkers Associated with Dulaglutide and Cardiovascular Events in REWIND","JONATHAN M. WILSON","2022","Diabetes","other_trial","article","10.2337/db22-725-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047247","Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity","Vladimir Ivanovich Kudinov","2011","Diabetes Mellitus","other","article","10.14341/2072-0351-5643",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047248","10 Jahresvergleich der Stoffwechselkontrolle und Verordnung antidiabetischer Medikamente bei Menschen mit Typ 2 Diabetes mellitus einer universitären Diabetesambulanz","Thomas B. Brunner","2021","Diabetologie und Stoffwechsel","other","article","10.1055/s-0041-1727347",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047249","Inkretin-basierte Glukose-senkende Therapie versus Basalinsulin: Eine Meta-Analyse klinischer Studien unter Berücksichtigung kürzlich entwickelter GLP-1 Rezeptoragonisten und dem GIP/GLP-1 Rezeptor Co-Agonisten Tirzepatide","Daniel Robert Quast","2023","Diabetologie und Stoffwechsel","systematic_review","article","10.1055/s-0043-1767841",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0047250","Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis","B.K.H. Tan","2024","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehae666.3313",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0047251","26-A-19403-ACC COMPARATIVE EFECTIVENESS OF GLP1RA VS SGLT2I ON CARDIOVASCULAR OUTCOMES AND HEALTHCARE UTILIZATION IN VETERANS WITH HEART FAILURE AND TYPE II DIABETES","Nelson Omar Reyes","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.1929",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047252","Quick Take Vol. 84","Scott R. Beach","2026",null,"other","article","10.64239/pi-it-qt84",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0047253","Protective effects of incretin mimetics in cardiomyopathy induced by doxorubicin","Alla P. Tarasova","2018","Journal of Pharmacy Research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047254","OR05-6 The Effect of the GLP1R Variant rs6923761 on Post-Prandial Glucose Levels during Treatment with Sitagliptin","Mona Mashayekhi","2019","Journal of the Endocrine Society","other","article","10.1210/js.2019-or05-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047255","Additional file 7: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Ling Li","2016","Figshare","systematic_review","article","10.6084/m9.figshare.4430720.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0047256","401 Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Moyamoya Disease","Joanna Mary Roy","2026","Neurosurgery","nonrandomized_study","article","10.1227/neu.0000000000003964_401",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047257","Metabolic effects of semaglutide after the first months of treatment: A new GLP-1-RA revolution?","Sara Rojas Jiménez","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep327",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047258","IDF2022-0909 Sustainability of HbA1c control of tirzepatide vs insulin glargine in people with T2D and CV risk (SURPASS-4)","S. Kahn","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110333",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047259","934-P: Real-World Evidence of Glucose Lowering Drug Use, Glycemic Outcomes, and Severe Hypoglycemia in Hong Kong: Eighteen-Year Trends in 0.9 Million Adults with Diabetes","AIMIN YANG","2022","Diabetes","nonrandomized_study","article","10.2337/db22-934-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047260","Glucagon-like peptide-1 modulation of calcium homeostasis in human coronary microvascular endothelial cells after ischemia and reperfusion.","Betsy B. Dokken","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047261","Abstract #239: Treatment Outcomes ith Liraglutide In iNew Onset Type 2 Diabetes – A Retrospective Analysis","Jothydev Kesavadev","2017","Endocrine Practice","nonrandomized_study","article","10.1016/s1530-891x(20)44359-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047262","Discussion: Metabolic Bridge Therapy before Microvascular Breast Reconstruction in Morbidly Obese Patients: A Proof-of-Concept Risk Analysis","Nicholas Till Haddock","2025","Plastic & Reconstructive Surgery","nonrandomized_study","article","10.1097/prs.0000000000011866","40294309",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047263","1409-P: Changing Trends in Glucose-Lowering Drug Initiation for Type 2 Diabetes in the Era of Tirzepatide","ELISABETTA PATORNO","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1409-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047264","149-OR: Liver Health in Adolescents with Youth-Onset Type 2 Diabetes","AMY S. SHAH","2024","Diabetes","other","article","10.2337/db24-149-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047265","Two birds with one stone — Semaglutide's impacts on obesity and knee osteoarthritis: From weight loss to pain relief","Liangbin Zhou","2025","The Innovation Medicine","other","article","10.59717/j.xinn-med.2025.100110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047266","PDB23 THE IMPACT OF TREATMENT MODIFICATION ON HEALTHCARE EXPENDITURE IN PATIENTS WITH TYPE-2 DIABETES INITIATING EXENATIDE BID OR INSULIN GLARGINE","Manjiri D. Pawaskar","2011","Value in Health","other","article","10.1016/j.jval.2011.02.531",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047267","Мрежов метаанализ разход/ефективност на неинсулиновите антидиабетни препарати","D Tsanova","2017","Conference proceedings - IEEE Instrumentation/Measurement Technology Conference","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","conference-paper"],["R0047268","RF25 | PMON76 Kissing carotid arteries: An unusual cause of male hypogonadotropic hypogonadism.","Jordan Bushman","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.1214",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047269","732-P: Real-World Impact of Oral Semaglutide (SEMA) vs. DPP-4 Inhibitors on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes (T2D)—An Observational Study (PAUSE)","James J. Amamoo","2025","Diabetes","nonrandomized_study","article","10.2337/db25-732-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047270","FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes","Минара Шамхаловна Шамхалова","2023","Diabetes Mellitus","nonrandomized_study","article","10.14341/dm13107",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047271","Drugs that melt away pounds still present more questions than answers, but Ozempic, Wegovy and Mounjaro could be key tools in reducing the obesity epidemic","Wesley David Dudgeon","2023",null,"other","article","10.64628/aai.y5anr5qg4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0047272","SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL","Naim Alkhouri","2024","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(24)05018-2",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047273","Liraglutide-induced oral hyperpigmentation: a case report and review of management strategies","Anhar K. Alzahrani","2025","International Journal of Research in Dermatology","case_report","article","10.18203/issn.2455-4529.intjresdermatol20251050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047274","35th Annual J . P . M organ healthcare conference","Abigail E. Dove","2017","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12532","28111923",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047275","A post-hoc pooled analysis of two placebo controlled phase 3 trials, Assessment of Weekly AdministRation of LY2189265 in Diabetes -1 and -5 (AWARD-1 and AWARD-5): dulaglutide compared with exenatide, sitagliptin, and placebo","O Adetunji","2014","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0034-1374980",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047276","Cost-Effectiveness Analysis of Exenatide Once-Weekly Versus Dulaglutide, Liraglutide and Lixisenatide for the Treatment of Type 2 Diabetes Mellitus: An Analysis from the UK NHS Perspective","Mata Charokopou","2015","Value in Health","other","article","10.1016/j.jval.2015.09.2090",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047277","WED-159-YI Positron emission tomography/magnetic resonance imaging with copper-64 DOTATATE identifies metabolic dysfunction-associated steatohepatitis and shows attenuated hepatic signal with glucagon-like peptide-1 receptor agonist treatment","Puria Nabilou","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)01697-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047278","EPAC‑1: un potencial mediador de las acciones protectoras a nivel cardiovascular del liraglutide","Cristina Hernández","2019","Endocrinología Diabetes y Nutrición","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047279","S36 GLP-1 RA Use is Associated with Lower Risk of Biliary Disease Outcomes in Non-Diabetic Patients with Obesity: A Multi-Center Analysis","Do Han Kim","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001028512.66584.2b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047280","Su1097: IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BOWEL PREPARATION FOR COLONOSCOPY; A META-ANALYSIS","Renuka Verma","2025","Gastroenterology","systematic_review","article","10.1016/s0016-5085(25)02527-2",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0047281","Once-Weekly Semaglutide in Adults With Alcohol Use Disorder","Michael B. Paladino","2025","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/ybv8-qp05",null,null,"ClinicalTrials.gov:NCT05520775","S000951","openalex","TRUE","paywalled","1","FALSE","article"],["R0047282","Effet d’un traitement par liraglutide sur la ferritinémie et le contenu hépatique en fer chez des patients diabétiques de type 2","Jean‐Michel Petit","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30412-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047283","Exploring the Evolving Role of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Managing Cardiovascular Injury Induced by Obesity: Spotlight on ROS as a Key Mediator","Lara Srour","2024","Oxidative stress in applied basic research and clinical practice","other","article","10.1007/978-3-031-62131-4_8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047284","OUTCOMES OF CONCOMITANT ENDOSCOPIC SLEEVE GASTROPLASTY WITH GLP-1 RECEPTOR AGONISTS IN THE US: A MULTICENTER STUDY","Anna H. Lee","2025","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2025.03.122",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047285","871-P: Weight Change as Mediator for Cardiovascular Benefits of Novel Diabetes Medications: A Meta-Regression Analysis","José M. Rodriguez‐Valadez","2022","Diabetes","randomized_trial","article","10.2337/db22-871-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047286","Clinical outcomes of GLP-1 receptor agonist therapy in paediatric patients in the thames valley: a retrospective audit","Agnieszka Brandt-Varma","2025","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.111.p143",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047287","Impact des effets indésirables gastro-intestinaux sur la perte de poids des diabétiques de type 2 traités par semaglutide","Emmanuel Disse","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047288","Évaluation du contrôle glycémique par la mesure continue du glucose chez les patients diabétiques de type 2 traités par IDegLira","Bertrand Cariou","2016","Annales d Endocrinologie","other","article","10.1016/j.ando.2016.07.781",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047289","Tirzepatide vs. Dulaglutide Is Associated with Reduced Major Kidney Events in Patients with Type 2 Diabetes, CVD, and Very High-Risk Kidney Diseases","Sophia Zoungas","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025dh60xrrs",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047290","Glucagon-like peptide-1 agonist therapy in patients with diabetes mellitus and obesity","Alina Yu. Babenko","2020","Clinical Medicine (Russian Journal)","other","article","10.30629/0023-2149-2020-98-3-210-217",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047291","1430-P: Early Real-World Experiences with Tirzepatide","Natalie Lambert","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1430-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047292","Rational Design of Dual-Agonist Peptides Targeting Glp-1 and Npy2 Receptors for Regulating Glucose Homeostasis and Body Weight with Minimal Nausea and Emesis","Jing Liu","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.5029797",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047293","LB1062 The impact of GLP-1 receptor agonists on major adverse cardiovascular events among hidradenitis suppurativa, psoriasis, and atopic dermatitis patients: A population-based cohort study","Elaine Ma","2025","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2025.06.1335",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047294","SAT-695 The Effect of GLP-1 Administration on Food Intake in People With Weight Loss Failure Post-metabolic Surgery","Kleopatra Alexiadou","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047295","26-A-13603-ACC TIRZEPATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN OBESE ADULTS WITHOUT DIABETES: REAL-WORLD CARDIOMETABOLIC OUTCOMES","Yasemin Bahar","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.678",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047296","Extended, 3-year, exenatide therapy shows sustainable effects on beta cell disposition index in metformin treated patients with type 2 diabetes","Mathijs C. M. Bunck","2010","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047297","Evaluation of cardioprotective effect of exenatide in type 2 diabetes mellitus and acute myocardial infarction in the clinic and experiment","Valery A. Zykov","2019","Translational Medicine","preclinical","article","10.18705/2311-4495-2019-6-4-22-34",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047298","Characteristics of included trials – GLP-1 receptor agonists","Norman R Waugh","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047299","O2‐09‐03: Endoplasmic reticulum stress links impaired insulin signaling and Alzheimer's disease","Mychael V. Lourenco","2012","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2012.05.674",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047300","Obesity is more than a number: a framework for treatment","RICARDO VITOR COHEN","2025","British journal of surgery","other","article","10.1093/bjs/znaf100","40314073",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047301","Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in individuals with prediabetes and obesity or overweight from the SCALE Obesity and prediabetes randomised, double-blind, placebo-controlled trial","Trisha O'Moore‐Sullivan","2019","Obesity Research & Clinical Practice","randomized_trial","article","10.1016/j.orcp.2016.10.259",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047302","Short-Term Effects of Low-Dose Tirzepatide on Lipid Profile in Non-Diabetic Adults: A Prospective Observational Study","Rodis Paparodis","2026","Journal of clinical lipidology","other","article","10.1016/j.jacl.2026.05.154",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047303","2870-LB: Glucagon-Like Peptide 1 Receptor Agonists for Antipsychotic-Associated Metabolic Dysfunctions In Patients with Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials","Jayesh Srivastava","2026","Diabetes","systematic_review","article","10.2337/db26-2870-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0047304","Role of Irisin in Endocrine and Metabolic Disorders—Possible New Therapeutic Agent?","Letiția Leuștean","2021","Applied Sciences","other","article","10.3390/app11125579",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047305","Exendin 4 Has Direct Effects on Signal Transduction Pathways and Gene Expression in Isolated HepatocytesIn VitroIndependent of the Pancreatic-Type GLP-1 Receptor and cAMP","Susan Leanne Samson","2011",null,"other","article","10.1210/endo-meetings.2011.part3.p5.p2-483",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047306","Weight management medication utilization and outpatient costs in patients with prostate cancer and diabetes.","Margaux E. Wooster","2025","JCO Oncology Practice","nonrandomized_study","article","10.1200/op.2025.21.10_suppl.13",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047307","The Central Actions of the Glucagon-like Peptide-1 Receptor Agonist, Exendin-4, in Suncus murinus: A telemetric study","Zengbing Lu","2018","Proceedings for Annual Meeting of The Japanese Pharmacological Society","other","article","10.1254/jpssuppl.wcp2018.0_po3-5-11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047308","OC21 - Additive effects of semaglutide and peptide YY3-36 dual agonism on HFpEF: focus on excitation-contraction coupling and mitochondrial function in obese rats","Niklas Geiger","2025","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvaf168.040",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0047309","De-intensification as a new trend in the treatment of type 2","Elena A. Yanovskaya","2024","FOCUS Endocrinology","other","article","10.62751/2713-0177-2024-5-2-15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047310","Su2059: SAFETY OF GLP-1 AGONISTS IN PATIENTS UNDERGOING ELECTIVE PROCEDURES REQUIRING ANESTHESIA OR SEDATION.","Nikhil Ravi Thiruvengadam","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03111-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047311","S472 Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Use Reduces Risk of Early-Onset Colorectal Cancer in Patients with Type 2 Diabetes-Mellitus (T2DM)","Temitope Olasehinde","2024","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001031256.48901.46",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047312","LBSUN206 Provider Prescribing Habits And Use Of Newer Agents For Type 2 Diabetes In A Large Multicenter Health Care System","Aseel Yaseen","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.586",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047313","756-P: A Phase 1c Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Weight Loss in Adults with Overweight and Obesity","Guang Wang","2023","Diabetes","randomized_trial","article","10.2337/db23-756-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047314","P2481The effect of DPP-4i, GLP-1RA, SGLT-2i and long-acting insulin on platelet function in patients with type 2 diabetes mellitus","Panagiota K. Stampouloglou","2019","European Heart Journal","other","article","10.1093/eurheartj/ehz748.0811",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047315","Abstract 4371433: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonists in Obese Adults Without Diabetes: A Propensity-Matched Real-World Study","Abdulraheem Hassan","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4371433",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047316","Abstract 4365716: Efficacy and Safety of Semaglutide According to Frailty Status in the SELECT Trial","John W. Ostrominski","2025","Circulation","other_trial","article","10.1161/circ.152.suppl_3.4365716",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047317","Annals for Educators - 3 November 2020","Christine M. Laine","2020","Annals of Internal Medicine","randomized_trial","article","10.7326/awed202011030","33137267",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047318","Evaluating community pharmacists’ dispensing and counseling practices of semaglutide for weight loss in the United Arab Emirates: A simulated patient study","Noor Kamal Raisan","2026","Pharmacy Practice","other","article","10.18549/pharmpract.2026.1.3476",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047319","Characterization of Treatment Intensified (Add-on to Metformin) Adults with Type 2 Diabetes: Real-world Clinical Experience (Cardiovascular Outcomes and Value in the Real-world with Glucagon-like Peptide-1 Receptor Agonists) from India in 2008 to 2017","Manoj Chawla","2025","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_8_25",null,null,"ClinicalTrials.gov:NCT05542420","S002642","openalex","TRUE","free_to_read","4","FALSE","article"],["R0047320","A Study of the Effects of glucacon-like peptide-1 agonists and Exercise on Inflammation in the Metabolic Syndrome","Wonchung Lim","2024","Asia-pacific Journal of Convergent Research Interchange","other","article","10.47116/apjcri.2024.12.43",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047321","Semaglutide. GLP-1 receptor agonist, Treatment of type 2 diabetes","Richard A. Chudleigh","2017","Drugs of the Future","other","article","10.1358/dof.2017.042.08.2653526",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047322","Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials","Maria Sejersten Ripa","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/ae5y-tp29",null,null,"ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446","S001496; S001933","openalex","TRUE","paywalled","1","FALSE","article"],["R0047323","1008-P: Efficacy of Dulaglutide on Renal Functions in the Real-World Clinical Practice for Diabetes in Japan","SHIORI TOGA SATO","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1008-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047324","GLP-1 receptor agonists for Parkinson's disease (Review)","Caroline A. Mulvaney","2020","Lancaster EPrints (Lancaster University)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0047325","Tirzepatide and Hurthle Cell Carcinoma Poster","Saketh Reddy Bathula","2026",null,"other","article","10.13140/rg.2.2.26661.46564",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047326","Abstract 4137917: Eligibility and Preventable CVD Events in US Adults with Cardiovascular Disease and Overweight or Obesity: Projections from the SELECT Trial","Hongmei YAN","2024","Circulation","other_trial","article","10.1161/circ.150.suppl_1.4137917",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047327","Repurposed therapeutics in alzheimer’s disease: a comparative analysis of generic and patent-protected agents (2016–2025)","Josie Lindle","2026","Alzheimer s Research & Therapy","other_trial","article","10.1186/s13195-026-02175-5",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0047328","2 A Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Patients with Parkinson’s Disease: Neuropsychological Outcomes","Jeffrey C. Wertheimer","2023","Journal of the International Neuropsychological Society","randomized_trial","article","10.1017/s135561772300200x",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0047329","Mo1947: PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) PRESCRIBED GLUCAGON-LIKE PEPTIDE-1 AGONISTS HAVE LESS SEVERE DISEASE AND REDUCED ADVANCED THERAPY UTILIZATION COMPARED TO THE GENERAL IBD POPULATION","Elizabeth A. Spencer","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03734-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047330","MP485GASTRIC BYPASS SURGERY IMPROVES ALBUMINURIA AND PODOCYTE INJURY IN EXPERIMENTAL DIABETIC KIDNEY DISEASE","Meera Goh Nair","2017","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfx174.mp485",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047331","Exenatide efficacy in unselected patients: Comparison with clinical trials","Carole Collet-Gaudillat","2012","Journal of Diabetes Mellitus","nonrandomized_study","article","10.4236/jdm.2012.21019",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047332","21 - Effect and Safety of Flexible Dose Adjustment With Oral Semaglutide vs Sitagliptin in Type 2 Diabetes: PIONEER 7","Daniel Ngui","2019","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2019.07.028",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047333","GLP-1 Receptor Agonists before Sedated Endoscopy: Divergent Guidance, Limited Aspiration Signal, and Operational Implications","Yavuz Özden","2026","Journal of Digestive Endoscopy","other","article","10.1055/s-0046-1824542",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047334","Preface: phys. stat. sol. (b) 244/3","Krzysztof Witold Wojciechowski","2007","physica status solidi (b)","commentary","article","10.1002/pssb.200790002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0047335","PDB119 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN","Kirsi Norrbacka","2019","Value in Health","nonrandomized_study","article","10.1016/j.jval.2019.09.1001",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047336","Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program","K B Sharan Kumar","2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.342129",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0047337","Editorial comments: focus on cardiovascular risk estimation and prevention","Gianluigi Guida","2024","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwae122","38634681",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0047338","GLP-1 ANALOGUES IN COMBINATION WITH REVISIONAL ENDOSCOPIC SLEEVE GASTROPLASTY : 24-MONTH FOLLOW-UP","Anna Carolina Hoff","2022","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2022.04.075",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047339","FRI075 Single Center Retrospective Matched Cohort Study Of glp1ra-induced Weight Loss In Patients With Post-bariatric Weight Regain Vs Non-surgical Controls","Ana Del Carmen Rivadeneira","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.085",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047340","First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients","Karina Oganesovna Galstyan","2015","Diabetes Mellitus","randomized_trial","article","10.14341/dm7233",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047341","Dual Receptor Agonist for Type 2 Diabetes","Anita J Slomski","2018","JAMA","other_trial","article","10.1001/jama.2018.20160","30575879",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047342","O-018 Association between ozempic use and stroke risk: a nationwide emergency department analysis","Ahmed Elbayomy","2025",null,"nonrandomized_study","article","10.1136/jnis-2025-snis.18",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047343","Glp-1 Receptor Agonists Are Associated With Weight Loss Among Lvad Patients With Diabetes And Obesity","Menatalla Mekhaimar","2023","Journal of Cardiac Failure","other","article","10.1016/j.cardfail.2022.10.175",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047344","Diabetes Management and Exenatide","Maren Stewart Mayhew","2008","The Journal for Nurse Practitioners","other","article","10.1016/j.nurpra.2008.08.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047345","945-P: Improved Glycemic Outcomes with the Omnipod 5 AID System in Adults with Type 2 Diabetes (T2D) Previously Using Basal without Bolus Insulin—Subanalysis of the SECURE-T2D Study","Anders L. Carlson","2025","Diabetes","nonrandomized_study","article","10.2337/db25-945-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047346","Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial","Athena Philis‐Tsimikas","2018","Diabetes","randomized_trial","article","10.2337/db18-127-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047347","Growth Differentiation Factor-15 (GDF-15) Inhibits Gastric Emptying in Rodents as Part of Its Anorectic Mechanism of Action","Simon A. Hinke","2018","Diabetes","preclinical","article","10.2337/db18-283-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047348","P159 Apport d’un critère composite dans l’évaluation d’un nouvel analogue du GLP1, le liraglutide","Bernard H. Charbonnel","2010","Diabetes & Metabolism","other","article","10.1016/s1262-3636(10)70307-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047349","P162 Suivi à court terme des patients diabétiques de type 2 mis sous exenatide deux fois par jour : efficacité et tolérance","Christophe Gaudillat","2009","Diabetes & Metabolism","other","article","10.1016/s1262-3636(09)71960-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047350","A Sustainable Approach to ε-Lys Branched GLP-1 Analogs: Integrating Green SPPS, Metal-free Alloc Removal, Waste Minimization and TFA/PFAS-free Resin Cleavage","Jan Pawlas","2025","Organic Process Research & Development","other","article","10.1021/acs.oprd.5c00341",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047351","Choosing Stones, Moving Mountains","John J. Dreyzehner","2018","Journal of Public Health Management and Practice","other","article","10.1097/00124784-900000000-99430",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047352","S1086 Weight Loss and Safety of Glucagon-like Peptide-1 Agonists in Inflammatory Bowel Disease Patients","Scott R. Anderson","2024","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001033712.16587.dd",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047353","Primary prevention of heart failure with glucagon-like peptide-1 receptor agonist","Keerthenan Raveendra","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.1408",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047354","Research Interest in and Use of Complementary and Integrative Health Therapies Among Older Adults on Glucagon-Like Peptide-1 Receptor Agonists","Sarah Jaehwa Park","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5363323",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047355","Etude de prise en charge, en vie réelle, de patients avec diabète de type 2 sous lâassociation degludec-liraglutide (Xultophy*)","Olivier Dupuy","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047356","Liraglutide with lifestyle modifications causing rapid weight loss in an adolescent with morbid obesity and life threatening sleep apnoea","Georgina Williams","2021","Endocrine Abstracts","other","article","10.1530/endoabs.78.p46",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047357","Pharmacotherapeutic options for the management of obesity in children","Ahmed J. Aldhafiri","2023","Journal of advanced Biomedical and Pharmaceutical Sciences","other","article","10.21608/jabps.2023.225432.1194",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047358","Liraglutide improves carotid intima-media thickness in pre-elderly and elderly patients with type-2 diabetes: an 18-month prospective, real life study","Ali Abbas Rizvi","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.gp108",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047359","GLP-1 analogs protect beta cells and prevent diabetes in models of Wolfram syndrome","Igoillo-Esteve Mariana","2018","Endocrine Abstracts","other","article","10.1530/endoabs.57.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047360","The law of therapeutic parsimony","Sanjay Kalra","2016","Indian Journal of Endocrinology and Metabolism","other","article","10.4103/2230-8210.180008","27186541",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047361","Sodium-glucose co-transporter 2 inhibitor treatment and risk of atrial fibrillation: Scandinavian cohort study","Arvid Engström","2022",null,"nonrandomized_study","article","10.2337/figshare.21562863.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0047362","Liraglutide in psychiatric patients: preliminary results","Silvia Di Volo","2016","European Neuropsychopharmacology","other","article","10.26226/morressier.5785edc5d462b80296c99223",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other; article"],["R0047363","2566-P: Silencing Hepatokine Activin E Promotes a Healthy Body Composition and Metabolic Profile in Mice","Hsiu‐Chiung Yang","2026","Diabetes","other_trial","article","10.2337/db26-2566-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047364","90 - Survey of Physicians’ Experiences and Treatment Satisfaction Prescribing Semaglutide for Patients with Type 2 Diabetes in Canada","Kamran Qureshy","2019","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2019.07.099",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047365","367-P: Cardiovascular Risk Categories in Patients with Diabetes According to 2019 ESC/EASD Guidelines in Clinical Practice: Use of a Dedicated App (AWARE)","Cesare Berra","2021","Diabetes","other","article","10.2337/db21-367-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047366","Effects of Semaglutide on Kidney Parameters in Patients with Obesity and Nondiabetic CKD","Hiddo Jan L. Heerspink","2024","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20242wv2xw41",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047367","OHP-004 Prescription of oral anti-diabetic agents recently marketed in a health area","B Arribas-Díaz","2014","European Journal of Hospital Pharmacy","nonrandomized_study","article","10.1136/ejhpharm-2013-000436.456",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047368","Recent Advances in the Management of Heart Failure, Including the Role of AI and Advances in Gene Therapy","Lakshmi Prasanna Vaishnavi Kattamuri","2026","International Journal of Angiology","nonrandomized_study","article","10.1055/a-2904-8847",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047369","Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials ofHeart Failure and Chronic Kidney Disease","John W. Ostrominski","2025",null,"other_trial","article","10.2337/figshare.28391639",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","other"],["R0047370","Lixilan ONE CAN: Randomisierte Studie zum Vergleich eines täglichen vs. wöchentlichen Titrationsalgorithmus für den Wechsel von Basalinsulin zur Fixkombination iGlarLixi bei Typ-2-Diabetespatienten in Kanada","IRENE M. HRAMIAK","2022","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-1746286",null,null,"ClinicalTrials.gov:NCT03767543","S001367","openalex","FALSE","paywalled","5","FALSE","article"],["R0047371","S5597 Late Onset Wilson Disease Presenting With Elevated Transaminases and Abnormal Ultrasound","Kalee Moore","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001149848.27601.5f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047372","The Management of Patients with Heart Failure and Diabetes","Tiffany A. Dong","2022","Heart failure","other","article","10.1201/9780429244544-27",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047373","1863-LB: The Confidence Trial—Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes","RAJIV AGARWAL","2025","Diabetes","randomized_trial","article","10.2337/db25-1863-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047374","CLINICAL AND SOCIODEMOGRAPHIC HETEROGENEITY FOR MORTALITY RISK BY OBESITY CLASS IN PATIENTS MEETINGELIGIBILITY CRITERIA FOR SEMAGLUTIDE CARDIOVASCULAR OUTCOME TRIALS: A NATIONAL POPULATION-BASED STUDY","Mohamad Badie Taha","2024","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(24)03911-1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047375","Low vitamin D and hypertension: a causal association?","Mark R. Rigby","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047376","A Case of Systemic Mastocytosis with Predominately Gastrointestinal Manifestations","Harsh Patel","2018","The American Journal of Gastroenterology","case_report","article","10.14309/00000434-201810001-01845",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047377","Comparative study of the neuroprotective potential of semaglutide injectable preparations in experimental ischemic stroke","Т. Л. Каронова","2024","Meditsinskiy sovet = Medical Council","preclinical","article","10.21518/ms2024-404",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047378","CHARACTERISTICS OF THE COURSE AND TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC LIVER DISEASE","Dilorom Kamardinovna Najmutdinova","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.20566967",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0047379","GLP-1 and GIP analogues in the treatment of obesity","Agata Jasińska-Balwierz","2024","Pediatria i Medycyna Rodzinna","other","article","10.15557/pimr.2024.0023",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047380","In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists","In Young Choi","2018","Diabetes","preclinical","article","10.2337/db18-1090-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047381","SAT-291 Impact of the Incretin Mimetic Drug Tirzepatide on Obesity-Associated Breast Cancer Growth: Findings from a Preclinical Model","Amanda L. Kucinskas","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.2433",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047382","Peer‑to‑Peer Referral Networks and Six‑Month Outcomes in a Tirzepatide‑Supported Digital Weight‑Loss Service: A Retrospective Cohort Study (Preprint)","Louis A Talay","2026",null,"nonrandomized_study","article","10.2196/preprints.105583",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0047383","Abstract PS5-11-16: Impact of GLP-1 Receptor Agonist Exposure on the Long-Term Survival in Breast Cancer Patients","R. Nelson","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-ps5-11-16",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047384","Applying the causal roadmap to longitudinal national Danish registry data: a case study of second-line diabetes medication and dementia","Nerissa Nance","2023","arXiv (Cornell University)","nonrandomized_study","article","10.48550/arxiv.2310.03235",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0047385","8088 Connecting the Dots: Semaglutide, Constipation, and Diverticulitis - A case report","Kavindra Nath Tiwari","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.715",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047386","Efficacy of dulaglutide to improve Vascular Health indexes in subjects with Type 2 Diabetes: A Randomized Trial","Antonino Tuttolomondo","2020","Research Square","randomized_trial","article","10.21203/rs.3.rs-51124/v1",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","preprint"],["R0047387","Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial","Carel Wynand le Roux","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2895",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047388","PD07-06 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USE IS ASSOCIATED WITH DECREASED POST-RADICAL NEPHRECTOMY ADVERSE COMPLICATIONS AND IMPROVES SURVIVAL IN T2DM PATIENTS WITH LOCALIZED RENAL CELL CARCINOMA: A TRINETX STUDY","Sam W Kwon","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191372.92267.2b.06",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047389","111In-DTPA-exendin-4 SPECT/CT scans localize hardly detectable insulinomas","Damian Wild","2009","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047390","EE117 Cost-Effectiveness of Tirzepatide Versus Semaglutide (Both Adjunct to a Reduced-Calorie Diet and Increased Physical Activity) in Patients With Obesity or Overweight From a UK Perspective","Matthew Capehorn","2024","Value in Health","other","article","10.1016/j.jval.2024.10.401",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047391","Weekly Semaglutide Use Shows Promise Among Type 2 Diabetes Patients at a Polyclinic in Alahsa, Saudi Arabia: A Retrospective Study","Abdullah Almulhim","2024","South Eastern European Journal of Public Health","nonrandomized_study","article","10.70135/seejph.vi.2413",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047392","494 IMPACT OF GLP-1 RECEPTOR AGONISTS ON CLINICAL OUTCOMES IN AUTOIMMUNE HEPATITIS: A PROPENSITY SCORE-MATCHED COHORT STUDY","Guy Nguefang","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03338-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047393","Semaglutide for type 2 diabetes control in metabolic dysfunction-associated steatotic liver disease (MASLD): a two-way effect?","Giovanni Petralli","2024","Digestive and Liver Disease","other","article","10.1016/j.dld.2024.01.084",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047394","Glucagon-like peptide 1 based treatments preserve left ventricular diastolic function irrespective of body weight changes - a systematic review and meta-analysis","I Hecker","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.935",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0047395","2073-P: Are Early Dumping and Postprandial Hypoglycemia after Roux-en-Y Gastric Bypass Related Events?","Caroline Christfort Øhrstrøm","2019","Diabetes","randomized_trial","article","10.2337/db19-2073-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047396","Abstract #1181499: Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?","Stewart Albert","2022","Endocrine Practice","other","article","10.1016/j.eprac.2022.03.096",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047397","794-P: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist","Charlotte E. Hinds","2025","Diabetes","other_trial","article","10.2337/db25-794-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047398","173-OR: Eligibility, Impact, and Costs for Tirzepatide for the Primary Prevention of Diabetes Mellitus","Jay B. Lusk","2025","Diabetes","other_trial","article","10.2337/db25-173-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047399","115. Incidence of New Eating Disorders in Adolescents and Young Adults Using Glucagon-Like Peptide-1 (GLP-1) Agonists","Morgan Homme","2026","Journal of Adolescent Health","other","article","10.1016/j.jadohealth.2025.12.118",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047400","1984. Effects of Semaglutide on Adipose Tissue in HIV-Associated Lipohypertrophy","Grace A. McComsey","2023","Open Forum Infectious Diseases","randomized_trial","article","10.1093/ofid/ofad500.111",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047401","Forced Degradation Products of Liraglutide: A Comparative Study of Similarity Between Originator and Analogue Version by Liquid Chromatography–Mass Spectrometry","Fatemeh Chavoshi","2024","International Journal of Peptide Research and Therapeutics","other","article","10.1007/s10989-024-10608-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047402","Retrospective Cohort Study Evaluating Liraglutide And Exenatide In A Veteran Population","Mark Bounthavong","2013","Value in Health","nonrandomized_study","article","10.1016/j.jval.2013.03.787",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047403","PREOPERATIVE TIRZEPATIDE THERAPY IN OBESE TOTAL HIP ARTHROPLASTY CANDIDATES: A MODELLING STUDY OF COST AND COMPLICATION REDUCTION","Frederick J. Thomson","2026","Orthopaedic Proceedings","other_trial","article","10.1302/1358-992x.2026.3.010",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047404","Cover Picture: PubChem and ChEMBL beyond Lipinski (Mol. Inf. 5/2019)","Alice Capecchi","2019","Molecular Informatics","other","article","10.1002/minf.201980501",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047405","[125I], [127I]‐and [14C]‐Labelling of the GLP‐1‐(7‐37) derivative NN2211","Jesper Bøggild Kristensen","2003","Journal of Labelled Compounds and Radiopharmaceuticals","other","article","10.1002/jlcr.689",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047406","Youth Along the T2D Risk Continuum Remain Concerningly Refractory to Therapeutic Interventions","Peter M. Wolfgram","2021","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgab292","33942103",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047407","2061-LB: Diabetes Staging System (DSS)—A Novel Approach to Improve SGLT2i/GLP-1RA Use and CVD/CKD Outcomes in DM2","Moahad Saeed Dar","2025","Diabetes","other","article","10.2337/db25-2061-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047408","106 - EFFICACY AND SAFETY OF GLP-1 RECEPTOR AGONISTS IN OBESE PATIENTS WITH INFLAMMATORY BOWEL DISEASE","Clara Ramos Belinchón","2023","Gastroenterología y Hepatología","other","article","10.1016/s0210-5705(23)00238-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047409","THE EFFECTS OF EXENATIDE ON SERUM CRP LEVELS IN PATIENTS WITH TYPE 2 DIABETES: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS","Bogdan Apan","2020",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0047410","Effect of glucagon-like peptide 1 receptor agonists on oral hormonal contraception (literature review)","Elena G. Deryabina","2024","Vestnik ohrany materinstva i mladenčestva.","narrative_review","article","10.69964/bmcc-2024-1-1-56-63",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047411","RETATRUTIDE IN INTERNAL MEDICINE: A NOVEL TRIPLE HORMONE RECEPTOR AGONIST FOR OBESITY, TYPE 2 DIABETES, AND CARDIOMETABOLIC RISK","Lívia de Oliveira Cardoso","2026","International Journal of Science and Research Archive","randomized_trial","article","10.30574/ijsra.2026.20.2.1669",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047412","Hypertension and the kidney: an update","Luis Miguel Ruilope","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad896","38326985",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047413","661 Retatrutide monotherapy matches the effectiveness of anti-PD-1 immunotherapy in a preclinical model of pancreatic cancer","Sandesh J. Marathe","2025","Regular and Young Investigator Award Abstracts","randomized_trial","article","10.1136/jitc-2025-sitc2025.0661",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0047414","2066-P: Dyrk1a Antisense Oligonucleotides Conjugated to GLP-1R Agonist Promote Pancreatic Beta-Cell Proliferation","Wuxia Fu","2020","Diabetes","preclinical","article","10.2337/db20-2066-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047415","Advancements in Obesity: Unravelling Pathophysiology, Treatment Strategies, and Innovative Approaches","Neil Panchal","2025","Biosciences Biotechnology Research Asia","other","article","10.13005/bbra/3339",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047416","To improve the quality of secondary prevention strategies in diabetic patients: the BRING-UP Prevention study results","Aldo Pietro Maggioni","2025","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf236.275",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047417","Abstract 608: Anti-Inflammatory and Vascular Protective Effects of Glucagon-like Peptide 1 (GLP-1) in Polymicrobial Septic Mice Induced by Cecal Ligation and Puncture (CLP)","Johanna Helmstädter","2019","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvb.39.suppl_1.608",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047418","TOPICAL ISSUES OF COMPLEX THERAPY OF INSULIN RESISTANCE AND CARBOHYDRATE METABOLISM DISORDERS IN ATHLETES WITH POLYCYSTIC OVARY SYNDROME","Виктор Владимирович Смирнов","2022","Медицина: теория и практика","other","article","10.56871/2762.2022.99.82.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047419","Two-year Effect of Semaglutide 2.4 mg Versus Placebo in Adults With Overweight or Obesity: STEP 5","Shahebina Walji","2022","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2022.09.038",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047420","Metabolic improvement during short-term treatment with a GLP-1 receptor agonist does not improve cardiac diastolic function in patients type 2 diabetes: a randomized double-blind placebo-controlled trial","Annemie Stege Bojer","2021","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehab724.2619",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047421","Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Agonist in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis","Sang‐Cheol Lee","2025","American Journal of Transplantation","systematic_review","article","10.1016/j.ajt.2025.07.1001",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0047422","3910SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes","Esteban Jódar","2017","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehx504.3910",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047423","300.04 GLP-1 Agonists Versus Placebo in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: An Updated Meta-Analysis of SUMMIT, SELECT, STEP-HFpEF, STEP-HFpEF DM, and FLOW Trials","Sanchit Duhan","2025","JACC: Cardiovascular Interventions","systematic_review","article","10.1016/j.jcin.2025.01.225",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0047424","413-P: Comparative Effectiveness of Glucose-Lowering Agents on Kidney Outcomes in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk","Joshua J. Neumiller","2024","Diabetes","nonrandomized_study","article","10.2337/db24-413-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047425","Increasing pharmacoequity for people with cirrhosis","Melanie A. Hundt","2024","Clinical Liver Disease","nonrandomized_study","article","10.1097/cld.0000000000000203","38860125",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047426","Diabetes Remission - The Holy Grail in Diabetes Management","Sunder R. Mudaliar","2024","Chronicle of Diabetes Research and Practice","randomized_trial","article","10.4103/cdrp.cdrp_15_23",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047427","61 Warfarin and GLP-1 Receptor Agonist Interaction Effects on Time in Therapeutic Range","Phillip Anjum","2025","Research and Practice in Thrombosis and Haemostasis","other","article","10.1016/j.rpth.2025.102780",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047428","The Relationship Between Serum S100B Levels And Microglial Activation In Rat Hipocampus After Lithium-pilocarpine Induced Status Epilepticus And The Effect Of Liraglutide, A GLP-1 Analogue On These Changes","Sevda Fatma Muftuoglu","2017",null,"preclinical","article","10.5505/2017ichc.pp-219",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047429","1115-P: Advanced Medical Therapy (AMT) for Youth-Onset Type 2 Diabetes (T2D)—Early Results from the Run-in Phase of ST2OMP","AMY S. SHAH","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1115-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047430","P0990RENINAAV DOSE-DEPENDENTLY EXACERBATE ALBUMINURIA AND GLOMERULOSCLEROSIS, AND REDUCE GFR IN FEMALE UNINEPHRECTOMIZED DB/DB MICE","Mette V. Østergaard","2020","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfaa142.p0990",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047431","780-P: Comparative Risk of Adverse Pancreatic Events with Second-Line Glucose-Lowering Therapies in Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk","Urja N Kalathiya","2025","Diabetes","nonrandomized_study","article","10.2337/db25-780-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047432","Disproportionality analysis on glucagon-like peptide-1 receptor agonists and retinal detachment: Insights from the FDA adverse event reporting system","R. Yukesh","2026","Perspectives in Clinical Research","nonrandomized_study","article","10.4103/picr.picr_356_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047433","Liraglutide has potent anti-inflammatory and anti-catabolic activity in two cell-types implicated in osteoarthritis","Françis Berenbaum","2021","Osteoarthritis and Cartilage","other","article","10.1016/j.joca.2021.02.467",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047434","26-A-16709-ACC BENEFITS OF TIRZEPATIDE VERSUS BARIATRIC SURGERY ON MORTALITY, CARDIOVASCULAR DISEASE, AND SLEEP APNEA","Ibrahim Mortada","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.525",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047435","Newer glucose‐lowering drugs and risk of dementia: A meta‐analysis of cardiovascular outcome trials","Huilin Tang","2022","Journal of the American Geriatrics Society","randomized_trial","article","10.1111/jgs.17895","35612586",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047436","An Update on Exenatide and Liraglutide for Type 2 Diabetes Mellitus","Sarah M. Webb","2010","Pharmacy and Wellness Review","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047437","LE MÉDICAMENT DU MOIS Bydureon ® : premier agoniste des récepteurs du GLP-1 en une injection hebdomadaire (exénatide à libération prolongée)","André Jacques Scheen","2014","RMLG. Revue médicale de Liège","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047438","4113Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials","Olivia R. Ghosh‐Swaby","2019","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehz745.0117",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0047439","Frequency, Characteristics, and Outcomes Associated with Various Definitions of Type 2 Diabetes Remission after Initiation of Glp-1 Receptor Agonists","Gian Paolo Fadini","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5350577",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047440","Outcomes of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in kidney transplant recipients with diabetes","Tarek Mahmoud","2021",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047441","1181 EXPLORING GASTROINTESTINAL AND HEPATOBILIARY ADVERSE EVENTS IN GLP-1 RECEPTOR AGONISTS THERAPY: A LARGE COHORT RETROSPECTIVE STUDY","Cheng Niu","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)01134-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047442","Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report","Ali Zahir","2026","Figshare","case_report","article","10.6084/m9.figshare.c.8229108.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0047443","SGLT2 Inhibitors, GLP-1 Receptor Agonists, or Bariatric Surgery and Risks of All-Cause Mortality, Cardiovascular Diseases, End-Stage Renal Diseases, and Severe Hypoglycemia in Obese Patients with Type 2 Diabetes Mellitus","Carlos King Ho Wong","2020","SSRN Electronic Journal","other","article","10.2139/ssrn.3551370",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047444","P277 - Efficacité de l’exenatide chez des patients diabétiques non sélectionnés : comparaison avec les études randomisées","Christophe Gaudillat","2011","Diabetes & Metabolism","other","article","10.1016/s1262-3636(11)70903-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047445","Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial","Frauke Becker","2018","Diabetologia","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0047446","S2397 Real-World Benefits of GLP-1RA Therapy in MASLD: Reductions in Cardiovascular, Renal, Hepatic, and Mortality Outcomes","Sana Rabeeah","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137048.94451.f7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047447","“Super-Responders” to Liraglutide Monotherapy and the Growing Evidence of Efficacy of GLP-1 Analogues in Obesity Management: A Longitudinal Prospective Cohort Study","Ellina Lytvyak","2025","Obesities","nonrandomized_study","article","10.3390/obesities5030063",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047448","Patients with Type 2 Diabetes Treated with IDegLira Have a Greater Chance of Achieving A1C Targets Without Hypoglycemia and Weight Gain Than with Basal Insulin or Basal-Bolus Therapy, Irrespective of A1C Target","Leonard E. Egede","2018","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2018.08.022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047449","Editorial: World diabetes day 2024: exploring mechanisms, innovations, and holistic approaches in diabetes care","Åke Sjöholm","2026","Frontiers in Endocrinology","randomized_trial","article","10.3389/fendo.2026.1808396","41869025",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0047450","Sustained Weight Reduction by Thresholds in Adults With Obesity and Prediabetes Treated With Tirzepatide Over 176 Weeks (SURMOUNT‑1)","Jamy D. Ard","2026","Diabetologie und Stoffwechsel","other","article","10.1055/s-0046-1819982",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047451","Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and hematologic cancer risk among older adults with type 2 diabetes.","Wei‐Han Chen","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.6592",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047452","CA-020: Tolérance, pharmacocinétique (PK), et pharmacodynamique (PD) du dulaglutide hebdomadaire chez des patients âgés atteints de diabète de type 2 (DT2)","Corina Loghin","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30152-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047453","Bariatric Surgery: It’s Not Just Incretins!","Rafael Ferraz Bannitz","2021","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgab694","34543416",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047454","Abstract 14741: Value of Coronary Artery Calcium Testing in Asymptomatic Individuals With Prediabetes: A Multi-Cohort Study","Mahmoud S Al Rifai","2023","Circulation","nonrandomized_study","article","10.1161/circ.148.suppl_1.14741",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047455","A Review: Comparison of Efficacy of Liraglutide Versus Sitagliptin add-on-to Metformin in Type 2 Diabetes Mellitus patients","A. Kavyasree","2021","Research Journal of Pharmacy and Technology","randomized_trial","article","10.52711/0974-360x.2021.00405",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047456","1.4 Harmony 8: Once Weekly (QW) GLP1 Agonist Albiglutide (Albi) vs. Sitagliptin (Sita) in Type 2 Diabetes (T2D) Pts With Renal Impairment (RI): Week 26 Results (68-OR)","Lawrence A. Leiter","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0029-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047457","Tu1818: ADVERSE OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON GLP-1 RECEPTOR AGONIST THERAPY","Jonathan Weng","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04347-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047458","Sa1939 DUODENAL MUCOSAL RESURFACING COMBINED WITH GLP-1 RECEPTOR AGONISM MAY ELIMINATE INSULIN TREATMENT IN TYPE 2 DIABETES WHILE IMPROVING GLYCEMIC CONTROL AND OVERALL METABOLIC HEALTH","Suzanne Meiring","2020","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2020.03.1284",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047459","GLP-1 Receptor Agonists and DPP-4 Inhibitors","Phillip E. Vinall","2012","MD Conference Express","other","article","10.1177/155989771210011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047460","Efficacy and safety of short- and long-acting GLP-1 receptor agonists on a background of basal insulin in type 2 diabetes: A meta-analysis","Jessica Annalena Huthmacher","2020",null,"systematic_review","article","10.2337/figshare.12272840.v1",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","other"],["R0047461","Glucagon-Like Peptide-1 and Diabetes 2012","Matteo Monami","2012","Experimental Diabetes Research","other","article","10.1155/2012/768760","23431286",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047462","PCR58 Social Media Research to Understand Reported Efficacy of GLP-1 RAs for Weight Loss","Murali Mohan","2023","Value in Health","other","article","10.1016/j.jval.2023.09.2497",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047463","47th SEMDSA congress 2012 : conference report","Glenda Hardy","2012","˜The œSouth African journal of diabetes & vascular disease","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047464","Mo1942 ASSESSING THE IMPACT OF GLP-1 AGONISTS ON WEIGHT REGAIN FOR POST-BARIATRIC SURGERY PATIENTS: A SYSTEMATIC REVIEW","Raj H. Patel","2024","Gastroenterology","systematic_review","article","10.1016/s0016-5085(24)03177-9",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0047465","749 GLP-1 AGONISTS CAN PREVENT LIVER DISEASE PROGRESSION IN PATIENTS WITH METABOLIC AND ALCOHOL-ASSOCIATED LIVER DISEASE (METALD).","Amir Gougol","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)04029-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047466","Abstract P121: Weight Loss is not a Major Mediator of GLP1-Receptor Agonists’ Risk Reduction in Heart Failure with Preserved Ejection Fraction","Sydney Elizabeth Hartsell","2024","Hypertension","nonrandomized_study","article","10.1161/hyp.81.suppl_1.p121",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047467","Effect of Subcutaneous Semaglutide on Diabetic Retinopathy among Adults with Type 2 Diabetes in Saudi Arabia. A Systematic Review","Al Anoud Al Garzaie","2024","European Journal of Medical and Health Research","systematic_review","article","10.59324/ejmhr.2024.2(5).07",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0047468","FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER","Vlado Perkovic","2019","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfz106.fp482",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047469","Predicting response to incretin-based therapy","Sanjay Kalra","2011","Research and Reports in Endocrine Disorders","other","article","10.2147/rred.s16282",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047470","Liraglutide Lowers Blood Pressure: Who Benefits Most and How?","Gregory Michael Weiss","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047471","Revolutionizing cardiometabolic health: the dual power of GLP-1 receptor agonists and SGLT2 inhibitors: a review article","Galya Tomova-Lyutakova","2024","Bulgarian Cardiology","narrative_review","article","10.3897/bgcardio.30.e140717",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047472","121-OR: Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study","RAJAMANNAR THENNATI","2024","Diabetes","randomized_trial","article","10.2337/db24-121-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047473","GLP-1 RECEPTOR AGONIST USE AMONG PATIENTS SEEKING ENDOSCOPIC BARIATRIC THERAPIES: A CROSS-SECTIONAL STUDY","Ankit Jain","2025","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2025.03.136",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047474","206. EFFECTS OF SEMAGLUTIDE ON BODY WEIGHT IN CLOZAPINE-TREATED INDIVIDUALS WITH SCHIZOPHRENIA AND OBESITY: A RANDOMIZED CONTROLLED TRIAL","Dan J. Siskind","2025","The International Journal of Neuropsychopharmacology","randomized_trial","article","10.1093/ijnp/pyaf052.020",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0047475","Confirming the bidirectional nature of the association between severe hypoglycemic and cardiovascular events in type 2 diabetes: Insights from Exscel","Mary Angelyn Bethel","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/1zz5-q530",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047476","POSTER: MDS-1221 Clinically Relevant Effects of GLP-1 Agonists in MDS: Unveiling the Therapeutic Benefits Beyond Glycemic Control—A Global Propensity Score-Matched Analysis","Asfand Yar Cheema","2025","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(25)00847-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047477","The GLP-1 analogue liraglutide improves first-phase insulin secretion and maximal beta-cell secretory capacity over 14 weeks of therapy in subjects with Type 2 diabetese","Sten Madsbad","2007",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0047478","Continuous glucose monitoring in type 2 diabetes patients treated with once weekly dulaglutide or once daily glargine, both combined with insulin lispro (AWARD-4 substudy)","JOHAN H. JENDLE","2015","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047479","Real-world analysis on the impact of GLP-1 receptor agonists on survival and metastatic risk in colorectal cancer.","Colton Jones","2026","Journal of Clinical Oncology","randomized_trial","article","10.1200/jco.2026.44.2_suppl.62",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047480","Abstract 6785: Evasion of hepatic ILC1 immunosurveillance drives breast cancer liver metastasis","Peng Li","2026","Cancer Research","nonrandomized_study","article","10.1158/1538-7445.am2026-6785",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047481","ASSESSMENT AND MANAGEMENT OF PATIENTS WITH OBESITY AND HYPERTENSION IN EUROPEAN SOCIETY OF HYPERTENSION EXCELLENCE CENTRES. A SURVEY FROM THE ESH WORKING GROUP ON DIABETES AND META","Christina Antza","2024","Journal of Hypertension","other","article","10.1097/01.hjh.0001019636.07151.09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047482","Association of GLP-1 agonists with breast cancer incidence in women.","E. Robert McDonald","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.10506",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047483","ABSTRACT: SA-OR081: Clinical Events in Type 2 Diabetes and Moderate-to-Severe CKD by Albuminuria Status: Dulaglutide vs. Insulin Glargine","Katherine R. Tuttle","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047484","26-A-13332-ACC GLUCAGON-LIKE PEPTIDE-1 ANALOGUE THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH AORTIC STENOSIS: A PROPENSITY-MATCHED ANALYSIS FROM A GLOBAL REAL-WORLD COHORT","Waasay Hassan Khan","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.4986",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047485","Effect of exenatide, metformin and folic acid on experimentally induced metabolic–cognitive syndrome in rats","Ahmed Bahriz","2020","Benha Medical Journal","preclinical","article","10.21608/bmfj.2020.86396",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047486","Exenatide Injection","Dennis J. Cada","2005","Hospital Pharmacy","other_trial","article","10.1177/001857870504001109",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047487","742-P: Impact of Virtual Patient Simulation on Improving T2D Diagnosis and Management","Amy T. Larkin","2025","Diabetes","other","article","10.2337/db25-742-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047488","GLP-1 RECEPTOR AGONISTS RISING ROLE IN HEART FAILURE MANAGEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS","Caique M P Ternes","2024","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(24)02381-7",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0047489","Neuroprotective effect of liraglutide and memantine in a rat model of Alzheimer’s disease","Duaa Bakhshwin","2024","Asian Pacific Journal of Tropical Biomedicine","preclinical","article","10.4103/apjtb.apjtb_937_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047490","FRI-329-Comparison of seladelpar and combinations with liraglutide or selonsertib for improvement of fibrosis and NASH in a diet-induced and biopsy-confirmed mouse model of NASH","Yun‐Jung Choi","2019","Journal of Hepatology","preclinical","article","10.1016/s0618-8278(19)31070-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047491","PSUN134 Loss of Glp-1r Signaling in the β-Cell Impairs Adaptive Proliferation and Insulin Secretion","Angela Crystal Olvera","2022","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvac150.748",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047492","P-62 Silent Corticotroph Adenoma or Cyclic Cushing's Syndrome?","Ozan Başkurt","2024","JCEM Case Reports","other","article","10.1210/jcemcr/luad146.059",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047493","Renal Insulin Sensitizing Effect of Exenatide in a High-fat Diet Obesity Rat Model","Vivian Boshra","2017","Journal of Advances in Medicine and Medical Research","preclinical","article","10.9734/bjmmr/2017/32349",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047494","A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial","Lawrence A. Leiter","2018","Diabetes","other_trial","article","10.2337/db18-1089-p",null,null,"ClinicalTrials.gov:NCT02058160","S001409","openalex","FALSE","paywalled","5","FALSE","article"],["R0047495","Semaglutide, single-agent therapy causing hyperosmolar hyperglycemic syndrome in a newly diagnosed type 2 diabetes mellitus","Shaikh Ambreen Fatema Abdul Hafiz","2024","The American Journal of the Medical Sciences","other","article","10.1016/s0002-9629(24)00145-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047496","Rapidly Evolving Lung Lesion in a Kidney Transplant Recipient","Aditi H. Jani","2024","Clinical Infectious Diseases","other","article","10.1093/cid/ciae556","40465485",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047497","Hepatic effects of GLP-1 receptor agonist Liraglutide in patients with type 2 diabetes","Maria Hayon","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.gp111",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047498","High-throughput parallel synthesis optimization of Glucagon-like Peptide 1 receptor agonists","Cyf N. Ramos-Colon","2018","Proceedings of the 35th European Peptide Symposium","other","article","10.17952/35eps.2018.110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0047499","SAT-550 A Hidden Culprit: Insulinoma Masquerading as GLP-1 Agonist-Induced Hypoglycemia","Abhishek Jain","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1081",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047500","Gout-Related Medication Use After Initiating Sodium Glucose Co-Transporter-2 Inhibitors in Patients with Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies.","Chio Yokose","2026",null,"nonrandomized_study","article","10.2337/figshare.30916430.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0047501","Effects of glucagon like peptide-1 receptor agonists and their combination with sodium-glucose cotransporter-2 inhibitors on myocardial deformation and work index in type 2 diabetes: 1 year follow up","Ignatios Ikonomidis","2021","European Heart Journal - Cardiovascular Imaging","randomized_trial","article","10.1093/ehjci/jeaa356.143",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047502","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 6-month analysis results","Francesco Giorgino","2021","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0041-1727333",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0047503","CARDIOVASCULAR OUTCOMES WITH FINERENONE ACCORDING TO STATUS OF GLYCEMIA AT BASELINE AND PRIOR TREATMENT WITH NEWER ANTIDIABETICS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS","Dimitrios Patoulias","2022","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0000837336.21736.d6",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047504","MON-817 Association of Semaglutide and Tirzepatide Use on Bone Density and Fracture Risk in Obese Patients with and without Diabetes","Yi Liu","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.558",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047505","Cost and effectiveness of exenatide combined with insulin, compared to exenatide combined with oral hypoglycaemic agents","Shantanu S. Deshpande","2011","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1642",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047506","Mo1908: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE IN PATIENTS WITH PERIANAL FISTULIZING CROHN’S DISEASE IS WELL TOLERATED AND LEADS TO WEIGHT LOSS AND CLINICAL IMPROVEMENT IN FISTULA ACTIVITY","Seth Bergenholtz","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03695-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047507","654-P: Greater Adherence and Persistence with Dulaglutide Compared with Semaglutide at 6- and 12-Months Follow-up in U.S. Real-World Data","Reema Mody","2021","Diabetes","nonrandomized_study","article","10.2337/db21-654-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047508","Improved Treatment of Type 2 Diabetes: Results from the 4B Trial","Brian D. Hoyle","2013","MD Conference Express","randomized_trial","article","10.1177/155989771317003",null,null,"ClinicalTrials.gov:NCT00960661","S000609","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0047509","Drugs That Affect Body Weight","Randa Ghazal Asswad","2023",null,"other_trial","article","10.1201/9781003432807-39",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0047510","Exenatide once weekly (revision number 2)","Filip Krag Knop","2012","Diapedia.org eBooks","other","article","10.14496/dia.8104336112.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047511","Effects of Glucagon-Like Peptide 1 Agonists (GLP-1 RAs) on Ectopic Fat Deposition in CKD: A Pilot and Feasibility Study (GLIMP)","Ragibe Gulsah Dilaver","2024","Journal of the American Society of Nephrology","other","article","10.1681/asn.2024vmhy4t7s",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047512","Patient Outcomes Under Varying Engagement Patterns on Real-World Lifestyle-Supported Pharmacological Weight-Loss Therapy","Louis A Talay","2026","Obesities","nonrandomized_study","article","10.3390/obesities6010002",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047513","HSD49 Medication Use Among T2DM Patients Initiating Treatment with Once Weekly (OW) Semaglutide","M. Frazer","2023","Value in Health","other","article","10.1016/j.jval.2023.03.1356",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047514","PDB43 LONG-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VS. SULPHONYLUREA IN POLAND","Maciej Niewada","2010","Value in Health","other","article","10.1016/s1098-3015(11)72101-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047515","1.6 Exenatide BID vs. Insulin Lispro TIDM Added to Titrated Insulin Glargine QD in Metformin-Treated T2DM Patients Resulted in Similar Glycemic Control but Weight Loss and Less Hypoglycemia: The 4B Study (70-OR)","Michaëla Diamant","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0031-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047516","Peptide Therapeutics for Weight Loss: Preventing Plasma Pancreatic Polypeptide Proteolysis","C. Bruce Verchere","2017","Endocrinology","other_trial","article","10.1210/en.2017-00393","28575431",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047517","More Semaglutide-Treated Subjects Achieved Hba1c <7% Without Weight Gain or Hypoglycaemia Vs Comparators in Sustain 1–5","Va Woo","2018","International Journal of Nutrology","other","article","10.1055/s-0038-1674838",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0047518","HYPERTENSION MANAGEMENT OF CKD PATIENTS REFERRED TO HYPERTENSION EXCELLENCE CENTRES IN 27 COUNTRIES; ON BEHALF OF THE ESH HYPERTENSION AND KIDNEY WORKING GROUP","Jean‐Michel Halimi","2024","Journal of Hypertension","other","article","10.1097/01.hjh.0001019608.27759.da",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047519","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USE IS NOT ASSOCIATED WITH IMMEDIATE WORSE OUTCOMES IN PATIENTS UNDERGOING ERCP: A MULTINATIONAL ANALYSIS","Donghyun Ko","2025","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2025.03.430",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047520","O-094 Management of subfertility in women with PCOS: expectations, problems and solutions","Robert John Norman","2023","Human Reproduction","preclinical","article","10.1093/humrep/dead093.113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047521","1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study","Kamlesh K. Khunti","2020","Diabetes","other","article","10.2337/db20-1590-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047522","1.3 Exenatide Once Weekly: Sustained Glycemic and Weight Control Through 3 Years Compared with Insulin Glargine (67-OR)","MICHAEL E. TRAUTMANN","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0028-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047523","SGLT2-Inhibitoren oder GLP-1-Rezeptor-Agonisten? Entwicklung eines Modells für personalisierte Behandlungsentscheidungen bei Menschen mit Typ 2 Diabetes Mellitus: Eine populationsbasierte, retrospektive Kohortenstudie","Tim Mori","2024","Diabetologie und Stoffwechsel","other","article","10.1055/s-0044-1785280",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047524","Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics","John B. Buse","2025","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/7bja-et06",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047525","A systematic literature review and evidence synthesis of anti-diabetes treatments in type 2 diabetes mellitus patients: Indirect comparison of exenatide with metformin + sulphonylurea","Denise King","2014","Value in Health","narrative_review","article","10.1016/j.jval.2014.03.1391",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0047526","Prevalence of comorbidities associated with type 2 diabetes and prediabetes and a case-control analysis of the emergence of new comorbidities in 2007 - 2019","Merja Laine","2026","Diabetes Epidemiology and Management","nonrandomized_study","article","10.1016/j.deman.2026.100318",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047527","88 - Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: LEADER and SUSTAIN 6","Lawrence A. Leiter","2019","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2019.07.097",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047528","Navigating retatrutide safety: comprehensive insights from systematic review and meta-analysis","Vikas Maharshi","2026","Journal of Public Health and Development","systematic_review","article","10.55131/jphd/2026/240123",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0047529","ADVERSE EVENTS ASSOCIATED WITH GLP1–RECEPTOR AGONISTS TREATMENT IN DIABETIC PATIENTS WITH HIGH CARDIOVASCULAR RISK: A META–ANALYSIS","Andrea Pozzi","2024","European Heart Journal Supplements","randomized_trial","article","10.1093/eurheartjsupp/suae036.288",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047530","SEMAGLUTIDE EXERTS POSITIVE INOTROPIC EFFECTS IN THE HUMAN ATRIUM","Nichole Joachim","2024","European Heart Journal Supplements","other","article","10.1093/eurheartjsupp/suae036.185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047531","Changes in Psychiatric Symptoms, Eating Disorder Behaviors, and Health Behaviors Following Six Months of GLP-1 Treatment for Obesity: A Pre-to-Post-Treatment Study","Thomas R. Rutledge","2026","Heart and Mind","other_trial","article","10.4103/hm.hm-d-25-00125",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0047532","RWD192 Real-World Use of Tirzepatide Among People Without Evidence of Type 2 Diabetes: Results From Merative Marketscan Commercial Database","Theresa M. Hunter","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.03.2489",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047533","Semaglutide 2.4 mg shown to reduce heart failure with preserved ejection fraction in overweight/obese people without diabetes","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.74",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047534","S2121 Timing of Glucagon-Like Peptide 1 Receptor Agonists Initiation Post-Bariatric Surgery and its Impact on Weight Loss Outcomes","Lavender Micalo","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037852.80049.d3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047535","Trial Design and Baseline Characteristics from REMODEL: A Mechanistic Study of Semaglutide vs. Placebo in People with Type 2 Diabetes and CKD","David Z.I. Cherney","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024wcjmwep0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047536","96. GLP-1 receptor agonist use is associated with increased risk of bone loss and thoracolumbar compression fractures: a national cohort study","Abdi Khalif","2026","The Spine Journal","nonrandomized_study","article","10.1016/j.spinee.2026.06.115",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047537","1015-P: Impact of Social Vulnerability on Resources for CGM Initiation across Michigan Primary Care Practices","Katherine L. Khosrovaneh","2023","Diabetes","other","article","10.2337/db23-1015-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047538","2P012 Structure Analysis of GLP-1 and Exendin-4 by Molecular Dynamics Simulation(01A. Protein:Structure,Poster,The 52nd Annual Meeting of the Biophysical Society of Japan(BSJ2014))","Sakiko Mori","2014","Seibutsu Butsuri","nonrandomized_study","article","10.2142/biophys.54.s196_6",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047539","S4062 A Serious Turn: Bowel Perforation Secondary to Semaglutide-Induced Constipation","Zainab Hassan Saeed","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001143708.14450.67",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047540","EE114 Cost-Effectiveness of Multiparametric MRI Compared to Liver Biopsy for the Detection of Nash Among Patients with Type 2 Diabetes Treated with Semaglutide","Mohsen Rezaei-Hemami","2023","Value in Health","other","article","10.1016/j.jval.2023.03.418",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047541","Type 2 diabetes mellitus in heterozygous familial hypercholesterolaemia: the hazardous intersection of cardiometabolic and genetic risk","Charles Amir German","2021","European Journal of Preventive Cardiology","commentary","article","10.1093/eurjpc/zwab057","33961017",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0047542","The Growing Obesity Epidemic: Integrating Lifestyle, Pharmacological, and Surgical Interventions for Effective Management","Jan Siwiec","2025","Journal of Education Health and Sport","other","article","10.12775/jehs.2025.77.56962",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047543","Candidate composite biomarker to inform drug treatments for diabetic kidney disease","Seyum Assefa Abebe","2023","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/p3s5-q060",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047544","Tu1886 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH IMPROVED OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE","Michael Saadeh","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)03787-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047545","EE8 SHORT-TERM COST AND HEALTH OUTCOMES COMPARISON OF SEMAGLUTIDE VERSUS TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA","Alexander Moreno-Calderón","2026","Value in Health","other","article","10.1016/j.jval.2026.03.304",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047546","668-P: Body Weight Loss with Oral Semaglutide Is Predominantly Mediated by Effects Other than Gastrointestinal Adverse Events","Juris Jendrik Meier","2021","Diabetes","other_trial","article","10.2337/db21-668-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047547","Abstract 12638: Autophagy-mitophagy Induction Improves Cardiovascular Inflammation in a Murine Model of Kawasaki Disease Vasculitis","Stefanie Marek‐Iannucci","2020","Circulation","preclinical","article","10.1161/circ.142.suppl_3.12638",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047548","8679 Case: The Sexual, Physical and Psychological Effects of Post-Finasteride Syndrome","Eibhlin Marie Lonergan","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.1570",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047549","872-P: Cardiovascular Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Meta-Regression Analysis of 17 Randomized Trials","José M. Rodriguez‐Valadez","2022","Diabetes","randomized_trial","article","10.2337/db22-872-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047550","51-OR: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity","Carel Wynand le Roux","2023","Diabetes","randomized_trial","article","10.2337/db23-51-or",null,null,"ClinicalTrials.gov:NCT04667377","S002375","openalex","FALSE","paywalled","1","FALSE","article"],["R0047551","Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: Results: from the STEP 9 randomised clinical trial","Henning Bliddal","2024","Osteoarthritis and Cartilage","randomized_trial","article","10.1016/j.joca.2024.03.003",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047552","Gabaergic System in the Regulation of the Functioning of Pancreas Beta-Cells in Normal Physiological Conditions and in Diabetes","Ivan Nikolaevich Tyurenkov","2023","Успехи физиологических наук","other","article","10.31857/s030117982302008x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047553","Sa2004: BARIATRIC ENDOSCOPY AND GLP-1 AGONISTS: WHO WINS THE BATTLE AGAINST OBESITY?","Ahmed Essam Salem","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02366-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047554","A RARE CASE OF A LARGE BOWEL OBSTRUCTION DUE TO TIRZEPATIDE","ARIEL GORDON","2023","CHEST Journal","other","article","10.1016/j.chest.2023.07.1569",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047555","1.1 IDegLira, a Novel Fixed Ratio Combination of Insulin Degludec and Liraglutide, is Efficacious and Safe in Subjects with Type 2 Diabetes: A Large, Randomized Phase 3 Trial (65-OR)","John B. Buse","2013","Nederlands Tijdschrift voor Diabetologie","randomized_trial","article","10.1007/s12467-013-0026-6",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047556","Misuse of Ozempic as a drug choice for weight loss, a potential threat","Uzma Aslam","2023","International Journal of Scientific Reports","other","article","10.18203/issn.2454-2156.intjscirep20233563",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047557","Reply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes?","Maria Corina Plaz Torres","2023","Hepatology","other","article","10.1097/hep.0000000000000312","36724446",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047558","Treatment of overweight and obesity during and after a pandemic. Let’s not wait for the development of complications — new guidelines for doctors","Magdalena Olszanecka‐Glinianowicz","2020","Arterial Hypertension","other","article","10.5603/ah.a2020.0019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047559","Antidiabetische Medikation von Patienten mit kardiovaskulärer Erkrankung – Zusammenfassung der Literatur und Anwendung in der klinischen Praxis // Antidiabetic Therapy of Patients with Cardiovascular Disease","Alexander Niessner","2019","Journal für Kardiologie (Krause & Pachernegg GmbH)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0047560","Analyse de la pharmacocinétique du liraglutide chez les adolescents atteints de diabète de type 2 en comparaison avec les résultats obtenus chez les adultes","S. Madani","2013","Annales d Endocrinologie","other","article","10.1016/j.ando.2013.07.539",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047561","Effect of liraglutide therapy on biochemical parameters of carbohydrate metabolism and amylase activity in adolescents with obesity","Margarita A. Ustyuzhanina","2025","Фарматека","other","article","10.18565/pharmateca.2025.1-s1.58-65",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047562","268-OR: Impact of the COVID-Pandemic on Antihyperglycemic Prescription Patterns in Canada","ALICE Y. CHENG","2022","Diabetes","other","article","10.2337/db22-268-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047563","Beurteilung der Blutzuckereinstellung mittels kontinuierlicher Glucosemessung bei mit IDegLira behandelten Patienten mit Typ 2 Diabtes","Matthias Blüher","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580799",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047564","#1696673 Weight reduction over time in tirzepatide-treated participants by early weight loss response – post hoc analysis in SURMOUNT-1","Kimberly Anne Gudzune","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.253",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047565","Repurposing drugs that slow down aging for the prevention of Alzheimer’s disease","Simone Tambaro","2024","Alzheimer s & Dementia","nonrandomized_study","article","10.1002/alz.089109","39751536",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047566","SAT-527 Addition of Dulaglutide to Immunosuppressive Therapy Markedly Reduces Insulin Requirements in a Patient with Insulin Antibody-Mediated Resistance","Mariya Mustafa Fatakdawala","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1059",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047567","S3214 Acute Pancreatitis and Shock Liver in a Diabetic Patient on Dulaglutide: A Case Report","Hezborn M Magacha","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001140316.61569.b7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047568","FRI-182 Semaglutide shows favourable safety across subgroups and a positive hepatic safety profile: findings from ESSENCE part 1","Philip N. Newsome","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)01920-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047569","MON-686 Incretin Therapy In Patients With Neurofibromatosis And Potential Clinical Manifestations Of Men Syndromes","Hery Mejia","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047570","ASSOCIATION OF GLP-1RA USE AND ASPIRATION PNEUMONIA AFTER THE ENDOSCOPIC PROCEDURE: REAL-WORLD DATA FROM A LARGE NATIONAL DATABASE","Yee Hui Yeo","2024","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.04.2837",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047571","Obesity in menopause care","Leonie Theresia van Hulsteijn","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvaf269","41492808",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047572","Zwei-Jahres-Daten mit Exenatide bei Patienten mit Typ-2-Diabetes: Anhaltende glykämische Kontrolle bei gleichzeitiger Gewichtsreduktion","Ken Herrmann","2007","Diabetologie und Stoffwechsel","other","article","10.1055/s-2007-982164",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047573","Sa1639: IMPACT OF SEMAGLUTIDE USE ON WEIGHT, FIBROSIS, AND STEATOSIS OF LIVER DISEASE PATIENTS","Omar Almetwali","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04859-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047574","Liraglutide, a once-daily human GLP-1 analogue","Michael Albrecht Nauck","2008","The British Journal of Diabetes","other","article","10.1177/1474651408100524",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047575","Patterns of TSH Test After GLP-1 RAs Initiation in Patients on Levothyroxine: A Trial Emulation Study (Online Supplemental Files)","Yishan Chen","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19394658",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0047576","Study on the physiological respiratory changes in patients on metformin therapy","Zainab Ahmad Hassan","2024","International Journal of Physiology Health and Physical Education","other_trial","article","10.33545/26647265.2024.v6.i1b.61",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0047577","S2417 Acute Pancreatitis Secondary to Olanzapine-Induced Hypertriglyceridemia: A Case Report","Udit Asija","2024","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001039036.40798.64",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047578","0458 Glucagon-like peptide-1 agonists as an adjunctive treatment for hidradenitis suppurativa: A quality improvement initiative by international dermatology outcome measures (IDEOM)","Sarah Romanelli","2025","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2025.06.463",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047579","S611 Glucagon-Like Peptide Receptor Agonist (GLP-1 RA) Use is Not an Independent Predictor of Gastroesophageal Reflux Disease (GERD) on Quantitative Reflux Testing","Robinderpal Sandhu","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001031812.30863.0e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047580","Su1752 EFFICACY AND SAFETY OF LIRAGLUTIDE IN PATIENTS WITH PATIENTS WITH AN ILEAL -POUCH-ANAL ANASTOMOSIS (IPAA) AND CHRONIC HIGH BOWEL FREQUENCY – PLACEBO-CONTROLLED, CROSSOVER, PROOF OF CONCEPT STUDY","Hans H. Herfarth","2024","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(24)02316-3",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047581","3 mg Liraglutide ameliorates inflammation and improves hypothalamic regulation of energy homeostasis by modulation of Sphingosine-1-Phosphate signalling in super-responders","Lewis Spencer","2021","Endocrine Abstracts","other","article","10.1530/endoabs.77.op4.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047582","P198 Resolution of metabolic dysfunction-associated steatohepatitis with semaglutide via modulation of multiple pathogenic pathways: insights from human and animal omics studies","Chalini Lankage","2025",null,"other","article","10.1136/gutjnl-2025-bsg.333",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047583","Beyond the Failing Heart: Deciphering the Multisystem Biology ofHeart Failure Through Remodeling, Immunometabolism, Fibrosis,and Interorgan Crosstalk","Camilo Fernández Bravo","2026","Japan Journal of Clinical & Medical Research","other","article","10.47363/jjcmr/2026(6)212",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047584","COMBINATION THERAPY WITH SEMAGLUTIDE AND VERICIGUAT AS AN EFFECTIVE THERAPY OF OF 5–FU INDUCED CARDIOTOXICITY: PRELIMINARY EVIDENCES IN CARDIONCOLOGY","Vincenzo Quagliariello","2025","European Heart Journal Supplements","preclinical","article","10.1093/eurheartjsupp/suaf076.253",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047585","Abstract 14383: Medical Therapy Before, During, and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: The Get With the Guidelines - Heart Failure Registry","Ankeet S. Bhatt","2021","Circulation","nonrandomized_study","article","10.1161/circ.144.suppl_1.14383",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047586","Efficacy and Safety of Semaglutide by Baseline BMI in SUSTAIN 1–5 and 7","Adie Viljoen","2021","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0041-1727321",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0047587","The Correlation of oral Semaglutide and NT-proBNP in Obesity-Related HFpEF in India","Pankaj Vinod Jariwala","2024","Indian Heart Journal","other","article","10.1016/j.ihj.2024.11.290",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047588","P0653 Patients with ileo-anal J-Pouch display altered, higher pouch contractility than controls as measured with motility MRI","William Blad","2025","Journal of Crohn s and Colitis","randomized_trial","article","10.1093/ecco-jcc/jjae190.0827",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0047589","FATAL CASE OF SEVERE ACUTE NECROTIZING PANCREATITIS IN THE SETTING OF RECENT GLP-1 RECEPTOR AGONIST INITIATION","J. M. STUART","2024","CHEST Journal","other","article","10.1016/j.chest.2024.06.1675",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047590","Acute effects of lixisenatide on intragastric meal distribution in health and type 2 diabetes - impact on energy intake","Ryan J. Jalleh","2019","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047591","EFEITOS DA TIRZEPATIDA SOBRE OS DESFECHOS GASTROINTESTINAIS E HEPÁTICOS: REVISÃO SISTEMÁTICA DAS EVIDÊNCIAS CLÍNICAS E MECANISMOS ENVOLVIDOS.","João Lucas Souza Ferreira Almeida","2026","Revista fisio&terapia.","other","article","10.69849/revistaft/dt10202602161747",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047592","Erratum to: 64Cu- and 68Ga-Labelled [Nle14,Lys40(Ahx-NODAGA)NH2]-Exendin-4 for Pancreatic Beta Cell Imaging in Rats","Kirsi Mikkola","2013","Molecular Imaging and Biology","notice","article","10.1007/s11307-013-0700-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0047593","Exenatide and motor symptoms in Parkinson's disease (PD)","Icíar Avilés-Olmos","2014","UCL Discovery (University College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047594","S2864 Efficacy and Safety of GLP-1 Receptor Agonists in Metabolic-Associated Steatohepatitis With Significant Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Sudheer Dhoop","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001138916.35861.29",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0047595","GLP-1 and liraglutide increase the platelet inhibitory effects of nitric oxide.","Isabella Russo","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047596","The Antidiabetics Market: Tendencies and Research Directions","Claudiu Morogvan","2010","Applied Medical Informatics (University of Medicine and Pharmacy Cluj-Napoca)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047597","The place of IDegLira in the management of patients with Type 2 diabetes","Andrew Kenneth Lansdown","2015","Diabetes Management","other_trial","article","10.2217/dmt.15.29",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047598","GLP-1 RECEPTOR AGONIST EFFECT ON RETAINED GASTRIC CONTENTS ON EGD: A QUALITY IMPROVEMENT STUDY","Luís Hernández","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.1297",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047599","Global trends in obesity-related cancer: risk factors, prevention, and policy interventions","Rosario Suárez","2026","Food and Agricultural Immunology","nonrandomized_study","article","10.1080/09540105.2026.2649422",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047600","FC 058THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES: RESULTS FROM THE LEADER AND SUSTAIN 6 TRIALS","Emilie H. Zobel","2021","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfab144.001",null,null,"ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446","S001496; S001933","openalex","TRUE","open_pdf","1","FALSE","article"],["R0047601","The communication of risks associated with GLP-1 receptor agonists: An AI-powered content analysis of TikTok videos (Preprint)","Carlos A. Almenara","2026",null,"other","article","10.2196/preprints.102913",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047602","Effects of Liraglutide on Gastric Emptying, Gastric Accommodation, Satiation and Satiety after 16 Weeks' Treatment: A Single-Center, Randomized, Placebo-Controlled Trial in 32 Patients","Disha Khemani","2017","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(17)32245-x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047603","#3000 EFFICACY AND SAFETY OF COTADUTIDE, A DUAL GLP1-GLUCAGON RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND T2DM","Viknesh Selvarajah","2023","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfad063a_3000",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047604","Research progress in clinical application of nuclear medicine molecular probes for gastroenteropancreatic neuroendocrine neoplasm","LIU Yu","2022","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047605","Comparative Effectiveness of SGLT2 Inhibitors, GLP1 Receptor Agonists, DPP4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: emulation of a target trial using healthcare databases","Yan Xie","2020","Journal of the American Society of Nephrology","nonrandomized_study","article","10.2337/figshare.12863786",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","other; conference-abstract"],["R0047606","New opportunities to use exenatide for the patients with type 2 diabetes mellitus and gastroesophageal reflux disease against the background of abdominal obesity","Elena Sergeevna Andreeva","2016","Medical news of the North Caucasus","other","article","10.14300/mnnc.2016.11109",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047607","Effects of 32 weeks treatment with semaglutide and empagliflozin on magnetic resonance imaging derived kidney parameters and on retinal function in people with type 2 diabetes:data from a randomised trial","Gullaksen, Søren; id_orcid 0000-0001-8275-1278","2023",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","dissertation"],["R0047608","The use of liraglutide, a GLP-1 agonist, in obese people with type 1 diabetes : learning from practice","Syed M.R. Gillani","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047609","S3708 Suspected Drug-Induced Liver Injury With Autoimmune Features (AI-DILI) in a Patient Taking Liraglutide","Ruchir Damjibhai. Paladiya","2023","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000964472.54085.c4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047610","Liraglutyd - analog glukagonopodobnego peptydu-1 w terapii cukrzycy typu 2","Aleksandra A. Uruska","2010","Forum Zaburzeń Metabolicznych","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047611","OR09-07 Dynamic Proteomic Profiling in a 5-week Crossover Trial of Liraglutide in Obesity Reveals Weight-Dependent Myostatin Downregulation and Multi-Pathway Effects Beyond Weight Reduction","Konstantinos Stefanakis","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.072",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047612","Semaglutide and lanifibranor differentially alter NASH and liver fibrosis in diet-induced obese hamsters with or without free access to alcohol","François Briand","2024","Metabolism","other","article","10.1016/j.metabol.2024.155837",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047613","63354 GLP-1 Agonists May Play a Role in Central Centrifugal Cicatricial Alopecia Disease Activity","Noelle Desir","2025","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2025.05.201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047614","1488-P: Indicators of Diabetes Remission in Six Integrated Health Care Systems—A Retrospective Cohort Study","LUIS A. RODRIGUEZ","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1488-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047615","672-P: Association of Different Antidiabetic Medications with Depression Scores in Veterans","Shannen Nicole Dean Ubalde","2025","Diabetes","other","article","10.2337/db25-672-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047616","Agonistas del receptor de GLP-1 para el tratamiento de la obesidad en pacientes con dermatosis inmunomediadas","Eva Vilarrasa","2023","Actas Dermo-Sifiliográficas","nonrandomized_study","article","10.1016/j.ad.2023.06.017","37451337",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047617","Editorial: Endocrinology, lipids, and disease: unraveling the links","Ashutosh Prince","2025","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1687649","40979717",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0047618","Prescribing trends of anti-diabetes medications near end-of-life among adults with type 2 diabetes: a cohort study","Alexander Kutz","2025",null,"nonrandomized_study","article","10.2337/figshare.28003451",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0047619","SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications","Anil Pareek","2020","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-020-00833-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047620","Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity","Ametov As","2025","Pharmacy & Pharmacology","randomized_trial","article","10.19163/2307-9266-2024-12-3-231-246",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047621","Advantages of glucagon-like peptide agonists in the light of prevention of cardiovascular and renal complications","Tatiana Yu. Demidova","2023","FOCUS Endocrinology","other","article","10.15829/2713-0177-2023-4-23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047622","P017 Association Between Tirzepatide and Fatigue and Functioning Based on Baseline Characterization: SURMOUNT-OSA Trials","Terri E. Weaver","2025","SLEEP Advances","other","article","10.1093/sleepadvances/zpaf053.077",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047623","EFFECTS OF ALBIGLUTIDE ON TYPES AND NUMBERS OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE IN THE HARMONY OUTCOMES TRIAL","Konstantin Alexander Krychtiuk","2023","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(23)01576-0",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0047624","CKD Is Associated with Attenuated Plasma Metabolome Response to Oral Glucose Tolerance Testing","Armin Ahmadi","2020","Journal of the American Society of Nephrology","other","article","10.1681/asn.20203110s1222c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047625","A Multicenter Study of Weight Loss and Side Effects in Pancreas Transplant Recipients Treated with GLP-1 Receptor Agonists","Ali Abbasi","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.440",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047626","Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes","Hemalkumar B. Mehta","2021","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/1yfd-sc03",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0047627","Consistent HbA1c and Body Weight Reduction with Semaglutide Independent of Diabetes Duration—SUSTAIN 1-5 and 7 Patient-Level Meta-analysis","Julio Rosenstock","2018","Diabetes","systematic_review","article","10.2337/db18-1081-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0047628","Pharmacist-Led Interventions to Optimize Guideline-Directed Medical Therapy in Diabetic Kidney Disease in Primary Care: A Scoping Review","Olivia O’Mahony","2026",null,"nonrandomized_study","article","10.17605/osf.io/954gb",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0047629","766-P: Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals—A Multiple Ascending Dose Study","RAJAMANNAR THENNATI","2023","Diabetes","randomized_trial","article","10.2337/db23-766-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047630","Tu1602 RENAL OUTCOMES WITH GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH NAFLD AND TYPE 2 DIABETES MELLITUS: A MULTICENTER PROPENSITY-MATCHED COHORT STUDY.","Arunkumar Krishnan","2023","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(23)03450-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047631","Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes","David Webb","2006","Drug Development Research","other","article","10.1002/ddr.20115",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047632","Exendin-4 Enhances GSIS By Upregulating Genes Related to Maturation, Glucose-Sensing Apparatus and Mitochondrial Oxidative Phosphorylation Machinery in hPSC-Derived Islets Without Increasing β-Cell Number","Abdoulaye Diané","2025","Fortune Journal of Health Sciences","preclinical","article","10.26502/fjhs.285",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047633","Comparative effects of randomized second-line therapy for type 2 diabetes on a composite outcome incorporating glycemic control, body weight, and hypoglycemia: An analysis of the Glycemia Reduction Approaches in Type 2 Diabetes - A Comparative Effectiveness (GRADE) Study","Marian Sue Kirkman","2024",null,"randomized_trial","article","10.2337/figshare.24534463",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0047634","Verlängerung der DURATION-1-Studie zu Patienten mit Typ-2-Diabetes: Wirksamkeit und Verträglichkeit von Exenatide einmal wöchentlich über 7 Jahre","Peter Öhman","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0037-1601750",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047635","946-P: The GLP-1 Receptor Agonist GL0034 Activates Central Regions Controlling Glucose Homeostasis and Feeding Behavior","Alexandre Picard","2020","Diabetes","preclinical","article","10.2337/db20-946-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047636","Editorial: Pharmaceutical care and wellness of diabetes","Havagiray R. Chitme","2026","Frontiers in Clinical Diabetes and Healthcare","nonrandomized_study","article","10.3389/fcdhc.2026.1910046","42453166",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0047637","GLP-1 receptor agonists, reproductive health, and the evidence gap in young women","Matthew Waite","2025","The Lancet Obstetrics Gynaecology & Women s Health","other","article","10.1016/s3050-5038(25)00149-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047638","The role of GLP-1 analog drugs in the weight loss process","Julia Menezes Vignoli","2024","Caderno Pedagógico","other","article","10.54033/cadpedv21n13-118",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047639","Liraglutide improves [beta]-cell function, measured by the C-peptide/glucose ratio, in obese patients with type 2 diabetes","Ana Maria Ramos-Levi","2015","Endocrine Abstracts","other","article","10.1530/endoabs.37.ep455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047640","P1078 Weight-loss medications and bariatric surgery are infrequently used in obese patients with inflammatory bowel disease in North and East Devon in the United Kingdom (UK)","Phoebe Hodges","2025","Journal of Crohn s and Colitis","other_trial","article","10.1093/ecco-jcc/jjae190.1252",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047641","Comparative Effectiveness of Semaglutide, Liraglutide, and Dulaglutide for All-Cause Mortality in Type 2 Diabetes (T2D) with and without CKD: An Emulated Clinical Trial Observational Study","Amara Sarwal","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024gedej30f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047642","Crisis in Care: Limited Treatment Options for Type 2 Diabetes in Adolescents and Youth","William V. Tamborlane","2013","Diabetes Care","randomized_trial","article","10.2337/dc13-0743","23704679",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047643","Interpretation of cardiovascular outcome trials results of new antidiabetic agents","Gwanpyo Koh","2024","Journal of Medicine and Life Science","other","article","10.22730/jmls.2024.21.3.62",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047644","BLOOD PRESSURE CHANGES DURING SMOKING CESSATION ON DULAGLUTIDE AND PLACEBO TREATMENT – A SECONDARY ANALYSIS OF THE RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED SKIP TRIAL","Julia Beck","2024","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0001021732.82658.1f",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article; conference-abstract"],["R0047645","Low Incidence of Anti-Drug Antibodies in Type 2 Diabetes Patients Treated with Once Weekly GLP-1 Receptor Agonist Dulaglutide: Incidence of anti-drug antibodies with dulaglutide","Zvonko Miličević","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047646","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS INCREASE SOLID GASTRIC RESIDUE RATES ON UPPER ENDOSCOPY ESPECIALLY IN COMPLICATED DIABETIC PATIENTS","Kevin Garza","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.1298",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047647","1177-P: Practice Patterns of Medical Management of Pediatric Obesity and Type 1 Diabetes (T1D)","Jade Doolan","2024","Diabetes","other","article","10.2337/db24-1177-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047648","EXTH-120. Exendin-4 Inhibits BMP4-Dependent Cell Migration and Induces Apoptosis in Glioblastoma","Veena Girijala","2025","Neuro-Oncology","nonrandomized_study","article","10.1093/neuonc/noaf201.1453",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047649","0629 Characterizing and Predicting Hypoglossal Nerve Stimulator Outcomes: Updated Analysis from an Urban Sleep Clinic","Shide Zhang","2026","SLEEP","nonrandomized_study","article","10.1093/sleep/zsag091.0628",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047650","ACEI plus GLP1-RA or SGLT2i, as well as ARNI, exerted distinct protective effects against diabetic nephropathy and heart failure with preserved ejection fraction in eNOS-/- dbdb mice","K K Yu","2026","European Journal of Heart Failure","preclinical","article","10.1093/ejhf/xuag193.566",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047651","Инъекционная терапия при сахарном диабете 2 типа: существуют ли эффективные способы повышения приверженности лечению?","Олеся Юрьевна Гурова","2018","Сахарный диабет","other","article","10.14341/dm9603-7526",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047652","GLP-1/Glucagon dual agonist affects amino acid metabolism","Rebecca Scott","2019","Endocrine Abstracts","other","article","10.1530/endoabs.65.p220",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047653","Sa1090 REAL-WOLRD IMPACT OF GLP-1 RECEPTOR AGONISTS ON ENDOSCOPIC PATIENT OUTCOMES IN AN AMBULATORY SETTING. A RETROSPECTIVE STUDY AT A LARGE TERTIARY CENTER.","Ernesto S. Robalino Gonzaga","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)01242-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047654","Optionen zur Intensivierung einer Basalinsulintherapie bei Menschen mit Typ-2-Diabetes – Stellenwert der GLP-1-Rezeptoragonisten in der Kombinationstherapie","Baptist Gallwitz","2015","Diabetes aktuell","other","article","10.1055/s-0041-107335",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047655","Behavioral Psychomotor Performance, Thyroid Functional and Structural Changes with Glucagon-Like Peptide-1 Receptor Agonists in Rats","Dalia Ibrahim Ahmed","2024","Suez Canal University Medical Journal","preclinical","article","10.21608/scumj.2024.438080",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047656","Association Between Glucagon-Like Peptide 1 Receptor Agonists and Dementia: A Population-based Cohort Study of Adults Aged 40 Years and Older in Ontario, Canada","Fabio Castrillon-Ramirez","2024","Canadian Journal of Diabetes","nonrandomized_study","article","10.1016/j.jcjd.2024.09.039",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047657","Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians","Vasiliki-Sofia Grech","2024","Review of Clinical Pharmacology and Pharmacokinetics - International Edition","other","article","10.61873/rjdb1796",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047658","Su1539 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USED IN VETERANS WITH RISK FACTORS FOR MASLD - THE ROLE OF ALCOHOL USE DISORDER","Sebastian Niezen","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)04208-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047659","Estimating natural history of a treatment-eligible type 2 diabetes mellitus population in Scotland using linked primary and secondary care data: Scottish Diabetes Research Network - National Diabetes Dataset","Lili S. Wei","2024","International Journal for Population Data Science","other_trial","article","10.23889/ijpds.v9i5.2673",null,null,"PROSPERO:CRD42020184174",null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0047660","Reduction in Urinary Albumin-to-Creatinine Ratio (UACR) in People with CKD and Type 2 Diabetes Initiating Finerenone: A Comedication Subgroup Analysis from the FOUNTAIN Platform","Csaba Pal Kovesdy","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024d8kamd04",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047661","PDB56 AN ASSESSMENT OF THE LONG-TERM OUTCOME FOR LIRAGLUTIDE+METFORMIN VERSUS METFORMIN AND VERSUS METFORMIN+GLIMEPIRIDE INTYPE-2 PATIENTS WITH INADE-QUATE GLYCAEMIC CONTROL","Mette Hammer","2005","Value in Health","other","article","10.1016/s1098-3015(10)67673-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047662","Taspoglutide","Christopher JL Kueh","2014","Practical Diabetes","randomized_trial","article","10.1002/pdi.1911",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047663","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): final 24-month primary endpoint analysis","Francesco Giorgino","2023","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0043-1767871",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047664","78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)","Bernhard H. Ludvik","2021","Diabetes","randomized_trial","article","10.2337/db21-78-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047665","405-P: Efficacy and Safety of Finerenone in Patients with CKD and T2D by Baseline Insulin Treatment","Peter R Rossing","2021","Diabetes","randomized_trial","article","10.2337/db21-405-p",null,null,"ClinicalTrials.gov:NCT02540993",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047666","THU371 Empagliflozin Associated Pancreatitis: A Case Report","Alekya Poloju","2023","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvad114.804",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047667","Acarbose and Pasireotide Reduce Hypoglycemia in Roux-en-Y Gastric Bypass Operated Subjects","Caroline Christfort Øhrstrøm","2018","Diabetes","randomized_trial","article","10.2337/db18-2046-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047668","Euglycemic Diabetic Ketoacidosis after the Initiation of Treatment in a Patient with New-Onset Type 2 Diabetes Mellitus","Omar A. Alhaj","2022","Journal of Diabetes and Endocrine Practice","other","article","10.1055/s-0042-1755440",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047669","LB1095 Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes","Noah M. Braun","2025","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2025.06.1368",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047670","Weight Management in Primary Care Validated by Evidence Based Algorithm","Denise G Jacks","2016","The FASEB Journal","other","article","10.1096/fasebj.30.1_supplement.701.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047671","Aktivitas Obat Golongan SGLT-2i dan GLP-1RA serta SGLT-2i dan DPP-4i dengan atau tanpa Metfomin pada Tikus Diabetes tipe 2 dengan Model Kerusakan Sel Beta Pankreas dan Resistensi Insulin","Neng Fisheri Kurniati","2024","Jurnal Sains dan Kesehatan","other","article","10.30872/jsk.v5i5.562",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047672","P304 GLP-1 AGONISTS AND SMOKING CESSATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS","Javad Heshmati","2025","Canadian Journal of Cardiology","systematic_review","article","10.1016/j.cjca.2025.08.294",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0047673","Abstract PO5-12-03: Cardiovascular Toxicities in Breast Cancer Survivors","Victoria Damilola Ayodele","2024","Cancer Research","nonrandomized_study","article","10.1158/1538-7445.sabcs23-po5-12-03",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047674","MP10-05 LITHOPROTECTIVE EFFECT OF GLP-1 AGONISTS IN DIABETIC STONE FORMERS","Kelley Zhao","2023","The Journal of Urology","nonrandomized_study","article","10.1097/ju.0000000000003225.05",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047675","Response to: Body Contouring After Weight Loss: Bariatric Surgery, Glucagon-Like Peptide-1 Therapy and Lifestyle Impacts on Complications","Emmanuel Giannas","2026","Aesthetic Surgery Journal","other","article","10.1093/asj/sjag104","42168758",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047676","26-A-16257-ACC GLP-1 RECEPTOR AGONISTS AS A POTENTIAL FIFTH PILLAR OF GDMT IN HFREF: A MULTICENTER REAL-WORLD PROPENSITY-MATCHED ANALYSIS","Osman K. Yousafzai","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1913",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047677","Effects of dulaglutide on oxytocin plasma levels in healthy men: a secondary analysis of a randomized, double-blind, placebo-controlled crossover study","Vera Reber","2025","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.110.p930",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047678","SAFETY AND EFFICACY OF TIRZEPATIDE FOR SURPASS-2 THROUGH -5 PARTICIPANTS OVER 65 YEARS OLD WITH BMI BELOW 30 KG/M2: A POST HOC ANALYSIS","Neda Rasouli","2023","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2023.10.217",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047679","Incretin-based Therapies and Fasting during Ramadan","Mahdi Kamoun","2018","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/13049_13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047680","Abstract 144: Glucagon-like Peptide-1 Receptor Agonists Reduce The Risk Of Ischemic Stroke","Eric D. Goldstein","2022","Stroke","randomized_trial","article","10.1161/str.53.suppl_1.144",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047681","Management of type 2 diabetes mellitus: insights into prescribing trends","Prasanna Kumar K. M.","2017","International Journal of Research in Medical Sciences","nonrandomized_study","article","10.18203/2320-6012.ijrms20170910",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047682","736-P: Association of Glucagon-Like Peptide 1 Receptor Agonists with Cancer Risk in Older Adults with Type 2 Diabetes","Ying Lü","2025","Diabetes","nonrandomized_study","article","10.2337/db25-736-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047683","GLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients With Abdominal Aortic Aneurysms","Catherine C. Go","2026","Journal of Vascular Surgery","other","article","10.1016/j.jvs.2025.12.074",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047684","26-A-12618-ACC IMPACT OF GLP-1 RECEPTOR AGONISTS AND DUAL AGONISTS ON LIVER ENZYMES AND IMAGING OUTCOMES IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A SYSTEMATIC REVIEW","Nicole Ann Tesoro","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.473",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0047685","Neuroprotective properties of GLP-1 receptor agonists and SGLT-2 inhibitors in experimental stroke","А. В. Симаненкова","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.p509",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047686","PDB76 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO LIRAGLUTIDE BASED ON CARDIOVASCULAR OUTCOME TRIALS","Michel Lamotte","2018","Value in Health","other","article","10.1016/j.jval.2018.09.781",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047687","Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug","Nina Alexandrovna Petunina","2020","Diabetes Mellitus","other","article","10.14341/dm12487",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047688","Diagnosis and treatment of prediabetes as prevention of type 2 diabetes: A review","Nina Alexandrovna Petunina","2023","Consilium Medicum","narrative_review","article","10.26442/20751753.2023.4.202312",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047689","26-A-11744-ACC GLP-1 AGONISTS VS DPP-4 INHIBITORS AND ATRIAL FIBRILLATION: A HEAD-TO-HEAD META-ANALYSIS OF RANDOMIZED TRIALS","Param Darpan Sheth","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.347",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0047690","Tu1755: RISK OF COLORECTAL CANCER AND COLONIC POLYPS WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS COMPARED TO DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN US VETERANS WITH DIABETES MELLITUS","Anwar Mari","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04284-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047691","Assessment of metabolic profile in type 2 diabetic patients after 12 weeks of treatment by Liraglutide","Chadia Zouaoui","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep540",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047692","DIFFERENTIAL LONGITUDINAL EFFECTS OF GLUCOSE-LOWERING MEDICATIONS ON GLUCAGON AND C-PEPTIDE RESPONSES IN THE GLYCEMIA REDUCTION APPROACHES IN DIABETES: A COMPARATIVE EFFECTIVENESS (GRADE) STUDY","Steven E. Kahn","2025",null,"randomized_trial","article","10.2337/figshare.30659303",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0047693","Effects of semaglutide on anthropometric measures, diet, and eating behaviors in obese women: a retrospective observational study","Agnieszka Gdańska","2026","Health Problems of Civilization","nonrandomized_study","article","10.29316/hpc/217969",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047694","La exenatida: un nuevo antidiabético","Alberto C. Frati Munari","2006","Medicina Interna de México","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047695","Integrating Clinical Decision Support Tools in CKD Management","Heather Thiessen‐Philbrook","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024zq778gdv",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047696","ACNMD26-244: EFFECTS OF GLP1-RAS AND SGLT2I ON LIVER STEATOSIS AND FIBROSIS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) WITH TYPE 2 DIABETES: INTERIM ANALYSIS OF AN OPEN TRIAL","Andrea Mega","2026","Digestive and Liver Disease","other_trial","article","10.1016/s1590-8658(26)00503-7",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0047697","Адипокины и их роль в патогенезе детского ожирения","Анатолий Ильич Хавкин","2025","Children s medicine of the North-West","other","article","10.56871/cmn-w.2025.85.14.009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047698","CHARACTERIZING PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE FOR SEMAGLUTIDE ELIGIBILITY IN A LARGE INTEGRATED HEALTHCARE SYSTEM: HM CVD LHS REGISTRY","Eleonora Avenatti","2024","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(24)03667-2",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047699","Efficacy of a Glucagon-Like Peptide-1 and Estrogen Dual Agonist in Pancreatic Islets Protection and Pre-Clinical Models of Insulin-Deficient Diabetes","Taylor T. Fuselier","2022","SSRN Electronic Journal","other","article","10.2139/ssrn.4009228",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047700","242. Adjunctive Treatment With Semaglutide for Cognitive Dysfunction in Major Depressive Disorder: Reduction in Depression Scores Associated With Increased HbA1c Function and Glucose Levels","Sebastian Badulescu","2024","Biological Psychiatry","other","article","10.1016/j.biopsych.2024.02.477",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047701","A lipopolysaccharide mouse model mirrors neuroinflammatory transcriptional signatures of human Alzheimer’s disease, and the Glucagon‐Like Peptide‐1 receptor agonist semaglutide attenuates neuroinflammation in this model","Mette Q. Ludwig","2022","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.063862",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047702","Amélioration de l’HbA1c et du poids selon l’indice de masse corporelle (IMC) initial (< 30, ≥ 30– < 35 et ≥ 35 kg/m2) chez des patients diabétiques de type 2 (DT2) à 52 semaines de traitement par dulaglutide (DU) en administration hebdomadaire","Esteban Jódar","2015","Annales d Endocrinologie","other","article","10.1016/j.ando.2015.07.067",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047703","Use of Guideline-Recommended Medication Therapy in a High-Risk CKD Population in the Kidney CHAMP Trial","Melanie R. Weltman","2023","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20233411s1804d",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047704","Exenatide einmal wöchentlich plus Dapagliflozin einmal täglich versus Exenatide oder Dapagliflozin allein bei Patienten mit Typ 2 Diabetes, für die eine Metformin-Monotherapie nicht ausreichend war (DURATION-8): Eine 28-wöchige, multizentrische, doppelblinde, randomisierte, kontrollierte Phase-3-Studie","Juan P. Frías","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0037-1601752",null,null,"ClinicalTrials.gov:NCT02229396","S000791","openalex","FALSE","paywalled","5","FALSE","article"],["R0047705","Tu1200: COMPARATIVE RISKS OF GERD, GASTRIC INTESTINAL METAPLASIA, AND UPPER GI CANCERS IN OBESITY PATIENTS: A PROPENSITY-MATCHED POPULATION-BASED STUDY OF BARIATRIC SURGERY VS GLP-1 RECEPTOR AGONISTS","Hsien Yao Yang","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03992-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047706","THU250 Therapeutic Inertia In Primary Care With Poor Information Transfer To Specialist Care - A Rural Irish Experience","Conor T Coughlan","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.687",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047707","Effects of exenatide on serum lipids parameters in overweight type 2 diabetic patients","Tomislav Bulum","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047708","Beyond Insulin: Liraglutide in Type 1 Diabetes Mellitus","Adrian C. Hui","2011","Fisher Digital Publications (St. John Fisher College)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047709","Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes","Kahn S.E","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/2s2m-qy50",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0047710","S2360 Racial, Ethnic, and Sex-Based Disparities in Met-ALD: A 10-Year Propensity Score Matched Analysis Utilizing a National Database","Himsikhar Khataniar","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001136900.25861.dd",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047711","A-81 | Short and Long-Term Outcomes of GLP-1 Receptor Agonist Use in Patients With Diabetes Undergoing Percutaneous Coronary Intervention","Komal Arora","2026","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2026.104572",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047712","Clinical outcomes of tirzepatide in a real-world follow-up cohort of patients with type 2 diabetes","Thein M Tun","2026","touchREVIEWS in Endocrinology","nonrandomized_study","article","10.17925/ee.2026.22.2.1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047713","OBESITY Medication Self-Injection Education Using “Digital Clinicians”: A Feasibility Randomised Controlled Trial (Preprint)","Seán Coleman","2024",null,"randomized_trial","article","10.2196/preprints.63503",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0047714","1188-P: Approaches to and Inertia in Cardiovascular and Renal Risk Management of Type 2 Diabetes Patients in Primary Care: Results from a Global Quantitative Survey","Stephen Brunton","2020","Diabetes","other","article","10.2337/db20-1188-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047715","399-P: Association of Social Determinants of Health with Initiation of Novel Glucose-Lowering Drugs in Patients with Diabetes—A Post Hoc Analysis of the Kidney-CHAMP Trial","Mitra Mosslemi","2024","Diabetes","other_trial","article","10.2337/db24-399-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047716","PDB30 IMPROVEMENT IN CARDIOVASCULAR RISK FACTORS AND LONG-TERM OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES TREATED WITH LIRAGLUTIDE OR GLIMEPIRIDE MONOTHERAPY","Raphael Alfonso","2009","Value in Health","other","article","10.1016/s1098-3015(10)73573-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047717","PP.19.07","Tomislav Bulum","2015","Journal of Hypertension","other","article","10.1097/01.hjh.0000468286.32213.0e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047718","26-A-13326-ACC INCOME-BASED DISPARITIES IN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE AMONG U.S. ADULTS","Thomas R. Basala","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.598",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047719","Discordance Between Glucose Management Indicator and Hemoglobin A1c in CKD","Mengyao Tang","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.20252c9cpsz8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047720","Nouvelles stratégies thérapeutiques dans la maladie de Parkinson","Anne-Laure Mahul-Mellier","2025","Revue Médicale Suisse","other","article","10.53738/revmed.2025.21.915.863",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047721","95-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects —A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study","J WU","2023","Diabetes","randomized_trial","article","10.2337/db23-95-lb",null,null,"ClinicalTrials.gov:NCT05347758","S000450","openalex","FALSE","paywalled","1","FALSE","article"],["R0047722","Abstract 018: Semaglutide Use Associated with Lower Blood Pressure in Patients with Cardiometabolic Multimorbidity: Real-World Evidence from the All of Us Research Program","Lydia Vassiliadi","2025","Hypertension","nonrandomized_study","article","10.1161/hyp.82.suppl_1.018",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047723","681-P: Medication Adherence in the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness (GRADE) Study","Jeffrey S. Gonzalez","2025","Diabetes","randomized_trial","article","10.2337/db25-681-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047724","Drug therapy for obesity in the Russian Federation: pharmacoepidemiological study","Valery V. Strizheletsky","2022","FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","nonrandomized_study","article","10.17749/2070-4909/farmakoekonomika.2022.149",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047725","Editorial: Cardiorenal disease: a practical approach","Pedro Caravaca Pérez","2024","Frontiers in Cardiovascular Medicine","nonrandomized_study","article","10.3389/fcvm.2024.1381924","38426115",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0047726","P164 Effet pro-angiogénique du liraglutide dans un modèle de transplantation intra-hépatique d’îlots pancréatique de rat : rôle du stress oxydant","A. Langlois","2014","Diabetes & Metabolism","preclinical","article","10.1016/s1262-3636(14)72456-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047727","Kommentar zu GLP-1- und GIP-Agonisten vor Gastroskopie aussetzen oder fortführen?","Daniel Robert Quast","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2858-2463",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047728","New indications for exenatide therapy of type 2 diabetes mellitus","Ol'ga Konstantinovna Vikulova","2010","Diabetes Mellitus","other","article","10.14341/2072-0351-5496",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047729","Diabetes Type 2 as a Risk Factor of Neurodegeneration Development and Cognitive Impairment in db/db Mice","Т. А. Короленко","2020",null,"preclinical","article","10.1109/csgb51356.2020.9214662",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047730","111 Management of Refractory Severe Hypoglycaemia Post Roux-en-Y Gastric Bypass Surgery- a Case Report","James C. Noyes","2025","British journal of surgery","case_report","article","10.1093/bjs/znaf270.069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047731","Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) Versus Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria Status: AWARD-7","Katherine R. Tuttle","2021","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0041-1727305",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0047732","EE111 A LIFETIME COST-UTILITY ANALYSIS OF IGLARLIXI VERSUS IDEGASP IN TYPE 2 DIABETES IN TURKIYE","Elif Hilal Vural","2026","Value in Health","other","article","10.1016/j.jval.2026.03.406",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047733","GLP-1 RECEPTOR AGONISTS AND OTHER ANTIHYPERGLYCEMIC AGENTS UNLIKELY TO AFFECT BOWEL PREPARATION: A RETROSPECTIVE COHORT STUDY","Adam Vinall","2024","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.04.1373",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047734","Sodium–glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead","Caroline Kaercher Kramer","2016","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehw158","27153862",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0047735","Perioperative anesthesia and aspiration-related outcomes in patients receiving GLP-1 receptor agonists undergoing urgent and elective procedures: a systematic review","Emre Adalier","2026","Trends in Anaesthesia and Critical Care","systematic_review","article","10.1016/j.tacc.2026.101660",null,null,"PROSPERO:CRD420261334646",null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0047736","Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813–820","Muhammad A Abdul‐Ghani","2017","Diabetes Care","other","article","10.2337/dc17-er11","28887407",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0047737","Abstract 4368263: Use of Contemporary Cardiometabolic Therapies in Cardiac Amyloidosis Treated with Tafamidis: A Real-World Propensity-Matched Analysis","Omar S. Obeidat","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4368263",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047738","Abstract 4341436: Semaglutide as an effective therapy for heart failure: Evidence from a meta-analysis of 6,479 patients","J. Ruiz","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4341436",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0047739","Real world outcomes comparing the use of GLP-1 agonists in patients with renal cell carcinoma (RCC) and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.","Yajur Arya","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.7_suppl.484",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047740","139-OR: Superior Effect of 1-Year Treatment with GLP-1 Receptor Agonist and Exercise on Weight Loss Maintenance and Body Composition after a Very Low-Calorie Diet: The S-LITE Randomized Trial","Charlotte Janus","2020","Diabetes","randomized_trial","article","10.2337/db20-139-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047741","Complicaciones centrales en un modelo murino de enfermedad de alzheimer y diabetes mellitus: papel de la liraglutida","Carranza Naval,  María José","2022","RODIN (Universidad de Cádiz)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0047742","Exenatide protects renal ischemia reperfusion injury in type 2 diabetes mellitus","Jitendra D. Vaghasiya","2010","International Journal of Diabetes in Developing Countries","other","article","10.4103/0973-3930.70863",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047743","Abstract 4351238: Use of GLP-1 is Associated with Improvement in Mortality Rates in ESKD Patients","Steph Karpinski","2025","Circulation","other_trial","article","10.1161/circ.152.suppl_3.4351238",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047744","Semaglutide reduces kidney disease severity and improves vascular endothelial function in mice with polycystic kidney disease in a diet-dependent manner","Randee Sedaka","2026","Physiology","randomized_trial","article","10.1152/physiol.2026.41.s1.2300525",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047745","Assessment of Semaglutide Therapy on Inflammatory Mediators in Diabetic Rats with Experimental Periodontitis","Soha M. Basha","2024","Egyptian Dental Journal /Egyptian Dental Journal","preclinical","article","10.21608/edj.2024.309230.3143",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047746","Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable","Francesco Cosentino","2018","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehy677","30445605",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047747","Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials","Ligia Maria Belalcazar","2017","Circulation","other_trial","article","10.1161/circulationaha.116.024627","28223324",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0047748","12608 Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With Glp-1 Receptor Agonist Treatment","Husam Ghanim","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.019",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047749","Peptide Co-Agonists for Combined Activation of the APJ and GLP-1 Receptors with Insulinotropic and Satiety Actions Show Potential for Alleviation of Metabolic Dysfunction in Type 2 Diabetes","Finbarr P.M. O'Harte","2023",null,"preclinical","article","10.3390/msf2023023001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0047750","SUN-685 A comparison of the metabolic effects of a long-acting GIPR agonist versus a GIPR antagonist","Iona Davies","2025","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaf149.194",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047751","1308 Pharmacists Expertise on GLP-1/GIP Receptor Agonists Current Shortages, Dose Conversions, and Alternative Sources: Identifying Knowledge Gaps","Luiza Fernanda Mendonça Nicolau","2025","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2025.102768",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047752","S4698 Esophageal Obstruction Secondary to Severe Gastroduodenal Retention in the Setting of Recent Semaglutide Initiation","Ali A. Aijaz","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001048160.95530.8a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047753","1440-P: Effects of Two Weight-Loss Medications, Liraglutide and Orlistat, on Liver Enzymes in Patients with Overweight or Obesity in a Real-World Setting","JUAN J. GORGOJO-MARTINEZ","2022","Diabetes","nonrandomized_study","article","10.2337/db22-1440-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047754","987-P: Comparative Cardiovascular (CV) Effectiveness of SGLT2 Inhibitors (SGLT2i) and GLP-1 Receptor Agonists (GLP-1 RA) in Patients with Type 2 Diabetes Mellitus (T2DM): A Large National Database Study","Omar Ali Alaber","2021","Diabetes","nonrandomized_study","article","10.2337/db21-987-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047755","High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program","Matthew James Armstrong","2010","Diabetes","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0047756","Evaluation of glucagon-like peptide-1 receptor expression in nondiabetic and diabetic atherosclerotic mice using PET tracer Ga-68-NODAGA-exendin-4","Mia R. Ståhle","2021","STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047757","PO-01-030 LONG-TERM ABLATION OUTCOMES IN THE LIRAGLUTIDE EFFECT ON ATRIAL FIBRILLATION (LEAF) STUDY","Jeffrey J. Goldberger","2025","Heart Rhythm","other","article","10.1016/j.hrthm.2025.03.296",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047758","738-P: Efficacy and Safety of Efsubaglutide Alfa in Patients with Obesity or Overweight—A Phase 2 Study","Yuqian Bao","2025","Diabetes","randomized_trial","article","10.2337/db25-738-p",null,null,"ClinicalTrials.gov:NCT06732960","S002349","openalex","FALSE","paywalled","1","FALSE","article"],["R0047759","6401 Exogenous Cushing Syndrome By Over The Counter Substance \"AK Forte\". Case Report","Mennaallah Mohamed Eid","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047760","The Era of Incretinization in India: Narrative review of GLP1-RA with focus on T2DM population with cardiovascular comorbidities","Anil Bhansali","2024","Indian Heart Journal","narrative_review","article","10.1016/j.ihj.2024.11.273",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0047761","PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS)","David A. Pattison","2016","Internal Medicine Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047762","LBP-019 Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo","Mary Eugenia Rinella","2025","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(25)00438-6",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047763","Liraglutide prevents high glucose-induced adhesion of endothelial cells to monocyte by targeting IKK/NF-κB","Hu Li","2019",null,"preclinical","article","10.3760/cma.j.issn.1008-1372.2019.06.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047764","Abstract 15707: The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of LEADER and SUSTAIN 6","Lawrence A. Leiter","2018","Circulation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047765","Abstract 1990: Cjc-1134-pc, a long-acting glp-1r agonist, effects in modulating pro-inflammatory cytokines in the tumor environment","Xiping Liu","2019","Tumor Biology","preclinical","article","10.1158/1538-7445.sabcs18-1990",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047766","Nephropathy in Diabetes","Ludwig Merker","2025","Experimental and Clinical Endocrinology & Diabetes","other","article","10.1055/a-2500-1124","40328263",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047767","Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects","Pranjal Sharma","2024","Endocrines","systematic_review","article","10.3390/endocrines5030023",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0047768","Sa1955 EXAMINING GASTROINTESTINAL COMPLICATIONS DURING THE INITIAL TITRATION PHASE OF GLP-1 RA THERAPY AND THEIR ASSOCIATED HEALTHCARE UTILIZATION","Benjamin Douglas Xun Liu","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01832-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047769","265-OR: Understanding Patterns of GLP-1/GLP-1 RA Use among Individuals with Type 1 Diabetes—A T1D Exchange (T1DX) Online Registry Analysis","KELLEE MILLER","2024","Diabetes","nonrandomized_study","article","10.2337/db24-265-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047770","Exenatide Response in an Adolescent’s Morbid Obesity","Ricardo Soriano Sánchez","2014","Pharmacology &amp Pharmacy","other","article","10.4236/pp.2014.54051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047771","Measures Related to Obstructive Sleep Apnea After Tirzepatide Treatment by Baseline OSA Severity: Post-hoc Analyses of SURMOUNT-OSA","Birong Liao","2025","American Journal of Respiratory and Critical Care Medicine","other_trial","article","10.1164/ajrccm.2025.211.abstracts.a5207",null,null,"ClinicalTrials.gov:NCT05412004","S000156","openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0047772","A-56 | Impact of GLP-1 Receptor Agonists on Cardiovascular and Renal Outcomes in Overweight Patients with Acute Myocardial Infarction (AMI) Undergoing PCI, a Multicenter retrospective study","Rakendu Jayasree Rajendran","2025","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2025.102806",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0047773","EVALUATING PARTICIPANT-LEVEL EFFECTS OF TIRZEPATIDE ACROSS SURPASS RANDOMIZED CLINICAL TRIALS USING A MULTIDIMENSIONAL COMPUTATIONAL PHENOMAPPING APPROACH","Phyllis Thangaraj","2025","Journal of the American College of Cardiology","randomized_trial","article","10.1016/s0735-1097(25)01187-8",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047774","Personalized risk assessment for heart failure and atherosclerosis in diabetes: radiomic analysis of coronary calcium and epicardial adipose tissue on cardiac CT","Prerna Singh","2025",null,"nonrandomized_study","article","10.1117/12.3047113",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0047775","Abstract 4113997: Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease","Christopher D. Stone","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4113997",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047776","Polish Forum for Prevention Guidelines on Diabetes: update 2017","Maciej Tadeusz Malecki","2017","Kardiologia Polska","other","article","10.5603/kp.2017.0111","28707289",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047777","IV Exenatide Has the Same Efficacy as Insulin in C ICU Patients, without Inducing Hypoglycemia","Robert E. Buckley","2011","MD Conference Express","other","article","10.1177/155989771108003",null,null,"ClinicalTrials.gov:NCT00736229","S001102","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0047778","Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass","Mitchell, Ryan K.","2017","reroDoc Digital Library","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047779","Tu1031 LOW PRESCRIPTION RATES OF ANTI-OBESITY MEDICATIONS AND BARIATRIC SURGERY IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH OBESITY COMPARED TO THE GENERAL POPULATION WITH OBESITY DESPITE NEW EFFECTIVE GLUCAGON LIKE PEPTIDE 1 (GLP-1) AGONISTS","T J Mathews","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)03275-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047780","Editorial: Pharmacotherapy for Obesity in Persons With Inflammatory Bowel Disease","James K. Stone","2023","Crohn s & Colitis 360","nonrandomized_study","article","10.1093/crocol/otad008","36937135",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0047781","38-OR: Deletion of the Mitofusins 1 and 2 (Mfn1 and Mfn2) from the Pancreatic Beta Cell Disrupts Mitochondrial Structure and Impairs Glucose-, but Not Incretin-, Stimulated Insulin Secretion","Eleni Georgiadou","2021","Diabetes","preclinical","article","10.2337/db21-38-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047782","112-LB: Melatonin and DPP-IV Inhibitor: A Novel Combinatorial Approach for ß-Cell Regeneration","Roma Patel","2019","Diabetes","preclinical","article","10.2337/db19-112-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047783","Additional file 6: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Ling Li","2016","Figshare","systematic_review","article","10.6084/m9.figshare.4430744.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0047784","1407-P: Gaps in the Initiation of Diabetes Drugs with Cardiovascular and Kidney Benefits by Medical Specialists","Rozalina Grubina McCoy","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1407-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047785","SEMAGLUTIDE DRIVES REGIONAL RE-MODELING OF THE INTESTINAL STEM CELL NICHE","Reem Gandhi","2026","Inflammatory Bowel Diseases","preclinical","article","10.1093/ibd/izag006.150",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047786","Potential Role for the Use of Gliptins in Cystic Fibrosis-related Diabetes","Heba Mohamed Atif Ismail","2021","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgab442","34139767",null,"ClinicalTrials.gov:NCT01851694",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047787","56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting","Filip Krag Knop","2023","Diabetes","other","article","10.2337/db23-56-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047788","1074 RE-EXAMINING THE RISKS OF GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR WEIGHT LOSS WITH MORE STRINGENT CRITERIA ON A COMPREHENSIVE LARGE DATABASE.","Benjamin Douglas Xun Liu","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)01067-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047789","Mass Spectrometry identification of 12 cases of AGLP1 (Glucagon-like peptide 1 analog) amyloidosis PC13 (#141)","Ambani Omgba Jeanne Julie","2024",null,"other","article","10.26226/m.65f9bf8ae6f73964e1d4ebc7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0047790","Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy","Matthew James Armstrong","2016","Hepatology","nonrandomized_study","article","10.1002/hep.28672","27287457",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047791","MON-527 Association of Acute kidney injury with commonly prescribed glucagon-like peptide 1 receptor Agonists: A Pharmacovigilance Analysis","Lakshmi Prasanna Vaishnavi Kattamuri","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.894",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047792","EFFECT OF TIRZEPATIDE ON OFFICE BLOOD PRESSURE LEVELS IN OVERWEIGHT OR OBESE INDIVIDUALS WITHOUT TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS","Dimitrios Patoulias","2024","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0001021832.58477.b1",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0047793","Neue Perspektiven auf die Behandlung von Typ-2-Diabetes mit chronischer Nierenerkrankung","Antje Bergmann","2025","Diabetes aktuell","other","article","10.1055/a-2560-2336",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047794","EE621 Cost-Effectiveness Analysis of iGlarLixi Compared With Basal Bolus Insulin Regimen in Triple Metabolic Goal in Type 2 Diabetes Mellitus in Latin America","Santiago Sánchez Londoño","2023","Value in Health","other","article","10.1016/j.jval.2023.09.886",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047795","PMON01 Alpelisib (PI3-K Inhibitor) Induced Severe Insulin Resistance Complicated by Diabetic Ketoacidosis (DKA) with Rapid Reversal Following Discontinuation: A Case Report","Jacob Lloyd","2022","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvac150.913",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047796","Investigations from the Belly of the Beast: N‑Terminally Labeled Incretin Peptides That Are Both Potent Receptor Agonists and Stable to Protease Digestion","Allison Ann Berger","2021","ACS Central Science","other","article","10.1021/acscentsci.1c00265","33791422",null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0047797","Once-weekly exenatide in type 2 diabetes","Dinesh M. Parmar","2011","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-011-0018-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047798","Blood‐based Biomarkers to Evaluate the Effectiveness of Individualized Alzheimer’s Risk Reduction Care: The Future of Preventive Neurology?","Kellyann Niotis","2024","Alzheimer s & Dementia","nonrandomized_study","article","10.1002/alz.088292",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047799","Prospective potential of Incretin-based therapy in managing radiation toxicity: Current evidence and mechanistic insights","Dina Elgalaly","2026","Archives of Pharmaceutical Sciences Ain Shams University","other","article","10.21608/aps.2025.426883.1248",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047800","Additional file 1 of Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists","Mahesh M. Umapathysivam","2026","Figshare","nonrandomized_study","article","10.6084/m9.figshare.32004906",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0047801","Elucidating the role of inhibitory G‐protein, Gz, in β‐cell preservation and regeneration (1062.3)","Allison L. Brill","2014","The FASEB Journal","preclinical","article","10.1096/fasebj.28.1_supplement.1062.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047802","SAT-323 USE OF LIRAGLUTIDE FOR WEIGHT LOSS IN KIDNEY TRANSPLANT RECIPIENTS: REPORT OF 14 CASES","Nizar M. Attallah","2020","Kidney International Reports","other","article","10.1016/j.ekir.2020.02.343",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047803","448-P: Clinical Conversations Exchange: A Cardiologist-PCP Collaboration Discussing GLP-1 Receptor Agonists for Reducing Cardiovascular Risk in Patients with Diabetes","RUSSIE ALLEN","2022","Diabetes","other","article","10.2337/db22-448-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047804","Experience of glucagon-like peptide-1 use in patients with obesity","S.R. Abdalova","2023","Voprosy dietologii","other","article","10.20953/2224-5448-2023-2-9-13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047805","Glucagon‐Like Peptide‐1 Receptor Activators","Michael Wagner","2021","Burger's Medicinal Chemistry and Drug Discovery","other_trial","article","10.1002/0471266949.bmc268",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0047806","Comparative Effectiveness of SGLT2i Versus GLP1-RA on Cardiovascular Outcomes in Routine Clinical Practice","Edouard L. Fu","2021","SSRN Electronic Journal","other","article","10.2139/ssrn.3947642",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047807","Sa2000: ENDOSCOPIC BARIATRIC THERAPIES AND GLUCAGON-LIKE PEPTIDE-1 AGONISTS ARE ASSOCIATED WITH A SIMILAR REDUCTION IN HEPATIC STEATOSIS","Alyssar Habib","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02362-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047808","Major adverse cardiovascular events (MACE) in cancer patients treated with tirzepatide compared to GLP-1 receptor agonists: A target trial emulation using real-world data.","Omer Sayed Ashruf","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.12027",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047809","RWD149 Real-World Comparison of Cardiovascular Benefits between Sodium-Glucose Cotransporter 2 (SGLT-2I) and Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Inhibitors in Patients with Type 2 Diabetes (T2D)","Dongyang Huang","2023","Value in Health","nonrandomized_study","article","10.1016/j.jval.2023.03.2178",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047810","Evaluating the Sub-chronic Effects of MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, on Weight Loss in Male ob/ob Mice","Stephanie N. Oldham","2018","Diabetes","preclinical","article","10.2337/db18-1890-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047811","SUN-545 Diabetes & Mitochondrial Dysfunction: A Case of G[3243] Mutation with MELAS Potential","Harika Chowdary Davuluri","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.1198",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047812","S3883 Emerging Gastrointestinal Risks of GLP-1 Receptor Agonists: A Case of Ischemic Colitis in a Young Woman on Semaglutide","Nancy Mayer","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001142992.25452.9d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047813","Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF","Nishanthi A. Vigneswaramoorthy","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4367243",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047814","1667-P: Patient-Reported Outcomes in Adults Initiating Treatment with Tirzepatide or Intensified Conventional Care Early in the Course of T2D: Results after Two Years of Treatment in SURPASS-EARLY","KRISTINA BOYE","2026","Diabetes","randomized_trial","article","10.2337/db26-1667-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047815","Advances in Patented CB1 Receptor Antagonists for Obesity","Mange Ram Yadav","2018","Pharmaceutical Patent Analyst","other","article","10.4155/ppa-2018-0020","30066594",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047816","Efficacy and Safety of Tirzepatide versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)","Stefano Del Prato","2022","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0042-1746267",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047817","1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?","GEORGE E. DAILEY","2019","Diabetes","other","article","10.2337/db19-1023-p",null,null,"ClinicalTrials.gov:NCT02057172","S001626","openalex","FALSE","paywalled","5","FALSE","article"],["R0047818","S791 Comparative Risk of Gastrointestinal Adverse Events Among GLP-1 Receptor Agonists: A Real-World Multicenter Study","Ahmed Salem","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130624.52234.9c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047819","FINANCIAL TOXICITY AMONG INDIVIDUALS MEETING CRITERIA FOR SEMAGLUTIDE IN A US REPRESENTATIVE POPULATION WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE","Izza Shahid","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03908-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047820","A Novel GLP-1/GIP Dual Agonist Normalizes Glucose Tolerance and Fat Mass in Diet Induced Obese Mice.","D Perez-Tilve","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","preclinical","article","10.1210/endo-meetings.2010.part2.p11.p2-511",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047821","MON-665 Experiences And Observations With Acquired Hypothalamic Obesity: A Qualitative Interview Sub-study","Christian Ludwig Roth","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.005",null,null,"ClinicalTrials.gov:NCT05774756",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047822","SUN-665 Meta-Analysis of Psychiatric and Quality of Life Outcomes in Patients With Obesity and Diabetes Treated With Glucagon-Like Peptide 1 Receptor Agonists","Aureliane C. S. Pierret","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.175",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0047823","Mo1918 GASTROINTESTINAL SYMPTOMS FROM SEMAGLUTIDE ARE COMMON IN REAL-WORLD CLINICAL PRACTICE, THOUGH MEDICATION DISCONTINUATION RATES ARE SIMILAR AMONG PATIENTS WITH OR WITHOUT PRIOR DIGESTIVE COMPLAINTS","Nicole Cornet","2023","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(23)03171-2",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0047824","228-LB: ß-arrestin-2 Deletion Influences GLP-1 Receptor Signaling in Pancreatic ß Cells In Vivo","Stavroula Bitsi","2021","Diabetes","preclinical","article","10.2337/db21-228-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047825","Vergleichbare Inzidenz gastrointestinaler Nebenwirkungen von IDegLira und Nicht-GLP-1RA-Vergleichsbehandlungen","Elmar Jaeckel","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580962",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047826","85-OR: A Novel Unimolecular Peptide Tetra-agonist (PTT-A) Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors with Superior Weight Loss Effects vs. Tirzepatide While Preserving Muscle in DIO Rats","Soumitra Ghosh","2025","Diabetes","preclinical","article","10.2337/db25-85-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047827","Abstract 19477: The Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Reduces Inflammation and Improves Cardiac Function in a Mouse Model of Obesity","Mohammad Hossein Noyan-Ashraf","2010","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047828","The use of GLP-1 receptor agonist therapy in patients with type 1 diabetes, a retrospective cohort study","Kevin Bowers","2026","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.115.p32",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047829","Does CKD Modify the Effects of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) and SGLT2 Inhibitors on Weight Loss?","Shalini Kasera","2024","Journal of the American Society of Nephrology","other","article","10.1681/asn.20247gpp3scv",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047830","Once-Weekly Semaglutide Provides Better Value for Money Than a Broad Range of Other Type 2 Diabetes Treatments in Canada: A Relative Cost of Control Analysis","Aiden Ranke Liu","2018","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2018.08.125",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047831","LBODP002 Phase II Open-label Pilot Trial Of Liraglutide In Adolescents With Obesity After Vertical Sleeve Gastrectomy: Interim Results From 8-weeks Of Treatment","Syeda Shamim Fatima","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.002",null,null,"ClinicalTrials.gov:NCT04883346","S000388","openalex","TRUE","open_pdf","2","FALSE","article"],["R0047832","1914-LB: The Combined Effect of CGM with Antidiabetes Medications and the Association with Improved A1C in People with Type 2 Diabetes (PWT2D) Not on Insulin Therapy (NIT)","Poorva M. Nemlekar","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1914-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047833","Effects of once weekly dulaglutide 1.5 mg on glycaemic control, weight and hypoglycaemia in patients with Type 2 diabetes in the AWARD-1 and AWARD-2 clinical trials","Hermione Clare Price","2017","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0037-1601748",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047834","Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to a glucagon-like peptide-1 receptor agonist: A real-world experience","Carolina García-Figueras-Mateos","2020","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.70.aep487",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047835","DPP‐4 Resistant Glucagon‐Like Peptide‐1 Analog LY548806: A Novel Agent for Control of Acute Hyperglycemia","Joy Krishna Saha","2007","The FASEB Journal","preclinical","article","10.1096/fasebj.21.5.a435-a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047836","Targeting inflammation in sickle cell disease: Association of GLP-1 agonist use with improved survival and reduced sickle cell crisis and cardiopulmonary complications","Asfand Yar Cheema","2025","Blood","randomized_trial","article","10.1182/blood-2025-2970",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047837","SP474TREATMENT WITH A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST LIRAGLUTIDE DECREASES ALBUMINURIA IN OVERWEIGHT TYPE 2 DIABETIC PATIENTS","Tomislav Bulum","2015","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfv195.18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047838","795-P: Elucidating the Role of Weight Loss and Glycemia with Observed Benefits of GLP-1 Receptor Agonist Treatment in Patients with T2D","Anukriti Sharma","2023","Diabetes","nonrandomized_study","article","10.2337/db23-795-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047839","Prefrontal cortex immaturity and reward circuit hijacking: Why anti-obesity policies fail to protect children from ultra-processed food overconsumption","Manuel Alejandro Vargas-Vargas","2026","World Journal of Clinical Pediatrics","other","article","10.5409/wjcp.120921",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047840","G.11 - BEHAVIOURAL PROFILE OF GLP-1 RECEPTOR AGONIST, EXENDIN-4 (EXENATIDE), IN NON-DEPRIVED MALE RATS PRESENTED WITH PALATABLE MASH","F Wright","2013","Behavioural Pharmacology","preclinical","article","10.1097/01.fbp.0000434879.77693.f7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047841","P.106: Prolonged Islet Allograft Function in Patients With Type 1 Diabetes After Islet Transplantation Is Associated With Female Sex of Donors and Recipients","Joana R. N. Lemos","2021","Transplantation","nonrandomized_study","article","10.1097/01.tp.0000804512.50554.05",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047842","Abnehmen mit GLP-1-RA klappt auch bei T1D","Nanette Cathrin Schloot","2021","Info Diabetologie","other","article","10.1007/s15034-021-3775-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047843","Improving Outcomes through Collaborative, Team-based Care","Susan A. Cornell","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047844","74-LB: Transition from Basal Bolus to Once-Weekly Subcutaneous Semaglutide and Basal Insulin in Patients with Type 2 Diabetes Mellitus (TRANSITION-T2D)—A Prospective Randomized Controlled Trial","Paloma Rodriguez","2023","Diabetes","randomized_trial","article","10.2337/db23-74-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047845","972-P: Liraglutide Attenuates Lipid-Induced Microvascular Insulin Resistance in Humans","Kaitlin M. Love","2020","Diabetes","preclinical","article","10.2337/db20-972-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047846","Efficacy and Safety of Liraglutide vs. Placebo as Add-On to Existing Diabetes Medication in Subjects with Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL)","Phuong Ngo","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047847","Metabolic effects of dapagliflozin QD and exenatide QW in obese adults without diabetes : a 24-week randomised placebo-controlled phase 2 study","Per Lundkvist","2016","Diabetologia","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0047848","Effect of glucagon-like peptide-1 agonists on ventricular tachycardia ablation outcomes","D T Zhang","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.625",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047849","EFFECTS OF SEMAGLUTIDE VERSUS COMPARATORS ON CARDIOVASCULAR EVENTS ACROSS A CONTINUUM OF BASELINE CARDIOVASCULAR RISK: COMBINED ANALYSIS OF THE SUSTAIN AND PIONEER TRIALS","Mansoor Husain","2020","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(20)32536-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047850","Sixty years on, and it is the quality that counts","Michael G. Kirby","2008","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2008.029",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047851","The use of Liraglutide in the treatment of childhood obesity","Louise Jayne Apperley","2021","Endocrine Abstracts","other","article","10.1530/endoabs.78.oc4.9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047852","Incretin-based Therapies and Fasting during Ramadan","Mahdi Kamoun","2014","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/11996_12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0047853","Effects of glucagon-like peptide 1 receptor agonist on short-chain fatty acids, carbohydrate and lipid metabolism in patients with type 2 diabetes","Lilit V. Egshatyan","2019","Endocrine Abstracts","other","article","10.1530/endoabs.63.gp208",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047854","1800-PUB: The Long-Term Effect of Glucagon-Like Peptide 1 Receptor Agonists on Glycemic Control Is Predominantly Related to Weight Loss","Marwa R. Al-Badri","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1800-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047855","Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials","Mohammed Altigani Abdalla","2023","Journal of Diabetology","randomized_trial","article","10.4103/jod.jod_16_23",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047856","2540-P: Weight Loss with Tirzepatide and Retatrutide Is Associated with Changes in Food Preference and Multiple Metabolic Benefits in the Free Choice Diet–Induced Obese Hamster Model","François Briand","2026","Diabetes","other","article","10.2337/db26-2540-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047857","Prediction of early response to liraglutide therapy in patients with obesity","Oksana Logvinova","2020","Obesity and metabolism","randomized_trial","article","10.14341/omet12274",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047858","High dose semaglutide 2.4 mg (once weekly) shown to reduce the risks of cardiovascular events in people without diabetes","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.82",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047859","1994-LB: Effects of Switching Glucagon-Like Peptide 1 Receptor Agonists on HbA1c, Body Weight, and Treatment Satisfaction among Patients with Type 2 Diabetes—A Meta-analysis","Xinyan Jia","2025","Diabetes","systematic_review","article","10.2337/db25-1994-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0047860","1684-P: CONCRETE—Characterization of Patients Receiving Telemedicine and Branded Antiobesity Medication for Medical Weight Management—A Retrospective Analysis","Alpana P. Shukla","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1684-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047861","The impact of semaglutide and tirzepatide on skeletal muscle: Significant benefit or substantial risk?","В. В. Салухов","2025","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2025-467",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047862","SGLT-2 inhibitors or GLP-1 receptor agonists as add-on to insulin therapy in patients with type 2 diabetes: comparative analysis","Carolina García-Figueras-Mateos","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p493",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047863","Expert consensus on the diagnosis and treatment of immunoinflammation in heart failure","Miao Yu","2025","Chinese Medical Journal","nonrandomized_study","article","10.1097/cm9.0000000000003840","41173656",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047864","Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes (GRADE) Study: A Comparative Effectiveness Randomized Clinical Trial","Andrea Cherrington","2024",null,"randomized_trial","article","10.2337/figshare.24653628",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0047865","Metformin in the management of antipsychotic-induced weight gain – why the ‘weight’?","Ita Fitzgerald","2024","Frontiers in Psychiatry","randomized_trial","article","10.3389/fpsyt.2024.1491417","39600786",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047866","Imaging of glucagon-like peptide-1 receptor expression after experimental myocardial infarction with 68Ga-NODAGA-Exendin-4","Mia R. Ståhle","2014","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047867","817-P: Identifying Modulators of Treatment Benefits of Albiglutide (GLP-1 RA) in Preventing Major Adverse Cardiovascular Events (MACE) among Individuals with Type 2 Diabetes in the HARMONY Trial Using Machine Learning","Hamed Kianmehr","2022","Diabetes","randomized_trial","article","10.2337/db22-817-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047868","PO-FPI-025 GLP-1 RECEPTOR AGONISTS VS SGLT2 INHIBITORS AFTER CARDIAC ARREST IN PATIENTS WITH DIABETES: A PROPENSITY-MATCHED EHR COHORT","Carlo El Khoury","2026","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2026.03.307",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047869","CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES *","Vivian Andrew Fonseca","2008",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047870","Glucagon-like peptide-1 receptor agonist diminishes endothelial dysfunction in type 2 diabetic patients","А. В. Симаненкова","2018","Regional blood circulation and microcirculation","other","article","10.24884/1682-6655-2018-17-2-57-63",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047871","GLP-1RA and 24-Hour Movement Behaviours: A Scoping Review Protocol","Jennifer Gale","2026","Open Science Framework","protocol","article","10.17605/osf.io/h65tj",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0047872","138 Symptomatic Remission of Ulcerative Colitis Following Initiation of GLP-1 Receptor Agonist Therapy","Budoor Alqinai","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001172976.34622.f1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047873","EFFECTS OF EXENATIDE ON CARDIAC FUNCTION, PERFUSION, AND ENERGETICS IN TYPE 2 DIABETIC PATIENTS WITH CARDIOMYOPATHY: A RANDOMIZED CONTROLLED TRIAL AGAINST INSULIN GLARGINE","Weena Jing Yan Chen","2016","Journal of the American College of Cardiology","randomized_trial","article","10.1016/s0735-1097(16)31353-5",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047874","When ‘Quick Fixes’ Go Viral: The Impact of GLP-1 Misinformation on Younger Females' Body Dissatisfaction and Disordered Eating Behaviours","Mackenzie Petie","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/kqgns",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0047875","A Novel Hybrid SPPS/LPPS Strategy for the Synthesis of Tirzepatide via Native Chemical Ligation","Ankur Jalan","2025","ChemRxiv","other","article","10.26434/chemrxiv-2025-g9qcl",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0047876","P1064 Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review","C L Birda","2026","Journal of Crohn s and Colitis","systematic_review","article","10.1093/ecco-jcc/jjaf231.1245",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0047877","Concurrent GLP1R-agonist use with chemoimmunotherapy for early-stage triple-negative breast cancer.","Bethania Santos","2025","Journal of Clinical Oncology","other","article","10.1200/jco.2025.43.16_suppl.1115",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047878","S96 Weight management in patients with decompensated obesity hypoventilation syndrome: understanding the changing landscape in the era of weight loss injections","Lim Ch","2025",null,"nonrandomized_study","article","10.1136/thorax-2025-btsabstracts.102",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047879","S2002 Association of Body Mass Index and GLP-1 in Outcomes in Inflammatory Bowel Disease","Regis Lee","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001135468.57678.f3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047880","S2340 Semaglutide and Tirzepatide Show Comparable Hepatic Outcomes in MASLD: A Propensity-Matched Analysis of a Multi-Institutional EHR Database","Ludovic Saba","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001136820.07930.f5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047881","Exendin-4 enhances osteogenic differentiation of adipose tissue mesenchymal stem cells through rank/ rankl/opg axis","Samar Habib","2021","Cytotherapy","other","article","10.1016/s1465324921003327",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047882","765-P: A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes","RAJAMANNAR THENNATI","2023","Diabetes","randomized_trial","article","10.2337/db23-765-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047883","666-P: Greater Proportions of Subjects Achieved HbA1c <7% without Weight Gain, Hypoglycemia, or Moderate/Severe Gastrointestinal Adverse Events with Semaglutide vs. Comparators in the SUSTAIN 7-10 Trials","Kamlesh K. Khunti","2021","Diabetes","other_trial","article","10.2337/db21-666-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047884","Exendin-4, a glucagons-like protein-1 receptor agonist, reduces proinflammatory conditions and increases insulin sensitivity and lipid oxidation in hepatocytes from non-alcoholic steatohepatitis rats","Gianluca Svegliati‐Baroni","2007","Digestive and Liver Disease","preclinical","article","10.1016/j.dld.2006.12.035",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047885","E-164 Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus and moyamoya disease: a propensity-score matched study","Joy Roy","2025",null,"nonrandomized_study","article","10.1136/jnis-2025-snis.279",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047886","Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program","Julio Cesar Nunes","2022","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.14832","35938182",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047887","Pharmaceuticals: GlaxoSmithKline offers $2.6 billion to buy Human Genome Sciences","LISA M. JARVIS","2012","Chemical & Engineering News","other_trial","article","10.1021/cen-09017-notw5",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0047888","Real-World Evaluation of Demographics, Treatment Pattern, and Economic Burden of Heart Failure and Kidney Disease in Type 2 Diabetes Mellitus Patient Population in Dubai, United Arab Emirates","Alaaeldin M. Bashier","2023","Dubai Diabetes and Endocrinology Journal","nonrandomized_study","article","10.1159/000530467",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047889","Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease","André Jacques Scheen","2024","Diabetes Epidemiology and Management","randomized_trial","article","10.1016/j.deman.2024.100197",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047890","In patients with uncontrolled type 2 diabetes, are GLP-1 agonists more effective than SGLT-2 inhibitors in lowering HbA1c?","Stuart Keith Johnson","2018","Evidence-Based Practice","other","article","10.1097/01.ebp.0000544890.57703.2b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047891","The effect of GLP-1 receptor agonists on outcomes in metastatic renal cell carcinoma patients undergoing immune checkpoint inhibitor therapy: A retrospective multi-institutional US cohort study.","Mohanad Elchouemi","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.4559",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047892","Semaglutide Associated Acute Necrotizing Pancreatitis: A Case Report","A. Araiza","2024",null,"case_report","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5691",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047893","POSITRON EMISSION TOMOGRAPHY TRACER [68GA]NODAGA-EXENDIN-4 DETECTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR EXPRESSION IN MOUSE ATHEROSCLEROTIC VASCULAR LESIONS","Mia R. Ståhle","2017","STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)","preclinical","article","10.1016/j.atherosclerosis.2017.06.188",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract; article"],["R0047894","Ocular Complications Associated with GLP1 Agonist Therapy","Jimmy J. Thomas","2026","Open Journal of Internal Medicine","other","article","10.4236/ojim.2026.161003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047895","A607 Can Incretin-Based Therapies augment results of Endoscopic Bariatric Procedures","Winni Mathur","2019","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2019.08.543",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047896","Exenatide und biphasisches Insulin Aspart bei Patienten mit Typ-2-Diabetes: Klinische Ergebnisse einer Nicht-Unterlegenheitsstudie","CHRISTOF M. KAZDA","2007","Diabetologie und Stoffwechsel","other","article","10.1055/s-2007-982147",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047897","Weight Regain After Discontinuation of High-Dose GLP-1 Receptor Agonists in Adults with Obesity Without Type 2 Diabetes: A Meta-Analysis of Long-Term Follow-Up Studies","Saja Saad Merzah Almusaferi","2026","Journal of Posthumanism","systematic_review","article","10.63332/joph.v6i3.4054",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0047898","111In-exendin SPECT imaging suggests presence of residual beta cells in patients with longstanding type 1 diabetes","Marti Boss","2021","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0041-1727079",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0047899","Precision medicine in diabetes—Finally some light at the end of the tunnel?","Gerard Marshall Raj","2020","British Journal of Clinical Pharmacology","nonrandomized_study","article","10.1111/bcp.14674","33284495",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047900","Diabetes Mellitus and Natural Product‐based Drug Discovery","David J. Newman","2023",null,"other","article","10.1002/9781119983347.ch1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0047901","The effectiveness and safety of exenatide in the treatment of polycystic ovary syndrome: A systematic review and meta-analysis","Yan Ping Hu","2022",null,"systematic_review","article","10.37766/inplasy2022.11.0055",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0047902","ODP195 EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY IN ASSOCIATION WITH USE OF SGLT2I.","Nishit Vaghasia","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.647",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047903","A Tag to Track Short Chain Fatty Acid Sensors","Frank M. Reimann","2013","Endocrinology","preclinical","article","10.1210/en.2013-1789","24058154",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047904","Weight loss and associated improvements in cardiometabolic risk factors with liraglutide 3.0 mg in the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial","Barbara M. McGowan","2017","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.48.p1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047905","Abstract 4139932: Glucagon-like peptide-1 Receptor Agonists reduce the Incidence of Echocardiographic Pulmonary Hypertension","Jonah David Garry","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4139932",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047906","Incretin therapy for obesity: efficacy, safety, and compliance","Mekan R Orazov","2026","Clinical review for general practice","other","article","10.47407/kr2026.7.2.00779",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047907","Sa1871 - Liraglutide Alters Taste Preferences and Reported Fullness in Individuals with Obesity","Victor G Chedid","2018","Gastroenterology","other","article","10.1016/s0016-5085(18)31694-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047908","642 DUODENAL MUCOSAL RESURFACING PREVENTS WEIGHT REGAIN AFTER TIRZEPATIDE WITHDRAWAL: REMAIN-1 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED CLINICAL TRIAL - MIDPOINT COHORT RESULTS","Shelby A. Sullivan","2026","Gastrointestinal Endoscopy","randomized_trial","article","10.1016/s0016-5107(26)04725-5",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047909","Saudi Consensus Report on Chronic Kidney Disease Management: Integrating the Latest Evidence and Clinical Practice Guidelines","Abdulrahman Alsheikh","2025","International Journal of Clinical Medicine","other","article","10.4236/ijcm.2025.161004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047910","925-P: Risk of Cardiovascular Events and Serious Hypoglycemia Comparing Patients with Type 2 Diabetes Initiating a GLP-1 Receptor Agonist or Basal Insulin: A Propensity-Score Matched Cohort Study","Jing Luo","2020","Diabetes","nonrandomized_study","article","10.2337/db20-925-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047911","Evaluating Antidiabetic Modulatory Effects on Drug-induced Pulmonary Arterial Hypertension Using Real-world Data","Venkatesh Kolli","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a4977",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047912","772-P: Cognitive Outcomes in Adults Treated with GLP-1 Receptor Agonists Compared with Nonusers—A Retrospective Chart Review","Clayton A. Dehn","2025","Diabetes","randomized_trial","article","10.2337/db25-772-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047913","Liraglutide: for obesity, not just type 2 diabetes","Ian Douglas Caterson","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047914","#1771083 Switching to tirzepatide 5 mg from GLP-1 RAs: Clinical expectations in the first 12 weeks of treatment","Brian D. Benneyworth","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.159",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047915","Obesity and Pulmonary Embolism: Can We Dismantle the “Obesity Paradox”","Samuel Zachary Goldhaber","2023","Thrombosis and Haemostasis","randomized_trial","article","10.1055/a-2187-0966","37802123",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0047916","1813-P: Coadministration of a GLP-1/Glucagon Receptor Agonist with an FXR Agonist and ACC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice","James L. Trevaskis","2020","Diabetes","preclinical","article","10.2337/db20-1813-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047917","Abstract 4348998: Glucagon-like Peptide 1 Receptor Agonists and Risk of Pulmonary Hypertension","Jonah David Garry","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4348998",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047918","Tu1841: EVALUATING THE OUTCOMES OF GLP-1 RECEPTOR AGONIST USE IN INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEW AND META-ANALYSIS","Hasan Jaber","2025","Gastroenterology","systematic_review","article","10.1016/s0016-5085(25)04370-7",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0047919","Su2054: ASSOCIATION BETWEEN SEMAGLUTIDE AND SEVERE GASTROINTESTINAL ADVERSE EFFECTS IN ADULTS WITH AND WITHOUT DIABETES: A REAL-WORLD CLAIMS DATA STUDY","Collin York","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03106-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047920","Dapiglutide, a Dual GLP-1 and GLP-2 Receptor Agonist, for Obesity: A Randomised, Double-Blind, Placebo-Controlled Parallel-Group, Proof-of-Concept Trial","Casper K. Nielsen","2025","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.5395622",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0047921","Impact of GLP-1 receptor agonists on cardiovascular risk reduction in patients with obesity without type 2 diabetes mellitus: a systematic review","Paquita del Rocío Quizhpe Donoso","2026","International Journal of Research in Medical Sciences","systematic_review","article","10.18203/2320-6012.ijrms20261347",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0047922","PO414 LIRAGLUTIDE IN COMBINATION WITH METFORMIN PROVIDES GREATER PPG CONTROL VS METFORMIN MONOTHERAPY ACROSS ALL 3 MAIN MEALS","Gregory R. Fulcher","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70708-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047923","Hypothalamic response to GLP-1 agonist exenatide is associated with reduced food intake","Stefan Kabisch","2011","Max Planck Digital Library","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0047924","Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity.","Е. В. Тихоненко","2018","Clinical Medicine (Russian Journal)","other","article","10.18821/0023-2149-2018-96-8-746-753",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047925","Morphofunctional changes in patients with obesity treated with liraglutide 3.0","María García‐Olivares","2024","Clinical Nutrition ESPEN","other","article","10.1016/j.clnesp.2024.07.464",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047926","1798-P: Chronic Administration of a Long-Acting Glucagon Analogue Results in Enhanced Insulin Secretory Activity in a Directly-Observed Murine Model","Kinga Suba","2020","Diabetes","preclinical","article","10.2337/db20-1798-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047927","Have we done everything possible for a patient with type 2 diabetes mellitus combined with obesity?","D.M. Antsiferova","2025","Meditsinskiy sovet = Medical Council","nonrandomized_study","article","10.21518/ms2025-446",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047928","Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.","Faiez M. Zannad","2017","European Heart Journal - Cardiovascular Pharmacotherapy","nonrandomized_study","article","10.1093/ehjcvp/pvx012","28541522",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0047929","Chromatographic separation and analysis of amidated vs. non-amidated novel heterologous produced exenatide using UPLC-QTOF-MS","Lucia H. Steenkamp","2025","Journal of Liquid Chromatography & Related Technologies","other","article","10.1080/10826076.2025.2502034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047930","GLP-1 agonist protects myocardial hypoxia-reoxygenation injury through PI3K/Akt signaling pathway: an experimental study","Hui Qing Sun","2018","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2018.01.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047931","412.4: Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors And Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients","Tarek Mahmoud","2022","Transplantation","randomized_trial","article","10.1097/01.tp.0000887616.86686.ae",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047932","Effects Of Semaglutide Across The Range Of Left Ventricular Ejection Fraction In Obesity Phenotype Of Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Trial","Javed Butler","2024","Journal of Cardiac Failure","other_trial","article","10.1016/j.cardfail.2023.10.465",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047933","Abstract 4146888: Safety report from a remote disease management program to improve sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonist prescribing in Type 2 diabetes","Shahzad Hassan","2024","Circulation","randomized_trial","article","10.1161/circ.150.suppl_1.4146888",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047934","Abstract 15280: Does Weight Reduction Drive the Reduction in Blood Pressure in People Living With Obesity Treated With Tirzepatide?: Insights From SURMOUNT-1 Study","Naveed A. Sattar","2023","Circulation","other","article","10.1161/circ.148.suppl_1.15280",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047935","763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study","Kun He","2023","Diabetes","randomized_trial","article","10.2337/db23-763-p",null,null,"ClinicalTrials.gov:NCT05152277","S000819","openalex","FALSE","paywalled","1","FALSE","article"],["R0047936","HPR113 Social Determinants of Health and Use of Glucagon-like Peptide-1 Receptor Agonists in the Pediatric Population","David F. Black","2024","Value in Health","other","article","10.1016/j.jval.2024.10.1539",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047937","Su1572: CONCOMITANT USE OF IMMUNE CHECKPOINT INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT INCREASE THE RISK FOR ACUTE PANCREATITIS: A POPULATION-BASED COHORT STUDY IN THE UNITED STATES","Luìs Manuel de Almieda Nieto","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)02800-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047938","Polycystic Ovary Syndrome (PCOS): Symptoms, Causes, and Treatment","Hai Bai","2024","Clinical and Experimental Obstetrics & Gynecology","preclinical","article","10.31083/j.ceog5105126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047939","Effect of Semaglutide on Kidney Outcomes in People With Overweight or Obesity and Established Cardiovascular Disease in the SELECT Trial","David Lau","2024","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2024.09.026",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047940","965 The Glucagon-Like Peptide 1 Agonist Liraglutide Reduces Jejunostomy Output and Improves Intestinal Absorption in Short Bowel Syndrome Patients With Intestinal Failure; A Pilot Study","Mark Hvistendahl","2015","Gastroenterology","other","article","10.1016/s0016-5085(15)30628-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047941","Efficacy of dulaglutide: an evidence-based review of its potential indications","Elena Valer'evna Biryukova","2021","Meditsinskiy sovet = Medical Council","narrative_review","article","10.21518/2079-701x-2021-7-18-30",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047942","1846-P: Effects of Intensification of Canagliflozin from 100 mg to 300 mg Daily on Insulin Initiation in the INTENSIFY Study","JUAN J. GORGOJO-MARTINEZ","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1846-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047943","Effect of Incretin-based Therapy on Lung Ischemia-reperfusion Injury in High-Fat Diet-induced Obese Mice","William N. Daccarett-Bojanini","2025","American Journal of Respiratory and Critical Care Medicine","preclinical","article","10.1164/ajrccm.2025.211.abstracts.a4346",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047944","Applying principles of enhanced recovery after surgery","Rachael N. Wright","2025","British journal of surgery","other","article","10.1093/bjs/znaf194","40971969",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047945","Portrayal and social response to the new era of medications for obesity","Stuart William Flint","2025","The Lancet Regional Health - Europe","other","article","10.1016/j.lanepe.2025.101426","40860253",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047946","746-P: Semaglutide Increases the Proportion of People with T2D Achieving a Metabolic Composite Endpoint","Linong Ji","2023","Diabetes","other_trial","article","10.2337/db23-746-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047947","CE-482907-002 IMPACT OF GLP-1 AGONISTS IN PATIENTS WITH ATRIAL FIBRILLATION ABLATION","Aakash Rajendra Sheth","2024","Heart Rhythm","other","article","10.1016/j.hrthm.2024.03.334",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047948","Abstract 15035: Liraglutide Reduces Major Cardiovascular Events in Patients With Chronic Kidney Disease: Results From the Leader Trial","Neil R Poulter","2017","Circulation","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","conference-abstract"],["R0047949","Cardiorenal Effectiveness of Empagliflozin vs. GLP-1 Receptor Agonists in Patients with Advanced Chronic Kidney Disease: Results from the EMPRISE study","Phyo Than Htoo","2024","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0044-1785399",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047950","SAT-161 TREATMENT OF DIABESITY WITH DIET AND NEWER ANTIGLYCEMIC MEDICATIONS IN PLACE OF INSULIN: EFFECT ON DIABETIC KIDNEY DISEASE","L.L. MYAT","2020","Kidney International Reports","other_trial","article","10.1016/j.ekir.2020.02.171",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","conference-abstract"],["R0047951","GLUCAGON–LIKE PEPTIDE–1 RECEPTOR AGONISTS REDUCE THE RISK OF COMPLETE ATRIOVENTRICULAR BLOCK IN PATIENTS WITH TYPE 2 DIABETES","Elisabetta Marchetti","2025","European Heart Journal Supplements","randomized_trial","article","10.1093/eurheartjsupp/suaf076.357",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047952","FRI639 Effect Of Early Initiation Of GLP-1 RAs On Weight Reduction Among People With Type 2 Diabetes","Chanadda Chinthammit","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.858",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047953","A review of the efficacy and safety of the finished fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus","Anna S. Pogorelova","2018","Meditsinskiy sovet = Medical Council","narrative_review","article","10.21518/2079-701x-2018-12-118-126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047954","758-P: PROs in Tirzepatide-Treated Adults with Type 2 Diabetes in SURPASS-1 to -6 by Age, Gender, BMI, and Weight Loss","KRISTINA BOYE","2024","Diabetes","other_trial","article","10.2337/db24-758-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047955","The GLP-1 receptor agonist dulaglutide reduces fluid intake in primary polydipsia: A randomised controlled trial","Bettina Felicitas Winzeler","2021","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.73.aep467",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047956","The impact of tirzepatide injection on weight loss in patients with obesity in the Al Madinah region","Osman Suliman","2025","International Journal of Medicine in Developing Countries","nonrandomized_study","article","10.24911/ijmdc.51-1741855756",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047957","Safety and Efficacy of Long-Term Use of GLP-1RA in Post-Transplant Diabetes Mellitus (PTDM): Analysis of Dulaglutide vs. Liraglutide","Ritwika Mallik","2022","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20223311s1558b",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047958","IMPACT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF): A SYSTEMATIC REVIEW AND META-ANALYSIS","Antony Gonzales-Uribe","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(25)02152-7",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0047959","The grade of inflammation in liver and fat tissue of obese elderly Sprague-Dawley rats treated with metformin and liraglutide","Vedrana Ivić","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047960","Abstract 16304: Contemporary Practice Patterns and Opportunities to Improve Type 2 Diabetes (T2D) Therapy in Patients at Elevated Cardiovascular and/or Kidney Risk","Alexander J. Blood","2023","Circulation","nonrandomized_study","article","10.1161/circ.148.suppl_1.16304",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047961","Changing the diabetes treatment paradigm from glucose control to cardiorenal protection","Preethika Subashini Ekanayake","2021","International Journal of Microbiology Research","other_trial","article","10.4103/ijmr.ijmr_3114_21","35532581",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0047962","Abstract WP333: Population-based Study of Stroke Recurrence in Overweight or Obese Patients: Considerations for Future Prevention Trials","Ian Yahnke","2025","Stroke","nonrandomized_study","article","10.1161/str.56.suppl_1.wp333",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047963","Metabolic effects of the liraglutide: a discussion of the results of clinical observations","E. A. Reznikov","2022","South Russian Journal of Therapeutic Practice","other","article","10.21886/2712-8156-2022-3-4-100-106",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047964","Continuous renal replacement therapy with oXiris ® in patients with hematologically malignant septic shock: A retrospective study","Juan Wang","2023","World Journal of Clinical Cases","nonrandomized_study","article","10.12998/wjcc.v11.i26.6073","37731565",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047965","SAT-450 ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD study","Rohit Seth Loomba","2025","Journal of Hepatology","other","article","10.1016/s0168-8278(25)01706-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047966","Effect of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on carotid intima-media thickness","Ignatios Ikonomidis","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2280",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047967","Drug-Induced Acute Pancreatitis in a Patient With Normal Renal Function: Metformin","Diego F. Hidalgo","2018","The American Journal of Gastroenterology","other","article","10.14309/00000434-201810001-01325",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047968","Sa1961 INCREASED RISK OF DE-NOVO GASTROPARESIS IN NON-DIABETIC OBESE PATIENTS ON GLP-1 RECEPTOR AGONISTS FOR WEIGHT LOSS: A MULTI-NETWORK STUDY","Sami Mesgun","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01838-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047969","P1105 Efficacité en pratique clinique et persistance sous traitement de patients diabétiques de type 2 nouvellement traités par le liraglutide. EVIDENCE®, une étude postinscription avec un suivi de 2 ans","S. Madani","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71851-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047970","Editorial: Personalized therapies for monogenic diabetes","Maurizio Delvecchio","2024","Frontiers in Genetics","preclinical","article","10.3389/fgene.2024.1496367","39399218",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0047971","4CPS-005 GLP-1 agonist liraglutide as add-on therapy in type 2 diabetes","David Blanquez Martinez","2019","Section 4: Clinical pharmacy services","nonrandomized_study","article","10.1136/ejhpharm-2019-eahpconf.154",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0047972","CCk8 Enhances Anti‐diabetic Efficacy of GLP1","Yanyun Chen","2013","The FASEB Journal","preclinical","article","10.1096/fasebj.27.1_supplement.1160.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047973","Mortality Risk of Noninsulin Glucose-Lowering Drugs in Type 2 Diabetes—A Network Meta-analysis of Observational Trials","Brenda W. C. Bongaerts","2018","Diabetes","systematic_review","article","10.2337/db18-1139-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0047974","Abstract 4367655: Comparative Cardiometabolic Outcomes of Tirzepatide Versus Semaglutide in Patients with HFpEF and Obesity: A Real-World Multicenter Cohort Study","Siddharth Agrawal","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4367655",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0047975","Exenatide Modulates Neuronal Insulin Signalling in Parkinson’s Disease (S27.002)","Dilan S. Athauda","2018","Neurology","other_trial","article","10.1212/wnl.90.15_supplement.s27.002",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047976","Glucagonoma: “A Diagnostic Challenge”","Aashka Shah","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.2126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0047977","How Novo Nordisk and Elil Lilly frame GLP-1 weight-loss drugs in corporate communications.","Charlotte Nuijten","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0047978","Obesity and taste perception disorders: peripheral and central mechanisms of a bidirectional association (narrative review)","Fatima Kh Dzgoeva","2026","Clinical review for general practice","narrative_review","article","10.47407/kr2026.7.6.00856",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0047979","984: ADDRESSING THE GROWING EPIDEMIC OF OBESITY: BARIATRIC SURGERY OR GLP-1 AGONIST IN PATIENTS WITH MASLD? A RETROSPECTIVE COHORT ANALYSIS OVER A 6-YEAR PERIOD","Kaitlyn Gernhard","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04679-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047980","PO346 THE USABILITY OF 34 GAUGE NEEDLE FOR PEN INJECTORS IN PATIENTS USING INSULIN/GLP-1 ANALOG","Daizo Saito","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70640-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047981","Injectable Semaglutide (Wegovy) in India: Promise, Pitfalls and the Way Forward","Mehul Kaliya","2025","NMO journal","nonrandomized_study","article","10.4103/jnmo.jnmo_55_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047982","GLP-1 agonist use is not associated with a reduction of paraspinal muscle quality in diabetic patients with lower back pain: A retrospective cohort study","Amin Zaki Zadeh","2025","Brain and Spine","nonrandomized_study","article","10.1016/j.bas.2025.104588",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0047983","Abstract 10370: Effects of Tirzepatide on 24-Hour Ambulatory Blood Pressure and Heart Rate in Adults With Obesity - Results From the SURMOUNT-1 Ambulatory Blood Pressure Monitoring Sub-Study","James A. de Lemos","2022","Circulation","randomized_trial","article","10.1161/circ.146.suppl_1.10370",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047984","GLP-1-based therapies yet to reach their peak potential","Mitchell A. Cheeseman","2008","Inpharma Weekly","other","article","10.2165/00128413-200816560-00003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047985","Preoperative GLP-1 Receptor Agonist Use and Postoperative Opioid Outcomes in Elective Surgery","Ellias Hanna","2026","IUScholarWorks (Indiana University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","other"],["R0047986","Treatment strategies for obesity","John P.H. Wilding","2007","Obesity Reviews","other_trial","article","10.1111/j.1467-789x.2007.00333.x","17316317",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0047987","90-OR: Effects of Glucagon-Like Peptide 1 (GLP-1) Agonist Therapy on Islet Function in Adults with Pancreatic-Insufficient Cystic Fibrosis ( PI-CF) and Abnormal Glucose Tolerance (AGT)—Preliminary Results","Sujatha Reddy","2025","Diabetes","randomized_trial","article","10.2337/db25-90-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0047988","Semaglutide-Associated Minimal Change Disease: A Potential Rare Complication of a Novel Medication","Gary Tan","2024","Journal of the American Society of Nephrology","other","article","10.1681/asn.2024jjazfwfy",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047989","A year in diabetic nephropathy","Jovanna Tsoutsouki","2021","British Journal of Diabetes","randomized_trial","article","10.15277/bjd.2021.293",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0047990","Abstract 4141358: Body weight reduction-associated and -unassociated changes in lipid profile in people with obesity, with or without T2D, treated with tirzepatide: post-hoc analysis of SURMOUNT-1 and SURMOUNT-2","Bruno Linetzky","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4141358",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0047991","GLP-1 Receptor Agonists in Elective Spine Surgery: A Systematic Review of Fusion Outcomes, Perioperative Safety, and Procedure-Specific Risk","Vinícius Ricieri Ferraz","2026","North American Spine Society Journal (NASSJ)","systematic_review","article","10.1016/j.xnsj.2026.100942",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0047992","S2308 Predictive Value of Gastric Myoelectrical Activity in Patient Satisfaction after Gastric Per-Oral Myotomy","Sulman Khan","2024","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001038600.00193.18",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047993","Promising Antidiabetic Drugs, Medicinal Plants and Herbs: An Update","Mohd Iqbal Yatoo","2017","International Journal of Pharmacology","other","article","10.3923/ijp.2017.732.745",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0047994","1950-LB: Real-World Use of Tirzepatide among People without Type 2 Diabetes—Results from Optum’s Deidentified Clinformatics Data Mart Database","Theresa M. Hunter","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1950-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0047995","Should we stop prescribing pioglitazone?","Panagiotis G. Anagnostis","2014","British Journal of Clinical Pharmacology","other_trial","article","10.1111/bcp.12342","24528104",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0047996","Glucagon-like peptide-1 analogues: a new way to quit smoking? SKIP - a randomised controlled study","Sophia Lengsfeld","2022","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.81.p76",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0047997","Effect of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on post-liver transplant mortality and major adverse cardiovascular events","Kelli Kosako Yost","2023","Journal of Hepatology","other","article","10.1016/s0168-8278(23)01170-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047998","Exenatide","Curtis L. Triplitt","2005","Drugs","other","article","10.2165/00003495-200565120-00009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0047999","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST FOR PRIMARY PREVENTION OF MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENTS IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE","Ahmed Kamal Siddiqi","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)03348-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048000","Abstract 4370534: Guideline-Directed Medical Therapy Prescribing Trends in Patients with Heart Failure with Preserved Ejection Fraction: A Nationwide Analysis","Joseph T. Kassab","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4370534",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048001","Neural origin plasma exosomes provide novel biomarkers for brain insulin resistance in Alzheimer's disease (S33.003)","Dimitrios Kapogiannis","2015","Neurology","other","article","10.1212/wnl.84.14_supplement.s33.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048002","Metformin/Pioglitazone/Exenatide Triple Therapy Superior to Stepwise Add-On Conventional Therapy in Newly Diagnosed Type 2 Diabetes","Mabel Korsah Cunningham","2013","MD Conference Express","randomized_trial","article","10.1177/155989771311007",null,null,"ClinicalTrials.gov:NCT01107717","S000437","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0048003","IS OBESITY PHARMACOTHERAPY A LIFETIME COMMITMENT? A STRUCTURED REVIEW OF WEIGHT REGAIN AND STRATEGIES FOLLOWING INCRETIN CESSATION","Kornelia Domagała","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.1(49).2026.5125",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048004","Uso de los agonistas del receptor del péptido similar al glucagón tipo 1 en pacientes trasplantados renales","Luis Alberto Vigara","2023","Nefrología","nonrandomized_study","article","10.1016/j.nefro.2023.06.010",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048005","954 GLP-1 RECEPTOR AGONISTS HAVE A POTENTIAL TO IMPROVE DISEASE ACTIVTY IN PEDIATRIC METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE","Andrea M. Tou","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01003-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048006","Real-world outcomes comparing the use of GLP-1 agonists in patients with colon cancer and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.","Yajur Arya","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.2_suppl.83",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048007","62940 Exploring the Impact of GLP-1 Agonist Medications on Hair Loss","Brianna Sa","2025","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2025.05.822",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048008","Effects of the Novel Dual GLP-1R/GCGR Agonist SAR425899 on Postprandial Glucose Metabolism in Overweight/Obese Subjects with Type 2 Diabetes","Britta Goebel","2018","Diabetes","randomized_trial","article","10.2337/db18-72-or",null,null,"ClinicalTrials.gov:NCT02411825","S003303","openalex","FALSE","paywalled","1","FALSE","article"],["R0048009","OP72 COMBINATION THERAPY WITH LIRAGLUTIDE AND INSULIN IN JAPANESE SUBJECTS WITH TYPE 2 DIABETES: THE LIRA-ADD2INSULIN JAPAN TRIAL","Yoshie Seino","2014","Diabetes Research and Clinical Practice","other_trial","article","10.1016/s0168-8227(14)70278-5",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0048010","Poster #218 GLUCAGON-LIKE PEPTIDE-1 ANALOGUES AGAINST ANTIPSYCHOTIC-INDUCED OVERWEIGHT: POTENTIAL PHYSIOLOGICAL BENEFITS","Bjørn Hylsebeck Ebdrup","2012","Schizophrenia Research","other","article","10.1016/s0920-9964(12)70789-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048011","Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831","Sylvie Feldman-Billard","2017","Diabetes Care","other_trial","article","10.2337/dc17-1527","29162589",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","letter"],["R0048012","Manic episodes triggered by weight loss in a patient with bipolar disorder: the importance of integrated lifestyle interventions in psychiatric care","Davide De Francesco","2025","European Psychiatry","other","article","10.1192/j.eurpsy.2025.1053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048013","Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Psychiatric Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists (Glp-1 RAs) Exposure","Yao Yao","2024","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.4901779",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0048014","Treatment of Nondiabetic Kidney Diseases with Sodium-Glucose Cotransporter-2 Inhibitors","Frank Chip Brosius","2023","Clinical Journal of the American Society of Nephrology","randomized_trial","article","10.2215/cjn.0000000000000194","37831467",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0048015","GLP1 receptor agonist and sulphonylurea treatment in KCNJ11 permanent neonatal diabetes","Mairead Crowley","2024","Endocrine Abstracts","other","article","10.1530/endoabs.104.cr6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048016","Novo buying KBP hypertension drug","Laura L. Howes","2023","C&EN Global Enterprise","other_trial","article","10.1021/cen-10135-buscon15",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0048017","Possible cardiac benefits of combination of oral semaglutide and empagliflozin in treatment of type2 diabetic rats","Heba A. El Noury","2025","Benha Medical Journal","preclinical","article","10.21608/bmfj.2025.394075.2470",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048018","Figure 3 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors","Jasmine Singh Sukumar","2026",null,"other","article","10.1158/2767-9764.31444537",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0048019","#3586 Demographics and comorbidities of dialysis patients using SGLT2 inhibitors and GLP-1 agonists","Suman Kumar Lama","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.0393",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048020","Exendin-4, a GLP-1 Receptor Agonist, Stimulates Rat Pituitary-Adrenocortical Axis","Ludwik K. Malendowicz","2001","Biomedical Research","preclinical","article","10.2220/biomedres.22.273",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048021","Semaglutide for the treatment of obesity: Results of two open randomized pharmacokinetic studies","S. M. Noskov","2024","Meditsinskiy sovet = Medical Council","randomized_trial","article","10.21518/ms2024-346",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0048022","Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos (Preprint)","Andy Wai Kan Yeung","2024",null,"other","article","10.2196/preprints.59767",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0048023","Additional file 8: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Ling Li","2016","Figshare","systematic_review","article","10.6084/m9.figshare.4430768",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0048024","26-A-14486-ACC CARDIOVASCULAR OUTCOMES OF GLP-1 RECEPTOR AGONISTS ADDED TO SGLT2 INHIBITORS VERSUS SGLT2 INHIBITORS ALONE IN TYPE 2 DIABETES MELLITUS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS","Maximiliano Lang","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.682",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0048025","THE EFFECT OF WEIGHT LOSS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ON STRUCTURAL CHANGES IN KNEE OSTEOARTHRITIS: SECONDARY ANALYSIS OF THE RANDOMISED, PLACEBO-CONTROLLED LOSEIT TRIAL","M.W. Brejnebøl","2025","Osteoarthritis Imaging","randomized_trial","article","10.1016/j.ostima.2025.100280",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0048026","Abstract #1003901: Once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History","William Timothy Garvey","2021","Endocrine Practice","other","article","10.1016/j.eprac.2021.04.638",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048027","Obesity may present challenges but does not preclude gastric ultrasound","Rafael Sousa Fava Nersessian","2025","Anaesthesia","nonrandomized_study","article","10.1111/anae.16587","40032613",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048028","P086 An unusual case of declining mobility following initiation of tirzepatide therapy","Aqsam Shahbaz","2025","Rheumatology Advances in Practice","other","article","10.1093/rap/rkaf111.115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048029","Autonomic neuropathy is associated with the lack of glucagon-like peptide-1 receptor agonists treatment efficacy in patients with type 2 diabetes","Lea Smircic Duvnjak","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048030","A Semaglutida aplicada ao tratamento da obesidade: perspectivas clínicas na literatura","Maria Carolina Alves Zanatta","2023","Research Society and Development","other","article","10.33448/rsd-v12i9.43295",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048031","Weight loss response to GLP-1 RA in adults with narcolepsy cataplexy","S. Li","2026","Sleep Medicine","other","article","10.1016/j.sleep.2025.107572",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048032","Percentage of patients with type 2 diabetes and baseline HbA1c ≥7.5% treated with once weekly dulaglutide, or exenatide twice daily, achieving HbA1c decrease of ≥1% and weight loss of ≥3% at 26 weeks in the Assessment of Weekly AdministRation of dulaglutide in Diabetes (AWARD)-1 and -5 studies","O Adetunji","2015","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0035-1549748",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048033","PDB4 MODELING HEALTH AND ECONOMIC OUTCOMES ASSOCIATED WITH EXENATIDE ONCE-WEEKLY VERSUS INSULIN AND PIOGLITAZONE TREATMENT FOR TYPE-2 DIABETES","Julia A. Gaebler","2011","Value in Health","other","article","10.1016/j.jval.2011.02.512",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048034","P294 Utilisation du liraglutide dans la « vraie vie » : il y a répondeurs et répondeurs","Olivier Dupuy","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72585-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048035","DURATION-NEO-1: Größere HbA1c-Wertreduktion mit wöchentlicher Depot-Exenatide-Suspension zur Autoinjektion im Vergleich zu Exenatide 2x tgl. bei unzureichend kontrolliertem Typ 2 Diabetes","C. Wysham","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549623",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048036","FRI631 Insulin Antibody Mediated Extremely Insulin Resistant In Pregnancy","Zhao Liu","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.851",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048037","GLP-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: Evidence from a real-world head-to-head comparison.","Colton Jones","2026","Journal of Clinical Oncology","randomized_trial","article","10.1200/jco.2026.44.2_suppl.18",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0048038","756-P: Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Endoscopy Failure or Aspiration—A Cohort Study","Wajd Alkabbani","2024","Diabetes","nonrandomized_study","article","10.2337/db24-756-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048039","Effects of liraglutide in an adolescent prediabetic transgenic pig model","Elisabeth Streckel","2014","Diabetologie und Stoffwechsel","other","article","10.1055/s-0034-1374961",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048040","Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus","Irina Vladimirovna Glinkina","2021","Meditsinskiy sovet = Medical Council","other","article","10.21518/2079-701x-2021-7-56-67",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048041","Sodium-Glucose Co-Transporter 2 inhibitors and the Short-term Risk of Bladder Cancer: An International Multi-Site Cohort Study","Devin Abrahami","2022",null,"randomized_trial","article","10.2337/figshare.21040987.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0048042","Exenatide prevents diabetic nephropathy in a rat model of type 2 diabetes mellitus (fat-fed and streptozotocin-treated rats)","Tarek K. Motawi","2017","Scientific Journal of October 6 University","preclinical","article","10.21608/sjou.2017.30448",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048043","GLP-1 agonist use in the management of obesity in Type 2 Diabetes: an Irish tertiary hospital experience","David Joseph Tansey","2019","Endocrine Abstracts","other","article","10.1530/endoabs.61.p001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048044","Safety of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients","Tarek Mahmoud","2022","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20223311s1544c",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048045","Abstract 122","Varun Garg","2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.363626",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0048046","(O-11) Effects of GLP-1 Receptor Agonists on Semen Quality in Men: A Systematic Review","Omer A. Raheem","2026","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdag062.018",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0048047","Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide (vol 36, pg 843, 2012)","Arne Vernon Astrup","2013","UCL Discovery (University College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048048","Cardiac Disease and Chronic Kidney Disease – a Fatal Alliance or New Opportunities of Treatment? (Review of the literature)","В. К. Тащук","2025","Family medicine European practices","narrative_review","article","10.30841/2786-720x.1.2025.324238",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048049","1013-P: Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects with Type 2 Diabetes","Juris Jendrik Meier","2019","Diabetes","other_trial","article","10.2337/db19-1013-p",null,null,"ClinicalTrials.gov:NCT02877355","S001380","openalex","FALSE","paywalled","5","FALSE","article"],["R0048050","GLP-1R Agonists & Cardiac Energy Metabolism in Type 2 Diabetes","Malak Ghazi Almutairi","2019","ERA: Education and Research Archive (University of Alberta)","randomized_trial","article","10.7939/r3-fhr3-cr50",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","dissertation"],["R0048051","Prescribing Patterns and Impact of Glucagon-Like Peptide-1 Receptor Agonists Among Kidney Transplant Population in British Columbia, Canada","Hee‐Dong Chae","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.925",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048052","Erratum: “Effects of exenatide on glycemia and renal water and ion excretion differ in frogs and rats”","Анна Вячеславовна Кутина","2016","Journal of Evolutionary Biochemistry and Physiology","notice","article","10.1134/s1234567816050153",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0048053","Glycemic Benefits of Liraglutide 1.2 mg daily in Overweight Pre-diabetic Compared to Overweight Normoglycemic Individuals","Rita Hajj Boutros","2017","Archives of Medicine","other","article","10.21767/1989-5216.1000203",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048054","A patient with hypothalamic obesity who responded well to GLP-1 agonist therapy and thereafter mini-gastric bypass surgery","Ahmad Moolla","2020","Obesity Abstracts","other","article","10.1530/obabs.02.p1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048055","Diabetes-induced edothelial dysfuction: Molecular pathways and clinical implication","Mohd Basheeruddin","2025","Multidisciplinary Reviews","other","article","10.31893/multirev.2025232",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048056","Changes in antidiabetic drug prescription patterns during follow-up of the GERODIAB cohort. Comparison with professional recommendations","J. Doucet","2022","Diabetes Epidemiology and Management","nonrandomized_study","article","10.1016/j.deman.2022.100084",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048057","Explainable Artificial Intelligence for Predicting Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists","Tadesse Melaku Abegaz","2026","AI in Medicine","nonrandomized_study","article","10.3390/aimed1030019",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048058","P1878Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5","Steve C Bain","2018","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehy565.p1878",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048059","Pharmacologic Treatment of Type 2 Diabetes in the United States, Sweden, and Israel","Beini Lyu","2022",null,"nonrandomized_study","article","10.2337/figshare.21126043.v2",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0048060","853-P: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes—Up to 52-Week Treatment","Lin Zhao","2025","Diabetes","randomized_trial","article","10.2337/db25-853-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048061","Effects of Glucagon-Like Peptide-1 Analog on the Early Phase of Revascularization of Transplanted Pancreatic Islets at Subcutaneous Site","Ryosuke Nishimura","2012","Transplantation","preclinical","article","10.1097/00007890-201211271-01387",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048062","Dulaglutide Treatment in Patients with Type 2 Diabetes and Moderate-to-Severe CKD Improves Kidney Fibrosis Biomarker Levels","Katherine R. Tuttle","2020","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20203110s1348c",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048063","Exenatide: role in management of Type 2 diabetes and associated cardiovascular risk factors","Zin Zin Htike","2012","Clinical Practice","randomized_trial","article","10.2217/cpr.11.132",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048064","Effects of Digitization of Self-Monitoring of Blood Glucose Records Using a Mobile App and the Cloud System on Outpatient Management of Diabetes: Single-Armed Prospective Study (Preprint)","Tomoko Handa","2023",null,"nonrandomized_study","article","10.2196/preprints.48019",null,null,"jRCT:jRCTs042190057",null,"openalex","FALSE","paywalled","4","FALSE","preprint"],["R0048065","Diagnosing and monitoring CKD in practice","Robert Joel Lewis","2009","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2009.027",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048066","PT38 REAL-WORLD ADHERENCE TO GLP-1RA AND DUAL GIP-GLP-1RA AMONG COMMERCIALLY INSURED US PATIENTS WITH TYPE 2 DIABETES AND OBESITY","Bernard Bright Davies-Teye","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.1988",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048067","133-LB: Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study","Elisabetta Patorno","2020","Diabetes","nonrandomized_study","article","10.2337/db20-133-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048068","Mo1239: PERIOPERATIVE RISK OF ASPIRATION AND POSTOPERATIVE COMPLICATIONS WITH GLP-1 THERAPY (PROTECT) STUDY","Luis M. Zuniga","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03352-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048069","Optimizing post-bariatric surgery weight management: The role of semaglutide","Tannaz Jamialahmadi","2025","Obesity Medicine","other","article","10.1016/j.obmed.2025.100675",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048070","S842 Bariatric Surgery Nearly Doubles 5-Year Reflux and Barrett’s Risk versus GLP-1 Agonists: A Propensity-Matched 81,410-Patient Cohort Analysis","Himsikhar Khataniar","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130828.05754.4d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048071","Liraglutide Reduces Insulin Dose without Affecting Glycemic Control in T1DM","Robert E. Buckley","2011","MD Conference Express","randomized_trial","article","10.1177/155989771111012",null,null,"ClinicalTrials.gov:NCT00993720","S001442","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0048072","26-A-15070-ACC THE ANTIARRHYTHMIC EFFECTS OF ADD-ON GLP-1 RECEPTOR AGONISTS VERSUS OTHER ANTIDIABETIC THERAPIES: A NATIONWIDE COHORT STUDY","Emmanuel Arega","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.358",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048073","Abstract 4138604: Impact of GLP-1 Agonist on the Incidence of Atrial Fibrillation in Obese Patients Following Heart Failure Hospitalization","Thomas Fretz","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4138604",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048074","Impact of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Kidney Failure Risk Prediction","Sydney Elizabeth Hartsell","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025b720vjd3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048075","1295-P: Economic Evaluation of Drug Combination Strategy for Type 2 Diabetes in China","Shuyan Gu","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1295-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048076","12-8: PERSISTENCE OF GRAFT FUNCTION FOLLOWING DISCONTINUATION OF IMMUNOSUPPRESSION IN AN ISLET TRANSPLANT RECIPIENT ON CHRONIC GLP-1 RA THERAPY","David A. Baidal","2025","Transplantation","other","article","10.1097/01.tp.0001123252.96174.7b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048077","IDF21-0323 Safety and efficacy of IBI362 (LY3305677) in Chinese patients with T2D: A randomized, placebo-controlled phase 1b study","Wenli Yang","2022","Diabetes Research and Clinical Practice","randomized_trial","article","10.1016/j.diabres.2022.109271",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048078","Abstract 13779: Metabolic Profiles Identify Distinct Cardiorenal Risk Factors in People With Diabetes Mellitus: Insights From the EXSCEL Trial","Daniel L. Edmonston","2022","Circulation","randomized_trial","article","10.1161/circ.146.suppl_1.13779",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0048079","Abstract 15586: Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial","Gilles R. Dagenais","2020","Circulation","other_trial","article","10.1161/circ.142.suppl_3.15586",null,null,"ClinicalTrials.gov:NCT01394952","S000147","openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0048080","A New Approach to Drug Therapy: Fc-Fusion Technology","Valeria Pechtner","2017","Primary Health Care Open Access","nonrandomized_study","article","10.4172/2167-1079.1000255",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048081","Possibilities of transition of the strategy from glucosecentricity to organoprotection when prescribing antidiabetic drugs in patients with type 2 diabetes mellitus in the perimenapause","Виктор Владимирович Смирнов","2023","Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH)","nonrandomized_study","article","10.20340/vmi-rvz.2023.5.clin.5",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048082","The effect of CPAP therapy on aortic inflammation in obstructive sleep apnoea: data from a proof-of-concept PET-CT study","Colm P. O’Donnell","2022","04.02 - Clinical and epidemiological respiratory sleep medicine","randomized_trial","article","10.1183/13993003.congress-2022.2126",null,null,"ClinicalTrials.gov:NCT04186494","S001827","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0048083","Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6","Jan Westerink","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.3069",null,null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","openalex","FALSE","paywalled","1","FALSE","article"],["R0048084","Efficacy of liraglutide in weight management post bariatric surgery patients: data from an Emirati cohort","Abdulla Mohamed Alnuaimi","2019","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.65.p194",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048085","2299-PUB: PNPLA3 I148M Involved in Mechanism of Variability in Antilipogenesis Response to Exenatide","Yunzhi Chen","2020","Diabetes","preclinical","article","10.2337/db20-2299-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048086","Multiagonists of the “incretin axis” as a promising tool for managing cardiometabolic risk in visceral obesity","М. A. Druzhilov","2021","Russian Journal of Cardiology","other","article","10.15829/29/1560-4071-2022-4755",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048087","Vergleich von iGlarLixi mit einem Basal-Bolusregime bei Patienten mit Typ-2-Diabetes mittels Propensity-Score-Matching (PSM)","JJ Meier","2021","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0041-1727306",null,null,"ClinicalTrials.gov:NCT02058160; ClinicalTrials.gov:NCT01768559","S001409; S001630","openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0048088","Long-term use of semaglutide and risk of diabetic retinopathy progression","Henry Stevens","2024","Endocrine and Metabolic Science","nonrandomized_study","article","10.1016/j.endmts.2024.100168",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048089","Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) Among Patients with Type 2 Diabetes Mellitus (T2DM) and Advanced CKD and ESKD: A Systematic Review and Meta-Analysis","Pajaree Krisanapan","2023","Journal of the American Society of Nephrology","systematic_review","article","10.1681/asn.20233411s1854b",null,null,"PROSPERO:CRD42023398452",null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0048090","Analog GLP-1 czy tirzepatyd w kontekście chorób układu sercowo-naczyniowego?","Anna Kochanowska","2024","Choroby Serca i Naczyń","other","article","10.5603/chsin.102918",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048091","IMPACT OF GLP-1 AGONIST USE ON POST-PROCEDURAL OUTCOMES IN ELECTIVE UPPER AND LOWER ENDOSCOPIC PROCEDURES: A NATIONAL DATABASE STUDY","Harsimran Kalsi","2025","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/j.gie.2025.03.444",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048092","771-P: Efficacy of CT-996, an Oral Small Molecule GLP-1 Receptor Agonist, in Human GLP-1 Receptor Knockin Mice and Obese Cynomolgus Monkeys","Jian Fei Luo","2024","Diabetes","other_trial","article","10.2337/db24-771-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048093","GLP-1 receptor agonists neuroprotective effect in type 2 diabetic patients is independent on glycemic control","А. В. Симаненкова","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.ep19",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048094","Treatment with a glucagon-like peptide-1 receptor agonist exenatide decreases albuminuria in overweight type 2 diabetic patients","Tomislav Bulum","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048095","Glucagon-like Peptide-1 Receptor Agonists for Weight Loss in Orthopaedic Surgery: A Comprehensive Review","Dominique B. Spence","2024","JBJS Journal of Orthopaedics for Physician Assistants","narrative_review","article","10.2106/jbjs.jopa.24.00005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048096","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND RISK REDUCTION OF OBESITY-ASSOCIATED CANCER IN OBESE NON-DIABETIC WOMEN","Heng‐Cheng Hsu","2025","International Journal of Gynecological Cancer","other","article","10.1016/j.ijgc.2025.102199",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048097","Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects","Robert F. Kushner","2025","Obesities","systematic_review","article","10.3390/obesities5020029",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0048098","Current Evidence On GLP-1 Receptor Agonists: Impact On Residual Gastric Content and Endoscopy Quality","Mark Young","2025","Journal of Gastroenterology & Digestive Systems","other","article","10.33140/jgds.09.01.03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048099","The Glucagon-Like Peptide-1 Analogue Exenatide Reduces Beta-Cell Apoptosis and Enhances Survival of Cultured Human Islets: Implications for Clinical Islet Transplantation","Ziliang Ao","2008","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(08)24150-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048100","Author Correction: The WHO Essential Medicines List can help to unlock access to GLP-1 therapies for metabolic syndrome","Kevin C Pottie","2026","Nature Health","other","article","10.1038/s44360-026-00168-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0048101","1016-P: Prescribing SGLT2 and GLP-1 for Patients with Type 2 Diabetes at Time of Discharge after MI Increases Their Likelihood of Having Active Prescriptions at One Year","Nathan Sumarsono","2023","Diabetes","other","article","10.2337/db23-1016-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048102","Étude LEADER - liraglutide et événements cardiovasculaires : analyse complémentaire chez les sujets âgés ≥ 75 ans","Michel Marre","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.203",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048103","Fat: bariatric surgery and procedures","Barbara M. McGowan","2022","British Journal of Diabetes","other","article","10.15277/bjd.2022.368",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048104","Effect of rimonabant and metformin on glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 in obese women with polycystic ovary syndrome","Thozhukat Sathyapalan","2009","Clinical Endocrinology","randomized_trial","article","10.1111/j.1365-2265.2009.03643.x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048105","Study of affordability of pharmaceutical provision for type 2 diabetes therapy in Ukraine","І. О. Власенко","2025","Medicni perspektivi","other","article","10.26641/2307-0404.2025.2.333711",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048106","Coronary calcium score predictor of coronary artery disease","Malay Parekh","2019",null,"nonrandomized_study","article","10.26226/morressier.5d9b6231ea541d6ca8493f8b",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0048107","Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions (Retracted article. See vol. 47, pg. 221, 2013)","Nazir Rampersaud","2012","UCL Discovery (University College London)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048108","No Superiority of Exenatide over Insulin in Diabetic Patients in Terms of Weight Reduction or Incidence of Adverse Effects: A Meta-analysis","Pooneh Salari","2011","International Journal of Pharmacology","systematic_review","article","10.3923/ijp.2011.749.756",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0048109","Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)","J. B. Buse","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","protocol","article","10.17615/2z9e-fc77",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0048110","Tu1917 – Impacts of Liraglutide Use in Weight Maintenance After Balloon Retrieval: A 12-Month Follow Up","Anna Carolina Hoff","2019","Gastroenterology","other","article","10.1016/s0016-5085(19)39900-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048111","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Cognitive Decline and Dementia Prevention: A Systematic Review and Semiquantitative Synthesis","Dharmendra Kumar Gupta","2025","Journal of Mental Health and Human Behaviour","systematic_review","article","10.4103/jmhhb.jmhhb_71_25",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0048112","1803-P: Protective Effects of HM17321, a Novel UCN2 Analog, on Obesity-Associated Musculoskeletal Diseases in Mouse Models","HYUNJOO KWON","2026","Diabetes","preclinical","article","10.2337/db26-1803-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048113","Emerging Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus","Channabasappa Shivaprasad","2016","BENTHAM SCIENCE PUBLISHERS eBooks","other","article","10.2174/9781681081854116020007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0048114","987-P: Real-World Weight Change, Adherence, and Discontinuation among Type 2 Diabetes (T2D) Patients Initiating GLP-1 Receptor Agonists (GLP-1RAs) in the UK","Tracey Weiss","2019","Diabetes","nonrandomized_study","article","10.2337/db19-987-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048115","CO218 Semaglutide Weight Outcomes Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Real-World Setting","Samantha E. Clark","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.09.319",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048116","Neuroplasticity in the use of a human glucone-like peptide-1 analog in an obese patient: clinical case","М.В. Матвеева","2023","Vrach","nonrandomized_study","article","10.29296/25877305-2023-11-18",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048117","AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES","Randa Ismail","2022","Bulletin of Pharmaceutical Sciences Assiut","other","article","10.21608/bfsa.2022.271789",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048118","785-P: Comparative Effectiveness of Second-Line Glucose-Lowering Medications—Emulation of a Target Trial Using Real-World Data","Yihong Deng","2023","Diabetes","nonrandomized_study","article","10.2337/db23-785-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048119","MON-715 Silencing Hepatokine Activin E Production in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile","Wei Liu","2025","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvaf149.050",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048120","Dulaglutide: a once‐weekly GLP‐1 for type 2 diabetes","Steve Chaplin","2015","Prescriber","other","article","10.1002/psb.1393",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048121","1285-P: Impact of Adding a GLP-1 Receptor Agonist to the Medication Regimen","Michelle L. Jacobs","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1285-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048122","1694-P: De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 with Semaglutide Improves Weight Loss and Preserves Lean Mass in Dio Mice","Monika Sharma","2025","Diabetes","preclinical","article","10.2337/db25-1694-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048123","Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2)","Juan P. Frías","2022","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0042-1746269",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048124","Effect of Oral Semaglutide on Weight & Cardiac Biomarkers In patients With Hypothyroidism Treated Using Liothyronine+Levothyroxine Combination Therapy","Vishal Anand Gupta","2023","Endocrine Abstracts","other","article","10.1530/endoabs.94.p349",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048125","Su2066: UNDERSTANDING PATIENT ADHERENCE TO GLUCAGON-LIKE-PEPTIDE-1 AGONISTS FOR WEIGHT LOSS: A SURVEY STUDY","Danyal O. Imam","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03118-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048126","Antidiabetic effect of withanolides and liraglutide on serum insulin level and pancreatic histology in diabetic rats.","Abdul Samad","2019","The Professional Medical Journal","randomized_trial","article","10.29309/tpmj/2019.26.11.3155",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048127","A multicentre, randomized, open-label, Phase IV study investigating management of pasireotide-associated hyperglycaemia with incretin-based therapy or insulin in patients with acromegaly or Cushing's disease (CD)","Marek Bolanowski","2019","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.63.p737",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0048128","S2315 Weight Loss Outcomes of Glucagon-Like Peptide 1 Receptor Agonists in Patients With Sleeve Gastrectomy vs Patients With Intact Stomach","Hellen Jumo","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001038628.55175.32",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048129","iGlarLixi Effectively Reduces Residual Hyperglycemia in Patients with Type 2 Diabetes on Basal Insulin: A Post-Hoc Analysis From the LixiLan-L Study","Francesco Giorgino","2018","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2018.08.128",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048130","100. Semaglutide associated with improved postoperative outcomes following single-level posterior lumbar fusion for patients with type II diabetes","Anthony E Seddio","2024","The Spine Journal","other","article","10.1016/j.spinee.2024.06.543",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048131","Danuglipron – an innovate GLP agonist - literature short review","Agata Frańczuk","2024","Quality in Sport","narrative_review","article","10.12775/qs.2024.19.53802",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048132","A28-03 Protective Role of GLP-1 Receptor Agonists in Sepsis-associated Acute Lung Injury: A Systematic Review of Mechanistic and Clinical Evidence","G Chilingarashvili","2026","American Journal of Respiratory and Critical Care Medicine","systematic_review","article","10.1093/ajrccm/aamag162.035",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0048133","GLP-1 RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION AND DIABETES","Gautam Rangavajla","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)02182-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048134","Tu1920 - Comparison of Effect of 16 Weeks of Liraglutide and Placebo on Proximal and Distal Gastric Volumes and Relationship of Baseline Gastric Accommodation with Weight Loss on Treatment with Liraglutide","Houssam Halawi","2018","Gastroenterology","other","article","10.1016/s0016-5085(18)33526-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048135","CO168 SIX MONTH OUTCOMES AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) THERAPY PERSISTENCE AMONG COMMERCIALLY INSURED ADULTS WITHOUT DIABETES IN AN OBESITY CARE MANAGEMENT PROGRAM","Landon Z. Marshall","2026","Value in Health","other","article","10.1016/j.jval.2026.03.263",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048136","Abstract #1184608: Exenatide Improves Cardiovascular Risk Factors in Absence of Clinically Significant Weight Loss in Overweight and Obese Women without Diabetes","Antea DeMarsilis","2022","Endocrine Practice","other","article","10.1016/j.eprac.2022.03.167",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048137","Real-World Effectiveness of Semaglutide and Liraglutide for Weight Management in Overweight or Obese Adults with or Without Type-2 Diabetes Mellitus: Emulation of Randomised Clinical Trials Using UK Electronic Medical Records","Franziska Sophie Ulrich","2024","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.4785364",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0048138","2643-P: Preliminary Data on Continuing Weight Loss at 52 Weeks and Durable Weight Loss Off Therapy with Nimacimab, a CB1R Antibody, in Combination with Semaglutide","Puneet S. Arora","2026","Diabetes","randomized_trial","article","10.2337/db26-2643-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048139","Retatrutide As a Novel Treatment for Obesity and Type 2 Diabetes","Nasser E. Mikhail","2023","Journal of Clinical and Laboratory Research","other_trial","article","10.31579/2768-0487/111",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048140","The GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue","Jonathan Edward Campbell","2022",null,"preclinical","article","10.2337/figshare.19184462",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0048141","Economic Burden of Parkinson's and Atypical Parkinsonism in the United States","Emily Parker","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20705357",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","report"],["R0048142","Retrospective audit of the current anaesthetic peri–operative approach to patients prescribed semaglutide","James J. Tsakas","2026","Perioperative Care and Operating Room Management","nonrandomized_study","article","10.1016/j.pcorm.2026.100708",null,null,null,null,"openalex","FALSE","free_to_read","4","FALSE","article"],["R0048143","Assessing gout risk associated with GLP‐1 therapy in obese patients with type 2 diabetes: A retrospective cohort study","Justin Riley Lam","2025","Rheumatology & autoimmunity","nonrandomized_study","article","10.1002/rai2.70015",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048144","Abstract 16844: Effect of Canagliflozin on Gene Expression and CD34+ Function on Type 2 Diabetes Subjects","Hassan B. Awal","2020","Circulation","randomized_trial","article","10.1161/circ.142.suppl_3.16844",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0048145","S1646 No Clinically Significant Change in FIB-4 Score With ESG or Combined Therapy With ESG and Pharmacotherapy","Jeong Hoon Kim","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035952.40911.0c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048146","Sa1962 DUODENAL MUCOSAL RESURFACING (DMR) COMBINED WITH GLP-1 RECEPTOR AGONISM MAY ELIMINATE INSULIN TREATMENT WHILE MAINTAINING GLYCAEMIC CONTROL AND IMPROVING OVERALL METABOLIC HEALTH IN TYPE 2 DIABETES","Annieke van Baar","2019","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2019.03.293",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048147","172-OR: Eligibility and Utilization of SGLT2i and GLP1-RA in T2D by Cardiovascular and Renal Indications","ALEXANDER BLOOD","2022","Diabetes","other","article","10.2337/db22-172-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048148","DPP IV degradation, receptor binding, insulin secreting and antihyperglycaemic characteristics of palmitate-dervitised GLP-1 analogues.","Brian Green","2003","Research Portal (Queen's University Belfast)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0048149","1732-P: The Impact of a Commercial Telehealth Medical Weight Management and GLP-1 Behavioral Program on Quality of Life and Eating Behavior Outcomes in a Six-Month Single-Arm Study","Leslie J. Heinberg","2025","Diabetes","other_trial","article","10.2337/db25-1732-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048150","845-P: MBX 1416, a Selective GLP-1 Antagonist, Elevates and Sustains Blood Glucose in Rats without Change in Body Weight","Kishore Thalluri","2025","Diabetes","preclinical","article","10.2337/db25-845-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048151","PDB37 COST EFFECTIVENESS OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS, GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS, DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: A SYSTEMATIC REVIEW","Dongzhe Hong","2019","Value in Health","systematic_review","article","10.1016/j.jval.2019.04.587",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0048152","Efficacy and safety of GLP-1 receptor agonists on motor function for patients with Parkinson's disease: a meta-analysis of randomized controlled trials","Jing Ping Zhao","2025",null,"systematic_review","article","10.37766/inplasy2025.6.0034",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0048153","Weight loss through lifestyle modification or liraglutide is associated with improvement of NAFLD severity and changes in amino acid concentrations","Joan Joo Ching Khoo","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep260",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048154","S2104 Hidden Burden of Clinical Time Required to Obtain Weight Loss Medications for Patients With MASLD","Jane Giang","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037784.88065.f9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048155","Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology","Evgeny Lvovich Nasonov","2024","Rheumatology Science and Practice","other","article","10.47360/1995-4484-2024-135-144",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048156","Efficacy of intra-articular injection of a GLP-1 agonist in an adhesive capsulitis rat model","Y. Jeon","2026","JSES International","preclinical","article","10.1016/j.jseint.2025.101466",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048157","39. Effect of semaglutide on 90-day and 2-year surgical and medical complications in diabetic patients undergoing anterior cervical discectomy and fusion","Uttsav Patel","2025","The Spine Journal","other","article","10.1016/j.spinee.2025.08.221",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048158","Mo2015 CLINICAL IMPACT OF GLP-1RA ON ENDOSCOPY: A RETROSPECTIVE COHORT STUDY IN ENDOSCOPY PATIENTS","Rebecca A. Karlson","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)03207-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048159","The Impact of GLP-1 Agonist Therapy in Tibiotalar and Subtalar Fusion: A Propensity-Matched Analysis","Michael F. Levidy","2024","Foot & Ankle Orthopaedics","nonrandomized_study","article","10.1177/2473011424s00536",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048160","What Is the Effect of GLP-1 Receptor Agonists on Anxiety?","Derick E. Vergne","2026",null,"other","article","10.64239/pi-qt8904",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0048161","GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS USE IS NOT ASSOCIATED WITH WORSE OUTCOMES OR INCREASED MORTALITY POST ENDOSCOPY: A MULTI-CENTER ANALYSIS","Pedro Palacios Argueta","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.1087",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048162","What’s New in Orthopaedic Rehabilitation","Reina Nakamura","2025","Journal of Bone and Joint Surgery","randomized_trial","article","10.2106/jbjs.25.00796","40938971",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0048163","PDB61 ECONOMIC EVALUATION OF LIRAGLUTIDE VS. ROSIGLITAZONE OR EXENATIDE FOR TYPE 2 DIABETES MELLITUS IN BULGARIA","Alexandra N. Ivanova","2010","Value in Health","other","article","10.1016/s1098-3015(11)72119-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048164","UTILIZATION OF GLUCOSE-LOWERING DRUGS IN PATIENTS WITH T2DM AND ESTABLISHED CVD IN US: A DESCRIPTIVE STUDY USING OPTUM CLINFORMATICS DATA","Michael Lee Ganz","2020","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(20)32644-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048165","Oral analogues of GLP-1: perspectives on glycemic control and cardiorenal risk in patients with type 2 diabetes mellitus","Jorge E. Rico-Fontalvo","2024","Nefrología Latinoamericana","other","article","10.24875/nefro.m24000021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048166","PO-04-215 IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON VT ABLATION OUTCOMES IN PATIENTS WITH OBESITY","Amro D. Aglan","2025","Heart Rhythm","other","article","10.1016/j.hrthm.2025.03.1327",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048167","Comparison of combination metformin-vildagliptin versus metformin-glimepiride in patients of type 2 diabetes mellitus with inadequately controlled metformin monotherapy","Anuradha T. Deshkar","2022","International Journal of Research in Medical Sciences","other","article","10.18203/2320-6012.ijrms20220520",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048168","PO36 Résultats de l’étude ROOTS, une étude multicentrique observationnelle et non interventionnelle Belge destinée à évaluer l’efficacité et la sécurité du liraglutide chez des patients diabétiques de type 2","Vanessa Preumont","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72294-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048169","Efficacité clinique du liraglutide dans la vraie vie chez les patients atteints de diabète de type 2 âgés de 65 ans et plus aux États-Unis","Amira Bouzidi","2014","Annales d Endocrinologie","other","article","10.1016/j.ando.2014.07.364",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048170","Metabolic modulation of the right ventricle and pulmonary circulation in pulmonary arterial hypertension: an interventional study using a Glucagon-like-peptide-1 (GLP-1) agonist","Chinthaka Bhagya Samaranayake","2022","13.01 - Pulmonary hypertension","preclinical","article","10.1183/13993003.congress-2022.1210",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048171","Long-Term Risk of Cognitive Impairment with GLP-1 Analogues in Older Adults with Type 2 Diabetes Mellitus (LS1.009)","Isaac Thorman","2026","Neurology","other","article","10.1212/wnl.0000000000217911",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048172","Baseline Characteristics of Participants in the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness Study (GRADE)","Deborah J. Wexler","2018","Diabetes","randomized_trial","article","10.2337/db18-1182-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048173","Efficacy and Safety by Baseline A1c with Once-Weekly Dulaglutide in the AWARD Program","Alaa R. Mostafa","2017","World Academy of Science, Engineering and Technology, International Journal of Medical and Health Sciences","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048174","Pancreatic uptake of radiolabeled exendin as a measure of beta cell mass in T2DM before and after bariatric surgery","Laura N. Deden","2021","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0041-1727078",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0048175","EVALUATION OF CARDIOPROTECTIVE EFFECTS OF THE INCRITIN MIMETICS EXENATIDE AND VILDAGLIPTIN IN THE EXPERIMENT","Alla P. Tarasova","2017","Open Access Repository (Belgorod State National Research University)","other_trial","article","10.18413/2313-8971-2017-3-2-57-63",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0048176","Better cardiorenal protection for patients with CKD and type 1 diabetes","Panagiotis I. Georgianos","2026","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfag076","41910194",null,"ClinicalTrials.gov:NCT06217302",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048177","Balancing the Risks and Benefits of GLP-1 Agonists for Weight Loss","Arun H. S. Kumar","2024","Biology Engineering Medicine and Science Reports","other","article","10.5530/bems.10.2.9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048178","Different antioxidative enzymes expression in aorta and brain blood vessels in obese prediabetic elderly rats of both sexes treated with metformin or liraglutide","Anita Ćosić","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048179","One of The Best Ways to Lower Hemoglobin A1c","William P. Chu","2021","Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048180","The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Hidradenitis Suppurativa: A Narrative Review","Abizairie Sánchez-Feliciano","2025","Current Dermatology Reports","narrative_review","article","10.1007/s13671-025-00481-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0048181","S6105 Small Bowel Obstruction Associated With Semaglutide Use","James E. McSweeney","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001152880.90446.bd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048182","COMBINATION THERAPY WITH SEMAGLUTIDE AND DAPAGLIFLOZIN REDUCES SYNERGISTICALLY ANTHRACYCLINE–INDUCED CARDIOTOXICITY UNDER HYPERGLYCEMIA: IMPLICATIONS IN PRIMARY PREVENTION OF CTRCD IN CANCER PATIENTS WITH T2DM","Vincenzo Quagliariello","2025","European Heart Journal Supplements","preclinical","article","10.1093/eurheartjsupp/suaf076.254",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048183","Su2064: THE ASSOCIATION BETWEEN DIABETES SEVERITY SCORE AND WEIGHT LOSS OUTCOMES OF TIRZEPATIDE: A MULTICENTERED STUDY","Wissam Ghusn","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03116-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048184","Editorial: Estrogens and neurodegeneration: a link between menopause and Alzheimer’s disease in women","Manuela Leri","2025","Frontiers in Molecular Biosciences","nonrandomized_study","article","10.3389/fmolb.2025.1727385","41280324",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0048185","More Subjects Achieved Composite Reductions of ≥1% HbA1C, ≥5% Body Weight and ≥5 mmHg Systolic Blood Pressure with Semaglutide vs. Comparators (SUSTAIN 1–5, 7)","Lawrence A. Leiter","2018","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2018.08.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048186","NOVEL APPROACHES TO OBESITY TREATMENT IN OLDER ADULTS","Barbara J. Nicklas","2024","Innovation in Aging","other","article","10.1093/geroni/igae098.1051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048187","SAT-251 Semaglutide can reduce alcohol use in patients with metabolic dysfunction-associated steatotic liver disease","Vladislav Fomin","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)00700-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048188","EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists","Maithili Shrikhande","2024","Value in Health","other","article","10.1016/j.jval.2024.03.2254",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048189","1949-LB: Clinical Characteristics and Dosing Patterns of Tirzepatide among Adults without Type 2 Diabetes—Real-World Results","Theresa M. Hunter","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1949-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048190","PO-05-145 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST IN PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION: A MATCHED ANALYSIS","Chadi Tabaja","2024","Heart Rhythm","other","article","10.1016/j.hrthm.2024.03.1380",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048191","Non-invasive Ventilation and GLP-1 Agonist to Treat Obesity Hypoventilation Syndrome in a Child With Prader Willi Syndrome and Parasomnias","S. R. Baker","2025","American Journal of Respiratory and Critical Care Medicine","other","article","10.1164/ajrccm.2025.211.abstracts.a4454",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048192","1038: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH AND MAY INDUCE ESOPHAGEAL DYSMOTILITY","Khushboo S. Gala","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)01528-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048193","Abstract 4142226: Quantifying the influence of baseline body weight on sex differences in semaglutide-associated weight loss","Matthew E. Levy","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4142226",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048194","Abstract 4138053: Chronic Kidney Disease Prevalence and Outcomes in Patients with Type 2 Diabetes or Prediabetes at High Cardiovascular Risk: Results from the CINEMA Program","Sanjana Datla","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4138053",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048195","Tu2068 A REAL-WORLD ANALYSIS ON MITIGATING ALL-CAUSE MORTALITY AND GASTROINTESTINAL COMPLICATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS WITH DIABETES: THE THERAPEUTIC ROLE OF GLP-1 AGONIST","Akil E. Olliverrie","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)04090-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048196","Comparative Effectiveness of Tirzepatide versus SGLT2 Inhibitors on Cardiovascular, Renal, and Limb Outcomes in Adults With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A TriNetX Target-Trial Emulation","M Rafiqul Islam","2026",null,"nonrandomized_study","article","10.17605/osf.io/xb7ty",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0048197","Insulin resistance and neurodegenerative diseases","Anil Kumar Prajapati","2024","IP International Journal of Comprehensive and Advanced Pharmacology","other","article","10.18231/j.ijcaap.2024.013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048198","Abstract 072: Cardiovascular Outcomes in Hypertensive Adults Treated with GLP-1 Receptor Agonists: A Retrospective Cohort Study","Muhammad Sabri","2025","Hypertension","nonrandomized_study","article","10.1161/hyp.82.suppl_1.072",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048199","GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: Cardiovascular Outcomes and Mortality Benefits","Karldon Iwuchukwu Nwaezeapu","2025","American Heart Journal","other","article","10.1016/j.ahj.2025.07.030",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048200","P156 L’évaluation de l’insulinoresistance par un test de tolérance à l’insuline prédit la baisse d’HbA1C du DT2 de moins de 10 ans d’évolution sous l’effet du Liraglutide : étude prospective","P. Juttet","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72448-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048201","Intensive glucose control and the clinical paradox of transient progression of diabetic retinopathy: Prioritising the relevance of eye screening intervals","Sarita Jacob","2024","The Journal of the Royal College of Physicians of Edinburgh","other","article","10.1177/14782715241254873","38747493",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048202","81-OR: Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults with Overweight/Obesity in the STEP 1 Trial","Leigh Perreault","2021","Diabetes","randomized_trial","article","10.2337/db21-81-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048203","Monitoring thyroid function in diabetic patients on treatment with glucagon-like peptide 1 analog","Rucsandra Danciulescu","2011","13th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048204","S643 Assessing Risk of Gastroesophageal Reflux Disease and its Complications in Patients Starting Tirzepatide","Benjamin Douglas Xun Liu","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001031940.76125.c4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048205","Effect Of GLP-1 Receptor Agonists On Cardiovascular Outcome In Type 2 Diabetic Patients With Cancer Treated With Anthracycline Therapy","Phuuwadith Wattanachayakul","2026","Journal of Cardiac Failure","other","article","10.1016/j.cardfail.2025.11.085",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048206","Leptin Decline is Associated With Improvement in Lung Function and Body Composition in a Longitudinal Tobacco-exposed Cohort","Amy Houghton Attaway","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a2859",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048207","MON-716 Real-world Weight Loss Observed With Semaglutide And Tirzepatide In Patients With Overweight Or Obesity And Without Type 2 Diabetes","Carmen D. Ng","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.051",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048208","Type 2 diabetes: getting off to a good start","Marion C. Devers","2007","Practical Diabetes","randomized_trial","article","10.1002/pdi.1033",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048209","Contribution à l’appréciation de l’efficacité du liraglutide dans la vraie vie","J.P. Courrèges","2014","Annales d Endocrinologie","other","article","10.1016/j.ando.2014.07.365",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048210","P330 Effets du lixisénatide vs liraglutide sur l’équilibre glycémique, la vidange gastrique et les critères de tolérance du traitement dans le diabète de type 2 (DT2) traité de façon optimisée par insuline glargine ± metformine","Bruno Guerci","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30443-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048211","Assessment of coronary artery plaque with non-contrast and T1-weighted magnetic resonance: promise for clinical use?","Thomas Hellmut Schindler","2015","European Heart Journal","commentary","article","10.1093/eurheartj/ehv246","26033980",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0048212","Glucagon-like peptide-1 receptor agonists decreases total and LDL cholesterol in obese type 2 diabetic patients","Tomislav Bulum","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048213","934-P: Association between CTRB1/2 RS7202877 (T>G) Polymorphism and Glycemic Response to Liraglutide in Greek People with Type 2 Diabetes","Artemis Kyriakidou","2020","Diabetes","other","article","10.2337/db20-934-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048214","Abstract 1004: Administration Of A Glucagon-like Peptide-1 Receptor Agonist Prevents Cardiac Rupture And Increases Survival In Mice Undergoing Myocardial Infarction","Mohammad Hossein Noyan-Ashraf","2007","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048215","RE-CELLULARIZATION VIA ELECTROPORATION THERAPY (RECET) COMBINED WITH GLP-1RA TO REPLACE INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES 6 MONTHS RESULTS OF THE EMINENT STUDY","CELINE B.E. BUSCH","2023","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2023.04.495",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048216","2028-LB: Clinical Factors Associated with Greater Glycemic Variability in Patients with Type 2 Diabetes","Seol A Jang","2025","Diabetes","other","article","10.2337/db25-2028-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048217","EFFECTS OF TWO YEARS OF LIRAGLUTIDE TREATMENT ON FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: ANALYSIS OF THE LEAD-2 EXTENSION TRIAL","Matthew James Armstrong","2010","Hepatology","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0048218","Effect of Orforglipron versus Placebo and Dulaglutide on Glycemic Control and Body Weight in Patients with Type 2 Diabetes","Juan P. Frías","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785387",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048219","Diabetes Drugs and Cardiovascular Event Reduction: A Paradigm Shift","Erik M. Kelly","2018","US Cardiology Review","other","article","10.15420/usc.2017:35:1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048220","Comparative evaluation of SGLT-2i and GLP-1RA neuroprotective properties in type 2 diabetic patients","A. V. Murasheva","2025","Diabetes Mellitus","other","article","10.14341/dm13255",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048221","Beyond glycemic control: the neuroprotective potential of tirzepatide","Milen Hristov","2025","Pharmacia","other","article","10.3897/pharmacia.72.e155150",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048222","Active Inclusion Bodies Protect the Target Protein from Degradation in Escherichia coli Cells","Aleksandr S. Komolov","2024","Applied Biochemistry and Microbiology","other","article","10.1134/s0003683824700236",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048223","Use of U-500 Regular Insulin via Continuous Subcutaneous Insulin Infusion: Clinical Practice Experience","Sirimon Reutrakul","2011","Journal of Diabetes Science and Technology","nonrandomized_study","article","10.1177/193229681100500429","21880247",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048224","68Ga-NODAGA-exendin-4 PET/CT for the localization of insulinomas","Marti Boss","2019","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0039-1683525",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0048225","PDB1 TREATMENT PATTERNS AND OUTCOMES AMONG OLDER EXENATIDE BID USERS COMPARED TO INSULIN GLARGINE USERS","Julia A. Gaebler","2011","Value in Health","other","article","10.1016/j.jval.2011.02.509",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048226","Response to the Letter by Kizilgul M., et al.","Iepsen EW","2015","The Journal of clinical endocrinology and metabolism","preclinical","article","10.1210/jc.2015-2874","26339738",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Comment; Letter; article"],["R0048227","S387 Single Center Assessment of the Boston Bowel Preparation Scale Score Among Patients With Obesity Who Are Receiving Semaglutide During the Time of Colonoscopy","Luis Miguel Nieto","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001030916.12140.a8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048228","Challenges in achieving racial and ethnic health equity in type 2 diabetes: access to newer medications","Milan K. Piya","2024","The Lancet Regional Health - Americas","other","article","10.1016/j.lana.2024.100784","38817955",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048229","Efficacy and Safety of Dulaglutide Versus Sitagliptin after 52 Weeks in Type 2 Diabetes (AWARD-5)","Michael Albrecht Nauck","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.128",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048230","Long-Term Cost-Effectiveness of Ideglira Versus Basal-Bolus Insulin As Intensification Therapies For People With Type 2 Diabetes Inadequately Controlled on Basal Insulin In Spain: Projections Based On The Dual VII Trial","FJ Ampudia","2017","Value in Health","other_trial","article","10.1016/j.jval.2017.08.461",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0048231","Abstract #1301: Liraglutide Acutely Inhibits Glucagon, Lipolysis and Ketogenesis in Type 1 Diabetes","Husam Ghanim","2016","Endocrine Practice","other","article","10.1016/s1530-891x(20)44869-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048232","Does sympathetic hyperactivity adversely impact on the effect of pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation?","Márcio Galindo Kiuchi","2019","EP Europace","other","article","10.1093/europace/euz316","31793998",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048233","7808 Effect of Oral Semaglutide on Hepatic Steatosis and Fibrosis, and Bone Microarchitecture in Non-alcoholic Fatty Liver Disease Complicating Type 2 Diabetes Mellitus: A Prospective, Interventional, Open-Label, Paired Study","Liza Das","2024","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvae163.576",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048234","Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3)","IRENE M. HRAMIAK","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.114",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048235","S98. Effect of GLP-1 Agonists Use on Cognitive and Affective Functioning in Type 2 Diabetes Mellitus Patients: A Preliminary Study","Candan Yasemin Eren","2018","Biological Psychiatry","other","article","10.1016/j.biopsych.2018.02.989",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048236","A randomised controlled, trial of the GLP-1 receptor agonist exenatide in idiopathic intracranial hypertension","James Michael Mitchell","2022","Journal of Neurology Neurosurgery & Psychiatry","randomized_trial","article","10.1136/jnnp-2022-abn.317",null,null,null,null,"openalex","FALSE","open_pdf","2","FALSE","article"],["R0048237","MANAGEMENT OF HYPERGLYCEMIA WITH THE ADMINISTRATION OF INTRAVENOUS EXENATIDE TO PATIENTS IN THE CARDIAC INTENSIVE CARE UNIT Running title: IV Exenatide for hyperglycemia in CICU","Mohammad Abuannadi","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048238","One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial","Stephen C. L. Gough","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/y8b3-er87",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0048239","S4137 Beyond Nausea: A Case of Colonic Bowel Obstruction Linked to GLP-1 Agonist Use","Sushmitha P. Diraviam","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001144008.40955.ab",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048240","Dying to lose weight: the potentially fatal side effects of GLP-1 receptor agonist use","Elsie Burger","2026","Pathology","other","article","10.1016/j.pathol.2026.01.206",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048241","Examining Weight Suppression, Leptin Levels, Glucagon-Like Peptide 1 Response, and Reward-Related Constructs in Severity and Maintenance of Bulimic Syndromes: Protocol and Sample Characteristics for a Cross-Sectional and Longitudinal Study (Preprint)","Pamela K. Keel","2024",null,"protocol","article","10.2196/preprints.66554",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","preprint"],["R0048242","SAT-626 Use of GLP-1R Agonists in Pediatric Patients with Type 1 Diabetes and Obesity: A Case Series","Leslie Saba","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1152",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048243","261-OR: ADA Presidents' Select Abstract: Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia after Semaglutide Withdrawal in a Murine Model of Obesity","Alice Liou Fitzpatrick","2024","Diabetes","randomized_trial","article","10.2337/db24-261-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048244","Efficacy of Tirzepatide in People with Early-Onset T2D in the SURPASS Program","Philip Scott Zeitler","2024","Diabetologie und Stoffwechsel","other","article","10.1055/s-0044-1785385",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048245","Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular disease: causal relationships and the role of anti-diabetic drugs","Tatiana Yu. Demidova","2023","FOCUS Endocrinology","other","article","10.15829/2713-0177-2023-17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048246","SP426HYPOGLYCAEMIC EPISODES EVALUATED BY CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH TYPE 2 DIABETES AND DIALYSIS-DEPENDENT END-STAGE RENAL DISEASE RANDOMISED TO 12-WEEK LIRAGLUTIDE OR PLACEBO TREATMENT","Tobias Bomholt","2018","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfy104.sp426",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0048247","26-A-17811-ACC ALLOCATION OF SEMAGLUTIDE BY PET-DERIVED MYOCARDIAL FLOW RESERVE","Maria Alwan","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.2319",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048248","Sa1962 DELAYED GASTRIC EMPTYING AS A CONSEQUENCE OF PATIENTS ON NEW-GENERATION GLP1-RAS: AN ANALYSIS FROM THE FAERS DATABASE","Kalpana Gopalkrishnan","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)01839-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048249","The effect of the combined treatment with dulaglutide and dapagliflozin in arterial elasticity, cardiac function, albuminuria and endothelial thickness in type 2 diabetes mellitus after 12 months","Ignatios Ikonomidis","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.3265",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048250","Hyperpolarized 13C and 31P magnetic resonance spectroscopy identify pyruvate dehydrogenase as a therapeutic target in obesity cardiomyopathy","Andrew J Lewis","2015","Journal of Cardiovascular Magnetic Resonance","preclinical","article","10.1186/1532-429x-17-s1-o16",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048251","7923 Latent Autoimmune Diabetes of Adulthood (LADA) Complicating Common Variable Immunodeficiency (CVID)","Leilani Pathak","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.829",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048252","Revolutionising CKD Care: Novel Treatment Paradigms and Cutting-edge Strategies","Dinesh Khullar","2024",null,"other","article","10.62830/mmj1-4-11b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048253","SUN-343 Is GLP-1 Receptor Agonist Contraindicated In MEN2A Syndrome Despite A Prophylactic Thyroidectomy?","Linda Ponce Rosas","2025","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaf149.2357",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048254","Practice Recommendations for Perioperative Management of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 RAs: A Scoping Review Protocol","Yigang Liu","2026","OSF Preprints (OSF Preprints)","protocol","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","preprint"],["R0048255","2125-P: Incretin-Stimulated Insulin Secretion Is Mediated by Gas Dependent and Independent Mechanisms","Megan E. Capozzi","2020","Diabetes","preclinical","article","10.2337/db20-2125-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048256","1534-P: Proof of Concept Validating a Pharmacogenetic Study on the Human Response to Oral Semaglutide","Bryan Kuo","2025","Diabetes","other","article","10.2337/db25-1534-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048257","Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials","Khalid A. Shaikh","2020",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048258","Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs","Ol'ga Dmitrievna Ostroumova","2018","Diabetes Mellitus","other","article","10.14341/dm9660",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048259","Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there","Faiez M. Zannad","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae399","38980800",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0048260","Současné poznatky v terapii perorálními antidiabetiky","Alena Adamíková","2014","Interní medicína pro praxi","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048261","Treatment of Pasireotide LAR-Associated Hyperglycemia In A Patient With Acromegaly","Cheryl Susan Rosenfeld","2016","Touro Scholar (Touro College)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048262","GLP-1 Receptor Agonists vs. Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors and Risk of Dementia in Patients with Diabetes Requiring Hemodialysis","Mark Duncan Kilpatrick","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025x0hs2ah8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048263","2339-PUB: Effect of IDegLira on HbA1c and Weight: Data from the Association of British Clinical Diabetologists (ABCD) IDegLira Audit","Sean Noronha","2019","Diabetes","nonrandomized_study","article","10.2337/db19-2339-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048264","Experience with Netakimab and a GLP-1 agonist in patients with psoriasis and metabolic syndrome","Larisa Sergeevna Kruglova","2026","Medical alphabet","other","article","10.33667/2078-5631-2026-3-28-34",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048265","Effects of SGLT2 inhibitors and GLP1 receptor agonists on risk of various arrhythmias: a meta-analysis of large randomized trials","Mei Hong Qiu","2021",null,"systematic_review","article","10.37766/inplasy2021.1.0102",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0048266","GLP-1 analogs: a comparison of new anti diabetic medications - presenting benefits and risks","Marika Dębik","2024","Journal of Education Health and Sport","other","article","10.12775/jehs.2024.62.014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048267","Verwendung der Fixkombination aus Insulin degludec und Liraglutid bei Erwachsenen mit Typ-2-Diabetes als Option bei unzureichender Blutzuckereinstellung unter einer basalunterstützten oralen Therapie","Belinda Wilhelm","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-103931",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048268","TCT-490 Long-term Outcomes of Glucagon-like Peptide-1 Agonist in Coronary Artery Disease and Obesity without Diabetes Mellitus: A Real-world Retrospective Cohort Study","Aravinthan Vignarajah","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2025.09.619",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048269","Combination Treatment for Cardiorenal Protection in US Adults","Massimo Nardone","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.20258naahvf7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048270","A peek into the pipeline: Expert views on emerging therapies","Ilse Dewachter","2025","Cell Reports Medicine","other_trial","article","10.1016/j.xcrm.2025.102083","40239631",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0048271","OC-016 Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, double-blinded, randomised, placebo-controlled phase ii trial","MJ Armstrong","2015",null,"randomized_trial","article","10.1136/gutjnl-2015-309861.16",null,null,"ClinicalTrials.gov:NCT01237119","S002015","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0048272","Glycemic and Weight Outcomes with Semaglutide in Middle Eastern Patients with Type 2 Diabetes","Fathelrahman Ahmed","2025","Clinical Diabetology","nonrandomized_study","article","10.5603/cd.106464",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048273","1800-P: Cotadutide, a GLP-1/GCG Receptor Co-Agonist, Improves Insulin Sensitivity and Restores Normal Insulin Secretory Capacity in DIO Mice","Rhianna Che Laker","2020","Diabetes","preclinical","article","10.2337/db20-1800-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048274","SUN-820 The Impact of GLP-1 Agonists on the Development of Body Dysmorphic Disorder","Keerthana Suhas","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1325",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048275","GLP-1 RECEPTOR AGONISTS AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CORONARY PLAQUE: A REAL-WORLD PROPENSITY-MATCHED ANALYSIS","Osman K. Yousafzai","2025","American Journal of Preventive Cardiology","nonrandomized_study","article","10.1016/j.ajpc.2025.101169",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048276","LBP-003 Semaglutide achieves resolution of metabolic dysfunction-associated steatohepatitis via modulation of multiple pathogenic pathways: insights from human and animal studies","Maximilian Jara","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)00571-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048277","Semaglutide as a safe and effective weight loss treatment in children with obesity","Boxel Elizabeth van","2022","Endocrine Abstracts","other","article","10.1530/endoabs.85.p76",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048278","GLP1 analogues in obese patients with type 2 diabetes: a weight-centered analysis","Carolina García-Figueras-Mateos","2018","Clinical Nutrition","other","article","10.1016/j.clnu.2018.06.1922",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048279","Can biomarkers help find the ‘sweet spot’ for treating patients with diabetes?","Naveed A. Sattar","2021","European Journal of Heart Failure","other_trial","article","10.1002/ejhf.2175","33786946",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048280","Liraglutide downregulates the expression of miRNA-424 in patients with obesity","Georgios K. Dimitriadis","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep374",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract; article"],["R0048281","Dulaglutid: GLP-1-Rezeptoragonist zur einmal wöchentlichen Therapie des Typ-2-Diabetes","Elke Heitmann","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-118174",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048282","225-OR: The Effect of Tirzepatide vs. Insulin Degludec on Post-meal Glucose Control in Patients with Type 2 Diabetes (SURPASS-3 CGM)","Tadej Battelino","2023","Diabetes","randomized_trial","article","10.2337/db23-225-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048283","Personalized Dosage System as a Tool for Detecting Adverse Drug Reactions: Pharmaceutical Intervention in a Polymedicated Patient","Adama Peña-Vera","2026","Scientia Pharmaceutica","nonrandomized_study","article","10.3390/scipharm94020035",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048284","Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme","Stephan Jacob","2019","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0039-1688352",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0048285","Integrated diabetes care in Derby: new NHS organisations for new NHS challenges","RD Rea","2011","Practical Diabetes","other","article","10.1002/pdi.1624",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048286","Wirkung von Exendin-4 auf die Expression von Wnt4 als neuem Regualtor der beta-Zell Funktion","Craig H. Heller","2011","Diabetologie und Stoffwechsel","other","article","10.1055/s-0031-1277468",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048287","factors predicting glucose and weight response to injectable semaglutide (Ozempic): real-world data from the Association of British Clinical Diabetologists’ audit programme","Tom Crabtree","2023","British Journal of Diabetes","randomized_trial","article","10.15277/bjd.2023.418",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0048288","Glucagon‐like peptide‐1 receptor agonist, exenatide, enhances Ca 2+ buffering by SERCA in coronary smooth muscle cells from lean, healthy Ossabaw swine (700.3)","Stacey L. Dineen","2014","The FASEB Journal","other","article","10.1096/fasebj.28.1_supplement.700.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048289","CAD-32: Évaluation de Lixisenatide dans le syndrome coronarien aigu (ELIXA : Evaluation of LIXisenatide in Acute Coronary Syndrome)","Jean‐Claude Tardif","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30128-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048290","SGLT2 Inhibitors and GLP-1 Receptor Agonists and the Risk for Adverse Outcomes After AKI or Acute Kidney Disease: Systematic Review and Meta-Analysis","Erin Frazee Barreto","2025","Journal of the American Society of Nephrology","systematic_review","article","10.1681/asn.2025mck1neet",null,null,"PROSPERO:CRD42024607838",null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0048291","P192 - ECE_1332 - Early changes in serum calcitonin during tirzepatide therapy in adults with obesity","Nicholas Angelopoulos","2026","European Journal of Endocrinology","preclinical","article","10.1093/ejendo/lvag096.368",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048292","Evaluating the Effectiveness of SGLT2i or GLP1RA vs. Sulfonylurea Initiation After Hospital Admission for Congestive Heart Failure and Type II Diabetes Mellitus: A Scoping Review","Alyssa Ptacek","2024",null,"narrative_review","article","10.21007/con.dnp.2024.0092",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0048293","Reno-Protective Effect of Liraglutide in Type 1 Diabetes Mellitus (T1DM): Shifting Macrophage Polarization Towards the M2 Anti-Inflammatory Phenotype Through NADPH/TRP Dual Inhibition","Natalie Youssef","2022","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20223311s1669c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048294","715-P: Tirzepatide as Monotherapy Improved Markers of Beta-Cell Function and Insulin Sensitivity in People with Type 2 Diabetes (SURPASS-1)","Clare J. Lee","2022","Diabetes","other_trial","article","10.2337/db22-715-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048295","2028-P: Adding Exercise to Liraglutide Treatment in Weight Loss Maintenance Abolishes the Increase in Heart Rate Seen with Liraglutide Alone: The S-LITE Randomized Trial","Julie Rehné Lundgren","2020","Diabetes","randomized_trial","article","10.2337/db20-2028-p",null,null,"ClinicalTrials.gov:NCT04122716","S000371","openalex","FALSE","paywalled","1","FALSE","article"],["R0048296","Impact of treatment with semaglutide, empagliflozin and their combination on markers of cardiovascular, renal, and retinal disease in patients with type 2 diabetes","Hald, Liv","2024",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0048297","Precision medicine in type 2 diabetes mellitus: Unraveling the role of TCF7L2, CTRB1/2, and GLP-1R genetic variants in response to treatment with glucagon-like peptide-1 receptor agonists","Artemis Kyriakidou","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.rc4.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048298","OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins","Sandro La Vignera","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.1701",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048299","GLP-1 and Inflammatory Mediators in Obese Asthma","David C. Watchorn","2023","Research Repository UCD (University College Dublin)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0048300","1550-P: Changes in Beta-Cell Function during Dapagliflozin Therapy in Combination with Exenatide in Type 2 Diabetes Patients (T2D)","Ralph Anthony DeFronzo","2024","Diabetes","other","article","10.2337/db24-1550-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048301","Quick Take Vol. 91","Amanda Koire","2026",null,"other","article","10.64239/pi-nl-qt91",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0048302","AM833, a Long Acting Amylin Analogue Induces Hypocalcemia in Young Rats via a Calcitonin Receptor Mediated Mechanism","Kirsten Dahl","2021","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvab048.084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048303","Instrumental Variable methods to target Hypothetical Estimands with longitudinal repeated measures data: Application to the STEP 1 trial","Jack Bowden","2024","arXiv (Cornell University)","randomized_trial","article","10.48550/arxiv.2407.02902",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0048304","PDB37 Cost-Effectiveness of Adding Twice-Daily Exenatide to Basal Insulin in Patients With Type 2 Diabetes in Scotland","N. Varol","2012","Value in Health","other","article","10.1016/j.jval.2012.08.1680",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048305","Long Acting GLP-1 Analog Treatment in Islet Transplantation","Eduardo Moraes Leao Peixoto","2012","Transplantation","other","article","10.1097/00007890-201211271-01386",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048306","S5010 A Challenging Case of Gastric Bezoar in a Patient on Tirzepatide","Kristen Fadel","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001049408.79846.f0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048307","The main directions and prospects in polycystic ovary syndrome treatment","Asie N. Useinova","2021","Сибирский научный медицинский журнал","other","article","10.18699/ssmj20210602",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048308","O5‐01‐01: Anti‐diabetic drugs protect the brain from defective insulin signaling caused by Alzheimer's toxic Aß oligomers","Theresa R. Bomfim","2012","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2012.05.1969",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048309","Abstract P3-02-10: The possible association among breast cancer, diabetes mellitus and GLP-1 receptor","Naoko Hashimoto Takigami","2020","Cancer Research","other","article","10.1158/1538-7445.sabcs19-p3-02-10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048310","Improving outcome in acute coronary syndromes: ischaemic conditioning, antithrombosis and bleeding, and inflammasome antagonism","Thomas Felix Lüscher","2017","European Heart Journal","other","article","10.1093/eurheartj/ehx085","28363224",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048311","THE UNSEEN CONSEQUENCES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) IN PATIENTS UNDERGOING UPPER ENDOSCOPY","Malcolm B. Chapman","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.1368",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048312","Ga-68-labelling of Exendin-4, preclinical evaluation of the resultant tracer for the imaging and quantification of insulinomas, and case patient examination","Irina Velikyan","2013","Journal of Labelled Compounds and Radiopharmaceuticals","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048313","ICA6150349, a Highly Selective Glucagon Agonist, in Combination with Exenatide Significantly Reduces Weight and Glucose in Obese and Diabetic Rats","Mark A. Paulik","2018","Diabetes","preclinical","article","10.2337/db18-1998-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048314","Deficiency of mitochondrial aldehyde dehydrogenase increases type 2 diabetes risk in males via autophagy dysregulation","Xiang‐Wei Liu","2021","Chinese Medical Journal","preclinical","article","10.1097/cm9.0000000000001408","33813505",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048315","Combination of Phentermine/Topiramate Er and Liraglutide 3 Mg for Intensive Therapy of Severe Obesity & T2Dm: A Case Series and Brief Review","Harris M. Baloch","2018","AACE Clinical Case Reports","case_report","article","10.4158/accr-2018-0125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048316","Problems of hypoglycemic therapy in diabetic patients with acute coronary syndrome","Lyudmila Alexandrovna Ruyatkina","2016","Meditsinskiy sovet = Medical Council","randomized_trial","article","10.21518/2079-701x-2016-4-100-109",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0048317","1027-P: Lower Admission HbA1c Is Associated with Lower Likelihood of SGLT-2 Inhibitor or GLP-1 Agonist Prescription in Patients with Type 2 Diabetes after Myocardial Infarction","Chaitanya Malladi","2023","Diabetes","other","article","10.2337/db23-1027-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048318","The Differing Impact Of Perioperative Glp-1RA Use On Surgical Outcomes In Diabetic Versus Nondiabetic Plastic Surgery Patients","Sophia Salingaros","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20087070",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0048319","Vildagliptin (LAF 237): A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes Mellitus","Susan A. Cornell","2006","Journal of Pharmacy Technology","other_trial","article","10.1177/875512250602200207",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048320","GLP1s: Hidden Menace! Novel Chronic Medication Regimen Leads to Pancreatopleural Fistula and Tube Feed Effusion","PHILLIP BRIER","2025","American Journal of Respiratory and Critical Care Medicine","other","article","10.1164/ajrccm.2025.211.abstracts.a3822",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048321","EFFICACY AND SAFETY OF TIRZEPATIDE IN IMPROVING CARDIOMETABOLIC OUTCOMES IN PATIENTS WITH OVERWEIGHT OR OBESITY. A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Xin‐Hui Pan","2023","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(23)02218-0",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0048322","Abstract 4115541: Association of Glucagon-like Peptide 1 Receptor Agonist Use with Incident Atrial Fibrillation","Suzan Khalil","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4115541",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048323","Real world effectiveness of fixed ratio combination of glargine 100 U/ml and lixisenatide therapy in outpatients with type 2 diabetes depending on body mass index and dose timing: post hoc analysis of the SOLO study","Mikhail Borisovich Antsiferov","2023","Endocrinology News Opinions Training","nonrandomized_study","article","10.33029/2304-9529-2023-12-3-12-19",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048324","Characterization of the Discriminative Stimulus Effects of GLP-1 Receptor Agonist Liraglutide in Rats (Abstract ID: 192381)","Leslie A. Sullivan","2025","Journal of Pharmacology and Experimental Therapeutics","preclinical","article","10.1016/j.jpet.2025.103458",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048325","Review of clinical use of glucagon‐like peptide‐1 in the management of type 2 diabetes","Gordon F. Rushworth","2014","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1886",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048326","Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA","Zornitsa Mitkova","2018","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-018-0657-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048327","1971-LB: Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial","JOHANNES F.E. MANN","2025","Diabetes","randomized_trial","article","10.2337/db25-1971-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048328","Modulation of Neuronal Insulin Signaling Rescues Axonal Transport Defects in an Alzheimer’s Disease Model","Oliver P. Takach","2013","Summit (Simon Fraser University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048329","Dulaglutide: Clinical Benefits and Contribution to the Treatment of Type 2 Diabetes","Elena Valer'evna Biryukova","2020","Effective Pharmacotherapy","other","article","10.33978/2307-3586-2020-16-12-30-40",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048330","Liraglutide, a once-daily human GLP-1 analog, reverses indices of prediabetes in obese subjects: A randomized placebo-controlled 20-week trial","Nick Finer","2009","Research at the University of Copenhagen (University of Copenhagen)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0048331","Incretin-Based Therapy for Cardiovascular and Cardiorenal Risk Reduction: A Systematic Review and Meta-Analysis of GLP-1 Receptor Agonist and Dual Incretin Randomized Trials","Maurice Tiotsop","2026","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.7028058",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0048332","Differences in weight reduction efficacy of tirzepatide in adults without versus with type 2 diabetes with overweight or obesity in SURMOUNT 1 and 2","Rodolfo Javier Galindo","2025","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0045-1807559",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0048333","The long acting GLP-1 analogue, liraglutide, induces beta cell differentiation during normal human pancreas development","Karen Piper Hanley","2006","ePrints Soton (University of Southampton)","preclinical","article","10.1007/s00125-006-0358-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048334","Biochemical Evaluation of Metformin and GLP-1 Therapy in Amelioration Metabolic Disturbance in Rats Induced Type II Diabetes","Ashraf Barakat Said","2024","Suez Canal Veterinary Medicine Journal SCVMJ","randomized_trial","article","10.21608/scvmj.2024.394171",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048335","GLP-1 Receptor Agonists in Gastrointestinal Practices: Enhancing Both Procedural and Patient-Related Outcomes","Chloé Lahoud","2025","SN Comprehensive Clinical Medicine","other","article","10.1007/s42399-025-01961-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048336","Patients Taking Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) Presenting to the Emergency Department, 2017–2025","Theodore C. Chan","2026","Emergency Care and Medicine","nonrandomized_study","article","10.3390/ecm3030022",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048337","Abstract 4341999: Clinical Outcomes Among Individuals with Persistent Systemic Inflammation Following Myocardial Infarction: Insights from the Veterans Affairs Healthcare System","Alexander T. Sandhu","2025","Circulation","other","article","10.1161/circ.152.suppl_3.4341999",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048338","Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial","Roland E. Schmieder","2026","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0046-1820049",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0048339","Plain Language Summary of the Manuscript. Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation","Domenica M Rubino","2026","Boehringer Ingelheim","other_trial","article","10.60915/boehringer-figshare.32103682.v1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0048340","907-P: Michigan Collaborative for Type 2 Diabetes: Mixed Methods Change Readiness Assessment of Provider Organizations and Clinical Champions","JACQUELINE RAU","2022","Diabetes","other","article","10.2337/db22-907-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048341","The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management","Blair Suter","2025","Current Cardiovascular Risk Reports","other_trial","article","10.1007/s12170-025-00761-0",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0048342","The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus","Marina Vladimirovna Shestakova","2010","Diabetes Mellitus","other","article","10.14341/2072-0351-5497",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048343","The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus","Ilya N. Dyakov","2021","Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice","other","article","10.37489/2588-0519-2020-5-4-14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048344","Endoscopic Sleeve Gastroplasty as Facilitator for Renal Transplantation in Patients with Obesity: Rationale and Protocol","Vítor Patrício Correia","2025","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","protocol","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0048345","CO08 - Tolérance et efficacité d’une injection par semaine d’une forme à libération prolongée d’exenatide durant 15 semaines chez des patients avec diabète de type 2","L Mac Conell","2006","Annales d Endocrinologie","other","article","10.1016/s0003-4266(06)72623-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048346","THU338 Risks Of Stroke, Its Subtypes And Atrial Fibrillation Associated With Glucagon-like Peptide 1 Receptor Agonists Versus Sodium-glucose Cotransporter 2 Inhibitors: A Real-world Population-based Study In Hong Kong","David Tak Wai Lui","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.771",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048347","1665-P: Whole-Brain Activation Signatures of Weight-Lowering Drugs","LOUISE S. DALBOEGE","2023","Diabetes","preclinical","article","10.2337/db23-1665-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048348","Promising outcomes from latest landmark diabetes trials: tirzepatide and finerenone in the spotlight","Lakshmi Sankaran","2023","Practical Diabetes","randomized_trial","article","10.1002/pdi.2432",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048349","Pregnancy Intention, Contraceptive Use, and Receipt of Reproductive Health Counseling among Women with Type 2 Diabetes Prescribed Glucagon-like Peptide-1 Receptor Agonists","Stacy  Cooper Bailey","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.6181456",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0048350","Automated radiosynthesis of pharmaceutical grade [68Ga]Ga-NODAGA-Lys40-Exendin-4 and demonstration of its efficacy for use in patients","Sreeja Raj Menon","2024","Journal of Radioanalytical and Nuclear Chemistry","other","article","10.1007/s10967-024-09535-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048351","A Systematic Review of Effective Fertility Adjuvant Therapy, Dulaglutide (GLP-1) in PCOD for Short Term","Hend Ahmado","2024","ASEAN Journal of Psychiatry","systematic_review","article","10.54615/2231-7805.10.1.141",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0048352","From glucose lowering to treatment of cardiovascular disease: the repositioning of glucose-lowering agents","Massimiliano Caprio","2020","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvaa019","32298414",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0048353","Sécurité du liraglutide versus placebo chez les diabétiques de type 2 insuffisants rénaux dans l’étude LEADER","Michel Marre","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.208",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048354","850 PATIENTS WITH MAFLD TAKING GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT HAVE HIGHER INCIDENCE FOR HEPATOBILIARY CANCER BUT HAVE LOWER OVERALL MORTALITY: A MULTI-CENTER ANALYSIS.","Luis Miguel Nieto","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)04036-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048355","Vom Pen zur Pille: Wird die GLP-1-Therapie beim Typ-2-Diabetes alltagstauglicher?","Peter Schwarz","2026","Diabetes aktuell","other","article","10.1055/a-2872-0959",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048356","The use of the GLP-1 analog - dulaglutide in the treatment of morbid obesity - case report","Agata JUDA","2022","Journal of Education Health and Sport","case_report","article","10.12775/jehs.2023.13.01.023",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048357","S854 Does BMI Affect Outcomes in Patients on GLP-1RA Undergoing Endoscopy via MAC Anesthesia: A Retrospective Cohort Study","Rabih Ghazi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032784.57616.96",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048358","Semaglutide as Treatment for Obesity in Adolescents","Nasser E. Mikhail","2023","International Journal of Diabetes Management","randomized_trial","article","10.61797/ijdm.v2i1.238",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048359","S1689 Use of Sodium-Glucose Transport Protein 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors in Patients with MASLD in a Real-World Setting is Associated with Lower All-Cause Mortality","Sophia Hurr","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001036124.61521.5f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048360","Stratification of direct retail pharmacotherapy costs for type 2 diabetes mellitus and obesity in Russia: an analysis of guideline-recommended regimens","Arthur Anatolievich Lee","2026","FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","other","article","10.17749/2070-4909/farmakoekonomika.2026.384",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048361","Abstract 4145254: Effects Of Semaglutide On Safety Outcomes In Patients With Type 2 Diabetes Mellitus And High Cardiovascular Risk: A Meta-Analysis Of Randomized Controlled Trials And Systematic Review","Masayuki Akabane","2024","Circulation","systematic_review","article","10.1161/circ.150.suppl_1.4145254",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0048362","The Impact of Semaglutide on Liver Fat Assessed by Serial Cardiac CT scans in Patients with Type 2 Diabetes: Results from STOP Trial","Venkat Sanjay Manubolu","2023","American Heart Journal","other_trial","article","10.1016/j.ahj.2023.08.057",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048363","Glucagon like peptide‐1 ( GLP ‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","nonrandomized_study","article","10.1002/doi2.89",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048364","Sa1646: GLP-1 AGONIST USE IS ASSOCIATED WITH OVERALL IMPROVEMENT OF SYMPTOMS IN PATIENTS WITH IBS-D AND OBESITY: A NATIONAL DATABASE ANALYSIS","Luis Miguel Nieto","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)02058-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048365","S228 Assessing Appropriate Bowel Cleansing For Veteran Patients Undergoing Colonoscopy Who Use GLP-1 Agonist Medications","Kyle C. Pierce","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001029280.37563.c0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048366","The role of incretin‐based therapies in the management of type 2 diabetes","David L Russell-Jones","2009","Practical Diabetes","other","article","10.1002/pdi.1368",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048367","Efficacy of tirzepatide in an adolescent with alstrom syndrome","Katherine Hawton","2025","Endocrine Abstracts","other","article","10.1530/endoabs.111.p62",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048368","Liraglutide exerts protective effects on MASLD independently of lipophagy, and the combination with kombucha presents no additional advantage","Jenifer Souza de Almeida","2026","Brazilian Journal of Health Review","preclinical","article","10.34119/bjhrv9n1-082",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048369","A Comparative Overview of Natural and Synthetic Anti-Diabetic Compounds","Yash Bhardwaj","2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.34s.106",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048370","Effect of SGLT2 Inhibitor and GLP-1 Receptor Agonist Treatment on Urine and Plasma Parameters Involved in Lithogenesis in Patients with Diabetes","Nadim Zaidan","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025e3yf1fnk",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048371","Abstract 4340495: Assessing the Economic and Healthcare Burden of Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Microsimulation Approach to Cost-Effectiveness and Resource Utilization","Hassan Mehmood Lak","2025","Circulation","other","article","10.1161/circ.152.suppl_3.4340495",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048372","Role of glucagon-like peptide-1 analogues in weight management","Bilal Hasan Chaudhry","2023","World Family Medicine Journal/Middle East Journal of Family Medicine","other","article","10.5742/mewfm.2023.95256110",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048373","1252-P: Glucagon-Like Peptide 1 Receptor Agonist Prescription prior to Pregnancy According to Health Insurance Type and Race/Ethnicity","CAROLINA I. BATLLE","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1252-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048374","S1688 GLP-1 Agonist Use is Associated With Lower Mortality and Improvement of Cardiovascular Outcomes in Patients With Obesity Who Have MAFLD and OSA: A Multi-Center Analysis","Sharon I. Narvaez","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001036120.40580.1d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048375","Diabetes and Metabolic Dysfunction–associated Steatotic Liver Disease in Adults: A Clinical Practice Guideline","James Kim","2025","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2025.04.003","40783292",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048376","Cholesterol 7 Alpha–Hydroxylase (CYP7A1) Activity and 7–Alpha–Hydroxy–4–Cholesten–3–One (C4) Are Not Translatable Biomarkers of Glucagon Receptor (GCGR) Activation","Raul C. Camacho","2018","Diabetes","preclinical","article","10.2337/db18-1113-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048377","PSUN188 Evaluating Response to GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Managed at a Veterans Affairs Hospital","C.J. Davis","2022","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvac150.778",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0048378","Effect of GLP-1 receptor agonists on obesity in patients with severe mental illness: A state hospital case series of clozapine-treated patients","Syed Sadat Ali","2024","Psychiatry Research Case Reports","nonrandomized_study","article","10.1016/j.psycr.2024.100231",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048379","Coexistence of Pituitary Adenoma Causing Acromegaly and Medullary Thyroid Cancer","Aurélie F. Paré","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.1809",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048380","Glucagon-like peptide 1 (GLP-1).","Timo D. Müller","2019","Apollo (University of Cambridge)","preclinical","article","10.17863/cam.47407",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048381","Incretin-based therapy on diabetic nephropathy","Yuichiro Yamada","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)30930-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048382","Kommentar zu Basalinsulin plus Bolusinsulin oder besser plus GLP1-RA?","Robert A. Ritzel","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2167-7456",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048383","92-LB: Higher Adherence and Persistence for Dulaglutide Compared with Oral Semaglutide at Six-Months Follow-Up with U.S. Real-World Data","Rosirene Paczkowski","2022","Diabetes","nonrandomized_study","article","10.2337/db22-92-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048384","3065-LB: Nonclinical Profile of AMB-702, a Potent and Novel Oral GLP-1 Receptor Agonist","Patrice A. Lee","2026","Diabetes","preclinical","article","10.2337/db26-3065-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048385","1266-P: The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk","ELISABETTA PATORNO","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1266-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048386","The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective","Manfredi Rizzo","2013","Clinical Lipidology","other","article","10.2217/clp.13.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048387","2180-LB: Bimagrumab Augments Metabolic Rate to Improve Incretin-Induced Weight Loss in Obese Mice","Jonquil Marie Poret","2025","Diabetes","preclinical","article","10.2337/db25-2180-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048388","227-LB: GLP-1 Activation of HCN Channels Increases Glucose-Stimulated β- and δ- Cell Ca2+ Oscillation Frequency","Karolina E. Zaborska","2021","Diabetes","preclinical","article","10.2337/db21-227-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048389","#3819 Comparative effects of GLP-1RAs on kidney transplant recipients and chronic kidney disease patients","Beatriz Sánchez Álamo","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.1839",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048390","Évaluation de l’impact à 6 mois d’un traitement par liraglutide chez des diabétiques de type 2 précédemment traités par antidiabétiques oraux ou par insuline","Y. Noirez","2012","Annales d Endocrinologie","other","article","10.1016/j.ando.2012.07.982",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048391","Self-Medication with Tirzepatide for Weight Loss Resulting in Life-Threatening Conditions: A Clinical Case","E V Dovgan","2026","Safety and Risk of Pharmacotherapy","other","article","10.30895/2312-7821-2026-577",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048392","The effect of glucagon-like peptide 1 receptor agonists on alcohol and tobacco craving among patients with type 2 diabetes mellitus: a cross-sectional, questionnaire pilot study","Jacek Budzyński","2024","Medical Research Journal","other","article","10.5603/mrj.101513",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048393","PDB56 Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients With Type 2 Diabetes Failing Metformin Monotherapy","Jakob J. Langer","2012","Value in Health","other","article","10.1016/j.jval.2012.03.977",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048394","The Role of GLP-1 Receptor Agonists (Ozempic and Mounjaro) as Secondary Therapy in Chronic Kidney Disease","Erick Adolfo Meza Soto","2025","SAGA Revista Científica Multidisciplinar","randomized_trial","article","10.63415/saga.v2i3.257",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048395","Unterschiedlicher Einfluss von Exenatide und Insulin Glargin auf die postprandialen Blutzuckerspitzen bei Typ 2 Diabetes","CHRISTOF M. KAZDA","2006","Diabetologie und Stoffwechsel","other","article","10.1055/s-2006-943779",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048396","Abstract 368: The GLP-1 Receptor Agonist Liraglutide Improves Autophagy Impairment in the Diabetic Heart","Antoinette Bugyei‐Twum","2017","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvb.37.suppl_1.368",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048397","Semaglutide use in adjunct to multidisciplinary lifestyle interventions improves weight and body composition in NAFLD patients","Rochelle Wong","2022","Journal of Hepatology","other","article","10.1016/s0168-8278(22)01780-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048398","Adherence to Liraglutide once daily or exenatide once weekly Over A 12-Month period among Commercially Insured Patients With Type 2 diabetes Mellitus: A retrospective observational study","Stephen S. Johnston","2015","Value in Health","nonrandomized_study","article","10.1016/j.jval.2015.03.374",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048399","Impact of glucagon-like peptide-1 receptor agonists on clinical outcomes in pancreatic cancer: A large-scale real-world cohort study.","Nneoma Ubah","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.2_suppl.688",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048400","Estrogen Protects Against Olanzapine‐induced Hyperglycemia","Kyle D. Medak","2020","The FASEB Journal","preclinical","article","10.1096/fasebj.2020.34.s1.04790",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048401","Industry update: the latest developments in the field of therapeutic delivery, December 2025","Peter A. Timmins","2026","Therapeutic Delivery","other_trial","article","10.1080/20415990.2026.2642514","41823185",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","other"],["R0048402","Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP ‐1 analogue","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.70003",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048403","LIRA-ADD2BASAL: Liraglutide Added to Basal Insulin Analogs Improves Glycemic Control","Kelsey Mann","2014","MD Conference Express","other_trial","article","10.1177/155989771432007",null,null,"ClinicalTrials.gov:NCT01617434","S000926","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0048404","Synergistically protective effects of metformin and liraglutide on endothelial cell oxidative damage induced by palmitic acid","Jing Ke","2014","Chin J Diabetes Mellitus","other","article","10.3760/cma.j.issn.1674-5809.2014.05.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048405","Use of Dual GIP/GLP-1 RA in HNF1A-MODY and HNF4A-MODY","Martin Broome","2025","Deep Blue (University of Michigan)","other","article","10.7302/25164",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048406","Distribution of GLP-I binding sites in the rat brain: evidence that Exendin-4 is a ligand of brain DLP-1 binding sites","R. Göke","1995","Research at the University of Copenhagen (University of Copenhagen)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048407","Effect of liraglutide on adipose insulin resistance and hepatic de-novo lipogenesis in non-alcoholic steatohepatitis: substudy of a phase 2, randomised placebo-controlled trial","Matthew James Armstrong","2014","The Lancet","randomized_trial","article","10.1016/s0140-6736(14)60284-1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048408","S3344 A Rare Case of Mirizzi-Like Syndrome in a Gastric Sleeve Patient With Recent GLP-1 RA Dosage Increase","Ekshika Patel","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001140836.25251.1d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048409","(153) GLP-1 AGONIST WEIGHT LOSS MEDICATIONS DECREASE SEXUAL DESIRE: A BIOPSYCHOSOCIAL MODEL FOR WHY WE DON’T “SEE” IT","Meghan Tveit","2025","The Journal of Sexual Medicine","other","article","10.1093/jsxmed/qdaf068.136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048410","Can cardiac autonomic neuropathy be a predictor of cardiovascular outcomes in diabetes?","Sanjay Kalra","2014","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.145795","25729680",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0048411","Pioglitazone-associated bladder cancer: the contribution of spontaneous reporting analysis on the basis of FDA_AERS database","Carlo Pasquale Piccinni","2011","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0048412","Semaglutide and Cardiovascular Outcomes by Baseline and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT","Ildiko Lingvay","2024",null,"randomized_trial","article","10.2337/figshare.25777446",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0048413","1986-LB: Feasibility and Acceptability of an Intervention to Improve Metabolic Liver Disease in Latino/a and Black Patients with Diabetes","Anastasia‐Stefania Alexopoulos","2024","Diabetes","other","article","10.2337/db24-1986-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048414","Real-world effectiveness and safety of fixed-ratio combination insulin glargine 100 u/ml plus lixisenatide in adults with type 2 diabetes (T2DM): subanalysis of the international, multicentre, prospective observational study SUCCESS in the Russian population","Ol'ga Konstantinovna Vikulova","2024","Diabetes Mellitus","nonrandomized_study","article","10.14341/dm13236",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048415","Combining Glucagon-Like Peptide 1 Analogues with Sodium-Glucose Cotransporter 2 Inhibitors to Treat Patients with Type 1 Diabetes, BMI > 25 Kg/M2, and Chronic Kidney Disease – a Randomised, Controlled Pilot Study","Ebaa Al‐Ozairi","2024","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.4735625",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0048416","Development of RybelsusⓇ, the world’s first oral GLP-1 receptor agonist","Norichika Moriwaki","2022","Drug Delivery System","other","article","10.2745/dds.37.169",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048417","Distinguishing prophylactic and therapeutic cricoid force","Andy Higgs","2025","Anaesthesia","randomized_trial","article","10.1111/anae.16714","40689685",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048418","S420 Effects of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) on Colonoscopy: A Systematic Review and Meta-Analysis","Gurjot Singh","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001129140.58869.18",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0048419","Impact of cardiovascular disease and diabetes on cerebral cognition in older adults: the role of routine echocardiography in a primary care setting of Northern Sweden","Samir Kanti Saha","2021","European Heart Journal","other","article","10.1093/eurheartj/ehab724.2722",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048420","ABSTRACT NUMBER: ESOC2026A1557 EFFICACY AND SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON STROKE RISK AND CEREBROVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A NETWORK META-ANALYSIS","Tasneem Hetta","2026","European Stroke Journal","systematic_review","article","10.1093/esj/aakag023.742",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0048421","1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials","YASMIN L.L. MESQUITA","2023","Diabetes","systematic_review","article","10.2337/db23-1704-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0048422","P173 Le liraglutide recrute l’axe intestin-cerveau en réponse au glucose oral et améliore sa sensibilité au cours du diabète","François Reichardt","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72464-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048423","756-P: Real-World Data Comparing the Effectiveness of Injectable vs. Oral Semaglutide—Association of British Clinical Diabetologist (ABCD) National Audit","KYAW LINN SU KHIN","2025","Diabetes","nonrandomized_study","article","10.2337/db25-756-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048424","In patients with type 2 diabetes, which GLP-1 receptor agonist results in the greatest HbA1C reduction?","Julie Holt","2020","Evidence-Based Practice","other","article","10.1097/ebp.0000000000000605",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048425","Normalized NEFA Dynamics During an OGTT After Islet Transplantation","Shireene Ratna Vethakkan","2012","Transplantation","preclinical","article","10.1097/tp.0b013e3182696a39","23038633",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048426","A narrative review: polycystic ovary syndrome (PCOS) and type 1 diabetes (T1D)","Angelina Valladares Bernier","2022","Pediatric Medicine","nonrandomized_study","article","10.21037/pm-22-3",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0048427","A review on the impact of the worldwide shortage of glucagon-like peptide-1 medications on control of diabetic patients","Abrar Ali Saiyed","2024","International Journal of Community Medicine and Public Health","narrative_review","article","10.18203/2394-6040.ijcmph20242990",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048428","Le point sur un médicament : le dulaglutide (Trulicity®)","Bernard Bauduceau","2019","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(19)30025-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048429","Abstract PS4-01-14: Evaluation of Metabolic Dysregulation, Endocrine Therapy Outcomes, and Tumor Biology in HER2-/HR+ Breast Cancer using a Multi-Omic, Real-World Analysis","J. Hundal","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-ps4-01-14",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048430","The year in cardiology 2016: heart failure","Aldo Pietro Maggioni","2016","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehw638","28043977",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0048431","Trends and expenditure of cardioprotective drugs in cancer survivors: Medical Expenditure Panel Survey (2016-2023).","Harshkumar Arvindbhai Patel","2026","Journal of Clinical Oncology","other","article","10.1200/jco.2026.44.16_suppl.e23005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048432","Editorial: Endocrine and metabolic consequences of childhood obesity, volume III","Elpis Athina Vlachopapadopoulou","2025","Frontiers in Endocrinology","randomized_trial","article","10.3389/fendo.2025.1546470","40196461",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","editorial"],["R0048433","P324 Tolérance à long terme (jusque 2 ans) du lixisenatide en une prise quotidienne vs placebo chez des patients diabétiques de type 2 non suffisamment équilibrés sous metformine (GetGoal-F1)","G. B. Bolli","2012","Diabetes & Metabolism","other","article","10.1016/s1262-3636(12)71426-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048434","Abstract 01: Association of Copayment Level and Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Adherence in Diabetes and Heart Failure","Utibe R. Essien","2023","Circulation","nonrandomized_study","article","10.1161/circ.147.suppl_1.01",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048435","Research Progress of Perioperative Application of GLP-1 and Its Protective Effects on Organs","Xi Hong","2023","Journal of Clinical and Nursing Research","other","article","10.26689/jcnr.v7i4.5033",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048436","ONE DRUG FOR MULTIMORBID HYPERTENSION AND TYPE 2 DIABETES? A DOSE-WISE NETWORK META-ANALYSIS OF TIRZEPATIDE","Yashendra Sethi","2024","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(24)03722-7",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0048437","GLP-1R Activation by Liraglutide Promotes Breast Cancer Through NOX4/ROS/VEGF Pathway","Zhanzhao Liu","2021","SSRN Electronic Journal","other","article","10.2139/ssrn.3977559",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0048438","Type 1 diabetes and cardiovascular disease : review","Oliver Schnell","2014","˜The œSouth African journal of diabetes & vascular disease","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0048439","Verbesserte postprandiale Blutzuckereinstellung bei Typ 2 Diabetes mit einer Fikombination von Insulin degludec und Liraglutid: Ergebnisse eines Mahlzeitentests","Jörg Lüdemann","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549746",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048440","665-P: Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses","John B. Buse","2021","Diabetes","other","article","10.2337/db21-665-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048441","Mo1780: IMPACT OF GLP1 AGONIST THERAPY ON ILEAL POUCH ANAL ANASTOMOSIS PATIENT FUNCTIONAL OUTCOMES AND QUALITY OF LIFE","Ece Unal","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)05604-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048442","Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial","Helen Martina Colhoun","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2792",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048443","Su2067: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS REVERSES THE KNOWN HARMFUL ASSOCIATION OF BODY WEIGHT VARIABILITY WITH CARDIOVASCULAR OUTCOMES ACROSS DIFFERENT METABOLIC PROFILES","Sarpong Boateng","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03119-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048444","Pathophysiological basis of sarcopenia— a chronic complication of diabetes","Алла Ковальчук","2022","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","other","article","10.22141/2224-0721.18.6.2022.1205",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048445","Original article Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany","Lesley-Ann Miller","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048446","S732 Cardiovascular and Hepatic Outcomes of Tirzepatide vs Aspirin in Patients With Obesity and Metabolic Dysfunction-Associated Steatohepatitis: A Real-World Analysis","Farirai Melania Marwizi","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130388.39934.cf",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048447","734-P: Use of GLP-1 Agonists and Perioperative Complications in Patients Undergoing Elective Surgery","Carlos E. Mendez","2024","Diabetes","nonrandomized_study","article","10.2337/db24-734-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048448","Abstract 4368871: Impact of Glucagon-Like Peptide-1 Agonists on Ventricular Tachycardia Ablation Outcomes: a Matched Analysis","Adele Watfa","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4368871",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048449","Current methods of treatment of type 2 diabetes mellitus (literature review)","E.A. Mineeva","2024","Glavvrač (Chief Medical Officer)","narrative_review","article","10.33920/med-03-24012-08",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048450","PPARα and PPARβ/δ Expression is Associated with Proinflammatory Markers in an Obese Pediatric Population","Karina Vargas-Sánchez","2020","Research Square","other","article","10.21203/rs.3.rs-47488/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0048451","Effect of Semaglutide on Weight, HbA1c Reduction, and Side Effect Profile in Type 2 Diabetes Patients","Waseem Abbas","2025","Pakistan Journal of Medicine and Dentistry","nonrandomized_study","article","10.36283/ziun-pjmd14-4/074",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048452","Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Pre-Specified Secondary Analysis","Peter R Rossing","2025",null,"randomized_trial","article","10.2337/figshare.29469482.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0048453","S2085 Comparing the Efficacy of Endoscopic Bariatric Interventions and GLP-1 Agonists to Endoscopic Bariatric Interventions Alone in Weight Loss; A Systematic Review and Meta-analysis","Nihal Ijaz I. Khan","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001037708.99179.76",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0048454","Emerging Therapies for Type 2 Diabetes","Anthony H. Stonehouse","2007","Current Drug Therapy","other","article","10.2174/157488507780619103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048455","Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation","James T. Lane","2011","Transplantation","other","article","10.1097/tp.0b013e3182347ea4","22067216",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048456","PO-02-074 COMPARATIVE OUTCOMES OF GLP1-RA AND SGLT2I ON AF RECURRENCE AFTER CATHETER ABLATION IN PATIENTS WITH TYPE 2 DIABETES: A POPULATION-BASED COHORT STUDY","Rebecca Hsieh","2025","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2025.03.556",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048457","The Use of Liraglutide Compared to Lifestyle Modifications in Weight Reduction in Lifestyle Clinic Patients: A Systematic Review","Awwatf S. R. Alshammari","2025","Scientia. Technology, science and society.","systematic_review","article","10.59324/stss.2025.2(3).01",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0048458","OP0011 EFFECT OF LIRAGLUTIDE ON BODY WEIGHT AND PAIN IN THE TREATMENT OF OVERWEIGHT AND KNEE OSTEOARTHRITIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY","Henrik Gudbergsen","2019","Annals of the Rheumatic Diseases","randomized_trial","article","10.1136/annrheumdis-2019-eular.1375",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0048459","#1704957 Tirzepatide Improves Health-Related Quality of Life in Participants With Obesity or Overweight and Type 2 Diabetes: Results From Phase 3 SURMOUNT-2 Trial","Theresa Hunter","2024","Endocrine Practice","other_trial","article","10.1016/j.eprac.2024.03.263",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048460","999-P: Liraglutide Treatment in Obese Diabetic Patients Modulates Gut Microbiota","Simona Moffa","2019","Diabetes","preclinical","article","10.2337/db19-999-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048461","Effects of Novel Dual GIP and GLP-1 Receptor Agonist, Tirzepatide, on Biomarkers of Non-Alcoholic Steatohepatitis in Patients with T2DM","Mark L. Hartman","2020",null,"other","article","10.2337/dc20-1234/suppl.12014322.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0048462","NASH – Ist die Zeit für eine medikamentöse Therapie gekommen?","Christian Labenz","2016","Zeitschrift für Gastroenterologie","randomized_trial","article","10.1055/s-0042-118409","27919110",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048463","Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial","Engelmann M.D.M","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/aayt-4b73",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0048464","Comment on Zhang et al. Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? Diabetes Care 2014;37:1338–1345","Jay Patrick Bae","2014","Diabetes Care","commentary","article","10.2337/dc14-1041","25147265",null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0048465","35-OR: Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 Inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy","Chintan V. Dave","2020","Diabetes","nonrandomized_study","article","10.2337/db20-35-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048466","Dual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence","Rahaf Wardeh","2023","Journal of Diabetes and Endocrine Practice","randomized_trial","article","10.1055/s-0043-1775966",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048467","Association of GLP-1 receptor agonist use with mortality and hospitalization in women with breast cancer and type 2 diabetes: A propensity score–matched cohort study.","Ahmad Habbas","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e12731",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048468","Glucagon Like Peptide-1 Receptor Agonists: Is It As Good as It Seems? A Systematic Review of Severe Adverse Effects","Pranjal Sharma","2024","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.4780856",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0048469","E-47 | 5 -Year Chronic Limb Ischemia Outcomes for Peripheral Artery Disease Patients with Type 2 Diabetes and Obesity on Semaglutide vs Liraglutide: A Propensity Score Matched Analysis","Divine Dele","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.105043",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0048470","300-OR: Beneficial Effect of the Combination Therapy of Cagrilintide, a Dual Amylin/Calcitonin Agonist, and Tirzepatide, a Dual GLP-1/GIP Agonist, on Body Weight Loss in Obese Rats","PILAR VALDECANTOS","2024","Diabetes","preclinical","article","10.2337/db24-300-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048471","120-OR: Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT-2","Naveed A. Sattar","2024","Diabetes","other_trial","article","10.2337/db24-120-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048472","Association of GLP1-RA with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: Biochemical and preclinical evidences.","Vincenzo Quagliariello","2025","Journal of Clinical Oncology","preclinical","article","10.1200/jco.2025.43.16_suppl.e24012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048473","Sustained Exendin-4 secretion through gene therapy targeting salivary glands in Zucker fa/fa rats and high fat diet fed mice.","Ilaria Dicembrini","2012","15th International & 14th European Congress of Endocrinology","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048474","86-LB: Real-World Impact of Oral Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE–Oral Semaglutide)","James J. Amamoo","2023","Diabetes","nonrandomized_study","article","10.2337/db23-86-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048475","Liraglutid in der Pharmakotherapie der Adipositas","Swantje Brede","2018","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/s-0038-1654052",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048476","Obesity Nephropathy: A Current Overview","Mounia Azizi","2024","Scholars Journal of Applied Medical Sciences","other","article","10.36347/sjams.2024.v12i10.011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048477","Effect of size on the in vitro / in vivo drug release and degradation of exenatide-loaded PLGA microspheres","Xia Lin","2018","Journal of Drug Delivery Science and Technology","preclinical","article","10.1016/j.jddst.2018.03.024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048478","The role of GLP-1 analogues in the treatment of obesity in women with Polycystic Ovary Syndrome","Martyna Koszyk","2025","Medical Science","other","article","10.54905/disssi.v29i156.e42ms3485",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048479","65-OR: Differences in the Use of Diabetes Medications with Cardiorenal Benefits between Rural and Urban America","Kyle G. Steiger","2023","Diabetes","other","article","10.2337/db23-65-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048480","GLUCAGON-LIKE PEPTIDE-1 PROTECTS AGAINST CARDIAC DYSFUNCTION AND EXTRACELLULAR MATRIX REMODELLING IN EXPERIMENTAL DIABETES","Mitchel Tate","2012","Heart","preclinical","article","10.1136/heartjnl-2012-303148a.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048481","COMPARISON OF THE EFFECTS OF SEMAGLUTIDE ON LIVER HISTOLOGY IN PATIENTS WITH NON-ALCOHOLICS STEATOHEPATITIS CIRRHOSIS BETWEEN MACHINE LEARNING MODEL ASSESSMENT AND PATHOLOGIST EVALUATION","Dimitrije Grbic","2023","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2023.10.286",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048482","Mo1466: ADVERSE EVENTS OF PANCREATITIS ASSOCIATION TO VARIOUS GLP-1 RECEPTOR AGONIST: ANALYSIS PER US FDA ADVERSE REPORTING SYSTEM","Akanksha Togra","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03538-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048483","SAT-473 Unilateral Adrenalectomy in a Patient With Overt Cushing Syndrome Caused by Primary Bilateral Macronodular Adrenal Hyperplasia: A Temporizing Measure","Kevin Liang","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.338",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048484","Abstract 4363968: Impact of Glucagon-Like Peptide-1 Receptor Agonists on 5-Year Risk of Major Amputation and Cardiovascular Outcomes in Diabetic Patients with Chronic Limb-Threatening Ischemia","Ashkan Yahyavi","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4363968",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048485","SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease","Pantelis A. Sarafidis","2019","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfz047","30820538",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048486","56. Semaglutide-Associated Depression After Remission: A Case Report","Chanel Zhan","2025","Journal of the Academy of Consultation-Liaison Psychiatry","case_report","article","10.1016/j.jaclp.2025.10.058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048487","Deficits and Disparities in Early Uptake of GLP-1 Receptor Agonists and SGLT2 Inhibitors among Medicare-insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure","SARA JANE CROMER","2022",null,"other","article","10.2337/figshare.21313254.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0048488","Liraglutide, a new diabetes treatment approved by NICE","Abd A. Tahrani","2010","Practical Diabetes","randomized_trial","article","10.1002/pdi.1526",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048489","META-ANALYSIS EVALUATING THE RISK OF ATRIAL FIBRILLATION WITH NEWER ANTIDIABETICS ACROSS THE CARDIOVASCULAR AND RENAL OUTCOME TRIALS","Dimitrios Patoulias","2021","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0000745428.72000.19",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0048490","ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE – EXECUTIVE SUMMARY","Adrian Liew","2020","Nephrology","other","article","10.1111/nep.13763","33111476",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048491","Glucose metabolism disorders in hidradenitis suppurativa: Current evidence and future directions","Wiktor Łapa","2025","Forum Dermatologicum","other","article","10.5603/fd.104845",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048492","EFFECT OF SEMAGLUTIDE ON EPICARDIAL ADIPOSE TISSUE VOLUME AND DENSITY IN TYPE 2 DIABETES: INSIGHTS FROM THE STOP RANDOMIZED TRIAL","Venkat Sanjay Manubolu","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/s0735-1097(24)03154-1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0048493","689-P: Association of Preoperative Glycemic Response to GLP-1 Receptor Agonists (GLP-1RA) and Outcomes of Bariatric Surgery","Daniel Boris Amusin","2021","Diabetes","nonrandomized_study","article","10.2337/db21-689-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048494","Treatment Patterns in Patients with Type 2 Diabetes Mellitus Treated with GLP-1 Receptor Agonists: Higher Adherence and Persistence with Dulaglutide Compared to Exenatide QW and Liraglutide","Carlos Elizondo Alatorre","2017","Diabetes Obesity and Metabolism","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048495","TCT-235 Impact of hyperglycemia on myocardium at risk and salvage in patients with ST elevation myocardial infarction and the association with exenatide treatment","Jacob Thomsen Lønborg","2013","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2013.08.970",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048496","Acute pancreatitis associated with saxagliptin treatment presented by metabolic acidosis","Ahmad Al-Ajaj","2016","Practical Diabetes","other_trial","article","10.1002/pdi.2026",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048497","Comparison of Low-Dose Liraglutide Use Versus other GLP-1 Receptor Agonists In Patients Without Type 2 Diabetes","Eric T Wittbrodt","2017","Value in Health","other","article","10.1016/j.jval.2017.08.952",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048498","IDegLira : une étude européenne d’efficacité-tolérance dans les conditions de la « vraie vie »","Pierre Gourdy","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.591",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048499","940-P: 14C-Tirzepatide ADME Studies in Rat and Monkey","Jennifer R Martin","2020","Diabetes","preclinical","article","10.2337/db20-940-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048500","930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program","Cyrus V Desouza","2020","Diabetes","randomized_trial","article","10.2337/db20-930-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048501","1414-P: Characteristics Associated with Sulfonylureas and Basal Insulin Use following Metformin in Older Adults","Kristen DeCarlo","2020","Diabetes","other","article","10.2337/db20-1414-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048502","Mo1246: IMPACT OF GLP-1 RECEPTOR AGONISTS ON GASTRIC CONTENT AND VOLUME: A POINT-OF-CARE ULTRASOUND (POCUS) PROSPECTIVE STUDY IN DIABETIC AND NON-DIABETIC PATIENTS","Enayat Shahidifar","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03359-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048503","Glucagon-Like Peptide-1 Receptor Agonists: An Overview of Perioperative Surgical Considerations","Hiley Cammock","2025","Current Surgery Reports","other","article","10.1007/s40137-025-00461-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048504","84-OR: siRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile","Hsiu‐Chiung Yang","2025","Diabetes","other_trial","article","10.2337/db25-84-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048505","1182-P: GLP-1 Agonist Therapy in Adolescents and Young Adults with Type 1 Diabetes","NITSAN SHACHAM","2024","Diabetes","randomized_trial","article","10.2337/db24-1182-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048506","Are professionals familiar with glucagonlike peptide-1 receptor agonists and their effects in oral surgery? A national survey","Samuel Macedo Costa","2025","Journal of the Brazilian College of Oral and Maxillofacial Surgery","nonrandomized_study","article","10.14436/2358-2782.11.2.e252521.oar",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048507","Efpeglenatide. Glucagon-like peptide 1 (GLP-1) receptor agonist, Treatment for type 2 diabetes","Jessica Reid","2019","Drugs of the Future","other","article","10.1358/dof.2019.44.6.2927591",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048508","Комбінована терапія пацієнтів із цукровим діабетом 2-го типу: міжнародні рекомендації і власний досвід","LIUBOV K. SOKOLOVA","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048509","Le Traitement par le Dulaglutide est Associé à une Baisse Inférieure du DFGe et à une Diminution Supérieure de l'Albuminurie dans le Diabète de Type 2 Associé à une Maladie Rénale Chronique de Stade 3-4 (AWARD-7)","Katherine R. Tuttle","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048510","Targeting Heart Disease in Cardiovascular–Kidney–Metabolic Syndrome: A Review of Novel Therapeutic Approaches with Prognostic and Quality-of-Life Impact","Adriana Florescu","2025","Romanian Journal of Military Medicine","narrative_review","article","10.55453/rjmm.2025.128.6.9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048511","Cardiometabolic Outcomes Associated with the use of Semaglutide After Heart Transplantation","ELENA M. DONALD","2024","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2024.02.1091",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048512","Development of a high-yield recombinant clone for the enhanced production of a long-acting Glucagon like peptide-1 analogue with improved biological efficacy","Praveen Kumar Reddy J","2024","Process Biochemistry","other","article","10.1016/j.procbio.2024.09.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048513","Characterization of tirzepatide-treated patients achieving HbA1c <5.7% in the SURPASS 1-4 trials","Julio Rosenstock","2024","Metabolism","other","article","10.1016/j.metabol.2024.155882",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048514","Targeting the intestinal L-cell for obesity and type 2","Nicolai Jacob Wewer","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048515","Herbal Remedies and Other Complementary and Alternative Treatments for Diabetes Mellitus","Hendrik Schatz","2009","Experimental and Clinical Endocrinology & Diabetes","commentary","article","10.1055/s-0028-1083823","19140092",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0048516","Quick Take Vol. 76","Scott R. Beach","2025",null,"other","article","10.64239/pi-qt76",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0048517","Prospects for Use of Incretin Mimetics in Metabolically Associated Fatty Liver Disease","Галина Владимировна Семикова","2026","Doctor Ru","nonrandomized_study","article","10.31550/1727-2378-2026-25-3-109-117",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048518","870-P: Combination Therapy of Icovamenib and Semaglutide Enhances Body Weight Loss and Glycemic Control While Increasing Lean Mass in a Type 2 Diabetes Animal Model","Priyanka Somanath","2025","Diabetes","preclinical","article","10.2337/db25-870-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048519","The roadmap to global access for GLP-1 receptor agonists: lessons from the HIV experience","Jennifer Manne-Goehler","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112792",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048520","Treatment completion rates with tirzepatide in adults with obesity: a systematic review and meta-analysis of randomized and real-world studies","Limna Mahaboob","2026","Romanian Medical Journal","systematic_review","article","10.37897/rmj.2026.2.12",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0048521","Abstract 12579: Empagliflozin and the Risk of Atherosclerotic Events and Hospitalization for Heart Failure: Updated Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","Phyo Than Htoo","2021","Circulation","nonrandomized_study","article","10.1161/circ.144.suppl_1.12579",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048522","Efficacy and Safety of ITCA 650, an Injection-Free GLP-1RA, in T2D Patients—A Pooled Analysis of Phase 3 Studies","Lise Kjems","2018","Diabetes","randomized_trial","article","10.2337/db18-1103-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048523","GLP-1 receptor agonists: effects on nonalcoholic fatty liver disease","Tomislav Bulum","2014","Diabetologia Croatica","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048524","Tailoring Weight Loss Before Hernia Surgery: Distinguishing Between Two Types of Obesity","John M. Findlay","2025","Journal of Abdominal Wall Surgery","other_trial","article","10.3389/jaws.2025.14322","40144576",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0048525","In vitro and in vivo characterization of a novel long-acting GLP-1 receptor agonist, exendin-4–Fc fusion protein","Lian Lu","2017","RSC Advances","preclinical","article","10.1039/c7ra10822b",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048526","Abstract #604 Obesity in a Paraplegic Multiple Sclerosis Patient Treated with Dulaglutide","Mohammad Umar U. Farooq","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47243-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048527","Erratum to: Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature","Carlo Bruno Giorda","2014","Endocrine","notice","article","10.1007/s12020-014-0240-z",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0048528","87-LB: Real-World Impact of Once-Weekly Injectable Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE-OW Injectable Semaglutide)","James J. Amamoo","2023","Diabetes","nonrandomized_study","article","10.2337/db23-87-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048529","Trockenes Auge bei Typ-2-Diabetikern: GLP-1-Agonisten scheinen einen protektiven Effekt zu haben","Björn O. Bachmann","2024","Kompass Ophthalmologie","nonrandomized_study","article","10.1159/000535820",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048530","Efficacy and Safety of Liraglutide vs. Placebo When Added to Basal Insulin Analogues in Subjects with Type 2 Diabetes (LIRA-ADD2BASAL): A Randomized, Placebo-Controlled Trial","James Conway","2014","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2014.07.017",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048531","PO416 LIRAGLUTIDE MONOTHERAPY PROVIDES SUPERIOR PPG CONTROL AFTER ALL THREE DAILY MEALS VS. SULPHONYLUREA MONOTHERAPY","Gregory R. Fulcher","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70710-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048532","Abstract 4371452: Viscous Soluble Fiber Supplement Improves Glycemic Control but not Novel Cardiometabolic Markers in Type 2 Diabetes; A Randomized Control Trial","Rachel Neff","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4371452",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0048533","0773 Does Glucagon Like peptide-1 Agonist, exendin-4 Affect Control of Breathing in Obesity Hypoventilation","Melanie Alexis Ruiz","2025","SLEEP","preclinical","article","10.1093/sleep/zsaf090.0773",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048534","Chronic kidney disease management in southeast England: a preliminary crosssectional report from the QICKD – Quality Improvement in Chronic Kidney Disease study","Simon de Lusignan","2009","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2009.034",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048535","Benefits of Glucagon-Like Peptide 1 Receptor Agonists in Kidney Transplant Recipients","Oscar A. Garcia Valencia","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024dtfe7jaj",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048536","S593 Risk of SIBO and Colorectal Cancer Among Non-Obese Patients With Irritable Bowel Syndrome Treated With GLP-1 Agonists","Sadaf Sadighian","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129832.69349.8c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048537","Abstract 4367751: Cardiovascular Outcomes of Oral Semaglutide in High Risk Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis","Haji Abdul Rehman Akhter","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4367751",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0048538","Dual and Triple-Action Peptides","Thinzar Min","2023",null,"other_trial","article","10.1201/9781003432807-41",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0048539","Abstract 4146844: Characterization of Novel Cardiovascular Medication Use by Clinical Specialty After Admission for Heart Failure or Coronary Artery Disease","Taufiq Salahuddin","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4146844",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048540","9232 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy","Mahmoud Nassar","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.672",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048541","The Effects of Exendin-4 on IRS-2 Expression and Phosphorylation in INS-1 Cells","Ji-Hyun Kim","2008","Korean Diabetes Journal","other","article","10.4093/kdj.2008.32.2.102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048542","FC 124: Real-World Use of Once-Weekly Semaglutide by Baseline Estimated Glomerular Filtration Rate—A Post-Hoc Analysis of Pooled Data From the Sure Studies (Canada, Denmark/Sweden, Switzerland and UK)","Gottfried Rudofsky","2022","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfac126.003",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048543","Role of glucose in regulating menstrual cycle","Irina Vasilieva","2024","Special journal of the Medical Academy and other Life Sciences","nonrandomized_study","article","10.58676/sjmas.v2i8.90",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048544","#1772053 Oral Semaglutide plus metformin vs. Myoinositol plus metformin in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial","SHARVIL S. GADVE","2024","Endocrine Practice","randomized_trial","article","10.1016/j.eprac.2024.03.387",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048545","IRWIS (IDegLira Real world Indian Study): A Real-World Observational Study For Use of IDegLira In Indian Patients","Kalyan Kumar Gangopadhyay","2020","Endocrine and Metabolic Science","nonrandomized_study","article","10.1016/j.endmts.2020.100057",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048546","Effects of treatment with liraglutide 3.0 mg in subjects with BMI < 35 and BMI ≥35 kg/m2: subgroup analysis of the SCALE Obesity and Prediabetes 56-week trial","Jens Aberle","2016","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0036-1580948",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048547","1310 Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight","Aristotle Leonhard","2025","SLEEP","other","article","10.1093/sleep/zsaf090.1310",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048548","1426-P: Utilization of Glucose-Lowering Drugs in Patients with T2DM and Established CVD in the U.S.","Michael Lee Ganz","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1426-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048549","Metabolic Dysfunction-Associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction: A Bidirectional Relationship with Clinical and Therapeutic Implications","Ana Rita Leite","2024","Endocrinology Insights","other","article","10.1159/000541442",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048550","INITIATION OF SGLT-2 INHIBITORS AND GLP1 RECEPTOR AGONISTS ACCORDING TO FRAILTY IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE- A DANISH NATIONWIDE COHORT STUDY","Mariam Elmegaard Malik","2023","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(23)02087-9",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048551","Étude SUSTAIN 5 : efficacité et tolérance du semaglutide une fois par semaine versus placebo en add-on à l’insuline basale seule ou en combinaison à la metformine chez des diabétiques de type 2","Patrice Darmon","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30418-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048552","THE IMPACT OF COVID-19 PANDEMIC ON THE CONSUMPTION OF ANTIDIABETIC DRUGS IN SERBIA: A JOINPOINT TREND ANALYSIS","Jelena Subaric Filimonovic","2025","Praxis medica","other","article","10.70949/pramed202504000f",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048553","Management of diabetes in patients with coronavirus disease 2019: A practical approach","MohsenS Eledrisi","2020","Libyan Journal of Medical Sciences","other","article","10.4103/ljms.ljms_34_20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048554","Treating, Masking, or Mismeasuring? A Measurement-First Reframing of GLP-1 Receptor Agonists Across the Eating-Disorder Spectrum","Maja Sosnowska","2026","Endocrines","other_trial","article","10.3390/endocrines7030048",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0048555","Automatic Detection of Osteoporosis in Electronic Consultation (eConsult) Service Using Natural Language Processing","Arya Rahgozar","2024","Healthcare informatics","other","article","10.1370/afm.22.s1.6029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0048556","Patients with type 2 diabetes on the maximum dose of insulin degludec/liraglutide (IDegLira) achieve glycaemic target: analyses from the DUAL programme","Luigi Meneghini","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048557","Adhärenz gegenüber Therapie mit GLP-1 Rezeptoragonisten bei Patienten mit Typ 2 Diabetes mellitus","Simon D. Johnston","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549603",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048558","126-OR: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks","Jiajun Zhao","2025","Diabetes","randomized_trial","article","10.2337/db25-126-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048559","MON-535 Glucagon-Like-Peptide-1 Receptor Agonists Are Effective in Patients with Cystic Fibrosis","Edward Mignone","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.902",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048560","S3824 From Weight Loss to Gut Loss: Semaglutide-Induced Ischemic Colitis","Kevin Chen","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001142756.12311.e8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048561","Quick Take Vol. 78","Kristin Raj","2025",null,"other","article","10.64239/pi-qt78",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0048562","Semaglutide improves non-alcoholic steatohepatitis: a 10-year retrospective study","Parth Shah","2023","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(23)02275-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048563","B15-07 Beyond Weight Loss: GLP-1 Agonists Improve Outcomes in COPD-OSA Overlap—A Trinetx Network Analysis","Navneet Gupta","2026","American Journal of Respiratory and Critical Care Medicine","randomized_trial","article","10.1093/ajrccm/aamag162.1752",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048564","Diabetes and bone. Focus on DPP-4 inhibitors","Alina Yu. Babenko","2015","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.21518/2079-701x-2015-17-108-113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048565","The lifetime healthcare costs of female obesity: modeling of England data and the costs of current pharmacotherapy","Adrian Hugh Heald","2024","Cardiovascular Endocrinology & Metabolism","other_trial","article","10.1097/xce.0000000000000310","39318473",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0048566","IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1A) USE IN PATIENTS WITH OBESITY AND HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF): A PROPENSITYMATCHED US POPULATION BASED COHORT STUDY","John H Malin","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(25)02142-4",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048567","OC-001 Efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion using endobarrier, 12 and 18 month data for the uk’s first nhs endobarrier service for diabesity","Marina Anderson","2017","Oral Presentations","randomized_trial","article","10.1136/gutjnl-2017-314472.1",null,null,"ISRCTN:ISRCTN00151053","S001522","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0048568","Practical aspects of the use of semaglutide (Ozempic®) in real clinical practice","Mikhail Borisovich Antsiferov","2021","Фарматека","other","article","10.18565/pharmateca.2021.4.16-23",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048569","Pharmacogenomics and efficacy outcome of therapy with glucagon-like peptide-1 receptor agonists in type 2 diabetes","Camille Beniga","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.ep283",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048570","364-P: Efficacy of IGlarLixi on Five-Year Risk of Diabetes-Related Complications: A Simulation Experiment","Hui Shao","2021","Diabetes","other_trial","article","10.2337/db21-364-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048571","S1990 Effect of Dual GLP-1/GIP and GLP-1 Agonists on Inflammatory Bowel Disease Activity Among Patients With Obesity","Jake Levine","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001135420.11072.6d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048572","L23 Effects of peripheral (co-)administration of liraglutide and ghrelin in the R6/2 mouse brain function","Ana Isabel Duarte","2016","Journal of Neurology Neurosurgery & Psychiatry","preclinical","article","10.1136/jnnp-2016-314597.278",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048573","767-P: No Effect of Food or Proton Pump Inhibitor on the Pharmacokinetics of TERN-601, an Oral Small Molecule GLP-1 Receptor Agonist","Cara Nelson","2025","Diabetes","randomized_trial","article","10.2337/db25-767-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048574","753-P: Eating Behavior in Adults with Type 2 Diabetes from a Phase 2 Study of Retatrutide","Chisom Kanu","2024","Diabetes","randomized_trial","article","10.2337/db24-753-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048575","Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland","Caparrotta Thomas M","2020",null,"nonrandomized_study","article","10.2337/figshare.12167802.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0048576","S594 Disparities in Colorectal Cancer Demographics, Mortality, and Survival: A SEER-Based Comparison of East Texas and the Rest of Texas (2017–2021)","Layth Alzubaidy","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129836.55082.bc",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048577","Abstract 17962: Lenalidomide Associated Coronary Thrombosis","Varshitha Kondapaneni","2023","Circulation","other","article","10.1161/circ.148.suppl_1.17962",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048578","CARDIOVASCULAR EFFICACY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS","Dimitrios Patoulias","2022","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0000837316.89812.46",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0048579","PDB11 Glycemic Outcomes Among Patients Receiving Exenatide BID or Liraglutide for Type 2 Diabetes in Clinical Practice: A Retrospective Analysis of the GE Centricity EMR Data","Jennie H. Best","2011","Value in Health","nonrandomized_study","article","10.1016/j.jval.2011.08.1314",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0048580","Managing high blood sugar (hyperglycemia) during pasireotide treatment: A plain language summary of the B2219 study","Susan Leanne Samson","2024","Future Rare Diseases","other_trial","article","10.2217/frd-2023-0025",null,null,"ClinicalTrials.gov:NCT02060383","S002111","openalex","TRUE","free_to_read","5","FALSE","article"],["R0048581","S1468 Semaglutide and Tirzepatide Have the Most Clinical Benefit Compared to Most Weight Loss Medications in Inflammatory Bowel Disease","Himaben Gohil","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001133332.90580.4f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048582","Pharmakologische Interventionen zum Management von Kindern und Jugendlichen mit Adipositas – ein Update eines Cochrane Reviews mit Metaanalysen","Gabriel Torbahn","2023","Adipositas - Ursachen Folgeerkrankungen Therapie","systematic_review","article","10.1055/s-0043-1771593",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0048583","Abstract 4369050: Eicosapentaenoic Acid (EPA) and GLP-1 Receptor Agonist Combination Enhanced Expression of Src Kinase and Related Pathways in Endothelial Cells during Inflammation","Samuel C. R. Sherratt","2025","Circulation","other","article","10.1161/circ.152.suppl_3.4369050",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048584","SGLT2 Inhibitors, Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists, and the Risk of Hypokalemia and Hyperkalemia in a National Cohort of Veterans with Type 2 Diabetes","Akhil Ramanujam Chakravartula","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024deq9zff3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048585","S3560 Hyperkinetic Biliary Dyskinesia Following Discontinuation of GLP-1 Receptor Agonist Therapy","Mary Andrews","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001141700.21998.40",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048586","902: BILIARY COMPLICATIONS OF GLP-1 AGONIST THERAPY: A 24-MONTH PROSPECTIVE STUDY OF GALLSTONE FORMATION IN TYPE 2 DIABETES","Ahmed Salem","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)01442-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048587","HSD121 Real-World Prescribing of Tirzepatide Labeled for Obesity in the United States","Patricia Rodríguez","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.03.2400",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0048588","Publication Alert: Survodutide in adults with obesity and metabolic dysfunction–associated steatotic liver disease: SYNCHRONIZE®-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial, Ph III Primary results","Lee M Kaplan","2026","Boehringer Ingelheim","randomized_trial","article","10.60915/boehringer-figshare.32993774.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0048589","Weight Regain After GLP-1 Receptor Agonist Discontinuation and the Role of Tapering and Maintenance Strategies: A Systematic Review","Nida Abraitytė","2026",null,"systematic_review","article","10.17605/osf.io/wpt7m",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0048590","POS1211 ASSESSING GOUT RISK ASSOCIATED WITH GLP-1 THERAPY IN OBESE PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY","Justin T. H. Lam","2025","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1016/j.ard.2025.06.561",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0048591","The glucagon-like peptide-1 analogue; exenatide","Norman R Waugh","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048592","TMAO: Trimethylamine-N-Oxide or Time to Minimize Intake of Animal Products?","Signe Abitz Winther","2020","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgaa428","32701146",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048593","2202-LB: Time to Reach Weight Reduction Thresholds with Tirzepatide vs. Semaglutide—A Post Hoc Analysis of SURMOUNT-5","Deborah Bade Horn","2025","Diabetes","randomized_trial","article","10.2337/db25-2202-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048594","Efficacy of Semaglutide vs. Dulaglutide across Baseline HbA1c in SUSTAIN 7","Richard E. Pratley","2018","Diabetes","other_trial","article","10.2337/db18-122-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048595","895-P: Proximal Intestinal Mucosal Ablation (PIMA) Eliminates the Need for Exogenous Insulin in Type 2 Diabetes—Initial STEAM-IE Trial Results","BENJAMIN NORTON","2025","Diabetes","other_trial","article","10.2337/db25-895-p",null,null,"ClinicalTrials.gov:NCT06655740","S003386","openalex","FALSE","paywalled","5","FALSE","article"],["R0048596","ASSESSING THE POTENTIAL OF DULAGLUTIDE IN DE-INTENSIFICATION OF BACKGROUND ORAL GLUCOSELOWERING DRUG (OGLD) AND INSULIN THERAPY IN MALAYSIANS WITH TYPE 2 DIABETES MELLITUS","Zanariah Binti Hussein","2024","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.039.s1.033",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048597","Targeting enteric release of therapeutic peptides by encapsulation in complex coacervated matrix microparticles by spray drying","Yuting Tang","2022","Journal of Drug Delivery Science and Technology","other","article","10.1016/j.jddst.2022.104063",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048598","SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1","Reshmi Srinath","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.108",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0048599","GLP-1 and its implications for neuroprotection in diabetes-associated neurodegenerative diseases","Christopher G. Ha","2016","Digital Commons @ UNT Health Science Center","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048600","286: MENTAL HEALTH OUTCOMES IN PEDIATRIC PATIENTS WITH OBESITY TAKING GLP-1 RAS: A POPULATION-BASED COHORT STUDY","Arleen M. Delgado","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)01132-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048601","Sa1951 CLINICAL PARAMETERS ASSOCIATED WITH SEMAGLUTIDE INTOLERANCE IN PATIENTS WITH DIABETES AND OBESITY","Wissam Ghusn","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01828-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048602","Liraglutide Stimulates Human β Cell Regeneration in Humanized Mice.","A. Ansarulla","2014","Transplantation","preclinical","article","10.1097/00007890-201407151-00952",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048603","Abstract #250: Liraglutide Acutely Suppresses Glucagon; Lipolysis and Ketogenesis in Type 1 Diabetes","Paresh Dandona","2017","Endocrine Practice","other","article","10.1016/s1530-891x(20)44370-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048604","Impacto dos Agonistas do Receptor de GLP-1 na Redução de Eventos Cardiovasculares: Uma Revisão Bibliográfica","Alanna Agatha Santos","2026","Editora Pasteur eBooks","other","article","10.59290/2506022060",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0048605","Dulaglutide: a once-weekly GLP-1 receptor agonist for type 2 diabetes","Gregory R. Fulcher","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048606","Assessing the association between GLP-1 receptor agonist use and diabetic retinopathy through the FDA adverse event reporting system","Tiezhou Wang","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/6egs-0964",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0048607","MP26-20 CHANGES IN 24-HOUR URINE PARAMETERS ASSOCIATED WITH SGLT-2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS","Ryan S. Hsi","2024","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001009408.66023.77.20",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048608","Aqueous Remote Loading of Peptides in PLGA Microspheres","Morgan B. Giles","2017","Deep Blue (University of Michigan)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0048609","LOWER RISK OF MACE AND ALL-CAUSE DEATH IN PATIENTS INITIATED ON SEMAGLUTIDE 2.4 MG IN ROUTINE CLINICAL CARE: RESULTS FROM THE SCORE STUDY (SEMAGLUTIDE EFFECTS ON CARDIOVASCULAR OUTCOMES IN PEOPLE WITH OVERWEIGHT OR OBESITY IN THE REAL WORLD)","Zhenxiang Zhao","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(25)00864-2",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048610","O27 Comparaison de l’efficacité du liraglutide, en substitution vs en association à un inhibiteur de la dipeptidyl peptidase-4 (iDPP-4) chez des patients diabétiques de type 2: résultats post-hoc de l’étude EVIDENCE®","Alfred Penfornis","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30027-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048611","Weight loss-induced improvements of endothelial function and cardiovascular risk factors are maintained with exercise, liraglutide or the combination","Julie Rehné Lundgren","2020","University of Southern Denmark Research Portal (University of Southern Denmark)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048612","Glucagon-Like Peptide-1 Receptor Agonists Decrease Platelet-Mediated Airway Inflammation","Dinah Foer","2021",null,"other","article","10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1410",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048613","S851 Effect of Glucagon-Like Peptide-1 Receptor Agonists on Quality of Bowel Preparation for Colonoscopy: A Matched Case-Control Study","Rabih Ghazi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032772.86958.ed",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048614","Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus","Alexander C. Martins","2024","Exploration of Drug Science","other","article","10.37349/eds.2024.00039",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048615","“Doctor, How Certain Are We That This Diabetes Medication Is Best for Me?”","LEONARD M. POGACH","2007","Annals of Internal Medicine","randomized_trial","article","10.7326/0003-4819-147-6-200709180-00181","17652707",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048616","985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8","Bernard Zinman","2019","Diabetes","randomized_trial","article","10.2337/db19-985-p",null,null,"ClinicalTrials.gov:NCT03021187","S002369","openalex","FALSE","paywalled","1","FALSE","article"],["R0048617","A case of euglycaemic ketoacidosis and concomitant acute pancreatitis in a diabetic patient treated with SGLT2i and GLP-1RA","Melpomeni Moustaki","2021","Endocrine Abstracts","case_report","article","10.1530/endoabs.73.aep823",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048618","PO3 Identification des facteurs prédictifs de la réponse au liraglutide dans le diabète de type 2 en utilisant une méthode d’analyse de partition récursive","J.P. Courrèges","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71699-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048619","Incretin-based therapies and pancreatic/biliary tract cancer","Diana Boj-Carceller","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.ep619",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048620","Symbiosis of cardiology and endocrinology","Andrey F. Verbovoy","2020","Meditsinskiy sovet = Medical Council","other","article","10.21518/2079-701x-2020-14-80-89",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048621","A51-26 Refractory Hypoglycemia With Acute Renal Failure in Setting of Tripeptide and Sulphonyl Urea Use","A Mittal","2026","American Journal of Respiratory and Critical Care Medicine","other","article","10.1093/ajrccm/aamag162.3166",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048622","CAN BIOMARKERS BE USED TO IDENTIFY INDIVIDUALS WITH THE GREATEST POTENTIAL BENEFIT FROM GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS? THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY","Arsalan Hamid","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01016-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048623","CARDIOVASCULAR OUTCOMES IN PATIENT WITH MINOCA TREATED WITH GLP-1 RA","Aravinthan Vignarajah","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)02392-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048624","2 ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)","Fasiha Kanwal","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)03985-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048625","Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit (Retracted article. See vol. 169, pg. 717, 2013)","Nazir Rampersaud","2012","UCL Discovery (University College London)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048626","Can GLP-1 Agonists Elevate Lithium Levels?","Paul A. Zarkowski","2026",null,"other","article","10.64239/pi-qt8303",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0048627","Sphenocentrum jollyanum furanoditerpenes activates Glucagon-like peptide 1 receptor (GLP-1R): a computational evaluation","Julianah Ore Abiola","2025","ABUAD International  Journal of Natural and Applied Sciences","other","article","10.53982/aijnas.2024.0403.03-j",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048628","Improving Upper GI Endoscopy Safety and Success in Patients on GLP-1 Agonists","R George","2026","Endoscopy","nonrandomized_study","article","10.1055/s-0046-1822114",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048629","Effect of Semaglutide on Hemoglobin A1c and Body Weight Change by CKD Stage: Post Hoc Analysis from the FLOW Trial","Allon N. Friedman","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2025fr6fq33q",null,null,"ClinicalTrials.gov:NCT03819153","S000953","openalex","FALSE","paywalled","1","FALSE","article"],["R0048630","The link between physical fitness and the reward system in schizophrenia","Lara Hamzehpour","2022","Neuroscience Applied","other","article","10.1016/j.nsa.2022.100098",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048631","The Expanding Role of GLP‐1RAs Beyond Diabetes: Cardiovascular and Renal Protection—A Narrative Review","Muhammad Ahsan","2026","Comprehensive physiology","narrative_review","article","10.1002/cph4.70246",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0048632","ESC CVD Prevention Guidelines 2021: improvements, controversies, and opportunities","Charalambos A. Antoniades","2021","Cardiovascular Research","other","article","10.1093/cvr/cvab371","35037062",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048633","The obese uremic patient: a newcomer in the nephrology clinic?","Sophia M Rössner","2013","Nephrology Dialysis Transplantation","other_trial","article","10.1093/ndt/gft348","24049106",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048634","Reply: Glucagon-like peptide-1 mediates cardioprotection by remote ischaemic conditioning","Marina V. Basalay","2016","Cardiovascular Research","preclinical","article","10.1093/cvr/cvw238","28069700",null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0048635","92 - Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter-2 Inhibitor: A Posthoc Analysis of SUSTAIN 9","Vincent C. Woo","2019","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2019.07.101",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048636","Sensory alien hand syndrome: case report and review of the literature","Hakan Ay","1998","Journal of Neurology Neurosurgery & Psychiatry","case_report","article","10.1136/jnnp.65.3.366","9728952",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048637","CAN GLP-1 AGONISTS PROTECT AGAINST ANTHRACYCLINE-MEDIATED CARDIOTOXICITY?","Sunnia T. Chen","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)03043-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048638","Chapter 13: Glucagon-Like Peptide-1 Receptor Agonists","Jennifer M. Trujillo","2022","American Diabetes Association eBooks","other","article","10.2337/9781580408172.ch13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0048639","S3424 A Case of Benign Spontaneous Pneumomediastinum","Yende Grell","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001043064.48053.66",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048640","S132 Evaluating the Severity of Acute Pancreatitis in Type 2 Diabetes Patients Treated With Incretin-Based Therapies vs Insulin: A Multicenter Retrospective Analysis Using APACHE II","Priya Kumari Maheshwari","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001126988.33169.a2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048641","748-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe","ALICE Y.Y. CHENG","2021","Diabetes","randomized_trial","article","10.2337/db21-748-p",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048642","Additional file 1: Figure S1. of The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia","Fangzhe Chen","2016","Figshare","other","article","10.6084/m9.figshare.c.3644831_d1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0048643","Greater adherence and persistence with dulaglutide compared to semaglutide at 6- and 12-months follow-up in U.S. real-world data","Reema Mody","2022","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0042-1746330",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048644","Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses","Buse John","2021","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2021.09.050",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048645","An assessment of factors contributing to the decline in risk of stroke complicating type 2 diabetes: The Fremantle Diabetes Study","Timothy M. E. Davis","2023","Diabetes Obesity and Metabolism","nonrandomized_study","article","10.1111/dom.15391","38073429",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048646","1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205","Richard E. Pratley","2019","Diabetes","other","article","10.2337/db19-1001-p",null,null,"ClinicalTrials.gov:NCT02075281","S000743","openalex","FALSE","paywalled","5","FALSE","article"],["R0048647","Pharmacovigilance in the Real World","William Donald Leslie","2018","Annals of Internal Medicine","randomized_trial","article","10.7326/m18-3550","30597488",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048648","Sa1097 A RETROSPECTIVE ANALYSIS OF GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONISTS ON BOWEL PREPARATION EFFICACY IN COLONOSCOPIES","Anas Zaher","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)01249-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048649","Triple Therapy with Liraglutide + Metformin + Insulin Detemir Improves Glycemic Control with No Weight Gain and Low Rates of Hypoglycemia","Maria Vinall","2011","MD Conference Express","other","article","10.1177/155989771111010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0048650","Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial","Robert John Mentz","2017","Circulation","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0048651","Investigating Semaglutide in Adult Patients on Body Weight Compared with Other GLP-1 Drugs","Shroug Farrash","2023","International Journal Of Pharmaceutical Research And Allied Sciences","other","article","10.51847/j9zsdr5dno",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048652","Karway et al. respond to “Enhancing uptake of antidiabetic drugs to reduce cardiometabolic risk and dementia burden”","George K. Karway","2025","Alzheimer s & Dementia","other","article","10.1002/alz.70615","40891393",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048653","ALBIGLUTIDE AND ATRIAL FIBRILLATION/ATRIAL FLUTTER IN PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE - A SECONDARY ANALYSIS OF THE HARMONY OUTCOMES TRIAL","Konstantin Alexander Krychtiuk","2024","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(24)03878-6",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0048654","Abstract 4370404: Glucagon-Like Peptide-1 Receptor Agonists and Anthracycline Therapy in Breast Cancer: A Real-World Propensity-Matched Analysis","Mohammed Najdat Seijari","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4370404",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048655","Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance","Lyudmila Alexandrovna Ruyatkina","2016","Diabetes Mellitus","randomized_trial","article","10.14341/7875",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048656","The GLP-1 analogue, LY307161, potently lowers post prandial blood glucose in subjects with type 2 diabetes","StevenJ. Pascoe","2000","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(00)81597-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048657","Sa2085 COMPARATIVE BIOCHEMICAL RESPONSE AND SIDE EFFECTS OF RESMETIROM VERSUS GLP-1 RA IN PATIENTS WITH MASLD AND OBESITY: A REAL-WORLD DATA STUDY","Hussam Almasri","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)03620-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048658","Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE™ Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial","Matthias Blüher","2015","Experimental and Clinical Endocrinology & Diabetes","randomized_trial","article","10.1055/s-0035-1549086",null,null,"ClinicalTrials.gov:NCT01272219","S000492","openalex","FALSE","paywalled","1","FALSE","article"],["R0048659","Comparison of National and Global Utilization Trends of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RA) in CKD","Iqra Nawaz","2023","Journal of the American Society of Nephrology","other","article","10.1681/asn.20233411s1378a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048660","CO65 Real-world Impact of Semaglutide, Liraglutide, and Tirzepatide on Weight Loss and Cardiometabolic Lab Measures: A Look into Drug Persistence and Reasons for Discontinuation (r/dc)","Katherine A. Cappell","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.150",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0048661","The role of dopamine and food reward in bulimia nervosa","Daniëlle Jongen","2022","Neuroscience Applied","other","article","10.1016/j.nsa.2022.100097",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048662","Effect of Exenatide on Apoptosis, Autophagy, and Necroptosis in the Hippocampus of STZ-Induced Diabetic Female Rats: An Immunohistochemical Study","Eman Mohammed Elsaeed","2022","Egyptian Academic Journal of Biological Sciences. D, Histology and Histochemistry","preclinical","article","10.21608/eajbsd.2022.214866",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048663","1685-P: Exploring Semaglutide's Effect on the ASCVD-Related Proteomic Signature and Their Prediction of MACE in SELECT","Maria Dermit","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1685-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048664","The protective effect of Liraglutide on retinal Müller cell apoptosis induced by high glucose through activating p-ERK / Nrf2 / Trx pathway","Xiang Shan Ren","2018","Investigative Ophthalmology & Visual Science","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048665","Semaglutide Reduces Body Weight vs. Dulaglutide across Baseline BMI Subgroups in SUSTAIN 7","Adie Viljoen","2018","Diabetes","other_trial","article","10.2337/db18-1083-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048666","ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG IN ADOLESCENTS WITH OVERWEIGHT OR OBESITY","Ali Kabir","2023","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2023.10.338",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048667","Glucagon-Like Peptide-1 Receptor Agonists and Primary Malignant Brain Tumor Risk in Type 2 Diabetes","Jordina Rincón-Torroella","2025","Brain and Spine","other","article","10.1016/j.bas.2025.105070",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048668","Su1088: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA): IMPACT ON OUTPATIENT COLONOSCOPY PROCEDURE QUALITY","Frederick B. Peng","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02518-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048669","Real-world evidence of the effect of adjunctive semaglutide on weight change, glycaemic control, and metabolic dysfunction associated steatotic liver disease in people with type 1 diabetes","Jonathan Mertens","2025","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.112.001",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048670","Reduced Risk for Cardiovascular Events with Albiglutide in T2DM","Gregory Michael Weiss","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048671","Le semaglutide améliore la glycémie post-prandiale, le métabolisme lipidique et retarde la vidange gastrique de la 1 re heure chez les obèses","Bruno L Vergès","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30420-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048672","An Indirect Comparison of Iwqol-Lite total Score Change In Subjects treated with Canagliflozin, Exenatide qw, Sitagliptin, or Pioglitazone In dual Therapy With Background Metformin","S. Traina","2015","Value in Health","other","article","10.1016/j.jval.2015.03.392",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048673","TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL","Mikhail Kosiborod","2021","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(21)02982-x",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0048674","FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US","Meredith M. Hoog","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.857",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048675","Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry","McCullen M.K","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/5bzv-n840",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0048676","55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4","Richard E. Pratley","2019","Diabetes","randomized_trial","article","10.2337/db19-55-or",null,null,"ClinicalTrials.gov:NCT02863419","S000133","openalex","FALSE","paywalled","1","FALSE","article"],["R0048677","GLP-1 Receptor Agonists in Diabetic Nephropathy: Clinical Evidence, Molecular Mechanisms, and Future Perspectives","Gerry George Mathew","2026","Turkish Journal of Nephrology","other","article","10.5152/turkjnephrol.2026.251208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048678","RWD150 Tirzepatide and Weight Reduction Among Individuals without Evidence of Type 2 Diabetes: Descriptive Results from Optum’s De-Identified Market Clarity Data","Theresa M. Hunter","2024","Value in Health","other","article","10.1016/j.jval.2024.03.1804",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048679","ELIGIBILITY AND UTILIZATION OF SEMAGLUTIDE IN PATIENTS WHO MEET SELECT STUDY CRITERIA: AN ANALYSIS OF CURRENT PRACTICE WITHIN A LARGE HEALTHCARE SYSTEM","John W. Ostrominski","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01047-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048680","Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial","Nick Finer","2009","UCL Discovery (University College London)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","conference-paper"],["R0048681","Quick Take Vol. 78","Kristin Raj","2025",null,"other","article","10.64239/pi-nl-qt78",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0048682","Innovation and Improvement in the Treatment of Obesity and Diabetes","Steven W. Ryder","2007","Clinical Pharmacology & Therapeutics","other_trial","article","10.1038/sj.clpt.6100189","17438532",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048683","2181-LB: Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis Responsiveness in Diet-Induced Obesity Model","Xun Sun","2025","Diabetes","preclinical","article","10.2337/db25-2181-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048684","S702 The Impact of Glycemic Control on the Quality of Bowel Preparation in Patients Undergoing Elective Colonoscopy: A Retrospective Multi-Center Study","Yash R. Shah","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000952448.52036.30",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048685","Repurposed Agents in Alzheimer’s Disease Drug Development","Clive G. Ballard","2022","Cambridge University Press eBooks","other","article","10.1017/9781108975759.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0048686","S3696 Ischemic Colitis in the Setting of Tirzepatide-Induced Constipation: A Potential Adverse Effect","Shambhavi Mishra","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001142244.19922.1a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048687","Glucagon-Like Peptide-1","Joel P. Giblett","2019","JACC: Journal of the American College of Cardiology","nonrandomized_study","article","10.25407/jacbts.c.4536203.v1",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0048688","Recommendations for Titration and Administration of Oral Semaglutide for the Treatment of Type 2 Diabetes during Ramadan","Mohamed Hassanein","2022","Dubai Diabetes and Endocrinology Journal","other","article","10.1159/000527475",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048689","GLP-1 Receptor Agonists, Glomerular Filtration Rates, and Survival in Type 2 Diabetes","Samuel Edward Weinberg","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2025cxg82ram",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048690","Reduction of Angiotensin II Induced Hypertension and Cardiac Fibrosis with GLP-1 Receptor Agonist and DPP-4 Inhibitor via Decreasing NADPH Oxidase Expression","Trenton Banks","2020","Mercer University Libraries (Mercer University)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048691","Quick Take Vol. 83","Scott R. Beach","2026",null,"other_trial","article","10.64239/pi-qt83",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","report"],["R0048692","958-P: Once-Weekly Exenatide Effects on EGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis","Lindsay E. Clegg","2020","Diabetes","other_trial","article","10.2337/db20-958-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048693","The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future","Juris Jendrik Meier","2020","Diabetes Mellitus","other","article","10.14341/dm11493",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048694","S893 The Impact of GLP-1 Receptor Agonists on Retained Gastric Contents, Aborted Procedures, and Aspiration During Esophagogastroduodenoscopy: A Systematic Review and Meta-Analysis","Eleazar Enrique. Montalvan-Sanchez","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001032940.79412.4b",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0048695","Comparative Effects of Tirzepatide and Other Glucose-Lowering Therapies on Fasting Lipid Parameters: A Random-Effects Network Meta-analysis of Randomized Controlled Trials","Omer Farooq Mohammed","2026","Journal of clinical lipidology","systematic_review","article","10.1016/j.jacl.2026.05.023",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0048696","P2857Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial","Jochen Seufert","2018","European Heart Journal","other_trial","article","10.1093/eurheartj/ehy565.p2857",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048697","S518 Frequency of GLP-1 Analog Use in Diabetic Patients With Delayed GES and Their Demographic Profile","M Ammar Kalas","2021","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000774548.78766.83",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048698","MON-LB055 A Single Center Experience of Multiple Endocrine Neoplasia Type 1 (MEN1) vs Sporadic Insulinoma: What Can We Learn and Where Are We Going?","Miho Itatani","2019","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/js.2019-mon-lb055",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048699","DUAL GIP-GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES GLUCOSE CONTROL AND INSULIN SENSITIVITY IN MIXED MEAL TESTS IN PEOPLE WITH TYPE 2 DIABETES","Andrea Mari","2022","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0042-1746270",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048700","GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment","Justin W. L. Wan","2024","Gastroenterology Insights","other","article","10.3390/gastroent15010014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048701","30-PUB: Comparison of Effectiveness of Canagliflozin 300mg plus Gliptin vs. Oral Semaglutide plus SGLT2i on Cardiorenal Markers in T2DM Patients","Vishal Kumar Gupta","2025","Diabetes","nonrandomized_study","article","10.2337/db25-30-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048702","Obesity and GI Diseases: A Major Problem Weighing on Our Guts and Minds","Jasmohan Singh Bajaj","2024","The American Journal of Gastroenterology","other","article","10.14309/ajg.0000000000002855","38832707",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048703","Le medicament du mois. Combinaison en proportion fixe insuline basale degludec-liraglutide (Xultophy(R)).","André Jacques Scheen","2018","RMLG. Revue médicale de Liège","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048704","Weighing the Risks and Benefits of Microdosing Tirzepatide Vials","Anne M. Komé","2026","Diabetes Obesity and Cardiometabolic CARE","other","article","10.2337/doc26-0083",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048705","Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.","Millie D. Long","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/vnc4-px11",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0048706","Association of glucagon-like peptide 1 receptor agonists with cancer risk in obesity adults with and without diabetes: A target trial emulation study.","Hao Dai","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.10508",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0048707","Porous Silicon Microparticles Enable Sustained Release of GLP‐1R Agonist Peptides for the Treatment of Type 2 Diabetes","Parham Sahandi Zangabad","2024","Advanced Therapeutics","preclinical","article","10.1002/adtp.202400136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048708","GLP‐1 AGONIST LIRAGLUTIDE ACTIVATES METABOLIC‐ AND CARDIOVASCULAR‐RELATED HYPOTHALAMIC NEURONS AND AUGMENTS REFLEX SYMPATHETIC ACTIVITY IN THE RAT","Stacia Jayce Lindsey","2020","The FASEB Journal","preclinical","article","10.1096/fasebj.2020.34.s1.05362",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048709","Clinical Guidelines from the 2025 International Symposium on Breast Diseases of Inland São Paulo: GLP-1 Inhibitors, Risk-Reducing Surgery in BRCA Carriers, Liquid Biopsy, and DCIS Treatment De-escalation","Eduardo Carvalho Pessoa","2026","Mastology","other","article","10.29289/2594539420250028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048710","Reduction of HbA1c with dulaglutide in type 2 diabetes (T2D) patients negative, low positive or high positive for GAD antibodies (GADA): a post hoc analysis of AWARD -2, -4 and -5","Paolo Pozzilli","2018","Diabetologie und Stoffwechsel","other","article","10.1055/s-0038-1641908",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0048711","GLP1 agonist based therapy has modest effect on weight and glycaemic control among UAE patients with diabetes: analysis of data on 3725 patients","Raya A. Almazrouei","2015","Endocrine Abstracts","other","article","10.1530/endoabs.38.p260",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048712","Additional file 4: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Ling Li","2016","Figshare","systematic_review","article","10.6084/m9.figshare.4430798.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0048713","836-P: Glucagon-Like Peptide 1 Receptor Agonists Use during Ramadan Fasting in People with Type 1 Diabetes—Observational Study","Etab Taghadom","2025","Diabetes","other","article","10.2337/db25-836-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048714","Effects of liraglutide on glucose-lipid metabolism in ApoE-/-mice with RNAi-mediated adiponectin gene inhibition","Zhihong Zhang","2010","Zhonghua neifenmi daixie zazhi","preclinical","article","10.3760/cma.j.issn.1000-6699.2010.10.012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048715","A Functional Inhibitory Role of Habenular Glucagon-Like Peptide-1 (GLP-1) in Forebrain Reward Signaling","Max R. Johnson","2021","Journal of Behavioral and Brain Science","preclinical","article","10.4236/jbbs.2021.119016",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048716","944-P: HbA1c Change Is Associated with Retinopathy Outcomes during GLP-1RA CVOT Follow-Up","Angelyn Bethel","2020","Diabetes","other_trial","article","10.2337/db20-944-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048717","1745-P: Long-Term Safety and Efficacy of Once-Weekly Dosage of 2.4 mg Semaglutide for Weight Loss in Patients with and without Diabetes—An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials","MIAN MUHAMMAD SALMAN ASLAM","2025","Diabetes","systematic_review","article","10.2337/db25-1745-p",null,null,"PROSPERO:CRD42024532538",null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0048718","782-P: Once-Weekly Semaglutide vs. Placebo for the Treatment of Type 2 Diabetes and Chronic Kidney Disease in Denmark—A Long-Term Cost-Effectiveness Analysis Based on Flow","Peter R Rossing","2025","Diabetes","nonrandomized_study","article","10.2337/db25-782-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048719","424 DOMINANT-NEGATIVE GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTOR (GIPRdn)TRANSGENIC PIGS — A LARGE ANIMAL MODEL FOR TYPE 2 DIABETES MELLITUS","Christiane Fehlings","2009","Reproduction Fertility and Development","other","article","10.1071/rdv22n1ab424",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048720","Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study","Ronan Roussel","2018","Diabetes","randomized_trial","article","10.2337/db18-1029-p",null,null,"ClinicalTrials.gov:NCT02738151","S002664","openalex","FALSE","paywalled","1","FALSE","article"],["R0048721","Pharmacological Modulation and Integrative Therapeutic Strategies in the Management of Type 2 Diabetes Mellitus: A Comprehensive Review","C. E. Ezerioha","2025","Asian Journal of Biology","narrative_review","article","10.9734/ajob/2025/v21i12593",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048722","1264 Enhancing Medication Adherence and Therapy Optimization: The Impact of Pharmacist-Driven Medication Assessment of Injectable Tirzepatide","A. Drobny","2025","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2025.102728",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048723","Dose Equivalence across GLP-1 Receptor Agonists: A Dose Response Meta-Analysis and Digital Tool Development","Ellice Caldwell-Dunn","2026","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.6509069",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0048724","Obstructive sleep apnea pharmacology","Bernie Young Sunwoo","2026","Canadian Journal of Respiratory Critical Care and Sleep Medicine","nonrandomized_study","article","10.1080/24745332.2026.2695024",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048725","640 SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients Undergoing Elective Coronary Artery Bypass Grafting","Yang Guan","2025","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znaf128.109",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048726","Exendin-4 inhibits the survival and invasiveness of two colorectal cancer cell lines via suppressing GS3Kβ/β-catenin/NF-κB axis through activating SIRT1","Attalla Farag El-kott","2021","Biocell","other","article","10.32604/biocell.2021.015464",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048727","PP.19.08","Tomislav Bulum","2015","Journal of Hypertension","other","article","10.1097/01.hjh.0000468287.70331.73",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048728","Controversies in Journal Publications","Ashok Kumar Das","2025","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_6_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048729","Exendin-4 dose not evoke pancreatitis or pancreatitis-associated histopathological and genetic changes in high-fat diet induced diabetic mice","Yi Qiong Sun","2018","Biomedical Research - India","preclinical","article","10.4066/biomedicalresearch.29-17-2708",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048730","Recovery of insulin/IGF‐1/GLP‐1 signaling protects the brain against cardiometabolic and neurodegenerative diseases","Ana Isabel Duarte","2024","Alzheimer s & Dementia","preclinical","article","10.1002/alz.89823",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048731","IDF21-0204 Patient-Reported Outcomes in Patients with T2D and increased CV risk on Tirzepatide or Insulin Glargine (SURPASS-4)","K. Boye","2022","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2022.109496",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048732","Sa1836 SHOULD GLP-1 THERAPY BE STOPPED AFTER DEVELOPING ACUTE PANCREATITIS? RECURRENCE OUTCOMES FROM A REAL-WORLD COHORT","Tasneem Jamal Al-Din","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)05063-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048733","Editor's Highlights — September 2024","Lajos V. Kemény","2024","International Journal of Dermatology","other","article","10.1111/ijd.17423","39097931",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048734","Therapeutic potential of a bi‐functional GLP‐1/Glibenclamide targeted to the pancreatic β‐cell","Nathaniel J. Hart","2013","The FASEB Journal","other","article","10.1096/fasebj.27.1_supplement.729.11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048735","Clinical Outcomes of Patients with MGUS and Diabetes/Obesity on GLP-1 Receptor Agonists: A Real-World, Propensity-Matched Study","Ioannis Ntanasis‐Stathopoulos","2025","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(25)03827-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048736","Comparative Real World Effectiveness of Liraglutide versus Sitagliptin in Patients with Type 2 Diabetes as an Add-On to Metformin Monotherapy in the United States","A.S. Chitnis","2014","Internal Medicine Open Access","nonrandomized_study","article","10.4172/2165-8048.s6-007",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048737","An open label, single site, 12 month, phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease","Icíar Avilés-Olmos","2012","UCL Discovery (University College London)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","conference-paper"],["R0048738","Sa1536: MORTALITY REDUCTION IN PATIENTS WITH OBESITY AND MASLD CIRRHOSIS USING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS): INSIGHTS FROM A GLOBAL RETROSPECTIVE STUDY","Varun Aitharaju","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04756-0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048739","Effects of MEDI0382 on Pancreatic and Incretin Hormones","Victoria Parker","2018","Diabetes","other","article","10.2337/db18-79-or",null,null,"ClinicalTrials.gov:NCT02548585","S000451","openalex","FALSE","paywalled","5","FALSE","article"],["R0048740","S1935 Acute Pancreatitis Due to Semaglutide: Another Medication to Worry About!","Arnold Gan","2023","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000957380.59667.f3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048741","SAT588 Cushing’s Syndrome Due To Ectopic ACTH Secretion From Ovarian Teratomas","Yu Mi Kang","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.1321",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048742","The long-acting GLP-1-receptor agonist albiglutide for the treatment of type 2 diabetes: a time course analysis of gastrointestinal adverse events in patients receiving concomitant background metformin","F. Yang J. Rosenstock","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33271-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048743","BPS2025 - The first GIP/GLP-1 dual agonist, tirzepatide, in high-fat diet- and L-NAME-induced heart failure with preserved ejection fraction (HFpEF) in a mouse model","Jeong Eun Park","2025","Biophysical Journal","preclinical","article","10.1016/j.bpj.2024.11.3196",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048744","1596-P: Evaluating Reports of Pancreatic Malignancy and Liraglutide: A Pharmacovigilance Study of the FDA Adverse Event Reporting System","CARLOS A. ALVAREZ","2020","Diabetes","randomized_trial","article","10.2337/db20-1596-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048745","56-OR: Liraglutide for Perioperative Management of Hyperglycaemia in Cardiac Surgery Patients (GLOBE): A Multicentre, Prospective, Superiority Randomised Trial","Abraham H. Hulst","2019","Diabetes","randomized_trial","article","10.2337/db19-56-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048746","Therapeutic Profile of Patients with Diabetes Treated at the First Level of Health Care","Gladys Mabel Maidana","2020","Asclepius Medical Research and Reviews","other","article","10.33309/2639-8605.030201",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048747","The efficacy of dulaglutide in the treatment of patients with type 2 diabetes and NAFLD in real clinical practice","Olga Nechaeva","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep491",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048748","Respuesta a Crespo et al., «Manejo preoperatorio de pacientes en tratamiento con análogos GLP-1: ¿suspender o individualizar?»","J.A. Velarde-Ruiz Velasco","2025","Revista de Gastroenterología de México","other","article","10.1016/j.rgmx.2024.12.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048749","Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2","Juan M. Maldonado","2024","Diabetologie und Stoffwechsel","other","article","10.1055/s-0044-1785390",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048750","Mo1957 STEEP INCREASE IN USAGE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN NON-DIABETIC AND NON-OBESE INDIVIDUALS IN THE UNITED STATES","Yee Hui Yeo","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)03192-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048751","Die HbA1c-Zielwerte werden mit Liraglutid bei Patienten mit Typ 2 Diabetes und einem Anfangs-HbA1c< 8,0% öfter erreicht als mit Sitagliptin oder mit Exenatid","King Ab","2013","Diabetologie und Stoffwechsel","other","article","10.1055/s-0033-1341813",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048752","1274 Infliximab for decompensated diabetes following immune checkpoint inhibitor therapy","Robert J. Weber","2023","Regular and Young Investigator Award Abstracts","randomized_trial","article","10.1136/jitc-2023-sitc2023.1274",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0048753","THE PROTECTIVE ROLE OF INCRETINS IN THE PREVENTION OF CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PERIMENOPAUSE","В. В. Смирнов","2023","Медицина: теория и практика","nonrandomized_study","article","10.56871/mtp.2023.25.14.005",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048754","247The glucagon-like peptide 1 agonist liraglutide increases heart rate in heart failure patients","Rasmus Stilling Tougaard","2017","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehx501.247",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048755","Liraglutide for overweight and obesity","Gautam Chandra Das","2021","Practical Diabetes","randomized_trial","article","10.1002/pdi.2313",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048756","Potentially modifiable factors to reduce severity of COVID-19 in type 2 diabetes","Nikhil V. Dhurandhar","2020","Nutrition and Diabetes","preclinical","article","10.1038/s41387-020-00133-0","32788586",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048757","618-P: Real-World Patient Perceptions of GLP-1 RAs and SGLT-2is with Cardiorenal Benefits","Natalie Lambert","2022","Diabetes","nonrandomized_study","article","10.2337/db22-618-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048758","Prediabetes: Risk factors instead of complaints?","И А Барсуков","2025","FOCUS Endocrinology","other","article","10.62751/2713-0177-2025-6-1-07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048759","PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides","Alice  Y. Yau","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.831",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048760","Semaglutide Consistently Reduces both Fasting and Postprandial Glucose Levels Across Sustain 1–5 Clinical Trials","Vanita R. Aroda","2017","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2017.08.136",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048761","Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial","Matthew James Armstrong","2013","Hepatology","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0048762","26-A-20501-ACC GLP-1RA USE IN OSA PATIENTS IS ASSOCIATED WITH A LOWER INCIDENCE OF ATRIAL FIBRILLATION INDEPENDENT OF OBESITY","Yara Menassa","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.233",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048763","SUSTAIN ‐6: cardiovascular safety of a once‐weekly GLP ‐1 receptor agonist","Ruth L. M. Cordiner","2016","Practical Diabetes","other","article","10.1002/pdi.2051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048764","SGLT2 inhibitors and outcomes in pancreatic cancer: A large-scale propensity-matched cohort study.","Chidiebube J. Ugwu","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.2_suppl.687",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0048765","S26 Risk of Biliary Diseases in Patients Treated With GLP-1 vs GLP-1/GI Receptor Agonists: A Real-World Comparative Analysis of Semaglutide and Tirzepatide","Medora Doris Rodrigues","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001126564.70811.7c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048766","Abstract 452: A Unique Acylcarnitine Profile is Independently Associated with Diabetic Heart Failure and Associates with Adverse Clinical Outcomes: Insights from the FIGHT Trial","Joseph B Lerman","2019","Circulation Research","other_trial","article","10.1161/res.125.suppl_1.452",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0048767","Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)","Mary Angelyn Bethel","2018","Diabetes","randomized_trial","article","10.2337/db18-522-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048768","EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES","Alla P. Tarasova","2017","Open Access Repository (Belgorod State National Research University)","other","article","10.18413/2313-8971-2017-3-4-13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048769","1.2 Efficacy and Safety of Dulaglutide versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1) (66-OR)","Carol Wysham","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0027-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048770","Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses","Buse J.B","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/b2w6-2e46",null,null,"ClinicalTrials.gov:NCT02607865; ClinicalTrials.gov:NCT02863419; ClinicalTrials.gov:NCT02827708; ClinicalTrials.gov:NCT02849080; ClinicalTrials.gov:NCT03021187","S000133; S001153; S002025; S002267; S002369","openalex","TRUE","paywalled","5","FALSE","article"],["R0048771","Effects of medium-long term regular treatment with exenatide in type 2 diabetic patients: A lombard multicenter initiative [Effetti del trattamento persistente con exenatide a medio-lungo termine in soggetti con diabete mellito di tipo 2: Esperienza multicentrica lombarda]","Anna Pulcina","2013","IrInSubria (University of Insubria)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0048772","S1600 Early Initiation of Glucagon-Like Peptide 1 Receptor Agonists After Transoral Outlet Reduction is Associated With Better Outcomes","Christine A. Lam","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035768.50481.2f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048773","Abstract #607: Early Responders to Liraglutide 3.0 Mg as Adjunct to Diet and Exercise from the Scale Obesity and Prediabetes Trial: Efficacy and Safety Results","David C.W. Lau","2015","Endocrine Practice","other_trial","article","10.1016/s1530-891x(20)42671-0",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0048774","1759-P: Effect of Meal Replacement Compared with Liraglutide 3.0 mg on Weight Loss and Hepatic Steatosis before Bariatric Surgery—A Randomised Study","Verena Parzer","2025","Diabetes","randomized_trial","article","10.2337/db25-1759-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048775","Preserving Muscle Mass and Function on GLP-1 Receptor Agonists","Jake Bears","2026","ScholarWorks -A service of University of Vermont Libraries (University of Vermont)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0048776","Cardiovascular Outcomes in Type 2 Diabetes Patients with Inflammatory Polyarthropathy: SGLT2 Inhibitors versus GLP-1 Receptor Agonists","Godbless Ebruvwiyor Ajenaghughrure","2025","American Heart Journal","other","article","10.1016/j.ahj.2025.07.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048777","727-P: Glycemic Effect of Tirzepatide by Duration of Diabetes","Christophe E.M. De Block","2022","Diabetes","other_trial","article","10.2337/db22-727-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048778","IMPACT OF ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG ON METABOLIC SYNDROME IN THE 2-YEAR, RANDOMIZED CONTROLLED STEP 5 TRIAL","Madona Azar","2023","Canadian Journal of Cardiology","randomized_trial","article","10.1016/j.cjca.2023.06.393",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048779","On the Basis of Sex: SGLT2i Confer Greater Cardioprotection Than GLP-1RAs in Australian Men, but Not Women, With Type 2 Diabetes (T2D)","Anurag Sharma","2022","Heart Lung and Circulation","other","article","10.1016/j.hlc.2022.06.108",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048780","Novel Small Molecule GLP-1R Agonists Based on 1H-Benzo[d]imidazole-5-Carboxylic Acid Scaffold (Supplementary File)","Elena V. Tolkacheva","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18684895",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048781","Incretins today: multiple effects and therapeutic potential","Oksana V. Tsygankova","2019","Diabetes Mellitus","other","article","10.14341/dm9841",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048782","Pharmacological characterisation of a novel long-acting CarboCarrier® D-Ala8GLP-1 for treatment of Type 2 diabetes","Steven Patterson","2013","ResearchOnline","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0048783","Improving functioning in affective disorders, a randomized controlled multimodule intervention design, presentation of a currently ongoing study","Rasmus Moeskjær Schwarz","2022","Neuroscience Applied","randomized_trial","article","10.1016/j.nsa.2022.100486",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048784","Efficacy and Safety of Once Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and Glimepiride in Type 2 Diabetes Patients (AWARD-2)","Francesco Giorgino","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048785","POS0565 Overview of authorised drugs to be repurposed for the treatment of osteoarthritis: a scoping review of clinical studies","Michelle W J Heijman","2025","Annals of the Rheumatic Diseases","randomized_trial","article","10.1016/j.ard.2025.05.947",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0048786","LEADER-8: Patienten mit Typ 2 Diabetes mellitus und hohem kardiovaskulären Risiko: ein Vergleich ost- und westeuropäischer Teilnehmer in der LEADER Studie","Edward Franek","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580964",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","FALSE","paywalled","5","FALSE","article"],["R0048787","Exploring metformin and GLP-1 analogues as therapeutic approaches for reactive hypoglycaemia in roux-en-y gastric bypass patients","Sefa Adwoa Nyarkoa","2024","Endocrine Abstracts","other","article","10.1530/endoabs.100.wh5.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048788","The era of combination of nephroprotective agents in CKD is there","Michel Y. Jadoul","2024","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfae260","39907537",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048789","PDB6 18 MONTH A1C AND WEIGHT OUTCOMES OF EXENATIDE THERAPY IN PATIENTS WITH TYPE-2 DIABETES IN A REAL-WORLD STUDY","Diana I Brixner","2009","Value in Health","nonrandomized_study","article","10.1016/s1098-3015(10)73550-6",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048790","Long-acting exenatide in the treatment of type 2 diabetes: a single technology appraisal","NR Waugh","2011","Bristol Research (University of Bristol)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0048791","Abstract 4141127: Combined use of cardioprotective glucose-lowering drugs and statins in individuals with type 2 diabetes is associated with the lowest risk of all-cause mortality","Tummas Ternhamar","2024","Circulation","randomized_trial","article","10.1161/circ.150.suppl_1.4141127",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0048792","Tirzepatide Reduces Albuminuria in Patients with T2D: Post-hoc Pooled Analysis of SURPASS 1-5","Hiddo J.L. Heerspink","2024","Diabetologie und Stoffwechsel","other","article","10.1055/s-0044-1785384",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048793","Liraglutide restores the endocrine function of islet's [beta]-cells and the altered lipid profile in early stages of life induced by food restriction in pregnancy","Yolanda Diz-Chaves","2016","Endocrine Abstracts","other","article","10.1530/endoabs.41.ep743",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048794","Association of Patient Cost-Sharing with Adherence to GLP-1a and Adverse Health Outcomes","Donglan “Stacy” Zhang","2025",null,"nonrandomized_study","article","10.2337/figshare.28570124.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0048795","A REVIEW ON ADVERSE DRUG REACTIONS AND PATIENT COUNSELLING OF ANTI-DIABETIC MEDICATIONS IN TYPE 2 DIABETES MELLITUS PATIENTS WITH CHRONIC KIDNEY DISEASE","Sona Manzoor M.*","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.20702456",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048796","Improving risk stratification in people with previous manifestations of cardiovascular disease: one size does not fit all in secondary prevention","Marcio Hiroshi Miname","2023","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwad334","37883702",null,null,null,"openalex","FALSE","paywalled","4","FALSE","editorial"],["R0048797","S784 Efficacy of Bowel Regimen on GLP1-RA-Induced Constipation","Suria Devarapalli","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130596.61749.e8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048798","Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness","Amelia Simenacz","2022","British Journal of Diabetes","nonrandomized_study","article","10.15277/bjd.2022.350",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048799","Incretin-based therapies for the failing heart","John Reyes Ussher","2016","Cardiovascular Endocrinology","other","article","10.1097/xce.0000000000000086",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048800","Expression of insulin and GLP-1 receptors in interneurons of the cerebral cortex","Eva Adrienn Csajbok","2019",null,"other","article","10.14232/phd.10078",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0048801","SAT-227 Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM","Stephen A. Harrison","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)01790-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048802","Can artificial intelligence ( AI ) educate your patient? A study to assess overall readability and pharmacists' perception of AI ‐generated patient education materials","Drew L. Armstrong","2024","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","other","article","10.1002/jac5.2006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048803","No impairment of hypoglycemia counterregulation via glucagon with the long-acting GLP-1 derivative, NN2211, in subjects with type 2-diabetes","Michael Albrecht Nauck","2003",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048804","Efficacy and Safety of an Expanded Dulaglutide Dose Range—A Phase 2, Placebo-Controlled Trial in T2D Patients on Metformin","Juan P. Frías","2018","Diabetes","randomized_trial","article","10.2337/db18-126-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048805","Évaluation des effets cardiovasculaires du liraglutide : Conception et données de base de l’étude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)","Michel Marre","2015","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(15)30080-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048806","S416 When the Checkpoint Fails: ICI Colitis as a Pathway to Inflammatory Bowel Disease","Irhoboudu Dickson Atogwe","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129124.16211.f4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048807","1046-P: ELEGANT-DM2—Early Intervention Addressing Therapeutic Inertia in Diabetes Mellitus-2","Archana Bandi","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1046-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048808","Impact of glucose-lowering medications on bone health in diabetes","Palak U. Choksi","2020","Diabetes Mellitus","other","article","10.1016/b978-0-12-820605-8.00004-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0048809","S2135 Prescription Patterns of Glucagon-Like Peptide-1 Receptor Agonists in the Pediatric Population","Danae A. Black","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037908.08734.f7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048810","Abstract 4365415: Comparative Efficacy of Glucagon-Like Peptide-1 Receptor Agonists and Co-Agonists for Weight Loss Among Patients Without Diabetes: A Network Meta-Analysis","Areesha Moiz","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4365415",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0048811","Efficacy of Semaglutide by Background Sodium–Glucose Co-Transporter-2 Inhibitor: a Post Hoc Analysis of SUSTAIN 9","Bernard Zinman","2021","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0041-1727320",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0048812","Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology","Matthew C. Riddle","2018","Diabetes Care","other","article","10.2337/dci18-0035","29934474",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048813","The Impact of Glucagon-like Peptide-1 Receptor Agonists on Obese Individuals’ Quality of Life and Eating Behaviors","Aya Saad Aldewachi","2025","Journal of Clinical Medicine of Kazakhstan","nonrandomized_study","article","10.23950/jcmk/17366",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048814","Exenatide and non motor symptoms in Parkinson's disease (PD)","Icíar Avilés-Olmos","2014","UCL Discovery (University College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0048815","Abstract 13166: Proteomic Pathways Across Ejection Fraction Categories in Heart Failure: An Exscel Substudy","Anthony E. Peters","2022","Circulation","randomized_trial","article","10.1161/circ.146.suppl_1.13166",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0048816","Abstract #245 Efficacy and Safety of Semaglutide in Elderly Subjects with Type 2 Diabetes: A Post Hoc Analysis of the Sustain 7 Trial","Vanita R. Aroda","2018","Endocrine Practice","other_trial","article","10.1016/s1530-891x(20)47090-9",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0048817","Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials","Wretlind, Asger","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.c.6853731.v1",null,null,"ClinicalTrials.gov:NCT02545738; ClinicalTrials.gov:NCT03449654","S001417; S001895","openalex","TRUE","paywalled","1","FALSE","other"],["R0048818","Management of type 2 diabetes in renal disease—the twilight of the gods","Bettina Johanna Kraus","2018","Nephrology Dialysis Transplantation","other_trial","article","10.1093/ndt/gfy222",null,null,"ClinicalTrials.gov:NCT00849056","S001136","openalex","TRUE","open_pdf","5","FALSE","article"],["R0048819","Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes","Mona Mashayekhi","2023",null,"randomized_trial","article","10.2337/figshare.24375271",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","other"],["R0048820","IDF2022-0370 Characterization of tirzepatide-treated patients achieving different categorical measures of weight loss in SURPASS 1-4","Rachel Louise Batterham","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110303",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048821","Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study","Abdulrahman Alsheikh","2024","Diabetes Epidemiology and Management","nonrandomized_study","article","10.1016/j.deman.2024.100209",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048822","Recommendations for Management of Diabetes During Ramadan","Monira Alarouj","2010","Diabetes Care","nonrandomized_study","article","10.2337/dc10-0896","20668157",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048823","Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer’s Disease (P11-9.013)","Philip Scheltens","2024","Neurology","randomized_trial","article","10.1212/wnl.0000000000205079","39977949",null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","openalex","FALSE","paywalled","1","FALSE","article"],["R0048824","THE ADDITION OF GLP-1 RECEPTOR AGONIST THERAPY 12 MONTHS AFTER ENDOSCOPIC SLEEVE GASTROPLASTY ENHANCES THREE-YEAR WEIGHT LOSS OUTCOMES","Ali Lahooti","2025","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2025.03.129",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048825","Distribution and function of glucagon-like peptide 1 (GLP-1) in the digestive tract of mammals and the clinical use of its analogues","Aleksandra Górska","2020","Medycyna Weterynaryjna","other","article","10.21521/mw.6374",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048826","Noi strategii terapeutice în boala renală diabetică | [Novel therapeutic strategies in diabetic kidney disease]","Laura Gîrdan","2024","Jurnal Medical Brasovean","nonrandomized_study","article","10.31926/jmb.2023.1.4",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048827","201-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes","Bochra Zareini","2023","Diabetes","nonrandomized_study","article","10.2337/db23-201-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048828","Spontaneous or Deliberate: Effects of Acute Variations in Glycemia on Gastric Emptying in Type 1 Diabetes","Michael Bruce Horowitz","2021","Diabetes Care","other","article","10.2337/dci20-0067","33472966",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048829","1730-P: Zenagamtide (Amycretin), a Novel Unimolecular GLP-1 and Amylin Receptor Agonist: Phase 2b Results in T2D","Pablo F. Mora","2026","Diabetes","randomized_trial","article","10.2337/db26-1730-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048830","Abstract 4373088: Genomic Insights into Incretin-Based Therapeutics for Peripheral Arterial Disease","Sabina M. Sorondo","2025","Circulation","other","article","10.1161/circ.152.suppl_3.4373088",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048831","Contemporary approach to diagnosis and treatment of patients with heart failure with preserved ejection fraction","Sara Tomović","2024","Srce i krvni sudovi","other","article","10.5937/siks2404110t",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048832","Roche to buy Carmot for $2.7 billion","Laura L. Howes","2023","C&EN Global Enterprise","other_trial","article","10.1021/cen-10141-buscon4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0048833","Ozempic isn’t approved for weight loss in Australia. So how are people accessing it?","Jessica E. Pace","2024",null,"other","article","10.64628/aa.cr3yx7mja",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0048834","P294 - ECE_2059 - Oral semaglutide—a novel stimulant for the hypothalamic-pituitary-adrenal axis?","Inge Nobbenhuis","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.449",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0048835","GLP-1 analogues","Robert A. Ritzel","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.s9.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048836","The weight-lowering effects of glucagon-like peptide-1 receptor agonists and the risk of breast cancer among patients with type 2 diabetes","Christina Santella","2019","Epidemiology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048837","Enhancing treatment success with incretin-based therapies: A comprehensive approach to the patient with diabetes","James R. LaSalle","2013","Osteopathic Family Physician","other","article","10.1016/j.osfp.2012.11.002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048838","IDegLira Offers Advantages over IDeg and Liraglutide in T2DM: DUAL I Results","Lynne Lederman","2014","MD Conference Express","other_trial","article","10.1177/155989771432015",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0048839","DYNAMICS OF MARKERS OF HEPATIC FIBROSIS ON THERAPY LIRAGLUTIDE AT PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH A METABOLIC SYNDROME","Alina Yu. Babenko","2018","Экспериментальная и клиническая гастроэнтерология","other","article","10.31146/1682-8658-ecg-157-9-86-94",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048840","Rethinking cardiovascular ageing","Patrick J. Lacolley","2025","Cardiovascular Research","other","article","10.1093/cvr/cvaf140","40796193",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048841","Abstract 39: GLP-1 Agonists Improve Cerebrovascular Integrity and Vascular Induced Cognitive Impairment and Dementia Beyond Glycemic Control via Restoration of Brain Pericytes Functions in Diabetic Mice","Joseph Bailey","2020","Stroke","randomized_trial","article","10.1161/str.51.suppl_1.39",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0048842","Mody-3 diabetes: is there a place for GLP-1 receptor agonists use?","Valentim Lopes","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.ep47",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048843","Effectiveness of a pragmatic prescribing pathway with multiple stopping rules for liraglutide 3 mg in people with and without diabetes: a post-hoc analysis of the strive study","Malak Hamza","2025","Endocrine Abstracts","other","article","10.1530/endoabs.109.p155",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048844","PGI7 EVALUATION OF LIVER OUTCOMES RELATIVE TO USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN REAL-WORLD POPULATIONS DIAGNOSED WITH TYPE II DIABETES (T2DM) AND NASH/NAFLD OR AT RISK OF NASH","Michelle Lai","2020","Value in Health","nonrandomized_study","article","10.1016/j.jval.2020.04.365",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048845","BASIC-LIVER, PANCREAS, AND BILIARY TRACT Glucagon-Like Peptide-1 and Its Receptor Agonist Exendin-4 Modulate Cholangiocyte Adaptive Response to Cholestasis","Marco Marzioni","2007",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048846","Abstract 18691: Stimulation of Glucagon-Like-Peptide-1 Receptor Through Exendin-4 Preserves Myocardial Performance and Prevents Cardiac Remodeling in Infarcted Myocardium","Megan DeNicola","2013","Circulation","preclinical","article","10.1161/circ.128.suppl_22.a18691",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048847","Statin therapy for secondary prevention of coronary heart disease: an update (part 2)","Kausik Kumar Ray","2008","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2008.024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048848","P284 - L’Exenatide pourra t-il remplacer l’analogue rapide dans le schéma basal bolus chez les patients diabétiques type 2 ayant un équilibre glycémique médiocre !","Dured Dardari","2011","Diabetes & Metabolism","other","article","10.1016/s1262-3636(11)70910-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048849","Use of Liraglutide in a Tertiary Bariatric Clinic: A Case Series","Daniel Ta","2019","Journal of Obesity and Chronic Diseases","nonrandomized_study","article","10.17756/jocd.2019-027",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048850","60888 Semaglutide Weight Loss Effects on Hidradenitis Suppurativa Severity","Marc A. Hill","2025","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2025.05.329",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048851","Cardio‐renal benefits of newer glucose lowering agents may be less effective in Black people","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.76",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048852","Nouveaux rôles du système GLP-1 dans la régulation de la balance énergétique via le bulbe olfactif : impact sur l'obésité et le diabète de type 2","Montaner Massana, Mireia","2022","theses.fr (ABES)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0048853","Reality of Real-World Experience with Oral Semaglutide in Type 2 Diabetes","Awadhesh Kumar Singh","2024","Clinical Diabetology","nonrandomized_study","article","10.5603/cd.103963",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048854","Preliminary baseline characteristics from evoke and evoke+: two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer’s disease","Philip Scheltens","2024","Arquivos de Neuro-Psiquiatria","randomized_trial","article","10.5327/cbn241336",null,null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","openalex","TRUE","free_to_read","1","FALSE","conference-abstract"],["R0048855","Exenatide Exerts Its Positive Effects on Liver by Reducing both Hepatic and Adipose Tissue Insulin Resistance","Amalia Gastaldelli","2016","Journal of Hepatology","other","article","10.1016/s0168-8278(16)00091-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048856","Metabolic footprint of the GLP-1 receptor agonist liraglutide in adolescent transgenic pigs with impaired incretin function","Simone K. Renner","2014","Diabetologie und Stoffwechsel","other","article","10.1055/s-0034-1375129",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048857","WCN26-3792 Mechanistic Kidney Effects of Semaglutide by Baseline SGLT2i Use in Type 2 Diabetes: A Post-hoc Analysis of the REMODEL Trial","David Z. I. Cherney","2026","Kidney International Reports","other_trial","article","10.1016/j.ekir.2026.106504",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048858","Comparative Glycemic Effectiveness of Dulaglutide vs. Liraglutide and Exenatide QW in a U.S. Real-World Setting","Reema Mody","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1071-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048859","Exenatide Treatment Improves Mitochondrial Metabolism and Hepatic Insulin Sensitivity in Mice with Nonalcoholic Steatohepatitis (NASH)","Srilaxmi Kalavalapalli","2018","Diabetes","randomized_trial","article","10.2337/db18-1846-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048860","Strength-endurance training and liraglutide treatment: impact on metabolic parameters in middle-aged ovariectomized female rats","Branka Šošić‐Jurjević","2024","Endocrine Abstracts","preclinical","article","10.1530/endoabs.99.p56",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048861","BNP infusion during reperfusion increases cardiac triglyceride accumulation and decreases cardiac contractility after myocardial ischemia in pigs","Birgitte S. Kousholt","2012","Regulatory Peptides","preclinical","article","10.1016/j.regpep.2012.05.046",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048862","Outpatient Diuretic Intensification Across the Cardiovascular-Kidney-Metabolic Spectrum","Pedro Sousa Marques","2025","European Journal of Heart Failure","randomized_trial","article","10.1002/ejhf.3611","39939305",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0048863","Anhaltende Blutzuckerkontrolle unter wöchentlichem Depot-Exenatide versus Insulin glargin: Assoziation mit Basischarakteristika und frühem Therapieansprechen","Marcel Trautmann","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549547",null,null,"ClinicalTrials.gov:NCT00641056","S001768","openalex","FALSE","paywalled","5","FALSE","article"],["R0048864","53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study","Richard E. Pratley","2019","Diabetes","other","article","10.2337/db19-53-or",null,null,"ClinicalTrials.gov:NCT02075281","S000743","openalex","FALSE","paywalled","5","FALSE","article"],["R0048865","1169-OR: Technology, Pharmacology, or Both? Real-World Effectiveness of CGM and GLP-1 Therapy in Primary Care","Jovan Milosavljevic","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1169-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048866","GLP-1 receptor agonists and plastic surgery: mapping the evidence on perioperative risks, anatomical changes, and surgical outcomes","Álvaro Caballero Romero","2026",null,"nonrandomized_study","article","10.17605/osf.io/j8etr",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0048867","PDB15 UTILIZATION PATTERNS AND HYPOGLYCEMIA IN PATIENTS WITH TYPE-2 DIABETES ON CONCOMITANT EXENATIDE AND LONG-ACTING INSULIN THERAPY","Rolin L. Wade","2009","Value in Health","other","article","10.1016/s1098-3015(10)73559-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048868","S5965 Diagnostic Dilemma: Overlap Syndrome in the Young—Antimitochondrial Antibodies Meet NAFLD","Ishita Ray","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001151320.47094.1d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048869","GLP-1R agonist treatment down-regulates cytokine-induced allergic inflammatory responses in human lung microvascular endothelial cells","Shinji Toki","2022","Journal of Allergy and Clinical Immunology","other","article","10.1016/j.jaci.2021.12.205",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048870","Tirzepatide: Failing the Acid Test","Wenchy YY. Tan","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.20254be3v64r",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048871","DURATION-2: Exenatide einmal wöchentlich erreicht nach 26 Behandlungswochen bessere Blutzuckerkontrolle und Gewichtsreduktion als Sitagliptin oder Pioglitazon","Richard M. Bergenstal","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1253759",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048872","1033-P: Improving T2D Collaboration and Patient Communication at the Primary Care Level—Findings from Team-Designed Quality Improvement Education Initiative","Vinni Makin","2023","Diabetes","other","article","10.2337/db23-1033-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048873","Lixisenatide Therapy in Older Patients with Type 2 Diabetes Inadequately Controlled on Their Current Anti-Diabetic Treatment: The GetGoal-O Study (NCT01798706)","Graydon S. Meneilly","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.127",null,null,"ClinicalTrials.gov:NCT01798706","S000904","openalex","FALSE","paywalled","5","FALSE","article"],["R0048874","Liraglutide 3.0 mg reduces severity of obstructive sleep apnea and body weight in obese individuals with moderate or severe disease: scale sleep apnoea tria","Adam Blackman","2015","Sleep Medicine","other","article","10.1016/j.sleep.2015.02.058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048875","SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial","Jena Shaw Tronieri","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-sat-105",null,null,"ClinicalTrials.gov:NCT02963935","S000712","openalex","TRUE","free_to_read","1","FALSE","conference-abstract"],["R0048876","THE ASSOCIATION BETWEEN PACEMAKER-DETECTED PHYSICAL AND HEART FAILURE WITH PRESERVED EJECTION FRACTION","Jackson Howie","2026","Journal of Clinical Exercise Physiology","other","article","10.31189/2165-7629-15-s2.141",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048877","Effect of liraglutide 1.8 mg in patients with non-controlled type 2 diabetes mellitus at an endocrinology clinic: LIED-2 Study","Alvaro J Muriel","2015","Endocrine Abstracts","other","article","10.1530/endoabs.37.ep404",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048878","P303 Efficacité de dulaglutide hebdomadaire à durée d’action prolongée, comparé à l’exénatide à action rapide, administré deux fois par jour chez des patients présentant un diabète de type 2 (DT2) : analyse post-hoc, déterminant l’impact du taux initial d’HbA1","Shadiamon Bain","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72594-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048879","Association between hemoglobin A1C response to glucagon-like peptide-1 receptor agonists and hemoglobin A1C and weight outcomes post-bariatric surgery","Daniel Boris Amusin","2022","Obesity Medicine","other","article","10.1016/j.obmed.2022.100450",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048880","720-P: Change in Body Weight from Baseline with Tirzepatide: Sex Subgroup Analysis of the SURPASS Studies","ARIAN W. PLAT","2022","Diabetes","randomized_trial","article","10.2337/db22-720-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048881","CAD-30: Étude DUAL V : supériorité de l'association degludec/liraglutide (IDegLira) en comparaison à l'insuline glargine (IGlar) sur la diminution de l'HbA1c, l'évolution du poids et le risque d'hypoglycémie chez le patient diabétique de type 2 insuffisamment contrôlés par insuline basale","S. Madani","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30126-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048882","POSTER: MPN-642 Glucagon-Like Peptide-1 Agonists and Clinical Outcomes in Polycythemia Vera: A Large-Scale Propensity-Matched Cohort Study","Asfand Yar Cheema","2025","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(25)00892-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048883","Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5","Lawrence A. Leiter","2017","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2017.08.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048884","Pathophysiological mechanisms of coronavirus disease (COVID-19) progression and fatal complications in patients with diabetes","Т. О. Брюханова","2020","Pathologia","nonrandomized_study","article","10.14739/2310-1237.2020.2.212812",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048885","Durabilité de l’efficacité du contrôle glycémique sous liraglutide dans l’étude LEADER","Michel Marre","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.227",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048886","The role of glucagon-like peptide-1 receptors in protein-induced suppression of food intake in rats","Alfred A. Aziz","2004","TSpace (University of Toronto)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0048887","Semaglutide treatment and renal function in the SUSTAIN 6 trial","Stephan Jacob","2019","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0039-1688340",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0048888","Parallel improvement of arterial stiffness with weight loss following intensification of antidiabetic treatment","Panagiota K. Stampouloglou","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae666.2929",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048889","866-P: The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection Fraction","SHIJUN YAN","2025","Diabetes","preclinical","article","10.2337/db25-866-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048890","CARDIOVASCULAR OUTCOMES IN NEW USERS OF ONCE-WEEKLY GLP-1 RECEPTOR AGONISTS VS OTHER GLUCOSE-LOWERING THERAPIES AMONG MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE","Adam de Havenon","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00900-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048891","O33 Amélioration significative du contrôle glycémique grâce à l’analogue du GLP-1 humain liraglutide par rapport à l’insuline glargine, en association à metformine + sulfamide dans le DT2","J. Pierre Courrèges","2009","Diabetes & Metabolism","other","article","10.1016/s1262-3636(09)71725-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048892","STRATIFIED PHENOTYPIC ANALYSIS AND MORTALITY OUTCOMES IN SEMAGLUTIDE-ELIGIBLE ASCVD PATIENTS: A NATIONAL HEALTH INTERVIEW SURVEY ANALYSIS","Harun Kundi","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03777-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048893","ACE Inhibition and GLP1 Receptor Agonism Have Direct Effects on the Glomerular Capillary Wall to Reduce Glomerular Albumin Permeability in Diabetes","Michael Crompton","2022","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20223311s1102c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048894","Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada","SAMANTHA L. HOCKING","2019","Obesity Research & Clinical Practice","nonrandomized_study","article","10.1016/j.orcp.2018.11.044",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048895","Bridging Preclinical Promise and Clinical Uncertainty: The Role of GLP-1 Receptor Agonists in Opioid Use Disorder — A Scoping Review Protocol","Charles Amoatey Odonkor","2026","Open Science Framework","protocol","article","10.17605/osf.io/ywk46",null,null,"ClinicalTrials.gov:NCT04199728","S001339","openalex","TRUE","paywalled","5","FALSE","other"],["R0048896","Early weight loss with liraglutide 3.0 mg is a good predictor of clinically meaningful weight loss after 56 weeks","Matthias Blueher","2016","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0036-1580953",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048897","LBP-032 Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis-a subgroup analysis from the SELECT trial","Sebastian M. Meyhöfer","2024","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(24)00599-3",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0048898","Assessment of Weight Loss by Amylin Receptor Agonists Alone and In Combination with GLP-1 Receptor Agonists: A Model-Based Meta-Analysis","Sima Ahadieh","2026",null,"systematic_review","article","10.70534/gfse7218",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-paper"],["R0048899","Glycemic and Weight Lowering Effects of Exenatide Once Weekly Are Associated with Blood Pressure Changes in Patients with Type 2 Diabetes","Sanjoy Ketan Paul","2011","Diabetes","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048900","Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-InsulinProducing Cells Expression","Amr Kamel Khalil Ahmed","2023","Qeios","nonrandomized_study","article","10.32388/g6uisp",null,null,"ClinicalTrials.gov:NCT06057077","S001485","openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0048901","IMPLEMENTING ADHERENCE TO SGLT2I AND GLP1RA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FINDINGS FROM A PHARMACIST-DRIVEN CARDIODIABETES CLINIC PROGRAM","Kevin Lee","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03928-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048902","The review of modern prospects for the pharmacological treatment of obesity and its complications – The role of GLP- 1, GLP1 / GIP, GLP1 / GIP / GCG receptor agonists","Michel Grzebyk","2025","Medical Science","narrative_review","article","10.54905/disssi.v29i157.e50ms3543",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048903","MEDICARE AND MEDICAID UTILIZATION AND ASSOCIATED SPENDING ON SGLT2 INHIBITORS AND GLP1 RECEPTOR AGONISTS","Warren Fernandes","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01028-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048904","Safety and tolerability of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes","Rupa Ahluwalia","2012","The British Journal of Diabetes","preclinical","article","10.1177/1474651411431846",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048905","Weekly, biweekly, monthly albiglutide improves measures of glycaemia in patients with type 2 diabetes on background metformin therapy","Julio Rosenstock","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33075-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048906","2308-PUB: Liraglutide 3 mg for Weight Loss in a Real-World Setting: Clinical Outcomes after 56 Weeks","Adam John Buckley","2019","Diabetes","nonrandomized_study","article","10.2337/db19-2308-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048907","Once-weekly Insulin Icodec – An emerging treatment option for type 2 Diabetes","Rubab Zahra","2024","Journal of the Pakistan Medical Association","randomized_trial","article","10.47391/jpma.20080","39160749",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048908","Abstract 4372125: Elevated Peri-coronary Adipose Tissue attenuation association with Coronary Plaque Progression in Type 2 Diabetes Mellitus Patients","Shannon Lee","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4372125",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048909","81-LB: Patient-Reported Outcomes in Patients with Type 2 Diabetes Treated with Tirzepatide or Placebo (SURPASS-1)","Kristina Secnik Boye","2021","Diabetes","randomized_trial","article","10.2337/db21-81-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048910","87 - Efficacy and Safety of Semaglutide 0.5 mg vs Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: Posthoc Analysis of SUSTAIN 7","Ronald Goldenberg","2019","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2019.07.096",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048911","RATES OF HEART FAILURE HOSPITALIZATIONS IN HFPEF AND DIABETES PATIENTS ON SEMAGLUTIDE","Apoorva Gangavelli","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)02353-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048912","1731-P: Optimising Prescribing in Type 2 Diabetes: Updating a Five–Drug Class Treatment Selection Model to Include Newer GLP-1RAs","Pedro Cardoso","2026","Diabetes","other","article","10.2337/db26-1731-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048913","Effect of Four-Week Semaglutide Therapy and Its Combination with Intranasal Insulin on Thyroid and Gonadal Status in Male Rats with Type 2 Diabetes","Kira Viktorovna Derkach","2025","Journal of Evolutionary Biochemistry and Physiology","preclinical","article","10.1134/s002209302503007x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048914","Changes in physical activity during a one-year weight loss trial with liraglutide in participants with knee osteoarthritis: secondary analyses of a randomised trial","Cecilie Rødgaard Bartholdy","2021","Osteoarthritis and Cartilage","randomized_trial","article","10.1016/j.joca.2021.02.554",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048915","Editors’ presentation: Focus on diabetes mellitus and diet","Géza Hálasz","2020","European Journal of Preventive Cardiology","randomized_trial","article","10.1177/2047487320969012","33200629",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048916","Sa1030 EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY ON BOWEL PREPARATION QUALITY AND ADEQUACY IN A RURAL, TERTIARY CARE CENTER","Rebecca Z. Strigenz","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)05501-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048917","Albiglutide","Julio Rosenstock","2010","Drugs of the Future","other","article","10.1358/dof.2010.035.09.1516042",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048918","Behavioural and lifestyle components used alongside GLP-1RAs in interventions for adults with obesity: a systematic scoping review of randomised controlled trials.","Anastasia Searle","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.19484486",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0048919","Journal of Diabetes NEWS","Benjamin M. Kozak","2010","Journal of Diabetes","randomized_trial","article","10.1111/j.1753-0407.2010.00104.x","21138543",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048920","Effetti di Exenatide a rilascio prolungato sul controllo metabolico di una paziente diabetica anziana con pluri-comorbidità","Francesco Mario Gentile","2018","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048921","Erratum to: Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus","André Jacques Scheen","2014","Clinical Pharmacokinetics","notice","article","10.1007/s40262-014-0205-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0048922","S4120 Delayed Onset Intolerance of GLP-1 Receptor Agonist Therapy: A Case Series of Adverse Reactions Requiring Hospitalization","Sweta Lohani","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001143940.03233.c9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048923","Abstract 4370661: Cardiovascular Benefits of GLP-1 Receptor Agonists in Non-Obese Patients With Type 2 Diabetes, Chronic Kidney Disease, or Coronary Artery Disease: A Real-World TriNetX Analysis","THIERRY KOCHKARIAN","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4370661",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048924","356-OR: Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial","Jonathan Edward Shaw","2020","Diabetes","randomized_trial","article","10.2337/db20-356-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048925","204 Machine learning for incident cardio-renal-metabolic disease and cardiovascular death: the optimise study","Ramesh Nadarajah","2024",null,"randomized_trial","article","10.1136/heartjnl-2024-bcs.199",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0048926","P138 Traitement par exenatide dans le diabète de type 2 : utilisation du modèle HOMA comme facteur prédictif de réponse et de suivi à 6 mois","Vanessa Preumont","2009","Diabetes & Metabolism","other","article","10.1016/s1262-3636(09)71936-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048927","Abstract Wed083: Low Dose Semaglutide Remodels Myocardial Proteomes and Reduces Lipid Droplet content in Cardiometabolic HFpEF Independent of Weight Loss","David J. Polhemus","2025","Circulation Research","preclinical","article","10.1161/res.137.suppl_1.wed083",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048928","Virus infections in pathogenesis of type 1 diabetes","Fabienne Brilot","2003","ORBi (University of Liège)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048929","Case 74: Glycemic Control in Older Adults with Diabetes and Use of New SGLT2 Inhibitors","Carolyn P. Horney","2015","American Diabetes Association eBooks","other","article","10.2337/9781580405713.74",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0048930","S738 Risk of Vision-Threatening Eye Complications Among GLP-1 Receptor Agonist Users: A Retrospective Cohort Analysis","Sarpong Boateng","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130412.76718.7d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048931","Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research","Oliver Schnell","2015","Diabetes Care","other_trial","article","10.2337/dc14-2919","26294772",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048932","MON-708 Effect of Incretin-Based Weight Loss Drugs on Testosterone Concentrations in Men","Shellsea Portillo Canales","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1941",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048933","#1032 Non-proteinuric kidney disease and Type II diabetes: CKM (cardio kidney metabolic) parameters and current recommended treatment modalities","Khalid Ahmed","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.1900",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048934","2256-PUB: Fixed-Ratio Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus Treatment in Type 2 Diabetic (T2DM) Patients with Diabetic Foot Ulcers (DFU) and Critical Limb Ischemia (CLI)","Pierpaolo Falcetta","2019","Diabetes","nonrandomized_study","article","10.2337/db19-2256-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048935","Sa1608 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH FEWER IBD-SPECIFIC COMPLICATIONS IN PATIENTS WITH CLASS III OBESITY","Shaina Ailawadi","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)02549-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048936","Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says","Aude Bandini","2024",null,"other","article","10.64628/aap.f4hntud33",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0048937","409Cardiovascular risk profiles and outcomes in patients with type 2 diabetes - Implications for choice of new diabetes therapies","Mariam Elmegaard Malik","2019","European Heart Journal","other_trial","article","10.1093/eurheartj/ehz747.0104",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048938","Possibilities of using continuous glycemic monitoring to assess the effectiveness of therapy in patients with MODY-diabetes","A. K. Ovsyannikova","2020","Meditsinskiy sovet = Medical Council","nonrandomized_study","article","10.21518/2079-701x-2020-7-26-31",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0048939","Bridging the Language Gap: A Simulated Experience to Teach Communication Using Virtual Interpreters - Encore Presentation","Jessica M. Downes","2026","Graduate Medical Education Research Journal","other","article","10.32873/unmc.dc.ihsej.0084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048940","Toma de posición sobre los agonistas del receptor de GLP-1","Sergio Giménez","2021","Revista de la Federación Argentina de Cardiología","other","article","10.63600/2c4sqe18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048941","Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study","Louis A Talay","2024","Obesities","nonrandomized_study","article","10.3390/obesities4040032",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0048942","Triple therapy for obese patients with type 2 diabetes: evaluating effectiveness of the metformin + exenatide + glibenclamide combination","Mikhail Borisovich Antsiferov","2015","DOAJ (DOAJ: Directory of Open Access Journals)","other_trial","article","10.21518/2079-701x-2015-11-66-71",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0048943","ODP002 ASSOCIATION BETWEEN OBESITY AND DIABETES POTENTIATES RENAL FUNCTION IMPAIRMENT IN BARIATRIC PATIENTS","Erika C. O. Naliato","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.016",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0048944","L’insuffisance rénale n’affecte pas l’efficacité glycémique ni l’innocuité du traitement par le liraglutide chez les patients diabétiques de type 2","J.P. Courrèges","2012","Annales d Endocrinologie","other","article","10.1016/j.ando.2012.07.1005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048945","Cost-Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes in Greece","Charalampos Tzanetakos","2016","Value in Health","other","article","10.1016/j.jval.2016.09.1871",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048946","Abstract 4147387: Outcomes of Heart Failure with Preserved Ejection Fraction with GLP1RA plus SGLT2i vs SGLT2i alone: A Propensity-Matched Nationwide Cohort Study","Talal Almas","2024","Circulation","randomized_trial","article","10.1161/circ.150.suppl_1.4147387",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0048947","Semaglutide Improves eGFR Slope vs. Placebo Regardless of Baseline HbA1c and Blood Pressure in People With Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6","David Z.I. Cherney","2022","Journal of the American Society of Nephrology","other","article","10.1681/asn.20223311s1675b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048948","Neuroprotective properties of incretin mimetics in brain ischemia and neurodegenerative diseases","Ivan Nikolaevich Tyurenkov","2017","Problems of Endocrinology","other_trial","article","10.14341/probl201763149-58",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048949","S3719 Tirzepatide-Induced Eosinophilic Colitis: A Rare Gastrointestinal Presentation of a GLP-1 Receptor Agonist","Keerthy Gopalakrishnan","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001142336.38560.05",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048950","Semaglutide and atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials","G Costa","2024","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehae666.442",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0048951","752-P: Improved BMI Category Is Associated with Better Patient-Reported Outcomes (PROs) in Adults with T2D Treated with Tirzepatide","Clare J. Lee","2023","Diabetes","other_trial","article","10.2337/db23-752-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048952","Opportunities and challenges for the development of pharmacological therapies for obesity treatment","Michael Anthony Cawthorne","2007","Obesity Reviews","other_trial","article","10.1111/j.1467-789x.2007.00332.x","17316316",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048953","Su2067 A Pilot Pharmacogenomic Study of the Effects of Exenatide on Gastric Emptying and Weight Loss in Patients With Accelerated Gastric Emptying","Andres Martin Acosta","2015","Gastroenterology","other","article","10.1016/s0016-5085(15)31996-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048954","Dual-modality imaging and quantification of GLP-1R positive insulinoma and pancreatic beta-cell mass using a bimodal PET/fluorescence exendin-4 peptide","Christian Brand","2014","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048955","Development of a novel alternative method for liraglutide production","Gabriela R. Barredo‐Vacchelli","2024",null,"other","article","10.17952/37eps.2024.p1173",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0048956","Cardiac natriuretic peptides in plasma: from prediction to precision medicine","Jens Peter Goetze","2016","The Lancet Diabetes & Endocrinology","other_trial","article","10.1016/s2213-8587(16)30221-2","27599813",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048957","The role of anti-obesity drugs in the management of obese diabetics","Dragan Micić","2018","Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma","other","article","10.5937/medgla1870015m",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048958","Impacts of Cottonseed and Extra Virgin Olive Oil Intake on Plasma Arachidonic Acid and Eicosanoids: A Randomized Controlled Trial","Mary P. Miles","2024","Current Developments in Nutrition","randomized_trial","article","10.1016/j.cdnut.2024.102588",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0048959","MicroRNA expression profiling in type 2 diabetes patients treated with liraglutide","Mohammad A. Irshad","2025","Journal of King Saud University - Science","nonrandomized_study","article","10.25259/jksus_103_2024",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048960","644-P: Racial Ethnic Disparities in Prescription of GLP-1 Receptor Agonists for People at High Risk for Diabetes on Atypical Antipsychotics","JITHIN SAM VARGHESE","2024","Diabetes","nonrandomized_study","article","10.2337/db24-644-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048961","Advancing CKD Screening and Therapy Provision for Hispanic/Latino and Black Patients with Type 2 Diabetes","Matthew R. Sinclair","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.20253thyv1px",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048962","696 Is semaglutide safe and effective at improving glycemic control in people with cystic fibrosis-related diabetes?","M. Gerges","2024","Journal of Cystic Fibrosis","other","article","10.1016/s1569-1993(24)01534-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048963","125-OR: Effect of CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist, on Liver-Related MRI Parameters in Patients with Obesity","ALEXANDRA STEINBERG","2025","Diabetes","randomized_trial","article","10.2337/db25-125-or",null,null,"ClinicalTrials.gov:NCT04838405","S002824","openalex","FALSE","paywalled","1","FALSE","article"],["R0048964","Modern approaches to the diagnosis, treatment and prevention of obesity","Т. Н. Петрова","2024","Russian Medicine","other","article","10.17816/medjrf627548",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048965","ACUTE PANCREATITIS ASSOCIATED WITH EXENATIDE AND LIRAGLUTIDE: A META-ANALYSIS","Carlos Alves","2015","DOAJ (DOAJ: Directory of Open Access Journals)","systematic_review","article","10.25756/rpf.v4i3.66",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0048966","Abstract P3134: Semaglutide Versus Liraglutide and Incidence of Diabetes and Cardiovascular Disease: an Analysis of Real-World Data","Ethan J. Cannon","2025","Circulation","nonrandomized_study","article","10.1161/cir.151.suppl_1.p3134",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048967","Additional file 1 of Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials","Wretlind, Asger","2024","Figshare","randomized_trial","article","10.6084/m9.figshare.26619862",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0048968","988-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Promotes a Dose-Dependent Increase in Gastric Emptying Time","Darren C. Robertson","2019","Diabetes","randomized_trial","article","10.2337/db19-988-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048969","Type 2 Diabetes Mellitus (T2DM) Patients with Inadequate A1C Control on Metformin (MET) + DPP-4i—A Network Meta-analysis (NMA) of the Efficacy and Safety of SGLT2i, GLP-1 Analogs, and Insulin","ANN MARIE MCNEILL","2018","Diabetes","systematic_review","article","10.2337/db18-1161-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0048970","Absolute benefits of empagliflozin in type 2 diabetes: a game changer?","Cyrus Rustam Kumana","2017","Postgraduate Medical Journal","other","article","10.1136/postgradmedj-2016-134741","28433975",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048971","Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity","John Edward Blundell","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31220-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048972","Comment on Andersen et al, Pancreatitis–Diabetes–Pancreatic Cancer","Alan Charles Moses","2014","Pancreas","randomized_trial","article","10.1097/mpa.0000000000000037","24713674",null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","TRUE","free_to_read","1","FALSE","letter"],["R0048973","Connection between Type 2 Diabetes and Alzheimer\\'s disease: Insights from epidemiology to mechanisms and treatment approaches","Anand Singh Chouhan","2025","IP Journal of Nutrition Metabolism and Health Science","other","article","10.18231/j.ijnmhs.2025.004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048974","Investigating changes in fluid biomarkers in early Alzheimer’s disease: design of plasma biomarker analyses and a cerebrospinal fluid sub‐study in the evoke and evoke+ trials of semaglutide versus placebo","Jeffrey L. Cummings","2022","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.062382",null,null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","openalex","FALSE","paywalled","1","FALSE","article"],["R0048975","143-LB: Changes in Perceptions and Confidence of Health Care Professionals across Medical Specialties Regarding Use of SGLT2 and GLP-1 for Cardiorenal Benefit in Type 2 Diabetes","Deena Zytnick","2021","Diabetes","other","article","10.2337/db21-143-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048976","Einfluss der Typ-2-Diabetesdauer auf die Wirkung von iGlarLixi gegenüber Insulin glargin 100 E / ml bei einer basalunterstützten oralen Therapie (BOT): Eine Subanalyse der LixiLan-L-Studie","Jochen Seufert","2021","Diabetologie und Stoffwechsel","other","article","10.1055/s-0041-1727315",null,null,"ClinicalTrials.gov:NCT02058160","S001409","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0048977","SEMAGLUTIDE REDUCED CARDIOVASCULAR EVENTS REGARDLESS OF METFORMIN USE: A POST HOC EXPLORATORY SUBGROUP ANALYSIS OF SUSTAIN 6 AND PIONEER 6","Mansoor Husain","2021","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(21)02961-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048978","Abstract 7603: Type-2 Diabetes, medications, and risk of multiple colorectal polyps: A colonoscopy-based study using natural language processing.","Jessica van Onselen","2026","Cancer Research","other","article","10.1158/1538-7445.am2026-7603",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048979","Additional file 1 of Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review","Adir Alper","2026","Figshare","systematic_review","article","10.6084/m9.figshare.31374977.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0048980","812-P: The Role of Industry and NIH/Academia in the Clinical Development of GLP-1 Agonists and SGLT2 Inhibitors","Brian R. Kocak","2021","Diabetes","other_trial","article","10.2337/db21-812-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048981","Successful Use of GLP-1 Receptor Agonists for Medical Optimization in Patients Undergoing Evaluation for Kidney Transplantation","Marianna Frazee","2026","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.12.184",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048982","Cardiovascular effects of treatment with Liraglutide in a population with type 2 diabetes","Marco Zavattaro","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.p473",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048983","Assessment of anthropometric parameters in type 2 diabetic patients on Liraglutide","Chadia Zouaoui","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep570",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0048984","Welche demografischen und klinischen Parameter sind entscheidend für die Vorhersage der Diagnose einer diabetischen Retinopathie im Erwachsenenalter? Ein Machine Learning-Ansatz","Sascha René Tittel","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1767948",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048985","980-P: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients","Melissa K. Thomas","2019","Diabetes","randomized_trial","article","10.2337/db19-980-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048986","L’ancienneté du diabète et le type de traitements antérieurs sont les facteurs prédictifs de la réponse au liraglutide : données de l’étude post-inscription EVIDENCE®","Alfred Penfornis","2013","Annales d Endocrinologie","other","article","10.1016/j.ando.2013.07.532",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0048987","Tirzepatide Protects the Kidney by Modulating Oxidative Stress, Inflammation, and Apoptosis in an Induced Ischemia-Reperfusion Rat Model","Layla Ameen Rasheed Alfatli","2025","Kufa Medical Journal","preclinical","article","10.36330/kmj.v21.i2.20688",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0048988","806-P: Effectiveness of a Hybrid Weight Loss Program for Obesity and Prediabetes Using GLP-1 Medications","Hala Zakaria","2024","Diabetes","nonrandomized_study","article","10.2337/db24-806-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0048989","The Effect of Semaglutide on Bone Turnover in Adults with Increased Fracture Risk: A Randomised, Double-Blinded, Placebo-Controlled Trial","Morten Steen Hansen","2023","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.4647909",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0048990","Abstract 13242: Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLinkTM Database","Byron J. Hoogwerf","2010","Circulation","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-abstract"],["R0048991","1275-P: Cost Effectiveness of Using DPP-4i and SGLT2i Combination Therapy vs. Switching to GLP-1 Therapy for the Management of Type 2 Diabetes","Manjiri D. Pawaskar","2019","Diabetes","randomized_trial","article","10.2337/db19-1275-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0048992","GLP-1 receptor agonists vs 5-alpha reductase inhibitors for prostate cancer primary prevention in high-risk men: A real-world head-to-head comparison.","Oscar A Hinojosa","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e17134",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0048993","Tirzepatide, the dual GLP ‐1 and GIP agonist showed ground breaking weight loss and HbA1c reduction in overweight or obese people with type 2 diabetes: Result of the SURMOUNT‐2 trial","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","other_trial","article","10.1002/doi2.65",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0048994","Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes","Phil Ambery","2018","Diabetes","randomized_trial","article","10.2337/db18-1067-p",null,null,"ClinicalTrials.gov:NCT02548585","S000451","openalex","FALSE","paywalled","1","FALSE","article"],["R0048995","The Effect of Efpeglenatide on Lipid Profiles and Overall Metabolism in Patients with Type 2 Diabetes and Obese Patients without Diabetes","Richard E. Pratley","2018","Diabetes","other_trial","article","10.2337/db18-2300-pub",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0048996","How Can We Increase the Utilization of Evidence-Based Medication After Myocardial Infarction?","Sidney C. Smith","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/7ak7-8g06",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0048997","Abstract 4143622: Efficacy of Semaglutide in Patients with Obesity and Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review&Meta-Analysis","Maneeth Mylavarapu","2024","Circulation","systematic_review","article","10.1161/circ.150.suppl_1.4143622",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0048998","GLP1s vs DPP4s and Risk of Dementia in Patients Requiring Hemodialysis, A Target Trial Emulation Study","Dustin Le","2025",null,"nonrandomized_study","article","10.2337/figshare.30438470",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0048999","772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk","Julie M. Paik","2024","Diabetes","nonrandomized_study","article","10.2337/db24-772-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049000","The gut-liver nexus: exploring gut microbiota dysbiosis in non-alcoholic fatty liver disease and its therapeutic implications","Dinesh Mohan Swamikkannu","2024","Egyptian Liver Journal","other","article","10.1186/s43066-024-00331-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049001","Prediction of weight loss response to liraglutide","Anna A Mosikian","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep1047",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049002","Metabolic–reproductive Crosstalk in Polycystic Ovary Syndrome: Therapeutic Implications of Dual Incretin Agonism with Tirzepatide","Ahmad Sajjad Ashraf","2026","Journal of Advances in Medicine and Medical Research","other","article","10.9734/jammr/2026/v38i16060",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049003","POS0031 Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis","Bindee Kuriya","2025","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1016/j.ard.2025.05.428",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0049004","Evaluation of potential therapeutic effects of GLP-1 receptor agonists on the state of secondary bile acid loss in mice","Nooshin Mohebali","2025","Zeitschrift für Gastroenterologie","randomized_trial","article","10.1055/s-0045-1810790",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0049005","Commentary and Critical Appraisal of a Systematic Review of GLP-1 Receptor Agonists and Bone Health in Type 2 Diabetes","Conor Corbett","2026","CLOK (University of Central Lancashire)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0049006","Diabetic Cardiomyopathy: Distinct Clinical Entity or Manifestation of Metabolic Heart Disease?","Saverio D’Elia","2026","Diabetology","other","article","10.3390/diabetology7080160",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049007","Triple-hormone receptor agonist retatrutide significantly improves lipoprotein and apolipoprotein profiles in participants with obesity or overweight","Stephen James Nicholls","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.1501",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049008","PS1 - 5. The GLP-1 receptor agonist exendin-4 reduces atherosclerosis development and NASH in APOE*3.Leiden.CETP mice","Edwin T. Parlevliet","2012","Nederlands Tijdschrift voor Diabetologie","preclinical","article","10.1007/s12467-012-0039-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049009","RF32 | PSUN59 Glucagon-Like Peptide-1 Analogues: A New Way to Quit Smoking? SKIP – a Randomised Controlled Study","Cihan Atila","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.536",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0049010","Efficacy and Safety of Once Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist Versus Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1)","Julio Rosenstock","2022","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0042-1746287",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049011","Effects of exenatide once-weekly (QW) on gastric emptying, postprandial glycaemia and glucose absorption in health","Kenneth Jones","2019","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0049012","1069-P: Effect of Sacubitril/Valsartan Combination Therapy in Type 2 Diabetes Mellitus Patients with Elevated NT-proBNB and Preserved Ejection Fraction","Vishal Anand Gupta","2020","Diabetes","other","article","10.2337/db20-1069-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049013","Herbal medicine in the treatment of patients with type 2 diabetes mellitus","Guoming Pang","2019","Chinese Medical Journal","preclinical","article","10.1097/cm9.0000000000000006","30628962",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049014","GLP-1-Rezeptor – GLP-1-Agonist-Bindung bestimmt das Ausmaß der Insulinfreisetzung","SABINE KAHL","2018","Der Diabetologe","other","article","10.1007/s11428-018-0350-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049015","Multiomic comparison of GLP1R analogues interaction networks","Zofia Wicik","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae666.3507",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049016","8707 Are We Adequately Prescribing Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) Or Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) In Patients With Type 2 Diabetes Mellitus (T2DM) And Established Atherosclerotic Cardiovascular Disease (ASCVD) Or Chronic Kidney Disease (CKD) In An Outpatient Setting: A Community Center Experience","R. Maan","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.1032",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049017","Incretin Mimetics Vildagliptin and Exenatide Improve Pedicle Skin Flap Survival in Rats.","Lyudmila M. Danilenko","2019","Journal of World s Poultry Research","preclinical","article","10.36380/scil.2019.wvj24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049018","Abstract 13814: Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials","Subodh Verma","2020","Circulation","randomized_trial","article","10.1161/circ.142.suppl_3.13814",null,null,"ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001933","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0049019","305-OR: Tirzepatide in Type 1 Diabetes—Safety, Tolerability, and Clinical Outcomes—Real-World Experience from a Large UK Center","Simon A. Berry","2025","Diabetes","nonrandomized_study","article","10.2337/db25-305-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049020","PERSISTENCE AND DISCONTINUATION OF SGLT-2I AND GLP-1RA AMONG PERSONS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE TREATED IN US CARDIOLOGY CLINICS: INSIGHTS FROM THE COORDINATE-DIABETES TRIAL","Adam J. Nelson","2024","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(24)03880-4",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0049021","1428-P: Cardiovascular Outcomes with Dulaglutide vs. Liraglutide","Andy Bowe","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1428-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049022","DISCOVERY AND DEVELOPMENT OF SEMAGLUTIDE AS ANTI-OBESITY MEDICATION TO REDUCE CARDIOVASCULAR RISK IN DIABETIC PATIENTS","Sengar Yashwardhan Pratap Singh","2023",null,"other","article","10.58532/v3bgpn10p2ch3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0049023","Real-world Use of Oral Semaglutide in Patients with Type 2 Diabetes in India: A Retrospective Study","Sachin Chittawar","2024","International Journal of Diabetes and Technology","randomized_trial","article","10.4103/ijdt.ijdt_31_24",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049024","Sa1665: PATTERNS OF PRESCRIPTION AND DISCONTINUATION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) AMONG PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS)","Misha Gautam","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02077-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049025","S919 Debunking Endoscopy Myths: GLP1-RA Use and GI Symptoms Do NOT Predict Bowel Preparation Success","Anshu Wadehra","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001033044.23298.e6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049026","Sa2179 GLP-1 RECEPTOR AGONIST THERAPY AND REDUCED POST-ERCP PANCREATITIS: CLUES TO A PROTECTIVE MECHANISM USING THE TRINETX NETWORK","Yash S. Shah","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)01407-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049027","Tu1778 EARLY-ONSET GASTROINTESTINAL MALIGNANCIES AMONG PATIENTS WITH OBESITY AND/OR DIABETES MELLITUS EXPOSED TO GLP-1 RECEPTOR AGONISTS","Paolo J. DiSano","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04974-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049028","D-65 | Major Adverse Cardiovascular Outcomes After Percutaneous Coronary Intervention in Patients Treated With GLP-1 Receptor Agonists: A Comparison of Single- Versus Dual-Incretin Therapy","Prabhjot Hundal","2026","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2026.104933",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049029","Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes mellitus: how to choose the right solution","Mikhail Borisovich Antsiferov","2023","Фарматека","other","article","10.18565/pharmateca.2023.12.116-126",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049030","Effect of baseline body mass index (BMI; < 30 kg/m2, ≥30-< 35 kg/m2, and ≥35 kg/m2) on glycaemic response and weight change in patients with type 2 diabetes (T2DM) with baseline HbA1c ≥7.5% after treatment with the once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA), dulaglutide, and active comparators in five clinical studies (AWARD 1 – 5)","M. H. Cummings","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549752",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049031","THU334 Trends In GLP-1 Agonist Utilization In Diabetics With And Without Vascular Disease","Pinar Sargin","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.767",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049032","Patient willingness-to-pay for liraglutide and exenatide in Sweden based on head-to-head clinical trial results","Martin Ridderstråle","2009","Lund University Publications (Lund University)","other_trial","article","10.1007/s00125-009-1445-1",null,null,null,null,"openalex","FALSE","open_pdf","5","FALSE","article"],["R0049033","Thioredoxin-interacting protein TXNIP as a promising diagnostic marker for metabolic-associated fatty liver disease in patients with type 2 diabetes","Ася Мелтонян","2025","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2024-532",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049034","Interim Results from FINE-REAL: A Prospective Study Providing Insights into the Use of Finerenone in Routine Clinical Settings","Susanne B. Nicholas","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s1857a",null,null,"ClinicalTrials.gov:NCT05348733",null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049035","Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection","Maribel Beaumont","2018","AAPS Open","preclinical","article","10.1186/s41120-018-0026-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049036","SUN-LB044 Effects of Glucagon-Like Peptide-1 (GLP-1) on the Hypothalamic-Pituitary-Gonadal Axis in Healthy Men","Chioma N. Izzi‐Engbeaya","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-sun-lb044",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049037","Indikationsgebiete inkretinbasierter Therapien: Analyse von Studienpopulation, Studiendesign und Effektivität in Exenatide- und DDP-4-Inhibitor-Studien","O Bachmann","2007","Diabetologie und Stoffwechsel","other","article","10.1055/s-2007-981274",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049038","Survival in patients with hepatobiliary and pancreatic cancers taking GLP-1 receptor agonist therapy.","Carolina Vélez-Mejía","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e16276",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049039","2614-P: Understanding the Lived Experiences of Dosing Practices among People Living with Obesity (PwO) Using Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) for Weight Loss (WL): A U.S. Qualitative Study","Vanita Aroda","2026","Diabetes","other","article","10.2337/db26-2614-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049040","The effects of exenatide treatment on thyroid","Derya Köseoğlu","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p1066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049041","Combined Therapy of GLP-1 Receptor Agonists and Basal Insulin in Type 2 Diabetes: An Updated Review","Helena Tristão Sanches","2025","Medical & Clinical Case Reports Journal","randomized_trial","article","10.51219/mccrj/helena-tristao-sanches/341",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049042","Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study (Preprint)","Amit R. Majithia","2021",null,"other","article","10.2196/preprints.31629",null,null,"ClinicalTrials.gov:NCT03865381",null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0049043","Su1036 GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA): IMPACT ON OUTPATIENT UPPER ENDOSCOPY PROCEDURE QUALITY","Frederick B. Peng","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01939-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049044","Differential impact of anti-diabetic treatments on pancreatic cancer cell growth in cell culture conditions mimicking different stages in the natural history of diabetes mellitus type","Yugong Feng","2008","Journal of Clinical Oncology","preclinical","article","10.1200/jco.2008.26.15_suppl.4640",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049045","Utilization of zebrafish larvae to monitor gastric motility in diabetes mellitus: targeting GLP‐1 and GIP receptors","Chung Man Jessica Hui","2022","The FASEB Journal","preclinical","article","10.1096/fasebj.2022.36.s1.r2310",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049046","Exploring the Potential of GLP-1 Receptor Agonists in Psoriasis Treatment: A Review Article","Aleksandra Maria Śledziewska","2025","Archiv Euromedica","nonrandomized_study","article","10.35630/2025/15/3.316",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049047","Lucinactant","Dennis J. Cada","2012","Hospital Pharmacy","other_trial","article","10.1310/hpj4710-788",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049048","36-OR: Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists","Insiya B. Poonawalla","2020","Diabetes","nonrandomized_study","article","10.2337/db20-36-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049049","The effect of dapagliflozin on alanine aminotransferase as a marker of liver inflammation: updated results from the ABCD dapagliflozin audit","Thomas SJ Crabtree","2020","British Journal of Diabetes","nonrandomized_study","article","10.15277/bjd.2020.239",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049050","#1701797 Waist-to-height ratio shifts over time in tirzepatide-treated participants – post hoc analysis in SURMOUNT-1 and SURMOUNT-2","Beverly Tchang","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.259",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049051","721 SAFETY AND CLINICAL EFFECTIVENESS OF GLP1 AGONISTS IN INFLAMMATORY BOWEL DISEASE PATIENTS","Priya Sehgal","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)00890-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049052","Study of the influence of GLP-1 receptor agonists on the metabolic activity of the intestinal microbiota in patients with type 2 DM","О.В. Zinych","2023","ScienceRise Medical Science","other","article","10.15587/2519-4798.2023.297535",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049053","Sex differences in the cardiovascular consequences of type 2 diabetes: the role of glucose-lowering therapy","Rishi Gupta","2026","Current Opinion in Physiology","other_trial","article","10.1016/j.cophys.2026.100930",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","review"],["R0049054","1098-P: Tracking Treatment Outcomes Using the Semaglutide Patient Support Solution App","Vaia Lambadiari","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1098-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049055","18-PUB: Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Patients with Type 2 Diabetes","Salvatore Crisafulli","2025","Diabetes","nonrandomized_study","article","10.2337/db25-18-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049056","PDB17 - REAL-WORLD DOSING BEHAVIOURS AND OUTCOMES WHEN SWITCHING TO IDEGLIRA FROM A FREE COMBINATION OF INSULIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY","Hermione Clare Price","2018","Value in Health","nonrandomized_study","article","10.1016/j.jval.2018.09.723",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0049057","Bariatric surgery: a call for greater access to coordinated surgical and specialist care in the public health system","Ahmad Aly","2022","The Medical Journal of Australia","randomized_trial","article","10.5694/mja2.51673","35964266",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049058","(368) Effects of GLP-1 Receptor Agonists on Male Reproductive Hormones, Semen Parameters, and Metabolic Outcomes: A Systematic Review","O Raheem","2026","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdag118.332",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0049059","PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS","Chakrapani Balijepalli","2018","Value in Health","narrative_review","article","10.1016/j.jval.2018.09.718",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0049060","238-OR: Effect of Baseline Antihyperglycemic Medications on Weight Reduction with Tirzepatide—SURMOUNT-2 Subgroup Analysis","Sriram Machineni","2024","Diabetes","other","article","10.2337/db24-238-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049061","Effect of Glucagon-Like Peptide-1 on Epicardial Fat in Patients with Type 2 Diabetes Mellitus and Obesity","D.G. Gusenbekova","2023","Doctor Ru","other","article","10.31550/1727-2378-2023-22-8-47-50",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049062","Études SUSTAIN 1-5 : perte de poids sous semaglutide selon la catégorie d’IMC initial","Guillaume Charpentier","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.597",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049063","Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type-2 Diabetes Mellitus in the UK","Max Schlueter","2016","Value in Health","other","article","10.1016/j.jval.2016.09.1886",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049064","O impacto mental do uso de Ozempic e Mounjaro em pacientes obesos","Gabriela Cardoso de Araújo","2025","Journal of Medical and Biosciences Research.","other","article","10.70164/jmbr.v2i2.600",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049065","Effect of GLP-1 Receptor Agonists on Inflammatory Markers, Nutritional Markers, and Erythropoiesis-Stimulating Agent (ESA) Use in Patients on Hemodialysis: A Propensity Score-Matched Analysis","Suman Kumar Lama","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025rqx87nvk",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049066","Production of EW,a Recombinant Analogue of Exendin-4,by Genetic Engineering and Its in Vivo Hypoglycemic Activity Analysis","Yi Chen Lu","2013","Zhongguo linchuang yixue","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049067","VAMP8 Is an Endosomal v-SNARE That Supports GLP-1 Receptor Recycling in Pancreatic β-Cells","Liangwen Liu","2025","Diabetes","other","article","10.2337/db24-0921","40608311",null,null,null,"openalex","TRUE",null,null,"FALSE","article; other"],["R0049068","Su2050: THE IMPACT OF PRE-PROCEDURAL DIET ON THE RISK OF RESIDUAL GASTRIC CONTENTS IN EGD WITH GLP-1 RECEPTOR AGONISTS","Ryan D. Plunkett","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03102-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049069","GLP-1 Receptor Agonist Use Is Associated With Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth","John Damianos","2025","Foregut The Journal of the American Foregut Society","other","article","10.1177/26345161251353437",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049070","7049 DUNNIGAN LIPODYSTROPHY AND SUCCESSFUL USE OF AID WITH U200","Tina Kader","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.741",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049071","GLP-1 Drugs Associated With Lower Overall Cancer Risk","Lauren M. Schneider","2025","JAMA","other","article","10.1001/jama.2025.13876","40938612",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049072","Abstract #299: Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Type 1 Diabetes, the Adjunct Two Randomized Trial","Bo Åhrén","2016","Endocrine Practice","randomized_trial","article","10.1016/s1530-891x(20)45007-4",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049073","4324Effects of the glucagon like peptide-1 receptor agonist on arterial stiffness, LV myocardial deformation and oxidative stress in newly diagnosed type 2 diabetes after 6-month treatment","Ignatios Ikonomidis","2018","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehy563.4324",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049074","208-OR: Comparable Improvement in NAFLD, Weight Loss, and Lipid Metabolism in Rats Treated with Dual GLP-1–GIP Receptor Agonist (Tirzepatide) and Gastric Sleeve","JEHAD ABUBAKER","2023","Diabetes","preclinical","article","10.2337/db23-208-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049075","418 Activation of the Glucagon-Like Peptide-1 Pathway in Obese Pre-Diabetic Individuals Improves Endothelial Function Independently of Weight Loss","Mona Mashayekhi","2022","Journal of Clinical and Translational Science","randomized_trial","article","10.1017/cts.2022.243",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049076","Sa1982 INTRAGASTRIC BALLOON TREATMENT IN ASSOCIATION WITH LIRAGLUTIDE: A NOVEL APPROACH IN THE EXCESS WEIGHT TREATMENT","Ricardo José Fittipaldi-Fernandez","2019","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2019.03.313",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049077","1110-P: Use of IDegLira Is Associated with High Persistency Rates Up to 12 Months (M) and Improved A1C after 6M in Swedish Clinical Practice","Björn Eliasson","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1110-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049078","1496-P: Clinical Inertia in Relation to Sociodemographic Factors among Patients with Type 2 Diabetes (T2D) in the United States","Gail F. Fernandes","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1496-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049079","Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on vascular function and liver steatosis in diabetes","Ignatios Ikonomidis","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.2560",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049080","1104-P: Prevalence and Clinical Determinants of Nonalcoholic Fatty Liver Disease by Liver Scores in Adults with T1DM","MICHELLE D. LUNDHOLM","2022","Diabetes","nonrandomized_study","article","10.2337/db22-1104-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049081","Exenatide Improves the Survival of Random-Pattern Skin Flap via TFE3 Mediated Autophagy Augment","Jiafeng Li","2020","SSRN Electronic Journal","other","article","10.2139/ssrn.3556620",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0049082","55 - Comparative Analysis of A1c and Weight Reduction Potential of Subcutaneous GLP-1 Receptor Agonists in a Real-World Setting","Jeffery Tong","2020","Canadian Journal of Diabetes","nonrandomized_study","article","10.1016/j.jcjd.2020.08.061",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049083","Ethylthio-1H-tetrazole (ETT) as coupling additive for the solid-phase synthesis (SPS) of hindered amino acid-containing peptides","Hlobisile Nzama","2024","Tetrahedron Letters","other","article","10.1016/j.tetlet.2024.155108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049084","804-P: Understanding Off-Label Use of GLP-1 (Glucagon-Like Peptide-1 Receptor) Agonists among Providers Participating in the T1D Exchange Quality Improvement Collaborative (T1DX-QI)","MARY PAT GALLAGHER","2024","Diabetes","other","article","10.2337/db24-804-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049085","S2816 Identifying Screening Deficits for MASLD in the Diabetic Population at an Academic Endocrinology Clinic","Ahila Manivannan","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001138724.42630.ab",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049086","1672-P: Weight Changes after Tirzepatide Cessation in Chinese Adults with Overweight/Obesity—A Real-World Follow-up Study of SURMOUNT-CN Trial","Ying Chen","2024","Diabetes","randomized_trial","article","10.2337/db24-1672-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049087","Role of NIB in connecting science to patients by assuring safe and quality anti diabetic products","Gurminder Bindra","2019","J Med Sci","other","article","10.33883/jms.v22i2.445",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049088","Multifaceted repurposing of Flozins, Glitazones, Gliptins and GLP-1 agonists as potential Pluritherapeutic agents","Bassam Mahfouz Ayoub","2020","Research Journal of Pharmacy and Technology","nonrandomized_study","article","10.5958/0974-360x.2020.00096.7",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049089","(189) Effects of GLP-1 Receptor Agonists on Erectile Function and Ejaculation: A Systematic Review","Abuzar Mahmood","2025","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdaf320.188",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0049090","Abstract 4148007: Cardiovascular outcomes with Glucagon-like Peptide-1 receptor agonists and Sodium-glucose Cotransporter-2 Inhibitors in patients with ischemic stroke in the community","Mohammad Ali Sheffeh","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4148007",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049091","Real-world evidence of the effect of adjunctive semaglutide on weight change, liver steatosis and metabolic control in people with type 1 diabetes","Jonathan Mertens","2025","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.110.p418",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049092","S1675 Tirzepatide vs Semaglutide in Obese Patients With MAFLD or MASH: A Comparative Analysis of Cardiovascular and Gastrointestinal Outcomes, and the Risk of Progression to Fibrosis or Hepatocellular Carcinoma","Olanrewaju Felix Adeniran","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001036068.77159.99",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049093","GLP-1 Analogues: Monotherapy","Sanjay Kalra","2013","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/11892_5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0049094","New and Promising Drugs for Obesity","Natalia G. Vallianou","2016","BENTHAM SCIENCE PUBLISHERS eBooks","other","article","10.2174/9781681081854116020009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0049095","SAT-736 Post-hoc analysis of weight reduction and physical function in participants with obesity or overweight and osteoarthritis in SURMOUNT-1","Thomas J. Schnitzer","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.592",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049096","Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in GRADE: A Randomized Clinical Trial","Jeffrey S. Gonzalez","2024",null,"randomized_trial","article","10.2337/figshare.25075580",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0049097","Sa1451 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USE DOES NOT INCREASE THE RISK FOR ACUTE PANCREATITIS AND IS ASSOCIATED WITH LOWER COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES WHO DEVELOP ACUTE PANCREATITIS: A MULTI-CENTER ANALYSIS","Luis Miguel Nieto","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01515-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049098","P4‐441: The diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of Alzheimer's disease (AD) cases","Konrad Talbot","2011","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2011.09.137",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049099","0990 Effect of Semaglutide on Apnea Hypopnea Index in Female Adolescents with Polycystic Ovary Syndrome and Obesity","Karolina Bohdan","2025","SLEEP","randomized_trial","article","10.1093/sleep/zsaf090.0990",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0049100","Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis","Sharon L. Mulvagh","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.4313",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049101","O79 Discontinuation of exogenous insulin therapy in type 2 diabetes following proximal intestinal mucosal ablation: the STEAM-IE trial","Benjamin Norton","2026",null,"other_trial","article","10.1136/gutjnl-2026-bsg.78",null,null,"ClinicalTrials.gov:NCT06655740","S003386","openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0049102","Parallel-access compounds: unregulated availability as a consideration in research ethics","Edward Jacobs","2026","JME Practical Bioethics","other_trial","article","10.1136/jmepb-2026-000292",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0049103","Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model","Sanbao Chai","2023","Chinese Medical Journal","randomized_trial","article","10.1097/cm9.0000000000002520","36723862",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049104","Abstract P140: Potential Mediators for Cardiovascular Benefits of Novel Diabetes Medications: A Meta-Regression Analysis","Jose M Rodriguez Valadez","2023","Circulation","other","article","10.1161/circ.147.suppl_1.p140",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049105","S243 Comparative Risk of Acute Pancreatitis in Hypertriglyceridemia Patients Treated With SGLT2 Inhibitors vs GLP-1 Receptor Agonists: A Propensity-Score Matched Analysis","Ibrahim Shanti","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001127432.56625.2e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049106","Pharmacological Management of Metabolic Syndrome in Crisis Settings: A Narrative Review and Three-Axis Model","Olena Mykhailenko","2025","Galician Medical Journal","narrative_review","article","10.21802/e-gmj2025-a27",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0049107","Once-Daily Lixisenatide in Combination with Basal Insulin ± Oral Antihyperglycemic Agents in Patients with Type 2 Diabetes Selectively Reduces Postprandial Hyperglycemic Daytime Exposure","HARPREET SINGH BAJAJ","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.090",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049108","FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment","Arad Jain","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.867",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049109","DOP57 GLP-1 based therapies and risk of Inflammatory Bowel Disease: real world evidence from a nationwide cohort study","Heidi S. Christensen","2023","Journal of Crohn s and Colitis","nonrandomized_study","article","10.1093/ecco-jcc/jjac190.0097",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0049110","Potentiel antidiabétique de métabolites de polyphénols : les urolithines","Morgane Bayle","2017","HAL (Le Centre pour la Communication Scientifique Directe)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0049111","PDB51 Medication Adherence and Medical Costs Associated With Exenatide Bid Versus Liraglutide: A Retrospective Database Analysis","E.M. Pelletier","2012","Value in Health","nonrandomized_study","article","10.1016/j.jval.2012.03.972",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0049112","GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Obstructive Sleep Apnea: Cardiovascular, Pulmonary, and Mortality Outcomes","Karldon Iwuchukwu Nwaezeapu","2025","American Heart Journal","other","article","10.1016/j.ahj.2025.07.034",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049113","684 Efficacy and safety of GLP-1 agonist therapy in overweight and obese subjects with cystic fibrosis-related diabetes: a pilot study","Amir A. Moheet","2025","Journal of Cystic Fibrosis","other","article","10.1016/s1569-1993(25)02300-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049114","Transcriptomics of SGLT2-Positive Proximal Tubule S1 Segments in Mice: Response to Diabetes, SGLT1/2 Inhibition, or GLP1 Receptor Agonist","Young Chul Kim","2023","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20233411s139c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049115","Heart Failure (HF) in the SGLT2 Inhibitor (SGLT2i) and GLP1 Receptor Agonist (GLP1-RA) Era: Does Hypertension (HTN) Matter?","Sydney Elizabeth Hartsell","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s1864c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049116","PDB39 Dosing Patterns Among Patients with Type 2 Diabetes (T2D) Initiating Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) in France and the Netherlands","Kirsi Norrbacka","2021","Value in Health","other","article","10.1016/j.jval.2021.04.436",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049117","062. DEVELOPMENTAL ORIGINS OF TYPE 2 DIABETES: EPIGENETIC MECHANISMS IN BETA CELL FAILURE","Rebecca Anne Simmons","2009","Reproduction Fertility and Development","preclinical","article","10.1071/srb09abs062",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049118","INFLUENCE OF ANESTHESIA TYPE ON POST-ENDOSCOPIC OUTCOMES IN GLP-1 RECEPTOR AGONIST USERS UNDERGOING ELECTIVE ENDOSCOPY: A NATIONAL DATABASE STUDY","Harsimran Kalsi","2025","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/j.gie.2025.03.264",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049119","ACNMD26-123: LONG-TERM REAL-LIFE EXPERIENCE OF SEMAGLUTIDE IN A MONOCENTRIC COHORT WITH TYPE 2 DIABETES AND METABOLIC DYSFUCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)","Giovanni Petralli","2026","Digestive and Liver Disease","nonrandomized_study","article","10.1016/s1590-8658(26)00598-0",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049120","OP60 EFFICACY AND SAFETY OF LIRAGLUTIDE VERSUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT (LIRA-RENAL): A RANDOMISED TRIAL","Chantal Mathieu","2014","Diabetes Research and Clinical Practice","randomized_trial","article","10.1016/s0168-8227(14)70266-9",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049121","The Short- and Long-Term Effect of Liraglutide on the Beta Cell Function in Type 2 Diabetic Patients","Toshinobu Suzuki","2014","Journal of Diabetes Mellitus","other","article","10.4236/jdm.2014.44046",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049122","PREOPERATIVE GLP-1 RECEPTOR AGONIST USE AND RISK OF POSTOPERATIVE PNEUMONIA IN OBESE PATIENTS UNDERGOING ERAS-BASED COLORECTAL SURGERY: A MULTI-INSTITUTIONAL COHORT STUDY","Chia-Yu Kuo","2026","Clinical Nutrition ESPEN","nonrandomized_study","article","10.1016/j.clnesp.2026.103543",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049123","Role of GLP-1 RA and GLP-1/GIP RA in comprehensive preconception preparation for women with obesity","Т. Л. Каронова","2025","Russian Medical Inquiry","other","article","10.32364/2587-6821-2025-9-10-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049124","Male health and obesity – diagnostic and therapeutic approach","Safar I. Gamidov","2019","Obesity and metabolism","other","article","10.14341/omet10314",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049125","Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue","Anna S. Pogorelova","2018","Meditsinskiy sovet = Medical Council","randomized_trial","article","10.21518/2079-701x-2018-4-36-41",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049126","Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis","Cho‐Han Chiang","2024","Blood","nonrandomized_study","article","10.1182/blood-2024-206409",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049127","Reduction in the Risk of Developing Type 2 Diabetes (T2D) with Liraglutide 3.0 mg in People with Prediabetes from the SCALE Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled Trial","David C.W. Lau","2016","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2016.08.100",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049128","The use of semaglutide for weight loss: a literature review","Gisele Karlec Jacobs","2023",null,"narrative_review","article","10.56238/homeiisevenhealth-004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0049129","472-P: Online Patient Education on GLP-1 Receptor Agonists in Patients with T2D and CVD Prompts Real-Life Changes","Amy T. Larkin","2021","Diabetes","other","article","10.2337/db21-472-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049130","Potential role of GLP‐1 receptors in emesis control in Suncus murinus (house musk shrew)","John Anthony Rudd","2011","The FASEB Journal","preclinical","article","10.1096/fasebj.25.1_supplement.lb423",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049131","Table 1 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors","Jasmine Singh Sukumar","2026",null,"other","article","10.1158/2767-9764.31444525",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0049132","Abstract TP098: GLP-1 Agonist Improves VCID by Preventing Mitochondrial Dysgenesis in Diabetic Mice.","Mohammed A. Abdelsaid","2026","Stroke","randomized_trial","article","10.1161/str.57.suppl_1.tp098",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049133","The Effect of Semaglutide on Kidney Function: Post Hoc Analysis of Three Randomized Controlled Trials in Non-Alcoholic Fatty Liver Disease","Katherine R. Tuttle","2022","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20223311s1850a",null,null,"ClinicalTrials.gov:NCT03357380; ClinicalTrials.gov:NCT02970942; ClinicalTrials.gov:NCT03987451","S000576; S000922; S001764","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0049134","Tu1226: GLP-1 AGONISTS USE IS ASSOCIATED WITH LOWER USE OF PPI, ESOPHAGITIS AND ESOPHAGEAL STRICTURES IN PATIENTS WITH OBESITY AND GERD WHEN COMPARED WITH GASTRIC BYPASS: A NATIONAL DATABASE ANALYSIS","Luis Miguel Nieto","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04018-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049135","Pediatric diabetes update","Jasmine Gujral","2022","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13317","36114692",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049136","Empagliflozin and the risk of Gout: Analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","Lisette Koeneman","2024","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0044-1785427",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049137","S1268 Evaluating Glucagon-Like Peptide 1 Receptor Agonist Use and Retained Gastric Contents: Safety Implications for Upper Endoscopy","Armin E. Frie�","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001132532.13017.95",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049138","AWARD-7 Post Hoc Analysis: Circulating Proteins Measured by Joslin Kidney Panel Identify Dulaglutide Responders","Brandon E. McFarlin","2023","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20233411s1135b",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0049139","Obesity","GERALD H. TOMKIN","2021","Current Research in Diabetes & Obesity Journal","other","article","10.19080/crdoj.2021.15.555901",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049140","S4332 I Miss Eating: Medication-Induced Gastroparesis from Semaglutide","P. Gallego Gomez","2023","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000966968.44182.37",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049141","Development of severe gastroparesis and gastric food bezoar following administration of glucagon-like peptide 1-receptor agonist (GLP1-RA) therapy","Veronica Angela Preda","2021","Obesity Abstracts","other","article","10.1530/obabs.3.p1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049142","Proinsulin Processing and Transplanted Islets","Michael Roehrhoff Rickels","2010","American Journal of Transplantation","other","article","10.1111/j.1600-6143.2010.03069.x","20346066",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049143","OS-119 Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial","Eric Lawitz","2024","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(24)00560-9",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0049144","I. Semaglutide: A New Kid on the Block for Nonalcoholic Steatohepatitis, but a Long Way to Go for India","Pankaj Puri","2021","Journal of Clinical and Experimental Hepatology","other","article","10.1016/j.jceh.2021.06.002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049145","Effects of liraglutide in the treatment of severe obesity in a young patient with parkinson’s disease","Michela Barichella","2019","Journal of the Neurological Sciences","other","article","10.1016/j.jns.2019.10.1402",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049146","Abstract #298 Efficacy and Safety of Semaglutide in Subjects with Type 2 Diabetes Across Race and Ethnicity Subgroups: A Post Hoc Analysis of the Sustain Trials","Cyrus V Desouza","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47143-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049147","S2477 Limited Approvals in MASLD Highlight the Need to Reevaluate FDA Guidance for Outcome Measures","Akanksha Togra","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001137368.57872.32",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049148","RWD112 MPACT OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS TO TREAT OBESITY ON NON-GLP-1 COSTS AMONG COMMERCIALLY INSURED MEMBERS WITHOUT DIABETES: A THREE-YEAR RETROSPECTIVE ANALYSIS","Jacinda Tran","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.2100",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049149","Therapy Simplification with Dulaglutide in Elderly Patients: A Real World Study","Margherita Occhipinti","2023","Journal of Diabetes Research Review & Reports","nonrandomized_study","article","10.47363/jdrr/2023(5)168",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049150","680-P: Once-Weekly Dulaglutide 3 mg and 4.5 mg Gastrointestinal Tolerability: Post-hoc Analysis of Incidence and Prevalence in Award-11","Joanna T Van","2021","Diabetes","randomized_trial","article","10.2337/db21-680-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049151","Evaluation of 18F-TTCO-Cys40-Exendin-4 as a PET probe for GLP-1R targeted imaging","Zhanhong Wu","2012","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049152","Antidiabetic effects of sub-chronic administration of stable incretin mimetics N-AcGIP and exendin-4 (1-39) amide in obese-diabetic mice","Finbarr P.M. O'Harte","2007","Diabetic Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049153","Abstract 12604: Prescribing Patterns of Cardioprotective Antihyperglycemics Among Medicare Beneficiaries Across United States Counties by their Socioeconomic Disadvantageousness","Jonathan M. Hanna","2021","Circulation","other","article","10.1161/circ.144.suppl_1.12604",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049154","The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study","Regina Castaneda","2026","The Lancet Obstetrics Gynaecology & Women s Health","nonrandomized_study","article","10.1016/s3050-5038(25)00145-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049155","SAT-245 Semaglutide for type 2 diabetes control in metabolic dysfunction-associated steatotic liver disease (MASLD): a two-way effect?","Giovanni Petralli","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)01801-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049156","A Prospective Observational Study of GLP-1 and GLP-1/GIP Receptor Agonists in Patients with Well-Differentiated Neuroendocrine Tumors","Aaron H. Pruitt","2026","Endocrine Abstracts","other","article","10.1530/endoabs.116.t12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049157","The effect of glucagon-like peptide 1 agonists on white and brown adipose tissue according to magnetic resonance spectroscopy in obese patients","N. Kurochkina","2023","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2023.06.775",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049158","LY3437943 (LY), A Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2D after 12 Weeks of Treatment","Shweta Urva","2023","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0043-1767868",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049159","S1255 Effect of Weight Loss Surgery and Weight Loss Medications on the Risk of Colorectal Cancer: A Nationwide Population-Based Cohort Study","Zryan Shwani","2021","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000778552.40501.29",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049160","THU-248 Unraveling the interplay of FGF21 and GLP1 analogue in metabolic dysfunction-associated steatohepatitis in vivo","Anouk Oldenburger","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)01710-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049161","Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats","Isabelle Padrutt","2015","Zurich Open Repository and Archive (University of Zurich)","other","article","10.5167/uzh-103815",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0049162","P10 Evaluation of the metabolic profile of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced fibrosis in anticipation of demand for future therapies","Georgeina L Jarman","2025",null,"nonrandomized_study","article","10.1136/gutjnl-2025-basl.27",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049163","Su1617: GLP-1 RECEPTOR AGONISTS AND RISK FOR ALCOHOL-ASSOCIATED CIRRHOSIS AND DECOMPENSATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ALCOHOL USE DISORDER","Soo Young Hwang","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02805-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049164","739-P: iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study","Rosemarie Lajara","2022","Diabetes","nonrandomized_study","article","10.2337/db22-739-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049165","Real-World-Ergebnisse der Zugabe von Insulin glargin 300 E/ml (Gla-300) zur GLP-1RA-Therapie bei Menschen mit Typ-2-Diabetes (T2D): Die DELIVER-G-Studie","Timothy Silleck Bailey","2022","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0042-1746337",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049166","8002 A Dose Beyond Limits: Semaglutide and Insulin Overdose - A Novel Approach to Management","Francine Fane Foo","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.644",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049167","Utilizing AI and Social Media Analytics to Discover Unreported Adverse Side Effects of GLP-1 Receptor Agonists Used for Obesity Treatment","Alon Bartal","2025","Proceedings of the ... Annual Hawaii International Conference on System Sciences/Proceedings of the Annual Hawaii International Conference on System Sciences","other","article","10.24251/hicss.2025.710",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0049168","OP0223 THE EFFECT OF WEIGHT LOSS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ON STRUCTURAL CHANGES IN KNEE OSTEOARTHRITIS: SECONDARY ANALYSIS OF THE RANDOMISED, PLACEBO-CONTROLLED LOSEIT TRIAL","M.W. Brejnebøl","2025","Annals of the Rheumatic Diseases","randomized_trial","article","10.1016/j.ard.2025.05.234",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0049169","IMPACT OF COMBINED TIRZEPATIDE (MOUNJARO®/ZEPBOUND®) AND RESISTANCE EXERCISE (T-REX) ON AEROBIC FITNESS IN OVERWEIGHT AND OBESE OLDER ADULTS.","Destiny R Underwood","2026","Journal of Clinical Exercise Physiology","randomized_trial","article","10.31189/2165-7629-15-s2.250",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049170","Network Propagation Analysis to Uncover the Mechanisms of Antidiabetics as Therapeutic Candidates in Pulmonary Arterial Hypertension","Mayur Sarangdhar","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a4976",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049171","Clinical Challenge: Managing Euglycemic Diabetic Ketoacidosis in a Post-Whipple Procedure Patient on SGLT-2 Inhibitors and GLP-1 Agonist","Hafiz Muhammad Hashim Butt","2025","American Journal of Respiratory and Critical Care Medicine","other","article","10.1164/ajrccm.2025.211.abstracts.a5709",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049172","Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","Jorge E. Rico-Fontalvo","2024","Nefrología Latinoamericana","other","article","10.24875/nefro.24000031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049173","Etudes SUSTAIN 1-3 : la diminution de la résistance à lâinsuline sous semaglutide est principalement liée à la perte de poids","Bruno Vergãs","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049174","Long-Acting Glucagon-Like Peptide-1 (GLP-1) Agonist Therapy in Post Solid Organ Transplant Patients.","Jill C. Krisl","2014","Transplantation","nonrandomized_study","article","10.1097/00007890-201407151-01757",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049175","Obesity: Genetic Insights, Therapeutic Strategies, Pharmacoeconomic Impact, and Psychosocial Dimensions","Gladious Naguib El-hadidy","2025","Obesities","other","article","10.3390/obesities5040086",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049176","Focus on risk factors and prediction","Géza Hálasz","2023","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwad103","37159484",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049177","Polycystic ovary syndrome: Pathophysiology, Symptoms, Risk factors, and Pharmacological treatment","Fatima Afzal","2024","Research Journal for Social Affairs","other","article","10.71317/rjsa.002.04.0035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049178","Diabetes News","Melissa L. An","2016","Journal of Diabetes","other_trial","article","10.1111/1753-0407.12429","27206787",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0049179","Glucagon‐Like Peptide (GLP1) Agonist Increases GFR and Suppresses Proximal Reabsorption","Scott Culver Thomson","2010","The FASEB Journal","preclinical","article","10.1096/fasebj.24.1_supplement.1059.32",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049180","7358 Profile of Circulating miRNAs Associated with Body Weight Reduction in Type 2 Diabetes Patients Treated with GLP-1 Receptor Agonist Dulaglutide: Secondary Analysis of AWARD-7 Trial","Eiichiro Satake","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.021",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049181","Consistency of treatment effect across the range of baseline HbA1c in patients with type 2 diabetes mellitus (T2DM) treated with once-weekly dulaglutide or comparators in AWARD-1, -5 and -6","Raffaella Gentilella","2016","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0036-1580999",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049182","Boehringer Ingelheim Licenses Zealand Pharma’s Drug Candidates for Type 2 Diabetes and Obesity","Heather N. Cartwright","2011","PharmaDeals Review","other","article","10.3833/pdr.v2011i6.1485",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049183","Semaglutide And Clinical Outcomes In Patients With Heart Failure With Reduced Ejection Fraction And Obesity: A Retrospective Cohort Study Using Real World Data","Ali Reza Rahmani","2026","Journal of Cardiac Failure","nonrandomized_study","article","10.1016/j.cardfail.2025.11.149",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049184","Effect of exenatide once-weekly (QW) on gastric emptying in health: impact on glycaemia and glucose absorption","Karen L. Jones","2019","HAL (Le Centre pour la Communication Scientifique Directe)","other_trial","article",null,null,null,"ANZCTR:ACTRN12616000955415",null,"openalex","FALSE","no_doi","5","FALSE","conference-paper"],["R0049185","Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Reduced Sepsis and Organ Injury in Adults Hospitalized With Infection","London Aman","2024",null,"other","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1108",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049186","ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia","Raashi Mamtani","2022","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvac150.625",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049187","Enzyme resistant N-terminally modified cholecystokinin-8 exhibits enhanced satiety and insulinotrophism compared with exendin-4","Finbarr P.M. O'Harte","2007","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049188","2100-P: Binding Kinetics, GLP-1 Receptor Internalization, and Effects on Insulin Secretion for GL0034 and Related GLP-1R Agonists","Gaëlle Carrat","2020","Diabetes","preclinical","article","10.2337/db20-2100-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049189","393-P: Combination Treatment with Lisinopril and Empagliflozin Improves Urine and Histological Markers of Diabetic Kidney Disease in Female Renin-AAV UNx db/db Mice","Mette V. Østergaard","2021","Diabetes","preclinical","article","10.2337/db21-393-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049190","192-OR: Effect of Video Conferences between Endocrinologists and Family Doctors on Levels of Recommended Medication among Persons with Type 2 Diabetes—Pragmatic RCT","Thim Prætorius","2024","Diabetes","randomized_trial","article","10.2337/db24-192-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049191","Historical overview of incretin based therapies","Anil Bhansali","2010","Journal of the Association of Physicians of India","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049192","2 Cardiovascular outcomes of GLP-1 receptor agonists in patients with coronary artery disease and heart failure: a meta-analysis","SN Notta","2025","The American Journal of the Medical Sciences","systematic_review","article","10.1016/s0002-9629(25)00011-4",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0049193","Baseline observations from the EVIDENCE Study: characteristics of type 2 diabetes patients initiating liraglutide","Luc Martinez","2013","Primary care diabetes","other","article","10.1016/j.pcd.2012.10.058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049194","Sustain 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes","Srikanth Bellary","2018","Atherosclerosis Supplements","other","article","10.1016/j.atherosclerosissup.2018.07.033",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049195","Abstract 4357466: Effect of Combination Therapy With GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes and ASCVD: A Systematic Review and Meta-analysis","Midori Torpoco Rivers","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4357466",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0049196","Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists","ROBERT J. CHILTON","2015","Journal of Diabetes & Metabolism","randomized_trial","article","10.4172/2155-6156.1000483",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049197","Diabetes, BMI, and Parkinson's","Thomas Foltynie","2020","Movement Disorders","other_trial","article","10.1002/mds.27941","32056307",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049198","GLP1-RA and Pediatric Populations: Psychosocial Issues and Eating Disorder Treatment Approaches for Co-Morbid Obesity and Eating Disorders","Susan M. Himes","2025","Current Pediatrics Reports","other","article","10.1007/s40124-025-00366-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049199","Lixisenatide added to basal insulin reduces glycaemic variability in patients with type 2 diabetes mellitus","David Norman O'Neal","2014","Repositorio Institucional E-DocUR (Universidad Del Rosario)","other","article","10.1007/s00125-014-3355-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0049200","SUN-484 Levoketoconazole Use Prior to Adrenalectomy","Ilja Hulinsky","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.449",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049201","S1594 Efficacy of Revisional Endoscopic Sleeve Gastroplasty After Laparoscopic Sleeve Gastrectomy","John J. Deng","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035744.80368.0d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049202","DEPRESSÃO, ANSIEDADE E IDEAÇÃO SUICIDA EM PACIENTES EM USO DE AGONISTAS DO RECEPTOR GLP-1: UMA REVISÃO SISTEMÁTICA DAS EVIDÊNCIAS CLÍNICAS E DOS MECANISMOS NEUROBIOLÓGICOS ENVOLVIDOS","João Lucas Souza Ferreira Almeida","2026","Revista fisio&terapia.","randomized_trial","article","10.69849/revistaft/dt10202602171027",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049203","1320-P: Raising Prediabetes Awareness and Reducing Type 2 Diabetes Risk through Virtual Care for Overweight and Obesity","Lauren Broffman","2024","Diabetes","other","article","10.2337/db24-1320-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049204","Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes","Pablo Mora","2018","Diabetes","other_trial","article","10.2337/db18-1072-p",null,null,"ClinicalTrials.gov:NCT02058147; ClinicalTrials.gov:NCT02058160","S001199; S001409","openalex","FALSE","paywalled","5","FALSE","article"],["R0049205","The Effect of Nutritional Transition on the Differentiation of Bone Marrow Stem Cells and the Therapeutic Effect of GLP-1","Wenfang Xia","2018","Diabetes","preclinical","article","10.2337/db18-1898-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049206","Semaglutid – ein neuer langwirksamer GLP-1-Rezeptor-Agonist mit nachgewiesener kardiovaskulärer Ereignisreduktion bei Typ-2-Diabetes","Jochen Seufert","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-105078",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049207","Efficacy of GLP-1 receptor agonists on weight loss, body mass index and waist circumference for obese or overweight patients: A systematic review, meta-analysis and meta-regression of 47 randomized-controlled trials","Hon Jen Wong","2025",null,"systematic_review","article","10.2337/figshare.27890331.v1",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","other; review"],["R0049208","S560 GLP-1 Agonists Use Is Associated With Lower Use of PPI and Do Not Worsen Outcomes in Patients With GERD: A National Database Analysis","Luis Miguel Nieto","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001031608.30677.6c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049209","Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial","Francesco Fusco","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.4487",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049210","Abstract 4360925: A phenomapping-informed machine learning tool estimates individualized cardiometabolic effects from Tirzepatide and generalizes to a new population.","Phyllis Thangaraj","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4360925",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049211","PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS","Hélène Sapin","2019","Value in Health","nonrandomized_study","article","10.1016/j.jval.2019.09.964",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0049212","Abstract P514: Evaluating the Concordance Between Trends in Prescription Volume and Online Interest for the Weight Loss Formulation of Semaglutide","Rishav Adhikari","2023","Circulation","other","article","10.1161/circ.147.suppl_1.p514",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049213","P346 Proportion de patients présentant soit un taux d’HbA1c < 7 %, soit une baisse d’au moins 1 % après 2 ans de traitement par le liraglutide: analyse post-hoc des résultats de l’étude EVIDENCE®","J.F. Gautier","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30459-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049214","PARTICIPANTS WITH OBESITY ACHIEVING WEIGHT LOSS ≥10%, SBP REDUCTION ≥5 MMHG AND NON-HDL CHOLESTEROL <130 MG/DL WITH TIRZEPATIDE: A POST HOC ANALYSIS OF SURMOUNT 1-4","Reshmi Srinath","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00861-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049215","PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES","Kirsi Norrbacka","2018","Value in Health","other","article","10.1016/j.jval.2018.09.817",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049216","Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial","Roland E. Schmieder","2026","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0046-1820050",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0049217","1397-P: Description of Prescribing Patterns of Antihyperglycemic Medications among Racially and Ethnically Diverse Populations in the All of Us Dataset","VERONICA J. BRADY","2024","Diabetes","other","article","10.2337/db24-1397-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049218","SAT-231 GL0034 (Utreglutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study","Rajamannar Thennati","2024","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(24)01792-6",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0049219","Pharmacological therapies for children with type 2 diabetes mellitus should be individualized","Tatsuhiko Urakami","2013","International Journal of Pediatric Endocrinology","other","article","10.1186/1687-9856-2013-s1-p32",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049220","PDB75 - COST-EFFECTIVENESS OF TREATING PATIENTS WITH TYPE 2 DIABETES POORLY CONTROLLED ON BASAL INSULIN WITH FIXED-RATIO COMBINATIONS OF BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS IN DENMARK: IDEGLIRA VERSUS IGLARLIXI","Christian A. Hvid","2018","Value in Health","other","article","10.1016/j.jval.2018.09.780",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049221","OR023: The Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Reduces Jejunostomy Output and Improves Intestinal Absorption in Short Bowel Syndrome Patients with Intestinal Failure; a Pilot Study","Mark Hvistendahl","2015","Clinical Nutrition","other","article","10.1016/s0261-5614(15)30123-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049222","SAT-203 Pegozafermin added to background GLP-1 therapy in patients with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: ENLIVEN 48-week extension data","Arun J. Sanyal","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)01773-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049223","FRAILTY AND THE EFFECTIVENESS AND SAFETY OF NEW GLUCOSE-LOWERING DRUGS IN OLDER ADULTS WITH TYPE 2 DIABETES","Dae Hyun Kim","2019","Innovation in Aging","nonrandomized_study","article","10.1093/geroni/igz038.2154",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0049224","Inkretin-Therapie ist auch bei bestehender Gastroparese sicher und effektiv","Christelle Beti","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0037-1601605",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049225","Lipoprotein Effects of Exenatide in Diabetic Subjects with Elevated Pretreatment Levels of Serum Lipoprotein(a) Cholesterol","Steven Richard Jones","2012","Journal of clinical lipidology","other","article","10.1016/j.jacl.2012.04.061",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049226","Effect of Biased GLP-1/Glucagon Receptor Co-agonists on Insulin Secretion","Gala Farooq","2018","Diabetes","preclinical","article","10.2337/db18-1100-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049227","Semaglutide and cardiovascular outcomes in patients with overweight or obesity who do not have diabetes","Melissa Leung","2024","Obesity Research & Clinical Practice","other","article","10.1016/j.orcp.2024.09.083",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049228","Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide","MICHAEL E. TRAUTMANN","2018","Diabetes","preclinical","article","10.2337/db18-1098-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049229","T1388 GTP-010 As a Therapeutic Tool in IBS Pain Relief: Prospective, Randomized, Placebo-Controlled Study of a GLP-1 Analog","Per M. Hellström","2008","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(08)62542-1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049230","Induction of Apolipoprotein A-I Gene Expression by Glucagon-Like Peptide-1 and Exendin-4.","JOE M Chehade","2010","The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego","other","article","10.1210/endo-meetings.2010.part1.or.or06-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0049231","Effect of endoscopic ultrasound guided gastric botulinum toxin injections and glucagon like peptide 1 receptor agonist on weight loss","Asmaa Gameel","2025","The Egyptian Journal of Internal Medicine","other_trial","article","10.1186/s43162-025-00443-8",null,null,"ClinicalTrials.gov:NCT05268627","S000104","openalex","TRUE","open_pdf","5","FALSE","article"],["R0049232","Off-label GLP-1 agonist treatment in 43 non-diabetic patients: are weight loss and treatment tolerance equally promising outside of clinical trials?","Nina Sauer","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.p760",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract; article"],["R0049233","One year of treatment with dapagliflozin QD plus exenatide QW in obese adults without diabetes : results of an open-label extension study","Jan W. Eriksson","2016","Diabetologia","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0049234","Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial","Kenneth W. Mahaffey","2022","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehac544.2617",null,null,"ClinicalTrials.gov:NCT03819153","S000953","openalex","TRUE","open_pdf","1","FALSE","article"],["R0049235","P1097 L’hypertriglycéridémie apparaît comme un facteur de bonne réponse glycémique au liraglutide, à un an, chez les patients diabétiques de type 2","Émilie Pupier","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71843-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049236","Glucose-lowering drug prescriptions in patients with newly diagnosed type 2 diabetes: statutory health insurance data from 2012 – 2016","Brenda W. C. Bongaerts","2019","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0039-1688177",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0049237","Abstract #295 GLP-1 Receptor Agonists and Death From Any Cause in Elderly Patients with Type 2 Diabetes Mellitus: A Post-Hoc Analysis","Konstantinos A. Toulis","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47140-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049238","1247-P: Anticipating the Impact of 2019 Guidelines: Use of SGLT2i and GLP-1RA in Patients with Diabetes and Cardiovascular Disease","Cori R. Rattelman","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1247-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049239","Effect of Daily or weekly Glp-1 receptor Agonists on glycemic Control In Insulin-NaÏVe patients With Poorly Controlled type 2 Diabetes: a real-world study","Mukul Singhal","2015","Value in Health","nonrandomized_study","article","10.1016/j.jval.2015.03.317",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049240","1280P Effects of semaglutide on the exposure of alectinib in patients with NSCLC","Daan A. C. Lanser","2024","Annals of Oncology","other","article","10.1016/j.annonc.2024.08.1337",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049241","5180 Atypical Presentation of Type 2 Diabetes Mellitus in a 72Year Old Caucasian Male with Hemoglobin J-Baltimore Variant: A Case Report","Chukwudi Muojieje","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.683",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049242","Metabolic Adaptation and Weight Regain Phenomenon After Cessation of GLP-1 Analogue Pharmacotherapy","Karolina Babik","2026","Journal of Education Health and Sport","other","article","10.12775/jehs.2026.90.70450",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049243","Efficacy and safety of dulaglutide in patients with type 2 diabetes and obesity","D.G. Gusenbekova","2025","FOCUS Endocrinology","randomized_trial","article","10.62751/2713-0177-2025-6-3-02",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049244","Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial","Silvio E. Inzucchi","2019","Diabetes Care","other_trial","article","10.2337/dc18-1355","30705060",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0049245","763-P: CagriSema Improves Insulin Sensitivity in Diet-Induced Obese Rats","Anna Secher","2024","Diabetes","preclinical","article","10.2337/db24-763-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049246","The effect of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists in nonalcoholic fatty liver disease in type 2 diabetic patients: a systematic review and meta-analysis","Atheer Alshutayli","2024","International Journal of Medicine in Developing Countries","systematic_review","article","10.24911/ijmdc.51-1725216272",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0049247","P2‐358: INSULIN RESISTANCE INFLUENCES HIPPOCAMPAL GLUCOSE METABOLISM RATHER THAN HIPPOCAMPAL VOLUME IN NON‐DIABETIC ALZHEIMER'S DISEASE PATIENTS","Grazia Daniela Femminella","2019","Alzheimer s & Dementia","other_trial","article","10.1016/j.jalz.2019.06.2765",null,null,"ClinicalTrials.gov:NCT01843075","S000689","openalex","FALSE","paywalled","5","FALSE","article"],["R0049248","The Application of Drug-Disease and Clinical Utility Models in the Design of AWARD-5: an Adaptive Seamless Phase 2/3 Study","Michael A. Heathman","2013",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0049249","Acute Interstitial Nephritis and Liver Injury After Long-Term Semaglutide Use","Nickolas Coombs","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.20255acyfbv7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049250","EFFECT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST PHARMACOTHERAPY ON WEIGHT LOSS IN PATIENTS WITH AND WITHOUT POLYCYSTIC OVARY SYNDROME","Emily Gaffney Gleason","2023","Fertility and Sterility","other","article","10.1016/j.fertnstert.2023.08.130",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049251","exendin-4 reverses biochemical and behavioural deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions (Retraction of vol 46, pg 183, 2012)","Nazir Rampersaud","2013","UCL Discovery (University College London)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049252","Liraglutide for the treatment of type 2 diabetes : a single technology appraisal","D Shyangdan","2011","Warwick Research Archive Portal (University of Warwick)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049253","LONG-TERM TREATMENT OUTCOMES WITH GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA)","Vanusha Devaraja","2023","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.038.s2.10",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049254","Achievement of HbA1c ≤6.5% (47.5mmol/mol), with ≥10% weight loss, without hypoglycemia in patients treated with tirzepatide vs. comparators in SURPASS program","Joshua A. Levine","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1767976",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049255","1665-P: Analysis of Glucose Biomarkers in Phase I and Phase II Studies of Survodutide in People with Type 2 Diabetes or Living with Overweight/Obesity","Elif Ilhan Ekinci","2024","Diabetes","other_trial","article","10.2337/db24-1665-p",null,null,"ClinicalTrials.gov:NCT04667377; ClinicalTrials.gov:NCT04153929; ClinicalTrials.gov:NCT03591718","S000172; S000327; S002375","openalex","FALSE","paywalled","5","FALSE","article"],["R0049256","Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy","Timothy J Wilt","2018","Annals of Internal Medicine","randomized_trial","article","10.7326/l18-0373","30285195",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049257","Induction of autophagy or mitophagy improves the cardiovascular lesions of Kawasaki Disease in a murine model of vasculitis","Stefanie Marek‐Iannucci","2020","The Journal of Immunology","preclinical","article","10.4049/jimmunol.204.supp.79.17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049258","Once-Weekly Exenatide Allows Sustained HbA1C Control","Brian D. Hoyle","2013","MD Conference Express","randomized_trial","article","10.1177/155989771317004",null,null,"ClinicalTrials.gov:NCT00641056","S001768","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0049259","Obesity Distinctly Influences Cardiac Function and Molecular Responses to Ischemia‐Reperfusion and GLP‐1 Receptor Agonism","Daniel Sassoon","2016","The FASEB Journal","other","article","10.1096/fasebj.30.1_supplement.770.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049260","797-P: Multiomic Comparison of GLP1R Analogues Interaction Networks","Zofia Wicik","2024","Diabetes","other","article","10.2337/db24-797-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049261","(107) Combating Metabolic Risks of Schizophrenia and Antipsychotics With Glucagon-Like Peptide-1 Receptor Agonists","Tyler A. Zahrli","2022","Journal of the Academy of Consultation-Liaison Psychiatry","other","article","10.1016/j.jaclp.2022.10.110",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049262","SA33 Real-World Comparison of Adherence and Persistence between Glucagon-like Peptide-1 Receptor Agonist (GLP-1) and Sodium-Glucose Cotransporter 2 (SGLT-2) in Patients with Type 2 Diabetes (T2D)","Nancy A. Risebrough","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.03.1880",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0049263","66 Acute coronary syndrome in type 2 diabetes treated using SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors: a comparative network meta-analysis of 127,731 individuals","Sean L. Zheng","2018",null,"systematic_review","article","10.1136/heartjnl-2018-bcs.66",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0049264","54813 Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of case reports","Carlos E. Salazar","2024","Journal of the American Academy of Dermatology","case_report","article","10.1016/j.jaad.2024.07.315",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049265","Combination of a Glucagon-Like Peptide 1 Analog and a Sodium-Glucose Cotransporter 2 Inhibitor Improves Lipid Metabolism Compared to the Monotherapies in Experimental Metabolic Syndrome","Isaías dos Santos Silva","2022","Journal of Endocrinology and Metabolism","preclinical","article","10.14740/jem843",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049266","Abstract 6202: Liquid biopsy multi-omic TempO-Seq platform for efficacy, safety, diagnosis, and subtyping using fingerstick blood","Bruce E. Seligmann","2025","Cancer Research","other","article","10.1158/1538-7445.am2025-6202",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049267","New class of drugs for the treatment of diabetes mellitus","A. I. Islamova","2024","Clinical Medicine (Russian Journal)","other","article","10.30629/0023-2149-2024-102-7-499-509",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049268","Kisspeptin Modulates Mitochondrial Metabolic State and Potentiates Glucose Stimulated Insulin Secretion in INS 832/3 Cells and Pseudo-Islets","Emily R Harnois","2023","Physiology","preclinical","article","10.1152/physiol.2023.38.s1.5733735",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049269","Identification of glucagon-like peptide-1 (glp-1) receptor agonists as a potential antidiabetic agent through molecular docking","Uddipta Das","2020","Research Journal of Pharmacy and Technology","other","article","10.5958/0974-360x.2020.00839.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049270","2538-P: Cardiorenal Protective Effects of a CRFR2-Selective UCN2 Analog, HM17321, in Spontaneously Hypertensive Rats (SHR)","SEON MYEONG LEE","2026","Diabetes","preclinical","article","10.2337/db26-2538-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049271","Not a light matter: obesity diagnosis rates among obese hospitalized patients","Irit Mazza Avivi","2025","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf236.262",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049272","134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review","Alexander Abitbol","2023","Diabetes","nonrandomized_study","article","10.2337/db23-134-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049273","Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)","Robin Conway","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049274","661 The Spectrum of Histologic Features Observed in Gastric Biopsies from Patients Using GLP-1 Agonists","Leah Osnis","2025","Laboratory Investigation","other","article","10.1016/j.labinv.2024.102892",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049275","EE109 A U.S.-SPECIFIC BUDGET IMPACT MODEL (BIM) OF SEMAGLUTIDE 2.4 MG IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) USING MOST FAVORED NATION (MFN) PRICING","AP McGovern","2026","Value in Health","other","article","10.1016/j.jval.2026.03.404",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049276","The Hidden Burden of International Gastric Balloon Tourism: A Five-Year Analysis of Removal Procedures Performed at Homerton University Hospital an NHS Bariatric Centre in London, UK","A Buckley","2026","Endoscopy","randomized_trial","article","10.1055/s-0046-1821213",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049277","Soft X-ray Tomography for Mapping and Quantifying Intracellular Organelle Interactions","Valentina Loconte","2023","Microscopy and Microanalysis","other","article","10.1093/micmic/ozad067.607","37613466",null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049278","88-LB: Kidney and Metabolic Benefits by Adding GLP-1 Agonists and/or SGLT2 Inhibitors on Metformin in Obese Type 2 Diabetes (T2DM) Patients: 24-Month Real-World Data from Both Urban and Rural Clinics","IOANNIS ZOUPAS","2021","Diabetes","nonrandomized_study","article","10.2337/db21-88-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049279","GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.","Cheng Guo","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.10557",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0049280","747-P: Improved Treatment Perceptions with IGlarLixi vs. Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient-Reported Outcomes (PROs) of the SoliMix Trial","William H. Polonsky","2021","Diabetes","randomized_trial","article","10.2337/db21-747-p",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049281","2165-P: In Vivo Islet Imaging Reveals that GLP-1 Paradoxically Increases Insulin Content","CORENTIN M.H. CRAS-MÉNEUR","2019","Diabetes","preclinical","article","10.2337/db19-2165-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049282","Twelve months exenatide treament in type 2 diabetes and severe obesity","Marta Diéguez Felechosa","2011","13th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049283","Acute coronary syndromes: mechanisms, reperfusion injury, antithrombotic therapy, and current outcomes","Thomas Felix Lüscher","2016","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehw142","27102807",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049284","PO18 Effet du Liraglutide sur l’apoptose et l’insulinosecrétion des cellules à insuline Rin-m5f en réponse aux microparticules, dans un modèle de stress inflammatoire et oxydant","Céline Gleizes","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71714-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049285","Extending Our Understanding of Exenatide: A Rare Case of Angioedema","Faisal Mahfooz","2020",null,"other","article","10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1345",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049286","477-P: Semaglutide Is Associated with Lower Risk of Diabetic Retinopathy in a Saudi Cohort with Type 2 Diabetes","Imad Addin Brema","2025","Diabetes","nonrandomized_study","article","10.2337/db25-477-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049287","Glucagon-like peptide-1 receptor agonist – a potential risk factor for suicidal behaviour","Ana Stojkovska","2024","Neuroscience Applied","other","article","10.1016/j.nsa.2024.104471",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049288","168 Myocardial stress perfusion and energetics improves in patients with type 2 diabetes after treatment with a glucagon like peptide-1 receptor agonist (liraglutide)- a randomised, single centre, open label, cross-over drug trial","Amrit Chowdhary","2023",null,"randomized_trial","article","10.1136/heartjnl-2023-bcs.168",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","conference-paper"],["R0049289","P4‐317: Liraglutide protects the brains of macaques against synapse loss caused by abeta oligomers","Fernanda Guarino De Felice","2015","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2015.08.147",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049290","The direct effects of exendin-4 on human non-diabetic isolated islets: possible use in islets transplantation","Roberto Lupi","2007","CINECA IRIS Institutial research information system (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0049291","The combination of elafibranor and semaglutide drastically improves fibrosing steatohepatitis and distinctly modulates liver inflammatory signature","Vanessa Legry","2020","Journal of Hepatology","other","article","10.1016/s0168-8278(20)30584-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049292","Abstract #1183459: Effect of Exenatide versus Hypocaloric Diet on High-sensitivity C-reactive Protein and Other Cardiovascular Risk Factors in Overweight and Obese Women without Diabetes","Antea DeMarsilis","2022","Endocrine Practice","other","article","10.1016/j.eprac.2022.03.159",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049293","The GLP-1 receptor in airway inflammation in asthma: a promising novel target?","Ashley Y. Wu","2021","Expert Review of Clinical Immunology","commentary","article","10.1080/1744666x.2021.1971973","34425713",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0049294","Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial","Clare R.M","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/ddy9-8209",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0049295","Effects of GLP-1 Receptor Agonists on Kidney Function: Meta-Analysis of Laboratory Biomarkers","Avinash Vangara","2025","Journal of the American Society of Nephrology","systematic_review","article","10.1681/asn.202589m6mbq2",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0049296","S1565 Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Decreased Risk of Recurrent Pouchitis in Obese Patients With Ulcerative Colitis and IPAA: A Propensity-Matched Cohort Study","Aakash Desai","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001133720.90877.e7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049297","Drug (vaccine)‐induced thrombocytopenia 2021: Diversity of pathogenesis and clinical features","Sanober Nusrat","2022","American Journal of Hematology","nonrandomized_study","article","10.1002/ajh.26482","35092624",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049298","Glucagon-like peptide-1 receptor agonists decrease systemic Th2 inflammation in asthmatics","Dinah Foer","2020","Journal of Allergy and Clinical Immunology","other","article","10.1016/j.jaci.2019.12.140",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049299","Obesity management medications for the surgeon","Matthew Harris","2026","Frontline Gastroenterology","other","article","10.1136/flgastro-2025-103307",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049300","Recent Advancements in the Prevention and Treatment of Genetic and Non-Genetic Obesity: A Pharmacological Perspective of Review","Trilochan Satapathy","2025","Journal of Drug Delivery and Therapeutics","narrative_review","article","10.22270/jddt.v15i7.7294",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049301","LBSUN306 Effects Of Glp-1 Receptor Agonism, Dpp4 Inhibition, And Hypocaloric Diet On Metabolic Parameters In Obese Pre-diabetic Individuals: A Randomized-controlled Trial","Mona Mashayekhi","2022","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvac150.603",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049302","In Reply: Antiobesity drug therapy","Yael Mauer","2021","Cleveland Clinic Journal of Medicine","commentary","article","10.3949/ccjm.88c.12002","34857600",null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0049303","Risk of Urogenital Infections in People with Type 2 Diabetes Initiating SGLT2i versus GLP-1RA in Routine Clinical Care: A Danish Cohort Study","Christine Ljungberg","2025",null,"nonrandomized_study","article","10.2337/figshare.28598729.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0049304","Semaglutide reduces cognitive dysfunction in experimental non-alcoholic steatohepatitis through anti-inflammatory and neuroprotective effects","Kristoffer Kjærgaard","2024",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0049305","783-P: Elucidating the Benefit of Pump-Delivered Subcutaneous GLP-1R Agonist—Exploratory Study in the DIO Mouse","Louise Thisted","2025","Diabetes","nonrandomized_study","article","10.2337/db25-783-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049306","1120-P: Use of Choice Architecture to Influence Inpatient A1C Ordering and Patient Outcomes","Kristen A. Breslin","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1120-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049307","Diabetes, Obesidad y Lípidos","Asociación Colombiana de Endocrinología Diabetes y Metabolismo","2017","Revista Colombiana de Endocrinología Diabetes & Metabolismo","randomized_trial","article","10.53853/encr.4.2.119",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049308","SUN-002 Lymphocytic Infundibulo-neurohypophysitis With Unusual Course Of Desmopressin-resistant Diabetes Insipidus","Andrea García-Bautista","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1596",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049309","Editorial: Endocrine disruptors in obesity","Carmela Asteria","2024","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2024.1526898","39777223",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0049310","Triple Therapy with Exenatide/Pioglitazone/Metformin vs. Conventional Therapy: Changes in Liver Fibrosis Scores after 2 Years of Treatment in Patients with New-Onset Type 2 Diabetes Mellitus","Olga Lavrynenko","2020","Metabolism","other","article","10.1016/j.metabol.2019.12.057",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049311","In T2D patients with baseline A1c <8.0%, liraglutide achieves A1c targets more often than sitagliptin or exenatide","Allen Bennett King","2013","Primary care diabetes","other","article","10.1016/j.pcd.2012.10.061",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049312","La semaglutide inibisce il carcinoma papillare della tiroide mediante la riprogrammazione dei macrofagi attraverso la via GLP-1R/PPARG/ACSL1","Cristina Luongo","2026","L Endocrinologo","other","article","10.1007/s40619-026-01789-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049313","Perioperative Management of Patients Taking GLP-1 Receptor Agonists","Adriana Dana Oprea","2025","ASA Monitor","other","article","10.1097/01.asm.0001125664.22893.9f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049314","PDB60 ASSESSMENT OF THE INTERVAL BETWEEN FIRST EXENATIDE CLAIM AND LAST PRIOR ORAL ANTIDIABETIC CLAIM","Derek A. Misurski","2009","Value in Health","other","article","10.1016/s1098-3015(10)73603-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049315","Pharmacotherapy of obesity and metabolic syndrome. Focus on sodium-glucose cotransporter type 2 inhibitors","Vadim V. Abramov","2024","Glavvrač (Chief Medical Officer)","other","article","10.33920/med-03-2407-04",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049316","1889-LB: Type 2 Diabetic Medication Regimen in Treating Depression and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in Veterans Using PHQ-9 and FIB-4 Scores","Shannen Nicole Dean Ubalde","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1889-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049317","How to treat diabetes in Arabs: A rational approach based upon the pathogenesis of the disease","Muhammad A Abdul‐Ghani","2012","Qatar Foundation Annual Research Forum Volume 2012 Issue 1","randomized_trial","article","10.5339/qfarf.2012.bmo1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0049318","26-A-17152-ACC BEYOND GLYCEMIC CONTROL: GLP-1 AGONISTS REDUCE ARRHYTHMIA AND DEATH POST-STEMI","Narathorn Kulthamrongsri","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.4930",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049319","A Lipopolysaccharide Mouse Model Mirrors Neuroinflammatory Transcriptional Signatures of Human AD, and the Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Attenuates Neuroinflammation in this Model (P1-6.007)","Mette Q. Ludwig","2023","Neurology","preclinical","article","10.1212/wnl.0000000000203487",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049320","990-P: Use of Glucose-Lowering Agents According to Cardiovascular Risk Factors in People with T2D and with or without CVD in the CAPTURE Study","Guillermo Dieuzeide","2021","Diabetes","other","article","10.2337/db21-990-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049321","Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use","Денис Владимирович Куркин","2023","Pharmacy & Pharmacology","nonrandomized_study","article","10.19163/2307-9266-2023-11-1-19-47",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049322","Su2055: TIRZEPATIDE SHOWS LOWER RISK OF GASTROINTESTINAL SIDE EFFECTS COMPARED TO OTHER GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: A REAL-WORLD ANALYSIS OF OVER 1 MILLION PATIENTS","Fouad H. Jaber","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03107-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049323","The drug of choice for comorbid patients with type 2 diabetes mellitus and postcholecystectomy syndrome","Ольга Владимировна Занозина","2018","Medical Almanac","other","article","10.21145/2499-9954-2018-6-131-133",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049324","Prospects for the use of drugs from the group of agonists of glucagon-like peptide-1 receptors in the treatment of non-alcoholic fatty liver disease","Л. А. Суплотова","2023","Meditsinskiy sovet = Medical Council","nonrandomized_study","article","10.21518/2079-701x-2022-16-23-148-155",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049325","Overview of Medications Used to Treat Type 2 Diabetes","John Robert White","2025","American Diabetes Association eBooks","other","article","10.2337/9781580408462-ch05",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0049326","#6884 THE BARRIERS TO TRANSPLANTATION IN OUR DIABETIC HAEMODIALYSIS POPULATION AT THE LEEDS TEACHING HOSPITALS NHS TRUST","Maria Angela Gauci","2023","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfad063c_6884",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049327","FRI-407 Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD","Martina Colognesi","2025","Journal of Hepatology","other","article","10.1016/s0168-8278(25)01632-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049328","Liraglutide is a Safe and Beneficial Adjunct to Insulin in Glycemic Control in Type 1 Diabetes","Brian D. Hoyle","2013","MD Conference Express","randomized_trial","article","10.1177/155989771317005",null,null,"ClinicalTrials.gov:NCT01536665","S002381","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0049329","Bone turnover in women with prior gestational diabetes after 52 week's treatment with liraglutide","Louise Vedtofte","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049330","1883-P: Phosphoproteomics Reveals Mechanistic Insight into Glucagon-Mediated Inhibition of Hepatic Lipogenesis and How MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Reverses Steatosis","Rhianna Che Laker","2019","Diabetes","preclinical","article","10.2337/db19-1883-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049331","Therapy of Type 2 Diabetes","Rüdiger Landgraf","2024","Experimental and Clinical Endocrinology & Diabetes","randomized_trial","article","10.1055/a-2166-6755","38599610",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049332","COPD and Metabolic Syndrome: Unanswered Questions and Opportunities for Innovation","Jamuna K. Krishnan","2024","Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation","other","article","10.15326/jcopdf.2024.0576","39576959",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049333","Exploring the Effect of GLP-1 Agonists on Multiple Sclerosis Disease Progression (P11-1.007)","Kashmaila Ali","2025","Neurology","other","article","10.1212/wnl.0000000000211085",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049334","OR03-1 Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program","Sheryl Elaine Allen","2022","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvac150.722",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0049335","New COST Action ‘EUropean network to tackle METAbolic alterations in HEART failure’ (EU-METAHEART)","Christoph Maack","2024","European Heart Journal","preclinical","article","10.1093/eurheartj/ehae457","39412117",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049336","Tu1032 EXAMINING DEMOGRAPHIC DISPARITIES IN RECRUITMENT FOR CLINICAL TRIALS AMONG ADULTS WITH OVERWEIGHT AND OBESITY TREATED WITH GLP-1 RA OR DUAL GIP AND GLP-1 RA: A COMPREHENSIVE SYSTEMATIC REVIEW","Lizeth Cifuentes","2024","Gastroenterology","systematic_review","article","10.1016/s0016-5085(24)03276-1",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0049337","S421 System-Based and Culturally Responsive Interventions to Enhance CRC Screening Uptake in a Safety Net Clinic","Ruchir Damjibhai. Paladiya","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129144.65825.9b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049338","PCR203 The Clinical and Financial Impact of GLP-1 Receptor Agonist and SGLT-2 Inhibitor Use in Type 2 Diabetes Management of Blue Cross and Blue Shield of Louisiana Members","T. Vandergrift","2023","Value in Health","other","article","10.1016/j.jval.2023.03.2382",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049339","Some useful pharmazooticals, now and in the future : review","Michael Paul Danckwerts","2015","Pharmacy management","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049340","142-OR: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Mediates Its Anorexigenic Effect in Mice Due to a Reduction in Homeostatic and Reward-Related Feeding","Richard H. Cosgrove","2020","Diabetes","preclinical","article","10.2337/db20-142-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049341","Differencial efficacy of a GLP-1/GCGR dual agonist versus a GLP-1 agonist in diet-induced obese mice","M. Pilar Valdecantos","2018","DIGITAL.CSIC (Spanish National Research Council (CSIC))","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049342","Type 2 diabetes and exercise unexplained dyspnoea: a new focus under the lens with a long way to go yet","Marco Guazzi","2022","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwac177","35959738",null,null,null,"openalex","FALSE","paywalled","4","FALSE","editorial"],["R0049343","Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics","Liana K. Billings","2018","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2018.08.143",null,null,"ClinicalTrials.gov:NCT02420262","S001760","openalex","FALSE","paywalled","5","FALSE","article"],["R0049344","Étude SUSTAIN 3 : efficacité et tolérance du semaglutide une fois par semaine versus exanatide-LP après 56 semaines chez des diabétiques de type 2","Guillaume Charpentier","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30421-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049345","1079 A CELL FREE DNA METHYLATION-BASED LIQUID BIOPSY FOR SEMAGLUTIDE WEIGHT-LOSS RESPONSE IN AT-RISK MASH","Rohit Seth Loomba","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04814-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049346","Additional file 1 of Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain","Sarah Elizabeth Jackson","2026","Figshare","other","article","10.6084/m9.figshare.31023455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049347","Association of metabolic phenotypes with cardiovascular events in primary and secondary prevention","Eva Steinacher","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae666.1476",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049348","Paper OK, title wrong","Nicholas D Moore","2011","BMJ","nonrandomized_study","article","10.1136/bmj.d2732","21558338",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049349","EFFECTS OF LIRAGLUTIDE ON VISCERAL ADIPOSITY INDEX IN WOMAN OF REPRODUCTIVE AGE WITH PREDIABETES","Mariana Ivanishchak","2024","Wiadomości Lekarskie","other","article","10.36740/wlek202408261",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049350","Impacto pronóstico de metformina en pacientes con diabetes mellitus tipo 2 e insuficiencia cardiaca aguda. Análisis combinado de los registros EAHFE y RICA","Marina Povar-Echeverría","2023","Revista Clínica Española","randomized_trial","article","10.1016/j.rce.2023.07.007",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049351","Newer Anti-Hyperglycemic Agents in Type 2 Diabetes Mellitus - Expanding the Horizon","Savita Jain","2013","Apollo Medicine","other","article","10.1016/j.apme.2013.05.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049352","Glucagon-like peptide-1 (GLP-1) receptor agonists as a new treatment option for hypothalamic obesity in the paediatric population: Preliminary data from a tertiary paediatric endocrine centre","Katherine Hawton","2023","Endocrine Abstracts","other","article","10.1530/endoabs.95.p51",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049353","P301 Efficacité du liraglutide chez les patients diabétiques de types 2 en fonction de l’HbA1c et de l’indice de masse corporelle de départ : résultats à 2 ans de l’étude prospective, post-inscription EVIDENCE®","Luc Martinez","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30414-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049354","Ozempic moet niet te breed beschikbaar zijn","Marcel F. Verweij","2025","Utrecht University Repository (Utrecht University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049355","GLP-1 receptor agonists and tendon healing: a systematic review and meta-analysis","Mohammed Y. Khayyat","2026","Archives of Medical Science","systematic_review","article","10.5114/aoms/225241",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0049356","Abstract 12365: Liraglutide Improves Myocardial Stress Perfusion and Energetics in Patients With Type 2 Diabetes- A Randomised, Single Centre, Open Label, Cross-Over Drug Trial","Amrit Chowdhary","2023","Circulation","randomized_trial","article","10.1161/circ.148.suppl_1.12365",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049357","Challenges and Novelties in the Treatment of Obesity in Adults. A review","Karolina Kuczapska","2025","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2025.77.57095",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049358","963-P: A Randomized Controlled Trial Comparing Liraglutide vs. Glargine Insulin for the Management of Patients with Type 2 Diabetes after Hospital Discharge","Francisco J. Pasquel","2020","Diabetes","randomized_trial","article","10.2337/db20-963-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049359","1059-P: Patterns of Telemedicine vs. In-Person Endocrinology Care for T2D","MARGARET ZUPA","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1059-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049360","Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine using disposable pen vs exenatide","Onur Başer","2011","F1000Research","other","article","10.7490/f1000research.1089524.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049361","NEW APPROACHES IN THE TREATMENT OF TYPE 2 DIABETES - TRANSITION FROM GLUCOSE-CENTRED TO PATIENT-CENTRED MODEL","Antoаneta Tsvetkova","2021","Journal of IMAB - Annual Proceeding (Scientific Papers)","nonrandomized_study","article","10.5272/jimab.2021273.3885",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049362","A New Era in the Management of Patients with Diabetic Kidney Disease using Four Pillars of Therapy","Christodoula Kourtidou","2026","Journal of Atherosclerosis Prevention and Treatment","randomized_trial","article","10.4103/aptj.aptj_27_26",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049363","A Retrospective Comparative Analysis on the Effectiveness of Pharmacologic Weight Loss","EMILY Z. DUNN","2018","UKnowledge (University of Kentucky)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0049364","PSUN192 Therapeutic Benefit of GLP-1 Agonists in Patients with Type 1 Diabetes on Insulin Therapy: an Updated Systematic Review and Meta-analysis","Jeayoung Park","2022","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvac150.782",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0049365","Effect of glucagon-like peptide-1 receptor agonists on growth and energy metabolism in human medullary thyroid cancer cells","Hong Tian Wang","2016","Zhongguo aizheng zazhi","other","article","10.19401/j.cnki.1007-3639.2016.06.002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049366","Prescription du liraglutide (un analogue du GLP-1) chez des patients diabétiques de type 2 en condition de vie réelle : l’étude Évidence demandée par la Haute Autorité de Santé","Guillaume Charpentier","2012","Diabetes & Metabolism","other","article","10.1016/s1262-3636(12)71486-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049367","Glucagon-like peptide-1 receptor agonists (GLP-1 RA) versus statins and the risk of hepatocellular carcinoma (HCC) and hepatic decompensation in patients with type 2 diabetes mellitus (T2DM).","Sarina Ailawadi","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.19_suppl.139",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049368","Lindernia ciliata Exhibits Anti-Diabetic effects in Streptozotocin-Induced Diabetic Model by Upregulation of GLUT-2 and GLUT-4 Gene Expression","Anju Das","2026","Research Journal of Pharmacy and Technology","preclinical","article","10.52711/0974-360x.2026.00121",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049369","Gutes Nutzen-Risiko-Verhältnis zwischen HbA1c-Reduktion und Hypoglykämien unter Exenatide 2x tgl. als Add-on zu Insulin glargin bei T2DM-Patienten","Jaret L. Malloy","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549674",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049370","0716 Cardiovascular Risk Reduction with Glucagon-Like Peptide-1 Receptor Agonists in Patients with Obstructive Sleep Apnea and Obesity: A Real-World Study","Jaeun Ahn","2025","SLEEP","nonrandomized_study","article","10.1093/sleep/zsaf090.0716",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049371","Comparative Persistency with Newer agents used to Treat Type 2 Diabetes (T2dm) In the united states: canagliflozin Versus Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors and Glucagon-Like Peptide-1 (Glp-1) agonists","Joris Diels","2015","Value in Health","other","article","10.1016/j.jval.2015.03.398",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049372","EE207 Healthcare Utilization and Costs in New Users of Once-Weekly GLP-1 Receptor Agonists vs Other Glucose-Lowering Therapies Among Medicare Beneficiaries With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease","Adam de Havenon","2025","Value in Health","other","article","10.1016/j.jval.2025.04.498",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049373","S2011 Real-World Characteristics of the Patients With Metabolic Dysfunction-Associated Steatohepatitis Prescribed Resmetirom: Data Derived From Two Tertiary Care Centers in the United States","Eda Kaya","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037412.40234.5d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049374","S427 Reduced Immunosuppression Requirements With GLP-1 Receptor Agonists Use in Patients Experiencing Immune-Mediated Diarrhea and Colitis","Cristina Natha","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129168.17549.64",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049375","Where did the iron go?—a case report of a patient with severe iron deficiency anemia despite parenteral and oral iron supplementation due to semaglutide application","Tomo Svaguša","2026","AME Case Reports","case_report","article","10.21037/acr-2026-0027",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049376","Comparative analysis of physicochemical properties, bioequivalence, safety and tolerability of the first domestic semaglutide","Ametov As","2024","Pharmacy & Pharmacology","randomized_trial","article","10.19163/2307-9266-2023-11-4-324-346",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049377","Mo2004 COLONOSCOPY PREPARATION MAY MITIGATE FOOD RETENTION IN PATIENTS USING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS WHO ARE UNDERGOING UPPER ENDOSCOPY","Jason Nasser","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)03196-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049378","РОЛЬ АГОНИСТА РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА-1 СЕМАГЛУТИДА И МЕТФОРМИНА В КОРРЕКЦИИ АНДРОГЕННОГО ДЕФИЦИТА У ПАЦИЕНТОВ С ТРИАДОЙ «ОЖИРЕНИЕ — ИНСУЛИНОРЕЗИСТЕНТНОСТЬ — САХАРНЫЙ ДИАБЕТ 2-ГО ТИПА»","Виктор Владимирович Смирнов","2025","Медицина: теория и практика","other","article","10.56871/mtp.2025.71.17.005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049379","GLP-1 receptor agonists for primary prevention of breast cancer in high-risk women: A real-world analysis of efficacy and safety.","Nico-al Paolo Gotera","2026","Journal of Clinical Oncology","randomized_trial","article","10.1200/jco.2026.44.16_suppl.10520",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049380","TREATMENT WITH EXENATIDE PRESERVES BETA CELL MASS IN HUMAN ISLETS DURING CULTURE: IMPLICATIONS FOR ISLET TRANSPLANTATION","Lucy Marzban","2010","Transplantation","other","article","10.1097/00007890-201007272-01963",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049381","Abstract 4146425: Impact Of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like-Peptide-1 Agonists On Cardiovascular and Renal Outcomes In Patients With Type 2 Diabetes Mellitus (T2DM) and Autoimmune Diseases: A Global Retrospective Study","Anderson C. Anuforo","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4146425",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049382","97. The 5-year incidence of progression to lumbar disc degeneration in patients prescribed glucagon-like peptide 1 receptor agonists","Abdullah N. Ghali","2025","The Spine Journal","other","article","10.1016/j.spinee.2025.08.280",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049383","Effectiveness and safety of liraglutide in the treatment of childhood obesity","Olga G. Sharshova","2024","Annals of the Russian academy of medical sciences","other","article","10.15690/vramn18011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049384","Influence of cerebral glucose metabolic rate on cognitive function in Alzheimer's subjects","Paul Edison","2020","Alzheimer s & Dementia","other","article","10.1002/alz.045899",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049385","Cutting Edge Developments in Diabetes","Peter Marshall Clifton","2023","Diabetology","other","article","10.3390/diabetology4030024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049386","EE476 Budget Impact Analysis of iGlarLixi for Treatment of T2DM in Algerian Setting","S Mimouni","2022","Value in Health","other","article","10.1016/j.jval.2022.09.720",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049387","Adding Liraglutide to insulin treated obese type 2 diabetics improves glycaemic control with sustained weight reduction and low hypoglycaemia rate","Rahul M. Jindal","2012","15th International & 14th European Congress of Endocrinology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049388","A Phase 1b/2a Study of Glutazumab for the Treatment of Type 2 Diabetes and Obesity","Shuqian Jing","2018","Diabetes","randomized_trial","article","10.2337/db18-2298-pub",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049389","1984-P: Promoting Weight Loss in Diabetes: An Insulin-Sparing Approach","Yamuna Gorantla","2020","Diabetes","other","article","10.2337/db20-1984-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049390","RETROSPECTIVE EVALUATION OF WEIGHT LOSS TREATMENT IN OVERWEIGHT AND OBESE PERSONS WITH DIABETES IN CLINICS IN LAGOS, NIGERIA","Olufemi Adetola Fasanmade","2022","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.037.afes.68",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049391","Treatment of Type 2 Diabetes Mellitus in a Young Patient with Prader – Willi Syndrome","L.Yu. Khamnueva","2024","Effective Pharmacotherapy","other","article","10.33978/2307-3586-2024-20-37-14-20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049392","NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): DISEASE MECHANISMS AND CONTEMPORARY THERAPEUTIC APPROACHES - A LITERATURE REVIEW","Konrad Strużek","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3662",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049393","Drugs for diabetes and obesity","Sheila Anne Doggrell","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049394","La malattia obesità ed il rischio cardiovascolare: evoluzione della terapia farmacologica","Guido Salvetti","2025","Cardiologia Ambulatoriale","other","article","10.17473/1971-6818-2025-2-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049395","Le 4P004 (liraglutide intra-articulaire) démontre une protection structurale supérieure à la dexaméthasone dans l’arthrose expérimentale post-traumatique","C. Meurot","2025","Revue du Rhumatisme","other","article","10.1016/j.rhum.2025.10.449",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049396","8139 Examining the Association of GLP1-RA or DPP4i with Bullous Skin Diseases in Veterans","Suhail Saad-Omer","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.768",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049397","Obesity Management and Health Outcomes: an umbrella review of systematic reviews and meta-analyses of randomised controlled trials","S Jugnundan","2026","Endoscopy","systematic_review","article","10.1055/s-0046-1822009",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0049398","[P3–063]: NOVEL BIODEVICE RELEASES DRUG IN VIVO FOR 14 DAYS AND AVOIDS DNA DAMAGE IN STRESS‐INDUCED NEUROBLASTOMA CELLS: A PROMISE FOR ALZHEIMER'S DISEASE TREATMENT","Geisa Nogueira Salles","2017","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2017.06.1273",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049399","Prospects for the use of new antidiabetic drugs in rheumatology","Evgeny Lvovich Nasonov","2026","Rheumatology Science and Practice","other","article","10.47360/1995-4484-2026-315-334",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049400","Long-Term Use of GLP-1 Receptor Agonists Alter GLP-1 Receptor mRNA Expression in Hindbrain Pathways That Regulate Gastric Motility in Mice","Peili Wang","2018","Diabetes","preclinical","article","10.2337/db18-1088-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049401","2302-PUB: Exenatide Once-Weekly in Diabetes Patients with Stage 2/3 Chronic Kidney Disease—A Pooled 6-Month Analysis","Cristian Guja","2019","Diabetes","other_trial","article","10.2337/db19-2302-pub",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049402","Perioperative medicine: what you need to know about new hypoglycemic medicines?","И. Н. Пасечник","2026","Clinical nutrition and metabolism","other","article","10.17816/clinutr713929",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049403","Medical Management of the Obese Patient","Paula Freitas","2020","Recent advances in obesity research","other","article","10.2174/9789811442636120010010",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0049404","Liraglutide","Dennis J. Cada","2010","Hospital Pharmacy","other_trial","article","10.1310/hpj4507-552",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049405","The Efficacy and Safety of GLP-1 Receptor Agonists in the Treatment of Chronic Heart Failure with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials","Yanchenhan Hao","2026","MEDS Clinical Medicine","systematic_review","article","10.23977/medsc.2026.070316",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0049406","Comparative analysis of newer classes of antidiabetics and the concept of pharmaceutical care – dealing with therapeutic problems","Anna Peneva","2024","Pharmacia","other","article","10.3897/pharmacia.71.e120141",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049407","Reduced food intake in response to the GLP-1 receptor agonist exenatide is associated with increased hypothalamic connectivity","Stefan Kabisch","2011","Max Planck Digital Library","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0049408","1156-P: Duodenal Mucosal Resurfacing (DMR) Combined with GLP-1 RA May Eliminate Insulin Therapy and Improve Metabolic Health in Type 2 Diabetes","Paul Smeele","2019","Diabetes","other_trial","article","10.2337/db19-1156-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049409","Thermally Hazardous 1,3-Dioxolane Coupling Reaction Required for a Pharmaceutical Candidate Starting Material, Made Safer by Employing Process Safety Data as Key Design of Experiments Output Variables","James Freeman Clarke","2025","Organic Process Research & Development","other","article","10.1021/acs.oprd.4c00519",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049410","Lira-Ramadan : tolérance et sécurité du liraglutide en comparaison au sulfamide hypoglycémiant, en ajout de la metformine chez des patients DT2 durant et après le jeûne du Ramadan","Bernard Bauduceau","2016","Annales d Endocrinologie","other","article","10.1016/j.ando.2016.07.101",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049411","SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ARE ASSOCIATED WITH A LOWER RISK OF ATRIAL FIBRILLATION COMPARED TO GLUCAGON-LIKE PEPTIDE-1 AGONISTS: A DIRECT METAANALYSIS","George G. Kidess","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(25)00661-8",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0049412","Abstract 4145988: Individual- and Community-level Socioeconomic Differences in Use of GLP-1 Receptor Agonists in Diabetes","Richard Chaudhary","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4145988",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049413","Abstract 15480: Liraglutide Inhibits Atherosclerotic Plaque Progression in Rabbits Through the Downregulation of Multiple Inflammatory and Metabolic Pathways","Mohamad Bassam Kassab","2022","Circulation","randomized_trial","article","10.1161/circ.146.suppl_1.15480",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049414","Special Features: Incretin-based therapies in type 2 diabetes mellitus","Chia Cw","2014",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0049415","Semaglutide: The First Anti-Obesity Agent Shown to Decrease Cardiovascular Events","Nasser E. Mikhail","2024","Annals of Cardiovascular Diseases","randomized_trial","article","10.47739/2641-7731.cardiovasculardiseases.1036",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049416","S799 Gastrointestial Outcomes in Patients With Concomitant Use of Immuno Checkpoint Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Study in the United States","Luìs Manuel de Almieda Nieto","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130656.38889.ff",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049417","Type-2 Diabetes Mellitus: A Review of Current Trends","Priya ​ Patel","2022","Journal of Pharmaceutical Research","narrative_review","article","10.18579/jopcr/v21i4.22.21",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049418","HTRS2025.O6C.1 Abstract Travel Award Glucagon-like peptide 1 receptor agonists and the risk of arterial and venous thromboembolism in breast cancer patients receiving hormone therapy: a propensity score-matched cohort study","Cho‐Han Chiang","2025","Research and Practice in Thrombosis and Haemostasis","nonrandomized_study","article","10.1016/j.rpth.2025.103135",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049419","Impact of liraglutide and dapagliflozin on steatosis, fibrosis, aminotransferases, and lipid profile in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: results of a 6-month randomized study","V.V. Cherniavskyi","2025","GASTROENTEROLOGY","randomized_trial","article","10.22141/2308-2097.59.4.2025.705",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049420","Diabetes, Impaired Fasting Glucose, and Heart Failure: Its not All About the Sugar","Abhinav Sharma","2014","European Journal of Heart Failure","nonrandomized_study","article","10.1002/ejhf.179","25315254",null,"ClinicalTrials.gov:NCT01800968","S002350","openalex","TRUE","open_pdf","4","FALSE","article"],["R0049421","Wirkungsunterschiede von Sitagliptin und Exenatide auf Nahrungsaufnahme, Körpergewicht, Glucosestimulierte Insulinsekretion und Magenentleerung in Tierexperimenten","Ken Herrmann","2008","Diabetologie und Stoffwechsel","other","article","10.1055/s-2008-1076224",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049422","415-P: Proteinuria and Progression of Kidney Disease in Patients with T2D Treated with SGLT2i and GLP-1RA—A Target Trial Emulation","Alexander Turchin","2025","Diabetes","nonrandomized_study","article","10.2337/db25-415-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049423","Improvement in Pulmonary Function in a Patient With ILD Following Semaglutide Therapy","Karina Mak","2024",null,"other","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2047",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049424","Correction of Potentially Modifiable Components of Metabolic Syndrome for the Primary Prevention of Atrial Fibrillation in Comorbid Patients with Premature Atrial Complexes","Aleksandr I. Olesin","2022","Cardiac Arrhythmias","other","article","10.17816/cardar105575",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0049425","Kidney Failure Risk Modifies Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Cardiovascular-Kidney-Metabolic (CKM) Events","Sydney Elizabeth Hartsell","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025gvpshbjk",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049426","A SHOCKING CASE OF SEMAGLUTIDE-INDUCED VENTRICULAR ARRHYTHMIA","Soumyadeep Bag","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)04056-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049427","BMI shift and associated cardiometabolic risk factors in people with type 2 diabetes and obesity and/or overweight: a post hoc analysis from SURMOUNT-2","N Sattar","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae666.2886",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049428","Abstract 9436: Sitagliptin Reduces Plaque Macrophage Content and Stabilizes Arteriosclerotic Lesions in Apoe-Deficient Mice","Mathias Burgmaier","2011","Circulation","preclinical","article","10.1161/circ.124.suppl_21.a9436",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049429","Abstract 138: Efficacy of oral semaglutide according to race: An exploratory subgroup analysis of the PIONEER trial program","Kunal Srivastava","2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.342263",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0049430","The Association of Baseline Factors with Glycemic Outcomes in the GRADE Study: A Comparative Effectiveness Randomized Clinical Trial","William Timothy Garvey","2024",null,"randomized_trial","article","10.2337/figshare.24543754",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0049431","Additional file 1 of Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report","Ali Zahir","2026","Figshare","case_report","article","10.6084/m9.figshare.30994854.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049432","Weight loss trajectories with a targeted prescribing pathway for liraglutide 3 mg using multiple stopping rules: findings from the STRIVE study","Malak Hamza","2025","Endocrine Abstracts","other","article","10.1530/endoabs.109.p133",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049433","DRA5 Endothelial dysfunction in patients of long standing rheumatoid arthritis","Ashish M. Sharma","2007","Indian Journal of Rheumatology","other","article","10.1016/s0973-3698(10)60314-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049434","Protocol: Examining changes in body weight and glycemic outcomes in Asian patients using GLP 1 receptor/ dual agonists","Michelle R. Demetres","2026",null,"protocol","article","10.17605/osf.io/8pgfn",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0049435","Efficacy of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA) for Weight Loss in Solid Organ Transplant (SOT): A Matched Control Study","Joseph M. Kahwaji","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.924",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049436","COMPARISON BETWEEN SEMAGLUTIDE, TIRZEPATIDE, AND NOVEL TRIPLE AGONISTS: EFFICACY, SAFETY, AND CLINICAL IMPLICATIONS","Hugo Calesso dos Reis","2026","Periódicos Brasil Pesquisa Científica","other_trial","article","10.36557/2674-9432.2026v5n3p3036-3048",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0049437","Role of Glucagon-like peptide-1 “Liraglutide” in Management of Type 1 Diabetes","Abdulrahman Jameel A Sehly","2021","International Journal of Pharmaceutical and Phytopharmacological Research","randomized_trial","article","10.51847/skbdqro7ng",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049438","PO-05-134 EFFECT OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS ON ATRIAL FIBRILLATION ABLATION OUTCOMES","Ashutosh Kumar Sharma","2024","Heart Rhythm","other","article","10.1016/j.hrthm.2024.03.1369",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049439","1097: ASSOCIATION OF GLP-1 AGONISTS WITH LIVER-RELATED OUTCOMES AND ALL-CAUSE MORTALITY IN PATIENTS WITH HARMFUL ALCOHOL USE","Binu V. John","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)01545-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049440","LEADER Trial: Liraglutide reduces mortality in patients with type 2 diabetes. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 [Epub ahead of print].","Jorge M. Thierer","2016","Redalyc (Universidad Autónoma del Estado de México)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","other"],["R0049441","Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes","Scott A. Reule","2025","Diabetology","randomized_trial","article","10.3390/diabetology6120161",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049442","A novel GLP-1/glucagon receptor dual agonist improves non-alcoholic fatty steatohepatitis and liver regeneration in mice","M. Pilar Valdecantos","2016","DIGITAL.CSIC (Spanish National Research Council (CSIC))","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0049443","Abstract PS15-03: Retrospective study of GLP-1 Receptor Agonists in Breast Cancer Survivors: Weight Loss and Patient Outcomes","Jasmine Singh Sukumar","2025","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs24-ps15-03",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049444","770-P: Persistence of Prescription Gaps of SGLT2i and GLP-1RA in Type 2 Diabetes and Cardiorenal Disease—A Current Global Perspective","Shubham Agarwal","2025","Diabetes","other","article","10.2337/db25-770-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049445","SAT-423 Survodutide, a glucagon/GLP-1 receptor dual agonist, in people with MASH with moderate-to-advanced liver fibrosis (stage F2-F3): rationale and design of an event-driven, multinational, randomised, placebo-controlled, phase 3 trial (LIVERAGETM)","Jörn Markus Schattenberg","2025","Journal of Hepatology","protocol","article","10.1016/s0168-8278(25)01686-1",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0049446","Efficacy comparison between liraglutide and insulin glargine in treatment of type 2 diabetic patients","QU Geng-r","2013","Chinese Journal of New Drugs and Clinical Remedies","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0049447","686-P: Exercise Alone and in Combination with Liraglutide Exert Clinically Relevant Improvements in Cardiorespiratory Fitness during 1-Year Weight Loss Maintenance: The S-LITE Randomized Trial","SIMON JENSEN","2020","Diabetes","randomized_trial","article","10.2337/db20-686-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049448","Cardiovascular kidney metabolic syndrome from pathophysiological interaction to integrated clinical management","Hermes Tóros Xavier","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22874153",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049449","P.1.j.027 Chronic exenatide treatment reverses the impaired spatial and emotional memory functions of type-2 diabetic mice","İpek Komşuoğlu Çelikyurt","2014","European Neuropsychopharmacology","preclinical","article","10.1016/s0924-977x(14)70532-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049450","GLP-1 Receptor Agonist Semaglutide and Risk of Incident Urinary Stone Disease","Calyani Ganesan","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20253gqh8bva",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049451","Abstract P4-13-07: Meta-analysis of epidemiological studies of Insulin Glargine and Breast Cancer Risk","Peter A. Boyle","2012","Cancer Research","systematic_review","article","10.1158/0008-5472.sabcs12-p4-13-07",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0049452","Effetti del trattamento persistente con exenatide a medio-lungo termine in soggetti con diabete mellito di tipo 2: Esperienza multicentrica lombarda","Anna Pulcina","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049453","P-227. Impact Of GLP-1 Receptor Agonists on Body Weight in Persons with HIV Compared to Persons Without HIV","Diamond Donaldson","2026","Open Forum Infectious Diseases","nonrandomized_study","article","10.1093/ofid/ofaf695.449",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049454","Restoration of the PINK1/Parkin/PGC-1α axis by Liraglutide and Pravastatin co-therapy mitigates Doxorubicin-induced cardiotoxicity","Nada Monir","2026","Advanced Pharmaceutical Bulletin","preclinical","article","10.34172/apb.46963",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049455","ENHANCED SURVIVAL BENEFIT FOR GLP-1 RECEPTOR AGONIST PRESCRIPTION IN PATIENTS WITH COEXISTING TYPE 2 DIABETES AND SLEEP APNEA: A REAL-WORLD ANALYSIS OF 1.8 MILLION PATIENTS","Cosmo Fowler","2025","CHEST Journal","nonrandomized_study","article","10.1016/j.chest.2025.07.3956",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049456","Poster 6: GLP-1 Receptor Agonist Use Is Not Associated With an Increased Risk of Complications After Anatomic Total Shoulder Arthroplasty","Arsen M. Omurzakov","2025","Orthopaedic Journal of Sports Medicine","nonrandomized_study","article","10.1177/2325967125s00120",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049457","GLP-1 receptor agonists and the skin: A suggested addition to the SAMJ obesity series","Magrietha Swart","2026","South African Medical Journal","other","article","10.7196/samj.2025.v116i8.5557",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049458","Liraglutide + Metformin Combination Therapy in Type 2 Diabetes: Clinical Benefits Associated with Early Use of Liraglutide and with Switching a Sulfonylurea for Liraglutide","Keith Bowering","2012","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2012.07.360",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049459","Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials","William David Strain","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.2424",null,null,"ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT02692716","S001381; S001496; S001933","openalex","TRUE","open_pdf","1","FALSE","article"],["R0049460","Analysis of Glucagon-Like Peptide Agonist Use in Patients with Transsphenoidal Surgery of the Pituitary Adenoma over Time","Maxwell W. Pickles","2025","Journal of Neurological Surgery Part B Skull Base","nonrandomized_study","article","10.1055/s-0045-1803738",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0049461","297-OR: Triglyceride Reduction and Effect on Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus Receiving Fixed-Dose Combination of Insulin Degludec and Liraglutide","Eleni T. Pappa","2021","Diabetes","randomized_trial","article","10.2337/db21-297-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049462","GLP-1 agonist liraglutide increases metabolic- and cardiovascular-related sympathetic activity of the central nervous system.","David Kyle Mounger","2019","Digital Commons - East Tennessee State University (East Tennessee State University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049463","922-P: LIRA-PRIME: A Randomized Trial in Primary Care Settings of Liraglutide vs. OAD for Glycemic Control in Patients with Type 2 Diabetes Not in Control on Metformin","Jeff Unger","2020","Diabetes","randomized_trial","article","10.2337/db20-922-p",null,null,"ClinicalTrials.gov:NCT02730377","S000508","openalex","FALSE","paywalled","1","FALSE","article"],["R0049464","Drug-induced Liver Injury Associated with the Glucagon-like Peptide 1 (GLP-1) Agonist Liraglutide","Emily Kern","2013","The American Journal of Gastroenterology","other","article","10.14309/00000434-201310001-01131",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049465","Efficacité du liraglutide, un analogue du GLP-1 en substitution d’un inhibiteur de la dipeptidyl peptidase-4 (iDPP-4), chez des patients diabétiques de type 2 : résultats d’EVIDENCE®","Guillaume Charpentier","2014","Annales d Endocrinologie","other","article","10.1016/j.ando.2014.07.137",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049466","982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects","Jae Duk Choi","2019","Diabetes","randomized_trial","article","10.2337/db19-982-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049467","Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide","Mark S. Fineman","2007",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049468","Sa1535: GLP1 RECEPTOR AGONISTS AND HEPATIC DECOMPENSATION IN PATIENTS WITH MASH CIRRHOSIS: A PROPENSITY-MATCHED ANALYSIS OF THE US COLLABORATIVE NETWORK","Adel Hajj Ali","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04755-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049469","Optimizing Drug Therapy in Diabetic Nephropathy: A Comprehensive Review","Jeewanjot Singh","2026","International Journal of Creative and Open Research in Engineering and Management","narrative_review","article","10.55041/ijcope.v2i4.408",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049470","PS16 - 82. GLP-1 receptor agonism inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high fat diet-fed APOE*3-Leiden mice","Yanan Wang","2011","Nederlands Tijdschrift voor Diabetologie","preclinical","article","10.1007/s12467-011-0107-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049471","Outcomes of Adult Kidney Transplant Recipients with BMI Changes on the Waitlist","Laura Newton","2025","American Journal of Transplantation","nonrandomized_study","article","10.1016/j.ajt.2024.12.198",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049472","144-LB: Medicaid Expansion and Utilization of Antihyperglycemic Therapies","Andrew Sumarsono","2020","Diabetes","other","article","10.2337/db20-144-lb",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049473","The research of the domestic market of medicines and dietary supplements for obese patients pharmacotherapy","Алла Василівна Кабачна","2025","Farmatsevtychnyi zhurnal","nonrandomized_study","article","10.32352/0367-3057.1.25.03",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049474","Abstract #301 Use of GLP-1 Agonist Exenatide to Treat Reactive Hypoglycemia After Gastic Bypass Surgery","Spandana J. Brown","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47146-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049475","Cardiovascular events associate with diabetes status rather than with early basal insulin treatment for the prevention of post-transplantation diabetes mellitus","David Topitz","2019","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfz244","31803915",null,"ClinicalTrials.gov:NCT03507829",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049476","Parkinson’s Disease: Current Knowledge and Future Focus","Caroline B. Pantazis","2026","Translational Neuroscience","other","article","10.1007/978-3-032-31497-0_7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0049477","ELIGIBILITY FOR AND USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 AGONISTS IN VETERANS WITH TYPE 2 DIABETES AND CORONARY ARTERY DISEASE: PROSPECTIVE ANALYSIS FROM THE CARDIAC CATHETERIZATION LAB CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM","Demetria M. McNeal","2020","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(20)30858-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049478","Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada","Sean Wharton","2018","Value in Health","nonrandomized_study","article","10.1016/j.jval.2018.04.1668",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049479","Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?","Dena R. Cohen","2013","BMJ","other","article","10.1136/bmj.f3680","23748128",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049480","Pigmented purpura dermatosis associated with compounded semaglutide: A case report and literature review of medication-associated pigmented purpuric dermatosis","Stephanie Y. Zhang","2026","JAAD Case Reports","case_report","article","10.1016/j.jdcr.2026.08.020",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049481","Abstract 168: A Real-World Claims Analysis of Costs Among Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease Receiving Empagliflozin or Other Antihyperglycemic Agents","Aditya Raju","2019","Circulation Cardiovascular Quality and Outcomes","nonrandomized_study","article","10.1161/hcq.12.suppl_1.168",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049482","Use of SGLT2 Inhibitors and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Australian Primary Care Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by CKD Status","Hannah Wallace","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024f7q40fk1",null,null,"ClinicalTrials.gov:NCT03819153","S000953","openalex","FALSE","paywalled","4","FALSE","article"],["R0049483","P2518Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events","Mansoor Husain","2018","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehy565.p2518",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","FALSE","paywalled","1","FALSE","article"],["R0049484","From #bodypositive to #weightlossjourney–exploring weight loss narratives within the body positive community","Ella Maria Holi","2025","Fat Studies","other","article","10.1080/21604851.2025.2554040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049485","S1426 Impact of GLP-1 Agonists on the Severity of Inflammatory Bowel Disease","Sarah Coats","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035072.02170.98",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049486","The expanding role of semaglutide in cardiovascular disease and its the effect on blood pressure","Cormac Kennedy","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2591",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049487","No, taking drugs like Ozempic isn’t ‘cheating’ at weight loss or the ‘easy way out’","Clare Elizabeth Collins","2024",null,"other","article","10.64628/aa.ju3syq59x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0049488","79. Patients receiving GLP-1 agonists have reduced odds of pseudarthrosis and revision following anterior cervical discectomy and fusion surgery","Paramveer Singh Birring","2025","The Spine Journal","other","article","10.1016/j.spinee.2025.08.261",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049489","Intra-Articular Administration of Liraglutide for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Evidence of Prochondrogenic Potential","C. Meurot","2025","Osteoarthritis and Cartilage","preclinical","article","10.1016/j.joca.2025.02.527",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049490","Comparative analysis of availability and affordability of hypoglycaemic medicines for Ukrainian patients during the war 2022-2023","І. О. Власенко","2024","Journal of Health Policy & Outcomes Research","nonrandomized_study","article","10.7365/jhpor.2024.1.6",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049491","Mo1391 EXCLUDED STOMACH AND BILIOPANCREATIC LIMB DISTENTION IN PATIENTS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AFTER ROUX-EN-Y GASTRIC BYPASS: A CASE SERIES","Rex K. Siu","2024","Gastroenterology","case_report","article","10.1016/s0016-5085(24)04813-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049492","Dyslipidemia: Diabetes lipid therapies","Haider Rehan","2024","i-manager s Journal on Life Sciences","other","article","10.26634/jls.3.1.20942",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049493","Tu1786 GLP-1 AGONIST USE IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: FREQUENCY, RELATION TO ENDOSCOPY ADVERSE EVENTS, AND CLINICAL CORRELATES","Christopher J. Lee","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04982-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049494","Epicardial fat and sleep apnea: perspective mechanisms, diagnostics, and therapeutics","Ron Thomas Varghese","2025","Obesity and Endocrinology","other","article","10.1093/obendo/wjaf009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049495","Verbesserung kardiovaskulärer Risikofaktoren und des Blutzuckers bei Patienten mit Typ 2 Diabetes nach 82-wöchiger Exenatide Behandlung im Verhältnis zur Gewichtsreduktion","Ken Herrmann","2006","Diabetologie und Stoffwechsel","other","article","10.1055/s-2006-943969",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049496","718-P: Patients Achieving an HbA1c <5.7% with =5% Weight Loss and without Hypoglycemia: A Post Hoc Analysis of SURPASS 1 to 5","ALICE Y. CHENG","2022","Diabetes","other_trial","article","10.2337/db22-718-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049497","LIRAGLUTIDE, A NOVEL GLP-1 ANALOGUE, PREVENTS THE IMPAIRMENT OF LEARNING AND LTP AND PLAQUE FORMATION IN AN APP/PS-1 MOUSE MODEL OF ALZHEIMER'S DISEASE","Paula L. McClean","2011","Irish Journal of Medical Science (1971 -)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049498","S685 The Relationship Between Eosinophilic Esophagitis and Autism Spectrum Disorder in Adult Patients","Steve M. D’Souza","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032108.20416.b1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049499","PD26-01 TESTOSTERONE LEVELS IMPROVE IN MEN UNDER GLP-1 RECEPTOR AGONIST THERAPY","Andres H. Guillén-Lozoya","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191720.97092.ae.01",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049500","59-OR: Liraglutide Preserved Insulin Secretion in Adults with Newly Diagnosed Type 1 Diabetes: The NewLira Trial","Thomas Fremming Dejgaard","2019","Diabetes","randomized_trial","article","10.2337/db19-59-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049501","THU122 Effects Of A GLP-1 Agonist On Consumption Of Alcohol In Patients Treated For Smoking Cessation","Leila Probst","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.1200",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049502","26-A-22915-ACC EFFECT OF GLP-1 RECEPTOR AGONISTS ON ARRHYTHMIA RISK IN OBESE PATIENTS WITHOUT DIABETES: A LARGE-SCALE REAL-WORLD ANALYSIS","Abdul-Rahaman Adedolapo Ottun","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.341",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049503","Applying the Causal Roadmap to longitudinal national registry data in Denmark: A case study of second-line diabetes medication and dementia","Nerissa Nance","2025","Journal of Causal Inference","nonrandomized_study","article","10.1515/jci-2024-0014",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049504","IDF23-0468 Evaluation of global longitudinal strain and EAT in patients with T2DM treated with oral semaglutide: a pilot study","Adina Braha","2024","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2024.111237",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049505","Microcirculatory dopplerography as a method to evaluate drugs endothelial protective properties in type 2 diabetic patients","А. В. Симаненкова","2018","Regional blood circulation and microcirculation","other","article","10.24884/1682-6655-2018-17-3-120-128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049506","1116-P: Glycemic Outcomes and Persistence with Basal Insulin and Glucagon-Like Peptide-1 Receptor Agonists among Patients with T2D: Simultaneous vs. Sequential Initiation","Xuejun Peng","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1116-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049507","1259-P: Adherence and Persistence for Dulaglutide (DU) vs. Basal Insulin (BI) in Injection-Naïve Patients with Type 2 Diabetes (T2D): The DISPELTM Study","Reema Mody","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1259-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049508","congenital hypothyroidism","Nurshadia Binti Samingan","2025","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.040.s1.230",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049509","Appetite Regulation and Gastric Emptying of Semaglutide in Non-Diabetic Obese Adults: A Systematic Review","Uchechukwu Bethel Abioke","2026","Epidemiology and Health Data Insights","systematic_review","article","10.63946/ehdi/18334",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0049510","Chinese Guideline on the Primary Prevention of Cardiovascular Diseases: Time to Start Better Cardiovascular Primary Prevention","Guang Ning","2021","Cardiology Discovery","randomized_trial","article","10.1097/cd9.0000000000000024",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049511","Obesity-Related Glomerulopathy: Epidemiology, Pathogenesis, and Current Treatments","Xinyu Yang","2024","Integrative Medicine in Nephrology and Andrology","other","article","10.1097/imna-d-24-00011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049512","#1698670 A Case of Fatal Fulminant Necrotizing Pancreatitis in a Patient with Recent Tirzepatide Initiation","Krista N. Grennan","2024","Endocrine Practice","case_report","article","10.1016/j.eprac.2024.03.258",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049513","Toward Guideline-Directed Medical Therapy in Nephrology","Evan M. Zeitler","2022","Clinical Journal of the American Society of Nephrology","randomized_trial","article","10.2215/cjn.12401022","36414317",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049514","Diffuse Podocytopathy Associated With Semaglutide","Rose Mary Attieh","2024","Annals of Internal Medicine Clinical Cases","other","article","10.7326/aimcc.2023.1383",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049515","Table 24, Randomized controlled trials comparing a combination of metformin plus a sulfonylurea with a combination of metformin plus a GLP-1 receptor agonist on all-cause mortality","Shari Danielle Bolen","2016",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0049516","PK/PD/PD Models Enable Quantitative Insights into the Exposure-Efficacy Relationships of Tirzepatide for Treatment of Obstructive Sleep Apnea","Karen Schneck","2026",null,"nonrandomized_study","article","10.70534/nbjx4219",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-paper"],["R0049517","129-OR: Effect of Tirzepatide on the Counterregulatory Response to Hypoglycemia during a Hypoglycemic Clamp in People with Type 2 Diabetes","Thomas Rudolf Pieber","2023","Diabetes","randomized_trial","article","10.2337/db23-129-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049518","Comparative safety and efficacy of novel multi-action incretins in the treatment of obesity and type 2 diabetes: results of early studies","A.S. Kenkishvili","2026","Spravočnik vrača obŝej praktiki (Journal of Family Medicine)","other","article","10.33920/med-10-2607-07",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049519","291-OR: Effect of Type 2 Diabetes Characteristics on Semaglutide Treatment in People with Type 2 Diabetes and Peripheral Artery Disease—A Post Hoc Analysis of the STRIDE Trial","Neda Rasouli","2025","Diabetes","randomized_trial","article","10.2337/db25-291-or",null,null,"ClinicalTrials.gov:NCT04560998","S001363","openalex","FALSE","paywalled","1","FALSE","article"],["R0049520","Case Report","Jennifer A Stewart Williams","2009","The Endocrinologist","case_report","article","10.1097/ten.0b013e3181a5875e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049521","Surgical treatment of macromastia in benign breast dysplasia and comorbidities","Natalia Evgenievna Manturova","2024","Plastic Surgery and Aesthetic Medicine","other","article","10.17116/plast.hirurgia20240425",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049522","6779 The Diversity of Immune Checkpoint Inhibitor Associated Diabetes","Vaidehi Alkeshbhai Mendpara","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.949",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049523","Retraction notice to exendin-4 reverses biochemical and behavioural deficits in a pre-motor rodent model of Parkinson’s disease with combined noradrenergic and serotonergic lesions [YNPEP 46 (2012) 183–193]","Nazir Rampersaud","2013","Neuropeptides","notice","article","10.1016/j.npep.2013.04.004",null,null,null,null,"openalex","FALSE",null,null,"TRUE","retraction"],["R0049524","221-LB: Effects of Liraglutide on Visceral and Ectopic Fat in Adults with Overweight/Obesity at High Cardiovascular Risk: A Randomized Clinical Trial","Ian J. Neeland","2021","Diabetes","randomized_trial","article","10.2337/db21-221-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049525","The Role of Glicentin and Oxyntomodulin in Human Metabolism: New Evidence and New Directions","Nikolaos Perakakis","2020","The Journal of Clinical Endocrinology & Metabolism","other","article","10.1210/clinem/dgaa329","32480410",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049526","Su1804 ECONOMIC EVALUATION OF PROXIMAL INTESTINAL MUCOSAL ABLATION IN INSULIN-REQUIRING TYPE 2 DIABETES: COST-EFFECTIVENESS AND PRICE THRESHOLD ANALYSIS FROM A US HEALTHCARE PAYER WITH COMPARISON TO SEMAGLUTIDE","Benjamin Norton","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04889-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049527","Abstract 3623: Effects of the anti-obesity medication tirzepatide on the tumor microenvironment in a mouse model of obesity-associated, hormone-dependent breast cancer","Charlotte Gibson","2026","Cancer Research","randomized_trial","article","10.1158/1538-7445.am2026-3623",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049528","Abstract #1161775: Semaglutide-induced leukocytoclastic vasculitis","Sadaf Farasat","2022","Endocrine Practice","other","article","10.1016/j.eprac.2022.03.067",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049529","Liraglutide alters hepatic metabolism in high-fat fed obese mice: A bioinformatic prediction and functional analysis","Isabelle Arruda Barbosa","2019","Meta Gene","preclinical","article","10.1016/j.mgene.2019.100553",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049530","Abstract 4367152: VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes","Karen M. Modesto","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4367152",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049531","Canagliflozin and liraglutide effect on myocardial damage in diabetic rats with experimental myocardial infarction","Н. В. Тимкина","2022","Endocrine Abstracts","preclinical","article","10.1530/endoabs.81.ep251",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049532","12602 The Effect of Three-Month Semaglutide Treatment on Serum TSH and Thyroid Hormones in Individuals with Obesity","Paulina Konopka","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.2085",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049533","Tirzepatide for Night Eating Syndrome (NES) and Sleep-Related Eating Disorder (SRED): a presentation of two cases","Kammi Grayson","2026","Sleep Epidemiology","other","article","10.1016/j.sleepe.2026.100128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049534","Abstract PR003: The combination of the glucagon like peptide-1 receptor agonist semaglutide and the progestin levonorgestrel is highly effective in preclinical studies of endometrial cancer","Kimberly Kay Leslie","2024","Clinical Cancer Research","other","article","10.1158/1557-3265.endo24-pr003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049535","Effects of Tirzepatide vs. Insulin Glargine on Kidney Function Evaluated by Cystatin C-Based eGFR: A Post Hoc Analysis From the SURPASS-4 Trial","Hiddo J.L. Heerspink","2022","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20223311s1677a",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0049536","Assessment of public awareness about Semaglutide (Ozempic) use, safety, and adverse drug reaction in Saudi Arabia","Abdullah Alshehri","2024","International Journal of Medicine in Developing Countries","other","article","10.24911/ijmdc.51-1698694582",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049537","Characteristics of Patients with CKD and Diabetes by Use of ACE Inhibitors or ARBs","Cami R. Jones","2021","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20213210s1270a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049538","Glucagon-like peptide-1 receptor agonists (GLP-1 RA) as adjunct to standard treatment in diabetic patients with chronic heart failure: a systematic review & meta-analysis","D.N Afaga","2020","European Heart Journal","systematic_review","article","10.1093/ehjci/ehaa946.1046",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0049539","GLP-1 Agonists Do Not Increase Risk of Bacterial Pneumonia in Obese Patients: A Real-world Retrospective Multicenter Study","M.B. Shaikh","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a7725",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049540","Impact of SGLT2i and GLP1 agonists on prostate cancer incidence and outcomes: A real-world propensity score–matched cohort study.","Sam Joseph King","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e17148",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049541","Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence","Olesya Y. Gurova","2019","Diabetes Mellitus","other","article","10.14341/dm9603",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049542","Rates of Major Adverse Cardiovascular Events and Mortality with Basal Insulin by Liraglutide Use: A DEVOTE Subanalysis","Kirstine Brown‐Frandsen","2018","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2018.08.021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049543","Experiment-selector cross-validated targeted maximum likelihood estimator for hybrid RCT-external data studies","Lauren Eyler Dang","2022","arXiv (Cornell University)","randomized_trial","article","10.48550/arxiv.2210.05802",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0049544","1494-PUB: Variable Responses to GLP-1 Receptor Agonists","Sandeep Kunwar","2022","Diabetes","nonrandomized_study","article","10.2337/db22-1494-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049545","Semaglutide as an add-on treatment to optimise glycaemic control in children and young people with type 1 diabetes (smile T1D trial) development and protocol","Kun Hu","2025","Endocrine Abstracts","protocol","article","10.1530/endoabs.111.p99",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0049546","Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes","Michael Fang","2023","Annals of Internal Medicine","other","article","10.7326/l23-0228","37722124",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049547","Combining SGLT2 inhibitor and GLP-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes","Kg Nilwala U Jayasinghe","2016","British Journal of Diabetes","other","article","10.15277/bjd.2016.092",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049548","In patients with type 2 diabetes who are maximized on metformin with HbA1C above 7%, are GLP-1 agonists more effective than sulfonylureas for lowering HbA1C?","Bernard D. Noveloso","2017","Evidence-Based Practice","other","article","10.1097/01.ebp.0000541636.61824.e5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049549","COST-RELATED MEDICATION NON-ADHERENCE IN SEMAGLUTIDE-ELIGIBLE US ADULTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM US NATIONALLY REPRESENTATIVE POPULATION","Izza Shahid","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03902-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049550","Similar weight loss with semaglutide regardless of diabetes and cardiometabolic parameters in individuals with non-alcoholic fatty liver disease","Matthew James Armstrong","2023","Journal of Hepatology","other","article","10.1016/s0168-8278(23)02295-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049551","Überlegenheit von Exenatide gegenüber Insulin bei der Einstellung des Blutzuckers (HbA1c ≤6,5%) bei gleichzeitig günstigerem metabolischen Profil","CHRISTOF M. KAZDA","2009","Diabetologie und Stoffwechsel","other","article","10.1055/s-0029-1221936",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049552","CARDIOVASCULAR BENEFITS OF GLP-1 RECEPTOR AGONISTS IN PATIENTS WHO ARE OBESE OR OVERWEIGHT: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS","Gustavo Yudi Orikassa de Oliveira","2024","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(24)03838-5",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0049553","CARDIOLOGIST USE OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS SINCE RELEASE OF FAVORABLE CARDIOVASCULAR OUTCOMES TRIALS: A NATIONAL STUDY","Rishav Adhikari","2021","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(21)02826-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049554","Abstract 4363938: Combination Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapy Reduces Admissions and Death in Patients with Heart Failure with Reduced Ejection Fraction","Samuel Mensah","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4363938",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049555","P018 Pharmacotherapy for OSA: a critical review of randomised placebo-controlled trials","Steven Luu","2025","SLEEP Advances","randomized_trial","article","10.1093/sleepadvances/zpaf053.078",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049556","A Long-Acting Glucose Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss Without Nausea or Vomiting","Edward John Pratt","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785388",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049557","Glicentin concentrations following Liraglutide treatment in patients with overweight/obesity","Wiaam Al‐Hasani","2022","Endocrine Abstracts","other","article","10.1530/endoabs.86.p330",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049558","Shortage of Obesity Medicine Specialists in the United States","Simar Singh Bajaj","2026","Mayo Clinic Proceedings","other","article","10.1016/j.mayocp.2025.10.015","41493442",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049559","Tirzepatide Improves HRQoL Compared to Insulin Lispro in Poorly Controlled Basal Insulin-treated Adults with Long-standing T2D (SURPASS-6)","Kristina Secnik Boye","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785382",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049560","329-OR: Cardiovascular Effectiveness of SGLT2i and GLP-1RA vs. Sulfonylureas by Socioeconomic Status—Analysis of U.S. and UK Health Care Systems","PHYO T. HTOO","2025","Diabetes","nonrandomized_study","article","10.2337/db25-329-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049561","1428-P: Type 2 Diabetes Drug Utilization by Claims-Based and Self-Reported Weight Status","PAUL WOLLERSHEIM","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1428-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049562","Dietary and Medical Management of Obesity","John P.H. Wilding","2022",null,"other","article","10.1093/med/9780198870197.003.0225",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0049563","263-OR: Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain","Owen Thomas Carmichael","2024","Diabetes","randomized_trial","article","10.2337/db24-263-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049564","HSD14 Characteristics of US Commercially Insured Patients with Type 2 Diabetes (T2D) Initiating Tirzepatide","K Desai","2024","Value in Health","other","article","10.1016/j.jval.2024.03.1237",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049565","Efficacité du liraglutide intra-articulaire, analogue de GLP-1, sur les paramètres inflammatoires et structuraux dans un modèle d’arthrose : étude comparative avec la dexaméthasone","C. Meurot","2024","Revue du Rhumatisme","other","article","10.1016/j.rhum.2024.10.428",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049566","Semaglutide, a GLP-1 Agonist Like 'Ozempic' and its Potential Role as a Preventive Anti-Cancer Agent","Maher Monir Akl","2024","Cell & Cellular Life Sciences Journal","other","article","10.23880/cclsj-16000195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049567","Neural origin plasma exosomes provide novel biomarkers for brain insulin resistance in Alzheimer's disease (I11-5B)","Dimitrios Kapogiannis","2015","Neurology","other","article","10.1212/wnl.84.14_supplement.i11-5b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049568","P1–155: The differential impact of diabetes medications on cognition","Elizabeth Lane","2013","Alzheimer s & Dementia","other","article","10.1016/j.jalz.2013.05.378",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049569","S786 Comparative Gastrointestinal Safety of Tirzepatide vs Semaglutide: A Real-World Multicenter Analysis","Bright Chizitere Nwatamole","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130604.96709.70",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049570","26-A-14216-ACC BENEFITS OF BARIATRIC SURGERY VERSUS GLP-1 AGONISTS ON MORTALITY, CARDIOVASCULAR DISEASE, SLEEP APNEA, AND DEMENTIA","Ibrahim Mortada","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.498",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049571","IDENTIFYING PHENOTYPIC CLUSTERS AMONG ASCVD PATIENTS ELIGIBLE FOR SEMAGLUTIDE THERAPY IN A LARGE INTEGRATED HEALTHCARE SYSTEM","Budhaditya Bose","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03920-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049572","SAFETY SIGNALS FOR HYPERKALEMIA IN TYPE 2 DIABETES: A FOCUSED REVIEW OF SGLT-2, GLP-1, AND DPP-4 DRUG CLASSES","Amber Shams","2025","Journal of medical & health sciences review.","narrative_review","article","10.62019/sw57nf20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049573","Lab Grown Paper","David C. Van Riper","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/etq39",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0049574","Molecular docking analysis and antidiabetic activity of Rifabutin against STZ-NA induced diabetes in albino wistar rats","Danish Ahmed","2017","Beni-Suef University Journal of Basic and Applied Sciences","preclinical","article","10.1016/j.bjbas.2017.04.010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049575","EFFECTS OF THE GLP-1 RA SEMAGLUTIDE ON VASCULAR STRUCTURE AND FUNCTION IN PATIENTS WITH TYPE 2 DIABETES: RESULTS OF A PROSPECTIVE RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY","Dennis Kannenkeril","2025","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0001115440.99912.21",null,null,"ClinicalTrials.gov:NCT05303857","S001690","openalex","TRUE","paywalled","1","FALSE","conference-abstract; article"],["R0049576","Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER","Vlado Perkovic","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/sk6q-9n39",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0049577","THE EFFECT OF TRIPLE-HORMONE-RECEPTOR AGONIST RETATRUTIDE, A NOVEL MEDICATION FOR WEIGHT LOSS, ON BLOOD PRESSURE - A META-ANALYSIS OF RANDOMIZED CONTROLLED PHASE 2 TRIALS","Sharath Kommu","2024","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(24)03870-1",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0049578","S236 Comparison of Safety and Efficacy of Endoscopic Biliary Stents for Malignant Biliary Strictures: A Systemic Review and Meta-Analysis","Haakim Waraich","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001127404.19651.2f",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0049579","Safety and Efficacy of Dulaglutide Versus Sitagliptin after 104 Weeks in Type 2 Diabetes (AWARD-5)","Bruno Guerci","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.129",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049580","The combination of dulaglutide and dapagliflozin improves arterial stiffness, endothelial glycocalyx and albuminuria vs DPP-4 inhibitors independently of glycemic control","Emmanouil Korakas","2021","European Heart Journal","other","article","10.1093/eurheartj/ehab724.2648",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049581","Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance","Natalia N. Rudovich","2014","Diabetes Care","randomized_trial","article","10.2337/dc14-1452","25538323",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049582","647-P: Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial","Matthew Capehorn","2021","Diabetes","other_trial","article","10.2337/db21-647-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049583","Will noninvasive screening for fibrosis/steatosis open Pandora’s box? Sharing the healthcare burden of state-of-the-art hepatology practice","Sarah Khorasani","2023","Hepatology","nonrandomized_study","article","10.1097/hep.0000000000000235","36680399",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049584","EFFECT OF THE GLP-1 RECEPTOR AGONIST SEMAGLUTIDE ON TOTAL CARDIOVASCULAR EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE AND OVERWEIGHT OR OBESITY BUT NO DIABETES IN THE SELECT TRIAL","Abraham Michael Lincoff","2025","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(25)00862-9",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0049585","EE4 BOOTSTRAPPING USED TO PROVIDE ROBUST MEAN AND VARIANCE ESTIMATES FOR COMPARING PATIENTS TREATED WITH LIRAGLUTIDE TO A LARGE COMPARISON COHORT","Carrie McAdam Marx","2011","Value in Health","nonrandomized_study","article","10.1016/j.jval.2011.02.058",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049586","Concerns regarding the reliability of subgroup effects","Mei Hong Qiu","2023","EClinicalMedicine","other_trial","article","10.1016/j.eclinm.2022.101794","36698682",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0049587","Synergistic activity of GLP-1 peptide analog XW003 and the long-lasting GIP receptor agonist XW017 in a diet induced obese mouse model","Xinle Wu","2022","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(22)01770-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049588","791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD","Xi Tan","2023","Diabetes","nonrandomized_study","article","10.2337/db23-791-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049589","OR09-05 Perioperative Weight Loss With GLP-1 Receptor Agonists in Patients Receiving Bariatric Surgery","Angela Rao","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.070",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049590","Exenatide for Inpatient Glycemic Control","Daniel David Dressler","2019","Journal watch","other","article","10.1056/nejm-jw.na48855",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049591","P2.008 Neuroprotective effect of GLP-1R agonist exendin-4 in rat model of Parkinson's disease involves D3-receptor mediated changes in neural precursor cells","Alexander Harkavyi","2009","Parkinsonism & Related Disorders","preclinical","article","10.1016/s1353-8020(09)70359-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049592","Association of GLP-1 receptor agonist use with overall survival in patients with colorectal cancer and type 2 diabetes: A multicenter real-world study.","Baqir Jafry","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e15556",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049593","S2411 Safety and Efficacy of Semaglutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Systematic Review and Meta-Analysis","Faseeh Haider","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001137104.21208.7e",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0049594","S1936 Glucagon Like Peptide 1 Receptor Agonist Use Is Associated With Improved Clinical Outcomes in Inflammatory Bowel Disease","Ahmed Eltelbany","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001135204.44495.0f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049595","Abstract 135: Assessing the Personalization of Glycemic Management Strategies Through the Diabetes Collaborative Registry","Suzanne V. Arnold","2017","Circulation Cardiovascular Quality and Outcomes","nonrandomized_study","article","10.1161/circoutcomes.10.suppl_3.135",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049596","Clinical Characteristics and Cardiometabolic Control of Persons with Diabetes in the Cardiology Office in Argentina","Ezequiel Hernán Forte","2020",null,"other","article","10.7775/rac.v88.i6.18201",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049597","Endoscopic argon plasma coagulation (APC) vs glucagon-like peptide-1 receptor agonists (ARGLP1) liraglutide and semaglutide for the treatment of weight regain (WR) after bariatric surgery (BS).","Sara Mera Carreiro","2024","Clinical Nutrition ESPEN","other","article","10.1016/j.clnesp.2024.07.988",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049598","Single-dose GLP-1-based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity","Alice Liou Fitzpatrick","2024","Metabolism","preclinical","article","10.1016/j.metabol.2024.155876",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049599","CVOT Summit Report 2024","Oliver Schnell","2026","DiRROS repository (University of Maribor)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0049600","Semaglutide dampens residual inflammation in individuals with type 2 diabetes","Reindert F. Oostveen","2024","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2024.118499",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049601","PDB31 LONG-TERM OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES RECEIVING GLIMEPIRIDE COMBINED WITH LIRAGLUTIDE OR ROSIGLITAZONE","Raphael Alfonso","2009","Value in Health","other","article","10.1016/s1098-3015(10)73574-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049602","Abstract 4139502: Projected Impact of GLP-1 adoption on 5-year coronary stent rates among Medicare beneficiaries with cardiovascular disease","Saif S. Rathore","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4139502",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049603","S863 Impact of Duration of GLP-1 Receptor Agonist Therapy in Endoscopic Outcomes","Beatriz Torre","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032820.41709.eb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049604","PREOPERATIVE GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ASSOCIATED WITH IMPROVED POSTOPERATIVE CARDIOVASCULAR OUTCOMES","Una E. Choi","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01001-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049605","LEADER-5: Prävalenz und kardiometabolischer Einfluss von Übergewicht und Adipositas bei kardiovaskulären Hochrisikopatienten mit Typ 2 Diabetes mellitus: Baseline-Daten aus der LEADER-Studie","Simon N. Jacob","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580965",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","FALSE","paywalled","5","FALSE","article"],["R0049606","1172 Assessing the Impact of Pharmacist-led interventions in an Integrative Care Team for Enhancing GLP-1 RA Medication Access and Treatment Outcomes","Heather Gibson Huddleston","2025","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2025.102649",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049607","Semaglutide for Weight Loss in Diabetic and Non-Diabetic Patients: A Comprehensive Systematic Review of Efficacy and Safety","Reema Salman Alfadliah","2025","Scientia. Technology, science and society.","systematic_review","article","10.59324/stss.2025.2(4).06",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0049608","Dose- and time-dependent effects of the dual GIP/GLP-1 receptor agonist tirzepatide on emotional overeating in a rat model of intracranial self-stimulation","Николай Сергоевич Деданишвили","2026","Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук","preclinical","article","10.29413/abs.2026-11.3.20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049609","THE EFFECT OF ADD-ON THERAPY OF LIRAGLUTIDE AND EMPAGLIFLOZIN ON AMBULATORY BLOOD PRESSURE IN PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES MELLITUS","Eleni-Margarita Tzouganatou","2021","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0000746872.52004.bf",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049610","Uso de medicamentos injetáveis para o emagrecimento","Ingrid de Oliveira Silva","2023","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2023v5n3p876-897",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049611","2834 Frailty in randomised controlled trials of glucose-lowering therapies for type 2 diabetes","H Wightman","2025","Age and Ageing","randomized_trial","article","10.1093/ageing/afae277.077",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049612","Prescribing practices and barriers to use of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like Peptide‐1 receptor agonists in adult kidney transplant recipients: A survey of endocrinology and nephrology prescribers","Krysta S. Walter","2024","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","other","article","10.1002/jac5.2060",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049613","Estimating the Health, Economic, and Social Benefits of Obesity Treatment Using Microsimulation Modeling","Fang Chen","2026","Diabetes Obesity and Cardiometabolic CARE","other","article","10.2337/figshare.31427249.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0049614","Abstract 4120229: Shift in body mass index category and associated cardiometabolic risk factors: a post hoc analysis from the SURMOUNT-4 trial","Naveed A. Sattar","2024","Circulation","randomized_trial","article","10.1161/circ.150.suppl_1.4120229",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049615","Microtopography enhances intestinal drug absorption via Piezo1‐mediated tight junction modulation","Yu Hu","2025","BMEMat","other","article","10.1002/bmm2.70052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049616","Long-term results of transferring the patient from therapy with glucagon-like peptide-1 receptor agonists in combination with metformin to a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone and inhibitor of type 2 sodium-glucose cotransporter in type 2 diabetes","В. В. Салухов","2024","Diabetes Mellitus","randomized_trial","article","10.14341/dm13062",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049617","Perioperative GLP-1 Use Improves Pituitary Function Recovery After Endoscopic Resection","Maunil Mullick","2026","Journal of Neurological Surgery Part B Skull Base","nonrandomized_study","article","10.1055/s-0046-1818680",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049618","Real Life Effects of Liraglutide Supports Those Shown in RCTs","Avraham Karasik","2013","Value in Health","other","article","10.1016/j.jval.2013.08.630",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049619","MPN-642: Glucagon-Like Peptide-1 Agonists and Clinical Outcomes in Polycythemia Vera: A Large-Scale Propensity-Matched Cohort Study","Asfand Yar Cheema","2025","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(25)02129-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049620","Socioeconomic position and initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study","Alexander Christian Falkentoft","2021","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehab724.2622",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049621","Mo1297 SHOULD GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS (GLP-1 RAS) BE HELD PRIOR TO AMBULATORY REFLUX TESTING? A RETROSPECTIVE COMPARISON OF QUANTITATIVE REFLUX TESTING RESULTS","Robinderpal Sandhu","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)02816-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049622","Machine learning to identify community-dwelling individuals at higher risk of incident cardio-renal-metabolic diseases and death","Ramesh Nadarajah","2024","Future Healthcare Journal","randomized_trial","article","10.1016/j.fhj.2024.100109",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049623","Evaluating the therapeutic benefits and safety of ecnoglutide for type 2 diabetes: evidence from a systematic review and meta-analysis","Saaed Abunada","2026","Diabetology & Metabolic Syndrome","systematic_review","article","10.1186/s13098-026-02250-9",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0049624","1784-P: Anti-inflammatory Effects of Liraglutide in Obesity","Assim Abdulaziz Alfadda","2025","Diabetes","other","article","10.2337/db25-1784-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049625","Metabolic syndrome : therapeutic strategies","Vivian Andrew Fonseca","2008","Clinical Publishing eBooks","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0049626","Do We Need New Therapies For Diabetes?","Dimiter V. Dimitrov","2015","Diabetes Research - Open Journal","other","article","10.17140/droj-1-112",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049627","SAT-168 A Secreted Protein Complement 1q Like-3 Protein Inhibits Insulin Secretion by an Adhesion G-Protein Coupled Receptor, BAI3 in Pancreatic β-Cells","Rajesh C. Gupta","2019","Journal of the Endocrine Society","preclinical","article","10.1210/js.2019-sat-168",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049628","Investigations of Enteric-Coated Propyl Gallate-induced Nephrotoxicity in Beagles and Human and Dog Renal Proximal Tubule Epithelial Cells","Si Mou","2024","ChemRxiv","other","article","10.26434/chemrxiv-2024-t80qn",null,null,"ClinicalTrials.gov:NCT03362593",null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0049629","P310 Effet de l’exenatide en add-on d’une insulinothérapie intensifiée dans une population de patients diabétiques de type 2: résultats de la phase 2 de l’étude EXEPUMP","Michaël Joubert","2015","Diabetes & Metabolism","other_trial","article","10.1016/s1262-3636(15)30423-7",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0049630","CagriSema: a novel dual-pathway approach to target obesity and its complications","Isabela Valdés-Calero","2026","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2026.101",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049631","Évaluation de l’intérêt du nouvel antidiabétique dulaglutide chez les patients diabétiques de type 2 traités par liraglutide","Estelle Cheli","2017","Le Pharmacien Hospitalier et Clinicien","other","article","10.1016/j.phclin.2017.01.057",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049632","2037-P: Characterization of Novel Unimolecular Amylin-Adrenomedullin Dual Agonists","LOUISE S. DALBOEGE","2019","Diabetes","preclinical","article","10.2337/db19-2037-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049633","Liraglutide launched in South Africa : drug trends","Julia Aalbers","2012","˜The œSouth African journal of diabetes & vascular disease","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049634","20-OR: GPR142 Agonists Increase Glucose-Dependent Insulin Secretion and Differentially Regulate Hormone Secretion in Preclinical and Phase 1 Studies","Edward John Pratt","2019","Diabetes","other_trial","article","10.2337/db19-20-or",null,null,"ClinicalTrials.gov:NCT03115099","S001731","openalex","FALSE","paywalled","5","FALSE","article"],["R0049635","Successful management with GLP-1 agonists in postprandial hyperinsulinemic hypoglycemia after roux-en-y gastric bypass: clinical case descriptionand review of the literature","Evelyn Dorado","2019","Advances in Obesity Weight Management & Control","narrative_review","article","10.15406/aowmc.2019.09.00278",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049636","Psychotropic and metabolic benefits of GLP-1 receptor agonists in a real-world psychiatric sample: a retrospective longitudinal study","M.B. Rescalli","2026","Neuroscience Applied","nonrandomized_study","article","10.1016/j.nsa.2025.105673",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049637","MON-622 Severe Insulin Resistance in a Patient with Generalized Lipodystrophy","Diksha Kaul","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.983",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049638","ABS0839 CARDIOVASCULAR OUTCOMES AND MORTALITY ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS IN INFLAMMATORY MYOSITIS AND NECROTIZING MYOPATHY: A RETROSPECTIVE COHORT STUDY","Rashid Ali","2025","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1016/j.ard.2025.06.1128",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0049639","CO52 Modelling Long-Term Outcomes of Tirzepatide Compared to Lifestyle Modification and Other Anti-Obesity Medications As Treatment for Overweight and Obesity","Meredith M. Hoog","2023","Value in Health","other","article","10.1016/j.jval.2023.03.126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049640","Streamlining and optimizing viral vector bioprocess and analytical development","Joseph Tarnowski","2021","Cell and Gene Therapy Insights","nonrandomized_study","article","10.18609/cgti.2020.188",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049641","A case series of Humulin R U‐500 in insulin resistant people with type 2 diabetes","Umesh Kumar Dashora","2021","Practical Diabetes","case_report","article","10.1002/pdi.2366",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049642","IP18-25 GLP-1 AGONIST USE IS ASSOCIATED WITH REDUCED RISK OF REPEAT KIDNEY STONE EVENTS IN A NATIONALLY REPRESENTATIVE COHORT","Bryan C. Kaps","2026","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001191368.71794.72.25",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049643","Entwicklung und Evaluation eines Zweikammerpens für wöchentliches Depot-Exenatide","Shane LaRue","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549774",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049644","Sa1943 ESG PLUS LIRAGLUTIDE IS SUPERIOR TO ESG ALONE FOR WEIGHT LOSS IN OVERWEIGHT AND OBESE PATIENTS","Dilhana Badurdeen","2020","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2020.03.1288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049645","Prostaglandin E2 (PGE2) Levels As a Predictor of Type 2 Diabetes Control in Human Subjects: A cross‐sectional view of initial cohort study data","Rachel J. Fenske","2017","The FASEB Journal","nonrandomized_study","article","10.1096/fasebj.31.1_supplement.675.6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049646","S793 Reduced Risk of Iron Deficiency Anemia With GLP-1 Use in Celiac Disease Patients","Jonathan Ghobrial","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130632.36905.cc",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049647","Targeting islet G-protein-coupled receptors for type 2 diabetes therapy","Shanta J. Persaud","2021","The Biochemist","other","article","10.1042/bio_2021_108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049648","Protective effects of intra-articular formulated liraglutide in osteoarthritis : preclinical studies","Françis Berenbaum","2020","Osteoarthritis and Cartilage","other","article","10.1016/j.joca.2020.02.760",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049649","The Importance of Addressing Multiple Risk Markers in Type 2 Diabetes: Results from the LEADER Trial","Emilie H. Zobel","2020","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20203110s1337c",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0049650","DRUG APPROVALS DECLINED IN 2010","Ann M. Thayer","2011","Chemical & Engineering News","other","article","10.1021/cen-v089n002.p005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0049651","44 Trends in Management of Chronic Kidney Disease among Adults with Diabetes, NHANES 1988-2020","Siddharth Venkatraman","2024","Journal of Clinical and Translational Science","other","article","10.1017/cts.2024.55",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049652","Evolving Body Contouring Strategies for Patients After Massive Weight Loss: Insights from Bariatric and Pharmacologic Interventions","Salvatore A. Giordano","2025","Surgeries","nonrandomized_study","article","10.3390/surgeries6020042",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049653","Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists for Treatment of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Stanley Wong","2025","Psychiatry International","systematic_review","article","10.3390/psychiatryint6030111",null,null,"PROSPERO:CRD42024537280",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0049654","37-OR: Racial and Socioeconomic Disparities in the Use of Newer Classes of Diabetes Medications","Ahmed Elhussein","2020","Diabetes","randomized_trial","article","10.2337/db20-37-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049655","RWD78 Characterization of Patients Treated with Semaglutide 2.4MG for Chronic Weight Management: A Retrospective Cohort Study","Adelaida Lazarova Ruseva","2023","Value in Health","nonrandomized_study","article","10.1016/j.jval.2023.03.2107",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0049656","The GLP-1 receptor agonists: what’s all the (cardiovascular) hype about?","John-Philip Taylor","2022","SA pharmaceutical journal.","other","article","10.36303/sagp.2022.3.4.0137",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049657","Treatment monitoring with the Agile 3+ score in patients with non-alcoholic steatohepatitis: analysis of data from a randomised placebo-controlled trial of semaglutide","Laurent Castéra","2023","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(23)02279-1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049658","Oral treatment of glucocorticoid‐induced diabetes mellitus: A systematic review","Carina Kirstine Klarskov","2020","International Journal of Clinical Practice","systematic_review","article","10.1111/ijcp.13529","32392375",null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0049659","118.6: The role of gastrin in human islet and type 1 diabetes animal model","LYNN N. MIAO","2023","Transplantation","preclinical","article","10.1097/01.tp.0000993908.49299.ea",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049660","S2868 Autoimmune Hepatitis-like Drug Injury of the Liver Associated with the Glucagon-like Peptide 1 (GLP-1) Agonist Dulaglutide","Emma Neahusan","2021","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000785004.17193.b9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049661","The beneficial hepatic effects of glucagon‐like peptide 1 receptor agonists in patients with diabetes and metabolic dysfunction‐associated steatotic liver disease are independent of weight loss","Roberta Forlano","2024","Liver international communications.","nonrandomized_study","article","10.1002/lci2.86",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049662","SU-GG-T-364: Development and Application of a Structural Quality Indicator for Radiotherapy Clinical Equipment","Mehran Goharian","2008","Medical Physics","other","article","10.1118/1.2962116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049663","Incretin-based therapies and cancer risk: a review of recent literature safety data","Cristina Scavone","2016","Diabetes Management","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0049664","FRI-151 Which comes first: GLP-1 RA vs resmetirom in MASH real world practice","Ana Maria Davila Morales","2026","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(26)01895-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049665","0781 Impact of Glucagon-Like Peptide-1 Analogs on Thromboembolic Outcomes in Obstructive Sleep Apnea Patients","Xin Ya See","2025","SLEEP","nonrandomized_study","article","10.1093/sleep/zsaf090.0781",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049666","Exenatide for treatment of obese type 2 diabetes: the Townsville Hospital experience","Durgesh Gowda","2013","ResearchOnline - JCU (James Cook University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0049667","Abstract 10770: Effects of Glucagon-Like Peptide-1 Receptor Agonists on Patients With or Without Heart Failure: A Meta-Analysis of Randomized Control Trials","Shota Obata","2022","Circulation","systematic_review","article","10.1161/circ.146.suppl_1.10770",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0049668","Diabetes","Asociación Colombiana de Endocrinología Diabetes y Metabolismo","2019","Revista Colombiana de Endocrinología Diabetes & Metabolismo","nonrandomized_study","article","10.53853/encr.6.2s.506",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049669","Journal of Diabetes NEWS","Melissa Yuwono Tjota","2011","Journal of Diabetes","nonrandomized_study","article","10.1111/j.1753-0407.2011.00140.x",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049670","The Possible Link Between Tirzepatide and Pulmonary Embolism: A Case Report and a Narrative Review","Anna Arecco","2026","Endocrines","case_report","article","10.3390/endocrines7020020",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0049671","Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care","Zin Zin Htike","2016","British Journal of Diabetes","randomized_trial","article","10.15277/bjd.2016.091",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049672","Glucagon-like peptide 1: biochemistry, secretion and main physiological effects","Amélia Maria Silva","2009","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049673","563 The Effect of Once-Weekly Semaglutide on MACE and Blood Pressure by Race and Ethnicity: SUSTAIN 6 Post Hoc Analysis","Timothy M. E. Davis","2020","Heart Lung and Circulation","other","article","10.1016/j.hlc.2020.09.570",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049674","Therapeutic potential of glucagon-like peptide-1 agonists in insulin-treated diabetes mellitus","John Dupré","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33334-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049675","P338 Comparaison de l’efficacité du liraglutide en ajout à un traitement par metformine vs en association aux autres traitements antidiabétiques à l’inclusion de l’étude EVIDENCE®: résultats post-hoc après 2 ans de suivi","É. Eschwège","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30451-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049676","Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use","Leonid Borisovich Lazebnik","2024","Экспериментальная и клиническая гастроэнтерология","other","article","10.31146/1682-8658-ecg-230-10-11-35",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049677","Protecting women heart in Type 2 diabetes mellitus: why, how, and when?","Mitja Lainščak","2023","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwad335","37897497",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0049678","Abstract PD8-06: Real-world Analysis on the Impact of GLP-1 Receptor Agonists on All-cause Mortality and Endocrine Therapy-Tolerability in Obese Breast Cancer Patients","C. F. Jones","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-pd8-06",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049679","Dual Assessment of Antidiabetic Efficacy and Adverse Outcomes of Semaglutide and Tirzepatide in Type 2 Diabetic Swiss Albino Male Mice","Elham Alzahrani","2025","Egyptian Journal of Veterinary Science","preclinical","article","10.21608/ejvs.2025.434679.3213",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049680","Evaluation of the effect of GLP ‐1 agonists on quality of bowel preparation for colonoscopy in patients with diabetes","Toishi Sharma","2017","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.2110",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049681","Ejaculate quality indicators of men with asthenozoospermia and asthenoteratozoospermia by treatment of obesity with liraglutide","Daniil N. Bobkov","2021","Obesity and metabolism","other","article","10.14341/omet12734",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049682","IDDF2021-ABS-0096 Selecting anti-diabetic medications for type 2 diabetics with non-alcoholic fatty liver disease. Evidence from a network meta-analysis","Cheng Han Ng","2021",null,"systematic_review","article","10.1136/gutjnl-2021-iddf.89",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-paper"],["R0049683","Glucagon-like Peptide-1 Receptor Agonists in Mental Health – Cognitive and Psychiatric Outcomes","Dev Desai","2026","Annals of Indian Psychiatry","nonrandomized_study","article","10.4103/aip.aip_279_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049684","Editorial (Thematic Issue: Nanotechnology as a Strategy to Improve Treatment of Diabetes)","António José Ribeiro","2014","Current Pharmaceutical Biotechnology","commentary","article","10.2174/1389201015666140915153104","25219862",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0049685","Exenatide versus Insulin Glargin als Add-on zur Monotherapie mit oralen Antidiabetika: Vergleichsstudie bei Patienten mit Typ 2 Diabetes","CHRISTOF M. KAZDA","2007","Diabetologie und Stoffwechsel","other","article","10.1055/s-2007-982151",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049686","1039-P: Examining Physician Case Studies on Success of Treatment Initiation in Patients with Type 2 Diabetes","KATHERINE L. KHOSROVANEH","2023","Diabetes","other","article","10.2337/db23-1039-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049687","1752-P: Investigating Cardiovascular Protective Molecular Mechanisms Associated with Liraglutide","Aparna Duggirala","2025","Diabetes","other","article","10.2337/db25-1752-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049688","Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial","Evan Raff","2017","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2017.08.018",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049689","Moderne Adipositas-Medikamente: Verschreibungsdaten und Trends von 2017 bis 2022 aus den USA","Philipp Berning","2023","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/s-0043-1771590",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049690","Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly","Charalambos V. Vlachopoulos","2020","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaa1022","33374009",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0049691","1251-P: Pancreatic ß-Cell Specific Deletion of Complement 1q Like-3 Secreted Protein Improves Glucose Tolerance by Increasing Insulin Secretion","M. Abdur Rahman","2021","Diabetes","preclinical","article","10.2337/db21-1251-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049692","The Role of Anti-obesity Drugs in Patients with Type 2 Diabetes","Priscilla A. Hollander","2013","US Endocrinology","other","article","10.17925/use.2013.09.02.101",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049693","A network meta-analysis of various pharmacotherapeutics for obstructive sleep apnea","Hatem Yaser","2025",null,"systematic_review","article","10.1183/13993003.congress-2025.pa3565",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0049694","Potentiation of the restorative effect of semaglutide on metabolic and hormonal parameters in rats with diet-induced type 2 diabetes mellitus with intranasally administered insulin","Kira Viktorovna Derkach","2025","Сибирский научный медицинский журнал","preclinical","article","10.18699/ssmj20250517",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049695","1648-P: Triagonism Targeting GCGR/GLP-1/GIP-1 Receptors Improves Insulin Sensitivity in Obese Mice","Teayoun Kim","2023","Diabetes","randomized_trial","article","10.2337/db23-1648-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049696","Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes","Giacomo Ruotolo","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.3056",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049697","Tu1549 IMPACT OF GLP-1 RECEPTOR AGONIST THERAPY ON CLINICAL OUTCOMES IN ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND OBESITY: A MULTICENTER REAL-WORLD ANALYSIS","Karecia Byfield","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03167-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049698","Cardiovascular, Kidney Outcomes and Mortality with Long-Acting Injectable and Oral Glucagon-Like Peptide-1 Receptor Agonists in Persons With Type 2 Diabetes – a Systematic Review and Meta-Analyses of Randomized Trials","Matthew M.Y. Lee","2025",null,"systematic_review","article","10.2337/figshare.28473485",null,null,"PROSPERO:CRD42024607253",null,"openalex","TRUE","free_to_read","3","FALSE","other"],["R0049699","Glucagon-like Peptide-1 Receptor Agonist May Cause Post-surgery Hypokalemia","Mehmet Yusuf Sarı","2024","Indian Journal of Surgery","other","article","10.1007/s12262-024-04073-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049700","1247 ARE GLP-1 RECEPTOR AGONISTS ASSOCIATED WITH INCREASED INCIDENCE OF PNEUMONIA AFTER ENDOSCOPY?","Natalia Tejada","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01155-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049701","The associations between retinol binding protein-4 and cardiometabolic profile: Intertwined-intricate relationship","HayderMutter Al-Kuraishy","2020","Biomedical and Biotechnology Research Journal (BBRJ)","nonrandomized_study","article","10.4103/bbrj.bbrj_6_20",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049702","FRI068 Gender Differences In Smoking Cessation? Results Of A Randomized Controlled Trial Of Dulaglutide-assisted Smoking Cessation","Fabienne Baur","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.078",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049703","Semaglutide and dapagliflozin synergistically prevent cancer therapy-related cardiac dysfunction in hyperglycemic conditions","N Maurea","2025","European Journal of Preventive Cardiology","preclinical","article","10.1093/eurjpc/zwaf236.461",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049704","Update to the Testosterone Guideline","Landon W Trost","2024","The Journal of Urology","randomized_trial","article","10.1097/ju.0000000000003855","38456434",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049705","Tu1391: GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH A LOWER RISK OF PANCREATIC CANCER COMPARED TO BARIATRIC SURGERY IN OBESE PATIENTS WITH DIABETES MELLITUS: A NATIONWIDE ANALYSIS","Saqr Alsakarneh","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04143-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049706","2067-LB: Pooled Safety Analysis of Enobosarm from Phase 2 and Phase 3 Placebo-Controlled Clinical Trials","Jeffrey Crawford","2024","Diabetes","randomized_trial","article","10.2337/db24-2067-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049707","Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial (Preprint)","TIFFANY M. CORTES","2024",null,"protocol","article","10.2196/preprints.62667",null,null,"ClinicalTrials.gov:NCT05786521","S000230","openalex","TRUE","free_to_read","5","FALSE","preprint"],["R0049708","62064 The Role of GLP-1 Agonists in Overweight and Obese Hidradenitis Suppurativa Patients: A Retrospective Analysis","Iain Noel Encarnacion","2025","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2025.05.1277",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049709","WCN26-3872 Effects of Incretin-based Therapies on Kidney Outcomes in Obese Patients without Diabetes","Takayuki Yamada","2026","Kidney International Reports","other","article","10.1016/j.ekir.2026.105734",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049710","Liraglutide: a new option in the management of type 2 diabetes","Milan K. Piya","2008","Future Prescriber","other","article","10.1002/fps.10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049711","Sa378 EFFECTIVENESS OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONIST IN NON-ALCOHOLIC FATTY LIVER DISEASE WITH COEXISTING TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Haoran Peng","2021","Gastroenterology","systematic_review","article","10.1016/s0016-5085(21)02737-2",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0049712","Editorial: Understanding obesity to determine the best therapeutic option: from lifestyle interventions to therapies","Evelyn Frías-Toral","2025","Frontiers in Nutrition","commentary","article","10.3389/fnut.2025.1560942","40008307",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0049713","Su2120 SEX AND MENOPAUSAL STATUS AS DETERMINANTS OF HEPATIC AND CARDIOMETABOLIC OUTCOMES AFTER GLP-1-BASED THERAPY IN OBESE ADULTS WITH MASLD/MASH: A PROPENSITY-MATCHED REAL- WORLD COHORT STUDY","Abidemi O. Akinrinmade","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03749-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049714","A GLP-1R/GCGR dual agonist exhibits differential effects on metabolic control versus a single GLP-1R agonist by activation of BAT and browning in diet-induced obese mice","M. Pilar Valdecantos","2017","DIGITAL.CSIC (Spanish National Research Council (CSIC))","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0049715","Efficacité du liraglutide dans le traitement du diabète de type 2 : données d’une cohorte de 86 diabétiques de type 2 traités par liraglutide suivis par des endocrinologues","H Narbonne","2013","Annales d Endocrinologie","other","article","10.1016/j.ando.2013.07.599",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049716","ost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios","Yuta Kamada","2026","Journal of health economics and outcomes research","nonrandomized_study","article","10.36469/jheor.2026.162614",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049717","ENDOSCOPIC GASTRIC FOOD RETENTION RATES FOR GLP-1RA USERS CAN BE POTENTIALLY MITIGATED BY PRE-COLONOSCOPY FASTING PROTOCOLS IN A PROPENSITY-MATCHED COHORT STUDY","Anam Rizvi","2024","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.04.1085",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049718","Perspective Chapter: Exploring the Potential of Vagus Nerve Neuromodulation as a Personalized and Enhanced Therapeutic Experience for Type 2 Diabetics","Jonathan J. Waataja","2023","IntechOpen eBooks","other","article","10.5772/intechopen.1002713",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0049719","Efficacia e sicurezza di Tirzepatide per il trattamento di soggetti affetti da obesità e sovrappeso","Lucia Manuella","2023","L Endocrinologo","other","article","10.1007/s40619-023-01221-w",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049720","Are there gender differences in liraglutide response in adults with type 2 diabetes?","Julia Sastre","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.p482",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049721","Efficacité et tolérance du liraglutide chez les patients diabétiques de type 2 pris en charge par les médecins généralistes en pratique clinique courante – analyse de sous-groupe de l’étude observationnelle EVIDENCE","Amira Bouzidi","2016","Annales d Endocrinologie","other","article","10.1016/j.ando.2016.07.823",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049722","PO424 THE EFFECT OF INSULIN DEGLUDEC IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN IN PATIENTS WITH TYPE 2 DIABETES REQUIRING TREATMENT INTENSIFICATION","Vanita R. Aroda","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70718-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049723","Cardiovascular Outcomes Of Glucagon Like Peptide 1 Receptor Agonist Irrespective Of Diabetes Status: A Meta Analysis Of Randomized Controlled Trials","Sammudeen Ibrahim","2025","Journal of Cardiac Failure","randomized_trial","article","10.1016/j.cardfail.2024.10.352",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049724","Abstract PS3-05-26: Triple incretin receptor agonist induced weight loss delays tumor latency in obesity-associated breast cancer","N. Pervaiz","2026","Clinical Cancer Research","preclinical","article","10.1158/1557-3265.sabcs25-ps3-05-26",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049725","O6 The beneficial hepatic-effect of glucagon-like peptide 1 receptor agonists in diabetic patients with non-alcoholic fatty liver disease","Roberta Forlano","2023","Oral Presentations","nonrandomized_study","article","10.1136/gutjnl-2023-basl.6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0049726","Efficacité du liraglutide chez les patients diabétiques de type 2 en fonction de l’HbA1c et de l’indice de masse corporelle (IMC) de départ – Résultats à 2 ans de l’étude prospective, post-inscription EVIDENCE®","Luc Martinez","2014","Annales d Endocrinologie","other","article","10.1016/j.ando.2014.07.092",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049727","113-LB: Oral Menin Inhibitor, BMF-219, Displays a Significant and Durable Reduction in HbA1c in a Type 2 Diabetes Mellitus Rat Model","Priyanka Somanath","2022","Diabetes","preclinical","article","10.2337/db22-113-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049728","Social Media Posts on Anti-Diabetic Drugs: Changes in Trends with the Rise in Popularity of GLP-1s (Preprint)","Chloe Stallion","2025",null,"nonrandomized_study","article","10.2196/preprints.87590",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0049729","Abstract 4369118: Lower Risk of Cardiovascular Events in Patients with Clinical Atherosclerotic Cardiovascular Disease Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-Clinical ASCVD Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Clinical Atherosclerotic Cardiovascular Disease Population)","Kim G. E. Smolderen","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4369118",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049730","A Bariatric Surgery-Derived Gut Metabolite Is a Potent Single and Combination Oral Therapy for Type 2 Diabetes","Andrei Moscalu","2022","Journal of the American College of Surgeons","preclinical","article","10.1097/01.xcs.0000893012.01926.b9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049731","Multi‐society consensus guidance on handling of GLP ‐1 therapy prior to general anaesthesia","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","other","article","10.1002/doi2.70009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049732","Hypertension","Jahangir Moini","2022",null,"other","article","10.1201/9781003226727-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0049733","728-P: Metabolomic Profiling of Obese Patients Treated with Liraglutide Suggests Its Role in Modulating Inflammation","Alice M. Murphy","2025","Diabetes","other","article","10.2337/db25-728-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049734","Semaglutide Improves Postprandial Glucose and Lipid Metabolism and Delays First-Hour Gastric Emptying in Subjects with Obesity","Hossameldin Saad","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.101",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049735","Review paper Effects of liraglutide – a GLP-1 receptor agonist – on the cardiovascular system","Zofia Ruprecht","2011","Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049736","Implications of cardiovascular outcome trials with injectable antidiabetic agents","Richard E. Pratley","2018","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12792","29971941",null,"ClinicalTrials.gov:NCT01147250; ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446; ClinicalTrials.gov:NCT01144338; ClinicalTrials.gov:NCT01455896; ClinicalTrials.gov:NCT01394952; ClinicalTrials.gov:NCT00069784","S000147; S000677; S000905; S001496; S001933; S001991","openalex","TRUE","open_pdf","1","FALSE","article"],["R0049737","A Novel Method for Liraglutide Synthesis and Purification","Gabriela R. Barredo‐Vacchelli","2024","Peptide Science","other","article","10.1002/pep2.24351",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049738","Einfluss des Body Mass Index auf HbA1c-Reduktion, Hypoglykämieraten und Insulinbedarf unter IDegLira bei Patienten mit Typ 2 Diabetes","Matthias Blüher","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549679",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049739","242-OR: Do GLP-1RA and SGLT2i Reduce Cardiovascular Mortality in African-American Patients with Type 2 Diabetes? A Meta-analysis","Basem M. Mishriky","2019","Diabetes","systematic_review","article","10.2337/db19-242-or",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0049740","Exenatide in the Treatment of Diabetic Patients with Non-Alcoholic Steatohepatitis - A Pilot Study: 2010 Presidential Poster","Patrick J Kenny","2010","The American Journal of Gastroenterology","randomized_trial","article","10.14309/00000434-201010001-00242",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049741","Abstract 4144048: Propensity Score-Matched Analysis of GLP-1 Agonists' Impact on Clinical Cardiovascular Outcomes in Patients with Concurrent Heart Failure and Atrial Fibrillation","Toluwalase Awoyemi","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4144048",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049742","645-P: Mobile Health Application as a Real-World Data Resource: Self-Recorded Weight Reduction with Once-Weekly Semaglutide","Ulrik Bodholdt","2021","Diabetes","nonrandomized_study","article","10.2337/db21-645-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049743","Abstract 4369369: Sex Differences in GLP-1 Receptor Mediated Effects on Exercising Blood Pressure Responses in Peripheral Artery Diseas","Ashley M. Baranczuk","2025","Circulation","preclinical","article","10.1161/circ.152.suppl_3.4369369",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049744","Electrophysiological characterization of catecholamine-containing GFP-expressing dissociated mouse area postrema neurons and their response to glucagon-like peptide-1 receptor agonists","Samantha C. Lee","2017","Mspace (University of Manitoba)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0049745","Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction","Gary Michael Felker","2025","New England Journal of Medicine","other","article","10.1056/nejme2415551","39879597",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049746","Semaglutide and beyond: An update on pharmacotherapy for obesity","John P.H. Wilding","2021","Obesity Abstracts","other","article","10.1530/obabs.3.ou2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049747","Nutrition and Allergy","Robert J. Boyle","2023","Clinical & Experimental Allergy","nonrandomized_study","article","10.1111/cea.14408","37798259",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0049748","Monocytes from CAD patients displayed M1 phenotype and released inflammatory mediators inducing endothelial dysfunction: M1 resolution and endothelial protection by SGLT2i + GLP-1Ra synergism","Ali Mroueh","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.4924",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049749","SGLT2 Inhibitors Rather Than GLP-1 Receptor Agonists Lower the Risk of Kidney Failure: A Systematic Review and Network Meta-Analysis","Niharika Katkam","2025","Journal of the American Society of Nephrology","systematic_review","article","10.1681/asn.2025ys83adxw",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0049750","Decreased Rate of Rejections Post Liver Transplant in Patients on a Glucagon-Like Peptide 1 (GLP-1) Analogue","Muhammad Salman Faisal","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.1120",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049751","Effect of Dulaglutide on Liver Fat in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial (D-LIFT Trial)","Mohammad Shafi Kuchay","2020","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.3582791",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0049752","Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2","Tatiana Ivanovna Romantsova","2009","Obesity and metabolism","other","article","10.14341/2071-8713-5241",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049753","OC-072 Does endoscopic duodenal-jejunal exclusion improve non-alcoholic fatty liver disease (nafld) in patients with diabesity?","Piya Sen Gupta","2015",null,"randomized_trial","article","10.1136/gutjnl-2015-309861.72",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049754","Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease","Ian A.C. Rowe","2023","Hepatology","nonrandomized_study","article","10.1097/hep.0000000000000327","36738088",null,"ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT04822181","S000511; S000716","openalex","FALSE","paywalled","4","FALSE","article"],["R0049755","Computational Approaches for Clinical, Genomic and Proteomic Markers of Response to GLP-1 Therapy in Type-2 Diabetes Mellitus: An Exploratory Analysis With Machine Learning Algorithms.","Angelina Thomas Villikudathil","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.4814934",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0049756","The role of sodium glucose cotransporter or glucagon-like peptide-1 receptor agonists in treating heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus","Laura Lungeanu-Juravle","2024","Romanian Journal of Medical Practice","other_trial","article","10.37897/rjmp.2024.1.2",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0049757","Frontiers of acute coronary syndromes: primary PCI time window, 15-year outcomes, bleeding and MINOCA","Thomas Felix Lüscher","2020","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaa105","33216912",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049758","Glucagon‐like peptide‐1 induced cardiac protection is dependent on caveolin‐3 expression","Eisuke Hamaguchi","2013","The FASEB Journal","preclinical","article","10.1096/fasebj.27.1_supplement.652.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049759","Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in adults with obesity or overweight, but without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial","Tania Markovic","2019","Obesity Research & Clinical Practice","randomized_trial","article","10.1016/j.orcp.2016.10.079",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049760","Management of obesity with semaglutide in antipsychotic-induced weight gain (MOSA) - a non-randomized open-label pilot study: research proposal","Bea C. M. Campforts","2022","Neuroscience Applied","randomized_trial","article","10.1016/j.nsa.2022.100336",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049761","912-P: Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes","Daniel L. Edmonston","2024","Diabetes","randomized_trial","article","10.2337/db24-912-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049762","OP03 Effects of two years of liraglutide treatment on fatty liver disease in patients with type 2 diabetes: analysis of the Liraglutide Effect and Action in Diabetes-2 extension trial","Matt Armstrong","2010","Gut","randomized_trial","article","10.1136/gut.2010.223362.3",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0049763","Legal, safety, and practical considerations of compounded injectable semaglutide","Allison Spitery","2024","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","other","article","10.1002/jac5.1999",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049764","MON-301 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials","Vanessa Lins de Menezes","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.2380",null,null,"PROSPERO:CRD42023482279",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0049765","HPR245 Baseline Characteristics of Patients Approved for Reimbursement of Liraglutide (Saxenda®) for Weight Management Under a Managed Access Protocol in Ireland","Russell L. Barrett","2024","Value in Health","protocol","article","10.1016/j.jval.2024.10.1669",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0049766","Evaluation of the effectiveness and safety of anti-obesity drugs - an update on the current state of knowledge on available and investigational drugs","Katarzyna Cichoń","2023","Journal of Education Health and Sport","other","article","10.12775/jehs.2023.35.01.008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049767","US FDA Regulatory Framework for Generic Peptides Referring to rDNA Origin Reference Products","Ankit Chincholkar","2022","Journal of Pharmaceutical Research International","other","article","10.9734/jpri/2022/v34i41a36276",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049768","Significant weight loss associated with GLP1 receptor agonist use in obese women with polycystic ovary syndrome- a retrospective cohort study","Fatimah Alawami","2023","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.94.p258",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049769","22-OR: Finerenone in Patients across the Spectrum of CKD and T2D by GLP-1RA Use","Peter R Rossing","2022","Diabetes","randomized_trial","article","10.2337/db22-22-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049770","Sex Differences in SGLT2 Inhibitor and GLP-1 Receptor Agonist Discontinuation in Patients with and Without CKD","Sydney Elizabeth Hartsell","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20251ctrq6jw",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049771","895-P: External Validation of the BRAVO Diabetes Model Using Data from the EXSCEL Study","Yixue Shao","2022","Diabetes","nonrandomized_study","article","10.2337/db22-895-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049772","Medication Compliance on Glycemic Control in Patients with Elevated HbA1c","A.M. El-Hassan","2018","Diabetes","randomized_trial","article","10.2337/db18-1077-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049773","11 CARDIOVASCULAR AND MORTALITY OUTCOMES WITH GLP-1 RECEPTOR AGONISTS VS. OTHER GLUCOSE-LOWERING DRUGS IN PATIENTS WITH NAFLD AND TYPE 2 DIABETES: A NATIONWIDE MULTICENTER MATCHED COHORT STUDY","Arunkumar Krishnan","2023","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(23)00958-7",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049774","Effects of semaglutide, PYY3-36, and empagliflozin on the adrenal gland transcriptome in diet induced obese rats","Simon Kloock","2023","Endocrine Abstracts","preclinical","article","10.1530/endoabs.90.p260",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049775","Abstract 4361120: Use Of Glucagon Like Peptide 1 Receptor Agonists In Non Diabetic Patients With Dilated Cardiomyopathy","Yaman Jarrar","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4361120",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049776","Patient-Reported Outcomes in Patients with T2D and increased CV risk on Tirzepatide or Insulin Glargine (SURPASS-4)","Kristina Secnik Boye","2021",null,"other","article","10.26226/morressier.6179df327c09fc044a974479",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0049777","0591 Clinical and Societal Impact of Tirzepatide in Patients with Moderate-to-severe OSA and Obesity: A Lifetime Modelling Study in China","Yi Xiao","2026","SLEEP","nonrandomized_study","article","10.1093/sleep/zsag091.0590",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049778","Nutrition therapy in the era of automated insulin delivery","Meryem Khadija Talbo","2025","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1690486","41244048",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049779","P1014INCRETIN BASED THERAPIES IN DIABETIC KIDNEY TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Theodora Oikonomaki","2020","Nephrology Dialysis Transplantation","systematic_review","article","10.1093/ndt/gfaa142.p1014",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0049780","EFFECT OF SEMAGLUTIDE ON PHYSICAL FUNCTION, BODY COMPOSITION, AND BIOMARKERS OF AGING IN OLDER ADULTS","TIFFANY M. CORTES","2024","Innovation in Aging","randomized_trial","article","10.1093/geroni/igae098.1054",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049781","ПЕРОРАЛЬНЫЙ СЕМАГЛУТИД - НОВАЯ ¬ИННОВАЦИОННАЯ ОПЦИЯ В ТЕРАПИИ САХАРНОГО ДИАБЕТА 2 ТИПА","Marina Vladimirovna Shestakova","2021","Сахарный диабет","other_trial","article","10.14341/dm12790-9938",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049782","739-P: Efficacy and Safety of Tirzepatide in Overweight (OW) and Obese (OB) Patients with Type 1 Diabetes (T1D)","Janet K. Snell‐Bergeon","2024","Diabetes","randomized_trial","article","10.2337/db24-739-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049783","Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2","Alfonso López Ruiz","2014","Pharmacology &amp Pharmacy","other","article","10.4236/pp.2014.54053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049784","Efectividad de IDegLira para el manejo de la diabetes tipo 2 durante la pandemia Covid -19: un seguimiento a través de teleconsulta","Gustavo Adolfo Parra-Serrano","2022","Revista Colombiana de Endocrinología Diabetes & Metabolismo","other","article","10.53853/encr.9.4.740",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049785","260-OR: Differential Effect of GLP-1RA and SGLT2 Inhibitors on Lower Extremity Amputation Outcomes in Type 2 Diabetes","Alexander T. Hong","2025","Diabetes","nonrandomized_study","article","10.2337/db25-260-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049786","Incretin Mimetics and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes","Baptist Gallwitz","2007","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2007.00.01.29",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049787","98: HYPOTHALAMIC GABAB RECEPTORS MAY BE INVOLVED IN EXENDIN-4-INDUCED EMESIS IN SUNCUS MURINUS","Sze Wa Chan","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)01015-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049788","‘Bariatric surgery for type 2 diabetes always produces a good outcome’","Robert Charles Andrews","2014","Practical Diabetes","randomized_trial","article","10.1002/pdi.1907",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049789","Engineering a Diverse Ligase Toolbox for Peptide Segment Condensation","Timo Nuijens","2016","Advanced Synthesis & Catalysis","other","article","10.1002/adsc.201600774",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049790","The effect of exenatide on specific non-motor symptoms in Parkinson’s disease – a post-hoc analysis.","Dilan S. Athauda","2018","Surrey Research Insight Open Access (The University of Surrey)","other","article","10.1111/ene.13700",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0049791","Abstract 4144520: Glucagon-like Peptide-1 Receptor Agonists for the Primary Prevention of Major Adverse Cardiac Events in Drug-naïve Type 2 Diabetes: A Propensity-score Analysis","Kuan Yu Chi","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4144520",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049792","Abstract 4357452: Glucagon-Like Peptide-1 Receptor Agonists Show Varied Impact on Venous Thromboembolism Risk: A Comprehensive Bayesian Network Meta-Analysis of Randomized Controlled Trials","Ibrahim Khalil","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4357452",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0049793","TIRZEPATIDE REDUCED SLEEP APNEA-SPECIFIC HYPOXIC BURDEN IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA AND OBESITY (SURMOUNT-OSA)","Ali Azarbarzin","2024","CHEST Journal","other","article","10.1016/j.chest.2024.07.189",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049794","P3‐460: Corrected cerebral flow reserve as a marker of dementia risk","Harold T. Pretorius","2011","Alzheimer s & Dementia","other","article","10.1016/j.jalz.2011.05.1904",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049795","Metabolic Dysfunction–associated Steatotic Liver Disease and Circadian Rhythm: Current Understanding and Implications for Future Therapeutic Interventions","William K. Slover","2026","Journal of Translational Gastroenterology","other","article","10.14218/jtg.2026.00003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049796","Experiment-selector cross-validated targeted maximum likelihood estimator for hybrid RCT-external data studies","Lauren Eyler Dang","2025","Journal of Causal Inference","randomized_trial","article","10.1515/jci-2024-0041",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049797","Su2048: GASTRIC ALIMETRY REVEALS INDEPENDENT EFFECTS OF GLP-1 AGONISTS ON GASTRIC MYOELECTRICAL ACTIVITY AND EMPTYING","Schynell Coutinho","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03100-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049798","Sa1954: IMPACT OF GLP-1 RECEPTOR AGONISTS ON SEVERITY OF CLOSTRIDIUM DIFFICILE INFECTIONS: A PROPENSITY MATCHED COHORT ANALYSIS","Mauricio Franco Jin","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)02316-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049799","PDB27 Projected Cost-Effectiveness of Exenatide Once Weekly Versus Exenatide Bid for the Treatment of Type 2 Diabetes in the UK","B.P. Wilson","2011","Value in Health","other","article","10.1016/j.jval.2011.08.1330",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049800","80-LB: Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist Delivered through the BIOJET Oral Biotherapeutic Delivery Platform in Porcine Model","Shaoying Nikki Lee","2023","Diabetes","preclinical","article","10.2337/db23-80-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049801","PDB45 THE BUDGET IMPACT OF SITAGLIPTIN VERSUS ORAL SEMAGLUTIDE FROM A US PAYER PERSPECTIVE","Adnan Alsumali","2020","Value in Health","other","article","10.1016/j.jval.2020.04.232",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049802","Incretin Learning and Excellence Academy for Diabetes (iLEAD)","Sarita Bajaj","2016","Indian Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/2230-8210.192902","27867903",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049803","Lixisenatide is Effective and Well Tolerated in Patients with Type 2 Diabetes Mellitus and Renal Impairment","Lawrence A. Leiter","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049804","S181 Impact of Glucagon-Like Peptide-1 Receptor Agonist on Gallbladder and Biliary Diseases","Khaled Alsabbagh Alchirazi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001029092.23386.b2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049805","ROLE OF LIRAGLUTIDE IN THE TREATMENT OF OBESITY IN CHILDREN","Нина Викторовна Евдокимова","2023","University therapeutic journal","other","article","10.56871/utj.2023.36.20.009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049806","C49-11 Unstoppable Shock, Unexpected Culprit: Metformin Toxicity Behind the Mask of Infection","Navneet Gupta","2026","American Journal of Respiratory and Critical Care Medicine","other","article","10.1093/ajrccm/aamag162.4845",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049807","GLP-1-mediated targeting of inflammation corrects obesogenic memory in male mice","Stéphane Leon","2025","Diabetes","preclinical","article","10.2337/figshare.28761890.v1","40215332",null,null,null,"openalex","TRUE",null,null,"FALSE","other; article"],["R0049808","THU283 Oral Semaglutide, Effectiveness, Safety And Tolerability In Real Life: A Short-term Retrospective Observational Study","Óscar Moreno","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.719",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049809","Does the hypothalamus-pituitary-adrenal axis play a role in the difference in treatment response to GLP-1 receptor agonists in type 2 diabetes?","Marti Boss","2023","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0043-1766184",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049810","Sa1528: TRANSFORMING MASLD OUTCOMES: A PROSPECTIVE STUDY ON THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON LIVER HEALTH AND METABOLIC PARAMETERS","Ahmed A. S. Salem","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04748-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049811","1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58","Avivit Cahn","2020","Diabetes","randomized_trial","article","10.2337/db20-1101-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049812","L’augmentation de la fréquence cardiaque sous semaglutide n’a pas entraîné d’augmentation des effets indésirables cardiaques dans l’étude SUSTAIN 6","Ronan Roussel","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.196",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049813","Modeling Allocation Of Semaglutide According To Coronary Artery Calcium And Body Mass Index In Persons Without Clinical Atherosclerotic Cardiovascular Disease And Diabetes: The Multi-Ethnic Study Of Atherosclerosis","Alexander C. Razavi","2024","Journal of cardiovascular computed tomography","other","article","10.1016/j.jcct.2024.05.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049814","877-P: Effect of Lobeglitazone, a Novel Thiazolidinedione, on Liver Fat in Patients with Type 2 Diabetes and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)—A Randomized Controlled Trial (Lobe-MASLD Trial)","SHARVIL S. GADVE","2024","Diabetes","randomized_trial","article","10.2337/db24-877-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049815","HbA1c Trends with Treatment Intensification following Inadequate Response to Two Oral Agents in Patients with Type 2 Diabetes","Kibum Kim","2018","Diabetes","nonrandomized_study","article","10.2337/db18-909-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049816","Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial","Tina Vilsbøll","2018","Diabetes","other_trial","article","10.2337/db18-1084-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049817","Association of Exenatide With Liver Enzymes in Patients With Type 2 Diabetes","Deepti G. Bulchandani","2009","The Endocrinologist","other","article","10.1097/ten.0b013e3181a48938",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049818","Editorial for BJCP Special Obesity Edition","Adrian Kuk Chong S. Park","2009","British Journal of Clinical Pharmacology","other_trial","article","10.1111/j.1365-2125.2009.03582.x","20002074",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0049819","Dulaglutide Noninferior to Liraglutide for Glycemic Control in Patients with T2DM","Maria Vinall","2014","MD Conference Express","other_trial","article","10.1177/155989771432008",null,null,"ClinicalTrials.gov:NCT01624259","S001184","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0049820","POS0373 LIRAGLUTIDE HAS POTENT ANTI-INFLAMMATORY AND ANTI-CATABOLIC IN VITRO ACTIVITIES IN OSTEOARTHRITIS","Françis Berenbaum","2021","Annals of the Rheumatic Diseases","preclinical","article","10.1136/annrheumdis-2021-eular.1849",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049821","POSTER: MDS-1747: Risk of Progression to Acute Myeloid Leukemia Among Patients With Myelodysplastic Syndromes and Type 2 Diabetes Treated With GLP-1 Receptor Agonists","Danh Q Nguyen","2026","Clinical Lymphoma Myeloma & Leukemia","other","article","10.1016/s2152-2650(26)00904-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049822","Improving Conformity to Diabetic Kidney Disease Clinical Guidelines","Nicole Piero","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20244e9kfmyk",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049823","Role for GLP-1 Agonists in Patients with Obesity and Heart Failure with Preserved Ejection Fraction","Kevan J English","2025","The Ulutaş medical journal/The ulutas medical journal","other","article","10.5455/umj.20250429034140",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049824","Liraglutide Effects in Insulin-Treated Patients in LEADER","CORNELIS TACK","2018","Diabetes","randomized_trial","article","10.2337/db18-438-p",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","FALSE","paywalled","1","FALSE","article"],["R0049825","1705-P: Effects of Tirzepatide in Obese Adults with Type 1 Diabetes on Hybrid Closed-Loop Continuous Subcutaneous Insulin Infusion: A 12-Month Observational Study","MUHAMMAD T. YOUNAS","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1705-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049826","Glucagon-like peptide 1 receptor agonists as a potential way to overcome treatment resistance in psoriasis and psoriatic arthritis","Aleksander M. Lila","2026","Modern Rheumatology Journal","other","article","10.14412/1996-7012-2026-3-84-90",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049827","Comparative Effectiveness of Tirzepatide with Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target Trial Emulation Studies","John W. Ostrominski","2026",null,"nonrandomized_study","article","10.2337/figshare.31301056.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0049828","Efficacy and Safety of Dulaglutide Versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1)","Carol Wysham","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.126",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049829","The 2 week fasting blood glucose (FBG) level as a predictor of HbA1c treatment response (HbA1c-TR) to once weekly dulaglutide 1.5 mg in patients with type 2 diabetes (T2DM)","Thomas M. Forst","2015","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0035-1549749",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049830","GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany","Vera Oettinger","2025","European Heart Journal","other_trial","article","10.1093/eurheartj/ehaf784.3653",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049831","GLUCAGON LIKE PEPTIDE-1 REDUCES RAISED INTRACRANIAL PRESSURE","Hannah Botfiled","2016","Journal of Neurology Neurosurgery & Psychiatry","preclinical","article","10.1136/jnnp-2016-315106.73",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049832","Figure 2 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors","Jasmine Singh Sukumar","2026",null,"other","article","10.1158/2767-9764.31444540",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0049833","Combination therapy in diabetic patients with insulin glargine and exenatide in the internal medicine service two of hospitals in Valencia","Belen Roig-Espert","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.p211",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049834","Endoscopic Sleeve Gastroplasty: can we predict its efficacy at an early stage?","Maria Valeria Matteo","2024","Endoscopy","nonrandomized_study","article","10.1055/s-0044-1782914",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049835","Semaglutide for patients with severe obesity: characteristics of a real word cohort and early effect on weight after 6 months","Hugo Noelle","2023","Clinical Nutrition ESPEN","nonrandomized_study","article","10.1016/j.clnesp.2023.09.359",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049836","TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL","ALEXANDRO R. ZARRUK","2023","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2023.10.380",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049837","Journal of Diabetes News","Eric M. Chang","2010","Journal of Diabetes","randomized_trial","article","10.1111/j.1753-0407.2010.00075.x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049838","Embryonic Organogenesis under the Effect of Dual GLP-1/GIP Receptor Agonist","Omirgul Bakenova","2025","Eurasian journal of applied biotechnology","preclinical","article","10.11134/btp.3s.2025.22",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049839","Effects of Glucagon-like Peptide-1 Analogues and Dipeptidyl Peptidase-IV Inhibitors on Hepatic Oxidative Stress and Non-Alcoholic Steatohepatitis in Male Albino Rats","Osama Mahmoud Mehanna","2020","International Journal of Clinical and Experimental Physiology","preclinical","article","10.5530/ijcep.2020.7.1.7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049840","780-P: Occurrence of Gastrointestinal (GI) Side Effects upon GLP-1 Receptor Agonist (GLP-1RA) Initiation with Concomitant Metformin Use","Klara Rachel Klein","2023","Diabetes","other","article","10.2337/db23-780-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049841","The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors)","Michael Albrecht Nauck","2007",null,"other","article","10.1007/978-0-387-69737-6_12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0049842","Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease Exenatide melhora o diabetes tipo 2 de ocorrência concomitante com doença hepática gordurosa não alcoólica","Hui Jie Fan","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049843","0774 Glucagon-Like Peptide 1 Receptor Agonists for Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis","Stanley Sau Ching Wong","2025","SLEEP","systematic_review","article","10.1093/sleep/zsaf090.0774",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0049844","Relationship between canagliflozin use and sarcopenia: Real-world data from the United States","Žhong Yuan","2025","Diabetes Epidemiology and Management","nonrandomized_study","article","10.1016/j.deman.2025.100280",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049845","Abstract MP36: Evaluation of Race and Ethnicity and Pharmacy Dispensing of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes","Luis A. Rodríguez","2024","Circulation","nonrandomized_study","article","10.1161/circ.149.suppl_1.mp36",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049846","ПАТОФИЗИОЛОГИЧЕСКИЕ АСПЕКТЫ ПЛЕЙОТРОПНЫХ ЭФФЕКТОВ ГАСТРОИНТЕСТИНАЛЬНЫХ ГОРМОНОВ","О. В. Корнюшин","2016","Экспериментальная и клиническая гастроэнтерология","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049847","Liraglutide Is Associated with Reduced Rates of Hypoglycemic Events Versus Glimepiride When Achieving Target HbA(1c)","Stephen Charles Langford Gough","2010","Diabetes","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049848","Additional file 1 of Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis","Guy Nguefang","2026","Figshare","nonrandomized_study","article","10.6084/m9.figshare.31931931",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0049849","Possibilities of using glucagon-like peptide-1 agonists and incretin multi-agonists in pharmacotherapy of obesity and metabolic syndrome","Vadim V. Abramov","2024","Glavvrač (Chief Medical Officer)","other","article","10.33920/med-03-2407-03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049850","COVID-19 era and GLP-1 RA era: Is it a renaissance when the dusk of global tragedy co-occurring with the dawn of magical remedy?","Deepak Kumar Gupta","2024","Medical Hypotheses","other","article","10.1016/j.mehy.2024.111516",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049851","LE MÉDICAMENT DU MOIS : Exénatide (BYETTA®) Incrétinomimétique indiqué dans le traitement du diabète de type 2 après échec et en complément des antidiabétiques oraux","André Jacques Scheen","2008","RMLG. Revue médicale de Liège","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049852","1729-P: Achieving BMI <25 kg/m2 Was Associated with Reduced Predicted Risk of Atherosclerotic Cardiovascular Disease in People with Obesity or Overweight—A Post Hoc Analysis of SURMOUNT-1, -3, and -CN","Lixin Guo","2025","Diabetes","randomized_trial","article","10.2337/db25-1729-p",null,null,"ClinicalTrials.gov:NCT04184622; ClinicalTrials.gov:NCT04657016; ClinicalTrials.gov:NCT05024032","S001077; S001086; S002157","openalex","FALSE","paywalled","1","FALSE","article"],["R0049853","Semaglutide: The first anti-obesity agent shown to decrease cardiovascular events","Nasser E. Mikhail","2023","International Journal of Diabetes Sciences","randomized_trial","article","10.33545/26649101.2023.v5.i1a.8",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049854","The Role of incretin-based therapies in maintaining glucose homeostasis and management of diabetes mellitus","Amir Fawzy Abdelhamid","2022","Delta University Scientific Journal","other","article","10.21608/dusj.2022.275439",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049855","Abstract #612: Efficacy and Safety of Liraglutide 3.0 Mg for Weight Management are Similar Across Race","Jamy D. Ard","2015","Endocrine Practice","other","article","10.1016/s1530-891x(20)42676-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049856","Heterogeneity of autoimmune diabetes mellitus in adults: real-world clinical practice","N. V. Rusyaeva","2025","Diabetes Mellitus","nonrandomized_study","article","10.14341/dm13319",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049857","S3342 Inpatient Initiation of Pharmacotherapy for Obesity to Improve Liver Transplant Eligibility: A Case Report","Maryam G. Ibrahim","2022","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0000870008.39652.54",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049858","Abstract 4140511: Synergistic insulinotropic and lipolytic actions of GLP-1 and a novel miniaturized designer GC-A peptide activator in Beta cells and adipocytes: Potential therapeutic insights for cardiometabolic disease","Ye Zheng","2024","Circulation","preclinical","article","10.1161/circ.150.suppl_1.4140511",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049859","Semaglutide for the treatment of resistant hypertension","Cormac Kennedy","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2590",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049860","SGLT2 Inhibitors Are Associated with Lower Risk of CKD Progression in Type 2 Diabetes (T2D) than Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs): An Emulated Clinical Trial","Sydney Elizabeth Hartsell","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20245wtk9af7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049861","Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595–2604","Samuel S. Engel","2013","Diabetes","commentary","article","10.2337/db13-0525","24065799",null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0049862","Effet du semaglutide sur la réponse de contre-régulation hormonale à l’hypoglycémie chez les diabétiques de type 2","Pierre Gourdy","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30422-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049863","GLP-1 analogues treatment was not associated with additional weight loss over intensive lifestyle intervention in severely obese patients with type 2 diabetes","Abd A. Tahrani","2015","Appetite","other","article","10.1016/j.appet.2014.12.169",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049864","A New Pharmacological Direction in Sleep Medicine: Tirzepatide’s FDA Approval for Obstructive Sleep Apnea","Laith Thamer Al-Ameri","2025","SN Comprehensive Clinical Medicine","other","article","10.1007/s42399-025-02111-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049865","Abstract Th0029: Genetic Evidence for Glucose-dependent Insulinotropic Polypeptide as a Therapeutic Target for Peripheral Artery Disease","Sabina M. Sorondo","2025","Arteriosclerosis Thrombosis and Vascular Biology","nonrandomized_study","article","10.1161/atv.45.suppl_1.th0029",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049866","Diet of individuals using antipsychotic medication and semaglutide","Karen Eir Einarsdóttir 1998-","2026","Skemman","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0049867","Diabetes medications and risk of Parkinson’s disease: a cohort study of diabetes patients","Ruth Brauer","2020",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0049868","Stereoselective Synthesis and Immunological Evaluation of Common O‐antigen of P. mirabilis OE and P. vulgaris TG103","Xiaopei Wu","2022","Chinese Journal of Chemistry","other","article","10.1002/cjoc.202200638",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049869","Weniger Hypoglykämien unter Exenatide vs. Insulin Aspart: Daten einer offenen, randomisierten Studie bei Metformin-behandelten Patienten mit Typ 2 Diabetes","Baptist Gallwitz","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1253883",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049870","Metamorphosis: from the Newsletter to the Journal","Peter H. Winocour","2014","The British Journal of Diabetes","nonrandomized_study","article","10.15277/bjdvd.2014.010",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049871","S92 Successful Use of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Short Gut Syndrome in Patients With Inflammatory Bowel Disease","Kimberly Darlington","2024","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0001082900.07254.67",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0049872","OR22-06 JUV-112: A Novel Biologic for Sustaining Weight Loss and Enhancing Metabolism through Energy Expenditure","Ritwik Datta","2025","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaf149.081",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049873","CO-29: LIRA-RAMADAN : Tolérance et sécurité du liraglutide en comparaison au sulfamide hypoglycémiant, en ajout de la metfor-mine chez des patients DT2 durant et après le jeûne du Ramadan","Amira Bouzidi","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30047-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049874","S4133 Semaglutide-Associated Portal Vein Thrombosis: A Rare Vascular Complication","Vishakh Prakash","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001143992.86103.45",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049875","S567 GLP-1 RAs Use is Associated with Lower 7-Days Repeat Esophagogastroduodenoscopy after Index Endoscopy in Patients with Achalasia: A Multi-Center Analysis","Donghyun Ko","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001031636.70614.ca",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049876","938-P: The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes","Raleigh Malik","2020","Diabetes","nonrandomized_study","article","10.2337/db20-938-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049877","Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer.","Neal A. Fischbach","2024","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2024.42.16_suppl.e24140",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0049878","Endothelial dysfunction in patients with COVID-19 is a key mechanism for the development of complications","I. O. Kokaeva","2023","Systemic Hypertension","other","article","10.38109/2075-082x-2022-4-37-44",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049879","“WHICH ONE SHOULD I CHOOSE, A GLP-1RA OR A SGLT2 INHIBITOR? OR MAYBE BOTH?’’. A POOLED ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS","Dimitrios Patoulias","2022","Journal of Hypertension","other","article","10.1097/01.hjh.0000837324.54362.4b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049880","229-OR: Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes","JULIO ROSENSTOCK","2024","Diabetes","randomized_trial","article","10.2337/db24-229-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049881","Real world outcomes comparing the use of GLP-1 agonists in patients with hepatocellular cancer (HCC) and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.","Arshi Syal","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.2_suppl.517",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049882","Highlights from the first ever virtual American College of Cardiology World Congress of Cardiology 2020 (ACC.20/WCC)","Thorsten Martin Leucker","2020","Cardiovascular Research","randomized_trial","article","10.1093/cvr/cvaa099","32406489",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049883","New frontiers in obesity care: key updates from the American Association of Clinical Endocrinology International Recommendations for the diagnosis and treatment of adults with obesity","T.L. Karonova","2026","Русский медицинский журнал","other","article","10.32364/2225-2282-2026-3-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049884","Bydureon: long‐acting exenatide for once‐weekly injection","Chitrabhanu Ballav","2012","Prescriber","other","article","10.1002/psb.852",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049885","Proteinopathy: Shared Feature Between the Heart and Brain in Alzheimer's Disease","Ghadir Amin","2023","Journal of Cardiovascular Pharmacology","nonrandomized_study","article","10.1097/fjc.0000000000001501","37890458",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049886","Management of Adult Obesity: Emerging Approaches and Challenges to a Global Problem","Sougat Ray","2023","Journal of Marine Medical Society","other","article","10.4103/jmms.jmms_99_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049887","SP081SHORT TERM HEMODYNAMIC EFFECT OF THE GLP 1 ANALOGUE - LIRAGLUTIDE IN PATIENTS WITH DIABETIC NEPHROPATHY","Małgorzata Jadwiga Wajdlich","2018","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfy104.sp081",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049888","2168-LB: Metabolic and Physiological Effects of Survodutide in Polygenic Type 2 Diabetic Mice (NZO/HILtJ) under Thermoneutral Conditions","JASMINE SWAGEL","2025","Diabetes","randomized_trial","article","10.2337/db25-2168-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049889","Exploring a synergistic approach: dual GLP-1 agonist combined with degludec basal insulin for early type 1 diabetes treatment and its impact on albumin-insulin producing cells expression","Amr Kamel Khalil Ahmed","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.p427",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049890","S792 Weighting on Methane: Weight Loss Medications Associated With Increased Incidence of SIBO","Robert M. Cutler","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032536.53564.9a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049891","Trends in prescribing preferences for antidiabetic medications among type 2 diabetes patients in the UK with and without chronic kidney disease, 2006-2020","Julia Liaw","2022",null,"nonrandomized_study","article","10.2337/figshare.20365554.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0049892","MON-605 Serum CD163, but Not Gal-3, Predicts Response to Liraglutide Therapy in Obese Patients","Arimin Mat","2020","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaa046.915",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049893","Fibular Mononeuropathy From Weight Loss Associated With GLP-1 Receptor Agonist Use (P3-9.001)","Jacob Farris","2026","Neurology","other","article","10.1212/wnl.0000000000216942",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049894","(420) Peptide Therapies as Emerging Trends in Men’s Health","Rohan Shad Arora","2025","The Journal of Sexual Medicine","other","article","10.1093/jsxmed/qdaf320.414",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049895","Die EIGHT Studie: Effects of Exenatide vs. Insulin on Glycemic Control and Hypoglycemia Trial","OP Bachmann","2007","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-2007-982426",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049896","Facilitating Living Kidney Donation: Retrospective Evaluation of Weight Loss Interventions to Support Kidney Donation","Julia Dumitrescu","2025","Graduate Medical Education Research Journal","nonrandomized_study","article","10.32873/unmc.dc.gmerj.7.1.100",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049897","89-LB: Oral Administration of Exendin, Using Diabetology’s Axcess Formulation: A Preclinical Study","Roger R. C. New","2021","Diabetes","preclinical","article","10.2337/db21-89-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049898","989-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity: Safety Study in Subjects of Japanese and Chinese Descent","Darren C. Robertson","2019","Diabetes","randomized_trial","article","10.2337/db19-989-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049899","82-LB: Total Costs of Care in Patients with T2D and Cardiovascular Disease: A Comparative Cohort Study (OFFSET)","Marc Evans","2021","Diabetes","nonrandomized_study","article","10.2337/db21-82-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049900","The positive effect of liraglutide treatment on body mass index and metabolic profile in adolescents with obesity","Elham H. Atiq","2023","Endocrine Abstracts","other","article","10.1530/endoabs.95.p63",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049901","Novel synthesis of the lipopeptide drug liraglutide and insights into its conformational behavior.","Ivan Guryanov","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049902","Approaches for the delivery of anti-parkinsonian therapeutic agents via the intranasal route","Jawad Banyyounes","2026","Discover Neuroscience","other","article","10.1186/s13064-026-00258-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049903","S4855 Post-Transplant Lymphoproliferative Disorder of the Small Bowel 13 Years After Kidney Transplant","Christopher J. Varlamos","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001048788.62851.50",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049904","Identifying Global Awareness of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) through Google Search Trend Analysis","Harshil A. Fichadiya","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024h41xjqp9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049905","MON-720 Beyond Age: Sex as the Key Weight Loss Predictor with Tirzepatide","Regina Castaneda","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.055",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049906","Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model","Luiz Sérgio Fernandes de Carvalho","2022","Circulation","randomized_trial","article","10.1161/circ.146.suppl_1.14830",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0049907","P299 - L’administration de l’analogue du GLP-1 (exenatide®) chez un patient diabétique atteint du VIH, favorise la perte de poids, améliore la sensibilité à l’insuline et la fonction ß-cellulaire sous antirétroviraux","Philippe Oriot","2011","Diabetes & Metabolism","other","article","10.1016/s1262-3636(11)70925-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049908","The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes (GRADE) Study","Priscilla A. Hollander","2023",null,"randomized_trial","article","10.2337/figshare.23800437.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0049909","Pegozafermin Added to Background GLP-1 Therapy Led to Greater Improvement in Non-invasive Markers of Liver Fat, Injury and Fibrosis as well as Glycemic Control in NASH Patients with F2/F3 Fibrosis at 24 weeks: A Posthoc Analysis from ENLIVEN","Rohit Seth Loomba","2024","Metabolism","other","article","10.1016/j.metabol.2024.155874",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049910","8007 The Effect of Glucagon-Like Peptide-1 Receptor Agonists in Reducing Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis","Pedro Henrique Carvalho Leite Romeiro","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.950",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0049911","Glucagon-like peptide 1 receptor agonists modulate the unfolded protein response and promote survival following induction of endoplasmic reticulum stress in islet cells","Bernardo Yusta","2004","VUBIR (Vrije Universiteit Brussel)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049912","Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist","Signe Vinsand Naver","2014","Clinical Investigation","other_trial","article","10.4155/cli.14.65",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049913","961-P: Efficacy and Safety of Once-Weekly Semaglutide vs. Once-Daily Sitagliptin as Add-On to Metformin in Subjects with Type 2 Diabetes (SUSTAIN China MRCT): A 30-Week Double-Blind, Phase 3a, Randomised Trial","Linong Ji","2020","Diabetes","randomized_trial","article","10.2337/db20-961-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049914","Cardiovascular Imaging of GLP-1–Based Therapies in Adults: A Scoping Review of Remodeling Domains, Imaging Modalities, and Evidence Gaps","Filipe Moura","2026","OSF Preprints (OSF Preprints)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","preprint"],["R0049915","Abstract 16940: Missed Opportunities for Screening and Management of Dysglycemia After Myocardial Infarction: The Prospective NORIN STEMI Registry","Muthiah Vaduganathan","2020","Circulation","nonrandomized_study","article","10.1161/circ.142.suppl_3.16940",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049916","217 The impact of preoperative glucagon-like peptide-1 receptor agonists (GLP1) utilization on bariatric surgery outcomes","Tarik K. Yuce","2025","Journal of Clinical and Translational Science","other","article","10.1017/cts.2024.870",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049917","A single centre retrospective study of the long-term real-world body weight responses to liraglutide or bariatric surgery in adolescents with obesity","Tariq Chukir","2026","Obesity Medicine","nonrandomized_study","article","10.1016/j.obmed.2026.100684",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0049918","Implementing the new NICE guidelines for type 2 diabetes (NG28): Focusing beyond HbA1c targets and clinically phenotyping patients to the appropriate second-line agent","Lakshminarayanan Varadhan","2022","British Journal of Diabetes","other_trial","article","10.15277/bjd.2022.385",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0049919","PO-07-068 IMPACT OF TIRZEPATIDE ON VENTRICULAR TACHYCARDIA: A PROPENSITY SCORE-MATCHED ANALYSIS","Aravinthan Vignarajah","2025","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2025.03.1828",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049920","Raised Intracranial Pressure Alters Cortical Vascular Function And Cephalic Allodynia. (S35.006)","Olivia Grech","2025","Neurology","other","article","10.1212/wnl.0000000000211242",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049921","Effectiveness of Injectable Semaglutide 1 mg/Week in Hepatic Markers, Fibrosis and Systemic Inflammation in Obese Type 2 Diabetes Patients: A 6-Month Retrospective Real-World Study","Rodrigo García-Pérez","2026","Endocrines","nonrandomized_study","article","10.3390/endocrines7030039",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049922","The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis","Dimitrios Patoulias","2021","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehab724.2950",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0049923","S2327 Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients With MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study","Basil Jalamneh","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001136768.40528.c9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049924","CONTINUED TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO SUSTAINED IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 4 TRIAL","Subodh Verma","2021","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(21)02965-x",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0049925","(1167) Weight It Out: Use of Semaglutide for Weight Loss in Patients Undergoing Lung Transplant Evaluation","K. Stryker","2023","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2023.02.1378",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049926","Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial","Bo Åhrén","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/6xvf-j016",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0049927","β-Cell Replication by Loosening the Brakes of Glucagon-Like Peptide-1 Receptor Signaling","Frans C Schuit","2008","Diabetes","preclinical","article","10.2337/db07-1578","18305147",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049928","Type I Acute Autoimmune Hepatitis in a Male Patient","Navakanth Gorrepati","2007","The American Journal of Gastroenterology","other","article","10.14309/00000434-200709002-00788",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049929","Effect of exendin-4 on lung function of diabetic patients: a preliminary report","Paola Rogliani","2017",null,"other","article","10.1183/1393003.congress-2017.pa1039",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049930","Body fat reduction as a predictor for liver steatosis regression in obese patients: An interim analysis of the DocWeight 2.3 behavioral weight loss program","Laura Hohenstein","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807497",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0049931","SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?","Raul Dias Santos","2016",null,"other_trial","article",null,null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","FALSE","no_doi","5","FALSE","article"],["R0049932","Cost-Effectiveness of Ideglira Versus Basal-Bolus Insulin Intensification Regimens in Patients with Type 2 Diabetes in Slovak Setting","Marek Psota","2016","Value in Health","other","article","10.1016/j.jval.2016.09.1881",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049933","Addition of sodium-glucose co-transporter type 2 inhibitors to diabetic patients type 2 in treatment with glucagon-like peptide-1 agonists: clinical results","Ma del Carmen Serrano Laguna","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p509",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049934","1-Jahresergebnisse der randomisierten, kontrollierten Duration-8-Studie: Wirksamkeit und Verträglichkeit von Depot-Exenatide in Kombination mit täglichem Dapagliflozin gegenüber Monotherapie mit Depot-Exenatide oder Dapagliflozin","Cristian Guja","2018","Diabetologie und Stoffwechsel","other","article","10.1055/s-0038-1641915",null,null,"ClinicalTrials.gov:NCT02229396","S000791","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0049935","420-P: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis","Jason T. Alexander","2020","Diabetes","systematic_review","article","10.2337/db20-420-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0049936","Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes","Buse J.B","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/2d2s-yg87",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0049937","466-P: Therapeutic Efficacy of Monthly Semaglutide-Loaded Microsphere Injections in Zucker Diabetic Fatty Rats","JIWON PARK","2024","Diabetes","preclinical","article","10.2337/db24-466-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049938","The Positive Effect of the Combination of GLP-1 Analogues and SGLT2 Inhibitors on Obese Patients with Noninsulin-Treated DM2","Ioannis L. Matsoukis","2018","Diabetes","other","article","10.2337/db18-2098-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049939","Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial","MJ Cziraky","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","protocol","article","10.17615/70xb-kj83",null,null,"ClinicalTrials.gov:NCT03596450","S000545","openalex","TRUE","paywalled","5","FALSE","article"],["R0049940","EFFECTS OF METFORMIN ALONE VERSUS METFORMIN AND TIRZEPATIDE ON WEIGHT LOSS IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS)","Alexa M. Sassin","2023","Fertility and Sterility","other","article","10.1016/j.fertnstert.2023.08.635",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049941","Renal Outcomes of GLP-1 Receptor Agonists (Semaglutide and Tirzepatide) in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Latin American Study","Emerson Javier García Ballesteros","2025","IECCMEXICO","other","article","10.64784/006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049942","Antidiabetic Medication-Induced Acute Interstitial Nephritis: Case Report and Literature Search","Nadia Tai Chaudhury","2021","British Journal of Diabetes","case_report","article","10.15277/bjd.2021.321",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049943","SGLT2 INHIBITOR AND GLP1 AGONIST USE ARE ASSOCIATED WITH REDUCED RISK OF INCIDENT PULMONARY HYPERTENSION IN PATIENTS REFERRED FOR ECHOCARDIOGRAPHY","Nicholas E. King","2023","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(23)02358-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049944","Beta-Cell Function and Its Underlying Mechanism 2015","Yanbing Li","2015","Journal of Diabetes Research","randomized_trial","article","10.1155/2016/7638120","26783538",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049945","The Impact of Diabetes Type 2 Treatment Interventions on Cardiovascular Outcomes – A Comprehensive Review","Ali Ahmed Al Qarni","2023","Series of Endocrinology Diabetes and Metabolism","randomized_trial","article","10.54178/jsedmv5i2004",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0049946","FRI080 Post Bariatric Hypoglycemia And Pregnancy: Successful Utilization Of Remnant Stomach Gastrostomy Tube Placement In Severe Refractory Hypoglycemia After Roux-en-Y Gastric Bypass Surgery","Samima Sultana Habbsa","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.090",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049947","FRI612 Tirzepatide For The Treatment Of Post-bariatric Surgery Hypoglycemia And Early Dumping Syndrome","Ethan Stortz","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.834",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0049948","Abstract 4118762: Large-scale multinational trends in the use of cardioprotective antihyperglycemic agents as first-line therapy in patients with type 2 diabetes and cardiovascular disease: a LEGEND-T2DM study","Phyllis Thangaraj","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4118762",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049949","TCT-499 Impact of GLP-1 Agonists on Cardiovascular Outcomes in Obese Adults with HFrEF receiving Guideline Directed Medical Therapy: A Propensity Score Matched Analysis","Osman K. Yousafzai","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2025.09.629",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049950","In-use Stability of Semaglutide Injection 15mg/3mL (5mg/mL) In-use Storage Conditions, Study Design, Study Outcome and Labelling Recommendations","M.E. Kannan","2026","Research Journal of Pharmacy and Technology","protocol","article","10.52711/0974-360x.2026.00321",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049951","Die Abnahme der Insulinresistenz bei Patienten mit Typ 2 Diabetes durch Semaglutid ist primär durch die Gewichtsabnahme vermittelt (SUSTAIN 1 – 3)","VF Fonseca","2018","Diabetologie und Stoffwechsel","other","article","10.1055/s-0038-1641839",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0049952","Abstract 4134637: Impact of Glucagon-Like Peptide-1 Agonists on Cardiovascular Outcomes in Chronic Kidney Disease Stage 5: A Propensity Score-Matched Analysis","Toluwalase Awoyemi","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4134637",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049953","Sa1834 PROTECTIVE ROLE OF GLP-1 RECEPTOR AGONISTS AGAINST RECURRENT ACUTE PANCREATITIS: A U.S. POPULATION-BASED PROPENSITY-MATCHED COHORT STUDY","Azhar Hussain","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)05130-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049954","Tirzepatide - Induced Diabetic Ketoacidosis in a Patient with Type 1 Diabetes: A Case Report","Umna Hussain","2025",null,"case_report","article","10.22541/au.174489139.99878107/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0049955","Liraglutide vs Other Daily GLP-1 Analogues in People with Type 2 Diabetes: A Network Meta-Analysis","Maria F. Lorenzi","2015","Value in Health","systematic_review","article","10.1016/j.jval.2015.09.2049",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0049956","Future Strategies in Management of Diabetes Mellitus: A Brief Report","Alok Pratap Singh","2019","International Journal of Medical Reviews and Case Reports","other","article","10.5455/ijmrcr.management-diabetes-mellitus",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049957","S1470 Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Comparison of Agent-Specific Outcomes in Type 2 Diabetes and Obese Inflammatory Bowel Disease Populations","Himaben Gohil","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001133340.09329.f1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049958","Quick Take Vol. 79","Scott R. Beach","2025",null,"other","article","10.64239/pi-qt79",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0049959","Predictors of Persistent Medication Use in Diabetic Kidney Disease (DKD)","Susanne B. Nicholas","2022","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20223311s1119d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0049960","Association between clinical and genetic factors and glycemic and weight loss response to liraglutide in patients with type 2 diabetes","Artemis Kyriakidou","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.p579",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049961","Антиаддиктивный потенциал двойного агониста инкретиновых рецепторов тирзепатида в тесте на эмоциональное переедание, вызванное внутримозговой самостимуляцией","Николай Сергоевич Деданишвили","2026","Pediatrician (St Petersburg)","preclinical","article","10.56871/ped.2025.78.21.005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049962","P1142 Facteurs prédictifs de la réponse aux analogues du GLP1 : données d’une cohorte de 262 diabétiques de type 2 traités par liraglutide suivis par des endocrinologues d’île de France","Olivier Dupuy","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71888-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049963","1768-P: Sustainability of Waist-Height Ratio in Surmount-1 Three-Year Study","Louis J. Aronne","2025","Diabetes","other","article","10.2337/db25-1768-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049964","1717-P: Assessing Type 2 Diabetes and GLP-1 Agonist Response Trajectories with a Proteogenomic Atlas of Disease Progression","Chirag J. Patel","2026","Diabetes","other_trial","article","10.2337/db26-1717-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0049965","Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients - A multicentre, prospective, randomised superiority trial","Abraham H. Hulst","2019","Journal of Cardiothoracic and Vascular Anesthesia","randomized_trial","article","10.1053/j.jvca.2019.07.101",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049966","Incretin peptides: new targets in correction of ischemic-reperfusion myocardial damages","Alla P. Tarasova","2020","Человек и его здоровье","other","article","10.21626/vestnik/2020-1/04",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049967","Recent advances in the management of type 2 diabetes mellitus","Drea N Agrawal","2025","Journal of Medical Society","other","article","10.4103/jms.jms_20_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049968","17-LB: Antihyperglycemic Use in Hemodialysis-Dependent Kidney Failure","Klara Rachel Klein","2022","Diabetes","other","article","10.2337/db22-17-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049969","Abstract #1161911: Acute Renal Failure: A Rare and Uncommon Side Effect of Semaglutide","Joumana T. Chaiban","2022","Endocrine Practice","other","article","10.1016/j.eprac.2022.03.068",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049970","688: FACTORS ASSOCIATED WITH SUCCESSFUL WEIGHT LOSS AFTER LIRAGLUTIDE TREATMENT FOR OBESITY","Wassel Sannaa","2022","Gastroenterology","other","article","10.1016/s0016-5085(22)60407-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049971","Effectiveness and Tolerability of Liraglutide Among Type 2 Diabetes Patients in Routine Clinical Practice: 1-Year Data from EVIDENCE®","Pierre Gourdy","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.115",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049972","EE190 Cost Comparison of Alternative Delivery Routes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) in the English National Health Service (NHS)","Celia Villalba Mendez","2025","Value in Health","other","article","10.1016/j.jval.2025.09.574",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0049973","Impact of BMI on HbA1C Reduction in Response to IDegLira in Subjects with Type 2 Diabetes (T2D) Uncontrolled on SU, GLP-1RA or Insulin Glargine: Analyses from Completed Phase 3b Trials","Stewart B. Harris","2017","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2017.08.158",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049974","Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2","Naveed A. Sattar","2024","Obesity Research & Clinical Practice","other","article","10.1016/j.orcp.2024.09.080",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049975","88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting","Julio Rosenstock","2020","Diabetes","randomized_trial","article","10.2337/db20-88-lb",null,null,"ClinicalTrials.gov:NCT02787551","S001125","openalex","FALSE","paywalled","1","FALSE","article"],["R0049976","324-OR: Global Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER","Suzanne V. Arnold","2021","Diabetes","other","article","10.2337/db21-324-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049977","2 IIH Pressure – a randomised, controlled, double blind physiology study of the effect of Exenatide on intracranial pressure","James Mitchell","2021","BMJ Military Health","randomized_trial","article","10.1136/bmjmilitary-2021-rsmabstracts.2",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0049978","Outcomes reported by patients during de-intensification of complex insulin therapy regimens for type 2 diabetes mellitus","Elena A. Yanovskaya","2025","FOCUS Endocrinology","other","article","10.62751/2713-0177-2025-6-2-08",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049979","Rischio di pancreatite e variazioni degli enzimi pancreatici in un campione ambulatoriale di diabetici tipo 2 in trattamento con liraglutide","S Buscemi","2014","Nova Science Publishers (Nova Science Publishers, Inc.)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049980","EFFECTIVENESS OF LIRAGLUTIDE IN REDUCING BODY WEIGHT AND IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM","Sifat Ullah","2022","Journal of Medical Sciences","other","article","10.52764/jms.22.30.4.15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049981","THE IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS USE PRIOR TO ESOPHAGOGASTRODUODENOSCOPY","Mark Ayoub","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.940",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049982","GLP-1 Receptor Agonists in Internal Medicine: Beyond Diabetes Toward Multisystem Disease Modification","Emerson Javier García Ballesteros","2025","IECCMEXICO","nonrandomized_study","article","10.64784/010",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049983","Dulaglutide Reduces HbA1c More Than Glargine When Used in Combination with Prandial Insulin","Maria Vinall","2014","MD Conference Express","other_trial","article","10.1177/155989771432009",null,null,"ClinicalTrials.gov:NCT01191268","S001198","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0049984","Semaglutide effects on cardiovascular outcomes in individuals with overweight or obesity who do not have diabetes: a systematic review","Anna Maria Klasa","2024","MEDICAL SCIENCE PULSE","systematic_review","article","10.5604/01.3001.0055.0721",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0049985","BURDEN OF OBESITY IN HEART FAILURE PATIENTS AT AN URBAN SAFETY-NET HOSPITAL AND IMPLICATIONS FOR GLP1-AGONIST PRESCRIBING","Tracey Yee","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)02513-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049986","S349 Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis","Syed Hamaad Rahman","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001030764.09309.1d",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0049987","S428 Impact of Cardiovascular and Metabolic Comorbidities on Immune-Mediated Diarrhea and Colitis Severity and Outcomes","Cristina Natha","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129172.13849.ff",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0049988","COMBINATION THERAPY WITH SEMAGLUTIDE AND INCLISIRAN REDUCES SYNERGISTICALLY ANTHRACYCLINE–INDUCED CARDIOTOXICITY UNDER HYPERLIPIDEMIA: IMPLICATIONS IN PRIMARY PREVENTION OF CTRCD IN CANCER PATIENTS","Vincenzo Quagliariello","2025","European Heart Journal Supplements","preclinical","article","10.1093/eurheartjsupp/suaf076.250",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049989","Investigating socioeconomic disparities in prescribing new diabetes medication","Frank H. Ardesch","2024","European Journal of Public Health","other","article","10.1093/eurpub/ckae144.1322",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0049990","How well are we doing in lipid management?","Richard F. Hobbs","2010","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2010.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049991","GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact","Ikaro Soares Santos Breder","2020",null,"other","article","10.1007/978-3-030-53370-0_51",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0049992","Editorial: Functional neuroendocrine tumors","Bojana M. Popovic","2025","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2025.1662247","40786182",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0049993","Comparative evaluation new glucagon-like peptide 1 receptor agonist semaglutide and sodium-glucose cotransporter-2 inhibitors empagliflozin on left ventricular diastolic function in patients with arterial hypertension, obesity and type 2 diabetes mellitus","Makka R. Azimova","2022","Systemic Hypertension","randomized_trial","article","10.38109/2075-082x-2022-1-39-48",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0049994","Amelioration du controle glycemique et perte de poids sous exenatide chez des patients diabetiques de type 2: resultats d'une etude retrospective observationnelle multicentrique belge.","Christophe E.M. De Block","2009","RMLG. Revue médicale de Liège","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0049995","Effect of Liraglutide on Weight Loss and BMI Among Patients Who Are Overweight and Obese with Type 2 Diabetes: A Systematic Review and Meta-analysis","C. Zorampari","2023","European Medical Journal","systematic_review","article","10.33590/emj/10306493",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0049996","EFETIVIDADE DOS SUPRESSORES DE APETITE NO TRATAMENTO DA OBESIDADE: UMA REVISÃO SISTEMÁTICA","Beatriz Carminati Pedroso","2025","Aracê.","nonrandomized_study","article","10.56238/arev7n1-088",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0049997","Beyond glycemic control: nephroprotective effects of glucagon-like peptide 1 receptor agonists","Минара Шамхаловна Шамхалова","2021","Kliničeskaâ nefrologiâ","other","article","10.18565/nephrology.2021.3.84-91",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0049998","CHARACTERISTICS OF PERSONS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PRESCRIBED SGLT-2I AND/OR GLP-1RA AMONG CARDIOLOGY CLINICS IN THE US: INSIGHTS FROM A LARGE IMPLEMENTATION TRIAL","Adam J. Nelson","2024","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(24)03879-8",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0049999","Use of Big-Data Algorithms to Characterize Patients with T2D on Basal Insulin (BI) Who Add a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) and Predict Their A1C Response","Esther Zimmermann","2018","Diabetes","nonrandomized_study","article","10.2337/db18-100-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050000","834-P: A Meta-analysis of Novel Glucose-Lowering Therapies in Kidney Transplant Recipients with Diabetes","Piyush Ratan","2025","Diabetes","systematic_review","article","10.2337/db25-834-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0050001","News in cardiovascular pharmacotherapy from the ACC.24 Meeting","Ricardo Caballero","2024","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvae034","38907602",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050002","Prescription trends for anti-obesity drugs and patterns in prescriber information between 2017 and 2022 in the United States.","Philipp Berning","2023","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0043-1767900",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050003","Short term effects of liraglutide versus vildagliptin on insulin secretion and sensitivity in type 2 diabetes (Liravis study)","Estelle Amandine Well","2018","Pan African Medical Journal Conference Proceedings","randomized_trial","article","10.11604/pamj.cp.2017.2.16.46",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-paper"],["R0050004","Deciphering ventricular GLP-1 action: time for a change of heart","John Reyes Ussher","2014","American Journal of Physiology-Heart and Circulatory Physiology","randomized_trial","article","10.1152/ajpheart.00680.2014","25260609",null,null,null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0050005","Effects of liraglutide on heart function and myocardial perfusion entropy in a type-2 diabetic rat model","Marjorie Canu","2020","Archives of Cardiovascular Diseases Supplements","preclinical","article","10.1016/j.acvdsp.2020.03.034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050006","The potential encapsulation of euphorbiaceae plant extracts: a review","Maizatul Akmal Johari","2021","The International Islamic University Malaysia Repository (The International Islamic University Malaysia)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050007","Miracle or misfortune? Analyzing Reddit users’ narratives about Ozempic medication for weight loss","Foluke Omosun","2026","Atlantic Journal of Communication","other","article","10.1080/15456870.2026.2623661",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050008","Abstract 4363403: The Effect of Tirzepatide versus Semaglutide on Post-Operative Outcomes in Type 2 Diabetics Following Coronary Artery Bypass Grafting","Shriya Chunduri","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4363403",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050009","Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies","В. В. Салухов","2018","Diabetes Mellitus","randomized_trial","article","10.14341/dm9570",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050010","Table 3 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors","Jasmine Singh Sukumar","2026",null,"nonrandomized_study","article","10.1158/2767-9764.31444519",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0050011","Effects of Glucagon-Like Peptide-1 Analogs on Sexual Desire: A randomized, double-blind, placebo-controlled crossover trial","Sophia Lengsfeld","2023","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.90.p69",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050012","Residual metabolic effect after cessation of liraglutide therapy in patients with type 2 diabetes","Margarita D. Samsonova","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep338",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050013","Looking Beyond the Hemoglobin A1c","Megan B. Coriell","2025","Pediatrics in Review","other","article","10.1542/pir.2021-005349","40449912",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050014","1981-LB: Elevated BMI and Antiobesity Medication Prevalence in Adults with Type 1 Diabetes—Cross-Sectional Study of the Epic Cosmos Database","María‐José Sánchez","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1981-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050015","Semaglutide reduces appetite and energy intake, improves control of eating and provides weight loss in subjects with obesity","John Edward Blundell","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31219-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050016","The Benefit of a Liraglutide-Based Weight Loss Regimen Alone or in Addition to Standard CPAP Therapy on Metabolic Function, Atherosclerosis and Inflammation in Patients with Obstructive Sleep Apnoea - an Explorative, Proof of Concept Study","Colm P. O’Donnell","2022",null,"other","article","10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2335",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050017","Semaglutide in type 2 diabetes management: review of current evidence from concept to date","Tatiana Yu. Demidova","2023","FOCUS Endocrinology","narrative_review","article","10.15829/2713-0177-2023-3-11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050018","Comparative Retinopathy Risk in People with Type 2 Diabetes Treated with Post Metformin Second-line Incretin Therapies: Study Based on US Electronic Medical Records","Sanjoy Ketan Paul","2020","Journal of Diabetes Metabolism and its Complications","nonrandomized_study","article","10.31487/j.jdmc.2020.02.03",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050019","P4608BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial","Kausik Kumar Ray","2019","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehz745.0991",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0050020","How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?","Joshua J. Neumiller","2019","Clinical Journal of the American Society of Nephrology","randomized_trial","article","10.2215/cjn.05340419","31575617",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0050021","S2339 Semaglutide Reduces Incident Cirrhosis, Complications, and Mortality in MASLD Patients With Diabetes: A Retrospective Cohort Study","Ludovic Saba","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001136816.79380.3d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050022","Ustekinumab","Dennis J. Cada","2010","Hospital Pharmacy","other_trial","article","10.1310/hpj4504-320",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050023","Treatment Utilization and Disease Burden Associated with CKD Progression in Patients with Type 2 Diabetes","James J. Amamoo","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s1859c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050024","1686-P: Novel Combination of a Mitochondrial Protonophore (MP) and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice","NATALIE SRODA","2025","Diabetes","preclinical","article","10.2337/db25-1686-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050025","968-P: Long-Term Quantitative and Qualitative Effect of Dulaglutide in Type 2 Diabetes Patients","Anastasios Koutsovasilis","2020","Diabetes","other","article","10.2337/db20-968-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050026","931-P: Optimal Treatment Intensification for Glycemic Control in Patients with T2D on Two Oral Agents: Real-World Comparison of GLP-1, OADs, and Insulin","Cyrus V Desouza","2020","Diabetes","nonrandomized_study","article","10.2337/db20-931-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050027","Нейропротективное действие агониста рецептора глюкогоноподобного пептида-1","А. В. Симаненкова","2014","Медицинский вестник Башкортостана","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050028","Clinical experience with exenatide and liraglutide in the internal medicine service two of hospitals in Valencia","Juan Jose Tamarit-Garcia","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.p209",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050029","PDB14 USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETES","Louis P. Garrison","2011","Value in Health","other","article","10.1016/j.jval.2011.02.522",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050030","From Gut to Brain: The Neurohormonal Basis of Appetite Suppression and Gastric Emptying Delay by Semaglutide in Non-Diabetic Obesity","Obiageri Ihuarulam Okeoma","2026","Journal of international research in medical and pharmaceutical sciences","randomized_trial","article","10.56557/jirmeps/2026/v21i310654",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0050031","Synthesis of 3-Fluoro-4-(hydroxymethyl)benzonitrile via Photobromination: Enabling Manufacturing Pathways for Danuglipron Starting Materials","Aaron F. Baldwin","2026","Organic Process Research & Development","other","article","10.1021/acs.oprd.5c00419",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050032","Biological mechanisms of dopamine D2-like receptor agonist therapy in diabetes","Zachary Z Freyberg","2025","Frontiers in Endocrinology","preclinical","article","10.3389/fendo.2025.1532414","39906261",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050033","Abstract #238 Efficacy and Safety of Lixisenatide as Add-On in Patients with T2D Aged ≥ 70 Years Uncontrolled on Basal Insulin in the GETGOAL-O Study","GEORGE E. DAILEY","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47084-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050034","Exenatide einmal wöchentlich: Anhaltende Blutzuckerkontrolle und Gewichtsreduktion über 52 Wochen","CHRISTOF M. KAZDA","2009","Diabetologie und Stoffwechsel","other","article","10.1055/s-0029-1221863",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050035","1772-P: Baseline Characteristics of Participants Who Achieved Normal BMI—Surmount-1 Three-Year Study Post Hoc Analysis","Reshmi Srinath","2025","Diabetes","randomized_trial","article","10.2337/db25-1772-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050036","Thrombocytopenia in a patient on antiretroviral therapy treated with liraglutide","Diliara N. Gubaeva","2022","Endocrine Abstracts","other","article","10.1530/endoabs.85.p40",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050037","Could 99mTc labelled glucagon-like peptide 1 analogue scintigraphy be an answer for patients with persistent hypoglycaemia?","Alicja Hubalewska–Dydejczyk","2015","Endocrine Abstracts","other","article","10.1530/endoabs.37.gp.28.03",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050038","Real-world evidence on the prescribing trends of glucagon-like peptide-1 agonists in UK primary care","William Hinton","2016","Surrey Research Insight Open Access (The University of Surrey)","nonrandomized_study","article","10.1111/dme.45_13048",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","conference-paper"],["R0050039","A Long-acting Glucose-dependent Insulinotropic Polypeptide Receptor Agonist Improved Insulin Sensitivity and Beta-Cell Function in Participants with Type 2 Diabetes","Tim Heise","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807435",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0050040","Abstract WP229: Comparing the Real-World Effects of Once-Weekly Semaglutide and Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcomes, Health Care Resource Utilization, and Medical Costs in Individuals With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease","Adam H de Havenon","2024","Stroke","nonrandomized_study","article","10.1161/str.55.suppl_1.wp229",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050041","Antidiabetische Polypharmakotherapie und Stoffwechselkontrolle von Menschen mit Typ 2 Diabetes mellitus einer universitären Diabetesambulanz","V Wegner","2021","Diabetologie und Stoffwechsel","other","article","10.1055/s-0041-1727346",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050042","Патогенетическое обоснование и эффективность применения вилдаглиптина у больных сахарным диабетом 2 типа","Tatiana Ivanovna Romantsova","2009","CyberLeninK (CyberLeninka)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050043","SAT-528 Real-world Treatment Patterns Of Tirzepatide Versus Semaglutide In GLP-1 RA-naive Patients With T2D","Meredith M. Hoog","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1060",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050044","Traitement par semaglutide et fonction rénale dans l’étude SUSTAIN 6","Ronan Roussel","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.211",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050045","The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist","Mikkel Christensen","2011","Expert Review of Endocrinology & Metabolism","other_trial","article","10.1586/eem.11.30",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050046","75601 Better Days Ahead: Semaglutide Boosts QoL in HS","Robert Adler","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.307",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050047","The year in cardiology 2016: prevention","Massimo Francesco Piepoli","2016","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehw637","28043976",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050048","Therapeutic Regression of Myocardial Fibrosis by Retatrutide via p-AMPK/TGF-β1 Signaling Pathways","Tato Zumbadze","2026","GEORGIAN SCIENTISTS","nonrandomized_study","article","10.52340/gs.2026.08.02.67",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050049","1429-P: Use of Guideline-Recommended Risk-Reduction Strategies among Patients with Type 2 Diabetes and Established ASCVD: A 1-Year Update from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)","Mikhail Kosiborod","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1429-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050050","Additional file 2 of Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain","Sarah Elizabeth Jackson","2026","Figshare","other","article","10.6084/m9.figshare.31023458.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050051","142-OR: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study","YIJUN DU","2025","Diabetes","randomized_trial","article","10.2337/db25-142-or",null,null,"ClinicalTrials.gov:NCT06640647; ClinicalTrials.gov:NCT06637020","S003300; S003314","openalex","FALSE","paywalled","1","FALSE","article"],["R0050052","Su1483: IMPROVEMENT IN HELICOBACTER PYLORI ERADICATION AMONG ADULTS RECEIVING SEMAGLUTIDE: A POPULATION-BASED PROPENSITY-SCORE-ADJUSTED ANALYSIS","Asaf Ness","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)02732-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050053","118-LB: Efficacy and Safety of iGlarLixi vs. IDegAsp: Systematic Review and Indirect Treatment Comparison (ITC)","Philip Home","2021","Diabetes","systematic_review","article","10.2337/db21-118-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0050054","Hormonal regulation of appetite","Stephen Robert Bloom","2007","Obesity Reviews","nonrandomized_study","article","10.1111/j.1467-789x.2007.00320.x","17316304",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050055","Identification des facteurs prédictifs de la réponse au liraglutide dans le diabète de type 2 en utilisant une méthode d’analyse de partition récursive","J.P. Courrèges","2013","Annales d Endocrinologie","other","article","10.1016/j.ando.2013.07.537",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050056","Real-World Experience of Semaglutide (Wegovy) Effectiveness in Weight Loss in an NHS Tier-3 Weight Management Service","Zin Thawdar Oo","2026","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.117.p150",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050057","DPP IV resistant GLP-1 analogue N-acetyl-GLP-1 has improved effects on pancreatic beta-cell associated gene expression.","Nigel Irwin","2003","Research Portal (Queen's University Belfast)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050058","Med Spas: Patient Safety and Accreditation","Robert Singer","2026","Aesthetic Surgery Journal","nonrandomized_study","article","10.1093/asj/sjag085","42028847",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050059","EVALUATION OF THE EFFECTIVENESS OF THE HUMAN GLUCAGON-LIKE PEPTIDE-1 ANALOGUE LIRAGLUTIDE IN PATIENTS WITH GOUT AND METABOLICALLY UNHEALTHY OBESITY PHENOTYPE","\"","2023","Baikal Medical Journal","other","article","10.57256/2949-0715-2023-3-41-43",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050060","Acceptance of Recommendations for SGLT2 Inhibitors and GLP1 Receptor Agonists in a High-Risk CKD Population","Melanie R. Weltman","2022","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20223311s1865b",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0050061","Abstract #1287517: Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients With Type 2 Diabetes: An Ambispective Study","Ayman Al Hayek","2022","Endocrine Practice","other","article","10.1016/j.eprac.2022.10.016",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050062","Online searches for SGLT-2 inhibitors and GLP-1 receptor can mirror prescription rates.","Philipp Berning","2023","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/s-0043-1771650",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050063","NO INCREASED RISK OF HEART FAILURE HOSPITALIZATION OR MAJOR CARDIOVASCULAR EVENTS OBSERVED WITH LIRAGLUTIDE IN PATIENTS WITH OR WITHOUT A HISTORY OF NEW YORK HEART ASSOCIATION CLASS II-III HEART FAILURE: RESULTS FROM THE LEADER TRIAL","Mansoor Husain","2018","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(18)31214-2",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0050064","Incretin Mimetics and Type 2 Diabetes","Maxwell Omabe","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050065","Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of AKI in Older Adults with Type 2 Diabetes","Min Zhuo","2021","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20213210s1132d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050066","679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes","Tamer Coşkun","2021","Diabetes","preclinical","article","10.2337/db21-679-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050067","P8.087: Semaglutide May Be Safe After Kidney Transplant","Nizar M. Attallah","2022","Transplantation","nonrandomized_study","article","10.1097/01.tp.0000888732.07133.a9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050068","Treatment With Once-weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults With Overweight or Obesity and Type 2 Diabetes: STEP 2 Post Hoc Analysis","David C.W. Lau","2022","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2022.09.079",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050069","Abstract 13426: The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes","Jonathan Matthew Wilson","2020","Circulation","randomized_trial","article","10.1161/circ.142.suppl_3.13426",null,null,"ClinicalTrials.gov:NCT04255433","S002212","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0050070","Trends in prescriptions of cardio-protective diabetic agents after coronary artery bypass grafting among US Veterans","Salil Vasudeo Deo","2022",null,"nonrandomized_study","article","10.2337/figshare.21159139.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0050071","The effect of semaglutide on body weight in patients with type 2 diabetes mellitus","Tatiana Yu. Demidova","2024","FOCUS Endocrinology","other","article","10.62751/2713-0177-2024-5-1-04",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050072","Improved perception of IGLARLIXI therapy compared to mixed insulin when transferred from basal insulin: outcomes reported by patients in the SoliMix study","Elena A. Yanovskaya","2023","FOCUS Endocrinology","other","article","10.15829/2713-0177-2023-3-13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050073","Prevalence of chronic kidney disease in patients with type 2 diabetes admitted to multidisciplinary hospitals: results of a prospective observational multicenter study (CREDO)","Mikhail Borisovich Antsiferov","2024","Diabetes Mellitus","other_trial","article","10.14341/dm13146",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0050074","Diabetes Mellitus: Is it Type 1 or Type 2? It May Not Be So Easy","Jason C. Baker","2015","BENTHAM SCIENCE PUBLISHERS eBooks","nonrandomized_study","article","10.2174/9781681080369115010011",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","book-chapter"],["R0050075","Decision modelling for the evaluation of diabetes outcomes","Anna A Mosikian","2017","FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","nonrandomized_study","article","10.17749/2070-4909.2017.10.3.047-058",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050076","IDegLira dans la","L. Bordier","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050077","830-P: CGM-Based Outcomes in Adults with T2D Receiving IcoSema vs. Comparators—Post Hoc Analysis of COMBINE 1 and 3","Concetta Irace","2025","Diabetes","randomized_trial","article","10.2337/db25-830-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050078","Liraglutide suppresses postprandial triglyceride (TG) and apolipoprotein B48 (ApoB48) responses to a fat-rich meal in patientes with type 2 diabetes","Kjeld Hermansen","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050079","We are what we eat","Mohammad Qasim Minhas","2025","Journal of Hypertension","randomized_trial","article","10.1097/hjh.0000000000004097","40910610",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050080","33-OR: A Novel Data Mining Approach to Detect Adverse Events of New Diabetes Drugs in Routine Care","Mike Fralick","2020","Diabetes","nonrandomized_study","article","10.2337/db20-33-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050081","S2120 Tirzepatide and MASLD: Real-World Outcomes in Patients With Overweight and Obesity","María Ángeles Espinosa","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037848.29175.a2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050082","Intestinal bacteria as endogenous glucose receptors: molecular mechanism and homeostatic regulation prospect of intelligent secretion of GLP-1","Yinxi Liu","2026","Advances in Engineering Technology Research","other","article","10.56028/aetr.17.1.1080.2026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050083","278-OR: Efficacy and Safety of Anti-interleukin (IL)-21 in Combination with Liraglutide in Adults Recently Diagnosed with Type 1 Diabetes","Matthias G. von Herrath","2020","Diabetes","randomized_trial","article","10.2337/db20-278-or",null,null,"ClinicalTrials.gov:NCT02443155","S001615","openalex","FALSE","paywalled","1","FALSE","article"],["R0050084","Retrospective, cohort review of pharmacists' impact on disparities in care in the management of type 2 diabetes with glucagon‐like peptide‐1 agonists and sodium glucose co‐transporter 2 inhibitors","Chandler Howell","2022","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","nonrandomized_study","article","10.1002/jac5.1626",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050085","Effect of Combination Therapy with Liraglutide plus Canagliflozin on HGP and HbA1c vs. Each Therapy Alone in T2DM","Muhammad A. Abdul-Ghani","2018","Diabetes","randomized_trial","article","10.2337/db18-109-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050086","Study of beta cells and neurons indicate incretin analogs as potential therapeutics for Friedreich’s ataxia. (S32.005)","Massimo Pandolfo","2015","Neurology","other_trial","article","10.1212/wnl.84.14_supplement.s32.005",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050087","Treatment with a glucagon-like peptide-1 receptor agonist exenatide decreases systolic blood pressure in overweight type 2 diabetic patients","Tomislav Bulum","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050088","SAT092 A Case Of Mature Onset Diabetes Of The Young","Lauren H Beshay","2023","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvad114.958",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050089","A fully automated radiolabelling of [68Ga]Ga-DOTA-exendin-4 using iPhase MultiSyn synthesis module","Lyzu Yasmin","2025","Nuclear Medicine and Biology","other","article","10.1016/j.nucmedbio.2025.109431",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050090","1132-P: Real-World Clinical Use of iGlarLixi in a Large U.S. Electronic Medical Records Database","Juan P. Frías","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1132-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050091","THE EFFECT OF TIRZEPATIDE DURING WEIGHT LOSS ON FOOD INTAKE, APPETITE, FOOD PREFERENCE AND FOOD CRAVING IN PEOPLE WITH OBESITY","Corby K. Martin","2023","Canadian Journal of Cardiology","other","article","10.1016/j.cjca.2023.06.367",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050092","Abstract Wed086: Transcriptome Reprogramming by Semaglutide in Heart Failure with Preserved Ejection Fraction Improves Cardiac Function and Exercise Performance","Natalie Gehred","2025","Circulation Research","preclinical","article","10.1161/res.137.suppl_1.wed086",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050093","With regard to the papers by Kumaret al.and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs","J. Rick Turner","2016","European Heart Journal - Cardiovascular Pharmacotherapy","other_trial","article","10.1093/ehjcvp/pvw047","28122792",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0050094","234-OR: Performance of a Machine-Learning Gene Risk Score Biomarker to Predict Weight-Loss Response to Tirzepatide and Semaglutide","Elif Tama","2024","Diabetes","nonrandomized_study","article","10.2337/db24-234-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050095","UEG 2025 Interview: Jörn Schattenberg","Jörn Markus Schattenberg","2025","EMJ Gastroenterology","other","article","10.33590/emjgastroenterol/nrbr7785",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050096","118-OR: HLA Matching and Clinical Outcomes in Islet Transplantation","Virginia Fuenmayor","2020","Diabetes","nonrandomized_study","article","10.2337/db20-118-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050097","461-P: Prothrombotic State Is Associated with Impaired Arterial Wall Elastic Properties in Patients with Type 2 Diabetes Mellitus","Gerasimos Siasos","2019","Diabetes","other","article","10.2337/db19-461-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050098","Abstract P444: Changes in Glucose-Lowering Medication Prescriptions After an Incident Cardiovascular Event Across eGFR Levels in an Integrated Health System","Jung‐Im Shin","2020","Circulation","nonrandomized_study","article","10.1161/circ.141.suppl_1.p444",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050099","Diabetes News","Abigail E. Dove","2016","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12451","27427410",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050100","Abstract 232: Initiating Empagliflozin vs. Glucagon-like Peptide 1 Receptor Agonists is Associated With Lower Healthcare Cost of Care Among Patients With Type 2 Diabetes and Cardiovascular Disease","Pratik M. Pimple","2020","Circulation Cardiovascular Quality and Outcomes","nonrandomized_study","article","10.1161/hcq.13.suppl_1.232",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050101","#2926 The impact of GLP-1 receptor agonists on metabolic control and diabetic kidney disease progression","João Venda","2024","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfae069.736",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050102","Cardiorenal effects of newer antidiabetic agents","Athanasia K. Papazafiropoulou","2020","Journal of Atherosclerosis Prevention and Treatment","randomized_trial","article","10.53590/japt.02.1010",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050103","S2607 Real-World Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Aspirin in Patients With Metabolic Dysfunction-Associated Steatotic Liver Diseases and Obesity: A Propensity-Matched Analysis","Olanrewaju Felix Adeniran","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137888.44462.29",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050104","MON-826 Impact Of Demographic And Social Determinants On Access To SGLT2 Inhibitors And GLP-1 Receptor Agonists: A Systematic Review And Meta-Analysis","Nisarg B. Shah","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.1291",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0050105","Data from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors","Jasmine Singh Sukumar","2026",null,"nonrandomized_study","article","10.1158/2767-9764.c.8332417",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other"],["R0050106","Semaglutide 2.4 mg for weight loss in overweight adolescents and adults without diabetes: an updated systematic review and meta-analysis of randomized controlled trials","Abdulrahman A. Azab","2026","International Journal of Medicine in Developing Countries","systematic_review","article","10.24911/ijmdc.51-1766048131",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0050107","PDB27 COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE-2 DIABETES IN TURKEY: A LONG-TERM HEALTH ECONOMIC ANALYSIS","David F. Bruhn","2009","Value in Health","other","article","10.1016/s1098-3015(10)75005-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050108","58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist","Shweta Urva","2019","Diabetes","nonrandomized_study","article","10.2337/db19-58-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050109","Exploring the Sequence Space of Antimicrobial Peptide Dendrimers","Xingguang Cai","2023","Israel Journal of Chemistry","other","article","10.1002/ijch.202300096",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050110","S91 Risk of Pancreatic Adenocarcinoma in Patients on Oral Hypoglycemic Agents for Type 2 Diabetes Mellitus","Oyedotun Babajide","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000950004.68230.50",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050111","Weight Loss Outcomes with Species-Specific Dual GLP-1R/GCGR Agonists in Animal Models","Ralf Elvert","2018","Diabetes","preclinical","article","10.2337/db18-2028-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050112","Experience in the Use of Fixed Combination Insulin Glargine 100 U/ml and Lixisenatide in Patients with Type 2 Diabetes Who Did not Reach the Targets After Using Oral Hypoglycemic Drugs","Ольга Владимировна Занозина","2019","Effective Pharmacotherapy","other","article","10.33978/2307-3586-2019-15-41-28-31",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050113","S1628 GLP-1 Agonists and Their Efficacy for Weight Loss: Unraveling the Best Option Through Network Meta-Analysis","Jena Velji-Ibrahim","2023","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0000956152.75833.3b",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0050114","14-LB: Clinical Utility of KidneyIntelX on Patients with Early-Stage Diabetic Kidney Disease—A Real-World Evidence Study","Joji Erik Tokita","2022","Diabetes","nonrandomized_study","article","10.2337/db22-14-lb",null,null,"ClinicalTrials.gov:NCT04802395","S002741","openalex","FALSE","paywalled","4","FALSE","article"],["R0050115","Frequency of Weight Loss Instruction Provision to Patients with Obesity and Hip or Knee Osteoarthritis: A Case-Series","Benjamin CY Wong","2025","Journal of Orthopaedic Experience & Innovation","nonrandomized_study","article","10.60118/001c.133634",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050116","1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203","Julio Rosenstock","2019","Diabetes","other_trial","article","10.2337/db19-1014-p",null,null,"ClinicalTrials.gov:NCT02057172","S001626","openalex","FALSE","paywalled","5","FALSE","article"],["R0050117","Renal Effects of Semaglutide in Adolescent Mice","Steven Didik","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2025dxnxmmq7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050118","Modern glucose-lowering treatment effect on bone remodeling in experimental diabetes mellitus and surgical menopause","Н. В. Тимкина","2023","Diabetes Mellitus","preclinical","article","10.14341/dm12967",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050119","Subcutaneous Administration of Exenatide Increases Nocturnal Cortisol Levels in Saliva of Type 2 Diabetic Patients","Wilfredo Guanipa-Sierra","2011",null,"other","article","10.1210/endo-meetings.2011.part4.p4.p3-498",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050120","Sustained usage of an app-based clinical-decision making aid for the management of atherosclerotic cardiovascular disease","Amritanshu Shekhar Pandey","2022","European Heart Journal - Digital Health","nonrandomized_study","article","10.1093/ehjdh/ztac076.2825",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050121","Potential role of glucagon like peptide ( GLP )‐1 receptor agonist to reduce risk of colorectal cancer?","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","nonrandomized_study","article","10.1002/doi2.85",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050122","Abstract #1213: The Combination of Insulin, Liraglutide and Dapagliflozin as Triple Therapy for Type 1 Diabetes","Nitesh D Kuhadiya","2015","Endocrine Practice","other","article","10.1016/s1530-891x(20)42441-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050123","Impact of GLP1 receptor agonists on severity of prostate cancer at diagnosis: A propensity score weighted analysis.","Muhammad Ali Khan","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.7_suppl.352",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050124","Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled trial","Barbara M. McGowan","2017","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.48.p11",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050125","SAT-212 Real-world use of Glucagon-like peptide 1 receptor agonists in patients with MASLD: a cross-sectional analysis from TARGETNASH","Alfred Sidney Barritt","2024","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(24)01779-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050126","1775-LB: Role for Glucagon-Like Peptide 1 Receptor Agonists in Symptomatic Post-bariatric Hypoglycemia","TAMIM ALQAZLAN","2024","Diabetes","other","article","10.2337/db24-1775-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050127","QUANTIFIED METRICS OF GASTRIC EMPTYING DELAY BY GLP-1 AGONISTS REVEAL MINOR DIFFERENCES: INSIGHTS FOR PERIPROCEDURAL MEDICATION AND DIETARY MANAGEMENT","Brent Hiramoto","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.1396",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050128","FRI657 Case Series On GLP-1 Receptor Agonist Related Acute Pancreatitis","Abhigna Uday Kumar Kulkarni","2023","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvad114.875",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050129","S1629 Outcomes of Anti-Obesity Glucagon-Like Peptide 1 Agonists vs Revisional Endoscopic Sleeve Gastroplasty for Weight Regain After Laparoscopic Sleeve Gastrectomy: A Case-Control Real World Experience","Firas Bahdi","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000956156.84258.17",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050130","Apabetalone, a selective BET protein inhibitor, reduces ischemic cardiovascular events and hospitalization for heart failure in patients with acute coronary syndrome and type 2 diabetes","Kausik Kumar Ray","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.1425",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0050131","GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical development","Lisbeth B. Knudsen","2001","Drugs of the Future","other","article","10.1358/dof.2001.026.07.628723",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050132","PA05 From papules to plasma: eruptive xanthomas revealing hypertriglyceridemia and diabetes in a teenager","Abiola Makanjuola","2026","British Journal of Dermatology","other","article","10.1093/bjd/ljag086.437",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050133","Re-examining the putative association between GLP-1 receptor agonists and nonarteritic anterior ischemic optic neuropathy","Sabrina Poonja","2025","Annals of Eye Science","other","article","10.21037/aes-24-38",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050134","Clinical Use of Incretin-Based Therapy in Type 2 Diabetes Mellitus","Mansur E. Shomali","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050135","Short Term Glucagon‐Like Peptide‐1 Receptor Agonist Therapy Does Not Influence Hepatic De Novo Lipogenesis in Polycystic Ovary Syndrome","Jacob J. Stuppy","2021","The FASEB Journal","other","article","10.1096/fasebj.2021.35.s1.01661",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050136","643-P: A Model-Based Evaluation of Glycemic and Weight Changes When Switching from Semaglutide to Additional Doses of Dulaglutide","Lai‐San Tham","2021","Diabetes","other","article","10.2337/db21-643-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050137","2084-LB: Real-World Effectiveness of Tirzepatide among People with Obesity or Overweight without Type 2 Diabetes (T2D)","Emily R. Hankosky","2024","Diabetes","nonrandomized_study","article","10.2337/db24-2084-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050138","GLP-1 agonists for weight management in antipsychotic-induced weight gain: systematic review and meta-analysis","Maarten Bak","2023","Neuroscience Applied","systematic_review","article","10.1016/j.nsa.2023.103085",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0050139","Semaglutide effects on insulin sensitivity and beta-cell function in patients with schizophrenia, prediabetes, and obesity treated with second generation antipsychotics","Ashok Ainkaran Ganeshalingam","2026",null,"randomized_trial","article","10.2337/figshare.31298458",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0050140","WCN26-4259 TIRZEPATIDE FOR RESISTANT HYPERTENSION IN NON-DIABETIC IGA NEPHROPATHY","SHAMINI AJIT KUMAR","2026","Kidney International Reports","other","article","10.1016/j.ekir.2026.106223",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050141","179-OR: Improved A1C and TIR with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1","JULIO ROSENSTOCK","2023","Diabetes","randomized_trial","article","10.2337/db23-179-or",null,null,"ClinicalTrials.gov:NCT04460885",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050142","Body Weight (BW) Outcomes with Canagliflozin 300 mg (CANA) vs. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s) in a Real-World (RW) Setting","Craig Ian Coleman","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1291-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050143","Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis","Helen Martina Colhoun","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.3350",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050144","An Innate Disposition for a Healthier Gut: GLP-1R Signaling in Intestinal Epithelial Lymphocytes","Wilfredo Rosario","2015","Diabetes","other","article","10.2337/db15-0436","26106193",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050145","676-P: Semaglutide Achieves Better Metabolic and Weight Control than Other GLP-1 RA in Real Life after 12 Months of Follow-up","María Dolores García de Lucas","2021","Diabetes","nonrandomized_study","article","10.2337/db21-676-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050146","SAT-696 A Comparison of Tirzepatide vs Semaglutide for Weight Reduction over 6 Months of Treatment in Adults with Obesity in US Clinical Practice Settings","Carel Le Roux","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.129",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050147","Su2057: A GENETIC RISK SCORE ASSOCIATED WITH NAUSEA RESULTING FROM GLP-1 RECEPTOR AGONIST TREATMENT: A POST-HOC ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL OF LIRAGLUTIDE","Thomas W. Fredrick","2025","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(25)03109-9",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050148","1664-P: An Observation of an Increase in the Metabolic Syndrome Parameters after Stopping GLP-1RA Medications in STEP-4 and SURMOUNT-4 Trials","Abdulghani Habib Alsaeed","2024","Diabetes","other_trial","article","10.2337/db24-1664-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050149","Evaluation of the impact of GLP-1 receptor agonists (RAs) on stage of PDAC diagnosis: A retrospective matched cohort study.","Sean O'Connor","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e16462",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050150","Report from the Congress of the American Diabetes Association (ADA): Orlando 2005","Peter E. H. Schwarz","2005","Experimental and Clinical Endocrinology & Diabetes","other_trial","article","10.1055/s-2005-865942","16151983",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050151","S4135 Ischemic Colitis Following Tirzepatide Therapy: An Emerging Clinical Observation","Alexa Plato","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001144000.01101.cf",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050152","779-P: Clinical Characteristics and Treatment Patterns among Glucagon-Like Peptide Receptor Agonist (GLP-1RA) Users in a U.S. EHR and Claims Linked Database","Mariam Samir Girguis","2024","Diabetes","nonrandomized_study","article","10.2337/db24-779-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050153","Liraglutide for weight loss in obese people – Authors' reply","Arne Vernon Astrup","2010","The Lancet","commentary","article","10.1016/s0140-6736(10)60227-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0050154","S4728 Glycemic Control to Gut Telescoping: Intussusception in a Patient on a GLP-1 Receptor Agonist","Bianca Thakkar","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001048280.45267.57",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050155","CO-28: Comparaison de l'efficacité du liraglutide à celle du lixisenatide en ajout de metformine chez des patients diabétiques de type 2 : essai randomisé contrôlé de 26 semaines","Amira Bouzidi","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30046-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050156","FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER","Vlado Perkovic","2019","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfz106.fp483",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050157","Dual therapeutic potential of ethanolic plant extracts in diabetes and liver cancer: Comparative study with liraglutide and doxorubicin","Mohsen Ali Khormi","2025","Journal of Radiation Research and Applied Sciences","preclinical","article","10.1016/j.jrras.2025.101961",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050158","520-P: Exenatide Ameliorates Diabetic Kidney Disease by Inhibiting Apoptosis via SIRT1/TXNIP Signal Pathway","Meijun Wang","2020","Diabetes","preclinical","article","10.2337/db20-520-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050159","Acute Interstitial Nephritis Associated with Oral Semaglutide","Mohamed Elshayeb","2026","Kidney International Case Reports","nonrandomized_study","article","10.1016/j.kintcr.2026.100147",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050160","S3043 Inpatient Video Capsule Endoscopy: Why the Incomplete Rates?","Jessica C. Petrov","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001139632.67794.91",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050161","Update on Pharmacotherapy for Type 2 Diabetes","Sheikh Salahuddin Ahmed","2013","KYAMC Journal","other","article","10.3329/kyamcj.v3i1.13661",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050162","Investigation of peripherally active and blood glucose-lowering dextromethorphan derivatives without central nervous side effects","Okka Scholz","2020","Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0050163","EE16 PROJECTED LIFETIME IMPACT OF TIRZEPATIDE ON HEALTH AND ECONOMIC OUTCOMES FOR MODERATE-TO-SEVERE OSA WITH OBESITY: A CHINESE MODELING ANALYSIS","Yi Xiao","2026","Value in Health","other","article","10.1016/j.jval.2026.03.312",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050164","1972-LB: Glucagon-Like Peptide 1 Receptor Agonists and NAION—A Systematic Review and Meta-analysis","Cindy Ho","2025","Diabetes","systematic_review","article","10.2337/db25-1972-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0050165","04 Nephroprotective therapies: which one and when to start? (SGLT2i, GLP-1, MRA)","Eva Vanessa Schrezenmeier","2025","Abstracts","nonrandomized_study","article","10.1136/lupus-2025-la.4",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0050166","Do incretin-based drugs accelerate muscle wasting during weight loss?","H.-E. Langer","2025","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0045-1807389",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0050167","Linagliptin-Induced Pancreatitis","Husam El Sharu","2023","Annals of Internal Medicine Clinical Cases","other","article","10.7326/aimcc.2023.0316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050168","Chronic heart failure and type 2 diabetes mellitus: prospects for optimizing pharmacotherapy of comorbid pathology","Sergey V. Povetkin","2021","Человек и его здоровье","randomized_trial","article","10.21626/vestnik/2021-1/03",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050169","GLP-1 Receptor Agonists and Endoscopic Procedural Optimization: How To Minimize Risk and Improve Outcomes","Trevor Stephen Barlowe","2025","Current Treatment Options in Gastroenterology","other","article","10.1007/s11938-025-00472-w",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050170","1974-P: Diet-Induced Weight Loss Improves Sleep Quality and These Improvements Are Sustained with One Year of Weight Maintenance with Exercise: The S-LITE Randomized Trial","Charlotte Janus","2020","Diabetes","randomized_trial","article","10.2337/db20-1974-p",null,null,"ClinicalTrials.gov:NCT04122716","S000371","openalex","FALSE","paywalled","1","FALSE","article"],["R0050171","1700-P: Weight Reduction Is Associated with Improved Quality of Life in Participants with Obesity or Overweight and Type 2 Diabetes—Results from Phase 3 SURMOUNT-2 Trial","Theresa M. Hunter","2024","Diabetes","randomized_trial","article","10.2337/db24-1700-p",null,null,"ClinicalTrials.gov:NCT04657003","S001712","openalex","FALSE","paywalled","1","FALSE","article"],["R0050172","THE EFFECT OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON CIRCULATING MYELOPEROXIDASE-DNA (MPO-DNA) COMPLEXES AND NEUTROPHIL STIMULATION","Petros Spyridonas Adamidis","2026","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2026.120962",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050173","799-P: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist","Billy P Baxter","2025","Diabetes","other_trial","article","10.2337/db25-799-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050174","Assistance to a health practitioner: how to prepare a patient receiving glucagon-like peptide-1 receptor agonists for endoscopic and sur- gical interventions?","Т. Л. Каронова","2025","Русский медицинский журнал","other","article","10.32364/2225-2282-2025-2-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050175","247-OR: Real-World Effectiveness of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease","Elisabetta Patorno","2019","Diabetes","nonrandomized_study","article","10.2337/db19-247-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050176","Cosmetic Considerations of Semaglutide","Alaina D Baggett","2025","Cosmetics","other","article","10.3390/cosmetics12050221",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050177","Development of immediate and sustained-release formulations of the glucagon-like peptide-1 receptor agonist exenatide for the treatment of patients with type 2 diabetes","Mark S. Fineman","2011","Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0050178","P0319 Association of GLP-1 Receptor Agonist Use With Clinical Outcomes in Diabetic Patients With Inflammatory Bowel Disease Receiving Adalimumab: A Propensity-Matched Cohort Study","Om Prakash Patel","2026","Journal of Crohn s and Colitis","nonrandomized_study","article","10.1093/ecco-jcc/jjaf231.500",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050179","Su2052: DOES WITHHOLDING GLP-1 RECEPTOR AGONISTS REDUCE ASPIRATION RISK IN ENDOSCOPY? A NATIONWIDE COHORT STUDY","Sami Mesgun","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03104-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050180","Why People with Overweight and Obesity Are Seeking Care Through Digital Obesity Services: A Qualitative Analysis of Patients from Australia’s Largest Digital Obesity Provider","Louis A Talay","2024","Telemedicine Reports","other","article","10.1089/tmr.2024.0031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050181","Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors","Virginia Pate","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","preclinical","article","10.17615/j59a-f258",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050182","TYPE 2 DIABETES IN YOUNG ADULTS: PREVALENCE AND RISK FACTOR CONTROL IN A TERTIARY DIABETES CENTRE","Gemma E. Currie","2023","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0000940964.50300.9d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050183","PO410 EFFICACY AND SAFETY OF LIRAGLUTIDE VS PLACEBO WHEN ADDED TO BASAL INSULIN ANALOGUES IN SUBJECTS WITH TYPE 2 DIABETES (LIRA-ADD2BASAL): A RANDOMISED, PLACEBO-CONTROLLED TRIAL","Andrew Ahmann","2014","Diabetes Research and Clinical Practice","randomized_trial","article","10.1016/s0168-8227(14)70704-1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050184","Should the Incretin hype be the same for older adults: Promise + cautions","Kathryn N. Porter Starr","2026","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/9sfn-sa15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050185","Proximal intestinal mucosal ablation (PIMA) enables discontinuation of exogenous insulin in type 2 diabetes: final results from the STEAM-IE trial","B Norton","2026","Endoscopy","other_trial","article","10.1055/s-0046-1822577",null,null,"ClinicalTrials.gov:NCT06655740","S003386","openalex","FALSE","paywalled","5","FALSE","article"],["R0050186","Non‐insulin Parenteral Therapies","Tina Vilsbøll","2024",null,"other","article","10.1002/9781119697473.ch36",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0050187","Orforglipron Improved Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes","Julio Rosenstock","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807434",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0050188","649-P: Impact of Early Initiation of Dulaglutide on A1C in Patients with Type 2 Diabetes","Meredith M. Hoog","2021","Diabetes","nonrandomized_study","article","10.2337/db21-649-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050189","Does dulaglutide impact a composite outcome reflecting atherosclerosis? A post-hoc analysis of the REWIND trial","Giulia Ferrannini","2022","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehac544.2400",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050190","GLP-1's Effect on Renal Perfusion and Oxygenation Measured with Quantitative MRI: A Potential Renoprotective Pathway in the Human GLP-1-Renal Axis","Bryan Haddock","2021","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20213210s1256b",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050191","Role and development of GLP-1 receptor agonists in the management of diabetes","Josephine Mary Egan","2009","Diabetes Metabolic Syndrome and Obesity","other","article","10.2147/dmsott.s4283",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050192","Results from the nationwide French glucose (GLP1RA and SGLT2I use by cardiologists survey)","Pierre François Sabouret","2023","Atherosclerosis","nonrandomized_study","article","10.1016/j.atherosclerosis.2023.06.651",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050193","Abstract 5714: Combination of glucagon-like-peptide-1 (GLP-1) receptor targeted therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors","Andreas N. WICKI","2012","Cancer Research","preclinical","article","10.1158/1538-7445.am2012-5714",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050194","Impact of COVID-19 on the endocrine system","Dariya Nikolaevna Zadumina","2023","Лечащий врач","other","article","10.51793/os.2023.26.3.001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050195","Variables Therapieansprechen von Menschen mit Typ-2-Diabetes und Adipositas auf SGLT-2 Inhibitoren und GLP-1 Rezeptoragonisten: Real-World Daten des DPV-Registers","Nicole Prinz","2023","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0043-1767869",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050196","Exploring Two Dose Regimens of ITCA 650 to Switch from Stable Liraglutide Therapy in Type 2 Diabetes (T2D)","Neda Rasouli","2018","Diabetes","randomized_trial","article","10.2337/db18-1102-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050197","Bone mineral density was not affected by exenatide therapy despite a significant reduction in body weight in patients with type 2 diabetes","Björn Eliasson","2010","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050198","1751-P: Induction of Sirt1-AMPK Pathway by GLP-1RA Liraglutide Reduces Hepatic Lipid Accumulation and Insulin Resistance","Chien‐Ning Huang","2020","Diabetes","other","article","10.2337/db20-1751-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050199","How Glucagon-Like Peptide-1 Medications Are Depicted in Instagram Posts Regarding Women’s Health, Nontraditional Access, and Barriers to Access: Content Analysis (Preprint)","Brittnie E. Bloom","2024",null,"other","article","10.2196/preprints.66400",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0050200","Long-term effects of re-sleeve endoscopic gastroplasty with GLP-1 agonists: weight reduction, liver function improvement, and insulin resistance insights over 24 months","Eyad Gadour","2025","Endoscopy","nonrandomized_study","article","10.1055/s-0045-1805402",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0050201","Effects of Glucagon-like Peptide-1 Receptor Agonists on Copeptin in healthy volunteers and patients with primary polydipsia-A secondary analysis of the randomized, double-blind, placebo-controlled, crossover GOLD & GATE trials","Svenja Leibnitz","2024","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.99.oc5.1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050202","P269 - Liraglutide et repaglinide, une association thérapeutique envisageable pendant le jeûne de Ramadan","Eric Benamo","2011","Diabetes & Metabolism","other","article","10.1016/s1262-3636(11)70895-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050203","Abstract 4135846: Cardiovascular Effectiveness of Glucagon-like Peptide-1 Receptor Agonists and Empagliflozin Combination Therapy in Adults with Type 2 Diabetes","Phyo Than Htoo","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4135846",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050204","New horizons in the management of metabolic diseases: Focus on the efficacy and safety of tirzepatide","Tatiana Yu. Demidova","2025","FOCUS Endocrinology","other","article","10.62751/2713-0177-2025-6-3-03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050205","The Impact of Sodium-Glucose Co-Transporter-2 Inhibitors on Weight Loss in Obesity","Semahat Karahisar Şirali","2023","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.8135541",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0050206","Incidence of nonarteritic anterior ischemic optic neuropathy among adults treated with GLP‑1 receptor agonists: A systematic review and single‑arm proportion meta‑analysis","Maria Isabel Arias Gallardo","2025",null,"systematic_review","article","10.37766/inplasy2025.8.0007",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0050207","PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS","L.E. García-Pérez","2019","Value in Health","nonrandomized_study","article","10.1016/j.jval.2019.09.998",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0050208","Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide","Nikolaus Marx","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.2751",null,null,"ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03914326; ClinicalTrials.gov:NCT03819153","S000716; S000953; S002179","openalex","TRUE","open_pdf","1","FALSE","article"],["R0050209","CO4 Overview of Recent Systematic Literature Reviews on Glucagon-like Peptide-1 Receptor Agonists for Weight Loss in Adults with Obesity","K.E. Smoyer","2023","Value in Health","narrative_review","article","10.1016/j.jval.2023.09.078",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0050210","194SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes","C Noergaard","2019","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehz747.0054",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050211","[SER8]GLP-1(7-36)amide is a GLP-1 analogue with improved plasma stability","Uwe Ritzel","1998","Gastroenterology","other","article","10.1016/s0016-5085(98)84777-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050212","Bioactive Nanofiber Matrix Formulations for the Delivery of Exendin-4 for Tendon Regeneration: In Vitro and in Vivo Assessment","Sangamesh  Gurappa Kumbar","2022","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4279437",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0050213","5183 Tirzepatide Improved Health-Related Quality of Life in People with Obesity or Overweight: Results from SURMOUNT-4 Phase 3 Trial","T M Gibble","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.042",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050214","SUN-149 Cardiologist vs. Endocrinologist Encounters in Patients with T2D and CVD: Potential Implications for Glucose-Lowering Therapy Use and Education","Felona Gunawan","2019","Journal of the Endocrine Society","other","article","10.1210/js.2019-sun-149",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050215","Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomized trial","Frank L. Greenway","2015","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0035-1556575",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050216","GLP ‐1 analogue use in patients with sub‐optimally controlled type 1 diabetes or obesity improves weight and HbA1c","Louise R Curtis","2016","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1991",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050217","Further Research on Internet Searches for On- and Off-Label Use of Weight-Loss Medications","Athanasios Tselebis","2023","Aesthetic Surgery Journal","other","article","10.1093/asj/sjad258","37562032",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050218","OR08-07 Real-World Evidence on GLP-1 Analogues: Insights into NAION Risk in Type 2 Diabetes Mellitus Patients","Maxim John Levy Barnett","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1022",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050219","MON-219 Presentation of Glucokinase-Maturity-Onset Diabetes of the Young (GCK-MODY 2) in Obesity and with Transient Autoantibodies in Children and Adolescents","Egor Volcotrub","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1693",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050220","Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes","Amir Hanna","2012","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2012.01.005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050221","GLP-1 RECEPTOR AGONISTS IN OBESITY-RELATED ASTHMA: EXPLORING NEW TREATMENT STRATEGIES","Sunanda Tah","2025","CHEST Journal","other","article","10.1016/j.chest.2025.07.3122",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050222","GLP-1 AGONISTS AND POLYCYSTIC OVARIAN SYNDROME: A TIKTOK CONTENT ANALYSIS","Fatima Z. Hussain","2025","Fertility and Sterility","other","article","10.1016/j.fertnstert.2025.07.142",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050223","420-P: Effects of Liraglutide on Sudomotor Function in Subjects with Type 2 Diabetes","CAROLINA M. CASELLINI","2021","Diabetes","randomized_trial","article","10.2337/db21-420-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050224","Evaluating Genetic Obesity Interventions: A Survival Analysis Approach","Shatha Ramadhan Zaidan","2025","Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )","other","article","10.54133/ajms.v8i2.1926",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050225","Once-weekly dulaglutide for the treatment of youths with type 2 diabetes","Arslanian SA","2023","Yearbook of pediatric endocrinology","randomized_trial","article","10.1530/ey.20.10.4",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050226","Radiotherapeutic for Glucagon-Like Peptide-1Receptor ^ Targeted Therapy for Insulinoma","Andreas N. WICKI","2007",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050227","752-P: Efficacy and Safety of Bofanglutide (GZR18), a Biweekly GLP-1RA, Compared with Semaglutide in Chinese Patients with T2D","Haiya Wu","2025","Diabetes","randomized_trial","article","10.2337/db25-752-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050228","MDS-1747: Risk of Progression to Acute Myeloid Leukemia Among Patients With Myelodysplastic Syndromes and Type 2 Diabetes Treated With GLP-1 Receptor Agonists","Danh Q Nguyen","2026","Clinical Lymphoma Myeloma & Leukemia","other","article","10.1016/s2152-2650(26)02299-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050229","P205 Effet bénéfique du liraglutide sur la stéatose hépatique indépendant de la perte pondérale dans le diabète de type 2 : illustration à partir d’une observation","Cyril Garcia","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72496-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050230","Areas of Interest and Attitudes Toward Antiobesity Drugs: Thematic and Quantitative Analysis Using Twitter (Preprint)","Miguel Ángel Álvarez-Mon","2020",null,"other","article","10.2196/preprints.24336",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0050231","Characteristics of meta-analyses of multi-indication drugs: a systematic review of systematic reviews","Baoqi Zeng","2026","BMC Medical Research Methodology","systematic_review","article","10.1186/s12874-026-03018-5",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0050232","S474 Epidemiological Characteristics and Risk Factor Associations of Colorectal Cancer in a Community Health Setting in the Appalachian Region (2020-2024)","Jasneet Gill","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129356.15858.1f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050233","Changing the Trajectory of Heart Failure and Kidney Disease","Janani Rangaswami","2022","Clinical Journal of the American Society of Nephrology","randomized_trial","article","10.2215/cjn.00470122","35232819",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0050234","P0033 Repositioning dual GLP-1/GIP receptor agonists for the treatment of colitis and colitis-associated cancer (CAC)","Bianca N. Islam","2026","Journal of Crohn s and Colitis","preclinical","article","10.1093/ecco-jcc/jjaf231.214",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050235","701 A RANDOMIZED, DOUBLE-BLIND, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY OF LIRAGLUTIDE TREATMENT IN PATIENTS UNDERGOING TRANSORAL OUTLET REDUCTION ENDOSCOPY","Ali Lahooti","2023","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(23)01308-2",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050236","Response to the Letter to the Editor by Athinarayanan","Jaime P. Almandoz","2024","Obesity","randomized_trial","article","10.1002/oby.24191","39675924",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","letter"],["R0050237","The effect of GLP-1 analogue based therapy on hepatic fat quantity - a prospective observational study.","Lea Smircic Duvnjak","2014","Diabetologia Croatica","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050238","New Horizons in Diabetes Therapy","Jens Juul Holst","2007","Immunology Endocrine & Metabolic Agents - Medicinal Chemistry","other","article","10.2174/187152207779802545",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050239","Postoperative Complication Risk in Idiopathic Intracranial Hypertension Patients Treated with Glucagon-Like Peptide-1 Receptor Agonists","Preston M. Carey","2025","Journal of Neurological Surgery Part B Skull Base","nonrandomized_study","article","10.1055/s-0045-1803082",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0050240","Industry Update: the Latest Developments in the Field of Therapeutic delivery, April 2019","Peter A. Timmins","2019","Therapeutic Delivery","other","article","10.4155/tde-2019-0035",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050241","Diabetes and COVID-19: A Tale of 2 Pandemics","Ali Abbas Rizvi","2021","Journal of Cardiovascular Pharmacology","other_trial","article","10.1097/fjc.0000000000001047","34173808",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0050242","TRENDS IN GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONIST USE AMONG WOMEN WITH POLYCYSTIC OVARIAN SYNDROME IN THE UNITED STATES FROM 2011–2025","Tina Yi Jin Hsieh","2025","Fertility and Sterility","other","article","10.1016/j.fertnstert.2025.07.495",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050243","The impact of incretin mimetics on systemic immunity and T-cell activation 3994","Claire E. Pillsbury","2025","The Journal of Immunology","other","article","10.1093/jimmun/vkaf283.1730",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050244","Comparison of long-acting and short-acting GLP-1 receptor agonists on copeptin in euvolemic participants - a secondary analysis of three prospective trials","Svenja Leibnitz","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.rc4.6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050245","Diabetes Mellitus: Classification, Pathophysiology, Risk Factors, Diagnostic Criteria and Advances in Management.","Monika S. Patil","2024","African Journal of Biomedical Research","other","article","10.53555/ajbr.v27i4s.4785",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050246","Controlling Insulin Secretion: An Exciting TASK","Patrick Edward MacDonald","2014","Endocrinology","preclinical","article","10.1210/en.2014-1667","25238133",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050247","OP25 Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells","Hanqing Liu","2024","Journal of Crohn s and Colitis","preclinical","article","10.1093/ecco-jcc/jjad212.0025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050248","PET-CT mit 18F Dopa und PET-MRT mit 68Ga-NODAGA-Exendin-4 zur Diagnostik des kongenitalen Hyperinsulinismus bei Neugeborenen und Kindern","U Seyfarth","2025","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0045-1804487",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050249","1007 Drug interactions of glucagon?like peptide?1 receptor (GLP-1) agonists in substance use disorder (SUD): A narrative review","Kwangcheol Casey Jeong","2025","Journal of the American Pharmacists Association","narrative_review","article","10.1016/j.japh.2025.102500",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0050250","Abstract PO5-20-06: Paraneoplastic cerebellar degeneration in anti-Yo antibody and HER2-positive metastatic breast carcinoma","You Kim","2024","Cancer Research","other","article","10.1158/1538-7445.sabcs23-po5-20-06",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050251","Anaesthesia management of a patient with non-insulinoma pancreatogenous hypoglycaemia syndrome (NIPHS) – A case study","Bhanupreet Kaur","2023","Indian Journal of Anaesthesia","other","article","10.4103/ija.ija_1017_22","38044917",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050252","OR18-07 Weight Reduction, Body Composition, and Cardiometabolic Changes in Patients with Adrenal Adenomas Treated with GLP-1 or GIP/GLP-1 Receptor Agonists","Emily Danica Zhang","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.279",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050253","CO37 Cardiovascular Effects of Semaglutide in Patients With Obesity, With or Without Type 2 Diabetes (T2DM): An Umbrella Review","Amit Dang","2025","Value in Health","systematic_review","article","10.1016/j.jval.2025.09.139",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0050254","1200-P: Predictors of Glycaemic and Weight Response to Empagliflozin Treatment: The ABCD Nationwide Empagliflozin Audit","Ken Y Thong","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1200-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050255","PDB5 GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS","Matthew E. Wintle","2007","Value in Health","other","article","10.1016/s1098-3015(10)64953-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050256","Abstract 15741: Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Individuals With Obesity or Overweight but Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Areesha Moiz","2023","Circulation","systematic_review","article","10.1161/circ.148.suppl_1.15741",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0050257","670-P: Time Spent in Glycemic Control after Initiating Treatment with Oral Semaglutide vs. Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial","Julio Rosenstock","2021","Diabetes","randomized_trial","article","10.2337/db21-670-p",null,null,"ClinicalTrials.gov:NCT02863328","S000251","openalex","FALSE","paywalled","1","FALSE","article"],["R0050258","Su1553 EXPLORING THE THERAPEUTIC POTENTIAL OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS IN PATIENTS WITH METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE","Brandon Havranek","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)04222-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050259","808-P: Economic Benefits of Initiating Empagliflozin vs. GLP-1 Receptor Agonists among Patients with Type 2 Diabetes","Pratik M. Pimple","2021","Diabetes","nonrandomized_study","article","10.2337/db21-808-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050260","Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, placebo-controlled trial","Wolfgang Kern","2016","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0036-1580798",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050261","The Effect of Liraglutide on 24-Hour Ambulatory Blood Pressure in Patients with T2DM—A Pilot Study","Dragana Lovre","2018","Diabetes","randomized_trial","article","10.2337/db18-16-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050262","CA-033: Relation entre la variation du poids et le contrôle glycémique avec dulaglutide en administration hebdomadaire chez des patients diabétiques de type 2","Guillermo E. Umpierrez","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30165-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050263","PDB69 Diffusion of New Technologies Post Reimbursement – Monitoring the Use of Liraglutide in Primary Care","Aisling C. O’Leary","2012","Value in Health","other","article","10.1016/j.jval.2012.08.1712",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050264","Impact of GLP‐1 and GLP‐1/GIP Receptor Agonist Weight Loss Post‐Lung Transplant on Lung Allograft Function","Spenser E. January","2025","Clinical Transplantation","nonrandomized_study","article","10.1111/ctr.70246",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050265","Clinical effectiveness of liraglutide as add-on therapy after OADs failure for two years in 77 type 2 diabetes cases","Yuan-Ching Liu","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31153-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050266","Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update [Internet]","Wendy L. Bennett","2011",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0050267","Comprehensive Obesity Management Part 1: Assessment and Initiation of Treatment.","Robert F Kushner","2025","PubMed","other","article","10.12788/fp.0636","42662599",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050268","Case: the glycaemic effect of GLP-1 receptor agonist semaglutide as an adjuvant therapy in HNF1-[alpha] MODY","Eibhlin Marie Lonergan","2024","Endocrine Abstracts","other","article","10.1530/endoabs.104.p65",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050269","P299 Efficacité du liraglutide, un analogue du GLP-1 humain, en substitution d’un inhibiteur de la DPP-4 chez les patients DT2 : données à un an de l’étude EVIDENCE®","Guillaume Charpentier","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72590-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050270","Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes","Nina Alexandrovna Petunina","2018","Diabetes Mellitus","other","article","10.14341/dm9623",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050271","640-P: Addition of a GLP-1 Agonist to Insulin Therapy in Type 2 Diabetes","Colleen Gavigan","2021","Diabetes","nonrandomized_study","article","10.2337/db21-640-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050272","PS5 - 24. Add-on treatment of GLP-1 agonists in type 2 diabetics treated with insulin: an observational study","Wouter T. Zandee","2011","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-011-0049-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050273","S1282 Bariatric Surgery vs Glucagon-Like Peptide-1 Analogues for Reducing Risk of Major Cardiovascular Events: A Multi-Center Retrospective Cohort Study","Ayowumi A. Adekolu","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000954768.41220.8b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050274","Identification of patients eligible for treatment with semaglutide after an acute coronary syndrome according to guidelines recommendations","A Cordero","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3748",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050275","Semaglutide in Overweight and Obese patients: Cardiovascular and/or Renal Metabolic Benefits","Jorge E. Rico-Fontalvo","2022","Revista Colombiana de Nefrología","randomized_trial","article","10.22265/acnef.9.3.614",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050276","Effects of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Heart Transplant Patients with Type 2 Diabetes: a Case Series","Yasser M. Sammour","2020","Journal of Cardiac Failure","case_report","article","10.1016/j.cardfail.2020.09.081",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050277","The GLP-1 analogue LY307161 is resistant to degradation by DDP-IV and is fully active in vitro","Sharon R Myers","2000","Diabetes Research and Clinical Practice","preclinical","article","10.1016/s0168-8227(00)81312-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050278","Abstract #232: Effect of Liraglutide on Post Prandial Glucagon, Carbohydrate Intake and on Inflammation in Patients with Type 1 Diabetes","Paresh Dandona","2015","Endocrine Practice","other","article","10.1016/s1530-891x(20)42538-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050279","The Role of Salivary PYY3-36 in Food Intake and Behavior - An Alternative Pathway for Satiety","Andres Borja Alvarez","2010","The American Journal of Gastroenterology","preclinical","article","10.14309/00000434-201010001-00074",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050280","SAT-661 1. Hepatic and Cardiovascular Outcomes of Patients with Metabolic Dysfunction-Associated Steatotic-Liver Disease and Diabetes Mellitus Type 2 Treated with Glucagon-Like Peptide 1 Agonists","Suleiman Al Ashi","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.096",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050281","MON-704 Effects of Semaglutide on BMI and Cardiometabolic Profile in Adolescents with Variants in Monogenic Obesity-related Genes","Mostafa A. Salama","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.041",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050282","#3691 Successful use of glucagon-like peptide-1 receptor agonists (GLP1-RA) in a patient with obesity and diabetic kidney disease under peritoneal dialysis: a Case Report","Pavlo Yavorskiy","2025","Nephrology Dialysis Transplantation","other_trial","article","10.1093/ndt/gfaf116.1683",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050283","IMPACT OF A DEDICATED CARDIOMETABOLIC CLINIC ON PRESCRIPTION OF INCRETIN-BASED THERAPIES – A US-BASED EXPERIENCE","Arpan A. Patel","2025","American Journal of Preventive Cardiology","other","article","10.1016/j.ajpc.2025.101158",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050284","Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD)","André Jacques Scheen","2023","Diabetes Epidemiology and Management","other","article","10.1016/j.deman.2023.100145",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050285","26-A-16782-ACC COMPREHENSIVE OUTCOMES OF GLUCAGON-LIKE PEPTIDE 1 AGONISTS VERSUS TIRZEPATIDE","Ibrahim Mortada","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.695",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050286","The effect of liraglutide therapy on body weight and carbohydrate metabolism and lipid profile in obese children","Olga G. Sharshova","2024","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2024-476",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050287","Efficacy and Safety of Once-Weekly Exenatide versus Daily Liraglutide in Subjects with T2DM (DURATION-6)","Robert E. Buckley","2011","MD Conference Express","other_trial","article","10.1177/155989771111007",null,null,"ClinicalTrials.gov:NCT01029886","S000352","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0050288","S2790 A Meta-Analysis of Type 2 Diabetes Mellitus Treatments for MASLD","Xavier C. Zonna","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001138620.38612.9c",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0050289","Pharmacotherapy for weight loss in adults with type 2 diabetes: a systematic review of randomised controlled trials","Cláudia Matta-Coelho","2021","British Journal of Diabetes","systematic_review","article","10.15277/bjd.2021.281",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0050290","Effects of semaglutide, PYY3-36, antagonists of the GLP-1/NPY-Y2 receptors, and empagliflozin on non-alcoholic fatty liver disease","Niklas Haerting","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.oc11.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050291","Abstract PS15-01: Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer","Margaux E. Wooster","2025","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs24-ps15-01",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050292","Cardiovascular effects of semaglutide: Multifaceted mechanisms of systemic organoprotection","Tatiana Yu. Demidova","2025","FOCUS Endocrinology","randomized_trial","article","10.62751/2713-0177-2025-6-2-06",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050293","Metabolic Aspects of Five Commonly Used Non-Insulin Anti-Hyperglycemic Medications in Type 2 Diabetes","Ali Abbas Rizvi","2021","Journal of Modern Medicinal Chemistry","other","article","10.12970/2308-8044.2021.09.03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050294","0283 Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity","Radhika Gupta","2025","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2025.06.287",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050295","75-OR: In-Silico Replay of Insulin Degludec and Liraglutide Clinical Trial Data in Subjects with Type 2 Diabetes","MOHAMMADREZA GANJIARJENAKI","2024","Diabetes","other_trial","article","10.2337/db24-75-or",null,null,"ClinicalTrials.gov:NCT01336023","S001276","openalex","FALSE","paywalled","5","FALSE","article"],["R0050296","744-P: Dosing Patterns of Tirzepatide (TZP) in Patients with Type 2 Diabetes (T2D) from a Commercially Insured U.S. Population","Reema Mody","2024","Diabetes","nonrandomized_study","article","10.2337/db24-744-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050297","1209-P: Relationship between Canagliflozin Treatment Response and Duration of Diabetes: The Association of British Clinical Diabetologists (ABCD) Nationwide Canagliflozin Audit","Robert E. J. Ryder","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1209-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050298","1010-P: Effects of MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, on Amino Acids, Ketones, and Free Fatty Acids","Victoria E R Parker","2019","Diabetes","randomized_trial","article","10.2337/db19-1010-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050299","IDF21-0447 Real-world clinical experience of IDegLira in the management of adolescents with type 2 diabetes","Tanveer Ashraf","2022","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/j.diabres.2022.109544",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050300","159. Sustained Weight Loss and Altered Lipid Taste Sensitivity Induced by Modulation of Salivary PYY and Excendin-4 in Mice","Sean M. Crosson","2016","Molecular Therapy","preclinical","article","10.1016/s1525-0016(16)32968-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050301","Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK","John P.H. Wilding","2009","The British Journal of Diabetes","other_trial","article","10.1177/1474651409342637",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050302","IP10-31 GLP-1 RECEPTOR AGONISTS: FROM METABOLIC BENEFITS TO SEXUAL HEALTH CONCERNS &NDASH; AN ANALYSIS OF US INSURANCE CLAIMS DATA","Ashkan Pourabhari Langroudi","2025","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001109900.23127.a9.31",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050303","Antihypertensive Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists","Marijana Vaso Tadic","2024","Cardiology Discovery","other","article","10.1097/cd9.0000000000000114",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050304","Cardiovascular effects of semaglutide and tirzepatide and their potential for cardioprevention","Dmitriy V. Cherkashin","2025","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2025-323",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050305","The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-α Expression in Macrophages","Shen Wei-Ren","2018","Institutional Repositories DataBase (IRDB)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050306","Use of Semaglutide in Diabetes Care Post Renal Transplantation","Omar Buraykan Alluhayyan","2025","Current Transplantation Reports","other","article","10.1007/s40472-025-00463-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050307","MP05-10 GLUCAGON-LIKE PEPTIDE-1 EXPRESSION IN PROSTATE CANCER","Mohammed Shahait","2024","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001008740.27639.cc.10",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050308","The WHO Essential Medicines List can help to unlock access to GLP-1 therapies for metabolic syndrome","Kevin C Pottie","2026","Nature Health","other","article","10.1038/s44360-026-00114-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050309","Case 41: Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) in an Individual With Type 2 Diabetes on High-Dose Insulin Therapy","Basem Mishriky","2021","American Diabetes Association eBooks","other","article","10.2337/9781580407663.41",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050310","Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy","Anuj Kumar Borah","2022","Phytomedicine Plus","preclinical","article","10.1016/j.phyplu.2022.100225",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050311","Effect of Liraglutide on Fat Distribution in Type 1 Diabetes","Stanley John Weisnagel","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.042",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050312","CP-153 Liraglutide adequacy and effectiveness in real practice type 2 diabetes therapy","J. F. Lucía","2017",null,"nonrandomized_study","article","10.1136/ejhpharm-2017-000640.152",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050313","Como tratar a obesidade associada à diabetes tipo 2?","Carina Proença","2024","Revista de Ciência Elementar","other","article","10.24927/rce2024.006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050314","Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia","Juraj Sečník","2024","Advances in Alzheimer's disease","nonrandomized_study","article","10.3233/aiad230016",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","book-chapter"],["R0050315","S1349 Glucagon-Like Peptide-1 Receptor Agonist and Pioglitazone Therapy Have Superior Mortality and Liver Outcomes for Patients With Type 2 Diabetes and a Diagnosis or at Risk for Undiagnosed Non-alcoholic Fatty Liver Disease","Benjamin Douglas Xun Liu","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000955036.53703.f0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050316","NO CHANGE IN SIGHT: THE IMPACT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ON BOWEL PREPARATION ADEQUACY FOR COLONOSCOPY","Malcolm B. Chapman","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.2919",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050317","Genomic Insights Into Incretin-based Therapeutics for Peripheral Arterial Disease","Sabina M. Sorondo","2025","Journal of Vascular Surgery","other","article","10.1016/j.jvs.2025.03.126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050318","719-P: Tirzepatide Induces Weight Loss in Patients with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies","ANITA KWAN","2022","Diabetes","randomized_trial","article","10.2337/db22-719-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050319","S740 Knowledge, Attitudes, and Practices Regarding Semaglutide Use in the US: A Nationwide Survey With Emphasis on Gastrointestinal Adverse Effects","Ujjwal P. Dutta","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130420.15367.f2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050320","Issue 30.08 focus on diabetes mellitus and cardiometabolic disorders","Géza Hálasz","2023","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwad135","37258061",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050321","EE23 Cost Utility Analysis of Once-Weekly Semaglutide and Dulaglutide for Patients With Type 2 Diabetes in Saudi Arabia","Mohamed Sayed Hassan","2023","Value in Health","other","article","10.1016/j.jval.2023.09.296",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050322","Four-month treatment with long-acting glucagon-like peptide-1 receptor agonists (GLP-1) or sodium-glucose co-trasporter-2 inhibitors (SGLT-2i) improves vascular function in type 2 diabetes mellitus","Ignatios Ikonomidis","2022","European Heart Journal","other","article","10.1093/eurheartj/ehac544.1940",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050323","Glicentin Concentrations Following Glucagon Like Peptide-1 Receptor Agonist Treatment in those with Overweight/Obesity; Open Label Trial","Wiaam Al‐Hasani","2026","Research Portal (King's College London)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0050324","Abstract 95: Glucagon Like Peptide-1 (GLP-1) Does Not Cause Vasodilation Even When Dipeptidyl Peptidase 4 (DPP4) is Inhibited","Jessica K. Devin","2013","Hypertension","randomized_trial","article","10.1161/hyp.62.suppl_1.a95",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050325","522 GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS USE IS ASSOCIATED WITH LOWER MORTALITY AND IMPROVEMENT OF CARDIOVASCULAR OUTCOMES IN PATIENTS WITH MAFLD AND OBESITY: A MULTI-CENTER ANALYSIS.","Luìs Manuel de Almieda Nieto","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)04015-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050326","Preservation of glucagon-like peptide-1 level with liraglutide and linagilptin protects against angiotensin II-induced renal fibrosis via inhibiting AT1 receptor mediated signaling pathways","Feng Bai","2020","Journal of Molecular and Cellular Cardiology","other","article","10.1016/j.yjmcc.2019.11.086",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050327","Empowerment and Motivation in Subjects with Reduced Medication Adherence and Poor Diabetes Control - A Pilot","Lone Jelstrup","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050328","GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes","Francisco Alfredo Farias Bandeira","2013",null,"other","article","10.1007/978-1-4614-8684-8_30",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050329","Editorial: Metabolic dysregulation in neurodegenerative diseases","María C. Jiménez-González","2025","Frontiers in Cellular Neuroscience","preclinical","article","10.3389/fncel.2025.1591313","40236501",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0050330","943-P: Role of Model-Informed Drug Development in Confirming Additional Clinical Benefits of Dulaglutide","Lai‐San Tham","2020","Diabetes","other_trial","article","10.2337/db20-943-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050331","The new NICE guidelines for type 2 diabetes – a critical analysis","Joseph Paul O’Hare","2015","The British Journal of Diabetes","other","article","10.15277/bjdvd.2015.006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050332","The Cardiac Glucagonlike Peptide-1 Receptor: Whither Art Thou?","Patricia Lee Brubaker","2018","Endocrinology","preclinical","article","10.1210/en.2018-00186","29509920",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050333","Abstract 10855: Cardiovascular Effectiveness of Empagliflozin Compared to Glucagon Like Peptide-1 Receptor Agonists and to Dipeptidyl Peptidase-4 Inhibitors in Older Patients: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","Phyo Than Htoo","2021","Circulation","nonrandomized_study","article","10.1161/circ.144.suppl_1.10855",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050334","A Novel Multi-Target Approach for Cardiometabolic HFpEF: Preclinical Evidence for Semaglutide and TY1 Combination Therapy","Mahmoud H. Elbatreek","2025","Journal of Molecular and Cellular Cardiology Plus","other","article","10.1016/j.jmccpl.2025.100352",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050335","S5741 Fulminant Liver Failure Linked to Tirzepatide (Mounjaro): A Case Report and Urgent Call for Vigilance","Fatma Mohamed Mahmoud","2025","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001150424.12266.b0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050336","53. Extensive DVT in a Patient on GLP-1 Receptor Agonist and Combined Oral Contraceptive: Considering a New Landscape of VTE Risk","Abigail R. Archibald","2026","Journal of Pediatric and Adolescent Gynecology","other","article","10.1016/j.jpag.2026.01.098",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050337","851-P: Are We There Yet? Increasing Use of Cardioprotective Antihyperglycemic Agents in Patients with T2D and CVD or CV Risk in the U.S.","Reema Mody","2021","Diabetes","nonrandomized_study","article","10.2337/db21-851-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050338","Epidemiology, natural history, and management of patients with CHB concurrent with MASLD","Wenjing Ni","2024","Clinical Liver Disease","nonrandomized_study","article","10.1097/cld.0000000000000171","38903875",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050339","Editorial: Therapeutic targeting of cell death in cardiovascular diseases: from mechanisms to clinical applications","Haiyan Xiang","2026","Frontiers in Cardiovascular Medicine","other_trial","article","10.3389/fcvm.2026.1885756","42755744",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0050340","EW, a novel recombinant analogue of exendin-4 expressed in Escherichia coli","Xiaoyan Wu","2011","Scientific Research and Essays","other","article","10.5897/sre10.1104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050341","Impact of GLP1-receptor agonists on diabetes after liver transplantation - A single-center experience.","Chiara Sicuro","2025","Digestive and Liver Disease","other","article","10.1016/j.dld.2025.08.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050342","To Be or Not To Be—Obese","Stuart R. Maudsley","2011","Endocrinology","randomized_trial","article","10.1210/en.2011-1615","21937750",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050343","TRIMMING THE FAT: DELABELING SEMAGLUTIDE ALLERGY","D. Mickey","2024","Annals of Allergy Asthma & Immunology","other","article","10.1016/j.anai.2024.08.544",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050344","CONTEMPORARY TREATMENT PATTERNS FOR NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS IN PATIENTS WITH AND WITHOUT CARDIOVASCULAR DISEASE","Efstratios Koutroumpakis","2020","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(20)32668-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050345","Modern views on pathogenesis of cognitive impairment in patients with type 2 diabetes mellitus","Tatiana Yu. Demidova","2024","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2024-411",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050346","PSUN124 Weight Loss from Combination Anti-Obesity Medications Including Glucagon-Like Peptide-1 Receptors Agonists can Approach that Achieved from Bariatric Surgery","Eric Morris Bomberg","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050347","Infarto del miocardio, edema maculare e fratture associate ai glitazoni: analisi del database di segnalazione spontanea FDA_AERS","Carlo Pasquale Piccinni","2010","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0050348","PDB49 Resource Use in Patients with Type 2 Diabetes (T2D) Who Initiated Exenatide BID (EXBID) or Starter Insulin (INS) Therapy: 6-Month Data from Choice","Michael J. Theodorakis","2011","Value in Health","other","article","10.1016/j.jval.2011.08.1352",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050349","PO-02-071 GLP-1RA USE IN HEART FAILURE PATIENTS IS ASSOCIATED WITH A LOWER INCIDENCE OF ATRIAL FIBRILLATION","Yara Menassa","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.462",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050350","GLP-1-Agonist verbessert Schlafapnoe bei adipösen Patienten","Alfred G. Wirth","2016","CardioVasc","other","article","10.1007/s15027-016-0959-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050351","IMPACT OF GLUCAGON-LIKE PEPTIDE-1 AGONIST USE ON THE INCIDENCE OF ATRIAL FIBRILLATION FOLLOWING HOSPITALIZATION FOR HEART FAILURE","Thomas Fretz","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01814-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050352","THU-518 Multi-displinary team initiation of GLP-1/GIP agonist Tirzepatide in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): single-centre UK study","R. B. Halley","2025","Journal of Hepatology","other","article","10.1016/s0168-8278(25)01752-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050353","62 - Once-Weekly Semaglutide Reduces HbA1c and Body Weight Across Baseline HbA1c Subgroups in the SUSTAIN 1–5 and 7–10 Clinical Trials","Oren Steen","2020","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2020.08.068",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050354","65 - Randomized Comparison of Initiating Insulin Glargine or Iglarlixi in South Asian Canadians With Type 2 Diabetes: VARIATION 2 SA Trial","HARPREET SINGH BAJAJ","2020","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2020.08.071",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050355","EP649 - ECE_2874 - Setmelanotide treatment in severe hypothalamic obesity: report of two cases","Dimitra Sinni","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.1076",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050356","A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease","Kyriaki Michailidou","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/dvr3-xw57",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0050357","Multivalent GLP‐1/Yhb for targeted therapy and imaging of pancreatic β‐cells","Kameswari Ananthakrishnan","2013","The FASEB Journal","preclinical","article","10.1096/fasebj.27.1_supplement.1154.18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050358","TREATMENT METHODS FOR OBESITY IN ADULTS: ADVANTAGES AND DISADVANTAGES – LITERATURE REVIEW","Dominika Karolak","2026","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.2(50).2026.5682",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050359","262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial","Louis J. Aronne","2024","Diabetes","randomized_trial","article","10.2337/db24-262-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050360","Glucagon-Like Peptide-1 Receptor Agonists: A New Frontier in Prostate Cancer Treatment?","Momina M. Ahmed","2025","Journal of Urologic Oncology","other","article","10.22465/juo.255000620031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050361","Semaglutide plus novel Noncoding RNA drug TY1 Exert Synergistic Benefits Against Diastolic Dysfunction in HFpEF","Mahmoud H. Elbatreek","2025","Journal of Molecular and Cellular Cardiology Plus","other","article","10.1016/j.jmccpl.2025.100329",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050362","Abstract #291: Efficacy and Safety of Liraglutide Addded to Insulin Treatment in Type 1 Diabetes, The Adjunct One Treat-Totarget Randomized Trial","Chantal Mathieu","2016","Endocrine Practice","randomized_trial","article","10.1016/s1530-891x(20)44999-7",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050363","POS1318 EFFECT OF ORAL SEMAGLUTIDE IN SERUM URATE LEVELS OF PATIENTS WITH TYPE 2 DIABETES: A REAL-WORLD RETROSPECTIVE, OBSERVATIONAL STUDY","María Rodríguez-Bedoya","2025","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1016/j.ard.2025.06.667",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0050364","Oprah and Ozempic: a commentary on Oprah Winfrey’s “shame, blame and the weight loss revolution”","Apryl A. Williams","2024","Critical Studies in Media Communication","other","article","10.1080/15295036.2024.2393755",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050365","6531 Assessing the Risk of Recurrence in Acute Pancreatitis Among Patients with Type 2 Diabetes Initiating GLP-1 Receptor Agonists Therapy","Mahmoud Nassar","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.673",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050366","Adiponectin-Anstieg, Verbesserung der glykämischen Kontrolle und Gewichtsreduktion bei Patienten mit Typ-2-Diabetes unter Langzeittherapie mit Exenatide","Oliver P. Bachmann","2008","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-2008-1076353",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050367","PDB14 Assessing Treatment Success of Diabetes Therapies - Number Needed to Treat to Reach a Clinically Relevant Composite Endpoint: Using a Meta-Analysis of the Liraglutide Clinical Trial Program","Jakob J. Langer","2012","Value in Health","systematic_review","article","10.1016/j.jval.2012.03.935",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0050368","REVISIONAL ENDOSCOPIC SLEEVE GASTROPLASTY (REDO-ESG) COMPARED TO ADJUNCTIVE PHARMACOTHERAPY WITH GLP-1 AGONISTS ON WEIGHT LOSS FOLLOWING PRIMARY ENDOSCOPIC BARIATRIC THERAPY","Leah N. Kim","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.783",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050369","674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD","Victoria Parker","2021","Diabetes","randomized_trial","article","10.2337/db21-674-p",null,null,"ClinicalTrials.gov:NCT03550378","S002039","openalex","FALSE","paywalled","1","FALSE","article"],["R0050370","Newer glucose-lowering drugs at discharge from cardiology hospitalization department: safetyness, effectiveness and mortality reduction","José Rozado","2020","European Heart Journal","nonrandomized_study","article","10.1093/ehjci/ehaa946.3349",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050371","S3884 Reflux Colitis: A Rare Complication Following Colonic Interposition","Sudiksha Veerareddy","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001142996.76816.4e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050372","The Cardiovascular Effects of Peptidase Inhibition","Nancy Jeanne Brown","2018","Proceedings for Annual Meeting of The Japanese Pharmacological Society","other","article","10.1254/jpssuppl.wcp2018.0_pl-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050373","Stratifying Patient Risk for eGFR Decline Over a Year","Zahra Mahmoodzadeh","2022","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20223311s1583c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050374","Cardiovascular disease risk stratification in type 2 diabetes","Harriet Esdaile","2022","Diabetic Medicine","nonrandomized_study","article","10.1111/dme.14922","35892178",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050375","Exenatide Attenuation of Cardiac Rhythm Abnormalities and Blood Pressure Changes Induced by Doxorubicin in Rats","Nancy S. Younis","2017","International Journal of Pharmacology","preclinical","article","10.3923/ijp.2017.1098.1102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050376","1884-LB: Real-World Impact of Once-Weekly Injectable Semaglutide (sema OW) vs. Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Health Care Resource Utilization (HCRU) Outcomes in Type 2 Diabetes (T2D)—An Observational Study (PAUSE)","James J. Amamoo","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1884-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050377","737-P: Acute Healthcare Utilization, Mortality, and Cardiovascular Events following GLP-1-RA Initiation by Patients with Advanced Chronic Kidney Disease—A Real-World Comparative Study","SHUYAO ZHANG","2024","Diabetes","nonrandomized_study","article","10.2337/db24-737-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050378","Dual Benefits of Tirzepatide: Anti-Obesity and Antidiabetic Efficacy: A Mini review","Praveen SV","2024","World Journal of Current Medical and Pharmaceutical Research","narrative_review","article","10.37022/wjcmpr.v6i3.342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050379","SAT-408 Effectiveness of bariatric surgery versus glucagon-like peptide-1 receptor agonists for prevention of adverse cardiovascular outcomes among patients with metabolic dysfunction-associated steatotic liver disease, diabetes, and obesity","Arunkumar Krishnan","2025","Journal of Hepatology","other","article","10.1016/s0168-8278(25)01675-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050380","A Causal Roadmap for Hybrid Randomized and Real-World Data Designs: Case Study of Semaglutide and Cardiovascular Outcomes","Lauren Eyler Dang","2023","arXiv (Cornell University)","randomized_trial","article","10.48550/arxiv.2305.07647",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0050381","Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial","John B. Buse","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/ap66-xf68",null,null,"ClinicalTrials.gov:NCT01952145","S001328","openalex","TRUE","paywalled","1","FALSE","article"],["R0050382","Effects of a combinatory treatment with semaglutide and a NPY Y2 receptor selective PYY 3-36 analogue in diet-induced obese rats: surpassing bariatric surgery?","Marie Oertel","2023","Endocrine Abstracts","preclinical","article","10.1530/endoabs.90.p326",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050383","Ideglira Versus other Intensification Strategies In Patients With Type 2 Diabetes Inadequately Controlled on Basal Insulin – An Indirect Statistical Comparison","Nick Freemantle","2015","Value in Health","other","article","10.1016/j.jval.2015.03.318",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050384","YH25724, a novel long-acting GLP-1/FGF21 dual agonist improves hepatic steatosis, inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) animal models","Jun Hwan Kim","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050385","Additional file 3: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Ling Li","2016","Figshare","systematic_review","article","10.6084/m9.figshare.4430678.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0050386","1970-LB: Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice","Timothy J. Kieffer","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1970-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050387","64 - Real-World Use of Once-Weekly Semaglutide in Patients With Type 2 Diabetes: Results From SURE Canada","Jean‐François Yale","2020","Canadian Journal of Diabetes","nonrandomized_study","article","10.1016/j.jcjd.2020.08.070",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050388","OR10-05 Improved Mental And Psychosocial Patient-Reported Outcomes Among People With Obesity Treated With Tirzepatide: Results From SURMOUNT-1 Study","Jiat Ling Poon","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.011",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0050389","GLP-1 medications versus surgery and balloon: evaluating cost-benefit in weight loss","Carlos Israel Verdugo Salazar","2025","International Surgery Journal","other","article","10.18203/2349-2902.isj20251200",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050390","Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus","Andrey E. Bagriy","2021","Russian Journal of Gastroenterology Hepatology Coloproctology","other","article","10.22416/1382-4376-2021-31-2-14-26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050391","V08-10 A CASE OF CONCURRENT RADICAL CYSTECTOMY AND ABDOMINOPLASTY: A PATIENT-CENTERED APPROACH","Prachi Khanna","2024","The Journal of Urology","case_report","article","10.1097/01.ju.0001009440.59296.9f.10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050392","The DPP4 Inhibitor Sitagliptin Increases Active GLP-1 Levels from Human Islets and May Increase Islet Cell Survival Prior to Transplantation","Scott A. Campbell","2019","OBM Transplantation","other","article","10.21926/obm.transplant.1902069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050393","SUN-178 A Not So \"Sweet\" DKA: A Case of Euglycemic Diabetic Ketoacidosis Caused by Dapagliflozin/Liraglutide Combination","Aristea Sideri Gugger","2019","Journal of the Endocrine Society","case_report","article","10.1210/js.2019-sun-178",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050394","857-P: Real-World Impact of Once-Weekly Injectable Semaglutide on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes—An Observational Study (PAUSE)","James J. Amamoo","2024","Diabetes","nonrandomized_study","article","10.2337/db24-857-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050395","2431-PUB: Distance from Glycemic Target at the Time of Intensification in Patients with Type 2 Diabetes (T2D) Failing Metformin Dual Therapy in the United States","Gail F. Fernandes","2019","Diabetes","nonrandomized_study","article","10.2337/db19-2431-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050396","MON-150 Restoration of Fertility in Polycystic Ovarian Syndrome with Glucagon-Like Peptide-1 Therapy","Daniel G. Fraser","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1887",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050397","Debate continues over safety of incretin mimetics","Lesley Erica Scott","2013","Reactions Weekly","other","article","10.1007/s40278-013-4523-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050398","GLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?","Grazia Piras","2026","Diabetology","randomized_trial","article","10.3390/diabetology7030050",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050399","839-P: Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial","Lixin Guo","2025","Diabetes","randomized_trial","article","10.2337/db25-839-p",null,null,"ClinicalTrials.gov:NCT06739044","S001349","openalex","FALSE","paywalled","1","FALSE","article"],["R0050400","1321-OR: Superior Quality of Weight Loss with a Novel Unimolecular Tetra-Agonist Peptide Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors vs. Tirzepatide and Cagrisema in Diet-Induced Obese Rats","Soumitra S. Ghosh","2026","Diabetes","preclinical","article","10.2337/db26-1321-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050401","Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)","Swaroop H Suresh","2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.342310",null,null,"ClinicalTrials.gov:NCT03548935","S000144","openalex","TRUE","free_to_read","1","FALSE","conference-abstract"],["R0050402","GLP-1 Receptor Agonist Use and Kidney Outcomes in Patients with Cancer and Type 2 Diabetes: Real-World Global Matched Cohort Analysis","Fayaz Aijaz Ahmed Khan","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025cqzf6qh7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050403","101-OR: Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial","Juan P. Frías","2021","Diabetes","randomized_trial","article","10.2337/db21-101-or",null,null,"ClinicalTrials.gov:NCT03989232","S001353","openalex","FALSE","paywalled","1","FALSE","article"],["R0050404","737 DIFFERENTIAL EFFECTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ON LIVER PHENOTYPES BASED ON PNPLA3 GENOTYPE","Esteban Urias","2023","Gastroenterology","other","article","10.1016/s0016-5085(23)03938-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050405","Effects of exenatide on glycemia and renal water and ion excretion differ in frogs and rats","Анна Вячеславовна Кутина","2016","Journal of Evolutionary Biochemistry and Physiology","preclinical","article","10.1134/s0022093016030054",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050406","Case report - success story of GLP-1 agonist (liraglutide) treatment in someone with type 1 diabetes: A life transformed","Adrian Hugh Heald","2023","Endocrine Abstracts","case_report","article","10.1530/endoabs.94.p230",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050407","1195-P: Metformin and Growth Differentiation Factor 15 (GDF-15) in Youth with Type 2 Diabetes","Samantha T. Matta","2021","Diabetes","other","article","10.2337/db21-1195-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050408","Relative Contribution of Basal and Postprandial Hyperglycemia Stratified by A1C Categories Before and After Treatment Intensification with Dulaglutide","Guillermo E. Umpierrez","2018","Diabetes","other_trial","article","10.2337/db18-1068-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050409","An antiinflammatory actions of exenatide","Svetlana Yu. Vorotnikova","2012","Obesity and metabolism","other","article","10.14341/2071-8713-5131",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050410","New analyses of pancreatitis risk with incretin-based therapies","Charles Wayne Weart","2014","Pharmacy Today","other","article","10.1016/s1042-0991(15)30773-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050411","Glucagon-like peptide-1 receptor agonist versus basal insulin in type-2 diabetic patients: An efficacy and safety analysis","Kaiping Lin","2020","Tropical Journal of Pharmaceutical Research","nonrandomized_study","article","10.4314/tjpr.v19i10.27",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050412","1000-P: Efficacy and Safety of Semaglutide 0.5 mg vs. Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 7","Richard E. Pratley","2019","Diabetes","randomized_trial","article","10.2337/db19-1000-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050413","Kann der zu erwartende therapeutische Effekt von Inkretinanaloga im Einzelfall vorausgesagt werden?","E Salzsieder","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1253805",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050414","Diabetes/Weight Loss Drug Associated With Risk for Type of Optic Neuropathy","Susan F. FitzGerald","2024","Neurology Today","other","article","10.1097/01.nt.0001050484.50871.d5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050415","2206-LB: Weight Conversations—Examining Clinicians' Approaches to Discussing Weight during Routine Diabetes Care","JUSTIN A. DOWER","2025","Diabetes","randomized_trial","article","10.2337/db25-2206-lb",null,null,"ClinicalTrials.gov:NCT05553912",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050416","Cardiorenal Benefit of Tirzepatide in Type 1 Diabetes: A Case Report","Khalid Ahmed","2024","Journal of Diabetology","case_report","article","10.4103/jod.jod_97_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050417","Real‐world observations of using compounded GLP ‐1 ± GIP agonists within a clinical pharmacist‐managed cardiometabolic clinic","Shannon W. Finks","2025","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","nonrandomized_study","article","10.1002/jac5.2071",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050418","Liraglutide 3.0 mg Reduces Severity of Obstructive Sleep Apnea and Body Weight in Individuals with Obesity and Moderate or Severe Disease: SCALE Sleep Apnoea Trial","Adam Blackman","2015","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2015.01.139",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050419","FRI-421 GLP-1 agonist lowers portal pressure by modulating hepatic vascular tone in a toxin-induced cirrhotic rat model","María Andrés‐Rozas","2026","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(26)00677-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050420","Additional file 1 of Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial–based analysis using NHANES (1988–2018) cycles","Mustafa Al-Jarshawi","2026","Figshare","other_trial","article","10.6084/m9.figshare.32353983.v1",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0050421","Tirzepatide Improves Metabolic Health but Is Associated With Hepatic Tumor Development in Aged Mice With Triple-Negative Breast Cancer","Evan M. Paules","2026","Current Developments in Nutrition","preclinical","article","10.1016/j.cdnut.2026.107732",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050422","THE CKM SYNDROME PARADIGM: A UNIFIED APPROACH TO PATHOPHYSIOLOGY, CLINICAL STAGING, AND MULTI-ORGAN PROTECTION","Azim Jamil ugli Odilov","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.20841791",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0050423","Use of gastric ultrasound to identify GLP-1RA users at high risk of aspiration during surgery","Alessandra T. Ayers","2025","Perioperative Care and Operating Room Management","other","article","10.1016/j.pcorm.2025.100562",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050424","Advances in GLP-1 receptor agonists: Molecular mechanisms, drug delivery innovations, formulation strategies, and emerging therapeutic applications","Ravikanth Geddam","2026","Obesity Medicine","other","article","10.1016/j.obmed.2026.100721",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050425","1679-P: Islet Autoimmunity in Adults with Impaired Glucose Tolerance (IGT) and Newly Diagnosed, Treatment-Naïve Type 2 Diabetes (NDX T2D) in the Restoring Insulin Secretion (RISE) Study","Barbara Brooks‐Worrell","2020","Diabetes","other","article","10.2337/db20-1679-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050426","POTENTIAL UNREALIZED CARDIOVASCULAR BENEFIT OF NOVEL DIABETES AGENTS IN THE VETERANS HEALTH ADMINISTRATION SYSTEM: INSIGHT FROM THE CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM","Taufiq Salahuddin","2020","Journal of the American College of Cardiology","randomized_trial","article","10.1016/s0735-1097(20)32463-3",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0050427","TỔNG QUAN HỆ THỐNG VỀ HIỆU QUẢ VÀ AN TOÀN CỦA SEMAGLUTIDE TIÊM DƯỚI DA TRONG ĐIỀU TRỊ ĐÁI THÁO ĐƯỜNG TÍP 2 KÈM BÉO PHÌ","Nguyễn Đức Duy","2026","Tạp chí Y học Cộng đồng","other","article","10.52163/yhc.v67icd8.5720",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050428","Impact of Once-Weekly Semaglutide on eGFR and Hemoglobin A1c (HbA1c) among Patients with Type 2 Diabetes and CKD: An Observational Study","James J. Amamoo","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024zeyxkd1g",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050429","Su2065: COMPARATIVE REAL-WORLD ANALYSIS OF WEIGHT LOSS OUTCOMES AND SIDE EFFECT PROFILES BETWEEN SEMAGLUTIDE AND TIRZEPATIDE: A MULTICENTERED STUDY","Wissam Ghusn","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03117-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050430","Influence du liraglutide (analogue du GLP-1) sur les caractéristiques hédoniques de la prise alimentaire et les performances gustatives, chez les patients diabétiques de type 2","Sophie Meillon","2011","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050431","Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials","Chuanjun Zhuo","2020",null,"systematic_review","article","10.37766/inplasy2020.8.0122",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0050432","Comparative study of the hypoglycemic and cardioprotective effects of glucagon-like peptide-1 receptors agonist exenatide, insulin and their combined use in myocardial ischemia/reperfusion injury in rats with experimental type 2 diabetes","Valery A. Zykov","2023","Regional blood circulation and microcirculation","preclinical","article","10.24884/1682-6655-2023-22-2-51-57",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050433","The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis","Davut Sakız","2022","Van Medical Journal","other","article","10.5505/vtd.2022.09815",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050434","Type-2 diabetes patients at high risk for cardiovascular events: time to challenge the ‘metformin-always first’ paradigm","Victor Aboyans","2021","European Journal of Preventive Cardiology","other_trial","article","10.1093/eurjpc/zwaa157","33580794",null,null,null,"openalex","FALSE","paywalled","5","FALSE","editorial"],["R0050435","Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials","Huilin Tang","2022",null,"systematic_review","article","10.2337/figshare.18057245",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0050436","Parkinson’s Disease, Diabetes and Cognitive Impairment","Marios Politis","2016","Recent Patents on Endocrine Metabolic & Immune Drug Discovery","nonrandomized_study","article","10.2174/1872214810666160630191119",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050437","Dipeptidyl Peptidase-4 Inhibitors and the Management of Hyperglycemia","Pamela M. Katz","2009","US Endocrinology","other_trial","article","10.17925/use.2009.05.1.63",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050438","Protective effect of exenatide (glucagon-like peptide-1 receptor agonist) on renal ischemia–reperfusion injury in diabetic rats","Mona A. Said","2020","Benha Medical Journal","preclinical","article","10.21608/bmfj.2015.69075",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050439","New once‐weekly formulation of exenatide for type 2 diabetes","Jason Seewoodhary","2010","Future Prescriber","other","article","10.1002/fps.71",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050440","Ageing liver in the era of MASLD: risks, mechanisms and treatment opportunities","Saleh A. Alqahtani","2026","Frontline Gastroenterology","other","article","10.1136/flgastro-2026-103677",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050441","Clinical impact of GLP-1 receptor agonist use on lung cancer incidence in high-risk patients: A real-world analysis.","Ariana N. Neely","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.10559",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050442","Treatment with Liraglutide, a Once-Daily Human GLP-1 Analog, for 52 Weeks Reduces Weight and Waist Circumference: A Randomized Placebo-Controlled Trial","Arne Vernon Astrup","2009","UCL Discovery (University College London)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0050443","Phenome-Wide Association Study of Common Genetic Variants in the DPP4 Gene and GLP1R Gene and Kidney Outcomes of European Ancestry Individuals in the Million Veteran Program (MVP)","Jefferson L. Triozzi","2022","Journal of the American Society of Nephrology","other","article","10.1681/asn.20223311s1117b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050444","Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists","Nour Ghostine","2026","JEADV Clinical Practice","randomized_trial","article","10.1002/jvc2.70266",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050445","S2740 Impact of Glucagon-Like Peptide-1 (GLP-1) Analogues Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation","Muhammad Saad Faisal","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001138420.47997.52",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050446","Real-World Effect of GLP-1 Receptor Agonist Initiation on Body Composition and Blood Pressure: A Distributional Causal Inference Analysis of Connected Device Data","Agathe Chabassier","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6246929",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0050447","Disparities in access of GLP-1 receptor agonists in cancer patients with obesity or type 2 diabetes: A cascade-of-care analysis across the semaglutide shortage timeline.","Omer Sayed Ashruf","2025","JCO Oncology Practice","nonrandomized_study","article","10.1200/op.2025.21.10_suppl.193",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050448","S866 The Impact of GLP-1 Receptor Agonists on Bowel Preparation for Colonoscopy","Akash Rajendrakumar Patel","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032832.86860.c8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050449","Abstract 4351008: Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies","Xi Tan","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4351008",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050450","Liraglutide (Saxenda®) as a Treatment for Obesity","Erin St. Onge","2016","Food and Nutrition Sciences","other","article","10.4236/fns.2016.74024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050451","1660-P: Efficacy and Safety of Tirzepatide for the Treatment of Obesity in Adults with Type 1 Diabetes—The Mayo Clinic Experience","Elif Tama","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1660-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050452","One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks discontinuation of treatment","Mathijs C. M. Bunck","2009","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050453","GLP-1 Receptor Agonist-Associated Minimal Change Disease: Emerging Adverse Effect?","Hussein Tahanulqiwa","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025wn3gee9r",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050454","800-P: Post Hoc Analysis of Phase III Study of Liraglutide Biosimilar with Reference Biologic in Obese Type 2 Diabetes Mellitus Indians","Shashank Joshi","2024","Diabetes","other_trial","article","10.2337/db24-800-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050455","Cognitive deficits in depressive disorder","Ruhui Geng","2023","Theoretical and Natural Science","other","article","10.54254/2753-8818/8/20240379",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050456","EE174 Evaluating the Budget Impact of the Co-Existence of Oral and Injectable Forms of Semaglutide in the Saudi Public Healthcare System","Mohammed Alluhidan","2023","Value in Health","other","article","10.1016/j.jval.2023.09.443",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050457","Efficacy of liraglutide in pediatric obesity: A review of clinical trial data","Marcello Agosta","2024","Obesity Medicine","other_trial","article","10.1016/j.obmed.2024.100545",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0050458","ASSOCIAÇÃO ENTRE BALÃO INTRAGÁSTRICO AJUSTÁVEL E TERAPIAS COM PEPTÍDEOS: EFEITOS NA PERDA DE PESO E DESFECHOS METABÓLICOS – REVISÃO SISTEMÁTICA E METANÁLISE","Bruno Sander","2026","Revista Científica Ipedss","randomized_trial","article","10.55703/27644006060402",null,null,null,null,"openalex","FALSE","open_pdf","2","FALSE","article"],["R0050459","Abstract 4345917: Trends in Atherosclerotic Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus: An Insurance Claims-Based Review","Andrea Caudill","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4345917",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050460","S2788 Colon Metastasis From Pancreatic Adenocarcinoma: A Diagnostic Challenge Resembling GLP-1 Receptor Agonist Effects","S Feldman","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001040520.59704.5a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050461","26-A-21545-ACC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION IN PATIENTS WITH OBESITY AND TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Bijay Mukesh Jeswani","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.1943",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0050462","Abstract P1072: Underutilization of Novel Guideline-Directed Medical Therapy in Patients with Heart Failure","Deepika Laddu","2025","Circulation","nonrandomized_study","article","10.1161/cir.151.suppl_1.p1072",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050463","Tu1610 IMPACT OF GLP-1 RECEPTOR AGONIST USE ON EXTRA-INTESTINAL AND INFECTIOUS OUTCOMES IN ULCERATIVE COLITIS: A PROPENSITYMATCHED COHORT STUDY","Junaid Ali Khan","2026","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/s0016-5107(26)03228-1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050464","Systematic review and meta-analysis of glucagon-like peptide 1 receptor agonists (GLP1-RAs) safety and efficacy in patients with inflammatory bowel disease","Omar Kherad","2026","Frontline Gastroenterology","systematic_review","article","10.1136/flgastro-2026-103640",null,null,"PROSPERO:CRD420261350546",null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0050465","Diabetic nephropathy: what should cardiologist remember","Natalia Trubitsyna","2021","Consilium Medicum","other","article","10.26442/20751753.2021.1.200712",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050466","58. Blood Pressure Reduction Effect of Dapagliflozin in Patients with Type 2 Diabetes Mellitus: a Systematic Review","Jonathan Vincent Lee","2023","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0000935612.24932.1d",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0050467","Glucagon-like peptide-1 receptor agonist initiation and subsequent risk of gallbladder and biliary tract cancers in type 2 diabetes","Anna Homeniuk","2026","Journal of Medicine Surgery and Public Health","randomized_trial","article","10.1016/j.glmedi.2026.100234",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0050468","IP38-23 GLP-1 RECEPTOR AGONISTS REDUCE MORTALITY AND HOSPITALIZATION IN DIABETIC PATIENTS WITH UROLOGIC MALIGNANCIES: A RETROSPECTIVE COHORT STUDY","Mahan Najhawan","2026","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001191508.89690.7a.23",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050469","Lixisenatide—Once-daily Glucagon-like Peptide-1 Receptor Agonist in the Management of Type 2 Diabetes","Celeste C.L. Quianzon","2011","US Endocrinology","other","article","10.17925/use.2011.07.02.104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050470","SUN-176 Euglycemic Diabetic Ketoacidosis withSGLT2 Inhibitor Presenting as Chest Pain in a Patient with Coronary Artery Disease on a Ketogenic Diet","Brenda Dorcely","2019","Journal of the Endocrine Society","other","article","10.1210/js.2019-sun-176",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050471","892-P: Potential for New Oral Insulin Sensitizers in Combination with GLP-1 Agonists","JERRY R. COLCA","2024","Diabetes","other_trial","article","10.2337/db24-892-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050472","Abstract 4140660: Clinical Outcomes of GLP-1 RA in Heart Failure with CKD patients: A TriNetX Based Global Study","Muhammad Touqeer Hanif","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4140660",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050473","Semaglutide Improves Cardiovascular Outcomes in Patients With High Risk for Metabolic Dysfunction-associated Steatohepatitis – A Subgroup Analysis From the SELECT Trial","Michael A. Tsoukas","2024","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2024.09.118",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050474","GLP-1 Receptor Agonists Reduce All-Cause Mortality and Non-Fatal Myocardial Infarction in Overweight and Obese Adults Without Diabetes Mellitus: Results of a Systematic Review and Meta-Analysis","Wanxiang Yao","2025","Heart Lung and Circulation","systematic_review","article","10.1016/j.hlc.2025.06.872",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0050475","Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)","Adrian F. Hernandez","2018","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050476","INSIGHT INTO PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS AND THERAPEUTIC ROLE OF GLP-1 AND SGLT INHIBITORS: A SYSTEMATIC REVIEW","Muhammad Uzair","2025","Insights-Journal of Health and Rehabilitation","systematic_review","article","10.71000/mph7kz17",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0050477","Sonar-AI discovers first comprehensively described cases of GLP-1 receptor agonist associated thrombocytopenia: Faster, cheaper, and better than the 20th century approach of RADAR/sonar","Mia Lynch","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-6581",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050478","PDB67 - ONCE-WEEKLY SEMAGLUTIDE VERSUS DULAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM COST-EFFECTIVENESS ANALYSIS BASED ON SUSTAIN 7","Samuel J. P. Malkin","2018","Value in Health","other","article","10.1016/j.jval.2018.09.772",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050479","Patient-Reported Outcomes (PROs) for Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial","Meryl I. Brod","2018","Diabetes","randomized_trial","article","10.2337/db18-101-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050480","Effects of IDegLira (Insulin Degludec/Liraglutide) in Patients with Poorly Controlled Type 2 Diabetes (T2D) with A1C >9%—Analyses from the DUAL Program","Danny H. Sugimoto","2018","Diabetes","other_trial","article","10.2337/db18-1092-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050481","ODP383 Clinical Presentation and Management of Diabetes Mellitus in Youth with Prader-Willi Syndrome","Emily L. Paprocki","2022","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvac150.1248",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050482","Exploring the mechanistic pathways of promising bioflavonoid Quercetin in diabetes management","Sujatha Kuppusamy","2024","Natural Resources for Human Health","other","article","10.53365/nrfhh/191951",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050483","A Novel Anti-Inflammatory Renoprotective Effect of GLP-1 Receptor Agonists in Type 1 Diabetes: Shifting Macrophage Polarization","Natalie Youssef","2021","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20213210s1237c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050484","Behavioural symptoms in Alzheimer’s disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism","Grazia Daniela Femminella","2020","Alzheimer s & Dementia","other_trial","article","10.1002/alz.045223",null,null,"ClinicalTrials.gov:NCT01843075","S000689","openalex","FALSE","paywalled","5","FALSE","article"],["R0050485","PDB14 Cost-Effectiveness of Liraglutide Versus Exenatide, BOTH in Combination with Metformin for Patients with Type 2 Diabetes in China","Hongchao Li","2020","Value in Health Regional Issues","other","article","10.1016/j.vhri.2020.07.173",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050486","Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-Diabetes trial","Alana Washington","2026","UNC Libraries","other_trial","article","10.17615/12y8-v516",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0050487","S806 Comparative Effectiveness of Transoral Outlet Reduction (TORe) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Post-Bariatric Weight Regain: A Real-World Study","ali h. osman","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130684.68009.47",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050488","Exploring the unmet needs of cardiometabolic risk factors and medicines optimisation among post-myocardial infarction patients with diabetes","Saeed M. Al-Asmary","2025","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwaf236.241",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050489","S1849 Watch out for Semaglutide: Potential Cause of Pancreatitis?","Femina S. Patel","2022","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000864036.15004.08",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050490","Semaglutid – ein neuer langwirksamer GLP-1-Rezeptor-Agonist mit nachgewiesener kardiovaskulärer Ereignisreduktion bei Typ-2-Diabetes","Jochen Seufert","2018","Diabetes aktuell","other","article","10.1055/a-0645-5727",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050491","Role of obesity-management medications before and after metabolic bariatric surgery: a systematic review","RICARDO VITOR COHEN","2024","British journal of surgery","systematic_review","article","10.1093/bjs/znae284","39612581",null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0050492","Type 2 diabetes in youth: Rationale for use of off‐label antidiabetic agents","Megan Moriarty Kelsey","2022","Pediatric Diabetes","other","article","10.1111/pedi.13350","35524343",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050493","Abstract 077: Semaglutide Attenuates High-Fat Diet-Induced Hypertension in Dahl Salt-Sensitive Rats","Adam A Lauver","2025","Hypertension","preclinical","article","10.1161/hyp.82.suppl_1.077",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050494","1858-LB: A Novel GLP-1 Analog, GZR18, Induced an 18.6% Weight Reduction in Subjects with Obesity in a Phase Ib/IIa Trial","Linong Ji","2024","Diabetes","randomized_trial","article","10.2337/db24-1858-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050495","Treatment of Obesity with GLP-1 Receptor Agonists - An Outcome Mapping Review","Anica Lara Bošnjak","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20074060",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0050496","Nicht-Diabetes-assoziierte Hypoglykämien","Gerlies M. Treiber","2020","Journal für Klinische Endokrinologie und Stoffwechsel","other","article","10.1007/s41969-020-00124-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050497","WED-140 AI based cell free DNA methylation blood test for semaglutide response in patients with at-risk MASH: Results from SAMARA randomized control trial","Rohit Seth Loomba","2026","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(26)01682-x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050498","Fertility-Sparing Practices in Uterine Malignancies: A Literature Review","Ravali A. Reddy","2025","Journal of Gynecologic Surgery","narrative_review","article","10.1177/10424067251384464",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050499","The dual GLP‐1/GIP receptor agonist DA4‐JC shows superior protective properties in the APP/PS1 mouse model of Alzheimer’s disease","Mark Peter Maskery","2020","Alzheimer s & Dementia","preclinical","article","10.1002/alz.039220",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050500","A GlP 1 analog improves the prognosis of type 2 diabetes with and without vascular disease. The ReWinD trial","Jorge M. Thierer","2019",null,"other_trial","article","10.7775/rac.v87.i4.15889",null,null,null,null,"openalex","FALSE","open_pdf","5","FALSE","article"],["R0050501","6488 Factors associated with the response to SGLT2 inhibitors and GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes","Sulman Hashmi","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.772",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050502","PO34 Efficacité et tolérance du liraglutide par rapport au placebo en association au traitement antidiabétique existant chez des patients diabétiques de type 2 avec une insuffisance rénale modérée (LIRA-RENAL)","Amira Bouzidi","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30111-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050503","Semaglutide exhibits antihyperalgesic effects in an animal model of chronic migraine","Katarina Sićović","2024","Neuroscience Applied","other","article","10.1016/j.nsa.2024.104004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050504","EP502 - ECE_3251 - Deficient glucagon like peptide-1 (GLP-1) secretion following oral glucose stimulation as a metabolic trait in insulin resistant polycystic ovarian syndrome (PCOS) patients: A case control study","Ayan Roy","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.993",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0050505","Insulin Glargine Compared with Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) or SGLT2 Inhibitors Is Associated with Higher Risk of Alzheimer Disease and Alzheimer Disease-Related Dementias (AD/ADRD) in CKD","Amara Sarwal","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024295x7sw8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050506","Abstract 4343615: Improvements in Cardiometabolic Risk Factors by Body Weight Reduction with Tirzepatide in Adults with Obesity and Prediabetes: A Post Hoc Analysis of the 3-year SURMOUNT-1 study","Luke Joseph Laffin","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4343615",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050507","6494 GLP-1/GIP/Glucagon Triagonist Improves Glycemic Control via Gαq Signaling Pathway and TRPM5 Activation","N. Khajavi","2024","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvae163.787",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050508","Efficacy of anti-obesity agents: a systematic review and network meta-analysis of randomized controlled trials","Nishant Babubhai Prajapati","2023","PERSPECTIVES IN MEDICAL RESEARCH","systematic_review","article","10.47799/pimr.1103.03",null,null,"PROSPERO:CRD42023465989",null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0050509","Abstract #290: Efficacy and Safety of Once-Weekly Semaglutide Vs Once-Daily Insulin Glargine in Insulin-NAÏVE Subjects with Type 2 Diabetes (Sustain 4)","Vanita R. Aroda","2016","Endocrine Practice","other","article","10.1016/s1530-891x(20)44998-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050510","GLP-1 receptor agonists in Parkinson’s disease progression: A systematic review and meta-analysis with trial sequential analysis","Wen-Wen Tsai","2024",null,"systematic_review","article","10.37766/inplasy2024.11.0119",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0050511","Effect of Semaglutide Add-on to Metformin on Visceral Adiposity Index and Markers of Visceral Adipose Tissue Activity in Type 2 Diabetic Patients","Abid Shaheer","2025","Biomedical & Pharmacology Journal","other","article","10.13005/bpj/3192",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050512","Combination Therapy Using Sodium-Glucose CoTransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Type 2 Diabetes","Nasser E. Mikhail","2020","Archives of Diabetes & Obesity","randomized_trial","article","10.32474/ado.2020.02.000149",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050513","EPH7 COMPARATIVE RISK OF PSYCHIATRIC OUTCOMES WITH GLP-1RAS ACROSS METABOLIC INDICATIONS: A POPULATION-BASED RETROSPECTIVE COHORT STUDY","Julia Liaw","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.840",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0050514","Response to Letter to the Editor From Banerjee and Mondal: “Management of Hyperglycemia in Hospitalized Adult Patients in Noncritical Care Settings: An Endocrine Society Clinical Practice Guideline”","Mary T. Korytkowski","2022","The Journal of Clinical Endocrinology & Metabolism","commentary","article","10.1210/clinem/dgac479","35962778",null,null,null,"openalex","TRUE",null,null,"FALSE","letter"],["R0050515","Diabetes mellitus und Herz","Katharina Marx-Schütt","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2312-0523",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050516","Sanofi exits diabetes, heart research","LISA M. JARVIS","2019","C&EN Global Enterprise","other","article","10.1021/cen-09748-buscon2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0050517","Abstract 4145147: Prescription of Sodium-glucose cotransporter-2 inhibitors and Glucagon-like peptide-1 receptor agonists among Veterans with diabetes and cardiovascular disease","Fatima Qaisrani","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4145147",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050518","EE178 CEA of Once-Weekly Subcutaneous Semaglutide Versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China","R Zhen","2022","Value in Health","other","article","10.1016/j.jval.2022.04.427",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050519","Successful Utilization of the GLP-1 Receptor Agonist Semaglutide in Treating the Manifestations of Recalcitrant Celiac Disease","David S.H. Bell","2025","Archives of Clinical and Biomedical Research","other","article","10.26502/acbr.50170480",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050520","Miméticos do “glucagon-like peptide-1” (GLP-1) e o seu potencial farmacêutico no controlo da diabetes tipo 2 e da obesidade","Tatiana Andreani","2009","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050521","Diabetes in the time of HIV","Jyothi Mariam Idiculla","2012","Indian Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/2230-8210.98052","22837951",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050522","MSR20 Reasons for Discontinuation of Ozempic Using a Natural Language Processing Pipeline on Unstructured Clinical Notes","V. Kumar","2024","Value in Health","other","article","10.1016/j.jval.2024.10.2254",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050523","Abstract WP278: Trends in GLP1RA and SGLT2i Use in Ischemic Stroke Patients With Diabetes","Matthew R Yanus","2024","Stroke","nonrandomized_study","article","10.1161/str.55.suppl_1.wp278",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050524","COMPARING PRESCRIPTION TRENDS FOR ORAL AND SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RA) IN THE UNITED STATES","Rishav Adhikari","2023","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(23)02312-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050525","183-LB: High Daily Doses of Insulin in Type 2 Diabetes—Predictors beyond Weight","JAVIER DURON TABORA","2022","Diabetes","nonrandomized_study","article","10.2337/db22-183-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050526","9189 Medullary Thyroid Cancer Due To A Novel Ret Oncogene Mutation In A Patient On Glp-1 Receptor Agonist","Kimberly D. Lamar","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.1999",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050527","S818 Nationwide Trends in GLP-1 Use: Examining Indications, Sociodemographics, and Cost Burden Using MEPS (2018-2022)","Erika Tsuchiyose","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130732.54979.85",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050528","Tirzepatide: Pillar of Diabetic Kidney Disease Therapy or Wrecking Ball?","Ashley Linder","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025v44bgybc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050529","Tirzepatide vs Semaglutide in Participants with Prediabetes: A Post Hoc Analysis of SURMOUNT-5","A Tönjes","2026","Diabetologie und Stoffwechsel","other","article","10.1055/s-0046-1819881",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050530","Early Clinical Benefit of Semaglutide in Adults with Overweight or Obesity and Cardiovascular Disease: A Secondary Analysis of the SELECT Trial","S Jacob","2026","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0046-1819888",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0050531","Practice Recommendations for Perioperative Management of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 RAs: A Scoping Review Protocol","Wei Ming Wilfred Lim","2026",null,"protocol","article","10.17605/osf.io/75tgx",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0050532","A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy","Filip Krag Knop","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785380",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050533","Effects of GLP‐1 receptor agonist on Ca2+ handling in coronary smooth muscle cells from metabolic syndrome Ossabaw swine with coronary artery disease","Mikaela McKenney","2013","The FASEB Journal","other","article","10.1096/fasebj.27.1_supplement.1195.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050534","349 – Baseline Glp-1 Level Correlates with Degree of Weight Reduction in Participants Treated with Liraglutide 3.0Mg","Houssam Halawi","2019","Gastroenterology","other","article","10.1016/s0016-5085(19)36961-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050535","GLP-1 Receptor Agonists in Pediatric Obesity: Evidence, Knowledge Gaps, and Clinical Implications","Amanda Dolores Abramowicz","2026","Archiv Euromedica","randomized_trial","article","10.35630/2026/16/iss.2.8",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050536","Su1638: ASSESSING THE EFFECTS OF GLP-1 RECEPTOR AGONISTS ON LONG-TERM OUTCOMES IN DIABETIC PATIENTS WITH ALCOHOLIC CIRRHOSIS: A RETROSPECTIVE COHORT STUDY","Laith  D. Alomari","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)02826-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050537","Renal Effects of Empagliflozin Alone or in Combination with Semaglutide in Albuminuric Type 2 Diabetes: A Randomized, Placebo-Controlled Trial","Frederik Persson","2023","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20233411s116c",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050538","THU275 Tacrolimus Levels And Kidney Function In Kidney Transplanted (KT) Patients With Diabetes On Glucagon Like-1 Receptor Agonists (GLP1-RA)","Mario S Campana","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.711",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050539","Abstract 16779: Tirzepatide Reduces High-Sensitivity C-reactive Protein in Patients With Type 2 Diabetes and High Cardiovascular Risk: A Post Hoc Analysis of the SURPASS-4 Trial","Deepak L. Bhatt","2023","Circulation","other_trial","article","10.1161/circ.148.suppl_1.16779",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0050540","Comparison of Linagliptin, Sitagliptin and Liraglutide Effects on Survival and Vascular Complications in Experimental Sepsis","Saule Agdauletova","2013","Free Radical Biology and Medicine","other","article","10.1016/j.freeradbiomed.2013.10.542",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050541","Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","Slobodan I Macura","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/n0b9-k834",null,null,"ClinicalTrials.gov:NCT03989232; EudraCT:2018-004529-96","S001353","openalex","TRUE","paywalled","1","FALSE","article"],["R0050542","Änderung von HbA1c, Nüchternglukose, Gewicht, Lipiden und Vitalparametern in Abhängigkeit vom Ausgangs-BMI: Daten aus 2 klinischen Studien mit Exenatide und Insulin-Vergleichsarm","Oliver P. Bachmann","2009","Diabetologie und Stoffwechsel","other","article","10.1055/s-0029-1221928",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050543","Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials","Katherine R. Tuttle","2020","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20203110s1349c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050544","Abstract 4143581: Dipeptidyl Peptidase 4 Inhibitor Linagliptin Improves Cardiac Function, Fibrosis and Apoptosis in a Swine Model of Chronic Myocardial Ischemia","Dwight Douglas Harris","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4143581",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050545","Hidden in Plain Sight: Weight Bias and Atypical Anorexia","Lisa Ditchek","2024","Clinical Pediatrics","other","article","10.1177/00099228241286289","39342437",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050546","1996-LB: Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model","Priyanka Somanath","2025","Diabetes","preclinical","article","10.2337/db25-1996-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050547","Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Hypoglykämien als Funktion des HbA1c in der SoliMix-Studie","Rory J. McCrimmon","2022","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-1746277",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE",null,null,"FALSE","article"],["R0050548","MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Shows Differential Brain Activation vs. Liraglutide in Mice","Luke K. Burke","2018","Diabetes","preclinical","article","10.2337/db18-1789-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050549","Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon–Like Peptide–1 Receptor Agonist (GLP–1RA)–Evidence from Preclinical, Modeling, and Clinical Studies","Julio Rosenstock","2018","Diabetes","randomized_trial","article","10.2337/db18-1111-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050550","Letter Regarding “Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR”","Limin Zhao","2021","Kidney International Reports","systematic_review","article","10.1016/j.ekir.2021.09.014","34805647",null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0050551","THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide","Susan Leanne Samson","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.1134",null,null,"ClinicalTrials.gov:NCT02060383","S002111","openalex","TRUE","free_to_read","1","FALSE","article"],["R0050552","GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management - a one-year nationwide cohort study","K Soerensen","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.2817",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050553","68-LB: Early Pharmacological Intervention (EPIC) to Preserve Beta-Cell Function in Prediabetes (PreDM)","Alberto O. Chávez","2023","Diabetes","randomized_trial","article","10.2337/db23-68-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050554","Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden","SG Terra","2015","Clinical Pharmacology & Therapeutics","other_trial","article","10.1002/cpt.154","26013760",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0050555","2032-P: The Effects of Liraglutide on Ameliorating Diabetic Kidney Disease Is via SIRT1/TXNIP Pathway","RIYING LIANG","2019","Diabetes","preclinical","article","10.2337/db19-2032-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050556","992-P: Dulaglutide (DU) Has Better Glycemic Effectiveness vs. Basal Insulin (BI) in Injection-Naïve Patients with Type 2 Diabetes (T2D): The DISPELTM Study","Reema Mody","2019","Diabetes","nonrandomized_study","article","10.2337/db19-992-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050557","IDF23-0145 Once-weekly semaglutide in type 2 diabetes patients with heart failure with reduced left ventricular ejection fraction","Alicia Trenas Calero","2024","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2024.111208",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050558","GLP-1 Agonists for Substance Use and Compulsive Behavior Disorders: A Scoping Review","Caylor W. Hafen","2026",null,"narrative_review","article","10.17605/osf.io/qa9hx",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0050559","EE139 Intensification with Insulin Glargine 300 U/Ml (Gla-300) or First- Generation Basal Insulins (BIs) in People with Type 2 Diabetes (T2D) on Once-Weekly Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): Deliver New-G","Guillermo E. Umpierrez","2024","Value in Health","other","article","10.1016/j.jval.2024.03.438",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050560","The Epidemiology of Bile Acid Diarrhea in Denmark [Letter]","Elanda Fikri","2023","Clinical Epidemiology","nonrandomized_study","article","10.2147/clep.s454145","38116044",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050561","Unmasking the Risks: Severe Hyponatremia From Glucagon-Like Peptide-1 (GLP-1) Agonist Therapy","An Tang","2025","American Journal of Respiratory and Critical Care Medicine","other","article","10.1164/ajrccm.2025.211.abstracts.a5708",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050562","Cardioprotective potential of glucagon-like peptide-1 receptor agonist – a new frontier","Kiran Rajendra Giri","2025","Medicine India","other","article","10.25259/medindia_17_2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050563","Pas d’augmentation des taux de calcitonine ni de cas de cancer à cellules C chez les patients traités par liraglutide dans l’étude LEADER","Michel Marre","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.587",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050564","Effects of Liraglutide on Caenorhabditis elegans","K Wongchai","2012","Diabetologie und Stoffwechsel","other","article","10.1055/s-0032-1314575",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050565","High-fat high-sugar diet and Liraglutide treatment introduce sex specific changes of adipocytokine receptors in the rat brain while Metformin has similar effect on both sexes","Vedrana Ivić","2017",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050566","SAT-445 Sustained improvements in non-invasive biomarkers with the novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis","Mazen Noureddin","2025","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(25)01701-5",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0050567","Bénéfice du liraglutide dans la réduction des complications podologiques des patients diabétiques de type 2 : analyses secondaires de l’étude LEADER","Michel Marre","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.193",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050568","1928-P: ß-Casein–Derived Peptides Prevents Obesity by Activating Adipose Tissue Thermogenesis","Hong Peng Zhong","2020","Diabetes","preclinical","article","10.2337/db20-1928-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050569","84-LB: HbA1c Reduction after Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Noninsulin Therapy","Eden M Miller","2020","Diabetes","nonrandomized_study","article","10.2337/db20-84-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050570","Mo1522 GLP-1 Analogues Do Not Improve Remission of Diabetes After Gastric Bypass","Andrew A. Taitano","2012","Gastroenterology","other","article","10.1016/s0016-5085(12)64212-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050571","Use Of Liraglutide For Weight Loss In Patients With Prior Bariatric Surgery","Collin Creange","2016","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2016.08.281",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050572","Abstract 332: Racial Differences in Prescribing of Sodium Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Among Veterans With Type 2 Diabetes and Coronary Artery Disease: Findings From the Veteran’s Administration Clinical Assessment, Reporting, and Tracking Program","Demetria M. McNeal","2020","Circulation Cardiovascular Quality and Outcomes","other_trial","article","10.1161/hcq.13.suppl_1.332",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0050573","HPR181 Semaglutide in Transition: A Nationwide Register-Based Study in Finland 2019-2024","Fredriikka Nurminen","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.09.1588",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050574","Su2061: SAFETY AND CLINICAL OUTCOMES OF ROUTINE ENDOSCOPIC PROCEDURES IN PATIENTS ON GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A SINGLE-CENTER STUDY","Adily N. Elmi","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03113-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050575","181-OR: Pancreatic Gene Therapy Durably Improves Glycemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes","Alice Liou Fitzpatrick","2023","Diabetes","preclinical","article","10.2337/db23-181-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050576","Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial","Dilan S. Athauda","2018","Yearbook of pediatric endocrinology","randomized_trial","article","10.1530/ey.15.14.17",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050577","64698 Cutaneous Adverse Events of Glucagon-Like-Peptide-1 (GLP-1) Agonists","Nelly Rubeiz","2025","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2025.05.637",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050578","Sa1964 INCIDENCE OF GASTROINTESTINAL SIDE EFFECTS IN PATIENTS PRESCRIBED GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGS: REAL-WORLD EVIDENCE","Piyush Nathani","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)01841-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050579","The initiation of new glucose lowering therapies may act to reduce physical activity levels: pooled analysis from three randomised trials","Thomas E. Yates","2022",null,"randomized_trial","article","10.2337/figshare.20409372.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0050580","WCN26-3666 Semaglutide Combined with Physical Training: Impact on Diabetic Kidney Disease Morbidity","Eloiza de Oliveira Silva","2026","Kidney International Reports","preclinical","article","10.1016/j.ekir.2026.104607",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050581","ORAL ABSTRACT: MPN-642 Glucagon-Like Peptide-1 Agonists and Clinical Outcomes in Polycythemia Vera: A Large-Scale Propensity-Matched Cohort Study","Asfand Yar Cheema","2025","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(25)00371-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050582","Exenatide (Byetta) : clinical outcomes and patient perceptions after 12 months treatment","Trisha L. Dunning","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050583","Abstract 4141896: Genetic Mimics of GLP-1Ra and SGLT2i Therapy, Heart Failure and Chronic Kidney Disease Outcomes","Subbaramireddy Remala","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4141896",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050584","1977-LB: Glucometabolic Outcomes in Patients with Concurrent Overweight/Obesity and Type 1 Diabetes following Prolonged Glucagon-Like Peptide 1 Receptor Agonist Treatment—A Systematic Review and Meta-analysis","AMANDA R. PURCELL","2025","Diabetes","systematic_review","article","10.2337/db25-1977-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0050585","Strategies to improve macroencapsulated islet graft survival","Anne K. Sörenby","2007","Figshare","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0050586","IP28-29 VULVAR TISSUE CHANGES IN NON-DIABETIC WOMEN RECEIVING GLP-1 RECEPTOR AGONISTS: A GLOBAL FEDERATED COHORT ANALYSIS","Muhammed A.M. Hammad","2026","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001191440.21691.12.29",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050587","Semaglutide improves contractile function in isolated human atrium","Philipp Hegner","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.3729",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050588","Muscle-targeted gene transfer enables continuous secretion of GLP-1 and exendin-4 in mice","Amr A. A. Mahmoud","2009","Human Gene Therapy","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050589","The Effect of Semaglutide on Mortality and COVID-19-related Deaths — A Pre-specified Analysis From the SELECT Trial","M. Morin","2024","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2024.09.023",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050590","S839 Glucagon-Like Peptide-1 Receptor Agonists and Capsule Endoscopy in Patients With Diabetes: A Matched Cohort Study","Tarek Odah","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032724.91132.32",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050591","GLP-1 Receptor Agonists: Advancing Kidney Transplant Access and Safety in a National ESKD Cohort","Babak John Orandi","2025","American Journal of Transplantation","nonrandomized_study","article","10.1016/j.ajt.2025.07.291",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050592","P356 Improving upper GI endoscopy safety and success in patients on GLP-1 agonists","Rubin George","2026","E-Posters","nonrandomized_study","article","10.1136/gutjnl-2026-bsg.465",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0050593","852-P: Factors Associated with the Use of Adjunct-to-Insulin Glucose-Lowering Agents in Patients with Type 1 Diabetes Mellitus","Jessica Liu","2025","Diabetes","nonrandomized_study","article","10.2337/db25-852-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050594","An Improved Process for the Preparation of Semaglutide Side Chain.","Mukul Pandey","2020","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0050595","Beneficial effects of long-term liraglutide monotherapy on glycemic control and diabetic microangiopathies in a female Japanese diabetic patient with familial partial lipodystrophy 1","Masanori Iwanishi","2021","Diabetes Updates","other","article","10.15761/du.1000150",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050596","Semaglutide-induced weight loss improves mitochondrial energy efficiency in mouse skeletal muscle","Takuya Karasawa","2026","体力科學","preclinical","article","10.7600/jspfsm.75.67",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050597","ANÁLOGOS DE PEPTÍDEO 1 TIPO GLUCAGON NA DOENÇA RENAL CRÔNICA: UMA REVISÃO SISTEMÁTICA COM METANÁLISE DE ENSAIOS CLÍNICOS RANDOMIZADOS","João Filipe Cavalcante Uchôa Furtado¹","2024",null,"other","article","10.65034/bjnabstract-cbn240168",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050598","OP0281 EXPLORING GLP-1 AGONISTS EFFECTS IN FIBROMYALGIA PATIENTS: A PROPENSITY MATCHED ANALYSIS USING TriNetX DATABASE","Nouran Eshak","2025","Annals of the Rheumatic Diseases","randomized_trial","article","10.1016/j.ard.2025.05.291",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0050599","Corrigendum to : Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV","Bakani Butale","2022","Sexual Health","nonrandomized_study","article","10.1071/sh22070_co",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","erratum"],["R0050600","FRI-305-Long acting GLP-1/Glucagon co-agonist ameliorates steatosis, inflammation and fibrogenesis in a rodent model of NASH","Jenny Egecioglu Norlin","2019","Journal of Hepatology","preclinical","article","10.1016/s0618-8278(19)31048-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050601","Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time","Carrie R. Howell","2024","Diabetes Obesity and Metabolism","nonrandomized_study","article","10.1111/dom.15450","38253946",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050602","PDB52 Adherence: A Real World Retrospective Database Study Among Type 2 Diabetes Patients Treated With Liraglutide or Exenatide","Mavrommati Maria","2012","Value in Health","nonrandomized_study","article","10.1016/j.jval.2012.08.1695",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0050603","207.6: Effect of HLA Matching on Long Term Islet Allograft Function","Joana R. N. Lemos","2021","Transplantation","nonrandomized_study","article","10.1097/01.tp.0000804300.48048.a1",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050604","The Effects of DPP4 Inhibitors on Lipid Status and Blood Pressure in Rats with Diabetes Mellitus Type 2","Stefani S. Bolevich","2019","Serbian Journal of Experimental and Clinical Research","preclinical","article","10.2478/sjecr-2019-0037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050605","Comparison of eligibility criteria and baseline characteristics between the patient populations of evoke and evoke+, Clarity AD, and TRAILBLAZER‐ALZ‐2","Howard Feldman","2024","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.083684",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050606","PCR12 Income and Utilization of GLP-1 RAs: A Role for Patient Wage in Type 2 Diabetes Management","Brenna L. Brady","2024","Value in Health","other","article","10.1016/j.jval.2024.10.3255",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050607","Biochemistry of Exercise Effects in Type 2 Diabetes","Barry Braun","2020",null,"other","article","10.4324/9781003123835-28",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050608","PO-453 Effect of GLP-1 on proliferation and migration in pheochromocytoma and colorectal cancer cells","Maha Mohamed Saber-Ayad","2018","ESMO Open","other","article","10.1136/esmoopen-2018-eacr25.474",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050609","P1006IMPACT OF GLUCOSE-LOWERING AND ANTIHYPERTENSIVE MEDICATIONS ON DEVELOPMENT OF MICROALBUMINURIA IN SUBJECTS WITH TYPE 2 DIATETES AND NORMOALBUMINURIA IN THE PRIORITY STUDY","Nete Tofte","2020","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfaa142.p1006",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050610","Comparison of Novel MicroRNA and Cell-Free DNA Biomarkers of Beta-Cell Death and Diabetes Progression","Mugdha V. Joglekar","2018","Diabetes","other_trial","article","10.2337/db18-231-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050611","Editorial: Advances in pharmacotherapy for alcohol use disorder: from mechanisms to clinical interventions","Regina A. Mangieri","2025","Frontiers in Pharmacology","preclinical","article","10.3389/fphar.2025.1671114","40894199",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0050612","410-P: Therapeutic Profile from the Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study","Lisa Chu","2021","Diabetes","nonrandomized_study","article","10.2337/db21-410-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050613","The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?","James P. Daniels","2023","JNCI Journal of the National Cancer Institute","randomized_trial","article","10.1093/jnci/djad140","37587090",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050614","1597-P: Insulin Sensitivity Dependent and Insulin Sensitivity Independent Insulin Secretion in Nondiabetic Individuals","MOHAMED ABU-FARHA","2025","Diabetes","other","article","10.2337/db25-1597-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050615","17-OR: ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4","Hiddo J.L. Heerspink","2022","Diabetes","other","article","10.2337/db22-17-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050616","S1669 Efficacy and Safety of Tirzepatide for the Management of Obesity in People With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials","Muhammad Ayyan","2023","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0000956316.34865.87",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0050617","AN ANALYSIS OF IMPACT, MECHANISMS, AND CONTROL MEASURES","Roxana Colette SANDULOVICI","2026",null,"other","article","10.66793/titum19proceeding13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0050618","866-P: Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study","Frederik Persson","2022","Diabetes","other_trial","article","10.2337/db22-866-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050619","Sa1777 IBD PATIENTS CONCOMITANTLY TREATED WITH GLP1 AGONISTS HAD FEWER HOSPITALIZATIONS AND DISEASE RELATED COMPLICATIONS: A US COHORT PROPENSITY-MATCHED STUDY","Khaled Alsabbagh Alchirazi","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)01662-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050620","PO-03-150 EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON ATRIAL FIBRILLATION RECURRENCE AFTER CATHETER ABLATION","Danish Iltaf Satti","2024","Heart Rhythm","other","article","10.1016/j.hrthm.2024.03.972",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050621","Mechanisms behind GLP-1 induced weight loss","Philip Just Larsen","2008","The British Journal of Diabetes","other","article","10.1177/1474651408100525",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050622","A STUDY OF SPECSIN IN OBESE CHILDREN ON THE BACKGROUND OF THERAPY WITH A GLUCAGON-LIKE PEPTIDE-1 ANALOG","Timofey V. Chubarov","2025","Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)","other","article","10.18499/1990-472x-2025-26-1-64-70",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050623","685: RISK OF PANCREATIC CANCER IN PATIENTS TREATED WITH GLUCAGON LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: A LARGE MULTI-CENTER COHORT STUDY","Shailendra Singh","2022","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(22)60404-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050624","Sécurité, tolérance et paramètres pharmacocinétiques/pharmacodynamiques du liraglutide chez les adolescents atteints d’un diabète de type 2","David J. Klein","2013","Annales d Endocrinologie","other","article","10.1016/j.ando.2013.07.538",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050625","O-B04 The effect of high fat diet and subsequent intentional weight loss on tumour burden in an animal model of spontaneous endometrial cancer","Piriyah Sinclair","2021","British journal of surgery","preclinical","article","10.1093/bjs/znab429.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050626","Beyond the Glomerulus—Kidney Tubule Markers and Diabetic Kidney Disease Progression","Alexander L. Bullen","2021","Kidney International Reports","other","article","10.1016/j.ekir.2021.03.879","34015067",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050627","Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the Exenatide study of Cardiovascular Event Lowering (EXSCEL)","Mary Angelyn Bethel","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/qvey-hf80",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0050628","Glucagon-like Peptide-1 (GLP-1): 25 Jahre Ansporn für die Diabetesforschung","Matthias A. Nauck","2012","Diabetologie und Stoffwechsel","other","article","10.1055/s-0032-1325427",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050629","Protection of the isolated rat heart by exendin-4, a GLP-1 receptor agonist","David Peick Sonne","2007","Journal of Molecular and Cellular Cardiology","preclinical","article","10.1016/j.yjmcc.2007.03.558",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050630","782-P: Efficacy of Tirzepatide in People with Young-Onset T2D in the SURPASS Program","PHILIP ZEITLER","2023","Diabetes","other","article","10.2337/db23-782-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050631","Need for a Paradigm Shift in Adult Overweight and Obesity Management - an EASO Position Statement on a Pressing public Health, Clinical and Scientific Challenge in Europe","Gema Frühbeck","2014","Obesity Facts","nonrandomized_study","article","10.1159/000370038","25503968",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050632","FUNCTIONAL FORM OF THE RELATIONSHIP BETWEEN ADHERENCE TO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY AND MEDICAL HEALTH CARE COSTS AMONG PATIENTS WITH TYPE 2 DIABETES IN THE UNITED STATES","Stephen S. Johnston","2016","Value in Health","other","article","10.1016/j.jval.2016.03.1249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050633","292.6: Hidden interaction: Dulaglutide significantly alters immunosuppressant pharmacokinetics after kidney transplantation.","Núria Montero","2026","Transplantation","other","article","10.1097/01.tp.0001250364.84543.99",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050634","CLINICAL OUTCOMES AND SAFETY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DURING UPPER ENDOSCOPY","Stephen A. Firkins","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.1201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050635","Liraglutide in the treatment of Type 1 Diabetes Mellitus follow-up study","In Lok L. Lam","2013","Fisher Digital Publications (St. John Fisher College)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050636","Panniculitis at the Site of Injection: Infection or Foreign Body Reaction?","Grant M. Williams","2020","American Journal of Clinical Pathology","other","article","10.1093/ajcp/aqaa161.058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050637","Efficacité et tolérance du Dulaglutide en injection hebdomadaire en fonction de l’HbA 1c initiale dans le programme AWARD","Samuel E. Dagogo-Jack","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30417-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050638","LBO-001 Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial","Rohit Seth Loomba","2024","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(24)00436-7",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0050639","Incretin-based drugs and the risk of acute liver injury among patients with type 2 diabetes mellitus","Richeek Pradhan","2022",null,"nonrandomized_study","article","10.2337/figshare.20218544.v1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","other"],["R0050640","Semaglutide modulates pro-inflammatory neutrophil phenotype induced by supraphysiological levels of the adipokine FABP4 in patients with cardiovascular disease","D Sanchez-Lopez","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae666.3885",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050641","Pharmakokinetik und Pharmakodynamik von Exenatide in langwirksamer Formulierung (LAR) als Einzeldosis und nach Mehrfachgabe","Marcel Trautmann","2008","Diabetologie und Stoffwechsel","other","article","10.1055/s-2008-1076354",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050642","935-P: Effect of CTRB1/2 RS7202877 (T>G) Polymorphism on Weight Loss Response to Liraglutide Treatment in Greek People with Type 2 Diabetes","Angeliki V. Kyriazou","2020","Diabetes","other","article","10.2337/db20-935-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050643","Semaglutide in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis","Maneeth Mylavarapu","2026","World Journal of Cardiology","systematic_review","article","10.4330/wjc.v18.i3.112189",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0050644","Significant improvement in response to the GLP1-agonist 'Liraglutide' following change in injection site","Daniel Border","2017","Endocrine Abstracts","other","article","10.1530/endoabs.50.ep054",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050645","Antidiabetic Drugs That Reduce Weight and Are Cardioprotective","Carolina María Perdomo","2023",null,"other","article","10.1201/9781003432807-36",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050646","Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes","McGuire D.K","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/xc1q-s677",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0050647","Pharmacology of the GLP-1 analog exenatide extended-release in healthy cats","Adam Joseph Rudinsky","2015","OhioLink ETD Center (Ohio Library and Information Network)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050648","Le medicament du mois. Combinaison a ratio fixe insuline basale glargine-lixisenatide (Suliqua(R)).","André Jacques Scheen","2019","RMLG. Revue médicale de Liège","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050649","S1810 Impact of GLP-1 Receptor Agonists on IBD Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis","Avneet Kaur","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001134700.23465.86",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0050650","Dulaglutide Has Higher Adherence and Persistence than Liraglutide and Exenatide QW—One-Year Follow-Up from U.S. Real-World Data","Reema Mody","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1264-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050651","Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study","Zainab Jassim","2018","Journal of Pharmaceutical Health Services Research","nonrandomized_study","article","10.1111/jphs.12240",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050652","The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients with Type 2 Diabetes Mellitus in Taiwan","Huan Lin","2016","Value in Health","other","article","10.1016/j.jval.2016.08.213",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050653","Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)","Louis J. Aronne","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785403",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050654","Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses","John B. Buse","2022","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-1746271",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050655","Étude LEADER : liraglutide et évolution de la fonction rénale dans le diabète de type 2","Michel Marre","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30205-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050656","Modalités d’instauration d’un traitement par association fixe Degludec-Liraglutide en situation de vie réelle : étude multicentrique française","Pierre Gourdy","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.206",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050657","The Effect of Tirzepatide vs. Dulaglutide on Major Adverse Cardiovascular Events (MACE‑4 and MACE‑5) in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease","D McGuire","2026","Diabetologie und Stoffwechsel","other","article","10.1055/s-0046-1819993",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050658","Cardiac responses to GLP‐1 receptor activation are impaired in the setting of metabolic syndrome (1078.7)","Abass M. Conteh","2014","The FASEB Journal","other","article","10.1096/fasebj.28.1_supplement.1078.7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050659","Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on mitochondrial-derived peptide-c and on markers of neurohumoral activation","Ignatios Ikonomidis","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2915",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050660","Short-term complications in elective joint reconstruction: A retrospective assessment of the impact of GLP-1 agonists","Richard A. Baum","2024","Journal of Orthopaedic Reports","nonrandomized_study","article","10.1016/j.jorep.2024.100501",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050661","S1509 Bariatric Endoscopic Gastric Remodeling (BEGR) With Versus Without Pharmacotherapy With Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RAs): An Analysis of 985 Patients","Abdul-Rahman Fadi Diab","2024","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001035404.34681.f8",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050662","Gastric Emptying and the Personalized Management of Type 1 Diabetes","Chinmay S. Marathe","2018","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/jc.2018-00849","29788123",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050663","Abstract 4339657: Glucagon-Like Peptide-1 Receptor Agonists with Guideline Therapy Lower Mortality and Hospitalizations in HFpEF: A Propensity-Matched U.S. TriNetX Study","Zainab Zaib Khan","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4339657",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050664","Management of type 2 diabetes: the GLP‐1 pathway","Abd A. Tahrani","2008","Future Prescriber","other","article","10.1002/fps.39",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050665","GLP-1 receptor agonists and atherosclerosis: a metabolic treatment for a cardiometabolic disease.","Georgios Georgiopoulos",null,"Open Access CRIS of the University of Bern","other","article","10.48620/96940",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050666","P6268Cardiovascular outcomes of new anti-diabetic agents - A meta-analysis of randomized controlled trials","Yan Lin","2019","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehz746.0867",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0050667","38-OR: Differences in Diabetes Medication Use between Commercial and Medicare Advantage Beneficiaries, 2013-2018","Rozalina Grubina McCoy","2020","Diabetes","other","article","10.2337/db20-38-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050668","S744 Underutilization and Racial Disparities in Obesity Management in the United States","Abdellatif Salah Ismail","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130436.97057.db",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050669","Az iGlarLixi-kezelés hatékonyságának és biztonságának vizsgálata a mindennapi gyakorlatban","Regina Szerencsi","2020","Diabetologia Hungarica","other","article","10.24121/dh.2020.s1.73",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050670","Semaglutide induced bullous pemphigoid","Hammad Hussain","2026","Journal of Clinical and Translational Endocrinology Case Reports","other","article","10.1016/j.jecr.2026.100214",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050671","Tirzepatide: unimolecular polypharmacology in the treatment of obesity","Tatiana Ivanovna Romantsova","2025","Endocrinology News Opinions Training","other","article","10.33029/2304-9529-2025-14-3-50-64",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050672","‘New therapies for type 2 diabetes have added little to improve glycaemic control compared to conventional therapies’","Charles J. Fox","2010","Practical Diabetes","randomized_trial","article","10.1002/pdi.1449",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050673","Sa1345: ANALYSIS OF UPPER GASTROINTESTINAL ADVERSE EVENTS AMONG GLP-1 RECEPTOR AGONISTS REPORTED IN US FDA ADVERSE EVENT REPORTING SYSTEM: FOCUS ON GERD, PEPTIC ULCER AND HEMATEMESIS","Akanksha Togra","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)01967-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050674","New study suggests weight loss drugs like Ozempic could help with knee pain. Here’s why there may be a link","Giovanni Esteves Ferreira","2024",null,"other","article","10.64628/aa.jfwk36eut",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0050675","Abstract 4362806: Effect of Glucagon-like peptide-1 Receptor Agonists on Cardiac Arrhythmias: Systematic Review and Meta-analysis","Carlos M. Patiño","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4362806",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0050676","Incretion hormones as a therapeutic target in sepsis: a review","Faraaz Ali Shah","2018","D-Scholarship@Pitt (University of Pittsburgh)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050677","Effects of bariatric surgery to induce weight loss and HbA1c reduction shown to persist at 12 years","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.71",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050678","Sa354 OUTCOMES OF NASH CIRRHOSIS IN TYPE 2 DIABETICS TREATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A NATIONWIDE STUDY","Stephen A. Firkins","2021","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(21)02713-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050679","Exenatide for Parkinson Symptoms: Early Results Are Positive","Dilan S. Athauda","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050680","GLP-1 RA treatment: a benefit-risk analysis from a retrospective cohort study","Emmanouela Konstantara","2018","Diabetologia","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0050681","HbA1c reduction strategies: An overview of pharmacological interventions","Krishna S. Upadhye","2025","National Journal of Pharmacology and Therapeutics","randomized_trial","article","10.4103/njpt.njpt_72_24",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0050682","Effects of a GLP-1 agonist on consumption of alcohol in patients treated for smoking cessation","Probst Leila Sofia","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.p422",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050683","Abstract #809: Effects of Exenatide on First- and Second-Phase Insulin Secretion in Response to Intravenous Administration of Glucose in Patients with Type 2 Diabetes","David G. Maggs","2005","Endocrine Practice","other","article","10.1016/s1530-891x(20)43659-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050684","Incretin-based weight loss therapies and heart failure with preserved ejection fraction: guideline impactful results, but mechanisms unclear","Katarzyna A. Stefanska","2025","Cardiovascular Research","randomized_trial","article","10.1093/cvr/cvaf001","39887081",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050685","Efficient Synthesis of Liraglutide by Using Oxyma as Coupling Reagent","Fengliang Wang","2016","Chinese Journal of Organic Chemistry","other","article","10.6023/cjoc201505014",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050686","Dermatología estética facial. Una visión holística","José Luis.","2021","Más dermatología","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050687","Diabetes medications and dementia risk: Comparisons of SGLT2 inhibitors, GLP-1 RAs, metformin, and their combinations","Gabrielle R. Nemeh","2025","Diabetes Epidemiology and Management","nonrandomized_study","article","10.1016/j.deman.2025.100288",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050688","IDF2022-0414 iGlarLixi Provides a Higher Derived Time-in-Range vs Insulin Glargine or Lixisenatide in Asian Pacific People with T2D","Xinyi Guo","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110307",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050689","829-P: iGlarLixi vs. Basal-Bolus (BB) or Premixed Insulin in Older Adult Ethnic Minorities with Type 2 Diabetes (T2D)","Guillermo E. Umpierrez","2024","Diabetes","nonrandomized_study","article","10.2337/db24-829-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050690","LOW TESTOSTERONE IN THE GLP-1 ERA Reframing male hormonal health, metabolic hypogonadism, testosterone replacement therapy and the emerging nutraceutical opportunity","Jose M. Lopez","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22870475",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050691","Interpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy","Dion Groothof","2026","The Lancet Primary Care","other","article","10.1016/j.lanprc.2026.100200",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050692","SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS","Vlado Perkovic","2019","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfz101.sao010",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050693","Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity","Andrew Overholser","2025","Translation The University of Toledo Journal of Medical Sciences","randomized_trial","article","10.46570/utjms-2024-1218",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050694","Abstract 4359390: Low-Dose Semaglutide Attenuates Coronary Artery Pathology and Improves Vascular Function Independent of Weight Loss in a Porcine Model of Cardiometabolic HFpEF","Mahmoud H. Elbatreek","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4359390",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050695","983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7","John B. Buse","2019","Diabetes","randomized_trial","article","10.2337/db19-983-p",null,null,"ClinicalTrials.gov:NCT02849080","S001153","openalex","FALSE","paywalled","1","FALSE","article"],["R0050696","LIRAGLUTIDE AS A NOVEL DNA DEMETHYLATING AGENT AND ITS POTENTIAL USE IN THE ADJUVANT TREATMENT OF HIGLY INVASIVE BREAST CANCER","Felipe F. de Campos","2019","Mastology","other","article","10.29289/259453942019v29s1g13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0050697","Cardiovascular outcome trials of GLP-1RAs and SGLT-2 inhibitors: a concise review from the clinicians’ perspective","Thinzar Min","2023","Metabolism and Target Organ Damage","narrative_review","article","10.20517/mtod.2023.09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050698","7-019 Evolving burden of cardiovascular disease in the West of Scotland","Anna L. Kamdar","2025",null,"nonrandomized_study","article","10.1136/heartjnl-2025-bcs.214",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0050699","Fracture risk in treatment with GLP-1RA compared to DPP-4i:a Danish nationwide cohort study","Zheer Kejlberg Al-Mashhadi","2022",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0050700","Thyroid dysfunction and critical care","Brian A. Mullan","2010","Cambridge University Press eBooks","other","article","10.1017/cbo9780511750441.019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050701","Novel Therapeutic Targets for Management of Type-2 Diabetes Mellitus","Anishkumar Chaurasia","2016","Immunology Endocrine & Metabolic Agents - Medicinal Chemistry","other","article","10.2174/1871522216666160216225721",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050702","Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators","Jorge Plutzky","2022","Circulation","other_trial","article","10.1161/circ.146.suppl_1.13440",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0050703","Use of GLP-1 receptor agonists among pediatric patients with Type 1 Diabetes: A scoping review of safety, efficacy, and potential for long-term usage","Eden Dowell","2025","SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050704","Antiatherosclerotic Effects of Sodium-Glucose Cotransporter 2 Inhibitors: An Underrecognized Piece of the Big Puzzle?","Theocharis Koufakis","2022","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgac116","35245937",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050705","Therapie des Typ-2-Diabetes","Rüdiger Landgraf","2022","Diabetologie und Stoffwechsel","other","article","10.1055/a-1789-5650",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050706","Mo1817 EFFICACY OF TRANSORAL OUTLET REDUCTION COMBINED WITH GLP-1 RECEPTOR AGONISTS ON THE SEVERITY OF METABOLIC SYNDROME AND WEIGHT REGAIN","Kelsy N. Larios","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)04950-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050707","Endoscopic Sleeve Gastroplasty as Facilitatorfor Renal Transplantation in Patients withObesity: Rationale and Protocol","Patrício Correia, Vítor","2025","Portuguese Kidney Journal (PKJ)","protocol","article","10.71749/pkj.105",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0050708","Efficacy and safety of once weekly dulaglutide and once daily insulin glargine treatment at 52 weeks in patients with type 2 diabetes (T2DM) in the Assessment of Weekly AdministRation of dulaglutide in Diabetes-2 (AWARD-2) study, stratified by duration of diabetes (< 5 years, ≥5 to < 10 years, ≥10 years)","Jiten P Vora","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549549",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050709","Effect of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on markers of neurohumoral activation and left atrial strain","Ignatios Ikonomidis","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.2571",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050710","1707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide—The Mayo Clinic Experience","Sima Fansa","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1707-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050711","1200.05 Effect Of Semaglutide Formulations On QTc Interval: A Retrospective Comparison Of Wegovy And Ozempic In A Tertiary Care Hospital","Vagisha Sharma","2026","JACC: Cardiovascular Interventions","nonrandomized_study","article","10.1016/j.jcin.2026.01.180",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050712","The Impact of GLP-1 Receptor Agonists on Ulcerative Colitis Patients – Following Restorative Ileal Pouch Anal Anastomosis","Ali Mahmood","2026","British journal of healthcare and medical research","nonrandomized_study","article","10.14738/bjhr.1304.12059",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050713","The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled Trials","Davy Vancampfort","2021","FOCUS The Journal of Lifelong Learning in Psychiatry","systematic_review","article","10.1176/appi.focus.19103","34483776",null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0050714","Early evidence for a GLP‐receptor antagonist for the pharmacological management of post bariatric surgery reactive hypoglycaemia","ISKANDAR RAUF IDRIS","2020","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.00014",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050715","Profils d’auto-surveillance glycémique des patients diabétiques de type 2 (DT2) traités par dulaglutide (DU) hebdomadaire versus exénatide (EX) en prise bi-quotidienne (BID) et liraglutide (LIR) en prise quotidienne (OD) dans les études AWARD -1 et -6","Francisco José Tinahones","2015","Annales d Endocrinologie","other","article","10.1016/j.ando.2015.07.238",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050716","563-P: How Continuing Education (CE) Supported Guideline-Based Treatment among Patients with Diabetes","RUSSIE ALLEN","2024","Diabetes","nonrandomized_study","article","10.2337/db24-563-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050717","S1485 Semaglutide Outcomes in Non-Alcoholic Fatty Liver Disease: A Multi-Centered Real-World Study","Wissam Ghusn","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000955580.73643.8b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050718","EE360 Short-Term (180-Day) Health Care Costs for Patients With Commercial or Medicare Advantage (MA) Insurance Initiating Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy for Diabetes","Jamie M. Tucker","2025","Value in Health","other","article","10.1016/j.jval.2025.04.1959",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050719","How much salt should i recommend to a patient with CKD: the real mechanisms of regulation of sodium metabolism in kidney pathology","Dmytro D. Ivanov","2024","Nephrology (Saint-Petersburg)","nonrandomized_study","article","10.36485/1561-6274-2024-28-3-62-70",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050720","Impact of the glucagon-like peptide-1 receptor agonist semaglutide on reproductive health of women with obesity: a review of clinical evidence","Yuliya V. Luzik","2026","V F Snegirev Archives of Obstetrics and Gynecology","narrative_review","article","10.17816/aog701296",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050721","Multiparameter Peptide Optimization toward Stable Triple Agonists for the Treatment of Diabetes and Obesity","Andreas Evers","2020","Advanced Therapeutics","other","article","10.1002/adtp.202000052",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050722","FRI-175 Effects of combination treatment with semaglutide, cilofexor and firsocostat on liver noninvasive tests in patients with cirrhosis due to metabolic dysfunction-associated steatohepatitis: a post hoc analysis of the WAYFIND trial","Rohit Loomba","2026","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(26)01916-1",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0050723","033 GLP-1RAs reduce stroke incidence in patients with type 2 diabetes mellitus: a meta-analysis","Mark Peter Maskery","2022","Journal of Neurology Neurosurgery & Psychiatry","systematic_review","article","10.1136/jnnp-2022-abn.358",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0050724","Effect of Tirzepatide on Kidney Parameters in People with Excess Body Weight and Type 2 Diabetes: A Post-Hoc Analysis of the SURMOUNT-2 Trial","Hiddo J.L. Heerspink","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807554",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0050725","IDegLira is Efficacious Across Baseline HbA1C Categories in Subjects with Type 2 Diabetes Uncontrolled on SU, GLP-1RA or Insulin Glargine: Analyses from Completed Phase 3b Trials","CHRISTOPHER H. SORLI","2017","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2017.08.157",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050726","Is Semaglutide Cost-Effective for the Secondary Prevention of Cardiovascular Disease in People with Overweight or Obesity in Australia?","Ella Zomer","2024","Heart Lung and Circulation","other","article","10.1016/j.hlc.2024.06.870",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050727","Methodological challenges in calculation of daily average consumption (DACON) for GLP-1 receptor agonist injectables from claims data","Ralph W. Swindle","2014","Value in Health","nonrandomized_study","article","10.1016/j.jval.2014.03.1472",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050728","Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in the United States","Sean Hennessy","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.3621",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050729","Abstract #833: Exenatide Monotherapy Provides Glycemic Control Equivalent to That of Exenatide Combination Therapy in Patients with Type 2 Diabetes","Orville Kolterman","2005","Endocrine Practice","other","article","10.1016/s1530-891x(20)43676-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050730","Real-World Comparative Effectiveness, Treatment Patterns, and Costs in Type 2 Diabetes Mellitus (T2DM) Patients Initiated on Canagliflozin 300 mg (CANA) or a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1)","Mukul Singhal","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1287-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050731","Health State Utilities Associated with Attributes of Weekly Injection Devices and Subdermal Implant for Treatment of Type 2 Diabetes","Anne M. Rentz","2018","Diabetes","other","article","10.2337/db18-1114-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050732","Glycemic and Metabolic Effects of Liraglutide as Additive Treatment to Different Therapeutic Regimens in Type 2 Diabetes Patients Followed in Primary Care Clinics","Turki Alharbi","2018","Diabetes","nonrandomized_study","article","10.2337/db18-2458-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050733","Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide","YOUNG JIN PARK","2018","Diabetes","preclinical","article","10.2337/db18-1091-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050734","Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) Patients","Sasan Fazeli","2018","Diabetes","other","article","10.2337/db18-2231-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050735","Dosing, Treatment Pattern, and Safety of Finerenone Use in Routine Care: An Interim Analysis of the Prospective, Real-World, and Observational FINE-REAL Study","Christoph Wanner","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024dfkkts8m",null,null,"ClinicalTrials.gov:NCT05348733",null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050736","Tu1968: GLUCAGON-LIKE PEPTIDE-1 AGONISTS IN INFLAMMATORY BOWEL DISEASE LEAD TO SIGNIFICANT WEIGHT LOSS AND IMPROVED CLINICAL REMISSION WITH MINIMAL SIDE EFFECTS","Stephanie Lauren Gold","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04486-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050737","Sa1963 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT INCREASE THE RISK FOR ACUTE PANCREATITIS AND ARE NOT ASSOCIATED WITH COMPLICATIONS IN PATIENTS WITH OBESITY WHO DEVELOP IT: A POPULATION-BASED COHORT STUDY IN THE UNITED STATES","Luìs Manuel de Almieda Nieto","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)01840-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050738","Pulmonary Benefits of GLP-1 Analogs Versus SGLT-2 Inhibitors in COPD Patients With Coexisting Type 2 Diabetes","Chung‐Kan Peng","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a2855",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050739","Additional file 5: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Ling Li","2016","Figshare","systematic_review","article","10.6084/m9.figshare.4430819.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0050740","#2022 Clinical outcomes in US patients initiating finerenone – a report from the FOUNTAIN platform","Nikolaus Gunter Oberprieler","2024","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfae069.1416",null,null,"ClinicalTrials.gov:NCT05703880",null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050741","RISK FACTORS OF LOW-ENERGY FRACTURES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Guzel Minnezufarovna Nurullina","2018","Кубанский научный медицинский вестник","other","article","10.25207/1608-6228-2018-25-4-115-123",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050742","Racial Differences in the Association of Glucagon-like Peptide 1 Agonist Use and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in US Veterans with Diabetes Mellitus","Nikhil Grandhi","2023","Blood","nonrandomized_study","article","10.1182/blood-2023-179135",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050743","400.3: Stable graft function and glycemic control 6 years after clinical islet transplantation on the omentum: A case report","David A. Baidal","2023","Transplantation","case_report","article","10.1097/01.tp.0000994620.47983.20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050744","Cardiovascular safety and GLP‐1 receptor agonists","David Carty","2013","Practical Diabetes","randomized_trial","article","10.1002/pdi.1785",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050745","Efficacité et tolérance du liraglutide dans le diabète de type 2 – résultats finaux d’EVIDENCE® : une étude prospective post-inscription avec 2 ans de suivi","Pierre Gourdy","2014","Annales d Endocrinologie","other","article","10.1016/j.ando.2014.07.136",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050746","EE170 A Cost-Effectiveness Analysis, with Public Healthcare Payers’ Perspective, of Oral Semaglutide Versus Luseogliflozin Hydrate for Patients with Type 2 Diabetes Mellitus in a Japanese Clinical Setting","Ryosuke Ota","2023","Value in Health","other","article","10.1016/j.jval.2023.09.439",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050747","Quality of care and clinical outcomes in clinical pharmacotherapy","Andrea F. Attanasio","2025","European Heart Journal - Quality of Care and Clinical Outcomes","randomized_trial","article","10.1093/ehjqcco/qcaf132","41412163",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050748","The supramammillary nucleus controls anxiety-like behavior; key role of GLP-1R","Lopez-Ferreras L","2025","UTUPub (University of Turku)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050749","CREATION OF THE PREGNANCY MICE MODEL TO STUDY THE EFFECT OF GLP-1/GIP AGONISTS","Galiya Akylzhanova","2025","Ġylym men densaulyķ saķtau.","preclinical","article","10.34689/sh.2025.27.4.008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050750","Abstract 637: Angiotensin Receptor Blockade Ameliorates the Hypertension Associated with Acute Glucagon-like Peptide-1 Receptor Activation","Rubén Rodríguez","2013","Hypertension","preclinical","article","10.1161/hyp.62.suppl_1.a637",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050751","Effects of glucagon-like peptide 1 analogue on eating behavior in patients with obesity","Oksana Logvinova","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.ep302",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050752","MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS","Katherine R. Tuttle","2020","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaa140.mo051",null,null,"ClinicalTrials.gov:NCT03819153","S000953","openalex","FALSE","paywalled","4","FALSE","article"],["R0050753","Heterogene Antworten auf GLP-1-Rezeptor-Agonisten bei Erwachsenen mit Typ-2-Diabetes in der klinischen Routine: Ergebnisse aus dem DPV-Register","Martin Heni","2024","Diabetologie und Stoffwechsel","other","article","10.1055/s-0044-1785278",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050754","Warfarin and GLP-1 Receptor Agonist Interaction Effects on Time in Therapeutic Range","Phillip Anjum","2024","Blood","nonrandomized_study","article","10.1182/blood-2024-211357",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050755","Étude SUSTAIN 4 : efficacité et tolérance du semaglutide une fois par semaine versus insuline glargine une fois par jour chez des diabétiques de type 2 naïfs d’insuline","Bertrand Cariou","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30239-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050756","Addressing weight loss management in obese gout patients: guidance for future trials","Robin Christensen","2024","Exploration of Musculoskeletal Diseases","randomized_trial","article","10.37349/emd.2024.00074",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050757","Effect of liraglutide on microcirculation in rats with experimental diabetes mellitus associated with absolute insulin deficiency","А. Н. Иванов","2020","Regional blood circulation and microcirculation","preclinical","article","10.24884/1682-6655-2020-19-4-61-69",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050758","The use of GLP-1 agonist therapy, liraglutide, is associated with significant weight loss in morbidly obese people without diabetes","Syed M.R. Gillani","2015","The British Journal of Diabetes","randomized_trial","article","10.15277/bjdvd.2015.011",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050759","The place of Glucagon-like 1 peptide receptor agonists (GLP-1RAs) in the new NICE guidelines – what is going on?","Stephen Charles Bain","2022","British Journal of Diabetes","other","article","10.15277/bjd.2022.381",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050760","The Metabolic & Weight Effects of Semaglutide","Vincent C. Woo","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050761","A Single-Center, Randomized, Placebo-Controlled, 16-Week Trial of Effects of Liraglutide on Weight Loss and Relationship to Change in Gastric Emptying in Obese Patients","Hoda C. Kadouh","2017","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(17)32248-5",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050762","93-LB: Preferences and Health State Utilities Associated with Routes of Administration for Oral Semaglutide, Injectable Semaglutide, and Dulaglutide","Kristina Secnik Boye","2020","Diabetes","other","article","10.2337/db20-93-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050763","Advances in detection, prevention and treatment of heart failure in type 2 diabetes: part II","Alice Cowley","2024","British Journal of Diabetes","other","article","10.15277/bjd.2024.442",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050764","1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial","Rory J. McCrimmon","2021","Diabetes","randomized_trial","article","10.2337/db21-1-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050765","The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes","Mikhail Borisovich Antsiferov","2023","Diabetes Mellitus","other","article","10.14341/dm13034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050766","Abstract 4129075: Racial and Ethnic Differences in Semaglutide Prescriptions in the Veterans Affairs Healthcare System","Rebecca Lauren Tisdale","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4129075",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050767","10-OR: In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out","Emilie Skytte Andersen","2021","Diabetes","randomized_trial","article","10.2337/db21-10-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050768","Glucagon-like peptide 1 receptor agonist liraglutide impacts immune cell phenotypes in apolipoprotein e deficient mice during progression and regression of pre-established atherosclerosis","Robyn Bruen","2018","Atherosclerosis","preclinical","article","10.1016/j.atherosclerosis.2018.06.886",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050769","308-OR: Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes","Stacey M. Sklepinski","2025","Diabetes","nonrandomized_study","article","10.2337/db25-308-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050770","Lifestyle Interventions Can Work with Super-Super Obese Patient BMI of 90.5 kg/m2: Case Report","Ghadeer Al Ghareeb","2024",null,"case_report","article","10.22541/au.171061815.55099261/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0050771","Sodium-glucose cotransporter-2 inhibitors and their combination with glucagon like peptide-1 receptor agonists improve endothelial glycocalyx and arterial stiffness in type-2 diabetes","Ignatios Ikonomidis","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.2376",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050772","Abstract 12343: A Real-World Disproportionality Analysis of Atrial Fibrillation Adverse Events for Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","Sahith Reddy Thotamgari","2021","Circulation","nonrandomized_study","article","10.1161/circ.144.suppl_1.12343",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050773","Can glucagon-like peptide (GLP)-1 analogs prevent or delay the development of type 2 diabetes?","Jane Burch","2019","Cochrane Clinical Answers","other","article","10.1002/cca.2574",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050774","S771 GLP-1 Receptor Agonist Utilization: A National Analysis of Access Disparities in US Adults","Tasnin Khan","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001130544.28760.eb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050775","RWD80 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF INDIVIDUALS INITIATING GLP-1 AGONISTS FOR OBESITY: A CLAIMS DATABASE ANALYSIS IN THE US","Vinod Kumar Yakkala","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.2068",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050776","991-P: Metformin Plasma Concentration as a Biomarker of Treatment Responsiveness in Youth-Onset Type 2 Diabetes","KATRINA B. DIETSCHE","2022","Diabetes","randomized_trial","article","10.2337/db22-991-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050777","GLP1-RA PRESCRIPTION RATES FOLLOWING AN MI AMONG PATIENTS WITH T2DM STRATIFIED BY CONCOMITANT USE OF INJECTED INSULIN","Paige L. Della-Penna","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03885-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050778","S921 Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Use on Retained Gastric Contents and Adverse Events With Upper Endoscopy: A Systematic Review and Meta-Analysis","Syed Hamaad Rahman","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001033052.14494.cb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0050779","Liraglutide 3.0 mg Reduces Body Weight and Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity: The SCALE Obesity and Prediabetes Randomised Trial","David C.W. Lau","2015","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2015.01.183",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050780","S2523 Long Term Cardiovascular Outcomes in Patients With MASLD Who Also Have Obesity and are Overweight Who Underwent Semaglutide Therapy","Delano Carty","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137552.12187.09",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050781","Liraglutide-Based Weight Loss versus CPAP Therapy in improving Sleep Quality and Quality of Life of Patients with Obstructive Sleep Apnoea - an Explorative, Proof of Concept Study","Cliona O’Donnell","2023",null,"randomized_trial","article","10.1183/23120541.sleepandbreathing-2023.110",null,null,"ClinicalTrials.gov:NCT04186494","S001827","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0050782","Coming of Age for the Incretins","Jens Juul Holst","2008","Contemporary Endocrinology","other","article","10.1007/978-1-59745-572-5_14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050783","1201-P: Characteristics and Treatment Outcomes of Patients Treated with Empagliflozin in the ABCD Nationwide Empagliflozin Audit","Ken Y Thong","2019","Diabetes","randomized_trial","article","10.2337/db19-1201-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050784","Effects of GLP-1RAs on cardiovascular outcomes in patients with type 2 diabetes mellitus: review of real-world data on target populations from diabetes registry in Russian Federation","Ol'ga Konstantinovna Vikulova","2022","Diabetes Mellitus","randomized_trial","article","10.14341/dm12803",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050785","Comparative Review of Drugs Used in Diabetes Mellitus—New and Old","Furqan Ul Haq","2021","Journal of Diabetes Mellitus","narrative_review","article","10.4236/jdm.2021.114009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050786","Comparison of The Long-Term Cost-Effectiveness of Ideglira Versus Multiple Daily Insulin Injections In The Spanish Setting Using Real-World Clinical Data","Pedro Mezquita","2017","Value in Health","nonrandomized_study","article","10.1016/j.jval.2017.08.458",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050787","2 Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 mg in Adults With Overweight or Obesity (STEP 1)","John P.H. Wilding","2021","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/s-0041-1735668",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050788","Lhx1 is Required for Beta Cell Function Via Regulation of Glp1 Receptor ( Glp1R )","Maigen Michelle Bethea","2017","The FASEB Journal","preclinical","article","10.1096/fasebj.31.1_supplement.1014.25",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050789","A Second Opinion From Observational Data on Second-line Diabetes Drugs","Alison Callahan","2018","JAMA Network Open","other","article","10.1001/jamanetworkopen.2018.6119","30646309",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050790","IDegLira améliore les marqueurs de risque cardiovasculaire chez les diabétiques de type 2(DT2) insuffisamment contrôlés sous insuline basale : analyses de DUAL II et DUAL V","E. Disse","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.586",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050791","Medicines prescribed elsewhere: don’t forget to record them in the GP record!","Richard C. Armitage","2024","British Journal of General Practice","other","article","10.3399/bjgp24x739761","39481896",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050792","Calcific aortic valve disease and atherosclerotic cardiovascular disease: Shared and distinct mechanisms and treatment strategies","Tong Khee Tan","2026","Cardiac Research","other","article","10.1097/re9.0000000000000009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050793","PS2 - 8. Liraglutide decreases beta-cell mass in normoglycemic and high-fat diet-fed mice","Rianne Ellenbroek","2012","Nederlands Tijdschrift voor Diabetologie","preclinical","article","10.1007/s12467-012-0042-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050794","Pharmacotherapy of obesity: State of the art and perspectives","Katarina Sićović","2024","Arhiv za farmaciju","other","article","10.5937/arhfarm74-50625",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050795","WED-468 Non-invasive markers to predict biopsy response in people with metabolic dysfunction-associated steatohepatitis and fibrosis: exploratory analysis of a phase 2 trial of glucagon receptor/ glucagon-like peptide-1 receptor dual agonist, survodutide","Mazen Noureddin","2025","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(25)01537-5",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0050796","Exendin-4 decreases food reward and directly targets the mesolimbic circuitry","Karolina Patrycja Skibicka","2011","Appetite","other","article","10.1016/j.appet.2011.05.271",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050797","Exendin-4 increases extracellular superoxide dismutase expression in cultured astrocytes","Ken'ichi Takano","2017","Global Drugs and Therapeutics","preclinical","article","10.15761/gdt.1000s1001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050798","Tirzepatide in the practice of obstetrician/gynecologist","M. R. Orazov","2025","Clinical review for general practice","other","article","10.47407/kr2025.6.9.00675",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050799","Sterblichkeitsrate nach akutem Myokardinfarkt und Schlaganfall unter Therapie mit GLP-1 Rezeptor Agonisten und SGLT-2 Inhibitoren: Eine systematische Analyse kardiovaskulärer Endpunktstudien","Daniel Robert Quast","2024","Diabetologie und Stoffwechsel","other","article","10.1055/s-0044-1785296",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050800","Successful resolution of gastric perforation caused by a severe complication of pancreatic walled-off necrosis: A case report","Byeong Gwan Noh","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6298","37731568",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050801","12413 Reversal Of Congenital Hypogonadotropic Hypogonadism (CHH) In A Woman With A Heterozygous Inactivating Variant In GnRHR Gene","Sandhi Nyunt","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.1750",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050802","Abstract 4145342: GLP-1 Agonists are Associated with Fewer Unplanned Hospital Visits in Patients with Cardiovascular Disease and Comorbid Substance Use Disorder","Jahanzeb Javed","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4145342",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050803","350-OR: A Novel Long-Acting GLP-1 Agonist (GL0034) Demonstrates Remarkable Efficacy on HbA1c, Weight Loss, and Triglycerides in a Model of Type 2 Diabetes, the db/db Mouse","Rajamannar Thennati","2020","Diabetes","preclinical","article","10.2337/db20-350-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050804","IBC Oxford University Poster Abstract 3 - Novel technique in reversal of RYGB leads to remission of postprandial hyperinsulinaemic","Kamran Ali Shah","2025","British journal of surgery","other","article","10.1093/bjs/znaf036.054",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050805","The Role of GLP-1 Receptor Agonists in Rheumatic Diseases: Cardioprotective Potentials, Anti-Inflammatory Effects, and Future Emerging Therapeutic Applications","Mahmoud Hassan Abdelnabi","2025","Current Treatment Options in Cardiovascular Medicine","other","article","10.1007/s11936-025-01124-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050806","S811 Metabolic and Bariatric Surgery vs Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison of Cardiometabolic Risk Profiles","Wissam Ghusn","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130704.37750.31",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050807","Impact of obesogenic medications on weight loss potential with glucagon-like peptide-1 receptor agonists","Hilary J. Little","2025","JAPhA Pharmacotherapy","nonrandomized_study","article","10.1016/j.japhar.2025.100022",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050808","[ldquo]Real world[rdquo] experience[rdquo] of treatment with wegovy (semagluatide) and saxenda (liragluatide) in a paediatric population living with severe obesity","Jo Searles","2025","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.111.oc10.6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050809","8348 A Rare Case Of Liraglutide-Associated Angioedema Requiring Emergent Intubation","Tasnuva Amin","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.651",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050810","Exenatide (revision number 4)","Filip Krag Knop","2012","Diapedia.org eBooks","other","article","10.14496/dia.8104335176.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050811","GLP-1 based therapies and cancer (revision number 21)","Edwin A M Gale","2013","Diapedia.org eBooks","other","article","10.14496/dia.6104477126.21",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050812","Weight Loss and Engagement in a Tirzepatide-Supported Digital Obesity Program: A Four-Arm Patient-Blinded Retrospective Cohort Study","Louis A Talay","2024","Telemedicine Reports","nonrandomized_study","article","10.1089/tmr.2024.0058",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050813","Réaction chronique du greffon contre l’hôte et atteinte rénale","Samia Barbouch","2011","Néphrologie & Thérapeutique","randomized_trial","article","10.1016/j.nephro.2011.07.391",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050814","Synergistic Role of Creatine Monohydrate in Mitigating Skeletal Muscle Wasting and Strength Decline during GLP-1 Receptor Agonist Therapy: A Comperhensive Review","Aladdin M Salama","2026","Quality in Sport","nonrandomized_study","article","10.12775/qs.2026.53.70226",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050815","Quick Take Vol. 91","Amanda Koire","2026",null,"nonrandomized_study","article","10.64239/pi-it-qt91",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","report"],["R0050816","Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist, for Patients with Type 2 Diabetes Mellitus and CKD","Victoria Parker","2020","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20203110s1348b",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050817","Studies on Leaves and its Volatile Oil of Citrus Aurantium L - A Promising Anti Infective with Antiplasmid, Innate Immunity Stimulation Agent.","Sowmya Dhanalakshmi","2011",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0050818","#462 Initiation of SGLT2i vs GLP1-RA and incidence of AKI in persons with type 2 diabetes mellitus","Simon Kok Jensen","2024","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfae069.111",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050819","SUN-695 Clinical Presentation of a Patient With Hemochromatosis After Bariatric Surgery With HFE (H63D) Mutation","Karla Baez","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.202",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050820","Proportion de patients présentant soit un taux d’HbA1c < 7 %, soit une baisse d’au moins 1 % après 2 ans de traitement par le liraglutide – Analyse post-hoc des résultats de l’étude EVIDENCE®","J.F. Gautier","2015","Annales d Endocrinologie","other","article","10.1016/j.ando.2015.07.233",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050821","Lesser eGFR Decline with Dulaglutide Regardless of Weight Changes in People with Type 2 Diabetes and Moderate to Severe Chronic Kidney Disease (AWARD-7)","Katherine R. Tuttle","2018","Diabetes","other","article","10.2337/db18-1066-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050822","THU-244 Synergistic hepatoprotective effects of semaglutide and resmetirom combination therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH","Kristoffer Voldum-Clausen","2024","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(24)01707-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050823","Le médicament du mois. Le dulaglutide (Trulicity®) : Nouvel agoniste des récepteurs du Glucagon-Like Peptide-1 en injection hebdomadaire pour traiter le diabète de type 2","André Jacques Scheen","2016","RMLG. Revue médicale de Liège","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050824","IC‐P‐090: Corrected Cerebral Flow Reserve from Brain SPECT as a Marker of Dementia Risk","Harold T. Pretorius","2011","Alzheimer s & Dementia","other","article","10.1016/j.jalz.2011.05.056",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050825","Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience","Mira Valentinova Siderova","2025","Pharmacia","other","article","10.3897/pharmacia.72.e163319",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050826","IDegLira Achieved Non-Inferior A1C Reduction, Weight Loss and Fewer Hypoglycemic Episodes While Using a Simple Regimen with Fewer Injections and Dose Adjustments Compared with Basal–Bolus Therapy","Eden M Miller","2018","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2018.08.144",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050827","Liraglutide, the Synthetic Glucagon-like Peptide-1 Receptor Agonist, Improves Insulin Sensitivity of 3T3-L1 Adipocytes and Affects the Kinetics of Mitogenic and Inflammatory Kinases","Elizaveta D. Mamontova","2021","Metabolism","other","article","10.1016/j.metabol.2020.154482",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050828","Abstract 4371988: Cardiovascular Outcomes of Oral Incretin-Based Therapies in Type 2 Diabetes: A Systematic Review and Meta-Analysis of 62,821 Patients","Muhammad Faizan Ali","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4371988",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0050829","P1149 L’association Exenatide et Glargine est t-il une association de longue durée chez les patients diabétique type 2 ?","Dured Dardari","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71896-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050830","Predictors of success and failure in achieving glycemic control targets in patients with type 2 diabetes on basal insulin: review of the real-world evidence studies","Vadim Valer'evich Klimontov","2022","Diabetes Mellitus","nonrandomized_study","article","10.14341/dm12950",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050831","ASSESSING THE RISK OF POST-ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY COMPLICATIONS IN TYPE 2 DIABETICS ON GLP-1 AGONISTS: A MULTICENTER ANALYSIS","Sanya Goswami","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.2653",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050832","S2100 Incidence of Gallstone Formation in Type 2 Diabetes Patients Treated With GLP-1 Agonists: A 24-Month Prospective Study","Ahmed E Salem","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037768.42959.91",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050833","735: GLP-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH INCREASED RISK REDUCTION OF COLORECTAL CANCER WHEN COMPARED TO BARIATRIC SURGERY IN OBESE PATIENTS WITH DIABETES MELLITUS: A MATCHED COHORT STUDY","Omar Al Ta’ani","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)01340-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050834","131 (PB119): Novel Androgen Receptor Antagonists with Improved Activity Against Common LBD Variants Associated with Therapeutic Resistance","Rohit Malik","2024","European Journal of Cancer","other","article","10.1016/j.ejca.2024.114654",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050835","Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes","Matthew A. Cavender","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.4319",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050836","S1098 Increased Diagnoses of IBS and Functional Dyspepsia in Patients With Uncomplicated Diabetes Mellitus on GLP-1 Receptor Agonists: A Propensity-Matched Cohort Analysis","Mohamed H. Eldesouki","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001131852.26831.fd",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050837","Review Article Advances in pharmacotherapy of Type-2 diabetes (Part-2: The incretin mimetics)","Tarik Abdelkareim Elhadd","2009",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050838","501. A Systematic Review Exploring the Neuropsychiatric Safety of GLP-1 Receptor Agonists in Patients Taking Second-Generation Antipsychotics","Ahmed Ahmed","2025","Biological Psychiatry","systematic_review","article","10.1016/j.biopsych.2025.02.740",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0050839","Patient experiences with tirzepatide in SURMOUNT-4","Irina Jouravskaya","2024","Obesity Research & Clinical Practice","other","article","10.1016/j.orcp.2024.09.079",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050840","E-book: Gewichtsverlies - Uitgave 2024","Carlien De Herdt","2024","Tijdschrift voor Geneeskunde","other","article","10.47671/tvg.80.24.e002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050841","Development of a self‐management education module for those with type 2 diabetes on injectable therapies","Heather Daly","2015","Practical Diabetes","randomized_trial","article","10.1002/pdi.1979",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050842","26-A-13389-ACC GLP-1 THERAPY REDUCES MORTALITY COMPARED TO DPP-4 INHIBITORS IN PEOPLE WITH HIV: EVIDENCE FROM A REAL-WORLD COMPARATIVE STUDY","Yussif Issaka","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.760",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050843","Bewertung des Gesundheitszustandes mithilfe des EQ-5D bei Teilnehmern der LEADER Studie mit Typ 2 Diabetes (T2D)","MA Nauck","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0037-1601617",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050844","128-LB: Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation Basal Insulins (BI) in Insulin-Naïve Type 2 Diabetes (T2D) Patients (Pts) With and Without Cardiovascular Disease (CVD): Outcomes of the Randomized Pragmatic Real-Life Clinical Trial ACHIEVE Control","Juan P. Frías","2019","Diabetes","randomized_trial","article","10.2337/db19-128-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050845","Metabolic effects of liraglutide in type 2 diabetic patients.","Mariola Méndez Muros","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p499",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050846","54-OR: Oral Semaglutide vs. Empagliflozin Added On to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2","Eduard Montanya","2019","Diabetes","randomized_trial","article","10.2337/db19-54-or",null,null,"ClinicalTrials.gov:NCT02863328","S000251","openalex","FALSE","paywalled","1","FALSE","article"],["R0050847","Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis","Awadhesh Kumar Singh","2016","Indian Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/2230-8210.196026","28217490",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050848","Pas d’interaction entre le bénéfice cardiovasculaire procuré par le liraglutide dans l’étude LEADER et l’existence d’une insuffisance cardiaque","Michel Marre","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.209",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050849","Thyroid calcitonin and C-cell hyperplasia increase with exenatide use: a rat model","Deepti G. Bulchandani","2011","The FASEB Journal","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050850","S853 Safety of MAC Anesthesia in Patients Taking GLP-1RA Undergoing EGD vs Colonoscopy vs Bidirectional Endoscopy: A Retrospective Analysis","Rabih Ghazi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032780.97000.21",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050851","Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatohepatitis (MASH)","HARPREET SINGH BAJAJ","2025","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2025.10.006",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050852","Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First in Human Dose Study in Healthy Subjects","Shweta Urva","2022","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0042-1746266",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050853","PO-02-096 CARDIOPROTECTIVE EFFECTS OF GLP-1RAS IN HEART FAILURE: ATRIAL FIBRILLATION RISK REDUCTION INDEPENDENT OF BMI","Yara Menassa","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.487",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050854","Economic effectiveness of fixed-dose combination of alogliptin and pioglitazone in diabetes mellitus treatment","Sergey Kensarinovich Zyryanov","2025","FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","nonrandomized_study","article","10.17749/2070-4909/farmakoekonomika.2024.290",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050855","Global Trends in Risk Factors and Therapeutic Interventions for People with Diabetes and Cardiovascular Disease: Results from the WHO International Clinical Trials Registry Platform","Musawenkosi Ndlovu","2023","Diabetology","nonrandomized_study","article","10.3390/diabetology4040050",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050856","Effect of 3-Month Therapy with Empagliflozin on Ambulatory Blood Pressure and Arterial Stiffness in Patients with Type 2 Diabetes Mellitus","Athanasia K. Papazafiropoulou","2021","Annals of African Medicine","other_trial","article","10.4103/aam.aam_19_20","34213486",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0050857","The language of GLP-1 medication in UK Media discourse: a diachronic perspective","Dawn Knight","2026","Applied Corpus Linguistics","other","article","10.1016/j.acorp.2026.100196",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050858","S720 Glucagon-Like Peptide 1 Receptor Agonists Reduce All-Cause Mortality and Healthcare Utilization in Patients With Type 1 Diabetes","Andrew M. Ford","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130340.87475.cf",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050859","Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020","Patrick Liu","2021","JAMA Network Open","other","article","10.1001/jamanetworkopen.2020.35064","33481031",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050860","Abstract 4370557: Cardiovascular Benefits of GLP-1 Receptor Agonists in Non-Obese Patients with Heart-Failure: A Real-World TriNetX Analysis","THIERRY KOCHKARIAN","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4370557",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050861","EE37 Validation of a De Novo Microsimulation Model to Assess the Cost-Effectiveness of Semaglutide 2.4MG in Adults With Overweight or Obesity","Chistopher Fawsitt","2024","Value in Health","other","article","10.1016/j.jval.2024.10.321",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050862","Abstract IA002: Early-Onset Colorectal Cancer as a Model for Precision Cancer Prevention","Andrew Tan Chan","2025","Clinical Cancer Research","other","article","10.1158/1557-3265.earlyonsetca25-ia002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050863","Interactions of a Glucagon-like peptide 1 and a Glucagon-like peptide 1 analogue, liraglutide, with the endogenous receptor","Tine Maja Frederiksen","2015","Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050864","A-6 | THE IMPACT OF GLP-1 AGONISTS ON ONE-YEAR AND THREE-YEAR ATRIAL FIBRILLATION INCIDENCE AMONG OBESE PATIENTS WITH OBSTRUCTIVE SLEEP APNEA ON PAP THERAPY","Samuel B. Governor","2026","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2026.104501",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050865","S848 Perioperative GLP-1 Receptor Agonist Impact on Endoscopy and Colonoscopy Outcomes: A Systematic Review and Meta-Analysis","Yahya Alsawaf","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001032760.30423.11",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0050866","The GLP-1R agonist exendin-4 reduces cerebrospinal fluid secretion and intracranial pressure","Hannah F. Botfield","2017","Endocrine Abstracts","other","article","10.1530/endoabs.50.oc3.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050867","Abstract #239 Insulin Degludec/Liraglutide (Ideglira) Achieved Non-Inferior A1c Reduction; Weight Loss and Fewer Hypoglycemic Episodes while Using a Simple Regimen with Fewer Injections and Dose Adjustments Compared with Basal–Bolus Therapy: An Analysis of Dual VII","Eden M Miller","2018","Endocrine Practice","other","article","10.1016/s1530-891x(20)47085-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050868","Semaglutide Rewires Placental Trophoblast Dynamics: Effects on Survival and Signaling","Juan Alberto Arroyo","2025","Placenta","other","article","10.1016/j.placenta.2025.08.302",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050869","927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4","Richard E. Pratley","2020","Diabetes","randomized_trial","article","10.2337/db20-927-p",null,null,"ClinicalTrials.gov:NCT02863419","S000133","openalex","FALSE","paywalled","1","FALSE","article"],["R0050870","Features of management of patients with endocrineand metabolic disorders during the COVID-19pandemic: the statement from European Societyof Endocrinology","С. М. Ткач","2020","Clinical endocrinology and endocrine surgery","other","article","10.30978/cees-2020-2-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050871","GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes","Juris Jendrik Meier","2005","Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents","other","article","10.2174/156801305774962150",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050872","Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes","Ralph A. DeFronzo","2004","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050873","Efficacité du semaglutide versus dulaglutide en fonction du taux initial d’HbA1c dans l’étude SUSTAIN 7","Bruno Guerci","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.188",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050874","Selenium and Exendin‐4 Combination is a Promising Therapeutic Approach for Diabetes Mellitus","Mohamed El‐Sayed Moustafa","2018","The FASEB Journal","preclinical","article","10.1096/fasebj.2018.32.1_supplement.670.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050875","8687 The Efficacy of GLP1 Receptor Agonists in Obese Women with PCOS in Promoting Weight Loss and Hormonal Regulation: A Systematic Review and Meta-Analysis","B Austregesilo Athayde H Morais","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.1073",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0050876","SEMAGLUTIDE IS AN INDEPENDENT RISK FACTOR FOR RETAINED GASTRIC CONTENTS AND RECOMMENDATION FOR REPEAT UPPER ENDOSCOPY: RESULTS FROM A REAL-WORLD POPULATION COHORT STUDY","Haarika Korlipara","2024","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/j.gie.2024.04.1135",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050877","Optimal control and stability analysis of a glucose-insulin-FFA dynamic model with GLP-1 incretin effects","Salma Al-Tuwairqi","2026","Mathematical Modelling and Analysis","other","article","10.3846/mma.2026.24231",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050878","TCT-206 Impact of GLP-1 Receptor Agonist Use on Outcomes Following PCI in Acute Coronary Syndrome: A Multicenter Real-World Analysis","Mohammad Alqadi","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2025.09.287",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050879","26-CVT-14097-ACC GLP-1 RECEPTOR AGONIST USE IN HEART FAILURE WITH REDUCED EJECTION FRACTION","Sahaana Veeravalli","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.3093",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050880","1269-PUB: Evaluating the Response to GLP-1 Agonists in Veterans with Type 2 Diabetes Mellitus","Brett Begley","2021","Diabetes","nonrandomized_study","article","10.2337/db21-1269-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050881","76-LB: Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)–Experienced Adults with Type 2 Diabetes (T2D) Switching to Once-Weekly (OW) Semaglutide in a Real-World Setting—SURE Program Post Hoc Analysis","Gottfried Rudofsky","2023","Diabetes","nonrandomized_study","article","10.2337/db23-76-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050882","Cost-effectiveness of liraglutide for subjects with type 2 diabetes in Spain","André R. Arellano","2014","Value in Health","other","article","10.1016/j.jval.2014.03.1455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050883","Safety and Efficacy of Semaglutide Therapy in Advanced Heart Failure Patients Awaiting Heart Transplantation","Gregor Poglajen","2024","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2024.02.701",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050884","Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH","Kenneth J. Cusi","2024","New England Journal of Medicine","other","article","10.1056/nejme2314365","38324491",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050885","Efficacy and Safety of Lixisenatide in Elderly Type 2 Diabetes Mellitus Patients: Subanalysis from the GetGoal Program","Richard Dumas","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.085",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050886","Overcoming mitochondrial dysfunction in neurodegenerative diseases","João Pessoa","2022","Neural Regeneration Research","preclinical","article","10.4103/1673-5374.360279","36571346",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050887","P1085 Impact et rôle du liraglutide, un analogue du GPL-1 humain, dans le diabète de type-2 : le rationnel et le design de l’étude LEADER® évaluant les paramètres cardiovasculaires","Florence Travert","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71831-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050888","MON-705 Initiation of Semaglutide: Understanding National Prescription Behaviors in Real-World Practice","Saman Modi","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.042",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050889","Abstract 4363148: Polygenic Modification of Weight Loss Response to GLP-1 Receptor Agonists","Buu Minh Thanh Truong","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4363148",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050890","Efficacy and Safety of Non-surgical Bariatric Therapies for Non-alcoholic Steatohepatitis and Metabolic Syndrome: A Comparative Meta-Analysis","Thomas R. McCarty","2016","The American Journal of Gastroenterology","systematic_review","article","10.14309/00000434-201610001-00844",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0050891","Appetite regulation: from the gut to the hypothalamus","Nicola M. Neary","2003","Clinical Endocrinology","other_trial","article","10.1046/j.1365-2265.2003.01839.x","14725674",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050892","Liraglutide in patients with heart failure with preserved ejection fraction and obesity without diabetes","Joseph Kassab","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.998",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050893","Effect of prior GLP-1 RA treatment on clinical outcomes in patients with type 2 diabetes initiating treatment with tirzepatide","Mohammed Ahmed Suliman","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.p455",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050894","Liraglutide-Induced Hypercalcemia with AKI","Nilam P. Patel","2021","Journal of the American Society of Nephrology","other","article","10.1681/asn.20213210s1148a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050895","105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study","Timothy Silleck Bailey","2021","Diabetes","nonrandomized_study","article","10.2337/db21-105-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050896","Abstract 40: Comparative Effectiveness Of Sglt2 And Glp1ra On Major Adverse Cardiac Events: A National Retrospective Cohort Of Patients With Diabetes","Tadarro Lee Richardson","2022","Circulation Cardiovascular Quality and Outcomes","nonrandomized_study","article","10.1161/circoutcomes.15.suppl_1.40",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050897","Glucagon-like Peptide-1 Receptor Agonists and New Opportunities in Primary Prevention of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus","Yu. Sh. Khalimov","2021","Doctor Ru","randomized_trial","article","10.31550/1727-2378-2021-20-2-21-29",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050898","Pharmacological Modifiers of Atrial Fibrillation Recurrence After Catheter Ablation: An Umbrella Review of Meta-Analyses","Nabeel M. Abdo","2026","Heart Rhythm O2","systematic_review","article","10.1016/j.hroo.2026.08.149",null,null,"PROSPERO:CRD420261361247",null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0050899","Higher dose oral semaglutide shown to produce remarkable weight loss and/or reduce Hba1c levels in overweight and obese patients with or without type 2 diabetes","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","other_trial","article","10.1002/doi2.66",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0050900","Add-on treatment of GLP-1 based therapy in patients with type 2 diabetes treated with insulin : an observational study","Wouter T. Zandee","2012","Data Archiving and Networked Services (DANS)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050901","GLP-1 Receptor Agonists and Risks of Hyperthyroidism and Hypothyroidism in Type 2 Diabetes: A Real-World Cohort Study","Jia-Ai Yeh","2025","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.5246544",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0050902","68Ga-exendin-4 PET/CT detects insulinomas in patients with hypoglycemia in multiple endocrine neoplasia type 1","Kwadwo Antwi","2019","Endocrine Abstracts","other","article","10.1530/endoabs.63.gp1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050903","[Artículo traducido] Exploración del impacto de la farmacogenética en la medicina personalizada: una revisión sistemática","Laura Amaro-Álvarez","2024","Farmacia Hospitalaria","other","article","10.1016/j.farma.2024.03.010","38851909",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050904","THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes","Anvitha Reddy Ankireddypalli","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.729",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050905","Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial","Christopher Bull Granger","2025","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/fxhs-bj80",null,null,"ClinicalTrials.gov:NCT03936660","S002431","openalex","TRUE","paywalled","1","FALSE","article"],["R0050906","The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.70001",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050907","Comparative Analysis of Mortality and Cardiometabolic Outcomes in Obese Patients with Type 2 Diabetes Treated with Semaglutide versus Tirzepatide: Insights from the TriNetX Database","Gloria Amoako","2025","American Heart Journal","nonrandomized_study","article","10.1016/j.ahj.2025.07.066",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050908","95-LB: LixilanONE CAN: Randomized Trial Comparing a Daily vs. Weekly Titration Algorithm for Switching from Basal Insulin to iGlarLixi Fixed-Ratio Combination in People with T2DM in Canada","IRENE M. HRAMIAK","2021","Diabetes","randomized_trial","article","10.2337/db21-95-lb",null,null,"ClinicalTrials.gov:NCT03767543","S001367","openalex","FALSE","paywalled","1","FALSE","article"],["R0050909","135-OR: The Effect of Fixed-Dose Combination of Insulin Degludec and Liraglutide on Serum Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus","Eleni T. Pappa","2020","Diabetes","other","article","10.2337/db20-135-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050910","964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program","Kathleen Marie Dungan","2020","Diabetes","randomized_trial","article","10.2337/db20-964-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050911","1549-P: Race and Gender Differences in the Initiation of Recently Approved Diabetes Drugs by Privately-Insured U.S. Adults","Rozalina Grubina McCoy","2020","Diabetes","other","article","10.2337/db20-1549-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050912","Pioglitazone for Type 2 Diabetes Mellitus and Pre-Diabetes: A Review of Safety [Internet]","Dave K. Marchand","2020",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0050913","Glucagon-Like Peptide 1 Receptor Agonists Use in Obese Simultaneous Pancreas-Kidney Transplant Recipients: A Single Center Experience","Mohammad Abuzeineh","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.2415",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050914","Tolerability and weight loss effects of liraglutide in obese adults: a 104-week randomised trial","Arne Vernon Astrup","2009","UCL Discovery (University College London)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0050915","PO415 GREATER PPG CONTROL ACROSS ALL 3 MAIN MEALS WITH LIRAGLUTIDE VS PLACEBO, WHEN ADDED ON TO METFORMIN AND ROSIGLITAZONE","Gregory R. Fulcher","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70709-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050916","Su2056: IMPACT OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS ON WEIGHT LOSS AND DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON TUMOR NECROSIS FACTOR-ALPHA INHIBITORS","Ravi Teja Pasam","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03108-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050917","Abstract 35: Association of SGLT2 Inhibitors and Other Second Line Therapies With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes","Wendy Wang","2024","Circulation","nonrandomized_study","article","10.1161/circ.149.suppl_1.35",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050918","233-OR: Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) vs. Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria Status: AWARD-7","Katherine R. Tuttle","2019","Diabetes","randomized_trial","article","10.2337/db19-233-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050919","GLP-1 agonists: a new approach for type 2 diabetes","Ashley N. Taylor","2003","Inpharma Weekly","other","article","10.2165/00128413-200314070-00020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050920","Practical application of semaglutide: From evidence-based research to expert decisions","В. В. Салухов","2025","Meditsinskiy sovet = Medical Council","randomized_trial","article","10.21518/ms2025-185",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0050921","Su1304: DIFFERENTIAL EFFECTS OF GLP-1 AGONISTS ON CHROMATIN MODULATION","Andrew Shing-Tao Chang","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02652-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050922","The contribution of hormonal disorders in the pathogenesis of metabolic-associated steatotic liver disease","G. D. Fadieienko","2024","Modern Gastroenterology","other","article","10.30978/mg-2024-2-26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050923","146 Glucagon-like peptide-1 analogues exert differential in vitro actions on macrophages and cardiac fibroblasts in experimental diabetes","Rawan A Abudalo","2018",null,"preclinical","article","10.1136/heartjnl-2018-bcs.142",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050924","OP06 Utilizing Health Technology Assessment Outputs To Develop Health Technology Management Protocols In The Irish Setting","Claire Gorry","2024","International Journal of Technology Assessment in Health Care","other_trial","article","10.1017/s0266462324000709",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0050925","1070-P: Bromocriptine-QR (BQR) Ameliorates a Pro-oxidative Stress/Proinflammatory (POS/PI) Monocyte Phenotype in Poorly Controlled T2DM Subjects","Michael Ezrokhi","2020","Diabetes","other","article","10.2337/db20-1070-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050926","S767 Head-to-Head Comparison of Tirzepatide and Semaglutide: A Dose-Stratified Review of 2 Randomized Controlled Trials","Rahul Tripathi","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001130528.82045.8d",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0050927","Association between dapagliflozin, cardiac biomarkers, and cardiac remodeling in patients with diabetes mellitus and heart failure: a post-hoc analysis of a randomized study","Αndrew Xanthopoulos","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.794",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050928","RF04 | PSUN295 Evolution of Monomeric Multi-Agonists of GLP-1 and NPY Receptors","Kylie S. Chichura","2022","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvac150.871",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050929","Risk factors associated with hypoglycemia in patients treated with either exenatide once weekly or insulin glargine","S. Paul","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050930","Real-Life Efficacy of Liraglutide Therapy on Weight-Loss in Patients with Overweight and Obesity","Michela Del Prete","2023","Journal of Surgery and Research","nonrandomized_study","article","10.26502/jsr.10020304",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0050931","Effect of GLP-1 analoque on weight reduction and metabolic parameters in type 2 diabetes","Elen Chmelařová","2026","Digital Repository (National Repository of Grey Literature)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0050932","1427-P: Factors Predicting Significant Improvement in Glycemic Control after Endocrinology Referral in Patients with Type 2 Diabetes Mellitus and Hemoglobin A1c ≥ 10%","Vanessa R. Williams","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1427-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050933","Durable HbA1c Reduction with Initial Combination Therapy with Metformin/Pioglitazone/Exenatide in Subjects with New-Onset Diabetes—Six-Year Follow-Up of the EDICT Study","Muhammad A Abdul‐Ghani","2018","Diabetes","randomized_trial","article","10.2337/db18-123-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0050934","P1‐181: DULAGLUTIDE IMPROVES LEARNING AND MEMORY IMPAIRMENT, HYPERPHOSPHORYLATED TAU AND NEUROFILAMENTS IN THE APP/PS1/TAU TRIPLE TRANSGENIC MICE","Mei Zhou","2018","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2018.06.185",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050935","WCN25-3765 Title: Acalculous Cholecystitis, A rare complication of GLP 1 Receptor Agonist (GLP1 RA) after kidney transplant","Harshil A. Fichadiya","2025","Kidney International Reports","other","article","10.1016/j.ekir.2024.11.963",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050936","Pharmacokinetics modeling of PET imaging with a GLP-1R targeted radiotracer in Ossabaw mini-pigs for noninvasive assessment of pancreatic beta-cell mass","Saleh M. Ramezani","2014","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050937","MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Enhances Leptin-Mediated pSTAT3 Induction in Key Neuronal Regions That Regulate Metabolism","Hani A. Jouihan","2018","Diabetes","preclinical","article","10.2337/db18-1788-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050938","The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 12-month data analysis","Bruno Guerci","2022","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0042-1746272",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050939","Novel stable Val8 glucagon-like peptide-1 analogue with potent insulin releasing activity.","Brian Green","2002","Research Portal (Queen's University Belfast)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0050940","Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH","Naga Chalasani","2026","Hepatology","randomized_trial","article","10.1097/hep.0000000000001792","42127430",null,"ClinicalTrials.gov:NCT04767529; ClinicalTrials.gov:NCT05039450","S002626","openalex","TRUE","free_to_read","1","FALSE","article"],["R0050941","Reopening the case for case reports","Chantal Cotter","2020","British Journal of Dermatology","case_report","article","10.1111/bjd.18464","31894875",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0050942","GW26-e1348 Exendin-4 protects adipose-derived mesenchymal stem cells (ADMSCs) from apoptosis induced by Hydrogen Peroxide through PI3K/Akt-Sfrp2 pathways","Hao Zhou","2015","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2015.06.1271",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050943","810-P: The Diminishing Cost-Effectiveness of the Newer Glucose-Lowering Drugs in the United States, 2010-2018","Piaopiao Li","2021","Diabetes","nonrandomized_study","article","10.2337/db21-810-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050944","Cardiorenalis-metabolikus szemlélet az orvoslásban – gondolatok, tudnivalók az új ajánlások nyomán az SGLT-2-gátlókkal és GLP-1-receptor-agonistákkal kapcsolatban","Laszlo Jozsef Wagner","2023","Hypertonia és Nephrologia","other","article","10.33668/hn.27.037",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050945","1090-P: Achievement of Guideline-Directed Diabetes Management in Patients Treated by Cardiologists vs. Endocrinologists after Myocardial Infarction—A Nationwide Population-Based Study","HYE-JIN YOON","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1090-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050946","Sa1107: INTERIM RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS OF GASTROESOPHAGEAL REFLUX DISEASE AND GASTROINTESTINAL MOTILITY RELEVANT SYMPTOMS IN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST-BASED RANDOMIZED CONTROLLED TRIALS.","Benjamin Douglas Xun Liu","2025","Gastroenterology","systematic_review","article","10.1016/s0016-5085(25)01757-3",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0050947","Effect of Tirzepatide on Glycemic Profile Based on Real‒time Continuous Glucose Monitoring in Two Patients with Type 2 Diabetes Undergoing Hemodialysis","Akiko N. Mizuno","2025","Nihon Toseki Igakkai Zasshi","other","article","10.4009/jsdt.58.294",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050948","SIU-ICUD: Prevention of Lethal Prostate Cancer via Modifiable Heart-Healthy Lifestyle Changes, Metrics, and Repurposed Medications","Mark A. Moyad","2025","Société Internationale d’Urologie Journal","other","article","10.3390/siuj6030040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050949","2237-PUB: Diabetes Inside: Regional Collaborative to Improve DM and CVD Care Quality","ROY E. FURMAN","2020","Diabetes","other","article","10.2337/db20-2237-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050950","Combined effect of Dapagliflozin and Tirzepatide on weight loss and glucose regulation","Jehad Ahmed Abubaker","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112530",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050951","Abstract 14549: Body Mass Index Shift and Associated Cardiometabolic Risk Factors in People With Obesity or Overweight: A Post Hoc Analysis From SURMOUNT-1","Naveed A. Sattar","2023","Circulation","other","article","10.1161/circ.148.suppl_1.14549",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050952","Oral Insulin and GLP-1 Receptor Agonist Delivery Technological Advances and Physiological Barriers Toward Non-Invasive Diabetes Therapeutics","Gnanasekaran Ashok","2026","Integrative Biomedical Research","nonrandomized_study","article","10.25163/biomedical.10210939",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050953","Abstract TH935: Glucagon-Like Peptide-1 Receptor Agonists Are More Frequently Prescribed to Individuals at Lower Predicted Cardiovascular Risk Than Those at Higher Risk Among People Without Diabetes","Shuhan Yang","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.th935",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050954","Signalling and Regulation of the Glucagon-like Peptide-1 receptor","Jing Nan Lu","2014","Figshare","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0050955","Semaglutide-Treated Participants in the Phase 3 ESSENCE Trial (Part 1) Have Greater Concordance of Non-invasive Test Improvements Compared With Placebo","HARPREET SINGH BAJAJ","2025","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2025.10.045",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050956","THE EFFECT OF GLP-1 AGONISTS IN PATIENTS WITH TYPE 2 DIABETES ON ALL-CAUSE MORTALITY AND CARDIOVASCULAR MORTALITY: AN UPDATED META-ANALYSIS OF 44 RANDOMIZED CONTROLLED TRIALS","Mohammed Al‐Sadawi","2022","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(22)02533-5",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0050957","Tirzepatide Improved Markers of Islet Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared to Semaglutide in People with Type 2 Diabetes","Katelyn E. Brown","2024","Metabolism","other","article","10.1016/j.metabol.2024.155883",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050958","Better improvements of indicators of β-cell function and insulin resistance with liraglutide compared to sitagliptin in Chinese T2DM patients","Yu Liu","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31142-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050959","Comparative Analysis of Arrhythmia Risk: SGLT2 inhibitors versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Inflammatory Arthritis","Godbless Ebruvwiyor Ajenaghughrure","2025","American Heart Journal","other","article","10.1016/j.ahj.2025.07.021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050960","OC3.01.1 EXENDIN-4 PROTECTS CHOLANGIOCYTES FROM APOPTOSIS, BOTH IN VITRO AND IN VIVO","Marco Marzioni","2008","Digestive and Liver Disease","preclinical","article","10.1016/s1590-8658(08)60091-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050961","The contributions of insulin to science in medicine","Peter Kurtzhals","2021","Diabetic Medicine","other","article","10.1111/dme.14623","34133769",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050962","PS257 Gender Differences in Peak-Stress Myocardial Blood in Patients with Suspected CAD: A Study with 13 N-Ammonia Pet","L.E. Juárez Orozco","2016","Global Heart","preclinical","article","10.1016/j.gheart.2016.03.198",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050963","Sequence of Unfortunate Events Leading to Persistent Acidosis Ending Fatally","Marwa Mohammed Fouad","2021","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.22038/apjmt.2021.19453",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050964","Nephroprotective potential of glucagon-like peptide-1 receptor agonists","Минара Шамхаловна Шамхалова","2020","Diabetes Mellitus","other","article","10.14341/dm12379",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050965","Treatment with GLP-1 Receptor Agonists","Sten Madsbad","2018","Endocrinology","other","article","10.1007/978-3-319-45015-5_20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0050966","MOUNJARO NO EMAGRECIMENTO: POTENCIAL TERAPÊUTICO E EFICÁCIA NO CONTROLE DE PESO EM PACIENTES OBESOS","João Sérgio de Sousa Moura","2025","Revista fisio&terapia.","other","article","10.69849/revistaft/fa10202501071942",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050967","Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial","Rohit S. Loomba","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807443",null,null,"ClinicalTrials.gov:NCT04166773","S000031","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0050968","455 PROSPECTIVE, MATCHED CASE-CONTROL STUDY OF ENDOSCOPIC SLEEVE GASTRECTOMY AND SEMAGLUTIDE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE","Ali Lahooti","2023","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(23)03909-4",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050969","PDB50 Long-Term Clinical and Economic Benefit Associated with Liraglutide Versus Sitagliptin Therapy When Added to Metformin in the Treatment of Type 2 Diabetes: a Core Diabetes Model Study","W.C. Lee","2012","Value in Health","other","article","10.1016/j.jval.2012.03.971",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050970","Abstract 4359422: Low-Dose GLP-1 Receptor Agonist Therapy Exerts Anti-Fibrotic Effects Across Multiple Organs in Cardiometabolic HFpEF","Mahmoud H. Elbatreek","2025","Circulation","other_trial","article","10.1161/circ.152.suppl_3.4359422",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0050971","IDF21-0036 Patient-Reported Outcomes in Patients with Type 2 Diabetes Treated with Tirzepatide or Insulin Degludec (SURPASS-3)","Melvin J. Yu","2022","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2022.109700",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050972","MSR2 COMPARING SELF-CONTROLLED CASE SERIES AND COHORT DESIGNS FOR ESTIMATING PANCREATITIS RISK ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS: A MONTE CARLO SIMULATION STUDY","Bryan L. Love","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.1501",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","article"],["R0050973","Semaglutide radiomarqué [3H] : absorption, métabolisme et excrétion après une dose unique en sous cutané chez le sujet sain","Bertrand Cariou","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30423-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050974","Preliminary results of dulaglutide treatment in patients with non-alcoholic fatty liver disease (DEMOS study)","Pavel Bogomolov","2020","Экспериментальная и клиническая гастроэнтерология","nonrandomized_study","article","10.31146/1682-8658-ecg-169-9-4-10",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050975","777-P: Predictors of Selection of a GLP1RA vs. SGLT2i in People with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease","Shubham Agarwal","2024","Diabetes","nonrandomized_study","article","10.2337/db24-777-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0050976","488-P: Effects of Novel Antidiabetic Therapy on Platelet Reactivity in Patients with Type 2 Diabetes Mellitus","Gerasimos Siasos","2019","Diabetes","other","article","10.2337/db19-488-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050977","THE IMPACT OF GLUCAGON LIKE PEPTIDE-1 AGONIST THERAPY ON HEART RATE IN ADVANCED SYSTOLIC HEART FAILURE: AN ANALYSIS FROM THE FUNCTIONAL IMPACT OF GLP-1 FOR HEART FAILURE TREATMENT STUDY","Amanda R. Vest","2017","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(17)34248-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050978","924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND","Helen Martina Colhoun","2020","Diabetes","other_trial","article","10.2337/db20-924-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0050979","Abstract 4370283: Real-World Effectiveness of GLP-1 Receptor Agonists on Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF).","Cheryl Kalapura","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4370283",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050980","International lack of equity in modern obesity therapy: the critical need for change in health policy","Pia Roser","2022","International Journal of Obesity","other","article","10.1038/s41366-022-01176-2","35778480",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050981","Mo2061: GLP-1 RECEPTOR AGONIST SEMAGLUTIDE INDUCES ENTEROENDOCRINE CELL ALTERATIONS PERSISTENT AFTER DISCONTINUATION","Alison Mcrae","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03831-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050982","S332 Association Between ICI and Chronic Colon Mucosal Inflammation: IBD and Microscopic Colitis Risk","Danah Al-Deiri","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001128788.87987.36",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050983","The use of fixed ratio combination of insulin glargine and lixisenatide in patients with type 2 diabetes mellitus in real clinical practice. Own clinical experience","L.Yu. Khamnueva","2020","Фарматека","other","article","10.18565/pharmateca.2020.12.107-111",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050984","Abstract 4361086: GLP-1 Receptor Agonists and Clinical Outcomes in Non-Diabetic Patients with Peripartum Cardiomyopathy: A Propensity-Matched Retrospective Cohort Study","Yaman Jarrar","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4361086",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050985","Medical Educator as Game Master: What Dungeons & Dragons Can Teach Us About Small Group Learning","Bryan T. Brown","2023","Journal of Graduate Medical Education","other","article","10.4300/jgme-d-22-00943.1","37637326",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050986","Confounder Analysis and Visualization Treatment Pathways Associated to Amputation in patients with Diabetes Using Sankey Diagrams: Enhancing Explainability (Preprint)","Rajashekar Korutla","2025",null,"other","article","10.2196/preprints.81311",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0050987","Exenatide Stimulates Hippocampal Autophagic Activity in Alzeheimer Rat Model","Eman M. Abdo","2020",null,"preclinical","article","10.22541/au.159103395.53489994",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0050988","S4655 Semaglutide Shadows: A Rare Glimpse Into GLP-1-Associated Liver Injury","Harsimran Kalsi","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001047988.25768.29",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0050989","PDB26 Projected Long-Term Clinical and Economic Outcomes of Exenatide Once Weekly Versus Sitagliptin for the Treatment of Type 2 Diabetes in the UK","Amélie Beaudet","2011","Value in Health","other","article","10.1016/j.jval.2011.08.1329",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050990","Epicardial adipose tissue-derived adipo-cytokines induce pro-oxidant and pro-remodeling responses in atrial endothelial cells: synergic inhibitory effects of SGLT2 inhibition and GLP-1R activation","W Fakih","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.4818",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050991","Abstract #1395974: Achieving Waist Circumference Targets with Once Weekly Tirzepatide for the Treatment of Obesity","Ian J. Neeland","2023","Endocrine Practice","other","article","10.1016/j.eprac.2023.03.084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0050992","Neuroimmune Mechanisms in Alcohol Use Disorder: Microglial Modulation and Therapeutic Horizons","Jiang-Hong Ye","2025","Psychoactives","preclinical","article","10.3390/psychoactives4030033",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050993","Jak zapobiegać wzrostowi masy ciała w trakcie terapii neuroleptykami? Jakie leczenie farmakologiczne wdrażać i kiedy? Dialog psychiatry z diabetologiem","Anna Zofia Antosik-Wójcińska","2024","Psychiatria Spersonalizowana","other","article","10.5114/psychs.2024.141669",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050994","S920 Clear Liquid Diet and Colonoscopy Bowel Preparation Are Effective in Eliminating Retained Gastric Contents in Those on GLP1-RA Agents Undergoing Endoscopic Procedures","Anshu Wadehra","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001033048.87672.a5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050995","Comprehensive risk factor management through a dedicated secondary prevention clinic: experience from hamilton, Ontario","Vijay Sardana","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae666.2797",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0050996","Beyond cardio-renal outcomes with GLP-1RA and SGLT2i in anthracycline-treated diabetic women with breast cancer: A propensity score–matched analysis from Global Federated Health Research Network.","Dhriti Sood","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e23079",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0050997","(096) Use of GLP-1 Agonists Associated with Diagnosis of Hypogonadism in Large Retrospective Cohort","Theodore C. Crisostomo-Wynne","2024","The Journal of Sexual Medicine","nonrandomized_study","article","10.1093/jsxmed/qdae001.092",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0050998","760-P: Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist","Ting Mao","2023","Diabetes","preclinical","article","10.2337/db23-760-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0050999","Non-alcoholic fatty liver disease. change from F3 to F1 fibrosis after 12 months of combined pioglitazone and dulaglutide treatment","Luisa Lener","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.ep219",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051000","SAT-094-YI Semaglutide prevents cognitive dysfunction in experimental metabolic dysfunction-associated steatohepatitis through antiinflammatory and neuroprotective effects","Kristoffer Kjærgaard Amby","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)01764-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051001","S1652 Comparison of Bariatric Surgery and Glucagon-Like Peptide-1 Analogs for Prevention of Nonalcoholic Fatty Liver Disease in an Obese Population: A Large Multi-Center Study","Ethan M. Cohen","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000956248.42228.0d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051002","The modulating effects of GLP-1 in type 2 diabetes","Michael Albrecht Nauck","2008","The British Journal of Diabetes","other_trial","article","10.1177/1474651408100521",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0051003","S2080 Analysis of Provider Preferences for AI-Generated Responses to Anti-Obesity Treatments","Thomas W. Fredrick","2024","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001037688.24010.4d",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051004","Glucagon-Like Peptide-1 (7-36)-Amide and Exendin-4 Strongly Stimulate the Hypothalamic-Pituitary-Adrenal Axis in Rodents and in Healthy or Diabetic Humans","Manuel Gil‐Lozano","2010","The Journal of Clinical Endocrinology & Metabolism","preclinical","article","10.1210/jcem.95.5.9984",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051005","277-OR: OCT1 and TCF7L2 Variants Modulate Metformin–Liraglutide Pharmacokinetics and Glycemia in African American Youth-Onset Type 2 Diabetes—The MIGHTY Study","SAMSON L. CANTOR","2025","Diabetes","other_trial","article","10.2337/db25-277-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051006","S938 Re-Examining the Association of Glucagon-Like Peptide-1 Receptor Agonists With Gastroesophageal Reflux Disease Through pH Impedance Testing","Benjamin Douglas Xun Liu","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001131212.65698.cc",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051007","PDB8 A Network Meta Analysis to Compare Glycaemic Control in Patients with Type 2 Diabetes Treated with Exenatide Once Weekly or Liraglutide","David Alexander Scott","2011","Value in Health","other","article","10.1016/j.jval.2011.08.1311",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051008","Liraglutide 3.0 mg for weight management in obese/overweight adults with Type 2 Diabetes: Results from the SCALE diabetes 56-week randomized, double-blind, placebo-controlled trial","Michael J. Davies","2015","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0035-1556576",null,null,"ClinicalTrials.gov:NCT01272232","S001792","openalex","FALSE","paywalled","1","FALSE","article"],["R0051009","Sweetening the Odds: Can Newer Glucose-Lowering Drugs Bend the Arc of Epileptogenesis?","Ifrah Zawar","2026","Epiliepsy currents/Epilepsy currents","nonrandomized_study","article","10.1177/15357597261484442","42688557",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051010","Abstract #20: Effects of Exenatide (Synthetic Exendin-4) on Glucose Control and Safety in Patients with Type 2 Diabetes Treated with Metformin, a Sulfonylurea, or Both: An Ongoing, Open-Label Phase 3 Trial","Terri Poon","2004","Endocrine Practice","other_trial","article","10.1016/s1530-891x(20)46299-8",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0051011","New horizons in Type 2 diabetes mellitus treatment and prognosis management with glucagon-like peptide-1 receptor agonists","Elena Valer'evna Biryukova","2026","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2026-103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051012","Bombesin Preserves the Exocrine Pancreas and Gut‐Islet Axis during Parenteral Nutrition","Joshua C. Neuman","2015","The FASEB Journal","preclinical","article","10.1096/fasebj.29.1_supplement.912.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051013","Caution on the broad prescription of new antidiabetics with favorable cardiovascular effects","Ricardo Víctor García-Mayor","2019","Endocrinology&Metabolism International Journal","other","article","10.15406/emij.2019.07.00249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051014","2P012 分子動力学シミュレーションによるGLP-1とExendin-4の構造解析(01A. 蛋白質:構造,ポスター,第52回日本生物物理学会年会(2014年度))","Sakiko Mori","2014","生物物理","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051015","Glucagon-like peptide-1 receptor agonist use is not associated with reduced postoperative complications in obese patients after total shoulder arthroplasty","Mark F. Megerian","2025","Seminars in Arthroplasty JSES","other","article","10.1053/j.sart.2025.05.006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051016","Alteration of gut microbiota composition in patients with prediabetes and type 2 diabetes mellitus","O. A. Myrinova","2025","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2025-032",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051017","P1757GLP-1 levels predict cardiovascular risk in patients with acute myocardial infarction","Florian Kahles","2019","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehz748.0510",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051018","Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study","Sean Wharton","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785400",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051019","Aflibercept","Dennis J. Cada","2012","Hospital Pharmacy","other_trial","article","10.1310/hpj4705-375",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051020","Effect of Semaglutide on Mortality Outcomes in the FLOW Trial","Richard E. Pratley","2024","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20249xpc35vs",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051021","THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor","Natalia Viera Feliciano","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.822",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051022","Glucagon like peptide-1 receptor agonists and their combination with sodium-glucose cotransporter-2 inhibitors improve myocardial deformation and work index in type-2 diabetes after 12-month treatment","Ignatios Ikonomidis","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.0115",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051023","The protective role of GLP-1 in neuro-ophthalmology","Sohum Sheth","2023","Exploration of Drug Science","other","article","10.37349/eds.2023.00015","37711214",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051024","Des taux plus faibles d’hypoglycémies avec insuline degludec / liraglutide (IDegLira) versus insuline GlargineU100 (IGlar U100) chez les diabétiques de type 2 quels que soient l’horaire d’administration ou le mode de définition des hypoglycémies","Michel Marre","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30435-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051025","ZGN-1061, a Novel MetAP2 Inhibitor, and Liraglutide Combine to Improve Glycemic Control and Reduce Body Weight in a Rat Model of Diet-Induced Obesity","Bryan F. Burkey","2018","Diabetes","preclinical","article","10.2337/db18-108-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051026","Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial","IRENE M. HRAMIAK","2018","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2018.08.126",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051027","S476 Unexpected Findings: GLP-1 Agonist Use Linked to Increased Colonic Polyp Risk in a Diverse U.S. Population","Boniface Mensah","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129364.85006.f0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051028","Quick Take Vol. 89","Scott R. Beach","2026",null,"other","article","10.64239/pi-qt89",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0051029","Insulin Resistance and Weight Loss in Obese Women with Polycystic Ovary Syndrome Treated with Liraglutide—Single Institution Experience","Andrew Robert Crawford","2018","Diabetes","nonrandomized_study","article","10.2337/db18-2452-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051030","Weight gain was associated with worsening glycemia and cardiovascular and kidney outcomes in type 2 diabetes patients independent of diabetes medication in the GRADE Randomized Controlled Trial","Deborah J. Wexler","2025",null,"randomized_trial","article","10.2337/figshare.28611941.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0051031","IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BOWEL PREPARATION FOR COLONOSCOPY","June Tome","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.1117",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051032","Efficacy and Safety of Once Weekly Dulaglutide vs. Once Daily Liraglutide in Type 2 Diabetes (AWARD 6)","Kathleen Marie Dungan","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051033","Preventing Weight Regain after Weight Loss","Stephen Douglas Anton","2023",null,"randomized_trial","article","10.1201/9781003432807-28",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","book-chapter"],["R0051034","Is remission of type 2 diabetes mellitus real?","Stephen N. Stranks","2023","The Medical Journal of Australia","nonrandomized_study","article","10.5694/mja2.52142","37903479",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051035","Association between Cancer and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review of Retrospective Cohort Studies","Hyun Jin Park","2025","Research in Clinical Pharmacy","systematic_review","article","10.59931/rcp.25.0004",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051036","Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial","Henrik Hegaard Sillesen","2021","European Heart Journal","protocol","article","10.1093/eurheartj/ehab724.2027",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051037","Liraglutide and semaglutide: comparative assessment of metabolic and side effects","Tatiana Ivanovna Romantsova","2024","Endocrinology News Opinions Training","other","article","10.33029/2304-9529-2024-13-4-72-83",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051038","WCN25-1900 Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial","Katherine R. Tuttle","2025","Kidney International Reports","other_trial","article","10.1016/j.ekir.2024.11.1358",null,null,"ClinicalTrials.gov:NCT05852938",null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051039","COMPARATIVE ANALYSIS OF MORTALITY OUTCOMES IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION TREATED WITH SEMAGLUTIDE VERSUS STANDARD THERAPY","Sandi Bajrami","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)02195-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051040","Improvement in myocardial energetics and perfusion with Liraglutide in patients with type 2 diabetes- A randomised, single centre, open label, cross-over drug trial","Amrit Chowdhary","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.1810",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051041","“Comment on: Does Prior Bariatric Surgery Predispose to Acetaminophen-Related Acute Liver Failure?”","Mehmet Akif Yağli","2025","Clinical and Translational Gastroenterology","other","article","10.14309/ctg.0000000000000910","40980921",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051042","The integration of patient preferences into quantitative risk-benefit assessment of sodium glucose co-transporter-2 inhibitors for the management of type 2 diabetes","Jennifer R. Donnan","2019","Memorial University Research Repository (Memorial University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0051043","FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist","Sima Fansa","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.088",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051044","Testing for association between exonic glucagon‐like peptide 1 receptor mutation with physical and brain health traits in UK Biobank","Joey Ward","2022","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.14879","36181450",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051045","26-A-12669-ACC REVISITING THE OBESITY PARADOX IN ISCHEMIC HEART DISEASE: OUTCOMES AFTER PCI IN PATIENTS ON GLP-1 AGONISTS","Viraj Shah","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.475",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051046","CO190 Clinical Outcomes of Semaglutide 2.4 Mg in Patients with Obesity or Overweight in a Real-World Setting: A 6-Month Retrospective Study in the United States","Adelaida Lazarova Ruseva","2023","Value in Health","nonrandomized_study","article","10.1016/j.jval.2023.03.2325",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0051047","Short lecture on basic aspects of incretin-based therapy of type 2 diabetes[含 日本語文] (インクレチンに基づいた2型糖尿病治療の可能性)","Jens Juul Holst","2009","Medical Entomology and Zoology","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051048","Quick Take Vol. 79","Oliver Freudenreich","2025",null,"other","article","10.64239/pi-it-qt79",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0051049","EFFECTS OF SGLT2 INHIBITORS ON CARDIOVASCULAR OUTCOMES WITH AND WITHOUT BASELINE USE OF GLP-1 RECEPTOR AGONISTS: A SMART-C COLLABORATIVE META-ANALYSIS","Brendon Lange Neuen","2024","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(24)03898-1",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0051050","Harnessing the Incretin System with Multi-Agonists","Martin Whyte","2022","EMJ Innovation","randomized_trial","article","10.33590/emjinnov/10115628",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051051","Application of liquid chromatography-mass spectrometry for the determination of semaglutide in human serum in clinical pharmacokinetic studies","P. K. Karnakova","2024","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2024-437",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051052","Mo2067: GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS ARE ASSOCIATED WITH REDUCED RISK OF GASTROINTESTINAL CANCERS: INSIGHTS FROM A NATIONWIDE REAL-WORLD ANALYSIS","Fouad H. Jaber","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03837-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051053","Early GLP-1 Receptor Agonist Therapy in Acute Ischemic Stroke and High-Risk TIA: A Systematic Review and Meta-analysis of Randomized Trials","Aasim Ali","2026",null,"systematic_review","article","10.17605/osf.io/9ut8r",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0051054","Possibility of Liraglutide for Prevention of Dementia Progression in Patients with Type 2 Diabetes","Mami Yoshida","2018","Diabetes","other","article","10.2337/db18-1110-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051055","miR-204 Antagomir Enhances GLP-1 Receptor Function and Glucose Control","SEONGHO JO","2018","Diabetes","preclinical","article","10.2337/db18-2149-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051056","1075 GLP-1 RECEPTOR AGONIST THERAPY REDUCES WEIGHT AND ALCOHOL INTAKE IN PATIENTS WITH METALD","Jonathan Melendez","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)03406-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051057","Association of GDF15, NTpoBNP and PLGF with subclinical cardiac dysfunction in type 2 diabetes: effects of novel antidiabetic treatment","Ignatios Ikonomidis","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.2558",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051058","E-106 | Outcomes of ST-Elevation Myocardial Infarction Among Diabetic Patients on Tirzepatide Versus GLP-1 Receptor Agonists: A Retrospective Study Using Real World Data","Mohammad Abdelhafez","2025","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2025.103367",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0051059","Tirzepatide vs. Semaglutide in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis of Metabolic Efficacy, Weight Loss, and Cardiovascular Safety","Matheus Jannuzzi Moreira de Mendonça","2025","Brazilian Journal of Implantology and Health Sciences","systematic_review","article","10.36557/2674-8169.2025v7n2p388-415",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051060","76. Abuse of a GLP-1 Agonist and Lithium Toxicity in Anorexia Nervosa: A Case Report","Aviva Caroff","2025","Journal of the Academy of Consultation-Liaison Psychiatry","case_report","article","10.1016/j.jaclp.2025.10.078",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051061","Abstract #615: Hispanic People Achieve Clinically Significant Weight loss with Liraglutide 3.0 Mg for Weight Management","Patrick J. O’Neil","2015","Endocrine Practice","other","article","10.1016/s1530-891x(20)42679-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051062","POSC18 The Real-World Clinical Effectiveness of GLP-1 Receptor Agonist Liraglutide Among Patients with Type 2 Diabetes in China: Based on Existing Healthcare Data","L L.I.U.","2022","Value in Health","nonrandomized_study","article","10.1016/j.jval.2021.11.164",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051063","Differentiation of Pancreatic β Cells from Human Pancreatic Duct Cells Derived from a Partial Pancreas Tissue","Ki‐Ho Song","2007","The Journal of Korean Diabetes Association","preclinical","article","10.4093/jkda.2007.31.3.236",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051064","Glucagon‐Like Peptide‐1 Receptor Agonists Are Associated With Improved Outcomes in Inflammatory Bowel Disease","Michael Saadeh","2026","GastroHep","nonrandomized_study","article","10.1155/ygh2/2239686",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051065","Tirzepatide Reduces Appetite, Energy Intake and Fat Mass in People with T2D","Tim Heise","2023","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0043-1767865",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article; other"],["R0051066","THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS LIRAGLUTIDE AND SEMAGLUTIDE IMPROVE CARDIOVASCULAR AND RENAL OUTCOMES ACROSS BASELINE BLOOD PRESSURE CATEGORIES: ANALYSIS OF LEADER AND SUSTAIN 6","L.A. Leiter","2019","Canadian Journal of Cardiology","other","article","10.1016/j.cjca.2019.07.522",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051067","Managing diabetes with new pharmaceutical agents","Jagannath Gopalappa","2010","Practice Nursing","other","article","10.12968/pnur.2010.21.12.634",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051068","Liraglutide Effect and Action in Diabetes and Cardiovascular Outcomes in Type 2 Diabetes Mellitus","Bipin Kumar Sethi","2017","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/13026_45",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0051069","2586-P: Real-World Weight Loss Outcomes of a Telehealth Medical Weight Management Program in Adults with Prediabetes or Type 2 Diabetes","Kelli M. Richardson","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2586-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051070","Obesity and musculoskeletal pain: possibilities of pharmacotherapy. A narrative overview","Andrey E. Karateev","2025","Russian Journal of Pain","other","article","10.17116/pain20252303173",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051071","Sa1200 REDUCED RISK OF BARRETT'S ESOPHAGUS WITH SGLT2 INHIBITORS/GLP1 RECEPTOR AGONISTS WHEN COMPARED TO METFORMIN ALONE: A NATIONAL DATABASE STUDY","Apoorva Krishna Chandar","2020","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(20)31472-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051072","762-P: Semaglutide Improves Intestinal Barrier Function in T2D—A Double-Blind Randomized Controlled Trial (RCT)","MARJAN REZAEI","2025","Diabetes","randomized_trial","article","10.2337/db25-762-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051073","Not just skin deep: Association of acne with elevated hemoglobin A1c levels in a retrospective case–control study of 1098 patients at an academic center","Lilly ChunHong Gu","2023","Journal of Cosmetic Dermatology","randomized_trial","article","10.1111/jocd.15851","37313617",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051074","986-P: Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter 2 Inhibitor: A Post Hoc Analysis of SUSTAIN 9","Bernard Zinman","2019","Diabetes","randomized_trial","article","10.2337/db19-986-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051075","S2548 Clinical Outcomes of GLP-1 Agonists on Patients With Compensated Cirrhosis and Type 2 Diabetes Mellitus: A Propensity Score-Matched Study Demonstrating a Reduction in Decompensated Cirrhosis From a Multinetwork Study","Tinsae Anebo","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137652.00354.00",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051076","P181 Glucagon-like peptide-1 receptor agonist use has increased 5-fold in a year and leads to meaningful weight loss in IBD","Christopher Roberts","2026","E-Posters","nonrandomized_study","article","10.1136/gutjnl-2026-bsg.307",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0051077","Weight Changes Following Diabetes Medication: A Population-Based Study","Beini Lyu","2021","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20213210s1543b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051078","Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial","Jonathan Edward Shaw","2020","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20203110s1348a",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051079","Liraglutide + metformin in type 2 diabetes: clinical benefits with early use of liraglutide and switch from sulphonylurea","Claus Bo Svendsen","2013","Primary care diabetes","other","article","10.1016/j.pcd.2012.10.060",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051080","Association of Hospitalizations with Randomized Glycemia-Lowering Treatment in the GRADE Study","Daniel S. Hsia","2025",null,"randomized_trial","article","10.2337/figshare.28898609",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0051081","Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial","Rodica Pop-Busui","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.4317",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051082","CAN GLP-1 AGONIST FOR WEIGHT LOSS CAUSE CARDIAC DYSAUTONOMIA? A STUDY OF THE FAERS DATABASE","Aashish Katapadi","2024","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(24)02017-5",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051083","Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm","Jens Aberle","2023","Diabetologie und Stoffwechsel","other","article","10.1055/a-2078-9491",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051084","HPR235 Utilization of Glucagon-Like Peptide-1 Receptor Agonists in the Irish Healthcare System","Stephen F. Doran","2025","Value in Health","other","article","10.1016/j.jval.2025.09.1642",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051085","Incretins Increase the Tissue Level of Endogenous Antioxidants in Experimental Diabetes Mellitus","Ernest Adeghate","2015","The FASEB Journal","preclinical","article","10.1096/fasebj.29.1_supplement.621.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051086","(106) GLP-1 Receptor Agonists Associated With Reduced Pelvic Complications in Postpartum Women: A Global Real-World Matched Cohort Study","M Moukhtar Hammad","2026","The Journal of Sexual Medicine","nonrandomized_study","article","10.1093/jsxmed/qdag063.098",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051087","SAT-201 Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests","Philip Noel Newsome","2024","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(24)01771-9",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051088","Safety and Utility of SGLT-2 Inhibitors & GLP-1 Receptor Agonists After Pancreas Transplantation","M. Barakat","2026","American Journal of Transplantation","other","article","10.1016/j.ajt.2026.05.2206",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051089","Effets à court terme du liraglutide versus vildagliptine sur la sécrétion et la sensibilité à l’insuline dans une population de patients diabétiques de type 2 (Liravis)","Estelle Amandine Well","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30371-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051090","Abstract 4133830: Uncovering the Gaps: Analyzing Prescribing Patterns of Combination Therapy with SGLT2-inhibitors and GLP-1 Receptor Agonists in Established Atherosclerotic Cardiovascular Disease (ASCVD) and Type 2 Diabetes (T2DM)","Sanchaya Khetrapal","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4133830",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051091","Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme","MJ Armstrong","2013","The Lancet","systematic_review","article","10.1016/s0140-6736(13)60460-2",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051092","QuaLLM-Health: An Adaptation of an LLM-Based Framework for Quantitative Data Extraction from Online Health Discussions","Ramez Kouzy","2024","arXiv (Cornell University)","other","article","10.48550/arxiv.2411.17967",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051093","Impact of Obesity Medications on Gastric Function","J. Alexander Torres","2026","Foregut The Journal of the American Foregut Society","other","article","10.1177/26345161261417564",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051094","Novel GLP‐1 mimetics in diabetes: lixisenatide and albiglutide","Jason Seewoodhary","2011","Future Prescriber","other","article","10.1002/fps.79",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051095","Evoke et evoke + : design de deux études de phase 3 randomisées en double aveugle, contrôlées par placebo, évaluant les effets neuroprotecteurs du semaglutide dans la maladie d’Alzheimer au stade débutant","Claude Guériot","2024","Revue Neurologique","other_trial","article","10.1016/j.neurol.2024.02.335",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051096","Correlated Increase of Omentin-1 and Adiponectin by Exenatide, Avandamet and Dietary Change in Diet-Induced Obese Rats (exenatide/avandamet/dietarychange/obesity/adipokines)","Haotian Feng","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051097","Automated production of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for the Glucagonlike Peptide 1 Receptor imaging","Junfeng Li","2016","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051098","1066-P: Gaps in Guideline-Indicated Prescribing of GLP1RA/SGLT2i in Patients with T2DM and Cardiorenal Disease according to ADA Standards of Care","ILDIKO LINGVAY","2023","Diabetes","other","article","10.2337/db23-1066-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051099","Impact of liraglutide on reaching target HbA1c without weight gain or hypoglycaemia, versus other T2D therapies","Bernard Zinman","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33185-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051100","Effect of Liraglutide on glycemic control in type 2 diabetic patients","Chadia Zouaoui","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep439",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051101","Abstract 7866: BMI- and subtype-specific molecular clusters reveal distinct obesity mechanisms in breast cancer across Nigerian and U.S. cohorts.","Oyomoare L. Osazuwa-Peters","2026","Cancer Research","other","article","10.1158/1538-7445.am2026-7866",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051102","2187-PUB: Identifying Risk Predictors for Gastrointestinal Adverse Events with Once-Weekly Semaglutide","Tina Vilsbøll","2020","Diabetes","other","article","10.2337/db20-2187-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051103","P1009RENAL OUTCOMES IN DIABETIC KIDNEY PATIENTS TREATED WITH GLP1 AGONIST RECEPTORS VS SGLT2 INHIBITORS","Alba Maroto","2020","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaa142.p1009",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051104","MT15 RtCGM Use is Associated with Improved Glycemic Control Compared to isCGM in Commercially Insured People with Type 2 Diabetes on Semaglutide and Insulin","Poorva M. Nemlekar","2025","Value in Health","other","article","10.1016/j.jval.2025.04.1125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051105","Méta-analyse des études SUSTAIN 1-5 : Perte de poids sous semaglutide dans le diabète de type 2","Bertrand Cariou","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.590",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051106","Etudes SUSTAIN 1-5 : plus de patients sous semaglutide atteignent un taux dâHbA1c < 7 % sans prise de poids, hypoglycémies ou effets indésirables gastro-intestinaux","Patrice Darmon","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051107","Liraglutid und renale Endpunkte bei Typ 2 Diabetes: Ergebnisse der LEADER Studie","J. F. E. Mann","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0037-1601747",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051108","Effect of Semaglutide on Kidney Outcomes: Pooled Analysis of the SELECT, FLOW, and SOUL Trials","Johannes F.E. Mann","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2025vd9epqq7",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051109","INCRETIN-BASED THERAPY IN THE MANAGEMENT OF TYPE 2 DIABETES","Constantin Ionescu-Tirgoviste","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051110","The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists","Sergey Kensarinovich Zyryanov","2022","Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice","other","article","10.37489/2588-0519-2021-4-15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051111","Medicine Matters: Special Considerations For Sglt2 Inhibitors And Prolonged Nothing Per Os Status Following Free Flap Surgery (Preprint)","Franca S. Kraenzlin","2021",null,"other","article","10.2196/preprints.35284",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051112","Méta-analyse des études SUSTAIN 1–5 : amélioration du contrôle glycémique sous semaglutide dans le diabète de type 2","Bertrand Cariou","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.245",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051113","26-A-15241-ACC PROJECTED REDUCTION IN MAJOR ADVERSE CARDIOVASCULAR EVENTS AMONG HIGH-RISK U.S. ADULTS WITH TYPE 2 DIABETES ELIGIBLE FOR ORAL SEMAGLUTIDE: A SOUL TRIAL BASED ANALYSIS USING NHANES 1988-2018 CYCLES","Mustafa Hussein Ajlan Al-Jarshawi","2026","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2026.02.778",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051114","S138 Comparative Risk of Pancreatic Pseudocyst Among Users of GLP-1 RAs: Findings From a Large-Scale EHR-Based Study","Lina AlQirem","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001127012.30891.29",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051115","#01842 The effect of GLP-1 receptor agonists on renal outcomes:a systematic review and meta-analysis","Takaya Sasaki","2025","Nephrology Dialysis Transplantation","systematic_review","article","10.1093/ndt/gfaf116.0511",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0051116","OP46 Assessing The Quality Of Pharmacoeconomic Evaluations About Type 2 Diabetes Mellitus Drugs In National Reimbursement Drug List","Shi-Yi Bao","2022","International Journal of Technology Assessment in Health Care","nonrandomized_study","article","10.1017/s0266462322001015",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051117","Incretin-based therapies for type 2 diabetes","David Lawson Morris","2012","Nurse Prescribing","other","article","10.12968/npre.2012.10.4.184",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051118","Allocation of Semaglutide by PET-derived Myocardial Flow Reserve and Coronary Artery Calcium Score","Maria Alwan","2026","EANM Innovation","other","article","10.1016/j.eanmi.2026.100246",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051119","Reductions in Post-Prandial Glucagon by the GLP-1 Receptor Agonist Lixisenatide Correlate to Reductions in PPG and A1C in Patients with Type 2 Diabetes Mellitus","Ronnie Aronson","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.025",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051120","Complex Gastrointestinal Case of SMA Syndrome with Vomiting and Weight Loss: A Clinical Report","Rama Mohan","2025","Endoscopy","other","article","10.1055/s-0045-1805878",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051121","Profil d’expression des mucines sous l’effet de l’exenatide sur une lignée de cellules canalaires pancréatiques humaines","Kenza Benomar","2014","Annales d Endocrinologie","other","article","10.1016/j.ando.2014.07.134",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051122","GLP-1 Receptor Agonism Attenuates the Exaggerated Blood Pressure Response to Exercise in Simulated Peripheral Artery Disease","Ashley M. Baranczuk","2025","Physiology","preclinical","article","10.1152/physiol.2025.40.s1.1252",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051123","P2483Differential effects of novel antidiabetics on arterial stiffness in patients with type 2 diabetes mellitus","Evanthia Bletsa","2019","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehz748.0813",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051124","Effect of resmetirom or placebo in NASH (MASH) fibrosis patients with<5% or≥5% weight loss and/or on baseline GLP-1 therapy in the MAESTRO-NASH 52-week serial liver biopsy study","Jörn Markus Schattenberg","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807552",null,null,"ClinicalTrials.gov:NCT03900429",null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0051125","S1371 Impact of GLP-1RA on MACE in Patients With IBD","Michael Saadeh","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001034852.99680.c3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051126","Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","Tsvetalina I. Tankova","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/1p1j-vc38",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051127","Multi-omic analysis of long COVID patients reveals obesity-associated metabolic dysfunction and inflammation in adipose-residing immune cells 2334840","Christopher Risley","2026","The Journal of Immunology","nonrandomized_study","article","10.1093/jimmun/vkag141.1863",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051128","Sustainable Scale-Up of GLP-1 Agonist Peptides through Green Solid Phase Peptide Synthesis","Lorenzo Pacini","2024",null,"other","article","10.17952/37eps.2024.p2050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0051129","OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind","Маниге Кониг","2020","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaa046.071",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051130","Prevalence and Overlap of Cardio-Renal-Metabolic Conditions in US Adults, 2015-2018","John W. Ostrominski","2022","Journal of the American Society of Nephrology","other","article","10.1681/asn.20223311s1217b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051131","A review of Non-Alcoholic Fatty Liver Disease (NAFLD) clinical trials registered in the clinical trials registry of India","N. Balaji","2026","Perspectives in Clinical Research","randomized_trial","article","10.4103/picr.picr_391_25",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0051132","Liraglutide","Jennifer C. Jiang","2023","RCSB Protein Data Bank","other","article","10.2210/rcsb_pdb/gh/dm/drugs/in/liraglutide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051133","Die neuen Gewichtsreduktionsmedikamente","Hanno Beck","2026","Hochschulschriftenserver der Universität Trier (Universität Trier)","other","article","10.60846/r4h4-gj14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0051134","Improvement in PAH After Semaglutide-induced Weight Loss","Blake E. Funke","2024",null,"other","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3955",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051135","Effects of glucagon-like peptide-1 analogs on prolactin: a randomized, double-blind, placebo-controlled crossover trial","Cyrill Muller","2024","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.99.p549",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051136","1757-P: The Rebound Effect—Weight Regain after Tirzepatide Discontinuation","Dima Bechenati","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1757-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051137","EFFECTS OF C -PEPTIDE AND GLUCAGON-LIKE PEPTIDE-1 ON DIABETIC MALE ALBINO RATS WITH AND WITHOUT ANTIOXIDANTS","Mohammad M. El‐Shawwa","2015","Al-Azhar Medical Journal","preclinical","article","10.12816/0018611",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051138","SGLT-2 Inhibitors vs. GLP-1 Receptor Agonists for Patients with Diabetes","Daniel David Dressler","2021","Journal watch","other","article","10.1056/nejm-jw.na54128",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051139","The Central-Versus Peripheral-Mediated Effects of Liraglutide Enhancement on Insulin Secretion is Dependent on the Stage of Diabetes","Chiara Saponaro","2023","SSRN Electronic Journal","other","article","10.2139/ssrn.4536758",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051140","785-P: First Report on the Small Molecule Oral GLP-1 Receptor Agonist RGT-075 in Obesity—A Randomized, Placebo-Controlled Phase 2a Proof-of-Concept Twelve-Week Study","Julio Rosenstock","2025","Diabetes","randomized_trial","article","10.2337/db25-785-p",null,null,"ClinicalTrials.gov:NCT06277934",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051141","EPH93 ASSOCIATIONS OF SOCIODEMOGRAPHIC AND CLINICAL FACTORS WITH GLP-1 RECEPTOR AGONIST UTILIZATION AMONG U.S. ADULTS WITH DIABETES, A CROSS-SECTIONAL ANALYSIS OF 2024 NHIS DATA","Julianne A. Mercer","2026","Value in Health","other","article","10.1016/j.jval.2026.03.925",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051142","Discovery of Once-Weekly, Peptide-Based Selective Glp-1 and Cholecystokinin 2 Receptors Co-Agonists","Feng Li Zhou","2022","SSRN Electronic Journal","other","article","10.2139/ssrn.4035245",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051143","443. Do people living with HIV lose weight on GLP-1 agonist therapy?","Lamiya Tauhid","2022","Open Forum Infectious Diseases","nonrandomized_study","article","10.1093/ofid/ofac492.518",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051144","An international perspective on cardiovascular risk management: recommendations for high-risk patients","Didier Duhot","2010","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2010.011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051145","Specific GLP-1 receptor agonists (revision number 3)","Tina Vilsbøll","2012","Diapedia.org eBooks","other","article","10.14496/dia.81043361170.3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0051146","Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: A secondary analysis of the SELECT trial","F. Shiele","2026","Archives of cardiovascular diseases","other_trial","article","10.1016/j.acvd.2025.10.206",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051147","726-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Clinical Characteristics and Treatment Pattern Analyses","Bruno Guerci","2022","Diabetes","nonrandomized_study","article","10.2337/db22-726-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051148","Abstract 4364588: GLP-1 Receptor Agonist in Patients Undergoing Percutaneous Left Atrial Appendage Occlusion: Impact on Outcomes","Aman Goyal","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4364588",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051149","S1390 Outcomes of Patients With Inflammatory Bowel Disease on GLP-1 Receptor Agonists: A Propensity Score-Matched Analysis","Tushar Khanna","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001034928.98373.b3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051150","26-A-17921-ACC TRENDS IN THE USE OF GLP-1 ANALOGS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: INSIGHTS FROM A 10-YEAR REAL-WORLD DATA","Farhan Ullah Afridi","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1755",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051151","Effetto della semaglutide in pazienti obesi con insufficienza cardiaca a frazione di eiezione preservata","Valerio Velardi","2024","L Endocrinologo","other","article","10.1007/s40619-024-01426-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051152","Le Liraglutide réduit le taux plasmatique de PCSK9 chez les patients diabétiques de type 2, non traités par statines","Bruno L Vergès","2021","Annales d Endocrinologie","other","article","10.1016/j.ando.2021.08.004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051153","LB-456089-1 PRE-ABLATION WEIGHT LOSS AS A PREDICTOR OF ATRIAL FIBRILLATION ABLATION OUTCOME IN THE LIRAGLUTIDE EFFECT ON ATRIAL FIBRILLATION (LEAF) STUDY","Jeffrey J. Goldberger","2023","Heart Rhythm","other","article","10.1016/j.hrthm.2023.04.029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051154","Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","Rohit Seth Loomba","2022","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(22)00440-8",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051155","GLP-1R targeting 68Ga-exendin-4 derivatives with lower renal retention for insulinomas and β-cell mass imaging","Tianqing Liu","2023","Nuclear Medicine and Biology","other","article","10.1016/j.nucmedbio.2023.108808",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051156","A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study","Fahrı Bayram","2022","Endocrinology research and practice.","other","article","10.25179/tjem.2021-86803",null,null,"ClinicalTrials.gov:NCT03811288; ClinicalTrials.gov:NCT03786406",null,"openalex","TRUE",null,null,"FALSE","article"],["R0051157","Real World Outcomes in Type 2 Diabetes: Lower Cost of Treating Patients to A1c<7% with Liraglutide Versus Exenatide","Mitch DeKoven","2013","Value in Health","nonrandomized_study","article","10.1016/j.jval.2013.08.664",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051158","0787 The Treatment Preferences for Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey","Ahmed Khalaf","2025","SLEEP","other","article","10.1093/sleep/zsaf090.0787",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051159","26-A-17673-ACC SEMAGLUTIDE IS ASSOCIATED WITH REDUCED RISK OF HEART FAILURE AND MORTALITY IN ADULTS WITH CONGENITAL HEART DISEASE","Ino Chough","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.907",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051160","GLP-1 Receptor Agonists Are Associated With Fewer Major Complications, Hospital Admissions, and Better Venous Ulcer Healing","Catherine C. Go","2025","Journal of Vascular Surgery","other","article","10.1016/j.jvs.2025.03.034",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051161","A case of GLP-1 RA-induced hypoglycaemia following RYGB in a patient with Type II Diabetes and autonomic dysfunction","Sophie Jones","2022","Endocrine Abstracts","case_report","article","10.1530/endoabs.86.p337",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051162","MODERN PATHOGENETIC APPROACHES TO THE THERAPY OF OBESITY IN CHILDREN","Timofey V. Chubarov","2025","Scientific and Innovative Therapy","other","article","10.64582/ivit.uz.290",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051163","P2523Cardiovascular risk according to add-on therapy in patients with type 2 diabetes","D T Aagaard","2018","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehy565.p2523",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051164","Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study","Stewart B. Harris","2017","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2017.08.156",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051165","Abstract 4145358: Cardiovascular Outcomes of Glucagon-Like Peptide 1 Receptor Agonists in Patients with or without Diabetes Mellitus, A Meta-Analysis of Randomized Controlled Trials:","M. A. Khan","2024","Circulation","systematic_review","article","10.1161/circ.150.suppl_1.4145358",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051166","Comparative efficacy of GLP-1 RAs and SGLT2is for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis","Liang‐Liang Ding","2020",null,"systematic_review","article","10.37766/inplasy2020.4.0177",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0051167","MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH","Michelle Beaton","2018","Diabetes","randomized_trial","article","10.2337/db18-1841-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051168","638-P: A Novel, Long-Acting Dual Agonist for GIPR/GLP-1R, HISHS-2001, Demonstrates Effects on HbA1c and Weight Loss in the db/db Mouse Model of Type 2 Diabetes","VINOD S. BURADE","2021","Diabetes","preclinical","article","10.2337/db21-638-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051169","S2090 Obesity Medication Prescribing Practices in an Urban Academic Medical Center","Sara Goff","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001037728.59970.45",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051170","O69 Le liraglutide en monothérapie apporte un meilleur contrôle de la glycémie postprandiale après les trois repas quotidiens en comparaison à un sulfamide hypoglycémiant en monothérapie","Samy Hadjadj","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72243-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051171","Abstract 4371548: GLP-1 Receptor Agonists Use in Pregnant Women Reduce Adverse Maternal and Fetal Outcomes: A Meta-Analysis","Lakshmi Sai Meghana Kodali","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4371548",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0051172","Exendin-4 Attenuates Experimental Diabetic Cardiomyopathy via Direct Actions on Inflammation","Mitchel Tate","2015","Research Portal (Queen's University Belfast)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051173","P2.096 Exendin-4 potentiates L-DOPA-evoked DA release in rat striatum","Amjad N. Abuirmeileh","2009","Parkinsonism & Related Disorders","preclinical","article","10.1016/s1353-8020(09)70447-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051174","P460: Case series of Nizon-Isidor syndrome by heterozygous variants in MED12L with one case generating chromosomal instability through diploid-triploid mosaicism","Russell J. Stewart","2025","Genetics in Medicine Open","case_report","article","10.1016/j.gimo.2025.103327",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051175","WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial","Naim Alkhouri","2024","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(24)01555-1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051176","Machine learning identifies individuals at higher risk of incident cardio-renal-metabolic diseases and cardiovascular death who have unrealised opportunities to reduce future cardiovascular risk","Ramesh Nadarajah","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.2689",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051177","TO IMPROVE THE QUALITY OF SECONDARY PREVENTION STRATEGIES IN DIABETIC PATIENTS: THE BRING–UP PREVENTION STUDY RESULTS","Matteo Rocco Reccia","2025","European Heart Journal Supplements","nonrandomized_study","article","10.1093/eurheartjsupp/suaf076.075",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051178","The effects of combination therapy with Glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporters 2 inhibitors on cardiometabolic indices: A GRADE assessed systematic review and meta-analysis","Seyyed Mostafa Arabi","2026","Advanced Pharmaceutical Bulletin","systematic_review","article","10.34172/apb.43187",null,null,"PROSPERO:CRD42023471047",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051179","SAT167 Risk Of Life Threatening Hypoglycemia When Using U-100 Insulin Syringes To Administer R U-500 Insulin","Tehlil Rizwan","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.1031",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051180","Gender differences in smoking cessation? Results of a randomized controlled trial of dulaglutide-assisted smoking cessation","Fabienne Baur","2023","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.90.p65",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051181","Rational approaches to the treatment of patients with overweight and obesity: a cardiologist’s view","S. V. Miklishanskaya","2024","Rational Pharmacotherapy in Cardiology","other","article","10.20996/1819-6446-2024-3087",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051182","Folyamatos glükózmonitorozás glargin inzulin + lixiszenatid fix kombináció használatakor","Zsolt Hermányi","2024","Lege Artis Medicinae","other","article","10.33616/lam.34.0417",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051183","New approaches to weight loss and glycaemic control in T2DM, focusing on tirzepatide and newer agents","Kusuma Boregowda","2024","British Journal of Diabetes","other","article","10.15277/bjd.2024.443",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051184","815-P: Performance of Previously Identified Predictors of >=15% Body Weight Reduction with Tirzepatide in Participants with Type 2 Diabetes in SURMOUNT-2","ILDIKO LINGVAY","2024","Diabetes","other","article","10.2337/db24-815-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051185","Evaluation of GPT-4 for common questions regarding anti-obesity medications. A comparative analysis","Monica Aggarwal","2024","Endoscopy","other","article","10.1055/s-0044-1783120",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051186","SGLT2 INHIBITORS VS. GLP1 AGONISTS AS TREATMENTS FOR OSTEOARTHRITIS","S. Reza Jafarzadeh","2024","Osteoarthritis and Cartilage","other","article","10.1016/j.joca.2024.02.062",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051187","REPOSITIONING DUAL GLP-1/GIP RECEPTOR AGONISTS FOR THE TREATMENT OF COLITIS AND COLITIS-ASSOCIATED TUMORIGENESIS","Bianca N. Islam","2026","Inflammatory Bowel Diseases","preclinical","article","10.1093/ibd/izag006.012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051188","DB1 REAL-WORLD SIX MONTH OUTCOMES OF PATIENTS INITIATING EXENATIDE IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE","Diana L. Brixner","2008","Value in Health","nonrandomized_study","article","10.1016/s1098-3015(10)70068-1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051189","Molecular imaging and immunotherapy in atherosclerotic cardiovascular disease","Mia R. Ståhle","2020","UTUPub (University of Turku)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0051190","COMPARISON BETWEEN BARIATRIC SURGERY AND TIRZEPATIDE (MOUNJARO®) IN REDUCING CARDIOVASCULAR RISK IN OBESE PATIENTS","Ana Carolina Cansanção Melro","2026","Seven Editora eBooks","nonrandomized_study","article","10.56238/sevened2026.009-001",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","book-chapter"],["R0051191","P7 CLINICAL OUTCOMES OF TIRZEPATIDE VERSUS DULAGLUTIDE ON TYPE 2 DIABETES WITH OBESITY AND HEART FAILURE","Septi Melisa","2026","Value in Health","other","article","10.1016/j.jval.2026.03.022",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051192","Mo1168: ADENOMA AND SESSILE SERRATED POLYP DETECTION RATES IN ADULTS ON GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN OUTPATIENT SCREENING COLONOSCOPY","Din Hoxha","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03280-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051193","The Glucagon-Like Peptide 1 Analog Liraglutide Impairs the Migration of Rat Intestinal Cells in vitro","Aline Gabriely Torres Duarte","2025","Brazilian Archives of Biology and Technology","preclinical","article","10.1590/1678-4324-2025240485",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051194","The Disconnect Between Patient and Provider Perceptions of Medications in Type 2 Diabetes: A Cross-Sectional Analysis of Health Narratives Shared in Social Media Forums Discussing Cardioprotective GLP-1RAs and SGLT-2is (Preprint)","Natalie Lambert","2022",null,"nonrandomized_study","article","10.2196/preprints.42137",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0051195","En la búsqueda de la nefroprotección: . Los pilares del tratamiento 2024","Inserra, Felipe","2024","Dialnet (Universidad de la Rioja)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051196","P576: Pharmacogenomic implications of genes on the American College of Medical Genetics and Genomics secondary findings list","Josiah D. Allen","2025","Genetics in Medicine Open","other","article","10.1016/j.gimo.2025.102424",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051197","Comparison of patients achieving treatment success with a glucagon‐like peptide‐1 receptor agonist for weight management between primary care provider and pharmacist co‐managed patients","Jacob Johnson","2025","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","nonrandomized_study","article","10.1002/jac5.70024",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051198","The Incretin Response After Successful Islet Transplantation","Shireene Ratna Vethakkan","2014","Transplantation","randomized_trial","article","10.1097/01.tp.0000437565.15965.67","24434489",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051199","Erratum: Late breaking abstracts","Philip Noel Newsome","2025","Hepatology","notice","article","10.1097/hep.0000000000001323","40258120",null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0051200","778-P: Efficacy and Safety of Supaglutide as Add-on to Metformin in Patients with Type 2 Diabetes","DILBAR ANWAR","2023","Diabetes","randomized_trial","article","10.2337/db23-778-p",null,null,"ClinicalTrials.gov:NCT04998032","S002121","openalex","FALSE","paywalled","1","FALSE","article"],["R0051201","Фармакоэкономический анализ лечения пациентов с сахарным диабетом 2 типа глимепиридом в комбинации с лираглутидом или росиглитазоном (обзор зарубежных исследований)","Ivan S. Krysanov","2009","Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0051202","Abstract #1169579: Achievement of HbA1c <6.5% with ≥5% Weight Loss and Without Hypoglycemia in Patients with Type 2 Diabetes Treatment with Tirzepatide: a Post Hoc Analysis of the SURPASS-1 to -5 Studies","Vivian Thuyanh Thieu","2022","Endocrine Practice","other","article","10.1016/j.eprac.2022.03.074",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051203","LITERATURE REVIEW OF ORAL TREATMENT OF TYPE 2 DIABETES MELLITUS","Mousa Sha’at","2020","The Medical-Surgical Journal","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051204","Metabolic syndrome in adults: Clinical-epidemiological characteristics and current diagnostic and therapeutic alternatives","Luis Fernando Puello Meza","2026","World Journal of Advanced Research and Reviews","nonrandomized_study","article","10.30574/wjarr.2026.29.2.3351",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051205","761-P: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuate Colon Cancer Development by Targeting HIF-1α Mediated Glucose Metabolism","YIKAI ZHANG","2025","Diabetes","preclinical","article","10.2337/db25-761-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051206","Diabetes Medication Choice cards improve patient knowledge and involvement in decision-making, but do not improve medication adherence or glycaemic control","Karen T. Chang","2010","Evidence-Based Nursing","randomized_trial","article","10.1136/ebn1023","20179069",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051207","Effects of new dipeptidyl peptidase IV inhibitors on depressive behavior of mice","Инга Геннадиевна Капица","2018","Nauchno-prakticheskii zhurnal «Patogenez»","preclinical","article","10.25557/2310-0435.2018.03.39-43",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051208","Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial","Giulia Ferrannini","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.3353",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051209","PSAT002 Unilateral Adrenalectomy as a Treatment Option in Patient with Cyclical Cushing's Syndrome","Aidar R. Gosmanov","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.180",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051210","Pancreatic β-Cell Imaging with High Affinity Peptide Ligands to the GLP-1 Receptor","Bikash Manandhar","2015",null,"other","article","10.17952/24aps.2015.154",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0051211","355-OR: Effects of a Six-Week Intervention with Glucagon-Like Peptide-1 Analogue on Pancreatic Volume, Edema, and DNA Synthesis in Obese Men","Maria S. Svane","2020","Diabetes","preclinical","article","10.2337/db20-355-or",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051212","Ozempic (semaglutide) - review of pharmacological properties, mechanism of action and clinical applications","Anna Maria Koman","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.16.52659",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051213","PDB27 ONCE-WEEKLY SEMAGLUTIDE COMPARED TO OTHER TWO GLP1-RAS AVAILABLE IN THE PUBLIC HEALTHCARE SYSTEM IN THE KINGDOM OF SAUDI ARABIA: A RELATIVE COST OF CONTROL ANALYSIS","Hana Abdullah Alabdulkarim","2019","Value in Health","other","article","10.1016/j.jval.2019.09.909",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051214","S736 Gastrointestinal Tolerability of Tirzepatide Compared With GLP-1 Receptor Agonists, Insulin and Placebo in Obesity: A Meta-Analysis of 11,000+ Subjects","Maitri Shah","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001130404.86228.5e",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051215","Current Strategies of New Drugs for Diabetes Management","Maliha Sarfraz","2023","Frontiers in clinical drug research. Diabetes and obesity","other","article","10.2174/9789815123586123070005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0051216","P200 Effet d’un traitement par liraglutide sur le contenu hépatique en graisse de patients diabétiques de type 2: étude prospective par spectroscopie-RMN","Jean-Marc Petit","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30313-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051217","Use of GLP-1 receptor agonist “weight-loss pens” and pancreatic complications: implications for clinical practice","Maria Julia Daniel Peixoto","2026","Derecho y cambio social.","nonrandomized_study","article","10.54899/dcs.v23i96.7001",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051218","GRP-016 Analysis and Consumption of Innovative Antidiabetic Drugs in Piedmont Patients","V Colombardo","2013","European Journal of Hospital Pharmacy","nonrandomized_study","article","10.1136/ejhpharm-2013-000276.016",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051219","Chronic Inflammation and Insulin Resistance as Links between Metabolic Syndrome and Musculoskeletal Disorders","Emilia Deka","2026","Journal of Education Health and Sport","other","article","10.12775/jehs.2026.91.70885",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051220","Abstract 12630: Cardiovascular Safety of Liraglutide: Pooled Analysis of Major Adverse Cardiovascular Events across Weight Management and Type 2 Diabetes Development Programs","Ian Douglas Caterson","2015","Circulation","other_trial","article","10.1161/circ.132.suppl_3.12630",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0051221","Preoperative GLP-1 Receptor Agonist Exposure And Postoperative Complications After Autologous Breast Reconstruction: A Real-world TriNetX Cohort Study","Sergio Andres Segrera","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20086419",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0051222","Su1917 THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON NEOPLASTIC PANCREATIC CYST BEHAVIOR","Megha Sheth","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)05283-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051223","131-OR: GLP-1R in the Nodose Ganglion Modulate Intestinal Lipoprotein Production via a Neuroendocrine Mechanism","SIMON S. HOFFMAN","2020","Diabetes","other","article","10.2337/db20-131-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051224","EE219 COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG COMPARED WITH RESMETIROM AND STANDARD OF CARE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN THE U.S. USING MOST FAVORED NATION (MFN) PRICING","AP McGovern","2026","Value in Health","other","article","10.1016/j.jval.2026.03.514",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051225","CARDIOVASCULAR OUTCOMES IN OBESE PATIENTS TREATED WITH GLP1 RA VS BARIATRIC SURGERY - A PROPENSITY MATCHED ANALYSIS","Aravinthan Vignarajah","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(25)00860-5",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051226","PS16.5: hSC-islets maintain their viability and function when shipped using gas-permeable silicone rubber membrane vessels.","Carola Davila","2025","Transplantation","preclinical","article","10.1097/01.tp.0001170576.36410.e4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051227","Glucagon‐like peptide‐1 treatment stimulates Neurogenin3 expression and pancreatic beta‐cell neogenesis in adult mice","Nidheesh Dadheech","2017","The FASEB Journal","preclinical","article","10.1096/fasebj.31.1_supplement.883.14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051228","Effects of GLP-1 analogs combined with physical exercise on total body mass in Individuals with obesity: a systematic review","Ana Maria Sales Gomes Filha","2025","Brazilian Journal of Kinanthropometry and Human Performance","systematic_review","article","10.1590/1980-0037.2025v27e103939",null,null,"PROSPERO:CRD42023454783",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051229","MON-030 Effective Use of Low-dose Glucagon-like Peptide-1 Receptor Agonist for Hypothalamic Obesity in a Patient with Type 1 Diabetes Mellitus","John A Aurora","2024","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvae163.2295",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051230","SUN-674 Metabolic Outcomes Combining Endoscopic Bariatric Procedures and GLP-1 Receptor Agonist Pharmacotherapy in Veterans with Obesity","Juan F Vasquez Mendez","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.184",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0051231","S3825 Uncovering Goblet Cell Carcinoma as an Incidental Finding: Epidemiology and Diagnosis","Sahil Sabharwal","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001142760.47867.4e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051232","Liraglutide Drug Loading with Double Layered Hydroxide- Synthesis and Characterization","Sevan Adeeb Doshan","2020","Al Mustansiriyah Journal of Pharmaceutical Sciences","other","article","10.32947/ajps.v20i1.683",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051233","Understanding immunometabolism in cardiovascular disease: translating research into practice","Giuseppe Danilo Norata","2024","European Heart Journal","other_trial","article","10.1093/eurheartj/ehae131","38450548",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051234","OA08.2. Impact of GLP1 Receptor Agonists on Progression of Non Dysplastic Barrett’s Esophagus: A Large Propensity Matched Cohort Study","Russaal Singh Mann","2026","Diseases of the Esophagus","nonrandomized_study","article","10.1093/dote/doag077.054",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0051235","Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D—The VIVID Study—All Randomized Population","George Grunberger","2018","Diabetes","randomized_trial","article","10.2337/db18-351-or",null,null,"ClinicalTrials.gov:NCT02561078",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051236","Focus on liraglutide : the LEAD studies : review","Julia Aalbers","2010","˜The œSouth African journal of diabetes & vascular disease","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051237","For adults with cardiovascular disease, how do dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors compare in reducing mortality and adverse effects?","Sera Tort","2022","Cochrane Clinical Answers","other","article","10.1002/cca.3910",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051238","Exposure to glucagon-like peptide 1 receptor (GLP1R) agonists is associated with reduced risk for glaucoma","Qi N. Cui","2021","Investigative Ophthalmology & Visual Science","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051239","Liraglutide Helps Achieve Significant Weight Loss in Overweight or Obese Patients","Brian D. Hoyle","2014","MD Conference Express","randomized_trial","article","10.1177/155989771447008",null,null,"ClinicalTrials.gov:NCT01272219","S000492","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0051240","2199-LB: Weight Loss Maintenance following Semaglutide Discontinuation—The Role of Concurrent Lifestyle Intervention","Qiaochu Xue","2025","Diabetes","nonrandomized_study","article","10.2337/db25-2199-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051241","751-P: Longer Time Spent in Glycemic Control after Initiating Tirzepatide vs. Comparators—Exploratory Analysis of SURPASS 1–5 Trials","JULIO ROSENSTOCK","2023","Diabetes","randomized_trial","article","10.2337/db23-751-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051242","Efficacité et tolérance du liraglutide dans le diabète de type 2. Résultats à 1 an d’EVIDENCE®, une étude prospective post-inscription avec un suivi de 2 ans","Pierre Gourdy","2013","Annales d Endocrinologie","other","article","10.1016/j.ando.2013.07.531",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051243","Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide","Kathleen Marie Dungan","2005","Clinical Diabetes","other_trial","article","10.2337/diaclin.23.2.56",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051244","797-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants—A Phase 1 Study","Wei Hu","2025","Diabetes","randomized_trial","article","10.2337/db25-797-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051245","S2065 GLP-1 Agonist Use is Associated With Lower Incidence of GERD, Lower Use of PPIs and Does Not Complicate GERD in Patients With Obesity Who Undergo Sleeve Gastrectomy: A National Database Analysis","Sharon I. Narvaez","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037628.17155.33",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051246","S1122 Association Between SGLT2 Inhibitors and Irritable Bowel Syndrome and Gastrointestinal Symptoms in Non-Diabetic Patients With Chronic Kidney Disease or Heart Failure","Xiaoliang Wang","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001131948.41098.23",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051247","Reporting of dietary intake and dietary quality in interventions evaluating the effects of liraglutide, semaglutide or tirzepatide on weight-loss and/or blood glucose in patients of all age groups with obesity and/or T2D: A systematic review of phase 3 and 4 randomised controlled trials","Anna Jansson","2024","Obesity Research & Clinical Practice","systematic_review","article","10.1016/j.orcp.2024.09.023",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0051248","12338 Risk Of Retinopathy In Patients With Type 2 Diabetes On Semaglutide","Ajay Kumar Gupta","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.920",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051249","‘Nature’s own Ozempic’ or berberine is all over social media. But does it really help you lose weight?","Tina Hinton","2023",null,"other","article","10.64628/aa.cmk4ntxqu",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051250","Editorial: Gastrointestinal damage and metabolic disorders","Carolina Silva Schiebel","2025","Frontiers in Physiology","randomized_trial","article","10.3389/fphys.2025.1648739","40661666",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0051251","Liraglutide as an Additional Treatment to Insulin in Patients with Type 1 Diabetes Mellitus—A 52-Week Randomized Double-Blinded Placebo-Controlled Clinical Trial","Paresh Dandona","2018","Diabetes","randomized_trial","article","10.2337/db18-3-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051252","Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi","Cyrus V Desouza","2018","Diabetes","other_trial","article","10.2337/db18-1093-p",null,null,"ClinicalTrials.gov:NCT02058147","S001199","openalex","FALSE","paywalled","5","FALSE","article"],["R0051253","S2919 A Novel Case of Gastric Outlet Obstruction From Spatz 3 Adjustable Intragastric Balloon","Jesse J. Xie","2021","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000785208.56590.8f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051254","P156: Effects of liraglutide on cardiovascular markers in obese old patients with type 2 diabetes: a pre–post clinical trial","Simone Perna","2014","European Geriatric Medicine","other_trial","article","10.1016/s1878-7649(14)70331-6",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0051255","Targeted noninvasive near-infrared fluorescence imaging of pancreas: Appropriate arsenal for the deliveryman.","Rao V. L. Papineni","2008","Clinical Cancer Research","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051256","CO64 Efficacy and Safety of Exenatide for the Treatment of Parkinson’s Disease: A Systematic Literature Review","P Rai","2023","Value in Health","narrative_review","article","10.1016/j.jval.2023.03.138",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0051257","Gs‐coupled GPCR‐mediated Activation of Rapgef2‐ and ERK‐dependent Gene Regulation and Neuritogenesis in NS‐1 Cells","Wenqin Xu","2022","The FASEB Journal","preclinical","article","10.1096/fasebj.2022.36.s1.r4867",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051258","A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects","JaeDuk Choi","2020","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(20)31393-3",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051259","Euglycaemic diabetic ketoacidosis associated with semaglutide use: a case report","Jennifer Miranda","2026","Endocrine Abstracts","case_report","article","10.1530/endoabs.117.p144",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051260","S862 Impact of GLP-1 Receptor Agonist Indication on Gastric Retention and Boston Bowel Preparatory Score","Michael J. DiMarino","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032816.34283.f3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051261","Patients with Type 2 Diabetes Reach Glycaemic Targets Faster with Tirzepatide Compared to Semaglutide and Titrated Insulin Degludec","Adie Viljoen","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1767992",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051262","The Effect of GLP1-RA/Basal Insulin vs. Basal Bolus Insulin Therapy in Type 2 Diabetes Inpatients Affected by COVID-19 Pneumonia","Ada Maffettone","2021","ICUS and Nursing Web Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051263","Diabetic nephropathy. Is renoprotection determined by the choice of hypoglycemic therapy?","Alina Yu. Babenko","2015","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.21518/2079-701x-2015-7-32-43",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051264","276: THE SHADOW OF SEMAGLUTIDE: A FATAL CASE OF DRUG-INDUCED PANCREATITIS","Doha Zoarob","2025","Critical Care Medicine","other","article","10.1097/01.ccm.0001099768.29187.ec",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051265","The effect of GLP-1 receptor agonists on obstructive sleep apnea in ambulatory patients with HFpEF, obesity, and type 2 diabetes","Petar Kalaydzhiev","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.1007",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051266","S270 Impact of Prior Bariatric Surgery on the Outcomes of Acute Pancreatitis in Obese Adults: A TriNetX Database Analysis","Thai Hau Koo","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001128540.09683.02",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051267","Association of Glucagon-Like Peptide-1 Receptor Agonists with Serious Liver Events: A Scandinavian Cohort Study","Arvid Engström","2023","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.4411413",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0051268","Abstract 369: Secondary Risk Reduction in Patients With Type 2 Diabetes and Cardiovascular Disease: Experience From a Cardiometabolic Center of Excellence","Merrill B. Thomas","2020","Circulation Cardiovascular Quality and Outcomes","nonrandomized_study","article","10.1161/hcq.13.suppl_1.369",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051269","The effects of once-weekly semaglutide on beta-cell function in subjects with type 2 diabetes","Christoph Kapitza","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31244-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051270","Reducing Metabolic Adverse Effects of Antipsychotic Drugs: A New Approach","Steven L. Dubovsky","2017","Journal watch","other","article","10.1056/nejm-jw.na44547",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051271","Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial","Prashanth S Prakash","2022","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.342148",null,null,"ClinicalTrials.gov:NCT02863328","S000251","openalex","TRUE","free_to_read","1","FALSE","conference-abstract"],["R0051272","GLP-1 receptor agonists for Parkinson's disease","Caroline A. Mulvaney","2018","Cochrane Database of Systematic Reviews","other","article","10.1002/14651858.cd012990",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051273","26-Week Treatment with Liraglutide Reduced Inflammatory Markers But Did Not Reverse Severe Polyneuropathy in Adults with Type 1 Diabetes: A Randomised, Double-Blind, Placebo-Controlled Trial","Christina Brock","2018","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.3218713",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0051274","160 IMPACT OF GASTRIC EMPTYING AND GENETIC VARIANTS RELATED TO GLP-1 ON WEIGHT LOSS WITH LIRAGLUTIDE IN TREATMENT OF OBESITY: A 16-WEEK, SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN 76 PATIENTS","Daniel Barry Maselli","2021","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(21)00837-4",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051275","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIVATION WITH LIRAGLUTIDE DURING MYOCARDIAL ISCHEMIA DECREASES INFARCT SIZE AND IMPROVES SYSTOLIC LEFT VENTRICULAR FUNCTION","Torsten Peter Vahl","2013","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(13)60222-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051276","Abstract 4369285: Lower Risk of Cardiovascular Events in Patients with Heart Failure Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-HF Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Heart Failure Population)","Kim G. E. Smolderen","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4369285",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051277","Abstract P364: Liraglutide Protects Against Angiotensin-induced Diastolic Dysfunction And Is Associated With Altered Acetyl-coa Metabolism","Cody A Rutledge","2021","Circulation Research","preclinical","article","10.1161/res.129.suppl_1.p364",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051278","Abstract 4139045: Suicide and Self-Harm with GLP-1 Receptor Agonists: A Meta-Analysis of Randomized Controlled Trials","Kaveh Hosseini","2024","Circulation","systematic_review","article","10.1161/circ.150.suppl_1.4139045",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051279","Abstract 4366502: Graduation from a Nurse Practitioner-led, Team-Based Cardiovascular-Kidney-Metabolic Clinic Improves Cardiovascular-Kidney-Metabolic Health and is Associated with Hospitalization Reduction: Initial Experience in an Academic Community Practice","Julie Vanourek","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4366502",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051280","3-OR: Differential Effects of Novel Antidiabetic Agents on Vascular Function Indices in Patients with Type 2 Diabetes Mellitus","Gerasimos Siasos","2019","Diabetes","other","article","10.2337/db19-3-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051281","Pipeline Diabetes Therapies","Anthony H Barnett","2011",null,"other","article","10.1002/9781118682197.ch7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051282","Patients Presenting with Acute Coronary Syndrome Exhibit Insufficient Previous Management of Cardiovascular Risk Factors: A Prospective, Observational, Single-Center Study","Christos Siafarikas","2022","Journal of Integrative Cardiology Open Access","other","article","10.31487/j.jicoa.2022.03.02",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051283","Digital augmentation of glucagon-like peptide-1 (GLP-1) for obesity management: A retrospective study (Preprint)","Belinda Davey","2026","Journal of Medical Internet Research","nonrandomized_study","article","10.2196/100728",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051284","P2.154 Exendin-4 promotes recovery of both behavioral and neurochemical deflcits in a “pre-motor” rodent model of Parkinson's disease","Nazir Rampersaud","2009","Parkinsonism & Related Disorders","preclinical","article","10.1016/s1353-8020(09)70505-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051285","Abstract 11928: Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","Elisabetta Patorno","2019","Circulation","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","conference-abstract"],["R0051286","Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes?","Naveed A. Sattar","2023","Cardiovascular Research","randomized_trial","article","10.1093/cvr/cvac186","36683167",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051287","A Case of Concomitant COVID-19 Infection-Induced Acute Respiratory Distress Syndrome and Diabetic Ketoacidosis: Another Challenge in Fluid Management","Panadeekarn Panjawatanan","2021","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvab048.727",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051288","Sa1966 GLP-1 AGONISTS AND GIP PRESCRIPTIONS ARE INCREASING MORE THAN ANY OTHER GASTROINTESTINAL MEDICAITON AND CORRELATE WITH SIGNIFICANT INCREASE IN ASSOCIATED ADVERSE EVENTS","Nancy Jhanji","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01843-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051289","7255 Tirzepatide Helps Achieve Glycemic Control and Lower Triglycerides in Seven Patients with Lipodystrophy","Rasimcan Meral","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.041",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051290","Clinical application of 99mTc‐labeled peptides for tumor imaging: Current status and future directions","Jiyun Shi","2024","iRadiology","other","article","10.1002/ird3.55",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051291","Novel insights into body fat distribution and cardiometabolic risk","Thomas Felix Lüscher","2019","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehz634","31539907",null,null,null,"openalex","FALSE","free_to_read","2","FALSE","article"],["R0051292","Tirzepatide: Dual GIP/GLP-1 Receptor Agonists, from Molecular to Clinical Practice for Treating Type-2 Diabetes and Obesity","Muhammad Aron Pase","2024","‎ InaJEMD - Indonesian Journal of Endocrinology Metabolic and Diabetes","other_trial","article","10.66266/2n6ev337",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0051293","Biochemical profiles and risk of cardiovascular events in patients withType 2 Diabetes: implications for choice of novel antihyperglycemic therapy","Mariam Elmegaard Malik","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.2824",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051294","Equity and Obesity Treatment — Expanding Medicaid-Covered Interventions","Hannah Stoops","2023","New England Journal of Medicine","other","article","10.1056/nejmp2303268","37339118",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051295","A Dash of Salt-Inducible Kinase 1 Keeps Insulin Levels in Check","Reid A. Aikin","2015","Diabetes","other","article","10.2337/db15-0692","26294426",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051296","Effect of antidiabetic drugs on gut endocrine function after metabolic and bariatric surgery: a systematic review","Aurélie Phan","2025","Obesity and Endocrinology","systematic_review","article","10.1093/obendo/wjaf012",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051297","P4‐053: DUAL INCRETIN AGONIST REDUCES NEUROINFLAMMATION IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE","Geisa Nogueira Salles","2018","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2018.06.2456",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051298","Hybrid acylated and non-acylated GLP-1 and apelin receptor co-agonist peptides, show promising acute in vivo anti-hyperglycaemic actions in normal healthy and insulin resistant diet-induced obese mice","Finbarr P.M. O'Harte","2024","Endocrine Abstracts","preclinical","article","10.1530/endoabs.104.op7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051299","Primary Care Patient and Practice Member Perspectives on Weight Loss Medications: Challenges and Opportunities","Jodi Summers Holtrop","2023",null,"other","article","10.1370/afm.22.s1.5139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0051300","BODY-MASS INDEX AND PER-CAPITA MEDICAL EXPENDITURES IN US ADULTS WITH ASCVD POTENTIALLY ELIGIBLE FOR SEMAGLUTIDE","Kobina Hagan","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03901-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051301","Peptides are cardioprotective drugs of the future. Glucagon-like peptide-1","Sergey V. Popov","2025","Сибирский журнал клинической и экспериментальной медицины","other","article","10.29001/2073-8552-2025-40-3-11-18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051302","Selective N-terminal modification of peptides and proteins using acyl phosphates","Laura Rodríguez Pérez","2025","ChemRxiv","other","article","10.26434/chemrxiv-2023-jm6sb-v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051303","RF24 | PSUN127 Congenital Leptin Deficiency: Metabolic, Reproductive, and Psychological Impacts of Therapy","Laura Christine Torchen","2022","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvac150.072",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051304","Injectable Semaglutide and Tirzepatide in Heart Failure With Preserved Ejection Fraction: Early 30-Day Experience From an Indian Tertiary Care Center","Pankaj Vinod Jariwala","2025","Indian Heart Journal","other","article","10.1016/j.ihj.2025.11.082",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051305","Tu1523 IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON POST-ERCP OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROPENSITY-MATCHED COHORT ANALYSIS","Muhammad Ali Ibrahim Kazi","2026","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(26)03210-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051306","Increased Incidence or Detection Bias? Global Cohort Study Finds No Link between GLP1-RAs and Thyroid Cancer Risk","Omar M. El Kawkgi","2025","Clinical Thyroidology","nonrandomized_study","article","10.1089/ct.2025;37.33-36",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051307","Эффективность аналогов глюкагоноподобного пептида 1 экзенатида для достижения метаболического контроля и коррекции массы тела у пациентов с сахарным диабетом типа 2","Саприна Татьяна Владимировна","2011","Бюллетень сибирской медицины","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051308","The Incretin System and Type 2 Diabetes","Anthony H Barnett","2009","US Endocrinology","preclinical","article","10.17925/use.2009.05.1.57",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051309","13. Lixisenatide as add-on treatment among patients with different beta-cell function levels as assessed by HOMA-beta index (1018-P)","Riccardo C. Bonadonna","2014","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-014-0038-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051310","The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis (Preprint)","Katie Stringer Lucero","2023",null,"nonrandomized_study","article","10.2196/preprints.48586",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0051311","Finerenone Use in Patients with Diabetes and CKD","Wei Lin","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025gmkn1mn0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051312","Effects of liraglutide on plasma ghrelin concentrations and oxidative stress in patients with type 2 diabetes: a 2-month prospective pilot study.","Giovanni Li Volti","2012","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051313","POST-KIDNEY TRANSPLANT OBESITY: TIRZEPATIDE AS AN EFFECTIVE AND SAFE OPTION IN REAL-WORLD SETTINGS","Byron Chiliquinga Morales","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7404805",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0051314","Liraglutide restores the hyperglycemic oxidative imbalance and induces the expression of CRH, UCN1, UCN2 AND UCN3 neuropeptides in macroendothelial cells","Sofia G. Gougoura","2019","Endocrine Abstracts","other","article","10.1530/endoabs.63.p617",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051315","ADVANCE","David Richard Matthews","2020","Diabetes Obesity and Metabolism","other_trial","article","10.1111/dom.14014","32250523",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051316","Obésité : pourquoi les nouveaux médicaments ne sont pas des remèdes miracles","Alexandre Duparc","2025",null,"other","article","10.64628/aak.n7nucgps7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051317","IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON ATRIAL ARRHYTHMIAS IN ADVANCED HEART FAILURE: A POST-HOC ANALYSIS FROM FIGHT","José Luis López","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00650-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051318","Switching to Tirzepatide 5 mg from GLP-1 RAs: Clinical Expectations in the First 12 Weeks of Treatment","Jim S Paik","2025","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0045-1807557",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0051319","Liraglutide for weight management in syndromic obesity: effects in overgrowth adult BeckwithWiedemann syndrome","Marina Medeiros Caputo","2021","Endocrine Abstracts","other","article","10.1530/endoabs.73.aep201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051320","Abstract #213: Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients with Type 1 Diabetes. A Randomized Clinical Trial","Nitesh D Kuhadiya","2016","Endocrine Practice","randomized_trial","article","10.1016/s1530-891x(20)44921-3",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051321","Statutory regulation of obesity pharmacotherapy: analysis of domestic and international approaches","Алла Василівна Кабачна","2025","Ukrainian Journal of Military Medicine","other","article","10.46847/ujmm.2025.3(6)-188",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051322","Positive control in a \"thorough QT/QTc study\".","Liu Q","2012","Journal of clinical pharmacology","nonrandomized_study","article","10.1177/0091270010388940","21209241",null,null,null,"pubmed; openalex","FALSE","paywalled","4","FALSE","Letter; Comment; article"],["R0051323","PDB2 GLYCAEMIC AND WEIGHT EFFECTS OF EXENATIDE FOR DIFFERENT AGE GROUPS","Matthew E. Wintle","2007","Value in Health","other","article","10.1016/s1098-3015(10)68719-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051324","Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (IDeg-100) in Insulin-Naïve T2DM on Antihyperglycemic Drugs ± GLP-1 RAs—The BRIGHT Randomized Study","ALICE Y.Y. CHENG","2018","Diabetes","randomized_trial","article","10.2337/db18-301-or",null,null,"ClinicalTrials.gov:NCT02738151","S002664","openalex","FALSE","paywalled","1","FALSE","article"],["R0051325","META-ANALYSIS ASSESSING THE IMPACT OF PRIOR HEART FAILURE AND CHRONIC KIDNEY DISEASE ON THE CARDIOVASCULAR EFFICACY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS","Dimitrios Patoulias","2022","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0000837320.01511.6f",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0051326","1968-LB: MWN105—A Next-Generation GLP-1/GIP/FGF21 Agonist for the Treatment of NASH","WEN-XIN SONG","2025","Diabetes","other_trial","article","10.2337/db25-1968-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051327","Connecting the Dots: The Mind–Body Interplay within Metabolic and Cardiovascular Health","Nisha Ravindran","2026","Heart and Mind","randomized_trial","article","10.4103/hm.hm-d-26-00025",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0051328","1969-LB: Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity","Nikolaj Klausholt Bak","2025","Diabetes","randomized_trial","article","10.2337/db25-1969-lb",null,null,"ClinicalTrials.gov:NCT06207877","S001463","openalex","FALSE","paywalled","1","FALSE","article"],["R0051329","Sodium–glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?","JENNIFER R. SNAITH","2022","The Medical Journal of Australia","other","article","10.5694/mja2.51637","35772726",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051330","RWD145 AN EXPLAINABLE MACHINE LEARNING ANALYSIS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) USE AND OPIOID-RELATED DIAGNOSIS RISK AMONG ADULT MEDICAID BENEFICIARIES","Bo Zhou","2026","Value in Health","other","article","10.1016/j.jval.2026.03.2133",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051331","PDB25 The Cost-Effectiveness of ORAL Semaglutide in Patients Treated with Currently Available GLP-1 Receptor Agonists - a UK Perspective","Barrie Chubb","2020","Value in Health","other","article","10.1016/j.jval.2020.08.622",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051332","Mehr Patienten unter Semaglutid erreichten ein HbA1c unter 7% ohne Gewichtszunahme, Hypoglykämie und gastrointestinale Ereignisse, im Vergleich zu Komparatoren in den Studien SUSTAIN 1 – 5","JH DeVries","2018","Diabetologie und Stoffwechsel","other","article","10.1055/s-0038-1641898",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051333","Ajout de levemir au liraglutide en association à la metformine améliorant le contrôle glycémique, avec une perte de poids maintenue: données à 52 semaines","J.P. Courrèges","2012","Annales d Endocrinologie","other","article","10.1016/j.ando.2012.07.1003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051334","14-PUB: The Effect of Structured Intensive Lifestyle Intervention on Muscle Mass in Patients with Type 2 Diabetes Receiving GLP-1 Receptor Agonists","Marwa R. Al-Badri","2024","Diabetes","randomized_trial","article","10.2337/db24-14-pub",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051335","200-LB: Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes","Bochra Zareini","2023","Diabetes","nonrandomized_study","article","10.2337/db23-200-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051336","Etude des effets de la glycation sur les interactions protéine-ligand dans le cadre du diabète et de l’athérosclérose : la liaison entre l’albumine et le liraglutide et entre l’apolipoprotéine A1 et ses partenaires de liaison","Marie Angélique Gajahi Soudahome","2018","theses.fr (ABES)","preclinical","article","10.70675/a8e7886czf1afz4beeza647z45aafd3f6103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0051337","P4.787: Metabolic benefits of GLP-1RA and SGLT2i use after kidney transplantation: A single center real-world experience.","Archana Sadhu","2026","Transplantation","nonrandomized_study","article","10.1097/01.tp.0001254672.97257.77",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051338","Exenatide QW – New Perspectives 5 Years after its First Use","Cristian Guja","2017","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","other","article","10.1515/rjdnmd-2017-0033",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051339","659-P: Cotadutide (MEDI0382) Is Well Tolerated at Doses Up to 600 µG with Blood Glucose-Lowering Activity in Japanese Patients with T2DM","M Asano","2021","Diabetes","randomized_trial","article","10.2337/db21-659-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051340","Efficacy and safety of semaglutide in elderly subjects with type 2 diabetes: a post hoc analysis of the SUSTAIN 7 trial","Wolfgang Ekkehard Schmidt","2019","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0039-1688354",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0051341","787-P: Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1)—A Double-Blinded Randomized Placebo-Controlled Trial (Study Protocol)","Ruth Frampton","2024","Diabetes","protocol","article","10.2337/db24-787-p",null,null,"ANZCTR:ACTRN12623001277639",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051342","Incorporating Treatment Pauses, Dosing Flexibility and Education to Support GLP-1RA Therapy Persistence","Vanita R. Aroda","2021","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2021.09.023",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051343","THE ROLE OF THE CENTRAL GLUCAGON-LIKE PEPTIDE-1 IN MEDIATING VISCERAL ILLNESS","Jennifer L. Lachey","2002","OhioLink ETD Center (Ohio Library and Information Network)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051344","Glucometabolic gut hormones: beyond the incretin effect","David Peick Sonne","2016","Cardiovascular Endocrinology","other","article","10.1097/xce.0000000000000092",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051345","Investigating the association between incretin-based therapies and thyroid cancer incidence among US Medicare beneficiaries with diabetes","Klara Rachel Klein","2025","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/fbay-4t58",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0051346","Metabolic Syndrome: An Interdisciplinary Approach","Tobias Keck","2016","Visceral Medicine","randomized_trial","article","10.1159/000452140",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051347","8752 The Ethical Concerns Of Improper Semaglutide Administration After Acquisition From A Compounded Pharmacy","Shozeb M Haider","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.959",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051348","Evidence review : liraglutide for the treatment of type 2 diabetes","Eleanor Cummins","2011","Warwick Research Archive Portal (University of Warwick)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0051349","Comparative analysis of bioequivalence, safety, and tolerability of semaglutide (tablets): results of an open-label randomized crossover comparative study","Ametov As","2026","Pharmacy & Pharmacology","randomized_trial","article","10.19163/2307-9266-2026-14-4-387-409",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0051350","SAT-446 Survodutide activates cAMP signaling and reduces steatosis and fibrosis through its glucagon component in human liver spheroids","Philip Vonschallen","2025","Journal of Hepatology","other","article","10.1016/s0168-8278(25)01702-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051351","1974-LB: The Molecular Basis of Survodutide (BI456906) Glucagon/GLP-1 Receptor Dual Agonism","Elita Yuliantie","2025","Diabetes","other_trial","article","10.2337/db25-1974-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051352","Meta-Analysis of Randomized Controlled Trials of Lixisenatide as Add On to Basal Insulin and/or Oral Antihyperglycemic Agents in Patients with Type 2 Diabetes Mellitus","Ronald Goldenberg","2013","Canadian Journal of Diabetes","systematic_review","article","10.1016/j.jcjd.2013.08.106",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051353","EFFECT OF A GLP-1 RECEPTOR AGONIST AND SGLT-2 INHIBITOR COMBINATION ON BLOOD PRESSURE LEVELS COMPARED TO SGLT-2 INHIBITOR ALONE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Dimitrios Patoulias","2021","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0000746848.72715.67",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0051354","771-P: Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo or Semaglutide Irrespective of Baseline Beta-Cell Function—Post Hoc Analysis from SURPASS-1 and SURPASS-2","Juan M. Maldonado","2023","Diabetes","randomized_trial","article","10.2337/db23-771-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051355","Outcomes with glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in obese adults with heart failure with preserved ejection fraction","R Ksayer","2026","The American Journal of the Medical Sciences","other","article","10.1016/j.amjms.2025.12.649",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051356","Treatment options for type 2 diabetes mellitus in patients with chronic kidney disease – old and new drugs","Ana Lúcia Anjos Ferreira","2019","Portuguese Journal of Nephrology & Hypertension","other","article","10.32932/pjnh.2019.07.021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051357","GLP-1-, but not GDF-15-, receptor activation increases the number of IL-6-expressing cells in the external lateral parabrachial nucleus","Fredrik Anesten","2019","UCL Discovery (University College London)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051358","PDB36 LONG-TERM Cost-Effectiveness Analyses of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Type 2 Diabetes in Three Countries: Bosnia and Herzegovina, Greece, and Slovenia","Nino Hallén","2020","Value in Health","other","article","10.1016/j.jval.2020.08.633",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051359","Editorial: Molecular insights into fatty liver disease: pathogenesis, progression, and therapeutic strategies","Haibo Dong","2026","Frontiers in Pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1805125","41821609",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0051360","Is there a Role for Incretin‐Based Therapy in Combination with Insulin?","Matheni Sathananthan","2011",null,"other","article","10.1002/9781444340280.ch10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051361","Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications","Elena Valer'evna Biryukova","2014","Diabetes Mellitus","other","article","10.14341/dm2014181-84",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051362","OS-098 Direct effects of survodutide on liver endpoints beyond weight loss: insights from a phase 2 trial of the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide in people with metabolic dysfunction-associated steatohepatitis and fibrosis","Mazen Noureddin","2025","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(25)00413-1",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0051363","Tirzepatide reduces body weight across body mass index (BMI) categories: A SURMOUNT-1 pre-specified analysis","Louis J. Aronne","2023","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0043-1767938",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051364","Abstract 15190: Association of Initiating SGLT2i and GLP1Ra Therapeutics on Insulin Utilization and MACE Outcomes Among Patients With Diabetes in an Integrated Healthcare System","Viet Trung Le","2023","Circulation","nonrandomized_study","article","10.1161/circ.148.suppl_1.15190",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051365","2258-PUB: Online CME Improves Clinical Knowledge and Confidence Related to Use of GLP-1 Receptor Agonists in Combination with Basal Insulin","Amy T. Larkin","2019","Diabetes","other","article","10.2337/db19-2258-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051366","S3505 Chronic Tirzepatide Use Mimics Histology Findings of Celiac Disease: A Case Report","Ahtshamullah Chaudhry","2024","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001043388.66546.8b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051367","COMBINED BARIATRIC SURGERY, GLP-1 AGONISTS, AND MULTIDISCIPLINARY MANAGEMENT IN SEVERE OBESITY HYPOVENTILATION SYNDROME AND OBSTRUCTIVE SLEEP APNEA: A CASE REPORT","Mohamed Elsayed Hassan","2025","CHEST Journal","case_report","article","10.1016/j.chest.2025.07.3986",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051368","THU0055 ANTI-DEGRADATIVE AND PRO-CHONDROGENIC PROPERTIES OF LIRAGLUTIDE, A GLUCAGON-LIKE-PEPTIDE 1 RECEPTOR AGONIST: EVIDENCE FROM PRECLINICAL STUDIES AND IMPLICATION FOR OSTEOARTHRITIS","Françis Berenbaum","2020","Annals of the Rheumatic Diseases","other","article","10.1136/annrheumdis-2020-eular.4606",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051369","MDS-1221: Clinically Relevant Effects of GLP-1 Agonists in MDS: Unveiling the Therapeutic Benefits Beyond Glycemic Control—A Global Propensity Score-Matched Analysis","Asfand Yar Cheema","2025","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(25)02069-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051370","315-OR: Trends in Racial and Ethnic Difference in Glucose-Lowering Medication (GLM) Use, Out of Pocket (OOP) Payment, and HbA1c Control in U.S. Adults with Diabetes, 2005-2018","Piaopiao Li","2021","Diabetes","other","article","10.2337/db21-315-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051371","Management of diabesity in primary care: individualisation of care","David B Haslam","2012","Practical Diabetes","randomized_trial","article","10.1002/pdi.1717",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051372","1234-P: Glucagon-Like Peptide 1 Receptor Agonists Use prior to Pregnancy Is Not Associated with Abnormal Birthweight","Jacqueline Maya","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1234-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051373","Unusual Polydipsia-Polyuria Syndrome, Hypernatremia, and Hypercopeptinemia: What Is the Diagnosis?","Aaron Henry","2023","Journal of the American Society of Nephrology","other","article","10.1681/asn.20233411s1934a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051374","Real-World adherence in Medicare Patients with type 2 Diabetes Mellitus (T2dm) for exenatide qw and Liraglutide qd","A. Tarr","2015","Value in Health","nonrandomized_study","article","10.1016/j.jval.2015.03.333",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051375","AACE2021-A-1035: Efficacy and Safety of Dulaglutide in Type 2 Diabetes Patients in Endocrinology Clinics of Islamabad, Pakistan","Matiullah Kamin","2021","Endocrine Practice","other","article","10.1016/j.eprac.2021.11.066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051376","What are ‘Ozempic babies’? Can the drug really increase your chance of pregnancy?","Karin Hammarberg","2024",null,"other","article","10.64628/aa.74v9t7vqe",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051377","Corrigendum: Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies","Alexander J. O’Donovan","2025","Frontiers in Endocrinology","randomized_trial","article","10.3389/fendo.2024.1548761","39936148",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","erratum"],["R0051378","Once Weekly Exenatide is Safe and Effective for Long-term T2DM Treatment","Lynne Lederman","2014","MD Conference Express","other_trial","article","10.1177/155989771432016",null,null,"ClinicalTrials.gov:NCT00308139","S002279","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0051379","Neurological and psychiatric outcomes associated with semaglutide in type 2 diabetes: a propensity-score matched cohort study","Riccardo De Giorgi","2024","Neuroscience Applied","nonrandomized_study","article","10.1016/j.nsa.2024.105187",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051380","778-P: SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors and Risk of All-Cause Hospitalization","Beini Lyu","2021","Diabetes","nonrandomized_study","article","10.2337/db21-778-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051381","S737 Risk of GERD and Psychological Symptoms in Patients Using GLP-1 Agonist and DPP-4 Antagonist vs Gastric Bypass Surgery Recipients","Jayson Mahalik","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130408.88075.ff",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051382","The development of PET/MRI dual modality probe based on IO nanoparticle for pancreatic beta-cell imaging","Zhanhong Wu","2011","Journal of Nuclear Medicine","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051383","Effect of Exenatide on Liver in an Iron Overload Rat Model","Mustafa Arslan","2015","AYBU AVESIS","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051384","Impact of Population Health Management to Modify Disparate Use of SGLT2 Inhibitors/Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs)","Linda-Marie Ustaris Lavenburg","2024","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2024hfarrmfb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051385","271-OR: Randomized Phase 1 Single-Ascending Dose Study of ENT-03 in Healthy Obese Subjects and Subjects with Type 2 Diabetes","Richard A. Larson","2025","Diabetes","randomized_trial","article","10.2337/db25-271-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051386","OS-006 Incretin-based therapies reduce alcohol intake in lean and obese hamster models of chronic alcohol consumption","François Briand","2024","Journal of Hepatology","other","article","10.1016/s0168-8278(24)00447-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051387","Pramlintide Acetate","Dennis J. Cada","2005","Hospital Pharmacy","other_trial","article","10.1177/001857870504000709",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051388","Early Use and Effectiveness of Finerenone in US Patients with CKD and Type 2 Diabetes: A FOUNTAIN Platform Analysis","Nikolaus Gunter Oberprieler","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s1856c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051389","638 PERFORMANCE OF A MACHINE-LEARNING GENE RISK SCORE BIOMARKER ON PREDICTING RESPONSE TO SEMAGLUTIDE: A PROSPECTIVELY FOLLOWED MULTI-CENTER BIOBANK AND OUTCOMES REGISTRY","Sima Fansa","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)00831-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051390","Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes After Treatment With Empagliflozin","Paris J. Roach","2015","Diabetes Care","other","article","10.2337/dc15-1797","26519331",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051391","Reducing Alzheimer’s Disease Risk in Diabetes: Synergistic Effects of Metformin, GLP-1 Receptor Agonists, and SGLT2 Inhibitors","Miski Abdi","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5502026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051392","Bariatric Surgery vs. GLP-1 Receptor Agonists: Mortality Risk and Access to Kidney Transplantation","Yuyao Chen","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.958",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051393","Exploring the impact of diabetes mellitus on dry eye disease and ocular health: a narrative review","Manuel Silva Tavares Correia","2025","Annals of Eye Science","narrative_review","article","10.21037/aes-25-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0051394","P82 Un traitement par exenatide administré pendant 6 mois chez des diabétiques de type 2 améliore davantage la fonction beta-cellulaire que la sensibilité à l’insuline","Vanessa Preumont","2010","Diabetes & Metabolism","other","article","10.1016/s1262-3636(10)70230-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051395","83-LB: Simplifying Insulin Treatment in Persons with T2 DM over 65 Years—Interim Report of the STOP Study","Alessio Mazzieri","2023","Diabetes","nonrandomized_study","article","10.2337/db23-83-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051396","Patients achieving a HbA1c less than 5.7% with greater than or equal to 5% weight loss and without hypoglycaemia: A post hoc analysis of SURPASS 1 to 5","ALICE Y.Y. CHENG","2023","Diabetologie und Stoffwechsel","other","article","10.1055/s-0043-1767999",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051397","3-year efficacy and safety for liraglutide 3.0 mg in adults with obesity/overweight, prediabetes and baseline BMI < 35 vs. ≥35 kg/m2 in the SCALE Obesity and Prediabetes, double-blind, placebo-controlled trial","Matthias Blüher","2017","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0037-1601675",null,null,"ClinicalTrials.gov:NCT01272219","S000492","openalex","FALSE","paywalled","1","FALSE","article"],["R0051398","Non‐Insulin Parenteral Therapies","Tina Vilsbøll","2016",null,"other","article","10.1002/9781118924853.ch32",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051399","0621 Glucagon-Like Peptide 1 Receptor Agonist and Positive Airway Pressure Use in Patients with OSA and Obesity","Anita Malik","2024","SLEEP","nonrandomized_study","article","10.1093/sleep/zsae067.0621",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0051400","Use of metformin and cardiovascular effects of new classes of glucose-lowering agents: A meta-analysis of cardiovascular outcome trials in type 2 diabetes","Buse J.B","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","systematic_review","article","10.17615/7330-b938",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0051401","WCN23-0212 LIRAGLUTIDE IMPROVES BOTH DIABETIC NEPHROPATHY AND CARDIOMYOPATHY IN THE SDT FATTY RAT, A CARDIORENAL MODEL OF TYPE 2 DIABETES","F. BRIAND PhD","2023","Kidney International Reports","preclinical","article","10.1016/j.ekir.2023.02.469",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051402","Abstract 4369293: Clinical outcomes associated with utilization of Glucagon-like Peptide-1 Receptor Agonists in heart failure patients in the United States","Andrei Loghin","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4369293",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051403","GLP-1 Receptor Agonist Treatment-Related Features Important to Type 2 Diabetes Mellitus (T2DM) Patients: A Preference Study in Germany","L Qin","2016","Value in Health","other","article","10.1016/j.jval.2016.09.1908",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051404","TIRZEPATIDE REDUCES ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES: POST HOC POOLED ANALYSIS OF SURPASS-1 to -5","Hiddo J.L. Heerspink","2023","Canadian Journal of Cardiology","other","article","10.1016/j.cjca.2023.06.231",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051405","Natural Peptides Versus Semaglutide: A Safer Approach to Obesity Management","Muhammad Affan Abid","2025","Medicine Advances","other","article","10.1002/med4.70021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051406","DISCONTINUATION OF SEMAGLUTIDE AMONG OLDER ADULTS WITH DIABETESIN THE US AND JAPAN","Kosuke Inoue","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01030-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051407","1292-OR: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonist Use among Adults with Type 1 Diabetes and Overweight or Obesity: A Target Trial Emulation Using Real-World EHR Data","Yixue Shao","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1292-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051408","1190: RACIAL AND ETHNIC DISPARITIES IN EARLY UPTAKE OF GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH AND WITHOUT MASLD","Sarpong Boateng","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04695-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051409","Ruolo di Exenatide LAR nella gestione del paziente con diabete mellito tipo 2","Riccardo Candido","2015","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051410","The Role of New Treatments in Managing Eating Behavior Disorders: A Systematic Review","Carlos Siopa","2025","Current Treatment Options in Psychiatry","systematic_review","article","10.1007/s40501-025-00357-w",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051411","Early weight loss responders to liraglutide 3.0 mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years vs early non-responders: SCALE Obesity and Prediabetes","Joseph Proietto","2019","Obesity Research & Clinical Practice","other","article","10.1016/j.orcp.2016.10.078",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051412","S4397 Drug-Induced Liver Injury Secondary to Recent Ozempic use","Hobie Hughes","2024","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0001046956.27175.a4",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0051413","Metformin-Associated Lactic Acidosis Triggered by Combined Use of Metformin and a GLP-1 Receptor Agonist: A Report of Two Cases","Hamed Shaik Mohammad Shoukat Hussain","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025796yzg54",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051414","Improved Leptin Sensitivity and Increased Soluble Leptin Receptor May Underlie the Additive Effects of Combining Pyy(3-36) and Exendin-4 on Body Weight Lowering in Diet-Induced-Obese Mice","Birgitte Schjellerup Wulff","2024","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4695155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051415","The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders","Francesco Cosentino","2024","European Heart Journal","other","article","10.1093/eurheartj/ehae112","38442294",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051416","749-P: Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin—Pooled Subgroup Analysis of SURPASS-5 and -6","HARPREET SINGH BAJAJ","2024","Diabetes","other","article","10.2337/db24-749-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051417","Additional file 2: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Ling Li","2016","Figshare","systematic_review","article","10.6084/m9.figshare.4430699.v1",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0051418","Combination therapy of olmesartan/exenatide decreases renal ER stress in a rat model of metabolic syndrome (1088.5)","Steven Duval Ruilova","2014","The FASEB Journal","preclinical","article","10.1096/fasebj.28.1_supplement.1088.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051419","Aktivitas Obat Golongan SGLT-2i dan GLP-1RA serta SGLT-2i dan DPP-4i dengan atau tanpa Metfomin pada Tikus Diabetes tipe 2 dengan Model Kerusakan Sel Beta Pankreas dan Resistensi Insulin","Neng Fisheri Kurniati","2023","Jurnal Sains dan Kesehatan","other","article","10.25026/jsk.v5i5.1964",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051420","Early Weight Loss and Cardiometabolic Parameters in Tirzepatide-Treated Participants in SURMOUNT 1-2","Tina Kaur Thethi","2025","Diabetologie und Stoffwechsel","other","article","10.1055/s-0045-1807553",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051421","300.21 Semaglutide in Patients With Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-Analysis of Randomized Controlled Trials","Zina Otmani","2025","JACC: Cardiovascular Interventions","systematic_review","article","10.1016/j.jcin.2025.01.230",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051422","Glucagon-like peptide-1 receptor agonists decrease total and LDL-cholesterol in obese type 2 diabetic patients","Vinko Roso","2017","Diabetologia Croatica","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051423","Weight loss with semaglutide treatment or time-restricted feeding differentially improves non-alcoholic steatohepatitis in diet-induced obese insulin resistant mice","François Briand","2022","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(22)01752-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051424","Promoting research that optimises primary care management of CVD","Michael G. Kirby","2009","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2009.066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051425","Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 ( GLP ‐1) receptor agonist being studied","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","other","article","10.1002/doi2.109",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051426","Semaglutide is precipitating a revolution in obesity care","Khaled A. Alabduljabbar","2022","Translational Metabolic Syndrome Research","other","article","10.1016/j.tmsr.2022.05.001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051427","Short-term treatment with liraglutide does not improve cardiac diastolic function in patients with type 2 diabetes: a randomised double-blind placebo-controlled trial","Annemie Stege Bojer","2021","University of Southern Denmark Research Portal (University of Southern Denmark)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0051428","Liraglutide chez les diabétiques de type 2 marocains : efficacité et tolérance","S. Derrou","2024","Annales d Endocrinologie","other","article","10.1016/j.ando.2024.08.417",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051429","Differential efficacy of a GLP-1R/GCGR dual agonist versus a single GLP-1R agonist in diet-induced obesity in mice","M. Pilar Valdecantos","2017","DIGITAL.CSIC (Spanish National Research Council (CSIC))","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051430","Efficacy and safety of oral semaglutide in Russian patients with type 2 diabetes: subgroup analysis of PIONEER 1, 2, 3 trials","Минара Шамхаловна Шамхалова","2022","Diabetes Mellitus","nonrandomized_study","article","10.14341/dm12941",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051431","Medication Adherence and Glycemia Reduction in Type 2 Diabetes: a Subanalysis from the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study","JEFFREY S. GONZALEZ","2026",null,"randomized_trial","article","10.2337/figshare.30657905",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0051432","162-OR: Beta-Cell Preservation with Early Oral Antidiabetic Medications in Prediabetes (PreDM)","Alberto O. Chávez","2025","Diabetes","randomized_trial","article","10.2337/db25-162-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051433","Mounjaro: type 2 diabetes drug more effective than Ozempic to launch in the UK — here’s what you need to know","Duane Daniel Mellor","2023",null,"other","article","10.64628/ab.f4avnspfp",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051434","Quelle place pour l’échographie gastrique en anesthésie ?","Lionel Bouvet","2026","Le Praticien en Anesthésie Réanimation","other","article","10.1016/j.pratan.2026.01.004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051435","Abstract 11459: Mitochondrial Metabolites Predict Cardiovascular Outcomes and Heart Failure in Individuals with Type 2 Diabetes Mellitus: An Exscel Biomarker Substudy","Jessica A. Regan","2021","Circulation","randomized_trial","article","10.1161/circ.144.suppl_1.11459",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051436","1112-P: Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial","Kieran F. Docherty","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1112-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051437","PDB2 LONG-TERM HEALTH OUTCOMES OF TREATMENT WITH LIRAGLUTIDE VERSUS GLIMEPRIRIDE IN TYPE 2 DIABETES PATIENTS IN ASIAN SETTING","Jianbo Wu","2010","Value in Health","other","article","10.1016/s1098-3015(11)73177-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051438","ODP181 Diabetes Mellitus and Advanced Liver Fibrosis – is Cirrhosis Reversible and Who Should We Screen?","Sarah Alicia Reda","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.633",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051439","Mo1462: PRIOR GLP-1 RECEPTOR AGONISTS EXPOSURE AND NEW-ONSET DIABETES FOLLOWING PANCREATITIS: ANALYSIS OF LARGE US REAL-WORLD DATABASE","Djibril Mari Ba","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03534-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051440","The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions","Maria Zasadzińska","2025","Journal of Diabetology","other_trial","article","10.4103/jod.jod_18_25",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0051441","PDB20 - PERSISTENCE TO LIRAGLUTIDE THERAPY IS ASSOCIATED WITH BETTER GLYCEMIC AND WEIGHT CONTROL IN PATIENTS WITH TYPE 2 DIABETES","C. Melzer Cohen","2018","Value in Health","other","article","10.1016/j.jval.2018.09.726",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051442","Auswirkung einer 2-jährigen Liraglutid-Behandlung auf bestehende Fettlebererkrankungen bei Patienten mit Typ 2 Diabetes: Auswertung der LEAD-2-Verlängerungsstudie","Armstrong Mj","2011","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0031-1277317",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051443","882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept","Shobha Bhattachar","2025","Diabetes","randomized_trial","article","10.2337/db25-882-p",null,null,"ClinicalTrials.gov:NCT06230523",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051444","Su1913 COST-EFFECTIVENESS ANALYSIS OF INTRAGASTRIC BALLOONS COMPARED TO SEMAGLUTIDE FOR WEIGHT LOSS IN PATIENTS WITH OBESITY","Muhammad A. Haseeb","2023","Gastroenterology","other","article","10.1016/s0016-5085(23)02653-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051445","Cardiovascular and Limb Outcomes with Tirzepatide versus SGLT2 Inhibitors in Peripheral Artery Disease and Type 2 Diabetes: A Real-world Cohort Study","Abdul Rasheed Bahar","2026","Michigan medical education and health bulletin.","nonrandomized_study","article","10.69735/001c.163881",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051446","Roles of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists in neuroprotection in diabetics","Neeraj Kumar Agrawal","2025","Elsevier eBooks","other","article","10.1016/b978-0-443-33355-2.00037-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0051447","Les patients atteints d’un diabète de type 2 (DT2) traités par dulaglutide en administration hebdomadaire sont plus susceptibles de présenter une glycémie à jeun (GàJ) ≤ 6,7 mmol/L à 2 semaines que ceux traités par metformine, sitagliptine ou exenatide deux fois par jour (2×/j) : données précoces et à long terme (52 semaines) issues de 3 essais cliniques","Heike Jung","2016","Annales d Endocrinologie","other","article","10.1016/j.ando.2016.07.762",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051448","S170 Incidence of Acute Pancreatitis With GLP-1 Receptor Agonists Use Across Obesity and Type 2 Diabetes Phenotypes: A Multi-Center Analysis","Ruchir Damjibhai. Paladiya","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001127140.53940.27",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051449","LESÃO RENAL AGUDA ASSOCIADA AO USO DE SEMAGLUTIDE","Tulio Coelho Carvalho¹","2024",null,"other","article","10.65034/bjnabstract-cbn240957",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051450","Tul33l SEMAGLUTIDE USE IS LINKED TO LOWER COLORECTAL NEOPLASTIC LESIONS IN ADULTS UNDER 50","Prem J. Minchu","2026","Gastroenterology","other","article","10.1016/s0016-5085(26)01225-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051451","Pharmacotherapy for the management of overweight and obesity?","Patrice M. Forner","2025","Australian Journal of General Practice","other","article","10.31128/ajgp-09-24-7411","40174617",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051452","Epicardial adipose tissue and cardiovascular disease: unmasking the hidden culprit","Fulvio Cacciapuoti","2024","Chest Disease Reports","other","article","10.4081/cdr.12.12044",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051453","Abstract 2189: Tirzepatide mitigates obesity-associated metabolic dysregulation and tumor progression in a mouse model of triple-negative breast cancer","Elaine M. Glenny","2024","Cancer Research","randomized_trial","article","10.1158/1538-7445.am2024-2189",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051454","IGF-1 and GLP-1 signaling: potential therapeutic target for neurological disorders – correspondence","Neeraj Gajwani","2023","Annals of Medicine and Surgery","preclinical","article","10.1097/ms9.0000000000000164","36742118",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051455","Current directions of incretinotropic therapy in children - balance of efficiency and safety","Angelina Zybenko","2025","Glavvrač (Chief Medical Officer)","other","article","10.33920/med-03-2504-09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051456","Streamline - machine learning guided development of novel GLP-1 receptor agonists with improved drug properties","Randi Bonke Mikkelsen","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.ep858",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051457","Efficacy and safety of fixed combination insulin glargine 100 u/ml and lixisenatide in patients with type 2 diabetes mellitus depending on age and baseline HbA1C in the SOLO study","Mikhail Borisovich Antsiferov","2022","Фарматека","other","article","10.18565/pharmateca.2022.11-12.41-46",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051458","[68Ga]Ga-DOTA-exendin-4 PET/CT for the localization of insulinoma: results of an international, dual-center, retrospective, open-label real-world imaging study","Emanuel Christ","2025","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.110.p468",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051459","Lixisenatide Reduces Glycemic Variability When Added to Basal Insulin in Patients with Type 2 Diabetes Mellitus","Ronald Goldenberg","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.112",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051460","Ozempic, Wegovy, Rybelsus… perd-on de vue la santé globale ? Voici ce que dit la science","Aude Bandini","2024",null,"other","article","10.64628/aap.g43s5h37q",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051461","Focus on New Diabetes Treatment Options with Cardiovascular Benefits","Jeany Kim Jun","2019","Journal of Contemporary Pharmacy Practice","other_trial","article","10.37901/jcphp18-00029",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051462","S1647 ESG Combined With Pharmacotherapy is Associated With Greater Patient Visit Compliance Compared to ESG Alone","Jeong Hoon Kim","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035956.23607.0c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051463","PDB33 The Associated Costs of Treating Type 2 Diabetes Patients to a Clinically Relevant Composite Endpoint With Liraglutide Versus Exenatide","Jakob J. Langer","2012","Value in Health","other","article","10.1016/j.jval.2012.03.954",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051464","Comparative efficacy of GLP-1 RAs and SGLT2 inhibitors for prevention of cardiorenal events in type 2 diabetes: a network meta-analysis of cardiovascular outcome trails","Liang‐Liang Ding","2020",null,"systematic_review","article","10.37766/inplasy2020.5.0081",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051465","Effects of Liraglutide 3.0 mg and 1.8 mg on Body Weight and Cardiometabolic Risk Factors in Adults with Overweight or Obesity and Type 2 Diabetes (T2D): The SCALE Diabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial","Sue D. Pedersen","2015","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2015.01.141",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051466","In Individuals with obesity, resting energy expenditure does not decrease after weight loss with GLP-1 agonist liraglutide","Mostafa Mohseni","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.p508",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051467","EXSCEL—Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus","Shelby D. Reed","2018","Diabetes","other_trial","article","10.2337/db18-1319-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051468","Safer use of clozapine","David M. Taylor","2022","Acta Psychiatrica Scandinavica","other","article","10.1111/acps.13427","35411581",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051469","Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists - mechanisms, clinical evidence, and therapeutic perspectives","Giacinta Ciancimino","2026","Hepatoma Research","other_trial","article","10.20517/2394-5079.2026.19",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0051470","Quick Take Vol. 72","David A. Gorelick","2025",null,"other","article","10.64239/pi-qt72",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0051471","Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Subanalyse der SoliMix-Studie bei Teilnehmern in Europa","ALICE Y.Y. CHENG","2022","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-1746288",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE",null,null,"FALSE","article"],["R0051472","Role of Glucagon-Like Peptide -1 Receptor in Pulmonary Circulation","N. Chandran","2021",null,"preclinical","article","10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3673",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051473","PO6 Le liraglutide chez les adolescents atteints d’un diabète de type-2 : Sécurité, tolérance et paramètres pharmacocinétiques/pharmacodynamiques","S. Madani","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71702-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051474","S2653 The Role of GLP-1 Agonist in Acute Cholecystitis After a Routine Colonoscopy: A Case Report","Ahmad Abdulraheem","2024","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001039980.58080.a2",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051475","OC30 - Effects of liraglutide and exercise on liver function in middle-aged rats","Dragana Vlahović","2025","European Journal of Endocrinology","preclinical","article","10.1093/ejendo/lvaf168.049",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051476","Cutting Calories or Cutting Corners? How Anti-Obesity Medication Use Sparks Effort-Based Sanctions and Social Penalties","Tassilo Tom Tissot","2025",null,"other","article","10.31219/osf.io/w3em8_v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051477","Treatment of type 2 diabetes: the stability of the effectiveness of hypoglycemic medications","Tatyana B. Morgunova","2016","Obesity and metabolism","other","article","10.14341/omet2016332-36",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051478","759-P: Effects of Once-Weekly Utreglutide (GL0034) in Individuals with Overweight and Obesity on Lipid Metabolism—A 10-Week Exploratory Proof-of-Concept Study","RAJAMANNAR THENNATI","2025","Diabetes","randomized_trial","article","10.2337/db25-759-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051479","Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus","Lora Petrova","2024","Pharmacia","systematic_review","article","10.3897/pharmacia.71.e132148",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0051480","Problems of preserving muscle mass during weight loss, particularly in the treatment of obesity and overweight. Review","G. D. Fadieienko","2026","Ukrainian Therapeutical Journal","narrative_review","article","10.30978/utj2026-2-70",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051481","Comorbidities in RA: bringing them to the limelight","Elena Nikiphorou","2023","Lara D. Veeken","nonrandomized_study","article","10.1093/rheumatology/kead487","37871916",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051482","GLP-1 Receptor Agonists in Kidney Transplant Recipients with Pre-Existing Diabetes","Babak John Orandi","2025","American Journal of Transplantation","nonrandomized_study","article","10.1016/j.ajt.2024.12.083",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051483","Economic evaluation of type 2 diabetes mellitus T2DM pharmaceutical treatment compared to an alternative, conducted alongside randomized controlled trials: A scoping review","Emma Agahi","2025","Journal of Public Health","randomized_trial","article","10.1007/s10389-025-02519-9",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051484","198 ISOLATION, CHARACTERIZATION, AND IN VITRO DIFFERENTIATION OF GOAT ADIPOSE-TISSUE-DERIVED MESENCHYMAL STEM CELLS INTO PANCREATIC ISLETS-LIKE CELLS","Amit Dubey","2013","Reproduction Fertility and Development","preclinical","article","10.1071/rdv26n1ab198",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051485","Efficacité et taux de maintenance du liraglutide chez les patients diabétiques de type 2 en pratique clinique courante en France Étude EVIDENCE : Une étude observationnelle, prospective, post-commercialisation, avec un suivi de 2 ans","Jean–François Gautier","2016","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(16)30122-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051486","Evaluating the use of glucagon‐like peptide‐1 receptor agonists in a matched cohort of kidney and liver transplant recipients","Isabel Baik","2024","Journal of Pharmacy Practice and Research","nonrandomized_study","article","10.1002/jppr.1953",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051487","Aspirationsrisiko während Ösophagogastroduodenoskopien von Menschen mit Typ 2 Diabetes und der Einfluss von GLP-1 Rezeptoragonisten: Eine retrospektive Multicenter-Analyse","Daniel Robert Quast","2025","Zeitschrift für Gastroenterologie","other","article","10.1055/s-0045-1810658",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051488","FRI-333 Exercise protects against semaglutide-induced muscle loss in obese Ldlr-/-.Leiden mice","José A. Inia","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)01575-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051489","Identification and characterization of a novel population of hypothalamic neurons sensitive to leptin and GLP-1","Olivier Lavoie","2023","Physiology","preclinical","article","10.1152/physiol.2023.38.s1.5729686",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051490","Stable analogues of the dual agonist dogfish glucagon show better therapeutic potential than exendin-4 in diet induced obese diabetic mice","Finbarr P.M. O'Harte","2015","Endocrine Abstracts","preclinical","article","10.1530/endoabs.37.gp.15.05",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051491","Long‐Acting Hydrogel‐Based Depot Formulations of Tirzepatide and Semaglutide for the Management of Type 2 Diabetes and Weight","Andrea d'Aquino","2026","Advanced Therapeutics","preclinical","article","10.1002/adtp.202500329",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051492","Rgs16 is an early marker for islet formation and beta cell expansion in diabetics","Ozhan Ocal","2010","The FASEB Journal","preclinical","article","10.1096/fasebj.24.1_supplement.587.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051493","#1704366 Gastroparesis Incidence Post-Initiation of Semaglutide Versus Sitagliptin in Type 2 Diabetes: A Retrospective TriNetX Database Analysis","William S. A. Jenkins","2024","Endocrine Practice","nonrandomized_study","article","10.1016/j.eprac.2024.03.189",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051494","Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus","Katherine Ann Lyseng-Williamson","2013","Drugs & Therapy Perspectives","other","article","10.1007/s40267-013-0059-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051495","O-070 Impact of GLP-1 agonists on stroke, SAH, and ICH: a propensity-matched multi-institutional cohort study","Matias Luis Costa","2025",null,"nonrandomized_study","article","10.1136/jnis-2025-snis.70",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051496","The rising threat of counterfeit GLP-1 receptor agonists: Implications for public health","Abdur Rehman","2024","Journal of Medicine Surgery and Public Health","other","article","10.1016/j.glmedi.2024.100136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051497","GLP-1 RECEPTOR AGONIST EFFECT ON RETAINED GASTRIC CONTENTS ON EGD: A QUALITY IMPROVEMENT STUDY","Luis Ortiz-Hernández","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.974",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051498","PO35 Analyse post-hoc des données poolées de deux essais de phase III contrôlés contre placebo AWARD-1 et AWARD-5 (Assessment of weekly administration of LY2189265 in Diabetes – 1 and – 5/ Évaluation de l’administration hebdomadaire de LY2189265 dans le diabète","O Adetunji","2014","Diabetes & Metabolism","other_trial","article","10.1016/s1262-3636(14)72293-1",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0051499","P2859Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme","Stephen Charles Bain","2018","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehy565.p2859",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051500","Tu1887 EFFICACY AND SAFETY OF SEMAGLUTIDE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND OBESITY","Aakash Desai","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)03788-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051501","Differential effect of novel antidiabetic agents on the arterial stiffness and endothelial function in patients with type 2 diabetes mellitus","Panagiota K. Stampouloglou","2021","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehab724.2962",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051502","Coadministration of the long‐acting amylin analog cagrilintide plus semaglutide ( CagriSema ), resulted in significantly greater weight loss, along with improved measures of glucose control, in a short phase 2 trial of patients with type 2 diabetes","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","other_trial","article","10.1002/doi2.68",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051503","1704-P: Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Patients with Type 2 Diabetes in Finland","JERA A. VADÉN","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1704-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051504","EE789 Cost-Effectiveness of Tirzepatide Versus Liraglutide (Both Adjunct to a Reduced-Calorie Diet and Increased Physical Activity) in Patients With Obesity or Overweight From a UK Perspective","Matthew Capehorn","2024","Value in Health","other","article","10.1016/j.jval.2024.10.1069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051505","FRI-187 Long-term real-life experience of semaglutide in a monocentric cohort with type 2 diabetes and metabolic dysfuction-associated steatotic liver disease (MASLD)","Giovanni Petralli","2026","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(26)01925-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051506","Perspectives from primary care providers and patients on the role of primary care in the NASH patient journey","E Tanner","2022",null,"other","article","10.1370/afm.20.s1.2649",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0051507","Development of the Synthetic Route to PF-06878031 Part 2: Amide Reduction Route","Maria S. Brown","2024","Organic Process Research & Development","other","article","10.1021/acs.oprd.4c00054",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051508","973-P: Initiation of Dexcom CGM Is Associated with Improved Renal Outcomes in Adults with Chronic Kidney Disease (CKD) on Insulin Therapy","Katia L. Hannah","2025","Diabetes","nonrandomized_study","article","10.2337/db25-973-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051509","Abstract #290: Real-World Persistence and HBA1C Goal Attainment in Patients with Type Ii Diabetes Mellitus Initiated on Canagliflozin or a Glucagon-Like Peptide-1 Receptor Agonist","Patrick Lefèbvre","2017","Endocrine Practice","nonrandomized_study","article","10.1016/s1530-891x(20)44410-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051510","61 - Comparable Efficacy of Once-Weekly Subcutaneous Semaglutide in Subjects With Type 2 Diabetes Aged <65 and ≥65 Years: SUSTAIN 1–5 and 7–10 Posthoc Analysis","Akshay Jain","2020","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2020.08.067",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051511","Long-term treatment with glucagon-like peptide-1 (GLP-1) receptor agonists: a real-life study","Sara Piccini","2022","Endocrine Abstracts","other","article","10.1530/endoabs.81.rc10.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051512","S2337 Illness Perception and Weight Loss Adherence in MASLD: A Retrospective Cohort Study With Psychological Profiling","Noor Albusta","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001136808.01427.6d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051513","Effects of Adding Semaglutide to Basal-Bolus or Mixed Insulin Therapy: A Retrospective Chart Review","Abdulaziz A Jaly","2025","Pharmacy Practice","nonrandomized_study","article","10.18549/pharmpract.2025.3.3203",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051514","A head-to-head comparison study of 68Ga-DOTA-Exendin-4 and 68Ga-DOTA-NOC PET/CT in insulinomas.","Shreedharan Thankarajan Arunraj","2020","Journal of Nuclear Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051515","Glycemic Control Impacts the Quality of Bowel Preparation in Patients Undergoing Elective Colonoscopy: A Multicenter Retrospective Cohort Study","Yash R. Shah","2024","Michigan medical education and health bulletin.","nonrandomized_study","article","10.69735/001c.121513",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051516","The effect of one year treatment with GLP1-RA, SGLT2i and their combination on plasma levels of oxidative and antioxidative biomarkers","Ignatios Ikonomidis","2021","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehab724.2959",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051517","#5867 EFFECT OF SGLT2I ON URIC ACID AND GLUCOSE URINARY FRACTIONAL EXCRETION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES MELLITUS","Paula Sánchez Briales","2023","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfad063c_5867",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051518","717-P: Glycemic Control with Tirzepatide in People with Type 2 Diabetes by Baseline HbA1c =8.5% or >8.5%","Grazia Aleppo","2022","Diabetes","other_trial","article","10.2337/db22-717-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051519","1103-P: The Mobile Insulin Titration Intervention to Transition from Basal Insulin to a GLP1-RA (MITI-GLP1)—Using Daily SMS Text Messages and Weekly Phone Calls to Transition Primary Care Patients with Well-Controlled Type 2 Diabetes Mellitus from Basal Insulin to a GLP1-RA at Bellevue Hospital","Natalie Koch Levy","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1103-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051520","67 - Diabetes Prescribing Patterns of SGLT2i and GLP-1RA in Northern Alberta Primary Care: A Closer Look at Those With Cardiovascular Disease, Heart Failure and Chronic Kidney Disease","Robin C. Hao","2020","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2020.08.073",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051521","Impact of Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Glycemic Control in People With Type 1 Diabetes","Mohammad A. Irshad","2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.09.145",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051522","ORIGINAL ARTICLE Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue","Arne Vernon Astrup","2012",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0051523","[Hedonic perception and taste of food in patients with type 2 diabetes - Impact of treatment with a GLP-1: Liraglutide] / P19 Perception hédonique et gustative des aliments chez les patients diabétiques de type 2 - Impact du traitement par un analogue du GLP-1 : le Liraglutide","Sophie Meillon","2012","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051524","The efficacy and safety of semaglutide use in women with polycystic ovary syndrome: results from a dedicated reproductive endocrinology clinic","Gina Dennehy","2026","Endocrine Abstracts","other","article","10.1530/endoabs.115.p24",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051525","Mo1238: REDUCED RISK OF RETAINED GASTRIC CONTENTS AFTER INSTITUTIONAL IMPLEMENTATION OF HOLDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS PRIOR TO ENDOSCOPIC EVALUATION","Adam M. Burton","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03351-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051526","734-P: VRB101 Is a Potent Oral GLP-1 Tablet with Once-Weekly Dosing Potential","Martijn Fenaux","2025","Diabetes","randomized_trial","article","10.2337/db25-734-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051527","PDB116 REAL-WORLD ADHERENCE AND PERSISTENCE AMONG ELDERLY PATIENTS WITH T2DM INITIATING DULAGLUTIDE VS. LIRAGLUTIDE OR EXENATIDE ONCE-WEEKLY IN THE US","Miao Yu","2019","Value in Health","nonrandomized_study","article","10.1016/j.jval.2019.04.663",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0051528","Glucagon-Like Peptide-1 (GLP-1) Therapies Combined with Structured Lifestyle Interventions in Adults with Type 2 Diabetes: A Systematic Review Protocol","Laura Chiavaroli","2026",null,"systematic_review","article","10.17605/osf.io/fgh9z",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0051529","THU-269-YI Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunctions-associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthaseinhibition","Niklas Geiger","2024","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(24)01726-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051530","Abstract 4126158: Persistence to once weekly GLP-1 RAs is associated with lower risk of MI, stroke, and 2-point MACE among patients with T2D and ASCVD in the real world.","Tyler J. Dunn","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4126158",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051531","Insulin Glargine/Lixisenatide Fixed Ratio Combination Improves Glycemic Variability in Type 2 Diabetes","Ronnie Aronson","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.129",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051532","26-A-17035-ACC A META-ANALYSIS OF EFFECTIVENESS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN PATIENTS WITH OBESITY AND HEART FAILURE WITH PRESERVED EJECTION FRACTION","Lissette Haydee García-Mena","2026","Journal of the American College of Cardiology","systematic_review","article","10.1016/j.jacc.2026.02.1915",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051533","Additional file 1: of Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies","Ling Li","2016","Figshare","systematic_review","article","10.6084/m9.figshare.4430780",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0051534","1.7 Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 diabetes (AWARD-5) (71-OR)","Michael Albrecht Nauck","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0032-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051535","Inheritance of Mildly Activating ABCC8 Mutation From a Mother With MODY Causes Permanent Neonatal Diabetes Mellitus (NDM) in Two Siblings Who Also Carry a Second Inactivating Mutation: Genetic Testing Allows for Improved Treatment With Sulfonylureas (SU)","Maria Victoria Salguero Bermonth","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.923",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051536","O68 Efficacité et tolérance du liraglutide dans le diabète de type 2. Résultats à 1 an d’EVIDENCE®, une étude prospective post-inscription avec un suivi de 2 ans","Pierre Gourdy","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72242-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051537","Glucagon-like peptide-1 (GLP-1) and its analogue exendin-4 promote the growth of the biliary tree","Marco Marzioni","2006","Digestive and Liver Disease","other","article","10.1016/s1590-8658(06)80085-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051538","Correction to: Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention","Massimo Volpe","2022","High Blood Pressure & Cardiovascular Prevention","notice","article","10.1007/s40292-022-00508-7","35254658",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0051539","Comparison Between GIP/GLP-1 Co-agonists and GLP-1 Agonists on Pulmonary Outcomes in COPD Patients","Chung‐Kang Peng","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a3255",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051540","Assessing the Real-World Use of Combination Insulin Glargine-Lixisenatide in Patients with Type 2 Diabetes Mellitus—A Retrospective Review from an Ambulatory Care Endocrinology Practice","Matthew Stryker","2018","Diabetes","nonrandomized_study","article","10.2337/db18-2290-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051541","Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers","Charles Michael White","2024",null,"other","article","10.64628/aai.t4574xn3c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051542","PDB41 COST-EFFECTIVENESS OF LIRAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES IN THE SLOVAK REPUBLIC","A Ilavská","2010","Value in Health","other","article","10.1016/s1098-3015(11)72099-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051543","Effects of Selenium in Comparison to Exendin‐4 on the Expression of GLP‐1R, IRS‐1 and Preproinsulin in the Pancreas of Diabetic Rats","Sandra E. Rizk","2016","The FASEB Journal","preclinical","article","10.1096/fasebj.30.1_supplement.428.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051544","Evaluating the Tolerability of Glucagon-Like Peptide-1 Receptor Agonists in Lung Transplant Recipients","Claire A. Walshe","2024","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2024.02.1019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051545","Intra-articular Administration of Liraglutide Mitigates Synovial Tissue Alteration and Cartilage Degradation in Preclinical Osteoarthritis Models","C. Meurot","2024","Osteoarthritis and Cartilage","other","article","10.1016/j.joca.2024.02.563",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051546","Diabetic Sensory Neurons, Dorsal Root Ganglia, and Neuropathy","Aparna Areti","2023","Contemporary diabetes","other_trial","article","10.1007/978-3-031-15613-7_18",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","book-chapter"],["R0051547","Trimming the fat, soothing the heart: Mediterranean diet as a potential game-changer for prevention of atrial fibrillation?","Aymen Bushra Ahmed","2023","European Journal of Preventive Cardiology","other_trial","article","10.1093/eurjpc/zwad379","38064582",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","editorial"],["R0051548","Quick Take Vol. 84","Scott R. Beach","2026",null,"other","article","10.64239/pi-qt84",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0051549","Meta-Analysis of GLP-1 Receptor Agonist Lixisenatide Use in Patients Insufficiently Controlled with Oral Antihyperglycemic Agents","IRENE M. HRAMIAK","2013","Canadian Journal of Diabetes","systematic_review","article","10.1016/j.jcjd.2013.08.109",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051550","Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","Mei Hong Qiu","2020",null,"systematic_review","article","10.37766/inplasy2020.11.0013",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051551","Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes. - eScholarship","Deborah A. Hinnen","2006",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0051552","Preoperative Optimization in Patients with Diabetes Undergoing Foot and Ankle Surgery: BMI, Glycemic Control, and GLP-1 Agonists","Kaitlyn Leslie Hurka","2026","Diabetology","other","article","10.3390/diabetology7030054",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051553","965-P: Real-World Evidence of the Effect on Glycemic Control with Relatively Simultaneous vs. Sequential Initiation of Basal Insulin and GLP-1 Receptor Agonists","Julio Rosenstock","2020","Diabetes","nonrandomized_study","article","10.2337/db20-965-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051554","Comparative Cardiovascular Efficacy of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists—A Network Meta-analysis","Alistair Roddick","2018","Diabetes","systematic_review","article","10.2337/db18-427-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0051555","Abstract 4371398: Glucagon Receptor Agonist Impact on Cardiac Amyloidosis. A Retrospective Propensity Matched Analysis","Efeturi Maxwell Okorigba","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4371398",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051556","Obesity and reproductive health: Pathophysiological mechanisms and emerging interventions","Anastasia Vladimirovna Poznyak","2025","International Journal of Innovative Research and Scientific Studies","other","article","10.53894/ijirss.v8i12.11000",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051557","P53 Inefficient surveillance of low-risk steatotic liver disease: a call for resource reallocation","Elliott Caddy","2026","E-Posters","nonrandomized_study","article","10.1136/gutjnl-2026-bsg.189",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0051558","As implicações do uso terapêutico de liraglutida em pacientes diabéticos","Carlos Gonzaga Melo Filho","2024","Research Society and Development","other","article","10.33448/rsd-v13i8.46569",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051559","86-LB: Real-World Effectiveness of Oral Semaglutide (OS) from a U.S. Commercially Insured and Medicare Advantage Population","Nitin Shivappa","2021","Diabetes","nonrandomized_study","article","10.2337/db21-86-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051560","Exenatide plus Thiazolidindion mit und ohne Metformin: Randomisierte Studie bei Patienten mit Typ-2-Diabetes","Oliver P. Bachmann","2007","Diabetologie und Stoffwechsel","other","article","10.1055/s-2007-982239",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051561","897-P: Insulin-Sensitizing Effects of Efruxifermin Improve Glycemic Control in Patients with MASH and Type 2 Diabetes","Kathryn Jean Lucas","2024","Diabetes","other_trial","article","10.2337/db24-897-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051562","1675-P: Patient Experiences with Tirzepatide in SURMOUNT-4","Irina Jouravskaya","2024","Diabetes","randomized_trial","article","10.2337/db24-1675-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051563","#79 Semaglutide enabled waitlisting and transplantation of otherwise unlisted obese renal transplant candidates","Caroline La","2025","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfaf116.1808",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051564","P326 L’ancienneté du diabète et les traitements antérieurs sont les facteurs prédictifs de la réponse au liraglutide: résultats de l’étude post-inscription EVIDENCE®","Guillaume Charpentier","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30439-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051565","602: TRENDS IN GLP-1 RECEPTOR AGONIST UTILIZATION AND BARIATRIC SURGERY RATES: A REAL-WORLD ANALYSIS FROM 2021-2024","Ahmed Eltelbany","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)05346-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051566","6989 Novel Use of Dual GIP/GLP-1 Receptor Agonist in HNF4A-MODY","Alina Mehdi","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.869",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051567","The Next Frontier: Biomarkers and Artificial Intelligence Predicting Cardiorenal Outcomes in Diabetic Kidney Disease","Gregory Lee Braden","2022","Kidney360","nonrandomized_study","article","10.34067/kid.0003322022","36245646",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051568","Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide","Ametov As","2023","Pharmacy & Pharmacology","randomized_trial","article","10.19163/2307-9266-2023-11-3-255-276",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0051569","743-P: Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes","CAROL H. WYSHAM","2024","Diabetes","randomized_trial","article","10.2337/db24-743-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051570","(157) Prescribing Ozempic and Wegovy for Weight Loss is Associated with an Increased Risk of Erectile Dysfunction and Hypogonadism in Non-Diabetic Males","Boshou Liao","2024","The Journal of Sexual Medicine","nonrandomized_study","article","10.1093/jsxmed/qdae001.148",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051571","Patient Adherence to a Digital Real-World GLP-1 RA-Supported Weight-Loss Program in the UK: A Retrospective Cohort Study","Louis A Talay","2024","Journal of Community Medicine & Public Health","nonrandomized_study","article","10.29011/2577-2228.100422",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051572","Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Under Renal Replacement Therapies: Bridging the Gap Between Cardiovascular and Systemic Benefit, From Heart Failure to Myocardial Infarction","Giuseppe Galati","2025","Journal of Cardiovascular Pharmacology","nonrandomized_study","article","10.1097/fjc.0000000000001677","39913314",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051573","Joint Treatment Effect Estimation from Incomplete Healthcare Data: Temporal Causal Normalizing Flows with LLM-driven Evolutionary MNAR Imputation","olivia jullian parra","2026","arXiv (Cornell University)","randomized_trial","article","10.48550/arxiv.2605.05125",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0051574","GLP-1 therapy and the immune system - can we predict responders from non-responders?","Dónal O’Shea","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.ep696",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051575","Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study) (Preprint)","Michael D Feher","2021",null,"protocol","article","10.2196/preprints.34206",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","preprint"],["R0051576","A-66 | Mortality Risk Factors and the Impact of GLP-1 Receptor Agonists in CABG Patients: A Three-Month Hazard Ratio Analysis","Abdallah H. Hussein","2025","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2025.102816",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051577","New therapeutic options for bile acid malabsorption diarrhea","Alejandro Valencia-Rodríguez","2019","Annals of Translational Medicine","other","article","10.21037/atm.2019.09.112","31930096",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051578","The effect of exenatide treatment on serum ghrelin levels in patients with type 2 diabetes","Figen Topyildiz","2015","Endocrine Abstracts","other","article","10.1530/endoabs.37.ep452",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051579","Seeing the Light: Improving Diabetic Retinopathy Outcomes by Bringing Screening to the Dialysis Clinic","Klara Rachel Klein","2022","Kidney360","other","article","10.34067/kid.0003752022","36245657",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051580","Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial","Francesco Cosentino","2021","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehab724.2650",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051581","On the need of the simultaneous control of arterial hypertension and diabetes mellitus","Luis Miguel Ruilope","2020","Journal of Clinical Hypertension","other_trial","article","10.1111/jch.13794","31944518",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051582","GLP-1-Based Therapies: What are the Safety Implications?","Alric V. Mondragon","2015","IMPERIAL COLLEGE PRESS eBooks","other","article","10.1142/9781783267378_0008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0051583","Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs insulin lispro TID added to titrated insulin glargine QD: the 4B trial","Bruce H. R. Wolffenbuttel","2013","University of Groningen research database (University of Groningen / Centre for Information Technology)","other_trial","article","10.1007/s00125-013-3012-z",null,null,null,null,"openalex","FALSE","open_pdf","5","FALSE","article"],["R0051584","Tirzepatide vs semaglutide for metabolic optimization in patients with cancer: A target trial emulation study.","Omer Sayed Ashruf","2025","JCO Oncology Practice","nonrandomized_study","article","10.1200/op.2025.21.10_suppl.528",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051585","The perioperative implications of GLP-1 receptor agonists: a narrative review","Paul Anthony Stewart","2026","Anaesthesia & intensive care medicine","narrative_review","article","10.1016/j.mpaic.2026.04.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0051586","Dampening HPA axis activity enhances the quality and durability of weight loss with GLP-1-based therapies","Jéssica Matheus Sá","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2300989",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051587","UPDATED META-ANALYSIS OF TRIALS ASSESSING THE CARDIOVASCULAR EFFICACY OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN BLACK PATIENTS","Dimitrios Patoulias","2021","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0000746888.24529.47",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051588","From Clinical Trial Evidence to Clinical Guidelines: Perspectives on REWIND from Clinicians in the Gulf and Levant Region","Talal Ashour","2023","Dubai Diabetes and Endocrinology Journal","nonrandomized_study","article","10.1159/000534713",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051589","Glucagon-like peptide-1 receptor agonists ameliorate inflammation and fibrosis in an optimized rodent NASH model via inhibition of inflammatory macrophage activation","X. Wang","2017","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(17)31660-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051590","Authors' reply to de Oliveira and Iverson","T. Vilsboll","2012","BMJ","commentary","article","10.1136/bmj.e1459",null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0051591","Clinical effectiveness study of dapagliflozin as add-on for 33 inadequate glycemic control patients using liraglutide and OADs","Yuan-Ching Liu","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31152-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051592","Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition","Anshu Joshi","2019","World Nutrition","other","article","10.26596/wn.201910264-75",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051593","Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","Luís Lobo","2024","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehae666.2917",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0051594","Editorial: Novel pathophysiologic mechanisms and reno-protective pharmacotherapies in diabetic kidney disease","Elias John Elenjickal","2024","Frontiers in Pharmacology","randomized_trial","article","10.3389/fphar.2024.1531748","39726783",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0051595","SEMAGLUTIDE: A POTENTIAL WEIGHT LOSS DRUG FOR OBESE PATIENTS","Ayesha Khan","2023","Northwest journal of medical sciences.","other_trial","article","10.69723/njms.02.01.0315",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051596","982: EFFICACY AND SAFETY OF DUAL GIP/GLP-1 AGONIST IN MASH AND LIVER FIBROSIS: A CLASS EFFECT META ANALYSIS","Amanda Rigdon","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04677-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051597","O SALUTARISMO NA CULTURA POP: Performance e biopolítica em relatos de celebridades no uso do Ozempic","Thiago da Silva Soares","2025","Comunicação & Inovação","other","article","10.13037/ci.vol26.e20259801",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051598","Safety and Efficacy of Exenatide Therapy for the Management of Hospitalized Patients with Type 2 Diabetes—Exenatide Hospital Trial","Maya Fayfman","2018","Diabetes","randomized_trial","article","10.2337/db18-1078-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051599","MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Acutely Inhibits Food Intake in Leptin-Deficient ob/ob Mice and Leptin Receptor–Deficient fa/fa Rats","VICTOR G. HOWARD","2018","Diabetes","preclinical","article","10.2337/db18-1891-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051600","The Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A Randomized Controlled Trial Exploring Weekly, Biweekly, and Monthly Dosing Running title: Albiglutide dose regimen study","Julio Rosenstock","2009",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0051601","*†GLP-1 Receptor Agonists Rarely Cause Acute Pancreatitis but Induce Non-Inflammatory Acinar Hypertrophy, Pancreatic Enlargement, and Mild Lipase Leak","Jianing Li","2026","Journal of clinical lipidology","other","article","10.1016/j.jacl.2026.05.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051602","Abstract 4139027: Glucagon-like Peptide-1 Receptor Agonist Use and Cardiac Outcomes in Patients with End Stage Kidney Disease","Benjamin Catanese","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4139027",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051603","Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin.","Iuliia V. Silko","2016","Obesity and metabolism","other","article","10.14341/omet201623-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051604","Semaglutide Reduces HbA1c Across Baseline HbA1c Subgroups Across SUSTAIN 1–5 Clinical Trials","George M. Tsoukas","2017","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2017.08.132",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051605","Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin","Naveed A. Sattar","2020","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaa879","33200189",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0051606","1687-P: Sequential Combination of the Mitochondrial Protonophore (MP) TLC-6740 with Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice","NATALIE SRODA","2025","Diabetes","preclinical","article","10.2337/db25-1687-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051607","Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement","Ansu Basu","2021","British Journal of Diabetes","other_trial","article","10.15277/bjd.2021.283",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0051608","ПЕРВЫЙ В РОССИИ ОПЫТ ПОСТРОЕНИЯ СИМУЛЯЦИОННОЙ МОДЕЛИ ИСХОДОВ САХАРНОГО ДИАБЕТА 2-ГО ТИПА С ДИСКРЕТНЫМ МОДЕЛИРОВАНИЕМ СОБЫТИЙ. КЛИНИКО-ЭКОНОМИЧЕСКАЯ ЭКСПЕРТИЗА","А. С. Колбин","2013","CyberLeninK (CyberLeninka)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051609","27. GLP-1 RA Added to Insulin Results in Durable Weight Loss and Glycemic Control in Type 2 Diabetes Patients: 2 Years Real-Life Follow-up Data (976-P)","Stefanie A. de Boer","2014","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-014-0052-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051610","Diabetes and Heart Failure in the Crosshairs: Where is the Target?","Justin Adrian Ezekowitz","2017","European Journal of Heart Failure","randomized_trial","article","10.1002/ejhf.703","28052547",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051611","Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway","Hongbo Liu","2020","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051612","Cotadutide. Dual glucagon-like peptide 1 receptor (GLP-1R)/glucagon receptor (GCGR) agonist, Treatment of diabetes, Treatment of nonalcoholic steatohepatitis, Treatment of obesity","Ambika Pinakini Amblee","2020","Drugs of the Future","other","article","10.1358/dof.2020.45.11.3140449",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051613","Liraglutide contre NASH","Alexandre E. Pariente","2016","Hépato-Gastro & Oncologie Digestive","other","article","10.1684/hpg.2016.1293",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051614","EE439 COST-EFFECTIVENESS OF SEMAGLUTIDE FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN THE UNITED STATES","Muhammed Rashid","2026","Value in Health","other","article","10.1016/j.jval.2026.03.733",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051615","THU-256 Without effect on weight loss, semaglutide does not improve MASLD in a dietary mice model for MASLD","Katharina Luise Hupa‐Breier","2024","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(24)01716-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051616","S244 Beyond the Triad: Diagnostic Delays and the Role of Biomarkers in Atypical Acute Cholangitis: A Systematic Review","Tanishq Kesani","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001127436.10004.af",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0051617","EFFECT OF LIRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN ELDERLY PATIENTS IN THE LEADER TRIAL","Matthew Philip Gilbert","2018","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(18)32259-9",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051618","Insulin Glargine and SGLT2 Inhibitors Have Higher Risk of Major Adverse Cardiovascular Events (MACE) Compared with Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in a National Cohort of Veterans with Type 2 Diabetes (T2D) and CKD","Niharika Katkam","2024","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2024sdjbfbv4",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051619","Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes","C. Wysham","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807442",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0051620","PMD177 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH DULAGLUTIDE AND SEMAGLUTIDE INJECTION DEVICES AMONG PATIENTS WITH TYPE 2 DIABETES IN ITALY","Louis S. Matza","2018","Value in Health","other","article","10.1016/j.jval.2018.09.1626",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051621","Rapid uptake of GLP-1 receptor agonists in patients with inflammatory bowel disease: a 14-month repeated cross-sectional survey","Christopher Roberts","2026","Frontline Gastroenterology","nonrandomized_study","article","10.1136/flgastro-2026-103717",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051622","Incretin-based Therapy and the Prevention of Hypoglycaemia","Klaus Georg Parhofer","2007","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2007.00.02.51",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051623","Exenatide Benefits Hold Up Long Term in Type 2 Diabetes","Nancy Pesta Walsh","2005","Family Practice News","other","article","10.1016/s0300-7073(05)70645-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051624","325-OR: Glucagon-Like Peptide 1 Receptor Agonists Preserved Vascular Endothelial Junction through Inhibition of STING Signaling–Elicited Inflammation in Diabetic Retinopathy","XUEMIN HE","2023","Diabetes","preclinical","article","10.2337/db23-325-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051625","Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet","Patricia Knoepp","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/ghnb-3t38",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0051626","738-P: Real-World Effectiveness among Patients with Type 2 Diabetes (T2D) Initiating Tirzepatide (TZP)","Reema Mody","2024","Diabetes","nonrandomized_study","article","10.2337/db24-738-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051627","2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","Απόστολος Τσάπας","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/ahdm-z546",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051628","7725 Could COVID-19 Be the Trigger for Type 1 Diabetes?","Elahe Ahsan","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.721",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051629","Adding Insulin Detemir to Liraglutide and Metformin Improves Glycemic Control with Sustained Weight Reduction: 52 Week Data","Vincent C. Woo","2012","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2012.07.357",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051630","Quick Take Vol. 91","Amanda Koire","2026",null,"other","article","10.64239/pi-fr-qt91",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0051631","S269 Comparative Risk of Cholangiocarcinoma With GLP-1 Receptor Agonists and Bariatric Surgery in Patients With Diabetes and Obesity: A Matched Cohort Study","Yahya Alhalalmeh","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001128536.23109.f4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051632","Current developments in the treatment of diabetes: the incretin therapies","David L Russell-Jones","2010","The British Journal of Diabetes","other","article","10.1177/1474651409357266",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051633","Herbal Medicines and Nutraceuticals for Diabetic Vascular Complications: Mechanisms of Action and Bioactive Phytochemicals","Eshaifol A. Omara","2010","Current Pharmaceutical Design","other","article","10.2174/138161210794455076","21128894",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051634","GLP-1 Receptor Agonists Target Autophagy Dysfunction in Diabetic Nephropathy","João Venda","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025c4nxz00s",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051635","eP330 Normalisation of glycaemia in a patient with type 2 diabetes within forty-eight hours of Roux-en-Y gastric bypass surgery","Elena Brachimi","2025","British journal of surgery","other","article","10.1093/bjs/znaf166.461",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051636","An Overview on Recent Analytical Methodologies for the Determination of Antiobesity Glucagon like Peptides-1 Receptor Agonists","Noura Mansour","2024","Delta University Scientific Journal","other","article","10.21608/dusj.2024.310117.1083",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051637","1693-P: Cagrisema-Induced Weight Loss in Diet-Induced Obese Rats Relies on Preserved Mitochondrial Leak Respiration in Skeletal Muscle","Ida Blom","2025","Diabetes","preclinical","article","10.2337/db25-1693-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051638","Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor AgonistS (GLP–1RA) in PatientS with Type 2 Diabetes—PROGRESS-DIABETES Study","Ruth E. Brown","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1096-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051639","Durability of Combination Therapy with Exenatide and Pioglitazone vs. Basal Bolus Insulin in Poorly Controlled T2DM Patients—Three-Year Follow-Up of the QATAR Study","Muhammad A Abdul‐Ghani","2018","Diabetes","randomized_trial","article","10.2337/db18-1062-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051640","Abstract 11760: Prevalence of Atherosclerosis, Heart Failure, and Chronic Kidney Disease Among Patients With Type 2 Diabetes and Management With Diabetes Pharmacotherapy","Jeff T. Mohl","2023","Circulation","nonrandomized_study","article","10.1161/circ.148.suppl_1.11760",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051641","The GLP-1 receptor agonist Semaglutide decreases vascular inflammation in a rabbit model of advanced atherosclerosis","Jacob Kildevang Jensen","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.0287",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051642","1073-P: Trends in Guideline-Directed Medication Therapy for Type 2 Diabetes in a Statewide Quality Collaborative between 2018–2023","KARA R. MIZOKAMI-STOUT","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1073-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051643","SODIUM GLUCOSE CO-TRANSPORTER-2 INHIBITORS VS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A META-ANALYSIS OF BENEFITS AND RISKS","Ashesh Kumar Das","2025","CHEST Journal","systematic_review","article","10.1016/j.chest.2025.07.240",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051644","#6005 COMPARISON OF SEMAGLUTIDE ORAL VS SUBCUTANEOUS IN CHRONIC KIDNEY DISEASE (CKD)","María Marqués","2023","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfad063c_6005",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051645","The Use of Incretin-Based Therapies and Cancer-Specific Risk in Type 2 Diabetes Mellitus Patients: A Systematic Review","Niamh McGuckin","2021","Research Portal (Queen's University Belfast)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0051646","Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management","Anca Pantea Stoian","2020","Metabolic Syndrome and Related Disorders","nonrandomized_study","article","10.1089/met.2020.0037","32271125",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051647","Exenatide verbessert bei Patienten mit Typ-2-Diabetes die postprandiale Glucosekontrolle, gemessen an der Konzentration von 1,5-Anhydroglucitol","CHRISTOF M. KAZDA","2008","Diabetologie und Stoffwechsel","other","article","10.1055/s-2008-1076368",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051648","Beneficial effect of the combination psilocybin-semaglutide in a murine model of Steatotic Liver Disease","Martina Colognesi","2025","Digestive and Liver Disease","preclinical","article","10.1016/j.dld.2025.01.135",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051649","Ozempic como estratégia terapêutica para obesidade: Uma revisão de literatura","Fernando Kawaminami Lopez","2025","Journal of Medical and Biosciences Research.","other","article","10.70164/jmbr.v2i5.856",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051650","FEASIBILITY OF COMBINATION SGLT2I AND GLP-1RA FOR TYPE 2 DIABETES AND ASCVD: REPORT FROM THE PILOT PHASE OF THE PRECIDENTD PRAGMATIC RCT","Deborah J. Wexler","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00946-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051651","The National Kidney Foundation's CKD Learning Collaborative: Transforming Care across University Health in Kansas City, Missouri","Jignesh Shah","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20242sykf8r5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051652","Glucagon receptor modulation: Its role in diabetes care","Krishna Seshadri","2023","Journal of Diabetology","other","article","10.4103/jod.jod_106_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051653","GLP-1 analogs prevent and revert diabetes in Wolfram syndrome","Mariana Igoillo‐Esteve","2019","Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051654","1978-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity and Type 2 Diabetes—STEP UP T2D Trial","ILDIKO LINGVAY","2025","Diabetes","randomized_trial","article","10.2337/db25-1978-lb",null,null,"ClinicalTrials.gov:NCT05649137","S001158","openalex","FALSE","paywalled","1","FALSE","article"],["R0051655","Safety analysis of tirzepatide in clinical practice","Ksenia O. Shnaider","2025","Glavvrač (Chief Medical Officer)","other_trial","article","10.33920/med-03-2508-03",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051656","Phenotypic and genetic clusters of type 2 diabetes mellitus: Associations with complication risk and therapeutic strategies","T. Yu. Demidova","2026","FOCUS Endocrinology","other","article","10.62751/2713-0177-2026-7-1-06",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051657","The synthetic glucagon-like peptide-1 receptor agonist liraglutide affects the kinetics of pro-inflammatory kinases and improves insulin sensitivity of 3T3-L1 adipocytes","Elizaveta D. Mamontova","2020","European Heart Journal","other","article","10.1093/ehjci/ehaa946.3038",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051658","Comparaison de l’efficacité du liraglutide en ajout à un traitement par metformine à l’inclusion de l’étude EVIDENCE® vs. en association aux autres traitements antidiabétiques : résultats post-hoc après 2 ans de suivi","Evelyne Eschwege","2015","Annales d Endocrinologie","other","article","10.1016/j.ando.2015.07.072",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051659","Efficacy of Bariatric Surgery (BSx) versus Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA) After Kidney Transplantation","Joseph M. Kahwaji","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.586",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051660","Sumatriptan Succinate/Naproxen Sodium","Dennis J. Cada","2008","Hospital Pharmacy","other_trial","article","10.1310/hpj4308-650",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051661","Digital Engagement Significantly Enhances Weight Loss Outcomes in Adults With Obesity Treated With Tirzepatide: Retrospective Cohort Study of a Digital Weight Loss Service (Preprint)","Hans H. Johnson","2025",null,"nonrandomized_study","article","10.2196/preprints.83718",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0051662","Effect of semaglutide vs placebo on HbA1c, weight, mental health and SF-36: a randomized clinical trial in people with pre-diabetes, obesity and schizophrenia","Ashok Ainkaran Ganeshalingam","2025","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.110.p316",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051663","Exendin-4: Orchestrating Molecular Signals with Cellular Responses in Vascular Homeostasis.","Ihab Harbieh","2026","Journal of Pioneering Medical Science","other","article","10.47310/jpms2026150509",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051664","Liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure within 2 weeks in patients with type 2 diabetes","Vivian Andrew Fonseca","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33184-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051665","A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults","William David Strain","2021","British Journal of Diabetes","systematic_review","article","10.15277/bjd.2021.292",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0051666","S130 GLP-1 Receptor Agonists Are Associated With Significant Protection From Acute Pancreatitis","Inuk Zandvakili","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001126980.74777.9c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051667","Obesity management: behaviour, drugs and surgery","Bernie Young Sunwoo","2026","European Respiratory Society eBooks","other","article","10.1183/2312508x.10030325",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0051668","REAL WORLD EXPERIENCE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY","Matthew Fordham","2024","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(24)02551-8",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051669","Type 1 diabetes mellitus and cardiovascular risk: A short review","Konstantinos Kitsios","2022","Journal of Atherosclerosis Prevention and Treatment","randomized_trial","article","10.53590/japt.02.1039",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051670","929-P: Dulaglutide Shows Sustained A1C Reduction: Two-Year U.S. Real-World Study","Reema Mody","2020","Diabetes","nonrandomized_study","article","10.2337/db20-929-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051671","Drug therapy of obesity in routine realities: tirzepatide efficacy and safety","Mekan Rakhimberdyevich Orazov","2025","Clinical review for general practice","other","article","10.47407/kr2025.6.4.00600",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051672","Impact of Semaglutide on Infections and COVID-19: Data from the FLOW Trial","Brian Lindsay Rayner","2024","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.2024czp076yc",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051673","775-P: Predictors of Glycemic Control in Older People with Type 2 Diabetes Treated with iGlarLixi—A Pooled Analysis","MEDHA MUNSHI","2023","Diabetes","randomized_trial","article","10.2337/db23-775-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051674","PCR83 DISABILITY AND ADHERENCE TO GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS AMONG U.S. ADULTS WITH DIABETES: EVIDENCE FROM THE MEDICAL EXPENDITURE PANEL SURVEY","Regina N. Nechi","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1856",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051675","Medical treatment of obesity: Modern approaches and prospects","Victoria V. Titova","2024","FOCUS Endocrinology","other","article","10.62751/2713-0177-2024-5-4-18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051676","High Prevalence of Obesity and Related Complications with Limited Utilization of Obesity Medication in Patients with Psoriasis or Psoriatic Arthritis: Real-World Clinical Insights from the US","Mark Lebwohl","2025","SKIN The Journal of Cutaneous Medicine","nonrandomized_study","article","10.25251/2eee8k43",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051677","MIR192 upregulates GLP-1 receptor and rescues statin-induced impairment of insulin secretion","Yu‐Lin Kuang","2026","Cardiovascular Diabetology","preclinical","article","10.1186/s12933-026-03353-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051678","Addition of GLP-1 Therapy to Insulin in C-Peptide-Positive Patients with Type 1 Diabetes","Nitesh D Kuhadiya","2018","Diabetes","nonrandomized_study","article","10.2337/db18-110-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051679","GLUCAGON-LIKE PEPTIDE-1 AGONIST ON INCIDENCE OF ATRIAL FIBRILLATION FOLLOWING HEART FAILURE HOSPITALIZATION IN A DIABETIC POPULATION","Thomas Fretz","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00510-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051680","Association Between Prokinetic Agents and Biliary Complications in Semaglutide Treated Patients with Type 2 Diabetes","Hanson Chan","2025",null,"nonrandomized_study","article","10.1370/afm.23.s1.8000",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0051681","Sa1950 IMPACT OF GLP1 AGONISTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE","Priya Sehgal","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01827-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051682","777-P: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat Accumulation","Qi Wu","2025","Diabetes","nonrandomized_study","article","10.2337/db25-777-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051683","Efficacité en pratique clinique et persistance sous traitement de patients diabétiques de type 2 nouvellement traités par liraglutide. EVIDENCE, une étude postinscription avec un suivi de 2 ans","Luc Martinez","2012","Annales d Endocrinologie","other","article","10.1016/j.ando.2012.07.1002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051684","GLP-1 Agonist–Associated Weight Loss: A Comparison by HIV Status in the MACS/WIHS Combined Cohort","Joshua Airgood","2026","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/sybt-dt02",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0051685","High prevalence of advanced NAFLD in type 2 diabetic patients with unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD Program","Matthew James Armstrong","2010","Diabetologia","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0051686","S761 Combination Transoral Outlet Reduction (TORe) Plus Pharmacotherapy vs Transoral Outlet Reduction (TORe) Alone for Treatment of Weight Regain After Roux-en-Y Gastric Bypass","Ronan P. Allencherril","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130504.83877.35",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051687","Effect of Tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the Tirzepatide treatment on coronary atherosclerosis progression (T-PLAQUE)","Hossein Hamidi","2024","Metabolism","protocol","article","10.1016/j.metabol.2024.155886",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051688","GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH ONCE-WEEKLY GLP-1RAS: COMPARISON OF A NETWORK META-ANALYSIS WITH A DIRECT ANALYSIS OF PLACEBO-CONTROLLED TRIALS","Michelle Elaine Orme","2016","Value in Health","systematic_review","article","10.1016/j.jval.2016.03.1313",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0051689","166 - Effects of GLP-1 Receptor Agonists on Testosterone Levels and Semen Parameters in Men: A Systematic Review","O. Raheem","2025","Continence","systematic_review","article","10.1016/j.cont.2025.102090",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0051690","Semaglutide Reverses CMR Features of Obesity-Induced Metabolic Heart Disease Independent of Reduced Food Intake in Mice","Thomas P. Skacel","2026","Journal of Cardiovascular Magnetic Resonance","preclinical","article","10.1016/j.jocmr.2025.102224",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051691","WEIGHT LOSS IN HYPERTENSIVE PATIENTS WITH OBESITY UNDER THE INFLUENCE OF LIRAGULTIDE IS ASSOCIATED WITH A REDUCTION IN INSULIN RESISTANCE AND INCREASED EFFECTIVENESS OF THERAPY","S. N. Koval","2024","Journal of Hypertension","other","article","10.1097/01.hjh.0001021840.60415.c0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051692","2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?","Mattía Galli","2024","European Heart Journal - Cardiovascular Pharmacotherapy","randomized_trial","article","10.1093/ehjcvp/pvae069","39289001",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051693","Persistence to Liraglutide Therapy Is Associated with Good Glycemic and Body Weight Control in Patients with Type 2 Diabetes","Cheli Melzer Cohen","2018","Diabetes","randomized_trial","article","10.2337/db18-2295-pub",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051694","Challenging the Dogma: Reversal of End-Stage Liver Fibrosis with Tirzepatide in MASH Cirrhosis","Thuy-Duyen Nguyen","2025","Transplantology","other","article","10.3390/transplantology6030025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051695","Response to comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267","Michael Albrecht Nauck","2007","Diabetologia","other","article","10.1007/s00125-007-0680-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051696","Abstract 2188: Tirzepatide treatment restores antitumor immunity in a model of obesity-driven cancer","Michael F. Coleman","2024","Cancer Research","randomized_trial","article","10.1158/1538-7445.am2024-2188",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051697","Effect of exenatide twice daily according to different meal schedules on glycemic control and variability in patients with type 2 diabetes mellitus","Esperanza Martínez Abundis","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051698","Intermittent Fasting: “New Kid on the Block or Old Wine in a New Bottle?”","Krishnan Shanmuganandan","2026","Journal of Marine Medical Society","other","article","10.4103/jmms.jmms_35_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051699","High-Resolution, Free-Running, Whole Heart Fat Fraction Mapping to Monitor Fatty Remodeling and Therapeutic Response to Semaglutide in a Porcine HFpEF Model","Xinheng Zhang","2026","Journal of Cardiovascular Magnetic Resonance","preclinical","article","10.1016/j.jocmr.2025.102310",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051700","6567 Novel Indication of GLP-1 Receptor Agonists Beyond Weight Loss: Addressing Post-Gastric Bypass Late Dumping Syndrome","Giuliana Arevalo","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.868",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051701","6ER-002 Efficacy of a fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus","V Ožana","2019",null,"nonrandomized_study","article","10.1136/ejhpharm-2019-eahpconf.600",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0051702","7018 Improved Tolerability After Transitioning from Glucagon-like Peptide-1 Receptor Agonists to Tirzepatide","Sydney Hudson","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.813",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051703","Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunction associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthase-inhibition","Niklas Geiger","2024","Endocrine Abstracts","preclinical","article","10.1530/endoabs.99.rc12.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051704","Efficacy of GLP-1 Receptor Agonists Combined with Lifestyle Modification on Weight and Cardiovascular Metabolic Biomarkers for the Treatment of Overweight and Obesity: Meta-Analysis of Randomized Controlled Trials","Joseph Chu","2025","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.5172447",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0051705","672-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Twelve-Month Data Analysis","Bruno Guerci","2021","Diabetes","nonrandomized_study","article","10.2337/db21-672-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051706","Abstract PS1-10-12: Impact of Glucagon-like peptide-1 receptor agonists Use on Survival and Metabolic Outcomes in Metastatic Estrogen Receptor Positive Breast Cancer: A Real-World Cohort Study","Fayaz Khan","2026","Clinical Cancer Research","randomized_trial","article","10.1158/1557-3265.sabcs25-ps1-10-12",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051707","Real world study on the Clinical and Safety Outcomes With GLP ‐1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.28",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051708","New way, new recommendation: Individualized treatment of novel antidiabetic drugs for people living with type 2 diabetes based on the cardiorenal risks","Xiang Ming Xu","2021","Journal of Evidence-Based Medicine","randomized_trial","article","10.1111/jebm.12452","34724335",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0051709","Liraglutide and acute pancreatitis in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit","Ryder Rej","2013",null,"nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0051710","335-OR: Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subjects","Minna Brændholt Olsen","2022","Diabetes","nonrandomized_study","article","10.2337/db22-335-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051711","Abstract 4137914: Eligibility for Semaglutide in US Adults with Diabetes and Potentially Preventable Cardiovascular Events Projected from the SUSTAIN-6 Trial","Nathan K. P. Wong","2024","Circulation","other_trial","article","10.1161/circ.150.suppl_1.4137914",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0051712","GLP-1 analogs protect beta cells in models of Wolfram syndrome","Calvin Ke","2018","Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051713","Le medicament du mois. Le lixisenatide (Lyxumia): nouvel agoniste des recepteurs du glucagon-like peptide-1 a action preferentiellement post-prandiale.","André Jacques Scheen","2014","RMLG. Revue médicale de Liège","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051714","Exenatide Has Lasting Benefits In Diabetes","Nancy Pesta Walsh","2005","Internal Medicine News","other","article","10.1016/s1097-8690(05)70377-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051715","Initiating injectable exenatide (Byetta) in primary care","Bhavisha Pattani","2011","Prescriber","other","article","10.1002/psb.717",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051716","TREATMENT WITH EXENATIDE REDUCES CASPASE-3 ACTIVATION AND APOPTOSIS AND ENHANCES BETA CELL SURVIVAL IN ISOLATED HUMAN ISLETS DURING CULTURE.","Z. Ao","2008","Transplantation","other","article","10.1097/01.tp.0000331993.11477.35",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051717","Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D—The VIVID Study, Primary Population","George Grunberger","2018","Diabetes","randomized_trial","article","10.2337/db18-1011-p",null,null,"ClinicalTrials.gov:NCT02561078",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051718","Is it Time to Transform Our Treatment Of Type 2 Diabetes","Michael Albrecht Nauck","2013","DOAJ (DOAJ: Directory of Open Access Journals)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0051719","Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin","Kjeld Hermansen","2008","Lund University Publications (Lund University)","other","article","10.1007/s00125-008-1117-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051720","PDB68 - COST-EFFECTIVENESS ANALYSIS OF EXENATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Margarita Capel","2018","Value in Health","other","article","10.1016/j.jval.2018.09.773",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051721","GLP-1 receptor agonists: Battling against both type 2 diabetes mellitus and obesity","Vincent C. Woo","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051722","Improved adherence to guideline-recommended treatments in a specialist preventative pharmacology clinic compared to standard cardiology clinics after an acute coronary syndrome","Mark Roland Thomas","2023","European Journal of Preventive Cardiology","other","article","10.1093/eurjpc/zwad125.125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051723","Effect of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on left atrial strain and arterial function","Konstantinos Katogiannis","2023","European Heart Journal - Cardiovascular Imaging","randomized_trial","article","10.1093/ehjci/jead119.163",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051724","2185-PUB: Once-Weekly Semaglutide 1mg vs. Empagliflozin 25mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: A Meta-regression Analysis of Individual Patient Data","Ildiko Lingvay","2020","Diabetes","other","article","10.2337/db20-2185-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051725","Efficacité et tolérance du liraglutide par rapport au placebo en association au traitement antidiabétique existant chez des patients diabétiques de type 2 avec une insuffisance rénale modérée (LIRA-RENAL)","Amira Bouzidi","2014","Annales d Endocrinologie","other","article","10.1016/j.ando.2014.07.140",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051726","Genetic Determinants Predicting Efficacy of Glucose-Lowering Drugs?","Michael Albrecht Nauck","2010","Diabetes Care","other","article","10.2337/dc10-1263","20805284",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051727","Impact et rôle du liraglutide, un analogue du GLP-1 humain, sur les fonctions cardiovasculaires des patients ayant un diabète de type 2 : le rationnel et le design de l’étude LEADER®","Florence Travert","2013","Annales d Endocrinologie","other","article","10.1016/j.ando.2013.07.535",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051728","IMPROVEMENT OF THE 10-YEAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK WITH ONCE-WEEKLY SEMAGLUTIDE 2.4 MG IN ADULTS WITH OVERWEIGHT OR OBESITY - POST-HOC ANALYSIS OF THE STEP 1 TRIAL","Subodh Verma","2021","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(21)02963-6",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0051729","307-OR: Effect of Oral Small Molecule GLP-1 Receptor Agonist TERN-601 in Healthy Participants with Obesity or Overweight—A First-in-Human Study","Cara Nelson","2025","Diabetes","randomized_trial","article","10.2337/db25-307-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051730","OR09-06 Tirzepatide as a Promising Treatment for Metabolic Hypogonadism in Obese Men: Effects on Metabolic and Hormonal Parameters","Sandro La Vignera","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.071",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051731","EXPLORING THE COMPLICATIONS OF TYPE 2 DIABETES MELLITUS: PATHOPHYSIOLOGY AND MANAGEMENT STRATEGIES","Ritika Deol","2024","EPRA International Journal of Research & Development (IJRD)","other","article","10.36713/epra17838",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051732","FRI-414 Reproducible hepatoprotective effects and clinical translatability of long-term semaglutide treatment in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH","Michael Feigh","2025","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(25)01635-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051733","S751 An Institutional Review of Upper Endoscopy Outcomes in Patients Taking Glucagon-Like Peptide-1 Receptor (Glp-1) Agonists: No Increased Risk of Aspiration or Retained Gastric Contents","Virginia Milner","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130464.09902.ee",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051734","8613 Diabetes remission: experience from a randomized control trial conducted in a tertiary care hospital in India","Ananda Mohan Chakraborty","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.731",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051735","Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations","Derek John Hausenloy","2016","European Heart Journal","other_trial","article","10.1093/eurheartj/ehw145","27118196",null,"ClinicalTrials.gov:NCT01435408; ClinicalTrials.gov:NCT01398384",null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051736","26. Liraglutide Reverses Pronounced Insulin-Associated Weight Gain, Improves Glycemic Control, and Decreases Insulin Dose in Patients with Type 2 Diabetes (973-P)","Helena de Wit","2014","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-014-0051-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051737","E-258 The impact of semaglutide (ozempic) on mortality and survival in patients with acute ischemic stroke: a nationwide and institutional retrospective analysis","Ahmed Elbayomy","2025",null,"nonrandomized_study","article","10.1136/jnis-2025-snis.373",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051738","ODP596 Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir","Ying Chen","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.157",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051739","Weight Loss Via Oral Semaglutide or Diet Intervention in Adolescent Females with Obesity and Polycystic Ovary Syndrome: Treating Pcos with Semaglutide vs Active Lifestyle Intervention (Teal) Study, a Randomized, Open-Label, Phase 3 Trial","Nazeen Morelli","2025","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.5368696",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0051740","Glucagon-Like Peptide 1 (GLP-1) in Diabetes and Aging","David D. D’Alessio","2000","Rejuvenation Research","other","article","10.1089/rej.1.2000.3.329",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051741","The role of glucagon-like peptide-1 receptor agonists in the treatment of dyslipidemia in patients with overweight and obesity (review)","M. G. Chashchin","2026","Rational Pharmacotherapy in Cardiology","randomized_trial","article","10.20996/1819-6446-2026-3246",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051742","Incretin Mimetics in the Treatment of Type 2 Diabetes Mellitus","Jens Juul Holst","2006","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2006.00.01.1g",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051743","Type 2 Diabetes — Controlling the Epidemic, Episode 4: Understanding Old and New Therapies for Diabetes","E. Dale Abel","2023","New England Journal of Medicine","other","article","10.1056/nejmp2308235","37851873",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051744","O045 Participants with OSA severity improvement following treatment: SURMOUNT-OSA post-hoc analyses","Susan S Redline","2025","SLEEP Advances","randomized_trial","article","10.1093/sleepadvances/zpaf053.045",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0051745","P330 The real-world impact of treatments for type 2 diabetes on outcomes in people with non-alcoholic fatty liver disease","Jake Cragg","2024","Poster presentations","nonrandomized_study","article","10.1136/gutjnl-2024-bsg.412",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051746","SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT","Jena Shaw Tronieri","2019","Journal of the Endocrine Society","randomized_trial","article","10.1210/js.2019-sat-097",null,null,"ClinicalTrials.gov:NCT02963935","S000712","openalex","TRUE","free_to_read","1","FALSE","conference-abstract"],["R0051747","1979-LB: GIP Alone or with GLP-1RA Had No Detectable Effect on Glucose Levels in Individuals with Type 2 Diabetes","Mads Marstrand Helsted","2025","Diabetes","randomized_trial","article","10.2337/db25-1979-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051748","Beneficial Changes on Body Composition and Circulating Adiponectin and hsCRP Levels Following One Year of Exenatide Therapy, Compared with Insulin Glargine, in Metformin-Treated Patients with Type 2 Diabetes","Mathijs C. M. Bunck","2009","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051749","2041-LB: Continuous Protein Sensor for Sarcopenia Management during GLP-1RA Therapy","Rebecca Gottlieb","2025","Diabetes","other","article","10.2337/db25-2041-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051750","Inhibition of STAT1 modulates GVHD after allogeneic BMT through induction of S100A8/A9 (169.38)","Nicole M. Nasholm","2011","The Journal of Immunology","other","article","10.4049/jimmunol.186.supp.169.38",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051751","Dosing, Treatment Patterns, Urine Albumin-to-Creatinine Ratio (UACR) Changes, and Safety with Finerenone Treatment in Routine Care: FINE-REAL Interim Analysis","Ricardo Correa-Rotter","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025nz0z1wct",null,null,"ClinicalTrials.gov:NCT05348733",null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051752","Efficacy of liraglutide in patients with metabolic-associated steatotic liver disease in type 2 diabetes mellitus","Yu.M. Stepanov","2025","GASTROENTEROLOGY","other","article","10.22141/2308-2097.59.2.2025.675",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051753","Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial","Stephen A. Harrison","2022","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(22)00570-0",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051754","Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes","Disha Subramaniam","2025","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/g4e9-6j51",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051755","The protective effect of metformin and exenatide on doxorubicin-induced nephrotoxicity in rats","Eman abdelhalim Mohamed Ali","2021","Menoufia Medical Journal","preclinical","article","10.4103/mmj.mmj_217_20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051756","357-OR: Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11","Juan P. Frías","2020","Diabetes","randomized_trial","article","10.2337/db20-357-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051757","Umstellung auf iGlarLixi gegenüber der weitergeführten Behandlung mit einem GLP-1-Rezeptoragonisten bei unzureichend kontrolliertem Typ-2-Diabetes: die randomisierte LixiLan-G-Studie","AL Birkenfeld","2021","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0041-1727314",null,null,"ClinicalTrials.gov:NCT02787551","S001125","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0051758","[18F]FDG PET in the era of glucagon-like peptide-1 receptor agonists – A retrospective single-center study","Adrien Holzgreve","2026","Nuklearmedizin - NuclearMedicine","nonrandomized_study","article","10.1055/s-0046-1818196",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051759","Metabolism and Target Organ Damage","Naomi M. Fearon","2022","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2022.12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051760","220-OR: Comparing Cardiovascular Benefits between GLP-1RA and SGLT2i as an Add-On to Metformin among U.S. Adults with Type 2 Diabetes (T2D)","Christina E. DeRemer","2021","Diabetes","nonrandomized_study","article","10.2337/db21-220-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051761","IDF21-0679 INTENSIFY: effectiveness of insulin degludec/liraglutide (IDegLira) in a real-world T2DM population in the UAE","Fatheya Al Awadi","2022","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/j.diabres.2022.109620",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051762","933-P: Greater Reductions in HbA1c and Body Weight with Once-Weekly Semaglutide vs. Comparators across Baseline BMI Subgroups: A Post Hoc Analysis of SUSTAIN 1-5 and 7-10","Vanita R. Aroda","2020","Diabetes","other_trial","article","10.2337/db20-933-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051763","1760-P: Mining Animal Venoms as a Source of Insulinotropic Peptides for Potential Diabetes Therapy","Natasha Hui Jin Ng","2023","Diabetes","other","article","10.2337/db23-1760-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051764","A Coronary Artery Calcium Score (CACS) Higher than 100 Agatston Units Is Associated with a Profile of Very High Cardiovascular Risk in the Diabetic Population","Paul Elie Valensi","2018","Diabetes","other","article","10.2337/db18-2189-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051765","Abstract 4359480: GLP-1 Agonist Therapy Attenuates Circulating Gut-Derived Trimethylamine N-Oxide (TMAO) and Improves Cardiac Function and Exercise Performance in Cardiometabolic HFpEF","Mahmoud H. Elbatreek","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4359480",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051766","Sympathetic Modulation By Glucagon Like Peptide 1 And Melanocortin 4 Receptors In The Carotid Body Of Wistar Rats","Pratik C. Thakkar","2021","The FASEB Journal","preclinical","article","10.1096/fasebj.2021.35.s1.02265",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051767","PDB40 BUDGET IMPACT SAVINGS OF LIRAGLUTIDE 1,2MG VERSUS INSULIN IN ALGERIAN T2D PATIENTS INSUFFICIENTLY CONTROLLED WITH ORAL MEDICATIONS","Yael Sellam","2019","Value in Health","other","article","10.1016/j.jval.2019.04.590",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051768","Glucagon-Like Peptide-1 Receptor Agonists","Heather P. Whitley","2024","American Diabetes Association eBooks","other","article","10.2337/9781580408387.ch13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0051769","Treating Acute Covid-19 — Final Chapters Still Unwritten","Rajesh Tim Gandhi","2024","New England Journal of Medicine","other","article","10.1056/nejme2402224","38598581",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051770","2169-LB: Comparative Metabolic Effects of Semaglutide, Tirzepatide, and Retatrutide in a Monogenic (db/db) Mouse Model of Obesity","KATHRYN A. ESCHETE","2025","Diabetes","randomized_trial","article","10.2337/db25-2169-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051771","Obesity and cardionephrology – guidance on the management","Radovan Hojs","2025",null,"other","article","10.46793/karnef25.204h",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051772","Abstract 555: The Effect Of Dipeptidyl Peptidase 4 Inhibition On Arterial Blood Pressure Is Context Dependent","Edwin Kerry Jackson","2014","Hypertension","preclinical","article","10.1161/hyp.64.suppl_1.555",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051773","Sustained weight loss and acceptable tolerability with the GLP-1 analogue Liraglutided in obese non-diabetic adults:a 2-year randomized trial","Lean, Michael E. J.","2010","Research at the University of Copenhagen (University of Copenhagen)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0051774","Patient Reported Outcomes for Tirzepatide versus Semaglutide in Participants with T2D from the SURPASS-2 Trial","Kristina Secnik Boye","2021",null,"other_trial","article","10.26226/morressier.617c37317c09fc044a975227",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","other"],["R0051775","Omega 3 Fatty Acids but Not Exenatide Can Help Nonalcoholic Fatty Liver Disease* †","Jagdish S. Nachnani","2011","Journal of clinical lipidology","other","article","10.1016/j.jacl.2011.03.020",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051776","Greater weight loss and regression to normoglycaemia, and reduced risk of T2D, at 3 years in early weight loss responders to liraglutide 3.0 mg vs early non-responders","John P.H. Wilding","2016",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051777","PDB83 TIME TO TREATMENT MODIFICATION AMONG PATIENTS WITH TYPE 2 DIABETES WHO INITIATED EXENATIDE OR INSULIN GLARGINE","Manjiri D. Pawaskar","2010","Value in Health","other","article","10.1016/s1098-3015(11)72141-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051778","SY15GUT-BRAIN AXIS AND REWARDSY15-1THE GUT-BRAIN AXIS AND ALCOHOL MEDIATED BEHAVIOURS: PRECLINICAL FINDINGS","Johanna Engel","2015","Alcohol and Alcoholism","preclinical","article","10.1093/alcalc/agv076.61",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051779","S864 Clinical Impact of GLP-1RA On Endoscopy: A Retrospective Cohort Study in Endoscopy Patients","Rebecca A. Karlson","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032824.49982.9d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051780","Racial Disparities in SGLT2 Inhibitor (SGLT2i) and Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) Use in the US Military Health System (MHS)","James D. Oliver","2024","Journal of the American Society of Nephrology","other","article","10.1681/asn.202492bypcyh",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051781","Liraglutide for Pediatric Patients With Type 2 Diabetes","Kellee Kaulback","2023","Canadian Journal of Health Technologies","other","article","10.51731/cjht.2023.698",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051782","Insulin Glargine/Lixisenatide Fixed-Ratio Combination Outcomes are Similar for North American and Rest of World Type 2 Diabetes Populations","HARPREET SINGH BAJAJ","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.128",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051783","P-1897. Employing Interactive Case-Based Continuing Education to Improve HIV Decision-Making","Bharati Hegde","2026","Open Forum Infectious Diseases","other","article","10.1093/ofid/ofaf695.2066",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051784","Semaglutide versus liraglutide for treatment of obesity","Nasser E. Mikhail","2021",null,"other","article","10.32474/ado.2021.03.000162",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051785","Su1529: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT INCREASE THE RISK FOR RECURRENT ACUTE PANCREATITIS AND ARE NOT ASSOCIATED WITH LOCAL COMPLICATIONS IN PATIENTS WHO DEVELOP IT: A POPULATION-BASED COHORT STUDY IN THE UNITED STATES","Luìs Manuel de Almieda Nieto","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)02757-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051786","Efficacy and Safety by Baseline A1c with Once Weekly Dulaglutide in AWARD Program","Samuel E. Dagogo-Jack","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.111",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051787","Presente y futuro del tratamiento farmacológico de la obesidad","Enrique Juan Díaz Greene","2025","Acta Médica Grupo Ángeles","other","article","10.35366/119477",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051788","SAT-694 Association Between Engagement With The WeGoTogether Digital Self-support App And Weight Loss In A Real-world Setting","Joshua C. Toliver","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.127",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051789","Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study","Mats Christian Højbjerg Lassen","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.2913",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051790","Treatment of Antipsychotic-Induced Weight Gain","Alkomiet Hasan","2025","Psychopharmakotherapie","other","article","10.52778/ppt20250028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051791","801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes","N Dyrby Johansen","2023","Diabetes","randomized_trial","article","10.2337/db23-801-p",null,null,"ClinicalTrials.gov:NCT03017352","S000283","openalex","FALSE","paywalled","1","FALSE","article"],["R0051792","ASSOCIATION OF GLP-1 AGONISTS WITH ARRHYTHMIAS AND SUDDEN CARDIAC DEATH IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS OF 27 RANDOMIZED CONTROLLED TRIALS","Mohammed Al‐Sadawi","2022","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(22)02516-5",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0051793","1676-P: Tirzepatide Improved Mental and Psychosocial Function in Adults with Obesity or Overweight in the SURMOUNT-3 Trial","Theresa M. Hunter","2024","Diabetes","randomized_trial","article","10.2337/db24-1676-p",null,null,"ClinicalTrials.gov:NCT04657016","S002157","openalex","FALSE","paywalled","1","FALSE","article"],["R0051794","Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide-1 receptor agonists: A systematic review","Poobalan Naidoo","2021","World Journal of Meta-Analysis","systematic_review","article","10.13105/wjma.v9.i3.297",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0051795","What’s New in Musculoskeletal Infection","Jesse E. Otero","2024","Journal of Bone and Joint Surgery","randomized_trial","article","10.2106/jbjs.24.00230","38781349",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051796","GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes","David Lawson Morris","2025","Independent Nurse","other","article","10.12968/indn.2025.10.24",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051797","#1771 The association of sodium-glucose transporter 2 inhibitor prescription and incident chronic kidney disease in a multi-ethnic Asian population: a retrospective cohort study using Singhealth Diabetes Registry","Yi Lin Ong","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.1343",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051798","The experience of using liraglutide in adolescents with exogenous constitutional obesity. Analysis of clinical outcomes","Kseniya A. Cherednikova","2025","Pediatrics Consilium Medicum","other","article","10.26442/26586630.2025.3.203357",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051799","Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients","Sahar Kmal Hegazy","2023","World Journal of Clinical Cases","other","article","10.12998/wjcc.v11.i26.6105","37731581",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051800","Applying Artificial Intelligence to Measure Abdominal Adipose Metrics in Obstructive Sleep Apnea Before and After CPAP Therapy","Johan Prevot","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a4759",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051801","Abstract 960: Dysregulation of the islet hormone cholecystokinin drives obesity-associated pancreatic cancer","Daniel C. McQuaid","2026","Cancer Research","preclinical","article","10.1158/1538-7445.am2026-960",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051802","SAT-529 Real-world Treatment Patterns Of Tirzepatide Versus Semaglutide In GLP-1 RA-experienced Patients With T2D","Kendra A. Terrell","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1061",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051803","S796 Comparing Glucagon-Like Peptide-1 Agonists and Lifestyle Modifications on Weight Loss in a Predominantly Hispanic Population","Jason N. Chen","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130644.66360.e0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051804","New Diagnostic and Therapeutic Tools for Thyroid Cancer","Eleonore Fröhlich","2013","International Journal of Endocrinology","commentary","article","10.1155/2013/312378","24376458",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0051805","Active lupus nephritis is an orphan disease","Marc Patricio-Liébana","2026","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfag056","41811967",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051806","928-P: Dulaglutide Has Higher Adherence and Persistence than Semaglutide and Exenatide QW: 6-Month Follow-Up from U.S. Real-World Data","Reema Mody","2020","Diabetes","nonrandomized_study","article","10.2337/db20-928-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051807","Optionen zur Intensivierung einer Basalinsulintherapie bei Menschen mit Typ-2-Diabetes","Baptist Gallwitz","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1553048",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051808","819 Carpe diem! Seize your weight loss! An association between GLP-1 agonists and seizures?","Juveriya Tasnim Shaikh","2025","The American Journal of the Medical Sciences","other","article","10.1016/s0002-9629(25)00824-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051809","RWD112 Real-World Utilization of Glucagon-Like Peptide-1 Receptor Agonists in Overweight and Obese US Adults","David Iwanyckyj","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.1695",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0051810","733-P: Initiation of iGlarLixi vs. Basal-Bolus Insulin (BB) in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: The SoliComplex Real-World Study","KEVIN M. PANTALONE","2022","Diabetes","nonrandomized_study","article","10.2337/db22-733-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051811","THE RELATIONSHIP OF THE KDIGO HEAT MAP TO PULSE PRESSURE IN PATIENTS WITH TYPE II DIABETES","Aisha Siddiqah Ahmed","2025","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0001117008.46988.26",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051812","802-P: A New Dawn beyond Basal Insulin? Dose-Response Meta-analysis for Efficacy and Safety of Tirzepatide Compared with Basal Insulin in Uncontrolled Diabetes Mellitus","Muhammad Aaqib Shamim","2024","Diabetes","systematic_review","article","10.2337/db24-802-p",null,null,"PROSPERO:CRD42023450278",null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0051813","839-P: Treatment Satisfaction and Time in Range (TIR) after 16 Weeks of iGlarLixi in Insulin-Naive Adults with Suboptimally Controlled Type 2 Diabetes","Viral N. Shah","2024","Diabetes","other_trial","article","10.2337/db24-839-p",null,null,"ClinicalTrials.gov:NCT05114590","S002030","openalex","FALSE","paywalled","5","FALSE","article"],["R0051814","Results of combined therapy with exenatide, metformin and hypolipidemic drugs in patients with diabetes mellitus type 2","Sergei Vorobiev","2013","European Journal of Internal Medicine","other","article","10.1016/j.ejim.2013.08.236",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051815","8699 Efficacy of Glucagon-like Peptide-1 Analogs In Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","Fran Kelly","2024","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvae163.1536",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051816","Exenatide Once Weekly Sustained Improvement in Glycemic Control with Weight Loss through 4 Years","Robert E. Buckley","2012","MD Conference Express","other_trial","article","10.1177/155989771216004",null,null,"ClinicalTrials.gov:NCT00308139","S002279","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0051817","S1093 Slowing Transit Without Consequence? Evaluating GLP-1 Agonist Use in Patients With IBS","Abdulmalik Saleem","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001131832.84329.02",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051818","Étude DUAL VI : efficacité et tolérance de l’insuline Degludec/liraglutide (IDegLira) en titration hebdomadaire versus bimensuelle chez des diabétiques de type 2 insuffisamment contrôlés sous Antidiabétiques oraux (ADO)","Emmanuel Disse","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30436-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051819","New era of type 2 diabetes mellitus therapy: cardiological indications for the use of glucagon-like peptide-1 receptor agonists","Elena Georgievna Starostina","2019","Фарматека","other","article","10.18565/pharmateca.2019.4.79-88",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051820","TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6","Katherine R. Tuttle","2020","Nephrology Dialysis Transplantation","other_trial","article","10.1093/ndt/gfaa141.to002",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051821","7944 Elevated Serum Alkaline Phosphatase without other Abnormalities of Liver Associated Enzymes as an early Indicator of Glucose Intolerance: A Case Series","Brendan K. Bowens","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.753",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051822","#2426 Exploration of cagrilintide's mechanism of action in the kidney","Vera Christine Wulfmeyer","2025","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfaf116.1902",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051823","1021-P: Liraglutide Improves Periodontitis by the Anti-inflammatory Activities of GLP-1","Noritaka Sawada","2019","Diabetes","preclinical","article","10.2337/db19-1021-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051824","Effect of Semaglutide on body weight in obese children with craniopharyngioma: a preliminary report","Marie Jourdren","2021","59th ESPE Annual Meeting (ESPE 2021 Online)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051825","228-OR: Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight","John J. Suschak","2025","Diabetes","randomized_trial","article","10.2337/db25-228-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051826","MO399: Remodel: A Mechanistic Trial Evaluating the Effects of Semaglutide on the Kidneys In People With Type 2 Diabetes and Chronic Kidney Disease","Petter Bjornstad","2022","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfac070.013",null,null,"ClinicalTrials.gov:NCT04865770","S000395","openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051827","Impact of notoriety bias on reporting of pancreatitis with antidiabetics: the case of exenatide","Emanuel Raschi","2011","Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","conference-paper"],["R0051828","12461 The Impact Of Switching From A Glp-1 Analog To Tirzepatide On Blood Glucose Levels, Body Weight, And Liver Function In Patients With Type 2 Diabetes","Riichiro Mizoguchi","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.961",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051829","MP444TREATMENT WITH A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE DECREASES ALBUMINURIA IN OVERWEIGHT TYPE 2 DIABETIC PATIENTS","Tomislav Bulum","2016","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfw193.18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051830","Impact of GLP-1 Receptor Agonists on Male Fertility: A Systematic Review of Human Studies","Arnold Peter Paul Achermann","2025","JBRA","systematic_review","article","10.5935/1518-0557.20263781",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0051831","Abstract 17701: Glucagon-Like Peptide-1 Receptor Agonist Weight Loss Results from an Allied Health-Led Atrial Fibrillation Risk Factor Modification Clinic","April Kathleen Watkins","2023","Circulation","nonrandomized_study","article","10.1161/circ.148.suppl_1.17701",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051832","GLP-1 agonists in anaesthetic practice - a review of clinical data and recommendations","Natalia Pokrywka","2025","Journal of Education Health and Sport","narrative_review","article","10.12775/jehs.2025.83.61812",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051833","118-OR: The Apelin Receptor Agonist Azelaprag Increases Weight Loss in Diet-Induced Obese Mice on Incretin Agonists and Restores Body Composition and Muscle Function to That of Lean Controls","Yan Wang","2024","Diabetes","other_trial","article","10.2337/db24-118-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051834","Unravelling mitochondrial succinate transport during I/R and devising a novel transport inhibitor show promise for targeting I/R injury, but will efficacy remain under more human-like conditions present during I/R?","Qian Wang","2026","Cardiovascular Research","preclinical","article","10.1093/cvr/cvag059","41843750",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0051835","7625 Functional and structural neuronal changes of dulaglutide compared to placebo during smoking cessation - a randomized placebo-controlled trial","Clara Odilia Sailer","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.1217",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051836","80-OR: Treatment with Once-Weekly Semaglutide 2.4 mg Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity and Type 2 Diabetes: STEP 2 Post-hoc Analysis","Robert F. Kushner","2021","Diabetes","randomized_trial","article","10.2337/db21-80-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051837","Effect of exenatide administered in different times of food intake on glucose variability in patients with diabetes mellitus type 2","Esperanza Martínez‐Abundis","2014","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2014.05.727",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051838","Complex vasoactivity of liraglutide. Contribution of three gasotransmitters","Eszter Sélley","2015","Artery Research","preclinical","article","10.1016/j.artres.2015.04.001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051839","Abstract 412: The Endothelial GLP-1 Receptor is Critical for the Cardiovascular Protective Effects of GLP-1 (Liraglutide) Treatment in Experimental Arterial Hypertension","Johanna Helmstädter","2019","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvb.39.suppl_1.412",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051840","Characteristics, treatment patterns, and glycemic control of older type 2 diabetes mellitus patients in China","Xiaoling Cai","2021","Chinese Medical Journal","nonrandomized_study","article","10.1097/cm9.0000000000001674","34406148",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051841","S1316 Patient Willingness to use ROSE-010: A Subcutaneous (SC) GLP-1 Analogue for IBS Pain Episodes","Bong Ki Cha","2010",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","conference-abstract"],["R0051842","GLP-1 RAs: assessing risk of ophthalmic complications",null,"2025","Reactions Weekly","other","article","10.1007/s40278-025-88610-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0051843","729-P: Relationship between Body Weight Change and Glycemic Control with Tirzepatide Treatment in People with Type 2 Diabetes","SUE PEDERSEN","2022","Diabetes","other_trial","article","10.2337/db22-729-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051844","1988-LB: Impact of Time of Injection Comparing iGlarLixi vs. IDegAsp in Chinese People with Type 2 Diabetes—Exploratory Analysis of the SoliD Study","Xin Li","2025","Diabetes","other_trial","article","10.2337/db25-1988-lb",null,null,"ClinicalTrials.gov:NCT05413369","S000073","openalex","FALSE","paywalled","5","FALSE","article"],["R0051845","Sa375 A META-ANALYSIS OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Chloe Wong","2021","Gastroenterology","systematic_review","article","10.1016/s0016-5085(21)02734-7",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051846","How eggs can help you come off Wegovy – cracking the problem of weight-regain","Adam L. Collins","2026",null,"other","article","10.64628/ab.dxfwmvaqw",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051847","Metformin Treatment of Pediatric Obesity","Vandana S. Raman","2021","PEDIATRICS","randomized_trial","article","10.1542/peds.2020-044982","33608414",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051848","0846 Severe OSA in a 17yr old patient with Prader Willi Syndrome and poorly controlled Diabetes Mellitus","Rashi Kochhar","2022","SLEEP","other","article","10.1093/sleep/zsac079.840",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051849","94 - Oral Semaglutide vs Placebo in Patients With Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5","Robyn L. Houlden","2019","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2019.07.103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051850","Abstract #611: The Impact of Gastrointestinal Adverse Events on Weight loss with Liraglutide 3.0 Mg as Adjunct to a Diet and Exercise Program","Michael E. J. Lean","2015","Endocrine Practice","other","article","10.1016/s1530-891x(20)42675-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051851","26-A-12216-ACC REAL-WORLD COMPARATIVE ANALYSIS OF GLP1 RECEPTOR AGONISTS ON CARDIOVASCULAR OUTCOMES","Yesh Dhruva","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.2109",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051852","Eligibility for and Practical Implications of Semaglutide in Overweight and Obese Patients with Acute Coronary Syndrome","Vincenzo De Sio","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.5055925",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051853","GLP-1 AGONISTS IN OBESITY-RELATED LUNG DISEASE: SEMAGLUTIDE'S IMPACT ON AIRWAY INFLAMMATION AND OSA SEVERITY BEYOND WEIGHT LOSS","Maida S Chaudhry","2025","CHEST Journal","other","article","10.1016/j.chest.2025.07.3510",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051854","Therapeutic durability of the GLP1-based therapy Liraglutide in patients with type 2 diabetes mellitus","Daniel Border","2014","Endocrine Abstracts","other","article","10.1530/endoabs.34.p278",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051855","Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type-2 Diabetes Mellitus in Spain: A Cost-Effectiveness Analysis","Antonio Ramirez de Arellano Serna","2016","Value in Health","other","article","10.1016/j.jval.2016.09.1884",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051856","1707-P: Association of GLP-1 Use and End-Stage Liver Disease (ESLD) Events in U.S. Adults with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)","Dominic Nunag","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1707-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051857","1168-OR: Pancreas-Targeted Glucagon-Like Peptide 1 Gene Therapy Enhances β-Cell Function and Suppresses Cellular Stress in Preclinical Type 2 Diabetes Models","Alice L. Fitzpatrick","2026","Diabetes","preclinical","article","10.2337/db26-1168-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051858","Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-Analysis","Ahmed B. Bayoumy","2025","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.5246533",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0051859","Steps Forward for Cardio-Kidney-Metabolic Research in Transplant Recipients","Kristin K. Clemens","2025","Kidney360","randomized_trial","article","10.34067/kid.0000000796","40440455",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0051860","PDB16 A POPULATION-ADJUSTED INDIRECT COMPARISON OF CARDIOVASCULAR BENEFITS BETWEEN ONCE-WEEKLY SEMAGLUTIDE AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK","Marc Evans","2020","Value in Health","other","article","10.1016/j.jval.2020.04.204",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051861","HPR191 Utilization of a Managed Access Protocol to Enable Reimbursement of Liraglutide (Saxenda®) for Weight Management for Patients in Ireland","Russell L. Barrett","2024","Value in Health","protocol","article","10.1016/j.jval.2024.10.1615",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0051862","GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice","Ken Y Thong","2014","The British Journal of Diabetes","nonrandomized_study","article","10.15277/bjdvd.2014.015",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051863","Trends in nephrology: kidney metabolism as a therapeutic target","Jessica S. Kleer","2025","Nephrology Dialysis Transplantation","other_trial","article","10.1093/ndt/gfaf155","40796294",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051864","S877 Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Systematic Review and Meta-Analysis of 84,065 Patients","Daryl Ramai","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001032876.50941.e0",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051865","Weight-Loss Interventions in Patients with Overweight/Obesity and CKD","Ryan P. Chang","2024","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2024a0855adb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051866","1113-P: The Use of Empagliflozin and Dulaglutide Improves Metabolic and Glycemia Outcomes in a Real-World Primary Care Setting","Ioannis Spiliotis","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1113-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051867","Tu1826 IMPACT OF GLP-1 RECEPTOR AGONIST ON CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE COLITIS: INSIGHTS FROM A LARGE-SCALE COHORT STUDY","Chengu Niu","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)03727-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051868","Cardiovascular Outcomes of Tirzepatide Compared with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) and Insulin in Patients with Type-2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","I Gusti Sri Agung Jaya Kusumadewi","2026","Eduvest - Journal Of Universal Studies","systematic_review","article","10.59188/eduvest.v6i9.53381",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0051869","Effect of Liraglutide on Metabolic and Renal Outcomes Over 12 Months in Community Diabetic Nephropathy Clinics","Joline Vretenar","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.077",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051870","Paramètres prédictifs de la réponse au liraglutide : résultats d’une étude dans la vraie vie","Olivier Dupuy","2014","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(14)70682-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051871","TIRZEPATIDE INCREASES RISK OF GALLBLADDER DISEASE IN OVERWEIGHT AND OBESE PEOPLE","Quy Phan","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)00866-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051872","Changes in lipid concentrations in patients with type 2 diabetes on once-weekly dulaglutide 1.5 mg: Post hoc pooled analysis of the AWARD trials","Imre J. Pavo","2018","Diabetologie und Stoffwechsel","other","article","10.1055/s-0038-1641919",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051873","1291-OR: Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial","HELEN M. COLHOUN","2026","Diabetes","other_trial","article","10.2337/db26-1291-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051874","148-OR: IDegLira Improves Glycemic Control in Japanese Patients with Type 2 Diabetes (T2D) Uncontrolled on Premixed Insulin Therapy","Hirotaka Watada","2019","Diabetes","randomized_trial","article","10.2337/db19-148-or",null,null,"ClinicalTrials.gov:NCT02911948","S002038","openalex","FALSE","paywalled","1","FALSE","article"],["R0051875","Liraglutide attenuates high glucose-induced 'trained immunity' in cd34+ hematopoietic stem cells","Giuseppe Damiano","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.4911",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051876","The glucagon-like peptide receptor agonist exenatide protects against glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans","Daniël H. van Raalte","2010","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0051877","Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial","Gabriele Berman","2025","Eye","randomized_trial","article","10.1038/s41433-025-03918-8","40670630",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051878","#1485 Hypertension management of CKD patients referred to Hypertension Excellence centres in 27 countries: on behalf of the ESH Hypertension and Kidney WG","Jean‐Michel Halimi","2024","Nephrology Dialysis Transplantation","other","article","10.1093/ndt/gfae069.1077",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051879","5PSQ-030 Effectiveness and safety of semaglutide in patients with type 2 diabetes: real-world usage data","CARMEN LASALA AZA","2025",null,"nonrandomized_study","article","10.1136/ejhpharm-2025-eahp.328",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0051880","Effects of Liraglutide on Cardiac Function and Myocardial Infarct Size in the Setting of Obesity","Adam Glenn Goodwill","2015","The FASEB Journal","other","article","10.1096/fasebj.29.1_supplement.954.9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051881","High serum amylase a contraindication to GLP1 analogue treatment?","Karolina M. Stępień","2014","Endocrine Abstracts","other","article","10.1530/endoabs.34.p258",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051882","Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit","Thomas SJ Crabtree","2019","British Journal of Diabetes","randomized_trial","article","10.15277/bjd.2019.227",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051883","Rol de los agonistas del receptor de GLP-1 en la diabetes mellitus tipo 2: un abordaje centrado en el paciente","Daniel Leonardo Piskorz","2021","Revista de la Federación Argentina de Cardiología","other","article","10.63600/rvt9bt23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051884","Impact of glucagon-like peptide-1 receptor agonists on morbidity and mortality in multiple myeloma patients with type 2 diabetes mellitus: A retrospective cohort analysis.","Moath Albliwi","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.e19538",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0051885","Nephroprotective Effects of Semaglutide in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","Stine Thorhauge Bak","2022","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20223311s1663d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051886","Combined dulaglutide-dapagliflozin treatment improves vascular dysfunction and albuminuria vs DPP4 inhibitors independently of glycaemic control","Emmanouil Korakas","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.p464",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051887","The pathophysiology underlying chronic kidney disease","Robert Joel Lewis","2009","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2009.028",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051888","Impact Of Tirzepatide On Outcomes In Patients With Heart Failure With Preserved Ejection Fraction And Ckd Stages 3-4","Nor Mohammed","2026","Journal of Cardiac Failure","other","article","10.1016/j.cardfail.2025.11.151",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051889","Prescribed Total Daily Insulin Dose and Predictors of Insulin Dose for Adults with Type 2 Diabetes on Multiple Daily Injections of Insulin: A Retrospective Cohort Study","Eugene E. Wright","2025","Diabetology","nonrandomized_study","article","10.3390/diabetology6020013",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051890","25. Sustained Glycemic Control with Exenatide Once Weekly (EQW) vs. Insulin Glargine (IG): Associations with Baseline Factors and Early Treatment Response (970-P)","MICHAEL E. TRAUTMANN","2014","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-014-0050-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051891","Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German‐speaking countries: Analysis based on the Diabetes Prospective Follow‐up Registry","Susanna Wiegand","2024","Diabetes Obesity and Metabolism","nonrandomized_study","article","10.1111/dom.15930","39295083",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051892","Are peptide drugs the future of medicine?","Maciej Miliński","2022","Farmacja Polska","other","article","10.32383/farmpol/153053",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051893","Reductions in HbA(1c) and the incidence of hypoglycaemic episodes are not affected by renal impairment in patients with type 2 diabetes treated with liraglutide","Stephen C. L. Gough","2011","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051894","S4714 Small Bowel Angioedema Secondary to ACE Inhibitor","James C. Barnett","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001048224.41507.6c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051895","Efficacy of semaglutide: an evidence-based review","Ashot Musaelovich Mkrtumyan","2022","Meditsinskiy sovet = Medical Council","narrative_review","article","10.21518/ms2022-010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051896","806-P: Correlation of Derived Time in Range (dTIR) and Time in Range (TIR) in People with Type 2 Diabetes (T2D) Treated with IDegLira (IDL) , Degludec, or Liraglutide: A Post Hoc Analysis of the DUAL I Trial","Athena Philis‐Tsimikas","2022","Diabetes","randomized_trial","article","10.2337/db22-806-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051897","Utilisation and expenditure on glucose-lowering drugs used for the treatment of type 2 diabetes mellitus in Ireland, a repeated cross-sectional study","Amelia Smith","2021","Diabetes Epidemiology and Management","nonrandomized_study","article","10.1016/j.deman.2021.100038",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051898","S1345 Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease Program","Ysabel C. Ilagan‐Ying","2022","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000862020.76034.41",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051899","EFFECT OF GLP-1 RECEPTOR AGONISTS ON OFFICE BLOOD PRESSURE LEVELS AMONG OVERWEIGHT OR OBESE SUBJECTS TREATED WITH ANTIPSYCHOTIC DRUGS: A META-ANALYSIS","Dimitrios Patoulias","2024","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0001021828.69534.09",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0051900","Adherence to Glucagon-like Peptide-1 Receptor Agonists (GLP-1s) in Obstructive Sleep Apnea Patients With and Without Type 2 Diabetes","Peter A. Cistulli","2024",null,"other","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6593",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051901","Diabetes and Cartesian Dualism: what is the evidence for a brain‐centred gluco‐regulatory system?","Paul S Grant","2014","Practical Diabetes","preclinical","article","10.1002/pdi.1820",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051902","671-P: Liraglutide Possibly Prevents Progression of Dementia in Patients with Type 2 Diabetes","Mami Yoshida","2021","Diabetes","nonrandomized_study","article","10.2337/db21-671-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051903","Efficacy and Safety of Once-Weekly Semaglutide vs. Once-Daily Insulin Glargine in Insulin-Naïve Subjects with Type 2 Diabetes (SUSTAIN 4)","Joanne Liutkus","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.115",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051904","Authors' Reply: Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation?","Norberto Perico","2023","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.0000000000000231","38039090",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","letter"],["R0051905","Risk of Acute Pancreatitis with Tirzepatide: A Systematic Review and Meta-Analysis of Randomized and Observational Studies v1","Olivia Benny","2025",null,"systematic_review","article","10.17504/protocols.io.5jyl887j9l2w/v1",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","preprint"],["R0051906","Online purchasing options for GLP-1 agonists: Accessibility, marketing practices, and consumer safety concerns","Corey Hannah Basch","2025","Journal of Medicine Surgery and Public Health","other","article","10.1016/j.glmedi.2025.100183",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051907","Risks associated with hypoglycemic pharmacotherapy in elderly patients with neurological and psychiatric disorders","Vasiliy Egorovich Novikov","2025","Психофармакология и биологическая наркология","other","article","10.17816/phbn678211",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051908","37 new drugs achieved FDA approval in 2022","Bethany A. Halford","2023","C&EN Global Enterprise","other","article","10.1021/cen-10103-feature1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051909","The choice of antihyperglycemic agents in patients with type 2 diabetes mellitus and very high cardiovascular risk (part 2)","Natalya A. Koziolova","2016","Arterial’naya Gipertenziya (Arterial Hypertension)","randomized_trial","article","10.18705/1607-419x-2016-22-5-441-455",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0051910","Dosimetry of [Ga-68]Ga-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human","Irina Velikyan","2015","Journal of Labelled Compounds and Radiopharmaceuticals","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051911","S233 Impact of GLP-1 Receptor Agonists on Transplant-Free Survival and Hepatic Outcomes in Diabetic Patients With Primary Biliary Cholangitis: A Real-World Multicenter Analysis","Laith Alomari","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001127392.18773.9a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051912","72364 | Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients Undergoing Transcatheter Aortic Valve Replacement: A Retrospective Propensity-Matched Analysis","Rakendu Jayasree Rajendran","2025","Structural Heart","nonrandomized_study","article","10.1016/j.shj.2025.100545",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051913","Blood pressure effect of semaglutide in patients with hypertension: an individual patient data analysis of randomised controlled trials","Cormac Kennedy","2024","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwae175.172",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051914","Abstract MP52: Population Health Impact of Sodium Glucose Co-Transporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in US Adults With Type 2 Diabetes","Girish N. Nadkarni","2018","Circulation","nonrandomized_study","article","10.1161/circ.137.suppl_1.mp52",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051915","Mechanism of Preventive Effects of Exendin-4 and Des-Fluoro-Sitagliptin in a Murine Model of Fructose-Induced Prediabetes","María Cecilia Castro","2022","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4309478",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0051916","SAT-669 Impact of GLP-1 agonist in patients with heart failure and dyslipidemia affected by Metabolic Dysfunction-Associated Steatotic Liver Disease: A prospective case control study","FERNANDO R. MATEO","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.104",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051917","1416-P: Differences in Treatment and Metabolic Outcome between Males and Females Living with T2D—Results from the Multicenter DPV Registry","Sascha René Tittel","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1416-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051918","Quick Take Vol. 91","Amanda Koire","2026",null,"nonrandomized_study","article","10.64239/pi-qt91",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","report"],["R0051919","SEMAGLUTIDE AND HEART FAILURE IN DIABETIC PATIENTS: A META-ANALYSIS","Zina Otmani","2024","Atherosclerosis","systematic_review","article","10.1016/j.atherosclerosis.2024.118835",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0051920","Комплексный подход в лечении сахарного диабета 2 типа – путь к снижению смертности от атеросклероз-ассоциированных заболеваний","Oksana Dmitrievna Rymar","2020","DOAJ (DOAJ: Directory of Open Access Journals)","other_trial","article","10.15372/ater20190407",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051921","The Incretin Mimetics","Anthony H Barnett","2011",null,"other","article","10.1002/9781118682197.ch4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051922","54-OR: Effect of Coadministered s.c. Semaglutide and s.c. Cagrilintide on Glycemic Levels Measured by CGM","Chantal Mathieu","2023","Diabetes","randomized_trial","article","10.2337/db23-54-or",null,null,"ClinicalTrials.gov:NCT04982575","S002064","openalex","FALSE","paywalled","1","FALSE","article"],["R0051923","Latent Autoimmune Diabetes in Adults Presenting as Diabetes “Recurrence” After Bariatric Surgery: A Case Report","Sean Manning","2013","Diabetes Care","case_report","article","10.2337/dc13-0810","23881974",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051924","S735 Psychiatric Risk in Obese vs Diabetic Non-Obese Patients on GLP-1 Receptor Agonists: A Retrospective Cohort Study","Budoor Alqinai","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130400.06843.35",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051925","Decoding endocrine cell differentiation: insights from high‐throughput CRISPR screening in human gut organoids","Lin Lin","2024","Clinical and Translational Medicine","other","article","10.1002/ctm2.1526","38279896",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051926","Properties of GLP‐1 agonists and their use in type 2 diabetes","Steve Chaplin","2016","Prescriber","other","article","10.1002/psb.1430",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051927","S2926 Craniopharyngioma-Induced Hypothalamic Obesity and a Red Herring Known as Binimetinib","Sindhura Kolli","2021","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000785236.78538.3d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051928","Additional Analyses of the Weight-lowering Efficacy of Liraglutide 3.0 mg in Adults with Overweight and Obesity: The SCALE Obesity and Prediabetes Randomized Trial","David C.W. Lau","2015","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2015.01.182",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051929","HPR4 INSURANCE DENIALS AND DISCONTINUATION OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS IN THE UNITED STATES","Joseph F. Levy","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1066",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051930","SaO012GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THE RISK OF CARDIO-RENAL OUTCOMES IN DIABETIC PATIENTS SURVIVING A MYOCARDIAL INFARCTION","Marco Trevisan","2019","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfz101.sao012",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051931","Abstract 15526: Glucagon-like Peptide-1 Receptor Agonists Reduce Adverse Cardiovascular Disease (CVD) Events in Patients With Type 2 Diabetes: An Assessment of Heterogeneity Among CVD Outcomes and a Meta-regression Analysis","Simran Grewal","2020","Circulation","randomized_trial","article","10.1161/circ.142.suppl_3.15526",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051932","681-P: Effect of 3-Month Therapy with SGLT2 Inhibitors and GLP-1 Agonists on Ambulatory Blood Pressure in Patients with Type 2 Diabetes Mellitus","Athanasia K. Papazafiropoulou","2021","Diabetes","other","article","10.2337/db21-681-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051933","Corneal confocal microscopy for the assessment of diabetic neuropathy and beyond in Brazil","Rayaz Ahmed Malik","2022","Arquivos de Neuro-Psiquiatria","randomized_trial","article","10.1055/s-0042-1756169","36252583",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0051934","432 Early GLP-1 Receptor Agonist Use Is Associated With Reduced Mortality and Neurologic Complications Following Traumatic Brain Injury: A Propensity Score Matched Cohort Study","Sean O'Leary","2026","Neurosurgery","nonrandomized_study","article","10.1227/neu.0000000000003964_432",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051935","Prescribing liraglutide to patients with type 2 diabetes in a clinical practice setting: the EVIDENCE study","Guillaume Charpentier","2013","Primary care diabetes","other","article","10.1016/j.pcd.2012.10.057",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051936","Effects of antagonists of the NPY-2 receptor, semaglutide, PYY3-36, and empagliflozin on metabolic dysfunction-associated steatotic liver disease in diet-induced obese rats","Simon Kloock","2024","Endocrine Abstracts","preclinical","article","10.1530/endoabs.99.rc12.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051937","P-1405 Glycaemic control improves in type 2 diabetes patients when switching from twice-daily exenatide to once-daily liraglutide","John B. Buse","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33267-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051938","26-A-11816-ACC GLP-1 THERAPY AND LEAN MASS IN CARDIAC REHAB PATIENTS","Mariana Pencheva-Yanev","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.4875",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051939","Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions","William V. Tamborlane","2016","Diabetes Care","other","article","10.2337/dc15-1649","26908928",null,"ClinicalTrials.gov:NCT01258075; ClinicalTrials.gov:NCT00658021; ClinicalTrials.gov:NCT01342484; ClinicalTrials.gov:NCT01541215; ClinicalTrials.gov:NCT01434186; ClinicalTrials.gov:NCT01204775; ClinicalTrials.gov:NCT01485614; ClinicalTrials.gov:NCT01472367; ClinicalTrials.gov:NCT01760447","S000357; S000452","openalex","TRUE","open_pdf","5","FALSE","article"],["R0051940","Su2069: TRENDS IN GLUCAGON-LIKE PEPTIDE-1 AGONIST (GLP-1A) PRESCRIBING FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE","Stephanie Lauren Gold","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03121-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051941","S5 GLP-1 Receptor Agonists and Pancreatic Cancer Risk in Drug-Naive Patients With Type 2 Diabetes","Khaled Alsabbagh Alchirazi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001028388.64456.1e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051942","TRANSFORM: Transplant Readiness Achieved through Novel Solutions for Obesity Reduction and Management","Jamie J. Benken","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.2340",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051943","Patient and clinical characteristics of heart failure patients concomitantly prescribed SGLT2 inhibitors and sacubitril/valsartan, a database cohort study using the Optum electronic health record data","Emil Loefroth","2020","European Heart Journal","nonrandomized_study","article","10.1093/ehjci/ehaa946.0981",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0051944","#451 The effects of early or late empagliflozin, liraglutide & combined therapy on the a-Klotho/autophagy pathway in renal and pancreatic-ß cells in diabetic db/db mice model","Farid M. Nakhoul","2025","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfaf116.0348",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051945","Editorial: The rapidly changing face of pediatric diabetes during the obesity epidemic","Dalia Al‐Abdulrazzaq","2025","Frontiers in Endocrinology","commentary","article","10.3389/fendo.2025.1615551","40620792",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0051946","1219-OR: Effects of Mifepristone in People with Difficult-to-Control T2D and Hypercortisolism on GLP-1RAs","Lance Sloan","2026","Diabetes","randomized_trial","article","10.2337/db26-1219-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051947","Abstract TH817: Development of a new diabetes classification algorithm for epidemiological studies: The Jackson Heart Study","Andrew C. P. Sims","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.th817",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051948","Quick Take Vol. 79","Oliver Freudenreich","2025",null,"other","article","10.64239/pi-nl-qt79",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0051949","Tirzepatida mostró resultados promisorios en pacientes con insuficiencia cardíaca con fracción de eyección conservada y obesidad","Karin Silvana Kopitowski","2025","Evidencia actualizacion en la práctica ambulatoria","other","article","10.51987/evidencia.v28i2.7151",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051950","Maintaining Operational Excellence During the COVID-19 Pandemic in the FLOW Trial","Richard E. Pratley","2021","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20213210s1b6a",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0051951","Efficacy and Safety of Novel Diabetes Drugs for Stroke Prevention: Systematic Review, Meta-analysis, and Meta-regression (P1-5.017)","Cecelia Barry","2024","Neurology","systematic_review","article","10.1212/wnl.0000000000205339",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0051952","#1817 An application of urinary peptidomics and in silico methods to guide multifactorial intervention in chronic kidney disease","Agnieszka Latosińska","2025","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfaf116.0516",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051953","Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial","Ofer M. Kobo","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.2568",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051954","777-P: Efficacy of SGLT2 Inhibitors and GLP1-Receptor Agonists in Asians with Type 2 Diabetes: A Systemic Review and Meta-analysis","Ryan S. Johnson","2021","Diabetes","systematic_review","article","10.2337/db21-777-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0051955","POSC359 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Reported Outcomes at 12-Months","Kristina Secnik Boye","2022","Value in Health","nonrandomized_study","article","10.1016/j.jval.2021.11.1184",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0051956","Tritium labelling of the GLP‐1 analogue liraglutide","Uffe S. Larsen","2007","Journal of Labelled Compounds and Radiopharmaceuticals","other","article","10.1002/jlcr.1264",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051957","3101-LB: Exploring a Lower Starting Dose of Aleniglipron, an Oral Small Molecule GLP-1RA, to Improve GI Tolerability in Obesity: Beyond the ACCESS Trials","Timothy Richard Smith","2026","Diabetes","other_trial","article","10.2337/db26-3101-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051958","Effects of a combinatory treatment with semaglutide and a selective PYY-Y2 receptor analogue in diet-induced obese rats: Surpassing bariatric surgery? (#64)","Marie Oertel","2022","Adipositas - Ursachen Folgeerkrankungen Therapie","randomized_trial","article","10.1055/s-0042-1755715",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051959","POSTER: ALL-036 Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist in Children With Chemotherapy-Induced Hyperglycemia","Amira A. M. Adly","2023","Clinical Lymphoma Myeloma & Leukemia","other","article","10.1016/s2152-2650(23)00362-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051960","Su1968 AGENT-SPECIFIC BILIARY RISK AMONG GLP-1RA USERS: FINDINGS FROM A MACHINE-LEARNING-DRIVEN ANALYSIS FROM LINE-LEVEL TRINETX DATA OF 100,000 PATIENTS","Benjamin D. Liu","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)00452-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051961","134-OR: Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D","Mark L. Hartman","2019","Diabetes","randomized_trial","article","10.2337/db19-134-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051962","87-LB: Binding Kinetics, Bias, Receptor Internalization, and Effects on Insulin Secretion for a Novel GLP1R-GIPR Dual Agonist, HISHS-2001","Yusman Manchanda","2021","Diabetes","preclinical","article","10.2337/db21-87-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051963","Incretin Analogues in the Therapy of Type 2 Diabetes and Obesity","Natalia V. Bulushova","2022","Applied Biochemistry and Microbiology","other","article","10.1134/s0003683822070031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051964","S784 Factors Relating to Slow Gastric Emptying on Glucagon-Like Peptide-1 Agonist Therapy, Lack of Prolonged Emptying Slowing After GLP1 Agonist Cessation, and Impact of Emptying Delays on GLP1 Agonist Prescription Patterns","William Lee Hasler","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001032504.94905.49",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051965","(051) DEGREE OF WEIGHT LOSS IS ASSOCIATED WITH NEW ERECTILE DYSFUNCTION AFTER GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST MEDICATION PRESCRIPTION","Bradley John Roth","2024","The Journal of Sexual Medicine","nonrandomized_study","article","10.1093/jsxmed/qdae167.049",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051966","Diabetic gastroparesis","Pamela A. Dyson","2015",null,"other","article","10.1002/9781119121725.ch35",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0051967","Late Breaking Abstract - Changes to pharyngeal soft tissue and fat volumes following tirzepatide treatment in SURMOUNT-OSA","Richard J. Schwab","2025",null,"other","article","10.1183/13993003.congress-2025.pa6031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051968","“A Review of Pharmacological Therapies for Obstructive Sleep Apnea and Impact on Cardiovascular Outcomes”","Reice Robinson","2026","Current Sleep Medicine Reports","narrative_review","article","10.1007/s40675-026-00373-z",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051969","S765 Examining the Associations Between Treatments for Morbid Obesity and Superior Mesenteric Artery Syndrome","Alexander K. Malik","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130520.38322.ba",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051970","ALL-036 Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist in Children With Chemotherapy-Induced Hyperglycemia","Amira A. M. Adly","2023","Clinical Lymphoma Myeloma & Leukemia","other","article","10.1016/s2152-2650(23)00932-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0051971","P717Glucagon-like peptide 1 (GLP-1) improves endothelial dysfunction and vascular inflammation in polymicrobial sepsis induced by cecal ligation and puncture (CLP)","Sebastian Steven","2019","European Heart Journal","preclinical","article","10.1093/eurheartj/ehz747.0322",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051972","P4991Effects of the glucagon like peptide-1 receptor analogue, sodium-glucose co-transporter 2 and their combination on myocardial work index and vascular function in diabetes after 3-month treatment","Ignatios Ikonomidis","2019","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehz746.0169",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051973","Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3)","Andrew Ahmann","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31023-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051974","812-P: Safety and Efficacy of Early Initiation of GLP1RA and SGLT2 inhibitors, in Post–Kidney Transplant Patients with Type 2 Diabetes","Francisca M. Acosta","2024","Diabetes","randomized_trial","article","10.2337/db24-812-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051975","Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159–2167","Carol Wysham","2014","Diabetes Care","randomized_trial","article","10.2337/dc14-er10",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051976","63 - Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program","Kathleen Marie Dungan","2020","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2020.08.069",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0051977","GLP-1 receptor agonists improve and preserve microvascular endothelial function - Focus on chemotherapy induced vascular damage","Yoshinori Nishijima","2026","Physiology","nonrandomized_study","article","10.1152/physiol.2026.41.s1.2301196",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051978","SGLT inhibitors for type 1 diabetes","Gautam Chandra Das","2020","Practical Diabetes","randomized_trial","article","10.1002/pdi.2273",null,null,"ClinicalTrials.gov:NCT02139943",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051979","354-OR: Cotadutide (medi0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content","Darren C. Robertson","2020","Diabetes","randomized_trial","article","10.2337/db20-354-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051980","Abstract A075: Association of Glucagon-like Peptide-1 Receptor Agonist Use and Long-Term Mortality after Acute Ischemic Stroke","Marialaura Simonetto","2026","Stroke","nonrandomized_study","article","10.1161/str.57.suppl_1.a075",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0051981","2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes","Anna R. Kahkoska","2020","Diabetes","randomized_trial","article","10.2337/db20-2160-pub",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051982","SP427GLUCOSE-LOWERING DRUGS ADDED TO EXISTING THERAPIES AND RISKS OF MORTALITY AND CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES: NETWORK META-ANALYSIS OF RANDOMIZED TRIALS","Suetonia C. Palmer","2017","Nephrology Dialysis Transplantation","systematic_review","article","10.1093/ndt/gfx149.sp427",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0051983","Effects of glucagon like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on vascular function and myocardial work index in patient with type-2 diabetes","Ignatios Ikonomidis","2020","European Heart Journal","randomized_trial","article","10.1093/ehjci/ehaa946.3066",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0051984","Survodutide, a promising agent with novel mechanism of action for treatment of obesity and type 2 diabetes","Nasser E. Mikhail","2024","Endocrinology and Disorders","other_trial","article","10.31579/2640-1045/184",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0051985","exendin-4 treatment pancreatic growth after partial pancreatectomy and Identification of transcriptional targets during","Klaus H. Kaestner","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051986","Agonistes des récepteurs du GLP-1 ou inhibiteurs de la DPP-4 : comment orienter le choix du clinicien ?","André Jacques Scheen","2012","Open Repository and Bibliography (University of Liège)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0051987","Effects of Incretin Mimetic Drugs on Diabetic Cardiovascular Functions","Ceren Uyar Boztaş","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0051988","Potential effects of incretin-based therapies on polycystic ovary syndrome in rats: a comparative study of linagliptin versus liraglutide","Hanan Abdelmoneam Shamardl","2021","International Journal of Research in Pharmaceutical Sciences","preclinical","article","10.26452/ijrps.v12i2.4632",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051989","Consistent Kidney Benefits With Semaglutide vs. Placebo Regardless of Baseline Urine Albumin Creatinine Ratio in Subjects With Type 2 Diabetes at High Cardiovascular Risk: A Post Hoc Analysis of SUSTAIN 6","Hiddo J.L. Heerspink","2022","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20223311s1676c",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0051990","A case report of multiple aggressive vertebral hemangiomas: a rare mimic of metastatic malignancy","Calvin Wing Hang Chin","2024","AME Medical Journal","case_report","article","10.21037/amj-24-99",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051991","Characteristics of Patients Newly Prescribed IDegLira in U.S. Real-World Practice","Michelle Mocarski","2018","Diabetes","nonrandomized_study","article","10.2337/db18-2285-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051992","FRI063 Effectiveness Of Liraglutide In Treating Obesity And Improving Hepatic Steatosis","Assim Abdulaziz Alfadda","2023","Journal of the Endocrine Society","other","article","10.1210/jendso/bvad114.073",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0051993","Tu1690: ASSESSMENT OF GASTROPARESIS AND RELATED ADVERSE EVENTS ASSOCIATED WITH GLP-1 RECEPTOR AGONISTS REPORTED IN THE US FDA ADVERSE EVENT REPORTING SYSTEM","Akanksha Togra","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04255-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051994","Abstract 4139912: Inflammatory biomarkers in people treated with tirzepatide living with overweight or obesity, without and with T2D: a post-hoc analysis from SURMOUNT-1 and SURMOUNT-2","N Sattar","2024","Circulation","other","article","10.1161/circ.150.suppl_1.4139912",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0051995","Glucagon-like Peptide-1 Receptor Agonists and Risk of Thyroid Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials","Dena Osama Khawandanah","2025","Saudi Journal of Clinical Pharmacy","systematic_review","article","10.4103/sjcp.sjcp_22_25",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0051996","The diagnosis of non‐alcoholic fatty liver disease: authors' reply","J. K. Dowman","2011","Alimentary Pharmacology & Therapeutics","randomized_trial","article","10.1111/j.1365-2036.2011.04917.x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","letter"],["R0051997","Efficacy and safety of liraglutide 3.0mg for weight management in overweight and obese adults: The SCALE Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial","Joseph Proietto","2014","Obesity Research & Clinical Practice","randomized_trial","article","10.1016/j.orcp.2014.10.210",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0051998","1183-P: Utilization of Low vs. High Dose of Newer Antihyperglycemic Agents","Dominik Lautsch","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1183-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0051999","Treatment with liraglutide leads to an important reduction in liver fat content, assessed by magnetic resonance spectroscopy, in people with type 2 diabetes","Bruno L Vergès","2015","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0052000","O uso do Ozempic (semaglutida) para o tratamento da obesidade: uma revisão integrativa","Juliana Campos Vieira","2024","Journal of Medical and Biosciences Research.","other","article","10.70164/jmbr.v1i5.369",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052001","Incretin mimetic exendin-4 influence the bioenergetics of human adipocytes","Joanna Góralska","2014","Biochimica et Biophysica Acta (BBA) - Bioenergetics","other","article","10.1016/j.bbabio.2014.05.012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052002","MODERN PHARMACOLOGICAL APPROACHES TO THE TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS: FOCUS ON EFFECTIVENESS AND SAFETY","Elena N. Saverskaya","2024","Bulletin of the Medical Institute of Continuing Education","other","article","10.36107/2782-1714_2024-4-3-77-85",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052003","SEMAGLUTIDE CONSISTENTLY REDUCES CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES REGARDLESS OF BASELINE CARDIOVASCULAR RISK LEVEL: POST HOC ANALYSES OF THE SUSTAIN TRIAL PROGRAM","L.A. Leiter","2018","Canadian Journal of Cardiology","other_trial","article","10.1016/j.cjca.2018.07.221",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052004","Incretin-based therapies and cancer: Are they enemies or allies?","Sandy R. Botros","2024","Bulletin of Pharmaceutical Sciences Assiut","other","article","10.21608/bfsa.2024.308996.2222",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052005","(GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening□S","Ra Koole","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052006","PO-01-075 IMPACT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST (GLP-1 RA) INITIATION ON HOSPITALIZATION AFTER ATRIAL FIBRILLATION ABLATION","Emmanuel Arega","2026","Heart Rhythm","other","article","10.1016/j.hrthm.2026.03.1616",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052007","Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity","Е. В. Тихоненко","2019","Obesity and metabolism","other","article","10.14341/omet9584",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052008","From vicious to virtuous: Changing the cycle of diabetes care","Sanjay Kalra","2014","Journal of Social Health and Diabetes","other","article","10.4103/2321-0656.130784",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052009","ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST USE AND INFECTIOUS OUTCOMES IN ADULTS WITH TYPE 2 DIABETES","Henry Siu Him Chan","2025","Annals of Allergy Asthma & Immunology","other","article","10.1016/j.anai.2025.08.222",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052010","The GLP-1 receptor agonist liraglutide improves glucose tolerance and reduces body weight in schizophrenia spectrum disorder patients treated with clozapine or olanzapine","Louise Vedtofte","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052011","Obesity and COVID-19: Insights from Two Pandemics","Yu. Sh. Khalimov","2022","Doctor Ru","randomized_trial","article","10.31550/1727-2378-2022-21-2-59-66",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052012","P320 - Efficacité et tolérance de l’exenatide chez des patients avec diabète de type 2 traités par thiazolidinedione associée ou non à la metformine","Santiago Durán García","2008",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052013","UTILIZATION OF OPTIMAL MEDICAL PHARMACOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM AN INTEGRATED HEALTHCARE SYSTEM","Izza Shahid","2023","American Journal of Preventive Cardiology","nonrandomized_study","article","10.1016/j.ajpc.2023.100573",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052014","Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease results of the LEADER trial","J.B. Buse","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/eqw9-qw52",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0052015","DURATION-3 Trial Results","Brian D. Hoyle","2013","MD Conference Express","other_trial","article","10.1177/155989771311012",null,null,"ClinicalTrials.gov:NCT00641056","S001768","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0052016","Interpreting the results of the VERTIS‐CV trial: Is this the end of the “class effect” perspective?","Theocharis Koufakis","2020","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.13105","32886864",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052017","Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?","Robert E. J. Ryder","2016","British Journal of Diabetes","other_trial","article","10.15277/bjd.2016.096",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052018","Diagnosis and Management of Gastroparesis","Gabriela Piovezani Ramos","2022","The American Journal of Gastroenterology","randomized_trial","article","10.14309/ajg.0000000000002003","36114770",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052019","PDB22 ‘Real-World' Clinical Outcomes of Exenatide Bid Compared to Insulin Glargine in Patients with Type 2 Diabetes","Manjiri D. Pawaskar","2011","Value in Health","nonrandomized_study","article","10.1016/j.jval.2011.08.1325",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0052020","Case-Based Review of Breast Imaging Changes Associated With GLP-1 Agonists","Joseph J. Villavicencio","2025","Current Radiology Reports","narrative_review","article","10.1007/s40134-025-00433-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052021","Exenatide and Its Indications For Use Among the Therapeutic Options Available For Treatment of Type 2 Diabetes","Jennifer Lynn Jones","2012","Research Exchange (Washington State University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0052022","Expert committee on introduction of incretin-based therapy in Russia: advance and failure","редакция журнала Сахарный диабет","2012","Diabetes Mellitus","other","article","10.14341/2072-0351-6095",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052023","445 LIRAGLUTIDE ESCALATED TO 3.0 MG REDUCES HEPATIC STEATOSIS DURING 16 WEEKS' TREATMENT IN NON-DIABETIC OBESE PATIENTS","Xiao‐Jing Wang","2020","Gastroenterology","other","article","10.1016/s0016-5085(20)30893-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052024","Mode of action of GLP-1 receptor agonists (revision number 5)","Filip Krag Knop","2012","Diapedia.org eBooks","other","article","10.14496/dia.81043351130.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0052025","5-LB: Dulaglutide in Youth with Type 2 Diabetes (T2D) —Results of the AWARD-PEDS Randomized, Placebo-Controlled Trial","Silva A Arslanian","2022","Diabetes","randomized_trial","article","10.2337/db22-5-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052026","Mitochondrial fitness in mouse Leydig cells is imbalanced by liraglutide upon glucose stimuli","Bruno Silvester Lopes","2023","Endocrine Abstracts","preclinical","article","10.1530/endoabs.90.p600",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052027","Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application","Marso S.P","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/c7mx-4407",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0052028","Quality Assessment of Medical Institutions’ Websites Regarding Prescription Drug Misuse of Glucagon-Like Peptide-1 Receptor Agonists by Off-Label Use for Weight Loss: Website Evaluation Study (Preprint)","Rintarou Oyama","2024",null,"other","article","10.2196/preprints.68792",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0052029","Real world study provided reassurance of the safety of GLP ‐1 therapy on mental health and suicide risk","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","nonrandomized_study","article","10.1002/doi2.70005",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052030","FDA is to assess data linking type 2 diabetes drugs with pancreatitis","Dan C. Cohen","2013","BMJ","other","article","10.1136/bmj.f1808","23512765",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052031","The study of pharmacists' opinions regarding to providing of pharmaceutical care to patients with obesity","Т. О. Шаповал","2025","Farmatsevtychnyi zhurnal","other","article","10.32352/0367-3057.5.25.04",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052032","Assesment of the Medical and Social Benefits of Incretin-Based Therapy","Guenka Ivanova Petrova","2016","Value in Health","other","article","10.1016/j.jval.2016.03.610",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052033","Abstract 9920: Utilizing Synchronous Healthcare Delivery to Optimize the Use of Guideline Directed Medical Therapies in Patients With Type 2 Diabetes: Results From the DECIDE-CV Clinic","Tara Gédéon","2022","Circulation","other","article","10.1161/circ.146.suppl_1.9920",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052034","Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine)","Chris Walton","2020","British Journal of Diabetes","nonrandomized_study","article","10.15277/bjd.2020.243",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052035","CLINICAL EVALUATIONS IN SYSTEMIC HYPERSENSITIVITY TO TIRZEPATIDE BUT NOT SEMIGLUTIDE: IMPLICATIONS FOR CURRENT BARIATRIC TREATMENT.","C. Nejat","2025","Annals of Allergy Asthma & Immunology","other","article","10.1016/j.anai.2025.08.332",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052036","Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)","Anwar Ali Jammah","2024","Endocrine and Metabolic Science","nonrandomized_study","article","10.1016/j.endmts.2024.100164",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052037","702 WEIGHT LOSS OUTCOMES WITH SEMAGLUTIDE BASED ON DIABETES STATUS AND SEVERITY USING THE INDIVIDUALIZED METABOLIC SURGERY SCORE","Wissam Ghusn","2023","Gastroenterology","other","article","10.1016/s0016-5085(23)01309-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052038","Health care costs among type 2 diabetes mellitus patients initiating glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy","Stephen S. Johnston","2014","Value in Health","other","article","10.1016/j.jval.2014.03.1425",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052039","Once weekly exenatide as adjunct management of type 1 diabetes mellitus","Toni Zahorian","2012","Fisher Digital Publications (St. John Fisher College)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052040","1548-P: Changes in Glucose-Lowering Medication Use in the Era of Cardiovascular Outcomes Trials: Risk/Treatment Paradox Persists","Rozalina Grubina McCoy","2020","Diabetes","other","article","10.2337/db20-1548-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052041","504-P: Success of Aligned Clinician–Patient Education Improves Clinicians’ Ability to Use GLP-1 RAs in Practice and Patients’ Understanding of GLP-1 RAs","Amy T. Larkin","2022","Diabetes","other","article","10.2337/db22-504-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052042","26-A-17360-ACC GLP-1 RECEPTOR AGONISTS IN HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION: DO BENEFITS VARY BY DIABETES STATUS?","Syed Sarmad Javaid","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.1916",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052043","The Long Acting GLP‐1 Receptor Agonist, Liraglutide, Augments Myocardial Contractile Responses and Cardiac Efficiency Under Sympathetic Stimulation in Obesity and Myocardial Infarction","Adam Glenn Goodwill","2016","The FASEB Journal","other","article","10.1096/fasebj.30.1_supplement.732.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052044","Efficacy and safety of once-weekly semaglutide versus sitagliptin as add-on to metformin and/or thiazolidinediones in subjects with T2D (SUSTAIN 2)","Francis C. C. Chow","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31227-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052045","1431-P: Synergistic Effect of GLP-1 Receptor Agonists and Opioids on Gastric Emptying and Symptom Burden: A Propensity-Matched Multicenter Analysis","Ankitha Vanaparti","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1431-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052046","Effectiveness of Different Prandial Regulators in Patients with Type 2 Diabetes and Morbid Obesity","V.V. Fadeev","2020","Effective Pharmacotherapy","randomized_trial","article","10.33978/2307-3586-2020-16-25-12-18",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052047","Delivering joined-up care for people with type 2 diabetes: rationale, challenges and examples","Stephen Charles Bain","2021","British Journal of Diabetes","other","article","10.15277/bjd.2021.294",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052048","Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)","Shin-ichi Harasfflma","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31226-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052049","QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia and Glycaemic Variability Determined by Simultaneous Ambulatory Monitoring","Timothy L. Middleton","2016","The Sydney eScholarship Repository (The University of Sydney)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0052050","Abstract 4145660: Limitations of the Generalizability of Semaglutide Trials Evaluating CV Outcomes","Ivy Shi","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4145660",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052051","Modulation of Proximal Tubule Sodium‐Proton Exchanger NHE3 by the Glucagon‐Like Peptide 1 Analog Exendin‐4","Luciene Regina Carraro‐Lacroix","2008","The FASEB Journal","preclinical","article","10.1096/fasebj.22.1_supplement.1158.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052052","P42 Semaglutide Reduces Cognitive Dysfunction in Experimental Non-Alcoholic Steatohepatitis Through Anti-Inflammatory and Neuroprotective Effects","Kristoffer Kjærgaard","2023","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0000948452.01988.0c",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052053","749-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe","Vivian Andrew Fonseca","2021","Diabetes","randomized_trial","article","10.2337/db21-749-p",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052054","Novo Nordisk incretin leadership summit, Cape Town : conference report","Peter Wagenaar","2012","˜The œSouth African journal of diabetes & vascular disease","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052055","Binge-Eating Disorder and Obesity in Adolescents: A Review of Behavioral and Pharmacological Treatment Advances","Sarah E. Hornack","2025","Psychiatric Annals","narrative_review","article","10.3928/00485713-20250915-02",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052056","S973 Esophageal High-Resolution Manometry Can Be Safely and Effectively Performed With Concurrent Glucagon-Like Peptide-1 Receptor Agonist Use","Khushboo S. Gala","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001131352.83647.05",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052057","3-PUB: Plasma MMP-9 Concentration Is Reduced by GLP-1 Receptor Agonist Treatment in People with Type 2 Diabetes Mellitus","Anusha Prem Kumar","2026","Diabetes","other","article","10.2337/db26-3-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052058","114: GLP-1 RECEPTOR AGONISTS RARELY CAUSE DE-NOVO ACUTE PANCREATITIS BUT MAY CAUSE SERUM LIPASE ELEVATIONS OF UNCLEAR CLINICAL SIGNIFICANCE","Jianing Li","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)01031-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052059","Die Wirkung von Liraglutid, Exenatid und Sitagliptin auf den zusammengesetzten Endpunkt von Blutzuckereinstellung und Gewichtsreduktion","Bernard Zinman","2012","Diabetologie und Stoffwechsel","other","article","10.1055/s-0032-1314553",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052060","Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure","Phyo Than Htoo","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/5s0p-d104",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0052061","Obesity, a disease that deserves clinical awareness","Alexis Elias Malavazos","2024","European Journal of Preventive Cardiology","commentary","article","10.1093/eurjpc/zwae205","38877964",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0052062","225-OR: The Oral Apelin Receptor Agonist Azelaprag Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with Tirzepatide","Yan Wang","2025","Diabetes","preclinical","article","10.2337/db25-225-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052063","Comparing Treatment Strategies for Patients with Very Elevated HbA1c—A Randomized Trial","Marconi Abreu","2018","Diabetes","randomized_trial","article","10.2337/db18-124-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052064","100-OR: ADA Presidents’ Select Abstract: Efficacy and Safety of Once-Weekly Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist vs. Placebo as Monotherapy in People with Type 2 Diabetes (SURPASS-1)","Julio Rosenstock","2021","Diabetes","randomized_trial","article","10.2337/db21-100-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052065","1060-P: A Novel Approach to Estimating Cost Savings and Return on Investment (ROI) for Weight/BMI Changes with Digital Health","Mansur E. Shomali","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1060-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052066","The emerging role of GLP-1 analogs in weight control","Silvio Stafi Filho","2024","Brazilian Journal of Health Review","other","article","10.34119/bjhrv7n1-426",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052067","FRI027 Regulation Of A Novel Sortilin Splice Variant Expression In Human Diabetic Adipocytes By GLP-1 To Maintain Glucose Homeostasis","Niketa A. Patel","2023","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvad114.038",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052068","Evaluating the Safety and Efficacy of GLP-1 Receptor Agonists in Kidney Transplant Recipients with Diabetic Nephropathy","Katherine N Berrian","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.2025qekafsd7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052069","Liraglutide Provides Cardiovascular Protective Effects via PI3K/Akt Pathway in Vascular Smooth Muscle Cells - an in vitro Transcriptomics Study","Agnieszka Lovett","2026","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.6345091",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0052070","Increased Mortality Risk with Insulin Glargine in Veterans with Type 2 Diabetes: An Emulated Clinical Trial Observational Study","Amara Sarwal","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s1858b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052071","SEMAGLUTIDE AND EOSINOPHILIC COLITIS: A RARE DRUG-INDUCED COMPLICATION WITH REVERSIBLE GASTROINTESTINAL INVOLVEMENT","Amina Khalid","2025","Annals of Allergy Asthma & Immunology","other","article","10.1016/j.anai.2025.08.421",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052072","83-LB: Adherence and Persistence in Patients with T2D Initiating Once-Weekly vs. Once-Daily Injectable GLP-1RA in U.S. Clinical Practice: STAY Study","Andreas Liebl","2021","Diabetes","nonrandomized_study","article","10.2337/db21-83-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052073","757-P: Comparative Glycemic Effectiveness of Four Second-Line Glucose-Lowering Medications in Type 2 Diabetes Mellitus","AVIK RAY","2025","Diabetes","nonrandomized_study","article","10.2337/db25-757-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052074","Glucagon-like peptide-1 receptor agonists decrease systolic and diastolic blood pressure in overweight type 2 diabetic patients.","Aleksandra Pavić","2014","Diabetologia Croatica","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052075","Comparative Effectiveness of SGLT-2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists in US Veterans with and Without CKD","Yoko Narasaki","2021","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20213210s1264b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052076","Doxorubicin-induced cardiometabolic disturbances: what can we do?","Ashot A. Avagimyan","2025","Frontiers in Clinical Diabetes and Healthcare","randomized_trial","article","10.3389/fcdhc.2025.1537699","40027901",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052077","Tirzepatide Induces Weight Loss in participants with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies","Anita Y. M. Kwan","2023","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0043-1767995",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052078","The Role of Nutrition and Exercise in the Prevention of Lean Body Mass Loss in Individuals on GLP-1 RAs","Stella Lucia Volpe","2026","ACSMʼs Health & Fitness Journal","other","article","10.1249/fit.0000000000001185",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052079","S309 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Patients Undergoing Colonoscopy","Samantha Rubin","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001030604.33841.74",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052080","S2083 Semaglutide and Liraglutide and Incidence of New-Onset Gastroparesis, Non-Alcoholic Steatohepatitis, Acute Liver Failure, Cirrhosis, Hepatocellular Carcinoma and Mortality in Obese Diabetic Patients","Azhar R Hussain","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037700.41113.c9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052081","Abstract 4147293: The GLP1 Receptor Agonist Semaglutide Ameliorates Myocardial Ischemia-Reperfusion Injury in a Porcine Model Mediated by the RISK and SAFE Molecular Pathways","Carlos Garcia Santos-Gallego","2024","Circulation","preclinical","article","10.1161/circ.150.suppl_1.4147293",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052082","Efficacy and Safety of Subcutaneous and Oral GLP-1 Receptor/Dual Agonists on Weight Loss: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","Jirawan Vienghirun","2025","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.5372118",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0052083","Evaluation of liraglutide in the treatment of Alzheimer's disease","Paul Edison","2021","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.057848",null,null,"ClinicalTrials.gov:NCT01843075","S000689","openalex","FALSE","paywalled","1","FALSE","article"],["R0052084","Abstract 14392: Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus are Reduced by Liraglutide","Rosa Bretón‐Romero","2016","Circulation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052085","S3107 Colonic Intussusception Associated With Glucagon-Like Peptide-1 Receptor Agonist Use","Joseph Robert Gunderson","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001041796.94769.bc",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052086","Combination of baseline body weight with active plasma ghrelin level could predict early response with liraglutide 3.0 mg in patients with obesity","Oksana Logvinova","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep312",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052087","Effect of Tirzepatide on Cisplatin and Doxorubicin-Induced Cardiotoxicity and Nephrotoxicity","Ahmad Hamad Alhowail","2025","International Journal of Pharmacology","preclinical","article","10.3923/ijp.2025.47.54",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052088","S2283 Risk of De Novo Gastroparesis in Non-Diabetic Patients With Obesity Taking Tirzepatide Versus Semaglutide: A Multi-Center Analysis.","Do Han Kim","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001038500.33915.6f",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052089","Actions of prolonged glucagon-like peptide-1 receptor activation on cognitive function in a model of diet-induced obesity","David William Porter","2010","Proceedings of The Nutrition Society","other","article","10.1017/s0029665110002144",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052090","S769 Trends in GLP-1 Receptor Agonist Therapy Post-Endoscopic Sleeve Gastroplasty","Jeong Hoon Kim","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001130536.81645.d8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052091","#4441 KIDNEY DISEASE OUTCOMES WITH SEMAGLUTIDE VERSUS PLACEBO ACROSS BASELINE KDIGO RISK CATEGORIES: A POST HOC ANALYSIS OF SUSTAIN 6","Katherine R. Tuttle","2023","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfad063b_4441",null,null,"ClinicalTrials.gov:NCT01720446","S001933","openalex","TRUE","open_pdf","1","FALSE","article"],["R0052092","Compounded GLP-1 Receptor Agonists in the Post-Shortage Era: Costs, Safety and Regulatory Challenges","Jamie Stitzel","2026","Current Cardiovascular Risk Reports","other","article","10.1007/s12170-026-00782-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052093","LE MÉDICAMENT DU MOIS L'albiglutide (Eperzan ® ) : nouvel agoniste des récepteurs du glucagon-like peptide-1 en injection hebdomadaire","André Jacques Scheen","2015","RMLG. Revue médicale de Liège","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052094","Mo2002 INCREASED RISK OF RESIDUAL GASTRIC CONTENT IN PATIENTS ON GLP-1 AGONISTS UNDERGOING ESOPHAGOGASTRODUODENOSCOPY","Lee Meluban","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)03194-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052095","Increased Risk of Serious Hypoglycemia with Insulin Glargine in Veterans with Type 2 Diabetes: An Emulated Clinical Trial Observational Study","Amara Sarwal","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s1858a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052096","8366 Weight Reduction is Associated with Improved Quality of Life in Patients in SURMOUNT-3","T H Gibble","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.053",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052097","THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD","Chioma N. Izzi‐Engbeaya","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.1546",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052098","Effect of Liraglutide on Gastric Emptying at 5 and 16 Weeks: A Single-Center, Randomized, Placebo-Controlled Trial in 32 Patients","Disha Khemani","2017","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(17)30625-x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052099","Understanding Searches for ‘Weight Loss’ Using Google Trends","Muhammad Iqbal","2024","Proceedings of The Nutrition Society","other","article","10.1017/s0029665124006256",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052100","The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on outcomes in metastatic non-small cell lung cancer (mNSCLC) patients treated with tyrosine kinase inhibitors (TKIs): Real-world retrospective analysis.","Khvaramze Shaverdashvili","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.8636",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052101","1163-P: Cost Effectiveness of Oral Semaglutide 14mg vs. Empagliflozin 25mg in Canada","Aiden R. Liu","2020","Diabetes","randomized_trial","article","10.2337/db20-1163-p",null,null,"ClinicalTrials.gov:NCT02863328","S000251","openalex","FALSE","paywalled","1","FALSE","article"],["R0052102","12355 An Adolescent Female With Congenital Lipodystrophy Presenting With Repeated Acute Metabolic Decompensations Rescued By A Novel Leptin Receptor Agonist","Darren Chambers","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.552",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052103","Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use—A DEVOTE Subanalysis","Kirstine Brown‐Frandsen","2018","Diabetes","randomized_trial","article","10.2337/db18-1065-p",null,null,"ClinicalTrials.gov:NCT01959529",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052104","S312 Glucagon-Like Peptide -1 Receptor Agonists Significantly Affects Quality of Prep in Screening Colonoscopies- A Private Practice Experience","Anika Koka","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001030616.49084.7e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052105","A Real-World Evaluation of the Association between Cardiovascular Outcomes and T2D Therapy","Ellen R. Thiel","2018","Diabetes","randomized_trial","article","10.2337/db18-1493-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052106","SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy","Sasha A. S. Kjeldsen","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.900",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0052107","Abstract 4145549: All-Cause Mortality and Cardiovascular Outcomes with Glucagon-Like Peptide-1 Receptor Agonists in People with Type 2 Diabetes and Systolic Heart Failure","Aravinthan Vignarajah","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4145549",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052108","Weight Loss From Bariatric Surgery Lowers Risk of Cancer & Death","Susan M. Jenks","2022","Oncology Times","randomized_trial","article","10.1097/01.cot.0000872276.40830.dd",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052109","Reduction in Estimated 10-Year Coronary Heart Disease Risk Using Reynolds Risk Score: A Post-Hoc Analysis of Exenatide-Treated Patients with Diabetes","Elaine Chiquette","2012","Journal of clinical lipidology","other","article","10.1016/j.jacl.2012.04.015",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052110","S1242 Glucagon-Like Peptide-1 Receptor Agonists and Upper Endoscopy: A Data-Driven Approach to Pre-Procedural Optimization","Danial Nadeem","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001132428.81674.49",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052111","S2277 The Role of Glucagon-Like Peptide-1 Agonists on Gastric Emptying Measured by Scintigraphy Imaging","Gowthami Sai KogilathotaJagirdhar","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001038476.01350.d1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052112","Riscos associados ao uso indiscriminado de Semaglutida (Ozempic)","Rosimeire Fernandes dos Santos","2024","Revista JRG de Estudos Acadêmicos","other","article","10.55892/jrg.v7i14.1185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052113","Efficacy and safety of glucagon-like peptide-1 receptor agonists therapy initiation in patients with type 2 diabetes hospitalized with coronavirus infection","Т. Н. Маркова","2023","Diabetes Mellitus","other","article","10.14341/dm13015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052114","4111Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis","Alistair Roddick","2019","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehz745.0115",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0052115","Préférences des patients selon leur âge pour les différentes caractéristiques des agonistes du récepteur du glucagon-like peptide-1 (GLP-1RA) dans le traitement du diabète au Royaume-Uni : un modèle de choix discret","O Adetunji","2016","Annales d Endocrinologie","other","article","10.1016/j.ando.2016.07.763",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052116","38 Effect of the GLP-1 Analogue Exenatide on Functional Connectivity Within Hedonic and Homeostatic Brain Networks in Lean and Obese Women","Kristen Coveleskie","2015","Gastroenterology","other","article","10.1016/s0016-5085(15)30038-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052117","Glucagon-like peptide-1 receptor agonist and the relation between metabolic effects and cardiovascular outcomes: insight into mechanisms of action","Luca Di Ienno","2021","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehab724.2956",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052118","1007-P: Incretin Therapy with DPP-4-I and GLP1-RA for the Hospital Management of Elderly Adults with Type 2 Diabetes","Maya Fayfman","2019","Diabetes","randomized_trial","article","10.2337/db19-1007-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052119","Glucagon-Like Peptide-1 Analogues and Anxiety and Abnormal Eating Behaviours in Type 2 Diabetes: A Case Report","Anne Marie Doherty","2014","Journal of Diabetes & Metabolism","case_report","article","10.4172/2155-6156.1000381",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052120","Impact of GLP-1 agonists on cardiovascular outcomes in patients with sickle cell anemia: A propensity score matched retrospective cohort study","Sam Joseph King","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-6495",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0052121","Efficacy of a non‐peptide GLP ‐1 analogue, orfoglipton to induce weight loss reported in a phase 2 study","ISKANDAR RAUF IDRIS","2023","Diabetes Obesity and Metabolism Now","randomized_trial","article","10.1002/doi2.67",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052122","Proportion of patients with systemic inflammation and their characteristics for groups at high cardiovascular risk in phase 3 randomized placebo-controlled trials of semaglutide (SELECT, SOUL, FLOW)","John Eric Deanfield","2023","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehad655.2752",null,null,"ClinicalTrials.gov:NCT03574597; ClinicalTrials.gov:NCT03914326; ClinicalTrials.gov:NCT03819153","S000716; S000953; S002179","openalex","TRUE","open_pdf","1","FALSE","article"],["R0052123","Semaglutide Is an Independent Predictor of Retained Solid Gastric Contents, but Same-Day Colonoscopy Mitigates Effect","Haarika Korlipara","2024","Techniques and Innovations in Gastrointestinal Endoscopy","other","article","10.1016/j.tige.2024.07.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052124","Effects of Tirzepatide Therapy on Arginine Vasopressin Deficiency: A Case with Reduced Desmopressin Requirement","Elif Yivli","2026","Endocrinology research and practice.","other","article","10.5152/erp.2026.25864",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052125","Influence of Liraglutide, Dulaglutide Versus Conventional Treatment on Fatty liver index and Fibrosis-4 Score in Egyptian Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.","Mohammed Ali Gameil","2021","Medical Journal of Viral Hepatitis /Medical Journal of Viral Hepatitis","other","article","10.21608/mjvh.2021.40184.1005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052126","P312 Liraglutide + metformine : bénéfices cliniques associés au switch ou à l’utilisation précoce du liraglutide dans le traitement du diabète de type 2","J.P. Courrèges","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72603-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052127","INPATIENT SEMAGLUTIDE BEFORE GASTRIC SLEEVE AS A BRIDGE TO TRACHEOBRONCHOPLASTY","RACHEL WALL","2025","CHEST Journal","other","article","10.1016/j.chest.2025.07.2350",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052128","117-OR: Effects of Triple-Hormone Receptor Agonist Retatrutide on Lipid Profiling in Participants with Obesity","Valentina Pirro","2024","Diabetes","randomized_trial","article","10.2337/db24-117-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052129","FRI-170 Results from two phase I trials evaluating the safety, pharmacokinetics, and efficacy of BI 3006337, a dual fibroblast growth factor 21/glucagon-like peptide-1 agonist, in healthy volunteers and people with overweight/obesity and hepatic steatosis","Rizwana Mohseni","2026","Journal of Hepatology","other_trial","article","10.1016/s0168-8278(26)01911-2",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0052130","Some useful pharmazooticals, now and in the future","Michael Paul Danckwerts","2014","Pharmacy management","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052131","Abstract 4366311: Cardiovascular-Kidney-Metabolic Syndrome: Comparing Outcomes between Sodium glucose co-transporter 2 inhibitor and Glucagon like petide 1 receptor analogue use - A Real world propensity Matched Analysis","Pushan Aggarwal","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4366311",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052132","Glucagon-Like Peptide-1 Analogs with Significantly Improved in vivo Activity","Jesse Z. Dong","2001",null,"other","article","10.1007/978-94-010-0464-0_312",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0052133","Ga-Exendin-4-guided surgery in children with congenital hyperinsulinism (CHI)","Laurina Buhner","2025","Endocrine Abstracts","other","article","10.1530/endoabs.110.oc8.6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052134","Human fatty pancreas in vitro model reveals specific effects on beta-cell function and incretin responsiveness in T2D","Estela Lorza‐Gil","2025","Diabetologie und Stoffwechsel","preclinical","article","10.1055/s-0045-1807370",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0052135","Re-imagining Oral Semaglutide in Routine Clinical Practice: Indian Expert Panel Recommendations","Aravinda Jagadeesha","2025","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_18_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052136","8-OR: Use of Guideline-Recommended Risk-Reduction Strategies among Patients with Type 2 Diabetes and Established ASCVD: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)","Mikhail Kosiborod","2019","Diabetes","nonrandomized_study","article","10.2337/db19-8-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052137","Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL Trial","Katherine R. Tuttle","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2025fdqxb4qe",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052138","Therapie des Typ-2-Diabetes","Baptist Gallwitz","2024","Diabetologie und Stoffwechsel","other","article","10.1055/a-2312-0315","42030955",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052139","Recent advances and future directions in the management of eating disorders","Janet L. Treasure","2024","Cutting Edge Psychiatry in Practice","other","article","10.65031/jnzn5917",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052140","Journal of Diabetes NEWS","Benjamin M. Kozak","2012","Journal of Diabetes","nonrandomized_study","article","10.1111/j.1753-0407.2012.00219.x",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052141","Effect of liraglutide on myocardial glucose uptake and blood flow in non-diabetic heart failure patients","Roni Ranghoej Nielsen","2016","European Journal of Heart Failure","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052142","S1658 Use of Antiobesity Medications With Endoscopic Bariatric Therapies: A Systematic Review and Meta-Analysis","Khushboo Gala","2023","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0000956272.22940.8a",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0052143","Additional file 2 of Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists","Mahesh M. Umapathysivam","2026","Figshare","other","article","10.6084/m9.figshare.32004909.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052144","META-ANALYSIS OF THE EFFECT OF DUAL GIP AND GLP-1 RECEPTOR AGONISTS ON BLOOD PRESSURE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Dimitrios Patoulias","2022","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0000838652.68523.bc",null,null,"ClinicalTrials.gov:NCT04255433","S002212","openalex","FALSE","paywalled","3","FALSE","review"],["R0052145","Incretin-Based Antidiabetic Agents: A New Option for Type-2 Diabetes Mellitus","Faruk Ahammad","1970","Faridpur Medical College Journal","other","article","10.3329/fmcj.v6i1.7412",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052146","1174-OR: Continuous Glucose Monitoring in Type 2 Diabetes Managed with Basal Insulin plus SGLT2 Inhibitor and/or GLP-1 Agonist: Subgroup Analysis from the FreeDM2 Trial","Lalantha Leelarathna","2026","Diabetes","randomized_trial","article","10.2337/db26-1174-or",null,null,"ClinicalTrials.gov:NCT05944432",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052147","P307 Efficacité et tolérance du liraglutide dans le diabète de type 2 – Résultats finaux d’EVIDENCE®: une étude prospective post-inscription avec 2 ans de suivi","Pierre Gourdy","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30420-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052148","Glucagon-like Peptide 1 Receptor Agonists Do Not Alter Calcitonin Levels in Humans","Daniel Joseph Toft","2019","Clinical Thyroidology","other","article","10.1089/ct.2019;31.253-255",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052149","Cardiovascular effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists or liraglutide in the EMPRISE study","Norbert Pötschke","2023","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0043-1767943",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052150","S4572 Weight Loss is the Boss: Hepatic Adenomas","Christopher J. Cieker","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001047656.73123.a7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052151","ERA4Health funded project: liver–heart crosstalk in heart failure","Mélanie Paillard","2026","European Heart Journal","preclinical","article","10.1093/eurheartj/ehag360","42237599",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052152","Acute pancreatitis and euglycemic non-diabetic ketoacidosis caused by an intentional semaglutide overdose","Anthony Acosta","2025","JEM Reports","other","article","10.1016/j.jemrpt.2025.100139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052153","Semaglutide provides superior glycemic control across SUSTAIN 1–5 clinical trials","Andrew Ahmann","2018","International Journal of Nutrology","other","article","10.1055/s-0038-1675019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0052154","724: GLP-1 RECEPTOR AGONIST USE IN PATIENTS WITH TYPE 2 DIABETES AND CIRRHOSIS IS ASSOCIATED WITH IMPROVED SURVIVAL OUTCOMES","Sajid Jalil","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04660-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052155","26-A-17375-ACC COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS AND BARIATRIC SURGERY IN OBESE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION","Ahmed K. Mahmoud","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.697",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052156","S2634 GLP-1 Agonist Therapy: Culprit or Coincidence in Acute Pancreatitis? A Case Report","Mohamed Ebrahim","2024","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0001039904.91017.0a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052157","THU-172 Eligibility for resmetirom or semaglutide therapy in a real-life Greek cohort of patients with metabolic associated steatotic liver disease","Μargarita Papatheodoridi","2026","Journal of Hepatology","nonrandomized_study","article","10.1016/s0168-8278(26)01564-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052158","60 - Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program","Cyrus V Desouza","2020","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2020.08.066",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052159","Sexual activity and erectile dysfunction in men with cardiovascular disease: assessing and managing risk","Michael G. Kirby","2009","Primary Care Cardiovascular Journal (PCCJ)","other","article","10.3132/pccj.2009.064",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052160","More Subjects Achieved Composite Reductions of =1% HbA1c, =5% Body Weight, and =5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)","Kathleen Marie Dungan","2018","Diabetes","other_trial","article","10.2337/db18-129-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052161","Mo1916 SEMAGLUTIDE WEIGHT LOSS AND METABOLIC PARAMETERS OUTCOMES IN PATIENTS AFTER BARIATRIC SURGERIES: A 1-YEAR MULTI-CENTERED STUDY","Wissam Ghusn","2023","Gastroenterology","other","article","10.1016/s0016-5085(23)03169-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052162","Will Evaluation of Cardiorespiratory Fitness Improve Risk Stratification of Patients With Stage B Heart Failure?","Eugene E. Wolfel","2026","Journal of the American Heart Association","nonrandomized_study","article","10.1161/jaha.126.048543","41676925",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052163","DIABETIC NEPHROPATHY: A NARRATIVE REVIEW FROM PATHOPHYSIOLOGY TO ITS TREATMENT","AKANKSHA B DANGE","2026","Asian Journal of Pharmaceutical and Clinical Research","narrative_review","article","10.22159/ajpcr.2026v19i2.57291",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0052164","Editorial: The impact of GIP/GIPR on metabolic diseases: how the field is evolving","Kirk M. Habegger","2025","Frontiers in Endocrinology","preclinical","article","10.3389/fendo.2025.1710843","41163683",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0052165","Orale semaglutide: een nieuwe en eerste orale GLP1-receptoragonist","E. Soubry","2022","Tijdschrift voor Geneeskunde","other_trial","article","10.47671/tvg.78.22.068",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052166","26-A-15961-ACC BARIATRIC METABOLIC SURGERY VERSUS GLP-1 RECEPTOR AGONISTS AMONG ADULTS WITH OBESITY: A PROPENSITY-MATCHED COHORT STUDY OF LONG-TERM MORTALITY AND CARDIOVASCULAR OUTCOMES","Abdelrahman Hafez Hafez","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.517",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052167","Efficacy of semaglutide vs. dulaglutide across baseline HbA1c in SUSTAIN 7","Wolfgang Ekkehard Schmidt","2019","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0039-1688355",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0052168","Efficacy of Oral Semaglutide in Heart Failure with Reduced Ejection Fraction: Comparative Outcomes in Diabetic and Non-Diabetic Indian Patients.","Pankaj Vinod Jariwala","2025","Indian Heart Journal","other","article","10.1016/j.ihj.2025.11.079",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052169","HPR116 Expediting Reimbursement and Access for Novel Drug Indications in Europe: A Case Study on Glucagon-Like Peptide 1 (GLP-1) Agonists","Evelyn Gomez Espinosa","2024","Value in Health","other","article","10.1016/j.jval.2024.10.1542",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052170","GLP-1 Receptor Agonist Liraglutide and Its Metabolites Improve AKI by Inhibiting HMGB1 Acetylation in Renal Tubular Epithelial Cells","Cong Xu","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20256v6f717w",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052171","Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias","Aristi Boulmpou","2021","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehab724.2952",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0052172","IP59-09 IMPACT OF PREOPERATIVE GLP-1 AGONIST USE ON 30-DAY OUTCOMES FOLLOWING PARTIAL AND RADICAL NEPHRECTOMY IN PATIENTS WITH KIDNEY CANCER","Justin R. LaClair","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191632.79764.15.09",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052173","Obesity, an emergent delinquent in recent Indian Health System","Apoorva Tripathi","2023","International Journal of Surgery Global Health","other","article","10.1097/gh9.0000000000000205",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052174","735-P: Impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) on Survival among Cancer Survivors with Type 2 Diabetes","Ying Lü","2025","Diabetes","nonrandomized_study","article","10.2337/db25-735-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052175","Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association’s Scientific Sessions 2023 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2023","Abraham Michael Lincoff","2023","Circulation","randomized_trial","article","10.1161/cir.0000000000001200",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052176","1684-P: A GLP-1 Analogue Optimized for cAMP-Biased Signaling Improves Weight Loss in Obese Mice","Jonathan D. Douros","2025","Diabetes","preclinical","article","10.2337/db25-1684-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052177","Synthesis and activity of proteolysis-resistant GLP-1 analogs","D. L. Smiley","2005","Kluwer Academic Publishers eBooks","other","article","10.1007/0-306-46862-x_268",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0052178","Turmeric-Induced Liver Injury in a Patient with Concurrent Semaglutide Use","Emily X. Zhang","2024","American Journal of Hospital Medicine","preclinical","article","10.24150/ajhm/2023.012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052179","Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain","Eric N. Kramer","2024","American Journal of Psychiatry","randomized_trial","article","10.1176/appi.ajp.20240111","39350623",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052180","Transient Small Bowel Intussusception in an Adult Patient: A Rare Complication of GLP-1 Receptor Agonist Therapy","Shmilah Choudhary","2025",null,"other","article","10.31986/issn.2689-0690_rdw.stratford_research_day.175_2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0052181","Efficacy and safety of 1 year treatment with Liraglutide in subjects with type 2 diabetes","Flavia Prodam","2013","Endocrine Abstracts","other","article","10.1530/endoabs.32.p467",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052182","Pancreatic panniculitis mimicking bilateral cellulitis: a case report","Jessie M Nelson","2024","Clinical and Experimental Dermatology","case_report","article","10.1093/ced/llae071","38430108",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052183","Digital Pharmacoepidemiology of Glucagon-like Peptide-1 Receptor Agonists in Russia: A Retrospective Search Query Analysis (2018–2026)","Stanislav Nikolaevich Kotlyarov","2026","Pharmacoepidemiology","nonrandomized_study","article","10.3390/pharma5030025",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052184","1967-LB: MWN109—A Novel Fatty Acid–Modified GLP-1/GIP/GCG Triagonist for Dual-Format Weight Management Demonstrates Superior Efficacy in Nonhuman Primates","WEN-XIN SONG","2025","Diabetes","other_trial","article","10.2337/db25-1967-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052185","804-P: A1C and Hypoglycemia Outcomes with Once-Weekly IcoSema vs. Comparators in T2D by Kidney Function","Linong Ji","2025","Diabetes","other_trial","article","10.2337/db25-804-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052186","Efficacité et tolérance du semaglutide hebdomadaire chez les diabétiques de type 2 âgés de plus de 65 ans : méta-analyse des études SUSTAIN 1-5","Bertrand Cariou","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052187","779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk","Stacey M. Sklepinski","2025","Diabetes","nonrandomized_study","article","10.2337/db25-779-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052188","Tu1693: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RA) AND COMBINED GLP-1 RA + GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE THERAPY IS ASSOCIATED WITH DEVELOPING SMALL INTESTINAL BOWEL OVERGROWTH WITHIN A YEAR","Donovan Veccia","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04258-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052189","P171 Effet à un an d’un traitement par exenatide dans une cohorte de patients diabétiques de type 2 obèses","Martin Buysschaert","2010","Diabetes & Metabolism","other","article","10.1016/s1262-3636(10)70319-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052190","Transition-Metal-Free Synthesis of a Densely Functionalized Benzodioxole Intermediate toward Lotiglipron","Jimmy Wang","2024","Organic Process Research & Development","other","article","10.1021/acs.oprd.3c00472",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052191","Handbook of Incretin-based Therapies in Type 2 Diabetes","Stephen C. L. Gough","2016",null,"other","article","10.1007/978-3-319-08982-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0052192","Wegovy: why half the people taking the weight loss drug stop within a year – and what happens when they do","Adam L. Collins","2023",null,"other","article","10.64628/ab.35dmrjjah",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0052193","Efficacy of long acting once weekly dulaglutide compared with short acting twice-daily (bid) exenatide in patients with Type 2 diabetes mellitus (T2DM): a post-hoc analysis to determine the influence of baseline HbA1c in the Assessment of Weekly AdministRation of LY2189265 in Diabetes-1 (AWARD-1) trial","Stephen Charles Bain","2014","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0034-1375120",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052194","Hypothalamic Insulin-Sensitizing Effect of Exenatide in Dietary Induced Rat Model of Obesity","Hanan Eissa","2017","Current Drug Therapy","preclinical","article","10.2174/1574885512666170106105548",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052195","Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus","Stephan Matthaei","2009","Experimental and Clinical Endocrinology & Diabetes","other","article","10.1055/s-0029-1239559","19876795",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052196","Effects of GLP-1(9-36) and exendin-4 on glucagon secretion from human islets of Langerhans: evidence of a novel GLP-1 receptor in islets?","Reshma D. Ramracheya","2014","Diabetic Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052197","Review of the potential effects of semaglutide and metformin in the management of polycystic ovary syndrome (PCOS) and obesity","Prabhleen Kaur","2025","Scripta Medica","narrative_review","article","10.5937/scriptamed56-57703",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052198","Protective effects of liraglutide on cardiovascular system","Yan Hui Gao","2013","Zhonghua neifenmi daixie zazhi","other","article","10.3760/cma.j.issn.1000-6699.2013.10.024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052199","A Phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide in individuals with non-alcoholic fatty liver disease","Manuel Romero‐Gómez","2023","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(23)00514-7",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052200","Dapagliflozin added to lixisenatide in type 2 diabetic patients","Tomislav Božek","2016","Endocrine Abstracts","other","article","10.1530/endoabs.41.oc6.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052201","763-P: Glycemic Control, Weight Reduction, and Safety with CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist—Results from a 12-Week Cohort in Adults with Obesity and Type 2 Diabetes","ALEXANDRA STEINBERG","2025","Diabetes","randomized_trial","article","10.2337/db25-763-p",null,null,"ClinicalTrials.gov:NCT04838405; ClinicalTrials.gov:NCT06628362","S002758; S002824","openalex","FALSE","paywalled","1","FALSE","article"],["R0052202","Abstract 4359454: Low-Dose Semaglutide Attenuates Cardiac Lipid Content and Hepatic Steatosis in Cardiometabolic HFpEF: Weight Loss Independent Actions of GLP-1 Receptor Activation","Mahmoud H. Elbatreek","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4359454",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052203","959-P: Indirect Treatment Comparison (ITC) of IGlarLixi vs. IDegLira in Adults Inadequately Controlled by GLP-1 Receptor Agonists (GLP-1RAs)","Philip Home","2020","Diabetes","other","article","10.2337/db20-959-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052204","Commentary: a comparison of glucagon‐like peptides 1 and 2","Gordon William Moran","2012","Alimentary Pharmacology & Therapeutics","commentary","article","10.1111/apt.12165","23252781",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0052205","755-P: A Phase 2 Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Glycemic Control in Adults with Type 2 Diabetes","Dalong Zhu","2023","Diabetes","randomized_trial","article","10.2337/db23-755-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052206","Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Clinical Trial","Sebastian Badulescu","2025","SSRN Electronic Journal","randomized_trial","article","10.2139/ssrn.5164525",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0052207","Abstract 11650: Cardiometabolic Disease Protein Signatures and Response to GLP-1 Receptor Agonist in the EXSCEL Clinical Trial","Rachel M. Ostroff","2022","Circulation","randomized_trial","article","10.1161/circ.146.suppl_1.11650",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052208","Abstract #1184056: Tirzepatide Improves Glucose Levels from Baseline Irrespective of Gender: A Post Hoc Analysis of the SURPASS-1 to -5 Studies","Juan M. Maldonado","2022","Endocrine Practice","other","article","10.1016/j.eprac.2022.03.112",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052209","Variable anti-edema and anti-granuloma effects of liraglutide and teneligliptin on experimental Wistar albino rat inflammatory models","R K Rajashekar","2017","National Journal of Physiology Pharmacy and Pharmacology","preclinical","article","10.5455/njppp.2018.8.0728808082017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052210","2184-LB: Novel Oral Small Molecule ACCG-2671—A Dual Amylin and Calcitonin Receptor Agonist Development Candidate for Obesity Therapy","Fang Xu","2025","Diabetes","preclinical","article","10.2337/db25-2184-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052211","C Myocardial stress perfusion and energetics improves in patients with type 2 diabetes after treatment with a Glucagon like peptide-1 receptor agonist (Liraglutide)- A randomised, single centre, open label, cross-over drug trial","Amrit Chowdhary","2023",null,"randomized_trial","article","10.1136/heartjnl-2023-bcs.301",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-paper"],["R0052212","#2003 Fine with finerenone in Croatia—advancing renal care for our diabetic chronic kidney disease patients","Matija Crnogorac","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.1928",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052213","Uptake of Evidence-Based Recommendations to Improve Care for CKD Patients in the Kidney Coordinated Health Management Partnership (Kidney CHAMP) Study","Melanie R. Weltman","2020","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20203110s1226b",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052214","Estimating the budget impact of innovative pharmacological treatments for patients with type 2 diabetes mellitus in Italy: the case of liraglutide (GLP-1).","Stefano Capri","2022","Epidemiology Biostatistics and Public Health","nonrandomized_study","article","10.2427/11082",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052215","Uso de medicamentos “da classe Glucagon-Like Peptide-1 (GLP-1), do Ozempic e, Mounjaro” na causa de pancreatite aguda","Monica Ribeiro Portela","2025","Research Society and Development","other","article","10.33448/rsd-v14i11.50085",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052216","0776 Participants with Improvement in OSA Severity Following Treatment: A Post Hoc Analysis of SURMOUNT-OSA Studies","Susan S Redline","2025","SLEEP","randomized_trial","article","10.1093/sleep/zsaf090.0776",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0052217","Antidiabetic agents as potential cytotoxic candidates for cancer therapy","Raniah I. Alnaser","2024","Forum of Clinical Oncology","other","article","10.2478/fco-2023-0041",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052218","Euglycemic diabetic ketoacidosis: The clinical concern of SGLT2 inhibitors","Jamila Abdedaim Benmoussa","2016","Journal of Clinical and Translational Endocrinology Case Reports","other","article","10.1016/j.jecr.2016.05.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052219","European drugs agency clashes with scientists over safety of GLP-1 drugs","Dan C. Cohen","2013","BMJ","nonrandomized_study","article","10.1136/bmj.f4838","23900829",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052220","S190 Increased Risk of Gallbladder and Biliary Diseases With GLP-1 Receptor Agonists: A United States Collaborative Network Study","Mohammad Kloub","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001127220.21310.63",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052221","MON-829 Sex-Specific Cardiometabolic Benefits of Tirzepatide: A Real-World Study on ASCVD Risk Mitigation","René de Jesús Rivera Gutiérrez","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.068",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0052222","26-A-20853-ACC CARDIOVASCULAR OUTCOMES OF GLP-1 RA USE IN NON-OBESE DIABETIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: A PROPENSITY MATCHED ANALYSIS","Efeturi Maxwell Okorigba","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1939",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052223","Circulating cetp is not related to the hepatic triglyceride content: Lessons from a liraglutide intervention trial and a population-based cohort","Huub J. van Eyk","2018","Atherosclerosis","nonrandomized_study","article","10.1016/j.atherosclerosis.2018.06.163",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052224","GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.","Zunairah Shah","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.10548",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052225","Comparative Study Between The Role of Metformin and Liraglutide in The Treatment of Polycystic Ovary in Adult Female Albino Rats (Histological and Immunohistochemical Study)","Dalia G. Osman","2026","Benha Medical Journal","preclinical","article","10.21608/bmfj.2026.480009.2995",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052226","Mixed-Pattern Autoimmune Hemolytic Anemia with Multi-Organ Failure Temporally Associated with Semaglutide Initiation: A Case Report","Samuel R. Briggs","2026","Journal of Maine Medical Center","case_report","article","10.46804/2641-2225.1265",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052227","Su2053: GLP-1RA IN ENDOSCOPY: ASPIRATION CONCERNS AND UNEXPECTED BENEFITS","Sami Mesgun","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03105-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052228","Journal of Diabetes NEWS","Benjamin M. Kozak","2011","Journal of Diabetes","randomized_trial","article","10.1111/j.1753-0407.2011.00180.x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052229","Abstract 14944: Drug Utilization Study in Heart Failure (HF) Patients Concomitantly Prescribed Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) and Sacubitril/valsartan (sac/val), a Database Cohort Study Using Optum Electronic Health Record (EHR) US Data","Emil Loefroth","2020","Circulation","nonrandomized_study","article","10.1161/circ.142.suppl_3.14944",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052230","1466-P: Genome-Wide Association Studies in the GRADE Study Identify Genetic Variation Influencing the Response to Pharmacotherapy for Type 2 Diabetes","Josephine H. Li","2023","Diabetes","randomized_trial","article","10.2337/db23-1466-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052231","2002-P: A Long-Acting GLP-1 and Y2-Receptor Dual Agonist Improves Body Weight and Glucose Control in Obese and Diabetic Rodent Models","Stephanie N. Oldham","2019","Diabetes","preclinical","article","10.2337/db19-2002-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052232","6-LB: Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL","Lindsay E. Clegg","2019","Diabetes","nonrandomized_study","article","10.2337/db19-6-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052233","Impact of exenatide once weekly and insulin glargine on glucose control and cardiovascular risk factors in subjects with type 2 diabetes","M. Diamant","2010","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0052234","26-A-13731-ACC REAL-WORLD COMPARATIVE OUTCOMES OF TIRZEPATIDE VERSUS SGLT2 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND PERIPHERAL ARTERY DISEASE","Yasemin Bahar","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.2582",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052235","26-A-20834-ACC GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IMPROVE SYMPTOMS AND PREVENT SERIOUS ADVERSE EVENTS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A POOLED ANALYSIS OF RECENT STUDIES","Musab Maqsood","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.1700",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052236","A Comprehensive Review on New Approaches for Management of Diabetes","Vijay Kumar Singh","2020","Archives of Medicine","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0052237","Once-Weekly Exenatide Effects on eGFR Slope and Urine Albumin-to-Creatinine Ratio (UACR) as a Function of Baseline UACR: An EXSCEL Post Hoc Analysis","Lindsay E. Clegg","2020","Journal of the American Society of Nephrology","other","article","10.1681/asn.20203110s1349a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052238","The amazing anti-type 2 diabetic drugs in neurodegeneration: the impact of exendin-4, liraglutide and linagliptin in type 2 diabetes, Alzheimer disease and Parkinson disease","Candeias, Emanuel Monteiro","2021","Estudo Geral (Universidad de Coimbra)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0052239","Exenatide","Jennifer C. Jiang","2023","RCSB Protein Data Bank","other","article","10.2210/rcsb_pdb/gh/dm/drugs/in/exenatide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052240","PCR10 Discontinuation Rates of Once-Weekly GLP-1 Receptor Agonists (GLP-1 RAs) in Patients With Type 2 Diabetes","Da Sol Kim","2025","Value in Health","other","article","10.1016/j.jval.2025.04.1333",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052241","Heart Failure With Reduced and Preserved Ejection Fraction: A Review of Guideline Directed Medical Therapy","Joseph Toole","2026","International Journal of Angiology","other_trial","article","10.1055/a-2874-9189",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052242","The co-administration of intranasal insulin and GLP-1RA as targeting drugs for prophylaxis and treatment of post COVID-19 smell and taste dysfunctions and brain fog","Amr Kamel Khalil Ahmed","2023","Advances in Biomedical and Health Sciences","other","article","10.4103/abhs.abhs_53_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052243","LIRAGLUTIDE SUPPRESSES IN VIVO ATHEROSCLEROSIS PROGRESSION AND INFLAMMATION IN RABBITS WITH NORMOGLYCEMIA","Mohamad Kassab","2022","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(22)02741-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052244","Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients","Ian R. Blumer","2019","Clinical Diabetes","other","article","10.2337/cd18-0102","31660014",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052245","Oral semaglutide: the innovation in type 2 diabetes management","Marina Vladimirovna Shestakova","2021","Diabetes Mellitus","other_trial","article","10.14341/dm12790",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052246","Abstract 15461: Proteomic Profiling Identifies Metabolic and Extracellular Matrix Markers That Predict MACE in Individuals With Type 2 Diabetes: An EXSCEL Substudy","Kristin Corey","2023","Circulation","other_trial","article","10.1161/circ.148.suppl_1.15461",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0052247","Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP 1–5 Randomized Trials","Robert F. Kushner","2020","Figshare","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT03548935; ClinicalTrials.gov:NCT03552757; ClinicalTrials.gov:NCT03611582; ClinicalTrials.gov:NCT03548987; ClinicalTrials.gov:NCT03693430","S000144; S000214; S000521; S000988; S001740","openalex","TRUE","no_doi","1","FALSE","article"],["R0052248","Abstract #278: Exenatide and Insulin Glargine Differentially Affect Postprandial Glucose Excursions in Patients With Type 2 Diabetes","Leonard C. Glass","2006","Endocrine Practice","other","article","10.1016/s1530-891x(20)44032-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052249","S1483 Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Prevalence of Inflammatory Bowel Diseases and Its associated Complications in Diabetic Patients: Global Healthcare Database Study","Mengdan Xie","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035300.28190.7c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052250","Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits","Daisuke Yabe","2015","EMJ Diabetes","other","article","10.33590/emjdiabet/10312637",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052251","The Two-Week Fasting Glucose as a Predictor of Response to Once Weekly Dulaglutide 1.5 mg","George Grunberger","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.142",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052252","Liraglutide Induces Brown Adipocyte Specific Genes in Mice Skeletal Muscle Tissue","Lixin Li","2016","The FASEB Journal","preclinical","article","10.1096/fasebj.30.1_supplement.851.11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052253","#2018 Real-world effectiveness and safety of voclosporin in the treatment of lupus nephritis with poor prognostic clinical and histological factors","Marc Xipell","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.1239",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052254","Circulating Total and Intact GDF-15 Levels are Not Altered in Response to Weight Loss Induced by Liraglutide and/or Lorcaserin Treatment in Humans with Obesity and/or Diabetes","Laura Valenzuela‐Vallejo","2023","Metabolism","other","article","10.1016/j.metabol.2023.155444",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052255","P1158 Association du liraglutide à la metformine chez les patients diabétiques de type-2 : bénéfices cliniques associés à la substitution ou à l’utilisation précoce du liraglutide dans l’évolution du diabète","J.P. Courrèges","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71904-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052256","1152-P: Effect of Initiating Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists on Health-Care Costs among Patients with Type 2 Diabetes","Pratik M. Pimple","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1152-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052257","Putting EMPA-REG into practice: a data-driven intervention","Ysaline Duvieusart","2024","British Journal of Diabetes","other_trial","article","10.15277/bjd.2024.444",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0052258","Abstract 9654: Dipeptidyl Peptidase-4 Inhibitors May Reduce the Risk of Major Adverse Cardiovascular Events and All-cause Mortality In Patients With Type 2 Diabetes: Meta-analyses Oof Randomized Controlled Trials","Xin Sun","2012","Circulation","systematic_review","article","10.1161/circ.126.suppl_21.a9654",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0052259","EPH32 Behaviors and Characteristics of Current and Previous Users of Glucagon-like Peptide-1 Receptor Agonists (GLP-1) in an Online Health Community","NJ Marshall","2024","Value in Health","other","article","10.1016/j.jval.2024.03.861",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052260","Cardiovascular and Cardiorenal Outcomes of GLP-1 Receptor Agonists and Dual Incretin Therapies: Systematic Review and Meta-analysis","Maurice Tiotsop","2026",null,"systematic_review","article","10.17605/osf.io/y2j3n",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0052261","Editorial: Advancing Health Technology Assessment and patient-reported outcomes: innovations and implications for health economics and outcomes research","George Gourzoulidis","2026","Frontiers in Public Health","randomized_trial","article","10.3389/fpubh.2026.1898322","42428934",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0052262","Cellular Senescence as a Pathogenic Hub Driving Mechanistic Networks and Reversal Strategies in Idiopathic Pulmonary Fibrosis","Sakina Ruhi","2026","Integrative Biomedical Research","other","article","10.25163/biomedical.10110925",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052263","Semaglutide","Agostino Milluzzo","2022","L Endocrinologo","other","article","10.1007/s40619-022-01061-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052264","EFFECT OF GLP-1 AGONISTS ON CLINICAL OUTCOMES IN OBESE AND DIABETIC PATIENTS WITH ASTHMA: A PROPENSITY MATCHED ANALYSIS","PALWASHA ZAFAR","2025","CHEST Journal","nonrandomized_study","article","10.1016/j.chest.2025.07.014",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052265","1810-P: Triple Combination Therapy of GLP-1 Receptor Agonist Semaglutide with an FXR Agonist and AC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice","Jenny Egecioglu Norlin","2020","Diabetes","preclinical","article","10.2337/db20-1810-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052266","P6271The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis","Cyrus V Desouza","2019","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehz746.0870",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052267","Current Risk Management Strategies in Type 2 Diabetes","Eugênio Cersósimo","2024","ASEAN Journal of Psychiatry","other_trial","article","10.54615/2231-7805.10001158",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052268","PDB1 EXENATIDE UTILIZATION AND EFFECTIVENESS IN A HEALTH PLAN POPULATION","Brock E. Schroeder","2008","Value in Health","other","article","10.1016/s1098-3015(10)70691-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052269","Peptide drugs and their use in surgical treatments","P. Jeyanthi","2024","International Journal of Surgery Open","other","article","10.1097/io9.0000000000000152",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052270","JNK3 contrôle la masse fonctionnelle des cellules bêta pancréatiques en réponse à la prise de poids et au Liraglutide","Amar Abderrahmani","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052271","CE-499645-002 SODIUM-GLUCOSE COTRANSPORTER2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS: ASSOCIATION WITH ATRIAL FIBRILLATION INCIDENCE AND MECHANISTIC INSIGHTS","Reina Tonegawa‐Kuji","2025","Heart Rhythm","other","article","10.1016/j.hrthm.2025.03.063",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052272","Diabetes 1.5: Ketone-Prone Diabetes","Sabina B. Safder","2015","Clinical Diabetes","other","article","10.2337/diaclin.33.3.150","26203209",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052273","PDB9 LONG-TERM CLINICAL OUTCOMES OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE 2 DIABETES PROJECTED USING THE CORE DIABETES MODEL","Louise Timlin","2010","Value in Health","other","article","10.1016/s1098-3015(11)72067-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052274","Evaluating the Utility of Glucagon-Like Peptide 1 Receptor Agonists in Potential Lung Transplant Candidates Requiring Weight Loss Prior to Transplant","Lynne J. Goebel","2024","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2024.02.1018",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052275","Effects of Tirzepatide on Eating Behaviour: A Phase 1 Study in People Living with Obesity","Corby K. Martin","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785402",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052276","OC.16.4: SEMAGLUTIDE FOR TYPE 2 DIABETES CONTROL IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A TWO-WAY EFFECT?","Giovanni Petralli","2024","Digestive and Liver Disease","other","article","10.1016/s1590-8658(24)00527-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052277","S2101 Weight Loss after Initial Bariatric Surgery Predicts Early Weight Loss After Revisional Endoscopic Bariatric Therapy","Meghna Yalamanchi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037772.95190.83",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052278","Tu1502 Longitudinal Monitoring of Lipase and Amylase in Adults With Type 2 Diabetes and Obesity: Evidence From Two Phase 3 Randomized Clinical Trials With the Once-Daily GLP-1 Analog Liraglutide","William M. Steinberg","2012","Gastroenterology","randomized_trial","article","10.1016/s0016-5085(12)63296-x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052279","EP86 SEMAGLUTIDE USE ACHIEVES WEIGHT LOSS AND FAT REDUCTION WITH PRESERVATION OF SKELETAL MASS IN PATIENTS WITH MASLD: A RETROSPECTIVE LONGITUDINAL STUDY","Rhea Fogla","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)04526-8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052280","New horizons in obesity pharmacotherapy: a clinical and pharmacological review of incretin agonists, from liraglutide and semaglutide to retatrutide","Maksim Leonidovich Maksimov","2026",null,"narrative_review","article","10.33920/med-13-2603-01",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052281","Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease","Paul Edison","2020","Alzheimer s & Dementia","other_trial","article","10.1002/alz.046068",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052282","Editorial: Molecular Endocrinology Special Feature Minireviews for August 2013: GPCRs in Endocrine Physiology and Pathophysiology","László Hunyady","2013","Molecular Endocrinology","preclinical","article","10.1210/me.2013-1198","23894115",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0052283","S3482 A Yellow Flower With Jaundice Power: A Case of Severe Liver Injury Attributed to Greater Celandine","Sydney Power","2023","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0000963568.40362.de",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052284","Kombination von DPP-4-/SGLT-2-Inhibitoren als Add-on zu Metformin bei Patienten mit Typ-2-Diabetes: Vergleich mit OAD, GLP-1RA und Basalinsulin","L Qin","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0037-1601751",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052285","1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction","Kari Uusinarkaus","2019","Diabetes","other_trial","article","10.2337/db19-1020-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052286","DPP-4 inhibitors and GLP-1 agonists in type 2 diabetes - early assessment of cardiovascular safety in a nationwide setting","Ulrik Madvig Mogensen","2013","European Heart Journal","randomized_trial","article","10.1093/eurheartj/eht311.5929",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052287","SUN-645 Leptin- And Incretin-based Combination Therapy In Lipodystrophy: A Promising Metabolic Strategy?","Merve Çelik Güler","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.155",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052288","Navigating the balance: risks of glucagon-like-peptide-1 receptor agonist and levothyroxine co-administration","Maxim John Levy Barnett","2025","Endocrine Abstracts","other","article","10.1530/endoabs.109.p243",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052289","P176 Stratégies d’administration du liraglutide pour optimiser la transplantation d’îlots pancréatiques chez le rat diabétique","A. Langlois","2014","Diabetes & Metabolism","preclinical","article","10.1016/s1262-3636(14)72467-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052290","1477-P: Insights from Type 2 Diabetes Patients Suggest Need for Cardiovascular Health Education","KEATON C. STONER","2019","Diabetes","other","article","10.2337/db19-1477-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052291","Safety and Efficacy of Semaglutide Use in Diabetes during Ramadan Fasting: A Real-world Experience from Bangladesh","Md Faruque Pathan","2024","Bangladesh Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/bjem.bjem_29_23",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052292","Perception hédonique et gustative des aliments chez les patients diabétiques de type 2 – Impact du traitement par un analogue du GLP-1 : le Liraglutide","Sophie Meillon","2012","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0052293","Perioperative glucagon-like peptide-1 receptor agonist exposure and persistent postoperative opioid use among adults with type 2 diabetes mellitus: a propensity score-matched cohort study","Hsiang-Ling Wu","2026","Scientific Reports","nonrandomized_study","article","10.1038/s41598-026-71924-1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052294","Risque de conduites suicidaires et exposition aux agonistes des récepteur du GLP-1 : une étude case-time-control à partir des données du SNDS","Julien Bezin","2025","Journal of Epidemiology and Population Health","other","article","10.1016/j.jeph.2025.202822",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052295","Incretin-based therapies and diabetic retinopathy: Real-world evidence in older U.S. adults","Tiezhou Wang","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","nonrandomized_study","article","10.17615/bgre-6k17",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0052296","EPH120 Clinical Characteristics and Healthcare Resource Utilization Among Patients Initiating Semaglutide 2.4mg Versus Those Not Treated With Anti-Obesity Medications","Aleksandrina Ruseva","2025","Value in Health","other","article","10.1016/j.jval.2025.04.651",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052297","Mo1273: IMPACT OF GLP-1 RECEPTOR AGONISTS ON BOWEL PREPARATION QUALITY FOR COLONOSCOPY: A META-ANALYSIS","Fariha Hasan","2025","Gastroenterology","systematic_review","article","10.1016/s0016-5085(25)03386-4",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0052298","993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes","Juan P. Frías","2019","Diabetes","randomized_trial","article","10.2337/db19-993-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052299","Abstract 4135582: Sociodemographic Trends in Diabetes Medications after Metformin: the BESTMED (oBservational Evaluation of Second line Therapy MEdications in Diabetes) Study","Maria Cecilia Lansang","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4135582",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052300","The Therapeutic Potential of Glucagon-Like Peptide-1 Receptor Agonists in Burn Recovery: Reduced Infection, Opioid Prescriptions, and Mortality","Matthew Dao","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20086786",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0052301","Comparing effects of weight loss by liraglutide with intensive lifestyle modification on hepatic steatosis, inflammation and stiffness, and insulin resistance in obese Asians with non-alcoholic fatty liver disease (NAFLD)","Joan Joo Ching Khoo","2017","Endocrine Abstracts","other","article","10.1530/endoabs.49.oc11.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052302","Higher doses of dulaglutide induce weight loss in patients with type 2 diabetes (T2D) regardless of baseline BMI: post hoc analysis of AWARD-11","Enzo Bonora","2022","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0042-1746329",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052303","EE464 The Cost-Effectiveness of Subcutaneous Semaglutide 2.4MG Injection in the Management of Obesity in Canada Using the Core Obesity Model","Anamaria‐Vera Olivieri","2022","Value in Health","other","article","10.1016/j.jval.2022.04.712",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052304","Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) and GLP-1/Gastrointestinal Peptide RA (GLP-1/GIP-RA) Use in Adolescents and Young Adults with Type 1 Diabetes and Overweight or Obesity","Chiara M. Lopach","2025","Diabetes Technology and Obesity Medicine","nonrandomized_study","article","10.1089/dtom.2025.0018",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052305","Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","Michael Albrecht Nauck","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/5vsp-zn15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052306","Change in hbA1c following treatment with and the short-term risk of major adverse cardiovascular outcomes","Bochra Zareini","2023","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehad655.2553",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052307","Abstract P729: Glp-1 Receptor Nitration Contributes to Brain Pericytes Dysfunction in Diabetes","Joseph Bailey","2021","Stroke","preclinical","article","10.1161/str.52.suppl_1.p729",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052308","The efficacy of liraglutide for weight loss in a patient with relapse in obesity after bariatric surgery - case report","Anna Maria Dąbrowska","2022","Endocrine Abstracts","case_report","article","10.1530/endoabs.81.ep347",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052309","192 GLP1-RA AND HEART FAILURE-RELATED OUTCOMES IN PATIENTS WITH AND WITHOUT HISTORY OF HEART FAILURE: A SYSTEMATIC REVIEW AND METANALYSIS","Alessandro Villaschi","2022","European Heart Journal Supplements","systematic_review","article","10.1093/eurheartjsupp/suac121.489",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0052310","What Are the Impacts of GLP ‐1 Drugs in Patients Needing Head/Neck Surgery?","Chelsea Gelboin‐Burkhart","2025","The Laryngoscope","other","article","10.1002/lary.70341","41449843",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052311","Promising areas of pharmacotherapy for obesity","М. A. Druzhilov","2021","Russian Journal of Cardiology","other","article","10.15829/1560-4071-2021-4279",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052312","Tu1753: ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST USE AND REDUCED COLORECTAL CANCER INCIDENCE IN TYPE 2 DIABETES: A REAL-WORLD COHORT STUDY","Abdullah Sohail","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04282-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052313","Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: Insights from the EXSCEL trial","N. Jakuboniene","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/wd7y-wk80",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0052314","The inhibitory effect of the glucagon‐like peptide‐1 analog exendin‐4 on NHE3 activity in proximal tubule cells is mediated by both PKA and EPAC signaling pathways","Luciene Regina Carraro‐Lacroix","2009","The FASEB Journal","preclinical","article","10.1096/fasebj.23.1_supplement.602.12",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052315","Editorial introductions","Bobby Yanagawa","2019","Current Opinion in Cardiology","other_trial","article","10.1097/hco.0000000000000606",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","editorial"],["R0052316","Common variants in the GLP-1 receptor are associated with glycaemic response to GLP-1 receptor agonists in observational and large RCT data: an IMI-DIRECT study","Adem Y. Dawed","2018","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052317","Efficacy and safety of once weekly injectable semaglutide among patients with type 2 diabetes in tertiary care hospital","Musarrat Jabeen","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112768",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052318","S2323 Addressing an Emerging Clinical Need: Nasal Metoclopramide's Impact on Diabetic Gastroparesis in Patients Taking GLP-1 Agonists","David C. Kunkel","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001038660.88079.93",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052319","Selective N-terminal modification of peptides and proteins using acyl phosphates","Laura Rodríguez Pérez","2023","ChemRxiv","other","article","10.26434/chemrxiv-2023-jm6sb",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0052320","S2114 Association of GLP-1 RA Or Dual GIP and GLP-1 RA for Obesity And Gastrointestinal Adverse Events: A Systematic Review","Lizeth Cifuentes","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001037824.19003.ab",null,null,"PROSPERO:CRD42023458537",null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0052321","Injecting care and negotiating pleasures with weight loss pharmaceuticals","Megan J. Warin","2024","Thesis Eleven","other","article","10.1177/07255136241285046",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052322","Gut Microbiota and Dietary Modulation in Osteonecrosis: Mechanistic Insights and Food-Based Therapeutic Strategies","Nourhan Nassar","2026","Food Science and Human Wellness","other","article","10.26599/fshw.2025.9250877",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052323","26-A-11826-ACC INCRETIN MIMETICS IN HEART FAILURE WITH REDUCED EJECTION FRACTION, A PROPENSITY MATCHED ANALYSIS OF SAFETY IN A LARGE HEALTHCARE DATABASE","Leslie K. Iverson","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1504",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052324","Intraarterial Autologous Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease","Lina S. Alatta","2025","Kidney International Reports","other","article","10.1016/j.ekir.2025.07.042","41141513",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052325","Nutritional Interventions for the Prevention and Management of Sarcopenic Obesity in Older Adults Enrolled in a Bariatric and Metabolic Surgery Program and/or Receiving GLP-1 Receptor Agonist Therapy – A Scoping Review","Filipa Sofia Simas Martinho","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/cqph6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0052326","Glucagon-Like Peptide 1 Receptor Agonists Protect Against Stroke In Patients With Diabetes: A Systematic Review And Meta-Analysis","Fotios Barkas","2019","Atherosclerosis","systematic_review","article","10.1016/j.atherosclerosis.2019.06.336",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0052327","Les diabétiques de type 2 traités par insuline degludec/liraglitude (IDegLira) ont plus de chances d’atteindre les objectifs glycémiques sans hypoglycémies ni prise de poids qu’avec l’insuline Glargine U100 (IGlar U100)","Pierre Sérusclat","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30434-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052328","Insulin Sensitizers as Anti-Aging Agents: Unveiling Synergies with Albumin, GLP-1RA, Klotho Protein, and Metformin in the Quest to Combat Aging","Amr Kamel Khalil Ahmed","2024","Cell & Cellular Life Sciences Journal","other","article","10.23880/cclsj-16000200",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052329","Role of anti-diabetic medications in the management of MASLD","Scott D. Isaacs","2025","Frontline Gastroenterology","other","article","10.1136/flgastro-2024-102856",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052330","Differential Treatment Effects on β-cell Function Using Model-based Parameters in Type 2 Diabetes: Results from the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study","Kristina M. Utzschneider","2025",null,"other","article","10.2337/figshare.28296884",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0052331","Utilization patterns of SGLT2 inhibitors and GLP-1 receptor agonists across drug categories, divisional allocation, and medical specialties: insights from a safety-net hospital context","Khalid Sawalha","2024","The American Journal of the Medical Sciences","other","article","10.1016/s0002-9629(24)00061-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052332","Effect ofglucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on left atrial strain and arterial function","Ignatios Ikonomidis","2021","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehab724.2652",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052333","L’ancienneté du diabète conditionne-t-elle la réponse au liraglutide au cours du diabète type 2 ?","G. Bourkadi","2023","Annales d Endocrinologie","other","article","10.1016/j.ando.2023.07.451",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052334","Liebe Leserin, lieber Leser,","B Gallwitz","2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2801-1586",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052335","224-OR: SURMOUNT-5 Tirzepatide vs. Semaglutide for Obesity—Rapid Responders and Associated Weight Reduction and Safety","Louis J. Aronne","2025","Diabetes","other","article","10.2337/db25-224-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052336","An Extreme Paradoxical Effect on Weight and Glycemic Control When Using Exenatide To Treat a Patient with Steroid-Associated Diabetes","Lydia Spurr","2011",null,"other","article","10.1210/endo-meetings.2011.part2.p11.p1-564",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0052337","Effectiveness of new generation incretin-based therapies in hypothalamic obesity: a single centre real-world experience","Ghaith Khaleel","2026","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.117.p286",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052338","Canagliflozin added on to dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 agonists with or without other antihyperglycaemic agents in type 2 diabetes mellitus","Gary E. Meininger","2013","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052339","ALL-CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES WITH TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH REDUCED EJECTION FRACTION","Aravinthan Vignarajah","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01909-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052340","Hemochromatosis and Cystic Fibrosis Carriers Identify Risk for GLP-1 Agonist Associated Pancreatitis","William A. West","2018","Diabetes","other","article","10.2337/db18-2296-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052341","Efficacy of GLP-1 Receptor Agonists in Patients with Prader-Willi Syndrome: A Retrospective Cohort Study","Sultan Samin","2026","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.117.op2.3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052342","Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or obesity in the select trial","Jorge Plutzky","2024","Atherosclerosis","other_trial","article","10.1016/j.atherosclerosis.2024.118518",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052343","Abstract GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database","Hongchao Pan","2025","Clinical Cancer Research","randomized_trial","article","10.1158/1557-3265.sabcs24-gs2-09",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052344","Effect of Tirzepatide on Kidney Function in People with Excess Body Weight: A Post Hoc Analysis of the SURMOUNT-1 Trial","Hiddo J.L. Heerspink","2023","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20233411s141b",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052345","Predicting Rapid eGFR Decline in the CURE-CKD Registry","Tyler A. Davis","2022","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20223311s1583a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052346","P296 Extension DURATION-1 : efficacité et tolérance de l’exenatide hebdomadaire à 6 ans chez des patients atteints de DT2","Elizabeth Tocque","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30409-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052347","P441 CARDIO–VASCULAR RISK STRATIFICATION IN T2DIABETES IN ITALY AND USE OF NEW DRUGS (SGLT2I AND GLP1–RA):DATA FROM THE AMD ANNALS:","Valeria Manicardi","2023","European Heart Journal Supplements","other","article","10.1093/eurheartjsupp/suad111.507",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052348","Glucagon-Like Peptide-1 Receptor Agonist Use and Survival Outcomes in Skull Base and Head and Neck Tumors","Emma J. Anisman","2026","Journal of Neurological Surgery Part B Skull Base","nonrandomized_study","article","10.1055/s-0046-1818751",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052349","Changes of Glucagonlike Peptide-1 Receptor Agonist (GLP-1 RA) and Sodium-glucose Co-transporter 2 Inhibitor (SGLT2i) prescription rates in Germany after the ADA/EASD Consensus Report: A Retrospective Study","Sebastian Dietmar Barth","2022","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0042-1746404",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052350","Comparison of DPP‐4 inhibition versus GLP‐1 analogue supplementation on survival and vascular complications in experimental sepsis (145.2)","Paul Stamm","2014","The FASEB Journal","preclinical","article","10.1096/fasebj.28.1_supplement.145.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052351","EV017/#1282 GLP-1 analogues reduce the incidence of endometrial cancer in an animal model","Michael Wilkinson","2024","International Journal of Gynecological Cancer","other","article","10.1136/ijgc-2024-igcs.136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052352","Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes","André Jacques Scheen","2023","Diabetes Epidemiology and Management","randomized_trial","article","10.1016/j.deman.2023.100135",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052353","The Long-Term Cost-Effectiveness of Twice-Daily Exenatide with Insulin Glargine Versus Once-Daily Liraglutide with Insuline Detemir in Adult Patients with Type 2 Diabetes in Russia","Ivan S. Krysanov","2015","Value in Health","other","article","10.1016/j.jval.2015.09.2092",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052354","S218 Characterizing Individuals With Recurrent Acute Pancreatitis and Exocrine Pancreatic Insufficiency: Findings From the PACT-CP Registry","Jane A. Diamond","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001029240.67546.ea",null,null,"ClinicalTrials.gov:NCT05762445",null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052355","Analyse de l’efficacité du liraglutide à la dose de 1,2 mg vs. 1,8 mg à l’issue des 2 ans du suivi de l’étude observationnelle EVIDENCE®","Pierre Gourdy","2015","Annales d Endocrinologie","other","article","10.1016/j.ando.2015.07.232",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052356","Buccal delivery of the GLP-1 against exenatide using ArisCrown technology","Andrew Scott Parker","2015","Journal of Diabetes & Metabolism","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052357","84-LB: Efficacy and Safety of Tirzepatide vs. Semaglutide Once-Weekly as Add-On Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2)","Juan P. Frías","2021","Diabetes","randomized_trial","article","10.2337/db21-84-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052358","Report all increases in serum amylase in patients starting incretins","Zoltán Lengyel","2013","BMJ","other","article","10.1136/bmj.f5333","24009264",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052359","886-P: Impact of Endocrine E-Consultation on SGLT2i and GLP-1 RA Prescription","Amna Rasheed","2021","Diabetes","nonrandomized_study","article","10.2337/db21-886-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052360","A comprehensive review of the multisystem benefits of antidiabetic drugs in aging beyond glycemic control","Fatema Tuz Zohora","2025","Translational Medicine of Aging","narrative_review","article","10.1016/j.tma.2025.08.005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052361","#1775120 Oral Semaglutide helps in maintaining β-cell function in patients with Recent-Onset Latent Autoimmune Diabetes in Adults: a 6 months Prospective Study","SHARVIL S. GADVE","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.160",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052362","Experimental and Computational Insights into Gangronema latifolium Leaf Compounds as GLP-1 Receptor Agonists","Ijeoma Akunna Duru","2024","Chemistry Africa","other","article","10.1007/s42250-024-00951-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052363","Bridging the Gap: A Literature Review of Advancements in Obesity and Diabetes Mellitus Management","Gheorghe Nicușor Pop","2024","Applied Sciences","narrative_review","article","10.3390/app14156565",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052364","Incretin-based pharmacotherapy: from physiological mechanisms to management of type 2 diabetes and obesity","E.V. Khaikina","2025","Clinical pharmacology and therapy","other","article","10.32756/0869-5490-2025-3-40-46",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052365","Mounjaro is more effective for weight loss than Ozempic. So how does it work? And why does it cost so much?","Paul Joyce","2024",null,"other","article","10.64628/aa.dcf53prmh",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0052366","ASSESSING THE REAL-WORLD EFFICACY OF DULAGLUTIDE IN MALAYSIAN MOH PATIENTS WITH TYPE 2 DIABETES MELLITUS","Zanariah Binti Hussein","2024","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.039.s1.034",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052367","Abstract 4142273: Pharmacosurveillance study of FDA Adverse Event Reporting System (FAERS) events of Tirzepatide and Semaglutide","Ilana K Logvinsky","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4142273",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052368","EP1227: OUTCOMES OF GLP-1 ANALOGUE OR SGLT-2 INHIBITOR THERAPY IN A VETERAN POPULATION WITH NON-ALCOHOLIC STEATOHEPATITIS AND DIABETES","Matthew A. Heckroth","2022","Gastroenterology","other","article","10.1016/s0016-5085(22)63788-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052369","243 Early GLP-1 Receptor Agonist Use Is Associated With Reduced Mortality and Neurological Complications Following Spinal Cord Injury: A Propensity Score Matched Cohort Study","Matias Luis Costa","2026","Neurosurgery","nonrandomized_study","article","10.1227/neu.0000000000003964_243",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052370","Seeking Multiorgan Benefits with Cardiovascular–Kidney–Metabolic Drug Therapy","Faiez M. Zannad","2025","New England Journal of Medicine","other_trial","article","10.1056/nejme2503600","40435470",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052371","Effect Of The Fixed-Dose Combination Of Insulin Degludec And Liraglutide On Serum Lipoprotein Metabolism In Patients With Type 2 Diabetes Mellitus","Eleni T. Pappa","2019","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2019.06.374",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052372","POSTER: MM-852: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Multiple Myeloma and Plasma Cell Disorders: Protective, Harmful, or Both? A Scoping Review","Yagnapriya Chirrareddy","2026","Clinical Lymphoma Myeloma & Leukemia","narrative_review","article","10.1016/s2152-2650(26)01374-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052373","Semaglutide reverses cardiovascular magnetic resonance indicators of early-stage cardiometabolic HFpEF in obese mice","Thomas P. Skacel","2025","Journal of Cardiovascular Magnetic Resonance","preclinical","article","10.1016/j.jocmr.2024.101314",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052374","One-year Heart Failure Outcomes On Glp1-ra Treatment And After Discontinuation: A Real-world Retrospective Cohort Study","Amin Tajerian","2026","Journal of Cardiac Failure","nonrandomized_study","article","10.1016/j.cardfail.2025.11.082",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052375","Abstract 9392: Cardiovascular, Metabolic and Safety Outcomes With Semaglutide by Age: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6","Mark Colquhoun Petrie","2021","Circulation","other","article","10.1161/circ.144.suppl_1.9392",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052376","#1705947 How Long is Too Long? Prolonged Honeymoon in a Patient with New-onset Type 1 Diabetes with GLP-1 Receptor Agonist Use","Palak Kachhadia","2024","Endocrine Practice","other","article","10.1016/j.eprac.2024.03.202",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052377","Impact of multidisciplinary cardiometabolic clinics on cardiovascular risk management and therapeutic optimization in patients with type 2 diabetes mellitus","V Tsigkou","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3790",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052378","Resolution on the results of the expert panel “IDegLira: is it 1+1 or anything more?”","Mikhail Borisovich Antsiferov","2020","Фарматека","other","article","10.18565/pharmateca.2020.12.91-98",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052379","FRI-562 Impact of Glucagon-like peptide-1 receptor agonists on diabetes after liver transplantation - a single-center experience","Chiara Sicuro","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)01245-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052380","Secondary Prevention after Ischemic Stroke","T Ples Spradley","2026","New England Journal of Medicine","other","article","10.1056/nejmc2603999","42202340",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052381","Semaglutide","Jennifer Bo Jiang","2023","RCSB Protein Data Bank","other","article","10.2210/rcsb_pdb/gh/dm/drugs/in/semaglutide",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052382","Effects of Glucagon like Peptide-1 agonists on patients with overactive bladder: A pilot study","Max D. Sandler","2025","Continence Reports","other","article","10.1016/j.contre.2025.100083",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052383","68Ga-DOTA-Exendin-4 PET/CT for the localization of insulinoma: Results of an international, dual-center, retrospective, open-label real-world imaging study","Lea Menz","2025","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0045-1807555",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0052384","877 GASTROPARESIS RISK IN PATIENTS WITH TYPE 2 DIABETES PRESCRIBED GLP-1 RECEPTOR AGONISTS","Thabet Qapaja","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)00962-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052385","Long-Term Metabolic Consequences of Neonatal Exendin-4","Daniella A Babu","2011",null,"other","article","10.1210/endo-meetings.2011.part3.p2.p2-437",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0052386","Exploring Liraglutide as a Possible Treatment for Oxycodone Addiction and Relapse","Carl M. Porto","2020",null,"other","article","10.36934/t2020-024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0052387","Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries","Sarah K. Lyons","2017","Diabetes Care","nonrandomized_study","article","10.2337/dc17-0403","28768688",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052388","Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes","Manfredi Rizzo","2011","Clinical Lipidology","other","article","10.2217/clp.11.46",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052389","GLP-1 Agonist Use In Patients Entering Alcohol Use Disorder Treatment","LaTrice Montgomery","2025","Drug and Alcohol Dependence","other","article","10.1016/j.drugalcdep.2024.111445",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052390","P1-174 - Comparaison entre exenatide et insuline glargine chez des patients traités par un seul antidiabétique oral","Marcel Trautmann","2006","Annales d Endocrinologie","other","article","10.1016/s0003-4266(06)72827-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052391","Abstract 14462: Baseline Characteristics of Tirzepatide-Treated Participants Who Shifted to a Normal Body Mass Index (<25 kg/m 2 ): A Post Hoc Analysis From SURMOUNT-1","Reshmi Srinath","2023","Circulation","other","article","10.1161/circ.148.suppl_1.14462",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052392","Use of GIP and GLP-1 receptor agonists in prostate cancer patients.","Amy L. Shaver","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.5024",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052393","GLP-1/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model","JOHN J. JUN. NESTOR","2020","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(20)31395-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052394","26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS","Khalid Sawalha","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.451",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052395","1163-P: Disparities in Glucagon-Like Peptide 1 Receptor Agonist (GLP-1RA) Utilization in Pediatric Type 2 Diabetes (T2D)","Patricia Y. Chu","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1163-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052396","Vitreous hemorrhage after weight loss therapy","Ahmed S. Al-Hinai","2026","Oman Journal of Ophthalmology","other","article","10.4103/ojo.ojo_60_26","41930026",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052397","Emerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care","Shahini Winson Gnanathayalan","2024","Journal of Diabetology","other","article","10.4103/jod.jod_110_23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052398","Are your kidneys ok? detect early to protect kidney health","Joseph A. Vassalotti","2025","Journal of The Egyptian Society of Nephrology and Transplantation","other","article","10.4103/jesnt.jesnt_12_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052399","CO23 Real-World Effectiveness of Tirzepatide vs. Semaglutide on HbA1c and Weight in GLP-1 RA Naïve Patients with T2D","Kendra A. Terrell","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.108",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0052400","1782-P: Impact of Treatment with Medication vs. Laparoscopic Gastric Banding (GB) on ß-Cell Function in Adults with Impaired Glucose Tolerance (IGT) or Type 2 Diabetes (T2D) in the Restoring Insulin Secretion (RISE) Study","David A. Ehrmann","2020","Diabetes","randomized_trial","article","10.2337/db20-1782-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052401","Does Metformin Assist New Anti-Diabetic Drugs to Succeed?","Hisayuki Kastuyama","2019","Journal of Clinical Medicine Research","other","article","10.14740/jocmr3706","30701009",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052402","Impact of GLP-1 Receptor Agonists on Intraocular Pressure in Glaucoma: A Case Series","Catherine A Johnson","2024","SSRN Electronic Journal","case_report","article","10.2139/ssrn.4861664",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0052403","757-P: Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes","JULIO ROSENSTOCK","2024","Diabetes","other_trial","article","10.2337/db24-757-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052404","Treatment and Clinical Measures after Initiation of Injectable Therapy for Type 2 Diabetes—A Real-World Observational Cohort Study","Orna Reges","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1076-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052405","Unveiling the Interplay of Klotho Protein, Chemotherapy-Induced Klotho Protein Deficiency and the Pivotal Role of GLP-1 Agonists like Ozempic in Cancer Survivorship Patient Survival Rate after Chemotherapy Treatment","Maher Monir Akl","2024","Cell & Cellular Life Sciences Journal","other","article","10.23880/cclsj-16000193",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052406","664-P: Incorporating Treatment Pauses, Dosing Flexibility, and Education to Support GLP-1RA Therapy Persistence","Vanita R. Aroda","2021","Diabetes","other_trial","article","10.2337/db21-664-p",null,null,"ClinicalTrials.gov:NCT02692716","S001381","openalex","FALSE","paywalled","5","FALSE","article"],["R0052407","N-lactoyl phenylalanine suppresses appetite and obesity with important implications for aging and age-related diseases","Antentor Othrell Hinton Jr.","2024","Aging advances.","preclinical","article","10.4103/agingadv.agingadv-d-24-00011","39845129",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0052408","State-of-the-art perspective: Advances in incretin-based therapy targeting progression of diabetes and cardiovascular-kidney-metabolic syndrome","Samar A. Nasser","2024","Global Translational Medicine","other","article","10.36922/gtm.4405",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052409","INSULIN, LIXISENATIDE, AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME","David Aguilar","2020","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(20)30721-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052410","S3720 Subacute Pseudo-Obstruction in End-Stage Scleroderma Bowel Disease: Transition From Neostigmine-Induced Decompression to Oral Pyridostigmine","Dharma Ayer","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001142340.25667.4d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052411","Differential Beta-Cell Response to Intravenous Exenatide (EXEN) and Arginine (ARG) in Prediabetic Subjects with Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","Tomoko Terasawa","2018","Diabetes","other","article","10.2337/db18-1810-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052412","MO624COMBINATION TREATMENT WITH LISINOPRIL AND EMPAGLIFLOZIN IMPROVES BIOCHEMICAL AND HISTOLOGICAL MARKERS OF DIABETIC NEPHROPATHY IN HYPERTENSIVE UNINEPHRECTOMIZED DB/DB MICE","Mette V. Østergaard","2021","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfab093.005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052413","Do glial‐reactivity and cerebral blood flow modulate cerebral glucose metabolism in Alzheimer’s disease?","Joseph Nowell","2024","Alzheimer s & Dementia","other_trial","article","10.1002/alz.088897",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052414","Ghrelin: A New Incretin Enhancer Therapy?","Vincent Gerard DeMarco","2015","Diabetes","other","article","10.2337/db14-1871","25908874",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052415","2322 Liraglutide-Induced Liver Injury With Superimposed Acute Pancreatitis","Eric O. Then","2019","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000598820.61328.e9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052416","Abstract 14678: Prevalence Of Sglt2 Inhibitor And Glp-1 Receptor Agonist Prescriptions In Patients With Comorbid Diabetes And Cardiovascular Disease In An Integrated Academic Health System","Hawkins C. Gay","2020","Circulation","randomized_trial","article","10.1161/circ.142.suppl_3.14678",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052417","Pioglitazone/Exenatide/SGLT-2 inhibitor combination therapy versus insulin therapy in patients with poorly controlled type 2 diabetes","Hakan Düğer","2024","Anatolian Current Medical Journal","nonrandomized_study","article","10.38053/acmj.1415215",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052418","Protective Effect of Exendin-4 (Glp-1 Analogue) in Acute Kidney Injury in Experimental Animals","Eslam Kamal Fahmy","2014","JOURNAL OF HEALTH SCIENCE","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052419","Safety and Efficacy of SGLT2i and GLP-1RA for Weight Loss in Heart Transplant Patients","A. Nikolova","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.1961",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052420","Risk of Gastroparesis Is Higher with Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) but Risk of Death Is Higher with Insulin Glargine in Veterans with Type 2 Diabetes and CKD","Amara Sarwal","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.202475pb8gyb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052421","1136-P: Glucose Kinetics during Oral Glucose Challenge following Administration of Exenatide and Dapagliflozin Alone and in Combination in Type 2 Diabetes","Mariam Alatrach","2020","Diabetes","randomized_trial","article","10.2337/db20-1136-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052422","Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer","Jennifer G. Haag","2024","Gynecologic Oncology","other","article","10.1016/j.ygyno.2024.07.032",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052423","Persistance et durabilité de l’efficacité du liraglutide : au-delà des études randomisées","Martin Eisinger","2018","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(18)30059-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052424","Impact of incretin mimetic therapy on weight change in patients with cancer: A pan-cancer analysis from a single institutional cohort.","Yan Leyfman","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.10598",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052425","SAT-688 One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women with and without Hormone Therapy","Dima Bechenati","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.122",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052426","S442 Comparative Outcomes of Pancreatic, Colon, and Liver Cancers in GLP-1 RA Treated Patients: A Retrospective Analysis","Mahmoud Nassar","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001031136.76287.b2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052427","GLP-1 RECEPTOR AGONIST FOR WEIGHT LOSS AND INFERTILITY: COMPARISON BETWEEN SOCIAL MEDIA PERCEPTION AND ONLINE SEARCH VERSUS EVIDENCE-BASED MEDICINE","Zaher O Merhi","2024","Fertility and Sterility","other","article","10.1016/j.fertnstert.2024.07.505",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052428","PDB58 CHANGES IN CONCOMITANT DIABETES THERAPIES ASSOCIATED WITH THE INITIATION OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES","Derek A. Misurski","2007","Value in Health","other","article","10.1016/s1098-3015(10)65006-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052429","778-P: Changes in HbA1c with GLP-1 Use in People with Type 1 Diabetes—Data from the T1D Exchange QI Initiative","Carol Joan Levy","2024","Diabetes","other","article","10.2337/db24-778-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052430","Hypothalamic neuroinflammation induced by obesity and the effect of Liraglutide","Nour Batarseh","2022","Journal Of Advanced Pharmacy Education And Research","preclinical","article","10.51847/n1hvob1ans",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052431","S1648 Cardiovascular Disease Risk Improvement With Semaglutide in Patients With Obesity: A Multi-Centered Study","Wissam Ghusn","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000956232.19702.5a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052432","DPP-4 Inhibition and the Known Unknown","Michael Bruce Horowitz","2016","Diabetes","other","article","10.2337/dbi16-0023","27456619",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052433","A contemporary view on obesity treatment in adults","Valentyna I. Velychko","2021","Reproductive Endocrinology","other","article","10.18370/2309-4117.2021.61.45-50",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052434","1324-P: Short-Term Effects of Glycemia-Lowering Medications on ß-Cell Function in the GRADE Study","Neda Rasouli","2022","Diabetes","randomized_trial","article","10.2337/db22-1324-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052435","Intersecting Pathways of Metabolic Dysregulation and GLP-1 Receptor Agonist Effects in Airway Smooth Muscle Cells","Daniel R. Gomez","2024",null,"other","article","10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4334",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052436","Practice Patterns of SGLT2 Inhibitor and GLP-1 Agonist Treatment in Eligible Type 2 Diabetic Patients Before and After the Publication of the 2018 ADA/EASD Position Statement","Bijin Thajudeen","2020","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20203110s1814c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052437","OP0172 EFFECT OF WEIGHT LOSS AND LIRAGLUTIDE ON SERUM URATE LEVELS AMONG OBESE KNEE OSTEOARTHRITIS PATIENTS: SECONDARY ANALYSIS OF A RANDOMISED CONTROLLED TRIAL","Kristian Zobbe","2020","Annals of the Rheumatic Diseases","randomized_trial","article","10.1136/annrheumdis-2020-eular.3088",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052438","I11 Effects of dual administration of liraglutide and ghrelin on brain mitochondrial metabolism in the r6/2 mouse","Ana Isabel Duarte","2018",null,"preclinical","article","10.1136/jnnp-2018-ehdn.247",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052439","O31 Effets de l’exenatide versus placebo sur la perte de poids, chez des patients diabétiques de type 2 suivant des mesures hygiéno-diététiques","Leonard C. Glass","2009","Diabetes & Metabolism","other","article","10.1016/s1262-3636(09)71723-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052440","Neuroprotective Activity of GLP-1 Analogues: General Understanding of Implementation Mechanisms","E. L. Golovina","2024","Personalized Psychiatry and Neurology","nonrandomized_study","article","10.52667/2712-9179-2024-4-2-11",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052441","Прогнозирование раннего ответа на терапию агонистом рецепторов глюкагоноподобного пептида-1 лираглутидом у пациентов с экзогенно-конституциональным ожирением","Oksana Logvinova","2020",null,"randomized_trial","article","10.14341/omet12274-9554",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052442","SAT-621 Real World Utilization of GLP-1 Agonists in Adolescents and Young Adults With Type 1 Diabetes (T1D) and Obesity","Michael Melitón Valencia Muñoz","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1147",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052443","Neuroprotective effects of glucose-lowering drugs in rat focal brain ischemia-reperfusion model","А. В. Симаненкова","2023","Arterial’naya Gipertenziya (Arterial Hypertension)","preclinical","article","10.18705/1607-419x-2023-29-6-579-592",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052444","De plaats van liraglutide in de behandeling van patiënten met diabetes mellitus type 2","VAN BOXELAER","2012","Tijdschrift voor Geneeskunde","other","article","10.47671/tvg.68.06.2001150",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052445","Use of new antidiabetic drugs in patients with cardiovascular diseases - real life data","Jasna Vučak","2024","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehae666.3314",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052446","747-P: Duration of Sustained Weight Loss in Clinical Trials Evaluating Tirzepatide vs. Comparators—An Exploratory Analysis of SURPASS 1–5","W. TIMOTHY GARVEY","2023","Diabetes","randomized_trial","article","10.2337/db23-747-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052447","Current pharmacological approaches in obesity treatment","Pelin TİRYAKİOĞLU","2023","DAHUDER Medical Journal","other","article","10.56016/dahudermj.1271677",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052448","1106 Assessing Weight Changes Post-Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Adults at a Federally Qualified Health Center","Mitch A. Phelps","2025","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2025.102592",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052449","Once-Weekly Dulaglutide Produces Superior Glycemic Control Compared with Metformin","Brian D. Hoyle","2013","MD Conference Express","randomized_trial","article","10.1177/155989771317007",null,null,"ClinicalTrials.gov:NCT01126580","S001786","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0052450","Influence of Liraglutide, a glucagon-like peptide-1 analog, on hunger and satiety, interdigestive motility, gastric accomodation and gastric emptying in healthy volunteers","Alessandra Rotondo","2016","United European Gastroenterology Journal","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052451","Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group","Lindsay E. Clegg","2018","Diabetes","randomized_trial","article","10.2337/db18-130-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052452","Identification des répondeurs au traitement par exénatide ou liraglutide : résultats de deux études en vie réelle","L. Groza","2018","Médecine des Maladies Métaboliques","other","article","10.1016/s1957-2557(18)30010-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052453","iGlarLixi vs. Basal- plus kurzwirksames Insulin bei Erwachsenen mit Typ-2-Diabetes, die von einer Basalinsulin-Therapie intensiviert werden: Die SoliSimplify-Praxisstudie","Rory J. McCrimmon","2023","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0043-1768002",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052454","Role of Tirzepatide in Obesity Management Among Women with Polycystic Ovary Syndrome","Jannatul Ferdous","2025","International Journal of Diabetes and Endocrinology","nonrandomized_study","article","10.11648/j.ijde.20251002.12",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052455","Mechanism of Action and Metabolic Effects of Exenatide in Obesity","Stefania Camastra","2013","CINECA IRIS Institutial research information system (University of Pisa)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052456","FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease","Vlado Perkovic","2022","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfac126.002",null,null,"ClinicalTrials.gov:NCT03819153","S000953","openalex","FALSE","paywalled","1","FALSE","article"],["R0052457","P5349Absence of QTc prolongation with semaglutide: a thorough QT/QTc study in healthy subjects","V. Demmel","2017","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehx493.p5349",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052458","CO234 The Association of Glucagon-Like Peptide-1 Receptor Agonists With Hepatopancreatobiliary Diseases in Individuals With Type 2 Diabetes Mellitus","Christian Billinghurst","2025","Value in Health","other","article","10.1016/j.jval.2025.09.335",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052459","Generalizable Electrochemical Biosensors Using DNA-Analyte Conjugates Integrated with Pneumatic Oscillators for Microfluidic Workflow Automation","Ajay B. Urgunde","2023","ECS Meeting Abstracts","other","article","10.1149/ma2023-01442390mtgabs",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052460","MP45-11 SEMAGLUTIDE UTILIZATION IN WEIGHT MANAGEMENT AND ITS IMPLICATIONS FOR URINARY TRACT INFECTIONS AND UROLITHIASIS","Anantha Soogoor","2024","The Journal of Urology","nonrandomized_study","article","10.1097/01.ju.0001008764.86460.8e.11",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052461","One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP-1RA","Ming Zhang","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112571",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052462","Abstract TP285: Ongoing Clinical Trial: Treatment With Exenatide in Acute Ischaemic Stroke (TEXAIS) Trial: Prospective, Randomised, Open Label, Blinded End-point Study of Exenatide vs. Standard Care in Post Stroke Hyperglycaemia","Christopher Bladin","2019","Stroke","randomized_trial","article","10.1161/str.50.suppl_1.tp285",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052463","49 Glucagon-like peptide-1 protects against cardiac remodelling after myocardial infarction via specific actions on the extracellular matrix","Emma S. J. Robinson","2011","Heart","preclinical","article","10.1136/heartjnl-2011-300920b.49",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052464","THU-299 A 4-week mouse model allows the rapid evaluation of resmetirom and tirzepatide benefits on metabolic dysfunction-associated steatohepatitis","François Briand","2024","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(24)01751-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052465","S2696 Glucagon-Like Peptide-1 Receptor Agonists Impact on Metabolic Dysfunction-Associated Liver Disease: A Retrospective Study","Amani K. Elshaer","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001138244.18055.5d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052466","Drug-specific Effects of GLP-1 Receptor Agonists on Dementia Risk: A Network Meta-analysis (P3-13.008)","Arkansh Sharma","2026","Neurology","systematic_review","article","10.1212/wnl.0000000000216715",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0052467","GLP-1 drugs like Ozempic show promise for more than weight loss. But what’s science vs hype?","Paul Joyce","2026",null,"other","article","10.64628/aa.y3rgpa3qr",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0052468","S28 Semaglutide added to anticoagulation in acute intermediate-risk pulmonary embolism is safe and downregulates immunometabolic glycoproteins","Chinthaka Bhagya Samaranayake","2024",null,"other_trial","article","10.1136/thorax-2024-btsabstracts.34",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0052469","Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","Rosane Ness-Abramof","2010","Yearbook of Endocrinology","randomized_trial","article","10.1016/s0084-3741(10)79555-x",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052470","Type 1 diabetes and fasting during Ramzan","Rakesh Kumar Sahay","2016","Journal of Social Health and Diabetes","other","article","10.4103/2321-0656.176571",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052471","EE115 Clinical and Economic Impact of Glucagon-like Peptide-1 Agonists in Patients with Obstructive Sleep Apnea: An Exploratory Analysis","Alexander Moreno-Calderón","2024","Value in Health","other","article","10.1016/j.jval.2024.03.414",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052472","1861-LB: Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Obese Adults—A Phase 2 Trial","Lin Zhao","2024","Diabetes","randomized_trial","article","10.2337/db24-1861-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052473","P3. Unveiling Weight Loss Trends and Complications in Body Contouring Surgery Among Glucagon Like Peptide Analogs Users: An Eight Year Experience","Alejandra Aristizábal","2025","Plastic & Reconstructive Surgery Global Open","nonrandomized_study","article","10.1097/01.gox.0001114204.22719.c4",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052474","Late Breaking Abstract - Liraglutide attenuates sepsis-induced endothelial dysfunction and Acute Lung Injury","Julie A. Bastarache","2023",null,"preclinical","article","10.1183/13993003.congress-2023.pa5233",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052475","1348-P: Trends and Independent Correlates of Cardioprotective Antihyperglycemic Agent Use in U.S. Adults with Cardiovascular-Kidney-Metabolic Syndrome","Mukoso N. Ozieh","2024","Diabetes","other","article","10.2337/db24-1348-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052476","Le liraglutide diminue les évènements cardiovasculaires majeurs chez les diabétiques de type 2 avec maladie rénale chronique : une analyse de l’étude LEADER","Michel Marre","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052477","Abstract 4346928: Recurrent Triple Vessel Spontaneous Coronary Artery Dissection following GLP-1 Receptor Agonist Use","Jacqueline T. Vuong","2025","Circulation","other","article","10.1161/circ.152.suppl_3.4346928",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052478","GLP-1 Receptor Agonist Use in Kidney Transplant Recipients","Corey Joseph","2025","Kidney News","other","article","10.62716/kn.001072025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052479","Clinical and economic evaluation of exenatide for formulary decisions","Fadia Tohme Shaya","2007","Journal of Medical Economics","other","article","10.3111/13696990701748415",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052480","Unmasking Type – 1 Diabetes Mellitus Following an Episode of Euglycemic Diabetic Ketoacidosis with SGLT-2 Inhibitor Use: A Case Report","Simant Kumar Jha","2020",null,"case_report","article","10.9734/ajrre/2020/v3i111",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052481","1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes—Soli De-escalation","Francesco Giorgino","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1867-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052482","Abstract 4145759: Guideline Directed Medical Therapy and the Impact of Sex on Patient Reported and Clinical Outcomes in a Specialized Heart Failure Clinic","Chen-Hsiang Ma","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4145759",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052483","Clinical Analysis of Resemblance and Dissimilarities of Glucagon-like Peptide-1 Receptor Agonists: Therapeutic Approach Towards the Management of Diabetes Mellitus","Sashi","2024","Current Drug Therapy","other","article","10.2174/0115748855276929231218053337",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052484","Exenatide einmal wöchentlich: Anhaltende Blutzuckerkontrolle und Gewichtsreduktion über einen Behandlungszeitraum von 2 Jahren","T Kim","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1253758",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052485","An Investigation of Insulinotropic Potential of Herbal Plants for Management of Diabetes","Yousef Ahmed Saleh Haimed","2022","Journal of Pharmaceutical Research International","preclinical","article","10.9734/jpri/2022/v34i44a36329",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052486","The protective effect of exenatide on islet INS-1 cells exposed to intermittent high glucose environment","Jing Li","2011","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052487","Cutting Calories or Cutting Corners? How Anti-Obesity Medication Use Sparks Effort-Based Sanctions and Social Penalties","Leopold Helmut Otto Roth","2025",null,"other","article","10.31219/osf.io/w3em8_v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0052488","Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","other","article","10.1002/doi2.70000",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052489","Efficient expression of glucagon-like peptide-1 analogue with human serum albumin fusion protein in Pichia pastoris using the glyceraldehyde-3-phosphate dehydrogenase promoter","Kai Guo Qian","2015","Biotechnology and Bioprocess Engineering","other","article","10.1007/s12257-014-0818-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052490","Relationship between exendin-4 and neurodegenerative diseases","Jun Feng Guo","2010","Zhongguo yaolixue tongbao","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052491","Combination Therapy to Target Reperfusion Injury After ST-Segment–Elevation Myocardial Infarction","Derek John Hausenloy","2017","Circulation","randomized_trial","article","10.1161/circulationaha.117.029859","28874421",null,"ClinicalTrials.gov:NCT01398384",null,"openalex","FALSE","paywalled","2","FALSE","editorial"],["R0052492","5.48 GLP-1 Agonists and Suicidality in Pediatric Patients","Muhammad Nouman","2025","Journal of the American Academy of Child & Adolescent Psychiatry","other","article","10.1016/j.jaac.2025.08.433",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052493","26-A-11357-ACC OUTCOMES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS VERSUS SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AND THEIR COMBINATION AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION","Adham Ramadan","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.056",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052494","333-OR: Genetic Variants Associated with Weight Change in Response to Glucose-Lowering Medications—Results from the GRADE Study","Łukasz Szczerbiński","2025","Diabetes","nonrandomized_study","article","10.2337/db25-333-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052495","197. Psychiatric Outcomes in Patients Treated With GLP-1 Receptor Agonists: A Retrospective Cohort Study","Anthony J. Maristany","2025","Journal of the Academy of Consultation-Liaison Psychiatry","nonrandomized_study","article","10.1016/j.jaclp.2025.10.199",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052496","Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis","Muhammad Hafizh Husain","2022","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehac544.1939",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052497","Synthesis of Danuglipron: Development of a Scalable Alkylation and Chemoselective Hydrolysis Sequence","Ijaz Ahmed","2026","Organic Process Research & Development","other","article","10.1021/acs.oprd.6c00144",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052498","PL-2 : What can we learn from cardiovascular outcome trials in diabetes","Vivian Andrew Fonseca","2019",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","dissertation"],["R0052499","Effect of the Glucagon-like Peptide-1 Mimetic on Ion- and Osmoregulating Renal Functions in Normoglycemia and Hyperglycemia","Анна Вячеславовна Кутина","2019","Human Physiology","preclinical","article","10.1134/s036211971904008x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052500","207-OR: Myostatin Inhibition Synergizes with GLP-1R Agonism to Accelerate Weight Loss in Male, Obese Nonhuman Primates","Jason W. Mastaitis","2023","Diabetes","preclinical","article","10.2337/db23-207-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052501","292-OR: Oral Semaglutide and Cardiovascular Outcomes by Baseline A1C and BMI in People with Type 2 Diabetes in the SOUL Trial","SILVIO E. INZUCCHI","2025","Diabetes","randomized_trial","article","10.2337/db25-292-or",null,null,"ClinicalTrials.gov:NCT03914326","S002179","openalex","FALSE","paywalled","1","FALSE","article"],["R0052502","Su2060: INVESTIGATING THE ASSOCIATION BETWEEN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THE RISK OF BOWEL OBSTRUCTION AND ILEUS: A LARGE POPULATION-BASED MATCHED COHORT STUDY","Tarek Odah","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03112-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052503","SA6 Changes in HbA1c and Body Weight in US Adults With Type 2 Diabetes and Chronic Kidney Disease Who Received Oral Semaglutide","James J. Amamoo","2025","Value in Health","other","article","10.1016/j.jval.2025.04.1762",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052504","Sa1957 EFFECTS OF SUBCUTANEOUS SEMAGLUTIDE AND TIRZEPITIDE INJECTIONS ON BODY WEIGHT: A COMPARISON OF RECENTLY VS CHRONICALLY OBESE POPULATIONS","Vahagn Aldzhyan","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01834-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052505","Endogenous oxyntomodulin in metabolic homeostasis and clinical utility as a prognostic biomarker: a systematic review","Mateusz Zwierz","2026","BMC Medicine","systematic_review","article","10.1186/s12916-026-05184-1",null,null,"PROSPERO:CRD420261308863",null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0052506","Wegovy: a new treatment for obesity","Monica Cheung Katz","2025",null,"other","article","10.47196/0602",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0052507","801-P: TRIM—Teen Obesity and GLP-1 Receptor Agonists—Insights from a Systematic Review, Meta-analysis, and Drug-Wise Network Meta-analysis","Muhammad Aaqib Shamim","2024","Diabetes","systematic_review","article","10.2337/db24-801-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0052508","1414 Tirzepatide Treatment of Obesity Hypoventilation Syndrome","Patrick Holman","2025","SLEEP","other_trial","article","10.1093/sleep/zsaf090.1414",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0052509","Diabetes through transitions in life; from fit to frail","William David Strain","2021","Endocrinology and Disorders","other","article","10.31579/2640-1045/064",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052510","5 THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENDIN-4 INHIBITS VLDL BIOSYNTHESIS AND SECRETION IN APOE*3-LEIDEN MICE","Ye Wang","2011","Atherosclerosis Supplements","preclinical","article","10.1016/s1567-5688(11)70006-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052511","Niedrigere Hypoglykämie-Raten mit Insulin glargin 300 E/ml vs. Insulin degludec 100 E/ml bei insulinnaiven erwachsenen Typ-2-Diabetespatienten: die randomisierte BRIGHT-Studie","GB Bolli","2019","Diabetologie und Stoffwechsel","other","article","10.1055/s-0039-1688241",null,null,"ClinicalTrials.gov:NCT02738151","S002664","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0052512","Continuous glucose monitoring - proved hypoglycemia in sodium-glucose co-transporter-2 inhibitors - treated type 2 diabetes patients: a link to ketosis development","Shmuel Levit","2019","Pharmacy Formulas","nonrandomized_study","article","10.17816/phf18536",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052513","PDB69 EXENATIDE (BID) AND LIRAGLUTIDE (QD) TREATMENT PATTERNS AMONG TYPE-2 DIABETES PATIENTS IN GERMANY","Lindsay Miller","2011","Value in Health","other","article","10.1016/j.jval.2011.02.577",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052514","Dermatologic Consequences of Ozempic-Induced Weight Loss: A Review of Facial Aging, Aesthetic Implications, and Treatment","Rehet Chugh","2026","Dermato","narrative_review","article","10.3390/dermato6030029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052515","Abstract 003: Contextual- And Personal-level Social Determinants Of Health And Real-world Adoption Of Novel Treatments For Improving Cardiovascular Outcomes In Type 2 Diabetes","Jingchuan Serena Guo","2022","Circulation","nonrandomized_study","article","10.1161/circ.145.suppl_1.003",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052516","A36-20 The Hidden Weight of Severe Asthma: Linking Metabolic Disease to Poor Control and New Solutions","R Gul","2026","American Journal of Respiratory and Critical Care Medicine","randomized_trial","article","10.1093/ajrccm/aamag162.345",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052517","SAT-142 Semaglutide improves metabolic and histological outcomes and reverses clinically relevant biomarker alterations in the GAN dietinduced obese and biopsy-confirmed mouse model of MASH","Henrik H. Hansen","2026","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(26)01802-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052518","Sa2003: THE IMPACT OF GLP-1 RECEPTOR AGONISTS AND ENDOBARIATRIC THERAPIES ON MUSCLE MASS IN OBESE PATIENTS: A PILOT CASECONTROL STUDY","Vismaya S. Bachu","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02365-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052519","P2522The combined treatment with glucagon like peptide-1 analogues and sodium-glucose co-transporter 2 causes a greater improvement of arterial stiffness than each treatment alone in type 2 diabetes","Ignatios Ikonomidis","2018","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehy565.p2522",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052520","Adhärenz unter GLP-1RA-Therapie in Deutschland: einmal wöchentliches Depot-Exenatide vs. einmal tägliches Liraglutid","Qing Qiao","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580785",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052521","Switching from liraglutide to dulaglutide, is it worth it?: Outcomes at 24 weeks follow-up","Manuel Cayón-Blanco","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep322",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052522","Un carcinome médullaire de la thyroïde chez une patiente diabétique traitée par liraglutide : à propos d’un cas","R. Hannachi","2017","Annales d Endocrinologie","other","article","10.1016/j.ando.2017.07.578",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052523","GLP1 Receptor Agonist Induced Guttate Psoriasis in an Adult Female","Savannah Cook","2025","SKIN The Journal of Cutaneous Medicine","other","article","10.25251/skin.9.3.9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052524","S415 Impact of GLP1RA on Immune-Related Colitis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Analysis","Nisar A. Amin","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001129120.29209.0c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052525","Association of SGLT2 Inhibitors and DPP-4 Inhibitors vs. GLP-1 Agonists with Incident CKD in US Veterans","Kamyar Kalantar‐Zadeh","2021","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20213210s1697d",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052526","a novel adaptive dose-finding study to develop LY2189265, a once-weekly GLP-1 analog","Margarethe Geiger","2009","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(09)33268-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052527","Novel Approaches to the Treatment of Type 2 Diabetes","Erin St. Onge","2009","Journal of Pharmacy Practice","other","article","10.1177/0897190008326578",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052528","Editorial: Diabetes and cardiovascular disease: new therapeutic interventions","Maria Consiglia Trotta","2024","Frontiers in Pharmacology","randomized_trial","article","10.3389/fphar.2024.1472636","39188950",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0052529","Ozempic is in the spotlight but it’s just the latest in a long and strange history of weight-loss drugs","Laura L. Dawes","2023",null,"other","article","10.64628/aa.4dcfpvujj",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0052530","S867 Evaluation of Bowel Preparation Regimens for Colonoscopy in Patients Receiving GLP-1 Receptor Agonists","Akash Patel","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032836.56300.18",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052531","Effect of injection site on relative bioavailability of exenatide (synthetic exendin-4)","Federico B. Calara","2004","Clinical Pharmacology & Therapeutics","randomized_trial","article","10.1016/j.clpt.2003.11.221",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052532","P050 Impact of weight-loss interventions on psoriasis severity: a systematic review and meta-analysis","Sarah Morrow","2025","British Journal of Dermatology","systematic_review","article","10.1093/bjd/ljaf085.078",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0052533","6926 Subgroup Analysis by Gender and Body Mass Index (BMI) in People Living With Overweight/Obesity in the Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, Phase II Trial","Carel Wynand le Roux","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.033",null,null,"ClinicalTrials.gov:NCT04667377","S002375","openalex","TRUE","open_pdf","1","FALSE","article"],["R0052534","Tirzepatide as a Novel Therapeutic Option for Patients with Type 2 Diabetes: A Pooled Analysis of SURPASS 1-5 trials","Mohammed Altigani Abdalla","2022","SSRN Electronic Journal","other","article","10.2139/ssrn.4247793",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0052535","NON-PROTEINURIC KIDNEY DISEASE AND TYPE II DIABETES: CKM (CARDIO KIDNEY METABOLIC) PARAMETERS AND CURRENT RECOMMENDED TREATMENT MODALITIES","Aisha Siddiqah Ahmed","2025","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0001117004.86638.b8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052536","Adjunctive Lixisenatide Treatment Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus Irrespective of β-cell Function","Jean‐François Yale","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.138",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052537","The Cardiologist’s Role in the Management of Type 2 Diabetes—A Review","Carrie Eshelbrenner","2012","US Cardiology Review","other_trial","article","10.15420/usc.2012.9.1.26",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0052538","Multivariate analyses to develop a novel drug delivery system: Trying to expanding the system to bio-sensing of the human serum albumin","Rezvan Izadi","2022","Sensing and Bio-Sensing Research","other","article","10.1016/j.sbsr.2022.100489",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052539","Stratified medicine for blood pressure targets in type 2 diabetes mellitus","Beatriz Fernández‐Fernández","2025","Nephrology Dialysis Transplantation","other_trial","article","10.1093/ndt/gfaf007","39805717",null,"ClinicalTrials.gov:NCT00000620; ClinicalTrials.gov:NCT03808311",null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052540","Case 39: Simplifying Insulin Therapy: Transitioning from Basal-Bolus Insulin Therapy to Basal Insulin With a Glucagon-Like Peptide-1 Receptor Analog (GLP-1RA)","Sevil Aliyeva","2021","American Diabetes Association eBooks","other","article","10.2337/9781580407663.39",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0052541","COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS VERSUS GLP1 AGONISTS ON PREVENTING POST-TRAUMATIC OSTEOARTHRITIS","S. Reza Jafarzadeh","2024","Osteoarthritis and Cartilage","other","article","10.1016/j.joca.2024.02.880",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052542","Direct comparison of the effects of liraglutide and dulaglutide on the dynamics of scales and markers of hepatic fibrosis","M. V. Martianova","2021","Экспериментальная и клиническая гастроэнтерология","randomized_trial","article","10.31146/1682-8658-ecg-194-10-82-90",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052543","Glucagon-like Peptide-1 Receptor Agonists Are Not Associated With Increased Incidence of Pneumonia After Endoscopic Procedures","Natalia Tejada","2025","Techniques and Innovations in Gastrointestinal Endoscopy","other","article","10.1016/j.tige.2025.250925",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052544","Healthcare Resource Utilisation Associated with Patients Treated with Either Exenatide Once Weekly or Basal Insulin: A Retrospective UK Database Analysis","Qing Qiao","2016","Value in Health","nonrandomized_study","article","10.1016/j.jval.2016.09.1864",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052545","P328 Analyse de l’efficacité du liraglutide à la dose de 1,2 mg vs 1,8 mg à l’issue des 2 ans du suivi de l’étude observationnelle EVIDENCE®","Pierre Gourdy","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30441-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052546","Clozapine: a fine balance","Dan J. Siskind","2020","Acta Psychiatrica Scandinavica","other_trial","article","10.1111/acps.13159","32096227",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052547","Real-world metabolic outcomes of semaglutide use in patients with type 2 diabetes: a retrospective study from a single centre in the United Arab Emirates","Matthew Allum","2021","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.77.p70",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052548","Adhérence et persistance observées plus élevées chez des patients avec un diabète de type 2 traités avec dulaglutide, par comparaison à l’exénatide en une prise hebdomadaire, ou au liraglutide","Laura Fernández Landó","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30416-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052549","Effect of Tirzepatide Versus Insulin Degludec on Liver Fat Content and Abdominal Adipose Tissue in Patients with Type 2 Diabetes (SURPASS-3 MRI)","Amalia Gastaldelli","2023","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0043-1767866",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052550","813-P: Successful Use of Hybrid Closed Loop Insulin Pumps with GLP1 Agonists in Diabulimia and Disordered Eating in Type 1 Diabetes","Navya Basavaraju","2024","Diabetes","other","article","10.2337/db24-813-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052551","Abstract 4370759: Bariatric Surgery vs. GLP/GIP Agonists: A Real-World Comparative Analysis of Cardiovascular Outcomes in Over 2 Million Patients.","Oluwamisimi Mary Abib","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4370759",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052552","294-OR: Tirzepatide Prevents Palmitate-Induced Apoptosis, Autophagy, and Senescence in Human Cardiac Progenitor Cells","CARMELA COLABUFO","2025","Diabetes","other","article","10.2337/db25-294-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052553","#5826 NEPHROPROTECTIVE EFFECTS OF SEMAGLUTIDE IN A MOUSE MODEL OF HYPERTENSION-ACCELERATED DIABETIC KIDNEY DISEASE","Michael Søberg Christensen","2023","Nephrology Dialysis Transplantation","preclinical","article","10.1093/ndt/gfad063c_5826",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052554","Ethnicity and risks of severe COVID ‐19 outcomes associated with glucose‐lowering medications: A cohort study","Francesco Zaccardi","2022","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.14872","36099041",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052555","323 Retatrutide vs. single and dual agonists: charting new territory in obesity and T2DM treatment","Eman Ali Toraih","2025","The American Journal of the Medical Sciences","other","article","10.1016/s0002-9629(25)00329-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052556","Weight Loss Drug Therapies: Current Evidence and Prospects for Use in Metabolic Clinics in Nigeria","Samson Aderemi Ojedokun","2025","Journal of Disease and Global Health","nonrandomized_study","article","10.56557/jodagh/2025/v18i29636",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052557","Obesity-prone rats are less sensitive to the satiating effects of exendin-4 than obesity-resistant rats","Stefany DePrato Primeaux","2008","Appetite","preclinical","article","10.1016/j.appet.2008.04.190",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052558","THE GLUCAGON-LIKE PEPTIDE-1 ANALOGUE EXENATIDE REDUCES AMYLOID-INDUCED BETA-CELL TOXICITY IN CULTURED HUMAN ISLETS","H. Chen","2010","Transplantation","other","article","10.1097/00007890-201007272-00597",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052559","Liraglutide Leads to Increased Weight Loss Response in Patients Without Diabetes","Robert E. Buckley","2015","MD Conference Express","other_trial","article","10.1177/1559897715583449",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0052560","Exendin-4 protects cholangiocytes from apoptosis, both in vitro and in vivo","Marco Marzioni","2008","Digestive and Liver Disease","preclinical","article","10.1016/j.dld.2007.12.065",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052561","325-OR: ß-Arrestin 1 Regulates Glucagon-Like Peptide-1 Receptor Mediated Insulin Secretion in a Ligand-Dependent Manner","Jonathan D. Douros","2020","Diabetes","preclinical","article","10.2337/db20-325-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052562","PDB68 A RETROSPECTIVE ANALYSIS OF MEDICATION USE, RESOURCE UTILIZATION, AND CLINICAL EFFECTIVENESS OF EXENATIDE COMPARED TO GLARGINE IN PATIENTS WITH TYPE 2 DIABETES","MD Pawaskar","2009","Value in Health","nonrandomized_study","article","10.1016/s1098-3015(10)75046-4",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0052563","Real-world weight change pattern after glucagon-like peptide-1 receptor agonist discontinuation: A 1-year observational study","Mona Abdel‐Bary","2025","Obesity Medicine","nonrandomized_study","article","10.1016/j.obmed.2025.100658",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052564","SAFETY OF ENDOSCOPIC PROCEDURES IN PATIENTS ON GLP-1 RECEPTOR AGONISTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Ahmad Alhomaid","2025","Gastrointestinal Endoscopy","systematic_review","article","10.1016/j.gie.2025.03.267",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0052565","Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss","Wolfgang Ekkehard Schmidt","2009","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052566","Comparison of the effects of liraglutide and sibutramine in obese patients","Georgy A. Matveev","2021","Obesity and metabolism","other","article","10.14341/omet12498",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052567","Su2049: GLP-1 AGONISTS USE IS ASSOCIATED WITH LOWER ALL-CAUSE HOSPITALIZATION AND DIVERTICULITIS IN PATIENTS WITH DIVERTICULAR DISEASE AND OBESITY WHEN COMPARED WITH GASTRIC BYPASS: A NATIONAL DATABASE ANALYSIS","Luìs Manuel de Almieda Nieto","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03101-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052568","Investigating the Effects of Semaglutide in Early Alzheimer’s Disease Using Single-cell Transcriptomics and Proteomics – Rationale and Design (P12-3.017)","Paul Mystkowski","2025","Neurology","protocol","article","10.1212/wnl.0000000000211162",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052569","Clinical effects of the GLP-1 receptor agonist exenatide in patients with type 2 diabetes","Mathijs C. M. Bunck","2011","Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0052570","LBSUN319 Characteristics And Treatment Patterns Of Hispanic/latino Patients Initiating First Injectable Glp-1ra Or Basal Insulin","Meredith M. Hoog","2022","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvac150.607",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0052571","Comparison of the activity of the novel dipeptidylpeptidase IV-resistant GLP-1 receptor antagonist (Lys9)GLP-1 with GLP-1(9-36)amide and exendin-4(9-39)","Finbarr P.M. O'Harte","2003",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052572","Sa1340: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND PEPTIC ULCER DISEASE RISK IN PATIENTS WITH TYPE 2 DIABETES","Philippa Seika","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)01962-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052573","Cardiometabolic Management—Success of Online CME at Expanding Diabetes Management Past Glycemic Control","Amy T. Larkin","2018","Diabetes","other_trial","article","10.2337/db18-1217-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052574","Tu1750: EXAMINING THE ASSOCIATION BETWEEN GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND DEVELOPMENT OF COLORECTAL CANCER: INSIGHTS FROM A GLOBAL DATABASE","Kaynat Khalid","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)04279-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052575","AB058. SOH26AB_0430. Peri-endoscopic management of GLP-1 receptor agonists: early audit of adherence and gastric findings during oesophagogastroduodenoscopy in a model-4 centre","Amy Doherty","2026","Mesentery and Peritoneum","other","article","10.21037/map-26-ab058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052576","Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult patients","Maneesh Udiawar","2012","Clinical Medicine Insights Therapeutics","other","article","10.4137/cmt.s7283",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052577","Evaluating the effects of the novel GLP-1 analogue liraglutide in patients with Alzheimer's disease (ELAD Study)","Grazia Daniela Femminella","2019","Bristol Research (University of Bristol)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052578","S2351 GLP-1 RA Use in Patients with T2DM is Associated with Lower Risk of Gastric Cancer: A National Analysis","Mark Ayoub","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001038772.01977.23",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052579","Die Auswirkung der initialen Insulin-Glargin Dosis auf das Ansprechen auf zusätzlich gegebenes Exenatide (2-mal täglich) oder Bolusinsulin: Subgruppenanalyse der 4B Studie","Bruce H. R. Wolffenbuttel","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580958",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052580","Abstract 4365838: Survodutide for the Treatment of Obesity: Baseline characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial","Elke Platz","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4365838",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052581","Klinische Studien zu Exenatide 1 × wöchentlich - Ein neuer, einmal wöchentlicher GLP-1-Rezeptoragonist zur Verbesserung der Therapie des Typ-2-Diabetes","Baptist Gallwitz","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1262710",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052582","Systematic search for peptide and protein ligands of human serum albumin capable of affecting its interaction with amyloid β peptide","Eugene V. Loktyushov","2022","Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук","nonrandomized_study","article","10.29413/abs.2022-7.5-1.3",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052583","The effects and side effects of liraglutide as a treatment for obesity","Jeonghoon Ha","2022","Cardiovascular Prevention and Pharmacotherapy","other","article","10.36011/cpp.2022.4.e18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052584","THE ROLE OF OXIDATIVE STRESS IN CHRONIC KIDNEY DISEASE (CKD)","Ara Aboolian","2025",null,"other","article","10.1002/9781119790419.ch17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0052585","P279 - Liraglutide réduit plus efficacement l’HbA1c que la Sitagliptine quel que soit le niveau d’HbA1c initial","J.-P. Courrege","2011","Diabetes & Metabolism","other","article","10.1016/s1262-3636(11)70905-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052586","ITCA 650 Provides Consistent Efficacy in T2D Irrespective of Baseline Characteristics—Results of a Pooled Subgroup Analysis","Prakash Prabhakar","2018","Diabetes","randomized_trial","article","10.2337/db18-1061-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052587","IDF21-0018 Patient Reported Outcomes for Tirzepatide versus Semaglutide in Participants with T2D from the SURPASS-2 Trial","K. Boye","2022","Diabetes Research and Clinical Practice","other_trial","article","10.1016/j.diabres.2022.109697",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052588","869-P: Reductions in Traditional Risk Factors Explain Most of the Cardiovascular Benefit of SGLT2 Inhibitors and GLP-1 Receptor Agonists: An Analysis Using the BRAVO Risk Engine","SHU NIU","2022","Diabetes","other","article","10.2337/db22-869-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052589","An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging","MICHAEL R. LEONE","2024","Medical Research Archives","other","article","10.18103/mra.v12i2.5138",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052590","BH10 Nailing the diagnosis","Lisa D. Murphy","2025","British Journal of Dermatology","other","article","10.1093/bjd/ljaf085.231",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052591","858-P: Online Clinician and Aligned Patient Education Improves Both Clinicians’ and Patients’ Ability to Manage T2D with GLP-1 RAs","Amy T. Larkin","2021","Diabetes","other","article","10.2337/db21-858-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052592","The effect of semaglutide on liver enzymes in subjects with obesity and elevated alanine aminotransferase: Data from a randomised Phase 2 trial","Philip Noel Newsome","2018","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(18)31421-1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052593","Effect of Type 2 Diabetes Characteristics on Semaglutide Treatment in People with Type 2 Diabetes and Peripheral Artery Disease – A Post Hoc Analysis of the STRIDE Trial","S Jacob","2026","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0046-1819978",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0052594","Obesity association with antidiabetic drugs’ prescription among patients with type 2 diabetes mellitus: a systematic review and meta-analysis","Feras A. Mahmoud","2022","International Journal of Pharmacy Practice","systematic_review","article","10.1093/ijpp/riac021.016",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0052595","Minimizing the Risk of Misprescribing GLP-1 RA Medications in a Digital Weight-Loss Service: Preliminary Retrospective Study (Preprint)","Louis A Talay","2024",null,"nonrandomized_study","article","10.2196/preprints.57169",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0052596","1431-P: Risk of Venous Thromboembolism amongst Initiators of SGLT2 Inhibitors Compared with Other Glucose-Lowering Agents","Chandrasekar Gopalakrishnan","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1431-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052597","The glucagon‐like peptide‐1 receptor antagonist exendin‐9 elevates blood pressure and worsens renal function in SHR (1136.18)","Gabriela Cozin Aragão","2014","The FASEB Journal","preclinical","article","10.1096/fasebj.28.1_supplement.1136.18",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052598","Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction ( HFpEF ) and obesity","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","other","article","10.1002/doi2.70008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052599","Su1239: EVALUATING OUTPATIENT COLONOSCOPY OUTCOMES AND BOWEL PREPARATION IN PATIENTS TAKING GLP-1 RECEPTOR AGONISTS AFTER IMPLEMENTATION OF ONE DOSING CYCLE HOLD PROTOCOL: A QUALITY IMPROVEMENT STUDY","Ruiyi Gao","2025","Gastroenterology","protocol","article","10.1016/s0016-5085(25)02599-5",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0052600","Abstract #302 Evidence to Experience for the Improved Glycemic Control with Onceweekly Dulaglutide Evaluated by Continuous Glucose Monitoring- Case Report","Alok Modi","2019","Endocrine Practice","case_report","article","10.1016/s1530-891x(20)46646-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052601","Shift in Body Mass Index Category and Associated Cardiometabolic Risk Factors: A Post Hoc Analysis from the SURMOUNT-4 Trial","Naveed A. Sattar","2025","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0045-1807556",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0052602","Glp-1 Receptor Agonists Are Associated With Reduced Risk of MACE and Mortality After Lower Extremity Revascularization in Patients With Diabetes","Ashwin K. Chetty","2026","Journal of Vascular Surgery","other","article","10.1016/j.jvs.2025.12.077",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052603","Semaglutide (S) Completely Reverses the Severe Chronic Myopathy of Hyperkalemic Periodic Paralysis","Kenneth Brand","2024","Journal of the American Society of Nephrology","other","article","10.1681/asn.2024qqwahgn4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052604","TCT-775 Clinical Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist on Cardiovascular and Limb Outcomes in Patients with Type 2 Diabetes and Peripheral Artery Disease: Findings from the TriNetX Database","Vikash Jaiswal","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2025.09.945",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052605","S764 Effectiveness of Early vs Delayed GLP-1 Receptor Agonist Initiation Following Bariatric Procedures: A Meta-Analysis of Randomized Controlled Trials","Daniel A. Guifarro","2025","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001130516.83820.d3",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0052606","Glucagon-like peptide-1 receptor agonist eligibility for weight management in 99 countries","Seul Ki Yoo","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112708",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052607","SAT-350-YH25724, a novel long-acting GLP-1/FGF21 dual agonist, exhibits marked anti-fibrotic effects in different experimental models of liver fibrosis","Dohoon Kim","2019","Journal of Hepatology","other","article","10.1016/s0618-8278(19)31580-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052608","The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials","D.L. Bhatt","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/wedy-fx52",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052609","1031-P: Impact of the Cardioprotective Effects of GLP-1 Agonists in the Management of Diabetes","Shayan Sinha Mahapatra","2019","Diabetes","nonrandomized_study","article","10.2337/db19-1031-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052610","Subcutaneous exendin-4 improves 24 hour glucose exposure in type 2 diabetes","H.A. Abdel Maksoud","2000","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(00)81601-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052611","Anti-Diabetic Medications: A promising therapeutic approaches for the Management of NAFLD","Ahmed Z. Ibrahim","2021","Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences","other","article","10.21608/rpbs.2021.79353.1103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052612","Comparative study of 18F-FBEM-Cys39-exendin-4 versus 18F-FBEM-Cys40-exendin-4 in insulinoma imaging","Min Yang","2014","Journal of Nuclear Medicine","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052613","1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States","Odette S. Reifsnider","2020","Diabetes","other_trial","article","10.2337/db20-1158-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052614","Efeito farmacológico da Tizerpatida sobre o emagrecimento e seus efeitos adversos: Uma revisão sistemática","Pedro Raposeiro da Silva","2024","E-Acadêmica","other","article","10.52076/eacad-v5i3.564",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052615","Mo1048: RACIAL DISPARITIES IN GLP-1 RECEPTOR AGONIST UTILIZATION IN PATIENTS WITH OBESITY: A U.S. COHORT STUDY","Mohamad-Noor Abu-Hammour","2025","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(25)03209-3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052616","Disparities in GLP-1 receptor agonist prescriptions among breast cancer survivors with type 2 diabetes.","Jasmin Hundal","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.e13831",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052617","Liraglutide pancreatitis: The ABCD nationwide liraglutide audit","REJ Ryder","2013","The British Journal of Diabetes","nonrandomized_study","article","10.1177/1474651413502685",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052618","Incretin mimetics examined at ADA 2008","Mitchell A. Cheeseman","2008","Inpharma Weekly","other","article","10.2165/00128413-200816440-00004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052619","23 gennaio 2022: 100 anni fa il miracolo della terapia insulinica che continua oggi","Geremia B. Bolli","2022","il Diabete","other","article","10.30682/ildia2201a",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052620","Recent Advances in Dietary and Drug Treatment of Obesity: Review Paper","Sulaiman Essa","2025","Libyan Journal of Medical Research","narrative_review","article","10.54361/ljmr.19.2.13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052621","Treatment Effects of Once-Weekly Dulaglutide vs. Insulin Glargine in Patients with Different Baseline Glycemic Patterns (Based on High/Low Fasting or High/Low Postprandial Glucose)—A Post-Hoc Analysis of the AWARD-2 Clinical Trial","Francesco Giorgino","2018","Diabetes","other_trial","article","10.2337/db18-1007-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052622","Glucagon‐like peptide 1 receptor activation acutely increases systolic blood pressure independent of aldosterone‐mediated sodium retention (1088.8)","Meagan Moreno","2014","The FASEB Journal","preclinical","article","10.1096/fasebj.28.1_supplement.1088.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052623","Endoscopy after Bariatric Surgery Case Series","Evelyn E Inga","2025","Journal of Gastroenterology & Hepatology Reports","case_report","article","10.47363/jghr/icge2025/2025(6)5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052624","Associations of Demographic and Clinical Comorbidities with Different PREVENT Risk Categories","L. Parker Gregg","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.202517k02rk8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052625","Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurology’s Stroke Study Group","Blanca Fuentes","2021","Neurología (English Edition)","randomized_trial","article","10.1016/j.nrleng.2020.04.022",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052626","Semaglutide: a game changer for metabolic diseases?","Agostino Milluzzo","2022","Exploration of Medicine","other","article","10.37349/emed.2022.00083",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052627","GLP-1 secretagogues potential of medicinal plants in management of diabetes","Rambir Singh","2015","Journal of Pharmacognosy and Phytochemistry","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052628","The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug","I.A. Lugovik","2025","Drug development & registration","other","article","10.33380/2305-2066-2025-14-2-2084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052629","S2094 Assessing Online Chat-Based Artificial Intelligence Models for Weight Loss Recommendation Appropriateness and Bias in the Presence of Guideline Incongruence","Eugene Annor","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001037744.39620.b5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052630","Real-world clinical and service outcomes of pre-bariatric weight loss interventions and post-bariatric outcomes among patients with insulin-treated Type 2 Diabetes living in the UK: public Health and epidemiological approach","Mohammed A. Alkharaiji","2020","Nottingham ePrints (University of Nottingham)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0052631","Initiation and shift of antidiabetic therapy and pancreatic cancer.","Philippe Autier","2017","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2017.35.15_suppl.4126",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052632","S1318 Semaglutide Is Effective in Achieving Weight Loss in Liver Transplant Recipients","Kenneth W. Chow","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000954912.01880.7c",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052633","Real world outcomes comparing the use of GLP-1 agonists in patients with bladder cancer and comorbid obesity: A propensity score matched analysis from the Global Federated Health Research Network.","Arshi Syal","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.7_suppl.712",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0052634","Species-Dependent Mechanisms Regulating Glucose-Dependent GLP-1 Secretion?","Patricia Lee Brubaker","2017","Diabetes","preclinical","article","10.2337/dbi17-0020","28733306",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052635","GLP-1 agonists and the kidney (revision number 10)","Edwin A M Gale","2013","Diapedia.org eBooks","other","article","10.14496/dia.8104778119.10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0052636","GLP-1 Receptor Agonists in Nonalcoholic Fatty Pancreas Disease: Evidence, Mechanisms, and Future Directions","Ahmed A. Abdelmoaty","2026","Clinical review for general practice","randomized_trial","article","10.47407/kr2026.7.4.00822",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052637","Predictors and Outcomes of Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in CKD","L. Parker Gregg","2023","Journal of the American Society of Nephrology","other","article","10.1681/asn.20233411s1857b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052638","Glucagon-Like Peptide-1 Agonists in Total Hip Arthroplasty: Complications, Readmissions, and Patient-Reported Outcomes","Robert James Magaldi","2024","JAAOS Global Research and Reviews","nonrandomized_study","article","10.5435/jaaosglobal-d-24-00148",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052639","Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014","Wanjun Guo","2022","Journal of Hepatology","other","article","10.1016/s0168-8278(22)01771-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052640","GS-006 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial","Arun J. Sanyal","2024","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(24)00430-6",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052641","Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes","Francesco Zaccardi","2020","Diabetes Care","systematic_review","article","10.2337/dc20-2080","33334809",null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0052642","Lower Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM on Oral Antihyperglycemic Therapy ± GLP-1RA—The BRIGHT Randomized Study","Geremia B. Bolli","2018","Diabetes","randomized_trial","article","10.2337/db18-1032-p",null,null,"ClinicalTrials.gov:NCT02738151","S002664","openalex","FALSE","paywalled","1","FALSE","article"],["R0052643","Adjunctive Therapy, Including Pharmacotherapy","Dalal Y. Al-Bazz","2022",null,"other","article","10.1002/9781119695257.ch21",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0052644","S3216 Ozempic-Induced Pancreatitis Leading to Recurrent Flares, Evolving Pseudocysts, and Superinfection: A Multidisciplinary Management Challenge","Deepak Kumar","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001140324.52799.c0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052645","O32 Le liraglutide, associé à un sulfamide (SU), permet un meilleur contrôle glycémique comparativement au traitement associant une glitazone à un SU chez le DT2","Michel Marre","2009","Diabetes & Metabolism","other","article","10.1016/s1262-3636(09)71724-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052646","Plant-Derived Phytochemicals as Natural GLP-1 Receptor Agonists: A Review of Evidence and Potential for Veterinary Applications","Mohamed Hussein","2025","Advances in Animal and Veterinary Sciences","narrative_review","article","10.17582/journal.aavs/2025/13.s1.56.69",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052647","Abstract 4362202: Combined associations of GLP-1 medications and healthy lifestyle with cardiovascular outcomes among individuals with diabetes: The Million Veteran Program","Xuan‐Mai T. Nguyen","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4362202",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052648","Fixed-Ratio Combination of Insulin Degludec and Liraglutide Improves Glycemic Control in Type 2 Diabetes","Wayne Kuznar","2013","MD Conference Express","randomized_trial","article","10.1177/155989771317015",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0052649","LEADER-4: Blutdruckkontrolle bei Patienten mit Typ 2 Diabetes mellitus und hohem kardiovaskulären Risiko: Baseline-Daten aus der LEADER Studie","Sylvia Jacob","2016","Diabetologie und Stoffwechsel","other","article","10.1055/s-0036-1580781",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","FALSE","paywalled","5","FALSE","article"],["R0052650","FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors","Sima Fansa","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.087",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052651","Patrones de prescripción de medicamentos para la diabetes mellitus tipo 2 en cinco departamentos de Colombia, en 2014","Organización para la Excelencia de la Salud","2018","Revista Facultad Nacional de Salud Pública","other","article","10.17533/udea.rfnsp.v36n2a08",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052652","Probiotic traits of lactic acid bacteria isolated from aerial surfaces of pomegranate","Milind H. Gajbhiye","2016","International Journal of Bioassays","other","article","10.21746/ijbio.2016.08.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052653","TCT-1003 Clinical Effectiveness of Glucagon-like peptide-1 receptor agonists on Cardiovascular outcomes Post-PCI in Type 2 Diabetes patients: Findings from the TriNetX Database","Vikash Jaiswal","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2025.09.1198",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052654","756-P: Bromocriptine-QR (BQR) Ameliorates Immunocyte Pro-Oxidative Stress/Proinflammatory (POS/PI) and ER Stress Phenotype in T2DM Subjects","Michael Ezrokhi","2021","Diabetes","other","article","10.2337/db21-756-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052655","Response to the Letter by Napoli N., et al.","Iepsen EW","2015","The Journal of clinical endocrinology and metabolism","commentary","article","10.1210/jc.2015-3142","26439159",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Letter; Comment; article"],["R0052656","Efficacy and safety of once daily liraglutideversus twice daily exenatidein type 2diabetic patients in Qatar: an observational study","Rana Moustafa Al Adawi","2018",null,"nonrandomized_study","article","10.5339/qfarc.2018.hbpd251",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0052657","Repurposing Existing Drugs For Dual Treatment of Alzheimer'S Disease and Type 2 Diabetes Mellitus: A Network Pharmacology Approach","ASKAROV Ibragim Rakhmanovich","2026","International Journal of Drug Delivery Technology","randomized_trial","article","10.25258/ijddt.16.44s.15",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052658","Le liraglutide en monothérapie apporte un meilleur contrôle de la glycémie post-prandiale (GPP) après les trois repas quotidiens en comparaison à un sulfamide hypoglycémiant en monothérapie","Adil Bouzidi","2014","Annales d Endocrinologie","other","article","10.1016/j.ando.2014.07.144",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052659","Cardiac tamponade and hypertension","Jessie A. Brown","1993","Biomedicine & Pharmacotherapy","preclinical","article","10.1016/0753-3322(93)90319-g",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052660","PSUN241 A Case of Dulaglutide-Induced Acute Pancreatitis in a Diabetic Patient – A Case Report","Randa Abdelmasih","2022","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvac150.808",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052661","Incretin-based therapy for cardiovascular and cardiorenal risk reduction: a systematic review and meta-analysis of GLP-1 receptor agonist and dual incretin randomized trials","Utsab Panta","2026","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0052662","Genetic GLP1R Gene Expression and Kidney Disease Progression: A Mechanistic Proteome-Wide Analysis in the Million Veteran Program","Jefferson L. Triozzi","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024z4j5t87e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052663","Optimizing Perioperative Carbohydrate Loading in Enhanced Recovery After Surgery Patients on GLP-1 (Glucagon Like Peptide 1) Agonists: A Proposal for Practice Update","Javier D. Lasala","2025","Clinical Nutrition ESPEN","other","article","10.1016/j.clnesp.2024.10.058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052664","Renal Cell Type-Associated Therapeutic Effects of Semaglutide in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","Stine Thorhauge Bak","2023","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.20233411s1846b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052665","Polyneuropathy Temporally Associated with Tirzepatide Use in Patients with Pre-Existing Risk Factors: Two Cases","Hira Shakeel","2026","SVOA Neurology","other","article","10.58624/svoane.2026.07.025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052666","704 MACHINE-LEARNING DRIVEN, FULL PHENOTYPE MODEL AND SURROGATE POLYGENIC RISK SCORE MODEL FOR APPETITE PREDICT RESPONSE TO GLP-1 RECEPTOR AGONIST IN PATIENTS WITH OBESITY","Lizeth Cifuentes","2023","Gastroenterology","other","article","10.1016/s0016-5085(23)01311-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052667","Efficacy of Oral Semaglutide in Non-Diabetic Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Insights from an Indian Single-Center Cohort.","Pankaj Vinod Jariwala","2025","Indian Heart Journal","nonrandomized_study","article","10.1016/j.ihj.2025.11.080",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052668","Anti-diabetic Agents and the Potentials for Reducing Cardiovascular Risks in Type-2 Diabetes Mellitus","IU Ezeani","2021","Annals of Health Research (The Journal of the Medical and Dental Consultants Association of Nigeria OOUTH Sagamu Nigeria)","other","article","10.30442/ahr.0703-02-131",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052669","Einfluss von Exenatide auf die Pharmakokinetik einer Statin-Einzeldosis und die Lipidwerte nach 30 Wochen","ME Trautmann","2006","Diabetologie und Stoffwechsel","other","article","10.1055/s-2006-944167",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052670","S1455 Real World Weight Loss Outcomes of Semaglutide in Patients With Overweight and Obesity After Bariatric Surgery","Wissam Ghusn","2022","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0000862460.34172.fc",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052671","A-84 | Cardiovascular Outcomes of GLP-1 And Dual GLP-1/GIP Agonists In Patients With Elevated Lipoprotein(A)","Ewuradjoa Ayirebi-Acquah","2026","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2026.104575",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052672","23. Insulin Degludec/Liraglutide (IDegLira) Is Superior to Insulin Glargine (IG) in A1c Reduction, Risk of Hypoglycemia, and Weight Change: DUAL V Study (166-OR)","John B. Buse","2015","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-015-0044-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052673","Efficacy and safety of liraglutide 3.0 mg in adult overweight and obese weight loss responders without diabetes: results of the randomised, double-blind, placebo-controlled 56-week SCALE Obesity and Prediabetes trial","Patrick J. O’Neil","2015","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0035-1556574",null,null,"ClinicalTrials.gov:NCT01272219","S000492","openalex","FALSE","paywalled","1","FALSE","article"],["R0052674","0175 Semaglutide use for decreasing psoriasis vulgaris resource utilization: A retrospective cohort study utilizing trinetx","MARGARET A. HILL","2025","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2025.06.179",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052675","6851 Rapidly Increasing Use of Anti-Obesity Medications among Veterans in the Veterans Health Administration (VA)","Varsha G. Vimalananda","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.024",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052676","ARTIFICIAL INTELLIGENCE ANALYSIS OF SOCIAL MEDIA POSTS ON GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA)","Aamir Javaid","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)04673-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052677","846-P: Risk of Anaphylaxis among New Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)","Mary S. Anthony","2023","Diabetes","nonrandomized_study","article","10.2337/db23-846-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052678","Abstract PS2-02-24: Comparative Effects of Semaglutide vs Tirzepatide on Weight Change and Cardiovascular Risk in Breast Cancer Survivors","J. Hundal","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-ps2-02-24",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052679","Insulin-releasing and glucose homeostatic effects of a low molecular weight GLP-1 receptor agonist.","Nigel Irwin","2009","Research Portal (Queen's University Belfast)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0052680","484-P: Newer Glucose-Lowering Drugs and Risk of Parkinson’s Disease—A Meta-analysis of Randomized Outcome Trials","HUILIN TANG","2023","Diabetes","systematic_review","article","10.2337/db23-484-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0052681","Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO","Mikhail Borisovich Antsiferov","2022","Diabetes Mellitus","randomized_trial","article","10.14341/dm12809",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052682","Sa1959 NO INCREASED RISK OF DE-NOVO ACUTE PANCREATITIS IN NONDIABETIC WITH OBESITY PATIENTS ON GLP-1 RECEPTOR AGONISTS FOR WEIGHT LOSS: A MULTI-NETWORK STUDY","Adily Elmi","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01836-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052683","Metabolische Effekte einer Kombination von Dapagliflozin und wöchentlichem Exenatide bei adipösen Erwachsenen ohne Diabetes: 24-wöchige, randomisierte, placebokontrollierte Phase-2-Studie","Per Lundkvist","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0037-1601677",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052684","Evaluation of use of combination dapagliflozin and GLP1 agonist treatment in type 2 diabetes","Jennifer Hayden","2015","Endocrine Abstracts","other","article","10.1530/endoabs.38.p93",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052685","33-OR: The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk","Helen Tesfaye","2024","Diabetes","nonrandomized_study","article","10.2337/db24-33-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052686","PDB6 Cost-Effectiveness of Liraglutide Versus Insulin Glargine, BOTH in Combination with Metformin for Patients with Type 2 Diabetes in China","Hongchao Li","2020","Value in Health Regional Issues","other","article","10.1016/j.vhri.2020.07.165",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052687","Effects of Liraglutide on Carotid Intima-Media Thickness in Patients with Type-2 Diabetes and Non-Alcoholic Fatty Liver Disease: An 8-Month Prospective Pilot Study","Giuseppe Montalto","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052688","Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment","Peter R Rossing","2021","American Heart Journal","other","article","10.1016/j.ahj.2021.10.038",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052689","Le semaglutide entraîne une réduction de l’appétit et de l’apport énergétique à l’origine d’une perte de poids chez les sujets obèses","Bertrand Cariou","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30424-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052690","Exenatide for type 2 diabetes – Authors' reply","Larry Zaiqian Shen","2009","The Lancet","commentary","article","10.1016/s0140-6736(09)60035-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","letter"],["R0052691","Medication use and treatment patterns of glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes mellitus","Stephen S. Johnston","2014","Value in Health","other","article","10.1016/j.jval.2014.03.1522",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052692","Abstract 4141929: Genetic Evidence for GIP as a Therapeutic Target for Peripheral Artery Disease","Sabina M. Sorondo","2024","Circulation","randomized_trial","article","10.1161/circ.150.suppl_1.4141929",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052693","1086-P: Disparities in GLP-1RA Prescription for Primary Prevention of ASCVD in Patients with T2D","Archana Sadhu","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1086-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052694","Use of GLP-1 receptor agonists (GLP1A) and/or SGLT-2 inhibitors (SGLT2I) in populations with NASH or at risk of NASH in US clinical practice","Michelle Lai","2020","Journal of Hepatology","other","article","10.1016/s0168-8278(20)31385-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052695","Early Weight Loss Responders to Liraglutide 3.0 mg had Greater Weight Loss, Regression to Normoglycemia and Reduced T2D Development at 3 Years vs. Early Non-Responders: SCALE Obesity and Prediabetes","David C.W. Lau","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.097",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052696","P3‐225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON‐DIABETIC ALZHEIMER'S PATIENTS","Grazia Daniela Femminella","2018","Alzheimer s & Dementia","other_trial","article","10.1016/j.jalz.2018.06.1584",null,null,"ClinicalTrials.gov:NCT01843075","S000689","openalex","FALSE","paywalled","5","FALSE","article"],["R0052697","The Role of Peptides in Pain Management","William Schultze","2026","Pain Medicine","other","article","10.1093/pm/pnag001","41520152",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052698","Abstract 4144387: The Prognostic Role of Glucagon-like Peptide-1 Receptor Agonist in Transthyretin Amyloid Cardiomyopathy","Kuan Yu Chi","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4144387",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052699","Cardiovascular-Kidney-Metabolic healthcare framework: Perspective from Hong Kong","Chiho Lee","2025","Chinese Medical Journal","nonrandomized_study","article","10.1097/cm9.0000000000003748","40757400",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","editorial"],["R0052700","Development of a Clinical Trial Protocol for the Use of a Dual GIP/GLP-1 Receptor Agonist in Patients with Heart Failure with Preserved Ejection Fraction","Diana Samatkyzy","2025","Eurasian journal of applied biotechnology","protocol","article","10.11134/btp.3s.2025.13",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052701","1111-P: The Qualitative and Quantitative Effect of IDegLira Compared with the Nonfixed Administration of Degludec and Liraglutide","Anastasios Koutsovasilis","2019","Diabetes","other_trial","article","10.2337/db19-1111-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052702","GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD)","Laura Pagès","2025","Current Hepatology Reports","other","article","10.1007/s11901-025-00692-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052703","Weight reduction course boosts impact of GLP-1 agonist","H. v. Lilienfeld-Toal","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785371",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052704","Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the Cranioexe randomized placebo-controlled trial","Blandine Gatta‐Cherifi","2023","Endocrine Abstracts","randomized_trial","article","10.1530/endoabs.90.p369",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052705","Estimated Glomerular Filtration Rate Slope, Chronic Kidney Disease Progression, and Pillars of Care in Patients With Diabetic Kidney Disease","Pamela R. Kushner","2026","Diabetes Obesity and Cardiometabolic CARE","other","article","10.2337/doc25-0017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052706","Use of the dual GLP-1/GIP coagonist, tirzepatide, in patients with advanced metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: real-world data","R. B. Halley","2026","Frontline Gastroenterology","nonrandomized_study","article","10.1136/flgastro-2026-103661",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052707","Sa1949 BARIATRIC SURGERY VERSUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A COMPARISON OF CARDIOVASCULAR OUTCOMES","Soban A. Maan","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01826-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052708","S1399 Safety and Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists for Obesity in Patients With Inflammatory Bowel Disease","Lindsay M. Clarke","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001034964.71202.42",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052709","The Once-Daily Human GLP-1 Analog Liraglutide Reduces the Prevalence of Prediabetes and Improves Systolic Blood Pressure in Obese Non-Diabetic Subjects: A 52-Week, Randomized Placebo-Controlled Trial","Nick Finer","2009",null,"randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0052710","Pleiotrope Effekte einer Therapie mit Liraglutide in Kombination mit Metformin auf die endotheliale Funktion der Retina","Thomas M. Forst","2011","Diabetologie und Stoffwechsel","other","article","10.1055/s-0031-1277482",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052711","Exenatide initiation in type 2 diabetes: do more people discontinue treatment after individual rather than group starts?","JM Ng","2009","Practical Diabetes","nonrandomized_study","article","10.1002/pdi.1333",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052712","Exenatide Extended-Release Injection","Dennis J. Cada","2012","Hospital Pharmacy","other_trial","article","10.1310/hpj4708-633",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052713","Cardiovascular protection in type 2 diabetes: time to ADVANCE management ACCORDing to the evidence","Rayaz Ahmed Malik","2013","Research Reports in Clinical Cardiology","other","article","10.2147/rrcc.s34415",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052714","SAT-065 Comparison of Long-Acting and Short-Acting GLP-1 Receptor Agonists on Copeptin in Euvolemic Participants - A Secondary Analysis of Three Prospective Trials","Svenja Leibnitz","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.1547",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052715","TCT-498 Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT2 Inhibitors on Cardiovascular Outcomes in Patients with Diabetes Undergoing Percutaneous Coronary Intervention","Ahmed A. Mahmoud","2025","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2025.09.628",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052716","Sa1900: TIRZEPATIDE AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IMPROVE CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH TYPE 2 DIABETES COMPARED TO INSULIN","Himaben Gohil","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)02262-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052717","606-P: Higher Derived Time-in-Range with IDegLira vs. Insulin Glargine U100 in Patients with T2D","Athena Philis‐Tsimikas","2021","Diabetes","randomized_trial","article","10.2337/db21-606-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052718","2842-LB: Risk of Pulmonary Aspiration with Glucagon-Like Peptide 1 Receptor Agonists in Mild-to-Moderate Sedation","Brian Hyung","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2842-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052719","GLP-1 Analogues and Insulin Combination","Vishal Anand Gupta","2013","Jaypee Brothers Medical Publishers (P) Ltd. eBooks","other","article","10.5005/jp/books/11892_7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0052720","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS ARE UNDERUTILIZED IN THE POST-ACS POPULATION: REAL-WORLD RESULTS FROM A LARGE INTEGRATED HEALTHCARE SYSTEM","Timothy C. Shuey","2024","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(24)03873-7",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052721","Incretin‐Based Therapy for the Management of Type 2 Diabetes","Kristin Gonzales","2021",null,"randomized_trial","article","10.1002/9781119603207.ch12",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","other"],["R0052722","784-P: Once-Weekly Semaglutide in Patients with Peripheral Arterial Disease and Type 2 Diabetes—Comorbidities and Concomitant Medications from the STRIDE Trial","Neda Rasouli","2024","Diabetes","randomized_trial","article","10.2337/db24-784-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052723","26-A-13176-ACC IMPACT OF GLP-1 RECEPTOR AGONISTS ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND TYPE-2 DIABETES MELLITUS: A PROPENSITY-MATCHED RETROSPECTIVE COHORT STUDY","Muhammad Hanif","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.676",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052724","Semaglutide enhances vascular relaxation to insulin in Western diet-fed female mice","Augustine Udefa","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2301426",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052725","Abstract 4366419: GLP-1 Receptor Agonist Semaglutide Improves Hepatic Metabolism and Reverses Hepatic Steatosis Independent of Weight Loss in Cardiometabolic HFpEF","Natalie Gehred","2025","Circulation","preclinical","article","10.1161/circ.152.suppl_3.4366419",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052726","Prevalence of, and effect of semaglutide on, features of non-alcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests","Jörn Markus Schattenberg","2023","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(23)02269-9",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052727","Editorial: Pharmacotherapy of energy metabolism in obesity","John Reyes Ussher","2025","Journal of Pharmacy & Pharmaceutical Sciences","preclinical","article","10.3389/jpps.2025.14099","40130087",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0052728","Abstract 15797: Cardiovascular Outcomes of Bariatric Surgery and Anti-Obesity Medications in Patients With New Onset Heart Failure and Obesity","Amgad G. Mentias","2022","Circulation","nonrandomized_study","article","10.1161/circ.146.suppl_1.15797",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052729","773-P: Trends in Obesity Drug Initiation after the Approval of Tirzepatide in Adults without Type 2 Diabetes","Julie M. Paik","2024","Diabetes","nonrandomized_study","article","10.2337/db24-773-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052730","(197) Peptides in Practice: Evaluating Efficacy and Safety in Men’s Health","Rohan Shad Arora","2025","The Journal of Sexual Medicine","randomized_trial","article","10.1093/jsxmed/qdaf320.196",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052731","PP.LB02.26","Elamin Abdelgadir","2015","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0000468591.08447.07",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052732","SUSTAIN 1: Efficacy and Safety of Once-Weekly Semaglutide Monotherapy vs. Placebo in Subjects with Type 2 Diabetes","CHRISTOPHER H. SORLI","2016","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2016.08.017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052733","Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base","Ilya N. Dyakov","2021","Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice","other","article","10.37489/2588-0519-2021-2-4-15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052734","Clinical characteristics and outcomes in patients with type 2 diabetes adding insulin glargine to exenatide or exenatide to insulin glargine in a US managed care setting","PHILIP A. LEVIN","2011","F1000Research","randomized_trial","article","10.7490/f1000research.1089301.1",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052735","Liraglutide improves metabolic profile, glycaemic dysregulation, quality-of-life and eating behaviours in adolescents with severe obesity","Louise Jayne Apperley","2023","Endocrine Abstracts","other","article","10.1530/endoabs.95.oc5.8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052736","LIRA-PRIME Trial Design and Baseline Data—Efficacy in Controlling Glycemia with Liraglutide in a Primary Care Setting","Jeff Unger","2018","Diabetes","randomized_trial","article","10.2337/db18-1082-p",null,null,"ClinicalTrials.gov:NCT02730377","S000508","openalex","FALSE","paywalled","1","FALSE","article"],["R0052737","The association between the utilization of SGLT2 inhibitors and diabetic retinopathy; a systematic review and meta-analysis of cohort studies","Shahriar Barkhordari","2024","Journal of Nephropharmacology","systematic_review","article","10.34172/npj.2024.12688",null,null,"PROSPERO:CRD42024523959",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0052738","Histological, Immunohistochemical, and Biochemical Study of the Effect of Semaglutide on the Cardiac Muscle of Obese and Non-Obese Albino Rat: The Role of Adiponectin, Tumor Necrosis Factor Alpha (TNF-α), and Caspase-3","Samah Kandeel","2026","The Egyptian Journal of Histology","preclinical","article","10.21608/ejh.2026.501877.2477",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052739","1685-P: Ectopic Hepatic GLP-1R Agonism Enhances the Weight Loss Efficacy of GLP-1 Analogues","Jonathan D. Douros","2025","Diabetes","preclinical","article","10.2337/db25-1685-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052740","Étude DUAL IV : IDegLira chez les patients diabétiques de type 2 naïfs d’insuline insuffisamment contrôlés sous sulfonylurées seules ou associées à la metformine","Pierre Sérusclat","2016","Annales d Endocrinologie","other","article","10.1016/j.ando.2016.07.779",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052741","Aspects of the safety of hypoglycemic drugs according to the results of clinical trials","А. Л. Хохлов","2023","Patient-Oriented Medicine and Pharmacy","other","article","10.37489/2949-1924-0016",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052742","88-OR: Long-Acting Amylin Analog AZD6234 in Combination with the GLP-1R Agonist Semaglutide Enhances Body Weight and Fat Mass Loss in Diet-Induced Obese (DIO) Rats","Gisela Geoghegan","2025","Diabetes","preclinical","article","10.2337/db25-88-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052743","Efficacy of oral semaglutide according to diabetes duration: An exploratory subgroup analysis of the PIONEER trial programme","Michelle E. Hauser","2021","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0041-1727309",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0052744","IDegLira : efficacité sur l’HbA1c, perte de poids et moins d’hypoglycémies versus basal-bolus - une analyse de DUAL VII","Pierre Sérusclat","2018","Annales d Endocrinologie","other","article","10.1016/j.ando.2018.06.254",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052745","Tu1752 Effect of Satiety Hormone Analog, Exenatide, on Resting State Brain Activity","Kristen Coveleskie","2013","Gastroenterology","other","article","10.1016/s0016-5085(13)63115-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052746","The Rise in Glucagon-Like Peptide-1 Receptor Agonist Related Calls to United States Poison Centers","Raymond E Farah","2024","European Journal of Public Health","nonrandomized_study","article","10.1093/eurpub/ckae144.1330",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052747","17-PUB: Glucagon-Like Peptide 1 Receptor Agonists' Heterogeneous Treatment Effects on Asthma Exacerbations—A Causal Machine-Learning Analysis","Tiansheng Wang","2024","Diabetes","nonrandomized_study","article","10.2337/db24-17-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052748","750-P: Association of Glucagon-Like Peptide 1 Receptor Agonists with Incident Parkinson’s Disease in U.S. Older Adults with Type 2 Diabetes","HUILIN TANG","2024","Diabetes","nonrandomized_study","article","10.2337/db24-750-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052749","Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies","Jean‐François Yale","2022","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0042-1746335",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052750","Semaglutide-inducing Non-arteritic Anterior Ischemic Optic Neuropathy and Ipsilateral Blindness -A Rare Presentation","Boran Mao","2025","Journal of Clinical Cardiology","nonrandomized_study","article","10.33696/cardiology.6.068",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052751","Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1","Jenny Tong","2014","Diabetes","other","article","10.2337/db13-1764","24464721",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052752","Exenatide Reduces Body Weight but Not Hyperandrogenemia in Overweight Women with Polycystic Ovary Syndrome","Alison J. Dawson","2011",null,"other","article","10.1210/endo-meetings.2011.part2.p32.p2-242",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0052753","Underrepresentation of Women in Recent Landmark Kidney Trials: The Gender Gap Prevails","Amanda Jean Vinson","2022","Kidney International Reports","randomized_trial","article","10.1016/j.ekir.2022.08.022","36531883",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052754","Is curcumin the new kid on the block for the treatment of MASH?","Shira Zelber‐Sagi","2024","Hepatology","randomized_trial","article","10.1097/hep.0000000000000949","38937942",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052755","Evaluating the Safety of Glucagon Like Peptide-1 Agonist Use in Nondiabetic Overweight Patients Undergoing Shoulder Arthroplasty","Amelia Hummel","2026","Journal of Shoulder and Elbow Arthroplasty","nonrandomized_study","article","10.1016/j.jsea.2026.100088",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052756","RWD76 POTENTIAL RISK OF ACUTE PANCREATITIS WITH GLP-1 RECEPTOR AGONISTS","Hadir Aljohani","2025","Value in Health Regional Issues","randomized_trial","article","10.1016/j.vhri.2025.101306",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0052757","Efficacy and safety of various hypoglycemic treatment regimens in individuals with irritable bowel syndrome in combination with type 2 diabetes mellitus","O. E. SUPRUN","2024","Practical medicine","other","article","10.32000/2072-1757-2024-1-38-46",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052758","Liraglutide Combined With Insulin or Oral Agents Leads to Both Improved Glycemic Control and Weight Loss in Type 2 Subjects with Diabetic Nephropathy","Joline Vretenar","2012","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2012.07.284",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052759","Switching from Sitagliptin to Liraglutide in Subjects with Type 2 Diabetes (T2D): Analysis of Composite Endpoints from the LIRA-SWITCH Randomized Trial","Damir Boras","2016","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2016.08.112",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052760","Platelet reactivity in patients with type 2 diabetes mellitus after treatment intensification with DPP-4i, SGLT-2i and GLP-1RA","Gerasimos Siasos","2019","Endocrine Abstracts","other","article","10.1530/endoabs.63.p602",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052761","Impact de l’IMC sur la réduction de l’HbA 1c sous IDegLira chez des diabétiques de type 2 insuffisamment contrôlés sous sulfamides, agonistes des récepteurs au GLP-1 ou insuline Glargine U100 : analyses d’études de phase IIIb","Bertrand Cariou","2017","Diabetes & Metabolism","other","article","10.1016/s1262-3636(17)30437-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052762","Igg4-Related Disorder and Endocrine Diseases: A Review of the Literature","Alaaeldin M. Bashier","2015","Journal of Diabetes & Metabolism","narrative_review","article","10.4172/2155-6156.1000631",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052763","1098-P: A Longitudinal Look at SGLT-2i/GLP-1RA Prescription Records in Evaluation of a Primary Care Quality Improvement Education Initiative","Vinni Makin","2024","Diabetes","other","article","10.2337/db24-1098-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052764","High‐fat feeding leads to decreased responsiveness to the GLP‐1 analogue, exendin‐4, in obesity‐prone (OP) rats","Frank Anthony Duca","2012","The FASEB Journal","preclinical","article","10.1096/fasebj.26.1_supplement.639.14",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052765","OP0035 Incidence of Autoimmune Rheumatic Diseases Following Treatment with Glucagon-Like Peptide-1 Receptor Agonists or Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Study","Derin Karacabeyli","2025","Annals of the Rheumatic Diseases","nonrandomized_study","article","10.1016/j.ard.2025.05.059",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0052766","P2858Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial","Subodh Verma","2018","European Heart Journal","other_trial","article","10.1093/eurheartj/ehy565.p2858",null,null,"ClinicalTrials.gov:NCT01179048","S001496","openalex","TRUE","open_pdf","5","FALSE","article"],["R0052767","PD13-08 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ASSOCIATED WITH REDUCED METASTATIC SPREAD AND MORTALITY IN DIABETIC PATIENTS WITH PROSTATE CANCER","Sohan S Shah","2025","The Journal of Urology","other","article","10.1097/01.ju.0001109880.25183.6b.08",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052768","1035-P: CGM Access in Primary Care—Feasibility Analysis of the First Six Months of an Urban Safety-Net Clinic Pilot Program","JESSICA TANENBAUM","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1035-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052769","Wegovy was inspired by Gila monster venom – here are some other drugs with surprising origins","Craig A. Russell","2023",null,"other","article","10.64628/ab.fdvevmujv",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0052770","Is Co-administration of Intranasal Insulin and GLP1 agonists as targeting drugs for prophylaxis and treatment of post-covid-19 smell and taste dysfunctions and brain fog","Amr Kamel Khalil Ahmed","2022",null,"other","article","10.31219/osf.io/7ybh3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0052771","Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity","John B. Buse","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/001p-8x98",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052772","0567 Tirzepatide for the Treatment of OSA: Rationale and Design of the SURMOUNT-OSA Phase 3 Trial","Atul Malhotra","2023","SLEEP","protocol","article","10.1093/sleep/zsad077.0567",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052773","Prädiktoren für das Erreichen von HbA1c-Zielen bei Patienten mit Typ-2-Diabetes unter Therapie mit Exenatide bzw. Insulin","CHRISTOF M. KAZDA","2008","Diabetologie und Stoffwechsel","other","article","10.1055/s-2008-1076471",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052774","Could favorable effects of liraglutide on steato-hepatitis be independent of weight loss in type 2 diabetes? A case report","Cyril Garcia","2014","Endocrine Abstracts","case_report","article","10.1530/endoabs.35.p476",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052775","73838 GLP-1RA Use Not Associated with Increased Incidence of Skin Cancer Relative to Healthy or Metformin Controls","Jack Woll","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.955",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052776","12442 Effectiveness Of An Electronic Decision Support Algorithm To Optimize Recommendation Of SGLT2i And GLP-1RA In Patients With Type 2 Diabetes Upon Discharge From Internal Medicine Wards","ERIC A. JAFFE","2024","Journal of the Endocrine Society","other","article","10.1210/jendso/bvae163.745",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052777","The Complement-1q-Like-3 Inhibits Insulin Secretion by an Adhesion G-Protein Coupled Receptor, BAI3 in Pancreatic ß Cells","Rajesh C. Gupta","2018","Diabetes","preclinical","article","10.2337/db18-2159-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052778","737-P: Targeted Maximum Likelihood Estimation (TMLE) to Estimate the Effect of Liraglutide on Cardiovascular (CV) Outcomes in Race/Ethnicity Subgroups: Post Hoc Analysis of LEADER","David Chen","2022","Diabetes","other","article","10.2337/db22-737-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052779","Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230))","Bernard Zinman","2010","Diabetes Care","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052780","59 - Greater Reductions in HbA1c and Body Weight With Once-Weekly Semaglutide Vs Comparators Across Baseline BMI Subgroups: Posthoc Analysis of SUSTAIN 1–5 and 7–10","Sara G. Stafford","2020","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2020.08.065",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052781","PEDIATRIC MORBID OBESITY AND HEART FAILURE: ROLE FOR GLP-1R AGONISTS?","Carmel Bogle","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)05127-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052782","91 - Efficacy and Safety of Semaglutide in Elderly Subjects with Type 2 Diabetes: Posthoc Analysis of SUSTAIN 7","Sara G. Stafford","2019","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2019.07.100",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052783","Do GLP-1 receptor agonists have a place in the treatment of people with type 1 diabetes?","Thomas Fremming Dejgaard","2024","Medical Research Archives","randomized_trial","article","10.18103/mra.v12i12.6110",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052784","Differences between randomized clinical trial patients and real-world initiators of liraglutide","Jakob Schöllhammer Knudsen","2018","University of Southern Denmark Research Portal (University of Southern Denmark)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0052785","Management of post prandial hypoglycaemia using liraglutide - comprehensive profiling pre and post intervention","Aminul Islam Ahmed","2017","Spiral (Imperial College London)","other","article","10.1002/bjs.10494",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0052786","The use of liraglutide, a GLP-1 agonist, in obese people with type 1 diabetes","Syed M.R. Gillani","2014","The British Journal of Diabetes","other","article","10.15277/bjdvd.2014.022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052787","Evaluating the therapeutic potential of GLP-1 Agonists in Neurodegenerative Disorders (S25.006)","Nabeela Siddeeque","2025","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000208642",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052788","NAVIGATING HYPERTRIGLYCERIDEMIA MANAGEMENT WITH GLP-1 AGONISTS IN THE SETTING OF PANCREATITIS","Ritika Gadodia","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)03379-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052789","PDB7 Cost-Effectiveness Analysis of Once-Weekly Semaglutide As the Second-LINE Treatment for Type 2 Diabetes Mellitus Patients","Ming‐Chin Yang","2020","Value in Health Regional Issues","other","article","10.1016/j.vhri.2020.07.166",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052790","#1981 Experience with the use of semaglutide in cardiorenal syndrome patients followed in a cardiorenal unit (CRU)","Maria De San Miguel Marques Vidas","2024","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfae069.648",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052791","7463 Assessing Glycemic Excursions in Patients with Type 2 Diabetes Mellitus Receiving Epidural Steroid Injections","Jamia Saunders","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.671",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052792","Patients with Type 2 Diabetes Treated with Insulin Degludec/Liraglutide Have a Greater Chance of Reaching Glycemic Targets Without Hypoglycemia and Weight Gain Than with Insulin Glargine","Ildiko Lingvay","2018","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2018.08.145",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052793","Insulin resistance and incident heart failure: a meta‐analysis","Sebhat A. Erqou","2022","European Journal of Heart Failure","nonrandomized_study","article","10.1002/ejhf.2531","35502564",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052794","S522 African American Patients Taking GLP-1RA are More Likely to Have Poor Bowel Prep: A Single Center Study","Noor Hassan","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001031456.34444.a9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052795","815-P: CGM-Derived Model-Based Postprandial Glucose with IcoSema vs. Other Insulin Regimens—A Post Hoc Analysis of COMBINE 1 and 3","Christophe E.M. De Block","2025","Diabetes","other","article","10.2337/db25-815-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052796","S235 GLP1-RA-Based Medications in Patients With Obesity and Chronic Pancreatitis Are Associated With Decreased Cardiac Events Without Increased Risk of Pancreatic Cancer","Shaina Ailawadi","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001127400.60446.ac",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052797","Semaglutide Provides Superior Body Weight Reduction Across Sustain 1–5 Clinical Trials","Emanuela Mello Ribeiro Cavalari","2018","International Journal of Nutrology","other","article","10.1055/s-0038-1675018",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0052798","Options thérapeutiques chez un patient diabétique de type 2 mal contrôlé par une insuline basale","André Jacques Scheen","2017","Revue Médicale Suisse","other","article","10.53738/revmed.2017.13.571.1416",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052799","GLYCEMIC AND NON-GLYCEMIC EFFECTS OF EXENATIDE IN PATIENTS WITH DIABETES MELLITUS OF TYPE 2 (DM2) WITH MYOCARDIAL INFARCTION","Alina Yu. Babenko","2016","Meditsinskiy sovet = Medical Council","other","article","10.21518/2079-701x-2016-9-116-122",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052800","489-P: Facilitating Collaboration through TeleECHO Education in Diabetes","RUSSIE ALLEN","2021","Diabetes","other","article","10.2337/db21-489-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052801","Antophagy inhibition can decrease AR42J cell apoptosis induced by exendin-4","Weidong Zhu","2018","Zhonghua gan-dan waike zazhi","other","article","10.3760/cma.j.issn.1007-8118.2018.12.013",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052802","Beyond Glycemic Control: Exploring the Prospective of Exendin-4 Clinical Utility as a Disease-Modifying Agent in Alzheimer's Disease; Preclinical and Clinical Evidence","Ahmed El-Sayed Hassan","2026","Journal of Pioneering Medical Science","other","article","10.47310/jpms2026150307",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052803","Untersuchung der Betazell-Sensitivität im IVGTT bei Patienten mit Typ-2-Diabetes: Pilotstudie zum Einsatz von Exenatide als Ersatz für Insulin","Oliver P. Bachmann","2008","Diabetologie und Stoffwechsel","other","article","10.1055/s-2008-1076470",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052804","156-LB: Nursing Burden Administering/Monitoring Complex Insulin Regimens vs. Basal Insulin/GLP-1 RA Fixed-Ratio Combinations (FRCs) for People with Type 2 Diabetes (PWT2D) in Long-Term Care (LTC)","HARLEY E. DAVIDSON","2023","Diabetes","other","article","10.2337/db23-156-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052805","2306-PUB: Long-Term Effect of Liraglutide on the Prevention of Progression of Diabetic Nephropathy in Elderly Patients with Type 2 Diabetes","Mami Yoshida","2019","Diabetes","nonrandomized_study","article","10.2337/db19-2306-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052806","400.4: Insulin independence with excellent glycemic control at 17-years post-islet alone transplantation: A case report","David A. Baidal","2023","Transplantation","case_report","article","10.1097/01.tp.0000994624.42482.84",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052807","Response to Letter to the Editor from Knobler et al: “Validation of the Swedish Diabetes Regrouping Scheme in Adult-Onset Diabetes in China”","Xia Li","2020","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgaa828","33164083",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","letter"],["R0052808","Su1568 A SYSTEMATIC REVIEW ON THE IMPACT OF GLP-1 AGONISTS ON NAFLD: A PROMISING NNT THAT CALLS FOR EARLY SCREENING AND TREATMENT","Mahmoud Mahdi","2024","Gastroenterology","systematic_review","article","10.1016/s0016-5085(24)04237-9",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0052809","Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Risk of Acute Pancreatitis: A Meta-analysis of Randomized Clinical Trial and Review of Literature","Stanley Yakubov","2015","The American Journal of Gastroenterology","systematic_review","article","10.14309/00000434-201510001-00020",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0052810","5B-4 Neonatal Exendin-4 administration normalizes epigenetic modifications of the proximal promoter of Pdx-1","Sara Elizabeth Pinney","2007","Early Human Development","other","article","10.1016/s0378-3782(07)70136-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052811","Real-World Clinical Effectiveness of Liraglutide in Type 2 Diabetes Patients Aged 65 Years and Above","Rasmus Skovgaard","2014","Canadian Journal of Diabetes","nonrandomized_study","article","10.1016/j.jcjd.2014.07.135",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052812","The Long Term Effects of GLP-1 Medications on Weight Loss: Mini Literature Review","Gabrielle Tracy","2024","Nursing & Primary Care","nonrandomized_study","article","10.33425/2639-9474.1275",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052813","Treatment options for patients with advanced osteoarthritis who decline knee surgery","Jakub Kacprzak","2026","World Journal of Orthopedics","other","article","10.5312/wjo.v17.i4.114991",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052814","Highlights from the 31st CROI: Key communications with potential impact on future HIV clinical practice","Jasmini Alagaratnam","2024","CMI Communications","other_trial","article","10.1016/j.cmicom.2024.100006",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0052815","932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program","Vanita R. Aroda","2020","Diabetes","other_trial","article","10.2337/db20-932-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052816","Glucagon-like peptide-1 receptor agonists versus naltrexone, acamprosate, or disulfiram for adults with type 2 diabetes and comorbid alcohol use disorder: a target trial emulation study","Joshua D. Wallach","2026","OSF Preprints (OSF Preprints)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","preprint"],["R0052817","LBMON139 A Case of Adipsic Diabetes Insipidus In Patient With Third Ventricular Tumor And Right Frontal Craniotomy.","Sirisha Reddy Thambuluru","2022","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvac150.975",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052818","Cardiologist as a cardiometabolic specialist","Vasiliki K. Katsi","2019","Journal of Clinical Hypertension","randomized_trial","article","10.1111/jch.13636","31355513",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052819","Do GLP-1 receptor agonists have compelling patient-oriented benefits in the treatment of type 2 diabetes mellitus?","Timothy F. Mott","2020","Evidence-Based Practice","other","article","10.1097/ebp.0000000000000527",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052820","Impact of glucagon-like peptide 1 receptor agonists on lung function of diabetic patients: a 52 weeks clinical trial","Paola Rogliani","2018",null,"other_trial","article","10.1183/13993003.congress-2018.pa4410",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0052821","P3‐328: DOES INSULIN RESISTANCE INFLUENCE WHITE MATTER LESIONS IN NON‐DIABETIC AD SUBJECTS?","Grazia Daniela Femminella","2019","Alzheimer s & Dementia","other_trial","article","10.1016/j.jalz.2019.06.3360",null,null,"ClinicalTrials.gov:NCT01843075","S000689","openalex","TRUE","open_pdf","5","FALSE","article"],["R0052822","Gliflozin monotherapy for type 2 diabetes: a review of NICE Technology Appraisal 390","Alicia Acevedo","2016","Practical Diabetes","other_trial","article","10.1002/pdi.2035",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052823","BOC.01.9 EFFECTS OF GLP1-RAS AND SGLT2I ON LIVER STEATOSIS AND FIBROSIS IN METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) WITH TYPE 2 DIABETES: INTERIM ANALYSIS OF AN OPEN TRIAL","A. Mega","2025","Digestive and Liver Disease","other_trial","article","10.1016/s1590-8658(25)00342-1",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052824","727-P: A Phase 3 Evaluation of CAMP-Biased GLP-1 Analog Ecnoglutide vs. Dulaglutide in Adults with Type 2 Diabetes","Xiaoying Li","2025","Diabetes","randomized_trial","article","10.2337/db25-727-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052825","PO-FP-056 EXPLORING THE EFFECTS OF TIRZEPATIDE IN ATRIAL FIBRILLATION: A PROPENSITY SCORE-MATCHED ANALYSIS","Min Choon Tan","2025","Heart Rhythm","nonrandomized_study","article","10.1016/j.hrthm.2025.03.223",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052826","EFFECTS OF 1 MG ONCE-WEEKLY SEMAGLUTIDE ON FUNCTIONAL CAPACITY IN PATIENTS WITH TYPE 2 DIABETES AND PERIPHERAL ARTERIAL DISEASE: TRIAL DESIGN AND BASELINE CHARACTERISTICS FROM STRIDE A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL","Marc P. Bonaca","2024","Journal of the American College of Cardiology","randomized_trial","article","10.1016/s0735-1097(24)04221-9",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052827","Exenatide and GLP-1: Novel Treatments for Type 2 Diabetes","Kathleen Marie Dungan","2005",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052828","SARS-CoV-2 myocarditis: what physicians need to know","Arsalan Khalil","2021","BMJ Evidence-Based Medicine","other","article","10.1136/bmjebm-2020-111527","33402328",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052829","Correction of Over-Dosed Insulin in a Type-2- Diabetic Led to a Better Control of Glycemia and Arterial Hypertension: A Case Report","Abimbola Abobarin-Adeagbo","2023","Journal of Pharmacy and Pharmacology Research","case_report","article","10.26502/fjppr.087",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0052830","Exenatide : review of a novel agent for type 2 diabetes : diabetes prescriber","Eric H. Decloedt","2008","˜The œSouth African journal of diabetes & vascular disease","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0052831","Resistant Hypertension in Adults in the Cardio–Renal–Metabolic Era: A Contemporary Position Statement","Silvia Palomo‐Piñón","2026","Annals of Clinical Hypertension","other","article","10.29328/journal.ach.1001044",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052832","Sleep‐Related Painful Erections in an Elderly Man Successfully Treated Using Clonazepam","Nitesh D Kuhadiya","2014","Journal of the American Geriatrics Society","other","article","10.1111/jgs.12667","24521385",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052833","7765 Exploring the Synergistic Effect of GHRH Receptor Agonist MR-409 and Incretin-based Therapies in Type 1 Diabetes Using a Low-dose Streptozotocin Model","Marel Gonzalez Medina","2024","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvae163.771",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052834","Efeitos renais do Peptídeo 1 Semelhante ao Glucagon (GLP1): das bases moleculares a uma perspectiva farmacofisiológica","Jorge E. Rico-Fontalvo","2024","Brazilian Journal of Nephrology","other","article","10.1590/2175-8239-jbn-2024-0101pt",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052835","Addressing cardio-metabolic risks in type 2 diabetes: evidence-based insights on efpeglenatide","Rajesh Kumar","2025","International Journal of Basic & Clinical Pharmacology","randomized_trial","article","10.18203/2319-2003.ijbcp20251843",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052836","The use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among people with severe mental illness","Claire Carswell","2026",null,"other_trial","article","10.17605/osf.io/ng8sk",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0052837","Acute effects of lixisenatide on intragastric meal distribution: impact on energy intake","Ryan J. Jalleh","2019","HAL (Le Centre pour la Communication Scientifique Directe)","other_trial","article",null,null,null,"ClinicalTrials.gov:NCT02308254","S000473","openalex","FALSE","no_doi","5","FALSE","conference-paper"],["R0052838","70-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—Post Hoc Analysis of the SURMOUNT-1 Trial","Emily R. Hankosky","2023","Diabetes","randomized_trial","article","10.2337/db23-70-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052839","1047 Changes in Liver Fibrosis Scores in Patients With New Onset Type 2 Diabetes on Triple Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy: Year Two Results","Olga Lavrynenko","2019","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0000593724.46248.7e",null,null,"ClinicalTrials.gov:NCT01107717","S000437","openalex","FALSE","paywalled","1","FALSE","article"],["R0052840","232-OR: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Suicide/Self-Harm in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study","HUILIN TANG","2024","Diabetes","nonrandomized_study","article","10.2337/db24-232-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052841","GW26-e1069 Exendin-4, An Gulcagon-like Peptide 1 Analogue, Attenuates Cardiomyocyte Hypertrophy Via AMPK/mTOR Pathway","Yue Zhou","2015","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2015.06.1142",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052842","71-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—SURMOUNT-1 Post Hoc Analysis by Prediabetes Status","Emily R. Hankosky","2023","Diabetes","other_trial","article","10.2337/db23-71-lb",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0052843","Impact of Incretin Mimetics on Thyroid Cancer Among Patients with Type 2 Diabetes: A Retrospective Cohort Time-to-Event Analysis","Michael W. Strand","2025","Pharmacoepidemiology","nonrandomized_study","article","10.3390/pharma4020009",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0052844","GLP1R expression in prostate cancer patients and effects of GLP1R agonism on prostate cancer cells.","Jordan E. Vellky","2025","Journal of Clinical Oncology","preclinical","article","10.1200/jco.2025.43.5_suppl.182",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052845","Exploring the Potential: GLP-1 Receptor Agonists for Advanced Therapies in End-Stage Heart Failure","Ayesha Azmeen","2024","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2024.02.1093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052846","Minimal contribution of nausea or vomiting to superior semaglutide-mediated weight loss vs. exenatide and dulaglutide in type 2 diabetes","Michael Albrecht Nauck","2019","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0039-1688353",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0052847","Association of Glucagon-Like Peptide-1 Agonists and Mortality Among Patients With Idiopathic Pulmonary Fibrosis","Esteban Kosak Lopez","2025","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1164/ajrccm.2025.211.abstracts.a1750",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052848","Diabetes, Diabetic Control, and Kidney Dysfunction in Adults with Sickle Cell Disease","Ryan Sun","2022","Blood","nonrandomized_study","article","10.1182/blood-2022-165314",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052849","Abstract 4349330: Bispecific Activation of GC-A and GLP-1 Receptors: A Novel Peptide Therapeutic for Cardiometabolic Diseases","Jasraj Singh","2025","Circulation","preclinical","article","10.1161/circ.152.suppl_3.4349330",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052850","P19 Perception hédonique et gustative des aliments chez les patients diabétiques de type 2 – Impact du traitement par un analogue du GLP-1 : le Liraglutide","Sophie Meillon","2012","Diabetes & Metabolism","other","article","10.1016/s1262-3636(12)71121-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052851","1.5 Efficacy and Safety of Dulaglutide vs. Metformin in Type 2 Diabetes (AWARD-3) (69-OR)","Guillermo E. Umpierrez","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0030-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052852","LBODP046 Reduction In \"Cardiovascular Death Or Hospitalisation For Heart Failure\" With Sglt-2is Is Dependent On Weight Reduction: A Meta-regression Analysis","Samit Ghosal","2022","Journal of the Endocrine Society","other","article","10.1210/jendso/bvac150.556",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052853","Comment on Monnier et al. Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes: Is This of Concern? Diabetes Care 2013;36:4057–4062","Richard David Carr","2014","Diabetes Care","other","article","10.2337/dc14-0352","24963116",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052854","Фармакоэкономические аспекты терапии сахарного диабета 2 типа современными сахароснижающими препаратами","Alla Vsevolodovna Rudakova","2011","Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052855","Incretin Biology- a practical guide: Chapter: GLP-1-Based Therapies: What are the Safety Implications?","Gabriela Da Silva Xavier","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052856","5257Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL","Robert John Mentz","2018","European Heart Journal","other_trial","article","10.1093/eurheartj/ehy566.5257",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052857","746-P: Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Nocturnal Hypoglycemia in the SoliMix Trial","Rory J. McCrimmon","2021","Diabetes","randomized_trial","article","10.2337/db21-746-p",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052858","Inflammatory Mediators in an Asthmatic Population on GLP-1 Analogue Therapy for Weight Management","David C. Watchorn","2021",null,"other","article","10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1424",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052859","CHARACTERISTICS OF PATIENTS INITIATING TREATMENT WITH DULAGLUTIDE AND OTHER GLP-1 RECEPTOR AGONISTS","Katherine Brown","2016","Value in Health","other","article","10.1016/j.jval.2016.03.1315",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052860","Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients","Jakub Tomasik","2020","Schizophrenia Bulletin Open","randomized_trial","article","10.1093/schizbullopen/sgaa044",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052861","Hypothalamic Inflammation and Hypothalamic Obesity: Case Report and Mini-Review","Sigridur Bara Fjalldal","2022","Journal of Endocrinological Science","case_report","article","10.29245/2767-5157/2022/1.1121",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0052862","Mo1877: ASSESSMENT OF THE IMPACT OF GLP-1RA USE ON CLINICAL AND ENDOSCOPIC MEASUREMENTS IN PATIENTS WITH ULCERATIVE COLITIS WHO HAVE AN ILEAL POUCH-ANAL ANASTOMOSIS","Riley Smith","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)03664-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052863","Novel unimolecular peptides targeting GLP-1 and APJ receptors exert potent satiety inducing effects in mice","Ethan S. Palmer","2024","Endocrine Abstracts","preclinical","article","10.1530/endoabs.104.p126",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052864","S2865 Hepatic Steatosis Is Associated With Amplified Hypoglycemia and Diabetic Ketoacidosis Risk in Type 2 Diabetes: A Multicenter Propensity-Matched Study","Sudheer Dhoop","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001138920.86464.42",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052865","CO3 A Systematic Literature Review and Network Meta-Analysis of Once-Weekly Icosema With Daily Fixed-Dose Combinations of Basal Insulin and GLP-1 RA in Patients With Type 2 Diabetes After 52 Weeks of Treatment","Aparajita Tyagi","2025","Value in Health","systematic_review","article","10.1016/j.jval.2025.09.106",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0052866","LIRAGLUTIDE REDUCES CARDIOVASCULAR EVENTS AND MORTALITY IN TYPE 2 DIABETES INDEPENDENT OF LDL CHOLESTEROL AND STATIN USE: RESULTS OF THE LEADER TRIAL","Sumit Verma","2018","Canadian Journal of Cardiology","other_trial","article","10.1016/j.cjca.2018.07.220",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052867","LIRAGLUTIDE AND WEIGHT LOSS AMONG PATIENTS WITH ADVANCED HEART FAILURE AND A REDUCED EJECTION FRACTION: INSIGHTS FROM THE FIGHT TRIAL","Andrew P. Ambrosy","2017","Journal of the American College of Cardiology","other_trial","article","10.1016/s0735-1097(17)34073-1",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052868","Was begünstigt das Anhalten eines erreichten HbA1c-Werts unter Exenatide einmal wöchentlich oder Insulin glargin über 3 Jahre? Eine retrospektive Analyse der DURATION-3-Studie","Marcel Trautmann","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0037-1601746",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052869","Abstract 4358: Glucagon-like peptide 1 agonist use and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus","Nikhil Grandhi","2023","Cancer Research","nonrandomized_study","article","10.1158/1538-7445.am2023-4358",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052870","Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes","André Jacques Scheen","2023","Diabetes Epidemiology and Management","randomized_trial","article","10.1016/j.deman.2023.100179",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0052871","EFFECTS OF ANTIDIABETIC MEDICATIONS LIRAGLUTIDE, CANAGLIFLOZIN, AND METFORMIN ON BONE MARROW ADIPOSE TISSUE IN KNEE OSTEOARTHRITIS: INSIGHTS FROM AN EX VIVO MODEL","Léa Loisay","2025","Osteoarthritis and Cartilage","other","article","10.1016/j.joca.2025.03.052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052872","International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)","RICARDO VITOR COHEN","2024","British journal of surgery","other_trial","article","10.1093/bjs/znae283","39612579",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052873","Binge eating and obesity as reward–interoception disorders: Neuroendocrine and neuromodulation perspectives","Vincenzo Maria Romeo","2026","Advanced Neurology","other","article","10.36922/an026230025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052874","P.4.a.011 Chronic exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses the neuropathy in a diabetic mice model","Oğuz Mutlu","2014","European Neuropsychopharmacology","preclinical","article","10.1016/s0924-977x(14)70933-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052875","RWD73 Real-World Utilization of Glucagon-like Peptide-1 Receptor Agonists in US Adults","K.E. Smoyer","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.10.3631",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0052876","An assessment of treatment satisfaction, adverse effects, cost of treatment among patients with type 2 diabetes for semaglutide when compared to liraglutide: a hospital-based cross-sectional study","Sakshi Pandey","2025","Discover Public Health","other","article","10.1186/s12982-025-00509-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052877","Investigating the Impact of GLP-1 Receptor Agonist-Induced Fat Loss on Collagen Synthesis and Skin Elasticity","Alejandra Sataray-Rodriguez","2025","Journal of Biomedical Science and Engineering","preclinical","article","10.4236/jbise.2025.183003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052878","799-P: Predictors of Glycemic Control by Derived Time in Range for People with Type 2 Diabetes Advancing with iGlarLixi—A Pooled Analysis","IRENE M. HRAMIAK","2023","Diabetes","randomized_trial","article","10.2337/db23-799-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052879","Influence of antidiabetic drugs on the course of bronchial asthma","В. В. Салухов","2025","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2025-208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052880","1002-P: HbA1c Improvement with the Addition of Continuous Glucose Monitoring to GLP-1 Agonist Therapy in People with Type 2 Diabetes","Susan Thapa","2025","Diabetes","nonrandomized_study","article","10.2337/db25-1002-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052881","P314 L’ancienneté du diabète et le type de traitements antérieurs sont les facteurs prédictifs de la réponse au liraglutide : données de l’étude post-inscription EVIDENCE®","Alfred Penfornis","2014","Diabetes & Metabolism","other","article","10.1016/s1262-3636(14)72605-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052882","Time Spent in Glycemic Control After Initiating Treatment With Oral Semaglutide Versus Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial","Jill Trinacty","2021","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2021.09.047",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052883","Gut Peptide Agonism in the Treatment of Obesity and Diabetes","Gerald Grandl","2020","Comprehensive physiology","other","article","10.1002/j.2040-4603.2020.tb00105.x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052884","S517 The Effect of GLP-1 Receptor Agonists on Bowel Preparation","Sabah Mahmood","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001031436.52308.00",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052885","P2519Comparison of SGLT-2 inhibitors, GLP-1 agonist and DPP-4 inhibitors for mortality outcomes in participants with type 2 diabetes: a network meta-analysis of 96 studies","Sean L. Zheng","2018","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehy565.p2519",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0052886","Abstract 4364028: Real-World Outcomes of Tirzepatide Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Peripheral Arterial Disease","Thitiphan Srikulmontri","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4364028",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052887","Obesity management for the pre–liver transplant and post–liver transplant patient","Carolyn G. Ahlers","2023","Clinical Liver Disease","randomized_trial","article","10.1097/cld.0000000000000039","37361255",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052888","Mo1265 IMPACT OF GLP-1 AGONIST TREATMENT ON GERD OUTCOMES IN DIABETIC PATIENTS: INSIGHTS FROM A PROPENSITY-MATCHED STUDY IN THE UNITED STATES","Osama Hamid","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)02784-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052889","#1702836 Tirzepatide Improved Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-3 phase 3 trial","Theresa Hunter","2024","Endocrine Practice","other_trial","article","10.1016/j.eprac.2024.03.260",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052890","Tu1695: CHARACTERIZATION OF REGIONAL TRANSIT DELAYS INVOLVING THE STOMACH, SMALL BOWEL, AND COLON ON GLUCAGON-LIKE PEPTIDE-1 AGONIST THERAPY: RELATION TO INDICATION FOR USE, GLYCEMIC CONTROL, AND LONG- VS. SHORT-HALF LIFE AGENTS","William Lee Hasler","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)04260-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052891","Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions","Anastasia Ntikoudi","2025","Diabetology","other","article","10.3390/diabetology6040023",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052892","Sixty seconds on . . . the woman who can smell Parkinson’s","Gareth Iacobucci","2022","BMJ","nonrandomized_study","article","10.1136/bmj.o2247","36109018",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052893","7-012 Novel preventive cardiology clinic associated with reduced risk of recurrent major adverse cardiovascular events for patients with prior acute coronary syndrome","Jun Yu Chen","2025",null,"other","article","10.1136/heartjnl-2025-bcs.208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0052894","Getting to the root of diabetes : the promise of liraglutide : drug trends","Peter Wagenaar","2011","˜The œSouth African journal of diabetes & vascular disease","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052895","Sympathetic hyperactivity after coronary artery bypass graft surgery: an important player in the development of postoperative atrial fibrillation?","Márcio Galindo Kiuchi","2020","EP Europace","other","article","10.1093/europace/euaa285","32964937",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052896","SEMAGLUTIDE (OZEMPIC) A POTENT WEAPON IN THE FIGHT AGAINST OBESITY","Bilal Bin Mukhtar","2024","Pakistan Postgraduate Medical Journal","randomized_trial","article","10.51642/ppmj.v35i01.694",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0052897","Diabetes Mellitus Secondary to Chronic Pancreatitis: Aspects of Clinical Course and Management","Ametov As","2023","Doctor Ru","other","article","10.31550/1727-2378-2023-22-4-59-63",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052898","P4449Incident cardiovascular disease in patients with type 2 diabetes: Established cardiovascular disease versus traditional risk markers","Jan Skov Jensen","2019","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehz745.0849",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052899","S28 Liraglutide 3.0 Mg Reduces Severity Of Obstructive Sleep Apnoea And Body Weight In Obese Individuals With Moderate Or Severe Disease: Scale Sleep Apnoea Trial","A. Collier","2014","Thorax","randomized_trial","article","10.1136/thoraxjnl-2014-206260.34",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0052900","Biochemical Evaluation of Bone Marrow Mesenchymal Stem Cells and GLP-1 Therapy as a New Approach for Type II Diabetes Treatment in Rat Model","Ashraf Barakat Said","2024","Advances in Animal and Veterinary Sciences","preclinical","article","10.17582/journal.aavs/2024/12.s1.478.490",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052901","Papel da liraglutida sobre a função quimiorreflexa e estresse oxidativo de ratas hipertensas ovariectomizadas","Thatiany Jardim Batista","2023","riUfes (Universidade Federal do Espírito Santo)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0052902","Abstract 4000: The significance of GLP-1R and its agonist in neuroendocrine neoplasms","Sophia A. Hueser","2025","Cancer Research","preclinical","article","10.1158/1538-7445.am2025-4000",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052903","Acute Dip in eGFR in Patients Treated with Tirzepatide: A Post Hoc Analysis of Long-Term Clinical Trials of Tirzepatide Treatment","Bruno Linetzky","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2025gxmxsbre",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052904","897-P: Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors on Solid Organ Transplant Recipients with Diabetes—A Systematic Review and Meta-analysis","Piyush Ratan","2025","Diabetes","systematic_review","article","10.2337/db25-897-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0052905","769-P: Bofanglutide (GZR18), a Novel GLP-1RA, Improved Glycemic Control and Cardiometabolic Risk Factors in Chinese Patients with T2D","Wen Li","2025","Diabetes","randomized_trial","article","10.2337/db25-769-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052906","Renoprotective effects of weekly dulaglutide in type 2 diabetes patients: A routine clinical practice study","Manuel Cayón-Blanco","2019","Endocrine Abstracts","other","article","10.1530/endoabs.63.p603",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052907","Optimal medical therapy for initial management of stable angina: a call to action","Raffaele De Caterina","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf596","40878861",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052908","Belimumab in kidney transplantation – Authors' reply","Gemma D. Banham","2019","The Lancet","randomized_trial","article","10.1016/s0140-6736(18)33066-6","30837145",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","letter"],["R0052909","Normalizing Myocardial Carbohydrate Metabolism Reverses Energetic Impairment and Diastolic Dysfunction in a Rodent Model of Obesity","Andrew D. Lewis","2014","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052910","Effect of exenatide on lisinopril pharmacodynamics in patients treated for hypertension","Prajakti A. Kothare","2005","Clinical Pharmacology & Therapeutics","randomized_trial","article","10.1016/j.clpt.2004.11.056",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052911","Is Liraglutide a Safe and Effective Medication to Treat Hyperglycaemia? A Systematic Review","Ameera Khaled Al Onezei","2020",null,"systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","review"],["R0052912","In patients with type 2 diabetes, which GLP-1 receptor agonist results in the greatest weight reduction?","Sandy L. Robertson","2021","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001201",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052913","Abstract 4134267: Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on In-Hospital Mortality and 30-Day Readmission in Type 2 Diabetic Patients with Acute Coronary Syndrome","Abraheim Al-Nasseri","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4134267",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052914","Modulation of autophagy as a therapeutic target in the treatment of metabolic dysfunction-associated steatotic liver disease: evidence from pharmacological, nutritional, and bioactive compound interventions","Jenifer Souza de Almeida","2026","Brazilian Journal of Health Review","other","article","10.34119/bjhrv9n1-050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052915","852-P: Duodenal Recellularization via Electroporation Therapy (ReCET) and GLP-1 RA to Replace Insulin in T2D Patients—EMINENT Study Six-Month Results","CELINE B.E. BUSCH","2023","Diabetes","other","article","10.2337/db23-852-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052916","IGlarLixi (glargin inzulin és lixisenatid fix kombináció) hatásossága és biztonásgossága bázis-bólus inzulinkezelési rendszerhez viszonyítva","Ádám Gyula Tabák","2020","Diabetologia Hungarica","other","article","10.24121/dh.2020.s1.75",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052917","Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial","Claudia K. Fox","2021","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvab048.128",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0052918","1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial","Nicklas Järvelä Johansen","2020","Diabetes","randomized_trial","article","10.2337/db20-1094-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052919","Therapie-assoziierte Faktoren bei Patienten mit Typ-2-Diabetes, die erstmalig mit einem injizierbaren Antidiabetikum behandelt werden sowie deren Behandlungsergebnisse nach 6 Monaten: Die CHOICE-Studie in Deutschland","Matthew D. Reaney","2012","Diabetologie und Stoffwechsel","other","article","10.1055/s-0031-1283989",null,null,"ClinicalTrials.gov:NCT00635492","S001805","openalex","FALSE","paywalled","5","FALSE","article"],["R0052920","P157 Un traitement par Exenatide peut-il permettre d’interrompre durablement une insulinothérapie dans le diabète de type 2 ?","Florence Galtier","2010","Diabetes & Metabolism","other","article","10.1016/s1262-3636(10)70305-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052921","Impact of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on myocardial work and coronary flow in liver steatosis and diabetes","I Ikonomidis","2026","European Heart Journal - Cardiovascular Imaging","randomized_trial","article","10.1093/ehjci/jeaf367.057",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052922","Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial","Katherine R. Tuttle","2024","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2024bjyvcgfe",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052923","Abstract 4368969: Cardiovascular and Rhythm Benefits of GLP-1 Receptor Agonists in Obese Patients: A Real-World Multicenter Study","Osman K. Yousafzai","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4368969",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052924","235 LARGE EFFECTS OF SGLT2 INHIBITORS/GLP1 RECEPTOR AGONISTS ON LIVER CIRRHOSIS IN NAFLD AND NASH WHEN COMPARED TO METFORMIN OR THIAZOLIDINEDIONES: A NATIONAL DATABASE STUDY","Omar Ali Alaber","2020","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(20)30796-4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052925","The role of GLP-1 agonists in preventing herniated vertebral disc disease: A TriNetX-based propensity score-matched retrospective analysis","Kuei‐Ting Tung","2025","Brain and Spine","nonrandomized_study","article","10.1016/j.bas.2025.104524",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052926","The effects of treatment with Liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls","Hassan Kahal","2014","Endocrine Abstracts","other","article","10.1530/endoabs.34.p229",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052927","EE318 Cost-Effectiveness Analysis for Soliqua in the Treatment of T2DM in Turkiye","Kağan Atikeler","2023","Value in Health","other","article","10.1016/j.jval.2023.09.584",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052928","1012-P: The Factors Influencing the Changes of Adipocytokines in Patients with Newly Diagnosed T2DM Treated with Exenatide","Hong Deng","2019","Diabetes","other","article","10.2337/db19-1012-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052929","374-P: Impact of Sulfonylurea (SU) Use on Hypoglycemia and Continuous Glucose Monitoring (CGM) Metrics after 16 Weeks of iGlarLixi in Insulin-Naïve Adults with Type 2 Diabetes (T2D) and Mean A1C >10%","ALEXANDRIA RATZKI-LEEWING","2024","Diabetes","other_trial","article","10.2337/db24-374-p",null,null,"ClinicalTrials.gov:NCT05114590","S002030","openalex","FALSE","paywalled","5","FALSE","article"],["R0052930","CO45 - Effets bénéfiques du Liraglutide, Analogue de la GLP-1, sur les facteurs de risque cardio-vasculaire du Diabétique de Type 2","Courrèges Jp","2008",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052931","105-OR: An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Cotadutide on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus","Rajna Golubić","2021","Diabetes","randomized_trial","article","10.2337/db21-105-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052932","Effect of Non-sugar Sweetener Consumption on Sweetness Perception in Mid- to Older-Aged Adults With Prediabetes","Wenjing Yu","2026","Current Developments in Nutrition","other","article","10.1016/j.cdnut.2026.108008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052933","ABSTRACT NUMBER: ESOC2026LT58 LT58 - GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN ACUTE LARGE VESSEL OCCLUSION STROKE TREATED BY REPERFUSION THERAPIES (GALLOP-2) – A MULTICENTER, RANDOMIZED, OPEN-LABEL, BLINDED END-POINT TRIAL","Hao Wang","2026","European Stroke Journal","randomized_trial","article","10.1093/esj/aakag023.1868",null,null,"ClinicalTrials.gov:NCT06788626","S000901","openalex","TRUE","free_to_read","1","FALSE","conference-abstract"],["R0052934","Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium‐glucose cotransporter‐2 inhibitors versus other medications: A systematic review and meta‐analysis of observational cohort studies","Anna Hodgson","2024","Diabetes Obesity and Metabolism","systematic_review","article","10.1111/dom.15571","38558251",null,"PROSPERO:CRD42022325598",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0052935","LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes: Baseline Data From Over 9000 Subjects in the LEADER Trial","William M. Steinberg","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/1j3p-pt08",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0052936","Glucagon-Like Peptide-1 Receptor Agonists for Aortic Stenosis: A Drug-Target Mendelian Randomisation Study","Jonathan Laurence Ciofani","2025","Heart Lung and Circulation","other","article","10.1016/j.hlc.2025.06.446",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052937","Abstract 15562: Coronary Artery Calcium Score for Allocating Emerging Obesity Therapies: Implications for the Ongoing SURMOUNT-MMO Outcome Trial","Erfan Tasdighi","2023","Circulation","other_trial","article","10.1161/circ.148.suppl_1.15562",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0052938","S730 Assessing the Risk of Recurrent Pancreatitis in Patients on GLP-1 Agonists","Arvind Bussetty","2025","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0001130380.47233.e9",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0052939","443-P: Effect of 3-Month Therapy with Liraglutide on Ambulatory Blood Pressure in Patients with Type 2 Diabetes Mellitus","Athanasia K. Papazafiropoulou","2020","Diabetes","other","article","10.2337/db20-443-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052940","Beneficial cardio‐metabolic effects of semaglutide in individuals living with overweight/obesity without type 2 diabetes. Additional analysis of the SELECT trial","ISKANDAR RAUF IDRIS","2024","Diabetes Obesity and Metabolism Now","other_trial","article","10.1002/doi2.107",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0052941","Table 2 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors","Jasmine Singh Sukumar","2026",null,"other","article","10.1158/2767-9764.31444522",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0052942","Epidemiology of Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus and Effects of Antiglycemic Therapy on Liver Fibrosis: A Retrospective Study","Muhammad Imran Butt","2024","Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.14740/jem937",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052943","Effects of incretin drugs on glycemic control and body weight","A. N. Levitskaya","2025","FOCUS Endocrinology","other","article","10.62751/2713-0177-2025-6-3-07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052944","SGLT-2 Inhibitors: Discrepancy Between MACE Reduction and Incident MI and Stroke","David Tyler Broome","2023","The Journal of Clinical Endocrinology & Metabolism","other","article","10.1210/clinem/dgad216","37061813",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052945","Effect of semaglutide on insulin dose requirements in adults with type 1 diabetes and obesity using automated insulin delivery systems: ADJUST-T1D post-hoc analysis","Kagan Karakus","2025",null,"randomized_trial","article","10.2337/figshare.30727271.v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0052946","Beta cell mass as quantified by exendin PET/CT imaging is similar in individuals with and without remission of type 2 diabetes after Roux-en-Y Gastric Bypass","Sevilay Tokgöz","2025","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0045-1804403",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052947","Fr281 IMPACT OF LIXISENATIDE ON MYOELECTRIC GASTRIC ACTIVITY ASSESSED BY ELECTROGASTROGRAPHY IN EXPERIMENTAL PIGS","Ilja Tachecí","2021","Gastroenterology","other","article","10.1016/s0016-5085(21)01403-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052948","Method development and validation of tirzepatide in bulk and pharmaceutical dosage form by using RP-HPLC","Mendi Tarun","2025","The Pharmacist","other","article","10.18231/j.pharmacist.14556.1759918868",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052949","1922-LB: CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1RA Therapy—Real-World Data","XIAOHAN WANG","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1922-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052950","0619 Depression and Treatment Use in Patients with Obstructive Sleep Apnea on Glucagon-Like Peptide 1 Receptor Agonists","Kate V. Cole","2024","SLEEP","other","article","10.1093/sleep/zsae067.0619",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052951","Abstract Th0029: Genetic Evidence for Glucose-dependent Insulinotropic Polypeptide as a Therapeutic Target for Peripheral Artery Disease","Sabina M. Sorondo","2026","JVS Vascular Science","other","article","10.1016/j.jvssci.2025.100307",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0052952","884-P: Duodenal Electroporation and Semaglutide Effectively Eliminate Need for Insulin in Type 2 Diabetes Patients","CELINE B.E. BUSCH","2024","Diabetes","other","article","10.2337/db24-884-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052953","299-OR: Discovery of Long-Acting Unimolecular Peptide Tetra-agonists Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors for Enhanced Metabolic Benefits in Animal Models of Obesity","Soumitra Ghosh","2024","Diabetes","preclinical","article","10.2337/db24-299-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052954","Liraglutide restores the hyperglycemia-induced endothelial oxidative stress in vitro","Sofia G. Gougoura","2017","Endocrine Abstracts","preclinical","article","10.1530/endoabs.49.ep618",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052955","GLP-1 Agonist Prescription and Joint Outcomes in Rheumatoid Arthritis","Faissal Stipho","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7099858",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0052956","Single‐Administration Self‐Boosting Microneedle Patch for the Treatment of Obesity (Adv. Therap. 9/2024)","Parbeen Singh","2024","Advanced Therapeutics","other","article","10.1002/adtp.202470019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052957","OP8 THE 2-WEEK FASTING GLUCOSE AS A PREDICTOR OF GLYCEMIC RESPONSE TO ONCE-WEEKLY DULAGLUTIDE 1.5 MG","Stephen C L Gough","2014","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(14)70214-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052958","Exercise, Pharmaceutical Therapies and Type 2 Diabetes: Looking beyond Glycemic Control to Whole Body Health and Function","Thomas E. Yates","2021","Translational Medicine and Exercise Prescription","nonrandomized_study","article","10.53941/tmep.v1i1.33",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0052959","Editorial: Venom Peptides: A Rich Combinatorial Library for Drug Development","Fernanda Caldas Cardoso","2022","Frontiers in Molecular Biosciences","commentary","article","10.3389/fmolb.2022.924023","35647027",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0052960","Comparison of the effect on Hyperglycemia and the Adverse Effects among Different GLP-1 Receptor Agonists Added to Basal Insulin and between GLP-1 Receptor Agonists and Basal Insulin Versus Basal-Plus or Basal-Bolus Insulin in Type 2 Diabetes: A Meta-Analysis","Andrey Manov","2021","Book Publisher International (a part of SCIENCEDOMAIN International)","systematic_review","article","10.9734/bpi/nfmmr/v10/4105f",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","book-chapter"],["R0052961","660-P: Greater Proportions of Subjects Achieved Composite Endpoints with Once-Weekly Semaglutide vs. Comparators in SUSTAIN Trials","Peter Gæde","2021","Diabetes","other","article","10.2337/db21-660-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052962","Exendin-4, a GLP-1 receptor agonist, stimulates entero-insular axis in the rat, through a mechanism involving adrenal medulla","Ludwik K. Malendowicz","2001","Biomedical Research","preclinical","article","10.2220/biomedres.22.295",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052963","[P2–107]: COMBINATION THERAPY OF TYPE 2 DIABETES MEDICATIONS AS A TREATMENT TARGET FOR ALZHEIMER DISEASE","Dana Atrakchi‐Baranes","2017","Alzheimer s & Dementia","preclinical","article","10.1016/j.jalz.2017.06.757",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052964","S922 Decrease Risk of Intubation and Aspiration Pneumonia Associated with Endoscopic Procedure Among Patients on Glucagon-Like Peptide 1 Receptor Agonists","Khaled Alsabbagh Alchirazi","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001033056.82634.02",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052965","2216-PUB: Patient Preferences for Newer Oral Therapies in Type 2 Diabetes","Gianluigi Savarese","2020","Diabetes","other_trial","article","10.2337/db20-2216-pub",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0052966","Improvement in SF-36-derived health utility score with liraglutide 3.0 mg versus placebo over 3 years in prediabetes","Cilla J. Haywood","2019","Obesity Research & Clinical Practice","other","article","10.1016/j.orcp.2016.10.242",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052967","A Case of Semaglutide-Associated Severe AKI in an Immunocompromised Patient","Devang B. Patel","2023","Journal of the American Society of Nephrology","case_report","article","10.1681/asn.20233411s1426e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052968","Semaglutide in modern medicine: therapeutic opportunities in obesity and the emerging challenge of NAION – a narrative review","Kamil Biedka","2025","Family Medicine & Primary Care Review","nonrandomized_study","article","10.5114/fmpcr.2025.150180",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0052969","Reasons of Liraglutide discontinuation in Tunisian type 2 diabetic patients","Chadia Zouaoui","2023","Endocrine Abstracts","other","article","10.1530/endoabs.90.ep571",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0052970","Human glucagon-like peptide-1 amide NH2 is cleaved by plasma enzymes not only at the N-terminus but also at the C-terminus; development of novel GLP-1 analogs which are highly resistant to enzymatic degradation","J. Z. Dong","2002","Journal of Peptide Science","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052971","How to descript a clinical case correctly: For inquiry scientists and demanding doctors","Oksana V. Tsygankova","2024","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2023-440",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052972","Women with polycystic ovarian syndrome are at increased associated risk of acute myocardial infarction and ischemic stroke","Eva Havers-Borgersen","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3974",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052973","EFFECT OF SEMAGLUTIDE VERSUS OTHER GLP-1 RECEPTOR AGONISTS ON OFFICE BLOOD PRESSURE LEVELS AMONG SUBJECTS WITH TYPE 2 DIABETES: A META-ANALYSIS","Dimitrios Patoulias","2024","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0001020820.64485.c0",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0052974","Abstract 4140276: Safety, Efficacy and Cardiovascular Benefits of Combination Therapy with Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Asma Mousavi","2024","Circulation","systematic_review","article","10.1161/circ.150.suppl_1.4140276",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0052975","Canagliflozin reduces both HbA(1c) and body weight in patients with type 2 diabetes on background dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 agonists","Woo","2015","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052976","EFFICACY OF GLUCAGON-LIKE-PEPTIDE-1 AGONISTS FOR WEIGHT LOSS IN ADULTS WITH CONGENITAL HEART DISEASE","Prinston Varghese","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01269-0",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052977","Efficacy and Safety of Semaglutide in Glycemic Control, Body Weight Management, and Lipid Profile among Obese Type 2 Diabetes Patients: A Systematic Review","Wurud Muteb D. Alshammari","2025","Saudi Journal of Medical and Pharmaceutical Sciences","systematic_review","article","10.36348/sjmps.2025.v11i04.008",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0052978","Abstract TMP104: Association of GLP-1 Receptor Agonist Use with Clinical Outcomes in Diabetic Patients Hospitalized for Ischemic Stroke","Varun Kumar Viswanath","2025","Stroke","nonrandomized_study","article","10.1161/str.56.suppl_1.tmp104",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052979","New GLP-1 agonist dulaglutide improves metabolic dysfunction and extenuates development of non-acoholic steatohepatitis in mice","Katharina L. Hupa","2017","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(17)31233-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052980","An Absorbing Sense of Sweetness","Fiona Mary Gribble","2015","Diabetes","preclinical","article","10.2337/db14-1477","25614668",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052981","Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus","Umar Adamu","2022","Journal of Endocrinology Metabolism and Diabetes of South Africa","other","article","10.1080/16089677.2022.2113206",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052982","1017-P: Continuous Glucose Monitoring Reveals Comprehensive Glucose Control with MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity","Victoria E R Parker","2019","Diabetes","other","article","10.2337/db19-1017-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052983","Evaluation of Dulaglutide in Acute and Subacute Inflammation Models of Male Wistar Rats: An Experimental Study","A. V. Bhosale","2025","JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH","preclinical","article","10.7860/jcdr/2025/81705.22108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052984","Targeting Two Epidemics: A Scoping Review of GLP-1 Receptor Agonists for Weight Management in Adults Living with HIV","Sigma Hossain","2026","OSF Preprints (OSF Preprints)","narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0052985","Boehringer buys into Yuhan NASH drug","LISA M. JARVIS","2019","C&EN Global Enterprise","other","article","10.1021/cen-09727-buscon15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0052986","Impact of GLP-1 Receptor Agonists on the Quality of Bowel Preparation in Screening Colonoscopies","Steven Quan","2025",null,"nonrandomized_study","article","10.11575/prism/51849",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0052987","Tu1944 GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONIST USE IS ASSOCIATED WITH LOWER INCIDENCE OF HEPATOBILIARY OR PANCREATIC CANCER IN PATIENTS WITH TYPE 2 DIABETES: A MULTI-CENTER COHORT STUDY ACROSS THE UNITED STATES","Luis Miguel Nieto","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)03826-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052988","S925 EGD Outcomes in Patients Receiving GLP-1 Receptor Agonists","Benjamin Young","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001033068.98401.05",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0052989","2094-LB: Electrocardiogram Abnormalities in Relatively Early Type 2 Diabetes—Prevalence and Incidence in the Glycemia Reduction Approaches in Diabetes (GRADE) Cohort","Rodica Pop‐Busui","2025","Diabetes","randomized_trial","article","10.2337/db25-2094-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0052990","547-P: Harnessing Continuing Education to Identify Drivers of Obesity Medication Use among Primary Care Providers","BHARATI HEGDE","2025","Diabetes","other","article","10.2337/db25-547-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052991","Investigating the role of the histone deacetylases-inhibitor suberanilohydroxamic acid in the differentiation of stem cells into insulin secreting cells","Ahmed Taher El-Serafi","2018","Hamdan Medical Journal","other","article","10.4103/hmj.hmj_29_18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052992","748-P: Tirzepatide Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ","Kagan Ege Karakus","2024","Diabetes","other","article","10.2337/db24-748-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052993","No such thing as an innocent bystander: the conundrum of obesity, diabetes, and heart failure with preserved ejection fraction","Petar M Seferovic","2023","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwad226","37421379",null,"ClinicalTrials.gov:NCT04847557","S000047","openalex","TRUE","open_pdf","1","FALSE","editorial"],["R0052994","Low-carbohydrate nutrition counseling with continuous glucose monitoring to improve metabolic health among Veterans with type 2 diabetes: a pilot quality improvement initiative (Preprint)","Cassie D. Turner","2025",null,"randomized_trial","article","10.2196/preprints.75672",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","preprint"],["R0052995","IcoSema: che differenza può fare la combinazione settimanale?","Gennaro Puocci","2026","L Endocrinologo","other","article","10.1007/s40619-026-01838-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0052996","The place of fixed combination of sulfonylurea derivatives and metformin in the modern treatment paradigm for type 2 diabetes mellitus","Alina Yu. Babenko","2026","Diabetes Mellitus","other","article","10.14341/dm13474",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052997","Incretin-based therapy: renal effects","Anton Ivanovich Korbut","2016","Diabetes Mellitus","other","article","10.14341/dm7727",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0052998","Economic evaluation of proximal intestinal mucosal ablation in insulin-requiring type 2 diabetes: cost-effectiveness and price threshold analysis from a UK NHS perspective with comparison to semaglutide","B Norton","2026","Endoscopy","nonrandomized_study","article","10.1055/s-0046-1821211",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0052999","278-LB: The Effect of Combining Very-Low-Calorie Diet with Semaglutide on Beta-Cell Function in Individuals with Type 2 Diabetes","Oluwaseun Anyiam","2023","Diabetes","randomized_trial","article","10.2337/db23-278-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053000","Effect of Type 2 Diabetes Disease Stage on Liraglutide Response in Clinical Practice: Data from the EVIDENCE® Study","Alfred Penfornis","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.116",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053001","Parkin Deficiency Disrupts Angiogenesis of GLP-1 Receptor Agonist by Modulating ER-Mitochondria Function and Ca2+ Homeostasis","Qiao Zhou","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5433771",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0053002","190 A case of euglycemic diabetic ketoacidosis caused by dulaglutide","Neil Patel","2025","The American Journal of the Medical Sciences","case_report","article","10.1016/s0002-9629(25)00198-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053003","S997 Examining the Effects of GLP-1 Receptor Agonist Therapy on Esophageal Motility Through High Resolution Esophageal Manometry (HREM)","Benjamin Douglas Xun Liu","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001131448.75516.0e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053004","Octreotide-Induced Hyperkalemia","Mohammad Waleed Abushawer","2023","Journal of the American Society of Nephrology","other","article","10.1681/asn.20233411s11106d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053005","Su1558 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS REDUCE HEPATIC FAT CONTEXT INDEPENDENT OF THE WEIGHT LOSS IN DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE","Huma Malik","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)04227-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053006","Exenatide und Insulin Glargin bei Patienten mit Typ 2 Diabetes: Klinische Ergebnisse einer Vergleichsstudie über 6 Monate","CHRISTOF M. KAZDA","2006","Diabetologie und Stoffwechsel","other","article","10.1055/s-2006-944162",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053007","P4476Cardiovascular benefits of GLP-1 (liraglutide) treatment in experimental arterial hypertension are mediated by the endothelial GLP-1 receptor","Sebastian Steven","2019","European Heart Journal","other_trial","article","10.1093/eurheartj/ehz745.0871",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053008","Predictors of Glycemic Control and diabetes-related costs among adult type 2 Diabetes Patients Initiating Therapy with Liraglutide","Emily Durden","2015","Value in Health","other","article","10.1016/j.jval.2015.03.316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053009","MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes—A Multiple-Ascending-Dose Study","Darren C. Robertson","2018","Diabetes","randomized_trial","article","10.2337/db18-1070-p",null,null,"ClinicalTrials.gov:NCT02548585","S000451","openalex","FALSE","paywalled","1","FALSE","article"],["R0053010","Rapido effetto di riduzione ponderale e normalizzazione dei valori glicemici con exenatide LAR in paziente diabetica obesa in precedente terapia insulinica intensiva","Antonello Carboni","2015","MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053011","Testosterone replacement therapy in metabolic dysfunction-associated steatotic liver disease: a bench-to-bedside narrative review","Yuchang Li","2026","Exploration of Digestive Diseases","randomized_trial","article","10.37349/edd.2026.1005135",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0053012","SAT-454 Therapeutic Effects of GLP-1 agonist versus SGLT2-i on patients with T2D and MASLD","Ermina Stratina","2025","Journal of Hepatology","other","article","10.1016/s0168-8278(25)01710-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053013","Targeted local activation of Fas in pancreatic beta cells for treatment of insulinomas and disorders of pathological autonomic insulin secretion","K Sözener","2005","Experimental and Clinical Endocrinology & Diabetes","preclinical","article","10.1055/s-2005-862849",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053014","The effectiveness of glucagon-like peptide 1 receptor agonist and prebiotic on short-chain fatty acids and carbohydrate metabolism in patients with carbohydrate metabolism violation","Lilit V. Egshatyan","2020","Endocrine Abstracts","other","article","10.1530/endoabs.70.aep464",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053015","Figure 1 from Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors","Jasmine Singh Sukumar","2026",null,"other","article","10.1158/2767-9764.31444543",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0053016","S3761 When Biopsy Lies: DNA Fingerprinting Exposes Hidden Contaminant","Guneet Singh Sidhu","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001142504.01607.77",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053017","Exploring the Role of SGLT2 Inhibitors in Preventing and Managing Diabetic Complications","Yu Jyun Lin","2023","ISEE Conference Abstracts","nonrandomized_study","article","10.1289/isee.2023.mp-106",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0053018","LY307161, a glucagon like peptide (GLP-1) analogue with prolonged action, does not cause hypoglycaemia","StevenJ. Pascoe","2000","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(00)81598-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053019","Glucagon-like peptide-1 based therapies as a novel approach for chronic heart failure","David Grieve","2016","Research Portal (Queen's University Belfast)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0053020","Baseline patient reported outcomes in patients with peripheral artery disease and type 2 diabetes from STRIDE: a phase 3, 52-week, randomised, double-blind, placebo-controlled trial","Subodh Verma","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2287",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053021","Metabolic Outcome 12 months Following the end of a Randomised Controlled Trial of Exenatide for Clozapine Associated Obesity and Diabetes","Dan J. Siskind","2019",null,"randomized_trial","article","10.26226/morressier.5d1a037957558b317a14099e",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","other"],["R0053022","2829-LB: STEP UP T2D: Participants Achieving BMI, WHtR, and Cardiometabolic Treatment Targets","CAREL LE ROUX","2026","Diabetes","other_trial","article","10.2337/db26-2829-lb",null,null,"ClinicalTrials.gov:NCT05649137; ClinicalTrials.gov:NCT05646706","S001158; S001354","openalex","FALSE","paywalled","5","FALSE","article"],["R0053023","SEMAGLUTIDE-ELIGIBILITY AMONG NATIONAL REPRESENTATIVE US ADULT POPULATION WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM NATIONAL HEALTH INTERVIEW SURVEY","Harun Kundi","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)03780-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053024","Influence of selected drugs used in the treatment of type 2 diabetes and cardiovascular diseases on depressive disorders in elderly patients","Daria Słomińska","2021","Pharmacotherapy in Psychiatry and Neurology","other","article","10.33450/fpn.2021.02.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053025","Action of incretin receptor based dual and tri-agonists in pancreatic islets","Farah Nabil Abbas","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112732",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053026","1872-LB: Therapeutic Potential of HM15275, a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Heart Failure","BYEONGJIN YE","2024","Diabetes","preclinical","article","10.2337/db24-1872-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053027","S2008 Unusual Case of Abdominal Pain - Medication Induced Biliary Colic","Patrick Tempera","2023","The American Journal of Gastroenterology","preclinical","article","10.14309/01.ajg.0000957672.15204.fd",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053028","Pharmakotherapie der Adipositas: Regulation von Hunger und Sättigung","VOLKER SCHUSDZIARRA","2006","Pharmazie in unserer Zeit","other","article","10.1002/pauz.200600195","17137080",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053029","Diabetic kidney disease, revisited: where do we stand?","Dae Ryong Cha","2022","Kidney Research and Clinical Practice","other","article","10.23876/j.krcp.22.002","36239060",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053030","Manufacturing and Transplantation of Stem Cell Derived Beta Cells","Daniel W. Clough","2021","Deep Blue (University of Michigan)","preclinical","article","10.7302/3835",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0053031","Challenges in the management of MetALD after liver transplantation","Monica Cucco","2025","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2024.144",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053032","7. Impact of GLP-1 Agonist Weight Loss Drugs on Surgical Wound Complications Following Plastic Surgery Procedures","Charles C. Lee","2025","Plastic & Reconstructive Surgery Global Open","nonrandomized_study","article","10.1097/01.gox.0001113872.50021.01",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053033","Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on arterial stiffness, coronary flow reserve and liver steatosis in diabetes","Ignatios Ikonomidis","2024","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehae666.2925",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053034","Liraglutide and the Preservation of Pancreatic Beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial","Ravi R. Retnakaran","2014","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2014.07.012",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053035","2840-LB: Semaglutide and Obstructive Sleep Apnea (OSA): A Post Hoc Analysis from SELECT","Silvio Inzucchi","2026","Diabetes","other","article","10.2337/db26-2840-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053036","1214-P: Prepregnancy Use of Glucagon-Like Peptide 1 Receptor Agonists and Gestational Weight Gain in Type 2 Diabetes","Jacqueline Maya","2024","Diabetes","nonrandomized_study","article","10.2337/db24-1214-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053037","Liraglutide 3.0 mg Reduces Body Weight and Improves Health-Related Quality of Life (HRQoL) in Overweight or Obese Adults without Diabetes: The SCALE Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial","Joanne Liutkus","2015","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2015.01.142",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053038","810-P: Role of Glucagon-Like-Peptide-1 Agonists as an Adjunctive Treatment in Adults with Type 1 Diabetes Mellitus and Overweight/Obesity, Retrospective Cohort, Saudi Arabia 2023","KHOLOOD HABEEB","2024","Diabetes","nonrandomized_study","article","10.2337/db24-810-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053039","The effect of glucagon-like peptide-1 receptor agonists on subcutaneous white/brown adipose tissue and non-alcoholic fatty liver disease according to magnetic resonance spectroscopy in obese patients","Natalia Kurochkina","2024","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2024.117951",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053040","1801-PUB: Efficacy and Safety of Once-Weekly Semaglutide in People with Type 1 Diabetes in Real-World Practice","Virginia Bellido","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1801-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053041","The Importance of Postprandial Hyperglycemia Position Statement of the Danube Mco Experts","László Barkai","2015","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","other","article","10.1515/rjdnmd-2015-0011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053042","Pharmacovigilance assessment of semaglutide safety","Ksenia O. Shnaider","2024","Spravočnik vrača obŝej praktiki (Journal of Family Medicine)","nonrandomized_study","article","10.33920/med-10-2404-08",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053043","PROPENSITY SCORE MATCHED COMPARISON OF HSI SCORE REDUCTION BETWEEN ESG + GLP-1 RA, ESG ALONE, AND GLP-1 RA ALONE","Ali Lahooti","2025","Gastrointestinal Endoscopy","nonrandomized_study","article","10.1016/j.gie.2025.03.119",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053044","CO-75: Le Liraglutide accélère le catabolisme de l'apoB48 au cours du diabète de type 2","Bruno L Vergès","2016","Diabetes & Metabolism","other","article","10.1016/s1262-3636(16)30093-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053045","1078 Impact of GLP-1 Agonist Use on Non-Alcoholic Fatty Liver Disease Among Patients at a Large, Tertiary Care Center","Soorya N. Aggarwal","2019","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000593844.88418.01",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053046","56 - Effect of Oral Semaglutide With or Without Background SGLT2i in Patients With T2D: Subgroup Analysis of PIONEER 4","Ronald Goldenberg","2020","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2020.08.062",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053047","Diabetes Mellitus-related Pathogeny: A Precipitating Factor for Alzheimer’s Disease—An Insight on Repurposing Diabetes Pharmacological Treatments in Alzheimer’s Disease","Chiamaka Onyekwuluje","2025","Journal of Pharmacology and Pharmacotherapeutics","other","article","10.1177/0976500x251365078",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053048","The effect of liraglutide on Gastric Accommodation (GA) and Gastric Emptying (GE) in conscious rats","Alessandra Rotondo","2012","Neurogastroenterology & Motility","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053049","LBP-027 ARO-INHBE demonstrates clinically meaningful reductions in liver fat as monotherapy and in combination with low-dose tirzepatide in adults with obesity","John Robert Baker","2026","Journal of Hepatology","other","article","10.1016/s0168-8278(26)00442-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053050","Pharmacological management of heart failure","Harish Kumar Gupta","2025","Journal of Family Medicine and Primary Care","nonrandomized_study","article","10.4103/jfmpc.jfmpc_1733_24","41041189",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053051","353-OR: Oral Small Molecule GLP-1R Agonist PF-06882961 Robustly Reduces Plasma Glucose and Body Weight after 28 Days in Adults with T2DM","Aditi R. Saxena","2020","Diabetes","randomized_trial","article","10.2337/db20-353-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053052","MO069: Therapeutic Effects of Semaglutide as Mono and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","Michael Søberg Christensen","2022","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfac063.021",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0053053","S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program","Albert Do","2023","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0000955964.73046.7b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053054","SAT658 Tirzepatide Reduces The Predicted Risk Of Developing Atherosclerotic Cardiovascular Disease: A Post-hoc Analysis Of The Surmount-1 Trial","Emily R. Hankosky","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.106",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053055","The impact of intragastric balloon and therapy by glucagon-like peptide‑1 receptor agonist on arterial hypertension and other components of metabolic syndrome","Е. В. Мельникова","2016","Arterial’naya Gipertenziya (Arterial Hypertension)","other","article","10.18705/1607-419x-2016-22-2-160-168",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053056","SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES","L.A. Leiter","2017","Canadian Journal of Cardiology","other","article","10.1016/j.cjca.2017.07.075",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053057","1992-LB: MYO4, a First-in-Class Antiobesogenic and Muscle Preserving Small Molecule Metabolic Modulator","JULIE HOLDER","2025","Diabetes","preclinical","article","10.2337/db25-1992-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053058","337-OR: Tirzepatide Improved Markers of Islet-Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared with Semaglutide in People with Type 2 Diabetes","KATELYN BROWN","2022","Diabetes","other_trial","article","10.2337/db22-337-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053059","Abstract 4368981: Early GLP-1 Receptor Agonist Initiation Reduces Major Cardiac and Renal Events in Older Adults with Type 2 Diabetes Without Prior Cardiovascular or Renal Disease: A Target Trial Emulation","Kuan Yu Chi","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4368981",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053060","COMBINED THERAPY WITH SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I) AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP1-RA)—TOLERABILITY AND CLINICAL IMPACT: THE INTERMOUNTAIN HEALTHCARE REAL WORLD EXPERIENCE","Viet Trung Le","2022","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/s0735-1097(22)02434-2",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053061","GLP-1 Receptor Agonists in Spine Surgery: Current Evidence and Future Directions","Luis M. Salazar","2025","Contemporary Spine Surgery","other","article","10.1097/01.css.0001113692.66197.4d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053062","The impact of GLP-1 receptor agonist-induced weight loss on 22 cancers in the next ten years using a markov state-transition model","Jiawen Dong","2025","Endocrine Abstracts","other","article","10.1530/endoabs.109.op2.1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053063","S1241 Impact of GLP-1 Receptor Agonist Guidelines Change on Post-Endoscopic Complications: A Propensity-Matched Multi-Center Study","Harsimran Kalsi","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001132424.22922.fd",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053064","PP.05.33","J.C. Fernández García","2015","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0000467874.18438.d0",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053065","EE323 Developing a Multi-Indication Wider Societal Value Model to Estimate the Economic Impact of Semaglutide in Canada","Marc Evans","2025","Value in Health","other","article","10.1016/j.jval.2025.09.707",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053066","Mo1915 REAL-WORLD WEIGHT LOSS AND METABOLIC PARAMETERS OUTCOMES OF SEMAGLUTIDE: A 1-YEAR MULTI-SITE STUDY","Wissam Ghusn","2023","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(23)03168-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053067","Social Circuitry: Wiring the ORganization – Highlights from the 2025 AACD Perioperative Leadership Summit","Thomas Schulte","2025","ASA Monitor","nonrandomized_study","article","10.1097/01.asm.0001118264.24641.dc",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053068","OC33 - Liraglutide and strength-endurance training as modulators of the stress axis in middle-aged female rats","Ivona Gizdović","2025","European Journal of Endocrinology","preclinical","article","10.1093/ejendo/lvaf168.063",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053069","Abstract 12263: The Role of Glucagon-Like Peptide-1 in the Immediate Improvement of Endothelial-Protective HDL Functions After Roux-en-Y Gastric Bypass in Obese Patients","Elena Osto","2014","Circulation","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053070","Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. Diabetes Care","Ajay Chaudhuri","2014",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053071","FRI483 Changes In Thyroid Function Test With Tirzepatide Use In Patients With Hypothyroidism","Gayoung Kaylee Yu","2023","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvad114.1829",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0053072","Effect of a 12-month treatment with liraglutide, empagliflozin and their combination on carotid intima-media thickness in patients with type 2 diabetes mellitus","I Ikonomidis","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3038",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053073","ADDITION OF EICOSAPENTAENOIC ACID TO A GLP-1 AGONIST ENHANCED EXPRESSION OF DETOXIFICATION PROTEINS IN ENDOTHELIAL CELLS DURING INFLAMMATION IN VITRO","Samuel C. R. Sherratt","2025","Journal of the American College of Cardiology","preclinical","article","10.1016/s0735-1097(25)00807-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053074","P021 - Exenatide vs insuline glargine chez des patients diabétiques de type 2 sous metformine + sulfamide : même contrôle glycémique, baisse du poids et du nombre d’hypoglycémies nocturnes avec exenatide","Robert J. Heine","2005","Annales d Endocrinologie","other","article","10.1016/s0003-4266(05)81862-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053075","Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era","Andrew J. Krentz","2018","Cardiovascular Endocrinology & Metabolism","other_trial","article","10.1097/xce.0000000000000150","31646270",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0053076","Can patient profile influence on GLP1 analogues prescription among physicians?: patient selection and perspectives","Manuel Cayón-Blanco","2018","Endocrine Abstracts","other","article","10.1530/endoabs.56.p492",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053077","Rare Liraglutide-Induced Dermatological Adverse Reaction in the Treatment of Obesity","Muhammad Masoud Alam","2024","Journal of Diabetes and Endocrine Practice","other","article","10.1055/s-0044-1788934",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053078","S3262 Lymphoethelial Cyst of the Pancreas: A Case Study","Sana Rabeeah","2025","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0001140508.69888.96",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0053079","Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice","Hermione Clare Price","2012","Practical Diabetes","other","article","10.1002/pdi.1660",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053080","THU255 Tirzepatide-induced Weight Loss In A Type 2 Diabetic Taking Oral Contraceptives","Amar Arunachalam","2023","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvad114.692",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053081","2097-LB: Generalizability of SELECT and SURMOUNT-MMO Trial Criteria to the U.S. OMM-Eligible Adult Population","Ambarish Pandey","2025","Diabetes","other_trial","article","10.2337/db25-2097-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053082","Diabete autoimmune dell’adulto trattato con Semaglutide: un caso clinico con follow-up quinquennale e valutazione periodica della funzionalità beta-cellulare","Martina Antonello","2024","il Diabete","other","article","10.30682/ildia2401g",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053083","Liraglutide effects on glycaemic control, body weight, blood pressure and lipid profile in obese patients with type 2 diabetes: real-life clinical practice","José Carlos Fernández‐García","2014","Endocrine Abstracts","other","article","10.1530/endoabs.35.p500",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053084","PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE","Kristina Secnik Boye","2019","Value in Health","nonrandomized_study","article","10.1016/j.jval.2019.09.995",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0053085","Efficacy and safety of domestic exenatide injection in treating type 2 diabetes: A multicenter, randomized, controlled, and non-inferiority trial","Qing Tian","2017","Zhonghua neifenmi daixie zazhi","randomized_trial","article","10.3760/cma.j.issn.1000-6699.2017.04.006",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053086","LIRAGLUTIDE AND SEMAGLUTIDE ATTENUATE INFLAMMATORY CYTOKINES INTERFERON-GAMMA, TUMOR NECROSIS FACTOR-ALPHA, AND INTERLEUKIN-6: POSSIBLE MECHANISM OF DECREASING CARDIOVASCULAR RISK IN DIABETES MELLITUS","Stanley Andrew Tan","2019","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(19)32472-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053087","Glycemic Variability in Youth Prescribed Obesity Pharmacotherapy: A Prospective Case Series with Continuous Glucose Monitoring","Jennifer Lynn Nguyen","2025","Diabetes Technology and Obesity Medicine","case_report","article","10.1089/dtom.2024.0002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053088","854-P: ENT-03, a Centrally Acting Endogenous Spermine Bile Acid with PTP1B Inhibitory Activity, Has Potent Effects on Metabolism and Weight in a Mouse Model of Diet-Induced Obesity (DIO)","Denise Barbut","2023","Diabetes","other_trial","article","10.2337/db23-854-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053089","Einjährige Behandlung adipöser Erwachsenen ohne Diabetes mit einer Kombination von Dapagliflozin und wöchentlichem Exenatide: Ergebnisse einer offenen Verlängerungsstudie","JW Eriksson","2017","Diabetologie und Stoffwechsel","other","article","10.1055/s-0037-1601676",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053090","Once-weekly exenatide in a real-world clinical setting: clinical outcomes and analysis of potential predictors of response","Mar Roca-Rodriguez Maria del","2015","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.37.ep483",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0053091","4CPS-055 Pharmacogenetics and its applications in personalised medicine: a systematic review","Leonor Amaro","2024","Section 4: Clinical pharmacy services","systematic_review","article","10.1136/ejhpharm-2024-eahp.159",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0053092","Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)","Dominik B. Dahl","2022","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0042-1746273",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053093","HSD72 Baseline A1C and BMI Trends for People with Type 2 Diabetes Receiving First-Time GLP-1 Ra Prescriptions","Brianna Cartwright","2024","Value in Health","other","article","10.1016/j.jval.2024.03.1295",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053094","PDB32 COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING","A. Liu","2020","Value in Health","other","article","10.1016/j.jval.2020.04.220",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053095","Abstract 10019: Access to Specialty Cardiovascular Care and Uptake of Cardioprotective Anti-Hyperglycemic Agents Among Adults With Type 2 Diabetes: A Cohort Study","Arash Aghajani Nargesi","2022","Circulation","nonrandomized_study","article","10.1161/circ.146.suppl_1.10019",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053096","Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020","Robert E. J. Ryder","2020","British Journal of Diabetes","other_trial","article","10.15277/bjd.2020.276",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0053097","Effectiveness of an Email-Based, Semaglutide-Supported Weight-Loss Service for People with Overweight and Obesity in Germany: A Real-World Retrospective Cohort Analysis","Louis A Talay","2024","Obesities","nonrandomized_study","article","10.3390/obesities4030021",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053098","Serious Adverse Effects Following use of Liraglutide in Individuals with Type 2 Diabetes","Benjamin M. Easow","2022","Journal of Diabetology","other","article","10.4103/jod.jod_78_22",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053099","Cost-effectiveness analysis and medication use for gangrene treatment in type 2 diabetes patients: A systematic literature review","Entris Sutrisno","2025","Pharmacia","nonrandomized_study","article","10.3897/pharmacia.72.e144858",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0053100","EE287 Cost-Effectiveness of Tirzepatide As an Adjunct to a Reduced-Calorie Diet and Increased Physical Activity Versus Diet and Exercise Alone in Patients With Obesity or Overweight From a UK Perspective","Matthew Capehorn","2024","Value in Health","other","article","10.1016/j.jval.2024.10.569",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053101","Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study (Preprint)","Amir Reza Ashraf","2024",null,"other","article","10.2196/preprints.65440",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0053102","GLP1R Agonists Activate Human POMC Neurons","Simone Mazzaferro","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.4855485",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0053103","NLRP3/IL-1 pathway was reduced by semaglutide and dapagliflozin in association therapy under exposure to anthracyclines in hyperglycemic conditions","Nicola Maurea","2025","European Heart Journal","preclinical","article","10.1093/eurheartj/ehaf784.4108",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053104","Body Weight Loss With Oral Semaglutide is Independent of Gastrointestinal Adverse Events","Juris Jendrik Meier","2021","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2021.09.048",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053105","Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)","Thomas A. Wadden","2024","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0044-1785401",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053106","Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin","Bernard Zinman","2011","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053107","Prevention: From Lifestyle Changes to Medication","Thomas Felix Lüscher","2018","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehy371","30052950",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053108","The Comparative Cardiovascular Effectiveness of Six Antidiabetic Medications among Insured Adults with Type 2 Diabetes","Matthew T. O’Brien","2018","Diabetes","nonrandomized_study","article","10.2337/db18-1125-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053109","GLP-101: A Diabetes Educator’s Guide to Glucagon-Like-Peptide-1 Receptor Agonists","Betsy A. Gillenwater","2019","AADE in Practice","other","article","10.1177/2325160319861453",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053110","526 COST-EFFECTIVENESS ANALYSIS OF LAPAROSCOPIC SLEEVE GASTRECTOMY COMPARED TO SEMAGLUTIDE FOR WEIGHT LOSS IN PATIENTS WITH OBESITY","Muhammad A. Haseeb","2023","Gastroenterology","other","article","10.1016/s0016-5085(23)04482-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053111","Preface: phys. stat. sol. (b) 242/3","Krzysztof Witold Wojciechowski","2005","physica status solidi (b)","commentary","article","10.1002/pssb.200590008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0053112","Diagnostic methods and pharmacological management of non-alcoholic fatty liver disease – There is still room for improvement","Chrysoula Boutari","2020","Journal of Atherosclerosis Prevention and Treatment","other","article","10.53590/japt.02.1008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053113","O7 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: results from a randomised, double-blind, placebo-controlled phase 2 trial","Arun Jayant Sanyal","2024",null,"randomized_trial","article","10.1136/gutjnl-2024-basl.5",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0053114","Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial","Gilbert H. Daniels","2021","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/4ena-v672",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0053115","LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST","Sergey Vladimirovich Nedogoda","2018","Russian Journal of Cardiology","other","article","10.15829/1560-4071-2018-4-89-92",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053116","Saxagliptin: a molecule for treatment of type II diabetes mellitus.","Devang S. Patel","2009",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053117","Safety and Efficacy of Glucagon-Like-Peptide-1 Receptor Agonists in Heart Transplant Patients","R Enríquez","2025","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2025.02.1380",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053118","EASD Watch : 2012 update from Berlin, Germany : summaries","Julia Aalbers","2012","˜The œSouth African journal of diabetes & vascular disease","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053119","Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis","Ella Zomer","2024","European Heart Journal","other_trial","article","10.1093/eurheartj/ehae666.3623",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053120","225-LB: Demographic and Clinical Comparisons of South Asians with Type 2 Diabetes vs. Caucasians and African Americans in an Urban Clinical Setting","Amiya A Ahmed","2019","Diabetes","nonrandomized_study","article","10.2337/db19-225-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053121","Insights into Myocardial Fibrosis in Advanced Chronic Kidney Disease Using Human Tissue","Nandan Kumar Mondal","2023","Kidney360","preclinical","article","10.34067/kid.0000000000000285","38032767",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053122","Efficacy and Safety of Glp1-Ras Compared to Sglt2is and Dpp-4is in Individuals with Schizophrenia and Diabetes: A Danish Nationwide Target-Trial Emulation Study","Søren Lundorff Jacobsen","2024","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.5048991",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0053123","TRIM: Teen Obesity and GLP-1 Receptor Agonists - Insights from a Systematic Review, Meta-Analysis, and Drug-Wise Network Meta-Analysis","Muhammad Aaqib Shamim","2023","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.4654257",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0053124","O41 Modalités d’utilisation du liraglutide par des endocrinologues de l’île de France dans le traitement du diabète de type 2 et résultats à 6 et 12 mois","Olivier Dupuy","2012","Diabetes & Metabolism","other","article","10.1016/s1262-3636(12)71019-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053125","Insulin treatment and longer diabetes duration both predict poorer glycaemic response to liraglutide treatment in type 2 diabetes: the Association of British Clinical Diabetologists Nationwide Liraglutide Audit","Ken Y Thong","2015","The British Journal of Diabetes","nonrandomized_study","article","10.15277/bjdvd.2015.046",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053126","#2496 Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial","Helen Martina Colhoun","2024","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfae069.692",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053127","PDB70 BASELINE CHARACTERISTICS AND ANTIDIABETIC EXPOSURE IN PATIENTS WITH TYPE-2 DIABETES TREATED WITH LIRAGLUTIDE","Carrie McAdam Marx","2011","Value in Health","other","article","10.1016/j.jval.2011.02.578",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053128","Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4)","Vanita R. Aroda","2016","Diabetes Research and Clinical Practice","other","article","10.1016/s0168-8227(16)31024-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053129","Sa1741 GLP-1 AGONISTS CONFER NO INCREASED RATE OF IBD EXACERBATION AMONG OBESE PATIENTS WITH COMORBID IBD","IRVING M. LEVINE","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01626-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053130","Liraglutide (revision number 2)","Tina Vilsbøll","2012","Diapedia.org eBooks","other","article","10.14496/dia.8104335182.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0053131","RISKS IN THE SUPPLY CHAIN DURING OFF-LABEL USE OF DRUGS IN OBESITY THERAPY AND EXAMPLES","Proton System, Beograd, Srbija","2024",null,"other","article","10.46793/jusk-icqxx.077k",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0053132","Biological roles of milk osteopontin","Rulan Jiang","2016","Current Opinion in Clinical Nutrition & Metabolic Care","other","article","10.1097/mco.0000000000000275","27504516",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053133","Incretin based therapies in type 2 diabetes","Mukhyaprana M. Prabhu","2014",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0053134","S2061 Comparative Efficacy and Safety of Bariatric Surgery, Bariatric Endoscopy, and GLP-1 Receptor Agonists in Obesity Management: A Network Meta-Analysis","Jena Velji-Ibrahim","2024","The American Journal of Gastroenterology","systematic_review","article","10.14309/01.ajg.0001037612.78551.4e",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0053135","1433-P: Protective Effect of GLP-1 Receptor Agonists (GLP-1 RA) and SGLT2 Inhibitors (SGLT2i) against Adverse Cardiovascular (CV) Events in HIV and Type 2 Diabetes Mellitus (T2DM) When Compared with Metformin Alone: A National Database Study","Omar Ali Alaber","2020","Diabetes","nonrandomized_study","article","10.2337/db20-1433-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053136","S917 Effectiveness and Safety of Weight Loss Medical Therapy in Ulcerative Colitis","Jonathan Pham","2022","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000860308.31550.96",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053137","1030-P: Effect of MEDI0382 on the Pharmacodynamics and Pharmacokinetics of Warfarin or Esmolol in Healthy Volunteers","H. Coleman","2019","Diabetes","other_trial","article","10.2337/db19-1030-p",null,null,"ClinicalTrials.gov:NCT03347968","S000590","openalex","FALSE","paywalled","5","FALSE","article"],["R0053138","Efficacy of investigational dulaglutide doses overall and by baseline HbA1c and Body Mass Index (BMI): exploratory subgroup analyses of the AWARD-11 trial","Enzo Bonora","2021","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0041-1727332",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0053139","7440 Both GLP-1RA and SGLT2i medications are associated with lower depression scores in veterans compared to metformin and insulin","Shannen Nicole Dean Ubalde","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.687",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053140","IDegLira bei Patienten mit Typ 2 Diabetes: Wirksamkeit und Sicherheit nach 1 Jahr","Marcel Kaiser","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549743",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053141","Glucagon-like peptide 1 receptor agonists and protection against stroke: a systematic review and meta-analysis","H.J. Milionis","2018","Atherosclerosis","systematic_review","article","10.1016/j.atherosclerosis.2018.06.170",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article; other"],["R0053142","1982-LB: MPC-Directed Insulin Sensitizer MSDC-0602K Combines with Tirzepatide to Maintain Muscle Mass/Function and Restructure Adipose Tissue","MOHAMED ABU-FARHA","2025","Diabetes","preclinical","article","10.2337/db25-1982-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053143","1006-P: Distributional Cost-Effectiveness Analysis of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) and Tirzepatide Compared with Sulfonylureas (SU) in People with Inadequately Controlled Type 2 Diabetes (T2D)","PIAOPIAO LI","2023","Diabetes","other","article","10.2337/db23-1006-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053144","Integrated In Silico and In Vivo Assessment of Weight Management Agents Setmanlotide and Orforglipron and Natural Products Berberine and Capsicum","Rasha Saad Suliman","2026","Applied sciences research periodicals.","other","article","10.63002/asrp.404.1661",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053145","Glucagon-like peptide-1 based therapies: Effects beyond blood glucose control","Subash Sivaraman","2013","The British Journal of Diabetes","preclinical","article","10.1177/1474651413504119",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053146","(Invited) Fast and Generalizable Electrochemical Sensing of Small Molecules, Peptides, and Proteins Using a Nucleic Acid Nanostructure with Analyte-DNA Conjugates","Christopher John Easley","2022","ECS Meeting Abstracts","other","article","10.1149/ma2022-01532233mtgabs",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053147","Emerging metabolic hormone therapeutics for metabolic dysfunction-associated steatohepatitis: incretin-based drugs, fibroblast growth factor analogs, and liver-targeting strategies","Sukwoo Han","2026","Journal of Pharmaceutical Investigation","other","article","10.1007/s40005-026-00815-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053148","Pharmacological treatment for obesity in adults: Scoping Review","Ana Ortiz","2026",null,"narrative_review","article","10.17605/osf.io/byrpt",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0053149","Effects of various weight-reducing drugs on eating behavior","German G. Zasypkin","2023","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2023-185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053150","Association of Cardio-Ankle Vascular Index (CAVI) and Duration of Diabetes Mellitus in the STOP (Semaglutide Treatment on Coronary Plaque Progression) Randomized Control Trial","Dhiran Verghese","2021","American Heart Journal","randomized_trial","article","10.1016/j.ahj.2021.10.061",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053151","The National Paediatric Medicines Forum: Who we are and what are we doing","Deshina Naidoo","2021","Journal of Paediatrics and Child Health","other","article","10.1111/jpc.15789","34643316",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053152","PDB60 COST-EFFECTIVENESS OF LIXISENATIDE COMBINED WITH BASAL INSULIN VERSUS INSULIN REGIMENS FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN IN CHINA","P. Men","2019","Value in Health","other","article","10.1016/j.jval.2019.04.609",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053153","Wirksamkeit und Verträglichkeit von Depot-Exenatide gegenüber Placebo als Add-on zu Insulin glargin bei Typ-2-Diabetes-Patienten mit unzureichender glykämischer Kontrolle unter Basalinsulin: Duration-7-Studie","JP Frias","2018","Diabetologie und Stoffwechsel","other","article","10.1055/s-0038-1641914",null,null,"ClinicalTrials.gov:NCT02229383","S000703","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0053154","Faculty of 1000 evaluation for A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.","Pat Griffin","2012",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053155","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) USE PREDICTS RETAINED GASTRIC CONTENTS BUT NOT INCREASED RISK OF MAJOR ADVERSE ANESTHESIA-RELATED EVENTS DURING UPPER ENDOSCOPY","Alexandria R. Markley","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.2871",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053156","Target trial emulation to reduce confounding in therapy effectiveness assessment - (Based on the Cohort Study by Wang et al. on Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder)","Ricardo S. Pietrobon","2025",null,"randomized_trial","article","10.31219/osf.io/mwthq_v1",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","preprint"],["R0053157","Exanetide and Pancreatic Cancer: A Case Report and Review of Relevant Literature","Timothy Lewis Cannon","2015","American journal of cancer case reports","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053158","A Dicyanocobinamide Conjugate of the GLP-1R Agonist Exendin-4 Improves Glucose Homeostasis in Tumor-Bearing Rats without Exacerbating Anorexia and Weight Loss","Nancy Cham","2026","Molecular Pharmaceutics","preclinical","article","10.1021/acs.molpharmaceut.6c00590",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053159","Pharmacotherapy of obesity: what’s new?","Ekaterina Anatol'evna Troshina","2018","Problems of Endocrinology","other","article","10.14341/probl9315",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053160","34-OR: Postprandial Glucagon Action in the Human Brain","Robert J. Wagner","2023","Diabetes","other","article","10.2337/db23-34-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053161","Transient elastography in adults with diabetes or prediabetes: steatosis prevalence and change in controlled attenuation parameter during incretin therapy","Adnan Agha","2026","Scientific Reports","other_trial","article","10.1038/s41598-026-71754-1",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053162","Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy","Scott V. Joy","2011","Osteopathic Family Physician","other","article","10.1016/j.osfp.2011.07.002",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053163","Histopathological features of non-insulinoma pancreatogenous hypoglycemia syndrome: A rare cause of hypoglycemia in non-diabetic adults","Shivani Sidana","2024","IJEM Case Reports","other","article","10.4103/ijemcr.ijemcr_23_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053164","New Drugs in Development for the Treatment of Diabetes","Terri L. Levien","2009","Diabetes Spectrum","other","article","10.2337/diaspect.22.2.92",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053165","HPR45 Trends in Semaglutide Prescribing and Dispensing – a Nationwide Register-Based Study","H. Kari","2023","Value in Health","nonrandomized_study","article","10.1016/j.jval.2023.09.1363",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0053166","MO462: Change in KDIGO Kidney Risk Category With Semaglutide Treatment—A Post Hoc Analysis of the Sustain 6 Trial","Katherine R. Tuttle","2022","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfac070.076",null,null,"ClinicalTrials.gov:NCT01720446","S001933","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0053167","Effects of Liraglutide on Genomic Instability in Swiss Mice That Received a Hyperlipidic Diet","Rafaela Cristina Silva De Almeida","2024",null,"preclinical","article","10.62922/4cbffc.cp070",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0053168","Analysis of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1-RA) Use in Patients with Idiopathic Intracranial Hypertension (IIH)","Amanda Bingaman","2025","Journal of Neurological Surgery Part B Skull Base","nonrandomized_study","article","10.1055/s-0045-1803718",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0053169","Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association","Alberto Arduan Ortiz","2022","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfac257","36216362",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053170","1980-LB: Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study","ALEJANDRA MACIAS PULIDO","2025","Diabetes","randomized_trial","article","10.2337/db25-1980-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053171","75595 Mind Over Metabolism: Semaglutide’s Psychiatric Benefits in HS","Robert Adler","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.1209",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053172","Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article","Varun Anil Damle","2026","Journal of Diabetology","narrative_review","article","10.4103/jod.jod_85_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053173","Effect of liraglutide 3.0 mg on eating behavior in patients with obesity","Oksana Logvinova","2021","Meditsinskiy sovet = Medical Council","other","article","10.21518/2079-701x-2021-7-156-164",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053174","4 Semaglutide 2.4 mg and Intensive Behavioral Therapy in Subjects With Overweight or Obesity (STEP 3)","Thomas A. Wadden","2021","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/s-0041-1735669",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0053175","Exendin-4 limits ß-cell apoptosis and loss of ß-cell area in amyloid-forming islets","Kathryn Aston‐Mourney","2010",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053176","Effects of SGLT2 inhibitors and GLP1 receptor agonists on risk of various fractures: a meta-analysis of large randomized trials","Mei Hong Qiu","2021",null,"systematic_review","article","10.37766/inplasy2021.1.0103",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0053177","6866 Real-world implications and limitations of GLP-1 prescriptions in adolescents","Gabriel Castano","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.1506",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053178","Impact of GLP1R and its agonists in pulmonary circulation","Dusan Jeremic","2024",null,"preclinical","article","10.1183/13993003.congress-2024.pa2641",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053179","57 - Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program","Sue D. Pedersen","2020","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2020.08.063",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053180","Cardiovascular-kidney-metabolic: Hype or a focus on front-line health?","Xinyi Cai","2025","Journal of Translational Internal Medicine","other","article","10.1515/jtim-2025-0049","41438464",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053181","Effects of glucagon-like peptide-1 receptor agonists on copeptin in healthy volunteers and patients with primary polydipsia","Svenja Leibnitz","2023","Endocrine Abstracts","other","article","10.1530/endoabs.93.oc10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053182","894-P: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist","JAMES S. MINNION","2025","Diabetes","preclinical","article","10.2337/db25-894-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053183","Efficacy of Semaglutide vs. Dulaglutide Across Baseline HbA1C in SUSTAIN 7","Paulina K. Wrzal","2018","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2018.08.131",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053184","Abstract 4135712: Mortality and Cardiovascular Complications Associated with Weight Loss Drugs among Breast Cancer Females Under Cardiotoxic Therapies: A Real-World Populational Study in the United States","Chuan Angel Lu","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4135712",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053185","TYPE II KOUNIS SYNDROME IN A PATIENT WITH ANAPHYLAXIS TO DULAGLUTIDE","Varun Kohli","2021","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(21)03912-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053186","SAT085 Oral Glucagon-like Peptide-1 Receptor Agonist As Adjuvant Treatment In HNF1A-MODY","David Tyler Broome","2023","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvad114.951",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0053187","Insights into the mechanisms underpinning the physiological effects of biased GLP-1 receptor agonists","Maria Lucey","2019","Endocrine Abstracts","other","article","10.1530/endoabs.65.p235",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053188","Position Paper of the German Diabetes Association, German Society of Angiology and Vascular Medicine, German Society for Vascular Surgery and Vascular Medicine and German Society for Interventional Radiology and Minimally Invasive Therapy on the Diagnosis and Treatment of Peripheral Arterial Occlusive Disease in Diabetes Mellitus","Kilian Rittig","2026","Experimental and Clinical Endocrinology & Diabetes","other","article","10.1055/a-2766-4074","42526880",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053189","A Case of Semaglutide-Induced Skin Burning","Maia Stokes","2025","Annals of Internal Medicine Clinical Cases","case_report","article","10.7326/aimcc.2024.0568",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053190","Are GLP-1 receptor agonists cost-effective at closing-the-gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity?","Satyen Hargovan","2025","Heart Lung and Circulation","other","article","10.1016/j.hlc.2025.06.802",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053191","Weight control issues: perspectives in aesthetic medicine","Larisa Sergeevna Kruglova","2024","Medical alphabet","other","article","10.33667/2078-5631-2024-25-8-12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053192","S343 Risk of Diverticular Diseases in Diabetic Patients on Semaglutide, a GLP-1 Agonist. A Retrospective Cohort Study Utilizing Big Data and Propensity Score Matching","Rashid H. Abdel-Razeq","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001030740.02660.da",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053193","Semaglutide intervention in overweight people with schizophrenia: the road back to better physical health - preliminary results from a feasibility study","Adrian Hugh Heald","2024","Endocrine Abstracts","other","article","10.1530/endoabs.104.p116",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053194","1003-P: Clinical Response (HbA1c ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA1c and Body Weight in the SUSTAIN Program","Vanita R. Aroda","2019","Diabetes","other","article","10.2337/db19-1003-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053195","Inclusion of oral glucose tolerance testing for diabetes screening in patients with ST-elevation myocardial infarction","Andreas Schäfer","2021","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwab004","34038506",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053196","The effect of metformin and liraglutide on markers of subclinical atherosclerosis in women with polycystic ovary syndrome","Mojca Jensterle","2015","Endocrine Abstracts","other","article","10.1530/endoabs.37.gp.06.07",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053197","Table 17, Liraglutide phase III clinical trials","Byambaa Enkhmaa","2015",null,"other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0053198","A Living Benefit-Harm Modelling Study of Glp-1 Receptor Agonists for Weight Reduction in Non-Diabetic Obese and Overweight Individuals","Hannah Moll","2024","SSRN Electronic Journal","other","article","10.2139/ssrn.4709105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0053199","745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes","N Dyrby Johansen","2022","Diabetes","randomized_trial","article","10.2337/db22-745-p",null,null,"ClinicalTrials.gov:NCT03017352","S000283","openalex","FALSE","paywalled","1","FALSE","article"],["R0053200","B45-18 Glp-1 Receptor Agonists Reduce Hospitalization, Respiratory Failure, and Mortality in Adults With Cystic Fibrosis and Diabetes: A Real-world Propensity-matched Study","M Alkharabsheh","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.2147",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053201","Exendin-4 Decreases Blood Glucose Levels, but Does not Affect Other Metabolic Parameters in Transplanted Human Islets from Old and Young Donors","Afaf Sahraoui","2012","Transplantation","preclinical","article","10.1097/00007890-201211271-01381",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053202","774-P: Impact of Newer GLP-1 RAs on HbA1c in U.S. Adults with Type 2 Diabetes—A Population-Level Time-Series Analysis","Lei Lv","2024","Diabetes","nonrandomized_study","article","10.2337/db24-774-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053203","P205 Effect of metformin on reducing the risk of COPD exacerbations: a UK nested case-control study","P. S. Tse","2023",null,"nonrandomized_study","article","10.1136/thorax-2023-btsabstracts.355",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0053204","Evolution of anthropometric and biochemical parameters after 6 months of treatment with exenatide compared to dapagliflozin in patients with type 2 diabetes.","Bogdan Apan","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053205","Glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus: a brief review","Manuel Menendez Gonzalez","2016",null,"narrative_review","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0053206","EE497 The Cost-Effectiveness of Semaglutide 2.4MG in Patients With Overweight/Obesity and Cardiovascular Disease From the Select Trial","Phil C. McEwan","2024","Value in Health","other_trial","article","10.1016/j.jval.2024.03.2261",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","conference-abstract"],["R0053207","Quick Take Vol. 84","Scott R. Beach","2026",null,"other","article","10.64239/pi-nl-qt84",null,null,null,null,"openalex","FALSE",null,null,"FALSE","report"],["R0053208","Geographic Variation in Prevalence of Adult Obesity in China: Results From the 2013–2014 National Chronic Disease and Risk Factor Surveillance","Xiao Zhang","2019","Annals of Internal Medicine","randomized_trial","article","10.7326/m19-0477","31658469",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053209","A Questionnaire-Based Study on the Use of Weight-Loss Medicines and Herbal Mixtures among Pharmacy Students in the Hail Region","Weiam Hussein","2023","Indian Journal of Pharmaceutical Education and Research","other","article","10.5530/ijper.58.1.37",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053210","Phytochemicals of Promise in the Management of Type 2 Diabetes Mellitus","Soumya Mitra","2023","BENTHAM SCIENCE PUBLISHERS eBooks","preclinical","article","10.2174/9789815136326123020011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0053211","939-P: Safety of Newer Glucose Medications in Adults with Type 2 Diabetes and Low to Moderate CV Risk","Julie M. Paik","2024","Diabetes","nonrandomized_study","article","10.2337/db24-939-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053212","318-OR: Tirzepatide Reduces Albuminuria in Patients with T2D—Post Hoc Pooled Analysis of SURPASS 1–5","Hiddo J.L. Heerspink","2023","Diabetes","other","article","10.2337/db23-318-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053213","26-A-16805-ACC THE LIRAGLUTIDE EFFECT ON ATRIAL FIBRILLATION (LEAF) STUDY: WHAT IS THE SECRET SAUCE?","Jeffrey J. Goldberger","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.159",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053214","Effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis: Protocol for a randomised, double blind, placebo-controlled, parallel group, single-centre trial.","Henrik Gudbergsen","2018",null,"protocol","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0053215","Abstract 14545: Glucagon-Like Peptide-1 Receptor Activation With Liraglutide During Acute Myocardial Infarction Improves Myocardial Salvage and Systolic Left Ventricular Function","Torsten Peter Vahl","2013","Circulation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053216","Effets du liraglutide (analogue de la GLP-1) sur l'équilibre glycémique et les facteurs de risque cardiovasculaire du diabétique de type 2","J.P. Courrèges","2007","La Revue de Médecine Interne","other","article","10.1016/j.revmed.2007.03.035",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053217","686-P: The Association of British Clinical Diabetologists (ABCD) United Kingdom Nationwide Semaglutide Audit","Thomas Simon James Crabtree","2021","Diabetes","randomized_trial","article","10.2337/db21-686-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053218","1981-LB: Modeling the Impact of Semaglutide 2.4 mg in U.S. Patients with Atherosclerotic Cardiovascular Disease and BMI ≥27 kg/m2","Mads D. Faurby","2024","Diabetes","other_trial","article","10.2337/db24-1981-lb",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053219","INCRETIN BASED THERAPIES","Sanjay Kalra","2013",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0053220","LBSUN151 The Impact Of The COVID-19 Pandemic On Diabetes & Weight Management","Hiba Z. Hashmi","2022","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvac150.577",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0053221","Abstract 14307: Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial","Gregory G. Schwartz","2020","Circulation","other_trial","article","10.1161/circ.142.suppl_3.14307",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0053222","Evaluation of the Cost Per Patient Achieving Composite and Single Treatment Targets with Once-Weekly Semaglutide and Exenatide ER in the United States","Richard Fulton Pollock","2018","Value in Health","other","article","10.1016/j.jval.2018.04.501",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053223","S2103 Investigation of Combined Effects of Glucagon-Like Peptide-1 Receptor Agonists With Bariatric Procedures for Weight Loss: A Propensity-Matched Multi-Network Study","Khushbu Patel","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037780.95877.ca",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053224","Tu1784 Impaired Satiety Effect of GLP-1 Agonist in Obesity Is Associated With GLP-1 Resistance in Intestinal Afferent Nerves","Ala'a Al-Helaili","2014","Gastroenterology","other","article","10.1016/s0016-5085(14)63060-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053225","Mo1917 PREVIOUS ANTI-OBESITY MEDICATION INFLUENCES THE WEIGHT LOSS OUTCOMES OF SEMAGLUTIDE TREATMENT FOR OBESITY","Wissam Ghusn","2023","Gastroenterology","other","article","10.1016/s0016-5085(23)03170-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053226","Duration-8-Studie: Mechanismen der glykämischen Kontrolle unter Depot-Exenatide+Dapagliflozin im Vergleich zu den Einzelsubstanzen","Ele Ferrannini","2018","Diabetologie und Stoffwechsel","other","article","10.1055/s-0038-1641910",null,null,"ClinicalTrials.gov:NCT02229396","S000791","openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0053227","Cost-Related Barriers to New Diabetes Medications—A National Physician Survey","Sandra A. Ham","2018","Diabetes","other","article","10.2337/db18-149-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053228","Abstract 4141989: Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists remain significantly lower than those for other cardioprotective medications: Results from a retrospective, cross-sectional study at a large academic medical center","Andrew H. Ling","2024","Circulation","nonrandomized_study","article","10.1161/circ.150.suppl_1.4141989",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053229","S1900 GLP-1 Receptor Agonists Reduce the Risk of Hepatocellular Carcinoma and Cirrhosis in Patients With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes","Saqr Alsakarneh","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001036968.88400.f3",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053230","Glucagon-Like Peptide-1 Agonists Confer no Additional Benefit during Bunion Correction Procedures with Regards to Complications and Adverse Effects","Nicholas R. Kiritsis","2025","Foot & Ankle Orthopaedics","nonrandomized_study","article","10.1177/2473011425s00270",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053231","Semaglutide: More Weight Loss than Placebo, No Diabetes Required","Gregory Michael Weiss","2018",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053232","PDG15 ECONOMIC ASSESSMENT OF SWITCHING FROM DIPEPTIDYL PEPTIDASE-4 INHIBITORS TO SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS OR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USING REAL-WORLD DATA","Samuel K. Peasah","2020","Value in Health","nonrandomized_study","article","10.1016/j.jval.2020.04.305",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0053233","Tu1670 USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN POPULATIONS WITH NASH OR AT RISK OF NASH IN US CLINICAL PRACTICE","Michelle Lai","2020","Gastroenterology","other","article","10.1016/s0016-5085(20)34283-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053234","Measure Real-Time cAMP Signaling in the Living Cell","Xiping Liu","2018","Diabetes","other","article","10.2337/db18-1734-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053235","Association between Glucagon-Like Peptide-1 Receptor Agonists and Asthma Exacerbations in Non-Diabetic Patients with Obesity: Cohort Study","Ruchi Patel","2026","Journal of Allergy and Clinical Immunology","nonrandomized_study","article","10.1016/j.jaci.2025.12.553",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053236","Baseline characteristics and clinical outcomes of patients with type 2 diabetes and cardiovascular disease treated with GLP-1 receptor agonists and SGLT2 inhibitors","Ziad Arow","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3793",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053237","Synthesis of new exenatide analogs and investigation of their influence on glycemia and renal function in rats","A. E. Bogolepova","2011","Problems of Endocrinology","preclinical","article","10.14341/probl201157342-47",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053238","2066-LB: Potential to Optimize Weight Loss with Enobosarm—Meta-analysis of Body Composition from Three Randomized Clinical Trials Support the Ability of Enobosarm to Preserve Muscle while Reducing Fat","Jeffrey Crawford","2024","Diabetes","systematic_review","article","10.2337/db24-2066-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053239","599: OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES WITH MASH AND MASLD: A COMPARISON BETWEEN BARIATRIC SURGERY AND GLP-1 AGONISTS","Zehra Naseem","2025","Gastroenterology","other","article","10.1016/s0016-5085(25)05343-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053240","Incidentalomas of the heart: lipomatous hypertrophy of the interatrial septum in the GLP-1 era","Muhammad Shahmeer Khan","2026","Annals of Medicine and Surgery","other","article","10.1097/ms9.0000000000004744","41675881",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053241","Promoting and supporting children’s health and healthcare during COVID-19 – International Paediatric Association Position Statement","Jonathan D. Klein","2020","Archives of Disease in Childhood","nonrandomized_study","article","10.1136/archdischild-2020-319370","32381517",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053242","Orforglipron zum Erhalt der Gewichtsreduktion mittels inkretinbasierter Therapien","SABINE KAHL","2026","Die Diabetologie","other","article","10.1007/s11428-026-01492-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053243","GLP-1 receptor variants markedly differentiate glycaemic response to GLP-1 receptor agonists : a DIRECT study","Adem Y. Dawed","2017","Site cant be reached","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053244","High-dose oral linezolid achieved rapid clinical and microbiological recovery in a severely overweight male with long-standing infected ulcers","Haresh Selvaskandan","2019","Journal of Antimicrobial Chemotherapy","nonrandomized_study","article","10.1093/jac/dkz071","30783670",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053245","Once-Weekly Semaglutide 1 mg vs Empagliflozin 25 mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: a Meta-Regression Analysis of Individual Patient Data","Ildiko Lingvay","2022","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-1746268",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053246","GLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES","Paulo Victor Gonçalves Secco","2025","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.1595172511043",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053247","Letter: Cerebrospinal Fluid Shunting for Idiopathic Intracranial Hypertension: A Systematic Review, Meta-Analysis, and Implications for a Modern Management Protocol","Susan P. Mollan","2022","Neurosurgery","systematic_review","article","10.1227/neu.0000000000002316","36700758",null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0053248","Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection","Rachel Therese McGrath","2015","Journal of Steroids & Hormonal Science","other","article","10.4172/2157-7536.1000.152",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053249","Abstract P365: Number of Beds and Volume of Patients Correlates With Increased Uptake of Novel Cardiovascular Medications in the Veterans Affairs System","Taufiq Salahuddin","2023","Circulation","other","article","10.1161/circ.147.suppl_1.p365",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053250","Differential hepatoprotective effects of semaglutide and lanifibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC","Malte Hasle Nielsen","2023","Journal of Hepatology","preclinical","article","10.1016/s0168-8278(23)01293-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053251","62918 The effect of Glucagon-like peptide (GLP)-1 agonists on hidradenitis suppurativa disease severity and musculoskeletal symptoms: A Quality Improvement Initiative by International Dermatology Outcome Measures (IDEOM)","Sarah Romanelli","2025","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2025.05.356",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053252","The Role of Glucagon-Like Peptide 1 Receptor PET/CT With Ga-68-NODAGA-exendin in Localising an Insulinoma: Lessons From a Clinical Case","Victoria Chatzimavridou-Grigoriadou","2021","Journal of the Endocrine Society","other","article","10.1210/jendso/bvab048.1252",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053253","899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice","Archana Vijayakumar","2024","Diabetes","preclinical","article","10.2337/db24-899-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053254","Association fixe Degludec-Liraglutide en situation de vie réelle : étude multicentrique française sur les modalités dâinitiation et lâefficacité à 6 mois","Chloé Noilhan","2019",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053255","993-P: A Real-World New User Cohort Study of Metformin vs. SGLT2i or GLP-1RA on the Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients with Cardiovascular Risk Factors","Caroline Foch","2021","Diabetes","nonrandomized_study","article","10.2337/db21-993-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053256","LE MEDICAMENT DU MOIS. Le liraglutide a la dose de 3 mg (Saxenda): indication dans le traitement de l'obesite.","André Jacques Scheen","2016","RMLG. Revue médicale de Liège","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053257","Abstract 4364791: GLP-1 Receptor Agonists Lower Readmission Rates Without Impacting Mortality After CABG in Adults with Congenital Heart Disease","Jason H. Yan","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4364791",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053258","SAT-661 Hepatic and Cardiovascular Outcomes of Patients with Metabolic Dysfunction-Associated Steatotic-Liver Disease and Diabetes Mellitus Type 2 Treated with Glucagon-Like Peptide 1 Agonists","Suleiman Al Ashi","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.097",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053259","S972 GLP-1 Use in the Obese Population and the Development of Barrett's Esophagus in a Rural State","Shawn Howell","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001131348.38207.76",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053260","Glucagon-Like Peptide-1 Receptor Agonist Use and Asthma Exacerbations Among Type 2 Diabetics with Asthma","Dinah Foer","2020",null,"other","article","10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2736",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053261","Attenuated Efficacy of Dulaglutide in Elder Type 2 Diabetes Mellitus (T2DM) Cases","Takako K. Abe","2018","Diabetes Research - Open Journal","other","article","10.17140/droj-4-136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053262","Efficacy and safety of semaglutide in patients with obesity-related heart failure: a meta-analysis of randomized clinical trials","Radhika Gulhar","2025","European Journal of Preventive Cardiology","systematic_review","article","10.1093/eurjpc/zwaf236.265",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0053263","Therapie des Typ-2-Diabetes","Rüdiger Landgraf","2023","Diabetologie und Stoffwechsel","other","article","10.1055/a-2076-0024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053264","Novel Peptides: An Alternative Approach for the Treatment of Diabetes Mellitus","Rumi Ghosh","2007","Current Drug Therapy","other","article","10.2174/157488507781695658",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053265","90-LB: Treatments and Trends in Glycemic Control for Patients with Type 2 Diabetes Mellitus Treatment following Metformin","Sanjay Kumar Bajpai","2019","Diabetes","nonrandomized_study","article","10.2337/db19-90-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053266","The Endocrine Society Centennial: Cleavage Matters","Patricia Lee Brubaker","2016","Endocrinology","preclinical","article","10.1210/en.2016-1667","27799010",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053267","A606 Use of Incretin-Based Therapy as An Adjunct to Endoscopic Revisions After Bariatric Surgery","Winni Mathur","2019","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2019.08.542",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053268","Continuous Deep Learning Approach for Accelerated MR Imaging Annotations for Subcutaneous and Visceral Adipose Tissue Quantification in Sleep Apnea Patients","Valentin Fauveau","2025","American Journal of Respiratory and Critical Care Medicine","other","article","10.1164/ajrccm.2025.211.abstracts.a4744",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053269","Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: Reflections From aDiabetes CareEditors’ Expert Forum","Julio Rosenstock","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other","article","10.17615/efp1-s866",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053270","ONE-YEAR RISK ASSESSMENT OF MAJOR ADVERSE CARDIOVASCULAR AND KIDNEY EVENTS IN BARIATRIC SURGERY PATIENTS TREATED WITH GLP-1 AGONISTS","Sanya Goswami","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.759",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053271","Audit of documentation of contraceptive advice and pregnancy avoidance counselling to patients starting glucagon-like peptide-1 receptor agonists at a hospital obesity clinic","Binti Tengku Mazlan Tengku Alya","2026","Endocrine Abstracts","other","article","10.1530/endoabs.115.p47",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053272","PDB57 ADMINISTRATIVE CLAIMS ANALYSIS OF NEW EXENATIDE PATIENTS WITH TYPE 2 DIABETES","Rosalind P. Fabunmi","2007","Value in Health","other","article","10.1016/s1098-3015(10)65005-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053273","FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS","А. С. Колбин","2015","PHARMACOECONOMICS (Eurasian Economic Community)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053274","Abstract P108: Natural Language Processing Extracted Social And Behavioral Determinants Of Health And Newer Glucose-lowering Drug Initiation Among Real-world Patients With Type 2 Diabetes","Jingchuan Serena Guo","2022","Circulation","nonrandomized_study","article","10.1161/circ.145.suppl_1.p108",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053275","Should we exclude hemato-oncological patients from obesity treatment with semaglutide? – A case report","J Dobrowolska","2025","Annales Academiae Medicae Silesiensis","case_report","article","10.18794/aams/207726",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053276","Rat organ distribution of [Lu-177]-DO3A-VS-Cys(40)-Exendin-4 for the estimation of human dosimetry : potential for radiotherapy","Irina Velikyan","2015","Journal of Labelled Compounds and Radiopharmaceuticals","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053277","New Antiobesity Medications, GLP-1, and GIP Receptor Agonists and their Anaesthetic Implications","Siobhan Stone","2024",null,"other","article","10.28923/atotw.535",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0053278","‘Gastric’ hypoglycaemia – an important concept in diabetes management","Michael Bruce Horowitz","2006","Neurogastroenterology & Motility","nonrandomized_study","article","10.1111/j.1365-2982.2006.00804.x","16700718",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053279","784-P: The First Real-World Experience of the Effectiveness and Safety of Tirzepatide in Improving Metabolic Parameters in Type 2 Diabetes—A Six-Month Observational Study from India","PURVI M. CHAWLA","2025","Diabetes","nonrandomized_study","article","10.2337/db25-784-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053280","951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (<600 µG) with Robust Effects on Blood Glucose in Patients with T2DM","Darren C. Robertson","2020","Diabetes","randomized_trial","article","10.2337/db20-951-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053281","Abstract 4368652: Real-World Risk Reduction of Cardiometabolic Comorbidities and Improvement of Biomarkers among Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg","Aleksandrina Ruseva","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4368652",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053282","Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”","Bradley Scott Miller","2023","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/clinem/dgad095","36869702",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","letter"],["R0053283","Incretin based drugs and the risk of cholangiocarcinoma in patients with type 2 diabetes.","Devin Abrahami","2018","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2018.36.15_suppl.e16126",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053284","145-OR: GLP-1 Analogue Effects on Neural Responses to High-Fructose Corn Syrup and Eating Behavior in Obesity","Kelly Joseph","2020","Diabetes","other","article","10.2337/db20-145-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053285","EFFECT OF EXENDINE-4 WITH OR WITHOUT MUSCULAR EXERCISE ON DIABETES MELLITUS IN MALE ALBINO RATS","Saad Kamal Taha","2016","Al-Azhar Medical Journal","preclinical","article","10.12816/0026270",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053286","806-P: Glycemic Outcomes When Switching to iGlarLixi from Premixed Insulin (PI) in People with Type 2 Diabetes (T2D) by iGlarLixi Pen Subgroups—Post Hoc Analysis of Soli-SWITCH","Martin Haluzı́k","2025","Diabetes","other_trial","article","10.2337/db25-806-p",null,null,"EudraCT:2021-003711-25",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053287","Individualizing therapy: Do we have the tools to do it? 个体化治疗：我们有具体的执行方法吗？","Jonathan Edward Shaw","2014","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.12218","25209957",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053288","651-P: Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11","Enzo Bonora","2021","Diabetes","randomized_trial","article","10.2337/db21-651-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053289","Abstract 15282: Individual Participant Meta Analysis of the Cardiovascular Safety of Taspoglutide Among Individuals with Diabetes","Kausik Kumar Ray","2012","Circulation","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053290","Mo2062 Liraglutide, a Long-Acting GLP-1 Agonist, Improves Parameters of Late Dumping Syndrome During Ogtt in Patients Without Gastrectomy","Tim Vanuytsel","2013","Gastroenterology","other","article","10.1016/s0016-5085(13)62714-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053291","In Search of Declining Weight, a Significant Decline in Kidney Function: A Rare Case of Liraglutide-Induced Interstitial Nephritis","Deepika Kumari Jain","2023","Journal of the American Society of Nephrology","other","article","10.1681/asn.20233411s1427b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053292","Three-year exenatide therapy, followed by a 4-week off-drug period, had a sustainable effect on beta-cell disposition index in metformin treated patients with type 2 diabetes","Mathijs C. M. Bunck","2010","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0053293","Raising the Bar When Assessing Cardiovascular Disease Outcome When Studies with Patients with Type 2 Diabetes Mellitus are Constructed: Revisiting ASCEND","Mouhamed Nashawi","2021","Austin Journal of Endocrinology and Diabetes","other_trial","article","10.26420/austinjendocrinoldiabetes.2021.1083",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0053294","De American Diabetes Association/European Association for the Study of Diabetes-consensus van 2022 en de implicaties voor België","Simon Caerels","2023","Tijdschrift voor Geneeskunde","other","article","10.47671/tvg.78.22.181",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053295","The Epidemiology of Bile Acid Diarrhea in Denmark [Letter]","Demes Nurmayanti","2023","Clinical Epidemiology","other","article","10.2147/clep.s453992","38116045",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053296","DURABLE EFFECTS OF DUODENAL ABLATION USING ELECTROPORATION COMBINED WITH SEMAGLUTIDE TO ELIMINATE INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES; 18 MONTHS RESULTS OF THE EMINENT STUDY","CELINE B.E. BUSCH","2024","Gastrointestinal Endoscopy","other","article","10.1016/j.gie.2024.04.1784",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053297","Efficacité du liraglutide, un analogue du GLP-1, en substitution d’un inhibiteur de la DDP-4 chez les patients DT2 : données à un an de l’étude EVIDENCE®","Guillaume Charpentier","2013","Annales d Endocrinologie","other","article","10.1016/j.ando.2013.07.536",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053298","Simplifying Treatment for Type 2 Diabetes: Egyptian Consensus Recommendations on Fixed-Ratio Combinations","Samir H. Assaad-Khalil","2026","Diabetology","randomized_trial","article","10.3390/diabetology7050090",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053299","Molecular and cellular mechanisms of GLP-1 receptor agonists and their emerging clinical applications","Mateusz Kurowski","2026","Medical Journal of Cell Biology","other","article","10.2478/acb-2026-0005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053300","MON-037 GLP-1 Receptor Agonists in MEN1-Associated Glucagonoma: Exploring Glycemic Control and Tumor Stability","Renato R Savian","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1369",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053301","Outcomes of Liraglutide as treatment for weight regain after bariatric surgery: A 2-year retrospective study","Majid Alameri","2019","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.65.p416",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053302","FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial","Christian Ludwig Roth","2023","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvad114.076",null,null,"ClinicalTrials.gov:NCT04725240",null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0053303","751-P: Effect Of Once-Weekly Semaglutide on Weight Change and Metabolic Control in People with Type 1 Diabetes—Six-Months Results from the Real-World STEMT Trial","Jonathan Mertens","2022","Diabetes","nonrandomized_study","article","10.2337/db22-751-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053304","1696-P: ENT-03 Has Additive Weight Loss and Insulin Normalization Effects with Semaglutide in Diet-Induced Obesity (DIO) in Mice","William A. Kinney","2025","Diabetes","other_trial","article","10.2337/db25-1696-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053305","2021 Korean Diabetes Association Clinical Practice Guidelines for Diabetes: Diabetic Kidney Disease","Nam Hoon Kim","2021","Journal of Korean Diabetes","other","article","10.4093/jkd.2021.22.4.268",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053306","Exploring the Use of Diabetic Medications for Non-Diabetic Conditions: A Comprehensive Literature Review","Rosemary Iriowen","2023","American Journal of Health Medicine and Nursing Practice","narrative_review","article","10.47672/ajhmn.1586",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053307","CRISPR-Cas9: A Promising Therapeutic Approach for Diabetes Mellitus","Shazma","2024","International journal of general practice nursing.","other","article","10.26689/ijgpn.v2i2.7433",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053308","Glucagon-like peptide-1 directly increases heart rate and shortens atrial refractoriness: an in vivo and ex vivo study in pigs","AF Lubberding","2021","EP Europace","other","article","10.1093/europace/euab116.576",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053309","1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event","Magnus Olof Wijkman","2020","Diabetes","other_trial","article","10.2337/db20-1421-p",null,null,"ClinicalTrials.gov:NCT01147250","S001991","openalex","FALSE","paywalled","5","FALSE","article"],["R0053310","Current Management of Type 2 Diabetes Mellitus: What to Pay Attention to in Outpatient Settings","Natalya Al'bertovna Chernikova","2021","Doctor Ru","other","article","10.31550/1727-2378-2021-20-2-40-44",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053311","706 INCIDENCE PROPORTION OF PANCREATIC COMPLICATIONS WITH INCRETIN-BASED THERAPIES: A MULTICENTER POPULATION-BASED STUDY","Vibhu Chittajallu","2023","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(23)01313-6",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053312","S2108 A Comparative Study on Symptomatic Gallstones: The Impact of Rapid Weight Loss From Bariatric Surgery Versus GLP-1 Agonist Treatment","Rashid H. Abdel-Razeq","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037800.85212.fc",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053313","352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study","Mariam Alatrach","2020","Diabetes","randomized_trial","article","10.2337/db20-352-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053314","Selected state of the art research in internal medicine, 2017","Ian A Scott","2018","Internal Medicine Journal","randomized_trial","article","10.1111/imj.13820","29898274",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053315","DURATION-1-Verlängerung: Wirksamkeit und Verträglichkeit von wöchentlichem Depot-Exenatide über 6 Jahre bei T2DM-Patienten","RR Henry","2015","Diabetologie und Stoffwechsel","other","article","10.1055/s-0035-1549544",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053316","About effectiveness of domestic drug liraglutide: results of clinical cases in pediatrics","Нина Викторовна Евдокимова","2024","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2024-324",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053317","Altered satiation signaling in obesity : the role of nutrients, gut peptides, and gut microbiota","Frank Anthony Duca","2013",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0053318","IMPACT OF SEMAGLUTIDE ON MORTALITY IN OBSTRUCTIVE SLEEP APNEA PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROPENSITY SCORE-MATCHED, RETROSPECTIVE COHORT STUDY","DALIAN LETREN","2025","CHEST Journal","nonrandomized_study","article","10.1016/j.chest.2025.07.3954",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053319","Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus","Ю. Г. Самойлова","2023","Russian Journal of Preventive Medicine","nonrandomized_study","article","10.17116/profmed20232612195",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053320","Gut–Brain Hormone Analogues and Metabolic Magic Wand","Jubbin Jagan Jacob","2024","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/ijem.ijem_460_24","39676777",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053321","S897 Impact of GLP-1 Agonist versus Opioid Use on Esophagogastroduodenoscopy (EGD) Outcomes: A Propensity-Matched Analysis of the U.S. Collaborative Network","Mouhand Mohamed","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032956.79643.e5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053322","CROI 2023: Metabolic and Other Complications of HIV Infection.","Sudipa Sarkar","2023","PubMed","randomized_trial","article",null,"37704199",null,null,null,"openalex","TRUE","no_doi","2","FALSE","review"],["R0053323","12506 Vagal Glp-1 Receptors Are Essential In The Efficacy Of Orally Administered Exendin-4","Maigen Michelle Bethea","2024","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvae163.1373",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053324","Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico","Gabriele Costanzo","2022","L Endocrinologo","other","article","10.1007/s40619-022-01064-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053325","2005-LB: Changes in Clinical Measures among U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) Receiving Once-Weekly Semaglutide (sema OW) vs. Oral Antidiabetic Medications (ADMs)","James J. Amamoo","2025","Diabetes","nonrandomized_study","article","10.2337/db25-2005-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053326","593: SEMAGLUTIDE USED IN ADJUNCT TO MULTIDISCIPLINARY LIFESTYLE INTERVENTIONS LEADS TO WEIGHT REDUCTION AND IMPROVEMENT IN BODY COMPOSITION IN PATIENTS WITH NAFLD","Rochelle Wong","2022","Gastroenterology","other","article","10.1016/s0016-5085(22)60355-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053327","The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations","Camilla Hage","2013","European Heart Journal","randomized_trial","article","10.1093/eurheartj/eht309.p4289",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0053328","The effect of liraglutide, a glucagon like peptide-1 (GLP-1) analogue, on streptozotocin induced neurodegeneration in cultured mouse neurons: a tool to study sporadic Alzheimer's disease","Cameron R. Learman","2015",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053329","Weight Loss with Liraglutide 3.0 mg is Associated with Improved Health-related Quality of Life (HRQoL) and Treatment Satisfaction in Adults with Overweight/Obesity and Type 2 Diabetes (T2D): The SCALE Diabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial","Sean Wharton","2015","Canadian Journal of Diabetes","randomized_trial","article","10.1016/j.jcjd.2015.01.140",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053330","EE315 Cost-Effectiveness Analysis of Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes in China","L Liu","2022","Value in Health","other","article","10.1016/j.jval.2022.09.562",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053331","12322 Unraveling The Complexity Of Stiff-Person Syndrome: A Case Of Ozempic-Induced Gastric Paralysis In A Patient With Comorbid Type 2 Diabetes Mellitus","Loveth Igburuke","2024","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvae163.993",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053332","Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes","Djordje S. Popovic","2023","Annals of Internal Medicine","randomized_trial","article","10.7326/l23-0227","37722122",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053333","2837-LB: Pharmacokinetic and Safety Evaluation of AUL009, a Monthly Semaglutide-Loaded Microsphere Injectables Utilizing ExTenna Drug Delivery Technology in Healthy Male Subjects","SEOA KIM","2026","Diabetes","randomized_trial","article","10.2337/db26-2837-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053334","Comparative effects of metformin and liraglutide on connexin 45 expression in kidneys of rats fed high-fat-high-sugar diet","Martina Milat","2019",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053335","PO419 ADDITION OF LIRAGLUTIDE TO OAD MONOTHERAPY IN JAPANESE SUBJECTS WITH TYPE 2 DIABETES: THE LIRA-ADD2OAD JAPAN TRIAL","Kohei Kaku","2014","Diabetes Research and Clinical Practice","other_trial","article","10.1016/s0168-8227(14)70713-2",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0053336","Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial","Michael Shechter","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.4244",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053337","Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity","Tatiana Ivanovna Romantsova","2018","Obesity and metabolism","other","article","10.14341/omet201813-11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053338","Effectiveness, tolerability, and pattern of liraglutide treatment use for weight loss: a mixed-methods cohort study","Sumaiah J. Alarfaj","2022","Journal Of Advanced Pharmacy Education And Research","nonrandomized_study","article","10.51847/wav0cpt0bt",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053339","Effects of exenatide on insulin sensitivity and glucose-lipid metabolism in insulin resistant rats induced with high fat chow","Tan Xing-rong","2008","Zhonghua neifenmi daixie zazhi","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053340","Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: A 52-week, randomized, open-label extension of the PIONEER 7 trial","Cho Y.M","2024","Carolina Digital Repository (University of North Carolina at Chapel Hill)","randomized_trial","article","10.17615/7bmd-2j28",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0053341","808-P: Impact of Fasting on Adherence to Dosing Instructions and Efficacy of Oral Semaglutide during Ramadan in People with Type 2 Diabetes in Real-World Setting—O-SEMA-Fast Subanalysis","Mohamed R. R.Hassanein","2024","Diabetes","nonrandomized_study","article","10.2337/db24-808-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053342","P1106 Le liraglutide chez les adolescents atteints de diabète de type 2 : analyse de la pharmacocinétique en comparaison avec les résultats obtenus chez les adultes","S. Madani","2013","Diabetes & Metabolism","other","article","10.1016/s1262-3636(13)71852-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053343","P87 Effect of exenatide, sitagliptin and vildagliptin on IGF-I in diabetic patients","Federico Gatto","2010","Growth Hormone & IGF Research","other","article","10.1016/s1096-6374(10)70187-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053344","5 Non-alcoholic fatty liver disease (NAFLD) -underdiagnosed but overtreated","Stephen David Howard Malnick","2019","Poster presentations","other_trial","article","10.1136/bmjebm-2019-pod.111",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0053345","Finerenone in Patients with Type 2 Diabetes and CKD by SGLT2 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonists Receptor Agonist Use: A FIDELITY Analysis","Ajay Singh","2024","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2024z6zpnkzd",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053346","039 Glucagon-like peptide-1 analogues and sodium-glucose co-transporter-2 inhibitors do not increase risk of bullous pemphigoid","Outi Varpuluoma","2021","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2021.08.041",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053347","GLP-1s Beyond Weight Loss: Insights from Social Media on Taste and Mental Health","Sarah L. Lathrop","2025","CHANCE","other","article","10.1080/09332480.2025.2473289",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053348","The Efficacy and Safety of SGLT2 Inhibitors and GLP1 Receptor Agonists in Kidney Transplant Recipients","Vikas S. Sridhar","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s11030a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053349","Comparative Cardiovascular Effectiveness of GLP-1 Receptor Agonists in Type 2 Diabetes and ASCVD: A Bayesian Network Meta-Analysis","Adithya Chandran","2026",null,"systematic_review","article","10.13140/rg.2.2.27575.28325",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0053350","Current Perspectives and Innovative Approaches in Treating Cystic Fibrosis-related Diabetes: Unveiling Mechanisms for Precision Medicine","Sunil Kumar Kadiri","2024","Current Drug Therapy","other","article","10.2174/0115748855304379240517043133",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053351","S1316 Patient Willingness to use ROSE-010: A Subcutaneous (SC) GLP-1 Analogue for IBS Pain Episodes","Brennan Mason Ross Spiegel","2010","Gastroenterology","other","article","10.1016/s0016-5085(10)61032-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053352","Safety and tolerability of exenatide once weekly pooled summary of 1095 patients from DURATION-1, 2 and 3","D Lee","2011","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0031-1277484",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053353","Kidney Fat by Magnetic Resonance Spectroscopy in Type 2 Diabetes and Diabetic Kidney Disease","Niels Søndergaard Heinrich","2022","Journal of the American Society of Nephrology","other","article","10.1681/asn.20223311s1111d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053354","MEDI0382, a GLP/Glucagon Receptor Dual Agonist, Significantly Reduces Hepatic Fat Content in Subjects with Type 2 Diabetes Mellitus","Meena Jain","2018","Diabetes","randomized_trial","article","10.2337/db18-78-or",null,null,"ClinicalTrials.gov:NCT02548585","S000451","openalex","FALSE","paywalled","1","FALSE","article"],["R0053355","Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and","NeuroprotectionT McGrath","2015",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053356","Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity","Zijing Zhang","2020",null,"other","article","10.22541/au.159819184.44503988",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0053357","Lower Day-to-Day Fasting Self-Measured Plasma Glucose (SMPG) Variability with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine 100 Units/mL (IGlar U100)","Ildiko Lingvay","2018","Diabetes","other","article","10.2337/db18-1025-p",null,null,"ClinicalTrials.gov:NCT01952145","S001328","openalex","FALSE","paywalled","5","FALSE","article"],["R0053358","The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes.","Tajana Juranovic","2025","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2025.43.16_suppl.7559",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0053359","Effecten van liraglutide in de behandeling van type 2 diabetes in Nederland","Wouter T. Zandee","2013","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-013-0010-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053360","1408-P: Use of Antihyperglycemic Medications among U.S. Patients with Limited English Proficiency","Omayma Alshaarawy","2023","Diabetes","other","article","10.2337/db23-1408-p",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053361","Effects of the treatment with liraglutide early after surgical in-tervention on clinical outcomes in patients with short bowel syndrome. A pilot observational “real-life” study","Fabio Dario Merlo","2023","Clinical Nutrition ESPEN","other","article","10.1016/j.clnesp.2023.09.798",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053362","Angiotensin receptor blockade and glucagon like peptide‐1 receptor activation ameliorates NADPH oxidase 4‐associated oxidative injury in insulin‐resistant rats","Benny Escobedo","2016","The FASEB Journal","preclinical","article","10.1096/fasebj.30.1_supplement.1218.6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053363","Experimental and clinical pharmacology: Incretin mimetics and enhancers: clinical applications","Anne T. Reutens","2008","Australian Prescriber","other","article","10.18773/austprescr.2008.059",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053364","319-OR: Renoprotective Effects of Glucagon and Incretin Agonist Combinations Mediated by Macula Densa Cells","Georgina Gyarmati","2024","Diabetes","preclinical","article","10.2337/db24-319-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053365","156-OR: Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults","Elisabetta Patorno","2019","Diabetes","nonrandomized_study","article","10.2337/db19-156-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053366","Small intestinal physiology relevant to bariatric and metabolic endoscopic therapies: Incretins, bile acid signaling, and gut microbiome","Nienke van Olst","2020","Techniques and Innovations in Gastrointestinal Endoscopy","other","article","10.1016/j.tige.2020.03.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053367","The effect of CPAP therapy on coronary artery plaque volume in obstructive sleep apnoea: data from a proof-of-concept study","Cliona O’Donnell","2023",null,"randomized_trial","article","10.1183/13993003.congress-2023.oa3287",null,null,"ClinicalTrials.gov:NCT04186494","S001827","openalex","FALSE","paywalled","1","FALSE","conference-abstract"],["R0053368","Cardioprotective pharmacotherapy in patients with type 2 diabetes across the Middle East and Africa: the PACT-MEA study","Subodh Verma","2023","European Heart Journal","other","article","10.1093/eurheartj/ehad655.2570",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053369","Effectiveness of Liraglutide in Type 2 Diabetes Patients Switched from a DPP-4 Inhibitor: 1-Year Data from EVIDENCE®","Guillaume Charpentier","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.114",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053370","Evaluation of the endocrine cells ratio in the pancreas of rats with type 2 diabetes mellitus following long-term therapy with incretin mimetics and their combination with sulfonylureas drugs","Таисия Павловна Тучина","2020","Endocrine Abstracts","preclinical","article","10.1530/endoabs.70.aep248",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053371","Semaglutide therapy in people with type 2 diabetes and obesity: efficacy on glycated hemoglobin and weight loss","Prete Michela Del","2024","Endocrine Abstracts","other","article","10.1530/endoabs.99.ep423",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053372","GLUCAGON-LIKE PEPTIDE-1 AGONIST USE AND OOCYTE RETRIEVAL IN CONTROLLED OVARIAN HYPERSTIMULATION","Victoria Lazarov","2024","Fertility and Sterility","other","article","10.1016/j.fertnstert.2024.07.814",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053373","Interrupção de Wegovy e Mounjaro leva à recuperação do peso perdido mais rapidamente do que se imaginava","Sam West","2026",null,"other","article","10.64628/ade.gscqh3ff5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0053374","Assessing the efficacy of large language models in data extraction for a meta-analysis on the role of glucagon-like peptide-1 receptor agonists in heart failure","S Christoforou","2026","European Heart Journal - Digital Health","systematic_review","article","10.1093/ehjdh/ztaf143.012",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0053375","S2088 Glucagon-Like Peptide-1 Receptor Agonist-Associated Colonic Ischemia: A Case Report","Thomas Adam Wichelmann","2022","The American Journal of Gastroenterology","case_report","article","10.14309/01.ajg.0000864992.88559.a6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053376","Chemoselective Saponification in the Synthesis of Danuglipron Facilitated with Trifluoroethanol","Lu Han","2024","Organic Process Research & Development","other","article","10.1021/acs.oprd.4c00085",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053377","Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease","Wiesje M. van der Flier","2024","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.088793",null,null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","openalex","TRUE","open_pdf","1","FALSE","article"],["R0053378","Accepting Living Kidney Donors with Preexisting Diabetes Mellitus","Karim Magdy Mohamed Soliman","2022","Clinical Journal of the American Society of Nephrology","nonrandomized_study","article","10.2215/cjn.09460822","36220190",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053379","The Place of DPP-4 Inhibitors in the Treatment Algorithm of Diabetes Type 2: a Systematic Review of Cost-effectiveness Studies","A Baptista","2015","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0053380","Étude DUAL III : efficacité et tolérance de l’association degludec/liraglutide (IDegLira) chez les patients diabétiques de type 2 naïfs d’insuline et insuffisamment contrôlés par agonistes du récepteur du GLP-1","D. Gouet","2016","Annales d Endocrinologie","other","article","10.1016/j.ando.2016.07.230",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053381","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT DECREASE THE RISK FOR CORONARY REVASCULARIZATION IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS OF CARDIOVASCULAR OUTCOME TRIALS","Dimitrios Patoulias","2022","Journal of Hypertension","systematic_review","article","10.1097/01.hjh.0000837028.88430.4f",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053382","Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved ejection fraction - A meta-analysis of randomised-controlled trials","R. Ravikulan","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.1032",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053383","Percentage and main features of patients referred to a cardiac rehabilitation program who would have an indication for a GLP1 receptor agonist based on the SELECT trial criteria","Joan Torres Marqués","2024","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwae175.430",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053384","Case Study: Challenges of Managing Diabetes in Commercial Truck Drivers","Jeremy B. Soule","2007",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053385","Su1604 COMPARATIVE EFFECTIVENESS OF GLP-1RAS, SGLT-2 INHIBITORS, AND OTHER GLUCOSE-LOWERING DRUGS ON ADVERSE CARDIOVASCULAR AND MORTALITY OUTCOMES AMONG PATIENTS WITH DIABETES, NAFLD, AND CARDIOVASCULAR DISEASES: A LARGE POPULATIONBASED COHORT STUDY","Arunkumar Krishnan","2024","Gastroenterology","nonrandomized_study","article","10.1016/s0016-5085(24)04273-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053386","Twelve-month treatment with glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter-2 inhibitors improves arterial function and myocardial deformation after ischemic stroke","I Ikonomidis","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.3021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053387","Influence of liraglutide, dulaglutide versus conventional treatment on fatty liver index and fibrosis-4 score in Egyptian patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease","Mohammed Ali Gameil","2020","Medical Journal of Viral Hepatitis /Medical Journal of Viral Hepatitis","nonrandomized_study","article","10.21608/mjvh.2020.125619",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053388","World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee","Linda L. Humphrey","2018","Annals of Internal Medicine","other_trial","article","10.7326/m18-1148","30178054",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053389","838-P: Changes in Clinical Measures in U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) Who Received Once-Weekly (OW) Semaglutide","James J. Amamoo","2025","Diabetes","nonrandomized_study","article","10.2337/db25-838-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053390","A79-13 GLP-1 Receptor Agonist Use and Outcomes in Older Adults With Obstructive Sleep Apnea: A Trinetx Propensity-Matched Survival Analysis","M Khan","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.6320",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053391","83-OR: Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)","Ildiko Lingvay","2021","Diabetes","randomized_trial","article","10.2337/db21-83-or",null,null,"ClinicalTrials.gov:NCT03552757","S001740","openalex","FALSE","paywalled","1","FALSE","article"],["R0053392","677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial","Natalia McInnes","2021","Diabetes","randomized_trial","article","10.2337/db21-677-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053393","GLP-1 agonists with basal insulin are a good treatment option in patients with type 2 diabetes","Anne Mounsey","2015","Evidence-Based Practice","other","article","10.1097/01.ebp.0000541004.85619.8d",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053394","Liraglutide 3.0 mg within a NHS Tier-3/4 weight management service results in similar weight loss compared to regulatory trials - The LIPOSAX first UK real-world evidence study","Georgios K. Dimitriadis","2021","Obesity Abstracts","nonrandomized_study","article","10.1530/obabs.3.cd1.2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053395","GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes","Francisco Alfredo Farias Bandeira","2022",null,"other","article","10.1007/978-3-030-90684-9_31",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0053396","GLP-1 Therapeutics Expand Beyond Metabolism: Implications for Mind–Body Medicine","Tobias Esch","2026","THE MIND - Bulletin on Mind-Body Medicine Research","other","article","10.61936/themind/202608036",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053397","Effetto scheletrico di semaglutide e tirzepatide nei pazienti con un aumentato rischio di fratture","Anna Arecco","2026","L Endocrinologo","other","article","10.1007/s40619-026-01880-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053398","Tu1946 GLUCAGON-LIKE PEPTIDE 1 (GLP-1) AGONISTS SEMAGLUTIDE AND TIRZEPATIDE AND COLORECTAL CANCER RISK: A CELL CULTURE STUDY","Priya M. Roy","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)03828-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053399","Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women","Siyuan Zheng","2017","Obesity Medicine","other","article","10.1016/j.obmed.2017.06.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053400","The Effect of Lixisenatide and Dapagliflozin in Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus Compared with Sitagliptin and Pioglitazone","Anastasios Koutsovasilis","2018","Diabetes","other","article","10.2337/db18-1235-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053401","Abstract PD8-05: A Retrospective Cohort Study on Mitigating Chemotherapy Side Effects in Breast Cancer Patients: The Role of GLP-1 Agonists","Elvis Obomanu","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-pd8-05",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053402","IMPACTO DO MOUNJARO NA PERDA DE PESO E QUALIDADE DE VIDA","Geraldo Henrique Kloss de Mello","2025","Revista Multidisciplinar do Nordeste Mineiro","other","article","10.61164/jyvyyv93",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053403","Tirzepatide Modulates Cardiometabolic Health Differentially by Sex in an HFD-Induced Model of Obesity in Male and Female Mice","Theresa L. Roberts","2025","Heart Lung and Circulation","preclinical","article","10.1016/j.hlc.2025.06.843",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053404","How does delayed bone healing associated with GLP-1 receptor agonists compare to that observed with other antidiabetic medications in orthopedic patient populations?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20312646",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053405","Therapieintensivierung bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie (BOT): Bessere klinische Ergebnisse mit iGlarLixi vs. BIAsp 30 in der SoliMix-Studie","Julio Rosenstock","2022","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-1746275",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE",null,null,"FALSE","article"],["R0053406","Patterns and Trends of Glucose‐Lowering Therapy in Alzheimer's Disease and Related Dementias","Huilin Tang","2026","Diabetes Obesity and Metabolism","nonrandomized_study","article","10.1111/dom.70817","42119996",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053407","Development of a Sustainable Transketalization Approach to a Chiral Benzodioxole-Containing GLP-1R Agonist","Sivaraman Balasubramaniam","2026","Organic Process Research & Development","other","article","10.1021/acs.oprd.6c00031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053408","Selecting weight loss strategies for kidney transplant candidacy: Weighty decisions","Babak John Orandi","2024","American Journal of Transplantation","other","article","10.1016/j.ajt.2024.08.022","39214311",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053409","Beyond Weight Loss: Reproductive Outcomes of GLP-1 Use in Women with PCOS - A Review of Current Evidence","Alice Scalzilli Becker","2025","JBRA","randomized_trial","article","10.5935/1518-0557.20263585",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053410","P403 Design of a novel MRI - metabolic meal study to combine measuring gastrointestinal motility and gut hormone levels","Christopher Bannon","2026","E-Posters","other","article","10.1136/gutjnl-2026-bsg.510",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053411","From Gut to Ovary: The Expanding Role of GLP-1 Analogues in PCOS and Fertility in Women","Aleksandra Maria Śledziewska","2025","Archiv Euromedica","randomized_trial","article","10.35630/2025/15/4.017",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053412","Top-line Results from evoke and evoke+: Two Phase 3, Randomized, Placebo-controlled Trials of Semaglutide in Participants with Early-stage Symptomatic Alzheimer’s Disease (P6-12.006)","Jeffrey L. Cummings","2026","Neurology","randomized_trial","article","10.1212/wnl.0000000000216975",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053413","1276-OR: GLP-1R Agonists Increase Irisin Levels in Patients with T2D through PKA/CREB-Dependent Muscle Stimulation","Valerio Galasso","2026","Diabetes","preclinical","article","10.2337/db26-1276-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053414","Renoprotection with Semaglutide and Liraglutide:Direct or Indirect Effects?","Johannes F.E. Mann","2019","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053415","The Impact of GLP-1 Receptor Agonists on Semen Parameters and the Hypothalamic–Pituitary–Gonadal Axis in Men with Obesity — A Literature Review","Aleksandra Mliczek","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.71.75106",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053416","How does tirzepatide indication (weight loss vs diabetes) affect the risk profile?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17672968",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053417","Discovery of Novel and Long Acting GLP-1 Analogs","Robert Grams Hunter","2015",null,"preclinical","article","10.17952/24aps.2015.197",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0053418","Understanding Semaglutide’s weight- loss efficacy: A review of GLP- 1 biology","Atufa Juveriya Mohammad","2026","International Journal of Pharmacology and Clinical Research","nonrandomized_study","article","10.33545/26647613.2026.v8.i2a.194",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053419","Impact of Tirzepatide on Body Weight and Metabolic Parameters in Obesity","Samantha Afrin","2026","Scholars Journal of Applied Medical Sciences","other","article","10.36347/sjams.2026.v14i08.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053420","Semaglutide e dulaglutide: comparative effectiveness analysis e disparità nel Piano Terapeutico Regionale","G. Basile","2022","The Journal of AMD","other","article","10.36171/jamd22.25.2.5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053421","A comprehensive approach to dermatocosmetological care of patients with body weight reduction during incretins therapy: From age-related characteristics of the structure of the subtlets to annual correction protocol","E. V. Svechnikova","2026","Meditsinskiy sovet = Medical Council","protocol","article","10.21518/ms2026-091",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053422","Effects of Tirzepatide on Pancreatic β-Cell Function in Adults With Type 2 Diabetes Mellitus: A Systematic Review","Rasha Mahmoud","2026","Cureus","systematic_review","article","10.7759/cureus.116733",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0053423","O papel emergente dos agonistas do receptor de GLP-1 na saúde reprodutiva feminina: perspectivas atuais e desafios pré-concepcionais","Sarah Estanislau de Oliveira","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22182198",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0053424","What are the current pharmacological treatment options for type 2 diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17932203",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053425","Evaluating Tirzepatide with Lifestyle Modification in Overweight Adults with Type 2 Diabetes: A Real-World Clinical Study","Chhavi Mehra","2025","International Journal of Science and Research (IJSR)","nonrandomized_study","article","10.21275/sr25919183931",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053426","Type 2 Diabetes and Obesity – The Role of Genetic Polymorphisms in the Response to Treatment with Sodium-Glucose Co-Transporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists","Gašper Tonin","2025","DiRROS repository (University of Maribor)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053427","What is the efficacy of semaglutide in treating early-stage Alzheimer's disease?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17832384",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053428","Small left ventricular volume in HFpEF: from phenotype to clinical implications","J N Julio Nunez","2026","ESC Heart Failure","randomized_trial","article","10.1093/eschf/xvag080","41832742",null,"ClinicalTrials.gov:NCT04745013; ClinicalTrials.gov:NCT06099891",null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053429","Combination of Technologies in Body Contouring: Evidence Mapping and a Decision-Making Algorithm","Igo Reichmann Losso","2026","Cureus","other","article","10.7759/cureus.116270",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053430","Advanced Peptide Blends Specification Sheet & Laboratory Protocols","KeJaun DuBose","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21340148",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053431","*\"The Glycemic Index Illusion — Antinutritional, Enteroendocrine, Mycotoxicological, and Beta Cell Consequences of Chronic Millet Consumption in Type 2 Diabetes Mellitus — A Comprehensive Mechanistic Analysis of Why Sorghum bicolor, Pennisetum glaucum, and Eleusine coracana Accelerate rather Than Ameliorate Type 2 Diabetes Mellitus Through Incretin Axis Abolition, Gut Microbiome Devastation, Beta Cell Dedifferentiation, and Mycotoxin Mediated Endocrine Disruption\"*","Mishra","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19684460",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0053432","What are the effects of GLP-1 receptor agonists on glycemic control in critically ill patients?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17771858",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053433","ИЗУЧЕНИЕ ГИПОГЛИКЕМИЧЕСКОГО И КАРДИОПРОТЕКТИВНОГО ЭФФЕКТА ЭМПАГЛИФЛОЗИНА В ТЕРАПИИ БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2-ГО ТИПА","Д.А. Урунбаева","2023","Research Focus International Scientific Journal","other","article","10.66073/researchfocus.v2i1.2819",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053434","TYPE 2 DIABETES MELLITUS: PATHOPHYSIOLOGY, DIAGNOSTICS, AND CONTEMPORARY THERAPEUTIC STRATEGIES. A REVIEW","Dominik Wiater","2026","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.3(51).2026.5814",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053435","Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality","Heidi S. Ahmed","2023","Hepatology","nonrandomized_study","article","10.1097/hep.0000000000000378","36932718",null,null,null,"openalex","FALSE","paywalled","4","FALSE","letter"],["R0053436","Innovations in Pharmacotherapy of Diabetes: A Review of Latest Reports","Katarzyna Czechowska","2025","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2025.83.61795",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053437","GLP-1 RECEPTOR AGONISTS IN CHRONIC KIDNEY DISEASE: NEPHROPROTECTION BEYOND GLYCEMIC CONTROL - A REVIEW OF CURRENT LITERATURE","Anna Mamach","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.2(50).2026.6653",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053438","Real-World Effectiveness of Oral Semaglutide in Indian Adult Diabetic Patients: Evaluation of EMR-based Data","Sandeep Gudibanda","2024","Journal of Diabetology","nonrandomized_study","article","10.4103/jod.jod_129_24",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053439","Which GLP-1 medications have the highest and lowest risk of causing pancreatitis?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19235229",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053440","Can tirzepatide lower the incidence of cardiovascular events in patients without diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18774125",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053441","GLP-1-Agonist kann Herzschwäche nicht mildern","DE","2015","CardioVasc","other","article","10.1007/s15027-015-0758-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053442","S222 GLP-1 RA Does Not Increase the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A U.S. Based Analysis","Mark Ayoub","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001029256.50348.1e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053443","Family, School And Society: An Integrated Approach To Cambating Childhood Obesity","Lema Khamkhoeva","2024","Vestnik of Saint Petersburg University Medicine","other","article","10.21638/spbu11.2024.307",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053444","How do I convert a weekly 2mg dose of semaglutide to the equivalent dose of tirzepatide?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18204033",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053445","Risk of Pancreatic Cancer Associated With Use of Incretin-Based Therapy and other Glucose-Lowering Agents: A Nationwide Case-Control Study in Denmark","Johnny Kahlert","2015","Data Archiving and Networked Services (DANS)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0053446","GLP-1 as Governance Architecture: The Three-Node Relay, Permeability Reinforcement, and Cancer Incidence (HLRP Paper #130)","James E. Dunn","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.19239705",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0053447","Are GLP-1 agonists effective for weight loss in obese nondiabetic pediatric patients?","Wala Tout","2022","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001644",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053448","Semaglutide: A Comprehensive Review of its Pharmacology, Clinical Applications, and Future Therapeutic Potential","Sitaram S. Pawar","2025","Journal of Drug Delivery and Therapeutics","narrative_review","article","10.22270/jddt.v15i12.7452",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053449","Comparative Efficacy of Lifestyle and GLP-1RA-Based Interventions for Visceral Adipose Tissue Reduction: Meta-Analysis of 40 Randomized Controlled Trials","Samit Ghosal","2025","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2025.09.171",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053450","The effectiveness of the glucagon‐like peptide 1 receptor agonist in improving cognitive function","Naoise Rasmussen","2023","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.076717",null,null,"PROSPERO:CRD42022366254",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053451","EP403 - ECE_3269 - Efficacy and safety of semaglutide injection in weight management: a subgroup analysis in patients based on Waist circumference","Unnikrishnan Gopalkrishnan","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.919",null,null,"CTRI:CTRI/2025/04/085487",null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0053452","Metformin is the most recognized first choice drug for patients with type 2 diabetes mellitus","A.M. Mkrtumyan","2018","Meditsinskiy sovet = Medical Council","other","article","10.21518/2079-701x-2018-4-20-27",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053453","870-P: Newer Glucose-Lowering Drugs and Risk of Dementia: A Meta-analysis of Cardiovascular Outcome Trials","HUILIN TANG","2022","Diabetes","systematic_review","article","10.2337/db22-870-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053454","Glp-1 receptor agonist use is associated with lower risk of progression from MGUS to SMM or MM in a large real-world cohort","Arooj Abidi","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-404",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0053455","0504 Glucagon-like peptide-1 receptor agonists and hair loss: Current evidence and possible mechanisms","G. Rachko","2026","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2026.06.535",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053456","P458 - LBA_ECE_1238 - Prevalence, vascular risk factors and complications of metabolic syndrome in a population of people living with type 1 diabetes: results from the French SFDT1 cohort","Adrien Burel","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.576",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0053457","2849-LB: Efficacy and Safety of cAMP-Biased Ecnoglutide vs. Unbiased Semaglutide in Adults with Obesity: Twenty-Week Results from a Multicenter, Randomized, Open-Label, Phase 2 Study","LINONG JI","2026","Diabetes","randomized_trial","article","10.2337/db26-2849-lb",null,null,"ClinicalTrials.gov:NCT07073417","S001568","openalex","FALSE","paywalled","1","FALSE","article"],["R0053458","New Trade Name and New Indication for Liraglutide","Diane S. Aschenbrenner","2015","AJN American Journal of Nursing","other","article","10.1097/01.naj.0000463021.63473.41",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053459","Can retatutride, a triple GLP peptide, be an effective therapeutic option for reducing inflammation in autoimmune disorders?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20390863",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053460","The Right Diabetes Medication for the Right Patient for the Right Outcome: Can a Network Meta-analysis Help Us Decide?","Christine G. Lee","2020","Annals of Internal Medicine","systematic_review","article","10.7326/m20-4266","32598225",null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0053461","Are there specific diabetes medications that have been shown to reduce the risk of developing dementia?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17831443",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053462","Results of the Interdisciplinary International Expert Council on Addressing the Management of Patients with Non-Alcoholic (Metabolic Dysfunction- Associated) Fatty Liver Disease","Marina V. Maevskaya","2026","Russian Journal of Gastroenterology Hepatology Coloproctology","other","article","10.22416/1382-4376-2026-36-3-7-20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053463","Betaine, a beneficial mimetic for long-term exercise","Xianhong Ji","2025","Protein & Cell","preclinical","article","10.1093/procel/pwaf057",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053464","1247-OR: Evolocumab Reduces CV Events in Patients with High-Risk Diabetes: Results from the VESALIUS-CV Trial","Lawrence Leiter","2026","Diabetes","randomized_trial","article","10.2337/db26-1247-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053465","An Overview of T2DM: A Model of Diabetes Mellitus","Katja Dumić Kubat","2024",null,"other","article","10.9734/bpi/dhrd/v2/3640",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0053466","NEPHROPROTECTIVE POTENTIAL OF SEMAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: CLINICAL EVIDENCE AND THERAPEUTIC PERSPECTIVES","Valéria Goulart Viana","2025","Seven Editora eBooks","other","article","10.56238/sevened2025.037-022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0053467","Diabetes und Migration","Sebahat Şat","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2592-9454",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053468","What is the best treatment for weight loss?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18271707",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053469","Neuroinflammation induced by intracerebroventricular infusion of palmitate, treated with Liraglutide (analogous to glucagon-like peptide 1 hormone): effects on the hypothalamus and hippocampus","André Rodrigues da Cunha Barreto Vianna","2017","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0053470","What are the findings from randomized controlled trials, systematic reviews, or guidelines on the use of glucose-lowering drugs in managing fasting plasma glucose levels?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.18019838",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0053471","MO634SEMAGLUTIDE IN REAL LIFE PRACTICE DECREASES ALBUMINURIA IN HIGH RISK PROGRESSION CHRONIC KIDNEY DIABETIC PATIENTS","Beatriz Avilés","2021","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfab094.002",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053472","NEXT-GENERATION GLP-1 PHARMACOTHERAPY: ADVANCES IN OBESITY TREATMENT WITH CONSIDERATIONS FOR PHYSICAL PERFORMANCE AND POPULATION HEALTH","Bartosz Michał Skorupski","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3678",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053473","Pathophysiological Mechanisms of Drug-Induced Appendicitis and Current Therapeutic Options","Sucheeta B Shetty","2026","Journal of Pharma Insights and Research.","other","article","10.69613/ey82ya41",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053474","Shifting the Paradigm in Global Diabetes Management: Beyond Glycohemoglobinism and Toward Etiological Mitigation via Minimizing Insulin Resistance on the Basis of Pharmacogenetics","Sidhartha D. Ray","2026","Diabetology","other","article","10.3390/diabetology7090176",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053475","Abstract 4365696: Virtual Decentralized Study of Patient Nausea Experience on Anti-Obesity Medication (COSMOS-DIGITAL)","Bethany A. Kalich","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4365696",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053476","Accelerated Chronic Lung Allograft Dysfunction After GLP1-Agonist Initiation","J. Kim","2026","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2026.02.752",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053477","Ozempic face: role of cosmetologists in preventing and treating skin and soft tissue changes","Lesia V. Kirsanova","2025","Russian Journal of Skin and Venereal Diseases","other","article","10.17816/dv678367",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053478","Safety analysis of semaglutide as part of comprehensive therapy for knee osteoarthritis in patients with obesity: data from a 24-week randomized study","Anatoly I. Surov","2026","HERALD of North-Western State Medical University named after I I Mechnikov","randomized_trial","article","10.17816/mechnikov708242",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053479","Which medication is more appropriate for a patient with type 2 diabetes, an HbA1c of 8%, and a BMI of 33: a DPP-4 inhibitor or a GLP-1 receptor agonist?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17793966",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053480","The Impact of Ramadan Fasting on Glycemic Control in Patients with Type 2 Diabetes : A Comprehensive Systematic Review","Gusti Arlan Tio","2026","The International Journal of Medical Science and Health Research","systematic_review","article","10.70070/4vng7x38",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0053481","Real World Evidences and Identifying the Gaps and Future Prospects with Incretin Therapy in India","Jaideep Khare","2026","International Journal of Diabetes and Technology","randomized_trial","article","10.4103/ijdt.ijdt_28_26",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053482","Epicardial Adipose Tissue","Doan T M Ngo","2015","Circulation Cardiovascular Imaging","commentary","article","10.1161/circimaging.115.003156","25752745",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0053483","Type 2 Diabetes Mellitus in Adult; Pathogenesis and Therapy: A review","Yunesh Kumar Mandavi","2025","International Journal of Advanced Multidisciplinary Research and Studies","nonrandomized_study","article","10.62225/2583049x.2025.5.1.3783",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053484","EP596 - ECE_2764 - A subgroup analysis of phase 3 study of semaglutide injection in type 2 diabetes mellitus patients aged <40 years, 40 to <50 years and ≥50 years","Dipesh Sonawane","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1042",null,null,"CTRI:CTRI/2025/02/080592",null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0053485","ANALYTICAL METHOD DEVELOPMENT AND VALIDATION AND STABILITY STUDY FOR THE QUANTITATIVE DETERMINATION OF TIRZEPATIDE IN BULK AND MARKETED PHARMACEUTICAL DOSAGE FORMS BY RP-HPLC","Pragati Ranjan Satpathy","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22205431",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053486","What is the evidence for pain management and GLP-1 antagonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18112195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053487","Are there clinical studies that have reported an increase in blood pressure among patients taking Mounjaro (tirzepatide)?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18117164",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053488","Lixisenatide Significantly Increases the Probability of a A1C Response in Patients Not Adequately Controlled on Oral Antihyperglycemic Agents","John Sigalas","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.124",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053489","CARDIOMETABOLIC STRATEGIES IN HEART FAILURE AND CHRONIC KIDNEY DISEASE: FROM GLP-1 RECEPTOR AGONISTS TO IMPROVED QUALITY OF LIFE AND TECHNOLOGY-ENABLED CARE","Daria Sztefka","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.1(49).2026.5402",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053490","2346-P: Access to GLP-1 Receptor Agonists (GLP-1RA) and Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) for Type 2 Diabetes Mellitus (T2DM) by Sociodemographic Factors in a Large Integrated Health System","Naomi Dillard","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2346-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053491","Are there any contraindications or specific risk factors that would make the use of GLP-1 agonists unsuitable in patients with prediabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18056204",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053492","S34 Therapeutic Advantages of GLP-1 Receptor Agonists: Survival and Insights from Large Retrospective Pancreatic Cancer Cohorts","Aditya Sood","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001028504.60450.b4",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053493","What is the most effective treatment for obesity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22804473",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053494","Drug Delivery Modalities and Mechanisms","Yu Tong Tam","2025",null,"other","article","10.1002/9781394236145.ch20",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0053495","EE113 COST PER CLINICAL WEIGHT-LOSS GOAL ACHIEVEMENT WITH SEMAGLUTIDE 2.4 MG VERSUS LIRAGLUTIDE 3 MG FROM A COLOMBIAN INSURER PERSPECTIVE","HAROLD J. MARIANO CANTILLO","2026","Value in Health","other","article","10.1016/j.jval.2026.03.408",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053496","1104-OR: Muscle-Preserving Weight Loss with RV-8451, a Novel, Oral Nonpeptide GLP-1 Receptor Agonist, in Diet-Induced Obese Nonhuman Primates","Sol Collado","2026","Diabetes","other_trial","article","10.2337/db26-1104-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053497","1691-P: A Meta-Analysis of Persistence and Adherence to Glucagon-Like Peptide 1-Based Treatments among Patients with Type 2 Diabetes in the United States","Leigh Perreault","2026","Diabetes","systematic_review","article","10.2337/db26-1691-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053498","2869-LB: Increasing Energy Expenditure with the Liver-Targeted Mitochondrial Protonophore TLC-6740 Enhances Weight Loss and Metabolic Benefits in Combination with Tirzepatide in Obesity: A Phase 2a Study","RYAN HUSS","2026","Diabetes","randomized_trial","article","10.2337/db26-2869-lb",null,null,"ClinicalTrials.gov:NCT05822544","S001909","openalex","FALSE","paywalled","1","FALSE","article"],["R0053499","Association between Antidiabtic Medications and Worsening of Parkinson’s Symptoms: A Case Report","Ghaida Aldajani","2021","International Journal of Medical and Pharmaceutical Case Reports","case_report","article","10.9734/ijmpcr/2021/v14i430143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053500","Tirzepatida no controle do diabetes mellitus e da obesidade","João Márcio Andreu","2025","Global Clinical Research Journal","nonrandomized_study","article","10.5935/2763-8847.20210085",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053501","Best treatment for type II diabetes","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17708963",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053502","What are the current prescribing patterns for SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17756835",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053503","What are the known effects of tirzepatide (Mounjaro) on inflammatory bowel diseases, specifically ulcerative colitis?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18098400",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053504","Liraglutide Associated Acute Pancreatitis: A Case Report and Review of the Literature","Muhammad Ghabra","2018","The American Journal of Gastroenterology","case_report","article","10.14309/00000434-201810001-01342",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053505","Positron emission tomography/magnetic resonance imaging with copper-64 DOTATATE identifies metabolic dysfunction-associated steatohepatitis and shows attenuated hepatic signal with glucagon-like peptide-1 receptor agonist treatment","Puria Nabilou","2026","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053506","S1368 The Pharmacokinetics of Long-Acting GLP-1 Analogue (NM-002) in Patients With Short Bowel Syndrome","Patrick H. Griffin","2021","The American Journal of Gastroenterology","randomized_trial","article","10.14309/01.ajg.0000779004.80713.37",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0053507","he efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) in the treatment of obesity in patients with type 2 diabetes mellitus (T2DM) - A literature review","Julia Brodziak","2026","Medical Science","nonrandomized_study","article","10.54905/disssi.v30i168.e41ms3772",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053508","Do GLP-1 agonists increase the incidence of gastroparesis?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21495266",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053509","Diabetes autoimune latente (LADA): um panorama do manejo terapêutico atual","Lara Cristina Alves Oliveira da Cruz","2024","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2024v6n9p3875-3887",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053510","Bile acids stimulate GLP-1 release predominantly by accessing basolateral GPBAR1 (TGR5)","Cheryl A. Brighton","2015","Endocrine Abstracts","other","article","10.1530/endoabs.38.p208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053511","For a patient with B12 deficiency on Mounjaro 7.5mg and maximum dose Metformin, with an HbA1c of 43, which medication should be reduced?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18471866",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053512","QnAs with Svetlana Mojsov, Joel Habener, and Lotte Bjerre Knudsen: Winners of the 2024 Lasker~DeBakey Clinical Medical Research Award","Prashant Nair","2024","Proceedings of the National Academy of Sciences","other_trial","article","10.1073/pnas.2416868121","39297682",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053513","DIABETES MELLITUS IN WOLFRAM SYNDROME 1: CHARACTERISTICS AND PERSPECTIVES IN TREATMENT","Dominika Darasz","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.2(50).2026.5533",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053514","Tirzepatide and the risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials","E Mansouri","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.3817",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053515","S1631 Exploring Patterns and Implications of Semaglutide Misuse: A Descriptive Study","Zryan Shwani","2023","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0000956164.29220.39",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053516","CO202 Real-World Effectiveness of Oral Semaglutide in Thai Patients With Type 2 Diabetes: An Observational Single-Arm Multicenter Retrospective Cohort Study (REALISED)","Taweesak Wannachalee","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.09.303",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053517","Can Ozempic exacerbate symptoms or ECG abnormalities in patients with Brugada syndrome?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17888766",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053518","Adverse Drug Reaction Monitoring of Semaglutide in India: Impact of Expanding Formulations and Generic Market Entry","T. Lakshmi Prasanna","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20951127",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0053519","ENDOCRINOLOGIA DE PRECISÃO E RESISTÊNCIA À INSULINA – AVANÇOS EM BIOMARCADORES E TERAPIAS PERSONALIZADAS: REVISÃO SISTEMÁTICA COM ABORDAGEM DE METANÁLISE","Iapunira Catarina Sant’Anna Aragão","2026","Revista Científica Ipedss","nonrandomized_study","article","10.55703/27644006060123",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053520","What is the risk of osteoporosis with GLP-1 receptor agonists?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20511826",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053521","Can antidiabetic medications cause glaucoma?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21374877",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053522","The Role of the Renin-Angiotensin-Aldosterone System and Endothelin-1 in the Progression of the Cardiorenal-Metabolic Triad","Souvik Dey","2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.62s.99",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053523","What are the differences in effectiveness between injectable and oral semaglutide for weight loss?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21419420",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053524","What effect does tirzepatide have on creatine kinase levels in patients?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17771701",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053525","The Role of GLP-1 Receptor Agonists in the Management of Polycystic Ovary Syndrome: A Narrative Review","Angelika Juszczyk","2026","Quality in Sport","nonrandomized_study","article","10.12775/qs.2026.67.74171",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0053526","Abstract 17139: Angiopoietin 2 Independently Predicts Heart Failure Hospitalization and is Beneficially Modified by GLP1RA: Results From the EXSCEL Trial","Josephine Harrington","2023","Circulation","other_trial","article","10.1161/circ.148.suppl_1.17139",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0053527","Identification et description du potentiel mésusage des agonistes du récepteur au GLP-1 en France","Nathan du Soulier","2025","Journal of Epidemiology and Population Health","other","article","10.1016/j.jeph.2025.202819",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053528","Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes","Olof Eriksson","2021","Journal of Nuclear Medicine","other","article","10.2967/jnumed.121.262506","34503957",null,"ClinicalTrials.gov:NCT03350191","S000574; S001309","openalex","TRUE","open_pdf","5","FALSE","article"],["R0053529","100 Years of Dialysis at University Hospital Giessen","Faeq Husain‐Syed","2025","Blood Purification","other","article","10.1159/000543874","39908004",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053530","Phân tích chi phí - hiệu quả của phối hợp lixisenatide + insulin glargin trong điều trị đái tháo đường típ 2 tại Việt Nam","Mai Kiều Thị Tuyết","2025","Tạp chí Nghiên cứu Dược và Thông tin Thuốc","other","article","10.59882/1859-364x/288",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053531","Diabetes Mellitus and the Heart","Katharina Marx-Schütt","2026","Experimental and Clinical Endocrinology & Diabetes","other","article","10.1055/a-2766-3079","42214437",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053532","Insulin vs. GLP-1 Receptor Agonist as First Injectable Therapy in Primary Care","HARPREET SINGH BAJAJ","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.113",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053533","Chapter 14. Formulations of Microspheres and Nanoparticles for Peptide Delivery","Jyothi Thundimadathil","2019","RSC drug discovery/RSC drug discovery series","other","article","10.1039/9781788016445-00503",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0053534","Effects of GLP-1 Receptor Agonists on Bone Metabolism and Fracture Risk in Type 2 Diabetes and Obesity: Mechanisms and Clinical Evidence — A Narrative Review","Hubert Bojanowski","2026","Journal of Education Health and Sport","narrative_review","article","10.12775/jehs.2026.90.70093",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0053535","What are the available treatments for type 2 diabetes in Canada?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18689936",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053536","Histopathological Evaluation of the Teratogenic Effects of Lixisenatide on the Cerebral Cortex of Developing Chick Embryo","Amit Kumar Srivastava","2024","HAL (Le Centre pour la Communication Scientifique Directe)","other","article","10.9734/bpi/ibs/v9/1440",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0053537","Dietary Approaches to Obstructive Sleep Apnea: Translating Mechanistic Pathways into Clinical Practice","Tatiana Palotta Minari","2026","Clocks & Sleep","randomized_trial","article","10.3390/clockssleep8040058",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053538","CURE Asthma: a unique opportunity for Australia","Anthony W. P. Flynn","2025","The Medical Journal of Australia","randomized_trial","article","10.5694/mja2.70093","41241857",null,"ClinicalTrials.gov:NCT02760329",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053539","182-OR: Clinical Effects of SGLT2 Inhibitors in HNF1A-Diabetes (MODY3) : A Case Series","Henrik Maagensen","2022","Diabetes","randomized_trial","article","10.2337/db22-182-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053540","Editorial: Metainflammation and metabolism in hidradenitis suppurativa","Nessr Abu Rached","2026","Frontiers in Immunology","randomized_trial","article","10.3389/fimmu.2026.1967931","42755483",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0053541","Comparative effects of liraglutide doses with and without exercise on glycemic control and lipid profiles: A Randomized Controlled Trial.","Uzma Dost Muhammad Rajar","2024","INTERNATIONAL JOURNAL OF ENDORSING HEALTH SCIENCE RESEARCH (IJEHSR)","randomized_trial","article","10.29052/ijehsr.v12.i3.2024.162-170",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053542","Weight management interventions before IVF in overweight and obese women: a scoping review","Constanza Arancibia","2026","Figshare","randomized_trial","article","10.6084/m9.figshare.c.8471011.v1",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other; article"],["R0053543","1413-P: Semaglutide 2.4 mg Improved Glucose Metabolism and Reverted Prediabetes to Normoglycemia in Adults with Overweight/Obesity vs. Liraglutide 3.0 mg (STEP 8)","JULIO ROSENSTOCK","2022","Diabetes","randomized_trial","article","10.2337/db22-1413-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053544","Real-world study evaluating long-term effectiveness of iGlarLixi in people with T2D in the USA: Soli-durability study","Rayaz Ahmed Malik","2025","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/j.diabres.2025.112564",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053545","Exploring the Sequence Space of Antimicrobial Peptide Dendrimers","Cai, Xingguang","2023","Open Access CRIS of the University of Bern","other","article","10.48350/191467",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053546","Optimization of injectable bioresponsive nanolipid clusters for long-acting peptide therapy with liraglutide: in vitro and in vivo evaluation","Sang-Won Jeon","2025","Journal of Pharmaceutical Investigation","preclinical","article","10.1007/s40005-025-00769-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053547","1870-LB: Evaluating Remission of Type 2 Diabetes Using a Metabolic Intervention Including Fixed-Ratio Insulin Degludec and Liraglutide—A Randomized Controlled Trial","Zubin Punthakee","2024","Diabetes","randomized_trial","article","10.2337/db24-1870-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053548","Rethinking Obesity Paradigms: Ethnic-specific Approaches for Asian Populations in Global Clinical Practice","Mohammed Muzammil","2026","Telangana journal of IMA.","other","article","10.4103/tjima.tjima_32_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053549","The Role of Neuropharmacology in Obesity Treatment: A Comprehensive Scientific Review","Reza Ghalamghash","2025",null,"randomized_trial","article","10.22541/au.175312428.81257507/v1",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","preprint"],["R0053550","What is the efficacy and safety of GLP-1 and GLP-2 in weight control?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20836240",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053551","The Glucagon-Like Peptide-1 Analogues therapy in the non-diabetic patients","Agnieszka Sienicka","2023","Prospects in Pharmaceutical Sciences","other","article","10.56782/pps.127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053552","Enfermedad por hígado graso no alcohólico y opciones de tratamiento con análogos de receptor de GLP-1","Alejandro Ramos Sánchez","2023","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7920850",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053553","75877 Synergistic Efficacy and Safety of Poly-L-Lactic Acid Biostimulator and Hyaluronic Acid Filler for Facial Fullness post Weight Loss due to Glucagon-like Peptide-1 Receptor Agonist Medication","Z Paul Lorenc","2026","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2026.04.1689",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053554","1693-P: Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes","MELISSA THOMAS","2026","Diabetes","other_trial","article","10.2337/db26-1693-p",null,null,"ClinicalTrials.gov:NCT06124807","S001915","openalex","FALSE","paywalled","5","FALSE","article"],["R0053555","Proteomic Signatures of Short-term Liraglutide Treatment: Mechanistic Parallels and Divergences from Semaglutide, and Implications for Lean Mass Preservation","Konstantinos Stefanakis","2026","Metabolism","other","article","10.1016/j.metabol.2026.156527",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053556","The role of the Mediterranean diet in the treatment of cognitive dysfunction in patients with type 2 diabetes mellitus","Chunyan Zheng","2025","Frontiers in Nutrition","randomized_trial","article","10.3389/fnut.2025.1654684","40896190",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053557","Efficacy of glucagon-like peptide-1 mimetics for neural regeneration","Kazunori Sango","2015","Neural Regeneration Research","other_trial","article","10.4103/1673-5374.169611","26807090",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0053558","(040) Can Glucagon-Like Peptide-1 Receptor Agonists Be Used in Men with Type 2 Diabetes Mellitus or Obesity Who Complain of Erectile Dysfunction? A Systematic Review and Meta-Analysis","J P C Lima","2026","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdag118.035",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0053559","What are the treatment options for a patient with type 2 diabetes and hypertension?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17708215",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053560","What are the effects of GLP-1 agonists, like liraglutide and tirzepatide, on liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18007656",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053561","MSR27 Analysis and Characterization of Variations in Conceptual and Operational Definitions for GLP-1 Agonist Treatment Eligibility for Weight Management","Jared H. Kamauu","2025","Value in Health","other","article","10.1016/j.jval.2025.09.3318",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053562","Nitric Oxide/Reactive Oxygen Species Generation and Nitroso/Redox Imbalance in Heart Failure: From Molecular Mechanisms to Therapeutic Implications","Chiara Nediani","2010","Antioxidants and Redox Signaling","other","article","10.1089/ars.2010.3198","20624031",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053563","What are the impacts of GLP-1 therapy on bone and muscle health?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19129177",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053564","Beyond GLP-1: underexplored peptide–receptor systems as the next frontier in drug discovery","Sarfaraz K. Niazi","2026","Frontiers in Drug Discovery","other","article","10.3389/fddsv.2026.1792418",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053565","Integrated Multidisciplinary Management of Diabetes Mellitus: Roles of Internal Medicine, Hematology, Nursing, Dental Care, Optometry, Health Informatics, Hospital Management, and Social Work","Hussain Mohammed Hussain Alwabari","2025","Saudi Journal of Medicine and Public Health","other","article","10.64483/202522286",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053566","Do GLP-1 receptor agonists influence the interpretation of mammogram results in patients with diabetes or obesity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21446973",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053567","Adiposopathy-Based Chronic Diseases and Therapeutic Role of Semaglutide","Ajoy Tiwari","2026","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_21_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053568","Insulin therapy de-intensification with iGlarLixi (IDEAL) ran domised controlled trial: CGM-related outcomes","Novodvorsky, Peter","2024","Diabetologia","other_trial","article","10.5281/zenodo.14228110",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0053569","Enhanced semaglutide bioavailability via spray freeze dried powder for inhalation: Unveiling safety and broad potential applications","Riwei Yang","2025","Journal of Drug Delivery Science and Technology","other","article","10.1016/j.jddst.2025.107112",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053570","Lixisenatide Reduces BeAM Value (Difference Between Bedtime (Be) and Next-Day Pre-Breakfast (AM) Glucose): A Clinical Indicator for Initiation of Prandial Therapy","Vincent C. Woo","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.149",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053571","Ten Minutes Hard","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22116606",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","report"],["R0053572","Ten Minutes Hard","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22116607",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0053573","What are the long-term contraindications for GLP-1 agonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18340789",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053574","Incidence and effects of nausea on weight loss and quality of life with the glp-1 analogue liraglutide:a 52 week randomised trial","Michael E. J. Lean","2011","Research at the University of Copenhagen (University of Copenhagen)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0053575","Industry Update: the Latest Developments in Therapeutic Delivery","Louise Rosenmayr-Templeton","2012","Therapeutic Delivery","other","article","10.4155/tde.12.102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053576","KHẢO SÁT TÌNH HÌNH SỬ DỤNG THUỐC VÀ ĐÁNH GIÁ VIỆC TUÂN THỦ DÙNG THUỐC TRONG ĐIỀU TRỊ ĐÁI THÁO ĐƯỜNG TÍP 2 CỦA NGƯỜI BỆNH NGOẠI TRÚ TẠI TRUNG TÂM Y TẾ HUYỆN TAM BÌNH, TỈNH VĨNH LONG NĂM 2025","Hồ Thế Phương Nguyễn","2026","Tạp chí Y học Việt Nam","other","article","10.51298/vmj.v559i1.17416",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053577","Principles Supporting CKD Management in Primary Care","Manjula Kurella Tamura","2026","Clinical Journal of the American Society of Nephrology","other","article","10.2215/cjn.0000001018","41615729",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053578","How safe are GLP-1 medications?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22005388",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053579","1.47 GLP1-RA Use and Sustained Depressive Symptoms in Diabetic Children: A Retrospective Study","Mariana Ortiz","2025","Journal of the American Academy of Child & Adolescent Psychiatry","nonrandomized_study","article","10.1016/j.jaac.2025.08.076",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053580","Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients","Alina Yu. Babenko","2014","Diabetes Mellitus","other","article","10.14341/dm2014472-80",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053581","The IRS-1 Framework Predicts the ELAD Trial Why the Primary Outcome Failed, What the VBM Pattern Means, and What the Next Trial Should Measure","Arthur Stewart","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19016137",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","report"],["R0053582","Digital Cognitive Behavioral Therapy Reduces Intensification of Antihyperglycemic Therapy in Patients With Type 2 Diabetes","Judith A. Hsia","2026","AACE Endocrinology and Diabetes","randomized_trial","article","10.1016/j.aed.2026.04.014",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053583","Reframing obesity as a chronic, multifactorial disease: Clinical implications of GLP-1–based therapies","Roopesh Jain","2026","Advances in Biomedical and Health Sciences","nonrandomized_study","article","10.4103/abhs.abhs_94_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053584","How does renal insufficiency affect the pharmacokinetics and efficacy of semaglutide in patients with type 2 diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21837345",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053585","Do GLP-1 receptor agonists increase the risk of clinical pulmonary aspiration events in patients undergoing upper gastrointestinal endoscopy?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22124191",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053586","Abstract 4116298: Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist, at 4 × 450 µg Doses Reduces Blood Pressure, Lipids, and Body Weight in Post-menopausal Females: A Phase I Study","Rajamannar Thennati","2024","Circulation","randomized_trial","article","10.1161/circ.150.suppl_1.4116298",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0053587","Therapieintensivierung bei mit basalunterstützter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Nächtliche Hypoglykämien in der SoliMix-Studie","Rory J. McCrimmon","2022","Diabetologie und Stoffwechsel","other","article","10.1055/s-0042-1746276",null,null,"EudraCT:2017-003370-13",null,"openalex","FALSE",null,null,"FALSE","article"],["R0053588","How do GLP-1 receptor agonists affect anesthesia management?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20431249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053589","Uso de análogos do GLP-1 no tratamento de Diabetes Mellitus tipo II e da obesidade em adolescentes","Sofia de Oliveira Fernandez","2026",null,"other","article","10.22533/at.ed.84026200517",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0053590","USE OF DUAL AND TRIPLE INCRETIN AGONISTS (TIRZEPATIDE AND RETATRUTIDE) IN THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS","Felipe Veiga Kezam Gabriel","2026","Seven Editora eBooks","other","article","10.56238/sevened2026.020-013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0053591","How do you switch between GLP-1 receptor agonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17749300",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053592","GLP-1 Receptor Agonists vs. SGLT2 Inhibitors and the Risk of Alzheimer’s Disease in Type 2 Diabetes: A Systematic Review and Meta-Analysis (N3.002)","Levi Da Silva","2026","Neurology","systematic_review","article","10.1212/wnl.0000000000215416",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0053593","The Role of Endocrine Factors in Childhood Obesity","Samuel, Harrison","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17865699",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0053594","GLP‐1 RA Use and Weight Loss Among Patients in a Weight Navigation Program Versus Primary Care: A Matched Cohort Study","Dina H. Griauzde","2026","Obesity Science & Practice","nonrandomized_study","article","10.1002/osp4.70136",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053595","Pharmacological Evaluation of SKL-18287, a New Long-Acting Glucagon-Like Peptide-1 Receptor Agonist with Enhanced Aggregation Propensity, in Rodent Models","Mitsuaki Takeuchi","2018","International Journal of Peptide Research and Therapeutics","nonrandomized_study","article","10.1007/s10989-018-9777-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053596","The Relationship Between Insulin Sensitivity And Insulin Therapy Effectiveness In Patients With Type 2 Diabetes: A Systematic Review And Meta-Analysis","Moamen Abdelfadil Ismail","2025","The Review of Diabetic Studies","systematic_review","article","10.70082/51ktw541",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0053597","Cardiometabolic Benefits and Weight-Loss Efficacy of the Oral GLP-1 Agonist Orforglipron in Non-Diabetic Adults","Ms.Ruchika A Gupta","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21103425",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0053598","What are the potential risks and side effects associated with GLP-1 receptor agonists?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18963958",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053599","Strategies to Prevent and Delay Chronic Kidney Disease Progression: A Pathway to Sustainability and Green Nephrology","João Venda","2023","Portuguese Journal of Nephrology & Hypertension","randomized_trial","article","10.32932/pjnh.2023.08.253",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053600","Microneedle Arrays and Transdermal Patches for Peptide Delivery in Diabetes: Design, Skin Penetration Strategies, and Patient-Centric Advantages over Subcutaneous Injections","Waghamare Suresh","2026","Research Journal of Pharmaceutical Dosage Forms and Technology","other","article","10.52711/0975-4377.2026.00037",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053601","What are effective interventions to improve metabolic risk screening in adults taking antipsychotic medications?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18870427",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053602","The Cardio Diabetology Era. A Concise and Illustrated Review: Four Phenotypes and Three New Evidence-Based and Practical Therapeutic Algorithms","Enrique Morales-Villegas","2022","Medical Research Archives","narrative_review","article","10.18103/mra.v10i10.3207",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053603","The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies","Yuxin Wang","2025","The Innovation Medicine","other","article","10.59717/j.xinn-med.2025.100150",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053604","Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists for Obesity among South Korean Patients: A Prescription Sequence Symmetry Analysis","Dayeon Nam","2026","Journal of Pharmacoepidemiology and Risk Management","nonrandomized_study","article","10.56142/perm.26.0008",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053605","INHIBITORY POTENCY OF WITHANIA SOMNIFERA EXTRACTS AGAINST DPP-4: AN IN VITRO EVALUATION","Praveen Kumar Kempegowda","2017","African Journal of Traditional Complementary and Alternative Medicines","preclinical","article","10.21010/ajtcam.vi15.1.2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053606","EP788 - ECE_3157 - Efficacy and safety of semaglutide injection in type 2 diabetes mellitus: a subgroup analysis of patients with mild renal impairment","Dipesh Sonawane","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1146",null,null,"CTRI:CTRI/2025/02/080592",null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0053607","Exendin-4 Improves Yield and Function of Isolated Pre- Weaned Porcine Islets","Jonathan Robert Todd Lakey","2018","Journal of Endocrinology and Diabetes","preclinical","article","10.15226/2374-6890/5/5/001115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053608","Multimodal management of the cardiometabolic syndrome: the essential triad of nutrition, exercise, and obesity-specific pharmacotherapy to reduce cardiovascular risk","Martin Halle","2025","European Journal of Preventive Cardiology","randomized_trial","article","10.1093/eurjpc/zwaf522","40889141",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0053609","Systemic Effects of GLP-1 and Dual GIP/GLP-1 Receptor Agonism in Obesity, Cardiovascular Health, and Neurodegeneration","Sri Venkatesh Uriti","2025","Journal of Pharma Insights and Research.","other_trial","article","10.69613/akgbn956",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053610","S2876 Novel Chemotherapy Combination Leading to Novel Problems: A Case Report on Sulfonylurea Toxicity Secondary to Hepatic Impairment","Jonathan Marks","2021","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0000785036.55393.38",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0053611","OR09-04 A novel Melanocortin and Gut-peptide Multiple Agonist for Obesity and Diabetes Treatment","Christian Ludwig Roth","2025","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaf149.069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053612","PHARMACOLOGICAL AND SURGICAL TREATMENT OF OBESITY: INTEGRATING THE ROLES OF INFLAMMATION AND GUT DYSBIOSIS- REVIEW","Karolina Zarówna","2026","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.1(49).2026.4791",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053613","ESTUDO DO USO DE FÁRMACOS DA CLASSE GLP-1RA NO CONTROLE TERAPÊUTICO DA DIABETES MELLITUS TIPO 2","Myrla Aguiar Gonçalves","2023",null,"other","article","10.58871/ed.academic21062023.61",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0053614","Awareness of GLP-1 Receptor Agonist Therapy on Weight Reduction and metabolic outcome Among Obese Adults","Yerni Jyothi Kolli","2026","International Journal of Versatile Research and Analysis","other","article","10.56975/ijvra.v4i7.709284",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053615","Comparative post-operative outcomes in glucagon-like peptide-1 receptor agonist users vs. non-users following total shoulder arthroplasty: a systematic review and meta-analysis","Joseph D. Giacalone","2026","Seminars in Arthroplasty JSES","systematic_review","article","10.1016/j.sart.2026.151594",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0053616","1810-P: Time-to-Event Nonadditive Analysis Identifies Novel Genetic Variants Associated with Treatment Response and Weight Loss in the GRADE Clinical Trial","THINLEY Y. WANGDEN","2026","Diabetes","randomized_trial","article","10.2337/db26-1810-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053617","evoke and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease","Alireza Atri","2022","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.062415",null,null,"ClinicalTrials.gov:NCT04777396; ClinicalTrials.gov:NCT04777409","S000624; S001717","openalex","FALSE","paywalled","1","FALSE","article"],["R0053618","Multimodal strategy to protect lean mass in people using semaglutide for obesity – case report","Roberto Zagury","2025","International Journal of Nutrology","case_report","article","10.54448/ijn25302",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053619","METFORMIN’S IMPACT ON BODY WEIGHT IN TYPE 2 DIABETES: A NARRATIVE REVIEW OF MECHANISMS, CLINICAL EVIDENCE, AND COMPARATIVE EFFICACY","Aleksandra Jóźwik-Szymańska","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(51).2026.6514",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0053620","Perioperative Considerations in Patients with Type 2 Diabetes Mellitus: A Narrative Review","Danuil Julián Melo Ascanio","2026","Health Care & Global Health","narrative_review","article","10.22258/hgh.v10i3.475",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0053621","The Application of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Obstructive Sleep Apnea: Breakthrough or Overhyped?","Lei Huang","2025","Exploratory Research and Hypothesis in Medicine","other","article","10.14218/erhm.2024.00700",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053622","Análogos do glp-1 e risco de broncoaspiração perioperatória: retardo do esvaziamento gástrico e tempo de suspensão pré-operatória","Vitor Bastos Mesquita","2026","Revista Goiana de Medicina","other","article","10.63162/v69n73e26727",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053623","Practical Considerations for the Use of Oral Glucagon-like Peptide-1 Receptor Agonist in India","Hamid Ashraf","2026","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_25_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053624","Body Contouring Surgery in the Era of GLP–1 Receptor Agonists: A Narrative Review","Miguel A. Sierra-Duque","2026","Indian Journal of Plastic Surgery","randomized_trial","article","10.1055/s-0046-1824526",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0053625","OC13.06: Diastolic deceleration area: novel MCA Doppler marker predicting neonatal hypoxia in early‐onset FGR","P. Ignatov","2026","Ultrasound in Obstetrics and Gynecology","other","article","10.1002/uog.70305_86","42672487",null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053626","Uso de agonistas de GLP-1 (Semaglutida e Liraglutida) e risco de eventos adversos psiquiátricos: evidências de ensaios clínicos e estudos observacionais.","Lara Lopes Barreto","2026","Revista Master Ensino Pesquisa e Extensão","other","article","10.47224/revistamaster.v11i21.857",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053627","WCN26-3755 REAL-WORLD EFFECTIVENESS OF SEMAGLUTIDE AND SGLT-2I VS SGLT-2I ALONE ON KIDNEY AND CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE","Edouard Fu","2026","Kidney International Reports","nonrandomized_study","article","10.1016/j.ekir.2026.104756",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053628","Clinical impact of the AISF STEPS-MASH algorithm: real-world application in tertiary hepatology practice","Nicola Pugliese","2026","Digestive and Liver Disease","nonrandomized_study","article","10.1016/j.dld.2026.07.026",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053629","Farmakovijilansın Önemi: GLP-1 Reseptör Agonistlerinin Etkinlik ve Güvenliliği","Gülcan Tanrıkulu Kayan","2026","Arşiv Kaynak Tarama Dergisi","other","article","10.17827/aktd.1976223",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053630","2819-LB: Adoption of GLP-1RA and SGLT2i Drug Classes among Patients with Cardiovascular or Renal Indications: Evolution of Prescribing Patterns over Time","HUGO A. TORRES","2026","Diabetes","other","article","10.2337/db26-2819-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053631","GLP-1 RECEPTOR AGONISTS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: THERAPEUTIC POTENTIAL AND CLINICAL CHALLENGES","Michał Bzoma","2025","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(47).2025.3493",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053632","The Interplay Between Obesity, Diabetes, and Metabolic Syndrome: Molecular Pathways and Future Directions","Devvrata Devvrata","2026","International Journal of Current Pharmaceutical Review and Research","other","article","10.25258/ijcpr.18.3.221",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053633","Beyond glycemic control: semaglutide's multifaceted impact on metabolic health","Parveen, Shaik","2025","International Journal of Science and Research Archive","other","article","10.5281/zenodo.16975736",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053634","In patients with type 2 diabetes, poor glycemic control with metformin and incipient nephropathy, does the use of SGLT2 inhibitors or GLP-1 receptor agonists, compared to other oral antidiabetics, improve glycemic control and reduce the progression of kidney disease and cardiovascular risk?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18040552",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053635","Semaglutide and Other GLP-1 Receptor Agonists as Potential Therapies for Addiction – Mechanisms, Evidence, and Clinical Implications","Katarzyna Wajda","2025","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2025.86.66921",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053636","Comparative Cardiovascular Benefits of Semaglutide Adjunctive to Bariatric Surgery: A Real-World Analysis Using TriNetX","Ekow Essien","2025","American Heart Journal","nonrandomized_study","article","10.1016/j.ahj.2025.07.063",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053637","DPP 4 (dipeptidylpeptidase-4) inhibitors: beyond glycemic control","Sunil Gothwal","2013","IOSR Journal of Pharmacy (IOSRPHR)","other","article","10.9790/3013-033108185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053638","Recent advances in the pharmacological management of diabetes mellitus","Sharma, Bhagwati Prashad","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.14536649",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0053639","O USO DO OZEMPIC (SEMAGLUTIDA) PARA PERDA DE PESO: VANTAGENS E DESVANTAGENS UMA REVISÃO DE LITERATURA","Aline Conceição de Araujo","2024","Revista fisio&terapia.","other","article","10.5281/zenodo.10989823",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053640","Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase)","Jizhou Liang","2026","BMC Pharmacology and Toxicology","nonrandomized_study","article","10.1186/s40360-026-01190-4",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053641","Pathophysiological aspects of obesity – effect of GLP-1 peptide on the regulation of appetite:Possibilities of using GLP-1 mimetics in the obesity therapy","Arne Vernon Astrup","2011","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053642","TİP 2 DİYABETLİ HASTALARIN TEDAVİSİNDE KILAVUZLARA NE KADAR UYGUN HAREKET EDİYORUZ?","İlkim Deniz Toprak","2020","Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi","nonrandomized_study","article","10.26650/iuitfd.2021.828573",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053643","Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates","Sabina Semiz","2025","Health Sciences Review","other","article","10.1016/j.hsr.2025.100244",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053644","What is the most effective treatment for obesity?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18160532",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053645","Is there any interaction between amiodarone and tirzepatide?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22813929",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053646","RESISTENCIA A LA INSULINA EN LA DIABETES MELLITUS TIPO 2 Y SU PAPEL EN LA PROGRESIÓN DE LA ENFERMEDAD RENAL CRÓNICA Y LAS COMPLICACIONES CARDIOVASCULARES: UNA REVISIÓN NARRATIVA CRÍTICA CON BÚSQUEDA ESTRUCTURADA","Telmo Eduardo Salas Joya","2026","VitalyScience Revista Científica Multidisciplinaria","nonrandomized_study","article","10.56519/71yk8030",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053647","What are patient perceptions or experiences of managing obesity with GLP-1 receptor agonists or weight loss drugs?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18140515",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053648","What are the risks of GLP-1 or GLP-1 analog use in patients with existing retinal detachment?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21427012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053649","What is the impact of incretin-based therapies on pregnancy outcomes in women with gestational diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20089803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053650","Medicamentos novedosos autorizados en abril de 2026 en la UE y EE. UU.","Santiago Cuéllar Rodríguez","2026","Panorama actual del medicamento","other","article","10.63105/50.493.7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053651","Computational Intelligence-driven DPP-4 Inhibitory Peptide Prediction and Bispecific Antibody Design: Integrating Deep Learning, Molecular Dynamics, and Nanodisc Validation","Taozhi Wang","2026","Advance in Biological Research","preclinical","article","10.26855/abr.2026.06.006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053652","RP06 Effects of GLP-1 receptor agonists on ovulatory function and reproductive hormonal parameters in women with polyendocrine metabolic ovarian syndrome: a systematic review","I Sirbegovic","2026","European Journal of Endocrinology","systematic_review","article","10.1093/ejendo/lvag128.074",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0053653","Are there any known adverse effects between Mounjaro and antidepressants?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21992806",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053654","Long-Term Follow-Up of GLP-1 receptor agonist therapy for type 2 diabetes mellitus","Liam Byrne","2024","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22812604",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0053655","Glucagon-like peptide-1 (GLP-1) receptor agonists: applications in childhood diabetes and obesity","Kun Hu","2025","Paediatrics and Child Health","other","article","10.1016/j.paed.2025.01.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053656","Comparative analysis of the pharmacokinetics, immunogenicity and safety of semaglutide drugs Semvelica and Ozempic in an open-label, randomized-controlled, parallel-group trial","V.V. Pisarev","2025","Endocrinology News Opinions Training","randomized_trial","article","10.33029/2304-9529-2025-14-4-45-52",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053657","How do GLP-1 receptor agonists affect different baseline characteristics in type 2 diabetes patients?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17755183",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053658","Faculty of Anaesthesiology, Reanimation and Perioperative Medicine | From Obesity Treatment to Surgical Readiness: Tirzepatide, Obstructive Sleep Apnea, and the Proposed AHMAD Pathway — A Surgeon–Anesthesiologist Framework for 90–180-Day Metabolic–Respiratory Prehabilitation Before Elective Surgery","Mahmood Ahmad","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22165041",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0053659","How do GLP-1 receptor agonists compare to other treatments in terms of efficacy and safety for type 2 diabetes mellitus?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22230536",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053660","GLP-1 Receptor Agonists for Obstructive Sleep Apnea: A Meta-analysis of Randomized Controlled Trials","Jafar Aljazeeri","2025","American Journal of Respiratory and Critical Care Medicine","systematic_review","article","10.1164/ajrccm.2025.211.abstracts.a2901",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053661","Does the use of GLP-1 agonists affect the prognosis of patients diagnosed with pancreatic cancer?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21453403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053662","Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","Arne Vernon Astrup","2013","International Journal of Obesity","notice","article","10.1038/ijo.2012.192",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0053663","What are the comparative safety and tolerability profiles of oral versus subcutaneous semaglutide in managing obesity and type 2 diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20324542",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053664","REVISIONS TO THE LABELING OF ERECTILE DYSFUNCTION AND DIABETES DRUGS","Diane S. Aschenbrenner","2008","AJN American Journal of Nursing","other","article","10.1097/01.naj.0000310354.67108.6e",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053665","Semaglutide and Tirzepatide Suppress Hepatic Fatty Acid Uptake and Fatty Acid β-Oxidation in High-Fat Diet-Induced Obesity Mice","Dhaval Patel","2026","Journal of Proteome Research","preclinical","article","10.1021/acs.jproteome.6c00404",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053666","GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-Analysis","Antonino de Jesus da Silva Francisco","2025","Brazilian Journal of Clinical Medicine and Review","systematic_review","article","10.52600/2965-0968.bjcmr.2025.3.1.acch12",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0053667","Biochemical Evaluation the Efficacy of Metformin and GLP1 Receptor Agonist Therapy on Glucose Homeostasis in Male Rats Induced Type 2 Diabetes","Ashraf Barakat Said","2024","Suez Canal Veterinary Medicine Journal SCVMJ","preclinical","article","10.21608/scvmj.2024.305936.1175",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053668","HIỆU QUẢ VÀ TÍNH AN TOÀN CỦA TIRZEPATIDE Ở BỆNH NHÂN BÉO PHÌ KHÔNG MẮC BỆNH ĐÁI THÁO ĐƯỜNG: TỔNG QUAN HỆ THỐNG VÀ PHÂN TÍCH TỔNG HỢP","Hà Văn Tân","2025","TNU Journal of Science and Technology","other","article","10.34238/tnu-jst.12801",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053669","Loss of CASK Accelerates Heart Failure Development","Julian Mustroph","2021","Circulation Research","preclinical","article","10.1161/circresaha.120.318170","33593074",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053670","What is the efficacy of dosing semaglutide every two weeks?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19140091",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053671","RWD115 ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST USE AND INCIDENT ALCOHOL USE DISORDER AMONG PATIENTS WITH DIABETES: A REAL-WORLD EVIDENCE STUDY","Aubree Seibert-Jeffrey","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.2103",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053672","The Immunometabolic Network of Diabetes Mellitus: A Review of its Mechanisms, Complications and Therapeutic Implications","Fakhraddeen Yahya Muhammad","2026","Journal of Biochemistry Microbiology and Biotechnology","narrative_review","article","10.54987/jobimb.v14i1.821",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053673","Glucagon-like peptide-1 receptor expression after myocardial infarction: Imaging study using [68Ga]NODAGA-exendin-4 positron emission tomography","Mia Ståhle","2022","UTUPub (University of Turku)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053674","In overweight adult patients with type 2 diabetes, is tirzepatide as effective for weight loss compared to existing GLP1 agonists (i.e. Ozempic)?","Taylor Thompson","2023","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001948",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053675","Comparative Effectiveness of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Reducing Cardiovascular Events in Type 2 Diabetes","Ahmed S.F. Belal","2025","International Journal For Multidisciplinary Research","randomized_trial","article","10.36948/ijfmr.2025.v07i04.51363",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053676","Precision Cardiometabolic Risk Stratification and Therapeutic Targeting in Patients with Cardiovascular-Kidney-Metabolic Syndrome Integrating Lipoprotein(a) Levels, Multi-Omics Biomarkers, Inflammatory Pathways, and Novel GLP-1/GIP Receptor Agonist Therapies to Mitilare Progression to Heart Failure with Preserved Eection Fraction - Results from Preserved Eection Fraction - Results from a Prospective Multi-Center Observational Cohort with Long-Term Composite Endpoint Analysis","MD/ PhD/ FACC Camilo Fernández Bravo","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.18612727",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","book-chapter"],["R0053677","BEYOND WEIGHT LOSS Incretin Companion Care and the Emergence of Pharmacoadaptive Nutrition A scientific, clinical, formulation and innovation framework for the GLP-1 era","Jose M. Lopez","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22900652",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0053678","Efficacy and safety of Xiang-Sha-Liu-Jun-Zi (XSLJZ) for treatment of Semaglutide-induced gastrointestinal side effects: Study protocol for a multicentre, randomized, open-label trial","Meixi Liu","2023","Medicine Case Reports and Study Protocols","protocol","article","10.1097/md9.0000000000000297",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0053679","ENDOTHELIAL PROTECTIVE EFFECT OF LIRAGLUTIDE IN TYPE 2 DIABETES MELLITUS","А. В. Симаненкова","2018","Arterial’naya Gipertenziya (Arterial Hypertension)","other","article","10.18705/1607-419x-2018-24-1-81-92",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053680","Which medication is effective in preventing weight gain associated with antipsychotic use?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17881519",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053681","Is Wegovy effective for weight loss?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17911604",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053682","Tirzepatide in Sport after Inclusion in the WADA Monitoring Program: An Updated Narrative Review of Body Composition, Muscle Preservation and Potential Performance Implications","Dominika Kochan-Olszewska","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.71.74956",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0053683","The Role of the Dietitian in Incretin-Based Obesity Therapies in Italy: Practical Clinical Challenges, Professional Clarity, and the Sarcopenic Obesity Perspective","Daniela Ojeda-Mercado","2026","Dietetics","other","article","10.3390/dietetics5010017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053684","Are there differences in outcomes for pediatric patients discontinuing GLP-1 compared to adults, and if so, what are they?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22866174",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053685","Sustainable, cost-efficient manufacturing of therapeutic peptides using chemo-enzymatic peptide synthesis (CEPS)","Jan Pawlas","2019","Green Chemistry","other","article","10.1039/c9gc03600h",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053686","How is diabetes treated in children?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17968380",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053687","GLP1 receptor agonists and CAD regression in diabetic patients after ACS","Mauro Gitto","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.1805",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053688","OS IMPACTOS CARDIOVASCULARES DA TIRZEPATIDA EM PACIENTES COM DIABETES MELLITUS TIPO 2: UMA REVISÃO INTEGRATIVA DA LITERATURA","MARIA EDUARDA CARVALHO LOBO","2026","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v12i9.27571",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053689","GLP1 receptor agonists and their role in the therapy of neurodegenerative diseases - a literature review","Paweł Jan Kuna","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.51.68584",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053690","1170-OR: CGM for Adults with Type 2 Diabetes Not on Insulin Therapy: The CONNECT Randomized Controlled Trial","TAMARA OSER","2026","Diabetes","randomized_trial","article","10.2337/db26-1170-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053691","0224 Dermatologic outcomes of patients taking semaglutide: A propensity-matched large cohort study","Andrew D. Gong","2025","Journal of Investigative Dermatology","nonrandomized_study","article","10.1016/j.jid.2025.06.228",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053692","PHYSICIAN-REPORTED EXPERIENCE WITH DAPAGLIFLOZIN IN TYPE 2 DIABETES: EVIDENCE FROM SOUTHERN INDIA","Karthik S.","2026","International Journal of Life Science and Pharma Research","nonrandomized_study","article","10.22376/ijlpr.v16i1.2027",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053693","\"Impact of GLP-1/GIP Receptor Agonist–Associated Delayed Gastric Emptying on Oral Drug Absorption and Pharmacokinetics\": A Narrative Review","RUPESH KUMAR","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22102668",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","review"],["R0053694","EFFECTS OF SGLT2 INHIBITOR INITIATION ON INSULIN-TREATED TYPE 2 DIABETES PATIENTS","Hong Lee Hoong","2025","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.040.s1.187",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053695","Physiological and Pharmaceutical Study of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus","Qader Idrees B","2025","Cuestiones de Fisioterapia","other","article","10.48047/zfwc2v85",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053696","INSULIN RESISTANCE IN POLYCYSTIC OVARY SYNDROME — A NARRATIVE REVIEW OF MECHANISMS AND MANAGEMENT","Yuliia Dubova","2026","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.3(51).2026.6176",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0053697","What is the financial impact of long-term use of tirzepatide or Mounjaro?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21925232",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053698","GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis","M Galli","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.4322",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0053699","Editorial: Expanding therapeutic horizons with non-invasive vagus nerve stimulation","Claire-Marie Rangon","2026","Frontiers in Neuroscience","randomized_trial","article","10.3389/fnins.2026.1803982","41847228",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0053700","Current options for pharmacotherapy of obesity","Ľubica Cibičková","2025","Vnitřní lékařství","other","article","10.36290/vnl.2025.069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053701","Do GLP-1 receptor agonists increase the risk of aspiration pneumonia in patients undergoing upper gastrointestinal endoscopy?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22124700",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053702","I need a summary of the evidence on weight loss in people with obesity from the medications semaglutide, liraglutide, tirzepatide, and orlistat, and their risks.","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22032867",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053703","The anti-inflammatory effect of the combination treatment of dapagliflozin and dulaglutide in atherosclerosis diabetic model","H.J. Lee","2023","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2023.06.121",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053704","Safety of GLP-1 Receptor Agonists During LVAD Support: A New “Bridge-to-Transplant\" Paradigm","E. Margolin","2026","The Journal of Heart and Lung Transplantation","other","article","10.1016/j.healun.2026.02.1308",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053705","Mechanotransduction of Collagen Biostimulators: Comparative Signaling and Implications for GLP ‐1 RA –Associated Facial Aging","Chang-Hwan Cho","2026","Journal of Cosmetic Dermatology","other","article","10.1111/jocd.71105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053706","Psychiatric Safety of GLP-1 Receptor Agonists Across Type 2 Diabetes and Obesity: An Integrative Review","Kavita Batra","2026","Diabetology","randomized_trial","article","10.3390/diabetology7080144",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053707","Serendipity (and Clinical Observation) Strike Again: GLP-1 Receptor Agonists","Andrew Alan Nierenberg","2023","Psychiatric Annals","other","article","10.3928/00485713-20230925-01",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053708","26-A-18754-ACC GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE AND OUTCOMES IN CARDIAC SARCOIDOSIS: A PROPENSITY-SCORE MATCHED ANALYSIS","Kriti Soni","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1662",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053709","Abstract TU204: Glucagon-like Peptide-1 Receptor Agonists: Are They Associated With Increased Cardiorespiratory Fitness?","Laura DeFina","2026","Circulation","nonrandomized_study","article","10.1161/cir.153.suppl_1.tu204",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053710","Data from: Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes","Mackenzie Jo Pearson","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20160801",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053711","ESC Congress 2015, London: hot lines truly hot?","E. E. van der Wall","2015","Netherlands Heart Journal","other_trial","article","10.1007/s12471-015-0750-1","26408033",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053712","Neuroprotective effects of GLP ‐1 receptor agonists and their potential in retinal diseases","Zaynab Ahmad Mouhammad","2024","Acta Ophthalmologica","other","article","10.1111/aos.16225",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053713","Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonist Use on Short-Term and Long-Term Outcomes Following Thoracic and/or Lumbar Fusion for Spinal Deformity: A BMI-Stratified Cohort Study","Harmon Singh Khela","2026","Spine Open","nonrandomized_study","article","10.1097/bn9.0000000000000051",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053714","WEGOVY E OZEMPIC: O FEITO DA SEMAGLUTIDA","Laura Belchior Vilas Novas","2024","Revista fisio&terapia.","other","article","10.5281/zenodo.10836474",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053715","Comprehensive Obesity Management in Clinical Practice: From Diagnostic Assessment to Evidence-Based Treatment Strategies","Vignesh Gunasekaran","2025","European Journal of Medical and Health Sciences","other","article","10.24018/ejmed.2025.7.6.2453",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053716","Three-year exenatide therapy, followed by a 4-week off-drug period, had a sustainable effect on β-cell disposition index in metformin treated patients with type 2 diabetes","Mathijs C. M. Bunck","2011","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0031-1277490",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053717","Alcohol Consumption for Consecutive TwentySix Days in a Patient with Metabolic Dysfunction– Associated Steatohepatitis under Tirzepatide Treatment: Alanine Aminotransferase Levels Remained Normal","Hsin-Fu Chen","2026","Annals of Case Reports","other","article","10.29011/2574-7754.102501",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053718","EFFICACY AND SAFETY OF TIRZEPATIDE, A DUAL GIP/GLP-1 RECEPTOR AGONIST, COMPARED TO INSULIN DEGLUDEC IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3)","Bernhard H. Ludvik","2022","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0042-1746289",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053719","Evaluation of the effectiveness of semaglutide in providing metabolic control and correction of insulin resistance in patients with type 2 diabetes mellitus in real clinical practice","D. M. Antsiferova","2026","Diabetes Mellitus","other","article","10.14341/dm13441",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053720","MODERN VIEWS ON METABOLIC SYNDROME IN CHILDREN AND ADOLESCENTS","Valentyna I. Velychko","2024",null,"other","article","10.32782/2226-2008-2024-2-10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053721","EXPLORING THE ROLE OF OZEMPIC IN WEIGHT MANAGEMENT FOR DIABETIC PATIENTS AND ITS CORRELATION WITH IMPROVED GLYCAEMIC CONTROL COMPARING TRADITIONAL INSULIN THERAPY","Muqadas Mukhtar","2025","Journal of Population Therapeutics and Clinical Pharmacology","other","article","10.53555/1e0pwf54",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053722","What are the novel treatment options with oral hypoglycemic drugs for type 2 diabetes mellitus in the UK?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17671451",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053723","GLP-1 Medications: Redefining Food Choices and Industry Trends","Avleen Dhody","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.18014212",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0053724","What are the latest guidelines for managing type 2 diabetes in adults?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18733630",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053725","What are the benefits of new medications for weight management?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20392272",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053726","Pharmacological Rescue After Bariatric Surgery Failure: The Role of GLP-1 Receptor Agonists in Weight Regain Management","Gabriela Piotrowska","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.65.73982",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053727","Response to \"Letter to the Editor: The effect of GLP-1RAs on mental health and psychotropics induced metabolic disorders: A systematic review\".","Breit, Sigrid",null,"Open Access CRIS of the University of Bern","systematic_review","article","10.48620/90875",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","letter"],["R0053728","(220) Assessing Changes to Sexual Function and Length of Taking GLP1 or GLP1/GIP Receptor Agonists in Cisgender Women","Emily K. Burr","2025","The Journal of Sexual Medicine","other","article","10.1093/jsxmed/qdaf320.217",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053729","Possibilities of Combined Injection Therapy at the Start of Insulin Therapy in Patients with Type 2 Diabetes","M.B. Antsiferov","2020","Effective Pharmacotherapy","other","article","10.33978/2307-3586-2020-16-26-38-42",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053730","POLYCYSTIC OVARY SYNDROME (PCOS) WITH PATHOPHYSIOLOGY AND EMERGING THERAPIES","Nahida Tabassum*","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17122528",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053731","In terms of weight loss outcomes, how does Mounjaro compare to Ozempic in patients with type 2 diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.17652858",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0053732","Future Treatments For Tobaco Dependence","CA Jimenez-Ruiz","2026","Open Respiratory Archives","other","article","10.1016/j.opresp.2026.100668",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053733","Semaglutide in MASH with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial","Carlos Jose Pirola","2026","Metabolism and Target Organ Damage","randomized_trial","article","10.20517/mtod.2026.13",null,null,"ClinicalTrials.gov:NCT04822181","S000511","openalex","TRUE","open_pdf","1","FALSE","article"],["R0053734","GLP-1 Receptor Agonists in Heart Failure and Cardiometabolic Disease: Emerging Evidence for Integrated Cardiovascular and Metabolic Care Across the Americas","Erik Fernández Godínez","2026","IECCMEXICO","randomized_trial","article","10.64784/226",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053735","Abstract Wed133: Title: Comparative Efficacy of GLP-1RAs Among Individuals With PAD And Type 2 Diabetes: A Network Meta-analysis of Randomized Controlled Trials","Paulami Deshmukh","2026","Arteriosclerosis Thrombosis and Vascular Biology","systematic_review","article","10.1161/atvb.46.suppl_1.wed133",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053736","The Prediabetes Wake-Up Call: Time for Proactive Endocrine Care","Ganapathi Bantwal","2025","Indian Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/ijem.ijem_780_25","40917317",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053737","Semaglutide, a Frontline Drug in Managing Type 2 Diabetes","Vinod K. Abichandani","2025","Clinical Diabetology","other","article","10.5603/cd.109919",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053738","Effects of Combined Exercise and GLP-1 Receptor Agonist Liraglutide Therapy on Weight Loss and Metabolic Health in Obese Patients: A Systematic Review and Meta-Analysis","Salma Tamer Abdelrahman","2026","Journal of Pioneering Medical Science","systematic_review","article","10.47310/jpms2026150613",null,null,"PROSPERO:CRD420251234320",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0053739","Eminent Effects of Glucagon-Like Peptide-1 Receptor Agonist on the Thyroid Gland of Male Albino Rats","Rasha M Salama","2026","Scientific Electronic Library Online (Scientific Electronic Library Online)","preclinical","article","10.4067/s0717-95022026000200542",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053740","Retrospective Analysis of Pharmacological Management and Referral Patterns of Patients with Type 2 Diabetes Mellitus Referred from Primary Care to Specialists","Dhruvi Hasnani","2026",null,"nonrandomized_study","article","10.5005/jodec-11035-0010",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053741","2592-P: Impact of Once-Weekly Injectable Semaglutide vs. Placebo on Fatty Liver Index Scores in People with Overweight/Obesity: A Post Hoc Analysis (STEP1)","GEMA FRÜHBECK","2026","Diabetes","other","article","10.2337/db26-2592-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053742","TIRZEPATIDE AND THE RISKS OF USE WITHOUT MEDICAL PRESCRIPTION","Bruna Eduarda Silva","2026","Seven Editora eBooks","other","article","10.56238/sevened2026.020-055",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0053743","1671-P: Heterogeneity of Treatment Effect of Glucagon-Like Peptide 1 Receptor Agonists for Secondary Prevention of Cardiovascular Events in Type 2 Diabetes","Jay B. Lusk","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1671-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053744","Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.","Mark David Orland","2026","Journal of Clinical Oncology","randomized_trial","article","10.1200/jco.2026.44.16_suppl.3143",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0053745","WCN26-6543 DEFINING THE ROLES OF SGLT2IS AND GLP-1 RAS IN THE MANAGEMENT OF CHRONIC KIDNEY DISEASE WITH TYPE 2 DIABETES AND OVERWEIGHT/OBESITY: A DELPHI CONSENSUS","Yehuda Handelsman","2026","Kidney International Reports","other","article","10.1016/j.ekir.2026.104633",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053746","Systematic review and network meta-analysis of the safety and efficacy of the triple incretin receptor agonist, retatrutide compared to the dual incretin receptor agonist, tirzepatide, for treatment of type 2 diabetes mellitus","Anastasia Tereshchenko","2026","Therapeutic Advances in Endocrinology and Metabolism","systematic_review","article","10.1177/20420188261474093",null,null,"PROSPERO:CRD420251014217",null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0053747","0068Real-world Change in Cardiometabolic Markers After Glucagon-like Peptide-1 (GLP-1)-Based Treatment Discontinuation Among US Patients with ASCVD","Daniel Edmonston","2026","American Heart Journal","nonrandomized_study","article","10.1016/j.ahj.2026.107569",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053748","What is the mechanism of action of Tirzepatide (Mounjaro), and how does it differ from other GLP-1 receptor agonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17708836",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053749","Sarcopenia and obesity: Two sides of the same coin. Incretin technologies in addressing the problem","T. Yu. Demidova","2025","FOCUS Endocrinology","other","article","10.62751/2713-0177-2025-6-4-06",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053750","P244The glucagon-like peptide-1 receptor agonist liraglutide ameriolates hypoxia-induced pulmonary hypertension in mice partly via recovery of ETB receptor expression","Junya Honda","2018","European Heart Journal","preclinical","article","10.1093/eurheartj/ehy564.p244",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053751","Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study","Yagiz Matthew Akiska","2025","EMJ Dermatology","nonrandomized_study","article","10.33590/emjdermatol/tyew1122",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053752","РМЖ. Медицинское обозрение. T. 9, № 10, 2025 / Russian Medical Inquiry. Vol. 9, № 10, 2025 Эндокринология / Endocrinology743 Обзоры / Review Articles Сахарный диабет 2 типа и неалкогольная жировая болезнь печени: протективные эффекты сахароснижающих препаратов Ю.А. Долгих, С.В. Булгакова, Л.А. Шаронова, О.В. Косарева, Е.В. Тренева, П.Я. Мерзлова, Д.П. Курмаев ФГБОУ ВО СамГМУ Минздрава России, Самара, Российская Федерация РЕЗЮМЕ Сочетание неалкогольной жировой болезни печени (НАЖБП) и сахарного диабета 2 типа (СД2) является достаточно распространен- ным, так как ожирение и резистентность к инсулину служат общими патологическими предикторами этих заболеваний. Для успешного лечения как СД2, так и НАЖБП необходимо влияние на инсулинорезистентность, уровень гликемии и массу тела пациента. Сахаросни- жающие препараты, используемые при СД2, могут также быть эффективными и при лечении НАЖБП. В данном обзоре обсуждают- ся гепатопротективные свойства метформина, агонистов глюкагоноподобного пептида 1 (ГПП1) и ингибиторов натрийглюкозного котранспортера 2го типа ( НГЛТ2). Применение данных групп препаратов приводит к снижению массы тела, уровней трансаминаз и уменьшению количества жира в печени. Лираглутид приводил к разрешению стеатогепатита и уменьшал прогрессирование фиброза. Семаглутид у пациентов с СД2 и умеренным или выраженным фиброзом печени также улучшал гистологические показатели. Активно изучается влияние на состояние печени нового комбинированного препарата тирзепатида. На фоне его применения отмечалось раз- решение НАЖБП и уменьшение фиброза. Ингибиторы НГЛТ2 продемонстрировали снижение уровня трансаминаз и процента жира в печени. Внимания также заслуживает препарат ипраглифлозин. Его длительное применение уменьшает фиброз печени у пациен- тов с НАЖБП. По данным многоцентрового рандомизированного клинического исследования, ипраглифлозин привел к уменьшению фиброза печени в 57,1% случаев и баллонной дистрофии гепатоцитов в 52,4% случаев (по данным парных биопсий печени). Кроме того, ингибиторы НГЛТ2 показали себя более эффективными в отношении снижения уровня трансаминаз по сравнению с агонистами ГПП1. Таким образом, при назначении сахароснижающей терапии стоит учитывать влияние препаратов на состояние печени и отда- вать предпочтение лекарственным средствам, имеющим гепатопротективные свойства. КЛЮЧЕВЫЕ СЛОВА: метформин, агонисты глюкагоноподобного пептида 1, ингибиторы натрийглюкозного котранспортера 2 типа, фиброз, стеатогепатит, инсулинорезистентность. ДЛЯ ЦИТИРОВАНИЯ: Долгих Ю.А., Булгакова С.В., Шаронова Л.А., Косарева О.В., Тренева Е.В., Мерзлова П.Я., Курмаев Д.П. Са- харный диабет 2 типа и неалкогольная жировая болезнь печени: протективные эффекты сахароснижающих препаратов. РМЖ. Медицинское обозрение. 2025;9(10):743–748. DOI: 10.32364/2587-6821-2025-9-10-7 Type 2 diabetes mellitus and NAFLD: the protective effects of glucose-lowering drugs","Yu. A. Dolgikh","2025","Russian Medical Inquiry","randomized_trial","article","10.32364/2587-6821-2025-9-10-7",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053753","GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly","Gilberto Pérez López","2025","Medicina Clínica (English Edition)","other","article","10.1016/j.medcle.2025.107122",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053754","Glucagon-like peptide-1 receptor agonists in the treatment of steatohepatitis in patients with type 2 diabetes mellitus","Abdel Raouf Fouad","2025","International Journal of Diabetes Research","nonrandomized_study","article","10.33545/26648822.2025.v7.i1b.34",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053755","GLP-1 Neuroprotection — P5 narrowing","James E. Dunn","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19708691",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0053756","Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis","Daniel J. Drucker","2003","Endocrinology","other_trial","article","10.1210/en.2003-1147","14645210",null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053757","MSR102 CHALLENGES IN MACHINE LEARNING PREDICTION OF RARE EVENTS : IPW-ADJUSTED PREDICTORS AND THE ASSOCIATION OF GLP-1 RA WITH INCIDENT ALCOHOL-RELATED DISORDERS","Rinoj Gautam","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1601",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053758","Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial","S. Marso","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/ct1e-g414",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0053759","Drugs used in the treatment of Alzheimer’s disease: a review of current clinical research and promising therapeutic targets","K. N. Sorokina","2026","Сибирский научный медицинский журнал","other_trial","article","10.18699/ssmj20260102",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0053760","Gut Hormones in T2 Diabetes Mellitus and Emerging Treatment Paradigm","Sudha Sreenivas","2025",null,"other","article","10.9734/bpi/msti/v10/4748",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0053761","Can early treatment with GLP-1 agonists prevent or delay the onset of type 2 diabetes in high-risk individuals?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18386122",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053762","TIRZEPATIDE AND METABOLIC TREATMENT OF OBSTRUCTIVE SLEEP APNEA IN OBESE PATIENTS - EMERGING THERAPEUTIC PERSPECTIVES","Magdalena Dubaj","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.2(50).2026.5603",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053763","SEMIRISH VA QORIN DEVORI KESMA CHURRALARI: XAVF OMILIDAN ZAMONAVIY DAVOLASH STRATEGIYALARIGACHA","Давронбек Батиров","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22893991",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053764","The impact of preoperative therapy with GLP-1 receptor agonists on weight loss and metabolic effects after bariatric surgeries – single-center preliminary study","Pamela Jeske","2026","Langenbeck s Archives of Surgery","nonrandomized_study","article","10.1007/s00423-026-04294-x",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053765","Acute ischaemic colitis after initiation of tirzepatide in an elderly patient with type 2 diabetes","Gianluigi Cuomo","2026","Emergency Care Journal","other","article","10.4081/ecj.2026.14970",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053766","Lifestyle Modifications and Nutraceutical Interventions in the Prevention and Management of Metabolic Syndrome","Anna Meiliana","2025","The Indonesian Biomedical Journal","other","article","10.18585/inabj.v17i3.3412",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053767","(825) Emerging Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Male Sexual Hormones and Behaviors","G Corona","2026","The Journal of Sexual Medicine","other","article","10.1093/jsxmed/qdag118.717",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053768","DEVELOPMENT OF A METHOD FOR ASSESSING GLP-1R RECEPTOR ON A CELL LINE IN VITRO UPON STIMULATION WITH TIRZEPATIDE IN THE “CALCIUM FLUX” ASSAY","D.O. Ermolaeva","2025",null,"preclinical","article","10.25205/978-5-4437-1843-9-254",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0053769","Rivaroxaban for the treatment of heparin-induced thrombocytopenia with thrombosis in a patient undergoing artificial hip arthroplasty: A case report","Fangfang Lv","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6147","37731576",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053770","What is the effect of GLP-1 receptor agonists on mammographic breast density in women undergoing mammography?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21844373",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053771","GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control","Rodrigo Gonçalves Corrêa","2026","International Health Sciences Review","other_trial","article","10.70164/ihsr.v2i4.211",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053772","What is the best treatment for obesity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22804526",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053773","Anti-Inflammatory and Antioxidant Mechanisms of GLP-1 Receptor Agonists: Molecular Pathways and Therapeutic Implications","Jayesh H Patil","2026","Journal of Pharmaceutical Research","other","article","10.18579/jopcr/v25.i2.128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053774","Do GLP-1 agonists help people quit smoking?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21358374",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053775","Are there specific diabetes treatments that are more effective in patients diagnosed with both dementia and diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17685789",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053776","Evaluation of GLP-1 Receptor Agonists Use in Post-Kidney Transplant Recipients with Type 2 Diabetes Mellitus","Ngan Thi Kim Pham","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.1811",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053777","Editorial: Exploring adverse drug reactions: monitoring, mechanism, intervention, and resolution","Li Tao","2026","Frontiers in Medicine","nonrandomized_study","article","10.3389/fmed.2026.1798711","41836924",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0053778","Commentary on the T1D Exchange Quality Improvement Collaborative Learning Session November 2025 Abstracts","Stephanie S. Crossen","2026","Journal of Diabetes","commentary","article","10.1111/1753-0407.70214","41974501",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0053779","In patients undergoing gastrointestinal endoscopy, does the use of GLP-1 receptor agonists increase the risk of residual gastric contents compared to non-use?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22177321",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053780","A INTERAÇÃO ENTRE OS AGONISTAS DO RECEPTOR GLP-1 E O EIXO INTESTINO-CÉREBRO: MECANISMOS NEUROIMUNES E PERSPECTIVAS TERAPÊUTICAS","Tercília Menezes Monteiro","2026","Revista Tópicos.","other","article","10.70773/revistatopicos/787496864",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053781","MM-1225: GLP-1 Agonists Improve Survival and Reduce Morbidity in Newly Diagnosed Multiple Myeloma: A Real-World Propensity Score–Matched Analysis","Chidiebube Ugwu","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)03010-7",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053782","Pharmacological Management of Obesity: An Evidence-Based Review of Emerging Anti-Obesity Drugs and Their Clinical Applications","Dr Gramle Amol","2026","International journal of research and scientific innovation","narrative_review","article","10.51244/ijrsi.2026.1307000300",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053783","Impacto psicológico do tratamento com agonistas do GLP-1 em pacientes com obesidade: uma revisão integrativa","Bernardo Nogueira Stelle","2025","Brazilian Journal of Health Review","other","article","10.34119/bjhrv8n5-041",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053784","Head to Head Comparison of Semaglutide and Colchicine for Treating Atrial Remodeling in Post MI Rats with Reduced Ejection Fraction","Or Levi","2026","Journal of Molecular and Cellular Cardiology Plus","preclinical","article","10.1016/j.jmccpl.2025.100531",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053785","Liraglutide, a GLP-1 Receptor Agonist, Enhances Proliferation and Secretory Function of Pancreatic β-Cells with Activated ABCC8","Y. Zhang","2025","Molecular Biology","preclinical","article","10.1134/s0026893325603854",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053786","Tirzepatide and Cancer Risk","Reena Alassam","2025","World Family Medicine Journal/Middle East Journal of Family Medicine","randomized_trial","article","10.5742/mewfm.2025.805257890",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053787","What are the latest treatment guidelines for managing type 2 diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17955352",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053788","Effect of single-dose semaglutide on taste reward processing in healthy volunteers - preliminary findings from an experimental medicine study","A. Guru","2026","Neuroscience Applied","other","article","10.1016/j.nsa.2025.106375",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053789","Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer’s Disease After 12 Weeks of Subcutaneous Treatment (P3-13.012)","Susan Alford","2026","Neurology","other","article","10.1212/wnl.0000000000216104",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053790","Does the semaglutide tablet versus semaglutide injection result in a significantly different amount of weight loss?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21419423",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053791","GLP-1 Receptor Agonists and Sarcopenic Risk in South Asian Adults: A Perfect Storm of Phenotypic Vulnerability and Pharmacovigilance Neglect","Varun Kumar Gone","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6862258",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0053792","A Survey on the Quality of Diabetes Normative Management at Grassroots Level","YANG  Rong, JIN  Hua, SHI  Ling, YI  Chuntao, HOU  Jin, CHEN  Chen, HUAN  Hongmei, NI  Hengru, YU  Dehua","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12114/j.issn.1007-9572.2024.0417",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053793","GLP-1 drugs and the rearticulation of fat stigma in Spain: public responses to pharmaceuticalization of fat","Lara Martín-Vicario","2026","Fat Studies","other","article","10.1080/21604851.2026.2630514",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053794","In which populations have GLP-1 receptor agonists not been studied?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17831771",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053795","Synthèse de peptides bioactifs inspirés des venins","Julien Giribaldi","2019",null,"other","article","10.70675/4396528bz40f7z47abz935az5799907cf557",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0053796","Evaluation of Pharmacokinetic Profile of GLP-1 Receptor Agonist Exenatide in Type 2 Diabetes Experimental Model","Arshad Nehal Jamali","2023","International Journal of Pharmaceutical Investigation","other","article","10.5530/ijpi.13.4.097",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053797","What are the guidelines for fasting in patients with special considerations, such as those with diabetes, prior to anesthesia?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17744256",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053798","Patient Adherence to Glucagon Like Peptide-1 Receptor Agonists in Obesity Management: A Narrative Review of Real-World Evidence","Zainab M. Al-Shammaa","2026","Maaen Journal for Medical Sciences","nonrandomized_study","article","10.55810/2789-9136.1091",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0053799","Semaglutide in the Era of Blockbuster Pharmaceuticals","Melisa Jahić","2026","UniCath journal of biomedicine and bioethics","other","article","10.64332/ujbb.3.1.7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053800","Are GLP-1 agonists more effective than metformin in improving menstrual regularity in people with PCOS?","Ami Dhyani","2025","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002452",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053801","Gegen den Mangel an GLP-1-Agonisten","Marc Donath","2023","Bulletin des Médecins Suisses","other","article","10.4414/saez.2023.22167",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053802","LC-MS/MS analýza GLP-1 analógu semaglutidu v plazme a mozgovom tkanive / LC-MS/MS analysis of the GLP-1 analog semaglutide in plasma and brain tissue","Petra Majerová","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19485363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053803","Tirzepatide-Associated Dysesthesia with Atypical Sensory Distribution: A Case Report","Drew A. Wells","2026","Stroke Clinician","case_report","article","10.59236/sc.v3i3.119",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053804","The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: A Narrative Review","Kamil Turlej","2025","Quality in Sport","narrative_review","article","10.12775/qs.2025.43.61264",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0053805","RWD79 INITIATION WITH GLP-1 RECEPTOR AGONISTS TREATMENT FOR OBESITY IN PATIENTS WITH MENTAL HEALTH CONDITIONS - A REAL WORLD DATA RETROSPECTIVE STUDY","Or Shaked","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.2067",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053806","Dual GLP-1/GIP agonist tirzepatide modulates hepatic mitochondrial fusion–fission gene expression and oxidative stress in diabetic rats","Shazia Durrani Fakhir","2025","Pharmacia","preclinical","article","10.3897/pharmacia.72.e175259",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053807","Evolving Trends in Type 2 Diabetes Management: Therapeutic Approaches for the Patients","F Mohd Azam","2021","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.4840587",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053808","Diabetes Mellitus Overview 2024","Ahmed Abdelhalim Yameny","2024","Journal of Bioscience and Applied Research/Journal of Bioscience and Applied Research ","other","article","10.21608/jbaar.2024.382794",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053809","Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review","Alex Carvalho Leite","2025","Brazilian Journal of Hair Health","narrative_review","article","10.62742/2965-7911.2026.3.bjhh38",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053810","Real-world survival benefit of glucagon-like peptide-1 receptor agonists (GLP-1 Ras) concomitant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy in hormone receptor-positive (HR+)/HER2− metastatic breast cancer: A large propensity-matched analysis.","Michela Palleschi","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.1070",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053811","Perioperative GLP-1 receptor agonist use and postoperative opioid consumption in gynecologic surgery: A retrospective cohort analysis","Paula Mateo-Kubach","2026","International Journal of Gynecological Cancer","nonrandomized_study","article","10.1016/j.ijgc.2025.103656",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053812","EP430 - ECE_3900 - Early changes in circulating immune cell populations following GLP-1 receptor agonist therapy in obesity","Kleopatra Alexiadou","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.939",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0053813","How do GLP-1 agonists affect inpatient admissions and hospital outcomes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21495385",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053814","NeuroLink-AD: A Modular Closed-Loop AI Platform Integrating Wearable EEG, Edge-AI, and Physician-Supervised Non-Invasive Therapeutics for Early Alzheimer's Disease","Adam Emad Bakr","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22854195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0053815","Diabetes mellitus: Clinical characteristics, glycemic outcomes, and insights from recent therapeutic trials - research study","Suyash Saurabh","2026","Southeast Asian Journal of Health Professional","randomized_trial","article","10.18231/j.sajhp.45553.1767956308",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053816","Метод лазерной допплеровской флоуметрии в оценке влияния лираглутида на микроциркуляцию у крыс с диет-индуцированным ожирением","Э. Б. Попыхова","2023","Оптика и спектроскопия","preclinical","article","10.21883/os.2023.06.55920.120-23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053817","GLP-1 Receptor Agonists: An Emerging Pitfall in FDG PET/CT Interpretation","Rabia Nizam","2026","Journal of Community Medicine and Health Solutions","other","article","10.29328/journal.jcmhs.1001079",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053818","Molecular hybridization strategies for developing antidiabetic agents with optimized therapeutic efficacy","Siddhartha Sankar Das","2026","Discover Chemistry.","preclinical","article","10.1007/s44371-026-00547-2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053819","OR1-3 | Impact of GLP-1 Agonist on Cardiovascular Outcomes in Patients with Peripheral Artery Disease without Diabetes: A Propensity Score-Matched Analysis","Emmanuel Daniel","2025","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2025.102654",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053820","Sodium/glucose cotransporters 2 inhibitors but not other antidiabetic drugs improve frailty in older adults with diabetes and heart failure with preserved ejection fraction","Pasquale Mone","2026","Cardiovascular Research","other_trial","article","10.1093/cvr/cvag065","41871939",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0053821","Preoperative localization of adult nesidioblastosis using (68)Ga-DOTA-exendin-4-PET/CT.","Christ, Emanuel","2015","Open Access CRIS of the University of Bern","other","article","10.7892/boris.70208",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053822","Glucagon-like peptide-1 receptor agonists and hair loss: Current evidence and potential mechanisms","Archie Spindler","2026","JAAD reviews.","nonrandomized_study","article","10.1016/j.jdrv.2026.07.002",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053823","Exploring Peganum harmala as a natural alternative to semaglutide: A novel approach to glucagon-like peptide-1 stimulation and insulin sensitization","Maher Monir Akl","2025","Innovative Medicines & Omics","other","article","10.36922/imo025060009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053824","Japanese Clinical Practice Guideline for Diabetes 2019","Eiichi Araki","2020","Journal of Diabetes Investigation","randomized_trial","article","10.1111/jdi.13306",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053825","Are GLP-1 agonists associated with malnutrition?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17753798",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053826","Effectiveness and safety of once-weekly semaglutide for weight loss in adults with overweight or obesity: a systematic review of randomized controlled trials","Snehashis Singha","2026","International Journal of Basic & Clinical Pharmacology","systematic_review","article","10.18203/2319-2003.ijbcp20260439",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0053827","SAT-604 Use of Adjunctive Therapy in Patients With Autoimmune Diabetes In the Renaced DT1 Registry","Aili Lupita Garcia Tuomola","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1131",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0053828","Modern Approaches to Non-Insulin Therapy of Patients with Type 2 Diabetes Mellitus","Mikhail Borisovich Antsiferov","2021","Doctor Ru","other","article","10.31550/1727-2378-2021-20-2-30-39",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053829","#1703800 Successful Treatment of Hypothalamic Obesity with Tirzepatide: A Case Report","Sharmela Brijmohan","2024","Endocrine Practice","case_report","article","10.1016/j.eprac.2024.03.351",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053830","GLP-1 receptor agonist usage on complications in patients undergoing surgical treatment of endometrial cancer","Tasnia Monir","2026","Gynecologic Oncology","other","article","10.1016/j.ygyno.2026.01.331",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053831","Contemporary Therapeutic Approaches in the Cardiorenal-Metabolic Continuum: Current Perspectives on Diabetes, Chronic Kidney Disease, and Cardiovascular Dysfunction","Santiago Avila Ak","2026","International Science Journal","nonrandomized_study","article","10.64784/247",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053832","What are the comparative long-term (≥1-year) results of GLP-1 receptor agonist therapy and bariatric surgery for weight loss?","Nathaniel Trona","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002326",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053833","256-OR: Five-Year Simulation of Diabetes-Related Complications in Individuals Treated with Once-Weekly Tirzepatide and Semaglutide vs. Once-Daily Insulin Glargine","SHU NIU","2022","Diabetes","other_trial","article","10.2337/db22-256-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0053834","A Multidisciplinary Nano-Platform for the Treatment of Alzheimer's Disease: Synergizing Chiral Gold Nanostructures with GLP-1 Analogs","Adam Emad Bakr","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20287158",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053835","What are the third-line agents for type 2 diabetes mellitus, and how do they compare?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17689316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053836","Analogues in Diabetes Management: Current and Future Prospects","Deepak Joshi","2025","International Journal of Newgen Research in Pharmacy & Healthcare","other","article","10.61554/ijnrph.v3i2.2025.183",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053837","How effective are GLP-1 receptor agonists in problem drinking?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18047412",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053838","EFFECTS OF SEMAGLUTIDE AND TIRZEPATIDE ON SKELETAL MUSCLE MASS AND SARCOPENIA RISK IN ADULTS WITH OBESITY OR OVERWEIGHT: A NARRATIVE REVIEW","Szymon Mokrzecki","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(51).2026.6230",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0053839","Continuous Glucose Monitoring in a Patient With Insulin-Treated Type 2 Diabetes","Monica Joyce","2013","Clinical Diabetes","other","article","10.2337/diaclin.31.2.79",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053840","OC29 - Genotype over phenotype: the road less travelled in diagnosing Bardet- Biedl syndrome","Neeraj Kumar Agrawal","2025","European Journal of Endocrinology","other","article","10.1093/ejendo/lvaf168.048",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0053841","Design and characterization of a surfactant‐conjugated, long‐acting, balanced GLP ‐1/glucagon receptor dual agonist","JOHN J. JUN. NESTOR","2021","Peptide Science","preclinical","article","10.1002/pep2.24221",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053842","SELECTing Treatments for Cardiovascular Disease — Obesity in the Spotlight","Amit Khera","2023","New England Journal of Medicine","other","article","10.1056/nejme2312646","37952130",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053843","Incident ocular outcomes with tirzepatide versus GLP-1 receptor agonists and conventional therapies in diabetes and obesity: a retrospective cohort study from a global federated health research network","Nguyen Ngoc Khoi Truong","2026","Diabetology & Metabolic Syndrome","nonrandomized_study","article","10.1186/s13098-026-02299-6",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053844","Comparative effectiveness of once-weekly semaglutide versus daily liraglutide on weight reduction and glycemic control in obese type 2 diabetics","Tomás Antonio Pérez Herrera","2023","International Journal of Endocrinology Research","randomized_trial","article","10.33545/26646579.2023.v5.i1a.64",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0053845","Obesity-related arterial hypertension: From pathogenesis to algorithm for de-escalation of antihypertensive therapy during incretin mimetic-induced weight loss","V. V. Salukhov","2026","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2026-136",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053846","Eficácia do Mounjaro em comparação à cirurgia bariátrica na perda de peso: evidências de uma revisão integrativa","Vicenzo Bellincanta Dallazen","2025","Contribuciones a las Ciencias Sociales","other","article","10.55905/revconv.18n.2-024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053847","Referral for Weight Management in Early Intervention in Psychosis","Richard John Chater","2025","BJPsych Open","other","article","10.1192/bjo.2025.10561",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053848","EndoCompass project","Chantal Mathieu","2026","DiRROS repository (University of Maribor)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0053849","12-PUB: Tirzepatide—Efficacy, Safety, and Satisfaction in Real World Type 2 Diabetes Application in Japan","Shizuka Kaneko","2024","Diabetes","nonrandomized_study","article","10.2337/db24-12-pub",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053850","Mise en place de la [68Ga]Ga-NODAGA[40Lys]-Exendin-4 en CLCC : bilan des premières synthèses","M. Ragot","2025","Médecine Nucléaire","other","article","10.1016/j.mednuc.2025.01.175",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053851","1821-P: Combination of Tirzepatide with CBL-514 an Adipocyte-Apoptosis Agent Improves Weight Loss Durability and Adipose Tissue Remodeling in Diet-Induced Obese Rats","Yu-Fang Ling","2026","Diabetes","preclinical","article","10.2337/db26-1821-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053852","GLP-1Ra en el manejo de diabetes mellitus tipo 2: una revisión de revisiones sistemáticas","Francy Cantor-Cruz","2022","Revista Colombiana de Endocrinología Diabetes & Metabolismo","other","article","10.53853/encr.9.2.601",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053853","Liraglutide – Effects on Lean Body Mass, Muscle Mass and Prevention of Muscle Loss. A Comprehensive Literature Review","Michał Oborski","2026","Quality in Sport","nonrandomized_study","article","10.12775/qs.2026.49.67959",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053854","What is the efficacy of semaglutide for weight loss compared to other weight loss medications?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18027459",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053855","Glucagon-Like Peptide-1 Receptor Agonists Taken for Weight Loss Do Not Affect Postoperative Outcomes Following Anterior Cervical Discectomy And Fusion","Joydeep Baidya","2025","Spine Open","nonrandomized_study","article","10.1097/bn9.0000000000000013",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0053856","MM-857: Survival and Cardiovascular Outcomes Associated With GLP-1 Receptor Agonist Exposure in Patients With Multiple Myeloma and Metabolic Comorbidities: A Propensity-Matched TriNetX Analysis","Nnamdi Omenuko","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)02945-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053857","What is the effectiveness of GLP-1 agonists in managing weight gain in menopausal women?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19387022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053858","GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications","Sedat Arslan","2026","Academia oncology.","randomized_trial","article","10.20935/acadonco8234",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0053859","Body composition, nutritional status and clinical outcomes in end-stage liver disease","Bot, D.","2025","Leiden Repository (Leiden University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0053860","SUN-591 GLP1-RA, SGLT2i and Risk of Advanced Fibrosis in Patients with T2D:a Target Trial Emulation","Alexander Turchin","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1242",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053861","Digital Behavioral Infrastructure for Glucagon-Like Peptide-1 Pharmacotherapy: Viewpoint on Persistence, Tolerability, and Postcessation Durability (Preprint)","Geoff Cook","2026",null,"randomized_trial","article","10.2196/preprints.104227",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","preprint"],["R0053862","OBESITY AS A CHRONIC LOW-GRADE INFLAMMATORY DISEASE - PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL IMPLICATIONS. A REVIEW OF THE LITERATURE","Iga Kuba","2026","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.2(50).2026.5981",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053863","What are the pharmacological treatments for weight loss in patients with Crohn's disease, excluding GLP-1 receptor agonists?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21457370",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053864","What medications can help patients with obstructive sleep apnea sleep without worsening their condition?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19657424",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053865","Abstract C031: Evexomostat (SDX-7320), a methionine aminopeptidase type 2 (METAP2) inhibitor, inhibits obesity-accelerated tumor growth and stimulates weight loss in obese mice","Peter Cornelius","2025","Clinical Cancer Research","preclinical","article","10.1158/1557-3265.earlyonsetca25-c031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053866","Difficulties in the differential diagnosis of granulomatous interstitial nephritis","N.L. Kozlovskaya","2023","Nephrology and Dialysis","other","article","10.28996/2618-9801-2023-2-313-321",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053867","Effectiveness of the combination of SGLT2 inhibitor and GLP-1 agonist on glycemic control and cardiorenal outcomes: A pilot real-world study in Indonesia","Fonny Cokro","2026","Journal of Applied Pharmaceutical Science","nonrandomized_study","article","10.7324/japs.2026.266181",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053868","PCR5 EASE OF USE OF TIRZEPATIDE: RESULTS FROM A US SURVEY OF INDIVIDUALS WITH OBESITY OR OVERWEIGHT","TD Hunter","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1778",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053869","2142-P: Preconception Use of GLP-1RA and SGLT2i in Pregnant Women with Diabetes in a Large Integrated Health Care System: Impact on Pregnancy Outcomes","FARNOOSH FARROKHI","2026","Diabetes","other","article","10.2337/db26-2142-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053870","How should the treatment plan be adjusted for patients with type 2 diabetes mellitus when switching from semaglutide to tirzepatide in terms of glycemic control and weight management?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20086224",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053871","1968-P: Impact of GLP-1RA Initiation on Medical Expenditures in Medicare Beneficiaries with Type 2 Diabetes","YU N. WANG","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1968-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053872","NP-009 Discontinuation and predictive factors in patients treated with GLP-1 receptor analogues: evidence from Sicilian distribution 'per conto' (DPC) data (2021-2024)","Tardibuono Vincenza Adriana","2026",null,"nonrandomized_study","article","10.1136/ejhpharm-2026-eahp.9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053873","Obesity and Cancer: Excess Body Fat as a Risk Factor in Carcinogenesis; Consequences Across Human Body Systems and Significance for Associated Medical Specialties","Nicholas A Kerna","2025","European Journal of Medical and Health Research","other","article","10.59324/ejmhr.2025.3(2).12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053874","GLP-1 e Estética: Ozempic Face, Flacidez e Recuperação","Talita Almeida","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21122763",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053875","What can be done when semaglutide weight reduction stops?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18213807",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053876","Muscle mass and function in MASLD patients eligible for incretin-based therapies: a cross-sectional study from a tertiary referral center","Agnese Salamone","2026","Digestive and Liver Disease","other","article","10.1016/j.dld.2026.07.058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053877","EE708 The Five-Year Budget Impact of Introducing Semaglutide 2.4 mg for Obesity Management in Saudi Arabia: A Real-World Patient Flow and Complication-Driven Model","Mohamed Alzahrani","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.09.1088",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053878","Descriptive analysis of TikTok videos posted under the hashtag #Ozempic","Corey Hannah Basch","2023","Journal of Medicine Surgery and Public Health","other","article","10.1016/j.glmedi.2023.100013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053879","1325 GLP-1 Agonists in Lymphedema: A Systematic Review of Clinical Evidence","J J E Wong","2026","British journal of surgery","systematic_review","article","10.1093/bjs/znag063.695",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0053880","CO39 Risk of Cutaneous Adverse Drug Reactions with GLP-1 Receptor Agonists: Insights from FAERS and Systematic Review","Shifa Taj","2025","Value in Health","systematic_review","article","10.1016/j.jval.2025.04.124",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","conference-abstract"],["R0053881","What evidence supports the use of Semaglutide in treating liver disease?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17944389",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053882","114-LB: GX-G6, a Novel Long-Acting Glucagon-Like Peptide Receptor Agonist: Result of Phase I Study in Healthy Volunteers","MISUN BYUN","2019","Diabetes","randomized_trial","article","10.2337/db19-114-lb",null,null,"ClinicalTrials.gov:NCT03651466",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053883","S2102 Battle of the Weight-Loss Titans: Semaglutide vs Tirzepatide – Which is Safer?","Zryan Shwani","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001037776.05558.59",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053884","Non-Alcoholic Fatty Liver Disease and Its Progression: Impact of Metabolic Syndrome and Future Treatment Strategies","Nasir Ayub Khan","2025","Indus journal of bioscience research.","other","article","10.70749/ijbr.v3i3.796",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053885","What an Ophthalmologist Should Know about the Side Effects of “Ozempic” and its Analogues","V. N. Trubilin","2026","Ophthalmology in Russia","other","article","10.18008/1816-5095-2026-2-234-241",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053886","If a patient stops taking the maximum dose of Rybelsus for one month, should they restart at a low dose or resume the same dose?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19091430",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053887","Management of type 2 diabetes mellitus in overweight patients: an updated review","S. V. Jargin","2026","Лечащий врач","nonrandomized_study","article","10.51793/os.2026.29.2.005",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053888","Liraglutide treatment fails to show neuronal repair or neuroprotective effects in patients with type 1 diabetes and diabetic symmetric polyneuropathy","Christina Brock","2018","VBN Forskningsportal (Aalborg Universitet)","other","article","10.1007/s00125-018-4693-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053889","B16-09 Attenuation of Respiratory Exacerbation Rate With GLP-1 Receptor Agonist Therapy in Patients With COPD","U Suresh","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.1758",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053890","Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials","J.B. Buse","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","other_trial","article","10.17615/65hn-mb69",null,null,"ClinicalTrials.gov:NCT01179048; ClinicalTrials.gov:NCT01720446","S001496; S001933","openalex","TRUE","paywalled","5","FALSE","article"],["R0053891","Use of Exenatide in Patients With Type 2 Diabetes","Robert C. Hood","2006","Diabetes Spectrum","other","article","10.2337/diaspect.19.3.181",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053892","Safety of GLP-1 receptor agonists in body contouring surgery: a systematic review and meta-analysis","Bernardo G. Collaco","2026","BMC Plastic and Reconstructive Surgery","systematic_review","article","10.1186/s44452-026-00024-w",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0053893","Commentary: Exenatide QW: A New Treatment Option for Type 2 Diabetes Offering Ease of Use, Improved Efficacy, and Reduced Side Effects","Charles F. Shaefer","2012","Clinical Diabetes","commentary","article","10.2337/diaclin.30.3.92",null,null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0053894","Development of the Synthetic Route to PF-06878031 Part 1: Selective Alkylation Route","Oriana Brea","2024","Organic Process Research & Development","other","article","10.1021/acs.oprd.4c00053",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053895","The role of novel antihyperglycaemic agents in the treatment of Type 2 diabetes: From glycaemic control to cardiovascular protection","Tatjana Žunić","2020","Arhiv za farmaciju","other","article","10.5937/arhfarm2004198q",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053896","Abstract 4370898: Long-Term Impact of GLP-1 Receptor Agonists on Cardiovascular Outcomes in Patients Treated with Hematopoietic Stem Cell Transplantation: A Propensity-Score Matched Analysis","Yong Hao Yeo","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4370898",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053897","The Impact of Tirzepatide on Cancer Development: a literature review","A. Klasa","2025","Medical Science","nonrandomized_study","article","10.54905/disssi.v29i161.e118ms3627",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053898","Pharmacotherapy of obesity - Amylin Analogs and Dual Amylin-Calcitonin Receptor Agonists. A literature review","Karolina Woźniak","2025","Medical Science","narrative_review","article","10.54905/disssi.v29i158.e62ms3558",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053899","O82 Experience de l’exenatide chez des diabetiques de type 2 (DT2) insulino traités","Marine Halbron","2010","Diabetes & Metabolism","other","article","10.1016/s1262-3636(10)70086-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053900","1969-P: Socioeconomic Differences in Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors among Eligible U.S. Adults with Type 2 Diabetes","YU N. WANG","2026","Diabetes","other","article","10.2337/db26-1969-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053901","Are there any studies or clinical trials evaluating the efficacy of Mounjaro in reducing the severity of sleep apnea?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18175117",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053902","GLP-1 receptor agonists in the regulation of the brain–metabolism axis: implications for mental health","Zuzanna Michalik","2026","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2026.91.70804",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053903","A Proficient Approach to the Production of Therapeutic Glucagon-Like Peptide-1 (GLP-1) in Transgenic Plants","Martin E. Brandsma","2009","The Open Biotechnology Journal","preclinical","article","10.2174/1874070700903010057",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053904","Effects of Liraglutide on Glycemic Control and Lipid Profile in Obese Type 2 Diabetes Mellitus Iraqi Patients","Ahmed Jamal Abdulrahman","2022","The Egyptian Journal of Hospital Medicine","other_trial","article","10.21608/ejhm.2022.266014",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053905","Obesity as a Stuck Program Mode of the Candida albicans Biochemical Computer","Jim Craddock","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19600443",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0053906","Metabolic Health: The key to preventing cancer treatment-related lymphedema?","Leslyn Keith","2025","Medical Research Archives","other","article","10.18103/mra.v13i12.7049",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053907","Can GLP-1 receptor agonists be safely used during pregnancy to manage diabetes, and what are the risks and benefits?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17705262",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053908","Morphofunctional characteristics of the pancreas in triple therapy (semaglutide + omeprazole + GABA) for type 2 diabetes mellitus","Andrey Anatolevich Nedorubov","2026","Research and Practical Medicine Journal","preclinical","article","10.17709/2410-1893-2026-13-3-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053909","Combining Resistance Training with Semaglutide Use: Effects on Body Composition, Muscle Morphology, Strength, and Indices of Metabolism","Charles K. Hill","2026","Obesities","other","article","10.3390/obesities6050067",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053910","NASH To MASH: A Rising Pandemic Hiding in Plain Sight","Ayesha Rani","2026","Journal of Wah Medical College","commentary","article","10.56559/jwmc.v3i01.137",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0053911","Oral Small-Molecule GLP-1 Receptor Agonists: Lessons from Clinical Candidates and a Blueprint for Next-Generation Design","Jinrong Hu","2026","Journal of Medicinal Chemistry","other","article","10.1021/acs.jmedchem.6c00175",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053912","Stability-Indicating RP-UPLC Analysis of Semaglutide: Integrating Green Analytical Chemistry Principles in Bulk and Pharmaceutical Formulations","Dandamudi Santhoshi Priya","2026","Journal of Pharmaceutical Innovation","other","article","10.1007/s12247-026-10993-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053913","GLP-1 Receptor Agonist Eligibility and Potential Cardiovascular Impact in a High-risk Ischaemic Cardiomyopathy Population","H. Chen","2026","Heart Lung and Circulation","other","article","10.1016/j.hlc.2026.07.999",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053914","What is the mechanism behind the anti-inflammatory effects of GLP-1 receptor agonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17648743",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053915","What is the best weight loss intervention for women aged 40-50 with a BMI in the obesity range?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17750645",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053916","Effects of glucagon-like peptide-1 agonist (GLP-1 agonist) and bariatric surgery on fertility-sparing management of endometrial cancer and oncofertility outcomes: experience from singapore’s oncofertility clinic","Qiu Ju Ng","2026","International Journal of Gynecological Cancer","other","article","10.1016/j.ijgc.2025.103595",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053917","Lifestyle modification and novel pharmacological treatment options for patients with peripheral arterial disease","Martyna Anna Kopiec-Ostrowska","2025","Acta Angiologica","other","article","10.5603/aa.106536",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053918","Glucagon-like peptide-1 (GLP-1) receptor agonists: treatment targets","Janice Davies","2025","Journal of Prescribing Practice","other","article","10.12968/jprp.2025.0099",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053919","Efficacy of GLP-1 Receptor Agonists for Fibrosis Regression in Patients with MASH and F2-F3 Fibrosis: A Systematic Review and Meta-Analysis","Naseem Eisa","2026","AACE Endocrinology and Diabetes","systematic_review","article","10.1016/j.aed.2026.06.006",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0053920","Obesity and Metabolic Surgery Society of India Position Statement on the Prescription of Glucagon-Like Peptide-1 Receptor Agonists and Other Obesity Management Medications by Metabolic and Bariatric Surgeons in India","Aparna Govil Bhasker","2025","Journal of Bariatric Surgery","other","article","10.4103/jbs.jbs_7_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053921","Mapping Out Food and Philosophy","Andrea Borghini","2025","Gastronomica The Journal of Food and Culture","other","article","10.1525/gfc.2025.25.3.39",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053922","Canagliflozin (CANA) Added on to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) or Glucagon-like Peptide-1 (GLP-1) Agonists with or Without Other Antihyperglycemic Agents (AHAs) in Type 2 Diabetes Mellitus (T2DM)","Vincent C. Woo","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053923","P297 - Intérêt de l’exenatide dans le traitement d’un diabète MODY3 avec obésité et insulino-résistance majeure ? A propos d’un cas","F. Moreau","2011","Diabetes & Metabolism","other","article","10.1016/s1262-3636(11)70923-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053924","Glucagon-like Peptide-1 Agonists and Exercise for Weight Reduction: A Review of Current Evidence","Julie Feras Owaidat","2025","JAP Academy Journal","narrative_review","article","10.4103/japaj.japaj_5_24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053925","SAT-701 Rising Above the Rest: Worldwide Trends in Public Interest for Semaglutide Among Weight Loss Alternatives","Matias Panchana‐Lascano","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.134",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053926","Comparative Economic Value of GLP-1 Obesity Medications Vs Standard Care in Egypt","Mohamed Shadi","2026","International Journal of Research and Innovation in Social Science","nonrandomized_study","article","10.47772/ijriss.2026.100400148",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053927","Stronger Together: How GLP-1 RAs and SGLT-2 Inhibitors Revolutionize Type 2 Diabetes Treatment","Hanna Sitarek","2025","Journal of Education Health and Sport","other","article","10.12775/jehs.2025.80.59642",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053928","Standards of Care in Diabetes. The position of Diabetes Poland – 2025","Aleksandra Araszkiewicz","2025","Current Topics in Diabetes","other_trial","article","10.5114/ctd/203685",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0053929","Perioperative glucagon-like peptide-1 receptor agonist use is not associated with increased complications in obese patients undergoing total shoulder arthroplasty: a propensity-matched large database study","Argen Omurzakov","2025","Seminars in Arthroplasty JSES","nonrandomized_study","article","10.1053/j.sart.2025.06.001",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053930","Abstract 4345579: Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist Reduces Liver Fat Content along with Blood Pressure in Post-menopausal Females with Obesity: A Phase 1a/2b Study","Rajamannar Thennati","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4345579",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0053931","What strategies are effective in improving blood glucose control in female patients with type 2 diabetes mellitus who are already using Ozempic but still have suboptimal glycemic control?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18054167",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053932","Impact Of Glp-1 Receptor Agonists On Clinical Outcomes In Patients With Cardiac Amyloidosis And Cardiomyopathy: A Trinetx Network Study","Karldon Iwuchukwu Nwaezeapu","2026","Journal of Cardiac Failure","other","article","10.1016/j.cardfail.2025.11.301",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053933","Enfermedad Renal Crónica: Definición, Estratificación de riesgo y un Paradigma Terapéutico Renovado","Maier Anderson Pérez Gómez","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22757959",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053934","How can healthcare providers effectively identify and manage nutritional deficiencies in patients taking GLP-1 receptor agonists?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18423505",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053935","Uso biológico do Ozempic e seus efeitos: Uma revisão narrativa da literatura","Anna Júlia Godoy Medeiros","2024","International Seven Journal of Multidisciplinary","other","article","10.56238/isevmjv3n5-005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053936","What are the effects of GLP-1 on sarcopenia?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22346810",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053937","EPH261 Trends in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Prescribing in England: A Data Analysis Using NHS Prescription Episodes Statistics (PES)","T Viering","2025","Value in Health","other","article","10.1016/j.jval.2025.09.1390",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0053938","PERDA DE PESO ASSOCIADA AO USO DE SEMAGLUTIDA: EFICÁCIA E MECANISMO DE AÇÃO","André Matheus Carvalho Silva Leite","2023","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2023v5n5p3095-3103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053939","Glucagon-like peptide-1 receptor agonists : A new step towards weight management","Mohamed Omar","2023","American Journal of Medical and Clinical Research & Reviews","other","article","10.58372/2835-6276.1073",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053940","IDF2022-0417 BMI category changes and percent meeting waist circumference goals with tirzepatide for type 2 diabetes from SURPASS 1-4","C. Lee","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110308",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053941","Is there a potential risk in using GLP-1 analogues for patients with concerns about postoperative paralytic ileus after intestinal surgery?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19233978",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053942","Effectiveness of combined intragastric balloon therapy and GLP-1 receptor agonists for weight loss in adults with obesity: a systematic review and meta-analysis","Gustavo Adolfo Vásquez-Tirado","2026","Obesity Medicine","systematic_review","article","10.1016/j.obmed.2026.100697",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0053943","Efficacy of Once Weekly Dulaglutide Compared with Twice-Daily Exenatide in Patients with Type 2 Diabetes: A Post-Hoc Analysis to Determine the Influence of Baseline HbA1c","Steve C Bain","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.143",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053944","Why is it important to treat patients with risk factors for developing type 2 diabetes with a GLP-1 agonist in terms of its effects on disease benefit?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17927795",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053945","Il trattamento farmacologico del diabete di tipo 2 e la prevenzione cardiovascolare: cosa aggiunge liraglutide?","Gianpaolo Reboldi","2009","Giornale italiano di cardiologia","other","article","10.1714/582.6879",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053946","Therapeutic Efficacy of Lixisenatide Added to Basal Insulin is Greater When FPG is Well Controlled","HARPREET SINGH BAJAJ","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.091",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053947","What are the recommended guidelines for starting Wegovy treatment in patients with obesity?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17889356",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053948","Lower risk of MACE and all-cause death in patients initiated on semaglutide 2.4 mg in routine clinical care: Results from the score study (semaglutide effects on cardiovascular outcomes in people with overweight or obesity in the real world)","F. Schiele","2026","Archives of cardiovascular diseases","nonrandomized_study","article","10.1016/j.acvd.2025.10.204",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053949","Glucagon-like peptide-1 receptor agonists are associated with a reduced cumulative incidence of obesity-associated cancers in obese non-diabetic women","Heng‐Cheng Hsu","2026","Gynecologic Oncology","other","article","10.1016/j.ygyno.2026.01.024",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053950","Potential of Glucagon-like peptide-1 receptor agonists (GLP1a) and Sodium-Glucose Co-transporter-2 inhibitors (SGLT2i) in the treatment of MASLD","Anna Török Zapletalová","2025","Vnitřní lékařství","other","article","10.36290/vnl.2025.098",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053951","Update in diabetology.","Cristian Guja","2011","PubMed","other_trial","article",null,"22879853",null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0053952","Paradigm Shift in the Pathophysiology and Treatment of Insulin Resistance: From Epigenetic Determinants to the Continuous Glucose Monitoring (CGM) Revolution","Emilia Piaszczynska","2026","Journal of Education Health and Sport","other","article","10.12775/jehs.2026.90.70467",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053953","Síndrome de ovario poliquístico: actualización diagnóstica y terapéutica","Ariana Carolina Correa Garcés","2026","RECIMUNDO","other","article","10.26820/recimundo/10.(1).enero.2026.430-435",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053954","Do GLP-1 antagonists help people with gut disorders, particularly those involving a disturbance of the gut-brain axis?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20716409",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053955","Editorial: Gut and circulating microbiota in the pathophysiology and clinical complications of diabetes","Vasudevan Dinakaran","2025","Frontiers in Clinical Diabetes and Healthcare","commentary","article","10.3389/fcdhc.2025.1717638","41142640",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0053956","Influence of type 2 diabetes on Parkinson’s disease: emerging insights into pathogenesis and progression","Irving Christian Rodríguez-González","2025","Ageing and Neurodegenerative Diseases","other","article","10.20517/and.2025.22",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053957","Beyond the Scale: The New Era of Synergy between Pharmacotherapy and Metabolic Surgery","Rui Ribeiro","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22163071",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053958","The Evolution of MASLD Management: From Revised Nomenclature to Disease-Modifying Therapies","Karolina Kornatowska","2026","Gastroenterology Insights","nonrandomized_study","article","10.3390/gastroent17020033",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053959","Concomitant GLP-1 Receptor Agonist Therapy Is Associated With Significant Weight Reduction In Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten","Estherland Duqueney","2026","Journal of Cardiac Failure","other","article","10.1016/j.cardfail.2025.11.294",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053960","Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report","Saud N. Alsifri","2022","International Journal of Clinical Medicine","other","article","10.4236/ijcm.2022.131002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053961","What are the potential side effects and efficacy differences between semaglutide and tirzepatide that should be monitored during the switch?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20086218",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053962","What does the current evidence say about the use of GLP-1 medications for treating ulcerative colitis?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22306705",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053963","Major evidence of the GLP-1 analog (liraglutide) in the treatment of obesity: a systematic review","Fabrício Bastos Fernandes","2023","International Journal of Nutrology","systematic_review","article","10.54448/ijn23211",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0053964","EP640 - ECE_3474 - Correlation of weight loss and SF-36 physical function score in weight management with semaglutide injection: post-hoc analysis of phase 3 Study","Unnikrishnan Gopalkrishnan","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1070",null,null,"CTRI:CTRI/2025/04/085487",null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0053965","Convergent Mitochondrial and Reward-Circuit Mechanisms Underlying Appetite, Addiction, and GLP-1 Therapeutics","George B. Stefano","2026","Journal of Surgery","other","article","10.29011/2575-9760.011545",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053966","What are the common side effects of glucagon-like peptide 1 agonists in older adults with diabetes?","Mark Wirtz","2021","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001393",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053967","Development and validation of HPLC method for determination of amino acid mole ratio in Semaglutide","Sukthankar, Sunil","2025","World Journal of Biology Pharmacy and Health Sciences","other","article","10.5281/zenodo.17377875",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053968","Application of Ga(68) -DOTA-exendin-4 PET/CT to localise an occult insulinoma","Cuthbertson, D J",null,null,"other","article","10.7892/boris.77624",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053969","Oral vs. Injectable Semaglutide: An Indirect Treatment Comparison of Weight Loss Outcomes","S Jacob","2026","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0046-1819894",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0053970","What are the mechanisms of action of GLP-1 agonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17760304",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053971","Ozempic Body: Flacidez Corporal Pós-GLP-1 e Tratamentos com Evidência","Talita Almeida","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21122897",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053972","Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review","Karolina Baran","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.30.56469",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053973","53028 Semaglutide and Hair Loss: A Real-World Analysis","Ruple Jairath","2024","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2024.07.1228",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053974","Variant of Guillain-Barré syndrome with anti-sulfatide antibody positivity and spinal cord involvement: A case report","Hua Liu","2023","World Journal of Clinical Cases","case_report","article","10.12998/wjcc.v11.i26.6274","37731563",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053975","Identification of potential DPP-4 inhibitors from Bryophyllum pinnatum by in-silico analysis","Shivaraj Kshirasagar","2024","International Journal of Ayurvedic Medicine","other","article","10.47552/ijam.v15i1.4316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053976","GLP-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS: CLINICAL IMPLICATIONS BEYOND GLYCEMIC CONTROL","Paula Lorenz Abella","2026","Open Minds International Journal","nonrandomized_study","article","10.22533/at.ed.5157272624031",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0053977","How do pharmaceutical weight loss treatments like Ozempic affect skeletal muscle structure and quality?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17813357",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053978","Semaglutide Impacts Proteomic Signatures Related to Dementia Risk in the SELECT Cardiovascular Outcomes Trial (P6-12.007)","Paul Mystkowski","2026","Neurology","other_trial","article","10.1212/wnl.0000000000215557",null,null,"ClinicalTrials.gov:NCT03574597","S000716","openalex","FALSE","paywalled","5","FALSE","article"],["R0053979","What are the comparative efficacies of Ozempic and Mounjaro in managing type 2 diabetes mellitus?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17689307",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053980","ONE PATHWAY, INFINITE POTENTIAL? THE FUTURE OF GLP-1 THERAPIES: A 2026 CLINICAL UPDATE","Magdalena Fidelis","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.1(49).2026.4980",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053981","Rapid Reduction of HbA1c and Weight in Elderly Patient with Type 2 Diabetes (T2D) And Depression by Oral Semaglutide (Rybelsus)","Hiroshi Bando","2022","Asploro Journal of Biomedical and Clinical Case Reports","other","article","10.36502/2022/asjbccr.6267",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053982","Top studies of 2025 relevant to primary care: From the PEER team.","Samantha S Moe","2026","PubMed","randomized_trial","article","10.46747/cfp.7205308","42128641",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0053983","Comparative Assessment of the Risk of Acute Pancreatitis Between GLP-1 Agonists: Exenatide, Liraglutide, Dulaglutide and Semaglutide (Abstract ID: 235118)","Aaronbir S. Randhawa","2026","Journal of Pharmacology and Experimental Therapeutics","other","article","10.1016/j.jpet.2026.104239",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053984","Compartmentalizing risk with sarcopenic obesity","Michele S. Barnhill","2023","Liver Transplantation","nonrandomized_study","article","10.1097/lvt.0000000000000061","36728605",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0053985","Weight and Health — Pathophysiology and Therapies","Louis J. Aronne","2022","New England Journal of Medicine","other","article","10.1056/nejmp2214423","36516089",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053986","O-220 Impact of glucagon-like peptide-1 receptor (GLP-1R) agonist therapy on the endometrium and embryo: a boon to infertility?","Anil Vasant Pathare","2025","Human Reproduction","other_trial","article","10.1093/humrep/deaf097.220",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-abstract"],["R0053987","Safety of glucagon-like peptide-1 receptor agonists in patients receiving chimeric antigen receptor T cell or bispecific T cell engager therapy.","Gideon Wolf","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e24016",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0053988","Modulação do apetite por agonistas GLP-1: relevância clínica no tratamento da obesidade","Júlia Andrade Pires Almeida","2026","Journal of Medical and Biosciences Research.","other","article","10.70164/jmbr.v3i2.1198",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053989","Can Wegovy lessen the need for bowel preparation before a colonoscopy?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20539562",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053990","2533-P: C. elegans PDF-1 and the Evolutionary Origin of Incretin-Like Peptides in Treatment of Diet-Induced Obesity","YOSHIYUKI WATANABE","2026","Diabetes","preclinical","article","10.2337/db26-2533-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053991","Liraglutide-induced reduction of myocardial ischemiareperfusion injury in rats via ERK1/2 signaling pathway","Zhao‐Ying Liu","2017","Tropical Journal of Pharmaceutical Research","preclinical","article","10.4314/tjpr.v16i8.12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053992","Corrigendum to ‘Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse’ [Obesity Medicine Volume 59 (2026) 100681]","Elaine Chiquette","2026","Obesity Medicine","preclinical","article","10.1016/j.obmed.2026.100749",null,null,null,null,"openalex","FALSE",null,null,"FALSE","erratum"],["R0053993","Antipsychotic-Induced Obesity: A Literature Review of Pathophysiology, Genetics, and Management Strategies","Krzysztof Brzezicki","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.66.74166",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053994","From medication to movement: The role of physical activity in the treatment of obesity","Patrycja Ochman-Pasierbek","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.16632878",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0053995","Pharmacology of GLP-1-based therapies","Jens Juul Holst","2008","The British Journal of Diabetes","other","article","10.1177/1474651408100523",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053996","Combination therapy with GLP-1 analogues and SGTL2 inhibitors in obese patients with DM2: Current data and future considerations","ALEXANDRA SIANNI","2022","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2022.06.181",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0053997","Redox Balance, Mitohormesis, and Organ Stress in Type 2 Diabetes Mellitus: Mechanistic Insights and the Therapeutic Role of SGLT2 Inhibitors","Toshiki Otoda","2025","Diabetology","other","article","10.3390/diabetology6100111",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0053998","Targeting NLRP3 with ofirnoflast, alone or in combination with semaglutide, ameliorates inflammatory anemia associated with obesity-induced inflammation in rodent models","Benjamin Bearss","2025","Blood","randomized_trial","article","10.1182/blood-2025-1127",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0053999","A79-05 The Impact of Tirzepatide Induced Weight Loss on Lung Hyperinflation and AHI Reduction in COPD-OSA Overlap Syndrome","M L Stanchina","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.6312",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054000","The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems","L.L. Hagenaars","2025","Pure Amsterdam UMC","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054001","Comparative Analysis of GLP-1 receptor agonist therapy versus Standard Care in gestational diabetes","Cormac Ryan","2022","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22812581",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0054002","How does semaglutide affect other medicines due to its effect on gastric emptying?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20036022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054003","75-LB: CT-388, a Novel Once-Weekly Dual GLP-1 and GIP Receptor Modulator, Is Safe, Well-Tolerated, and Produces More than 8% Weight Loss in Four Weeks in Overweight and Obese Adults","Manu V. Chakravarthy","2023","Diabetes","randomized_trial","article","10.2337/db23-75-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054004","CARNIVOROUS DIET, MOUNJARO AND INTERMITTENT FASTING: THE HARMS OF NEW DIETARY TRENDS AND THEIR IMPACT ON HEALTH","Larissa Ayanna Pessoa Santos","2025","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.1595252507071",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054005","Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review","Martyna Małek","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.60.72834",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0054006","What is the cost-effectiveness of behavioral and pharmacological approaches to weight management?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18143670",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054007","Association Between Tirzepatide Therapy and Thyroid Function in Euthyroid Patients With Obesity","Yusuf Elma","2026","Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.14740/jem1617",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054008","The Dual Faces of Semaglutide: A Comparative Analysis of Ozempic Side Effect Profiles in Western Populations and Saudi Arabia","Ghulam Muhammad Kundi","2025","Open Access Organization and Management Review","nonrandomized_study","article","10.59644/oagmr.4(1).212",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054009","The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review","Silvia Tempia Valenta","2024","Current Treatment Options in Psychiatry","systematic_review","article","10.1007/s40501-024-00331-y",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0054010","Inhibition of glucagon secretion by GLP-1 agonists and DPP4 inhibitors","Morten Hansen","2011","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054011","What is the recommended method for tapering off Wegovy in patients with obesity?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17828709",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054012","GLP-1 RECEPTOR AGONISTS AND ALCOHOL USE DISORDER: PROMISE FOR A NEW TREATMENT APPROACH","Jakub Fidelus","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.2(50).2026.5617",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054013","Cancer-Specific Disproportionality Signals Associated with Metformin Versus Other Antidiabetic Agents: A Real-World Pharmacovigilance Analysis of FAERS","Daniel Obinna Eke","2026","Oncology Nuclear Medicine and Transplantology","nonrandomized_study","article","10.63946/onmt/18529",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054014","Thermal Therapies and Peptide Signaling in Women’s Health: A Systems-Based Review","Noelle Cutter","2026","Open Journal of Regenerative Medicine","other_trial","article","10.4236/ojrm.2026.153004",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054015","Exploring access, motivations and impact of GLP-1RA use in eating disorder populations","Lauren Bruha","2026",null,"other","article","10.17605/osf.io/t4w7y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0054016","What are the benefits and risks of using a GLP-1 receptor agonist or tirzepatide for a 63-year-old female with obesity and type 2 diabetes, who regained 17 kg after sleeve gastrectomy, with an adrenal incidentaloma and mild urinary metanephrine excess?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20258719",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054017","339-OR: Oral Small-Molecule GLP-1R Agonist Danuglipron Robustly Reduces Plasma Glucose and Body Weight after Eight Weeks in Japanese Adults with Type 2 Diabetes Mellitus","Ryosuke Ono","2022","Diabetes","randomized_trial","article","10.2337/db22-339-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054018","SUN-680 First-in-Class Oral Dual GLP-1/Glucagon Agonist for Patients with Obesity and Metabolic Disorders: In Vivo Pharmacokinetic and Pharmacodynamic Results","Gregory Burshtein","2025","Journal of the Endocrine Society","other_trial","article","10.1210/jendso/bvaf149.190",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054019","Mitochondrial Dysfunction, Genetic Predisposition, and Targeted Interventions in Neurodegenerative Diseases and Cognitive Decline: A Meta-Analysis of Mechanisms and Treatments","Sher Bano","2025","Indus journal of bioscience research.","systematic_review","article","10.70749/ijbr.v3i3.715",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054020","Is weight loss with GLP-1 receptor agonists sustainable after stopping them?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17749342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054021","Clinical outcome of off-label drugs for weight loss: a systematic review","Tiago Loureiro","2025","International Journal of Nutrology","systematic_review","article","10.54448/ijn25s310",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054022","From Pills to Injections: Comparing the Pharmacokinetics and Clinical Impact of Oral Semaglutide and Injectable GLP-1 Agonists","Gajaram Sirvi","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.21943336",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0054023","The effect of liraglutide on natriuretic peptides and copeptin in heart failure patients","Roni Ranghoej Nielsen","2019","University of Southern Denmark Research Portal (University of Southern Denmark)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0054024","Beyond Glycaemic Control: The Expanding Role of GLP-1 Receptor Agonists in Obesity, Obstructive Sleep Apnoea, Cardiovascular Disease, and Steatohepatitis: A Narrative Review","Abdul Malik","2026","Journal of Health Wellness and Community Research","randomized_trial","article","10.61919/7n09x564",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0054025","How much weight loss can be expected from tirzepatide compared to metformin?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17950098",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054026","Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial","Naveed Sattar","2025","European Heart Journal","other_trial","article","10.1093/eurheartj/ehaf784.3755",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054027","2167-P: Postpartum Weight Retention after Glucagon-Like Peptide 1 Receptor Agonist Discontinuation for Pregnancy","Jacqueline Maya","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2167-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054028","Are there any clinical guidelines for co-prescribing GLP-1 receptor agonists and antipsychotics in patients with comorbid diabetes and schizophrenia?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17754187",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054029","The Ozempic Pregnancy Phenomenon: What Medical Research Reveals","N Heimann","2025","Clinical Medicine And Health Research Journal","randomized_trial","article","10.18535/cmhrj.v5i05.511",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054030","CO37 Glucagon-like Peptide-1 Receptor Agonists for Adult Obesity: Where Next?","Sheena Singh","2024","Value in Health","other","article","10.1016/j.jval.2024.10.114",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054031","Exploring the Potential of Nephroprotective effect of Flavonoids present in Cassia auriculata A Review","C. Senthil Kumar","2026","Research Journal of Pharmacology and Pharmacodynamics","narrative_review","article","10.52711/2321-5836.2026.00012",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054032","2876-LB: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide, and Dapagliflozin (TTT1): A Phase 3 Clinical Trial","HUSAM A. GHANIM","2026","Diabetes","randomized_trial","article","10.2337/db26-2876-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054033","Tailoring Biomaterials for Metabolic Diseases","Zhen Nan Gu","2019","Advanced Healthcare Materials","other","article","10.1002/adhm.201900632","31355543",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054034","Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa","Esteban González Ballerga","2020","Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana","other","article","10.52787/zojs3069",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054035","Impacts of Adding GLP-1 Receptor Agonist on Weight Loss, Self-Esteem, and Depression Compared to Diet and Exercise Alone in Women Aged 30-45","Lori Henderson","2026","International Journal of Nursing and Health Care Research","other","article","10.29011/2688-9501.101711",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054036","Soups, shakes and other slimming strategies: GLP-1 agonists vs. NHS type 2 diabetes path to remission programme in the battle against T2DM and weight management","Divanshi Trivedi","2025","Clinical Medicine","nonrandomized_study","article","10.1016/j.clinme.2025.100459",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054037","1649-P: Biased GLP-1 Improves Weight Loss with Additional Benefits on Glucose Homeostasis via Biased GIP in Diabetic Rodent Models","Rubén Rodríguez","2023","Diabetes","preclinical","article","10.2337/db23-1649-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054038","What patient characteristics increase the risk of developing non-arteritic ischemic optic neuropathy (NAION) in patients using GLP-1 receptor agonists and analogs?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21343911",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054039","Overview of the burden of illness and the role of once-weekly glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes","Deborah A. Hinnen","2018","Journal of the American Association of Nurse Practitioners","other","article","10.1097/jxx.0000000000000115",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054040","NEUROPROTECTIVE EFFECTS OF SEMAGLUTIDE AND TIRZEPATIDE DURING THE TREATMENT OF OBESITY AND TYPE 2 DIABETES MELLITUS","Alyson Oliveira Mergulhão","2025","Seven Editora eBooks","nonrandomized_study","article","10.56238/edimpacto2025.087-010",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","book-chapter"],["R0054041","A Case of Compounded Tirzepatide-induced Psychiatric Adverse Effects","Shauni Bobbs","2024","Current Developments in Nutrition","case_report","article","10.1016/j.cdnut.2024.102316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054042","Short-Term Weight Loss, Long-Term Metabolic Health: GLP-1 Therapy versus Lifestyle-Driven Biological Rewiring","Shweta Arora","2026","World Journal of Biology Pharmacy and Health Sciences","other","article","10.30574/wjbphs.2026.25.1.0059",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054043","A Heavy Price for Lightness: Pulmonary Embolism Following Tirzepatide Initiation","Muhammad Aleem","2026","AACE Endocrinology and Diabetes","other","article","10.1016/j.aed.2026.02.005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054044","GLP-1 receptor agonists should be rigorously tested as longevity therapeutics","Nicola Marino","2026","Nature Health","other","article","10.1038/s44360-026-00109-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054045","PS19.1: Long-term islet graft function, improved insulin secretion and continued function after discontinuation of immunosuppression in islet allograft recipients treated with GLP-1 Receptor Agonists as adjunct therapy.","Camillo Ricordi","2025","Transplantation","other","article","10.1097/01.tp.0001170640.37492.0b",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054046","Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome","Zeynab Yousefi","2026","Figshare","preclinical","article","10.6084/m9.figshare.c.8259348",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0054047","StockWatch: Novo Nordisk Shares Soar as Ozempic Aces Phase III CKD Trial","Alex Philippidis","2023","GEN Edge","other_trial","article","10.1089/genedge.5.1.137",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054048","Blood pressure reduction in glucagon-like peptide-1 receptor agonist users in a family medicine clinic","Julia Mesawich","2025","JAPhA Practice Innovations","nonrandomized_study","article","10.1016/j.japhpi.2025.100083",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054049","Ten Minutes Hard","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22116782",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0054050","GLP-1 ANALOGUES IN OBESITY THERAPY: CURRENT EVIDENCE AND FUTURE DIRECTIONS – A SYSTEMATIC REVIEW","Natalia Strumnik","2025","International Journal of Innovative Technologies in Social Science","systematic_review","article","10.31435/ijitss.3(47).2025.3723",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054051","HPR239 Which Country Is Currently Reporting the Lowest Global Prices for Semaglutide, and Why?","Janet D. Beal","2025","Value in Health","other","article","10.1016/j.jval.2025.09.1646",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054052","SEMAGLUTIDA E BENEFÍCIOS MEDICAMENTOSOS NO CONTEXTO CARDIOMETABÓLICO","Janielle Carvalho Benfatti","2025","ULAKES JOURNAL OF MEDICINE","other","article","10.56084/ulakesjmed.v5i2.1262",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054053","Abstract 4345655: Sodium–Glucose Cotransporter 2 Inhibitors are Cost-Effective and Dominate Glucagon-Like Peptide-1 Receptor Agonists for Patients with Type 2 Diabetes and High Cardiorenal Risk in Canada","Abhinav Sharma","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4345655",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0054054","What is the effectiveness of obesity interventions on glucose control and type 2 diabetes in children and adolescents, including lifestyle interventions, drug, and surgical trials?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20762687",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054055","Can I perform a blood test to detect the presence of Wegovy or Mounjaro in a patient who is losing weight but denies taking these drugs?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20555746",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054056","Significantly Better Glycemic Control and Weight Reduction with Liraglutide, a Once-Daily Human GLP- 1 Analog, Compared With Glimepiride: All as Monotherapy In Type 2 Diabetes.","A. J. Garber","2008","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(08)24117-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054057","Is there any evidence supporting the use of GLP-1 type drugs in children and adolescents?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19334696",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054058","SAT-693 The Wealth of Nations and the Weight Loss Revolution: Demographics and Economic Influences of Semaglutide","Ivo Diaz-Djevoich","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054059","Liraglutide","Qing Zhong","2026","Elsevier eBooks","other","article","10.1016/b978-0-443-44037-3.00999-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0054060","III. Incretin-based Therapeutics for Type 2 Diabetes","Yohei Seno","2025","Nihon Naika Gakkai Zasshi","other","article","10.2169/naika.114.624",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054061","Impact of GLP-1 receptor agonists on outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A multicenter propensity-matched real-world analysis.","Mohammmad Amer Al Tamimi","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e16180",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054062","TREATMENT OF SLEEP APNEA WITH GLP-1 RECEPTOR AGONISTS AND THEIR EFFECTS ON THE CENTRAL NERVOUS SYSTEM: A LITERATURE REVIEW","Lais Meyer Golendziner","2024","International Journal of Health Science","narrative_review","article","10.22533/at.ed.1594882426097",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054063","What is the most effective treatment for type 2 diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18094427",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054064","A glukagonszerű-peptid-1-receptoragonisták anyagcsere-, ér- és vesehatása, a kénhidrogén lehetséges szerepe","István Wittmann","2021","Diabetologia Hungarica","other","article","10.24121/dh.2021.13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054065","Development and validation of a novel, commerical ELISA kit for the quantification of Tirzepatide in biological samples 3472","Kalpesh Jain","2025","The Journal of Immunology","other","article","10.1093/jimmun/vkaf283.1274",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054066","From genes to care: the expanding therapeutic horizon in rare genetic obesities","Sarah Chalopin","2025","Obesity and Endocrinology","other","article","10.1093/obendo/wjaf007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054067","Diabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With Chronic Kidney Disease Stages 3-4 and Type 2 Diabetes","Panupong Hansrivijit","2026","Kidney Medicine","other","article","10.1016/j.xkme.2026.101518",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054068","Adverse effects of GLP – 1 Receptor Agonists","Anna Kasprzak","2025","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2025.78.57774",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054069","When Patent Territoriality Meets Integrated Border Economies: Lessons from the Tirzepatide Market between Brazil and Paraguay","Gabriel Oliveira de Aguiar Borges","2026","Beijing Law Review","other","article","10.4236/blr.2026.173047",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054070","Early Weight Loss as a Predictor of Six-Month Response to Liraglutide in Adults With Obesity Without Diabetes: A Retrospective Real-World Study","Hasan Açık","2026","International Journal of Biological-Medical Science and Technology","nonrandomized_study","article","10.22399/ijbimes.33",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054071","INDISCRIMINATE USE OF LIRAGLUTIDE AND SEMAGLUTIDE FOR WEIGHT LOSS","Maria Luiza Saad Carvalho","2023","International Journal of Health Science","nonrandomized_study","article","10.22533/at.ed.1593492303076",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054072","Scalable and Sustainable DMF-Free Solid-Phase Synthesis of Liraglutide by 1-Tert-Butyl-3-Ethylcarbodiimide-Mediated Couplings and Catch-and-Release Acylation and Purification Strategies","Lorenzo Pacini","2025","International Journal of Peptide Research and Therapeutics","other","article","10.1007/s10989-025-10703-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054073","26-A-17208-ACC GLP-1 RECEPTOR AGONISTS AND CARDIOPROTECTION AFTER AMI REVASCULARIZATION: A TRINETX ANALYSIS","Narathorn Kulthamrongsri","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.4931",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054074","O uso dos Inibidores do SGLT2 no tratamento do paciente com doença renal do diabetes: uma revisão de literatura","Mateus Rodrigues Linhares","2023","STUDIES IN HEALTH SCIENCES","other","article","10.54022/shsv4n4-016",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054075","Is there any evidence that GLP-1 use in adolescents has adverse mental health outcomes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19250310",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054076","Eficácia e segurança da semaglutida (OZEMPIC®) no tratamento da Obesidade: uma revisão bibliográfica","Dayane Camilo Pimentel","2023","Cuadernos de Educación y Desarrollo","other","article","10.55905/cuadv15n11-052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054077","HIGH PREVALENCE OF ADVANCED CARDIOVASCULAR–KIDNEY–METABOLIC SYNDROME IN CARDIAC REHABILITATION PATIENTS AND THERAPEUTIC IMPLICATIONS: A SINGLE–DAY OBSERVATIONAL STUDY","F Monego","2026","European Heart Journal Supplements","nonrandomized_study","article","10.1093/eurheartjsupp/suag058.459",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054078","Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse","Elaine Chiquette","2025","Obesity Medicine","preclinical","article","10.1016/j.obmed.2025.100681",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054079","Ocena i następstwa nieprawidłowej masy ciała — jak wyjaśnić paradoks otyłości?","Stanisław Surma","2024","Choroby Serca i Naczyń","other","article","10.5603/chsin.99234",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054080","Tissue-specific metabolomics in experimental HFpEF reveals hepatic remodelling modulated by SGLT2 inhibition","Muhammed Kiyar","2026","Cellular and Molecular Life Sciences","preclinical","article","10.1007/s00018-026-06393-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054081","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97963-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054082","Exploring GnRH pulsatility in PCOS and the role of GLP-1 as a targeted therapeutic approach","Vidya Bhat","2025","International Journal of Gynaecology and Obstetrics Sciences","randomized_trial","article","10.33545/26649004.2025.v7.i1a.39",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054083","Is there any evidence that GLP-1 receptor agonists for weight loss can impact binge eating, disordered eating, or emotional eating?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17749338",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054084","What are the recommended steps to safely de-escalate a GLP-1 receptor agonist for a patient experiencing adverse effects?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17806906",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054085","Unraveling the Dual Burden of Diabetes and Obesity: Precision Strategies for South Asian Populations","Shambo Samrat Samajdar","2025","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_15_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054086","Modulating Reward and Satiety: Tirzepatide’s Neural and Behavioral Pathways of Appetite Regulation","Julian Lloyd Bruce","2025",null,"other","article","10.71123/rjismhs.v2.i2.25001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054087","EPH74 Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population","Shivani Aggarwal","2025","Value in Health","other","article","10.1016/j.jval.2025.04.605",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054088","THE ROLE OF INCRETIN-BASED THERAPIES IN ALZHEIMER’S DISEASE: FOCUS ON SEMAGLUTIDE - LITERATURE REVIEW","Honorata Derlatka","2025","Archiv Euromedica","randomized_trial","article","10.35630/2025/15/iss.5.501",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054089","Nor-1 ist ein neuer Regulator von Insulingenen und spielt eine Rolle bei der Insulinsekretion","AM Ordelheide","2012","Diabetologie und Stoffwechsel","other","article","10.1055/s-0032-1314433",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054090","What are the side effects of Wegovy?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17889325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054091","How can sarcopenia be prevented after treatment with semaglutide?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17686348",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054092","Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?","Gerit-Holger Schernthaner","2010","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfq199","20388630",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054093","Short-Term Real-World Clinical Outcomes of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes","Enes Üçgül","2026","Gazi Medical Journal","nonrandomized_study","article","10.12996/gmj.2026.4631",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054094","Clinical pathophysiological and health system implications of the transition from NAFLD to MASLD: a narrative review","Eslam Abady","2026","Discover Medicine","nonrandomized_study","article","10.1007/s44337-026-00653-1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0054095","Amylin and Analogs in Treating Obesity and Metabolic Disorders","Menglong Hu","2024","MedScien","other_trial","article","10.61173/r0zzct29",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054096","The “relay approach” in obesity management: From incretin mimetics to bariatric surgery and back to pharmacotherapy","V. V. Salukhov","2026","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2026-155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054097","3082-LB: The Selective Amylin Analog Eloralintide Enhanced Weight-Loss Efficacy when Combined with Tirzepatide in DIO Rats","Daniel A. Briere","2026","Diabetes","preclinical","article","10.2337/db26-3082-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054098","Incretin-based therapies: a new era in metabolic liver disease management","Sakktivel Elangovan","2026","Hepatoma Research","nonrandomized_study","article","10.20517/2394-5079.2026.15",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054099","Protein-protein interaction network construction and analysis to identify synergistic effects for sodium-glucose cotransporter-2, glucagon-like peptide-1 and mineralocorticoid receptor","G Tse","2026","European Journal of Preventive Cardiology","nonrandomized_study","article","10.1093/eurjpc/zwag249.433",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054100","Counteracting Muscle Loss in Individuals Using GLP-1 Receptor Agonist for Weight Loss: Evaluation of Physical Exercise and Humanized Monoclonal Antibody Therapies","Xiao Yu","2026","BIO Web of Conferences","other","article","10.1051/bioconf/202623702005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper; article"],["R0054101","What are the efficacy and safety of tirzepatide in patients with multiple endocrine neoplasia type 1 (MEN1)?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17704755",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054102","What is the best treatment for diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18686246",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054103","Pickwickian syndrome: A comprehensive narrative review from historical origins to emerging therapeutic frontiers","Anu Anna Babu","2026","World Journal of Biology Pharmacy and Health Sciences","narrative_review","article","10.30574/wjbphs.2026.26.3.0333",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0054104","Jak postupovat v boji s inzulinovou rezistencí u pacientů s DM 2. typu","Martin Haluzı́k","2020","Vnitřní lékařství","other","article","10.36290/vnl.2020.128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054105","What impact does semaglutide have on mental health outcomes in individuals with pre-existing mental health conditions?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18389565",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054106","What is the effectiveness of semaglutide in treating metabolic syndrome in patients taking olanzapine?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18324950",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054107","What are the results of a comparative randomized controlled trial of oral hypoglycemics in type 2 diabetes in the UK?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.17689315",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0054108","2363-P: A1C and BMI Changes by Sociodemographic Groups among Patients Using GLP-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors in a Large Integrated Health System","RASHON LANE","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2363-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054109","2815-LB: A Novel, High Drug-Loading Long-Acting Injectable (LAI) Enables One Monthly Subcutaneous Administration of Tirzepatide and Retatrutide","JINWOO LEE","2026","Diabetes","preclinical","article","10.2337/db26-2815-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054110","ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES","Aleksandra Wielogórska","2026","International Journal of Innovative Technologies in Social Science","other_trial","article","10.31435/ijitss.3(51).2026.5972",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0054111","Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study","Onur Başer","2024","Obesity Science & Practice","nonrandomized_study","article","10.1002/osp4.762",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054112","Porównanie skuteczności eksenatydu stosowanego dwa razy na dobę i dwufazowej insuliny aspart u chorych na cukrzycę typu 2 leczonych wcześniej z umiarkowanym efektem pochodnymi sulfonylomocznika i metforminą: badanie nie mniejszej skuteczności (non-inferiority)","Nauck, M.A.; Diabetes Center, Bad Lauterberg im Harz, Niemcy","2008","Via Medica Journals","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0054113","Once-weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial","John Doupis","2019","US Endocrinology","other_trial","article","10.17925/use.2019.15.2.65",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054114","Effects of liraglutide on weight reduction and metabolic \\nparameters in obese patients with and without type 2 diabetes mellitus","García Cantú, E. A.","2014","El Repositorio Academico Digital de la UANL (Universidad Autónoma de Nuevo León)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054115","Clinical Practice Guideline for the Treatment and Follow Up of Type 2 Diabetes Mellitus in the Colombian Adult Population: Colombian Association of Endocrinology, Diabetes and Metabolism, 2025","Karen Fériz","2025","Revista Colombiana de Endocrinología Diabetes & Metabolismo","other","article","10.53853/encr.12.3.907",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054116","Characterizing Geographic Variation in GLP-1 Receptor Agonist Prescribing Using Interpretable Machine Learning","Zhouzhou Chu","2026",null,"nonrandomized_study","article","10.1109/ichi69079.2026.00061",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0054117","1135-OR: One-Year Outcomes from the Surgical or Medical Treatment for Pediatric Type 2 Diabetes (T2D): ST2OMP Study","AMY SHAH","2026","Diabetes","other_trial","article","10.2337/db26-1135-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054118","Comparative Efficacy of Lifestyle Modifications versus Pharmacotherapy on Weight Loss and Metabolic Health Outcomes: A Comprehensive Review","Abiodun O Aboaba","2024","Journal of Biosciences and Medicines","narrative_review","article","10.4236/jbm.2024.127003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054119","Semaglutide for Organ Protection","Sandeep Kharb","2026","International Journal of Diabetes and Technology","other_trial","article","10.4103/ijdt.ijdt_27_26",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0054120","Can GLP-1 increase the risk of age-related macular degeneration?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21066001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054121","E-043 GLP-1 receptor agonists and risk of rupture of untreated intracranial arteriovenous malformations","M McIntyre","2026",null,"other","article","10.1136/jnis-2026-snis.147",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054122","OC2.2 - ECE_3929 - JUV-161 restores glucose homeostasis and skeletal muscle function in Type 2 diabetic mouse model","Vengadeshprabhu Karuppagounder","2026","European Journal of Endocrinology","preclinical","article","10.1093/ejendo/lvag096.084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054123","What is the effectiveness of Tirzepatide (Zepbound) in weight management and improving sleep disorders in individuals with obesity or high BMI?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17756291",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054124","Treatment response between Asian and non-Asian patients with type 2 diabetes","Xiaoling Cai","2019","Chinese Medical Journal","randomized_trial","article","10.1097/cm9.0000000000000012","30628952",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054125","Nuclear deformation mediates liver cell mechanosensing in cirrhosis.","Guixé Muntet, Sergi","2020","Open Access CRIS of the University of Bern","preclinical","article","10.7892/boris.148107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054126","26-A-13845-ACC EFFECT OF ORAL SEMAGLUTIDE VERSUS PLACEBO ON FIRST AND TOTAL MACE IN SOUL TRIAL PARTICIPANTS WITH T2D AND ASCVD AND/OR CKD","Nikolaus Marx","2026","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2026.02.490",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054127","Managing Hyperphagia, Obesity, and Hyperglycemia in Prader-Willi Syndrome: A Meta-Analysis of GLP-1 Agonists and SGLT2 Inhibitors","Saumika Mulluri","2025","International Journal of Medical Students","systematic_review","article","10.5195/ijms.2025.3992",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054128","Sudden Cardiac Death Following Acute Myocardial Infarction With Obstructive and Nonobstructive Coronary Arteries in Brazilian Patients Receiving Tirzepatide (Mounjaro®): Exploring the Convergence of Plaque Destabilization, Coronary Vasomotor Dystunction, Microvascular Ischemia, Prothrombotic Remodeling, and Cardiometabolic Transition Through a Multimodal Mechanistic Case Report","MD/ PhD/ FACC Camilo Fernández Bravo","2026","Zenodo (CERN European Organization for Nuclear Research)","case_report","article","10.5281/zenodo.21361831",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054129","EE85 Budget Impact Analysis of GLP-1 Receptor Agonists for Type 2 Diabetes Management in India","Lalit Thakur","2025","Value in Health","other","article","10.1016/j.jval.2025.09.469",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054130","GLP1-receptor-agonisták: antidiabetikumok kardiovaszkuláris előnnyel","György Jermendy","2020","Cardiologia Hungarica","randomized_trial","article","10.26430/chungarica.2020.50.4.283",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054131","The foundation and the four pillars of treatment for cardiorenal protection in people with chronic kidney disease and type 2 diabetes","Rajiv Agarwal","2022","Nephrology Dialysis Transplantation","randomized_trial","article","10.1093/ndt/gfac331","36535638",null,"ClinicalTrials.gov:NCT03819153","S000953","openalex","TRUE","open_pdf","1","FALSE","article"],["R0054132","Post Stroke Epilepsy: Epidemiology, Risk Factors, Prevention, Management, and Future Directions","Joseph Nguyen","2026","Current Treatment Options in Neurology","randomized_trial","article","10.1007/s11940-026-00887-5",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054133","Efficacy and safety of metformin and liraglutide combination therapy in comparison with metformin in managing metabolic and endocrine levels of PCOS: A systematic review","Carl Jefferson E. Bernales","2026","International Journal of Pharmaceuticals Nutraceuticals and Cosmetic Science","systematic_review","article","10.24191/ijpnacs.v9i1.10",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0054134","Semaglutide ameliorates diabetes-induced steatotic liver disease in rats: Role of AMPK, mTOR, ERK and ABHD6","Sultan A. Alfawaz","2025","Tropical Journal of Pharmaceutical Research","preclinical","article","10.4314/tjpr.v24i2.4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054135","GLP-1 receptor agonist therapy and surgical procedure rates in hidradenitis suppurativa","Karishma Sidhu","2026","Archives of Dermatological Research","other","article","10.1007/s00403-026-04755-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054136","Which medications result in safe and effective weight loss in patients with obesity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20425436",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054137","Effects of Sodium-Glucose Cotransporter-2 Inhibitor Use on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Treated With Tirzepatide Versus Dulaglutide (SURPASS-CVOT)","D D’Alessio","2026","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0046-1819979",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0054138","(048) Impact of GLP-1 and GLP-1/GIP Dual Receptor Agonists on Female Reproductive Function: A Survey-Based Study","I Varea","2026","The Journal of Sexual Medicine","other","article","10.1093/jsxmed/qdag063.048",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054139","A-95 | Semaglutide Versus Tirzepatide After Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus and Obesity: A Real-World Retrospective Cohort Study","Roopeessh Vempati","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104586",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0054140","‘Efficacy of GLP-1 Receptor Agonists’ in Hypertriglyceridemia: A Systemic Review and Meta Analysis","Tahsin Jahan","2025","Asian Journal of Medicine and Health","randomized_trial","article","10.9734/ajmah/2025/v23i41205",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054141","IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS BY BODY WEIGHT REDUCTION WITH TIRZEPATIDE IN ADULTS WITH OBESITY AND PREDIABETES: A POST HOC ANALYSIS OF THE 3–YEAR SURMOUNT–1 STUDY","L Laffin","2026","European Heart Journal Supplements","randomized_trial","article","10.1093/eurheartjsupp/suag058.163",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054142","A Systematic Review of Oral Semaglutide for Type II Diabetes","A.Suseendra kumar","2021","International Journal of Pharmaceutical Sciences Review and Research","systematic_review","article","10.47583/ijpsrr.2021.v68i01.031",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054143","Abstract 2014: Metabolic adaptations of obesity-accelerated breast cancer.","Amandine Chaix","2026","Cancer Research","preclinical","article","10.1158/1538-7445.am2026-2014",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054144","IP52-05 ASSOCIATION OF PATERNAL GLP-1 RECEPTOR AGONIST USE WITH PRE-TERM BIRTH AND NICU ADMISSION","Nicholas C. Sellke","2026","The Journal of Urology","other","article","10.1097/01.ju.0001191592.83826.54.05",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054145","1180-OR: Health Effects of Two Strategies to Enhance Health Care Affordability: Medication-Targeted vs. Broad Out-of-Pocket Cost Reductions","James Frank Wharam","2026","Diabetes","other","article","10.2337/db26-1180-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054146","1228-OR: First-in-Human Study Demonstrates GIP Receptor (GIPR) Antagonist AT7687 as Well-Tolerated and Suitable for Once-Weekly Subcutaneous Injection for Treatment in People Living with Obesity","Ayna Baladi Nejad","2026","Diabetes","randomized_trial","article","10.2337/db26-1228-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054147","Effects of GLP-1 receptor agonists and dual GIP/GLP-1 agonist on muscle mass and bone health during obesity treatment — a narrative review","Iga Machała","2026","Forum Leczenia Otyłości","randomized_trial","article","10.5603/flo.112937",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","review"],["R0054148","GLP-1/GIP/Glucagon Triple Agonist Alters the Cardiac Proteomic Signature Providing Multifaceted Functional Benefits in HFpEF","Trung Van","2026","Physiology","preclinical","article","10.1152/physiol.2026.41.s1.2301552",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054149","GLP‑1 RECEPTOR AGONISTS IN THE MANAGEMENT OF OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: EFFECTS ON BODY WEIGHT, METABOLIC PROFILE, AND REPRODUCTIVE FUNCTION – A LITERATURE REVIEW","Patrycja Mularczyk","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.2(50).2026.5668",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054150","0672 Pharmacokinetics, Efficacy, and Safety of AD109 (Aroxybutynin and Atomoxetine) in Participants with Obstructive Sleep Apnea and Obesity Taking a GLP-1","Hsuan‐Ming Yao","2026","SLEEP","other_trial","article","10.1093/sleep/zsag091.0671",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0054151","Comparison of Metformin and Metformin Plus Liraglutide for Treating Metabolic Syndrome in Patients with Polycystic Ovarian Syndrome (PCOS)","Yousra Naz","2025","Indus journal of bioscience research.","randomized_trial","article","10.70749/ijbr.v3i3.818",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054152","2200-P: Real-World Effectiveness of Novel Antidiabetic Medications on Cardiovascular Outcomes among Medicare Beneficiaries by Race","WENJUN FAN","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2200-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054153","Is it necessary to withhold GLP-1 receptor agonists before surgery?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18666265",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054154","2358-P: Utilization and Persistence of Weight Management Therapies among Adults with Type 2 Diabetes (T2D) and Obesity","ADITI SINGH","2026","Diabetes","other","article","10.2337/db26-2358-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054155","What is the efficacy of high-dose semaglutide 7.2 mg weekly for weight loss?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20041284",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054156","Impact of Semaglutide on Body Composition and Muscle Mass Maintenance in Patients Undergoing Semaglutide Induced Weight Loss Therapy: A Systematic Review","Daniel Zieliński","2026","Quality in Sport","systematic_review","article","10.12775/qs.2026.56.71992",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054157","Risk of Postoperative Complications in Patients Who Underwent Transsphenoidal Pituitary Surgery Treated with Glucagon-Like Peptide Agonists (TRINETX)","Maxwell W. Pickles","2025","Journal of Neurological Surgery Part B Skull Base","nonrandomized_study","article","10.1055/s-0045-1803739",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0054158","Effect of Semaglutide and Tirzepatide on LDL and VLDL Levels in Adults With Type 1 and Type 2 Diabetes: A Comparative Study in Men and Women.","Nageswara Rao. T","2025","Student s Journal of Health Research Africa","other","article","10.51168/sjhrafrica.v6i12.2351",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054159","Abstract 3: Developing a translational tool for GLP-1-based therapeutic agonists in humanized GLP1R mice","Yuelei Shen","2022","Cancer Research","other_trial","article","10.1158/1538-7445.am2022-3",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0054160","Glucagon-Like Peptide 1 Receptor Agonists in Anterior Cervical Discectomy and Fusion—A Notch in the Equivocal Column:","Patrick K. Cronin","2025","Spine Open","nonrandomized_study","article","10.1097/bn9.0000000000000012",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054161","EPH202 Assessing Trends in Utilization and Off-Label Prescribing for Ozempic, a Glucagon-like Peptide Receptor Agonist","Elkin Muñoz","2024","Value in Health","other","article","10.1016/j.jval.2024.03.2316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054162","Injectable semaglutide versus oral semaglutide in obesity management: a 68-week prospective comparative study","Antaryami Sahoo","2026","Medical Research Journal","nonrandomized_study","article","10.5603/mrj.112993",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054163","Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis – a subgroup analysis from the SELECT trial","Melissa Leung","2024","Obesity Research & Clinical Practice","other_trial","article","10.1016/j.orcp.2024.09.021",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054164","Effects of Exenatide on both fat mass loss and cardiometabolic risk in obese subjects with type 2 diabetes mellitus","Carmela Colica","2017","Clinical Practice","other","article","10.4172/clinical-practice.1000134",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054165","Type 2 diabetes mellitus and comorbid conditions: from clinical recommendations to daily practice","O.A. Shatskaya","2026","Лечащий врач","other","article","10.51793/os.2026.29.6.013",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054166","1220-OR: Survodutide: Differentiated GLP-1R and Glucagon Receptor (GCGR) Pharmacology Compared with Endogenous Ligands via Time-Resolved Assays","BENEDICT BERGER","2026","Diabetes","other_trial","article","10.2337/db26-1220-or",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054167","What are the alternative therapies to CPAP for treating obstructive sleep apnea?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20582123",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054168","Impact of GLP-1 agonists on heart failure with preserved ejection fraction in obese patients: a meta-analysis of cardiometabolic and functional outcomes","Anne M. May","2025","European Heart Journal","systematic_review","article","10.1093/eurheartj/ehaf784.1048",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0054169","302-OR: The Antimyostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity","MELISSA A. FULHAM","2024","Diabetes","preclinical","article","10.2337/db24-302-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054170","DIFFERENCES IN SAFETY PROFILE AND ADVERSE EFFECTS OF ORAL AND SUBCUTANEOUS GLP-1 ANALOGUES: A SYSTEMATIC REVIEW AND REAL-WORLD DATA ANALYSIS (2024–2026)","Aleksandra Olga Pakulska","2026","International Journal of Innovative Technologies in Social Science","systematic_review","article","10.31435/ijitss.2(50).2026.5685",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054171","Development of a Manufacturing Process for a Key ( S )-5-(2,2-Dimethyltetrahydro-2 H -pyran-4-yl)-1 H -indole Intermediate for Orforglipron. Part III. Development of a Telescoped Phase-Transfer-Catalyzed Alkylation and Cyclopropanation Process","Qiang Yang","2025","Organic Process Research & Development","other","article","10.1021/acs.oprd.5c00185",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054172","The role of bariatric and metabolic surgery in the management of obstructive sleep apnea and obesity: a narrative review","Qing Zhou","2026","Bulletin of the National Research Centre/Bulletin of the National Research Center","randomized_trial","article","10.1186/s42269-026-01400-3",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0054173","L'économie pharmaco-alimentaire","Sandrine DOPPLER","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21194803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054174","Sustained improvements of bile acid diarrhoea symptoms upon statin treatment","Mads Bank Lynggaard","2026","Gastroenterology report","randomized_trial","article","10.1093/gastro/goag076","42483431",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054175","THE THERAPEUTIC POTENTIAL OF INCRETIN-BASED THERAPIES AND THE EMERGING ROLE OF METABOLIC MODULATION IN THE MANAGEMENT OF OBSTRUCTIVE SLEEP APNEA: A MECHANISTIC AND CLINICAL REVIEW","Sandro Gentile","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.21370777",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054176","1217-OR: ApoC3 Inhibitor Olezarsen Markedly Reduces Triglycerides and Risk of Pancreatitis in Severe Hypertriglyceridemia Patients with Diabetes Mellitus: Insights from CORE-TIMI 72a and CORE2-TIMI 72b","Yu Mi Kang","2026","Diabetes","randomized_trial","article","10.2337/db26-1217-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054177","Exenatide","Qing Zhong","2026","Elsevier eBooks","other","article","10.1016/b978-0-443-44037-3.01001-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0054178","L’orforglipron, une nouvelle classe thérapeutique pour la prise en charge du surpoids et du diabète de type 2","Fabrizio Andreelli","2026","Médecine des Maladies Métaboliques","other","article","10.1016/j.mmm.2026.02.005",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054179","Individual Effects of Liraglutide on Cardiorenal Risk Markers:Results from the LEADER Trial","Frederik Persson","2019","Research at the University of Copenhagen (University of Copenhagen)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0054180","Comparison of Safety and Efficacy of Metformin and Vildagliptin versus Metformin and Glimepiride in Patients of Type - 2 Diabetes Mellitus (T2DM)","Derangula Sambasivaraju","2023","International Journal of Pharmaceutical and Clinical Research","other","article","10.5281/zenodo.13146254",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054181","Safety and Feasibility of Simultaneous and Gradual Initiation of Combination Renoprotective Therapy in Patients with Type 2 Diabetes and CKD: A Real-World Analysis","Manja Antonič","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20258z6ec0wf",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054182","Influence of Combination Therapy of Oral Anti Diabetics on HbA1c Values","Ponnaluri Lalitha","2022","International Journal of Science and Research (IJSR)","other","article","10.21275/sr22607185749",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054183","Fluorescence Optical Imaging of Juvenile Arthritis","S. G. Werner","2011","The Journal of Rheumatology","randomized_trial","article","10.3899/jrheum.101351","21724713",null,"ClinicalTrials.gov:NCT02905864","S001734","openalex","TRUE","open_pdf","1","FALSE","article"],["R0054184","Polarizing the immune system towards neuroprotection in brain ischemia","Diana Amantea","2015","Neural Regeneration Research","preclinical","article","10.4103/1673-5374.169633","26981089",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054185","O uso da Tirzepatida no tratamento da obesidade","Vinicius Mascoli","2025","Contribuciones a las Ciencias Sociales","other","article","10.55905/revconv.18n.8-325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054186","Emerging and Novel Molecular Targets in Obesity: Advances Toward Precision Anti-Obesity Pharmacotherapy","Ansh Tripathi","2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.9s.21",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054187","What are the potential adverse effects of GLP-1 agonists in patients with prediabetes or risk factors for type 2 diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18460518",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054188","In nondiabetic patients with obesity, do injectable GLP-1 agonists result in increased muscle loss when compared with other weight loss measures?","Brooke Passolt","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002276",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054189","What's next in medical science—Precision, Prevention, and Prediction","China The Innovation Medicine Editorial Team","2026","The Innovation Medicine","commentary","article","10.59717/j.xinn-med.2026.100185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0054190","Most Clinical Studies Do Not Report FDA Recommendations For Endpoints In NAFLD/NASH","Debora de Melo Behrens","2021","Medicine & Science in Sports & Exercise","randomized_trial","article","10.1249/01.mss.0000764484.54799.31",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054191","What is the effect of Ozempic on skeletal muscle?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17906101",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054192","DIFFERENCES IN GUT MICROBIOTA MODULATION BY SEMAGLUTIDE, LIRAGLUTIDE AND TIRZEPATIDE","Julia Nowakowska","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3563",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054193","Cardioprotective Effects of Antidiabetic Medications in Type 2 Diabetes - Mechanisms and Clinical Outcomes: A Narrative Review","Abdullah Heshmat","2025","Archives of Pharmaceutical Sciences Ain Shams University","other_trial","article","10.21608/aps.2025.393133.1231",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","review"],["R0054194","1309-OR: Dementia Progression with GLP-1 Receptor Agonists in People with Type 2 Diabetes and Mild Cognitive Impairment: Retrospective Cohort Study","Meir Schechter","2026","Diabetes","randomized_trial","article","10.2337/db26-1309-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054195","162-LB: Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome—The ELIXA Biomarker Study","Hertzel C. Gerstein","2022","Diabetes","other_trial","article","10.2337/db22-162-lb",null,null,"ClinicalTrials.gov:NCT01147250; ClinicalTrials.gov:NCT00069784","S001991","openalex","FALSE","paywalled","5","FALSE","article"],["R0054196","What are the recommended protocols for deprescribing tirzepatide in patients who no longer meet the criteria for its use in managing obesity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21241673",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054197","Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults With Overweight/Obesity in the STEP 1 Trial","Sarah Chapelsky","2022","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2022.09.012",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054198","Is physical activity still the key to treating obesity? - semaglutide, a new position among therapies","Karolina Makowska","2024","Quality in Sport","other","article","10.12775/qs.2024.20.54194",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054199","Isopropanol‐Dimethyl Sulfoxide, as a Green Solvent Mixture for Solid‐Phase Peptide Synthesis","Sikabwe Noki","2026","Chemistry - Methods","other","article","10.1002/cmtd.70116",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054200","Advances and Ethical Challenges in Modern Aesthetic and Reconstructive Surgery","J Velázquez","2025","SAGA Revista Científica Multidisciplinar","other","article","10.63415/saga.v2i3.267",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054201","What research supports the use of GLP-1 inhibitors in mental health disorders?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19253837",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054202","NEWLY-EMERGING SIDE EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE USAGE ASSOCIATED WITH WEIGHT LOSS TREATMENT","Paula Bieganek","2024","Health Problems of Civilization","other","article","10.5114/hpc.2024.140505",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054203","EPH163 Off-Label Use of Semaglutide in the United States: Increasing Prevalence, Variability in Prescribing Provider Specialty, and Patient Characteristics","Virginia Noxon","2024","Value in Health","other","article","10.1016/j.jval.2024.03.991",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054204","1818-P: BGM2618, a Selective Myostatin Inhibitor, Preserves Lean Mass during GLP-1/GIP–Induced Weight Loss in Obese Mice","Jiandong Yuan","2026","Diabetes","preclinical","article","10.2337/db26-1818-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054205","Unsaturated glycoceramides as molecular carriers for mucosal drug delivery of GLP‐1 analogues","Yvonne M. te Welscher","2013","The FASEB Journal","other","article","10.1096/fasebj.27.1_supplement.588.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054206","Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycemic Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin.","Anders H. Frid","2008","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(08)24121-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054207","FROM BASEMENT MEMBRANE DEFECTS TO PRECISION MEDICINE: ADVANCES IN ALPORT SYNDROME","Karolina Krowiak","2025","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(47).2025.3654",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054208","Tolerability of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) in Kidney Transplant Recipients with Diabetes","Henry Zelada","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054209","Glucagon-like peptide-1 receptor agonists improve cholesterol metabolism by inhibiting SREBP-2 via SIRT6-AMPK pathway in HepG2 cells treated with palmitic acid","Jinmi Lee","2025","Cardiovascular Prevention and Pharmacotherapy","other","article","10.36011/cpp.2025.7.e11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054210","Can semaglutide cause pancreatitis?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21803624",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054211","Can GLP-1 receptor agonists be used in the treatment or prevention of dementia?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17831427",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054212","Modulation of Shift-Work Induced Metabolic Chronodisruption and Neurovascular Risk in Healthcare Professionals: A Prospective Real-World Three-Arm Incretin Study","Glauco Messina","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20681849",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0054213","In obese adults, is topiramate plus phentermine more effective than GLP-1 receptor analogs (GLP-1RAs) on weight loss?","Viviane Sachs","2025","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002354",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054214","What are the guidelines for optimizing treatment regimens in patients with type 2 diabetes who experience suboptimal outcomes with GLP-1 receptor agonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17958017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054215","What is the evidence for GLP-1 receptor agonists in Parkinson's disease?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18188361",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054216","10.51847/hpur8NS","Afaf Sayed Osman","2000","Time to knit","preclinical","article","10.51847/hpur8ns",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054217","How can clinicians manage or mitigate weight gain in patients taking antipsychotic medications?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18986257",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054218","Role of GLP Agonists in treatment of diabetes and metabolic disorders: A review of underlying mechanisms","Ashutosh Mishra, Nupur Garg, Sanjay Mendiratta, Gurminder Bindra, Charu Mehra Kamal","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.20508982",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054219","1344-OR: Near- and Long-Term Improvements in A1C and CGM Metrics with Dexcom CGM Use in over 7,000 Adults with Type 2 Diabetes","MINGKAI PENG","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1344-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054220","[20] EXENDIN-4 RESTORES PPAR-ALPHA AND PPAR-GAMMA ACTIVITY IN NASH AND REDUCES INSULIN RESISTANCE, PRO-INFLAMMATORY MEDIATORS AND TOTAL FATTY ACID CONTENT","G. Svegliati-Baron","2007","Journal of Hepatology","other","article","10.1016/s0168-8278(07)61618-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054221","Comparative Efficacy of Metformin and Liraglutide in Pediatric Type 2 Diabetes","Aamir Naseem","2024","Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University","randomized_trial","article","10.48036/apims.v20isuppl-1.1228",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054222","What is the effect of GLP-1s on eGFR?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22895221",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054223","Is the effectiveness of drug treatments maintained when used as a second-line treatment following bariatric surgery due to surgical failure or weight regain?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22764188",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054224","What are the risk factors for pancreatitis in users of GLP-1 receptor agonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17773706",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054225","OZEMPIC® E A DITADURA DA ESTÉTICA: IMPLICAÇÕES DO USO INDISCRIMINADO PARA EMAGRECIMENTO","Angela Kaylanne Lemos Araujo","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17486505",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054226","Flow – SPPS towards greener and more efficient peptide manufacturing","Oliver Kracker","2024",null,"other","article","10.17952/37eps.2024.p1029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054227","Neuroprotective Effect of Combined Therapy of Liraglutide with Vitamin D on Streptozotocin-Induced Diabetic Neuropathy in Rats.","Hala M. ElBadre","2020","Sohag Medical Journal","preclinical","article","10.21608/smj.2020.28543.1149",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054228","Perioperative Adverse Events in Women Taking GLP1-RAs in Gynecologic Surgery","Madeline Carmain","2026","Obstetrics and Gynecology","nonrandomized_study","article","10.1097/aog.0000000000006204.2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054229","Liraglutide for Weight Management in Children and Adolescents with Prader-Willi Syndrome and Obesity","Diene Gwenaëlle","2022","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.7143490",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0054230","The DAR Survey of Physicians' Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors during Ramadan","Mohamed M. Hassanein","2025","Journal of Diabetes and Endocrine Practice","nonrandomized_study","article","10.1055/s-0045-1811584",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054231","(152) Effects of GLP-1 Receptor Agonists on Male Reproductive Hormones, Semen Parameters, and Metabolic Outcomes: A Systematic Review","Mohammad Ghassab Deameh","2025","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdaf320.152",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0054232","Incidence and Cardiovascular Risk Factors Profile in Obese and Non-obese Type 2 Diabetes Mellitus subjects aged between 30 and 80 years in the polyclinic, in an Omani Population: ICD OMAN a Decade-Long Bawshar Study","Shiju Raman Unni","2021","INTERNATIONAL JOURNAL OF DIABETES & METABOLIC SYNDROME","nonrandomized_study","article","10.52106/2771-1331.1002",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054233","(119) Exploring the Impact of GLP-1 Analogues on Libido and Sexual Function","M Cameira","2026","The Journal of Sexual Medicine","randomized_trial","article","10.1093/jsxmed/qdag118.105",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054234","Which of the two agents, tirzepatide or semaglutide, provides better glycemic control and weight loss compared to metformin?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20210884",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054235","Changes in serum calcitonin concentrations and incidence of adjudicated medullary thyroid carcinoma in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)","Brian G. Katona","2018","Diabetologia","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054236","Adiposity-based Chronic Diseases and the Therapeutic Role of Glucagon-like Peptide-1 Receptor Agonists","Rajiv Kovil","2025","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_22_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054237","Does weight loss medication cause muscle loss?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18822316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054238","Glucagon-like Peptide-1 (GLP-1) Agonists: A Review","Naresh Lenkapothula","2021",null,"narrative_review","article","10.51521/ijmhr.2021.1104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054239","Knowledge, attitudes, and willingness of professionals regarding glucagon-like peptide-1 receptor agonists in anesthesia","Jingjing Liu","2026","Scientific Reports","nonrandomized_study","article","10.1038/s41598-026-66967-3",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054240","Is there any evidence around GLP-1 receptor agonists and anxiety?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17970202",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054241","Efficacy of GLP 1 Receptor Agonists in Managing Weight Regain Following Roux-en-Y Gastric Bypass: A Therapeutic Avenue to Restore Metabolic Control?","F Da Canal","2026","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znag055.002",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054242","A Novel Peptide with Similar Pharmacology to Exenatide in Rodents as GLP-1 Receptor Agonist","Guangji Zhang","2017","International Journal of Peptide Research and Therapeutics","preclinical","article","10.1007/s10989-017-9612-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054243","Evidence Shows Few Drugs Cause Acute Pancreatitis","Dennis Khodasevich","2016","The American Journal of Gastroenterology","randomized_trial","article","10.14309/00000434-201610001-00030",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054244","328: OUTPATIENT BARIATRIC SURGERY AND GLP-1 AGONISTS: A CASE STUDY ON THE COMPLEXITIES AND RISKS","Jessen Burk","2025","Critical Care Medicine","other","article","10.1097/01.ccm.0001099976.49814.36",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054245","Liraglutide (Saxenda) Combined with Lifestyle Coaching for Weight Loss in a Bariatric Center","Inge H. Palm‐Meinders","2024","Journal on Surgery","nonrandomized_study","article","10.52768/2691-7785/1157",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054246","Digital healthcare solutions to better achieve the weight loss outcomes expected by payors and patients","Louis A Talay","2024","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.15513","38379435",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054247","In This Issue: Regional Guideline and Global Insights in Diabetes and Endocrinology","SALEM A. BESHYAH","2026","Journal of Diabetes and Endocrine Practice","nonrandomized_study","article","10.1055/s-0046-1818545",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054248","How does GLP-1 receptor agonist treatment affect lean mass in individuals with obesity or metabolic disorders?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18840484",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054249","Impacts of Glucagon-like Peptide-1 Receptor-Agonist (GLP-1 RA) Treatment for Metabolic Disturbances and Weight Gain in Patients on Clozapine/Olanzapine: A Systematic Review","Karan Varshney","2025","Obesities","systematic_review","article","10.3390/obesities5040072",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054250","the FINE-HEART pooled analysis","Maria A. Pabón","2026","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other_trial","article",null,null,null,"PROSPERO:CRD42024570467",null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0054251","AGONISTAS DO RECEPTOR DE GLP-1 NA SAÚDE REPRODUTIVA FEMININA: UMA REVISÃO INTEGRATIVA SOBRE FERTILIDADE E FUNÇÃO OVULATÓRIA EM MULHERES COM SÍNDROME DOS OVÁRIOS POLICÍSTICOS","CLAUBA MONIK PEREIRA ALVES DINIZ","2026","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.22182204",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0054252","What evidence exists on the effectiveness of semaglutide in patients with heart failure?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21838509",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054253","Head to head comparison of semaglutide and colchicine for treating atrial remodeling in post-MI rats with reduced ejection fraction","O Levi","2025","European Heart Journal","randomized_trial","article","10.1093/eurheartj/ehaf784.4757",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054254","S880 Risk of Aspiration for Patients on GLP-1 Agonists Undergoing EGD","Brennan W. Gioe","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032888.40013.2e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054255","UNDERSTANDING PRADER-WILLI SYNDROME: FROM MOLECULAR DIAGNOSIS TO THERAPEUTIC INNOVATIONS","Paulina Redel","2025","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(47).2025.3455",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054256","Pregnancy and preexisting diabetes: Bridging evidence, technology, and care in 2025","Tahmina Ferdousi","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","nonrandomized_study","article","10.3329/jacedb.v4i20.84901",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054257","3102-LB: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results","WEIKAI C. FANG","2026","Diabetes","randomized_trial","article","10.2337/db26-3102-lb",null,null,"ClinicalTrials.gov:NCT06252220",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054258","The efficacy of liraglutide-based drugs on the model of induced metabolic syndrome in experimental animals","Alexander A. Andreev-Andrievskiy","2025","Pharmacy & Pharmacology","preclinical","article","10.19163/2307-9266-2025-13-3-171-183",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054259","Models of body-weight regulation: set-point, settling-point, and the thrifty and drifty gene hypotheses","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21464949",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report; article"],["R0054260","Can tirzepatide cause small bowel obstruction?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17964543",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054261","ISBE & Cochrane Portugal Newsletter nº 370: A eficácia na perda de peso dos agonistas do recetor do peptídeo-1 semelhante ao glucagon (GLP-1 RA) é superior nas mulheres","António Vaz Carneiro","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19049976",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054262","National Trends in Use of CKD Guideline-Directed Medical Therapies","Rishav Adhikari","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2025ejx8sf08",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054263","Type 2 diabetes mellitus: emerging mechanistic insights, evolving therapeutic strategies, and future perspectives","Himanshu","2026","Discover Endocrinology and Metabolism","other","article","10.1007/s44417-026-00025-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054264","COMPARISON BETWEEN TIRZEPATIDE AND SEMAGLUTIDE IN OBESITY MANAGEMENT: CURRENT EVIDENCE ON WEIGHT REDUCTION, METABOLIC PROFILE, AND TOLERABILITY","Valéria Goulart Viana","2025","Seven Editora eBooks","randomized_trial","article","10.56238/sevened2025.031-015",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","book-chapter"],["R0054265","Hepatic and osteogenic effects of dulaglutide and semaglutide in an acute model of hepatotoxicity in mice","Bruna Christ Faria","2024","Pharmacological Research - Reports","preclinical","article","10.1016/j.prerep.2024.100019",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054266","GLP-1 RECEPTOR AGONISTS AND THE RISK OF CHOLELITHIASIS: A LITERATURE REVIEW","Julia Pająk","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.1(49).2026.5421",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054267","Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes","Josep Vidal","2026","Advances in pharmacology","other","article","10.1016/bs.apha.2026.08.009",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0054268","Semaglutide in different indications","Ľubica Cibičková","2024","Vnitřní lékařství","other","article","10.36290/vnl.2024.078",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054269","Evaluation of the effectiveness of the liraglutide (victoza) on carbohydrate metabolism in type 2 diabetes with obesity","I.M Tillyashaykhova","2021","Asian Journal of Multidimensional Research","other","article","10.5958/2278-4853.2021.00592.9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054270","1142-P: Fat Distribution in Youth-Onset Type 2 Diabetes","Tyler J. Dobbs","2024","Diabetes","other","article","10.2337/db24-1142-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054271","Remarkable Improvement in Plaque Psoriasis with a 4 week Short Course Liraglutide Therapy in an Obese Type 2 DM Patient","Santosh Ramakrishnan","2020","Journal of Endocrinological Science","other","article","10.29245/2767-5157/2020/1.1106",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054272","What are the mechanisms by which tirzepatide might impact pregnancy and recurrent pregnancy loss?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17691996",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054273","Antiproteinuric effect of dulaglutide in IgAN treated with SGLT2i and RAASi","Malighetti, M.E.","2024","The Journal of AMD","other","article","10.36171/jamd24.27.4.9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054274","SAT-682 Innovative Artificial Intelligence (AI) SXR platform use to aid diagnosis of metabolic dysfunction associated steatohepatitis (MASH) and liver fibrosis","Veronica Angela Preda","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.116",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054275","1658-P: Characterization and Preclinical Efficacy of a Novel Unimolecular Amylin and GLP-1 Receptor Dual Agonist, VRB-104","Martijn Fenaux","2026","Diabetes","preclinical","article","10.2337/db26-1658-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054276","How do off-label medications for binge eating disorder compare to FDA-approved treatments in terms of outcomes and patient satisfaction?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20595708",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054277","Effect of tirzepatide, a GIPR and GLP1R dual agonist, on endothelial cell function and metabolism","A Kirsch","2026","Cardiovascular Research","other","article","10.1093/cvr/cvag092.158",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054278","A LONG-TERM COST-EFFECTIVENESS ANALYSIS OF TREATMENTS FOR TYPE 2 DIABETES IN PORTUGAL: ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS ONCE-DAILY EMPAGLIFLOZIN 25 MG","Davide Maurício Carvalho","2021","Revista Portuguesa de Endocrinologia Diabetes e Metabolismo","randomized_trial","article","10.26497/ao200073",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054279","What are the differences in metabolic outcomes when using GLP-1 analogues compared to other treatments for obesity in adolescents?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19002140",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054280","SAFETY OF GLP-1RA THERAPY: SIDE EFFECTS AND THE NEED FOR MONITORING","Małgorzata Piasta","2024","Health Problems of Civilization","other","article","10.5114/hpc.2024.142668",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054281","Translational Advances in GLP-1–Based Therapies for Cardiometabolic Disease","Sandeep Kumar Yadav","2026","Journal of Integrative and Translational Biomedicine","nonrandomized_study","article","10.67316/jintb.v1.i3.21",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054282","How does the management of COPD exacerbations differ in patients with type 2 diabetes compared to those without diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18530016",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054283","Incretin Hormones: Mechanisms, Therapeutic Implications, and Future Directions in Glucose Regulation and Diabetes Management","Abrar Ahmad Zargar","2025","Current Proteomics","nonrandomized_study","article","10.1016/j.curpro.2025.100014",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054284","Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide","Viktoria E. Toth","2026","Journal of Molecular and Cellular Cardiology Plus","preclinical","article","10.1016/j.jmccpl.2025.100763",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054285","Risk of hepatocellular carcinoma in adults exposed to oral antidiabetic drugs: a systematic review","Shadman Newaz","2025","DOAJ (DOAJ: Directory of Open Access Journals)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0054286","Liraglutide Suppresses Postprandial Triglyceride (TG) and Apolipoprotein B48 (ApoB48) Responses to a Fat-Rich Meal in Patients with Type 2 Diabetes","Kjeld Hermansen","2012","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2012.07.325",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054287","Combinations of Renin-Angiotensin-Aldosterone System Inhibitors, Statins, SGLT2 Inhibitors, and GLP-1 Receptor Agonists and Survival","Scott A. Reule","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.20255z5fynqt",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054288","1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5","Ofri Mosenzon","2019","Diabetes","randomized_trial","article","10.2337/db19-1004-p",null,null,"ClinicalTrials.gov:NCT02827708","S002025","openalex","FALSE","paywalled","1","FALSE","article"],["R0054289","Abstract WE445: Effects of a Weight Management Program Integrated with Continuous Glucose Monitoring on Cardiometabolic Risk Factors: A Randomized Controlled Trial in Patients with Type 2 Diabetes","Peter Katzmarzyk","2026","Circulation","randomized_trial","article","10.1161/cir.153.suppl_1.we445",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0054290","301-OR: Synergistic Effects of Dapagliflozin and Tirzepatide Combination Treatment on Weight Loss and Glucose Regulation in Diet-Induced Obese Animals","MOHAMED ABU-FARHA","2024","Diabetes","preclinical","article","10.2337/db24-301-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054291","A review on recent advances in cardiovascular pharmacotherapy: Emerging therapies, novel anticoagulants, and cardiometabolic innovations","Sajid Muhammad Arsalan Ali","2026","World Journal of Advanced Research and Reviews","randomized_trial","article","10.30574/wjarr.2026.30.3.1668",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054292","Incretin-based Antidiabetic Therapy and Pancreatitis: A Case Series","Debarati Bhar","2023","Bengal Physician Journal","randomized_trial","article","10.5005/jp-journals-10070-8012",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054293","Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity","Santi Arana-Ballestar","2023","Boletín de información farmacoterapéutica de Navarra","other_trial","article","10.54095/bitn20233104en",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054294","Use of GLP-1 Analogues in Patients with Schizophrenia and Other Neuropsychiatric Disorders: A Literature Review","Maja Pernal","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.54.70410",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054295","Correlation Between Hemoglobin A1c and High Sensitivity C-Reactive Protein in Population with Type II Diabetes Mellitus in the Semaglutide Treatment on Coronary Plaque Progression (STOP) Trial","Khadije Ahmad","2021","American Heart Journal","other_trial","article","10.1016/j.ahj.2021.10.031",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054296","GLP-1 Receptor Agonists, Gut Microbiota, and Chronic Pain: Nutritional Signaling at the Gut–Brain Axis","Charles Amoatey Odonkor","2026","Nutrients","other","article","10.3390/nu18193120",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054297","How GLP-1 Drugs Are Shifting Power over Food Demand","Sandrine DOPPLER","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22806115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0054298","Gut hormones beyond the gut: enteroendocrine control of systemic metabolism","Lu Yu","2026","Life Metabolism","other","article","10.1093/lifemeta/loag030",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054299","Polysaccharide-based bioactive materials for diabetes integrating translational design mechanisms and clinical applications","Taruna Ikrar","2026","Discover Materials","other","article","10.1007/s43939-026-00655-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054300","S879 Are ASA Guidelines Regarding the Holding of GLP-1 Agonists Before Endoscopy Enough to Reduce Aspiration Risk?","Brennan W. Gioe","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032884.63067.9b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054301","76. GLP-1 RECEPTOR AGONISTS AND ALZHEIMER'S DISEASE: ASSESSING THEIR THERAPEUTIC POTENTIAL","Tarlan Kehtari","2025","American Journal of Geriatric Psychiatry","other","article","10.1016/j.jagp.2025.04.078",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054302","Dynamics of turnover of sugar-lowering drugs in the retail segment of the pharmaceutical market from 2020 to 2024","Денис Владимирович Куркин","2025","Pharmacy & Pharmacology","other","article","10.19163/2307-9266-2025-13-2-84-97",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054303","The Renoprotective Effects of Liraglutide and Alfacalcidol against Cisplatin Induced Nephrotoxicity in Mice","Basma I. Fehil","2024","Journal of Advances in Medicine and Medical Research","preclinical","article","10.9734/jammr/2024/v36i45401",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054304","Tirzepatide Versus Semaglutide: A Structured Narrative Review of Direct Comparative Clinical Studies and Post Hoc Analyses on Clinical and Laboratory Outcomes","Julia M. Umińska","2026","Obesities","other_trial","article","10.3390/obesities6030038",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","review"],["R0054305","What are alternative medications that have a lower risk of ocular issues compared to GLP-1 for patients with existing retinal detachment?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21427015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054306","EP148 - ECE_3551 - Three newly diagnosed patients with Addison’s disease presenting with adrenal crisis: illustrative case reports","Gergő Csitári","2026","European Journal of Endocrinology","case_report","article","10.1093/ejendo/lvag096.738",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054307","Lipedema as a Hormone-Driven Gynecological Disorder: The Estrogen Receptor Connection","Diogo Pinto da Costa Viana","2025","IntechOpen eBooks","other","article","10.5772/intechopen.1012036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0054308","Erratum to “Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society” [Obesity Pillars 15C (2025) 100181]","Dariush Mozaffarian","2026","Obesity Pillars","notice","article","10.1016/j.obpill.2026.100268",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0054309","Alcohol y envejecimiento:: impacto sobre la longevidad y la salud cerebral","Redolat Iborra, Rosa","2025","Repository of Digital Objects for Teaching Research and Culture (University of Valencia)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054310","Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy and Lifestyle Modifications for Morbid Obesity in a Patient With Paroxysmal Atrial Fibrillation, Severe Osteoarthritis, and Obstructive Sleep Apnea: A Case Report","Brian Morris","2026","Cureus","case_report","article","10.7759/cureus.116307",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054311","Complications of Tirzepatide (Mounjaro®) on the Optic Nerve and Retina in Patients with Type 2 Diabetes Mellitus","Abdel Raouf Fouad","2024","International Journal of Diabetes Sciences","nonrandomized_study","article","10.33545/26649101.2024.v6.i1a.22",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054312","2822-LB: Semaglutide Improves Postprandial Glucose Metabolism after Spinal Cord Injury: A First Mechanistic Study","Azam Alamdari","2026","Diabetes","other","article","10.2337/db26-2822-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054313","The Masstige of Movement: How Mass Endurance Events Democratize Status Signaling in the Era of Pharmaceutical Weight Loss","Min Jinseong","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21859590",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0054314","67 Analysis of the mayfield lifestyle medicine and mounjaro (MaLMoun) project. A group consultation and health coaching course delivering tirzepatide, exercise and education on the 6 pillars of lifestyle medicine to type 2 diabetics with obesity","Zara Gandon","2026",null,"other_trial","article","10.1136/lma-2026-bslm-10th.53",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0054315","Which drug can cause pancreatitis in diabetic patients?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18312211",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054316","(417) Compounding Pharmacies: Trends Among Cisgender Women Taking GLP1 or GLP1/GIP Receptor Agonists","Emily K. Burr","2025","The Journal of Sexual Medicine","other","article","10.1093/jsxmed/qdaf320.411",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054317","A Comprehensive Meta-analysis of Efficacy, Cardiovascular Protection, and Emerging Therapeutic Innovations of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus","Mohammed Muzammil","2025","Telangana journal of IMA.","systematic_review","article","10.4103/tjima.tjima_31_25",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0054318","Clinical observation of the transition from short-term intensive insulin therapy to IDegLira combined with metformin in Chinese patients with type 2 diabetes mellitus","Xiaoxia Tan","2025","Current Science","other","article","10.18520/cs/v128/i2/195-200",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054319","Differences in Efficacy and Safety between the Glucagon-Like Peptide-1 Receptor Agonists. Therapy Management During the Shortage Period","José Seijas‐Amigo","2022","SSRN Electronic Journal","other","article","10.2139/ssrn.4282934",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0054320","26-A-14458-ACC PROTECTIVE EFFECT OF GLP-1 RECEPTOR AGONISTS ON POST-TAVR CONDUCTION AND ARRHYTHMIC COMPLICATIONS: A RETROSPECTIVE COHORT STUDY","Abdalhakim R. M. Shubietah","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.103",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054321","Cardiometabolic Continuum and Integrated Cardiovascular-Endocrine Risk Management in Contemporary Clinical Practice","Martín Gómez-Luján","2026","IECCMEXICO","randomized_trial","article","10.64784/208",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054322","Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends","Lauren M. Ching","2025","JEADV Clinical Practice","nonrandomized_study","article","10.1002/jvc2.70208",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054323","Is tirzepatide more effective than semaglutide?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18754166",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054324","Semaglutida no controle da obesidade: repercussões sistêmicas e efeitos adversos","Augusto César Romão Asseis","2024","Brazilian Journal of Health Review","other","article","10.34119/bjhrv7n2-113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054325","What is the evidence for the use of tirzepatide in individuals over 65 years of age?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18199652",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054326","What is the impact of glucose-lowering medications on fasting blood glucose as demonstrated in randomized controlled trials, systematic reviews, or guidelines?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.18158464",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0054327","In patients with type 2 diabetes mellitus and incipient nephropathy on metformin, what treatment should be used?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18040877",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054328","O uso off-label da semaglutida (Ozempic®) para emagrecimento e a atenção farmacêutica na dispensação","Marília Barreto Rodrigues","2025","Brazilian Journal of Health Review","other","article","10.34119/bjhrv8n1-165",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054329","Peri-operative Complications from Semaglutide Use","Aaron Patel","2025","Dental Update","other","article","10.12968/denu.2025.52.7.477",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054330","Development of a Manufacturing Process for a Key (S)-5-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1H-indole Intermediate for Orforglipron. Part I. Selection of an Evans Auxiliary-Assisted Asymmetric 1,4-Addition Route","Qiang Yang","2025","Organic Process Research & Development","other","article","10.1021/acs.oprd.5c00183",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054331","SAT-812 Can Sglt-2 And Glp-1 Ra Combination Therapy Facilitate Insulin Discontinuation In Patients With Long-standing Uncontrolled Type 2 Diabetes?","Amna Ali Shaghouli","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.1300",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0054332","FP39 Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study","Arkadeep Dhali","2026",null,"nonrandomized_study","article","10.1136/gutjnl-2026-bsg.115",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054333","What are the disease-related benefits of treating patients with risk factors for type 2 diabetes mellitus with a GLP-1 agonist?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18239799",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054334","What is the best anti-obesity drug?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18136949",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054335","GLP-1 Receptor Agonist Therapy in Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles","Yao Li","2026","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.6752746",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0054336","Effects of Semaglutide on Alzheimer’s Disease-related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment (S1.008)","Kristian Frederiksen","2026","Neurology","other_trial","article","10.1212/wnl.0000000000216961",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054337","What are the treatment options for patients with type 2 diabetes mellitus in the UK?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17689318",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054338","Effects of Retatrutide on Learning and Memory in Streptozotocin-Induced Diabetic Rats","Ulya Keskin","2026","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.6177785",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0054339","What is the mechanism by which Mounjaro could potentially lead to high blood pressure in patients?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22118356",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054340","The Effect of Liraglutide on A1C and Body Weight is Largely Independent of Diabetes Duration","Jochen Seufert","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.103",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054341","E-97 | Semaglutide Use and One-Year Mortality and Heart Failure Outcomes Following Transcatheter Edge-to-Edge Mitral Repair","Chris James","2026","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2026.105092",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054342","Patterns of care of subjects with type 1 and type 2 diabetes according to their cardiovascular risk","B. Pintaudi","2021","The Journal of AMD","nonrandomized_study","article","10.36171/jamd20.23.4.12",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054343","Immune And Metabolic Mechanisms of Development and Modern Approaches to The Treatment of Heart Failure in Patients with HIV Infection","E. V. Gazieva","2026","The Russian Archives of Internal Medicine","other","article","10.20514/2226-6704-2026-16-3-165-174",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054344","ONE-YEAR TREATMENT OUTCOMES WITH SUBCUTANEOUS SEMAGLUTIDE AT HOSPITAL QUEEN ELIZABETH II:","Yee Weai Cheong","2024","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.039.s1.052",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054345","Semaglutide and kidney function: friends or enemies?","Federica Giofrè","2024","Italian Journal of Medicine","other","article","10.4081/itjm.2024.1694",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054346","Cardiovascular Outcomes with SGLT-2 Inhibitors vs. GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and CKD: A Systematic Review and Network Meta-Analysis","Takayuki Yamada","2020","Journal of the American Society of Nephrology","systematic_review","article","10.1681/asn.20203110s1346c",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0054347","Estimation of Lexisinatide in Bulk and Tablets by RP‐UPLC Method Developed by Quality by Design Concept","Ramreddy Godela","2024","Macromolecular Symposia","randomized_trial","article","10.1002/masy.202300142",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054348","Chronic Spontaneous Urticaria with Angioedema Refractory to Standard Therapy: Insights Into the Protean Nature of a Common Presentation","Nadia Makkoukdji","2026","Journal of Human Immunity","other","article","10.70962/cis2026abstract.126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054349","1886-P: Efficacy and Safety Noninsulin Hypoglycemic Drugs as Adjunctive Therapy to Automated Insulin Delivery System in Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","Yi Zhou","2026","Diabetes","systematic_review","article","10.2337/db26-1886-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0054350","Metabolic dysfunction-associated steatotic liver disease: Pathogenesis, complications and pharmacological treatment","Kyung-Soo Kim","2026","Leibniz-Institut für Arbeitsforschung an der TU Dortmund (IfADo)","other","article","10.17179/excli2026-9310",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054351","Redefining diabesity management: Tirzepatide's role in improving cardiovascular outcomes","Mohammad Atiqur-Rahman","2025","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other","article","10.3329/jacedb.v4i20.84909",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054352","Passage du dulaglutide au tirzépatide dans le DT2 : analyses en sous-groupes de l’essai SURPASS-SWITCH","F. Logeay","2025","Annales d Endocrinologie","other","article","10.1016/j.ando.2025.101850",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054353","EE329 COST-EFFECTIVENESS ANALYSIS OF GLP-1 RA TO PREVENT TYPE 2 DIABETES AMONG TEENAGERS IN THE UNITED STATES","Satoshi Koiso","2026","Value in Health","other","article","10.1016/j.jval.2026.03.627",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054354","Combination Gastrokinetic Therapy for the Treatment of Gastrointestinal Side Effects of GLP-1 Receptor Agonists: A Randomized Controlled Trial","Abdel Raouf Fouad","2024","International Journal of Gastroenterology Research","randomized_trial","article","10.33545/26646439.2024.v6.i2a.22",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054355","The Role of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Cardiovascular Complications in Type 2 Diabetes Mellitus","Saffanah Rizkah Muttaqinah Anwar","2026","Journal of Asian-African Focus in Health","randomized_trial","article","10.71435/741778",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054356","The Effect of Dulaglutide on Metabolic Adaptation in Patients with Type 2 Diabetes Mellitus and Obesity","D.G. Gusenbekova","2024","Doctor Ru","other","article","10.31550/1727-2378-2024-23-4-54-59",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054357","Efficacy of liraglutide in combination therapy of patients with psoriasis combined with metabolic disorders: a meta-analysis of observational and controlled studies","T. V. Korotaeva","2025","Obesity and metabolism","systematic_review","article","10.14341/omet13204",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054358","In adults on antipsychotic therapy who develop weight gain or metabolic syndrome, does treatment with GLP‑1 receptor agonists compared with placebo or standard care improve weight and metabolic outcomes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18870741",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054359","Algorithmic Approach to Pharmacotherapy in Obesity Management and Diabetes, Considering Comorbidities and Medication Suitability: Introducing the G-SLIM™ Algorithm","Zaid W. Jabbar","2026","International Journal of Diabetes & its Complications","other","article","10.64030/2573-8895.04.01.04",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054360","What are effective drug therapies for managing semaglutide-induced constipation when fibers don't work?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17805923",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054361","Innovative imaging for the assessment of cardiovascular risk modulation","R.F. Oostveen","2025","UvA-DARE (University of Amsterdam)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0054362","Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence","Timothy Reid","2012","Clinical Diabetes","other_trial","article","10.2337/diaclin.30.1.3",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054363","Comment remdier la pnurie","Marc Donath","2023","Bulletin des Médecins Suisses","other","article","10.4414/bms.2023.22167",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054364","Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes","Gagik Radikovich Galstyan","2017","Diabetes Mellitus","other","article","10.14341/dm8804",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054365","Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials","Wojciech. Kijowski","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.54.70307",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054366","Unraveling the oxidative stress inflammation nexus in metabolic syndrome and therapeutic opportunities","Priscilla Oluwabusayomi Ojo","2026","Discover Medicine","other","article","10.1007/s44337-026-00686-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054367","Does initial therapy with a GLP-1 agonist in adults diagnosed with type 2 diabetes mellitus lead to better outcomes than traditional initial therapy with metformin?","Starr Harmon","2023","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001828",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054368","SAT-662 GLP-1 And Advanced NASH: Impact On Liver Fibrosis Regression","Ana Clara Bocato","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.098",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054369","Optimizing the Clinical Use of the GLP-1 Receptor Agonist Exenatide Once Weekly","Susan M. LaRue","2013","Diabetes Spectrum","other","article","10.2337/diaspect.26.1.46",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054370","Metabolic Enzyme‐Inspired Molecular Clusters for Advanced Type 2 Diabetic Complications by Alleviating Immunosuppression","Si Sun","2025","Advanced Materials","other","article","10.1002/adma.202518331",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054371","0892 Photoinduced lichenoid dermatitis resembling lichen planus actinicus in the setting of sertraline, aripiprazole, and tirzepatide therapy","I.M. Trenholm","2026","Journal of Investigative Dermatology","other","article","10.1016/j.jid.2026.06.923",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054372","Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1","David G. Parkes","2001","Drug Development Research","preclinical","article","10.1002/ddr.1195",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054373","The Pharmacist's Role in the Use of Incretin‐Based Therapies for Weight Management: An Opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy","Sara E. Lingow","2025","JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY","other","article","10.1002/jac5.70111",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054374","Novel tirzepatide: A torchbearer in type 2 diabetes mellitus and obesity","Arfan Musaliyar","2026","Journal of Medical Society","other","article","10.4103/jms.jms_28_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054375","What therapy is effective for weight loss while taking olanzapine?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18324883",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054376","Influência dos hormônios ovarianos na ação da Liraglutida no rim de ratas SHR","Felipe Tonon Firmino","2023","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0054377","Editorial: Integrated PK/PD and drug metabolism approaches in drug development and evaluation","Fenglei Huang","2026","Frontiers in Pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1941847","42682743",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0054378","ACHIEVE-2: Orforglipron vs. Dapagliflozin bei unzureichend kontrolliertem Typ-2-Diabetes","Juliane Weiner","2026","Die Diabetologie","other","article","10.1007/s11428-026-01510-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054379","A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes","Yogish C. Kudva","2025","Obstetrical & Gynecological Survey","randomized_trial","article","10.1097/ogx.0000000000001463","41194356",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054380","Ten Minutes Hard","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22122281",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0054381","Sarcopenia as a Risk of Modern Obesity Treatments: A Review of Molecular Mechanisms and Prevention Strategies","Anna Meiliana","2025","The Indonesian Biomedical Journal","narrative_review","article","10.18585/inabj.v17i6.3583",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054382","Semaglutide and the Skin: An Overview of Current Evidence","Natalia Gołąbek","2026","Quality in Sport","nonrandomized_study","article","10.12775/qs.2026.50.67988",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054383","origins of type 2 diabetes medications","Clifford J. Bailey","2022","British Journal of Diabetes","other","article","10.15277/bjd.2022.388",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054384","OR3-24 | Impact Of Glp-1 Receptor Agonists On Clinical Outcome In Non-DIabetic Obese Patients With Non-Rheumatic Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement","Godbless Ebruvwiyor Ajenaghughrure","2025","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2025.102720",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054385","CO151 Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With the Risk of Developing Dementia in People With Type 2 Diabetes Mellitus","Danny J.J. Wang","2023","Value in Health","other","article","10.1016/j.jval.2023.09.223",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054386","Various Approaches and Future Prospective for Therapies for Diabetes: A Review","Yogesh K. Tiwari","2024","International Journal of Pharmaceutical Quality Assurance","narrative_review","article","10.25258/ijpqa.15.3.88",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054387","Use of glutide class drugs for treating type 2 diabetes and obesity in family medicine","Vsevolod Vladimirovich Skvortsov","2026","Spravočnik vrača obŝej praktiki (Journal of Family Medicine)","other","article","10.33920/med-10-2603-04",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054388","Anti-Obesity Effects of Artocarpus integer Stem Bark Extract via Appetite and Lipid Metabolism Modulation in Obese Rats","Anton Bahtiar","2026","Applied Biosciences","preclinical","article","10.3390/applbiosci5030079",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054389","(470) Preservation of Lean Mass under GLP-1/GIP-Based Pharmacotherapy: Effects of Testosterone and Resistance Training – A Five-Arm, Randomized, Open-Label Parallel-Group Study in Obese Men","F Sommer","2026","The Journal of Sexual Medicine","randomized_trial","article","10.1093/jsxmed/qdag118.413",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054390","Efficacy and safety of Glucagon-Like Peptide-1 receptor agonists in polycystic ovary syndrome: A systematic review and Meta-Analysis","Yeri Estu Risunang","2026","Perinatal Journal","systematic_review","article","10.57239/prn.26.0342002",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054391","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92708-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054392","THE ROLE OF GLP-1RECEPTOR AGONIST IN MODULATING ALCOHOL INTAKE: INSIDES FROM SEMAGLTIDE THERAPY","Mekala Anusha","2025","International Journal of Research in Pharmacology & Pharmacotherapeutics","other","article","10.61096/ijrpp.v14.iss4.2025.759-775",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054393","WCN26-6327 SEVERE HYPOMAGNESEMIA IN A DIABETIC PATIENT ON MULTIPLE LONG-TERM MEDICATIONS","Yusuke Sumitani","2026","Kidney International Reports","other","article","10.1016/j.ekir.2026.103840",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054394","Anti-Diabetic Drugs & Cancer Risk Challenge","A. Abdel-Mageed Eman","2019","Diabetes & its Complications","nonrandomized_study","article","10.33425/2639-9326.1053",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054395","Data Mining Approach to Estimate the Duration of Drug Therapy from Longitudinal Electronic Medical Records","Olga Montvida","2017","The Open Bioinformatics Journal","nonrandomized_study","article","10.2174/1875036201709010001",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054396","What are the clinical considerations and guidelines for switching a patient from tirzepatide to semaglutide for the management of type 2 diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17717867",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054397","Impact of agonists of glucagon-like peptide-1 receptor in individuals with type 2 diabetes: A meta-analysis","Mohamed, S. Imam","2025","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.17906204",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0054398","Tirzepatide: A Paradigm Shift in the Management of Type 2 Diabetes and Obesity","Rutuja Anil Sonawane","2026","Journal of Bio-X Research","other","article","10.34133/jbioxresearch.0092",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054399","The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature","Jakub Waszczyński","2025","Quality in Sport","narrative_review","article","10.12775/qs.2025.37.57253",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054400","Oltre il controllo metabolico: GLP1-RA e riduzione del rischio di tumori legati all’obesità","Martina Botta","2026","L Endocrinologo","other","article","10.1007/s40619-026-01761-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054401","Effectiveness of Tirzepatide and Semaglutide Within a Hybrid Care Model with Exploratory Dose–Response Analyses: A Real-World Evidence Study","Hala Zakaria","2025","Diabetes Technology and Obesity Medicine","nonrandomized_study","article","10.1177/29986702251404471",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054402","How does GLP-1 affect inflammatory conditions?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20445019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054403","How do GLP-1 agonists affect bone mineral density and fracture risk in patients?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20281026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054404","P354 Efficacité du liraglutide sur le contrôle glycémique et pondéral dans la vraie vie","J.P. Courrèges","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30467-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054405","What is the best treatment for a 50-year-old obese patient with type 2 diabetes and normal renal function?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19960567",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054406","WCN26-5648 EVIDENCE-BASED POSITIONING OF SGLT2IS AND GLP-1 RAS IN THE MANAGEMENT OF CHRONIC KIDNEY DISEASE WITH TYPE 2 DIABETES AND OVERWEIGHT/OBESITY: A SYSTEMATIC LITERATURE REVIEW","Yehuda Handelsman","2026","Kidney International Reports","narrative_review","article","10.1016/j.ekir.2026.104628",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0054407","Current trends in pharmacotherapy of overweight and obesity","Anna Ürgeová","2025","Vnitřní lékařství","other","article","10.36290/vnl.2025.099",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054408","As consequências clínicas do uso de Ozempic para tratamento da obesidade: uma revisão de literatura","Rhamid Kalil Trabulsi","2023","Brazilian Journal of Health Review","other","article","10.34119/bjhrv6n3-305",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054409","Current and Innovative Molecular Targets in Diabetes Mellitus Therapy: A Systematic Review","Divya Pathak","2026","Current Signal Transduction Therapy","systematic_review","article","10.2174/0115743624488705260825073021",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0054410","ROLE OF LIRAGLUTIDE IN A MAJOR COMPLICATION OF DIABETES: A CRITICAL REVIEW OF CLINICAL STUDIES","Gaurav Gupta","2018","Bulletin of Pharmaceutical Research","randomized_trial","article","10.21276/bpr.2018.8.1.4",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054411","In-clinic Patient Conversations on Improving Obesity Care with Glucagon-Like Peptide-1 Receptor Agonist","T. Thiyagarajan","2026","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_23_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054412","The Effectiveness of SGLT-2 Inhibitors vs GLP-1 Receptor Agonists in Enhancing Kidney Function and Glycemic Control for Diabetes Mellitus Patients with CKD: A Narrative Review","Putu Ngurah Pradnya Wibawa","2026","Babali Nursing Research","nonrandomized_study","article","10.37363/bnr.2026.71506",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0054413","Is there evidence of weight and diabetic control benefits from using GLP-1 agonists in patients with LADA diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18769487",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054414","Molecular mechanisms and emerging pharmacotherapies of insulin resistance","Sachin Dangi","2026","International Journal of Pharmacology and Clinical Research","other_trial","article","10.33545/26647613.2026.v8.i4a.243",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054415","06 How to measure and manage cardiovascular risk in SLE: from data to daily clinical practice","Lévi-Dan Azoulay","2026","Abstracts","other","article","10.1136/lupus-2026-la.6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054416","Gut–Brain–GLP-1 Axis Beyond Glycemic Control: Emerging Neuroprotective and Anti-Obesity Mechanisms","Sourabh Kosey","2026","Current Research in Diabetes & Obesity Journal","other","article","10.19080/crdoj.2026.18.555998",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054417","When Depression Mimics Dementia: A Case of Acute Cognitive Decline in Later Life","Maneesha Kallukkadan Paul","2026","BJPsych Open","case_report","article","10.1192/bjo.2026.11788",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054418","Should a GLP-1 receptor agonist be used with bolus insulin?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17680488",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054419","PD55 Living Recommendations Within A Type 2 Diabetes Mellitus Guideline","Soledad Isern de Val","2024","International Journal of Technology Assessment in Health Care","randomized_trial","article","10.1017/s0266462324003131",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054420","Repurposing antihyperlipidemic drugs beyond lipid lowering: In silico approach into its GLP-1 receptor agonist potential","Kerem Buran","2026","Journal of Research in Pharmacy","other","article","10.12991/jrespharm.1822102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054421","What are the current first-line treatments for managing type 2 diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20703788",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054422","Semaglutide in obesity-related knee osteoarthritis: Interpreting STEP 9 and implications for practice","Lemeng Ren","2026","The Innovation Medicine","other","article","10.59717/j.xinn-med.2026.100244",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054423","Comprehensive review on the emerging role of liraglutide in MASLD and MASH","Sainath Ganesh Gadewar","2025","International Journal of Gastroenterology Research","narrative_review","article","10.33545/26646439.2025.v7.i1a.11",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054424","What factors influence the effectiveness of semaglutide in the Indian population?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20565813",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054425","A brief review on newer Glucagon like Peptide-1 analogues","B Dharmaraj","2020","International Journal of Preclinical and Clinical Research","narrative_review","article","10.51131/ijpccr/v1i1.7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054426","Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care","Timothy Reid","2013","Clinical Diabetes","other","article","10.2337/diaclin.31.4.148",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054427","USO DA RETATRUTIDA NO TRATAMENTO DA ESTEATOSE HEPÁTICA E OBESIDADE: REVISÃO INTEGRATIVA","Gabriela Vitória dos Santos","2026","LUMEN ET VIRTUS","nonrandomized_study","article","10.56238/levv17n62-013",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054428","5.22 Comparing Psychiatric Safety Profiles of Semaglutide and Metformin in Pediatric Patients: A Retrospective Study","Brianna M. Papoutsis","2025","Journal of the American Academy of Child & Adolescent Psychiatry","nonrandomized_study","article","10.1016/j.jaac.2025.08.407",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054429","26-A-16318-ACC COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS VERSUS BARIATRIC SURGERY IN PATIENTSUNDERGOING ATRIAL FIBRILLATION ABLATION","Harsh Patel","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.145",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054430","1067-OR: A Multicenter Trial Assessing the Efficacy and Safety of the Novel Twiist Automated Insulin Delivery (AID) System in Adults with Insulin-Treated Type 2 Diabetes (T2D)","Carol Levy","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1067-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054431","Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Heart Failure: A Systematic Review","Evira Agustina Putri","2025","Medicinus","systematic_review","article","10.19166/med.v14i3.10164",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054432","Potential effect of GLP-1 RA in reducing arterial stiffness in diabetic patients: a systematic review and meta-analysis","C.C. Soekamto","2025","Diabetes Research and Clinical Practice","systematic_review","article","10.1016/j.diabres.2025.112542",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0054433","Obesity and Semaglutide: Benefits and Risks","Centro de Información de Medicamentos de la Universidad Nacional","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.15346189",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054434","1323-OR: Zenagamtide Targets Key Feeding-Related Brain Regions and Induces Weight Loss by Preferentially Reducing Consumption of Unhealthy Solid and Liquid Diets in Rats","David Ipsen","2026","Diabetes","preclinical","article","10.2337/db26-1323-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054435","EP509 - ECE_3401 - Effect of semaglutide injection in physical function: a post-hoc analysis of a phase III study of in weight management","Unnikrishnan Gopalkrishnan","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.996",null,null,"CTRI:CTRI/2025/04/085487",null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0054436","Cardiorenal and survival outcomes of GLP-1 receptor agonist and SGLT-2 inhibitor therapy in diabetic kidney disease: two stage-stratified real-world comparisons","Mona Mohammed Alshahrani","2026","Scientific Reports","nonrandomized_study","article","10.1038/s41598-026-63134-6",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054437","THE ROLE OF GLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF PSORIASIS: A POTENTIAL THERAPEUTIC APPROACH","Antoni Majda","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.1(49).2026.5073",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054438","Overcoming Barriers to Adoption of Glucagon-Like Peptide-1 Antagonists in India","Shweta Arora","2025",null,"other","article","10.38124/ijisrt/24may2403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054439","Histological assessment of the hippocampus in type 2 diabetic rats: Neuroprotective roles of exenatide, empagliflozin, and quercetin","İLKNUR ÜNDAĞ","2026","Revista Científica de la Facultad de Ciencias Veterinarias","preclinical","article","10.52973/rcfcv-e362847",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054440","Exploring Reversal of Type 2 Diabetes: A Path Toward Sustainable Health","Maida Ali","2025",null,"other","article","10.61440/jmdr.2025.v2.07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054441","Cotadutide as an Innovative Approach to Glycemic Control and Weight Reduction in Patients with Type 2 Diabetes - A Contemporary Review","Zuzanna Wątek","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.54.70704",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054442","Diabetes, Obesity, and Metabolic Syndrome","Christian Basile","2026",null,"other","article","10.1201/9781003642497-17",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0054443","USO INDISCRIMINADO DE MOUNJARO E CIRCULAÇÃO DE PRODUTOS DE ORIGEM DUVIDOSA COMO EXPRESSÃO DE CRISE SANITÁRIA NA SAÚDE COLETIVA","Lucas Andrade Menezes","2026","Revista Multidisciplinar do Nordeste Mineiro","other","article","10.66104/qc09as49",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054444","Study on LDL-cholesterol lowering effect and mechanism of GLP-1 receptor agonist in Ldlr -/- mice","Mika Hori","2019","The Molecular Biology Society of Japan","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054445","Can GLP-1 be taken with antipsychotics?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17749298",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054446","Glucagon-Like Peptide-1 Receptor Agonists in Asthma and Chronic Obstructive Pulmonary Disease – A Review of the Latest Research","Aleksandra Sagan","2025","Archiv Euromedica","narrative_review","article","10.35630/2025/15/3.309",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054447","Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment","Mohsina F. Patwekar","2025","BIO Integration","other","article","10.15212/bioi-2024-0047",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054448","Importance of glycemic control.","Edward J. Shahady","2011","PubMed","other","article",null,"21912776",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054449","Tirzepatide vs Semaglutide in Coronary Artery Disease and Obesity: Real-World Cardiovascular Outcomes Analysis from the TriNetX Research Network","Ekow Essien","2025","American Heart Journal","nonrandomized_study","article","10.1016/j.ahj.2025.07.060",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054450","Incretins beyond weight and hyperglycemia management: a consensus statement by AASD","Inass Shaltout","2026","The Egyptian Journal of Internal Medicine","nonrandomized_study","article","10.1186/s43162-026-00689-w",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054451","Positioning of Semaglutide among Evolving Guidelines in the Management of Obesity and Related Comorbidities","Mohan Badgandi","2026","International Journal of Diabetes and Technology","other_trial","article","10.4103/ijdt.ijdt_20_26",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0054452","S2574 Pancreatic Aftershock: Acute Pancreatitis With Recent Semaglutide Use","Rahul Borra","2024","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0001039664.96658.f0",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0054453","Use of glucagon-like peptide-1 receptor agonists in patients with diabetes mellitus type 2 and cardiovascular disease: A review study","Suljo Čelebić","2024","Galenika Medical Journal","nonrandomized_study","article","10.5937/galmed2412038c",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054454","Repurposing incretin-based therapies for alcohol use disorder: a systematic review of efficacy and safety relative to standard pharmacotherapies in a recent comparative context","Aristomenis G. Alevizopoulos","2026","Therapeutic Advances in Psychopharmacology","systematic_review","article","10.1177/20451253261457548",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0054455","Advancements in RP-HPLC Methodology for Tirzepatide Estimation in Human Plasma: Development, Validation, and Applications","Vaishnavi N.Bitne","2025","Asian Journal of Pharmaceutical Research and Development","other","article","10.22270/ajprd.v13i3.1579",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054456","Optimizing the Efficacy of Anti-Obesity Medications: A Practical Guide to Personalizing Incretin-Based Therapies","Afua K. Takyi","2025","Current Treatment Options in Gastroenterology","other","article","10.1007/s11938-024-00465-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054457","RC11.1 - ECE_1833 - Additive effects of semaglutide and peptide YY3-36 dual agonism on HFpEF: focus on mitochondrial function in obese rats","Niklas Geiger","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.203",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0054458","Exercise alone and in combination with liraglutide improves cardiorespiratory fitness and physical functioning during weight loss maintenance","S�ren Buus Jensen","2020","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054459","CRISE SANITÁRIA E INOVAÇÃO FARMACOLÓGICA: UMA ANÁLISE MULTIDIMENSIONAL DO USO DA TIRZEPATIDA (MOUNJARO) E OS DESAFIOS DA VIGILÂNCIA NO BRASIL","Eliel Messias dos Santos","2026","Revista Tópicos.","other","article","10.70773/revistatopicos/786067351",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054460","Practice Assessment of Registered Dietitians' (RD) in Nutritional Management of Adolescents Managed with Glucagon-like Peptide (GLP-1) Agonist for Weight Management","C. Figueredo","2025","Journal of the Academy of Nutrition and Dietetics","other","article","10.1016/j.jand.2025.06.309",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054461","From Sports Performance to Healthy Aging, Creatine Finds New Momentum From phosphocreatine and athletic performance to brain bioenergetics, cellular resilience and muscle preservation during pharmacological weight loss","Jose M. Lopez","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22901003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054462","Inibidores de SGLT2 e agonistas de GLP-1 na ICFEp x ICFEr: uma revisão de literatura","ANDRIELLE OLIVEIRA DE ALMEIDA","2026","Editora Pasteur eBooks","other","article","10.59290/6203010883",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0054463","Rehabilitation for Alcohol Use Disorder: Interdisciplinary Advances, Challenges, and Opportunities","Guilin Meng","2026","ENGINEERING Health & Rehabilitation Engineering","other","article","10.2738/enghre.2026.0008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054464","Ageing reserve governs tipping and drug response in Parkinsonian multimorbidity","Ying Ye","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22004483",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054465","64828 Synergistic Efficacy and Safety of Poly-L-Lactic Acid Biostimulator and Hyaluronic Acid Filler for Facial Fullness post Weight Loss due to Glucagon-like Peptide-1 Receptor Agonist Medication","Michael T. Somenek","2025","Journal of the American Academy of Dermatology","other","article","10.1016/j.jaad.2025.05.1211",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054466","C-54 | Association of Tirzepatide Use with Clinical Outcomes After TAVR in Obese Patients: A Propensity-Matched Real-World Study","Ibrahim Mortada","2026","Journal of the Society for Cardiovascular Angiography & Interventions","nonrandomized_study","article","10.1016/j.jscai.2026.104790",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0054467","Safety of glucagon-like peptide-1 agonists: data from the Russian National pharmacovigilance system","Yu. M. Gomon","2026","Real-World Data & Evidence","nonrandomized_study","article","10.37489/2782-3784-myrwd-092",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054468","WCN26-1383 Recurrent Paralytic Ileus Associated with Tirzepatide Administration in a 72-Year-Old Male after Robot-Assisted Radical Cystectomy with Ileal Conduit Construction","Shinichiro Koga","2026","Kidney International Reports","other","article","10.1016/j.ekir.2026.103812",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054469","P356 Effets du Bydureon® sur le contrôle glycémique et le poids: résultats préliminaires","Vanessa Preumont","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30469-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054470","Incretin-based Therapies for Type 2 Diabetes—Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","Timothy Silleck Bailey","2011","US Endocrinology","other","article","10.17925/use.2011.07.02.82",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054471","GLP-1 Receptor Agonists: Potential Psychiatric Risks and Clinical Implications","Georgios Schoretsanitis","2025","Psychopharmakotherapie","other","article","10.52778/ppt20250025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054472","GLP-1 Receptor Agonists in Alcohol Use Disorder: Neurobiological Mechanisms and Therapeutic Potential","Zuzanna Czach","2025","Journal of Education Health and Sport","randomized_trial","article","10.12775/jehs.2025.85.66493",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054473","Characteristics of Patients with Type 1 Diabetes (T1D) and CKD Receiving Novel Kidney Protective Therapies (KPT)","Maria Luiza Caramori","2024","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20241gdh8x5e",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054474","Safe and Effective Use of the Single-Use Pen for Injection of Once Weekly Dulaglutide in Injection-Naïve Patients with Type 2 Diabetes","Glenn Matfin","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.072",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054475","Development and Validation of a Predictive Model for Glycemic Response to Dorzagliatin in Type 2 Diabetes: A Retrospective Real-World Study","Yue Liu","2025","X-Disciplinarity","nonrandomized_study","article","10.63174/xdi.dbxs5758",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054476","What are the important adverse effects of semaglutide?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17794331",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054477","Bridging the Gap: Pragmatic Strategies to Overcome Barriers in the Implementation of Cardiometabolic Care","Lauren Eyadiel","2025","Journal of Cardiac Failure - Intersections","other","article","10.1016/j.yjcafi.2025.08.015",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054478","EPH113 Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population","Shivani Aggarwal","2025","Value in Health","other","article","10.1016/j.jval.2025.04.644",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054479","Should a GLP-1 receptor agonist be combined with bolus insulin in treatment?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17760345",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054480","26-YIA-7853-ACC GLP-1 RECEPTOR AGONISTS USE IN OBESE PATIENTS WITH STABLE HEART FAILURE WITH REDUCED EJECTION FRACTION: A TARGET-TRIAL EMULATION","Kuan-Yu Chi","2026","Journal of the American College of Cardiology","other_trial","article","10.1016/j.jacc.2026.02.4865",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054481","Semaglutide and the skin: A brief review of dermatologic implications","Arisha Salam","2025","Cosmoderma","narrative_review","article","10.25259/csdm_97_2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054482","Total Healthcare Costs and Cost Savings after Bariatric Surgery and Glucagon Like Peptide (GLP-1) Receptor Agonists Treatment for Obesity and Diabetes Vary with Insurance Coverage","Mohammad E. Alomari","2026","Surgery for Obesity and Related Diseases","other","article","10.1016/j.soard.2026.09.012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054483","OR1-7 | Impact of GLP-1 RA on Coronary Disease Progression After PCI in Obese Adults Without Diabetes: Synergy With Statin Therapy","Sultana Jahan","2026","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2026.104410",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054484","The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis.","Salman Jajja","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.11000",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0054485","Early-onset type 2 diabetes and kidney disease in a growing surgical generation: insights from a global burden analysis","YiQing Yang","2026","International Journal of Surgery","nonrandomized_study","article","10.1097/js9.0000000000004822","41556923",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054486","A Shift from Diabetic Clinical Therapy to Aesthetic Use: The Ozempic Phenomenon","Nadya Theresia Sibarani","2026","Journal of Biosciences and Medicines","other","article","10.4236/jbm.2026.142019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054487","What will we see in diabetes in the next 10 years?","Zachary T. Bloomgarden","2024","Journal of Diabetes","other","article","10.1111/1753-0407.13594","38890754",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054488","Prevalence and Impact of Obesity in Patients With Diabetes and Myocardial Infarction","Viveca Ritsinger","2025","JACC Advances","nonrandomized_study","article","10.1016/j.jacadv.2025.101644","40080921",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054489","DIABETES MELLITUS: PATHOPHYSIOLOGY, CLASSIFICATION, DIAGNOSIS, TREATMENT, AND NEW TREATMENT APPROACHES","Vikas Gupta","2026","GLOBAL JOURNAL OF PHARMACEUTICAL AND SCIENTIFIC RESEARCH","other","article","10.66204/gjpsr-1240-2026-2-8-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054490","Specific Guidance for Women Embarking on Pregnancy with Cardiovascular Diseases -Precautionary Measures for Avoidance of Complications by Utilization of Multidisciplinary Team Strategy -A Review","Obstetrics & gynecology (Reproductive neuroendocrinology & Infertility specialist), Punjab, India","2025",null,"preclinical","article","10.61440/jgor.2025.v3.45",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054491","The Interplay Between Insulin Resistance, Affective Dysregulation, and Binge Eating in Obesity: Toward an Integrated Biopsychosocial Treatment Model","Luna Carpinelli","2026","Obesities","other","article","10.3390/obesities6010001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054492","What are the cardiovascular benefits of using GLP-1 agonists in patients with risk factors for type 2 diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18371407",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054493","Untapped diamonds for untamed diabetes: The α-glucosidase inhibitors","Sanjay Kalra","2014","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.129102","24741507",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054494","“Efficacy and safety of liraglutide in pediatric Obesity:A systematic review and meta analysis of randomized controlled trials”","Abdullah Afridi","2025","Obesity Medicine","systematic_review","article","10.1016/j.obmed.2025.100605",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0054495","The Varanasi Declaration 2026: an India-specific consensus policy framework for integrated cardiovascular–kidney–metabolic care","Ashutosh Mishra","2026","The Lancet Regional Health - Southeast Asia","nonrandomized_study","article","10.1016/j.lansea.2026.100865",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054496","GLP-1 수용체 작용체가 불러온 비만 치료의 변화 ver.1","Yejin Ho","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22538004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0054497","Cardiovascular Outcomes in Obese Patients with Sleep Apnea Treated with Tirzepatide Versus Bariatric Surgery: A Propensity-Matched Analysis Using the TriNetX Research Network","Ekow Essien","2025","American Heart Journal","nonrandomized_study","article","10.1016/j.ahj.2025.07.039",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054498","A19-09 Comparative Cardiopulmonary Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Older Adults With Pulmonary Hypertension: A Real-world Propensity-matched Analysis","A Chaaban","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.5485",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054499","The early initiation of treatment of overweight and obesity with liraglutide in patients with different obesity phenotypes","Stefan Farsky","2025","Journal of Clinical Images and Medical Case Reports","other","article","10.52768/2766-7820/3415",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054500","Combination Therapy of SGLT 2 Inhibitors and GLP 1 Receptor Agonists for Glycaemic Management through Weight Reduction","Vinod Kumar","2025","Journal of Drug Delivery and Therapeutics","nonrandomized_study","article","10.22270/jddt.v15i1.6914",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054501","WCN26-4078 EFFECT OF ONCE-WEEKLY SEMAGLUTIDE 1.0 MG ON KIDNEY OUTCOMES BY BASELINE CHARACTERISTICS: EXPLORATORY DATA FROM THE FLOW TRIAL","Srikanth Bellary","2026","Kidney International Reports","other_trial","article","10.1016/j.ekir.2026.104616",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0054502","An evaluation of the public's knowledge regarding the risks associated with weight loss injections in Saudi Arabia","Anas Ali Alhur","2025","Modern phytomorphology","other","article","10.5281/zenodo.14557363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054503","Insulin treatment simplification with iGlarLixi in relatively well-controlled patients with type 2 diabetes","Zoltán Jamal Taybani","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112614",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054504","PERAN ORFORGLIPRON DALAM TATALAKSANA PASIEN DENGAN OBESITAS","Sugianto Mukmin","2026","Ibnu Sina Jurnal Kedokteran dan Kesehatan-Fakultas Kedokteran Universitas Islam Sumatera Utara","other","article","10.30743/ibnusina.v25i2.1231",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054505","GLP-1 receptor agonists in the management of obesity: Metabolic and cardiovascular benefits beyond weight loss","Marina Knebel Bacchieri","2026","International Health Sciences Review","other_trial","article","10.70164/ihsr.v2i2.137",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054506","1164-OR: Prescribing Trends and Comparative Risk of Type 2 Diabetes Progression in Prediabetes by Antihyperglycemic Drug Class","GABRIELA M. SIEW","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1164-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054507","Glucagon-like peptide-1 receptor agonists and tirzepatide in gynecologic cancer therapy: a literature review of their dual effects on weight loss and tumor control","Alicja Pełszyk","2026","Lekarz Wojskowy","narrative_review","article","10.53301/lw/215520",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054508","Ethyl oleate-based in situ forming gel for long-term peptide delivery via water-triggered lamellar phase transition","Huang Lu","2026","Materials & Design","preclinical","article","10.1016/j.matdes.2026.116515",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054509","SUN-675 Very Low Energy Ketogenic Therapy In Combination With Liraglutide As A Synergic Strategy For The Treatment Of Obesity: A Real-world Clinical Evaluation","Elisabetta Camajani","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.185",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054510","Resultados renales de GLP-1 y agonistas duales de GIP/GLP-1: una nueva frontera en nefrología","Martín Gómez-Luján","2025","Imperium Académico Multidisciplinary Journal","other","article","10.63969/xgt2jm52",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054511","Combination of Icovamenib and GLP-1-based Therapeutic Agents Improves Beta Cell Function and Insulin Secretion","Mini Balakrishnan","2025","Metabolism","other","article","10.1016/j.metabol.2025.156226",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054512","Les analogues du GLP1, notamment le Semaglutide, induisent une perte de poids chez les patients en situation d’obésité secondaire à un craniopharyngiome","F. Lambert","2022","Annales d Endocrinologie","other","article","10.1016/j.ando.2022.07.133",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054513","What are the most effective lifestyle and pharmacological interventions for managing obesity?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18154847",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054514","Tirzepatide Use in Overweight and Obese Middle Eastern Patients With Type 1 Diabetes Mellitus","Jessica Abou Chaaya","2026","AACE Endocrinology and Diabetes","randomized_trial","article","10.1016/j.aed.2026.04.003",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054515","EP639 - ECE_3171 - Efficacy and safety of semaglutide injection in weight management: a subgroup analysis in mild renal impairment patients","Unnikrishnan Gopalkrishnan","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1069",null,null,"CTRI:CTRI/2025/04/085487",null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0054516","Getting Ready for Certification","Linda S. McKenna","2023","Journal of Wound Ostomy and Continence Nursing","other","article","10.1097/won.0000000000001037","37966083",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054517","1702-P: Molecular Basis of Type 2 Diabetes Prevention by Semaglutide in SELECT","Dylan M. Belmont-Rausch","2026","Diabetes","randomized_trial","article","10.2337/db26-1702-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054518","What are the comparative long-term health outcomes of patients treated with GLP-1 receptor agonists versus those undergoing bariatric surgery?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20274352",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054519","ROLE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN MANAGING ANTIPSYCHOTIC INDUCED WEIGHT GAIN CAUSING NON-COMPLIANCE IN BIPOLAR DISORDER PATIENTS: A CASE SERIES","Ozge Ozkan","2026","International Journal of Advanced Research","case_report","article","10.21474/ijar01/23462",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054520","MM-852: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Multiple Myeloma and Plasma Cell Disorders: Protective, Harmful, or Both? A Scoping Review","Yagnapriya Chirrareddy","2026","Clinical Lymphoma Myeloma & Leukemia","narrative_review","article","10.1016/s2152-2650(26)02943-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054521","Psychiatric Illness Unmasked by GLP-1 Agonist in Alström Syndrome","Md Alam","2025","Endocrine Practice","other","article","10.1016/j.eprac.2025.09.169",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054522","Is there an association between GLP-1 receptor agonists and chronic cough?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17919905",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054523","TARGETING MULTIPLE PATHWAYS WITH ONE MOLECULE: THE THERAPEUTIC VERSATILITY OF TIRZEPATIDE","Patrycja Jędrzejewska-Rzezak","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(47).2025.3902",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054524","What are the common nutritional deficiencies that patients on GLP-1 receptor agonists may experience?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18423510",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054525","Cardiorenal Syndrome and Contemporary Therapeutic Paradigms in Chronic Kidney Disease: A Comprehensive Narrative Review","Joel Shon D’ sa","2026","International Journal of Research Publication and Reviews","nonrandomized_study","article","10.55248/gengpi.07.0826.2507",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0054526","How does the use of GLP-1 agonists in individuals at risk for type 2 diabetes affect the long-term incidence of metabolic complications?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18371409",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054527","Incretin Mimetics in the Indian Context: Revisiting Exenatide","Santanu Kumar Tripathi","2022","Bengal Physician Journal","other_trial","article","10.5005/jp-journals-10070-7073",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054528","Investigate the incidence and prevalence of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) in patients taking semaglutide (Ozympic).","Muhammad Usman Amiruddin","2025","Journal of Neonatal Surgery","nonrandomized_study","article","10.63682/jns.v14i32s.9542",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054529","Managing Blood Glucose with the Use of Oral Semaglutide and Life Style Modification Among Indian Patients","Amit Bhatnagar","2023","Journal of Endocrinology and Metabolism Research","other","article","10.37191/mapsci-2582-7960-4(1)-032",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054530","753-P: Safety, Tolerability, PK, and Efficacy of MET097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management","Mark Stroh","2025","Diabetes","randomized_trial","article","10.2337/db25-753-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054531","The Ameliorative Effect of Liraglutide (Saxenda® and Victoza®) Treatment on Overweight and Induced Diabetes Mellitus Type 2 in Male Rats.","Hanadi A Hafth","2025","Basrah Journal of veterinary Research","preclinical","article","10.23975/bjvr.2025.166936.1261",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054532","EP636 - ECE_3154 - A subgroup analysis of Phase 3 study of Semaglutide Injection in Type 2 Diabetes Mellitus patients based on BMI: <23 kg/m2, 23 to <25 kg/m2 and ≥25 kg/m2","Dipesh Sonawane","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1066",null,null,"CTRI:CTRI/2025/02/080592",null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0054533","Dose-Response Assessment of Semaglutide: High-Dose-Induced Hepatotoxicity in Male Albino Rats","Fatima Noori Sakr","2026","AMPLITUDO Journal of Science & Technology Innovation","preclinical","article","10.56566/amplitudo.v5i2.616",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054534","S1464 GLP-1 Agonists are Associated With Lower Rates of IBD-Related Complications in Patients With Elevated BMI Compared to Bariatric Surgery: A Nationwide Cohort Analysis","M Housam Nanah","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001035224.59649.53",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054535","What is the best treatment for obesity?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18193519",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054536","Uso de Ozempic para redução de AVCs: o novo oriente pós-SELECT STUDY","Gabriela Carminati Lino","2025","Editora Pasteur eBooks","other","article","10.59290/1029121091",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0054537","SEMAGLUTIDE FOR WEIGHT REDUCTION: A COMPARATIVE ANALYSIS WITH OTHER PHARMACOLOGICAL TREATMENTS","Marta Handzel","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.2(50).2026.5726",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054538","“Oh, oh, oh, Ozempic!”1: The Glamorization of Ozempic and Restrictive Eating Disorders","Serar Omar","2025","SSRN Electronic Journal","other","article","10.2139/ssrn.5243583",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0054539","Pharmacological Modulation of the Nrf2–Keap1 Pathway in Diabetes: Mechanisms, Therapeutic Advances, and Future Directions","Aditi Saxena","2025","Journal for Research in Applied Sciences and Biotechnology","other","article","10.55544/jrasb.4.5.4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054540","Severe Diarrhea Following Tirzepatide Therapy in a Woman with Celiac Disease","Omercan Topaloğlu","2025","DergiPark (Istanbul University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054541","Eicosapentaenoic acid (EPA) and a GLP-1 agonist caused synergistic changes in protein expression and mediators of endothelial endoplasmic reticulum function during inflammation","Samuel C. R. Sherratt","2025","Atherosclerosis","other","article","10.1016/j.atherosclerosis.2025.119699",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054542","Abstract 2970: Anti-diabetic drug, semaglutide, prevents doxorubicin-induced endothelial cell toxicity","Sandra Bakhit","2024","Cancer Research","other","article","10.1158/1538-7445.am2024-2970",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054543","Comprehensive Review of Diabetes Mellitus: Current Perspectives, Challenges, and Emerging Frontiers","Anjana Jayasree","2025","International Journal of Research in Pharmacology & Pharmacotherapeutics","narrative_review","article","10.61096/ijrpp.v14.iss1.2025.67-76",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054544","Impactos dos agonistas do receptor de GLP-1 na eficácia dos anticoncepcionais hormonais orais","Giulia Mara Tomás Bortolato","2026","Revista Master Ensino Pesquisa e Extensão","other","article","10.47224/revistamaster.v11i21.851",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054545","How frequent is acid reflux with injected semaglutide?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.19113461",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0054546","Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.","Zobair M Younossi",null,"Open Access CRIS of the University of Bern","other","article","10.48620/100386",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054547","Angioedema secondary to exenatide","Mariana Esteves","2023","Revista Portuguesa de Endocrinologia Diabetes e Metabolismo","other","article","10.26497/ie220065",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054548","Glucagon-Like Peptide 1 Receptor Agonists in Alzheimer’s Disease","Qiao-Qiao Wang","2023","Neurochemical Journal","nonrandomized_study","article","10.1134/s1819712423020204",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054549","IMPACTO CARDIOVASCULAR DO MOUNJARO EM PACIENTES COM DIABETES TIPO 2: EVIDÊNCIAS ATUAIS E DIREÇÕES FUTURAS","Wilson Espósito Júnior","2025","Aracê.","other","article","10.56238/arev7n12-333",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054550","ITU and Pharmacology: A Single-Axiom View of Drug Discovery, Receptor Pharmacology, ADME, Pharmacogenomics, Antibody Medicines, Vaccines and Immunotherapy, AI Drug Design, and FDA Regulation — Pass-1 Extension Paper #2, Block B 6/6 COMPLETE","Munehiro Terada","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.20258191",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0054551","Early Diabetes Remission Following Tirzepatide-Based Combination Therapy in a Young Indian Adult with Recent-Onset Type 2 Diabetes: A Case Report","Tanuj Diyora","2026","International Journal of Science and Research (IJSR)","nonrandomized_study","article","10.21275/sr26211120026",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054552","Tirzepatide: a dual approach to combat obesity and obstructive sleep apnea","S M Naseem","2025","International Journal of Community Medicine and Public Health","other","article","10.18203/2394-6040.ijcmph20252496",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054553","Should SGLT2 inhibitors be discontinued in the presence of recurrent balanitis, and what are the alternative treatment options?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20093556",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054554","Diabetic Retinopathy: management of glycemic control and the impact of new anti-hyperglycemic drugs","Fosci, M.","2024","The Journal of AMD","other","article","10.36171/jamd24.27.4.8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054555","Longitudinal shifts in diabetes care delivery during the COVID-19 pandemic: implications for post-pandemic models of chronic disease management","HENG YEH","2026","BMC Endocrine Disorders","nonrandomized_study","article","10.1186/s12902-026-02502-9",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054556","Смена парадигмы лечения сахарного диабета 2-го типа – от метаболической коррекции к органопротекции","Т.В. Мохорт","2026","Кардиология в Беларуси","other","article","10.34883/pi.2026.18.3.009",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054557","Efficacy of liraglutide 3 mig therapy in obesity and associated diseases","K. A. Komshilova","2018","Meditsinskiy sovet = Medical Council","other","article","10.21518/2079-701x-2018-4-86-89",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054558","Is GLP-1 RA effective for managing postprandial hypoglycemia?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18421831",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054559","20-PUB: A Meta-Analysis of Real-World Effectiveness of Glucagon-Like Peptide 1s among Patients with Type 2 Diabetes in the United States","Neda Rasouli","2026","Diabetes","systematic_review","article","10.2337/db26-20-pub",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0054560","Utilization of the Nonsteroidal Mineralocorticoid Receptor Antagonist (MRA) Finerenone with or without Previous Steroidal MRA","Zihe Zheng","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024s37vndhj",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054561","Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","Vincent Lingzhi Chen","2024","Hepatology","randomized_trial","article","10.1097/hep.0000000000001112","39422487",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054562","State-of-the-Art Drug Therapies of Obesity","Mikhail Borisovich Antsiferov","2021","Doctor Ru","other","article","10.31550/1727-2378-2021-20-2-45-50",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054563","Sarcopenia in Asian Patients in the Era of SGLT2i and GLP-1RA: A Clinical Concern?","Ahmad Alam","2026","Bangladesh Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/bjem.bjem_30_26",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054564","2820-LB: Durability of Glycemic Improvement With and After GLP-1 Therapy in a Real-World Remote Monitoring Diabetes Program (RMDP)","ROBERTA A. JAMES","2026","Diabetes","randomized_trial","article","10.2337/db26-2820-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054565","0589 Concomitant Aroxybutynin and Atomoxetine (AD109) with GLP-1 Agonists: An Analysis of the SynAIRgy and LunAIRo Trials in Obstructive Sleep Apnea","Patrick Strollo","2026","SLEEP","randomized_trial","article","10.1093/sleep/zsag091.0588",null,null,"ClinicalTrials.gov:NCT05813275; ClinicalTrials.gov:NCT05811247",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054566","What is new in cardiorenal syndrome? A narrative update","Juan S. Serna-Trejos","2026","Revista Colombiana de Cardiología (English Edition)","nonrandomized_study","article","10.24875/rccare.m26000230",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054567","Semaglutide in Hypothalamic Obesity: Lasting Benefits Beyond Weight Loss","Gjersdal, Erlend","2025","VBN Forskningsportal (Aalborg Universitet)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0054568","Remission in Type 2 DM with Personalized Medical Interventions Including Life Style Modification and Appropriate Pharmacotherapy - A Case Report","Kumar Prafull Chandra","2022","Journal of Endocrinology and Metabolism Research","case_report","article","10.37191/mapsci-2582-7960-3(2)-028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054569","Semaglutide and the Heart: Focus on Their Love–Hate Relationship","Ezaan Khan","2026","Hearts","other","article","10.3390/hearts7030022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054570","Optimising hepatology referral in metabolic dysfunction: diabetes and obesity drive advanced fibrosis while GLP-1 receptor agonists remain underused","Antonio Liguori","2026","Digestive and Liver Disease","nonrandomized_study","article","10.1016/j.dld.2026.07.068",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054571","Emerging Role of Natriuretic Peptides in Diabetes Mellitus","Alexander Е. Berezin","2020","Heart and Mind","other","article","10.4103/hm.hm_3_20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054572","Case Report: Dual Orexin Receptor Antagonists (DORAs) as a Target Mitigation Strategy for Tirzepatide-Induced Insomnia in a Patient with Historical Neuroleptic Exposure and Complex Neurodivergence","Grace Lynch","2026","Zenodo (CERN European Organization for Nuclear Research)","case_report","article","10.5281/zenodo.22167864",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0054573","What is the efficacy of semaglutide in achieving weight loss in patients with obesity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18784617",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054574","INDISCRIMINATE USE OF GLP-1 ANALOGUES, SUCH AS SEMAGLUTIDE (OZEMPIC®), FOR AESTHETIC PURPOSES AND MULTIDISCIPLINARY ACTION IN CARE AND RISK PREVENTION","Valdemar Mendes de Morais Filho","2025","Seven Editora eBooks","other","article","10.56238/edimpacto2025.060-023",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0054575","Sa1967 THE IMPACT OF SEMAGLUTIDE ON RETAINED GASTRIC CONTENTS DURING ENDOSCOPY","Garrick H. Gu","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01844-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054576","PLEIOTROPIC EFFECTS OF GLP-1 RECEPTOR AGONISTS: A LITERATURE REVIEW","Wiktoria Marzec","2026","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.1(49).2026.4911",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054577","DPP-4阻害薬併用の臨床的有用性を評価したMODY3の2例","美保 滝澤","2017","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054578","Effect of GLP-1 receptor agonism on anthracycline- and HER2-targeted therapy–induced cardiac dysfunction and systemic inflammation in non-diabetic preclinical models.","Vincenzo Quagliariello","2026","Journal of Clinical Oncology","randomized_trial","article","10.1200/jco.2026.44.16_suppl.e12524",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0054579","Survodutide for Treatment of Obesity: Baseline Characteristics in the SYNCHRONIZE™-1 Phase 3 Trial","Carel W. le Roux","2026","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0046-1819897",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0054580","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-97970-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054581","What medications are available to treat elevated fasting insulin levels?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17929485",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054582","ITU Tier 1+ #32: Pharmaceuticals (K_pharma)","Munehiro Terada","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.20281172",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0054583","Sex and Gender in Science, Medicine, and Nephrology","Farah Wehbe","2025","Clinical Journal of the American Society of Nephrology","other_trial","article","10.2215/cjn.0000000677","39908095",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0054584","Experience with Oral Semaglutide in Clinical Practice: Efficacy and Safety Data from the Multicentric Croatian Study","Klara Ormanac","2025","Diabetology","nonrandomized_study","article","10.3390/diabetology6110127",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054585","Emerging Therapeutic Strategies Targeting Insulin Resistance in PCOS to Improve Fertility","Mishaal Noor","2026","Journal of Health Wellness and Community Research","randomized_trial","article","10.61919/50evkb85",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054586","A real-world analysis on the impact of GLP-1 receptor agonist use on all-cause mortality and hematological outcomes in AML/CML patients with obesity","Muluken Megiso","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-2857",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054587","Do glucagon like peptide-1 receptor agonists lead to long-term weight loss?","Amna Karim","2022","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001725",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054588","1254-OR: Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin","MICHELLE D. WELCH","2026","Diabetes","randomized_trial","article","10.2337/db26-1254-or",null,null,"ClinicalTrials.gov:NCT06192108","S001651","openalex","FALSE","paywalled","1","FALSE","article"],["R0054589","Effect Of Withania Coagulans And Liraglutide On Serum Glp-1, Postprandial And Fasting Blood Glucose In Streptozotocin Induced Diabetic Rats","Abdul Rahim Samad","2019","Journal of Bahria University Medical and Dental College","randomized_trial","article","10.51985/jbumdc2018125",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054590","Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials","Ying Lü","2024","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.15822","39075921",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054591","Liraglutide-Mediated Renoprotection in Type 1 Diabetes: Modulating M1/M2 Macrophage Balance via NOX/TRP Cross-Talk","Natalie Youssef","2024","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2024v6fcttj1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054592","A IMPORTÂNCIA DA INTERVENÇÃO NUTRICIONAL NO TRATAMENTO DA OBESIDADE COM TIRZEPATIDA (MOUNJARO)","Diulio César Lopes Pechim","2026","REVISTA MULTIDISCIPLINAR INTEGRADA - REMI","other","article","10.61164/n0gxpf53",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054593","Tirzepatide and Obesity: A Narrative Review","Arya Singh","2025","Advances in Human Biology","randomized_trial","article","10.4103/aihb.aihb_244_25",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0054594","Abstract #1307599: Successful Treatment of a Case of Congenital Lipodystrophy With 1 mg Subcutaneous Semaglutide","Rana Almudhammed","2022","Endocrine Practice","case_report","article","10.1016/j.eprac.2022.10.021",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054595","Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients","Takehiro Kawata","2013","Diabetology International","other","article","10.1007/s13340-013-0137-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054596","YOUNG-ONSET TYPE 2 DIABETES FROM THE TARGET T2D STUDY COHORT IN MALAYSIA:","Siew Hui Foo","2023","Journal of the ASEAN Federation of Endocrine Societies","nonrandomized_study","article","10.15605/jafes.038.afes.17",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054597","EP657 - ECE_2738 - On the road to type 2 diabetes: metabolomic profiling for early detection, risk stratification, and complementary assessment of metabolic trajectories","Diana Drettwan","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.1081",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054598","1469-P: Real-World Weight Loss with Digital Health with and without GLP-1 Therapy","Yifat F. Hershcovitz","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1469-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054599","Liraglutide in Obesity Management: Evidence of Weight and Lipid Improvements in a UAE Cohort","Fathelrahman Ahmed","2025","The Open Public Health Journal","nonrandomized_study","article","10.2174/0118749445420434250723055026",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054600","Agonistas Glucagon Like Peptide – 1 (GLP-1) y retraso del vaciamiento gástrico: Consideraciones anestésicas y clínicas","Gonzalo Irizaga Dávila","2024","Revista Chilena de Anestesia","other","article","10.25237/revchilanestv53n1-06",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054601","Letter to the Editor: Fibroblast activation protein and the CaMKIIδ–Calcineurin–NFAT pathway in diabetic HFpEF","Xinyu Nie","2026","Clinical Science","other_trial","article","10.1042/cs20258366","41510778",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","letter"],["R0054602","Bioanalytical Method Development and Validation for Empagliflozin and Semaglutide: A Comparative Review","Krishana Kumar Sharma","2025","Journal of Carcinogenesis","narrative_review","article","10.64149/j.carcinog.24.4s.905-913",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054603","Insulin therapy de-intensification with iGlarLixi in people with type 2 diabetes: the IDEAL randomised controlled trial","Peter Novodvorský","2025","Diabetes Research and Clinical Practice","randomized_trial","article","10.1016/j.diabres.2025.112854",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054604","SUN-576 Glucagon-like Peptide-1 (GLP-1) Receptor Agonists For Alcohol Use Disorder: a Systematic Review and Meta-analysis","Aminah Abrão Fauaz Ritter Lima","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.1227",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0054605","Is it safe to use GLP-1 receptor agonists in a patient with a history of thyroid nodules and a family history of thyroid cancer with unknown pathology?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18419898",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054606","EP1730 - LBA_ECE_1107 - Impact of pharmacological therapeutic transition in obesity: analysis of anthropometric variations and metabolic profile","Ignacio Nocete Aragón","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1792",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0054607","Monitoring Drug Safety Information - Recommendations of Foreign Regulatory Authorities","Artiсle Editorial","2020","Safety and Risk of Pharmacotherapy","other","article","10.30895/2312-7821-2020-8-1-52-54",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054608","FROM LIFESTYLE INTERVENTIONS TO BARIATRIC SURGERY: AN OVERVIEW OF OBESITY TREATMENT MODALITIES","Krzysztof Jamroch","2025","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.4(48).2025.4420",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054609","Liraglutide, a once-daily human GLP-1 analogue, reduces body weight and improves obesity-related risk factors in obese non-diabetic subjects: A randomised placebo-controlled trial","Arne Astrup","2008","Research at the University of Copenhagen (University of Copenhagen)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0054610","12621 Convergence Of Sglt2 Inhibitors And Glp1 Agonists: Unveiling The Recipe For Euglycemic Diabetic Ketoacidosis","Usheem Syed","2024","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvae163.720",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054611","What is the latest treatment for type 2 diabetes in an 89-year-old with an HbA1C of 82 mmol/mol?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19351486",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054612","Tirzepatide in weight management and metabolic fitness: clinical efficacy, safety, and future applications in type 2 diabetes, obesity, and sports nutrition","Klaudia Głodowska","2025","Medical Science","other","article","10.54905/disssi.v29i163.e190ms3723",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054613","1679-P: Concurrent Ondansetron Use during Semaglutide Initiation Is Associated with Increased Biliary Complications in a Large Real-World Cohort","Hanson Chan","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1679-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054614","GLP-1 Agonists and Dual Agonists in Obesity Treatment: Benefits, Risks, and Clinical Challenges in Geriatric Patients","Lidia Wydeheft","2026","Quality in Sport","other","article","10.12775/qs.2026.49.67673",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054615","HPR40 COST-EFFECTIVENESS AND ACCESS CONSIDERATIONS FOR GLP-1-BASED THERAPIES IN TYPE 2 DIABETES AND OBESITY: INSIGHTS FROM US PAYER AND HTA PERSPECTIVES","H Jedidi","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1102",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054616","P152 - ECE_1208 - Metabolomic disparities between men and women with diabetes and obesity; differential predictors of tirzepatide response determined by obesity status","Ipsita Mishra","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.340",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0054617","OR19-05 Efficacy of Tirzepatide versus Semaglutide in Achieving Therapeutic Targets in Type 2 Diabetes: a post hoc analysis of SURPASS-2 Trial","Ana Rita Leite","2025","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvaf149.1025",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054618","What is the second line treatment for type 2 diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18136962",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054619","Metabolic health and risk of early-onset cancers in obese young adults: Real-world insights from a large cohort study.","Anushareddy Muddasani","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e22670",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0054620","P158 The association between GLP-1 receptor agonist use and mortality among COPD patients","Hossny Alaws","2025",null,"nonrandomized_study","article","10.1136/thorax-2025-btsabstracts.339",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054621","Diagnosis, Management and Pathophysiology of Polycystic Ovarian Syndrome","Meghana A","2026","Journal of Pharma Insights and Research.","other","article","10.69613/e52arj05",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054622","Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome","Jaya Raju Nandikola","2025","Journal of Neonatal Surgery","other","article","10.52783/jns.v14.1517",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054623","Le liraglutide exerce une puissante activité anti-inflammatoire et anti-catabolique dans deux types cellulaires impliqués dans l’arthrose, les chondrocytes et les macrophages","C. Meurot","2021","Revue du Rhumatisme","other","article","10.1016/j.rhum.2021.10.118",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054624","Nonalcoholic Steatohepatitis","Taha Sachak","2018","New England Journal of Medicine","other","article","10.1056/nejmc1716786","29466150",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054625","Nutrition Strategies for Patients on New Incretin Therapies for Type 2 Diabetes","Susan Keen","2014","Nutrition Today","other","article","10.1097/nt.0000000000000044",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054626","1716-P: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2","ANDREEA CIUDIN","2026","Diabetes","other","article","10.2337/db26-1716-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054627","1120 Impact of GLP-1 Receptor Agonists on Chronic Low Back Pain in Patients With Obesity: A Pilot Study","Braeden Christopher Benedict","2026","Neurosurgery","nonrandomized_study","article","10.1227/neu.0000000000003964_1120",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054628","10 minutes: Glucagon-like peptide-1 receptor agonists","Benjamin Tyler","2026","InnovAiT Education and inspiration for general practice","other","article","10.1177/17557380261441197",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054629","What is the evidence for using GLP-1 receptor agonists in treating people with schizophrenia?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17753214",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054630","Efficacy and Safety of High-Dose Retatrutide in Adults with Obesity and Type 2 Diabetes: A Systematic Review and Bayesian Meta-Analysis","Matheus Hissa Lourenço Ferreira","2026","SN Comprehensive Clinical Medicine","systematic_review","article","10.1007/s42399-026-02580-9",null,null,"PROSPERO:CRD420251275485",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054631","Komplex inzulinkezelési rezsimek deeszkalációja a jó glikémiás kontroll megőrzésével 2-es típusú diabetes mellitusban","Zoltán Jamal Taybani","2020","Diabetologia Hungarica","other","article","10.24121/dh.2020.4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054632","International Federation for the Surgery and Other Therapies for Obesity (IFSO) global consensus recommendations for optimizing outcomes after sleeve gastrectomy","RICARDO VITOR COHEN","2025","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znaf188","41092404",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054633","S418 Use of Flavored Polyethylene Glycol and Sulfate Solution Bowel Preparation in Patients with Obesity, Diabetes, or Taking Glucagon-Like Peptide-1 Receptor Agonists","Eric J. Vargas","2024","The American Journal of Gastroenterology","other_trial","article","10.14309/01.ajg.0001031040.88351.23",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0054634","Comment on ‘Effect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China’ by Liang et al.","Atsushi Nakamura","2026","Journal of Cachexia Sarcopenia and Muscle","nonrandomized_study","article","10.1002/jcsm.70288","41992825",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054635","Ten Minutes Hard","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22116705",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0054636","Adjuvant therapy in glucagon-like peptide-1 receptor agonist treatment: Enhancement of efficacy and mitigation of adverse events. A review","Д. Н. Андреев","2026","Consilium Medicum","randomized_trial","article","10.26442/20751753.2026.8.203814",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054637","Vomiting as Common Adverse Event of Exenatide: A Case of Diabetic Patient with Type 2 and Duodenal Bulb and Gastric Ulcers who Showed Severe Vomiting Increased Gradually after Exenatide Injections","Kyuzi Kamoi","2015","International Journal of Clinical Case Studies","case_report","article","10.15344/2455-2356/2015/108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054638","Pharmacological treatment of obesity: an overview of different groups of anti-obesity drugs available in Poland","Barbara Woch","2024","Journal of Education Health and Sport","other","article","10.12775/jehs.2024.58.004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054639","Tirzepatide for OSA and obesity: do we know the effect on cardiometabolic outcome?","Zachary T. Bloomgarden","2026","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2026.115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054640","Recombinant Fusion of Glucagon‐Like Peptide‐1 and an Albumin Binding Domain Provides Glycemic Control for a Week in Diabetic Mice","Parisa Yousefpour","2020","Advanced Therapeutics","preclinical","article","10.1002/adtp.202000073",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054641","Does zepbound increase the risk of kidney stones?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17794884",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054642","Mechanism of Action of DPP-4 Inhibitors—New Insights","Adrian V Vella","2012","The Journal of Clinical Endocrinology & Metabolism","randomized_trial","article","10.1210/jc.2012-2396","22869847",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054643","Beeldvorming van de GLP-1-receptor in type 2-diabetes en obesitas","Sevilay Tokgöz","2026","Nederlands Tijdschrift voor Diabetologie","other","article","10.1007/s12467-026-1627-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054644","INVESTIGATING GLP-1 FOR PCOS MANAGEMENT AND FERTILITY ENHANCEMENT","Umaima Khan","2025","Northwest journal of medical sciences.","other","article","10.69723/njms.04.01.0434",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054645","Recognizing Type 5 Diabetes: A Distinct and Urgent Clinical Challenge","Maha Imam Ahmed","2025","INNOVAPATH","other","article","10.63501/bfr22868",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054646","Is there evidence for the beneficial effects of collagen supplements when taking semaglutide?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20845363",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054647","2841-LB: Glucagon-Like Peptide 1 Receptor Agonists Lower the Risk of Stroke and Vascular Dementia among Individuals with Obesity","WEI-HAN CHEN","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2841-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054648","26-A-13667-ACC DULAGLUTIDE PROMOTES CORONARY PLAQUE STABILIZATION IN PATIENTS WITH TYPE 2 DIABETES: AN OPTICAL COHERENCE TOMOGRAPHY STUDY","Koshi Matsuhama","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.488",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054649","Glucagon-like peptide-1 receptor agonists and the risk of ventricular arrhythmia in patients with acute myocardial infarction and type 2 diabetes mellitus: a propensity score-matched cohort study","Chunqin Hu","2026","BMC Cardiovascular Disorders","randomized_trial","article","10.1186/s12872-026-06354-y",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054650","Integrating Diet and Physical Activity When Prescribing GLP-1s-Lifestyle Factors Remain Crucial.","Mehrtash F","2025","JAMA internal medicine","other","article","10.1001/jamainternmed.2025.1794","40658434",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0054651","SAT-685 Low-dose Tirzepatide For The Treatment Of Patient With Lipedema: A Case Report","Juliana Bicca","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.119",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054652","The “Ozempic Limb”: Understanding the Impact of GLP-1 Agonists on Prosthesis Use and Residual Limb Care in Amputee Patients","Janelle Bykowski","2026","Scholarship at UWindsor (University of Windsor)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054653","What are the best evidence-based strategies to prevent nutritional deficiencies in patients being treated with GLP-1 receptor agonists?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19566798",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054654","Once weekly semaglutide for treatment of obesity","Nasser E. Mikhail","2021","Journal of Clinical and Laboratory Research","randomized_trial","article","10.31579/2768-0487/015",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054655","Fragility Index of SGLT2 Inhibitor, GLP-1 Receptor Agonist, and Nonsteroidal Mineralocorticoid Receptor Antagonist (nsMRA) Clinical Trials for Kidney and Cardiovascular Protection","Sarvesh Sankar Dass","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.2025tk01943m",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054656","CO53 Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study","Anubhav Chauhan","2023","Value in Health","other","article","10.1016/j.jval.2023.03.127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054657","GLP1-RA AND SGLT2-I. Comparison of the Effectiveness of the Newer Antidiabetic Medication in Everyday Practice. The Experience of a Diaberic Outpatient Clinic of a Tertiary Hospital of Athens","Ioannis Gastouiniotis","2023","Metabolism","other","article","10.1016/j.metabol.2023.155415",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054658","Real-World Clinical Effectiveness of Liraglutide in Individuals 65 Years and Older with Type 2 Diabetes in the United States","A.S. Chitnis","2014","Journal of Diabetes & Metabolism","nonrandomized_study","article","10.4172/2155-6156.1000403",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054659","Association Between GLP-1 Agonist Use and Site-Specific Fracture Risk: A Retrospective Cohort Analysis","Nathan Zou","2025","Stony Brook Orthopaedic and Musculoskeletal Journal","randomized_trial","article","10.31259/3065-2677.1035",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054660","Marked Recovery of Total Testosterone From 150 to 530 ng/dL Over 86 Days During Predominantly OMAD Fasting, Weight Reduction and Approximately Six Weeks of Trigonelline Supplementation","Kavitha PS","2026","International Journal For Multidisciplinary Research","other","article","10.36948/ijfmr.2026.v08i04.86584",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054661","Expanding Medicare Part D Coverage of Weight Loss Medications: The Impact on Plastic Surgery","Rishub Karan Das","2023","Aesthetic Surgery Journal","other","article","10.1093/asj/sjad160","37226551",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054662","Are current systemic endothelial anti-inflammatory therapies effective/safe, and only in secondary prophylaxis?","Lucian Petrescu","2025","Romanian Journal of Cardiology","randomized_trial","article","10.2478/rjc-2025-0029",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054663","Physician perspectives on dapagliflozin use in Indian type 2 diabetes practice: Insights from real-world experience","Deepak Chouhan","2026","International Journal of Diabetes Sciences","nonrandomized_study","article","10.33545/26649101.2026.v8.i1a.17",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054664","Effect of Health Literacy on Treatment Results of Type-2 Diabetes Mellitus Patients Admitted for Insulin Pen Use Education","Sumeyye Tuna Guner- Hakan Demirci","2021","European Health Literacy Journal","other","article","10.29228/ehlj.50816",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054665","Liraglutide on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review","Rana A. Alotaibi","2026","Journal of Advanced Trends in Medical Research","systematic_review","article","10.4103/atmr.atmr_146_25",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0054666","1227-OR: RAY1225, a Biweekly Biased GLP-1/GIP RA for Weight Management: A Phase 2 Trial in Chinese Overweight/Obese Adults (REBUILDING-1)","LINONG JI","2026","Diabetes","randomized_trial","article","10.2337/db26-1227-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054667","Tirzepatide and HFpEF: a look at cardiovascular outcomes","Kevin Fraser","2025","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002517",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054668","Among patients with Parkinson disease, are GLP-1 receptor agonists effective in improving motor symptoms compared with usual care?","Lauren Della Grotta","2021","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001514",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054669","(O-10) Impact of GLP-1 Receptor Agonists on Testosterone and Gonadotropin Profiles in Men: A Systematic Review","Omer Raheem","2026","The Journal of Sexual Medicine","systematic_review","article","10.1093/jsxmed/qdag062.017",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0054670","Societal value and health economic benefits of GLP‐1 drugs in the United States","Frederik Cyrus Roeder","2025","Economic Affairs","other","article","10.1111/ecaf.70011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054671","2462-P: Glucagon-Like Peptide 1 Receptor Agonism Ameliorates Colonic Inflammation in a Murine Model of Inflammatory Bowel Disease via Central and Peripheral Mechanisms","BIREN DESAI","2026","Diabetes","preclinical","article","10.2337/db26-2462-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054672","What are the weight loss treatment options for a patient with Crohn's disease?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21283757",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054673","Avaliação ultrassonográfica gástrica point-of-care orientando anestesia segura em paciente em uso prolongado de semaglutida oral","Pedro Gabriel Carvalho Alkas","2025","Revista Goiana de Medicina","other","article","10.63162/v66n68e25625",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054674","Efficacy of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis","Mohamed Nabil Elnaggar","2026","Current Hepatology Reports","systematic_review","article","10.1007/s11901-025-00718-2",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054675","Review on Analytical Method Validation on Tirzepatide","Asmita Mishra","2025","Asian Journal of Pharmaceutical Research and Development","narrative_review","article","10.22270/ajprd.v13i5.1632",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054676","Semaglutide reduces hypothalamic glial cell damage in a streptozocin-induced model of Alzheimer's disease","Dmitry N. Voronkov","2025","Research Results in Pharmacology","other","article","10.18413/rrpharmacology.11.804",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054677","Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels","Line Engelbrechtsen","2016","Metabolomics","other","article","10.1007/s11306-016-1128-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054678","Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus","Masao Toyoda","2017","Journal of Diabetes and Obesity","nonrandomized_study","article","10.15436/2376-0494.17.1300",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054679","Comparative Cardiovascular Outcomes of Tirzepatide vs Liraglutide in Obese Patients with Sleep Apnea: A Propensity-Matched Analysis Using the TriNetX Research Network","Ekow Essien","2025","American Heart Journal","nonrandomized_study","article","10.1016/j.ahj.2025.07.038",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054680","Association of Glucagon-like Peptide-1 Receptor Agonist Use With Postoperative Outcomes After Femoral Endarterectomy","Lilly Fernandes","2026","Journal of Vascular Surgery","other","article","10.1016/j.jvs.2026.03.402",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054681","ARTIFICIAL INTELLIGENCE AND PRECISION MEDICINE IN OBESITY MANAGEMENT: CURRENT APPLICATIONS, CHALLENGES, AND FUTURE DIRECTIONS","Alicja Włodarczyk","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(51).2026.6101",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054682","747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial","Richard E. Pratley","2022","Diabetes","randomized_trial","article","10.2337/db22-747-p",null,null,"ClinicalTrials.gov:NCT03819153","S000953","openalex","FALSE","paywalled","1","FALSE","article"],["R0054683","Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial","Morag Nelson","2024","Obesity Research & Clinical Practice","randomized_trial","article","10.1016/j.orcp.2024.09.114",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054684","26-A-16629-ACC PROJECTING THE BENEFITS OF GLP-1RA THERAPY IN OBESE PATIENTS WITHOUT DIABETES UNDERGOING COMPLEX PCI","Johny Nicolas","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.1274",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054685","What is the efficacy of tirzepatide in reducing the incidence of recurrent pregnancy loss?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17691999",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054686","Synergy Between GLP-1 Receptor Agonists, Nutritional Therapy, and Physical Exercise in Optimising Body Composition and Cardiometabolic Health","Rodolfo Melo Raiol","2026","Periódicos Brasil Pesquisa Científica","other","article","10.36557/2674-9432.2026v5n1p2201-2205",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054687","G01 : Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, doubleblinded, randomised, placebo-controlled phase II trial","Matthew James Armstrong","2015","Journal of Hepatology","randomized_trial","article","10.1016/s0168-8278(15)30002-7",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0054688","Management of Hirsutism and Acne in Women with Polycystic Ovary Syndrome: A Narrative Review of Current Evidence and Emerging Therapies","Aleksandra Papuga","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.58.72655",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0054689","Synergy of pharmacotherapy and physical activity in the treatment of obesity and cardiovascular prevention in patients with type 2 diabetes","Karolina Mędrysa","2025","Quality in Sport","other","article","10.12775/qs.2025.42.60480",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054690","Navigating Postpartum Weight Loss: Evidence and Interventions","Gabriela Dellapiana","2024","Current Obstetrics and Gynecology Reports","other","article","10.1007/s13669-024-00398-7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054691","Challenges and risks of using GLP-1 antagonists in treating type 2 diabetes and obesity","Agnieszka Głuszczyk","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.17.53683",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054692","Semaglutide, an Anti-Diabetic and Anti-Obesity Drug: A Perspective","Ravi Varala","2026","Journal of Chemistry & its Applications","other","article","10.47363/jcia/2026(5)158",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054693","Correction: Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?","Nele Steenackers","2025","Frontiers in Endocrinology","notice","article","10.3389/fendo.2025.1656611","41113718",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0054694","18th European Symposium on Radiopharmacy and Radiopharmaceuticals","Atiq-ur-Rehman","2016","EJNMMI Radiopharmacy and Chemistry","other_trial","article","10.1186/s41181-016-0012-6",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054695","How Diabetes Mellitus Leads to Dialysis: A Narrative Review","Mohammad Talat Ul Tuba Dar","2026","International Journal of Research and Review","narrative_review","article","10.52403/ijrr.20260648",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0054696","SUN-691 Permeate: A Novel Platform for Enhanced Incretin Peptide Bioavailability","Patrick Derrian Susilo","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.198",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054697","Semaglutide – a long – awaited cure for obesity or an elusive treatment?","Izabela Oleksak","2024","European Journal of Clinical and Experimental Medicine","other","article","10.15584/ejcem.2024.4.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054698","Are GLP-1 agonists a safe and effective adjunct therapy for type 1 diabetes management?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19081719",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054699","Better Glycemic Control and Less Weight Gain with Once Weekly Dulaglutide vs. Once Daily Insulin Glargine, Both Combined with Pre-Meal Insulin Lispro, in Type 2 Diabetes Patients (AWARD-4)","JOHAN H. JENDLE","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.136",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054700","Can semaglutide cause high ocular pressure?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.21374108",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054701","Critical care drugs","Daniel A. Hussar","2011","Nursing Critical Care","other","article","10.1097/01.ccn.0000403407.36145.c0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054702","What is the evidence for Retatrutide in weight reduction?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18113478",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054703","Effects of Liraglutide 3.0 mg Injection on Weight Reduction and Metabolic Parameters for Patients Living with Obesity and Type 2 Diabetes Mellitus","Hanadi Alnageeb","2023","Advances in Research","other","article","10.9734/air/2023/v24i2936",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054704","Are GLP-1 receptor agonists effective in treating neuropathy due to diabetes mellitus?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19473850",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054705","OR22-05 Weight Loss and Change in Body Composition in a DIO Mouse Model by the Combined AMPK and Mitochondrial Activator, ATX-304, Alone, in Combination With Semaglutide, and After Semaglutide Withdrawal","Erik J Schneider","2025","Journal of the Endocrine Society","preclinical","article","10.1210/jendso/bvaf149.080",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054706","Efficacy and Safety of Oral Semaglutide (Rybelsus) for Weight Reduction in Individuals with Obesity and Type 2 Diabetes: A Systematic Review","Azhar M. Al Ibrahem","2025","Journal of Healthcare Sciences","systematic_review","article","10.52533/johs.2025.50101",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054707","Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide","Durul Huda","2024","Saudi Journal of Medicine","other","article","10.36348/sjm.2024.v09i10.003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054708","Abstract TP202: Quality Improvement Project of Increasing Utilization of Antihyperglycemic Medications with Cardiovascular Benefits in Patient with Diabetes admitted with Acute Ischemic Stroke","Reny Mathew","2026","Stroke","nonrandomized_study","article","10.1161/str.57.suppl_1.tp202",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054709","A Comparison of Patient Characteristics Between Glp-1 Ra and Insulin Initiators in China","K Wang","2018","Value in Health","other","article","10.1016/j.jval.2018.07.318",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054710","MON-636 Growth of Pancreatic Heterotopic Tissue: A Rare Adverse Effect of Semaglutide","Alexander Barsegian","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.996",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054711","2199-P: GLP-1 Receptor Agonists and Cardiovascular Events in Adults with Obesity and Autoimmune Disease: A Target Trial Emulation","HAO DAI","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2199-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054712","GLP-1 for Weight Loss and Ozempic: 6 Things Science Actually Knows","Narayan Rout","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.20743108",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0054713","A Retrospective Cohort Study of GLP-1 receptor agonist therapy in pregnant women with insulin resistance","Fionn Walsh","2025","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22812609",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0054714","Editorial: Prevention and treatment advancements in diabetic retinopathy","Tomislav Bulum","2026","Frontiers in Endocrinology","randomized_trial","article","10.3389/fendo.2026.1807742","41788770",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0054715","Musculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System","Akshita Wadhwa","2026","Cureus","other","article","10.7759/cureus.116758",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054716","Beyond Weight Loss and Glycemic Control: Molecular Mechanisms and Hypothesis-Generating Therapeutic Potential of Incretin-Based Therapies Against Peritoneal Fibrosis in Peritoneal Dialysis","Yi‐Chen Li","2026","Pharmaceuticals","other","article","10.3390/ph19101502",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054717","26-CCC-10293-ACC A SHOCKING SIDE EFFECT: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST INTOLERANCE CAUSING TORSADES DE POINTES","Stephen J. Brand","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.3179",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054718","C-42 | Semaglutide Use and Clinical Outcomes Following Transcatheter Aortic Valve Replacement","Chris James","2026","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2026.104778",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054719","THE IMPACT OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS ON LIPID METABOLISM: A NEW AVENUE FOR CARDIOVASCULAR DISEASE PREVENTION—A META-ANALYSIS OF RANDOMIZED CONTROL TRIALS","Nwachukwu O Nwachukwu","2026","Postgraduate Medical Journal","systematic_review","article","10.1093/postmj/qgag039.008",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0054720","EAST MEETS WEST—Medicated Driven Weight Loss Face (“Ozempic Face”): Unveiling the Profound Influence of Prescription Medications on Injectable Aesthetic Trends and Energy Based Device","Ma. Rowena Aguilar-Joven","2026","Journal of Cosmetic and Regenerative Medicine","other","article","10.65381/jcrm.2025.01010012",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054721","Real-World Use of GLP-1 RA-Based Therapies for Weight Management in Ireland: A Cross-Sectional Study of Prescribing and Care Pathways, Costs, and Self-Reported Outcomes","Catherine Caro","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.6994968",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0054722","1669-P: Effect of Semaglutide for Weight Management on Blood Pressure in Adults with Uncontrolled Hypertension and Overweight/Obesity: A Post Hoc Analysis from the STEP and OASIS Programs","Beverly Tchang","2026","Diabetes","other_trial","article","10.2337/db26-1669-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054723","Inferior Vena Cava Filter Use and Rates of Deep Venous Thrombosis in High-risk Oncological Patients Undergoing Abdominopelvic Surgery","Mohyee Ayouty","2026","Journal of Vascular Surgery Venous and Lymphatic Disorders","nonrandomized_study","article","10.1016/j.jvsv.2025.102405",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054724","B52-20 A Broken Heart: Ozempic-Induced Takotsubo Cardiomyopathy","S Shah","2026","American Journal of Respiratory and Critical Care Medicine","other","article","10.1093/ajrccm/aamag162.1466",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054725","P-350. Prescription of Weight Loss Medications in HIV Patients at a Rural Federally Funded Clinic: A Retrospective Study","Diviya Bharathi Ravikumar","2026","Open Forum Infectious Diseases","nonrandomized_study","article","10.1093/ofid/ofaf695.568",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054726","Prediction of the pharmacokinetics of the GLP-1 receptor agonist semaglutide in humans via a population pharmacokinetic model integrating interspecies scaling","Joonhee Kim","2024","Journal of Pharmaceutical Investigation","other","article","10.1007/s40005-024-00717-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054727","OPTIONS AND LIMITATIONS OF OBESITY TREATMENT WITH GLP-1 RECEPTOR AGONISTS","Katarína Babíková","2026","Ateroskleróza","randomized_trial","article","10.33542/ate2026-12-6",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054728","BEYOND GLYCEMIC CONTROL AND WEIGHT REDUCTION: PLEIOTROPIC EFFECTS OF GLP-1 RECEPTOR AGONISTS ON HUMAN PHYSIOLOGY - A NARRATIVE REVIEW","Matylda Król","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.2(50).2026.6208",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0054729","OZEMPIC COMO MODULADOR INFLAMATÓRIO: IMPACTO NOS NÍVEIS DE TNF-Α E IL-6 EM PACIENTES COM DIABETES TIPO 2, OBESIDADE E DOENÇAS AUTOIMUNES","Huendel Batista de Figueiredo Nunes","2025","Aracê.","other","article","10.56238/arev7n4-223",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054730","Ozempic Face: An Update and Critical Review","Kar Wai Alvin Lee","2026","Journal of Cosmetic and Regenerative Medicine","narrative_review","article","10.65381/jcrm.2026.01010019",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054731","MON-436 Understanding The Mass Effect, Chronic Grave’s Ophthalmopathy Improvement After Significant BMI Reduction","Zygy Roe-Zurz","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.2207",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054732","Abstract 7940: Pharmacokinetics of TNX-1700 in non-human primates and human FcRn/serum albumin transgenic mice","Mayanka Awasthi","2026","Cancer Research","preclinical","article","10.1158/1538-7445.am2026-7940",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054733","What evidence supports the use of glucagon-like peptide-1 receptor agonists in treating alcohol use disorder or substance use disorder?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20639084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054734","Dipeptidyl Peptidase 4 Inhibitors: Therapeutic Options","S. V. Podachina","2024","Effective Pharmacotherapy","other","article","10.33978/2307-3586-2024-20-8-26-30",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054735","The Risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) and Worsening Diabetic Retinopathy (DR) with Semaglutide","Varsha Narayanan","2025",null,"other","article","10.9734/ajrrop/2025/v8i1124",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054736","EP689 - ECE_2790 - Efficacy and Safety of Semaglutide Injection in Weight management: A subgroup analysis of patients based on BMI","Unnikrishnan Gopalkrishnanl","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1097",null,null,"CTRI:CTRI/2025/04/085487",null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0054737","LIRAGLUTIDE AND PHYSICAL ACTIVITY EFFECTS IN ADIPOCITE TISSUE OF MICE OBESE","Aline de Freitas Brito","2020","Medicine & Science in Sports & Exercise","preclinical","article","10.1249/01.mss.0000687200.03223.49",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054738","Practice Patterns of Usage of Glimepiride and Metformin FDC Along with Other OADs: A New Age Approach to Diabetes Management in Indians","Dr J George","2024",null,"nonrandomized_study","article","10.59793/1p03cf62",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0054739","Nye antidiabetiske lægemidler og kardiovaskulære komplikationer","Manan Pareek","2018","VBN Forskningsportal (Aalborg Universitet)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0054740","Kardiológiai vonatkozású diabetológiai újdonságok","György Jermendy","2018","Cardiologia Hungarica","other_trial","article","10.26430/chungarica.2018.48.2.151",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054741","What are the effects of GLP-1 receptor agonists, such as Mounjaro, on patients with rheumatoid arthritis?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20599296",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054742","S2455 Effects of Bariatric Surgery on Non-Invasive Markers of MASLD","Junaid Khan","2025","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001137280.23777.90",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054743","Impact of GLP1 receptor agonists on survival of breast cancer patients.","Tim Prior","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.639",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054744","Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149","Silvio E. Inzucchi","2015","Diabetes Care","other","article","10.2337/dc15-0812","26207068",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054745","Cardiovascular Effects of Diabetes Drugs: Making the Dark Ages Brighter With CAROLINA","Julio Rosenstock","2013","Annals of Internal Medicine","randomized_trial","article","10.7326/0003-4819-158-6-201303190-00017","23553039",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054746","What are the most effective treatments for obesity?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17751022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054747","Effect of Gastrointestinal Adverse Events on Treatment Satisfaction in Semaglutide Treatment of Type 2 Diabetes","JOHAN H. JENDLE","2017","Value in Health","other","article","10.1016/j.jval.2017.08.481",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054748","Strength, Not Scans","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21217581",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054749","Diabetic nephropathy: Mechanisms, disease progression, and advances in treatment strategies","Manzoor Ahmad Qurashi","2025","International Journal of Diabetes Research","other","article","10.33545/26648822.2025.v7.i1a.20",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054750","Weighing up the options: childhood intervention to tackle obesity","Owen R. Vaughan","2025","Pediatric Research","randomized_trial","article","10.1038/s41390-025-04483-2","41068311",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054751","Effects of Glucagon-like Peptide-1 Receptor Agonists on Upper Endoscopy (EGD)","Eleazar Enrique. Montalvan-Sanchez","2024",null,"randomized_trial","article","10.37766/inplasy2024.6.0028",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","report"],["R0054752","CONTEMPORARY MANAGEMENT OF PEDIATRIC OBESITY: A NARRATIVE REVIEW","Wiktoria Modrzejewska","2026","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.2(50).2026.5342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0054753","Role of incretin-based therapies in pain management","Antonio Alcántara Montero","2026","Medicina Clínica (English Edition)","other","article","10.1016/j.medcle.2026.107263",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054754","Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity","Thomas Leth Jensen","2023","Drugs of the Future","other_trial","article","10.1358/dof.2023.48.3.3521861",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054755","Positron emission tomography imaging of disease activity in atherosclerosis","Virta, Jenni","2024","UTUPub (University of Turku)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0054756","Cardiovascular Benefits of GLP-1 and Dual GIP/GLP-1 Agonists: A Paradigm Shift in Cardiology and Metabolic Care","Erick Adolfo Meza Soto","2025","IECCMEXICO","other","article","10.64784/008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054757","Modern pharmacotherapy of obesity: molecular mechanisms, clinical efficacy and future therapeutic directions","Navneeth Selvan","2026","International Journal of Basic & Clinical Pharmacology","other_trial","article","10.18203/2319-2003.ijbcp20260443",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054758","What should we know about muscle loss and GLP-1 agonists, and what advice should we provide to our patients?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18260290",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054759","Insulin therapy DE-intensificAtion with iGlarLixi: the IDEAL randomised controlled trial","Haluzik, Martin","2024","Diabetologia","randomized_trial","article","10.5281/zenodo.14235366",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0054760","The analysis study of effectiveness, safety and outcome of semaglutide in patients with CKD on hemodialysis and T2DM","Guinanti Novettiandari","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112596",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054761","Profound weight reduction with GLP ‐1 agonist therapy: a delayed hyper‐response","Andrew McGovern","2014","Practical Diabetes","other_trial","article","10.1002/pdi.1887",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054762","Can Ozempic cause an ileus?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19665540",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054763","Self-monitoring","Chris Gunstone","2013","British Journal of General Practice","other","article","10.3399/bjgp13x665143","23540456",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054764","Liraglutide reduces postprandial hyperlipidaemia by increasing apoB48 catabolism and by reducing apoB48 production","Bruno Vergès","2016","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0054765","Pathophysiological pathways linking diabetes to cardiac hypertrophy: From insulin resistance to personalised cardioprotection","Gaurav Joshi","2026","Scripta Medica","other","article","10.5937/scriptamed57-60346",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054766","TEMPORARY REMOVAL: Understanding self-reported treatment behaviors among people using glucagon-like peptide-1 receptor agonists for weight loss: A United States survey observational study","ZEB I. SAEED","2026","Obesity Pillars","other","article","10.1016/j.obpill.2026.100328",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054767","PANCREATITE MEDICAMENTOSA: REVISÃO SISTEMÁTICA SOBRE EPIDEMIOLOGIA, DIAGNÓSTICO E MANEJO","Yasmin Vitória Morais Baú","2026","South American Sciences","other","article","10.63330/sasciencesv6n2-147",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054768","(416) Education Levels and Sexual Dysfunction in Cisgender Women Taking GLP1 or GLP1/GIP Receptor Agonists","Emily K. Burr","2025","The Journal of Sexual Medicine","other","article","10.1093/jsxmed/qdaf320.410",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054769","Acute administration of the GLP-1 receptor agonist, Exenatide, restores impaired central responses to food ingestion in type 2 diabetes","Y. Nathan","2010","Research Portal (King's College London)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054770","QbD Approach for Analysis of Tirzepatide in its Bulk and Marketed Formulation by Stability Indicating RP-HPLC","Vanga Mohan Goud","2023","International Journal of Pharmaceutical Quality Assurance","other","article","10.25258/ijpqa.14.2.27",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054771","Can GLP-1RA be utilised for pre-operative liver optimisation prior to hepatectomy? A scoping review of MASLD evidence with surgical translation","Ruhi Vaitha","2026","Clinical Surgical Oncology","other_trial","article","10.1016/j.cson.2026.100136",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0054772","Considerazioni sugli ultimi documenti dell’OMS sull’ Obesità. Dall’ Acceleration Plan to Stop Obesity al Round 6 dell’ European Childhood Obesity Surveillance Initiative","Rita Tanas","2025","QUADERNI ACP","other","article","10.53141/peqacp.2025.1.d1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054773","1712-P: Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) and Metformin","LIMING CHEN","2026","Diabetes","randomized_trial","article","10.2337/db26-1712-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054774","Abstract B041: GLP-1 receptor agonists associated with improved response to immune checkpoint inhibitors in solid tumors: a multi-institutional retrospective cohort study","Mostafa Eysha","2026","Cancer Immunology Research","nonrandomized_study","article","10.1158/2326-6074.io2026-b041",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054775","Tubules, Targets, and Translational Promise in Diabetic Kidney Disease","Victor Martinez Leon","2026","Kidney360","nonrandomized_study","article","10.34067/kid.0000001088","41609741",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054776","Better together: glucagon-like peptide-1 receptor agonists with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes mellitus","Diana Kinney","2026","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002565",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054777","Semaglutide and Tirzepatide Use and Reduction of Cardiovascular Risks in Adults with Overweight and Obesity","Onur Başer","2024","Medical Research Archives","nonrandomized_study","article","10.18103/mra.v12i8.5714",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054778","A Novel Comprehensive Program Combining Optimal Medical Treatment with Lifestyle Modification for Type 2 Diabetes","Chunsong Hu","2024","Cardiovascular Science","other","article","10.35534/cvs.2024.10004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054779","Expert Opinion on Cardio-Renal-Metabolic Approach to Management of Adults with Type 2 Diabetes Mellitus Using Oral Semaglutide: An Indian Perspective","Rajesh Rajput","2025","Clinical Diabetology","randomized_trial","article","10.5603/cd.103785",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054780","1133-OR: Safety, Tolerability, and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Trial","CHUNXIU GONG","2026","Diabetes","randomized_trial","article","10.2337/db26-1133-or",null,null,"ClinicalTrials.gov:NCT06536023","S001192","openalex","FALSE","paywalled","1","FALSE","article"],["R0054781","ESVE-O-8 A PLACEBO-CONTROLLED STUDY ON THE EFFECT OF THE GLP-1 ANALOGUE, EXENATIDE, ON BODY COMPOSITION, LEPTIN AND ADIPONECTIN IN OBESE, CLIENTOWNED CATS","Kirsten Madsen Hølmkjær","2015","Research at the University of Copenhagen (University of Copenhagen)","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0054782","SGLT2-INHIBITORS AND GLP1-RECEPTOR AGONISTS DECREASE PLASMA NT-PROBNP IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HEART STRESS: A LONGITUDINAL MULTICENTER REAL-LIFE STUDY","Francesco Spannella","2026","Journal of Hypertension","other","article","10.1097/01.hjh.0001195680.73738.f2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054783","The Global Access Crisis for GLP-1 Receptor Agonists: From Scientific Breakthrough to Health Equity Challenge","Jindong Xie","2026","MedMat.","other","article","10.1097/mm9.0000000000000052",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054784","Semaglutide slows the progression of cognitive impairment and pathological changes in the hippocampus in a model of Alzheimer's disease","A. K. Pavlova","2025","Neurology neuropsychiatry Psychosomatics","preclinical","article","10.14412/20742711-2025-6-54-60",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054785","S909 Adverse Events With Glucagon-Like Peptide-1 Receptor Agonists During Upper Endoscopy","Sahib Singh","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001033004.29882.4a",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054786","A cross-sectional study of prevalence of heart failure in diabetic patients in a Tertiary Care Centre of West Bengal","Prasun Chatterjee","2025","Asian Journal of Medical Sciences","nonrandomized_study","article","10.71152/ajms.v16i6.4534",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054787","Treatment of obesity - A review through the eyes of a primary care physician","Hanna Porwolik","2024","Pakistan Journal of Medical and Health Sciences","nonrandomized_study","article","10.53350/pjmhs020241852",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054788","Do statins increase the risk for the development of diabetes?","C. Anthony Burton","2023","Evidence-Based Practice","randomized_trial","article","10.1097/ebp.0000000000001990",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054789","Nature-Inspired Continuous N-C Chain Elongation Enables Sustainable Peptide Synthesis","Jingjun Yin","2026","ChemRxiv","other","article","10.26434/chemrxiv-2025-9zf56/v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0054790","Management of chronic liver diseases and cirrhosis: current status and future directions","Jinghang Xu","2020","Chinese Medical Journal","randomized_trial","article","10.1097/cm9.0000000000001084","32925282",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054791","Non-Alcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease: Current Insights into Epidemiology, Diagnosis, Treatment, and Global Health Challenges","Charu Sinha Sinha","2026","Journal of Pharmacology Genetics and Molecular Biology","nonrandomized_study","article","10.64062/jpgmb.vol2.issue4.5",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054792","ORAL MANIFESTATIONS ASSOCIATED WITH THE USE OF GLP-1 RECEPTOR AGONISTS","Ana Karine Brito do Couto","2026","Seven Editora eBooks","other","article","10.56238/sevened2026.032-001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0054793","Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users: Implementation of the CRAVE Study Protocol","Demsina Babazadeh","2024","Current Developments in Nutrition","protocol","article","10.1016/j.cdnut.2024.103642",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0054794","A long and winding road to understand latent autoimmune diabetes in adults","Shuoming Luo","2021","Chinese Medical Journal","randomized_trial","article","10.1097/cm9.0000000000001321","33395070",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054795","EE269 Health Economic Assessment of High-Protein Diet Using High-Protein ONS for Weight Maintenance Following Weight Loss Using GLP-1RAs","Bjoern Schwander","2025","Value in Health","other","article","10.1016/j.jval.2025.04.1868",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054796","The Effects of Combined h[Gly2]Glucagon-Like Peptide-2 and Exendin-4 on Parameters Relevant to Short Bowel Syndrome","Arjuna Srikrishnaraj","2021","TSpace (University of Toronto)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0054797","DUAL GIP/GLP-1 AGONISM AND LEAN MASS PRESERVATION: AN INTEGRATIVE REVIEW OF TIRZEPATIDE AND A PROPOSED AMAZONIAN DIETARY MODEL","Ana Tereza Gomes Braga","2026","Seven Editora eBooks","randomized_trial","article","10.56238/sevened2026.009-046",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","book-chapter"],["R0054798","In obese adults without diabetes, does treatment with tirzepatide (a glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) lead to improved weight loss outcomes compared with pure GLP-1 receptor agonists?","Matthew J. Haney","2025","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002472",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054799","Comparative Efficacy of various GLP-1 Receptor Agonists in the Managamenet of type 2 Diabetes Mellitus","Zaid Muthana A. Abdelkarim","2026","Fortune Journal of Health Sciences","randomized_trial","article","10.26502/fjhs.399",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054800","Laundered Survival: When Target Trial Emulation Doesn’t Emulate—Implications for GLP-1 Receptor Agonists and Cancer Outcomes","James Brophy","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7119801",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0054801","GLP-1-BASED THERAPIES BEYOND DIABETES: EMERGING CLINICAL APPLICATIONS AND FUTURE PERSPECTIVES","Anna Maria Szeszko","2026","Archiv Euromedica","randomized_trial","article","10.35630/2026/16/iss.4.14",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054802","Diabetes mellitus im Alter","Andrej Zeyfang","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2592-8139",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054803","1698-P: Three-Month Response Threshold as a Predictive Biomarker for Long-Term Weight Loss Sustainability in GLP-1 Receptor Agonist Therapy: A Real-World Cohort Study","B. M. Makkar","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1698-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054804","EPH85 Real-World Temporal and Indication-Specific Variation in Drivers of GLP-1 RA Discontinuation","Brianna Cartwright","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.616",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0054805","How well are the effects of liraglutide on cardiovascular events for patients without diabetes documented?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18769922",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054806","INTEGRATED ANTIVIRAL AND ANTIDIABETIC THERAPY IN CANCER PATIENTS WITH COVID-19: A RETROSPECTIVE CLINICAL STUDY","Florin Dan Ungureanu","2026",null,"nonrandomized_study","article","10.66793/titum19proceeding1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0054807","SP 2.07 A National Prospective Audit of Acute Pancreatitis in the era of GLP-1 agonists (PANDORA): Breaking Results","White Rose Surgical Collaborative","2026","British journal of surgery","other","article","10.1093/bjs/znag087.026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054808","COMPARATIVE ANALYSIS OF CHEMICAL DRUGS AND PHYTOTHERAPEUTIC AGENTS IN THE TREATMENT OF OBESITY","Irodaxon Yusupovna Mamatova","2026","Journal of Chemistry of Goods and Traditional Medicine","other","article","10.55475/jcgtm/vol5.iss3.2026.688",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054809","Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines","Dedong Li","2023","New England Journal of Medicine","preclinical","article","10.1056/nejmc2216233","36856580",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054810","Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes","Dhiren K Patel","2018","Journal of the American Association of Nurse Practitioners","other","article","10.1097/jxx.0000000000000112",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054811","Az orális szemaglutid terápiás helye a mindennapi gyakorlatban","Csaba Lengyel","2022","Diabetologia Hungarica","other","article","10.24121/dh.2022.s1.4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054812","A topical approach to GLP-1/GIP agonist-induced tissue changes in the face, neck and décolletage: a case series evaluation","Hazel Parkinson","2026","Journal of Aesthetic Nursing","case_report","article","10.12968/joan.2025.0058",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054813","Nyhedsbrev for Netværk for udvikling af Apotekspraksis (NUAP) Juni 2024","Tina Olesen Linde","2024","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0054814","Leading the Charge in Obesity Management","Eryn Bryant","2025","The Journal of Cardiovascular Nursing","other","article","10.1097/jcn.0000000000001192","40146810",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054815","Effects of liraglutide on progenitor cell lineage and maturation in cd34+ hematopoietic stem cells: a single-cell rna sequencing analysis","Giuseppe Damiano","2025","European Heart Journal","other","article","10.1093/eurheartj/ehaf784.4923",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054816","INTERNATIONAL GUIDELINES ON PERIOPERATIVE MANAGEMENT OF GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW","Karol Grela","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.4(48).2025.4724",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0054817","The Impact of Oral Hypoglycemic Agents on Elderly Patients: A Meta-analysis (2000–2025)","Mohammed Riyaz","2025","Telangana journal of IMA.","systematic_review","article","10.4103/tjima.tjima_21_25",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0054818","Treatment regimens for type 2 diabetes mellitus with metformin, including all considerations.","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18262683",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054819","Comparative Effectiveness of Liraglutide, Semaglutide, and Dulaglutide on Kidney Outcomes","Catherine G. Derington","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.202533kyg5gr",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054820","A Regional Examination of Weight Bias Before and After the Rise of Ozempic","Anabelle Jimenez","2026","Open Science Framework","other","article","10.17605/osf.io/yd5f8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0054821","Abstract 14413: Contemporary Prevalence, Comorbidity Burden, and Treatment of Overweight and Obesity: Insights From the Multicenter Mass General Brigham Healthcare System","John W. Ostrominski","2023","Circulation","nonrandomized_study","article","10.1161/circ.148.suppl_1.14413",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054822","Beyond GLP-1: Charting the Future of Peptide Therapeutics in Metabolic Disease","Babak Pezeshki","2026","Galen Medical Journal","other","article","10.31661/gmj.v15i.4342",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054823","RWD130 Real-World Adverse Event Profile of Glucagon-Like Peptide-1 Receptor Agonists in Overweight and Obese US Adults","Rohan Vashi","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.1713",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0054824","MOLECULAR MECHANISMS AND ALGORITHMIC REALITIES: A SOCIO-MEDICAL ANALYSIS OF GLP-1 RECEPTOR AGONISTS IN THE CONTEXT OF EATING DISORDER SPECTRUM","Weronika Mazurkiewicz","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.2(50).2026.5166",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054825","What is the best management for renal protection in patients with diabetes and hypertension?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20131115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054826","Exploring the impact of social media on patient perceptions and utilization patterns of glucagon-like peptide-1 agonists: A comprehensive analysis in the digital health era","Khalid Abdullah Alfares","2025","Saudi Journal of Internal Medicine","other","article","10.4103/sjim.sjim_34_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054827","Parental pharmacology and metabolic programming: how far does incretin modulation reach?","Crespo, Javier","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17782392",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0054828","Mo1548 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ARE ASSOCIATED WITH IMPROVED GLYCEMIC CONTROL AND LOWER SURGICAL RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE","Fares Jamal","2026","Gastrointestinal Endoscopy","other","article","10.1016/s0016-5107(26)02918-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054829","Efficacy and safety of semaglutide and tirzepatide in the therapy of obesity and type 2 diabetes – current state of knowledge","Julianna Rozalia Chyl","2026","Quality in Sport","other_trial","article","10.12775/qs.2026.70.74691",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054830","GLP-1 in multiple sclerosis: preclinical evidence, clinical prospects and future directions","D. Satanovsky","2025","INTERNATIONAL NEUROLOGICAL JOURNAL","nonrandomized_study","article","10.22141/2224-0713.21.7.2025.1218",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054831","Liraglutide – A Once-daily Human Glucagon-like Peptide-1 Analogue Treatment for Type 2 Diabetes","Chantal Mathieu","2009","touchREVIEWS in Endocrinology","other","article","10.17925/ee.2009.05.00.38",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054832","Incretin-Based Multi-Agonist Therapies for Type 2 Diabetes Mellitus and Obesity: Mechanisms, Clinical Efficacy, and Future Directions","Dhruba Podder","2026","Diabetology","nonrandomized_study","article","10.3390/diabetology7030046",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054833","How much more effective is semaglutide in achieving weight loss than other glucagon-like peptide-1 receptor agonists?","Karime Bolivar","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002262",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054834","Novel Approaches in the Treatment of Type 2 Diabetes","Sawera Saleem Khan","2024","Journal of Health and Rehabilitation Research","randomized_trial","article","10.61919/jhrr.v4i3.1460",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054835","Exploring the Cytoprotective Role of Liraglutide in Non-Alcoholic Fatty Liver Disease Experimentally Induced in the Rat Model (Histological and Biochemical Study)","Sahar Shaban","2024","Zagazig University Medical Journal","preclinical","article","10.21608/zumj.2024.321384.3582",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054836","Once-Weekly Glucose-Lowering Therapy for Type 2 Diabetes","Susan M. LaRue","2012","Clinical Diabetes","other","article","10.2337/diaclin.30.3.95",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054837","Abstract 4360264: Real World Evaluation of the Eligibility, Uptake, and Cardiometabolic Effects of Tirzepatide: An Analysis from the Platform for Evidence GeneraTion in CArdiometabolic HeaLth (PETAL) Study","Nishant P. Shah","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4360264",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054838","Once-weekly glucagon-like peptide-1 receptor agonists: An overview","MELISSA L. MAGWIRE","2018","Journal of the American Association of Nurse Practitioners","other","article","10.1097/jxx.0000000000000119",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054839","Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes","Erin St. Onge","2017","Medical Research Archives","other","article","10.18103/mra.v5i11.1603",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054840","Abstract 11649: GLP-1 Receptor Agonists in Heart Failure: Insights From a Cardiometabolic Center of Excellence","Yasser M. Sammour","2021","Circulation","other","article","10.1161/circ.144.suppl_1.11649",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054841","Association of concurrent GLP-1 receptor agonist use with survival outcomes in patients with metastatic colorectal cancer receiving immune checkpoint inhibitors.","Shalin Rawal","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.3605",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054842","Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?","Maria Sudoł","2024","Quality in Sport","other","article","10.12775/qs.2024.35.56304",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054843","GW27-e1177 Semaglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca2+-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/Survivin pathways","Ying Zhang","2016","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2016.07.158",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054844","The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register","И. В. Мисникова","2019","Diabetes Mellitus","other","article","10.14341/dm10084",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054845","The Impact of GLP-1 Receptor Agonists on Physical Functioning and Quality of Life in Adults with Obesity: A Narrative Review","Marcela Łupina-Romaniuk","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.55.70903",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0054846","How does the efficacy of retatrutide compare with tirzepatide and semaglutide in promoting weight loss among obese individuals without diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17808644",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054847","What is the pancreatic cancer risk for GLP-1 receptor agonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17673332",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054848","Is there weight gain after discontinuing GLP-1 treatment in patients with obesity?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17749337",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054849","What is the average weight loss for overweight patients without diabetes using semaglutide?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18771827",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054850","C104-17 Impact of Sglt2 Inhibitors on Mortality and Clinical Outcomes in Patients With Sarcoidosis: A Real-world Analysis From Trinetx","S S Shama","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.2831",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054851","Fat just disappears... Increasing the efficacy and safety of glucagon-like peptide-1 receptor agonists using standardized human placenta extracts","O. A. Gromova","2026","Pharmacoinformatics and pharmaconutritiology Current trends in data analysis","other","article","10.63769/3034-7459-2026-2-1-14-24",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054852","Histopathological Evaluation of the Teratogenic Potential of Lixisenatide on the Cerebral Cortex of Developing Cheek Embryo","Amit Kumar Srivastava","2024","UTTAR PRADESH JOURNAL OF ZOOLOGY","other","article","10.56557/upjoz/2024/v45i104063",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054853","TIRZEPATIDA, AGONISTA DO RECEPTOR DUPLO DE GIP E GLP-1, NO TRATAMENTO DE DIABETES MELLITUS TIPO 2: EFICÁCIA E SEGURANÇA","Rodolfo Alvarenga Bastos","2024","RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218","other","article","10.47820/recima21.v5i4.5133",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054854","THE SOCIO-CLINICAL IMPACT OF GLP-1 RECEPTOR AGONISTS ON ORAL HEALTH: BRIDGING THE BIOPSYCHOSOCIAL GAP THROUGH DIGITAL HEALTH TECHNOLOGIES","Marta Krzyżanowska","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.2(50).2026.5572",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054855","Formulation, Optimisation, and In Vitro Evaluation of Polymeric Nanoparticles for Enhanced Oral Delivery of Semaglutide","Satyendra Kumar","2026","International Journal of Drug Delivery Technology","preclinical","article","10.25258/ijddt.16.19s.17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054856","Widening Waistline: Rising Burden of Obesity in India","Shrikanth N. Hegde","2025","APIK Journal of Internal Medicine","nonrandomized_study","article","10.4103/ajim.ajim_100_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054857","Add-on GLP-1 agonists in the treatment of intermediate risk acute pulmonary embolism: a biomarker-driven proof-of-concept study","Chinthaka Bhagya Samaranayake","2024",null,"other","article","10.1183/13993003.congress-2024.oa5556",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054858","Review on diabetes mellitus type-2 in adults: Pathophysiology, prevention and medications","S Yameen","2025","International Journal of Pharmacognosy and Life Science","narrative_review","article","10.33545/27072827.2025.v6.i2c.181",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054859","Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes","Clive G. Ballard","2020","Alzheimer s & Dementia","randomized_trial","article","10.1002/alz.042909",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054860","Preserving Kidney Function Instead of Replacing It","Alan S. Kliger","2019","Clinical Journal of the American Society of Nephrology","randomized_trial","article","10.2215/cjn.07820719","31594804",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054861","Abstract 4367191: Cardiovascular Safety of Semaglutide: An Updated Systematic Review and Meta-analysis with Focus on Sex, Race, and Renal Function","Muhammad Waseem Tahir","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4367191",null,null,"PROSPERO:CRD420251066136",null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0054862","Comprehensive approaches in AlzheimerÓ?s disease: from general aspects to stem cell therapy and antidiabetic use","Renata Murguiondo Pérez","2025","Revista de Fomento Social","other","article","10.24875/rmn.24000049",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054863","1982. GLP-1 Receptor Agonists Promote Weight Loss Among People with HIV","Quynh Nguyen","2023","Open Forum Infectious Diseases","nonrandomized_study","article","10.1093/ofid/ofad500.109",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054864","Perioperative GLP-1 Analogue Exposure and Postoperative Outcomes in Mommy Makeover Surgical Procedures: A Nationwide Propensity-Matched Analysis","Aneeq Chaudhry","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.20086937",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-paper"],["R0054865","Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications","Anniek Frederike Lubberding","2023","Elsevier eBooks","other","article","10.1016/b978-0-323-99991-5.00017-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0054866","A Case Study Showcasing the Impact of the InSilicoTrials Platform on Obesity Clinical Trials","Jane Knöchel","2026",null,"other_trial","article","10.70534/gjih6056",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-paper"],["R0054867","The potential for precision medicine to improve care and speed the development of new treatments in breast and gynecologic malignancies","Gottfried E. Konecny","2018","Current Opinion in Obstetrics & Gynecology","other","article","10.1097/00001703-900000000-99282",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054868","Do controle glicêmico à proteção cardíaca: efeitos cardiovasculares dos agonistas do receptor de GLP-1","Atila Gonçalves Almeida","2025","Brazilian Journal of Health Review","other","article","10.34119/bjhrv8n5-151",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054869","(118) Psychiatric Manifestations of Micronutrient Deficiency in a Post-Operative Bariatric Surgery Patient on Semaglutide","Zehra Aftab","2023","Journal of the Academy of Consultation-Liaison Psychiatry","other","article","10.1016/j.jaclp.2023.11.591",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054870","Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes","Wiktor Biesiada","2025","Quality in Sport","nonrandomized_study","article","10.12775/qs.2025.37.57025",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054871","Is semaglutide an established cause of NAION?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18790222",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054872","The Impact of GLP-1 Analogues and Tirzepatide on Female Fertility: Mechanisms, Clinical Evidence, and Implications","Klaudia Elżbieta Niwińska","2026","Journal of Education Health and Sport","other","article","10.12775/jehs.2026.87.67444",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054873","Semaglutida e Tirzepatida: efeitos dos agonistas GLP-1/GIP na microbiota intestinal e potencial associação com SIBO.","Lara Ferreira Reis","2026","Revista fisio&terapia.","nonrandomized_study","article","10.69849/7wmx9h50",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054874","1794-P: New Insulin Sensitizer CIS-0602K Potential to Expand Treatment Options to Manage Diabetes","MOHAMED ABU-FARHA","2026","Diabetes","other_trial","article","10.2337/db26-1794-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054875","EE60 Assessing the Cost-Effectiveness of Subcutaneous Semaglutide 2.4 mg in the Management of Individuals With Obesity and Prediabetes in England","Mafalda Ramos","2025","Value in Health","other","article","10.1016/j.jval.2025.09.444",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054876","Management of type 2 diabetes in adults: summary of updated NICE guidance","Hugh McGuire","2016","BMJ","other","article","10.1136/bmj.i1575","27052837",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054877","1060-P: Effect of Dulaglutide and Long-Acting Insulin Combination Therapy in Patients with Type 2 Diabetes","Kohei Ito","2019","Diabetes","other","article","10.2337/db19-1060-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054878","37-PUB: Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors among Pregnant Women with Diabetes at Time of Conception Stratified by Socioeconomic Factors","Miranda Antuna","2026","Diabetes","other","article","10.2337/db26-37-pub",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054879","EE74 Budget Impact Analysis for Semaglutide, Tirzepatide, and Dulaglutide for Type 2 Diabetes Mellitus Management in Saudi Arabia","Hussain Abdulrahman Al‐Omar","2024","Value in Health","other","article","10.1016/j.jval.2024.10.358",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054880","EFFICACY OF GLP-1 RECEPTOR AGONISTS ON GLYCAEMIC CONTROL AND WEIGHT REDUCTION IN TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS","Nadhira Iriani Djatmiko","2026","The Indonesian Journal of General Medicine","systematic_review","article","10.70070/bbvjb653",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054881","Can GLP-1 receptor agonists be taken with antipsychotic medications?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17753301",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054882","Glucagon-like Peptide-1 Receptor Agonists: Limitless Potential","Tatiana Yu. Demidova","2020","Doctor Ru","other","article","10.31550/1727-2378-2020-19-2-6-12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054883","Comparative Effectiveness of GLP-1 Receptor Agonists: A Network Meta-Analysis Using Chatgpt","Eleftherios Teperikidis","2025","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.5103748",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0054884","Effect of exenatide once-weekly (QW) on the blood pressure and glycaemic responses to a mashed potato meal in type 2 diabetes: relationships to gastric emptying","Lian Q. Huynh","2023","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0054885","Adverse effects of GLP-1 receptor agonists: Clinical Implications, regulatory perspectives, and future directions","Riad Mohammed Abdelrahman","2026","Obesity Medicine","other","article","10.1016/j.obmed.2026.100699",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054886","Role of Glucagon-Like Peptide-1 Analogues on Obesity and Type-II Diabetes Mellitus: A Review","L A Maheswary","2020","International Journal of Pharmaceutical Sciences Review and Research","narrative_review","article","10.47583/ijpsrr.2020.v64i02.017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054887","Real-world use of oral semaglutide in adults with type 2 diabetes: the PIONEER REAL Switzerland multicentre, prospective, observational study","F Acquistapace","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3796",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054888","Response to “Early‐ and later‐stage persistence with antiobesity medications: a retrospective cohort study”","Angela Fitch","2024","Obesity","nonrandomized_study","article","10.1002/oby.24038","38659125",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054889","Cost-utility analysis of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease in Thailand","Sirada Limwongse","2026","World Journal of Hepatology","other","article","10.4254/wjh.123353",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054890","From risk to reward: Redefining the role of GLP-1 receptor agonist in pancreatic cancer primary prevention.","Colton Jones","2026","Journal of Clinical Oncology","randomized_trial","article","10.1200/jco.2026.44.16_suppl.e16449",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054891","FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists.","van Beurden, Wiebke",null,"Open Access CRIS of the University of Bern","nonrandomized_study","article","10.48620/85882",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0054892","What are the comparative side effects of tirzepatide and semaglutide in obese patients without diabetes?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17706895",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054893","Dual-action hope: DeepSeek responses to Tirzepatide’s role in metabolic health","Sai Praneeth Chaparala","2025","International Journal of Research in Medical Sciences","nonrandomized_study","article","10.18203/2320-6012.ijrms20253657",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054894","Editorial: Are glucagon-like peptide-1 receptor agonists the functional cure for patients with metabolic dysfunction-associated cirrhosis?","Dajti, Elton",null,"Open Access CRIS of the University of Bern","commentary","article","10.48350/196183",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0054895","2595-P: Tirzepatide vs. Semaglutide and the Risk of Incident Gastroparesis: A Propensity-Matched Analysis of 828,426 Patients","Ankitha Vanaparti","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2595-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054896","What is the best treatment for a person with a glycated hemoglobin level of 8%?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21043002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054897","What is the current evidence base for weight management in people with serious mental illness?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17934824",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054898","What are the clinical uses of tirzepatide?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18287413",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054899","The influence of correction of carbohydrate metabolism and body weight on endogenous testosterone production in men with type 2 diabetes mellitus, obesity and hypogonadism","М. О. Чернова","2024","Bulletin of Reproductive Health","other","article","10.14341/brh12711",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054900","Late Breaking Abstract - Tirzepatide and Nocturnal Hypoxia (T90): SURMOUNT-OSA post hoc analyses","Ingo Fietze","2025",null,"other","article","10.1183/13993003.congress-2025.pa6032",null,null,"ClinicalTrials.gov:NCT05412004","S000156","openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0054901","DPP-4-gátlók a 2-es típusú diabetes kezelésében – megújult irányelvek, változó klinikai gyakorlat","György Jermendy","2020","Diabetologia Hungarica","other","article","10.24121/dh.2020.6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054902","SAT-526 Trends In Diabetes Medications After Metformin In High Versus Moderate Cardiovascular Risk Patients","Maria Cecilia Lansang","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0054903","Comparison of the Safety and Weight Loss Efficacy of Metformin and Liraglutide in Psychiatric Outpatients at a University Hospital: A Retrospective Chart Review","Mi-Gyeong Seo","2024","Mood and Emotion","nonrandomized_study","article","10.35986/me.2024.22.1.1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054904","The Neuroprotective Effects of GLP-1 Analogues on Alzheimer's Disease – A Literature Review","Wiktoria Ulicka","2025","Journal of Education Health and Sport","narrative_review","article","10.12775/jehs.2025.80.59398",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054905","What is the pancreatic cancer risk for GLP-1 receptor agonists in patients with a family history of pancreatic cancer?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17673325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054906","The glucagon-like peptide-1 receptor agonist liraglutide reduces jejunostomy output and improves intestinal absorption in short bowel syndrome patients with intestinal failure:A pilot study","Mark Hvistendahl","2015","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054907","Orchestrating muscle health and nutritional integrity via companion food systems during incretin-mimetics induced weight loss","Taemin Kim","2026","Food Science and Biotechnology","other","article","10.1007/s10068-026-02259-w",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054908","TIRZEPATIDE, ELAMIPRETIDE (SS-31), TESAMORELIN AND BREMELANOTIDE: MECHANISTIC FOUNDATIONS, CLINICAL EVIDENCE AND THERAPEUTIC APPLICATIONS IN METABOLIC, MITOCHONDRIAL AND NEUROENDOCRINE CONTEXTS","Luiz Felippe Mendes Caquetti","2026","INTERNATIONAL BLEST SCIENTIFIC","randomized_trial","article","10.65671/g269y606",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054909","GLP-1 Receptor Agonists: Current Applications and Future Directions","Duhanur Aksoy","2025","DergiPark (Istanbul University)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0054910","In which guidelines is semaglutide recommended?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19857131",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054911","What are the clinical considerations when transitioning a patient from semaglutide to tirzepatide in terms of dosing and titration?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20086106",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054912","糖尿病患者の口腔保健行動の実態とその関連要因","Yumi Kuwamura","2013","Institutional Repositories DataBase (IRDB)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0054913","MON-521 GLP-1 Receptor Agonists and Risk for Dialysis, Cardiovascular Disease and Mortality in Patients with Type 2 Diabetes Mellitus and End Stage Renal Disease","Ashni Dharia","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.888",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054914","S2111 Partnership With An Independent Telehealth Obesity Medicine Program After Endoscopic Bariatric Procedures Improves Weight Loss Outcomes At 12 Months","Philip A. Kozan","2024","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001037812.69655.6a",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054915","P1050 Impact of GLP-1 receptor agonist therapy on clinical outcomes in diabetic patients with Inflammatory Bowel Disease treated with infliximab: a propensity-matched cohort study","J Johal","2026","Journal of Crohn s and Colitis","nonrandomized_study","article","10.1093/ecco-jcc/jjaf231.1231",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054916",null,"Antje Bergmann","2025","Diabetes aktuell","commentary","article","10.1055/s-015-61907",null,null,null,null,"openalex","FALSE",null,null,null,"editorial"],["R0054917","Abstract 4371834: Targeting Cerebrovascular Risk in Diabetes: GLP-1 Receptor Agonists as Neuroprotective Agents","Hem prajapati","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4371834",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0054918","What is new and what has changed in the 2026 Global Heart Failure Implementation Guidelines and why","Vijay Chopra","2026","Global Cardiology","randomized_trial","article","10.4081/cardio.2026.118",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054919","The Effect of Tirzepatide on Metabolic Dysfunction-associated Steatotic Liver Disease: A Literature Review","Effrosyni Blathra","2025","Journal of Atherosclerosis Prevention and Treatment","randomized_trial","article","10.4103/aptj.aptj_16_25",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054920","Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes","Edoardo Mannucci","2010","Journal of Receptor Ligand and Channel Research","other","article","10.2147/jrlcr.s6345",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054921","Renal Transcriptomic Profiling Reveals Beneficial Effects of Semaglutide and Lisinopril in Advanced Diabetic Kidney Disease","Louise Thisted","2025","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2025xfpr4wez",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054922","The Cost of Inaction in Treating Obesity in the U.S.","Tanvi Sapra","2026","Diabetes Obesity and Cardiometabolic CARE","other","article","10.2337/doci25-0011",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054923","O IMPACTO DO TIRZEPATIDE NA ESTEATO-HEPATITE ASSOCIADA À DISFUNÇÃO METABÓLICA COM FIBROSE HEPÁTICA: REVISÃO DA LITERATURA","Phelipe dos Santos Araújo","2024","Revista fisio&terapia.","other","article","10.69849/revistaft/th10247011004",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054924","Tanycytes Control the Hypothalamic Uptake and Metabolic Actions of Liraglutide","Mónica Imbernón","2021","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054925","Considering Pramlintide Therapy for Postprandial Blood Glucose Control","Belinda P. Childs","2007","Diabetes Spectrum","other","article","10.2337/diaspect.20.2.108",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054926","THE DARK SIDE OF GLP-1 ANALOGS: ADVERSE EFFECTS, LIMITATIONS, AND SAFETY CONCERNS","Katarzyna Dudzińska","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.2(50).2026.5655",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054927","Management of metabolic dysfunction and cardiovascular risk in patients with MASLD","Pojsakorn Danpanichkul","2026","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2025.32",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054928","Elevated liver enzymes and comorbidities in type 2 diabetes: A multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database.","Meyhöfer, Svenja",null,null,"nonrandomized_study","article","10.48350/167186",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0054929","Therapeutic Convergence in the Era of Geroscience A Comprehensive Review on Longevity, Obesity and the Role of Dual GLP-1GIP Agonists, with Emphasis on Tirzepatide","Correia Belonci, Caio Juan","2025","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.17699842",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0054930","Do sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like-peptide-1 (GLP-1) receptor agonists improve patient-oriented outcomes in patients with type 2 diabetes mellitus?","John D. Adame","2025","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002465",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054931","Glucagon-Like Peptide-1 Receptor Agonist Exposure During Pregnancy: Maternal Characteristics and Birth Outcomes from the HEALthy Brain and Child Development (HBCD) Study","Galya Bigman","2026","AACE Endocrinology and Diabetes","nonrandomized_study","article","10.1016/j.aed.2026.08.019",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054932","Antiobesity Activity of Liraglutide on High Fat Diet-Induced Obesity in Wistar Rats","Vinay Kumar","2017","Current Research in Diabetes & Obesity Journal","preclinical","article","10.19080/crdoj.2017.03.555602",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054933","Effect of weight-loss medications on obstructive sleep apnea. Systematic review","César Luis González-Cuello","2025","Gredos (University of Salamanca)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0054934","POSTER: MM-1225: GLP-1 Agonists Improve Survival and Reduce Morbidity in Newly Diagnosed Multiple Myeloma: A Real-World Propensity Score–Matched Analysis","Chidiebube Ugwu","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)01434-5",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054935","Danuglipron. Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity","Alexander James Sperry","2022","Drugs of the Future","other","article","10.1358/dof.2022.47.6.3373535",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054936","Evaluation of the symptomatic and disease-modifying effects of Parkinson's disease drugs","Masahiro Nagai","2022","Proceedings for Annual Meeting of The Japanese Pharmacological Society","other_trial","article","10.1254/jpssuppl.96.0_3-b-s24-1",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054937","Positive effect of vitamin D supplementation on weight loss in obese patients treated with glucagon-like peptide 1 and lifestyle interventions","Maksym Gorobeiko","2022","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","other","article","10.22141/2224-0721.18.5.2022.1186",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054938","Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus","Vilsbøll, Tina","2007",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054939","Lixisenatide","Qing Zhong","2026","Elsevier eBooks","other","article","10.1016/b978-0-443-44037-3.01000-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0054940","Holistic Treatment of Obesity: The Importance of Integrating Pharmacotherapy, Dietary Therapy, and Physical Activity for Effective and Sustained Weight Loss","Magdalena Maria Iwaszko","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.73.75186",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054941","RETATRUTIDE USE IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND OBESITY: AN INTEGRATIVE REVIEW","Gabriela Vitória dos Santos","2026","Seven Editora eBooks","nonrandomized_study","article","10.56238/sevened2026.020-072",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","book-chapter"],["R0054942","865-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes","Weijun Gu","2025","Diabetes","randomized_trial","article","10.2337/db25-865-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0054943","What is the effect of GLP-1 receptor agonists on bone healing in orthopedic patients with delayed bone healing?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20312828",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054944","New prospects in the treatment of diabetes mellitus","Минара Шамхаловна Шамхалова","2012","Diabetes Mellitus","other","article","10.14341/2072-0351-5547",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054945","GLP-1 Receptor Agonists for Weight Control: Emerging Insights from Clinical Trials and Future Perspectives","Shiyi Zhang","2026","Health and Metabolism","nonrandomized_study","article","10.53941/hm.2026.100005",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054946","EXPLORING THE POTENTIAL BENEFITS OF GLP-1 RECEPTOR AGONISTS IN PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM A LARGE DATABASE STUDY","SAUD ALAWAD","2025","CHEST Journal","nonrandomized_study","article","10.1016/j.chest.2025.07.3690",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054947","A Single Dose, Bioavailability Study Mounjaro (Tirzepatide) Solution for Injection in a Pre-Filled Pen 2.5 Mg/0.5 Ml in Normal Healthy Adult Human Subjects Under Fasting Condition","Arjun Arumugam","2025","European journal of applied sciences","other","article","10.14738/aivp.1303.18833",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054948","Localization of Hidden Insulinomas with 68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study.","Antwi, Kwadwo",null,null,"randomized_trial","article","10.7892/boris.70209",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0054949","GLP-1 수용체 작용체가 불러온 비만 치료의 변화 ver.1","Yejin Ho","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22538005",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0054950","Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive","Xiaodong Zhou","2024","npj gut and liver.","other","article","10.1038/s44355-024-00004-w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054951","Digesting Ozempic: How information sources on the type 2 diabetes drug Ozempic can affect patient understanding and decision making","Cooke, Emily","2023","Lu Zone Ul (Laurentian University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0054952","Efficacy and Safety of Tirzepatide in the Treatment of Obesity in Adults: A Comprehensive Review","Karolina Skonieczna","2025","Quality in Sport","narrative_review","article","10.12775/qs.2025.41.60368",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054953","The Role of GLP-1R and GIPR Agonism in Heart Failure","Phelopater Sedrak","2025","Canadian Diabetes & Endocrinology Today","other_trial","article","10.58931/cdet.2025.3138",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0054954","EE213 Cost-Effectiveness Analysis of Oral Semaglutide As a Third-Line Treatment for Patients With Type 2 Diabetes Mellitus","R. Chen","2025","Value in Health","other","article","10.1016/j.jval.2025.09.597",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0054955","GLP-1 and its Analogue Liraglutide Affects Human Endothelial Cell Signaling by Reducing VEGF-A Induced Ca2+ Signaling and Activating Protein Kinases","Cecilie Egholm Rotbøl","2015","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054956","Trends in Glucagon-Like Peptide 1 Receptor Agonists Utilization for Weight Management in Children","Daniel Mak","2025","Diabetes Technology and Obesity Medicine","nonrandomized_study","article","10.1089/dtom.2025.0027",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054957","MPN-1144: GLP-1 Receptor Agonists and Major Clinical Outcomes in Adults With Classic Myeloproliferative Neoplasms and Type 2 Diabetes and/or Obesity: A Global Propensity Score-Matched Analysis","Muluken Megiso","2026","Clinical Lymphoma Myeloma & Leukemia","nonrandomized_study","article","10.1016/s2152-2650(26)02399-2",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054958","Weight loss maintenance with exercise but not with GLP-1 receptor agonist treatment decreases atherosclerosis development","R. M. Sandsdal","2025","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054959","Role and place of dulaglutide in type 2 diabetes mellitus management","Ametov As","2023","Endocrinology News Opinions Training","other","article","10.33029/2304-9529-2023-12-4-72-77",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054960","2488-P: Glucagon Agonism Alleviates Hepatic Steatosis, Fibrosis, and Inflammation","SARAH A. HANNOU","2026","Diabetes","preclinical","article","10.2337/db26-2488-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054961","GLP-1 receptor agonist-induced post-procedural gastrointestinal and biliary complications in cardiothoracic surgery","Z Wright","2026","European Journal of Heart Failure","nonrandomized_study","article","10.1093/ejhf/xuag193.1304",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054962","(021) Identifying Changes in Sexual Function in Cisgender Women Taking GLP1/GIP Receptor Agonists","Emily K. Burr","2025","The Journal of Sexual Medicine","other","article","10.1093/jsxmed/qdaf320.021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054963","Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control","Guanghong Jia","2016","Diabetes","other","article","10.2337/dbi16-0014","27222394",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054964","Unveiling the heterogeneity of T2DM: a narrative review of clustering algorithms in stratifying comorbidity and complication risk","Namra Aziz","2026","Cardiovascular Diabetology – Endocrinology Reports","narrative_review","article","10.1186/s40842-026-00273-9","41761293",null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0054965","Impatto degli agonisti del recettore del GLP-1 sulla funzionalità tiroidea: una revisione della letteratura degli effetti sul volume tiroideo, sul rischio di neoplasie e sui livelli di TSH","Stefania Capuccio","2025","il Diabete","other","article","10.30682/ildia2404b",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054966","Role of GLP-1 receptor agonists in weight management of adolescents with Bipolar disorder and Type 1 DM.","Ozge Ozkan","2026","International Journal of Advanced Multidisciplinary Research","other","article","10.22192/ijamr.2026.13.03.004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054967","DURATION-8 Randomized Controlled Trial 104-Week Results—Once-Weekly Exenatide (ExQW) plus Once-Daily Dapagliflozin (DAPA) vs. ExQW or DAPA Alone","Serge A Jabbour","2018","Diabetes","randomized_trial","article","10.2337/db18-104-lb",null,null,"ClinicalTrials.gov:NCT02229396","S000791","openalex","FALSE","paywalled","1","FALSE","article"],["R0054968","CLINICAL OUTCOMES OF RESMETIROM IN NASH: A FOCUSED THERAPEUTIC ANALYSIS","Thanh Tuan Le","2025","International Journal of Medicine and Public Health","other","article","10.70034/ijmedph.2025.3.405",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054969","The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology","Sofía Echeverry-Guerrero","2024","Pharmacoepidemiology","other","article","10.3390/pharma3040025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054970","One-Year Outcomes of Compounded Semaglutide Therapy in a High-Touch Telehealth Platform: A Retrospective Cohort Study","Melissa M Rubio","2025","Journal of Clinical Medical Research","randomized_trial","article","10.46889/jcmr.2025.6310",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0054971","Transient Increase in Serum Uric Acid and Gout Attacks After Weight Loss Effect on Tirzepatide and Semaglutide","Jessica Abou Chaaya","2026","AACE Endocrinology and Diabetes","other","article","10.1016/j.aed.2026.04.006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054972","682-P: Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice","Yanyun Chen","2021","Diabetes","preclinical","article","10.2337/db21-682-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054973","The impact of GLP-1 receptor agonists on postoperative outcomes following total shoulder arthroplasty","Ankit Choudhury","2024","Seminars in Arthroplasty JSES","other","article","10.1053/j.sart.2024.10.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054974","0540 Varying Hypopnea Definitions and Missed Treatment Opportunities in Obstructive Sleep Apnea","Hnin Oo","2026","SLEEP","nonrandomized_study","article","10.1093/sleep/zsag091.0539",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0054975","Neuroprotective and Disease-Modifying Potential of GLP-1 Receptor Agonists in Parkinson’s Disease: A systematic Review of randomized Controlled Trials and Cohort Study","Rizqiana Arum Sari","2026","International Journal of Health Engineering and Technology","systematic_review","article","10.55227/ijhet.v4i5.567",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0054976","In which populations have GLP-1 receptor agonists been studied?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17831460",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054977","EPH18 ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST INITIATION AND ALCOHOL USE DISORDER AND ALCOHOL-RELATED MEDICAL CONDITIONS IN A U.S. ADMINISTRATIVE CLAIMS DATABASE","Wouter van der Pluijm","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.851",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0054978","What is the management of type 2 diabetes in a 30-year-old?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22871485",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054979","GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular practice: insights from a national survey of French cardiologists.","Pierre François Sabouret","2026","Archives of Medical Science","other","article","10.5114/aoms/226415",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054980","MON-411 Effects Of Selenium Supplementation In A Patient With Hashimoto’S Thyroiditis And Autoimmunity: A Case Report","Iasmin Fontes Murta","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.2185",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054981","Abstract 4368175: GLP-1 Analogues and Cardiovascular Outcomes in Heart Failure Patients: A Network Meta-Analysis","Jahanvi Kasodariya","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4368175",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0054982","AMD Annals 2020 - Synopsis on Type 2 Diabetes. Evaluation of AMD quality indicators of type 2 diabetes care in Italy","Alfredo de Michelli","2021","The Journal of AMD","other","article","10.36171/jamd20.23.4.14",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054983","Features of treatment of heart failure in patients with metabolic dysfunction-associated steatotic liver disease. Literature review","Y. S. Rudyk","2026","Ukrainian Therapeutical Journal","randomized_trial","article","10.30978/utj2026-1-74",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0054984","Saccharine is a body horror film for the Ozempic era","Erin Harrington","2026",null,"other","article","10.64628/aa.xuwy3xst9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0054985","Predictive biomarkers for cardiovascular diseases in a Saudi cohort of patients with type 2 diabetes mellitus","Assim Abdulaziz Alfadda","2026","Endocrine and Metabolic Science","nonrandomized_study","article","10.1016/j.endmts.2026.100311",null,null,"ClinicalTrials.gov:NCT05697991",null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0054986","Do you have any information about the benefits of liraglutide in Parkinson's disease?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17981629",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054987","Eksenatid Tedavisinde Tiroid İnce İğne Aspirasyon Biyopsisi ve Kalsitonin Yıkamanın Yeri Role of Thyroid Fine Needle Aspiration Biopsy and Calcitonin Wash-Out During Exenatide Therapy","Bengür Taşkıran","2017","OSMANGAZİ JOURNAL OF MEDICINE","nonrandomized_study","article","10.20515/otd.308303",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054988","Eating disorders and the incel community","Siobha Murphy","2026","Frontiers in Psychology","other","article","10.3389/fpsyg.2026.1940859","42761224",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054989","The Effect of Oral Semaglutide in Combination with other Hypoglycemic Agents in Patients with Diabesity","Vivek Raskar","2022","International Journal of Diabetes and Technology","other_trial","article","10.4103/ijdt.ijdt_7_23",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0054990","Spotlight on Emerging Health Technologies and Responsible Science","Cinthya Souza Simas","2026","Journal of Science Humanities and Arts - JOSHA","other","article","10.17160/josha.13.4.1170",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054991","Broadband pulsed light therapy and silicon magnetophoresis for rosacea in a patient taking glp-1 receptor agonists for weight loss","E.V. Filatova","2026","Восстановительные биотехнологии, профилактическая, цифровая и предиктивная медицина.","other","article","10.17116/rbpdpm2026301144",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0054992","Conference report","Andrew J. Krentz","2015","Cardiovascular Endocrinology","other_trial","article","10.1097/xce.0000000000000064",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0054993","HTA7 Hurdles to Reimbursement for GLP-1 Therapies in Weight Management","Adrian John Stanley","2024","Value in Health","other","article","10.1016/j.jval.2024.10.1832",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054994","Structure of initial therapy for type 2 diabetes mellitus in 2025 in Moscow: Analysis of real-world clinical practice","N.A. Demidov Demidov","2026","FOCUS Endocrinology","nonrandomized_study","article","10.62751/2713-0177-2026-7-2-03",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054995","Insulin pathways in epilepsy: Link between metabolism and brain activity","Mohd Anash","2026","American Journal of Biopharmacy and Pharmaceutical Sciences","other","article","10.25259/ajbps_19_2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0054996","The Effectiveness and Safety of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Binge Eating in Patients with Obesity: A Systematic Review and Meta-Analysis","Isobel Emptage","2026","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.6176554",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0054997","Glucometabolic Outcomes of GLP-1RA-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","Irene Caruso","2023","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.4442851",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0054998","Long‐term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy","Jeffrey Shi Kai Chan","2022","European Journal of Clinical Investigation","nonrandomized_study","article","10.1111/eci.13932","36468787",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0054999","Comprehensive approaches in Alzheimer’s disease: from general aspects to stem cell therapy and antidiabetic use","Renata Murguiondo Pérez","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055000","Response by Kosiborod et al to Letters Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”","Mikhail Kosiborod","2018","Circulation","randomized_trial","article","10.1161/circulationaha.117.031847","29483180",null,"ClinicalTrials.gov:NCT01730534",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055001","Subgroup analysis by gender and body mass index (BMI) in people living with overweight/obesity in the survodutide, a glucagon/GLP-1 receptor dual agonist, phase II trial","Elif Ilhan Ekinci","2024","Obesity Research & Clinical Practice","other_trial","article","10.1016/j.orcp.2024.09.090",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055002","In-vitro Antioxidant and DPP-IV Enzyme Assay of Ethyl Acetate Extract of Enicostemma littorale","Venugopal Muralidharan","2022","Journal of Pharmaceutical Research International","other","article","10.9734/jpri/2022/v34i15b35726",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055003","Editorial: Exercise intervention for prevention and management of type 2 diabetes","Céline Aguer","2023","Frontiers in Physiology","commentary","article","10.3389/fphys.2023.1320101","37936578",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0055004","Role of Lrp5/6-Activated Wnt Signaling in the Promotion of Implant Osseointegration and Regulation of Osteogenic & Lipogenic Induction Via Exenatide in T2dm Rats","Zijun Chen","2023","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4567104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0055005","What is the evidence of GLP-1 receptor agonists in people with pre-existing mental health problems?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18138060",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055006","The association between GLP-1 receptor agonists and fractures: an observational Case-Control Study","Annika Vestergaard Kvist","2025","VBN Forskningsportal (Aalborg Universitet)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0055007","1706-P: Impact of GLP-1–Based Treatment Discontinuation on Weight Loss and Glycemic Goals among Patients with Type 2 Diabetes: Quantifying an Opportunity to Improve Treatment Benefits","VIVIAN FONSECA","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1706-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055008","MON-241 Efficacy and Safety of Liraglutide in Managing Obesity in Children and Adolescents: A Systematic Review and Meta-Analysis","Hideki Zimermann Kamitani","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.1715",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055009","RWD40 DECLINING BASELINE HBA1C AT GLP-1 RECEPTOR AGONIST INITIATION IN U.S. ADULTS WITH TYPE 2 DIABETES, 2015-2024","Anuja Panthari","2026","Value in Health","other","article","10.1016/j.jval.2026.03.2028",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055010","Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Management of Diabetes Mellitus: A Review","Vivek Singh","2025","Journal for Research in Applied Sciences and Biotechnology","narrative_review","article","10.55544/jrasb.4.6.15",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055011","Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey","Catherine M. Lockhart","2025","Journal of Managed Care & Specialty Pharmacy","other","article","10.18553/jmcp.2025.31.2-a.s15","39888854",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055012","Вебометричний аналіз наявності препаратів проти ожиріння на основі семаглутиду","Кремінь, Юлія","2024","Scientific periodicals of Ukraine","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055013","Hypothesizing glucagon-like peptide 1 (GLP-1), agonists promote hypodopaminergia, resulting in heightened addictive reward-seeking and altered mood: Breaking the bubble and adding salt to a wound","Kenneth Blum","2025","Medical Hypotheses","other","article","10.1016/j.mehy.2025.111612",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055014","Cannabidiol improves metabolic profiles and alleviates liver inflammation and fibrosis in conditions of androgenic obesity and polycystic ovary syndrome","Francisco J. Ponce‐Díaz","2025","Diabetes Obesity and Metabolism","other","article","10.1111/dom.16602","40635171",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055015","TRENDS IN OBESITY TREATMENT: A REVIEW OF THE LITERATURE FROM THE LAST SIX YEARS","Adam Sobiński","2025","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.4(48).2025.4326",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055016","Can semaglutide lower the incidence of cardiovascular events in patients without diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18771916",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055017","Investigating the potential neuroprotective effect of semaglutide in the mouse retina","Alexander von Spreckelsen","2022","Acta Ophthalmologica","preclinical","article","10.1111/j.1755-3768.2022.0809",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055018","GLP-1 analogue as a novel approach for fertility treatment: unravelling the therapeutic potential: A narrative review","Frederikke Lindenberg","2023","Obstetrics & Gynecology International Journal","narrative_review","article","10.15406/ogij.2023.14.00708",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055019","26-A-17762-ACC GLP-1 RECEPTOR AGONISTS AND RISK OF CARDIAC ALLOGRAFT VASCULOPATHY AFTER HEART TRANSPLANT: A MULTICENTER RETROSPECTIVE ANALYSIS","Soad Al Osta","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1918",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055020","The Dark Side of GLP-1 Receptor Agonists: Risks and Adverse Events","CL Nawal","2026","Journal of the Association of Physicians of India","other","article","10.59556/japi.74.1655",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055021","Pharmacological Evaluation of Novel Antidiabetic Agents Targeting GLP-1 Receptors","N William","2025","Journal of Pharmacology Genetics and Molecular Biology","preclinical","article","10.64062/jpgmb.vol1.issue4.17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055022","Glucagon peptide-like 1 receptor (GLP-1R) expression per se: a new insight into neurodegenerative disease?","Soo-hyun Park","2015","Neural Regeneration Research","other_trial","article","10.4103/1673-5374.160078","26330822",null,"ClinicalTrials.gov:NCT01255163","S000009","openalex","TRUE","free_to_read","5","FALSE","article"],["R0055023","MON-516 Effectiveness of Semaglutide on Cardiovascular Outcomes in Chronic Kidney Disease (CKD) Patients with Type 2 Diabetes Mellitus: A Systemic Review and Meta-analysis","Faizan Ahmed","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.884",null,null,"PROSPERO:CRD42024617222",null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0055024","1670-P: Heterogeneity of Treatment Effect of Glucagon-Like Peptide 1 Receptor Agonists for Primary Prevention of Cardiovascular Events in Type 2 Diabetes","Jay B. Lusk","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1670-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055025","Short-term changes in NT-proBNP levels following initiation of SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and heart stress","Francesco Spannella","2026","Scientific Reports","other","article","10.1038/s41598-026-72444-8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055026","Glucagon-Like Peptide-1 Receptor Agonists and Neovascular Age-Related Macular Degeneration in Type 2 Diabetes: A Review of Emerging Clinical Evidence","Timothy Yu Yee Ong","2026","Current Ophthalmology Reports","nonrandomized_study","article","10.1007/s40135-026-00357-w",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055027","1230-OR: Lean Mass Effects of Anti-GDF8 (Trevogrumab) ± Anti-Activin A (Garetosmab) in People Living with Obesity Treated with Semaglutide with or without Low Lean Mass at Baseline","Jesse Chao","2026","Diabetes","randomized_trial","article","10.2337/db26-1230-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055028","EFEKTIVITAS PEMBERIAN OBAT ANTIDIABETES TERHADAP PENURUNAN GULA DARAH PADA PASIEN DIABETES","Lintang Fajar","2025","Medical and Dental Journal ( MEDIDENJ )","other","article","10.33085/hmj.v1i2.6747",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055029","Obesity and schizophrenia: results of a feasibility study with semaglutide to assist weight loss","A. Heald","2026","Neuroscience Applied","other","article","10.1016/j.nsa.2025.105758",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055030","The coverage gap in PREVENT: Why cardiovascular risk prediction needs a lab-free complement","Rebecca Arden Harris","2026","American Journal of Preventive Cardiology","nonrandomized_study","article","10.1016/j.ajpc.2026.101782",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055031","GLP-1 Receptor Agonists in Recurrent Weight Gain after Metabolic Bariatric Surgery","Ángel Alois Osorio Manyari","2026","IntechOpen eBooks","other","article","10.5772/intechopen.1016875",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055032","Complex protocols for correction of age-related changes caused by drug-induced loss of subcutaneous fat tissue of the face and body using a PLA-based preparation","M. A. Morzhanaeva","2025","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2025-365",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055033","Slimmer’s paralysis: a case report","Md Rezwanul Haque","2026","BIRDEM Medical Journal","case_report","article","10.3329/birdem.v16i1.87670",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055034","Effects of Letrozole And Metformin Versus Metformin alone on incretin in Iraqi patients with PCOS","Shatha Salih Mahdi","2024","South Eastern European Journal of Public Health","other","article","10.70135/seejph.vi.1127",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055035","PHARMACOLOGICAL TREATMENT FOR OBESITY: MECHANISMS OF ACTION, SAFETY AND THERAPEUTIC EFFICACY","Raquel Ribeiro Leão dos Santos","2026","International Journal of Health Management Review","other","article","10.47172/ijhmreview.v12i1.461",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055036","Therapie mit GLP1 Agonisten: Effektivität bei Problempatienten mit Diabetes mellitus Typ 2 (DM 2)","B Milke","2014","Diabetologie und Stoffwechsel","other","article","10.1055/s-0034-1375126",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055037","Experience in validating a method for assessing GLP-1R receptor activation in vitro upon stimulation with tirzepatide","A. N. Afanaseva","2026","Drug development & registration","preclinical","article","10.33380/2305-2066-2026-15-2-2145",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055038","HSD8 Assessing the Environmental Value of Semaglutide: Reduction in GHG Emissions Resulting From the Treatment of Obese Individuals With Type 2 Diabetes","Emily Archer Goode","2025","Value in Health","other","article","10.1016/j.jval.2025.09.1669",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055039","Incidence Rate and Predictors of Diabetic Retinopathy among Type 2 Diabetes Patients Using Subcutaneous Semaglutide: A Cross-Sectional Study","Jawhara Abdullah Alosaimi","2025","Journal of Diabetes and Endocrine Practice","other","article","10.1055/s-0045-1815649",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0055040","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evolving Insights into Pathogenesis, Progression, and Personalized Treatment Approaches","Paweł Kukiełka","2025","Quality in Sport","other","article","10.12775/qs.2025.43.61408",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055041","Erratum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl. 1):S158–S178","Nuha A. ElSayed","2024","Diabetes Care","other","article","10.2337/dc24-er07a","38696224",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0055042","Association Between Plausible Genetic Factors and Weight Loss from GLP-1 Receptor Agonists and Bariatric Surgery: A Review","Deborah Mayne","2025","Dinkum Journal of Medical Innovations","randomized_trial","article","10.71017/djmi.4.7.d-0453",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055043","The effectiveness of GLP-1 analogues compared to DPP-4 inhibitors for beta cell function and diabetes related complications among adults with type 2 diabetes: a systematic review protocol","Susan M. Bellman","2014","The JBI Database of Systematic Reviews and Implementation Reports","systematic_review","article","10.11124/jbisrir-2014-1858",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0055044","Tirzepatide – a new analogue of incretin hormones","Gabriela Anglart","2023","Farmacja Polska","other","article","10.32383/farmpol/174068",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055045","Semaglutide reduces body weight, but...","E. V. Kolmakova","2026","Nephrology (Saint-Petersburg)","other","article","10.36485/1561-6274-2026-30-1-103-111",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055046","Insights into the Early Use of Oral Semaglutide in Routine Indian Clinical Practice","Supratik Bhattacharyya","2022","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_15_23",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055047","An Integrated Approach to Obesity Management: Clinical Synergy Between GLP-1 Receptor Agonists and Sports Medicine. A Narrative Review.","Julia Kociuba","2026","Quality in Sport","other_trial","article","10.12775/qs.2026.55.71209",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","review"],["R0055048","Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review","Denise Deo Dias","2025","Obesities","randomized_trial","article","10.3390/obesities5040088",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0055049","A review on impact of glucose-lowering therapies on cardiovascular system in type 2 diabetes mellitus patients","Khatoon Ruquiyyah","2020","World Journal of Advanced Research and Reviews","narrative_review","article","10.30574/wjarr.2020.7.1.0242",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055050","CURRENT THERAPEUTIC APPROACHES IN THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME","A. Wojtala","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.2(50).2026.5328",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055051","2090-P: High Day-to-Day Glycemic Variability in Youth-Onset Type 2 Diabetes","Nicole Rangos","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2090-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055052","EP393 - ECE_1290 - Modulation of mitochondrial function and Ca2⁺ dynamics by semaglutide in pancreatic beta cells","Éverton Vogt","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.909",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055053","The Global Shortage of Glucagon-Like Peptide-1 Receptor Agonists","Dongwon Yi","2024","Journal of Korean Diabetes","other","article","10.4093/jkd.2024.25.1.1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055054","GLP-1 Analogues in Rheumatology - The Influence of Obesity on the Effectiveness of Biological Treatment","Julia Agnieszka Michalak","2026","Quality in Sport","other","article","10.12775/qs.2026.49.67355",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055055","What is the current best indication for using semaglutide in type II diabetic patients on two or more antidiabetic medications?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18079338",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055056","Water-enabled organometallic and enzymatic catalysis: Sustainable technologies supporting API manufacturing","Alessandra Tolomelli","2026","Current Opinion in Green and Sustainable Chemistry","narrative_review","article","10.1016/j.cogsc.2025.101058",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055057","178-OR: Prescription Patterns of Cardiovascular and Kidney Protective Therapies among Patients with Type 2 Diabetes","JULIO A. LAMPREA MONTEALEGRE","2022","Diabetes","nonrandomized_study","article","10.2337/db22-178-or",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055058","26-A-19858-ACC COMPARATIVE EFFECTIVENESS OF TIRZEPATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH HFPEF AND TYPE 2 DIABETES: A REAL-WORLD ANALYSIS","Mohamad Hasan Jawadi","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.560",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055059","Outcomes of glucagon-like-peptide-1 receptor agonists and patients undergoing total shoulder arthroplasty: a systematic review and meta-analysis","Troy B Puga","2026","Seminars in Arthroplasty JSES","systematic_review","article","10.1016/j.sart.2026.151583",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0055060","O RISCO DE INTOXICAÇÃO PELO USO DO OZEMPIC (SEMAGLUTIDA) EM PACIENTES NÃO DIABÉTICOS","Rebecka Marques Gomes Sagratzki","2023","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2023v5n4p1826-1837",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055061","2560-P: Development of FBL-140, a Best-in-Class, Once-Monthly Subcutaneous ActR2A/B Antagonist Antibody for Obesity and Related Comorbidities","SHUN HE","2026","Diabetes","preclinical","article","10.2337/db26-2560-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055062","Real World Effectiveness Of Lixisenatide And Other Intensification Therapy In The Management Of Type 2 Diabetic Patients Uncontrolled With Basal Insulin.","Obeid, Youssef","2018","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.1485177",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0055063","2838-LB: Cardiometabolic Effects of Semaglutide in OASIS 4 Participants by BMI Class","DOMENICA RUBINO","2026","Diabetes","randomized_trial","article","10.2337/db26-2838-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055064","Consistent Reduction of Postprandial Glucagon and Insulin by Lixisenatide in the GetGoal Clinical Trial Program","Sean N. Wharton","2013","Canadian Journal of Diabetes","other_trial","article","10.1016/j.jcjd.2013.08.108",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055065","The role of metformin in the light of the most recent Guidelines","G. Corigliano","2020","The Journal of AMD","other","article","10.36171/jamd20.23.1.07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055066","Impact of Preoperative Glucagon-Like Peptide-1 Receptor Agonists on Cervical Spine Fusion Outcomes: A 10-Year National Body Mass Index–Stratified Cohort Study","Arman Kishan","2026","Spine Open","nonrandomized_study","article","10.1097/bn9.0000000000000048",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055067","Novel Biomarkers in CKD","Bo Liang","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.0000000846","40911359",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055068","FLOW: Effects of Semaglutide on Kidney Failure Using the Kidney Failure Risk Equation","L. Sreenivasa Murthy","2025","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.20257qtjpx6z",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055069","Cardiovascular outcomes in a SELECT-like obesity population: real-world insights from the swedish AROS study","Viveca Ritsinger","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3760",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055070","Osteoarthritis May Be Partly a Metabolic Disease: Visceral Fat and the Joint","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.22121955",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","report; article"],["R0055071","HPR2 Baseline Characteristics of Patients Applying for Reimbursment of Liraglutide (Saxenda®) for Weight Management Under a Managed Access Protocol in Ireland","Conner Gorry","2023","Value in Health","protocol","article","10.1016/j.jval.2023.09.1321",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055072","P172 Weight management and GLP-1 receptor agonists in psoriatic disease: insights from a survey of rheumatology and dermatology professionals","J. Williams","2026","Lara D. Veeken","randomized_trial","article","10.1093/rheumatology/keag121.205",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0055073","Risk of suicidal thoughts and dizziness associated with tirzepatide: A systematic review and meta-analysis","Ranakishor Pelluri","2026","Journal of Applied Pharmaceutical Science","systematic_review","article","10.7324/japs.2026.284323",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055074","FiOCA Study:Comparative Transplant-Free Survival in Primary Biliary Cholangitis Patients Receiving Obeticholic Acid or Fibrates","Vincenzo Ronca","2026","Research at the University of Copenhagen (University of Copenhagen)","other","article","10.1016/j.dld.2026.01.146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055075","Use of GLP-1 Analogues in the Management of Obesity: An Updated Review","Gabriela Moura Romagna","2025","Medical & Clinical Case Reports Journal","narrative_review","article","10.51219/mccrj/ian-caldeira-ruppen/238",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055076","Navigating the kidney disease care cascade in type 2 diabetes: insights from the national diabetes registry","Soong Yiing Yap","2026","BMC Public Health","nonrandomized_study","article","10.1186/s12889-026-28520-9",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055077","An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis","Marina Vladimirovna Shestakova","2020","Diabetes Mellitus","nonrandomized_study","article","10.14341/dm12205",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055078","Perioperative Management of GLP-1 Receptor Agonists: Pathophysiology, Clinical Evidence, and Guideline Synthesis","Arshak Asefi","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.21641413",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0055079","Role Of Sglt2 Inhinitors in Modern Medicine","Jayesh M. Trivedi","2023","Clinical Sciences and Clinical Research","other","article","10.58489/2836-8959/003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055080","Effect of Submaximal-Dose Semaglutide on MASLD Biopsy-Free Scoring Systems in Patients with Obesity","Boris Focko","2026","Livers","other","article","10.3390/livers6010003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055081","TIRZEPATIDE BEYOND WEIGHT LOSS: A NARRATIVE REVIEW OF METABOLIC AND ORGAN-SPECIFIC EFFECTS","Jowita Wiktoria Maksymiuk","2026","Archiv Euromedica","randomized_trial","article","10.35630/2026/16/iss.4.13",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0055082","P2480Sub-optimal anti-diabetic treatment in patients with pre-existing and newly diagnosed diabetes admitted for acute myocardial infarction. A study from the FAST-MI 2015 registry","François Schiele","2019","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehz748.0810",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055083","GLP-1 Receptor Agonists and Reproductive Health","Florence Porterfield","2026","Endocrinology and Metabolism Clinics of North America","other","article","10.1016/j.ecl.2026.07.003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055084","What are the main risks of GLP-1 RA?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17926681",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055085","Target Trial Emulation: A Rigorous Framework for Causal Inference in Real-World Data Studies (Motivated by the OneFlorida+ Study on GLP-1RA and SGLT2i Use and Dementia Risk in Type 2 Diabetes by Tang et al.)","Ricardo S. Pietrobon","2025",null,"randomized_trial","article","10.31219/osf.io/yfpt8_v1",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","preprint"],["R0055086","Experimental and in silico models in molecular toxicology of NAFLD: Emerging role of combination therapeutics","Tejaswi .","2026","IP International Journal of Comprehensive and Advanced Pharmacology","preclinical","article","10.18231/j.ijcaap.93742.1771319163",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0055087","What is the best exercise to recommend alongside GLP-1 medications?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17790209",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055088","Semaglutide and Hospitalizations in Patients with Obesity and Established Cardiovascular Disease","Muhammad Hussain","2025","European journal of clinical pharmacy","nonrandomized_study","article","10.61336/ejcp/25-12-554",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055089","RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care","Anna Rubinski","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.09.2916",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055090","Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Mechanisms, Efficacy, and Safety","Michał Stasiak","2025","Quality in Sport","randomized_trial","article","10.12775/qs.2025.42.60634",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055091","Is the glucose ketone index a biomarker of metabolic flexibility?","Shaminie J. Athinarayanan","2026","Frontiers in Science","other","article","10.3389/fsci.2026.1963812",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055092","P363 - ECE_1283 - The effect of submaximal doses of semaglutide with metformin on fertility outcomes in obese PCOS patients: a prospective observational study","Tomáš Bolek","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.504",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0055093","NEW ERA IN DIABETES AND OBESITY TREATMENT - THE EFFECTS OF GLP-1R, GIPR AND GCGR TRIAGONISTS","Michał Duliński","2026","International Journal of Innovative Technologies in Social Science","other_trial","article","10.31435/ijitss.3(51).2026.6156",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055094","Metabolic Bariatric Surgery vs GLP-1 Receptor Agonists in Dialysis Patients with Diabetes and Obesity: A Target Trial Emulation Study","Chenxi Gao","2026","Surgery for Obesity and Related Diseases","nonrandomized_study","article","10.1016/j.soard.2026.09.014",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055095","GLP-1 ANALOGUES: THE NEW FRONTIER IN OBESITY TREATMENT","Marcus Vinícius Ferreira de Araújo","2025",null,"other","article","10.63330/aurumpub.009-007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055096","64792 Impact of GLP-1 Receptor Agonists on Psoriasis: A Systematic Review and Single-arm Meta-Analysis","Jiandra da Luz","2025","Journal of the American Academy of Dermatology","systematic_review","article","10.1016/j.jaad.2025.05.219",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0055097","Glucagon-like peptide-1 receptor signaling attenuates RSV-induced type 2 responses and immunopathology","Melissa Harintho Bloodworth","2017","The Journal of Immunology","preclinical","article","10.4049/jimmunol.198.supp.153.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055098","Dermatological, Trichological and Quality of Life Consequences of GLP ‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey","Janet Wangari‐Olivero","2026","Journal of Cosmetic Dermatology","nonrandomized_study","article","10.1111/jocd.71145",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055099","Eficacia dos diferentes agonistas do GLP-1 no tratamento da obesidade e melhora do padrão de sono em pacientes com apneia obstrutiva do sono","Alberto Lima de Souza Medeiros","2026","Contribuciones a las Ciencias Sociales","other","article","10.55905/revconv.19n.3-040",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055100","Positionspapier der DDG, DGA, DGG und DeGiR zur Diagnostik und Behandlung der pAVK bei Diabetes mellitus","Kilian Rittig","2025","Diabetologie und Stoffwechsel","other","article","10.1055/a-2593-4467",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055101","GLP-1 RECEPTORIŲ AGONISTŲ REIKŠMĖ 2 TIPO CUKRINIU DIABETU SERGANČIŲ PACIENČIŲ SVORIO MAŽINIMUI","Miglė Viliušytė","2024","Health Sciences","other","article","10.35988/sm-hs.2024.021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055102","Beyond Conventional Methods: Exploring New Avenues in Diabetes Care","Srinivasa Rao Y","2024","International Journal of Zoological Investigations","other","article","10.33745/ijzi.2024.v10i02.106",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055103","The ‘10 commandments’ for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","Katharina Schütt","2024","European Heart Journal","other_trial","article","10.1093/eurheartj/ehad881","38195096",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055104","MT2 EFFICACY AND MARKET SHARE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS FOR CURRENT OFF-LABEL USES: A TARGETED LITERATURE REVIEW","Rachel Gamburg","2026","Value in Health","narrative_review","article","10.1016/j.jval.2026.03.1462",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055105","Is there any best practice guidance on adding a GLP-1 to existing insulin therapy?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20185615",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055106","Obstructive Sleep Apnea in Obesity: The Role of Tirzepatide and Incretin Therapies","Natalia Kasterka","2026","Journal of Education Health and Sport","randomized_trial","article","10.12775/jehs.2026.92.72391",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055107","Body Composition and Physical Readiness in Military Servicemembers: Cross-Disciplinary Advances and Current Challenges","Christopher L. Chapman","2025","Exercise Sport and Movement","other","article","10.1249/esm.0000000000000050",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055108","Semaglutide Associated with Central Serous Chorioretinopathy: A Case Report","Lívia Peregrino Rodrigues","2025","Brazilian Journal of Case Reports","case_report","article","10.52600/2763-583x.bjcr.2025.5.1.bjcr93",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055109","Improved localization of insulinomas using 68Ga-NODAGA-exendin-4 PET/CT","Marti Boss","2023","Nuklearmedizin - NuclearMedicine","other","article","10.1055/s-0043-1766182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055110","Agonistas de receptor de GLP-1 para perda de peso em transtornos psiquiátricos : uma revisão sistemática e metanálise","Alves, Klara Müller","2025","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055111","26-A-19047-ACC PUBLIC INTEREST IN GLP-1 RECEPTOR AGONISTS FOR CARDIOVASCULAR DISEASE: GOOGLE TRENDS ANALYSIS REVEALS CRITICAL AWARENESS GAPS","Smith Frimpong","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.816",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055112","Are GLP-1 analogues safe for long-term use in adolescents with obesity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19002142",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055113","26-A-19312-ACC GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE AND OUTCOMES IN PERIPARTUM CARDIOMYOPATHY: A PROPENSITY-SCORE MATCHED ANALYSIS","Jyoti Jain","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.2647",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055114","Preconception, pregnancy and postnatal use of GLP-1RA based therapies in diabetes: a systematic review and international expert consensus statement on clinical need and human safety data in women with type 1, type 2 or gestational diabetes","Sarah Dib","2026","Research Portal (King's College London)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0055115","Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022","Maria Cecilia Lansang","2026","Diabetes Obesity and Cardiometabolic CARE","nonrandomized_study","article","10.2337/doc26-0027",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055116","Effectiveness of Switching to Insulin Soliqua in Type 2 Diabetes Mellitus Patients: Real-World Evidence (Soliqua Switch Study)","Ashwin Karuppan","2026","International Journal of Drug Delivery Technology","nonrandomized_study","article","10.25258/ijddt.16.36s.25",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055117","Beyond Glycemic Control: Neuroprotective Effects of Antidiabetic Drugs in Alzheimer’s Disease","Aishiq Hussain Ganie","2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.59s.140",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055118","Type 2 diabetes in obese people: between prevention and remission","Barana, L.","2025","The Journal of AMD","other","article","10.36171/jamd25.28.1-2.17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055119","Alopecia Universalis After Semaglutide: A Rare Adverse Event","Nina Modanlo","2026",null,"other","article","10.13140/rg.2.2.22910.14403",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055120","A NEW APPROACH TO TREATING OBESITY: INTEGRATING ADVANCED PHARMACOTHERAPY AND METABOLIC SURGERY IN A PERSONALISED TREATMENT ALGORITHM","Katarzyna Kleszczewska","2025","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.4(48).2025.4222",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055121","An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK . Diabet Med 2019; 36: 1063–1071","Stephen Charles Bain","2019","Diabetic Medicine","randomized_trial","article","10.1111/dme.14172","31691349",null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055122","Hydration as a Potential Modulator of Body Composition in Males and Females: A Literature Review","Niraj Shah","2025","International journal of high school research","narrative_review","article","10.36838/v7i12.23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055123","ORAL GLP-1 RECEPTOR AGONIST (ORFORGLIPRON) IN THE MANAGEMENT OF OBESITY AND TYPE 2 DIABETES","Valéria Goulart Viana","2026","Seven Editora eBooks","randomized_trial","article","10.56238/sevened2026.009-004",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","book-chapter"],["R0055124","MULTIDIRECTIONAL CLINICAL BENEFITS OF GLP-1 AGONISTS: A REVIEW OF EFFICACY IN WEIGHT LOSS AND CARDIOVASCULAR PROTECTION","Natalia Strugała","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(51).2026.6003",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055125","iGlarLixi vs BIAsp 30 patient-reported outcomes in people with type 2 diabetes—SoliMix trial subanalysis in India cohort","Veerabahu Ramasamy Mohan","2025","Diabetes Research and Clinical Practice","nonrandomized_study","article","10.1016/j.diabres.2025.112735",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055126","S1692 Post-Transplant Exposure to GLP-1RA Therapy May Be Associated With Improved Survival in Liver Transplant Recipients With Type II Diabetes Mellitus at 5 Years Post-Transplant Or Longer","Sudharshan Achalu","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001036136.50230.72",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055127","26-A-20019-ACC IMPACT OF GLP-1 RECEPTOR AGONISTS ON CLINICAL OUTCOMES IN PATIENTS WITH GROUP-2 PULMONARY HYPERTENSION: A REAL-WORLD EVIDENCE STUDY","Revanth Reddy Bandaru","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.1937",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055128","The Efficacy of Imeglimin and Metformin on Insulin Sensitivity and Secretion Using Oral Minimal Model: Sub‐Analysis of an Exploratory Randomised Controlled Trial","Ryota Usui","2026","Diabetes Obesity and Metabolism","randomized_trial","article","10.1111/dom.70693","41853858",null,"jRCT:jRCTs051220075",null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055129","In adults with severe obesity and comorbidities, does pharmacological treatment with GLP-1 agonists (such as semaglutide) achieve sustained weight loss and similar long-term metabolic improvement compared to bariatric surgery, with fewer complications?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22758276",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055130","3PC-031 Study on the adsorption of radiopharmaceuticals on syringe walls and sterilisation filters","Samuel Journo","2025",null,"other","article","10.1136/ejhpharm-2025-eahp.63",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0055131","Metabolic Syndrome in Lung Disease Patient and Its Impact on Other Organs","Firoz Khan","2026","Pan-African Journal of Health and Psychological Sciences","other","article","10.64261/v06s3029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055132","Managing Advanced Diabetic Kidney Disease in the UAE: National Consensus Recommendations for Dialysis, Transplantation, and Emergencies","Alaaeldin Bashier","2026","Journal of Diabetes and Endocrine Practice","nonrandomized_study","article","10.1055/s-0046-1824337",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055133","EFFECTS OF GLP-1 AGONISTS IN PATIENTS WITH CHRONIC HEART FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS","Natanael de Paula Portilho","2025","Journal of the American College of Cardiology","systematic_review","article","10.1016/s0735-1097(25)02078-9",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0055134","Hyderabad Obesity Trial (HOT): Role of Semaglutide in Obese Non-Diabetic Patients of Hyderabad Sindh","Imran Shaikh","2025","Medical Forum Monthly","other_trial","article","10.60110/36710",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055135","Gravicentric approach to Type 2 Diabetes therapy. The success prediction. A proof-of-concept","Shmuel Levit","2020","Pharmacy Formulas","other","article","10.17816/phf34728",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055136","P21 TRANSPORTABILITY-INFORMED CLINICAL AND ECONOMIC EVALUATION OF TIRZEPATIDE FOR LOCAL HTA DECISION-MAKING","Nathaniel Dyrkton","2026","Value in Health","other","article","10.1016/j.jval.2026.03.040",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055137","Application of Glucagon and Glucagon-Like Peptide Agonists in Disease Treatment","Jinqi Guo","2024","Transactions on Materials Biotechnology and Life Sciences","other","article","10.62051/bt1xqy29",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055138","Obesity, inflammation and HFpEF: Parts of the same circulus vitiosus","Katarina Milisavljević","2026","Srpski medicinski casopis Lekarske komore","nonrandomized_study","article","10.5937/smclk7-65653",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055139","GLP-1 RECEPTOR AGONISTS VERSUS METFORMIN IN POLYCYSTIC OVARY SYNDROME: METABOLIC BENEFITS, REPRODUCTIVE OUTCOMES AND THE EVIDENCE GAP IN LEAN PCOS","Nicole Bulińska","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.2(50).2026.5563",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055140","SARCOPENIC OBESITY IN THE ERA OF INCRETIN-BASED THERAPIES: DIAGNOSTIC CHALLENGES, THE RISK OF MUSCLE MASS LOSS, AND PREVENTION STRATEGIES","Anna Wolszczak","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(51).2026.5940",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055141","The glucagon-like peptide 1 agonist liraglutide increases heart rate in heart failure patients","Rasmus Stilling Tougaard","2017",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0055142","Association of glucagon-like peptide 1 receptor agonist use with erythropoietic indices and anemia risk in diabetes","Sean Woo","2026","Blood Red Cells & Iron","other","article","10.1016/j.brci.2026.100089",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055143","Application of Adult-Learning Principles to Patient Instructions: A Usability Study for an Exenatide Once-Weekly Injection Device","Gayle M. Lorenzi","2010","Clinical Diabetes","other","article","10.2337/diaclin.28.4.157",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055144","From PCOS to PMOS: a critical narrative review of the new nomenclature, diagnosis, and reproductive implications.","José Manuel Navarro-Pando","2026","The Journal of Reproduction","narrative_review","article","10.58779/tjorvol4num1/3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055145","Abstract 4345595: Five-Year Outcomes of Glucagon-Like Peptide-1 Agonists in Obstructive Hypertrophic Cardiomyopathy: A Population-Based Retrospective Study","Tze Ern Ong","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4345595",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055146","Does POLG2 Play a Role in Cerebellar Ataxia and Hypogonadotropic Hypogonadism?","Christian A. Koch","2026","Hormone and Metabolic Research","preclinical","article","10.1055/a-2773-6627","41617173",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055147","1687-P: Circulating miRNAs as Predictors of Weight Reduction in Type 2 Diabetes Treated with GLP-1 Receptor Agonist Dulaglutide: Secondary Analysis of AWARD-7 Trial","ANNA NOWAK-SZWED","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1687-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055148","Semaglutide (Ozempic), a Possible Cause of Focal Segmental Glomerulosclerosis (FSGS)","Jahanzeb Khan","2023","Journal of the American Society of Nephrology","other","article","10.1681/asn.20233411s1247c",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055149","Effect and Safety of Oral Semaglutide Monotherapy in Type 2 Diabetes—PIONEER 1 Trial","Vanita R. Aroda","2018","Diabetes","randomized_trial","article","10.2337/db18-2-lb",null,null,"ClinicalTrials.gov:NCT02906930","S001741","openalex","FALSE","paywalled","1","FALSE","article"],["R0055150","OUTCOMES OF PATIENTS WITH DIABETES MELLITUS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION STRATIFIED BY TREATMENT WITH OR WITHOUT GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONISTS","Bhavanadhar Penta","2024","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(24)02908-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055151","Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease: A Randomized, Double-Blind, Placebo-Controlled Trial (P9-11.005)","Camille Malatt","2022","Neurology","randomized_trial","article","10.1212/wnl.98.18_supplement.3068",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055152","The therapeutic inertia in T2 Diabetes management during Covid-19 pandemic","Elena Cimino","2022","The Journal of AMD","other","article","10.36171/jamd22.25.1.3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055153","Critical real‐world patient data observation of repurposable drugs from Alzheimer's disease drug development pipeline using Target Trial Emulation","Feixiong Cheng","2025","Alzheimer s & Dementia","nonrandomized_study","article","10.1002/alz70859_105905","41449788",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055154","All obesity is not created equal: implications for NP-agnostic HFpEF enrichment using the HFpEF-ABA score","Nicolas Bakinde","2026","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehag118","41790459",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055155","What is the evidence for GLP-1 receptor agonists in people with schizophrenia?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17753167",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055156","Editorial: Exploring innovative therapies for rare inflammatory skin diseases","Dennis Niebel","2026","Frontiers in Medicine","nonrandomized_study","article","10.3389/fmed.2026.1822888","41939760",null,"ClinicalTrials.gov:NCT07335588; ClinicalTrials.gov:NCT07013201; ClinicalTrials.gov:NCT07219420; ClinicalTrials.gov:NCT06588283; ClinicalTrials.gov:NCT06588296; ClinicalTrials.gov:NCT05263206","S000032; S001889","openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0055157","As consequências clínicas do uso de Ozempic no combate à obesidade: uma revisão","Maria Eduarda Diógenes de Freitas Queiroz","2024","STUDIES IN HEALTH SCIENCES","other","article","10.54022/shsv5n4-028",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055158","A Review of Obstructive Sleep Apnea Treatment: The Role of Surgery in Therapy and Alternative Treatment Modalities","Kacper Zielonka","2025","Quality in Sport","narrative_review","article","10.12775/qs.2025.40.59647",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055159","1258-OR: Performance of a Next-Generation Algorithm for Omnipod in Adults with Type 2 Diabetes: Findings from the STRIVE Randomized Trial","Anne Peters","2026","Diabetes","randomized_trial","article","10.2337/db26-1258-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055160","Impact of 1-Year Tirzepatide Use on Glycemic and Metabolic Profile in Overweight to Obese People with Type 1 Diabetes: A Systematic Review and Meta-Analysis","Deep Dutta","2025","Diabetes Technology and Obesity Medicine","systematic_review","article","10.1089/dtom.2025.0048",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055161","Racial and Ethnic Disparities in Prevalence and Care of Patients With Type 2 Diabetes","José E. Rodríguez","2017","Clinical Diabetes","other","article","10.2337/cd15-0048","28144049",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055162","GLP-1 receptor agonists and ischemic optic neuropathy in patients with type 2 diabetes and obesity: A TriNetX cohort study","Filipi Fim Andreão","2026","AJO International","nonrandomized_study","article","10.1016/j.ajoint.2026.100275",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055163","A comparative study of the antidiabetic and cardiopulmonary protective effects of Moringa oleifera and liraglutide in a rat model of alloxan-induced diabetes","Amal Naif Alshammari","2026","Journal of King Saud University - Science","preclinical","article","10.25259/jksus_1770_2025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055164","AGONISTAS DO RECEPTOR DE GLP-1 E SEUS EFEITOS PLEIOTRÓPICOS: DA TERAPIA METABÓLICA À PROTEÇÃO CARDIOVASCULAR E RENAL","Rafael Bavaresco Fiorante","2026","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v12i6.27178",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055165","Abstract Wed073: BRP3, a BRINP3-derived peptide hormone, reduces atherosclerotic burden via vascular cell-specific actions distinct from GLP1R-agonists","Alexa Berezowitz","2026","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvb.46.suppl_1.wed073",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055166","What is the recommended duration to stop GLP-1 receptor agonists before undergoing anaesthesia?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22202354",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055167","What is the latest information on GLP-1 access for different socioeconomic populations?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19644602",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055168","Semaglutide – sodium-glucose cotransporter-2 inhibitor combination therapy and ketoacidosis risk: A disproportionality analysis from the Food and Drug Administration Adverse Event Reporting System","R. Yukesh","2026","Perspectives in Clinical Research","nonrandomized_study","article","10.4103/picr.picr_153_26",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055169","26-A-21020-ACC LIFETIME COST-EFFECTIVENESS OF SEMAGLUTIDE FOR SECONDARY PREVENTION IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN VA: A SELECT-BASED SIMULATION STUDY","Sai Rahul Ponnana","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.834",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055170","MON-689 Medication Access and Outcomes for Real-World Treatment of Obesity and Diabetes with GLP-1s","Kaelen L. Medeiros","2025","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvaf149.027",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055171","Sodium‐Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction‐Associated Steatohepatitis","Jiayang Lin","2026","Journal of Diabetes","randomized_trial","article","10.1111/1753-0407.70206","41793082",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055172","Case report: Acute gastric remnant dilation following laparoscopic mini-gastric bypass in a patient using GLP-1 receptor agonist","Sana Shakil Ali","2025","GSC Biological and Pharmaceutical Sciences","case_report","article","10.30574/gscbps.2025.33.3.0501",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055173","Editorial: Nutrition as a pharmacological approach to metabolic disorders and ageing","Chiara Ruocco","2026","Frontiers in Pharmacology","nonrandomized_study","article","10.3389/fphar.2025.1770988","41635925",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","editorial"],["R0055174","Dietary Modulation and Clinical Outcomes During GLP-1 Receptor Agonist Therapy. A Literature Review","Kacper Rychlica","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.49.67649",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055175","GLP-1 and SGLT2 Therapies in Type 2 Diabetes Mellitus. Cutting-Edge Approaches to Advancing Diabetes Care","Agnieszka Parfianowicz","2025","Journal of Education Health and Sport","other","article","10.12775/jehs.2025.78.57478",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055176","Erratum: \"The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug\"","I. A. Lugovik","2026","Drug development & registration","notice","article","10.33380/2305-2066-2026-15-1-249-250",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0055177","A INFLUÊNCIA DAS REDES SOCIAIS NA AUTOMEDICAÇÃO: USO DO OZEMPIC","Francidete Fontenele de Brito","2025",null,"other","article","10.22533/at.ed.630112526029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055178","Dispensing practices, knowledge gaps, and educational needs of community pharmacists in Jordan regarding the use of diabetes medications for weight management","Jumanah D. Al-Shawabkeh","2026","Pharmacia","other","article","10.3897/pharmacia.73.e197960",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055179","METFORMIN VERSUS PHARMACOLOGIC AND NON-PHARMACOLOGIC INTERVENTIONS IN PCOS: A REVIEW OF METABOLIC AND ANTHROPOMETRIC OUTCOMES","Martyna Bukowiec","2025","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.3(47).2025.3839",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055180","Association between sodium-glucose cotransporter 2 inhibitors and the risk of chronic lower respiratory disease in type 2 diabetes mellitus: findings from two target trial emulations","Yuhao Li","2026","Respiratory Research","nonrandomized_study","article","10.1186/s12931-026-03861-6",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055181","The PICS Endotype Hypothesis: A Neuroimmunometabolic Framework for Precision GLP-1 Neurorecovery","Irami Araújo Filho","2026","Clinical Sciences and Clinical Research","other","article","10.58489/2836-8959/021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055182","Molecular Predictors for Fertility-Sparing Treatment in Endometrial Cancer and Atypical Hyperplasia","Luana Messias","2026","Journal of Cancer Therapy","nonrandomized_study","article","10.4236/jct.2026.176029",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055183","Insulin/GLP-1 Treatment for Patients with DM","Mette Zacho","2016","Journal of mucopolysaccharidosis and rare disease","other_trial","article","10.19125/jmrd.2016.2.2.50",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055184","Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycem1c Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin.","Anders H. Frid","2008","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(08)24118-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055185","Does treatment with semaglutide increase the risk of colon cancer recurrence?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18147790",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055186","Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.","Shah, Viral N",null,"Open Access CRIS of the University of Bern","randomized_trial","article","10.48620/77469",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0055187","In patients undergoing upper gastrointestinal endoscopy, does the use of GLP-1 receptor agonists increase the risk of residual gastric contents compared with non-use?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22179355",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055188","GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","B. K. Harvey","2020","Carolina Digital Repository (University of North Carolina at Chapel Hill)","preclinical","article","10.17615/4rxg-ny50",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055189","1766-P: VRB-103 Is a Potent, Orally Bioavailable Amylin Analog with a Strong Selectivity towards Human Amylin Receptors vs. Calcitonin Receptor","Martijn Fenaux","2026","Diabetes","preclinical","article","10.2337/db26-1766-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055190","(022) Age Trends in Decreased Sexual Function in Cisgender Women Taking GLP1 or GLP1/GIP Receptor Agonists","Emily K. Burr","2025","The Journal of Sexual Medicine","other","article","10.1093/jsxmed/qdaf320.022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055191","EVIDENCE-BASED MANAGEMENT OF OBESITY - ADVANCES IN LIFESTYLE INTERVENTIONS AND PHARMACOTHERAPY","Agaaj Shaikh*1, Dr. Kelgaonkar Prajakta2, Pratiksha Jadhav1, Vedika Mali1, Ashwini Khandagale1","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22896553",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055192","Comparative Effects of GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors on Lipid Profiles: A Large Real-World Propensity-Matched Analysis","Ahmed Ghanem","2026","Journal of clinical lipidology","nonrandomized_study","article","10.1016/j.jacl.2026.05.172",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055193","Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome and Women’s Reproductive Health: Metabolic and Reproductive Effects and Preconception Strategies","Aleksandra Płusa","2026","Reproductive and Developmental Medicine","randomized_trial","article","10.1097/rd9.0000000000000178",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055194","SGLT2 inhibitor treatment does not increase risk of osteoporotic fractures compared to GLP-1 receptor agonists: a Danish population-based cohort study","Zheer Kejlberg Al-Mashhadi","2022","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.81.oc8.2",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0055195","Fixed-dose glargine and lixisenatide: a practical option to minimize hypoglycemia and weight gain in type 2 diabetes","S. Samrat Samajdar","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112579",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055196","VALIDATION OF A METHOD FOR ASSESSING GLP-1R RECEPTOR IN VITRO UPON STIMULATION WITH TIRZEPATIDE","D.O. Ermolaeva","2025",null,"preclinical","article","10.25205/978-5-4437-1843-9-255",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0055197","OPÇÕES FARMACOTERAPÊUTICAS NÃO INSULÍNICAS PARA O MANEJO DO DIABETES MELLITUS TIPO 2: UMA REVISÃO DE LITERATURA","José Rodrigues dos Santos Júnior","2025","Revista fisio&terapia.","other","article","10.69849/revistaft/fa10202507032221",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055198","The impact of tirzepatide on the development of pancreatitis: a literature review","Filip Jacek Maj","2025","Medical Science","nonrandomized_study","article","10.54905/disssi.v29i158.e74ms3568",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055199","A scoping review of the bidirectional relationship between incretin mimetics and nutrition in adults and children","Arden L. McMath","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/vc8hg",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0055200","What are the protocols for safely discontinuing GLP-1 agonists in pediatric patients with type 2 diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22866146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055201","Glucagon-like peptide-1 receptor agonists: prospects for use in the treatment of age-related diseases and aging","Natalia Bobok","2025","Problems of ageing and longevity (Ukraine)","nonrandomized_study","article","10.71012/pro-ageing-2025-4-05",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055202","Impact of Baseline Characteristics and Medications on GLP-1RA Cardiovascular Outcomes: A Meta-Analysis","Samit Ghosal","2025","Endocrine Practice","systematic_review","article","10.1016/j.eprac.2025.09.142",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0055203","Can semaglutide tablets be crushed for patients with swallowing difficulties?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18946961",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055204","RWD5 TRENDS IN THE USE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS), DIAGNOSIS REQUIREMENTS, AND BENEFICIARY USE AMONG US SELF-INSURED EMPLOYERS","Richard A. Brook","2026","Value in Health","other","article","10.1016/j.jval.2026.03.1994",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055205","Chitosan-based multimodal polymeric nanoparticles targeting pancreatic β-cells","Lorenzo Rossi","2024","Carbohydrate Polymer Technologies and Applications","preclinical","article","10.1016/j.carpta.2024.100610",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055206","Residual gastric content and aspiration-related outcomes in perioperative patients treated with semaglutide: A systematic review and meta-analysis","Vinicius Remus Ballotin","2026","World Journal of Gastrointestinal Surgery","systematic_review","article","10.4240/wjgs.121449",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0055207","Is there clinical evidence supporting the use of semaglutide for patients with dumping syndrome after gastric surgery?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20510155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055208","Evaluation of GLP-1 Receptor Agonist Liraglutide in Zebrafish Model of Alzheimer’s Disease using Behavioral and Biochemical Correlates – A Preclinical Study","Vasudha Krishnen","2026","Journal of Pharmaceutical Innovation","preclinical","article","10.1007/s12247-026-10685-w",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055209","Reevaluating the comparative effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RA) vs aspirin for colorectal cancer prevention in type 2 diabetes.","Junmin Song","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e15690",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055210","Differential effects on metabolic parameters between sitagliptin and alogliptin in drug naïve subjects with type 2 diabetes","Eiji Kutoh","2012","journal of Diabetes Research and Clinical Metabolism","other","article","10.7243/2050-0866-1-17",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055211","2637-P: Safety, Tolerability, and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial","ILDIKO LINGVAY","2026","Diabetes","randomized_trial","article","10.2337/db26-2637-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055212","Prescription Drugs and Dietary Supplements for Weight Loss","Robert Emrie Smith","2015","Advances in Obesity Weight Management & Control","other","article","10.15406/aowmc.2015.03.00045",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055213","Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA) in Lung Transplant","Helen Sweiss","2025","American Journal of Transplantation","other","article","10.1016/j.ajt.2025.07.1157",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055214","‘Dulaglutide induced weight loss in a morbidly obese adult with Type 2 diabetes mellitus: A Case Report’","Sohail Bade","2024",null,"case_report","article","10.22541/au.172115447.70859792/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0055215","Is there any guidance for using a GLP-1 in combination with insulin?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20185575",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055216","Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity","Kornela Kotucha","2025","European Journal of Clinical and Experimental Medicine","nonrandomized_study","article","10.15584/ejcem.2025.4.24",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055217","Weight and Glycemic Outcomes Following GLP-1 Receptor Agonist Therapy in People Living with HIV: A Retrospective Study at a Bronx Hospital","Dimitri A. Raptis","2026","Diabetology","nonrandomized_study","article","10.3390/diabetology7080155",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055218","E-107 | Role of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Meta-analysis","Muhammad Faizan Ali","2025","Journal of the Society for Cardiovascular Angiography & Interventions","systematic_review","article","10.1016/j.jscai.2025.103368",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0055219","Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis","Kia Vosoughi","2022","Obesity Medicine","systematic_review","article","10.1016/j.obmed.2022.100456",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0055220","MODERN APPROACHES TO OBESITY TREATMENT WITH CONSIDERATION OF PHARMACOTHERAPY AND DIET THERAPY","Kacper Szkodziński","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(51).2026.5735",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055221","Semaglutide sustained-release microspheres with single-phase zero-order release behavior: Effects of polymer blending and surfactants","Wenjing Jiang","2025","Journal of Drug Delivery Science and Technology","other","article","10.1016/j.jddst.2025.106793",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055222","Diabéticos sem semaglutido: que implicações?","USF Linda-a-Velha","2024","Revista Portuguesa de Clínica Geral","other","article","10.32385/rpmgf.v40i2.13744",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055223","Can sleep clinics manage patients with obstructive sleep apnea using GLP-1/GIP medications?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22904126",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055224","Primary Care Approaches to MASLD in Type 2 Diabetes","Ethan Lam","2026","Journal of the Osteopathic Family Physicians of California","other","article","10.58858/050301",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055225","Glycogenic Hepatopathy Mimicking Overlapping with Metabolic Dysfunction-Associated Steatotic Liver Disease in Newly Diagnosed Type 2 Diabetes: A Case Report","Pooja Khatiwala","2026","SAGE Open Medical Case Reports","case_report","article","10.1177/2050313x261492855",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055226","EFFECT OF TIRZEPATIDE ON THE REDUCTION OF CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Pedro Henrique Souza e Silva","2026","Seven Editora eBooks","randomized_trial","article","10.56238/sevened2026.020-037",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","book-chapter"],["R0055227","Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists","Christopher Vannabouathong","2022","Canadian Journal of Health Technologies","nonrandomized_study","article","10.51731/cjht.2022.434",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055228","Semaglutide in Obesity (STEP-1 Trial)-2021","Samantha P. Flanagan","2023",null,"other_trial","article","10.1007/978-3-031-25620-2_44",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","book-chapter"],["R0055229","Advanced Transdermal Systems for Non-Invasive Delivery of GLP-1 Agonists in Treatment of Diabetes","Kumari Preeti Jaiswal","2026","Current Chemical Biology","other","article","10.2174/0122127968426164251211151238",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055230","3089-LB: Comparative Efficacy of Obesity Treatments on Major Adverse Cardiovascular Events, Heart Failure, and All-Cause Mortality in Adults with Overweight and Obesity: A Systematic Review and Network Meta-analysis","Shohinee Sarma","2026","Diabetes","systematic_review","article","10.2337/db26-3089-lb",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0055231","Comprehensive Evaluation of GLP1 Receptor Agonists in Modulating Inflammatory Pathways and Gut Microbiota","Yawen Wang","2024","Journal of improved oil and gas recovery technology.","preclinical","article","10.53469/wjimt.2024.07(06).23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055232","What role will physiological resilience play in brown-white fat dynamic in obesity management?","Oksana Zayachkivska","2026","Frontiers in Pharmacology","other","article","10.3389/fphar.2025.1691149","41560730",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055233","Pharmacological Management of Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Multi-Pillar Cardiorenal-Protective Approach","Mosrur Ahmed","2025","Journal of Prevention Diagnosis and Management of Human Diseases","nonrandomized_study","article","10.55529/jpdmhd.51.90.102",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055234","SAT-813 Effect Of Glucagon-like Peptide-1(glp-1) On Weight Reduction In Non-diabetic Pcos Women With Obesity In Kuwait","Amna Ali Shaghouli","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1301",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055235","P1 Phase 3 ESSENCE trial evaluating semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): part 1 results and secondary analysis","Philip Noel Newsome","2025",null,"randomized_trial","article","10.1136/gutjnl-2025-basl.19",null,null,"ClinicalTrials.gov:NCT04822181","S000511","openalex","FALSE","paywalled","1","FALSE","conference-paper"],["R0055236","WCN26-5615 A 6-WEEK TREATMENT WITH SEMAGLUTIDE IMPROVES BOTH KIDNEY DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION IN THE SDT FATTY RAT MODEL","François Briand","2026","Kidney International Reports","preclinical","article","10.1016/j.ekir.2026.104481",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055237","ONE DRUG TO FIX IT ALL? THE ROLE OF TIRZEPATIDE IN TREATING COMPONENTS OF METABOLIC SYNDROME","Sylwia Tomasiczek","2025","International Journal of Innovative Technologies in Social Science","other_trial","article","10.31435/ijitss.4(48).2025.4180",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0055238","Liraglutide (analogous to the hormone GLP1) activates the central anorexigenic pathway in diet-induced obese male mice","André Rodrigues da Cunha Barreto Vianna","2014","LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055239","Poster Viewing Session I","Thompson, G.J.","2017","Journal of Cerebral Blood Flow & Metabolism","randomized_trial","article","10.1177/0271678x17695982","28366130",null,"ClinicalTrials.gov:NCT01469351","S001707","openalex","TRUE","open_pdf","1","FALSE","article"],["R0055240","305 Are Obese Individuals More Responsive to the Gastric Effects of GLP-1 Receptor Agonists? a Meta-Analytic Perspective","Hazem Maarouf Abosheaishaa","2025","British journal of surgery","nonrandomized_study","article","10.1093/bjs/znaf270.222",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055241","Real-world effectiveness of tirzepatide among individuals with obesity or overweight","C Chinthammit","2026","Diabetologie und Stoffwechsel","nonrandomized_study","article","10.1055/s-0046-1819893",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-paper"],["R0055242","A real-world analysis on the management of post-mastectomy lymphedema in breast cancer patients: The therapeutic promise of glucagon-like peptide-1 receptor agonist.","Muluken Megiso","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.e12695",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055243","Beyond GLP-1R: Dynamic Glucagon Receptor Family Signalling May Determine Antifibrotic Responses to Incretin-Based Therapies.","María Andrés‐Rozas",null,"Open Access CRIS of the University of Bern","other","article","10.48620/99513",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055244","Microvascular Recruitment in Insulin Resistance","Kim Anker Sjøberg","2014",null,"preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055245","Emerging Biomaterial, Non-Surgical and Minimal Invasive Therapies Based Strategies for the Management of Hyperlipidemia","Vikas R. Dhole","2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.56s.144",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055246","Significantly Better Glycemic Control and Weight Reduction with Liraglutide, a Once-daily Human GLP-1 Analog, Compared with Insulin Glargine: All as Add-on to Metformin and a Sulfonylurea in Type 2 Diabetes.","O. Schmitz","2008","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(08)24116-x",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055247","Nature-Inspired Continuous N-C Chain Elongation Enables Sustainable Peptide Synthesis","Jingjun Yin","2025","ChemRxiv","other","article","10.26434/chemrxiv-2025-9zf56",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0055248","Abstract 4364820: Impact of GLP-1 Agonists on Cardiovascular Outcomes in Patients with Heart failure with Preserved Ejection Fraction: Analysis of Real-world studies","Abdul-Rahaman Adedolapo Ottun","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4364820",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0055249","MON-572 Characterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2-1.8, and >1.8 µg/dL: Findings From the CATALYST Part 1 Study","Richard Joseph Auchus","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.938",null,null,"ClinicalTrials.gov:NCT05772169",null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055250","Evaluating gastrointestinal side effects and discontinuation rates of semaglutide in routine clinical practice: A prospective observational study.","Monika Patel Kodela","2025","Student s Journal of Health Research Africa","nonrandomized_study","article","10.51168/sjhrafrica.v6i9.2037",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055251","Are GLP-1 receptor agonists safe for adult patients with lysosomal disorders?","Giovanna Jost Tibolla","2026","Molecular Genetics and Metabolism","other","article","10.1016/j.ymgme.2025.109490",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055252","Abstract 15300: Tirzepatide vs. Semaglutide for Weight Loss in Patients With Type 2 Diabetes Mellitus - A Value for Money Analysis","Joseph Azuri","2022","Circulation","other","article","10.1161/circ.146.suppl_1.15300",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055253","Pharmacology and Clinical Efficacy of Semaglutide in the Management of Type 2 Diabetes Mellitus","Naga Lakshmi A","2025","Journal of Pharma Insights and Research.","other_trial","article","10.69613/9dd27k52",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055254","How effective is semaglutide in reducing weight while taking olanzapine?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18354633",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055255","A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies","Laura Răducu","2024","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","FALSE","no_doi","3","FALSE","preprint"],["R0055256","Multidisciplinary Management of Diabetic Ketoacidosis as an Emergent Complication of Diabetes: Integrating Epidemiology, Primary Care, Radiology, Pharmacy, Nursing, Dental Hygiene, and Family Medicine in a Community Health Framework","Musaad Ibrahim Saleh Altuwayjiri","2025","Saudi Journal of Medicine and Public Health","other","article","10.64483/202522672",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055257","Quantitative Systems Pharmacology (QSP) Modeling of efficacy and nausea of GLP-1 mono and dual (GLP-1/GIP) receptor agonists (RA) to support weight management and glycemic control in obese patients","E Shivaani","2026",null,"other_trial","article","10.70534/uset1356",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","conference-paper"],["R0055258","Non-Pharmacological and Pharmacological Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): An Update","Mariya Tabassum","2025","Mugda Medical College Journal","other","article","10.3329/mumcj.v7i2.78800",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055259","Effect of the GLP-1 Analog Liraglutide on Glycemic Control and Weight Reduction in Patients on Metformin and Rosiglitazone: a Randomized Double-Blind Placebo- Controlled Trial.","Bernard Zinman","2008","Canadian Journal of Diabetes","randomized_trial","article","10.1016/s1499-2671(08)24115-8",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055260","Ozempic (Glucagon-like peptide 1 receptor agonist) in social media posts: Unveiling user perspectives through Reddit topic modeling","Seraphina Fong","2024","Emerging Trends in Drugs Addictions and Health","other","article","10.1016/j.etdah.2024.100157",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055261","The Influence of GLP-1 Receptor Agonists on Wound Healing After Surgery: What Current Evidence Tells Us","Karolina Fengler","2026","Quality in Sport","other","article","10.12775/qs.2026.61.73196",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055262","GLP-1RA and aspiration risk in moderate sedation for endoscopy","Lucia Costanza","2026","JCA advances.","nonrandomized_study","article","10.1016/j.jcadva.2026.100239",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055263","Development and Characterization of Modified Release Dosage Form Utilizing Semaglutide","Aanchal Dangi","2025","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.15.2.28",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055264","Efficacy and Safety of oral Semaglutide in type 2 “Diabetes Mellitus” – A Systemic review and its Analytical Techniques.","Krimal Somani","2024","African Journal of Biomedical Research","nonrandomized_study","article","10.53555/ajbr.v27i4s.5178",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055265","Risk of Suicide From GLP-1 Agonists: Weighing Risks and Benefits","Andrew A. Nierenberg","2024","Psychiatric Annals","other","article","10.3928/00485713-20240916-01",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055266","EP600 - ECE_2544 - Metabolic-reproductive restoration in obese women with polycystic ovary syndrome treated with tirzepatide: a one-year single-arm interventional study","Valentina Gavazova","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1044",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0055267","Are there alternative medications to GLP-1s and GLP-1 analogs that have a lower risk of macular oedema, optic neuritis, and NAION for patients with existing ocular conditions?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21342969",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055268","EE69 Cost-Effectiveness Analysis of Introducing Semaglutide Oral and Semaglutide Injection for the Treatment of Diabetes Type II From the Perspective of the Saudi MOH Using Bespoke Utility Mapping Method","Ahmed Al Jedai","2024","Value in Health","other","article","10.1016/j.jval.2024.10.353",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055269","Two-year Effect of Semaglutide 2.4 mg on Control of Eating in Adults with Overweight/Obesity: STEP 5","Wharton, S","2021","UCL Discovery (University College London)","randomized_trial","article",null,null,null,"ClinicalTrials.gov:NCT03693430","S000214","openalex","TRUE","no_doi","1","FALSE","article"],["R0055270","Impact of GLP-1 Receptor Agonists on Body Composition and Physical Performance in Patients with Obesity: A Comprehensive Review of Current Research","Konrad Turczynowski","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.51.68929",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055271","Tirzepatide Safety and Efficacy in Managing Type 2 Diabetes and Obesity: A Systemic Review and Meta-Analysis","Abrar Abdullateef Soqati","2024","Journal of Healthcare Sciences","systematic_review","article","10.52533/johs.2024.40902",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0055272","Structural Mass Spectrometry Resolves the Conformational Dynamics of Semaglutide Oligomerization","Si Huang","2026","Journal of the American Chemical Society","nonrandomized_study","article","10.1021/jacs.6c12077",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055273","The developmental trajectory of GLP-1 receptor agonists","Binbin Kou","2025","Elsevier eBooks","other","article","10.1016/b978-0-443-27402-2.00001-2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0055274","The neuroprotective effects of the anti-diabetic drug linagliptin against Aß-induced neurotoxicity","Chien‐Ning Huang","2016","Neural Regeneration Research","other","article","10.4103/1673-5374.177724","27073371",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055275","SA66 Temporal Trends in Prescription of GLP-1RAs for Weight Loss: Insights From a Five-Year Retrospective Analysis in the US","Vishal Choudhary","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.1821",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0055276","Efeitos adversos dos análogos do GLP-1: Uma revisão sistemática","Benjamín Santos","2025","Research Society and Development","other","article","10.33448/rsd-v14i1.47981",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055277","Barriers to Use of Cardio-Kidney Protective Medications in CKD: Results of a Nephrology Provider Survey","Melanie R. Weltman","2025","Journal of the American Society of Nephrology","other","article","10.1681/asn.202558bynnp9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055278","Abstract 4349177: Adiposity and Cardiac Function in South Asian Americans: Findings from the MASALA Study","Alka M. Kanaya","2025","Circulation","other","article","10.1161/circ.152.suppl_3.4349177",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055279","Community pharmacies as platform for collection of real-world evidence of medicines usage explored through a pilot study: From standard T2D medication to treatment with the injectable combination product Xultophy","N Alkis","2019","Research at the University of Copenhagen (University of Copenhagen)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0055280","Gut microbiome-focused dietary interventions in weight management: causal evidence, precision nutrition and emerging gut-targeted therapies","Enoch Chi Ngai Lim","2026","Nutrition & Food Science","other","article","10.1108/nfs-05-2026-0239",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055281","Semaglutide and cognitive function in individuals with mental disorders","R. De Giorgi","2026","Neuroscience Applied","other","article","10.1016/j.nsa.2025.106243",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055282","Faculty of Anaesthesiology, Reanimation and Perioperative Medicine | The AHMAD Pathway for Surgical Readiness: A Multidisciplinary Metabolic-Respiratory Prehabilitation and Perioperative Decision Instrument","Mahmood Ahmad","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22182032",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055283","Perioperative Management of GLP-1 Receptor Agonists: Balancing Aspiration Risk with Therapeutic Benefit","Enoch Chi Ngai Lim","2025","SN Comprehensive Clinical Medicine","other","article","10.1007/s42399-025-02079-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055284","TCT-767 Clinical Outcomes of GLP-1 Receptor Agonist Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement: A Large-Scale Propensity-Matched Analysis","Amer Muhyieddeen","2025","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2025.09.936",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055285","Hémoglobine glycquée (HbA1c), facteur indépendant de mortalité chez des patients non diabétiques présentant une maladie rénale chronique","Claire Trivin","2013","Néphrologie & Thérapeutique","other","article","10.1016/j.nephro.2013.07.144",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055286","Correction: A non-invasive method for screening mitochondrial diabetes","Hangyu Fang","2025","Frontiers in Genetics","notice","article","10.3389/fgene.2025.1645252","40697536",null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0055287","(348) Clinical Pharmacology and Real-World Performance of Hezkue: A Novel Sildenafil Oral Suspension Without the Negative Food Effect Seen in Conventional Formulations","Steven A. Kaplan","2025","The Journal of Sexual Medicine","nonrandomized_study","article","10.1093/jsxmed/qdaf320.343",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055288","26-A-17349-ACC COMPARATIVE OUTCOMES OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS AFTER CABG IN PATIENTS WITH TYPE 2 DIABETES","Navya Pillikunte Doddareddy","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.696",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055289","FFA1/Gq - Gi interaction determines glucose-induced insulin secretion of neonatal beta cells","Felicia Gerst","2022","Research at the University of Copenhagen (University of Copenhagen)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055290","In New Zealand, can a patient be eligible for empagliflozin and GLP-1 RA?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18615397",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055291","Neuroendocrine Mediators, Food Intake and Obesity: An Updated Narrative Review","Carella Am","2022","Book Publisher International (a part of SCIENCEDOMAIN International)","narrative_review","article","10.9734/bpi/cimms/v4/7781f",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0055292","High discontinuation rates of oral semaglutide: a barrier to tackling diabesity in Indian patients","A. Kedia","2025","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2025.112589",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055293","IP10-11 PRELIMINARY ASSESSMENT OF GLP-1 RECEPTOR AGONISTS ON TESTOSTERONE LEVELS, ERECTILE FUNCTION, AND METABOLIC OUTCOMES IN MEN WITH OBESITY OR TYPE 2 DIABETES","Nathalie Eid","2025","The Journal of Urology","other","article","10.1097/01.ju.0001109900.23127.a9.11",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055294","L26/O-097 Preconception GLP-1 receptor agonist exposure in couples and fertility outcomes: a danish nationwide cohort study","K.V.R. Hviid","2026","Human Reproduction","nonrandomized_study","article","10.1093/humrep/deag083.097",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055295","Do GLP-1 receptor agonists vary in their effects on muscle quality compared to one another?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22388986",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055296","Nonalcoholic Fatty Liver Disease in the Era of MAFLD: Emerging Insights into Mechanisms, Diagnosis, and Personalized Management Global Burden and Economic Impact","Jampala Raghu Ram","2026","Journal of Pharmaceutical Research and Integrated Medical Sciences","nonrandomized_study","article","10.64063/3049-1681.vol3.issue7.000282",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055297","“New Horizons in T2DM Management: A Review of Emerging Antidiabetic Medications”","Sarojit Das","2025","Faridpur Medical College Journal","narrative_review","article","10.3329/fmcj.v20i2.83147",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055298","Semaglutide-induced status epilepticus","Jelena Findeis","2026","Clinical Epileptology","other","article","10.1007/s10309-026-00835-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055299","Insulin Resistance: Implications for Nutrition, Oncology, and Diabetes Management-An Updated Review","Amira Mansoor Salman Alenazi","2026","Saudi Journal of Medicine and Public Health","narrative_review","article","10.64483/202522547",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055300","Wegovy, Mounjaro & Co. – Der Anfang vom Ende der bariatrischen Chirurgie?","Tim C. Werner","2025","Adipositas - Ursachen Folgeerkrankungen Therapie","other","article","10.1055/s-0045-1810555",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0055301","Abstract 14504: Gender and Racial Disparities in Patients Using Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Analogues in a Real-World Scenario","Aakash Tuli","2022","Circulation","nonrandomized_study","article","10.1161/circ.146.suppl_1.14504",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055302","White Adipose Tissue Browning and Cross Talk With Metabolic Diseases and Tumors: From Molecular Mechanisms to Clinical Translation","Yingjiao Wang","2026","Med Research","other","article","10.1002/mdr2.70056",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055303","Management of obesity in pregnancy","Lauren Ferris","2022","Australian and New Zealand Journal of Obstetrics and Gynaecology","randomized_trial","article","10.1111/ajo.13610","36250401",null,"ANZCTR:ACTRN12620001238965; ANZCTR:ACTRN12621000128897",null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055304","Patients with normal spirometry results in community diagnostics: the role of BMI","D. G. Ward","2025",null,"nonrandomized_study","article","10.1183/13993003.congress-2025.pa4137",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055305","1682-P: ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment","SeungHwan Lee","2026","Diabetes","randomized_trial","article","10.2337/db26-1682-p",null,null,"ClinicalTrials.gov:NCT06635226",null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055306","AI-Assisted Pharmacovigilance via Multi-Source Data Integration: A Comparative Safety Signal Analysis of Semaglutide and Sertraline","Sharath Kasula","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.21286904",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0055307","Euglycemic Ketoacidosis After the Addition of Glucagon-Like Peptide-1 Receptor Agonist: A Case Report","Ernest Oji Kanu","2024","Annals of Internal Medicine Clinical Cases","case_report","article","10.7326/aimcc.2023.0565",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055308","Integrated management of cardio-renal-metabolic syndrome: Egyptian multi-society expert consensus and clinical practice algorithm","Mohamed Sobhy","2026","European Heart Journal Supplements","nonrandomized_study","article","10.1093/eurheartjsupp/suag109.004",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055309","Semaglutide e obesità grave in età pediatrica: benefici, rischi e questioni etiche","Federico Marchetti","2026","Medico e Bambino","other","article","10.53126/meb45017",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055310","The mode and mechanism of action of once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes","Terry Ridge","2018","Journal of the American Association of Nurse Practitioners","other","article","10.1097/jxx.0000000000000114",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055311","Perceptions and Preferences Toward GLP-1 Receptor Agonists in Type 2 Diabetes Management in Saudi Arabia: A Cross-sectional, Two-arm Study","Abdulrahman Alshaikh","2022","Acta Scientific Medical Sciences","other","article","10.31080/asms.2022.06.1388",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055312","Abstract 4363572: Comparative Effectiveness of SGLT2 Inhibitors with and without GLP-1 Receptor Agonists in Patients with Heart Failure and Type 2 Diabetes Mellitus","Sultana Jahan","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4363572",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055313","Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists","N.M. Bobok","2025","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","other","article","10.22141/2224-0721.21.3.2025.1544",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055314","Diabetes Mellitus in the 21st century: Challenges, Breakthroughs, and Unmet Needs","Vishu Verma","2026","Pan-African Journal of Health and Psychological Sciences","other","article","10.64261/p91hzy25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055315","Unveiling Hidden Microbial Metabolites for Polypharmacology in Obesity Therapeutics - GLP-1 Updated","Youngs, Ross","2024","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.16908246",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055316","Impactos sistêmicos do uso off-label da semaglutida","Gabriela Hühne Porto","2024","Revista Eletrônica Acervo Científico","other","article","10.25248/reac.e18999.2024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055317","Novel obesity treatments","Shohinee Sarma","2023","Canadian Medical Association Journal","other","article","10.1503/cmaj.230820","37984936",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055318","THE ROLE OF HYPOGLYCEMIC AGENTS IN AMELIORATING COGNITIVE FUNCTIONS AND PSYCHIATRIC SYMPTOMS: FROM THE PSYCHIATRIC PATIENT TO EVIDENCE-BASED AND PHARMACOEPIDEMIOLOGIC APPROACHES FOR SUPPORTING THE CLINICAL PRACTICE","E.G.I. Clementi","2024","Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0055319","2201-P: Effectiveness and Safety of SGLT2i, GLP-1RA, and DPP-4i in Adults with T2D at Low-to-Moderate Cardiovascular Risk: An International Cohort Study","HANSEUL CHO","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2201-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055320","Pharmacological and Non- Pharmacological Strategies for the Prevention and Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia: A Narrative Review","Aleksandra Pietrucień","2026","Medical Science","narrative_review","article","10.54905/disssi.v30i172.e106ms3884",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055321","#2545 Home medication in the US based on the assignment of NDC to ATC codes","Judith Wiegand","2025","Nephrology Dialysis Transplantation","nonrandomized_study","article","10.1093/ndt/gfaf116.1649",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055322","Glucagon-like-peptide-1 receptor agonists in diabetes mellitus","Mohamed Mustapha Abu","2025","Diabetes Mellitus","other","article","10.1016/b978-0-443-29129-6.00006-3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055323","Tirzepatide vs. Cagrilintide/Semaglutide: A New Frontier in Pharmacological Management of Obesity","Marcelina Rybińska","2026","Journal of Education Health and Sport","other","article","10.12775/jehs.2026.95.73651",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055324","Shared Hyperphagia phenotypes and variable response to semaglutide in adults with neurodevelopmental obesity","Emilie Guillon","2026","Journal of Neurodevelopmental Disorders","nonrandomized_study","article","10.1186/s11689-026-09731-y",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055325","MON-183 Effect of GLP-1 Receptor Agonists on Anthropometric, Metabolic and Fertility Parameters in Polycystic Ovarian Syndrome: A Systematic Review and Meta-Analysis","Nidhi Lanka","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.1915",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055326","A Scoping Review on Recent Advances in Antidiabetic Medications: From GLP-1 Receptor Agonists to Dual and Triple Agonists","Gülali Aktaş","2025","Advances in Clinical Pharmacology and Therapeutics","narrative_review","article","10.63623/8cv4gh26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055327","EP824 - ECE_1397 - Phased management of type 2 diabetes, obesity, and stress urinary incontinence using GLP-1 receptor agonist therapy and artificial urinary sphincter: a case report","Ivana Mickovski","2026","European Journal of Endocrinology","case_report","article","10.1093/ejendo/lvag096.1161",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055328","Poster Viewing Session II","O. Henriksen","2017","Journal of Cerebral Blood Flow & Metabolism","randomized_trial","article","10.1177/0271678x17695989","28366134",null,"ClinicalTrials.gov:NCT01469351","S001707","openalex","TRUE","free_to_read","1","FALSE","article"],["R0055329","3D screen printing for advanced pharmaceutical manufacturing","Marcel Enke","2026","Infinite Science GmbH","other","article","10.18416/ammm.2026.26062769",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055330","CO12 REAL-WORLD WEIGHT OUTCOMES FOLLOWING INITIATION OF GLP-1 RECEPTOR AGONIST ANTI-OBESITY MEDICATIONS IN A MISSISSIPPI MEDICAID POPULATION","Liang-Yuan Lin","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.107",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055331","GLP‐1 analogue ameliorates hepatic steatosis and cardiac hypertrophy in mice fed transfat and high fructose corn syrup diet","Jamie E. Mells","2011","The FASEB Journal","preclinical","article","10.1096/fasebj.25.1_supplement.212.2",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055332","INCRETIN-BASED THERAPIES FOR OBESITY MANAGEMENT: THE IMPACT OF PATIENT EDUCATION AND LIFESTYLE MODIFICATION ON LONG-TERM TREATMENT OUTCOMES","Natalia Senatorska","2025","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.4(48).2025.4225",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055333","GLP-1 receptor expression in a molecularly characterized cohort of endometrial carcinoma: Results from the GEICO 163-T/SPECTRUM study.","Carlos González-Merino","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.5625",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055334","INCIDÊNCIA DE PANCREATITE AGUDA DEVIDO AO USO DE AGONISTAS DO RECEPTOR DE GLP-1","Vitor Fernando Silva","2024","RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218","other","article","10.47820/recima21.v5i9.5669",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055335","From pathophysiology to personalized care: A comprehensive review of diabetic kidney disease","Abiy Tereda","2024","Journal of Medical and Scientific Research","narrative_review","article","10.17727/jmsr.2024/12-46",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055336","THE EFFECTS OF GLP-1 RECEPTOR AGONISTS ON OCULAR DISEASES: A NARRATIVE REVIEW","Dawid Gąsowski","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(51).2026.6144",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0055337","2568-P: Obese Rhesus Monkeys Recapitulate Human Efficacy Profiles of Semaglutide, Bimagrumab, and Retatrutide","LI GONG","2026","Diabetes","randomized_trial","article","10.2337/db26-2568-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055338","SEMAGLUTIDA E PANCREATITE UMA REVISÃO","André Matheus Carvalho Silva Leite","2024","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2024v6n9p619-624",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055339","Scope and Efficacy of Semaglutide in Metabolic Dysfunction-associated Steatohepatitis: A Critical Review of Recent Evidences","Raphael Ijeokwu","2026","Journal of Advances in Medicine and Medical Research","randomized_trial","article","10.9734/jammr/2026/v38i86177",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055340","Suicide risk and depressive symptoms in obese patients treated with GLP-1 receptor agonists","Margarita Martı́n","2025","European Psychiatry","nonrandomized_study","article","10.1192/j.eurpsy.2025.1394",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055341","In adults with type 2 diabetes, what are the comparative benefits and risks of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors versus glucagon-like peptide-1 (GLP-1) receptor agonists?","S. T. Turner","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002290",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055342","The Effect of High-Fat Diet on Adipose Tissue Glycerol Metabolism Is Influenced by Sex and GLP-1 Agonist Treatment","Iena, Francesco Maria","2019",null,"preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0055343","1776-P: Early Real-World Liver Biomarker Changes among Resmetirom-Treated MASH Patients, with and without Concomitant GLP-1 Use: A Descriptive Cohort Study","YESTLE KIM","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1776-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055344","SELF-MEDICATION WITH SEMAGLUTIDE FOR WEIGHT LOSS IN BRAZIL","Fernando Ramos Martins Pombeiro","2026",null,"nonrandomized_study","article","10.63330/aurumpub.044-007",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","book-chapter"],["R0055345","Role for Glucagon‐Like Peptide‐1 (GLP-1) Receptor Agonists in Symptomatic Post–Bariatric Hypoglycemia","Aseel Ali AlSaeed","2025","Journal of Diabetes and Endocrine Practice","other","article","10.1055/s-0045-1815626",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0055346","Pharmacological Treatment of Obesity: A Review of Current and Future Methods","Angelina Lęgas","2024","Quality in Sport","nonrandomized_study","article","10.12775/qs.2024.22.54691",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055347","CO86 RISK OF SEVERE GASTROINTESTINAL EVENTS IN COMMERCIALLY INSURED PATIENTS INITIATING GLP-1RAS FOR DIABETES MELLITUS AND OBESITY: A TARGET TRIAL EMULATION STUDY","Alin Kalayjian","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.181",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055348","Cardiovascular risk in metabolic dysfunction associated steatotic liver disease","Carolina Jiménez","2026","Clínicas de gastroenterología de México (English Edition)","other","article","10.24875/cgme.m25000042",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055349","Ozempic : mécanisme, intérêt de prescription chez le diabétique non insulino-dépendant et ses mésusages","Lanu, Alexandre","2024","HAL (Le Centre pour la Communication Scientifique Directe)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055350","Survodutide for Weight Reduction in Obesity and T2D: Baseline Data From SYNCHRONIZE™-2 Phase 3 Trial","Carel W. le Roux","2026","Diabetologie und Stoffwechsel","other_trial","article","10.1055/s-0046-1819895",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-paper"],["R0055351","Strength, Not Scans","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.21219383",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055352","Utilization of Guideline-Directed Medical Therapies in Finerenone Users","Zihe Zheng","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.2024yzeyp6ds",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055353","EE59 Assessing the Cost-Effectiveness of Semaglutide 24 mg in the Management of People With Obesity and Knee Osteoarthritis in the UK","Mafalda Ramos","2025","Value in Health","other","article","10.1016/j.jval.2025.09.443",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055354","EP1787 - LBA_ECE_1348 - Real-world treatment persistence and metabolic outcomes with a GLP-1 receptor agonist (tirzepatide) in adults with obesity: an observational cohort study","Mirjeta Guni","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1827",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-abstract"],["R0055355","What are the potential side effects of tirzepatide in patients with type 1 diabetes compared to those with type 2 diabetes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19454873",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055356","De-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review","Wares Jalil","2026","Cureus","randomized_trial","article","10.7759/cureus.116412",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0055357","PDG25 COST-EFFECTIVENESS OF ONCE WEEKLY DULAGLUTIDE 1.5 MG VERSUS ONCE DAILY LIRAGLUTIDE 1.8 MG FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CHINA","Sheng Han","2019","Value in Health","other","article","10.1016/j.jval.2019.04.704",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055358","Pharmacodynamics and Pharmacokinetics of Exendin-4 Orally Delivered via an Enteric Coated Capsule Containing Nanoparticle in Diabetic Rats","Ho-Ngoc Nguyen","2012","World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany","preclinical","article","10.1007/978-3-642-32183-2_16",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0055359","GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives","Megha Pawar","2025","BioMed Target Journal","other_trial","article","10.59786/bmtj.322",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0055360","2648-P: A Phase 1, Randomized, Double-Blind, Single-Ascending Dose Study of KAI-9531, a Novel Dual GLP-1/GIP Receptor Agonist in Development for People Living with Overweight/Obesity","LLOYD KLICKSTEIN","2026","Diabetes","randomized_trial","article","10.2337/db26-2648-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055361","Glucagon-like Peptide-1 Receptor Agonists in Kidney Transplant Recipients – A Retrospective Single Center Study","Joana C Freitas","2024","Brazilian Journal of Transplantation","nonrandomized_study","article","10.53855/bjt.v27i1.563_eng",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055362","26-A-8403-ACC TARGETING GLP-1 RECEPTORS TO PREVENT ANTHRACYCLINE AND HER-2 BLOCKING AGENT-RELATED CARDIAC DYSFUNCTION: EVIDENCE FOR SEMAGLUTIDE CARDIOPROTECTION","Nicola Maurea","2026","Journal of the American College of Cardiology","other","article","10.1016/j.jacc.2026.02.2660",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055363","Recent Use Of Weight Loss Drugs - Exploring Patient Claims Data","Randall W. Dick","2025","Medicine & Science in Sports & Exercise","nonrandomized_study","article","10.1249/01.mss.0001157904.83008.3b",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055364","Weight Loss And Changes In Self-Reported Healthcare Utilisation After Semaglutide-Pathway Assignment In A Digital UK Tier-3 NHS Programme: A Retrospective 9-Month Observational Cohort Study","Dagmara Woźniak","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7348399",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0055365","Biology, Evolution, and Molecular Diversity of Venoms","Shailesh Tawade","2025",null,"other","article","10.70593/978-93-7185-998-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0055366","THE EXERCISE PILLAR OF LIFESTYLE MEDICINE: EMERGING EVIDENCE, NOVEL MODALITIES, MOLECULAR MECHANISMS, AND PHARMACOLOGICAL SYNERGIES A NARRATIVE REVIEW","Chatbongkoch Khemacheewakul","2026","International Journal of Advanced Research","randomized_trial","article","10.21474/ijar01/22957",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0055367","Real-world comparative effectiveness of liraglutide, exenatide once weekly and lisixenatide in patients with type 2 diabetes mellitus","Martinez Amparo Marco","2016","Endocrine Abstracts","nonrandomized_study","article","10.1530/endoabs.41.gp97",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0055368","Effects of combined GLP-1 receptor agonist therapy and exercise on body composition in individuals with obesity: a systematic review","Paulina Żuk","2026","Quality in Sport","systematic_review","article","10.12775/qs.2026.66.74239",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055369","Does the use of GLP-1 receptor agonists increase the risk of aspiration pneumonia in patients undergoing gastrointestinal endoscopy compared with non-users?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22132368",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055370","CO27 Bayesian Network Meta-Analysis of Weight Loss Efficacy for GLP-1 Receptor Agonists and Tirzepatide","Rishabh Dev Pandey","2025","Value in Health","systematic_review","article","10.1016/j.jval.2025.09.129",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0055371","In patients with atrial fibrillation and reduced ejection fraction, are GLP-1 agonists associated with positive outcomes?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20958816",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055372","GLP-1 Receptor Agonists: Emerging Indications, Limitations, and Future Directions","Simran Kaur","2026","Pharmacology &amp Pharmacy","randomized_trial","article","10.4236/pp.2026.172003",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055373","A retrospective chart review of medication deprescribing trends following GLP-1 agonist initiation at the wright center","Lark Amoa","2026","International Journal of Science and Research Archive","nonrandomized_study","article","10.30574/ijsra.2026.20.1.1487",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055374","In Silico Analysis of Semaglutide Binding Affinity of Divergent GLP-1 Receptors Across Major Ethnic Clusters: An Integrated Computational Pharmacogenomics Study","Narendra Kumar S","2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.65s.60",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055375","Targeting Orexin Neurons for Treatment of Obesity is It Feasible in Human Being-A Systematic Review","Kulvinder Kochar Kaur","2019","Journal of Neurology Research Review & Reports","systematic_review","article","10.47363/jnrrr/2019(1)104",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055376","Detailed plan for the treatment of type 2 diabetes and its complications.","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18171285",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055377","Le liraglutide comme traitement intra-articulaire potentiel pour la régénération du cartilage dans l’arthrose : études in vitro et in vivo supportant un effet pro-chondrogénique","Françis Berenbaum","2020","Revue du Rhumatisme","preclinical","article","10.1016/j.rhum.2020.10.087",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055378","MULTIDISCIPLINARY MANAGEMENT OF LIPEDEMA: EVIDENCE ON DIETARY, PHYSIOTHERAPEUTIC, PHARMACOLOGICAL, AND SURGICAL INTERVENTIONS","Katarzyna Kraska","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(51).2026.6192",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055379","Abstract 4373350: Efficacy of GLP-1 Receptor Agonists VS SGLT2 Inhibitors on Cardiovascular Outcomes in Women with Type 2 Diabetes and Premature Coronary Artery Disease: A Propensity Score Matched Analysis","Abdul-Rahaman Adedolapo Ottun","2025","Circulation","randomized_trial","article","10.1161/circ.152.suppl_3.4373350",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0055380","AKT question relating to side effects of tirzepatide","Yasser Abdel Kerim","2025","InnovAiT Education and inspiration for general practice","other","article","10.1177/17557380251360588j",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055381","New Drugs, High Stakes: SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplant Recipients","Vineeta Kumar","2026","Kidney News","other","article","10.62716/kn.003412026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055382","GLP-1-receptoragonista-kezelés diabeteses vesebetegségben","Gábor Áron Fülöp","2021","Diabetologia Hungarica","other","article","10.24121/dh.2021.7",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055383","Anti-Insulin Receptor Antibodies Related to Hypoglycemia in a Previously Diabetic Patient","Jean-Christophe Maïza","2013","Diabetes Care","other","article","10.2337/dc12-2664","23704685",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055384","Atualizações no tratamento da obesidade: cirurgia bariátrica e novos fármacos em perspectiva","Adriano Barros Gonçalves","2025","Brazilian Journal of Health Review","other","article","10.34119/bjhrv8n5-182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055385","1753-P: CGM-Based Metrics in Insulin-Naive Adults with T2D Receiving IcoSema vs. Glargine U100: Post Hoc Analysis of COMBINE 4.","Concetta Irace","2026","Diabetes","randomized_trial","article","10.2337/db26-1753-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055386","P292 Efficacité et tolérance de l’adjonction du liraglutide à une insuline basale en comparaison au placebo chez des patients diabétiques de type 2 (résultats de l’essai randomisé contrôlé LIRA-ADD2BASAL)","Amira Bouzidi","2015","Diabetes & Metabolism","other","article","10.1016/s1262-3636(15)30405-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055387","EP854 - ECE_3854 - Off-label use of semaglutide (Ozempic®) for weight reduction: a real-world case series of 20 patients","Entela Puca","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1175",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0055388","Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment","Łukasz Zdziebkowski","2025","Quality in Sport","randomized_trial","article","10.12775/qs.2025.43.62342",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055389","Modificazioni epigenetiche nell'obesità: pathway molecolari, nutrienti bioattivi e target terapeutici","MILA VALENZA","2026","Electronic Theses and Dissertations Repository (University of Pisa)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055390","Mechanisms of neuroprotective action of incretin mimetics","Timur Dmitrievich Vlasov","2016","Diabetes Mellitus","other","article","10.14341/dm7192",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055391","A Meta-Analysis Evaluating the Efficacy of Liraglutide in Reducing Cardiovascular Complications Among Patients with Type 2 Diabetes","Michelle Panol Del Rosario","2025","Philippine Journal of Internal Medicine","systematic_review","article","10.65564/pjim.1586c116b6",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0055392","P5 Pegozafermin treatment demonstrates long-term benefit in subjects with metabolic dysfunction-associated steatohepatitis and fibrosis: results from the Phase 2b ENLIVEN clinical trial","William Alazawi","2025",null,"randomized_trial","article","10.1136/gutjnl-2025-basl.22",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0055393","Comparative Efficacy and Safety of Semaglutide and Tirzepatide in Obesity Management: A Literature Review","Lena Apanowicz","2026","Polish Journal of Sports Medicine","randomized_trial","article","10.5604/01.3001.0055.8587",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055394","Metabolic Syndrome and Cardiovascular-Kidney-Metabolic Dysfunction: An Integrative Review of Pathophysiology and Clinical Outcomes","Yurany Duarte Torres","2026","IECCMEXICO","narrative_review","article","10.64784/209",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055395","Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker prize for pioneering work on GLP-1","Hossein Ardehali","2024","Journal of Clinical Investigation","other","article","10.1172/jci186225","39295302",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055396","GLP-1RA, SGLT2I AND RAASI COMBINATION THERAPY REDUCES MORTALITY AND KIDNEY EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","Janis Casper","2025","Journal of Hypertension","nonrandomized_study","article","10.1097/01.hjh.0001115716.93531.61",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055397","The use of sglt-2 inhibitors in heart failure with preserved ejection fraction (hfpef): a bibliometric analysis","A Bashir","2026","European Journal of Preventive Cardiology","other","article","10.1093/eurjpc/zwag249.432",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055398","Obesity and fertility","Matilde Contessa","2026","Obesity and Endocrinology","other","article","10.1093/obendo/wjag003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055399","Night eating syndrome (NES). A case report of NES","B. Pascual Garcia","2023","PubMed Central","case_report","article","10.1192/j.eurpsy.2023.1796",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055400","GLP-1 Receptor agonists and risk of suicide or suicide attempts – A cohort and self-controlled case series study","C. Stanislaus","2026","Neuroscience Applied","nonrandomized_study","article","10.1016/j.nsa.2026.106931",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055401","SUN-031 Efficacy Of The Glp-1 Agonists In The Treatment Of Idiopathic Intracranial Hypertension: A Systematic Review And Meta-analysis","Luisa Montejano","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.1620",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055402","A Systematic Review of the Cutaneous Adverse Effects of GLP-1 Agonists","Sydney DeVore","2025","ARC Journal of Dermatology","systematic_review","article","10.20431/2456-0022.0802005",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055403","Abstract PS3-01-28: Effects of 6 Months of Tirzepatide on Risk Biomarkers for Development of Breast Cancer","C. J. Fabian","2026","Clinical Cancer Research","nonrandomized_study","article","10.1158/1557-3265.sabcs25-ps3-01-28",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055404","Can Ozempic cause an ileus?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19665539",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055405","2917-LB: Prescribing Practices and Clinical Support for GLP-1 Receptor Agonists in Youth-Onset Type 2 Diabetes: Data from the T1DX QI Collaborative","YASHODA NAIK","2026","Diabetes","other","article","10.2337/db26-2917-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055406","What are the risks of pancreatitis in users of GLP-1 receptor agonists?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18016813",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055407","SEMAGLUTIDA COMBINADA AO TREINAMENTO FÍSICO: IMPACTO SOBRE A MORBIDADE DA DOENÇA RENAL DIABÉTICA","Eloiza Terezinha Fernandes da Silva","2025",null,"other","article","10.65034/bjnabstract-cpn25278",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055408","SEMAGLUTIDE IN OBESITY AND EXERCISE MEDICINE: A REVIEW OF CLINICAL EVIDENCE, PERFORMANCE IMPLICATIONS, AND IMPLEMENTATION CHALLENGES","Aleksandra Romaniuk","2026","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.2(50).2026.5070",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055409","2830-LB: A Single Injection of Ultra-Long-Acting GLP-1 Receptor Agonist AM-710 Produces Durable >20% Weight Loss in Obese Nonhuman Primates","BRIAN KEARNEY","2026","Diabetes","preclinical","article","10.2337/db26-2830-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055410","New incretin analogs in the treatment of obesity and non-alcoholic fatty liver disease in family medicine","В.В. Скворцов","2026","Spravočnik vrača obŝej praktiki (Journal of Family Medicine)","other","article","10.33920/med-10-2605-04",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055411","What are the potential side effects of GLP-1 analogues for weight loss in Type 2 diabetes patients?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17748166",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055412","BEYOND WEIGHT LOSS: THE DUAL IMPACT OF GLP-1 AND DUAL GIP/GLP-1 RECEPTOR AGONISTS ON THE SKIN A SYSTEMATIC REVIEW OF SAFETY, ADVERSE REACTIONS, AND THERAPEUTIC POTENTIAL IN INFLAMMATORY DERMATOSES","Adrian Mikołajuk","2026","International Journal of Innovative Technologies in Social Science","systematic_review","article","10.31435/ijitss.2(50).2026.5581",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055413","Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study (Preprint)","Hans Johnson","2024",null,"nonrandomized_study","article","10.2196/preprints.69466",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0055414","Gut Hormones in Glucose Homeostasis and Current Treatment Approach in the Control of T2DM: A Succinct Review","Sudha Sreenivas","2025",null,"narrative_review","article","10.9734/ajrre/2025/v8i1105",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055415","IDF2022-1118 A comparative effect of DPP4 inhibitor and GLP-1 agonist on lipid profile among obese patients with DMT2","N. Bostoganashvili","2023","Diabetes Research and Clinical Practice","other","article","10.1016/j.diabres.2023.110365",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055416","Desenvolvimento de biomarcador específico de células beta pancreáticas (incretina radiomarcada) para imagem da massa beta funcional em diabéticos e obesos: estudo em modelo animal","Daniele Seo","2017",null,"other","article","10.11606/t.85.2017.tde-23032017-153731",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055417","An Update on the Innovative Mechanistic Modes for the Avoidance of Heart Failure with Preserved Ejection Fraction Using Glucagon Like Peptide 1 Receptor Agonism Particularly in Type 2 Diabetes Mellitus & Metabolic Syndrome: A Review","Kulvinder Kochar Kaur","2025","International journal of research in medical and clinical science.","narrative_review","article","10.70829/ijrmcs.v03.i02.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055418","2073-P: Cost-Effectiveness of Tirzepatide among Adolescents with Recent-Onset Type 2 Diabetes","FRANCESCA LIM","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2073-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055419","1265-OR: Tirzepatide: Effect on Insulin Resistance and Human Fat Cells","RACHEL L. HUYNH","2026","Diabetes","randomized_trial","article","10.2337/db26-1265-or",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055420","2350-P: Unmet Need in Post-Stroke Antidiabetic Treatment Patterns among Individuals Newly Diagnosed with Type 2 Diabetes (T2D) during Ischemic Stroke Hospitalization","忠才 陈","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2350-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055421","Empagliflozin/Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-72642-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055422","TIRZEPATIDE IN OBESITY MANAGEMENT: EFFICACY AND SAFETY - INSIGHTS FROM RECENT CLINICAL TRIALS","Jakub Cecot","2024","Archiv Euromedica","randomized_trial","article","10.35630/2024/14/4.412",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055423","Abstract 10159: Underuse of Evidence-based Therapies for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease: Insights from Clinical Research Networks in the United States","Adam J. Nelson","2021","Circulation","nonrandomized_study","article","10.1161/circ.144.suppl_1.10159",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055424","GUT MICROBIOTA AND PHARMACOLOGICAL TREATMENT RESPONSE IN OBESITY: IMPLICATIONS FOR PERSONALIZED MEDICINE","Julia Burtowicz","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(51).2026.5930",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055425","Sodium-glucose transporter 2 inhibitors/Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98200-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055426","Finerenone in CKD from Estimands to Clinical Interpretability under Competing Risk","Andrew Wang","2025","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.0000000925","41563827",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055427","MULTIDISCIPLINARY COMPREHENSIVE MEDICATION MANAGEMENT OPTIMIZES CARDIOMETABOLIC OUTCOMES IN CARDIO-RENAL-METABOLIC DISEASE","Helena Orehovački","2026","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0001196596.57903.71",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0055428","The Neuroprotective Potential Of Semaglutide In Modulating Brain Cravings For Alcohol, Nicotine, And Opioids: A Comprehensive Review","Sujal E Durge","2026","IARJSET","randomized_trial","article","10.17148/iarjset.2026.13142",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055429","Weighing the hype: What poisonings data reveals about the weight loss drug boom","Jordan Miller","2026","Significance","other","article","10.1093/jrssig/qmag007",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055430","REVIEW OF TIRZEPATIDE AND CHROMIUM PICOLINATE FOR GLYCEMIC CONTROL AND WEIGHT LOSS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)","Dr. Kailash Singh Bisht*","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.19332956",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0055431","GLP-1 use and protein demand","Justin D. Bina","2025","Food Policy","other","article","10.1016/j.foodpol.2025.103026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055432","438-P: Cardiorenal Benefits of Newer Glucose-Lowering Drugs by Hispanic Ethnicity: A Meta-analysis of Results from Randomized Outcome Trials in Type 2 Diabetes","HUILIN TANG","2022","Diabetes","systematic_review","article","10.2337/db22-438-p",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0055433","Glucagon-like peptide-1 receptor agonists in the perioperative period: Navigating the evidence, minimizing harm, and finding the way forward","Anjan Trikha","2026","Journal of Anaesthesiology Clinical Pharmacology","other","article","10.4103/joacp.joacp_419_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055434","THE EVOLVING LANDSCAPE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: FROM PATHOGENESIS TO PRECISION MEDICINE","Magdalena Kossmann","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(51).2026.6277",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055435","S781 Impact of Obesity Duration on Weight Loss Outcomes Following Endoscopic Sleeve Gastroplasty and GLP-1 Receptor Agonists","Farnoosh Vahedi","2025","The American Journal of Gastroenterology","other","article","10.14309/01.ajg.0001130584.41119.07",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055436","Gastrointestinal adverse effects of glp-1 receptor agonists compared with nonglp-1 anti-obesity medications: A literature review","Marta Owczarzak","2026","Humanities & Social Sciences Reviews","narrative_review","article","10.18510/hssr.2026.1425",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055437","Risk Factors and Outcome in Living Kidney Donors: A Narrative Review","Lucas-Gabriel Discălicău","2026","Kidney and Dialysis","nonrandomized_study","article","10.3390/kidneydial6020028",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0055438","Saudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report","Ali Alromaih","2023","Journal of Diabetes Mellitus","other","article","10.4236/jdm.2023.132017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055439","From model to medicine","Ann-Sofie Scheike","2026",null,"preclinical","article","10.33540/3258",null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0055440","PUBLIC INTEREST IN THE OFF-LABEL USE OF GLUCAGON-LIKE PEPTIDE 1 AGONISTS (OZEMPIC) FOR COSMETIC WEIGHT LOSS","Abdallah Marey Aboshhran","2023","Journal of Population Therapeutics and Clinical Pharmacology","other","article","10.53555/jptcp.v30i2.4746",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055441","Ten Minutes Hard","Edward Leatham","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.22122590",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","report"],["R0055442","TIRZEPATIDE - A NEW ERA IN OBESITY TREATMENT? A REVIEW OF THE CURRENT STATE OF KNOWLEDGE","Adam Solarz","2025","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.4(48).2025.4143",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055443","Intelligent commissioning to improve lipid target attainment in secondary prevention: a [region]-wide population health approach","E.T. Ojo","2026","Atherosclerosis Plus","nonrandomized_study","article","10.1016/j.athplu.2026.100595",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055444","Intestinal Macrophage-Mediated Exosomal Repackaging Establishes Bioactive Reservoirs for Long-Acting Oral Peptide Therapy","Linjie Wu","2026","ACS Nano","preclinical","article","10.1021/acsnano.6c08460",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055445","Current Concepts and Advances in the Management of Diabetes in Liver Cirrhosis","Supriya M","2026","Asian Journal of Advances in Research","other","article","10.56557/ajoair/2026/v9i1574",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055446","E144 Using social media data to understand the lived experience of people with psoriatic arthritis receiving biologic therapies and weight management interventions","James Kimpton","2026","Lara D. Veeken","nonrandomized_study","article","10.1093/rheumatology/keag121.366",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055447","Health-related quality of life and psychological distress among patients with type 2 diabetes using semaglutide","Wejdan M. Alshehri","2026","International Journal of Research in Medical Sciences","nonrandomized_study","article","10.18203/2320-6012.ijrms20262169",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055448","GLP‐1 receptor agonists and insulin: where are we now?","Jenna Cowan","2012","Practical Diabetes","other","article","10.1002/pdi.1720",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055449","Short-Term Effects of Liraglutide versus Vildagliptin on Insulin Secretion and Sensitivity in Type 2 Diabetes: A Single Blinded Randomized Controlled Trial (LIRAVIS Study)","Martine Claude Etoa Etoga","2023","Journal of Diabetes Mellitus","randomized_trial","article","10.4236/jdm.2023.131005",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055450","WCN26-3459 COMPARATIVE CARDIOVASCULAR EFFECTIVENESS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS VERSUS DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN DIALYSIS PATIENTS WITH TYPE 2 DIABETES MELLITUS: A TARGET TRIAL EMULATION","Hiroki Shimada","2026","Kidney International Reports","randomized_trial","article","10.1016/j.ekir.2026.104604",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055451","26-A-18955-ACC COMPARATIVE EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS VS SGLT2 INHIBITORS FOR SECONDARY PREVENTION IN PATIENTS WITH T2DM AND PERIPHERAL ARTERY DISEASE: A RETROSPECTIVE COHORT STUDY","Anwar Zahran","2026","Journal of the American College of Cardiology","nonrandomized_study","article","10.1016/j.jacc.2026.02.548",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055452","DEVELOPMENT AND VALIDATION AND STABILITY STUDY OF A NEW ANALYTICAL RP-HPLC METHOD FOR THE ESTIMATION OF ANTI-DIABETIC DRUG SEMAGLUTIDE IN API FORM AND MARKETED PHARMACEUTICAL DOSAGE FORM","Pragati Ranjan Satpathy","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19277277",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055453","The Effect of Antipsychotic-Induced Weight Gain in Individuals with Severe Mental Illness: Understanding the Impact and Looking at a Novel Pharmacological Intervention","Riddhita De","2025","TSpace (University of Toronto)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0055454","Drug-Class-Oriented Pharmacogenomics in Type 2 Diabetes: Implications for Personalised Therapy","Swayamsiddhi x","2026","International Journal of Science and Research (IJSR)","other","article","10.21275/sr26211221734",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055455","Case report Liraglutid and insuline resistance","Stefan Farsky","2023","Medical Research Archives","nonrandomized_study","article","10.18103/mra.v11i10.4614",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055456","OZEMPIC (SEMAGLUTIDE): A NEW WEIGHT LOSS DRUG FOR CHRONIC WEIGHT MANAGEMENT","Khalid Abdullah Alsefri","2022",null,"preclinical","article","10.53555/jptcp.v29i03.4454",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055457","Efficacy and safety of once-weekly IcoSema compared to active comparators in adults with type 2 diabetes: A systematic review and comparator-stratified quantitative synthesis of randomized controlled trials","Gautham Kolla","2026","International Journal of Diabetes in Developing Countries","systematic_review","article","10.1007/s13410-026-01648-5",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0055458","CO77 External Control Arm With Real World Data to Assess the Effect of Semaglutide on Chronic Kidney Disease Risk Among Patients With Type 2 Diabetes","Onur Başer","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.162",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0055459","Diabetes-Induced Cardiomyopathy: Updates in Epidemiology, Prevention, and Management","Ernest Adeghate","2024","IntechOpen eBooks","other","article","10.5772/intechopen.1006679",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055460","2647-P: GLP-1 Receptor Agonists (GLP-1RAs) and Clinical Outcomes of Binge Eating Disorders","Serena Jingchuan Guo","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2647-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055461","Tirzepatide: sleep apnea's biggest nightmare","Anton Dahbura","2026","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002593",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055462","Changing Paradigm for Reducing Proteinuria and Slowing Renal Insufficiency in People with Diabetic Kidney Disease","Charan Bale","2026","Chronicle of Diabetes Research and Practice","nonrandomized_study","article","10.4103/cdrp.cdrp_24_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","editorial"],["R0055463","Beyond Semaglutide: The Rise of Multi-Agonist Incretin Therapy in Obesity and Metabolic Disease – A Comprehensive Pharmacological Review","Dr. R. L. Manisha","2026","International Journal of Innovative Science and Research Technology (IJISRT)","other_trial","article","10.38124/ijisrt/26may1659",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055464","1370-P: Semaglutide Demonstrates Cardiorenal Benefits in the SDT Fatty Rat, a New Model of Cardiovascular–Kidney–Metabolic Syndrome","François Briand","2026","Diabetes","preclinical","article","10.2337/db26-1370-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055465","Clinical outcomes and 30-day readmission following heart failure hospitalization in patients previously treated for obesity with GLP-1 agonist versus bariatric surgery","Nameer E. Ascandar","2025","Next research.","other","article","10.1016/j.nexres.2025.101062",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055466","Glycemic Outcomes of Oral Hypoglycemics Versus GLP-1 Receptor Agonists in Type 2 Diabetes: A Comparative Clinical Study","Iftikhar Hayat","2025","Developmental medico-life-sciences","other","article","10.69750/dmls.02.010.0168",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055467","1668-P: Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial","KRISTINA S. BOYE","2026","Diabetes","other_trial","article","10.2337/db26-1668-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055468","Liraglutide-Metformin Combination Therapy in Type 2 Diabetes: A Comprehensive Review of Clinical Efficacy, Safety and Cost-Effectiveness","Aashish Choudhary","2025","International Journal of experimental research and review","randomized_trial","article","10.52756/ijerr.2025.v48.007",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055469","Kidney, Cardiovascular, and Death Outcomes with Semaglutide Treatment Among Two Race and Two Ethnic Groups: Post Hoc Analysis from the FLOW Trial","Christian W. Mende","2025","Journal of the American Society of Nephrology","other_trial","article","10.1681/asn.2025nztajebj",null,null,"ClinicalTrials.gov:NCT03819153","S000953","openalex","FALSE","paywalled","5","FALSE","article"],["R0055470","Agonistes du récepteur du peptide-1 de type glucagon durant la grossesse et l’allaitement","Jonathan S. Zipursky","2025","Canadian Medical Association Journal","other","article","10.1503/cmaj.240768-f","40064499",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055471","Which GLP1 receptor agonist approved for weight loss is the most effective at achieving weight loss?","Allison Abresch","2024","Evidence-Based Practice","other","article","10.1097/ebp.0000000000002179",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055472","Liraglutide in obese adults is effective and has acceptable tolerability over 2 years","Arne Vernon Astrup","2011","Research at the University of Copenhagen (University of Copenhagen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055473","Semaglutide-induced nonarteritic anterior ischemic optic neuropathy","Shruti Kochar","2026","Indian Journal of Ophthalmology - Case Reports","nonrandomized_study","article","10.4103/ijo.ijo_1588_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055474","Neuroprotective Potential of Glucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Retrospective Cohort Study Using TriNetX (P3-3.013)","Aayma Irfan","2026","Neurology","nonrandomized_study","article","10.1212/wnl.0000000000217904",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055475","Prevention of biliary diseases associated with GLP-1 receptor agonist therapy","Е.А. Лялюкова","2026","Лечащий врач","randomized_trial","article","10.51793/os.2026.29.4.014",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055476","1802-P: Myo-004 Induces Body-Weight Loss in DIO at Thermoneutrality by Switching Metabolism from Fat to Carbohydrate Oxidation","Xavier Jacq","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1802-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055477","SARCOPENIA E INCRETINOMIMÉTICOS: O PARADOXO DO EMAGRECIMENTO MEDICAMENTOSO","Laura Silva Munhoz","2026","Editora Pasteur eBooks","other","article","10.59290/1256200210",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055478","HSD105 REAL-WORLD CLINICAL CHARACTERISTICS AND FACTORS ASSOCIATED WITH CONCURRENT GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1 RA) THERAPY AMONG PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) PRESCRIBED RESMETIROM","Sammy Saab","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.1342",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055479","P28-01 Multi-and trans-generational effects following administration of a GLP-1 receptor agonist during pregnancy","S. Storrar","2026","Toxicology Letters","other","article","10.1016/j.toxlet.2026.112700",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055480","CO4 Systematic Evaluation of Bone Health Dynamics Associated With GLP-1 Receptor Agonists in Type 2 Diabetes Patients: Fracture Risk and Osteoporotic Complications","Arunima Sachdev","2025","Value in Health","other","article","10.1016/j.jval.2025.04.089",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055481","Non-arteritic Anterior Ischemic Optic Neuropathy and Semaglutide Use: An Advisory to Ophthalmologists and Other Health Care Professionals","Aubhugn Labiano, MD","2025","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055482","Obesity-Related Chronic Kidney Disease: Current State of Knowledge","Martyna Grabowska","2026","Quality in Sport","other","article","10.12775/qs.2026.50.68085",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055483","Design, preparation, and characterization of injectable thermosensitive polymer-based hydrogels with enhanced mechanical properties for sustained liraglutide release","Wei-Jie Cheng","2025","Journal of Drug Delivery Science and Technology","other","article","10.1016/j.jddst.2025.106909",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055484","Efficacy and Safety of Tirzepatide in Overweight and Obese Individuals: A Meta-Analysis of Randomized Controlled Trials","Liya Fu","2026","Medical Research Frontiers","systematic_review","article","10.57237/j.mrf.2025.04.001",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055485","Holistic Metabolic Clinic for One-Stop Detection of Subclinical Target Organ Damage in Asymptomatic and Controlled Type 2 Diabetes: A Prospective Observational Study","Dr Harish kasarabada","2026","JOURNAL OF ADVANCE AND FUTURE RESEARCH","other","article","10.56975/jaafr.v4i7.512994",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055486","2656-P: Analyzing Daily Weights to Improve Estimates of Weight Loss while Minimizing Impact of Random Day-to-Day Variation in Weight","Sayna Bagheri","2026","Diabetes","other_trial","article","10.2337/db26-2656-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055487","Oral Biguanide Use Is Associated with Lower Incidence of AKI and Mortality in COVID-19 Patients: A Nationwide Study Using the Diagnosis Procedure Combination System in Japan","Mari Sugimoto","2024","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20245k7kzb8j",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055488","Update in Nephrology","Mohammad Tinawi","2024","Trends in General Medicine","other_trial","article","10.33425/2996-3893.1015",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055489","Obesity and Metabolic Syndrome: Pathophysiological Mechanisms Driving Cardiovascular Risk","Sudeep Edpuganti","2025","JUNIOR RESEARCHERS","other","article","10.52340/jr.2025.03.03.03",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055490","Effect of Semaglutide in Individuals with Obesity or Overweight Without Diabetes: An Umbrella Review of Systematic Reviews","xiaoye hu","2024","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.4959966",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0055491","GLP-1 medication use is associated with stronger implicit preferences for healthy foods based on enjoyment and taste","Oskar Pineño","2026","Food Quality and Preference","other","article","10.1016/j.foodqual.2026.106111",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055492","Are there differences in the efficacy of once-weekly GLP-1RAs in patients with type 2 diabetes?","Jodi L. Strong","2018","Journal of the American Association of Nurse Practitioners","other","article","10.1097/jxx.0000000000000113",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055493","Pragmatic Considerations in Switching to Semaglutide for Obesity Management: Real- World Perspectives","Dr SANJAY KALRA","2026",null,"randomized_trial","article","10.59793/bzsxq840",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0055494","Comprehensive analytical characterization and release behavior of liraglutide-loaded PLGA implants prepared by hot-melt extrusion","Yagni Shah","2026","Journal of Drug Delivery Science and Technology","other","article","10.1016/j.jddst.2026.108822",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055495","Abstract 4368319: Effects of Glucagon-Like Peptide-1 Receptor Agonists on Endothelial Function and Cardiometabolic Outcomes in Polycystic Ovary Syndrome: A Systematic Review","Aymen Arain","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4368319",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0055496","What is the maximum oral dose of semaglutide for type 2 diabetics?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22808173",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055497","A1C Improvement with Liraglutide Evaluated by Baseline BMI","Eduard Montanya","2013","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2013.08.104",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055498","Reported cardiovascular events and cardiometabolic risk markers with orforglipron and danuglipron in adults with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized trials","Guanglan Zou","2026","Diabetology & Metabolic Syndrome","systematic_review","article","10.1186/s13098-026-02264-3",null,null,"PROSPERO:CRD420251067874",null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0055499","Endocrine and Metabolic Disorders","Annapurna Anusha Kotwala","2025",null,"other","article","10.69613/4gknk872",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055500","Stabil-nor: an interventional, multi-center, randomized, double blinded, placebo-controlled study to investigate semaglutide add-on treatment for metabolic control in antipsychotic-using patients","R.A. Kroken","2026","Neuroscience Applied","randomized_trial","article","10.1016/j.nsa.2025.106788",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055501","Novel personalised patient decision aid on GLP-1 receptor agonists in obesity care: Design and development","Hannah Moll","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7237739",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0055502","Liraglutide‐induced acute kidney injury","S Koppa Narayana","2012","Practical Diabetes","other","article","10.1002/pdi.1727",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055503","883 OUTCOMES ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USE IN PATIENTS UNDERGOING OUTPATIENT UPPER ENDOSCOPY","Sarjukumar Panchal","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)00968-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055504","Issue 4 of Cardiovascular Endocrinology","Andrew J. Krentz","2012","Cardiovascular Endocrinology","other","article","10.1097/xce.0b013e32835d22f0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055505","WCN26-3778 MECHANISTIC EFFECTS OF SEMAGLUTIDE ON KIDNEY DISEASE IN TYPE 2 DIABETES: THE REMODEL TRIAL","Katherine Tuttle","2026","Kidney International Reports","other_trial","article","10.1016/j.ekir.2026.104610",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0055506","DPP-4-Inhibition verbessert die Glukosehomöostase, reduziert jedoch nicht die Atheroskleroseentstehung in LDL-Rezeptor-defizienten Mäusen","Kersten S. Rabe","2010","Diabetologie und Stoffwechsel","other","article","10.1055/s-0030-1253763",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055507","GLYMPHATIC RESERVE AS A DETERMINANT OF RESPONSIVENESS NEURO-METABOLIC REHABILITATION DRIVEN BY GLP-1 RECEPTOR AGONISTS: A NOVEL PARADIGM FOR MANAGING ALZHEIMER’S DISEASE AS TYPE 3 DIABETES IN CENTRAL ASIA","Sayat Oraz","2026","Central Asian Journal of Medical Hypotheses and Ethics","randomized_trial","article","10.47316/cajmhe.2026.7.2.03",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055508","1266-OR: Tirzepatide and Pioglitazone Combination Therapy Synergistically Improves Insulin Sensitivity and Adipose Tissue Remodeling","MOHAMED ABU-FARHA","2026","Diabetes","preclinical","article","10.2337/db26-1266-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055509","Multisystem Complications of Type 2 Diabetes: A Comprehensive Narrative Review","Jayakrishnan B.","2025","IFR Journal of Medical Science and Case Report","nonrandomized_study","article","10.70146/mscrv01i03.010",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","review"],["R0055510","1977-P: Medical Spending Before and After GLP-1RA Initiation among Commercially Insured Adults Aged 18–64 Years with Type 2 Diabetes","YU N. WANG","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1977-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055511","1683-P: Fracture Risk Associated with Tirzepatide: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Evidence","FAROUQ B.F. ALAHMED","2026","Diabetes","systematic_review","article","10.2337/db26-1683-p",null,null,"PROSPERO:CRD420261278843",null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0055512","Unexpected Therapeutic Effect of GLP-1 Receptor Agonists in Patients With Refractory IBS-D: A Case Series","Solangel Isabelle Suarez","2026","Annals of Internal Medicine Clinical Cases","case_report","article","10.7326/aimcc.2025.1308",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055513","Transitions in Obesity – an opportunity for GLP-1 drugs?","Ian G. Duncan","2024","Medical Research Archives","nonrandomized_study","article","10.18103/mra.v13i1.6138",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055514","Characterizing Intake & Eating Behaviors Among Individuals Prescribed GLP-1 Anti-obesity Medications: A Pilot Study","Marie P. St Onge","2025","OSF Preprints (OSF Preprints)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","preprint"],["R0055515","The Blockbuster Drug and the Sluggish Stomach: A Case of Mistaken Blame?","M Souto","2026","Endoscopy","nonrandomized_study","article","10.1055/s-0046-1822575",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055516","META-ANALYSIS OF CARDIOPROTECTIVE EFFECTS OF COMBINED SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS VS. MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE: IMPACT ON MORTALITY AND HOSPITALIZATION OUTCOMES","Aisha Alyassi","2024","Insights-Journal of Health and Rehabilitation","systematic_review","article","10.71000/ijhr139",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0055517","Artificial Intelligence in the Optimisation of Glucagon-Like Peptide-1 Receptor agonist Therapy for Obesity and Type 2 Diabetes: A Critical Narrative Review of Treatment Monitoring and Clinical Decision Support","Mirembe Katabaazi Lillian","2026","Journal of Medicine and Health Research","randomized_trial","article","10.56557/jomahr/2026/v11i210991",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0055518","Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists Versus either Agent Alone in Type 2 Diabetes: A Network Meta-Analysis with An Exploratory Analysis of Treatment Initiation Design","Adili Tuersun","2026","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.7256960",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0055519","Abstract 4368269: Association between Glucagon-like peptide-1 receptor agonists and risk of Arrhythmias: A Contemporary Real-World Analysis","Vikash Jaiswal","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4368269",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055520","76142 GLP-1 receptor agonists and reduced risk of melanoma and nonmelanoma skin cancer (NMSC): A retrospective cohort study of patients with obesity","Rashwan Alameddine","2026","Journal of the American Academy of Dermatology","nonrandomized_study","article","10.1016/j.jaad.2026.04.951",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055521","OZEMPIC NO TRATAMENTO DA OBESIDADE E RISCOS ASSOCIADOS AO USO INDISCRIMINADO","Danyele Karla de Souza Silva","2023",null,"other","article","10.51161/inofarm/21642",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0055522","Are incretin-based therapies replacing metabolic bariatric surgery? A narrative review of surgical eligibility, perioperative integration, and patient decision-making","M. Arbogast","2026","Obesity Medicine","narrative_review","article","10.1016/j.obmed.2026.100742",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0055523","In patients with type 2 diabetes, do glucagon-like peptide-1 receptor agonists reverse non-alcoholic fatty liver disease?","Mohammed Zayd Mughal","2023","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001945",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055524","SÍNDROME CARDIOVASCULAR–RIÑÓN–METABOLISMO (CKM): AVANCES EN LA PREVENCIÓN Y EL MANEJO INTEGRAL BASADOS EN EVIDENCIA CIENTÍFICA","Telmo Eduardo Salas Joya","2026","VitalyScience Revista Científica Multidisciplinaria","randomized_trial","article","10.56519/mjmh0g15",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055525","Obesity-associated pathologies: Recent advances in stimuli-responsive nanocarriers for adipose tissue browning and beyond","Asmaa M. Elsherbini","2026","OpenNano","other","article","10.1016/j.onano.2026.100290",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055526","Effect of retatrutide on body weight, lipid profile, liver function, oxidative stress, and inflammation in experimental obesity in male rats","Zinah Meteab Rah AL-shibil","2026","European Journal of Clinical and Experimental Medicine","randomized_trial","article","10.15584/ejcem.2026.1.26",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055527","336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects","EDWARD J. PRATT","2022","Diabetes","randomized_trial","article","10.2337/db22-336-or",null,null,"ClinicalTrials.gov:NCT03929744","S001347","openalex","FALSE","paywalled","1","FALSE","article"],["R0055528","What is the evidence for the use of GLP-1 in type 1 diabetics to improve blood sugar control?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.19334306",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055529","Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies","Marina Vladimirovna Shestakova","2015","Diabetes Mellitus","randomized_trial","article","10.14341/dm20151s1-112",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055530","Interaction of Race and Treatment with GLP1-RA, SGLT2i, and Insulin on Mortality in Veterans with Type 2 Diabetes Mellitus (T2DM) and CKD","Stephen R. Sammons","2023","Journal of the American Society of Nephrology","nonrandomized_study","article","10.1681/asn.20233411s1729d",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055531","The Efficacy and Safety of Semaglutide-Based Medications for Long-Term Weight Loss and Cardiovascular Health","Sadaf Khalid","2025","Pakistan Journal of Health Sciences","other_trial","article","10.54393/pjhs.v6i4.2541",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055532","Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) Prescription and Dispensing Trends Prior to Pregnancy","LAUREN BERUBE","2026","Current Developments in Nutrition","other","article","10.1016/j.cdnut.2026.109115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055533","Prolonged metabolic acidosis following intramuscular tirzepatide injection: A social media driven case","Wael Hafez","2025","Annales de Toxicologie Analytique","other","article","10.1016/j.toxac.2025.10.001",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055534","NEW PERSPECTIVES ON ALZHEIMER’S DISEASE TREATMENT: A STRUCTURED SCIENTIFIC REVIEW (2020–2025)","Hanna Wilska","2025","International Journal of Innovative Technologies in Social Science","other_trial","article","10.31435/ijitss.3(47).2025.3854",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055535","GLP-1 and the Shortcut Fallacy: Predicting the High Cost of Easy Fixes","Bomi Joseph","2026","Journal of Medical Phyto Research","other","article","10.5281/zenodo.18379882",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055536","CHILDHOOD OBESITY: EPIDEMIOLOGY, RISK FACTORS, AND EVIDENCE-BASED PREVENTION AND TREATMENT — AN UPDATED NARRATIVE REVIEW (2019–2025)","Helena Szelka","2025","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.4(48).2025.4323",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055537","Glucagon-like peptide-1 receptor agonists and the risk of major adverse cardiovascular events in patients with chronic kidney disease","Kevin Yuan Tzer Yau","2025","TSpace (University of Toronto)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","dissertation"],["R0055538","Glucagon-like peptide-1 receptor agonist use in lung cancer patients receiving immune checkpoint inhibitors: A real-world study.","Wern Lynn Ng","2026","Journal of Clinical Oncology","nonrandomized_study","article","10.1200/jco.2026.44.16_suppl.8598",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0055539","Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?","Peter C. Butler","2009","Diabetologia","preclinical","article","10.1007/s00125-009-1591-5","19894028",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055540","Liraglutide and Dulaglutide Have Comparable HbA1c Reduction in Emirati Patients with T2DM","Aml Mohamed Nada","2021","Open Journal of Endocrine and Metabolic Diseases","nonrandomized_study","article","10.4236/ojemd.2021.114008",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055541","Evaluating the clinical outcomes of GLP-1 receptor agonists in untreated indolent non-Hodgkin's lymphomas undergoing active surveillance","Patrick Willard","2025","Blood","nonrandomized_study","article","10.1182/blood-2025-5385",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0055542","What is the mechanism of action by which Mounjaro (tirzepatide) might affect sleep apnea severity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22257910",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055543","984-P: Real-World Adherence and Discontinuation of GLP-1 Receptor Agonist (GLP-1RA) Therapy in Type 2 Diabetes (T2D) Patients in the U.S.","Tracey Weiss","2019","Diabetes","nonrandomized_study","article","10.2337/db19-984-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055544","Az elhízás és a testsúlycsökkentés szerepe obstruktív alvási apnoéban = The role of obesity and weight reduction in obstructive sleep apnea","Gellért Horváth","2026","Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0055545","Extending Healthspan via GLP-1 Receptor Agonist: Insights and Perspectives","Swarup K. Chakrabarti","2026","Exploratory Research and Hypothesis in Medicine","other","article","10.14218/erhm.2025.00036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055546","Ozempic no emagrecimento: um novo paradigma no tratamento da Obesidade","Pedro Ricardo Primo Ferreira de Oliveira","2024","Caderno Pedagógico","other","article","10.54033/cadpedv21n8-107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055547","Construction and Characterization of Sodium Alginate/Pectin Hydrogel Beads With Surfactant‐Tailored Release Behavior for Targeted Intestinal Delivery of Exenatide","Yanhao He","2026","Journal of Applied Polymer Science","preclinical","article","10.1002/app.70902",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055548","Association of Glucagon-like Peptide-1 Receptor Agonist Use With Postoperative Outcomes After Carotid Endarterectomy","Lilly Fernandes","2026","Journal of Vascular Surgery","other","article","10.1016/j.jvs.2026.03.268",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055549","Trends in Reporting of Psychiatric Adverse Events Including Suicidal Ideation for GLP-1 Receptor Agonists","Anish Ghosh","2026","Scholarly review .","nonrandomized_study","article","10.70121/001c.162536",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055550","THERAPEUTIC POTENTIAL OF GLP-1 RECEPTOR AGONISTS IN ALZHEIMER’S DISEASE: INSIGHTS FROM PRECLINICAL AND CLINICAL EVIDENCE","Lidia Jurczenko","2025","International Journal of Innovative Technologies in Social Science","other_trial","article","10.31435/ijitss.4(48).2025.4385",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055551","272-OR: Weight Loss with Time-Restricted Feeding or Treatment with Obeticholic Acid/Semaglutide Combination Have a Different Impact on Nonalcoholic Steatohepatitis in Diet-Induced Obese Mice","François Briand","2022","Diabetes","preclinical","article","10.2337/db22-272-or",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055552","Warning and Recommendations from the Department of Cardiovascular Imaging Regarding Transesophageal Echocardiography in Patients Using GLP-1 Analogs","Alex dos Santos Félix","2023","ARQUIVOS BRASILEIROS DE CARDIOLOGIA - IMAGEM CARDIOVASCULAR","other","article","10.36660/abcimg.20230092i",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055553","MON-100 Recurrent Cushing Disease Presenting with Obesity Unresponsive to Surgical and Medical Interventions - A Case Series","Sobrina Sarah Mohammed","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.1430",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055554","Agonisty receptora glucagon like peptide 1: nová farmakologická liečba chronického srdcového zlyhávania so zachovanou ejekčnou frakciou ľavej komory / Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment for chronic heart failure with preserved left ventricular ejection fraction","Norbert Nagy","2024","Cardiology letters","other","article","10.4149/cardiol_2024_6_3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055555","885 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS (GLP1-RA) PRIOR TO ENDOSCOPY HAVE LOW GASTRIC RETAINED CONTENTS: A MULTICENTERED STUDY","Jennifer Phan","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)00970-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055556","Young Boy’s Battle with Childhood Obesity: Unmasking A Rare Case of Prader-Willi-Syndrome","Madhabi Karmaker","2026","Journal of Medicine","other","article","10.3329/jom.v27i2.92098",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055557","GLP-1 RECEPTOR AGONISTS IN METABOLIC HEALTH: EXPANDING APPLICATIONS, WEIGHT MANAGEMENT, AND EMERGING SAFETY CONSIDERATIONS","Natalia Kostecka","2026","International Journal of Innovative Technologies in Social Science","nonrandomized_study","article","10.31435/ijitss.3(51).2026.6416",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055558","Indian Expert Consensus on Heart Failure with Preserved Ejection Fraction: A Phenotype-based Approach to Diagnosis and Management","Sandeep Seth","2026","Journal of the Practice of Cardiovascular Sciences","other","article","10.4103/jpcs.jpcs_64_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055559","Once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes: main results from the STEP-HFpEF DM trial","Andrew Sindone","2024","Obesity Research & Clinical Practice","other_trial","article","10.1016/j.orcp.2024.09.085",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055560","Muscle Mass Preservation as a Therapeutic Challenge in GLP-1 Receptor Agonist Therapy","Artur Szafraniec","2026","Quality in Sport","other","article","10.12775/qs.2026.56.72375",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055561","Changes to Pharyngeal Soft Tissue and Fat Volumes Following Tirzepatide Treatment in SURMOUNT-OSA","R J Schwab","2026","Diabetologie und Stoffwechsel","other","article","10.1055/s-0046-1819889",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0055562","REDUCTION OF PULSE PRESSURE BY TREATMENT WITH GLP-1 RECEPTOR AGONIST SEMAGLUTIDE IS ASSOCIATED WITH REDUCTION IN BMI: ANALYSIS OF A PROSPECTIVE RANDOMIZED PLACEBO-CONTROLLED STUDY","Thorsten Kliem","2026","Journal of Hypertension","randomized_trial","article","10.1097/01.hjh.0001195672.80545.cb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-abstract"],["R0055563","624-P: Effects of Semaglutide Treatment on Dietary Behavior in Japanese Patients with Type 2 Diabetes Mellitus","SHIORI T. SATO","2022","Diabetes","other","article","10.2337/db22-624-p",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055564","Non-Insulin Antidiabetic Agents in the Management of Hyperglycaemia of Non-Critical Hospitalized Patients","Monteiro Lopes, Sofia","2024","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055565","CO14 Glycaemic Control, Obesity Management, and Cardiovascular Outcomes of Semaglutide for Type 2 Diabetes Mellitus Patients: An Umbrella Review of Meta-Analyses of Randomized Clinical Trials","Pranab M. Barman","2024","Value in Health","systematic_review","article","10.1016/j.jval.2024.10.091",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","conference-abstract"],["R0055566","The role of functional foods in enhancing endogenous GLP-1 for type 2 diabetes therapy","Afreen Khan","2026","International Journal of Diabetes Research","other","article","10.33545/26648822.2026.v8.i1a.43",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055567","Impact of Various Oral Hypoglycemic Agents on Hepatic Steatosis Reduction in MASLD and Type 2 Diabetes: Exploring the Bidirectional Relationship. A Narrative Review","Emilia Kowalczyk","2025","Clinical Diabetology","nonrandomized_study","article","10.5603/cd.104353",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0055568","Pharmacological treatment options for obesity in children with insulin resistance: a targeted review","Marta Drozdowska","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.54.70352",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055569","2701-LB: Independent Prognostic Value of the Novel Early Biomarker uPTM-FetA/Ucr in Diabetic Kidney Disease: Overcoming Treatment Confounders in a Real-World Cohort","Hala Zakaria","2026","Diabetes","nonrandomized_study","article","10.2337/db26-2701-lb",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055570","The role of markers of chronic inflammation in the progression of sarcopenic obesity in type 2 diabetes mellitus","Yu. G. Samoilova","2026","Molekulyarnaya Meditsina (Molecular medicine)","other","article","10.29296/24999490-2026-01-05",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055571","900.06 Impact Of GLP-1 Receptor Agonist Use on Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Propensity-Matched Analysis from a Global Federated Network","Sammudeen Ibrahim","2026","JACC: Cardiovascular Interventions","nonrandomized_study","article","10.1016/j.jcin.2026.01.216",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055572","Safety profile of semaglutide in people aged 55 years and over: pooled data from the PIONEER, SUSTAIN and STEP phase 3 clinical programmes","Marwan Sabbagh","2023","Alzheimer s & Dementia","other_trial","article","10.1002/alz.076540",null,null,"ClinicalTrials.gov:NCT02207374; ClinicalTrials.gov:NCT02254291","S001498; S002082","openalex","FALSE","paywalled","5","FALSE","article"],["R0055573","1200.07 Comparison Of the Efficacy of Oral and Subcutaneous Semaglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","Ishaque Hameed","2026","JACC: Cardiovascular Interventions","systematic_review","article","10.1016/j.jcin.2026.01.182",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0055574","6468 Once-Weekly Semaglutide and Taste Perception in Women with Obesity","M Jensterle Sever","2024","Journal of the Endocrine Society","randomized_trial","article","10.1210/jendso/bvae163.013",null,null,"ClinicalTrials.gov:NCT04263415","S000894","openalex","TRUE","open_pdf","1","FALSE","article"],["R0055575","Patient-Reported Quality-of-Life Profile in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes: Baseline Findings from a Tirzepatide Study","Laura Danyarova","2026","Astana Medical Journal","other","article","10.54500/2790-1203-2026-4-126-amj029",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055576","Những cập nhật trong điều trị rối loạn chuyển hóa – nội tiết trên phụ nữ hội chứng buồng trứng đa nang","Luong Dai Ly","2021","Tạp chí Phụ sản","other","article","10.46755/vjog.2021.2.1198",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055577","GLP-1 Receptor Agonists: The Next Multifunctional Class of Drugs","SHUBHAM MARBADE","2026","International Journal of Medical and Health Sciences","other","article","10.64823/ijmhs.2601007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055578","Increasing Motivation for Lifestyle Change Is Not Enough to Treat Obesity","Sandra Wittleder","2022","Annals of Internal Medicine","commentary","article","10.7326/m22-0715","35344377",null,null,null,"openalex","FALSE",null,null,"FALSE","editorial"],["R0055579","Once-weekly semaglutide in heart failure with preserved ejection fraction and obesity: main results from the STEP-HFpEF trial","Andrew Sindone","2024","Obesity Research & Clinical Practice","other_trial","article","10.1016/j.orcp.2024.09.084",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055580","Tirzepatide effectively modulates cardiometabolic health differentially by sex in an HFD-induced model of obesity in male and female mice","Timothy Roberts","2026","Journal of Molecular and Cellular Cardiology Plus","preclinical","article","10.1016/j.jmccpl.2025.100624",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055581","The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review.","Breit, Sigrid",null,"Open Access CRIS of the University of Bern","systematic_review","article","10.48620/87415",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0055582","Diabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies","Bhumika Munda","2026","Letters in Applied NanoBioScience","other","article","10.33263/lianbs151.011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055583","Orforglipron as a Small-Molecule GLP-1 Receptor Agonist: A New Era of Incretin-Based Oral Therapy?","Małgorzata Blecharczyk","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.56.72512",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055584","Guidelines for the prevention of psychosis from the World Federation of Societies of Biological Psychiatry (WFSBP) and EPI Canada","Marco Solmi","2026","Research Portal (King's College London)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055585","New approvals","Michele B. Kaufman","2011","Dialysis & Transplantation","other_trial","article","10.1002/dat.20611",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055586","Low utilization of GLP-1RAs and SGLT2i in high-risk cardiovascular patients with diabetes: nationwide insights from myocardial Infarction and stroke survivors","P Sedova","2025","European Heart Journal","nonrandomized_study","article","10.1093/eurheartj/ehaf784.3655",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055587","A81 GASTROINTESTINAL ADVERSE EVENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS IN OVERWEIGHT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS","Yash Verma","2025","Journal of the Canadian Association of Gastroenterology","systematic_review","article","10.1093/jcag/gwae059.081",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0055588","RISK OF HEART FAILURE EXACERBATION IN PATIENTS ON COMBINED TREATMENT WITH SLGT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS WHO UNDERGO TRANSCATHETER AORTIC VALVE REPLACEMENT","Alan Fahoury","2025","Journal of the American College of Cardiology","other","article","10.1016/s0735-1097(25)01620-1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055589","INTEGRATED THERAPY WITH GLP-1 RECEPTOR AGONISTS AND NUTRITIONAL INTERVENTIONS IN THE TREATMENT OF OBESITY IN PATIENTS WITH TYPE 2 DIABETES","Mirsad Šljivić","2025","University of Zagreb University Computing Centre (SRCE)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0055590","Activity-Balanced GLP-1/GDF15 Dual Agonist to Treat Obesity in Mice and Non-Human Primates","Yuanyuan Zhang","2022","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.4126596",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0055591","Impact of Semaglutide on Diabetic Retinopathy: A FAERS Database Analysis and Preclinical Study","Xinxin Yue","2026","Acta Poloniae Pharmaceutica - Drug Research","nonrandomized_study","article","10.32383/appdr/216204",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055592","The Endoscopic Optimization for Obesity in Patients Undergoing Abdominal Wall Reconstruction","Victoria L. Walker","2025","Journal of Abdominal Wall Surgery","randomized_trial","article","10.3389/jaws.2025.15383","41209724",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055593","Patiënten met type 2-diabetes en een laag cardiovasculair risico:Welke glucoseverlager volgt na metformine?","Erik H. Serné","2023","Pure Amsterdam UMC","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0055594","Impact of GLP-1 Receptor Agonists on Body Weight and Cardiovascular Outcomes: A Systematic Review","Ahmed Al Mutairi","2025","Bangladesh Journal of Medical Science","systematic_review","article","10.3329/bjms.v24i10.79201",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055595","Impact of glucagon-like peptide-1 receptor agonists on cutaneous events: A systematic review and meta-analysis","Chun-Chiao Yu","2025","JAAD reviews.","systematic_review","article","10.1016/j.jdrv.2025.04.009",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0055596","735-P: Association between Glucagon-Like Peptide 1 Receptor Agonists and Risk of Depression in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study","Ying Lü","2024","Diabetes","nonrandomized_study","article","10.2337/db24-735-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055597","Side effects of androgen deprivation in prostate cancer and their correction: Systematic review","L. T. Savin","2026","Meditsinskiy sovet = Medical Council","systematic_review","article","10.21518/ms2026-151",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0055598","Is this the end of intensified insulin therapy and obesity in light of updates with novel medicines?","Hakan VAROL","2022","Journal of Translational and Practical Medicine","other","article","10.51271/jtpm-0022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055599","EP565 - ECE_3436 - Correlation between weight loss and reduction in waist circumference in weight management with semaglutide injection: post-hoc analysis of phase 3 study","Unnikrishnan Gopalkrishnan","2026","European Journal of Endocrinology","randomized_trial","article","10.1093/ejendo/lvag096.1026",null,null,"CTRI:CTRI/2025/04/085487",null,"openalex","TRUE","free_to_read","2","FALSE","conference-abstract"],["R0055600","Pharmacological, behavioral, and sociocultural dimensions of GLP-1 and dual incretin therapies in Saudi Arabia: clinical evidence, misuse patterns, and policy priorities","Lamar K. Aloufi","2025","International Journal of Basic & Clinical Pharmacology","randomized_trial","article","10.18203/2319-2003.ijbcp20254166",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055601","Are GLP-1 agonists recommended prior to conception to reduce adverse pregnancy outcomes in women with diabetes or obesity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.18389847",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055602","Synthesis of Danuglipron: Design and Development of a Robust Telescoped C–O Coupling─Deprotection Sequence","Unjila Afrin","2026","Organic Process Research & Development","other","article","10.1021/acs.oprd.6c00006",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055603","Factors contributing to non-persistence of glucagon-like peptide-1 agonists: a cross-sectional study","Shania Liu","2025","Obesity Medicine","other","article","10.1016/j.obmed.2025.100674",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055604","Exploring the Outcomes of Tirzepatide in a Cohort of Kidney Transplant Recipients","H. Aldahham","2026","American Journal of Transplantation","nonrandomized_study","article","10.1016/j.ajt.2026.05.1255",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055605","Rapid and substantial reversal of hepatic steatosis and fibrosis with liraglutide in a young, obese, non-diabetic male with metabolic dysfunction-associated steatotic liver disease: A case report","Sainath Ganesh Gadewar","2025","International Journal of Gastroenterology Research","case_report","article","10.33545/26646439.2025.v7.i1a.10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055606","Glucagon-Like Peptide-1 Agonists and Weight Regulation","George Bray","2014",null,"other","article","10.1201/b16472-28",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0055607","GLP-1 receptor agonists and skeletal muscle: The risk of sarcopenic obesity and the role of resistance training. A narrative review","Roksana Milaniuk","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.69.74557",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055608","Exploring the Role of Microbiome Dysregulation in PCOS: Pathophysiology, and Emerging Therapies Toward Targeted and Personalized Treatment","Katelyn Brown","2026","RVU Elevate","nonrandomized_study","article","10.82451/k51016",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","conference-abstract"],["R0055609","P6 REAL-WORLD COMPARATIVE EFFECTIVENESS OF SEMAGLUTIDE 2.4 MG VERSUS OTHER COMMERCIALLY AVAILABLE MEDICATIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH OBESITY IN THE UNITED STATES: A PRAGMATIC CLINICAL STUDY","Warren Peters","2026","Value in Health","nonrandomized_study","article","10.1016/j.jval.2026.03.021",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055610","Comparative Effectiveness of GLP-1 Receptor Agonists in Patients with Heart Failure with Preserved or Minimally Reduced Ejection Fraction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials","Ibrahim Khalil","2025","American Heart Journal","systematic_review","article","10.1016/j.ahj.2025.07.049",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0055611","Differentiation of walleye pollock (Theragra chalcogramma) of the Sea of Okhotsk based on the microsatellite loci","Vladimir V. Savenkov","2018","The researches of the aquatic biological resources of Kamchatka and of the north-west part of the Pacific Ocean","other","article","10.15853/2072-8212.2018.48.5-18",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055612","LITERATURE REVIEW : Cost Effective Analysis of Sitagliptin for the Treatment of Diabetes Mellitus Type 2","Anak Agung Pradnya Paramitha Vidiani","2024","Science and Community Pharmacy Journal","narrative_review","article","10.63520/scpj.v3i1.546",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055613","THE IMPACT OF OBESITY ON THE DEVELOPMENT OF HYPERTENSION IN CHILDREN – A LITERATURE REVIEW","Klaudia Ostrowicz","2025","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.3(47).2025.3807",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055614","MON-637 A Case of Euglycemic Ketoacidosis Following Treatment With an SGLT2 Inhibitor and Tirzepatide","Eli J. Louwagie","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.997",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055615","EP1673 - ECE_1097 - The association between type 2 diabetes and the risk of developing bronchial asthma using the Korean national health insurance service data and upper respiratory disease claims database","Heung Yong Jin","2026","European Journal of Endocrinology","nonrandomized_study","article","10.1093/ejendo/lvag096.1189",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-abstract"],["R0055616","Trends in use of cardiorenal protective medication among people with type 2 diabetes and chronic kidney disease in Denmark","Rasmus Rørth","2025","Diabetes Epidemiology and Management","other","article","10.1016/j.deman.2025.100286",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055617","Pharmacovigilance of Semaglutide and Liraglutide: A Narrative Review of Safety Profiles, Emerging Signals, and Risk Management Strategies","Alessia Mihich","2026","Indian Journal of Clinical Biochemistry","nonrandomized_study","article","10.1007/s12291-026-01421-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","review"],["R0055618","Least Glucose Variability Is Observed with the Combination of a GLP-1 Receptor Agonist and Basal Insulin Among Four Commonly Used Insulin Regimen in Type 2 Diabetes (VARIATION Study)","HARPREET SINGH BAJAJ","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.114",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055619","Association of GLP-1 agonists with metabolic and acid–base disorders after radical cystectomy","Sri Saran Manivasagam","2026","Urologic Oncology Seminars and Original Investigations","other","article","10.1016/j.urolonc.2026.03.008",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055620","The Chemistry of Temptation: GLP-1 Agonists, Body, and Religious Interpretations of Compulsive Eating in Brazil","Flávio Lopes Arantes","2026","International Journal of Latin American Religions","other","article","10.1007/s41603-026-00345-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0055621","What is the best initial medication for a 28-year-old patient with IBD, newly diagnosed diabetes, and hypertriglyceridemia, considering mildly elevated LFTs?","Tripdatabase","2025","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.17949523",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055622","Tirzepatide and Semaglutide for the Treatment of Obstructive Sleep Apnea and Obesity: A Retrospective Analysis","Onur Başer","2024","Medical Research Archives","nonrandomized_study","article","10.18103/mra.v13i1.6236",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055623","The Incretin Revolution: Transforming Metabolic Medicine Review Article","Kola prudvika","2026","International journal of research and scientific innovation","randomized_trial","article","10.51244/ijrsi.2026.1305000213",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055624","The Niels Lassen Award Session and Oral Sessions","Wong, D.F.","2017","Journal of Cerebral Blood Flow & Metabolism","randomized_trial","article","10.1177/0271678x17695978","28366133",null,"ClinicalTrials.gov:NCT01469351","S001707","openalex","TRUE","open_pdf","1","FALSE","article"],["R0055625","Clinical impact of GLP-1 and GIP/GLP-1 agonist access barriers in primary care","Alexandra Cochran","2025","JAPhA Practice Innovations","nonrandomized_study","article","10.1016/j.japhpi.2025.100081",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055626","2970-LB: High Prevalence of Endogenous Hypercortisolism in Patients with Type 2 Diabetes and Resistant Hypertension: Results from the MOMENTUM Study","GUILLERMO UMPIERREZ","2026","Diabetes","other_trial","article","10.2337/db26-2970-lb",null,null,"ClinicalTrials.gov:NCT05772169; ClinicalTrials.gov:NCT06829537",null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055627","Nutrition specifics in type 2 diabetic patients with binge eating disorder and the effects of glucagonlike peptide I receptor agonists","Elena Georgievna Starostina","2026","Obesity and metabolism","other_trial","article","10.14341/omet13343",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0055628","Glycemic equipoise","Sanjay Kalra","2016","Indian Journal of Endocrinology and Metabolism","randomized_trial","article","10.4103/2230-8210.194361","28217492",null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055629","Functional-vs-Cognitive Decline Heterogeneity in Alzheimer’s Disease Revealed by LLM-Curation of Decades of Clinical Notes has Implications for Semaglutide Trial Design","Karthik Murugadoss","2026","SSRN Electronic Journal","other_trial","article","10.2139/ssrn.6841482",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","preprint"],["R0055630","2821-LB: Semaglutide Improves Tissue-Specific Insulin Action and Reduces Liver Fat in Type 2 Diabetes with Spinal Cord Injury","Azam Alamdari","2026","Diabetes","other","article","10.2337/db26-2821-lb",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055631","OBESITY AS A MODIFIABLE DETERMINANT OF THYROID DYSFUNCTION, STRUCTURAL CHANGES, AND THYROID CANCER","Klaudia Baran","2025","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.4(48).2025.4647",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055632","ESI Clinical Practice Guidelines for the Evaluation and Management of Obesity in India – An Update (2025)","Sri Venkata Madhu","2025","Indian Journal of Endocrinology and Metabolism","nonrandomized_study","article","10.4103/ijem.ijem_680_25","40917319",null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055633","Physiology and pharmacology of glucagon-like peptide-1 receptor","Денис Владимирович Куркин","2024","Pharmacy & Pharmacology","nonrandomized_study","article","10.19163/2307-9266-2023-11-4-347-380",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055634","C-103 | GLP-1 Receptor Agonists in HFrEF: Outcomes in Patients With Concomitant Cardiac Amyloidosis","Didien Meyahnwi","2026","Journal of the Society for Cardiovascular Angiography & Interventions","other","article","10.1016/j.jscai.2026.104838",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055635","ASSOCIATION BETWEEN GLP-1 ANALOGUES AND PANCREATITIS: AN INTEGRATIVE REVIEW OF CURRENT EVIDENCE","Alexandre Alves Neves Pereira","2026","Seven Editora eBooks","narrative_review","article","10.56238/sevened2026.020-002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055636","Obesity Conundrum: Blockbuster New Medicine or Bariatric Surgery: A Mini Literature Review","Muhammad Muneer","2025","Journal of Diabetes and Endocrine Practice","narrative_review","article","10.1055/s-0045-1815678",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0055637","Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions","Giuseppe Floresta","2024","Scientia Pharmaceutica","other","article","10.3390/scipharm92020017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055638","Disparities in Medication Treatment of Type 2 Diabetes and Obesity","Rachel Whooten","2026","PEDIATRICS","nonrandomized_study","article","10.1542/peds.2025-074840","41765354",null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055639","Abstract 4361308: Tirzepatide Reduces the Risk of Major Adverse Cardiovascular Events: An Individual Participant Data Meta-analysis of Phase 3 Randomized Clinical Trials","Arya Aminorroaya","2025","Circulation","systematic_review","article","10.1161/circ.152.suppl_3.4361308",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0055640","GLP-1 RAs and Muscle Function Outcomes in Active Adults and Athletes","Anna Świerczek","2026","Quality in Sport","nonrandomized_study","article","10.12775/qs.2026.66.73870",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055641","Fármacos GLP1AR y trastorno por consumo de alcohol. ¿Representan una solución terapéutica definitiva o solo otra promesa incumplida?","Albert Batalla","2025","Adicciones","commentary","article","10.20882/adicciones.2497","41099481",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0055642","Does starting a GLP-1 agonist in adults with prediabetes provide benefits over usual treatment?","Christian D. Hoag","2023","Evidence-Based Practice","other","article","10.1097/ebp.0000000000001885",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055643","Mediterranean Diet Still Holds a Place in Obesity Treatment Despite the Considerable Effectiveness of the Very Low-Calorie Ketogenic Diet: A Short Communication","Kulvinder Kochar Kaur","2023","Obesity Research - Open Journal","other","article","10.17140/oroj-10-150",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055644","Pathophysiology, Clinical Sequelae, and Therapeutic Paradigms in Type 2 Diabetes Mellitus","Syed Afzal Uddin Biyabani","2025","Journal of Pharma Insights and Research.","other","article","10.69613/6c9zbh95",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055645","Effect of treatment intensification on glycemic control in patients with subcontrolled type 2 diabetes who failed on two oral antidiabetic agents","Malinda Sunnita Tan","2023","Diabetes Epidemiology and Management","nonrandomized_study","article","10.1016/j.deman.2022.100127",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055646","S727 GLP-1 RA Use in Patients with T2DM is Associated with Lower Risk of Esophageal Cancer: A National Analysis","Mark Ayoub","2024","The American Journal of Gastroenterology","nonrandomized_study","article","10.14309/01.ajg.0001032276.20421.fe",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055647","722-P: Tirzepatide Improves Multiple Aspects of Beta-Cell Function","Andrea Mari","2022","Diabetes","randomized_trial","article","10.2337/db22-722-p",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055648","New Avenues in Adjunctive Pharmacotherapy for Substance Use Disorders","David Crockford","2026","The Canadian Journal of Addiction","other","article","10.1097/cxa.0000000000000276",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055649","Recomendaciones de buena práctica clínica para el manejo de la enfermedad por reflujo gastroesofágico. Revisión por expertos latinoamericanos","Miguel Angel Valdovinos","2025","Revista de Gastroenterología de México","other","article","10.1016/j.rgmx.2025.02.001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055650","EPH59 Application of Prevalent New-User Cohort Designs to a Claims Data Study of Incidence of Nutritional Deficiency in People With Diabetes Using GLP-1 Receptor Agonists","Thadchaigeni Panchalingam","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.590",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0055651","Cardiorenal Protective Effects of Semaglutide in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","Sarah Torp Yttergren","2025","Journal of the American Society of Nephrology","randomized_trial","article","10.1681/asn.20252580qcqf",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055652","The Compounding Enforcement Wave: Drivers, Deficiencies, and a Quality System Roadmap for 503A and 503B Facilities","Nansiben Patel","2026","Advances in Chemical Engineering and Science","nonrandomized_study","article","10.4236/aces.2026.163004",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055653","Advancing Peptide Synthesis: Liquid-Phase Assembly of Tirzepatide’s C-Terminus (30–39) via Crystalline Pentamer Building Blocks","Paridhi Agrawal","2025","Organic Process Research & Development","other","article","10.1021/acs.oprd.5c00304",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055654","Incretin-Based Therapies: What Do We Need To Know?","Marlene Shehata","2011","Journal of Diabetes & Metabolism","other","article","10.4172/2155-6156.1000146",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055655","Abstract 13465: Tirzepatide vs. Semaglutide for Secondary Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus With an Initial HbA1c of >8.5 - A Value for Money Analysis","Joseph Azuri","2023","Circulation","other","article","10.1161/circ.148.suppl_1.13465",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055656","O75 Glucagon-like peptide-1 receptor agonists and risks of opioid use and invasive interventions in chronic pancreatitis: a real-world cohort study","Arkadeep Dhali","2026",null,"nonrandomized_study","article","10.1136/gutjnl-2026-bsg.74",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0055657","Tight glycaemic control-caution in high risk groups","Anthony H Barnett","2011","International Journal of Clinical Practice","nonrandomized_study","article","10.1111/j.1742-1241.2010.02593.x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055658","Food Supplements for Body Weight Reduction: A Systematic Review of Systematic Reviews","Igho Onakpoya","2010","Obesity","systematic_review","article","10.1038/oby.2010.185","20814412",null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0055659","530 SINGLE-DOSE GLP-1-BASED PANCREATIC GENE THERAPY MAINTAINS WEIGHT LOSS AFTER SEMAGLUTIDE WITHDRAWAL AND REDUCES HEPATIC TRIGLYCERIDES IN A MURINE MODEL OF OBESITY","Alice P. Liou","2024","Gastroenterology","preclinical","article","10.1016/s0016-5085(24)00763-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055660","Therapeutic Spectrum of GLP-1 Receptor Agonist: From Glycemic Control to Metabolic Protection","Marta Kamińska","2026","Quality in Sport","other","article","10.12775/qs.2026.49.68001",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055661","CO158 Leveraging Generative AI for Efficient Patient Safety Narrative Drafting: A Semaglutide Case Study","Manuel Cossio","2025","Value in Health","other","article","10.1016/j.jval.2025.09.260",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055662","Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective","Davida F. Kruger","2018","Journal of the American Association of Nurse Practitioners","other","article","10.1097/jxx.0000000000000126",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055663","Affective Destabilisation Associated With Tirzepatide in a Patient With Narcissistic Personality Traits","Gayathri Rangith","2026","BJPsych Open","other","article","10.1192/bjo.2026.11887",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055664","ПРОМЕЖУТОЧНЫЕ РЕЗУЛЬТАТЫ КЛИНИЧЕСКОГО ИССЛЕДОВАНИЯ ПРЕПАРАТА СИБУТРАМИНА И МИКРОКРИСТАЛЛИЧЕСКОЙ ЦЕЛЛЮЛОЗЫ (ГОЛДЛАЙН® ПЛЮС) ПОСЛЕ ОТМЕНЫ АГОНИСТОВ РЕЦЕПТОРОВ ГПП-1 И ДВОЙНЫХ АГОНИСТОВ РЕЦЕПТОРОВ ГПП-1/ГИП: ОЦЕНКА ПИЩЕВОГО ПОВЕДЕНИЯ И СОСТАВА ТЕЛА","Н.А. Петунина","2026","Axis of endocrinology","other","article","10.46393/30337380_2026_2_34-40",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055665","Clinical precision","A Micheli","2019","The Journal of AMD","other","article","10.36171/jamd19.22.1-2.07",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055666","Cost-Effectiveness of Liraglutide: Comparison of Costs and Benefits Versus Insulin Glargine and Sitagliptin","Cardoso, C","2015","Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055667","The Role of GLP-1 Receptor Agonists in Obesity Management: Evidence from Glycemic and Non-Glycemic Populations","Ayushi Jain","2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.30s.55",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055668","1729-P: Tirzepatide Enhances Metabolic Outcomes in People with Type 1 Diabetes and Overweight/Obesity: A Retrospective Cohort Study at Sydney's Royal North Shore Hospital","AMANDA R. PURCELL","2026","Diabetes","nonrandomized_study","article","10.2337/db26-1729-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055669","CARDIOVASCULAR BENEFITS OF GLP-1 RECEPTOR AGONISTS: EVIDENCE FROM CARDIOVASCULAR OUTCOMES TRIALS (CVOTs)","Nicol Szerenos","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(51).2026.6150",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055670","The impact of GLP 1 analogues on fertility restoration in patients with Polyendocrine Metabolic Ovarian Syndrome (PMOS) - Narrative Review","Martyna Więcławek","2026","Quality in Sport","nonrandomized_study","article","10.12775/qs.2026.68.74321",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0055671","Major Adverse Cardiovascular Events (MACE) in Cancer Patients Treated With Tirzepatide Compared to Semaglutide: A Target Trial Emulation Using Real-World Data","Omer Sayed Ashruf","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7040885",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0055672","Impact of Obesity in Women Health and Approach to Optimize Obesity Care with Glucagon-like Peptide-1 Receptor Agonist","Sruti Chandrasekhar","2026","International Journal of Diabetes and Technology","other","article","10.4103/ijdt.ijdt_26_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055673","Comparative cost-effectiveness analysis of therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and high cardiovascular risk or a history of atherosclerotic cardiovascular diseases in the Russian healthcare system","М.V. Zhuravleva","2026","Russian Journal of Cardiology","other","article","10.15829/1560-4071-2025-6687",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055674","Heart failure with preserved ejection fraction as a systemic inflammatory–metabolic disorder: through the cardio–hepato–pancreatic axis lens","Han Naung Tun","2026","Frontiers in Cardiovascular Medicine","other","article","10.3389/fcvm.2026.1806841","42131092",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055675","Особливості лікування серцевої недостатності в пацієнтів із метаболічно-асоційованою стеатотичною хворобою печінки. Огляд літератури","Ю. С. Рудик","2026","The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0055676","Development and validation of a UPLC-HR-SIM method to quantify semaglutide for its pharmacokinetic study","Jiang Xinyi","2025","Intelligent Pharmacy","other","article","10.1016/j.ipha.2025.01.002",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055677","New insights into atherosclerotic cardiovascular disease through the lens of metabolism: expanding our approach","Junbo Ge","2025","Cardiology Plus","other","article","10.1097/cp9.0000000000000112",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055678","Abstract 4365133: Impact of GLP-1 Analog Use on Clinical Outcomes Following Bariatric Surgery: A Propensity-Matched Retrospective Cohort Study","Abdul Wali Khan","2025","Circulation","nonrandomized_study","article","10.1161/circ.152.suppl_3.4365133",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055679","Tirzepatide",null,"2024","Reactions Weekly","other","article","10.1007/s40278-024-68160-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0055680","Regenerative Medicine in Orthopedics: Evaluating PRP, MSC Therapies, BPC-157, TB-4/TB-500, CJC-1295, Retatrutide, and Osteostatin as Complements to Conventional Care: A Narrative Review","Nathan Tebben","2026","RVU Elevate","narrative_review","article","10.82451/k51067",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055681","Effectiveness of Switching from a DPP-4 Inhibitor to the Human GLP-1 Analogue Liraglutide in Patients with Type 2 Diabetes","Lucette Farah","2014","Canadian Journal of Diabetes","other","article","10.1016/j.jcjd.2014.07.127",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055682","O42 Comparative effectiveness and gastrointestinal safety of orlistat versus liraglutide in obesity and type 2 diabetes adults: a real-world cohort study","Arkadeep Dhali","2026",null,"nonrandomized_study","article","10.1136/gutjnl-2026-bsg.41",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0055683","Unexpected Pregnancy Following Tirzepatide Therapy for Obesity in a Woman with Polycystic Ovary Syndrome (PCOS)","Brian McCully","2026","Juniper Online Journal of Case Studies","other","article","10.19080/jojcs.2026.16.555929",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055684","Renal Cell Type-Associated Therapeutic Effects of Semaglutide in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease","Adam Bøgh Marstrand-Jørgensen","2024","Journal of the American Society of Nephrology","preclinical","article","10.1681/asn.2024gferenjj",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055685","Safety and Efficacy of Exenatide in Patients of Asian Descent with Type 2 Diabetes Taking Metformin or Metformin with a Sulfonylurea","Joanne Lorraine","2008","Canadian Journal of Diabetes","other","article","10.1016/s1499-2671(08)24095-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055686","OBSTRUCTIVE SLEEP APNOEA SYNDROME: ETIOLOGY, DIAGNOSIS, AND CURRENT TREATMENT METHODS","Zuzanna Muszkiet","2025","Archiv Euromedica","randomized_trial","article","10.35630/2025/15/iss.5.521",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055687","Development of disease-modifying drugs for Parkinson's disease. Is it a tough road?","Masahiro Nagai","2022","Proceedings for Annual Meeting of The Japanese Pharmacological Society","other_trial","article","10.1254/jpssuppl.95.0_2-s24-4",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055688","Association between GLP-1 receptor agonists and nonscarring hair loss: a population-based, propensity score matched cohort analysis","Matthew H. Lanehart","2026","Archives of Dermatological Research","nonrandomized_study","article","10.1007/s00403-026-04603-w",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055689","GLP-1 RA-Semaglutide a game changer drug for management of obesity with and without Diabetes - A narrative review","Quazi Tarikul Islam","2024","Bangladesh Journal of Medicine","narrative_review","article","10.3329/bjm.v53i3.75561",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055690","P447 - LBA_ECE_1469 - From valve to algorithm: first report of advanced hybrid closed-loop insulin delivery during major cardiac surgery","Martha Scherer","2026","European Journal of Endocrinology","other","article","10.1093/ejendo/lvag096.566",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055691","Su1100 ASSOCIATION BETWEEN PERIOPERATIVE GLP-1 AGONIST USE AND POST OPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING UPPER ENDOSCOPY","Duha Zaffar","2024","Gastroenterology","other","article","10.1016/s0016-5085(24)01955-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055692","ORAL COMMUNICATION | Semaglutide plus empagliflozin improves renal outcomes compared with monotherapies in type 2 diabetes: a real-world study","P. Villari","2026","Italian Journal of Medicine","nonrandomized_study","article","10.4081/itjm.2026.2593",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055693","A Case Report on Acute Pancreatitis Associated with Sitagliptin Therapy in Type 2 Diabetes Mellitus","Syed Afzal Uddin Biyabani","2026","Journal of Pharma Insights and Research.","nonrandomized_study","article","10.69613/gv1dqg56",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055694","MON-631 Double Diabetes Case Series: A Hybrid Pathology Requiring Hybrid Therapy","Jacqueline Silvia Martins Torrontegui","2025","Journal of the Endocrine Society","case_report","article","10.1210/jendso/bvaf149.991",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-abstract"],["R0055695","The pharma race to develop increasingly more potent incretin-based therapeutics—what is for the clinicians to know","Jerzy W. Kolaczynski","2025","Exploration of Endocrine and Metabolic Diseases","other_trial","article","10.37349/eemd.2025.101449",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055696","Preoperative management algorithm for endoscopic or surgical interventions in patients receiving incretin mimetics","V. V. Salukhov","2026","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2026-161",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055697","2847-LB: PT403, a Once-Monthly Long-Acting Semaglutide: Preclinical Efficacy and Interim Safety and Tolerability in Healthy Subjects","MYUNG-JOO CHOI","2026","Diabetes","randomized_trial","article","10.2337/db26-2847-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055698","Control of eating with semaglutide 7.2 mg in adults with obesity: The STEP UP trial","S Jacob","2026","Diabetologie und Stoffwechsel","randomized_trial","article","10.1055/s-0046-1819891",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","conference-paper"],["R0055699","TERAPIA BASEADA EM AGONISTAS DO GLP-1 VERSUS INSULINA BASAL EM IDOSOS PORTADORES DE DIABETES MELLITUS TIPO 2: IMPLICAÇÕES NO CONTROLE GLICÊMICO E DESFECHOS CLÍNICOS","João Carlos de Arêa Leão Costa Neto","2026","INTERFERENCE A JOURNAL OF AUDIO CULTURE","other","article","10.36557/2009-3578.2026v12n2p84-109",null,null,"PROSPERO:CRD420251104563",null,"openalex","TRUE",null,null,"FALSE","article"],["R0055700","GLP-1 and dual GIP/GLP-1 receptor agonists’ psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill–informed, systematic, evaluation","Amira Guirguis","2026","Cronfa (Swansea University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055701","Myocardial GLP-1 Receptor Activation in the Presence of Glucose: Strong Partners","Ewald Kolesnik","2018","International Journal of Peptide Research and Therapeutics","other","article","10.1007/s10989-018-9706-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055702","THE EMERGING ROLE OF TIRZEPATIDE IN THE MANAGEMENT OF OBSTRUCTIVE SLEEP APNEA","Kelson Palhari Crüz","2025","Seven Editora eBooks","other","article","10.56238/edimpacto2025.060-021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055703","ANTI-OBESITY THERAPY: A REVIEW","Chandana Kamili A *, Sai Krishna K.V.S A, Abbulu Konda A, Rama Mohan Reddy Tummaluru A, Ravi Shankar Kakaraparthi B, Uma Maheshwararao Vattikutti C","2019","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.2677997",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055704","Duodenal Ulcer Perforation Following Tirzepatide Injections for Weight Loss Management: A Case Report","Hayder Al-Azzawi","2026","Cureus","case_report","article","10.7759/cureus.116411",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055705","EPH135 Real-World Prescribing Patterns of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in Germany","Claude-Émilie Jacob","2024","Value in Health","nonrandomized_study","article","10.1016/j.jval.2024.10.1264",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0055706","An Original PEG‐Functionalized PS Resin Enables Synthesis of Difficult Peptides: Application to Tirzepatide","Ashish Kumar","2026","ChemistrySelect","other","article","10.1002/slct.202506541",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055707","SUN-676 Impact Of Once-weekly Semaglutide On Heart Failure Hospitalizations And Weight Loss In Obese Patients With Preserved Ejection Fraction (Hfpef): A Meta-analysis","Elizabeth Caroline Palaparthi","2025","Journal of the Endocrine Society","systematic_review","article","10.1210/jendso/bvaf149.186",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0055708","SUN-572 Microscale Magnetic Resonance Profiling Of Plasma Oxidative Stress (os) Reveals Early Metabolic Dysfunction In Normoglycemic And Prediabetic Individuals","Rodolfo Rohr","2025","Journal of the Endocrine Society","other","article","10.1210/jendso/bvaf149.1223",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055709","Comparative study of the efficacy and safety of tirzepatide drugs in metabolic syndrome","A. A. Andreev-Andrievsky","2026","Pharmacy & Pharmacology","preclinical","article","10.19163/2307-9266-2026-14-1-109-132",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055710","Impact of GLP-1 Agonists on Depression Treatment: A Literature Review","Paulina Lemieszek","2024","Journal of Education Health and Sport","nonrandomized_study","article","10.12775/jehs.2024.69.55353",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055711","From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus","Ralph Anthony DeFronzo","2009","Diabetes","other","article","10.2337/db09-9028","19336687",null,null,"S000911; S002311; S003395","openalex","TRUE","open_pdf","5","FALSE","article"],["R0055712","Targeting the gut microbiome: an integrated probiotic and prebiotic strategy for polycystic ovary syndrome management","Muchu Ni","2026","Journal of Ovarian Research","other","article","10.1186/s13048-026-02164-0","42449405",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055713","Nutritional Assessment and Management in MASLD: A Practical Guide for Primary Care","Arpan B. Patel","2026","Livers","randomized_trial","article","10.3390/livers6040069",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055714","Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?","Barbara Szostak","2025","Prospects in Pharmaceutical Sciences","other","article","10.56782/pps.361",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055715","Effect of 52-week liraglutide treatment on diabetes risk and glycaemic control in women with obesity and prior gestational diabetes. A randomized, double-blind, placebo-controlled study","Roosa Perämäki","2025","Obesity Medicine","randomized_trial","article","10.1016/j.obmed.2025.100596",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055716","RWD171 Baseline BMI and HbA1c Trends in US Diabetic Patients Initiating GLP-1 Therapy: A Retrospective Cohort Study","Wouter van der Pluijm","2025","Value in Health","nonrandomized_study","article","10.1016/j.jval.2025.04.1754",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0055717","A Review on Resmetirom: An Oral Thyroid Hormone Receptor-β Agonist for the Treatment of Metabolically dysfunction-Associated Steatohepatitis (MASH)","Sakshi Mahalpure","2026","Journal of Pharmaceutical and Biopharmaceutical Research","nonrandomized_study","article","10.25082/jpbr.2026.01.002",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055718","Associations of mortality and sepsis after GLP-1 receptor agonist initiation versus SGLT2 inhibitor or metformin initiation in people with HIV, overweight or obesity, and type 2 diabetes: A target trial emulation","Yu‐Nan Huang","2026","Therapeutic Advances in Endocrinology and Metabolism","nonrandomized_study","article","10.1177/20420188261490985",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055719","1395-P: Effect of the Dual GLP-1/GIP Receptor Agonist Tirzepatide on Circulating Proteins Associated with ESKD Risk in Patients with Type 2 Diabetes","Eiichiro Satake","2026","Diabetes","other_trial","article","10.2337/db26-1395-p",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055720","A Review on Diabetes Mellitus","Alok Yadav Alok Yadav","2025","International Journal of Pharmaceutical Research and Applications","narrative_review","article","10.35629/4494-100222732280",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055721","Time to Retire the Glycemic Dogma of Early Worsening in Diabetic Retinopathy","Ming Lu","2026","Journal of Endocrinology Diabetes & Obesity","other","article","10.47739/2333-6692.endocrinology.1128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055722","A dual-mechanism oral therapy targeting UCP-1 and GLP-1 pathways for obesity management: Interim results from the DUAL-ACT trial","Kiran Rukadikar","2026","International Journal of Endocrinology Research","nonrandomized_study","article","10.33545/26646579.2026.v8.i1a.12",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055723","Impact of incretin-based therapies on pancreatic exocrine function markers in long-duration type 2 diabetes mellitus","Mathieu Tremblay","2024","International Journal of Endocrinology Research","other","article","10.33545/26646579.2024.v6.i1a.21",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055724","ANTI-OBESITY THERAPY: A REVIEW","Chandana Kamili A *, Sai Krishna K.V.S A, Abbulu Konda A, Rama Mohan Reddy Tummaluru A, Ravi Shankar Kakaraparthi B, Uma Maheshwararao Vattikutti C","2019","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.2677998",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055725","THERAPEUTIC MANAGEMENT OF MENOPAUSE: HORMONAL APPROACH AND NON-HORMONAL ALTERNATIVES","Ryan Rafael Barros De Macedo","2026","International Seven Journal of Multidisciplinary","nonrandomized_study","article","10.56238/isevmjv5n1-020",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055726","GLP-1 (Glucagon-Like Peptide-1) Is Physiologically Relevant for Chylomicron Secretion Beyond Its Known Pharmacological Role","Avital Nahmias","2021","Arteriosclerosis Thrombosis and Vascular Biology","preclinical","article","10.1161/atvbaha.121.316311","33951941",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055727","Efecto de terapias farmacológicas para el control glicémico en pacientes con diabetes mellitus tipo 2 en los desenlaces vasculares","John Mauricio Lopera Vargas","2020","Revista Colombiana de Nefrología","other","article","10.22265/acnef.7.1.372",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055728","Perspectives on Newer Antiobesity Drugs (Semaglutide and Tirzepatide) among Healthcare Professionals Treating Obesity in South Asia: A Cross-sectional Survey","Khushboo Agarwal","2026","Journal of the Association of Physicians of India","other","article","10.59556/japi.74.1709",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055729","Exploring the Phytochemicals from Gardenia jasminoides Ellis with GLP-1 Receptor Activation","Saisree Gollapudi","2026","Physiology","nonrandomized_study","article","10.1152/physiol.2026.41.s1.2297278",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055730","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-92245-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055731","The new slim: Rising use of glp-1 receptor agonists for weight loss in India—promise, pitfalls, and public health concerns","Amol Hartalkar","2025","Journal of Preventive Medicine and Holistic Health","randomized_trial","article","10.18231/j.jpmhh.16801.1766129544",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055732","Die Diabetes- und Abnehmmedikamente Semaglutid und Tirzepatid sowie SAR441255 beeinflussen COPD-assoziierte inflammatorische Prozesse in glatten Atemwegsmuskelzellen.","Julian Jacobsen","2026","Pneumologie","other","article","10.1055/s-0046-1816404",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0055733","400.09 Comparative Outcomes of Tirzepatide to DPP4 Inhibitors In Patients With Heart Failure And Type 2 Diabetes","Ibrahim Mortada","2026","JACC: Cardiovascular Interventions","other","article","10.1016/j.jcin.2026.01.147",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055734","GLP-1 Obesity and Diabetes Gerald H Tomkin and Daphne Owens","GERALD H. TOMKIN","2019","Interventions in Obesity & Diabetes","other","article","10.31031/iod.2019.03.000553",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055735","Pharmacotherapeutics of GLP-1 receptor agonists: a comprehensive scoping review of mechanisms, efficacy, safety, and emerging applications in metabolic and cardiovascular diseases","Hariny Muthuraj","2026","Clinical review for general practice","narrative_review","article","10.47407/kr2026.7.6.00858",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055736","Analogue of glucagon-like peptide-1 - properties, mechanisms of action, prospects for use","FSBEI HE SPbGUVM","2023",null,"other","article","10.52419/3006-2023-8-39-44",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0055737","Cardio-Kidney-Metabolic Syndrome and Role of Oral Semaglutide","Nirmalya Roy","2026","International Journal of Diabetes and Technology","nonrandomized_study","article","10.4103/ijdt.ijdt_24_26",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055738","GLP-1 Receptor Antagonists in Heart Failure with Reduced and Preserved Ejection Fraction: A Scoping Review of Pathogenesis, Efficacy and Future Directions","Fajr Imran","2025","Indus journal of bioscience research.","nonrandomized_study","article","10.70749/ijbr.v3i5.1533",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055739","1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis","Stephanie L. Samuels","2023","Diabetes","nonrandomized_study","article","10.2337/db23-1100-p",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055740","Evaluation of the effect of semaglutide on certain cardiovascular risk factors in overweight or obese healthcare workers. The “Start with yourself” program: a post-registration, single-center, prospective study of routine clinical practice","Лариса Александровна Балыкова","2026","Pharmacy & Pharmacology","other","article","10.19163/2307-9266-2026-14-4-410-422",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055741","376 Community Pharmacist Perspectives on GLP-1 Receptor Agonist Medications: Attitudes, Stigma, and Professional Practice in Obesity and Diabetes Care","A. Lopez","2026","Journal of the American Pharmacists Association","other","article","10.1016/j.japh.2026.103387",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055742","Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?","Lis Marina de Mesquita Araújo","2016","Open Journal of Endocrine and Metabolic Diseases","other","article","10.4236/ojemd.2016.61007",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055743","GLP-1 RECEPTOR AGONISTS IN AESTHETIC MEDICINE: THERAPEUTIC BREAKTHROUGH OR CATALYST FOR UNREALISTIC BODY IDEALS?","Olga Kowalczyk","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.1(49).2026.5160",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055744","Tirzepatide - a new drug with great potential in controlling glycemia and body weight","Magdalena Stabrawa","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.52.69364",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055745","Weight loss injections for the obese and unemployed in the UK: is wellbeing the missing link?","Vishal Madan","2025","Discover Social Science and Health","other","article","10.1007/s44155-025-00213-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055746","Neuroprotective Potential of GLP-1 Receptor Agonists in Neurodegenerative Diseases: Narrative Review","Paulina Orzechowska","2026","Biuletyn Głównej Biblioteki Lekarskiej","randomized_trial","article","10.2478/bgbl-2026-0014",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0055747","Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.","Fox, Claudia K",null,null,"randomized_trial","article","10.48620/76208",null,null,"ClinicalTrials.gov:NCT04775082","S000318","openalex","TRUE","paywalled","1","FALSE","article"],["R0055748","CARDIOPRODUCTIVE EFFECTS OF EXXENATE AMID AND VILDAGLIPTIN INCRETIN MIMETICS IN DOXYRUBRICINE CARDIOMYOPATHY MODELING","A. P. TARASOVА","2017","Кубанский научный медицинский вестник","other","article","10.25207/1608-6228-2017-24-3-100-105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055749","Development of a Manufacturing Process for a Key (S)-5-(2,2-Dimethyltetrahydro-2H-pyran-4-yl)-1H-indole Intermediate for Orforglipron. Part II. Development of a CSTR Process for Evans Auxiliary-Assisted Asymmetric 1,4-Addition","Qiang Yang","2025","Organic Process Research & Development","other","article","10.1021/acs.oprd.5c00184",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055750","Semaglutide Oral (Rybelsus) pada Diabetes Melitus Tipe 2 di Ras Asia: Tinjauan Pustaka","Ghilda Ainun Nisaa S","2022","Bandung Conference Series Medical Science","other","article","10.29313/bcsms.v2i1.546",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0055751","B24-21 Glucagon Like Peptide 1 Receptor Agonists and Outcomes in Obese Adults With COPD","A Lohana","2026","American Journal of Respiratory and Critical Care Medicine","nonrandomized_study","article","10.1093/ajrccm/aamag162.1780",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055752","Targeting Metabolic Pathways for Neurodegeneration: The Emerging Role of Anti-Diabetic and Lipid-Lowering Agents","Vaishnaav M","2025","International Journal of Allied Medical Sciences and Clinical Research","other","article","10.61096/ijamscr.v13.iss4.2025.633-642",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055753","Tratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos","Julio Sagredo Pérez","2024","Atención Primaria","other","article","10.1016/j.aprim.2024.103074","39260235",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055754","2845-LB: Safety, Pharmacokinetics, and Weight Loss Effects of the Oral GLP-1/GIP Dual Agonist BGM0504 in Healthy and Overweight or Obese Adults: A Phase 1 Multiple-Ascending Dose Study","Jiandong Yuan","2026","Diabetes","randomized_trial","article","10.2337/db26-2845-lb",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","article"],["R0055755","Incretin-based pharmacotherapy in the obesity phenotype of heart failure with preserved ejection fraction - Pathophysiology and clinical evidence","Tomaszek Barbara","2026","Medical Science","randomized_trial","article","10.54905/disssi.v30i174.e151ms3920",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055756","Beyond BMI and Reflux: Metabolic Phenotypes and Metabolic Change as Modifiers of Barrett’s Esophagus Progression — A Scoping Review","Sidra Saif","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/kpnqs",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0055757","Tirzepatide for Weight Recurrence After Metabolic and Bariatric Surgery: A Critical Review of Direct and Indirect Evidence with Emphasis on Sleeve Gastrectomy, Nutritional Safety, and Clinical Implications","Karolina Ciołkosz","2026","Nutrients","randomized_trial","article","10.3390/nu18193131",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055758","A Systematic Review: What is the current evidence on the use of point-of-care gastric ultrasound to risk-stratify patients taking GLP-1 receptor agonists pre-procedurally?","Shreya Mittal","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/bxhf8",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0055759","GLP-1 Receptor Agonists: Geometric Series, Exponential Decline and a Hypothetical Preoperative Management Strategy","Keira Beisel","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7500779",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0055760","GLP-1 receptor agonists and the developing brain: a scoping review protocol for childhood epilepsy and autism spectrum disorder","Günce Başarır","2026","Open Science Framework","protocol","article","10.17605/osf.io/b5py3",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0055761","Use of GLP-1RA and risk of major adverse cardiovascular events in women with PMOS","Noémie Roland","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/h4z9c",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0055762","SEMAGLUTIDE RECONFIGURES METABOLIC PHARMACLOGY: A NEW FRONTIER IN INCRETIN -BASED THERAPY (Ozempic®, Rybelsus®, and Wegovy®)","Akinsola O Emilayokan","2026",null,"other","article","10.13140/rg.2.2.25754.40649",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055763","Medical news in brief: GPs’ Wegovy warning, NICE rejects lenacapavir, deep fried food ban in schools, and other stories",null,"2026","BMJ","other","article","10.1136/bmj-2026-100908",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055764","Tpl2 inhibitor and GLP-1 receptor agonist : A promising combination therapy to fight type 2 diabetes ?","Morgane Delobel","2021","theses.fr (ABES)","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055765","GLP-1 Signaling, Mitochondrial Energy Regulation, and Evolutionary Conservation: From NAD⁺ Bioenergetics to Microbial Ecosystems","George B. Stefano","2026","Biomedical Journal of Scientific & Technical Research","other","article","10.26717/bjstr.2026.66.010394",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055766","Use of Antidiabetic Drugs In Cardiovascular Therapy","Ahmed Esawy","2026","University of Debrecen Electronic Archive (University of Debrecen)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055767","Efficacy and safety of liraglutide and semaglutide in obese children and adolescents: a systematic review","Ella A. Kovaleva","2026","Medical Technologies Assessment and Choice","systematic_review","article","10.17116/medtech202648031110",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0055768","Body Composition Changes With Standard Versus Low-Dose Tirzepatide Titration in Women With Lipedema: A Retrospective Observational Study","Paula Frederichi de Souza","2026","Cureus","randomized_trial","article","10.7759/cureus.116779",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055769","Trifluoroacetic Acid (TFA) Use in Pharmaceutical Manufacturing and Potential Environmental Implications","Sheng Peng","2026","Journal of Geoscience and Environment Protection","other","article","10.4236/gep.2026.149010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055770","Semaglutide-Induced Weight Loss and Metabolic Changes in Bangladeshi Adults with Obesity: A Prospective Study in Diabetic and Non-Diabetic Populations","H N Masuk Rahman","2026","Bangladesh Journal of Medicine","nonrandomized_study","article","10.3329/bjm.v37i3.91693",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055771","Molecular and Functional Analysis of Amylin Receptor Signalling in AgRP Neurons","Guillaume Bogaerts","2026","Zurich Open Repository and Archive (University of Zurich)","preclinical","article","10.5167/uzh-436244",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055772","CASE REPORT OF TETRAPARESIS REHABILITATION CHALLENGES POST BARIATRIC SURGERY","Mihaiela PENTIUC","2026","Romanian Journal of Medical Rehabilitation Physical Medicine and Balneoclimatology","case_report","article","10.59277/rjmrpmb.2025.3.07",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055773","Metabolic syndrome as a nexus of diabetes and cardiovascular disease: pathophysiological insights, epidemiological evidence, and therapeutic implications","Md Rakibul Islam","2025","Lu Zone Ul (Laurentian University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055774","AGONISTAS DUAIS DE GLP-1/GIP NO TRATAMENTO DA OBESIDADE E DAS DOENÇAS METABÓLICAS","Luíza Fricks Cabellino","2026","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2026v8n9p1352-1371",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055775","GLP-1 receptor agonists, reproductive function and pregnancy: metabolic benefits, fertility, and safety considerations","Malvina Todorova","2026","Endocrinologia","other","article","10.3897/endo-bg.31.202392",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055776","“Proliferation of Pancreatic Heterotopia Following Semaglutide Therapy: A Case Report of a Possible Association”","Abdullah Al-awad","2026","AACE Endocrinology and Diabetes","case_report","article","10.1016/j.aed.2026.09.004",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055777","Bridging Gaps in Chronic Kidney Disease Screening and Early Intervention in Type 2 Diabetes","Sarabu, MD, Raj","2026","The Medicine Forum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055778","Preconception GLP-1 Receptor Agonist Therapy and Reproductive Outcomes in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis","Yara El Deghel","2026","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/c3jax",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0055779","Efficacy of Incretin Agonists in MASH: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","Sabrina Schlesinger","2026","SSRN Electronic Journal","systematic_review","article","10.2139/ssrn.7511460",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","preprint"],["R0055780","New generation anti-obesity drugs and bone health in postmenopausal women","Jana Tomasová Studýnková","2026","Vnitřní lékařství","other","article","10.36290/vnl.2026.022",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055781","Ozempification of Aesthetics: Why Plastic Surgeons Must Lead the GLP-1 Era","Johnny Franco","2026","Aesthetic Surgery Journal","other_trial","article","10.1093/asj/sjag060","41875370",null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055782","Prevention of cholelithiasis: focus on the comorbid patient","Е.А. Лялюкова","2026","Лечащий врач","other","article","10.51793/os.2026.29.9.010",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055783","Cardiorenal effects of SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists in type 2 diabetes: a systematic review and meta-analysis","Yavuz Ayar","2026","BMC Endocrine Disorders","systematic_review","article","10.1186/s12902-026-02586-3",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0055784","Visualizing Emerging Trends and Global Hotspots in Ozempic, Weight Loss, and Pancreatitis Research: A Scientometric Analysis","Fran Espinoza‐Carhuancho","2026","International Journal of Preventive Medicine","nonrandomized_study","article","10.4103/ijpvm.ijpvm_217_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055785","Incretinotherapy for obesity and hormonal contraception: working in one play","Mekan Rakhimberdievich Orazov","2026","Obstetrics and gynecology News Opinions Training","other","article","10.33029/2303-9698-2026-14-3-134-139",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055786","Interaction of insulin hormone with neurotransmitters in the pathogenesis of Alzheimer's disease","Sam Torabi Goodarzi","2026","فصلنامه علوم پزشکی دانشگاه آزاد اسلامی واحد پزشکی تهران","nonrandomized_study","article","10.66224/iau.36.3.281",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055787","Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework.","Li H","2026","Frontiers in medicine","narrative_review","article","10.3389/fmed.2026.1957367","42866022","PMC13655674",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0055788","Glucagon-like peptide-1 receptor agonists versus insulin and the risk of diabetic retinopathy complications and other ocular disorders in type 2 diabetes: a systematic review and meta-analysis","Ana Carolina Ferreira Vianet Ribeiro","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/qmjr6",null,null,"PROSPERO:CRD420261349536",null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0055789","Preoperative GLP-1 Receptor Agonist Use Improves Thromboembolic, Infectious, and Wound-Related Outcomes Following Unicompartmental Knee Arthroplasty","Zachary Fuller","2026","Journal of Orthopaedic Experience & Innovation","nonrandomized_study","article","10.60118/001c.162883",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055790","62 | Establishing Pathways—A Public, Private and Executive Partnership for Temporal Artery Biopsies (TAB) to Facilitate Diagnostic Reclassification and Treatment De‐Escalation in a Suspected GCA Cohort",null,"2026","International Journal of Rheumatic Diseases","nonrandomized_study","article","10.1111/1756-185x.70608_55",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055791","modulation of the incretin axis (glp-1/gip) in behavioral compulsions: a new neuropsychopharmacology frontier","Luís Jesuino de Oliveira Andrad","2026","Endocrinologia & Diabetes Clínica e Experimental","other","article","10.29327/2413063.23.3-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055792","Expanding the therapeutic potential of GLP-1 receptor agonists: implications for male reproductive and perioperative urologic health.","Yellu A","2026","Translational andrology and urology","commentary","article","10.21037/tau-2026-0618","42866413","PMC13657707",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Editorial; Comment; article"],["R0055793","Reproductive and Gynecologic Effects of Glucagon-Like Peptide-1 Receptor Agonists in Women With Polycystic Ovary Syndrome: A Scoping Review","Jacklyn Snytte","2026","Cureus","narrative_review","article","10.7759/cureus.117072",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055794","Obesidad y síndrome metabólico: un desafío para la Medicina Interna","Jorge Enrique Soria Segovia","2026","RECIMUNDO","other","article","10.26820/recimundo/10.(3).julio.2026.633-644",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055795","Glucagon-like peptide-1 receptor agonists for osteoarthritis: a systematic review","Harry Claireaux","2026","Spiral (Imperial College London)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0055796","Efeitos Neuroprotetores dos Agonistas do Receptor de GLP-1 na Função Cognitiva e Demência: Uma Revisão Sistemática","Ana Livia Rodrigues Sanches","2026","Brazilian Journal of Implantology and Health Sciences","other","article","10.36557/2674-8169.2026v8n9p1540-1556",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055797","LA PLACE DES NOUVELLES CLASSES THERAPEUTIQUES (ANALOGUES DU GLP-1 ET INHIBITEURS DU SGLT2) CHEZ LE SUJET AGE DIABETIQUE [À PROPOS DE 29 CAS]","KEBBARA OUSSAMA","2025","Toubkal","other","article","10.83129/toubkal-29817",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0055798","Eating behaviour, eating disorder risk and body image in adolescents using GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists: a scoping review protocol","Daniela Marchetti Noia Baldo","2026","OSF Preprints (OSF Preprints)","protocol","article","10.17605/osf.io/kzs9y",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","preprint"],["R0055799","A Comparative Study of the Cardioprotective Effects of Sacubitril/Valsartan and Liraglutide in a Rat Model of Hypertension Induced by Deoxycorticosterone Acetate.","Sawsan Abd El-Aziz Sadik","2026","Fayoum University Medical Journal/Fayoum University Medical Journal ","preclinical","article","10.21608/fumj.2026.298715.1558",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055800","Ischemic Colitis in the Setting of Tirzepatide Use: A Potentially Underrecognized Adverse Effect","Isabel Jaszewski","2026","Cureus","other","article","10.7759/cureus.116973",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055801","Childhood obesity: on the issue of the efficacy and safety of modern weight loss medicines","Maksim Leonidovich Maksimov","2026",null,"other","article","10.33920/med-13-2604-02",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055802","GLP-1 Receptor Agonists and Radiation Toxicity in Prostate Cancer: A Propensity-Matched Cohort Analysis","H. Markus","2026","International Journal of Radiation Oncology*Biology*Physics","nonrandomized_study","article","10.1016/j.ijrobp.2026.06.1191",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055803","Enteroendocrine Cells as a Microbiome-Immune Checkpoint","Heather A. McCauley","2026","California Digital Library","preclinical","article","10.48321/d190fb1c90",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0055804","The effect of pre-operative weight-loss strategies on medical and surgical complications following anatomic total shoulder arthroplasty","George Bcharah","2026","Journal of Shoulder and Elbow Arthroplasty","nonrandomized_study","article","10.1016/j.jsea.2026.100083",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055805","The Association Between Glucagon-Like Peptide-1 Receptor Agonists and Depression in Adults: A Narrative Review","Alexander Vermilion","2026","American journal of student research.","narrative_review","article","10.70251/hyjr2348.45927934",null,null,null,null,"openalex","FALSE",null,null,"FALSE","review"],["R0055806","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98360-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055807","GLP-1 RECEPTOR AGONISTS IN HUMAN CANCERS: A NARRATIVE LITERATURE REVIEW","Theodoros Rizopoulos","2026","World Journal of Advanced Research and Reviews","narrative_review","article","10.30574/wjarr.2026.31.3.2484",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055808","Comparative Effectiveness and Safety of Tirzepatide Versus Semaglutide in Adults with Obesity and Metabolic Syndrome: A One-Year Prospective Comparative Study","Md Momenuzzaman Khan","2025","TAJ Journal of Teachers Association","randomized_trial","article","10.70818/taj.v38i04.0887",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055809","Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis","Linge Jian","2026","Open Research (University of Surrey)","systematic_review","article","10.1002/viw2.70204",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055810","The Latest Topic of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) as Bofanglutide (GZR102)",null,"2026","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/212",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055811","Impact of GLP1Ra and SGLT2i on atrial fibrillation in overweight, non-diabetic patients: A meta-analysis of randomized evidence","Luca Sgarra","2026","Scientific Reports","systematic_review","article","10.1038/s41598-026-67548-0",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055812","Agonistas do receptor de GLP-1 e saúde mental: efeitos sobre comportamento alimentar, sintomas depressivos e ansiedade em indivíduos com obesidade – uma revisão sistemática","Kelly Cristina de Amorim da Silva","2026","Journal of Medical and Biosciences Research.","other","article","10.70164/jmbr.v3i5.1361",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055813","Semaglutide and Tirzepatide in Cardiovascular and Cardiometabolic Risk Management: Evidence Maturity, Patient Selection, and Real-World Implementation","Fayez Salahedin Alkhateeb","2026","SN Comprehensive Clinical Medicine","nonrandomized_study","article","10.1007/s42399-026-02716-x",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0055814","Effective Change from Semaglutide (Rybelsus) to Tirzepatide (Mounjaro) in a Patient with Type 2 diabetes (T2D)",null,"2026","International Journal of Endocrinology and Diabetes","other","article","10.36266/ijed/211",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055815","A retrospective case-control study to assess the correlation of weight loss and GLP-1 analogs in patients with TYPE 2 diabetes","M Aamir Mirza","2026","Advancements in Life Sciences","nonrandomized_study","article","10.62940/als.v13i3.3665",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055816","Overview of GLP-1RA Medications","Thomas A.F. Cordaro","2026","Transformative Medicine","other","article","10.54299/tmed/cdwi6557",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055817","Objective Exercise Outcomes During GLP-1 Based Therapy: Distinguishing Cardiorespiratory Fitness from Walking Capacity. A Narrative Review","Julia Nowak","2026","Quality in Sport","narrative_review","article","10.12775/qs.2026.76.75671",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055818","Perioperative Safety Considerations and Surgical Outcomes Associated With GLP-1-Based Therapies: A Systematic Review","Mayte Rodrigues da Cunha","2026","Cureus","systematic_review","article","10.7759/cureus.116901",null,null,"PROSPERO:CRD420261289189",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0055819","Childhood Obesity: An Update on Prevention, Evaluation, and the Expanding Treatment Landscape","Olivia Lennon","2026","Texas Family Medicine Research Journal","randomized_trial","article","10.65738/001c.165881",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055820","Associations of metformin-based antidiabetic combinations and Alzheimer’s disease onset: a retrospective EHR cohort study","Miski Abdi","2026","BMC Neurology","nonrandomized_study","article","10.1186/s12883-026-05392-5",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055821","Meta-Analysis of Glucagon-Like Peptide-1 Receptor Agonist Therapy and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention","Minesh","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/vqtpx",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0055822","Hidradenitis Suppurativa",null,"2026","Australasian Journal of Dermatology","nonrandomized_study","article","10.1111/ajd.70104",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055823","Periprocedural Risk Mitigation in Patients Receiving GLP-1–Based Therapies: Effects of Drug Interruption, Fasting Strategies, and Clinical Risk Modifiers on Residual Gastric Content—An Updated Systematic Review and Meta-analysis","Hiva","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/3uwdy",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0055824","Tirzepatide for Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Reductions in Hypoxic Burden and Cardiometabolic Risk Markers","Yun Jeong Lee","2026","Drug Targets and Therapeutics","other","article","10.58502/dtt.26.0018",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055825","MANEJO PERIOPERATÓRIO DE PACIENTES EM USO DE AGONISTAS DO RECEPTOR GLP-1: RISCO DE ASPIRAÇÃO, ESVAZIAMENTO GÁSTRICO E COMPLICAÇÕES ANESTÉSICAS — REVISÃO SISTEMÁTICA","Rossana Corbellini Henz","2026","Brazilian Journal of Health Review","other","article","10.34119/bjhrvxnx-074",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055826","Tirzepatide Failed to Improve Neuropathy in a Murine Nonobese Streptozotocin-Induced Type 1 Diabetes Model, Despite Alleviating Systemic Inflammation","Pavlina A. Andreeva-Gateva","2026","Diabetology","preclinical","article","10.3390/diabetology7100190",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055827","Real-world Prescribing and Patient-Reported Outcomes of Glucagon-like Peptide-1 Receptor Agonists in a Residential Substance Use Treatment Population","Steven Klein","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7519246",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0055828","Orforglipron versus oral semaglutide in type 2 diabetes, clinical implications of the ACHIEVE-3 trial","Davide Bernasconi","2026","Metabolism and Target Organ Damage","other_trial","article","10.20517/mtod.2026.142",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055829","Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities","E. E. Sakhnova","2026","Meditsinskiy sovet = Medical Council","nonrandomized_study","article","10.21518/ms2026-324",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055830","In Silico Screening of Natural Compounds for Identification of GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus","Aniket Aayush","2025","Journal of Applied and Integrative Biology","other","article","10.66994/intbio.vol1.issue1.4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055831","Arthroplasty",null,"2026","Bone and Joint 360","other","article","10.1302/2048-0105.155.360368",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055832","Incretin-Based Therapies in Adiposity-Driven HFpEF: Mechanisms, Clinical Evidence and Therapeutic Implications","Saahil Eeshwar","2026","American journal of student research.","other_trial","article","10.70251/hyjr2348.45740749",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055833","24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL","Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica","2026","Dermatology Reports","randomized_trial","article","10.4081/dr.2026.11086",null,null,"ClinicalTrials.gov:NCT06588283","S000032","openalex","TRUE","open_pdf","1","FALSE","article"],["R0055834","GLP-1 RAs Potentially Risky in Patients With Eating Disorders","Terri D’Arrigo","2026","Psychiatric News","other","article","10.1176/appi.pn.2026.10.10.5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055835","Clinical Observation of GLP-1RA and Substance Use (COGS) Study Preliminary Data Outcomes","Akshara S Narahari","2026","Digital Commons-TMC (Texas Medical Center)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055836","59 | EXPLORATORY THERAPEUTIC APPROACH IN DERCUM’S DISEASE: IMMUNOMODULATORS AND GLP-1 RECEPTOR AGONISTS","Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica","2026","Dermatology Reports","other","article","10.4081/dr.2026.11109",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055837","GLP-1 Receptor Agonist Use and Postoperative Complications After Body Contouring Surgery Following Massive Weight Loss","Nulvin Djebbara-Bozo","2026","Journal of Plastic Reconstructive & Aesthetic Surgery","nonrandomized_study","article","10.1016/j.bjps.2026.09.040",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055838","26 | CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL","Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica","2026","Dermatology Reports","other_trial","article","10.4081/dr.2026.11088",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055839","Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis","Silvia Fisch","2026","Frontiers in Pharmacology","nonrandomized_study","article","10.3389/fphar.2026.1936967",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055840","Glucagon-like Peptide-1 Receptor Agonists and the Eye: A Review of Ocular Implications and Clinical Guidelines","Madhu Uddaraju","2024","Journal of ophthalmology clinics and research.","nonrandomized_study","article","10.4103/jocr.jocr_10_26",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055841","Spine",null,"2026","Bone and Joint 360","other","article","10.1302/2048-0105.155.360371",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055842","P354 GLP-1 RECEPTOR AGONISTS REDUCE MORTALITY AND CARDIOVASCULAR EVENTS IN SERIOUS MENTAL ILLNESS: A MULTINATIONAL TARGET TRIAL OF 1.5 MILLION ADULTS","A.T.H. Kwan","2026","Canadian Journal of Cardiology","other_trial","article","10.1016/j.cjca.2026.07.322",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","conference-abstract"],["R0055843","GLP-1 Receptor Agonists and Wound Healing in Diabetic Foot Ulcers: A Scoping Review","Merlin Sajeev","2026","ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0055844","Genetically proxied GIP GIPR pathway perturbation and fracture risk Running title: GIP-GIPR Signalling and Fracture Risk","Wenjie Cheng","2026","Research Explorer (The University of Manchester)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055845","Trump, Mounjaro, and medical misogyny articles win BMJ honours at prestigious awards","British Medical Journal Publishing Group","2026","BMJ","other","article","10.1136/bmj-2026-100959","42785797",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055846","Quality, Reliability, and Comprehensiveness of Turkish- and English-Language YouTube Videos on Incretin-Based Therapies: Cross-Sectional Content Analysis (Preprint)","Miraç Vural Keskinler","2026",null,"other","article","10.2196/preprints.113096",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0055847","P197 TIRZEPATIDE VERSUS SEMAGLUTIDE AND THE BROADER GLP-1 RECEPTOR AGONIST CLASS ACROSS CARDIOMETABOLIC PHENOTYPES: WHAT DOES THE OBSERVATIONAL EVIDENCE SHOW?","V. Vaibhav","2026","Canadian Journal of Cardiology","other","article","10.1016/j.cjca.2026.07.189",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0055848","Beyond Weight Loss: Practical Considerations for use of Glucagon like Peptide-1 (GLP-1) and Incretin Therapy in Inflammatory Skin Disease","Jeffery Shi","2026","Canadian dermatology today.","other","article","10.58931/cdt.2026.73168",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055849","Análisis del desempeño térmico de la cadena de frío mediante monitoreo continuo en un centro de distribución farmacéutica","Karen Dayana Quintero Villalobos","2026","Institutional Repository of the National University Open and Distance UNAD (Universidad Nacional Abierta y a Distancia)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","book"],["R0055850","Evaluating Family Perspectives on Pediatric Weight Management: A Qualitative Review","Reagan Squire","2026","ScholarlyCommons (University of Pennsylvania)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0055851","Pancreatic β-Cell Dysfunction and Protection: Emerging Insights from Glucocorticoid Signaling and Islet Microcirculation","Hideaki Kaneto","2026","Diabetology","other","article","10.3390/diabetology7100191",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055852","Weight Regain After Bariatric Surgery: Anatomical, Metabolic, and Behavioral Mechanisms and the Role of GLP-1/GIP Therapy","Mariia Hataliak","2026","European Journal of Medical and Health Research","randomized_trial","article","10.59324/ejmhr.2026.4(5).21",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055853","Pharmacokinetic and ADME challenges of GLP-1 based Multireceptor therapeutics: mechanisms, models and development strategies.","Srinivas Lenkalapelly","2026","Natural Resources for Human Health","other_trial","article","10.53365/nrfhh.2283",null,null,null,null,"openalex","FALSE","paywalled","5","FALSE","article"],["R0055854","Liraglutide-associated body composition change: muscle mass loss and determinants","İhsan AYHAN","2026","Çukurova medical journal (Online)/Çukurova medical journal","nonrandomized_study","article","10.17826/cumj.1925099",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055855","Contraceptive awareness, practices and counselling gaps among women of reproductive age using GLP-1 receptor agonists for weight management: A cross-sectional research","Cosmina Frîncu","2026","International Journal of Contraception Gynaecology and Obstetrics","other","article","10.33545/26649861.2026.v8.i1a.48",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055856","Antidiabetic Agents in the Management of Hepatic Fibrosis in Type 2 Diabetes Mellitus and MASLD/MASH: A Narrative Review","Muhammad Ifham Hanif","2026","Medicina Moderna - Modern Medicine","narrative_review","article","10.31689/rmm.2026.33.3.201",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055857","Agonistas de GLP-1 e Contraceptivos Orais","Iasmin Ketlin Brandão e Torres","2026","Revista de Divulgação Científica Sena Aires","other","article","10.36239/revisa.v15.nesp1.p18a23",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055858","Semaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives","Enrico Maggio","2026","Journal of Personalized Medicine","other","article","10.3390/jpm16100506",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055859","Uso Indiscriminado de Tirzepatida (Mounjaro) para emagrecimento: desafios para a atuação farmacêutica","Kamylle Vitoria Monteiro de Oliveira Miranda","2026","REVISTA MULTIDISCIPLINAR INTEGRADA - REMI","other","article","10.61164/j00ydn49",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055860","GLP-1-Based Therapies and Relative Energy Deficiency in Sport Among Physically Active Individuals: Plausible Pathways, Evidence Gaps, and Monitoring Considerations","Jakub Jonakowski","2026","Quality in Sport","other","article","10.12775/qs.2026.77.75467",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055861","HETEROCYCLIC COMPOUNDS: AS ANTIDIABETIC DRUGS","Manjeela Subba","2023","Universal Journal of Pharmaceutical Sciences and Research","other","article","10.61114/ujpsr.9.2.2023.32-51",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055862","Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Multicenter Propensity-Matched Cohort Study","Sajjad Ahmed Khan","2026","International Journal of Medical Students","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0055863","MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management","Hubert Krzewiński","2026","Journal of Clinical Medicine","randomized_trial","article","10.3390/jcm15197540",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0055864","Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists","Amer Majeed","2026","Saudi Journal of Anaesthesia","narrative_review","article","10.4103/sja.sja_127_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055865","BIMAGRUMAB NA REDUÇÃO DE GORDURA CORPORAL E MANUTENÇÃO/INCREMENTO DE MASSA MAGRA: REVISÃO SISTEMÁTICA COM COMPARADOR SEMAGLUTIDA","Eros Andria Maliska Lovatel","2026","Revista Ibero-Americana de Humanidades, Ciências e Educação","other","article","10.51891/rease.v12i9.30696",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055866","Cardiorenal Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes: Observations from Real-World Clinical Practice","William George Oliver Hinton","2026","University of Surrey Open Research repository","nonrandomized_study","article","10.15126/thesis.902256",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","dissertation"],["R0055867","Mapping the Knowledge Landscape of Antidiabetic Agent Research: A Scientometric Analysis of Trends, Collaboration, and Emerging Themes (2020–2026)","Anam Khan","2026","International Journal For Multidisciplinary Research","other","article","10.36948/ijfmr.2026.v08i05.88761",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055868","New avenues in metabolic disease treatment: duodenal mucosal resurfacing and gene therapy","Christina Dias","2026","Exploration of Endocrine and Metabolic Diseases","other","article","10.37349/eemd.2026.101482",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055869","Nutrition Management Strategies for Obese Patients with Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists","Hee Jung Ahn","2026","Journal of Korean Diabetes","other","article","10.4093/jkd.2026.27.3.155",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055870","Perioperative management of patients taking GLP-1 receptor agonists: A comparative review of international clinical guidelines","Thomas Moore","2026","Saudi Journal of Anaesthesia","narrative_review","article","10.4103/sja.sja_314_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055871","Dana Simmons: On Hunger: Violence and craving in America, from starvation to Ozempic","Teresa Mares","2026","Agriculture and Human Values","other","article","10.1007/s10460-026-10956-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055872","INOVAÇÃO NO TRATAMENTO METABÓLICO: A TIRZEPATIDA E OS AGONISTAS INCRETÍNICOS DE NOVA GERAÇÃO NO CONTROLE DA OBESIDADE E DO DIABETES TIPO 2","Ananda Medeiros Nava","2026","LUMEN ET VIRTUS","other","article","10.56238/levv17n64-135",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article; book-chapter; conference-paper"],["R0055873","Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease","Chrysoula Boutari","2026","Life","other_trial","article","10.3390/life16101656",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0055874","Triple agonist drug retatrutide shows 21% weight loss in patients with diabetes",null,"2026","Pharmaceutical journal/˜The œpharmaceutical journal","other","article","10.1211/pj.2026.1.431913",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055875","Semaglutide/Sodium-glucose transporter 2 inhibitors",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98655-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055876","Anti-obesity medications for the management of obstructive sleep apnoea","Tarryn Collings","2026","SA pharmaceutical journal.","other","article","10.36303/sapj.4699",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055877","Preserving Muscle Health During Weight Loss: Evidence Across Lifestyle, Surgical, and Pharmacological Interventions","Aleksandra Iwanicka","2026","Cureus","other","article","10.7759/cureus.117182",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055878","JIGARNING ALKOGOLSIZ YOG'LI KASALLIGINI ZAMONAVIY DAVOLASHNING DOLZARB MASALALARI"," АГАБАБЯН Ирина Рубеновна","2024","Journal of Biomedicine and Practice","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055879","GLP-1 receptor agonists in intermittent claudication: molecular mechanisms and clinical implications: a narrative review","Fernando Elí Olvera Camacho","2026","Angiología","narrative_review","article","10.20960/angiologia.00901",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055880","Ghrelin Analogs & Islet Function","Riccarda Granata","2009","Institutional Research Information System University of Turin (University of Turin)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0055881","Incretin-based therapies: a new potential treatment approach toovercome clinical inertia in type 2 diabetes","A. Nicolucci","2008","Acta bio-medica dell'Ateneo parmense/Acta biomedica","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055882","RECENTLY APPROVED ANTIDIABETIC DRUGS BY FDA AND METABOLITE CHARACTERIZATION STUDIES USING LC/MS: A COMPREHENSIVE REVIEW","Ms. Kajal Pal","2026","International Journal of Advanced Research and Multidisciplinary Trends (IJARMT)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055883","2형 당뇨병의 새로운 치료","고정민","2009","AJOU Open Repository (Ajou University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055884","Perinatal brain damage-phagoptosis and neuroprotection","Andrea Jonsdotter","2024","Gothenburg University Publications Electronic Archive (Gothenburg University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0055885","Editorial: The gut-liver axis in MASLD: microbiome, metabolism, disease progression and therapeutic pathways","Zhengyang Bao","2026","Frontiers in Medicine","randomized_trial","article","10.3389/fmed.2026.1947178",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0055886","Restoring Metabolic Architecture in the South Asian Thin-Outside-Fat-Inside (TOFI) Phenotype: A Mechanistic Rationale for Combining Abscisic Acid and β-Aminoisobutyric Acid","Anshu Bhutani","2026","Cureus","randomized_trial","article","10.7759/cureus.117275",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055887","Advancing Precision Medicine in Type 2 Diabetes through Machine Learning: Treatment Comparisons and Risk Predictions","Moa Lugner","2024","Gothenburg University Publications Electronic Archive (Gothenburg University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0055888","Central Neural Mechanisms Underlying Weight Loss Driven by GLP-1 Receptor Agonism and Immune Challenge","Júlia Teixidor Deulofeu","2026","Gothenburg University Publications Electronic Archive (Gothenburg University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0055889","Post-transplant diabetes mellitus: mechanisms of development, risk factors, diagnosis, treatment","M. K. Vagabov","2026","Diabetes Mellitus","other","article","10.14341/dm13540",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055890","Prescribing Patterns and Clinician Perceptions of GLP-1 Receptor Agonists Beyond Diabetes Management: A Cross-Sectional Study","Mahrukh Badar","2025","Journal of Precision Medicine and Health Research","nonrandomized_study","article","10.68279/y23fqn68",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055891","Effetti dell’exenatide sul controllo glicometabolico e su alcuni fattori di rischio cardiovascolare in pazienti con diabete di tipo 2","Nicola PASSARIELLO","2012","Archivio Istituzionale della Ricerca - Università degli Studi della Campania \"Luigi Vanvitelli\"","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0055892","Tirzepatide prevents neurodegeneration through multiple molecular pathways: An emerging therapeutic strategy for the treatment of cognitive impairment","Puja Ghosh","2025","Archivio Istituzionale della Ricerca - Università degli Studi della Campania \"Luigi Vanvitelli\"","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0055893","Preformulation Studies Of Semaglutide For The Development Of Extended-Release Tablets","Aanchal Dangi, Dr. Komal Sharma, Dr. Meenakshi  Bharkatiya","2024","Nanotechnology Perceptions","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055894","THE RISK OF SELF-MEDICATION FOR WEIGHT LOSS PURPOSES","Renara Duarte Pereira","2025","CIPEEX","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055895","Cardiovascular Effects of Tirzepatide: A Glucagon-Like Petide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist","Fatemeh Taktaz","2025","Archivio Istituzionale della Ricerca - Università degli Studi della Campania \"Luigi Vanvitelli\"","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0055896","Semaglutide’s slimming properties shifts the scales towards scarcity and shams","Ilze Vermaak","2024","SA pharmaceutical journal.","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055897","effetti dell’aggiunta di exenatide al pioglitazone nel diabete mellito di tipo 2 non ben controllato","Nicola PASSARIELLO","2011","Archivio Istituzionale della Ricerca - Università degli Studi della Campania \"Luigi Vanvitelli\"","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0055898","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98654-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055899","Fueling the fire: Obesity's role in acute pancreatitis","Max Ole Hubert","2026","Best Practice & Research Clinical Gastroenterology","other","article","10.1016/j.bpg.2026.102140",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055900","Les médicaments antiobésité Wegovy et Mounjaro sont désormais remboursés : quelles sont les premières implications ?","Jean‐Daniel Lalau","2026",null,"other","article","10.64628/aak.we9kjdhdh",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0055901","Quantitative liver fat assessment in magnetic resonance imaging: moving beyond binary reporting toward measurable radiology","Hamza Eren Güzel","2026","Çukurova medical journal (Online)/Çukurova medical journal","other","article","10.17826/cumj.1917064",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055902","Mechanisms and effects of bariatric surgery on metabolic outcomes: experimental and clinical evaluation study","Rebekah Laurel Jane Wilmington","2026","Nottingham ePrints (University of Nottingham)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0055903","Clinical Outcomes Associated With Glucagon-Like Peptide-1 Receptor Agonist Use During Systemic Therapy for Endometrial Cancer","Elsa Lamah","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7398818",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0055904","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98679-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055905","A systematic literature review of the assosiation between GLP-1 receptor agonists and depression","Khan Madiha","2026","UEF eRepo (University of Eastern Finland)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055906","Som man betalar får man banta. En kvalitativ analys av hur traditionella nyhetsmedier gestaltar Ozempic","Elvira Jansson","2025","Gothenburg University Publications Electronic Archive (Gothenburg University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055907","Making Obesity Care Affordable: Patient Views on Deprescribing GLP-1 RAs","Sarah Vordenberg","2026","The American Journal of Managed Care","other","article","10.37765/ajmc.2026.89946",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055908","Gut-brain peptides and drugs of abuse: highlighting the role of GLP-1 and amylin","Cajsa Aranäs","2025","Gothenburg University Publications Electronic Archive (Gothenburg University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0055909","Liraglutide in type 2 diabetes: from pharmacological development toclinical practice","M. C. Rossi","2009","Acta bio-medica dell'Ateneo parmense/Acta biomedica","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0055910","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98678-9",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055911","Comparative Safety of GLP-1 Receptor Agonists: A Nationwide Retrospective Cohort Study on Respiratory Outcomes in Patients with Comorbid Asthma and Type 2 Diabetes Mellitus","陳俞孜","2026","Taipei Medical University Repository","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0055912","WOLFRAM SYNDROME: FROM POINT MUTATION TO CELL DYSFUNCTION","S. Torchio",null,"Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055913","Efectos de los agonistas del receptor de péptido similar al glucagón tipo 1 como tratamiento en pacientes con obesidad y diabetes mellitus tipo 2","Henry Williams Mejia Zambrano","2022","Revista Habanera de Ciencias Médicas","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055914","Editorial: Sepsis awareness month 2024","Bojan Jovanović","2026","Frontiers in Medicine","commentary","article","10.3389/fmed.2026.1990102",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0055915","DIABETES MELLITUS: CAUSES, COMPLICATIONS, TREATMENT, AND STRATEGIES FOR EFFECTIVE PREVENTION AND CONTROL OF THE DISEASE","Zanaya Vieira Leonel","2025","CIPEEX","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0055916","ФЕРТИЛ ЁШДАГИ АЛКОГОЛСИЗ ЁҒЛИ ЖИГАР КАСАЛЛИГИ БЎЛГАН АЁЛЛАРДА ГПП-1 АГОНИСТЛАРИНИНГ САМАРАДОРЛИГИНИ БАҲОЛАШ","Sadykova Shakhboza Shakhobiddinovnа","2025","UZBEK MEDICAL JOURNAL","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055917","Treatment-Induced Neuropathy Presenting as Thoracic Radiculopathy and Abdominal Wall Protrusion After Marked Glycemic Improvement With Tirzepatide","Kian Bagheri","2026","Cureus","other","article","10.7759/cureus.117153",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055918","Polycystic Ovary Syndrome: Insights and Advances in Diagnosis and Management","P Lazaru","2024","Pharmaceutical Sciences & Analytical Research Journal","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055919","Multifunctional Nanoparticles for Oral Delivery of Anti-hyperglycemia Protein Drugs","莊爾元","2013","Taipei Medical University Repository","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0055920","GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS","Violeta Bösel da Costa","2026","Open Minds International Journal","other","article","10.22533/at.ed.51572172608095",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055921","Tirzepatide Transdermal Patches for Diabetes management: Formulation and evaluation:A Research","Shilpi Gautam,Vishal Dubey*, Alka Maral, Shweta Sahu","2024","International Journal of Pharmacy and Life Sciences","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055922","GLP-1-Based therapies for obesity-related heart failure with preserved ejection fraction: an umbrella review incorporating broader heart failure and cardiometabolic evidence","Qiang Li","2026","Frontiers in Cardiovascular Medicine","systematic_review","article","10.3389/fcvm.2026.1930278",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0055923","Global Pharmacovigilance Signals for Liraglutide and Semaglutide in Obesity: A VigiBase Disproportionality Analysis","Daeun Cho","2026","Journal of Pharmacoepidemiology and Risk Management","nonrandomized_study","article","10.56142/perm.26.0014",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0055924","Patient Safety in the Era of Compounded Obesity Therapy: A Case Report of An Unintentional Semaglutide Overdose: Unintentional Semaglutide Overdose Case Report","Richard Ly","2025","Oklahoma State Medical Proceedings","case_report","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055925","Effect of Combination Treatment with GLP-1 Receptor Agonist and SGLT-2 Inhibitors on Incidence of Cardiovascular and Serious Renal Events","Rizwan Qasim , Faisal Moin , Kamran","2024","Medical Forum Monthly","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055926","Effect of Tirzepatide in prediabetes remission among Thai people with obesity and prediabetes: A real-world study from a tertiary care in Bangkok","Yotsapon Thewjitcharoen","2026",null,"nonrandomized_study","article","10.13140/rg.2.2.27715.16160",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0055927","A INFLUÊNCIA DA PRESSÃO MIDIÁTICA NA BUSCA POR CORPOS PERFEITOS E SUAS IMPLICAÇÕES NOS TRANSTORNOS ALIMENTARES EM MULHERES JOVENS","Espirito Santos de OLIVEIRA,, Gabrielle","2025","Revista Corpus Hippocraticum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055928","Chemical structure versus biological activity relationship and drug versus molecular target interactions of contemporary antidiabetic drugs: a literature review: Gabriel da Silva Carvalho, Guilherme Santos Vasconcelos, Nycolas Muller Teixeira de Oliveira, Juçara Barga do Nascimento, José Eduardo Pandini Cardoso Filho",null,"2024","UNISANTA. BioScience","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0055929","GLP-1 Receptor Agonists and The Gut: Interactions Between Appetite, Diet and The Gut Microbiome","Sauda Rahat ","2026","International Journal of Research and Analysis in Science and Engineering","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055930","The Risks of Taking Ozempic","Babaev Isfandier Sharofutdinovich","2026","Research Journal of Trauma and Disability Studies","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055931","Efeitos da Liraglutida (Saxenda®) e Semaglutida (Wegovy®) na Saúde Cardiovascular","Nathália Prado","2026","Revista dos Seminários de Iniciação Cientifica","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055932","Manejo desde Atención Primaria de pacientes con obesidad mórbida que no se plantean cirugía bariátrica.","Laura Couto Ramón","2023","XORNADAS AGAMFEC","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055933","Effects of Sodium Glucose Cotransporters (SGLT2) Inhibitorstype 2 on Hepatosis in Patients Type 2 Diabetes Mellitus","Ismoilova Shaxnoza Samandarovna","2024","World of Medicine : Journal of Biomedical Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055934","Oral GLP-1 RA (Semaglutide) Versus SGLT 2 Inhibitors in Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin - A Clinical Observational Prospective Study","Dr. Guramol Singh Dhillon, Dr. R P Ram, Dr. Sejal Tripathi, Dr. Sejal Tripathi","2025","Frontiers in Health Informatics","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055935","COMPLEX OF EXERCISE AND GLP-1 RECEPTOR AGONIST TREATMENT REDUCES SEVERITY OF METABOLIC SYNDROME AND INFLAMMATION","Toshmatova  G.A.","2024","Ethiopian International Journal of Multidisciplinary Research","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055936","Safety and efficacy of semaglutide in the management of overweight and obesity in patients without diabetes: a review of the recent literature.","Isabella Ramirez-Hurtado","2026","Salutem Scientia Spiritus","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055937","Impact of Tirzepatide on body composition and functional status in Thai individuals with obesity and/or type 2 diabetes","Yotsapon Thewjitcharoen","2026",null,"other","article","10.13140/rg.2.2.31070.60487",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055938","Association of SGLT2 inhibitors and GLP-1 receptor agonists with mortality and renal outcomes in patients with diabetes and chronic kidney disease: the diabetic nephropathy management and outcome (DINAMO) study","Keren Cohen‐Hagai","2026","Cardiovascular Diabetology","nonrandomized_study","article","10.1186/s12933-026-03382-y",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0055939","Pathophysiology of Diabetes Mellitus and Recent Advances in Its Treatment: An Integrative Review","Kakani Philip Kumar","2025","IJPAR JOURNAL","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055940","Application of dapagliflozin in the treatment of diabetic myopathy: morphological aspects of risks and benefits","A.-N. Habren-Syller","2026","INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","preclinical","article","10.22141/2224-0721.22.6.2026.1763",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055941","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98680-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055942","ИЗУЧЕНИЕ ЭФФЕКТИВНОСТИ КОМБИНИРОВАННОЙ ТЕРАПИИ иДПП-4 И аГПП-1 С МЕТФОРМИНОМ У БОЛЬНЫХ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА С ПОВЫШЕННОЙ МАССОЙ ТЕЛА И ОЖИРЕНИЕМ","Рахимова Г.Н.","2022","ЦЕНТРАЛЬНО АЗИАТСКИЙ ЭНДОКРИНОЛОГИЧЕСКИЙ ЖУРНАЛ","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055943","Supporting Patients Transitioning from Incretin Therapy – A Framework for Integrative Health Professionals","Michael Wakeman","2026","IntechOpen eBooks","other","article","10.5772/intechopen.1017612",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0055944","THE EFFICACY AND SAFETY OF SEMAGLUTIDE IN GLYCEMIC CONTROL, WEIGHT REDUCTION, AND CARDIOVASCULAR RISK MANAGEMENT IN TYPE 2 DIABETES PATIENTS: A SYSTEMATIC REVIEW","MOAMEN ABDELFADIL ISMAIL, MAJED MOHAMMED ALANAZI, BUSHRA F. ALQURASHI, RUBA M. ABUTALEB, YOUSEF FAHAD ALRESHOODI, RIYADH T. IZZZULDEEN,","2025","TPM Testing, psychometrics, methodology in applied psychology","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0055945","Efficacy, Safety, and Implementation of Alternative Smoking Interventions: A Systematic Review","Indra Narayan Shrestha","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/zd635",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0055946","Efficacy of SlimSEB® in enhancing health-related quality of life and weight regulation among GLP-1 treated type 2 Diabetes patients: A single-arm, placebo-controlled, sequential, pilot study","Mayur Agrawal","2026","Journal of Clinical Trials and Experimental Investigations","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0055947","Exercise for the Preservation of Muscle Health During GLP-1-Based Therapies: A Scoping Review","Mehmet Akif Güler","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/d859u",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0055948","Retrospective pharmacovigilance protocol: phenotype-specific reporting of neuropathy signals with GLP-1 receptor agonists in the US FDA Adverse Event Reporting System (FAERS), with external replication (JADER, Canada Vigilance)","Tao Li","2026","Open Science Framework","protocol","article","10.17605/osf.io/q29vy",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0055949","Sequencing and combination of therapies in the cardiovascular-kidney-metabolic syndrome: GLP-1 RA, SGLT2 inhibitors, lipid-lowering drugs and mineralocorticoid receptor antagonists","Michal Dubský","2026","Vnitřní lékařství","other","article","10.36290/vnl.2026.072",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055950","Hepatoprotective Effects of Dulaglutide against Methotrexate-Induced Liver Injury in Rats","Omar W. Maher","2026","Journal of Neonatal Surgery","preclinical","article","10.63682/jns.v15i1s.10625",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055951","GLP‐1s among most effective in reducing weight in antipsychotic‐treated patients",null,"2026","The Brown University Psychopharmacology Update","other","article","10.1002/pu.31510",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055952","O USO DE SEMAGLUTIDA (ANÁLOGO DE GLP-1) COMO COADJUVANTE NO CONTROLE DA OBESIDADE","Enoghalliton de Abreu Arruda","2023","Conhecendo Online","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055953","From insulin dependence to cardiometabolic harmony: GLP-1 RA therapy in a complex multisystem case","Sharif Ahmad","2026","UiTM Institutional Repositories (Universiti Teknologi MARA)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055954","Efficacy of SGLT2 Inhibitors and GLP-1/GIP Agonists in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Systematic Review and Network Meta-Analysis Protocol.","Shamama Niaz","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/6mnzr",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0055955","Cardiovascular and Renal Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes: From Mechanistic Synergy to Clinical Evidence","翁晓帆","2026","International Journal of Pharma Medicine and Biological Sciences","other","article","10.18178/ijpmbs.15.3.85-89",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055956","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98681-8",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055957","Metabolic and Bariatric Surgery in Adults with Obesity and Pre-Existing Chronic Kidney Disease: Kidney, Cardiovascular, Perioperative, and Transplant-Pathway Outcomes — Protocol for a Scoping Review","Mohamed Hany","2026","Open Science Framework","protocol","article","10.17605/osf.io/mj3vz",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","other"],["R0055958","GLP-1 receptor agonists in obesity treatment: where we are today and what can we expect?","Dita Pichlerová","2026","Vnitřní lékařství","other","article","10.36290/vnl.2026.070",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055959","Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review.","Pischetola A","2026","Translational andrology and urology","systematic_review","article","10.21037/tau-2026-0541","42866845","PMC13657777","PROSPERO:CRD420261366483",null,"pubmed; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Review; article"],["R0055960","Research trends and knowledge structure of pancreatic cancer and type 2 diabetes mellitus research: a two-decade CiteSpace analysis","Zilin Dong","2026","Frontiers in Endocrinology","other_trial","article","10.3389/fendo.2026.1945735",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0055961","Medicamentos para bajar de peso, ¿una alternativa saludable?","Julio César Alonso-Vázquez","2025","Revista de divulgación científica iBIO","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055962","Farmacoterapia de la obesidad: revisión de revisiones sistemáticas","Mercedes Ganduglia","2022","DIAETA","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0055963","Valutazione del profilo di sicurezza dei GLP-1 RAs: un focus sugli eventi avversi correlati al cancro alla tiroide utilizzando il database europeo di farmacovigilanza","Valerio Liguori","2026","Archivio Istituzionale della Ricerca - Università degli Studi della Campania \"Luigi Vanvitelli\"","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0055964","Integrating Pharmacy and Medical Records for Optimized Management of Chronic Diseases: A Case Study on Diabetes Mellitus Type-II","Abdullah Nasser Alyahya","2024","Review of Contemporary Philosophy","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0055965","ANALYSIS OF MODERN RISK FACTORS CONTRIBUTING TO THE DEVELOPMENT OF ATHEROSCLEROSIS","Don A. N.","2024","American Journal of Interdisciplinary Research and Development","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055966","СЕМИЗЛИКНИ ДАВОЛАШНИНГ ЗАМОНАВИЙ УСУЛЛАРИ","Нажмутдинова Дилором Камардиновна","2025","ЦЕНТРАЛЬНО АЗИАТСКИЙ ЭНДОКРИНОЛОГИЧЕСКИЙ ЖУРНАЛ","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055967","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98653-y",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0055968","Experimental Evaluation of the Combined Effects of a GLP-1 Agonist and a SGLT2 Inhibitor in a Metabolic Syndrome Model","Djanaev G.Yu","2025","Research Journal of Trauma and Disability Studies","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055969","OS RISCOS DO USO INDISCRIMINADO DE SEMAGLUTIDA POR VIA SUBCUTÂNEA","Aminarry MARTINES","2026","Revista Corpus Hippocraticum","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055970","Peptide Therapeutics and Next Generation Drug Delivery Systems: Emerging Frontiers in Drug Discovery and Medicinal Chemistry","Farooq Ahmad Mir","2025","Inventum Biologicum: An International Journal of Biological Research","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055971","Semaglutide improves drinking outcomes in patients with higher‐severity AUD",null,"2026","The Brown University Psychopharmacology Update","other_trial","article","10.1002/pu.31508",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0055972","SEMAGLUTIDA, LIRAGLUTIDA E TIRZEPATIDA: QUAIS AS REPERCUSSÕES PARA A SAÚDE BUCAL?","Leonardo Rinaldi","2026","Revista de Ciências da Saúde - REVIVA","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055973","CARDIOVASCULAR RISK IN TIRZEPATIDE MANAGEMENT FOR OBESITY IN TYPE 2 DIABETES PATIENTS: A SYSTEMATIC REVIEW","MOHAMMED SAAD ALNAWMASI","2025","TPM Testing, psychometrics, methodology in applied psychology","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0055974","Type 2 Diabetes Mellitus: Pathophysiology, Management, and Future Directions","ZULFKAR LATIEF QADRIE","2025","International Journal of Pediatrics and Genetics","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055975","Weight Regain and Maintenance After Discontinuation of Anti-Obesity Medications: A Scoping Review","Icy Ballentine","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/w5me8",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0055976","Dietary and Nutritional Considerations for Metabolic Dysfunction-Associated Steatotic Liver Disease in Psoriasis and Hidradenitis Suppurativa: A Narrative Review","Woo Chiao Tay","2026","Nutrients","narrative_review","article","10.3390/nu18193253",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055977","II. INTERNATIONAL SCIENCES CONGRESS-CONFERENCE BOOK","Nehir Özdemir Özgentürk","2024","Yildiz Technical University - AVESIS","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0055978","MODERN APPROACHES TO THE TREATMENT OF DIABETIC POLYNEUROPATHY: INTEGRATED NEUROLOGICAL AND ENDOCRINOLOGICAL PERSPECTIVES","Shodmonov Sardor Qahranom o’g’li","2025","European Journal of Interdisciplinary Research and Development","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055979","ขอแนะนำดานอาหารสำหรบผปวยโรคอวนทไดรบยากลม Glucagon-Like Protein-1 Agonist (GLP-1 agonist) เพอลดนำหนก","ฮานีฟ มูดอ","2025","Academic Journal for Primary Care and Public Health Development","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055980","Type 2 Diabetes Mellitus: Pathogenesis, Clinical Challenges, and Evolving Therapeutic Paradigms","Zulfkar Qadrie","2025","International Journal of Pediatrics and Genetics","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055981","Sarcopenic Obesity in the Era of Incretin-Based Weight-Loss Therapies: A Narrative Review of Pathophysiology, Clinical Implications and Nutritional Management","Josyula Hema Sisira ","2026","International Journal of Research and Analysis in Science and Engineering","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0055982","Diagnostic Tools and Therapeutic Stratergies in Polycystic Ovarian Disease: A Review","S. Karpagam Kumara Sundari","2026","International Journal of Pharmacology and Clinical Research (IJPCR)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055983","Is the use of Semaglutide cost-effective in the treatment of obesity – a literature review","Katariina Voutilainen","2024","UEF eRepo (University of Eastern Finland)","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0055984","Cardiovascular Outcomes After Adding GLP-1 Receptor Agonists To SGLT-2 Inhibitors In Type 2 Diabetes: A Target Trial Emulation","Edouard L. Fu","2026","SSRN Electronic Journal","nonrandomized_study","article","10.2139/ssrn.7536110",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0055985","EXPOSIÇÃO A AGONISTAS DO RECEPTOR DE GLP-1 NO PERÍODO PERICONCEPCIONAL E NA GESTAÇÃO: EVIDÊNCIAS ATUAIS E IMPLICAÇÕES PARA A PRÁTICA OBSTÉTRICA","Luis Paulo Zica","2026","Revista Contemporânea","other","article","10.56083/rcv6n10-003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055986","Avaliação do efeito da tirzepatida na perda de peso: revisão sistemática","Karla Scorsatto dos Santos","2025","Revista brasileira de obesidade, nutrição e emagrecimento","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0055987","Do We Truly Understand the Scope of GPLIs?","Gulfreen Waheed","2026","Avicenna Journal of Health Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055988","Genetic Evaluation of THRB as a Drug-Target Proxy and Modifier of GLP-1–Based Treatment Response","Manga Diane Mbombichoru","2026","ScholarlyCommons (University of Pennsylvania)","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","other"],["R0055989","Comparator and time-alignment sensitivity of associations between GLP-1 receptor agonists and incident cancer: a systematic review and meta-research study of within-cohort design contrasts","Han Sang Kim","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/u5cef",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0055990","Transforming Obesity Management: Integrating AI-Driven Digital Health and Novel Pharmacotherapy","Eun Kyoung Kang","2026","aSSIST Business Review","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0055991","A Question of Need, Not Want: The Misuse of GLP-1 Agonists","Shahzaib","2025","Bolan Journal of Medical and Allied Health Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055992","Efficacy of Semaglutide for Weight Management in Individuals with Obesity but without Diabetes: A Meta-Analysis","W.Epstein","2024","Medical Education in The United States and Canada","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","article"],["R0055993","PHARMACOTHERAPEUTIC APPROACHES TO OBESITY: NEW DRUG CLASSES AND MECHANISMS OF ACTION","Mona Piplani","2021","Innovations in Pharmacy Planet","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055994","Type 2 Diabetes Management: Advances in Pharmacological and Non-Pharmacological Approaches","Dr. Adnan Sheikh","2024","Non-Communicable Diseases and Care","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055995","Open‐label extension trial of ketamine for depression shows short‐term benefit",null,"2026","The Brown University Psychopharmacology Update","randomized_trial","article","10.1002/pu.31512",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0055996","KNOWLEDGE, ATTITUDE, AND PRACTICES ON THE USES OF ANTIDIABETICS FOR WEIGHT LOSS PURPOSES AMONG SAUDI POPULATION","Khalid A. Alghamdi, Fawziah M. Jamah, Sultan A. Alqasim, Umar A. Abdul Hai, Marwah N. Ahmad, Saleh F. AlKhalifah, Hawraa A. Almubark, Waled K. Alotibi, Ayman F. Almohammadi , Salma M. Almatrafi, Ghala M. Asiri, Khames T. Alzahrani","2025","CAHIERS MAGELLANES-NS","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055997","Evaluation of Antiobesity Activity Potential of Bioactive Constituents in Some Natural Plants","Nidhi Nitin Chauhan, Anasuya Patil, Neelam Pawar, S. Prema, Swati Bhimrao Kale, Roop Ranjan Srivastava, Shubhashree Das, Ankur Patel,","2023","Journal of Propulsion Technology","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055998","Bridging Medicine and Reconciliation: Decolonizing Obesity Care and Expanding Access to GLP-1 Therapy for Indigenous Peoples in Canada","Beth Neilson","2026","NP Current","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0055999","Liraglutid ile ilişkili vücut kompozisyonu değişikliği: kas kütlesi kaybı ve belirleyicileri","İhsan AYHAN","2026","DergiPark (Istanbul University)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0056000","Role of Liraglutide in improving diabetes and suppressing appetite in Biedl-Bardet syndrome","Aamir Qayyum","2024","Journal of Pakistan Endocrine Society","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056001","Advanced Fibrosis Risk Stratification in MASLD Among Adults With Type 2 Diabetes: A Critical Narrative Review of Practical Gaps and Implementation Solutions","Hadeeba Arfan","2026","Journal of Evidence-Based Medical Research","nonrandomized_study","article","10.66687/jebmr.2.03.2026.44",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0056002","MANAGEMENT OF DIABETES MELLITUS: INNOVATIONS IN TREATMENT","Asma Riaz","2024","International journal of applied biology and forensic","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056003","Perioperative Management of GLP-1 Receptor Agonists in Anesthesia: A Narrative Review","Ahmed Jamal Yassen Abdelrahim","2023","THE STETHO","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0056004","O USO DA SEMAGLUTIDA (OZEMPIC) COMO MEDICAMENTO PARA AUXILIAR NO TRATAMENTO DA OBESIDADE","ANA CAROLINA RAFAELLI KUNRATH","2023","Salão do Conhecimento","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056005","Manyetik Rezonans Görüntülemede Karaciğer Yağlanmasının Kantitatif Değerlendirilmesi: Ölçülebilir Radyolojiye Geçiş","Hamza Eren Güzel","2026","DergiPark (Istanbul University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056006","The culprit of chronic complications of diabetes-from glucose to insulin resistance","Lin Liao","2025","International Health Sciences Journal (online)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056007","Exenatide extended release","Navya M","2025","UPI Journal of Pharmaceutical Medical and Health Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056008","LIRAGLUTIDE: THE FIRST HUMAN GLP-1 ANALOGUE","Doina Catrinoiu","2009","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056009","Combined therapy with analogue of glucagon-like peptide 1 liraglutide and basal insulin: physiological basing, review of clinical studies and practical experience of their use","L.K. Sokolova","2015","Endokrynologia","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056010","A comparison of food noise, shape, and weight concerns among diet-alone or glucagon-like peptide receptor agonist-weight loss groups and a non-dieting control group.","K. L. Gore","2026","UC Research Repository  (University of Canterbury)","other","article","10.26021/16677",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0056011","AGONISTAS DO RECEPTOR DE PEPTÍDEO SEMELHANTE AO GLUCAGON-1 E A FISIOLOGIA DA PERDA DE PESO: UMA REVISÃO NARRATIVA DE LITERATURA","Luiza Monteiro Fernandes","2025","Anais do Momento Científico da IFMSA Brazil","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056012","Incidencia y fisiopatología de la insuficiencia cardíaca en pacientes con diabetes mellitus sin buen control metabólico: revisión narrativa","Raúl Leiva Castro","2026","Multimed","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056013","Comparative Analysis Of Treatment Outcomes In Patient With Diabetes Mellitus","Dr. Aditya More, Dr. Prithvirajh Patil, Dr. Mubin Momin, Dr. Manoj Munde","2024","Frontiers in Health Informatics","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056014","NEW MOLECULES I DIABETES","Amorin-Remus Popa","2010","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056015","Reframing Obesity Treatment: Integrating Incretin-Based Therapy with Metabolic Surgery in a Multimodal Longitudinal Care Model","Elizabeth H. Bruenderman","2026","Current Surgery Reports","other","article","10.1007/s40137-026-00537-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056016","GLP-1 AGONISM BY SEMAGLUTIDE DISRUPTS AKT SIGNALLING AND ENHANCES PROGESTERONE-INDUCED FOXO1 ACTIVATION IN ENDOMETRIAL CANCER","Vishal Chandra","2026","International Journal of Gynecological Cancer","other","article","10.1016/j.ijgc.2026.105156",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056017","Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Analysis of the Modern Healthcare Challenge Khasanov O.G. (PhD) Assistant in the 3rd Department of Internal Medicine Samarkand State Medical University Harsh Saini 4th year student in","Khasanov O.G., Harsh Saini, Kholboyev A.E.,","2025","MEDICAL RESEARCH JOURNAL","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056018","Twin Cretins as Potential Therapy for Type 2 Diabetes Mellitus; Systematic Review","Ammar Saeed Mohammad Alqahtani, Hamoud Sulaiman Hamoud Alharbi, Marzouq Munaji Abdan Alotaibi, Bandar Bader Malawi Alanazi, Naif Mutlaq Hammod Alotaibi, Muayad nasser saad almutaiwea, Turki Mansour Mutlaq Alosaimi, Khaled Sattam Sultan Alota","2024","The International Journal of Multiphysics","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0056019","A new agent for ideal weight management before abdominal hernia surgery: Semaglutide injection: Ideal weight for abdominal hernias","Hüseyin Kılavuz","2024","The Injector","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056020","Diabetic Nephropathy: Pharmacological and Emerging Approches","Himanshu Peshwani","2024","Journal of Drug Discovery and Therapeutics","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056021","The Use of GLP-Receptor Agonists for Improving Fertility in PCOS Patients","Afifa Khaleelullah","2024","Journal of Asian Medical Students Association","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056022","GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RAS) AND THE RISK OF GYNECOLOGICAL MALIGNANCIES IN DIABETIC PATIENTS","Alberto Farolfi","2026","International Journal of Gynecological Cancer","other","article","10.1016/j.ijgc.2026.105099",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056023","Diabetes, Cardiomyopathy, And Heart Failure-An Updated Review Article for Nursing."," Rawan Yaseen Ahmed Alqasem","2024","Review of Contemporary Philosophy","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056024","Nutritional Depletion After GLP-1 Discontinuation: A Narrative Review on Recognizing the Signals and Guiding Care","Dhriti Gaur","2026","Open Science Framework","other_trial","article","10.17605/osf.io/p4esn",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","review"],["R0056025","CiteSpace-based Visualization of Xanthone Capsule for Diabetic Nephropathy Treatment","冯晓青","2024","Journal of Theory and Practice in Clinical Sciences","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056026","Urologic Adverse Events Associated with GLP-1 Receptor Agonist Use: A Systematic Review","Yara El Deghel","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/fxacp",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0056027","Comparative study of Retatrutide vs Tirzepatide vs semaglutide in the management of obesity","Hazem Ayesh","2026","Open Science Framework","other","article","10.17605/osf.io/rufjp",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056028","Wegovy®: redefiniendo la historia de la obesidad","Mónica Katz","2025","Lugones Editorial","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056029","Memahami Risiko Penggunaan Semaglutide Masa Transisi Penggunaan Off Label","Julitasari Sundoro","2024","Jurnal Etika Kedokteran Indonesia","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056030","METHOD DEVELOPMENT AND VALIDATION OF LIRAGLUTIDE IN BULK AND MARKETED DOSAGE FORM BY USING RP-HPLC TECHNOLOGY: Enhancing Quantitative Analysis through RP-HPLC Technology","Pranjali S. Sonune","2024","International Journal of Pharmaceutical, Biological and Chemical Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056031","Oral Anti-Diabetic Agents-Review and Updates","Patience Ogoamaka Osadebe","2014","Journal of Advances in Medicine and Medical Research","narrative_review","article","10.9734/bjmmr/2015/8764",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056032","Real-World Pharmacovigilance Analysis of Suicidal Ideation and Self-Injurious Behavior Associated with GLP-1 Receptor Agonists: Disproportionality and Mechanistic Insights","PAKISTAN JOURNAL OF MEDICAL AND CARDIOLOGICAL REVIEW","2026","Pakistan Journal of Medical & Cardiological Review","nonrandomized_study","article","10.5281/zenodo.23010672",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056033","THE BURDEN OF MICROVASCULAR AND MACROVASCULAR COMPLICATIONS IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE FERGANA REGION AND THE POTENTIAL ROLE OF SEMAGLUTIDE","Anvarjonova Layloxon Anvarjon qizi","2026","International journal of scientific researchers ( IJSR ) INDEXING","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056034","GLP-1 RECEPTOR AGONISTS FOR OBESITY: MIRACLE THERAPY OR EMERGING MISUSE?","Farooq Ahmed","2026","Journal of Medical Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056035","A Simple Stability-Indicating UPLC Method for quantification of Tirzepatide in Bulk drug and Pharmaceutical Formulations","Chandana Mannepalli","2024","International Journal of Pharmacy and Industrial Research","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056036","Glucagon-like peptide-1 receptor agonists are associated with an increased risk of repeat colonoscopy: a real-world retrospective cohort study","Shao Chi Lo","2026","BMC Gastroenterology","nonrandomized_study","article","10.1186/s12876-026-05391-3",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056037","Is there evidence that GLP-1 agonists reduce breast cancer risk?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23065281",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056038","Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors","Matthew Gilbert Richard E. Pratley","2023","The Review of Diabetic Studies","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0056039","Cardiovascular Effects of Incretin-Based Therapies","Nikolaus Marx Michael Lehrke","2023","The Review of Diabetic Studies","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056040","GLP-1 AND GIP REVOLUTION","Anca Victorita Trifan","2025","The Medical-Surgical Journal","other","article","10.22551/msj.2025.02.01",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056041","What research exists on GLP-1/GIP medication usage and its effects on respiratory health outcomes and respiratory function?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23067434",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056042","Interacciones farmacológicas de estatinas con agentes antidiabéticos no insulínicos","Cristian Suárez Cordo","2023","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056043","Do Gastric Balloons Have a Future? Intragastric Balloons in the Era of Highly Effective Obesity Pharmacotherapy","Rhea Sibal","2026","Medicina","randomized_trial","article","10.3390/medicina62101916",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056044","TIRZEPATIDA (MOUNJARO®): USO INDISCRIMINADO E AUMENTO DE CASOS DE PANCREATITE","Vinícios Oliveira Ribeiro Souza","2026","Anais Colóquio Estadual de Pesquisa Multidisciplinar","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056045","BEYOND GLYCEMIC CONTROL: ORGAN-PROTECTIVE EFFECTS AND SAFETY PROFILE OF GLP-1 RECEPTOR AGONISTS – A COMPREHENSIVE REVIEW","Magdalena Bukowska","2026","International Journal of Innovative Technologies in Social Science","narrative_review","article","10.31435/ijitss.3(51).2026.6563",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056046","Tirzepatide Injections in Miami for Weight Management","Tirzepatide Injections Miami","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23079706",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056047","Pre-registered mechanistic prediction: VK2735 in VANQUISH-2 (NCT07104383)","Natalija Karpichina","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.23044760",null,null,"ClinicalTrials.gov:NCT07104383","S001333","openalex","TRUE","paywalled","4","FALSE","preprint"],["R0056048","Spectrum of dermatological effects associated with GLP-1 and GIP receptor agonists: a scoping review","ELIANA PEREIRA DE ARAUJO","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/4w5u6",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0056049","Activating nucleus tractus solitarius neurons that project to the nucleus accumbens attenuates cocaine seeking via enhanced GLP-1 signaling in the ventral striatum of rats","Riley Merkel","2026","Translational Psychiatry","preclinical","article","10.1038/s41398-026-04493-6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056050","GLP-1 Receptor Agonists and Narrow-Therapeutic-Index Drug Failure: A FAERS Disproportionality Analysis","Nabgha Zafar","2026","Kashmir Journal of Academic Research and Development","nonrandomized_study","article","10.71317/kjard.2.10.2026.785",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056051","Multifactorial Interventions Before Laser Photocoagulation Improve Outcome of Diabetic Macular Edema","Ramandeep Singh","2006","Diabetes Care","other","article","10.2337/dc06-1302","17130221",null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056052","EFICÁCIA DA SEMAGLUTIDA NO TRATAMENTO DA OBESIDADE EM ADULTOS SEM DIABETES","Vitória Silva Ferreira","2026","Anais Colóquio Estadual de Pesquisa Multidisciplinar","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056053","Review on QBD Approaches to HPLC Method Development and Validation on Tirzepatide","Ravina Mule","2026","Asian Journal of Pharmaceutical Research and Development","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056054","Benefícios, riscos e lacunas no uso dos agonistas do GLP-1 para emagrecimento. O fim da bariátrica?","Giovanni Ricardo da Silva Filho","2025","Revista Remecs - Revista Multidisciplinar de Estudos Científicos em Saúde","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056055","Hybrid Fuzzy Pattern Classifier and ARAS for Evaluating Type 2 Diabetes Medications: A Computer-Aided Decision-Making Approach","Søren Atmakuri Davidsen","2024","Journal of Electrical Systems","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056056","PROSPECTS OF EXENATIDE IN THE TREATMENT OF DIABETIC GASTROPARESIS"," Kostitska I. O.","2016","World of Medicine and Biology","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056057","Metabolic dysfunction–associated steatotic liver disease (MASLD): Evidence based approach","M Golam Azam","2026","Bangladesh Journal of Medicine","other_trial","article","10.3329/bjm.v37i20.89589",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0056058","A New Stability-Indicating and Validated RP-HPLC Method for the Estimation of Liraglutide in Bulk and Pharmaceutical Dosage Forms","Jhansi Naga Lakshmi Pedaprolu, Mohan Gandhi Bonthu,  Bhaskara Raju Vatchavai,  Srinivas Sumanth Kamatham,  Srinivas Kolli,  Andal Naga Jyothi Kapuganti","2017","Eurasian Journal of Analytical Chemistry","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056059","Obesity and Orthopedic Disorders: An Overview, Epidemiology, Diagnosis, Public Health, Pharmacological Treatment, and Nursing Intervention Protocols.","Abdulkareem Dhemayan A Alenizi","2024","Review of Contemporary Philosophy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056060","Strategie neuroprotettive nella demenza di Alzheimer The program GLP-1.exe is running","Alberto Granzotto","2019","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22936843",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056061","Efficacy and Safety of Semaglutide in Non-Alcoholic Fatty Liver Disease: A Clinical Based Study","Saeed Anwar , Fawad Majid , FarhanTariq , Sajid Ali Ahmad , Muhammad Ali","2024","Medical Forum Monthly","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056062","Os efeitos do Ozempic no processo de perda de peso em adultos obesos: uma mini revisao de literatura","Maria Eduarda Jardim Jácomo","2024","Revista Educação em Saúde/Revista Educação em Saúde Unievangélica","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056063","Clinical Benefit Versus Affordability: A Narrative Review of Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes","CHIRANTH KRISHNASHETTY RAMESH","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.23100951",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","review"],["R0056064","SGLT2 INHIBITORS AND GLP-1 RAS: REAL-WORLD CARDIOVASCULAR OUTCOMES","Swaliha Sulfi*1, Shifana S.2, Ameen Labba N.3, Dr. Rincy Robinson","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.23031244",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0056065","Sarcopenic Obesity: Current Concepts, Diagnosis and Management","Damian Broda, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Ewa Wiench, Magdalena Kloc, Alicja Zając, Bartosz Niciński, Alicja Benecka, Marcin Kutkowski, Aleksandra Broda [AB]","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23035492",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056066","Effects of lixisenatide on acute and subacute models of inflammation in male Wistar rats.","Dr. Aarti Bhosale , Dr. Nayana Hashilkar , Dr. Sunita Patil","2024","Frontiers in Health Informatics","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056067","ALTERAÇÕES NA MICROBIOTA INTESTINAL INDUZIDAS POR AGONISTAS DO RECEPTOR DE GLP-1 E SUAS IMPLICAÇÕES METABÓLICAS","Adrielly Ferreira Monteiro Castro","2026","Anais Colóquio Estadual de Pesquisa Multidisciplinar","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056068","Does the use of GLP-1 agonists affect the absorption or efficacy of lithium?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22948779",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056069","Tirzepatide: a new treatment for obesity - literature review","Sara Correia","2026","Athena health & research journal.","randomized_trial","article","10.62741/ahrj.v3isuppl.2.199",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056070","Transcriptomic Analyses of the Association Between GLP-1 Receptor Agonist Use and Non-Hodgkin Lymphoma Risk","Cho Han Chiang","2026","International Journal of Cancer Care and Delivery","other","article","10.53876/001a.129852",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056071","Tirzepatide, A New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Narrative Review","Madhvi Ghadge, Aarti, Ashwani Kumar, Ishu, Aashutosh Sinwal, Nisha","2024","Journal of chemical health risks","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0056072","Study on the Structural Effectiveness Of (Semaglutide - GLP-1 Ras) In Weight Loss and Its Effect on Reducing the Risk of Heart Attacks and Strokes","Nawaf.A.Alshamrani, Hasan.S.Alshughaybi, Sameer.H.Ahmed, Haytham.A.Alrahily, Samar.S.Almabadi, Ahmad.S.Alrizgy, Khaled.M.Alharbi, Manar.A.Zahrallayali, Mohammed.A.Alhamdi, Ahmed.O.Alsuhaymi","2024","Evolutionary Studies in Imaginative Culture","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056073","Monitoreo continuo de glucosa en diabetes mellitus tipo 2","Carolina Gómez Martín","2024","Revista de la Sociedad Argentina de Diabetes","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056074","Effectiveness of Metformin in Management Latest Type 2 Diabetes Mellitus : A Literature Study","Ilham Hariaji","2025","Buletin Farmatera","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056075","Do GLP-1 agonists affect the risk of hormone-receptor-positive breast cancer?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23068357",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056076","Can a patient with MASLD be treated with a statin or a GLP-1 receptor agonist?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23021107",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056077","A REVIEW OF OZEMPIC'S OFF LABEL USE FOR WEIGHT LOSS IN NON-DIABETIC INDIVIDUALS: CLINICAL EVIDENCE, SAFETY AND ETHICS","Tuba, Anum Sattar, Sidra Javed, Mizna Masood, Zunaira Shaikh","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.23120158",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056078","Is Tirzepatide associated with the risk of acute cholecystitis?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23087714",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056079","Editorial: Bone: Endocrine Target and Organ","Giacomina Brunetti","2017","Frontiers in Endocrinology","randomized_trial","article","10.3389/fendo.2017.00354","29312144",null,null,null,"openalex","TRUE","open_pdf","2","FALSE","editorial"],["R0056080","Simposio: Enfermedad cardiovascular en la mujer con diabetes. Aspectos a considerar de la enfermedad cardiovascular en la mujer con diabetes","Carolina Gómez Martín","2021","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056081","Iatrogenic hypercalcemia in a patient with type 2 diabetes and chronic kidney disease","Maja Mačković","2026","European Journal of Case Reports in Internal Medicine","other","article","10.12890/2026_007398",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056082","Glucagon-like peptide-1 receptor agonist (GLP-1-RAS) treatment in patients with cirrhosis: A scoping review","Juan Sebastián Hernández","2024","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056083","SOCIAL PERCEPTION OF PHARMACOLOGICAL OBESITY TREATMENT IN THE ERA OF INCRETIN THERAPIES: AN ANALYSIS OF STIGMA IN MEDICAL AND NON-MEDICAL POPULATIONS","Kinga Głodek","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(51).2026.6421",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056084","A NOVEL TRIPLE HARMONE RECEPTORS AGONIST FOR WEIGHT MANAGEMENT OF OBESITY","Dr. Gandikoti Durgadevi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23080918",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056085","Adverse Effects of GLP-1 Receptor Agonists","Theodosios D. Filippatos, Thalia V. Panagiotopoulou, Moses S. Elisaf","2023","The Review of Diabetic Studies","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056086","How do incretin-based therapies influence nutritional outcomes in adults, and what nutritional guidelines should be considered?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22920891",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056087","Histopathological Changes in Kidneys of Developing Chick Embryo on Exposure to Lixisenatide","Amit Kumar Srivastava, Yogesh Yadav, Ashok Kumar Gupta","2023","Journal Of Advanced Zoology","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056088","Tratamiento farmacológico versus cirugía bariátrica en diabetes mellitus y obesidad","Susana Fuentes","2024","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056089","Étude PIONEER 6 : La sécurité cardiovasculaire du sémaglutide oral chez les diabétiques de type 2","Catherine Poitras","2021","Pharmactuel","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056090","The eye in the era of GLP-1 receptor agonists ‒ a narrative review of current evidence","Hanna Rusinek","2026","European Journal of Clinical and Experimental Medicine","nonrandomized_study","article","10.15584/ejcem.2026.3.8",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","review"],["R0056091","The Study of the Effect and Mechanism of Glucagon Like Peptide-1 in Bleonivcin-induced Pulmonary Fibrosis in Mice","Si,  CHEN Hai-tao. et al, LIU Mei,  GOU","2022","四川大学学报：医学版","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056092","In which patient subgroups can the use of semaglutide lead to vision loss?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23005336",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056093","Are there specific mental health medications that have known adverse effects when co-administered with GLP-1 receptor agonists?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22948783",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056094","O uso do Ozempic como medicamento off-label no emagrecimento: uma revisão de literatura","Leonardo Figueira Magno","2024","ACTA MSM - Periódico da EMSM","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056095","What is the evidence for GLP-1 agonists affecting the absorption or pharmacokinetics of other medications, particularly those used for mental health?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22947293",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056096","A \"Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) Correlated With Mitigated Risks of Early Mortality, Cardiovascular and Renal Risks in Type 1 Diabetes (T1D) Subjects: Perspectives on the Economic Impact\"","Chrysanthus Chukwuma Sr","2026","Medico Research Chronicles","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056097","GLP-1 Receptor Agonist Repurposing Across Indications: Mechanism, Evidence and Trial Sequencing","Kristaps Rudzītis","2024","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.22649326",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0056098","OC 51.3 Tirzepatide and Incident Venous Thromboembolism in Type 2 Diabetes: A Propensity-Matched Real-World Analysis","Divya Samat","2026","Research and Practice in Thrombosis and Haemostasis","nonrandomized_study","article","10.1016/j.rpth.2026.103716",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056099","Efficacy and Safety of Different Weight Reduction Strategies: A Study at Southwell Hospital Kuwait Oil Company","Aref Alabassi , Hussain Haji Ali , Khaled Khudadah , Ghaida Alshoraian , Reda Anbar","2025","South Eastern European Journal of Public Health","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056100","A review of pharmacotherapy in type 2 diabetes mellitus and its possible cardiovascular risk","Bhishma Ghimire3,, Dilli Ram Thanait1, Dr. Nandish C2, Sandip KC1,","2017","Journal of Biomedical and Pharmaceutical Research","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056101","What is the efficacy of semaglutide in managing symptoms of dumping syndrome with reactive hypoglycemia?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23068105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056102","Potential Physiological Convergence Between GLP-1 Receptor Signaling and Hepatocyte TAZ in Metabolic Liver Disease: From Metabolic Homeostasis to Fibrotic Remodeling","Mohammed F. Gholam","2026","Cells","other","article","10.3390/cells15191813",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056103","RECENT ADVANCES IN THE PHARMACEUTICAL MANAGEMENT OF DIABETES MELLITUS: EMERGING THERAPIES AND THE ROLE OF ONCE-WEEKLY INSULIN ICODEC (AWIQLI)","Anushka Jaysing Khese*1, Pooja Macchindra Ukale2, Prof. Shubham Hanumant Dhavale3, Prof. Sonal Arun Phule4, Dr. Santosh Waghmare5","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23019110",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056104","PRECISION PHARMACOTHERAPY IN TYPE 2 DIABETES MELLITUS: EVALUATING THE CARDIO-RENAL AND GLYCEMIC EFFICACY OF TARGET-SPECIFIC PATHWAY MODULATION","Raxmonova Xosiyat Boburjon qizi","2026","World Bulletin of Public Health","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056105","Bioanalytical Method Development Of Tirzepatide In Rat Plasma Using Lixisenatide As Internal Standard Using Liquid Chromatography Coupled With Tandem Mass Spectroscopy And Application To Pharmacokinetic Studies","Dr. S. Nirmala Gummalla Vijayamma","2024","Frontiers in Health Informatics","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056106","EMERGING TRENDS IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS","Sukh Chain, Smriti Bhargava, Rakesh Kumar Ola","2025","South Eastern European Journal of Public Health","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056107","OZEMPIC E ALIMENTAÇÃO: INTERAÇÕES FÁRMACO-NUTRIENTES E IMPLICAÇÕES NO ESTADO NUTRICIONAL","Candido Pereira do Nascimento","2025","Encontro de Extensão, Docência e Iniciação Científica (EEDIC)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056108","Associations between glucagon-like peptide-1 receptor agonist use and sensitivity to thyroid hormones in type 2 diabetes mellitus adults: a cross-sectional study","Yongping Liu","2026","Diabetology & Metabolic Syndrome","nonrandomized_study","article","10.1186/s13098-026-02320-y",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056109","GLP-1 AND DUAL GLP-1/GIP RECEPTOR AGONISTS AS NEUROPROTECTIVE AGENTS: MECHANISMS, CLINICAL EVIDENCE, AND TRANSLATIONAL PERSPECTIVES","Beata Tekieli","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(51).2026.6110",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056110","What meta-analysis and systematic review evidence supports the use of semaglutide for improving metabolism and treating obesity?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.23049925",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0056111","Use of GLP-1 receptor agonists and dual agonists in patients with inflammatory bowel disease","Michał Dróżdż","2026","Quality in Sport","randomized_trial","article","10.12775/qs.2026.77.76265",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056112","The Preliminary Investigation of GLP-1 Receptor Agonist on Liver Steatosis in Obese Mice","He,  LIANG Li-bo. et al, WANG Xia,  HE","2022","四川大学学报：医学版","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056113","CURRENT DEVELOPMENTS IN THERAPEUTIC STRATEGIES FOR THE MANAGEMENT OF DIABETES: AN EXTENSIVE REVIEW","Akash Upadhyay 1, Abdul Wadood Siddiqui2, Sailesh Narayan3, Brishnendra Mishra4","2023","Journal of Research Administration","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056114","Management of Obesity in Liver Cirrhosis: A Delicate Balance of Risks and Benefits","Seung Kak Shin","2026","Korean Journal of Medicine","other","article","10.3904/kjm.2026.101.5.226",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056115","Uso da Tirzepatida no Emagrecimento – uma revisão de literatura","Barbara Costa Filippe Kamhaji","2026","ACTA MSM - Periódico da EMSM","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056116","Weight loss drugs compared: 3-receptor vs blood sugar pick 2026","Dr. Leah Fontaine","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22926320",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056117","Regulatory requirements for antidiabetic drugs as per CDSCO in India comparison with USA","Ashok Kumar P","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22937056",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056118","Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular–Kidney–Metabolic Disease: A Narrative Review","Boknyun Kim","2026","Pharmaceuticals","randomized_trial","article","10.3390/ph19101572",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0056119","ABCD Renal Association Abstracts 2019","Admin Two","2019","British Journal of Diabetes","preclinical","article","10.15277/bjd.2019.218",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056120","GLP-1 Receptor Agonism and Artificial Intelligence in Reward System Modulation and Human Agency Review of Del Valle (2026)","Syed Muntasir Mamun","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.22992360",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056121","Exendin-4 Improves Impaired Endothelial Dependent Vasodilation in Obese Rat","Ye-rong,  WANG Ben, HAN Li-na,  YU","2022","四川大学学报：医学版","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056122","The Leukemic Niche as a Bistable Attractor: Hypoxia, Acidosis, and Sympathetic Neuropathy in the Bone Marrow","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23030191",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056123","GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients","Zena Adel Alwaily","2026","Archives of Medical Science - Atherosclerotic Diseases","systematic_review","article","10.5114/amsad/226416",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056124","Comparative Pharmacovigilance of GLP-1, Dual GIP/GLP-1, and SGLT-2 Receptor Agonists: A Complete 3×3 FAERS Disproportionality Analysis of Pancreatitis, Gastroparesis, and Diabetic Ketoacidosis Signals","Ameera Zulfiqar","2026","Figshare","nonrandomized_study","article","10.6084/m9.figshare.33977968",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0056125","Durability of semaglutide effects after treatment discontinuation in HIV-associated lipohypertrophy: a randomized, double-blind, placebo-controlled phase IIb clinical trial","Ruth O. Adekunle","2026","Open Forum Infectious Diseases","randomized_trial","article","10.1093/ofid/ofag631",null,null,"ClinicalTrials.gov:NCT04019197","S001425","openalex","TRUE","free_to_read","1","FALSE","article"],["R0056126","Metabolic dysfunction-associated fatty liver disease: Current updates and the Bangladesh perspective","Shahinul Alam","2026","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other","article","10.3329/jacedb.v5i20.93852",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056127","Agonistas do receptor de GLP-1 e inibidores da serino-protease dipeptidil-peptidase-4 no tratamento de diabetes tipo 2 - Uma revisão","Glauciemar Del-Vechio Vieira","2020","Brazilian Journal of Health Review","other","article","10.34119/bjhrv3n4-036",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056128","Additional file 1 of Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice","Alejo Mosqueira","2026","Figshare","preclinical","article","10.6084/m9.figshare.34076515",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056129","The incretin-bone axis: molecular mechanisms and clinical implications","Andrea Muscarà","2026","Frontiers in Endocrinology","other","article","10.3389/fendo.2026.1907875",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056130","Semaglutide: A Revolutionary Diabetes Drug, or a Fad Celebrity Endorsement?","Poorva Kasture","2025","Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056131","Effects of Blueberry and Collard Greens Dietary Intervention on Metabolic and Inflammatory Biomarkers in Zucker Obese Rats","Jacqueline Afua Yeboah","2026","Nutrients","randomized_trial","article","10.3390/nu18193246",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056132","Repurposing Retatrutide for Neuroprotection in Parkinson’s Disease: A Comprehensive Review","Sivakumar G.","2026","International Journal of Innovative Science and Research Technology (IJISRT)","narrative_review","article","10.38124/ijisrt/26sep1305",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056133","O EFEITO DA SEMAGLUTIDA (OZEMPIC) ALÉM DA BULA: UMA ANÁLISE DAS CONSEQUÊNCIAS METABÓLICAS E CLÍNICAS DO USO OFF-LABEL PARA FINS ESTÉTICOS","Davi Rodilha dos Santos","2026",null,"other","article","10.51161/iv-conasus/89566",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0056134","Scaling up incretin-based therapies under policy scenarios: projected changes in the global burden of diabetes and diabetic kidney disease to 2050, with equity analysis","李树光","2026","OSF Preprints (OSF Preprints)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0056135","Cardiorenal Syndrome: From Hemodynamic and Humoral Pathophysiology to New Frontiers in Modulation and Enabling Therapy—Part 2","Alfredo Mauriello","2026","Biomedicines","other","article","10.3390/biomedicines14102257",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056136","Economic evaluation of SGLT2 inhibitors and GLP-1 receptor agonists in Thai patients with type 2 diabetes and established atherosclerotic cardiovascular disease","Tanawan Kongmalai","2026","Scientific Reports","randomized_trial","article","10.1038/s41598-026-73139-w",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056137","Suspensión de agonistas GLP-1 en el manejo de la obesidad: ¿cuándo y cómo hacerlo con criterio clínico? Discontinuation of GLP-1 agonists in obesity management: When and how to do it using clinical judgment?","Jorge Andrés Hernández Navas","2025","Gaceta Médica de Caracas","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056138","Type 2 Diabetes Mellitus in Kyrgyzstan: Epidemiology, Risk Factors, Complications, and Clinical Management Challenges in a Resource-Limited Central Asian Setting — A Comprehensive Review","Md Siam Hayat","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.23192682",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","preprint"],["R0056139","Tirzepatide: A new indication for cardiovascular risk reduction in type 2 diabetes","Md Kamrul Azad","2026","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","randomized_trial","article","10.3329/jacedb.v5i20.93922",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056140","ประสทธภาพของยากลมยากระตนตวรบเปปไทดตวเหมอนกลคากอนชนดท 1 ตอ ดชนมวลกายและเสนรอบเอวในผปวยโรคอวนหรอนำหนกตวเกน: การทบทวนวรรณกรรมอยางเปนระบบและการวเคราะหอภมานเครอขาย","Jirawan Vienghirun","2025","Thai Journal of Pharmacy Practice","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056141","The Impact of GLP-1 Receptor Agonists on the Brain’s Addiction and Satiety Networks","Noreen Adoni","2025","Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056142","Cardioprotective Effects of Losartan and Semaglutide, Alone and in Combination, Against Naproxen-Induced Myocardial Infarction","Saritha B","2026","Journal of chemical health risks","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056143","Chronic Systemic Inflammation in Patients with Multimorbidity: Pathogenetic Mechanisms and Therapeutic Strategies.","Ratmir Shakirov","2026","Journal of chemical health risks","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056144","Type 2 Diabetes and Central Obesity in the Cardiovascular Kidney–Metabolic Continuum: A Critical Narrative Review","Dini Aulia Cahya","2026","Biomedical & Pharmacology Journal","randomized_trial","article","10.13005/bpj/3489",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0056145","Calibrated AI approach to pharmacovigilance using FAERS","Zhouzhou Chu","2026","npj Digital Medicine","nonrandomized_study","article","10.1038/s41746-026-03273-2",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056146","Incretin-Based Therapies and the Associated Impact on Bone Health","Krzysztof Łupina","2026","International Journal of Pharmacology","other","article","10.31083/ijp53550",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056147","GLP-1 Receptor Agonists: A Potential Treatment for AUD","Robert Kemp","2025","Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056148","Efeitos dos agonistas dos receptores de GLP-1 na doença de Alzheimer: uma revisão integrativa","Anna Elisa Massa Lisboa","2026","Revista Educação em Saúde/Revista Educação em Saúde Unievangélica","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056149","Translational Highlights from Endocrinology",null,"2013","The Journal of Clinical Endocrinology & Metabolism","preclinical","article","10.1210/jcem.98.1.zeg405",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056150","Clinical outcome and safety profile of combination therapy with low dose semaglutide and metformin vs. metformin alone in polycystic ovary syndrome with obesity","Md Rafayel Islam","2026","Bangladesh Journal of Medicine","randomized_trial","article","10.3329/bjm.v37i20.89338",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056151","RESUMO SIMPLES: Complicações abdominais associadas ao uso de canetas emagrecedoras em pacientes submetidos à cirurgia de urgência","Afonso Leite Justino Pires","2026","International Journal of Health and Surgical Research","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056152","Lithium Toxicity Following Initiation of Semaglutide in a Patient With Bipolar Disorder: A Case Report","Annika Dhingra","2026","Cureus","case_report","article","10.7759/cureus.117235",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056153","Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition","Richa Chaturvedi","2026","Frontiers in Endocrinology","other","article","10.3389/fendo.2026.1969433",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056154","Effect of Antidiabetic Medications on Cancer Risk: Mechanisms and Clinical Evidence","Satish Chandra","2026","Journal of chemical health risks","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056155","A Comprehensive Review of Treatment Options for Polycystic Ovary Syndrome (PCOS)","Nillohit Mitra Ray Kshama","2025","Journal of chemical health risks","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056156","Role of GLP-1 Receptor Agonist Medications in Substance Use Disorders","Tatjana Svjetlanovic","2026","UND Scholarly Commons (University of North Dakota)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056157","Étude STEP 8 : essai clinique à répartition aléatoire comparant le sémaglutide au liraglutide par voie sous-cutanée pour la perte de poids chez les patients non diabétiques en surpoids ou obèses","Clémentine Beucher","2023","Pharmactuel","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056158","Prevalence of Obstructive Sleep Apnea (Osa), Risk and Associated Factors among Patients with Type-2 Diabetes Mellitus: A Comprehensive Narrative Review","Ashok Pingoliya","2026","Journal of chemical health risks","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","review"],["R0056159","Plain Language Summary of the Manuscript: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomised, double-blind, placebo-controlled phase 3 trial","Lee M Kaplan","2026","Boehringer Ingelheim","randomized_trial","article","10.60915/boehringer-figshare.34012725",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0056160","Is non-response real? True between-patient heterogeneity in weight-loss response to incretin-based anti-obesity medications: a systematic review and dose-response network meta-analysis of variability, with an evaluation of early stopping rules","XIAO MA","2026","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/c598r",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0056161","Effects of contemporary glucose-lowering agents on the hemostatic system: From molecular mechanisms to clinical practice","L. A. Asadova","2026","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2026-337",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056162","Mounjaro® Re-define treatment expectations on chronic weight management","Tania Tofail","2026","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","other_trial","article","10.3329/jacedb.v5i20.93918",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0056163","The Incretin Axis in Cardiovascular Disease","Jorge Plutzky","2011","Circulation","preclinical","article","10.1161/circulationaha.111.064139","22105195",null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0056164","Cost-Effectiveness And Threshold Prices Of Tirzepatide And Semaglutide Versus Metformin For Preventing Type 2 Diabetes In Indian Adults With Obesity: A Modelling Study","Idris Dawaiwala","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7564189",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056165","Modernizing the Regional Research Data Engine: A Zero-Trust Operating Model to Close the \"Data-When-Needed\" & DevEx Gaps in the South West Secure Data Environment (SWSDE)","Ashwin Yadhav Kumar","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.23135137",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056166","Efficacy of low-dose semaglutide added to metformin on clinical and metabolic parameters in women with polyendocrine metabolic ovarian syndrome and obesity: A phase II randomized controlled trial","Md. Rafayel Islam","2026","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","randomized_trial","article","10.3329/jacedb.v5i20.93925",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056167","Comprehensive benefits of originator molecule in diabetes management and beyond","Rahila Sarwar Bhatti","2026","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","nonrandomized_study","article","10.3329/jacedb.v5i20.93923",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056168","Cardiovascular-kidney-metabolic syndrome: Beyond glycemic control","Muhammad Arslan Khan","2026","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","nonrandomized_study","article","10.3329/jacedb.v5i20.93924",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056169","Watching What We Eat: Information Quality and Body Image in Diet-Related YouTube Videos","Maddalena Ghiotti","2026",null,"other","article","10.1145/3794786.3830741",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0056170","Effects of Zinc Leachate on the Structure and Activity of Semaglutide","Emilia K. Doran","2026","ChemRxiv","preclinical","article","10.26434/chemrxiv.15009850/v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056171","Therapy for Obesity Based on Gastrointestinal Hormones","Jonatan I. Bagger, Mikkel Christensen, Filip K. Knop, Tina Vilsbøll","2023","The Review of Diabetic Studies","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056172","Metabolic–osmoregulatory coupling in insulin physiology: revisiting Epple and Brinn fifty years later","Kathleen Bell","2026","Figshare","preclinical","article","10.6084/m9.figshare.34020561",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056173","Impact of Obesity and Its Treatment on Inflammatory Bowel Disease Outcomes: A Narrative Review","Carlo Redavid","2026","Gastroenterology Insights","narrative_review","article","10.3390/gastroent17040057",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0056174","Non-ST Elevation Myocardial Infarction Following Significant Weight Loss During Tirzepatide Therapy: A Case Report","Aparajita Roy","2026","Cureus","nonrandomized_study","article","10.7759/cureus.117278",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056175","Metformin and GLP-1 receptor agonists for antipsychotic-induced metabolic disturbances: a systematic review and network meta-analysis","Ye-xin Chen","2026","BMC Medicine","systematic_review","article","10.1186/s12916-026-05280-2",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0056176","Old is gold: When experience meets evidence (Gliclazide MR): A proven legacy in modern diabetes care","Somia Iqtadar","2026","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","nonrandomized_study","article","10.3329/jacedb.v5i20.93879",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056177","Effects of intensive insulin therapy combined with non-insulin antihyperglycemic agents on glycemic control, variability, and metabolic outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","Zixuan Shen","2026","Frontiers in Endocrinology","systematic_review","article","10.3389/fendo.2026.1948361",null,null,"PROSPERO:CRD42024582974",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056178","In this Issue",null,"2015","Journal of Neurochemistry","preclinical","article","10.1111/jnc.12918",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0056179","How to Inject Tirzepatide_ A Comprehensive Guide","Core Trust Labs","2026","Figshare","other","article","10.6084/m9.figshare.34024128",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056180","Ketosis and ketoacidosis reported with tirzepatide and semaglutide in JADER: overall and non-approved or inappropriate use","Seiji Nishikage","2026","Figshare","nonrandomized_study","article","10.6084/m9.figshare.34021683",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0056181","Pre-Procedural SGLT2 Inhibitor Use and the Risk of Post-ERCP Adverse Events Among Patients With Type 2 Diabetes: A Prevalent-User Target Trial Emulation (The SGLT2i-PEP Study)","Zachary L. Smith","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/yuhsg",null,null,"OSF:osf.io/jv7qy",null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0056182","GLP-1 receptor agonists in adults with diabetes undergoing coronary artery bypass grafting: a scoping review","Ego Wong","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/b29xt",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056183","Liraglutide improves diabetes and suppresses appetite in Biedl-Bardet syndrome","Aamir Qayyum","2026","Journal of Pakistan Endocrine Society","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056184","MODERN METHODS OF TREATING DIABETES","Samadjon Sultanov","2025","Современная наука и исследования","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056185","Management of Non-alcoholic Steatohepatitis (NASH): A Systematic Review of Pharmacological Therapies","W.Weinberg","2021","Medical Education in The United States and Canada","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0056186","Structural Modifications of Semaglutide and GLP-1-Like","Peng Zeng","2026","Theoretical and Natural Science","other","article","10.54254/2753-8818/2026.hz37364",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056187","FREQUENCY OF CHOLELITHASIS IN PATIENTS WITH DIABETES MELLITUS AT SUGHRA SHAFI MEDICAL COMPLEX","Dr. Asadullah","2025","The Research of Medical Science Review","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056188","GLP-1 Receptor Agonists Across the Coronary Disease Continuum in Type 2 Diabetes: A Systematic Review of Ischemic Events, Revascularization, and Stent Healing","Batool I Abuzenah","2026","Cureus","systematic_review","article","10.7759/cureus.117500",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056189","Effects of approved anti-obesity medications on depression symptoms, psychiatric adverse events, and quality of life in adults who are overweight or obesity: a systematic review and Bayesian network meta-analysis","Jin Peng","2026","BMC Psychiatry","systematic_review","article","10.1186/s12888-026-08721-7",null,null,"PROSPERO:CRD420261400491",null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0056190","Gastric Emptying in Obesity and Weight‐Loss Interventions: Physiology, Assessment, and Clinical Implications","Maxime Amoyel","2026","Comprehensive physiology","other","article","10.1002/cph4.70275",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056191","Decoding the cellular crosstalk between obesity and osteoarthritis through single-cell transcriptomics","Wei Hang","2025","ORCA Online Research @Cardiff (Cardiff University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0056192","Comparative Cardiorenal Effectiveness of GLP-1 Receptor Agonists and SGLT2 Inhibitors, Alone or in Combination, in Older Adults with Type 2 Diabetes: A Target Trial Emulation Study Using TriNetX","張玲華","2026","Taipei Medical University Repository","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","dissertation"],["R0056193","Sémaglutide en injection pour les adultes en surpoids ou obèses : étude STEP-1","Yannick Harvey","2022","Pharmactuel","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056194","Response by Albanese et al to \"GLP-1 Receptor Agonists in Aesthetic Surgery: An Expert Video Roundtable Discussion\" by Austin et al","Damiano Tambasco","2026","Aesthetic Surgery Journal Open Forum","other","article","10.1093/asjof/ojag197",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056195","Intra-articular injection of liraglutide attenuates capsular fibrosis and improves shoulder range of motion in a rat model of adhesive capsulitis","Hyun Gon Kim","2026","Scientific Reports","preclinical","article","10.1038/s41598-026-73949-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056196","Corrigendum to: Impact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study",null,"2026","Endocrinología Diabetes y Nutrición (English ed )","other","article","10.1016/j.endien.2026.501844",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0056197","Primary Colonic Mucosal-Associated Lymph Tissue Lymphoma: A Case Report","Rutvi Katariya","2026","Case Reports in Gastroenterology","case_report","article","10.1159/crg/abwag006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056198","Comparative Effectiveness of GLP-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review","Adesh D. Mishra","2026","Journal of chemical health risks","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0056199","Evaluation of high-technology medicines considering budget impact and societal value: a three-tier approach using incretin-based therapy as an example","Arthur Anatolievich Lee","2026","FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology","other","article","10.17749/2070-4909/farmakoekonomika.2026.412",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056200","Efficacy and safety of once-weekly Semaglutide for weight management in adults with overweight or obesity with or without type 2 diabetes: A real-world clinical trial in Bangladesh","Quazi Tarikul Islam","2026","Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh","randomized_trial","article","10.3329/jacedb.v5i20.93921",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056201","Do First Generics Reach Medicaid Pharmacy Markets Equally After Approval? An ML.NET Framework for Measuring Diffusion and Access Gaps","Tanvir Mahmud Khan","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.20837672",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056202","แนวคดการพฒนายา semaglutide แบบรบประทาน และการนำไปใชในทางคลนก","กาญจน์นภา จตุเทน","2020","Thai Journal of Hospital Pharmacy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056203","BARIATRIC SURGERY VERSUS INCRETIN AGONISTS IN OBESITY: COMPARISON OF WEIGHT LOSS, METABOLIC CONTROL, AND CARDIOVASCULAR RISK REDUCTION","Victor Hugo Sanches","2026","Seven Editora eBooks","other","article","10.56238/sevened2026.031-021",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0056204","Retatrutide","Robert Peterson","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23246771",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056205","Revisiting colchicine pharmacology: structural and pharmacokinetic insights into GLP-1 receptor engagement","Kerem Buran","2026","Journal of Research in Pharmacy","other","article","10.12991/jrespharm.1948337",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056206","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98861-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056207","Active Development Portfolio for Obesity Pharmacotherapy: An Analysis of Data from the ClinicalTrials.gov Registry","Roza Ismailovna Yagudina","2026","Safety and Risk of Pharmacotherapy","nonrandomized_study","article","10.30895/2312-7821-2026-14-3-263-277",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056208","Advances in Precision Medicine for Chronic Kidney Disease: Biomarkers, Risk Stratification, and Personalized Therapeutic Approaches","Dr RAKESH VENUTURUMILLI","2026","KIDNEYS","other","article","10.65327/kidneys.v15i2.666",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056209","Diabetes-Associated Cognitive Dysfunction: Pathophysiology, Molecular Mechanisms, and Emerging Therapeutic Strategies","Ravin Sarkar","2026","ACS Pharmacology & Translational Science","other","article","10.1021/acsptsci.6c00440",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056210","AI-Guided De Novo Design Pipeline for Oral, Gut-Active Peptides That Stimulate GLP-1 Secretion and Promote Weight Loss in Diet-Induced Obese Rats","Eden Goldfarb","2026","ACS Nutrition Science","preclinical","article","10.1021/acsnutrsci.6c00031",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056211","GDF-15/GFRAL Axis Dynamics and Vulnerability Windows in Bariatric Surgery: Pathophysiological, Microbiomic, and Pharmacological Perspectives","Alin Constantin Pînzariu","2026","Cells","other","article","10.3390/cells15191823",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056212","Liraglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98809-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056213","Semaglutide Exposure and Adverse Pregnancy Outcomes",null,"2026","Kidney News","other","article","10.62716/kn.004982026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056214","Mechanism-Based Pharmacotherapy of Obesity: From Pathophysiology to Precision and Next-Generation Therapeutics","Sattar J. Abood","2026","Journal of Advances in Medical and Pharmaceutical Sciences","other","article","10.9734/jamps/2026/v28i10898",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056215","Sarcopenia and GLP-1 Receptor Agonists: A Bibliometric Review","Sabrina Gabrielle Gomes Fernandes","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/mkphq",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056216","52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study","MJ Stewart","2013","Newcastle University ePrints (Newcastle Univesity)","other","article","10.25405/ncl.34214547",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0056217","MODULAÇÃO HEMODINÂMICA E PROTEÇÃO CARDIORRENAL POR MEIO DA AÇÃO DOS INIBIDORES DE SGLT2 E AGONISTAS DO RECEPTOR DE GLP-1","Jorge João dos Santos Castro Filho","2026","EPITAYA eBooks","other","article","10.47879/ed.ep.20260415p811",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0056218","PROTOCOL How can waiting times and prioritisation of eligibility for weight loss drugs be effectively communicated to patients? A rapid systematic review","Jack Michael Birch","2026","Zenodo (CERN European Organization for Nuclear Research)","systematic_review","article","10.5281/zenodo.23236919",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0056219","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98863-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056220","Semaglutide for metabolic dysfunction-associated steatotic liver disease in Asian and lean populations","Yeo Wool Kang","2026","Kosin Medical Journal","randomized_trial","article","10.7180/kmj.26.193",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056221","Perioperative GLP-1 Analog Management in Abdominoplasty: A Multicenter Comparative Study of Cessation and Resumption Timing on Weight Outcomes and Complications","Anvar AHMEDOV","2026","Journal of Plastic Reconstructive & Aesthetic Surgery","other","article","10.1016/j.bjps.2026.09.055",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056222","Tirzepatide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98862-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056223","The Backcountry Pharmacy Chapter Fifteen","Casey C. Sears","2026",null,"other","article","10.67999/b0003.c15",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0056224","Personalization and Safety of Pharmacotherapy: Evolution of Approaches to the Treatment of Obesity and Eating Disorders","Dmitry Borisovich Nikityuk","2026","Safety and Risk of Pharmacotherapy","other","article","10.30895/2312-7821-2026-14-3-243-248",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056225","The Backcountry Pharmacy Chapter Nineteen","Casey C. Sears","2026",null,"other","article","10.67999/b0003.c19",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0056226","Abstract Tue182: Cardiometabolic Outcomes in Polycystic Ovary Syndrome With GLP-1 Receptor Agonists Versus Metformin: A Propensity-Matched Analysis","Aishwarya Yannamani","2026","Circulation Research","nonrandomized_study","article","10.1161/res.139.suppl_1.tue182",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0056227","Semaglutide รปแบบรบประทาน: ทางเลอกใหมสำหรบการรกษาโรคเบาหวานชนดท 2","Nuttaporn Chaiyakittirattana","2022","Thai Journal of Hospital Pharmacy","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0056228","DIABETIC NEPHROPATHY: THE SILENT THREAT TO YOUR KIDNEYS","Jigyasa Kapoor","2026","Iterative International Publishers eBooks","other","article","10.58532/nbennur3326c6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0056229","Beyond Weight Loss: The Emerging Dermocosmetic Opportunity in the GLP-1 Era From pharmacological weight reduction to a new platform for skin, hair and body adaptation","Jose M. Lopez","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.22939316",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056230","Semaglutide across cardiovascular and kidney outcome trials: a systematic review and stratified synthesis","Antonio Maria Labate","2026","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","systematic_review","article",null,null,null,"PROSPERO:CRD420261441534",null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0056231","What is the evidence supporting the use of GLP-1 agonists in managing heart failure with preserved ejection fraction?","Tripdatabase","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23201880",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056232","Ultra-compact amyloidogenic fusion tags mediated efficient production of liraglutide precursors and molecular insights","Pavan Reddy Regatti","2026","Microbial Cell Factories","nonrandomized_study","article","10.1186/s12934-026-03138-z",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056233","Analytical Challenges in Forensic Chemistry Identification of Emerging Peptide and Protein Substances in Seized Materials","Jakob Hansen","2026",null,"other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0056234","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98852-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056235","Pharmacotherapy for Nonalcoholic Fatty Liver Disease: Comparative Efficacy","Beil","2026","European journal of scientific research","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056236","Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Stroke in Patients with Atrial Fibrillation and Type 2 Diabetes: A Danish Nationwide Cohort Study","Maria Pham","2026","EMJ Cardiology","nonrandomized_study","article","10.33590/emjcardiol/2pk1zs6y",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056237","Clinical Outcomes Associated With Glucagon-Like Peptide-1 Receptor Agonist Use Following Recent Hospitalization for Heart Failure With Preserved Ejection Fraction","Chandler O’Leary","2026","SSRN Electronic Journal","other","article","10.2139/ssrn.7552826",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056238","Tirzepatide May Lower Cardiovascular Risks in People With Diabetes With Atherosclerosis",null,"2026","Kidney News","other","article","10.62716/kn.004942026",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056239","Endocrine and Metabolic Pharmacology","Srikalyani Vemuri","2025",null,"other","article","10.61096/978-81-981372-2-7_6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0056240","PHARMACOLOGICAL MECHANISMS AND CLINICAL EFFICACY OF GLP-1 RECEPTOR AGONISTS IN APPETITE REGULATION AND GLYCEMIC CONTROL: A SYSTEMATIC REVIEW IN OBESE PATIENTS WITH INSULIN RESISTANCE","MOAMEN ABDELFADIL ISMAIL, ALI MUSAAD ALGHAMDI, ABDULLAH S. ALMOHAMMED, MARYAM ALI ALANAZI, RAZAN IBRAHIM SANGOURA, JANA WAEL ALGHAMDI","2025","TPM Testing, psychometrics, methodology in applied psychology","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0056241","Retained gastric contents in patients taking GLP-1 receptor agonists: CT recognition, gastric ultrasound triage, and peri-procedural radiology decisions","Zhufeng Sze","2026","European Society of Radiology","other","article","10.26044/ranzcr2026/c-265",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056242","Semaglutide",null,"2026","Reactions Weekly","other","article","10.1007/s40278-026-98851-7",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056243","Una visión actual del tratamiento farmacológico para la obesidad","Marc Callau de la Parte; Alex Figueras Pérez; Marta Romeu Ferran","2022","Rovira & Virgili repository","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056244","Efficacy of GLP-1 Receptor Agonists on Major Adverse Cardiovascular Events in Type 2 Diabetes: A Systematic Review","S.Emrani","2025","Medical Education in The United States and Canada","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0056245","The metabolic paradigm shift in gastroenterology and hepatology: Clinical applications of incretin-based co-agonists","Abdulrahman Ismaiel","2026","Best Practice & Research Clinical Gastroenterology","nonrandomized_study","article","10.1016/j.bpg.2026.102146",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056246","Real-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study","Olatz Vergniory-Trueba","2026","Healthcare","randomized_trial","article","10.3390/healthcare14193355",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056247","Professional Knowledge, Clinical Practices, and Regulatory Alignment Regarding GLP-1 and Dual GIP/GLP-1 Therapies Among Pharmacists and Physicians in Tripoli, Libya","Eman Derbi","2026","AlQalam Journal of Medical and Applied Sciences","nonrandomized_study","article","10.54361/ajmas.2691007",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056248","The Nutritional Impact of the Expansion of GLP-1 Receptor Agonists: The Role of Food Biotechnology","Sidi Mohammed Medjadi","2026","International Journal of Nutrition and Biotechnology Advancements","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056249","Abstract Tue181: Sex-Specific Incident Cardiovascular Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Added to Statins in Patients With Obesity, Without Diabetes, and With Coronary Artery Disease: A Propensity-Matched Cohort Study","Aishwarya Yannamani","2026","Circulation Research","nonrandomized_study","article","10.1161/res.139.suppl_1.tue181",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0056250","Non-surgical techniques for managing skin laxity after abrupt weight loss: a scope review","Rud machado varela","2025","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/fkdva",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0056251","Multi-target hypoglycemic agents in glucose metabolism disorders and neurodegenerative diseases","Guangyu Han","2026","Journal of Translational Medicine","other","article","10.1186/s12967-026-08878-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056252","Visualizing the Invisible","Tania Allen","2026","Routledge eBooks","other","article","10.4324/9781003610564-13",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0056253","Multisystem adverse drug events of low-dose tirzepatide in a normal - Weight individual: A case report and literature review","美霞 李","2026","Therapeutic Advances in Drug Safety","case_report","article","10.1177/20420986261492895",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056254","Cardiovascular promise requires endpoint discipline: interpreting tirzepatide after SURPASS-CVOT","Mulavagili Vijayasimha","2026","Therapeutic Advances in Endocrinology and Metabolism","other","article","10.1177/20420188261497184",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056255","Case Report of Near-Complete Remission of Relapsing Proteinuria Following GLP-1 Receptor Agonist Therapy in IgM-Positive Minimal Change Disease","Hasindu Arumapperuma","2026","Kidney International Case Reports","case_report","article","10.1016/j.kintcr.2026.100164",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056256","Case Report: Panic attacks after tirzepatide injection in two female patients with recurrent depressive disorder","Ulrich Palm","2026","Frontiers in Drug Safety and Regulation","case_report","article","10.3389/fdsfr.2026.1880796",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056257","CONTRAINDICAÇÕES E PRECAUÇÕES PARA A ADMINISTRAÇÃO DE TIRZEPATIDA EM CRIANÇAS E ADOLESCENTES: ASPECTOS CLÍNICOS, FARMACOLÓGICOS E DE SEGURANÇA","Daniela Avila Rojas","2026","Aurum Editora eBooks","other","article","10.63330/aurumpub.068-029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0056258","Beinaglutide modulates abdominal subcutaneous adipose tissue microenvironment and lipid metabolism in diet-induced obese mice: a multi-omics analysis","Lihua Zhou","2026","SSRN Electronic Journal","preclinical","article","10.2139/ssrn.7571325",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056259","การใช tirzepatide ในการควบคมนำหนก","Arunsri Sittiwasutha","2024","Thai Journal of Hospital Pharmacy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056260","Glucagon-like peptide-1 regulates lipid metabolism through actions in the gut and liver","Gary F. Lewis","2026","Metabolism and Diseases","other","article","10.1016/j.metdis.2026.100023",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056261","Tirzepatide and Semaglutide in Type 2 Diabetes Mellitus and Obesity: A Comparative Assessment of Efficacy and Safety (Review)","E. M. Eliseeva","2026","Safety and Risk of Pharmacotherapy","nonrandomized_study","article","10.30895/2312-7821-2026-14-3-249-262",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056262","Efficacy and Safety of Oral Glucagon-like peptide 1 Receptor Agonists in Obesity and Overweight: a Systematic Review and Meta-analysis of Randomized Controlled Trials","Luiza Marinho Lopes","2025","Open Science Framework","systematic_review","article","10.17605/osf.io/84ch9",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0056263","¿Cuáles son los principales desafíos en el manejo glucémico del adulto mayor?","Carina Parisi","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056264","Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence","Diana-Maria Mateescu","2026","Pharmaceutics","other_trial","article","10.3390/pharmaceutics18101277",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0056265","Enfermedad cardiovascular en la mujer con diabetes","Celina Bertona","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056266","Innovación y alternativas farmacológicas para uso en la persona que vive con obesidad","María Yuma","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056267","Maturity onset diabetes of the young: Current insights into genetics, diagnosis and management","Qian Zhang","2026","World Journal of Diabetes","other","article","10.4239/wjd.123249",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056268","Polycystic Ovary Syndrome as a Metabolic Disorder Involving Insulin Resistance, Chronic Inflammation and Adipose Dysfunction","Gilmutdinova Kamila","2026","Journal of chemical health risks","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056269","Most potent GLP-1 therapy yet","Carissa Wong","2026","The New Scientist","other","article","10.1016/s0262-4079(26)01596-4",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056270","Boerhaave Syndrome: Case Report on a Rare Complication of Semaglutide Use","Molly McMahon","2026","Cureus","case_report","article","10.7759/cureus.117633",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056271","Oral Obesity Medicines in the Era of Cardiovascular–Kidney–Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification","Abdulhameed Alhazmi","2026","Drug Design Development and Therapy","other_trial","article","10.2147/dddt.s637685",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article; review"],["R0056272","GLP-1 RAS E BIOESTIMULADORES DE COLÁGENO: MECANISMOS E EVIDÊNCIAS NO REJUVENESCIMENTO FACE-CORPO","DAVI HENRIQUE DE SOUSA FERREIRA","2026","Editora Pasteur eBooks","other","article","10.59290/2050029026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0056273","Refractory Polymicrobial Fungal Keratitis Leading To Corneal Perforation And Requiring Therapeutic Penetrating Keratoplasty In A Patient Receiving Glp-1 Receptor Agonists: A Case Report","Mr Luis Alcalde Blanco","2026","ESCRS Abstracts","case_report","article","10.82333/e5ce-ga10",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056274","Semaglutide Alleviates Age-Related Dry Eye Disease By Restoring Lacrimal Gland Structure And Function","A/Prof. Honghua Yu","2026","ESCRS Abstracts","other","article","10.82333/qpdt-0113",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056275","Beyond Telogen Effluvium: Alopecia Phenotypes Associated With GLP-1 Receptor Agonists and a Dermatologist-Led Management Framework (Preprint)","Raj Patel","2026",null,"randomized_trial","article","10.2196/preprints.113526",null,null,null,null,"openalex","FALSE","paywalled","2","FALSE","preprint"],["R0056276","Recomendaciones nacionales sobre lipodistrofia","Amanda Benitez","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056277","Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review","Aditya Kumar Gupta","2026","Medical Sciences","systematic_review","article","10.3390/medsci14060652",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0056278","Diabetic Nephropathy is One of the Biggest Complications of Diabetes",null,"2026","Current Research in Diabetes & Obesity Journal","other","article","10.19080/crdoj.2026.19.556003",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056279","UBTI as a Permissive Environment Index: A Pre-Intervention Readiness Test for External Interventions","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23253928",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056280","Intervención nutricional","Estrella Menéndez","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056281","IMPACT OF GLP-1 RECEPTOR AGONISTS ON LIVER ENZYMES AND FIBROSIS SCORES IN TYPE 2 DIABETIC AND NON-DIABETIC PATIENTS WITH FATTY LIVER DISEASE","Dr. Uroosh Tariq Khanzada, Dr. Fatima Jehangir, Dr Rukhsana Rashid, Dr. Shariq Nawab, Dr. Ambrina Qavi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23260006",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056282","CHILDHOOD OBESITY AND GLP-1 RECEPTOR AGONISTS: CURRENT EVIDENCE, CHALLENGES AND FUTURE PERSPECTIVES – A NARRATIVE REVIEW","Wiktoria Skowron","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(51).2026.6241",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0056283","Utilidad del péptido C: ¿cómo, cuándo y dónde?","Adrián Proietti","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056284","Abordaje de la diabetes tipo 2 en la población pediátrica y adolescente","Carla Mannucci","2026","Revista de la Sociedad Argentina de Diabetes","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056285","Fini les injections : comment l’orforglipron simplifie le traitement du diabète","Shaïli Baer","2026","JMIG","other","article","10.53738/revmed.2026.22.978.48917",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056286","PQ-12674-21 - Richard Boyd Barrett","Health Service Executive","2021","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056287","Desde la esteatosis al riesgo cardiorrenal","Alessandro Mantovani","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056288","Generic GLP-1 receptor agonists in India: an opportunity to close the cardiovascular evidence gap","Mohammad Riashad Monjur","2026","The Lancet Regional Health - Southeast Asia","other_trial","article","10.1016/j.lansea.2026.100880",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0056289","Nefropatía y albuminuria: la entrada al riesgo cardiovascular. Uso de ISRAA y fármacos nefroprotectores","Florencia Aranguren","2026","Revista de la Sociedad Argentina de Diabetes","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056290","Obesidad y síndrome metabólico: de la doble diabetes al riesgo aterosclerótico","Natalia Nardelli","2026","Revista de la Sociedad Argentina de Diabetes","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056291","Safety and efficacy of the insulin Degludec/Liraglutide co-formulation compared to multiple daily insulin injections in the transition from hospital to uutpatient management in patients with type 2 diabetes, evaluated by continuous glucose monitoring : the DELI-transition trial","Lina Paola Villamil Castañeda","2024","Repositorio Institucional (Pontificia Universidad Javeriana)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0056292","Metabolic Rejuvenation in Type 2 Diabetes: A Network Biology Perspective on Functional Restoration and Disease Modification","Hiroshi Yamamoto","2026","Diabetology","other","article","10.3390/diabetology7100195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056293","GLP-1 receptor agonists for organ protection and survival in preclinical models of sepsis: a systematic review and meta-analysis","Sai‐Wai Ho","2026",null,"systematic_review","article","10.37766/inplasy2026.10.0029",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","report"],["R0056294","Complicaciones oculares y nuevos tratamientos para la diabetes: ¿qué sabemos hoy?","Santiago Lima","2026","Revista de la Sociedad Argentina de Diabetes","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056295","Real-World Effectiveness, Documented Adverse Events, and Treatment Adherence of Semaglutide and Liraglutide in Omani Patients: A Retrospective Observational Study","Najwa Al Himali","2026","Journal of Clinical Medicine","nonrandomized_study","article","10.3390/jcm15207797",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056296","Adultos: fármacos aprobados y su aplicación en la práctica clínica","Pilar Cean","2026","Revista de la Sociedad Argentina de Diabetes","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056297","Effects of glucagon-like peptide-1 receptor agonists on asthma outcomes in patients with obesity and/or metabolic comorbidities: a systematic review of observational cohort studies","Saad Alhumaid","2026","BMC Pulmonary Medicine","systematic_review","article","10.1186/s12890-026-04798-8",null,null,"PROSPERO:CRD420261361548",null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0056298","COMORBIDITY BETWEEN OBESITY AND MIGRAINE, POSSIBLE IMPACT OF GLP-1 RECEPTOR AGONISTS ON THE COURSE OF MIGRAINE – A NARRATIVE REVIEW","Inga Kokuszko","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(51).2026.6163",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0056299","Comorbidity in Internal Medicine: Shared Mechanisms of Cardiovascular, Metabolic and Kidney Diseases","Ulyana Likhosherstova","2026","Journal of chemical health risks","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056300","ประสทธภาพของยาลดระดบนำตาลในเลอดในการลดนำหนกสำหรบผปวยโรคอวนทมโรคเบาหวานประเภทท 2 รวมดวย","Kankanok Chaipadung","2024","Thai Journal of Hospital Pharmacy","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0056301","GLP-1 AGONISTS IN PSYCHIATRY — A NEW THERAPEUTIC DIRECTION FOR DEPRESSION, ADDICTIONS, AND EATING DISORDERS","Karolina Klusek","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(51).2026.6114",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056302","Cutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Samyak Ganjre","2026","Cureus","systematic_review","article","10.7759/cureus.117270",null,null,"PROSPERO:CRD420261464289",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056303","POTENTIAL USE OF GLP-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF CHRONIC PAIN SYNDROMES: ANTI-INFLAMMATORY AND NEUROPROTECTIVE PERSPECTIVES","Dominika Krupnik","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(51).2026.6275",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056304","P173 GLP-1 THERAPIES AND CARDIOVASCULAR OUTCOMES IN YOUNG-ONSET TYPE 2 DIABETES: A GLOBAL TARGET TRIAL EMULATION ACROSS 275 MILLION PATIENTS","M. Lakhani","2026","Canadian Journal of Cardiology","nonrandomized_study","article","10.1016/j.cjca.2026.07.166",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0056305","THE SOCIAL PARADIGM SHIFT IN OBESITY MANAGEMENT: PSYCHOLOGICAL IMPACTS AND STIGMA REDUCTION IN THE ERA OF GLP-1 AGONISTS","Jakub Klepacz","2026","International Journal of Innovative Technologies in Social Science","other","article","10.31435/ijitss.3(51).2026.6638",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056306","ROLE OF DPP-IV INHIBITORS IN TREATMENT OF TYPE II DIABETES","Patel Kishan D","2010","International Research Journal of Pharmacy","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056307","Warning of the Risk of Acute Pancreatitis with GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists: MHRA Information","N. Yu. Velts","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056308","Emerging pharmacological treatment options for MASLD/MASH","Jimena Soto-Campillo","2026","Metabolism and Target Organ Damage","other","article","10.20517/mtod.2026.124",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056309","OBESITY, ENDOMETRIOSIS, AND GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW","Oliwia Wróblewska","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(51).2026.6411",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0056310","Estrategias de tratamiento en personas con diabetes","Susana Fuentes","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056311","PQ-11172-21 - David Cullinane","Health Service Executive","2021","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056312","GLP-1 Receptor Agonists for Prevention of Stroke and Ischaemic Cerebrovascular Events in Type 2 Diabetes Mellitus: A Trial-Level Meta-analysis","Zaid Nabeel Alkhalidi","2026","SN Comprehensive Clinical Medicine","systematic_review","article","10.1007/s42399-026-02747-4",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","article"],["R0056313","MASLD y grasa ectópica","Belén Redolfi","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056314","Engineering E. coli Nissle 1917 for production and outer membrane vesicle-mediated delivery of a computationally designed GLP-1R/GIPR/GCGR tri-agonist","Daliang Huo","2026","Microbial Cell Factories","preclinical","article","10.1186/s12934-026-03141-4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056315","A coordinated paracrine islet cell network regulating β-cell Ca2+ dynamics","Philip Tröster","2026","Advances in Biological Regulation","preclinical","article","10.1016/j.jbior.2026.101184",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056316","Nuevos tratamientos en diabetes ¿qué tenemos y a qué accedemos en Latinoamérica?","Edgar Mora","2026","Revista de la Sociedad Argentina de Diabetes","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056317","Enfermedad arterial periférica: la complicación olvidada","Maria Ranz","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056318","PQ-12672-21 - Richard Boyd Barrett","Health Service Executive","2021","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056319","PQ-12969-21 - Cormac Devlin","Health Service Executive","2021","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056320","Tratamiento farmacológico en la diabetes tipo 2","Alejandra Cicchitti","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056321","Obesidad en la etapa menopaúsica","Paola Polo","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056322","Musculoskeletal health in people living with obesity and the effects of glucagon-like peptide-1 receptor agonists on bone, muscle, and joints: a narrative review","Julien Paccou","2026","Therapeutic Advances in Musculoskeletal Disease","randomized_trial","article","10.1177/1759720x261460301",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0056323","Nuevos tratamientos en diabetes ¿qué tenemos y a qué accedemos en Latinoamérica?","Andrea Ortiz","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056324","¿Cuándo es el momento de iniciar insulinoterapia en diabetes tipo 2?","Jimena Soutelo","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056325","Diabetes en personas que viven con VIH","Ramiro Heffes","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056326","EXPLORE THE LATEST ADVANCEMENT IN DIABETES MANAGEMENT INCLUDING NEW MEDICATION AND LIFESTYLE INTERVENTIONS","Hamdullah","2025","The Research of Medical Science Review","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056327","Efficacy and Safety of Oral GLP-1 Receptor Agonists for Weight Loss in Adults Without Diabetes: An Updated Meta-Analysis","Mukesh Kumar Sharma","2026","OSF Preprints (OSF Preprints)","systematic_review","article","10.17605/osf.io/fker5",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","preprint"],["R0056328","GLP-1 Receptor Agonists Beyond Metabolic Control: Cardiovascular Benefits, Renal Protection, Neurological Effects and Socioeconomic Implications of Widespread Use.","Weronika Wrona","2026","Quality in Sport","other","article","10.12775/qs.2026.77.76169",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056329","Intervenciones farmacológicas","GUSTAVO FRECHTEL","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056330","Anestesia em pacientes com obesidade: evolução das evidências científicas e desafios na prática clínica","Sara Fim Rodrigues","2026","Revista fisio&terapia.","other","article","10.69849/myre2648",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056331","Investigating risk of cancer with SGLT-2 Inhibitors: A Case/Non-Case Study in the WHO Global Pharmacovigilance Database Vigibase","P. Gautier","2025","Archives of cardiovascular diseases","nonrandomized_study","article","10.1016/j.acvd.2024.10.254",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056332","Neuroprotective efficacy of semaglutide in preclinical in vivo rodent models: a systematic review and quantitative meta-analysis","Ekaterina Chepeleva","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/ht6xe",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0056333","Suicidal Ideation and Glucagon-like Peptide-1 Receptor Agonists: An Examination of Real-Word Data Gathered from the European Pharmacovigilance Database","B.KrishnaKrishn","2022","International Journal of Pharmacetical Sciences Letters","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056334","Heterogeneous response to semaglutide in long-standing T2DM and obesity: a case report","Nur Asilah Shariffudin","2026","UiTM Institutional Repositories (Universiti Teknologi MARA)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0056335","Semaglutide and Obesity: Real-World Clinical Applications and Outcomes","Swati Sucharita Dash","2024","International Journal of Medical Science Research and Practice","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056336","Flare of knee osteoarthritis triggering weight regain despite semaglutide therapy: a case report","Siti Norasikin Ah","2026","UiTM Institutional Repositories (Universiti Teknologi MARA)","case_report","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056337","A-129 Enhanced Suppression of PANC-1 Cell Viability by Combined Semaglutide and Vitamin D Treatment","Gloria Rashid","2026","Clinical Chemistry","other","article","10.1093/clinchem/hvag086.103",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0056338","Efektivitas Obat Generasi Baru (Amylin-based, CagriSema) dalam Mengelola Obesitas sebagai Penyakit Kronis","Yoga Prasetyo","2026","MUARA KESEHATAN Jurnal Ilmiah Ilmu Kesehatan","nonrandomized_study","article","10.64365/murakes.v2i3.365",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056339","1.43 Weight and Metabolic Outcomes Following GLP-1 Receptor Agonist Initiation in Youth Receiving Atypical Antipsychotics","Lucia Liu","2026","Journal of the American Academy of Child & Adolescent Psychiatry","other","article","10.1016/j.jaac.2026.08.077",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056340","Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study","Wan-Hsuan Hsu","2026","Frontiers in Pharmacology","randomized_trial","article","10.3389/fphar.2026.1917340",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056341","Semaglutide: A Tool to Empower Indian Women Against the Twin Challenges of Diabetes and Weight","Tejal Bipin Lathia","2026","Journal of Diabetology","other","article","10.4103/jod.jod_44_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056342","1.23 Pharmacovigilance Analysis of Psychiatric Adverse Events Associated With Semaglutide and Liraglutide","Qiyang Pan","2026","Journal of the American Academy of Child & Adolescent Psychiatry","nonrandomized_study","article","10.1016/j.jaac.2026.08.057",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056343","Alzheimer's Disease and the GLP-1 Receptor: Pathophysiology, Mechanisms and Therapeutic Evidence.","M. pavani","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.23116131",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0056344","The ghrelin gene products and exendin-4 promote survivalof human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways.","Enrica Favaro","2012","Institutional Research Information System University of Turin (University of Turin)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056345","Comparing Allopathic and Herbal Treatments in Non-Alcoholic Fatty Liver Disease: A Novel Review of Emerging Phytopharmacological Interventions","H. S. Mamatha","2025","Journal of Neonatal Surgery","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056346","Síndromes Coronarios Agudo con intervención coronaria percutáneo","Deyaneira Marcela Chávez Ruiz","2025","Polo del Conocimiento","other","article","10.23857/pc.v10i10.10618",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056347","Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes","Sarwat Anjum","2024","History of Medicine/ru","nonrandomized_study","article","10.17720/h7ycmf16",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056348","Gastronomic displeasure? When medicines alter taste and food enjoyment","J. Paulo-Fernandes","2026","Food and Humanity","nonrandomized_study","article","10.1016/j.foohum.2026.101561",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056349","Efektivitas dan Keamanan Pengobatan Farmakologis pada Pasien Diabetes Melitus Tipe 2: Systematic Literature Review","Meilinda Ayu Saputri","2026","Jurnal Lantera Ilmiah Keperawatan","randomized_trial","article","10.52120/p1w10b74",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","review"],["R0056350","Tirzepatide-associated non-hyperglycemic ketosis and ketoacidosis: a pharmacologically amplified starvation response with a potential role for glucagon","Seiji Nishikage","2026","Figshare","other","article","10.6084/m9.figshare.33991366",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056351","The Effect Of Metformin On Clinical And Metabolic Outcomes In Women With Polycystic Ovary Syndrome: A Systematic Review And Meta-Analysis","Moamen Abdelfadil Ismail, Ali Khalifah Alkhalifah, Ayman Fahad Alshammari, Fay Fahad Aljumah, Shouq Waleed Almgamsi5, Razan Saud Alshalawi, Maram Abdullah Almatrafi","2025","The Review of Diabetic Studies","systematic_review","article","10.70082/6aq1as96",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0056352","REVIEW ON ROLE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN CARDIOVASCULAR DISEASE IN CONJUGATION WITH OBESITY MANAGEMENT","Dr. Sai Pallavi Tata","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.22975739",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056353","Riscos e benefícios da terapia medicamentosa para emagrecimento em mulheres no Brasil","Escarlet Evangelista de Souza","2024","Journal of Multidisciplinary Sustainability and Innovation","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056354","Glucagon-Like Peptide-1 Receptor Agonist and Gastrointestinal Adverse Effects: A Comprehensive Review","Julio Zúñiga Cisneros","2026","Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana","narrative_review","article","10.52787/agl.v56i3.690",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056355","INDUCTION OF FERTILITY THROUGH THE MANAGEMENT OF INCRETIN MIMETIC DRUGS IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME","GIOVANNA SACRAMENTO SLUZEK FACCIOLI","2025","CIPEEX","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056356","Relación con la conducta ingestiva y elección del tratamiento farmacológico","Susana Gutt","2024","Revista de la Sociedad Argentina de Diabetes","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056357","THERAPY WITH GLP-1 AGONISTS AND DIPEPTIDYL-PEPTIDASE IV INHIBITORS IN TYPE 2 DIABETES MELLITUS","Rigas F. Nikos","2011","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056358","Terapia combinada con GLP-1 e iSGLT2: ¿mayor impacto cardiorrenal?","Gustavo Lavenia","2026","Revista de la Sociedad Argentina de Diabetes","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056359","Global Research Landscape of Diabetes Mellitus Type 2 in the SGLT2 Inhibitors and GLP-1 Receptor Agonists Era: A Bibliometric Analysis of The Top 1000 Publications","AlObaid Abdulrahman","2026","International Journal of Medicine in Developing Countries","nonrandomized_study","article","10.24911/ijmdc.51-1786306992",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056360","Obesidad en el adulto mayor: ¿cuándo tratar con fármacos?","Romina Clemente","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056361","GLP-1 RA : Efektivitas Terapi Dalam Mengurangi Komplikasi Mikrovaskular Organ Ginjal Pada Penderita Diabetes Melitus Tipe 2","Mohd Ilham Fat-Thur Rahman","2024","Best Journal (Biology Education Sains and Technology)","other","article","10.30743/best.v7i2.10352",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056362","Beyond the scale: evaluating skeletal muscle preservation and its impact on metabolic health during GLP-1RA therapy.",null,null,"Digital Repository Service (Northeastern University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056363","O USO DE ANÁLOGOS DE GLP-1 NO CONTROLE DA GLICEMIA E OS SEUS BENEFÍCIOS CARDIOVASCULARES: UMA REVISÃO DE LITERATURA","Jordanna Maia Onofre Pereira","2023","Informativo Técnico do Semiárido","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056364","From Adipose Tissue Dysfunction to Venous Thromboembolism","Andrea Boccatonda","2026","Journal of Clinical Medicine","randomized_trial","article","10.3390/jcm15197500",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056365","El doble desafío del manejo del peso: evaluación del impacto de los agonistas del receptor GLP-1 sobre la masa corporal magra en ensayos clínicos globales (2020–2025)","Yasir Mohammed Zaroug Elradi","2025","Revista de Ciencias Médicas de Pinar del Río","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056366","GLP-1RA Exposure and Incident Persistent Cytopenias","James Brogan","2026","International Journal of Cancer Care and Delivery","other","article","10.53876/001a.129890",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056367","USE OF OZEMPIC FOR WEIGHT LOSS IN NON-DIABETIC INDIVIDUALS: ETHICAL AND HEALTH IMPLICATIONS","Ellen Cristina Ribeiro da Silva","2025","CIPEEX","randomized_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","2","FALSE","article"],["R0056368","Cardiometabolic therapy for rhythm control: A case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity","Frederike Marie Weitkamp","2026","European Heart Journal - Case Reports","case_report","article","10.1093/ehjcr/ytag727",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056369","ภาวะนำหนกลดจากยายบยง Sodium-glucose co-transporter 2","Sornwichate Rattanachaiwong","2021","Thai JPEN วารสารโภชนบำบัด","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056370","Using glucagon-Like Peptide-1 Agonists for Post-Bariatric Surgery: A Narrative Review","Bahador Oshidari","2026","Novelty in biomedicine","narrative_review","article","10.22037/nbm.v14i1.49143",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0056371","Cardiovascular outcomes of oral incretin-based drugs in type 2 diabetes: a GRADE-assessed meta-analysis of 67,679 patients","Muhammad Faizan Ali","2026","Frontiers in Cardiovascular Medicine","systematic_review","article","10.3389/fcvm.2026.1884895",null,null,"PROSPERO:CRD420251113835",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056372","Anti-Obesity Medications Versus Metabolic Bariatric Surgery as Pathways to Heart Transplant Eligibility in LVAD-Supported Patients: A Narrative Review","Noah Sicouri","2026","Journal of Clinical Medicine","nonrandomized_study","article","10.3390/jcm15197489",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","review"],["R0056373","P187 POPULATION-LEVEL IMPLICATIONS OF INCREASING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST UPTAKE AMONG TREATMENT ELIGIBLE CANADIANS: A DECISION ANALYSIS","R. Kanji","2026","Canadian Journal of Cardiology","other","article","10.1016/j.cjca.2026.07.179",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0056374","Role of energy metabolism disorders in renal tubular epithelial cells in the pathogenesis and progression of diabetic kidney disease","T. Liu","2026","DOAJ (DOAJ: Directory of Open Access Journals)","other","article","10.12467/j.issn.2096-3882.20250689",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056375","Repurposing metabolic drugs: Anti-diabetic and anti-obesity agents with potential in cancer therapy","Daniel Ejim Uti","2026","Obesity Medicine","nonrandomized_study","article","10.1016/j.obmed.2026.100747",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056376","Effects of GLP-1 Medications on Causal Attributions of Weight and Weight Stigma","Persky, Susan","2023","OSF Preprints (OSF Preprints)","other","article","10.17605/osf.io/xme4w",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056377","Assessment of the Effectiveness of Glp-1 Agonists in Non-Alcoholic Fatty Liver Disease Associated With Obesity and Insulin Resistance","Sadykova Shakhboza Shakhobiddinovnа","2025","International Journal of Integrative and Modern Medicine","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056378","Beyond Glycemic Control: Tirzepatide in a Woman With Prior Gestational Diabetes and High Cardiometabolic Risk","Augusto Carducci","2026",null,"other","article","10.63620/mkjgomh.2026.1047",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056379","Development of a Polar Tag Platform for Sustainable Tag-Assisted Liquid-Phase Peptide Synthesis (TA-LPPS)","David Ndaleh","2026","ACS Sustainable Chemistry & Engineering","other","article","10.1021/acssuschemeng.6c05800",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056380","ANALYSIS OF THE RELEVANCE OF MEASURES TO IMPROVE PHARMACOTHERAPY FOR KIDNEY DISEASES","Sokhib Rashidov Zamon o'g'li,Davronbek A'zamov Salim o'g'li,Zukhriddin Oʻrishboev Alisher oʻgʻli","2026","International Multidisciplinary Journal for Research & Development","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056381","Yurak-qon tomir-buyrak-metabolik sindrom (YQTMB sindrom) haqida umumiy koʻrinish","Gulshon Mukhitdinova","2025","Профилактическая медицина и здоровье","other","article","10.47689/2181-3663-vol4-iss3-pp57-70",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056382","Quality and sustainability of weight loss with injectable incretin therapies in adults with obesity: an umbrella review of systematic reviews and meta analyses","Danilo Ferreira de Sousa","2026","Journal of Social Issues and Health Sciences (JSIHS)","systematic_review","article","10.5281/zenodo.22207914",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0056383","GLP-1 Based Therapies for Obesity in Older Adults: Current Evidence and Emerging Treatments","Anna Pendrey","2026","Global Journal of Obesity Diabetes and Metabolic Syndrome","other","article","10.17352/gjodms.000071",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056384","OC 51.5 Impact of Bariatric Surgery, Semaglutide, and Tirzepatide on Thromboembolism and ISTH Major Bleeding in Obese Adults: A Multicenter TriNetX Cohort Study","Sujan Niraula","2026","Research and Practice in Thrombosis and Haemostasis","nonrandomized_study","article","10.1016/j.rpth.2026.103718",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056385","Modulation of the inflammatory profile and metabolic endotoxemia by passiflora ligularis juss in adults with obesity","Luz Adriana López González","2026","Cahiers de Nutrition et de Diététique","randomized_trial","article","10.1016/j.cnd.2026.08.044",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056386","Assessing the potential protective effects of tirzepatide against renal ischaemia-reperfusion injury in male rats: inhibition of Foxo1 expression and pyroptosis","Hajir Karim Abdul-Husseein","2025","Pharmakeftiki","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056387","Additional file 1 of Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study","Phyo Than Htoo","2026","Figshare","other","article","10.6084/m9.figshare.34132017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056388","GLP-1 Receptor Agonists and Eating Disorders: Emerging Evidence, Risks, and Clinical Considerations","Felicia G. Gallucci","2026","Journal of the American Academy of Child & Adolescent Psychiatry","other","article","10.1016/j.jaac.2026.07.325",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056389","Differential functions of ROCK1 and ROCK2 in liver fibrosis and advances in targeted therapeutic strategies","Ting He","2026","Frontiers in Pharmacology","randomized_trial","article","10.3389/fphar.2026.1929302",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056390","FGF21 Contributes to Metabolic Improvements Elicited by Exenatide and Pioglitazone in Patients with Type 2 Diabetes","Ricardo J. Samms","2022","UEF eRepo (University of Eastern Finland)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056391","P058 THE ROLE OF GLP-1 RECEPTOR AGONISTS IN THE PREVENTION OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION IN BREAST CANCER (GLACIER STUDY)","O. Oyateru","2026","Canadian Journal of Cardiology","other","article","10.1016/j.cjca.2026.07.067",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0056392","IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis","Mahmoud Ismail Nouh","2026","Cureus","systematic_review","article","10.7759/cureus.116875",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056393","40.3 Prescribing GLP-1 Receptor Agonists in Pediatric Obesity: Practical Dosing and Monitoring Considerations","Hiba Salhah","2026","Journal of the American Academy of Child & Adolescent Psychiatry","other","article","10.1016/j.jaac.2026.07.272",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056394","Os efeitos dos agonistas dos receptores de GLP-1 sobre a perda de peso em adultos: revisão sistemática","Daniel Castro dos Santos","2024","Revista Educação em Saúde/Revista Educação em Saúde Unievangélica","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056395","Impactos nutricionais dos efeitos colaterais da terapia com análogos de GLP-1em pacientes com obesidade: um estudo umbrella de revisões sistemáticas e meta-análises","Filipe Lacerda Leopoldino","2025","Revista brasileira de obesidade, nutrição e emagrecimento","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056396","RESPONSE OF COMBINED TREATMENTS FOR OBESITY AND TYPE 1 DIABETES WITH GLP-1","Syeda Quratulain Farhan","2024","Journal of Population Therapeutics and Clinical Pharmacology","other","article","10.53555/2bbfv043",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056397","2-TUR DIABET VA SEMIZLIGI BOR BEMORLARDA GLP-1 RETSEPTORI AGONISTINING YURAK-QON TOMIR TIZIMIGA TA'SIRI","Саидова Шахноза Ариповна","2025","Journal of Biomedicine and Practice","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056398","Impact of GLP-1 Receptor Agonists on Cognitive Performance in Adults at Risk of Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","Angela Marie Abbatecola","2026","Nutrients","systematic_review","article","10.3390/nu18203312",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0056399","Evaluation of the Anti-Obesity Effect of Sitagliptin in Animal Model of Obesity","Mohit Kulmi","2024","International Archives of BioMedical and Clinical Research","preclinical","article","10.21276/fd4p2585",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056400","Enfoques clínicos preventivos en el envejecimiento activo","Dario Martínez-Vázquez","2026","Revista de Ciencias Médicas de Pinar del Río","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056401","PB1059 Glucagon-like peptide-1 receptor agonists are associated with reduced Endogenous Thrombin Potential in subjects with type 2 diabetes mellitus: results from an observational cardiovascular cohort study","Nicola Osti","2026","Research and Practice in Thrombosis and Haemostasis","nonrandomized_study","article","10.1016/j.rpth.2026.103922",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","conference-abstract"],["R0056402","Metabolic Implications of Obesity in Polycystic Ovary Syndrome: A Systematic Review of Current Evidence and Therapeutic Strategies","Katarzyna Marut","2026","African Journal of Biomedical Research","systematic_review","article","10.69980/8vsmth73",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0056403","PHARMACOLOGICAL ASSOCIATION OF ATOGEPANT AND TIRZEPATIDE: PRELIMINARY CLINICAL SAFETY PROFILE IN A CASE SERIES: S. Sorrenti1, M. Ciuffreda1, E. Pisello1, C. Pellegrino2, A. Monacelli2, G. Cucè3, C. Piangatelli1, D. Galante4 | 1U.O.C. Anestesia Rianimazione Terapia del Dolore, AST Ancona, Fabriano (AN), Italy; 2Scuola di Specializzazione in Anestesia Rianimazione, Terapia Intensiva e del Dolore, Università Politecnica delle Marche, Ancona, Italy; 3Scuola di Specializzazione in Igiene e Medicina Preventiva, Università degli Studi di Messina, Italy; 4U.O.C. Anestesia e Rianimazione, ASL Foggia, Cerignola (FG), Italy",null,"2026","Advancements in health research.","case_report","article","10.4081/ahr.2026.282",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056404","Multimorbilidad geriátrica ECNT: HTA-DM2-ECVH-Brechas terapéuticas","Alex Diaz Barzola","2026","Journal of America health","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056405","Renal and cardiovascular effects of glucagon-like peptide receptor agonists in established chronic kidney disease: Systematic review and meta-analysis","Kirolos Eskandar","2026","World Journal of Nephrology","systematic_review","article","10.5527/wjn.126698",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056406","Gastric ultrasound as a decision-making tool in the anesthetic management following recent discontinuation of a glucagon-like peptide-1 receptor agonist: a case report","Letícia Lopes MACHADO","2026","Perioperative Anesthesia Reports","case_report","article","10.61724/2965-3681/e00132026",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056407","ASSESSMENT OF AWARENESS OF SAFE SEMAGLUTIDE USE, NUTRITIONAL SUPPORT, AND ASSOCIATED SIDE EFFECTS AMONG IRAQI ADULTS SEEKING WEIGHT LOSS","Zainab G. Aljassim","2026","Asian Journal of Pharmaceutical and Clinical Research","other","article","10.22159/ajpcr.2026v19i10.60572",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056408","OZEMPIC®: O Impacto da Semaglutida no Tratamento da Diabetes e Obesidade","Carolina Cunha Baptista","2025","ACTA MSM - Periódico da EMSM","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056409","OC 74.3 Paradoxical Thrombotic Risk: The Impact of GLP-1 RAs on VTE Incidence Among Obese Hormonal Contraceptive Users","Colton Jones","2026","Research and Practice in Thrombosis and Haemostasis","other","article","10.1016/j.rpth.2026.103831",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056410","Therapeutic role of the dimerized Kringle 1 domain of hepatocytegrowth factor/scatter factor in liver disease and diabetes","Michele Lodato","2024","HAL (Le Centre pour la Communication Scientifique Directe)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0056411","Beyond the Procedure Day: Chronic Gastrointestinal and Nutritional Sequelae of Sustained Glucagon-Like Peptide-1 Receptor Agonist Therapy: Implications for the Internist","Ahmed Salman","2026",null,"other","article","10.14740/jcp5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056412","Graphical Abstract: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE®-MASLD, a randomised, double-blind, placebo-controlled phase 3 trial","Lee M. Kaplan","2026","Boehringer Ingelheim","randomized_trial","article","10.60915/boehringer-figshare.33995691",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0056413","Novel Pharmacological Advancements in Obesity Management. The era of incretins and their analogs","Charalampos Triantis","2026","Pharmakeftiki","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0056414","GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity–Neurodegeneration Interface: A Narrative Review","Elena Popa","2026","International Journal of Molecular Sciences","randomized_trial","article","10.3390/ijms27198738",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0056415","Effects of Liraglutide Combined with Low Fat Diet on Neural and Thermogenic Activities of 5' - AMPK in the Hypothalamus: Expectations","Hayder Al-Domi","2022","Progress in nutrition","other","article","10.23751/pn.v24i1.11502",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056416","GLP‑1 receptor agonists and their dental implications: A practical guide for dental practitioners (Review)","David Kadakampally","2026","World Academy of Sciences Journal","nonrandomized_study","article","10.3892/wasj.2026.514",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056417","Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework","Ahmed Elhassan","2026","Cureus","randomized_trial","article","10.7759/cureus.117614",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056418","Comparative Assessment of Metformin vs GLP-1 RAs on Triad of Metabolic Syndrome Among Diabetics: An Observational Study","Majid Khan","2026","Pakistan Journal of Medical & Cardiological Review","other","article","10.66021/pakmcr1570",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056419","Heterogenidad de la diabetes en el adulto mayor","GUILLERMO UMPIERREZ","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056420","Emerging and Disease-Modifying Treatments for Alzheimer’s Disease: Current Evidence, Safety, and Future Directions","Mateusz Stefański","2026","African Journal of Biomedical Research","randomized_trial","article","10.69980/p3pezf52",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0056421","Efficacy And Safety Of GLP-1 Receptor Agonists In The Management Of Obesity Among Saudi Adults: A Systematic Review","Moamen Abdelfadil Ismail, Hadeel Abdullah Al-Rashidi, Asmaa Y. Alotaibi, Shadin Abdullah Albebi, Razan Abdulmohsen Alqarni, Abdulaziz Yousef Alfredi, Afnan Ahmed Alsahli","2025","The Review of Diabetic Studies","systematic_review","article","10.70082/9dsp4e91",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0056422","GLP1 Agonists Beyond Established Therapeutic Indications: A Narrative Review of Emerging Therapeutic Applications","Usmaan Hafeez Farooq","2026","Scholars Journal of Applied Medical Sciences","randomized_trial","article","10.36347/sjams.2026.v14i09.004",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","review"],["R0056423","Maternal and Fetal Outcomes Following Preconceptional and Early Pregnancy Exposure to Glucagon-Like Peptide-1 Receptor Agonists: A Review of Current Evidence","Angeliki Gerede","2026","Open Science Framework","preclinical","article","10.17605/osf.io/t5qd2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056424","Semaglutide and Neuroprotection: Exploring Mechanisms Against Ischemia-Reperfusion Injury Beyond Glycemic Control","El-Sayed Mohamed  Kamel, Amira Mohamed Abdelhamid, Haidy Mohamed Ali Mohamed ,  Yasmeen Mahmoud Elsayed","2024","Cuestiones de Fisioterapia","other","article","10.48047/5fa5a083",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056425","Optimising metabolic outcomes using glp-1 receptor agonist therapy in severe obesity and poorly controlled diabetes mellitus","Nur Haziqah B","2026","UiTM Institutional Repositories (Universiti Teknologi MARA)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056426","Dermatology in the Age of Obesity: The Good, the Bad, and the Ugly of GLP‐1 Receptor Agonists and Tirzepatide","Sebastian Guerrero L ́ópez","2026","Dermatologic Therapy","randomized_trial","article","10.1155/dth/5742100",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056427","Цукровий діабет 2-го типу і хронічна хвороба нирок: сучасні можливості цукрознижувальної терапії","О.М. Didushko","2020","The Practitioner","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056428","Liraglutide as an effective tool for obesity management in type 1 diabetes – case report","Федір Ланюш","2023","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","case_report","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056429","5.4 GLP-1 Receptor Agonists In Youth With Mental Disorders: Evidence-Based Application and Development/Repurposing as Psychiatric Drugs","Roger S. McIntyre","2026","Journal of the American Academy of Child & Adolescent Psychiatry","other","article","10.1016/j.jaac.2026.07.844",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056430","EFEITOS DELETÉRIOS DO USO DE AGONISTAS DE GLP-1 NA CIRURGIA: UMA REVISÃO NARRATIVA","Isabella Vilela Dias","2025","Anais do Momento Científico da IFMSA Brazil","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056431","THE UNSEEN COST OF WEIGHT LOSS: PREVENTING VISION LOSS IN THE GLP-1 ERA","Halima Sadia","2026","Pakistan Journal of Medical & Cardiological Review","other","article","10.66021/pakmcr908",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056432","Efeitos da semaglutida nas funções renais e cardiovasculares em pacientes com diabetes mellitus tipo 2: uma revisão integrativa","Amanda Brun Clemente","2025","Revista Educação em Saúde/Revista Educação em Saúde Unievangélica","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056433","Renal function in patients with Type 2 diabetes treated with glucagon-like peptide 1 (GLP-1) analogues","A.J. Heggie","2013","Newcastle University ePrints (Newcastle Univesity)","other","article","10.25405/ncl.34225743",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0056434","Long-Term Effects of GLP-1 and GIP Receptor Agonists on Quality of Life: A Systematic Review","Sophie Awad","2026","Current Developments in Nutrition","systematic_review","article","10.1016/j.cdnut.2026.109114",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0056435","Gastric residual volume in patients with obesity receiving GLP-1 receptor agonists: A comparative gastric ultrasound pilot study","Abdulaziz Ejaz Ahmad","2026","Saudi Journal of Anaesthesia","other","article","10.4103/sja.sja_177_26",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056436","THE EFFICIENCY SEMAGLUTIDE FOR OBESITY WITH DIABETES WOMAN : REVIEW","A. Rialdi Prananda","2024","Jurnal Kesehatan Tambusai","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056437","A Novel Approach to Mitigating the Systemic Health Impacts of Postprandial Hyperglycemia","Mohammad Hesham Hoshmand","2026","Kateb Journal of Medical Sciences and Biotechnology","nonrandomized_study","article","10.66943/kjmsb.v4i1.69",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056438","CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis","Zehra Khatoon Rasool","2026","Frontiers in Endocrinology","systematic_review","article","10.3389/fendo.2026.1903335",null,null,"PROSPERO:CRD420261380458",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056439","Early treatment response to tirzepatide in obesity: a case series","Nur Haziqah B","2026","UiTM Institutional Repositories (Universiti Teknologi MARA)","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0056440","Lipodistrofia: impacto metabólico y desafíos terapéuticos","Carla Musso","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056441","Metabolic Syndrome in Patients Treated with Second-Generation Antipsychotics: Prevention, Monitoring and Management","Hazim Bozeyeh","2026","African Journal of Biomedical Research","randomized_trial","article","10.69980/ajbr.v29i1s.9727",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0056442","Cardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia","Guido Gembillo","2026","Medicina","randomized_trial","article","10.3390/medicina62101855",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056443","Future perspective of GLP-1 receptor agonists across the spectrum of steatotic liver disease","Kamela Gjini","2026","Hepatoma Research","other","article","10.20517/2394-5079.2026.70",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056444","Lorcaserin requires preproglucagon neurons to reduce food intake in mice and acts additively to liraglutide-induced hypophagia","N. U. Ertugrul","2022","DSpace - FIRAT (Fırat University)","preclinical","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-paper"],["R0056445","Potential Effects of Liraglutide on Male Reproductive Dysfunction Associated with Obesity","Mohamed Abdel Raouf ElGhannam, Reham Hassan Ibrahim, Nada Abdel Maksoud  Mohamed Salah Eldeen, Lamiaa Goda Mohammad","2024","Cuestiones de Fisioterapia","other","article","10.48047/kz03d733",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056446","GLP-1 Receptor Agonists and Total Knee Arthroplasty Outcomes: A Systematic Review","Damon Ross","2026",null,"systematic_review","article","10.61440/jop.2026.v4.64",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056447","P318 MICROVASCULAR ISCHEMIC RISK ASSOCIATED WITH SEMAGLUTIDE: A GLOBAL POPULATION-BASED ANALYSIS OF OVER 30 MILLION SAFETY REPORTS","A. Al-Ani","2026","Canadian Journal of Cardiology","nonrandomized_study","article","10.1016/j.cjca.2026.07.292",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","conference-abstract"],["R0056448","Preparedness Of Emergency Care Tactician Coordination For Complications Of Diabetes Associated Weight-Loss Pharmacotherapy: Roles Of Medical Secretarial Coordination In Nursing Practice, And X-Ray Imaging","Dalal Mutheb Alotybi, Mubarak Jaber Al Saleh, Ali Mahdi Al-Yami, Rana Ali Alzahrani, Mashael Alsulami, Khloud Mohammad Alqahtani, Zinab Ahmed Walis","2024","The Review of Diabetic Studies","nonrandomized_study","article","10.70082/8jp0e927",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056449","Avanços farmacológicos no tratamento da obesidade em adolescentes: revisão sistemática da literatura","Fernanda Abigail Mejía Cayancela","2026","Maestro y sociedad","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056450","Dual and triple incretin agonists in type 2 diabetes: A new frontier in metabolic therapy","Syed Afzal Uddin Biyabani","2026","International Journal of Pharmacy and Pharmaceutical Science","randomized_trial","article","10.33545/26647222.2026.v8.i10a.510",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056451","ВИЗНАЧАЛЬНІ НОВОВВЕДЕННЯ В РЕКОМЕНДАЦІЯХ АМЕРИКАНСЬКОЇ ДІАБЕТИЧНОЇ АСОЦІАЦІЇ ЗА 2025 РІК","O.P. Kikhtyak","2025","The Practitioner","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056452","Auto-adaptation des doses d’insuline basale en vie réelle : résultats de l’étude BASALIA","Blandine Tramunt","2026","Annales d Endocrinologie","other","article","10.1016/j.ando.2026.102925",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056453","Obesity pharmacotherapy: 2026 update recommendations for the care of persons with obesity in Romania","Cornelia Bala","2026","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","article"],["R0056454","Evaluation Of The Effect Of Rybelsus On The Histological Structure Of The Liver In The White Mouse","Thekra Atta Ibrahim","2024","Nanotechnology Perceptions","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056455","Sarcopenic obesity in older adults: the dual burden of muscle loss and fat gain. Clinical consequences, diagnostic challenges, and integrated management strategies","Harishchandra Rameshchandra Chaudhari","2026","Geriatric Care","other","article","10.4081/gc.2026.15195",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056456","Molecular signaling networks that connect tissue dysfunction to systemic insulin resistance","Rashid Mir","2026","Frontiers in Endocrinology","other","article","10.3389/fendo.2026.1952238",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056457","Timing of GLP-1 Receptor Agonist Initiation and Cardiovascular Events in Men Receiving Androgen Receptor Pathway Inhibitors","K.M. Atkins","2026","International Journal of Radiation Oncology*Biology*Physics","other","article","10.1016/j.ijrobp.2026.06.634",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056458","SGLT2 inhibitors versus GLP-1 receptor agonists and DPP-4 inhibitors for incident and recurrent nephrolithiasis: An EAU Endourology Systematic Review","Arianna Pischetola","2026","European Urology Open Science","systematic_review","article","10.1016/s2666-1683(26)01909-9",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0056459","5.66 GLP-1 Receptor Agonists and Transcranial Magnetic Stimulation for Adolescent Mood Disorders, Obesity, and Substance-Use Vulnerability: A Focused Review","Darius M. Hardie","2026","Journal of the American Academy of Child & Adolescent Psychiatry","narrative_review","article","10.1016/j.jaac.2026.08.395",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056460","OBGYN Involvement and Reproductive Outcomes in Reproductive-Aged Women Undergoing Bariatric Surgery","Sanjana Sharma","2026","North American Proceedings in Gynecology and Obstetrics - Supplemental","nonrandomized_study","article","10.54053/001c.171855",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056461","Advancing Knowledge, Collaboration, and Impact—Highlights from the FIU 2025 Diabetes Awareness Day","NOEL BARENGO","2026",null,"nonrandomized_study","article","10.25148/fiuir.156",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","preprint"],["R0056462","51.2 Benefits of GLP-1 Receptor Agonists in Adolescents With Obesity and Loss of Control Eating","Aisa M. Moreno-Megui","2026","Journal of the American Academy of Child & Adolescent Psychiatry","other","article","10.1016/j.jaac.2026.07.327",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056463","GLP-1 receptor agonists and lymphedema: from weight loss to potential direct modulation of lymphatic function","Eva Klara Merzel Šabović","2026","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1980239",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056464","ffect of empagliflozin or semaglutide on endothelial function and arterial stiffness, other clinical parameters and laboratory biomarkers in type 1 diabetic subjects","Maja Preložnik Navodnik","2025","University of Maribor digital library (University of Maribor)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0056465","analysis of safety risks associated with GLP-1 RA use in the direct-to-consumer telehealth model compared to traditional care model",null,null,"Digital Repository Service (Northeastern University)","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056466","Effects of liraglutide on blood pressure and renal function in patients with type 2 diabetic nephropathy: a meta-analysis of randomized controlled trials","Shengning GAO","2026","Frontiers in Medicine","systematic_review","article","10.3389/fmed.2026.1921737",null,null,"PROSPERO:CRD420251232844",null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056467","Disproportionate Reporting of Optic Ischemic Neuropathy in FAERS with GLP-1-Based Therapies Compared with SGLT2 Inhibitors","Sedra T. Alabed","2026","Neuro-Ophthalmology","nonrandomized_study","article","10.1080/01658107.2026.2741570",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056468","Reply - Letter to the Editor - Signal Thresholds and Causal Inference in Pharmacovigilance Studies of Glucagon-like Peptide-1 Receptor Agonists","Angela T.H. Kwan","2026","Clinical Nutrition","nonrandomized_study","article","10.1016/j.clnu.2026.106809",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","letter"],["R0056469","P214 DO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IMPROVE OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION? A SYSTEMATIC REVIEW AND META-ANALYSIS","A. Shokravi","2026","Canadian Journal of Cardiology","systematic_review","article","10.1016/j.cjca.2026.07.204",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","conference-abstract"],["R0056470","UNDERSTANDING THE ADOPTION AND PERCEPTIONS OF TIRZEPATIDE IN CLINICAL PRACTICE: A QUALITATIVE SYSTEMATIC REVIEW","DR. SHRINIDHI B","2025","TPM Testing, psychometrics, methodology in applied psychology","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0056471","Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review.","González-Cruz DC","2026","BMJ medicine","systematic_review","article","10.1136/bmjmed-2026-002780","42866418","PMC13656128","PROSPERO:CRD42023429170",null,"pubmed; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; Systematic Review; review"],["R0056472","Changing Paradigm of Fatty Liver Management","Musarrat Mahtab","2026","Public Health - Open Journal","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056473","In-vitro pharmacological profiles of dual and selective GLP-1R/GIPR agonists","Sandeep Badole","2024","International Journal of Pharmaceutical and Biological Science Archive","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056474","Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, Current Management, and Future Directions","V. Jenila Jose Jancy","2026","Book Publisher International (a part of SCIENCEDOMAIN International)","other","article","10.9734/bpi/dhrrd/v3/7916",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0056475","Linda de morrer: Impactos e controvérsias na publicidade de medicamentos","Júlia Oliveira de Sousa","2025","XIX CONGRESSO ABRAPCORP","other","article","10.55592/abrapcorp2025.v3i3.12281",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056476","51.4 Eating Disorder Screening Prior to GLP-1 Receptor Agonist Initiation: Current Recommendations and Clinical Gaps","Jessica D. Leuchter","2026","Journal of the American Academy of Child & Adolescent Psychiatry","other","article","10.1016/j.jaac.2026.07.329",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056477","Retatrutide 2026: The Emerging Triple-Agonist Market","Aj Pakpour","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.23283183",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","report"],["R0056478","Маркетингові дослідження фармацевтичного ринку: теорія та практика","Tamara A. Germanyuk","2017","Reports of Vinnytsia National Medical University","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056479","Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective","Ishtiaque Ahmad","2026","Pharmaceutics","other_trial","article","10.3390/pharmaceutics18101281",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0056480","O Transtorno de Compulsão Alimentar e Terapia com GLP-1: Uma Revisão das Evidências Científicas","Clara Laís Ferreira Soares","2025","Bioethics Archives, Management and Health.","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056481","Tip 2 Diyabette İnsülin Glarjin ve Liksisenatid Sabit Oranlı Kombinasyonunun Kısa Dönem Gerçek Yaşam Klinik Sonuçları: Tip 2 Diyabette İnsülin Glarjin/Liksisenatidin Kısa Dönem Sonuçları","Enes Üçgül","2026","Gazi Medical Journal","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056482","GASTRIC ULTRASOUND FOR ASPIRATION-RISK STRATIFICATION IN PATIENTS RECEIVING GLP-1 RECEPTOR AGONISTS: AN INTEGRATED SYSTEMATIC REVIEW AND EVIDENCE UPDATE OF ULTRASONOGRAPHIC, ENDOSCOPIC, AND ANESTHETIC OUTCOMES","Ángel Augusto Naranjo-Ramos","2026","REVISTA CIENTÍFICA MULTIDISCIPLINARIA ARBITRADA YACHASUN","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0056483","P167 Glucagon-like peptide-1 receptor analogues for obese patients needing liver transplantation","Gwilym Webb","2026",null,"nonrandomized_study","article","10.1136/gutjnl-2026-basl.165",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0056484","Real-World Outcomes of 25 Indian Patients Treated with Tirzepatide for Weight Loss: A 20-Week, Resource-Constrained Case Series","dixant chhikara","2025","Journal of Surgery and Medical Case Reports","nonrandomized_study","article",null,null,null,null,null,"openalex","FALSE","no_doi","4","FALSE","article"],["R0056485","EFFECTS OF DIABETES MELLITUS ON SPERM QUALITY AND FERTILITY OUTCOMES","Muhammad Suleman","2026","Pakistan Journal of Medical & Cardiological Review","other","article","10.66021/pakmcr880",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056486","2.85eP GLP-1 receptor agonist therapy in obesity with Duchenne muscular dystrophy: a case highlighting risk-benefit tradeoffs","Hannah Walsh","2026","Neuromuscular Disorders","other","article","10.1016/j.nmd.2026.106774",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056487","Access to GLP-1 Medications Among Adults with Obesity and Related Conditions","Chinasa Ekweariri","2026","Open Science Framework","other","article","10.17605/osf.io/x5bv3",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056488","2-TUR QANDLI DIABET BILAN OG'RIGAN BEMORLARDA IGLARLIXI (SOLIQUA) DORI VOSITASINING GIPOGLIKEMIK SAMARADORLIGINI O'RGANISH","Дилором Анваровна Урунбаева","2025","ЦЕНТРАЛЬНО АЗИАТСКИЙ ЭНДОКРИНОЛОГИЧЕСКИЙ ЖУРНАЛ","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056489","Interpretation of the World Health Organization guideline on glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults","Tianyi Ma","2026","Precision medication.","other","article","10.1016/j.prmedi.2026.100115",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056490","Retatrutide counteracts liver impairment in high- fat/sucrose diet induced obesity in male rats","Zinah Meteab Rah AL-shibil","2026","Kufa Journal of Pharmaceutical Sciences","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056491","ANALYSIS OF ADVANTAGES AND DISADVANTAGES OF MODERN HYPOGLYCEMIC DRUGS","Iroda Brodarovna Takhirova","2025","Oriental Journal of Medicine and Pharmacology","other","article","10.37547/supsci-ojmp-05-02-13",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056492","Periostin in diabetic kidney disease: mechanistic insights, biomarkers, and therapeutic perspectives","Xuhao Li","2026","Frontiers in Endocrinology","other","article","10.3389/fendo.2026.1979232",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056493","Sarcopenia","Oriana Belén Franceschinis y colab.","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056494","From Blood Sugar To Brain Health: Understanding Type 3 Diabetes and Alzheimer’s","Ritam Moitra","2025","Journal of Neonatal Surgery","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056495","NOVEL WEIGHT-LOSS MEDICATIONS AND THEIR CARDIOVASCULAR BENEFITS: A COMPREHENSIVE REVIEW","Karimova Madina Ganisher qizi","2026","JOURNAL OF INTERNATIONAL SCIENTIFIC RESEARCH","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056496","Incretin-Based Obesity Care: A Step-by-Step Education Model for Preserving Physical Function","Cezary Orzechowski","2026","African Journal of Biomedical Research","other","article","10.65327/aphm0k02",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056497","CASE REPORT - THERAPEUTICAL OPTIONS FOR OPTIMIZING THE GLYCEMIC PROFILE IN A PATIENT WITH TYPE 2 DIABETES MELLITUS","Ilie-Robert Dinu","2010","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","case_report","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056498","Oral Delivery of Semaglutide via Nanostructured Lipid Carriers (NLCs): A Review of Formulation, Stability, and Intestinal Uptake","Swati Raturi","2026","International Journal of Multidisciplinary Science and Innovation","narrative_review","article","10.62896/ijmsi.2.s2.12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056499","THE BIOMARKER-PRIMED RECOVERY MODEL: SYNERGISTIC MODULATION OF THE IDOL-LRP1 PATHWAY AND METABOLIC FLUX TO OPTIMIZE FUNCTIONAL MOTOR REHABILITATION IN ALZHEIMER’S DISEASE","Muhammad Yaseen","2026","Review journal of neurological & medical sciences review.","other","article","10.63075/25h2jz54",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056500","Type 2 Diabetes Mellitus and Cardiovascular Complications in Adults: Pathophysiology, Clinical Management, and Preventive Strategies","Хамраева Насиба Абдурасуловна","2026","World of Medicine : Journal of Biomedical Sciences","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056501","Strategies to Mitigate Weight Regain Following Discontinuation of GLP-1 Receptor Agonists in Adults with Obesity: A Scoping Review","Antonis Ioannou","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/6zt92",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056502","Editorial: Unraveling the complex interplay of risk factors in SLE-associated cardiovascular disease","Ulises De la Cruz-Mosso","2026","Frontiers in Lupus","commentary","article","10.3389/flupu.2026.1991587",null,null,null,null,"openalex","TRUE",null,null,"FALSE","editorial"],["R0056503","Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss and Cardiovascular Protection in Obesity and Type2 Diabetes: A Systematic Review and Meta-Analysis","Maria Sultana","2026","Journal of Diabetes Research Review & Reports","systematic_review","article","10.47363/pstgch08",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0056504","Novas fronteiras no tratamento da obesidade: uma abordagem farmacológica","Emanoel Gomes da Silva","2025","Revista brasileira de obesidade, nutrição e emagrecimento","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056505","AUTOMEDICAÇÃO E ACESSO IRREGULAR ÀS CANETAS EMAGRECEDORAS: UM DESAFIO DE SAÚDE PÚBLICA","Loanda Carvalho Ribeiro Oliveira","2025","Anais do Momento Científico da IFMSA Brazil","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056506","Stability Indicating RP-UPLC Method Development Validation and Dissolution Testing of Semaglutide","Vijey M Aanandhi","2022","Journal of Pharmaceutical Negative Results","other","article","10.47750/pnr.2022.13.04.205",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056507","EFFICACY AND RISKS PROFILES OF “GLP-1 RECEPTOR AGONISTS” IN TYPE 2 DIABETES AND OBESITY: A SYSTEMATIC REVIEW OF BENEFITS AND RISKS","Beenish Khurshid","2025","Review journal of neurological & medical sciences review.","systematic_review","article","10.63075/fmkjkn28",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0056508","Mirada del neurólogo","Victor Gastón Moreno-Milicich","2026","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056509","METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE MASLD A Comprehensive Review of Epidemiology Pathogenesis Diagnosis and Management","Lakshmi. S","2026","International Journal of Versatile Research and Analysis","narrative_review","article","10.56975/ijvra.v4i6.707684",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056510","The GLP-1–Gut Microbiota–Autoimmunity Axis in Type 1 Diabetes: Emerging Evidence and Mechanistic Perspectives","Anna Arecco","2026","Diabetology","other","article","10.3390/diabetology7100187",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056511","Development and validation of qualitative methods for the detection of GLP-1 receptor agonists in serum and dried blood spots by LC-HRMS/MS for doping control purposes","Lisa Borschel","2026","Journal of Chromatography B","preclinical","article","10.1016/j.jchromb.2026.125326",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056512","From Food Structure to L-Cell Exposure: How Processing and Digestion Shape Endogenous GLP-1 Responses","Roko Šantić","2026","Molecules","other","article","10.3390/molecules31193375",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056513","Prevalence and Risk Factors of Polycystic Ovary Syndrome (PCOS) Among Reproductive-Age Women","Asma Iqbal","2026","Pakistan Journal of Medical & Cardiological Review","other","article","10.66021/pakmcr885",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056514","O uso da Tirzepatide no tratamento da diabetes tipo 2: uma revisão de literatura","Mariana Paiva","2024","Revista Fluminense de Extensão Universitária","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056515","PQ-43245-22 - Peadar Toibin","Health Service Executive","2022","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056516","Hormonal Dysregulation of Energy Expenditure and Adipose Tissue Metabolism in Non-Diabetic Adults with Obesity: Implications for Metabolic Inflammation and Weight-Loss Resistance","Obiageri Ihuarulam Okeoma","2026","Journal of Medicine and Health Research","randomized_trial","article","10.56557/jomahr/2026/v11i211157",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056517","Semaglutide Beyond Diabetes: Efficacy, Equity, and Ethical Boundaries","Kumar Roushan","2026","Medical Journal of Dr D Y Patil Vidyapeeth","other","article","10.4103/mjdrdypu.mjdrdypu_599_25",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056518","Pharmacological Selection and Management Progress for Chronic Conditions in Overweight/Obese Patients with Type 2 Diabetes Mellitus","Yue Kan","2026","Journal of Clinical Medicine Research","other","article","10.32629/jcmr.v7i3.5458",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056519","Comparison of the GLP-1 Receptor Agonists with other anti-obesity/anti-diabetic medicines: a systematic review","Beenish Khurshid","2025","Review journal of neurological & medical sciences review.","systematic_review","article","10.63075/w16p9p55",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","review"],["R0056520","Comparative Evaluation of Regulatory Registration & Approval Pathways for Semaglutide 14 mg Tablet in Emerging South American Markets: Chile, Peru and Bolivia","Vishesh Modi","2026","International Journal of Drug Regulatory Affairs","other","article","10.22270/ijdra.v14i3.884",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056521","Clinical Decision-Making for Incretin-Based Therapy in Neurofibromatosis Type 1","Ugur Deniz Ayar","2026","AACE Endocrinology and Diabetes","other","article","10.1016/j.aed.2026.07.024",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056522","Effects of Liraglutide on Thyroid Stimulating Hormone and Level of Depression: Liraglutide Effects on TSH and Depression","Uzma Dost Muhammad Rajar","2025","Annals of Punjab Medical College","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","article"],["R0056523","Impact of Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) Receptor Agonists on Intraocular Pressure in Glaucoma: A Case Series","Coy Steel","2026","Journal of Ophthalmology and Advance Research","nonrandomized_study","article","10.46889/joar.2026.7306",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056524","Metabolic-associated fatty liver disease (MAFLD) 2024–2026: modern approaches to diagnosis and treatment — a practical guide for a clinician","A. R. GARIPOVA","2026","Practical medicine","other","article","10.32000/2072-1757-2026-4-85-92",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056525","EFLÚVIO TELÓGENO ASSOCIADO A AGONISTAS DOS RECEPTORES DE GLP-1 E GLP-1/GIP: INCIDÊNCIA E FATORES DE RISCO DA QUEDA CAPILAR DURANTE O TRATAMENTO DA OBESIDADE","Matheus Alonso Shimizu","2026","Brazilian Journal of Medical and Health Sciences","other","article","10.64597/eb91a803",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056526","Heart Failure: Classification, Diagnosis and Management","Aamir Shafi","2026","J Med Sci","other","article","10.33883/jms.v30i2,3.1521",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056527","Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): Biochemical Pathways, Clinical Spectrum, and Biomarker Profiling: A Comprehensive Review","Dunia Abbas Khudhair","2025","Hammurabi Journal of Medical Sciences","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056528","Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review","Marco Marchetti","2026","Metabolites","systematic_review","article","10.3390/metabo16100757",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0056529","Successful management of type 2 diabetes, obesity and urinary incontinence in a 45-year-old female patient","Ivana Mickovski","2025","Romanian Journal of Diabetes Nutrition and Metabolic Diseases","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056530","Safety profile and potential favorable reporting signals of liraglutide in patients with ulcerative colitis: A FAERS pharmacovigilance and network pharmacology study","Keliang Liu","2026","Pakistan Journal of Pharmaceutical Sciences","nonrandomized_study","article","10.36721/pjps/2026.40.16851.1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056531","Essai de phase 3 du survodutide administré une fois par semaine pour le traitement de l’obésité chez l’adulte : SYNCHRONIZE™-1","Emmanuel Disse","2026","Annales d Endocrinologie","other_trial","article","10.1016/j.ando.2026.102741",null,null,"ClinicalTrials.gov:NCT06066515","S000367","openalex","TRUE","open_pdf","5","FALSE","article"],["R0056532","Obesity","Tom Barber","2026","Wiley eBooks","other","article","10.1002/9781394391073",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book"],["R0056533","GLP-1 Receptor Agonists And Osseointegration: Bone Health Implications For Implant Dentistry In The Era Of Widespread Weight-Loss Therapy","Paulo Vinícius de Oliveira Bastos","2026","IOSR Journal of Dental and Medical Sciences","randomized_trial","article","10.9790/0853-2508010106",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056534","Cardiovascular and functional outcomes of glucagon-like peptide−1 receptor agonists in heart failure with preserved or mildly reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials","Ahmed Elazab","2026","European journal of medical research","systematic_review","article","10.1186/s40001-026-05199-7",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0056535","Influencia de la diabetes mellitus tipo 2 en la progresión del síndrome cardiorrenal-metabólico: abordajes y estrategias terapéuticas: Influence of type 2 diabetes mellitus on the progression of cardiorenal-metabolic syndrome: approaches and therapeutic strategies","Aleifel Antonio Esqueda Jiménez","2026","Revista estudiantil CEUS","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056536","Particularités de l'Association Syndrome Métabolique-Diabète de Type 2 Chez le Congolais : Une Étude Transversale Hospitalière à Brazzaville : Features of the Metabolic Syndrome‑Type 2 Diabetes Association in Congolese Patients: A Cross‑Sectional Hospital Based Study in Brazzaville","Farel Elilié Mawa Ongoth","2026","HEALTH SCIENCES AND DISEASE","other","article","10.5281/zenodo.19063259",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056537","Pharmacotherapies and the Future of Obesity Management","Tom Barber","2026","Obesity","other","article","10.1002/9781394391073.ch10",null,null,null,null,"openalex","FALSE",null,null,"FALSE","other"],["R0056538","SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study Comparing Adherence and Persistence with Specific Reference to Cardiovascular Disease","M. Asunción González-González","2026","Pharmaceuticals","nonrandomized_study","article","10.3390/ph19101607",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056539","O9 Selecting patients with MASLD for pharmacotherapy using American or European threshold values of non-invasive fibrosis tests: Implications for workload from an analysis of over 4,000 patients in a UK MASLD clinic","Arash Akhavan Rezayat","2026",null,"other","article","10.1136/gutjnl-2026-basl.6",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0056540","GLP-1, the Gut-Brain, and Brain-Periphery Axes","Cendrine Cabou","2023","The Review of Diabetic Studies","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056541","Liraglutide as a Novel Strategy for Improving Metabolic and Hormonal Profiles in Obese Women with Polycystic Ovary Syndrome","Sara Medhat Georgy","2026","Journal of Pharmaceutical Innovation","other","article","10.1007/s12247-026-10995-z",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056542","The Ocular Sentinel: Choroidal Hypoperfusion and the Hypoxic Cascade in Age-Related Macular Degeneration","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23076209",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056543","Tailored therapy in type 2 diabetes unintended effects of glucose-lowering agents","Judith de Ruijter-van Dalem","2022",null,"nonrandomized_study","article","10.26481/dis.20220602jd",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","dissertation"],["R0056544","Comparative Efficacy and Safety of Novel Pharmacological Interventions for MASH: A Systematic Review and Network Meta-Analysis","Yuvraj Jadhav","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/gct74",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0056545","Efficacy And Safety Of Glp-1 Analogs In Children With Obesity","Aleksandra Schmidt","2026","African Journal of Biomedical Research","other","article","10.53555/ajbr.v29i1s.9381",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056546","THE NEW SURGICAL PATIENT IN THE ERA OF GLP-1 RECEPTOR AGONISTS: PERIOPERATIVE IMPLICATIONS AND EMERGING CHALLENGES FOR ABDOMINAL SURGERY","Roberto Tussi","2026","Artefactum","other","article","10.23900/artefactum.v25i11.4573",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056547","Peptide and Macrocycle Chemistry in the Development of Metabolic and Obesity Therapeutics","Sau Har Lee","2026","Integrative Biomedical Research","other","article","10.25163/biomedical.10210960",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056548","Semaglutide and Drug Craving: Emerging Perspectives in Addiction Psychiatry","Vincenzo Maria Romeo","2026","JOURNAL OF MENTAL HEALTH AND CLINICAL PSYCHOLOGY","randomized_trial","article","10.29245/2578-2959/2026/3.1378",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056549","Real-World Effectiveness of Liraglutide in Children with Type 2 Diabetes","Gabriel Castano","2026","Journal of the Endocrine Society","nonrandomized_study","article","10.1210/jendso/bvag230",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056550","PHARMACOECONOMICS OF ORAL WEIGHT-LOWERING DRUGS IN TYPE 2 DIABETES: A COMPARATIVE STUDY OF SGLT-2 INHIBITORS AND GLP-1 ANALOGUES IN INDIA","SULTHAN AL RASHID1","2025","TPM Testing, psychometrics, methodology in applied psychology","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056551","How Can We Increase the Utilization of Evidence-Based Medication After Myocardial Infarction?","Matthew Aaron Cavender","2024","JAMA Network Open","nonrandomized_study","article","10.1001/jamanetworkopen.2024.47075","39602126",null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056552","INNOVACIONES TERAPÉUTICAS EN EL MANEJO DE LA DIABETES TIPO 2: ENFOQUE EN LOS MODULADORES DEL RECEPTOR GLP-1","Olivia Elizabeth Altamirano Guerrero","2025","Correo Científico Médico","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056553","Analysis of fibrosis-related histology endpoints and NITs in a phase 2 trial of survodutide in people with MASH and fibrosis","Elisabetta BUGIANESI","2026","Institutional Research Information System University of Turin (University of Turin)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0056554","Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity","Samit Ghosal","2026","Obesity Pillars","other","article","10.1016/j.obpill.2026.100339",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056555","Diagnostic Problem of Hyperbilirubinemia in Diabetes Mellitus Patient: Case Report: Hyperbilirubinemia in Diabetic Patients: Diagnostic Approach","Gunar Isya Firdauzi","2025","Gaceta Médica de Caracas","case_report","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056556","Padrões de prescrição de medicamento para a Diabetes Mellitus tipo 2 em cinco departamentos da Colômbia em 2014","Noël Christopher Barengo","2018","Revista Facultad Nacional de Salud Pública","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056557","Liraglutide plus Metformin versus Metformin alone in women living with Polyendocrine metabolic ovarian syndrome (PMOS): A Systematic Review and Meta-analysis of Randomized Controlled Trials","Indrajit Banerjee","2026","Nepal Journal of Epidemiology","systematic_review","article","10.3126/nje.v16i3.99703",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0056558","Examining clinicians’ approaches to discussing weight during routine diabetes care: an observational study","Justin A. Dower","2026","BMC Family Practice","randomized_trial","article","10.1186/s12875-026-03588-9",null,null,"ClinicalTrials.gov:NCT05553912",null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056559","PQ-22800-23 - Verona Murphy","Health Service Executive","2023","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056560","GLP-1 Receptor Agonists in Paediatric obesity: A Systematic Review of Lived Experiences [abstract only]","Claire Williams","2026","SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","review"],["R0056561","Abstract Wed062: Cardiomyocyte-Specific Actions of Incretin-Based Therapeutics: Cardioprotection Beyond Weight Loss","Julia Gardner","2026","Circulation Research","preclinical","article","10.1161/res.139.suppl_1.wed062",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0056562","Dyslipidemia–Renin–Angiotensin System Crosstalk in Diabetic Kidney Disease: A Critical Narrative Review of Experimental Mechanisms and Clinical Evidence","Hamid Nasri","2026","Bratislavské lekárske listy/Bratislava medical journal","randomized_trial","article","10.1007/s44411-026-00884-9",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0056563","Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanisms","Arundhati Nittur","2026","Addictive Behaviors","narrative_review","article","10.1016/j.addbeh.2026.108878",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056564","IN SILICO INVESTIGATION OF THE EFFECTS OF GLP-1R VARIANTS ON EXENDIN4 BINDING PROPERTIES","Alper Erdem Yılmaz","2026","Yildiz Technical University - AVESIS","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0056565","Euglycemic Diabetic Ketoacidosis Precipitated by Tirzepatide in adult Patient with Type 1 Diabetes Mellitus","Abubakr M. Sowilem","2026","Egyptian Society of Diabetes and Lipidology Journal","other","article","10.21608/esdlj.2026.503751.1003",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056566","Preoperative GLP-1 receptor agonist versus DPP-4 inhibitor use and 30-day outcomes after non-cardiac surgery in adults with type 2 diabetes: a Swedish nationwide active-comparator cohort study","Jesper Eriksson","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/bvfju",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0056567","Cascades from a Drug (CFADs): Characterization of a Newly Described Pharmacovigilance Process","Eli D. Ehrenpreis","2026","Open Science Framework","nonrandomized_study","article","10.17605/osf.io/qztg9",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","other"],["R0056568","GLP-1 Receptor Agonists in Paediatric obesity: An Umbrella Review [abstract only]","Fiona McGinnes","2026","SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","article"],["R0056569","Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: Metabolic Preconditioning and Reproductive Implications","Marta Śliwińska","2026","African Journal of Biomedical Research","randomized_trial","article","10.53555/ajbr.v29i1s.9334",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0056570","Cardiovascular and Kidney Outcomes of Tirzepatide versus Semaglutide in Stage 2 Cardiovascular-Kidney-Metabolic Syndrome: A Propensity Score-matched Cohort Study","Abdul Qadeer","2026","Clinical Medicine Insights Cardiology","randomized_trial","article","10.1177/11795468261496357",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056571","Mechanism-Targeted Therapy in Adult Obstructive Sleep Apnea: Aligning New Treatment Modalities with Pathophysiological Endotypes","Elsie O Osiogo","2026","Observations and Insights in Pulmonary and Critical Care","other","article","10.2458/001c.170855",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056572","Trends in bariatric and pharmacologic obesity management: an analysis using epic cosmos database","Ahmad El Khatib","2026","Langenbeck s Archives of Surgery","nonrandomized_study","article","10.1007/s00423-026-04243-8",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056573","PQ-51554-23 - Patricia Ryan","Health Service Executive","2023","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056574","PQ-49795-23 - Thomas Pringle","Health Service Executive","2023","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056575","Beyond Weight Loss: Tolerability, Acceptability, and Patient-Centered Outcomes of GLP-1 Receptor Agonists in Polycystic Ovary Syndrome","Urvah Tauseef","2026","Reproductive Medicine","other_trial","article","10.3390/reprodmed7040055",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0056576","Neuroprotective efficacy of semaglutide in preclinical in vivo rodent models: a systematic review and quantitative meta-analysis","Kateryna Nohejlova","2026","OSF Preprints (OSF Preprints)","systematic_review","article",null,null,null,null,null,"openalex","TRUE","no_doi","3","FALSE","preprint"],["R0056577","Status note on the RPN preprint series (11 October 2026)","Michael Warrington","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23298161",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056578","FAERS Signal Triangulation: Verify Live Data Before Trusting PRR ≥2, n ≥3 Screens","Madison Hayes","2026","Zenodo (CERN European Organization for Nuclear Research)","nonrandomized_study","article","10.5281/zenodo.23305411",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0056579","A retrospective real-world study on semaglutide effectiveness in patients with obesity: differences between patients with and without food craving","Simona Bertoli","2026","Frontiers in Endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1927180",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056580","Ameliorative Effects of Cistanche deserticola Polysaccharides on Metabolic Associated Fatty Liver Disease in Mice and Its Mechanisms","Jing WANG","2026","DOAJ (DOAJ: Directory of Open Access Journals)","preclinical","article","10.13386/j.issn1002-0306.2025090284",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056581","The Impact of GLP-1 Receptor Agonists on the Gut-Brain Axis: Adverse Effects or Therapeutic Mechanism? A Narrative Review","Paula Biernat","2026","African Journal of Biomedical Research","randomized_trial","article","10.69980/ajbr.v29i1s.9889",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","review"],["R0056582","Effects of Incretin-Based Pharmacotherapies on Lean Body Mass in Adults With Overweight, Obesity, or Type 2 Diabetes: A Systematic Review With Prespecified Network Meta-Analysis Feasibility Assessment","Zahi M Alhamad","2026","Cureus","systematic_review","article","10.7759/cureus.117738",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056583","Individualisation of HbA1c targets and treatment strategies in people with diabetes: real-world observational studies","Thomas Simon James Crabtree","2024","Nottingham ePrints (University of Nottingham)","randomized_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","2","FALSE","dissertation"],["R0056584","PQ-25689-23 - Jennifer Murnane O'Connor","Health Service Executive","2023","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056585","Discussions of Oral Versus Injectable Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss on Reddit: Content Analysis (Preprint)","Yiran Liu","2026",null,"other","article","10.2196/preprints.113990",null,null,null,null,"openalex","FALSE",null,null,"FALSE","preprint"],["R0056586","Dual Benefits of Antidiabetic Drugs: Mechanistic Insights into Blood Glucose Control and Cancer Suppression","Al Darraji Raad kareem Alwan","2026","Asian Pacific Journal of Cancer Biology","randomized_trial","article","10.31557/apjcb.2026.11.3.931",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056587","SP07 Glucagon-like peptide-1 receptor agonist-associated myopathy: a metabolic double hit","Bryce Chang","2026","Neuromuscular Disorders","other","article","10.1016/j.nmd.2026.106700",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0056588","GLP-1 Receptor Agonists and Muscle-Sparing Adjuncts in Athletes: Clinical and Anti-Doping Implications for Sports Medicine Practitioners","Sang-Seo Park","2026","Open Science Framework","other","article","10.17605/osf.io/btsk5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056589","Title: Figure-generation code for \"One receptor, two molecular strategies: orforglipron, peptide GLP-1 receptor agonists, and the translational pharmacology of cardiovascular–kidney–metabolic care\"","Ashutosh Mishra","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23227749",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056590","Efectos cardiovasculares de los agonistas del receptor GLP-1 en pacientes con diabetes mellitus tipo 2","Christian Enrique Iglesias Espín","2025","Revista de Ciencias Médicas de Pinar del Río","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056591","GLP-1 and GLP-1/GIP Incretin Agonists and Related Therapies in Metabolic Obesity: A Narrative Review of Pivotal Trials, Pathophysiological Foundations, and Practical Management of Complications","Belmontes - Gutiérrez , D.A.,","2026","Revista de Ciencias Médicas Torreón","narrative_review","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0056592","PQ-32311-24 - Eoin Ó Broin","Health Service Executive","2024","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056593","Building Trustworthy Information Systems: A Unified Framework For Comparative Risk Detection","Parisa Momeni","2026","Digital Commons - University of South Florida (University of South Florida)","other_trial","article",null,null,null,null,null,"openalex","TRUE","no_doi","5","FALSE","dissertation"],["R0056594","Endocrine determinants of MASLD: mechanisms and therapeutic targets","Richa Chaturvedi","2026","Frontiers in Endocrinology","other","article","10.3389/fendo.2026.1967494",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056595","Prediction of liver histology response by non-invasive tests: exploratory analysis of the survodutide phase 2 trial","Mazen Noureddin","2026","Institutional Research Information System University of Turin (University of Turin)","other_trial","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","article"],["R0056596","Process Mining for Characterizing Adverse Event Transition Patterns in GLP-1 Receptor Agonist Using OpenFDA Data","Adil Priman Hati Hulu","2026","Journal of Intelligent Computing & Health Informatics","nonrandomized_study","article","10.26714/jichi.v7i2.22677",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056597","การประเมนตนทน-ประสทธผลในระดบโรงพยาบาลของยา Semaglutide ในการควบคมระดบนำตาลในเลอดของผปวยเบาหวานชนดท 2","Sakonwan Pounghom","2026","Hua Hin Medical Journal","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056598","GLP-1 Receptor Agonists as a Therapeutic Strategy for Metabolic Dysfunction in Patients Receiving Long-Term Antipsychotic Treatment: A Narrative Review","Jan Kownacki Kownacki","2026","African Journal of Biomedical Research","narrative_review","article","10.53555/ajbr.v29i1s.9343",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review"],["R0056599","Avaliação da eficácia da semaglutida e tirzepatida na perda de peso e prevenção de doenças crônicas não transmissíveis em indivíduos obesos: uma revisão sistemática","Osvaldo Soares de Araújo","2025","Revista Educação em Saúde/Revista Educação em Saúde Unievangélica","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056600","The Effect of Exanatide on Recovery of the Facial Nerve Crush Injury in the Rat.","Yılmaz B","2026","The journal of international advanced otology","randomized_trial","article","10.65717/iao.2026.252134","42867352",null,null,null,"pubmed; openalex","TRUE","open_pdf","2","FALSE","Journal Article; article"],["R0056601","Kein klar erhöhtes Risiko durch GLP-1-RA in der Schwangerschaft","Thomas Müller","2026","gynäkologie + geburtshilfe","other","article","10.1007/s15013-026-6554-0",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0056602","Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.","Steven E Kahn","2026","UNC Libraries","nonrandomized_study","article","10.17615/t892-3m21",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056603","Oral adverse effects reported among patients treated with GLP-1 receptor agonists: a scoping review","Houram Emadi","2026","Open Science Framework","narrative_review","article","10.17605/osf.io/xd2g4",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056604","Targeting macrophages GLP-1 receptor pathways as emerging therapies to ameliorate cardiac remodelling associated with diabetes","Rawan A Abudalo","2026","Research Portal (Queen's University Belfast)","preclinical","article","10.17034/32629608",null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0056605","Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials","Massimo Nardone","2026","EClinicalMedicine","systematic_review","article","10.1016/j.eclinm.2026.104251",null,null,"PROSPERO:CRD420251146441",null,"openalex","TRUE","free_to_read","3","FALSE","review"],["R0056606","Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.","Eisa N","2026","The Journal of clinical endocrinology and metabolism","systematic_review","article","10.1210/clinem/dgag284","42867450",null,"PROSPERO:CRD42026137255",null,"pubmed; openalex","FALSE","paywalled","3","FALSE","Journal Article; review"],["R0056607","GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials.","Sun SP","2026","Frontiers in medicine","systematic_review","article","10.3389/fmed.2026.1800909","42865473","PMC13654773","PROSPERO:CRD420261287573",null,"pubmed; openalex","TRUE","open_europepmc","3","FALSE","Journal Article; review"],["R0056608","The Dopamine Brain: Wanting: Why You Chase What You Don't Enjoy","Gurpreet S. Padda","2026","Zenodo (CERN European Organization for Nuclear Research)","other_trial","article","10.5281/zenodo.22941230",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","book"],["R0056609","From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease","Christiano Argano","2026","Frontiers in Pharmacology","other","article","10.3389/fphar.2026.1784959",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056610","Effet du tirzépatide par rapport au dulaglutide sur les événements cardiovasculaires indésirables majeurs (MACE-4 et MACE-5) chez des patients vivant avec un diabète de type 2 et une maladie cardiovasculaire athérosclérotique établie","M. Le Bleis","2026","Annales d Endocrinologie","other","article","10.1016/j.ando.2026.102922",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056611","The Effects of GLP-1RA-Based and SGLT2 Inhibitor Therapy on Perirenal Adipose Tissue in CKD Patients.","Checa-Ros A","2026","Diabetes, obesity & metabolism","nonrandomized_study","article","10.1111/dom.71441","42865317",null,"ClinicalTrials.gov:NCT07309094","S000128","pubmed; openalex","FALSE","open_pdf","4","FALSE","Journal Article; article"],["R0056612","Woo S, Park K, McPherson T, Woo J. Association of glucagon-like peptide 1 receptor agonist use with erythropoietic indices and anemia risk in diabetes. Blood Red Cells Iron. 2026;2(3):100089.",null,"2026","Blood Red Cells & Iron","other","article","10.1016/j.brci.2026.100134",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056613","Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data","Xianwen Wang","2026","European Archives of Oto-Rhino-Laryngology","nonrandomized_study","article","10.1007/s00405-026-10708-9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056614","Short-term semaglutide exposure is associated with increased osteoblast-covered surface in male Swiss mice: a histomorphometric exploratory study","Rosangela Roginski Rea","2026","Diabetology & Metabolic Syndrome","preclinical","article","10.1186/s13098-026-02321-x",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056615","Comparative Outcomes of GLP-1 Receptor Agonist Users vs Nonusers in Obese Patients Undergoing Body Contouring Surgery: A Propensity-Matched Cohort of 4,352 Patients","Olivia G. Leonovicz","2026",null,"nonrandomized_study","article","10.13140/rg.2.2.20237.50403",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056616","ANAIS DA XII JORNADA ODONTOLÓGICA DO TOCANTINS (JONT) DO CURSO DE BACHARELADO EM ODONTOLOGIA DA FACIT","João Nivaldo Pereira GOIS","2026","JNT - Facit Business and Technology Journal","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056617","Semaglutide, Other GLP-1 Receptor Agonists, and Papillary Thyroid Carcinoma: A Narrative Review of Risk, Progression, and Mechanisms","Luiza Barseghyan","2026","Journal of Clinical Medicine","randomized_trial","article","10.3390/jcm15207834",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0056618","Profil psychocomportemental et comportements alimentaires chez les patients diabétiques de type 2 sous liraglutide","A. Haddad","2026","Annales d Endocrinologie","other","article","10.1016/j.ando.2026.102999",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056619","Comparative Effects of GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs on Kidney Cancer Risk: A Target Trial Emulation in Post-Bariatric Patients","Jesús Hernández","2026","Epidemiology","nonrandomized_study","article","10.1097/01.ede.0001280296.77292.d8",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056620","The Hyperamylinemia–Inflammation–Coronary Artery Disease Axis in Type 2 Diabetes Mellitus: Exploring Amylin as a Potential Cardiometabolic Therapeutic Target",null,"2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.66s.170",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056621","The Prostate as a Sentinel Organ: Hypoxia, Chronic Inflammation, and the Prostatitis–BPH–Cancer Continuum","Sameer Rohatgi","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23318292",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056622","Erratum: Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study) (Trials (2019) 20 1 (191))","Grazia Daniela Femminella","2020","Newcastle University ePrints (Newcastle Univesity)","notice","article","10.25405/ncl.34410459",null,null,null,null,"openalex","TRUE",null,null,"FALSE","erratum"],["R0056623","The GLP-1 Access Paradox: Effects of Semaglutide Shortages, Compounded Products, and Treatment Interruptions on Safety, Weight Regain, Glycemic Control, and Health Equity","David Gettman","2026",null,"other","article","10.13140/rg.2.2.27212.17284",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056624","Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes","Andreas L. Birkenfeld","2026","Universitätsbibliothek Tübingen","other","article","10.15496/publikation-125550",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056625","PQ-22493-20 - Fergus O'Dowd","Health Service Executive","2020","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056626","New Pharmacological Treatment of Obesity: The Role of GLP-1 and Dual GIP/GLP-1 Receptor Agonists","Asena GÖKÇAY CANPOLAT","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23341565",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056627","The Imperial Satiety Protocol – long-term weight loss outcomes for a lifestyle based intervention in a real-world NHS setting","Saira Hameed","2026","Spiral (Imperial College London)","protocol","article","10.1002/oby.70336",null,null,null,null,"openalex","TRUE","paywalled","5","FALSE","article"],["R0056628","The Impact of Absorbable Antibiotic Beads in Implant-Based Breast Reconstruction: A Single-Surgeon Experience","Katrina Fernandez","2026","Plastic & Reconstructive Surgery Global Open","nonrandomized_study","article","10.1097/01.gox.0001279432.31971.29",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056629","Intramyocellular lipid droplet–mitochondria uncoupling drives muscle atrophy via metabolite-directed epigenetic reprogramming: a review","Lingfeng Wu","2026","Frontiers in Endocrinology","narrative_review","article","10.3389/fendo.2026.1980958",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056630","Knowledge, attitudes, and practices among users of GLP-1 receptor agonists in Saudi Arabia: a cross-sectional study","Abdullah Ali Alshehri","2026","Frontiers in Pharmacology","other","article","10.3389/fphar.2026.1912202",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056631","Pleiotropic effects of artichoke leaf extract in functional biliary disorders and metabolic dysfunction-associated steatotic liver disease","Aleksandra Kaplina","2026","Almanac of Clinical Medicine","other","article","10.18786/2072-0505-2026-54-017",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056632","Emerging Anti-Obesity Medications for Obesity Management: A Systematic Review of Efficacy, Safety, and Outcomes","Kishna Ram","2026","Acta Medica International","systematic_review","article","10.21276/amit.2026.v13.i3.1066",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","article"],["R0056633","Longitudinal Evaluation of Mobile 3D Body Scanning for Body Composition Assessment During Pharmaceutical Weight Loss Therapy","Matthew S. Gilmer","2026",null,"other","article","10.15221/26.29",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0056634","Discordance between creatinine- and cystatin C-based glomerular filtration estimates during incretin-induced weight loss and its impact on dosing of renally cleared narrow therapeutic index drugs","Callum Kirwan","2026","International Journal of Pharmaceutical and Clinical Research","nonrandomized_study","article","10.33545/26647591.2026.v8.i2a.227",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056635","Five-Year Glycemic Trends in a Remote Diabetes Monitoring Program (RDMP): Contributions of Program Engagement and Evolving Pharmacotherapy Adoption and Adherence","Roberta A James","2026","medRxiv","nonrandomized_study","article","10.64898/2026.10.08.26363772",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0056636","Clinical Inertia in the Treatment of Hypertension for Individuals with Diabetes","Joseph R. Herges","2026","Diabetes Obesity and Cardiometabolic CARE","nonrandomized_study","article","10.2337/figshare.33301926",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","other; article"],["R0056637","Computational design and prioritization of database-absent small-molecule GLP-1 receptor agonist candidates from public bioactivity data","JOGU MOHAN","2026","ChemRxiv","nonrandomized_study","article","10.26434/chemrxiv.15010310/v1",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0056638","Comprehensive dermatological support for patients on tirzepatide therapy: Procedure algorithms, Ozempic face/body prevention, and an interdisciplinary approach","Natalia V. Shperling","2026","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2026-368",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056639","From weight loss to weight maintenance in lower-BMI Asian adults: how low is too low with incretin-based therapy?","Akriti Singh","2026","International Journal of Diabetes in Developing Countries","other","article","10.1007/s13410-026-01747-3",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056640","GLP-1 receptor agonists multi-state network meta-analysis: analysis code and data","Junhui Bai","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/cyjfp",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","article"],["R0056641","Efeitos sobre a saúde bucal do uso das canetas emagrecedoras: revisão integrativa da literatura","Gabriele Cristina Oliveira Palheta","2026","Revista fisio&terapia.","nonrandomized_study","article","10.69849/tsz23s15",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056642","PQ-4032-20 - Jackie Cahill","Health Service Executive","2020","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056643","Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes","Norman Waugh","2012","University of Warwick","other","article","10.82444/warw.33665407",null,null,null,null,"openalex","TRUE",null,null,"FALSE","report"],["R0056644","GLP1 and Network Dynamics in a Mouse Model of Binge Like Eating","Marcelo Febo","2026","California Digital Library","preclinical","article","10.48321/d169bd6105",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056645","Albiglutide provides effective glycaemic lowering across diabetes duration subgroups","Philip Home","2015","Newcastle University ePrints (Newcastle Univesity)","other","article","10.25405/ncl.34271736",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0056646","Étude OPTIC : préférences en matière de traitements médicamenteux de l’obésité chez les personnes en surpoids ou en situation d’obésité","L. Vigié","2026","Annales d Endocrinologie","other","article","10.1016/j.ando.2026.103029",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056647","Mini Review: GLP-1 Modification, Development, and Improvement","Fedric Intan Damai","2022","ANNALES BOGORIENSES","preclinical","article","10.14203/ann.bogor.2022.v26.n1.1-12",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056648","Efficacy and safety of semaglutide for weight loss among adults with overweight or obesity: a systematic review and narrative synthesis","Razan Suliman Alhumayed","2026","BMC Endocrine Disorders","systematic_review","article","10.1186/s12902-026-02641-z",null,null,"PROSPERO:CRD420261296560",null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0056649","Manejo de la terapia hipoglucemiante en adultos mayores: desafíos y oportunidades","Marcela Martínez","2024","Revista de la Sociedad Argentina de Diabetes","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056650","Beyond Weight Loss: Facial Remodeling Associated with GLP-1 Receptor Agonists-A Systematic Review and Therapeutic Framework.","Maglitto F","2026","Aesthetic plastic surgery","systematic_review","article","10.1007/s00266-026-06331-y","42864543",null,"PROSPERO:CRD420261415797",null,"pubmed; openalex","TRUE","open_pdf","3","FALSE","Journal Article; Review; review"],["R0056651","DPP-4 Inhibitor Exposure Among Patients with Pancreatic Cancer: A Single-Center Retrospective Study","Barış Sarıakçalı","2026","Journal of Pioneering Medical Science","nonrandomized_study","article","10.47310/jpms2026150932",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056652","GLP-1 Receptor Agonist as Modulators of Immunometabolic Pathways in Inflammatory Skin Diseases: A Scoping Review of Omics, Immune Regulation, and Exercise-Technology Interplay","MUHAMMAD SULTHAN ARYA RASYAD","2026","Open Science Framework","randomized_trial","article","10.17605/osf.io/sg78j",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","other"],["R0056653","Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review","Gabriel Jose Paredes Yacaman","2026","Cureus","systematic_review","article","10.7759/cureus.117774",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056654","Diagnosis and management of type 3c diabetes– a consensus statement by Endocrine Society of Bengal","Neeti Agrawal","2026","AACE Endocrinology and Diabetes","other","article","10.1016/j.aed.2026.09.020",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056655","Immunometabolic crosstalk between dysfunctional adipose tissue and the brain: implications for postoperative cognitive dysfunction in obesity","Ya-Jiao Hu","2026","Frontiers in Immunology","other","article","10.3389/fimmu.2026.1965479",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056656","Global barriers to GLP-1 receptor agonist treatment in women: access, safety, and equity","Claire L. Meek","2026","The Lancet Obstetrics Gynaecology & Women s Health","other","article","10.1016/s3050-5038(26)00228-1",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056657","MOUNJARO (TIRZEPATIDA) NO TRATAMENTO DA OBESIDADE: CONSEQUÊNCIAS DA PERDA DE PESO ACELERADA","Aliny Vitória Farias Silva","2026","Aracê.","other","article","10.56238/arev8n10-051",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056658","Body Weight is Not Enough to Monitor Incretin Therapy in India","Rahul Garg","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.23301837",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0056659","EFEK PEMBERIAN EKSTRAK DAUN Punica granatum L. TERHADAP STEATOSIS HATI PADA TIKUS OBESITAS YANG DIINDUKSI DIET TINGGI LEMAK = EFFECT OF PUNICA GRANATUM L. LEAF EXTRACT ON LIVER STEATOSIS IN OBESITY RATS INDUCED BY HIGH FAT DIET","Sitti Mughniati","2025","Hasanuddin University Repository","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0056660","Avanços no tratamento do diabetes mellitus tipo 2: a intersecção entre nutrição e novas medicações","Celine Miho Miho Shiguematsu","2026","Revista brasileira de obesidade, nutrição e emagrecimento","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056661","STABILITY INDICATING RPHPLC METHOD DEVELOPMENT AND VALIDATION FOR DETERMINATION OF GLP-1R AGONIST SEMAGLUTIDE",null,"2026","International Journal of Drug Delivery Technology","other","article","10.25258/ijddt.16.67s.27",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056662","Incident Inflammatory Skin Conditions After GLP-1 Receptor Agonist Initiation: A Propensity Score–Matched TriNetX Cohort Study","Colette Cooper","2026",null,"nonrandomized_study","article","10.13140/rg.2.2.28498.31687",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","article"],["R0056663","Glycemic control, medications, and onset of Alzheimer’s disease and related dementias: A scoping review on diabetes management in people with mild cognitive impairment","Piaopiao Li","2025","Healthcare and Rehabilitation","narrative_review","article","10.1016/j.hcr.2024.100008",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056664","Genetic Polymorphisms in Obesity: Molecular Mechanisms, Clinical Implications and Precision Medicine Approaches","Demin Cao","2026","IntechOpen eBooks","other","article","10.5772/intechopen.1018078",null,null,null,null,"openalex","TRUE",null,null,"FALSE","book-chapter"],["R0056665","Oraler GLP-1-Agonist Aleniglipron zur Gewichtsreduktion",null,"2026","Diabetologie und Stoffwechsel","other","article","10.1055/a-2884-6457",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056666","Diabetes and Cardiovascular–Microvascular Disease: Pathophysiology, Clinical Recognition, and Therapeutic Strategies-Updated Review.","Amani Khamash Hassan Asiri","2025","Saudi Journal of Medicine and Public Health","narrative_review","article","10.64483/202522786",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056667","Glucagon-Like Peptide-1 Receptor Agonist Use Is Associated with Increased Peripheral Nerve Compression after Bariatric Surgery","Andrea P. Biaggi-Ondina","2026","Plastic & Reconstructive Surgery Global Open","other","article","10.1097/01.gox.0001279540.59213.a8",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056668","Side effects of GLP-1-based weight loss therapies","Paul, Papon Kumar","2025","Lu Zone Ul (Laurentian University)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0056669","Semaglutide in adults receiving dialysis: anthropometric outcomes and transplant-access milestones in a systematic review with exploratory meta‑analysis","Yiwei Shang","2026","BMC Nephrology","systematic_review","article","10.1186/s12882-026-05448-1",null,null,null,null,"openalex","TRUE","free_to_read","3","FALSE","article"],["R0056670","Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat","Hussein Zaitoon","2026","EClinicalMedicine","other_trial","article","10.1016/j.eclinm.2026.104258",null,null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0056671","MOUNJARO (TIRZEPATIDA): MECANISMOS DE AÇÃO, BENEFÍCIOS, RISCOS E A IMPORTÂNCIA DA ATUAÇÃO MULTIDISCIPLINAR NO TRATAMENTO DA OBESIDADE","Bruna Angélica Strunkis","2026","Aurum Editora eBooks","other","article","10.63330/aurumpub.068-049",null,null,null,null,"openalex","FALSE",null,null,"FALSE","book-chapter"],["R0056672","Semaglutide and Other GLP-1 Receptor Agonists: Clinical Efficacy and its Safety Review","Navaneeth krishna B","2026","Zenodo (CERN European Organization for Nuclear Research)","narrative_review","article","10.5281/zenodo.22606789",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056673","Real-world Evidence of GLP-1 receptor agonists and Cardiovascular Outcomes among Diabetes: A Target Trial Emulation","Motohiko Adomi","2026","Epidemiology","nonrandomized_study","article","10.1097/01.ede.0001280828.22914.1e",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056674","Exendin-4 mitigates metabolic dysfunction and neuroinflammation associated with a high-fat high-cholesterol diet, along with antioxidant and cytoskeletal remodeling","Danbi Jo","2026","Current Molecular Pharmacology","other","article","10.1016/j.cmp.2026.09.011",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056675","A Randomized, Multicentric, Double-Blind, Active Controlled, Parallel Group, Phase III, Non-Inferiority Clinical Trial To Evaluate The Efficacy, Safety And Tolerability Of Oral Semaglutide Tablets Of Dr. Reddy’s Laboratories Ltd. Compared With Rybelsus® (Semaglutide) Tablets In Adult Patients With Inadequately Controlled Type 2 Diabetes Mellitus.","Dilip Shah","2026","Journal of Clinical Endocrinology and Metabolism","randomized_trial","article","10.52338/jocem.2026.6017",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056676","Semaglutide Clinic Miami for Personalised Weight Management Care","Semaglutide weight loss Miami","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23338834",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056677","397 Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors and Their Association With Sarcopenia in Older Emergency Department Patients in Taiwan","H.-H. Huang","2026","Annals of Emergency Medicine","other","article","10.1016/j.annemergmed.2026.08.408",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056678","Body Composition and Anthropometric Change in Real-World Weight Loss: An Exploratory Analysis of a Large Longitudinal Mobile-Scan Dataset","Matthew S. Gilmer","2026",null,"nonrandomized_study","article","10.15221/26.03",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","conference-paper"],["R0056679","Weight change following discontinuation of a medicated digital weight loss program: a retrospective cohort study from Australia and the United Kingdom (Preprint)","Louis A Talay","2026",null,"nonrandomized_study","article","10.2196/preprints.113195",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","preprint"],["R0056680","Advances in MASLD Management: From Lifestyle Intervention to Pharmacotherapy","Nikhil Roy","2026","Bangladesh Journal of Gastrointestinal and Liver Diseases","other","article","10.66025/b8127j91",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056681","Obesity-driven inflammation and immune dysregulation in cancer development and progression","Pritika Pandey","2026","Frontiers in Oncology","other","article","10.3389/fonc.2026.1947958",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056682","Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin-Dose Reduction, Metabolic Outcomes and Safety Assessment","Robert P. Matson","2026","Diabetology","randomized_trial","article","10.3390/diabetology7100189",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056683","CONTEMPORARY REHABILITATION IN HIP AND KNEE OSTEOARTHRITIS: EXERCISE PRESCRIPTION, MUSCLE HEALTH, WEIGHT MANAGEMENT, AND PERSONALIZED CARE","Dmytro Fedkov","2026","Anti-Aging Eastern Europe","randomized_trial","article","10.56543/aaeeu.2026.5.3.02",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056684","GLP-1 receptor agonists counteract the detrimental effects of pasireotide on pancreatic beta-cell function and survival","Giuseppina Biondi","2026","Scientific Reports","other","article","10.1038/s41598-026-73563-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056685","Adherence and Persistence to Injectable versus Oral GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Comparative Systematic Review and Analysis","Ahmed M. Ashour","2026","Diabetes Metabolic Syndrome and Obesity","systematic_review","article","10.2147/dmso.s614243",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056686","Efsubaglutide Alfa: A Comprehensive Pharmacological Review","Haolin Zheng","2026","Clinical Pharmacokinetics","narrative_review","article","10.1007/s40262-026-01713-6",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056687","Nurse Practitioner-Led Integration of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Prospective Clinical Effectiveness Study.","Cline L","2026","The Journal of cardiovascular nursing","randomized_trial","article","10.1097/jcn.0000000000001370","42864707",null,null,null,"pubmed; openalex","FALSE","paywalled","2","FALSE","Journal Article; article"],["R0056688","Current Evidence and Practical Considerations for GLP-1 Receptor Agonists in Gynecologic Oncology","Joannie Neveu","2026","International Journal of Gynecological Cancer","other_trial","article","10.1016/j.ijgc.2026.105660",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0056689","Orforglipron Improved Physical and Psychosocial Functioning in Adults with Obesity: Results from ATTAIN Phase 3 Randomized Trials","Michelle Look","2026","Obesity Pillars","randomized_trial","article","10.1016/j.obpill.2026.100347",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056690","From Lifestyle Advice to GLP-1 Agonists: The Transformation of Pediatric Obesity Care","Surendra Gupta","2026","Turkish Archives of Pediatrics","randomized_trial","article","10.65717/turkarchpediatr.2026.26339",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056691","Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice.","Brancato D","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1907270","42865447","PMC13654747",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; Review; article"],["R0056692","Liraglutide Dose Affordability and Durability in Real-World Obesity Care.","Zafar A","2026","Endocrinology, diabetes & metabolism","nonrandomized_study","article","10.1002/edm2.70364","42867112",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0056693","07O An interdisciplinary evaluation of the impact of GLP-1 receptor agonists in individuals with Duchenne muscular dystrophy","Lily Deng","2026","Neuromuscular Disorders","other","article","10.1016/j.nmd.2026.106940",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056694","Development of Diabetes Mellitus in Alcoholic Cirrhotic Patients","Abhishek Yadav","2026","Acta Medica International","other","article","10.21276/amit.2026.v13.i2.900",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056695","Hypoglycemic Agent Targets and Susceptibility to Lower Respiratory Infection: A Pharmacogenomic Mendelian Randomization Study","Taikang Yao","2026","Genes","other","article","10.3390/genes17101258",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056696","Complementary Effects of Berberine and Intermittent Fasting on AMPK Activation and GLP-1 Modulation: A Potential Strategy to Mimic Semaglutide Metabolic Benefits","Eman Ibrahim Elgizawy","2026","Bulletin of Egyptian Society for Physiological Sciences","other","article","10.21608/besps.2026.493174.1258",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056697","Should oncology teams reassess GLP-1 receptor agonist management during cancer care? A meta-analysis.","Zouina Sarfraz","2026","JCO Oncology Practice","systematic_review","article","10.1200/op.2026.22.10_suppl.533",null,null,null,null,"openalex","FALSE","open_pdf","3","FALSE","conference-abstract"],["R0056698","Efficacité de setmélanotide chez des patients atteints d’obésité hypothalamique acquise (OHa) précédemment et/ou concomitamment traités par GLP1-RA","C.L. Roth","2026","Annales d Endocrinologie","other_trial","article","10.1016/j.ando.2026.103019",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0056699","Impact of GLP-1 Analogues on Five-Year Overall Survival in women with Breast Cancer treated with Tamoxifen","J Templin","2026","Geburtshilfe und Frauenheilkunde","other","article","10.1055/s-0046-1828649",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056700","Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the “Liver–Other Organs” Axes","Stanislav Nikolaevich Kotlyarov","2026","International Journal of Molecular Sciences","other","article","10.3390/ijms27198614",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056701","Nuevas drogas en el embarazo: rol de GLP1 y SGLT2","Rosa Corcoy","2026","Revista de la Sociedad Argentina de Diabetes","nonrandomized_study","article",null,null,null,null,null,"openalex","TRUE","no_doi","4","FALSE","article"],["R0056702","Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series.","Perumpail BJ","2026","JPGN reports","case_report","article","10.1002/jpr3.70246","42865987","PMC13656291",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0056703","Rationale for the use of GLP-1 receptor agonists in COPD","Oscar M.P. Jolobe","2026","QJM","other","article","10.1093/qjmed/hcag252","42755047",null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056704","UK Yellow Card Reporting for GLP-1-Based Therapies Using Partial NHS Primary Care Prescribing and Hospital Medicine Data from England","Ahmed Asiri","2026","Diabetology","nonrandomized_study","article","10.3390/diabetology7100200",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056705","Semaglutide Use and Risk of Diabetic Retinopathy and Non-Arteritic Anterior Ischemic Optic Neuropathy in Type 2 Diabetes: A Single-Center Retrospective Cohort Study","Parinee Kemchoknatee","2026","Clinical ophthalmology","nonrandomized_study","article","10.2147/opth.s629343",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056706","Síndrome cardiorrenal","Mirlene Gonçalves Santos","2026","Revista de Divulgação Científica Sena Aires","nonrandomized_study","article","10.36239/revisa.v15.nesp4.p41a46",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056707","Previous bariatric surgery before knee arthroplasty: A cautious interpretation","Xia Qu","2026","Knee Surgery Sports Traumatology Arthroscopy","nonrandomized_study","article","10.1002/ksa.70640",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056708","Physical activity as an adjuvant to GLP-1 receptor agonist therapy: A scoping review protocol","Sjaan R. Gomersall","2026","OSF Preprints (OSF Preprints)","protocol","article",null,null,null,null,null,"openalex","FALSE","no_doi","5","FALSE","preprint"],["R0056709","BEYOND WEIGHT LOSS: EMERGING EXTRA-METABOLIC APPLICATIONS OF GLP-1 RECEPTOR AGONISTS IN CARDIOVASCULAR, RENAL, NEUROLOGICAL AND INFLAMMATORY DISORDERS: A NARRATIVE REVIEW","Paulina Bigda","2026","International Journal of Innovative Technologies in Social Science","randomized_trial","article","10.31435/ijitss.3(51).2026.6153",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","review"],["R0056710","Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement","Sarah Dib","2026","The Lancet Obstetrics Gynaecology & Women s Health","systematic_review","article","10.1016/s3050-5038(26)00266-9",null,null,null,null,"openalex","FALSE","paywalled","3","FALSE","review"],["R0056711","Patient-centred outcomes with incretin-based therapies and sodium-glucose cotransporter 2 inhibitors in obesity-related heart failure with preserved ejection fraction: a programme-level systematic review and meta-analysis","Muhammad Daniyal Khan","2026","Cardiology in the Young","systematic_review","article","10.1017/s1047951126124317",null,null,null,null,"openalex","TRUE","open_pdf","3","FALSE","review"],["R0056712","Мультидисциплинарный консенсус Казахстана по лечению ожирения: путь пациента, роли мультидисциплинарной команды и приоритеты внедрения.","В.Н. Локшин","2026","Репродуктивная медицина (Центральная Азия)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056713","O5 A multi-centre randomised controlled trial with nested cost-effectiveness evaluation ofscreening for liver disease in people living with type 2 diabetes in primary caref","Ryan Buchanan","2026",null,"randomized_trial","article","10.1136/gutjnl-2026-basl.3",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","conference-paper"],["R0056714","Cross-sectional retrospective analysis assessing the role of GLP-1 receptor agonists in reducing cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa","Megan Lau","2026","Archives of Dermatological Research","nonrandomized_study","article","10.1007/s00403-026-04968-y",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056715","Target Trial Emulation of Semaglutide vs Tirzepatide on Cardiovascular Outcomes in Patients with Obesity and Established CVD","Rafeya V. Raquib","2026","Epidemiology","nonrandomized_study","article","10.1097/01.ede.0001280036.48687.e9",null,null,null,null,"openalex","FALSE","paywalled","4","FALSE","article"],["R0056716","Semaglutide and Linagliptin are Finally Here in Pakistan",null,"2021","Journal of Pakistan Society of Internal Medicine.","other","article","10.70302/jpsim.v2i4.2180",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056717","Beyond glucocentric control: Multisystemic efficacy and pleiotropic effects of tirzepatide: A literature review","Luis Fernando Torres Flores","2026","International Journal of Research in Medical Science","nonrandomized_study","article","10.33545/26648733.2026.v8.i10a.265",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","article"],["R0056718","WEIGHT REBOUND AFTER GLP-1 DISCONTINUATION IN INDIA: A HIGH-RISK CARDIOMETABOLIC TRANSITION","Dr. Depti Bellani1*, Dr. Anish Desai1, Dr. Sunaina Anand1, Dr. Shivani Mishra1, Dr. Srishti Priya Maldahiar1","2026","Zenodo (CERN European Organization for Nuclear Research)","randomized_trial","article","10.5281/zenodo.23275960",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0056719","Non-prescription dispensing of injectable weight-loss medicines in iran: regulatory, ethical, and patient-safety concerns","Hamed Mirzaei","2026","Journal of the Iranian Scientific Association of Medical Ethics","randomized_trial","article","10.66224/jirme.2.3.61",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056720","Transient proximal tubular dysfunction (Fanconi-like Syndrome) associated with semaglutide therapy in the setting of rapid weight loss and severe dietary restriction: a diagnostic challenge","S. Prasad","2026","BMC Nephrology","other","article","10.1186/s12882-026-05405-y",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056721","OPTICAL COHERENCE TOMOGRAPHY AND C-PEPTIDE FOLLOW-UP IN A CHILD WITH WOLFRAM'S SYNDROME TREATED WITH LIRAGLUTIDE","E Tirelli","2020","Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056722","Long-term metabolic regulation in the era of GLP-1 receptor agonists: An integrative review of Ayurvedic and biomedical perspectives","Trupti Naikare","2026","Journal of Ayurveda and Integrative Medicine","narrative_review","article","10.1016/j.jaim.2026.101406",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056723","Liraglutide reduces lipid accumulation in human orbital fibroblasts in Graves’ orbitopathy","Chih-Wei Shih","2026","Frontiers in Endocrinology","preclinical","article","10.3389/fendo.2026.1914378",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056724","Insights from multi-omics on GLP-1 receptor agonists in type 2 diabetes and obesity","Asma A. Elashi","2026","Frontiers in Pharmacology","other","article","10.3389/fphar.2026.1812193",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056725","Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications","Shaminie J. Athinarayanan","2026","medRxiv","nonrandomized_study","article","10.64898/2026.10.09.26365158",null,null,null,null,"openalex","TRUE","open_pdf","4","FALSE","preprint"],["R0056726","Polyendocrine metabolic ovarian syndrome (PMOS, formerly Polycystic Ovary Syndrome): a systems-biology perspective on neuroendocrine, immuno-metabolic and epigenetic mechanisms across the life course","Yao He","2026","Journal of Ovarian Research","other","article","10.1186/s13048-026-02290-9",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056727","Tirzepatide Injections in Miami: What You Should Know Before Starting","Tirzepatide Injections Miami","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23338486",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056728","Investigating the Effects of Tirzepatide on NAFLD/NASH Progression Using 3D Human Liver Organoids","Barry Wei","2024","Insight Indiana University Medical Student Research Journal","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056729","Energy-Based Devices for GLP-1 Receptor Agonist–Associated Facial Aging: A Tissue-Specific Safety Framework","Chang-Hwan Cho","2026","Dove Medical Press (Taylor and Francis Group)","narrative_review","article","10.2147/ccid.s628537",null,null,null,null,"openalex","TRUE",null,null,"FALSE","review; article"],["R0056730","Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials","Andrea Mari","2023","Newcastle University ePrints (Newcastle Univesity)","randomized_trial","article","10.25405/ncl.34464717",null,null,null,null,"openalex","TRUE","paywalled","2","FALSE","article"],["R0056731","Pharmacological therapy and dietary intervention for obesity management: A one-year prospective cohort study in Baghdad","Duaa Mohammed Al-Atta","2026","Journal of Education and Health Promotion","nonrandomized_study","article","10.4103/jehp.jehp_2134_25",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056732","Exendin-4 Anti-Inflammatory Pleiotropy: Decoding Molecular Signaling Pathways from Metabolic Control to Tissue Protection","Heba Samy Shoukry","2026","Journal of Pioneering Medical Science","other","article","10.47310/jpms2026150903",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056733","In Silico Development of a Retatrutide Injectable Formulation for a Multidose Cartridge","Ilyan Kan","2026","Preprints.org","other","article","10.20944/preprints202610.0866.v1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056734","12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study","Nicholas Angelopoulos","2026","Obesity Pillars","nonrandomized_study","article","10.1016/j.obpill.2026.100344",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056735","Drug-specific industry payments and cardiologists' adoption of semaglutide in Medicare Part D, 2019-2024: a staggered difference-in-differences study","Joseph Anthony Mardini","2026","Open Science Framework","other","article","10.17605/osf.io/qsx5t",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056736","Comparative effectiveness of GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas on weight change among people with HIV: a real-world longitudinal cohort study","Lara Haidar","2026","BMC Medicine","nonrandomized_study","article","10.1186/s12916-026-05219-7",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056737","Insulin Intensification and Simplification Strategies in Patients with Type 2 Diabetes and Overweight or Obesity: A Scoping Review","Chew Huey Chua","2026","International Journal of Molecular Sciences","nonrandomized_study","article","10.3390/ijms27209050",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056738","Efficacy of low-dose pioglitazone in combination with exenatide on glucose control in patients with T2DM","Muhammad A Abdul‐Ghani","2026","BMJ Open Diabetes Research & Care","other","article","10.1136/bmjdrc-2026-006294",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056739","Effects of liraglutide on thyroid function tests in euthyroid patients with obesity","Yusuf Elma","2026","Gazzetta Medica Italiana Archivio per le Scienze Mediche","other","article","10.23736/s0393-3660.25.06282-5",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056740","GLP-1 receptor agonists as potential disease-modifying agents in Parkinson’s and Alzheimer’s disease: mechanisms, clinical trial evidence, and the neuroprotection horizon","Mohamed Alsharif","2026","Frontiers in Aging Neuroscience","other_trial","article","10.3389/fnagi.2026.1969490",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0056741","Tirzepatide use and the risk of endometrial cancer in women with overweight or obesity: a retrospective cohort study","Pin-Ni Kao","2026","Diabetology & Metabolic Syndrome","nonrandomized_study","article","10.1186/s13098-026-02329-3",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056742","Obstructive sleep apnea and initiation of GLP-1 receptor agonists versus SGLT2 inhibitors in type 2 diabetes","Chien‐Yu Tseng","2026","Sleep Epidemiology","other","article","10.1016/j.sleepe.2026.100178",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056743","High-Loading Seplife Fmoc-RinkAmide-PS-PEG Resin: A Robust Solid Support for the Synthesis of Complex Peptides and Tirzepatide","A. Kumar","2026","European Peptide Symposium (EPS)","other","article","10.17952/38eps.2026.p025",null,null,null,null,"openalex","TRUE",null,null,"FALSE","conference-paper"],["R0056744","Cardiometabolic Substrate Modification in Atrial Fibrillation: Obesity and Epicardial Adipose Tissue in the Era of Incretin-Based Therapies and Catheter Ablation","Andrea Matteucci","2026","Journal of Cardiovascular Development and Disease","randomized_trial","article","10.3390/jcdd13100512",null,null,null,null,"openalex","TRUE","free_to_read","2","FALSE","article"],["R0056745","Glucagon-like Peptide-1-based and Emerging Cardiometabolic Therapies in Heart Failure with Preserved Ejection Fraction: Linking Molecular Mechanisms to Clinical Outcomes.","Merolla A","2026","Cardiac failure review","narrative_review","article","10.15420/cfr.2026.22","42865775","PMC13655748",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0056746","Zauberformel mit Schattenseiten – Abnehmspritzen","Mona Herz","2026","physiopraxis","other","article","10.1055/a-2881-7259",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056747","Modern methods for the diagnosis and management of obesity","Мыринова Ольга Александровна","2026","Meditsinskiy sovet = Medical Council","other","article","10.21518/ms2026-296",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056748","Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis.","Shah P","2026","Blood cancer journal","nonrandomized_study","article","10.1038/s41408-026-01618-4","42864319",null,null,null,"pubmed; openalex","TRUE","open_pdf","4","FALSE","Letter; article"],["R0056749","In the Era of GLP-1 and Obesity Surgery, Weight Loss Modality Matters: Anatomical Patterns of Body Contouring Across 703,438 Weight Loss Patients","Adam Boukind","2026","Plastic & Reconstructive Surgery Global Open","other","article","10.1097/01.gox.0001279428.67162.e1",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056750","Association of semaglutide or tirzepatide and tobacco use disorder in patients with cancer history and type 2 diabetes: A real-world cohort study.","Chuan Angel Lu","2026","JCO Oncology Practice","nonrandomized_study","article","10.1200/op.2026.22.10_suppl.649",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","conference-abstract"],["R0056751","International Society of Sports Nutrition position stand: diets for body weight reduction.","Aragon AA","2026","Journal of the International Society of Sports Nutrition","narrative_review","article","10.1080/15502783.2026.2740266","42867412",null,null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; Review; article"],["R0056752","Pancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reports.","Wu Y","2026","Frontiers in endocrinology","nonrandomized_study","article","10.3389/fendo.2026.1941948","42865361","PMC13654742",null,null,"pubmed; openalex","TRUE","open_europepmc","4","FALSE","Journal Article; article"],["R0056753","Evidence on the Use of GLP-1 Receptor Agonists to Dual GIP/GLP-1 Receptor Agonists in the Management of Obstructive Sleep Apnea: A Scoping Review","Jéssica Coutinho Furtado","2026","OSF Preprints (OSF Preprints)","nonrandomized_study","article","10.17605/osf.io/ns74u",null,null,null,null,"openalex","TRUE","paywalled","4","FALSE","preprint"],["R0056754","A GPCR-Signaling Addiction Hub in the Murine Nucleus Accumbens and Its Partial Restitution by a GLP-1 Receptor Agonist: A Retrospective Transcriptomic Analysis","Ruby Baik","2026","Preprints.org","nonrandomized_study","article","10.20944/preprints202610.0695.v1",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","preprint"],["R0056755","Obesity-associated cancer mortality in the United States, 1999–2023: Diverging racial trends in the era of emerging GLP-1 receptor agonist therapy.","Mobeen Sajjad","2026","JCO Oncology Practice","nonrandomized_study","article","10.1200/op.2026.22.10_suppl.220",null,null,null,null,"openalex","FALSE","open_pdf","4","FALSE","conference-abstract"],["R0056756","Project Genesis: MANIFESTO — STABLE DESTABILIZATION LOOP TITLE: Cheap Sugar Institutionalization 1941-2026","David Michael Seagal","2026","Zenodo (CERN European Organization for Nuclear Research)","other","article","10.5281/zenodo.23338543",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056757","Elevated circulating Netrin-4 levels in women with polycystic ovary syndrome: a cross-sectional study and multiple intervention studies","Xueting Cui","2026","BMC Endocrine Disorders","other","article","10.1186/s12902-026-02584-5",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056758","GLP-1 Revolution and Future of Food Systems: Current Evidence, Emerging Trends, & Projected Impacts","Claire Darizu Munialo","2026","Food and Humanity","other","article","10.1016/j.foohum.2026.101569",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056759","Incretin-Based Agents and Reproduction, Fertility and Pregnancy: A Systematic Review and Meta-Analysis","Károly Szili","2026","Open Science Framework","systematic_review","article","10.17605/osf.io/rthdu",null,null,null,null,"openalex","TRUE","paywalled","3","FALSE","other"],["R0056760","Signature Definition Shapes Associations Between Exenatide-Related Transcriptional Programs and Macrophage Senescence Scores in Colorectal Cancer","Yunying Song","2026","Genes","preclinical","article","10.3390/genes17101266",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056761","Recovery from liraglutide-induced acute liver injury assessed for causality using the updated RUCAM as global gold standard: A case report and literature review.","Su F","2026","International journal of clinical pharmacology and therapeutics","case_report","article","10.5414/cp205028","42867191",null,null,null,"pubmed; openalex","FALSE",null,null,"FALSE","Journal Article; article"],["R0056762","Counterfeit and unregulated GLP-1 receptor agonists: an unmeasured variable in emergency department procedural sedation risk","Sidhant Ochani","2026","Emergency Medicine Journal","other","article","10.1136/emermed-2026-216495",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056763","Abstract A055: Dissecting the role of GLP-1 signaling during PDAC initiation and progression","Chunxiao Ren","2026","Cancer Research","preclinical","article","10.1158/1538-7445.pancreatic26-a055",null,null,null,null,"openalex","FALSE",null,null,"FALSE","conference-abstract"],["R0056764","Body Weight Changes and Exploratory Metabolic Outcomes During Semaglutide and Tirzepatide Treatment: A Real-World Longitudinal Cohort Study from Türkiye","Esra DEMİR","2026","Journal of Clinical Medicine","nonrandomized_study","article","10.3390/jcm15207876",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056765","Real-World Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Gout Outcomes and Metabolic Profiles","Merna Abdelsalhen","2026","Ibnosina Journal of Medicine and Biomedical Sciences","nonrandomized_study","article","10.1055/s-0046-1827830",null,null,null,null,"openalex","TRUE","free_to_read","4","FALSE","article"],["R0056766","Sannleikur eða glans","Petra Reykjalín Helgadóttir 2000-","2026","Skemman","other","article",null,null,null,null,null,"openalex","FALSE",null,null,"FALSE","dissertation"],["R0056767","Electron Beam Terminal Sterilization of a Thermolabile Retatrutide Injectable in a Multidose Cartridge","Ilyan Kan","2026","Preprints.org","other","article","10.20944/preprints202610.0866.v2",null,null,null,null,"openalex","TRUE",null,null,"FALSE","preprint"],["R0056768","GLP-1 as a Regulator of Oxidative Signalling in Metabolic Health and Disease","Natalia Kurhaluk","2026","Antioxidants","other","article","10.3390/antiox15101283",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056769","User-Generated Health Information on TikTok: Engagement, Risk Disclosure, and Consumer Implications of GLP-1 Weight Loss Content","Raphaela Barboza Arruda Farinha","2026","Journal of Consumer Health on the Internet","other","article","10.1080/15398285.2026.2742794",null,null,null,null,"openalex","FALSE",null,null,"FALSE","article"],["R0056770","EFEK PEMBERIAN EKSTRAK DAUN PUNICA GRANATUM L. TERHADAP KADAR GLP-1 PADA TIKUS OBESITAS YANG DIINDUKSI DENGAN DIET TINGGI LEMAK = EFFECTS OF PUNICA GRANATUM L. LEAF EXTRACT ADMINISTRATION ON GLP-1 LEVELS IN OBESE RATS INDUCED WITH HIGH-FAT DIET","EVITASARI EVITASARI","2025","Hasanuddin University Repository","preclinical","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","dissertation"],["R0056771","Effets de l’utilisation d’un inhibiteur du cotransporteur sodium-glucose de type 2 sur les évènements cardiovasculaires indésirables majeurs chez des participants vivant avec un diabète de type 2 et une maladie cardiovasculaire athérosclérotique traites par tirzépatide versus dulaglutide (SURPASS-CVOT)","M. Le Bleis","2026","Annales d Endocrinologie","other_trial","article","10.1016/j.ando.2026.102759",null,null,null,null,"openalex","TRUE","open_pdf","5","FALSE","article"],["R0056772","Hope, hype, and high costs: Navigating glucagon-like Peptide-1 based therapy initiation among young adults.","Das Gupta S","2026","Obesity pillars","other","article","10.1016/j.obpill.2026.100338","42859781","PMC13653475",null,null,"pubmed; openalex","TRUE",null,null,"FALSE","Journal Article; article"],["R0056773","Lithium toxicity following initiation of tirzepatide in a patient with bipolar I disorder","Janvi Bhupendrakumar Patel","2026","International Journal of Research in Medical Sciences","other","article","10.18203/2320-6012.ijrms20263555",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056774","Semaglutide Weight Loss Miami for Personalised Medical Support","Semaglutide weight loss Miami","2026","Zenodo (CERN European Organization for Nuclear Research)","preclinical","article","10.5281/zenodo.23339692",null,null,null,null,"openalex","TRUE",null,null,"FALSE","other"],["R0056775","Cautious Optimism Warranted for Stem Cell-Derived Islet Transplantation in Type 2 Diabetes","Hanne Scholz","2024","Transplant International","other_trial","article","10.3389/ti.2024.13358","39131791",null,null,null,"openalex","TRUE","free_to_read","5","FALSE","article"],["R0056776","PQ-37878-24 - David Cullinane","Health Service Executive","2024","Lenus, The Irish Health Repository (Dr Steevens Hospital Library)","other","article",null,null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056777","Accuracy, potential harm, weight stigma, and commercial influence in short-form social media content on incretin-based therapies for obesity","Yeo-Jun Yoon","2026","Frontiers in Endocrinology","other","article","10.3389/fendo.2026.1844311",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056778","ROS–NLRP3 Inflammasome Axis in Obesity: A Critical Review of Oxidative Stress-Driven Inflammation and Emerging Therapeutic Strategies","Sungeun Ahn","2026","Medicina","narrative_review","article","10.3390/medicina62101969",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056779","Research trends in GLP-1 receptor agonist marketing, social media, and safety: A bibliometric analysis and focused narrative synthesis","Derren DCH. Rampengan","2026","Obesity Medicine","other","article","10.1016/j.obmed.2026.100751",null,null,null,null,"openalex","TRUE",null,null,"FALSE","article"],["R0056780","Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","Blicher, Thalia Marie","2019","Repository@Hull (Worktribe) (University of Hull)","randomized_trial","article","10.1016/s2213-8587%2819%2930192-5",null,null,null,null,"openalex","TRUE","open_pdf","2","FALSE","article"],["R0056781","The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide.","Wettergren A","1998","Peptides","preclinical","article","10.1016/s0196-9781(98)00020-5","9663453",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056782","GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.","Deacon CF","2002","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00452.2001","11882507",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056783","Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.","Vahl TP","2003","The Journal of clinical endocrinology and metabolism","other","article","10.1210/jc.2002-021479","12679472",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S."],["R0056784","N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.","Green BD","2004","The Journal of endocrinology","preclinical","article","10.1677/joe.0.1800379","15012592",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056785","The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice.","Rolin B","2004","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2004.05.013","15212985",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056786","Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.","Nikolaidis LA","2005","American journal of physiology. Heart and circulatory physiology","preclinical","article","10.1152/ajpheart.00347.2005","16024574",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, N.I.H., Extramural"],["R0056787","The GLP-1 system as a therapeutic target.","Edwards CM","2005","Annals of medicine","nonrandomized_study","article","10.1080/07853890510037400","16179267",null,null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Review"],["R0056788","Biophysical signatures of noncovalent aggregates formed by a glucagonlike peptide-1 analog: a prototypical example of biopharmaceutical aggregation.","Doyle BL","2005","Journal of pharmaceutical sciences","other","article","10.1002/jps.20420","16258989",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056789","The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.","Zander M","2006","Diabetologia","randomized_trial","article","10.1007/s00125-005-0098-y","16385384",null,null,null,"pubmed","FALSE","open_pdf","2",null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0056790","The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.","Meier JJ","2006","American journal of physiology. Endocrinology and metabolism","other","article","10.1152/ajpendo.00576.2005","16403774",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056791","[New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].","Kluz J","2006","Postepy higieny i medycyny doswiadczalnej (Online)","narrative_review","article",null,"16407790",null,null,null,"pubmed","FALSE",null,null,null,"English Abstract; Journal Article; Review"],["R0056792","Relative contribution of incretins to the glucose lowering effect of DP IV inhibitors in type 2 diabetes mellitus (T2DM).","Hinke SA","2006","Advances in experimental medicine and biology","narrative_review","article","10.1007/0-387-32824-6_13","16700515",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056793","Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.","Parker JC","2006","The Journal of endocrinology","preclinical","article","10.1677/joe.1.06904","17065392",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056794","Preliminary studies of the physical stability of a glucagon-like peptide-1 derivate in the presence of metal ions.","Christensen S","2007","European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V","other","article","10.1016/j.ejpb.2006.11.019","17196802",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056795","Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function.","Saraceni C","2007","Drugs in R&D","narrative_review","article","10.2165/00126839-200708030-00002","17472410",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056796","Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.","Gallwitz B","2007","Vascular health and risk management","narrative_review","article","10.2147/vhrm.2007.3.2.203","17580730","PMC1994027",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056797","Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway.","Liu J","2007","Neurochemistry international","preclinical","article","10.1016/j.neuint.2007.04.021","17629357",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056798","Adverse effects of incretin therapy for type 2 diabetes.","Grouzmann E","2007","JAMA","commentary","article","10.1001/jama.298.15.1759-b","17940229",null,null,null,"pubmed","FALSE",null,null,null,"Comment; Letter"],["R0056799","Clinical decisions. Management of type 2 diabetes.","Goldberg RB","2008","The New England journal of medicine","other","article","10.1056/nejmclde0708469","18199869",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056800","The GLP-1 concept in the treatment of type 2 diabetes--still standing at the gate of dawn?","Schmitz O","2008","The Journal of clinical endocrinology and metabolism","commentary","article","10.1210/jc.2007-2750","18258781",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0056801","Insight into antidiabetic therapies: a report from the 43rd annual meeting of the European Association for the Study of Diabetes.","Rabasseda X","2007","Timely topics in medicine. Cardiovascular diseases","other","article",null,"18297140",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0056802","From insulin to incretins: a report from the 67th scientific sessions of the American Diabetes Association.","Rabasseda X","2007","Timely topics in medicine. Cardiovascular diseases","other","article",null,"18297152",null,null,null,"pubmed","FALSE",null,null,null,"Conference Proceedings"],["R0056803","Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.","Miranda LP","2008","Journal of medicinal chemistry","other","article","10.1021/jm701522b","18412318",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056804","GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide.","Elahi D","2008","Obesity (Silver Spring, Md.)","other","article","10.1038/oby.2008.229","18421270",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't"],["R0056805","[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].","Gabbay Mde A","2008","Arquivos brasileiros de endocrinologia e metabologia","other_trial","article","10.1590/s0004-27302008000200015","18438538",null,null,null,"pubmed","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0056806","New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.","Gagliardino JJ","2008","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.9.9.1495","18518780",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056807","Managing postprandial glucose levels in patients with diabetes.","Tenzer-Iglesias P","2008","The Journal of family practice","narrative_review","article",null,"18662529",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056808","[Antidiabetics and the incretin system].","Høibraaten E","2008","Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke","commentary","article",null,"18787580",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0056809","Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period.","Padidela R","2009","European journal of endocrinology","other","article","10.1530/eje-08-0807","18952761",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056810","Current and emerging therapies in nonalcoholic fatty liver disease.","Kashi MR","2008","Seminars in liver disease","narrative_review","article","10.1055/s-0028-1091984","18956296",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056811","GLP-1 regulates gastroduodenal motility involving cholinergic pathways.","Schirra J","2009","Neurogastroenterology and motility","randomized_trial","article","10.1111/j.1365-2982.2008.01246.x","19220754",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0056812","Gateways to Clinical Trials.","Tomillero A","2008","Methods and findings in experimental and clinical pharmacology","other","article",null,"19229381",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056813","Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention.","Karaca M","2009","Diabetes & metabolism","narrative_review","article","10.1016/j.diabet.2008.09.007","19251449",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056814","Minireview: Gut peptides: targets for antiobesity drug development?","Moran TH","2009","Endocrinology","narrative_review","article","10.1210/en.2009-0003","19372201","PMC2689798",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0056815","The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart.","Ossum A","2009","Pharmacological research","preclinical","article","10.1016/j.phrs.2009.06.004","19540343",null,null,"S000566","pubmed","FALSE","paywalled","5",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056816","Novo awaits green light for diabetes drug.","May M","2009","Nature biotechnology","commentary","article","10.1038/nbt0809-682c","19668159",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0056817","New therapies for diabesity.","Bailey CJ","2009","Current diabetes reports","narrative_review","article","10.1007/s11892-009-0057-y","19793506",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056818","A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism.","Burcelin R","2009","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2009.09.003","19800290",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056819","[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].","Gallwitz B","2010","Pharmazie in unserer Zeit","narrative_review","article","10.1002/pauz.201000358","20196038",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056820","[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].","Menge BA","2010","Medizinische Klinik (Munich, Germany : 1983)","case_report","article","10.1007/s00063-010-1026-6","20349294",null,null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article; Review"],["R0056821","Intein-mediated expression and purification of an analog of glucagon-like peptide-1 in Escherichia coli.","Ma C","2010","Protein and peptide letters","preclinical","article","10.2174/092986610792231582","20441562",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056822","Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?","Olansky L","2010","Cleveland Clinic journal of medicine","other","article","10.3949/ccjm.77a.09167","20682512",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056823","Glucagon-like peptide 1--a cardiologic dimension.","Treiman M","2010","Trends in cardiovascular medicine","narrative_review","article","10.1016/j.tcm.2010.02.012","20685571",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056824","Improving treatment success rates for type 2 diabetes: recommendations for a changing environment.","Triplitt C","2010","The American journal of managed care","narrative_review","article",null,"20809668",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056825","Oral hypoglycaemics - a review of the evidence.","Phillips PJ","2010","Australian family physician","narrative_review","article",null,"20877770",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056826","A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1.","Patterson JT","2011","ACS chemical biology","preclinical","article","10.1021/cb1002015","20939591",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056827","The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients.","Combes J","2011","Diabetes, obesity & metabolism","narrative_review","article","10.1111/j.1463-1326.2010.01311.x","21199263",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056828","What's new in diabetes: incretins and C-peptide.","Marks V","2011","Medical principles and practice : international journal of the Kuwait University, Health Science Centre","narrative_review","article","10.1159/000321278","21252561",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056829","Development of controlled release formulations by means of ALRISE's ImSus(®) platform technology.","Seemann H","2010","Journal of controlled release : official journal of the Controlled Release Society","preclinical","article","10.1016/j.jconrel.2010.07.009","21529597",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056830","Disulfide bond prolongs the half-life of therapeutic peptide-GLP-1.","Li Y","2011","Peptides","preclinical","article","10.1016/j.peptides.2011.05.003","21600946",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056831","GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.","Roth JD","2012","British journal of pharmacology","narrative_review","article","10.1111/j.1476-5381.2011.01537.x","21671898","PMC3415643",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056832","Incretins yesterday, pleiotropic gastrointestinal hormones today:glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).","Kiec-Klimczak ME","2011","Recent patents on endocrine, metabolic & immune drug discovery","narrative_review","article","10.2174/187221411797265863","21913887",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056833","[Role of oxidative stress in pathogenesis of diabetic nephropathy].","Inoguchi T","2011","Nihon Jinzo Gakkai shi","narrative_review","article",null,"22073866",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056834","[Microinflammation in diabetic nephropathy].","Ogawa D","2011","Nihon Jinzo Gakkai shi","narrative_review","article",null,"22073867",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056835","The diabetologist/cardiologist debate: a meeting of the minds.","Mohamed F","2012","Cardiovascular journal of Africa","other","article",null,"22447480",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056836","Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice.","Porter D","2012","Peptides","preclinical","article","10.1016/j.peptides.2012.03.014","22465882",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056837","Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.","Salcedo I","2012","British journal of pharmacology","narrative_review","article","10.1111/j.1476-5381.2012.01971.x","22519295","PMC3419902",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Intramural; Review"],["R0056838","Update on drugs to treat diabetes.","Game F","2012","Annals of the Royal College of Surgeons of England","other","article","10.1308/rcsann.2012.94.4.221","22613296","PMC3957497",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056839","Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.","Issa CM","2012","Current diabetes reports","narrative_review","article","10.1007/s11892-012-0291-6","22767380",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056840","[Prospects for incretin-related drugs].","Kurose T","2012","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"22768602",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056841","[Perspective of new and future treatment of type 2 diabetes].","Sasaoka T","2012","Nihon rinsho. Japanese journal of clinical medicine","other","article",null,"22768603",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056842","A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1.","Egom EE","2012","Therapeutic advances in cardiovascular disease","narrative_review","article","10.1177/1753944712457598","22902834",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056843","Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling.","Lockie SH","2012","Diabetes","preclinical","article","10.2337/db11-1556","22933116","PMC3478556",null,"S002367","pubmed","FALSE","open_pdf","5",null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0056844","Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice.","Ma T","2012","The Journal of neuroscience : the official journal of the Society for Neuroscience","preclinical","article","10.1523/jneurosci.2107-12.2012","23035082","PMC3475870",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0056845","[Incretin modulators, a new perspective in diabetes mellitus treatment].","Lupaşcu FG","2012","Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi","other","article",null,"23077965",null,null,null,"pubmed","FALSE",null,null,null,"English Abstract; Journal Article"],["R0056846","Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.","Li N","2012","PloS one","preclinical","article","10.1371/journal.pone.0047936","23094100","PMC3477139",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056847","Cycloart-23-ene-3β, 25-diol stimulates GLP-1 (7-36) amide secretion in streptozotocin-nicotinamide induced diabetic Sprague Dawley rats: a mechanistic approach.","Badole SL","2013","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2012.10.002","23117087",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056848","Mechanisms of current therapies for diabetes mellitus type 2.","Thulé PM","2012","Advances in physiology education","narrative_review","article","10.1152/advan.00094.2012","23209008","PMC3776431",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review"],["R0056849","Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control?","Araújo F","2012","Journal of diabetes science and technology","narrative_review","article","10.1177/193229681200600630","23294796","PMC3570891",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056850","[Effects of glucagon-like peptide 1(9-36) on endothelial nitric oxide synthase in human umbilical vein endothelial cells].","Ding L","2012","Zhonghua yi xue za zhi","other","article","10.3760/cma.j.issn.0376-2491.2012.42.016","23328297",null,null,null,"pubmed","FALSE",null,null,null,"English Abstract; Journal Article"],["R0056851","Medicinal chemistry of glucagon-like peptide receptor agonists.","Jones LH","2013","Progress in medicinal chemistry","narrative_review","article","10.1016/b978-0-444-62652-3.00002-8","23384666",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056852","Glucagon-like peptide-1(9-36) inhibits chemokine-induced migration of human CD4-positive lymphocytes.","Liberman A","2013","PloS one","other","article","10.1371/journal.pone.0058445","23469279","PMC3587602",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056853","Hyperlipidaemia and cardiovascular disease -- newer antihyperglycaemic agents and cardiovascular disease.","Peter R","2013","Current opinion in lipidology","commentary","article","10.1097/mol.0b013e32835ec5f5","23481234",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0056854","Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects.","Sathananthan M","2013","Diabetes","other","article","10.2337/db13-0140","23545708","PMC3717878","ClinicalTrials.gov:NCT01218633",null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0056855","Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.","González-Ortiz M","2013","Diabetes technology & therapeutics","randomized_trial","article","10.1089/dia.2013.0020","23617250",null,null,null,"pubmed","FALSE","paywalled","2",null,"Comparative Study; Journal Article; Randomized Controlled Trial"],["R0056856","Resistant starch from high amylose maize (HAM-RS2) and dietary butyrate reduce abdominal fat by a different apparent mechanism.","Vidrine K","2014","Obesity (Silver Spring, Md.)","preclinical","article","10.1002/oby.20501","23630079",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0056857","The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.","Shah P","2013","The Journal of clinical endocrinology and metabolism","other","article","10.1210/jc.2013-1029","23633194",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056858","The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.","van Leeuwen N","2013","Clinical pharmacokinetics","narrative_review","article","10.1007/s40262-013-0076-3","23719679",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056859","Use of non-insulin therapies for type 1 diabetes.","Garg SK","2013","Diabetes technology & therapeutics","narrative_review","article","10.1089/dia.2013.0281","24131372",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Review"],["R0056860","Complications of diabetes therapy.","Corathers SD","2013","Endocrinology and metabolism clinics of North America","narrative_review","article","10.1016/j.ecl.2013.06.005","24286957","PMC6533625",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056861","Developments of glucagon like peptide-1 (GLP-1) and long-acting analogs in clinical and preclinical studies for treatment of type 2 diabetes.","Li Y","2013","Current pharmaceutical biotechnology","narrative_review","article","10.2174/1389201014666131227120546","24372261",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056862","The nonhuman primate as a model for type 2 diabetes.","Pound LD","2014","Current opinion in endocrinology, diabetes, and obesity","preclinical","article","10.1097/med.0000000000000043","24569549",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Review"],["R0056863","Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs.","Eng H","2014","Xenobiotica; the fate of foreign compounds in biological systems","preclinical","article","10.3109/00498254.2014.897011","24588343",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056864","Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance.","Punjabi M","2014","Endocrinology","preclinical","article","10.1210/en.2013-1447","24601880",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0056865","Beyond insulin: what else might help?","Scheiner G","2014","Diabetes self-management","other","article",null,"24640060",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056866","Characterization of [¹²⁵I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta.","Kuc RE","2014","Life sciences","preclinical","article","10.1016/j.lfs.2014.03.011","24641952",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056867","Incretin therapy and pancreatic pathologies: background pathology versus drug-induced pathology in rats.","Egan JM","2014","Diabetes","preclinical","article","10.2337/db13-1909","24651798","PMC3964500",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Intramural; Comment"],["R0056868","The safety of incretin based drugs.","Montori VM","2014","BMJ (Clinical research ed.)","commentary","article","10.1136/bmj.g2779","24764568",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0056869","Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.","Faillie JL","2014","BMJ (Clinical research ed.)","nonrandomized_study","article","10.1136/bmj.g2780","24764569","PMC4002758",null,null,"pubmed","FALSE","open_pdf","4",null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0056870","JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, improves hyperglycemia and dyslipidemia independent of suppression of food intake in diabetic rats.","Sakata S","2014","Journal of diabetes research","preclinical","article","10.1155/2014/803832","24895641","PMC4033514",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056871","A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification.","Nolte WM","2014","Nature chemical biology","other","article","10.1038/nchembio.1581","24997604",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056872","Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism.","Goodwill AG","2014","Basic research in cardiology","preclinical","article","10.1007/s00395-014-0426-9","25005062","PMC4259250",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0056873","Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.","Tremblay AJ","2014","Metabolism: clinical and experimental","other","article","10.1016/j.metabol.2014.06.004","25034387",null,"ClinicalTrials.gov:NCT00660075",null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0056874","Understanding incretins.","Deane AM","2014","Intensive care medicine","narrative_review","article","10.1007/s00134-014-3435-0","25138228",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056875","The role of prediction modeling in propensity score estimation: an evaluation of logistic regression, bCART, and the covariate-balancing propensity score.","Wyss R","2014","American journal of epidemiology","nonrandomized_study","article","10.1093/aje/kwu181","25143475","PMC4157700",null,null,"pubmed","FALSE","open_pdf","4",null,"Comparative Study; Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S."],["R0056876","The shot clock.","Berg EG","2014","Diabetes forecast","other","article",null,"25189001",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056877","A potent α/β-peptide analogue of GLP-1 with prolonged action in vivo.","Johnson LM","2014","Journal of the American Chemical Society","other","article","10.1021/ja507168t","25191938","PMC4183665",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0056878","Medical treatment of obesity: the past, the present and the future.","Bray GA","2014","Best practice & research. Clinical gastroenterology","narrative_review","article","10.1016/j.bpg.2014.07.015","25194183",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056879","Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.","Heruc GA","2014","American journal of physiology. Endocrinology and metabolism","randomized_trial","article","10.1152/ajpendo.00370.2014","25231186",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0056880","Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.","Tsuchimochi W","2015","Endocrine journal","other","article","10.1507/endocrj.ej14-0393","25252844",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056881","[Hormonal deficiencies in the elderly: is there a role for replacement therapy?].","Racaru-Honciuc V","2014","Revue medicale suisse","other","article",null,"25272673",null,null,null,"pubmed","FALSE",null,null,null,"English Abstract; Journal Article"],["R0056882","Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.","Otsuka Y","2015","Endocrine journal","randomized_trial","article","10.1507/endocrj.ej14-0148","25328079",null,null,null,"pubmed","FALSE","open_pdf","2",null,"Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0056883","[Hypertension and diabetes: target blood pressure and blood pressure lowering by new antidiabetic drugs].","Kintscher U","2014","Deutsche medizinische Wochenschrift (1946)","other","article","10.1055/s-0034-1387420","25409409",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056884","Obesity and type 1 diabetes mellitus management.","Chillarón JJ","2015","Minerva endocrinologica","other_trial","article",null,"25413942",null,null,null,"pubmed","FALSE","no_doi","5",null,"Journal Article; Review"],["R0056885","Gut hormones in the treatment of short-bowel syndrome and intestinal failure.","Jeppesen PB","2015","Current opinion in endocrinology, diabetes, and obesity","other_trial","article","10.1097/med.0000000000000120","25485516",null,null,"S001709","pubmed","FALSE","paywalled","5",null,"Journal Article; Review"],["R0056886","[New medications for patients with type 2 diabetes].","Meillet L","2014","Soins; la revue de reference infirmiere","other","article",null,"25518129",null,null,null,"pubmed","FALSE",null,null,null,"English Abstract; Journal Article"],["R0056887","Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development.","Mittermayer F","2015","Current diabetes reviews","other_trial","article","10.2174/1573399810666141224121927","25537454","PMC4428473",null,null,"pubmed","FALSE","open_pdf","5",null,"Journal Article; Review"],["R0056888","(7) Approaches to glycemic treatment.","American Diabetes Association","2015","Diabetes care","other","article","10.2337/dc15-s010","25537707",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Practice Guideline"],["R0056889","Pharmacological strategies for protection of extrahepatic islet transplantation.","Omori K","2015","Minerva endocrinologica","narrative_review","article",null,"25651758",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review"],["R0056890","In vitro bioactive properties of intact and enzymatically hydrolysed whey protein: targeting the enteroinsular axis.","Power-Grant O","2015","Food & function","preclinical","article","10.1039/c4fo00983e","25666373",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0056891","Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men.","Asmar A","2015","American journal of physiology. Endocrinology and metabolism","other","article","10.1152/ajpendo.00429.2014","25670826",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0056892","Hormone replacement therapy in heart failure.","Arcopinto M","2015","Current opinion in cardiology","randomized_trial","article","10.1097/hco.0000000000000166","25807222",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056893","Soluble dietary fiber (Fibersol-2) decreased hunger and increased satiety hormones in humans when ingested with a meal.","Ye Z","2015","Nutrition research (New York, N.Y.)","randomized_trial","article","10.1016/j.nutres.2015.03.004","25823991",null,"ClinicalTrials.gov:NCT01305291",null,"pubmed","FALSE","paywalled","2",null,"Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't"],["R0056894","Care of type 2 diabetes: where do the new medications fit?","Clem CO","2015","South Dakota medicine : the journal of the South Dakota State Medical Association","other","article",null,"25906502",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056895","Treating posttransplantation diabetes mellitus.","Pérez-Sáez MJ","2015","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2015.1039983","25911206",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056896","Recent advances in glucose-lowering treatment to reduce diabetic kidney disease.","Hanssen NM","2015","Expert opinion on pharmacotherapy","narrative_review","article","10.1517/14656566.2015.1041502","25912195",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056897","Improvement of glycemic control in streptozotocin-induced diabetic rats by Atlantic salmon skin gelatin hydrolysate as the dipeptidyl-peptidase IV inhibitor.","Hsieh CH","2015","Food & function","preclinical","article","10.1039/c5fo00124b","25946069",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056898","Childhood obesity: Current and novel approaches.","Sabin MA","2015","Best practice & research. Clinical endocrinology & metabolism","narrative_review","article","10.1016/j.beem.2015.04.003","26051294",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056899","Dual actions of a novel bifunctional compound to lower glucose in mice with diet-induced insulin resistance.","Chen K","2015","American journal of physiology. Endocrinology and metabolism","preclinical","article","10.1152/ajpendo.00045.2015","26058862","PMC4525113",null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, N.I.H., Extramural"],["R0056900","Effects of flavanols on the enteroendocrine system: Repercussions on food intake.","Pinent M","2017","Critical reviews in food science and nutrition","narrative_review","article","10.1080/10408398.2013.871221","26067747",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056901","Another Agent for Obesity--Will This Time Be Different?","Siraj ES","2015","The New England journal of medicine","commentary","article","10.1056/nejme1506236","26132945",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0056902","Does GLP-1 suppress its own basal secretion?","Elahi D","2016","Endocrine research","other_trial","article","10.3109/07435800.2015.1038353","26186406","PMC5168718",null,null,"pubmed","FALSE","free_to_read","5",null,"Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't"],["R0056903","Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.","Nonogaki K","2015","Diabetes & metabolism","preclinical","article","10.1016/j.diabet.2015.06.005","26234524",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Research Support, Non-U.S. Gov't"],["R0056904","GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop.","Giacco F","2015","Diabetes","other","article","10.2337/db15-0084","26294429","PMC4542449",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0056905","[Liraglutid can support weight loss].","Müssig K","2015","Deutsche medizinische Wochenschrift (1946)","commentary","article","10.1055/s-0041-103438","26360942",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0056906","Contribution of Macrophage Polarization to Metabolic Diseases.","Komohara Y","2016","Journal of atherosclerosis and thrombosis","preclinical","article","10.5551/jat.32359","26412584",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056907","An ex vivo potency assay to assess active drug levels of a GLP-1 agonistic peptide during preclinical safety studies.","Schäfer M","2015","Bioanalysis","preclinical","article","10.4155/bio.15.189","26440381",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056908","Medical treatments of elderly, French patients with type 2 diabetes: results at inclusion in the GERODIAB Cohort.","Doucet JA","2016","Fundamental & clinical pharmacology","nonrandomized_study","article","10.1111/fcp.12160","26478566",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't"],["R0056909","A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.","Gaitonde P","2016","Clinical pharmacokinetics","narrative_review","article","10.1007/s40262-015-0359-y","26798033",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056910","Comment on Giacco et al. GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop. Diabetes 2015;64:3273-3284.","Ceriello A","2016","Diabetes","commentary","article","10.2337/db15-1344","26798129",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0056911","Response to Comment on Giacco et al. GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop. Diabetes 2015;64:3273-3284.","Brownlee M","2016","Diabetes","commentary","article","10.2337/dbi15-0031","26798130",null,null,null,"pubmed","FALSE",null,null,null,"Letter; Comment"],["R0056912","Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathway.","Ma ZG","2016","British journal of pharmacology","preclinical","article","10.1111/bph.13449","26845648","PMC4831312",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056913","L-arginine promotes gut hormone release and reduces food intake in rodents.","Alamshah A","2016","Diabetes, obesity & metabolism","preclinical","article","10.1111/dom.12644","26863991","PMC4982043",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056914","[Drugs affecting the incretin system and renal glucose transport: do they meet the expectations of modern therapy of type 2 diabetes?].","Gumieniczek A","2016","Postepy higieny i medycyny doswiadczalnej (Online)","narrative_review","article","10.5604/17322693.1201126","27180961",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056915","Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.","DeFilippis EM","2016","Current heart failure reports","narrative_review","article","10.1007/s11897-016-0291-y","27188181",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056916","[Management of Type 2 Diabetes: a Practical Approach].","Donath M","2016","Praxis","narrative_review","article","10.1024/1661-8157/a002368","27269776",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article; Review"],["R0056917","Access to diabetes drugs in New Zealand is inadequate.","Krebs J","2016","The New Zealand medical journal","commentary","article",null,"27355224",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0056918","Interplay between bone and incretin hormones: A review.","Mabilleau G","2017","Morphologie : bulletin de l'Association des anatomistes","narrative_review","article","10.1016/j.morpho.2016.06.004","27423214",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056919","The molecular basis for the prolonged blood circulation of lipidated incretin peptides: Peptide oligomerization or binding to serum albumin?","Wang Y","2016","Journal of controlled release : official journal of the Controlled Release Society","other","article","10.1016/j.jconrel.2016.08.035","27578099",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056920","Classification of non-insulin glucose lowering drugs.","Kalra S","2016","JPMA. The Journal of the Pakistan Medical Association","other","article",null,"27812078",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056921","Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes.","Kosiborod M","2017","Journal of diabetes and its complications","other_trial","article","10.1016/j.jdiacomp.2016.08.017","27839923",null,null,null,"pubmed","FALSE","paywalled","5",null,"Journal Article; Review"],["R0056922","[Oral antidiabetic drugs in treatment of type 1 diabetes mellitus].","Brunerová L","2016","Vnitrni lekarstvi","narrative_review","article",null,"28139129",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056923","Bioactivity of a modified human Glucagon-like peptide-1.","Xu F","2017","PloS one","preclinical","article","10.1371/journal.pone.0171601","28152036","PMC5289641",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056924","Resistant maltodextrin or fructooligosaccharides promotes GLP-1 production in male rats fed a high-fat and high-sucrose diet, and partially reduces energy intake and adiposity.","Hira T","2018","European journal of nutrition","preclinical","article","10.1007/s00394-017-1381-7","28161724",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0056925","A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite.","Wewer Albrechtsen NJ","2017","American journal of physiology. Endocrinology and metabolism","other","article","10.1152/ajpendo.00005.2017","28420649",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056926","Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy.","Hasan AA","2017","Journal of molecular endocrinology","narrative_review","article","10.1530/jme-17-0005","28420715",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056927","Recommendations on the effect of antidiabetic drugs in bone.","Rozas-Moreno P","2017","Endocrinologia, diabetes y nutricion","other","article","10.1016/j.endinu.2016.11.001","28440761",null,null,null,"pubmed","FALSE",null,null,null,"Consensus Statement; Journal Article; Practice Guideline"],["R0056928","Do we know the true mechanism of action of the DPP-4 inhibitors?","Andersen ES","2018","Diabetes, obesity & metabolism","narrative_review","article","10.1111/dom.13018","28544214",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056929","[Combination of oral antidiabetic drugs: What fits together?].","Siegmund T","2017","MMW Fortschritte der Medizin","narrative_review","article","10.1007/s15006-017-9902-0","28718116",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056930","Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity.","Will S","2017","Current opinion in pharmacology","narrative_review","article","10.1016/j.coph.2017.07.010","28802873",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056931","Noninsulin Diabetes Medications.","Varghese S","2017","The Nursing clinics of North America","narrative_review","article","10.1016/j.cnur.2017.07.003","29080575",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056932","Optimization of peptide-based polyagonists for treatment of diabetes and obesity.","Knerr PJ","2018","Bioorganic & medicinal chemistry","narrative_review","article","10.1016/j.bmc.2017.10.047","29153547",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056933","Poor responders after bariatric surgery - Are there second chances?","Pérez-Pevida B","2018","Endocrinologia, diabetes y nutricion","commentary","article","10.1016/j.endinu.2017.11.002","29221732",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0056934","The downregulation of sweet taste receptor signaling in enteroendocrine L-cells mediates 3-deoxyglucosone-induced attenuation of high glucose-stimulated GLP-1 secretion.","Wang F","2018","Archives of physiology and biochemistry","preclinical","article","10.1080/13813455.2017.1419366","29277113",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056935","Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB.","Garton M","2018","Proceedings of the National Academy of Sciences of the United States of America","nonrandomized_study","article","10.1073/pnas.1711837115","29378946","PMC5816147",null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056936","New pharmacological approaches for cardiovascular risk.","Mazón Ramos P","2018","Medicina clinica","commentary","article","10.1016/j.medcli.2017.12.015","29496244",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0056937","Latest Developments and Future Perspectives in the Field Of Obesity.","Pérez-Pevida B","2017","European endocrinology","randomized_trial","article","10.17925/ee.2017.13.01.17","29632600","PMC5813439",null,null,"pubmed","FALSE","open_pdf","2",null,"Editorial"],["R0056938","Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.","Huang CJ","2018","Diabetes, obesity & metabolism","systematic_review","article","10.1111/dom.13342","29722116",null,null,null,"pubmed","FALSE","open_pdf","3",null,"Journal Article; Meta-Analysis"],["R0056939","Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?","Rayner CK","2018","Lancet (London, England)","commentary","article","10.1016/s0140-6736(18)30936-x","29945728",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Comment"],["R0056940","Automated radiosynthesis of [18F]FBEM, a sulfhydryl site specific labeling agent for peptides and proteins.","Lim K","2018","Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine","preclinical","article","10.1016/j.apradiso.2018.07.033","30098587","PMC6119497",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056941","Blackcurrant Extract Ameliorates Hyperglycemia in Type 2 Diabetic Mice in Association with Increased Basal Secretion of Glucagon-Like Peptide-1 and Activation of AMP-Activated Protein Kinase.","Iizuka Y","2018","Journal of nutritional science and vitaminology","preclinical","article","10.3177/jnsv.64.258","30175788",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056942","Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect?","DeVore AD","2018","JACC. Heart failure","commentary","article","10.1016/j.jchf.2018.07.014","30196074",null,null,null,"pubmed","FALSE",null,null,null,"Editorial; Comment"],["R0056943","Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease.","Buckley LF","2019","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2018.08.019","30201240",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056944","The role of calcium sensing receptors in GLP-1 and PYY secretion after acute intraduodenal administration of L-Tryptophan in rats.","Acar I","2020","Nutritional neuroscience","preclinical","article","10.1080/1028415x.2018.1521906","30222528",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056945","Role of β Cell Precursors in the Regeneration of Insulin-Producing Pancreatic β Cells under the Influence of Glucagon-Like Peptide 1.","Skurikhin EG","2018","Bulletin of experimental biology and medicine","preclinical","article","10.1007/s10517-018-4232-5","30225696",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056946","Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas.","Brooks LK","2019","The American journal of medicine","narrative_review","article","10.1016/j.amjmed.2018.10.033","30472322",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056947","Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.","Camins A","2019","Expert opinion on investigational drugs","commentary","article","10.1080/13543784.2019.1552677","30480461",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0056948","Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements.","Evers A","2019","Journal of pharmaceutical sciences","other","article","10.1016/j.xphs.2018.11.043","30528197",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056949","Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo.","Fremaux J","2019","Nature communications","other","article","10.1038/s41467-019-08793-y","30804332","PMC6389962",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056950","Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer's Disease.","Day SM","2019","Neuroscience bulletin","narrative_review","article","10.1007/s12264-019-00355-y","30843143","PMC6754471",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056951","Anti-diabetic treatment leads to changes in gut microbiome.","Xourgia E","2019","Frontiers in bioscience (Landmark edition)","narrative_review","article","10.2741/4743","30844705",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056952","Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome.","Day SM","2019","eNeuro","preclinical","article","10.1523/eneuro.0031-19.2019","31040160","PMC6520642",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't"],["R0056953","[Not Available].","Schmid T","2019","Revue medicale suisse","commentary","article",null,"31599534",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0056954","Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?","Rehfeld JF","2019","Scandinavian journal of gastroenterology","randomized_trial","article","10.1080/00365521.2019.1690673","31725337",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article"],["R0056955","A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice.","Wang ZJ","2020","Hormones and behavior","preclinical","article","10.1016/j.yhbeh.2019.104640","31765661",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056956","Developing an injectable co-formulation of two antidiabetic drugs: Excipient impact on peptide aggregation and pharmacokinetic properties.","Lainé AL","2020","International journal of pharmaceutics","preclinical","article","10.1016/j.ijpharm.2020.119019","31911116",null,null,null,"pubmed","FALSE",null,null,null,"Comparative Study; Journal Article"],["R0056957","Structural insights into probe-dependent positive allosterism of the GLP-1 receptor.","Bueno AB","2020","Nature chemical biology","other","article","10.1038/s41589-020-0589-7","32690941",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056958","Glucagon-like peptide-1 cleavage product GLP-1(9-36) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes.","Huang J","2020","European journal of pharmacology","preclinical","article","10.1016/j.ejphar.2020.173581","32949596",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056959","Diabetic Kidney Disease.","Bonner R","2020","Primary care","narrative_review","article","10.1016/j.pop.2020.08.004","33121634",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056960","The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium-glucose cotransporter 2) inhibitors.","Borghi C","2020","European heart journal supplements : journal of the European Society of Cardiology","other","article","10.1093/eurheartj/suaa129","33239977","PMC7673624",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056961","The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review.","Melo FJ","2021","Inflammatory bowel diseases","systematic_review","article","10.1093/ibd/izaa324","33295607",null,null,null,"pubmed","FALSE","paywalled","3",null,"Journal Article; Research Support, Non-U.S. Gov't; Systematic Review"],["R0056962","Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids.","Alhabeeb H","2021","Nutrients","narrative_review","article","10.3390/nu13020481","33572661","PMC7911102",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056963","Metformin in the era of new antidiabetics.","Rajjoub Al-Mahdi EA","2021","Future cardiology","other","article","10.2217/fca-2020-0195","33754810",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056964","The Role of Mitochondria in Immune-Cell-Mediated Tissue Regeneration and Ageing.","Su YJ","2021","International journal of molecular sciences","narrative_review","article","10.3390/ijms22052668","33800867","PMC7961648",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056965","[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures.","Mieczkowska A","2021","Frontiers in endocrinology","preclinical","article","10.3389/fendo.2021.721506","34421828","PMC8371440",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056966","Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus.","Fauchier G","2021","Diabetologia","commentary","article","10.1007/s00125-021-05551-y","34435218",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0056967","Autophagy Dysregulation in Diabetic Kidney Disease: From Pathophysiology to Pharmacological Interventions.","Gonzalez CD","2021","Cells","narrative_review","article","10.3390/cells10092497","34572148","PMC8469825",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't; Review"],["R0056968","Cardioprotective Effects of Glucagon-like Peptide-1 (9-36) Against Oxidative Injury in H9c2 Cardiomyoblasts: Potential Role of the PI3K/Akt/NOS Pathway.","Nuamnaichati N","2022","Journal of cardiovascular pharmacology","preclinical","article","10.1097/fjc.0000000000001159","34694244",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056969","Determining When to Recommend Glucose-Lowering Drugs That Reduce Cardiovascular Risk.","Robertson S","2022","American family physician","commentary","article",null,"35029936",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0056970","Guidelines for When to Consider Mortality-Reducing Treatments for Patients With Type 2 Diabetes Mellitus.","Shaughnessy AF","2022","American family physician","other","article",null,"35029952",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056971","Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis.","Kuchay MS","2022","Diabetes & metabolic syndrome","nonrandomized_study","article","10.1016/j.dsx.2022.102446","35259705",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0056972","Can Newer Anti-Diabetic Therapies Delay the Development of Diabetic Nephropathy?","Aziz S","2021","Journal of pharmacy & bioallied sciences","narrative_review","article","10.4103/jpbs.jpbs_497_21","35399797","PMC8985833",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056973","Role of therapeutic inertia in glycemic control according to individualized objectives in a cohort of patients with type 2 diabetes. Results from CONCARDIA2.","Hidalgo Rodríguez A","2022","Endocrinologia, diabetes y nutricion","nonrandomized_study","article","10.1016/j.endien.2022.07.003","36038497",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0056974","Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control.","Zaawari A","2022","Annals of medicine and surgery (2012)","other","article","10.1016/j.amsu.2022.104536","36147162","PMC9486725",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056975","Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin.","Theofilis P","2022","Life (Basel, Switzerland)","narrative_review","article","10.3390/life12101663","36295098","PMC9605243",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056976","Medications for the treatment of obesity.","Carette C","2023","Journal of visceral surgery","other","article","10.1016/j.jviscsurg.2022.12.002","36725455",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056977","Molecular Mechanisms, Diagnosis and Treatments in Digestive Malignancy.","Kanda T","2023","International journal of molecular sciences","commentary","article","10.3390/ijms24076471","37047443","PMC10095111",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0056978","Diagnosis and Non-Invasive Treatment of Obesity in Adults with Type 2 Diabetes Mellitus: A Review of Guidelines.","Łuniewski M","2023","Journal of clinical medicine","narrative_review","article","10.3390/jcm12134431","37445466","PMC10342979",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056979","Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults.","Plattner C","2023","Expert opinion on pharmacotherapy","commentary","article","10.1080/14656566.2023.2244420","37599563",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0056980","Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model.","Nogueira ACC","2023","Health economics review","nonrandomized_study","article","10.1186/s13561-023-00466-3","37878108","PMC10599033","PROSPERO:CRD42020194415",null,"pubmed","FALSE","open_pdf","4",null,"Journal Article"],["R0056981","Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis-multivariable Mendelian randomization to GLP1R gene region.","Patel A","2024","Genetic epidemiology","other","article","10.1002/gepi.22551","38379245","PMC7616158",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056982","GLP-1, Parkinson's Disease, and Neuroprotection.","Standaert DG","2024","The New England journal of medicine","commentary","article","10.1056/nejme2401743","38598580",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0056983","The optimal second-line therapy for older adults with type 2 diabetes mellitus: protocol for a systematic review and network meta-analysis using individual participant data (IPD).","Wang J","2024","Systematic reviews","systematic_review","article","10.1186/s13643-024-02558-5","38872216","PMC11170882","PROSPERO:CRD42021272686",null,"pubmed","FALSE","free_to_read","3",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056984","Environmental factors related to the origin and evolution of differentiated thyroid cancer: a narrative review.","Paz-Ibarra J","2024","Expert review of endocrinology & metabolism","nonrandomized_study","article","10.1080/17446651.2024.2377687","38975697",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article; Review"],["R0056985","Emerging pharmacological targets for alcohol use disorder.","Brockway DF","2024","Alcohol (Fayetteville, N.Y.)","narrative_review","article","10.1016/j.alcohol.2024.07.007","39069210","PMC11638729",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural"],["R0056986","Heightened Vigilance Needed When Patients Are Prescribed GLP-1 and GIP Agonists.","Johnson TA","2024","JAMA internal medicine","commentary","article","10.1001/jamainternmed.2024.3732","39102248",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Comment"],["R0056987","Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management.","Janota O","2024","Expert opinion on pharmacotherapy","narrative_review","article","10.1080/14656566.2024.2392017","39150280",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056988","Overweight and Obesity in People Living With Type 1 Diabetes: A Cross-Sectional Analysis of the BETTER Registry.","Lalanne-Mistrih ML","2024","Diabetes/metabolism research and reviews","nonrandomized_study","article","10.1002/dmrr.3837","39193662",null,null,null,"pubmed","FALSE","open_pdf","4",null,"Journal Article; Research Support, Non-U.S. Gov't"],["R0056989","Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps.","Jeyakumar Y","2024","BMJ global health","systematic_review","article","10.1136/bmjgh-2024-017177","39608857","PMC11603712",null,null,"pubmed","FALSE","open_pdf","3",null,"Journal Article; Systematic Review; Meta-Analysis"],["R0056990","Thermogenic adipose tissues: Promising therapeutic targets for metabolic diseases.","Pahlavani M","2025","The Journal of nutritional biochemistry","narrative_review","article","10.1016/j.jnutbio.2024.109832","39653156",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, N.I.H., Extramural"],["R0056991","Biotechnology Revolution Shaping the Future of Diabetes Management.","Kundnani NR","2024","Biomolecules","narrative_review","article","10.3390/biom14121563","39766270","PMC11674738",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review; Research Support, Non-U.S. Gov't"],["R0056992","The Chimeric Peptide (GEP44) Reduces Body Weight and Both Energy Intake and Energy Expenditure in Diet-Induced Obese Rats.","Goldberg M","2025","bioRxiv : the preprint server for biology","preclinical","article","10.1101/2025.01.06.631534","39829931","PMC11741413",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Preprint"],["R0056993","Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus.","Ponce MB","2025","Cutis","narrative_review","article","10.12788/cutis.1148","39946251",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056994","Companies seek second GLP-1 revolution-in pill form.","Brazil R","2025","Science (New York, N.Y.)","commentary","article","10.1126/science.ady2624","40245133",null,null,null,"pubmed","FALSE",null,null,null,"News"],["R0056995","Pediatric Metabolic and Bariatric Surgery and Antiobesity Medications: Weighing Efficacy, Risks, and Future Directions.","Chinn JO","2025","The Journal of pediatrics","other","article","10.1016/j.jpeds.2025.114610","40252955","PMC12369949",null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056996","What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?","Gómez-Martín M","2025","Current obesity reports","narrative_review","article","10.1007/s13679-025-00632-0","40332727","PMC12058953",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056997","Bioactive peptides PIISVYWK and FSVVPSPK improve glucose homeostasis by targeting DPP-IV and glucose transport in type 2 diabetic mice.","Suryaningtyas IT","2025","International immunopharmacology","preclinical","article","10.1016/j.intimp.2025.114844","40359889",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article"],["R0056998","Adverse effects and other aspects of drugs with incretin effect.","Ballesteros-Pomar MD","2025","Medicina clinica","narrative_review","article","10.1016/j.medcli.2025.107041","40609282",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0056999","Response to \"Development and Validation of the Food Noise Questionnaire\".","Hayashi D","2025","Obesity (Silver Spring, Md.)","commentary","article","10.1002/oby.24349","40685549",null,null,null,"pubmed","FALSE",null,null,null,"Letter"],["R0057000","Beyond the Skinfolds: Diagnostic and Therapeutic Hope for the Obese and Formerly Obese.","Miller DD","2025","The Canadian journal of cardiology","commentary","article","10.1016/j.cjca.2025.07.014","40744124",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0057001","Obesity-related glomerulopathy, A growing kidney burden in the obesity pandemic.","Mashayekhi M","2026","Clinical and experimental nephrology","narrative_review","article","10.1007/s10157-025-02804-7","41410808","PMC12950009",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0057002","Critical evaluation of therapeutic targeting in chronic kidney disease: where do we stand 5 years on?","Cozzolino M","2026","Expert opinion on therapeutic targets","commentary","article","10.1080/14728222.2025.2608857","41420476",null,null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0057003","Disparities in Prescription of Long-Acting GLP-1s.","Wasden K","2026","Obesity (Silver Spring, Md.)","nonrandomized_study","article","10.1002/oby.70152","41771653",null,null,null,"pubmed","FALSE","paywalled","4",null,"Journal Article"],["R0057004","The Extent and Phenotype of Coronary Artery Disease in Diabetes and Prediabetes: Insights From Imaging Studies and Potential Therapeutic Implications.","Gurgoglione FL","2026","Reviews in cardiovascular medicine","narrative_review","article","10.31083/rcm47550","41789328","PMC12959996",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0057005","Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial.","Ahmad AI","2026","JAMA internal medicine","randomized_trial","article","10.1001/jamainternmed.2026.0027","41837981","PMC12993733","ClinicalTrials.gov:NCT06533527","S002295","pubmed","FALSE","open_pdf","1",null,"Journal Article; Randomized Controlled Trial; Multicenter Study; Comparative Study; Research Support, Non-U.S. Gov't"],["R0057006","GLP-1 and its derivatives are associated with the reduction of macrophage infiltration and inflammation in systemic chronic inflammatory diseases: a systematic review and meta-analysis of animal models.","Sha H","2026","Immunologic research","systematic_review","article","10.1007/s12026-026-09764-4","41843040",null,null,null,"pubmed","FALSE","paywalled","3",null,"Journal Article; Systematic Review; Meta-Analysis"],["R0057007","Not all 'natural' is safe: A naturally occurring glucagon-like peptide-1 mimetic associated with drug-induced hypersensitivity syndrome.","Xu A","2026","JAAD case reports","case_report","article","10.1016/j.jdcr.2026.02.034","42027855","PMC13101617",null,null,"pubmed","FALSE",null,null,null,"Case Reports; Journal Article"],["R0057008","Revisiting the relationship between weight loss and bone health in people living with obesity: insights from the latest evidence.","Paccou J","2026","Current opinion in endocrinology, diabetes, and obesity","randomized_trial","article","10.1097/med.0000000000000962","42083415",null,null,null,"pubmed","FALSE","paywalled","2",null,"Journal Article; Review"],["R0057009","Low Weight Loss Response to Incretin Analogs: A Systematic Review.","Gaskin PS","2026","Obesity reviews : an official journal of the International Association for the Study of Obesity","systematic_review","article","10.1111/obr.70145","42083728","PMC13655991",null,null,"pubmed","FALSE","free_to_read","3",null,"Systematic Review; Journal Article; Review"],["R0057010","GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation.","Cruz P","2026","Frontiers in physiology","narrative_review","article","10.3389/fphys.2026.1826699","42131480","PMC13160734",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0057011","Efficacy and safety of finerenone in chronic kidney disease stages 3-4 in diabetic and non-diabetic patients with an eGFR 20-60 mL/min: a prospective cohort study.","Aledan H","2026","Frontiers in nephrology","nonrandomized_study","article","10.3389/fneph.2026.1716452","42179848","PMC13194097",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article"],["R0057012","[Blood pressure effects of potent GLP-1 and GIP analogues].","Oweini W","2026","Revue medicale suisse","narrative_review","article","10.53738/revmed.2026.22.974.49244","42717611",null,null,null,"pubmed","FALSE",null,null,null,"Journal Article; English Abstract; Review"],["R0057013","Heart Failure With Preserved Ejection Fraction: A Practical, Stepwise Guide to Evidence-Based Therapy in 2026.","Chabalout MN","2026","Cureus","other_trial","article","10.7759/cureus.115294","42741491","PMC13574263",null,null,"pubmed","FALSE","open_pdf","5",null,"Journal Article"],["R0057014","Molecular Synergy and Inflammatory Activation in Pathogenesis and Therapy of Atrial Cardio-Metabolic Cardiomyopathy.","Guichard JB","2026","JACC. Basic to translational science","commentary","article","10.1016/j.jacbts.2026.101661","42804836","PMC13524713",null,null,"pubmed","FALSE",null,null,null,"Editorial"],["R0057015","Continuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance.","Koceva A","2026","Frontiers in endocrinology","narrative_review","article","10.3389/fendo.2026.1892632","42865881","PMC13656005",null,null,"pubmed","FALSE",null,null,null,"Journal Article; Review"],["R0057016","When weight-loss drugs reduce drinking: glucagon-like peptide-1 receptor agonists as phenotype-enriched harm-reduction therapy for alcohol use disorder.","Singh S","2026","Annals of medicine and surgery (2012)","randomized_trial","article","10.1097/ms9.0000000000005709","42866353","PMC13657514",null,null,"pubmed","FALSE","free_to_read","2",null,"Editorial"],["R0057017","Advances in pharmacologic management of obesity: oral semaglutide for weight management.","Zainab F","2026","Annals of medicine and surgery (2012)","nonrandomized_study","article","10.1097/ms9.0000000000005161","42866773","PMC13657554",null,null,"pubmed","FALSE","free_to_read","4",null,"Journal Article"]]}